From 18d3d744492c03055def3316c75307b8528fdd74 Mon Sep 17 00:00:00 2001 From: "vladimir.buzalka" Date: Thu, 18 Jun 2026 09:31:33 +0200 Subject: [PATCH 1/5] z230 --- ...SipIQ_V1_13MAY2026_June+18,+2026_01.27.csv | 550 ++++++++++++++++++ Feasibility/TRASH/sipiq_report_v1.0.py | 216 +++++++ Feasibility/sipiq_report_v1.1.md | 33 ++ Feasibility/sipiq_report_v1.1.py | 220 +++++++ KPC/_list_cats_v0.py | 34 ++ KPC/_process_clk_v0.py | 92 +++ KPC/_read_v0.py | 51 ++ ... platbě [ČLK příspěvek Buzalková 2026].kpc | 6 + 8 files changed, 1202 insertions(+) create mode 100644 Feasibility/77242113UCO2001/ImportSIPIQcompled/ICONIC+Phase+3b+UC+Study+(77242113UCO3002)_SipIQ_V1_13MAY2026_June+18,+2026_01.27.csv create mode 100644 Feasibility/TRASH/sipiq_report_v1.0.py create mode 100644 Feasibility/sipiq_report_v1.1.md create mode 100644 Feasibility/sipiq_report_v1.1.py create mode 100644 KPC/_list_cats_v0.py create mode 100644 KPC/_process_clk_v0.py create mode 100644 KPC/_read_v0.py create mode 100644 KPC/output/2026-06-17 KPC k platbě [ČLK příspěvek Buzalková 2026].kpc diff --git a/Feasibility/77242113UCO2001/ImportSIPIQcompled/ICONIC+Phase+3b+UC+Study+(77242113UCO3002)_SipIQ_V1_13MAY2026_June+18,+2026_01.27.csv b/Feasibility/77242113UCO2001/ImportSIPIQcompled/ICONIC+Phase+3b+UC+Study+(77242113UCO3002)_SipIQ_V1_13MAY2026_June+18,+2026_01.27.csv new file mode 100644 index 0000000..689190c --- /dev/null +++ b/Feasibility/77242113UCO2001/ImportSIPIQcompled/ICONIC+Phase+3b+UC+Study+(77242113UCO3002)_SipIQ_V1_13MAY2026_June+18,+2026_01.27.csv @@ -0,0 +1,550 @@ +StartDate,EndDate,Status,IPAddress,Progress,Duration (in seconds),Finished,RecordedDate,ResponseId,RecipientLastName,RecipientFirstName,RecipientEmail,ExternalReference,LocationLatitude,LocationLongitude,DistributionChannel,UserLanguage,Q2,Q6_2,Q6_1,Q6_4,Q6_3,Q6_9,Q6_10,Q6_5,Q6_6,Q6_7,Q6_8,Q6_11,Q7,Q8_2,Q8_1,Q8_3,Q8_8,Q8_9,Q8_4,Q8_5,Q8_6,Q8_7,Q9_1,Q9_2,Q9_3,Q9_4,Q9_5,Q10,Q11_1,Q11_2,Q11_3,Q11_4,Q11_5,Q12,Q13_2,Q13_1,Q13_3,Q13_8,Q13_9,Q14,Q15,Q16,Q17,Q18,Q19,Q21,Q25,Q26,Q26_12_TEXT,Q27,Q29,Q30,Q30_4_TEXT,Q31#1_1,Q31#1_2,Q31#1_3,Q31#1_4,Q31#2_1,Q31#2_2,Q31#2_3,Q31#2_4,Q32,Q33,Q34,Q36,Q37_1,Q38_1,Q38_2,Q40_1,Q40_2,Q40_3,Q40_4,Q40_5,Q40_6,Q40_6_TEXT,Q41_1,Q41_2,Q42_4,Q42_5,Q42_6,Q43_1,Q43_2,Q45,Q46,Q47,Q48,Q49,Q51,Q53,Q54#1_1_1,Q54#1_2_1,Q54#1_3_1,Q54#1_4_1,Q54#1_5_1,Q54#2_1_1,Q54#2_2_1,Q54#2_3_1,Q54#2_4_1,Q54#2_5_1,Q54#3_1_1,Q54#3_2_1,Q54#3_3_1,Q54#3_4_1,Q54#3_5_1,Q57_1,Q58_1,Q59_1,Q60_1,Q61_1,Q63#1_1,Q63#1_2,Q63#1_3,Q63#1_4,Q63#1_5,Q63#1_6,Q64#1_1,Q64#1_2,Q64#1_3,Q64#1_4,Q64#1_5,Q65,Q66_1,Q66_2,Q67,Q69#1_1,Q69#1_2,Q69#1_3,Q69#1_4,Q69#1_5,Q69#1_6,Q69#1_7,Q69#1_8,Q71,Q72_1,Q73_1,Q74_1,Q75,Medical Specialty,Survey Type,Therapeutic Area,ProtocolID,type,network_affiliations,fac_to_support_edcp,acc_to_overnight_fac,accom_latenight_pkpd,site_accommodations,site_allow_witness,has_satellite_loc,has_pharmacy,source_doc_storage,is_emer_power_avail,emer_power_loc,is_pharmdisp_adm_bdg,is_doc_trans_proc,is_daily_ded_pharma,acc_ltd_to_prep_area,has_auth_storcontsub,have_lam_flow_hood,storage_conditions,pharm_temp_moni_loc,lab_type,time_for_lab_rslts,is_lab_cert_avail,has_search_patientdb,no_patient_db_desc,is_phys_on_prem,cont_safety_moni,des_unblinded_persn,does_min_based_or,min_based_or_desc,has_acc_to_sourcedoc,source_doc_type,is_esrm_avail,can_cta_neg_parallel,cta_neg_para_desc,req_adtl_comt_apprvl,addtl_cmt_app_desc,avg_ethirb_aprv_time,can_work_para_irbiec,signature_type,irb_type,fire_site_id,fire_investigator_id,irb_meeting_freq,tot_time_comm_rev,has_board_cert,med_degree_type,site_training_rqt,is_asian_pp,is_pi_or_haw_pp,is_asian_indian_pp,is_blk_af_ameri_pp,is_hisp_latino_pp,is_amerind_or_ak_pp,is_multiracial,is_white_caucasian,overnight_fac_desc,accom_ln_pkpd_desc,firstName,lastName,email,phone,investigator_street,investigator_postcode,investigator_city,investigator_state,extRef,satellite_loc_num,no_phys_on_prem_desc,no_acc_sourcedoc_des,board_cert_desc,cont_safetymon_other,irb_meeting_freq_oth,dedicated_phase_1,site_name,site_address,site_city,site_country,site_state,site_postcode,pi_first_name,pi_last_name,pi_phone,pi_email,survey_generated_by,sdl_site_id,mailinglist_id,Date,Time +Start Date,End Date,Response Type,IP Address,Progress,Duration (in seconds),Finished,Recorded Date,Response ID,Recipient Last Name,Recipient First Name,Recipient Email,External Data Reference,Location Latitude,Location Longitude,Distribution Channel,User Language,Please confirm if the Investigator should complete an abbreviated sipIQ.,Principal Investigator: - First Name:,Principal Investigator: - Last Name:,Principal Investigator: - Institution Name/Department:,Principal Investigator: - Medical Specialty:,Principal Investigator: - Email:,Principal Investigator: - Phone:,Principal Investigator: - Address:,Principal Investigator: - City:,Principal Investigator: - State/Province:,Principal Investigator: - Postal Code:,Principal Investigator: - Country:,Has your site identified a research coordinator?,Research Coordinator: - First Name:,Research Coordinator: - Last Name:,Research Coordinator: - Institution Name/Department:,Research Coordinator: - Email:,Research Coordinator: - Phone:,Research Coordinator: - Address:,Research Coordinator: - City:,Research Coordinator: - State/Province:,Research Coordinator: - Postal Code:,Contact information of the person responsible for scheduling the qualification visit: - First Name:,Contact information of the person responsible for scheduling the qualification visit: - Last Name:,Contact information of the person responsible for scheduling the qualification visit: - Role/Title:,Contact information of the person responsible for scheduling the qualification visit: - Email:,Contact information of the person responsible for scheduling the qualification visit: - Phone:,Person responsible for CDA negotiation:,Contact information of the person responsible for CDA negotiation: - First Name:,Contact information of the person responsible for CDA negotiation: - Last Name:,Contact information of the person responsible for CDA negotiation: - Role/Title:,Contact information of the person responsible for CDA negotiation: - Email:,Contact information of the person responsible for CDA negotiation: - Phone:,Who is completing the questionnaire?,Person completing the questionnaire: - First Name:,Person completing the questionnaire: - Last Name:,Person completing the questionnaire: - Role/Title:,Person completing the questionnaire: - Email:,Person completing the questionnaire: - Phone:,"Note: Each platform user is asked to review the statement below and acknowledge your individual role in maintaining the confidentiality of Janssen’s proprietary information. You are not being asked to make an acknowledgement on behalf of your institution. + + + + + +Confidentiality Statement + + + +The information contained in this platform or otherwise provided in furtherance of the Purpose (collectively, “Confidential Information”) are confidential and proprietary to Janssen Research & Development or its affiliates. By accessing this platform and checking this box, you explicitly undertake to protect the confidential nature of the Confidential Information provided by Janssen Research & Development or its affiliates and not to disclose the Confidential Information to any third party, unless such disclosure is to other institution personnel on a need to know basis for the Purpose, and you undertake that such institution personnel protect the confidential nature of the Confidential Information in the same way. You further agree that the Confidential Information will only be used for the limited purposes of (i) determining whether your institution wishes to participate in the conduct of a clinical trial, (ii) initial planning as to prepare for the conduct of a clinical trial your institution’s facility, and (iii) interest in engaging in the negotiation of a Clinical Trial Agreement with Janssen Research & Development or its affiliates (the “Purpose”). Your data will be included in an investigator database controlled by Janssen Research & Development. The purpose of the investigator database is the management of the relationship with clinical trial investigators in view of, among others, the management of clinical trials. Your submission of the questionnaire constitutes your consent with respect to the collection and processing of your personal data in line with Janssen Research & Development's privacy policy. + + +Click here to go to the Janssen Research & Developments privacy notice for principal investigators and investigational staff members. + +Additional information for European Economic Area countries: + + + +* Janssen R&D LLC, 920 US Route 202, PO Box 300, Raritan NJ 08869, United States, who is represented in European Economic Area by Janssen Cilag International NV, Turnhoutseweg 30, B-2340, Beerse, Belgium. + + +Do you agree to the Confidentiality Statement above? + +(Note: Once the confidentiality agreement has been accepted or denied you will not be able to change it.)","Confidentiality Statement + + +The information contained in this platform or provided in any other way for the Purpose (collectively, Confidential Information) is confidential and proprietary to Janssen Research and Development or its affiliates, as except for the right to use the Company's Confidential Information for the Purpose (which will expire upon the first occurrence of the completion of the Purpose or expiration of this Agreement), no other rights or licenses, express or implied, under any copyrights, patents, trademarks, trade secrets, or other proprietary rights, are granted to the Recipient by this Agreement. By accessing this platform and checking this box, you explicitly commit to protecting the confidential nature of the confidential information provided by Janssen Research and Development or its affiliates and not to disclose the Confidential Information to third parties, unless such disclosure is to other employees of the institution based on a need to know for the Purpose, provided that any disclosure must have prior written consent from Janssen, as you agree that such personnel of the institution will protect the confidential information that will be used only for the limited purpose of (i) determining whether your institution wishes to participate in conducting a clinical study, (ii) initial planning to prepare for conducting a clinical study, and (iii) interest in engaging in the negotiation of the clinical trial contract with Janssen Research and Development or its affiliates (the Purpose). The obligations will necessarily remain in effect for an additional 10 years after the termination of this Agreement. At the Company's request, the Recipient must immediately destroy or return all tangible items containing Confidential Information, whether upon request from Janssen. The Recipient may retain a copy of the Confidential Information in a secure location, solely to ensure compliance with this Agreement, for no other purpose. Your data will be included in a database of investigators for managing the relationship with the clinical trial investigator, aiming, among other things, at managing clinical trials. The submission of the questionnaire constitutes your consent regarding the collection and processing of your personal data in accordance with Janssen Research and Development's privacy policy. + + + +This Agreement shall be governed by and construed in accordance with the laws of Brazil, excluding any conflicts of legal provisions. The Parties agree to submit all their disputes arising from or in connection with this Agreement to the Courts of São Paulo/SP. + + + +Click here to go to the Janssen Research & Developments privacy notice for principal investigators and investigational staff members. + + + +Do you agree to the Confidentiality Statement above? + +(Note: Once the confidentiality agreement has been accepted or denied you will not be able to change it.)","Note to the user: Each platform user is asked to review the statement below and acknowledge its individual role in maintaining the confidentiality of Janssen’s proprietary information. As, platform user, you are not being asked to make an acknowledgement on behalf of your institution. + + + +By checking the box below, agree with the following Confidentiality Statement: + + + +The information contained in this platform or otherwise provided in furtherance of the Purpose, as defined below (collectively, “Confidential Information”) is confidential and proprietary to Janssen Research & Development or its affiliates (the “Company”), as except for the user’s right to use the Confidential Information for the Purpose. This confidentiality obligation will remain in effect for 10 years as from completion of the Purpose. + + + +By accessing this platform and checking this box, you explicitly undertake to protect the confidential nature of the Confidential Information provided by Janssen Research & Development or its affiliates and not to disclose the Confidential Information to any third party, unless such disclosure is to other institution personnel on a need to know basis for the Purpose, and you undertake to guarantee that such institution personnel protect the confidential nature of the Confidential Information in the same way. + + + +You further agree that the Confidential Information will only be used for the limited purposes of (i) determining whether your institution wishes to participate in the conduct of a clinical trial, (ii) initial planning as to prepare for the conduct of a clinical trial your institution’s facility, and (iii) interest in engaging in the negotiation of a Clinical Trial Agreement with Janssen Research & Development or its affiliates (the “Purpose”). + + + +Your data will be included in an investigator database controlled by Janssen Research & Development. The purpose of the investigator database is the management of the relationship with clinical trial investigators in view of, among others, the management of clinical trials. Your submission of the questionnaire constitutes your consent with respect to the collection and processing of your personal data in line with Janssen Research & Development's privacy policy. + + + +The obligations derived from this confidentiality statement shall be governed by and construed in accordance with the laws of Argentina, without regard to any conflicts of laws provisions. Any disputes arising hereof shall be settled by the Buenos Aires city ordinary courts. + + + +Click here to go to the Janssen Research & Developments privacy notice for principal investigators and investigational staff members. + + + +Do you agree to the Confidentiality Statement above? + +(Note: Once the confidentiality agreement has been accepted or denied you will not be able to change it.) + + + +The confidentiality statement may be accepted either by the Principal Investigator or by a duly authorized third party acting on their behalf. Such acceptance shall carry the same legal validity. The accepting party represents and warrants that they have obtained the express authorization of the Principal Investigator.","Confidentiality Statement: + + + +The information contained in this platform or otherwise provided in furtherance of the Purpose (collectively, “Confidential Information”) are confidential and proprietary to Janssen Research & Development or its affiliates. By accessing this platform and checking this box, you explicitly undertake to protect the confidential nature of the Confidential Information provided by Janssen Research & Development or its affiliates and not to disclose the Confidential Information to any third party, unless such disclosure is to other institution personnel on a need to know basis for the Purpose, and you undertake that such institution personnel protect the confidential nature of the Confidential Information in the same way. You further agree that the Confidential Information will only be used for the limited purposes of (i) determining whether your institution wishes to participate in the conduct of a clinical trial, (ii) initial planning as to prepare for the conduct of a clinical trial your institution’s facility, and (iii) interest in engaging in the negotiation of a Clinical Trial Agreement with Janssen Research & Development or its affiliates (the “Purpose”). + + + +All the rights and obligations herein will necessarily remain in effect for 10 years after you will be provided the Confidential Information or, if subsequent, after you will disclose the Confidential Information to other employees of the institution in accordance with this Confidentiality Statement. + + + +Your data will be included in an investigator database controlled by Janssen Research & Development. The purpose of the investigator database is the management of the relationship with clinical trial investigators in view of, among others, the management of clinical trials. Your submission of the questionnaire constitutes your consent with respect to the collection and processing of your personal data in line with Janssen Research & Development's privacy policy. + + + +Click here to go to the Janssen Research & Developments privacy notice for principal investigators and investigational staff members. + + + +Additional information for European Economic Area countries: * Janssen R&D LLC, 920 US Route 202, PO Box 300, Raritan NJ 08869, United States, who is represented in European Economic Area by Janssen Cilag International NV, Turnhoutseweg 30, B-2340, Beerse, Belgium. + + + +Do you agree to the Confidentiality Statement above? + +(Note: Once the confidentiality agreement has been accepted or denied you will not be able to change it.)","Confidentiality Statement + + + +The information contained in this platform or otherwise provided in any way by Janssen Cilag, S.A. de C.V., and its affiliates related to the clinical trial in furtherance of the Purpose (collectively, “Confidential Information”) are confidential and proprietary to Janssen Research & Development or its affiliates. By accessing this platform, filling your data and checking the acceptance box expressly related to the personal identity provided in your data, you explicitly agree to protect the confidential nature of the Confidential Information provided by Janssen Research & Development or its affiliates and not to disclose the Confidential Information to any third party, unless such disclosure is to other institution personnel on a need to know basis for the Purpose, and the institution personnel agreed to protect the Confidential Information in the same way. You further agree that the Confidential Information will be used for the limited purposes of (i) determining whether you as a PI or your institution wishes to participate in the conduct of a clinical trial, (ii) initial planning as to prepare for the conduct of a clinical trial your institution’s facility, and (iii) interest in engaging in the negotiation of a Clinical Trial Agreement with Janssen Research & Development or its affiliates (the “Purpose”). By means of this document, it is acknowledged that the acceptance of these terms and conditions will be understood as an agreement with full legal applicability, not being a promise of future contracting, all information will be considered as confidential regardless of whether it is labeled or not, the validity of these obligations will be considered as indeterminate even in the event of not participating in the clinical trial. + + + +Click here to go to the Janssen Research & Developments privacy notice for principal investigators and investigational staff members. + + + +Do you agree to the Confidentiality Statement above? + +(Note: Once the confidentiality agreement has been accepted or denied you will not be able to change it.)","Would your site still be interested in participating in the clinical trial if a Confidential Disclosure Agreement (CDA) is signed offline prior to filling out the survey? +If you select ""Yes,"" our local team will contact you to arrange for the signing of the CDA, after which you will be provided with the protocol information and be able to complete the questionnaire.","Confidentiality Statement + + + +The information contained in this platform, otherwise provided in furtherance of the Purpose or arising as part of the negotiations between Janssen Research & Development and your institution (collectively, “Confidential Information”) are confidential and proprietary materials owned by Janssen Research & Development or its affiliates. Maintaining the confidentiality of the Confidential Information is essential for Janssen Research & Development and the Confidential Information is only disclosed upon the undertaking to maintain the confidentiality thereof. By accessing this platform, you explicitly agree to protect the confidential nature of the Confidential Information provided by Janssen Research & Development or its affiliates and not to disclose the Confidential Information to any third party, unless such disclosure is to other institution personnel on a need-to-know basis for the Purpose, and the institution personnel agreed to protect the Confidential Information in the same way. You further agree that the Confidential Information will only be used for the limited purposes of (i) determining whether your institution wishes to participate in the conduct of a clinical trial, (ii) initial planning as to prepare for the conduct of a clinical trial at your institution’s facility, and (iii) interest in engaging in the negotiation of a Clinical Trial Agreement with Janssen Research & Development or its affiliates (the “Purpose”). A breach of these obligations will result in legal action. Your data will be included in an investigator database controlled by Janssen Research & Development. The purpose of the investigator database is the management of the relationship with clinical trial investigators in view of, among others, the management of clinical trials. Your submission of the questionnaire constitutes your consent with respect to the collection and processing of your personal data in line with Janssen Research & Development's privacy policy. + + +Click here to go to the Janssen Research & Developments privacy notice for principal investigators and investigational staff members. + + + +* Janssen R&D LLC, 920 US Route 202, PO Box 300, Raritan NJ 08869, United States, who is represented in European Economic Area by Janssen Cilag International NV, Turnhoutseweg 30, B-2340, Beerse, Belgium. + + + +Do you agree to the Confidentiality Statement above? + +(Note: Once the confidentiality agreement has been accepted or denied you will not be able to change it.)","Upon review of the protocol information, are you interested in conducting this trial?","If you are not interested, please specify why: (Check all that apply) - Selected Choice","If you are not interested, please specify why: (Check all that apply) - Other, please specify: - Text",Please share any additional comments or feedback you may have:,"Is vedolizumab approved in your country for the treatment of ulcerative colitis (UC), including intravenous (IV) induction followed by subcutaneous (SC) self‑administration?",Is vedolizumab reimbursed and/or covered by insurance in your country for the treatment of ulcerative colitis (UC)? - Selected Choice,Is vedolizumab reimbursed and/or covered by insurance in your country for the treatment of ulcerative colitis (UC)? - Other (please specify): - Text,"At your site, at what line(s) of treatment do you most commonly prescribe vedolizumab for patient... - Please select up to three options: - First-line treatment:","At your site, at what line(s) of treatment do you most commonly prescribe vedolizumab for patient... - Please select up to three options: - Second-line treatment:","At your site, at what line(s) of treatment do you most commonly prescribe vedolizumab for patient... - Please select up to three options: - Third-line treatment:","At your site, at what line(s) of treatment do you most commonly prescribe vedolizumab for patient... - Please select up to three options: - Fourth-line treatment:","At your site, at what line(s) of treatment do you most commonly prescribe vedolizumab for patient... - Please indicate the approximate percentage at each selected line: - First-line treatment:","At your site, at what line(s) of treatment do you most commonly prescribe vedolizumab for patient... - Please indicate the approximate percentage at each selected line: - Second-line treatment:","At your site, at what line(s) of treatment do you most commonly prescribe vedolizumab for patient... - Please indicate the approximate percentage at each selected line: - Third-line treatment:","At your site, at what line(s) of treatment do you most commonly prescribe vedolizumab for patient... - Please indicate the approximate percentage at each selected line: - Fourth-line treatment:",Does your site have access to commercially available local assays to assess biologic drug levels when required for eligibility?,"Based on the protocol summary, do you anticipate any challenges enrolling participants?","If yes, please describe:",How many ongoing and planned studies for moderate to severe active ulcerative colitis are you committed to in Feb 2027 – Feb 2028?,"Based on your review of the protocol summary, your pool of eligible patients, patient interest to participate, competing clinical studies at your site, other resource constraints, and factoring in your start-up timelines, how many total patients with ulcerative colitis can your site enroll in the study (excluding screen failures) in ~11-month enrollment period starting February 2027: - Number of UC patients your site can enroll:","Out of these UC patients your site anticipates enrolling during the ~ 11-month enrollment period, how many are the following? + +Note: The total sum should equal the number of UC patients your site can enroll entered in the question above. - Advanced therapy-inadequate responders (ADT‑IR) UC patients:","Out of these UC patients your site anticipates enrolling during the ~ 11-month enrollment period, how many are the following? + +Note: The total sum should equal the number of UC patients your site can enroll entered in the question above. - Advanced therapy naïve (ADT naïve) UC patients:",Races (total percentages should equal 100%): - White/Caucasian:,Races (total percentages should equal 100%): - Asian:,Races (total percentages should equal 100%): - Black or African American:,Races (total percentages should equal 100%): - American Indian or Alaskan Native:,Races (total percentages should equal 100%): - Native Hawaiian or Other Pacific Islander:,"Races (total percentages should equal 100%): - Other, please specify:","Races (total percentages should equal 100%): - Other, please specify: - Text",Ethnicity (Please add ‘0’ if not applicable): - Hispanic/Latino:,Ethnicity (Please add ‘0’ if not applicable): - Non-Hispanic/Latino:,Age (total percentages should equal 100%): - Under 18:,Age (total percentages should equal 100%): - 18 - 64:,Age (total percentages should equal 100%): - ≥65:,Sex assigned at birth (total percentages should equal 100%): - Male:,Sex assigned at birth (total percentages should equal 100%): - Female:,Does your site have multilingual staff to communicate effectively with all patients?,Would your site prefer patient materials available in multiple languages?,"If yes, please indicate the languages predominantly spoken by your patient populations:","Does your site partner with patient and community groups (medical community, patient advocacy and support groups, churches etc.) to improve recruitment and retention of patient populations disproportionately impacted by ulcerative colitis?","Does your site currently have any decentralized trial capability (home nursing, drug delivery etc.)?","To successfully participate in the study, please describe what areas of support may be needed from J&J.",Do you have any concerns related to the study requirements which are not captured elsewhere in the questionnaire?,Are there any sites or other investigators you would recommend for this study? - PI Name: - No Name - -,Are there any sites or other investigators you would recommend for this study? - PI Name: - No Name - -,Are there any sites or other investigators you would recommend for this study? - PI Name: - No Name - -,Are there any sites or other investigators you would recommend for this study? - PI Name: - No Name - -,Are there any sites or other investigators you would recommend for this study? - PI Name: - No Name - -,Are there any sites or other investigators you would recommend for this study? - Institution: - No Name - -,Are there any sites or other investigators you would recommend for this study? - Institution: - No Name - -,Are there any sites or other investigators you would recommend for this study? - Institution: - No Name - -,Are there any sites or other investigators you would recommend for this study? - Institution: - No Name - -,Are there any sites or other investigators you would recommend for this study? - Institution: - No Name - -,Are there any sites or other investigators you would recommend for this study? - Email Address: - No Name - -,Are there any sites or other investigators you would recommend for this study? - Email Address: - No Name - -,Are there any sites or other investigators you would recommend for this study? - Email Address: - No Name - -,Are there any sites or other investigators you would recommend for this study? - Email Address: - No Name - -,Are there any sites or other investigators you would recommend for this study? - Email Address: - No Name - -,"On average, how many adult (≥ 18 years of age) patients with moderate to severe active ulcerative colitis do you treat at your site per year? - Number of adult patients with moderate to severe active UC per year:","Of the adult patients with moderate to severe active UC that you treat per year, how many have never received advanced therapy (i.e., are biologic‑naïve or advanced therapy‑naïve)? - Number of advanced therapy–naïve UC patients per year:","Of the adult patients with moderate to severe active UC that you treat per year, how many are currently receiving advanced therapy treatment (e.g., TNF inhibitors, integrin receptor antagonists, dual interleukin-12/23 inhibitors, interleukin-23 inhibitors, JAK inhibitors, S1P receptor modulators) for the treatment of UC? - Number of UC patients currently receiving advanced therapy:","Of the patients currently receiving advanced therapy, approximately how many are currently receiving or have previously received vedolizumab? - Number of UC patients currently receiving or previously exposed to vedolizumab:","Of the patients currently receiving advanced therapy, approximately how many are currently receiving or have previously received an anti‑IL‑23p19 antibody (e.g., guselkumab , risankizumab or mirikizumab) - Number of UC patients currently receiving or previously exposed to anti‑IL‑23p19 antibodies:",Do you or your site staff have experience in performing the following types of study assessments/... - Q63#1 - Video endoscopy,Do you or your site staff have experience in performing the following types of study assessments/... - Q63#1 - Flexible sigmoidoscopy or full colonoscopy (video) with biopsy,Do you or your site staff have experience in performing the following types of study assessments/... - Q63#1 - Mayo Score (Full/Modified and Partial),"Do you or your site staff have experience in performing the following types of study assessments/... - Q63#1 - UC e-diaries (Mayo stool frequency, rectal bleeding, and AP-NRS (abdominal pain) e-diaries)","Do you or your site staff have experience in performing the following types of study assessments/... - Q63#1 - ePRO (HRQoL, IBDQ, PROMIS-29, PROMIS Fatigue Short Form 7a)",Do you or your site staff have experience in performing the following types of study assessments/... - Q63#1 - Biopsy sample collection,The following personnel are required to run the study. Will your site have the following available? - Q64#1 - Sub-Investigator with clinical trial experience,The following personnel are required to run the study. Will your site have the following available? - Q64#1 - Study coordinator or dedicated research nurse,The following personnel are required to run the study. Will your site have the following available? - Q64#1 - Licensed healthcare professional to administer and monitor IV infusion and subcutaneous injections,The following personnel are required to run the study. Will your site have the following available? - Q64#1 - Site staff with experience collecting PK samples,The following personnel are required to run the study. Will your site have the following available? - Q64#1 - Staff with IATA training certification for handling and packing the central lab samples,"Based on your responses to the previous question, it appears that you may currently not +have all the personnel that is required to conduct the study. Would you be willing/able to hire resources in the future?",How many ulcerative colitis studies have you conducted in the past 5 years as a principal investigator? - Phase II: Number of studies:,How many ulcerative colitis studies have you conducted in the past 5 years as a principal investigator? - Phase III: Number of studies:,"In the past 2 years, how many clinical trials have you participated in that used central review of the video endoscopy?",The following equipment and facilities are required to run the studies. Are these available at yo... - Q69#1 - Endoscopy,The following equipment and facilities are required to run the studies. Are these available at yo... - Q69#1 - Incubator for TB sample processing,The following equipment and facilities are required to run the studies. Are these available at yo... - Q69#1 - IGRA testing (either QuantiFERON-TB® or T-SPOT® TB),The following equipment and facilities are required to run the studies. Are these available at yo... - Q69#1 - Chest radiograph,The following equipment and facilities are required to run the studies. Are these available at yo... - Q69#1 - 12-lead ECG,The following equipment and facilities are required to run the studies. Are these available at yo... - Q69#1 - Local laboratory,The following equipment and facilities are required to run the studies. Are these available at yo... - Q69#1 - Refrigerator for Investigational Product (IP) storage,The following equipment and facilities are required to run the studies. Are these available at yo... - Q69#1 - Freezer -70°C or -80°C with adequate space for blood sample storage,Does your site work with a local or central EC/IRB?,How long does it take to receive approval from the Central EC/IRB? - Duration in weeks:,How long does it take to receive approval from the Local EC/IRB? - Duration in weeks:,"On average, what is the turnaround time for contract execution at your site? - Duration in weeks:","At your site, can EC/IRB review and contract negotiation proceed in parallel?",Medical Specialty,Survey Type,Therapeutic Area,ProtocolID,type,network_affiliations,fac_to_support_edcp,acc_to_overnight_fac,accom_latenight_pkpd,site_accommodations,site_allow_witness,has_satellite_loc,has_pharmacy,source_doc_storage,is_emer_power_avail,emer_power_loc,is_pharmdisp_adm_bdg,is_doc_trans_proc,is_daily_ded_pharma,acc_ltd_to_prep_area,has_auth_storcontsub,have_lam_flow_hood,storage_conditions,pharm_temp_moni_loc,lab_type,time_for_lab_rslts,is_lab_cert_avail,has_search_patientdb,no_patient_db_desc,is_phys_on_prem,cont_safety_moni,des_unblinded_persn,does_min_based_or,min_based_or_desc,has_acc_to_sourcedoc,source_doc_type,is_esrm_avail,can_cta_neg_parallel,cta_neg_para_desc,req_adtl_comt_apprvl,addtl_cmt_app_desc,avg_ethirb_aprv_time,can_work_para_irbiec,signature_type,irb_type,fire_site_id,fire_investigator_id,irb_meeting_freq,tot_time_comm_rev,has_board_cert,med_degree_type,site_training_rqt,is_asian_pp,is_pi_or_haw_pp,is_asian_indian_pp,is_blk_af_ameri_pp,is_hisp_latino_pp,is_amerind_or_ak_pp,is_multiracial,is_white_caucasian,overnight_fac_desc,accom_ln_pkpd_desc,firstName,lastName,email,phone,investigator_street,investigator_postcode,investigator_city,investigator_state,extRef,satellite_loc_num,no_phys_on_prem_desc,no_acc_sourcedoc_des,board_cert_desc,cont_safetymon_other,irb_meeting_freq_oth,dedicated_phase_1,site_name,site_address,site_city,site_country,site_state,site_postcode,pi_first_name,pi_last_name,pi_phone,pi_email,survey_generated_by,sdl_site_id,mailinglist_id,Date,Time +"{""ImportId"":""startDate"",""timeZone"":""America/Denver""}","{""ImportId"":""endDate"",""timeZone"":""America/Denver""}","{""ImportId"":""status""}","{""ImportId"":""ipAddress""}","{""ImportId"":""progress""}","{""ImportId"":""duration""}","{""ImportId"":""finished""}","{""ImportId"":""recordedDate"",""timeZone"":""America/Denver""}","{""ImportId"":""_recordId""}","{""ImportId"":""recipientLastName""}","{""ImportId"":""recipientFirstName""}","{""ImportId"":""recipientEmail""}","{""ImportId"":""externalDataReference""}","{""ImportId"":""locationLatitude""}","{""ImportId"":""locationLongitude""}","{""ImportId"":""distributionChannel""}","{""ImportId"":""userLanguage""}","{""ImportId"":""QID90""}","{""ImportId"":""QID1323447063_2""}","{""ImportId"":""QID1323447063_1""}","{""ImportId"":""QID1323447063_4""}","{""ImportId"":""QID1323447063_3""}","{""ImportId"":""QID1323447063_9""}","{""ImportId"":""QID1323447063_10""}","{""ImportId"":""QID1323447063_5""}","{""ImportId"":""QID1323447063_6""}","{""ImportId"":""QID1323447063_7""}","{""ImportId"":""QID1323447063_8""}","{""ImportId"":""QID1323447063_11""}","{""ImportId"":""QID1323447053""}","{""ImportId"":""QID1323447065_2""}","{""ImportId"":""QID1323447065_1""}","{""ImportId"":""QID1323447065_3""}","{""ImportId"":""QID1323447065_8""}","{""ImportId"":""QID1323447065_9""}","{""ImportId"":""QID1323447065_4""}","{""ImportId"":""QID1323447065_5""}","{""ImportId"":""QID1323447065_6""}","{""ImportId"":""QID1323447065_7""}","{""ImportId"":""QID137_1""}","{""ImportId"":""QID137_2""}","{""ImportId"":""QID137_3""}","{""ImportId"":""QID137_4""}","{""ImportId"":""QID137_5""}","{""ImportId"":""QID138""}","{""ImportId"":""QID139_1""}","{""ImportId"":""QID139_2""}","{""ImportId"":""QID139_3""}","{""ImportId"":""QID139_4""}","{""ImportId"":""QID139_5""}","{""ImportId"":""QID1323447069""}","{""ImportId"":""QID1323447060_2""}","{""ImportId"":""QID1323447060_1""}","{""ImportId"":""QID1323447060_3""}","{""ImportId"":""QID1323447060_8""}","{""ImportId"":""QID1323447060_9""}","{""ImportId"":""QID1323447058""}","{""ImportId"":""QID1323447045""}","{""ImportId"":""QID1323447044""}","{""ImportId"":""QID1323447043""}","{""ImportId"":""QID1323447042""}","{""ImportId"":""QID1323447070""}","{""ImportId"":""QID1323447048""}","{""ImportId"":""QID1323447068""}","{""ImportId"":""QID1323447054""}","{""ImportId"":""QID1323447054_12_TEXT""}","{""ImportId"":""QID143_TEXT""}","{""ImportId"":""QID92""}","{""ImportId"":""QID93""}","{""ImportId"":""QID93_4_TEXT""}","{""ImportId"":""QID142#1_1""}","{""ImportId"":""QID142#1_2""}","{""ImportId"":""QID142#1_3""}","{""ImportId"":""QID142#1_4""}","{""ImportId"":""QID142#2_1""}","{""ImportId"":""QID142#2_2""}","{""ImportId"":""QID142#2_3""}","{""ImportId"":""QID142#2_4""}","{""ImportId"":""QID95""}","{""ImportId"":""QID96""}","{""ImportId"":""QID97_TEXT""}","{""ImportId"":""QID104""}","{""ImportId"":""QID105_1""}","{""ImportId"":""QID106_1""}","{""ImportId"":""QID106_2""}","{""ImportId"":""QID122_1""}","{""ImportId"":""QID122_2""}","{""ImportId"":""QID122_3""}","{""ImportId"":""QID122_4""}","{""ImportId"":""QID122_5""}","{""ImportId"":""QID122_6""}","{""ImportId"":""QID122_6_TEXT""}","{""ImportId"":""QID123_1""}","{""ImportId"":""QID123_2""}","{""ImportId"":""QID124_4""}","{""ImportId"":""QID124_5""}","{""ImportId"":""QID124_6""}","{""ImportId"":""QID125_1""}","{""ImportId"":""QID125_2""}","{""ImportId"":""QID127""}","{""ImportId"":""QID128""}","{""ImportId"":""QID129_TEXT""}","{""ImportId"":""QID130""}","{""ImportId"":""QID131""}","{""ImportId"":""QID133_TEXT""}","{""ImportId"":""QID134_TEXT""}","{""ImportId"":""QID135#1_1_1""}","{""ImportId"":""QID135#1_2_1""}","{""ImportId"":""QID135#1_3_1""}","{""ImportId"":""QID135#1_4_1""}","{""ImportId"":""QID135#1_5_1""}","{""ImportId"":""QID135#2_1_1""}","{""ImportId"":""QID135#2_2_1""}","{""ImportId"":""QID135#2_3_1""}","{""ImportId"":""QID135#2_4_1""}","{""ImportId"":""QID135#2_5_1""}","{""ImportId"":""QID135#3_1_1""}","{""ImportId"":""QID135#3_2_1""}","{""ImportId"":""QID135#3_3_1""}","{""ImportId"":""QID135#3_4_1""}","{""ImportId"":""QID135#3_5_1""}","{""ImportId"":""QID99_1""}","{""ImportId"":""QID100_1""}","{""ImportId"":""QID101_1""}","{""ImportId"":""QID102_1""}","{""ImportId"":""QID103_1""}","{""ImportId"":""QID141#1_1""}","{""ImportId"":""QID141#1_2""}","{""ImportId"":""QID141#1_3""}","{""ImportId"":""QID141#1_4""}","{""ImportId"":""QID141#1_5""}","{""ImportId"":""QID141#1_6""}","{""ImportId"":""QID108#1_1""}","{""ImportId"":""QID108#1_2""}","{""ImportId"":""QID108#1_3""}","{""ImportId"":""QID108#1_4""}","{""ImportId"":""QID108#1_5""}","{""ImportId"":""QID109""}","{""ImportId"":""QID110_1""}","{""ImportId"":""QID110_2""}","{""ImportId"":""QID111""}","{""ImportId"":""QID112#1_1""}","{""ImportId"":""QID112#1_2""}","{""ImportId"":""QID112#1_3""}","{""ImportId"":""QID112#1_4""}","{""ImportId"":""QID112#1_5""}","{""ImportId"":""QID112#1_6""}","{""ImportId"":""QID112#1_7""}","{""ImportId"":""QID112#1_8""}","{""ImportId"":""QID115""}","{""ImportId"":""QID116_1""}","{""ImportId"":""QID117_1""}","{""ImportId"":""QID119_1""}","{""ImportId"":""QID120""}","{""ImportId"":""Medical Specialty""}","{""ImportId"":""Survey Type""}","{""ImportId"":""Therapeutic Area""}","{""ImportId"":""ProtocolID""}","{""ImportId"":""type""}","{""ImportId"":""network_affiliations""}","{""ImportId"":""fac_to_support_edcp""}","{""ImportId"":""acc_to_overnight_fac""}","{""ImportId"":""accom_latenight_pkpd""}","{""ImportId"":""site_accommodations""}","{""ImportId"":""site_allow_witness""}","{""ImportId"":""has_satellite_loc""}","{""ImportId"":""has_pharmacy""}","{""ImportId"":""source_doc_storage""}","{""ImportId"":""is_emer_power_avail""}","{""ImportId"":""emer_power_loc""}","{""ImportId"":""is_pharmdisp_adm_bdg""}","{""ImportId"":""is_doc_trans_proc""}","{""ImportId"":""is_daily_ded_pharma""}","{""ImportId"":""acc_ltd_to_prep_area""}","{""ImportId"":""has_auth_storcontsub""}","{""ImportId"":""have_lam_flow_hood""}","{""ImportId"":""storage_conditions""}","{""ImportId"":""pharm_temp_moni_loc""}","{""ImportId"":""lab_type""}","{""ImportId"":""time_for_lab_rslts""}","{""ImportId"":""is_lab_cert_avail""}","{""ImportId"":""has_search_patientdb""}","{""ImportId"":""no_patient_db_desc""}","{""ImportId"":""is_phys_on_prem""}","{""ImportId"":""cont_safety_moni""}","{""ImportId"":""des_unblinded_persn""}","{""ImportId"":""does_min_based_or""}","{""ImportId"":""min_based_or_desc""}","{""ImportId"":""has_acc_to_sourcedoc""}","{""ImportId"":""source_doc_type""}","{""ImportId"":""is_esrm_avail""}","{""ImportId"":""can_cta_neg_parallel""}","{""ImportId"":""cta_neg_para_desc""}","{""ImportId"":""req_adtl_comt_apprvl""}","{""ImportId"":""addtl_cmt_app_desc""}","{""ImportId"":""avg_ethirb_aprv_time""}","{""ImportId"":""can_work_para_irbiec""}","{""ImportId"":""signature_type""}","{""ImportId"":""irb_type""}","{""ImportId"":""fire_site_id""}","{""ImportId"":""fire_investigator_id""}","{""ImportId"":""irb_meeting_freq""}","{""ImportId"":""tot_time_comm_rev""}","{""ImportId"":""has_board_cert""}","{""ImportId"":""med_degree_type""}","{""ImportId"":""site_training_rqt""}","{""ImportId"":""is_asian_pp""}","{""ImportId"":""is_pi_or_haw_pp""}","{""ImportId"":""is_asian_indian_pp""}","{""ImportId"":""is_blk_af_ameri_pp""}","{""ImportId"":""is_hisp_latino_pp""}","{""ImportId"":""is_amerind_or_ak_pp""}","{""ImportId"":""is_multiracial""}","{""ImportId"":""is_white_caucasian""}","{""ImportId"":""overnight_fac_desc""}","{""ImportId"":""accom_ln_pkpd_desc""}","{""ImportId"":""firstName""}","{""ImportId"":""lastName""}","{""ImportId"":""email""}","{""ImportId"":""phone""}","{""ImportId"":""investigator_street""}","{""ImportId"":""investigator_postcode""}","{""ImportId"":""investigator_city""}","{""ImportId"":""investigator_state""}","{""ImportId"":""extRef""}","{""ImportId"":""satellite_loc_num""}","{""ImportId"":""no_phys_on_prem_desc""}","{""ImportId"":""no_acc_sourcedoc_des""}","{""ImportId"":""board_cert_desc""}","{""ImportId"":""cont_safetymon_other""}","{""ImportId"":""irb_meeting_freq_oth""}","{""ImportId"":""dedicated_phase_1""}","{""ImportId"":""site_name""}","{""ImportId"":""site_address""}","{""ImportId"":""site_city""}","{""ImportId"":""site_country""}","{""ImportId"":""site_state""}","{""ImportId"":""site_postcode""}","{""ImportId"":""pi_first_name""}","{""ImportId"":""pi_last_name""}","{""ImportId"":""pi_phone""}","{""ImportId"":""pi_email""}","{""ImportId"":""survey_generated_by""}","{""ImportId"":""sdl_site_id""}","{""ImportId"":""mailinglist_id""}","{""ImportId"":""Date""}","{""ImportId"":""Time""}" +2026-05-24 18:25:21,2026-05-24 22:12:05,IP Address,60.240.239.56,100,13603,True,2026-05-24 22:12:05,R_9QJCotESlZBgeFW,Bampton,Peter,peter.bampton@sa.gov.au,,-34.9643,138.5715,gl,EN,Yes,Peter,Bampton,SA Gastrointestinal Services,Gastroenterologist,peter.bampton@sagroup.net.au,61882044964,520 South Road,Kurralta Park,SA,5037,Australia,Yes,Lorelle,Smith,IBD SA,lorelle.smith@sagroup.net.au,,,,,,Lorelle,Smith,Research Manager,lorelle.smith@sagroup.net.au,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,31-45%,16-30%,≤15%,,No,No,,1 study,5,3,2,90,10,0,0,0,0,,0,0,5,70,25,50,50,No,No,,No,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30046544,60517844,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SA Gastrointestinal Services,520 South Road,Kurralta Park,Australia,SA,5037,Peter,Bampton,61882044964,peter.bampton@sa.gov.au,jmorais7@its.jnj.com,135471,CG_3G1ByQZC9nUXySR,25 May 2026,09:42 +2026-05-24 18:24:44,2026-05-24 22:37:03,IP Address,203.0.172.250,100,15139,True,2026-05-24 22:37:04,R_46y7416rpXkMPvz,Thin,Lena,lena.thin@health.wa.gov.au,,-31.9474,115.8648,gl,EN,Yes,Lena,Thin,Fiona Stanley Hospital,Gastroenterology,lena.thin@health.wa.gov.au,61861511154,Robin Warren dr 11,Murdoch,Western Australia,6150,Australia,Yes,Jacqui,Wong,IBD research,fsh.ibdresearch @health.wa.gov.au,0403128519,11 Robin Warren Drive,Murdoch,WA,6150,Jacqui,Wong,Nurse Co-ordinator,jacqueline.wong@health.wa.gov.au,+61404342181,Different from the above,Alissa,Monk,Research Governance officer,smhs.rgo@health.wa.gov.au,61522646,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,31-45%,≤15%,,,Yes,No,,More than 2 studies,4,2,2,80,20,0,0,0,0,,0,100,5,80,15,50,50,No,Yes,Mandarin and Hindi,No,No,"WA is a large state, and many of our patients have to fly in from country regions. It is imperative the cost of their flight and accomodation will be covered",capping to 15% of >3 AT failure may make it hard to recruit bio IR patients,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,false,,,,,,,,,30047914,60229959,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fiona Stanley Hospital,Robin Warren dr 11,Murdoch,Australia,Western Australia,6150,Lena,Thin,61861511154,lena.thin@health.wa.gov.au,jmorais7@its.jnj.com,135463,CG_2YGiuOZqZC7sfQm,25 May 2026,10:07 +2026-05-24 18:26:41,2026-05-25 21:36:16,IP Address,165.86.81.72,100,97774,True,2026-05-25 21:36:16,R_9ASiSSTrKJP6HrG,Croft,Anthony,anthony.croft2@health.qld.gov.au,,-27.4417,153.0197,gl,EN,No,Anthony,Croft,Royal Brisbane and Women's Hospital,Gastroenterology - IBD,anthony.croft2@health.qld.gov.au,61736463456,Butterfield st,Herston,Queensland,4029,Australia,Yes,Alex,Schmidt,RBWH Department of Gastroenterology and Hepatology,IBDTrials@health.qld.gov.au,07 36464273,"Level 9, Ned Hanlon Building, Royal Brisbane and Women's Hospital, Butterfield St",Herston,QLD,4029,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,Reimbursed if PBS criteria are met.,1,,,,46-60%,,,,Yes,Yes,"The need to be intolerant or failing thiopurine will decrease recruitment by over 50% in the Australian context. Suggest revising this to include failure of 5ASA (2g or more of mesalazine daily). ",1 study,6,2,4,81,15,0,0,2,2,Indigenous Australian,0,0,5,70,25,48,52,Yes,No,,Yes,No,"Additional funding for SC hours to identify and pre-screen trial candidates greatly increases our recruitment in previously completed global UC P2 and P3 trials. +",,,,,,,,,,,,,,,,,200,100,50,40,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,5,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,4,,6,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,true,,,,,,,,,30044316,60248658,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Royal Brisbane and Women's Hospital,Butterfield st,Herston,Australia,Queensland,4029,Anthony,Croft,61736463456,anthony.croft2@health.qld.gov.au,jmorais7@its.jnj.com,135468,CG_3esnjV8SKs7BxlE,26 May 2026,09:06 +2026-05-24 18:26:52,2026-05-27 00:14:46,IP Address,147.161.213.1,100,193674,True,2026-05-27 00:14:47,R_94gBehsdvZVP0gp,Garg,Mayur,Mayur.Garg@nh.org.au,,-37.8159,144.9669,gl,EN,No,Mayur,Garg,Northern Health,Gastroenterology,Mayur.Garg@nh.org.au,+61 38 405 2290,185 Cooper st,Epping,Victoria,3076,Australia,Yes,Gloria,Sepe,Gastroenterology,gloria.sepe@nh.org.au,+613 8405 8000,185 Cooper St,Epping,Vic,3076,Gloria,Sepe,Gastroenterology Clinical Trials Coordinator,gloria.sepe@nh.org.au,+61384058000,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,16-30%,16-30%,16-30%,,Yes,No,,1 study,5,4,1,55,40,5,0,0,0,,0,100,1,70,29,50,50,Yes,Yes,"Arabic, Macedonian, Punjabi",Yes,No,,,,,,,,,,,,,,,,,,700,200,450,150,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,4,3,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,6,,6,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30047872,60433127,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Northern Hospital Epping,Cooper st 185,Epping,Australia,Victoria,3076,Mayur,Garg,+61 38 405 2290,Mayur.Garg@nh.org.au,jmorais7@its.jnj.com,135472,CG_1nPxoI5U5gJbx3B,27 May 2026,11:44 +2026-05-24 18:26:28,2026-05-27 05:51:23,IP Address,76.66.128.34,100,213895,True,2026-05-27 05:51:24,R_4n7yEFcU2XCdZam,O'Connor,Sam,oconnorsama@gmail.com,,43.7306,-79.4217,gl,EN,No,Sam,O'Connor,"Gallipoli Medical Research, Greenslopes Private Hospital",Gastroenterology,oconnorsama@gmail.com,+61733241500,Newdegate Street,Greenslopes,Queensland,4120,Australia,Yes,To be assigned - Institute has many research nurses and one will be assigned to this trial post selection,To be assigned - Institute has many research nurses and one will be assigned to this trial post selection,To be assigned - Institute has many research nurses and one will be assigned to this trial post selection,To be assigned - Institute has many research nurses and one will be assigned to this trial post selection,,,,,,Ajani,Jeyakumar,"TIDHI, Clinical Operations Manager",ajeyakumar@tidhi.ca,+1-647-812-2113,Different from the above,Rebecca,Morgan,,MorganRebecca@gallipoliresearch.org.au,,Other,Ajani,Jeyakumar,"TIDHI, Clinical Operations Manager",ajeyakumar@tidhi.ca,+1-647-812-2113,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,31-45%,16-30%,≤15%,,Yes,No,,0 studies,5,1,4,75,15,1,0,0,9,,1,99,0,85,15,49,51,No,No,,Yes,No,This will be a new site under the TIDHI Site Management Organization. TIDHI will provide site level support. The Institution conducts clinical trials in Oncology and have experienced staff to support this trial,No,,,,,,,,,,,,,,,,250,175,75,50,0,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,0,0,None,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,3,,6,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,77982,77982,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Queensland Gastroenterology, Greenslopes Private Hospital",Newdegate Street,Greenslopes,Australia,Queensland,4120,Sam,O'Connor,+61733241500,oconnorsama@gmail.com,jmorais7@its.jnj.com,135470,CG_ZKasduJxJywxMqd,27 May 2026,17:21 +2026-05-27 03:50:51,2026-05-27 08:00:32,IP Address,176.0.54.161,100,14981,True,2026-05-27 08:00:33,R_2QnFiDgyYdNzyRa,Schubert,Stefan,drstefanschubert@email.de,,52.5203,13.3849,gl,EN,Yes,Stefan,Schubert,MVZ für Gastroenterologie am Bayerischen Platz,GASTROENTEROLOGY IBD,drstefanschubert@email.de,004930814591920,58 Innsbrucker Straße,Berlin,Berlin,10825,Germany,Yes,"Concetta ","Casali Clack ","Gastrostudien ",studynurse.concetta@web.de,,Innsbrucker Str. 58,"Berlin ",Berlin,14163,"Concetta ",Casali Clack,,,,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,31-45%,31-45%,16-30%,≤15%,Yes,No,,0 studies,6,3,3,90,10,0,0,0,0,,0,0,0,100,0,55,45,Yes,No,,Yes,No,None,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78013,78013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MVZ für Gastroenterologie am Bayerischen Platz,58 Innsbrucker Straße,Berlin,Germany,Berlin,10825,Stefan,Schubert,004930814591920,drstefanschubert@email.de,mraddatz@its.jnj.com,135751,CG_DFQqdhOJrlwIJ2x,27 May 2026,19:30 +2026-05-27 03:42:28,2026-05-28 00:32:45,IP Address,141.76.249.180,100,75016,True,2026-05-28 00:32:46,R_2WPA03BN8qAVTbD,Schmelz,Renate,schmelz.studien@ukdd.de,,51.054,13.7447,gl,EN,Yes,Renate,Schmelz,Universitatsklinikum Carl Gustav Carus Dresden,GAstroenterology,schmelz.studien@ukdd.de,493514582986,Fetscherstraße 74,Dresden,Saxony,01307,Germany,Yes,Eva,Metzler,Universitatsklinikum Carl Gustav Carus Dresden,eva.metzler@ukdd.de,035145812986,Fetscherstr. 74,Dresden,Sachsen,01307,Eva,Metzler,,eva.metzler@ukdd.de,035145812986,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,≤15%,16-30%,,,Yes,No,,2 studies,3,2,1,100,0,0,0,0,0,,0,100,0,90,10,50,50,Yes,No,,No,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,false,,,,,,,,,30029711,60526299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Universitatsklinikum Carl Gustav Carus Dresden,Fetscherstraße 74,Dresden,Germany,Saxony,01307,Renate,Schmelz,493514582986,schmelz.studien@ukdd.de,mraddatz@its.jnj.com,135749,CG_10Tcr5OhaD40Sw2,28 May 2026,12:02 +2026-05-24 18:25:48,2026-05-28 00:54:18,IP Address,138.44.6.178,100,282509,True,2026-05-28 00:54:19,R_9gN8xIgOEHHVCzS,Leong,Rupert,rupert.leong@sswahs.nsw.gov.au,,-33.8582,151.127,gl,EN,Yes,Rupert,Leong,Macquarie University Hospital,Gastro IBD,rupertleong@hotmail.com,61298123880,Technology Place 2,Macquarie Park,New South Wales,2109,Australia,Yes,Esther,Lee,Macquarie University Clinical Trials Unit,esther.lee@muh.org.au,0466 505 463,"Faculty of Medicine, Health and Human Sciences Clinical Trials Unit Level 3, 75 Talavera Road",Macquarie University,NSW,"2109 ",,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,46-60%,31-45%,,,No,No,,0 studies,8,6,2,80,20,0,0,0,0,,0,0,0,75,25,50,50,Yes,No,,Yes,Yes,"N/A conducting several JNJ studies eg GALAXI, DUET ENCORE","Clarify the washout for immunomodulators as 12 weeks is unnecessarily long. Are patients on tioguanine permitted? ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30154962,60454037,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Macquarie University Hospital,Technology Place 2,Macquarie Park,Australia,New South Wales,2109,Rupert,Leong,61297677321,rupert.leong@sswahs.nsw.gov.au,jmorais7@its.jnj.com,135467,CG_1ezxWDBWj4WtIz1,28 May 2026,12:24 +2026-05-27 03:53:29,2026-05-28 03:43:54,IP Address,193.175.73.195,100,85825,True,2026-05-28 03:43:55,R_2Fg5aY51gKgOI7t,Siegmund,Britta,britta.siegmund@charite.de,,52.5203,13.3849,gl,EN,Yes,Britta,Siegmund,Charite Universitatsmedizin Berlin - Campus Benjamin Franklin,Gastroenterology,britta.siegmund@charite.de,4930450514342,Hindenburgdamm 30,Berlin,Berlin,12203,Germany,Yes,Brigit,Roeders,"Division of Gastroenterology, INfectious Diseases, Rheumatology",brigit.roeders@charite.de,+49 30 450 514135,Hindenburgdamm 30,Berlin,Berlin,12203,Patricia,Schaafs,Study Nurse,patricia.schaafs@charite.de,+49 30 450 614 876,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,,,,46-60%,,,,No,Yes,"Prior anti-p19 Exposure will stay a problem in recruitment as well as prior therapy failures, it is not entirely clear what the limit is here",2 studies,2,2,0,98,1,1,0,0,0,,0,100,5,85,10,60,40,Yes,Yes,"English, Turkish",Yes,No,"advertisement ",none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30147560,60073636,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Charite Universitatsmedizin Berlin - Campus Benjamin Franklin,Hindenburgdamm 30,Berlin,Germany,Berlin,12203,Britta,Siegmund,4930450514342,britta.siegmund@charite.de,mraddatz@its.jnj.com,135742,CG_33Cj9veUaxf7ITO,28 May 2026,15:13 +2026-05-27 01:54:59,2026-05-29 00:19:11,IP Address,193.197.70.13,100,167051,True,2026-05-29 00:19:11,R_2koVUrL4MQ3COkA,Klaus,Jochen,jochen.klaus@uniklinik-ulm.de,,48.4179,9.9656,gl,EN,Yes,Jochen,Klaus,Universitatsklinikum Ulm (University Hospital Of Ulm),Gastroenterology,jochen.klaus@uniklinik-ulm.de,4973150044609,Albert-Einstein-Allee 23,Ulm,Baden-Württemberg,89081,Germany,Yes,Jochen,Klaus,Uniklinik Ulm,jochen.klaus@uniklinik-ulm.de,073150044686,Albert-Einstein-Allee 23,Ulm,Baden-Württemberg,89081,Claudia,Link,Study Coordinator,claudia.link@uniklinik-ulm.de,073150044686,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,16-30%,≤15%,,,Yes,No,,2 studies,8,4,4,100,0,0,0,0,0,,0,0,0,95,5,50,50,Yes,No,,Yes,No,as usual,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,true,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,,,,,,,,30147211,60002180,,,,,,,,,,,,,,Overnight stay in the hospital ward,,,,,,,,,,,,,See Details in ESDCAQ of Sponsor.,,,,true,Universitatsklinikum Ulm (University Hospital Of Ulm),Albert-Einstein-Allee 23,Ulm,Germany,Baden-Württemberg,89081,Jochen,Klaus,4973150044609,jochen.klaus@uniklinik-ulm.de,llaufner@its.jnj.com,135737,CG_1BQv05aHuHvt718,29 May 2026,11:49 +2026-05-29 02:34:16,2026-05-29 04:07:12,IP Address,217.151.148.214,100,5575,True,2026-05-29 04:07:12,R_8GvrTI9FlFmLlcS,Kuehbacher,Tanja,t.kuehbacher@medius-kliniken.de,,49.4258,8.4285,gl,EN,Yes,Tanja,Kuehbacher,St. Marien und St. Annastiftskrankenhaus,Gastroenterology,tanja.kuehbacher@st-marienkrankenhaus.de,+49+62155012224,Salzburger Strasse 15 St. Marienkrankenhaus Klinik fuer Innere Medizin Gastroenterologie Kardiologie Pneumologie Palliativmedizin Diabetologie,Ludwigshafen am Rhein,Rhineland-Palatinate,67067,Germany,Yes,Tina,Dr. Sartorius,St. Marien-und Annastiftskrankenhaus,tina.sartorius@st-marienkrankenhaus.de,+49+62155012599,Salzburgerstr.15,Ludwigshafen a. R.,Rheinland-Pflaz,67067,Tina,Dr. Sartorius,Coordinator,tina.sartorius@st-marienkrankenhaus.de,+49+62155012599,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,>60%,31-45%,16-30%,≤15%,Yes,No,,2 studies,5,2,3,98,1,1,0,0,0,,1,99,10,75,15,50,50,Yes,No,,Yes,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30031951,60160764,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,St. Marien und St. Annastiftskrankenhaus,Salzburger Strasse 15 St. Marienkrankenhaus Klinik fuer Innere Medizin Gastroenterologie Kardiologie Pneumologie Palliativmedizin Diabetologie,Ludwigshafen am Rhein,Germany,Rhineland-Palatinate,67067,Tanja,Kuehbacher,4970227821400,tanja.kuehbacher@st-marienkrankenhaus.de,mraddatz@its.jnj.com,135752,CG_3QFOXKsyqrtxgPc,29 May 2026,15:37 +2026-05-27 03:28:50,2026-05-30 07:47:50,IP Address,95.91.192.58,100,274739,True,2026-05-30 07:47:50,R_8ri1WZ6eBmwkagG,Seidler,Ursula,seidler.ursula@mh-hannover.de,,52.1377,9.9759,gl,EN,Yes,Ursula,Seidler,Medizinische Hochschule Hannover,Gastroenterology- IBD,seidler.ursula@mh-hannover.de,495115329427,Carl-Neuberg-Straße 1,Hannover,Lower Saxony,30625,Germany,Yes,Swetlana,Schek,same as PI,schek.swetlana@mh-hannover.de,+495115323988,,,,,Ursula,Seidler,PI,seidler.ursula@mh-hannover.de,017615323355,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,16-30%,16-30%,≤15%,≤15%,Yes,No,,1 study,8,4,4,80,18,2,0,0,0,,5,95,5,90,5,55,45,Yes,Yes,"German, Turkish, Russian, English",Yes,Yes,rapid contract negotiations,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30030847,60546013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Medizinische Hochschule Hannover,Carl-Neuberg-Straße 1,Hannover,Germany,Lower Saxony,30625,Ursula,Seidler,495115329427,seidler.ursula@mh-hannover.de,mraddatz@its.jnj.com,135733,CG_231MOgVmBP7stpo,30 May 2026,19:17 +2026-05-27 03:39:57,2026-05-31 03:10:39,IP Address,185.104.138.128,100,343842,True,2026-05-31 03:10:39,R_2zIlcoaRure9Sq1,Ehehalt,Robert,ehehalt@hd-gastro.de,,51.2993,9.491,gl,EN,No,Robert,Ehehalt,Gastroenterology Outpatient Clinic Prof. Ehehalt,Gastroenterology,re@hd-gastro.de,00491776257712,Bergheimer- Str. 59-61,Heidelberg,Baden-Württemberg,69115,Germany,Yes,Wolfgang,Reindl,GI Ouptatient Clinic,wr@hd-gastro.de,00491776257712,Bergheimer-Str- 59-61,Heidelberg,BW,69115,Bettina,Hartmann,Study Nurse,th@hd-gastro.de,,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,>60%,16-30%,≤15%,≤15%,Yes,No,,1 study,6,4,2,85,10,5,0,0,0,,10,90,5,50,45,50,50,Yes,Yes,"German, English",Yes,No,,,,,,,,,,,,,,,,,,300,30,220,80,50,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,3,2,3-5,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Central and Local,4,4,1,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30025823,60544699,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gastroenterology Outpatient Clinic Prof. Ehehalt/Dr. Hemstäd,Burgstraße 61,Heidelberg,Germany,Baden-Württemberg,69121,Robert,Ehehalt,49622125346,ehehalt@hd-gastro.de,mraddatz@its.jnj.com,135745,CG_3Rxzx5ddfGSXJAT,31 May 2026,14:40 +2026-05-24 18:24:17,2026-05-31 16:29:48,IP Address,202.151.32.19,100,597931,True,2026-05-31 16:29:49,R_4Cx2mrpTJNUMQ7y,Christensen,Britt,britt.christensen@mh.org.au,,-37.8335,145.0012,gl,EN,Yes,Britt,Christensen,"Melbourne Gut Clinic, Epworth Hospital","gastroenterologist ",britt.christensen@mh.org.au,+61 41 639 9988,"St 5.3, 126 Grey St",East Melbourne,Victoria,3002,Australia,Yes,Ashleigh,Poh,Epworth HealthCare,ashleigh.poh@epworth.org.au,0421485710,89 Bridge Road,Richmond,VIC,3121,Ashleigh,Poh,Research Program Manager,ashleigh.poh@epworth.org.au,0421485710,Same as above,,,,,,Other,Ashleigh,Poh,Research Program Manager,ashleigh.poh@epworth.org.au,0421485710,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,16-30%,,,No,No,,0 studies,7,3,4,90,8,2,0,0,0,,5,95,10,70,20,40,60,No,No,,No,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30163663,60444833,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Melbourne Gut Clinic, Epworth Hospital","St 5.3, 126 Grey St",East Melbourne,Australia,Victoria,3002,Britt,Christensen,+61 41 639 9988,britt.christensen@mh.org.au,jmorais7@its.jnj.com,135469,CG_3gXBr6enyhRpzFE,1 Jun 2026,03:59 +2026-05-31 13:29:19,2026-05-31 17:45:39,IP Address,181.169.100.54,100,15380,True,2026-05-31 17:45:39,R_70VeLRVVYKMv9LU,Balderramo,Domingo,dcbalderramo@yahoo.com,,-31.3487,-64.3996,gl,EN,Yes,Domingo,Balderramo,Hospital Privado Universitario de Córdoba,Gastroenterology,dcbalderramo@yahoo.com,543514688837,Naciones Unidas 346,Córdoba,Córdoba,X5016,Argentina,Yes,Francisca,Goycoolea,Hospital Privado Universitario de Córdoba,francisca.goycoolea@hospitalprivadosa.com.ar,+54935146888200,"Friuli 2786, Barrio Parque Vélez Sársfield",Cordoba,Córdoba,5016,Francisca,Goycoolea,SC,francisca.goycoolea@hospitalprivadosa.com.ar,+5493516064961,Same as above,,,,,,Principal Investigator,,,,,,,,Yes,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,31-45%,16-30%,,,No,No,,1 study,2,1,1,100,0,0,0,0,0,,100,0,0,70,30,50,50,Yes,No,,No,Yes,Improve recruitmen through local (city) derivations,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,,,,,,,,,,30129613,60185068,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Privado Universitario de Córdoba,Naciones Unidas 346,Córdoba,Argentina,Córdoba,X5016,Domingo,Balderramo,543514688837,dcbalderramo@yahoo.com,zpatrign@its.jnj.com,136285,CG_3PGBlY7bHTfgjfP,1 Jun 2026,05:15 +2026-05-31 14:22:31,2026-05-31 20:30:16,IP Address,72.187.245.74,100,22065,True,2026-05-31 20:30:16,R_7MWAOBZ03MhgUEy,De Maria,Julio,Juliodm9@hotmail.com,,27.4843,-82.5813,gl,EN,Yes,Julio,De Maria,Global Psy Asociacion Civil,Gastroenterologia,Juliodm9@hotmail.com,5492214005154,1075 Calle 67,La Plata,Provincia de Buenos Aires,B1904,Argentina,Yes,Julio,De Maria,Hospital el cruce,juliodemaria0@gmail.com,02214005154,Av calchaqui,Varela,Buenos Aires,1896,Julio,De Maria,Pi,juliodemaria0@gmail.com,02214005154,Same as above,,,,,,Principal Investigator,,,,,,,,Yes,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,46-60%,31-45%,≤15%,≤15%,Yes,No,,0 studies,2,1,1,80,0,0,0,0,20,,95,5,0,30,70,50,50,Yes,No,,No,No,No,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,136387,136387,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Global Psy Asociacion Civil,1075 Calle 67,La Plata,Argentina,Provincia de Buenos Aires,B1904,Julio,De Maria,5492214005154,Juliodm9@hotmail.com,zpatrign@its.jnj.com,136387,CG_1dfYMri2af1P3j2,1 Jun 2026,08:00 +2026-05-24 18:25:34,2026-05-31 23:39:28,IP Address,165.225.233.5,100,623634,True,2026-05-31 23:39:29,R_4js8jn7iIsOcfZa,Corte,Crispin,crispincorte@me.com,,-33.8672,151.1997,gl,EN,Yes,Crispin,Corte,Royal Prince Alfred Hospital,Gastroenterology,crispincorte@me.com,61295198689,Missenden rd,Sydney,New South Wales,2050,Australia,Yes,Lisa,Lo,Gastroenterology,lisa.lo@health.nsw.gov.au,02 9515 7383,"Level 9 West, Building 75, Royal Prince Alfred Hospital, Missenden Road",Camperdown,NSW,2050,Lisa,Lo,Clinical Trials Coordinator,lisa.lo@health.nsw.gov.au,"02 9515 7383 ",Same as above,,,,,,Other,"Daniel ",Lightowler,Clinical Nurse Consultant,Daniel.Lightowler@health.nsw.gov.au,0295157829,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,16-30%,≤15%,,,Yes,No,,1 study,4,3,1,60,30,0,0,0,10,,1,99,5,80,15,50,50,Yes,Yes,"Mandarin, Spanish, Vietnames",Yes,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30150943,60189420,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Royal Prince Alfred Hospital,Missenden rd,Sydney,Australia,New South Wales,2050,Crispin,Corte,61295198689,crispincorte@me.com,jmorais7@its.jnj.com,135466,CG_3rN7CywNovc3EyV,1 Jun 2026,11:09 +2026-05-31 13:33:51,2026-06-01 06:59:28,IP Address,181.28.85.125,100,62736,True,2026-06-01 06:59:28,R_7mtdnuQTbrqVH8Z,Rausch,Astrid,astridrausch@hotmail.com,,-36,-59.9964,gl,EN,Yes,Astrid,Rausch,Hospital Britanico de Buenos Aires,gastroenteroogist,astridrausch@hotmail.com,+54 115 504 1140,Perdriel 74,Buenos Aires,Buenos Aires,C1280,Argentina,No,,,,,,,,,,Antonella,Ferrero,Administrative,aferrero@hbritanico.com.ar,+5491127698713,Same as above,,,,,,Principal Investigator,,,,,,,,Yes,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,31-45%,16-30%,≤15%,≤15%,No,No,,0 studies,4,2,2,100,0,0,0,0,0,,100,0,5,80,15,50,50,Yes,No,,No,No,none,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,true,,,,,,,,,,,,,,,,,,,,,,,,,true,,true,,,,,,,,,,,30115408,60595298,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,Hospital Britanico de Buenos Aires,Perdriel 74,Buenos Aires,Argentina,Buenos Aires,C1280,Astrid,Rausch,+54 115 504 1140,astridrausch@hotmail.com,zpatrign@its.jnj.com,136286,CG_10Noh11DWX5UaG2,1 Jun 2026,18:29 +2026-05-31 14:11:23,2026-06-01 07:37:49,IP Address,200.69.244.253,100,62786,True,2026-06-01 07:37:50,R_5Gv5I7DQdMYlDrN,Calcagno,Ramiro,dr.ramirovcalcagno@gmail.com,,-34.6049,-58.4455,gl,EN,Yes,Ramiro,Calcagno,Instituto de Investigacion Clinica T y T,GASTROENTEROLOGY,dr.ramirovcalcagno@gmail.com,+54 91 13 401 9925,Av Acoyte 76,Buenos Aires,C A B A,C1405,Argentina,Yes,CAMILA,ASENZO,TYT,ASENZO.CAMILA@GMAIL.COM,,,,,,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,Yes,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,16-30%,≤15%,≤15%,≤15%,No,No,,0 studies,3,2,1,100,0,0,0,0,0,,100,0,0,70,30,60,40,Yes,No,,Yes,No,,NO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30161911,60817813,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Instituto de Investigacion Clinica T y T,Av Acoyte 76,Buenos Aires,Argentina,C A B A,C1405,Ramiro,Calcagno,+54 91 13 401 9925,dr.ramirovcalcagno@gmail.com,zpatrign@its.jnj.com,136293,CG_2zvdns2CXuI9g93,1 Jun 2026,19:07 +2026-05-31 13:18:02,2026-06-01 12:33:55,IP Address,181.110.142.89,100,83753,True,2026-06-01 12:33:56,R_1sAfpWIJ6BB8lwi,Fuxman,Claudia,cfuxman@ffavaloro.org,,-36,-59.9964,gl,EN,Yes,Claudia,Fuxman,Centro de Investigación y Prevención Cardiovascular (CIPREC),Gastroenterology,cfuxman@ffavaloro.org,5491161417488,Avenida Pueyrredón 1746,Buenos Aires,Buenos Aires,C1119,Argentina,Yes,Paola,Hut,CIPREC,ciprec.paola@gmail.com,+54 9 11 3199-1324,,,,,,,,,,Different from the above,"Fernando ",Guerloy,MD,fguerlloy.ciprec@gmail.com,+54 9 11 5388-243,Principal Investigator,,,,,,,,Yes,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,,,,16-30%,,,,No,No,,1 study,3,1,2,100,0,0,0,0,0,,100,0,0,70,30,50,50,Yes,No,,No,No,,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,true,,,,,,,,,30113910,60118132,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centro de Investigación y Prevención Cardiovascular (CIPREC),Avenida Pueyrredón 1746,Buenos Aires,Argentina,Buenos Aires,C1119,Claudia,Fuxman,5491161417488,cfuxman@ffavaloro.org,zpatrign@its.jnj.com,136283,CG_3LjYzAmpvjDMClW,2 Jun 2026,00:03 +2026-06-01 03:51:57,2026-06-02 05:18:05,IP Address,87.126.134.34,100,91568,True,2026-06-02 05:18:06,R_23X0R5reUZx7bUm,Petrov,Asen,dr_assenp@abv.bg,,42.6826,23.3223,gl,EN,No,Asen,Petrov,Acibadem City Clinic University Multiprofile Hospital for Active Treatment,"Gastroenterologist ",dr_assenp@abv.bg,359896889557,"Boulevard ""Tsarigradsko shose"" 66A",Sofia,Sofia City Province,1784,Bulgaria,Yes,Georgi,Vlahov,Acibadem City Clinic,georgi.vlahov@acibademcityclinic.bg,0884246669,,Sofia,,1113,Georgi,Vlahov,SC,georgi.vlahov@acibademcityclinic.bg,0884993718,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,,,,,,,,Yes,No,,0 studies,5,3,2,100,0,0,0,0,0,,0,100,0,95,5,50,50,Yes,No,,No,No,"No particular support is required at this time. The center has an established patient population with long medical histories who rely on the expertise of our specialists. In addition, treatment-naïve patients are frequently referred to or seek care at our center based on the positive reputation of the study team and the hospital. All other study-related procedures and operational requirements are standard for our center, and we are experienced in conducting clinical trials. Of course, should any specific issues arise during the study, any support and guidance from J&J would be greatly appreciated.","Regarding Q31- It is difficult to estimate what percentage of patients receive vedolizumab as a first-, second-, third-, or fourth-line treatment, as this depends on the individual patient's disease history, previous treatments, and clinical circumstances. +In our experience, vedolizumab is most commonly used as one of the first advanced therapies after a patient has failed conventional treatment. Therefore, it is usually prescribed as a first or second advanced therapy, and most often as a second-line treatment following inadequate response or intolerance to conventional therapies (per PI confirmation on 4Jun26)",,,,,,,,,,,,,,,,40,8,20,12,8,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,5,7,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,2,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30127885,60086720,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Acibadem City Clinic University Multiprofile Hospital for Active Treatment,"Boulevard ""Tsarigradsko shose"" 66A",Sofia,Bulgaria,Sofia City Province,1784,Asen,Petrov,359896889557,dr_assenp@abv.bg,imitkova@its.jnj.com,136278,CG_1ouPr6PsjlLXy9Z,2 Jun 2026,16:48 +2026-06-01 11:23:00,2026-06-02 06:06:08,IP Address,77.221.43.224,100,67388,True,2026-06-02 06:06:09,R_8eimAMCz1HrCupH,Takats,Alajos Tamas,takatsal@gmail.com,,46.905,19.6958,gl,EN,No,Alajos Tamas,Takats,"Endomedix Kft./Budapest Gasztroenterológiai Központ ",gastroenterologist,alajos.takats.study@endomedix.hu,06309922940,Esztergomi ut 66 A epulet fszt 3,Budapest,Budapest,1138,Hungary,Yes,Beáta,Berta,Endomedix Kft./Budapest Gasztoenterológiai Központ,berta.beata@endomedix.hu,06202365614,Esztergomi út 66. A. ép. Fsz. 3.,Budapest,Budapest,1138,Csaba,Jaczina,Clinical Operation Manager,jaczina.csaba@endomedix.hu,06204744035,Same as above,,,,,,Other,Csaba,Jaczina,Clinical Operation Manager,jaczinamcsaba@gmail.com,06204744035,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,"Vedolizumab (active ingredient) is a biologic medication marketed under the brand name Entyvio, which is subsidized in Hungary by the NEAK (National Health Insurance Fund Management) within the framework of increased or highlighted indication-bound financing.",,,,,,,,,Yes,No,,2 studies,3,0,3,100,0,0,0,0,0,,0,0,0,80,20,50,50,Yes,No,,Yes,No,"A brief summary in Hungarian of the expected patient pool to support referrals, as well as financial support for referrals in the form of a referral fee.","Dr. Takáts confirmed that responses provided for Q31, Q60, and Q61 are correct. +The PI explained that the patient population is primarily bio-naïve and has not received biologics previously. Patients with prior biologic exposure are mostly clinical trial participants. +Since site is a private center for UC treatment, they do not typically initiate biologic treatments. Advanced therapy for UC is typically managed at bigger hospitals or designated clinical centers. It has also been confirmed that the PI, Dr. Takáts, previously worked in hospital and UC treatment center and has strong experience with advanced biologic treatments for UC patients (clarification provided by PI on 03June2026)",,,,,,,,,,,,,,,,300,280,10,0,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,1,≥6,Yes,Yes,No,No,Yes,No,Yes,Yes,Local,,4,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30110241,60927530,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Endomedix Diagnosztikai Kozpontok - Gasztroenterologia Kozpont - Budapest XIII.,Esztergomi ut 66 A epulet fszt 3,Budapest,Hungary,Budapest,1139,Alajos Tamas,Takats,36309922940,takatsal@gmail.com,anochta@its.jnj.com,136247,CG_3sd1ijnJtlJwmNK,2 Jun 2026,17:36 +2026-06-01 08:56:03,2026-06-02 08:06:49,IP Address,78.83.237.6,100,83445,True,2026-06-02 08:06:49,R_8R1lN9HTlUXtaRp,Popadiyn,Ivan Emilov,ivan.popadiin@heraclinics.com,,42.6826,23.3223,gl,EN,No,Ivan Emilov,Popadiyn,Medical Center Hera EOOD,Gastroenterologis,ivan.popadiin@heraclinics.com,359024048656,"ulitsa ""Klisura"" 20",Sofia,Sofia City Province,1510,Bulgaria,No,,,,,,,,,,Stoyan,Isaev,Associate Project Lead,stoyan.isaev@heraclinics.com,+359884941998,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"No, I am not interested",Insufficient patient population,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30104312,60868576,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Medical Center Hera EOOD,"ulitsa ""Klisura"" 20",Sofia,Bulgaria,Sofia City Province,1510,Ivan Emilov,Popadiyn,359024048656,ivan.popadiin@heraclinics.com,imitkova@its.jnj.com,136274,CG_u8tgCkArKfvlfAR,2 Jun 2026,19:36 +2026-06-01 09:04:45,2026-06-02 13:07:02,IP Address,79.129.30.244,100,100936,True,2026-06-02 13:07:02,R_8orhJ4BnFufJxiF,Dimitrov,Dimitar,dr.dimitar.dimitrov.md@gmail.com,,37.9842,23.7353,gl,EN,No,Dimitar,Dimitrov,20 Diagnostic and Consultation Center (DCC) - Sofia,Gastroenterology,dimitar.dimitrov.ge@gmail.com,+3598778304281,Blvd. \Gen. Stefan Toshev\ No 15-17,Sofia,Sofia City Province,1618,Bulgaria,Yes,Radostina,Angelova,DCC XX Sofia,r.ivanova@rdservices.org,+359892226074,"15, General Stefan Toshev str.",Sofia,N/a,1000,Radostina,Angelova,SC,R.ivanova@rdservices.org,+359892226074,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,1,1,≤15%,≤15%,≤15%,≤15%,No,No,,1 study,4,1,3,100,0,0,0,0,0,,0,100,10,65,25,55,45,Yes,No,,Yes,No,N/a,No,,,,,,,,,,,,,,,,40,30,10,1,2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,6,6,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,8,,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30104559,60856123,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,20 Diagnostic and Consultation Center (DCC) - Sofia,Blvd. \Gen. Stefan Toshev\ No 15-17,Sofia,Bulgaria,Sofia City Province,1618,Anna,Dimova,+3598778304281,dr.dimitar.dimitrov.md@gmail.com,imitkova@its.jnj.com,136270,CG_4OT8FNtTVthDIJ3,3 Jun 2026,00:37 +2026-06-02 13:38:04,2026-06-02 15:37:14,IP Address,170.78.119.19,100,7150,True,2026-06-02 15:37:14,R_7lIOWmSsZtWc2nn,Parra,Rogério,rogeriosparra@gmail.com,,-21.1746,-47.7996,gl,EN,No,Rogério,Parra,Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP,IBD,rogeriosparra@gmail.com,5516981644244,Avenida Bandeirantes 3900,Ribeirão Preto,São Paulo,14015-130,Brazil,Yes,Jaqueline,Carias,USP,jcarias@hcrp.usp.br,,,,,,Jaqueline,Carias,coordinator,"jcarias@hcrp.usp.br,",,Different from the above,Henrique,Pereira,,haspereira@hcrp.usp.br,,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,16-30%,≤15%,≤15%,No,No,,2 studies,6,4,2,80,0,20,0,0,0,,100,0,10,70,20,45,55,Yes,No,,Yes,No,Dedicated coordinators (to help),No,,,,,,,,,,,,,,,,450,10,350,50,8,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,20,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,12,16,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,,,,,,,,,,30127824,60151886,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP,Avenida Bandeirantes 3900,Ribeirão Preto,Brazil,São Paulo,14015-130,Rogerio,Parra,5516981644244,rogeriosparra@gmail.com,gcompian@its.jnj.com,136677,CG_5BWnJYAtQAXJalb,3 Jun 2026,03:07 +2026-05-27 03:54:53,2026-06-03 02:08:44,IP Address,141.35.213.35,100,598430,True,2026-06-03 02:08:45,R_2EB0dRXgsNs5yzc,Stallmach,Andreas,andreas.stallmach@med.uni-jena.de,,50.8929,11.5963,gl,EN,Yes,Andreas,Stallmach,Universitatsklinikum Jena,"Internal Medicine, Gastroenterology",andreas.stallmach@med.uni-jena.de,4936419324220,Am Klinikum 1,Jena,Thuringia,07747,Germany,Yes,Anja,Schauer,Jena University Hospital,anja.schauer@med.uni-jena.de,+4936419324582,Am Klinikum 1,Jena,,07747,Anja,Schauer,Study/Research-Coordinator,anja.schauer@med.uni-jena.de,+4936419324582,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,46-60%,,,Yes,No,,2 studies,6,5,1,98,2,0,0,0,0,,0,100,0,70,30,50,50,Yes,Yes,english,Yes,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,true,,,,,,,,,,,true,true,,,"1,2,5",,,,,,,,,,,,false,,,,,,,,,,,30147156,60511127,,,,,,,,,,,,,,inpatient area,,,,,,,,,,,,,No access to eSource possible for monitoring purposes. Certified copies will be generated and cross-checks via over the shoulder is common sense.,,,,true,Universitatsklinikum Jena,Am Klinikum 1,Jena,Germany,Thuringia,07747,Andreas,Stallmach,4936419324220,andreas.stallmach@med.uni-jena.de,mraddatz@its.jnj.com,135744,CG_Xk2fEH1GHB6MOAh,3 Jun 2026,13:38 +2026-06-02 01:02:04,2026-06-03 03:00:36,IP Address,91.228.248.251,100,93512,True,2026-06-03 03:00:36,R_80dEQbe1y661oUU,Levartovsky,Asaf,asafLevartovsky.research@sheba.health.gov.il,,31.9829,34.8519,gl,EN,Yes,Asaf,Levartovsky,Sheba Medical Center,gastroenterology,asafLevartovsky.research@sheba.health.gov.il,972523894508,Derech Sheba 2,Ramat Gan,Tel Aviv,52621,Israel,No,,,,,,,,,,sandra,neuman,sc,sandra.neuman@sheba.health.gov.il,97235307072,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,31-45%,31-45%,≤15%,≤15%,Yes,No,,2 studies,3,0,3,100,0,0,0,0,0,,0,100,0,100,0,50,50,Yes,No,,No,No,we enjoy with J&J,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,false,,,,,,,,,,,,,,,,,,,,,,,,,false,,true,,,,,,,,,,,30104652,60736504,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,Sheba Medical Center,Derech Sheba 2,Ramat Gan,Israel,Tel Aviv,52621,Asaf,Levartovsky,972523894508,asafLevartovsky.research@sheba.health.gov.il,bmayer1@its.jnj.com,135865,CG_2319I8z2wzaOSRf,3 Jun 2026,14:30 +2026-06-01 03:43:27,2026-06-03 04:40:45,IP Address,95.43.221.38,100,176238,True,2026-06-03 04:40:46,R_8JCDkiUY0nlCJDH,Tankova,Ludmila,drtankova@abv.bg,,42.6826,23.3223,gl,EN,No,Ludmila,Tankova,Diagnostic and Consulting Center Convex EOOD,Gastroenterology,drtankova@abv.bg,359888932556,Ulitsa Sinanishko Ezero 11a,Sofia,Sofia City Province,1680,Bulgaria,Yes,Yana,Lozanova,"Diagnostics and Consultation Center Convex ",yana@clinical-trials-bulgaria.com,+359884297644,"11A Sinanishko ezero str. ",Sofia,Sofia,1680,"Yana ",Lozanova,"Site Manager ",yana@clinical-trials-bulgaria.com,+359884297644,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,,,,>60%,,,Yes,No,,1 study,2,1,1,100,0,0,0,0,0,,0,100,0,80,20,50,50,Yes,No,,No,No,None for now. Thank you!,"None for now ",,,,,,,,,,,,,,,,10,6,4,2,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,4,3,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,6,,6,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30107975,60272628,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Diagnostic and Consulting Center Convex EOOD,Ulitsa Sinanishko Ezero 11a,Sofia,Bulgaria,Sofia City Province,1680,Ludmila,Tankova,359888932556,drtankova@abv.bg,imitkova@its.jnj.com,136276,CG_0vSAlBPtGgQUICJ,3 Jun 2026,16:10 +2026-06-02 11:50:56,2026-06-03 05:55:59,IP Address,131.0.19.83,100,65102,True,2026-06-03 05:55:59,R_6cNWU2aWQcsJ6zD,Harlacher,Luciana,luharlacher@yahoo.com.br,,-30.1188,-51.168,gl,EN,No,Luciana,Harlacher,Hospital de Clinicas de Porto Alegre,Gastroenterologist,luharlacher@yahoo.com.br,555133596331,Rua Ramiro Barcelos 2350,Porto Alegre,Rio Grande do Sul,90035-003,Brazil,Yes,Maria Eduarda,Claus,Hospital de Clínicas de Porto Alegre,eduarda.claus@gmail.com,+5551985193856,"Av. Protásio Alves, 211, Santa Cecília",Porto Alegre,Rio Grande do Sul,90035-003,Maria Eduarda,Claus,Primary Study Coordinador,eduarda.claus@gmail.com,+5551985193856,Same as above,,,,,,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,IV is covered in insurance and public system. SC only covered in insurance.,1,1,1,,46-60%,16-30%,≤15%,,Yes,No,,2 studies,5,3,2,90,0,10,0,0,0,,0,100,10,85,5,45,55,Yes,No,,Yes,Yes,"Advertising the study to other collegues and social medias. ","No. ",,,,,,,,,,,,,,,,300,150,150,90,10,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,10,18,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,4,4,8,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,true,,,,,,,,,30092962,60056727,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital de Clinicas de Porto Alegre,Rua Ramiro Barcelos 2350,Porto Alegre,Brazil,Rio Grande do Sul,90410-004,Luciana,Harlacher,555133596331,luharlacher@yahoo.com.br,gcompian@its.jnj.com,136652,CG_1pJRvxokSIv8uiY,3 Jun 2026,17:25 +2026-05-31 13:11:20,2026-06-03 06:05:16,IP Address,181.116.210.89,100,233635,True,2026-06-03 06:05:16,R_6JXv1yH6UBgfwzV,Ortiz,Maria Jimena,ortizmariajimena@gmail.com,,-34.6022,-58.3845,gl,EN,Yes,Maria Jimena,Ortiz,Universidad Nacional de Rosario UNR - Hospital Provincial del Centenario,gastroenterology,ortizmariajimena@gmail.com,+54 93 41 569 1303,Urquiza 3101,Rosario,Santa Fe,S2002,Argentina,Yes,Juaristi,Gabriela,Hospital Provincial del Centenario,gabriela.juaristi@hepagastro.org.ar,,,,,,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,Yes,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,"Our center developes in public system so reimbursed is ",1,1,1,1,16-30%,>60%,≤15%,≤15%,No,No,,1 study,3,1,2,100,0,0,0,0,0,,100,0,0,100,0,50,50,Yes,No,,No,No,"Patient materials, viatics reimbursment, providance of anticonceptional methods","Study desingn, lenght, post trial acces to medication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30115118,60805121,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Universidad Nacional de Rosario UNR - Hospital Provincial del Centenario,Urquiza 3101,Rosario,Argentina,Santa Fe,S2002,Maria Jimena,Ortiz,+54 93 41 569 1303,ortizmariajimena@gmail.com,zpatrign@its.jnj.com,136280,CG_2V7o9FKalWmgerK,3 Jun 2026,17:35 +2026-06-01 14:58:28,2026-06-03 07:27:48,IP Address,91.231.13.101,100,145760,True,2026-06-03 07:27:49,R_2Mg3wNFG5Tv42Yg,Wojcik,Katarzyna,k.wojcik@etg-network.com,,51.2542,22.5105,gl,EN,Yes,Katarzyna,Wojcik,ETG Zamosc,Gastroenterologist,k.wojcik@etg-network.com,48606923548,Gesia 3,Zamość,Lublin Voivodeship,22-400,Poland,Yes,Sandra,Czochrowska,ETG Zamosc,s.czochrowska@etg-network.com,+48 577037367,Gesia 3,Zamosc,lubelskie,22-400,Sandra,Czochrowska,SC,s.czochrowska@etg-network.com,+48 577037367,Different from the above,Anna,Walczak,Proxy,anna.walczak@krpws.pl,+48 512935592,Other,Paulina,Sobczak,Site Director,p.sobczak@etg-network.com,+48 537858147,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,1,1,,,16-30%,46-60%,,No,No,,1 study,6,2,4,100,0,0,0,0,0,,0,100,0,90,10,60,40,Yes,No,,No,No,"To ensure successful study participation, the primary area of support needed from J&J is a highly collaborative and responsive Clinical Research Associate ",no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30088336,60501784,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ETG Zamosc,Spadek 41,Zamość,Poland,Lublin Voivodeship,22-400,Katarzyna,Wojcik,48845387818,k.wojcik@etg-network.com,kfacdabr@its.jnj.com,136331,CG_3R7Rlh3jntBMtpF,3 Jun 2026,18:57 +2026-06-01 14:45:47,2026-06-03 07:54:35,IP Address,188.252.7.89,100,148128,True,2026-06-03 07:54:36,R_8VYCIt7WQY7RIYh,Kleczkowski,Dariusz,szach999@wp.pl,,54.2615,18.649,gl,EN,Yes,Dariusz,Kleczkowski,Endoskopia Sp z o.o.,gastroenterogy,szach999@wp.pl,48602601103,Bolesława Chrobrego 68,Sopot,Pomeranian Voivodeship,81-783,Poland,Yes,Lidia,Zaszczyrynska,Endoskopia sp z o.o,lidia.endoskopia@gmail.com,501011879,"ul.Chrobrego, 6/8",Sopot,Pomorskie,81-756,Marek,Horyński,SI,homar@mp.pl,501011879,Different from the above,Dariusz,Kleczkowski,PI,szach999@wp.pl,602601103,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,,1,,,,16-30%,,No,No,,More than 2 studies,8,3,5,100,0,0,0,0,0,,0,100,0,80,20,50,50,Yes,No,,Yes,No,social media info,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30128613,60171219,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Endoskopia Sp z o.o.,Bolesława Chrobrego 68,Sopot,Poland,Pomeranian Voivodeship,81-783,Dariusz,Kleczkowski,48602601103,szach999@wp.pl,kfacdabr@its.jnj.com,136323,CG_239KDgQ8bRonNb7,3 Jun 2026,19:24 +2026-06-01 09:14:24,2026-06-03 08:19:23,IP Address,176.77.135.251,100,169499,True,2026-06-03 08:19:23,R_8Ebpl1zu9NgIEdx,G.Kiss,Gyula,gkissgyula@gmail.com,,47.5,19.0412,gl,EN,Yes,Gyula,G.Kiss,Vasutegeszsegugyi Nonprofit Kozhasznu Kft,Gastroenterology,gkissgyula@gmail.com,36202283688,Erzsebet utca 11-13,Debrecen,Hajdú-Bihar,4025,Hungary,Yes,Orsolya,Gkiss,Vasutegeszsegugy,"gkissorsi1@yahoo.com ",06202283688,Erzsebet str 11-13,Debrecen,Hb,4033,"Same ",,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"No, vedolizumab is not approved for the treatment of UC",,,1,1,,,≤15%,≤15%,,,No,No,,1 study,2,1,1,100,0,0,0,0,0,,0,100,0,100,0,80,20,Yes,No,,Yes,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30111395,60035989,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Vasutegeszsegugyi Nonprofit Kozhasznu Kft,Erzsebet utca 11-13,Debrecen,Hungary,Hajdú-Bihar,4025,Gyula,G.Kiss,36202283688,gkissgyula@gmail.com,anochta@its.jnj.com,136238,CG_UXyoYSDpllxlO9j,3 Jun 2026,19:49 +2026-06-01 14:59:11,2026-06-03 09:12:19,IP Address,37.31.150.25,100,151987,True,2026-06-03 09:12:20,R_8rJfHdZ6to4I0KF,Wos-Zaniewska,Anna,annawos1982@gmail.com,,53.7401,20.4864,gl,EN,Yes,Anna,Wos-Zaniewska,Medicus Zaniewski i Bilski,"gastroenterology, internal medicine",annawos1982@gmail.com,48 515 320 823,Ul Melchiora Wankowicza 5,Olsztyn,Wojewodztwo warminsko-mazurskie,10-684,Poland,Yes,Natalia,Basista,Milestoneone,Natalia.Basista@milestone-one.com,+48609181404,Melchiora Wańkowicza 5,Olsztyn,warminsko-mazurskie,10-684,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,,,≤15%,31-45%,≤15%,≤15%,Yes,No,,2 studies,6,2,4,100,0,0,0,0,0,,0,100,0,80,20,60,40,Yes,No,,No,Yes,"Comprehensive briefings on study objectives, endpoints, and methodologies during investigator's meeting, detailed training for all study staff on protocol requirements and data collection procedures, clear protocols for the shipment, storage, handling, and accountability of the study drug or device, dedicated helpdesk for troubleshooting electronic CRF and IXRS.",NO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30161789,60394663,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Medicus Zaniewski i Bilski,Ul Melchiora Wankowicza 5,Olsztyn,Poland,Wojewodztwo warminsko-mazurskie,10-684,Anna,Wos-Zaniewska,48 515 320 823,annawos1982@gmail.com,kfacdabr@its.jnj.com,136346,CG_234EqVAjNH2vSYq,3 Jun 2026,20:42 +2026-06-02 12:39:06,2026-06-03 12:57:58,IP Address,177.69.36.49,100,87531,True,2026-06-03 12:57:59,R_3QrULCPYB7sbT17,da Silva,Daniel,danieldecastilho@hotmail.com,,-23.6293,-46.6351,gl,EN,No,Daniel,da Silva,Hospital Santa Catarina,"Coloproctology ",danieldecastilho@hotmail.com,5511981582928,Av Paulista 200,São Paulo,São Paulo,01310 000,Brazil,Yes,Felipe,Candelaria,Hospital Santa Catarina,felipe.candelaria1@redesc.org.br,+55 (11)30162551,Avenida Paullsita n 200,São Paulo,SP,01311-200,Daniel,Da Silva,"Medical ",danieldecsatilho@hotmail.com,+55(11) 981582928,Same as above,,,,,,Research Coordinator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,46-60%,16-30%,≤15%,,No,No,,2 studies,10,8,2,60,5,5,0,0,30,brown,70,30,5,80,15,40,60,Yes,Yes,"portuguese, english and spanish",Yes,No,"TDM +",,,,,,,,,,,,,,,,,80,60,100,30,15,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,1,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Local,,2,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30150858,60900219,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Santa Catarina,Av Paulista 200,São Paulo,Brazil,São Paulo,01310 000,Daniel,da Silva,5511981582928,danieldecastilho@hotmail.com,gcompian@its.jnj.com,136662,CG_24ed5tsv0SIzTpY,4 Jun 2026,00:27 +2026-05-31 13:04:07,2026-06-03 13:17:36,IP Address,190.122.56.211,100,260008,True,2026-06-03 13:17:36,R_6xV4h0mDQ891gsj,Brunatto,Luciana Soledad,dralugastro@gmail.com,,-32.1819,-64.0997,gl,EN,Yes,Luciana Soledad,Brunatto,Sanatorio Duarte Quiros,Gastroenterología,dralugastro@gmail.com,5493514891398,Duarte Quirós 1948,Córdoba,Córdoba,X5002AOQ,Argentina,Yes,Valentina,Gazal,Sanatorio Duarte Quiros,gazalvalentina@gmail.com,+543516763222,Duarte Quiros 1948,Cordoba,Cordoba,5000,Valentina,Gazal,Study Coordinator,gazalvalentina@gmail.com,+543516763222,Same as above,,,,,,Principal Investigator,,,,,,,,Yes,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,,1,,,,>60%,,Yes,No,,0 studies,2,2,0,100,0,0,0,0,0,,100,0,0,50,50,0,100,Yes,Yes,ESPAÑOL,Yes,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30131154,60308074,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sanatorio Duarte Quiroz,Duarte Quirós 1948,Córdoba,Argentina,Córdoba,X5002AOQ,Luciana Soledad,Brunatto,5493514891398,dralugastro@gmail.com,zpatrign@its.jnj.com,136281,CG_2rHhGfMsTNreZQG,4 Jun 2026,00:47 +2026-06-01 14:43:54,2026-06-03 14:40:54,IP Address,45.11.61.107,100,172619,True,2026-06-03 14:40:54,R_26ocDdOdiulub3b,Kempinski,Radoslaw,radoslaw.kempinski@cmoporow.com,,51.0384,16.972,gl,EN,Yes,Radoslaw,Kempinski,Centrum Medyczne Oporow,Gastroenterology,radoslaw.kempinski@cmoporow.com,48604911743,Ludwika Solskiego 4,Wrocław,Lower Silesian Voivodeship,52-411,Poland,Yes,Piotr,Klepacki,Centrum Medyczne Oporow,piotr.klepacki@cmoporow.com,+48501104243,Solskiego 4a/1,Wroclaw,,52416,Piotr,Klepacki,MD,piotr.klepacki@cmoporow.com,+48501104244,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,1,,,,≤15%,,,Yes,No,,More than 2 studies,20,10,10,100,0,0,0,0,0,,0,100,10,80,10,50,50,Yes,No,,Yes,No,Support with contact with vendors eg Clario,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,,,,,,,,,,30086237,60597158,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centrum Medyczne Oporow,Ludwika Solskiego 4,Wrocław,Poland,Lower Silesian Voivodeship,52-411,Radoslaw,Kempinski,48604911743,radoslaw.kempinski@cmoporow.com,kfacdabr@its.jnj.com,136326,CG_3isgtCwiRD8yplr,4 Jun 2026,02:10 +2026-05-24 18:26:13,2026-06-03 23:33:10,IP Address,54.252.143.95,100,882416,True,2026-06-03 23:33:10,R_9DClpsgo6Usk7KX,Ding,Nik John,nik.ding@svha.org.au,,-33.8672,151.1997,gl,EN,Yes,Nik John,Ding,St Vincents Hospital Melbourne,Gastroenterology,nik.ding@svha.org.au,61392313518,41 Victoria Parade,Fitzroy,VIC,3065,Australia,Yes,Jacinta,McMahon,St Vincent's Hospital Melbourne,jacinta.mcmahon@svha.org.au,61392313518,41 Victoria Parade,Fitzroy,Victoria,3056,"Jacinta ",McMahon,Clinical Trials Manager,jacinta.mcmahon@svha.org.au,61392313518,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,"fully covered by medicare, insurance not required",1,1,,,16-30%,,,,Yes,No,,0 studies,3,2,1,95,2,1,0,2,0,,0,100,0,80,20,50,50,Yes,No,,Yes,No,"courier can organise direct to patient drug deliveries, but we do not have capacity for home nursing - is this sponsor can provide?",no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,true,,,,,,,,,30131320,60026864,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,St Vincents Hospital Melbourne,41 Victoria Parade,Fitzroy,Australia,VIC,3065,Nik John,Ding,61392313529,nik.ding@svha.org.au,jmorais7@its.jnj.com,135465,CG_1iaEv22JDPeCU6d,4 Jun 2026,11:03 +2026-06-01 14:40:19,2026-06-03 23:36:13,IP Address,3.70.126.251,100,204953,True,2026-06-03 23:36:13,R_2HEZIvbO6rppkyt,Danilkiewicz,Wit,wdanilk@gmail.com,,50.1169,8.6837,gl,EN,Yes,Wit,Danilkiewicz,Medrise Sp. z o.o.,Gastroenterologist,wdanilk@gmail.com,48795404502,ul. Onyksowa 10,Lublin,Lublin Voivodeship,20 582,Poland,Yes,Maciej,Putowski,"Medrise ","Maciej.Putowski@medrise.pl ",+48572300747,Onyksowa 10,LUBLIN,Lubelskie,20-582,Wit,Danilkiewicz,PI,wit.danilkiewicz@medrise.pl,795404502,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,1,1,,,≤15%,≤15%,Yes,No,,1 study,5,2,3,100,0,0,0,0,0,,0,0,2,80,18,45,55,Yes,No,,No,Yes,Advertising in social media,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30171921,60165243,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Medrise Sp. z o.o.,ul. Onyksowa 10,Lublin,Poland,Lublin Voivodeship,20 582,Wit,Danilkiewicz,48795404502,wdanilk@gmail.com,kfacdabr@its.jnj.com,136343,CG_u7wwosSMklAEW9r,4 Jun 2026,11:06 +2026-06-02 03:13:44,2026-06-04 00:17:55,IP Address,212.179.165.129,100,162250,True,2026-06-04 00:17:56,R_2UGe4lYxoKYODct,Rainis,Tova,tova.rainis@b-zion.org.il,,32.8259,34.9968,gl,EN,Yes,Tova,Rainis,Bnai Zion Medical Center,Gastroenterology,tova.rainis@b-zion.org.il,97248359736,Golomb Street 47,Haifa,Haifa,3339419,Israel,Yes,Dalia,Nissim,Bnai Zion MC,dalia.nissim@b-zion.org.il,+972-542204563,47 Golomb st',Haifa,/,3339419,Dalia,Nissim,SC,dalia.nissim@b-zion.org.il,0542204563,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,≤15%,31-45%,16-30%,≤15%,Yes,No,,1 study,2,1,1,100,0,0,0,0,0,,0,100,0,95,5,50,50,Yes,No,,Yes,No,NONE,NO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,true,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,,,30141025,60487637,,,,,,,,,,,,,,Medicine wards,,,,,,,,,,,,,,,,,false,Bnai Zion Medical Center,Golomb Street 47,Kiryat Tiv'on,Israel,Haifa,31048,Tova,Rainis,97248359736,tova.rainis@b-zion.org.il,bmayer1@its.jnj.com,135869,CG_bveSfpko8cr5EJ3,4 Jun 2026,11:47 +2026-05-27 01:52:25,2026-06-04 00:39:16,IP Address,139.30.157.102,100,686810,True,2026-06-04 00:39:16,R_8K39JurpHQOF4c1,Reiner,Johannes,johannes.reiner@med.uni-rostock.de,,54.0882,12.1147,gl,EN,Yes,Johannes,Reiner,Universitaetsmedizin Rostock(Rostock University Medical Cente),Gastroenterology,johannes.reiner@med.uni-rostock.de,+49 38 149 414 7483,"Schillingallee 35, Rostock, Germany 18057",Rostock,Mecklenburg-Vorpommern,18057,Germany,No,,,,,,,,,,Johannes,Reiner,Oberarzt,johannes.reiner@med.uni-rostock.de,0381 494 147483,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,≤15%,31-45%,31-45%,≤15%,Yes,No,,1 study,5,3,2,95,0,0,0,0,5,arab,1,99,0,85,15,35,65,Yes,No,,Yes,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,,,,,,,,,,30031374,60830078,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Universitaetsmedizin Rostock(Rostock University Medical Cente),"Schillingallee 35, Rostock, Germany 18057",Rostock,Germany,Mecklenburg-Vorpommern,18057,Johannes,Reiner,+49 38 149 414 7483,johannes.reiner@med.uni-rostock.de,llaufner@its.jnj.com,135735,CG_2c0ZSXJiGD379jE,4 Jun 2026,12:09 +2026-06-03 00:34:08,2026-06-04 01:48:22,IP Address,188.47.82.123,100,90853,True,2026-06-04 01:48:23,R_8kOd4L3zjtV93ad,Manerowski,Marcin,marcinmanerowski@cm-medis.pl,,53.0176,18.6202,gl,EN,Yes,Marcin,Manerowski,Centrum Medyczne Medis ManerMed Sp Z O O,Gastroenterology,marcinmanerowski@cm-medis.pl,48885336063,Ul Garbary 5 / L4,Bydgoszcz,Kujawsko-Pomorskie,85 229,Poland,No,,,,,,,,,,MARCIN,MANEROWSKI,"PI, SITE MANAGER",marcinmanerowski@cm-medis.pl,0048885336063,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,only for patient met croteria for National helth IBD program (access limited),1,1,1,1,16-30%,≤15%,≤15%,≤15%,No,No,,1 study,8,4,4,99,0,0,0,0,1,latino,1,99,0,80,20,50,50,No,No,,Yes,No,patient travel or accomodation reimnursement,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30158141,60825219,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centrum Medyczne Medis ManerMed Sp Z O O,Ul Garbary 5 L4,Bydgoszcz,Poland,,85 229,Marcin,Manerowski,480525153970,marcinmanerowski@cm-medis.pl,kfacdabr@its.jnj.com,136340,CG_2pJM2sFPZ2qZtjv,4 Jun 2026,13:18 +2026-06-01 14:41:26,2026-06-04 02:29:07,IP Address,176.111.17.28,100,215261,True,2026-06-04 02:29:08,R_8A6rs0LvD32PhIZ,Filip,Rafal,r.s.filip@wp.pl,,49.4167,20.9564,gl,EN,Yes,Rafal,Filip,Centrum Medycznego Medyk,gastroenterology,r.s.filip@wp.pl,48509130097,aleja Tadeusza Rejtana 53,Rzeszów,Podkarpackie Voivodeship,35-001,Poland,Yes,Karolina,Bugajska,"CM ""Medyk""",Karolina.bugajska1@gmail.com,,Rejtana 53,Rzeszów,,,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,1,,,,16-30%,,,Yes,No,,1 study,6,4,2,100,0,0,0,0,0,,0,100,0,90,10,50,50,Yes,No,,Yes,Yes,support nor needed at the moment,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30087552,60102049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centrum Medycznego Medyk,aleja Tadeusza Rejtana 53,Rzeszów,Poland,Podkarpackie Voivodeship,35-001,Rafal,Filip,48509130097,r.s.filip@wp.pl,kfacdabr@its.jnj.com,136330,CG_1P6qmoVTlCxE7f8,4 Jun 2026,13:59 +2026-06-03 09:02:21,2026-06-04 02:49:29,IP Address,154.117.188.158,100,64027,True,2026-06-04 02:49:29,R_88IXZoDLoQpHBvD,Seabi,Manoko,manoko.seabi@wits.ac.za,,-26.2309,28.0583,gl,EN,No,Manoko,Seabi,Wits Clinical Research Unit,Gastroenterology,manoko.seabi@wits.ac.za,27113566196,32 Princess of Wales Terrace,Johannesburg,Gauteng,2193,South Africa,Yes,Wilma,Laranja,Wits Clinical Research,wlaranja@witshealth.co.za,,,,,,Courtney,Farland,Sub I,cfarland@witshealth.co.za,0739622844,Same as above,,,,,,Other,Courtney,Farland,Sub-I,cfarland@witshealth.co.za,0739622844,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","No, not reimbursed/covered by insurance",,1,1,1,,≤15%,≤15%,>60%,,Yes,No,,1 study,4,1,3,30,20,50,0,0,0,,0,0,0,70,30,50,50,Yes,Yes,"Eng, Afrikaans, Zulu",Yes,No,Our participants are usually from the state sector and would require data to complete the epros.,,,,,,,,,,,,,,,,,200,180,0,5,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,5,10,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,8,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30116073,60765402,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wits Donald Gordon Clinical Trial Site,Eton rd 18,Johannesburg,South Africa,Gauteng,2193,Manoko,Seabi,27113566196,manoko.seabi@wits.ac.za,nmadliwa@its.jnj.com,135767,CG_3MtVtiOuB69piaT,4 Jun 2026,14:19 +2026-06-02 03:17:50,2026-06-04 03:50:35,IP Address,91.227.71.250,100,174764,True,2026-06-04 03:50:35,R_8doB7jM4V4TctmM,Weisshof,Roni,r_weisshof@rambam.health.gov.il,,32.8259,34.9968,gl,EN,Yes,Roni,Weisshof,Rambam Health Care Campus(Rambam Hospital),Gastroenterology,r_weisshof@rambam.health.gov.il,972502062249,HaAliya HaShniya Street 8,Haifa,Haifa,3109601,Israel,Yes,Gili,Zisman,"Rambam Health Care Campus, Gastroenterology ",G_ZISMAN@rambam.health.gov.il,972545970161,HaAliya HaShnia 8,Haifa,North,3525408,Gili,Zisman,Study Coordinator,G_ZISMAN@rambam.health.gov.il,972545970161,Different from the above,Anastasia,Weis,Head of Clinical Trials Coordination Team,a_weis@rambam.health.gov.il,972544518702,Other,Anastasia,Weis,Head of Clinical Trials Coordination Team,a_weis@rambam.health.gov.il,972544518702,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,1,1,16-30%,16-30%,31-45%,31-45%,Yes,No,,2 studies,3,2,1,100,0,0,0,0,0,,0,100,0,50,50,50,50,Yes,Yes,"Hebrew, Arabic, Russian",No,No,Advertisment and patuent reqruitment programs,not yet,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,false,,,,,,,,,30104248,60582177,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rambam Health Care Campus(Rambam Hospital),HaAliya HaShniya Street 8,Haifa,Israel,Haifa,3109601,Roni,Weisshof,972502062249,r_weisshof@rambam.health.gov.il,bmayer1@its.jnj.com,135864,CG_1OprscO9dtdjNS3,4 Jun 2026,15:20 +2026-05-29 01:33:40,2026-06-04 04:02:29,IP Address,167.103.66.83,100,527328,True,2026-06-04 04:02:30,R_4RdOFyzui5PRjI1,Limsriwilai,Julajak,alimsrivilai@gmail.com,,1.2872,103.8507,gl,EN,No,Julajak,Limsrivilai,Mahidol University-Siriraj Hospital,gastroenterology,alimsrivilai@gmail.com,+66 81 496 8895,Wanglang Road 2,Bangkok,Bangkok,10700,Thailand,Yes,Marianee,Salaemae,"Faculty of Medicine Siriraj Hospital, Mahidol University ","ianee@hotmail.co.th ",+66838394751,"2 Wanglang Road, Bangkoknoi",Bangkok,Bangkok,10700,Marianee,Salaemae,"Research coordinator ","ianee@hotmail.co.th ",+66838394751,Different from the above,Julajak,Limsrivilai,"Principle Investigator ",alimsrivilai@gmail.com,+66814968895,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only",Other (please specify):,"Second line after failure of infliximab. ",1,1,1,,46-60%,31-45%,≤15%,,Yes,Yes,"Many patients may have been exposed to vedolizumab. ",1 study,10,5,5,0,100,0,0,0,0,,0,100,0,70,30,50,50,No,No,,No,Yes,,No,Chalermrat Bunchorntavakul,,,,,Rajavithi Hospital,,,,,dr.chalermrat@gmail.com,,,,,100,30,70,40,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,2,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,8,8,8,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,,,,,,30102995,60686185,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mahidol University-Siriraj Hospital,Wanglang Road 2,Bangkok,Thailand,Bangkok,10700,Julajak,Limsriwilai,+66 81 496 8895,alimsrivilai@gmail.com,ychanjar@its.jnj.com,136161,CG_2QVOIABV3PRQcBi,4 Jun 2026,15:32 +2026-06-01 10:56:34,2026-06-04 04:45:44,IP Address,84.206.66.106,100,236949,True,2026-06-04 04:45:45,R_8c4etsuATyQ6Eut,Csizmadia,Csaba,csizi13@gmail.com,,47.5,19.0412,gl,EN,No,Csaba,Csizmadia,PTE KK Mohácsi Kórház,gastroenterology,csizi13@gmail.com,+36 202689900,Szepessy tér 7,Mohács,Baranya,7700,Hungary,Yes,Csilla,Major Dr,PTE KK Mohácsi Kórház,major.csilla18@gmail.com,06302703423,Szepessy street 7,Mohács,,7700,Csilla,Major Dr,SC,major.csilla18@gmail.com,06302703423,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"No, vedolizumab is not approved for the treatment of UC",,,,,,,,,,,No,No,,0 studies,3,0,3,100,0,0,0,0,0,,0,100,0,95,5,70,30,No,No,,No,No,,"The PI clarified that the patient population is primarily biologic-naïve. Patients with prior biologic exposure are typically enrolled in clinical trials rather than treated in routine practice. Additionally, the PI noted that as a country hospital, initiation of biologic therapy is not standard practice at their site. Advanced UC treatments are usually managed at larger hospitals or designated clinical centers. (received via email 10 June 2026)",,,,,,,,,,,,,,,,12,11,1,0,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,3,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Central and Local,6,4,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30008499,60374770,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mohacsi Korhaz,Szepessy tér 7,Mohács,Hungary,Baranya,7700,Csaba,Csizmadia,+36 30 939 9575,csizi13@gmail.com,anochta@its.jnj.com,136253,CG_3OjmQUR2ts63ACB,4 Jun 2026,16:15 +2026-06-03 09:56:25,2026-06-04 05:30:48,IP Address,41.23.68.42,100,70463,True,2026-06-04 05:30:48,R_2s70sS1ah2EOfGV,Unassigned,Unassigned,eduan@gidoc.co.za,,-33.914,18.4129,gl,EN,No,"Malgorzata ",George,Spoke Research,Gastroenterology,gosia@gidoc.co.za,2783284462,"Office 15, Block C, Park Lane Office Park, 80 Alexandra Rd, Pinelands ",Cape Town,"Western Cape ",7405,South Africa,Yes,"Vanesha ",Naidoo,Spoke Research,vanesha@gidoc.co.za,+27660764645,"Office 15, Block C, Park Lane Office Park, 80 Alexandra Rd, Pinelands",Cape Town,"Western Cape ",7405,"Maryna ","Van Eeden ","Study coordinator ",info@spokeresearch.co.za,+27660764645,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only",Other (please specify):,"mostly Partially reimbursed if the ""correct"" treatment algorith has been followed, otherwise it is not reimbursed.",,,1,1,,,16-30%,≤15%,Yes,No,,2 studies,5,2,3,40,0,20,0,0,40,Coloured,0,0,0,95,5,50,50,Yes,No,,Yes,No,"we do not have a -70*C freezer ( only a -20*C freezer); Approved Social media ads may be helpful in recruitment ",No,,,,,,,,,,,,,,,,100,60,40,20,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,4,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Local,,6,3,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30128310,60000000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,University of the Witwatersrand-Charlotte Maxeke Johannesburg Academic Hospital,7 York Road,Johannesburg,South Africa,Gauteng,2193,Unassigned,Unassigned,2783284462,eduan@gidoc.co.za,nmadliwa@its.jnj.com,135782,CG_1n9kvoG4lda5hNP,4 Jun 2026,17:00 +2026-06-04 08:36:11,2026-06-04 08:36:44,IP Address,136.226.69.26,100,33,True,2026-06-04 08:36:45,R_51bfmzmN1elfT7f,Altwegg,Romain,r-altwegg@chu-montpellier.fr,,38.9653,-77.338,anonymous,EN,,Romain,Altwegg,CHU de Montpellier - Hopital Saint-Eloi,gastroenterology,r-altwegg@chu-montpellier.fr,3367337064,Avenue Augustin Fliche 80,Montpellier,Occitanie,34000,France,Yes,CATHY,COURT,HOPITAL SAINT-ELOI,c-court@chu-montpellier.fr,+33467337545,"80, avenue Augustin Fliche ",MONTPELLIER,NA,34295 cedex 5,CATHY,COURT,STUDY CO,c-court@chu-montpellier.fr,+33467337545,Different from the above,,,,CONTRATS - Promotion Externe ,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30154174,60149341,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHU de Montpellier - Hopital Saint-Eloi,Avenue Augustin Fliche 80,Montpellier,France,Occitanie,34000,Romain,Altwegg,3367337064,r-altwegg@chu-montpellier.fr,rbelhadj@its.jnj.com,136231,CG_2OPc9A5T4E3AcfZ,4 Jun 2026,20:06 +2026-06-01 14:54:45,2026-06-04 08:58:31,IP Address,93.159.16.167,100,237825,True,2026-06-04 08:58:31,R_20oYAHqkEt9si0V,Smolinski,Patryk,psmolinski@poczta.onet.pl,,51.101,17.0295,gl,EN,Yes,Patryk,Smolinski,EuroMediCare Szpital Specjalistyczny z Przychodnia,gastroenterology,psmolinski@poczta.onet.pl,48721295002,Wejherowska 28,Wrocław,Lower Silesian Voivodeship,54-239,Poland,Yes,Piotr,Blaszczyszyn,"Pentahospitals Przychodnie, Wrocław Wejherowska ",piotr.blaszczyszyn@pentahospitals.pl,721295002,"ul. Wejherowska 28 ",Wrocław,,53-439,Piotr,Blaszczyszyn,Site Coordinator,piotr.blaszczyszyn@pentahospitals.pl,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,,,,≤15%,>60%,16-30%,46-60%,No,No,,More than 2 studies,3,2,1,100,0,0,0,0,0,,0,100,0,100,0,80,20,Yes,No,,Yes,Yes,recruitment strategies,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30088695,60608845,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EuroMediCare Szpital Specjalistyczny z Przychodnia,Pilczycka 144,Wrocław,Poland,Lower Silesian Voivodeship,50-220,Patryk,Smolinski,48721295002,psmolinski@poczta.onet.pl,kfacdabr@its.jnj.com,136333,CG_TecR2GeInTjfafL,4 Jun 2026,20:28 +2026-06-04 13:19:13,2026-06-04 14:05:04,IP Address,64.225.229.2,100,2751,True,2026-06-04 14:05:05,R_5t9I71rNmWnKoM0,Naem,Mohamed,mnaem@northshoregastro.org,,41.4519,-81.921,gl,EN,No,Mohamed,Naem,"Northshore Gastroenterology Research, LLC",Gastroenterology,mnaem@northshoregastro.org,4408081212,Columbia rd 850,Westlake,Ohio,44145,United States,Yes,Landon,Wellendorf,Gastro Intestinal Research Institute of Northern Ohio,lwellendorf@northshoregastro.org,440-250-7632,850 Columbia Road Suite 200,Westlake,Ohio,44145,Landon,Wellendorf,Research Manager,lwellendorf@northshoregastro.org,440-250-7632,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,16-30%,16-30%,16-30%,16-30%,Yes,No,,More than 2 studies,3,2,1,60,5,34,0.5,0.5,0,,15,85,5,55,40,50,50,No,Yes,"English, Spanish",Yes,No,No additional support is needed,None at this time,,,,,,,,,,,,,,,,1000,50,950,300,300,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,7,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,3,,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30072602,60611465,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Northshore Gastroenterology Research, LLC",Columbia rd 850,Westlake,United States,Ohio,44145,Mohamed,Naem,4408081212,mnaem@northshoregastro.org,jnowak2@its.jnj.com,137116,CG_3HH0q3DuZvcnvt7,5 Jun 2026,01:35 +2026-06-02 11:55:52,2026-06-04 16:01:24,IP Address,152.249.89.43,100,187531,True,2026-06-04 16:01:25,R_6WBTkUxOw6FBZZI,Yukie Sassaki,Ligia,lsassaki.pesquisa@gmail.com,,-23.5475,-46.6361,gl,EN,No,Ligia,Yukie Sassaki,Universidade Estadual Paulista - Faculdade de Medicina de Botucatu,Gastroenterologu,ligiasassaki@gmail.com,551438801663,"Rua Professor Doutor Armando Alves, S/N",Botucatu,São Paulo,18618687,Brazil,Yes,Fernanda Stringuetta,Belik,UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - UNESP,f.belik@unesp.br,+551438801663,"Rua Prof. Dr. Armando Alves, s/nº",Botucatu,São Paulo,18.618-686,Fernanda Stringuetta,Belik,Study Coordinator,f.belik@unesp.br,+551438801663,Same as above,,,,,,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,31-45%,,,No,No,,1 study,6,3,3,70,0,30,0,0,0,,100,0,10,70,20,50,50,Yes,No,,Yes,No,,,,,,,,,,,,,,,,,,40,10,30,15,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,5,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,6,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30000728,60543986,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Universidade Estadual Paulista - Faculdade de Medicina de Botucatu,"Rua Professor Doutor Armando Alves, S/N",Botucatu,Brazil,São Paulo,18618,Ligia,Yukie Sassaki,551438801171,lsassaki.pesquisa@gmail.com,gcompian@its.jnj.com,136668,CG_2w5k44jOEWBa2cV,5 Jun 2026,03:31 +2026-05-31 13:59:06,2026-06-04 19:07:26,IP Address,190.190.105.226,100,364100,True,2026-06-04 19:07:27,R_71cmVqIryKXgyY6,Gonzalez,Raquel,rgonzalez@cinme.com.ar,,-34.6438,-58.6096,gl,EN,Yes,Raquel,Gonzalez,Hospital Aleman,Gastroenterology,rgonzalez@hospitalaleman.com,+5491162931080,Avenida Pueyrredón 1640,Buenos Aires,Buenos Aires,C1118,Argentina,Yes,Candela,Souza,Hospital Alemán,csouza@hospitalaleman.com,1132316595,Av Pueyrredón 1640,Buenos Aires,Buenos Aires,1118,Paula,Perez,Head of research management,pperez@hospitalaleman.com,1124500328,Same as above,,,,,,Principal Investigator,,,,,,,,Yes,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,≤15%,>60%,16-30%,,No,Yes,Wash out time,1 study,2,1,1,99,1,0,0,0,0,,100,0,0,50,50,50,50,Yes,No,,No,No,"Our site is well‑equipped to conduct the study; however, to ensure optimal execution, we may require support from J&J in the following areas: +• Timely provision of study materials (lab kits, IMP, manuals, and updated documents). +• Efficient communication channels for rapid resolution of operational or protocol‑related questions. +• Support with patient‑facing materials to facilitate recruitment and retention. +• Clear guidance on data entry expectations and timelines. +• Prompt access to the electronic systems and training for all study staff.","We do not foresee any major concerns beyond what is already captured in the questionnaire. +If additional clarifications are needed regarding operational workflows, patient flow, or system access, our team is available to provide further details",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,,,,,30115376,60019261,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Aleman,Avenida Pueyrredón 1640,Buenos Aires,Argentina,Buenos Aires,C1118,Raquel,Gonzalez,541152364056,rgonzalez@cinme.com.ar,zpatrign@its.jnj.com,136288,CG_esK9og18A1I7c41,5 Jun 2026,06:37 +2026-05-29 01:50:51,2026-06-04 23:38:23,IP Address,202.28.119.60,100,596852,True,2026-06-04 23:38:24,R_9dQ9VQKyQUuql4O,Suttichaimongkol,Tanita,tanisu@kku.ac.th,,16.4465,102.8288,gl,EN,No,Tanita,Suttichaimongkol,Srinagarind Hospital - Khon Kaen University,Gastroenterology,tanisu@kku.ac.th,+66 89 424 9699,Thanon Mittraphap 123,Mueang Khon Kaen,Khon Kaen,40002,Thailand,No,,,,,,,,,,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,16-30%,,,No,No,,0 studies,10,2,8,0,100,0,0,0,0,,0,100,0,80,20,50,50,Yes,Yes,Thai,No,No,,No,,,,,,,,,,,,,,,,120,70,50,30,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,0,None,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,12,12,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30101987,60008007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Srinagarind Hospital - Khon Kaen University,Thanon Mittraphap 123,Mueang Khon Kaen,Thailand,Khon Kaen,40002,Tanita,Suttichaimongkol,+66 89 424 9699,tanisu@kku.ac.th,ychanjar@its.jnj.com,136160,CG_2qxAXcQsaQX34IS,5 Jun 2026,11:08 +2026-06-01 08:58:49,2026-06-05 01:43:00,IP Address,93.152.164.171,100,319450,True,2026-06-05 01:43:01,R_8pb9cQtWImC9Vo6,Pavlov,Dimitar,md.pavlov@mail.bg,,42.6826,23.3223,gl,EN,No,Dimitar,Pavlov,Multi-Profile Hospital for Active Treatment (MHAT) Hadji Dimitar,gastroenterology,md.pavlov@mail.bg,359887396768,Ulitsa Dimitar Pehlivanov 5,Sliven,Sliven Province,8800,Bulgaria,Yes,Gergana,Paunova,SMO R&D Services,g.paunova@rdservices.org,0892226012,,Sofia,,1000,Gergana,Paunova,,g.paunova@rdservices.org,0892226012,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"No, I am not interested",Competing trials,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30107845,60340117,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Multi-Profile Hospital for Active Treatment (MHAT) Hadji Dimitar,Ulitsa Dimitar Pehlivanov 5,Sliven,Bulgaria,Sliven Province,8800,Dimitar,Pavlov,359887396768,md.pavlov@mail.bg,imitkova@its.jnj.com,136275,CG_1mW7je4HN0rHjww,5 Jun 2026,13:13 +2026-06-01 14:55:32,2026-06-05 02:18:22,IP Address,77.65.122.42,100,300170,True,2026-06-05 02:18:22,R_8cAdiGVHtXUzMC4,Tyszkiwski,Oleg,o.tyszkiwski@rivermed.pl,,52.3742,16.8769,gl,EN,Yes,Oleg,Tyszkiwski,RiverMED Poradnie Specjalistyczne Poznań,Gastroenterology,o.tyszkiwski@rivermed.pl,48692132092,28 Czerwca 1956 r. 382/U4,Poznań,Greater Poland Voivodeship,61-441,Poland,No,,,,,,,,,,MONIKA,JAKUBOWSKA,Medical Director,monika.jakubowska@rivermed.pl,692132092,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","No, not reimbursed/covered by insurance",,,,1,,,,31-45%,,No,No,,1 study,10,3,7,100,0,0,0,0,0,,0,100,0,100,0,50,50,Yes,No,,No,No,Vedolizumab should be delivered by Sponsor,NA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30089997,60607954,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RiverMED Poradnie Specjalistyczne Poznań,28 Czerwca 1956 r. 382/U4,Poznań,Poland,Greater Poland Voivodeship,61-441,Oleg,Tyszkiwski,48616414155,o.tyszkiwski@rivermed.pl,kfacdabr@its.jnj.com,136336,CG_3MoDTVBvIzrPBjM,5 Jun 2026,13:48 +2026-06-01 14:44:51,2026-06-05 03:00:35,IP Address,5.173.192.102,100,303343,True,2026-06-05 03:00:36,R_8hDYxIBmYPQBHvs,Kierkus,Jaroslaw,j.kierkus@med-net.pl,,52.2299,21.0093,gl,EN,Yes,Jaroslaw,Kierkus,WIP Warsaw IBD Point Profesor Kierkus,gastroenterology,j.kierkus@med-net.pl,48533092697,Bobrowiecka 9,Warsaw,Masovian Voivodeship,04-501,Poland,Yes,Jaroslaw,Kierkus,Medical Network WIP IBD Point Profesor Kierkus,j.kierkus@med-net.pl,500111648,,Warszawa,mazowieckie,04-501,Jaroslaw,Kierkus,PI,j.kierkus@med-net.pl,500111648,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,if national program,,,,,≤15%,>60%,≤15%,≤15%,Yes,No,,2 studies,15,10,5,100,0,0,0,0,0,,0,100,0,90,10,50,50,Yes,No,,No,No,NA,NA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30088449,60537250,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,WIP Warsaw IBD Point Profesor Kierkus,Bobrowiecka 9,Warsaw,Poland,Masovian Voivodeship,04-501,Jaroslaw,Kierkus,48533092697,j.kierkus@med-net.pl,kfacdabr@its.jnj.com,136332,CG_1rpotJslP59TgUt,5 Jun 2026,14:30 +2026-06-01 09:06:41,2026-06-05 03:17:14,IP Address,149.62.207.213,100,324633,True,2026-06-05 03:17:15,R_83I2hbyThDzFaj7,Stoynov,Nikolay,'+dr_nstoinov@abv.bg,,42.6826,23.3223,gl,EN,No,Nikolay,Stoynov,Medical Center St Ivan Rilski Chudotvorets-2010,Gastroenterologist,'+dr_nstoinov@abv.bg,+359883587916,"144 ulitsa ""Vasil Levski"" Northern Industrial Zone",Plovdiv,Plovdiv,4003,Bulgaria,Yes,Slavina,Toncheva,R&D services,s.toncheva@rdservice.org,+359892226012,Shesti Septemvri 17,Sofia,Sofia,1000,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,,,16-30%,16-30%,≤15%,≤15%,Yes,No,,0 studies,8,4,6,100,0,0,0,0,0,,0,0,0,100,0,40,60,Yes,Yes,"bulgarian,english,german,russian",No,No,Technical support only,No,Gergana Karavelova-Kasabova,"Christo Ivanov Geche ",,,,St.Ivan Rilski,St.Ivan Rilski,,,,,,,,,3,4,38,7,5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,1,1-2,Yes,No,No,Yes,Yes,Yes,Yes,No,Central,1,,1,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78543,78543,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Medical Center St Ivan Rilski Chudotvorets-2010,"144 ulitsa ""Vasil Levski"" Northern Industrial Zone",Plovdiv,Bulgaria,Plovdiv,4003,Nikolay,Stoynov,+359883587916,'+dr_nstoinov@abv.bg,imitkova@its.jnj.com,136272,CG_3NO0dOReh9lk4pJ,5 Jun 2026,14:47 +2026-06-01 14:56:27,2026-06-05 04:24:37,IP Address,217.97.60.45,100,307689,True,2026-06-05 04:24:37,R_8YXjAjtrM2ELeeu,Walczak,Michal,michal.walczak@clinsante.pl,,53.0176,18.6202,gl,EN,Yes,Michal,Walczak,Osrodek Badan Klinicznych CLINSANTE S.C.,gastroeterology,michal.walczak@clinsante.pl,48501564324,Tytusa Chałubińskiego 6,Bydgoszcz,Kuyavian-Pomeranian Voivodeship,85-794,Poland,Yes,Ewa,Galczak-Nowak,Ośrodek Badań Klinicznych CLINSANTE S.C. Ewa Galczak-Nowak Małgorzata Trzaska,ewa.galczak-nowak@clinsante.pl,+48 733 473 999,Chałubińskiego 6,Bydgoszcz,kujawsko-pomorskie,85-794,Ewa,Galczak-Nowak,Site Owner,ewa.galczak-nowak@clinsante.pl,+48 733 473 999,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,1,1,,≤15%,≤15%,≤15%,Yes,No,,More than 2 studies,8,2,6,100,0,0,0,0,0,,0,100,0,95,5,50,50,Yes,No,,No,No,"short patient information brochure, simple explanation of the study purpose and procedures - for subjects",NO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30086478,60466327,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Osrodek Badan Klinicznych CLINSANTE S.C.,Tytusa Chałubińskiego 6,Bydgoszcz,Poland,Kuyavian-Pomeranian Voivodeship,85-794,Michal,Walczak,48501564324,michal.walczak@clinsante.pl,kfacdabr@its.jnj.com,136347,CG_2c7Qx9g4XzEx6Zz,5 Jun 2026,15:54 +2026-06-01 09:01:49,2026-06-05 04:30:39,IP Address,212.122.166.32,100,329329,True,2026-06-05 04:30:39,R_28iDBC2Pzzdkf17,Simonova,Marieta,marietta.simonova@gmail.com,,42.6826,23.3223,gl,EN,No,Marieta,Simonova,Medical Institute Ministry of Interior,Gastroenterology,marietta.simonova@gmail.com,+359888983955,булевард „Генерал Михаил Д. Скобелев 79,Sofia,Sofia City Province,1606,Bulgaria,Yes,Svetla,"Beganova ",Medical Institute Ministry of Interior,"svetla_beganova@abv.bg ",+ 359894252909,булевард „Генерал Михаил Д. Скобелев 79,"Sofia ",Sofia,1606,"Marieta ",Simonova,"Head of Clinic of Gastroenterology ",marietta.simonova@gmail.com,00359888983955,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,31-45%,16-30%,,,No,No,,0 studies,2,1,1,100,0,0,0,0,0,,0,0,0,70,30,60,40,Yes,No,,No,No,"Submitting process, monitoring process ",No,,,,,,,,,,,,,,,,6,2,4,0,1,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,No,No,0,0,None,Yes,No,No,Yes,Yes,Yes,Yes,Yes,Local,,4,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30147716,60465335,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Medical Institute Ministry of Interior,булевард „Генерал Михаил Д. Скобелев 79,Sofia,Bulgaria,Sofia City Province,1606,Galina,Kibarova,+359888983955,marietta.simonova@gmail.com,imitkova@its.jnj.com,136263,CG_ePW99RKOUgSFNYJ,5 Jun 2026,16:00 +2026-06-02 09:17:39,2026-06-05 05:31:03,IP Address,185.67.199.3,100,245604,True,2026-06-05 05:31:03,R_8xSm2IBQa4W4mfk,Seibold,Frank,frank.seibold@magendarmsuisse.ch,,46.4912,6.6349,gl,EN,Yes,Christoph,Matter,"Intesto KLG, Crohn-Colitis Zentrum",Gastroenterology,studien.matter@intesto.ch,41313023234,Bremgartenstrasse 119,Bern,Bern,3012,Switzerland,Yes,Gaby,Saner,"Intesto KLG, Crohn-Colitis Zentrum",sanerg@intesto.ch,+41313003481,Bremgartenstrasse 119,Bern,Bern,3012,Gaby,Saner,Clinical Research Coordinator,sanerg@ntest.ch,+41313003481,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,,,>60%,31-45%,,,Yes,Yes,"≥3 approved advanced therapies (agents, not number of classes) +as listed above (in biologic or oral advanced therapies section) will be limited to 15% of the ADT-IR population. +ustekinumab will be capped at 20% of the ADT-IR population",0 studies,5,5,0,100,0,0,0,0,0,,0,0,0,90,10,50,50,Yes,Yes,"German +French",No,No,na,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30100525,60401863,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gastroenterologische Praxis Balsiger und Seibold - Lindenhofspital Bern,Bremgartenstrasse 119,Bern,Switzerland,Bern,3012,Frank,Seibold,41313023234,frank.seibold@magendarmsuisse.ch,cgruener@its.jnj.com,136006,CG_2XinIQYbLksDksu,5 Jun 2026,17:01 +2026-06-02 09:19:37,2026-06-05 05:55:01,IP Address,185.67.199.3,100,246923,True,2026-06-05 05:55:01,R_24Bmj6hJimeHp9T,Juillerat,Pascal,pascal.juillerat@insel.ch,,46.4912,6.6349,gl,EN,Yes,Pascal,Juillerat,Intesto KLG Bern and Fribourg,GI and IBD Specialist,juilleratp@intesto.ch," +41 31 302 32 34","Bremgartenstrasse 119 ",Bern,Bern,3012,Switzerland,Yes,Gaby,"Saner ",Intesto KLG Bern and Fribourg,sanerg@intesto.ch," +41 31 302 32 34","Bremgartenstrasse 119 ",Bern,Bern,"3012 ",Gaby,Saner,Coordinator CTU,sanerg@intesto.ch," +41 31 302 32 34",Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,31-45%,16-30%,≤15%,≤15%,Yes,Yes,Exclusion of all patients with previous exposure to the study drugs.,1 study,6,4,2,98,1,1,0,0,0,,0,0,1,85,14,48,52,Yes,Yes,"German, French, English",Yes,No,"We need to get additional information on the protocol, and help JnJ improving it to fit clinical the reality of our clinical practice (e.g. caps in subgroups , etc..) ",Available for the review of the full protocol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,,,,,30101878,60499037,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Universitaetsspital Bern-Inselspital,Freiburgstrasse 4,Bern,Switzerland,Bern,3010,Pascal,Juillerat,41316325900,pascal.juillerat@insel.ch,cgruener@its.jnj.com,136009,CG_bOqZCzmoZPjso49,5 Jun 2026,17:25 +2026-06-03 05:43:58,2026-06-05 07:32:46,IP Address,41.193.144.74,100,179327,True,2026-06-05 07:32:46,R_81Bd3Tebt4wo20n,Moodliar,Ronelle,r.moodliar@think.org.za,,-29.8553,31.0428,gl,EN,No,Ronelle,Moodliar,Cornerstone Clinical Research Centre,Gastroenterology,drmoodliar@ccrc.co.za,0317681198,"Busamed Hillcrest Hospital, 471 Kassier Road ",Hillcrest,KwaZulu-Natal,3610,South Africa,No,,,,,,,,,,Ronelle,Moodliar,PI,drmoodliar@ccrc.co.za,0837770667,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,,1,1,,,46-60%,31-45%,,No,No,,0 studies,2,1,1,50,25,25,0,0,0,,0,0,0,80,20,50,50,No,No,,Yes,No,"Recruitment material +Advertising budget +Patient milestone rewards +Finders fees/incentives for health care professionals that refer patients for screening ",No,,,,,,,,,,,,,,,,50,25,25,10,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,0,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,12,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30107923,60001738,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hillcrest private,Kassier Road 471,Durban,South Africa,KwaZulu-Natal,3610,Ronelle,Moodliar,27313094438,drmoodliar@ccrc.co.za,nmadliwa@its.jnj.com,135779,CG_2ffHnMXn2v8As2P,5 Jun 2026,19:02 +2026-06-03 10:33:29,2026-06-05 07:45:43,IP Address,41.160.168.60,100,162734,True,2026-06-05 07:45:44,R_8aWzXZCeTIIWozW,Coetzer,Thomas,tf.coetzer@clinresco.co.za,,-26.2309,28.0583,gl,EN,No,Jennifer,Rosa,Clinresco Centres,GP,j.rosa@clinresco.co.za,27113943400,"Central Professional Suites, 1st floor, 20 Central Avenue",Kempton Park,Gauteng,1619,South Africa,Yes,Maureen,Mohata,Clinresco Centres,m.mohata@clinresco.co.za,011 394 3400,"Central Professional Suites, 1st Floor, 20 Central Avenue",Kempton Park,Gauteng,1619,Jennifer,Rosa,"PI, General Manager",j.rosa@clinresco.co.za,011 394 3400,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","No, not reimbursed/covered by insurance",,,,,,≤15%,46-60%,31-45%,≤15%,No,No,,More than 2 studies,2,0,2,75,0,25,0,0,0,,0,100,0,100,0,40,60,Yes,Yes,English and Afrikaans,Yes,No,Recruitment support,No,,,,,,,,,,,,,,,,10,8,2,1,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,4,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,12,,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30108189,60503596,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Clinresco Centres,"22 Pine Avenue, Arwyp Medical Suites.4th Floor",Johannesburg,South Africa,Gauteng,2092,Thomas,Coetzer,27113943400,tf.coetzer@clinresco.co.za,nmadliwa@its.jnj.com,135780,CG_2aRyjRwRnrVLmwz,5 Jun 2026,19:15 +2026-06-05 07:36:56,2026-06-05 08:22:37,IP Address,194.167.179.10,100,2740,True,2026-06-05 08:22:37,R_8JE5X8pOs0OAPw5,Riviere,Pauline,pauline.riviere@chu-bordeaux.fr,,44.8442,-0.6378,gl,EN,Yes,Pauline,Riviere,Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Sud - Hopital Haut Leveque,gastroenterology,pauline.riviere@chu-bordeaux.fr,33786959357,Avenue Magellan,Pessac,Nouvelle-Aquitaine,33600,France,Yes,Maude,Charbonnier,CHU Bordeaux,maude.charbonnier@chu-bordeaux.fr,0557623169,Avenue Magellan Hopital Haut-Leveque,PESSAC,,33604,Maude,Charbonnier,study co,maude.charbonnier@chu-bordeaux.fr,0557623169,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,46-60%,31-45%,,,Yes,No,,1 study,2,1,1,100,0,0,0,0,0,,0,0,0,80,20,50,50,No,No,,Yes,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30149895,60076080,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Sud - Hopital Haut Leveque,Avenue Magellan,Pessac,France,Nouvelle-Aquitaine,33600,Pauline,Riviere,33786959357,pauline.riviere@chu-bordeaux.fr,rbelhadj@its.jnj.com,136233,CG_2V3c0bBrMQMO2iK,5 Jun 2026,19:52 +2026-06-01 09:00:36,2026-06-05 08:33:13,IP Address,172.225.224.85,100,343957,True,2026-06-05 08:33:13,R_2fIc0v4PnSDD9nz,Kadish,Medain,medain@abv.bg,,42.6951,23.325,gl,EN,No,Medain,Kadish,University Multiprofile Hospital for Active Treatment Sofiamed (University Hospital Sofiamed),"internal medicine and gastroenterology ",medain@abv.bg,+359876102079,16 G.M. Dimitrov blvd,Sofia,Sofia City Province,1797,Bulgaria,Yes,Nevin,"Idriz ",UMHAT Sofiamed,Nevin_Idriz@abv.bg,+359 87 7841991,blv. G.M. Dimitrov 16,"Sofia ","Sofia ",1797,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,,,,31-45%,,,No,No,,2 studies,2,1,2,100,0,0,0,0,0,,0,100,0,100,0,50,50,Yes,Yes,bulgarian,Yes,No,n/a,n/a,,,,,,,,,,,,,,,,5,4,25,6,2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,0,0,None,Yes,No,No,Yes,Yes,Yes,Yes,No,Local,,2,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30163034,60807257,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,University Multiprofile Hospital for Active Treatment Sofiamed (University Hospital Sofiamed),16 G.M. Dimitrov blvd,Sofia,Bulgaria,Sofia City Province,1336,Stratieva,Stratina,+359876102079,medain@abv.bg,imitkova@its.jnj.com,136262,CG_25d0IKwjacVJ3k5,5 Jun 2026,20:03 +2026-06-05 08:28:14,2026-06-05 10:23:18,IP Address,147.161.132.249,100,6903,True,2026-06-05 10:23:18,R_6txM6zOjv9nyU93,Altwegg,Romain,r-altwegg@chu-montpellier.fr,France,52.3716,4.8883,gl,EN,Yes,Romain,Altwegg,CHU de Montpellier - Hopital Saint-Eloi,Gastroenterology,r-altwegg@chu-montpellier.fr,3367337064,Avenue Augustin Fliche 80,Montpellier,Occitanie,34000,France,Yes,CATHY,COURT,HOPITAL SAINT ELOI,c-court@chu-montpellier.fr,+33467337545,"80, avenue Augustin Fliche",MONTPELLIER,,34295 cedex 5,CATHY,COURT,STUDY CO,c-court@chu-montpellier.fr,+33467337545,Different from the above,,,,CONTRATS - Promotion Externe ,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,31-45%,31-45%,16-30%,,No,No,,More than 2 studies,4,2,2,75,0,5,0,0,20,north african,0,100,0,80,20,50,50,Yes,No,,Yes,No,none,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30154174,60149341,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHU de Montpellier - Hopital Saint-Eloi,Avenue Augustin Fliche 80,Montpellier,France,Occitanie,34000,Romain,Altwegg,3367337064,r-altwegg@chu-montpellier.fr,,136231,,5 Jun 2026,21:53 +2026-05-31 14:02:58,2026-06-05 11:50:54,IP Address,186.22.17.175,100,424076,True,2026-06-05 11:50:55,R_1DuPITiVy4omoN3,Balaban,Ezequiel,dr.ebalaban@gmail.com,,-36,-59.9964,gl,EN,No,Ezequiel,Balaban,Nexo Salud Investigacion Clinica,Gastroenterology,dr.ebalaban@gmail.com,+54 91 13 516 5370,Riobamba 429,Buenos Aires,Buenos Aires,C1025,Argentina,Yes,Mariana,Delhon,"Nexo Salud ",mdcardioba@gmail.com,01138553246,Riobamba 429,Buenos aires,Autonomous City of Buenos Aires,1025,MARIANA,Delhon,Study Coordinator,mdcardioba@gmail.com,01138553246,Same as above,,,,,,Principal Investigator,,,,,,,,Yes,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,≤15%,16-30%,,,Yes,No,,1 study,3,2,1,100,0,0,0,0,0,,100,0,0,70,30,50,50,Yes,No,,Yes,No,,If there is going to be long term period in the study?,,,,,,,,,,,,,,,,300,30,270,27,20,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,0,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Central,2,,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30128996,60900385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nexo Salud Investigacion Clinica,Riobamba 429,Buenos Aires,Argentina,Buenos Aires,C1006,Ezequiel,Balaban,+54 91 13 516 5370,dr.ebalaban@gmail.com,zpatrign@its.jnj.com,136291,CG_DiMDAaIFq0H4USd,5 Jun 2026,23:20 +2026-06-05 11:32:37,2026-06-05 12:47:05,IP Address,92.137.9.2,100,4467,True,2026-06-05 12:47:06,R_8cXI4s1bZjWGRoZ,Roblin,Xavier,xavier.roblin@chu-st-etienne.fr,,45.5387,4.1811,gl,EN,Yes,Xavier,Roblin,Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord,"Gastroenterology ",xavier.roblin@chu-st-etienne.fr,33477828320,Avenue Albert Raimond,Saint-Priest-en-Jarez,Auvergne-Rhône-Alpes,42270,France,Yes,Xavier,Roblin,"Gastroenterology ",Xavier.roblin@chu-st-etienne.fr,0616963645,Chu saint etienne,saint etienne,Loire,42000,xavier,roblin,Pr,xavier.roblin@chu-st-etienne.fr,0616963645,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,46-60%,31-45%,,,Yes,No,,1 study,15,10,5,100,0,0,0,0,0,,0,0,0,80,20,50,50,Yes,No,,Yes,No,easy to meet JandJ,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,30048805,60076008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord,Avenue Albert Raimond,Saint-Priest-en-Jarez,France,Auvergne-Rhône-Alpes,42270,Xavier,Roblin,33477828320,xavier.roblin@chu-st-etienne.fr,rbelhadj@its.jnj.com,136225,CG_2VpVVVFR3Jctj2t,6 Jun 2026,00:17 +2026-06-01 14:48:16,2026-06-06 01:28:33,IP Address,37.109.147.174,100,384017,True,2026-06-06 01:28:34,R_2Lxdjvg7K84fjuV,Krogulecki,Michal,mkrogulecki@gmail.com,,51.7734,19.476,gl,EN,Yes,Michal,Krogulecki,WSD MEDI Clinical Sp. z o. o.,Gastroenterology,michalkrogulecki@medi-clinical.pl,+48 504 440 092,al. Jana Rodowicza Anody 22 lok U4,Warsaw,Masovian Voivodeship,02-786,Poland,Yes,Mateusz,Marczak,WSD Medi Clinical,"mateuszmarczak@medi-clinical.pl ",to be added,Aleja Jana Rodowicza Anody 22/U4,Warsaw,Mazovian Voivodeship,02-786,Mateusz,Marczak,Study Coordinator,"mateuszmarczak@medi-clinical.pl ",to be added,Different from the above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,16-30%,,,No,No,,2 studies,6,3,3,100,0,0,0,0,0,,0,100,0,85,15,50,50,No,No,,No,No,Patients material and advisory,Not so far,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30161918,60900480,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,WSD MEDI Clinical Sp. z o. o.,al. Jana Rodowicza Anody 22 lok U4,Warsaw,Poland,Masovian Voivodeship,02-786,Michal,Krogulecki,+48 50 444 0092,mkrogulecki@gmail.com,kfacdabr@its.jnj.com,136342,CG_2bKkqkr7EiTnDU7,6 Jun 2026,12:58 +2026-05-27 03:47:23,2026-06-06 05:47:38,IP Address,195.37.151.100,100,871214,True,2026-06-06 05:47:38,R_8pZHhsRwIDdiTKN,Schnoy,Elisabeth,elisabeth.schnoy@uk-augsburg.de,,48.3781,10.8567,gl,EN,Yes,Elisabeth,Schnoy,University Hospital Augsburg(Universitaetsklinikum Augsburg),Gastroenterology,elisabeth.schnoy@uk-augsburg.de,498214002351,Stenglinstraße 2,Augsburg,Bavaria,86156,Germany,No,,,,,,,,,,Jacqueline,Figlak,Study nurse,jacqueline.figlak@uk-augsburg.de,,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,16-30%,16-30%,16-30%,16-30%,No,No,,2 studies,5,4,1,100,0,0,0,0,0,,0,100,0,95,5,50,50,Yes,No,,No,No,adequate financing of the study,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30024799,60251957,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,University Hospital Augsburg(Universitaetsklinikum Augsburg),Stenglinstraße 2,Augsburg,Germany,Bavaria,86156,Elisabeth,Schnoy,498214002351,elisabeth.schnoy@uk-augsburg.de,mraddatz@its.jnj.com,135738,CG_3J9o6zLVuKXvQZW,6 Jun 2026,17:17 +2026-05-27 01:42:58,2026-06-06 09:40:35,IP Address,141.67.15.214,100,892656,True,2026-06-06 09:40:35,R_8o0IouaD3ivAetB,Atreya,Raja,raja.atreya@uk-erlangen.de,,49.5939,11,gl,EN,Yes,Raja,Atreya,Universitätsklinikum Erlangen Medizinische Klinik 3,Gastroenterology,raja.atreya@uk-erlangen.de,4991318535115,Ulmenweg 18,Erlangen,Bavaria,91054,Germany,No,,,,,,,,,,Raja,Atreya,,raja.atreya@uk-erlangen.de,091318545107,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,,,46-60%,31-45%,≤15%,≤15%,No,No,,1 study,5,4,1,94,6,0,0,0,0,,2,98,0,90,10,50,50,Yes,No,,Yes,No,None,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30147205,60406804,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Universitätsklinikum Erlangen Medizinische Klinik 3,Ulmenweg 18,Erlangen,Germany,Bavaria,91054,Raja,Atreya,4991318535115,raja.atreya@uk-erlangen.de,mraddatz@its.jnj.com,135731,CG_242TlwfKTALwpde,6 Jun 2026,21:10 +2026-06-02 12:34:42,2026-06-07 13:38:45,IP Address,179.152.105.252,100,435842,True,2026-06-07 13:38:45,R_537cydk2eBu4HAU,Flores,Cristina,Cflorespesquisa@gmail.com,,-30.0273,-51.2353,gl,EN,No,Cristina,Flores,Hospital Ernesto Dornelles,Gastroenterology,Cflorespesquisa@gmail.com,55999624012,Avenida Ipiranga 1801,Porto Alegre,Rio Grande do Sul,90160-093,Brazil,Yes,"Bianca ",Comerlato,Hospital Ernesto Dorneles - Instituto Ceos,bcomerlato@institutoceos.com,+5551 991002215,"Ipiranga Avenue, 1801 - 7th floor ",Porto Alegre,RS,90160-093,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,46-60%,16-30%,16-30%,≤15%,No,No,,1 study,6,3,3,70,0,10,0,0,20,pardos,90,10,5,85,10,50,50,Yes,No,,Yes,Yes,Support for reimbursement for patient transportation and meals,I don't have any Concerns,,,,,,,,,,,,,,,,320,32,280,130,12,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,5,8,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,4,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30095256,60631084,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Ernesto Dornelles,Avenida Ipiranga 1801,Porto Alegre,Brazil,Rio Grande do Sul,90160-093,Cristina,Flores,55999624012,Cflorespesquisa@gmail.com,gcompian@its.jnj.com,136658,CG_2ARw2BG0PedtNzC,8 Jun 2026,01:08 +2026-06-02 11:53:01,2026-06-07 18:17:53,IP Address,177.32.77.241,100,455092,True,2026-06-07 18:17:54,R_3QN8eR6YhM4HkOb,Silva Junior,Roberto,1982roberto@gmail.com,,-23.5475,-46.6361,gl,EN,No,Roberto,Silva Junior,BR Trials,gastroenterologist,1982roberto@gmail.com,551126722734,"Av. Arnolfo Azevedo, 40",São Paulo,São Paulo,05003-090,Brazil,No,,,,,,,,,,Silvana,Glikmanas,Recruitment and Partnerships Manager in Clinical Research,silvana.brtrials@gmail.com,+55 (11) 98345 4545,Same as above,,,,,,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,31-45%,≤15%,≤15%,≤15%,Yes,No,,1 study,4,2,2,20,5,75,0,0,0,,100,0,0,80,20,50,50,Yes,No,,Yes,Yes,Safety monitoring: Adverse event reporting systems and medical monitor access.,"No, I do not have any concerns.",,,,,,,,,,,,,,,,300,150,150,50,5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,6,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Central,4,,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30093193,60638484,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BR Trials,"Av. Arnolfo Azevedo, 40",São Paulo,Brazil,São Paulo,05003-090,Roberto,Silva Junior,551126722734,1982roberto@gmail.com,gcompian@its.jnj.com,136653,CG_33ruPTROBXiHcSu,8 Jun 2026,05:47 +2026-05-27 01:48:59,2026-06-07 23:44:04,IP Address,212.53.178.250,100,1029305,True,2026-06-07 23:44:05,R_2mDDatwzvAZje8s,Baer,Florian,florian.baer@uksh.de,,53.9172,10.6946,gl,EN,Yes,Florian,Baer,Praxis für Gastoemterologie Lübeck,Gastroenterology,baer@gastroenterologie-hl.de,+494517073430,"Kronsforder Allee 69 ",Lübeck,Schleswig-Holstein,23560,Germany,Yes,Florian,Bär,"Praxis für Gastroemterologie Lübeck ",baer@gastroenterologie-hl.de,+494517073430,"Krosnforder Allee 69 ",Lübeck,Schleswig Holstein,23560,Florian,Bär,,baer@gastroenterologie-hl.de,+494517073430,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,31-45%,16-30%,≤15%,≤15%,Yes,No,,1 study,8,5,3,85,5,5,5,0,0,,0,0,2,85,13,50,50,Yes,No,,Yes,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30147221,60583287,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Universitatsklinikum Schleswig Holstein Campus Lubeck,Ratzeburger Allee 160,Lübeck,Germany,Schleswig-Holstein,23562,Florian,Baer,4945150044356,florian.baer@uksh.de,mraddatz@its.jnj.com,135734,CG_2tnRKp3zOqLN7fA,8 Jun 2026,11:14 +2026-05-29 03:42:45,2026-06-08 01:35:24,IP Address,182.62.75.79,100,856359,True,2026-06-08 01:35:25,R_9XeYdcTspkbjgit,Limun,Mohd Fairul,mohdfairul511@gmail.com,,3.1572,101.6695,gl,EN,Yes,Mohd Fairul,Limun,Hospital Kuala Lumpur,"Gastroenterologist ",mohdfairul511@gmail.com,+60 12 247 6282,Jalan Pahang,Kuala Lumpur,Kuala Lumpur,50586,Malaysia,Yes,Michelle,William Santhiagu,Hospital Kuala Lumpur,michelle@clinicalresearch.my,0162343869,"Hospital Kuala Lumpur (HKL), 50586 Jalan Pahang, Wilayah Persekutuan, Kuala Lumpur, Malaysia.",Kuala Lumpur,Wilayah Persekutuan Kuala Lumpur,50586,"Michelle ",William Santhiagu,Study Coordinator,michelle@clinicalresearch.my,0162343869,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,,,,31-45%,16-30%,≤15%,≤15%,Yes,No,,1 study,4,2,2,0,100,0,0,0,0,,0,100,20,70,10,50,50,Yes,Yes,"english, malay",Yes,No,"looking forward more IBD clinical trials ",no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30116082,60722568,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Kuala Lumpur,Jalan Pahang,Kuala Lumpur,Malaysia,Kuala Lumpur,50586,Mohd Fairul,Limun,+60 12 247 6282,mohdfairul511@gmail.com,wchan26@its.jnj.com,136170,CG_0CERLMFLETcgLwR,8 Jun 2026,13:05 +2026-06-01 14:51:03,2026-06-08 01:53:53,IP Address,213.108.84.57,100,558169,True,2026-06-08 01:53:53,R_2tofPL7uZcaPgSE,Orleanski,Jakub,inv.2419787.3@dd-proxy.com,,50.8381,16.49,gl,EN,No,Jakub,Orleanski,Dc Med Sp z o o,surgeon,j.orleanski@dc-med.pl,48533599794,Dworcowa 5,Swidnica,Lower Silesia,58 100,Poland,Yes,Wiktoria,Surówka,DC-MED Michal Kowalski S.K,w.surowka@dc-med.pl,48533599794,Dworcowa 5,Swidnica,lower silesia,58-100,Katarzyna,Hliwa,SC,k.hliwa@dc-med.pl,48533599814,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,Vedolizumab is completely free of charge once the patient qualifies for the drug program,,,,,,,,31-45%,No,No,,0 studies,8,3,5,100,0,0,0,0,0,,0,100,0,98,2,70,30,Yes,Yes,"Ukrainian, English",Yes,Yes,"Centralized patient recruitment as a support tool, patient brochures, posters","regarding Q31 - Dr Orleanski responded that +Vedolizumab is most commonly prescribed as a fourth-line treatment, accounting for approximately 40% of prescriptions. Its use in the first-, second-, and third-line treatment settings is close to 0%. received via email 10 June 26)",Witold Marczynski,Janusz Romanowski,,,,DC-MED Michal Kowalski S.K,DC-MED Michal Kowalski S.K,,,,"Dworcowa 5, 58-100 Swidnica","Jana Kilinskiego 6, 26-610 Radom",,,,15,9,5,2,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,2,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Local,,4,3,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30135488,60603767,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Dc Med Sp z o o,Dworcowa 5,Swidnica,Poland,Lower Silesia,58 100,Jakub,Orleanski,48533599794,inv.2419787.3@dd-proxy.com,kfacdabr@its.jnj.com,136325,CG_2TpEWAbUHWQGQ0R,8 Jun 2026,13:23 +2026-06-02 12:32:18,2026-06-08 05:41:30,IP Address,150.164.89.120,100,493751,True,2026-06-08 05:41:31,R_7iephDVFCNLNKmZ,Andrade Pinto,Jorge,jorgeandradepinto@gmail.com,,-19.9029,-43.9572,gl,EN,No,Jorge,Andrade Pinto,Universidade Federal De Minas Gerais - Hospital das Clínicas,Clinical Immunology,jorgeandradepinto@gmail.com,553134099822,Avenida Professor Alfredo Balena 110,Belo Horizonte,Minas Gerais,30130-100,Brazil,Yes,"Laura ",Costa,UFMG,lavlc@hotmail.com,3134099822,,Belo Horizonte,MG,30130-100,Laura,Costa,SC,lavlc@hotmail.com,3134099822,Same as above,,,,,,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,1,1,1,,16-30%,46-60%,31-45%,,Yes,No,,2 studies,10,4,6,30,0,70,0,0,0,,70,30,20,60,20,40,60,Yes,No,,Yes,No,"None. ",,,,,,,,,,,,,,,,,180,50,130,20,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,3,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,4,6,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,,,,,30095740,60433725,,,true,1,,,,,,,,,,,,,,,,,,,,,,,,Clinical Immunology,,,,Universidade Federal De Minas Gerais - Hospital das Clínicas,Avenida Professor Alfredo Balena 110,Belo Horizonte,Brazil,Minas Gerais,30130-100,Jorge,Andrade Pinto,553134099822,jorgeandradepinto@gmail.com,gcompian@its.jnj.com,136675,CG_1hT14ylg53fnvu1,8 Jun 2026,17:11 +2026-06-02 12:14:01,2026-06-08 06:28:25,IP Address,107.151.163.164,100,497663,True,2026-06-08 06:28:26,R_72Y3ku3O6RpL3xN,Vasconcelos Fernandes,Jose Eduardo,jeduardovf@icloud.com,,-23.5475,-46.6361,gl,EN,No,Maria Ligia,Lyra Pereira,Irmandade da Santa Casa da Misericórdia de Santos,Colorrectal surgeon,ligia.lyra@uol.com.br,5513997819332,Avenida Doutor Cláudio Luiz da Costa 50,Santos,São Paulo,11075-101,Brazil,Yes,Yasmin,Souza,SCIENCE VALLEY RESEARCH INSTITUTE,yasmin.gondim@svriglobal.com,13974058289,RUA CLAUDIO LUIS DA COSTA 50,Santos,sp,11075900,yasmin,souza,study coordinator,yasmin.gondim@svriglobal.com,13974058289,Different from the above,Daniele,Komar,manager,daniele.komar@svriglobal.com,1140408670,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,16-30%,16-30%,≤15%,≤15%,No,No,,0 studies,10,8,2,40,10,45,0,0,5,brasilian indian,90,10,5,80,15,50,50,Yes,No,,Yes,No,"educational programs for doctors ",,,,,,,,,,,,,,,,,60,10,50,15,8,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,1,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,3,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30095035,60392884,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Irmandade da Santa Casa da Misericórdia de Santos,Avenida Doutor Cláudio Luiz da Costa 50,Santos,Brazil,São Paulo,11075-101,Jose Eduardo,Vasconcelos Fernandes,5513997113072,gastrocor@gastrocor.med.br,gcompian@its.jnj.com,136674,CG_2aLgegPLwfiu15O,8 Jun 2026,17:58 +2026-06-03 00:51:00,2026-06-08 06:36:17,IP Address,105.245.113.14,100,452716,True,2026-06-08 06:36:17,R_2M6h5JuAZyew080,Breedt,Johannes,jbreedt@emmed.co.za,,-25.757,28.1443,gl,EN,No,Johannes,Breedt,Netcare Jakaranda Hospital - Emmed Clinical Research,General Practitioner,jbreedt@emmed.co.za,27123436844,213 Middelberg St Suite 101,Pretoria,Gauteng,0002,South Africa,Yes,"Hendrihet ",van Rensburg,Emmed Research(Pty)Ltd,hendrihet@emmed.co.za,+27123436844,"Suite 2, Netcare Jakaranda Hospital, 213 Middelberg Street, Muckleneuk",Pretoria,Gauteng,0002,Johannes,Breedt,PI,jbreedt@emmed.co.za,+27123436844,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,1,,≤15%,46-60%,31-45%,,Yes,No,,0 studies,6,3,3,60,10,15,0,0,15,mixed race,0,100,5,85,10,60,40,Yes,Yes,"Afrikaans, English",Yes,No,Central advertising if possible,No,,,,,,,,,,,,,,,,40,20,20,5,3,No,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,4,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,8,,1,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30153576,60377714,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Netcare Jakaranda Hospital - Emmed Clinical Research,213 Middelberg St Suite 101,Pretoria,South Africa,Gauteng,0002,Johannes,Breedt,27123354767,jbreedt@emmed.co.za,nmadliwa@its.jnj.com,135781,CG_2YM0DQQHGK9qQXy,8 Jun 2026,18:06 +2026-06-05 10:24:43,2026-06-08 08:45:50,IP Address,216.68.176.166,100,253266,True,2026-06-08 08:45:50,R_30WS9UsGz4sEgaB,Jones,Michael,mjones-research@tsddc.com,,39.1057,-84.5036,gl,EN,Yes,Michael,Jones,Tri-State Gastroenterology Assoc,gastroenterology,mjones-research@tsddc.com,8593413575,Centre View Boulevard 425,Crestview Hills,Kentucky,41017,United States,Yes,Theresa,McKinley,Tri-State Gastroenterology Associates,theresa.mckinley@stelizabeth.com,8596554472,"3812 Gregory Lane ",Erlanger,KY,41017,Theresa,McKinley,Research Coordinator,theresa.mckinley@stelizabeth.com,8596554472,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,different for every patient due to deductables and max out of pocket with co pay card support,1,1,1,1,16-30%,≤15%,≤15%,≤15%,Yes,No,,1 study,2,1,1,90,5,5,0,0,0,,5,95,0,80,20,50,50,No,No,,No,No,"To supply vedolizumab to the site due to potential patient's insurance varries. +","same as support with getting vendolizumab +",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30060022,60219000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tri-State Gastroenterology Assoc,Centre View Boulevard 425,Crestview Hills,United States,Kentucky,41017,Michael,Jones,8593413575,mjones-research@tsddc.com,jnowak2@its.jnj.com,137099,CG_pLgvEpVNfVKC9Q5,8 Jun 2026,20:15 +2026-06-04 13:05:49,2026-06-08 15:38:27,IP Address,64.54.15.152,100,354758,True,2026-06-08 15:38:28,R_5S4uSg57tlhDpxT,Lewin,Sara,Sara.Lewin@ucsf.edu,,37.7562,-122.4866,gl,EN,Yes,Sara,Lewin,University of California San Francisco - Parnassus Campus,Gastroenterology,Sara.Lewin@ucsf.edu,14155024444,505 Parnassus Avenue,San Francisco,California,94143,United States,Yes,Dylan,Odom,"University of California, San Francisco/Center for Colitis and Crohn’s Disease",Dylan.odom@ucsf.edu,4155144896,1701 Divisadero St Suite 120,San Francisco,California,94115,Dylan,Odom,Clinical Research Coordinator,Dylan.odom@ucsf.edu,4155144896,Different from the above,Don,Colburn,Sr Industry Contracts Officer,Don.Colburn@ucsf.edu,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,31-45%,16-30%,,,Yes,No,,2 studies,3,3,0,50,30,5,5,10,0,,15,85,0,80,20,48,52,Yes,No,,No,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30153679,60445494,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,University of California San Francisco - Parnassus Campus,505 Parnassus Avenue,San Francisco,United States,California,94143,Sara,Lewin,14155024444,Sara.Lewin@ucsf.edu,jnowak2@its.jnj.com,137149,CG_2B9XtcTSlykWEOE,9 Jun 2026,03:08 +2026-06-01 05:59:51,2026-06-09 00:35:35,IP Address,193.55.227.254,100,671744,True,2026-06-09 00:35:36,R_8hsRn9ze0Sc7XUW,Caron,Benedicte,b.caron@chru-nancy.fr,,48.6822,6.1862,gl,EN,Yes,Benedicte,Caron,Centre Hospitalier Regional Universitaire de Nancy - Hopitaux de Brabois,Gastro-Enterology,b.caron@chru-nancy.fr,+33 38 315 7488,Rue du Morvan,Vandœuvre-lès-Nancy,Grand-Est,54500,France,Yes,Séverine,PETIT,CHRU de Nancy Plateforme MICI,s.petit@chru-nancy.fr,+33 3 83 15 74 50,rue du Morvan,VANDOEUVRE LES NANCY,FRANCE,54500,Séverine,PETIT,Site coordinator,s.petit@chru-nancy.fr,+33 3 83 15 74 50,Different from the above,,,,promotion.externe.nancy@chru-nancy.fr,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,31-45%,31-45%,≤15%,,Yes,No,,More than 2 studies,3,3,0,90,5,5,0,0,0,,0,100,0,95,5,60,40,Yes,No,,Yes,Yes,triptych for patients,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,true,,,,,,,,,,,,,,,,,true,,,,,,,,,,,30151559,60472328,,,,,,,,,,,,,,Multiple room (about 12 beds in intensive care) to follow patient during night. Dedicated night team,,,,,,,,,,,,,,,,,true,Centre Hospitalier Regional Universitaire de Nancy - Hopitaux de Brabois,Rue du Morvan,Vandœuvre-lès-Nancy,France,Grand-Est,54500,Benedicte,Caron,+33 38 315 7488,b.caron@chru-nancy.fr,rbelhadj@its.jnj.com,136237,CG_3KAseZFEBbVCum6,9 Jun 2026,12:05 +2026-05-29 03:46:19,2026-06-09 01:32:45,IP Address,113.211.134.115,100,942385,True,2026-06-09 01:32:45,R_4y6KVUgKVXTCe0V,Ngeoh,Siang Yee,syngeoh@gmail.com,,3.1621,101.5976,gl,EN,No,Siang Yee,Ngeoh,Hospital Selayang,"Gastroenterology ",syngeoh@gmail.com,0124356369,Lebuhraya Selayang - Kepong,Selayang,Selangor,68100,Malaysia,Yes,Nor Azizah,Mohamad Nazri,CRC,azizah@clinicalresearch.my,,,,,,Nor Azizah,,,azizah@clinicalresearch.my,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,1,1,,,31-45%,46-60%,,No,No,,0 studies,4,2,2,0,99,0,0,0,1,Indigenous East Malaysia / Orang Asli / Expatriates,0,100,2,80,18,60,40,Yes,Yes,"bahasa Malaysia, English, mandarin , Tamil ",Yes,Yes,"Support from J&J in streamlined coordination with the central imaging/endoscopy reading vendor (e.g., rapid upload portals, clear grading feedback, and prompt turnaround of Mayo Endoscopic Scores) is essential to prevent screening overruns and dropouts. +If the protocol mandates specific video recording formats or dedicated hardware for transferring high-definition mucosal biopsies/videos to a central reader, providing these tools pre-configured to our endoscopy suite will eliminate local IT bottleneck issues. +Hospital Selayang serves as a national tertiary hub, meaning some eligible moderate-to-severe UC patients may travel significant distances from outside the immediate Selangor/Klang Valley region. A structured, ethics-approved patient travel reimbursement program (covering transport, parking, or overnight stays if required for early-morning procedures) is vital for minimizing participant attrition.",-,,,,,,,,,,,,,,,,35,25,10,4,1,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,0,0,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,8,,12,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78447,78447,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Selayang,Lebuhraya Selayang - Kepong,Selayang,Malaysia,Selangor,68100,Siang Yee,Ngeoh,0124356369,syngeoh@gmail.com,wchan26@its.jnj.com,136174,CG_1QosGAOxoNNNBiO,9 Jun 2026,13:02 +2026-06-01 08:59:29,2026-06-09 02:55:21,IP Address,78.83.10.229,100,669352,True,2026-06-09 02:55:22,R_2nYyuLriVcLmae5,Stoev,Svetoslav,s.stoev@vita.bg,,42.6826,23.3223,gl,EN,No,"Vasil ",Koynarski,MHAT Vita,"gastroenterology ",s.stoev@vita.bg,+359887593915,"ulitsa ""Dragovitsa"" 9",Sofia,Sofia City Province,1407,Bulgaria,Yes,Svetoslav,Stoev,"MHAT Vita, Clinical trials department",slavi1702@gmail.com,0887593915,"Filip Kutev 10 ",Sofia,Sofia,1407,Svetoslav,Stoev,"Reserach coordinator ",slavi1702@gmail.com,0887593915,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,1,,,31-45%,16-30%,,Yes,No,,2 studies,3,2,1,100,0,0,0,0,0,,0,100,0,95,5,40,60,Yes,Yes,"Bulgarian, it is a local regulatory requirement all the patient-facing materials to be in the local language. ",Yes,No,,,,,,,,,,,,,,,,,,120,45,75,5,11,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,4,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Central,5,,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30104539,60908765,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MHAT Vita,"ulitsa ""Dragovitsa"" 9",Sofia,Bulgaria,Sofia City Province,1505,Vanushka Georgieva,Markova,+359887593915,s.stoev@vita.bg,imitkova@its.jnj.com,136260,CG_rrvMSkKDDBusnPX,9 Jun 2026,14:25 +2026-06-02 09:24:08,2026-06-09 04:42:23,IP Address,193.134.32.99,100,587895,True,2026-06-09 04:42:24,R_2NxDbtUeb0gOoPg,Brand,Stephan,stephan.brand@h-och.ch,,47.4234,9.3696,gl,EN,Yes,Stephan,Brand,HOCH Health Ostschweiz-Kantonsspital St.Gallen,Gastroenterology,stephan.brand@h-och.ch,41714941065,Rorschacher Strasse 95,St. Gallen,St. Gallen,9000,Switzerland,Yes,Caroline,Dietrich,"HOCH Kantonsspital St. Gallen, Gastroenterologie/Hepatologie",caroline.dietrich@h-och.ch,0714947065,Rorschacherstrasse 95,St. Gallen,,9007,Caroline,Dietrich,SC,caroline.dietrich@h-och.ch,0714947065,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,46-60%,16-30%,≤15%,≤15%,Yes,No,,More than 2 studies,3,2,1,95,3,2,0,0,0,,1,0,0,80,20,50,50,Yes,No,,Yes,No,,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,true,,,,,,,,,30099366,60378884,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HOCH Health Ostschweiz-Kantonsspital St.Gallen,Rorschacher Strasse 95,St. Gallen,Switzerland,St. Gallen,9000,Stephan,Brand,41714941065,stephan.brand@h-och.ch,cgruener@its.jnj.com,136005,CG_1H5lwJqbv6b888r,9 Jun 2026,16:12 +2026-05-27 01:47:37,2026-06-09 05:39:02,IP Address,91.65.178.10,100,1137084,True,2026-06-09 05:39:02,R_8UqGRMgnTuJn0kx,Buening,Carsten,c.buening@waldfriede.de,,52.45,13.2012,gl,EN,Yes,Carsten,Buening,Krankenhaus Waldfriede Mitte,internal medicine,c.buening@waldfriede.de,4930818108509,Argentinische Allee 40,Berlin,Berlin,14163,Germany,Yes,Bianca,Deparade- Berger,Krankenhaus Waldfriede,b.berger@waldfriede.de,030818108534,Argentinische Allee 40,Berlin,,14163,Bianca,Deparade-Berger,SC,b.berger@waldfriede.de,030818108534,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,1,,≤15%,16-30%,46-60%,≤15%,Yes,No,,2 studies,3,2,1,100,0,0,0,0,0,,0,100,0,85,15,50,50,No,No,,Yes,No,,NONE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30027467,60088804,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Krankenhaus Waldfriede Mitte,Argentinische Allee 40,Berlin,Germany,Berlin,14163,Carsten,Buening,4930818108509,c.buening@waldfriede.de,mraddatz@its.jnj.com,135730,CG_2wmY26tSb0WAf7u,9 Jun 2026,17:09 +2026-06-01 14:54:00,2026-06-09 06:02:20,IP Address,109.95.203.62,100,659300,True,2026-06-09 06:02:20,R_8koX7ma14cv62dZ,Romanczyk,Tomasz,romanczyk@htcentrum.pl,,50.1299,18.9857,gl,EN,No,Tomasz,Romanczyk,H-T Centrum Medyczne Endoterapia,Gastroenterology,romanczyk@htcentrum.pl,+48515342221,aleja Bielska 103a,Tychy,,43-100,Poland,Yes,Izabela,Suszka,H-T. Medical Center,i.suszka@htcentrum.pl,+48515342221,al. Bielska 103 a,Tychy,,43-100,"Izabela ",Suszka,Lead Study Coordinator,i.suszka@htcentrum.pl,+48515342221,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,in drug programs as part of hospital treatment,1,1,1,1,31-45%,16-30%,≤15%,≤15%,No,No,,More than 2 studies,8,4,4,100,0,0,0,0,0,,0,100,0,80,20,60,40,Yes,No,,No,No,,,,,,,,,,,,,,,,,,240,100,80,40,40,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,24,4,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,12,,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30090104,60607004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,H-T Centrum Medyczne Endoterapia,aleja Bielska 105,Tychy,Poland,Silesian Voivodeship,43-100,Tomasz,Romanczyk,48322178866,romanczyk@htcentrum.pl,kfacdabr@its.jnj.com,136337,CG_2TBk1slbhNgDSp6,9 Jun 2026,17:32 +2026-06-02 12:08:44,2026-06-09 08:25:46,IP Address,200.144.1.109,100,591421,True,2026-06-09 08:25:46,R_5nMAxjMzqaz2ENP,Poli,Debora Dourado,deborapoli@hotmail.com,,-23.6293,-46.6351,gl,EN,No,Debora Dourado,Poli,Instituto de Assistencia Medica ao Servidor Publico Estadual IAMSPE,Gastroenterology,deborapoli@hotmail.com,551145738552,Rua Pedro de Toledo 1800,São Paulo,São Paulo,04039-004,Brazil,Yes,Rafaela Almeida Bacci,Domingues,Instituto de Assistencia Médica ao Servidor Publico Estadual - IAMSPE,conhecerpesquisa2@gmail.com,1145738552,"Rua: Pedro de Toledo, 1800",São Paulo,São Paulo,04039901,Rafaela Almeida Bacci,Domingues,SC,conhecerpesquisa2@gmail.com,1145738552,Same as above,,,,,,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,1,1,≤15%,>60%,16-30%,≤15%,Yes,No,,0 studies,2,1,1,80,5,15,0,0,0,,95,5,0,85,15,40,60,Yes,No,,No,No,NA,NA,,,,,,,,,,,,,,,,20,2,12,8,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,6,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,4,4,No,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,3,false,,,,,,,,,30155023,60205286,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Instituto de Assistencia Medica ao Servidor Publico Estadual IAMSPE,Rua Pedro de Toledo 1800,São Paulo,Brazil,São Paulo,04039-004,Debora Dourado,Poli,551145738552,deborapoli@hotmail.com,gcompian@its.jnj.com,136654,CG_1o6atEiCR8G39gt,9 Jun 2026,19:55 +2026-06-09 06:17:27,2026-06-09 09:11:09,IP Address,46.135.104.124,100,10421,True,2026-06-09 09:11:10,R_8gv9rVAh2gwEWIt,Svoboda,Pavel,pavel.svoboda@fno.cz,,49.5864,17.2537,gl,EN,No,Pavel,Svoboda,Fakultni nemocnice Ostrava,gastroenterology,pavel.svoboda@fno.cz,420597374191,17. listopadu 1790,Ostrava,Moravskoslezský kraj,708 00,Czech Republic,Yes,Tereza,Filipska,FN Ostrava,tereza.filipska@fno.cz,+420597374187,17. listopadu 1790,Ostrava,,70852,Tereza,Filipska,SC/Mgr.,tereza.filipska@fno.cz,+420597374187,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,>60%,16-30%,16-30%,≤15%,Yes,No,,1 study,4,2,2,100,0,0,0,0,0,,0,100,0,95,5,50,50,Yes,No,,Yes,No,inzerce náboru do studie,ne,Lukáš Bajer,,,,,Endohope,,,,,bajer@endohope.cz,,,,,200,80,120,60,10,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,6,3,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,6,12,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,30045883,60628391,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fakultni nemocnice Ostrava,17. listopadu 1790,Ostrava,Czech Republic,Moravskoslezský kraj,708 00,Pavel,Svoboda,420597374191,pavel.svoboda@fno.cz,vbuzalka@its.jnj.com,137443,CG_1jvnDPuBytyLiUX,9 Jun 2026,20:41 +2026-06-05 08:13:21,2026-06-09 09:20:45,IP Address,77.159.187.248,100,349643,True,2026-06-09 09:20:46,R_8F4fwSfLfahYXzy,Nachury,Maria,maria.nachury@chru-lille.fr,,50.6375,3.0542,gl,EN,Yes,Maria,Nachury,CHU Lille - Hôpital Claude Huriez,Gastroenterology,maria.nachury@chu-lille.fr,+33320445321,Rue Michel Polonowski,Lille,Hauts-de-France,59037,France,Yes,Virginie,Suffys,Service Maladies Appareil Digestif - Hôpital Claude HURIEZ,virginie.suffys@chu-lille.fr,+33320445620,"Rue Michel Polonovski ",LILLE CEDEX,59 - NORD,59037,Virginie,Suffys,"Study Coordinator ",virginie.suffys@chu-lille.fr,+33320445620,Different from the above,Aline,Carliez,,aline.carliez@chu-lille.fr,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,31-45%,,,Yes,No,,2 studies,2,2,0,100,0,0,0,0,0,,0,100,0,100,0,50,50,No,No,,Yes,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30153851,60562514,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez,Rue Michel Polonowski,Lille,France,Hauts-de-France,59000,Maria,Nachury,33320445321,maria.nachury@chru-lille.fr,rbelhadj@its.jnj.com,136232,CG_3IPIfDVT5vJx828,9 Jun 2026,20:50 +2026-06-09 08:32:22,2026-06-09 09:50:46,IP Address,89.214.151.110,100,4703,True,2026-06-09 09:50:47,R_2E09vVPVMPdlvjn,Torres,Joana,joanatorres00@gmail.com,,40.2057,-8.4213,gl,EN,Yes,Joana,Torres,Hospital Beatriz Angelo,Gi,joanatorres00@gmail.com,351219847213,Avenida Carlos Teixeira 3,Loures,Lisbon,2674-514,Portugal,Yes,Joana,Torres,Hba/GI,joanatorres00@gmail.com,+351919740545,,,,,,,,,,Different from the above,Susana,Saraiva,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,,,,,,,No,No,,2 studies,2,2,1,90,0,10,0,0,0,,0,0,0,90,10,50,50,No,No,,Yes,No,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,,,,,30098738,60500732,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Beatriz Angelo,Avenida Carlos Teixeira 3,Loures,Portugal,Lisbon,2674-514,Joana,Torres,351219847213,joanatorres00@gmail.com,shenriq1@its.jnj.com,137454,CG_yWqHsOIsop306e5,9 Jun 2026,21:20 +2026-06-09 08:31:01,2026-06-09 10:25:14,IP Address,213.146.212.43,100,6852,True,2026-06-09 10:25:15,R_80xY6248DA4vyHn,Fernandes,Samuel,samuelrmfernandes@gmail.com,,38.7219,-9.1398,gl,EN,Yes,Samuel,Fernandes,ULS Santa Maria - Hospital de Santa Maria,Gastrenterology,samuelrmfernandes@gmail.com,351968644836,Avenida Professor Egas Moniz 1649,Lisbon,Lisbon,1600,Portugal,Yes,Susana,Ponte,Hospital Santa Maria,sp.ensaios.cic@gmail.com,351 961087069,Avenida Professor Egas Moniz MB,Lisboa,Lisboa,1649-028,Susana,Ponte,,sp.ensaios.cic@gmail.com,351 961087069,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,1,1,1,1,≤15%,≤15%,≤15%,≤15%,Yes,No,,2 studies,6,3,3,100,0,0,0,0,0,,0,100,0,100,0,50,50,Yes,Yes,english portuguese,No,No,,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,Digital storage,,,,,,,,,,,,,,,,,,,false,,,,,,,,,,,,,30102853,60086017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ULS Santa Maria - Hospital de Santa Maria,Avenida Professor Egas Moniz 1649,Lisbon,Portugal,Lisbon,1600,Samuel,Fernandes,351968644836,samuelrmfernandes@gmail.com,shenriq1@its.jnj.com,137457,CG_bHiyoVA4f9hNA3v,9 Jun 2026,21:55 +2026-06-09 06:19:30,2026-06-09 10:47:07,IP Address,92.180.242.11,100,16057,True,2026-06-09 10:47:08,R_8QXkvy89DtW8R3p,Fedurco,Miroslav,fedurco@endomed.sk,,48.4669,21.7556,gl,EN,No,Miroslav,Fedurco,ENDOMED s.r.o,gastroenterology,fedurco@endomed.sk,421905271215,Americká trieda 19,Košice,Košice Region,040 13,Slovakia,Yes,Lenka,Botoňková,"ENDOMED, s.r.o.",botonkovalenka@gmail.com,+421951755780,Americka trieda 19,Košice-Ťahanovce,Slovensko,04013,Miroslav,Fedurco,principal investigator,fedurco@endomed.sk,+421905271215,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,,,,,,,,Yes,No,,More than 2 studies,4,2,2,100,0,0,0,0,0,,0,100,0,90,10,45,55,Yes,No,,Yes,Yes,,no,,,,,,,,,,,,,,,,400,180,220,60,15,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,5,10,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,4,,1,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30104497,60171411,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ENDOMED s.r.o,Americká trieda 17,Košice,Slovakia,Košice Region,040 13,Miroslav,Fedurco,421905271215,fedurco@endomed.sk,vbuzalka@its.jnj.com,136443,CG_2e4OcyIm2ovnnWs,9 Jun 2026,22:17 +2026-06-02 12:30:17,2026-06-09 11:51:03,IP Address,200.238.32.2,100,602445,True,2026-06-09 11:51:03,R_67DQJ6mfngd70hB,Stifft,Jonathas,jstifft@icloud.com,,-30.1188,-51.168,gl,EN,No,Jonathas,Stifft,Hospital Moinhos de Vento (HMV),GASTROENTEROLOGIA,jstifft@icloud.com,555133143109,Rua Ramiro Barcelos 910,Porto Alegre,Rio Grande do Sul," 90560-032",Brazil,No,,,,,,,,,,Núcleo,Start-up,Research Assistant,contato.pesquisaclinica@hmv.org.br,55 (51) 3537-8258,Same as above,,,,,,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,31-45%,16-30%,≤15%,,Yes,No,,1 study,5,3,2,40,5,20,0,0,35,No Brasil é complicado separar as etnias,80,20,0,80,20,50,50,Yes,No,,No,Yes,"Additional support for patient recruitment would be highly appreciated. Providing a dedicated budget for recruitment initiatives and outreach activities could significantly enhance the site's ability to identify and engage potential participants. This may include support for advertising campaigns, digital outreach, patient awareness materials, and other locally approved recruitment strategies. Such resources would help increase study visibility within the target patient population and contribute to achieving enrollment goals in a timely manner.",No,,,,,,,,,,,,,,,,140,40,100,40,2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,5,5,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,4,,8,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,false,,,,,,,,,,,,,30092235,60179422,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Moinhos de Vento (HMV),Rua Ramiro Barcelos 910,Porto Alegre,Brazil,Rio Grande do Sul,90035-001,Jonathas,Stifft,555133143109,jstifft@icloud.com,gcompian@its.jnj.com,136671,CG_2YVs6wuYZ9uBvuU,9 Jun 2026,23:21 +2026-06-01 14:30:30,2026-06-09 11:51:08,IP Address,217.119.64.70,100,681638,True,2026-06-09 11:51:09,R_2Iaqtj7osSwURfc,Bochenek,Anna,anna.bochenek@cbwt.eu,,52.2331,20.9982,gl,EN,Yes,Anna,Bochenek-Mularczyk,Medon Clinical Research,Internal medicine,anna.bochenek@medoncr.com,+48691539115,Ul Zygmunta Modzelewskiego 6 LU1,Warsaw,Masovian Voivodeship,02-679,Poland,Yes,Michal,Fedorczyk,Medon Clincial Research,michal.fedorczyk@medoncr.com,+48505024164,Zygmunta Modzelewskiego 6/LU1,Warszawa,Mazovia,02-679,Michal,Fedorczyk,Study Coordinator,michal.fedorczyk@medoncr.com,505024164,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",Vedolizumab is fully reimbursed/covered if in National Health Fund drug programs,,,1,,,,>60%,,Yes,No,,1 study,15,2,13,100,0,0,0,0,0,,0,100,0,90,10,60,40,Yes,No,,Yes,No,Materials about the trial (electronic and paper) which could be distribute to potential patients,"no, the in/ex criteria are clear. regarding ongoing and planned studies - 1 study recruiting, 3-6 studies ongoing but not recruiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30160485,60624068,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Medon Clinical Research,Ul Zygmunta Modzelewskiego 6 LU1,Warsaw,Poland,Masovian Voivodeship,02-679,Anna,Bochenek,48006659764,anna.bochenek@cbwt.eu,kfacdabr@its.jnj.com,136341,CG_3vCF9BLIrQKVCQ9,9 Jun 2026,23:21 +2026-06-09 11:04:21,2026-06-09 11:55:43,IP Address,12.216.111.81,100,3081,True,2026-06-09 11:55:43,R_7atzruX8oCDpZKr,Dryden,Gerald,gerald.dryden@louisville.edu,,37.751,-97.822,gl,EN,Yes,Gerald,Dryden,"University of Louisville ",Gastroenterology,gerald.dryden@louisville.edu,15028526105,627 S. Preston Street,Louisville,Kentucky,40202,United States,Yes,"Kimiko ",Kasama,Research,Kimiko.Kasama@louisville.edu,502-852-7402,"501 E Broadway, Suite 210",Louisville,KY,40202-1617,,,,,,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,16-30%,,,Yes,No,,0 studies,4,3,1,70,2,28,0,0,0,,5,0,0,75,25,46,54,Yes,No,,Yes,Yes,None needed outside of normal support,None that haven’t been discussed already,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30153261,60536900,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Jewish Hospital,Abraham Flexner Way 200,Louisville,United States,Kentucky,40202,Gerald,Dryden,15028526105,gerald.dryden@louisville.edu,hsantosm@its.jnj.com,137148,CG_3sgcwSVsCUzaqao,9 Jun 2026,23:25 +2026-06-09 06:18:42,2026-06-09 12:28:17,IP Address,195.113.79.2,100,22174,True,2026-06-09 12:28:18,R_8HGNipndvlGLmlL,Pesta,Martin,pestam@seznam.cz,,50.0687,14.3947,gl,EN,No,Martin,Pesta,Fakultni nemocnice Bulovka,gastroenterolog,pestam@seznam.cz,420732701307,2 Budinova Bulovka,Praha,Hlavni mesto Praha,180 81,Czech Republic,No,,,,,,,,,,Martin,Pešta,MUDr.,pestam@seznam.cz,732701307,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,≤15%,46-60%,16-30%,,No,No,,0 studies,3,2,1,100,0,0,0,0,0,,0,100,0,100,0,50,50,No,No,,No,No,nic mne nenapadá,ne,,,,,,,,,,,,,,,,80,20,60,7,5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,2,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,4,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,137444,137444,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fakultni nemocnice Bulovka,2 Budinova Bulovka,Praha,Czech Republic,Hlavni mesto Praha,180 81,Martin,Pesta,420266082560,pestam@seznam.cz,vbuzalka@its.jnj.com,137444,CG_2Eh0EBGmVnU0xUL,9 Jun 2026,23:58 +2026-06-09 06:19:08,2026-06-09 12:37:12,IP Address,185.61.84.107,100,22684,True,2026-06-09 12:37:13,R_2bJMyWHG1eLzpfP,Tichy,Michal,michal.tichy@kzcr.eu,,50.6675,14.0345,gl,EN,No,Michal,Tichy,"Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o.z.",gastroenterology,michal.tichy@kzcr.eu,420477112450,Socialni pace 3316 /12A,Ústí nad Labem,Ústecký kraj,400 11,Czech Republic,No,,,,,,,,,,Michal,Tichy,PI,michal.tichy@kzcr.eu,+420603153151,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,"Vedolizumab is covered: 1) in adult patients with moderately to severely active ulcerative colitis who have failed conventional therapy and are contraindicated for treatment with anti-TNF agents. 2) in adult patients with moderately to severely active ulcerative colitis who: a) are not responding to, are intolerant to, or have a contraindication to full and adequate therapy with corticosteroids and/or immunosuppressants, or b) are not responding to, or are intolerant to, full and adequate therapy with a tumor necrosis factor alpha (TNFalpha) antagonist.",,1,1,1,,>60%,≤15%,≤15%,No,Yes,"If the treatment is not for several years, there will not be much interest from patients.",0 studies,2,1,1,0,0,0,0,0,100,Caucasian,0,0,0,100,0,50,50,Yes,No,,No,No,reimbursement of travel expenses for patients and administrative costs for the center,n.a.,,,,,,,,,,,,,,,,100,50,50,20,20,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,3,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Local,,6,16,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30148534,60083897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o.z.",Socialni pace 3316 /12A,Ústí nad Labem,Czech Republic,Ústecký kraj,400 11,Michal,Tichy,420477112450,michal.tichy@kzcr.eu,vbuzalka@its.jnj.com,137446,CG_2rdTFopxJbe9dmh,10 Jun 2026,00:07 +2026-06-09 06:17:49,2026-06-09 13:22:18,IP Address,86.49.230.244,100,25469,True,2026-06-09 13:22:19,R_81e0HH368l265xL,Falc,Matej,matesfalc@seznam.cz,,50.0948,14.4785,gl,EN,No,Matej,Falc,Centrum gastroenterologie a hepatologie s.r.o.,Gastroenterology,matesfalc@seznam.cz,+420 731168856,Hutska 211,Kladno,Středočeský kraj,27280,Czech Republic,Yes,"Matej ",Falc,Centrum gastroenterologie a Hepatologie s.r.o.,matesfalc@seznam.cz,+420731168856,Hutska 211,"Kladno ","Czechia ",27280,Matěj,Falc,PI,matesfalc@seznam.cz,+420731168856,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,,,,,,,No,No,,1 study,3,0,3,100,0,0,0,0,0,,0,100,0,80,20,50,50,Yes,No,,No,No,a budget that reflects the difficulty and complexity of the study,,,,,,,,,,,,,,,,,8,0,0,0,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,0,3-5,Yes,Yes,No,Yes,No,Yes,Yes,No,Central,3,,1,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30160650,60715322,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centrum gastroenterologie a hepatologie s.r.o.,Hutska 211,Kladno,Czech Republic,Středočeský kraj,27280,Matej,Falc,+420 312 575 338,matesfalc@seznam.cz,vbuzalka@its.jnj.com,136311,CG_3Htyrw6knVIFC8V,10 Jun 2026,00:52 +2026-06-09 06:18:23,2026-06-09 13:35:35,IP Address,185.219.167.139,100,26232,True,2026-06-09 13:35:36,R_8rMsHW6HduKWQHz,Stepek,David,dstepek@vnbrno.cz,,49.1161,16.7276,gl,EN,No,David,Stepek,Vojenska nemocnice Brno,internal medicine,dstepek@vnbrno.cz,+420602642327,Zábrdovická 3,Brno,Jihomoravský kraj,615 00,Czech Republic,Yes,Lenka,Kubicikova,Endoscopy center,ibdcoordinator@vnbrno.cz,,Zabrdovicka 3,Brno,Czech Republic,61500,David,Stepek,PI,dstepek@vnbrno.cz,+420602642327,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,not in our center,,,,,,,,,Yes,No,,1 study,4,2,2,100,0,0,0,0,0,,0,0,0,90,10,50,50,Yes,No,,No,No,,,,,,,,,,,,,,,,,,100,40,20,20,15,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,10,10,≥6,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Central,4,,10,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30152540,60171876,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Vojenska nemocnice Brno,Zábrdovická 3,Brno,Czech Republic,Jihomoravský kraj,615 00,David,Stepek,420973445401,dstepek@vnbrno.cz,vbuzalka@its.jnj.com,136310,CG_9FeryDORkma6dln,10 Jun 2026,01:05 +2026-06-09 05:47:14,2026-06-09 13:48:36,IP Address,79.116.139.163,100,28881,True,2026-06-09 13:48:37,R_8GDKTFriabbY76L,Varela Trastoy,Pilar,trastoy@hotmail.com,,43.3693,-5.8478,gl,EN,Yes,Pilar,Varela Trastoy,Hospital of Cabuenes,"Gastroenterology, IBD",trastoy@hotmail.com,34659897266,Los Prados 395,Gijón,Asturias,33394,Spain,Yes,"GONZALO ",MARTÍNEZ MARTÍN,FINBA,gonzalomrtz9@gmail.com,0034 659897266,"los Prados, 395",Gijón,asturias,33394,"Pilar ","Varela Trastoy ",MD,trastoy@hotmail.com,0034 659897266,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,≤15%,16-30%,46-60%,>60%,Yes,No,,1 study,4,2,2,90,0,0,10,0,0,,90,10,10,80,10,50,50,Yes,No,,No,No,Nothing special,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,,,,,30088574,60434486,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital of Cabuenes,Los Prados 395,Gijón,Spain,Asturias,33394,Pilar,Varela Trastoy,34659897266,trastoy@hotmail.com,jalons12@its.jnj.com,137347,CG_3RjxCwztWejmVIx,10 Jun 2026,01:18 +2026-06-09 09:43:56,2026-06-09 15:32:11,IP Address,209.53.33.162,100,20894,True,2026-06-09 15:32:11,R_3VfMe9jJfFW8Y8l,Leung,Yvette,leungyvette@hotmail.com,,49.2462,-123.108,gl,EN,Yes,Yvette,Leung,GIRI Gastrointestinal Research Institute Foundation,Gastroenterology,leungyvette@hotmail.com,16046886332,Hornby st 1190,Vancouver,British Columbia,V6Z 2K5,Canada,Yes,Maria,Ancheta-Schmit,(G.I.R.I.) GI Research Institute Foundation,marias@giribc.com,604-688-6332,"#770-1190 Hornby St",Vancouver,BC,V6Z 2K5,Maria,Ancheta-Schmit,Research Manager,marias@giribc.com,604-688-6332,Different from the above,Christine,Tran,Regulatory Coordinator,christinet@giribc.com,604-688-6332,Other,Christine,Tran,Regulatory Coordinator,christinet@giribc.com,604-688-6332,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,16-30%,≤15%,,,Yes,No,,0 studies,5,5,0,80,20,0,0,0,0,,0,100,5,95,0,50,50,Yes,No,,No,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30092662,60546751,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GIRI Gastrointestinal Research Institute,Hornby st 1190,Vancouver,Canada,British Columbia,V6Z 2K5,Yvette,Leung,16046886332,leungyvette@hotmail.com,tresuell@its.jnj.com,136420,CG_33kXdeK6oqH2z1P,10 Jun 2026,03:02 +2026-06-09 09:44:40,2026-06-09 16:00:07,IP Address,136.159.160.123,100,22526,True,2026-06-09 16:00:08,R_5FYCE40fxnZjq8x,Ma,Christopher,christopher.ma@ucalgary.ca,,51.0605,-114.1102,gl,EN,No,Christopher,Ma,University of Calgary - Foothills Hospital Campus,Gastroenterology,christopher.ma@ucalgary.ca,14032206014,3280 Hospital Dr NW,Calgary,Alberta,T2N 4Z6,Canada,Yes,Karen,Graham,University of Calgary,kagraham@ucalgary.ca,4032206014,3280 Hospital Drive NW,Calgary,AB,T2N 4Z6,Karen,Graham,Clinical Research Nurse,kagraham@ucalgary.ca,4032206014,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,>60%,31-45%,16-30%,,Yes,No,,0 studies,4,3,1,70,10,10,10,0,0,,30,70,0,80,20,40,60,Yes,No,,No,No,none required at this time,none noted,,,,,,,,,,,,,,,,2000,500,1500,750,200,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,3,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,8,12,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,,,,,,,,,,30093020,60010540,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,University of Calgary - Foothills Hospital Campus,3330 Hospital Dr,Calgary,Canada,Alberta,T2N 4N1,Christopher,Ma,14032206014,christopher.ma@ucalgary.ca,tresuell@its.jnj.com,136427,CG_3scgdFGVXAS0xeQ,10 Jun 2026,03:30 +2026-06-09 08:47:50,2026-06-09 16:44:44,IP Address,70.95.71.166,100,28614,True,2026-06-09 16:44:45,R_3gF4DDHd7XnkiaJ,Bhanvadia,Amit,abhanvadia.cr@gmail.com,,32.9511,-117.2241,gl,EN,Yes,Amit,Bhanvadia,Clinnova Research,Gastroenterologist,abhanvadia.cr@gmail.com,9498890249,"100 S Anaheim Blvd, Suite 250",Anaheim,California,92805,United States,Yes,Tanvi,Nakrani,Clinnova Research,tnakrani@clinnovaresearch.com,9497712772,"100 S Anaheim Blvd, Suite 250",Anaheim,"CA ",92805,Prahar,Parikh,Director of Clinical Operations,prahar@clinnovaresearch.com,9495352341,Different from the above,Aashish,Patel,CEO,aashish.patel@clinnovaresearch.com,9495352346,Other,Prahar,Parikh,Director of Clinical Operations,prahar@clinnovaresearch.com,9495352341,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,,,,16-30%,,,Yes,No,,0 studies,3,1,2,40,40,15,0,5,0,,40,0,0,85,15,55,45,Yes,Yes,Spanish,No,Yes,None for now,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30012778,60499406,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Clinnova Research,100 s anaheim blvd ste 250,anaheim,United States,California,92805,Amit,Bhanvadia,19493545353,abhanvadia.cr@gmail.com,hsantosm@its.jnj.com,137090,CG_2YDM5diLgDujiHS,10 Jun 2026,04:14 +2026-05-29 03:43:27,2026-06-09 18:51:24,IP Address,219.92.29.133,100,1004876,True,2026-06-09 18:51:24,R_9rNJ4p9AaNyRfBF,Nik Razima,Wan Ibrahim,nikrazi@yahoo.com,,3.1325,101.6922,gl,EN,Yes,Wan Ibrahim,Nik Razima,Hospital Ampang,Gastroenterology,nikrazi@yahoo.com,60162601975,Jalan Mewah Utara,Ampang,Selangor,68000,Malaysia,No,,,,,,,,,,Nabila Azirah,Zakaria,Study Coordinator,nabila@clinicalresearch.my,+601112159329,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,16-30%,,,No,No,,2 studies,3,1,2,0,100,0,0,0,0,,0,0,0,100,0,50,50,Yes,Yes,"Malay, English, Mandarin",No,No,poster to blast via social media eg whatsapp for other physician,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30099619,60810289,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Ampang,Jalan Mewah Utara,Ampang,Malaysia,Selangor,68000,Wan Ibrahim,Nik Razima,60162601975,nikrazi@yahoo.com,wchan26@its.jnj.com,136168,CG_3peUIU2l4pMeArW,10 Jun 2026,06:21 +2026-05-29 03:41:56,2026-06-09 20:54:29,IP Address,180.75.238.123,100,1012353,True,2026-06-09 20:54:30,R_9yr5V2jCe8odoeR,Hilmi,Ida Normiha,ida.hilmi@gmail.com,,3.033,101.7142,gl,EN,Yes,Ida Normiha,Hilmi,University Malaya Medical Centre,Gastroenterology,ida.hilmi@gmail.com,60192774545,Lembah Pantai,Kuala Lumpur,Kuala Lumpur,59100,Malaysia,Yes,Lorainne,Angal,University Malaya Medical Centre,lorainne@um.edu.my,+6019-8609606,"Endoscopy Unit, 6th Floor Menara Selatan, Lembah Pantai",Kuala Lumpur,Wilayah Persekutuan,59100," Zulaikha Syazwani ",Zulkifly,Science Officer,zulaikhasyaz@ummc.edu.my,+603-7949 2351,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,1,1,,,31-45%,46-60%,,,No,No,,1 study,2,1,1,0,100,0,0,0,0,,0,100,10,70,20,50,50,Yes,Yes,"English, Chinese, Malay",Yes,No,"We have sufficient facilities to manpower to conduct the trial. ",No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30102186,60165515,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,University Malaya Medical Centre,Lembah Pantai,Kuala Lumpur,Malaysia,Kuala Lumpur,59100,Ida Normiha,Hilmi,60192774545,ida.hilmi@gmail.com,wchan26@its.jnj.com,136164,CG_3HYXtPpg0zI8IVX,10 Jun 2026,08:24 +2026-06-09 05:27:31,2026-06-09 23:29:48,IP Address,86.110.249.250,100,64936,True,2026-06-09 23:29:48,R_80VuXxoGWFxXaQl,Hlavaty,Tibor,hlavaty.studie@cliniq.sk,,48.157,17.0915,gl,EN,No,Tibor,Hlavaty,Cliniq s.r.o.,gastroenterologist,hlavaty.studie@cliniq.sk,421248234905,Bezručova 2531/5,Bratislava,Bratislava Region,811 09,Slovakia,Yes,"Michaela ",Hudecova,Cliniq sro,hudecova@polibez.sk,0917723264,Bezrucova 5,Bratislava,SLOVAKIA,81109,"Michaela ",Hudecova,"study coordinator ",hudecova@polibez.sk,0917723264,Different from the above,"Anna ",Gojdicova,"PI designee, Clinical trials manager ",krajann@hotmail.com,+421902709203,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,>60%,16-30%,≤15%,≤15%,No,No,,1 study,3,2,1,100,0,0,0,0,0,,0,100,10,80,10,50,50,Yes,Yes,"hungarian ",No,No,"good monitors ","no ",,,,,,,,,,,,,,,,500,50,450,300,80,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,6,10,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Central,4,,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30127614,60149726,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cliniq s.r.o.,Bezručova 2531/5,Bratislava,Slovakia,Bratislava Region,811 09,Tibor,Hlavaty,421248234905,hlavaty.studie@cliniq.sk,vbuzalka@its.jnj.com,136448,CG_2b4c8TpD1NIpYl1,10 Jun 2026,10:59 +2026-06-02 06:10:18,2026-06-10 01:17:13,IP Address,87.58.81.16,100,673614,True,2026-06-10 01:17:15,R_8rSc9RmaIMdOAdJ,Lahat-Zok,Adi,adi.lahat@sheba.health.gov.il,,32.0804,34.7807,gl,EN,Yes,Adi,Lahat-Zok,Assuta Medical Centers,"Gastroenterologist ",adi.lahat@sheba.health.gov.il,0526667501,126 Menachem Begin Boulevard,Ashdod,Southern,7747629,Israel,Yes,Sandra,Gur-Arie,Samsung university hospital of Maccabi Assuta Ashdod,sandragu@ashmc.co.il,972-8-3004100,"Ha-Refu'a st 7 ",Ashdod,Israel,7747629,Sandra,Gur-Arie,SC,sandragu@ashmc.co.il,+972-546217700,Same as above,,,,,,Other,Ofra,Kriger - Sharabi,Dr,p-ofrak@ashmc.co.il,+972-50-9422211,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,31-45%,46-60%,,,No,No,,More than 2 studies,5,2,3,100,0,0,0,0,0,,0,0,0,80,20,50,50,Yes,Yes,"Russian, English, Hebrew, Franch",No,No,Regular support,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30155089,60572608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Assuta Medical Centers,126 Menachem Begin Boulevard,Ashdod,Israel,Southern,7747629,Adi,Lahat Zok,0526667501,adizo@assuta.co.il,bmayer1@its.jnj.com,135871,CG_XLMIFuRUVoivAzv,10 Jun 2026,12:47 +2026-06-08 02:48:01,2026-06-10 01:44:46,IP Address,103.101.255.2,100,169005,True,2026-06-10 01:44:47,R_9Q0qJ84YhSFFf5P,Lee,Chong Chearn,leecc84.hctm@ukm.edu.my,,3.1079,101.7321,gl,EN,Yes,Chong Chearn,Lee,Hospital Canselor Tuanku Muhriz UKM,Gastroenterology,leecc84.hctm@ukm.edu.my,60172281908,Jalan Yaacob Latif,Kuala Lumpur,Wilayah Persekutuan Kuala Lumpur,56000,Malaysia,Yes,"KHA CHIN ",LONG,HOSPITAL CANSELOR TUANKU MUHRIZ / MEDICINE,khachin.long@hctm.ukm.edu.my,+60391455582," Jalan Yaacob Latif, Bandar Tun Razak ",Kuala Lumpur,Wilayah Persekutuan,56000,YONG SHEN,TAN,Sub Investigator,skyton9205@hotmail.com,+60102539838,Different from the above,NURUL NADIAH,MOHD ZAIDI,Sub Investigator,nurul.nadiah@clinicalresearch.my,+60164474255,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,≤15%,,,No,No,,1 study,3,2,1,0,100,0,0,0,0,,0,100,0,70,30,50,50,Yes,Yes,"English , Malay , Mandarin ",No,No,"Brochure, Grant funding / test kit/ storage / research asistance",NIL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,137346,137346,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Canselor Tuanku Muhriz UKM,Jalan Yaacob Latif,Kuala Lumpur,Malaysia,Wilayah Persekutuan Kuala Lumpur,56000,Chong Chearn,Lee,,leecc84.hctm@ukm.edu.my,wchan26@its.jnj.com,137346,CG_27rK2CLl7Wkcash,10 Jun 2026,13:14 +2026-06-01 14:43:07,2026-06-10 01:52:33,IP Address,77.252.101.186,100,731365,True,2026-06-10 01:52:33,R_2KqPdJa6oHs5siL,Gawdis-Wojnarska,Beata,gawdis@twojaprzychodnia.com,,51.8947,21.6199,gl,EN,Yes,Beata,Gawdis-Wojnarska,Twoja Przychodnia Szczecińskie Centrum Medyczne Sp. z o.o.,"gastroenterology ",gawdis@twojaprzychodnia.com,48664929399,Juliusza Słowackiego 19,Szczecin,West Pomeranian Voivodeship,71-434,Poland,No,,,,,,,,,,Jakub,Jaszczak,Clinical Research Manager,jaszczak@twojaprzychodnia.com,+48 609 900 745,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,1,,,,31-45%,,No,No,,More than 2 studies,10,3,7,100,0,0,0,0,0,,0,100,20,60,20,50,50,Yes,No,,Yes,No,"no support is anticiapted ",no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30090168,60430545,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Twoja Przychodnia - Szczecinskie Centrum Medyczne,Juliusza Słowackiego 19,Szczecin,Poland,West Pomeranian Voivodeship,71-434,Beata,Gawdis-Wojnarska,48664929399,gawdis@twojaprzychodnia.com,kfacdabr@its.jnj.com,136338,CG_1LZsmvfPWkOjdOl,10 Jun 2026,13:22 +2026-06-01 14:57:48,2026-06-10 03:12:46,IP Address,87.99.120.158,100,735297,True,2026-06-10 03:12:47,R_2fkmko4sJ7zZgdB,Wloch Targonska,Magdalena,m.wloch-targonska@m2m-badania.pl,,50.2693,18.9347,gl,EN,No,Magdalena,Wloch Targonska,M2M Badania Kliniczne,"Gastroenterology, Rheumatology",m.wloch-targonska@m2m-badania.pl,+48 453 10 0640,Lwowska 34,Chorzów,Silesian Voivodeship,41-500,Poland,Yes,Wiktoria,Uznańska,M2M Med Badania,w.uznanska@m2m-badania.pl,+48 572 706 190,ul. Lwowska 34,Chorzów,Silesian,41-500,Monika,Pacuła,Managing Director,m.pacula@m2m-badania.pl," +48 518 424 470",Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,16-30%,46-60%,≤15%,≤15%,Yes,No,,1 study,12,6,6,100,0,0,0,0,0,,0,100,0,90,10,50,50,Yes,No,,No,Yes,NA,NA,,,,,,,,,,,,,,,,130,25,105,30,5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,2,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,6,,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30089300,60873642,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M2M Badania Kliniczne,Lwowska 34,Chorzów,Poland,Silesian Voivodeship,41-500,Magdalena,Wloch Targonska,+48 453 10 0640,m.wloch-targonska@m2m-badania.pl,kfacdabr@its.jnj.com,136351,CG_3IQxEPGpXQJLn8y,10 Jun 2026,14:42 +2026-06-02 09:18:07,2026-06-10 03:18:33,IP Address,161.62.252.40,100,669626,True,2026-06-10 03:18:34,R_8ccI0fTCuzp7AfL,Krupka,Niklas,niklas.krupka@insel.ch,,46.9354,7.4271,gl,EN,Yes,Niklas,Krupka,Universitaetsspital Bern-Inselspital,Gastroenterology,niklas.krupka@insel.ch,41316325957,Freiburgstrasse 4,Bern,Bern,3010,Switzerland,Yes,Michael,Hostettler,Inselspital,michael.hostettler@insel.ch,+41 31 632 17 86,Anna Seiler Allee 20,Bern,Bern,3010,Michael,Hostettler,SC,michael.hostettle@insel.ch,+41 31 632 17 86,Different from the above,Niklas,Krupka,PI,niklas.krupka@insel.ch,+41 31 632 59 57,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,≤15%,16-30%,31-45%,>60%,Yes,No,,2 studies,5,4,1,90,5,5,0,0,0,,5,95,0,80,20,50,50,Yes,Yes,"french, english",No,No,recruitment,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,,,,,30101878,60420974,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Universitaetsspital Bern-Inselspital,Freiburgstrasse 4,Bern,Switzerland,Bern,3010,Niklas,Krupka,41316325957,niklas.krupka@insel.ch,cgruener@its.jnj.com,136007,CG_37R13DdZvTJAdhL,10 Jun 2026,14:48 +2026-06-09 04:57:57,2026-06-10 04:29:26,IP Address,87.58.88.198,100,84689,True,2026-06-10 04:29:27,R_81gQhUVc5kbJ4Hc,Arguelles Arias,Federico,farguelles@telefonica.net,,40.4153,-3.694,gl,EN,Yes,Federico,Arguelles Arias,Hospital Universitario Virgen Macarena,Gastroenterology,farguelles@telefonica.net,34955008000,Avenida Doctor Fedriani 3,Sevilla,Sevilla,41009,Spain,Yes,Jesus,Martin,Digestivo,jesusmartindue@gmail.com,627621785,,SEVILLE,seville,41009,,,,,,Different from the above,carlos,Garcia,,administracion.eecc.hvm.sspa@juntadeandalucia.es,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,,,,,,,Yes,No,,1 study,2,1,1,100,0,0,0,0,0,,0,0,0,100,0,50,50,Yes,No,,No,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30089920,60584434,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Universitario Virgen Macarena,Avenida Doctor Fedriani 3,Sevilla,Spain,Sevilla,41009,Federico,Arguelles Arias,34955008000,farguelles@telefonica.net,jalons12@its.jnj.com,137349,CG_2ZUOZ0NaLlb2h2m,10 Jun 2026,15:59 +2026-06-09 05:13:34,2026-06-10 04:42:25,IP Address,213.0.53.143,100,84531,True,2026-06-10 04:42:26,R_2E1nknKtHojnWWJ,Martín Arranz,María Dolores,martinarranz.lapaz@gmail.com,,40.3907,-3.6997,gl,EN,Yes,María Dolores,Martín Arranz,Hospital Universitario La Paz,Gastroenterology,martinarranz.lapaz@gmail.com,34917277264,Paseo de la Castellana 261,Madrid,Madrid,28046,Spain,Yes,"Laura ",García Ramírez,Hospital Universitario La Paz,eiiclapaz@gmail.com,+34912071350,"Paseo de la Castellana, 261",Madrid,Madrid,28046,Laura,García Ramírez,Study Coordinator,eiiclapaz@gmail.com,+34912071350,Different from the above,María Dolores,Martín Arranz,Principal Investigator,martinarranz.lapaz@gmail.com,+34912071350,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,,1,1,,,,,,Yes,No,,2 studies,2,1,1,98,1,1,0,0,0,,10,90,2,73,25,55,45,No,No,,No,No,none,none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,true,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,,,,,,,,30149940,60184509,,,,,,,,,,,,,,"The site provides full capability for overnight and prolonged stays in the phase 1 unit. +They have 8 beds for treatment administrations and hospitalizations. +The Phase 1 Unit, which operates 24/7 and is staffed with experienced clinical research nurses and on site medical coverage. +The unit manages the full administration, immediate monitoring, and allearly protocol required assessments. +The medical team is highly experienced in managing CRS, ICANS, and advanced therapies, with constant physician availability. +In the Phase 1 Unit, staff coverage can be ensured 24/7 if needed. During the working hours, the unit is staffed directly by the dedicated Phase 1 +personnel. Outside these hours and during weekends, a pool of hospital physicians and nurses is available in the unit to provide support as +required. All of them are included in the internal delegation log.",,,,,,,,,,,,,"At the rheumatology service, the sponsor does not have full, direct electronic access to all source documents. The patient’s medical information is documented in the electronic medical record (HCIS), and only site staff have direct +access to it. The sponsor/monitor has access to all required source documents during monitoring visits, but only through the printed and investigator validated records, not through direct EMR access. Crosscheck will be performed with site satff to confirm all medical records are printed and filed at patient file. + +Please note that in the phase 1unit sponsor will have direct access to EMR (HCIS)",,,,true,Hospital Universitario La Paz,Paseo de la Castellana 261,Madrid,Spain,Madrid,28046,Maria Dolores,Martín Arranz,34917277264,martinarranz.lapaz@gmail.com,jalons12@its.jnj.com,137353,CG_3MARYmhEI4WsnwW,10 Jun 2026,16:12 +2026-06-02 01:57:42,2026-06-10 04:52:58,IP Address,147.236.208.4,100,701715,True,2026-06-10 04:52:59,R_8Ra0xaqhjUS1WjG,Koslowsky,Benjamin,binyaminkos@szmc.org.il,,31.5,34.75,gl,EN,Yes,Benjamin,Koslowsky,Shaare Zedek Medical Center,Gastroenterology,binyaminkos@szmc.org.il,97226666064,Shmu'el Bait Street 12,Jerusalem,Jerusalem,9103102,Israel,Yes,Hana,Shlomov,Gastro,hanas@szmc.org.il,97226666916,"12 Shmuel Beit Street, Bayit vegan",Jerusalem,ISRAEL,9101002,Chava,Kaniel,Lead SC,chavak@szmc.org.il,026666916,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,46-60%,31-45%,,,No,No,,More than 2 studies,4,2,2,90,10,0,0,0,0,,0,0,0,90,10,50,50,Yes,Yes,"Hebrew +English +Arabic +Russian",Yes,No,"Advertising +Pre-screening activity +",No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,true,,,,,,,,,,,,,,,,,,,,,,,,,true,,true,,,,,,,,,,,30108075,60064981,,,,,,,,,,,,,,Patients are admitted to the hematology department.,,,,,,,,,,,,,,,,,false,Shaare Zedek Medical Center,Shmu'el Bait Street 12,Jerusalem,Israel,Jerusalem,9103102,Benjamin,Koslowsky,97226666064,binyaminkos@szmc.org.il,bmayer1@its.jnj.com,135866,CG_2yjCG8Y6SNhpGY9,10 Jun 2026,16:22 +2026-06-05 08:51:25,2026-06-10 06:15:18,IP Address,193.57.201.2,100,422633,True,2026-06-10 06:15:19,R_8LB5zY1mkuwIWn3,Gilletta de Saint Joseph,Cyrielle,gilletta.c@chu-toulouse.fr,,43.6046,1.4451,gl,EN,Yes,Cyrielle,Gilletta de Saint Joseph,Chu De Toulouse Hopital Rangueil,gastroenterologist,gilletta.c@chu-toulouse.fr,33561322231,Avenue du Professeur Jean Poulhès 1,Toulouse,Occitanie,31400,France,Yes,Emilie,BERGEREAU,"CHU RANGUEIL ",bergereau.e@chu-toulouse.fr,0561323080,1 avenue du pr jean poulhes,TOULOUSE,Occitanie,31059,Emilie,BERGEREAU,study co,bergereau.e@chu-toulouse.fr,0561323080,Different from the above,agnes,blanchard-lamazere,,blanchard-lamazere.a@chu-toulouse.Fr,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,>60%,46-60%,16-30%,≤15%,Yes,No,,More than 2 studies,3,3,0,80,3,17,0,0,0,,0,0,1,77,22,55,45,Yes,No,,No,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30139365,60254638,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Chu De Toulouse Hopital Rangueil,Avenue du Professeur Jean Poulhès 1,Toulouse,France,Occitanie,31400,Cyrielle,Gilletta de Saint Joseph,33561322231,gilletta.c@chu-toulouse.fr,rbelhadj@its.jnj.com,136224,CG_1N4eXKps1kSDVgJ,10 Jun 2026,17:45 +2026-06-09 10:38:35,2026-06-10 08:07:38,IP Address,92.175.106.145,100,77342,True,2026-06-10 08:07:38,R_2BJEQ9mWDAM5g0V,Goutorbe,Felix,fgoutorbe@ch-cotebasque.fr,,43.5417,-1.4628,gl,EN,Yes,Felix,Goutorbe,Centre Hospitalier de la Cote Basque,Gastroenterology,fgoutorbe@ch-cotebasque.fr,33670520199,Avenue de l'Interne Jacques Loeb 13,Bayonne,Nouvelle-Aquitaine,64100,France,Yes,Clémence,gallissaires,CHCB,cgallissaires@ch-cotebasque.fr,,,,,,,,,,,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,46-60%,16-30%,≤15%,,Yes,No,,2 studies,3,1,2,80,0,20,0,0,0,,0,0,0,90,10,50,50,Yes,Yes,"freanch, english, spanish",Yes,Yes,,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30050872,60191784,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centre Hospitalier de la Cote Basque,Avenue de l'Interne Jacques Loeb 13,Bayonne,France,Nouvelle-Aquitaine,64100,Felix,Goutorbe,33670520199,fgoutorbe@ch-cotebasque.fr,rbelhadj@its.jnj.com,136229,CG_3h0JOt9tF4utGAM,10 Jun 2026,19:37 +2026-06-03 13:39:27,2026-06-10 08:19:38,IP Address,201.6.144.143,100,585611,True,2026-06-10 08:19:39,R_5yd9Z8bcxkM1Kid,Lamanna,Renata,renata.lamanna@cepic.com.br,,-23.5475,-46.6361,gl,EN,No,Renata,Lamanna,Centro Paulista de Investigaçăo Clínica - CEPIC,Gastroenterology,renata.lamanna@cepic.com.br,(11) 99307-493,Rua Moreira e Costa 342,São Paulo,São Paulo,04266-010,Brazil,Yes,"Vanessa ",Padua,CEPIC,vanessa.padua@cepic.com.br,+551122713466,"Rua Moreira e costa, 342",São Paulo,São Paulo,04266010,"Vanessa ",Padua,study coordinator,vanessa.padua@cepic.com.br,+551122713466,Same as above,,,,,,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","No, not reimbursed/covered by insurance",,1,1,1,,≤15%,31-45%,46-60%,,Yes,No,,0 studies,10,4,6,75,10,15,0,0,0,,100,0,5,90,5,40,60,Yes,Yes,Brazilian portuguese,No,No,,,,,,,,,,,,,,,,,,50,35,15,6,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,1,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,10,,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30095562,60910498,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centro Paulista de Investigaçăo Clínica - CEPIC,Rua Moreira e Costa 342,São Paulo,Brazil,São Paulo,04266-010,Renata,Lamanna,(11) 99307-493,renata.lamanna@cepic.com.br,gcompian@its.jnj.com,136816,CG_8kV6eHDERHg24b7,10 Jun 2026,19:49 +2026-06-02 12:23:38,2026-06-10 10:14:07,IP Address,129.148.27.45,100,683428,True,2026-06-10 10:14:07,R_6g7UGm0YHnPQbnu,Nunes,Fernanda,fcruznunes@gmail.com,,-23.5475,-46.6361,gl,EN,No,Fernanda,Nunes,Complexo Hospitalar de Niteroi,"Gastroenterologista ",fcruznunes@gmail.com,5521988912187,Travessa Lasalle 12,Niterói,Rio de Janeiro,24030-103,Brazil,Yes,Suelen,Silva,Complexo Hospitalar de Niterói,suelen.cunha@americasmed.com.br,+5521972144822,Travessa La Salle n.12,Niterói,Rio de Janeiro,24020077,"Suelen ",Silva,Study Coordinator,suelen.cunha@americasmed.com.br,+5521972144822,Same as above,,,,,,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,46-60%,31-45%,≤15%,≤15%,No,No,,0 studies,11,5,6,60,0,40,0,0,0,,50,50,2,80,18,50,50,Yes,No,,Yes,No," +Promotional materials, participant diaries, flexibility in questionnaires and vendors.",No,,,,,,,,,,,,,,,,50,30,20,5,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,1,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,1,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,,,,,30093883,60907059,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Complexo Hospitalar de Niteroi,Travessa Lasalle 12,Niterói,Brazil,Rio de Janeiro,24030-103,Fernanda,Nunes,5521988912187,fcruznunes@gmail.com,gcompian@its.jnj.com,136673,CG_1jZdqEmLNRJPZ1B,10 Jun 2026,21:44 +2026-06-10 05:43:35,2026-06-10 10:25:02,IP Address,220.137.36.251,100,16886,True,2026-06-10 10:25:02,R_4IzJ71RJ20ak2JZ,Luo,Jiing-Chyuan,jcluo@vghtpe.gov.tw,,25.053,121.5259,gl,EN,No,Jiing-Chyuan,Luo,Taipei Veterans General Hospital,Gastroenterology,jcluo@vghtpe.gov.tw,886228757506,"Section 2, Shipai Road 201",Taipei,Taipei City,112,Taiwan,Yes,Jiing-Chyuan,Luo,Taipei Veterans General Hospital/Medicine/Gastroenterology,jcluo1783j@gmail.com,886-963077736,"No 201, Section 2, Shih Pai Road, Taipei City",Taipei,Taiwan,112,Yi-Wen,Lo,SC,wendylo96084@gmail.com,886-933656509,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,1,,≤15%,46-60%,≤15%,,No,Yes,"patient want to or wait for medicine covered by health insurance ",1 study,2,1,1,0,100,0,0,0,0,,0,100,0,90,10,50,50,Yes,Yes,"Chinese, Taiwanese, then English",Yes,No,"education, nutrition, travel fees ",no,,,,,,,,,,,,,,,,40,8,22,12,4,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,4,0,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,6,,8,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,30102655,60610728,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Taipei Veterans General Hospital,"Section 2, Shipai Road 201",Taipei,Taiwan,Taipei City,112,Jiing-Chyuan,Luo,88622871212181783,jcluo@vghtpe.gov.tw,yyu126@its.jnj.com,135759,CG_2ZNqnxRNyPthyyc,10 Jun 2026,21:55 +2026-06-10 10:44:59,2026-06-10 10:55:13,IP Address,165.225.216.191,100,613,True,2026-06-10 10:55:14,R_1tEIeSy1AlbfT7q,Kaur,Manreet,kaur.manreet@mayo.edu,,32.7797,-96.8022,gl,EN,Yes,Manreet,Kaur,Mayo Clinic - Scottsdale/Arizona,Gastrtoenterology,kaur.manreet@mayo.edu,17133879648,East Shea Boulevard 13400,Scottsdale,Arizona,85259,United States,No,,,,,,,,,,Gabrielle,Reckard,SENIOR PROGRAM COORDINATOR-RESEARCH,reckard.gabrielle@mayo.edu,(480)301-6292,Different from the above,Manreet,Kaur,PI,Kaur.Manreet@mayo.edu,(480)301-6292,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,46-60%,≤15%,≤15%,≤15%,Yes,No,,1 study,2,2,0,85,7,5,3,0,0,,0,100,0,40,60,50,50,Yes,No,,Yes,No,patient outreach,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30132823,60768265,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mayo Clinic - Scottsdale/Arizona,East Shea Boulevard 13400,Scottsdale,United States,Arizona,85259,Manreet,Kaur,17133879648,kaur.manreet@mayo.edu,hsantosm@its.jnj.com,137143,CG_3HLyN9j3WULKh2J,10 Jun 2026,22:25 +2026-06-09 05:14:24,2026-06-10 11:40:18,IP Address,90.167.202.164,100,109553,True,2026-06-10 11:40:18,R_2M4IbmslXD75fkB,Ponferrada Diaz,Angel,angelponmedicina@yahoo.es,,40.3908,-3.6598,gl,EN,Yes,Angel,Ponferrada Diaz,Universidad complutense de Madrid (UCM) - Hospital Universitario Infanta Leonor,Gastroenterology,angelponmedicina@yahoo.es,34911918000,Avenida Gran Vía del Este 80,Madrid,Madrid,28031,Spain,Yes,Angel,Ponferrada Diaz,Gastroenterology department. Hospital universitario Infanta Leonor,angel.ponferrada@salud.madrid.org,+34 676106076,Gran Via del Este 80,Madrid,madrid,28031,"Pedro ",Parbole Menendez,Clinical Study Coordinator ,pedro.parbolemenendez.sc@gmail.com,+34 676106076,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,1,1,,16-30%,31-45%,31-45%,Yes,No,,1 study,4,2,2,98,2,0,0,0,0,,90,10,5,70,25,50,50,Yes,No,,No,No,,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30149938,60164071,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Universidad Complutense de Madrid (UCM) - Hospital Universitario Infanta Leonor,Avenida Gran Vía del Este 80,Madrid,Spain,Madrid,28031,Angel,Ponferrada Diaz,34911918000,angelponmedicina@yahoo.es,jalons12@its.jnj.com,137357,CG_3HtSFSJFuiE5qn0,10 Jun 2026,23:10 +2026-06-10 03:36:22,2026-06-10 11:50:38,IP Address,85.237.234.55,100,29656,True,2026-06-10 11:50:39,R_8SC3x0aTunuoo81,Horvath,Frantisek,fhorvath.studie@gmail.com,,48.1715,17.1678,gl,EN,No,Frantisek,Horvath,"Accout Center, s.r.o., Gastroenterologická ambulancia",Gastroenterology,fhorvath.studie@gmail.com,421905499894,Hviezdoslavova 19,Sahy,Nitra Region,936 01,Slovakia,Yes,Marianna,"Kováčová ","Accout Center s.r.o., Gastroenterologická ambulancia ",mkovacova.studie@gmail.com,+421905702264,Hviezdoslavova 19,Sahy,Nitriansky kraj,93601,Frantisek,Horvath,"MD, PI",fhorvath.studie@gmail.com,+421905499894,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,≤15%,46-60%,16-30%,,No,No,,0 studies,4,1,3,100,0,0,0,0,0,,0,100,5,85,10,40,60,Yes,No,,No,No,N/A,N/A,,,,,,,,,,,,,,,,200,60,110,14,4,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,4,5,≥6,Yes,Yes,No,No,Yes,Yes,Yes,No,Central,4,,2,No,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30104583,60008812,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Accout Center, s.r.o., Gastroenterologická ambulancia",Hviezdoslavova 19,Levice,Slovakia,Nitra Region,936 01,Frantisek,Horvath,421905499894,fhorvath.studie@gmail.com,vbuzalka@its.jnj.com,136447,CG_2UbIVT8cqpOD1eg,10 Jun 2026,23:20 +2026-06-01 11:04:54,2026-06-10 11:57:01,IP Address,87.97.108.17,100,780727,True,2026-06-10 11:57:02,R_8wFiIfKtMw7Z5S3,Szalóki,Tibor,szalokitdr@vnet.hu,,47.7803,19.1374,gl,EN,No,Tibor,Szalóki,Javorszky Odon Korhaz,Gastroenterology,szalokitdr@javorszky.hu,3627620620,Argenti Döme tér 1-3,Vác,Pest,2600,Hungary,Yes,Miklosne,Czegledi,"Javorszky Hospital, Outpatient department of Gastroenterology",marika.czegledine@gmail.com,+36309687716,Argenti ter 1-3.,Vac,Pest,2600,Tibor,Szalóki,"PI, PhD",szalokitdr@javorszky.hu,+36302001489,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,,,1,,,,,No,No,,1 study,4,0,4,100,0,0,0,0,0,,0,0,0,75,25,40,60,No,No,,No,No,"Few vendors, not too complicated study conduction, good CRA",0,"Dr. Csizmadia Csaba ",,,,,Mohacs Hospital,,,,,tel: 30/9012809,,,,,45,40,3,1,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,5,6,≥6,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Central,8,,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30004432,60005504,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Javorszky Odon Korhaz,Argenti Döme tér 1-3,Vác,Hungary,Pest,2600,Tibor,Szalóki,3627620620,szalokitdr@vnet.hu,anochta@its.jnj.com,136244,CG_3rYeUOxHVuuQa7h,10 Jun 2026,23:27 +2026-06-10 10:33:54,2026-06-10 12:23:17,IP Address,50.145.232.202,100,6563,True,2026-06-10 12:23:17,R_5r1WPWADe53GxK9,Kiyasu,Phillip,pkiyasu@orclinic.com,,45.5282,-122.6355,gl,EN,Yes,Phillip,Kiyasu,The Oregon Clinic,Gastroenterology,pkiyasu@orclinic.com,15039632784,1111 NE 99th Ave Suite 301,Portland,Oregon,97220-9428,United States,Yes,Angelina,Kobenko,The Oregon Clinic,akobenko@orclinic.com,5039358322,"1111 NE 99th Ave, Suite 301",Portland,Oregon,97220,Angelina,Kobenko,Research Coordinator,akobenko@orclinic.com,5039358322,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,≤15%,≤15%,≤15%,,Yes,Yes,"In general, Vedolizumab is no longer considered the agent of choice in patients who have lost response to or not responded to other biologic therapy. Vedolizumab is a preferred agent in patients who have existing comorbidities or are of older age. Finally, a comparator requiring IV/SC administration compared to an oral drug may be of suboptimal appeal to a patient considering participation in a clinical trial. ",More than 2 studies,1,1,0,70,15,10,3,2,0,,25,75,0,65,35,50,50,No,Yes,"English, Spanish, Vietnamese, Russian",Yes,No,Marketing and social media support,See previous comments regarding vedolizumab as the comparator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30163456,60495993,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Oregon Clinic,1111 NE 99th Ave Suite 301,Portland,United States,Oregon,97220-9428,Phillip,Kiyasu,15039632784,pkiyasu@orclinic.com,hsantosm@its.jnj.com,137155,CG_UAD2lM7ior6IrmN,10 Jun 2026,23:53 +2026-06-01 08:58:19,2026-06-10 12:24:22,IP Address,178.48.50.144,100,789962,True,2026-06-10 12:24:23,R_265qXGBahSobjLE,Miheller,Pal,pmiheller@gmail.com,,47.5,19.0412,gl,EN,Yes,Pal,Miheller,Semmelweis Egyetem (Semmelweis University),gastroenterology,pmiheller@gmail.com,36208250460,Balassa janos utca 6,Budapest,Pest,1082,Hungary,Yes,Kinga,Kover,"Dept. of Surgery, Transplantation and Gastroenterology",kover.kinga@semmelweis.hu,0036206632783,Ullői u 78,Budapest,Pest,1082,Kinga,Kövér,study coordinator,kinga.kover@semmelweis.hu,0036206632783,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,1,1,≤15%,31-45%,31-45%,≤15%,Yes,Yes,drug exposure criterias can be a challange,More than 2 studies,3,3,0,100,0,0,0,0,0,,0,0,0,100,0,50,50,Yes,No,,Yes,No,none,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,true,true,true,"1,2,3",true,false,,PI's room,true,"1,2,3",,,,,,,,,,1,,,,,,,false,,false,,,,,,,,,,,30110519,60641861,,,,,,,,,,,,,,Yes,Yes,,,,,,,,,,,,under the supervision of an investigator,,,,true,Semmelweis Egyetem (Semmelweis University),Balassa janos utca 6,Budapest,Hungary,Pest,1082,Pal,Miheller,36208250460,pmiheller@gmail.com,anochta@its.jnj.com,136256,CG_2w6OZ9MXIMz5136,10 Jun 2026,23:54 +2026-06-10 00:19:42,2026-06-10 12:45:27,IP Address,201.172.174.22,100,44745,True,2026-06-10 12:45:28,R_6RlviRuSRHVuBMc,Cortez Hernandez,Carlos Alejandro,dr.carloscortezz69@gmail.com,,25.7524,-100.4092,gl,EN,No,Carlos Alejandro,Cortez Hernandez,Hospital Universitario Dr Jose Eleuterio Gonzalez,GASTROENTEROLOGIA,dr.carloscortezz69@gmail.com,528183333664,Avenida Francisco I. Madero y Avenida Gonzalitos S/N,Monterrey,Nuevo León,64020,Mexico,Yes,JORGE,CORTEZ,HOSPITAL UNIVERSITARIO,drjorge.cortez25695@gmail.com,8111855955,"Hospital Universitario ",Monterrey,Nuevo Leon,64460,Jorge,Cortez,Dr.,drjorge.cortez25695@gmail.com,8183333664,Same as above,,,,,,Principal Investigator,,,,,,,,,,Yes,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","No, not reimbursed/covered by insurance",,,1,,,,>60%,,,No,No,,1 study,3,0,3,0,0,0,0,0,100,hispanos,100,0,0,100,0,50,50,Yes,Yes,español,Yes,No,MATERIAL DE APOYO PARA DIFUSIÓN.,NO,,,,,,,,,,,,,,,,10,5,5,1,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,3,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,8,8,8,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,30114841,60156595,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Universitario Dr Jose Eleuterio Gonzalez,Avenida Francisco I. Madero y Avenida Gonzalitos S/N,Monterrey,Mexico,Nuevo León,64020,Carlos Alejandro,Cortez Hernandez,528183333664,dr.carloscortezz69@gmail.com,vcastan4@its.jnj.com,136588,CG_3s4kjGUjNSaGsT0,11 Jun 2026,00:15 +2026-06-05 10:01:16,2026-06-10 13:09:21,IP Address,150.231.246.19,100,443285,True,2026-06-10 13:09:22,R_737SrSFfJfSzbgw,Clarke,Kofi,kclarke@pennstatehealth.psu.edu,,40.2859,-76.6502,gl,EN,Yes,Kofi,Clarke,Penn State Health Milton South Hershey Medical Center,Gastroenterology,kclarke@pennstatehealth.psu.edu,7175315226,University dr 500,Hershey,Pennsylvania,17033,United States,Yes,Zvjezdana Stella,Sever Chroneos,"Penn State MS Hershey Medical Center, Dept. Medicine",zchroneos1@pennstatehealth.psu.edu,7175318259,"500 University Dr. ","Hershey, PA",PA,17033,Zvjezdana Stella,Sever Chroneos,Study manager,zchroneos1@pennstatehealth.psu.edu,7175318259,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,31-45%,,,Yes,No,,1 study,2,2,0,90,2,5,1,1,1,undetermined,7,93,0,45,55,47,53,Yes,No,,No,No,central recruitment campaign,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30075859,60590505,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Penn State Health Milton South Hershey Medical Center,University dr 500,Hershey,United States,Pennsylvania,17033,Kofi,Clarke,7175315226,kclarke@pennstatehealth.psu.edu,jnowak2@its.jnj.com,137125,CG_3kjoWpARJpPxacO,11 Jun 2026,00:39 +2026-06-09 09:48:12,2026-06-10 14:23:57,IP Address,68.151.70.54,100,102944,True,2026-06-10 14:23:57,R_1DXCopvK42G7FZd,Siffledeen,Shaalan Jesse,shaalan@ualberta.ca,,53.4609,-113.3714,gl,EN,Yes,Shaalan Jesse,Siffledeen,South Edmonton Gastroenterology,Gastroenterology,shaalan@ualberta.ca,17806191972,3017 - 66 st NW ste 214,Edmonton,Alberta,Code: T6K 4B2,Canada,Yes,"Christie ",Cor,South Edmonton Gastroenterology,"christie.cor@sedmgastro.ca ",7808875178,"#214, 3017-66 st NW",Edmonton,"AB ",T6W3G7,"Christie ","Cor ","Operations Manager ","christie.cor@sedmgastro.ca ",7808875178,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,"There may be a small dispensing fee, but for 90% of people, the cost to receive Entyvio is covered/nil.",1,1,1,,46-60%,31-45%,≤15%,,Yes,No,,1 study,8,50,50,60,15,5,20,0,0,,0,0,0,97,3,50,50,Yes,No,,No,No,"We would rock this study. No issues, 5-10 patients no problem. Please pick less sites to start up, so that high enrolling sites like ours can have more than 2-3 spots! + ","no ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30093774,60137795,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,South Edmonton Gastroenterology,3017 - 66 st NW ste 214,Edmonton,Canada,Alberta,Code: T6K 4B2,Shaalan Jesse,Siffledeen,17806191972,shaalan@ualberta.ca,tresuell@its.jnj.com,136421,CG_2Ej9nPbOtcxQWU7,11 Jun 2026,01:53 +2026-06-04 13:42:12,2026-06-10 14:38:20,IP Address,97.71.180.115,100,521767,True,2026-06-10 14:38:20,R_6STsvFMkiSS7rKp,Weintraub,Alan G.,alanw@gcpclinicalresearch.com,,28.5436,-81.3738,gl,EN,Yes,Alan G.,Weintraub,GCP Clinical Research,Gastroenterology,alanw@gcpclinicalresearch.com,18132409734,110 South MacDill Avenue Suite 300,Tampa,Florida,33609,United States,Yes,Neelima,Nambiar,"GCP Clinical Research ",NeelimaN@gcpclinicalresearch.com,8132409734,110 S. MacDill Ave. Suite 300,Tampa,FL,33609,Mayra,Ferreira,Site Manager,MayraF@gcpclinicalresearch.com,8132409734,Different from the above,Marlene,Lewis,President,marlenek@gcpclinicalresearch.com,8132409734,Other,Marlene,Lewis,President & Site Director,marlenek@gcpclinicalresearch.com,8132409734,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,depends on the insurance company,,,1,,,,≤15%,,Yes,No,,More than 2 studies,3,1,2,40,10,30,0,0,20,mixed,35,65,0,80,20,55,45,Yes,No,,Yes,No,none anticipated,none known,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30012395,60509797,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GCP Clinical Research,South MacDill Avenue 110,Tampa,United States,Florida,33609,Alan G.,Weintraub,18132409734,alanw@gcpclinicalresearch.com,jnowak2@its.jnj.com,137089,CG_1gqKT6BJNkpoTAR,11 Jun 2026,02:08 +2026-06-10 09:59:04,2026-06-10 15:06:50,IP Address,50.27.124.133,100,18466,True,2026-06-10 15:06:52,R_3h5S1AcdY6vHMZA,Sameer Islam,Rafiul,sameerislam@gastrosiresearch.com,,32.4716,-100.3942,gl,EN,No,"Rafiul Sameer ",Islam,"West Texas Research Institute ","Gastroenterology and Hepatology ",sameerislam@gastrosiresearch.com,18067497155,4505 82nd St. Ste 5,Lubbock,Texas,79424,United States,Yes,Kendall,Cope,"West Texas Research Institute ",kcope@gastrosiresearch.com,8067497155,"4505 82nd St. Ste 5 ",Lubbock,TX,79424,Kendall,Cope,"Primary Coordinator ",kcope@gastrosiresesrch.com,8067497155,Different from the above,"Lorena ",Stubblefield,"Finance Management ",sifinances@gastrosiresearch.com,8067497155,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,1,1,≤15%,16-30%,31-45%,46-60%,Yes,No,,1 study,6,3,3,30,5,15,5,5,40,"Hispanic ",40,60,0,70,30,50,50,Yes,Yes,"Spanish ",Yes,No,"Support from J&J may be needed in providing clear study information, timely communication, and resources to help participants understand requirements and expectations. Assistance with scheduling, technical issues, and access to study-related materials would also help ensure successful participation. ","None ",,,,,,,,,,,,,,,,300,200,100,50,50,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,3,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,2,,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30137452,60926460,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,West Texas Clinical Research,80th st 5115,Lubbock,United States,Texas,79424,Rafiul,Sameer Islam,18066964440,sameerislam@gastrosiresearch.com,hsantosm@its.jnj.com,137050,CG_3imVOJ3O4kDvWVq,11 Jun 2026,02:36 +2026-06-10 10:08:18,2026-06-10 16:02:34,IP Address,198.205.17.200,100,21256,True,2026-06-10 16:02:35,R_5vZdpB29nSpsHQP,Dassopoulos,Themistocles,Themistocles.Dassopoulos@BSWHealth.org,,32.8372,-96.769,gl,EN,Yes,Themistocles,Dassopoulos,Baylor University Medical Center,Gastroenterology/IBD,Themistocles.Dassopoulos@BSWHealth.org,13146862623,"3409 Worth Street, Suite 600",Dallas,Texas,75246,United States,Yes,"Mariana ",Hurutado,Baylor Research Institute,mariana.hurutado@bswhealth.org,214-820-7755,3409 Worth Street - 6th Floor,Dallas,TX,75246,"Mariana ",Hurutado,"Mgr Clinical Research, Baylor Research Institute",mariana.hurutado@bswhealth.org,214-820-7755,Different from the above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,16-30%,≤15%,,,Yes,No,,0 studies,2,1,1,88,2,10,0,0,0,,25,75,0,100,0,50,50,Yes,Yes,English and Spanish,No,No,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30154986,60358727,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Baylor University Medical Center,Worth st 3410,Dallas,United States,Texas,75246,Themistocles,Dassopoulos,13146862623,Themistocles.Dassopoulos@BSWHealth.org,hsantosm@its.jnj.com,137151,CG_77fcHmWysiwsCBz,11 Jun 2026,03:32 +2026-06-09 11:27:46,2026-06-10 16:13:14,IP Address,76.93.164.230,100,103527,True,2026-06-10 16:13:14,R_6D5Am083vlLAW8B,Enayati,Pedram,petlcresearch1@gmail.com,,34.1794,-118.4313,gl,EN,Yes,Pedram,Enayati,"TLC Clinical Research Inc ",GI,petlcresearch1@gmail.com,13104359728,"8631 W 3rd Street, Suite 815E","Los Angeles ",California,90048,United States,Yes,"Kelly ","Delarosa ",TLC Clinical Research Inc,kdtlcresearch1@gmail.com,13104359728,"8631 W 3rd Street, Suite 815E",Los Angeles,"California ",90048,Kelly,"Delarosa ","Administrator ",kdtlcresearch1@gmail.com,13104359728,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,46-60%,31-45%,16-30%,,Yes,No,,2 studies,5,3,2,60,15,20,0,5,0,,40,60,10,70,20,55,45,Yes,No,,Yes,No,"Patient advertisement: pamphlets, pt material","None ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30013450,60133733,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wallace medical group- paul wallace md,w 3rd st 8631,West Hollywood,United States,California,90048,Pedram,Enayati,13239392442,petlcresearch1@gmail.com,hsantosm@its.jnj.com,137047,CG_1QbkOA3M2L76zJb,11 Jun 2026,03:43 +2026-05-31 13:55:12,2026-06-10 17:46:57,IP Address,181.238.11.254,100,877904,True,2026-06-10 17:46:57,R_5n3zNRtFqT7Bv4l,Martinez,Eduardo,martinezedu1980@hotmail.com,,-34.6022,-58.3845,gl,EN,No,Eduardo,Martinez,Centro Medico Privado de Reumatologia,Gastroenterologia,martinezedu1980@hotmail.com,+54 38 14 200 180,Lavalle 506,San Miguel de Tucumán,Tucumán,T4000,Argentina,Yes,"XIMENA ",VALDECANTOS,CENTRO DE INVESTIGACIONES MEDICAS TUCUMAN,ximenavaldecantos@gmail.com,3815726037,LAVALLE 506,SAN MIGUEL DE TUCUMAN,TUCUMAN,4000,EDUARDO,MARTINEZ,INVESTIGADOR,martinezedu1980@gmail.com,3815688080,Different from the above,AIDA,BERMAN,CONTRATO,aidaberman@yahoo.com.ar,3815730043,Principal Investigator,,,,,,,,Yes,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,≤15%,31-45%,,,Yes,No,,1 study,4,2,2,100,0,0,0,0,0,,100,0,0,100,0,40,60,Yes,Yes,Castellano,Yes,Yes,,no,,,,,,,,,,,,,,,,8,2,6,4,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,3,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,4,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30152402,60268775,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centro Medico Privado de Reumatologia,Lavalle 506,San Miguel de Tucumán,Argentina,Tucumán,T4000,Eduardo,Martinez,+54 38 14 200 180,martinezedu1980@hotmail.com,zpatrign@its.jnj.com,136289,CG_1JXGCwLkw6uibjf,11 Jun 2026,05:16 +2026-05-29 03:46:15,2026-06-10 19:29:31,IP Address,175.143.67.253,100,1093396,True,2026-06-10 19:29:32,R_41MkCkYKS5tVsTC,Bahar,Norhaniza,drnorhaniza@gmail.com,,3.139,101.72,gl,EN,No,Norhaniza,Bahar,"Tengku Ampuan Rahimah Hospital, Klang","Internal Medicine, Gastroenterology and Hepatology",drnorhaniza@gmail.com,60333757000,Jalan Langat,Klang,Selangor,41200,Malaysia,No,,,,,,,,,,"Farhana Nadiah ",Abd Ghani,Study coordinator,farhana.nadiah@clinicalresearch.my,0195004710,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,≤15%,≤15%,,,No,No,,0 studies,4,2,2,0,100,0,0,0,0,,0,0,0,100,0,70,30,Yes,Yes,"Malay language, English, Mandarin, Tamil",No,No,"To provide whatever equipment which is not available and to support investigation not offered in my hospital eg TB spot test, TB quantiferon gold plus. Is there possibility of offering vaccination prior to biologics? ",no,,,,,,,,,,,,,,,,40,30,10,0,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,No,0,0,1-2,Yes,No,No,Yes,Yes,Yes,Yes,Yes,Central and Local,8,8,16,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30099590,60709237,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tengku Ampuan Rahimah Hospital, Klang",Jalan Langat,Klang,Malaysia,Selangor,41200,Norhaniza,Bahar,600389475555,,wchan26@its.jnj.com,136172,CG_2WvSbfbu4rYpoFR,11 Jun 2026,06:59 +2026-06-10 20:38:40,2026-06-10 21:49:44,IP Address,103.114.194.72,100,4264,True,2026-06-10 21:49:45,R_9NtzauUTRnB1TE4,Guo,Hong,guohongxq@163.com,,22.2578,114.1657,gl,EN,Yes,Hong,Guo,Chongqing General Hospital,Gastroenterology,guohongxq@163.com,8613508389768,No 118 Xingguang Avenue Liangjiang New District Chongqing,Chongqing,Chongqing,400014,China,No,,,,,,,,,,Hong,Guo,PI,guohongxq@163.com,+86 135 083 89768,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, partially reimbursed/covered by insurance",,,1,,,,>60%,,,Yes,No,,More than 2 studies,3,2,1,0,100,0,0,0,0,,0,0,10,80,10,50,50,Yes,No,,Yes,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30172669,60105245,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Chongqing General Hospital,No 118 Xingguang Avenue Liangjiang New District Chongqing,Chongqing,China,Chongqing,400014,Hong,Guo,8613508389768,guohongxq@163.com,hzhang04@its.jnj.com,137010,CG_2qpWeOliCdGhkjE,11 Jun 2026,09:19 +2026-06-02 05:33:57,2026-06-10 23:52:40,IP Address,84.110.114.28,100,757123,True,2026-06-10 23:52:40,R_2LAnlcG4C0ADJVp,Avni-Biron,Irit,iritab@clalit.org.il,,32.0123,34.7705,gl,EN,Yes,Irit,Avni-Biron,Rabin Medical Center - Beilinson Campus,Gastroenterology,iritab@clalit.org.il,97254611,Jabotinsky Street 39,Petah Tikva,Tel Aviv,4941492,Israel,Yes,Maor,Pauker,Rabin Medical Center/Gastroenterology,maorha11@clalit.org.il,972-3-6613785,39 Jabotinsky st.,Petach Tikva,Israel,4941492,Maor,Pauker,SC,maorha11@clalit.org.il,972-3-6613785,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,,,,>60%,16-30%,≤15%,≤15%,Yes,No,,More than 2 studies,3,0,3,100,0,0,0,0,0,,0,100,0,85,15,50,50,Yes,No,,Yes,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30147529,60226815,,,,,,,,,,,,,,"This facility includes a large (26-bed) inpatient hemato-oncology unit with dedicated infrastructure and a medical team, staffed with a physician 24 hours a day.",,,,,,,,,,,,,"The CRA will have full access to the paper SD. The CRA will not have direct access to the data in the EMR. All source data from electronic medical records will be printed, signed, and dated by the investigative staff. The site monitor (SM) can perform a cross-check of the certified copies against the original eSource subjects’ records to verify that they are complete and accurate copies of the eSource records.",,,,,Rabin Medical Center - Beilinson Campus,Jabotinsky Street 39,Petah Tikva,Israel,Tel Aviv,4941492,Irit,Avni-Biron,97254611,iritab@clalit.org.il,bmayer1@its.jnj.com,135870,CG_YSVieQvqD3yYgb7,11 Jun 2026,11:22 +2026-05-29 01:46:05,2026-06-11 03:01:51,IP Address,161.82.225.4,100,1127745,True,2026-06-11 03:01:52,R_9kPmYFSRvUKQek1,Aniwan,Satimai,satimai@gmail.com,,13.8638,100.5998,gl,EN,No,Satimai,Aniwan,King Chulalongkorn Memorial Hospital,Gastroenterologist,satimai@gmail.com,+66 84 695 8822,Thanon Rama IV 1873,Bangkok,Bangkok,10330,Thailand,Yes,Natanong,Kongtub,Chulalongkorn University,joeymeny@gmail.com,,King Chulalongkorn Memorial Hospital,Bangkok,Bangkok,10330,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,1,1,,,16-30%,46-60%,,,Yes,No,,0 studies,10,5,5,0,100,0,0,0,0,,0,100,0,80,20,60,40,Yes,No,,No,No,,,,,,,,,,,,,,,,,,40,20,20,10,5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,5,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,4,4,1,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,false,,,true,,,,,,30099228,60444468,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,King Chulalongkorn Memorial Hospital,Thanon Rama IV 1873,Bangkok,Thailand,Bangkok,10330,Satimai,Aniwan,+66 84 695 8822,satimai@gmail.com,ychanjar@its.jnj.com,136158,CG_bjQtlC3R8B4Di9P,11 Jun 2026,14:31 +2026-06-01 04:39:44,2026-06-11 03:05:32,IP Address,62.176.77.116,100,858347,True,2026-06-11 03:05:32,R_2w0HrjXRdEHmjxx,Kulinski,Ruslan,kulinskimd81@gmail.com,,41.6517,24.6887,gl,EN,No,Ruslan,Kulinski,"University Multiprofile Hospital for Active Treatment, Kanev",Gastroenterology,kulinskimd81@gmail.com,+359 89 980 5965,"ulitsa ""Nezavisimost"" 2",Ruse,Ruse Province,7002,Bulgaria,No,,,,,,,,,,Ruslan,Kulinski,PI,kulinskimd81@gmail.com,0899805965,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"No, I am not interested",Competing trials,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30103910,60345344,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"University Multiprofile Hospital for Active Treatment, Kanev","ulitsa ""Nezavisimost"" 2",Ruse,Bulgaria,Ruse Province,7002,Ruslan,Kulinski,+359 89 980 5965,kulinskimd81@gmail.com,imitkova@its.jnj.com,136273,CG_3kGovGo79hgUZBn,11 Jun 2026,14:35 +2026-06-10 03:41:01,2026-06-11 03:14:45,IP Address,137.204.99.250,100,84823,True,2026-06-11 03:14:45,R_2qvYIUICdT5KGnn,Rizzello,Fernando,fernando.rizzello@unibo.it,,44.4847,11.328,gl,EN,Yes,Fernando,Rizzello,Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna,Internal Medicine,fernando.rizzello@unibo.it,390512144120,Via Giuseppe Massarenti 9,Bologna,Emilia-Romagna,40138,Italy,Yes,Eleonora,Filippone,IRCCS AOU OF BOLOGNA,eleonora.filippone2@unibo.it,0512145312,"Via Massarenti, 9 ",BOLOGNA,,40138,Eleonora,Filippone,,eleonora.filippone2@unibo.it,0512145312,Different from the above,Fernando,Rizzello,MD - Principal Investigator,fernando.rizzello@unibo.it,0512145312,Research Coordinator,,,,,,,,,Yes,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,16-30%,46-60%,≤15%,,No,No,,More than 2 studies,5,4,1,100,0,0,0,0,0,,0,100,0,80,20,50,50,Yes,No,,No,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30154952,60234421,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna,Via Giuseppe Massarenti 9,Bologna,Italy,Emilia-Romagna,40138,Fernando,Rizzello,390512144134,fernando.rizzello@unibo.it,esilva52@its.jnj.com,137465,CG_9z3eI1PKqbjmyGZ,11 Jun 2026,14:44 +2026-06-01 08:46:04,2026-06-11 03:20:20,IP Address,77.85.221.122,100,844455,True,2026-06-11 03:20:20,R_2DC3Az1PYptZX1v,Draganova,Raina,drdraganova@abv.bg,,41.6439,25.3594,gl,EN,No,Raina,Draganova,Neoclinic,gastroenterology Internal medicine,drdraganova@abv.bg,029040131," 20 ""Petko Todorov"" blvd",Sofia,Sofia City Province,1330,Bulgaria,Yes,Katya,Mitakeva,Neoclinic,katyaasklepion@abv.bg,"359899568670 ","20, ""Petko Todorov""blvd ",Sofia,Sofia,1330,Raina,Draganova,MD PI,drdraganova@abv.bg,359888503539,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,"It is reimbursed for limited time ",,,,,≤15%,≤15%,16-30%,16-30%,Yes,No,,2 studies,3,1,2,100,0,0,0,0,0,,0,100,0,70,30,60,40,Yes,No,,No,No,Timely reimbursed patients travel costs,No,NA,,,,,,,,,,,,,,,40,30,15,5,7,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,4,1,3-5,Yes,Yes,No,Yes,Yes,Yes,Yes,No,Central,4,,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30158039,60583033,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Medical centre Asklepion,"ulitsa ""Damyan Gruev"" 8A",Sofia,Bulgaria,Sofia City Province,1303,Raina,Draganova,35929591648,drdraganova@abv.bg,imitkova@its.jnj.com,136266,CG_2fiDZiigSC754xl,11 Jun 2026,14:50 +2026-05-29 03:45:01,2026-06-11 03:24:51,IP Address,175.138.16.34,100,1121989,True,2026-06-11 03:24:52,R_4LButy6sSiFbrA3,Kok,Shinq Ling Victoria,vksl@hotmail.com,,3.1408,101.6852,gl,EN,Yes,Shinq Ling Victoria,Kok,Sarawak General Hospital,Gastroenterology & Hepatology,victoriaksl@moh.gov.my,60194859099,Jalan Hospital,Kuching,Sarawak,93586,Malaysia,Yes,TBC once site is selected,TBC once site is selected,TBC once site is selected,TBC once site is selected,TBC once site is selected,"Jalan Hospital, 93596 Kuching, Sarawak",Kuching,Sarawak,93586,"Syaidatul Annisha ",Binti Sarum,Clinical Trial Administrator,syaidatul.annisha@clinicalresearch.my,010-8013100,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","No, not reimbursed/covered by insurance",,,1,1,,,≤15%,≤15%,,No,No,,0 studies,2,1,1,0,100,0,0,0,0,,0,0,0,100,0,50,50,Yes,Yes,Malay. English. Mandarin,No,No,no,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30154998,60726261,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sarawak General Hospital,Jalan Hospital,Kuching,Malaysia,Sarawak,93586,Shinq Ling Victoria,Kok,60194859099,vksl@hotmail.com,wchan26@its.jnj.com,136169,CG_2alE5AKIlsCADdU,11 Jun 2026,14:54 +2026-06-10 03:39:07,2026-06-11 04:18:48,IP Address,159.213.49.200,100,88780,True,2026-06-11 04:18:48,R_8aLFKyvO4IS8J9f,Dragoni,Gabriele,gabriele.dragoni@unifi.it,,43.7825,11.2516,gl,EN,Yes,Gabriele,Dragoni,Universita degli Studi di Firenze - Azienda Ospedaliero Universitaria Careggi,gastroenterology,gabriele.dragoni@unifi.it,39055794111,Largo Giovanni Alessandro Brambilla 3,Florence,Tuscany,50134,Italy,Yes,Irene,Simeone,AOU Careggi,irene.simeone7@gmail.com,3446383961,"Largo Brambilla 3, Firenze",Firenze,FI,50134,Irene,Simeone,Study Coordinator,irene.simeone7@gmail.com,3446383961,Different from the above,Paolo,Pantaleo,Site Management Organization,pantaleop@aou-careggi.toscana.it,055 794 7736,Research Coordinator,,,,,,,,,Yes,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,,,,16-30%,,,Yes,No,,1 study,3,2,1,95,3,2,0,0,0,,5,95,1,69,30,50,50,Yes,No,,Yes,Yes,"Clinical Instruments, such as scale, sphygmomanometer etc.",none,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30084784,60516638,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Universita degli Studi di Firenze - Azienda Ospedaliero Universitaria Careggi,Largo Giovanni Alessandro Brambilla 3,Florence,Italy,Tuscany,50134,Gabriele,Dragoni,39055794111,gabriele.dragoni@unifi.it,esilva52@its.jnj.com,137462,CG_D37onBpuXR2ggr7,11 Jun 2026,15:48 +2026-06-05 07:32:24,2026-06-11 05:52:50,IP Address,128.127.20.228,100,512425,True,2026-06-11 05:52:51,R_81Zu59Rlq9ojtvi,Bouhnik,Yoram,yoram.bouhnik@aphp.fr,,48.8558,2.3494,gl,EN,No,Yoram,Bouhnik,CMC Ambroise Pare Hartmann,Gastroenterologyst,yoram.bouhnik@institutdesmici.fr,33141430210,Boulevard Victor Hugo 25-27,Neuilly-sur-Seine,Île-de-France,92200,France,Yes,Marie Claude,Bassene,CMC Ambroise Paré Hartmann,"marie-claude.bassene@institutdesmici.fr ",+33141430210,25/27 Boulevard Victor Hugo,Neuilly sur Seine,Hauts de Seine,92200,Marie Claude,Bassene,,"marie-claude.bassene@institutdesmici.fr ",,Same as above,,,,,,Other,CARMEN,STEFANESCU,SI,carmen.stefanescu@institutdesmici.fr,0625679368,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,16-30%,,,No,No,,2 studies,4,1,3,60,10,10,0,20,0,,0,0,0,70,30,60,40,Yes,No,,No,No,,,,,,,,,,,,,,,,,,1200,900,1200,700,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,5,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Central,6,,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30137565,60571035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Clinique Ambroise Pare,Boulevard Victor Hugo 25-27,Neuilly-sur-Seine,France,Île-de-France,92200,Yoram,Bouhnik,33140875630,yoram.bouhnik@aphp.fr,rbelhadj@its.jnj.com,136226,CG_bxRsGUvdTwKqBzP,11 Jun 2026,17:22 +2026-06-10 03:44:35,2026-06-11 05:54:30,IP Address,89.97.66.102,100,94195,True,2026-06-11 05:54:31,R_8IbYHYv69X6dvq7,Savarino,Edoardo Vincenzo,edoardo.savarino@unipd.it,,45.413,11.8806,gl,EN,No,Edoardo Vincenzo,Savarino,Azienda Ospedaliera di Padova,Gastroenterology,edoardo.savarino@unipd.it,393498728491,Via Nicolò Giustiniani 2,Padova,Veneto,35128,Italy,Yes,Daria,Maniero,UOC GASTROENTEROLOGIA - Azienda Ospedale Università Padova,dariamaniero@gmail.com,+390498218717,,Padova,PD,35128,Daria,Maniero,,dariamaniero@gmail.com,+390498218717,Different from the above,Unità ricerva clinica - Team,,,prc.unitaricercaclinica@aopd.veneto.it,,Principal Investigator,,,,,,,,,Yes,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,≤15%,16-30%,≤15%,,Yes,No,,More than 2 studies,2,1,1,90,5,5,0,0,0,,0,0,0,75,25,50,50,Yes,No,,Yes,No,none,,,,,,,,,,,,,,,,,150,80,400,100,40,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,10,30,≥6,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Central and Local,12,16,12,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30084923,60630770,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Azienda Ospedaliera di Padova,Via Nicolò Giustiniani 2,Padova,Italy,Veneto,35128,Edoardo Vincenzo,Savarino,393498728491,edoardo.savarino@unipd.it,esilva52@its.jnj.com,137469,CG_21G7B4KMvBji1fE,11 Jun 2026,17:24 +2026-06-09 06:19:14,2026-06-11 06:09:28,IP Address,194.160.68.3,100,172213,True,2026-06-11 06:09:29,R_8UK6iQC2QBNtxPH,Lukac,Ludovit,ludo.lukac@gmail.com,,48.157,17.0915,gl,EN,No,Ludovit,Lukac,univerzitna nemocnica bratislava unb nemocnica Stare Mesto,gastroenterology,ludo.lukac@gmail.com,421903722618,Mickiewiczova 13,Bratislava,Bratislava Region,813 69,Slovakia,Yes,Ludovit,Lukac,"Univerzitna Nemocnica Bratislava, Nemocnica Stare Mesto",ludo.lukac@gmail.com,+421903722618,"Mickiewiczova 13, 81369 Bratislava",Bratislava,Slovak Republic,,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,,,,>60%,,,,No,No,,0 studies,5,3,2,100,0,0,0,0,0,,0,0,0,90,10,50,50,Yes,Yes,slovak. english,Yes,No,none,no,,,,,,,,,,,,,,,,100,60,40,20,3,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,0,0,None,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,4,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30160470,60469942,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,univerzitna nemocnica bratislava unb nemocnica ruzinov,Ružinovská 4810/6,Bratislava,Slovakia,Bratislava Region,821 01,Ludovit,Lukac,421903722618,ludo.lukac@gmail.com,vbuzalka@its.jnj.com,137449,CG_2CZfUhbstRdpm1D,11 Jun 2026,17:39 +2026-06-04 09:11:19,2026-06-11 06:46:23,IP Address,50.201.210.38,100,596103,True,2026-06-11 06:46:24,R_7Kdd8vb2Wz5FHQB,Ahmad,Adnan,aahmad@gicare.com,,40.2708,-76.8564,gl,EN,Yes,Adnan,Ahmad,Susquehanna Gastroenterology Associates,Gastroenterology,aahmad@gicare.com,17172383111,Sturbridge Drive 4387,Harrisburg,Pennsylvania,17110,United States,Yes,Jessica,Balay,Susquehanna Research Group,jbalay@gicare.com,717-914-7770,4387 Sturbridge Drive,Harrisburg,PA,17110,"Jessica ",Balay,Study Coordinator,jbalay@gicare.com,717-914-7770,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,Coverage varies by insurance,,,,,,,,,Yes,No,,0 studies,2,1,1,82,3,8,1,1,5,more than one race,12,88,0,65,35,45,55,No,No,,No,No,nothing additional,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30073603,60311491,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Susquehanna Gastroenterology Associates,Sturbridge Drive 4387,Harrisburg,United States,Pennsylvania,17110,Adnan,Ahmad,17172383111,aahmad@gicare.com,jnowak2@its.jnj.com,137120,CG_10Yh3ERC1ippUs5,11 Jun 2026,18:16 +2026-06-10 20:38:12,2026-06-11 07:01:32,IP Address,124.88.2.60,100,37399,True,2026-06-11 07:01:32,R_938bw0ESCLdcUeh,Gao,Feng,drxjgf@sina.com,,43.8006,87.6012,gl,EN,Yes,Feng,Gao,Xinjiang Uygur Autonomous Region People's Hospital,Gastroenterology,drxjgf@sina.com,8609918560328,No 393. Altay Rd,Ürümqi,Xinjiang,830003,China,No,,,,,,,,,,Huan,He,SI,,18690965362,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, partially reimbursed/covered by insurance",,1,,,,,,,,No,No,,0 studies,3,2,1,0,100,0,0,0,0,,0,0,10,80,10,60,40,Yes,No,,Yes,Yes,Maintain good communication with the CRC,NO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30042585,60619904,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Xinjiang Uygur Autonomous Region People's Hospital,No 393. Altay Rd,Ürümqi,China,Xinjiang,830003,Feng,Gao,8609918560328,drxjgf@sina.com,hzhang04@its.jnj.com,136984,CG_ABa3qzZu9c7qHHr,11 Jun 2026,18:31 +2026-06-10 05:27:26,2026-06-11 07:04:54,IP Address,140.112.125.74,100,92248,True,2026-06-11 07:04:55,R_9Y3op86a5t07QZR,Wei,Shu-Chen,shuchenwei@ntu.edu.tw,,25.053,121.5259,gl,EN,Yes,Shu-Chen,Wei,National Taiwan University Hospital,Gastroenterology,shuchenwei@ntu.edu.tw,886223123456,Zhongshan Road 5-7,Taipei,Taipei City,100,Taiwan,Yes,Chen-Nai,Wang,National Taiwan University Hospital,toberich_2008@yahoo.com.tw,886937635931,"2F., No. 1, Changde St., Zhongzheng Dist.",Taipei,Taiwan,100,Chen-Nai,Wang,study coordinator,toberich_2008@yahoo.com.tw,886937635931,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, partially reimbursed/covered by insurance",,,1,,,,16-30%,,,Yes,No,,More than 2 studies,5,3,2,1,99,0,0,0,0,,0,100,1,97,2,70,30,Yes,Yes,English and Traditional Chinese,Yes,No,Storage space for study materials.,The flow chart was not included.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,30102068,60231465,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,National Taiwan University Hospital,Zhongshan Road 5-7,Taipei,Taiwan,Taipei City,100,Shu-Chen,Wei,886223123456,shuchenwei@ntu.edu.tw,yyu126@its.jnj.com,135753,CG_1JFvrOOJKzTICn7,11 Jun 2026,18:34 +2026-06-09 10:47:46,2026-06-11 07:08:05,IP Address,82.76.204.60,100,159618,True,2026-06-11 07:08:05,R_223Gr7noW1WabkZ,Stoian,Marilena,marilenastoian@yahoo.com,,44.55,26.0724,gl,EN,No,Marilena,Stoian,Spitalul Clinic 'Dr. Ioan Cantacuzino',INTERNAL MEDICINE AND NEPHROLOGY,marilenastoian@yahoo.com,400212107100|400212106455,Strada Ion Movilă 5-7,Bucharest,Bucharest,030167,Romania,Yes,BOGDAN IOAN,GAVRILA,"DR IOAN CANTACUZINO HOSPITAL / INTERNAL MEDICINE ",bogdan.gavrila @umfcd.ro,0040724556396,"ION MOVILA STREET, NR-5-7",BUCHAREST,ROMANIA,030675,IRINA,DUMITRACHE,INVESTIGATOR /MD,irina.dumitrache07@gmail.ro,0040786199163,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,1,1,1,1,≤15%,16-30%,46-60%,>60%,Yes,No,,0 studies,5,3,2,100,0,0,0,0,0,,,100,0,90,10,20,80,Yes,No,,No,No,technical and monitoring supprt,,,,,,,,,,,,,,,,,20,10,5,0,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,2,1-2,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Local,,1,1,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30105720,60546393,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Spitalul Clinic 'Dr. Ioan Cantacuzino',Strada Ion Movilă 5-7,Bucharest,Romania,Bucharest,030167,Marilena,Stoian,400212107100|400212106455,marilenastoian@yahoo.com,ftoma@its.jnj.com,135999,CG_3suXVjkRUMQdPrX,11 Jun 2026,18:38 +2026-06-05 08:02:45,2026-06-11 08:20:57,IP Address,164.2.240.58,100,519492,True,2026-06-11 08:20:57,R_2fqjzNh9K9wThb5,Kirchgesner,Julien,julien.kirchgesner@aphp.fr,,48.8558,2.3494,gl,EN,Yes,Julien,Kirchgesner,Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Saint-Antoine,Gastroenterology,julien.kirchgesner@aphp.fr,+33149283172,Rue du Faubourg Saint-Antoine 184,Paris,Île-de-France,75012,France,Yes,Camille,VINCENT,Hôpital Saint Antoine,camille.vincent@aphp.fr,+33149283170,184 Rue du Faubourg Saint Antoine,PARIS,,75012,Camille,VINCENT,Clinical research engineer,camille.vincent@aphp.fr,+33149283170,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,>60%,16-30%,16-30%,≤15%,Yes,No,,1 study,2,2,0,100,0,0,0,0,0,,50,50,0,80,20,50,50,Yes,Yes,French,No,No," ",no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30150240,60816066,,,,,,,,,,,,,,60 beds authorized for phase 1 studies in our intensive care department,,,,,,,,,,,,,,,,,,Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Saint-Antoine,Rue du Faubourg Saint-Antoine 184,Paris,France,Île-de-France,75012,Julien,Kirchgesner,33149283172,julien.kirchgesner@aphp.fr,rbelhadj@its.jnj.com,136236,CG_2xXYeLiuxPZ3lMz,11 Jun 2026,19:50 +2026-06-09 06:17:38,2026-06-11 08:21:13,IP Address,195.178.83.128,100,180214,True,2026-06-11 08:21:13,R_8QQEBwiWlFZDgyN,Konecny,Stefan,konecny.stefan@fnbrno.cz,,49.1633,16.5741,gl,EN,No,Stefan,Konecny,Fakultni Nemocnice Brno (University Hospital Brno),gastroenterology,konecny.stefan@fnbrno.cz,420775161464,Jihlavská 20,Brno,Jihomoravský kraj,625 00,Czech Republic,No,,,,,,,,,,Stefan,Konecny,PI,konecny.stefan@fnbrno.cz,775161464,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,16-30%,16-30%,≤15%,≤15%,Yes,No,,2 studies,3,1,2,100,0,0,0,0,0,,0,0,0,85,15,45,55,Yes,No,,Yes,No,,,,,,,,,,,,,,,,,,300,30,270,50,36,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,1,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,12,,24,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30132711,60813376,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fakultni Nemocnice Brno (University Hospital Brno),Jihlavská 20,Brno,Czech Republic,Jihomoravský kraj,625 00,Stefan,Konecny,420775161464,konecny.stefan@fnbrno.cz,jeche@its.jnj.com,136307,CG_ereKd3k72axs66l,11 Jun 2026,19:51 +2026-05-31 13:37:44,2026-06-11 08:45:27,IP Address,168.96.255.82,100,932862,True,2026-06-11 08:45:27,R_5dg84NVeF6LFZuC,Daffra,Pamela,pamela.daffra@gmail.com,,-32.9204,-68.8293,gl,EN,Yes,Pamela,Daffra,Sanatorio Maipu,Gastroenterologist,pamela.daffra@gmail.com,+54 91 12 191 9736,Godoy Cruz N 650,Maipu,Mendoza,M5515,Argentina,Yes,"Eugenia ",Yañez,Sanatorio Maipu,"eyanezic@gmail.com ",+54 9 2616 59-4152,Avenida Godoy Cruz 650,Maipu,Mendoza,5500,Myriam,Laconi,Dra.,mlaconi@yahoo.com,+54 9 2615061954,Same as above,,,,,,Other,Myriam,Laconi,Director de Operaciones Clínicas,mlaconi@yahoo.com,+54 92615061954,,,Yes,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,16-30%,46-60%,16-30%,,No,No,,2 studies,2,1,1,100,0,0,0,0,0,,100,0,0,70,30,50,50,Yes,No,,Yes,No,"CRA´s ",No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30161071,60905343,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sanatorio Maipu,Godoy Cruz N 650,Maipu,Argentina,Mendoza,M5515,Pamela,Daffra,+54 91 12 191 9736,pamela.daffra@gmail.com,zpatrign@its.jnj.com,136294,CG_3PRmNEQjOQsvBVL,11 Jun 2026,20:15 +2026-06-10 02:23:37,2026-06-11 10:38:32,IP Address,92.86.215.118,100,116094,True,2026-06-11 10:38:32,R_8HLI3vVfltBjCJf,Mateescu,Radu Bogdan,bogmateescu@gmail.com,,44.4946,26.0578,gl,EN,Yes,Radu Bogdan,Mateescu,Spitalul Clinic Colentina,Gastroenterology,bogmateescu@gmail.com,40213152590,Șoseaua Ștefan cel Mare 19-21,Bucharest,Bucharest,020125,Romania,Yes,Sorina,Telescu,Colentina Clinical Hospital,telescu.sorina@gmail.com,+40773992173,19-21 Stefan cel Mare St,Bucharest,Romania,020125,Sorina,Telescu,Study Coordinator/SI,telescu.sorina@gmail.com,,Different from the above,Bogdan,Mateescu,PI,bogmateescu@gmail.com,0213152590,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,31-45%,31-45%,≤15%,,Yes,No,,2 studies,3,2,1,100,0,0,0,0,0,,0,0,0,100,0,50,50,Yes,No,,Yes,No,Site management,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30105793,60417562,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Spitalul Clinic Colentina,Șoseaua Ștefan cel Mare 19-21,Bucharest,Romania,Bucharest,020125,Radu Bogdan,Mateescu,40213152590,bogmateescu@gmail.com,ftoma@its.jnj.com,135990,CG_55yBPLbkT9g2y65,11 Jun 2026,22:08 +2026-06-10 03:54:38,2026-06-11 10:41:54,IP Address,78.210.200.142,100,110835,True,2026-06-11 10:41:55,R_8sSEQcdaXTvjaRe,Ferracane,Concetta Laura,c.ferracane@policlinico.unict.It,,43.1479,12.1097,gl,EN,No,Concetta Laura,Ferracane,Policlinico Universitario di Catania,Gastroenterology,c.ferracane@policlinico.unict.It,3275333569,Via San Sofia 78,Catania,Sicily,95125,Italy,No,,,,,,,,,,Concetta,Ferracane,Doctor,c.ferracane@policlinico.unict.it,3275333569,Same as above,,,,,,Principal Investigator,,,,,,,,,Yes,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,≤15%,≤15%,>60%,,No,No,,0 studies,2,2,0,100,0,0,0,0,0,,0,0,2,70,28,50,50,Yes,Yes,italian,No,No,,,,,,,,,,,,,,,,,,500,250,250,50,50,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,1,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,8,8,No,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30084684,60911159,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Policlinico Universitario di Catania,Via San Sofia 78,Catania,Italy,Sicily,95125,Concetta Laura,Ferracane,390953782912,C.FERRACANE@POLICLINICO.UNICT.IT,esilva52@its.jnj.com,137460,CG_238JcewXowe98G9,11 Jun 2026,22:11 +2026-06-09 09:39:11,2026-06-11 11:53:28,IP Address,76.66.128.34,100,180857,True,2026-06-11 11:53:28,R_6U1sOgzLrNI3jTH,Petroniene,Rima,petroniener@barriegi.ca,,43.7306,-79.4217,gl,EN,Yes,Rima,Petroniene,Barrie GI Associates,Gastroenterology,petroniener@barriegi.ca,17057213344,Gallie Court 15,Barrie,Ontario,L4M 7G1,Canada,Yes,Lindsay,Magi,Research,researchnurse@barriegi.ca,(705) 721-3344 ext. 155,"15 Gallie Court, Suite 306",Barrie,ON,L4M7G1,Stella,Rho,"Clinical Research & Site Network Manager ",srho@tidhi.ca,647-812-2113,Different from the above,Ajani,Jeyakumar,Clinical Operations Manager,ajeyakumar@tidhi.ca,647-812-2113,Other,Stella,Rho,"Clinical Research & Site Network Manager ",srho@tidhi.ca,647-812-2113,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,,,,46-60%,,,,Yes,No,,1 study,4,2,2,85,5,2,8,0,0,,30,70,5,75,20,50,50,No,No,,No,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30092288,60550197,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Barrie GI Associates,Gallie Court 15,Barrie,Canada,Ontario,L4M 7G1,Rima,Petroniene,17057213344,petroniener@barriegi.ca,tresuell@its.jnj.com,136426,CG_3HXQAjmlOdyOZbW,11 Jun 2026,23:23 +2026-06-02 12:49:29,2026-06-11 11:57:37,IP Address,189.6.19.92,100,774488,True,2026-06-11 11:57:38,R_3h4iyyTDSw2HkIW,Clemente,Cintia,cintia.clemente@icape.com.br,,-15.7783,-47.9319,gl,EN,No,Leticia,Adorno,Chronos Clinica Medica LTDA - Chronos Pesquisa Clinica,Gastroenterology,leticia.adorno@icape.com.br,5561999024698,Q QNM 34 AREA ESPECIAL 1 – Taguatinga Norte,Brasília,Distrito Federal,72145450,Brazil,Yes,Anna,Ribeiro,Chronos Clínica Médica Ltda,anna.pesquisabrasil@gmail.com,5561999024698,Q QNM 34 AREA ESPECIAL 1 – Taguatinga Norte,Brasilia,DF,72145-450.,Anna,Ribeiro,SC,anna.pesquisabrasil@gmail.com,61999024698,Same as above,,,,,,Research Coordinator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,,,1,,,,16-30%,,No,No,,0 studies,6,3,3,20,0,0,0,0,80,Mixed,100,0,25,60,15,50,50,Yes,No,,Yes,No,Support for promotional campaigns.,"No. ",,,,,,,,,,,,,,,,15,8,7,2,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,0,None,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Local,,2,3,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30092832,60644831,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Chronos Clinica Medica LTDA - Chronos Pesquisa Clinica,Q QNM 34 AREA ESPECIAL 1 – Taguatinga Norte,Brasília,Brazil,Distrito Federal,72115-160,Cintia,Clemente,5561983143109,cintia.clemente@icape.com.br,gcompian@its.jnj.com,136672,CG_6AmDxA0M31Q7fjj,11 Jun 2026,23:27 +2026-06-09 09:51:27,2026-06-11 12:24:51,IP Address,192.0.249.105,100,182004,True,2026-06-11 12:24:52,R_5JdzZPT3WJs9gD7,Gould,Michael,mgould@tdda.ca,,43.8503,-79.5128,gl,EN,No,Michael,Gould,TDDA Specialty Research,Gastroenterology,mgould@tdda.ca,+1 416 650 0017,4600 Highway 7,Vaughan,Ontario,L4L 4Y7,Canada,Yes,"Kimberly ",Hammond,TDDA Specialty Research,khammond@tdda.ca,4166500017,4600 Highway 7,Vaughan,Ontario,L4L 4Y7,Henika,Lobo,"Director, Research Operations & Business Development",hlobo@tdda.ca,4166500017,Same as above,,,,,,Other,Henika,Lobo,"Director, Research Operations & Business Development",hlobo@tdda.ca,4166500017 ext 301,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,1,,,,46-60%,16-30%,≤15%,Yes,No,,1 study,5,3,2,45,35,10,0,0,10,Mixed Race,15,85,0,85,15,60,40,Yes,No,,Yes,No,Site has used decentralized sponsor-provided services in the past,,Arya,,,,,TDDA Specialty Research - Richmond Hill,,,,,aarya@tdda.ca,,,,,150,50,75,20,30,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,5,7,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,3,,8,No,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30171816,60600980,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Toronto Digestive Diseases Associates,89 Humber College Boulevard,Toronto,Canada,Ontario,,Michael,Gould,+1 416 650 0017,mgould@tdda.ca,tresuell@its.jnj.com,136430,CG_SN57Gr6C599fwwp,11 Jun 2026,23:54 +2026-06-09 11:40:00,2026-06-11 12:58:25,IP Address,23.245.35.75,100,177505,True,2026-06-11 12:58:26,R_3XoY6yOIQ5BUUz2,Happe,Marc,mhapperesearch@yahoo.com,,39.9001,-79.7164,gl,EN,No,Marc,Happe,Frontier Clinical Research - Smithfield - Laurel View Drive,Gastroenterology,mhappe@frontierclinical.com,17245504099,300 Spring Creek Lane,Uniontown,Pennsylvania,15401,United States,Yes,Julie,Black,"Frontier Clinical Research, LLC",jblack@frontierclincial.com,724-550-4099,300 Spring Creek Lane,Uniontown,PA,15401,Julie,Black,Clinical Research Manager/Study Coordinator,jblack@frontierclinical.com,724-550-4099,Different from the above,Tancredi,Calabrese,Business Development/Contracts,tcalabrese@frontierclinical.com,724-569-8036,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,1,,16-30%,16-30%,16-30%,,No,No,,1 study,2,1,1,80,3,10,0,0,7,Mixed race,5,95,0,60,40,40,60,No,No,,No,No,"Central recruitment is always helpful for sites. ",Not at this time.,,,,,,,,,,,,,,,,400,50,250,100,100,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,3,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,4,,4,No,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30074615,60744972,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Frontier Clinical Research - Smithfield - Laurel View Drive,Ridgeview Drive 100,Smithfield,United States,Pennsylvania,15478,Marc,Happe,17245504099,mhappe@frontierclinical.com,hsantosm@its.jnj.com,137122,CG_yjAh9Fx2LUQdY4h,12 Jun 2026,00:28 +2026-06-02 11:57:24,2026-06-11 13:34:44,IP Address,179.246.130.155,100,783439,True,2026-06-11 13:34:45,R_6T8sJc1ZBrHMc3n,Meyer De Mattos Correa,Bruna,brunameyercecip@gmail.com,,-22.2974,-48.5606,gl,EN,No,Bruna,Meyer De Mattos Correa,Centro de Estudos Clínicos do Interior Paulista - CECIP,Coloproctologist,brunameyercecip@gmail.com,5514991670303,Rua Bento Manoel 304,Jaú,São Paulo,17201-130,Brazil,Yes,Edilaine,Sabio,Research center,cecipjau@gmail.com,+55 14 99167-0303,"Rua Bento Manoel, 304 ",Jaú,SP,17201-130,Hellen/ Marcia,Cassiano/ Pavanelli,Pharmacist/ Research assistant,hellencecip@gmail.com/ marciacecip@gmail.com,+55 14 99167-0303,Different from the above,Roni,Peterson Sabio,administrative manager,ronicecip@gmail.com,+55 14 99167-0303,Research Coordinator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,,,≤15%,>60%,16-30%,≤15%,No,No,,2 studies,5,3,2,90,5,5,0,0,0,,90,10,10,75,15,40,60,Yes,Yes,portuguese,Yes,Yes,General support,No,,,,,,,,,,,,,,,,120,15,90,40,28,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,3,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,1,3,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30091898,60825766,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centro de Estudos Clínicos do Interior Paulista - CECIP,Rua Bento Manoel 304,Jaú,Brazil,São Paulo,17201-130,Bruna,Meyer De Mattos Correa,5514991670303,brunameyercecip@gmail.com,gcompian@its.jnj.com,136651,CG_6KEST10TR32y08N,12 Jun 2026,01:04 +2026-06-11 13:37:30,2026-06-11 14:08:20,IP Address,50.217.8.50,100,1850,True,2026-06-11 14:08:21,R_7Hp2N7TLqDxn7gt,Feuerstadt,Paul,pfeuerstadt@pactmd.com,,41.3571,-72.9334,gl,EN,No,Paul,Feuerstadt,Medical Research Center of Connecticut,Gastroenterology,pfeuerstadt@pactmd.com,12032815161,2200 Whitney ave Suite 370,Hamden,Connecticut,06518,United States,Yes,Jennifer,Nikolich,MRCC,jnikolich@pactmd.com,2032815161,2200 Whitney Avenue Suite 370,Hamden,Connecticut,06518,Jennifer,Nikolich,Research Nurse Administrator,jnikolich@pactmd.com,2032815161,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,≤15%,>60%,31-45%,,Yes,No,,0 studies,6,1,5,75,5,20,0,0,0,,30,70,0,60,40,50,50,Yes,No,,Yes,No,None at this time. We are a very experienced Research Center with 20 years experience performing IBD trials.,,,,,,,,,,,,,,,,,300,75,200,50,20,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,5,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,2,,8,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30067421,60587766,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gastroenterology Center of Connecticut,2200 Whitney ave,Hamden,United States,Connecticut,6518,Paul,Feuerstadt,12032815161,pfeuerstadt@gastrocenter.org,jnowak2@its.jnj.com,137051,CG_ZfSOkqQu8QMf1ex,12 Jun 2026,01:38 +2026-06-11 14:20:58,2026-06-11 14:33:35,IP Address,187.35.189.220,100,756,True,2026-06-11 14:33:35,R_5w2WCeG6cRx3fsR,Rocco,Rodrigo,rodrigo.rocco@ymail.com,,-23.5475,-46.6361,gl,EN,Yes,Rodrigo,Rocco,Hepatogastro,Gastroenterologist,rodrigo.rocco@ymail.com,5511999158070,"Avenida Moema 300, Moema conj 85 ",São Paulo,São Paulo,04077-020,Brazil,No,,,,,,,,,,Rodrigo,Rocco,PI,rodrigo.rocco@ymail.com,11999158070,Same as above,,,,,,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,31-45%,,,Yes,No,,0 studies,8,4,4,80,10,10,0,0,0,,0,100,5,75,20,50,50,Yes,No,,Yes,No,"study coordinator suport ",no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30094623,60169890,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hepatogastro,Avenida Presidente Juscelino Kubitschek 1454,São Paulo,Brazil,São Paulo,04543-000,Rodrigo,Rocco,5511999158070,rodrigo.rocco@ymail.com,gcompian@its.jnj.com,136655,CG_3IS1RRQhibUN1mX,12 Jun 2026,02:03 +2026-06-02 12:21:42,2026-06-11 14:45:43,IP Address,187.32.189.33,100,786241,True,2026-06-11 14:45:44,R_5QLILurP0LpIhmm,Celani,Livia,livia.medeiros@liga.org.br,,-5.8111,-35.2235,gl,EN,No,Livia,Celani,Liga Norte Riograndense Contra O Cancer,gastroenterologist,livia.medeiros@liga.org.br,+55 84 4009-5595,Avenida Miguel Castro 1355,Natal,Rio Grande do Norte,59062-000,Brazil,No,,,,,,,,,,Janilta,Moura,,janilta.moura@liga.org.br,8440095595,Different from the above,Juliana,Araújo,Nurse,contratos.pesquisa@liga.org.br,8440095595,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,1,1,1,1,31-45%,16-30%,≤15%,≤15%,Yes,No,,2 studies,3,2,1,10,0,90,0,0,0,,0,100,5,80,15,50,50,Yes,No,,Yes,No,"It would be important to use a company (vendor) responsible for reimbursement, including transportation and meal expenses.",No,,,,,,,,,,,,,,,,100,10,90,45,3,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,1,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,1,12,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,,,,,30097002,60334839,,,,,,80,,,15,15,,,,,,,,,,,,,,,,,,,,,,Liga Norte Riograndense Contra O Cancer,Avenida Miguel Castro 1355,Natal,Brazil,Rio Grande do Norte,59052-700,Livia,Celani,8440097401,livia.medeiros@liga.org.br,gcompian@its.jnj.com,136676,CG_z86r26uA6dAlvzz,12 Jun 2026,02:15 +2026-06-02 11:54:55,2026-06-11 15:37:03,IP Address,177.92.46.229,100,790927,True,2026-06-11 15:37:03,R_5feFKBarvIO8bEl,Ramos Junior,Odery,oderyramos.cdc@gmail.com,,-25.5026,-49.2908,gl,EN,No,Odery,Ramos Junior,CDC - Centro Digestivo de Curitiba,Gastroenterologist,oderyramos.cdc@gmail.com,5541999410821,Alameda Doutor Carlos de Carvalho 655,Curitiba,Paraná,80430-180,Brazil,Yes,Sandra,Ramos,CDC - Centro Digestivo de Curitiba,sandraramos.cdc@gmail.com,5541999410820,"Alameda Dr. Carlos de Carvalho,655 6o andar",Curitiba,Paraná,80430-180,Sandra,Ramos,Study Coordinator,sandraramos.cdc@gmail.com,5541999410820,Same as above,,,,,,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,16-30%,31-45%,16-30%,,Yes,No,,1 study,8,3,5,70,0,30,0,0,0,,100,0,5,65,30,35,65,Yes,No,,Yes,Yes,,No,,,,,,,,,,,,,,,,320,190,130,45,15,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,6,10,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,4,2,No,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30090807,60619008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CDC - Centro Digestivo de Curitiba,Alameda Doutor Carlos de Carvalho 655,Curitiba,Brazil,Paraná,80430-180,Odery,Ramos Junior,554133221115,oderyramos.cdc@gmail.com,gcompian@its.jnj.com,136670,CG_ZrV0cwZrrlvir8R,12 Jun 2026,03:07 +2026-06-11 13:50:01,2026-06-11 16:04:02,IP Address,155.190.7.93,100,8040,True,2026-06-11 16:04:02,R_1AFOkZv4ux8GMQX,Hanauer,Stephen,shanauer@northwestern.edu,,44.9834,-93.2622,gl,EN,No,Stephen,Hanauer,Northwestern University,Gastroenterology,shanauer@northwestern.edu,3126958952,211 E. Ontario,Chicago,Illinois,60611,United States,Yes,"Rose ",Arrieta,Northwestern,rarrieta@northwestern.edu,3126955878,same,,,,same,,,,,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,46-60%,31-45%,,,Yes,No,,1 study,5,2,3,80,10,10,0,0,0,,20,80,5,85,10,50,50,Yes,Yes,Spanish,Yes,Yes,na,no,,,,,,,,,,,,,,,,500,50,50,200,200,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,8,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,4,4,6,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30074546,60716260,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Northwestern University,676 N St Clair St,Chicago,United States,Illinois,60611,Stephen,Hanauer,(206) 598 4303,,hsantosm@its.jnj.com,137078,CG_808Q7rdb9uafpoR,12 Jun 2026,03:34 +2026-06-11 15:59:30,2026-06-11 18:56:50,IP Address,136.32.248.175,100,10640,True,2026-06-11 18:56:51,R_5uCAZHPXD7jAENk,Kapur,Saurabh,skapur@kumc.edu,,38.8868,-94.8223,gl,EN,No,Saurabh,Kapur,University of Kansas Medical Center,"Gastroenterology ",skapur@kumc.edu,17857647662,Rainbow blvd 3901,Kansas City,Kansas,66103,United States,Yes,Na,Yu,"The university of Kansas medical system ",Nyu3@kumc.edu,9135886158," 2106 Olathe BLVD CATES EAST RM#G011A Kansas City, KS 66160","Kansas City ","Kansas ",66160,,,,,,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,,,,,Yes,No,,0 studies,28,20,8,60,5,35,0,0,0,,0,0,1,69,30,60,40,Yes,No,,Yes,Yes,"Ultrasound ",,,,,,,,,,,,,,,,,700,300,1200,400,200,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,4,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,8,,12,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,true,,,,,,,,,30060434,60690510,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,University of Kansas Medical Center,Rainbow blvd 3901,Kansas City,United States,Kansas,66103,Saurabh,Kapur,17857647662,skapur@kumc.edu,jnowak2@its.jnj.com,137065,CG_RPLNIjh9UCTapX3,12 Jun 2026,06:26 +2026-05-29 03:44:38,2026-06-11 19:33:55,IP Address,113.211.113.201,100,1180156,True,2026-06-11 19:33:56,R_4dKEvVnXRLCHTM9,Abdul Kadir,Noor Purdah,npurdah@gmail.com,,3.1325,101.6922,gl,EN,Yes,Noor Purdah,Abdul Kadir,Hospital Pulau Pinang,Gastroenterology &Hepatology,npurdah@gmail.com,+60 14 240 7466,Jalan Residensi,George Town,Penang,10450,Malaysia,Yes,Noor purdah,Abdul kadir,Hospital pulau pinang,npurdah@gmail.com,0142407466,Jalan residensi,Georgetown,Pulau Pinang,10450,noor purdah,Abdul kadir,Dr,npurdah@gmail.com,0142407466,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,>60%,31-45%,≤15%,,Yes,No,,0 studies,3,2,1,0,100,0,0,0,0,,0,100,0,100,0,50,50,Yes,Yes,"Mandrin,malay,english",Yes,No,Meeting with detail discussion about study,Nil,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30100086,60921661,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Pulau Pinang,Jalan Residensi,George Town,Malaysia,Penang,10450,Noor Purdah,Abdul Kadir,+60 14 240 7466,npurdah@gmail.com,wchan26@its.jnj.com,136167,CG_24CWfDlnhcRdRSj,12 Jun 2026,07:03 +2026-06-11 06:43:09,2026-06-11 20:54:08,IP Address,175.107.153.57,100,51059,True,2026-06-11 20:54:09,R_4oReC6W1o7dpfIr,Masuo,Takashige,tmasuo08@gmail.com,,35.6893,139.6899,gl,EN,Yes,Takashige,Masuo,Isesaki Municipal Hospital,Gastroenterology,tmasuo08@gmail.com,81270255022,12-1 Tsunatori Honmachi,Isesaki,Gunma Prefecture,372-0047,Japan,Yes,Sayaka,Kayumi,"I'rom Co., Ltd.",kayumi-sayaka@iromgp.com,81-80-1098-4710,,,,,Wataru,Nakayama,Site Manager,wnakayam@its.jnj.com,81-80-9203-8926,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,,,>60%,16-30%,,,No,No,,0 studies,2,1,1,0,100,0,0,0,0,,1,99,1,74,25,60,40,No,No,,No,No,Not currently required.,None.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30035261,60061626,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Isesaki Municipal Hospital,12-1 Tsunatori Honmachi,Isesaki,Japan,Gunma Prefecture,372-0047,Takashige,Masuo,81270255022,tmasuo08@gmail.com,mhorii@its.jnj.com,135933,CG_6P8nSssMV6XEkX7,12 Jun 2026,08:24 +2026-06-01 08:49:10,2026-06-11 22:04:58,IP Address,89.134.12.97,100,911747,True,2026-06-11 22:04:58,R_8rvgqckKKtrtbgk,Mihaly,Emese,emesemihaly@hotmail.com,,47.5,19.0412,gl,EN,Yes,Emese,Mihaly,Semmelweis Egyetem (Semmelweis University),Gastroenterology,emesemihaly@hotmail.com,36208250480,Balassa janos utca 6,Budapest,Pest,1082,Hungary,Yes,Krisztina,Kovács,"Semmelweis University, Department of Internal Medicine and Hematology",k.kiki78@gmail.com,+36206701428,46 Szentkirályi street,Budapest,Pest,1088,Emese,Mihaly,Associate professor/PI,emesemihaly@hotmail.com,+36208250480,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,,1,,,,≤15%,Yes,Yes,"Would you specify: previous IL23, previous integrin therapy is exculsionary? +If yes, that would be a chalenge. If only within a certain peroid of time from baseline- than not!? +In the protocol is the latter, but without defining the washout period.",1 study,4,3,1,95,0,0,0,0,5,roma,0,100,0,85,15,50,50,Yes,No,,Yes,No,None for this time,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,true,true,true,"1,2,3",true,false,,PI's room,true,"1,2,3",,,,,,,,,,1,,,,,,,false,,false,,,,,,,,,,,30110519,60404403,,,,,,,,,,,,,,Yes,Yes,,,,,,,,,,,,under the supervision of an investigator,,,,true,Semmelweis Egyetem (Semmelweis University),Balassa janos utca 6,Budapest,Hungary,Pest,1082,Emese,Mihaly,36208250480,emesemihaly@hotmail.com,anochta@its.jnj.com,136246,CG_w1SP11TtqNUi22Z,12 Jun 2026,09:34 +2026-06-11 03:59:44,2026-06-11 23:01:46,IP Address,223.181.42.198,100,68522,True,2026-06-11 23:01:47,R_9LqCGRNjFexu16M,Kalla,Mukesh,drmkalla@rediffmail.com,,26.9136,75.7858,gl,EN,Yes,Mukesh,Kalla,S. R. Kalla Memorial General Hospital,"Gastroentrologist ",drmkalla@rediffmail.com,1414039432,Dhuleshwar Garden 78,Jaipur,Rajasthan,302001,India,Yes,vipin,jain,"SR Kalla Memorial Gastro and General Hospital ",vipinjainkalla@gmail.com,+91-7877777277,"78-79 Dhuleshwar Garden , Behind HSBC Bank Sardar Patel Marg C-Scheme ","Jaipur ","Rajasthan ",302001,vipin,jain,CRC,vipinjainkalla@gmail.com,+91-7877777277,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","No, not reimbursed/covered by insurance",,,,1,1,,,16-30%,31-45%,Yes,No,,1 study,10,03,07,0,100,0,0,0,0,,0,100,0,90,10,60,40,Yes,Yes,"Hindi , and English ",No,No,"Timely study start-up activities, including contract and regulatory support. +Investigator meeting and protocol training for site staff. +Assistance with study procedures, protocol clarifications, and operational guidance. +Timely supply of study-related materials, laboratory kits, and investigational product, as applicable. +Support for subject recruitment strategies and enrollment planning. +Prompt resolution of data management, safety reporting, and technical queries. +Regular communication and monitoring support to ensure smooth study conduct and compliance with protocol requirements. +Timely processing of study payments and reimbursement-related activities.","No ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30021329,60533782,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,S. R. Kalla Memorial General Hospital,Dhuleshwar Garden 78,Jaipur,India,Rajasthan,302001,Mukesh,Kalla,1414039432,drmkalla@rediffmail.com,skulk105@its.jnj.com,135882,CG_3kbsXpFtV94H7Sx,12 Jun 2026,10:31 +2026-06-10 03:57:26,2026-06-12 00:21:36,IP Address,87.13.25.103,100,159849,True,2026-06-12 00:21:37,R_8OlgdKYmaUcei9L,Caprioli,Flavio,flavio.caprioli@unimi.it,,45.5495,9.1607,gl,EN,No,Flavio,Caprioli,Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico,Gastroenterology,flavio.caprioli@unimi.it,39255033368,Via Francesco Sforza 35,Milan,Lombardy,20122,Italy,Yes,Ambra,Lovati,"Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano",ambraelenora.lovati@gmail.com,+390255032141,"Via Commenda, 19",Milan,Milan,20122,Ambra,Lovati,Study Coordinator,ambraelenora.lovati@gmail.com,+390255032141,Same as above,,,,,,Principal Investigator,,,,,,,,,Yes,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,>60%,16-30%,≤15%,,No,No,,1 study,4,1,3,90,5,5,0,0,0,,5,95,0,90,10,50,50,Yes,Yes,"Italian, English",No,No,,None,,,,,,,,,,,,,,,,400,80,200,40,50,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,15,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,8,,6,No,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,,,,,30084768,60478547,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico,Via Francesco Sforza 35,Milan,Italy,Lombardy,20122,Flavio,Caprioli,39255033368,flavio.caprioli@policlinico.mi.it,esilva52@its.jnj.com,137479,CG_3smsIoPVX5m2RGX,12 Jun 2026,11:51 +2026-06-12 00:49:44,2026-06-12 01:24:18,IP Address,167.103.16.255,100,2074,True,2026-06-12 01:24:19,R_9LeeBo9NFl6NHhn,Tokito,Satoki,tokito_satoki_proxy@parexel.com,,35.6893,139.6899,gl,EN,Yes,Satoki,Tokito,Tokitokai Tokito Clinic Coloproctology Center,Coloproctology,tokito_satoki_proxy@parexel.com,81488786411,1941-1 Daimon,Saitama,Saitama Prefecture,336-0963,Japan,No,,,,,,,,,,Tomofumi,Oga,Site Manager,toga@its.jnj.com,81-80-1289-4861,Same as above,,,,,,Other,Gaku,Sugawara,SMA,sugawara.gaku@neues.co.jp,81-70-6577-9066,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,,1,1,,,16-30%,>60%,No,No,,2 studies,2,1,1,0,100,0,0,0,0,,0,100,5,80,15,70,30,No,No,,No,No,"Preparation of awareness materials (e.g., posters).",None.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30037315,60279507,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tokitokai Tokito Clinic Coloproctology Center,1941-1 Daimon,Saitama,Japan,Saitama Prefecture,336-0963,Satoki,Tokito,81488786411,tokito_satoki_proxy@parexel.com,mhorii@its.jnj.com,135916,CG_2P89oqqAn0U2jO7,12 Jun 2026,12:54 +2026-06-11 01:47:37,2026-06-12 01:26:29,IP Address,89.24.16.116,100,85132,True,2026-06-12 01:26:29,R_2PLlLgEjHTkNK3S,Balaz,Jozef,balaz@scouting.sk,,50.0883,14.4124,gl,EN,No,Jozef,Balaz,Fakultna Nemocnica s Poliklinikou F. D. Roosevelta Banska Bystrica,gastroenterology,balaz78@gmail.com,421915071770,Námestie Ludvíka Svobodu 1,Banská Bystrica,Banská Bystrica Region,97401,Slovakia,No,,,,,,,,,,Jozef,Balaz,Principal Investigator,balaz78@gmail.com,+421905838606,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,16-30%,46-60%,≤15%,,Yes,No,,2 studies,4,2,2,90,0,0,0,0,10,Roma,0,100,0,80,20,50,50,Yes,No,,Yes,No,"freezer -70°C is available at our laboratory, we would welcome equipment provided for the study to be at the study room",no,,,,,,,,,,,,,,,,300,140,160,90,10,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,4,8,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,4,,6,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30103783,60476371,,,,,,0,,,0,0,,,,,,,,,,,,,,,,,,,,,,Fakultna Nemocnica s Poliklinikou F. D. Roosevelta Banska Bystrica,Ludvíka Svobodu 1,Banská Bystrica,Slovakia,Banská Bystrica Region,976 32,Jozef,Balaz,421915071770,balaz@scouting.sk,vbuzalka@its.jnj.com,136442,CG_24FNxWE4qrLQ4Ec,12 Jun 2026,12:56 +2026-06-10 02:07:53,2026-06-12 01:55:30,IP Address,82.76.62.252,100,172057,True,2026-06-12 01:55:30,R_8mkaGPiJzIWjSsF,Seicean,Andrada,andradaseicean@gmail.com,,46.7656,23.5945,gl,EN,No,Andrada,Seicean,Gastro Med S R L,Gastroenterology,andradaseicean@gmail.com,+40744332107,Strada Moldovei 3,Cluj-Napoca,Cluj County,400380,Romania,Yes,Horea-Alexandru,Pitutiu,Gastro Med,horeapitutiu@yahoo.com,+40745602092,Moldovei street No 3,Cluj Napoca,Cluj,400380,Horea-Alexandru,Pitutiu,Study Coordinator/Sub-investigator,horeapitutiu@yahoo.com,+40745602092,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,31-45%,31-45%,≤15%,≤15%,Yes,No,,0 studies,3,2,1,100,0,0,0,0,0,,0,100,0,85,15,45,55,Yes,No,,No,No,,,,,,,,,,,,,,,,,,70,10,60,10,25,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,3,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Local,,2,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30107049,60172569,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gastro Med S R L,Strada Moldovei 3,Cluj-Napoca,Romania,Cluj County,400380,Andrada,Seicean,+40744332107,andradaseicean@gmail.com,ftoma@its.jnj.com,135992,CG_21cfJc7w8MOJ4VO,12 Jun 2026,13:25 +2026-06-01 14:57:08,2026-06-12 02:22:45,IP Address,31.175.40.92,100,905136,True,2026-06-12 02:22:45,R_8tzIPCIbCDnsPHR,Wiechowska-Kozlowska,Anna,anna.kozlowska@sonomedszczecin.pl,,54.3521,18.6484,gl,EN,Yes,Anna,Wiechowska-Kozlowska,Sonomed Sp. z o.o.,gastroenterology,anna.kozlowska@sonomedszczecin.pl,48503050199,księdza Biskupa Władysława Bandurskiego 98,Szczecin,West Pomeranian Voivodeship,71-685,Poland,Yes,Tomasz,Kwiecien,Sonomed Sp. z o.o.,april@inet.pl,+48 604427077,Bandurskiego 98,Szczecin,,71-685,as above,,,,,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only",Other (please specify):,upon agreement with National health Fund,,1,,,,,,,No,Yes,"Attached Protocol Summary does not indicate the study length, so we are unable to answer this question with full confidence.",More than 2 studies,8,4,4,100,0,0,0,0,0,,0,100,0,100,0,50,50,Yes,No,,No,No,-,study length - it is unknown upon information delivered,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30089954,60064004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sonomed Sp. z o.o.,księdza Biskupa Władysława Bandurskiego 98,Szczecin,Poland,West Pomeranian Voivodeship,71-685,Anna,Wiechowska-Kozlowska,48503050199,anna.kozlowska@sonomedszczecin.pl,kfacdabr@its.jnj.com,136345,CG_3PY38ud9JFuSWJO,12 Jun 2026,13:52 +2026-06-09 10:30:14,2026-06-12 04:36:23,IP Address,85.120.181.208,100,237968,True,2026-06-12 04:36:24,R_81TITB5TA0Pzcbv,Tiereanu,Cristian,tieranucristian@gmail.com,,44.4205,26.169,gl,EN,No,Cristian,Tieranu,S C Delta Health Care S R L,Gastroenterology,tieranucristian@gmail.com,0765490005,Strada Nicolae G. Caramfil 85A,Bucharest,Bucharest,014142,Romania,Yes,Alice,Mihai,SC Delta Healthcare SRL,alis.mihai@reginamaria.ro,+40726767514,alis.mihai@reginamaria.ro,Bucharest,Bucharest,014142,Alis,Mihai,"Clinical Trials Manager ",alis.mihai@reginamaria.ro,0726767514,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,>60%,16-30%,≤15%,≤15%,No,No,,0 studies,3,1,2,100,0,0,0,0,0,,0,100,0,90,10,40,60,Yes,No,,Yes,No,"We propose a patient recruitment platform and a stipend covering each study visit day for employed patients, to compensate for the fact that the sick leave day taken to attend the visit is not reimbursed",no,,,,,,,,,,,,,,,,120,30,80,20,20,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,2,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,4,,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30117862,60301262,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,S C Delta Health Care S R L,Strada Nicolae G. Caramfil 85A,Bucharest,Romania,Bucharest,014142,Cristian,Tiereanu,0765490005,tieranucristian@gmail.com,ftoma@its.jnj.com,136000,CG_3Oe5l6kqGXvNIhU,12 Jun 2026,16:06 +2026-06-12 00:23:30,2026-06-12 05:46:15,IP Address,116.72.30.127,100,19364,True,2026-06-12 05:46:16,R_9jUqzG7pOch4Vps,Kabrawala,Mayank Vasantlal,mayankkabrawala@hotmail.com,,21.1981,72.8298,gl,EN,Yes,Mayank Vasantlal,Kabrawala,"SIDS Hospital and Research Centre, A Unit of SIDS Healthcare Private Limited",Gastroenterology,mayankkabrawala@hotmail.com,919825130363,"Off Ring road, Near Shell Petrol Pump, Ring road - Sosyo circle lane, ",Surat,Gujarat,395002,India,Yes,Dr Viral,Parekh,"SIDS Hospital and Research Centre, A Unit of SIDS Healthcare Private Limited",viral.parekh11@gmail.com,919825905350,"SIDS Hospital and Research Centre, A Unit of SIDS Healthcare Private Limited, Off Ring road, Near Shell petrol pump, Ring road-Sosyo circle lane,",Surat,Gujarat,395002,Dr Viral,Parekh,Research Coordinator,viral.parekh11@gmail.com,919825905350,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, partially reimbursed/covered by insurance",,1,1,1,1,≤15%,≤15%,16-30%,16-30%,Yes,No,,0 studies,16,7,9,0,100,0,0,0,0,,0,100,10,75,15,50,50,Yes,Yes,"Gujarati, Hindi, English",No,No,Nil.,CLARIO Handheld device is the most diffcult and tidious task used by JJ. Instead of CLARIO prefer Medidata handheld device.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,,,,,,,,,,30022908,60474202,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surat Institute of Digestive Sciences (SIDS) Hospital and Research Centre,"Vijay Nagar Gate No-3, Besides Nirman Bhavan,",Surat,India,Gujarat,395001,Mayank Vasantlal,Kabrawala,919825130363,mayankkabrawala@hotmail.com,skulk105@its.jnj.com,135890,CG_pKwL1qj8MINCkAF,12 Jun 2026,17:16 +2026-06-12 04:42:23,2026-06-12 06:34:03,IP Address,188.57.134.170,100,6700,True,2026-06-12 06:34:04,R_2OPjKKHjKPuMiCl,Karaogullarından,Umit,umit2462@hotmail.com,,37.1726,35.2958,gl,EN,No,Umit,Karaogullarından,"Cukurova University, Faculty of Medicine",gastroenterology,umit2462@hotmail.com,00905052798137,Sinanpaşa Mh. Balcalı Hst. Acil Girişi,Adana,Balcalı,01330,Turkey,Yes,Asya,Bostancıoglu,Gastroenterology,asya.bostancioglu@sentez-cro.com,05349169694,"Serinevler neighborhood, Ege Bagatur Boulevard, Yüreğir State Hospital, 01240 Yüreğir, Adana",adana,yuregir,01240,"kaan ",nisanoglu,MD,dr.kaannisanoglu@gmail.com,05378460678,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,1,1,,,16-30%,16-30%,,,Yes,No,,0 studies,4,4,4,99,0,1,0,0,0,,0,100,0,70,30,50,50,Yes,No,,No,No,.,,,,,,,,,,,,,,,,,260,80,180,50,0,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,,0,0,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,4,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,,,,,,,,,,30108506,78154,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Cukurova University, Faculty of Medicine",Sinanpaşa Mh. Balcalı Hst. Acil Girişi,Adana,Turkey,Balcalı,01330,Umit,Karaogullarından,00905052798137,umit2462@hotmail.com,bsaribek@its.jnj.com,135838,CG_1eEIkyWyrxLT6PQ,12 Jun 2026,18:04 +2026-06-11 02:13:01,2026-06-12 06:39:55,IP Address,5.176.132.223,100,102414,True,2026-06-12 06:39:55,R_8aISgcolNhgvCs2,Karakan,Tarkan,tkarakan@gmail.com,,39.9806,32.7975,gl,EN,Yes,Tarkan,Karakan,Gazi Universitesi (Gazi University Hospital),Gastroenterology,tkarakan@gmail.com,905053192257,"Emniyet, Mevlana Blv. No:29",Ankara,Anatolia,06560,Turkey,Yes,"Şefika ",Özcan,Gazi University Hospital,sefika.ozcan@ethic-cro.com,+90 545 951 92 37,"Emniyet Mahallesi, Mevlana Bulvarı",Yenimahalle,Ankara,06560,"Tarkan ",Karakan,Prof,tkarakan@gmail.com,+90 505 319 22 57,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,1,1,1,1,≤15%,31-45%,46-60%,>60%,No,No,,0 studies,2,1,1,100,0,0,0,0,0,,0,100,0,70,30,50,50,Yes,Yes,Türkçe,No,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30109931,60327998,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gazi Universitesi (Gazi University Hospital),"Emniyet, Mevlana Blv. No:29",Ankara,Turkey,Anatolia,06560,Tarkan,Karakan,905053192257,tkarakan@gmail.com,bsaribek@its.jnj.com,135840,CG_3iKKEp2bRTIQr2i,12 Jun 2026,18:09 +2026-06-12 05:43:18,2026-06-12 06:51:57,IP Address,27.107.168.34,100,4118,True,2026-06-12 06:51:58,R_4qrayzoJARKtl3b,Mukewar,Shrikant,shrikant_mukewar@yahoo.com,,21.1463,79.0849,gl,EN,Yes,Shrikant,Mukewar,Midas Hospital,GASTROENTEROLOGY,shrikant_mukewar@yahoo.com,917720033280,Wardha rd 392 Behind Empress Palace Opp Singh Saab Dhaba,Nagpur,MH,440010,India,Yes,NEHA,WANI,MIDAS HOSPITAL,NGONDHALE0604@GMAIL.COM,+919322768717,"392, PARSODI, WARDHA ROAD",Nagpur,Maharashtra,441108,NEHA,GONDHALE,CRC,NGONDHALE0604@GMAIL.COM,+919322768717,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","No, not reimbursed/covered by insurance",,1,1,,,≤15%,≤15%,,,Yes,No,,1 study,3,1,2,0,100,0,0,0,0,,0,100,5,70,25,45,55,Yes,No,,No,No,NA,NA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30017257,60254816,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Midas Hospital,Wardha rd 392 Behind Empress Palace Opp Singh Saab Dhaba,Nagpur,India,MH,440010,Shrikant,Mukewar,917720033280,shrikant_mukewar@yahoo.com,skulk105@its.jnj.com,135873,CG_24LSZBFUesbj1AC,12 Jun 2026,18:21 +2026-05-31 13:51:14,2026-06-12 06:54:14,IP Address,181.29.37.180,100,1011780,True,2026-06-12 06:54:15,R_6WYXgrNhrNOS7sq,Tron,Emiliano,tron10@hotmail.com,,-36,-59.9964,gl,EN,No,Emiliano,Tron,Mautalen - Salud e Investigacion,Gastroenterólogy,tron10@hotmail.com,+54 91 134 373779,Azcuénaga 1860,Buenos Aires,Buenos Aires,C1128,Argentina,Yes,Maria Jose,Mangini,Mautale Salud e Investigacion (EXPERTIA S.A),mariajose.mangini@mautalen.com,+541145143408,Azcuenaga 1860,CABA,CABA,1128,Maria Jose,Mangini,SC,mariajose.mangini@mautalen.com,+541145143408,Different from the above,"Karina ",Rietti,Admin,karina.rietti@mautalen.com,+541145143408,Research Coordinator,,,,,,,,Yes,,,,,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,,1,,,,≤15%,,,Yes,Yes,Vedolizumab IV,2 studies,2,1,1,100,0,0,0,0,0,,100,0,0,90,10,70,30,Yes,No,,No,No,none,,,,,,,,,,,,,,,,,30,4,7,1,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,10,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Local,,4,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,30114055,60593605,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mautalen - Salud e Investigacion,Azcuénaga 1860,Buenos Aires,Argentina,Buenos Aires,C1128,Emiliano,Tron,+54 91 134 373779,tron10@hotmail.com,zpatrign@its.jnj.com,136287,CG_4PdNzS982kuTBbH,12 Jun 2026,18:24 +2026-06-10 03:40:51,2026-06-12 07:52:36,IP Address,194.27.90.188,100,187904,True,2026-06-12 07:52:37,R_2TyF2SjrtAaTKMh,Erkut,Murat,drmerkut@gmail.com,,40.8945,39.7973,gl,EN,No,Murat,Erkut,"Karadeniz Technical University, Faculty of Medicine",Gastroenterology,drmerkut@gmail.com,+905333482676,"Farabi Cd. No:66, 61080 Merkez Ortahisar",TRABZON,,61080,Turkey,Yes,Sena,Cubukcu Gor,"Karadeniz Technical University, Faculty of Medicine",sena.cubukcu@co-research.com,+905309187860,"Farabi Cd. No:66, 61080 Merkez Ortahisar",TRABZON,,61080,,,Principal Investigator,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,1,1,1,1,≤15%,>60%,16-30%,≤15%,No,No,,1 study,5,3,2,100,0,0,0,0,0,,0,100,0,90,10,50,50,Yes,No,,No,No,"Let's say ""none"", if possible...",None.,,,,,,,,,,,,,,,,100,60,40,10,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,2,3-5,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Central and Local,8,2,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30109247,60423155,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Karadeniz Teknik University Medical Faculty,"Farabi Cd. No:66, 61080 Merkez Ortahisar",TRABZON,Turkey,,61080,Murat,Erkut,905333482676,drmerkut@gmail.com,bsaribek@its.jnj.com,135839,CG_33yxDAvL27no3Rm,12 Jun 2026,19:22 +2026-06-02 12:35:44,2026-06-12 08:35:57,IP Address,177.154.26.78,100,849612,True,2026-06-12 08:35:58,R_7n30hwxCkh3AFLZ,Oliveira,Dilendson,ipec.dilendson@grupocliged.com.br,,-22.3822,-41.7793,gl,EN,No,Dilendson,Oliveira,IPEC,Gastroenterology,ipec.dilendson@grupocliged.com.br,5522992065830,Rua Alfredo Backer 252,Macaé,Rio de Janeiro,27910-190,Brazil,No,,,,,,,,,,Jaqueline,Barros,Study Coordinator,ipec.jaqueline@grupocliged.com.br,+55 22 99224-7181,Different from the above,Dilendson,Oliveira,Principal Inivestigator,ipec.dilendson@grupocliged.com.br,+55 22 99206-5830,Other,Jaqueline,Barros,Study Coordinator,ipec.jaqueline@grupocliged.com.br,+55 22 99224-7181,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,≤15%,46-60%,,,Yes,No,,2 studies,6,4,2,70,0,30,0,0,0,,100,0,5,80,15,50,50,Yes,Yes,Português,Yes,Yes,Data-entry.,None,Renata Froes,,,,,Instituto de Pesquisa e Ensino CLIGEDIMUNO - IPEC,,,,,"Av. das Américas, 2480 - Bloco 1, Salas 216 e 217 - Barra da Tijuca, Rio de Janeiro - RJ, 22640-101",,,,,350,100,150,12,4,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,2,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,1,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30095280,60358554,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cliged,Rua Alfredo Backer 252,Macaé,Brazil,Rio de Janeiro,27910-190,Dilendson,Oliveira,5522992065830,dilendson.infusao@gmail.com,gcompian@its.jnj.com,136659,CG_UucKcdmMktY3iGl,12 Jun 2026,20:05 +2026-06-10 09:35:39,2026-06-12 08:51:17,IP Address,107.211.227.240,100,170137,True,2026-06-12 08:51:17,R_7vm7sA2P1lnacBH,Shukla,Richa,richa.shukla@bcm.edu,,29.5422,-95.3212,gl,EN,No,Richa,Shukla,Baylor College of Medicine – McNair Campus,Gastroenterology,richa.shukla@bcm.edu,17137988220,Cambridge st 7200,Houston,Texas,77030,United States,Yes,Genesis,Vidales,Baylor College of Medicine,genesis.vidaleslopez@bcm.edu,713 798 7616,7200 Cambridge St,Houston,Texas,77030,Genesis,Vidales,Research Coordinator,genesis.vidaleslopez@bcm.edu,713 798 7616,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,1,,,,31-45%,,,Yes,No,,1 study,4,3,1,50,20,30,0,0,0,,60,40,5,85,10,50,50,Yes,Yes,english and spanish,Yes,No,"a central lab from sponsor ",no,,,,,,,,,,,,,,,,200,100,100,30,30,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,3,≥6,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Central and Local,1,2,6,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30127714,60353625,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Baylor College of Medicine – McNair Campus,Cambridge st 7200,Houston,United States,Texas,77030,Richa,Shukla,17137988220,richa.shukla@bcm.edu,jnowak2@its.jnj.com,137141,CG_PAjBmSeBdX9iPL3,12 Jun 2026,20:21 +2026-06-11 16:08:30,2026-06-12 09:22:21,IP Address,157.139.31.94,100,62030,True,2026-06-12 09:22:22,R_7SrdOBMzUeb6Lbi,Mintz,Michael,mjm9042@med.cornell.edu,,40.781,-73.9501,gl,EN,No,Michael,Mintz,NYP Brooklyn Methodist Gastroenterology and Hepatology Clinical Trials Team,Gastroenterology,mjm9042@med.cornell.edu,+1 929 470 9115,515 6th Street Park Slope,Brooklyn,New York,11215,United States,Yes,"May ",Frederick,New York Presbyterian- Brooklyn Methodist Hospital,mrp9017@nyp.org,,515 6th Street,Brooklyn,"NY ",11215,"May ",Frederick,Research Coordinator,mrp9017@nyp.org,,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,≤15%,,,Yes,No,,1 study,5,2,3,45,15,40,0,0,0,,30,70,0,75,25,50,50,Yes,Yes,"English, Spanish",Yes,No,"No additional specific needs other than standard funding per negotiated contract. ",No,,,,,,,,,,,,,,,,400,160,240,65,75,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,1,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,8,12,12,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30172184,60924156,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NYP Brooklyn Methodist Gastroenterology and Hepatology Clinical Trials Team,515 6th Street Park Slope,Brooklyn,United States,New York,11215,Michael,Mintz,+1 929 470 9115,mjm9042@med.cornell.edu,jnowak2@its.jnj.com,137056,CG_1IsVW96sU42vcDr,12 Jun 2026,20:52 +2026-06-02 11:54:02,2026-06-12 09:42:46,IP Address,187.57.163.15,100,856124,True,2026-06-12 09:42:47,R_3NQjhb4QLg1pUDT,Rolim,Alexander de Sa,pesquisare@rolim.med.br,,-23.673,-46.5302,gl,EN,No,Alexander de Sa,Rolim,Pesquisare Saude,coloproctologista,pesquisare@rolim.med.br,551144322953,Avenida Dom Pedro II 125,Santo André,São Paulo,09080110,Brazil,Yes,Tabata,Almeida,Pesquisare saude S/S Ltda,tabata.almeida@pesquisre.com.br,11983724239,,SANTO ANDRÉ,SP,09080110,DEBORAH,ZATTA,Site Manager,dm.zatta@pesquisare.com.br,11983724239,Same as above,,,,,,Other,DEBORAH,ZATTA,Site Manager,dm.zatta@pesquisare.com.br,11983724239,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,1,,,≤15%,31-45%,,Yes,No,,1 study,11,7,4,85,0,15,0,0,0,,99,1,0,97,3,50,50,No,No,,Yes,No,financial assistance in marketing,no,,,,,,,,,,,,,,,,500,300,200,50,15,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,01,08,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,08,06,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30090801,60262687,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pesquisare Saude,Avenida Dom Pedro II 125,Santo André,Brazil,São Paulo,13735-400,Alexander de Sa,Rolim,551144273339,pesquisare@rolim.med.br,gcompian@its.jnj.com,136669,CG_3HZYjFLHoJsWCOr,12 Jun 2026,21:12 +2026-06-11 15:51:13,2026-06-12 10:40:36,IP Address,216.120.158.117,100,67762,True,2026-06-12 10:40:37,R_1Y93VS69qklIuk0,Hudesman,David,david.hudesman@nyulangone.org,,40.7428,-73.9712,gl,EN,Yes,David,Hudesman,NYU Langone Medical Center,IBD,david.hudesman@nyulangone.org,+1 646 501 9327,Marcus ave 1999,North New Hyde Park,New York,11042,United States,Yes,Nathasha,Melukkaran,"NYU IBD Center, 305E 33rs Street, NY10016",nathasha.melukkaran@nyulangone.org,5164399305,,New York,NY,10016,,,,,,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,>60%,16-30%,≤15%,≤15%,Yes,No,,1 study,4,3,1,62,5,12,1,1,19,"Middle easter, ",15,85,2,68,30,47,53,Yes,Yes,spanish,Yes,No,at home nursing,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30072463,60900449,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NYU Langone Medical Center,Marcus ave 1999,North New Hyde Park,United States,New York,11042,David,Hudesman,+1 646 501 9327,david.hudesman@nyulangone.org,jnowak2@its.jnj.com,137083,CG_OwWgd4phkR3bb6V,12 Jun 2026,22:10 +2026-06-11 14:32:59,2026-06-12 10:57:27,IP Address,144.125.5.139,100,73468,True,2026-06-12 10:57:28,R_1Pvfs7nLssdgtP5,Shuster,Dmitry,dmitryshuster@sfc.allscriptsdirect.net,,40.7126,-74.0066,gl,EN,No,Dmitry,Shuster,Springfield Clinic,Gastroenterology,dshuster@springfieldclinic.com,+1 217 5287541,2501 South 6th Street,Springfield,Illinois,62703,United States,Yes,Ayaa,Tamam,Springfield Clinic/Research,atamam@springfieldclinic.com,2175287541,900 N. First Street,Springfield,Illinois,62702,Sara,Ditchen,Director of Research,saditchen@springfieldclinic.com,2175287541,Same as above,,,,,,Other,Sara,Ditchen,Director of Research,saditchen@springfieldclinic.com,2175287541,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,31-45%,31-45%,16-30%,≤15%,Yes,No,,1 study,8,4,4,64,1,35,0,0,0,,8,92,5,70,25,50,50,Yes,No,,Yes,Yes,"CTE support is always helpful for education and marketing materials can be used and the most preferred method is IRB waiting room TV ads, social media ads, phys. to phys. letters",None at this time,,,,,,,,,,,,,,,,500,140,260,1504,40,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,2,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,3,,6,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30075015,60822319,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Springfield Clinic,n 1st st 800,Springfield,United States,Illinois,62702,Dmitry,Shuster,+1 217 525 4538,dmitryshuster@sfc.allscriptsdirect.net,jnowak2@its.jnj.com,137055,CG_ysCiSgEk82BTmsp,12 Jun 2026,22:27 +2026-06-02 12:58:55,2026-06-12 11:19:09,IP Address,8.243.62.96,100,858013,True,2026-06-12 11:19:09,R_1FgOqz05YPW4wHB,Cintra,Aderson,aderson_damiao@uol.com.br,,-23.6007,-46.9212,gl,EN,No,Aderson,Cintra,Hospital São Luiz Itaim (D’Or Institute for Research and Education - SP),Gastroenterology,feasibility@idor.org,+55 11 95089-9269,"R. Dr. Alceu de Campos Rodrigues, 95 - Vila Nova Conceição",São Paulo,São Paulo,04544-000,Brazil,No,,,,,,,,,,Deborah,Rocha,National Feasibility Analyst Senior,feasibility@idor.org,11950899269,Same as above,,,,,,Other,Deborah,Rocha,National Feasibility Analyst Senior,feasibility@idor.org,11950899269,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,,,,46-60%,,,,Yes,No,,1 study,20,10,10,70,0,30,0,0,0,,90,10,0,90,10,50,50,Yes,Yes,Portuguese / English,Yes,Yes,,"About this question: At your site, at what line(s) of treatment do you most commonly prescribe vedolizumab for patients with moderately to severely active ulcerative colitis? + +Please select up to three options: Please indicate the approximate percentage at each selected line: + +First-line treatment: Vedolizumab 50-60% Anti-TNF 30-40% JAKi 10-20% + +Second-line treatment: Anti-IL23 JAKi 50% 50% + +Third-line treatment: Anti-IL-23 50% JAki 50% + +Fourth-line treatment: Anti-IL-23 50% JAKi 50%",,,,,,,,,,,,,,,,500,100,300,200,200,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,2,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,1,10,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30155011,60137210,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Clinica OncoStar - Rede D'Or,Avenida Presidente Juscelino Kubitschek 180,São Paulo,Brazil,São Paulo,04532-030,Aderson,Cintra,551130696617,aderson_damiao@uol.com.br,gcompian@its.jnj.com,136664,CG_33m4KDfpXCZqCS7,12 Jun 2026,22:49 +2026-06-02 12:47:43,2026-06-12 11:36:21,IP Address,177.141.15.222,100,859718,True,2026-06-12 11:36:22,R_3fO6ZBCPrTFapv0,Argollo,Marjorie,marjorieargollo@hotmail.com,,-23.5475,-46.6361,gl,EN,No,Marjorie,Argollo,Solare Trials,gastroenterology,marjorieargollo@hotmail.com,5511943855195,Rua Frei Caneca 558,São Paulo,São Paulo,01307-000,Brazil,Yes,Carolina,Miranda,Solare Trials,carolina.miranda@solaretrials.com.br,5511989094807,"R. Frei Caneca, 558 conjunto 107",São Paulo,SP,01307-000,Carolina,"Miranda ",Study coordinator,carolina.miranda@solaretrials.com.br,5511989094807,Different from the above,"Rodrigo ",Rocco,Investigator,rodrigo.rocco@solaretrials.com.br,5511999158070,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,"IV in both public and private practioice, SC maintenance only private ",1,1,1,,46-60%,≤15%,≤15%,,Yes,No,,1 study,08,04,04,60,0,40,0,0,0,,70,30,10,70,20,50,50,Yes,Yes,portuguese,Yes,No,,,,,,,,,,,,,,,,,,300,150,150,75,10,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,15,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Local,,12,6,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30161064,60382224,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Solare Trials,Rua Frei Caneca 1380,São Paulo,Brazil,São Paulo,01307 002,Marjorie,Argollo,551130036373,marjorieargollo@hotmail.com,gcompian@its.jnj.com,136667,CG_1oGdEYMcZiNvHkA,12 Jun 2026,23:06 +2026-06-02 12:12:47,2026-06-12 11:49:51,IP Address,45.172.162.195,100,862624,True,2026-06-12 11:49:53,R_69tPXp5pVSIs4yN,Teixeira Campos,Luciana,lucianatcampos@hotmail.com,,-15.7783,-47.9319,gl,EN,No,Luciana,Teixeira Campos,L2IP Instituto de Pesquisas Clinicas,"Gastroenterology ",lucianatcampos@hotmail.com,556134454300,"SGAS 613, Conj. E, Bloco A, Sala 6 – Subsolo – Asa Sul",Brasília,Distrito Federal,70200-001,Brazil,Yes,Fernanda,Fernandes,L2IP - Instituto de Pesquisas Clínicas,fernanda.pereira@l2ip.com.br,+55(61)34454300,"SGAS 613, lote 95, bloco A, sala 04-06",Brasília,Distrito Federal,70200730,Fernanda,Fernandes,SC,fernanda.pereira@l2ip.com.br,,Same as above,,,,,,Research Coordinator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV infusion only",Other (please specify):,"Yes, but we have frequent distribution problems of this drug in our public health system.",1,1,1,,16-30%,46-60%,≤15%,,Yes,No,,2 studies,3,1,2,50,0,50,0,0,0,,100,0,0,75,25,50,50,Yes,Yes,Portuguese,Yes,No,,No.,,,,,,,,,,,,,,,,70,35,35,20,2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,8,2,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,5,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,,,,,30091026,60370159,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,L2IP Instituto de Pesquisas Clinicas,"SGAS 613, Conj. E, Bloco A, Sala 6 – Subsolo – Asa Sul",Brasília,Brazil,Distrito Federal,70200-001,Luciana,Teixeira Campos,556134454300,lucianatcampos@hotmail.com,gcompian@its.jnj.com,136680,CG_3hcMjNVaohnuzMY,12 Jun 2026,23:19 +2026-06-02 12:19:17,2026-06-12 13:09:27,IP Address,186.237.128.154,100,867009,True,2026-06-12 13:09:27,R_5eXTzDeln9mXp6m,Cunrath,Geni Satomi,geni.satomi@gmail.com,,-20.7701,-49.3577,gl,EN,No,Giovana,"Dalmedico de Castro ",Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto,"Coloproctologist ",g.dalmedico@hotmail.com,+55 19 99302-8427,Avenida Brigadeiro Faria Lima 5544,São José do Rio Preto,São Paulo,15090-000,Brazil,Yes,Cristiani,Butinhao,Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto/CIP - Centro Integrado de Pesquisa,cristiani.butinhao@centrodepesquisacip.com.br,'+551732015000e1780,"5544 Brigadeiro Faria Lima Avenue, Vila Sao Pedro",Sao Jose do Rio Preto,SP,15090-000,"Osvaldo ",da Silva Junior,Clinical Research Leader,osvaldo.junior@centrodepesquisacip.com.br,'+551732015000e5657,Different from the above,Horacio,Ramalho,Executive Director,diretoria@hospitaldebase.com.br,+551732015000,Other,Osvaldo,da Silva Junior,Clinical Research Leader,osvaldo.junior@centrodepesquisacip.com.br,'+551732015000e5657,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,1,,,,16-30%,,Yes,No,,More than 2 studies,2,2,0,51.8,0.8,5.8,0,0,41.6,"Brown, other.",9.9,90.1,23.5,57.9,18.6,47.72,52.28,Yes,No,,No,Yes,,,,,,,,,,,,,,,,,,80,40,40,20,20,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,0,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,6,10,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,true,,,,,,,,,30095250,60204632,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto,Avenida Brigadeiro Faria Lima 5544,São José do Rio Preto,Brazil,São Paulo,15090-000,Geni Satomi,Cunrath,551732015083,geni.satomi@gmail.com,gcompian@its.jnj.com,136657,CG_1FD6tJwBWQqcZ9M,13 Jun 2026,00:39 +2026-06-09 09:49:17,2026-06-12 13:13:42,IP Address,99.242.28.198,100,271464,True,2026-06-12 13:13:43,R_3j547maRdwjzmi5,Jairath,Vipul,vipul.jairath@lhsc.on.ca,,43.0461,-81.2436,gl,EN,Yes,Vipul,Jairath,London Digestive Disease Institute,Gastroenterology,vipul.jairath@lhsc.on.ca,519-204-6333,785 Wonderland Road South Suite 253A,London,Ontario,N6K 1M6,Canada,Yes,Heather,Prins,LDDI,hprins@lddi.ca,5192047902,253A-785 Wonderland Rd. S.,London,Ontario,N6K 1M6,Heather,Prins,Study Coordinator,hprins@lddi.ca,5192047902,Different from the above,Melanie,Vitez,Study Coordinator,mvitez@lddi.ca,519-204-6333,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,1,1,16-30%,16-30%,16-30%,≤15%,No,No,,More than 2 studies,3,2,1,60,10,10,10,10,0,,10,90,0,70,30,50,50,No,No,,No,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30160648,60156315,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,London Digestive Disease Institute,785 Wonderland Road South Suite 253A,London,Canada,Ontario,N6K 1M6,Vipul,Jairath,1519685850033655,vipul.jairath@lhsc.on.ca,tresuell@its.jnj.com,136422,CG_3iOaZkDPNSF8pjn,13 Jun 2026,00:43 +2026-06-10 04:25:39,2026-06-12 13:17:54,IP Address,188.25.171.142,100,204734,True,2026-06-12 13:17:55,R_2N5ktPPjswWRsYx,Chioncel,Camelia,cameliachioncel@yahoo.com,,44.447,26.0185,gl,EN,Yes,Camelia,Chioncel,S C Delta Health Care S R L,"Gastroenterology ",cameliachioncel@yahoo.com,40745086735,Strada Nicolae G. Caramfil 85A,Bucharest,Bucharest,014142,Romania,Yes,Alis,Mihai,Delta Health Hospital SA,Alis.mihai@reginamaria.ro,,,,,,Gabriela,Palade,SC,Gabriela.palade@reginamaria.ro,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,46-60%,16-30%,,,Yes,No,,0 studies,3,2,1,100,0,0,0,0,0,,0,0,0,90,10,60,40,Yes,No,,Yes,Yes,I see nothing special now,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30117862,60204476,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,S C Delta Health Care S R L,Strada Nicolae G. Caramfil 85A,Bucharest,Romania,Bucharest,014142,Camelia,Chioncel,40745086735,cameliachioncel@yahoo.com,ftoma@its.jnj.com,135995,CG_2hofTKBiRfntMc1,13 Jun 2026,00:47 +2026-06-09 12:30:37,2026-06-12 13:23:56,IP Address,47.224.223.252,100,262398,True,2026-06-12 13:23:56,R_7GDpZysPlEHztGq,Morey,Anjali,anjali.morey@objective.health,,39.5272,-119.9129,gl,EN,No,Anjali,Morey,"DSI Research, LLC d/b/a ObjectiveHealth Clinical Research-Springboro",Gastroenterology,anjali.morey@objective.health,19374698047,"77 W. Eleanor Dr, Suite 1",Springboro,Ohio,45066,United States,Yes,Georgia,Dresslar,ObjectiveHealth Clinical Research - Springboro,georgia.dresslar@objective.health,19374698047,"77 W. Eleanor Dr, Suite 1",Springboro,Ohio,45066,Georgia,Dresslar,Site Director,georgia.dresslar@objective.health,19374698047,Different from the above,"Christian ",Cook,"Executive Director, Contracts & Budgets",christian.cook@objective.health,615-502-4310,Other,Melissa,Kennish Knowlton,Feasibility Manager,melissa.knowlton@objective.health,607-280-3029,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,1,1,16-30%,46-60%,16-30%,≤15%,Yes,No,,0 studies,3,1,2,76,2,15,0,0,7,3% Hispanic and 4% two or more races,3,97,0,90,10,48,52,Yes,No,,Yes,Yes,"We feel that a robust digital and printed advertising campaign would be an important recruitment driver for Dr. Morey's site. Additionally, if Johnson & Johnson has plans to utilize a patient referral program, we would be very interested in participating. ","All our sites are equipped with a proprietary machine learning, study matching technology called ObjectiveScreen. After trials are awarded, ObjectiveScreen is programed with study specific I/E criteria and will provide a curated list of qualified patients to contact. This is the primary tool we used to find patients, and it has increased our randomization and retention rates. In addition to recommending Dr. Morey for consideration, we have four other PI's and sites with UC trial experience that we think would be successful in the ICONIC study. Interested sites and PI's are recommended below, please copy feasibility@objective.health on surveys for timely completion. If multiple ObjectiveHealth sites are selected, we can clone contracts and budgets for faster start-up.","Brian McMorrow, MD","Michael Williams, MD","Kiran Rao, MD","Alexander Pontikos, MD",,Gateway GI Research,GI Associates Research,Premier Health Research,Akron Gastro Research,,brian.mcmorrow@objective.health,micheal.williams@objective.health,kiran.rao@objective.health,alexander.pontikos@objective.health,,100,60,24,4,20,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,3,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,4,,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30072853,60009449,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Digestive Specialists, Inc",w Eleanor dr 77,Springboro,United States,Ohio,45066,Anjali,Morey,19375347330,anjali.morey@objective.health,hsantosm@its.jnj.com,137118,CG_3g13oKScM70toqm,13 Jun 2026,00:53 +2026-06-10 03:32:18,2026-06-12 13:29:27,IP Address,109.81.26.133,100,208629,True,2026-06-12 13:29:28,R_88U2q1tqvVGkevQ,Gregar,Jan,jan.gregar@fnol.cz,,50.0766,14.4464,gl,EN,No,Jan,Gregar,MUDr. Gregar s.r.o.,"gastroenterology, GI endoscopy, internal medicine",jan.gregar@fnol.cz,420583 211 542,Čajkovského 14,Olomouc,Olomoucký kraj,779 00,Czech Republic,Yes,"Michaela ",Pluskalova,MUDr. Gregar sro,studie@mudr-gregar.cz,420583211542,Cajkovského 14,Olomouc,Czech republic,77900,Jan,Gregar,PI,jan.gregar@fnol.cz,420777284842,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,,,,,,,No,No,,1 study,2,1,1,100,0,0,0,0,0,,0,100,0,90,10,40,60,No,No,,Yes,No,"support for patient recruitment, support for advertising in the media, social networks etc",,,,,,,,,,,,,,,,,20,10,20,5,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,2,3-5,Yes,No,No,No,Yes,Yes,Yes,No,Central and Local,6,6,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30047487,60300321,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MUDr. Gregar s.r.o.,Čajkovského 14,Olomouc,Czech Republic,Olomoucký kraj,779 00,Jan,Gregar,420583 211 542,info@mudr-gregar.cz,vbuzalka@its.jnj.com,136303,CG_tRmcjonUmvgxtex,13 Jun 2026,00:59 +2026-06-09 15:58:20,2026-06-12 13:34:14,IP Address,189.196.192.156,100,250554,True,2026-06-12 13:34:14,R_32DZDLDN6i8fAd0,Cruz Neri,Roberto,robertocruzneri@gmail.com,,20.6381,-103.348,gl,EN,No,Roberto Ulises,Cruz Neri,Centro Medico Clínico Quirurgico Especializado en Investigación,Coloproctology,robertocruzneri@gmail.com,523311946664,"1401 Avenida Adolfo López Mateos Sur, 5th Floor , 501 & 502",Tlajomulco de Zúñiga,Jalisco,45640,Mexico,Yes,"MArcela Angelica ",Salazar Parra,Cenrto Medico Clinico Quirurgico Especializado en Investigacion,marcela.salazar@cqein.mx,+526621418894,"Lopez Mateos Sur Av 1401. 5th Floor, 501 & 502","Tlajomulco de Zuñiga ",Jalisco,45640,"Marcela ",Salazar,Study Coordinator,marcela.salazar@cqein.mx,+526621418894,Same as above,,,,,,Principal Investigator,,,,,,,,,,Yes,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,,,≤15%,≤15%,,,No,Yes,Latent Tb is a frequent finding in mexican population.,1 study,5,2,3,0,0,0,100,0,0,,100,0,0,95,5,50,50,Yes,No,,Yes,No,,,,,,,,,,,,,,,,,,80,30,10,5,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,7,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,10,2,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78235,78235,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centro Medico Clínico Quirurgico Especializado en Investigación,1401 Avenida Adolfo López Mateos Sur,Tlajomulco de Zúñiga,Mexico,Jalisco,45640,Roberto,Cruz Neri,523311946664,robertocruzneri@gmail.com,vcastan4@its.jnj.com,136595,CG_3efzNVLPqYtYbNs,13 Jun 2026,01:04 +2026-06-09 12:01:21,2026-06-12 13:57:11,IP Address,139.137.128.75,100,266150,True,2026-06-12 13:57:12,R_1YFmfhLCUXOPEWS,Cohen,Benjamin,COHENB3@ccf.org,,41.5053,-81.5566,gl,EN,No,Benjamin,Cohen,Cleveland Clinic-Main Campus,"Gastroenterology ",COHENB3@ccf.org,12164449252,Euclid ave 9500,Cleveland,Ohio,44195,United States,Yes,Jason,Soltis,Digestive Disease Institute - Inflmmatory Bowel Diseases,soltisj@ccf.org,2163461197,"9211 Euclid Ave, JJ North Building, 4th Floor, Cube 434",Cleveland,ohio,44195,Arrielle,Cook,Research Coordinator,cooka11@ccf.org,216 538-9039,Different from the above,Jason,Soltis,Department Manager,soltisj@ccf.org,216-346-1197,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,16-30%,,,Yes,No,,0 studies,2,1,1,85,3,7,2,3,0,,10,90,0,80,20,50,50,Yes,No,,No,No,"We can partner with a 3rd party for mobile nursing (Fortrea). + +Home Health Care/Mobile Nurse +If your study doctor thinks it is safe for you, study visits may occur at your home. These home visits may start after month 3 treatment visit in the OLE (Open Label) portion of the study. You do not have to agree to home visits and disclosure of your personal data to the provider as described in this form, to participate in the trial. + +Fortrea will need personal information that identifies you (such as name, address, telephone number and date of birth {DOB}), if you chose to receive visits at home, Fortrea will use this information to identify and provide a qualified nurse in your area. To do this Fortrea will need to share your information with nursing agencies and couriers. Your personal and medical information identifying you will be kept confidential. Your information will be handled in compliance with Clinical Research regulations. Fortrea cannot guarantee you will see the same nurse at every visit. +If you choose to have the study drug delivered to your home, a trained mobile nurse will set up a visit to give you the study drug and observe you for 60 or 30 minutes to ensure you are feeling fine. The visit will also include: +● Measurement of your vital signs (breathing rate, heartrate, blood pressure and body temperature) +● Measurement of your body weight +● Physical examination +● Review of eDiary +● Completing questionnaire +● Collection of blood samples approximately 2 – 3 Tablespoons +● Collection of Urine and Stool sample +● Medication review +● Assessment of any side effects or changes in health + +Courier Deliveries +If you chose to participate in Home Health care/Mobile nurse visits the trial medication and/or trial supplies need to be delivered to your home, and or laboratory samples are picked up from your home, the Sponsor will use a courier for this service. Laboratory samples include blood, urine, and stool samplings. The mobile nurse will take care of the communications with the courier company and handing over samples to the courier. + +The courier service that will be used is called QuickSTAT, Miami. Their contact information is QuickSTAT Miami A Kuehn + Nagal Company, 7859 NW 46th St Miami Florida 33166. They will need personal information that identifies you (such as name, address, telephone number and date of birth {DOB}). This information will be required in order for delivery and pick up of all study materials. The sponsor will not have access to these contact details. + +QuickSTAT will only keep your personal data for the purpose of delivering trial medication and supplies only. They will keep this personal data until the end of your participation in the trial and will ensure appropriate destruction of your personal data records art this time. The sponsor will not have access to these contact details. + +If you do not choose to participate in Home Health /Mobile nurse care, your personal information will not be released to either party listed above. +",,,,,,,,,,,,,,,,,1600,300,900,200,200,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,2,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,9,12,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30153692,60593034,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cleveland Clinic-Main Campus,Euclid ave 9500,Cleveland,United States,Ohio,44195,Benjamin,Cohen,12164449252,COHENB3@ccf.org,hsantosm@its.jnj.com,137150,CG_ywOQylzC5Dyx5Bf,13 Jun 2026,01:27 +2026-06-02 11:59:05,2026-06-12 14:57:03,IP Address,177.67.241.76,100,874678,True,2026-06-12 14:57:04,R_6qfSLpg1eyNqWHY,Escorsi Valerio,Herlon,herlon.integral@hotmail.com,,-20.4811,-50.0146,gl,EN,No,Herlon,Escorsi Valerio,INTEGRAL Pesquisa e Ensino,Gastroenterologist,herlon.integral@hotmail.com,5517996212128,"Avenida Vale do Sol, 4755, Vale do Sol - CEP 15500-269",Votuporanga,São Paulo,15501-405,Brazil,Yes,CARLA,TEIXEIRA DA SILVA,INTEGRAL Pesquisa e Ensino,csilva.pesquisa.mg@gmail.com,55 17 99755-7979,Avenida Vale do Sol 4755,Votuporanga,São Paulo,15500-269,GRACIELLY,DE SOUZA PANTANO,Director,integral.pesquisa.mg@gmail.com,55 17 99139-9066,Same as above,,,,,,Other,GRACIELLY,DE SOUZA PANTANO,Director,integral.pesquisa.mg@gmail.com,55 17 99139-9066,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,1,1,,31-45%,31-45%,≤15%,No,No,,0 studies,8,4,4,65,1,7,0,0,27,Mixed race / Pardo,100,0,0,90,10,50,50,Yes,No,,Yes,Yes,"Our site has access to commercially available local laboratory testing for therapeutic drug monitoring of some biologic agents, particularly anti-TNF agents such as infliximab and adalimumab. However, local commercially available testing for vedolizumab serum levels and/or anti-vedolizumab antibodies is not routinely available based on currently identified local laboratory options. If vedolizumab drug-level testing is required for eligibility, this would likely need to be confirmed with the sponsor/central laboratory or arranged through a specialized reference laboratory, potentially outside routine local testing pathways.","Although the form was filled out by me, Gracielly Pantano, as the center's director and SI for this therapeutical area, the information provided was simultaneously discussed and endorsed by the PI (Project Intervention).",,,,,,,,,,,,,,,,40,18,18,8,3,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,3,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,4,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30134657,60189548,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,INTEGRAL Pesquisa e Ensino,"Avenida Vale do Sol, 4755, Vale do Sol - CEP 15500-269",Votuporanga,Brazil,São Paulo,15501-405,Herlon,Escorsi Valerio,5517996212128,herlon.integral@hotmail.com,gcompian@its.jnj.com,136678,CG_3nq01SKdQd5zyN8,13 Jun 2026,02:27 +2026-06-10 14:09:00,2026-06-12 15:19:08,IP Address,189.250.191.251,100,177008,True,2026-06-12 15:19:08,R_7Cx4w1Cb6pi7y9W,Vera Heredia,Ana,factibilidad@redosmo.com,,17.1225,-96.793,gl,EN,No,Ana,Vera Heredia,Oaxaca Site Management Organization S.C.,Gastroenterology,ana.vera@oax.redosmo.com,+529515147056,Humboldt 302,Oaxaca,Oaxaca,68000,Mexico,Yes,Beatriz Elena,Mayoral Moreno,Oaxaca Site Management Organization S.C.,beatriz.mayoral@osmomexico.com,9515147056,Humboldt 302 Col. Centro,Oaxaca de Juarez,"Oaxaca ",68000,Andrea,Córdova Amador,Feasibility Operator,factibilidad@redosmo.com,+52 9511886527,Different from the above,Victor Casildo,Bohórquez López,CEO," victor@redosmo.com",+52 951 229 0849,Principal Investigator,,,,,,,,,,Yes,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,1,1,1,,≤15%,31-45%,46-60%,Yes,No,,0 studies,6,1,5,0,0,0,0,0,100,Latino,100,0,0,50,50,50,50,Yes,Yes,Spanish,No,No,,No,,,,,,,,,,,,,,,,10,9,1,0,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,1,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,2,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,false,,,,,,30112991,60936784,,,,,,100,,,0,0,,,,,,,,,,,,,,,,,,,,,,Oaxaca Site Management Organization S.C.,Humboldt 302,Oaxaca,Mexico,Oaxaca,68000,Ana,Vera Heredia,5201951954297,factibilidad@redosmo.com,vcastan4@its.jnj.com,136600,CG_12r0esRlpGwLet6,13 Jun 2026,02:49 +2026-06-02 12:45:06,2026-06-12 16:50:05,IP Address,45.190.39.167,100,878699,True,2026-06-12 16:50:05,R_6qmXA3PAx30hDiB,Freire,Caio,caiofreire@yahoo.com.br,,-3.7145,-38.5419,gl,EN,No,Caio,Freire,ATO Terapias,Médico gastroenterologista,caiofreire@yahoo.com.br,5585986857910,1674 Rua Bárbara de Alencar,Fortaleza,CE,60140 025,Brazil,Yes,Maiane,Medeiros,Centro de Oncologia Leonardo da VInci - ATO Terapias - Pesquisa Clínica,pesquisa@atooncologia.com.br,55 85 3224-0552,"Rua barbara de alencar 1674, Aldeota",Fortaleza,Ceará,60140025,Maiane,Medeiros,Farmacêutica / Coordedanora de pesquisa clínica,pesquisa@atooncologia.com.br,85 3224-0552,Same as above,,,,,,Research Coordinator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,"Some patients have vedolizumab fully reimbursed, others partially; we only measure infliximab and adalimumab antibodies, and anti-adalimumab antibodies.",1,1,1,,46-60%,16-30%,16-30%,,Yes,Yes,"We do not have serum level measurements for istekinumab, vedolizumab, and golimumab.",1 study,03,02,01,20,0,10,0,0,70,latino,0,100,5,80,15,45,55,Yes,Yes,PORTUGUÊS,Yes,No,,,,,,,,,,,,,,,,,,150,08,140,50,03,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,1,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,4,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30159805,60900301,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ATO Terapias,1674 Rua Bárbara de Alencar,Fortaleza,Brazil,CE,60140 025,Caio,Freire,5585986857910,caiofreire@yahoo.com.br,gcompian@its.jnj.com,136665,CG_27C3B91ipAHZobt,13 Jun 2026,04:20 +2026-06-11 22:12:50,2026-06-12 18:03:49,IP Address,219.89.118.172,100,71459,True,2026-06-12 18:03:50,R_4jJNcIQ1MYAEoIj,Schultz,Michael,michael.schultz@otago.ac.nz,,-42.0009,173.998,gl,EN,No,Michael,Schultz,Dunedin Hospital,Gastroenterology,michael.schultz@otago.ac.nz,6434740999,Great King Street 201,Dunedin,Otago Region,9016,New Zealand,Yes,Ling,Yap,"University of Otago, Gastroenterology Research Unit",ling.yap@otago.ac.nz,03 474 0999,201 Great King Street,Dunedin,Otago,9054,Luke,Schofield,Research Unit Manager,luke.schofield@otago.ac.nz,034740999,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,,1,1,,,16-30%,16-30%,,Yes,No,,1 study,6,2,4,85,5,7,0,3,0,,0,0,0,75,25,50,50,Yes,No,,Yes,No,"none, we are fully set up and would welcome the chance to participate in this trial.",no,,,,,,,,,,,,,,,,100,50,50,30,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,5,5,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,4,,8,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30099455,60279987,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Dunedin Hospital,Great King Street 201,Dunedin,New Zealand,Otago Region,9016,Michael,Schultz,6434740999,michael.schultz@otago.ac.nz,jmorais7@its.jnj.com,138896,CG_2c6eZZKbV9N9nYW,13 Jun 2026,05:33 +2026-06-10 13:47:11,2026-06-12 21:22:24,IP Address,189.155.198.233,100,200113,True,2026-06-12 21:22:25,R_6IyjRh4Gtqm9V9G,Nunez,Dra. Marina,dra.marina.iics@gmail.com,,24.0222,-104.6392,gl,EN,No,Dra. Marina,Nunez,Instituto de Investigaciones Clínicas para la Salud,Gastroenterología,dra.marina.iics@gmail.com,+526182167455,Calle Patoni 404,Victoria de Durango,Durango,34000,Mexico,Yes,Víctor Hugo,"Lira Martínez ",Instituto de Investigaciones Clínicas para la Salud A.C.,v.h.lira.mtz@hotmail.com,+526181342987,"Paroni No. 404, Zona Centro",DURANGO,DURANGO,34000,Víctor Hugo,"Lira Martínez ","CEO ",victor.hugo@iics.com.mx,+526181342987,Same as above,,,,,,Principal Investigator,,,,,,,,,,Yes,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,"Los planes de seguros de gastos médicos mayores sí cubren y reembolsan el vedolizumab, siempre que la colitis ulcerosa de moderada a grave esté diagnosticada médicamente y no sea una enfermedad preexistente al momento de contratar la póliza.",1,1,1,1,31-45%,31-45%,16-30%,≤15%,Yes,No,,0 studies,14,7,7,100,0,0,0,0,0,,100,0,0,70,30,55,45,Yes,No,,Yes,Yes,"Para tener éxito en el enrrolamiento se requiere un buen esquema de alianzas estrategicas, publicidad y refrenencias de colegas, del sector publico y privado. previo al inicio del estudio. ",,,,,,,,,,,,,,,,,45,28,0,0,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,3,3-5,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Local,,1,1,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30153317,60605414,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Instituto de Investigaciones Clínicas para la Salud,Calle Patoni 404,Victoria de Durango,Mexico,Durango,34000,Dra. Marina,Nunez,,dra.marina.iics@gmail.com,vcastan4@its.jnj.com,136606,CG_25NO1vdpLmQugRs,13 Jun 2026,08:52 +2026-06-02 12:36:46,2026-06-12 22:02:32,IP Address,189.62.47.49,100,897946,True,2026-06-12 22:02:32,R_6OGRipOSvUhf5Tr,Leite Barros,Luisa,luisa.barros@hc.fm.usp.br,,-23.5475,-46.6361,gl,EN,No,Luisa,Leite Barros,Universidade de Sao Paulo-Campus Sao Paulo,Gastroenterologist,luisa.barros@hc.fm.usp.br,5511971871131,"R. Dr. Ovídio Pires de Campos, 225",São Paulo,São Paulo,05403-010,Brazil,Yes,Patricia,Momoyo,Clinics Hospital,patricia.momoyo@hc.fm.usp.br,+5511 2661 3339,Av Dr. Eneas Carvalho de Aguiar 255,São Paulo,São Paulo,05403-010,Patricia,Momoyo,Study coordinator,patricia.momoyo@hc.fm.usp.br,+ 55 11 2661 3339,Same as above,,,,,,Principal Investigator,,,,,,,Yes,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,46-60%,16-30%,,,Yes,No,,0 studies,10,8,2,45,5,50,0,0,0,,,100,0,80,20,50,50,Yes,Yes,"Portuguese,",Yes,Yes,"Our institution has the infrastructure, resources, and expertise required to successfully conduct a Phase 3b clinical trial.",Not at this time.,,,,,,,,,,,,,,,,500,100,250,200,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,3,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,6,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30147523,60689740,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Universidade de Sao Paulo-Campus Sao Paulo,"R. Dr. Ovídio Pires de Campos, 225",São Paulo,Brazil,São Paulo,05403-010,Luisa,Leite Barros,5511971871131,luisa.barros@hc.fm.usp.br,gcompian@its.jnj.com,136661,CG_2vjF9lJ778z18dP,13 Jun 2026,09:32 +2026-06-11 01:47:47,2026-06-13 07:00:02,IP Address,109.80.173.97,100,191534,True,2026-06-13 07:00:03,R_21yYdhemVSh41pf,Konecny,Michal,konecnymi@seznam.cz,,49.5864,17.2537,gl,EN,No,Michal,Konecny,"MUDr. Michal Konecny, Ph.D. s.r.o.",GE,konecnymi@seznam.cz,420 581 201 691,Budovatelu 197/6,Prerov,Olomoucky kraj,750 02,Czech Republic,Yes,Katerina,Konecna,"MUDr. Michal Konečný, PhD. sro",kkacer@email.cz,734876969,Krameriova 29,Olomouc,CR,779 00,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,1,1,,31-45%,16-30%,≤15%,Yes,No,,1 study,4,2,2,100,0,0,0,0,0,,0,100,0,90,10,50,50,Yes,No,,Yes,No,,,,,,,,,,,,,,,,,,250,15,60,15,2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,2,1-2,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Central and Local,10,6,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30044902,60346176,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"MUDr. Michal Konecny, Ph.D. s.r.o.",Budovatelu 197/6,Prerov,Czech Republic,Olomoucky kraj,750 02,Michal,Konecny,420 581 201 691,konecnymi@seznam.cz,vbuzalka@its.jnj.com,136318,CG_p6mOBtk7bJkh10R,13 Jun 2026,18:30 +2026-06-10 09:02:01,2026-06-13 08:10:58,IP Address,170.173.74.42,100,256137,True,2026-06-13 08:10:59,R_5LGMhMPoCVHTD3q,Liu,Eashen,Eashen.Liu@providence.org,,47.6901,-122.3747,gl,EN,No,Eashen,Liu,Providence Medical Group,Gastroenterology,Eashen.Liu@providence.org,5094892600,East Central Avenue 212,Spokane,Washington,99207,United States,No,,,,,,,,,,Kelli,"Kuykendall, MA-P, CCRC","Research Project Manager ",kelli.kuykendall@providence.org,Office 509-474-3820,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,16-30%,31-45%,,,Yes,No,,1 study,2,1,1,80,10,10,0,0,0,,0,0,0,80,20,60,40,No,No,,No,No,promotion of this study,,,,,,,,,,,,,,,,,346,10,325,30,40,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,1,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,9,12,16,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30173022,60372276,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Providence Medical Group,East Central Avenue 212,Spokane,United States,Washington,99207,Eashen,Liu,5094892600,Eashen.Liu@providence.org,hsantosm@its.jnj.com,137156,CG_27fWq4Fl47Z7nf6,13 Jun 2026,19:40 +2026-05-31 12:51:34,2026-06-13 11:19:27,IP Address,186.57.178.51,100,1117672,True,2026-06-13 11:19:27,R_6ahlR9cvpbkNXY5,Gimenez,Edgardo,edgardo.gimenez@institutocer.com,,-34.719,-58.2997,gl,EN,Yes,Edgardo,Gimenez,Cer Instituto Medico,Gastroenterologist,edgardo.gimenez@institutocer.com,541154287683,Avenida Vicente López 1441,Quilmes,Buenos Aires,B1878,Argentina,Yes,Cintia,Schenkel,CER Instituto Medico,cintia.schenkel@institutocer.com,"+54911 5263-3113 ",Vicente Lopez 1441,Quilmes,Buenos Aires,B1878,Cintia,Schenkel,Study coordinator,cintia.schenkel@institutocer.com,+54911 52633113,Different from the above,monica,coronel,COO,monica.coronel@institutocer.com,+54911 6681-4427,Principal Investigator,,,,,,,,Yes,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,,1,,,,≤15%,,Yes,No,,0 studies,4,3,1,0,0,0,0,0,100,Latin,100,0,0,60,40,40,60,No,No,,No,No,Data review fee,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30112380,60586489,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cer Instituto Medico,Avenida Vicente López 1441,Quilmes,Argentina,Buenos Aires,B1878,Edgardo,Gimenez,541154287683,edgardo.gimenez@institutocer.com,zpatrign@its.jnj.com,136279,CG_bHmjDwJJYaUm5Xz,13 Jun 2026,22:49 +2026-06-09 06:19:21,2026-06-13 12:26:01,IP Address,87.197.183.203,100,367599,True,2026-06-13 12:26:02,R_81HTdNnIHXlpyqk,Mihalkanin,Lubomir,mihalkanin@gmail.com,,49.0689,20.2968,gl,EN,No,Lubomir,Mihalkanin,GASTRO I. s.r.o.,gastroenterology,mihalkanin@gmail.com,421905794001,Puškinova 18,Prešov,Prešov Region,080 01,Slovakia,No,,,,,,,,,,Lubomir,Mihalkanin,,mihalkanin@gmail.com,0905794001,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,31-45%,,,Yes,No,,1 study,4,2,2,100,0,0,0,0,0,,0,100,0,0,100,50,50,Yes,No,,Yes,Yes,---,---,,,,,,,,,,,,,,,,150,15,150,80,8,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,5,10,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Central,2,,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30108419,60483311,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GASTRO I. s.r.o.,Puškinova 18,Prešov,Slovakia,Prešov Region,080 01,Lubomir,Mihalkanin,421905794001,mihalkanin@gmail.com,vbuzalka@its.jnj.com,136434,CG_22rWEVcobSG74Gk,13 Jun 2026,23:56 +2026-06-12 04:29:42,2026-06-14 01:20:14,IP Address,86.124.142.55,100,161431,True,2026-06-14 01:20:14,R_2fISB8n2nR2f2Xh,Diaconescu,Razvan Gheorghe,diaconescu_razvan@yahoo.com,,45.7537,21.2257,gl,EN,No,Razvan Gheorghe,Diaconescu,Oncohelp Medical Center,Gastroenterology,diaconescu_razvan@yahoo.com,0040767152254,57 59 Strada Ciprian Porumbescu,Timisoara,TM,300425,Romania,Yes,Razvan,Diaconescu,"Oncohelp/ Gastroenterology ",diaconescu_razvan@yahoo.com,0767152254,"Timisoara Ciprian POrumbescu, 57-59",Timișoara,Timiș,300002,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,≤15%,16-30%,46-60%,46-60%,Yes,No,,1 study,4,3,1,100,0,0,0,0,0,,0,100,0,70,30,50,50,Yes,No,,Yes,Yes,"settlement of transportation expenses, hotel and other expenses for subject outside the town ",no,,,,,,,,,,,,,,,,40,10,20,10,10,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,4,≥6,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Central,4,,4,No,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30107029,60909709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Oncohelp Medical Center,57 59 Strada Ciprian Porumbescu,Timisoara,Romania,TM,300425,Razvan Gheorghe,Diaconescu,0040745459223,office@oncohelp.ro,ftoma@its.jnj.com,135987,CG_1ez87GpyRiLqqvW,14 Jun 2026,12:50 +2026-06-02 06:04:47,2026-06-14 03:39:05,IP Address,84.110.114.28,100,1028057,True,2026-06-14 03:39:06,R_22A7xNkjEvbmZ5v,Openhaim,Michal,Michal.openhaim@clalit.org.il,,32.0123,34.7705,gl,EN,Yes,Michal,Openhaim,Meir Medical center,gastroenterologist,Michal.openhaim@clalit.org.il,+972-9-7471272,59 Tchernichovsky Street,Kefar Sava,Center District,4428164,Israel,Yes,LEE,ABRAMAS,"MEIR MEDICAL CENTER GASTROENTEROLOGY DEP ",meleeabr@clalit.org.il,+97297471017,Tchernicovsky 59," kfar saba",Israel,4428164,Lee,Abramas,Studt Coordinator,meleeabr@clalit.org.il,+972-54-9090393,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,,,,>60%,,,,No,No,,2 studies,2,2,0,95,0,5,0,0,0,,0,100,0,80,20,50,50,Yes,Yes,"Hebrew, Russian, Arabic",Yes,No,"Travel expanses for the patients +dedicated CRA for the team +",no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78151,78151,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meir Medical center,59 Tchernichovsky Street,Kefar Sava,Israel,Center District,4428164,Michal,Openhaim,+972-9-7471272,Michal.openhaim@clalit.org.il,bmayer1@its.jnj.com,135863,CG_324mUlUkTrtPrkd,14 Jun 2026,15:09 +2026-05-29 01:04:16,2026-06-14 06:29:06,IP Address,167.103.63.8,100,1401890,True,2026-06-14 06:29:07,R_4dLe1znNhLMfbQg,Pinyopornpanish,Kanokwan,knp_02@hotmail.com,,1.2872,103.8507,gl,EN,No,Taned,Chitapanarux,Maharaj Nakorn Chiangmai Hospital(Chiang Mai University),Gastroenterology,taned.chi@cmu.ac.th,6653280828,"110 Intavaroros Road, Muang",Mueang Chiang Mai,Chiang Mai,50200,Thailand,No,,,,,,,,,,Arawan,Larplertsakul,Associate Director,arawan.crc@gmail.com,66818818274,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,,,,>60%,,,Yes,Yes,Number of biologic-naive and biologic-experienced patients.,1 study,3,1,2,0,100,0,0,0,0,,0,100,0,100,0,50,50,Yes,Yes,"Thai, English, Chinese",Yes,Yes,None,,,,,,,,,,,,,,,,,12,5,7,1,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,2,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,6,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,,,30099003,60183129,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Maharaj Nakorn Chiangmai Hospital(Chiang Mai University),"110 Intavaroros Road, Muang",Mueang Chiang Mai,Thailand,Chiang Mai,50200,Kanokwan,Pinyopornpanish,66053221122,knp_02@hotmail.com,ychanjar@its.jnj.com,136157,CG_24HogJwxt0XyfZ3,14 Jun 2026,17:59 +2026-06-10 00:00:15,2026-06-14 10:26:44,IP Address,172.226.122.40,100,383188,True,2026-06-14 10:26:44,R_6HYBwOw2pA5Y0WF,de Leon Rendon,Jorge Luis,jlfarmaclinica@gmail.com,,19.4324,-99.1229,gl,EN,No,Jorge Luis,de Leon Rendon,"Hospital General de Mexico ""Dr Eduardo Liceaga""","Colorectal - IBD Surgery ",dr.jorgedeleon@hotmail.com,523323437024,Doctor Balmis 148,Mexico City,Ciudad de México,06720,Mexico,Yes,Nora,Godinez Cubillo,Hospital General de Mexico / Department of Pharmacology,noragcm@gmail.com,525513334151,DR Balmis 148,Mexico,"Ciudad de Mexico ",06720,"Nora ",Godinez Cubillo,Research Coordinator,noragcm@gmail.com,525513334151,Same as above,,,,,,Principal Investigator,,,,,,,,,,Yes,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,16-30%,,,No,No,,1 study,6,3,3,1,0,0,0,0,99,Hispanic/Latino,99,1,0.5,86.5,13,53,47,Yes,No,,Yes,No,"The only anticipated challenge would be identifying an alternative certified laboratory to perform QuantiFERON testing when required. This is considered a minor logistical issue and is not expected to impact study feasibility or execution. + +Our institution is a certified Inflammatory Bowel Disease (IBD) Center of Excellence accredited by the Pan American Crohn's and Colitis Organisation (PANCCO). We operate through a well-established multidisciplinary care model that includes gastroenterologists, colorectal surgeons, specialized nurses, nutritionists, psychologists, radiologists, pathologists, and dedicated research personnel. + +The center has extensive experience in the management of complex IBD patients, administration of advanced therapies, prospective patient follow-up, and participation in clinical research. We have the required infrastructure, trained personnel, and operational capacity to successfully conduct this study, ensuring timely recruitment, protocol adherence, high-quality data collection, and full compliance with Good Clinical Practice (GCP) standards.","None. ",,,,,,,,,,,,,,,,126,40,86,70,5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,2,3-5,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Local,,8,10,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30132960,60818870,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital General de Mexico,Doctor Balmis 148,Mexico City,Mexico,Ciudad de México,06720,Jorge Luis,de Leon Rendon,523323437024,jlfarmaclinica@gmail.com,vcastan4@its.jnj.com,136604,CG_Uo8htulc2uK50Bz,14 Jun 2026,21:56 +2026-05-29 03:46:23,2026-06-14 19:38:49,IP Address,175.143.42.62,100,1439546,True,2026-06-14 19:38:50,R_4lyOuiqp4R3AOmD,Wan Abdullah,Wan Zaharatul Ashikin,wzaharatul@yahoo.com,,2.9935,101.745,gl,EN,No,Wan Zaharatul Ashikin,Wan Abdullah,Hospital Putrajaya,Gastroenterology,wzaharatul@yahoo.com,60148919450,Presint 7,Putrajaya,Putrajaya,62000,Malaysia,Yes,"NOR FAIZAH BINTI ",ABDOL MUTALIB,Putrajaya Hospital,faizah.abdolmutalib@clinicalresearch.my,,,,,,,,,,,Same as above,,,,,,Other,Shu Hui,Cheng,Feasibility Specialist,shuhui@clinicalresearch.my,0132033981,,,,,,,Yes,"No, I am not interested",Insufficient patient population,,PI Dr Zaharatul has declined due to insufficient patient pool,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30098175,60926469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Putrajaya,Presint 7,Putrajaya,Malaysia,Putrajaya,62000,Wan Zaharatul Ashikin,Wan Abdullah,60148919450,wzaharatul@yahoo.com,wchan26@its.jnj.com,136173,CG_1q2Jzv8C7jVVJRD,15 Jun 2026,07:08 +2026-06-04 10:16:13,2026-06-14 22:58:40,IP Address,167.103.63.9,100,909747,True,2026-06-14 22:58:40,R_4DHm6qpQrfBCuRv,Bunchorntavakul,Chalermrat,dr.chalermrat@gmail.com,,1.2872,103.8507,gl,EN,No,Tanyaporn,Chantarojanasiri,Rajavithi Hospital,Gastroenterology,chtunya@gmail.com,66023548137,Phaya Thai Road 2,Bangkok,Bangkok,10400,Thailand,No,,,,,,,,,,Chalermrat,Bunchorntavakul,Sub-Investigator,dr.chalermrat@gmail.com,66023548137,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only",Other (please specify):,Fully reimbursed with condition,1,1,,,≤15%,>60%,,,No,No,,0 studies,5,1,4,0,100,0,0,0,0,,0,100,0,90,10,50,50,No,No,,No,Yes,,,,,,,,,,,,,,,,,,50,40,10,5,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,0,None,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,6,8,8,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30099599,60295504,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rajavithi Hospital,Phaya Thai Road 2,Bangkok,Thailand,Bangkok,10400,Chalermrat,Bunchorntavakul,66023548137 66023548108 66023548081,dr.chalermrat@gmail.com,ychanjar@its.jnj.com,137212,CG_2WOS6kRlEdcmBRI,15 Jun 2026,10:28 +2026-06-11 23:54:37,2026-06-14 23:53:58,IP Address,1.38.92.38,100,259161,True,2026-06-14 23:53:59,R_9JryN8t8ndg0WMo,Mehta,Chetan,mehtacn@hotmail.com,,22.2904,70.7915,gl,EN,No,Chetan,Mehta,Shree Giriraj Multispeciality Hospital,"Gastroenterology ",mehtacn@hotmail.com,+91-9825077472,"27, Navjyot Park, 150 Feet Ring Rd",Rajkot,Gujarat,360005,India,Yes,Sneha,Jagani,"Shree Giriraj Hospital ",crcsneha29@gmail.com,+91-8866633615,27 Navjot Park Main Road,"Rajkot ","Gujarat ",360005,"Dr Chetan ","Mehta ",PI,mehtacn@hotmail.com,+91-9825077472,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,,,,,,,No,No,,1 study,20,2,18,0,100,0,0,0,0,,0,100,10,80,10,60,40,Yes,Yes,"Gujarati, Hindi, English ",Yes,No,"Patient facing study material in local language ",No,,,,,,,,,,,,,,,,150,130,10,3,4,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,5,10,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Local,,2,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30022063,60578155,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Shree Giriraj Multispeciality Hospital,"27, Navjyot Park, 150 Feet Ring Rd",Rajkot,India,Gujarat,360004,Chetan,Mehta,,mehtacn@hotmail.com,skulk105@its.jnj.com,135887,CG_3BOaexahMMxRRV7,15 Jun 2026,11:23 +2026-06-11 14:31:22,2026-06-15 00:33:34,IP Address,20.7.103.242,100,295332,True,2026-06-15 00:33:34,R_6J1SxIAEfJXpVXm,Schwartz,Marc,schwartzm@upmc.edu,,36.6694,-78.3877,gl,EN,No,Marc,Schwartz,University of Pittsburgh Medical Center,Gastroenterology,schwartzm@upmc.edu,7735958533,200 Lothrop Street,Pittsburgh,Pennsylvania,15213,United States,Yes,"Lori ",Snyder,UPMC/Pitt,lbs18@pitt.edu,412-647-8362,200 Lothrop Street,Pittsburgh,PA,15213,"Lori ",Snyder,,,,Different from the above,Claudia,Rivers-Ramos,Regulatory coordinator,riverscr@upmc.edu,724-984-3011,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,≤15%,≤15%,≤15%,16-30%,Yes,No,,0 studies,4,3,1,80,5,15,0,0,0,,15,85,1,74,25,50,50,Yes,No,,Yes,No,"Support for patient travel. +Recruitment materials.",,,,,,,,,,,,,,,,,100,25,75,10,10,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,1,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,16,16,16,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,,,,,,,,,,30075991,60121112,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,University of Pittsburgh Medical Center,Centre ave 5150,Pittsburgh,United States,Pennsylvania,15213,Marc,Schwartz,4125789533,mbs53@pitt.edu,hsantosm@its.jnj.com,137081,CG_2PASUPCrSsOOQhB,15 Jun 2026,12:03 +2026-06-10 03:30:10,2026-06-15 01:05:40,IP Address,85.237.234.43,100,423330,True,2026-06-15 01:05:41,R_2RaMdhAagTwaLct,Durina,Juraj,inv.1768681.3@dd-proxy.com,,48.1715,17.1678,gl,EN,No,Juraj,Durina,Fakultna nemocnica s poliklinikou Nove Zamky,Gastroenterology,inv.1768681.3@dd-proxy.com,+421356912095,Slovenská 11A,Nové Zámky,Nitra Region,940 02,Slovakia,Yes,Veronika,Mitasova,Fakultna nemocnica,veronika.mitasova@nspnz.sk,035/6912095,Slovenska11A,Nove Zamky,Nitriansky kraj,94001,Juraj,Durina,PI,jdurina@gmail.com,035/6912095,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,>60%,16-30%,≤15%,≤15%,Yes,No,,1 study,5,2,3,100,0,0,0,0,0,,0,0,0,90,10,45,55,Yes,Yes,"slovak, hungarian",No,No,,,,,,,,,,,,,,,,,,15,10,230,120,13,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,3,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,1,1,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30107876,60658585,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fakultna nemocnica s poliklinikou Nove Zamky,Slovenská 11A,Nové Zámky,Slovakia,Nitra Region,940 02,Juraj,Durina,421356912418,inv.1768681.3@dd-proxy.com,vbuzalka@its.jnj.com,136444,CG_1l3ROWOHGfI2eJA,15 Jun 2026,12:35 +2026-05-29 03:43:31,2026-06-15 01:42:15,IP Address,147.158.200.189,100,1461523,True,2026-06-15 01:42:15,R_9nd4ObRAvQJHA5j,Md Salleh,Muhammad Firdaus,Mufi2299@gmail.com,,1.5061,103.706,gl,EN,Yes,Muhammad Firdaus,Md Salleh,Hospital Sultanah Aminah,Gastroenterology and Hepatology,Mufi2299@gmail.com,60173135491,Persiaran Abu Bakar Sultan,Johor Bahru,Johor,80100,Malaysia,Yes,Rainianti,Daman,Hospital Sultanah Aminah,rainianti@clinicalresearch.my,+60137804119,"Clinical Research Centre, Hospital Sultanah Aminah, Jalan Persiaran Abu Bakar Sultan",Johor Bahru,Johor,80100,Rainianti,Daman,Study Coordinator,rainianti@clinicalresearch.my,+60137804119,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only",Other (please specify):,Covered intravenously by most of providers,,1,,,,≤15%,,,No,No,,More than 2 studies,1,1,0,0,100,0,0,0,0,,0,100,0,100,0,50,50,Yes,No,,No,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30154999,60503752,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Sultanah Aminah,Persiaran Abu Bakar Sultan,Johor Bahru,Malaysia,Johor,80100,Muhammad Firdaus,Md Salleh,60173135491,Mufi2299@gmail.com,wchan26@its.jnj.com,136165,CG_3lrJ5iisIXwgEiM,15 Jun 2026,13:12 +2026-06-01 11:33:27,2026-06-15 03:13:08,IP Address,213.157.112.8,100,1179581,True,2026-06-15 03:13:08,R_23SfCp0ADua7gZz,Viranyi,Zsolt,szaboaki1@gmail.com,,46.6826,21.1004,gl,EN,No,Zsolt,Viranyi,Egeszseggyar Kecskemet,gastroenterology,szaboaki1@gmail.com,+36203875260,16 László Károly utca,Kecskemét,Bács-Kiskun County,6000,Hungary,Yes,Anikó,Pálfi,Trial Pharma Kft,czeneaniko@gmail.com,+3620406095,16 Street László Károly,Kecskemét,Bács-Nagykun,6000,Mónika,Dér,project coordinator,moni.der@gmail.com,+36208244122,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"No, I am not interested",Lack of scientific appeal/not scientifically interesting,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78541,78541,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Egeszseggyar Kecskemet,16 László Károly utca,Kecskemét,Hungary,Bács-Kiskun County,6000,Zsolt,Viranyi,+36203875260,szaboaki1@gmail.com,anochta@its.jnj.com,136252,CG_1Cey8b2vIFxmNi9,15 Jun 2026,14:43 +2026-06-11 08:00:30,2026-06-15 05:17:53,IP Address,106.192.41.143,100,335842,True,2026-06-15 05:17:54,R_44qms9MbANdrw1K,Peddi,Kiran Kumar,kiranpeddi0@gmail.com,,17.3843,78.4583,gl,EN,Yes,Kiran Kumar,Peddi,Yashoda Hospitals - Somajiguda,"Gastroenterology ",kiranpeddi0@gmail.com,917730066888,Raj Bhavan rd,Hyderabad,Telangana,500082,India,Yes,"Shivaprasad ",K,"Yashoda hospital ",shivagastroyh@gmail.com,9949535235,yashoda hospital,Hyderabad,Telangana,500082,"Dr Srinivaarao ",Ba,Head,drraoyashoda@gmail.com,9441266519,Different from the above,Dr Srinivasarao,B,Head,drraoyashoda@gmail.com,9441266519,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,1,,16-30%,16-30%,16-30%,,No,No,,0 studies,6,3,4,0,100,0,0,0,0,,0,0,0,100,0,50,50,Yes,Yes,"Telugu, Hindi, English",Yes,No,Close supervision of the site,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30022672,60531600,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Yashoda Hospitals - Somajiguda,Raj Bhavan rd,Hyderabad,India,Telangana,500082,Kiran Kumar,Peddi,917730066888,kiranpeddi0@gmail.com,skulk105@its.jnj.com,135889,CG_1Y2y6hcgZNue53P,15 Jun 2026,16:47 +2026-05-29 03:44:57,2026-06-15 06:22:57,IP Address,167.103.63.28,100,1478279,True,2026-06-15 06:22:57,R_4u8lme2ocMIoLMR,Ng,Keat Keng,keatkeng@yahoo.com,,1.2872,103.8507,gl,EN,Yes,Keat Keng,Ng,Hospital Tuanku Jaafar Seremban,Gastroenterology,keatkeng@yahoo.com,+60 12 699 5251,Jalan Rasah,Seremban,Negeri Sembilan,70300,Malaysia,No,,,,,,,,,,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"No, I am not interested","Operational concerns,Lack of resources at site",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30101432,60900271,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Tuanku Jaafar Seremban,Jalan Rasah,Seremban,Malaysia,Negeri Sembilan,70300,Keat Keng,Ng,+60 12 699 5251,keatkeng@yahoo.com,wchan26@its.jnj.com,136171,CG_3NQFmh7L45YYMQb,15 Jun 2026,17:52 +2026-05-29 03:44:47,2026-06-15 06:30:59,IP Address,167.103.63.28,100,1478771,True,2026-06-15 06:30:59,R_90w9PUeQuPNQCrD,Adnan,Syuhada Dan,drsyuhadadan@gmail.com,,1.2872,103.8507,gl,EN,Yes,Syuhada Dan,Adnan,Hospital Sultanah Nur Zahirah,Gastroenterology,drsyuhadadan@gmail.com,60096212121,Jalan Sultan Mahmud,Kuala Terengganu,Terengganu,20400,Malaysia,No,,,,,,,,,,,,,,,,,,,,,Principal Investigator,,,,,,,,,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78445,78445,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Sultanah Nur Zahirah,Jalan Sultan Mahmud,Kuala Terengganu,Malaysia,Terengganu,20400,Syuhada Dan,Adnan,60096212121,drsyuhadadan@gmail.com,wchan26@its.jnj.com,136175,CG_2w4gg9kJimRN3a6,15 Jun 2026,18:00 +2026-06-02 03:22:26,2026-06-15 06:59:35,IP Address,31.168.96.254,100,1136229,True,2026-06-15 06:59:35,R_2dFs9D8mnsSgSX2,Israeli,Eran,Erani@wmc.gov.il,,31.5,34.75,gl,EN,Yes,Eran,Israeli,Edith Wolfson Medical Center,Gastroenterology,Erani@wmc.gov.il,97235028500,Ha-Lokhamim Street 62,H̱olon,Tel Aviv,5822012,Israel,Yes,Orit,Shevah,Wolfson Medical Center,oritsh@wmc.gov.il,+972502562560,"62 Halohamim Str. ",Holon,,5822012,Orit,Shevah,SC,oritsh@wmc.gov.il,+972502562560,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,16-30%,,,No,No,,2 studies,4,2,2,100,0,0,0,0,0,,0,100,0,90,10,50,50,Yes,Yes,"Hebrew Russian Arabic, English",Yes,No,-,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30108073,60529009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Edith Wolfson Medical Center,Ha-Lokhamim Street 62,H̱olon,Israel,Tel Aviv,5822012,Eran,Israeli,97235028500,Erani@wmc.gov.il,bmayer1@its.jnj.com,135872,CG_BPK0OmBK3CVNSzT,15 Jun 2026,18:29 +2026-06-01 11:02:22,2026-06-15 07:17:46,IP Address,188.157.243.170,100,1196123,True,2026-06-15 07:17:47,R_8wzga5ZFS4tOQsd,Horvat,Gyula,horvatgyula@gmail.com,,47.5,19.0412,gl,EN,No,Gyula,Horvat,Clinexpert - Obuda Egeszsegcentruma,Gastroenterology,horvatgyula@gmail.com,36209650290,7 kaszasdulo utca,Budapest,Budapest,1033,Hungary,Yes,Nóra,Nagybákay,Clinexpert Kft.,nora.nagybakay@clinexpert.hu,+36707196599,Kaszásdűlő utca 5.,Budapest,Hungary,1033,Nóra,Nagybákay,research coordinator,nora.nagybakay@clinexpert.hu,+36707196599,Different from the above,Dávid,Gulyás,Chief Legal and Strategy Officer,"david.gulyas@clinexpert.hu ",+36 30 844 6275,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,1,1,1,,≤15%,≤15%,≤15%,No,No,,1 study,2,1,1,100,0,0,0,0,0,,0,100,0,99,1,50,50,Yes,No,,No,No,,No,,,,,,,,,,,,,,,,120,60,50,10,10,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,7,13,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,3,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30110140,60196369,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Clinexpert - Obuda Egeszsegcentruma,7 kaszasdulo utca,Budapest,Hungary,Budapest,1033,Gyula,Horvat,36209650290,horvatgyula@gmail.com,anochta@its.jnj.com,136257,CG_3GiIsqBex69wGLW,15 Jun 2026,18:47 +2026-06-11 08:41:43,2026-06-15 07:32:39,IP Address,84.110.114.29,100,341455,True,2026-06-15 07:32:39,R_844bWwlDA8QhCjD,Ilani,Nadav,nadavil@clalit.org.il,,32.0123,34.7705,gl,EN,Yes,Nadav,Ilani,Lev Talpiot,Gastroenterology,nadavil@clalit.org.il,00-972-2-6778899,75 Beit Lehem Road,Jerusalem,Jerusalem District,5457010,Israel,Yes,Sabin,Asayag,Gastroenterology Lev Talpiot,sabineas@clalit.org.il,0508762228,"75 , Bet Lehem road",Jerusalem,Israel,9392410,Sabin,Asayag,Study coordinator,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,31-45%,>60%,,,Yes,No,,2 studies,4,2,2,100,0,0,0,0,0,,0,0,0,80,20,50,50,Yes,Yes,arabic,No,No,,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,138538,138538,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lev Talpiot,75 Beit Lehem Road,Jerusalem,Israel,Jerusalem District,5457010,Nadav,Ilani,00-972-2-6778899,nadavil@clalit.org.il,bmayer1@its.jnj.com,138538,CG_3eq9WMAPUIkpaKS,15 Jun 2026,19:02 +2026-06-10 00:09:32,2026-06-15 09:33:06,IP Address,200.68.168.19,100,465814,True,2026-06-15 09:33:07,R_5Ob6SFKwOm1cIyR,Lopez Mata,Graciela,lopezmata.graciela@gmail.com,,20.6288,-100.4828,gl,EN,No,Graciela,Lopez Mata,Centro de Investigacion Clinica Medica Morales Vargas S.C. (Morales Vargas Centro de Investigacion) (CIMOVA),"Gastroenterology ",lopezmata.graciela@gmail.com,524776367381,Boulevard Adolfo López Mateos 218,León,Guanajuato,37320,Mexico,Yes,Jorge,Morales Vargas,"cimova ",jorge.morales@cimova.com.mx,4777227555,Blvd adolfo lopez mateos 218 D Pte,Leon,Guanajuato,37000,"Jorge ",Morales Vargas,Research center director,jorge.morales@cimova.com.mx,4777227555,Same as above,,,,,,Principal Investigator,,,,,,,,,,Yes,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,1,1,1,≤15%,≤15%,31-45%,16-30%,Yes,No,,0 studies,3,2,1,100,0,0,0,0,0,,100,0,0,80,20,50,50,Yes,Yes,Spanish,Yes,No,"Training for great protocol understanding ",No,,,,,,,,,,,,,,,,25,18,10,3,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,4,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,4,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30152419,60025622,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centro de Investigacion Clinica Medica Morales Vargas S.C. (Morales Vargas Centro de Investigacion) (CIMOVA),Boulevard Adolfo López Mateos 218,León,Mexico,Guanajuato,37320,Graciela,Lopez Mata,524776367381,lopezmata.graciela@gmail.com,vcastan4@its.jnj.com,136605,CG_2rx8pQcQQcie2eb,15 Jun 2026,21:03 +2026-06-12 02:23:03,2026-06-15 12:03:55,IP Address,176.234.110.80,100,294051,True,2026-06-15 12:03:56,R_8QdM3z2XMcG2pDH,Hamzaoglu,Hulya,hulyaoverhamzaoglu@yahoo.com,,41.0108,28.9482,gl,EN,No,Hulya,Hamzaoglu,Acibadem Fulya Hospital,Gastroenterolog,hulyaoverhamzaoglu@yahoo.com,902123437474,Dikilitas Mahallesi Hakki Yeten Cad. No23,Istanbul,None,34349,Turkey,Yes,saadet,ilhan,Fulya Acıbadem Hospital,saadetilhan@hotmail.com,+905389659251,Fulya Acibadem Hospital,İstanbul,Turkey,34394,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,1,,,,31-45%,,,,Yes,No,,0 studies,3,2,2,100,0,0,0,0,0,,0,100,0,0,100,50,50,Yes,Yes,türkçe,No,Yes,,,,,,,,,,,,,,,,,,20,20,50,10,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,10,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,4,4,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30109204,60149448,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Acibadem Fulya Hospital,Dikilitas Mahallesi Hakki Yeten Cad. No23,Istanbul,Turkey,None,34349,Hulya,Hamzaoglu,902123437474,hulyaoverhamzaoglu@yahoo.com,bsaribek@its.jnj.com,135829,CG_21uOkQkWpjN0MjH,15 Jun 2026,23:33 +2026-06-10 08:13:22,2026-06-15 13:40:12,IP Address,128.91.127.10,100,451609,True,2026-06-15 13:40:12,R_7q3g4Xa5RaYJ5BM,Bewtra,Meenakshi,mbewtra@pennmedicine.upenn.edu,,39.9597,-75.1995,gl,EN,Yes,Meenakshi,Bewtra,University of Pennsylvania,IBD/GI,mbewtra@pennmedicine.upenn.edu,12672409347,3400 Spruce St,Philadelphia,Pennsylvania,19104,United States,Yes,Theresa,Tellez,University of Pennsylvania,Theresa.Tellez@Pennmedicine.upenn.edu,,,,,,Theresa,Tellez,Research coordinator,Theresa.Tellez@Pennmedicine.upenn.edu,,Different from the above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,≤15%,≤15%,,,Yes,No,,More than 2 studies,2,1,1,77,4,12,0,0,7,Unknown/unspecified,5,95,0,24,76,46.5,53.5,No,No,,No,No,"reimbursement for parking, transportation, etc for patient. +sharing pathology results from trial specimens and/or coverage for pathology fees incurred by patient.",No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30073863,60901094,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,University of Pennsylvania,3400 Spruce St,Philadelphia,United States,Pennsylvania,19104,Meenakshi,Bewtra,12672409347,mbewtra@pennmedicine.upenn.edu,hsantosm@its.jnj.com,137072,CG_24oXIvtAkjetn4T,16 Jun 2026,01:10 +2026-06-11 13:42:16,2026-06-15 14:33:43,IP Address,73.219.216.125,100,348687,True,2026-06-15 14:33:44,R_5Wut3VtZTSUvmlr,Gaidos,Jill,jill.gaidos@yale.edu,,41.3079,-72.9268,gl,EN,No,Jill,Gaidos,Yale New Haven Hospital,Gastroenterology,jill.gaidos@yale.edu,12037854138,20 York St,New Haven,Connecticut,06510,United States,Yes,Elizabeth,Ruggiero,Yale University,elizabeth.ruggiero@yale.edu,,"40 Temple Street, Suite 1A",New Haven,CT,06510,,,,,,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,≤15%,≤15%,,,Yes,No,,1 study,3,3,0,85,7,8,0,0,0,,15,85,0,75,25,45,55,No,No,,No,No,None,No,,,,,,,,,,,,,,,,500,200,300,100,150,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,4,8,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,4,,6,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,,true,,,,,,,,,30064106,60568654,,,,,false,,,,,,,,,,,,,,,,,,,,,,,,,,,Yale New Haven Hospital,20 York St,New Haven,United States,Connecticut,06510,Jill,Gaidos,12037854138,Jill.gaidos@yale.edu,jnowak2@its.jnj.com,137108,CG_323kpcoFBrAWaPY,16 Jun 2026,02:03 +2026-06-11 13:53:47,2026-06-15 14:59:32,IP Address,50.190.159.93,100,349545,True,2026-06-15 14:59:33,R_3FInz2X96eVczeN,Guha,Sushovan,sguha@hrgastro.com,,30.1038,-95.5057,gl,EN,No,Sushovan,Guha,Houston Regional Gastroenterology Institute,GI,sguha@hrgastro.com,832-707-5011,9731 Wortham Boulevard Commons At Crossroads,Houston,Texas,77065,United States,Yes,Anna,Fehr,Research,Anna@1-oak.net,346-847-9375,"19701 Kingwood Blvd Building 5 ","Kingwood ",TX,77339,"Anna ",Fehr,CRC,Anna@1-oak.net,60346-847-9375,Different from the above,alexandria,Hull,CEO,Alexandria@1-oak.net,6023097850,Other,Alexandria,Hull,CEO,Alexandria@1-oak.net,6023097850,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, partially reimbursed/covered by insurance",,,1,1,,≤15%,16-30%,31-45%,,Yes,No,,0 studies,3,2,1,40,10,40,5,5,0,,45,55,5,80,15,53,47,Yes,Yes,"Spanish, english",Yes,No,None at this time,None at this time,,,,,,,,,,,,,,,,400,150,200,60,24,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,2,3-5,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Central,2,,8,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30175161,79432,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Houston Regional Gastroenterology Institute,9731 Wortham Boulevard Commons At Crossroads,Houston,United States,Texas,77065,Sushovan,Guha,832-707-5011,sguha@hrgastro.com,jnowak2@its.jnj.com,137049,CG_r6YUghT2taHbcRP,16 Jun 2026,02:29 +2026-06-10 09:21:19,2026-06-15 15:35:24,IP Address,172.85.72.5,100,454444,True,2026-06-15 15:35:25,R_7CxRQ6ugtDhJWi0,Tamerisa,Radha,radha.tamerisa@drtgastro.com,,37.751,-97.822,gl,EN,No,Radha,Tamerisa,Katy Integrative Gastroenterology,Gastroenterology,radha.tamerisa@drtgastro.com,+1 281 869 3009,Kingsland Boulevard 25230,Katy,Texas,77494,United States,Yes,"Sara ",Kelley,"Vitality Research ",sara@vdiresearch.com,7132899401,25230 Kingsland Blvd Suite 102,Katy,Texas,77494,Sara,Kelly,Director of Operations,sara@vdiresearch.com,7132899401,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,,,,>60%,,,,Yes,No,,1 study,50,25,25,55,20,15,5,5,0,,30,70,0,70,30,40,60,Yes,Yes,spanish,Yes,No,protocol review and training,,,,,,,,,,,,,,,,,500,75,425,300,125,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,6,2,3-5,Yes,No,Yes,No,Yes,Yes,Yes,Yes,Central and Local,3,3,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30069503,60162677,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Katy Integrative Gastroenterology,Kingsland Boulevard 25230,Katy,United States,Texas,77494,Radha,Tamerisa,+1 281 869 3009,radha.tamerisa@drtgastro.com,hsantosm@its.jnj.com,137063,CG_PZ3yMY6S1BpIClj,16 Jun 2026,03:05 +2026-06-09 08:25:58,2026-06-15 16:13:13,IP Address,94.61.236.198,100,546435,True,2026-06-15 16:13:14,R_85Lgjg3qR94o2sx,Arroja,Bruno,brunoarroja@gmail.com,,41.4456,-8.2929,gl,EN,Yes,Bruno,Arroja,Hospital de Braga,"Gastroenterology ",brunoarroja@gmail.com,351253027249,Rua das Sete Fontes,Braga,Braga,4710-348,Portugal,Yes,Bruno,Arroja,Gastroenterology,brunoarroja@gmail.com,919917216,Lugar das Sete Fontes,Braga,Braga,4710-243,Diana,Sousa,Site Coordinator,diana.sousa@ccabraga.org,+351937374563,Different from the above,Sara,Anjos,Local Coordinator,sara.anjos@ccabraga.org,+351964371677,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,,,≤15%,16-30%,31-45%,≤15%,Yes,No,,1 study,3,2,1,95,0,5,0,0,0,,0,0,0,75,25,50,50,Yes,Yes,Portuguese,Yes,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30133257,60313565,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital de Braga,Rua das Sete Fontes,Braga,Portugal,Braga,4710-348,Bruno,Arroja,351253027249,brunoarroja@gmail.com,shenriq1@its.jnj.com,137458,CG_28IGEVJ9Q6lXhUM,16 Jun 2026,03:43 +2026-06-11 14:42:17,2026-06-15 16:17:01,IP Address,165.1.156.235,100,351284,True,2026-06-15 16:17:01,R_3HePd7nWeENMYDv,Kwapisz,Lukasz,lkwapisz@gastrohealth.com,,33.7485,-84.3871,gl,EN,No,Lukasz,Kwapisz,"Gastro Health Holdco, LLC",Gastroenterology,lkwapisz@gastrohealth.com,949-316-5507,"9408 SW 87th Ave, Suite 200",Miami,Florida,33176,United States,Yes,Vivian,Rosales,Gastro Health Research,vrosales@gastrohealth.com,305-772-2857,"9408 SW 87th Ave, Suite 200",Miami,FL,33176,"Vivian ",Rosales,CRC,Vivian Rosales,305-772-2857,Different from the above,Gisela,Spear,Clinical Research Manager,giselaspear@gastrohealth.com,9097477503,Other,Gisela,Spear,Clinical Research Manager,giselaspear@gastrohealth.com,9097477503,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,46-60%,31-45%,≤15%,,Yes,No,,2 studies,2,1,1,60,3,25,1,0,11,Multiracial,55,45,0,85,15,50,50,Yes,Yes,Spanish,No,No,"Our site has the personnel, patient population, and research infrastructure necessary to successfully conduct this study. Support from J&J with study start-up, recruitment materials, enrollment strategies, protocol training, and participant retention resources would be appreciated to help optimize enrollment and study conduct.",No,,,,,,,,,,,,,,,,250,80,130,35,15,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,2,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,2,,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30011448,79275,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Miami Cancer Institute at Baptist Health / Baptist Health Medical Group,n Kendall dr 8900,Miami,United States,Florida,33176,Lukasz,Kwapisz,949-316-5507,lkwapisz@gastrohealth.com,hsantosm@its.jnj.com,137076,CG_XGIPJBjLPOg9lLz,16 Jun 2026,03:47 +2026-06-08 14:17:44,2026-06-15 16:25:27,IP Address,73.176.135.172,100,612463,True,2026-06-15 16:25:28,R_5pbsvXNzV5fS6gV,Rosenberg,Jonathan A,jrosenberg@illinoisgastro.com,,42.3546,-89.0435,gl,EN,No,Jonathan A,Rosenberg,Illinois Gastroenterology Group Glenview,Gastroenterology,jrosenberg@illinoisgastro.com,18472442960,20 Tower ct,Gurnee,Illinois,60031,United States,Yes,Emma,Lamblin,GI Alliance - Gurnee Research Department,Emma.Lamblin@iterativehealth.com,2244412217 Ext. 03,20 Tower Court Suite F,Gurnee,Illinois,60031,"Lionel ",Gassmann,Site Manager,lionel.gassmann@iterativehealth.com,2244412217 Ext 03,Different from the above,Peter,Chu,Technical Services Engineer,peter.chu@iterative.health,,Other,Lionel,Gassmann,Site Manager,Lionel.Gassmann@iterativehealth.com,2244412217 Ext 03,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,Depending on type of insurance determines fully or partially covered,1,,,,>60%,,,,Yes,No,,2 studies,3,2,1,82,10,7,1,0,0,,56,44,0,80,20,50,50,No,Yes,Spanish,No,No,"Marketing, Diversity and Cultural Outreach",None,Nina Merel,,,,,GI Alliance - Glenview Research Department,,,,,nmerel@illinoisgastro.com,,,,,220,30,190,155,35,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,6,6,≥6,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Central,2,,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30075209,60387810,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Illinois Gastroenterology Group Glenview,20 Tower ct,Gurnee,United States,Illinois,60031,Jonathan A,Rosenberg,18472442960,jrosenberg@illinoisgastro.com,jnowak2@its.jnj.com,137124,CG_1eKwDlfBHNueasU,16 Jun 2026,03:55 +2026-05-29 03:42:31,2026-06-15 18:58:55,IP Address,167.103.63.28,100,1523784,True,2026-06-15 18:58:56,R_9Fgpg44xPQxcrIQ,Hj. Md. Said,Rosaida,drrosaida@moh.gov.my,,1.2872,103.8507,gl,EN,Yes,Rosaida,Hj. Md. Said,Hospital Serdang,Gastroenterology,drrosaida@moh.gov.my,60196662174,Jalan Puchong - Kajang,Kajang,Selangor,43000,Malaysia,No,,,,,,,,,,,,,,,,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","No, not reimbursed/covered by insurance",,1,1,,,≤15%,16-30%,,,No,No,,0 studies,3,1,2,0,100,0,0,0,0,,0,100,0,70,30,40,60,Yes,Yes,"Malay, English, Tamil, Chinese",No,No,NA,NA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30101262,60318614,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital Serdang,Jalan Puchong - Kajang,Kajang,Malaysia,Selangor,43000,Rosaida,Hj. Md. Said,60196662174,drrosaida@moh.gov.my,wchan26@its.jnj.com,136163,CG_2ccOWXJoNT8NVuD,16 Jun 2026,06:28 +2026-05-29 03:45:06,2026-06-15 20:35:26,IP Address,202.170.48.12,100,1529420,True,2026-06-15 20:35:27,R_4M0toO7uUmNUhjN,Mohamad Mustaffa,Nazri,nazri.mustaffa@usm.my,,6.059,102.2306,gl,EN,Yes,Nazri,Mustaffa,"Hospital Pakar Universiti Sains Malaysia, Department of Internal Medicine",Gastroenterology,nazri.mustaffa@usm.my,60199228118,"2nd Floor, Hospital Administration Block, Jalan Raja Perempuan Zainab II",Kota Bharu,Kelantan,16150,Malaysia,Yes,Nur Diyana,Mohamed Hashim,"Hospital Pakar Universiti Sains Malaysia, Clinical Trials Unit",nurdiyana@usm.my,60139441057,"Clinical Trials Unit, 2nd Floor, School of Medical Sciences, USM Health Campus",Kubang Kerian,Kelantan,16150,Nur Diyana,Mohamed Hashim,Study Coordinator,nurdiyana@usm.my,60139441057,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,≤15%,>60%,≤15%,,Yes,Yes,Difficulty in identifying an adequate number of subjects with moderate-severe UC who have failed conventional treatments,0 studies,3,0,3,0,100,0,0,0,0,,0,100,10,80,10,60,40,Yes,Yes,"Bahasa Melayu +English language",No,No,Increase visibility of study availability to local and regional health care practitioners and encourage referrals of potential subjects,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30099753,60648666,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital University Sains Malaysia,Jalan Raja Perempuan Zainab II,Kota Bharu,Malaysia,Kelantan,16150,Nazri,Mohamad Mustaffa,60199228118,nazri.mustaffa@usm.my,wchan26@its.jnj.com,136166,CG_3KvFiHhBbhOdWNG,16 Jun 2026,08:05 +2026-06-10 00:05:54,2026-06-15 21:12:11,IP Address,200.92.183.220,100,507976,True,2026-06-15 21:12:11,R_6objbrs6KqvKBC9,Ramirez Ibarra,Karina Guadalupe,dra.ramirez.sic@gmail.com,,28.998,-106.229,gl,EN,No,Karina Guadalupe,Ramirez Ibarra,SCIENTIA Investigacion Clinica SC,gastroenterology,dra.ramirez.sic@gmail.com,+52 61 427 53253,Sierra de la campana 3701 col. zona comercial plaza del sol,Chihuahua,Chihuahua,31207,Mexico,Yes,Samantha,Gamboa,Scientia Investigación Clínica S.C.,sc.gamboa.sic@gmail.com,6141314403,Sierra de la campana 3701 col. plaza del sol,Chihuahua,Chihuahua,31207,Samantha,Gamboa,Study coordinator,sc.gamboa.sic@gmail.com,6141314403,Different from the above,"Gabriela ",Magallanes,"legal representative ",sc.talamas.sic@gmail.com,614 196 6806,Research Coordinator,,,,,,,,,,Yes,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,1,,,,≤15%,,,Yes,No,,0 studies,5,1,4,0,0,0,100,0,0,,100,0,0,100,0,60,40,Yes,No,,No,No,support for participants' travel expenses,n.a.,,,,,,,,,,,,,,,,12,10,2,2,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,3,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,1,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30115640,60543797,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SCIENTIA Investigacion Clinica SC,Trasviña y Retes 3106,Chihuahua,Mexico,Chihuahua,31203,Karina Guadalupe,Ramirez Ibarra,+52 61 427 53253,dra.ramirez.sic@gmail.com,vcastan4@its.jnj.com,136589,CG_2Bghk8RrIQ6Dbd4,16 Jun 2026,08:42 +2026-06-11 08:30:54,2026-06-15 22:07:44,IP Address,103.211.37.191,100,394609,True,2026-06-15 22:07:45,R_4niVmJxF376tobo,Bagepally,Ravi,b_ravishankar@yahoo.com,,17.3843,78.4583,gl,EN,Yes,Ravi,Bagepally,Yashoda Hospitals - Secunderabad,"Gastroenterology ",b_ravishankar@yahoo.com,9030037483,Sardar Patel rd,Secunderabad,Telangana,500003,India,Yes,"Madhu Sudhan ","Ediga ","Yashoda Hospitals ",madhusudhanediga@gmail.com,9030037483,"Yashoda Hospitals Secunderabad ",Secunderabad,Telangana,500015,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,1,1,1,,>60%,46-60%,31-45%,,No,No,,1 study,4,2,2,0,100,0,0,0,0,,0,0,0,90,10,60,40,Yes,Yes,"Hindi, Telugu & English",No,No,"Need safety material brouchers for patient education and short notes of title, design, objective and inclusion exclusion criteria ",NO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30156931,60185234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Yashoda Hospitals - Secunderabad,Sardar Patel rd,Secunderabad,India,Telangana,500003,Ravi,Bagepally,91676996053,b_ravishankar@yahoo.com,skulk105@its.jnj.com,135896,CG_2aUBo9F6uFNwIV3,16 Jun 2026,09:37 +2026-05-28 21:23:39,2026-06-15 22:26:09,IP Address,61.19.201.8,100,1558950,True,2026-06-15 22:26:10,R_971ZmzTEGkJFnuA,Wetwittayakhlang,Panu,wet.panu@gmail.com,,13.7442,100.4608,gl,EN,No,Panu,Wetwittayakhlang,Prince of Songkla University (Songklanagarind Hospital),Gastroenterology,wet.panu@gmail.com,+66 955595695,15 Kanjanavanich Rd Kho Hong Floor 4 100 Years Bld Clinical Research Center,Songkhla,Songkhla,90110,Thailand,Yes,"Supattra ",Uppanisakorn,"Clinical Research Center (PSU CRC) ",poohsupattra@gmail.com,"+66 856781034 ","4th Floor, 100 years Building, Songklanagarind Hospital, 15 Karnjanavanich Road, Kho Hong, ","Hat Yai,"," Songkhla",90110,"Supattra ",Uppanisakorn,"Head of Clinical Research Center ",poohsupattra@gmail.com,"+66 856781034 ",Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,46-60%,31-45%,,,No,No,,1 study,8,4,4,0,100,0,0,0,0,,0,0,0,80,20,50,50,Yes,Yes,Thai,No,No,,,,,,,,,,,,,,,,,,40,15,25,15,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,1,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,8,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,"1,2",,true,,,,,,false,,,,,,,,,,,,,30102249,60804070,,,,,,100,0,0,0,0,0,0,0,,,,,,,,,,,,,,,,,,,Prince of Songkla University (Songklanagarind Hospital),15 Kanjanavanich Rd Kho Hong Floor 4 100 Years Bld Clinical Research Center,Songkhla,Thailand,Songkhla,90110,Panu,Wetwittayakhlang,+66 86 772 5277,wet.panu@gmail.com,ychanjar@its.jnj.com,136156,CG_3FXMJhTg65LBu1E,16 Jun 2026,09:56 +2026-06-15 09:19:40,2026-06-16 00:02:35,IP Address,193.219.162.247,100,52975,True,2026-06-16 00:02:36,R_2UYDXSJjuVLb73n,Jonaitis,Laimas,laimasjonaitis@yahoo.com,,54.9048,23.8958,gl,EN,No,Laimas,Jonaitis,Hospital of Lithuanian University of Health Sciences Kaunas Clinics,Gastroenterologist,laimasjonaitis@yahoo.com,37037326264,Eiveniu St 2,Kaunas,Kaunas City Municipality,50161,Lithuania,No,,,,,,,,,,Laimas,Jonaitis,PI,laimas.jonaitis@lsmu.lt,+37068517472,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,16-30%,31-45%,31-45%,,No,Yes,"AS we have good access to Advanced therapies in Lithuania, majority of our patients are AT- experienced. Therefore, we have to start study as early as possible - to have posibility to enroll AT-experienced patients. There could be not so quick enrolment of AT-naive. It is still not clear, if the Mesalasine failure only is suffitient inclusion criterium?",1 study,5,3,2,100,0,0,0,0,0,,0,100,0,80,20,50,50,Yes,No,,Yes,No,,,Darius Kriukas,Ieva Stundiene,Ilma Vilcinskaite,,,Panevezys Hospital,Vilnius Santaros University Hospital,Klaipeda University Hospital,,,drkriukas@gmail.com,ieva.stundiene@santa.lt,vilcinskaite@yahoo.com,,,400,200,200,120,60,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,6,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,8,,6,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30127775,60648561,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital of Lithuanian University of Health Sciences Kaunas Clinics,Eiveniu St 2,Kaunas,Lithuania,Kaunas City Municipality,50103,Laimas,Jonaitis,37037326264,laimasjonaitis@yahoo.com,iuscina@its.jnj.com,139201,CG_9SSYVfrO8kUqpZT,16 Jun 2026,11:32 +2026-06-11 20:30:16,2026-06-16 00:43:46,IP Address,117.136.90.56,100,360809,True,2026-06-16 00:43:46,R_9oJp8NAf7F8gGjL,Tian,Linglin,tianlinlin587@163.cm,,37.8648,112.5636,gl,EN,No,Linglin,Tian,First Hospital of Shanxi Medical University,gastroenterology,tianlinlin587@163.cm,13935192515,Jie Fang Nan Lu,Taiyuan,Shanxi,030001,China,No,,,,,,,,,,Tian,Linglin,Pi,tianlinlin587@163.com,13935192515,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,1,1,1,,31-45%,16-30%,≤15%,,No,No,,More than 2 studies,100,50,50,0,100,0,0,0,0,,0,0,0,80,20,45,55,No,No,,Yes,Yes,,,,,,,,,,,,,,,,,,200,20,150,35,20,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,3,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,4,4,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30042503,60921747,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,First Hospital of Shanxi Medical University,Jie Fang Nan Lu,Taiyuan,China,Shanxi,030001,Linglin,Tian,8603514044111,tianlinlin587@163.cm,hzhang04@its.jnj.com,138402,CG_1KkiNur7tYkXYcU,16 Jun 2026,12:13 +2026-06-01 11:25:15,2026-06-16 01:43:35,IP Address,91.82.202.3,100,1261099,True,2026-06-16 01:43:35,R_29XGDzNNQJPqfJL,Szita,Istvan,szitaistvan1@gmail.com,,47.4919,19.05,gl,EN,No,Istvan,Szita,Szofia Maganklinika,Gastroenterologist,szitaistvan1@gmail.com,+36306262070,2 Szófia utca,Veszprém,Veszprem,8200,Hungary,Yes,Barbara,Kustan,Veszlife Magánklinika,barbara.kustan.szofiaklinika@freemail.hu,+36204854055,,,,,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,≤15%,16-30%,31-45%,≤15%,No,Yes,"A participant who has had extensive UC for ≥ 8 years, colonoscopy with dysplasia assessment per local pathology ",0 studies,5,2,3,100,0,0,0,0,0,,0,100,0,100,0,60,40,Yes,Yes,Hungarian,No,No,"Food and travelling reimbursement, referral fee for referral physician",-,,,,,,,,,,,,,,,,300,150,100,15,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,3,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Central and Local,8,0,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78277,78277,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Szofia Maganklinika,2 Szófia utca,Veszprém,Hungary,Veszprem,8200,Istvan,Szita,+36306262070,szitaistvan1@gmail.com,anochta@its.jnj.com,136248,CG_3oR6AC3xrmXOA6s,16 Jun 2026,13:13 +2026-06-12 05:50:26,2026-06-16 02:23:49,IP Address,176.54.125.180,100,333203,True,2026-06-16 02:23:50,R_8ZsgJt4JMt6pcNb,Basaranoglu,Metin,metin_basaranoglu@yahoo.com,,41.0529,29.0013,gl,EN,Yes,Metin,Basaranoglu,Bezmialem University Medical Faculty,"Gastroenterology ",metin_basaranoglu@yahoo.com,+90 5323448718,Adnan Menderes Bulvarı Vatan Caddesi,Istanbul,Istanbul,34093,Turkey,Yes,"Serra ",Saglam,"Bezmialem hastanesi ",serra.saglam@medismart.com.tr,00905537751997,"Bezmialem hastanesi ",Istanbul,Istanbul,35010,Serra,Saglam,SC,serra.saglam@medismart.com.tr,00905537751997,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,,,,,,,,,Yes,No,,2 studies,10,7,3,100,0,0,0,0,0,,0,0,0,70,30,50,50,Yes,Yes,Turkish,Yes,Yes,"Road expence and food expence for the patients. +ECCO congress support for PI. ",No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30110582,60179584,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bezmialem University Medical Faculty,Adnan Menderes Bulvarı Vatan Caddesi,Istanbul,Turkey,Istanbul,34093,Metin,Basaranoglu,+90 212 453 1800,metin_basaranoglu@yahoo.com,bsaribek@its.jnj.com,135835,CG_2E79w4u1SjageYD,16 Jun 2026,13:53 +2026-06-01 09:03:27,2026-06-16 02:37:13,IP Address,46.254.135.33,100,1272826,True,2026-06-16 02:37:14,R_2b2ht2MogbpNdPL,Sariyan,Simon,simonsariyan@gmail.com,,42.6826,23.3223,gl,EN,No,Simon,Sariyan,MHAT Sv. Karidad EAD,Gastroenterology,simonsariyan@gmail.com,359876439711,"bulevard ""Nikola Vaptsarov"" 23A",Plovdiv,Plovdiv Province,4004,Bulgaria,Yes,Slavina,Toncheva,SMO R&D Services,s.toncheva@rdservices.org,+359892226009,"17, 6th Septemvri str.",Sofia,n/a,1000,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"No, I am not interested",Competing trials,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30152443,60843583,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MHAT Sv. Karidad EAD,"bulevard ""Nikola Vaptsarov"" 23A",Plovdiv,Bulgaria,Plovdiv Province,4004,Simon,Sariyan,359876439711,simonsariyan@gmail.com,imitkova@its.jnj.com,136264,CG_30f8Nb56OG9FikV,16 Jun 2026,14:07 +2026-06-11 03:00:34,2026-06-16 02:39:49,IP Address,103.114.194.72,100,430754,True,2026-06-16 02:39:49,R_8e9HDWp18MfjwOq,Feng,Baisui,ibdgroup@163.com,,22.2578,114.1657,gl,EN,No,Baisui,Feng,The Second Affiliated Hospital of Zhengzhou University,Gastroenterology,ibdgroup@163.com,8613703715648,Jing Ba Lu,Zhengzhou,Henan,450014,China,No,,,,,,,,,,Baisui,Feng,Chief Physician,ibdgroup@163.com,8613643713068,Same as above,,,,,,Other,Li,Geng,Sub-I,gengli0421@163.com,13213058073,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, partially reimbursed/covered by insurance",,,,1,,,,16-30%,,No,No,,More than 2 studies,2,2,0,0,100,0,0,0,0,,0,100,10,70,20,50,50,No,No,,No,No,,,,,,,,,,,,,,,,,,600,30,570,150,40,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,8,3-5,Yes,No,Yes,Yes,Yes,Yes,Yes,Yes,Local,,6,8,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30148713,60732966,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Second Affiliated Hospital of Zhengzhou University,Jing Ba Lu,Zhengzhou,China,Henan,450014,Baisui,Feng,8613703715648,ibdgroup@163.com,hzhang04@its.jnj.com,137009,CG_2zvbwWDNMUI0fSM,16 Jun 2026,14:09 +2026-06-01 09:02:39,2026-06-16 03:14:34,IP Address,84.225.149.129,100,1275114,True,2026-06-16 03:14:35,R_2iR0gbB1VHYLhkJ,Golovics,Petra,golovics.petra@gmail.com,,47.5,19.0412,gl,EN,No,Petra Anna,Golovics,Semmelweis Egyetem (Semmelweis University) Institute of Pancreatic Diseases,IBD Ambulance,golovics.petra@gmail.com,36202920326,Tömő u. 25-29.,Budapest,Pest,1083,Hungary,Yes,Petra Anna,Golovics,Semmelweis University Institute of Pancreatic Diseases,golovics.petra@gmail.com,+36202920326,Tomo u 25-29,Budapest,Budapest,1083,Petra,Kovy,"Study coordinator ",dr.kisarine.dr.kovy.petra@semmelweis.hu,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,≤15%,≤15%,≤15%,>60%,Yes,No,,1 study,3,3,1,100,0,0,0,0,0,,0,100,0,90,10,50,50,Yes,No,,No,No,Technical and administrative,"According to the local regulation vdz only available in 4th line it will be pleasant to give it sooner +Too many colonoscopies",,,,,,,,,,,,,,,,250,30,250,50,3,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,0,≥6,Yes,No,No,Yes,Yes,Yes,No,Yes,Central,4,,2,Yes,,sipIQ,,,,,true,true,true,"1,2,3",true,false,,PI's room,true,"1,2,3",,,,,,,,,,1,,,,,,,false,,false,,,,,,,,,,,30110519,60402605,,,,,,,,,,,,,,Yes,Yes,,,,,,,,,,,,under the supervision of an investigator,,,,true,Semmelweis Egyetem (Semmelweis University),Balassa janos utca 6,Budapest,Hungary,Pest,1082,Zsolt,Tulassay,36209274900,golovics.petra@gmail.com,anochta@its.jnj.com,136258,CG_1gSK59HRmInBBls,16 Jun 2026,14:44 +2026-06-10 03:53:10,2026-06-16 04:33:04,IP Address,77.83.12.62,100,520794,True,2026-06-16 04:33:05,R_2FQBOFHh8lQIzzQ,Annese,Vito,vito.annese@grupposandonato.it,,45.4722,9.1922,gl,EN,No,Vito,Annese,IRCCS Policlinico San Donato,Gastroenterology,vito.annese@grupposandonato.it,02 52774195,Piazza Edmondo Malan 2,San Donato Milanese,Lombardy,20097,Italy,Yes,Antonella,Bianchi,Gastroenterology,antonella.bianchi2@grupposandonato.it,02 5277 4722,Piazza Malan,San Donato Milanese,Mi,20097,Orsola Raffaella,Sociale,Research Nurse,orsolaraffaella@grupposandonato.it,0252774951,Same as above,,,,,,Principal Investigator,,,,,,,,,Yes,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,46-60%,16-30%,,,No,No,,2 studies,3,2,1,95,5,0,0,0,0,,95,0,0,85,15,50,50,Yes,No,,No,No,Efficient and supportive CRO,,,,,,,,,,,,,,,,,300,150,100,50,15,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,7,3,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,6,,4,No,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30083875,60469560,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IRCCS Policlinico San Donato,Piazza Edmondo Malan 2,San Donato Milanese,Italy,Lombardy,20097,Vito,Annese,02 527741,vito.annese@grupposandonato.it,esilva52@its.jnj.com,137467,CG_333F1tSMbh6MGU0,16 Jun 2026,16:03 +2026-06-05 07:58:43,2026-06-16 06:06:34,IP Address,213.30.141.134,100,943670,True,2026-06-16 06:06:35,R_81ifBSETPTygocc,Mathieu,Nicolas,nmathieu@chu-grenoble.fr,,45.1769,5.7204,gl,EN,Yes,Nicolas,Mathieu,Institut Prive MICI Clinique des Cedres,Gastroenterology,nmathieu@chu-grenoble.fr,33476765597,21 rue Albert Londres 2eme etage Hopital de Jour,Échirolles,Auvergne-Rhône-Alpes,38130,France,Yes,Charif,SAID ABDALLAH,"MICI Institut prive, Clinique des Cèdres",contact.rechercheclinique@miciinstitutprive.com,0456581195,21 rue Albert Londres,Echirolles,Auvergne Rhone-Alpes,38130,Charif,SAID ABDALLAH,Research Coordinator,contact.rechercheclinique@miciinstitutprive.com,0456581195,Different from the above,Kevin,KAMALANAVIN,Delegation for Clinical Research and Innovation,administration@cliniquedescedres.com,04 56 58 10 05,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,1,,≤15%,31-45%,31-45%,,No,No,,1 study,3,2,1,100,0,0,0,0,0,,0,0,0,60,40,50,50,No,No,,Yes,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30049449,60355627,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Institut Prive MICI Clinique des Cedres,21 rue Albert Londres 2eme etage Hopital de Jour,Échirolles,France,Auvergne-Rhône-Alpes,38130,Nicolas,Mathieu,33476765597,nmathieu@chu-grenoble.fr,rbelhadj@its.jnj.com,136234,CG_R4R595QLQijGDV7,16 Jun 2026,17:36 +2026-06-15 23:05:04,2026-06-16 06:19:04,IP Address,106.192.193.4,100,26039,True,2026-06-16 06:19:05,R_9b8XUYPaps26m6l,Bansal,Naresh,drnbansal@ymail.com,,28.6327,77.2198,gl,EN,Yes,Naresh,Bansal,Sir Ganga Ram Hospital,gastroenterology,drnbansal@ymail.com,919999336476,Sir Ganga Ram Hospital Marg,New Delhi,Delhi,110060,India,Yes,Somya,Duhan,Sir Ganga Ram Hospital,somyaduhan@gmail.com,9971234716,"SGRH Marg, Rajinder Nagar",New Delhi,Delhi,110060,Somya,Duhan,CRC,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","No, not reimbursed/covered by insurance",,,1,,,,31-45%,,,Yes,No,,0 studies,15,8,7,0,100,0,0,0,0,,0,100,0,100,0,50,50,Yes,Yes,Hindi,No,No,NA,NA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30021552,60129483,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sir Ganga Ram Hospital,Sir Ganga Ram Hospital Marg,New Delhi,India,Delhi,110060,Naresh,Bansal,919999336476,drnbansal@ymail.com,skulk105@its.jnj.com,135883,CG_ALtpUnN2IJwSo25,16 Jun 2026,17:49 +2026-06-10 03:49:42,2026-06-16 06:47:26,IP Address,176.240.136.87,100,529064,True,2026-06-16 06:47:27,R_2CTkAbS31J6VyCt,Yuksel,Ilhami,ilhamiyuksel@yahoo.com,,39.9806,32.7975,gl,EN,Yes,Ilhami,Yuksel,Ankara Bilkent Sehir Hastanesi (Ankara Bilkent City Hospital),Gastroenterology,ilhamiyuksel@yahoo.com,9003122912525,Universiteler Mahallesi 1604. Cadde No: 9,Ankara,Ankara,06800,Turkey,Yes,Ilhami,Yuksel,Ankara Bilkent City Hospital,ilhamiyuksel@yahoo.com,5053835676,Ankara Bilkent City Hospital,Ankara,Türkie,06100,Ilhami,Yuksel,Prof Dr,ilhamiyuksel@yahoo.com,5053835676,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,16-30%,16-30%,,,No,No,,0 studies,5,4,3,100,0,0,0,0,0,,0,100,0,80,20,60,40,Yes,No,,Yes,No,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30111282,60691130,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ankara Bilkent Sehir Hastanesi (Ankara Bilkent City Hospital),Universiteler Mahallesi 1604. Cadde No: 9,Ankara,Turkey,Ankara,06800,Ilhami,Yuksel,9003122912525,ilhamiyuksel@yahoo.com,bsaribek@its.jnj.com,135831,CG_29uAZ2LdVAiWKoA,16 Jun 2026,18:17 +2026-06-10 03:00:05,2026-06-16 07:15:55,IP Address,46.141.65.18,100,533750,True,2026-06-16 07:15:55,R_8Il36p9OxKLhPIR,Variola,Angela,angela.variola@sacrocuore.it,,45.5342,10.9398,gl,EN,Yes,Angela,Variola,Ospedale Sacro Cuore Don G. Calabria,Gastroenterology,angela.variola@sacrocuore.it,393389864162,Via Don Angelo Sempreboni 5,Negrar,Veneto,37024,Italy,Yes,Marianna,Passiu,IRCCS Sacro Cuore Don Calabria,marianna.passiu@sacrocuore.it,+390456014853,Via Sempreboni 5,Negrar di Valpolicella,Verona,37024,Marianna,Passiu,SC,marianna.passiu@sacrocuore.it,+390456014853,Different from the above,Elvia,Malo,Pharmacist,elvia.malo@sacrocuore.it,+390456014854,Other,Alessia,Todeschini,"MD, SI",alessia_todeschini@sacrocuore.it,+390456014857,,,,Yes,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,46-60%,31-45%,,,No,No,,1 study,3,2,1,95,5,0,0,0,0,,0,100,0,80,20,50,50,No,No,,No,No,NONE,NO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,,,,,,,,,,30084603,60324950,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ospedale Sacro Cuore Don G. Calabria,Via Don Angelo Sempreboni 5,Negrar,Italy,Veneto,37024,Angela,Variola,393389864162,angela.variola@sacrocuore.it,esilva52@its.jnj.com,137461,CG_3jdi6mVb1IrGeQ5,16 Jun 2026,18:45 +2026-06-10 02:52:18,2026-06-16 07:29:49,IP Address,85.43.58.49,100,535050,True,2026-06-16 07:29:49,R_28FFHTgmusq7KnT,Gasbarrini,Antonio,antonio.gasbarrini@unicatt.it,,41.8905,12.5127,gl,EN,Yes,Antonio,Gasbarrini,"Universita Cattolica del Sacro Cuore-Policlinico Universitario ""Agostino Gemelli""",internal medicine and gastroenterology,antonio.gasbarrini@unicatt.it,390630156018,Largo Agostino Gemelli 8,Rome,Lazio,00168,Italy,Yes,caterina,fanali,fondazione policlinico gemelli,caterina.fanali@policlinicogemelli.it,3494703368,"largo A gemelli ",Roma,roma,00168,,,,,,Same as above,,,,,,Research Coordinator,,,,,,,,,Yes,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,≤15%,16-30%,≤15%,≤15%,Yes,No,,More than 2 studies,3,1,2,96,1,1,1,1,0,,1,99,0,95,5,50,50,Yes,No,,No,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,true,,,,,,,,,,,,,,,,,,,,,,,,,false,,true,,,,,,,,,,,30084515,60461555,,,,,,,,,,,,,,overnight facilities at the Hematology and Hematopoietic Stem Cell Transplant Department,,,,,,,,,,,,,,,,,true,"Universita Cattolica del Sacro Cuore-Policlinico Universitario ""Agostino Gemelli""",Largo Agostino Gemelli 8,Rome,Italy,Lazio,00168,Antonio,Gasbarrini,390630156018,antonio.gasbarrini@unicatt.it,esilva52@its.jnj.com,137474,CG_UayEOAm1IKK3Tpv,16 Jun 2026,18:59 +2026-06-08 10:04:23,2026-06-16 09:15:39,IP Address,80.82.235.27,100,688276,True,2026-06-16 09:15:40,R_2CJUwMoIgr4O69y,De Maissin,Astrid,astrid.demaissin@ght85.fr,,47.1872,-1.5694,gl,EN,No,Astrid,De Maissin,Centre Hospitalier Departemental Vendee (CHD Vendee),Gastroenterology,astrid.demaissin@ght85.fr,33251446161,Boulevard Stéphane Moreau,La Roche-sur-Yon,Pays-de-la-Loire,85000,France,Yes,MAUD,ROSSO,Recherche Clinique,maud.rosso@ght85.fr,0251446467,CHD VENDEE Bd Moreau,La Roche-sur-Yon,vendee,85000,MAUD,ROSSO,CRA,maud.rosso@ght85.fr,0251446467,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,>60%,≤15%,≤15%,≤15%,Yes,Yes,"5-ASA is not included in the list of conventional thérapies = a patient who has received only 5-ASA and has failed treatment would therefore not be eligible. in our standard , we can administer vedolizumab to a patient who has failed only to 5-ASA This will reduce our potential for inclusion",1 study,2,1,1,99,0,1,0,0,0,,0,100,0,83,17,45,55,No,No,,No,No,,no,,,,,,,,,,,,,,,,200,100,100,40,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,5,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,4,,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30050676,60620866,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centre Hospitalier Departemental Vendee (CHD Vendee),Boulevard Stéphane Moreau,La Roche-sur-Yon,France,Pays-de-la-Loire,85000,Astrid,De Maissin,33251446161,astrid.demaissin@ght85.fr,rbelhadj@its.jnj.com,136230,CG_usJzbO00gP569fb,16 Jun 2026,20:45 +2026-06-01 14:53:13,2026-06-16 09:18:27,IP Address,193.143.76.20,100,1275914,True,2026-06-16 09:18:28,R_87U6876WEIYC9X8,Ramos,Przemyslaw,przemyslaw.ramos@researchsolutions.pl,,50.1372,18.9664,gl,EN,Yes,Przemyslaw,Ramos,NZOZ Vita Longa,Internal Medicine,przemyslaw.ramos@researchsolutions.pl,48668440994,Uniczowsa 6,Katowice,Lesser Poland Voivodeship,40-748,Poland,Yes,Aleksandra,Zając,Vita Longa Sp. z o.o.,aleksandra.zajac@researchsolutions.pl,+48600937136,Uniczowska 6,Katowice,,40-748,Aleksandra,Zając,,aleksandra.zajac@researchsolutions.pl,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,1,,,,16-30%,,No,No,,1 study,15,5,10,100,0,0,0,0,0,,0,100,0,80,20,50,50,Yes,No,,Yes,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30086746,60031343,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NZOZ FORMED,Lwowska 93,Wadowice,Poland,Lesser Poland Voivodeship,34-100,Przemyslaw,Ramos,48668440994,przemyslaw.ramos@researchsolutions.pl,kfacdabr@its.jnj.com,136327,CG_W9kcFsbCDXBgFIl,16 Jun 2026,20:48 +2026-06-09 09:49:53,2026-06-16 09:34:50,IP Address,76.9.204.122,100,603897,True,2026-06-16 09:34:51,R_6SdciF9zfLojnpe,Afif,Waqqas,waqqas.afif@mcgill.ca,,45.5075,-73.5887,gl,EN,Yes,Waqqas,Afif,Clinique IMD,Gastroenterology,waqqas.afif@mcgill.ca,1514934193436537,1980 Sherbrooke West,Montréal,Quebec,H3H1E3,Canada,Yes,Sandy,Anderson,Clinique IMD,nurse@cliniqueimd.com,5149254100,500-1980 sherbrooke West,Montreal,Quebec,H3H1E8,Sandy,Anderson,"Nurse manager ",nurse@cliniqueimd.com,5149254100,Different from the above,Pascale,Germain,Admin manager,admin@cliniqueimd.com,5149254100,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,>60%,46-60%,16-30%,,No,No,,0 studies,4,3,1,50,20,15,0,0,15,hispanic,15,0,0,70,30,55,45,Yes,Yes,french and english,No,No,Community GI Outreach,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30161641,60536066,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Clinique IMD,1980 Sherbrooke West,Montréal,Canada,Quebec,H3H1E3,Waqqas,Afif,1514934193436537,waqqas.afif@mcgill.ca,tresuell@its.jnj.com,136423,CG_3NvLxNIseSAeiY5,16 Jun 2026,21:04 +2026-06-10 10:38:35,2026-06-16 09:47:06,IP Address,69.12.49.186,100,515311,True,2026-06-16 09:47:06,R_6lsoRxtM6rCNU2Z,Kim,Hyun Sil,hyun.kim@marginc.com,,32.9661,-117.1202,gl,EN,Yes,Hyun Sil,Kim,"Medical Associates Research Group, Inc.",GI,hyun.kim@marginc.com,18582775678,Frost Street 8008,San Diego,California,92123,United States,Yes,Maria,Lopez,MARG Inc,maria.lopez@marginc.com,8582775678,8008 Frost St. #200,San Diego,CA,92123,Margaret,Perroud,Director,margaret.perroud@marginc.com,8582775678,Same as above,,,,,,Other,Margaret,Perroud,Director,margaret.perroud@marginc.com,8582775678,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,depends on insurance,,,,,,,,,Yes,No,,0 studies,2,1,1,52,6,10,1,1,30,mix,30,70,0,80,20,50,50,Yes,No,,No,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30016513,60770726,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Medical Associates Research Group, Inc.",Frost Street 8008,San Diego,United States,California,92123,Hyun Sil,Kim,18582775678,hyun.kim@marginc.com,hsantosm@its.jnj.com,137093,CG_2zuPL5YOCAXHrWO,16 Jun 2026,21:17 +2026-06-12 15:07:31,2026-06-16 10:04:25,IP Address,170.223.207.26,100,327414,True,2026-06-16 10:04:26,R_3Ood9tUTjnGCfTP,Allegretti,Jessica,Jallegretti@bwh.harvard.edu,,42.3268,-71.1341,gl,EN,No,Jessica,Allegretti,Brigham & Women's Hospital,Gastroenterology,Jallegretti@bwh.harvard.edu,13053383662,Francis st 75,Boston,Massachusetts,02115,United States,Yes,Alexander,Carlin,Brigham and Women's Hospital,acarlin@bwh.harvard.edu,6175257322,20 Shattuck St,Boston,MA,02115,Alexander,Carlin,CRC/Lab Manager,acarlin@bwh.harvard.edu,6782313302,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,,,,,,,Yes,No,,0 studies,3,3,0,60,13,20,1,6,0,,10,90,0,85,15,48,52,Yes,No,,No,No,,N/A,N/A,,,,,N/A,,,,,N/A,,,,,1000,10,900,300,300,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,6,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,12,12,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30150811,60559690,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Brigham & Women's Hospital,Francis st 75,Boston,United States,Massachusetts,02115,Jessica,Allegretti,13053383662,Jallegretti@bwh.harvard.edu,hsantosm@its.jnj.com,137146,CG_dcXc0BgBaxcsEOl,16 Jun 2026,21:34 +2026-05-27 03:36:00,2026-06-16 11:35:35,IP Address,141.2.181.140,100,1756774,True,2026-06-16 11:35:36,R_8fEYuonOtMgyUz7,Blumenstein,Irina,blumenstein@em.uni-frankfurt.de,,50.3388,8.7511,gl,EN,Yes,Irina,Blumenstein,Frankfurt University Hospital,"Gastroenterology ",blumenstein@em.uni-frankfurt.de,4969630187687,Theodor-Stern-Kai 7,Frankfurt,Hesse,60596,Germany,Yes,"Data protections applies ","Data protections applies ","Medizinische Klinik 1 ","Data protections applies ","Data protections applies ",same as PI,same as PI,same as PI,same as PI,Christiane,Bott-Rafee,Admin. Site Manager,bott@em.uni-frankfurt.de,069630187769,Same as above,,,,,,Other,Christiane,Bott-Rafee,"Admin. Site Manager ",bott@em.uni-frankfurt.de,"+49 69 6301 87769 ",Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,46-60%,46-60%,,,Yes,No,,2 studies,5,4,1,100,0,0,0,0,0,,0,100,0,100,0,50,50,No,No,,Yes,No,"On site monitoring on a regual basis, well structured site file, pre filled forms, as much admin. support as possible, well functioning systems such as CRFs, patient diaries, endoscopy video transmission, monitor who is quickly available for questions via phone etc. ",no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30029606,60552214,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Frankfurt University Hospital,Theodor-Stern-Kai 7,Frankfurt,Germany,Hesse,60596,Irina,Blumenstein,4969630187687,blumenstein@em.uni-frankfurt.de,mraddatz@its.jnj.com,135739,CG_3JwQPRz4d7uvOJc,16 Jun 2026,23:05 +2026-06-10 10:42:38,2026-06-16 11:39:25,IP Address,172.56.223.146,100,521806,True,2026-06-16 11:39:25,R_74ql2YkB8cwAnqD,Patel,Sanket,spatel11@virtua.org,,40.0598,-75.1448,gl,EN,Yes,Sanket,Patel,"Virtua Medical Group, P.A. d/b/a Virtua Cardiology Group",GI,spatel11@virtua.org,1 856 762 0045,Young Avenue 401,Moorestown Township,New Jersey,08057,United States,Yes,Jacquelyn,Bordelon,Virtua,JBORDELO@virtua.org,856-325-3223,301 Lippincott Drive Suite 130,Marlton,NJ,08053,Kristin,Wade,Clinical Research Manager,KMWADE@virtua.org,609-969-1175,Different from the above,Teresa,Troy-Koff,Senior Project Manager,TTROY@virtua.org,856-355-1218,Other,Kristin,Wade,Clinical Research Manager,KMWADE@virtua.org,609-969-1175,No,,,,,"Yes, we are interested in participating and would like to sign a CDA offline before proceeding with the survey.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30080108,60190892,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Virtua Medical Group, P.A. d/b/a Virtua Cardiology Group",Young Avenue 401,Moorestown Township,United States,New Jersey,08057,Sanket,Patel,1 856 762 0045,spatel11@virtua.org,jnowak2@its.jnj.com,137806,CG_2absE0gIuQRB0l6,16 Jun 2026,23:09 +2026-06-15 04:12:55,2026-06-16 12:45:19,IP Address,87.110.160.33,100,117144,True,2026-06-16 12:45:20,R_21gqL8LVUHAzwSS,Pukitis,Aldis,pukitis@latnet.lv,,56.9473,24.0979,gl,EN,No,Aldis,Pukitis,Pauls Stradins Clinical University Hospital,Gastroenterology,pukitis@latnet.lv,37129253394,Pilsoņu iela 13,Riga,Riga,1002,Latvia,No,,,,,,,,,,Aldis,Pukitis,PI,pukitis@latnet.lv,+37129253394,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,1,1,,16-30%,31-45%,≤15%,No,No,,2 studies,6,2,4,100,0,0,0,0,0,,0,0,0,80,20,35,65,Yes,Yes,"Latvian, Russian",Yes,No,,No,,,,,,,,,,,,,,,,900,600,250,50,3,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,4,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,3,3,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30102379,60240407,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pauls Stradins Clinical University Hospital,Pilsoņu iela 13,Riga,Latvia,Riga,1002,Aldis,Pukitis,37129253394,pukitis@latnet.lv,iuscina@its.jnj.com,139195,CG_2YR2u8QmPYOoVy0,17 Jun 2026,00:15 +2026-06-15 13:25:35,2026-06-16 14:03:32,IP Address,192.231.86.237,100,88677,True,2026-06-16 14:03:33,R_7Pyz2uF9nEiPYwp,Yarur,Andres,andres.yarur@cshs.org,,34.0758,-118.3764,gl,EN,No,Andres,Yarur,Cedars Sinai Medical Center,Gastroenterology,andres.yarur@csmc.edu,13104230035,Beverly blvd 8700,Los Angeles,California,90048,United States,Yes,"Gabriela ",Cervantes-Limon,Cedars Sinai Medical Center,gabriela.cervantes@cshs.org,310-423-3779,"250 N Robertson Blvd. 5th Floor, Ste 518",Beverly Hills,CA,90211,Melissa,Myers,Research Program Administrator,melissa.myers@cshs.org,310-423-0035,Same as above,,,,,,Other,Melissa,Myers,Research Program Admin,melissa.myers@cshs.org,310-423-0035,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,16-30%,≤15%,,,Yes,No,,2 studies,3,3,0,90,0,0,0,0,10,middle eastern,10,90,0,100,0,60,40,Yes,No,,Yes,No,central ad campaign,,,,,,,,,,,,,,,,,500,50,450,300,150,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,6,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Local,,24,24,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30016049,60322791,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cedars Sinai Medical Center,Beverly blvd 8700,Los Angeles,United States,California,90048,Andres,Yarur,13104230035,andres.yarur@cshs.org,jnowak2@its.jnj.com,137157,CG_AuDvNyotW80Rv33,17 Jun 2026,01:33 +2026-06-15 06:07:56,2026-06-16 14:39:21,IP Address,89.254.161.250,100,117085,True,2026-06-16 14:39:22,R_26LLXteERcdMBNf,Erne,Linda,liepaajaa@inbox.lv,,56.5128,21.0154,gl,EN,No,Linda,Erne,Regional Hospital of Liepaja,GASTROENTEROLOGIST,liepaajaa@inbox.lv,37163403222,Slimnīcas iela 25,Liepāja,Liepāja,3414,Latvia,Yes,Linda,Erne,Outpatient,liepaajaa@inbox.lv,29526821,Slimnicas 25,Liepaja,,,Linda,Erne,PI,liepaajaa@inbox.lv,29526821,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, partially reimbursed/covered by insurance",,,,1,,,,46-60%,,No,No,,0 studies,4,1,3,100,0,0,0,0,0,,100,0,0,85,15,70,30,Yes,Yes,"Latvian, Russian",Yes,Yes,"Training, collaboration with the monitor, easily understandable data systems.",,,,,,,,,,,,,,,,,7,5,3,2,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,2,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,2,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30103621,60847315,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Regional Hospital of Liepaja,Slimnīcas iela 25,Liepāja,Latvia,Liepāja,3414,Linda,Erne,37163403222,liepaajaa@inbox.lv,iuscina@its.jnj.com,139196,CG_1F2R2asrjr3HCBe,17 Jun 2026,02:09 +2026-06-09 12:35:39,2026-06-16 14:51:30,IP Address,208.69.133.68,100,612950,True,2026-06-16 14:51:30,R_3TLsMgPBOuuR5Cx,Charilaou,Paris,paris.charilaou@atriumhealth.org,,35.2522,-80.8263,gl,EN,Yes,Paris,Charilaou,Atrium Health Gastroenterology - Morehead Medical Plaza,Gastroenterology & Hepatology,paris.charilaou@atriumhealth.org,17043554593,"Morehead Medical Dr 1025, STE 300",Charlotte,North Carolina,28204,United States,Yes,Jamie,Crawford,Atrium Health Center for Gastroenterology and Surgery,jamie.crawford@adovcatehealth.org,704-355-0282,"1025 Morehead Medical Drive, Suite 300",Charlotte,NC,28204,Jamie,Crawford,Research Nurse,jamie.crawford@advocatehealth.org,704-355-0282,Different from the above,Jessica,Kearney-Bryan,Research Director,jessica.kearney-bryan@advocatehealth.org,704-355-0244,Other,Jessica,Kearney-Bryan,Research Director,jessica.kearney-bryan@advocatehealth.org,704-355-0244,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,46-60%,,,Yes,No,,2 studies,8,5,3,69,1.5,22,0.5,0,7,Other or no response,25,75,0,71,29,45,55,Yes,Yes,Spanish,Yes,No,NA,Not at this time.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,true,,,,,,,,,,,,,30074580,60801759,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Atrium Health Levine Cancer Institute,Morehead Medical dr 1021,Charlotte,United States,North Carolina,28204,Paris,Charilaou,17043554593,paris.charilaou@atriumhealth.org,hsantosm@its.jnj.com,137121,CG_0As2FhyuoJAsdQ5,17 Jun 2026,02:21 +2026-06-11 14:27:13,2026-06-16 15:12:04,IP Address,168.250.62.65,100,434691,True,2026-06-16 15:12:05,R_5CKhUtndAfTVuaE,Ertem,Furkan,furkan_ertem@bshsi.org,,37.3923,-77.5668,gl,EN,No,Furkan,Ertem,Bon Secours St. Francis Primary Care Downtown,Gastroenterology,furkan_ertem@bshsi.org,864-335-7555,Saint Francis dr 1,Greenville,South Carolina,29601,United States,Yes,"Jyoti ",Patel,Bon Secour St. Francis Gastroenterology,jyoti_patel@bshsi.org,864-359-6241,317 St. Francis Dr. Suite 170,"Greenville ",SC,29601,"Jyoti ",Patel,"APRN, MSN, FNP-C",jyoti_patel@bshsi.org,,Different from the above,"Furkan ","Ertem ",MD,Furkan_Ertem@bshsi.org,832-228-2090,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,"subject to insurer-specific requirements such as prior authorization and in cases, step therapy",1,1,1,,16-30%,≤15%,≤15%,,Yes,No,,1 study,3,1,2,45,7,35,3,1,9,,25,75,0,65,35,50,50,Yes,Yes,"Spanish, English,",Yes,No,"To successfully participate in this Phase 3 study, our site may require operational and study-execution support from J&J, including: (1) timely site initiation and staff training on the protocol, study procedures, and safety reporting; (2) clear, protocol-specific guidance for eligibility screening, visit schedules, assessments, and documentation requirements; (3) rapid access to qualified clinical trial support (e.g., central monitoring contacts) for questions during conduct of the study; (4) efficient processes for investigational product (IP) ordering, receipt, storage/handling requirements, accountability, and timely delivery; (5) support for eClinical/data capture workflow, including guidance on completing ePRO/eCRFs (if applicable), query resolution timelines, and technical assistance; and (6) logistical coordination for any required assessments (e.g., laboratory logistics, imaging/central reading procedures, and specimen handling) to ensure adherence to protocol timelines.” +",Not at this time,Furkan Ertem,,,,,Bon Secour St. Francis Gastroenterology,,,,,Furkan_Ertem@bshsi.org,,,,,53,53,21,32,21,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,0,0,None,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,8,8,12,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30157228,60940927,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bon Secours St. Francis Primary Care Downtown,Saint Francis dr 1,Greenville,United States,South Carolina,29601,Furkan,Ertem,864-335-7555,furkan_ertem@bshsi.org,jnowak2@its.jnj.com,137544,CG_1It3rgltbjVzQNc,17 Jun 2026,02:42 +2026-06-11 14:09:44,2026-06-16 15:46:10,IP Address,108.226.149.207,100,437786,True,2026-06-16 15:46:11,R_6JFUxO22aMXB7Z7,Govani,Shail,Shailgovani@gmail.com,,40.1578,-83.0752,gl,EN,No,Shail,Govani,Ohio Gastroenterology Group Inc,"Gastroenterology ",Shailgovani@gmail.com,+2142263357,3400 Olentangy River rd,Columbus,Ohio,43202,United States,Yes,Shona,Taylor,Ohio Gastro,staylor@ohiogastro.com,6147545400,3400 Olentangy River Rd,Columbus,OH,43202,Shona,Taylor,Research Manager,staylor@ohiogastro.com,6147545400,Same as above,,,,,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,16-30%,16-30%,,,Yes,No,,2 studies,8,3,5,90,3,5,1,1,0,,3,97,0,60,40,50,50,No,No,,Yes,No,we would work with a central IRB. we do not have a local IRB. our study sponsors have worked through the IRB process through a CRO,,,,,,,,,,,,,,,,,2000,800,1200,300,150,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,4,3-5,Yes,No,No,No,Yes,Yes,Yes,Yes,Central,4,,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30076317,60018948,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ohio Gastroenterology Group Inc,3400 Olentangy River rd,Columbus,United States,Ohio,43202,Shail,Govani,+1 210 617 5300,Shailgovani@gmail.com,hsantosm@its.jnj.com,137082,CG_1rpjAwF9OXOpd7s,17 Jun 2026,03:16 +2026-06-10 03:42:38,2026-06-16 16:43:59,IP Address,151.31.108.92,100,565280,True,2026-06-16 16:43:59,R_8wphayqUL2qejUa,Cicala,Michele,m.cicala@policlinicocampus.it,,41.8905,12.5127,gl,EN,No,Michele,Cicala,"FONSAZIONE POLICLINICO UNIVERSITARIO Campus Bio -Medico ",Gastroenterologist,m.cicala@policlinicocampus.it,0039 06225411606,"via Alvaro del Portillo, 200, Roma",Rome,Lazio,00128,Italy,Yes,"Daniela ","Rossi ",Gastroenterology,dr.rossid@gmail.com,00393275886185,Via Alvaro del Portillo 2p0,Roma,Roma,00128,"Daniela ",Rossi,,,,Different from the above,Silvia,"Bartolucci ",Contract specialist,S.bartolucci@policlinicocampus.it,,Research Coordinator,,,,,,,,,Yes,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,,,≤15%,>60%,16-30%,,Yes,No,,1 study,4,2,2,100,0,0,0,0,0,,0,100,0,90,10,50,50,No,No,,No,No,"Give support with forms for: study visits at sites, IV administraion, mayo calcualtion ... +Less complexity in trial management. Good CRF design and a clear CRF without queries not according to protocol.",,,,,,,,,,,,,,,,,250,30,220,80,50,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,4,6,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,00,8,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30147329,60175736,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Campus Bio Medico University of Rome,"via Alvaro del Portillo, 200, Roma",Rome,Italy,Lazio,00128,Michele,Cicala,3906225411606,m.cicala@policlinicocampus.it,esilva52@its.jnj.com,137468,CG_24oR45wW4KNjXQg,17 Jun 2026,04:13 +2026-06-16 13:05:53,2026-06-16 17:26:56,IP Address,73.53.78.67,100,15663,True,2026-06-16 17:26:57,R_3dEV7VGuXSbcQVJ,Holderman,William,wholderman@washgi.com,,47.6131,-122.2053,gl,EN,Yes,William,Holderman,Washington Gastroenterology,Gastroenterology,wholderman@washgi.com,12535032514,South Cedar Street 2202 #330,Tacoma,Washington,98405,United States,No,,,,,,,,,,Leslie,Lee,Site Manager,leslie.lee@iterativehealth.com,4256337895,Same as above,,,,,,Other,Leslie,Lee,Site Manager,leslie.lee@iterativehealth.com,4256337895,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,1,1,,,31-45%,31-45%,,Yes,No,,2 studies,2,1,1,90,6,2,0,0,2,mixed,50,50,0,70,30,50,50,Yes,No,,No,No,none,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30063350,60347637,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Digestive Health Specialists,South Cedar Street 2202,Tacoma,United States,Washington,98405,William,Holderman,12535032514,wholderman@washgi.com,hsantosm@its.jnj.com,137105,CG_27kF0MoPfIwYlxH,17 Jun 2026,04:56 +2026-06-16 14:37:21,2026-06-16 17:48:33,IP Address,174.102.16.82,100,11472,True,2026-06-16 17:48:34,R_5GEbnqfZ7AQlEO7,Sangha,Thalvinder Steven,drsangha@atlgastrospec.com,,38.9924,-84.6462,gl,EN,Yes,Thalvinder Steven,Sangha,"Atlanta Gastroenterology Specialists, PC",Gastroenterology,drsangha@atlgastrospec.com,16789570057,4395 Johns Creek Pkwy #130,Suwanee,GA,30024,United States,Yes,Zenisha,Bain,Atlanta Gastroenterology Specialists,zenisha@atlgastrospec.com,678-957-0057,4395 Johns Creek Pkwy #130,Suwanee,GA,30024,Missy,Randolph,Study Coordinator,research@atlgastrospec.com,678-957-0057,Different from the above,Jessica,Blake,Chief Operating Officer,Jessica@atlgastrospec.com,678-957-0057,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,,,16-30%,46-60%,16-30%,≤15%,Yes,No,,2 studies,4,2,2,65,20,10,0,5,0,,15,85,0,75,25,40,60,No,No,,Yes,No,"centralized recruitment campaign, prescreening tools",no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30079287,60937535,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Atlanta Gastroenterology Specialists, PC",Johns crk pkwy 4395,Suwanee,United States,Georgia,30024,Thalvinder Steven,Sangha,16789570057,drsangha@atlgastrospec.com,jnowak2@its.jnj.com,137872,CG_1Kj7FUrdSii0Z1O,17 Jun 2026,05:18 +2026-06-10 13:10:00,2026-06-16 19:42:13,IP Address,189.215.49.179,100,541932,True,2026-06-16 19:42:13,R_3FtcpDP2EsKPcVa,Mena Quintero,Axel,amenaquintero@gmail.com,,20.9867,-89.6452,gl,EN,No,Axel,Mena Quintero,Medical Care & Research SA de CV,Gastroenterologist,amenaquintero@gmail.com,529999008619,Calle 32 217,Mérida,Yucatán,97070,Mexico,No,,,,,,,,,,Myriam,Pech Sáenz,Clinical Research Manager,myriam.pech@medicalcare.mx,9992969186,Same as above,,,,,,Principal Investigator,,,,,,,,,,Yes,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,≤15%,>60%,≤15%,,No,No,,1 study,2,1,1,0,0,0,10,0,90,mexican mestizo,90,10,0,80,20,50,50,No,Yes,spanish,Yes,No,"national recruitment platform, budget for social media advertising",no,"Dr. Roberto Cruz Neri ",,,,,,,,,,rneri@brcrglobal.com,,,,,4,2,2,1,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,1,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Central and Local,12,4,8,Yes,,sipIQ,,,,,,,true,,,,,,,,,,,,,,,,,,,,,,,,false,,,,,true,,,,,,,,30112516,60584258,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Medical Care & Research SA de CV,Calle 32 217,Mérida,Mexico,Yucatán,97070,Axel,Mena Quintero,529999008619,amenaquintero@gmail.com,vcastan4@its.jnj.com,136586,CG_24l1h3s7WaftYrH,17 Jun 2026,07:12 +2026-06-16 19:03:58,2026-06-16 20:22:31,IP Address,165.132.230.251,100,4712,True,2026-06-16 20:22:31,R_9aQ77zsCH7qW24o,Kim,Hyun Soo,hyskim@yonsei.ac.kr,,37.3468,127.9424,gl,EN,No,Hyun Soo,Kim,Yonsei University Wonju Severance Christian Hospital,Gastroenterology,hyskim@yonsei.ac.kr,+82 33 741 1224,"20, Ilsan-ro",Weonju,Gangwon Province,220-050,South Korea,Yes,Yoona,Jeong,"Wonju Severance Christian Hospital ",jyn3553@naver.com,+82-33-741-1227,"20, Ilsanr0",Wonju,Kangwon,26426,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,16-30%,,,Yes,No,,1 study,3,1,2,0,100,0,0,0,0,,0,100,5,75,20,50,50,Yes,Yes,Korean,Yes,No,transport assistance system would be helpful.,No,,,,,,,,,,,,,,,,100,60,30,20,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,4,6,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,4,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,false,,,,,,30115473,60608831,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Yonsei University Wonju Severance Christian Hospital,"20, Ilsan-ro",Weonju,South Korea,Gangwon Province,220-050,Hyun Soo,Kim,+82 33 741 1224,hyskim@yonsei.ac.kr,yjung21@its.jnj.com,137740,CG_1l63F7brmXiphqD,17 Jun 2026,07:52 +2026-06-10 05:50:53,2026-06-17 00:45:28,IP Address,220.128.118.58,100,586474,True,2026-06-17 00:45:29,R_4GfFJLkuqVHecq7,Le,Puo- hsien,puohsien@gmail.com,,24.9977,121.2965,gl,EN,Yes,Puo- hsien,Le,Linkou Chang Gung Memorial Hospital,GI,puohsien@gmail.com,886332812008101,Fuxing Street 5,Taoyuan,Taoyuan City,333,Taiwan,Yes,Yu-Syuan,Huang,"Chang Gung Memorial Hospital, Linkou ",yshuang1107@gmail.com,,,,,,Yu-Syuan,Huang,Clinical Research Nurse,yshuang1107@gmail.com,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,>60%,31-45%,≤15%,,No,No,,1 study,10,3,7,0,100,0,0,0,0,,0,0,0,90,10,50,50,Yes,No,,Yes,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,true,,,,,,,,,30102392,60817850,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Linkou Chang Gung Memorial Hospital,Fuxing Street 5,Taoyuan,Taiwan,Taoyuan City,333,Puo- hsien,Le,886332812008101,puohsien@gmail.com,yyu126@its.jnj.com,135755,CG_oZ9kVTmB8Jt4vTP,17 Jun 2026,12:15 +2026-06-10 03:48:01,2026-06-17 02:25:22,IP Address,109.69.144.54,100,599840,True,2026-06-17 02:25:23,R_2QJXLxlYwCZrl3n,Ribaldone,Davide,davrib_1998@yahoo.com,,45.0729,7.689,gl,EN,No,Davide Giuseppe,Ribaldone,AOU Città della Salute e della Scienza di Torino,Gastroenterology,davidegiuseppe.ribaldone@unito.it,39116296547,Corso Bramante 88/90,Turin,Piedmont,10126,Italy,Yes,Alessandra,Risso,"AOU Città della Salute e della Scienza di Torino, SC Gastroenterologia U.",alessandrarisso82@gmail.com,+393496601413,Corso Bramante 88/90,Torino,Piemonte,10126,Alessandra,Risso,Study coordinator,alessandrarisso82@gmail.com,+393496601413,Same as above,,,,,,Research Coordinator,,,,,,,,,Yes,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,≤15%,≤15%,≤15%,≤15%,Yes,No,,More than 2 studies,2,1,1,90,5,5,0,0,0,,0,100,0,70,30,50,50,Yes,No,,No,No,agreement,no,,,,,,,,,,,,,,,,1300,280,280,55,60,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,5,5,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central and Local,8,8,8,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,,,,,,,,,,30131957,60587367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino,Corso Bramante 88,Turin,Italy,Piedmont,10126,Davide,Ribaldone,39116296547,davrib_1998@yahoo.com,esilva52@its.jnj.com,137471,CG_1gnpAvkTMPXUgtf,17 Jun 2026,13:55 +2026-06-11 20:38:14,2026-06-17 05:13:32,IP Address,61.246.125.41,100,462917,True,2026-06-17 05:13:32,R_4PYNNGxGIx2ovXB,Banerjee,Rupa,rupabanerjee.aig@gmail.com,,18.4266,77.9062,gl,EN,Yes,Rupa,Banerjee,Asian Institute of Gastroenterology (AIG) - AIG Hospitals,Gastroenterology,rupabanerjee.aig@gmail.com,919849287530,Plot No 2 3 4 5 Survey No 1361 Mindspace rd Gachibowli,Hyderabad,Telangana,500032,India,Yes,Harshitha,KB,Inflammatory Bowel Disease,harshitha.kalavaralah@aighospitals.com,7330887685,"AIG Hospitals, Gachibowli",Hyderabad,Telangana,500032,Harshitha,KB,Research Coordinator,harshitha.kalavaralah@aighospitals.com,7330887685,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,1,1,1,1,31-45%,16-30%,≤15%,≤15%,Yes,No,,More than 2 studies,20,10,10,0,100,0,0,0,0,,0,0,10,80,10,50,50,Yes,Yes,"English, Hindi, Bengali, Telugu",No,No,Nil,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30022427,60067546,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Asian Institute of Gastroenterology (AIG) - AIG Hospitals,Plot No 2 3 4 5 Survey No 1361 Mindspace rd Gachibowli,Hyderabad,India,Telangana,500032,Rupa,Banerjee,919849287530,rupabanerjee.aig@gmail.com,skulk105@its.jnj.com,135888,CG_2VEWjLcGxnwCI4p,17 Jun 2026,16:43 +2026-06-15 23:12:27,2026-06-17 05:27:22,IP Address,106.216.229.164,100,108895,True,2026-06-17 05:27:23,R_4c7n68JRSRCMStu,Balekuduru,Avinash,avinashbalekuduru@gmail.com,,12.9753,77.591,gl,EN,No,Avinash,Balekuduru,M S Ramaiah Medical College and Hospital,Medical Gastroenterology,avinashbalekuduru@gmail.com,919731879792,"MSR College Rd, M S Ramaiah Nagar",Bengaluru,Karnataka,560054,India,Yes,SHRRUTHI,M,M S RAMAIAH MEDICAL COLLEGE AND HOSPITALS,shrruthi@msrcrc.com,09481604610,"M S RAMAIAH NAGAR, MSRIT POST",Bangalore,Karnataka,560090,SHRRUTHI,M,"LEAD AND QUALITY HEAD, Ramaiah Clinical Research Centre",shrruthi@msrcrc.com,09481604610,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration",Other (please specify):,depends on different insurance providers,1,1,,,≤15%,31-45%,,,Yes,No,,1 study,4,1,3,0,100,0,0,0,0,,0,100,5,70,25,50,50,Yes,Yes,"English,Hindi, Kannada, Tamil, Telugu",Yes,No,Participant materials about trial with description,no,,,,,,,,,,,,,,,,20,20,10,0,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,7,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,6,8,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30019747,60524955,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M S Ramaiah Medical College and Hospital,"MSR College Rd, M S Ramaiah Nagar",Bengaluru,India,Karnataka,560054,Avinash,Balekuduru,919731879792,avinashbalekuduru@gmail.com,skulk105@its.jnj.com,135879,CG_3Rl99fIyoxmgt5R,17 Jun 2026,16:57 +2026-06-01 14:42:19,2026-06-17 05:27:57,IP Address,85.222.67.26,100,1349137,True,2026-06-17 05:27:57,R_2Jko3HDb88URm9b,Frysna,Bernardeta,b.frysna@vistamed.pl,,52.2372,21.0123,gl,EN,Yes,Bernardeta,Frysna,Przychodnia Vistamed,Gastroenterologist,b.frysna@vistamed.pl,48600411536,Racławicka,Wrocław,Lower Silesian Voivodeship,53-149,Poland,Yes,Ewelina,Krymska,Przychodnia Vistamed,e.krymska@vistamed.pl,+48 514810834,ul. Racławicka 105/1b,Wrocław,Wrocław,53-149,Ewelina,Krymska,Managing Director,e.krymska@vistamed.pl,+48514810834,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,≤15%,16-30%,31-45%,,No,No,,1 study,15,7,8,100,0,0,0,0,0,,0,100,0,90,10,50,50,Yes,No,,No,Yes,N/A,N/A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30089086,60358882,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Przychodnia Vistamed,Racławicka,Wrocław,Poland,Lower Silesian Voivodeship,53-149,Bernardeta,Frysna,48600411536,b.frysna@vistamed.pl,kfacdabr@its.jnj.com,136334,CG_ueHtJ0u7Yte092N,17 Jun 2026,16:57 +2026-06-17 04:59:03,2026-06-17 06:46:48,IP Address,194.160.223.2,100,6464,True,2026-06-17 06:46:48,R_8emkgGCdLNLWevN,Bruncak,Michal,michalbruncak@gmail.com,,48.7386,19.1477,gl,EN,No,Michal,Bruncak,Fakultna Nemocnica s Poliklinikou F. D. Roosevelta Banska Bystrica,gastroenterologist,michalbruncak@gmail.com,421944354644,Ludvíka Svobodu 1,Banská Bystrica,Banská Bystrica Region,976 32,Slovakia,Yes,"Andrea ",Sustekova,FNsP FD ROOSEVELT HOSPITAL,sustek.andrea@gmail.com,421902270648,L Svobodu 1,BANSKA BYSTRICA,Banska Bystrica,97401,"Michal ",Bruncak,PI,michalbruncak@gmail.com,421944354644,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,46-60%,16-30%,,,Yes,No,,1 study,4,3,1,100,0,0,0,0,0,,0,100,0,95,5,50,50,Yes,No,,No,No,none,no,,,,,,,,,,,,,,,,200,50,200,80,15,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,4,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,4,,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30103783,60417323,,,,,,0,,,0,0,,,,,,,,,,,,,,,,,,,,,,Fakultna Nemocnica s Poliklinikou F. D. Roosevelta Banska Bystrica,Ludvíka Svobodu 1,Banská Bystrica,Slovakia,Banská Bystrica Region,976 32,Michal,Bruncak,421944354644,michalbruncak@gmail.com,vbuzalka@its.jnj.com,136446,CG_1QhIdpDbIGn3BSt,17 Jun 2026,18:16 +2026-06-03 00:33:09,2026-06-17 07:08:56,IP Address,95.48.232.129,100,1233346,True,2026-06-17 07:08:57,R_2Xpaxj0lEEnYHsY,Korga,Patryk,patryk.korga@kermed.pl,,53.1316,18.0269,gl,EN,Yes,Patryk,Korga,NZOZ Centrum Medyczne KERmed,gastroenterology,patryk.korga@kermed.pl,48523787043,Królowej Jadwigi 16,Bydgoszcz,Kuyavian-Pomeranian Voivodeship,85-000,Poland,Yes,Ewa,Kowalińska,Centrum Medyczne KERmed,ewa.kowalinska@kermed.pl,+48 784 655 065,Królowej Jadwigi 16,Bydgoszcz,Kuyavian-Pomeranian Voivodeship,85-231,Ewa,Kowalińska,Director,ewa.kowalinska@kermed.pl,784655065,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,16-30%,46-60%,16-30%,,Yes,Yes,"Yes. We anticipate moderate enrollment challenges, mainly due to the requirement for centrally confirmed endoscopic disease activity, restrictions related to prior advanced therapies, exclusion of patients previously exposed to vedolizumab/anti-integrins or IL-23 agents, and the need to balance ADT-naïve and ADT-IR participants. However, given our access to UC patients and experience in IBD clinical trials, we believe recruitment should be feasible with appropriate pre-screening.",0 studies,10,4,6,100,0,0,0,0,0,,0,100,0,95,5,50,50,Yes,No,,No,No,"To successfully participate in the study, our site would appreciate support from J&J in patient recruitment activities, including the possibility to publish approved information about the study on our social media channels, as well as providing IRB/EC-approved patient-facing materials such as leaflets and posters.",No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30086565,60125397,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NZOZ Centrum Medyczne KERmed,Królowej Jadwigi 16,Bydgoszcz,Poland,Kuyavian-Pomeranian Voivodeship,85-000,Patryk,Korga,48523787043,patryk.korga@kermed.pl,kfacdabr@its.jnj.com,136324,CG_emRSvti4UjFal5D,17 Jun 2026,18:38 +2026-06-12 04:59:07,2026-06-17 07:12:03,IP Address,136.226.230.175,100,439976,True,2026-06-17 07:12:04,R_4D0GOooLoz5sgfR,Choudhuri,Gourdas,gourdas.choudhuri@fortishealthcare.com,,28.6327,77.2198,gl,EN,Yes,Gourdas,Choudhuri,Fortis Memorial Research Institute,Gastroenterology & Hepatobiliary Sciences,gourdas.choudhuri@fortishealthcare.com,919650643222,"Sector - 44, Opp. Millenium City Centre metro Station, ",Gurugram,Haryana,122002,India,Yes,Prerna,Rani,Fortis Memorial Research Institute,clinical.research2@fortishealthcare.com,+917979881455,"Sec- 44, Opp Millenium City Centre Metro Station",Gurugram,Haryana,122002,Prerna,Rani,CRC,clinical.research2@fortishealthcare.com,+917979881455,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","No, not reimbursed/covered by insurance",,,,,,,,,,No,Yes,vedolizumab should be provided from Sponsor's end as it's not possible for the site to procure these medicine,1 study,6,4,2,0,100,0,0,0,0,,0,100,5,85,10,60,40,Yes,Yes,Hindi & English,Yes,No,Trial specific supplies/equipments with adequate travel reimbursement to the patient to enhance the patient retention for the longer run.,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30022016,60257955,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fortis Memorial Research Institute,Sector - 44,Gurugram,India,Haryana,122002,Gourdas,Choudhuri,919650643222,gourdas.choudhuri@fortishealthcare.com,skulk105@its.jnj.com,135886,CG_3EYiZ38URQ76q0u,17 Jun 2026,18:42 +2026-06-12 02:35:13,2026-06-17 08:06:06,IP Address,176.238.19.32,100,451853,True,2026-06-17 08:06:07,R_86h1jBkrOzX2yEp,Eren,Fatih,drfatiheren@hotmail.com,,41.0207,28.9285,gl,EN,No,Fatih,Eren,Uludag University Medical Faculty,Gastroenterology and Hepatology,drfatiheren@hotmail.com,00905326669501,"Gorukle Campus, Nilufer",Bursa,Turkey,16059,Turkey,Yes,"Fatih ",Eren,"Uludağ University Faculty of Medicine Hospital, Department of Gastroenterology",drfatiheren@hotmail.com,+90 532 666 95 01,"Uludağ University Faculty of Medicine Hospital, Department of Gastroenterology Nilüfer/Bursa",BURSA,'-- OTHER --,16059,"Beste ",ASLAN,SC,beste.aslan@medismart.com.tr,05415093005,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,,1,,,,≤15%,,,No,No,,0 studies,3,2,1,100,0,0,0,0,0,,0,0,5,85,10,50,50,Yes,Yes,Türkçe,No,No,metal cabinet for kits and files,no,,,,,,,,,,,,,,,,40,15,35,2,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,10,3-5,Yes,Yes,No,Yes,Yes,Yes,Yes,Yes,Central and Local,1,1,3,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30132303,78153,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Uludag University Medical Faculty,"Gorukle Campus, Nilufer",Bursa,Turkey,Turkey,16059,Fatih,Eren,00905326669501,drfatiheren@hotmail.com,bsaribek@its.jnj.com,135837,CG_XIl1x5BWLg1GETv,17 Jun 2026,19:36 +2026-06-16 13:10:43,2026-06-17 09:34:06,IP Address,47.206.123.213,100,73402,True,2026-06-17 09:34:06,R_1VkZsghfxnhyGbq,Rodriguez,Manuel,manuel.rodriguez@fdhs.com,,27.4499,-82.3774,gl,EN,Yes,Manuel,Rodriguez,Florida Research Center Inc.,Gastroenterology,manuel.rodriguez@fdhs.com,9417277772,"10910 Technology Terrace ","Lakewood Ranch ",Florida,34211,United States,Yes,Myrlande,Elichne,"Florida Research Institute ",myrlande.elichne@fdhs.com,9417277772,"10910 Technology Terrace ","Lakewood Ranch ","FL ",34211,Michele,Patterson,Regulatory Specialist,michele.patterson@fdhs.com,9417277772,Different from the above,"Mandy ",Burdine,Director of Site Operations,mandy.burdine@fdhs.com,9417277772,Other,Mandy,Burdine,Director of Site Operations,mandy.burdine@fdhs.com,9417277772,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,,,,,,,,,Yes,No,,1 study,3,2,1,85,5,10,0,0,0,,15,85,0,90,10,50,50,Yes,Yes,Spanish,Yes,Yes,"Posters, Education, Electronic Advertising for social media",no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30009689,60668288,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Florida Research Center Inc.,Technology Terrace 10910,Bradenton,United States,Florida,34211,Manuel,Rodriguez,9417277772,manuel.rodriguez@fdhs.com,hsantosm@its.jnj.com,137085,CG_3PRdzRdcm2nzXYf,17 Jun 2026,21:04 +2026-05-27 03:38:09,2026-06-17 10:03:02,IP Address,213.138.58.146,100,1837493,True,2026-06-17 10:03:03,R_8fdO49CuDhocB8g,Dignass,Axel,axel.dignass@agaplesion.de,,50.1573,8.6843,gl,EN,No,Axel,Dignass,"Agaplesion Frankfurter Diakonie Kliniken GmbH, Markus Krankenhaus",gastroenterologist,axel.dignass@agaplesion.de,496995332201,Wilhelm-Epstein-Straße 4,Frankfurt,Hesse,60431,Germany,Yes,Christina,Büttner,Markus Krankenhaus,christina.buettner@agaplesion.de,+496995332296,Wilhelm-Epstein-Str. 4,Frankfurt,Hessen,60431,"Christina ",Büttner,SC,christina.buettner@agaplesion.de,+496995332296,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,,,,,Yes,No,,More than 2 studies,3,2,1,97,1,1,1,0,0,,0,0,0,85,15,50,50,Yes,Yes,"english, turkish, croatian",Yes,No,,,,,,,,,,,,,,,,,,1400,500,500,400,180,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,10,15,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Central,12,,12,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30116238,60231941,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Agaplesion Frankfurter Diakonie Kliniken GmbH, Markus Krankenhaus",Wilhelm-Epstein-Straße 4,Frankfurt,Germany,Hesse,60431,Axel,Dignass,496995332201,axel.dignass@agaplesion.de,mraddatz@its.jnj.com,135740,CG_578H5btKmpxlmCZ,17 Jun 2026,21:33 +2026-06-10 14:31:15,2026-06-17 10:53:29,IP Address,128.94.23.47,100,591733,True,2026-06-17 10:53:29,R_11Y70r5eenINNVD,Guerra,Nathyeli,dranathyeli.guerra@gmail.com,,15.834,-92.7557,gl,EN,No,PAULINO,MARTINEZ HERNANDEZ MAGRO,TOGETHER CLINICAL AND RESEARCH SA DE CV,COLOPROCTOLOGIST,paulino.martinezz@togetherclinical.com.mx,4423054703,"Guadalupe Street No. 205, Suite 214, Dowtown, Celaya, Guanajuato 38000 Mexico",Celaya,Guananjuato,38000,Mexico,Yes,BRENDA PAMELA,IBARRA RESENDIZ,TOGETHER CLINICAL AND RESEARCH SA DE CV,pamela.ibarra@togetherclinical.com.mx,4423054703,"Guadalupe Street No. 205, Suite 214, Dowtown, Celaya, Guanajuato 38000 Mexico",Celaya,Guanajuato,38000,BRENDA,IBARRA,SITE COORDINATOR,pamela.ibarra@togetherclinical.com.mx,4423054703,Same as above,,,,,,Research Coordinator,,,,,,,,,,Yes,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,1,31-45%,31-45%,16-30%,≤15%,Yes,No,,0 studies,5,3,2,100,0,0,0,0,0,,100,0,10,80,10,55,45,Yes,Yes,Spanish,Yes,No,"The site is fully capable of conducting the study. However, support in the following areas would be beneficial to maximize recruitment and study execution: +-Patient recruitment and educational materials written in clear, patient-friendly language, minimizing complex medical terminology to improve patient understanding and engagement. +-Adequate patient travel reimbursement and transportation support to reduce participation barriers and enhance retention throughout the study. +-Timely and consistent support from both medical and non-medical study team members, including prompt responses to protocol, eligibility, operational, and logistical questions. +-Comprehensive protocol training and ongoing communication regarding study updates and recruitment strategies.","At this time, the site does not have any significant concerns regarding the study requirements. + +We are enthusiastic about the opportunity to participate in this study. Our research center is located within a hospital setting, providing access to the necessary infrastructure, certifications, calibrated equipment, and experienced staff required to conduct the study efficiently. + +In addition, our site serves a large patient population and is strategically located, attracting patients not only from our city but also from neighboring cities and states, including Querétaro. This broad referral network supports access to a substantial population of patients with ulcerative colitis. + +To facilitate rapid enrollment, our site prioritizes patient pre-screening activities before study initiation whenever possible. This approach allows us to identify potentially eligible participants early and positions us to enroll our first patient within the first week following site activation.",,,,,,,,,,,,,,,,160,84,56,20,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,2,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,2,5,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30115387,136597,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital SMIQ,Av. Balaustradas S/N Col. Balaustradas,Santiago de Querétaro,Mexico,Querétaro,76070,Nathyeli,Guerra,4422703418,dranathyeli.guerra@gmail.com,vcastan4@its.jnj.com,136597,CG_xlPbbCWRtgn3i4V,17 Jun 2026,22:23 +2026-06-10 00:14:50,2026-06-17 11:46:42,IP Address,187.190.156.1,100,646311,True,2026-06-17 11:46:42,R_5huS5QjMQ0FXLpB,Cruz Palacios,Aracely,aracely.cruz@faicic.com.mx,,19.2129,-96.22,gl,EN,No,Aracely,Cruz Palacios,FAICIC S. de R.L. de C.V.,Gastroenterology,aracely.cruz@faicic.com.mx,2291612893,Avenida 16 de Septiembre 1165,Veracruz,Veracruz de Ignacio de la Llave,91900,Mexico,Yes,"Liz Nalleli ",Saldivar Cruz,FAICIC (Consultorio de atención médica especializada: Gastroenterología),liz.saldivar@faicic.com.mx,+52 229 932 7808,"Av.16 de Septiembre no. 1165 Col. Ricardo Flores Magón ",Veracruz,Veracruz de Ignacio de la Llave,C.P. 91900,"Keren Stefania ",Uscanga Domínguez,Feasibility,"factibilidades@faicic.com.mx ","+52 229 323 9109 ",Different from the above," Sharzhaad ",Molina Guizar,Legal Representative,"sharzymg@faicic.com.mx ",+52 228 140 0537,Principal Investigator,,,,,,,,,,Yes,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","No, not reimbursed/covered by insurance",,1,1,,,>60%,16-30%,,,No,No,,0 studies,2,1,1,0,0,0,100,0,0,,100,0,0,70,30,50,50,Yes,No,,Yes,Yes,"At this time, no additional support from J&J is anticipated to successfully participate in the study.",No concerns.,,,,,,,,,,,,,,,,5,2,6,2,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,2,4,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,1,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30111950,136596,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FAICIC S. de R.L. de C.V.,Avenida 16 de Septiembre 1165,Veracruz,Mexico,Veracruz de Ignacio de la Llave,91900,Aracely,Cruz Palacios,2291612893,aracely.cruz@faicic.com.mx,vcastan4@its.jnj.com,136596,CG_10PprKtTJEEAzYg,17 Jun 2026,23:16 +2026-06-08 13:32:52,2026-06-17 11:50:35,IP Address,181.198.203.236,100,771463,True,2026-06-17 11:50:36,R_59mHxX9KuhGLKL5,Soofi,Najm,soofin@hurongastro.com,,-2.2038,-79.8819,gl,EN,No,Najm,Soofi,Huron Gastroenterology Associates Center for Digestive Care,Gastroenterology,soofin@hurongastro.com,7344346262,Elliott dr 5300,Ypsilanti,Michigan,48197,United States,Yes,"James ",McMullen,Huron Gastroenterology Associates,jmcmullen@fomatmedical.com,8054831185,"5300 Elliott Dr, Ypsilanti, MI 48197 ",Ypsilanti,MI,"48197 ","Johnny ",Moreno,Feasibility and Site Strategy,jmoreno@fomatmedical.com,8054831185 ext 123,Different from the above,Brandon,Johnson,Manager Business Development,bjohnson@fomatmedical.com,8054831185 ext 824,Other,"Johnny ",Moreno,Feasibility and Site Strategy,jmoreno@fomatmedical.com,8054831185 ext 123,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,1,1,,,46-60%,31-45%,,Yes,No,,2 studies,6,3,3,81,4,14,1,0,0,,8,92,0,75,25,50,50,Yes,Yes,Spanish and English,Yes,Yes,"Recruitment materials and outreach tools would be valuable to enhance patient engagement. Additionally, responsive communication during the screening phase would help optimize enrollment, particularly when clarifications on eligibility are needed. Some degree of operational flexibility would also be appreciated.","The main consideration is the limited eligible population due to prior biologic exposure, particularly vedolizumab,commonly used in the target population, thus affecting screening efficiency. However the sote is experienced in managing these challenges and will implement targeted recruitment strategies to optimize enrollment. +Dr. Najm M. Soofi, MD, MPH is a board-certified gastroenterologist at Huron Gastroenterology with specialized expertise in Inflammatory Bowel Disease (IBD). As Principal Investigator, he has extensive experience managing moderate-to-severe ulcerative colitis and Crohn’s disease, including patients requiring advanced and biologic therapies.He completed his medical training at Wayne State University, Internal Medicine residency at Rush University Medical Center, and Gastroenterology fellowship at New York University Medical Center. He also holds a Master of Public Health from the University of Michigan, supporting a strong foundation in clinical research. Dr. Soofi practices within a high-volume gastroenterology group of seven physicians serving a patient population exceeding 150,000, providing access to a robust pool of moderate-to-severe UC patients and experience with complex eligibility criteria and advanced therapies. +FOMAT Medical Research provides strong operational support, including study start-up, regulatory expertise, patient recruitment strategies, and dedicated research staff, enabling efficient, high-quality study execution and supporting successful enrollment and conduct of this trial","Erica Cohen,M.D.","Kenolisa Onwueme, M.D.","Geeta Kutty, M.D.","Rajesh Jain, M.D.","Howard Gogel, M.D.",Capital Digestive Chevy Chase,Woodholme Gastroenterology Associates,"San Jose Gastro ",Rocky Mountain Gastroenterology,Southwest Gastro,bd@fomatmedical.com,bd@fomatmedical.com,bd@fomatmedical.com,bd@fomatmedical.com,bd@fomatmedical.com,435,153,285,103,38,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,2,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,2,,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30078073,60281696,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Huron Gastroenterology Associates Center for Digestive Care,Elliott dr 5300,Ypsilanti,United States,Michigan,48197,Najm,Soofi,7344346262,soofin@hurongastro.com,jnowak2@its.jnj.com,137128,CG_OkaUeWvG4BAdMrf,17 Jun 2026,23:20 +2026-06-16 14:48:27,2026-06-17 12:30:24,IP Address,107.201.173.158,100,78116,True,2026-06-17 12:30:24,R_5xUSGDViWoczqFj,Sakuraba,Atsushi,atsushi_sakuraba@rush.edu,,42.0648,-87.9356,gl,EN,No,Atsushi,Sakuraba,Rush University Medical Center,Gastroenterology,atsushi_sakuraba@rush.edu,312-942-5861,"1725 W Harrison St, Suite 206",Chicago,Illinois,60612,United States,Yes,Amanda,Lin,"Rush University Medical Center, Department of Internal Medicine",amanda_f_lin@rush.edu,312-563-3907,"1725 W Harrison Street, Suite 206",Chicago,IL,60612,Amanda,Lin,,amanda_f_lin@rush.edu,312-563-3907,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,16-30%,16-30%,≤15%,,Yes,No,,More than 2 studies,4,3,1,59,5,34,0,0,2,unknown or prefer not to report,15,78,9,63,28,40,60,Yes,Yes,"English +Spanish",No,No,"Other than routine sponsor support, we do not expect any extra support from the sponsor.",No.,,,,,,,,,,,,,,,,500,100,300,100,50,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,3,3,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,7,9,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,false,,,,true,,,,,,,,,30077053,60784154,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rush University Medical Center,1620 W Harrison St,Chicago,United States,Illinois,60612,Atsushi,Sakuraba,312-942-5861,atsushi_sakuraba@rush.edu,hsantosm@its.jnj.com,137543,CG_3Ok5fxXsX05yAsl,18 Jun 2026,00:00 +2026-06-17 13:38:27,2026-06-17 13:46:08,IP Address,12.13.169.90,100,461,True,2026-06-17 13:46:09,R_1L2MblL9hjxvprH,Alayo,Erick,alayo.erick@gmail.com,,33.8718,-118.3369,gl,EN,Yes,Erick,Alayo,Gastro SB Clinic,gastroenterology,alayo.erick@gmail.com,6193823315,587 3rd Ave,Chula Vista,California,91910,United States,Yes,"Marilyn ",Rodriguez,gastrosb clinic,marylin@gastrosb.com,,,,,,,,,,,Different from the above,erick,alayo,MD,alayo.erick@gmail.com,,Principal Investigator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,1,,≤15%,31-45%,46-60%,,Yes,No,,1 study,2,1,1,10,10,0,0,0,80,latino,80,20,0,60,40,40,60,Yes,Yes,spanish,Yes,No,marketing,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30015513,60458883,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gastro SB Clinic,587 3rd Ave,Chula Vista,United States,California,91910,Erick,Alayo,6193823315,alayo.erick@gmail.com,hsantosm@its.jnj.com,137092,CG_yUffBLzT43rDeQF,18 Jun 2026,01:16 +2026-06-16 13:37:10,2026-06-17 15:23:06,IP Address,12.8.91.186,100,92755,True,2026-06-17 15:23:06,R_1PhOeZcwE2maLc1,Hassanein,Tarek,thassanein@researchscrc.com,,32.717,-116.8761,gl,EN,Yes,Tarek,Hassanein,Southern California Research Center,"Gastroenterology, Transplant Hepatology, and Internal Medicine",thassanein@researchscrc.com,6195220330 and 6199901698,"Orange Avenue 131, Suite 101",Coronado,California,92118,United States,Yes,Kasey,Seyer,Southern California Research Center,kasey@researchscrc.com,6195220330,"131 Orange Avenue, Suite 101",Coronado,California,92118,Kasey,Seyer,Senior Clinical Research Coordinator,kasey@researchscrc.com,6195220330,Different from the above,Fatma,Barakat,Admin/Clinical Research Scientist,fbarakat@researchscrc.com,6193193993,Other,Fatma,Barakat,Admin/Clinical Research Scientist,fbarakat@researchscrc.com,6193193993,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,,1,,,,31-45%,,,Yes,No,,1 study,2,1,1,98,0.5,0.5,0,0,1,Mixed,45,55,0,90,10,55,45,Yes,Yes,Spanish,No,Yes,"None. However, recruitment will be boosted if J&J can provide outside referrals as well as adequateparticipant stipends, compensation and transportation assistance.",None.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30015378,60022066,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Southern California Research Center,Orange Avenue 131,Coronado,United States,California,92118,Tarek,Hassanein,6195435459,thassanein@researchscrc.com,jnowak2@its.jnj.com,137091,CG_2EfPrfaTOSnlJYp,18 Jun 2026,02:53 +2026-06-10 13:55:33,2026-06-17 15:46:28,IP Address,189.216.168.63,100,611454,True,2026-06-17 15:46:28,R_6NzF3Plduoi9SVF,Rodriguez Negrete,Elda Victoria,jev_rn@yahoo.com.mx,,19.3837,-99.1757,gl,EN,No,Elda Victoria,Rodriguez Negrete,Hidra Investigacion - Mexico City,Gastroenterologia,jev_rn@yahoo.com.mx,5215517019736,Av. Rio Churubusco No. 594 4o piso Colonia del Carmen,Mexico City,Coyoacan,04100,Mexico,Yes,Lizeth Aidee,Albores Velazquez,"Centro de Investigación Clínica Chapultepec S.A. de C.V. ",lizeth.albores@hidrainvestigacion.com,4431478500,"Av. Rio Churubusco No. 594, 4° Piso Col. Del Carmen, Coyoacán, C.P. 04100",Mexico City,Mexico City,04100,Ana Julieta,Valdez Ventura,Regulatory Affairs,julieta.valdez@hidrainvestigacion.com,4431478500,Same as above,,,,,,Other,Ana Julieta,Valdez Ventura,Regulatory Affairs,julieta.valdez@hidrainvestigacion.com,4431478500,,,,,Yes,,,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,1,1,1,1,31-45%,31-45%,31-45%,31-45%,Yes,No,,0 studies,4,2,2,10,0,0,0,0,90,Mestizo,95,5,0,90,10,45,55,Yes,Yes,Spanish,No,Yes,Is important that recruitment material will be provided.,No,,,,,,,,,,,,,,,,180,40,140,18,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,1,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,5,5,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30113017,60905957,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hidra Investigacion - Mexico City,Av. Rio Churubusco No. 594 4o piso Colonia del Carmen,Mexico City,Mexico,Coyoacan,04100,Elda Victoria,Rodriguez Negrete,5215517019736,jev_rn@yahoo.com.mx,vcastan4@its.jnj.com,136601,CG_uf6Us9sgaYYVZ2F,18 Jun 2026,03:16 +2026-06-15 07:54:55,2026-06-17 16:21:39,IP Address,216.59.243.6,100,203204,True,2026-06-17 16:21:40,R_1NthoNoWBRy3C5r,Liu,Eddie,eliu329@gmail.com,,43.0832,-81.3851,gl,EN,Yes,Eddie,Liu,Niagara Gastroenterology & Specialists,Gastroenterology,eliu329@gmail.com,905-351-8581,3250 Schmon Parkway,Thorold,Ontario,L2V 4Y6,Canada,Yes,Heather,Prins,Niagara Gastroenterology & Specialists,hprins311@gmail.com,5197193408,"3250 Schmod Parkway, Unit 10",Thorold,ON,L2V 4Y6,Heather,Prins,SC,hprins2@lddi.ca,519-204-7902,Different from the above,Melanie,Vitez,SC,mvitez2@lddi.ca,519-204-7903,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,1,1,16-30%,16-30%,16-30%,≤15%,No,No,,1 study,3,2,1,60,10,10,10,10,0,,10,90,0,70,30,50,50,No,No,,No,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,139522,139522,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Niagara Gastroenterology & Specialists,3250 Schmon Parkway,Thorold,Canada,Ontario,L2V 4Y6,Eddie,Liu,905-351-8581,eliu329@gmail.com,tresuell@its.jnj.com,139522,CG_1pRxtMGMwd8yOGJ,18 Jun 2026,03:51 +2026-06-15 07:55:43,2026-06-17 16:46:59,IP Address,216.59.243.6,100,204676,True,2026-06-17 16:47:00,R_6onT6rrirNjBH57,Rai,Rajbir,dr.rai.rs@gmail.com,,43.0832,-81.3851,gl,EN,No,Rajbir,Rai,Brantford GI Research Group,Gastroenterology,dr.rai.rs@gmail.com,416-845-4583,17 Corporate Place,Brantford,Ontario,N3R 8A6,Canada,Yes,Heather,Prins,Brantford GI Research Group,hprins3@lddi.ca,519-204-7902,17 Corporate Place,Brantford,ON,N3R 8A6,Heather,Prins,SC,hprins3@lddi.ca,519-204-7902,Different from the above,Melanie,Vitez,SC,mvitez3@lddi.ca,519-204-7903,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, partially reimbursed/covered by insurance",,1,1,1,1,16-30%,16-30%,16-30%,≤15%,No,No,,1 study,3,1,2,60,10,10,10,10,0,,10,90,0,70,30,50,50,No,No,,No,No,,,,,,,,,,,,,,,,,,250,150,90,50,20,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,5,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Central,2,,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,139523,139523,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Brantford GI Research Group,17 Corporate Place,Brantford,Canada,Ontario,N3R 8A6,Rajbir,Rai,416-845-4583,dr.rai.rs@gmail.com,tresuell@its.jnj.com,139523,CG_32LaoSVetKGHSli,18 Jun 2026,04:16 +2026-06-16 19:00:52,2026-06-17 19:30:38,IP Address,165.229.210.7,100,88186,True,2026-06-17 19:30:39,R_9jqVUX4h6NDEd9A,Jang,Byung Ik,jbi@med.yu.ac.kr,,35.8385,128.5888,gl,EN,No,Byung Ik,Jang,Yeungnam University Medical Center,"gastroenterology ",jbi@med.yu.ac.kr,82536203897,170 Hyeonchung-ro,Daegu,North Gyeongsang Province,705-033,South Korea,Yes,"jungsoon ","jang ","yeungnam ",img01@ymc.yu.ac.kr,01085842494,"Division of Gastroenterology, Department of Internal Medicine, Yeungnam University Hospital",Daegu,NA,42415,ByungIk,Jang,PI,jbi@med.yu.ac.kr,01074707172,Same as above,,,,,,Research Coordinator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,,,,,,,,No,No,,1 study,3,0,3,0,100,0,0,0,0,,0,100,0,85,15,45,55,Yes,No,,No,No,NA,NA,,,,,,,,,,,,,,,,210,140,70,16,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,4,5,3-5,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,2,2,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30113565,60202950,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Yeungnam University Medical Center,170 Hyeonchung-ro,Daegu,South Korea,North Gyeongsang Province,705-033,Byung Ik,Jang,82536203897,jbi@med.yu.ac.kr,yjung21@its.jnj.com,137745,CG_2verizDWXuW6NNG,18 Jun 2026,07:00 +2026-06-05 10:13:21,2026-06-17 19:36:58,IP Address,68.129.188.252,100,1070616,True,2026-06-17 19:36:58,R_301zegJMULv0ScO,Desai,Jay,jay.desai@nygahealth.com,,40.8205,-73.9183,gl,EN,Yes,Jay,Desai,New York Gastroenterology Associates,"Gastroenterology ",jay.desai@nygahealth.com,+1 212 369 2490,"311 East 79th Street ",New York City,New York,10075,United States,Yes,Salitah,Qureshi,New York Gastroenterology Associates,Salitah.qureshi@nygahealth.com,3472488719,311 East 79th Street,New York,NY,10075,Salitah,Qureshi,Research Manager,Salitah.qureshi@nygahealth.com,3472488719,Same as above,,,,,,Research Coordinator,,,,,,Yes,,,,,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,,,>60%,46-60%,,,Yes,No,,2 studies,2,1,1,50,20,20,5,5,0,,30,70,0,60,40,50,50,Yes,Yes,Spanish,Yes,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30070245,60019653,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,New York Gastroenterology Associates,East 79th Street 311,New York City,United States,New York,10075,Arthur,Kornbluth,+1 212 369 2490,asher.kornbluth@nygh.md,jnowak2@its.jnj.com,137115,CG_ZqS8IHsmqnw123T,18 Jun 2026,07:06 +2026-06-10 13:04:14,2026-06-17 20:18:40,IP Address,177.232.88.186,100,630866,True,2026-06-17 20:18:41,R_5mVqLUoh8cMjouD,Vega Fonseca,Jose Luis,vfjljol@yahoo.com.mx,,22.1384,-100.9364,gl,EN,No,Jose Luis,Vega Fonseca,Centro de Alta Especialidad en Reumatologia e Investigacion,Gastroenterology,vfjljol@yahoo.com.mx,524448084352,José I. Puebla 210,San Luis Potosí,San Luis Potosí,78213,Mexico,Yes,Rodrigo,Martínez de la Luz,"Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, S.C.",rodrigo.martinez.delaluz@gmail.com,+524448084352,"Jose I. Puebla 210, Col. Burocratas del Estado",San Luis Potosi,San Luis Potosi,78213,Rodrigo,Martinez de la Luz,Clinical Research Director,rodrigo.martinez.delaluz@gmail.com,+524448084352,Different from the above,"Juan Cruz ",Rizo Rodriguez,Main Director,cerisc2009@gmail.com,+524448084352,Principal Investigator,,,,,,,,,,Yes,,,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","No, not reimbursed/covered by insurance",,1,1,,,≤15%,≤15%,,,No,Yes,there is a competitive clinical trial at site (UC subjects) sponsored by the same Sponsor,1 study,4,2,2,99,0,0,1,0,0,,95,5,0,60,40,40,60,Yes,Yes,Spanish and english,Yes,No,Regulatory timelines and support due to there is competitive clinical trial at site,Competitive clinical trial at site,NA,,,,,NA,,,,,NA,,,,,10,2,8,1,0,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,0,2,1-2,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Local,,2,3,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30113494,60326087,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centro de Alta Especialidad en Reumatologia e Investigacion,José I. Puebla 210,San Luis Potosí,Mexico,San Luis Potosí,78213,Jose Luis,Vega Fonseca,524448084352,vfjljol@yahoo.com.mx,vcastan4@its.jnj.com,136603,CG_3PoAwutNervumhl,18 Jun 2026,07:48 +2026-06-16 18:51:37,2026-06-17 22:53:11,IP Address,221.162.243.100,100,100894,True,2026-06-17 22:53:12,R_4Oe2lqWLvzEl9vE,Kim,Taeoh,kto0440@paik.ac.kr,,35.1692,129.1738,gl,EN,No,Taeoh,Kim,Inje University Haeundae Paik Hospital,Gastroenterology,kto0440@paik.ac.kr,82517970200,"875, Haeun-daero, Haeundae-gu",Busan,South Gyeongsang Province,612-030,South Korea,Yes,"kyoungmi ",cho,Inje University Haeundae Paik Hospital,ckmlove0@naver.com,+82+51-797-0475,"Clinical Trial Center (B2 floor) 875, Haeundae-ro, Haeundae-gu",Busan,Busan,48108,,,,,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV induction followed by SC self‑administration","Yes, fully reimbursed/covered by insurance",,1,1,1,,31-45%,16-30%,≤15%,,Yes,No,,More than 2 studies,4,2,2,0,100,0,0,0,0,,0,100,0,90,10,60,40,Yes,No,,No,No,,,,,,,,,,,,,,,,,,1000,500,450,200,150,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,10,13,≥6,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Local,,4,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30116477,60238626,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Inje University Haeundae Paik Hospital,"875, Haeun-daero, Haeundae-gu",Busan,South Korea,South Gyeongsang Province,612-030,Taeoh,Kim,82517970200,kto0440@paik.ac.kr,yjung21@its.jnj.com,137749,CG_72nB8tKDi1Djbnr,18 Jun 2026,10:23 +2026-06-01 04:33:56,2026-06-17 23:55:05,IP Address,213.222.56.114,100,1452068,True,2026-06-17 23:55:05,R_2gcnAwYoz17s69F,Churchev,Jordan,churchev@abv.bg,,42.7128,23.282,gl,EN,No,Jordan,Churchev,Multiprofile Hospital for Active Treatment - Doverie,gastroenterology,churchev@abv.bg,35924036211,2 Friedrich Grunanger str.,Sofia,Sofia City Province,1632,Bulgaria,No,,,,,,,,,,Jordan,Churchev,MD,churchev@abv.bg,,Same as above,,,,,,Principal Investigator,,,,,,,,,,,,Yes,"Yes, I am interested",,,,"Yes, approved for IV infusion only","Yes, fully reimbursed/covered by insurance",,,1,,,46-60%,≤15%,≤15%,≤15%,Yes,No,,0 studies,3,2,2,100,0,0,0,0,0,,0,100,0,80,20,60,40,Yes,No,,Yes,No,,,Jordan Churcheb,,,,,MHAT Doverie Sofia,,,,,churchev@abv.bg,,,,,5,3,2,1,1,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,,1,1,1-2,Yes,No,No,Yes,Yes,Yes,Yes,No,Central,8,,4,Yes,,sipIQ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30107177,60632406,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Multiprofile Hospital for Active Treatment - Doverie,2 Friedrich Grunanger str.,Sofia,Bulgaria,Sofia City Province,1632,Jordan,Churchev,35924036211,churchev@abv.bg,imitkova@its.jnj.com,136268,CG_1owhhUuVaLgXGfK,18 Jun 2026,11:25 diff --git a/Feasibility/TRASH/sipiq_report_v1.0.py b/Feasibility/TRASH/sipiq_report_v1.0.py new file mode 100644 index 0000000..64cd5b3 --- /dev/null +++ b/Feasibility/TRASH/sipiq_report_v1.0.py @@ -0,0 +1,216 @@ +#!/usr/bin/env python3 +# -*- coding: utf-8 -*- +""" +sipiq_report_v1.0.py +==================== +Verze: 1.0 +Datum: 2026-06-17 +Autor: Claude Code (pro MUDr. Vladimíra Buzalku) + +Popis +----- +Přehledný Excel report SIPIQ odpovědí: OTÁZKY ve sloupci A (v pořadí SIPIQ, seskupené +dle sekcí), CENTRA ve sloupcích (B+). Buňka = odpověď daného centra na danou otázku. +Tj. vyplněné SIPIQ všech center vedle sebe (= transponovaná rekonstrukce dotazníku). + +Zdroj: MongoDB feasibility (sipiq_questions = slovník + pořadí + sekce + items; +sipiq_responses = odpovědi + answers_supplement z doplnujici_dotazy). + +Layout: + - hlavička 2 řádky: příjmení PI + název centra (a země) + - blok IDENTITA (země/město/PI/e-mail/sdl_site_id/datum vyplnění) + - sekce SIPIQ jako barevné mezititulky, otázky a položky matic v řádcích + - Yes = zelená, No = červená; doplněné odpovědi (answers_supplement) = oranžová + kurzíva + komentář + - freeze panes (sloupec A + hlavička), ohraničení, vhodné šířky + +Výstup: u:\\Dropbox\\!!!Days\\Downloads Z230\\SIPIQ_prehled_center_.xlsx +Závislosti: pymongo, openpyxl (.venv). Mongo 192.168.1.76:27017, bez auth. +""" +import os +import re +from datetime import datetime + +from pymongo import MongoClient +from openpyxl import Workbook +from openpyxl.styles import Font, PatternFill, Alignment, Border, Side +from openpyxl.comments import Comment +from openpyxl.utils import get_column_letter + +MONGO_URI = "mongodb://192.168.1.76:27017" +DB = "feasibility" +OUT_DIR = r"u:\Dropbox\!!!Days\Downloads Z230" +SKIP_SECTIONS = {"Confidentiality Statement"} # dlouhé právní souhlasy, ne data +COUNTRY_ABBR = {"Czech Republic": "CZ", "Slovakia": "SK"} + +# barvy +C_SECTION = PatternFill("solid", fgColor="1F4E78") # tmavě modrá +C_STEM = PatternFill("solid", fgColor="DDEBF7") # světle modrá +C_IDENT = PatternFill("solid", fgColor="F2F2F2") # světle šedá +C_HEAD = PatternFill("solid", fgColor="305496") # hlavička center +C_YES = PatternFill("solid", fgColor="C6EFCE") # zelená +C_NO = PatternFill("solid", fgColor="FFC7CE") # červená +C_SUPP = PatternFill("solid", fgColor="FFE699") # oranžová (doplněno) +THIN = Side(style="thin", color="BFBFBF") +BORDER = Border(left=THIN, right=THIN, top=THIN, bottom=THIN) +WRAP_TOP = Alignment(wrap_text=True, vertical="top") +WRAP_CTR = Alignment(wrap_text=True, vertical="center", horizontal="center") + + +def fmt_date(s): + if not s: + return "" + try: + return datetime.strptime(str(s)[:10], "%Y-%m-%d").strftime("%d%b%Y").upper() + except Exception: + return str(s)[:10] + + +def main(): + client = MongoClient(MONGO_URI, serverSelectionTimeoutMS=8000) + db = client[DB] + client.admin.command("ping") + + questions = list(db.sipiq_questions.find().sort("order", 1)) + resp = list(db.sipiq_responses.find()) + # seřadit centra: CZ -> SK, pak příjmení + resp.sort(key=lambda r: (COUNTRY_ABBR.get(r.get("site_country"), "ZZ"), + (r.get("pi_last_name") or "").lower())) + n = len(resp) + print(f"Otázek: {len(questions)} | center: {n}") + + wb = Workbook() + ws = wb.active + ws.title = "SIPIQ přehled" + + # --- hlavička center (2 řádky) --- + ws.cell(1, 1, "OTÁZKA \\ CENTRUM").font = Font(bold=True, color="FFFFFF") + ws.cell(2, 1, "").font = Font(bold=True, color="FFFFFF") + ws.merge_cells("A1:A2") + for j, r in enumerate(resp): + col = 2 + j + c1 = ws.cell(1, col, r.get("pi_last_name") or "?") + cc = COUNTRY_ABBR.get(r.get("site_country"), "?") + c2 = ws.cell(2, col, f"{r.get('site_name') or ''} [{cc}]") + for c in (c1, c2): + c.font = Font(bold=True, color="FFFFFF", size=9) + c.fill = C_HEAD + c.alignment = WRAP_CTR + c.border = BORDER + ws.cell(1, 1).fill = C_HEAD + ws.cell(1, 1).alignment = WRAP_CTR + + row = 3 + + def ident_row(label, getter): + nonlocal row + a = ws.cell(row, 1, label) + a.font = Font(bold=True) + a.fill = C_IDENT + a.alignment = WRAP_TOP + a.border = BORDER + for j, r in enumerate(resp): + c = ws.cell(row, 2 + j, getter(r)) + c.fill = C_IDENT + c.alignment = WRAP_TOP + c.border = BORDER + row += 1 + + # --- IDENTITA --- + sec = ws.cell(row, 1, "■ IDENTITA CENTRA") + sec.font = Font(bold=True, color="FFFFFF") + sec.fill = C_SECTION + for j in range(n): + ws.cell(row, 2 + j).fill = C_SECTION + row += 1 + ident_row("Země", lambda r: COUNTRY_ABBR.get(r.get("site_country"), r.get("site_country") or "")) + ident_row("Město", lambda r: r.get("site_city") or "") + ident_row("PI", lambda r: f"{r.get('pi_first_name') or ''} {r.get('pi_last_name') or ''}".strip()) + ident_row("E-mail PI", lambda r: r.get("pi_email") or "") + ident_row("sdl_site_id", lambda r: r.get("sdl_site_id") or "") + ident_row("Datum vyplnění", lambda r: fmt_date((r.get("meta") or {}).get("recorded_date"))) + + # --- OTÁZKY po sekcích --- + cur_section = None + for q in questions: + section = q.get("section") or "Other" + if section in SKIP_SECTIONS: + continue + if section != cur_section: + cur_section = section + sc = ws.cell(row, 1, f"■ {section.upper()}") + sc.font = Font(bold=True, color="FFFFFF") + sc.fill = C_SECTION + sc.alignment = WRAP_TOP + sc.border = BORDER + for j in range(n): + cc = ws.cell(row, 2 + j) + cc.fill = C_SECTION + cc.border = BORDER + row += 1 + + base = q["_id"] + items = q.get("items") or [] + if not items: + _emit_answer_row(ws, row, f'{base} — {q.get("text") or ""}', base, resp, stem=False) + row += 1 + else: + # stem řádek (text otázky) — bez hodnot + sc = ws.cell(row, 1, f'{base} — {q.get("text") or ""}') + sc.font = Font(bold=True) + sc.fill = C_STEM + sc.alignment = WRAP_TOP + sc.border = BORDER + for j in range(n): + cc = ws.cell(row, 2 + j) + cc.fill = C_STEM + cc.border = BORDER + row += 1 + for it in items: + lbl = it.get("label") or "(odpověď)" + _emit_answer_row(ws, row, f" – {lbl}", it["key"], resp, stem=False) + row += 1 + + # --- formátování --- + ws.freeze_panes = "B3" + ws.column_dimensions["A"].width = 58 + for j in range(n): + ws.column_dimensions[get_column_letter(2 + j)].width = 20 + ws.row_dimensions[1].height = 28 + ws.row_dimensions[2].height = 40 + + os.makedirs(OUT_DIR, exist_ok=True) + ts = datetime.now().strftime("%Y%m%d_%H%M") + out = os.path.join(OUT_DIR, f"SIPIQ_prehled_center_{ts}.xlsx") + wb.save(out) + print(f"Uloženo: {out}") + client.close() + + +def _emit_answer_row(ws, row, label, key, resp, stem): + a = ws.cell(row, 1, label) + a.alignment = WRAP_TOP + a.border = BORDER + for j, r in enumerate(resp): + ans = (r.get("answers") or {}) + supp = (r.get("answers_supplement") or {}) + c = ws.cell(row, 2 + j) + c.alignment = WRAP_TOP + c.border = BORDER + if key in supp: + val = (supp[key] or {}).get("value") + c.value = val + c.fill = C_SUPP + c.font = Font(italic=True) + src = (supp[key] or {}).get("answer_source") or "doplněno" + c.comment = Comment(f"Doplněno mimo SIPIQ: {src}", "sipiq_report") + else: + val = ans.get(key) + c.value = val + if val == "Yes": + c.fill = C_YES + elif val == "No": + c.fill = C_NO + + +if __name__ == "__main__": + main() diff --git a/Feasibility/sipiq_report_v1.1.md b/Feasibility/sipiq_report_v1.1.md new file mode 100644 index 0000000..7d580cf --- /dev/null +++ b/Feasibility/sipiq_report_v1.1.md @@ -0,0 +1,33 @@ +# sipiq_report_v1.1 — přehledný Excel report SIPIQ (centra × otázky) + +**Verze:** 1.1 · **Datum:** 2026-06-17 · **Studie:** 77242113UCO3002 (ICONIC / DAWN) + +## Co dělá +Excel report: **otázky ve sloupci A** (v pořadí SIPIQ, seskupené dle sekcí), **centra ve sloupcích** +(B+). Buňka = odpověď centra na otázku → vyplněné SIPIQ všech center vedle sebe. +Čte z MongoDB `feasibility`: `sipiq_questions` (slovník+pořadí+sekce+items) + `sipiq_responses` +(answers + `answers_supplement`). + +## Layout +- Hlavička 2 řádky: **příjmení PI** + **název centra [země]**; centra seřazena CZ→SK, pak příjmení. +- Blok **IDENTITA** (země/město/PI/e-mail/sdl_site_id/datum vyplnění). +- Sekce SIPIQ jako barevné mezititulky; jednotlivé otázky a položky matic v řádcích. +- **Yes=zelená, No=červená**; doplněné odpovědi (`answers_supplement`) = oranžová + kurzíva + komentář se zdrojem. +- **Freeze panes B3** (sloupec A + hlavička), ohraničení, šířky (A=58, centra=20). + +## Změny proti v1.0 +- **Contact Information SBALENA** do 5 řádků (má koordinátora? / koordinátor jméno+e-mail / + CDA vyjednává / dotazník vyplnil) místo ~44; PI je už v IDENTITA. → `COMPACT_CONTACT`. +- **Q54** (doporučení dalších center) = JEDEN zřetězený řádek místo rozbitých „PI Name: - No Name" řádků. +- Confidentiality Statement (Q14–Q21, právní souhlasy) se vynechává (`SKIP_SECTIONS`). +- Řádků: 179 → 126. + +## Použití +``` +.venv\Scripts\python.exe Feasibility\sipiq_report_v1.1.py +``` +Výstup: `u:\Dropbox\!!!Days\Downloads Z230\SIPIQ_prehled_center_.xlsx`. +Bez argumentů — vždy aktuální stav DB (vč. doplněných odpovědí). pymongo + openpyxl. + +## Stav 17JUN2026 +56 otázek × 15 center, 126 řádků. v1.0 v `Feasibility\TRASH`. diff --git a/Feasibility/sipiq_report_v1.1.py b/Feasibility/sipiq_report_v1.1.py new file mode 100644 index 0000000..f75da0a --- /dev/null +++ b/Feasibility/sipiq_report_v1.1.py @@ -0,0 +1,220 @@ +#!/usr/bin/env python3 +# -*- coding: utf-8 -*- +""" +sipiq_report_v1.1.py +==================== +Verze: 1.1 +Datum: 2026-06-17 +Autor: Claude Code (pro MUDr. Vladimíra Buzalku) + +Změny proti v1.0 +---------------- +- Contact Information SBALENA do kompaktního bloku (koordinátor jméno+e-mail, má koordinátora?, + kdo vyjednává CDA, kdo vyplnil dotazník) místo ~44 řádků; PI je už v bloku IDENTITA. +- Q54 (doporučení dalších center) sloučeno do JEDNOHO řádku (zřetězené neprázdné hodnoty) + místo rozbitých „PI Name: - No Name - -" řádků. Stará v1.0 v TRASH. + +Popis +----- +Přehledný Excel report SIPIQ: OTÁZKY ve sloupci A (pořadí + sekce), CENTRA ve sloupcích (B+). +Zdroj MongoDB feasibility (sipiq_questions + sipiq_responses + answers_supplement). +Yes=zelená, No=červená; doplněné odpovědi oranžová+kurzíva+komentář; freeze panes B3. + +Výstup: u:\\Dropbox\\!!!Days\\Downloads Z230\\SIPIQ_prehled_center_.xlsx +Závislosti: pymongo, openpyxl (.venv). Mongo 192.168.1.76:27017, bez auth. +""" +import os +from datetime import datetime + +from pymongo import MongoClient +from openpyxl import Workbook +from openpyxl.styles import Font, PatternFill, Alignment, Border, Side +from openpyxl.comments import Comment +from openpyxl.utils import get_column_letter + +MONGO_URI = "mongodb://192.168.1.76:27017" +DB = "feasibility" +OUT_DIR = r"u:\Dropbox\!!!Days\Downloads Z230" +SKIP_SECTIONS = {"Confidentiality Statement"} +COUNTRY_ABBR = {"Czech Republic": "CZ", "Slovakia": "SK"} + +# kompaktní Contact Information: (label, [answer keys], spojovník) +COMPACT_CONTACT = [ + ("Má centrum koordinátora?", ["Q7"], ""), + ("Koordinátor (jméno)", ["Q8_2", "Q8_1"], " "), + ("Koordinátor (e-mail)", ["Q8_8"], ""), + ("CDA vyjednává", ["Q10"], ""), + ("Dotazník vyplnil", ["Q12"], ""), +] + +C_SECTION = PatternFill("solid", fgColor="1F4E78") +C_STEM = PatternFill("solid", fgColor="DDEBF7") +C_IDENT = PatternFill("solid", fgColor="F2F2F2") +C_HEAD = PatternFill("solid", fgColor="305496") +C_YES = PatternFill("solid", fgColor="C6EFCE") +C_NO = PatternFill("solid", fgColor="FFC7CE") +C_SUPP = PatternFill("solid", fgColor="FFE699") +THIN = Side(style="thin", color="BFBFBF") +BORDER = Border(left=THIN, right=THIN, top=THIN, bottom=THIN) +WRAP_TOP = Alignment(wrap_text=True, vertical="top") +WRAP_CTR = Alignment(wrap_text=True, vertical="center", horizontal="center") + + +def fmt_date(s): + if not s: + return "" + try: + return datetime.strptime(str(s)[:10], "%Y-%m-%d").strftime("%d%b%Y").upper() + except Exception: + return str(s)[:10] + + +def main(): + client = MongoClient(MONGO_URI, serverSelectionTimeoutMS=8000) + db = client[DB] + client.admin.command("ping") + + questions = list(db.sipiq_questions.find().sort("order", 1)) + resp = list(db.sipiq_responses.find()) + resp.sort(key=lambda r: (COUNTRY_ABBR.get(r.get("site_country"), "ZZ"), + (r.get("pi_last_name") or "").lower())) + n = len(resp) + print(f"Otázek: {len(questions)} | center: {n}") + + wb = Workbook() + ws = wb.active + ws.title = "SIPIQ přehled" + state = {"row": 1} + + # --- hlavička center --- + h = ws.cell(1, 1, "OTÁZKA \\ CENTRUM") + h.font = Font(bold=True, color="FFFFFF"); h.fill = C_HEAD; h.alignment = WRAP_CTR + ws.cell(2, 1, "") + ws.merge_cells("A1:A2") + for j, r in enumerate(resp): + cc = COUNTRY_ABBR.get(r.get("site_country"), "?") + for rr, val in ((1, r.get("pi_last_name") or "?"), (2, f"{r.get('site_name') or ''} [{cc}]")): + c = ws.cell(rr, 2 + j, val) + c.font = Font(bold=True, color="FFFFFF", size=9); c.fill = C_HEAD + c.alignment = WRAP_CTR; c.border = BORDER + state["row"] = 3 + + def section_header(title): + row = state["row"] + sc = ws.cell(row, 1, f"■ {title.upper()}") + sc.font = Font(bold=True, color="FFFFFF"); sc.fill = C_SECTION + sc.alignment = WRAP_TOP; sc.border = BORDER + for j in range(n): + c = ws.cell(row, 2 + j); c.fill = C_SECTION; c.border = BORDER + state["row"] += 1 + + def combo_row(label, keys, sep, fill=None): + row = state["row"] + a = ws.cell(row, 1, label) + a.alignment = WRAP_TOP; a.border = BORDER + if fill: + a.fill = fill; a.font = Font(bold=True) + for j, r in enumerate(resp): + ans = r.get("answers") or {} + supp = r.get("answers_supplement") or {} + c = ws.cell(row, 2 + j); c.alignment = WRAP_TOP; c.border = BORDER + if fill: + c.fill = fill + vals, supp_hit, supp_src = [], False, None + for k in keys: + if k in supp: + vals.append((supp[k] or {}).get("value")); supp_hit = True + supp_src = (supp[k] or {}).get("answer_source") or "doplněno" + elif ans.get(k): + vals.append(ans.get(k)) + val = sep.join(x for x in vals if x) + c.value = val or None + if supp_hit: + c.fill = C_SUPP; c.font = Font(italic=True) + c.comment = Comment(f"Doplněno mimo SIPIQ: {supp_src}", "sipiq_report") + elif val == "Yes": + c.fill = C_YES + elif val == "No": + c.fill = C_NO + state["row"] += 1 + + # --- IDENTITA --- + section_header("Identita centra") + for label, getter in [ + ("Země", lambda r: COUNTRY_ABBR.get(r.get("site_country"), r.get("site_country") or "")), + ("Město", lambda r: r.get("site_city") or ""), + ("PI", lambda r: f"{r.get('pi_first_name') or ''} {r.get('pi_last_name') or ''}".strip()), + ("E-mail PI", lambda r: r.get("pi_email") or ""), + ("sdl_site_id", lambda r: r.get("sdl_site_id") or ""), + ("Datum vyplnění", lambda r: fmt_date((r.get("meta") or {}).get("recorded_date"))), + ]: + row = state["row"] + a = ws.cell(row, 1, label); a.font = Font(bold=True); a.fill = C_IDENT + a.alignment = WRAP_TOP; a.border = BORDER + for j, r in enumerate(resp): + c = ws.cell(row, 2 + j, getter(r)); c.fill = C_IDENT + c.alignment = WRAP_TOP; c.border = BORDER + state["row"] += 1 + + # --- OTÁZKY po sekcích --- + cur_section = None + contact_done = False + for q in questions: + section = q.get("section") or "Other" + if section in SKIP_SECTIONS: + continue + + if section == "Contact Information": + if contact_done: + continue + section_header("Kontakty (koordinátor / CDA / vyplnil)") + for label, keys, sep in COMPACT_CONTACT: + combo_row(label, keys, sep) + contact_done = True + cur_section = section + continue + + if section != cur_section: + section_header(section) + cur_section = section + + base = q["_id"] + # Q54 = doporučení dalších center -> jeden zřetězený řádek + if base == "Q54": + keys = [it["key"] for it in (q.get("items") or [])] or [base] + combo_row("Q54 — Doporučená další centra/investigátoři", keys, "; ") + continue + + items = q.get("items") or [] + if not items: + combo_row(f'{base} — {q.get("text") or ""}', [base], "") + else: + row = state["row"] + sc = ws.cell(row, 1, f'{base} — {q.get("text") or ""}') + sc.font = Font(bold=True); sc.fill = C_STEM + sc.alignment = WRAP_TOP; sc.border = BORDER + for j in range(n): + c = ws.cell(row, 2 + j); c.fill = C_STEM; c.border = BORDER + state["row"] += 1 + for it in items: + lbl = it.get("label") or "(odpověď)" + combo_row(f" – {lbl}", [it["key"]], "") + + # --- formátování --- + ws.freeze_panes = "B3" + ws.column_dimensions["A"].width = 58 + for j in range(n): + ws.column_dimensions[get_column_letter(2 + j)].width = 20 + ws.row_dimensions[1].height = 28 + ws.row_dimensions[2].height = 40 + + os.makedirs(OUT_DIR, exist_ok=True) + ts = datetime.now().strftime("%Y%m%d_%H%M") + out = os.path.join(OUT_DIR, f"SIPIQ_prehled_center_{ts}.xlsx") + wb.save(out) + print(f"Uloženo: {out}") + client.close() + + +if __name__ == "__main__": + main() diff --git a/KPC/_list_cats_v0.py b/KPC/_list_cats_v0.py new file mode 100644 index 0000000..e798ffb --- /dev/null +++ b/KPC/_list_cats_v0.py @@ -0,0 +1,34 @@ +"""_list_cats_v0.py — DOČASNÉ: vypíše nedávné e-maily mailboxu (argv[1]) + jejich kategorie.""" +import sys +sys.stdout.reconfigure(encoding="utf-8") +import msal, requests + +TENANT_ID="7d269944-37a4-43a1-8140-c7517dc426e9" +CLIENT_ID="4b222bfd-78c9-4239-a53f-43006b3ed07f" +CLIENT_SECRET="Txg8Q~MjhocuopxsJyJBhPmDfMxZ2r5WpTFj1dfk" +AUTHORITY=f"https://login.microsoftonline.com/{TENANT_ID}" +mailbox = sys.argv[1] if len(sys.argv) > 1 else "vladimir.buzalka@buzalka.cz" +BASE=f"https://graph.microsoft.com/v1.0/users/{mailbox}" + +app=msal.ConfidentialClientApplication(CLIENT_ID,authority=AUTHORITY,client_credential=CLIENT_SECRET) +tok=app.acquire_token_for_client(scopes=["https://graph.microsoft.com/.default"]) +H={"Authorization":f"Bearer {tok['access_token']}"} + +# 1) nejnovějších 20 e-mailů (napříč schránkou) +r=requests.get(f"{BASE}/messages",headers=H,params={ + "$top":20,"$orderby":"receivedDateTime desc", + "$select":"subject,from,receivedDateTime,categories"},timeout=30) +print(f"[{mailbox}] nejnovějších {len(r.json().get('value',[]))}:") +for m in r.json().get("value",[]): + cats=m.get("categories") or [] + frm=m.get("from",{}).get("emailAddress",{}).get("address","") + flag=" <<< KATEGORIE" if cats else "" + print(f" {m.get('receivedDateTime','')[:10]} | {frm:28.28} | {str(cats):28} | {m.get('subject','')[:50]}{flag}") + +# 2) cokoliv s kategorií obsahující KPC/Claude (zkus víc názvů) +print("\nHledám kategorie ~ KPC/Claude:") +for cat in ["ForKPCGeneration","KPCzpracovánoClaudem","KPC","ForKPC","Claude","Pro Tebe","ProClaude"]: + rr=requests.get(f"{BASE}/messages",headers=H,params={ + "$filter":f"categories/any(c:c eq '{cat}')","$select":"subject","$top":5},timeout=30) + n=len(rr.json().get("value",[])) if rr.ok else f"ERR{rr.status_code}" + print(f" '{cat}': {n}") diff --git a/KPC/_process_clk_v0.py b/KPC/_process_clk_v0.py new file mode 100644 index 0000000..c90c269 --- /dev/null +++ b/KPC/_process_clk_v0.py @@ -0,0 +1,92 @@ +"""_process_clk_v0.py — DOČASNÉ: zpracuje manželčin ČLK příspěvek (mini-agent). +Telegram potvrzení → ano → KPC (plátce ordinace) → Dropbox → přehození kategorie. +""" +import sys +from datetime import date +from pathlib import Path + +sys.stdout.reconfigure(encoding="utf-8") +sys.path.insert(0, r"U:\ordinaceprojekt") +import dropbox, msal, requests +from Knihovny.telegram_notify import zeptej_se_telegram, posli_telegram + +# ── data platby ─────────────────────────────────────────────────────────── +today = date.today() +ddmmyy = today.strftime("%d%m%y") +fdate = today.strftime("%Y-%m-%d") + +DEBIT_NUM = "2800046620" # ordinace (plátce) +CREDIT_NUM = "244484339" # ČLK, bez předčíslí → holé číslo +CREDIT_BANK = "0800" +VS = "5141811171"; KS = "0000" +AMOUNT = 400000 # 4000,00 Kč v haléřích +AV = "clensky prispevek OS CLK 2026 Buzalkova" +SUMMARY = "ČLK příspěvek Buzalková 2026" + +# e-mail ke zpracování (manželčina schránka) +MAILBOX = "michaela.buzalkova@buzalka.cz" +MSG_ID = "AAMkADFkMzE3NDlmLTg3NjQtNDQwNy05Nzc2LWJjYWJkNmNjMjIxZABGAAAAAABEaZtIoWAPQbVWi-ATA8XVBwB8gYSLibM0Q7crRJXlxBlcAAAAAAEMAAB8gYSLibM0Q7crRJXlxBlcAALrbxJcAAA=" + +# ── KPC ─────────────────────────────────────────────────────────────────── +CRLF = "\r\n" +lines = [ + "UHL1" + ddmmyy + " " * 20 + "0" * 28, + "1 1501 000000 2010", + f"2 000000-{DEBIT_NUM} {str(AMOUNT).zfill(14)} {ddmmyy}", + f"{CREDIT_NUM} {str(AMOUNT).zfill(12)} {VS} {CREDIT_BANK}{KS} AV:{AV}", + "3 +", + "5 +", +] +content = CRLF.join(lines) + CRLF +data = content.encode("ascii") +fname = f"{fdate} KPC k platbě [{SUMMARY}].kpc" + +print("=== NÁHLED KPC ===") +print(content.replace("\r\n", "\\r\\n\n"), end="") +print(f"=== {fname} ({len(data)} B) ===\n") + +# ── Telegram potvrzení ──────────────────────────────────────────────────── +msg = ( + "💳 Návrh platby (KPC agent)\n\n" + "ČLK členský příspěvek 2026 — MUDr. Buzalková\n" + "4 000 Kč → 244484339/0800, VS 5141811171\n" + "Z účtu: ordinace 2800046620\n" + "Splatnost: dnes (17.06.2026)\n\n" + "FIO: 2026 zatím nezaplaceno (poslední 2025-04-09) ✅\n\n" + "Vytvořit KPC a nahrát do Dropboxu? Odpověz: ano / ne" +) +odp = zeptej_se_telegram(msg, timeout=150) +print("TELEGRAM odpověď:", repr(odp)) + +if not odp or odp.strip().lower() not in ("ano", "ano.", "yes", "ok"): + print(">> NEPOTVRZENO (ano nepřišlo) — nic nevytvářím.") + sys.exit(0) + +# ── lokální archiv + Dropbox upload ─────────────────────────────────────── +out_dir = Path(__file__).parent / "output"; out_dir.mkdir(exist_ok=True) +(out_dir / fname).write_bytes(data) +print("lokální kopie:", out_dir / fname) + +env = {} +for line in Path(r"U:\PythonProject\Janssen\EmailsImport\.env").read_text(encoding="utf-8").splitlines(): + line = line.strip() + if "=" in line and not line.startswith("#"): + k, v = line.split("=", 1); env[k.strip()] = v.strip() +dbx = dropbox.Dropbox(app_key=env["DROPBOX_APP_KEY"], app_secret=env["DROPBOX_APP_SECRET"], + oauth2_refresh_token=env["DROPBOX_APP_REFRESH_TOKEN"]) +res = dbx.files_upload(data, f"/!!!Days/Downloads Z230/{fname}", + mode=dropbox.files.WriteMode.add, autorename=True) +print("NAHRÁNO →", res.path_display) + +# ── přehození kategorie na manželčině e-mailu ───────────────────────────── +TENANT="7d269944-37a4-43a1-8140-c7517dc426e9"; CID="4b222bfd-78c9-4239-a53f-43006b3ed07f" +SECRET="Txg8Q~MjhocuopxsJyJBhPmDfMxZ2r5WpTFj1dfk" +app=msal.ConfidentialClientApplication(CID,authority=f"https://login.microsoftonline.com/{TENANT}",client_credential=SECRET) +tok=app.acquire_token_for_client(scopes=["https://graph.microsoft.com/.default"]) +H={"Authorization":f"Bearer {tok['access_token']}","Content-Type":"application/json"} +BASE=f"https://graph.microsoft.com/v1.0/users/{MAILBOX}" +rp=requests.patch(f"{BASE}/messages/{MSG_ID}",headers=H,json={"categories":["KPCzpracovánoClaudem"]},timeout=30) +print("PATCH kategorie:", rp.status_code, "" if rp.ok else rp.text[:300]) + +posli_telegram(f"✅ KPC vytvořeno a nahráno:\n{fname}\n4 000 Kč → 244484339/0800 (ČLK Buzalková), z ordinace.\nV bankingu stačí podepsat.") +print(">> HOTOVO.") diff --git a/KPC/_read_v0.py b/KPC/_read_v0.py new file mode 100644 index 0000000..bfd31fa --- /dev/null +++ b/KPC/_read_v0.py @@ -0,0 +1,51 @@ +"""_read_v0.py — DOČASNÉ: přečte ForKPCGeneration e-maily z mailboxu (argv[1]).""" +import sys +sys.stdout.reconfigure(encoding="utf-8") +import msal, requests + +TENANT_ID = "7d269944-37a4-43a1-8140-c7517dc426e9" +CLIENT_ID = "4b222bfd-78c9-4239-a53f-43006b3ed07f" +CLIENT_SECRET = "Txg8Q~MjhocuopxsJyJBhPmDfMxZ2r5WpTFj1dfk" +AUTHORITY = f"https://login.microsoftonline.com/{TENANT_ID}" +SCOPE = ["https://graph.microsoft.com/.default"] +CATEGORY = "ForKPCGeneration" + +mailbox = sys.argv[1] if len(sys.argv) > 1 else "vladimir.buzalka@buzalka.cz" +CATEGORY = sys.argv[2] if len(sys.argv) > 2 else CATEGORY +BASE = f"https://graph.microsoft.com/v1.0/users/{mailbox}" + +app = msal.ConfidentialClientApplication(CLIENT_ID, authority=AUTHORITY, client_credential=CLIENT_SECRET) +tok = app.acquire_token_for_client(scopes=SCOPE) +assert "access_token" in tok, tok +H = {"Authorization": f"Bearer {tok['access_token']}"} + +params = { + "$filter": f"categories/any(c:c eq '{CATEGORY}')", + "$select": "id,subject,from,receivedDateTime,categories,hasAttachments,body,bodyPreview", + "$top": 25, +} +r = requests.get(f"{BASE}/messages", headers=H, params=params, timeout=30) +if not r.ok: + print(f"CHYBA [{r.status_code}] pro {mailbox}: {r.text[:400]}") + sys.exit(1) +msgs = r.json().get("value", []) +print(f"[{mailbox}] e-mailů s kategorií '{CATEGORY}': {len(msgs)}\n") + +for i, m in enumerate(msgs, 1): + frm = m.get("from", {}).get("emailAddress", {}) + print("=" * 78) + print(f"[{i}] {m.get('subject')}") + print(f" od: {frm.get('name')} <{frm.get('address')}>") + print(f" datum: {m.get('receivedDateTime')}") + print(f" přílohy: {m.get('hasAttachments')}") + print(f" id: {m.get('id')}") + body = m.get("body", {}) + print(f" --- TĚLO ({body.get('contentType')}) ---") + print(body.get("content", "")) + if m.get("hasAttachments"): + ra = requests.get(f"{BASE}/messages/{m['id']}/attachments", + headers=H, params={"$select": "id,name,size,contentType,isInline"}, timeout=30) + if ra.ok: + print(" --- PŘÍLOHY ---") + for a in ra.json().get("value", []): + print(f" • {a.get('name')} ({a.get('size')} B, {a.get('contentType')}, inline={a.get('isInline')})") diff --git a/KPC/output/2026-06-17 KPC k platbě [ČLK příspěvek Buzalková 2026].kpc b/KPC/output/2026-06-17 KPC k platbě [ČLK příspěvek Buzalková 2026].kpc new file mode 100644 index 0000000..eba5c44 --- /dev/null +++ b/KPC/output/2026-06-17 KPC k platbě [ČLK příspěvek Buzalková 2026].kpc @@ -0,0 +1,6 @@ +UHL1170626 0000000000000000000000000000 +1 1501 000000 2010 +2 000000-2800046620 00000000400000 170626 +244484339 000000400000 5141811171 08000000 AV:clensky prispevek OS CLK 2026 Buzalkova +3 + +5 + From 220cbbd9acaef7db6383de225cafa45cd4624e7f Mon Sep 17 00:00:00 2001 From: vlado Date: Thu, 18 Jun 2026 09:32:01 +0200 Subject: [PATCH 2/5] tw22 --- ...cument Inventory Report - Study Level.xlsx | Bin 0 -> 216307 bytes ...rt - Country Level - Selected Country.xlsx | Bin 0 -> 31639 bytes ...ort - Site Level All Sites by Country.xlsx | Bin 0 -> 109337 bytes ...cument Inventory Report - Study Level.xlsx | Bin 0 -> 8149 bytes ...cument Inventory Report - Study Level.xlsx | Bin 0 -> 246024 bytes ...rt - Country Level - Selected Country.xlsx | Bin 0 -> 35976 bytes ...ort - Site Level All Sites by Country.xlsx | Bin 0 -> 122692 bytes ...cument Inventory Report - Study Level.xlsx | Bin 0 -> 300515 bytes ...rt - Country Level - Selected Country.xlsx | Bin 0 -> 31265 bytes ...ort - Site Level All Sites by Country.xlsx | Bin 0 -> 136817 bytes ...cument Inventory Report - Study Level.xlsx | Bin 0 -> 216948 bytes ...rt - Country Level - Selected Country.xlsx | Bin 0 -> 31640 bytes ...ort - Site Level All Sites by Country.xlsx | Bin 0 -> 112618 bytes ...cument Inventory Report - Study Level.xlsx | Bin 0 -> 8149 bytes ...cument Inventory Report - Study Level.xlsx | Bin 0 -> 246320 bytes ...rt - Country Level - Selected Country.xlsx | Bin 0 -> 35977 bytes ...ort - Site Level All Sites by Country.xlsx | Bin 0 -> 123019 bytes ...cument Inventory Report - Study Level.xlsx | Bin 0 -> 300645 bytes ...rt - Country Level - Selected Country.xlsx | Bin 0 -> 31265 bytes ...ort - Site Level All Sites by Country.xlsx | Bin 0 -> 136817 bytes ...cument Inventory Report - Study Level.xlsx | Bin 0 -> 217096 bytes ...rt - Country Level - Selected Country.xlsx | Bin 0 -> 31640 bytes ...ort - Site Level All Sites by Country.xlsx | Bin 0 -> 113989 bytes ...cument Inventory Report - Study Level.xlsx | Bin 0 -> 8149 bytes ...cument Inventory Report - Study Level.xlsx | Bin 0 -> 246320 bytes ...rt - Country Level - Selected Country.xlsx | Bin 0 -> 35976 bytes ...ort - Site Level All Sites by Country.xlsx | Bin 0 -> 123435 bytes ...cument Inventory Report - Study Level.xlsx | Bin 0 -> 300645 bytes ...rt - Country Level - Selected Country.xlsx | Bin 0 -> 31265 bytes ...ort - Site Level All Sites by Country.xlsx | Bin 0 -> 136817 bytes VTMFDownloadFiles/export_from_seaweed_v1.2.py | 276 ++++++++++++++++-- 31 files changed, 244 insertions(+), 32 deletions(-) create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-27-05 study Document Inventory Report - Study Level.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-27-17 country Document Inventory Report - Country Level - Selected Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-27-26 site Document Inventory Report - Site Level All Sites by Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-27-36 study Document Inventory Report - Study Level.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-27-45 study Document Inventory Report - Study Level.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-27-55 country Document Inventory Report - Country Level - Selected Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-28-04 site Document Inventory Report - Site Level All Sites by Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-28-13 study Document Inventory Report - Study Level.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-28-24 country Document Inventory Report - Country Level - Selected Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-28-32 site Document Inventory Report - Site Level All Sites by Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-56-57 study Document Inventory Report - Study Level.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-57-08 country Document Inventory Report - Country Level - Selected Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-57-17 site Document Inventory Report - Site Level All Sites by Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-57-26 study Document Inventory Report - Study Level.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-57-34 study Document Inventory Report - Study Level.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-57-44 country Document Inventory Report - Country Level - Selected Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-57-54 site Document Inventory Report - Site Level All Sites by Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-58-03 study Document Inventory Report - Study Level.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-58-14 country Document Inventory Report - Country Level - Selected Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-58-23 site Document Inventory Report - Site Level All Sites by Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-25-48 study Document Inventory Report - Study Level.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-00 country Document Inventory Report - Country Level - Selected Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-09 site Document Inventory Report - Site Level All Sites by Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-18 study Document Inventory Report - Study Level.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-27 study Document Inventory Report - Study Level.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-37 country Document Inventory Report - Country Level - Selected Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-46 site Document Inventory Report - Site Level All Sites by Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-56 study Document Inventory Report - Study Level.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-27-08 country Document Inventory Report - Country Level - Selected Country.xlsx create mode 100644 VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-27-17 site Document Inventory Report - Site Level All Sites by Country.xlsx diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-27-05 study Document Inventory Report - Study Level.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-27-05 study Document Inventory Report - Study Level.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..3497aaf50eacad725e0d6f14a5a6104f963bb237 GIT binary patch literal 216307 zcmaI71yCDa@Ggo=v7kYUd!fPI-K|ih#l5(@yL)k`1&X`7yA+4u?!_H$+TVTi?wdFF zpP9%^GUx1m`>mX_8)Z3II2BqS&UqG@fY|KouT`TSMP*2c-i#z{}j-Oj{O2jpgL zRj)c~)58pS{ywzuf%97VGp@fF=^);(Ygld1M9q8Z%Dg{!I*8m!pTghSUmBU3nQGh` zH`q6P5fjDs>K*Xv`|#(3`F3lFH>2*6r@BG1t{f3RyA{fi>CCVp5i~=|&0>|{{yiC7 z2}!0n35A>Ja$M$^lYCa#r;jFxTQ2M^*dOju1s9sls}6UNzckl0dw^GghatoGQ~sg$;-;q*yRunyzMQzKdIuSriD(xa1rcV&NBh|=1UKY zL~cBS6=%Y@-3NAC(g=!b`kgC+GeMs;MmAJczGFuEi%_jv>YNBe%k_pEo;qd1%6@dL z#9qeq{GHLzKKDQiJCSy@fw~j;HIUcvOa^r<@pXg0gEdy6e|~^|+E%prxa}umgROr) zqp_a6pRUW2S1WgeQra<1;q^KzJBoyq&36kJlZ%@zjVK$uC`Pl#jNdm>)BbS8?|f94 zg07cH7rkNrqGQ8~B)1FET^8nlLI(i(g|V%XvV*OiBa?xh-CtTN#B{%d&{F)|M`Eab z^+-hgcTxaS_KAoP*^d>@DJ#($S)ujJ+3hjr*rJy4%B^VnR^f8+LNtyvXH?9dx*+Mo z5fxv%s@OYBY`(Gl_jHX81~F!SR={hT1(U)Wd2;t&>Oz7ZcAm%-eLa%!%_(-NuIPBl z_oesnvgMEX8fIuf#8oNPIK!rOoaeiDKIo6If7RLaa$Ssv2-^sG{@;y_`G2ZoWb0t^ zS0C%RRoOmffTZ5fosO)!;EJGzNIH~&tpJ7yS8{?C!z(eY)3cR~`T78llpQ|DRIi)c z;(;C5EYc_&>1>sRTs%qi7R#Y+gB0DkKEw)Y(&&MZ%&A1{uPCEI_D!w>`6#fDR33F^ zJ)A!=!^Jk-Eu@lz~b9Eul!$_m)gexh^0J6Q&0{H7iMUPk#-3o5gpIHkWkTJ15V zp}F%#iTQW5(1omoi=I1S)Y z1!$<;FAzx)k?cAbY1|-kh5wJ{NBiHBJGon#{1drdO~E#U8NcIPLvz03Bb8-A1uX9` ztQqvBpK0vhmb<$V${t{s3Ikss+Z$wLOO1ayXrkZW5DAgC@jJM1N&AzeRcn{NX9B54 zrIxVomJDCqDY)AQo=3Q*ITz?-d^AFb7G8SaIN{tVV_2FjW60z@i1Vy!Nf{nk{tat| zK(hFTj6T66y#h<7sYjyFLrd07<)`PaLmRkJS-ay?RZU9|-S1V)5r^li7YUE=KF<>L zUn&>OgGeoGe~OFKWQpepZtswd-^ipRDbQ$0s9WAxox#RLQ`9OQ#3SWitHKEX4CV}D z7(qag)C6D>%(BJNlFBra{9YxZ+D^cS-}KueA9-Ifv#{^^)o_SgEC@cR zaakGZNYTUJwVVRG%ms?M?c2+d)Ba#V)(qCW5t#y9%xs6y)OWe%sQ?VYHK8LQSWF;N z#xmV@aDm+{{JIPSPtZ zr^j!UTO; zjmoI3@pKv+E%kvHLm{dmeb|skC86ha^_+O4inz136erJ#A%w}%4YEMoruo( zr0BflaO$@1zC8|c$ikY5p1t-~DNtIbFMAXX2eI|V_W*hy)m=zR){RMHkWrJ`e_&9v z7xP0`Ms!?KA8x!wwHs?9HWyJ>$Vq#Wb~0zPV$iY`{|b`ujkVo&pqI6CWI=E#nJgGn z49ZhbrbG*GTy!n>Q7$cD^{7ji!5vay*&sAhFSLrbU?JNsR(~gQp%k!!skRT*IBc1) zJM5VtV6q*c*Hy}Zi+E+Qenj-w7aua4@JS)q?);BYgz!IX|4Y69C&K@w;dlkhUS?F` zw}@$P``_L81vX4ZQ}){k~pw)V~oBl2BSMg8%_sMGe14&+tY6GVVj z_#Bw8UvMmDwo&!w<^kUy(7g$OB}ff3X#ZmKO_*M9@h<$c0UYOs#P5uGD}m^t&+<4U zh0*Tf^poJjpxZFwLkXSE1Fum(9#!j1|2BKHVu8JwJ}A$z9hU?-LJfFrb=CYgbEB2p z#=j^@D^aC(_8u2(z4BH zVdfK{M1=gh9*tghJKrqp>qru;GHm93U%Clagfxdes+(mN8hu|jQ!r=?{)E20Hoje^ zRA!uv-hyOYl8ZanUT;EMSI=HM+db-az|^H~d~0A@OO;Fa#PY4Ido!0O3(p+t3k93H zFCB&r#BE>t4WLu~Z|3_jGDg`&jRG_$MS*y{yhKR$Wo}YxB?V zmd3l^)wAQj>wS5UR2TV%i?4O@JAz0n_~&PHW8ClR@$uh{NIOiQreoX*U1EE;zj^Jz zhS%_+0z%W4h(p4RI3+WC$?V4@!yWNyV&=KsKR>%&<}9nUMZ#0ojB79?3Xxvi1wUup z8+=`PzN7MSI`l}ZNIce|fr@)Ky1E|28QBiiJ>fxGnb6s`j9gT+F}GzK{9p-w?rroO zvWWPqb1rnM-%AO$Yl&)Hxpr&`a}Ch;dtsSgHf|mI{e-ZMy;`wcDM(GQv4M8Baj(}( z^>tA0_;JN0r7XSW`QzCx|JqquTIzejqT%S9N1}~QoV!2Oso%$I)dLL;8rBc?2w##=Qi=pDje zcrKpWTC8_7T!{HR^3)dPu#E~-gJ(D)fzQ_V&EDP1+2`?fHTLZy=V|@D}m@!xC{dlCrmC?_yon0*=wGOEnfa4~qSg_y3_dc_5NaPu%* zZ_P;<4VrHxswS%z1pi!$b|x@uwVjvfFvq-l7(y=7dLB3AbSx(&?ZetD>X}sXb-#JA z^>x4h>go&msJ#1W8p8%Vg(RyG`Py00d7L2!xd-MpvV+E2slC@lq3}zQudwMh&Pxfyn zIF85v#Oh6PH2b@mg8P9@5~ql-wKvc3=VqfuV2rk*@-~16zoC_j6P2!=Zv)I^gZs|a z(h2ESuy6<2qcT1&6H-woTP#luUwZ=0#0*NOJkt&ezW6F_SWA1157(vW*)5dH0Ni!W zD_O~7smSapf{KnKOnwuQQP|em1T_y=PI)J()7S$Y(pYC{et7%%Itt z;t;hq4YD6wc;nL4Po!ccDCBdFgP7YY_}rIDXum)~vIZ(rA2cWT-hH}=jU}IJie$1w zq5Q$iBLY2u$0SdCu5~8nUvYjREUyV~lqKB;SRBKA@#bm&V5z2Om-&d|a|&;YV#lY5 z-;~+jnH|x%JE=?8s3Skln8pBJ)7?`8p0f@kRWb`VzIDwz01*7%D zonCI$h9NlQT#(t_?>sMd7p09Jqa47i`*xRiZp`T+B{d(LF<_mBc`XRO4UUo1u$_Nn zy?WebIhez#)wW{1UUp37Dc!GX`8xIW9_MPS(qVu|YyOaTHGC3P!3h?v z$&1sd!;k$c&n#3-#X7%t1w+B9N#aU8bVb2tTZgfusy~JOAsyrsXv(LQbqX_xGAQT> ztHl2)T&R9&Le;DqoG-Wnee)c*GGZlF2c32rrknVc(81VbO24x!8V&E}6&vwIH}q$! zS-&<;`=xG3U?OZL#RaN%aN?aPo%ni{q*x~#nlpbcdmr(^4B)OnqW7WCpN@OVjzM|9 zx+{hPU8Rb#L#0um3)%R^f-oy_Z)8)+Z(pT1BDCs2(|n} zg4kbQU_k{C#swutHf_QUV{ZfthoFRn>XDr$z_o$if|JSItf{QuOJx-hKQ7r&**;~t zS&C4R%hu$?pS#gRd=Q9oSI`=jQD)9x>}A6Mh40f&{Tbd&z<3b@m?DPmcS$p0dD-MzRN68$5nzm|*Wi zFcHz8NTG|!JAS%A<|^wXJ<=_uQDeRq!J|W#L}Bn~n@)5<8yh?X4IBs>s(?Gy^Hi0! zLB6Fyz$F5q4q}D9%?c>0t*tnOzwH;`(k{|;XVV2(%3TZE&TwjuBHyqFxLGms_5xM? z@Vjo{i4gsZNIW3MVO9oO-R}?jNnPWk^A}WyK{I*5=q?_o`D2Rs097TX=qI7S^e1uIm2uFvz%LW8Sl6ZZ8p~$4sD+2)c^?MU`S~*ty=B-! zqie>?<-iwPm-(W;$fBQm)k8M!gV@v!xQDd zU1g~>;tpayd3qPp?a?JdaFHm?EUzipclc>y^TCf_w*QZ`&@N)V(ASx9-RC1Y={GCP zzJc{3$%?~ykrV8y1_}lBAjG12K`P#&)M-+6in1Kjj+apTH>!ub* zX3wwAjX-E%!(bo3AkSOQ&##YAXGwf$9g%Wz!%JLmQ5)ecAj)xCa=`Y$mPo>8>ffv{=%1oZ_BZd zt9*4YbcWLm>Y;kpC*jQxfEPP&`{w$>C&p1Dnma8LeRA60@s=7zCWT{nFZX5R*DCw8 zc#w#KjdJE^MakZX4cbANLxe{V*}Bi#eESpcQ>Y5*lFf z4iXxka%x|%?6Xr^I25&Dd_+1Vvak|>KeNB5|H)Y5pL~F;{52p$ex6I~a?XSJyo>%c ziJ3OwN!F6AWzzMTU;7K=d&|0y)(7{3#rZ&q_@1vND1eQ0*L!$_d}d*tVb96=Lq+fC z@k?NF*MXVkS421eIgQRq%l9y|#$mbEC}Vto95jXbw**m0_1uKqeeF3O28W#SWv@#N z#}8c#I5#j+c!aNu6vr0M3#LEU;KcO7ShZ-C-yVN5Yar$Ur-Ow~KmVdS-}t3yS47!u z|HL)SJKVK?i)pYlMG-gORJ47V@!&*Yb~w-iHg5H@&Z%%6=GA4wIv&5d3D!jR#TD11 zo@dmuW(i4wPOl!*|ya_D8KM8#+qs$^05U>FvrD z#V^ArZDkjX6I$+&r0Y{%PDsI?&LMARD1y_H?fLNN;IX^Ysujz$%fzkJ$~99UcejL6 z>)U2<0~{d~>1!velb}r&Y|``!U%yFIz4$m(zqk#=yi^{GB=3A>X3zsz^5?KDN$j=; zso+E)j$95)wgKD?hkLD9j7JDn@R>uOlrY3x4kF31NJz7eCh8Iohi<)DrXTy)`+<|j zwkf`@#7}0HE-Xajng>yrx;~F7QAcmg*rjMbK3+0edOWy1B{QXQQ}r)XcLa9D7R73%zR`$sVpYCR+wrS@`(&4hPU`$uiCBgju0JSt}M$Bf~fIH(^@52^)R zDW<>HfVkx_*cC^-e|0%(ZTNpxmr(Ie=G4fjCm zt8*4#eGkU0nHBE18H8?Icop8x%yxT))_qflnUJ!6FgTbMX?(LlUylp+O_FIT7)q-e zr1=K^ZJaP5ke7JP-pM2V%$8G3dXVOk+kMGSj0n2t*TI`Jvv4G5Gce><#lAE(EJU~- z@0TYY5)f2UoV($pd@tOLsx%kZN03>vVws6NgRaVPcK@b0_vTviYEyI+k-BoIrETd+ z66i$m-CkR<%6ENm)ah=#MV4geXKbiukk_Y#ygl0CqCK=f6K6+>F0LXC$tceN>^r}D zKxUu4>&)@58*&}$QQLW$mZYMBTH}8?+m)dn22IWY*Jz)#$48-jrN2_&{E@vfls)b~lk=b%B zdr9YaoX*(Wl`pdj#m)UrJInD;o8_rcRAM=uf4n|fXPUTgv}SudYbml3)}GV?14dA4 z9q*cDUPbrAo2|f|-wJ&^x?%4I1=>Ge?K3q^>MGB}?GDoRe3<@KnZNGpp{~X@>8J@O z?>#B?jz`1(*s$8tNA2{aLh!~}W8Jd3t4I(WcrhE=T2LrxY219j!!V3LXI4Q2Kg*{SuU>jdwxe=IkA*dj2$|lH&qxH;Z*@AnlgwA>~L9EVg3s~6O=no zLsmNizMJ-(kK6pXw=4@&swlntgz7n#NvS{Q4HTo5ng=VDESQFhZS~c*v@B&{RB$-L$-BoITY%29rZ;hw*p? zw<$G&{fB+ien8vvRp~%9Br#8NzyJoxZ9^DCC^Y{O?AJ(`K~(IsAo~1G$Y$dG!4?Xi z-Czaw!`Ni(*%3Cp(^W9L3e7tkL6y2r_(0ZE%lxTU=56>KSFiLzIv)n0Gxv+GCg4G2 z=MU6kCaVc;75UtN1aW8kYP*Qr?{20u5z@{e((rW^=5#Qa>Nw-YVh3vUrfaVOwsH!Q zkgQ)Yaa3&56uJ)nGu|A%yf%A)a%xj~_X&Q;BZxx_Roi1Tw1W#>3rD6pQ&oxnass-d zenWP`zA53*tQE2ax5q@4YZrHUd>@L$AQKE~ zV;ZpuuyW^TIImq=rA~8h0VO1i)^}xGlWUE(QkHrxjWng!y1lqbrLIb^`*%bO3P zRmq3lIfIC(y$%|Pj5*F8uWzPjaCs#x-?o+BBHsAr8dmN(=>sGpQg+63ecxi;oZt45 zk&g2Qw5#tJ3t$5Q;ABwbQ5|PzivOcUMq<=f$ocloR)%x)L%QGk5$JgY!Qs;Y$c}euidSS?LaoDpJ6uB zPIkOq>-$a~7q3pdShYRR=A2ndu{2jpTMEft?wcWm4x!3&zmNh|DR3p6w;G2&L}!c{ z`WJ5Rej011UGiy-1k#7S3ASaj(5*O8If{lVQ1~KP+~qmVDEChxn);(77kxF(98h2m zNgUmd;7`9PaWlbm?T5v#f%hl3$}u@K>;zYq#U6qbC0)!FZW~vtq@T(tV0Y4;~oZV_ZgPjM<6#G{kSd> z5|$te63K?Ep8+gfCFhp4>wL4D8$2@iRB?$R`WUV@-W;-dg)FtaIgCrKkdfcJdMbV8 zy^PZJ-$NV5T~N^f?F09}_km`36q_#%E5k1(r)q!e1yr?Ssf@xa3d?rSh4=+2QNrl1 z_aFE1%913bMRxgzd=7RbPyJTQSVB3aogtk%g>+)-J3#i?&|mm$-%?npgc9(ZFaT+` zjGL0spJJ+MlnE(O5veR}TCbkU+F zTCwPocl-H!&iX&fV8^d8uxZ#~T92vbHJ|b^I(<{qHSFlMnGq;D9N?dMUWg}o#H=bG7x3^ zXZ-KV3H}|Y_LHv7I-N-|{<3so{^_`8;*`n=gsu+EjM z2_v)8?gyKy+JnP1Ux$PI?stt}cq>(_J=fGBjKD?ymgwRs!jDCmGI)=FY|dF<2rRlv zWYqPAUgDZ^;|=O+vgyjx4hYTXeHyE6z@llHX7P68F^Y?z8=1+KLc~?c3XBVrPN#bh z$KWBG`4naTZbW4JtdmT>#crw`$qAhO8F)!4US@{Q+UR(l8-7KIs6$MTJ|XfENQa1w zvC1vYjmUk!X9HWIsTe}2gt$12C}M}Ei8seBU5B$pW{^MJt=pE_tQ_(Af}MYlF)Dvc zwDeJ|8s(?vcTQ(O0B*0a!Z(FFc-TDmx4$+N)>N5pdZ9^Af?aTZ(gn2Kq68>A>mriJ zx2YipLC^+#awp^SkDHn-CVS?PS=h4fGK$X&nZ^F&HE(BYt*d61*DM*rJZ)k?sym@A z%%xhT%!oMpWQmIhE$IZPS_eYPiVj0`=oc)&53) zlg6iK7}UwcyGEUWN{PpBnvDMqW(sVS<*|xO85DUb=5Hv{gJVk^#;v0e=FHERt!Y~` z{<`K+7SEwjqw}b>S1nsMZe~eA*4i=b$Qy}nCA-c)EBzr+m0Pikn~sn^@(76?7!9Bq zXBFv*!?J7D#~T_Va6DVg#tsv5hHpeM^^Zz|U**w`FNML(N25DMQvKApS`1Ic?;2nz zA+>c&c&3MLQVu2h&cNVYSxsO*Z&61~v`IKGETh4XViOQVVTso7FZt=am;R!YmRe|j zvt1CgNNyNWf-)Q&B@PZWF%qgol_3&8dLuAOxsW*b-k}AnF`vQSQymJGU?>$Dv23 zT!Z5ZX8WvD%8N4PmYq&IP@KFhf+6C_j%^_bK%;SCdziAA{+!$sbZqFo7vK>`7AL}d zNhp7zr-QK-z#1z&E{mYP^WJU1x)PCGKAfE~$eA|m^AB>HNtS2Bp~q}>{wP^8)0Xa{ z&3tqg(RvY4)W$)wkgpaZQOdvrv8Zrei=ahe%B^@c@J+WMq+jI_I(hk+m_{Y3znor zoTb89tqqQ<_AI?55|ebq<}H4|o!rL=%u6Wmi01qhLVC`rFt;zZ!RSp7>W~7<6f{aE zPZ!}_E$ApB6Y?XK!EIZD^X`a+4n$YyM~3iuM-Zy|HUhOLDPVCloDCeo-FwOrwdVYO z(lk4n86wy(9y#k60-+QM+EfhNr%CRlLEi%9sRWgM%RT56ve!XLOD0Ij;rrNaak-cIl0i_3U=jdpKkp z2^a|BN|<~;gTphEW81{+l9kQkGW$ zH`i@ZF;6BBsM-oK)rY4df=Q@=D{cFuth=kRVAbS@L)oa(^-evgYgxBeixG z<+8SVGpkuQ38<^mh5cTC#u z6KM2i;He1tskOBg1+}vjm1yUWw@Wbw_myKZ*nnd!s%0jDm-w0@pj0D-FQWmt%^xuG z9$~~l@jpU^&qnDb+9E#n9dpzOtz+B1n4f($dveyOnbV#f+QUphi?9k35asOo6lxWO z68Ivacl`-_GK3IQNs1gj@TNmTCE84!R+yhsKJ2Amao&vN$LY`=5O(m!F=Eb0i(j)k z?~JJjm)OLghcewyB#N1uOj6S|KvQCO^M*KKvZren6Ya?`Q!ub^~|Rs3@S3bY>MmZ-a}hq;zDzpbdh+cJ*)833bb zPmt$TAX>7{@~i6i$31=MTef6HQhjI0L_7KC!zF6vd9KHqxXozdTJFkM=g2~J5e6tRREsM7#Q8nRDE(5LklcY;29viI~G^T zD&ONpE2(9_Jw^iZJ~@-*F4Nr}d$kU^7Lmle`4Pf`D+3uEZo-0&P@*b=z`?o4qcUu5 z5$wI5{=(0>yE5X7I_Y^$#bRXz?15E-Wb-=dB2CP0vuK##1|Sjbo2ug2iNcd}e(?mG z<2M8Y(bEOz1XH)@->B>Mee2p6Md&O#-w-t8L%RxWJR#r9ik$5JAkdXa-)t8q>sV)1 zq&@e?mqYemeYmwY@7`uysiA8=bHsYBKVOiY>)V*}Le_Xk9wd5pb+P`u43`#=O9Ae$p>^87MCm+rIeUeE$hOTV#@LYWe7%b z^E$;MO;dWQJe>KQL>A&|R3_wYU)6Eu>`g(lWb(zqT9Dw2G3FDG@@7pE>`(bROO8NO z?>BFvEO7=4uwx^{;YLqqi+zXV_Z5brbEJ zRK`hmh(O5sef+JkuF+j3%V}=}xkub+&UtyYKMm2eb!Za)8TKkERE0SbzRm#_azL`C z{Q_GK?UD5Z8*ommJL*(Fw92Y(|zZ!_paL#&ht&Q>V zg4{lc{Z|370>8xHQ%w$VjaArJo?{xg6lI5t8@z5g)&@SR4lK^X8ME(S=d*dG2OR|+ z7w40muyiTQ+vqu@61frij3wJ++7cqEfDGTPvPmy#33AuV zXTM;T4j-qZUmv}=je=XA5Y=~3b2U8);0SQk7pqn1N|6Og}FpE~4q0uPITwargcQD0WqIG*ENxg-qRErASk%9L6A4 zrL0xm-_AgoCFXq}ItRsvg)%<<56d;hiY$&xFb1M3Wsx^&7!kOafs28;pZ)RaME+%Z zXh^320{<`5f5Ux_Q13n$V$FK^f;^}O6P$I9r=s&W3X}@}jRF;)|3v}uGdu!_|9}7& z>A$6i@_GBl>fZ$+!&fVQf$vl)CBrkYNt4M}WYMXH(T@KW!2qcX`+380k^bTnh6}-G zCUS=J zT}d5TtRV3-=@df}ZK*%;UW(-hBFJeGnqMoJ!GW6RB+48xQmyC!-}CsyuT_3P_nb|+ z=Y63+!>Sv*lr>4L26XOnnNoVk%d>G!4R# zb~sefl^D%wvq6k9Dhht|ZqxOu1##&mq7ssu3DSN46JWoCL-5gW=94BgG$TrPCLXAY z(TeFiBs^qxWUBR4N>e|t!EX15hApd)MyfW0!lD~o`(@4Wi9A7S8vML$ALovWqle6U`)Ad2Vg&+th zg{+=!w6;5~IeWGxzvm*z`1zlKKKvJ^zyCGRSUz*IPKiuixa1D?Kt4!-Zq@}oh$>Ixz_shupNoG~Rb#7kObR{9m#oM&x`gi`AqN`# z5(D)FcVCW*S;IG{9~=9D@9!T$^4AN<7#0c%Emr+$rIAv>#+WVn#>##s#w zLaV-(QUoO6<1+04=IIQ?y(#Q0xDy#8AZu&Og2wf3i z)hqq~yqiP#pLcTruHRFFDyyo$N`7+cjQ`~P*SqJS{&}~BpPhjNB{gNmkM|auYA!ui z+(!*`B?V*JyuzsmV5`~Hel4g7q#c^HW7eGA4=}qASZbJ18OC<~!tE2$gwpu4yuXkj zS}2zmBL(;v4fIaAzzX1Y|83jN^I86D+c{yL{~q_?t0A6gXZ2Qc?!!!nd3d5d+a%N0 zPom79*_8CJ>J`v2%~&<9*80-gJ8pBC-{1d`+ex+jmHw$54zdZfQ=+}n`ZX5)otqu)q zINi|ILdpAW!2W?{fLUn4EEnDk%~0fex&bj<+&QwGq5IM{K~91}x%qNP9v!SX5-J-m z+xccKFNNp7CL~0E=Jxi_i^BK(4vG{Xdl3EdMPu0aY=*I!9>D;lySV<9loKXZNLTOe zGVyavW{qBX!MGvQS8Ho*EtO|DykQqUU2EI@hS1X$H1>R1tj7*w_dk@jkZR{gbBjN7 z+FJjTLoIgJBWO4o+39AAeluW?DmAj(elVW&(H{uYtP0EA8<4*6(3Y29Vx2oc5F(S0 zvSM_(Tf+{A>nt+mXvK2{qja9uglx07(0J%sVw5mNc%WZX5B95K@21*3Y_i5mw|HHAygX@@b2h+11u{o5kwz1KJc45fQUGYa!1d`&!NKh! z#c0xd#C()&8k1C|C8LwF^9!b+lY#=-LTi2C` zduiz7WQ*pB2YK$+FGXR|#$2(k`QLxB^J^+PG=1S2S8r~wZ;f=FU%%_If8-hNLwUoj zJbSb9#@AVgj5Hj2q!{0AH4>&+j+Wo2H_k6OHP_AOKdTygW1ZRdIjHKEcHs6B_~etA ztKsrrYZ|wX1uARd&8d8=aLIktMEstmlL;SpMt&JkeeNz1VKMPN5lea!0DV**64B*u z>$wTbqxNByqcEozm!K+bQI}5S#=!HSJu`%&*qkmPd;1{m6fQ40y&m&( zy8w0K@;p@RZT7nrqKj99R*6;@3dIZ}SZ+buP-;_?R8_Q5c*_^vPJf2^e z7ix-Uci<)AY*W6}G0mrEcro`f^!X3WZVot}HDP+4K>A@a-zvs)5hBp(?SZz5*EIDY zt|t?iK&)Al#R{Ax4xI-aKL-?|Ma7^GqBWZNm~?dEAS;ZKltimP5ypXcM7gArJM%JhWFQhbvK*`^R<@$gi|ynsb`fpQzDKK8A=iZ>KVId?ea7H1 zFR7juu75B9HI$Hx`XZGvr1G3G!h)Hq1ulTxK$Jw-wN7YTUlD0y0DQ|&vRggPf#slC zo0plA$)%=tOA5IXWX8fOJe85=J`?YWI19WZ+&$-wF=L}WkQVJdzPJ{clUY=O7hN>M zr|N@4!0!_n9=!xb78o6m3%1jP9MUro=#Ujg<{jMblOB|BULB`aoimP=vS^ zPyEH~VmYWXVl24oUR5Y}&u<4JSRC?a90ph1 zw9|U}9d3!*NX+^5-J60o3dq5$gt9MI)(bAg$~*am=D^M4ru)$(!#KgfliuwDqo!Ry z2xfjrg1E$O_Vv)Dqk*Bzt-Z5TkF#7KS?DsANB87+sCYKZ=ublm;nt?Fw#gY^%`H#D zF7MlZkr^P1Oief62;p6{-`sh(+*1h7?^DUmNB+=Un-F>(hR)-gx~CgH^2k07)L>1L za6U*cHABLNYiZi-XZ4mgIzHVyrdaU`Azg+Zj@l>`xE1Ad_#SAD9;SbJ^v<+9g0qU% zx-vOWo^;EJ!1oKyLx;O_%5xRFwWOUKHCnVjF`jxIXPa3X++BYLrB+{#Fv2eC?*tK| z=HgmF?CgTHgPdDe_IB(337PhLkD=wgf^(Xc^)DCWA9P0Zw8Y=29%^R|YkdH|iBE9J zy;Av;k_tuZVrX#=mA_*|FH+HMjPN9!@zamZkrIbJTpP6_*Utne64v{e6UO5|J|M$U z(Jw5Y^-)fmFfLZz!@yuA%|YhOvR8HV)`Bbf+m9nGHX+Zxrc|_mWC)vU{{krtR4EAFHVr zk(O;(r>W;-7hEqMITd}=g^*IX=J%~?Yfg%1cZO!1TIF-#Y_rkX-;H*SOxaODSfZk4|y47YPAU5S%D(O}#YGkni%(L1L{-7X}a8KrKGJnX!fW)>B)Qde=g zzko>Y$V9ZUwh(ho$Y|`jF1rrW7zi*Z)ho${5eU(g%mlXH*ok4o-&ASSnx{gTMWjQB z(&JI%mT^Lbbaz(%MB}`Vo9ZeO((hMBBPj|Y3Sp(V8a6fSUpa*g3CH6bc0`qbZjoSQJ>(ltDA} zg)*|){H!H!Kr*}E(UV)ttENrElRWC&3ghqvjqN0JpN-zR>b`?3M|?6$=4cXofy9i69rn2+OGcK@ zy`7iUc#K(PY-QPSM(OtU(!~>oDg)3 zB-FrBY}4S7CE?pf7!n}M+C0L5v)}bT0?=NL9|&s?!lT>Ea{dPPh2KpF-9OOC&Ck1M z29y>g<_&DARwb{-Nw(0Hh=H{UBvQ!$gJ|Pq=wSsB+#nEBQbPDp(m00jCETFB2(Gmr zZafy6D7g*z92hiw2X#@E-|^1#^K_EX`*MXHA@083vyqRG)=D2TM!QI+Th7AaC&=A# z&g}yczel}KCW(R%tKp-vSS^eV20Aum234N+5zdg;;P;qQ&s5kUdG6(hv@_xz)SK__ zNX3o9#eulw#n>Nva&6WwAltb@-$cYQo@ilF6)aysfzRQOf{+vtk05Q8VpWf}d znTKFx!bNTMqX}{g0oIn6P9?*EaDfh88fo;Hk>4HR-TS~0KXyPNx7sv9%^F00`u|7% ziwHuN6AeW5XFFZHL2!6kfpH##>dBS&5zcuwr#z%1YyY9(lOE3CdeQD>X3(RsQLU^E zw{SItbF10~kbRWTRSNJ$3Hz~*T-up5eu?n}3$jn4YFgQ&A!HwG;1OXw2o`N}Bmi7Xv~ZNI zv)|H8mBcL4v{r!69@LlH&&kW=*c9wsAx5ZVSB|chw2)M+ZOeqf@t@;vct~IpcKE%+ zkV^^rb4#T&cr1~fc7V)vN#o+qC9}}(h`sL|;JV;r(cFb>Q~Y9O#S~@@b}y*psb3~B zxBKjzY4>cPqE=MX+?U8KQVcHWW3x(jLjZ4!9Po{77FP6Omzh76i07CCWKA5yX(6g9 zH$!IDpHk)?hAM+e4hE zw%G=<{t&pphRtf$It0_P`{_Rnu#jt)^teWF-F9 zV-NYvg`xM(8s-+w!o%`z2a={e?rdquySvJPr61C4)pc8(cd4hX!bXB**uEo+QGSpb z9~tdR2CCE+lSpD6zGLc+h|>)<2S}P+{YQWg8bK*4Z=zgW7L9z-ezl(Fjp0|k-&^Gv z>$Nx3IFmHfRR~~FhZEo$!#%rk?3C63BCFT=N6m@{Dl=vr zQy?dv!;IqU7|)iTMLqZ*yBqw8nAQ|jYUH!LT7vvt2K;5lJ9$|3t-w3mmwkUW%zbX> zqkQ0iwbwj3Sm(TW7iJtm%#ADqxh7>w8MMu~x|7lWt*xqJdvf?}MY}DKdR@US+t+FE zHq+h20vOi=i&h9z->{GPJ|+n=WrM>BWWk~_ZLTY}{VZS7IWTJcWQ|sXAIJKrvJ=xk zNv20S`gX*OKo!v(4P#VncmQL$bNfZIr!L_nU7kt0=}|}ci^=7r`i>_!7HsaoZnTTy z)8~zs%#=G@5k^vw?QD9v=h?V_81UrmZuaKV7o{=rn0*vPqZX<*0)lj4 z?W8q1>yUz2&gd~bOL?n7DHqFxS~1b4;`kQYYQIUCf!YW_31_H`V+>?$V*+r&D|5hg zs01j8wRlN=2xa7*zc!LxKR^?qae)-8aAsU^GTmL@wnZ-6k^2pCXmkEU|N7{srhJho zUE%#*i&JIo$o)gFi`#1_?>eoM-A9KNii7bf9pcJW+~6-DK`NH(UIB`z>H+^B)OF#c z&OKBigoJa82C1cxqhRSCmT*Z*M)Pt39J56dREWr8ReLT2G#rB{v=zjj6)v)>(wc7| zylS0`FDkH--f|T?Xk0$7ZG<@k1TCf8^{ov`qY{+5$XTiMy2#%*q}o;M{RbrB^IeR( z0wMEbbJ{Ud&W>z)o=MvhRqvH9=l0MiZ6}H?%P2Kt5uxyAw?zgmPH)_H^!uToUgWOw zBiNaa^qzJezodNsB;KZZB407W?4*Hc<(ik394Xm_74T8D3oD^L)|h!o_M>9w^^IpwAq_&n;SN3GdA1SX4|&w&hx+b#eFkxe@EZr&zau5Pbpo5 zRaF29=Z19I?Gli!sa0%3Q;G7YLBRom@3yFP)^l@xV4S^<+>!bFbRNgdZR@x9JqKk8 z5Z+yt!8TW1@j4(x!N9{fIJcEgr&V_IuP#Sza-3dTZ8BiSyCBF$3_UW!qhhP05i&~p z_S2APu6Nw}OnDKP6LkfY=(8|g`q>)x^D;A_WJP~b5<``^Vxx0_snmQmFN<2*2e6E< z-9MNpWh4Km*=8Yq)r>6>j`#y4Q zgkxr8)FzWEYftW3UA4naDCGlitGo#EsR+Kn;BtO1ZG~IrG*jbeg;8xd%SWV}jApe( z1Q(-pcl;2@+BpH+r%AD#wGJ231N#7hycktq`z~nM5Sq!s?C^B^Q>7<@956> zcwn>ky*F^9lYNi*3la05Z`vG3yLokIFp}{X2<8}w1H`|p6uj(2wrc}Y)x%dBMWtT5 z+Fbf@l4kj?xgB!>sY*uEef=akef{!xVUaI6;iE7dYR=Wr%H5V?9!Gi7T0M1rlBiM5>@G;HJbWS}2nS#~U;bsJGu_4|1$$MqH> z6gatV$x+08Q`SU7(VkMxZqmi z{x!gtUTGx44JLRH`3o?G?2VniElIoN`(5352hQAy)vgsb);51QTeVMcMe@_v3wqlu z=_Y9i`L`u;uiGY`HEgM7qH#^3XnP7=5-)^`=;P9pai@AKbKws;$a)My#ks?CMGkSrEJZvD|XE<*~nbE3kid;Byp&l00+P&b=D(?5}X(BeyAxWyniroC=Un|{R z*eo4c`z3K$Wqp0{q@Vl5@rDz+v!gEX?PsAizWYube80r^JIbm+8Tk)F@Cv$;Jhxv1 z(K2d-^hzj?-avMWOvjvWQiNfW&+;hwL!Gmq^}ETp^Fh#i3?fMB;<;6m!&RU1Mg8!h z^u*9;$tV#(8?uBtRopLnFbHhKy0cuI zO@jN3CJmaSqEZ$)+EJe=s&9(YOVLs-QDU5X?t`n>Rm|sOs=&!rZ^s_i=a1kZ^NuXC z$6Fp2#eO?>cSfJ&RlC~XZB6%pz0%e!CuS{6c}%oZ@+{pa(vTQrXkRX_g!*Hx0b)B)sNh6{bL4V$JK?K zE0r77D{*-Ax||CU@p=|bUIXpp|N8Z6fl=;_PlPNpEUeb#d%wmZa1>kCG)g8p)55k6*r~6itzqo%v-B2=?z1t=R5{)W;2&n2TA!?-A5OE+L91Hjt%7b zfy5pgQ3OfStu2fxN`ckc%~FDqxvQ^?eEaSc4ZWrAH%p&BTgbjPxMcL3T2wq-mkw6A zeOce5F56DBvqC1*(z@myc3kSWg{Ab&QFdzb7{G}=w^wP%lLj|5!$sG2r}PL$OkqqM zbI)AX9PnR1!#!oUSfLG1S=-l%)$K=F;$T=Zd^UW6suS+`S^?kP%h3Iu>@LOZq@v64 zyd}n>Eu(`rcr$1*iiYPLikipPQrv!Z4hoLc9HCl)B$TX|PeQ+j4!44#^1S zuajlaC-8s`a{`?>e5l^?|FC^}AP>Wr&?(f|ZFh}9l=bkxRx~R!K_aqtp6LlQM}LX3 zpzS9QGFHZ4AK!>p(tMo^)zHL zTem^jg-&`o8dn|)U(0sxFZWG%U9AGYx?ua5 z>Zd`UG}}f8ALC0?rVm%=PXCTx)sY#-j$tvGK5-2FD0dforIk(RKnD{~Mw2HDJ3))R z?h>DeiuC*3+#=K1&awI|lb0KR34cM%Ow2gHjYhJP0*P8?qThzY&hWn1G(O>5*(EJ#EV^ z%3r6FY=HYg3!#WVT9SKWq7*QGq)w_9W%=G-od_8FRh<~ecvO=J_;4~P&Z;dQQTYC& zn6r6_G4V{a&CkFo2U^4M2a>53T_iB70Z^d4!5pA0`hfqD;uBsmY)5b612HTNYivHplJ(^CI_c)ocao#qM1X;YhgPNWUmfW zOW7Tf_J!dJqNFp>zdZ%=0j$6j!S=PO@5Qtp&s-*$T8N4HfNt9d&?b&5c8T}jXh~IWezx++P zdZ&r5IFU!G!&cK=s`Lsmizf<>DegPq&#@i}fl2EU|4!T_A3_*U$B(=MT3S-EFNB{d ztsFj5kEiGun!58Y9u%QTlRdF$Uo<95Jl6E5Cm&>m{3J{V(vveCL8%J5OE<$XAzYZW z%I}?pME3FFjCIZDz(&_N<`RT`Y!X?HQUvESsVUClMc4xy1-^o=IS(`+ z6go8hV)Few6_9#?ajeKhoFwvM@(8OA($Uhuq9B`CRvUVse*qTi#=Ezl(doHLJ%Z`+ z#&kO1;}4TbsL-+eb`%iq6q-^d7$(b&*BmH|3bHDFDP(utHH<2-ele!HQjm-) zXNc46^oWmZbpg5wo(Hg91mC8Y8VAR}(Z?Zaq(^yuf&X;$WZz;t&c%Inz|qXR`Kf46 zB(PMMYdLqPHx&k=ZYG_uxDq=+F178S+;tPbV`+U_PK@8uMN#mz10ZY5^f7=awdM@0 zxYR5wSef_NVVD~&rP? z*CdQ_xt@Gn_X=AU=_?xh_GK6trhpD@KwxMg<61a4-@t>3Xz?P*a(`Vt#sxs8 z+#u-qR~Y(J8A_byq(@vFJ1D5i3q7WCAww@K&CA1C1(`hIlhb#^)Sz}z30)t1;ONWH zW#0lHbJ5kCZ8kV`QYz`K4!66F9UDcEuTAKgHG{V2MAs!+Fm=u31-+AP4J{-_OA;O#ruf5Pr_2APw-{Msl9klJQu$b zZYmG|9HzA~kyTJAUE8wEAff(>BfGFstHbg|wHL+)vPP^K{ADH3PL(+l=u{6l0&wBC zl#Ho14zo2VaG#j8F7{pqi1R5QM#1u<@w$>I3jF(g8_>u7Pr5MGbev!bn4~X`sB(L( z=-FGkOf+8x)8njp80zuQ4oSfOzQ3170qC)n`=EW>qnC5rBQJkAH=r7s+cY}UUy#(Fa%G9HN?=8vRI|$*AGR58cDkNi``XY|FhBD_1Tz$sQuP((8zAMEt$R&BwFSyg? zO(xpP{?QRAu<~R=!qRCoQ$aIlZv}4_w7AW-!OEgqa&~c%D(_BaE`=znYnl-}mg&O7 zZ2lF_OZ>^&oIZ-*SfU?7RSp{Em0l=+&esA)6$1%6A(~Womlm7lINl4UBWN&QJloMB z1QK4Za_A|@k1t&Ot!vF;$a}xJ;o|cZ#|4Ju9lNsmLZ`OsNo$t!SvR!gEd@NQphOsM zS1Al&{^!?(sV)EYXdXr3F@c${rt-LvjLkBU+0R4wAlIYe+k^^1hMbuMuYyi$6|YvC zApmdTYGz-gQ`&jQQCIY{h-ReW0M~aSFgKhV>6&1&KspiXM8Tu#1 zd87LJqJ!c@%ekkkPRPQ@lC}a*bMl;lEe6Ns$lxrQQ$9c~I7tG9Tc<>{q(eel#%t15 ziy=g(E#-}Ih9rF5JHy24%9*OO`xfqI%U)=|k_bpY4y<5 zhGu8H&B^N+ZVcK7)><1zi5KQukV9c~FWso7@YvL2QP}E(NI2LWxM_w8gyMMF!ppy0 z70Z94diCD-;{Vtql-v-3E%6GwgCi2u)YJviA6k*Gl3BCfZlw&CIX#VgkeF%J2C}EK zOV?w;dl4_6laE#g@JUCI+o;V#UZXO4x3ZKIX)vE4wdCjU44q`truKmuJh6rD8?yJ9 zr31_GFVgo|wrGn|K4ixCSfGq0?&eH6@H0ARP-z$}H34J~p@$mSzu zOKeYemTex%d#NZ&=dVf0n+mUINw=Bwn5VK8Uo*$Rws1G79s+X znEHUft8uCX%DeU<1riaOZ&M+{yT}hXe_^EysBOjnY8#{&;k*~R*P~&Q<*lkxUwcn< z7nabVo zzW_4U|XDwKc8Q*1i^= zERfcNR*QbY!>GyUvUc9i*SbA8N?Ha=`u66NFi0dSbo=?-hgSHFKa@sI(6uZ-D=0U^#bbMgks9vN?iZqP(ncy z)n>eN3;8rcCD8KImtz$@ML5ZmrX~fK{I_-tj_@%ibf#bj3!sQywB)zMmx?=Hy@+s1 zJ)PniO8hWb^a974Lq2l5MM=g8AldeBhnDr>OPr_nun>nsjE*3+?qHT}jNCKL zIAHVG&3Sazs1%zMwN$*wzr>C8WN8wE))*W#hBX-b#H+Xb7i7x%F6lVz!AJ7DLnxhe zyy)g=+T`6Tp|W2`wCpCa8(|%~FxP+;zW`EjCfVeQlUuX;ZKtq_%<|#x>gxOl55b@$Iqm;_QAmtf=a5S{iCra)&0i5Sgs3S!yi5}|75cEki1!;qa z;<2xj{&-Q}vkfOT>$g;v%ae5k;jm z6>>3=6Uc#OCwJnp;qEdTH%P3V43Ou7441$!Mv&QSl03KOHyl>mPSGHv+2h}qje(jx z0LJ78WrJ|U#glH8K}2X-QT}OC#w%_Z1NVgf6BgFbh=k7SWIcojdD4bIP@hl@18Y7t z&YDsu;T0NCn;AL;r?ey^7xMcXBGX7->*Nbk~-8J9wrr4;h{uAN|$= zk6nfM7d{K2FkS(?1vQT!$qZyljGqIk-zBF;u5Ihu0}XknN<1kj?3(22=~N7sL|Mfa z4XXQ?>J5=cP2m{DKs>?XN`};oA^w`k2Ykvwi|nPmJfEZa-vero`o30`CSN_{@;wS% z{~bIN9nrKb1?-%u*bm`7XMe2 z+TZFq^(R}9Hjr(`4=MIs+a_zBYQCRq%nv%@(K>Ei(rGzSQl6>il7SYgq`)MkaPY|L z=yNK++&t2QpD1sHjEG{zqJQ@WR~R00>WV>fuRg2XKM(`j-bz{SgH7g)=Wc-Y7ofdv zYjL?=>n@UPLu!g{$)%|lqDl|Mo^0A-aSAo%-&Wt_(4SNZoBFBO4ph)~;)}d#b=1u6 zD|=E4liEF;qR5KD3~&pIDO6s)p6^2OY1fAEGINawFVicY0RU{`V~9@os;!)hoOf$~uzEQW(N2yR$$q z)@kgi!>(agJw2jql*`LSZ^6x@M>0PtX|rW$Ma5JD_3%)kc?=E@hRI5BZ#$NId`}zh z2tf~mG067MxPX#yqVPQ5s>>>C`FG!!bA$XFP1LzvjGS!p^g#Civ508KzppOAu3yyy zPt!q|(Q2qThFUTF-e9&*FNCwdRdeq#Hgg4Ljh#~ZYYf`@-^m$1lR199{>G!{`IfKS zL{}KXUzx@gzkQjPxEiJj^m(BTjQ+!hXV&*?bhGaQ@_Kr3jqrOAD9LTzQ>+`0C>r|u zV6vEhlMv6c5&jgyootSW)Zr_Yj+Uq3+7v*`XXQqS&q2lj?+8JxJnEMQPP1FPC3eKs z(hA?jMz4SXtA4CIpAgbMmSw8TSUwd8-Hn28^ZPKNmekT>dSPTMPrQX>aO_G^MTh^u zH+Xwyd~Q`pb!-*?7*yT82vI^c=D#}N=?&%|&N)3H=^~iA|3xz738DXeu!RY#Y#FCY z0~yR~Q2#Ic)z)w^kVaw@5n4=DJ^~jFxp}wj`fNPCaGr7R+t!Q`%v3z5} zaIh0GP*7U_uNMHHBRSpNFwS1v;L@)X79*F_ux(|H`g?@{6SQ29Kf*V7S0T4F7p;Q0 z>fl2NGtyx?mT`cDj3g??e)n7$Q6+Jh0Hyy$WsDwNN9>*=BBU}1RC%H6!?CR)3gz{; zUo|2@cnT&=P!ZcFCcr0!da#>&Ds$>l`yIm9D@aqVq%?;ain0JwGzT#4QU#$)f>%`n z1LEQea>y`G1(p@{FanMNaRLAFB4&@$FclBsg-&xW-mP8oHg!jxC3NH>IY97G48jVK zV=mNOInKTm431Wf_YYA^{%Ig5r&T~!9V`tY9RMMn43H2CL=w>bm%|JPo<~ zCFgcWz4G7lB$ zp~t^mEeR#EJXAA&H3*hcR+A!`)&w{Qp$G8wsBi-Z5P_f{kJ)GTHAOhS$6YtjYY4>e zh;z4sm_rG29Ek8)?t|YCW5!&%$`}M*JJ`RwW#K)&K}~x5Ukc9^!?b~bAZ;O}&Gw+4 zK>KI>cUnI)yxE) zP6Zo$~3mPO#{Y4DbM~x5NKeR?{FCFT=;8po9CmC;AJM}#IzomxYKCr|u z2GU~51|9w0)hr*H2^_S0vX`lAu)&nl{q&;Auh6Ck+Gsm)Z=|Z+CD&{T->S!E#DNwM zZVSYzFN%JE7Y$fXr9QR-o7KEr$J)i{q8yoWF-@hfpu355XTDiZlw zoVH2(8=@K_8Rm!no$*=CBv}IERp*MmC95i#l&-k&t78nulE<>(w-Bd78{06tWRyFmQNNR=#*F5Qf;ppFkx`PuKP zVdC^fs`>0njzo!^NW=-%XjL>l!R;a6=d2zD4;+znLB9|VA#j9XO}VJklD9k0aUo#! zUCton!+!D_vC0i-G#OgjvHVwIaV9^Pm~O;!NTMJgmv|~52+G4>xBMId;T@p!AMek@ zms_w2kzEb>HKfg4n9XPNsfCc~Y==?45qc#ue3nz3uF`L5!HABW=boxkme;Hq=0$V7qz2@igKSIFryPV4Z>|9<$&)-O1QT}T5PLe{P&p{BXKsP7d zpK8oQ3P&OwO9Od454f|OoE$!g56k)`8fmD02EpQS1$DVlj1%`T_`1CW2AGnf^m
`@7nMbe5SXUm<=1iqc5_Y{@G!P|fm-aTq?HT&%7TymtGm1A6fMz6r-X()p$1~y zpz4Syz)%u_)&3v|Ac2sW@8UGaJBKemU;%Z6ET9yP;*d8*PcFyS1Rr=UomY*RPA_!K zf$9;*3vp!@l1)?j1X~4?btl7ntH>MQy^`8tx2;R2?VBp~%9-(_>helr*z?-SCXk5W z%z_G;Ct!G7B{(qJ#p3MRA>x*F{tB)5>%S_}Qz=WiUHUQ#Qaja^j*uVnDy*4qkA4w2 z^)gYO6{>7p3hk)_si8q$T-H%3zET#JLe^(>#RcwR@7ff4Uq*NL1DBfS50|M5{WHi_ zxU23ui#M)Wd-^~7_S{ZgC$b|H@NP^d=t1ZR0;>t%DiCsV{GWEZV(=TqG+vdZ5swM* zs~rQa_y9+IhXf_(`O?L-Hd8P<>cfCrqMzqMa;AUn5V`jMV(ysV=lWG3>IFc;k#$Q8 z9MHPuI?x^D=!sXn)Go4M+Fl<+y1gePeEXLxyWfNiscAzyF#}OKD@9s?{Gs+5M3~{5swBQui;Niv0rQNW!8)Q!f+CHwRO_|CU+_djAHpedF1dVT)U_ zS~XP8`G+y0xmBY0U-uPuQzXe8QGq}2fo{1y$Bn!s0xv*6e@v^dUFoZ>_HSa=iyTH9 zU&owhrOSmtAb1qfUs#VGCPKJJrl!(UyEiS16pfP)gFC7z_l#RtC;>9ew8{lT8VZ$L zDTJduBK82DF@n&J3wRi-ZQ&n?%ur5n&GBEks*74Qxbw9G5~B}=Bdk5PVVUC8>k+_{ z{=1A}#2Pvwo!=wvguct_GVj#4;T;*(uzQPA|E8lm0sqL^+Yx1s__xA8)Q`0%YC|~2 zMse@`Y^s0K;6BU^9`dEhE6&nR@07)QGz`td&fwlhAml`(#&H!a20NtV(fe7E3qz>u z+DbVv;(F%9js4ijvAaAq&{u4?iG@{U{3?dQv?3w_&IxkJwq+nbP`25r2#v14LC|7jMJS9S8P_uD%E3`2*6#zYF z6+k?Kv!aBJWJsy)k1Y=Y;{e9ZH@C&hj!^?T?4I#H8{r-bxy~E(<#CZ)6<`OO3!0-r zG7j;4P6R&jnXkxKk6nLw3bO?f3CTkd<#YtRId=nwB7t%BQ-ly_G1RgjfJBz;PvT}Q zJa+Mx>^p0wC@nx1t@g{G(|eEJS+X83G%aQf%6|!U1TCO+jO_5?{+-ovjczK50CNB6 zdRM`oY|Xol26Fdk#$?wG5k2X>R(>P3hmXRMZ;hJjm_t{WR<=gu6TZKUR5%9VG9qj& zfK*pIam_ZdBGGRC*4#*s8q?yMvy;(8|5(O1ttW@bygG@)xZ{l7EwO@5MPxzLTg2NH z>Cj$Q8-`Tm56BG=L#ZQRB-Jr$!^r?Ax49{*Os*sk63INtfs9f9A9i5=K%Sedg8ZqQs~arbSMrX= zg;pm{9#os|x3n}vePWu4e6vIRj0kUJXkA3&5Eqfn#DOs@B61n7^FH}zXN06}m*~6R zcfyhp8gih|swjRKz1D^9#cYQKjgL~~iL*a3 zPLE}_O;(TQv*zjjw#7Aaz}Oez`Kg=yuB155|DEKf@5tfsSCA}z#^}2dttC3UFw9i> zhm_;Y`t@#mVl<{slJdmE*SAwH@pSlV{yCGGv>B<+J_q_IPo2Feh8gc5;`+v9oo>|0ms(zU-oL|I~@2smz@_rI!A zD3&85zhkXOJ!;_SU+PmHMM9HU3Tfhz#0ek#D1%XQtPyB#mKo)J7I>$Um}y)Fa=84d z2E@X08;~DK2YM&*h;=rzLP!5Vp$$a;g|fdH_31~vsE8;cYkcC=n`y>57Xi@bE#=m4 z6SI-(5;2@r`n9{6g6x%->2d)ao6GM)#9~81jE_}SI`yOL35aX~Z`k}m(HyhVjvkR#A3CYmlp zrTaKv>K0=%Si%@&#`_@JA5slNJpODg5}vE`6EX+iBQ}gYg;khT{0N0yY&z01hBoJD zb0GePL)f-}@3n9*I>Bl8sVNKPwV2J?SgW$cbaa(eS!?n+j_v_=qm$Q1xSc0mj_FGXOP$k;%^t!%zUi*W z&XN6=2-yJ4*bt;wM755iC{Lm_c>1T2Wv4%tVqO{p(M0_%<@EHw%b~c!cix%Qo#D## z87w*&HiB6y>!w%2d*bac4R1_OEpITSP4*)A+fs%+_rE+J^X+k!Ja@Sm%sBtIUBhct z-rxLR?X86qc@qQk|rk~ zno~jYS)fpK72dd^)oB_^nWCxVRfJW*L8l$J=aEWiF8Wb_uO8v$b+;{ZL~4GQE(=-Y zVw;Eu=Fz0uU#-;D<{S~)Ek^~HzM86IY;+iig6%6yNKy9H@|6m6c-e!9cE!ZIPK%}E z6;%>MhKqbUMdbNkW8))Vw{Q>|D~uK9oMWnjmvRteM1Z6j=^Ab=TQ^8!kD|>C-EZ8@ z+zMXfpmQs+@KH(1!YiY{49j>f@|%-UnX?z2Qg82UeO5}eF5t^N-$bc=&>vG8LgmZ} z(sZM;P(rdF22rErq%pZ}@+YZ2s9b3= zd9pK%xlc(y)`BQZ198l>)aiO&lA(kAFP6q;^hf463MoU=OlRjIBN6mi^#zLbc+?1U z(+NUn%Ajn%*-Bd4o7jnLrqJ+r%cLs|PU)}aOBjumJP6fvDsJbV{*mMsAqcIqpOX>~ zxGr1DP3*jT+b^hrMUng+dkas1{U8D+NdyJFF_ZXzJ^3#qj!$s| z^HS6GGF({S@3(DXt=4#c#q{hOFO2?d519OIkbr#Ygt?}=cex2 z?TKD!7C(#gq&-;48YVi!AIk|5MgH~{=l>^){$jigi!$2I2cC5VLdMX|PYZYH+X~kd z@ODi9)FCFYj)W61;6q4PV&7APiA2vs7i&+J^WVf)Uc`T1UfPgLNjWE2om^t^C*-IK zqLj-Ee7e;G49A>2i8(pwR|PBwJ09E=+HX#n=*xWT0_sTb6ixKVhGwfsTkF;DM3$$- zWVrCe^NT4G&K+3Z(AUw`;73VKh4-||1jdGf0efH4i}TG}9P(csJ@tcQsA92uPoIxV zAU73&m9-T7cBRO=%o6noVkC2+aK~dItT8R6rWB{#a6*pWSF2MP&UKLf-s2Ue7fO9Z$t^Sib-v8^Co zoGJ+f)Sdy>%jio<+kxP?EDDne9wbaW6$f}fgHjZLpVGKeJD0oUJqk*ftqju`0xL#W zX%NLJCx$+nK8@YPGzOFf1+MX&tZ=XbQ;^(Pp5YK#C~WcB-;k3K?)>rP$T#kpyJR zX^WhkEM~|??H`!a9j@SleAz#-Qb!cEr)}mpy`efY);;0+1cl-lbB9k`*yHe7#7kQF z%v^h0yHV{L&5F&t=lj*+wbON?m#Ix1hV_9qm;&Tj5iGvipJBoT@=ald;#}9u|ILaP z9WY!m%^2Re9p4njo@JVGHt*3sY!Xw4snxa~L0ZS?A7;gqD(v^5xL5Mq%r6gnHu<@fAF5Eue+UcWQKYMBoSX%w0mN}kx0t44xS zAAozph6#$RU%SoPsYS0~vXWf!9I~)h5%Q9&^9pivpo&mx%zmZ!{pibn;iic3Q5XAy zA;=5!r*c6~r3B;>8N>?W3xnFSID!&Pg0h5Dkl98ueyPuchgk~ZNBF8~hFUOM5O0J! zArn@flTxG5>IF>~4X+@wDcQ|OH?23P_NswOwd84vF!aSNk88DB8XUeG$b6k`;n!Iehq4bgbl(TZJ zer?KC?~E)7ftWYz@geYNM1Cc$r{P=_2_0|TdZupfM~1T6)695ktS|5Cq=t9#_CCsR z_sRFl{nYD^%#H~~ZsNhKW33qj3Ji{^5mnvTNNO@VBuMT@(Ew0_JZ3Bh+4QhDFN*DV zo;Z4o$RPoV6++QcB#QzH<^Mb76eoFu3+Q{l#WqwI#=0j0*s+7)m_7Fh$gZwp#@Nmj zC7w3Zrs6L1{i<67ddA?Le}VZ`(~-rLXOzG3F&JI7g=n_rA`ETi?NnP>K@tz8dC@PB z#Dk793Bid`AIXxYiG3dnlcXqUCpZTsKuqedz5HQVL!f@ZG5_&qo^ZRk=A3NMTM-jd z^NE!HEd%T3;+=P`o36O^4*{99S*cHStmFhoGKN~Nb3q}I`x3viY%26v+oHB7G1EvA zkNS77+#1IQ1XBe$U3I6OYYz;X&^atIEa#^%VINm>=~Oo7MWrC**i$m@Fm}|f50oYU z8gPMeVBH`?5AF@9(JXl~ba+TW;gu#Nk5(J%=FIKaM#O@j!v^j?V=D)#V?mspt^ghg z_9M9rx|w4`Aoga()$ZTj*-%Vrt9d2HI)@jX!3lFV#A496dK%U#@GVSL!bceiY*3YG zxaUKubZjal&evLG6B#FPT{o_!W>4}l>uOEjH@TQLAXXHbDHwzOWWOt;TmYyHP70`g z`e^oC*l%zs*L$g|wk&m#*N7GrAU%HCy(hOB{3_tW*PgA&P(QwyPN$+TqoBCIV0UTK z+q2yQhRRFio;(#4lrN`F45)&FV`hx8pJ$LzC;{GOG;m07QMQsv8nLS)5g1@tk82oNei&P{31)p>vHsMu@y*2?{O4jRDXz& zaQd%;xAW(;sTVKBtp}ziVVTw6l98QqX_y3~@j|@_|4vD#-;RW5}ZWsqp?vmNz31FHkuca53sv(i7i z&io&II<^_GKTo*JjeOL8FFrakR-GI67P;drH#2bhV{avff-%-S-(QA9KifIpjoysU z#5vtq{L4x{R_5#kZF}h9H1fUny}Ya8PcX zaHawa2$2ZLLc|zK)-PFgSiY^;9JMnoL?)ExJ528_23vA+L?to~B^W(8?KkR;F*Ahc z=Gu-Tx8Q+F1GAq!f$U)gwa&^s>m1qpTDWi?RBHkxI^R3Z7HFtRisRxo+6DcBSmP0p z{l#lM6*)G$zCHH$@Y8ozHe?(Pc23I{8GEm+@i61f)CYjJ=Tdh)q zh1WCgPO;y#E6IL`GxEsQ(S80`{T$1;OIe8QEU{HvMJ+*#YGL%~dI{=B%S&XG1jaO$ zA2@spKEedk`rzF`@pX$6I>Celf_`@iIi)F(%NNIYoY_hPpB+Tcmu*<+o!9`tDOCb# zS|OqwYzs!)SNfKgzoJS+z$u+iycJdEOGq*fn zQx^Mg0Oh2MNqfaQ&4{^F%#KY1lz*Ar)+CQp2fHG)zJt*Q`Gu})8QX$gWC>SrxJ$kZ*Q}9jySgYC$p-TczOT;p@OzQZJn@la8LaVLku3sIfrLmY>=`w@2f{H_*jCPg zC<&dkvxuDVjC52`BHayTvUdSyj)E48r}jW!v+bs-+x=1+Y?JUwogx<^O7Th;rLb(T zz(0n>{>#!!W>ZiWs5fqa9D*}YtSjGA1$0YLXoaK?$X1$8fskbMV?RN~G zWUD`n;U&_&DDMhg9QzKXh|@D-uT#9@m@g{+OX|jfkT%cB^Ni+GGr0R zyVFd6WGaId{IW)#sG5o}%+z1)oP3TjUEd?2~k#NUf+CA#ub9 zp85sxte&l&TwY%Z8kG*sF*COlo&anG0|(maf&i>on!kc;tcDceSqpas{k}(9-?g6T z^iMMoL3_begx(2%$P9l-L`Z8RV!-d{j3a7UT`%36(z*0rFzY)|SuW+sl7;@1sFErN zKgOF(uOPb~bSln6U7U4$>JvH2Op>DM7ZTl1897HGYZomtoDX2a%jL0qf8$ z(j)0xG2$^gY}I62hU3fQTx)kM`nblY zdu6zf2*yG%LL;URqeKr@@-AFhQ1LEA%tndi5yGXINSg;d*F^CQnjM%~fM}X0=q_%B zR~+@cuQ;W%P|{C{XK_u}r+41s7Ca%5?o~^}U`l4XF%Yxga*bME%)mm|7jUy?bvJ*)dsnaL zbj9DQ*(bsn$pEGrt6d8e*l_v6@2TolFN(L8aNRuReTgPM3B@{-i5F-(c$z>NG#L;M6#tvxHwQ0}eaTTCN<1&BxPK{qnVv7c0!A zUkS!#U?fy%4Pm?t{PGWTcP{+<$HSXU{qgbJNedrrr9e|Ai?9YQ>F@G)ZRT%v&uaNc zTAagq7ThXThvE@`!xBM*c^w5)woS(VMm)>VgD~Y%an3leyR2pANoUJAdM|5Ogm)AQ zkj1+-XiOfVd$+r$)ykDT6sCa|-~BQsw9`$28MZVF1=o>K3E}~8X+8Qynk<;>wt^V1 zj5T_rt)iPl2zr!52*_$PRe2Mb|KhylW;FN5=48%BYu(*}<>~Ad z@`rYBK3-1edJ}e|dy-?B-y->I8?Khj1q(cpQ=gUBZ+t2{3NCG$WFgdcEHwf3ZYMID zO0@09Gxp{U9uPKMz^ynRCCbE02|N+RYY3RULh}fY69SP_lRt)<1=Tv~^5`ZUegR3{s}_-D)L%K^XlvpRD}4Eo@4vq%`3XQ3EaK0n7$0ku@q6z%M6 zePLZw@*&ln<#S3;z^;vWh+rf^NGm8MJD&;+LD!&ELK|c?7<*NZ@a4Rz{N`HLf69)| z_BHCVERou~Q?SalanlD&r{2Q?=)kCHd zp*lJ=zGACK1Nmrmo&me|`5pZ1z&(6Y6do?~l_uBC_7{7a_m7Rv^*MgUV?7Gmn`8SM z4?&~pRwM^5Z7Fj^eTOWXzn4?`DsEi5ZX#dA7UZ6+6Q9m{%XQs4lW+R*uA9;#nfoUU zZ72KrA?vX+AF#Lw6+QV!oPvJbvZ7!U0_+P{?^!>whV=G(tc6Nwj| zHQF=6@wj>^ygTeaFgWTDh4JubzspefzhS9+Dg887^LVE1{l_Jk<7Ptt!|AVG`)@Ja zIcU*cnJq|6HbD3a6Sf64Af=y_G5+eZ->#LKfk>zqlpObL;YBB@V$?>U<_mPfssxkd z=S5nlmC(lI5N%Dvx1__jtRkcOGcv+e#4IpdoS!eQJBa9MVR#aQO923Y{Z#kY1b;6~ACawp#WKA{9J==|@eXyyhEBm?dGP z%yY)rS2~nBwG+2Ok48UQzW#X~@6zo4B0jXEwc{1mh9eVYx>^ma$b3cRs>_j>U8U9qs2@?6W(0@sR| z5IJo6ZSDJAksL{l^129Efs0c|VJiC4Yvv0YepoX*8q5+a60sd@Y%k9oNeYwM=*lto zn@LAA4)=Q#^GT0w^oNjrZ-@^wyt%L zo+8GpfWqq$_f=~SG5PD3lcTfy?N$=Pru5pe`-$XvqNme}ED99*Da;pIip)_CrSY*Fk>D6!)q!3>K5rXsi~_xul?1VM{3#1 zqjk8G`PK=az!0zJ`4@ z7>8(?MZo`Q(Y36Cd&T;jk${p7KH$w}KfE(-q{HkQL`@9$Z7B$%d-vE^R+a=F2c-Ef zQobcFg>pX}9-y|t-0(E!H=$*Oa=tm(tn2IwjqgRNq%BwHjn0$`^L)BYH zMcI9Sph|a#BFz8;(jeVALzi?&3P?$ZfTT1GAl);>5Gsfu-7P(+fOLa&_kDc7zq{7G z|IgabK4Kv>kel$ceU{XQD#}>-pa4h?a?4@Se~;p)(P??i^5=d;j*8ed?9}6ARkb-GY!L)JcCECNZJU9Yq}a(<8&wCl4VpL6c4Yl2t$3;~K01ud??TwPXo%U*qDdmgg;WNgS6l-)F*aHuP)f#!ikuU+slB z8ii#)r#Uy1o&Jr}b<0Os`zZ}koQ|Qt9nV<0v1&Vxj(v6PFX|(k1U9Dl4@w6NZ;o)kh?RJTZ`Hs!{*T~s(-Oci4i057?kK~spK|Z%dy#SatcBf`jT+$bt$DQ{&EU( zo6(TG=}`B@(*QpgDq1}zFxCbY8O*bor(i1d+OPKDF^9f`M?&&w@1ob>E+k?`N@CBd zKYOwI$4SBszXLvKli-vFs529jBrTm)59U{E5v6O?=BJ-_xuRTk4jx}H8E3Jus5VY; z>tTNQ=e5@^jnD@gzdFg!RN&56kjt_4?aw?|GH!OXP7F-|dCM%8$GeSlLeSayghW&G z^9=I8_tx{HAr6d9Kq8yv7pOWfzTpEXc=%&RkT*j_O_NSkH57766$vY)MHV$ ztV~NNe$MCH=@ieo_341)sY?0xJCkwGNfznt$^USECo^0(`eFR_pPRWoX|@SfYs~x> z%tCA};E;#FA(xPPP0N@sT1Dcf3#PB4iuZ2ouaUb2cMe}k3;0c4%iM?(WoR`P(|02? zUmE5-52U6YRo?ZP&xi7#4{bxeJ)xcDp?l%<9N{|B$Cp<17FG3glW*vG5_D?wA!M|r zjwu&;YcwgCN@THcFEuA?7pvR%M(Bx6hV#kMKvzJ<^rEs%YkC8MH zr{{lip-Xlrk+L&o_j;~}0X3jRx&vO4uM;Ma3CllbMD*n11u^nisbOT|gB4t#xEHQ9Nxm?VaME z92mNQ+Uj728{gtcJ@MDx7Agh(J`xqu3$gZF|N*W=lzRG+W4mPx$YTFC*8G8ph*PP_Gu|5EOr>0N) zL`auBzK>a2^*6$`H->Te1mrEA{^R1?H5_Cxuq`_S=&9CdD~AN*SC8}LCq_Q_l63s7 z!@&P(F1|2fnLGrP!D${%>x?bYg2|1CV@t^0OP1h+=BoyW1bz-Z_JNgdA%a`3>fgvr zai;Y}46zrxY^L^#ggRclT;k?A;@ttlTB2YJAB;Bvb6rBhKSZWXBUm2U+vC0=<(!$nl!Mf*lAV|!9BnxXao#v30R1SLy z*SeysOAI3vF6!IJM}HM)GOI)W9O1>d4t$e+eE~t6eC3~veAoBbKfZ4?ry<0zxqav1 za3LhCy0vm<{#{MxokGM<{4GHk!YqXRFSm&Gt0oJBt&;EV!X}1$KO<}T2)9{y0YuD^ zu!kN1e$tar{^T?|b{=7(lJTiO|LTm*M}xnyLt?0lywqOi<^lzZ+^)&qV_fV|1A{>3 zhNh?jYJZY-@j@w?#v>m*9@JECh}0<6$(}F2qp|C+%HAp7%Z(0(cTTXlG3~?Q8*Fw$ zOTX(CijdKPlS?h_zlF^uq>=-lGxN=~vdQB)-CD%Pw{kAOH*YZfvU_Ree9bL(S~e|6 zX)};qx&^uWB9S+c)Rk~7*GRyQV(rOkN;g~hZVUSRy_JhL!=7lo#7 zAwQ1Bra3{ZPIoYXm)Q|0cEv}!Iy^VFg4LR&<#77xjZlE0VLz!x4@}(Twc52D*;#bj z8Ea%TRxC+?J^|^~0MwjeJD~nb(sW7@bXMr(FBO+6FI$k^nmU=(WFL&2_Xyh$XJ_^c zh>i{rNTwpSyI}X=vcgz-z^le&Vlg2^y*GOoC9i0~KF-XnIiaOUmo*R@9qxrY!el#6 zz?9l?vHh{A=Gsa^lYm7=6Ixc=ig+|7i-pEd%XbBli~uPWf~C~&B#C3cU&H^Z#6ntC z<`ez@ebhCAy)-euk7O$EoP2OrYwc%ad4Q9dL+kvlW6a=l43nN7j_VlYDycCk`K|k} z)Yn$WPOVLrV{Pw{PW}(OznjhGA)Ki!3sx`NLe(K*OO|g?Wygt(%k&`7SC9x&RvQ0%=YpLFqgP@KVE_ zvK&SmS6xTxu%w2CSqhm6Srq0*^kd%v1h!LoPQj&UBRVN=G!@Cj3JH2q+w3KwW z=0bBK-CbcI#Ux>IXOZOZTvh1tGE8Mp!7LbfYnKL2f;(HH5BqJ!wDU+SFtPEHIFOQ; zZ2_|3w^jOKwUb28-<_B#M>5qzi)5%bivJ3Z+0OFwgff+e-T_Y9`WTj(8F9sOj|L@5 z1(7exeH*XV?@z!fC`;4{Mb7-wEo?Tw0G!Ny$pXmvJLX^By0vBmSAc#yZ@H>d7Zg28 z{e@NcK1S~pT~CF!7Hxx(Tb?|#@sWM<)!Wa9f(9~wg>|mwAjJGY>cU4D!9ddem>gFI zC(|n?KTLv6keNF_y8MM)1Hs2w7`YdNBwy#0LWkGui=Ntf^5&O3w~W;7WH&Tc_BWQ( zIx;rYnfz|VTaWZulz92%s-*Zju?gOJU)5a884M?l;V;W6lX+Gp{;uAl@TW?NwGDL4 z$Xu#P?!n+E;Fklv3xBG&?jI{Ep+G5PeyV}&1?$G*2*q6Bc%*jHvs8+FV~TSxkrAuT9Z zF}aIQbaF{440YdnO|Cidn$;CfD@Nt+z*$iW{h^Dt&9$M|;EuWmZz0`NbkD_lqRU5u zuk7=x$uThrf4~5fJtCS^C#V|`^9N#XX=pVd&Q~V0;{3)N{TIYje4}xoq#g#~b4T<} zc`aqEZ{LxAC#KKzsUQ8~`U73B-rKr?ERx~15^R5)we;2R1;ZfJnD%=|w_OLs7WPJ) z3*F&k`;Pd0gP?2WOh8*d_1L7?^0y+(8~-_ojmQ5v2m*Ea4P-?tU7vsMYbz52ehlI8MqKa`&m4&KQ8|u$*QltUjHI1`hWBS?24#Pocfx;RbhKPev6y~pIhL{9-0f4M z5Pe>@GJMknt~|l%y4>1rYVescl0tAF(b>N>N`C%(k2TT`E1xiW*$6;e=z_jW%Sg){ zCng0;G)dlBX1`8*lNuxDLM7rN4s*_IRp6U_C26a+gFh(NE*kpA5Z8}H@ z4G5WNgkC^$&qU(&{UPXLSwyZQsZ6AQQ|JL)z@|0TT^DWLE*7avH>Q)VPKiL%{s)%g z63de861?C4kz*w6X5GJ_ps!eD@q%vi(VECSF$S zwE2vGtr&YhoG_!;Bwl61J+(aK58GG3yO#^8rJWc?&n*1+DC@lTPk~<{g>E} zhm^{dR7Mo>g!g(gtT^(ig&f?E2e)nz9C!jRyt{&B&WT!1cAp>Eh@L(4pOE_yi0Z0r z`%uIdS&S`YZKQO`pci2FxZkd_@EYVC?}lGk)!!Zz|DAD#&~Q(iiIPMl30U5$BPNj>$(tk_R#p3}&x#Yr2`*9i`7BrWFY;%y-lAu&-N=F!M1sVut$_e#DvrbH(`!KD0>m)t;b3H`qGt#xZiF&6q zAMTtw(_Y!WUcV^v!2K}$t`vW~Cn7n;R_Ubyllo-7XPrKwYDDgHKRnN-ei zpOl_HYdxRjIq9f|{XpkO&%&;Che z5A>R7f5vwtC$?pvw@n!`Tq}%PFSOuy{8`vOC+Hj7I1G{}vP#s3KUQTnRu{KU-t_Ho zbE75^0sLCWpBfQ|qaC-8_!a#7Ur(*lSw(=tygumA_Ke(bK%TC$Mr`R|BU@NZqk6XI zwkE!`OzFr!S!mRgCo{%{=DPM$ONpLN$$Pdh5D!XxdCG98+5c+^AmrXBaSt5qy5EoG zER+3<9a3xT4PbyL1Z#vOf@%Kmgrzn}byX5RgO1`Pi(hk;??P$a~)s(pf4s$*Q90p7+d2&fGn%N)n1DI8a)CbN|4Wqh#OFva> z;t5^O3k`g1ok@vDg6tRWYKNf9NUMh#ox1K2WJS1h?vQ+R{+C-A_|48(lN^=QVcjxgVOVAfqx_})hPK0#W|y=q}{`8id_U@JS|_nfiV zu%ed-`c!sc34HvMj5x$BZ#k$RK=)t=mfKiyWu<5HDKvG)nNPNGnd=(KxyX#aK>nl` z;)GQN=!g@zRC=!~yHKqg+~(6?j+J545-8KCmlUe^mpqzNt@Aj{fy&0_KSLmU%K{S5 zM@4e_C*c{!{X5k2p^ssgoP&n$0DNVQ#e*5W%m{FR($d7qVLpq4#E%|#U938-ApbH# zaa4+lbeWVJK%?Z3F1i#5POCdH)8xA3j8ebF^z6}JGXChQ14miAtZEE-m?nrcF+sdR zZG`iu0-VWHN30}kvV$=j{lyng!j0~+90!h`F7md*&jNV*k`_j8gSYc|TXV2szB?)( ztZ_(6rv`6)HyIWz7u7YjWOCaBPeSZ1+wRBK4-OJTaxBdJ7_=7iTH5pLpB;>bNF619 zO6-wQchFBn{c4gk-`XS%qHywr%9Vt=0l=w#nA=9&R;A(B<}2$7!Jlx|RE*$&OvBgi z)3aH+AhDv@M16ivw!vc%r#AbRw4Zu*GnG4Sd6^-tWr66R|``p8hpYqE+h_*@w%ZN#dgd$72>NdaSQ$26ITRBg~^vh%??#;J)0hQ}vCdT5=szsoTh`5OQ z3<_nM?@U0Z4`PUU3Z-I2KAquk+wpOzMd1uWDp*G#_?Q^IvwXT*#QfH_oHxwKxh_(T z&-adtcBSHN*snkXodRS%G<;-sX;1tGulVwQ2v4t!jD&AJXJ6lY?FMG;-_a7l8-rqtP&ViOC#{)^-`Rnx@3Q_)u0q_ zmr{k~DN>wS=;>fA3+O5LDH+8Z1!bwTp7{9MxRfRye1LMn`G{@BY6_zO8hI!y{8LP^ zmU6NV^Xk#yD6NFU(`~}{Ymj*;v(?1c)|xhi?4+zdkZXaiAOz5+Ask|8lMfCiw1Slo ziqC-AJ1eU@_L4sw!SxyO$vdLL@J;^LYjk;C6=}I-3{`Y|sJXWiLki=nAgI;n@<~gk zBXR#4gih6-$=_Z9Xa^ud7tyRm)sJCMQtRfrY*Gvi!0Ni(j_M`@+~A*BsR1i-Puc9q z*}VS>>j%!)cFy&3lq-$$BklG1kT$i9>S!`yy@*fP@FZw*P2bw-?XT4B5!+e&+%}F3 zJ8$c~iJ-=ooS5f(GBvw1HfJE*uwWU6ppQvd=|Gxs3EY)*N|btU|Mv+S90fMkR_c@_ zeYJMRH5qpXNrsU(A7!O?W(4iurFmzgYJ_zzc0yl2y_bFG#rW$ztt7))HI2D+Sp3*K z$%9oJ4JDcw7H|5jK-;^N^OP_}^i8ZDcgPwGKN-g|789)2!2vYcMi{Axzlha4%cwKf z!mm(VwSw3`i#BTr8zhca#O5R#=wz8_j71lyeZ~TJvRON%TeI=z@b9)6n;`{Kqcp5O zAdi%Fbo_(B>eHxj`IF4;sBQ8@1h}NMKp|J%neWi~K+;B;!?YL%oHU~NXUXB%C7!ET zwkWLi-rg^Ht2SrPpT^uZGqczkg8X=dxD$e&opQ^X&|C^5>)jOU5sr?_bA?9FO!g-l zpmvLF^B;&wAL{D7mga!Na_8L$GqRMfUo`{CAj9Y)ZIEBcyvf2;D*S=4R3$ZMDktaU z;sCTAII!f2NMslM8ggTca4irbc?-Z`dTONXFG$|%x{!WwhOVOId*o__Md#tssYA?~ zP1xRD5B}6Xw9%rB*hzYu%tQlQPs+mg`f8dA)JO00GGI+7lO2Bm< zz7gQI$jNFS;I@2!;?JP1C;MEu zAY`d#MTSI?E?SBan^ASQ?J3|GhyLjbmgw^NamT7~*IvWdkgDmW+cZOCKKsvs*l(qAR7wu^!|N7fT z;4g(n+?2AnccxAqnyYr7hnI61pBkRuQek+$^bpBt!$0wnyvLYxUNSx91Z zW-4j;%TWdi1L;DX-1;mOZ^DP9DwMOTXzUVOlSSjd{uvAi+^7BMq>TBINS`G+T&2Ww z8prl;9xM*m-$G-6mm#BpcxuO;*fJo9!+thHg&~nm??~2-p(WTp5!GzMrwmQG5)uUR zGC{&B7LsoMsY&r6$S#Pa~Sdu7}S%0U<4&g&V_VN2*daw@3c-?p+AS0oRayq+O zpER+b3OlZQwnKNE<6ebyfRKdp-l#CLL~Jmu%fA~g*=ifMYZNZqgv_hU+se9W0ubP- z(3fNY0@PB&=V0LmDQf8|FmFTOKq#cRg+PEKACq!|WK}WQCAyGIRO5?GZd8s>g+^g` z9G-f8VhW8<&OdvbQ(&Ltfx`wC_mVOG@C znoK2*URZ|bHllySS$j2zYfU(SD|SSrHOoS`Wce{j@vfk>$fL`p=hWtxPK)Q;=j6c5ch(JgawI6Km_ z9miHE;9>izpci74Ewol;!kLGI-~|c5X1}&t4Vb-`xkr1Fi}|T)juM3e_YZ*0?s2JX zrAB9fP0Xb0^|n+g)kx2%il>xO;=tjE@{2}Cn3G{P4m$j&4lDD()Wpd~$!1K@t1sz7 z2EM7(@eWd78xh*54t4;sRN@XQ&OMFkFwxb-QvxYDo(-^rotP+!jGo2r>wt&siom{A zUa0xm80}L|3U5XVKqHj$@Rb-@5L?6FKrHTwsBT;FNoIQhPALl&!mt)~H&Im(;~->m zPx(oLt2xVC+~H_N2#|B%pP(7Cdjt063f7-*a@W1Nc-gVtL4zjd=Puq5C9901>A2&n zI09?Rh*viG23!G3=r9(Ll!n@8FncSrqJ}OPGZOk7Lh*vT=bxlTq+*pCxqvI6O9mu` z#J}Z4c`;G}?7hf~`^VnK^b}$~HarbuhZlTS~?{?WaUiRo09qdEDX@015JO9X-zsWm97egntp`CJi^u_4 z>h9~XbK2&W{|;Y-i7}U~Hj2S?m`c#|{zb%XGj{o>Z*=MPDfxCd>V21>AG!i7wT@@{ zSGLbaTl;rZ#>oE)?Y{Wg%Nm)8l}`dVGly+l%GP{s?MofGDIHVtV$*BYe=U*x#2etj za3|o8xU#ituwz&}->&`H9iIqg1El2T^$E8qUdt<&Nc7pgu9-!Eie*p#!l>j`S-^Es z%hxH(n?;+%>0QvPjn<8(?}#rbSvtV3)wrjNiVf+kjVfG-Cb*&LCYcK0pHU@&LLcyE zXgSY|d~RDikXaZmYH-u1)~gjz{uLAqfrG`o~%@CO{}Z3< zVk8$CWgwpj=>j`BFH`XtuM%_@3n*jI6BHa z33)KQ&gR7ac)54uN9ytUS6`p|{jJGedh?w-{u_e;CXIerQ%cLTRH|_xA)x!OVKOnH zi_Qrq#Bo6(-r(zWE7#glk-x9|@*emg%YcSjp3VSUR{#Ieic4zDl0j=IOo-&~&7fhHVWFFTB$3GI&^#@uQv z!)*lN`_q~}1g&^9dxQX875JNOYA(6DAJd4{V^B6cD0u9o@zSr%`5@{g@>yIWZ`%!cc+(i=uB77pUEE9Nn%8X(gG= zO{Mv4GzJ{)uKuW(n%`L*Xf$&DS~19peDW4~SC*bcs3Y^zgd|}ICO$1l99~ELaU~^e zXqgP)U)z!W$m8hW^?_`6ZuT(x>U9mK+T2b+3%(I3Litdm-rAJ8MJi zBn=GuCdlDpP8H`J2iP8Ix`8Ar9F`w8z%wap<&84{S+q`+_@6?RIQR(K5P>~bn@_N4JpI@b8kX@vA+)HY;(KP%H%v0!q-O!t+z z**+jD^}V%x9*aoF{j#@DO60zn-rTuR!_oC>S#k9|8?gIkJG??%wbot>sMD!Ydw;(7 zUyPh>mI7lF>-};i9&!)|yBLep7PEMZWTmzC6UV9HDSnWU21kXL=dDil5{H9X_s2^@;ANMc6I)0P7+```tR+`TJT#vA6OY+w}27?CVqA zJz`qZ@pxK$>x^mPo5(j}IQH)>3aNkpG0t!k4!Uoel}6#8JadHxBV0kBo2On=hyY7X zMAYHh1lTGP{N-^B^`OtsvCis#c%UV2Sd#$nNUhTM7RpkEqixEokSJ@O`?g`xqGMYF zUcHO7ho*zn_Ai4o+cEI6>dHvEFK-3hlnazFy}9=Cq9sI5dXbgG&mIJoBT&#iC1gs$ zY9#~y=1jMcn{LCC4dTb0ip(hx9hXe_-umKY|*7nh?K@c4XXK`hlk@<$Q=eG!CGq699!P7C&5n5 z5Fq>%Q1Ot(ep}w8H%G|&z|b~lA<0-WyfSp(A&l5#TAMs%0}j$T4Q8S=m5YOw3UUu! zI)&pXSwkQuYH)j(6lxh-QzfFgn8&z6CsFc-Kvp9(5C23l(4@O$K?@B(Eh|Byo8zu6 zIqsMlqCM5HKdq;wL-r4T`8#jT%fmtYLi;1Yl8)L-jxD{9qKQtGssKxHs)~OsZPC9h zku~^;cCiAX5!Lx<5eX;KXH5>@EcbkgYfCF$*!3Ei1}=c#c_n4*GQLp_^|b8K!e`Hs*V`m`Dac9SUC04=euca@ zs$lpa2Md$9oo$sS>w)Qxc{Ftfg+2`g0t`@dfvZ;>~tssp*uxf1SYGj zk#e5@i(>%8bvdBb0&~0 zs9wS~Fg*X6hMtWJZjf4XY0xa$g}A<{X|ZXF(6{k)Ai8N>lygVc)>AYYLMDI5)SuD_ z5z;xRF=DIfk-U-BOV;^NI)c>Lt02=|U59bROw@?y_6${pe9$XZKkP(j;m5On5?}lo z+e+xKXZmr+*d&-bB-T7WYIc-tKBWu%otO#^{)q->{6?p2_nO1Y4Td<{ofx_|g5YkGxV?C9U%Rj$Tqt*I$_fG-z@IwGu9eO3* z>w<68iUKP^czJ)lhH_8zN6HUTq3wXgB)#`}0f|YD2ssCI|0=OL6Wh*ncxVL01n}Sj zg$Xo4gAFK5QqHs0?>?(3xTMCoX5C-_LSy@%(A0~Z1tRwoQovpU0zs51;(S>^LW3C9 zU`y6XMZ{{j4UNMBa#}v2-h}^W&$q1q*|R0y%`IzU(d<2NV8EW+|7Xu39BFqYeMQ*s0b-!L&FC;iUQwNBZQelw;+37YtVX3xoW|x$HOH5v_#xbXm_bWa?c{K8# zsWZX{;}_E5EN7xmf&aNKZ-P-s@@K>Q0?4m}8C3$`aPiYl|I7i@T!s4-xUudDsU3}? zDv`)QZ~(c)M9x36K4tsQtXuzoX8mwJp*|yxmrpgKZBv6AB$8b8?~GASaT)+yMO4-R zTUJ~2y`|bzIr0~=F$JRjg4q(U%d>T?%F$~8kMnfL%vt_v0i&o?<(l6?Q_E-ZovNKu z3qth+0LD_kUU%X66l`AI;8IO;Rpx(f^)K~r4US4g&E?BIJwNcqi)q!wk|&Q|e&WO- z6xk}TM|Jr&IaVgCOWUOgP=Mz^i%i-tYG2C%4Y~J(6JMh!um%*Hn+rJxyb7bxe_jP& zgVE+eROr|EUyWZ`$~&IN*188d6A^xbPK<&;zKlp0(EDu~9%KA^GCk`*H(>iejT%yi zaS1BjxU1#DyT6E1fL&ZlGw?MCp)&bx68<6c9{R6NZ|D1`a)>wG5~YDIRc?N;XvjsW z+A5u2rxoa4h1f)8CxTn%4n?hJNmf0=idl^n0NmQR6H-J8v59m>!2_-mZ$F z@yZ8S!4hpW5dF^~kKa@gfjb5F7(SQo_)W{E0kP7MTL~FWQNsC2xyX-4iN2>X?4`!t zc5NAJ%u9S7yx!SY-buy!pg3Kajg`{r&Tn52&C|+P)1hF1ypcDLYEk@HFLZ(Kr4pp+ z8pJ!CIxb6#+?CYhJq*OoUP(byME?bZ71=tkJmyL7icq8IV0tP?BQX1>N;ckhy$XT~s>(fO^75U$P`m5SOmh)JX^~R{xyCKG=#I@G*V4 zdkgg3FdqM00D5lX|9Wl*e{bg}SV#I{;=0(KTm8xBSH^Ln? zJbgk%5J|V(w60>Th9bhqR1t{q+TTcE0Dt-yVCLT1Xo`dG8~3-FTf4H;q0xX1X?yc9 zhsJ*DCy=B@R783MwpiGtvI|bHhWimu zs%&)ShR~IZe@O%+S}|G;NVK;ybUA0;u_F;h&Kk>h_Zf}s?B)B=U?838FxgRg`#BiZ zt|9%i{vY&a$^93A-nxHD&8pNmGxP=~%Lq`P-|ikxhXw&$z4LZu2#sfZC$)3g1fOhX z*@Fb>_BlS>JoYwx>{lw}m=Fm%C6u3}!GYG)Cj-zT^bHdTfTJe&bs({JOdLLLA2G7x zGz>p0m|)A34RogdY)l5w?m(%fSOkDm&Mf{7;YhCF#UxN?0|tswleV!p8l}N0PI3QY zB!Y_hpLK21E0r2iWm#W%s3tdxay)oLc4Te;%ipN8WR)S48SJp{;Xp~I$!7m><&X3T zruTCeQcuVOpR&qjo=fQ5@l6{P0|!;-P6JcCL7$T1)Tyab?EOTU;e>xNhOdXMN-@yc zjcO#r6u9oxm!z7+EazODE=w4Ymu<)AGf+tpzP(6zv8#qhPiV$Lf^Pn(`7(|tI2oU0 zs*7S7ZJZklF~QLT8ipx>6s6Y2nX%@9Jku)`ae~>!9bzD$jsnr)=mCu`=w=tiz(9g% zc&Hl`F2!}1gpyd-&}&Vv_>M^a)zO8<|EB{r*&gfofX8(=g+}#4pahc(bL`*Fnb!sT zt5B5B_(#ktKZe@4IPzQz>?R@%uH^6!pFAJq+eVBBiH$5`8>;NQ7m(bh@dug`m00zZ z(aYbR98G)K>R(p5m;&J1CzIa>0Jv5eSXWIpQ?GiyRA;Lx{LqeNNRC}kIne1r*+b(_ zY3n7C>3!zp9=yHrZ;%zc*y6MjycgkjGuKuV_!PlU|v3dLdld$-h3Ny;l@teIzMN zQ`#3yd7Z+j9(c!zRXQ6$3FtL4(gKJFubNa^IbmlNw!~p-M^kO#8njz4f!ovD44@n^ zsyX^@=C)a|(ZD?7b>6T{VmT%ji*Ig1A_OZ!gb84>`*0OndS zI?tY5GkZ<(#k4?vq*}|y8{{9NH#Rzcof4*kZUuxNzdDL^G7}?f5h>QXFN)3qfFtp% zBl%Y<&|iSLSZlweeNR`Zu(&%(YNn{e>W@H;x z7&u@-h@NjxbkCgF*_GPyz;u^D4NI)LDNQyMEoV#!V)(WGYerd)bz~40kVep*|LY?# z<(`UF0rW9M9g#Gwbxu8=DFz8(&B+SVUMT)FPVcO{M^c3jbER^OsY1_~hYZdcR+{0z zUDlOVmotd)nZmV8eGBhiPlTd-Qx8I7#B?v-3_RTornp(7ho7gQy+oG-u10&E<^MLu zEUJ4gZG~P!ML32qUiOAu1s9=g{O5W>s`08Xo9tAzr@J(OLS28_GqsM9vl0@cH^ahp zEE+qxR8YjNh|eEo;)}wsW~xBwG2($3gQB|>X-Fc)u;kOme2?~53IhwVRaE*H7B?Fz z_X5uR+swv-k4i%=A8>UaBOOKR&Rp#ahW309Z0qx0+$6WOYq@H=24`8cKiC9ZyI$8E zZ>w2YQB@)I0wU(yv?SCLc>NhBlv9+Z=PhScc~LF5 zbP=eSQ+XXcGimrUfo)6KFL7T>1jxLV%W7TIM88R8yXLXWFd2nz!HEqrA?Q_n{jy(< zuf)Hkn9;>fFSf59uIdrmi_HQS_cZocf&5m zu!#byKk-3Tqf^PeLwGVV11w6jYR%dh#8DB<(N={x%={F3y7;kS-Nog8Mh~wuVmLT% z6jfWthcmdp(f47@lc}kY+_-)_v(FjX@!`3i&1*3C7d#k#r{h{*$$B<`kz_t3llLXWYAnJQ`yPTC_Q3h7Z6iM?_Xc`$UdlqI4r*mkF1! zt_y@GP$2pHdn@8FzP+q6M8nmg^y#n|e{7cYs zE59HNzX}^=Yn4}7D%hGL%_JWgQ&%9lCz$nBpCVZc2}m_;MLhrYb#JxlbV0_ob(;Mk zpq`@O=7RX(bBJTL{QApw%D zaIo7wxU!D}*_M28EClSZ=N;az*(C9fJ-B^S@@WH}+p`-&OnUAH;>waIG*bUf4!c$CS2Pt_I{2W) zIGrCDf6IHg*=S$4%o&rq1pUZD44icD7#82bi4<{}N{MujfMpP1`ZZ4LFvw^{Z!CYJ ztBh+Hp*bC;EjbN>oDLP5KU|NUOxb+)FaO#b%HS`u{!1>phl7Fu%^xvhRO9|Fh@^1K z!>xeZ&Y8u0u5^~@ zv(LM?`3wuW7B7?h0@`LI4IY@C9xz8HU;#!AmTb_l@2^9wgP_ahp_1s<-;3CEk^8-M zTZoomL{LQ>PbbmyyDjY>opFrS_vMv+5#+!gWcmMg6X277@@KMoW!mS+1h22^*Vs}8AHjIWI63%9ZKwWAOo1{qeV6;!-&dTF zo<&%LR_5fh=Uo(d+h$_iU>NSUtSa5)9`3T0{blE>xufR3#0J|8JkahQCLJL)eGek-K{j{@H!q z5MT5AkfamuAhzz*k8_{$p8QB9OyLyrVl6IIWD~;RSiYNjk1^Z*?qo)y>8{1>?i=_Z zdsT2pYC0_GF;FZvO;5cOp=A7;2$6plz)2}s$cq_LXkbYmLzD{+2_APJ_049=WJ^NEY zqiB=nj=UVNgutA@!Vh0qv4Hq1#Lkd@{oCBvjw}6+Mu;JO3HVTNa;(5~ZGZ;!{Y00s zoEAywL|#$KV3g{{Pc?8)54+~ss7JX0xOHk|&w1ir`Sa#kSZOA@zl!Atx-~w=j4(y) zGpjm}mIs4Rz;jmEoV~cJ6M-Luu4P-ZXW9+le1`gqEjsU-#|RB8@6hl45sB{A{vhpK z)QI@^#z@|8SZJk_+7=yhFU{h6u(EmD`aDaSmi1HgYi70@tIUn*$F)UaVne1#YyBTEZb9p2 z#_yE$o=cC>Slx_%tsArLa%9=?7t#>kAc=+-M%`o>s-%N-wHiMqx(AsN$jv630rLnH z7LUb#qkoliKB%6ESWV5NZ}-p6uK$4l@D!W7z4=^A=qzn4xQ3Iqhq~SJT)`cY zINkPXxEs93ubHiehd~%m4uAs5NiAGz2T3!_2v6VNx9A5;%RcO{cLnHRV z5+@7M*r&3BV?3Qo8LvJB$oXXU>A==>&QvB81yt|L!}R~^aDNRm`itq?WkbBJ_b4#1 zsyJoP8nWRx7fcnE#qc25^}9LuuF*sU8{exr#pa;u_G@4}mE)2o`-d>G;PA_u%Wu?E z6IUVs4_p5jUFY|Ojl!`Tn>$W}#>S2s+eu@iN!r-9(b#HiHMW{GXlyjLjrY#)|D0#M zXN>dd9{bCl3lrCzYp!dJ@}G&R*9QqqU*i|?W~`1M6;z%Rpnwt`VmZ!2c*!XaPOM)V zy;J^fXLa)Df8$_rf&-TzID55&2mN&8o!j2m;u;A;8pZxE$y z0d`*Mg83|zE!``fA0=`&cE3N0)2O(}Cd?W#@~@X934*y4_qh=y$z7+=&i!GZblOF* z3FTbTrH<&=K|boxUOu15UtCA`9Aa8S7Jp4wbED5Vj$+7mM;AHxj!BlHXEgch!drAD z4!;6dA3Wf=-~rk_ct$v;edQ$C04gE5dd3g+bYWM*{-o-$g%Qeml1(Tj&F;8dKy$r+ zHh%_XqHWCB_tmg6%HsGJZNy>~*v>8pIR$aV6=M|Bl8o9rbyaGEg@0L%6gx*k$6Sy{&g3e=g&bhOuh;{(#b zvlU*Fv|}gJ818ioqqyK#v_JelCcn7OfJwOlliFU*Jvrq#`($olF%#>?rNiu={VM{_ z+fnEH`;C=+;CjFsWVuMBtJ+Cyh^rOpE`jzFWdXg%ByjO2p}k&-<39-pL@gEe+f{et zn!b)im!Hm0+>3V?cJ#*2j^=hqq}csjL5ZYi!kA2JB(}TkXVw}|cvQE8hm4mqjeF|) z-d1>?8{}~d(5xu8!iBiE4t1@P(H&GwTaOc;Zh#-~p9O*JsX{&1bF(DWn5l%jLi1`S zktAxxRz8%X#6{jZ%i=RS13{}yd7@YzX_wWP3=gk#a)3h7O2vLsLZTnK|qxx2+kPx zkOHm##<+1cd2QLDgYM(^UE-bl%FOjY9p$tC@(W)gGRsgCo?eYIC9Kl%T2k-m1qutp zbt{itq?^ao925YGI02YiE&-=v;H^-Pc>c97IXLbKmN@Xr+PIGZZ(Roo+AJ{=TF>iu zJJgg8Tcd3^4gx&8slf&Z@YD=Z`h83)6@iD7zqd@~}q8Jbrh|l%4363(_YFgaC2b zH4q4w5C8ZhFE)Arz z9vmjIuRuFg(KL@FG$JPpGHxo#+f_n<_kz{yy|4;FkC`Zx{w1=5k{#mVUH#CzwXu60 z;arUtj`Xh-yUi!5^e%wg5>T38g`3G&_ndeVFlFcF4Ugi(ZnSbvm zP(Op_Ank%AsolH~LQiL+bv3vhnw@b24zs?NG?y^g z+=xPg>v4HqEOvP65Ns?>@z>$yKtPB>eKogwy!Z&Nuo#v9Qd@Z#u{?AdM1N*D|BCx2 zA>eqygZ4^%(Khxm8SBnHK`cd%+Jj-Tt)RBZvF>D8uInIRO8$p6KtS3+p#8&|~8Nc(5vQXA*c z8?*1E@zDJMERlfbh5^Py^dP0mm2e{van2G^*IDr5P$vW5Vyp9?$O(xJJtMAGRZ%2u z#E+S$m$A?7VHAJ+PdTO&TQgC#TugXx#*Z1twb*Mf*cGj?fpR6d(`$uo7BRcGs z{XWlMtScueuCJrxfI1WTSN=c3(g9)0t3NisK9B#O6&w!)Q3ZGWryW_a|BrTH#>f)( z&t~#{Z~&LSmLyt>>H*hzdEV(Tmj7)cps=Dyy3)&%moo;d(vn~H3CKCDV-Uk9#}Q>K z`%~5sG;EY4i9yG7e`EEhq|al+j@kNt%d8eV+ql#mp`3l&@eSxw|Hd(?H<>cp9UsdP zOlj3sXuP5IA(`DnMV^o8P&@cP=zi+P1%-i7Kb7@QWjIE5Q%x5=CoA~#q4mc7tIJU; zpo=(MP&*=#(SUs}Ak5%lab124tydOM2zlQxT)(_rNbhbNfHteZA1km^HzeAt@FNkT zEX~J!VHDy%it1(`_y|HR^h;Ti!ruSvjTBANFw2OiHPHx3JLKbv2a-=JtWUmrT-77V ztwv7!?%LkYAV8mYh&h%a^N$E+kbDuF?$Yz9dK9QQoup6lY!_rCxX9n_mkOh>v2aU@ zp-b^x72W%XPzw@O7CQxYFd`aX!Wshu%JQEA?!wJo#NUsF1}N$D=Z=BLw#M$n>Xf8K z+~}R7WH{gX@hAmm<&cvm!yIXUVb^V_@Ko_(;Q3_ReB$BmGUh(3=32Wb*hd+ybiMpl zHOS71gZgY~$!VOJiF6tVo39+G$}sd~zvIE)<(sRLnTvg{V0C*TJ@IyP@jUDq|M*>X zZC3DFiz6E#MR~IBz@+@aY_NZE22|q8ZnEk@cdD&lRe`IhdH(ajK(V2͚!4Hy#_ z`;OO5vw|W&^^GGMeE*iJHV~TeM(1H5Qu5I`4oM6cwHpH?N)NPGRZq;UMVt*fl37mC zH{CeVsII<-N#0Wqsc3&LHI}Ew9qaqrhCOZfX#`Q`a_g2ZHxH&wn7{Q4 zQ-5{pFqf?(w|CV;kOw{;=K~$-=Czyhc=9xmaMO)N&pEeJc16%dcq%}bGoKiu3X&l? zo@bm45Jz}%FAI&~Uj1!*uxSFVv+Fv2bb$-Ba?%oCH45Y36YM+zD3#6e9N&oyGIW7u;`x3RfmFw4zn`cU~%T5GbKsB~GX z`pB!U1YlW!T>FL$<5P}u&KQ~Qgy=HLRTS!uewS&tI&hq9D}%W74xfoOt>8)5K})=< zU}JE+)!r}S&vdQ&mTX0<;FE^3l>I4G1PG4?U@<4{v^FuBmS%Hq6I?=l!?i1a;iP*| zI+GoE>*3#a{$3U=zy9DM!EqyZgNj`$BKUi|5^S}wQG}(FRQ_H<2_7prp{-@ z>tV!e2tkKSX*eN>^vY*Rfvl@)cJ$-zh?BE?ln`Z6iPB;Dqp(SQEYX$a8z&6QWibk|r2SF@{+MU<+2&G#n<+&A1a6&2RV)+hJbZ;NPH+FpauErP+`+dONux}G4gYuwI1L@Z|YzBneA+ll0k}j8}%x2C^qpc z@^5EZ;Vh72Zq$CG;z*KLDilI2ef-FYXabH%_yI$%juQ-*_pbJ2q(OXx;hzvz4`}@> za$sUe0$Qk^nkS5eIWNNdm(g+oJ-hB?Fh>hdsu;eIGn zc<$@MLs?mT7XaD#6-Q23=mS5lu9QhniVdxx5{e~V%uJ5y<L|5yl8(2ao%jj=IkT?9iJ(NS3P z_%Bbnf6JdFLVe!3Iegq6d9ihbt3<97gOj^!(?ERR(Vy?@ja?m(rHZ7%Of9g}v5M2& z44t2d9@X(H-agk`|7FKTvBHm;iOmkjyHkuaF%Cc>{Qxg!G6gGs*cW%LXN?~b`U7CS zW8m+C{%cHb^sZs2p`m$V>#*B|Fk*|Yh{VXq&a|%=w8N(>cyTgVAv&kXA>=tf(L%N? zj=8?NN)__rPZ1NBB9GJ@kzfOzuJApon>@e;I6oX2j}e6|Gu#6QHr!jPJ=y78eV4i5)n)*r zGq+B2{C)CW=An{-$|QU?OsJ3vCoqSC*lShm>jA5kNyRMm#5qJn@OvN-6L=ZtD2w^j{q(+g2KG~!ipX5sFVkW_dyYxrzM`@Mk6^?Wfz-+W= zBPsl^I$rbN2EhVHE8!G?IvuTqQGn#v1HQFfyuNOJ@3;|rYkB9U5KBxXu6+vo&Oc3TB&)@Z7P3F-;0Tz*a91b&ncW)uG zjmA@&ZZz+ARVIQP>~|`F5hs)AX9s*FY-HuopsY0QD%L0!Z4RIxfwOg}KOZozJJ=AM zOv7N*loOCt!q1+p>R~GE{PJX?CsF=8km_fj%%cEA7#Y$rP~;u4Va0I)NlHfhHzopUylbO$wnN@OAQK3El@@X|I zOEwn0>rp{_5k<*ct3myvsyHViTFn1g(2ZBYIxnJs`P(U8>`%VZL>4NPij~SlG-`f| zL{a9RcLfXW>BFs~``)V1Sn{2*=(Fa!@{5UcdWem2ZlWnccssz$AP~4kweNXMcHloe z-6eBTZN4@ugHmUaW3?1ND_wV9Q%0wYE&bym;t}KTfV60Ui>Yja3+^GjhhL!Op27=) z*$t&ryL#7a8{gmZap`aLiM&OcL8`QoqWrFh@POU%a|55N%Y*pPJ6T%O@DckPgOr_) z`+jRUFYX+sBMie}3AIYA3LokZ*A5;gFId`^F(vLM&Jy(n=i+Mm~TR z>=wCqr1cJ}yT)k!B&qyTNrE2>=SW*1LLC_ZcKr*?DjduWd&lC z^xYiE1TaX_$@=*C6~z~y5wh%-?ceCR`K}Di(hd~xIU_~IU3cFXQk;8tsGEcBqBV9OgIT#93bHXoL zt+H?ymkJ|xj`|I5r5*qy??4NNiaa|Odj-{9V(?YdlD{UVUruyZA!dEv%;DdGF8sTl zLj-)j^HF$J?XPJbJ62RtEUo_l7|{>*ZcB;K%@_a z`}}#5`_Fk??93LqwnpKW5ixBknVR#(j0lA`QxHu4|487%P@UsNyh$LG=RS)L@xPX5 zXW-i>`-HPiM+aEr!iJqX0rrj+W(RzJS`=(VG6irRAIjuvD?%34dW^A8ZgroTWC8bA zV|)=fj-qzZXA&oOd*4$uC#@Q~i)qH{@|n_VXz9g3DiUp>AgZij+<@$L(BGD6QBiGV zL=yYs>L=U#KD3t=D{?@)4puD5LGow^*=QmQBnx_3N;!^PI>qtfbIq5^dMbuPV0c28 zK|;Vo5-!AZik78ky2tOP{W%0=t}M6* z6t0)Ro=ft@iKjS${wV#e9atSYQ&$T0VE6p8VA6BH=K9^f#=wM}y4(%#n&IjnBd_-YHpJ5_3 zKN_%ZW9n$$@lf_DUbM*imp_`<%N%({_vc0YS$RWJ;~umLka7i_28ZT|k;4F?60D67 zt~+m6@>o;*%0>9Rg806C&npPz9#$be)k_dkqA;M*!M8magOb@?+*kPIyz5K{4~k4I$2Br-P`8J{c&i>QjU-N zgV2yxaAQ6;j9hXn*Jn(*{6uFT{syv}^C%t~2O(9V`RUH%pq%&y97; zZ<2YWhj*Li;2}Te z;v+redQHe`U1Ra?RD`Wp7&pCqjo=3rakYb`r zFcUib;O#>?1lu@DO;PR|C;lF%ntQRP@~&Ac>aWCq6vYlZ_k@)FBb?a| z9q=(H6F(-QjG3u6J=}Q_9>W0<;*;%{oBLVXdx>`pN&=+Zst;1iLKL<;V((^*tSBD( zd#Gl797|b4h+-a=B%e+ppDa7<^vD1H5%>(2UiQQQcC0or7Wtf=@C{()35Dy0f6OKz zUP2~Q?mCahvr>*mQ)l4$i!0>x-`?>!(Rra99zcZFony3ox=^}VA@hx2$U28qvDyNj zkbwOAYtZOy<6EH+HD$HyEY*^pl3O4tmb{n=HH^6RR2=XO2_cP7+~<$#^i+R21V1(Y zhcsB6_JdFk_aH**urOQJ*9?FQ+QCMf^5*N6MkS`ohWq1)fMOW!4@{lZ8v6`zAu4^7`o^%Yo&a?J3qnW2co(7E2{U1g391m6 z{=zFZ?j#JA#-O*MVm%0qTlueptk-cOk2in5=;jw~2IU2*j1biY+JvC%E`n6ih#)uc zDQL%b;=wRK*{bDBb5e7f$W8|;B9hQ8Fy3b<#1B#*coKxdb2Z8Bm>B{Z0K^hMBQEt{ zag={^b6<&$VCD>x*es9A`99`)b(L2Wr6Mz^vX=0}dO8lXg%5Nc1HBva&&H>z8&EZcGSsimWpRf`wF|eG4sB z{xPE^#xYW3Cf*`Q|A(0=1zw0fX!`iL6v2z^;Uq^8vpV`(so5nsu%8rWRO;!j9rx0J zVP8A`OY`HHJL+eiy7$Vq#-5ZSF0~(t?0K;`I6DQ7)JgH8#Z6`bJqE?&%189IBRv1g z#$o9FE_XyJBft6IgD#W;m?RN2eIER=;@TYHdMSQk&va~6RUCwvtKl@j957eIXh45R zjaAs999wis)|}|0?-JIZc5$An^`0 zXa$H!=xO^}1t%o5dBfkxoX?hZo8wL0eUpf4F^Hxy3YJTt4h_Z_(h^pGd{(7wS)LHG z$8RpR38#!uQz~pfRqX191tr+=1ocYUFd}lJi-zcb(LY&a&-{R@>mYU}PwHzz7UG z(h?*T&CW1E>UJgFD&i#r4I;I>FQVi~8vDd#;P4N|eR1tuc;TO>$KqBpZE#DrLIhagUW*2q~+h z;aPp9h&T>u&iGvj#D^u4mo+w1M;;^{>66HzF%J+s|J#)D^#;+6KZ~3R5Y;S^r^VejQ&M&MSe7C2rJrIVWM$qPR$<- z(oz3C<0AcCE6wB6&$R&d{oaZpM$VlTX3(raasX8+BdnFGwujalW$JGWZPH4clRwob z+ez%lp}9u;_?3naS`7iIyq2H&trbSy`|vGw)S6sFTakL48eN7Z$@_j8KcPYVYi@h@Yo#{DEYxKSy$zVQgm;%7Ug3yvXAU zwfh589ra)iRsAeCu)*2)GjPrbLw|J9N$%@3YY_?d>W(ba{qCm#mX@jY-U^uNov#9* zS-JM{x(mjk^33Fon-b!CD#J#Cwam*IU8~X0DIVGBedu}S0aoxYKZ*^~^DDWE(W26h zp$nqQQ9Dkg8HCx}(8gBMEcUfcwQw6w{B$D?36@>ttcpK3JEmNFzB=~SWmdu$rX!AO zH)ZeC{Fuhn3J`5M>0u+tWw7l_O?cKU_6dXF=s6Gcxr7ql8Rl)ALa})`NN3Qpd8)pO z@N#9Vh!2I`ANx;&A8x}lAOV8#i;tXDwFDr6PT(yQg2@6As?;3HDVf@mS9qrZCb#}j z>L-O$Q8d1^_)Su+v3`uhccukn25>67pvWI0bpw=8*=Rt zwsnFg7r0F$Jo&vQWm{Q?Yh<03KaI(t>x^r{sQeM%XEc~{2>NY>C|dlIG`)gyqN3>N zShRZgA;!9HLxNlUSK0=nDEOOyM$0%wA73PWo3n`3vi@3{Mo7pFvU-d^4LFhYO8|U) zp7x|Rj001E`7t9~ksjGelkN4Jn`N>islOU~9`C4o197^;($1bjr?oP@vgT6y)c5)_ zTE%>I`LJ|DDbY3&kaZRLNKHr~v~p$X6SHJcNyTUwH9a_y(mI3;k!hVGKlzF>Z6Vea ziAWq3uY{WE+iRvc)1D@e40yv7xEqHo&B0HS%@^$*Cu$A zX*Mcs71E^)(b}_RO`&~sX0%6w#)~5p+Y4!%DxyctVOcx6GBhq9(|W7o`wSiiI$LO; z*6_@!j~Vxj0SR@E$&psP{5uT<#Z&HgPl0U*<&EKchcZv>Laqv3#FhKh;GWr_rl9Uw zUCqQa2TpfzGBJ&)7yI%IhwCnZ2RcDHth_vEo}yy#CynZYB<9y|=K9KiUY7g9caLv( z4_|Lj4|i90XKzk_CXRG1`sz5LWMzeKs5Wt5F9g^Xhq)<5FXZUvQqVDC_o^$qS!iSoR#`kB{iy zlI4stuT8t}aa6&%rgiJdH_uFK`7?|dtQyb0_dZB>$974mo!^VmU%ztK1v8OIH2Wg{ zd3vp1Uw8F2oNzg5DWvX6lxehxZ2P?Bnz@x~qj8J#{QP=&YU|3@+GX4&mz@g(KDNI- zX-NnsKoImHOg07$MdIPvD=2UYj&b>dAMP%|*#bvg^DljSe->x|^u4@ZeJ)xmI@E}u zUeI|mM$hDCD#5nDIS7qGgq!oH#t*|lfTK{Xaz#7YbidlYjo3-q852AqaXb0}c9Jno zr`8#-E3n=j9-L4c8~S>VPti5G<;`DL`wX@DFXtq2exen;{O0rQT7%NCuwjCnLD%l; zV$N|@vTDvbK3>jwz23*9tp*PK z;s6!@rTdL7@{2>vXZTuFqeS@Hq}u^a6)U~^9mWuHs9G3LuT zt-Kj(ooFxfU^QD0GY|@@Q7n*k1p2Gp&667fwT|roF|du+P9)FmF?vA~d~X1Q6?*On z#T|igB376%G-;ByFmz|e(dz2#$?o;P(^c}>)Vfgo*s3I#?(X6x4*$1YJ`@ZmYJ6GY zsGv{0mjka?d*!36yP<6_dv^lu_+P?p&j!Dob-E;w4}51b!R3Wf_NZmYk*r4ff~W%) zuXa~R;P4oj!~CK)Wx%kbrv8T^ZZy}zN*N(DU=nyAaUwS*Q@9Y1C2TA|CG#J6S#|#8 zM(ob&>S|Z|33TGPvSR*!d^T+uf;V@3-s=03r7 z`*qxxbJBHOZ4dT7#v1G1kojU|m{n%Oe?ebKMu9KK66%MK7?@jt!iaETEcab)jC|(H zzsz#f6eSO2Gh(t({NExjKUq=W+1tr2Au-_h7DfK@;6I6dwF>sZYLIyr${ph0d7j8& zf!)kyB=DWvkrDgPR{gG7 z{k3mTXW0zh3158{D#%`=lE=Uy9>NO!JgwQV^*1wOe9S;cAXb|GwidZZ%mnq!7J?Jo`Bvs zbf>aLIyl5!u#2SF@XR#gmA{NZFUxoufs$0qI`Zn!k3tdpF$J(e5&`%%H)ExACfY=w zRc$}0`Y+d2g@u$7j!u|jByZ*j%ZA2SUom1?Aw&vdHh*4sn+vdE zjOwyI;Ci=VD0=;{jB$IniDf%M`!1zFyFe8U%*GvXZv+iw6g;x$oWPP>bgKq-f>^5H z=ynV%kg!xx?aVz3%>0s#tc4>({kSHE;@}z<77QbihK^*cik&X;g04oNR@fJnk)SxV zM+BfP9iT8QyR%u4ExR4!&tZ*K4Q=td;PP|by6-Q$yT#MTM`MY{GtFgG19zPCkY<=`F&Hz% zWC%d8T#VPv_1=6jZLuQvx}fjN)m4hUTY7Dk-)*+#>||VFhX+=At+DT|!^pU)Rk9JX zuxywm*92~yI6K}GjIOqz+iZ}`eE4Mpr{%7LHx$TUoE@Dn(i|iyUVqE?U@!T!&D_UO zU!7fI&mQvmW%TFY6C?#6crBYY6e;#5D*?|v;*c0C_~g(ck}wQQc#5g4Y1UgvtoC)C zqc-}tHM)Eq$Ec4R=wduW6WctYw?F!M8{GUHK?1Rkwcg!0vr$Ke>4Ti%ndNwQPyHVe z_8d;2LH@%nP`8kAl$+x%bEx3y67Q>kZMb5Okd|Fy=Tz z2nrsqhT?*X`=?d;{qbVDO7NFZ$D-cb>%-v{LPKO(awkMZBa=j0nv0Gi-6XKbR*0lf z=#=Ci5cls4ZZo=0PEV`um-=JaG1Nrt15uOeTFXctU^aMcAQ-^^EIcGakh8_$mWZ)> z8W>F$tCAjYJmGY;2i(+~ElhGsS}VE1t3D%w-Xuk!=ifIdelQdrNN#Y#F`L&nPUz#= zKCjO;XV>*9nmK51eWS~+0@WHzaD6zn%6h>>x3>#u82Z%s@PN}V*Zt>b5(Q18)ojap zinHE2&uZrzHVq9}y-lZ{9$`QVmd# zzH$GqZzdG8!TgKu4>P2FJ|wG(VpjE=+#488e--fceS&|_Kj(eLr$CU6yA8xgG?JQ+ z`4nH#w4PR}DKCGt#ivnm7WVOAXGTs!6pmD6P&2!NEQmQ@y<*EXIB9uYs~mHEty+{p z`-?!N#sQxXI$x|tb?^)%J>AyVtDb zb&8OpS1|u@eW1)&Q)5++z(%)htm0tpWSioQ4pv0J>X3{I-CtAq2F;<+t47xf9tBUT zeAx!Knh|h+J($-oAPEZmZ|WP(W|_TRWo5RWh!vhKum?UTTB|+-CBJ{A(ZCGqp^}P+ zXlD141?}}PXxz8;KH431lpW{b>$f2J#t8>$LI#6}htQI|;}44!3>V)5?XDJR#uQr+H)u%&<&`4Oj@?WG(g#z_|t!Fq}j#_#PBjre&iu z^^L1?p+P+sm;rX7#{X3>M{HW?Nkt%vqIXUu(AK;1x23B8L(;(FLf z)~ie|i>DLafr&J+V+wLTGSye$) z>qdj6K)vODgJj!00rSRquHE<=|JZT)0D&m}11Ih&koepZ87f$R&8j6pYc|z|PtY8mUFR0`Z5X^63QvA)k|>0d zi}t__L4?KA(MgV%)}9bd2pgCz^B2tIdGc?9{=sa>D?H0hc#%NFQaG|qutW4-@!)&H zd2K>na4jfVd^^AMLVf+@z%tJcY$!3~1_1=G;b`kmy_|3~C>z^gNR2_*O6@Da@OhFq zumHm!^6U0d80DMbL{`$UwQb|drneQ;eC^6mBp)3ADiylPeosu%e;EZedJAa%0^UYs zSx;z_X}D0adMY(TvIPsnDh`C`9;@tl?S7Hk4 z0mQq(-Xh=sz1cWgdN3t9K|23^gABO&b|m0$Vm9xc8^Et_T>Lsie@1|MhvpgS=_50e z-is}%1H;LWYR*RQl0`JAK6HQG08NN~sklT+i=^e-uUCFmp^5W}1~6K95Sq3bIU^3A z`k4JR(7&Hzyg&&7@_Glh8gIE8mu~4ZNB@(z_n$mi^`LZ@qMyuJ47QQ}y3VSc$)Nxu z&P_JN1D0#%@)#=Hmdr4{(&nq+^*oh;i6<1kXlV)-yLPtO!uz6S3+C&A`d$2$ei3`s zjHmW1DA26GiK`G_F>Wux3PXikfShnAgkyqa_jLFTH&kn6)Z1O_$@nDj+>CMcKoY`u zVf`uN-HWjF%T6@TCRU1nx(OiYb!Lut`sKvd%Cqu9(R+fEQT>pE_WT)|kb-)b&c|~# zX*-#|!0NVWK*kBfXhN1l3@dMx`^7(J+SsPp|CCq1GG6fsQ~J~+1NficBI_Y;!pIfz zxmS)FMouMIR|=-og{eSB18#p zpoS}etV;>2pnL2PA_B2iA2tdGB#G3a zu>@(boH~>4y9!3Z@Sxs*6NwUM25NsDZZ}

8(#Iqb?{2?TQy&O0E+@d=&qSbB^Li3|ufK@~m%LbBg`@Dty-#o8jyEdi=+L3#_l_vyl1rcr;(IT;1&Y zk9)!nd};dT)5yf8%dy<`kLk_Z5uf6#EDM@nYO$;4)6vn(?&9ld46Uxlb0q8QK84O= zWpm?2l}&=3G;d5d7e)y}i~c1$Nu`Jr9GSSOu6`RNdMAQatpx}h*I#pdL2bfsB*iKY z8^-G41Wp(U!wOaxnr^7vBBOX-^UMx)@G2H~Cbxj6PiiZwk*kl6q1>yF8xubSp&gSL z5+uQw3i(GZwY!9r?ReT1MwXVvJ&hHyY>9-ThRw$)!< z?QF9_GY4nq*!r}!`gVnvJL#%5-SKdKA+-W*u6EtMAj@1{p$}a|CqNZ2XsJX>-=$UE z*G_lmr{&ie`v+{E0zdm>E=w{|y|i0ANJ84TyP1NAgd8h|Q&6%Iws3jqr;J!jY=l~6 z5O%V!>r0ihvGj+Gvt6o>2$K%c0AxpKfRX?J^G;;948P%5?5|N=Unj1N!fF_LAOID1 z8Hs1_M5sCR)wH*rHSV}QVSfA>HG4fRABtav%|MlSL~W?ugGkj8np z3l@9%4<263y#0)rd0X}U=n-wn{HkuPsgSaslvv2KwRqn?A|QqclbtuoDfF-noEVDZaiL^=gvl$*H_RRLh@8J@a7Ogn({_X-GfJu=C%p5V^#% zNLeiam~p}{KZ)EN-f4THWw;>=LHL_2`=T5b)WBH!hVN6zZL_p&CU}d&gFE`4i_fiP z=T!chnKu;YpGOsZ#N5O-U z{6Zss=2$Xd7G6 z60NTv#9+RR2EWot^d=MY7EA(ECQ?x4H**?En?%`B@6xO<*heaXbBGAJO2$$^ns_D6 z&pAq|M!ozpV;pNU`X^^Q1jY=_n zuo0_c5;0##s=7>2lFt>#OdpayZH7jM-ru-k`lzPiTbe}zht-6|Woo&Nni=iol+q%8 z$=cUs)ad@n%o~!tY(y4SO(Y?Ax*A_>v_|iNc;BR36>CftJ1>#1nHa zXHA*pxTx~Y^#P@X@1ig0zfuejM7@7`g_*``o~)~J(P$ghx;)|4poNw+&q`P7LQh&HU&!Zq#E{8l6=aR4%L_qY(b`X%pC>$-0Qg*iA{E=~c&M167>Jt}HIOp{OvUulxvtk0C0+3y$x?}bEGAFGLYppa7u-dnpG6@0a zjH=zSm|+5=c;^MgA2B0=;@16CEmG3v;w&153)B2z0e-k%n)=HSjO2CM>YTdXYX50v zD$Thu)qN;F60;ADYo#3CQQtd;6sYYi^+KucRXOP^zTURk0Wb#k5wP9umjjPwG6NZ^4&V5!~fgPje_frI>{zLu-&(*MRt1l|~C(q9UOZ=ex^$8Ws( zZB0)J$Gzj{udP?c{rj{K-j+OhYJXHFQV0@+3242qP)fl^t=xKO5&el@hBY04z~R(F z0|DR&JxDBw;rMe8+e#9ah*6z7D^k4|bP>&f6|#P*eJC2_dk^{A#+Sxr06*z-CVyn% zA0)P6O`W&FVoy^gbVDc5cL!32Z1`%e^Xdrtj?kaj;f*XB0BGO%A80>EbHJu!A)<0# z0%Eb9S}()b_f>~6d5^{LL`=h>9D`U8NMkXq>@!x+azN^p4bk8Rq+au|-6acDxxZ!l z(3l3l8Yi~It(S)vf-*-r5dp}!hm;BfK*qQxt)!+ouCS$%(vTN{Ni+-}Y91J%1^}Rk zLFwo#`0K1)U0ZkW$}P1w-R73kv<7RSj-F=d{tAJfEm^a`lKUH}uY4nGYFAONMz;?D zx|kJyMiARPIt7s_ZNAwnYu-x&-Y!d1NBKy4%q`)n3o>7f#FMUCH^C0KVnN1;q(FsB z871s!{U#}t8LWHa+t&JwhsHKer=;CxdtkScXF2#isflbT*Flpa$jT@i-l%+M`Jyf3 zb1NJdX~<7_;Ei;uJ_8ccG`cAu90cCnma{Pw>^qOa>jsT`!OLycXD#=kYtswW913D z^I)bW^*kCz0<{*LaFlqR?x>$J6SUs+*w4$KcPQuywGt3Nt#)VR6yoBI2!uyNrEbHL zA#uLIscC<3^R1QgneT!cabN@j(U(Ea_h`y1oitK>uvG4OojKYC z>YNR__JCSIRr+y5Y=?;x>f!w~xP3x95iBWpaH-`T?`l~fPCmNLdFoq-Z0Gi_{J=Ih zVyDO$)8zu_$5%ueKtJN;|Gx^6?X^r0>DD$$Wc((W?X|%#M1wiw6NMmwz%SDMU$Rvp zf-E-WhZG?7G#>Om7F(xyU5(jUiK-C)li%Y5vI|6eAiG!-j)8$Z0kVr@e*!i2dZ;C% z{ZxaEaBUxde18KFrU4h{JQRqdDOmGuJnEv@rmDu*FnvURY(ec+L7n~ppe=aHkbNe?cQV3{NP3Sztmbl#wXs|J`R!2 zij=zXGN)s}&{@)CzWoMN>3M+zjuw;x2;hLDMUn$)e}OI+nW1Yr()VfJ33E>^$rd~J zy_We7&460wJ2bny>eg8%zvP^)h;zZGAeLo;0#wb!VLJ+o$Oe{2D?0=(y)bYWpS|yr zgEcYU-VZ)rI@tmi$SSBJDgtD|B$}I2vwx;CUAM=WtOqi_MqQU8cL@$AQ#;`)wBUgjx(=$|oDT5Eisn!PA6p#y_cn zR)_jw!;F9EZjS5Oux>R>OC4-O#$tY-%An?ZIHGM56ir(?(k+pCYjwo{ZBnW5BL^}o zciSc)n+DDf%R9FCEpEkNG!cb>>eMEZlVx`(%OH%Q7gkf}E#I{PCt^9i*&BICT||!b zr|frFslav*#dBAikb!P!xqA2$}B-@tajIVC|5Q29TZRIO@yTFNpVM-nLED{yOIOz>Z z)`lPNyGORJqfX#m!Y2Fs#j>dz?D-j>?WgcP2eH*$iob#c&K7VYpPe^F&*e*gNI&Vc zp!PU?eg&+)28seGqn0#==SHck0|i?HYE7VETRappZ*VOZWQk}D)Uz-?@G)#xCq&Ko z-qSDA>D5-Ib5L&N0B>uKo4O~H-$+J=y4{AU_>#!JIBzizhm^KYn+7J*w7BdFr%ycxcYvVd@n(8j#^PnhDpof%c^Xs+hf){Xi8{ z6klmzy?xo>jH|er`)MKtO<(}uy9-gi!`Axbr9aYBqR}@j5Br}5+oR7l6~(~r{!_5c zwt)8=qve2uk6u%uXHjFb^JQB#_mg7FB%h2(ZW6;DJfgTMPTW->u`H_5iHtnf*CN~h zA6su37S$K_jSk%{0)nK3(jXv+w4#K9N;gP%_s}Jwh=4STfG{w0$IvMy(%m54IdInS zf1dZf&biJrr{p-={Hda>YVKcI-1<4aeg<4W5bXdbzwT>cg`>2W*%z&~B2#7o9~ z!r=Zznyy&h05t`xpEaXy5w)hTb%ig#oAd{)7>RZNJ_- zA74(qNWS|0Q8nha?kN19x})H@h#<0RDs3~l?eqrb&!e$PLJly5%wrr;@;g-4+y3_c z2cbpv08DaY?K+i?YJ*QJ+z4rGATVNK(XI;a!irA41vTi`;tk_TTnz$ut}KwG4fLwb z2A%lVwZ$JU2MyWx^^$rLbwA$;1^_Vhv(!%wG%U$3)l8KDozxqT_c3z0k-Li zM-I+H2~W|eUmyO}N~n?$=hWIg0p;HhM8*WG^W+9s@UB3ww{9HZr>EKOYmxNr461DE zo}Tp(cl|@aKH*??@1^v*_+Yo_-M=@g3jg@3MjOK~O%Kwufs}+>dWOXKL1uR>sYPlr zL;0Tq(HaSo$8I@BAI#?YKVXH26ZYbA$Jy-Rg!g^4M>5l5vUZHAR7`q9u3*8@v}FLV%2ts&ZGS+|%+uPrG6Iz2e& zF(IM~K9ZjsG?NU`-OVOpboyH?0|OAI8g}0P$+jeht-|jWuzb(R z6-?=DM*MmkUN4#73)QE|K`V!b>wmJi_se8h3W@7FpCT#P;B*Oqc0e$Jq9X?VRGIrY zPsh4WF1jzJTf%jlR9Y{v4D7|PUTa#FH}Z=%*qIUMf7qEV#=miM6{@>m zpU$aeDX!@LHRg$TmPe&GU+mlTCV}ypWdzFf38b+$L!t4_lqopLKa3sjTNPC( zA{0-0Zc^%_m3ho6>T{mXdu zj?`o29y%yR^|1)i7&`+4X=_EE?8}r^RJQwb&$&qIB!D=>q#eirPJvt;i^1-->#`RBG9T)mHaxp_U%7CJ z!!G~ztj3N!!Ywt3k$a3BT$PuchIkOs(8KY=IEEL&u5SLGYo!3C8($Ey*z|}3M3o8N zB8XK+fWyB2U!|eFeUUqZ$5;MIKOL;9ig>(6w}tBEolhoRjtHli4_8VrUSg-qv1z3r z0b(qcE8$us1cqQ}EMyl;xrTiIYrUe1A6TNh0Wz|2f&USx?iOB+ZIi!7oEcam+5!m@ zTw6(v^a4*n3MuFvz80~`g=j?%6(8S-a$`S@!_f;p0jUFhhQ;b8Me}m*4yE^|%1AWP zzalnD7XzXdHX0Ydm(o(~im_{V^06Mu{iRg738L#Px+ZyZ^v}y(aCflsj~g|yS;Yy_ zoQxr=&>OrC0)?KGz$e&Z0y_cO10${O`x-SISz)CkxSG%3SaU{0gV%SD>sZL}!M6Hi^Kjv`e(QP##yfT%6kE zDLgYaLy{V42IhkW2zxj04mu=Xx2EuoR3S~pZiG|cX82Kb^aBX#`v$0K&W^*Ap%m5^ z%0}BK-}|0l@NX^X&H8>pAq?FkNBl|b-13V`vDa$@*m7xDZ#g(2kVWG^EdKwnYrR=NU z5jMtbWPj4X}Ocw$CYAafkPyX%bzSMW=v@wPBN#BFw}0Dl{leUs47|BEB0 z#GPLDl7L_C?ThP!)lJ<@8qC^58>avuKerFjv7{obdSMFV+kXoHD~RIYDIm5Dot9G* zjYB!l=bU_}(&Ljasxz8DEnS&3V}=1Z>F^o3cxY6SxT_?tfgDWpxBbWb%FTRl-vtU7 z$LKlt?^pOTFkOCdmHy=We*?v>19M>oM#rO~T3K@MzyHE;^T=H;0h3M1r#PQ=H+Pyu z-!^TmN4P?DRz=e>@QNqADqCFN`_;+BWb`^kD zy`(2uD9}pI2oVtiHZS(1b#wYde_EA0_zhwJTc`G-z$Jj6;9g3{u-czb#V4;$C`>VX z#qXZAJVTN$Xaz#S;SvWBK5eC&q(|?7`m*`lL7AXsM26rIwZOo^(Irr+n3q83zH*Pk z?`_(|TfDbAFr|KgwV-9U4eGCDEwp2auGothn`}M4{MJB$E5&Q0@Oe(@N>CvAbjOy> z#+KCjZdaw*Ddh!WC;V*?E}%1THWz@hou*65R)10_nAwi>6 zBSY{dkdd?M<$oQ84cK%~RaE=5JvVy(aU>kTwHkO!rj^9%G&-!%k2b=*^l;}S*RO$moEll64Ey~k za|lN?J>$y3v0SwFM!&P8JHQ%6?|3*}ZWeVK)~P7hg$`5o#0&q{{3SnDY4qj;;4pLp zzcRF?*3Zr8&CSm3ib(G4!cP&0#h_=H-W5S?!A~>%5DTiExEIk?R+|l#jhD=W*O5}6 zhBg=iIgZAYLf?Hh<+zaM3Z7*d-4H2ho4b?XRK;$dlFw*;a2X$W2h*#D9Hnm1M~eXJ z1}7CApq)sRhow1fQS}*xt8hvGCNcgQq-_@gZS6TPobyuiEUfLhd-S&Z;}N%e-Usu0 zJ8zSi*5rG`=8wajptQZ`wpufl2eZMSHL2Z*JSKES!NxWd1osD00ZuWheWozW?p0%mKKBrU`LJN*bYJo)hJ8X=fq^~rj)+I&c{dlIt z8)|AA=3Mh{`nHQw;>_Q?5y=&?y_i`+jwB*ikFSTfXMDYB3|H#+)Vq8?I+hbmQx z-u2&@qy{J0t^}*;F3--+JvE#|4Ylm~zN_yg9`S7=$w3gFF|7Z}WORsVjCSl^wf1JN z1QhF6{JxL!4K#f3k@O)r%KB)1H=VG}IgvRadpbFtW*DO~31n&aGp%|J+j-Id^{A@g zE5caeVj#^k6v&>`)7ODEXYn1^MHOHyN1rl~D=+!UDWZuvI`mK?!IezK55JaNtUoHEawarjEBKa*n8-!E|>y~Fj)YYwTBgb_rUZ^3EH@VhR)P`Wrqac z6?+=T8>aBZ$h7W7&Q@%Hb&`cmGFymnCE9pP?T#!)Yg?5W8-j!m4Bttx#sDQ=I%P4M zKONR=GELsx3V>#-yjUCrz*L({CRM@;YjDOJ0yfhJxlP5wJ2+<6%5 z>?sV;)6SZ4Y(s+0h6du<2aQ5HAeo*J&53M5^%b~v)dOG zwKJv07{q6`!&`L)}0Nf(ZP54pioW>zX1~2#&)F@q`JvIXCni-Lj!jHrIrV z?&U63e2#L|N@NB$)z+KUS45!rmTtIrMd4B!JwhL}FAY*LH$J23cyNY` z+R-hj5jmmfz+gJ^?gRa2|V-OGvV z-s_8#;Z6y(j(Kez%YqmqSWnpqGVHqvVPLiiKdvz*VPKbNh#(y&a?EQ=k4+ZEAMZaA zRUayf*gjyDjN34WhNeHqWYU&~$N&(uMe}mEr>B;r!R^l{M^1mfsx}Y}1B?9+7?w5v z1a&LSbd60?sb;Z0n~1Kz&-`8yXq>1ctcptlJ$PMp+x-TEx*c7wCgSdcLRmX>8dWGy zvh*PJxK7RvZKUY(@KyH`-<^T_|oX z`PUnO9VOC5>}JQPURQ|>)q3ZthpY}31&8<0Wvv5!8c=W3z7Qu!m&?&eKLM5g5T`Ik zbxY~4tm<-`7Y%HXbBqwguA@ib7>eSDn-{)!b}QT_r|L=PGX)LvKXL%PzmU;OS8U?v zL3=Md#s9~zF;rMGZbdir6@;69ahfF=Q`d&v!BlN7Z1cHQu2SO7F_4G;zgQQae%r5c z+UP|U28}bKYPLD>tZh`(P`r&A&UjDySskilD%WZj6fw~5=OWjNvbL0z&C;8dSp#_n zSb+vhimDD%S2entSTE_|?>!kF#6Q4lN+oWRgRnG62~<#Y566Z82dD`v5tuDozlYkG z+vnDRD>gZ%p-mE8jA9R0cl?d1iFP`^uDhiGv-Tk*%&nZa3(Ql31+*N`zSC;GtdFj} zYLU8?ktqW9V?nKn72@>se zT^aWBodYgWZ5ZM~KymUEkQzZ6TOL-~3G~pl9AV3qE+WXNpv^8d5eIh4% z3q3?$XL!zGzr;tc)inotpFp^O8Dv?L`PJd}TV+2CO~6*y3N|*np`;A+B4CZ7%nVt! zd%MD)SuM-@uz{X2_UYy=m+5JSK?=A`h7=+n)sSl93W8C#SvjPI;DBh&{cO-}B)0cD z|FaIdL;eTo8h-}RDb3}2jJ(#@qdS>>K6bXTcr|9g8#;Hi$gu5H@zs0(G=pux*4j2< zA;sVJM%qf<<0;|&cf?#oilU^4N2}M!?Y`X<5t6z(Bw|u|=4q;9is zb7qa?DSUVXrKlkYtki+g?mjm7+A0VSkR>&m1BNjNtp_Ion(uwRSFtlfYR6yC6ZCd8 zi1f1=ye-qo0i>vFjT`zcDf$$xt7LtP?f8Y3wSkYd{}1*fT2OLm2c|*VaLq+XBl_*q zD=1tVRBcAy=PVx4f`2%)i=HJV=;{m%nsiA~N$PdrjRb#+tv>TBf^W^UdL%C2`FNh+_gj#ti+C?7Rs{0I#m- ztQW&u+WfF9k{=JSzU#olz=hjTZ;}NUj;;@=yyhf6V7F4e0VsJRxh|ktS`z6*mn=Hm zNCrnnCuE0+;5(t_-slbtqUT8;>om;H&;bnQ@$3h0Q)eT@pwg{AU#Sj{!WWI{hK2o= zGL54s?5>&Md} zF}T0=U-vy&3F!w0)xDlWtlPZ=D^y!tHAk=Av;kQn)_<}@bN~*%Eoa0N8J*-Qk&SCG z1*L@x-ZhHVBTjz2oOoj+k2X=iF(HAL>JXHMl9I{%2b6MSN>q}bwP^3l24%DrB{3n| zDPBoGNwj7HPux#g48XO#>)eV;>A$}%e`Kmi%ALg<(tzhh_`ku(_**@T?wgUDV|~ze z?0KNu38@?yZc}>Ug-tKVrkQRDWRzrF!bE339y#2fL`dtU`SkrxNRPb}Y*>>6bb${v z(S|_@=G2E$SO4HQuUJyV1l^JTEw|JR+!$!Q@OFRumeH|3j@0Z^CAhN`70~SU|BYI~ z6OT|T5@$zow;EfRdm)r_lfO>fG8Bro7R$l+)PPf&!F2mNNFUVqj& zAV8|w|K$$}%`N0HFyHwP+%X0%HuF^a$c;u{WdpO$uyxmZFLV^5;+V?^TD?-qRtQR@ zxkW|rL#)x`IJ$6$mI3 z3>aU`0|8}jaZ@GkuivAZ8fwYMX*iX#QtjbgY-R#`=p@W71l$b%RH%r}wLub+JtbVN zptiBs^YsYyQu;Ljm_RATUrBbMUD|}c?i@gL8CY`?{u1E%E2Q((gc`hr%05W)#!}Z3 zxdUc~*;neeh4urvIUATJm>j{8^Gmz^|55fk~GyO6C@_T{Z<=#klj_=RE zYHkr)$$<`>8a1GrntqfyjU#$jGuDMQ{)?Wqft7!UF?L8A$y zk{KqtFtUc$5HDW;{?Pa$u=DeIeC{g1L2ybm`xx*eD@fvDe*#YScsBJUlz|KgwhAbr zOiC3%2^|t7SBQIih~zC8SnIT@^=h^PDUe4(<^n*w29{rT392{pQavUpc$C3u(b0c& zwCom2FT1Lh4h1E|KG*1OSc}jM33}IK*XIOTx|D!L^hkisfxn(kIk+1{CvV?=7sfR@ zNgTUAqP%Hzf2cLEb4@gXYZWI}P(QZB_&SJwG{s7WlvXoZf;~L#+pBxxX`mKVO}Kq} zj>wU#?*$2U2al@R3ey~Vzw3UdR+d)z@A1FhK7Qm*GDtdeLK>4)S>gqiLPb9JLve@6 zA73-RFur%B(q%5FzA*P!M+ax-Z6Vwm|FL@29G~wxo0*e)A7O~3wm4?F{QI*o%>@R9 zL?4oP0n7LsoqI$Xw9Y%p08Sosq69=C&;kN`fJwJr*)G1g60&qw zj&r~~m5HN5+Hq39cI^ zd6=f&u|^x^L~QXgAQrZKyI(2?L3Dipi!#thOaM5*0Ej|oZPIOk8uEJV`T%-(IJ0xm znhv`STm4F z^A=j}k85=J^QtVIlJis+{QOoA&B%BZg=YFzU=CwjkJ=7sB1`Z&PNies?+$5C8P0zh zdA&cIWfacHDcuMf)(iT7Z_~@aBMn^1Kb1z=WBy(;%76Ul3annUcq#dCHaM6AfL??- zA`u=tk9G0D(1Sl2dGe`jVsdgc{%|WKmTZy1n4|tIY1)!gw)9g1N%Q9ZgUiZ~4=#c9 z5t$=9W;vQAG%qA!FHo<7j;7DyLR_yBb45;7Yo+1vuYKHViq-3qGRGh)#N^NSm4%mK z#yPLTn42R@_*1?4S2s_t*P_LE9QixusZ8DpK3tnmCx3!N^=6e0e_$!~qo{`FAKS04 z%8N|OE3gkJVY8B}qynQ8kHO3*r=JbfI<{0%Eo0iWB1766z}a4*JO1ewp%T=Oihda5 zTC%NLIMkX_vP5NK^1Ea*o_-|9?Cn05*Bu%oty<`v#&AtBHg!v+o2|=_hd%d>P5)g0 z$)DzVE%YnPJK@Snx3m0-(``#5nf^J@IdLZ*W>MqmC9RxyVs_5sPo0GSbY0&(Bz5Xj zJ9^W%3{dR#u+6ZpV~>weoe}KYQD3?XYnu!s#c&Egr~WQAOf6DlCV8{~Y4_yih_?(EJ>njYfRD+?r_!$*|0Nh$1 zR>_`NC*Uf@iF%!7cqE6>3k}b-uCZWf2NJf|cs>eC_rtNJ<@7#6cI>*L+}RK{urO~opeCivw1t8`bvshdZ$z50L2u_->Op3~ZoR1P(C zAdt@yczlaUS<>h9l5yU!1fIh%0uQO#l*<#tCYGXazvt8?*mM^Twzeaxk=`8f4y~*L zVGbbhEqplM=W1akK&q~bxAYCa`E*SACOr*N`@~XpH2o1=-6~NAk_ymdxh$ zT`?v>9m^`hvwx4oI4Va6_~g1Or-}THAC#hzAqh)MMy_C1*3tCD&PU8W3G2BdMg|9h zdYLQG`M7Yy6cZfMrb>&ay@mw*FsG@&cmk(a9_<_OX~!J0brS_}veL#?;O z4-BbxVu+glpF$<=nau==wZzjJ_Oh%yosf4m!~l9ir^Zdg;`?kOjYl{G|GP|PQ)o-p zeQvF8FHCr!f`|)4@i8e2DUsX{5;QCA4M{b0lc=QcM{DMPs_e|y`Q_5Tw_}K7+{X6n z{DO|UB8p^9bXoh^Ey7&QX8%-_UYHI z8u2(#s4anJUFA9JB2G|b5jg=`A@FX*fj zo-V8@m{Jd*5joUxO=xnJC#}5ryf4lr(E#m%Q$+X)qAh`0B!7haYn&xhfy#B)tBqY> zZ1d{g&20xQ|6d2q0&&V*b*!};Gyeyv{G(1Cc_uQe+32Y&31o_fcOm?O+D&P9yY`KL zJL+yBoNe8x{NT~k)Xuui8M5~z;}X7v3@|fu4~Q1qto2|c_7^5M3h|HQJdQ?@VJ@yFqMrc9J^nGe&SdP60_99N})Ny>&rq~o{fmy&Fx z7Sxm)9oTZ9&wemTwTD8~)QO=M&$qwq#!X}wze4HwP|7Qy<3lO0xVY*jfoL@54Tsm&sb^CIqx(~pv*W8@kqB5>7aKeD9Bls3X+uo%)bYq zP%hD1Pai2mY`|8`QRddgGTiK6qZMM16n}Uw86G_Lva(jP`bDYG<%IQvr*SJ9p{W3b zS{z#f2KPs!r?8fanF{zMLjP?*0{16YP!WBY*{53~f62sL=-&d2fRp!9X8NXF5fu)Y`P-#(!*8Kapr># z+BdH$`aeEdBJz`k`X?pQ5=KbyvAnDBNJ~ zo&6fFd5yZb_rb*#1FdiXsuf0C(N!yJ>;+OrJs@Rt0}P}dBRPU=xL^x$7;3GPva0eS zLHDr`Y&BPSAGonZy#m8=>AH1&^H**Ab7a;B+7GM9`P5-6zR?Y9Pbaze+SUr z-{azAEP+p|t8IBg#0n5Ldbi~Muiirpi%}9rcY&dTo{U40eL<~$(=)XHTyYFioluD0 z`}sm&iyN6g5%G_cRhN_dMQ;@^B)5u}c^rtSKAqIbqKBmJl?T*qC}ZBkr?8wLRDfFS zan7Rk4M4vQ@B{!By`TuV{QZ9yr+w~q0K0hR-s#29cE-|_DmXPbONac<%uSYH`JxfX z!XQ8vR`{(cs0-3daRC_O`j4*23;y>r5eAsaK6;=O@Q8A29^pQX3 zi#+cGF`s`t;|@4*#ZK)=ueZ~0^usnLlCL9@qWlT34trC3hL3{w>Vwn^HpZTZOp86q zR!bvtpAJijVnlt`SS3Vr9MckO07 z*egVdpkOwD$-?Hz-=Z99 zZKF%xU+{=S;P(OM4WkcPov|;1hw~r&(Ud+p`G5r*;w>l%n&M%*;1f7d0ydfMA=Phy zR_Yc#clX zuv|%m#4}Of+Vh?B&5R6$PwTrF&Q*rw1gFV|yBzb?2Ujyb_)px}2&xHJB(P&!LM$?cw1!<7ufi+-{u_pn048Pl(F>%3!UXJMt ztiJx(QxCg}dOUm)nlIH4fB5En=6X7e6Jt(u00lC2^G_VRMJAp=V>fL}n+w|;6N@$< z(t(S`n#(_o@l@~aSrUEC_F0Dc9&Xz6$Dfx*%7)hrijoXyIkobV2eiEn8NU*BJg)x- zpny=6mr|ecg+Enz>X2rh*`4b&!-ADWv3go-Ke7eQzV#ClX-vZ_CGEN`LWz%Y4}t>Jyo76*?y6c7#(YKh5r(hfyo=xtX=r&&v-mlXJbPL)<2| z>(@EEDaFSXc=>tJ2chc*)~|i%uv9fm1g&!pusq0V)IG&~fgum{MnKBh z?xy!JBj2y$oLm4^%xhEw+~MdEBfuT7y`D*)8~Mz+delfp8gp(3m#7$L*|tu$0P}PS z<~HctIN0R-$<+Q9cp2msIJ_E|g4r3ZWy=r>z z%Nv)M62XQ3CAu^qz5+Q>6nGcWV89iyGKv*RRpER#8GhaE+pAc5gqBZyRj{KSUQr)%a z+ozZ-rMreS7e3|w>uE@F-)k=YcBiXan~GyuHOjPcoNha4E%M7{$0n%n)Zll)!M0SB ziUf9*;`|S0gY2Y92&R^78D|OkIz)h1E6UFi4f$^5d zC2zxlBKk0K(bYa zO-L)fS)PnWSiXsuuCGUJwaBCas;3#g-QfPHgyBnX;yZw0Yt?uG1qr4)S_9BwXor~> z0!tmthcEet8N{X!tn2%?y6bBQf^bP;Ut@JoK#6mfUdtKl1TZOFZfwt|P{XD)Jp+Bf z>01AYb?&OQa{T>efT{M>jU{dZXBP;3fs~}nK#1%WS^b(;*b`sJ(m;+#?(c{Fk8a_N z+|se&J$|k{Jg|Nd`^hWvuWqw%r3cn6ImY}SIriuvMKgBpj+)74ruA_3hs?BX=zzD* zi??(bh20v<|CcG~yf>Cr=(N9jV240VOm8EA!)D57%deB*c)Mj|k}}mtr*hPd=8lQ- z-s>`fC{Q#w8#-$CgQCHi(W%3>Y@z4yvd7joONZlr&tV)18j*&}+%Omqm}@3rC2+(+ zzBz~5JeK&jzbuy6+)a;$q#hXuk!_NWC0 z56Z7@wU*V0hg{nyvsUpIB&X*m4!7FhX>eDiI6>kTC3i6elIR6rEmNEJENg1!bp=wC zT1l^F@j8^^G%SC%viI$2-)wk%>B5~$)Fpy#ll(qa1S0wRgL35UxQ9x_L)bd}ylTsWrWqMS^;PjL9mRxz6d-XksW$eQR?N9Nk{ zuX74=>a3FIZ3UXJ)vSq|fZ@}>`{R;UQU4!TB=8}$+_lWfu<6jRALtiG!Y@4$m*eTZ z#48=p`r4~v(VOG3{nQQ?yXCB7%xXiu4HCXz$rFUnCO-RdfQX2{QC1yszbO@YV8C03 zAOaV|;k?K1vkay#+6vInoY+eFT?)^)+hYJb;5vp>>sSNue{7N~0fy9AukuxT!BB$$(~6z^zS3{t zeOJi|ftI<2?rrZbVoSttYGy{ykyl7RYQIyDx6bL_`>9Z$!h5fzKPTu+fzKbH-b4>^y2B@f^{NG2 zmxyGp5il*2fmv6Pj~w)u*2P1CSCn5}$-0n<$w{OBiC17!NuSS9I(bO~5W)nn-Jdbm zkbd|6wZ!z(D}%U6-jK7Hq)}g#7cZ{8zbwXXqY)iUmT@^;p6rF^9amXfkrw5lwv@+8 ztDi_V*copJgOtUQcq@2D(tcN1a)%yjTBp}Qz4VDEPr+4NZ+LU;CC&Fx*#2&ffDAAY zJVls(BN_bn{cwsUnIw7KXYdYX(xxG8q3aJQ_cG!W02J1p`fz{@qXvBy1N8eM5E=`V zojgx>>Fc6U4N$OX2c7~hOX~kmwrgEAs;)Lu?PmFSfktO3gY!8UtL2%n@C<0WiR}*S zah&%|jbQ-~b4pMaMxyN^>dGI^VZ2r~$~9Dh5op;ba~B!~I_>3}JCjf0D5 zJ^_0LOWz{4F>@TApTP;2PIo8t{*YAM4M zK?{%dNLXXzi%NkAnF~b8``h=o4g94W5SYdU%8mj0A!S2jk${H99-|Ont`!JAlT2Sq6{I< zr%YSxVYox&O4vZncyDmk#3*b*7klQkHwT{bJp>YPZ|%Mz!V{1caW59MhPLP zQ|W9P+Ma{{?)}?YyOG)wi3h#}XDt3-8nFiN1RIr(d){sRV~Yi1LTeL6>N8Q%OD{-D z7%cvzNrUbDWRNcaW*0vHs97Bt^mWl#uL*S>bI{jZ$I`kvOm*K4#UMh<@SnVPMt!z; zqeoH%;T}Q*@A)D%O2V4%zzOWt+zq z^IZXWDeQI_ghl)mO;d3iTJ1q}qa#J(GNI0H25j~Tf1JuT@G<_*2QD{YJZho7#86tu z-;qGVN~t}u>;KH4+*S3-Za+702c?QQ++Ot%~7?swt8wTyLoEF+X zh)zZEGg0nJ`doFR&~tUFUyfG!A5@;oX(k$?yjq(Fwb;}h7=wv~2ipkmQ4B+BQ%M7X z@Qm(2o>mM%KnCoP)nR`dzhj6Gt0$>||B=v!W7O)t0{{ph`5yw3Uj>5*VhgYYDlro^ zYEXA-2VQ`nFV*|*hE^TPJ0>MqaFKy^Z_dUaLp${1zm%PSqg-$;Vj9`)o<^x`O!GbA zMa}kx1prp2)Bl^aFbSm46}iC9$N2BZ#yR>l(2{E03YD*VwjUZ+r=$A@DVy6^)EWdE z>gGZ!n}Lt41A&R+H1*$r!4mStnxppkV=?wFd#eM$jjIJpOHd{kFf5-9oGiO~BL@#R z|99wM|B3ySq|^VIJ6IjmScCZAk%J^%Q>nA%I`c+Nb7jaxjgfq3e`NTaF}lRC^gQ(TB!KI5`Kn-Sd zgXp|JEev|69n$s&*XnR_LF|+ME%SQ+KjxJfFzJKVfP4AXD`T4Sk-Os=YG4Y-?Z6bn zs-~mG@|)SDlP%M)dC9~EnEI(dKx*7GHg`(H1aQJ$&+v5+N;Uu-1n(F1VA>k}Y^|J^ z#0n@0iyKOO<3Xu%{r_RFEQ-F)JUiMsK}>S4uCCS1tl(6BYdwW+2Nv1)Ob*j*J^%wE zn#hAuJ@q#_(X|T;nruIB1gxrq^Ud?JgxDR1oOfRPf=Tv}`G+68Rw~FL3z3Gv$Y-k> zaJs-PPw~e}2#&$2VkGKLF$+JBua?91<5s$NF1%(Vth3Yj8vhC~?Xkm+ z!Xcc}|3GnR2xP?m?H0((Q$01)N-bSNnR|RtbMieaBSz3?R6}3QLmH;p4&(-K6x0q~F$_d!z!n2a^#0z2~VP)sU4AG^d7Qhe(4In$+5c znp#A|WzRjePWCJ_;(SAF8P3d&jOQ>>U@hL-l`v@V9?13xeM|R@iiAh>x%W*SqM^P4 zdaycteeiD#)~o#WXzzJxNiPVuvMc8zp)jCAAblbo%Jp4n0S zKHKTgaDQ&;10WMV1hR|GtM-U%*r3f+Ya+4lsdJ0a>uxX^0^XPE8A|_rRa?K?kF+t| z8t9M{5^Toehs*RGkuKhc%SR)teV4Fn#p|-E-mo1>y1$S&<=T_@9+na<;#xM-IkPkM zGe_fIhkF~t$IA_GUq8NbzFuJXlsi`-esy@jg^BmZpyB*_aWAxhWo~EH>8A51RgWT3 z(AcCx>&zeQrN>j~z#THK2;3voc;3I_+xpbZ`ESncZWc~@cWRN6^uF~3QnuE+x+|MI zRL_R@g&{jT-TmduGm|u4^hv%=c>4!OH&Z@-Bi94F*S^k9mk!Q;BAI)0BKGi|Q}VmL zu6V^IOic-tP>mN!C%eByHN_F0?o;N_l7&R9zv&HHybBAjcG$XW^*|9rNo`uPpu1P z$J1gw_~ilon`HP9!vDs82aF&u_xs7<=6>l{aarJiJLv- zW*={rJA(vbZg-bAe~@SSF{Z}k8;p&DO6{`ta4^KS8PfngJT~T|({cf=z?#ypd@JjJ zCuk&;Os@j$de4b!sqyPkv)!}0nsn;d*Er0`_KZ&hxH)NdMb-_iEFAzG-vOXaNa~kS=Z~|B8aKqhG3;ow-P}8l0}Ws<~A(&sAa0a#XTk7yTd$_P;`3ULiA{uTbQZ3 zw0#YPoBT%($(Qz-I`C&kZs;#XL{-seR`XgqE9j0~FXIk#JAc%+hNX|ad6S`64ii1E zF)36Q@)=(Lw|#K`6QIiLF%2*PM8+=9JkOtlts`1>thQ}qpp;mBk8Vlr38v~|iJ;b^ zY4yDX-m~)-WljoSH=gR2_6=9thKJJiW|m>~+2^?XPS1$SD5MsG#&bFXny<)2}Qh**0d2I(WUJm2dO9}M4X?;Af);L(p zu30yuZ1oGhABww8PDjmX_Wdr_hm@@6j;TzoW6;eY{0{XV z+Jn3nNA*aa&>x@E^17`Ng4KM?_*6HH{Zu<w_6m zlSXC6?$7a+f;Cg+_1VRmi20lV-82K$&6&Z+uxW)$({o}}KG-?Ym^E6Z7J1=);iU6!gH+eMRpVz&k%{`rBmQwVHBH#0V9Fzau$~XGSpCH^-H!WM3q!vy;Ff+Ny^X=31^>-xwVz}JG5?yD0 z*w&i*Tw4jc{?xG)jK(e-r0(mD1jAJ7Fe$LZV=dU_e-LmjH9UDNb0Sv$c>Q1eJIO*5 zI!fKsWx$hA%GVO^wjW?g8dPhU{%MEfYrMalofSzfvWdt_;q{4RJ;&W}(xU`h{wLl| z%|G~6(bnWhYGWI`Jg-9=EuM&I%EgSDxlNJpJ?I!coE|XKuchp{D%QVnU#s0Q_}Nmk zv_+~%%1ZzAo%8OtKomtU)s@dePJ9FvExWGK_qum*x3Xlkp5Q;OTKD<;13gWV(G>7sfAqXfk~^qK$v4fuc2J_zcgy?#w+Q-wi=3+r z@vP3Y?(DcPm;l2*Og@F!b%djmaE(vySK|D42*0AFy1y{JvxGWdBmR=MVFgR$PGlAZ zoq%10EMYs7WL%z0*xeUxMuA1f6ESxk*G&vUcnd!6PS3`3gI_naL)>X!P;E4!yU;ag z-@?QVV;pj#3k-hv#DEAMRfi}(#>l5l^VPfd{ z8muDaQ|0EgQVt=QXG!Vj9+B!V78edO+Rj_Jxexi=jL%AcoL?Wi(9qvSj!GYr(XWc} zgVQR`wcQ56i;O%OoqRtO7M)y`4kQ&Jc&`abS*F9JA5@cg!yDQbQsnh2I9vS=_jJc_ zPf|MDlvZU3>1EmU11U@KqAy%C1*>7B>595?^p!?Q?v*Amh9Ls zImmW*-}p)ROvOt$7F2{S?oxBjgG5n{Nej*$B+;~WuYhQ2FCt5QTkor*k;iCAv+w-3 zZ{6=h(Mgz=xSK;tY{GgxBK4>ne;MlIyz`v<`ed;1QFobdlW5eX**LpKPzC?pF#dU=S7EKeQ9TTua=)DWDlKT4Wx7}B!|&IS8jZ=% zXyj&J?|g&IDx_Fl#SEP_CEfvp@%G5Cs6iE*P8Z?dIl+@!sRa2upQw zU$7?9CUn>MJTQZIx?Eu2crJu@YNY8>p-M8GxsA3~>kiATs)S6v?i@G(pFOgDsThsO z_rWD%LoM^9Gw+3HFS-5g9Wwtvcc|APXHr|kdqjUKWr=0$lSvd4{~eF5-=XJj1nDx^ z`hmPA6Y22*RF?uist+58Ywfr3ca_GK(E&|K$OUkKyGn@v|aDunDdf_~jsy2@QX{$*6o)0ZSjv}e#u;6QNx^f9~CWur+N?0xCcT$*t!3CAzH9=dtm3VQ9GBZJu;qeMhQ4VH2pw( zjJB6ey$7})9aTm$*;BpnlkdW*_N{_;QDDL|y~r?5$1m*LjkEusjT83Ka`hdIhAHFC zg>w2#fH1e`}+mkgnojV5~`x?$kGaD6~X*b4}LXn#K0USFFI9jF?uyw^0Er1or}9{6oN z4WDbS27C+IJ(sE!-91M)A8_cetkU02GqG<7IMj9F4-TOaq;bdArj7{d^&+g>^CZ@^eV`3^*Iwz6mpZA2Prc$dPemZi&Kv z!vG-iTQJ?R!^vLzF_NcVqffE7{wu^&rpOOsiiUi$hc-`pohKcc?9q7P(|F*mMwxo6 zW9!@W<9-^PYf9i4SR|P9dWHI6&i{R|KCsG<9Mg;1y3w2quUuQdeYAVC!D**rm?`>Tpj9$*8{aow+7cnf!Y8d9(NKn;g_v z+P-)Dl`5_MgCADSxbfS!J7HSe7A$aR(C%{YHgAXF9+B7IV>H|F)#w-AZ0t>X61czZ zJGS04Hp43;+n+qtu5zzG)f1cQ#ZRNa2$PA>1WW3aCo)D24e)==dO|MLySX72FAvD> zttLMKq4Y7A?IHwEaHo#qfv)8{qSr*QdV;MKgi-iszUDSG-z* z3G#e;Zg$J_7rzA2RH==%Orh=el)+EG7lzYRpt=x(vJK;si$@VwU}j*4YhhN5=aS(o z{^QJ*(VJ)0*NaC6f{y0b%Ee>w04ki@!w|gTa<7b>XdsBl-)AY@A1yWD4rOX-K>hF7 z>ckOw76&)NwZ2iUsrAWxFnW`It;C`H@oaBIQaRDtf2YFkzf-Z*fomFa*n_#I5FUp> z%m4i_W|gI>*VP0>+5nBoXf*OKq0(7&SoG`alj5y;eeZj$?%IH>tP{A2-uBWEBleKk zCF;B-zr()JK2!$dD4|F55i$Q)`zxgm4+8oZt2%+_#uInr&+n%2${3~jT$)%=72wY4 zi|bN78@#{5;?pZ+09HCzpY%Z^XRE}kO_vx1K``{4POhM^jY+vtxC3vq4>*N8rb)c$ z=8b#s$qTXfYQvNf=Ci#e>G+-DpTQjDOVZedM$N|gH3E@BrTTGSGW=6vi%$r)I~?TN zu+j=O3shJ?{V%M~fUvHe7f{!G+9E#@Upb;F^IW5OU*Rh>oR7EJ1I;)A`nAtKiEKQ9 zCVFZz6K9Q^{{veb8cT2@sf z0jPcQr00ga8K2Kmb`Mp4b8{DnPm$D8WuHeJ z+5F)uH+HSzy}Us(js|R)0k+GJysU(^_$=r=8o9j`OoKz*My4@JKqkFw>go5o8#Y-s z-<%=xK)N9paRQUO-cXZ@!sqKQIRY=hZ5n<;dS87lW1TzB|K4#YKaHWGX*%4e`+a|# zY~W7sx#x@d&S;k}D!-6r=-o3P3vA>%`q@IS93{c`|G%kZZ_yRcFTws_rhnP1gFk>XI z*ie55A1RiMBJYPjAt%_6K@40gXOtfkS1_!zV#t~hulio94c=bwoCcFAiZFtpXU{T9ok)9>f*CqiU43sOP` z0YOj%pqa2!?0MIsH?_>Ft1IkW_MOjEgl%sLD~LE1`rQ5SKI6Dhtn&>QacUBV>XT81 zenp0s9M5s`H~yNQON`Sd{H-171Nd1U6?}vm9gG7gz(b3Z9d`ur0?jXsn~xM+&x9+> z7bv;ekP^}d5X248HDSly^Cresa&>d4bWKj@ZdgFuvDgZ0=s@cj=@Xs}DGU2p&>e8O zJ@UGLcDA-}@Au%Uy5xFWEJRsZ50hV;x5L;7=qF`Fkc>`>g2r+>AbiN>=rA^3?zZrV zo~>z}NPz7jb#@xqxB$EFd=D3?-78IWU0tHwv611b|I#juM;hQ_f=ha^3*imjAKT}h zbY1QJymF*8u_5p_Jk;UW+`iWKvQt|9wF~KY*6T|c6g6IsW8vD}S+JJEZ28|Xc*Nut zG3BUWF+(I#x?OK_LBy}$c=)D?xGe5AWe0&>6e;#dvRZ$E+C+FT3ysm1FXCEXQQAV~ z;e@2v=241dHy{Rt07_GKggtLe1cS5X4cnPl4b|vADY18sz2NlslF(+GDB?) zFu{%wf$-t=D8U4D2Z{Lq_K$r#JZd}q{{7)y@oOF9fvot`N6{Hly5h(!vDmOG6KG6z z2ckqUCSB>@>1?OrIcX945bS45g!a=9Amn!>l@JUAXcqhr&-fKb{rNtf16!G(VqAC= zGPSP*;O5Og%#{6Y*PHlFU%=<~=CY!P(XQbzXh=djAGj#Tv8fBXPlgFPQxF}Ams0kP zxi2cgrdw?MLw79@R#vmE$s|;50tF%jBz0S=FJ=m$m;Gnbf9A>{yg_2z@nP~>^a8C> zu{b5ut=SNsA3-*Db?~lZNs~oHeEVctj6Z{bJw9aN62xkHnz30y6$?wm3x8gnqEfrM zB2tmzx=g}}^#I5Q>Q8Vc2N4YR1Q)L6nz6!oa7a8#=6evtOs4{%2MJW%7VOHp0psCn zGf1HL(h04L2&63VY2IWIim58zXLcq6s{0;MsZb)o_-iM!(lC%B0|J4-*HuZd(fFZya-5}Rj5|jPO`0Sx6_MTrg-dz)4Mk)CE=dsmisd9p5hPkef znZtQ>*N?ol`NRew=aaN~AxMyPRYls@bKIup=9>SR`K`SQ+~d8NHR=`|Z~x8C-uQFS zN6V`J_4&=u%lQgxqTxsVq_R9sNzuN-P!IZ+Zr}uTuZ%a85LR{lJid>f?ufnJlc^%9 zFGfJl_9Rw6*s00$;KNIg7oH#dUN6r8nay zW9kp6i{Dk1(7PtcgJGW?vM+y~HD=K@RL$=b#8?b-w{MRy1Ac3ZV2<(M(PX_+CVh*N z<by$DO= zA3@sk%SkV4bP|7LgfrAN`UXGf)?0sY=5lkrcUHW?J+a&)X~1&sJEVIRUa)W)M zu`F*wpf-mSYp&!3>|^{II0obh<-p-PRWUZ#Uq~Vgj@i`I$;x-q+|=ZwXMq6b*WdRu zU|kTT&;Z6=s;9(%{8;~0_LW&vWc?YAXKzDQman@RQYscu!U-agph)}o`7t`$+WC3H zr?{|X5B>2~G>j|iMn2#eOd;Tq`UiZ20g?9VwE?G&Sax&N2jG~xhmTPtBgxOieM}Sv zwx`OHb9ZM3qcn$`av4{7SGUxP9@0nf4~Y2ufSK+x+MYr@=s({CMyBOk|J!k?_c?AE zn`mfQAgwrOZSOet_4;k_{IYkW836ZJmLEtTDK!WydG-z zWGSx7?YX$KN&p<7^npK-9x^&hOiDj67OIy?O#gI8Ii!Uv_)cq?lREC+{H>JgDrOpE z7w5uhbQlz;xi|p2lFhc|pIV=I8oB4zOxA2k9~)YGz2GNBb;EnJT)4j26bQQnytl9{ox>*bez229WX-q8E=yJItw9+ne8N+nVc2OhSuY@ zdHfLuNa)KMpS>%kAF3LsX0+-SXB^{`hNk^rl9`&QdFQnAS?~BWxCNA)ArhSNjWDsO z$clc=)ZLdMvK1>Jz9M7(W6RdhwrQK>p6;~1jP41;n^nMlgk2<*iL&X&Gq*usoM)Sz z!P3!qAiU#aW-=04gz^epM4IG!+_)rSDnh%n)LqD_zMsVEOEo~D@>A?{?{JGdNB80k ztl0X|6D>$3>2ON^kg<~F^Y6Z?PZ;0N1f}XlgTFuZFmA4_Nc@@H4ZfEYbElIOGh!>Y zJ0Y|`+xMqtu%;jCrL@sKWGCq=RyV0LiQ@BZ#}2oaJnM5EGYX*>TpK|qhHc%{C0^I` z#c;qTYfWLmE>U2I1F6r(^XJQ(X9oxG{Qwh`x=&|(*5PUjxbSd;07FPXa~(Fs3;_x;G~B3+++J;OX@J ziSrhxJE)E}D;K?e#ALc9p`c2xC4ecX4Hb$br4_*sLJ08Rb9Gbz< z535*#`u-79Z&@3L>}@#(}ZfGLVLz5AX6C( zbW5FA=Y3W=*g2KyDXVjhA09W0R?}G|+O#BNXE_bQxyf-9MXN0*$I)cK8O=KEQs>JV z(5|8#Y=scde?#f$GWKMzw6mNXOg|pmRNGY=Y=sX6-X81`kAgy#&3b+MLl4@6GP(?R zK_={{2AB3AQI0k6;@uGS-5f_r)F6Sbnlg$o7g+j`6I+o%z^Vq3&;hHu0IUk{YB>)! z`YUAsUDg{xwjE_SAt0JvNnEZt?+T8TFE?#0#_|IAJkxA8%J<3lxx94{yx)=aA%{F?)M8yE33{DQh~xsjiEj(F^2yMJ(z z-317W-oZ2y{h!(R*trGuuN!3}_}KI;B})n_4=Y+!vj(2H<0rv%#j#wrN>}zxf3v-4dMx(N4&RDCxS9J)- zN6^b>xkq?TPfd10k-Sy30pSG|aU|JM-zG|#EP*a|$%#@-sx&_0A@Hbu#Pldx#og*m zb_2F`AbSvqO+V%fG%N3#+5B8Ya74$d&8=-pWcaS%nkGs?4M&i4P%#0w?XTg_$9|^+ zI-RX0fwqkSf~q1Tk`=uu4WJlU%o#X)?Ukv)807>1(CmV8E9~3qc{w-u2ByG#z`;?t z0S9j+f8f*P7$2Dcdpy|5lJimOZAkiHkw^}T!pCq8wtt9_mpQN+ns2Yqu4;i6LyvG0 zL67Jya?`e8M{#ZxJxKPkh&4&r%7W&R!hU$oJUsC$epl0>%@e^AI|Fg>6TwbCYhX4Y zOHl(;VL+C7l_{D!QgC;tSUX0`(VP{_aGh=%*u`OtnZicgutjTz1W*wYRtws^L4_Vt zV+>N(suL~WVOOyV^!=l!-eTT8q-3FI)o@x zgp(6%IgJ$TF@cp3dB)!^3nR2778O`Sv}5|hx<&RrmY(P~kS8EeBriKbN^omp781qv zvr>2)yyv@9dd1%&Q*A(;wly~k?Gjlzo?X&}2Tmk8q%mEgOmfEI<2|g#(>;jD=2K+H zCD0vSlp=Goid=~b8ePHg{6F;awv(m=x25XKN>SSCMR*|xWR6o9Kuh;9!ilvH#=s_^ zQDi?jykuLr9oV6-S8(^MwD{>))}JU``RdxY+nZRa&rp|n5Qcu?nYLVU&={vzbzEC* z9unJvZ~?f>Ws_eU6mbcfmK`4h{nFc)(4m74K}O_hc2t7QknqMWF(2Gf4+M zHx%Fzt*}VrdMvahWfW|^5-Qww_(W*f^#Fds9ys#u7bd33P(uqIz(#(U_3F?`Uq3l} z-;}N2jOvLnt)Okdn<4crqoa|_szn>q;QLh=MoEc0l=qM!Nm^E?uoi*an!|}a-U$}r zZ7m;5;kqdK?BSSkw&GGze`z>hI%4XURDSn_U~suT*+a9r-z<>P{Chonxb5?pZhBt9 z#&kQ~CbB8_!I`@%zvfg~GtG7M?*P1A8GqlwG^azfSK?#*$D!P7?T?GY5HSo8UUD#} zMp7(2DBYk}SWK)>_cll*+PlUG=6}q$Rv!ClO`vn%1>HX=2AAM~PjEJ8gvJoVIj(bf zB9tZ65L+y5k1gNVWe$fKp@PB5&%hv;@T)AXLQ-;Z!M_AvV-KPf-_Z4@V+&a2@Nrhk zq;We^AhEWdKm*0b&~xuE?i(zFOPHuutVtGF7iL}P6L)}*;Vf@Yh;ci#b4i5h0tLch z?gSd9Y{qv5hJ}(%n2y7{t9*kc`hX52+5=T!=)d)Uwhych0yY24uv7kV2vJG12>?Qx z1lzikJ*@h!Y=&*c_p1@vWWqIH^yruY{scp_Zg>g!Qv}@4{gUv3tBNqAs&!a+ff8Ee zR)~}TEd-Acv30-Ea9zZGzjD(&VU1sDL7((6h7q~TM6P#=Uo{123hq48wb{Q$bM@*J zYnYW^i~Ncrxk77_CVPv+hkJ{YiSk4KF2wLkKd$`~%gQd$ylN73fp&@j`~{iz?f({q zx8-9vaI<7bX*y0jt-1HBq_QyZ>CfPDU$O_i=OAQsw8d!7EFFmxItevy?JA-iZvf{O zL+DA7)r62wp_OjKVCFUqs|G+_sK*FBES>-UZ#}58AtGgR-GUb6@%VSdywk%HcnR2N zz*o~9sG$S@HM`sn4HswiYn6#?H%gRJ+*wn%p|zeJdEf4Hgwd9+GC-kMs1?0N?zAQ4 z9u{Zr=8gd<@a{P$AV}8E+e5#BcP#6)Y5Bl(RmMrNg2z+@b_|%i^fo)-@ zeYH)1cIL|JOtLw?Uj@mc?1}v@4hoPx6wR7p9UyyIxH6K^?gA$951U_URWr#gvIm45 zhvI56ef2Wu$$b_6LvSg?0%l7Rj@0~Rzu7w{N{nrEm4s|ITmH?a@3 zSp`WPa+ykPlqfZ@-{s6AyHz`yhm1EN5&@iJXB*u$j2j}yNiB(z9p<1%b31shiRJbF z2{UeTcg73gxI!n01`cxu>~H53B)P84TJp-w*puxkxmv8xm?_!$KSurE8Qma%8QnP_ z71$h4Yokv_x-J|gN&k}TV03?dCbMIy^s(DAt2^#j8q**OItKvpyXfpt9_=u#$XWZ} zyKg!ChR1T5@0if4n9K0foeY&=$F3k-qh9ZyiVh52I4XV{RSiDv!Kh{wZ$%}3iTzbG zqa6j#F?x??@U(k?Xhyi=xDNk|iw@3@ikY&0LS3&$vqu6nq2FcpHI3YzeImxIs(*e} zU2s1+9u6`H_KgH@Yc!F=9^+3&s2eJk`g0t`|8nec@Q(om9%!IDVCZB+gH8?~n`<(7 z$Ih@7+o-{Z;{;e@BK|gMOr0pota11Yy{HfWvLY3nbp@Dyj>MFbs5uA0 z3mTTrx^w)h|7qKw!$&9~!g?X#rC5F9IAiDU70?S!-{7I!KS=pEiMv?(BVkkv)45J) z<~h2X2QMYY5r>EdvG@ayxD1YXxTWsDc5DEKh(0)we^YJ>tAq;bwrPAT%URi`msx_cFRcI zU3Pf?yLWE?M#DRhaMR?8pK$&>mT~d2WUF&XdaH2t2=n$gdsw|mcl0fL|Fc74>`CHKZe7>0y42=o(vG1c`H0P}!vnmT*9Xfhq)_=6vBLG?{QM5mI?WzG&nuvG9=OI+M>)C0vddrV*DxLhek}9$>d%a({?_T0n}uJWXu1 z%ifL00lnyEKC&pkHFQztS>AL}8q@yU!cbLy+^SwUe=+21K8T}?uCK)EJD0YD6|_b} zSE-6!6_s@>fTI>A?;9omCaUh^UZx;B$pNB2TKX3GH6lG>@a05u$h}Bz{ge7t38tu& zX`0-A!+h4Q`*BKe?Hvyv zcX_vPEog*f2pzH~J!|~zpw*-e_Eq=-Cy=z+;K92bx8{JhEk}Rh)Mizq%-`wN)gKB~ zH|XE#in{0juRCHBD`C1^+;be1DLJqUVY!txk2*~6N@71rQJoF$tNB+|E`9tU7Mt1^ zcHBGKL2Yq@_ky(=ckeK^MLE`CA`??QzH8?~6I&+0xwG>3_8=Q-==|)tEiNhr-&aOz zHI0nw{@S)()Ol>--eTyF_o9QiU&q;EEa!BJO%RrzG!SeTp-$RXp)GW&?P5u$B1U|| zS0(p>HD_4GGPd@&4C?z3QF^JC+4}oLKs#ojX#6 zq0(W}hh6JcM@i#Y=mmEM<#mmKt3d|oisE_CtIZuzRLY!WEM9>+7|n))Nu-K!qir}% ziBAZDHkHQsuoVQQTaT5%*h(0gYeCn7yi)3DIE3U-(U90FL@fMM5=ppZ=<=gkt?mzl z1n}O09-{Y5YIJN_1q07HNSRCJGKI z;|}zkA)kj;o3A$R$KvhI4RBLol`;&%?G&(W>aMvts%@!po6b=3vT z?^3@jyOfhRWM?L*xn_{)bCamxG@+2GS5MTZm&p{A3f_6eX9!i`X3rB+lWFp5k@eEWw0xK0uIC}KulHrkO{kFj zIZBs@`@&?Z$-1zXwqVjq z#V=ACab~Udt~g`GGNr?_@PdVoPFrMM+^v!FFOz7ge$Yx`?9s#Lw~eA-vndUoHm{xy zj}_NA3bw~`4&F)k?xoR?6c4B?;7Y;aD=Zctb<$BldKhA>rBS8FMIp&*Go+kxIt{9+ zK=T+NoR(fg5~Db#RV`9Fab~^ruH0e8mKCaTz?{=ZJa)$vNT+yu z{cZ0KAzdlGd7sRzLP6R$ZbD`sL>pu!J95sf+u(vLi9?Lvv{Y^<7Z28SZyGGO5Oj$K zT=ENS3etpnC?DxHGkOvynuqd^AleX~ut_*2XS4bec^y64Jm|KV^N1(Yoqt$h4LN5q zir$iXK_Y5>=97Wsf$N zRURKrT~o4!Q!Yco%)!`~ao%cGQZe=3nY1`HUuDSzXi=OY6svrz-_bNPeyiDW>&u5) zL6v)BwsG|UxqV01Us&4}2h1-a*e`VoKdJ|7HJmsd0NVn6%GvN9Ve=Xl#qcCKaW=$s7Z zr2SEdCCXP^3Ym~BABCb&MGGp!q+Hkz-FKVHh^t&iO0yf2mH4Dw#{R)aKk z)T5SDK#d~(QZA%H{*^NdZH#k@V9X`r)omObJmkg! zQZNrPWH&U!d%j#^4ld{Ip;fi)eH7{D#${LJbAnSz%9Nou9C3crHuJ= zM2XO6O4Wg{1$j4?YusU8) z!UFui)0rAk(Tl5;WaqXwY;8S=p;moMS=ti1NVzS$Jn@D zRE_ki77O)qb5gioqI5xqat^*H=Xqad7O;jF^v@Iml9mz7V*zwp zRO}HwOM0C7GGnamy~Gk(@E1H64{KB#Eu0+KOX&}mZ%x|uZPym~OG73;Kxi`P(5 zb=X&C%c%O%9)(nJaVBY`krit9QXf{UlsTtgwFux_L@@6oz_&i^;zH4=xX1yS-V z4VOxpC;Mm0fe*&Q{&2Ys=CV2wA#ROmg^}oggErFQ=}!Bgf?{c80-A4MZes&5;|mycY4zEx1k(0 zXagG1w*VZz#-hccKkdi3xa$&XI!z~I#eey{zhmU8H=zB;lOXH0x&(7c$_8B;ryjnZ zGVK1k6SG*UNO0o9qyPA$_$_ggV4?!R+q~;=SDb_=oXm#5=;kq;MfwfdX~HD@s$-xQ168zjLRuPWC`HUYX zBsIHb)^+jCV)>wv@!(`kd}XqOv0>t5u0CVUU~OIT)*;Z?2>Dez?Io_}>1t_J06&ou zCH>5C68aRAqpc|WbJ_s)EyZU@(QoWSKZ;9QuM9Z^kEJq^%bu1=ZwVc>y zatY?w4pkRy^L5cQ1T8|b1b+mFdHgizo4DYF=bOIqXdh70 zK2(oq9^sc0SuOqvfMqQKiU23DgK|J?&E;GMZCn;Zl6#?$mW1hHgV+! z$*2fvZpq0W<|IoA7uWvD4zf?p1X^d%05doY-`@^_~4gOdHa#;oX9y+E; znq?qbbeG0Bwn3Vylxig}F3Q&aBC71qfYWe?-DvFPu;(u`eQPe(v3go7AzMNowx*B) z_Zsws;cKofLv2gHDK@4jFELZsU(y%G?d~iZbI{H&HL1y3c7@gbtG>x*G%%ohNG=6j zPPj#}MYt1xb4NRBggK3bG@r=B2S=Bigt5;hh6&gr4-YX}BIL?|XS5QZBjz$i(?So` zqf=38HVj1=^WGYKz06OSS#M=}s;oqox6kFs!hR1q4-DxCqsP~U&}D%GXu9RY&xecq zjz#^JuATLH%5SSfb%Uh3O3*J9vw^^KAL177NuFd@0`}*tv^3$X&Y){n6_DCJ%!nCdVQ4g}v+0I=Q zl`i@k^XcXe&IOa&DCd&`t}+}x|Kh=l;6^VjLCuu3XpLgp9+n^st%}w!KExUa6|2P>LKy@QO@B_q7!V}v6>yfw4?@g<7R0>yn&0k)l)p*)h|W4{_-Tep=xLx&sJKLsWA4Mz){NW? z&SnH0QC6{KL{N>m54S~`tAXYMXRxw+2xDE#(L`y3_w~A!V^T$XHRX;E%zP*x6OC`< zGBP!HO;Md=ICtB(@C&V7 zTeMi(k{1RDZGTHri1IDOLRZuAi7a*reSwpVHws~`WSm?q{kiZ2CVD{t- zhc;&v*`@m)+d-BcUTk&__JLMp%t=t!fuc*p;;X&_mLHSm-asD<@0$I{S-s9t(`tD( zs^0@mZKXl$j*WiIr%-)vBgAn-?0E%TM7VzfGRWq8dLcCKwMvc<5?Kn+TLlj$APhCv z#yZWH|3Dj^8$C>eERf*v;L)AE>i1pA;O$p@Gl6TqP=z-cW{n}2YESQ}@F~@_;$q|L zz2Lz+&T*uG_6R1(en!mTf@a3-h4c#T9DeNfX499;6GYdSC)MjOel)r-9dqP~u-|Y0 z%?iq2e#cJ@zxn3m>g;lF;_T();457DA#yAzEB^e`N!a5Se^UjjL3&$D%DR4bdrJyN zse|WIsc;O}Dj|(?mK@|xjeU(HZzo91SdT**sHM_&S&I>*(*2yP3qJKpMP$M-WeqfN zy9q|cmSX808(MF8Zvja5)NcVmgFAO|laAr*N7&B+II<#Pvv{n$_&uHjDe(<6X0-8x zaeJ##o-ndBp`G1!fSBowX_uq_N>Fd3;bF{;KY7U=85?v633@1Ct)U=mr8nL8MqZ%N z%F>r=YQ$9fEw~rEho&-Ldz-jhFNyOXW8D;aU$IF?GP|NhmyK`X zuO~C}rOHBw&dp9nzsHz4>oFh;Y<&M+h?h9(bGoDjW$}ipe3{XG@BqwpEx;~vFS0p0 zqEtHw;iT_*T9i5cOgDRgks>;1d=7c}2A zotq}fWBoWN`RVIdZoP8{HiA5e^r;@*f?mg3^}7yC$qbs{$jp|fzm59!`rK0z+^wEhf`aX?Y9blwih-V>cCc- zc>Bre=jK}R7V{c6wtkGTzvRiqnw`t)#JkM1)B&HQo#w*Cr>OuZ&}$Fs6=y0+4?Dzn z{)@U1MtX{B@x8k?!*q^487|?G^(iIDXQQc2yfweLE!jKrYba94;n=szFvBf!@bE`! zyG}_Ki3BrxRedvJ18|XhZTZ?-w+814%;&ujX1Bpu@KKS#D*3eULVl#u*|PMBzK3p&T`$SWn&Vqo=cQf++L!)pm!I9)4BdCSW1VbF-( zo6pL3O6BM>%8I^O@>^3Bn?^m#x2|#DZ^u&1LU9qUlJUz5fQ6r+(L;tB2pCH_85Jy^JK;hMPDt}12g>UuO#Oj6OQMY!bRLW?7 z!RDLT%wsyXuUy({-!{-_=R!RRvB> zgxbi88n{(ZAMLZ$%iU~Wp$?}3+UmHT-uqnkmPm+ zv3?WGKO!oayVMgyICsq(<36b+bW*&;!)X!;`*P)Wcbq< z0t(MVIM=0gcJ0o^Hq_{S4cp@SAIYOdWxhG&1HX{ogG33pg?Qrk@mAuZT;q{x7G<*U z+A$-1GpI;H5`NKu4Z{z&DDYMI_e&S48v1&Sn}XLF^o=fGiJ_3;vi2XS_L34?`KTth z@i&I*%80OeXh>j>X7I4X}7`pDwfl?5M1c_6ZZHb4!FA>-G<#)VfUm4&#D5DlUpu8q+ShZ#a^N_zNV{ zG^t0NdCsU!rN9A|NfBzbpi9sxsPAm7@x22G(-iOa2a^I&=b)4!J#3wCtY0%QQcTlO)WT@r;#0x!Z+NL5pkw|bT;7+YJ zbj$w9H3#7yDRB<6uu1HcErI*d8Y-V_(D-(-|0r(0_srtbEu|U%0vZ+PoW6sTnf2N7 zR8~zWwDr!5ch`VO7!I?PL8P4$FzKKsgx0f_u!>I2h9eyFKZ{%db+Gu}Yodc^4?3K+$ZFrgW5W_cJQLJxsFpYvKk zm7Zm0n;uGrfwc&R4ob%MVAim83o+M&=x3} z5+vLBRS;woRH&fJbW&#vAG|4ar|I?SyMHUx?=(Tl9P69fv_MfE`#P((r(wm%bbJ@t z1|Bo8*1$AEWmQ*x&he~wh5Sw8SVY(A$~JHDs*{|7^{;WWXlQ%UF$@C1#fd3FT*NSp zEb~GwT+RG3_Vz<`r@6n+akCqcI|z0z+_YFQy zO`jOa5njOLNzg?uOBPbxt^ia;n`}rC2L1u$L9?M?Xn+ChcnL_z2xz%ota!|CHR$kM zGH7hg0xl@1uIn6FpfFhcs1wIojBp&^}TqIDU5>fFGWfq~jhYf&}p# zK`o}Mq9?j~#|rudwt>jRF4|vWU6tjVWXHgrE~XMCz?Kn{2&ITI+63~)fj|e8MqftU zY_7&Kal0}5)upqwrSi09br&PL(W-c%SHY6T1jwvZKwmwNn(Up%ddT0Tw~?WUA;&1W zFjTk@1IE}ykbw!H(Er%oGGDyJ4)mp58LO%n6QOXxOpg5WC^!$=riTVhE)<3i8Zfz& z)c0CA#1n_?(ZsAa;jR$CFx9#D0onD%4(+)+b^U{AVEV`SHvk%4#Npy zCRf)R=w8KL&s9$TEE4~MbIICz5`YA{X6fdsmw;A(EfipIoJdtr0wy+TnVg(G8W2+rSCE39h#Kj|Tg zhzVAI$DyA9!U^%#QiRVQKjUX-lNv5zPoFCTZCl@Ufw$Yga!CvVOs}<$1Vrf3(U>Qv z@=CIA^ZxJ$-Z~^PXkxLR(%)WuCQ8)mmix+4FS8B-40~oF^2JN+ zaat64R>Sag!U87M`9BYWUA=65XQQ*O4Mga+(#Xp~t-j<2p(o$~XalAZ!T};eaCLBN zHTF}>Tq19p{!dcAhI{~(?}+oucS=@(GJVFAYo{#{6Ea!+p#~~qIAj`!dZsZow$^+M zBr1dwwFG+=?RP$Ipp6zuGJ$)@UB8BHvjWL^uIQ97oMg6P#7`J)fkal?N{4HRl6l1KCP=_R%3vBHv#Jj{iX9NPtEEJOSP~fH z0~lcy5+&=lT;PG1&rzt8<;3yj98@M|6v_Fi@bU`$dQSF{x9?k2`#;pL+bMlVeKnh3 zP@L!MPR8Sh&mRUHCf$$UwPFoAhQRf5`}zDu7c%`ySbzAef>1%zg4>~TTyZ^{gn0d{ z6%+|SpVZ?ak$EZw#Ra4#(2unB|K#7>$b(ygqAWv1rWdQOh(A`AmO1~02)hOZA68_h zd<3$(2P|$IcJY6z^8Zg&XiXpbDDXC*4BsFA!0Uu;1u?n8cltIq@(7X--8E&TH(0Yx zND(4bPO2pM7v}@zr-{{jnEj>AM@Si}aSj<`HUTX2r%biDVOesL9OIl2j>d8bM`v_E zQyC;m#K5xCt*uL(f48#c`gSSCU62`<#5)?|L;IFv@JJ0u$ z55UNQQd}5;C9xVD>ePM?>XQ=}lpy3`FZo86>W#6UK(8^s2Rud92AL~m6*Gb97w$Aw z$r97njihs9Z4EZ}zHYSJzd`BAnN6eZszM##aUpkP5do`$evE)!tn22Ha5l)u*2@wf z!H85@Od_>GKBG@YL|_#J3eyl_BZx93;Gp=MVB|7GGVDzFAF3~Z(h+~^w5)wBVH2(J zHvzXF9o>!?MSe|7j~qmiG!K+62Cua3 zBBkRf?pl)^%Q|A*uOX>*{EX*B{EHf7hL!@G!Jd3J^6Nu5ZTg@#rtCM56VrV zy-TD`&=}9<7cUfz~(j6PCF64 z`^K_KyBi4d^6xl08tH*32DO0kceg!|v{!ToDI9e15faB~2gWR-^ZRya>H2tocDuy0O|3qR8lvzXG}p({_wz*Jo;fw2FreSGg&!-Urp*v-WMQJX!suT z+Bof?T}Gl7d4s<`oZVDDqNPM#>V=n|iJ8W`b&seOb${-1%Vz?AmI6j+rAR@Ll=(`i z!BOYfFGGtqwGXHMN%jIosqMvP+~m@P+Frs02;zF_7CqU@Dh_PZaaMteZ7%g&)d+9HWZWOzjFOz^%DL$wg%{JjAIq zQ_1d*f2Oq^Z!YQBcpi5}HV+l2NMp{u@%|>(y1AY6Zoe+bWo5{NQAWGsVZT7})4=3j z$XDCf@bKgWLSgP~=kPo0Fp(~#`=#B7zj=KTVvd}TfCN3 zt~Er*6a=Kf=uC;>lnEJ!KQS=4EF^{Nq1vAG$epraT%BkXES<@^e8fccD1(oW>Elc$ z^S$^mR>G~FFk-M(Ip{)SLl8fd5+ys-Je`Ep8%v(IPE)5CSO4Rmp2|YZnmfw?iV_ z(wY?*;}Vn?%@!mf`%Z?AVTULEFJ6<4IMfFfM9~&i)u(iC&vTFk(vMThvv}yK=p3QS z4td*R1}EwBt`HM9}mua?SCHLv{Lc19^Bga3Bwv+;@)hR z(#e!PC8NFRkGq9O1yViiUm32FGxYw777%V6&8T-4UWQJh$;QWVt zDg$#uU6G)%ahek-h!}9o*L8IxV0v6im%f$B*e{@+m|gNCf2zWUm8E4GNy(Wb1=||> zAVFqe?yUS5wb_a@8g+91e>7cnSXIr}rMnwxxTHvlbmv7<8l@Yhk#3~((w(BDbVx{d z3W&6HNH@~o@cy3fuX%hB&dfP8JJwozPtdj~ObB8Hb$7`o>*#gxwEfl`v}{ixC-xe$v?s)>jYsJn^(YJ4Hr;(iC43o_!dqAwa2-s55@s^s$D({82qgU{?BxQ49b zCu8_W`NCFd^S!0Lva|oi)IyXCnFT{kT&T{kq~k%!B#=oBp^(vl6Kesu$RzkS`3kF2 zLJp%hmIrz!0ljaK=UD!W1yd{#%b+F46<%YPA4e65=c87R1(;%M5=$HBw_@5NoT>P@BB!yF#BQ~qW*=Nna z2!iuPjKVfE5c%|}9vg?m^-MIm>lgaPJ06x)p?JStp?Bh4*h}pui1EoPK$Dv`Bxducw&_4XDjNk)D-=4>Z`|6g@5f0gJw;N z4O?`debPFSC~bCl(-`#n(3Ls>G6pRfMz*V*!ME+g)W5&le3;rMmf zkg&w?!=HvSAB%2Y_smW6+O#9LzSZI+OgtD)%xRF&SQ?%{QK)5r3@0b7d}#SPXu1ri z45m#G0jvS=o^Kku03O{*5Uf77q@dpYD_R|Ni zmla>Oh1(ucj-ys=Xa%#5r8fe_j-??17=97yIEHqOoSS^tX4SWvxZUC-egtG*4A`-J zb1N@;K^@l*_zOW$3Ua;}Z}=0D7!%1WPXJyDltM{yN>odjO6P4C>0*5{Txc?W(>RnV znf+yQFIb$kw5_cKGvrTWI{S_+*9#b>$_^d11kFy9#ywDA?^#uy^?oinaZ0GO$Bu4^ z5AA(;l>=!)7`Fmw+#+`IGH~aPVQ2`sk)zH(ro@-plQJ#PM>Cf9T_{^O3I7Hwc24fn zD6*QVncxtbosB(#CnWqwu}rUN(?5BnHjYM!ICG;&PO;xl9dpF3DAEe*w@ORh9^)un ztc%;9pC9f|?&JA!EyRrvUw4(KSzl_|otY;4uq3A1UBh7+!l(K75+T`UxLq>f6x0}5FdYH}5vq2BEXxjH+tDyBD#ZaT| z*H4RH|GiwYJJnMqPH5cI-V9i3CQm;aTC+(Z@VynHDeZqISUIZ^{b{Nbkgsb2UUWd= z5RS;Oyw6~Vx2tFG!q#@N%Y}M?i5L9jD2cyI?!;oln}~!kI6SBH+*rC{Eei6YLOICO za!BmvPwf4H2C5dj2St@Ob~;5lbGys2mw&Y6GF^}8)+Mj{xZ zrWv9o!FNI7CND%qSt=P3g_3VZC+Z2^=4H|hp<+vToVpwMainfp(EALX>6&d_uxu;6 z{%1S|Y{x2`FcJki4nZ@+@NKGHwZi=GL*J&7KkYeV+o5<|)SU!$(aJSSj`2=A18tP$ zx19kzX-{eTbkm7P9R?kA%aGT0kKS`b2&YNO^U&3N*&p*6{bYYp?-pItt1=|2kX0Cx z3Xy3u6qo37-pIcoOs`t6JkjR5?zarDRTUA1C@;->|3Xk=$CipaxO|jweUq<5JruX; zb0wq`jGOoD1EsI%zL?_b!7JB9*#UStbb@ty2!Wn$r0R{FxM*_bfj#zbC*ZRXvI03} zHAr=JC6GS&O31GOIx>JPFBzCTiRkU54Z9*p+`FH2%EYU@MB)5r28Bf%pOi@O7z7xh zILw6Wf{f78;gE+xMHQO!qOb6k*M~(}AW(K|TLoP@`^p)Q&qHqi_%NQd~s02YnXR z3x*I7n$_YTqVMzq!Q-33ncD2P9bFYC4Tdjr3jx~l_D@pe0{ZwRnJ+s z+Z}!{GiCgsCOoS|?->K4&R@%SpVE~%XdZM$BpA+|>+tJPX;dQuRL{#Y*_m+ER6%tZ z?*x^n_s!wq?*1FQBMwQliBwj%5`9h3dYwY1P&qi1Ps%2%(X@9{k>jIe)=Pc zKz?C%R(dRRc4T5gu&4NgLoDqoa?s$KhBGQAG%ttpPYT67?|o8MgOOXG3P+!fXm-W#hQk=iOol6M^+*tI}Fl}E8#iXHRe2`Nc zS79P6EwNlYqcOsgxzVrd4^ifI5y%JoioCY}mFMgE>8D+wLn|m@17-%3;e}0`HL)j@U6d}485zq+Nkys8$v}HG#vmqP%x6!m$f7=?sEqez zRzd2T`Nl+ail5n^2$?@5x*m(_*j{91S>DN14@Utqu|%%Ndj4|G-_yc_FHPtZh87VM z2;{=EEC%CD_QuU((skNc|J0vUy%&<9apsgbH(|)9@P%%4Tv*{;v%IcW=+o^}#~?P@ zhFKs?{%iz}MTi+2MAFYdh&54l@cDQ)A&^z?Vmsdii3WLawa`R_23g?(`(h+oRh(yh zCUbl4P9xun&9Z58>6*xL8OmU8^!L*QRz=kxUcG&aynJAgE<--BP_iQ=Oe$0yVOEx+ zznc=nNx2MA84UAs3*eBDmNb=?Ag!cDb9l!r;=GC~O38?gY@mSxuooO2y}T&nY+#e~ zqO7uMOK`p=4u^P37Sp`vkJ{at`SzfG_Fl5rw!?5tz4Sc8<6k%v?G$`h*IVB7KE%&(!x?c$ru z`0Mf>hiB**BOh_s@#yVHMt5yDwUuuN_2g~h zzYZcS!(Aaoke@Glxh9o6THD4zrwH_ie&j(E!fBp zwYd}x5A%rtG%1_eh~Jvy!)uf#))qBte>H58G8zB3=ZZfTy^po>@K3qZac)b8xMRBb zJmMZ5MfiPHzu`PG63f#6CYHLev^Mbzt9UEE%u@^RV|DhP({&ANV$?yauA3Ge5WsQ0 z%7Z+^#?a>i!A2-fl{PrZ8~7zQYiAo+tZXHI4Wq=v=}5%HI1$XO|03}~$jQ77CyN|` zZDJ}S8`4NjOs)5#IJEk1iff{X1HG?jH3frUJ}Tl+(`fIf!O~$7Q*T%ZYpYmh#(UPX z{^0v0P3qbb7}j&a)X&(deDfXhTVDqY{=g9;M>xG1r}`@^Iw0Lyj5^22braCE-nI5MT>Kpz;IO4dtt1`W7s*sd zzqV$6b>;S2$P1xpl6GcoYZ0V#AS4;9&nBRrLxU0zB7P8> ze-CD$ok6htpEU;*=VSYh6Fjo~H1ve-hz^f7w1oGZc3mF)Z&zyXYNg@HXtVG-I6}Pul3LLlAr0Y!3j-m7fNcvseJQ#`auP2t zyS>t9s%B%08b`8DVo7HKC$e$k&bFxCJimEQwZ{sf;@sVZ=_Wg`^7tBYUb=A^oOXut zO!hTwM>!DepPeQ}mpW6H0;_`dz0@2y>@aW$A0i&@) zPL5^1O4L2n<)}v=4*r(jhDG;>=SrRNeQ(~yeZr*$6T!fN$%Ba?<9qg)F-OClX2oe@YHYYorR|yYqj>#=8O;OQZ`pWKkRudiE0wSA3dI35R*&MD3(m_k_ zxm3Pxy1f(0D9Q8OFi7hzio)GX&7R|^eK$TcyrBtPLDPIN#J{8{SUh`4bB}Hzwqylr zRy;?*GLrdXmZ2h(oexJ%60Dj6AGOO$RtAnE{2_*p$+Ovrc8pyBAyl5&tQ*8Nlw3Q4 zrN#o(qsWpxVV%`4!omky?k!5ChC8h$7EPZgBKM;?qa}2s_j`b0_c*xI%U;0SpRY`A z(@n?cE{&aZ!Js~KYi++=Ot%wsQ<=IvapHVzPK`~R54MC<;}Q!U;VR| z<@=b%lDUaUy8jczH909raLs$&9je^kIlSj^nVfem{{W7kX&MqZ~rvSn*sXjsl zm?q-6;FOETp&?(Dn8@!An+4~U8mIq+Y9`>>PeL`X926u%r9#30K7^=`j;bx1J5RLv zV=Pk|ZMyeK<%_iNfi{V+0=SDZiHr_2xeTIWH0Cw`NF}+z{=X(w<&so?btf!b8Jq3r zpQ3Njwygc=*ZywLYOD65M$ogYG|0BEz@~MHeMBx}>FaEAoKYJ`TNcFTtApJY#u@Z; zspsc`^ZoD+<{H3CQljdz0Nf<@5XvbKL=Xu}%+gSi)uNj7TR>}ObemY;i_M`dFbfC? z>IwaM5>66n{f>pcMo|LFVX?F3QZ5>%&4ihX&rSphBTPL3!?c6N_3f#mbDIbIg>-HH z(%!c~Pq0a69f-`?Lvo`5a_^2vLMB5wQx_juhe4`IE}?$1KU9-Q94Wk6)TIgKJ{m_gsj?A9< z*LD^{!8y^!DIgnP1lhPFu7Ydzd~)V?%pB{#QJbK~y-^jTH6xA+`^StsHL5;GL%$07 zE!UHp41a_s{@=wm(*=pFt>2p83vEz4^Gh7kapN4)#TzC{phrT!DrKv)iZAk954W|; zM>NOgz+J=k920O`P`d}i%yBXv2OG5L8Cnp!SX4|{%m@Dtn-LMcO=l;Pt9lLg9#LQI zYnbM?(6pIdf_^0pq0395y9D=SqptIqJ)dXPA4Yh+Eej{bagJBt0W_ow-VX#(2&=~J zGE#mKM7CX1(Wgqg;zLrj<}m=?4|G&T3w-)76hR#xei62}j64mb9oA#g5u_g;>yiiQ zsZH_zW%b8xI1+H?7zGuUvi-zQDdEMfl;HoJHg}Y#(xg`P23VyYij@RohE7Ql_l=I1 zSB#q3GOS{QX{=fq8UFj^bha^YR)@EMSWn&VTb;Oj^4gRQt_0)@6nN3FD&#e8Co)Oq z|7^Z0v!uH3^g%+|)zx6bGrM*U>Y-OY9lN^Srg8P`iR3=T+Dqp64go6QfQ6G*BtmtW z=@LbVZ&D>U6Ll+ZAp42B6#12%IaD5)#|p4nyw>Y$h@r=aJq8|o;&3m@uopYA5shd! zz}iGKdVpbf?;-W^^)4aN(CF_G5x;M49Z~@lHpX?VDXxedwQ&3$=pY0Lz~scG?>wa? zTj?mJpFIwZ%$jnd{Oz;Ghx!B84j?i*&Q`u~qz|9c5KT36 zECj6*;06#C{Un%sBt(T_q$?kR`xrQL5ej`_TE~b>?px_MWHHM`lA@nNQvjvbW{L{L zhv0%_Ebs&j#Kv$_8z%YU$Gu^x_qVMUj7XUpHA2+3^3R?dZN?}C^>+c@5((AgiTemz zH4NK77drKN#Hb39_41~29A8WbEt>uEo!o=B5^-=5)6=d}T5c)Oi1mPc7$Kf?PZ#NV zVn{2RA;3E#T0OvkA#%Rbo={e_ZQ7=&(zxK<^6f#p`)Fxx@UG5{D3szuM;(sP$_nNW zpo{tgX93pg#3{9khb~AlO^ybcCQY-Xua8Adf`!B91pWkk05x6{3ID&?ueQKQ27(58 z1I6!7GMy;3na!1sWx0645jgIB$qUmYEkms(oD=!mz#CI}g=)D7HT#Ur125E~oY?yv zKI5sIoj#JXv{Z)Ns6fJIwBvohVN%EjCYdwX^3LGrZVU*t?lQ{K4X?1t-N!{&)zSJ8 zO88&2$#`{%4w%2;l(NAC@6+o<2^*69Zc4z2$TF=WHzzg9^c82O#+!@Lcg$C37hi2J z4?1iqZIE8!Ha5|w2jIE`5T6gHitj(KxV&0DOMKHe=5Lhb&%Sl+$wA=Ae?G#O?bydy zM#YyI6OaHPYg;65o)sC=ebX#kk&M;}hhpJ3#q+13k*(N9<|S(;6xyfO!YSXB!dNu% zHvs;M83MJYAu7;OFK-y0iA*Pk+l!=GP~9`A(LMO>8d69=>7V*JCeas^BVPERWnqD$ zj1K7v8YF6hbvSB*zpuzOVHNrQ*h=R|LD40YUMpI#a1&GZKd$FUV=NLCy@SI0Vp!W$ z34+!f#q&d9WOCXt)I66ClC-`6Uf#AMPR;PyM6{O?T%RCpX#U;juF4_ zZ2yJYta*93X^QMO^^`r_PgXqa3$dYq3L;e0r+%1#&4tR$Xc^1meHjVj99BRfr@$yb z%Qv${=n@Sir*S5>N1z^^-QoYb)B#{%w$nrJF^!6@hVRknt!TuO;Ja`2zT|^xR$BdI zd`!+tm%bTs{iYMO0fKn56B=I?y=)_mAlsgTsht zj8C>Z2j2(hju?RrZzkd{UB84)?4Bs5fSwGo#TSTcIO-iT59AJN3EXfD;?8LaENm8O z=Pg?HSE`udjIwjSJiFcSdL!m0av96Z^eo_S1XkiP(^IRY1vsZCT>ORpqFUZ}y6~K{ z2~Epsn!Q)K2))?w`yWERw|?7jXzagTv=z?y9%zo^y>FLE$#xj(oAA8WhZwCzSCJNc z4Yz^cel!lGgR8*?B8i9!7Kf5U#k3;1@oEn4<=j){wp@&!7_X^8F5L~EfXYWe$@Nhl z=iH5W!xxWojJG>ZUM0c7vAHnRy0%;tMLMtxDgIV2%^90Ht1qLwtfn$-uHy z9^sgS2~DX(FGO+*Www5GF&KMka`RC?QPlsvMHRIF-l9r)Wb0Axu+k&-ZD8oc@t&O6 zGibNNQ!&X(FaSn)qql=;OEMC6F38auGf$hW{dkn8hiRhhEZP}o_O6ef#cy+3oUTSS zxpR7zvbZ0okD0|}-FtpX*dS>AU;xCzA=yF7Dy#K-0ct)BQuQrYQsYU7M)`pe$AX4cj zJOjZYIvtM$B|wny$dxJI*eFtRKjOO+>2Pj8LSz<=d6-Dn` zX2+r`FT-=1c5;Wld1~6DY~fCaxB7EzZ%GPGNV+zSIJEgWgX0d5?^IWP9{GcPRA?ii z^lw1;tY}bpc(2FELk0Z?Kw#lVY0si{wIna^op{_X>ITCN!lI&gM9Gxo*j)xT-h3&H z85$T1$P21f(`;kajyL3_Hm^~Om_??pB(0`Y(UhxIs?wY$zvdk#C#~gmboH#`u3Z)! zeRa7)_<4^BGvZ#9@FV1-3PJUNNhRr(9_}T*`l~^n`{#uZW~=yBuRliLdrdqQW(x6B z$8F{s1FR0#U_+)wn#abVUuY7>X&w5boL-p{mq(8m>q@nXQstT4nQE1$krC%uhU?bB z@KmCpGu`G5b@CRq@=%c}yqDYOm;}o|sb~65j^CPWYW~d_v2~j2-$@rH6os_4i<4w3 zH|e@qR#{pA^Y?y)rW;Xagvtnq7BoF@A|gljQ&k;McE_U znYQ=DwTE3#)CT((^oA~cc^mPW)}hkY{uS@ppcrjpwi)a^mpbZIWTfQr1Ev~2ul+c3 za)w6T8Vx1I9~>?faBvNjnMH<)HMFWBn6Y^_1^b_^guGsRPrY*EwilotR`@HpxWsO5 zM^kelaI;e~LVf{7Y^%>tey-rMVsM8LTqsUGODOsnpKtAaxZ>Rd) zPwBKPz{=hahb20&l>wl9FmBVWW!AohL`CkIvfXKC(FBm55Zwy1=tg5kcD{mMvffDI z*Fhy%KzT6>&Xsc2EFO#8nX=~4f?D)DS^8v|;*Rwz**atbkSq5(E+Y-E2AlFOBPnXN z6J*(qhI_k|1rG4IoEkTA-wXm`@U27HOB=V`A#FWn7p_rt_qTsJ@0yg9ct^UP6gVR3 zHk4?v5FqF6dT_%aSvNItWKHmm{8VI`qO3c1^$z#IJ=8b^-;zdpY9jG1v!^l;Aax(> zx?!XU?q}y)PjOe+sNwEcAt!SGB{R$db15|A6-HLP@G_p+*JEZKP1nzeSlESWEBDS# zpI>erF8y6_uU*)Sn!1hJI9xlYWLkwHevJ`6#x|KUkFRRa20>l zE!bEU7ThgM#LgESJRw7rJjC~}U>9jr0A~u;k7V>cJZRG~h%+NR=u1}z|9?^se>WF* z_$m9sHTgO z_o+0ZqYm_2uA``kGp?qqizkb=1UycL`LEeqZF_GtMgE~J3_H$ipspcI38d=F+!w<|uRj`Z15Nk)XR z??cz7<%wD=b?>X`ohg64rLxn%(oKIw5+P8x27h{l6FWd%+ZWY%;)ss6sCff&Cb zxWeFqSB#N(-T|6*Kyup-3HDwnZUz0_X{eL6;sR zMo8;=^iZ}-0NgAr-Q&6+9Tq9vf4X;d_Gs4^Nm|%|c=~($-5eqq?vs7U<4u~%nu3Fa z*9HAGC}{z5X?W=95zBu|iON2*(WA-0RbO^avp1I(uqn%f7V4;KEQ|#j9gtCvK9l6R zGBtWfK=;P|p9Z6VmENoyXeeuq4E(*A3<0=U%~2Hz{h(LOoo(-*R+G3WVroZlLylfRD6F%B zvOFR46gG|3%iZ&=@%q2J-2 zgZa{B3=) zu!9ZMQ#xmyu%Ey9lbLE!*yw?p&VDHi;{&P5WpCnBYC@5!df_UP_CW!9`f#29Q+g8b z*tYhMed2KH^rBBhm#rgTs=eW1rwFCZEN@hOkke2{(Gp0DSK*>SHgJMhP1>sM&`D3L zq;&pmkSPD>+6&z|M3&4y(^Eo({-ADvB1}F}05;;gBfmg^8q@kHmQ0RaPRRaQfl?bZ z2vEA>yBbj7`ay34a=ZVm+U1n34Q!KkZ=4cv6(l zxaOK?CC-4JRUFOiYFxsRkTUZo_s&N>`|j=np&jBLb#SDmFnZSOe4<;iWpSEXcH8pT z=<0XoM?D9#n9nKmDW5nAGMO-A5tG0!MwXYk?pQ@br>VbS(n!v*FtM4ypA?YT!`?@q z;+FUaR6aW%GOM2&LU5lotw@iBXy#|;^nW%(T16aOMKTvzMO3&@o?bn3Zky#>Fwy?t zg0kXseX7QEG*;PYx%KbRr}WW1c`^IJD}FK8Fs>$EsBCsSA|#*?d8K#9B;ype+F1M46|Gepk( zlIOMxi;V+7ZZ^BY8<0dI5&nFeC!U<4Q!dC1ydu6`_n5IVD`(4g+vK}{ynv2^Jn zANf-@g6WcYV$FmOvJtd}HME#AL_8H)>OG4MG+LP+{JRsc@2`S_FAIz-mo97Fw`lJT zoZBD1-+rD=invzqZ7APm8U2&J1mSn!%R;D!N>avz z8HE^30O<>ng-n*!5FjrSV3*k@JkQS!9mx#q&W5({f5JgWE!P0j3tckWQ~+eLM>D7X zY|xilXG4@JR2o!^uooebgFWdRDEkr>e?GTSd7VbmQqx@OrF_$43~AD5AC-Koa?}&i z4I-Fsk(^CEl%YP*^0*uR4*)m2R*jE>5&odhv{N$ai!&x9y;QJ8lA1?f4KPBzLc%A@ z%Lb1`i!RFk+2AJi83S39HHDR+`RJz2C-z+Igf=mx18x3)+!+{3L$maZ{B*|rm&@Cg z(}~K$Ha_avyS)?TUliNptofJ6;AYfzfO_Uoi2rL}31Xu{)@lPJ3;*~f6aZ3qC#{K9 zsS_HInDAVRIS4xTB_ViDE1cChLsOCuqcexq@jD6dPejzC3V;du@zPe9mA5o9Prd=7 zSxr*|$5*;>eqHb8NYW(-{FI#e@QXdW??q(}J=ons9+ZV1ecwD(r#%vG zQJa@q|5iS)Yxq;9oGgkQd`C!V?t;6ofZp)~P6L_327WP0M?AQpm+0Ay5UrBGTA(7s zatEt524J_jNF|kklOZQnRgzS%Pf04v<{RY>YJWjJw6SGTRLSXC78aKC_$@WpqG~=YSE|@=>stesmOuN7;ht#Vph_c1Q z%-n&Nv!@?=t$iW)#K>xr-=UTxGKg7Bfg1-gOEpJp5E}CHa5U3DM_+i#9%ic$_kz$c zO=hS>n?ib7-Co$wQYni`@}PEdd{|)7)3lMm-5<$vy0r>4AnBBobpCD}7JL~dRs^8k7EUR@bL@XE+=^eV{MlHoAZ zgYycv5TroTNFwtp`fsjfL#iwbB_JvhxN^*b3>9j3Ka7}lD1GGuwP%zsVCZTkpbK;# zcGVLZy55BuVjjRh$rU?e#br*i21j0q2%2BxIl<3A5rhKbc0HI*c8ZXwcL#wRP4pY% zFZ-j6BY?XMkFtsYG7bB;43j@R*E24BU#<%K3S4`N`r8T5wcmRm>t0cPh<+ttuKyaN z9Se}2>Nv2c2eK~3^Q(qDFls)vokr+`t*3{C9eV2u_flGxbLitJ5LLg5)WJiXMUA|J(|-n z=yPvO?JNG`{Hi70|3>`>N2|C$zuj9)OP4}HH+acSC}L^)3BHsDiYf|#A(9cR-Ufm53;TI0<$n@9VWSue zUGgN}itW_1ydRm*J^n?h1%qew7>O((D!A6)*aj!}n-&#$-PYrZ{(aF{YcxFl>0wx! z{Ci0|&Xi-J3Qzw+jN=qE>Ra4w@UowPj=BXwtl+fqJZEaO!P1cDCjGGPFI3^&W&PrGiIFaxF3rN~Fr9pVjD&L6~pidL`8G-gG$WQHjDk;4~5OBgTDA z0K6w{T>U6MiRWWGbo2_p=H1piwUGUk>X%gXak5}VaLz!y4~A)e#>k6xhrQn&#uPTXyqwo8 zsG_OqU5MYcf!jylN{@KZ?Rj z{!APsem_58(y{O6_?7aM1f#Ku>D;qa6i7O31{)&Lfz2FjC_;y%FwG{$uXt!ACi0?T z+Kuc!Vo!dlpEH7bbA0bx+x!hI_{u8T$h}2xWRxCyQQVR(Vn<`eMJ@kK78_A8xrvCD z8l2}i#F3}-EZ>7AsW{HvfjP)XOjtqVdcnZXOM_${$JQgqFqx94ktf+BL%k(W^H(G z`;nr&r9r3)74|}4W}pQ>7FV6{_>*H z`a`<2`^ZCg0IO~npX_^&>VB%d{IQo=%)(l5Q225g#_-ql4OF5Znhla|5ZQd$@GdOq z)0d8QuB7SLK0hQ3%V4C2(qg=QRo4B5EwBXrpQ^ZVXpa-JoKUlj4G`;rDV{ zy4;G68^0=POJvEl$n&>?HMP68SXiBbB#N>^^|+^Zc)`Yk<`Pw5q(MEiw9u6hnFB*8 zSthEX5Cz?fm-&dCIC5xisFeTQr5GTk6m<9}CVoq2p~BZr%I^j3AMwOF=((g|l-dsy zh%G|z2OBI)K_b6{!h0kKbb_20f)*|T;{Y2|Pa)#2L6My6uk2)}g zEmgpx_K1*-98DX-5cn*(eW}3 z9P6h8Z-bMhQT}>;2b^}y$IF2QpX{1Jk)=AH5!Cloh61m5o(vUPHir!Q;(zK&13YTTK&cAamc z9PyNVD|Gq&aJULzjslOOSi%czI{p-|hV4s=c6E8TF6_VKvs!RPp|F$wmM%I^KQVb% zLn%~94TQV9CeQP;y`biNa}`s>Eqb;!{aT*6%yYZ%#D-_DZNCP>O~O7cNfOOTtzL(0 zVWzcFCh;o`EV<Or?XK>Wt_-*B=`Rl|v=VUE${8?F{Tsv^( zC4AUhWn%0vq%Pls-@h^ss0pJ2yF|h!PNpG@(w32+kDGXM#L-rLLfp|nD>b-=$kAm#$-Lls_V<( z#GJn~uS8mBUG9}&rGKL02lHqH$-xOwhmB!LsuL?7_+I*c``0+Az5jR;^Pcl;4LZW4 zn7evfEd4EMCV@i|!T!3G4$(t&A9ue(FCc7|#vlOoAB{zQD$5Fe#5pITN5F4*9q+$F zF3|>&R36NP0Kt=ouRQd2oJ_pU=PZDbsEBT0DBaT{{=t2I414*IEk?3`h3KI#KXQUr}3JTSncVR&o2c)wFp5Xt`%^$OdH~ z5n@<&V#tV=VHgO15ec9OVL_ymBKCF(Iz(L@{sZyC^58d>H6+>d6G{Pq0ph+)X z_9=kdN*reNn#aVq&-4Su3`CO3919+b)5pYqT=P!sI@Z%h#mQJ*E1oc`iZ2=DEE^eU z*VeLKYTH4gB1`sk)^+3SeU3vtg?<*4Wv6TzPn5qOSh2y4LW-z9`9(cv^Bg@KGAsEW zXO3<~ayKRYr}ktggQTg!tfy35@Qf&dABJSdC?hq&S0rlSJux(d;*b2-T+;SSvefTPXqZ~8sJ7Dkhzw;@0<*LtxueK& zhz>DHG#W_5P+q&Q2VZficv!6$S}-BKMqNjWaE0GQk0CVVR}t`aK~Mjl{T*jOMV}%a zOO1ex8H)3qE1c>Q>U&6rR{5Jbg`u@9Hu3S=WF#v(49s;BMe-+V_~;1Tz|bj zFwXiO6eJ(JeUrK8)OUcnrzkd$QJT$|$}bIW5I|}vc6Xi8i?mVByWD&`sBv78oWb%U zg@l@r6fBZ-e1E*+Izo9%;#wR?!>TQfa^#f;0fxmL30p>BCn>3wP$Ybsb3N%*m@KFru?EV3~4 zHy%t#Z&0<6Tkvu44!)M22Nf5$JP-OMT`V${YdOV&_BMf5&=yZtDlU*EVORZ&7duUK zeMVUGVBn}S_50CZ$mai`Zh{}7(i?^WyfUWjy!#Z__N3^|gEef!uHh2!Q0A&ktZ~p% zPCt-15L%9i5I-W1Us+Lvrk+m=?OJ0_Av}?);VGA6`s9IR00oO$n;>U{mPT#*G|KAx zy%9$x+4D*CAD*?iZ1vIq!l`<#)X1(fXXm8iv>W!Dr(F75hQT+jTo+thb#-j=k-hwU zV|Tpe{v~6<U`B0R6D+K<1a~;Cymd*%zX% zT@r#jknTLmpvHy3;9wPkA8E$0-Am*q)I9Jav<0RNeTcV#Z|5ip#X7#I0+lZdmblfb zj*EeIuRq?~94c^hU|=KIiXlwr+NYzRjCG2F-R|Mu#m88{@fl6MmljrCWV9oU04sf{ ziywre4U7g>2LYxcC#g=gSogOmswIwQw%@k)EgQ<$GMY#~tM#)utAl?O*7=&zXTi(} z-w722%~vYJqJnxpE?mvIw2q#JWi7pEJSz|R6p+xht`;pdjw@C2!6p4xOoEryR0${O zC1M_qxHFX-PL7g-Ah<2ET1Q76$?j!@=_^$G7k@*0s3kE8AYsJbA75i6?BaRr>{7gK z=QbQqiBfKxO`*9q;M5r}XP@@^n)c7=-4901MD01VX0HKiM?RdojQ4QSt5$2y1IA{! zddLxf`{cZFvSQTY5`tph|dj}SH*XzN;>P#LAQ%&OG>TQR7t0tr++k^iW+oU*4*Fu*UVX7EeCFG^-ka3 z#%(w5uTNhyws`qpn>e4W9*U>mEXV2W@;|mV-C&}uODNh{vC1bX9;Y`wJj1f{<1avHb04nI~>iGbAp=*e>FXzI!r$@JDj;z1?&R+YL0ZYx6B)<1sFFjYL@EUk{ zvXNwoK|ht!f^c4=6YNQK60$KCR3xF9277PZW1J;NVNe8ZX4fI?H7eUcT_ zjr9#DMh&0+op#9>pO&s}mOO~-LHri8+mz}(86~;={TWZ%j5H{4upOzDck_6Mkj^-H zCFevG-hfeoKp^)K79nD7nML-pe>QnG-kql&X>dQZwfQZ5I2D3{oXU&601Quf@>2vf zPo(!xc1uL49!b&FLi0@A%wdc#yP->}8<>>LDM4asx4PB(Y8m09`YXawc&k%ha za|7N++t+DVn%;?%)~1Zfdqtr0jkV69y;%_&R;_L*pFe8lw-_bjAzPohqJ8m0jFmsY@6vIrjh5|=aJzZBQRXN?Bzb5)b$>sM>FL1< zxQPm$#16w3UKUGO`8n`0ygRLfLehEGF+7<1lQblmj)Jt&vh3l9Ya{=!q2h**=&6Qq zDP>74MS2`Ey6x5fQ$>8@VbeZCo1SN#am>p|KXQ$|WR znj1o#!TobQ%9-Byvf!!t$SZ&~kGXSr1y3>OX(fSs!y7@0iRA+P^ z@$t^$%h7lpo9#Egz>A7QN7lXk-%1w+(mlJwSncQ>VOV6BKS9Pyfprj1lQaEr#Nj)z z?eg7U0qcVE#EkpY*LO%TG{dt`O@rVSF&v#hB89wl->mDbqz8{4_{=C>&7uTTe1*qd zJy$;l@Pjquy5yJ;gTqCBZh|<%1eq>dG^mj6c1hM`?WAP;hDGF8#+>+3Y5Obvkgt?H z60_0_o!UXj!IuL$ab4USDG-b}6P6Gd`bJ6*j5{H~V_yJ7JlRxn%r1)HEKO8ZB=i)9 zN@xjA9VlJEcp+*)-md*@vIGJxo!?vWuin#ofF06A_1lQ)wCnvT-@kTgs1c#Ut$Vwx zRrF3k7mJ*7e>D+oC7gMN7Rty7x_G3L+Go;UXu4MQz^RL(#sjAwXviO5xSUgEpVCto z^L)tl;P<{c6oViQ)L1@8{yRbd(K;w!5udfYxi)R`GTBpZo@)?!#HnN7RYDZUDi6h4 zyik(?uk&y}KHCwsi4K%Jtb>vV5yGzQPZU8t%_|j|6qC5_u6hur!{@90IcQ7f@!`H{ zcHxfhu)z+hK=!A+DOLs0DF*sE%Xiv)v!3m*N%!X1{B7)h3;yaVE+&B(4y^7@Zo=SO zsdrHc%n+%ay@h|=!wJXANb$e;y@}UJ+R8l(g&=(Vo|4{yX}Dp!KOmfb7ijJ#ZMcLI zp%8b5%7acX?zXV%);M22C-nmM{`tSZ1;s;NPU!27d9oTmPP9JPeDRS2exxc45ya$<;R3Wf6YXU0 z*$6Pj5(0BQ6ex?0m@xAV>4XN%=|l)w$iwv`vO}0PKoo1wUjCex`!Dz7&l&83rgztA zqMcbr$Y4q&1W(H3=a_$q@E}@qZTEo&qE-OLs9};gUv{aAcCxmO^&s{8VtTN3cU(6)ylX71HY{zpO~>(z?6WJZ~oSdv^$23Fz6`` zQmmFfHdjYWxMta!rh=uN6ZscY+x}Ya{${xX8)0yi0K02z0tCIK!(O$Qo20+v0~3P+ z+wWNYLdXSvuFbvTOc4pqglS5nAbNw@M#lt(BTR+_1|ZS<)N4f*!svfp)CSaY1uVQl zO2~eVMVr*4by`A*h)_LO6jzaIOhC)}p-3u&2V_AKu)J-6o?%D|VS-XD z_WGGAU$&U$s+Q?flQOlUhevkr*@~L_w%^~LU0XQ2xbr`_zO5J%uhp7RhfsQIh^sf& z3B2-n+@8DWKS}Qo*{;6bzqY8TdOLBke8ufI+Ymu%y{bh+J*4IYK@!(t55o$$R8y$p z3_{Mk98dwh+3;6oS6S4J=*XFyPwPBOpH)dl(h}yai~teACw{Pb;gZHE;$0nN2o~V= zq0263azvL6E(NOixI9z{ngkxe{!mE7|1^V(EG+%O{E&+Be=J>fSXABDrD3Rn0ZFN0 zC@BFIq&oxw>F!XZrKE(RLl{6oK)OM?TS`g^0SQ4$q=qg@zr*|c{^5Ce80Ox4&W^R# z-uv7?c8`rmW}91z@dGTs+Ux(j)@rb6Isf~ou`H$(Mcg`?b#ms6*Qw6vaH5k%`$h0r z&XwMfgh7j}nVT6mfrbb-VL;tQAF+|V|D5tN7;Zcsy@^7?9w>?|CD(n$nTP#0`b62g zEBA&Fo|+-4`OdRZUds&@oJYUPH?d84!UFag4ryCsV52Gz>z$;>6k68lY9`0<6~ z$F)Bbwr<1V(p@D+Xcw>LLz~Z45yr^gV^NxbSBanYybPg?UABURJ-z%I#`t)mGX3&c zN^ZB1T;E=4ebA8-ar7+z(=bP36H}O#KYSt1_*G4~CxDvoaLPetP*3aoAcu14+3Z=p zFOXnICL3)Jmde@MzG)X`X4sp@9A3wtE1Ei1vsY5ZPu&r^Hn~>NZ}<`BaN1|~uRPGj zGL5vZ!YgB2mSrXR(O@4+W`Yq(2($iaG{?%X|FeG>O)u8jTFnZ3pymHKvG3^NCxK;BFz#-hQV&zu?$w=q>t$d8tJ{inP7K?t*0v9*mLfeQ025C#1>0EkY% zc?!)EF1!?atnJld_VTU+VIg$*bwg&CzMsU5ZwW(h@OB;G6X(91T)?{hBNLIC;|VB~ zR_6G#^xwICNpA8=vS|<>`665PWBDEM#npUc+wA!sNV5g0gx+?}W4QYKMfXBKwkrCJNjYikMy2@2<>iSok*m+Q6Eeel+NKX59m71^;V$C0*Sx4x%r zqsTF*ED{)=P_BYN2*d%Q5XWc3ZA~KmocB^6zKs`+pdzu7iW6^Kx9H-lr6u1d6{P(v zNBpkH|K#)T_bGP#MTCh38iz2^RKRGG^@7J zLW4vUfH6zS%WNEX=XbtEhB7Kh`<3S6JtaF-?wuGr4;z$zSqL|VQ!wH%9|HpFD`7(k zD0=oSMc2aFdbZN{i!;_|VEEO;Kh9*167cNND^XyWDfa!#gT!}$VTybr;!6A>z!@LW zd_I6go8%@8er5?q-6j^4y0VPc+lhKU37=Q}zvkOI+b)`-XT{jX%cC)*a;V5?DiLYg)U(g}4indZ0! z!YWe8V=QdkLCdha8NtZ>i_X3M6HTH@brqjg15#Ry9m`4!a~vY+g`GQ)S#C~g77koI zP7w;6;*j?LMHaIJPd|mkCpa?QtDJ`mb+$5If9D2lFy4JO15h6GiG3w=30*`b$IsEx z^OmKbYwitG`VAEWjduT70|L*XrACg=+qCw6OR%5G8J;4w3&)~wd!&#%T3u%_{-G8q);7Ng2elz z5{x1z2b5xudz<5n5(X{q$`FCW3f{YUqyhEc6I*1V)qC?-yD{Ywcc~X|vSa%qQ-x=9 zM9RXI%aoiO*}DLZrLzG!-eSUt?)WDBECvwSwN70%0Sw_HPtT>`!Ym6N9$-?aUh4j| z`yL}xSzs|AAtDsSxoPpv;_P#9A_v+faq>=5r~xj4EsVoifsxMf)h`I&CovhUKAb_z z0z`%tvY^Gvdovy@>TGuFwM6?R=j)~OoDaV`+pS!r)OMYBM_p!5BH|t0Umf7L`uM%_ zJ3rWxxMU-gSfo&a-H7^{NvT^tAgzn`x+2OCI%#tlkhX^A08uAroH2??NR9cu{8p~H zII;Nh`Qg5Gu#}fTL@##SY~9z;nT@4HU~7)~uT&CSR1;Axm|Lxi-ZmcG7xxCXZq*h_ zSQ7#O1;R}e7~=hDbLoW8*+u>EO2T!5%hD)Tgc0mg@Q0xKQsT`Ts;i!{g#c!~N@w-N zWA0Gqi!!W_mGAm`n=Hf$MUWe!*3cys+~GCQH#6%cXbZq?!(N#f0^(L1t-M1Py4~R- zGQ&a&@y(}Gv0!7!kVfWT$A52@-Mm)VvBoq&<>b7fkNsbp&dWpUYZrT$MYTZN zRmY<`e~Ycl*9Qc=6Wd*S8n{x7eU`+X2!Oo#PRZ239#JnCXCN%fC`yR_5z(eYyDj!$ zkat%R_DE?Dz|ah+nE^vnG38QGE(nt5H6O9ozj^jv5Ad2Rx#M6y`_hD4USr6nd@lgn zHj|PNTUhr%(Wr2N)Mt)1g3p!5_HHeKCBqU}LR!sSaO(AC z;-zjHKjnJSTRcwfN9XHVj@oa#4g&$@-%ix9C)gl89m#fu=c!D~K_^ovbPH4so)f-OMA`i@cugQYt} zcGq&9G&fSSjy=B?&NJ5sKTpIDcjiO4h%UHQr}m2YH)Xq?@%|WA4b*!Yl5mU7xcVGq z$E@h7fC+}`)|`HSC1XdUs?Af$~X zA<`3*jpYObt3)r4sl^%6&o!02&zyuQgN1n;+L$wf0H4|7o)_=@8nexrH8J%56W{)@ z!}+J1*c7I+tAiIkzxdXnvrn=^ z??GS_n}~;rt4_&MzX_v$zW!136ekwO7-2=ZD=LdQIuOLJ)%!s@)E-OWIcmEK`@lvP z0+1^6kFdnhChjo)fRnKm0{K#5c0jlyalqet2<1g{K=JMe#a4<`h`HhG)VEM*jG#%n zZMpqqSWBQM0~($&8uL%{Yul*S^AHb-nbNsVMRlLaA999J+E}z@II*t;->a^IsC1NodaU9xefQXGflfr6Wss77<`2J&)ZV7E%{N=DWCL*m@ zR{6mxfqZT=AA1Mimy`b((!Y5-?hP@}y2WHP9GkN%2;PpE7mslVBlFerhX~}3aDNR?&=xcGy@H(HUwgkc+ zGn+0vz4IU{qr#?w@aC+kwbObrH(}b{>KTRWR{vJA;b|r|ZwkY{2vp=RT_K&Ip-)>M z60iQvz>L)Kg5+_KpUnLyx%Wv6oE6>}VE8fhzGV*bThjU9ca2N+U?$3Mfil^7K89{S z&*^1Can>^#MBpmveA3CpgZVH&MfN1W-M1QJ2(R6QRBi_TFY~Z1Dvi(TRk;4x4|vl#Y1010*FRIMRrL%D~k&X)l{J1Ht=;PPf^87c6`7lk!&;a z``gg=>pKrlMPPHUbc-m5u_E4%G8ktIk9{v@5)74k!4sjj!QfJoEu*(FD<^hWW`12{ zi+DwnP%3oh(VarmH$u21Ub&{i!UgO7F}cA~Ry)$=lk%=b-_6{ozw|cOr6dgYX0=uV zqgjprY9RB9!RxwhnDNk~cE}#RyBbk{qmr=w-BjB=)6~5Eg+z?Vd|F9{h}shD;TmeN zZ`Jh9gW^>VZtbXkh?*0n*&@i`< zu>1}g6v5(p&d+Lk6}_RU0h^k!1wEOh8AIhiW!cRYRL~2Om|r-%<`UD+&xp=I#rDp; z%~BYqKLJ?jX74r>Sn0En$msE%YkcMc*AhmX<`zZMrKwK`EzlK3vLJESd-w^{=BiyT z;Y5cmQCt#dAvImnM&r!nIn*Lv!A$RhcWVgKdPk%MO>w{Jx)7Ci>Ylt@dh`BYN$cmz zX@$2vgJ>>4&C5Ft2F?beqfFGZ*q50unWqoUjV&IJ$B0C8_ED zZs-lH+MPi42CP`rj>B-Na%vzc}D8 zfmwg7N?>1a2UIS$Ol1cL0wz#Y@~5ZzV>7E{FGf$CTb(=ZW%5!hNR_OqPFXm-FR%4@ z=yz|+s;sh_kLc8J-2Lp5*Y)mmwjJ(f!Y)>_xHS}{|8_G52$jC-jaO>dG`Cb!_d!e7 za>L>+^xrWvhN=*pA6xHJ}kj?7uVj&8bc_a$YS&!dj*A@0YeK^{&UYiVFC~MI~ z$semgh9^!C6S9Cu7x3Bm#p`eLf>YRIk*26SZBFjwLx{1y?c_EX?UPh&UXDn&Yy_=j-2dUpv$p;g;&y_37 zZ2x`vrNPcLGW0zZ8J9Q8Nc%OCDt%g@U0c3Ji~9HGaz1rcEjDAI=R4CRO?`k~Ent?>ql33=wR{{okfALo_c;xe zG?Qp`y7yI%8j1_?T4BkFSP>Sd%+ld0j!SE9_f;QIXQ4|~W7P8DRECMcAQF^_=?=XW zm#I!ulbV?A%gZ-a>9g*&MuFd`%j$j%1U6q}MJJc7p)`ACUi z=-#i+q^h0X(}8jh2T{f^C|}O+(E4dcYAN%A+mVM9P$8z>ip8yy*WO6Xcb8C*`7>yf zq`IQ58^ME$h&Eczu8UB`WtU;~kY^Hhk1M>CL1rw?Jbk$d=?`CDp%^As+3@QwC)mk$ zl~>>_{rPMH=8yHJuCinlj6*==smW=32m?8z@kT|1P8#bcLe5F(?} zmV4Nkhgg#01LSEC14BxF8xiXseY@Wy{3SJvmk5mRo5Wf1t;{4@`uJFF#s`oIBQYLz zcMuOKQbX`A8{92dx!7nrS-Sq_%ZBhVeEi$-_w|f2OBb^WS`+ck0%dYpv}Y$6&`{J7 zZ&Evb`2(*nnCj`tJyDnz-qOzx4g;Z9OhkB)8rgBiIn3ywOZXKh&8Flxr}wV@pPxUI zSt4?H?m$Fo`kNXt1Bnhjj9EmP`_I|Y2ci|sXvCs|NZcPs1p)sLraUA{1hGi=9CvU^ zFQrvGquTt2_>DsJ+v`L7<1*F0>YU`2T~z#UxZ2W@R3A#^hh!!R%!aM()pkliT+gah z7iXe_7~|zdXgfr|I4_12Yl*Ni3UhfYcb2(J-IZyQ9F@B0SgXcybpgzj4$Tf%bz=$s$A z1w*bHcv$lsdUEVsmj(}jLBBg4<6CEud84?qvSJW9rm^JxD4T);nWZYLy^8bQ9u*@a z@>(^hCOEysuK<*zuC-M3$9-;3XyT`Lq~Q)P`BOOc>cTFx3+VA6`2(0h^ktc-jygLqlbYFE~}SAys5Qtfi^CwPmPUHUyNbD2Q4&1tbh- z_HD7OGP)*|h)pzvv`(A^1XFqP_ice8-GyBUD)Z&ZEN$<+=vtJ1X}uVw@a66=!elx2 zn~P#TWz?NFkqhG`hXxo;eBzL9@-sR91Ej&V;Pqz=GJ|MNjG!eQrbFxmB3TR{(P>3bwCaNsbCj zMI){Iwmue1mEHe0v-k5#Cgo@9FaNZv!P6tdW~-Q|2Rv`MZb&D#O{jBxNbZ#$+oV$s z`xbkiUclMjxzhH#4}`v8dI-F_oATw=cSvCneUI%*yw#@LxH}C8hJOm2z=BI;YTi3; zd|SrASM(vUpn>ng;>7L!jn%B+ zn?)N&lfYMp0|JhIo?om}TSN3_gRnjNe@(>c*!#rHAYvY@8i{KTds+@&tPMxM?oN6}!Xd@1h{gPj5&!u!@Y)c>+D zp66F#R!Z5S{EAfL9InobGd>@;cL(3@U5jPadRB`})1O#;Yv9jYKUtkj+3GM-ems^o zmvW*mj(H0E6t1Rq>Slyu=H}w^?Z>g$`!GQ7#)+^OejuK)=00DexHMg5f~7^zay(@&->a^GFiTk5`kR`n z_V<|qAIP6q1iaMfJvZ++{T(GwrL_Zp@synuN%81#>NI|8_wUslE^t4WJ(;2DdP+LP zLJ=D9`wn8Dg#}G};mqW_^vLgqlhm3I*7V%~qnNWB%G^ksxka1B9yeYl-Q+F$5?3XF z@~k^N9|rT@CdeIowe5JH^Gr6nkY5?beTJIJYl^s*FlvryN6RFIp8&+BOqG^e5CJor=P)aiJ*gV7uBK3h`QIOuP`;efa4e z>W9d_H9rB2<8fv79hF*cp`<|x`KQXAHt9^d=|w-hZXfoHppO!f(g9^W!zMoj2eh;_ zQhGKnFDyEp@}}4Bh#J>dxn_seR$5XF5%BE;w8VqXE4A3}`XcN19CX`FL6_6}*!@i2 zpZO-1cdWH|hVC#tA(-J-I7qv%)`lQG=1+>#454QF`%EObK;=7fh;cGpsrpIS621Q z1?&m;v)UV|XCu|Hi&LdZxDoHAvw>hDuM>6*OVXPF|66b))tf2W+1@N=p9IaiIeSfX zB~7i^6@_n^ANXjaapVtv91CYtPS65Y@uK|I6ro?Wf3YG6_1QLZZOq5r-B8}-UyLrc_H&vdc2mLo?qCFz* z8b^CCRINYfP(2~>sVQ((|1TwVAVErc4&C`8J7CCV$eGjdo#l6SodsDYq1BjzJ^+;W zeTGK(EPKo$FVa1Hp5@+PNsT87hIIno0ur9NjQiA+(VLiuF^X5J3;ExYI*ezJ)*Wrh zjlzxi#ePR|25GG6$gz`L67T}x5Dt*=0~}i_E+u%P_zSKK3Z!66X!KBn8g9Y{ycXnE zWi)&3vAk7}GbF0@rF@H1%TE@ktc=dFkJBIzD$Ap(+G1%EyGG<>>v0D?U8g5k4{XkD zk0eZO)&2>zSk_grHe@Ep90?k)#}l0{+a^h^zey>8OSW~kwET4qq{6=_=zp+3_036Y zTx7C)&a?fnAhJt~dz{Kw$Pznj|@@8O8nsUP2!Z*4stTRN1@56A9|b%Hv^lz4dyAy8NaOPQ`Pje zz*ED-_#j~b$A|5zYPR`|9IK*_6h!}3k4zJ$dmniu2bk%(l(_63yOe~Pd8qGroVsNz z=u~21a`WHvf5{&W}CgK^}$b7GP zokzb@P)&Ct_5&E32l*xa8Z(l_?ZI7WY7Ky(B*qC@qkb^m;S^)X*lO73D2xsmACKmO zo9R6*ATsy;IHDake(ZRd8)&@z{<_}e4u9oQSmDP1mr=Q(3Q7*0xH;IomC;Fp``yWO zVr!_VG07T$R24X_qCMm|XV40NSxp^yqhb7UUx!3l!0$l>xJB;8132yy1hN`M-XabqN&sLw`MSvg5@_V>#Avgo~Bc}{cyI9Y-5?+e?9HWuW~!uP2XnCYn!#%_C> zqb`=Gz6XgS=Q?^@KFYggKKp0g(HfO)#wTF#6f2XCuJnYa9VSMWU_s5y*f>Yd{K!8o zQYS_;#_;;%pTSXV`E@>iWjrx5h%FsL-`lB5r`UL0iWnV)R6V# z9Fi?QiZ_%Xh z?Z&w&gg%nog0jro6h4X}x{g{=xaf8kIx+41?$>v$#H`4xcK7)jn&;&XT~C2GV2Dux zp&*F1=z;^Ei*ze?y<04(XP>-zTKmv1y_{-uh2>?58aZZo?7o7CmY5QwqQHikQqYMO z4yMh2GU#2|FB1?!<*n6$88REVLwoS66K^*J>r{>sYm$m$Z^(vDDwc{B2Wt*<$nWoG zT}cEN@zMDivw;8Bwl*c~qT8iR>G^f;h0OHNq3Een#?HO(DUJnt_8ou!TAI%M z_TDltya-nh`Rq&RUOZJVwnft`h~Wf|Mzwj)lm*h9ASGnSi%<|NmToy>ob#Y*v|Sko zvR_QnB&a|p{WT8U87@n&c!u7q`9^Hnui*+5<3{9tX`~Bg--w^6_2zC$tKo;?frR=& z>E!DS`O(ViIal!Gv6a$i)dghEk8QAOipl3-QYw!eyA- zE$Bq2!|ysQqoYznUCV0#E4O5dz%zzEqM4KPlM3$9B4G;4A$a|ph$U$HXVpFI@71f5 z0={7c3>x-Rz}@q#drG6!ndL?FMo0$I2!YTds%7vH#3BYrIdH6r9!cx^pA%T0gMTP~ zizIjL+;ktnv0yR;ONE7!O^%wgO*Kv7S@Kl#HZ0r*-z!0|tIjdZT(V%3TFf#mUso4tnrP`P3{m-3&5%i)^;`G?V&o+m7>W@wz@TCq24 z3Xq?pWjxoV>0~3xWhqqRq;(#p)At2qZHT99cq7!rPsuF-24>vJ$=K4C*Sw_RCsZP* z&WxqFo`vs=;yDoJSG8(aKx4qG((q3$ipcb@eaBX$EGj-@|luJa5I70 z)d1H;KeNgw&_o=c%aZu=O`QEjZVlyA-6LG%J@tLH{`G(7!B6=l{oAavcKJs4DlG^| z>#a&TEcprGET1EOyAK30yVF|`0D+GHo|C~mkYgrj#-sSGd+Iv4G4iehSzd@5Ubi;u zMifo+T`_DB&G6tQ@zxeS0n5F-GSPQ-E|9j;c<^0SVLZ_dez3E|b?d$o!!yc-Qt(e% zFGCZ}p^chb{vm$-K&-mB0H7IlCjg}AjS#xN?2V9?&bn+Uh-9OEo*s$7oYtl#2$UMa`UIh&&%8IrUUmqHt#1osC8A9(?grwn)q`7NuH^U zorcLdnQQ9EI++`30#^2H)2hvadkXh`=ocav8vc(n#!KP{3}WS^(N73haaF98*m4e# zzeRa|8RQ;i+({$gkEs=F`7oP%PVJbpF8$K!tie#3wvO@@Pq>=zshbVhVu_s`rc5ws zqRMo5-lkCeCmTkA%c|iM2w$=*zk6&Vok#a^4yjJfh6nMI<;a2c&_5yOct}5lrPX~d zrNaVFaG=x>)KM%2x6+HuLi?9#agWHyaa#M zIa-0mn@JvpUw5lqhcb_6VTDyFQE<4#gv%t(s3>!OW^S(dmsWGU%(58J z@nJL>{bwbu+#^Sz9_l||S~jnn_#yczUWj!1M0x+Ka3hI3Se`7hq#eE`;cB9%)y7~o z7!sTXMw{n~J5}_{94Fi<6Xe>h^7r1Zh$KK#ENRmCvmQ_4D&k}Mgcg2*=!B6s)8NDx z2^pg%<9r;8`94l67E?8Cr+>gaP#(XJr()I5nzMua{oSW6&E(@^=C%f`2yLxvqx6$k zfBWf;iAQw@=)qdInl+kkDBt1T(;M!8&-bP*=tAH!*?v(B=8=u7*N-q6YPc&1nN#ux zONFB#`qhJ(bJDz!x%jxJi3g7qeLtr{fR`Ywuz`8uDY)^_n&V)9_E+h{kRpPuzVERLj!zKauCRBMBpbk>;7&G|-P1j#j7saR)^V9n1SvqK^DWZ~6He7^&tu(}uSX-Fb z*wwc8aO8ixqow7Mra_VUUN}}gIplQ?^3A=bS!MV*@Gv<5nXnVaa%9|hf(>-&v^B5r z{ZcwO$*43xO=w>CYxhg6YHk;e$W)OUKD2??#2bN3NUoCogP=HuI9j<_Sd9q2T*3@D zoumVTal*o6T4tnU(<7u_)IL_$t1L12VUMF+=s<`XJDl7*cOsn@gtdgw3X(+CMf}Ah z*2NU<(dPSqHHnI_ENBKAYA66U|02mp(!l8GSQl{`AjFy-CkUAi>$25sPZe;3ct)v+ z=uo%aCao|6K8>R3|B|6xC3)RY2z6*RWd#Q-em-lM*)0xC(5#ekZx8$PX(#ihRGIWO4;v>b57V0 z1EFYxgUJ3Ie(WY_4u;MLH~}+U{0<^F<{`*XC@o zwpUz&zrV^ZIEfxWAkAk%>X5kf5eDoo6Qqt~9Qtq1eV=6d$b1S^Ny@Z1qWO@yuY=0u z+aiIX!R$5zPHyb_j^*Zr)u*__5@!%djV98nB|&;}=Q6$NcU}>@-Jrn9Rp3 zbQgWUKJd#9)5aWIhm$V#@3{}ySTk+kB9KS72qaMMo;s|!-=+Qzv>9VmfpDNw1#ADH z^?x7)tozFUKu8;TomHq>KEJ}g@sf1E>-46y5U*=aUcz90-m4^9LKBh{O^pH@L-UbN|0R5vCds#N~UlNTKM_oNb zteSSYQiNt}V*e<`DEcCh@5nkG6149j`^~NFE~aHq7I{9Me06@(%#Mu)wz>LGdDbL| z?B(EP9CViS=2nF!+G%!x&Q3TCn)2EIT+e;5%R-|x`trH9zr=j>Yc|uB;37Y8Wn@4v z@K-_^zvuWxniz4haGm?GOIiC4!wMyg6;*OvWRaD^ zw|<8K94jV}{A#d35e7F>lPDDySxv37TxQM=&FQ$$D-Og6agXs^IfOB@CM@>(Ujd|! zD<`$jir0*rCZpD00RZ)&kZT$QH3W)p#P@ImvhQg9(B`lz9tzy^b>!ds3_b+2_t~Iq z`rP6WA1rZJxj0oKGT^9WrXDoFQ6q~cEmy)xDUt|DeZ%lGt?|QHf@!oj?gNdDEMX=u zDDqD!_V{Mk>tfy7h%7qi%VSL_t%fpE zaWAX@FH*{yJ%19=y1vb)+ZkcR+xq=i4wgA+1F{6$@fB7$swbnE|L4p z$<=>fM=FoIf)vUD&%p`#?R$bVTADIo`!BS1Az1(@8!>j{85;c1P4ZGyAD0)RTwU-Ylw;vw_GU~t;i31V%gBI(E9MX{AbFbWuifqo` zev@<*-m>qiTUzEOHO3GbL%uHf2xZa%$}z_2GYbGBFm`enFbMwgvtf8zL*8}{`0v25 zwN&Z+wO{}CGb?sZrmjj^6J7khDELTw`qRx8I&1n2{WI;`3B}nJzOl_# zj%Iw(Hh7N-HIquin0xlxNp!DtP{HRimZao>chrc1C#t}8jIcUXRa8qJ0r&aGFYp4Q z%;QuC?6}V3z!ccAk=K!F%Xm#rV{dOVGBQAcL&?a@PAFIZK7d+A@C;i~G!?@<72;Gx zXYN(ISJe&mL_5Ly*2|P?siO!-!(;Woqid&&MnS@3ge5lbXY?(wxu-zcZ2!WC2S95d zKrA&Hp|6M7hugxugR0=-QgkKs6v^$@K^jz;LAKD7g6W|m~l|S@~Jm} zOQt@}baaV$K+N6}7ibKcXuo^m!v&rOyiYWEg>-8k34VO} zj%>ZnLV8m8#^qah;Qsc zrQb*AWr4+`fsf!4%1KLhSrQPiIo-cqyh=_nVvY4okY12Ej>YVWO(}}iX{L*WP<*+l zVs;VY1Y+=C)k%) z0D5FeEh(QHXjrC^cP5CHK@5b;ASnB?aZD&ELty(#M)zlKAt41PIIlmuyrX&o#;(9ZuRi|Kzu>}%=J6S6DM>vy*4D+~jx zkKQO#3)R0gsoK*peAe=^>`}tjKM9+3$CFR6+Rhp@ckAP$nWICNe~D!rFEZ-GQn1Ub zL@AdGbph-dmV87ABuO^7MRr@LJmtF-lu zGe7xWJ~lr?J_WERv$7Rd-?>y~ z2WTQX(kNJq++9ucp6oAWqB~;h40$O?%>$2U2&jtOdqhd0@{*XcY}Q*>4KF{p)(QxS z+6kHhpetlgirb_%Mv8B=V%OQ=^zx*CTEd2C2lP34<_Fv7gJ|Ft5DNp*KukVg`UO6O zjdO=tH9yP?nA8EAby;7zAfR(NJ1?g~4cxtDyI92~|;cX0dc|P4$)AW$SZmJ1-H4fMk zAAAUBNI{uFrkUWJnb+ihj@aEdQNjuwv1vwA2~kZ$cIkFZ!BCzsvPA$mg@UXn&Y-8y z^j6D3x`&XTl|buL>iD0>0@f+RdokyN0T!$1*Ug!D%WG2#e*cPdlE>nF=i_aMhu>S> zrte0a|I)W_dgUFG_02+sf~0Jt+sT1g!3&23Jf+xD1xod4QmjNtSRQHWC< zo8J*5?V7&|Vlw#9GeqFzr9nA+FkNY}&XQw<{9U>`_fm-RZOfM9H@OZUn^hg*DdYTF zwd?Kpf;m<`{nM!Hw#`_{;(WNw;Q<+r-tpSg1R;uG)1BQR_9I9|Y z5X~`9A2k-AIJUZ#5~Vc8zO1;}{j;Hj+=h--AGvhkv7*vgzepZWav%@$!;RwbUvGKv zu=uevHE2=t$=^VMDg;I1m;}JE9rEKYaqCjYtFIcI{Wuw)o9ZA`{YTH1p+v(h6z&23 z6aYIt&WAopVa$bjs5gzZXE#;2lTfuJXRCDQuwFT1cqKr=DA`;o1DtLWaja|8qn}WB&6k+_BW>F--TUX` z@%1Q>V;r>Vlt3mdQ7Qfe=sajDdNZR)<2C$+!HDN^+k7i-{ijL`)exE1H+e@WfBhgaG3K*B zT0Q#@r*B7;f{z1%C3!Qc7!`nOJn)i*7CZ#WPd1j_Sn_?%(29?Di*yPsfFXR$-^c@o z@G4Q$r|X8%`^+0X>Zq&p<~?itLL7&hlPy*JY}&$Y-?Zvi#=_bj#S@35X1;w<+Qz%T z7#(PJM<;?gWT8An&qz`u(Rp>iOXam57^r;4<2HK$(?SG8PxVzk7jiKw->%Q!wHcMy zqUE6cdzXgZNL6<-|Kv7vTEiQ6ZpUu_GWhrg|)`v#3nd2hJ) zvDfM*^B(^>fCpGMI>;rJ7n&dYZM`5XNf+@WlqZ7W8%c}po0r5S%x zWQ>4L0()YF%c=@9ii+?8@lU*Nz0}k0#zVmNjVYyHXNvA=ld@;lJG-|ZZyWZw>B6_D z8s7AZOdggnzH8=Sg$9Q6MX1r80$jw*O|p|?nwf*S8m78P-=~Eqc-sBfmFcQqGLl{f zgS4xJaS}xd^q`0$A+uX`q{^}l(VL09i17*DKHa}%);)k(lX4jq1Ia=J@y-loQpp(` zm_;>QX(y32T05mkQEimkQa1EgDq!>oD@@*#o>%$qbBL~zH|5_@sD1)aWf7;(Zf^tz zR9Q0(j-cIc3dVR!;(|a05?OLrgJ@=q=>17DWNyqZ5=TrXLDO4>u0>TAeb1+*zM*Va zaL_C=8=Q?83Wq=3;D-&#<1gP1{cAOfO?uig_tD9G=G8ge z&dAFxGj?y*H&e=H`vsX=#V$|r-RG9N;>XRq7R0$VcLkr#Dj~am#E`rnNDy}}Y@{doy~1& z>dh2eW*l)4=A}*IijV z{YD!iV-BS(nn6yVN?DTP0>tS-&Q(0A67?{U zS-Y);hYQ!eYH}73`A_7ly8~`0oH)4Z=s~AX3gGC;+YUzSYm-ZB$3ZE+(+2mCmfxrN zrZ*cF#CY1Gd8l7))E%9;a+l!^&;)jAlcu84tUrM_d%EPS`_sD`u=d}OQ|yC~N@xHLmX=q^cOSuZ=c zsO^;M`MbqkbdOiw_TP`yXR~j%WgBNzXNCX#IcLi#>EAOo58L{hZ#LSg?`%yZhHqpv z^*UR*oRD-^3;>UefGe;FL+XCdBl2W5S!tyxS-IqYzfRCZKNyF2MvTi~h~C1SX=L`1 z2e{$|jn;+PLi_kXg_e)kGiOc4v@wyU_E}NNuTh(*cdf(TaJJ-L#V0(cG+I{8eEfa0 zMNw&MDSJW3+j|Rdgh!t3Qhtn|y->Keq~#ut3K75Sh^aev)T4>G4+TSGj8@*bzgehk zmRYFg*1rAa>kn?q2xaAa3|;EBZ)JAIp;dNFrK9H`@84K6NQlH0V4a8XjRrYKv72#<|AwX6JyUBsV{d#SY&b69v`r6UD$2gXn zblb8UW$a|fT-lR?)HWQ)G&sQ$oA@1(7jeHB#P~JXe_52ouiDNmv6Vc|nVS1R)R^># zJT>yUjo|AjPO8lm$0Iojy$&Az3(Q*F)ayQao>LKD5f;Luha2&Z-fqotVhp_~`-2D)d z)7Aa;9M<575H=uDj`Vc7o0?~C6Fvtcki`~mUxJ(;1p79S8o7#$J((5Y*IdkBat15s zHY3;Ah5RJqG415_m~@spK6i|NG(lBv@E0xv7Ri{?Tp<$uYRsw1g5z|2^U+o}J({%v zj=cXTbK5>rhZKy9+Aw`LEu_D^xO`-Qc0<>KYSn;{?xf#Lsqw44j_0kp@kzOn6@mEI z>H)Y#jhpMU?kBmK*-lt17Tfmrv|HVCyjWHOHn8dl-4I;EDA3fRC_h%dd=N==^2!9~ zqBqZN$&GrdOWHA=P^aW`1-{J6Al+As5{AXvNIcf4%MdVlc`03a^3Rx7Wogtx1s$7z zWM5_Swr5#)^Jh&N(pgyO_H>7;wROiSGh*+mJ4exyEL~c5plP>{F`AglrU0Hh;E@YQ z3{vX+X4Kqs6Yivdf-nPRxT4{iiHcab`j9CeOD~RaX3N$0Ci^EYjv%wELU=KLhX@%| z%w--t(kC+sEcx}gauz;(%n{?;BXYh^Ee4&O@R)wODos?}AauNhR}Sj`{fu$oa(#Jz z{As471o1gzF0v~F!nBZ7e%@FhX2g1+Y`_{TW@;uLNX%LwoEFL2dkfAe1Yij^qHQ_5 zE&~?T{g~e~w~HgTsOU)RbQ}g^mUlma#>gJVA4K3ea{OXaO-VP%jr67Cu}_9MS88Ln zLghe|mcu{5CGzTChV)S{s?v$%*Hg4HA5tuy;2sBwAjr(Y!@$2s@f%dM{}pWiI$i5@ zo~v-3bRBq|@XaBk)nSdP`g%pWY`y*+Ewu&hyu$#(2HJ>AR09JV_FI(ZOWJRu2?GdN z%Nv&cA=)kK2`puwdj!h(?ckDFh@4+5!pBruKh!z(k4KLZay4=qL1|SSlvY<*61VG* zS5FoSobL&}`3urDk9n2%rfSRQCE-b}5^}!q?d11zcvq?C=2RS7Enetmjg2!m;S|45{K5)O4g->@jw_1pqwKF z!l0zA6X=ZPPbrcTyAq;#js6qYK3)XVM|TvL6$SpYYM!C2sdc8*F6KKkydXY{qIJAR zmp&w{U&R(90eTSGIJRY$ zd_-$OukPt@w6G3!Rs(M2#latiZqFhSW?qQz0I<XM}Ub$y;vu?uhz_6jRR6 z76gZ#-LlteShIcA-toGEil@lwfgy@{+qv3)qcvcIh2Wf19cES+El?)7izMB|V;FKy zB}9%X7y|KFTDkbsUlQBCqK8oN_%fy+Qsigoq6IPcQ5i!StN2w$JKRZMjk1NMdzY0? z9rr3!dt6#aKHR+1yw;ta>f1v<&X6b}R^vZ6=|tXK<&{=VAbW%LzQ_5gkSXr}{Np|# zZ^aaW+gh}68Z&Y`fp^zRkTyz_y{#Bx+4154lLe??_d)qfU~{D+yKE9OX<`0-=4D^_ z*OjDugfeiC$KH)MkjnB^(`L}A(X7H!3lQZz;+-MNL_Y@q?Jy88ws%o0v}Fr#723i*YJKH5Acgds2$;lMZiX@MJZP4NTh>eQL0Vgj6gP>bG*qLDF zgqch{qZf2kg<9NBpOl9(M_p_7N|EF2*st;rcXSb8Gvwb&fOznmuGM?o-q8+wBF2&% z7Z%Y`4pE~u5j*#c%NBl%PvPDXo-IA0=mT4EsI!Zj_x4~?7@1$C5pGiB68net=YWq1^@-hMN9<%N@OS=pd5Ar#Hmx4YbjPPmGZsX*C%>_Z=`*P)_PIHYRnCkgrA?fnE=H2 zfV?^Hrz9-V#OC)~A9#M?308-H@bR4&KRTM7(&>=%9s;IS>C4^UwA1(kdpr(aq`#(o zDehKAEWjzur3P99GSWi}!Hqec=H?2Yr?p$Y`BS!&c71sIEvvI;_-q~B(Vc_$LN_Jd z^xIMY{~F9GRrzZT&F*?kYMW`B>Xb;9BK|jJU+7N7b;nT3-l3<(;C9N@Nkh9`JHVh| z@#kqVHgBJVHufmCMwGrByYr=pkg{gKhCoJA+fNRGE^cvtg6mx3Fo@Ye)C)|0kvn*m zF_Iw*#MJv<6ZS1`4VJ@y>)uMi7{jB;q@ea0PPgTtn$QN&RKB(1oyWi2HM;#`if5V6 zw6gR6X!^>4sJicKx}_wg8M<@m9=bcEySq!erMpWhr5mIhK~g|Ky1N_S%k%rcALq-Q zd+yz5*IH{I)_ISFhP@rG^+QrU;aOtqmt&+6(3;ayES>}n@e>`OjPPK!#rQD+T;0U~ z>$iwrCHG^ZFbKqlE!#7nVpsG&n>Q?%fCPRWV25o@NfrP{&DmQnV905oQ@9SQC@|13 z{_$s_f9aGJfYU&*4*{Gez+CNwyXE0g)`?HVD(6hM*%&`#9^rBp-me7AdFZFjlU~uy z$9lN&ccmio?mEjMf9BmsrdVNp&35}H%LezNyS#((alwUxXcmv2Jq{yOJw!dyYg)dA#f2|38{<`i&4o)hC70!OCWG1b-+oyN3Iup zkNm@1@1Q{aFmhHB(0SV4%$_(j>y^ev9y?_gLeIqv;g8Bh=|t!+eCCpefmiuNNMerN zXu&WSgV4q+AXX=^C8`2+@Otd&1fjo&Yz!YpGrCrN;G<)s#~}sIN@f@eM)FZ&`h;Ud zhEFB_-lgsdt%p;eZAzu%da|PBxTcn-rc>{>=(zQ;crOUucNI9aqrx;8*ye*&n;nAb zv^zFPQt^;fgj z#7f`z2s6r+AKXG!*{@0gjzr}~XTl7taSoOtQi0)C)f+gXxIjT1b_V6{lWaWDFWMN8 zPZ$)U1k+RyTqakT#pub0grmH7>8^h&MAk~=sx11=yu7C1tmEeFLuxXPD@O8wlB{?e z;^=&NxnGXM>t6PktLHj8sx^H-a zpHe}sgemc@Os9CJx8O79Xh_%sFug1rfJm$$dW>azkuv0aHaUC8* zsOIRz9KfY-_No^dasedS0fD?B0B2jF0dwUCwYEhWZcUz9AVA0^-97*|5gbMe*o0-0 z)Af!5IL7TM@{DGVM$E~f3MV+xF5e>{Yoh7Gt#{lB)%7XK$4sq zlflZ2JKnkh>P#t0usn}c$f^yBl++=@!+8#V?H1ZkAcq-|!EZwBAY_RX{PO2L*Ia&( zPX83Y6EPpVT4F^!kW?h$*aBZ-QbxQ9anz#>)$m&tC86k+csE^v)=V9I6fARk_WCL% zKOpqMeBu=Vu$L&DNhP3G41Y4CLnP-7fFuSyHxw5tF);#w6P`*-x<0n28 z>G)N0Q+H_b&Yk;Bt)*R4;<9HVEOT{C4CMt3GTz$v2nFNYI!D0#*pigEe?0(XjFf7v zrLSM+J)mO16l8;f=RTNKMqjPp_uQi0`+fk#i8GRoz;`$H858Cf>+eL4nuwN>I%K`P zntIRf)IL2c)&=AiC1pYjA}xAmOgZc;FFr+T!sbVzw1-bT9m?c9^6APqI%Gb7#>dILq7pQ|BHqrZypdNoQ^I z%b4b8EuR%=H0k|GfM`}3)`gy2wX|)?aa+7L_s_ZcHQ&in*+LmI4*MXA`X#UsF)$Wr zJFp#_Edb^~fbHIlEZT-3a0ENXeXdL9TnUFE+CIYlCiPOLUkH2GMniRK)F-rBuvKPa z5;elzy8PL^HUtx3L5Bfa;0`Sjnpc{6rtO&U*x~QR!X5g7Mn5xbY`kj9f@||n32l*2 zR0+ljPXB456Q)8O-zmsajY!E-U4xCv>^YQq=+QdBprOu`dtkLMO@WPm;G4ugyzY zG^yfi9WaL(!Z1jwH}F@G74rFicj0Qbg95RO6Mp;%d$>h4MJLZgZkX|;QI z-Tr^9%~vJb5dbOcHe?B3doz&8YX6a3I}6-`M3!WLV|E-Oh`B3R!)J z|2J;kqEAAkcO#VFF-yI!H7^;QjMH0;wzHMxdiZ6setHX@*!BQn6j zcc8{38Vk3_?$XI?c5){Beg-y_-P$Mjzup29gcI*set=VoDK4<&4We(16vrH2Py z7YqCoZT$~fq6itEeP9QWrTxVz6LGz~UVOEG7J;PvYHt(@fQ9QpK(&yh>18kJ8KK9G z`_KCu7|l5eSQcVNhWwTpU>(uTeHl?gl40w^|0@IOx;7IDdRz_*S^~)1-T(xlHI=|>|c9J3RVtcYrqt+-wZTR)7tN{_K&t2fP;IjdL56v z>^BV8MH};%9SXjKCn2~j`*ED$2YFaXnVTL!dBm~jWv2LHvMyO&K#49RhEfLDSs8iJ zEMR9Un5U5jE44pwfBO{fT%riC*;y2S;K*8(mI3ynP>QM6r$sS{0nv@b^FCNHkO?m9 zlX1sV1JdY_0d*956A2mQXrWL#Z2cQESg@n9n_>C8d9%$mrH0}W$_&Z4) z$n;!JmrFn$$5h`^UJYIy8SVM>k?EVkh{6BQVEnpup!0CE;`&A|Nk8DJ76yJa07^aq$Hvk8|w+)H;J~IRV$*zEG!BsZ$FBvZsu(qLA*?LNW3BWGgX$W6+e2D zvmqA2IbJ{w0mpvS%Dc??Mc>*fEaVgUVI&+aOn#}_aG2@3|LAU>{DA7#9Rl>~h9hdR zvE-5dsJ=ws#$$!o0tgL2cGD4a&8o@sAjvD6zkG1(GQN9oyG^L1W9~4jEI=}<*VO9# zqy$t(AHDOxgY9mARdN1`-GWfbqH-hZsc<*&ZG4|`>r=G7t$ULxas#DbVb$Iv3^$Iph1E59&n0{eu@^guLl%_6X8A%DI(vU!4;3cL{A~0y&l-GS( zlpheXW%VK%mQw@uEm5P9Hu3j)Do<*4qok0r+N4r6^i^JhNwJTyUV8lYKBYcE|>=cgx&b~cU#nyVEk*!z3O2Pgi=s3uX{;J=*8Rc z1Zh7O4>HQ8yV&ckCf1b;-l?$)cD7(t5r9-d`ozn+7*e|dFs+CZ3gJUHurxjz3wq`P zG9%31tpg?kAfxrRmtn=K=upA4NOv6Uqtb^SGLI(ps zlvsdLx%xj4@LC{m4yb|sG)cIbGNR_Rr|eelh#682 zH_}}vGJnRp>=^_5J^RBecC9;v+dR20VF!SDM`flDsYCRB;Fzb9Vh9pe8qp9Iy)rZZ zPy2xZXg_pW00$+ySgTKY2wbzfCH{)163j*pYXTLL*yjpF2r(J!Hu5(9V7A8}@By&j zQ%Kgl2R43T0w7sHfIA*lIc&EhT{2MX@r4-+ZZ>E9avsM!-)J=hWxgo};FQZ+f!Gsj z+;1Hn6%PNSm85DIy`89(?M*0$g#7^!$|+$&#<$U$jBQ6kjaYyR^4${wK!o=I$(Xc4 z3OCf)*c1d=u@9xPhTA|YAA>0XAvndpX{)hUKYYk4S_Uu)4~ZG8uBdRK@j03_nm+8U z9uEl<2g+Uoq`!h?3FoLKM;pI?G9HI5%p3ye2avkH3H*plYxO9nZ0UJNgbw_=wu7U^ zR5brjWp3I8h>zhzSHGn@64=WyO(SPp+&h-pQ!R-B%)w}}m}&;#gCihQ1ER7Gv4MWG zsDFl?Tl&l~BH{+OPdkTvd3&F%Fpf)Jh0<9_b$q=(eex7)qvmS>W)oGBDd3z~;e|)f z3X=lTtwDORlJxQ)smZ;UH)ktS<^4{*nT*QN%}naWGIr4aR&RYCblAcA~~f6B4r86@N{dX z4K+rW54izWfKocAc@sf#a&>%gP14Bq~!=iGg--RWXtA(&B^+E9U;BKQ517=|Q07x5v{K*CL%7N1k zXVR~~F#!0rtxMWJAT?lm$y?-}z@^HV9zVOeZ9I1>Y*LNPwcjh?dRUOw1kCukL`9Rg zyb|X*<#7jh@l$x{EAr3o|NZB)Kwc&ApW8+fni~T%!8l^;i-{I0uM~imqK;73bdRj4 z5@3?FR9)r*H~8UA<_D<~Hw#f8z2#u`xBw4-9q8X5al1_!$-1xBdf%=d(+% zEAEe-?UQ>Md-i$4-9I_^F#t`*#oQ#_<2qwHP)nMVRR9e_>|}9^jS~idHKFH@z`u5N z${@e+-~24nd?gDpH33I5B1hCRr=bnR>V#h!0VqJWM@|oL0;5S1!yHjP*_}KK@HpUy zNA1%r+LO|RlgtX$CssAw7L>7v-DPR{XW@b1VFcSY(CbSksBX3%Jy~Q!P(7 z&Zx&t0b)>2oPcjD4$ucQbttMR_z^9he#kI4W;7fLRsd1saApZA|3e6-hpGvXG{8)& zgZ(z%@kFHfqPH{q67!RqDa`ecqGCY+UIeD(O6Gq9N!4zk&`%p#rqDb?uwwwBO8@(f zo51pvos5Y)_p~|(mq|aNfD}hdWhV10_ls6d5s^hf`Gu_4DOXpIVLg$0VrzQMguj8< zkCZS4W8)O>GXhfIlmqg9`~NqQbOujFyj}sD3Y0{Zl+j4MAB;vo0vGgukT;z&?KpAE zJ{AkuoKT60$(u4Nd3|q#QgZlBJM=lM9xb`*-ah%MPUe1&_TJgGFs;GLz)n3B=-3*Q z&BK4h1f%7D-9be>$(SMvFPgFlgBj#_pHMghv-N*sGg4)%ZotL&l~^ybhRj(YVKn-h48V4cu?d$SAgFfAY&*!l;$2{1nu=i3~d z&4vMJTET-L`eMNCb8-Gc{q)tN%Lm`Xt|qc|LfeUB(Xv>Deq3AtBn=Lr0_u@5(d{8G zV{-G>0kybfomC=e?F7ukW^DQW8&pAD%fi?Vph?Vro*EHrO~4YOqZx(5zJ?V8sWJMg zK!Zb%_V%7*!Xi-9k7DMdyl)ORUqK!ElfU`zfYzWImtRMK68@9h-@`w&J5M%)va6zh zV8()fPoHYaUDQ!Nr+*>f5L=S=0nU0M#JvQ)5H28tjc_m@|1tPL0#(HrxoCJZy<#eh zWLq3lCV$ccI3eQo8|_G@pMxV!u>V04A^I8UzedrEQ33t}1=jS==G{SWUJmKE5}TW` z9n-!pE4Q1biA8z-C%wz*kl|phsrX>QOS5}jU}V(AqI4Lru6JYPUrWL#Mokg#Kv4_c zzb9K5Ya-)GGR2}V=Tj4UKkNBmxIR+uYk&lCX-Z?^-UJVqsn~JWGHf9l?no~(FXtKg zAc|p|3kcH+GLZXGQH8?++6Rebl@KvkO}`P~l7^g)Rja3iJ^y^CK!xE4-|q>>knV<@ zZegWN;V-cNR9Z%S<=@uW~>E zhV%%@W}qqw$vVYuHs+-L!LY14;MH6^V7wU#_`z}*ySk$ERr?n(VBSyCgO=HEFjz~q ziDEmy`X1@@%}`-J<%-Sye8mn^`bjnbsiZ7NDpcm8zX6#^}{UM@lRVnFpkig@+;r-)%k|Ro20x|ZcD={z3I`P zGXW)Tqz9bwBoZr5PC^S&xFOBBozfKCVw(lOpOe2B7zPiBNXA9 zG^}Jr7#U7ODd-;hHIyzCP$w(;RhJY#jL(-DJ*Bu6N^16(z};m7u>)ZfQ?dH|n&kxPxlvD3pL5Ye-sm)ZNwHat z!41CKUl$$F8*>eN>4dsJXU$wGTHdmo*Am&8eHCit;e>WWu%apKZ)9)ypRR;c*=iE- zH)fXoxmW|Qq1Rhft^!Pabe!~mega_BPbw~}MEyYjua3jIE&^jM%iTX1<$}8z2m2}y zm&{Wfo9)1p^?hS3vEhuBEb|l3$rIq?=Z)hN*X9D}p-I+LC*e*jua>>Dk23sIlvU33 zxV)yBr2sNJBb@v;n2KIZgbL-Z9InATwEm+nW3212M-==AUcV$C+b$LFH0#ed z>|una&)_M`mSV`ZH4988v_-asw57MDv?YrLs%W7wUQi~fq<7%V&s)ISB|-H{i<XIM^kYp_z{dB?u{wp9;_%9S<)lERK4f$i z0DhWtrzO3UZm%l5jxZK<w(I4TU-?z%#EC&6-@duPkC%74*ax7CNvHEDf)ORCczZ@h zdkH)&sdTNr?iznmlaa+sDB_dx{KCg86&^}shKBf}!5c_?9OYdW! zde4Ihig668=`MJ=rJK$AH*~%|M11WV#5;ZH0})ajQfyWPV@i~Qdq$842<9!QDw->T z%iW9W4~G#b=}U@&ffa&zrCi=tzvNt#P0al20fyt2#MuGzeiV_#qK{xjY z?cdI875#Ne28&+a`?`HRtqhA#izt8WzPd~yJY&5ZKe@4OQ(_Trx%vJp@P`7+nFujA z>do=CML_tK^ySBw{b zl9coXr+!T0#;LI;j$#B_X{9!fZUneSrK~TY+n~BqaMR+-$TG!8_tX;?4 zk}`!-HK=I=8=834t-?`){(&f58*^!Y5Ga*m~J_`LuhHbL(X}BEMU5cAB8KS1nsc76(V40>d{o^BsBodr&F35~M5$@{m4niIf5`(~8piwHzdhR| zmgKy)q$(+i8dKk5_wKnH1H)|J7O+HY(4lQmjV-Cp82l{zA-+7G>;CMMhPMi@YU^uZ%_`?&2b4UEG3ih+YXTzDCGNP7?ufF(=68s zn9Vv4qx%!qO_URZpe++oLC7_mUTu`J zKIR{jJpC}7l8u`??tq75g-hViFg1x|ivpOa{>0;{&R#{9+prgi+b;U>F1Z1Yk%5O<=Sz7BBFyKL93U@Oc#zP zo&wX|JZfnjl@CwAM|cPpVs7!u3E=4Vb@5ZLUdRzn#ty+ts(05)(>@u8t42zbbATky zH5?J6BPHS}P*K@H=3@@awKOz5#L~68H`KtXrF*z+e;s)|RGfc&s-O%X7df1e|IY8H zl1akOet$~!hjGc=V|WCEg7F*&qD3B!oRdM?*KTz5d~(p?#6nD-XDvjUPim`WT|c6* zY#z!5If04GCHKfNT&eE*mOi@1^GV-uut;(V_55)!EdW5Kvk{ODPewE4~=ZROmKh zHwdbKV=ggXYowDaR@22|yFTWR+=6CvC+cQ@I@)n;Y11Rg_he1!01nu)({G`LUp-rF zf}Rj2hDwB@*QR{@iUqR~X`_vF)@9mz!imDYtSA{Pd0Do92INmgd^K?m8*4sgEWs_5dEs6nLyCSs4Sks(h=BxwEK1Vu=YN0s>ihgErk>upVt@A2 zSBYi(SJBh3SiA#od;e}^50*Dd2uP*hTTudoXtkQmPdE3wwjU>S{Euyj{IPQysDV=c z;A4LKD2-XvU%-4u0nY{k(fe);eoL&-(#YTFpW-#ogHo<$}uwN4)uCyK)v5$Cu-!qLSa=;rgV z`A&f2W4!_&6yLO*fcX)gI8LcTyF)!RA!Ru50z`oq044i7ZuI6`d+qOb-*dWX+5~gz z%#|78f+w%M{tGDa5TCHHxN=8T5|7xJZ<=gX%C86n@p%2ho$Y5mF>5&pe@i`F^L){UY z7Cx~|g!RpT%)gtX5e4e1#MgbPmd4ZcH^l@uKZmK?NE#VkaUSa6_2PRL4uXnq6^tkapFMLW)cnAmum zUt!H)vxMBsO`Sb${#@#`z(*XN^Vu2!izxVo4eWW%&0p^=e!;a9*hcLSJ+zd0btk$2 zCR(KoqOga{4_QPS;M-c<_xx*7k~O?qt=~VKs?OXRSsX%{;T~i@YYyUodF`cKo zelQ&4W!zD#pNyNH@M~uPsgho`gOb$jKDn}3?)Abxob$}dGcqk1sa7SW8M=~EN<;!aK4b-_be^h@dxpu_TeX7U?~*4H^7<9jQF6wjf=aD`{h|hK z%dn%@k|B)76G#u^ifGt@m0xCfUvoq`vR4p%P(n((S7@M;9ruJ1nbfj6z$x#UTb-!3 zbD0cR!Apr~s>@IyTB>0B2r7yu8;S~b8t-f&=INKm-VxN~e1kn_Ca7c(kZJ}JPzlHp zk?7*|Qp;cU$`R3ywjaC#!#aIE@9gf6bs_y=9r*}~*E zyw8ebw!L_Sj583t5*=q3c1|r1;Hc=ku?`e|>pJ^+CY6>(pwZl&@JC8O2f?WWmaS@6 zBA^GX2;1AVOZgdoMC;l!b=M3hy8p*=X57~{vHTFWgPJyIw`mEvmVYs+h(5(+w6uEe zhy>ZYae+)rTuZrVSbu@N(XM{YOwkA+WRA&N&l)*0tsVf$R$41qK%8gZ!V0{zYw141 zBF2`vw0p@G1Er2?=Gs)~RtV;(4w#15y45QuWqO-uL>-g%WrxQkci=-VEbWg11*OJQ zbXq$KH%Wx-mbY|16)0k&<&0x6R>RPSiDRn%a8g>$XXUhaQ8aS*DbNhcy~PQRS=vE3+3LBDvq!oV{yV+pcrVi~#CBdTkkPP8T;q82G-aG;@s z=hIH$Uf~Xe@r+yvr=oD&2w0O@!kn*XM0Omho>(!xWMfHTjKN9y%Q!{8S~9mKug}^E zkhMm_2Jxw-!5&9KHptHHU&N#$K(2lxt3l<=M`Keu8Z7p-mFiOeQZ2Gj)eMB4& zFX~##fw+hfYA&5s0@B7(4c}z=qd5sXBz1rv>DNL*s8|vT#FiPOlJ^L*EuS9Y&`s%R z^}H~A9VdJe66+l6bqS060iUWBVk>3Ho|=kYhW$bAtIrsRMc^@)Shm{2l$z7pe_?h! zNgQ~6VHtt}Oam3KIDGmN&g{I3m{i$;@t8${XUaZ4nO`qD!}4Lgqy6J|s4tZ-XGmzc zmfHQI;FHA@GXxxF)eVc;Q#v71=!W9z*8`X9J?QV% z3sZ}|gkeT~RLfDR6p~{!Yk9$50OV)GtZ475!ADi|CzVQi-UAO?DYeRJtgN))hakMZ zlKP^A1PuB5pdEUyX6gC3RZ(#A#z7xs?$!|CdkE_$q9%2hL zz(oNi5^xiJPlne5AL-{Dw?LzqZGX2Lf$A%M=K$E_3-nt`d`el)2JZ8jC6xh&2w}r( zS5q?#9HNUp(%X$5(nOql(_bfF(~xLb9mlI)JR1xRsI87La{L;ye&`1>-5I5P?K5eT zeBPLkZ5a0w5w5VjqCN{>gBDvMGcgphCyj3C0=Z!psqq? z(fGHx58`5Tca%AMv-lw4Zq^8%$IS{W?`)4Le9fOdO_N#YjJ;EVPx)H(=Jsr_{v=CC za2Jot_f!3%thA9Za{=T6Hy+#SH&Y8~MH_()LXb$-K(il(Io4^!*6Eg6$D^Sid6o)M z6FYl!U4thbd|ew>{yN@1arhWGI>{dv^;aR%DjN^~6jq+!;F%Wz#%f?T5HKctx@%vG z3W(pq&|;HXZygwVXM3IFX-2CsuPE5m)SjL}JCXnSi{WIbB#b6#OKpG_N3PXM5E~GN_xn|6JSs9ADQsaf~u8OBp_Ed}noUnS-wa z+~$D%z~4bRyUX}@1w!nT9!I!7CRHea`8wci+0p4x!;Ox4)Un|F)F-S|l#pL^s{-8j z^l#Iuzh^DQXrbz#hm+yP>bNAg*-B9D_l-xgPQ-}!--{%WGc{b4wA%saOMnoiv5vSA zLZRY$FSr4U?Ju=Wx0yIZGxJ0a3sp5C#G)(h!1fj9{lJ3~e37wp==sq5Z9gH$;qpHC zYAreCs^K5Vr;UTA03Fd7pK}XY&zpfiDvp6^UGI`>K5GrV?zO&Pb$-o_Q;hYs)AcQeUoec#{E?h)-u@ONZGw{F zl?r3ajI$mbSSpG+b8bw_0c4O_&fCdLjKV` zlo(AU^M71(!O5+eFuoNHDX~0Ow9?)AOn>lwyidG#s`VXf9Fw<>Ccg8TYq73&hDxpp z=r}tF#~zmKQ=CBTZYZ>9&607@fZmr4Y#7_f{^082t=;97YX|e)T-y~eH%S|VG=B<= z%V`r>hNLyc^Cxvo@=J0t^J*Gh?q>v8>myK9MNMr${ME%AyWl*@zLXaIej^IYO~~oN zlh4bb0JBK;1y#d8GaxJlSD)1!614Ld?i%=f)WW#i-C5nGn@G;siKJj(V>j%NV4Gt1 zhKFejcvh>HhrJ}-hB@e&V!xa6Ozbgsd2~F@UuT~G9a7i}J%CK!CIelMJUjVvma`^ttkp=08CGoLV_qV}McD4_MfusY>JnH6le z_*wBc)@bdbDZE4AN1rb@$fDT<*(Dg7bgzr74Fp}9ItQT6q8xyh zIZd%S)5*^< zTK)x5;)dq?zEC?#DE0%^zjYKjl{9IDPv$OBFfe?0@+f2cpPdBO=8pULS&uYD)3KP< zs(A?~WGGaaV!`sgY-Odxu4|q?i}sNw2A3>_vLWe>l_y*1Z&Ly=aR7bz&W=v&}$FInjC^`%H}9VhR(a zS7QP@$82y8TfQ7gR4D3;g9s3q$Msgt z-*Z9o!i3rI#l+rG0aJo=25uBSl-EjSI=)ZEAy#b~@@;pe1W|uLCEsuTzz>_jNp3Ce zIVAs>zc( z3YJ;Fbv@k7sqcgcgaVM{{u28DRZSgKYCK~dr?UZUs^_*0lVj2Q^sfvPoeWZN#!5n; zTFZb>Ew_q-B$5hzYE_hN)+81Fa+&A_%SKxFz)EWGsDnB9g+}2noBBFJN;UCG2Z!PN3qPfhl4qtz}Y(bSE2DC2PU zT&TOCOJ|en$x;s4EiS^Psdm;L+-?lfOc_D?cF9d5v|DMqAG~ zo5t6c!UgorvLld^rXu%>E0*WX-pe5+Lb9*2WIPO!8WdRxTv8w-F}92_W$xP8Wo9@s z*4PwEpqO|aY4?Fm24RNFvcs&+4DZK8?t>*~+wO?Zvq;6D_5RPZvJmNYO>xhnfH$jZ z#t_h@{z8j!=8!TmfjN!!n5w@*%*bz=x*zq$-V#9vM@{pA&%s_zt~h_M(0n0vV3%MT zD_bIJBB~hl7mMVgl`?_r*Tm>SR(_~!dgqeA&)>bmTflQ|V?m^QBH!oqfU&{7Rbj>r zw9Yn_)QhL|sMVRptm`>6s5!&*u+4+!aV5C#tqE!Kx% zZR8D0Wwoh_^mXX?5LDSi&SjdM912^|HGNwvpO(ddY+909LnrS5^U}g;ZYnyxT*1Mz z2l_DZ<_M{69S$mva2W^g@XY0}4o4u_5vgTtEH-NJ1Y6<@qj92@S)Z zgViwLjw3g|mmqGcauZmt?()gMRQGA`_J6WzepiK2wLJf7cbV{nLYs5r+xACzTSmbD zD87|nkmNdIZ4tkA8c73r9<}eKFfw7hojH`R4l>Aq3?(_@0h>ds#eJ|qEso;gep%*SJWh)0eu zb{Zy9)*81j4JWg%9`0OiXe@8hW5s8rVl@Mce02y32vhtDDf*BW6J>mVR3L_ew2dWh zjPr`(CDo7e_SoU_$~M5jF+t}wF~6K4AnA!??w~iK^rHk@ArWa?~W0pE1(k z;g-~#;fyn*P64)a`S4cdaqx?!pSh#aK6Lje1_tZvR>+QG`$Yb7b_JfApOjM8E}wyM zIneYYD1H(nON@<@xpVVS|4T!gbJDDTyPk;sS}Q*J^U_LJ*~M9@!iV5T?_2XP6q*-q zC_ecEK^m5%SSJW&Q`Le%e=q#E ($`OBXiryWh704Ffx{Lo3D&qs<=Rh0zoFGbK@ z_Im9%FcQ|tLJw2eBV>;ee_)l)(@A@Ld~R<~1l#=YZa=VarUP`o8Z76LrraA>p)vd@gdPj?zUW-1pfi3&G04kuM*?c^x4Fu@UT94t_b zzqj;uKPbbe0N~cTV=;Krv zW%{tTcnj-b3-@G9h<$U-nL19nKd*h2+Hg(bB^>a+Y(EuguI6k_XvxEcRZ3 zHVqe)UynD=EoG&hx3ob&2wxpbuTtZ6K&Z~E?Xl7DbRvVNt&@KIB}HyyCBu91^E&~| zqBD=G&5f;@&b+5zhMiXzze%hy4iQkyD(Ai2AKE(g0`v{2%XS==1Vt1kc?u54I)vDA ztq&TX1iw@jw{PRs{@0@ZBvufD8sRvry~F=t(a`p{x?1F>E|H-}T@w>O?k-(mOGA^S z{n%Ssn<1VE4WSm3z;EHt_urjPMfoP<1$E(b3;6@x;HR|MG*aPxlUwrHle6CW(XTO!6&v0@pS)UD z0)^&;|Fy2JQ14xhZ~uGhem&d1zirm-=sq1|Zjuh<+bHH=$uBQ1GX*-ESDX-pP+>xR zk>E*Nzkdgf&&kByLI6Zs4Zhok@w-{y8;w`1%#!2V(){5n7Dk(ljV~KP>kGs}3g{S^ zEioLAV9sJ&nxk^d`toG>>NK1g&VPE5P**!$-{QYZ(|_t@zZO<~;;q-o3NG{~(|WuY z{dRp}@-A_R%K66K>H#y%&0fme0Fk@iiS?#`XLPXRAwibgFE%yj;JD_2cV3(yiao=J z!CLFLA|7M!ag1FGMo;kCctfbA1)L$AT6HCrBedbaOdTO=}Z*Et5Ylw=2)a{(K zc^&$LKwl-u|K4KC=WSzWMB5vTcf z#<#68{`Cuq{1xRM6%v2~hfz=xT=TVxBFSy0cB~%SWm&$-F45%h=|3&wF5Kx+n6~x5GII5E|s4?J8Y%A>Q?X-`W+al6i zrgDAZpe&d1qORbT8Vre(R-IPf*pwcOFQktBCNV{+IhYB{`M$2)nh%(wQbZf9aXnp1 z&H!xs%Vr_eKRM_|S(X~`vNWs8_g_vi855oh#JQgY1Oi;9B?hDMrlA8A#`6U-zK(u1 zjmm@%U|?ZrS2SAr?$}Ku!rHRzy5_c=jAe=^@m-ENFZ-PfNw-<-6Nh-Q+D9y%H;-BZ zt>Z7nJzhJAUc0E;VD1tdQ`+_rkoUCXc3hN2nkzZHkn~v+V*_cRIN=`7WV%0+6>qgV z-yRR3BKX%U`rF;IMs_$RG+aTd_9$Eke)+{vfEB?Q5~WN%NDeoXQhwey>l-%l#Nd>A zI*$C5=w43ouK<#xQQD!mM6~D378LWV+#0$oQnjwcdX#efedQw8&?mKCjpMIbnj0F8 zBug6CmSZ~VDYxyZ8o~*n6LE3`AuiDVKi$#%K^C#5vEx)V`_h7sQbdq(3Asbd+e*Y%?3m?p70q$g9ho|LgX6PiIe zDWov(M`X#8P&P{=F^rU8HYVmRyH}sP^qewAF>3yH@>iCnG#oq0-jvyze)?uc%yZW? zvv=XawPz_zvM~Mrdue~3+fWk~d@zvK4Pn}#JzDGAyXQRCCaDbJ$W>+S?yfP_yizR6 z>>JoJhJ1F{PX26G$_|7XqL)&36MB#OcrBV(CT}{8d=wEK$I}*Vi@X~yDzcK_aMD`O5E)Y053!SKp81UmK0m)IE%mFHBa;6-O=54MqieeBu| zg(9Ipk$8!hruzIpTYm;1&86cM0McZy3UKo@J64x}BE*l)DXg_8E3OWIdItIaR*k8%o#!Ok&kr1mm z1@WBsl<9xQA}E%)=QW&p2tE@<^zcGO0Qf3_rv{79${!*HbMd`EY0I9P8g`TW`F9e9 zHs_&5%cJB3A$OcO5sqH-zu6pIF#`I@>mrY#Hz26xUks8gY@~#>>~rifBg*xsXxCwi zmgf+|!p0*(d zV%g-o=p8O_En%XmwiX_EiA^~i!iuSF6vt*M;qJA^>ouNfxvI4kkFJt0X(o5{vSZ`7 z9!99M71vUqA$`0o&kkdnXVA>o{7$^SIS<^z?KtIXsg5Z_@JzSw$q^N@{(|p0nRvelgxPa;qqiOF>gm*kV=CSu)hzhK4^xE)!FwGBjcJ zioNx808iiIf`kZ?)4hyOrB0|6XB+1=+a-zHF{YKh)j`(-HVZQyLWa1igy4eNSx`jm z-XX8+no5A3pRPS=V1j{2t0#)MXi=fTH__WZx@#O22Oj{#f(}C%i-=f}&16$#$uVy6 zyYy2npA4>EMH~`(vcV`MWyUE#+$7v3tF^LhBDmBFlEQvG;e|HynR+ zV$WIgD^^GZOx)zF&&4h;U!d9R&7*hV?e67`3kI54TlzoWtJgED;ZY}67UfA_V;Nhu z8UL?T`1NHnno5TXYL}Opr*ej*2}z}eS>^SyPI-MPCRGHrH6@&*AUotrZYEHz@{mQr z&ZK35KrTuBFNf1XVe%k?$u2RhM`>y0RC-IJ2Zy=Qt&AFO2BUk^rsdU~wZHo9?0nPM zegoo)8E1Cc_6iXrnp0&ve`wkj*GRiRd3l;ndAmN}ZC&C2n}?NF1A0HIJA^55OoE9i zA8k|V%vJ9Qcu76< z{?Yl;{_*6{pHb7Kq6iBN>#u9f6g0NJ-cjaR(cYEs0T5-LbOi(phsQ=ef$Jo(^&7`P4qp*Tq$~AAKSN*0ZP4xAw_q`MHnX zsfdA9iusE+M*OjWMIIRk2)l(Az5+zSnic>s+X`0(LgfjmY@lxYy%(@Daa?YoZEU|P zKN?Wnal{<;Mw=l1KeFCBtjZ^98{KrvM!HkF8>AbgQ;=?u?iP^Pba!_n-6)8_M!KXC zq`MpBd+_(2bKY~kf9{KmXJ*!{`<^v3>t1u);EnVH9^(0RJKi%lR>&Kv(wkW{>*=hv zQo>-zy8PH#4*ojdvCzU*?z$4qRf={JAg^6l%-=Czo!n8_NdrY1k`+?N)Kj(?(q=J( zL>fd;=Wy~HzWY#AgUXb6mru7loMp_ObzTDlW|C;<*~HDsunqB6~GSk%OK{Pz_f#d&CNs8 zfT2bDL~20O#b57@FDVY2jgAr{elo}dCA)1G)&^IZ>utYll1s`{y5MPdGg599BXhyT ztIQv71I`(m!TrdYKmo4h(ygs0hjt}0$4l1XqqJGAz1nttFlVBKjqtEbN%~k7Ik9^P zZ!w*gNm8A z>_FkxK}27|cU&z{&^4_d1yak9;*<^cA}z5mB`g;A2J2zF(&u_vJW=_6W+r~7eY4t} zcLfw^nehS^f(G67d@`c2(f)P#YHaFmmsHX-pyx^-m6W_4-$6rke`F_4WZ$(Xc;oS- z`hi^YFwr{+*h8fzF*3#_i_9be_@$RdP{IFSBYY+Bo^IE(M&hA)im zx6-W75i?P0YViDoQo^SJu;n|~x3|hgpqUqAO=xclmL)y&DDhrNND*2O7|gh4A!@`W z+U!b8I zPUa)p*N!Aabi7rOyuDnGuh`bhH;d}6$ak*|q@nd74JdrZRBDIw>*2=n3y%M2e2OCR zc@plcvX0SdP;W;sQnYXnk`Owak!%Mg)!>?IN?Gng{np1by#vQQJ6JXU%S}$ z(zLL8Uk#RcxaDN%bgr4h3NY2h*GK?hZk9`Xm#LeHf{BkKG-oWrj&LS|XN-_5;eE@h z_^t;ayud76Q~l(HKQU%=;Rshe)BJSON<<~IhY5JoHQ-G>xl0=xWxgcFj)e$Q4J>IR zk8wZ#Ge6}2H9zzmXDb^QO|t14^}8qA@vMcZR2#b z@RycJ@JWsjM+gxByM1YVTTmR&)%)DNrogQ32s|j5`7nIX&*v&?|V!c4vZ4J4rPq^m&APX4YNq8A{( zKyEUWsAt2>pJ?#~Y$Y$0tW1XKD}dN{w|-k8$!1SW|uN7VvNXC382N6BmxSeO69 z8g21f6DzPyZ^tj35#u`kvwA_#179(tn!?I=5c3`nXiTkRSy{*NFb2yOWJV5fk}V`w zRZ=Rp?~8WxCDX+Nohe(GDjYvyNcXM;#@g9giVRF0-z2Q}kCt45)c@6WIFmRW+lhHJ zEZe|(*uxk+TM%Yn-5i!J1Zr}NpptQW{Ds>T`K7n>QLI33$&G9R-QZt5Wy$U5n~V>Y z_6_y;h0{Pszpq~Ga>G|lPqg}LS(pTmG`YQO+*Br#}t5Rsi7Flu@wYw|-xk=fJn{@9?+90c!6@>PZjgMB+ zg%Snh*jk?}Q%jY@44~HW>6OC>q4yaAQ%yCvuJbK_>Lj2QU$Pt~8~wYXTLI$f?d<|t z$84bB%psBdC*Wp9<0Zv|9}(zS7+xs7f}ozPs^kdSH`^x54N zlfc&r(~DrBJ62J0Am+Q(_7+g-Da{5-z=`of%!R|;frEp~!+7M`{~W~@fuV+`dj$y9 zjzgi`6VaV*H$t2k@=)%Pc99ygV}^pM?~n5;H#7y);EMc)Iw&{?k$`z^)j9|9ls($F ztFODw8~P=F39!e2&l9!b3eBn~@q{eWX8BSI zz8LISI8IsewID`gFN>vaW?5x9f-U?Fa*2$+v=f_D1q>ou8=qbUFdZ9)vK5pYh<_TH zcQQYn#NC*qmjIZ8_)ez0VCtBo=LN4Y4(j{W;lA!kqut<=7rfr&0{?|l5@xJ8+Q8V} z^=mtM7+6~rViqAih7k4tWh-%bBC)0>RRQrtM{M!B()xq^5^??ywAQa4ZRw|+Sa;Hu?;CiiK?~)OpFleFnXRIW0)Hm zCZ51>ljQ??9`j`}zY7!#b-x>NW{%|lW>^Q{OO_iN?Ec^&iqwDh*RzqQ%>(oq$NyOf z@S=YfLhr2%_ieyfZLE+*=848gvC#}e=IK#|xsm~F5N5GTh*A<_gmDX}L1yk| z0E~?R7z6&PEGhk}FD*l1_9h^y%JhXT01~a829bR@v?zp9zQl+uOO+e?;``kHg2aF5 z0_aFtQVl>CUoGtW_lD&okMr|I=0u9Box->PPyAc3fKP;(#Cg`?3!ob9EAE~clopsm z|NA^E@HcWZOrfPLTY&3mT~=I^mbd})B-nt8C_Hk6@%SD&3sgfduN0Q`!8DS{7UBx9~3=4jt=pVbNuhz~uUb_bV0OodB z*mYt$JKz}DgUF$)If06dX++{WBop>y86|B>wKARWofIqILeWe9`}FaDpFUP4bq|ju z>KZ>_5!?5K^Lt+Zl&bTvc{J7Y$M&jSmx>OMkYObOw;t~52pji>&JZr*1d3PP+<9^9 zA0*qSM`xdM?y?Lp8G;=0{fk)H%2o{z*RO#L^5eYWr6m`mB|6V{uB^+nMn8{g&vnyS zXw(EIzuS0Ozk+DRDx;>@C&l~(&mv`d&J_?c7iJy(B*==W-Cj^Uvs~#Dt)vM5(_g)& zV9B@>N~=7iDIEI~vX=L9{{K3kjQwwe{tByT`rd8Z0&SV4Lkp10I4k(~g9}CBf~wuk zC$4ADPb+^5km9hkC@PC!)zm&ew%4Lkpna2c6P;{>KxCIPVr0QzM3CdejMgG#McG!p zNN|)-(ntG$pUmZrjJcm#Yx|x8ofTwP=ep3g_5=1#B9b%Iz}{(n+W!8JgZl%|op<|6 z>ciIh>HAaW!0FMrzn>H=P6dO_EoLf!G9t@K#c!5&OGxnwlA) zISHo=hfhBrd+*{NTy#c%0@u2!vNoyNsX9m_7I5hikMnKtCdZ$hP~1>*+b%Dr2yHMK zkPz1BWQSh%dz)Lf_F+C>^*(j*4ZFLiJhpTh81T*8y}It)3~yahdSX>~{q@%8`ItUM z`Wo;%Iz4?B$`oh`O^K&{62>?f1C?FS@Whe#UZoz@Dm+ z*)i!`TGdjg#c#vpYP`aW3}ua!9k)^hX>GL0&6pU#{JErj>Oszm#WKm|<*`!I(pnTw zIe6I>ZcxKZ6jW(WqX3MBFe*`Ab#e43ielKI&vfcfUAGkOs&3DJ?CeGEAF6)tIh+kY z?RPA*Y!6>Oo&RFL?7yErvh|z}AC16M9UfpF=agP`1#*dbC25#@tl4>2jvwpfwTKfK zv-T8SFGM-3)zoHX01LmQ!FYKr&%+OJ)Dx<06bcgI<7$03zDCjVX2<%9&6C{8EE@Ma zVllwZE|}m^d>%d%MaAyk`>c1H!o8<(V>14H^UrNL_p<^k-_26hl%1O6@Jd`1UcT^S zw)GpHcy2475*}}pRo;b1bgVv5QSYN$=fwt{ZcE5PMzXi1s<;gZSGPGtgOJ>(BT+?c zP|i5sS>0}c;98toFSGDjsWoqU*yuNlwocZQ$Hjwfw*gtC2dny%x!eNMA67qwP6(wQH_iX7LK(-z8C03y3r}_`K zJZFHSDRW_z5n;d)R(>$ZkNVeVj$a@3M)4OPl$!O)&XkhYlK|X*1yf=G84~xovT{X3 z!F0&}=H1vt{x7FiAt3*vEv}wE_DlCoF2M#tDlPrnH}JkjtS5=yy1Z=)jhhyC1>aLn zL&zFhop*{nGuY;aRV=QozaV)!(1qVj!||WKB8w|WvUk9=@i4bsFV79#SGYgi+&$cx z-lVTEa1^2S#+;b-Y`m`dLLQx~D$jvxY(6KU3L>WV5XaUPZE;;6R@rwsKW@5rcxE9S zXpFstm`UOnW3qdr4s$oBub4N_?c*2)Tx*8;YE>QXZ(tCo{CY?P1dB4IxPXJ zzA^pI#MIe(`RhnStH8Df0ldq|5xf(67aV3RMr67Q9v$27Z=!Ab#qAk|Rm4a=w0h{_ zoX!G#qclChZortb5^TH)PcR|jr+1uYIi&yemGSw#0idxlHAlc2unZL!N)iTBGeOwT zo8;YWIs2a)J3QJLY6Hg z>|oibI8?|NlwWH5x!63AVw&Xq$xovfwJCLy2J#V12@rlpOoPc&A-I9b*xLck@Rdz^lu zO#=fSRT@ZUY?Od~CC%vPk4N8G>|a$3x>70LViA>)oIBnumdF?u1)w$vZ+<7I0zM3o zn-)q7Yr<4GFYfu{m7oKpL%Ae5AmfPT5Pc?$(wF#y2rfTGi&#?!@rN~1FXQ2(0{@2R z19@VQgZAci)B*ub=aRzB?B|+@)E@DlZ_bmG7(;>cUTug13?S9r;`MKRoZG*#aC!WK zYw^6_`?n(V-G~c=mbRwuK8mdx5nM&ZB8i)hw9JR-1nPW-keSGGjtSD3pjdr}pbG9` ziQJ%wgz+9`-z+_mM35XyE4CO5;Q!?a5-mH=k8ixsPro8*Vf!D4GYw{=5NQGQPzkO9 zvAYzarmrS{y!deDa%bb+{iuFz-zaAhIA$fC+S1AVhcglVhEDncXqN2NAU)iKxtL-9 zG(!5TI4`XyhT|{umFZ(X*Z^65 z(Io7WrTj(Hy?seJI_?kjRmG0(7|UfeZwYWy6Qmn*YZ1=Y$S?-vIr$?3&7lFB@1;{4 zUM*71Nq`mUzxn0kWiG-QuW19gnB2zB$DG{ufSo{G4MJK(>=)HA!4+oDvL+P5@nnWC zduIxy9*@9M-6bSoTT+az?6g1iMi^{yr0H!-%b+Y_%8+T1b$5=Pc`XaUT_AhovDu2g z^F}gC*l0em)1;)6_n+5A_%qzldWK7BOD+I&OGMlpCls>rvCv|IlTjmdp)%nXz`Gwp z$PqO)-B+>XPV%o%Q(XNqDMnP*1M-8#Gh?my+VJ0YYqdxENidx9tzZ^EB`v`ZE_2f;ElWfazMC7L!|ozm+UmQk5an}24e zFeE1w5J&vJ^du$|eqhz8h;Q@Dv$ojmG~zTOx7MR#K!7YR%WUKO6%wmaPkmQkJv3py z*-z+t`q?R5x8frE#J>v^t}H4UG!96Fs4-Xhl9T+8?H5rcTe;sj(gS&h#xO8R4MJr+a5rPNAU%HO(L;D_?4s{1kjxW`8njrGRYfB}@xqZ;uPG^fO&vcoOBjo| zz>4wmvXguBudIF&Wcfzp$hYLrL%?bd| zt18I=68VqLZ^)dm>hGv#XB(fGv4t6!Uumlp4M42`z`3aKQt^_HQPZRu*#)fSD!QxU z@u)A6JRBHt!uU4WEnAe>I~FlZ)B)|Q^76hX_jVFJw93dRoUPfAf0l|`cVer^Fm_|M zn>N>Ap|Aryq5{!$<>}f?>hPqS3RRtq)aINv{IA{G%`iKuQ;}>rNV8Y( zgKp(poG79nqdaqZPJgk9zfups{c{w^l5y07s2g$%IAEZi-J{6)>88%I=`E#eCGO-v zC!TbruY?J(&Rf7ZKS7~GoUIHaeXdTY=Dw*z8OioG)4^V*GKl+Do5#_|3N(sRW-tWA z_|u|Jd#{#r>XqX~qlm|AP+9f~sD#r$O7CQJla28#1@-gbQIC=HJG)|Z!;SE)^)BWM zBdly-5G%C|{rXWbmK2{sGxUpB*BlV(Ct(o42<3<)krn)n9@);@&oIrt2_4|%l>VeJ zJ2%vv%*-V_a;T+s5083=oFB%Gm~3BHDY(>{7d9+6fXtYw*SnO*9~{Q_Pk0eOJf4%q>NWNM#AYYcEkJL4d5WJFr4$ z7m=C=q|3{+xlZ!4#*P4~>U#qfvdl+NweSj{mj~MwBZB5J;k0GpdI|^qT-8GK(Vz(h zM5)~v)dWO93!slph#)UxPG%2}O083Ru@*W$nQ8M4CYp0{0)aCG5zBA$x-#K^JI$;J zN$*wq$EFO9x)*^DuYEM%6|Ez0hdHo@nRk^63J=Lu>S-j<13r0b*MtZ1@=9jeaQUlR zc5m+O`!Ri>IHTb2+p!Am?;H7_^t4vF7ZlMZ;ea7b7w*EmhmZx{9l-3?a!(KJ!c0g> zlnR%T1-f5?m~Hj>=Qu|jg!1npCR0@pOKRg|x${ekQ3XgKWze+D0Zbs0r_X#fk|j1v z&^1>2l)~2KbbaYim@b4HL?B=iR=B>hXM%aHGS&CfkM?~fmwYy31pD)1pcuhI%E%>L z7z~(K9Sd|Aj#WhsGIpl^Hocr3=nbLLpmpRmlEFHN=vJyGfCYvG{@4Tpd0Bg!e9KK& z0tzKJ;^)Twpw)x3_p-w^?%#zj0GagKa+jj)E>y$z`xjz)z%#sV%{M>QO=3qcyWe2- z8xdozQFSgZjBGoxgY>E4{sPiuCwJJtx|>dp6(u+@&C=-#u_vN2pfn4|&rC8sqE4_q zJc4WFUh_t|e^d1XSifkK>*y#AeH3+5YC>IPNwLvE&|L&hmL_puUt&gQ?-Hd&KN~-r zx0YNgS~7n81YyC?FfmHN!gtf5Qep;l1ar{9PsXC>GxI37RtaWZ-nkXr=oUri`b*cm zKTY8u;pjjXML@5@jj^^hhu7kl7Qs=|()}+OrY!gi)aGd*0KkNPrLv%iH>IfJ&t-EF zjs9C@sLWV%PBRHV$&Bi0Qb;0KI{MNoNA43IpMh_si&kAA(wz{g&emuPupm;80C>73 zBHhLm@_Q>`_~`M-d*|EUwep*Wj&E!BB#*D^>hBUZ`>)US5vh{C=9*MT?FB$)OmwK! z9UL{?z;dafprQ=o{f;dys%{GI*hN|J^c<#4sD+d&Kq4iyaD6a1#Du$;he&GCo`3GW zH-(NAb~w@Gw)z&@E{g3P)uIQH_mPyBaU@Sb8t7h5q8%p@HR-k}B<6ppHr#RmX%`hf z0k;yX@g@~Mr*ycy@|*oR81OWZe7l`f7Wg9sKF#tC*lNK&LjAq-0L*XG-uycR48pcWyTzK9uSdf z$)Sts=VpjhHyFIkCf-XZzT)bTsY!Eu>B(j}?v@db~hiWWv_r9-PO&deNch z$zlvT{Gef^K+n5ywxwQLMSLI4?gv2F&W%9i^prl)J)!HpgX1^albxZct1=J8ZAZ2f z(d8PC&V7_;3k~JHk1pn8Y1_z6YhAchS7MHZ&F69kG()~WTZY06<#vG{NdReO&MHF@ zZBN=>$y^ouS{#qYm*z_;YC8%IAGh)-R@3YJxg+Ae0!$u)ejNNbyMSUXt3&m}Nx1LY z)D>E~mAVL=AA3+JR(JUW)=YX*?F+}d{lgr;e#@SWy8(R3kTT%`kSntp@3&eM!QNyj zT7`~j(DLJ2^;Q`B$)M8h)fPLwMn^jRXud2`M;=xMlz@vP&dw>#P?m)Kf$jhliYVf> zRynlS??;|SQU=w^gzv#&K6`ySmamEsxxU63!Wp;LYgXc|kuW_EN=VYCMS;PgP9F-i-{dTB11fEqP<_noQvih#w8sG)Jlh_D7{EB${zjDvGJk9N39eE+KdIY z#78Qw<0NTDp!5W8BxV@gEe|IS`8;Ny799>Sdwtt_)E`oSHKry*T*! zMT|NE%DWyE(EM(^-&!xJM6WM9@8oN1-8ZhOrI*zA!1dUBIU&FiOzq5tMCdloTse|# zGOhIL^*M;m%%lC4$%uz)2_xz`)^DB2zypup&z{O>Bfjn=^wmaHs%y#J+KRAZrT=sP zOW}X+e^2Ix9Q!rTmXIXz(^dtJoBT@Y5Uq~fr7*ioB9qLeFkR6}BV(b&KAzDJ1Zu(n z$Fdxen-jr7IG2l$=C@CE7HGG#DBpIRH)^t?RVlG>?%IR|Te?TT5Uk(ypsda9p8Bo@ z?U;D?mg*tIVQwnPvMgj!f_z68RU3Q%~({o1(Bt27-iC&|>EM3dO zb>yCrBZ5JN@i-le@jsnib$<8`9J{=mxo(G4PU3gR_?JyVoz%R!PGiW}<9 zc4^koF;x2gA1A4!htxc%MJwjzm2tV^jZ`8xsk&t)GOQRNYjTG$zX zcs^dAmpWJnyEv|L(6KQBQN9`F+97FJc7OSS+oEtHGL-;GjA)kl zehILX9yQmNm1e1*!ES~k!j41&D0XdRidyZtBOx1=>nTUt8*hzYl%EaY-&UJOr>V);QwvwaR7BydI&gMQe0 z!ZQ8@q;*+?U}SAUflp9>16iE-{uo5QokWS^$FdQm2pztI+1ZAvl|${kUqgG_`(I5b zv8Lm0tTXV*p8OZe-DH{bc)xYRFsz6eX6LpUWJ}<8OCFl+uwV6bZu~Z+8Qe*G-Vpuk zoAGxC^CWc}q}{z|)`-cC%wzTUV)VRYnKmu2b?e;6(+qmIL6z}E#QuPa_PO^HzxR!c zni9JayM1X_<{7y!h2Ui7N6c;^t?duWx#57)p^y?4-gt9aBslQts_fh&BisJh*75$= z@Eo`6PdvjK+HXc{1MJ+U7M?2}Erks#(3`Be9o+7rn5;L$EX~JkVYR-%GtrL}QAA#2 z?v$>jXl&{ZRY{*0%CZTEj|`qd-zvNnCo_z{bTzw}Bz^5~O3=jf-nJzfiBauC2lnnk znu`IEk#L|?A+oQRupK1f5WdpW?MYeE0_@6@P`mD=T_N^#b|?F)YmPtL8O zO3m7f{+ZPbat`a6v}i7X{t;Rbx)w;n-rdF(9^X2AFne^Ah^Vjp6T88*)GKpOFluo6 zVf#NJB;43PAtVNWo}$f*x58$lgv(qXT+h#rXC|YS#o>$NhZReiU8)^wrKHjIm z_%+Ms8nQh58zxT14R{}?Mobiju7w?s84+eXn$n$NOh65{vrW0aZRX;A=5fQWBHWW@ z?Ja~uEa%D~zXo9bR6+^^C_yRIT7h)BO9bDqh+{+PQ~TDXqYgCmwz4W-GgposucxyY z`x8uzOmIz+Ewl)!!8PT+OQ0@;Nm*Adh68vs{^;xR?{Y{a3(f7vnFOHGh(Qz+DQ{dy~Sm(Yo2n?PuNy zKZV$-arV;ZEN8jE^-=!TBH&7gzn%F+d-&>pb?s;_^5dY6&a8psc`eM+y9-odsVr+} zzrIw(Js)@=C8-IF0MG8?u(DhlKtauei3>fKsBaRi5$VnecrxCS=6p%{2J~RPNq`N) z5~``)pc^u6b5SV|DRR$A@`zGMWHhe6PD$tytX=Zk9+$^YTS7KpvoLY0Jgnj(%;7!>hf6C8@P_n7z$gu;C0(l6rk> z^Uu5Xl^T(iOQ})suL;Mj4 z+}i6eT%4utT6{k1Pb$r-F8D5BIZ z99vBtL6O+Bo!1ji(O}q7%3>2KN~u*WiA`s&)3Qv4QlX8Ir~DKQ)(PKLX(2FFlF9XcJbzbz^RcnT!mD7?SjN zOayD+oAXo4?X3WB`_)`>Wjehi%#oSxGNdxCq?l>&6B6KZIJ-1{&I$~oMA_#;Rl_&) z<8ROu#?%P0xZiY6ag!E3igBUX5UIhdy8+MFZSsHWb)yxMEb}kmYod`UH_IwLhPaDn znv%cDq^f};X9nLst5hwWf5Ue)Y9+by7ZI5CvE9H#qqPv<<_D6pUWe_<0M~vY4jNv3 z8u6J4R5|js(!C{jYP_)Wq;ld0n$rfZjNRmVoDT583?azT6ebgIWf-8S z;Hh9w-_kY8-3gwFn;Q6R3=65o#M=q!zf&u)8M>>d0GzZ(~29ZMsx!@3;#)@ruLe^4wAp;Zvs>jS~I)Wtmc_N8%3jk4&&T)>fgs{OD6gg}CW3 zMiZkWfF{eb!_goCe{e-9JenA#&5y*p&9{sYAjiAjq7;B}DekS`!v^ho*u!zu2YPvB z?}GkFRUL3#?aBh`7mOcZ3p92Y*h%}yAUSPV4m;pcNu(3iv$qJktDh06R#M>q5E!6k zN+AD$bfgv*ePp1j!mNBJ`I{TfaM`rFQkFx11b=NF(G=bwDjX9DoToAet1r4V8kMn& zU{=Pad|xu5Q8VP&I$L?OU1Hn7K~x9Ri-6( zL9c;IC6X>1ZpC7j^NUFQN66-pP|h%+Br02en&BkAEVl6=jp2HroCGW(Ci$yukvuWP zHiy%@^OgRro562g<+-AUV{zl-S)X}t+JZBz4M^3iI9YgDUIU7BnlPvtu)0M!On+l* zt-4}tKZKzyh+$|lZKUFXI-)+krl5gmYsQ6{n_0Cfo|4z0~1p_zz{ z#_soNFedQ!(ZEQN^Hhl8^xul_y5b8@cHGOnO}Q@4t9?&08R>$kRYE9R@Kzy z!5NN-vX;0sjfP@SE~IR)5%{BLib8uK_XLxZgOIic#8l22*KwfYZ=3pfaa=v=2NE2t zOAa!TdjaI=K__sV1HYHc$FI3r{R=DS)3#50yN7eb4pR_AbmiviR}8&VR650arS=W% z$YCmG09&ymE3OdW6idjQ>#7O!;cN;wQE0K5`+2J9>@!dkgk=R=--8i=^Hfw1cuuNX z?gHJ~fUB@)41oM8HURSP-NA-}<{VHt<$5DhXQ^lQ0#I#(gDE3{OaHIj0-vuzp~dqh zGL-l>hQidzyl79&tilHJc(IcmAhVJ05Iy|K$qoqA{mpw;E?f;}>-a1BStY5OsH1sH z6Zo1JA3@7gIe-Noudll~_O7&;g^knFV%~Lm0|>FcgWFNrU5=4gN>7h<;{|bRtf(~X z2?ZbQn4t~S9`0)wxwR>uf7m~B%8JgoCm!I^hqz=LA}KooLDtOGcuiQ#jL~J`o=dHr@&m3*1q8* zChFj>)&z+Jj?7FIB-T*+$1GlYT&R3MHLZ4a#MKqyYo^6mdmNdGDz96o{L{Nj#vb?2 z-!Jm;)3#=xTJ$x)Vv0x5?OCmr8_ zOKIiZ>zyipZbQi+odDc|A2XK2G8ofFfF%U|Z6z+2fsV0u^=(xTd$4VPUpQRY zc$pqd?FRx@Q5w&5LUz>%6!&btqFXPA$Yw+gjUtsERx* zqL?Vul4>Ev@(;l}YNiDA2jn~MBvvh?Z3;FOkJExmG>*`Cll0=8k95CQmoa%o#Le`ejcNS~(5N0Cz^h^;= z@gA5k(E0_6cHl?ikSp5Lr{(_Mh+k9G^YWZ$K#GqmyOeb>?azL3-_k_zMWr_*FcCQQ{|Q5_O`dl^VN_P+JO@+p3Nk-$qM&^Dtba@zOJjd zv-ul5aV=95U5*X)gRj-Ef|-9LCiqHpFb#d@FvaE$jSt1@r!A!B#Y&Kdu^dt`c+`3i zyqfW6y|4HC4t5r3PDOeIgE%R?a-5e~z<5In?T8p8y_&RE;Lxx@P$&YBAa92f2XO@~ z3lA|aTSHfXi*;HSzUD#-89z`QjXzc`KVKlkDY{%NffOM!nh|$RZ%e&`o0jBlsHW-n zNf*0bH5t`>uiM>lYIZU>*|iRA3k{(D+Z-kaITGF`fhS;tsA1x%&c(CGA(!_Df)yu{~tf#O7XVbGT( zpipWHhQ!2@y6n+Pe<$h*Un12@An37Sv}5$dSmB|@;+IJa-Ud^#7qUuwxG`|n2IlKF z{`nHzgWT~lBzTcLR)jWMtlK)$L)kT{;XSM!_=*vrrX+mWt{MQSAnGgn#Hk`~WX*6V z$v^Rm`)bzkQ&YIFgUl}JtzS{XQtzvo%f?YrMul$KG!3^VZzrP-^we!sam&88G-oLQZ0Ea6^PpAYg_85YC`nb-jXmFVj z{iRd)XjcmS;aK+e88o?Ht)y&k5e%Vb%0q`CiMR_1)zG#`SnZT=Lq%a$J8`&!97V5L z26@@2<+O$T_`UA@5^>k=DJR#@_Rju{o{dM5@6Z1rN77!)vh{ABgmlr5m{P#u0>>-S zl)<<_4%3EQZzK%@6LVIE5mCEMvyEJuay=(u?v1-rMRB+>L0}klKO^7~7;jB+33ZKB z+2+!RjGi@#WWX;(IB|OSgR!R>6GJ%BM5VcljFRo3%tU5_UFs_kxp0%{T1qEcXfqNu zaBsK=`JzU+o#CA8g&rzUJ4f3gj8aOON-ablLbc5|Gx0JOzE-8<9(&W-yD!6CVGr`Y zriQ+ZC;ry20e7u~MaaE{U*se=19-#bHp`l!S#~{}BV`(e6iCMUL|F+8eCSs`Ek?vi58BWIzT$v6Av*jbIiv6AbBvRN^kE)j*+tf}?TuhQFaAQkTCp!G7yk ziMzHqKoL%mZOtHD$BNBh;NN7^z(G)`0RR=9$|Rl-aqpZS7m-VAQ`o(b#(*qz6Zr1t z8bLp5CKj-gM*`oihC(F(P4K{-inq`!kDt&TECFkQ76AhB`WI5@-O;E9&6)4_;X5j` zb+lt%7}6^@)#{xSQfvzQ_5oM0rVufpI(GrTdOnqWP~?b}_g|+uyB(3_;{A|Vewt3y zN;zQyG~;!-Ak;eY9}=@z<>hV7%$Yn)&s5BsSn!NMw4e(_3w7W&L}qhHs76hdY!A~e z`(f#jDJ6mEsD$yRDJ6R-vt}}HiKWTFxjwX#tZ`IAnnBqb58xZT;QBUQ$TqkhJdbH+ zBAZ?KN4rT*BVosT=8#vgomo^=azSXRe)K!?pBL2NiRAGkv^g-`{@F~E^?cKtca1XN!C!NAy(*;73i{H%3KAf62vE@*HEy9_kPO-5dbIc$$1aj}od z*66C{T&Q)8>|af1=CNX~!6DTMcpD%Yhh=;noRS*pog&}WVc1e32T_g2YPSKNqbaqorNPts^SG7uA2Wb zytH=J?2(&A-UTr9+ zfa>-vaM}DKp&)zN!DH+9>*#h!CeG|+ae4VZs5Z)$6m$M@_V+rzk@noyePwkEp5=vU zz)6iLX~_cRzTBr{AY31Y_rb0CZ1QHp6tfj zEgJNV=;*Q@t^yu-+S`6R4sXql_My?dyg72+;WL_~lyX}of^M|>d!^?3x8RdiqNS{5 zZCqvh@%oMw+7}aZS~OQfn#Pr;mvnP;24HSgTK9%VU3@zivc`AZ+q+r5U9Tm9OK=!< zxGLT=N|z>2@d~4q$lFUzB<(X2wzH8?E5Hmm@;;ciFWJ{>TlN~#Jt#FO9&5L5IegRA z*eOTbJrhex@+`wu`kRVwW-HrTScr<&rv39!8Zmjz_4Vmw(3~jP3K(sLhy)f?6UbE6 z%=2VVuJ{c5ltezJ%(|MLL-OQvzVYY$@M!4{AboU|QK3#R!O6n6G`$R!zIuY9$}8p< z+)|@}!w9)&eP!>u&3x=yb{H0J-Zm8W@^XPHUu0}6y_P=D)WcFpS&YnQSV{R=ge(JR zz0doqz(y(~Y9FevsYwbum&ufi&%s;FjNywe@S_Mrh1>uoq-+T#ux$J-0jf&t`1X*Q z`WD(pk~a@o4R>E$K9<_GazPXqTXRUVlqT2fZC8I);`dio`2QL!9B%G{P0OwC2W<{{%UGhs7GfE zQNcrh;twc^Xj$TTY5kjM!ATBupd^tKV|v;Z5zL+I;gq|uzZ(JG4^D4$9$OYORyHux zo^Ou^du2VfNiz04?0M+)eB;JKIFE@>?$&1Og@9U{lrC=qW9!l5`C? z!URV(Dl>mVK+LnvNOflL{5|~ebpeUlVm%(*f{Z@(n6y-+Cl;3*-CL80)p7KQu)mJr zLBDoL(GjYbtUeDJq$Ldvj$YT^>$u!`H?C?ue=`brZ1eJR$V@*v4sdO5e+rwjwXEX0 zDkL?H?eLfgzRsApip&fV{$A3KB$lv^AWTUnBvh^zv`6JrX=pmA_m z?vtOM=j!s8FX0kyl{`1;$!^Y>r9;8=>1;%WJ<#Si2&H7ZGa=_lg&NqlWM<|DggH0v zZzfR?H)QD8Uy0G3@;iuDzFnjs{ZI|;__UtCGGAeBh^2PqfKut;|gu*c8T2qQY!|3uQDh_hNnIWM|!->;n$!-Nf{M z1}r=0bai}-K~Y^Q!cZk|e+6H@gaRsm@qX2{#;$w+PWiFl<4GH$sY@;f#~$tkdp6#! z0?TtJ%j5FC6atg`w&b4s)vs|ARV095B$2X`(s(n3X2Q-}7-cruN3Oz68;5gz-vt6s z#~`n2A>{--@uV=;>jk0%3c6%pPGch+3%!MId;d-~SG!~I+(Al~h5ohA=;p$U^~Hz?X#FPAkIswl^fZ<+8(qNo14vl zeLd=~mBi=WuE*wxKQfZ@8Q_6@yidUg`V5KD|A;{PHE`b#)N+!PsRT~QOT(h|P_&=t z&5KcgYXT2-FbE|6nn`&}fKIUiB@zH)vui;;YEqqRHR;35-x3@3X)zG(b7w0vwy>Yb z{4nzu+JtvN<#H$YfWHTihoff?QJzZ3yLYy&d{zf9w;r2Mmaa?31W9vMRloTx;W8|h z3hG4uDm5hoFDsRH zZTKjDj6R4AnV^yQdp8scdlN+Z6dzl4t*WqT6Yal7z|$G`mKeg3ED5Aj6t=oR@gWZ3 zEXS*>%$^pB3q&4B_q2N4EWgvo-jACN0NG(i5GlYjCwF+S#K}ug6GJoi6y-81nSFh> zfcSowVZ7YQql2kJ3h6Vn^dTu(|W~xM$jL{ckI&Z@I>3oh?3{g;)F<7sseTHJFHC0`@b(lpSQo zmw)2+7Xvc7R`eYm(lpP)xDNZ^!u_?JlBe2dwC<3o<_Eu_zFOfaD&90^2Zd8tt)YJy z3=AOM10E^JoQRe`drrD(8Mfb;|9f0hXIpu_S4&id0)`*TREe}JJ8Ged+cNhU$4@bB z#6C)W6K8HEsPT-s!#j4A!z2KbA1bVagtpdgG&cJBcp_I@zyy>3v3RPp!%d*5UB=W< zT&}o8qg)ivrnuz7J4&A#XS9N@TM$o9+7r{cw-t5emM6r`S+TDK#R+3nk=|`4f?rKn zL}}7@SUZEMk7iUIZNE#f<0@xkHl)ASE*V4gKU z$vX=T_!J?i_y?MbnxBY)Iz*|Vk#AE%DKB{-*dd_<_e2_a`=noWtI4;seh-g|ca27c zZKLhw>#M+7ihlb)Bwb@*UQN@EZ98{tv$1X4wr$%^n#ML7r(t6|ZEUu&)9*a*_iKM7 z_nDp9nc3NyYj(}CW+S(-sx#ad#z9hglfDe*2rBrPxM6O&I+Zx={rZZ}njwDKI=ZVy zo?4L@L1gu!tS7mLFwGrKMrklPw>M4J{c%0!(^q^$i0(O@?(2~W6|eeLV5l~z*b*ABR10FQ8FO;gCzZ`zlhS^GC8RdJ>bFGTshdDzwcVj z6JZ^!nK~%}ONU@pW?8a*Z`b@)dgdOn)x!{*){`nDTviO-Vq%hO53!=aW#d|5jB7fx~%c1Lk>$n4x zNp;Wq*=COdM=xlC6Q&u9LB%VjAKrv^CYceb1!xwTeKV^IOlnv;Cvp>Ig{f{;r@Ahl z$W7=MQ5`%TV9?N^&1**&-naX7?aLLe=P{GX%4do1xjn+NST*nv=f_)Lve^t}K8BB6 z8}Lk>6oGw!1w>uc_-cN#=ffuh`{jTw)YFx})Vu-QI~-q|xHM4|?X>c-tD^%3XbLFl3}ZdohMF9^lz8^Y z5MsjkF-Ivx^8&UE^RAo zPeyOZwO$uZm!Xs57ZHE-qu)Hs0ZqL2p)4NENjWLJ1LU2-f1&3COq9_6LazpxprERw zEz80~-5Lda<1E>|mG27pf)WcTGh~8bVwE8R?xZh*QTRMowTXvHsEL#wE6n(Hi@RIF zRwN3$mW6CuC^&mj1>`m|r_yy87c5!nw|B_aCra~ea`X9t59;|T?pCglmZrhb8ve`# z@Ou!TTnV8MAa2FYPD%JjP9GF;@WBmJ^)j(}(T7lcTe6rcp@b4B@GV#pD!7<0-6c?i zHEeiPr^Rm~J?N1pyj!sG@i=#4(Kja%^I)cILfX231aomko&X8v;OYRw<@~@*8H`g0 zk55To*XwSTM6jo)^RRL19-sR)t=j*z2|XCQY;AHHaQ45 zrs6$Hx`B3hLrqaBzZfZ2^MX`xNs2Nm0y0r(Ftfjt8fV{mK7&ycD9I!!VlV|M5`{vM zDbS;}d{vszhWdXl2wlN5u|JcqbjyT-7V%l3&?&aC(Al_(NY5r?hIF+?_J0+RWsAMH z@UY8Juc%^2kS^j0zBeh2>_)G@)u+kIYm43ZyMSm=@Ml?XVhRw6K0mHK+(A~z} zf|8!&@wb^??d6o5UNixTI<}C6`H7@%vEVX6fg5wLhLt+-kSc~PX(HqnV=*l|rRX+< z(&~$13z+-JJ}cVKZ*hQq$B_a5f*BE4d_)y9JoRGN!=xRzc@0Z2<~rMQId*y_>2VX( zy|klQ$>>k3#m2450M&!`wQkTtS-jrVG|x&G!nj)#w>rl|wFD%!X$mD)6MM=L59@dvyM&Grvg*5^R+BK|+wG9~Hn*Z9k z|4c|+Ky}{!!QaQn|FMveCWzbxiFKP~F|C;@CyQH;U{+RMwvAOuS*1}t8dCY7xH4e5 z!e4rT%_SqNQw^cEC|w=qNhT-DQ66{j(_Fq=4B`UG4Z}L}pWp{)QqxR-rB68W9Xr#Zqw;e~$d7jdu8N{o2+7I*}zFMpixFVli?T%|-Z z<JlfurV~eRGgnEKUHJH)XBVYfC)T`!D#{$coaj_M2lwWXqwy_##Z6BX<)`P?$C8ZD)pB?AGv4&`^kRzY#N)v#R`>xH9Feg9N1PyNJ}RpOF!nbj#*z!rO1kCKhmsz(-9j zY=D7v+`+BSpwTLQ<@Vz8d+%GX-up$DgzLsq3crQfX5y5_Xn8z43>*7kxwBrzS6F$2 zur4JNgCR{(gV%9$G;^YC@FTV|s$?=zPsEw^haXh?$^({gzDWB}gO)bHzzW6O$a8cM zpl-b|OuMlp!!JP=Af}F6o#CMhL_pLT_gdplt8*KzKq(fPg6Z=YPa%qG&%8=(A|m~ zYcc#1MIvO=E{Z;!bkX6FNwIgV=F4(w^ z+g;O|_f3pkPSV;d`stpl?D1))0{#jvtS(N2sGHUrjbdw$+stlARE1sq6eJI44IhBb z6zR#D(t=ipP!O8D@DoIIpD_)33<4KwD=#h%jYQ6%q@y7l@JSI8g2GGwU2TF?Tnu;w z6QufLQ6iEt38NX|?RuW%g;P5}w0n+H4Uexd;eyCTQJ(NKc;Re1xYc+bsy~6C63LIj zoVF@K_N-{!O|Hy^6}X&<6ye-Z?G&Lfsb*f#LdG5q#ZS)s5{5ObFN-q@Mw4~fK9_tT z6$!D&PwRK}IwDyjKz1FGDN&RtPKdKJ{q4iU$A{xd-l-qoQm@>^nBqbNWt?BxNFsGo z9M=)atn7%aM1y^otSYHGBh0rzh1#7HQUHpJzfUOP*{j~;3RLU4g35_HwYYc=kuOccRR--KXD^NWNyDL&F_G%YeDwL>w}3LAWEeVph6I()n|e-)w9EMaeD4Wg#1r%Cj)p`bgP_Ut0XMDA7)l* zMGR9dB>hK)Oyt-2UBIUfF-Po1hJ|G-{7vGjHQl8qMu^j4NAoe!MA<3}Z-WIdtlWlf ze)^5$0B>Tm-b*OSy!{KDJ?9f13W+QP5F->4Q^+8Z7!>eE_iBZ1{u=>5|Kbr{v~x7D z_ri6L>!MLGK|NGNp+%H2`l6$D+E`8_Qh!#VK|RpzdYYN6puoM#=r#pOkUcZCexJ|! z9tpEbG-68~Rrd51U6$y67H;J$!XVlv&Imlj;5;zwxspm%-c`PcVj82w3C}lNLIom! z+oE$JvkGuY>hG30DvGy&W@C@dzR9XnQE5p_0jDt#LF|VM3**ax!VvM+h-^R+CkStv zS8p-ni9x?_r)1!43JPH@gw_G?&^;3Tr@mEvib$plaCVBwqzmY!)p@$M$R$RbhW8YS zB%xPGW98t|eBy1%X-ooey87D{qYRv`pyu^G#Y9)&u{6?H|BB$%AwbSa zdxSlZAqa3R#2y?rmWvgewpt&4v5t5)22Vx1+1XQjtiINOh*BvA77rpys~Ci043*H#6-wpK$$7CbfR5+xh`rl?+X2UWZt5i3MtyRMfSkO>^V`!SmycI; zH(Pvq(%p8Aj3{Ukl@$V=f*1l_9TJMVNPv<7rpt!3+UqkXFINa$k`&+L##CCbUS^b1AQN!HE z_g6EmMCBFUd_On&nwcEO@@uqmE~P_#SzlV8e?0m*&siu_`6!UnP}uo;(y#VUc#hDu zVXd&uBiYsFY}@DTb>uzFY;HjjI7t;|pG_m^?8Oa7oRf(^Dtst=hksq3X)P(j(KGLrT7+n%FG zcfWto`pNUh-lfNVX%QyJZo#&mWxi0%?*vB~g@0!HO_Zb`##iV8#$&lwgd=Gdh+M3n=r<;|J5(Mst z5=t&Kt}~=VHk`c@(g!tfqag+M0||(4RzdGA*RSw)7GsTBQ55h5wk+u!KW!b_6t1XK zCb~78>u=>r?;U@#P{Qm)82jORy|=`ff0NzOzEEzBU)h&!@D;8vJ=&Mw0BH}*FqdxU3s?*#MsZVY5}l+pKukZ%iI)r7+lU`tbK_5VP}C`8JeV; zm<@{fTN;GczfLP&GbpfLEAZzpJ*v1ISqSCbf)sTlX?(KdF9W`tVaxH!y%4Hug-y_ue80ylza z{sRxIXyWDkYMKhAD8*j74icYO+#giO*AxeiwzELIV#Pm0D2_52uXpC|mhNTUnISy_ zJvrMF@hj>t)%}sqJ>NPfDgyMr*-$$RCgvIX$PB6bJZxZ97q~AdgQR{ob;F&UyZt%m zjbSEa&0E1g*@wzm7S)5dg-$`OLr9;K)-wI~RY8S<|F*phQ+C$@C89!r3*qZUcEBsI z1IH~HJc+`1rMIcH(C@YTmxF&9-pUIPXD?1#JPgu2Ct=<_?bRsGg2;))!)il_&;1MC zGNbwN>=0}%L;4`?Y=7-B9|jn@@&a#4SviqD35eMX6I*B*9@4&u4{dgU>(kXm3Chs$ z%~*lq+2F~5(=6WwCdjjjvJb$0>ma+UA{|e5w$gGQA9x@?BROG))$pWKWn3jXi z{0SBc3dt*Ofhe-l@l4>6M&-Kb|5haBrD9)AoHoCKVUtC=bZ8mO zWyMk*($v=ET6F{#c`xh#7rAp~k(RRf4!23bd}r?^ROo&qL0<;c4c~FkeA!w41pSS4 znjFhi5IKgpvP`U)qF7S1jC@)$I0R3Zi50S|`*#nY6ajHr!HEF6{3V15K|u#ZcO70s zUZ|?A&=AyHqeU2jE?Z*z2rQ$=dneJ*i}x631*#>t8NvQ=gl!BWLk0db#P>OJ52Mw! z7+#R}wri=CW|;`GEiV$+$T*B$v4P>Wp{UAKdIkq8CUp3cyokz06~fj)Qkxtq*Z;o0 zAzDwxVj^ljgem5(giv~s@fxWIh7Z0!4EH}lExn1+*tLb*0t^rs&?(Y}=dNN^E4ZV> zgQT<+5D)*ShVR^@F}g_DDzM5Bc#NbWSY;KOV>Y#D699enL+}@-F;qdjd3JewLUD<~ zBv?|G=RQL!EQ=I_g*J$=*Yio~M~ciys)yhKvoEJJ5iK1%Lc`gKQq>v_D#j5}4|!${ z(-Tn)9UMCo*e+{5r@yoD;3z%w=}%SL*yw4s>3MFW|5GYg-EHJ4(pZUpC-yyo#&CWr zsbgWMgm?*DP@<;qsA0n6=z9ReNT?Q8YAsCY=?%_a9kqd%-B8eMw3*^W+iW}1g zI3l4Uvr)U6{UuzN_r*#q>1mQcRTCmenDy_CYk%bSN+odZN15hQ8Ork6$HyJD-)7-9 ziZw0^Tc>8-_227;fPlQl>q+M3ci-Uf(omcO_;QoqQb0g9Eom2mccvtYzH||99IcJJ zaP)Vp3DPX2KLk?>Ms{+)cT-*6oExu*peg|@MpW|vkMB()FHB@w(&Rs()KRgTn2L|W z(?Gjx1wVo{gNZ>xk`lz|$|Ir0oPB(CUL9Jfbo2U{y0kNp6>;XdTY2no!(2JQ>ivDy z`y+Hgg&sS-0c#nJQ<8qbfDi_e^{Y|0$8Bi6XEZMvM#Y@vjq;Ljt^v}0ZbACZyg>Z4QQ z5+MaWkH99}a@M*bKy)CmfzE%lKvcnKUgc!Jz(M{0mZ@4#g=S)U&=1dISnN^?%M#I==dm2Y9O>Bf=wKGgKVYXnB5^)5(3^c%EQi;3t=)rKfKl5XF;AEHn zWE+4lgTV-K9=5E4gAT>Ww@7i6zfH|>r^(Bm1vm{f6h=uv(kiuZ!u)Y_h|}=ul7VPS zT5Ohgj%!7n2Zuwj45vIuz`bSWEGa>Zxo%7V^BB}D&UZ+y0G+y_Lx7~bPVL~qb=Lh) z;>$o8f4{|$^)zJPt-zNr90j!ZSY_p?)lO+0X@X&c?GK+$V`zhqQ+t9Y=^b7VABSaq zgE)l9>SXqHS6JSJ@-s^(nuIzoO|*^8OS-P>x}lKz;p>^z_KwJ5fGzm%V!jd6_dALy>_WI+Cs6EQ^fCY!m7b(>)=qpOXk7*`_OOn^;grh1GDEQq6_twhYh0$VBH% zpOlhzX|BqjdMlwyG?YTUEWap!6t3!k>k@$ONpDOc*hfa?^G!0yj`=cDb9;jyi`Gzd za3+M}WqwPT4%l4S=UiS3$mfc=_2y!-VHhmH+=Cm-(R7G_cL8w@xtJvcLiSG&NIg!dNJ-(S)Gcf}^z#t6lll12eXkG<#7>WA ziND>sQY^z9O2xYEzt(s>E6to?mj&*IajO9dd0br<6>aa?@Wnadq8{Dad-UsQy;M(D z&g?t=dXK^X=(+6Ji2mV0EBr*IOY24aDkTYy=I3LXFz{*^j>cbpI$| zG9A(!klU_&L%VwzJM?ejVuOr?ou^=3%=g{?9Mbj#Ou`yWzoe1Nj_%{+yn&O4P9p4* z8DJj*kJ*9|rd^z@EFIf(>NRv68JE%zUS0oS(9jA#6DiL<7nvCF79@^?z5hEHF+%Ai z$jhBeOT91Z_8vkkER#(7SBqK%p&Z6R(BvVU7;0x3&*HrFepfYday1;v2P7P1M9G+( zds=qf%860q!%%g-@SO#ByaMM_Jot_PQ-zoKBey8ISNqKg9-~F+BIpg~_ z_|mgC>iD+syw-95Ec#)2Nut0~>6m`Df>PhTluJO zC#i=2;i?MNohN`lk9Tl8$&VDpS-MaB{z~T4=uD-1CrJ>w*pSz25);A*VF#<)SsM2U z-mJ_J=Ts4SC!**$Vl7g>HP4F20(pTk9}Hc{u6NiR&sqm7?>FIA-FDy<845wk6q2e zh5LeTRu))Ic3Zl4H8Xl@hS&F{r%SLW&#QNNfQV)vdK9Qh9NQwi~u!{pc_Y5boXBezt8pD8t#$%&lDJn+DeMF2^%SnT7SG%Ffol^f<`} zMZ9iq*%aTo#rd&02Ey_^%tCXN-nsP~1{i3_BfppnIUXl}!}TU^y0nkcl%dpB&{ZP4 zd1;U-FOOe^f1~znlYm)%^}TDO{~={P#S-5D4MyuNw+^C^&7y)5f`+D2fX6xl*Dg=l zgttWwlN))S3TQ3}HptRkEL@7j6N*osbCdbUwONl+;~sA1+4SaoFEXgWQqBm&neO5- zS5<;Fv$#p;@9Xjrl+n9v;(Ntm`}sN4egJ#r4>8=*5$s_N1N`yejUf-1=Q?6%*tNIGsYAzJTJz=Qazh$ zYi&9cXWOVt3x`(k=9Jb09CD)>jqYk6ioqGL-xuPIkUH`d3QY7BV=k*diS3o5jrHQE zryi8TA6>>Ssw%;|<(+Uq&?D!*m+FSE(q6_F#nee< z+;XDFt5d5xzoi?$u6Keyx|4hq4G6I=PUS_>yg!iNL#qXff@I!yk*jxQfYr51|tBk$Ej_y_u#u-#0X}>U!IwP~4>O1Ne)mp3OvBl!Jo@sdIWU^-@G34hwxK;x zdG)(br5hXfe&3^??_c&z`(OCd2_^E{L+jgLgBGXifh%69m71Q?x5uL0JXx}KS-we7 zfW!>0obz(xc#?dOW1kjYr}q1Q_Xdni`re0*)B0C@n|Pr9$bWMeM9c=<5vx>P|cSHUS0P=+a3I{q1Zkk1vgp}gC?SCF~!?@Vd5tK{P3`BlfH+ElqB2Ctt;`^jPB!6_Z?yq z$0<^>FBqvh4uV$$z6#f_PrtFG^-612VNmxk+(Xfa2Qe$s#SPMf&kZ$SkFkdTgTU*U zpF3&b{MO0l8d%K&wH3HP6xEJms+=J13Z)t6tH2K9nsUiSFdfg-tv&3&-meDNU)%7< z@d;VAjP;QX4ZezXrSQ_0IB0U67qV@#Lq)~7o=Ew_63#4Vif|?ptcES6cid+KQF{YI zXVNHwhVmS>$QYPcPsv7*V_^Gd#1iK;s>DZ%Xg_GVY~&E^`M zf9$Ulm$aD*nL&m{BfLf(8e8hjn6r&xv1`|9p8Q+*JO#sRK_X~xtkI(J)?S1wFfp7j zIWg5CX%HPXc^KHXS%pK5I(cl9P$oCqYA zW~FiD1u@H?dO!63xM?;wP=bdAw#GP(_b!<)=oCz!DMCDX>TV*_y0P)RRBdvYE(Lq% z*?s6WGTnSNb_yb-x|JVmKqliIWz0wZ_k=jZ-61awv+n0MZ)J8!t_zARwB^(nd+>dH zJCE_MTDSJkmZTsu%I-|(-!zEJ51bMxzA(O?` zYjR0_O*UKlw9hG$Dy*`nd+;&I)hw8l2TN4-)^zH)SkZc?p5Z{e5ZM>Gw}?OUH6Mxn8Qa->uY|d z+@&6D1Vdsjk0;qOZDFGp9MTlKDuu|Tqp-H8n2B?as~qJT9heSr^uZz)Lc4lI@$sG0 zEqIsK?#+yr6^?wBz^(0>40hki^HC#S_%QE#349BdEIn#{Hr$r5%_Os9;1Rp9zq}Tb zCOCiKjPlyJS}eGOC^IrFQ=5~lj>NOAj?T$59Qrxvp-PEgCdnvnedt62Cd_J#6*?QE zubH@aLb2KMkDU5D1xcu}e9kB&4V+whLK@ze!&56fH=kl2jlIfjvEOXqv4%=Zq|^Knxm};%8YSAV4&^q(_G1k5h?+_{V_FrvkyUQE(hN?#m4tl zJv!y4HY5JMW>9MC*#@pxqp&OwrH~Ut%b7XTrp{`W58e|oom zqKKUv7W^~E=`+y5m?>#}v3lX^CYH9YRqnC5)a4BPd~RBIs)bChOng55M)@xF4VS?N z_M-QP>k^Sm%%VW(oX|OWrZ=-3$%xDpe_yq11|sG0gb&}iExGd-2#zrqouYK{x+w#l zlhX6%e<;*dsV9Td^3+3+G{R}xs;YN7S#AtdSYbjlYKk z4mwDx+`GKtYE~<}rJS-g4(0T-MVvasyzc1!CiRO4)2|GG4QugE>4haSI#8GSjYIGp z{*&dM>ZQVoffX(wn^km)>RgX6lCE5MsW8|I%zECu{(P%05SH+E`{v?JOf0KBmGo=> zm4E>jiNfU4RlRH%`3w=yIVKgwIfgE&14%AtWtVAAb`VcJ{Dz$t5htNzTGBVPT`r#I zt$shq8x6pY z{r9ijVDf_77^g;q<;5JV_Q}BLv35> z_t_@d@q_D>PT6@KabyH=%b{241#b*8aDW`ZjZM6dXzB3<*;M~G%;;%-kx-w%l!e<} z=r{MwC_3D|BuVERzkT`(g16$zZ4-N`?~_sh#5S|n-}=fyH?Zb1|G~T}M6EIozUO1+ zW)TJCXP9vYg8mile{sPY{ouE8%>7;C3{6^RFURDKA_6_qPrXrfyY3k&-Rn)=Lf&5x1m%K7Jt|GLVh4lBV3UWje z)VUGDlQ**bjv9!YU0LovcZ!x=%J0<^+*qU+>Al`1vL^;(a}&vLPbY47?cK0P9~#@g z$48Nz-a3sOr|>6~r+Th09$yKBVNIs?Je&Xwl>n|FFb7MLk}m_fYgFa5qkjc^RwPz+F`wSj`5qH1GoZBD9iyJ@iUf(Is-# zE*JzdlZGxhGC;ar$K(-!bURlu#4JKFbt!vgINT%gyyU-5FE%q?T&lCoSr&xnWD2lY zqOGk73OHa{?d-$WYCPbWfk=oNW)Ls`i&`Fq2)4F0I(j8=aeEpJr?tH;@Bc*VaLl{*UY&ZVq+b~DV*Y_}8vX5wC&+sPB1VHMbZ^WvHO>IH3;L1jETxu* zIB+{=qIcJkZoJ2rp2uY1;Anep;fkREg;!R0vCLR?0ntihPvtgqTGBPN4Mmj2%)xh! zWPcWAl8H$QhnHU}ZB*BkqzgAM@u&NW^G&!Wtv`b(8Y;62%6|bCt$&Mw;{{jWi$*5Yk>6tw@I={z?zhuB!VMV zcod(7&?Ip1^83TYiO^E|Oc_XkWPYK&lmGnw%#|LUv)54$GXY^8E@Q*INrze}3~^Q^%)xdbe-8eb^`nRN$CAo3N)sb(8bC zr)Gk##5!Z~ez|cJ?NZvqE44JeP@eBO1To%!bzRag4D)f>v-%rB88c??w4LEiC^}>3 zC-mFlxK_`*R}#nuj`Nj~`OGM&mxV1#HiQKd^QoLGDvH2U(Nv4({!CD>)&?iIhQy((^oNKTYIQN!VwSq!gC*U!Q1XV!Wf;TasaK1Qy9ixj-ph+CsDe8LPRCpRWq z{&pC_NH`+*u%Cdqppo;c@sT9i@4HG>{T_=tBPa@kh-J0+$H*cpIr@bEyN0!dlL z{(1i|d?xxvOckzhub%2o{#lg(m7d{px-8_KItyYF#{-1Q&R$eSUCAT`qa;bzU(3k# zW8#=UU(Zk81<satM6AKX8izf>?(wl+CM6iwjJtS*b6`vD2CJ2rm)m>$=g^ z#d*VQ6?yT;HQ;)?w=}nkrU%=ohu}g=~nm0_8Qsgb4Os@Q`UvGFq6v$v9P&a!ZAk9F-d zIU7%T(J9eGulD7F9DJyskJ$R5;sL#Tc_w*sCi_J$h)sCPz^wM|R+xAmnoBeR^_J08 z5`hL~MpPCpe6g;rhCqBx8Y2S#ml#ix4y|)+@<`cJ+$Y28l}!-A1kQYVSNjSah2Bj#WaYG-BhJG92XmRp{waz?mh7>|+XchkYI*YhF z5fEe)-_WRv~UM8%{(5RH)ifm{Q`d&%>rQ6 zn#Sa*zT|_5^@))9Fa8Fw6*U^r7Rs6EBAU1xn2W3tHKvxzG5q{B-z}7Vcd=+z22gPM z{?b>SGi3oZRk%8J0Geu^?-v>4{KB=mmxfF61mlmKIHy#Brd(>km&d7YFsuwHeR_+o>gz`OxP&^mSYq!t6SiQ~ zJWzgztQSli5Dyx%HUeC`7A_OEnMIVAF=@6xX_igoBA92|SXD0RCiLgk`lr zr=S@3d+YrD))ejlPDK$$rr&APloEAD7LTtlhU01tyO9M`3s+!WL9o78(q#l~(U++o z1B*KjqwPdS(nA(MWBf)C8vP!@5xOi%uV*--4{)vb|6G?~Px>u~YT=&Y09@Cbmg@st zw=Lr6K~{EF!+3SN)N6-oIS=CQ4?@=uLL0|Oqt)Z6uN6k^flH|KrW+WR-L6PJMB?S% ztgMY4ZAViX7uU%X2Y9LmlOc;g6KH)zcD5ea%U^0jWp2!qQwtot)8NE3_LS&)<{Eee z@g#g=x%SVs$5vRm2ZIJ()FgoAb&q$aWRY4TJ9S=BDdaI4CrAaTy4NI!@&!(JYK@Un)CrnI?LMkThltMu+iJ zI()4#faOvP`7nUx-en5DxncENvxoBELQF!MxI=TifZV7c>vpbiMx>*Glf-(WmC zNAGo{I-x0bxSVuV56ud5aWu-AK!fKc_3==Mw)kSdnlKmvb9B_ls3UJWmPD~3af0O;g?8aT5esSCEx%BajgaputF`fR4R?Tgd}^kxwT*NTh;xf^xQQF-_d zx`r-bP97*)u1cmw2BPw9N1>Tv7opYeJ5DZZ?RU->phUN46pDIqDGO?9V23 zFcE8^^FAdjbg4whXWT;cTdDazjve^DF&;}+&Jp?=FFjPew*j@$eyP%j4zh+9RIS{L z`gy==S$R6e5N~W2L#Hft=K|4RA31fNVzBM)eOSITtDRkx{2J;UJq|S+FN#5YW!~*oaGxep=L=aVLfhZHp>1L?NKyI#2?xc&{&JN5y_28+81lkH?mvWN2C_%aOKeAxYW z;;SI8VS#b+R12yJC(Iort?vvOpWIcLphP~S$`VfUMuG2-{d;tN;*4!l^d>vzv*r1X--r$M(FghJ2I&dz zF$brtFR=$wZ-}i?ae+;ynL8XL$zMZQmQ#%`o>Az0NP7jV084=Rlh`Lv@)C$@hX5=2-0F<^GhhocXl>x=vJGn1SFL2 zo0^F?XJn&diHKAP5<3;XeTllyAN?=$sHNeoi(^_(Jo zd$(d%B`Fpr-7xz+@WrMJVb%xhS}2M=4a+c=L@gp8`;v0N)$FedL@;L)MhYe_>*(1A zm-YTeEQuOKwj+^QskmYv&nD%_#^;1)GDFX~PX_Ntjnw^--j*??P~<#2*4X4mk5t6Gz*FHzhf7l59u4 zdRUOHq9R};@YZPfgEd$M$bRENM122Y0aMxRQ`uY!^A&nynVf3=IZd20ObrU;q^kZI zj!5uB6&-($oUE&>^rvqjPvWmyUox?uA3HL_?^JM#)1c>zac8Aq!bVpwh*Ke_g6CDb zlgbg#%s=+hlG5S)Uq0Vtq5FiUDwP=L4hLu0sv=gGMBS>v*8%eK-ijzL(y&1T?3Lb% z71auC`HdAEbW0}@eCf%ymfsHA8xBvPet(lG{4?9oC~e5mTPQW|WXz(7m^Ppv1oWh_ z!+IhCE0Mc>Z}s_hBI!ZVe|>d=k|pYwLp}#%X1e|kt^zY*T819NK3rqo#soK6_dn=k zah**ukWI?*E6S7Z3V@}(%Pch^nO3QIG7V!tRNtj7C8oWwjUf6P=UHH+AxS?;1Vx>b zieu@g4w)gkpGIKWr8ABFmz#u=`Aj7DKcoT|EItKTS93u`YJO^&l z`wK0__9E&?IQk?SDGcqf5Oh)tl$5S9McE#m&d}m_$=2vV@u* z!lZ$)gpR+6_twZlXGK;<`fcfC0D%9b=Gfl~|AU_~+S~HTtV7Yb8Xacjoa}v|=p5IN zhzR5~D*&ryIbJ!S`;$*+bqQ|cYspVph@JFbSk;W~3;(5@vd$Edbzmy`WS77z@o9+B zsh|}6A?=tH0Nmww5N+%AGl08{Zplgtid$F^W*hZ~VWWbdm6AK!gvw-DhFBTNHNXXhPEa2xTpGy>)h zLze3~_aBHSt^FRE(uUVxtjgf>M~!T52LZ&5i4?nnYG^vr3l`o)%iz|dJnW1g0mY0g zRibXeaC8oEq~XAwfCTzfa<`X5tcteDtRShgvOJdw!8lZ|(ZsEDh&4rXUSf#;AEPr^ zN96_z4PP8p&`RJzY+fY`-Oj32qfbquvnW1b_pB6~(O(VmVGYmgr~|)oA=>nx+?GDL zwQcSEHLEmL`C_KKEv>(xIj8Si{4k^F(Y`JOf9~nhP`TIoiv{zj*PNjqIOv^}*aAqF zf~EZa7lD8Gp8X%ax)Q@PcXCo=8S*lC0RXs+=({Ma?9Wz>3cKO~T^evG#7yiEfhIc$ zr?0pl|ek?cUl}ElIfI_dMgnDu=g=73IRZG&xHoAp)h;D^9HlWqaZZzC567|y7l=G1o?U9T$Mx!f_AE^6 zSBCiTR&1QUdPyx#ooIG^_BR$c4`Va5AoUWq(W%KEmvD$ARLmvkkFNRNU%Ur>QW1E7 zX8w!4$Iz#44XAy|6_o@tt&37bfcIA*YuRZNAZ<~GIB;h|w@f5`Ru_p&^vA;U{9>yGm#&m=ZZ}i}EZ5u@S6i>>-EWsb-D|mkwTV}WE@q%Y zMzSdW9Kh|61I@^hA|k;cYNv^i^f0bpZX!N#Mf6p5U@&2t94_j!(jg}Qi2uu>!+eK= zqjd4{WzJk{*nc}ab8J#yQ8K3g(+e~V!g6f;%A=v7N?&Mi2)Eh~^4?TikseQt2Cm4q z`n4OwV_3P_5@O;T!0b0v7B4AWxaC>6oX1!E2OeSv0H*s&&U{&G?Gik9SAXu32&LeP z6n5Dt!V^YZPmn2~<_R^lzz+YzTK@#4xTjK^9IU~(wNWV+4MNT>_0ke4lRSDGeYWxM zy9;}r-j|Cc`Nd5% z6aqP*PuNy6IdMzbxc3xCGtg7KsFMJEmqGln1N^E?@~qGJn#r0CVxNvi+b)!y&|BnY;zL%AcE)j^-%u4kEO?Z zFJ3~Xll)OXtt9HaI|{7x+3$ocq}^-Uj3c6?8g|1@2l+BghnD(-JLTKnhOQypJ0DmzvHrTQykU`DbG z0Avohi1Le3xX&idx{Ds}o!VWXj1xp1U1obFm-LkQ*10#$NL4W{WMi-xG3mG=Xi zKHs_`>D3<#8`)0#51b)hx%fW6Q?n}QfS&6T6Tq#FEae*+zw`BW$1q3#i6Sn7ghrC( zEAl0;Dzucdm}c=WJwP+G%=KN-#pdG`$qNgal^ihP@k5_)heG0Xf$~$3)k2%%MaNRe zLMNB{)R^~`#{(u*#F5H+DpJ|uEb?f@&Ge^`=SU%ldZL|wuzdkIH9OkUZ2A$f^9NZ{ z{>hmJvLl-Y5{N)u$`QbZIyR|^GO8?@jd4HphJ@Wh`e4Au6PU#~3dupgCH=P@I@r@; z+w7uwG<%^r@2!1_y<4RR+~~ShiROH>qO)-`Q=aAxF)1$amcY{5Y4lA#sdoT}VcjFA zgAqu};;*J7P%GfUJ%Rvwq4Kw}P6%nWivm(8BSs&{v3Cipbc=R>BR3#?jV5;#eLgPH z{a=Y>k#T+?^o(r^&%80+dHWn1@Etn}%ZPmaXIHg~9s0gMUTyli8A!j4!1@JXO{o)4 z1KSzD*^%T=IHcAZnaJFDAHYb5kl46(d?6zd*+`o#zDY~1WUHwp6;0MQOaqoFMW*4d z$_$hzH0G zA?U|fbZRhN3@rXyc47Pb(nU+9(6daoJ`Si))8hVDpT4hnZbQyspbSWH%Q|vJ8ar20 ziAV_v;Q#`)UtwUgl8t~;fj5+E7lk^vXP;X=%60ti8yl50iC~t ztI@#bBG4R^7rzL2SPVtyI80;=f|LSe8|H3m77~1 z%1_EE1~Ld$v}~~Rut^!o|KsT^gYsyau5k_S1i6r4!QI`1yF+kycMA@|-QAtw?(QBW zxCYlC-*P{1eSfGxs&=+#rtNf}UIHCeJ`>!6^BJ4z-`t_i=Oq@ZqK zt_pUEjLh~PF_um43Yd7thqx3_HuP;!K)<*RovtwYJ;e(r{lF>6FKOK>yqO;S${>VY zUKhg9k41l@h8X+ZLdD{}sh~9kk)W3jlxhPZI2K2meM+cgps zTTY))esC%|BvC`uA@%6bFOA)2(Mp4GU|IhY&zU~|Lp*0XMPYQ#KAjFb^X!hP#j<89 zKsXp~c|{0A2DeRd_5O@VDcH3(^%B15L_**r8gBu!YFK6FPP3#y)Z0i>d|(bK3UAT7 z;!k0b6^A({l@2Bi`5n3*&}>3_P_*#M|72PDPnLpl3!SisD|uSlbq#}GOtChbz$*md zt@Db(hxvSC_q$?zC---Cy#MR&FvbnPJnwG7m^@Q>D!d6?(acDEKrZwt<>**{%it&^ z+^>b`;3^Z8xqV=m+P$h=&V+Dtn88-`hJa8pR&-2&P&2>>=bSRT<*Gd*(EvlKbAw3+ zx_|FTt84xTXBfy$ej`CkwZfLq1 zw038+9X@uws0Ny9@b#GD?Ga9qPe`#$=-VKHAd`7u!5ba{4t0(+rA=`PE{UVL>^TSu z6$@Z%&2N`0(0CNe!p-a4!UBcrd9CLla(e@=Z_Iit#qsZQuFD;FAMU%@;{*luU%JI1 zM}k{(f3sP`slMs_)#XWf-+E=+sfgZQ@v70OMF%V9H>tSZ(NrM7wWk+`0`dvYPHOZS z7=TdeJOYXqgZwj2g(0Y^unHyvSz!vA_ZEe__xUg-sY~c2c6WD&%xGK8#ppB(0I}ez#bK>#e2eN4-m;U&{Zn&8oA}?E zi5rV}=NgNgon}xzP-RFZP9h^qwjWyfd|btA);z)+px0dJ^PD5DjfR`WOvrsB^%^df zFjYLbyocKK+QJVi$RucJXG{cj)k8Olu@?^dozDDQi#-xav z@`LB8tfFFA+wWA%G*3%r*cRX20MAvLkuHnd*b| zzGe47z-C0MLVc;ZF?BeglLzjN(6n;4|4MV9yT0e)7u6h%wrb5e9N;FeT+SYn|5+nr!czTv7nu=y)~vaK)QZ-LTEPQ7i60K^3XIN(6u zxvx(J4jEKWBbmq~XOY4lDU^oJ{RpcT-7CvO{2KU*!&pbS0Qau-42{i6lyyT|@+3(j+r;rK$UH_Awrx7Lx*fEK@_Dm%Rial?k!v#y&Y zfgkwAy5|M?2`)BL<%Ssmx9(lX8QC=m|BwE+L*VVJZ)jr@)W-zuvLFH9@0ZODJFpq= zHm@D*#)p)HQ(8pm77f%`E_8xX0M?~j-Zc}WBsj_Jpp?umZ=9dXrciwd@@9bQpQr4f z5PffmKwph(hZQwQWBbyT%Ru>_+vBjxAK34!DP{106-56|;!W{?K)*V-$ni5i9z(|t zA&xH4aW@7$UgP0N0bBa9CwBsoZOmNJZUc*EEY})=kP5P*Pojpu5B49!N9#;pq2p(Mvy z1{N~S6b^o*n`y?gWjN5xpM8PdcV%bSLoMwdq5?aSMZLKg?``~umTKGRT@or_!*Z^2Dz%u|l z#}Jtt0o`MAO6}nzGrX!ucJ@Ka#K|nu{k8~jObF-D7>@yP=a^C1 zXs*bgHJ?H^?u%G@P`fR4uG91){^@qnHo5Cyzmu zsvsfB34MqB!HR0Xh^ur;7A<^qkRJdzY=A^5SQucm!Xmx1=VGa)Y=;B|TqfIWe7J!( z&Jbh0FQPsy{}gP087^{T@UavyVJZ8kx-nLlpfy0IX$&}?CzXKC$99`8Rgko+>|4W5~r%+we>*QZg&m^i^s5B+^2@sGvR8r1Oxm2bG&YA*b*K6(ORy zJ^)T8xC5PAL{}r6UY&2Of@G?=H6jqu>^4Fw4Gf4_OVlA+#@k1k#woTo|ss_KFnjZu>lcLF|fORXdr!io=r zx1@|8`@MJwgAG|4i@EL=6A9}*p)6;yh!PeW4zKa{thC(N8@C{O&S>)O^M}RNu(H5% zUwL$5GQ4?7+C=T^Z2HKp08fO4`tOe;iQoNB6=LEW5&dsD z5$@^MNC?54)mcHs=0vc_2M%GQpvkry6h}smAkVV(Bo83{z=U$94}|$IJ{N*S`J6xx zIcN07o#5Znq3$Cm@Wy82z%Hpi$LJS@-o1aWx zg(r4-USZ84dcV?YN*$|g#3_yg@a=m~W1l&x>_!kghV7)4DbyN!_K+87;mG_wfWcs5 zr(||O+z@^)D4x0;&v99Mb-XC(Q$$Mtm(C7wV@%V^oBk{Pc@8f88LqV>9#4w>&DkN7 z-~-HzRMpf!`7#VKbpxi6(m+&o{B7yOvZ6;KYyk*mHT^Tcv zBWIi~CrvV^w}b%*pN$Huc$}q{Bdh+Gx~?#AcDX7fp^nlS0JS7q`0^m%5-`k{OG<2) zwE@S$Gn_tE?ctsur{e8;FmS~P&iqFS7PH=4y`yoX3OV3NG zWEgj~?9sJNrw#0u!-VoL{}o~ep*q2q!UVwVWWpGUdYeOR!YpH!1v|yj0;kb;EbGu0 z5b+})*IwLEttfO#rALScD&8N1O`%qS>f6%CeXyqwgl<=i1grj{vHcx#4qldeynY#; z)24O)N=7KVklS7ls= zm_rY?r5A<bb7*^jv`*#N zFi$PqJ924E2s5mJnPE&gcmP&blv?tM1kwa9-Z0$Us7M5i!Xoz$f7Qzvx{lcc7gIqx>pw_Fp7Ld>JoFo3Llb|d)}HLx`d0ri6nE()!=ePpk;N9&u# z{4}Ah0w^U}YDp>Bzfb)Qavr6;mxWiC4)b&rM^-JYD~9CXc>aO|Q*H8F!{7lQItyga zvmm;FPooCZ;}JA5B8$={v65ghyGNzv){W7?lr;^fSquPw)37>*ukRt*G0emUd|kH3 zDLmloG;S6!a_`OMOr-Ywa;1-eY)6agsV?Fifq;#1QX(Jx%13pnMgS~ia9G9(3@6FK9=}FuZ8i1yyE@Nl zQJNG_d(qNTO0N`fK*|W{q2LWBu5oOSf8iDA8$LLeeSkX*!Y8H60kBGhn+XX6gRP4X z^xljvKnR=DI`bwqb~$Z}<^~%VSit>&nz82$1;XBp!G7MqvIM-oKsDVtu#!ee=pg?q z@NCe{0+w-ZHE2I5xQMsPX$*2)L4hv!fTM-E<^zU|oeeQ9nj-8tOpnxm$Qd@23q1m4`&EU6?xqs%o)F})MX%A7YRh>`QbESe zk+aVOE!WI%-y@h-IeCOlM>|yjG=#GYL&3BQdu7_3l9Qn1=tnUF>Ozl=@x&GU;*UxJ z(K`GL&?`!~);`fG>3W9ALoCQcKCEI0E3sYvy&<^AJt3*c>N#WkylomaW9J(zQNIXc zaSOR9gM!H&gf%mnRC$vi*8%_p@v{!w52y@w%tSxnj6Us4n3s_|lrhO_{tb3z zFvKn23T}8Y)OP)|9o_QA!%w7SR2+Y}E_Fe$(JDe^trZSHug;^8!*@9H2y&%LsU@iG z;>k)AA%kIb69FAbyqP6maeEzb1tUwevOvGi6*_b*#Rf{z(T_G$DIiM1k9?1#L#GKya(bn?2-MpX*^aP5gwySIRvms4}J$45M<^or4rqvu95bZY-{4EDK0Z1Da zj0VO~?VIM%O=2l55?8JmFi)eWS5>IzX$1SM-Pe%E6|JYq7|~+|_cj$HokzU=HQfIO zn-)+XutRDM!80C(#rcP=%P^BwZ9mP+!T z$O*FY^yE=PO=!6+pHD#eY6tz{qt&tzpa$OD+0~wS=$a$tE9UR|z3bN0)cwX)R1$|@ z+`-O|m*y2#$!IY!;*i@$Nt0~p^8uvr8;Aa^5OM_awQ(%wB$rTS1hS)o6j-qp(?_i; zka1GX*?_|wt++`P)?>xsI(2C0HJ+O=Lan=T_U`4c8#vfE<)p7dtjRU9bmtM*M=hyy7P4Ji5AkJcaULt$Icb=gDWA~a9hI{pZc#gac# zBWHjLf$*pBDGp6p2(6&Tk>lJp-?F!Y2qZ^AAq7ovf}jfF6fc9xS*HmxYrw)dRDNL} z=^u($H)4DG%XL8a^?#v|n*WMA!DsrE*_1)otHx-4`ooH?pYZo7^uc$mw8&gZE@ZUI zXa}TBfF*+y>ARLig(>}nA6!Q&ThFODU$^IPpNnWEF|J0aO^Uh9i>wbKwY4=|!?9FT!7jJ#YRQ z-dS`Pn0$#kVODEVbsvX9MH!%vXZFa_+~hC zP^~=6K=kge=_2qIBU{Nne-V>9tp1`rN0E#$A60p^fBbG<8ShoeHhEtiR|&cjN)pCG zIOFsD!k{7eSMXff8a34dIlKb8`T4Q`sF&^fd$W^eFJf<}S9a`yHOZ2>aGy_gf9~#i z^`|t$0mdSN;WYP{WnlzOpU>w!Gz#M36o7yA=}F#z(T_p&!kj>RZ5GBYf?70hiIl`CyzD zr_1|y|Hog>jrC6-DrRTOq7RoTh9!tR|uM%9i#mH#`*>k^;W`y=YeiDj-_XgDi|0faww zr5v4UTRwpLn0Kxw-XK%-rG1JJ8d6GD0so~UMw*!o77qo`9>``T2tIltto;yCA$|>j zi_L7?Gns0}Q{GY@2nimD2*RMx@H`S<8AuDBQk}9an4@&8x^s5&wTCyZcs0ZdozL1l zUAAOKdJ5?1a7^Q0W)V2l1UUm!%?PI?g;+FRRdC7*o#HTo#AWVSR#p<0f?e_{mkJ?1 zHZWWO2u>!{z&5E?%Pph0i4_B0Q$D7uDJ-L7VG5BAS}2BDa6!@wW$`X`J2&i(j!MP~ zAtYBH5HDvu&3oRkr31se5$nhk5NigdNkv_ccJyd_`F)eHE|xNer9(K$jvKub)usJm zvG`sUu&O9X!EH1~MrK9}+aRy!4`XJ~2PB*XhK)R$A8i~S=B}?glstu31VplY3%dRq z*vj|2QGPAbO!vpp2FMRiy1~dR>H=F61vhus@LDYTxd$oxG@k8xTXxtFIb+CwAuK~1 zL93twW}H+V4@edn!9E2%@D-qHffE9X7BV=^cdh-r1!t{o8A@solvB+tUx6o zrYEVge)HYIYCndS*Rstr<<_z}1omQwpScB9sg8J-cK!7SIe@NfDEy#@UWx>1#+W|!Ek+% zA_O7T&M0&`{IBQidtT&Bzb%N2)*7BKqNn#|aRvIX`oM}R(3DZI#f|>2XQn4lS_I=5 z8u&qpi-g7$_!+4x|4jC|4ljqN_TL@0Up@5N+vB0Zf_inb*AW^_(lUfjba6Iu2CE0$os>#*^I$wV1R=z>h9z6 z^ttFrZ$pH1LL)jA4KN3zbm5=9Xp!nKunOdJkcoVOO=v%7@uwI9fLx%&9cIW#_D$&| zD=ijXX$Uj;6M`H();o=RemwB2B$ZVL%%$O0loB~tkaiP;o#jGmL}bCJX- z8BE$&zkHFhID9?1Xn9&;v}_p$H-3HqUR+L;c1K)}Wj{!N*)_JIq|V*Ge4|bcfJ+^@ zB|T^C@X1Ox3AlDP(?leG^G>$jkGWsueDA z2;8u7$j?58x$_wrGH8E(6OQcQ%Z-53R|7-e?JZcBaD!ctuL;J5B5Ubw>getN!aQje zPgPc!p*!qgezw?_GRcza`jqGbY}pdY94g0>rW9c#;Yx2?w)k}K1X7n3Kuy#<1kLwG z(KchLdH+jC9SO4Ns-D535jwoIg^mdqKD%Kn$ev2nmq5;}8)N}b*g zqM0wi*jv^jK`pXMCb&fcQKr;5_n&o@xz64+7det|_(g%YJAQ+=uh5Z3_sd~sV(FNf zi)?edu&d)i$46#!ZT-Tn3p<`PtD{NU^l$k49%D+p{iV+ISx^Lc`~EYInHdAQE89~+Yx&)R1M_rrCS9n4 z9w4r$Lw3Zy{X9bga2WzM1mF9l@KKnD8d9CDksw zjNuNk`dm-wbhF@iVVu2|abXW1mT>XY&|woz6IZW)9W4wd?Y~%_tk??9I$pvU(g{1u z5)pHKn4AI?|9&>tXDs=ZwbBc;EGs!BXijK?Q?gn_s2p%n>Caq<4D)tUx2c4P(rfm? za)n36SX1y6s4zkJ!>av2iQ^NcN8SKx+qjcTS6?XYs>P+)epm}g?gs^FQhu+}G~+|s z58mS){TMED2j%dvz2Q7SgF#1QHqlC?ZU*he4H|>cqnl>>Aq9|8IqA|^) zp5&xlwf9asqAdUCVUavfE3e_m*A_q&CZCSQD}^zed{uMzlh1u-!p7*zi+YXY?atQoKySijSEFF7i_ppE7!ONFcM$~W5FM1PcOV&1|JDXheCD;uk zAacHeZoQ>VU*R7FjTS?04?|JR3FhR$Xq;d7?$!rOR1asXT&%~st z0ER4OCowj#FC}n6?Bv^+(9dAs?iGvV8VC#Evl-ecC{Sfo``faaz&Lwd-Ai3)vr2Hv zLm~w7&`qFkj65M&2I0ywA1eceXu;Z6K*6$6->%T}3juHG_YGgcpIc#jkKoT!ylZ90 zD{ZTMEuCCg7h#p2v7`3Uvx`{K7;By&y@A3ze>OJeY^J`DU46}_^#(76&Wnh>{a$C@ z>h*ZXE7z~)>|I24OORJn1|=KHVMx{uDAY;R#b8cM#OiI=F_26tU{JVIw+^a zG7AzaKIBM)`WWey>K78SHRPJ4MGC@JEjaOmQ zBVv_n=-6h$(O;Y{e9lr}*YltUk(h?x!G4P&QYqNm7us#S^KT-mZ4*a3)N#If3xa?9 z68^Z@{rXh=MxYswI7Xg^%Xs&=!dL1?DS0ZyVud}wA*{6Lscyu<(ajx1G_wo)+mxGu zVsr*_Z7mJkCj4h}c~Ym9=L?9-w@2nz`$I(-hf59fo#L97RqXDd#H*EQE$?V#@IDiU z&m66MI_ypZ)hQMPZ!Y_{%-Lg?e*qeSjl`MVpY?wC{Y2kTI(A%R_tfMWgvJ;zG458e z6o};y!~N%x9WB4LL@aP9Hsnrp5o(ql*MYk5+s&EYmu+yH^dJ9d1Fb3aA1{gnO?tab zp2xa;qh0dp;^ubP;mEcW*n|{(L+PZSHCyLIm}1$+tC7lAWmNKxSNv;yBlDsiOM|If z0^8T9R`0z7b4=J8Vfx82V_Hf;<*>o~eF+04I3w_HRz%2v=t_8s&cEI_S<+OH@(IBs zDql9!{hW~D;20N!`2)J^gTaLnCwKU~N~OX4bGHYLC;jTX8>yc_D93wN{8_Ntb{TfB zVg3REIva|H-h1{JhKjv(IAB~@c_vE}_R=~2qO^7lrOEN@wLyG`H~p2t`@c=!o}R_$ zyUXX->Cs-#*N^E?gzD!l0IitZP_Ve*PkY`MB)V0@xGOdqshqKoYBW7;HFSp+?yH(7eRh$n~G@9DPxK|@UtN$m(> zmlSTR_5{bf*nE(ePC^1KfC?4GwQCNvX4Ai{hRv1U6o95BK+z; z_`8*;nwX#xxqHKN#q;U3p+$B<;yeM${HlBbt}gutPR(njC>NU5UW#T)+tjC8^WRly zp#>HV$g6yu-O^fYz-=gs#LY59c&*1PpvNB!!*1AmJZMWB(Wb?JuoC?vIJNOGuhcEJ z%b`i8v`2gLZWbv%%(gQq))4c!6gf0xVHYWW`i11H(v`(vdtitTnHB^5A{Ge4=|>@_ z&Sg_da3~`GLzB+%+|hV zSQXqgn8XvNeDn8IDZ?K%SkkT2(Uu_o%m+X`n1w}0sOQXM*s1r{0k%(W6Y=vy1hc%M4d=Rh=0*Tx&M z1!QarPK+65J1KDu#&l}j_3A89j-Bl83qfQmXhLVcdPE{UH2qjr%71VPpqQ94UDD^M zEomS-Dn0U>X71TGmgKryWq_*Rg>7{;0m++x{9_e9TF^-6m5AVnI#CtgK!o6nZQaYu zNe;}{z@6gr9E3>nhM|^ire4z2RbT=3EX^H5pc=Cg5w#o^34MM6-tZ<3>SWjyS62#jq^Hz zyQoP+Z%_J|2#K}ig8lvnIo1wM%6yJ*k+x=Bq-3oB8jh%}PT-FsF=Iv|(^TEU*{n@h z{YC~`M)@gb3S8x2}^3hT_C!0qA7reRr>{GmnxP55*32KJ_iSy0CUygh~ z(FqgmJp~T=bV_koTqt&%_W{=%=UnWpOkS1iBIR4-SYDNq3`)b`y}T?8W$M>ml=wE` zwLt+VO{$dFE)y37cxIIiIMWHg%C6`P<%dMmioa(rW9>!k({Br!S;hyIl@Uow)ClpH zn0mrF#cTY ziDy%*P33eL(qC|DFj@5ug3gQ?rFk$w7u6PUa&zsynNpcc* zXB8S*6Y^Uai}N^=xr;9Fg+dI<@G)jn>;#2(%a(xdvu`CwX`s{v3zsVFX*i0{ghhk} zgh3TjQG!VmY_DC+VaAq^ zM4~y*Jr%iX&!`XNB)kI&wJStuX$iyRR&we+rfj_GiGzb#r;<1@wmwqfd3hG!m z)~>={f@ApXQ$g6U5fVv)4GvPE$r~bU?%iTjW;E6`%m3Vzh!N#dGaHTXK+|PR5Pye> zMCtSmB8O*={8BUi_%>TS%6HPd*tK=lWNR)|0=c{GF4r}eXuzs9jjBy!!yezb2Mcjb}p=w_{85-8Swwt7pva`-*WQ%}G#+o3rIKXkQh zz8S^oll5)#kDt85Kc#k5chEbq3-2y#+(vG)D(YX^#adDBoaj$1ji!-wekL!~{|-%O zbvnT#*XI_ShWgVbCtx-psWJ_AXXV&*Vi}+XrC9T&H6QHh?|^4#GP%o$d9+{^BX$xL zXt7eKmC?-Z?fhtNd9BjzPv?_>!B@Rb?VnFRZlxy3OClwkY40%{JASD?5A|8cUz-^B z-DtC>ip`WcT&E%ouyGFWTOBUg)5F?Aw7KGW16~9;x;xiwlS2nLpU)KzI0x;&#A~0s zEy=5QN4p9XJe9}8QoK9MvO*>~2JYpAp>)1rIMBEqZ+q9*aC%7LCj@86$BW4DhiCF+ z${V@~#mbWwqfZOz*6vf%#ofJx%_JHpo`s>}Snt9YC)NY@ijqu@da>r^6WcRO(F?!Q z*zy$9duU;zWX!4+%#&H)qgh{RG9&vlWt-{0?O9QftN&U%&Bj+HP`q3xFMa#yLug~B zmv~OPu1!O`OPe0=`yf7jiU;)sH#b}yBeIG1l<^s4Ubrau5r9$LT z<3xMR5;St@$QZ(tynze!nLK>)csmTYjG}Jps|&e;j1$|P>U-7o=KGa}t$f-=4vO;o zM6}=0@0MAq8Md{RNm;`{3l4C{UGE%C9Q8(S?>IV?b?afwv}{cQ-6&IH263|-aRKcj zq0Uep3dP~!00uqtbPte(ZyU)}@2A#o4$~WB3|+XQOal*KY&3~zCVuyr`h1RdQQfbv zw9)5Ze^orIuTz$htx)E14^T{V%OawYsZL_;$Wi3M;N!uBpCe0VDcaa%3u`iREjoC zz(V^!;p-xxmEeC0jL`D3TnLxj`DN{uy75@#RV*w`}P? z;xwi<%jZi5RNk>>mI%?I+!v4Q?36lRE-}}k2P=FCe4IavLL)3L{V%*j$l}j71%XN> z@{@Mw7PFmtQbim~N9agVlmC=SC{Ip+wuwqyVdaQt2mc&O2x8fx0QG3|Uby;Ye$xCg z&U>Dn=lQO4ifHb(X zrvqk4(;;jyP0kPX>?Bf&tBx9hp%zVY2MK~3It-SfwjGuUVjH>}Ggv)E9CVTblt)H+ zwQ69!*xv)wRP?(@g}_$KDR$CrF9byhk8-9MqYiKfg`3{ezmlM`n30(0(}g8sd-I`zt6Q)Y_psnLeDLm69jUe`)YF4o>N1}ha)s2Q=`UKdn&k_I>?`71(Mz#Sl-hB>!KU?hTU5(BQTWgRk80 zH6m($UJ@BeG@4kQb+~M^2_I|CE+0t+a;kQO5SZR$N|qShK2F?fn4Yjw_u7VrrER1q zv?w^CC#ES3qam{ZOHG{3W&Yn%X{$$Mz*55sMX-H*87H5gj~$w%Qies%L zDmyZiI`hoV=qGY43)&?fuCDBp^{>_boXkV7w3(!75jlgrIbtCG4nnV=$Kbm z{Mu&PsE$SpzkH+_snIA+k_y@G-#O??+SX0mmDF#K9i)E$t$dcfz6*Ha_|)4)T0lzJ zTJ#GAA+%iN6I5Izm%ORFgz%cZ;R3)WJf}$3T83_JM7RMLM|Cm zOpirMOb@&Qy*;_Cewn({C70|RKktjR8&d5?`WuFI=YO;cn)g_yNr`ij@r+;`TmQuc zD#>B9oL*zyMN5~qSzC7Z>zN`GQ*snd2^8!F14Jv;cEjMm*#~%%6s5CnOvX!nOE~?( zA~Ms!awSs*ik@g*>uGYnMmwP^Jf%ST5Xd`rP6l{?{o3(n_@`18!3(Mi>CaCy6@oup z-{WI*Xz&`brLM>>K$60ksDh_qK8jfale{E%PjmG)sk!v*(Hkc3IGE?`i@atci zM@X@b{Tv7=UD5bU&V?$*zwFpB<{AkxrMzZLUBG-_88OFVbX1|#u(NGG_Eh)oubTDw_4tdlgUd^+Xk;j^X~D~n%xM>Ki90P>qO&>(^nt4&77dIY{SZ(JVG&Y zENDedB16S8vQ?odQ4~tF`9Hc(l4e(Q)4tOtJom7TM*5lVwNSG+&baXK z?$*%Q#2j8?vA2Qf}raR6NO^SJmobINnnsO=< zz{V})>&ClQJDQfArw*3FpZ`q602d!T$YLxf&q&4a?7FQxVdw^6`0zMcQJ}#ovWG@z>)K8d_RMMrh2N@&h z1swal3t0)A1l8j!<2hzdI$W9IH^M^vL^uzm@K`goPr`^ufmE?1R1K87o=cYw6@Ak1 zIJ8)UfzYisgmoxazmQ4UcknqK zs;^r&ub65orl=ei-cY8r56&x}5q^H-bS3B&6WS-i&gSkT9guX4ENMspju(2ClZbpz z7+Oe?VnCR6A%F_RMS201g!tWz!k>y%O=)E(Z-?XfoG7Ruyfb8Ngr(vRwCaJm9w#GB zjU;)8l!IKYc^`3yXn7_^P8ENK<#jxwS9gO_@b#4YU%JgPm%gc2{DWi5nz9Zd%QU$o zq5G9Ckzs3j0ZE^2uK88;z$^_Pt;Nq0B$Pt`Fe-9CzA!@u*9a4iOLCSuaB2|c&iQ?q zyfl=OXxOb5h>f#h#fmDNw*dkb{n7#Vkr~7{)zeBLFtU2V#ust%mUdd&r#wrDD1)Iz zN=+%r#J;Y<#~b?BgZWssuaca;td zf5j`!aK?zJ^=bu8>kRc$-Z!4M9C}LOco7p3!96@|Lr%TzA*G*8H4Rt}jhpix-%()K zNGnQ{xSSwPDZEsumlGcbAkY<0ejlzExrq7pIo5`G1$&|j%weuOPDMhB?#YZ?d$n75 zroYo^$7yR=?_et38J+4^%;;i4pBHU(bR(}p4GnM?&)}K|Oo8O3q0_zB5K&gvb zh`R#;M9%fo$l1XePcL5|FJJgYece=h=CZ6ttMzm6tagK8Mf5iKO9IweA&SyRhn~aS z5pPRy=E3BwSZYdyc;VtL)Z52mlh5QMkRz~8yOZyfZfiMwjc*a3&TX1 z4$cmBZ-YehoclNo4^BgBMv+TuxcVa^%!-YM-B_?o(MKF@H=98A6}7fX##L5y*F5Rk^unia`W_iHoh^JC9Czs-eu5e)p9Rky7Dvv{ z^WS!OQ;_fY)bAjJ3$@l1oLk^7+U*MkQN}7`Tq#?xhUdVT2>6QJ?`9+!uQ;F&>5bUs zUkP_QdKK6H7)5kRIzoCt;*#=yS>gsNc&nLLB?pdk>bOojmf|h>nmM${Zuq+ zW!b+}lf!VR6j-|$YVLm;oP617p5BY}Vad*t<(I3xa+dScrCnb0Zu;%^8!h+6Px>jw6E+;TSOsNbj!_Q8>Uq9tv? zR!dvBiv^B%y_xHaG(Xh?d}`xO{EgBucU>T0;+xJbIUnr~|nZ<0Iym+?KUWP*9R2YSVWqXk8I1(KWQ%OP61L|#^=oS-wJ= zw#}Q%$JO}a!%G>-`RnJJMblOt*9x+Zn-!-47iBW6H~H4zn~fM(Yp9e7vW0#{N*0~7 zo081xwMahH`gr<8P03mE9RglegmI!a2f(f8T$MEOIOY&{wQ&^)r{D^a^ePS zsi~l)cAu#w*fp2bNo1|?8Ji|6MXhHzFf~n$Z(hlZukThQGzfU#W4834uRJo)+97ME-4rgin4!psmocoKVM3k?SbDRmqF*Td{B69Vz+e3 zlS!ovNVx`b;$FJkoGC%#CQh{?eG%o|&qU=roZ+9rNb6y0^|GHem**R1G4+|8XfSrt(ti6?O^OEX~Y0IF<*4`aP@^23+p-L%p?KAF}4n!d0(!`pIOP;=S%7^5H;G@5vsJ3l8y(d16J5*c07i+^>awV^ z5qYl`MyuW(L%n-^TlVa`QsTYr7+=tr<=K_Q0;h#p&hGJty?F1Dxy83^opx*1&-E#_ zD{<5+A(>f;ZhYbrQVjJGP5rn84%&o)iq>>iX7=X4ix^GQ@8j7lJJf~BBkiKNrWv@m}|dq8tNfElq|?%zUY9e zjZ;7bJAdGc-MG$cb@>!UG(uZ~TSIW81!5yrax1fTb!|9)X6Ux9Y1-+HnIHK@ncn93 zeSPzI{TspJTU>Kls+Ji}%*C{VozFcWDEDgVD;Qk}T3#J4yayMYqEwJKge53NJqlA= zh%RDA4 z%Q_p^C%J=G5c7NPI3?#5<4Zrw&Ng6@$UZGisF2|crLPO7&&KC@1o=h&H!^aa{TtDzJH{Y)~6ruyg*?j4CDbf6D{ zBcJ#lLmItScQk^_#i6@gMb)(R`$RZr;VHFB`IJW2c?*AwhytOZP)R|WU{v+I-9xL3 zY>9!B>;G%(Dxjilx^zOPB1@r8GzhC=C*_QnCmlDGeei z(nu;I`hW2Kf8TlE@4W1J;G8}DesgE$&dj}c=9#O2lFgkavy9@ZE%WmESgkcMPZt+m zm6aHsNl2GuqEL(zXVOh7F|CyXCoO{52V1MNAVA#OId7;M?x(;8ZY`G=h$MvC(GZ#&C=ov4+qS$L>9y@|`c*9gye zYkiOVLYIznx`nEjpD{PFHM8SZ-_V8$jL3UQ#r`1810;IwiKNFW=lLQTWurtC8TKh4 z8+c1~GkDHoI4T%=>b>;Z^ol6*b435o!q=|t^9pzT%;!z`yD&tW*61*RDE}il;C>vf zghziBMf^?)HkYc{u#B}fw^%(YQ#pCc^X(Z2QL7Z`?l&i3B`a+NIS`B(#Bdz%$wqwL zC~s`3#ysXgs4^PIGCXo5mm+!^$NyTdCs}%F@ba_OURA-FXItd2JhlGfvgaDbNAmVh zfY9Hw($suRvAboZp!->iW(DzmQ4?>HI6r;5rEmvlgrqO$NBR&ZaUdpH0E7&g!9>QK zAKweV4tb1&-bqXAA6q0q$Fh*QyiG+u;J=u7>rfCm)y}eiP9r6?q}qJAVV}n4*i=;> zqMZD=(QRm^B5>wyu_hmjpS(Q&>PvDkA&wmrgyQ^VEBRj)GHxghCmUC#PqF704LRbN3l*kM! zEYer`)AfsHLC3x1W#AGCr6?Cs(bwgTm<0Tn9|YJ|u&{OsxG1=Iu;NJ_Akbho?1N2) zw?04TI7)sC;+%o7;){4_k@x~woOiehkikY_oZx&?2Z9S)bv}J1YB0GFxflhc9-Bl3 zt%Vy?d7~5i+v^-(m*>w_5+Vsm_EtBe3v*Oy(2j+MD(6>XYAMtF^ArYguEbkK93(I$ z`>TcgRoW$^g~#`^V~Tj_f%*|~nt-|at4)h-*Ty=(`}=J=?yZ|K53tZ((C7|2b`K?S zr9YavQI2)u|0>5pQ{H6nw{2;UNv^zQZnEeFmIq-2oh zrY~K~3=?U-o-nKZjxzspW!>^Rt;wZt)*>=GI31h0at&Hcg7DI5Jveo56Y|K_EZ`B| zUn-I|{WQ8Wvu;#ZRZ{(up>#tIvo>9ryvcMb!<|DzTs^|ZM$dzO^fq4;Gl{A^S=ss| z+m*A(bl!_eQMqtF47Wup(sOw+6H+G}H_`+R=*z=mqHHgb(tvNxSmGGkALPU*vIi{O zDDl=+$lSy^Nod@39_{}CW@`S_5#J4NJU(1Agn8i(QjDT}{L--p6x5ercTxpIt@(S& zth(F{bypc}$2T@2_|>PsXr%dMQZyu*DYx9cMtu5cP){nCvRcZNv2-#&R0b4@MV@>6 zT5}6pbPi-dk*$8WEo@XRK-)N;M1J9|e)tn?`20g{?z?_W3&Ut5MO#0tam4)sAadyZ zr>zA=_HK6*U>>Uj$x1nzotj@(QpYV^#~W#eQerJ8trua$xqFICAEEW6{3+w4UecE? zIEDI3{+zs)nX6O!IZfThtqT{ZYJhkMu?n99y10}j#k8jIZeUS;P66WQ z(;4zNzhC{z%d>pjXJ@Els%Y$YjgCc40d4SehhLlmh~7B!e$?}jIRGgf_O^FL{j!F% z4U(-92Ds`=CL62}t(LU$s$FM~n8q@%*{fwy<_lMdsF_PWxiSFHTOfdL-Y7{XQ$wpf z%MVav*%v?>*ylvGaKBI!!Vj2cKxRndliry3rm_sXa0(jdUY2P(=jxTrJP$Y*3yeTq zwT0)*g#e+%i!YxfN7 zSmUThN6A*#p^bWYBxY7M!1G3qaju@b?KI^2W+F-%f_a5A zzM1bhJj#kSb~6KXGcgvp_9_;6T?21yxDjsN<&_*7PVtIg6rYmIf-L{0viv}08T}}u znMl)P&C#c_)e*X`FZxp8jir-FlDU~Fii>^rtk|LeMnL<>hPTBbET$$dxoh@@D*i;M zsPVq2&n2l~Y#r4;$jy&$mX{_Cj0fKfNF{3ygJ^>B(pgjSno6tFCuZ#sD=?#Y-{a zhj89=JefCr@x|QYg19AFIM@wFs+YqoBN}r@QKhQga+t4*%`XCG(}87le$H4eW;e~leGf|5kd5B(EtxYxPoMJGjN=Y) z0b@EuZk-YhZC-Fm`!?&<`RfZ2%)xJR`Nq(g9#c0~;P5xp>O~nfbZco!d=L$J$X9J8 zLAQoAy93pr;F6k^lH|&m^o^7;D4aM}9Vo`*Dg7=n{WzaxbQ#wz1rWtB)D(|l z=rZhqwaqr{tli29FS>DN>)ztOH1xAya#+t&f^EcVY4T8E3TANV^a>eT@svf-yS`Al z)-50+AYyLL7=jKc5pM7kmgg1)tR&dhYtwXM5Xlp30E3l(pPxZxKTkS*Da=kXQsB11%Al%4OJA2yK=eh_QD?kl)b%?X9B5^E`eBlna{X-$&$L7BSp z5?kEG12z$PUxg2o2uReOxXlO-%+_?K<`5qrg>Kn>>rn9W513Wum)4Tu#AD0QsXR_qm2d% zZgI;2L(aJrMZ1Qx@d+H?kBmvL$2chf#XgZsRHg_`xMx1rTdZ{Fu#R(ui%Iq?dS(>MAz<|#?m(3(xC9OZ{KcNzyktM+i5+^-HAK46n-Hx?%6g!Q164|F z$Lg)ByEf{fm6*w;ixu&PDmnK1(W)Y9P0ua@e}lgc6qx~uy#&63?ihUqU5Ix6==^O) z+#^cjL~i};9)iIixab0ZdVA~P`QxhDFaBL4ZEC8Q1J`(+0`zYc^gRqmM=h38@obe5 zANmw?omdYvNZe&$%!>`Z>)GRC=U3u@ApxG9@J4IAKV0V4QCLc#{o?s}`xWDg0cvbo zS)mDMuXavZVTiJ}+!njZr^@?L&x5x2N3$EFYWY(UBiuoL!*vU}?E*{pt4#$gsBla1 zgIsTuHw{f0Lpe023dtNg4T4tgj?8(rHHKeffqlZVxHA=X1ZZJs6h#9?-ZlBHAAxfZG4SU0%= zG&UR;Ub*2+pDc3SILH}OSbSh*&;b$R*!=%*YFKyp0CuUtjBcaeH5~SLui?|wbEr2DOKmG5uauiF{)*k z@!&24Rn);bup&Dq@KiQCBaB%|xS?`_gaPFOA@Q7@JKH?m zT-FUS+};HIjxDW6ZAa(_lWNxWa0cFN=Q`2x+yNUmcO2l5Wzewt2H*z{KrfDgj4AGt zJ*`Vr(t1=VL|di z>uCjinBPMZGX$N8VKT?7&h>!HWT?p=%^+3JiU?g+(DNX#Gfk~!-iRYR3*7nLG(SbD ze&f7S(>NGvvPCmIH?9YzAx8~#N+=5<^=Fo}cuzK&p16(Nt#2U!)?i)P&%Vcg(^?6> zi!*S$R>+ojdZAH+nZL>XRM+HLV zAA}ZuZfMQmTzi~SxlNczP{oy~oIFi1N1=}1a^nD(hLtNY+|9fqQgF(K7pVg`T3Ngi z$a(a%T!YhPZy=>2v$cUgIHRVMt-U2-iO#=!?v*dQ5tju|4I!`?lGZq%J0^x(t`Jk` zYp$07fv@qq5J}diSW8nbh$ocU@pOu$P^~(r7@jEX zokrDuO|jcG_T(yxNt=3fL@y~@n%KiQg`y5*iyR&2fpcDN z1t?P1wSWOHN>}o;;Gy625XodnVvGsw0V<`#C=-xj&q|E z*_>rNQ0nP2CXl6C0Y$-6(N)Na*LDb}rP~4Kx=J>5`18V->I}xRa~j;L`Sr0<9)vjn z0N%NGFU!l5pgi5uBS@&^k}{IXFLM*%%un4`7Je}R(Pb)&MgOeD;LD_EJyUyG(Nc|Z z%%LrbCf1Wg4-riMNQ|L|^&O}HyUCN&4IlBRwX&gq>_iWUu0I5S7l<(l;X+J$WF%&) zHITFE?A%+ZU-FcqJipR-EZs8x5=?6G?}Eku5saVsFTt+Uzq%>`f=T>PS%xMSKSM(0 zhOt`#t}SV#Ye!@x&Ah?)t^*S8q9?!$^%i9UIc`A5Qc1C}H;3g}mHW4k->=a(>tBnX z0(tGy`7+FzSetSXFHdZZv;!v*lBXzHIW(xuSXdPS4Hj;Gbj;z)l5@W*ds~YP2>Sra zG*roT2T-P=SqgS;4c!q%zEs#?&iD+}UEx5`)5e=_rPgqd_L?2HgK*!XJ0P2bgRSDR zDb*cY10+R_oB-MRbR1!M&1Ka&{mBa+FYAX*pWK3$RJG-mI3NDXySOUpZBbhkCy28( z1es(A`)+W=l>*C8X;nFJPp5Zr(A9plntYSMZ908rVO16qtP{RO6#>;UE_EnFQ8(qS z233PyM=w%#_Vxn4uc#B_FT5kB8;on#Y60mChaK#Qz*TI+WDCfQ`{1$sMI}R1Iz7=v zXZd{IhIv;1Vws&HMHC)ui}Pc~QVyIYtq+6;h40tO=B*E%WgpX^x|x^B3f_S(pXXI3 z`8>P`?f(8nWR`#F&NG~BlwEC&zjm`4zuUt(yX2X(7DaX#`&}TsS6yzYoE&El;g$XP zL@9Uh)@U>rco1}fAF(Z~LiK8sd}&Q)GDGN(x6sQ~mSJJllTy34pHRq%NXu1)`aDA| zyJl2f!L;Z2o}Z^TG%rWAjDf#O^1Es=ImV-5O`X(yWUpS}t?lq~Cl}jc7S}q_6^lzS z7zGc5DSJ&|p9qUH#S`dby8Yi()EqLaj*T96+dBA7ESSWxUT!1AgucHZYucX908;;{ z`X}nUk?-95>I7WV^s+H;9($?v+V`5Jxo({b*!S$Oj;JBnRgY1pPSw}*tw`06B}%9$ zP1hosdn@0TMI-#%7)JIkapPgm(Ke8pPERfi&9xgfP|_iE6`y}}afubOEu%V`_7oAT zBz6?^Cfd8KR-L$eW;3##$xq z@}a}Cn=+s!mrXZ^uJ0G*WMA~Y=S@dgl75C}YyGM!ych_?G4Pk9x*1xM?taLCwoMLl z6omV%cG9C|19Pmzp3|Lxm#Y8SiR8;tK9v>xRkYb6|7xSgZ`Iy+jPJ1w_78C2Q<8jp zpMb+|&Z_8h8hk#Mq_w(FClpCw)^|7|{VtSlZ^kPwutBL8*QCl0o@HG5H@biunX)?%p?MnmVO7 z6RpXJ>^_r2p+t3!7E@;;8m`{uG?+lV-LWQY?O7N;IyZ1yZ6oGT@~d;I90lvidQ_Y* zlO44#?(;axJSh@{$+M+i;`X)=bn>cXrZ&JerNJ8vIG&cNjY+KI2(#Znq$^hL2l3g~ zd)_eKpL!ljUQ~E5wL8D~E_(CI5s}=?sQHc*jyVL_rLwXb&QFKMwj=X|cYN0;o-Fcb zLvr@24+Eg`-W$ik4G6`gh?vQ1)N^uYFN zcL?~7%9UfQLeJ?iMBaa#KqUPhRudXZx8lQK44nG>K}jNlx0T%<#1g;Bk^74^g{G+z zbl7WPLIMu!*0I5PuTm&mr|FC$MKjj#@V$Dmr{m>umIQvFEt?32y@;ZC;OHcU2C+jp zgEmU*tCYdKu41o>M0bHAcGIo+m03B@`~2Dr$aq_01IIM3C=dxY_s*N(Qxic@2K~uX z>V6>eYE0i~;YY6KF1(KO{`>8zU9=&nIRZUHal_PMqwi3%Km5nPb27 z^)a1@f%BFQKFhO>hIF1*EieY{al#BMBGXo6Fh?8ZZx?jreU*5At(;)BiFf0y=nb4q z>QH*$>~JUy!29bd+a#r`z9L~g(bD}h-_E`)W-az@lY40i+=-X2V6jV@ugwJrqACi%_V zL{P*CRi9tSO}Aigmlm*_5u0TDFmV!+0%{)N*bP$S=lGI88EJ*{hEWD>E5rwK z?!2OYaev`GbA~za~$fHF2VQm zlZ##IGgQ4|qw(~+@AeLSw^5Y`9yzmSoy%Vs(}Enyk6HrSaIF$kjF&DLA29F*o-6^c z64sKr5QG$Us}zroZ84{g1M z3{8OSvv;qcpQAG*IEX)?Zw<#rFVCB(qn{hse7Fg#ibf~KWZZfXJko}Oy&G_lnZa?5 zj6-jS=z)%PQ7e_XsRn8qYYf7{LDYPStSjLgYw*{M#a43*F+wCKX12RF2SZG3hy06J zG17)Hsdo(+6y&I=a4V=ECzJok!l$MZa~&sgtDD2W9bv_)V9{&Ed}F z3cHqTiHBK(qiw6phFPac1$$5H3I<^rk#!7mk-%gG!nvT8;n`A9f>SY%(A21rU}kt? zQ&XTsu&^8}{iXEi`j><|w1CdbKW*ILXGu4m*QP4iLXiAoQQkIUX!@QNzC)u#j}w_` zm%_>Xb3oM{*pyg|1Lk~A(jXNWKVA> zgojFf+p91nY56v6x+*YuQ`yK%Lu1XS@Zbb>9(<~NZxAKhC8sXo^5Sj)_%*QiBv{Q8 zP2HDr1bACVl9kT(8mgZX^e0`1HSvW%4SeD_!x}Gth9E0AlqJJy%B2jn@wM|%d#!dG z`>lKmh#}D-$!OHeXcVUSx(LUZ0rRujpbrfzy~AkRdzd`C3(6<&{GxH>SNFqV`h}mu z+9LNZ+b>am?_0F*sP;IY!lX*{p`R^2oz)f8#y$E<(7F|+?{p_VeiHTT z@cY1Ed&_SHKd8N2-G{8VAUXr44Pj9(P@$wgU#q((EmH{g$;K*AD)Cvc(qgq@g^5hQ zPTaBMlfyvn=r7GWPPMqM6>nd}kM)UJ9oRy=Nrq@5h3+MIHi+FzsFSU|D=jxC7BaWO zs)U<4?naxgC2$iI&>9ldpVIasY8-AlXx58cHirA35d%g>0$9W0S=cRL?~|nV)Ba%# z%<#TQS*EPvnYepk@*>x#=_UT^Av)dFH}Cw+CjwWjoIfDN)K z7`_Zc;$DlK$R4)%Tl^jryy_IOJr|jk?m;R2x{5e8U!dyoiQt0>-08Rbtz@K&PhefG z#igl?jgfl-!Z6as#G=8V!5|FDF*`ETXA?Uhx}03b=Ak(mAgJ|p-8{;SFVPVukJ|97Qe p_y-Rq(SL>TgSxo*`vHvs{1N+08eF`aexw$qyPDg(8mf6Yn!D&TdfM4GtB%|E zGo!wxjV#e|-YKbL1&NXjV^`im>iMK-JyF&bUOno=a;K_9!8_fU{;>F=`C!)K)S@FQ zg5f*x$9ItKiq3McGu)5C0O+G(oNgdXz{hTjF!Ez=)Pw+>zUqFtUf}476sn3iSB#j< zQ)D$UcfwWfXQawEbJ$&X_6`iXCq#jzcFX#ceK?)=U+v!O8#pK7qqsH7tf~wR4=++p zn+P{h?%PHVWSgi#>eB=&E6t)btWMzrPR8F=HwciZ@Q^;Eu~!#qW`t`9(;R84@Lh>8 z&{R3=r@v>=_R2^G2amXjC?~S_4!$yDW1;7oYenLGCw7Zr37TJqG_&~rz#8N~9c3_g ziAq54k6N2a?rS=<>6Qt3;DhNET#SWbPZXKO_ws~G zNf!1?5(7;aFE|(&5fm7h(*M`?2q4=VI-A?NFfsmnu1W5bfn-4qH>8~C&as0=vs#V$ z(j7Gqi<`2tQJ*6xC9%=d-51khE8Mro%(nH(GU_fEA>FOYm{%O+HWyrEx$?YB;Q3vk z_Cg4&@7Qry3PwTAsCP|ZE>uNxY+F@14J{@}m}0|5|4ay6b|A{++%*?c=9^0$#wwc6 zY)(t}!ZS7GR2Fa>aX&;igvaDU8gU}!W1FvsH9>x8@el1^2a)#Eu2R?*hoB+`GefyR z1NRl*PVN@PtW&D8yDe6B1aV3GG;0X+>-$~JSbOYP28)-R*?Y;qK~O~S{>n_DcPk{z zeh~kxW6%0U_5j3P2I7CS4l3vyW)7xG&JK<)Ova9m|J+hOz7HPcmSUIw;v?M~Kw+`j z)Zj09XTpM{C2O2Bwj#e|1h;bM_a>MV$~z|OcH?L}g=*H9;xMH+W8)7s1W1;E6ujN4 zqVQ-Kyc0!)G_B6Y@fLx$ICoS_=4HR+zIqK%mf`iYe~-y9G9-@LnPHdw9hW3Q2zY{) zsd>TGv_Qgv-H=pGG-=zye0zlVM}C3)M`y>^V>t=5*jCW>|KDu1|4GNx!P)#DAG<_- z*#TzE@K2c$znrEt1(CI{V?s)VT27ug$)>ut0#ZdAAKg|zvF1A|E?tNfHm!Zs$X~#Y zV2f>XOEJl3`bUI4IQ*?WMkyr(9KStVvd=$35j*6_Xi>$6bhBaW;r=c@{+kD;qt#kjQ0N~YXoXIBF6`}!6?<2ZFl-X|j%*MjzBC?v5^5slG~ znJMMgsEd=|+=XMxT$h|>mRU|ZHp5o^*={LW@1e!c(n{MQ9ri5bs^I$6`iowYAO~0e zKO@fk{(}YsikJq__5U{_Cdi1MwoERT#?Izus;p z&HN|z!DtuZ4m`9rtb`#IdhhmN--$H^@5o_&J|a4F5Jn*cM*M6R-IL?WTOeLDvwVO? zB~3OC5M;oP>{I-j{~9tBSjVx2I^-3t5uO^==~a$ycdn(8syD*88)dzIRecX#jD*Pj z4q7Sf7suXZDo@b5qW;(INBX}jclEM0|Id=U)#M#=m~ne9HMJINzfsr}*Fy4CqR%0( zlxDG8t@ic7R6j$ml!bh}bhk*$0L&_#wUD3g2?R;H_?+Fjq=JaE8uS2!OpL0rnN{ou zRioFB@?K6Mm(dXs}+ zNvs`8#l)z7iscLJ?UPR4OJ{$Pr_vPHu(`LrfQ*kLYg9Z=`ciPG3L#V)#u-UJ1_L9* zC7dsXt+;{F*Bbu%L!JW1)RxJQ9MO)4x_y@FSTgO2Z{&9MH>ds2lNB$hx=kariTmr= zFsR7y4q9)nZKzBFKOHc&C38(B(&~j(yYYB&+h(nc;Eoh>%Ld;*Oh&jxL!m=kSCzg1 z6}*EyYRE9E-NBfHi8@|+_w;R|XqQBedo1%Wv0qWm$+K+%#1 zO5E%*DGaW>fGO;DizYy$^1qR;KXGNx<3dL;@hFOwlW8M9aA)n7w|`jS z1NWTA+4etnK9DX2xYn!(^1*BUe<HJ)zvIri&*OLJQ@U z$dRHRmpuUf%79{4@1|^NtPy#ZZG2OWGTS(77Sg>64S3;e#o#qGwIi^{QQhQ&Q47|o zKhV7(jW|8{$fv$9wBK2Ns23dG9Dpwlcp@)L|c2FVlG9!(AI1-Y`AqD)C(Gh%LhEU$7JXWpu05o07QYkH zju3U`^$Bk!Xs-{Bu+Qw#_f!U)Il&JRfh>!UtHG;Pz@#upBOB!XQ59^R=RR{{PX0sb#`ov&S=YM8K!Z|{>I zB!a#?g!Uh=qbctE$$aMtlJ(iw@-<&+|%>o+fZ^p-tz28G${onR^4DI}% zp3BD<+!|;FXV$PtKCcH@UUx>P1=Rztm(;JpusfpfxdsYy>PVSk-FH#I-EIt|hU z-%vK)KJtNEy)}#|`5)J!#~IV6UY&xrb)VXwdY~;yXDldJ59Epzuww8KgI0?u(&ZMuKl0k zmlYOTE_*hG@;!@MI@;bH1CjE{^!1Nk-+_D9StL;A;IFFt(pawt_HJxOZ*q?;TLu9% z?tvjk*0747E;Q~rzUTVB8zj-Eg*!Z|K3++eD4ViLBLcPIFz0&bJ4-zD-eW=eXuhev zXblMO%uMt4@ecOxYfQUIa;-~Tr@Kms&t8?^IdLN196MnNyHt2R8`l_P-u*4*49LO# z+PdH9{KMBKjbZsGxFVn7-?EPINnU2oqJ)O|g`W6@JP)EY^B&R?5(EW5x40CydboW! zUQYwwx7N;gE)T{mn9>Cdk(WrQ4WoBuKT7os<d5U}f==J1g3 z@+Hig>(MVHu%gAURX6JUi~>w#Oh^8P7b7Zh61B2&X*fX3V6$P?C*=}(b7e(@Z}*sH zmqBU;?KZ(T;M%6gKz|X&L2){s(cnez%>w4HTM6#l{l@qlIU~=g$`r|;`H->*mK(iy zGg3LgH|sy5j_w$7jjQrn?XGTR#_jbc}P2?@C^3f9>J0>xtevi!ORYnRejPd{%giXcXuF#2 z3HTZ15S6iJT*0(OO`xLqW(RrPyzD9B-LX) zS4QWJWcWxOr)G+wT}+DMVD z23*pjF5VZL5lE=~1N_Sed6=R66Ek8;Vg%}2P8spr0t#$!ufEXFwXA7~tas&f$3B0- z2W|YQ0Piytvj76XQRmlY^aBb$1{`-g`P+jL0PAVUaxO~ z8%6TW{k*j4FKxrsKA|WZ)z=I5^Cg;VyP%7nL2)5{x38v(>6GjF#>HP9Z2YNF^ILEE z+N84|Z=!f!9Hul9pg46{7}2E59%!uhj!PN~_!ho&WnW~6EkZaQES(sx_ZBO>`^dTw zgSy*Rf9#@1oo*CQo=z9v%l%4n=}IYA>#fxLxi=&niZ|$aKkPpqOD(yfXD4jr>pJ~3 zaz0_^k01IbEoH`cslrpjYVhlVMPT-)TU|@A#2$G_BC7!RoETsT)x2_3O*jXVkeGC?nq;2a7ujM%c3$;d zDh|%_({CwKNUxguAfENV_H+d=MSaaYk32AK(0^~(VqF_m=F-$fUCvu?}^ z&k$2-Yq8!*V=uSDsQb8_*QVVE*r-^kZ5aYxnhpAPmBSBHuZyM51TMW;{NBgt z#mN^))@Nwu-_^eprmsPZ%30zZUIdHB)zY6+IZ|YR=og8fqBypat;p@bbE( z{E&b@P+*k)y+kapDmYn@kCgc%F^O1#?E=DM@d;v9Zntp+#We4pYX~1Bjv?euHO(AV z)k9n2U3kki{cFTJAxohd-sUK)!hQbzJmR~cY`So2N(n>pgZLmLlyjTAUy+0rtM)`qG3MGqwzdh-IYDKV>dm-Mku zsTmeHn?sczbbJOI*apd+qg>?BZq${7Cq_L{bN)Tbf|Sf#q^1J74(nl8)z{DmIovYj z$CPrWMM(~c{#7?fCP2om3c=%?DX#s*9CE5u-#KM9wsMhWZ|e^)gCSCM6_uWU<|Gh1 z1*AEEaBq={w*2?m*;E)joTWLNEHpUp=MeQ5;*jngvz>6-*j$~#@G_O z2qxGLU+gF5_4A(nDL3vi|3UE0DZ8|(g{du8(I~pklZ;Y+1UN>H!!lhuWYm`fek%sBc z3YtGKN@mH(FfF@Co_GY%l>cY1D6--!a=$M?Evd4-%ynf6&o`A&fc8q7HS$cGeiXD< z)Oce3AGq!2C14j6iAKjI&MWiN-(1ysIeP}$hxFT~a7pd!Tx7?z{tSsmhxprr&!0Qm zvt+b_P@Kmf0ha$o*-wwJ_}RYr^;P?~oBBEAQkWzRx`)2z``M1vRs54O!dEm?J-EvE zlM$k($owE#%LF&3!h7vY9%p9FSj@z@mkq@tc1RcTx%p`s5|8>YKHym<+!HEO9vi~8SyJn1aP>TT}?DQWO+5lNp0e4sLbVny>oRV@h zCxzsB777Q$2XbasMS#3dnAs2=k*a)R)blnT{)#w`*^rBJ(-Yxy$-SHquBU}Uc~~Ap zVu|R{PD~{OB<@6_u`+-60-IeBsJkOZJ{yeGF8#b@5^gatBb5kDo-dbZLi{?jQr-Q@ zKke%73&?ju&wlgjcwT5J=CTONkpa$ri(EcEjE(jrpH&(DRrm(Q-@8H5WAA*qd-?<6 z{9O^vrzHL7s#bC4PtZCR&QReVMo)fcgxpYxm!4Xf4lQjMDCHup=WB7@0~Y??1D6Nz zYc(x!Y}k;k=EuA9mK7nV3J99HDU>5xA`*LOZ5CE!=Obbk{CcZgz0E)|3ctf!<$9qu zM!?+g1KyXn|Ms^}R;Tvoc@tCm6CUR?IOM%8dD1EFg0Bf#B=Unig7Df5 z{`XtxjzXdaSyEQN^+e;dbV`FRH8~X$>c5+aNJDm|z^tbuJq)n#L~S6L1=*_Xs3ZgY z@n>qWtNnvwpM+-v-R`Y54*(1PwuYoGE!>-zG4DNel!iwr%)GIfDRwoTnMh_4WtI6v zh}PN!IF0V04MC3j-N^nE$_abe7;L?6>MNS36`46~Oz>iY_TQJ+1;06R+xSeSU!sza zlaQ@!EXZ@DaruMUE5_e^;Z#7a$5Lw!49jbApxe?zgT4QZ+u}5;bx`pK4siEVvP-(7bxuzxK^|Lks();s1 z<8wct?$h22*!+?3vzI9V0ERInwX>40hF)O?o=F2N^Dj~oWMNjWkjISbm(QHS7woP> zi&fmUtU#4Coqfgc+fSC2B1wx9v0Lr*dN*;Sx$rk65+RyGw;l%NchZQZfB8KsUMHth zv#l)Y!XvV?@rnL=elis?Gsa)Sv7%SP7mWfTlKR_daBafP_aIsb+RJw(ut(ODK67%f$ zY~cC`adG{QRE`y4hXXptk&+9P&3@hZOA8{V?`o6~F5lSGzw{Vhv+@7=S0B+_2dCGY z-Pz5*F4g>bw9jA?j2Q<0gfnHqPNT>wg*l33=f9tWAOpu1+_z4Nd7>>}-v&VE$gD*+ zSnqwIpZz9?n)n$>^{Vf6G`k@S=OA#OK6If(kG73pLwYS4{R{ilDYXo8urB*$u$(>> z4Fmd`XmC9?WOkoDOAJj>H9hR0PT*A7&KY~Gnrn$_j%43va6c!UTi-l3Q;Bp_8PBD> zXe#iU8}+?Dh#Lhd9^T3uD5_U8H5b|z_Zyc*Lzpmy%0@)*9464Sxwnq$c}Nzy$hSnx zX8Myk?+H>eq^e9{>;%GOP%Ow9Hi>I5(7TOiA0xx!2f#(Rp(y}zBw{B-`0&Q~CB!!_ z(|3-h91skO+%euNqYJITlkzMQ;O0IOB=@yK42pshqZhDvJ&6kUI%G!AuDa-Z8P#G* z`>OmcS?juE#2Q4!SE6E^MC&oXJB^P|J7c9xtH(n^d0n zQEQI7VCY(+-pxF9dkY`>_f{+NE%8`&is8`SYzocJzf{jF^nFeOzps<}t5*c0_DCmx zvvJC+=I^=6Gny1_x8)S%IMvI!5h@nZ+=EhR$uh*L8UjYt-eI=hOYwim6PC-`p;XdBu4`)Cq{*8Z6`@TvP-6{YiqIEzM`~tK~ zYmJ1&2PSnaKvsA-?M-Q+tr!3>Sf;i&9y%(geLGNbSd^K!l2Ez8!rF4>`$;F>O4dtG zmazTM0%i23%noztold52I81Kj+433d#pP%wj))F5a4YR-K^SS#)}SidW@g63Gc{95?Q16e1!5D^%W7Hn`-{MYt}cDBBNgN zEIY6<+Y}>oNhh^p!SiC0)D@~5Wd2!6%9qiE|KJwq*XDt6k1s1MLVjQ407>OcCh6TV z>whqMxSKin-2o^qUXC?ig=gwG7lnFP!I9pr4c&Qpx3jVvAR0D$Mw1gmhRJiv1Wp!E zpeVXm#e}`NcDQZc?xd!dOZYytd!x<$W?@lJ@aji2AC;xOZ~nWvCDflyE`y;WFYyqZ zjy3!f$uu*32en3xebOEvvL_2Ntar0=gT!CER<%N|tYO*v$*TPaY^@ zM4!%WH|D8%_3xrHX-4dE{2ReAJIYolcEFFc{ZxJ>xGEjf*;16`An2b=U;VQ$`OjJ- z5KpN~8ZF3jvi=uB=PK=HC)|FjqfOe)7b#7f{<}wD(pZ~y6CjRbrq*3Zl(%SVL4wy` z`cMmP`TIp)Af+FO=GqCX#-LcAJC_qT0vMc)AFe>$`xic8JTP>PD+WH0U3dSlUCHxm z93|$aoFiVCiUH52p8nGvr)5{}jXr@Sm0HPUG#guAmyGa*` zwQLevR^BB&Rsl~)sy)BEx%=wKD2R9aT^DSjw10$&sOs)CP3B^P|GnmaTOhE+)jFCN~^^lzUBi?@o3{4&9 z6&~$Qb+tU1XvFe(HhJ*jE@1iyF_}uvLXrps+-Wp7v9}b_Si>yk4vKWqil6s)$Hyg4 ziI-KS1-R-gx`UVTT8j|+-FIA$^V5jd(yO;7`nJvvEsV7e(fZ0aSQ7|52X=;s1VM|x zbdB6+oUUJF8`kP-1%!$7$cO`nA%DO(XJ|&u4Xqr?HV9VV&?lYnvAl7es(<(CIw&`J zUOA1MEQ%T$x{krgJAN%|Gg}$o`}`IGHGxJxWYVZh^5Z~Q-jTf59(eSnLvK+!@+a># zD+1VoZR*Q4MSPCx(|gW1gb=r`w$w_$9(PPu_Lg3_r++4lki?vNZKSk=|J$*0!A4Ry zO#FSM6Y3ztZ}U1Vn*^rbRFCX4`q(pola+(enVy0Fe&Yo|MemEvQD=gCv&^|`_XbwZ z0o`N#63I|7R#yo6wQw8gsl*MIa#!@SFKC7u?giT<^UcWVSBDPKSRF&gCa*Bj^-%dT zih=ldjV8`Bg%F0joySHuRgzQJdj`&e0oj1pwp{1}XHGaOZCpt!%m~_)_{EU16-;h7 z)7so2IgYVRHJah}_zBtEQ`ZH0yW|RHVt2K=LemCg^i;{pt8NdM`CZ;?_Z}Zy6c)JM z3m0X7`KgS27>%PyScpM1MIBU0-%L?LCtr_~w^*hQXz5z$*71D8!{ z`>!Rr-{fB^hE0@%yeH=IfDJ1#MR@}2pac^95)b5XtzyBP3vN_8qCkQhz9ug+xY>~8 zFXJ0jPN0#3tB~AJ(W#IWi$1K7r0Dgius~4?=vqsIMgSxbkn&DXZS^W8`jw#CUrz=z zz?lC6m8dh=DzGzL%6RjkTMyLF& zwFAYR*%8q%UUgK?EqlLV9~P&_*y6oz+)sa+u`tUi_hhKL z^%&!o-7`No%%h4tr}Flv%os&+CoNyRwn^LS$aDLS-#9}{@_vbP9CgbD$RXWmGSn#GoAIRaszm6lC&^D^A2* zy-Cy<8J+UT-?!e#BpzK5prO$8nI&&ujes7NM(?!NLt8v*XeH^#%d~@xj@7fzb z?^tFUuc{YaJ2MTt&8y$b#05O~2+gGphC^2`=q=qE_| zfKK~`4v)Z#wS=bXp(ja2H|2H{IBnG^F?t`*%;8#%QcV>e&V2v6)1kvxHtc30u7{@R zttVL$eyB%%azCnwmE_1(ou0FPfV(weTKfx~?gBS# zSPkmbWLQmRC2ubIEynP7{ZyG82ANzBvC6`|vGj$(kqKNh-=I#|~gBr)VnTWrc$1a5Ej?o76D1;fGc@0NT(SQIb6uDxADu z{98ErjgU)tN|O`TK$Z!>9QTlX$kxMwkl_#{f83#I?Z0`b2r zMubF%XFGw*7x~dUTJJJ%zGOv`jwOr?-kAEU`gq(mxK)bu@t89k z1Ba01SO8F&KhaUKosW=qAn0gBO^w$$n!&)n7JCC4o)8DGDjySew7X-nxea^i($f01 z9f7ptEzyDHu~v+xe9YDKpjUMd<&>92hw@+w@ezqES2VZ8_c~u%>+rWElg@EB&(>~x zAbEZ*+Yp2i?sJPWAA)h3Rn!~1Gz3hAoT!pH{MRi#^XRM&(Vm*I)c?eP;9Es8YaFp? zQn_-_UZ=3XSq-Z=A8KNP=d6gp?f~I)q$%d}W6s5Pp9J}F0@eo6uK{!Z>@woJBuN-y z5`-Y(W8L9v2K@OPDuKtjg13co{}Oucp?(!%KTw*vZ-|Oj$rsrCr&HeJx7nR*7BOyv zd9iap8s=NEbIFKl<~>Nc#eKDu3^g5jgx*#1n|j~t>watwtK>D+?Mwe?BcZMCl#4)V z2LJYGRa+CaDovQU7(K(7TpgZ@?#5~+KcBjNb_HK z!9K=w_$_qJR8+mcZxaLTqxLqlV6d)BB3_4Q3&`T-v7f^$NN7uV`A}fSc+}?3v2X`05c$_4q7DUYA2J3Bhv0Ff$@CfQm1AEAI>c_E%H{k zZ|^jiPPKkZa=Lt@DC0%^YQ8ACkKl3Y)q|S5oE)lXrd`MAyF%)&a4dfQX9sc3k88lI zQC)kk41lu?!xZQ4)~=x97Ey>L5v^nPtOunhc^jR<#=IoGz6wZgYK*t+aKw-bTcr=B zkirA!PTy7en8>7*bh4%RIB-%;$`aIt;hy!7x@PZ7BjKRyi2SVfTihvbP1BvuP2)WR zW4q^eL;MS^Cpr=|o3mwY-fdLtFDyuROL=is{h^_pd-2g=_ZQP!=| zv2r%tyK6Oi*Afi;J*dntYd9lnGY- znE@ry8P_ZtlOnJtx4knDf5V_m_tC`e>u zKWbK%f6WvCjsIQ>=+zo5@f1i}z6!<&`B|eY7RgbBa!bvr>1>6(sBNdam3WNp8`mk? z-9Wb(ngA3_QU3X)SxmeDhcn#~0&Wa?-idwqoYE9}he?){Nq{8 z!Tl!{u_Y=TUwZq&NIzol6JY;114MJZ6?2pqrkbR62|5Xyo)br+OISNLHk(@py=`;- z-E}@_CaH(!(Ny1H(_C;IQs?8TBJ%gz-!OA=W6oo7FTl3O9h5wuK*@7gaFO8YyD*p} z9};+%`!d=u?})XHvbH-dYna=H;JdtKCsr*>MfQ86cs{Bxhs)e3wYN1PZrB6Ki=ODE z2c4G;=Ek4EY+Q||FZ}zQ{Pd1pafgZr<$0Wj|<{bl|4hRou*) zPII(p!OU8aHP$Io&}KHPx-Utu=*`RCg!|2K^x~BJ`-~gAx+=+@Yb71$_5f~cdetA% zdzE5_yPQTIze?+BU1qG4yyU$H6?MD#wP^Jdasf~>AUq<9=T(1zE`rROc0&YUY$XIz!$KhH!@UR;%WMN(As511`a}ULh78A|4lq;YZyeHxk6z`+QD8 zxQnh0v?fJPCL0107A$%M3;ANg*pv+5V|v4mPHKi_E$wHZswZuyyF=@D{IBY*675(K z^7UhW?FoJ_uB^fKwo)eeTaH#y^H3sbSHcBl4dCz2DO#fn-zKJ|>vSddq}AcL@2l}= zAZ=Tq;@NINp3~k7hPn{KSqEOw_Qhp(Kyk5hI69_8_=9Gczc?mX@QM{*>7$pkWaG(1kr_fSE6+X#{_! zov?Lzru_j-UTKL|eOdmu^^LsIbIT29329ruT$zmCBrjy6pJ}Y;AwPaTM~+p;M_5b;S+|p1)b=M(|S0!_VN75aOqE zv?o0InY{8~F58@CM=xB8@&sbR+(|AR_tW~^S{V9sic_N6yfhLPzL97|rePB`)2+YP2*w>E4ZyAWLOD^Nu-v=772PW`0zH5%3D zxF3n*ql#PyC4l5L9xV$v(iGcT(Gyi(@cpE17`Rz_tY#L~i1|NMFfw*8LjNc<^WKaM zHf%E>zcbwDhic6Gdy+_7O4_Yx=dW6KCr>#OI0^T)K>AUD{J3Qy?|5xFGTN`&(iVX~ zlqE(*=>v50<6165kc=u@GkH1Um;rn!5tQ<@(9M+9%iB@xln~(7C4=7+=`0hkV zf*dWevp7NyqIHg9$3Ol0GG_fB9V)n@Uu1#0=h7(aQVw6XHGF>YUq_(%mdu>#VPJ*i ztb&@&ZD0f>Iw9W1P7PXf;UQ9B9L_e(Z_#}l$T>E+gUWkdv6thc09%cG%S+Vd)jf@nDEo{#R%lZ2lo75y4Gu)S)b`8zMk zsgDzdbjJLvfwjVW1SZBjeI!1FRAD^&aaM((It}jYnjUIYR)<(i4QaB#KZM}3cv4m; zIwAVrq#x1~-?k)gZfx&0C2>ASr(Q-{aKy+MX(rrBBL}@jjapXcEO9>Kuu460$l<1i ztbFF?CAsyfqB1QnplA)@mwLk2lb`Bw=C*~;!?4XnHltDEK zGu#6zIZ72vho4tPH)wwZv6X2#s;z)|JxBx{R19{k6+;lG>l_C8c)i@t5O>MLPWUTB zz&3d*b6!x(V<miOo&m5TdW;LCzy z_&y3>c3}_F1-z(>PoPH6;0O@M^}dvFKr;B7=s9RuEi7voey!!jd29~~TVqk)@7G*d z+OiSyWxZC!J_C4KniYFga7Ar3ZQ7z-$Cyk_{uSly-^RGAo+tXjRsA4BTZwJk@)!nC zc&zb~jSn`*$32_C-ErG066c@KO5Uy5GmVJpDJ@?JB}U!<$v&5Qp9nwiF0%BSpr)Hh z!0dZuP~4uQ2Wh=qS4t|*+JVegO%tjD^u|G7+=$7TY5$Edic%MY4b|9NQ>@9sAFxwi z9qbq^g^oSslX8SOh;oogcYbplxE!IXIMD8qB!7>(x??e%gm=0i@u(LGY^KPEn4yny zl5-}peUG4lL?`VYkF)cy0k^O3M1K;rwCX+|)9#%+X(vB>p=A^Pjduhx@g$<3@jnZv zMFhbWOSt6UCxkM*O_G>%@y<%~;IuH=VyKN#ozl(y(O+iMk+rbcQs{3;-&O5TV%4!Q zazs2?3Fhp3Tc%7%`o%;H$O>iA118zr2)d8)p$>6)eiHN9*I-_8xadxaiZyw3u zQXlYlNW0zVl65I?_BR7nZ&sjV$l?O_%8Qm}gR{zoSYdO}wZ?hx!3z5H^~F zmq)$3&I26_fcmSPUKZc%d(idea}ciIAS}AAfZ_`*9Y{$m!a-DSc;%C3$9-j1T%WhI zE30t+9isPF8Y)kUHbPPSNERv`Um_cV=)+>bkoea}2JAjuaAjXpcDbMDw2D%nPH8wr z+-ynLOIJR=5Hx)%{sb1N#p#?k0vMM5r?D!5*_1|#9|~URVy;!cJ}-yysiEHuPR1v+ z)Nk0-Du-$QWaV&GbR}NEsGCHY=;Xany&#Rs^vNWi+BEchT|K&-b%6MOf>w91R|!P_Ize0?=U(bx)487P@q={ZXhHFeJdq8_xL4Af*EB}ygSEjRG$kIl(yd8%g9428=LQ#4=dN{% zLpo%R5SN?FJC70hN6+R;VZ&}Gc!7;igEGlsPj?9yG-Wr|;~s_F?hSF% z$4Vh4=7Y#K7tVu8*~M=M`qTdkmB3!|Q+c9O%ArB2H^J+V-fk#dkf!T}gkuK9;1zkP zDlBrc`~2@?tJ#WquSCU^c&w+Ntv!FQv(e8N&FYZ-(gHO4&vZdXs3wv(Z2c%kOMI^OydD6@|Z+8{n`1=gB zV%rKzpkez>Kp|rVj)Q%gkJ0gJzkOUkBh|14{kg3fR?(a2AJ50bOr0r{e7@(M4w1Z1 zMGe(Vs{K&~rWP6I66_TQ8pP@=)MI`9FNCv*WN0oAj#;#qvEJX;wQ0BqGBeP|QFEhy zHSKPgf?Fjso2-LJ!5oPicR(Va47JC{Rl|ua^A9hOO=)<-okD$>-FKDBCVc){XUHTq zEbW#yD)pF(XTo64%2{`XD6B~Z>Yxyl+)_ugT!eoBEq3xbMa>?@Kp0;|N%NXmp%w|& z5QCn|eQkv1Ei_JytF2~6!TAW~P`W&Jrd{@FMNYsG;`{E5NOl`-r7{SgJ-9UQdWFq8 z`prrLs@?*#c*aqdt3_@h{eFXb2ueZMP!NuKStf44rUPnLH#44-@F)s$=%|)M^(`c$ zoO>!sELX;#Y>1ywV1`;7?DsB^`kArNe;n=Wai}ar`}ao@yi_ikq}zoxvtsWQvk3mE zP?@s9Pb0aSvzmyEB6Xz@5X!P+U_%+3WE1d6F1#;`Qz`MBxfs^m&s98zc@`LL1s&s_ zPF^)ad`*ywg|+sVA2QVYcH6AoUDr_5_zieKEew_+S(o#&T!s)?6LPk`I=}!KHV8U> z#}>6(5UBO09<_Q1VKOmq>;-Nsv%Ov>8wsj$t-R>F432_qyT`BlEjn%G19oEeQrj)7 zDa5Two2czI51fPNT%8LUzRwFjNe;F4w*ZI(E-mUG)imcqJjgK5M6iDTfPAD8hczSK z)(2+L9O{i26Na4=pH$OB5zZN;l}3`j2Z!YH-GP)0#7(>qw~N8-{Itm)xnKapNDaaT zXmCgBQSd(GEeh4H{deP)fEY1jn|#Qkyq2;0z%KjcOSz3#Lm|=T_lCG>Z5SD^6i;+Y zspg0_Virmr+q5*Etm|@brGPLbXlrWxfi} z9&zbe<7~IKli{$rjXLPcGx~M?Ybv*hQQpG|&nZ$A#`L?J(Y<2}1wYk4}s zycXJNg>3(}NI=$$=2WvX^{9{aM;uJWr{vhS$}#GJ2C@?5B9-zuQznqSa&~LSx#ofP zoDXcA(puP8?BEqhBR}X7K>PJe8>E?xo{|sUN zP~mLT+H(R9j=qMk#YnIzv1h}iRII<$ekPG3S4o7$K{>fB(EI?R@3wUOcftlSn6-r# zpB~`It2(F`6_V`!EE|c_Iya^zX-vQhd9M_nlAEvaPcIIn)4VUA8yo zFfmN1(}aX6(FLiTMNPto3}0pmpY^7R%<9x)MK5*+OT3%%kkkC)*O9*~LCNc+Fo&5) zQ3uuI&co=f+_Jv6;|HHc>1(pwEF=`^yr@n^?}fkg&f|Rvb4jkDc##EkVmCv0;h#|F z#8U=cJCHFN|C)4kQ#9U#GxHley~>*K(2PN4+1HMV+5KeQ(8#hvg>;z+A9UR`?=XGO zd7{d3GClCe>C1YW)69^|Ae517WrB}+CS}stWg~ypOb*R*+!K&o{c)`C&S^Yc|%KVWx9=iCKcWcS_bjKy0P|n(%DP}{_93MFi5(>yRDKd z6mWb&B-C2#_EulODi{;<#LT~HGS+Pvzf*_0xq#DHpJJZ2peu#o{sX9%)UW1EUy6E0 zccg}${RFFC!?7LmO{~8Vf{%WPh<0n{9a{BsU<4=nCdIpt{7bk3HVewF;|pfv-{20v zq{T&8sC#zVQx$@D43?TCGpf+6>Y?f8^Dqj(SY5EWTtTu+ErNYx0gnDaaw{#f3o^>JZ^OaaJ~?0 zt;*MkUYrAW>iZATF<2`u5^nWpXn#yew55#%LH#JqcWWP-__qciM`06VbHy!r~=n!kg>=r?CK|VaJt8Jd<{|A ziQ8&Qo1-WQ@Cpt^lqXsYML_5Gh|^OlKEP5IG;pn%CqU67wpcBzQU1~yNJ;xhzLEC8 zkAK<9`Q_2Fa)R<#mAbZ$nRv7VnVGsS{b&`Z_(=5IwzpZgrx$y{8y>BHHbSjT6u<9* z?Ht9|G{)^gTQ#ZXxL?|*yI)nb`>BoF57_E|f>&_T6W~=I{*s?qgsE&{l@Bq_Gv&lA z`Bkfw@*QgcT29O@_qfO0m$An+8f|^U&%^)5KEvSwU`?ech&4Way71w+AF=s-9zLRL zy5)zU>)vgWi~Y~^SNJG`4K=5*1&LAxz3ejWCQTZF=3?P?Tw^gA5xtd z+PDp@tm5>a#D1K<{XxI0Uah-{WV`$#?Dy?#Cj4A0Y5r`CiUEt>$Z??M|J3!CQE@F@ zyC|-~HMlhH*+_!B1_A_aym5CLPq1LYHMobMK^m7NGz1IouEE_c+{L@U@9cfwdv5WA z!5CDns+wA}X3fVbvDYpyPu4-p0v6MyzgN&`Mp>%_LSs_3$O%sDQ}1|Ax|fylnKZGF z%=&RX^2oXT7YX<$VRjfrxX#<-ym_7kJsKPfzVy*N5xzUsnsMm z{$N=Q{a}^u4LTnYuFTeN^|@GLb?PFkV``9RlB@wTJtL&Bpwe@*Zwgg*ek88>wSjsw z#@Li}bHuE0VI|Bi0dPS8PMWW>OF$iBQGoxDh;Oi4jU#m==q3znu+s(CYqv_;lnav9 zi?OBd`Rg8SIZ61IxBhJ95R`LI@TzG}Os8ZVq-Lu){7%7ltth<+;?sRFHT_-Ys5J<~ z>DS*wf;c6kUGPM<1_?qZskPk6YCL<4EWmayX+SgzumFoy@$s*8Y*L6q_l(ca$roVU zcM;8WuDS=x(XDo57|_WcJe}qNw>qz;mpm#!x`k$fSCQoIipPpzNsAIgWzYm(jYh&$ zON;p)5`!b*gl2r8&(A6O@Osi)@xiI*ww17ebE#ZFUygaf0tRawl>PfK*Ci6`BNVsZ znY8-_dhI{lo%*`^>p(l|cm8{IrdPu^)Bf!(=W5V-`(bM&g2`8H zSD9UQ2PfzC*XktK;Df71%U8k2_g+SSP|153yTK|8p*0q!=8blVrVezYG7eh24bc<& zdwJn&5pP~dU?7_skZEnmeRD-GvbTF?z25Uo}QGr>f@haMdJP2(l41q>!P;^Xm|pwwPS1#~8JjeR0ZY@2xqNGmi7*g#V zDv||^Z$}h)ed}j+nKrNg6tqIoE+Qk$^~d*2whU&>1~epoxIC(XA0h=ZicJmenG#hG zXH|7kygK&wFgxXQ80qa_0BP(hE$#j$&4ibw-C#|J;_LY2ohUXMWZ0z}KO7Yk25?^~ zz8#|;pljk1_uc!Ini-b0JN z?v4l`S~{vGp%^3UQ$h-ns@p4Kq-q-|+H4a)V3Ku$4y9`a(_2Yv1%dIQm2yu1nLY90 zX;p7bt2T}{5om;@Squr<>SL%Tx=3BIQkB@_XnD7e#NhMADtS#QO9~jxh)k0Si~a$QEEE>y5-H zpk)kL zY?2)k!-bK)`;d?^3U84@)OUFdL&2VvSIZ?z!Sz9jIMnF(x5{_NSuk9j86(!-G2AD#3wcxpcm!2n6IrIUh?-kP#4!tp-WnkGF?=* zpZ<~0Q?>HMo3xM*&XKjU;I@nZBnp4hd%vrm0atuH0^>pNSS-BMC4j{+)J5O=0E>CS zcq?YxzK=1)C}$r2Enfm-Yb0&OA+K0QK^A!kxBs`Rr1tc;R~8x@Ap=&D+Cm7{*xJ;j zSD=>$99!EmqJXpMa>%~b^j6^Q%3s`uyQJ#A0oNeKlVKyzLgTkl`GJ{_4j09&&bjsx z^%AGZM=&~~gG*12N5cNef=}ZYIxDu#{q5@)KM$-r!}Jf;(!!g@ESl$(9uV&EoW=v( zc;}Un7^O}>iElT3VSm!*GyHws-v{lSaLw%0mfgM0& zRqmY`ak>ajRG{5`<=Rtvvy`&o`jg^|9e8``;Vj_9i0k|4Mym*nc1=0y$d0AQpQSH_ zy#qb?Xx_8NB-P&Ayf=>cmr-I!HA5yd<|$f~ghLidd}G{<{$41CPiZL4Gau|eS}S{G zANv&AfYL3vZQ%!h-OZnic6H>@-u)ic;~>fOo1ANIo7{!SDh*tG)D=^=4w1cz!b z;|s~Rz2*|X57kqr2Jqy3u6!ptF&?7C8Ds9$Rlj0JZk!d{T$){p_^*P)PiX{h6VeTjRl+V_$gj8YI zp2H0fU8)icudRdpF{~C$+iVEzXf^a-mDxK>C}`9V#oj(cSuk|Y0F_WGlGeCt^Dc@@ zTURF0j1vh)5*>!y4#IgNck-p^Y>-b;70#BbFZ_T$IL& zoSj=)06!=`aX~PvD~-owT#)%FSb&RWHD!l3?o6^WYOL$kT4=C4JcVY6fTiT6!UEDu zYljp0!KO(!&m>)y^M^~XM$R_t#_|D3`mTAHGuh%Xi~&eB-|Y=S_!0|TFHKU1ZdZ6p z7y2Ufa+{Sg254zg*TM3H1^Had#>0KpvRLfOpedYDGo^b3b z$hK~nNVkF?iko$ypBd#0Z3$`E@@$m7_kY404bd76M%BvC^(^mzrHWyHx3* zX?a8HDiaI~KvaN-?IwKxD0tO)O{h8(d{W{@KDd*>P&><`RAztstuh&<>HE>E%k{1- z!Kq;3$X@-ul6Os_>2Oi(!kKW~H1zl6K&q3HBRyKT1G*AU*DUx^iFOH43c>EWkI$R5 z2l;-x4>A4{xLg$NxNezU+Sg5amQ;l>=E`WM#|0Z}9s_QrrN0Jj%EQCXKbjtvWw!jpB zC9`4Nz7}eQO5{xXsc_qgsWWy265(@q@~A2dHj+{X4CSuay_s=d4e0 zf(YnEc98v-ELw}#S8#gClMo^Npj?cBTM@sp`ZA(vB=qG}oPV9kvRQI{qN}Sv~9*z{e&hYl(IQY64g)t-!xD73et#eq>JT6lTZVK`x zs?m^I=%BJduoF^=_{n+xpk7gHj=7fSMHJc;=0#K&AR1x7A+n?K6otV*Vi!UFIoI@F z?$c$B>-&y`E4#a}rZ1K2^1)4D?P5<xtSSK=uTD;0Dtmy3t3!WV6L$$F_3S) zcc`mPaCM@ehda>XZA}%Z`HBwmQ4$Wd77Tr>d0CYq(gI_7RLm;Z*7kh~{X7Eb&sD<% zX`(GVmMT4(8~=z+#_siyj%PK7{7Rfc`1TBfV9rL|Y5hH9h)+f8a5PiD#}uSj|D~6#!Bm_$ccKDS89LLy)k&(K%a= z+K>0>oUgkj#-x(*wQR8{pRbX!s}5eC&^cAE7AbrOG^JD)l>Sf;Q#W;gykm&8s5bj$!{ zP?qu&P?G#IlHITH9B1_P`I(;^c8sQiQN~XsSq!`f#_@1ZDPbC^6v#T4d|GlIR3OW2 z#ceFY1tVZtXqjUxKPX4xXAFu5%thJ0n(9QVpc!!Ve@$}p+g5o=zw#%~>3lcpRKW>$ zd`%w4Y4o-4*QP@HDr4As$e(X7a>|q-O}97Sp6SkSJEY7j>{VQhCY`}gK&L+CO=(Mh zg7OI#pgO}vIe`I!`Jd*mUW5qfso_QdgogO&);|}X`o_d*dhci2>=@Gx8~{Syio8p3 z`+;w3RCz%>@~9xbzgaj{K3w(zSt95Gh(3V*6%~rNWDqP9Xm-pS0+R)3Sn;#PB`O^2 z!|_Qik*o<4aLeeOxclovn_w16G^l{bigHqA@s|f@JoY-j${pKbmIE@A3~* z10=mbTy67DiBEa#wRit&$kOYMUBhB^=PlYu>NkcA0U|KoOC)|DoKieDH%6;T&lOG= zjQ1m(=vM#pYXsgr7deYIz&k-S6pou7N0J770^y=oDYzwQ4NyM^wKE*zGLk23rCG0k zoW@u`#L2ozp6Ji^f*RHRAq{Z~ZuZ?QVpvZR#|@)y>uo(_vXVgZ-6c6(x|v_ENM~bY z-3&07h~1?an%h^1T=SLODrmi|^CQ7L7)yj3HtcCltc^N;V}(zVRP`loU`>;rgTs2J`Ij4?pgGPJ&ZY^A zimcGQOIiPTJ*VnRSwoxJg->%t9pW6ZJ`~R?yMQwddO(n~@s|vcHzkG`AQNrW+afZO z%g^tCj3v#~S`_hj7#N})l%JMJk=_8Jxb4VwToew7V*ZH8E|w@`qjZaJe>%3PLLszB zN8fgo@9ZUS9)=5C-Ws|fu4i3| zN7%|Rqr7eKUuvYS z(!C4tWb(FfLDHB`k@fJ)W?5V7u;%UZEXuxk-8;?u!&9R3%)<0zId!&UhlB3G4+Bqj z#pI+tTm5A-4Tq{*khO;2@$saq-yyG30Vm}g0WAkP?K!F_6galf38{NA2u7tedD;N7 z((VpK?IX=e_#3c_@EMSFw8B3SI94td#hnAHi9Q2LaG*z@=2oLP z+U`pAo81}>+sR0muwasbyZ@6ifcSgX3kL@Hdw0n`K!xeta^i-O8_59&ZQUop#=t z-H=7^;dNIHeJ*Zo6$o(t_U`<{fuDrLEu1ij#lsn2$cBlA>;z5 zZ|n=+tOzX~V^{SYm1IRcMR9<*=cI{m2B%`rr)t%1)rSF#wbNQV#OfVto9}n(f-t;5 zy~CtSxHCz}AvRVXU|OVWuorK9b*2F%!mD{;7>ear@#XTvFW$nCp%X~wKvXrhrbC+TVALb zfPAvtgf)J)Rv3pW;5Dko`af>(r(8dNU-RzdxxCv|RMzL16%jcrYp(4VGsF7JuV}^L z+hD<9c=5Gr65IiK2XFu&4XUL>;Ikz*Vw%?lFJtTv+C5s$Q2GQ_D4$Q0KE<+er>DkV z-?BdKXI1OiU~eUH>`l#)JuL;5sl!G#DeVGh8L+KYj+X9k2T?ybP-~P>%mUoOU~mx8 z*7d7!{Bx()5&Mx>6Qe|LtrY#R-giKRj?4SYlz!9&aRYi`bykqyx-xnxN?3`7KqaI| z{DO=6Huf8P2BwP-{g{kEA=gIw%fd>gwDbI@fQmenDJ|h`0OjzQUXk_U_0BNu zFVibwN#_Yq6XAuzk`mU-LJ`ef^Zcs&=u~&QUw9fRnKn$TGjQ|r?)5THnm$o)u=HLN zZ;&T$`7(7-6!M2RT>6OLt|NG72_yqIr=UYly*K?-E*e01F-n&oL6s$ztc}g0ue0}JuKY3;= zx#-v@c~oD?FHA%Pd~!Z5FW8{?XbX$8?k<_ZInj3%KK3@1E;kYrYau1F;p^nOoSc&P zk>A+=m6?Y9JDNp|)rpE@B4g7T-vTo{8a$;+_#Ouy6A^>;jXT(Bs%57#w$O!8;d}fy zJ|xswf^+5(>6M6?%OMq$3f%6+BfQ2mWh4U*@*Np5zz(7uvXe7@uI1xqm>+K94&pi8 zqf9`b|L*+ zX=*iIwbs(D<&oFgCYn0aeSkAaBKplM=D@gbbvt{KSZTyh5lLDBO*mp;L(gZhIO&BQ z7-rD}zE`BZ1l$zFcMBvEJ!+d)o5TdmijTxAaR+-QKsM%zg5gdOt?Sye``#`5Z%5Q7 zPSf3i`Z*MAc=68;;ig|qD_(YP1rT;=Qv*dO*d=M6r(=ChCs#wAsu8m{Lij>Q@=EiW zN`}>g7QRgPi|<Yz%uMBlQAZCr_Z)o@WYw&#_K%#sUY%NLr5b&&$b-aZtn^Jy8-VmHg>Y{5MZZ9H# z36=6OF+MTq{&1;k9&%kefufld8S{<}IISEX!k#o-TOHbIXHF8*9z zPhK}Rpi)~+G27G0n`9~TEDNP9B`$OV1 zqymJr#myDZ`qmr>nGYs66I&!c@aJ-(8gDRUYlWCF{_yB?syr@=I{>yap}qY0Bl6W5 z-PE5S$3_W8l}lsHA`D`M@kT&UU_XLLrFMO(Js^A^r*mNVQ&eXg__sZEdK@wQ3XaR5 z-oDJQ#H%ZTO8&by>Fu`#Il%1{LKu82abliZOps*bpv=d1A3P5~C1kIFt2Hz_NXQ*O4HHw3i3 z%}Q|a`T}ST@tqoPK0&nu-=gtyh3<`&{sdX=!eR8O)@JymS9?1<<^gaJ{qzveyi>Kn z622p*InhA!X`N2#d$IR8XmnnZK5AxrA=QSqwr)zHQ_o#Ea-2V6jn^_?i-H?%z`y4` zDdtXo#%e?nQTqkHd!CdNvMMV?h5@QeMA4eMYRPHQ!W1+Y24UMV=F%0q_;AR-Y(#Uj zu;L)nmn&&Qh%F4wZ(q+al ztF+M&vV>@6%w;qRO$SNhYcKWeztCihSUV62b`UzaWQ)=(W&8~|ly}y}0c~`B$gXVu z)2-ta%lBZuu7k^e-d=@(4CKq0C@bc>_iD7b(dvs@<1<<|aRYU0Ta;y~C4Qx6Lh+f9 zt^(7h_67bA8zq7I{anBNbCNqZR0$NFc4dke;&ICeoOpyL<(goZ$-s@!;D^xTs!M(^ zc8rQxmoRk!w-;_PLxP(3N*IkigMfohPemZGOK&(F$^C=CwVdFG&)lI49u*%IoA}W% z0qz1f@J$RM{0gwbTyuN0{+_hBJ^9@xcK}K(mDsnAr_Slkx#$p=yO65_P)xo72dzUY>S&?RA+_$2RYpi%5C+ly81+)AJjSp1c(f=WfUV zu7W4z4Rsbl6{h`*t}~T z$AOHdQ&vf1^L5@fM+kLt-Bh=XGK;Gq!3`@0k@25I^=wJI(J@77fiW4TGCl)nX^$0i ztle$XaOAjr%x)E!-<2l-oADqT*|cNM;ge|xiG7@TerLMC}Y@*!Ifk z-p$|D&Hn>uWr*7BuaBs+D`3BhCjXJN{D;JfH?Xalx}aG{&c6ECG2nW3jv4bFqKHrf*Gfv!b5KfxZ_GD)!~!}Q-T3k zxNpte)>5~y#52kH>=r`TVoXOd7K#z(FYtc_C80G7B;8hzwth1_YP!W^9sb8Knk|fM z>S6ilUN0h$r5Q$bBM_OLMGIDTFeDyqh#1zlU;GJ^h)iO&aJ^75wnLWg?^i@?2#Y7I z^Tcql&t?kf-GVdao;v)=*hFsIvg@Wl9G`FGAu`Z z1IBiQVao=D=#^J>$-T~JL8{X~*s2mX_)F#QDonm}UKQ2Vcws)U)7acEX`bMoC*^QKuqNG@&D>N`mJdHLQ~ zC7~>S!2}D&GyO#=f!wD`9#(}i;M31TfTwBO$^blF$>PK;V1+Sot)ux-0Mi?r!x}D0 z$NpGvXU}BI7g@w@OQ5uFq>XtLbDVBMvgAKEUsuXL$TK8Z9&(NK)wJ!)BJ#Lr(R=$w zP?O$$5c+urb7U3Tt=v8V`?ekB`?@JP=bOx0rDP1_DQ#}cw&2=s;?jwbbM+YA(>ni{ z+3l4{$uAKz@yB!8?7&MMGlsc!I%N-z!td(OvRAcFL8~OAibjVzH}d{45n`dt$!XMQ1Sb;vCL28TpU9ouz=Ex0R9QRAp8DY^flpED~l|(e#)$Z z3gK90DYA;^nAw!_!lfU$Z!|i396S{5>3+&MC>9;`pAa@)+~^U9a@NfSZ2}d5*R3Ad zeG(PRNqe>{O%`pB@pY9Cft(-DW)%WfZRkfD<>~IBw;xQSrxFS(SFOpJ3GUs>Z4*cA z=&FD;0~=UuhyGsS&nddhQ2pNV-9+p!#1=>qyX=&oDoG23_nS?z!S=;e0lZJPyw0fD za7`;g%jl5M#V9{4{XX;Iw&PsEhvV1?xGrnuDCK5479JU(7gt=-Zv9~-+HJ&2L;e~P z+;!=+m3Z*(s^syMyThqL=x(yZkTJTU%d6SQuX+2y@`lJ8D71UXj!izn*uD1B5?mY1c=m$wfZ-}KU5e=s{?rkObLR7c6&ly#%@DB}fOme_?wk@^wPPQsRYb1Grc zpVOlc-4O|*XF9(ez2z3Xqo~{D>yz0$E149-wwRwZ=&15Kaffy}H zf&VokCRTP9sE$z?M`QaJaPO87l2}%+lv~f17f|j18UyTjA}O}dMlu(q3eo7c^ht_6 zT7w%VzPOZrLTs6Q-4k8~HY`9ll1(i_HZmZ4!$DJ|h9JR|q46tFxu%LYz(yIum8wksZstLRGPXc?5>ehs+Z z&`D8HKz;xPleut@c0U^&@5-k3V~e_dK$D`g4b5C zx}DZK>~E862RpN)=Zm8_?K4UpiseDNM)Q@{6F88Oep;bQ?oP zFF(Q5e06n7zJoC4DLIN|ez1YuRPrFIie!`T1*>7YZ&FsdaHEJ172crlp^d$SmxMRd zPNIw5WgXdVYJT=D@kK(7+Er~a#a(nWc4KihuFM$S5G^1ZTW$M*9eNhA8`0w{vu zLpX8jSQYOjmtbff-pKWhBdcZ&r1hT_&(Cd~>1Jgd_HC9YkBikTwSKwvAs#R`)~78f z)$4LV`EBF28$E2QSCR6?3j7O3mqzsK%HB1$4_z(Q8M&rBUjH87kUbV3(_5G(NugVc zBd%N|@fU4tiep-$jQB$(yVQ)$Qa6QJ-xTMql^uW!T0qA7hPYtBioj=pz3|o}*tbb& z1cyP;tLX>}^KGN&_!z&++hv-oL1%&YYA!sjNiNko__k{_qiQ=V#$BkvezHMwUG4dG zXjd#ZX_J`)|tJrYNB7 ztgkv!mG+t>B2G^;8fhghwe`}<`$lPL#GRv!$-#SK&yBducbi%=axGnV-=7DKhqdpk zF|>nYij;h1lS^cLamX-s2n5Jt&OZ#1R!8j}xYdE9XuV-ehtRalYDmt0^h5rP&m9ku zbL!Dl^VNV?V>|bs_D4hiIbV}Dq1O8=$akce?stTEh6X}9vW*<~{1|^7tJ;r)icyeZ zg(2Ib&{YfIs~H9EKn!2P#MRMIPmZn4{lTMG3ldys2PTC-e``gXR~= zW!VHRf#ssT>4KNE}Advzfu}ldIcjz20&PnY=q^H_~o38WvE~bCZA||8$m*TDZKh zCyXHBy0>buOB`{g`|ODy_V*0hRp=gEG&{npNUsoX=>;5Z84H)CRe_1*EjMTU&qN-K z1b~U;>Z#>T{Q0$iy$#JT0hXJ;3|0k}Td=I9ddK{zS<#+k)FDyPkJ^E|ssCd|g{TK> zjJqElS6@e!a1%$i9vA6wAuLIM52ZkK04aw#FkUe^T(+KflS>xJIYiyej<(r(dMmNd zx=b=^6$^{hPeiQ=5u<9{a<+gHZW=|{5U_xg8%akQXd;q@NJewES`PxV-w{Y0)e2kp zdEzb??Ys~5s^E2m+7q6TpEDm=%QdsmZqS1|`(NMPQjxpvsZ z+={#!ky63N;j*$v^xdKW`{Dz4^CBZqf%;Dd-DVk<&)rXS1l_TH`?67d$tb|^NYd>} zf%*t^hHX`W`p&9>u=@+Ug9rCJKOfq;U~90!=L9zN^R&zl4kBI2@jQvM@ywAC#wsg2b|7;Q&Ako)U z(7z~zb$j_rFNnsy0MVC=OnJndMlnywtD%Vl_uRgtjl>F^Wz8A$UAL|<%+~K$5Uo5i zNycso%~s78itCbG@Be77SGlj@S82D$I4XA>w^OBfx3WlLQwk*88V2Sgh54#z?NWa) zyN-L?$R6*3Kf-fhcXrP_W>F~*nitpo#ML^q(LPUHP3w1A>~B0?z|Qy?iYXnRYOsvI z2{>1zoBH@ak*^lC06Op7>Um_Lb3`>o0O`j?JW-ZN2fuE7c2ENB$90waxKw=S!@~Aic}f1-QuG~wP!e|?&HeVq!V$~&PPG`@MLQGCE%`*MMq%Xf}Q+c+{ccU&;Bq$7>VF4$b%eZP+ zsH*vD&+9=W_Ye~qs3K1K8Hy3dn1egg?vS`$6{ya;m{6lLvM3HDM-Y8F)S!4Vik0=* z*3o0T>aZZ=FrpH5F~M6fPsC?sD?NsKv5R|gF$$|r>%OZ=Y?1M)jyCloprRM4BTV>M zz#fexoe-J`4PGNNag88jm;Y z#G*2PfwLMEmVJKXW#t3uWNqV?)!TX;$A^-8bHY13i%F+}FLGG`*npJNO4WBexb1HQ zrdtXcNIjsHo&x08udK`!u9{S!Kcl{L#sn;5F7iZCrg1E z{W5i-&mC;*XJlBF3N62S{Sh(vs#ca-kJP_j(lK?L(}EKXY6awXAMLVuHoPKkRW*(U zcU;2VMfOiOzl-$Y-Guv_c)ue7kaJe3-phtEpufa#Z&0K8{r;n660a?P^%!-^e=NwW zZ-(cGIrInvd@Z;4$fF#;WjWAiqKx_Q z;8dpUz5(2~dg5O_0qC72_bT_DHa-0x_q1$^^8)_FEDkGnA!SNy5i!4Tolfsf*Eut4tvL2W!)Qg%8F>adWqCA5*#b!`tg)1fH-sG+;iE=7~R%)W`wgx zgV?04hD(4Etrt;m0jM+LRPF&#XVj_8loxVf23VSmpXfkrN& zS>J$t!>Xit?4UXh;xm3|;+(ox)MF(KLS}Q=D{Ac7`VLY&I;>14L@WyBa@>$LtqPTM z6URM1@e#%`Mp z7Jmpnv*W!4j3(AjMY)elx=w?*E!@jlkM^e7bt5L}8o=NM&}t{PSaeIdEqBZN>gJ$I0=L z@LoGBu4TY+(qd5+(VnYL)%j|Ypt;=dMTimS`Rq604u@SvY9C&@v6>oc`Ie;XESS@6 zw1=Qlt>S&U+0AZIoCjK@feIz&jv`Bn;!g(>#oUf3BpWT1^WRuTHH@_8@1ed_PgbZ6 zno>3RC5rd>`J431=FI8vH;{%$_eR1xV}B?ajn_1ZO`CN&PZ)H@m#mTY57*3BiPOK1 zVArWC>+LD;*bqyZ>^|=uRLyYeHbdL~=y9u=-80&?7TgPVUhb0k4lIdfq2X6rJS4GY zi*{#C;C+2u5nN-&5l=M`^19{!G%hBfxlep*r(xfJ;wqntyR z7tIMLLgO}&NN|VNqU*p(GSe6bJh&-Bf1t~Re=%X~G+Dp@`xt%BHt${p3 ziD5zjnAbDzZE6mzI$n#Q!@cQ7$i)fMG8J5_v!jEnx|aQ?%{%yOos-)kP$;8Y)0-Qo zc9P~FnE>Dtq9f=vA1(OquZX9sSA2a0w1zp4mDz9cI<32b*u6q&OI=4KOLg;;masSO z8!6?!3AnMl&#&ZPKcxY`-HK+cIb^^3a)k4Flk|-%E6(RfNXKyVHK7asUn(e{ydi0H zm^m?|od=0aaY(d1fr}usWl12aQ~K4Jx(~PkdK|>b1&Jylk(O{K4;j5s#5b7hooK{| zLnIb2bvTnco?xX+__1#<$^*+CP$QLf8R_BvZJ^&wRJF*a z?vBw(ODe2hU=^OT#YwxmEAa@7S>wlb^mmC7h!0JRSRtox3QTgN?oSW# z_SV+(Zw(~8Tiv>vZXV41#%HiP-vrJdit8F(-#nr}!3n-dJ@MXmLO?j2LIDu;5Rr%x z{=rcGH^T1|hVuWr{a+B3|9gOcgWx^^0sqtd0rbLu!2D1)|HfH;f~5VY*&_d|_x}Ra{&)9(gPlHsvHsJl0I1{t8#L>GkMM8!%O_COf0_*d zi1{?a|A9#T@2>xbcYMOf{HLX(|EKG}!5sg)^S|K_pAaDbX=fP!>HPnL2l?OQ{F^DB jz!Lvy_*nmE68|6QM0FKZw5R{X1b!p{GD-V9{q_F<vA~-(1e|-8FE*PwKz+t{j21ni+#%Tt!M0^}}D1#O=LncJfjAgfrH3A0@JvmNOAVrQU!22wosGFw*ND()3DDl7@RsN4CWR}BQ=RC_ z2;E3syA<#-xNp8^HzGWKC|IE&*gHms73IuyY7jrvTR+fLyl}X()uYBJ=cB-T3GyQ3TJgu8dxzHYp;4*>1^gs5l^Z>lP%VnqiEQ?J?Tp9n$A_C}hVx@E%3FuPXc zEMs|3XEe6YJ${BA|8=y9x*Mz;%wuvUjXIkAw#nD=C0@RN{tx|>qe#nfTM=TTV_-g$ znW0>O0dUC&{Jl}}*D-DJ&BhlF6mdz1R2vxc%iC?u7zex08OEKsXX)KV{aC znVOX@=kyRgB719_@hZ3|M#2DpHL9k+SEsA}5wvsX55ajh^m)G^D&+T35 zpIz82vKR-cY~`d}JPGtx+rb^<9|j41h*dOXv46rcCzI`UQAR?Xo8AB9qrg5UbZ6lGc#>m70M*8L*JqO1Y?B=6WnJtzxkz-{<$%!VA+257C0b9}zFPyL+y$O#%xS zCHr?c|3K`O_U=M}+%X`?p(>BL7GCqx~<<-8}8g|D$rdn!IBM+oz6mO|AJVW@_7lDp;Q1 z*fZ!$MZY+#m%F1%FTYeXrVvc5($#E@wouGqykBQf%M9WSy@zL zewK0Ul?`3q%X>NppGUd>0u&fwFq@)73oQ{hjRTsbP0G`xO;`Z~xG$=tb)+A@~PMc#WZZL3X6dL1e?wXHpL(`&ZFE-%-w;$EqKFXHq% z)eBZ3WHydPVq&yeVmSgkyX0fH(&w@lOil}vr$8@yib;&jM5T=ImgUN^!T zy}gVHg^S>J)OvAi#$*-9a>Uh^%ruoqtr1pjC*b|mJZ+Qz;Xom?xbNl7WbnIa2z*G> zvJ%pff>)q>B_&P;5Q?qM`t``|V4xst1{--;y5J*LwoCX=2@OW?C((z$eVVpk z+_bPJJlb&?`MUeI^@esXz_nu2n*()Zder%144#3%vIw<$&}D5JP1)-C&Q{XmCbhzT zdi?%7OO8AE=rNz=?LXNMahRI#782#F@c&b!WBgaVxI4Ponm9Vz{tNQh#1VyFHcat* zpHKpG*(|6%ESld5Wio5zn4$LHVn4^K3sSE5`Uoh<=B|NitM|u$@dDYot@?qxZS}<= zb}2Aas=5?otsxWrC;K00=hQ(>4t2G_-u$%(>}AZ>OjpCE!l`&WNm>oUV~#Mowe;t4 zEaVMr_{s>8{8G@H?B`%wT$PYmh;(-T5E02;qNW`(LH^za#u#WjImZwwDc6 z=sjx6*Lk}8Q-K4k>7=coUqDUjcMec&QNu`QHMn~1IS-M?@xm7o}G=P$vznt8J(|Uw0DXcwc6%fhx>Pqg0EMPufh*A?=R2q_X`_! zFDrK}(m=fDbFP)nSGT4W{+IYB$EI@duE4rNZMa$QxX;+tv&R7X^-9x9IA5gWaPIT1 zuFcBZ%JcWNmz(>}^}_q1;^y4c&xY@JGZc@9ryK7&Z{Z8pSI=qBV0FEF*)(59^nEV> z=g75nmN%EwisU&K;{mWw4(^mA@7DQ2KS)uzJ}zHTxo@B#lV?~t z%H^0&lYY3ofUk(IGwv!iKZu7xDGK?xREeIUtbnqJ&V(y|Nh8`@CjQ_hw@OSenLK0! zQ<1Vt8Y@4Is!$p`KaHkP8Ye&PbD=bDej0tD^he56M#u6W4L%L=+xnwFQ!G1mJuh2p zJFBBQ*%P!@u3pVqJzKR)GIni#eBCT$a=E`Ruxqf~T+%+c^u1bW;-%He^Z-A3e|%FQ z7BK&AItp6%MKmedUYyt<%Vi{uEU3CO1UhY^w#)(A)`|^h)Z0u`;I}uZm{aXEJ)b6V ze3({7pPyN!(UE*GQAXcdWUu7g8ml@S-G_WPcG9EO6?RU?c}z)`7V6LQvLZfKl^aZ9 z3p|7dNnGNmfhWVcKaLO!@a-;9*(O;7-)j_r(mCV5cI#S}`@yexnBVbH^mdmRmK>h5 zha{=<+@CYfPrjaTfr)KKQKoVm_f_>M%^HSnJyOygrA&xBb-5 z9-qMXe~N!^p8)#PO9<$4-gvIA`DgLb4w=4a#jw(rpS+z4_DH|i8;R4?gnf2Vfg ze`of!)y#9OIC}SD`9QhSR8mqh3;f%Cv#`_+#vpy}>}#}lVPg#A@@$mWoL6t0(A?XJ zD-X~4Lj?3`UaK8Y5*Su|Hq$Mfr&YM_dzv{pvhsR3oIsqLh-R6CM+Hfk^*-|!U-+ypE_H?Xjx|2VHD2}NSmpmXWviRQYrS6L;7)BO-wZsuO& zUz5I2h>`OZq&A0*2{hkkf?;&rnF;ku%eITP)g zAI}#r+Dt?4cTXJX1e4}<_uanI)x!RGo$!6UR4B)+#xd!9IUn!i(xl*P3H%u?Ch+Hw z=dD(O>F#!zM`me9vGXK)*2h#{@!);LE2lPLg-at;GwhCd_&t8RT+W}mocH*P=c2!M z31jgKD*zQhD^;GIKdf2F76~f=g@U@O4&DTa=YsQUEuo!JIXS# zhhxRpX}wv0Q+;rE-LjyStMU)Qi`+Mbmu{UHe^cl8&BYMhcg%-C+10wbce8iQc94&V z$i|1ik8`sPAHdKX4X5N+L06r04ljFx5B-8Qn*G;|Xc>*~d6;O{f4w*=-U1^LNYQ+9 z;KD6W1fq&Rz#OTFWFGEKjrc#9KY<<)l}k?f+?V5|IaKb13)o`Tu^SXJ_;>BDzqK2; zOAuDithpawa4HUW{0(@Rmu>@<%9G4+NC7=Z0}?Htc{$rcy!1f< zV%3ZkO7aIcZVlTH>&1ayhM-x3=bnUJjq2^I*OuGFJ^YbOnoI3E{K}3@QWBl#Z~)#$ zjU&?GpLE6ew3GK&y*8zajDXgw#H)sr8fi0L0UF%DBN?id<9e%7*Yb~R6&_l9O<0@> z@tRpM}^6BM!M{Mwq%90y*j1&S2+Ij_~FhirM-N=W{)-E5-L~)Z?Vp1D2t0Pf^dLw|qH3!^`50Y`-=phpLnB z#Ru}y@Ii6Cpvw4@_S4fOIfkZIYR!jHzqNOxwGYSG9WKT;ZouJ0r*7VEgN@6Y@W7dLgPf%r`FBxj;)VG9oH)kBlc^&MtLfT@a5mrtyN7_sQG6*HfMeUX-sY$~WNA0a_ zhyR{2dy4Bzln5sha;u}+@jkkRCO)D#?3iM?b&u?yKLZ|hjI;>n_Zd&_VW-fSi?$a^ zH5;(rA6;831^RIWvI~6ty;JyVS?^qrof;U5bMg$tnXb4kPsCe4f_j{5rLR2DZa;5# zWm^P#;eaMjvfF3o!QYP6&~+w)ZV|~Q4pfhS{01cMfjwRYnKM~v#)>d`E;J&BK zijF-3(Qf-zM!zh2a<-M#`BP*5iXHvSXaAvSnbXZ5hwl@De5J_*^hM>_eKhDq8-ZDJ zzGZVm5i2-HW_?(%Suv5g1|C9OIEhZ!UM$Ccuy>#B0AEQb$Hb_Q+`ewF-~hgE4?Yc$ z+qRB3O0U&%_*eTeGoa@>AhZ;`G=5^S-{zX%>Ufy%P*^hDpgCS~^PhN28W5cRb_~1t z?9;0tcRu`HzxLQR5lzOwt~DU-N9Nd3*IDDNd5J-G$8_m>hjBe7Prc^@icv{m5wIE!9S^N9m0gZiy*ap?`7`zYk+d8l0%Y6wPA@g_e?+ne-iNM@Zf^gD1D{cDGS~IU%ZK0qL8KPg9$6fN^o!{bO{zAX z>wuBqeP~U@Hjcd_dRF;IaPbQu9Z`?u0>9`*GWUh#`~UdeJVwGNPs>ko;i{k*dBb?0 zuW5+w5m+L5#rQ7ew?{Tqy}F|1@4Jcdz-yJ=gQW}5>3c$~83+P4p{_lxHv5IGNF8wnXc$=_;$LSF^UeE&z=O6l$^}+z52iRe< ziv{bSTBIBk2mBc4|34_M{`u*Fm;8kU^9>!z9|8<)&j$3?dBBDHq|eEY`|9UPbUOe4 z__Pa!qe+$If;}YO`fT&3+yu-Q>{&MvEb=k5YmahRYYGc;rVUY zA8uHd>u;w2{>tXp4TPM>_}5?Wi~sdfnDZ!k^~)a_^6BE2_m~1pbF{{P3lIu_OlL%S zT}{Ln0Fpn+e_|kH(k}ghD6VJr=R4oG{ftaWCp*EI)xqA9KT%{7QHm=Sxu%BW$>I7f zYAnyg9V7yHw!02H`e}9NnM+3wIiC@MW+XI>kJewlE?CL`dfcv_Xv#1n(*5y#6W$Qv zztZnHp~!AR5Se2_4QHmgM?v<%@tc)|JQI(9Q)YFoezvbHmuFjMXPpICnj>?hKSxIG zANQQM!;Aetl>I${h6>T)weDGU7rf8m|H%X7mnLW_0jJCsKhOJ`P?u5r?M%wG;qY1e;!n!;$8 zK{?F(#on$}>;@N^$b$EiM85y>t8<&0sW3GcIauFd^vC(mZIo}2{#AwtuAmAsmndKX zV24QB|D!}F7rzMs&g<(Tz(m3VE2zN3eH$Fw^800`#}6rP8@wp#pcLRst+G5wCB~oh zhwdnGK{v+Bxd!H_z;aeHtn>6~_Jb&3wr;%9?xA(SmwS~jR}JH`?1;HuvIp2{Fu--_ zJB(2KOm_K1Bn1Ek^$F>V2my0h(y%!{!U5G-9A0KpkUjWSNI8`ngXvI>4Im1&;rUBN zEDXXPll-(jSf&hGl*{~Z908;AY7J(gL>gx*M6^TIJp6pY7Vm{a7(w(`#769=qpWo?IT^)H23- zG;I=F9op9Uz%7bg^QP2))!H({~G-LGPO4A{-{8b2wJtug|M;v>FwpGrs!|3T>J zyY^0t&?wQ-(|8wiJ(;>mT9R^Lwn^p8UX$Kzrj8NW4l9g3;3*zEINKxui$mvvl$N%x zJsaz`PdRmq_BxosqfwR5ZdrEjO9<-?Vm`*iTM6UUSkF~r#3Mv)cLV+s(~Bd&yT z9u{8x+aZX4S$gb+9mk4RFEPI*DuCR_t7#)jyaX+Qy}eANXw5i^8ETBFx!!o_QDIl% zpW_A@q&QJSB3o3?mx=)bgXpT512a+$Nva~T|8|(d-W`CiJ#uf0JRo9=S*rB-IqsbS z^<6D7^!v)q|@1>5tRit7+W8@E_z^bfPxiI7Id~ zfjNujr?~Hn1&5Z+k*hkGR;rl^i#VLv7{oca{>!N0zCjbEeKQ|5}7SEUAr*(ZQSyIh4d1D2PKji;xz=r@cAeb0R91 zOTRml3WJkPP#;l?6e~|ity9PD1%Bf~5+z!M2eLuSPgvd@H4a62v{4V0o#xE`yP+7& z)PWeJ@u`Mm7~!0GM%EeoY8e$rep1xCZaEH>y*^D7Uysem4u;~l=^`DstgUgh8_9E} zlO%99ESj0;p8*H#Ldn$dR=le;^vSKS^>Yn;lrW#{V}Fr;IPjvj;5Vgqiz;Ki{k_RD1%*om0p%jtu)@PQSP z)YLeFF))HRQj2e!C2&`?coZbd=v<$N3mpXQ0s7$)P!hVP9ilx17?Iio_?P@Y5QONn zyVZP(K+JC=#M`M!g_VtaO1j2jbfuFTO9AeD8h-q*fAJ(7HqM>)8O~WYGcA8YmdyvT`opin4VC&TaH0xJE5;(nS*zYa`hqIw+zk#z1*8 z4c)t~j+e9w;5^vPHF?)AlLU0m+rCIjFPuSk{b{bdc46!{XX9LZuv7%p3hlI$u<&^< zkz5=3&2huf=@2GzI^vpxy7Dew=&A&tPj5@5EqdQF$yOt~EBW4N;4J&I&ZG&RUDp+I zNJSt3+tDC)1%g2n)kq9 zd--R0Dt%(sxtDas9Z(kQaEXXG#f*-XyCO!*Vv~y3dg`=OCwH=_S%lqj&u}M;T{+!02aeNr-PQM{#sIe6v^8=R9iWoKv z-7b8+HJkHVuG26iPfdok1&B)_F88(vNR=Yg1KRzx>Zm3;_iqa_7vc#4nsbi*0k;5u zJ1Z&#GHI)5_1!$?`NXislo*(LtaeK)e-=AE-eZm>v-n>PE2`RDikY6eF*=X1X|`~C}&A=?$+e7gI&~W9_Chr zrPKEwz*q!CBP1>hiNZ{RL_*GJPvBsfQZbf-Appx=vpv?SLMNZN2jW{K{9`F9JsAn; ztq6nL6|-yz$C`v2-B@|3U;EUk&;+LWAXY9TAv0xhh;(Z;;ZO`I3C(k_F_3UyrNwrJ zgnRzZ7pG@V==Nyb8y23mX|_QUs`oX&#Ay*f#D_711bL}8t#&m6fnSy!G3u75tb*nZR{Tag(}5@@mwM%@Sq6K3F%oJ z#QBSr$C-WUB*snb2Zg=dpGkWC>L*cpCSP)OUCA)jZ}Gq+puD{LC@o#fJ_8E%nk|yJP~Fq@aANZiul!_-vKNEu z=ESZHvL9zV`~)ltHNZ`P4sCr~T*TAO*#+4Teu?}mWx7&hjy+Re^BOl!I`;0@PolSVX_VX#ga>_qZ`g)#f+_-0!Kb3NGM&YY2%2f5E#GoF zngl+d@I8;~+wB#qBX{+ETuI^Dt`$=&Mg?+%Pm!85{D5Dr%&nUGzk z)?VBJ;>Iz4EC?nSooXDb8vTt=SsnZ1*RQ?Up_*kQYPjYZ$v@@ym&n`y z&9?~tB>TbRBQ?BJL96)*kJtc-=a#DDs=j5styXsTqTUupl7X9PCRXAv4DZcgQ>dS3 z*L?b?3(wxiJZt@tcP_%#OPqQAVWo9$0DS!OZuOT7!}lNUAKq{Mg+!v&sT=Q;m78UN z;;|onFj?kjB4|#%Ja3r|1{^C;V#cUw$PkS@ z@W7C>U0o|Twzt8n9cQ8wO34KA5W-7J$~E~ZrEXjWH+G9CMGo3W8L@|o;}kJCHUT16 z8Ji7xfYdH}Xbh(s5|(j& z6+Jdq*C+c?+(V~gse$I}(dfUO-8Tp-^h!xn%ik~{;s}`MRg5@HI3eQx7;f7~{$)g+ zqS_;yFzzIq@*|o$8kamtyro(e8)wcGI4}j3|QRRhUR@w$bOcEoi z6XwZ8n`S>|Dwkk~y)!>Grbnx|KAHNS53aQrqoP5i!K&2fQ=Kf3?diBoc*G(1M)1ds1a7qe^P=UW$qDh73ZQ1pY>2;Xe|N)4xq zHUU)eZtyAXj&lVuN*sgJxg0v|wy(ijEr; zI3Is`JtQQ13}Gzr6waOy7ATGfQ_(>Lxkdz@LjtP8Ruf`36j2=`Pp1A9yA51Hf0Eh& z8Jk3h5$g+suhIFt&-G6`_e1+p@=204>;;~sYJd^n4UaurG>O#0@dItUqU-V6n`GM? zf~q!Hq97*d22-bkX32@XB9SM-jJw@0uhoaFT62D>R?liM#nCkF*U7nbc4gfPhqi*h zew82f$o3(zN6L2!Zt}aN=Fgp(c<+rN2Dv*RmG)vEF}nf8*Q49tK*ZcL&ptxV@lG1> z;?p;SweFEag_}B$EvRuxR@9ddXzAY;vvSCw4@?QB4-vw6$snDs@Z(DmyKh$C3fw7~ z8*^d=)V$!QIzVXhV=!xRv#|E zXiA)XxW9hHhkIo;jbHTgnT8j4v@IsJVf6;t+1t`U%2xOaad$?fbb!?KTx&y$ltpjw zv-VgU?%wX&wj#&5-^T7pR<03W z(w1No?hk1#-VHqDr%!FN?C(8I+9$5OPYt=z^lD;#`#6DM=|&KsMbTd?`hhFWoF9)^ zOcLP*8+m#Y-}W~r)go*J>r}bAzh;E{kfVHjO?^SZQoZBIA}Fc-4C*Dp1I~cRAj{?+ z?MOiGMEd?7%_0e~B_bfVg8n&CwxHByuihJRFkCyt%`1FMK#r-t$sMY@`nVku6&FO; z2CXTuoyy*X&oU<-d6o`t8xzKyF9J)B5^(KLZ%Whz}CpfG;B{TDk|V z$hR@FxpWU&8V$0RuORSkb0w25MFY&}So6r`JwY0Zwt;M9g=%uUP*e}Sb*|A`bxT{& z;u6Sk8Fu4dLajV*zL4}h`dE2&S5Cpe|9?=u1hCE)XlSJIi?d!RDnbWBh9Xz|L$Z_6#mNM|w%7kSEc zHchp2{!W7?&{?A!Ehq8_%Y%u^Vp5C8G_*Nx^b_uHe{-JCtrbW`7~TDmU zIVX|DWl+CD+>fES*Hq=s6hnh#6PCT2oC&HTWB$MBk&fY;lo?NI852k2$`!Xyk9M?Z z_$+@(06o&1$`j78!*6bXwsJjZq5o|4jumM2reL0ti5;hlU_qny{E^FJu|x)prC&wJ zo(z)KfMhPk_t`BRFF3%R8;;ZJ+zuNm%$997zqac@h6cNG?vwL#UA_ z)#ZxLe0sVKlw-iWeDrV?H zxv{DU7pn`(aa85VB~4|)2_(XW+8dA#%hzCtc%i?>xf!cABc^6{!J>h=rBD1j$Q?8d znQJ+W9Qm3Tyl-d8a+NbpB+og#t_?4h@`4rp*>VMIY#~d!d5yWKD_ZnRvpRKDf&rFd zWvccu;^*|L$>?E}Dxr zeiDbbFZcU2+xXj@AAcbxr#Z*+zNpisAKhU(=uNu=(&R3I4QAt0n!Zig|L~w_KKOSg z@dBVQrqR8YawY#p!7ppEM%?O)KM9cNv-Ibw36FAEo)k&lV$oo_0T@*uJBh=wEfTpl zw`TUvebYUvDNX-439XBIBcff$lF;TrbZ64L_}fmL9FoxPOyIFj`V$#yBuCw^RgGZ6 zVy6Nh@%@l}-<@E8WPT@QWX*|sgY#vB5Maht4wC)Yd1U(*U!1o@#J`Vt35}~dN1%`9 zF=Q$Ulkd`ovMpTXqldRtk$m)~!u&~8SKyUNGWXT)D^3TvIad4?rm%gqsZ2=U=M=?(^E|Owx=$_Bi*FA&8JKEn9Z9@0Jl5FAbLoTBybjjcyWaYQBw6aJhD$K zJiucb)_O4*z+WGA?+F&Z;SkUS>~>HVJId=&uva3lap>a(0pWWoLHs-F|m;bD0b++5)xfo8qQp=b<0?Pg$=`rDhxI_+J z52GSEYohPbP(d)?(RCl4NK`1gWM*n@ zIP?vr>Na=QOvmql$L>~f)mh++IJgk4V1VG2mpA+8j$88g-`{r*eJgIO2<6(kc2k-Co_fgpztO}XVJK46*ttD3Md5aL!cHua4 zd(M>MoRev|4Vm_j0V7mDQo5Sbeql#ybaPo2-;6FuqOL-7W?pgojPKOztvtJ^(q$0l zHrE4*_9Ykqlnh_!ekhe%EulDlfNxF}ilZv7FE1Y{|JwE;F7fK_ z*M={=C!`?MmlIKd24>=cI0UU1p-p@b&js&hzF zvFI>*|JSuca>GZsmyV53U1U|$%v%!N58RMykrxvWI{kud(l|mlSVy8fWBzRZLQ_?& zQAJ)KpV~;=N#c~}?pqcLEOaKXH&rabKb63C+q$3Mijgvt+*?;;u6?crd{5-XO(a42 zCJNkT_`ZY%9dZImU`yNug^r628gYIIc8ZjRj%G%Ak@dig6O)Bxrlp3{L9lVvbqN^Ni6#^_pDvbrA%~p(BMZ5TwP$Mw$`AMgR&9_D zWT(!4#w1*SI@|A3c*lHkO%Sg|oMJqjh}Ez{4Qobk!7P#=He~;gT$+Go?G4FJbp#Gt z{ouRpB=M!8^fWOjkbY9Hf?Cp5%#?hrzYKo#J@M?!;p*Yu<2A%Birlx*$9ErynJ7?L zr)pmqE%-IUt?=?W(SZ^NzX3VGZF~9F<%)BPL_0tFTuI7}dKPsmu?h1t&lM78K4iER zG5(9)cg7s<)aW88%^xkFN`hHBpURIN9`a6zK7VI_ltK)@98WB#)}N{IHEsV&C9``C*UBpGnA z`qOgefG?wCsW!MjVgLJbTq4O22doZ1{7d;b2<5deVa1WG~5# zdz((xh=ge8S^$4*Ac*cKP}AH5*mY#q}T`WxeC%xIzO( z^%-lr~ca$eq@oBP?AkFw-VSyk1;m}M=!VvTehA=269KUY)tdUiPSLWJXpVp zCET~#mBd2pH6HaFX&tFHtgJnHTxgXG05tg1`B5_ZeJvkUdc9V%DK{(_vj?FZdy#Au z-dj7gue?VrY#3SDuJD-Sn%QT4(Gf>8c?^R!X6_i~);6GR>Nh$%Y?{2kWYCAS0UAq@ zr{|Tr^TxXbyi!+oS!=~ZE>FiUw^Z7AY=Reb&LS>CCo~}0;8GH%2@K&s@hMjgzXW3z zD+9eF|B)e@_Yo%XH942dLv0t(-lg~mXMK5NJOg*wK(dVl*&JX_@}MxsTJ^%05&aj}vq zIv_JgRSyT^gbk^iDPmH;_!NmT0VWP3Qzeh+G|0iD>4;XPg5oKB0|CcoE7(9~CHsMt zBBmg2=1f{fp-0dzI|3!!NY8!}pedV;^ zc)Wb7ULE~Vg5rQ0yhsbv$E)G~zM(S~5X-(s_UfNUd3JQi`i$StXT>_?C6dD(79U%V zc`i7leaptI0g|P8Zak1~@xnN|l=o7f%ft~Y_5~ee98Sju__9h76-r3iSS1SS5+dwJ zDF~g=r@GqaSlq%;6YmYt_cI2}z_N}z`pU%aIR}R}ofd|W?c0UJ!bNqB_#N1)$$W34 zKIW)WsTzF=Vc<51?K2wWwus_qN+HfnYIr->DCMP_Bsyf{6nwt3d-Aj|%(s9d;$MqAhNF%; z>1tTHrGi=fyF>ysb*J0@X40KPreiAeJ-lHw6H+w7=?9GK(7Aa{+FidJWnAX7`Y_Fx z%hx?WzZSnO*?J4vwPXLeYPH{{jQg@AjV&e_)?yO6W0t(T`O_^-?5-XSNeeV>muz_q z;8s-`{dLkb?|JnM)K5#)!hU`|(Vvt)%PYOUp2(>W`k9x}lU z)>=Q0_W{}?Ug5PcNQL6YC<}Y{w&LWO)HveC?=tk?Ui*_S@O5Ke0NHQa!B(u5Z zuLFDktoNp$U!Ylq_|5{Z*i$;KK$_^2k)N&;5HiC#oJKqPSc>9^ZrmwnMySy5 z-f&JVkIfoJmI9p3opCzh*GcEC+l&XoSL|!o(sG~bS@%(D$Nu-t=^g`%5R@h`1xWma z-JD-rD4MJ$4YDGAGg=Z6B8NepN6w#0HD9I!dlF;@!|cR7to5jUPn~_5jJaM`&NFvr z)|Z2NV%A4-zWpMbHZU*V=quG^J;88=^SY}ui_N-FAeP5Z&xw84eM<)z9J!^#sv(7M z;Ws`H3XxH4jF#0T|KYim!)D#)kA>3sgm3uZE6g+}vP>i!`kJ}I!FIG!khsHbCUrP* zFWn}8d~280?y7i~v31SGFl_G?jb==?2<3yL8x3%IPuP_{*F-us$@zk;DLoZ=tE|g3 zxgthB$c}S3aQ%2=J-ZqwdY*UFZqezF1Y;#a6wfsa?a<%*;UE>&#cu0EsbC)In; zjEfxAg$wvGi$ebkZqG%|i0l@sCMgYzq#2_r$t2IhPg=a{OTg*$x=QA$i^Pnu-9cta zp!Q0(J}P3E8VY~(%oxj33hd#`3DEZSkj_(1b0`PHZj66HJ!Qp?Ynww{Z6ALx>cU2& zO$)X|0cX-O>aX7EqSFQ5lLDV8rME7U81MF;>HEdcv+X^^yFB#8<1F2ga`iTav>A^q zzu$5)BPB@$)MkpgjwEARElW%`Zjgc4=Qzm0ZN6Mr1|+#S;YF1;4ON?hSB}TeOKpBQ zd-lS=OBagAL+MTz(w+!YT;cFC3b6u%I11|~yh3U@dnHL4;u?5NNxO7=TRjT3o zxXO+~9WpW352Ls)|06>A(X>L%k#%Zf+tJQ8TBC^~bp)Mnp*+f6;pC@++bVLWZdk0aR#G0Mqg11lRd63H@je$~>~)ytaqk z;@Pu1t5w`G_$xNc%u3-AYl`Tz5m9iZ=C~n@9+=R=RKg(=v*aT2sW#uj2t4@6Xx#v1 z;#Rkc90S?Xta-82bChtXwFXuzIG+956zOVo_-CH)Pd?&--@Ru}?``6Xauj~L#6Ui`jgwNxs?Gi+L5s3;wA~*NI}=AopykWK;~_BCU)c5R$$Th1!xY7Eghxc^ z-nL2=2z0FpvtU$8TM3v742Xj{!=nd?1gNLY6mHvhET-ZNQV{|w(3{CSPl=o_m$ z`#fvJM+-?+J5B_~RfZ`eBX=VqcW~QJR>fq;3g+saIUYZ;r=UcYM^8j!!n?`5o)_~!1k(EqiF8U)BiOW6{`q*p3d03R|4K3ff z1lN|Zu&j`iqDa0ydJlncDG}m6tV5RT(;cOiajY?G7rBNULcPs^2kKyNWd@W<9#p z2KdgBy2Pg>DO%8MxNngRLh6f4xwj@razT)>+K~9$$=51`?9+s}X!?}f3d$y0>KmsC z1`(?@ol?lIn3ZXRlIXZQAz|a~BXCo4cm$o~*T=PM8}X*IPkIM3{|{Gh85LL1v}@z; z?ykX|;O-8=2X}Xe;O+76nYSPxMN4ribHP4{t#n7 zD27pgh2jt~S2vHPjmoiM9Ua!Q>4OLC_!S9)4o%(V#itbsez>nEu_8t7bs-GS*fdB@ zdBll7CNFn_n8U~r#pIo}VWt0AWDRHFr%w0}aA>g2rwZoqp`CBTp%2QmsU($R%NWJR z;N%9%=z3~ov}PNv>OehJ;+d(=`i5xRs{`~&tTAWM5L)~>yD=Lv!@+$|gazKQ<>)zcj$y^T5ov}h>;Z`Ly_Id=7PlZ-2g z&BY1$j3D$kS!awYc9{Qks>N(2p^wrQQS>|hLmOEmw<2kVuId|Z#=l>sMBZ!P#i%m{ zRD$HpM=PHfd#Y9(bgOr&$DyC8UYvBFO%Z$O$L~;8FDpz4Wbt7=1Vc%PduY;7Xpx{* z740aeFliMcZRjZ)TL*^BK<_9HwcXc!J&=1BQc}YVtoi~{63a&yZm6LH*{$l`W@Op{ zuYKDj`Bj5(;*?wEJm}tZH4>RK7@+`TCi@vZ4q}gpLiFmur`2hwBFrVn#;(Dg!B)~r6g|D*m$2Jj0^5uwxNEvA^-7WN6&34W-8$48OOZ?(R9T&#h_Ax%-}-bcawo3|2c$n!OP@E|Mkl01!w>wEm27N3tw!;Jj{}q zdL+pkh6@SCq(Ys|C@%_L_{S@;k+J4ExFqx!lGyo!Wm-WmuL zv;l#FDunf!Y2Sh?NQp8Il(7E#=G(=PQr^A&x@d$|X%d#XOj5hIzJV=tvM&G$SR1Df zGE@>G4wTp;lwg#btQMRK0~04kx2WZ$+o^ofF<{Uvu{lZ*Jo^~^W6-Hn7K zol5*dV^vrnXFGiJCas}C%mx62=f$PoNoeekg9c603L11fdN-~*)kNjX@bK#G-RR7J z*eUXJ@cU%nVyx;L1!A7!>*$`-|K}po1SrSQWY7OY2=-U^QI28B(p^vNIjK`&RDe4G z)Tx%v;o9P|C@80~@Uxl=vG?#F(c^o z{BGUj)xo0-{;NP0jlor9cCL-99*{076t2y_n7|SWpLznF#~HwnK=(F($ZeJi1-mgA zm#qDXbktIVj$!K&x;_${h;A7gtDrY?9{8)3uT@wGOMosCdrP<~`!;YEhwQH4bzD22?j#>=gqK`2iHFXY% z>eL`%dj7!*O$o~?l*I)q^1k;S6uBy$A^l}{Q4{+ZCtxNb`>uXslFpXS&4dc8S?zT~ zCqGQ!iO|gaVnBCqYt1}JjX|$!vdf;0WMBmVhlhQgu!Y~3|C&1veE%R#oL&2r!iQe% z{)xuaRxW}>>CtdTZJYlb=l=hvl#~;Odt}kyE6uz?n3DSp=XnI?$5RqDJKeWJ|ovPIv$MR+cXWUUmW zAm-FC8e&I=_Q~Vu+2sBbY?;5%0Q^m>@+hlFm{7k`@C&Xtq?hW}jR-MI*xrvn?5-(1 zG7;dzt&o&wBsB#Bhqi}C9MnSXIG2zb=cptLyObMuay-0G64Qt>kPj)5r1KQ~k;Fq~tpA#;efl0M&|9#ud`Tzr_j7}XdtZvKH-W63HRmhg02BpAwhnRziGO0 z6ul#A+MN#=T4leQ$#18T%BXXx=IzRzh&-IJjh8=~;}!|ID*p7MuhOU|uq_CQ|ZxG@!FLaZ_2aYSM8Z+Alfq!A!^ zQQcpGeE;~JS~6WZNn5U8H_sG_Z0v$5zZS;%i)!B&sy;J|1e|_DHbZ*V?-~nJv?No? z2mI8#nDxsNVX(TwV!0A-p@X<2p@v1YEPn>*cKAk*=VD=(T1)tCq4MQI8p$x3cH|B^ zNq-@zT={zZs=@}{v5!+VF`U`8`e0 z{79jaCGm%=&IG|K!f0|p?mY4e4GC8nX|>hbw=ZEj|M7+o=x=HNoJrH$>giAJ6PATN z%nyJx8A!Pz7!rHHAS!lDoO^!G++V+cM5+1`DjTVbc!`s!CwGO-plNH{B`e~(-f4Xf5e2X5AymqAF z!HrYt3~l7Od5@flbfi6GZN;U*EOr^*1v;6+8g)G%hf1iNwx~y1-_rV3x0PbC7g$X3fhq# znXL;w$^$W|Pl~gmUZt@gsrH%l=3~%srT2UV{0#Xw17q#@9~5Pjw__QE{BGGImw)Z&CJizmZmi?Y@-R>gM?l&^SRyTfb5_4xtZy5c#hAlk4;Jr~KCY3LwU z$YyJ$U}sNZi5&U|0L}Vy4vP8e!b&x1+juz5^xQF@P0eO#-7JU3t$2FpIINHnmR!rU zKZWWFpZ;=kt`Oe=kJmhRMx?VFnUfQdt`w&+kP-jGC5=8ic?xz%J%${8Q)z5LER-Wv z^F`cV(2)V7M#BEL`g&D)qQ7{wz$jHSW%miXHxQ+H__FDLi!trGp8pkNe)c!_^kOHW zfkNPlA^V|A9$|n%^(_@Wt38OV2fR`nbVbzSd=TfUo$&k;9bcG!CgDh zQ2(2E6jH3tMPsE0fBEi!?y<{JC%eS$isYL~D_R4c&lT)mxC{kexDgCHxt@y{gAas) zqsSZJ2a=T$N%lP@FaDsDX((8&yR(Uddkx={i9kfRz=V~1s#XCJvtp-O2DX%Bupfwr zJq--^UQI)`OGR}#WZP|^YBTUBuu_Jl5(uYknQBSOI~Q;hEbLx2A8y-%A~Gq@KhU>r zIHCXtTQB{3?N!MyN2}A(t?PDaBg43Z0E^)z{|=>=PP_R*2m4BfqQHjroW-6$>&^Hb`ClxW5V5&L4QR_I9FR-t zaNeTNmpsxa5a>Fm+U4M{zEFoNx>F(ev2XLt1~dg!%vN+-?}N;(#Cgq`tyVh{{nuQh z-s+3jKXd7d%cvAyl#j0(5kSa|9PMm`6?=+i(8wl6t>iFM~UwJPalD^*4 zgdLNd?kz~Swj5!qip<$h-^qH-(6XIp+}UTWh+FpMR|jc%$~JItoW;d>pxOVvh=P+9 zT`OK!mpeCi?Jtu$w;AVaulCLdqO6XYS5?^^_H~cNZ5PQbmZL1gw(-`F;5q?QV^aE< zmA>!#NaCYMApe&2ROLP2g?e=Czf_O(5NDpgocR%)w!hY+crMvj;4s}P>$OGW9R`u; z7UcXhELxoFQYMgKH3oqwV}oeL_b$L4@@$%ffIR1JPyFgSPq1Rip8spn!PCGE7tLJipC z!$Uhzy4(%UL@a$7_Y8AR@xKCW4rgcY`ZH{e07x8L!j5_fS}hH$v%S=-0yiD2*BLuk zH3y%0mbk`V>e-+05ADo0N4-5Nro4;oMW#&?O7rie8rKf3Z$`EXDN5&3XZDt7Mg(Z-OM#7;IH3Vj;FMR(DCVKYC2x+L`3-qdrCw#e{&waEvt?f_<&z;bf*&Rc1v{}|EW~1V(Ixw^etMYx zfrEhiH7v7c2XWX$kqxj82b$>$JeE+uQY|}9PLt35;bFDIKKm4S)Gt9kFabG!#0?%E zyCmko4fcxnLi+cnWw9@F7a1tqDf|HYN%t5D)x@Jtm^RR?ihn^#>-HPm&$B0YfLe`w z&GuQMUR%9snL8Xb$1kSv#pxZ9eoZrUu|Og)eFRyvJle_58!%Ez`ohD zvcANLxhEEBdKiIjdU!{U_b9Glp^minIX4=q%!^5k+4;fdpxoNiDSn|ob-2CfLtP4D zust*sVH!OFIAN$Tyg@>b-fk!<_#Z`S@B(~9rK%ZvgFDF$Wbd_qf$6sz*7uG^=0LV4 z*bRaa6~-m3wq`&Aq^tbKoB(zytw z;Lw0_C|uv0WFdrwzIR<}jt+wy4;w zU;<3vu2_~oz zrd?m(=ngJ^E|kU8dg%rCy*!Z&f@(5!Mks5zu|Z#wUq|*l{)oonPT<6X@D>HFFQKIL zmiergVcmnzyBZPKkU6E=cZhI~6r{LuNFvW5wnf!1<2vxJDdL)7TAgtTZKoMfvJ%n< z=QwRH=bb^%b#}xsBJRMOdaXQcJ8hCa+wPu3+nQ}+stFSeNpNz7R^Stc0z}u!Vg#c5 zW+MR6uZoC(&QB*Cz;!0i{>?1pH(2P?7#1y+UQI*)jQnnV`lNj6EA%c$knR}r0oq>9 z+u`aQDO5pM6X<{1?(RIt{6wzzWzrv6ufoSSKw^s@KKg7`F3E{H`mROIW?@omNvTx) z%P4lS*M!g9KdOc3VA+So{>%Ck}$9YI%9dFF1$8Xu&nP7C4ZAn0)SW}gv&*W>ofN8EohwlFrX+RwR--N9FE$|<| zVmzIYdirq5W;}F>d|$m(%9lgBtv5`P6L_~~-DSn8+xZ&`#IJDIPvjeipzMJ!+u+Ze zcZJ(x$8bGhR<+n-tBQ0&yViV*@T}&O>i*7&aGuBqnIZOR>xLM=qDiyJL`J|442}(T zYbB$!D9{sO9_$D^ZTT<50z1qDRW7u%pE19?l@4`|F(P;O<1I;X5KdoJC*Q^sUS=W? z0D<9(bF`HVu=^mWz1;49iwe>=;3T-{={NOuj{wrB4-8oU6 zwsvnEUyfJQ}V<)pSj2p_TkRkPwYFErdD>kN$yHUdPX|X4! zcxZ7XD1H&A&Rd5$Y}NMy0=4h5i!$%krB&U?B3ixGHVxoC#*v3dDsKtc44R!`;U8XTFoRqDSNiv_5=PtYL6yK@JM6ue;LWy1 z_8bKI_eJ{8CY&d+*Xdkdc5og$v!<2ujgf524C|@}+HtJ5fg()X9bnW|V&9GIO{uAg zi;?mdR`d{HY2xahms--q7^~h)N^~d#TlP~iU;K%v5>^uVbFqk5|9qb~dm(7o>ia&ew)?Y10xq=0SlH9nl=Tlz# zxdsW9SNsO%t{2mV^1k{>omh~YiKE}3uh#;!B*3A&zV=oQz5$3EA4Rz}5u*4D7Sx(; zu2(G_bIs4MbPW6sEH8c>ye{&?0E$AqIMS3so9vLh4B0vk8HQI#zZt0tq=pg2YThZCUtkQjuLwkFcDd)N2=kIj8*#%;5o!8^QYT!5e$_P|U~o8k=!;^nmEJdW zXsoHjstOdxZ|;*nKF=c?f~EpbGS1{}e;jx>e8E@Yi*{3Gq+S)R&HC~yG8W5c7-Mvt zX1u@t6bbQy8!2`L++B85uJp&xb2pJ4V*E;V;vtmlM3Wh{Ky40pS>iEq8{eIwD8E|A zzW`YFBv6DsWRoegxPC{8Lpi7>C{Kq`Go-eOahln@ysC8kTx1U@$&e;`ey6>jS~_2x zUS+j0ckWHB_x$`cp6WSo*c-gyUUitr?-9C)xmsAYz%2DP`LOnI=M;RuKY}E8mTq&3 zm@r9MHuVuX57f=TjhOIUjUP~1ViEpANiKXqj#H@%CDo`0xA$ynnON}gc686RsobbQm-;J1ufy{4NU@b5^7lJv)&B&SQaQhYmpY`m4dK=DDy^r)#KEN1Q0{x>KG$1lc0Km!KH&f6;43mV4 zE$v<$^OJ&y{!$ESRiSh>pmCzNcSY?`vj6NB?9xDkvCIV+(?tEP$T#V(6y?-Ff3xoN z2aD#(8i>Go=XYaaHsMb>H$cOGxr9c?aA%Pz8^45ZPqle!=xU3(d-HlAKDQi^^X%a` zp})|`vw7l>F%A4cddz%#!>5Grv@%P5#nJTpc9PmDx)8aBb&9!RHAR%S3CMP8(U>`qj@deq3e@3cjIQyx*ZP5W{OjZCYOa`ZXbX9aLydXU`$QMGL*GMTTr7@M`L z7_VmeNsK63V(eEw?r{VN)@GgP-wa9jzhP^Zt{&R1o&Oz6@F{)WI|F6#efVs9;{!Td zcmK)YL3)BzW5e0M9KQ19tZg_GU&0l%WE_GkX;vvhTX84p#z>Wf9nNMwtKvNmA?kPX z`-57XfIRbqE4B)hvB#G*e^f<6L_4?!Xl6V$c1XpA4%afr(A@yQn|sav}&LcZk3OP4<4=$F}!me3OE}*V;oUS_+0|Uh-pe4luCe-^k+; z{!P0it2X2x;w-Gzz^&KIpLFDPU2_eR{V!qL4C-OY`?{mtK(nZN9CIsog$nL`mj2Vt z2{qH8G85&JOQH63>IFRppZ$U9%;VuXU&xn^+0vhw`(eu07%+G!x%B{$_LjILC92UJ zAFR2TH#e-t?ab?%Xj}veDWgQzn#L3R#G!1MN1L%T|80aleP!0chqo5Tp`e+wVBJMu zJ$LzPXx=ICmhN!t^|iA;;Bia4F+1P?>|Zam@AZ)^6<3^^o7~yB5_yU~k6d)h?r_3= zZZU#d;5+UvE_0!+OJiuhyK5xX7Q>xpu-z@&O>N=JI5GZV#MX)Ozull3Gy$X*yujyBY(otb_CcsFAI+C9T;m2YKA*5eC0Pe6ymnAT~^QI`M`DP5cCZ z6g9GFzi3C51k*c;c}c zw~E0nIk^`S)Ue)jDRgRAl@GJ5N$P`m^`K3Cbgc}}oem3I!!^-kRYUKuG2gF+m~1@K zCFSS;RpQ2AuO8%ahHBF~w;#`vLV02zpv;=v7$XGMT=k?SC6e}1N^SI{2YbikId746 z8}`I#-4HH~Z9N)>W=qGXg>fZ|Ka#3=&4it5L@YtZwyvaL&g#;h;V62=EGeb1eEUPNEaF}D0z{t`Y;R?XWzARo1Qyl9>mf{Hh_dKM1=%{A7& zg}BfX-W5P$qnT1as0VQy7NSxgB&}~(P8%ZQnxGCVhcxmn6ea^SAwlt-K@%C-52&Ge zM0vOu$n$>1Id(`gl3ZWgnAJfM)*U#B_W2yVl|#XF1tNhFvFEO8hF2c(+#^EXJWWZQ zn-w2m5G-cchS6@0xf+zxk8x}1F7D-46I_{Awz9g*M ztjY=zt)0Hw+xfD$^nC8{U<6=)SM=CA3-doG5jC5z-fog|OKgGgj+4#P)#}wJHqgB} zU8i~T&)v`voc|L)y?bSztHCcYL*iSiGV*&qdeNXy<|3r>H>f5mmNK7oi1(5Ajjbjv zCWhvnx?dJgDW~sguq;!o&_38VvAHSo1dXWuD|vs?3U0hA+CnB6icOV0y2?M*h%enS|7zL{U3T z6Q}CLGN^SvCJAa_*0}=uoI7B};*XmeF#^jRNl95mbLpAJ7=uVzk#q_NNiGdp zP4NOV;W6ajO8GQMjK+rY5(0l)AZ3wg?=SpJ=_^zc`Ix07_Dq0X;x%Uj@Y>?B*RL$= ziN)*dgr7EqPm)w*bC~&bksq(Zv=NW?&!t%E_J3QJT0QW*aIBVnTSbh5-Z>G>wmsPy>1YHH1^ zG1b*SHPvM}`}tfwLJ6#j@TowqL{bL#o&ZLL@ey0J)*eg}OJz2jBhaS{e1YS<+?0|; z%+OM)WV0h0hL0woo55Ygv80Qhf)d&X5QR^}hIS8GksY6wGNq&)`byIFB+IEC^&m0I~IyANR_1besZ3C5G17xVHXn#{DpQVbIxD_=*0U{6lem}XVXaF z3G}gua|?wD!u^tQ4Q4cPWn%7vP@>fuV#i^w3L3H5ncO66RGwzAs9=HAskYA2eGzKd%W}84(bQ8ysgRl<_0~ROtV#qRX z*S2tAsEWMUPUD~4Ov}tv(Z;pq5qm@Ca2>6d-1lz$LNx~*r#}rhqmXijcU7Dc<4kxh zUaN^l#`=|$NtAuIVN8Jia@)2D*@=alW~td^VJW$jb`(o5y}@0wKi_+}btNe!l=@5k zu&R}4FfpY)uG_c)%z;5U^To|Cps!7&-x z0vC}n#ptBC75u_v;a~GG?m(m87`)3Iauoj&=92S_)phI1Lmf$ue(-0NRd_lvtJkU4 zC9Z3Ts!GU^?5Xj6!IOrPkEQ)DedOXCVW-ZnsVQ_NxeHTw1JWFK9>FT9FerChlpdLW zI2mPQ)QY&@^v28ofdnMaGE-jvW9(v83K36s4VO)0{yjRD~cM>scv3HN2+b9fVmN#Bp&wIcX5DU<7|r`Qkoxc0qXN)Z006doNucb>mx1bwCE> zIIdB0e-`XhjT(x4u1<-Kp&{CBy;|eeUi$-^n@ZNhm6Iw{h0@cUo2>oQ^qKo8_1?R* z_$u=|#{js}xG--Ix-?d}qjMWX&#>6-bNV0EejbWvf%=ai|AkI7f77{$MV!G$nep-Z zRZpLKphu=(pAc89y>l$wI-e}aiR5+>+|?DQZgm$jrh0y^CU!BV?sai=@H*2zJ9ysAt7~B(UodX5Z{aW?Y>07G{4aZ|UV@dI(w2 zS{GZUu{jT;Y@(BGFwo&Z(1U;5@o7E5zjwXTDc| zC26^AU@2dWyx+<(+=o)RvD=VIgkygk-2|D=%vfY719=t?`>Pa_1t$U#iyN$+giF7{ z-*2ydR@X(kyKeufSK8dtTRvfCmQTn%=i&1r@%hJgIM9~MAw+`M4#o6li6JUN)Da$& zUsV4?c4WD?2)rFcve5&8^$a|JeVjd;ay~osKV;GmP&WUU@c0~Ok(7mTl-*V`E>5i- zCuO66*+#f|)hJcR+pZYW<@vu|Uj|PwAz%J!ivV#nC5X{-!D|Q0!ZuVdhKT})t%9BE zArr$w8X6bbEG6-o#HdgPcLLC+$YZFM2oo}LLzV#LKFxWw3F@jcA9wuix5U6NA2fLQ z7ZM4^lC?l5Es7o~9mhC^1f2}MK^w}1v;}1boK;WwHce&sig_la>+dEBn%4l)TBVXL zE!z1g?b@T~(2tXQ$Uo-nN!gfBkm3_&1Ch&*ekRCq9P~~*?HeKa7fB_9id&E5I8m+ulOcGM<$bSyE^&#Y%NQgYyIi+^}B{m=hm5}R^}Nmi|hkyg-gCc~C_=PQOWw~nX^&M$BYKS$-7Ey_)| z+nY*>RJ<#uZ1%-Ns-#Sys+QzhBr!LcAV?9F*W}t7JVu z@63SsL$QNVJgkdD&ICHh*WJV>z^hR`hEBRd$^1s&(KVXc-9CT*8PF@Mbx`2wYoy+t zi*(@5zp>~VOtHf*ZZ5IQyGrHV74FP{a$${~*`e(&u4L@Z)!W9~NK)Qh`83j?9WPLo zf-zVLdUwLq)m!-8=uc|X?%P>p|3_kC{Z#GT(>kv}bgT(T@R*0#0&s2C`3Kq>LZ2Q) zO)iu^pDf0b2@_;eIvfT9-n(Ybvm58TCybqsY;qHC#vmub1dz@a>hzm(qv|8RO$iNc zi)bLKx)r&o%K>)Br$>cKA7RG?o_t`qP!3Mo#*yYp2c)>QJd1d{5FYVBx2GuPRWA#Y zUU)S%**-GgL-Gg5+-a2Z)sbw!4&}9hE&0^UfVuc%oGKC#@TEc}S_=p2=SwQ!E)moy zgU|w_>I=AG5;z!J*ZA2$&rq27)!J-PEN`>G<}%z0m1P1_?TZ7=xkLI&i@#uNagamdQGl(sn6OX zQ#FFUUXb>#5O;Ex?}L)oRTgo|eb?jMsV+xd&I{#)gTJU^tNQC(d$;9z!qmgY)(r|k zi&{aj!Mzj-j1*|I!07fiwK7`aI(jWsCJMRtFt9EI&Rxvvjfm0~vnd;^^^Z8^c4-2XU$ve*dV z&d?LlDUQ2maJ(T0*vAhn?USI59J~#JFcwfJ$BVlmkaHYdg=PYuykVs5Jtcu(_?wWY zlTyRn4Zt@5K$JH0h_wrv)sdwGp$}uG-7OF2&7&FV&|);^bTkTmqKeRKay3x>SRU0u z?2}|3@R#8q8#;r`r0C^~@Q));ot|~(a#s&89f3sZhtuBv0#bVOY#$pc3T}a3wcOLd zfIxMu33Tw|sp69&bQ@f~JKCNzwbS%(7oC%^lSSq#87~ADs-WALS!+)P3X~7CIg(+z zk~mrQD_P+-W=ZNiO<1x+mS3zJE7y&CR>ItWI5?P`k)AkY*!57o*#DXF^KYf2AUEsb z)rfkDthNt80Lv34-u3O%?ae=>q&9DCk0xxpF3|%~35&4Wg7u7ODnJDaW`e@UX$G@h zFXQgp;?8TRssenlU-3!nSmJ=egK}_C;VA8+l#vRLO*)9U zK+P1mqCL}5)SOa#0JY>0kjhzFrF_RE zMrlK98i5X&<;|cV^*H_*B#>`aA}G4eB4ckensgj5vC5j%*G4+ni&GZ`7Om$LvTq}& z1?h+r683tvaP+A}rEvYpR>yY=Lg_%)%Vg|$s7?o+-O$5ZyD@a4BuLA5{g@#k^yDLn zygb!_1w!Veg2p!cU;4tfVW^ch{^+ggi{}=xhj`v^ihsC=GWCCOk4Lrt;2z%e;+yjL z1YB)%k?!nfkr@r7)%jnVPA^^gw;}93A|eMBl7W%2NS)2p79hsLp&GCEDmWqwHD?%8>er_$*;^3l<&R6>-$am#A zmKID}crm5@v6Q+BTmGfO-(_FHXfU=Es9g4AF*S?tHCv|&$vdaM&r{pYJA3$^=*B1= zzHCzIs7~%yMGh3dQZix9z(<%9Qx*~eiV=Wxj|a2J(^WwZ1%b23197uJ9?Qd?4=3y2 zZDC&ocR8tfD(q2ZWm;LSik7sluOb$4={0N$>-4ZBuU>k9KjD1`{TT zDKn&*>kiWjXf?z3$nZm;52iy1d$GTR)}VXz#^Rv{XFKg_va;7Sh7Xsqs|-bJm>y(TGZ;Xy$7=>cNelZ|LqBR77Is7Wt+9-?(ga~!`{yEuoH8V-sJ0nXH zeKd4Sd7$22Cr|FtR*jo=aas8hcj|B8jnNgb(xI4{nJ+H(wa&&m-4l|X<^UL&YT(U7 z6}%oF-lhAf{%!7J_xyCPAs{pl+vTTXj=KBGsExfdK?=?EV%9;VV2WhVJ z+&Eg;h8Rh>fQj?;zIA#eguu5kWc^%crTm^$doZI`Zi#Wv-`@_OFAnQok8IxHyyMA)RcrkzyftI1 z2x?Jf6I)sRiwFw>yYg*vU#yyya3WOEzb*1nkJ#d#LE)BLbalVXhu%zED7#Uj?R{hk z-u0|q_`+J2rzGz}5K^yK6p>qN$vGjiRZHbry9!y`%&(wDY0E zf7jCtGE{`QSIFD?&g$bLNOv0GPS<<+WvdXZAD(3cw>dLUw1~gX<>U{s*KdVm6rvCx zx6#9S+748`OF01!{u^AF1yI>%Q9xzSC*b>|MN#}arwhiLOxD&wsIl<3PCh&Lg= z)1nmex|x)=u?m;jp|L!-kmL_MIXXp6P z2&|INcd>{5Ggg<~zm3fup4Cg?P=5&qg=#V6uPfACtyV%gGQlYO5xJ9ptv57pb)Z^r?8LbD>Hr?f0+Iz#zb%jH%AJx_ZS82J=lrz{js|!%+S^#^GMc&BWu&|)7NDh%JFG8 z|0&`WTED5%3;SvjqJa=kFIOy>>$=Ta_ai74rwK@0ECRuUH|1i=b1-ZMtYaY3u;-8r zn6*QdZEA6fEFvr}XiiXSIW`M7PkUjE*ZFafvqn>2kW=(6R>2;&lrEBsqOp+>i%x|7 z%{2t4OWC4#sgpH9XByiq@4LX6F^B)q;Y*7?DeCUHA#As*el!0g&_mrDE@b}g?e?>W zx!`lBu&Y+3Ue6xI{CfHBtnuX}qBob$Td+ThI=a%{Xp4uIankESssqchI7h0jGfP8S z%(sOwl8Z?UQjeCspftDi^cQh%3Ki10^$}=Ub3hECi&RBTH}pN$k5Mw!#$nF=#$Cy| zqmzDs(LrBog@+j?*pFQ?cQHY)>nK^X-4XRo!^+mlV4d$(e0C2F*l9#W{b>4wZh`Q}n_7k!ioWR&dF-Irwt-Vu zV-Cg|Av6ab>TVTuxMpFkkP}@#x5l|L*x(GU<=S+uEzOAa#n-0;maX4|7oROv=^}ZX z0h@3q)GR;N3fyv|%R6kfOz7miCda~}rpW1u%f1WeqAajgICmvDw1e(JbHuIAk6+)S zEGvGy68=;@z}GM4!!I+<2k&K&SEVFHJqv1p{_LM(9q84aK>q8$WxccBpMkA|^B3=P zZ1VcAytl6wiRLIQTbqL=c(8J%{lg`_%H5v+``(cUyngfg*m>yP_Q&grqHhF;MJBpH zj*1*c08zQf2$?Jx?a$}&-GiWM#8Z{Q5!wDcdx+jMzM2#W5EJv8uP#+nJL; zIg{Qy9dfk1bV>H!2G^j2DN7q2^=i?X%0~Z(k*XK7DWX`yc*j%nN%baR=O+s@UsnIC z)U<_8@_}=Ai_~X_{4?MT@8x5l|0>$V-yg`u)^!?WxDHkc9w5k5Mg08sxH3>%$*Pbn zV2MLW)&;Ql7T)6E_jc$=Laq0Ca8eu1b=-%g^uQlmgLsu9HuZ5rfXPYsD9Z$R0 zEnVH%e+le7&LUkBopEnU6m>S%n6uwy|SM5)pKsex_a=bL;nl#Y%Z zJfDYnb!q_)y9|6ERHYpJSb%jZMqq>!)F<}K)$&`X%edIw<4^uwg+->$VX57qiE-4K z3v&23oJTFUGpv=Td1R1RoQTzU8HxmyPnj_Gm1oS_mok44xYYF&X*;g)-1M9p8?GZ( z2Kft`RuMnGDXk8)wyO#lwhzNRou-KypFeUNRWR?6W|BPI)Z(!B_3Fxer%q0fAD5#d z)2@~9@#RwvzIz#F->f7ew`~**G=y6IP8<6igB3yzJC;84<+z^Y1g< zT@o*JS!fjZHnG0A{9C^T03?3$v^iE@lJqrG9x2R6Dog-%{qo1+K=C&OIM2bOQwF3D zO&RbEM&&WXh?4?J5MJq)NM2P|@m^)-pk8GrkYB4%{cC9y46fjG8a zK7zFM#K+#G_j!uhIzwJoI#V`Pc#IQ7PupyN(#ftgtZ>3?t1cIkRUEGhs0$6PaK@*U zYiflJgtNQ;S~nYfpmiC1JYHwfyh?o3t>ZAoL9HJX&!388%uP)V*3Dr{cvdj4hoQn; zc9lh=HmtER>V$V@N<=4lJ2>Kp*9T}i4}4mKdw!2MEpS|sw+h2lg8CxqBDws|-flzH?7y(k+a!JBzqMuJYeczQL=e23&D4q@ zR295b2UdzF<1*q7g739wo$sHjw4`7RU0TNz@yw@>AtQx$?2kYjkhgPDrH(Kb7g*5| ztd2Y`#*Fjn^ZZK2LI;>s2vU)+ZzLl+#zL$L@hyWE@9CD%MqboAv92x&9p3liHE3$J z#7Voi-FjA>G#riC2>{{<1@xGiBebb^=6%-rRxF)?@l@7^SB@{?p2wiULyzr}3x;>M zwnHFKi&FSn=Hb(%=%L~4(x{9z<$eVnIT9O|Y>(T%Zvf-l z*+j5GkLKXH00bEYQ{gbf)_m07+TOXG{4(`N4|$n^xj3w3mEEp(cbrWT=p%o(0ZCf% z$+2SDoZF&T(x|&s$MnOlZbzJv*B`-8_Surrf(Q?#+tQJLU0QV5#!fJ|T+65FqIXx? zro9|k*`_Ho$_ZOJWbwiAUfpP2auAm~g80^i!e zMZ8LYcouqH0o@6(eC)>5M&25pqtqZ}%|!DB9xY!j##sOUpl(}Lo#NR&lsIokNptVa zr}E480h)w83bsuoaxJBlPL~Y@Jqn)d{gdSN_V}uFD7=YE?AX%nxQ~3?6!*6H31eL> zH`(RG#85j|Wri*`1hcn);gdz=xl_87>W@Ro>G1XwMO+REZZ1g2E32@26prhf2fZW+ ziH6qKY5~SqnMa%VJ?M#|BG$a1nbFe8Gu5jNe?NO?2>9tf$5KSgBaGThj3Zr)wZ{9A z%Sq65GkAjMoc0!T(B2?Pp0&ID|HyjFs5rXd-8aD!AcO$H0|W~a+@0WV!5JKayF0-` zaJS$tgA?3>yEE9}9^3~QgW_q&ttu5w;VPv#S|zV%{W z0ZQdJ{p*$j=$^ej9HyQW{_nm85B)|Zx**jpjEC(W-;wrdjd~&Wk(%Dut#b4SB+ry{ zA3~+l_K32=_RmAkvHLc+UD}yWqpus(08p`W;;l}2X5F52q!jvi5ADenK&8ZYk2~h2 zY5`*y*!RJKQ+t%=pPztf+q&*dlwj&yP|&+D%ilx_p6f}EbUZ8my84x{fu5(vv6E_@ ztTh{};b-d1kS+u6*6W*%qF=eZ?ag%V+?b6o;ZXmOsl_{=SzA7J`xCB+$UZqI`BO@5 zviLvt8(b1FotJ)%SuOiWC?^H66Ppwfn-pQSEb&FdgqGYGJI24Ox9H+9ja@@;Q#26{ zpib9XZl*q>C>dXA#P;tM(fQ~+KI@DSp6|=bXBOnSZ+RLMnHL2c1S2$U$P1dWt-3t$oe_rk=Et4 zw_(HtCR`b(QX%1ix|E)rkhvxUmzu1`-SAakevYQ~dMC2j#4h(fR@@cc`(L=S{|VQ0 zl`*y{Aln;51$${&Ae@Nxr0kL;Tkd@ks$;m)%O-20H&4MA=qjjLf;R{Mq`cesj#{oK zm8Rc%26e&BjdV@yQbiAS(eF*x7fJNR6BMP7tkbd_C5$$is@Ju4ktAjeagmG4V26$w}k3bm^R1ou<|JDn$RW;kn@d$I0%Qo|zV=fxspRPioFa6l zL7&wqhQG4V2976-33WVg6c(t3pwKaz!pqK3gRkO_Tf1qn zZRmacKqPjWhigI1>9%1Tf-0v+IKLY7fY*WtXn{#25^c4z-C;_Gpc~XWPSYgH*=A5a zPV;r{dt-Vhb}(^QI&9;(-8j!ffI;BK-@yZ1p{#SJAxH2B#8`l7&q#vff!IZ~dUsEw_fxuTmtpvV`!^eeD_tO)yx7Q7<>IuxAdE&R?B)@k! zVm31p;318nRKXw~2H@sy2=Q$KiN!~OQFF@-+_sv2x!1*Sk|S|YL>x!luaaGb0IyWi+Y7oL*^C|8x~;uCvDG6cTL~o~Jr( z{nV@(s`J=E1SgAnuBd^KUL~#BF`b)or23=rd(=vF&FZ5V88O**!=->lnjIaDJmTCUB}0f7W|2B z|7T6aE%@P2)6Lmk=g74Rol~@UBq&}H`5-~VI9Xr8FLrv2o5iLto~TWFv44Xg;}oeSL48s z?w?mrZNJ)1A=@1zM3O4q3?0Gr)_Qy=4#q`{Q&1%mg^&3rvGZ}tnvXBhid;DYK8&q| z@#$*DRSXgk)6Hp+#Wz_Sb&7LKcIgSba`0+Pv5(Tnw0UqGFm`@Bi4WlrGmfDLUePBV zTI34A?q|x4{^>QhvC~@Mkl;M~XkLLKUPO0Q?`7xeGU^8b@LP6&o)27yp~pS8XO_;o zNi+-?`oc%Lw>I9SVGt|xq`CgJFJkDkMA%Ej{)nt&{rPtl$$lfrmr4`gsz~il-x`0s z<$Kq>>Fv4_C^vE^oP6k?G;+|NL6srF%Wt$1Us&butNFMR&-B2e&Ta2#aP~VV>h_qN z4o9nrS0$qIZD-Pe`dJL*o>=gQ-*GM`GhdX5(BMUy$9rv+N#dW*Wk1YusrC?G8PJ6L z1|SHpC-Q}LkDZ}*D_~2^a{EYTjk&68Go&+GND*9F)q%n~tIR05V28&~Pa=`b2FI9< zM(Vd1dM_YqYy z#P|HaFr+6DIWZ;?k&(RK*&*F`C~#a@_2P&XR{yHZcyWd0T)K3$6O6qNv16%lN6N|V z^U5w13P>fJ3o1+S@oebyaSPnpf_8u1vJGf|x{lhkH7b+J@uq$aXfbV!v!Mlvh8q$R z3T5XF>#OPbnf+(BLyACt@wOtz-%&BjfJw&~au6j~&M zWCY2EBQ(#<7&--T=Y3U~kMGdY$0wBhx1Vu?o1Fl(QRPe2%kJgq<1HQ793qIjV%>MU zT2aiz_tMiRJJ|8pnf${Lb@&XjaOrt_5I1h$!T8Oaxg7%er|+L9$ve|Saf6BDI!}$F zC^{#U$HNEBU;!~Z_h;3-a}&=Hw|ah5bnb2I*RtiBt)m=TRd^P{;Rp+d7H!Y^q$k`4 zom21>#4w|gNgHmbLDcN+%A;(t-e4owW_67RBl{6 zJ*M0$qm0r`4qrR}DplVFDc>)(U^2A~c6s%4WKj#yZ*s_?G5JbH-TSFl zWZ&ZHZ7c$0_F&^wImgLo1vr%g0r!}t1-|!dYb)vVA8l8j6Ehj)4apCups$n@ik%F* zmdRe*9v7k?Qe3E`gRoOPf{*n}ainP-E8lWGC7u9V}q zw*EY;%${FWd~NFQ)krR}RwcepwxV)`QdNSqlvQGs-&C&fZROz*I0>eI6Zo8$NB{K6 z78!>cPxqDEm}4cs+KtP4OPw(8qhYVB|I=*AsZx{x|C7h3uboPj#lEK{Qk8No*z+QB za-*&=oy;$yL$0nRSo2eucP%(gLTe;9P+LKcbTkNfs?_cU|0Ee#N38~H&p}D}%(3^hd2lf~je&MO21OQe z_csC-zxGks`1akBdFJCMCAcRkrUcao4sRU7F5}v9p<-e#>CZ)S3q@P|H`DcanWLA4 z3FU+45_k>ycBm_?8*AmjQO)@gYPrOH9Uoe{(l{qE-oI-RX~JrO>rX7$Pe~+)(#0^| zO#5~itQEfFU!FU}b%R0XtCno(QV&c|fAfbTIT(&jFB@PDrXE$jF1WhU6sKr9wkSg! zFsv`!>|0Ed&Vo>0+0aOMZNSt>ZX8>Cd7}PKc{xjqc7(9w)VCwt2>}Z|f!yuu8&4jt z8En-gQDAgZmwH*6{o&{bpD{JK+vH41mpk_Wu;Fgidek`rN_m*UDS|)Vw4lnngLNG;5tLorP;kw-0D!p6COg zT3(_J!uR7M6n}gdi0CQ#SwfeVdSN>q>3(LLr==9>4yf0}0R*QL>4dQMG{JMlY+MIfYXK~%~iU8#{!FY`EGaMIjN zTU4iJxhjo`EU4nUzCOLLD&%&@ogf3$bddEOl#a7Hjx)9+^$ zBh9bQhMlH6UaEL7iH=Sy4FX05bK$>~#`^D1b!hHBH))i;a!w+naIyh7KqJ5H8M{rV zf*U$^?jAKZ=UKPNHcj#2${yo~f{&8s&*HGBwtbEtaGL%) z>E&1!Gs|CQ*hgVsi(Dh$c!z#1qSb(1G7#iM+2*)v3|g`WZB< zonKJagZain*+?pF1i%EEyK))m!>^NwGZad{yxc|c zFPd$#myPoEMs&_H=K^oRFhgAlGb*CNIQ<_Ui)9(ZuB|2(ibrt9<7s);NJe^AjGPTn z$f^{BvTxL+(kM9@4_f&Z<9byQr{28UFi)Y(zYOD>*{W=e4Bf6Bx``DxM9-(QLhoaU z9Eh&ppWR+@%%_N1AP6eWD=?BiDt^tRF=nXrL$%k?+#L|#-`wmmMZr&|7pjJs<-r`* ztU~r?8R?JJhep}D7PGix8pW|cj|Ys#6FF#F_w05hSibovHo-Ku{DYEiQBdrJi% zP}K>aS}en&`~4VwjQYis8wf}=`*udeRC{ueznsam<*d!h-#Riqojdby@G)Z!XxA4W z!>^|TW=?1lOE3h?S`3sRY$=-8RFXksR!hdMbW$Ce2%iDD)ny~h`MuSG#~25?XHwN< zX^Y^56h}&@&u7d=IJEZO4DQ%jtnALJ&3w8~itnkYnDIN5>I_7nKDDC$eN9Rjs2UK@ zE^YAejk=7z)TzFyRT!I|@e`=4lv{G5M+kN(SNSEg^rmrO|7-}l4qZQDP&daB`ce`GI6LAqV%m_d)7QeyrhouvPzWa0`z@msvUKFRQf zLBT7Sac%Uf66KJ`51Ai?C>)4sMw1w%6D;~IfZ>I8m<3fEGijJ*og#@4rB5-|NO^#3 zf@Qxl&6FT#C)wzpYq_@$95-NWYTgo@9YRxl=<4aNdp!58o?=_u^=I~5_%(M|t<`36 z<5-o^*BYVFM5%`bhk(fO?fB^6n|XteMN@7rPs$_uPwz8MgqfJ<;af(}P&0Qe#tHkt z&H`biJ#K%Qpqcda?@!76>YcXuwzU*Hgm=`rf>hLR&;f*;9Ui}?M+`6K71W;x$mGqlf~cf>3_3aU_YTi zu{NQACsjm7^HiRpNqi#DTct6x+4dt?Xb)mcKYl14?dX^HbpP6!HH&1+$5nc>?Y?m; z<5iVzkFTj_o`T5HzxF?Eb4YvPD zzapyb=LJIyW08Y?SYw$&t1+C=SW#>07}frq^N+GNLj96zas5{^3yTeHvCWq93kYoj z1TEiI++=CnX=#i-=<;|d9kK`68ynjV{f>KV>`kiadLCeFCJ|_$otvpubRZ&euwHT+_;WmwoPK579JXhb zA~PyZ#QnLoPlM_bMOm2s`mqOCx-xTSo`h4ovR^@g*FJV3o`{7=0@2|DG;=yN0}lF)sOd#A`_ zen>#L@pfGMJ=}?yIEejFS#L(3U((gzY^lJ$NI{_WO>@)qq{~<|skJaidBsTal3nJO z$EUD^Kb6IDuI}~~fJrF6x}c>-?!U0dG6umJaU<5i{s3XjsM>#`Ejh`LVFU~cKLzB? z9TNx0CwjAW^Z5RHVuZ<3?o%YG!L~i?b6V;!@BnfPuj~5cOKh__-#lnMu5EEXcD3T? z?&OK9>knOq)Xhy4i;3=X3302Z>|;DQw^*CZvY}W5M}8bnKvFU1r*qSze(=0&YiseV zZ~JB7r(|YxXLhYk^(z$Ob~j>FzZfQU={Gdf2=1{EIVttB=GMy+SCKz;oBI&&VZTv_ z%u2rs-%kP%Gf&94nI)ct%(aYX6WudlpyCP1de`QDHXo?vG-N8c7PzOM!B`KVrin*w ztAvh1u5(>(cFZ~|_7!Y}cd$pjzMtVHU?_iF+|by2Fe4^dVg(fUV}+~b%HgvNhXqhyEP|H4$e>Jp? z)-|o1f6W>pm+Sco(hmfynZLxSY7V>_$J6_dt}wL7tmUP9RMyf>3!pzg%XtZZ()(y4 z?q#?=OWCf|i}N>t{f_W2nb6uiI?=yc?L7@|B5dd2V^-Hpdb zJ8PM%Ah22w8Y!dIGfT+j#Ce7d>y2B1ZBLT1On3 z&=-W65H3FKgX{AzB2&s7xlsz4{}jxDdJfh-Dt7?&xidzV?f26*9p*bT@)3HbMcsy- zOGlL^vXo4Z*i1^$*BojIY6O^?%h4-;m%cHVQGh4Ua$LZJO;xg%1eY(0VzDWBMC)?ioSj!h#8ULe1%Zn5&G! z?Oymkn3ZqA{z)bf$<6uB4iz=xv@)=8@_Rautc0N)UMgxtSM;f&7r)CS>#<;dK(>cM zM~-Rks8u1iBf~oCYv1zElb{-Sj|QQ8+1v4lixVJK&7u`AoJ07QX*I8WD@ym`GaWzF z(mtvPi0V7_ffdvPerF{vELSzc;a07EEpKiw1$(;*FB3TA6=}a=)`uvFlZALWJf1$^ z3B>a)Ggk9q-F&yScgA+V{#Vz4vZpV;{@+ zFog%*$0o8c2-HPCp45Z?0Ofh*lDrwJT;FHxc0-zDxOu(b0m!A$JQRX|(CiV4FyM@m z`8H#vc0V-7WqpD%{br@MbZVHO3SMb@U-cthj(GBoAX4wo>&j0&!<`_e&^YV)_`t&it5@pqUab#rFzOJSXF zg;F-x`f$`&k+S>5+;EQEyY4p}N;C{A5B4%2P=P09xH#~qF@e%~yCBv1N_T)YG*cfW z#nd9*EMTl#Z71h-cgd^`NiK_d%_JY?5?a=9<0=OrAC{BdK>+y>obo%VPPj>Aee)zp zQ-Z~8ayh0$=I4`GD&6`mKe}ToKETa7e=Q9nj?oO)L><%*tR+Agy&zoUR zOTKx2^KTn@mAV5fsir@~OWPVH{2$Cht6z~E>6|6$$)vvMHG`a{(26+!_x3k`^-{;X zj!fHz{a2Je@Vdn!-*nr9HQm9>QJ?p#pkzkkkvaZrD43+y~mHYZtJzc+kTeRV**RoWvbY~aEs zejuG!Vwh195pU`3(Zxy6{>q9lXfz<}TL!PPNzmxa?kF~?waIi(F1}jYn8?F?%@0-f z{eG}-GXVvinU4=qm!Sp`IMSXk3EptF>wl3nXByJp)RhagU?SS+x10UXlM%%wUz@lJ zs^F!{UFbH7SW*ixCeyP9EDyW)5!FnN-T78!!pXalY{Nz%e@CQ zPOQ0uWSL_39}|+p|Hp*YKIOnUF(f%|T5=LpC@ z?fjWm%TG7QDAt(sRCKl8SF)vX%Piw<@Mp?)^Rg`eRh)XUmp$}8N=Mc?9OdV}($J{H zk(pi<#62xt#Q>9&d&ahKXi9BVT037K+VEOB-M#3c%ef~jqKW_@^v5T%059Y98n;Rjqb1E z%ibbN*yB_qz~g&+kc#}fp8Cj}Rsx;l_m49o>?jjgm&NvIq!oFNl7OKEM&?~WJt9+L zUeoJnea*Dy%h&m|bFq2#Pd(hTS6t0_a=D+`S^TzDRkk}lv8E^8QFe4SAF-r)eUc~% zc-tEFl83ai`dOQe>v*ZiSGxTUSGV-NC$(INCf44fC6C9)*5!TVmKiT0Y5?5YZlOd# zVyub*0utkc)@COFa$UnKmq(r3C#{qm!S;<4C@Ew8`}!!4M0wbI0lbRt9+-@$!@i6cWP(@dpNEm#izLfM2~92p{iuU`CK_h zc6$ADa-o2@*?TJx-CgiRSy4MQ$kwoZyWB+zp5n}AoKyS0v`7>|L>#b`&B=8LGGU+i z(PMS~qA{cHt_P6p>40Z8fJlq>`b!i^gIA8m;nf$x=Z3{qi+ImGzXeb!n|?4=d_?Sb zGKGZ2rQ3tTS4@0_fup4!Sf$)UiROyZYoBGzUaf&84Q8q9>ilszxhU#{pRML#Rc2Wc zt{O_>rg!95m||waA*KP5SZM(vDlwxAQDstQ${$mRM6EYH^TroIL8Q^|G0HJzJQ~g_ z@-#Hp7nODvBFjI3ws=t!%2%}{yVV0YO{)#)Q>~prtK?@f?~ANiYSz>q2MInM z?^k!B0XlIAHS0PYIWKJo(Pw6hXlMU5=cK9v7r5q|sv7r`ajmBL>NI_;F}>#?8(i^( zkQnB5j5BoUU`kXdL?yD?Eg5e29pS>yrhw3v5;qpVio!OIChUBP>nk7!_Xqt0gKnw+ z0|t$L!AOdl?e}z3!+q?BZVyFjn*Kv|w%;j~*H38cd3s_`o5^0$#jDyn5mGQ1kFIen8X08TQY%{@?GFS(IxFQWLMpw9NH#XYS%0SY%e-D_@HjJ9l|Hm`dMykg6*3vbT;4;o8GDRyVd@-Ivd z_Nt#hoY_G&mwBIY+FN~dQr*lP6r)+(rQ}_fKN|N7?`kD8PkOU7z#=&4tWM60`c^Ho z6x^T|>?y63!yQWX0z@G0>lQPw4*@zN0H@1FAWSYu?J4|$D90rwCSf2x#9IWrSK zzeE7ScCB!+#j1PwZrq*}-2|l>tEv4b!Yo}z@p>D)=8dI;_t<>_G72;Mn5MtaD#%~z zivDX0QE;uNSGWpmF^V|mVc=;e_V$*hXgRlU5ofh0<$`tn-MDpFcvVHF5qe<&=}ZDw zQRZ8dk=O$phBE27Hp7=J2r=uhbuTnW94%huZROW6C)aYU%78?aN(kD!`2z<^U6^1- zvpMF6k-Bo0%Isc6FRI($&1-6P<^P#$kwpAY6M@1!b;hR|nnvY;$ehO1w!)YNNDKcw zwPSWBm|Oo0lh6ceItoP{PoO+*W%Nk{%HyIo->Vu48urxJsNjkQ0_y{+kc&j_ok2j# zP~_)f11wd?^9bYRL9TiUpExgJFGGlp+U=)D1?MA8wc}I^_pxlM-hP8O#}E+n2Ljef zQEry(zj@I1Pi4`)uFZ_|TRnDauU&uVT9^@oaDm<(hZw_XkGM#dRz50LXt!UOU1Z?@ zHqYACsEj9!Va?v0%yh2 zn&MH~Hu2_uPGMC1*hP3d;j(e0-#YtmuNHNOiRDP-d*(&Mn);0T^RYPQL#a4Gx6CT( z^pi*VfEk$33f7Zn(RO}O{%WJMz+G4zzf`=gxFsJi-_pGElk)fdo4xr_xZl{av*iHA zu(MsHou5;Sev115#7+-roSXnJJ-aMabqanM#u*Qs2WK7^Gyq=2?}rQfNIcJLSPrfD zl#sYdg8+m#?oDGBzYrH62X=P6`~{Bup+|4QJ9i3aDOaKE54+5k4qnbUkqn>GO6nRw znz$->G*l-*b#}t|kg;z@?{GSeg|ByO7<5sPO3kZ85B8-$c1%wwl*X}oabmb7Uel7u zO-qBJSQ_N6*GZ!;@`#AW-R-@0ng*|*2&4IgV~@4#;a^{xj52SX&;3uD@1W;h<8k?r zYnR86t2>}r{H58O`YQ>lZz8x)5)_Woq;qruSp@G0cT|<-O$j4qCy%8lwfJ1AWuC>2 z(M=3;eg{MXC?2Vz%hvk^x4$kCOuGGU41Oe4D=;I5fb2+CFt{+)vR(^IhlT9q(mFHaqMv5=@%OBmd0tFy}Z-cUz${{_Y$kCYrrw z#VY29SZvmJ3iRFF5f{M3_0CYIux!VHPOGa17V|u4QBI>=3dm&xsXd{3Fh7#WMKw$Q z*UH;0c_8sQa=Wq2^A21%o+#G7^8FQJ;0=0QPn`&VR$0{BUs&m1#OQWisG!Upv-@b) zZ}(B74u0RT93BS)QMVQ!1p0o7iEhi^Xjl-=CzGuuUTJW2<9BVAz*nq+JFeMV8n@+S zBvG|@LFoQQ85=~eu8$I3NxCCX5(g7cwVqBeJm5*#kY+A_Zm+}7Z!BP#BIYT6*S=z# z3Y3pm8WDukAV!TDxRpPx{fR%$3xkrELMqHhD!)SWU+m=~IiSO-TAb0ow_ddX@m>m) z?J1b{n2O+SQ=K0hri#}v|Fk#9q;8>kz4j!Khx-#@E4udF(R zH60(-Afd%Vp9GR6)=ad;^~o@k%`M}#9NjOE@hju+##>%+ehU6b8wGh6X3JVLwA?~j0s`+BFAjo~=%2PJHRikQvV@gNUe)lWM5rJ$8Pr!mL z;b6(?LCn5f8?NQ}nn_W?!S%@JxtgEU&)$uyKm-Gc;|sL=$&|5fEZTuu7}EUS)GAO4Y51iqo^O@uMx&FV z7H}LH;VD(0(rP7Ft4T9B1?&IQ^>lq^xi!eDn*66+RYv)xnezR4*=lo@BaMdlwJp#p zN6zrBMd$<*T%|T4D3zOEA(l^YJEH*|+Y{T`(oUgRoaM(#9&vK7>ohn$E%^)>S-E!hxU@m5Bwv05dNpa%n~{i+q%*Ot*6QY9q%we&%M zsizYP*?2j1-OscDw=PwC9R!>9%QU=B2hSJ$Z3D8?k4`ET5|yCukMm_*&rQscKSA7U zon(f(y_I@Kd-H>gR{ZKhp$DsWwhgz4On2gr%XJ8#fO(W{<=drsZPI9F%^M}vo+2ooAcu3(U>G%wD8NOd;F>x$zSF&#%*h# zg*_YBAcqy5wkP!AZ{~DbadlZV$^JB1Q(uQtYwcnWS@_S015i8Uvm%GNP zI<>vEoK>PJ#3;Nml-gL!N971z289``ExTQ4xNY>>1>EcC4>(d}=}wxQrj zz0z;}MPrmtsqf9MBuRdHxl|{mAV8>L-TJ)VhVqua*V^Xu>~_75boRUs-={W|K&7@P z?T1T@=~(`P~h2G`hf!)G$+`7s-}^@z>a;+V(V4 zyoPDP?OL&0QflF5H#4%kB<6VVIU!EcpU(zS7`Gen#lL`Bk^9;JS7u23dTybk?PO^9(Kza&3{23K5V9YiI!4OH%CCR5~mg@vU zzaL7^>)D)eFjxSP@y-EQHD8zHFwiNdJiux4;PnoWLnaRRCc<4SLnN};&5V}sg7TM# zw8OeFlq>P3rJ9qYQHKKzqb|Vq;GScvNAHnKYI9i&rCD}1el%v<_jU`u4Vb!&#G3K-UWrtSHM4h+& z#Et+aN0+GpzTgMr(d1cbvqPSB4k0x!HUkQBUpL_TtBGF=nKTl_80fXz3Tut0M25Ap zM4tiHSh#w;lq2cXVJD#Mb&oNo(MpCmkdXlX)Hgy}KkgW!>MHXJgPn$d4S9&>EU*3w zGuBf+vFZ)6;?bs9d_Mm$Lm3x zD#h&Dc~C!-ql=E1KfyUs+nAmpq~1ofPG-6YkdmLg`pDE~q8ak1D z{xx*6OCzKaOzdfAa2}%XFnsak*H&Z%)xg}k8(tQ;Uz>O1Nfy9%CnCGcmAoeOn}*x0 zRSox)M7=WOgNX`Wk+R}UBd!&Z{)JFvNmmICIZq4wbX0Ki-EA@6Yd@N3x8wR~rom#1o8UbL%S`Ud26=W{)D8W}RB6c`NItcro*iX7Wh@y9^TjIr9KRS}bCQ)Y_2ZpG)=}gCWa?_xVcRt$E>e z`1%C4?sa#dcQ#|xSk=Gu&m-#3K4m%?S z`3e=I9WK7-IV61Ox+hiMg&5P2=CGK@_4z!!_Ur##TBG~L=TJ~P74XDzrY>z4CUJiM zp*S}gH#tu9W%M`h(ACTF^JM0Uo0R0cpno=03V(UXV=EQb1q03A0aUE#;pML%qhuw# zoEM?qO8PEDJr8lCy(AcK~k6yIOqrYG=sBlxS8gL6)xLq+*|O&JaLWdbfoxNn2ymp5x_^+Gg< zLwa|O942%!cYwdd6J5AWHOA{0uLDT6Mm}#DCs#Ar(}bJ0Bvj6(YT;m3Dk```_R6tniby{5- zfc$-yC|rz`EBPzx92T?CUBl$-`+64uyv5sZ+}fG{f5aXd3=NAW2Q=hZ?Kpft~iz2yEFSJ@XeV4QyDi zEiuv|*!Vk@0!K_GNg?otue;ESl#sBMThHK* zFeu9QeG4`u^T0jNfiW3OoyedWN>uaV{YyrB7zFPL2EpV@G|&u9M?2X0Cx1x!Edg^i zDxCvs+X&8IafVXafl|e%NHiUwrFQ1{LL8wQLeJIo_#$aygqCj$@fZRlRC|_k?TQi0 zGo$kNe|*$}vq#rj9P$T@l~^LgkrpZGm`>&)DA5ID3G z5;Be)0NdXJKEm(1HJp`qNEZHnN^>x8woaiY7EBX;Ej3GPyMIc8bCYe>mEYLb9dVvd zJ7FonC&;04*9uhmA$EHQ={nfr&Qou=nOk_Z2M&esFKBbY;(%L27ev4U@Ck?G!ars- z><@W^W|mlP2Jd$QIKTY?aEu*4@aLn5Bx5o2IitpOPr!gz(`vtJs^9KXAF4e$LDRa% zWr2|}-eST%+`tpiYbVU52sktB_Pl-p?W9KyERKqh^Q;dS0(sy%;O4r4Qh7uowOzS{ zS8Rc)MnCR(WXr||!Ow9Xiah*>AJg{Ujw=G?w1B&t9|H2Av;Vl#oVy>}gaoFi#`{s@ zTBOan`u?ImRH`g*x`r^*-ySErHmY)>>3h2nE}BD+6(laDOWLBnhQt4QN>WP{a7`SU zlQ{X)Ha@s>$t48W1ZQo1Lbv|$zJ(+smG%aC>eyxw3GLm=)0?z5`@!uj5=(g(%=EIs zEz`%zaVH+TB4fuu@)lkeC(AtI!TlWQf0PG*2={a!`*;H0HomOEEE~Y@gDZ zjMAg?p>p#&E^HGDvD$GH;cb-ew2Y&>iRiUx@e5IvU;FF;!^shf`J5rQ@|Po&4auVu z{!h&Y*@R%UNK-uG%GvVUo$94o>roW=&po@=#B@u!UbjmT;AQpITAD+@TSY1gP$xt= z$^)j(ZCL=Xn$>{V`FG@hBem*(0wcAUQiM-WVQZSgNa(-zaa;%7dP&S3Z9j9(4IPd1a8U#{`!$Xu0d`r?IQZTN{pb4!&78XHj5k zjn$=4{UhJh!9YRvS@Uy1>GAGQqz#?fx!5njhb5PbmaQ!3CP6B`AFybjhmBcEPvinF zaT^d1rOMXl>f_zW?L_w4F1HUgkt&b`-fxiwHOGdL;x!%B$47qR?k|j>+3+~nN{oP4 zz(B9D|G6+rLqHmu5pimlOLYZ#0Pryiw5`uTgJx?$FB-`Ll{kLW97GASu{&YO0&NHl z_wF;3C<;~I8{{ScGV}g-LL@$e!i;>NTLFgcbzf;NhOw^*$d`!3B8dNcPQ_d9K({sN zAwloC3znT4>fhODsJdu1J+`)O&=t-8eKXDCUfWQSR%hvV^QA#Q(S=_SCUj$dk*zvI z{3ilz=>Z}@*|meC+qI*%uqY9Pr0AeJ2G@I&gWS9ifM@eSjZ|`ss|%YV#Ls-AGD@>; zG?;J28vdI$BLPpYtOc=2mUI1>F?m8G0I`D~L_d}J#Rq0yy6r1R4Lh>MiIG#&(xQJ3 zx;-hjqKReQJOQok+1L5O%~|Wwx!yNeKq@x7WL_vv;PYU62|!i1 z89$`$qtJdlEw-Vd$xOrD*8U)Q^;DJNViq6i?qK$xW7y63e}sXsA-JOaNoR)@8 z3$k7h;ct9^0I}tp_*a~wA#xyu_y0Ah3(bBPRWG#}SUjuU(_z01L_CB!dG9O~#wp}} zskF&^9LHy@Q$T_n8{K}rTU{Iu`{xuE{!DWU0=gFCe;BEkLF3QngPdYCLoW_1YlG3> z@uVF5<_!{e7cS%lg0A=`?ut{W(Txuzw_;C>R+f#GD*5Ub)TtXhR|yk)cSB{}pejW4Oy79rx=En$cP2&Uhgg$tY;z{!t zW4s*+)0!T4iEuIryvGab+q3E=uC=)`-o za&oUBYG8rl-J3N&V~9}oeU#J|$oH4K&7$s2&u-Iw+rJ52^QDGuKA6HAgbdGI>iGWU z=Ndnszw6emeu%%dGa>^9W$kz`!_R?1S&64ZJ=&ve$KfUdwpHXaa(<~Y>6w4Q1*=>F&bo|Ae_TOrw0=*;W=hF!o!H z^W&WZX5W@uxWGW|YFy|^1$&JVsRyoF=0d@VX zlJccSGa~A;A;)19MlxW%=yB5*Fy$p%>?#DBPnWwn!tG)Mw}to?ffk5&f)VBtA3l)_ zreMcG*d!w5U0z)RleGxTDd{lSS_#F06_@6jJ*to4**54*`U4N=Z`Cm5u_#l(_XHU& zf4!xxjw~siR_=oayw#7XamNmqq2Zdqt?dajc51U)V{z2BnRK99$LM#O#XUmk{=;MI z$lcI`&E27o=iQ;J!}Hl)2VM2`ktozxKQO00iiy%uOtQmW5uysMaZ6PrUXAZL+l@uC zM?a)(0i$`q_tXB(bd>kNl4L*k_gwZlOuLIKpbpJf7)jDH$DSvOq6$+pi^kZrU}2@OeG_jkCd%QfJ%Xz$uB|SF zito{j)|xh}nu6!^JZ^b28^*12^7Qv5)|;Z`$A+?SjmplbGXs*UK7S02HA_u>8Vk+&(B zo|nu<6i++PbW8q(GQtOSIaicVdD8h*n-9m(XUeBQ%x8)x@F(}sq&uV=h90_GnxRv=LHgNT*ZsRc_dm}Ym~+pbbIw@DTHoVv$-t-iL1&eS zO;>HU?dHGu2qLBEF|Md%j)HplVM*R{HsiBPfzBU}`V_H~!DLC6r<6(gs);a4UP%CzgFkanyqh6#@w#$AG z+z3P_zQvd#M6?VOqK{CeTYVy}TkbN6Fd$fE$*5@HhbDn!H?SUPT98isr07c*G66F( zaqfHRJib;PL7B(SFB9RsPv2dtR@t{8JJRUGeur|m5!D_7%BKH1fp?o~#$GMCcj`hh zV(02^?FRre1?i9mU>g9;6ab|lN>`N}dV9|04?l{4H%uD@9ReTy;?1g=5+>12pO&0cDC6m+9#4D4^Z#$ z9;o~fjU4|TzG~3Ye~}8rpMjxT5N9O_F&$B2b|+&yc02abSAU-S)h1^F7#jF;p}(=OZ?7J~`nx5PydSCQ~kEAYLxWMktEs;l%*6@H3m(aqCm1 z4&>a*LG4@+M9u*{udLl&Da#T6Gc`_p{*#UMIrIo%sV4{|M_ydT~qFIHqb%~}|s$d3}m8Sr}3$5}dYQOvl z9v%L#D$@RzCJ@?R_;qdXneWdX|XtejJLr(ZObwQEuaUna)l|5%Upuh>rXmyrB z`D?YI06d9z>kWWE5}?@|@6Kbzv!km?|7s^$xeJd~Y{K>}nzI_xTnc1yj&9UunNQNC zxBk4zLfxvEe>po+O|Pt9s7U&z*9hp(D}erd1nAF4&xQB+j=kGi#WpwR(v>)7?6WX4bdNmV#R0~4=T_j93F+npFa*8Mjk5jua}sZA z8Zr~sVP<>bfk=Y^7akdqp7%j7j_k+iN%uefXfbIf5Y92fNCSe7=H%AAk5^|OR zf4~5?D{bNbV2uE&+h%=6;D<};Q9L53*)@vIZ$E86K`>D zy?`!^6B=YEWi|$N%&scl-X(?PwJpMyd^^H^kS(uXKVLj= zT^#gy4yD+K4G9x8bVLWz;Vt3Ef3wz)hGX~|`9Ot-8-w#%MN0Yy5m`fTZ`WG@njn92 z(5PxQG{q%lHEanaz6%nnqhbf9y{qURQ%acCflF z)HN%}z>&^v$*}v8z1#lnC26RWesf*(2Nqs~WKh#SN^p zvT8NrTmDUV)~{+f*Xj+Ttn0?E_A8~~u2Z0J#8YqQYgtrvBkdJeXS6(#>o6hji%T=_ zSCR3!P&=vLX8d09U%g%P>RgIONgjJQUQq+sLLq;Sq$UN+4X)TIz?}j^R7$4=Dr<|)X{t* zX7G!rz-4nl7Qx8zC=oEZ8(_Yg+{rTh@P}4PIJH_k#4|qOP|UkGh6FFOyvQV<^+!6) zOYH%2KtP39w-F|}9UB$hSOHmJQ7vkGQv@IfXk%D(>`=?k=`qUlO9OI%^a&sZRynik z7}0E{1~oiMa=#poX=|I*HtxJUZrCoA6M^10b`_1;sbmG3+1{Vc22FtW;?yfZa%RWN zD9rWz6`yn49oW#OExFUy%=a7rQKLZ>vuGK#d<{QCcVE;iUsUMIJnZ9bF?WsvgGRpb zJYDDAw~}jj=$8_%#)I|r6K((V-t-rQqnbG%RSDI)_*4&VuFmcnLQYx%7kmjna+e!s z9nGFyiUjFdV71j8gZ&rV>Q{w|avMsvB!Oi4F@t!SQsm4#{Olw}YI@Y5aO9nrj+Ha@ z`Ry!s@2+?I%9@(-!9T2q2;EnTDeg(79C7YXruwfx4|b6oQp`wy4+(iij{&5Hn0J4J-%`<+E#2R#(a8`(vLPMY)%u-!FgvOR+X@ny2N7aq{emhAq zOTBH?=iC^Nh7_XZvWb61aaDRG8n35AuGx`p;r0#>(si@ASf*=$Wr)a`38=>Ej6A$D0P&zH zn{aNP>4tw%eov~BAY0EnWVG(NDH4urT5pWKuZz-%n%M^7Uf9~MXN zJZa`bLdI&mkE%drD+q?xZ`PRM$Xm(?j0_$fG4dhn_iHbgZh^<h86?XJ1Lb!#VV!n$ z{3}e?f@p+Y?(%HlOw0svyCU{e%$cW;$3r!w{P6Sk6T;rgQW9eRMkJ1dhMHP;U7>(2 zDydWdvUym9J%HEM#2q-8jDycDL8hs_ygjAcqv#m#^B6ri^EB9X_o5upZn!Z4A4tB? zaD24l72OQuG-%X|Lr|UGEdc8721qefp#t1qRx59@w72y>8RAaFAGn$Q5+Oqe{FdMO z&S_h^>v|55W_#9h`FDt03Do8xDUF8vC)pO!F{d`DF!tlr?YWfGYghDn2j#HPDRmy_Nk{$7jF zwanW}E-uBX_o7<2d*U+p(KEeu6EUWr_jsGLt}G;7w_6IR?FcaPdbM1tiV(;WwE*SZ zj^HV_ip%ftaz(#mWp0|xW(4x&bH07NKVWAmH*?xD%r6}qp|t|Q*#Ia5{eRN}zN`A2 zQsE>+>PZ+qeUCOR*i7!QQoHQ!1mTvPlaR##0L+lr$oJm-_ifG>Zxna^c%!(nxo=}* z3#VX9)J7I@!U$|#@B5~V4!h@mGdq~DJ#R^C7#!Nt*5u`xIO4R3{#KE(u@X)lF1O5D zL2jY#HfMl3`7gM@VCJ|8Y$C`m^rk670~bgN&U&;DPD28j>QUp18VNFTfu;uGq(JDe z8ZxGW*e$b=d81uevR50X@g1WisLT<+!bY>+zVYi2CIxma*Yy_t8%EBffB6N*0KZ`I zm0$2nWHU5I+1~;cW${14Z{5GbuaKG#`$(;Ny|a_tf7rWqnW`k$Yxs)SQ%IB05n`Bd2W=o;mdZP z5kb`slT_UgxRtS28bp@-KQxFx0D{qk-3)y^zTV+kd@ehYW)ny8k2A0$E?@~a)=>de zIL8O3pkDx+x~iW;C(sRhF%b`!;xHt*yb`ZP{hzV2UdQ?iI6wX!%LVXj5>z#82$%3< zaTxvv*pF5l3&H^VvGHH_<3x&)8>du6V2GRYQ{1FX6Dy!9te{rP0Fpgm{dfJx`j0wM ze|jcO+7Xb=E$wDmvomrjb59qvumRGktZuF1^`0e^>YAB{kDy7Zlq zG^+}nqI>#Rk`K$y%(Jt#*`;0>^y8Jn7v+SxrVxtXU!F=hkG2TI?9yVt05SMLPXN&s z_kKyo&-35@2oQ>3Zsc?c`+Yo9yn-4p5$7T78dIGoE3UCZg zy|PUX=3&%$=oIu7dhYl_Pdft(M_kt7nKrnp9|6r3PY}>t5p({3nydJh2_QYU1=)RE zfqJw3@9~E}t5089c$TmkeT(Y!%b4ri(=XxIy{@J{Us^tdoO_5@L@^W4|xAc8`1uD6enHmEQbslLQdw#C{Yupy6%Ma%U9ZeG0stA_8<} zfxjdc$t{C{MHv~)8w42{lye_9GEuVsh!S@{FnRv+>M=c7H2s&+0FiuUG*JD^XsB=p z7!7m*|1cUlj|-(-^thOExvJp~rU-C>>|%U8m#lgOj%hpmYKp?w|&q^ z3`vCd9lEEhx)rq!v+iE0ztzJq>UqPC@Z~%RpN%g>*uFtP%3?wo5MT?Hg#*`)yl3-S~;Exi(O>4+d#xMKkiNvO&*0;+MX`bun_jP zZ)gA`z&Ylwg5xwsq{~S+;3{m=G~kZt^?GNR^sA%|HJ(xpfF*dkP^yI+ICTu>`L)+6 zVNiA^u1`><-DKvKs14|7#&p`Z-}{J5%C~~A6#ZMn0I)qD`H#>$afF;&Doxhpr)rK$ zUbd1PcP?9+W(F0k)7jZjG3Tj@_Y(V^-H8XQ2)h3yJ(R~#l0YnMWDZJ_7<`2h*1l58 zrtoi-N+nEeopXWY8_r|1{4^Me<=Py+oHctK`@x}urkKarJ+*5kw3IYA8;7~q(+K|B zjD`tzN!P2C?zt(jU`mBx1hGuE%mjQJfh z2AUr*Py8N4XGg1azm4|zhhR$WroWGo5eanf6vIf}wblc12K8F-nE=C8@KomAtx0e>7EiRGzRMdtB7HJPs2bC?}5#Yiw38 z3Ens~)4G)D)zH2w;BMHOn6O6m?By!20f0MLnpn^C5zSBvEFP46-i?ndvaDT?mR`n~e%kha7wNm^Qe_gi77|f2W4`65 zd+@w8Lv11E*;OYvm30pA@FeYS5de7T8)GpO~Kb!-AW z;du%EoPRG$vkI+62WH!@oRxl4llx6J{LOVVYktL97>#jr{)4kvYQ>2BLC1G;+t~G= zeh3A(LI5+~#sv=>LuJg&-R3oK%06SoPl0Od@+nM+prlo~_9sr{sR+9Gg{P%v8mmc@ zV!XNpES+K|JAb*^6K4d0mqHat{Ofup4*92sBu&MAO%tXy6;h4vc!Y%T>ye<4kCGC7 zF{wbdr~pf^Te%R+sd)YhCL?_8>3eixvW^MDKQIfGPZV?~Gk1h+8fo1!Z=@?LT%RcIetLD?Ba~+b#*KJi zg7#t+5sO`#HGDKxV)m{NPS#%3xN}~fi8u@Os%SF$f5%Sh?8EjlFGb6eceXzKtKw>% z#)LfCq_5~Vcv1@!oh0wErE}Ii{tpZIKHSdTLFoigb^}VAkbX*jIhb6Lz1B!O_h0P= z^O6;!BN@`SOoc0N=GOt84+Opt#9@0>UJ4iujQ#lfsKgScJ1CU`G4Phv_!>%`8-`Cnm-lR8E|%SP%HC( zmhHtDJ2P`)V2$d_!B`AEDnk*UC*VF4*3-X!!%!-`UX)D7nY*DW!Y$>Nri{1w(PPsz zalR2qPWuJSV*yQSt~M;+i@xXV?%?yVoojq+>K$P{_g>nhtybyr#i}k@iYwdx{#t&n z&7J}bu7-14XPOCVYsFI+6ZBblpAkhWBT7oBmC_W++0^|oYivu|QHgq;@(jXQS_7Jh z+U#t2FP7^pA+}||17}CVzA`j~?Nnp?I)Ht3oz@eab-xHy!Xjit*LeE%d1tgd}n z<#P2=pjnz0^K&(ArI+^&y*0fZyLVn2wecI@jT`dbrVn&|Rt(+4*!0tvCptel(E*YS zy|58^A2z#!a7dns%1$4ISi++8`4lFOQ5J>V8_XQU{o8{g=9OYRj-`G~At+Q&O#3tG z6kKq>*WV-XYY)i8>f`KOUF<@_AU=BHaIFIeuw818GsWa}yH10)3tqmwY?GFnE3a9x zT}NK*KY6+N=sIlm2(i?(tsSeT3*kIoKi*q<-*4DZsBU@1P$b0%Eot9+IdpeNsy%1y z$UTr2T?V$!s{vb>Tyb9-W^SFotPy{@Ezp}~rNDEvHU;Dhcr&UsQ)~gwv-C9kZ5gni zWR&mKu}1+})&1F$z&j9XJk^OFSfpl2iTQd!`^|LbN+Uls<4X1e>uIZv!$j~}G6dCPaEk0K1(zk3M%LuVgMWex(K08ikXMcyox+#9jo5rlWK zHs`)}g#rb&W33Rqse4k+8AI@}ky%&frY;ZdBQm?K&8WVOmWOn$Mi}T;!qBqUq0TxH zfJv2a)%;jbJzOsb4?p(CQw}ResKnrwdqHYh5oAwML9GW(nG$)N)hGvw+O+v1POq#L zeF>)qN||eblC2p*7R@AjssZrfi>)8i={BAe^47f3!AMVpJ206=Ee0@!;u<^1vMNNK!c*| zkY1bgR`$Xi|VZ^jkC+UD%OiS4ySYNZHOV1URO z&u5e$4fklIU6NH$bnn!#Xe|7sfU6@I%>wEXo(1UYd&!@sW4iXnPJUfH1;&-K z14gJTv$85m0*52DS8g#j=YP4ypPiu%?LJH=Wo6vhpr`x#MJSWvH_;HFogA$Jnlw-b z=}5hON^iEo%5W7_jM!Q8u?>XfOZt~t{MJdX;RAq5_O~TgCvD5<;6r)lJ6ZK=v?ABs z^85sYf;K2i2{l@L<1-99=jVj1P(bo!QpI-RtIiiNW)pwNG=j z81t|!-R-xPrQ?A9oLFho-!jD-@b`|In0xi|6M`2vXa-)zcyKjmWcTODIwAaimhv=W z(Lg)AA@)O~caaYoOfG_>S(D?^h+FVLUqK6hJ44ei=AMCe9^<1x?`mmUkJSST;b#A7 zxfnaWuK2ztby4W89Ptw7{z6CPZ>Vs(-=1^bSL)MsF%HL)$3`#FhQx-ac`HMl)k{$A z$mY*X{INd_S#58XCn%6|?2nU4Sg()6)qEjiyD`k`7b9!j8yLO!9vyXtmbwXa#f^B| zSAP9CPsUN@Eq;OQT1_T_YP2nZ8dxAfSCr3hPo|#mconlBl3qHLtoe(HFB`lv&ZE|Q zUQ=7o=fOB==lmyjYuzvb|1ASdwB}I121Pz|O?;fQO!(G1Nf7?q8hCuM;gqf7bLatq zCiH;^=h4y1>oKWm_9zyRz}teT7F>_2^U4IZJ$5=)Rc)I2+vdyp9c#66KFpmSTNFOx z0)G3NSneUNa$^aOfuso{F{MG_cy_=v_T|XXT_4TOtQTdPX}DRV@646W z*4khFV;de9n;%SXE6<+E?(MntJh>Vzs<2r&-fX zj}lw3aRJ7$Tr;OWMr{3?VIi3mCf`8fd%8 zzwb7IF6yDTE2*hF{xKSZ;5ze}G~X1jZg}o#) zfBQ(Og zA!wnAToVU(a8Uisn5=-U{EdO5!;~KUTubYn2-wwgc-{g&0+{fR&R>`PJ#MnaB+&Zo6#!FS$2w}IiVCR{7`sfQ`elf{}dw;wz_Sh=}d($J3 z?&uaj$!hDCr>;543i5<`^Ulg6X`m>YmbL$;>z$M7^sE4*~H7#)MSxifbi$w=FH#=VMX6FHP!d@ z7cnzf`K2})qB4Cv`cn3A~nyEZx=~-Hb=ylu0s&($xk-smO64{WDGSS z?PeK%b+Z25&X~sfyI*n#^wTTLB=jMj&0z*s`jCZwAkPh|SY#J!G~FuquHlO-uBjS^ z(uKWMsU904)N8fC>cO!hBlWYULeOv|WpHyOB@ea^E;yK-e_VOIXZuhoHqx~k>GVxY zj)}dO<-QoBazh)hw;^*h-H8#dmUO;Mm)1UEQ5#v5wMG0xt$sOyQ4d_upeQ2LBBd6> zq7Km_DB@G?fQadv4Y?4@njlG_y^{)4A=!2uEvAwH>$m2Wv8oIEORLO|I}{R+0{kO8 zjtlrW0yq5H*^1<|N`zP|(o10W1XX7XO7AJ`Fn=5+*=u7S$2aPb`+mfJU&bsmV2HG= z@z2TqVO^#+fKR&tR-2W`PthX&O}GhFVOGKp6oyBJpN+sq zu3`ID2WUrgKg;kTUS=gx9GYY?EuGOZfHxktRZe{K*LMrS%Ehe?bzUaijH(U{$jZfM zQ}Ok;ojS`_ig^*HE0?y#n40-U=F_AoRI*aygE6&z2Jx?cOB%2Ju_70~!EySEN{f9~^(6>m*DA?>_dpP246C&%qL2B!`Meo5 zrO@=zCNVmX^ZmSn??pl_6Jvh^Gw_2xAl9TP=t6VbyIdY#-tFJ#9+RwA^9r)dFex55 zXFUvF!zYEYg|Oe0d9WRm&2n)u0=vrXu9)|49F9AVbZ~;wfuU~RArIB1obrKgZl~Hl zqI71~*>qlIXWBHAW4^bV-YmRYOraJ*(H@k+D&0KC!^7}o(=wfE`Z1U$qcQy=3qrK~(d}Xx@{4ryuXV<*~UI!X}>r zO879SI-k4J_?R8HykGRzlJ*L}J4mLlnAB+0MBnRYo_@{JVtR*b6GB%tGNp5L6t4~+ zMpmF_Ger>I3%?X@(vqZnD%Hu*I`iN@f_<7iJ-tPmEqW`ye|KTdDgnQ?R4atvGOL|` zmV~H-nDT48JRt`^-&<16`NY5obMX(CsDAlT@rzyr)=zrqUnYtLP@iqaq;Xp$h%TII zJ$2HW;?hfno^QRt-%r4`tdF%c&)!XY6{aBlmOS5 zPC)S3LYdzSC+b!=+`iS*wSY`EF0i=a$9jO&civBBRmVbqGQ2fbu?|J1z@*O4F&&Sj zFZ6pZK7>ul18lR}?4|I>YC^4zkx4Zx)_=Tl0ndnnyI1HIxMd%sFSN;qg3UB@azk`~ zicGT2I*Od{R>)1RjF|A{epLwrqTn?Qwsa;teQtxSHNO2(p1vd#2h-ca(rWhSmsdH2 zZZ$>3JCDJ+g9>xUySePG!+crWDtP$^y(oeJ>RKlRt`#OqjElqDQ7Fb-gD8pUb<1|KZ=X5A&4&0X^11{P_#j{>s4jT>W0TagUE7@ zbLIw|yT{7Ln=46ntlCGwvYPRs6rZ<%pDzu z8$#<_9pwoux*_jwz9<|xIefwQm!PJK*!WOxLmpIE9>rWOn2-$Y5xo%14?gO?CYT|1l<)E)fY}GMVUVqT`b3Tg~ z+3%6KSRcNTgG#6L&I#jzQ~s^#PhU=V5~vyA zm_75bsx(o1N`J91uNY;X3)Df&`DjOq(x}Hpx_;MlxA1hdrpnPrFLxfv6!jypkHSu5 z6yzfeiVLhNZz@Xykg&9y;oZ@?DfB7=TQRdg?~i(C@i#jw^w~wMzCtxd&7?Uo@>Q}8 z)#fZkMO@2k40^L$e)OK^3?2aatzq;HgTZY}M;V^2D>O-NEIJET8Ov_pD;L;0$K0V- z`Z1Mrpr))Q{15KD93gbo>SJHcE%Cld&y56^>&$RGUBmC#qmlze`(LH*ayJ?4`GYCY+K8YH6p&T{Q6o1arX>para2cbsD|+v435OxAF9DXx%Yo z_OO16?6oSGD^IwyBg-<{Cqv3F{=Sz*2AC*VfqlT$F(3jX53d(Y($Z&|B+#f1ou`Rk z2_XD)XX=iI%UI>YSy%(il4v}26+Iu+F}S!sQm7{i)i2bL*YV)p_CDkoIkLuE8H)s1X@TqdlV zC2uz@>jR&3elkUpx(~THgu=E5O98}ts4G=OXJ7OO3nz_p?Cg96XbpO z#2Qg`eL1whb=BSVsfxU#-S&dJi>ti}+J;qqyg_^GhQdeD0u3_=864E05aM4&S|LXI zs`-Avb$D8WX|;1Y%z&0*b)gZ+mKe10to@q5wQ>h(+giuNrP1@hh+x0Z_+A_NHi_X= zKkR%q{+3<40&RZ;K)mm;Y$uWW8)tvR)t}FdPvYqmO4=6e@R6m%_l)%dxJ;o1PQ(}E z^j!uPS*2rapjf6;&Y^Ea(Pq3BQXzG=?p{bmrt>UnF(HcD-9EQ4I=eKvQhO~lgmbg* zKj8gKtuxN06lR%h9p6UNYqY=~rXsHRA;?CbEEL@d-u5K5noNwQJq5vB_Z5{Dua(k+ zhbLAe69?(@Z%0XQtt{W$EzDQ@=7;dcwya>cgZfslf0Ho`EPuh=>;Uel>0P+?x7}nY}xlzJ~FBmcLA4)zf};H^R7m zF=ECfeDVA`>ePMc@gU{PllagoU8+Rg;4Q2@i;P1kX?ySh#tJ9&e$+>|IWv6gJZxDQ zXQJRX@xZS7=nX0xy>B8lN#T@!(}Rx4Ceey$mA@JOdWn_T%(l%dGrnWSFMQ!72%rb~ zNjM?%3;i;Tjf*|OHtMBuL|$huH~c~8(XqTkl#ZHvA5A<@9k@yBJRo_cqaB?{6S_pm zd4$0aiOqxwjaxLB=T0}xgjcC0HRRF5t^683Su!j7xw=#;}wS8`zg%r!%f9wfV&n?{<@v$j*PW zGIt8F9~vAus2ScLIuy|mUR;0=a5y(W6bFcwqbuuwwjJG>+0B?#VVpg>1CJt&atm+J z#H>&vzMA&}Ez%2(fb~A)6Kl7`QL93R>k-#`Im=Q?^G`h=A)N)`238*+3vqzas^*wO z(W^twvbCQ-35CwX2steCI~i+H-v>=g)K)G&g9*F!j7k@gJ1x4#AO{DpqsNw9bmQ=u zf@&*kHWBo95aP$}j4W{+>eQBsK)?+*L!0dY$aCZMLsvyvd^c zic&UXQj7A6l5K?noF-!u2^?OlIM7wDng^?7%_Z*MZ>8whMSyD-y#FmxOz-UO@*u}5 zAGWW?7BYTiU+}j@S}eavj3RQfZBu1mY;%sZErY53mB$;;=XuYD@76?X?8)7X&W6VO z5iC@N6hjapd`MsRPZO>mj?fS*qmA-}Tyr(Dl063-L5L6i#&;NCIpYlV3Nm-1R3cxe zQ}wmQ3Zd?5KV`bs?K;{!91Z2ay5G0x$>f85>%!G12@Jh#)gm94Lb$A-stA9}cljW5 zUGW@sS(I`@T4?ruLxEHLmU8D$<%Wbv1zk>SW=p|y4n50-()`#X<(8>Tfmg{oNnapQ z2O*WD8bWvaq9U-zZajdL*D6OQqVk!Cm_de?n71tN-JbG}?R%cvsLJ+de*GAWGi9&I zb3%+h?ZwBATzgnBvCz9oKmpV!dqwYy1m%`CTldzy81@ zyt5`9GRYi;?rPUVHE4s7jhT18XA88*vklV8sp_%4=H9 z%SUEem{gI-4(%u3v9huI(Cfs;n327ER-nuevu|nm6P> z7Apm~C}(gSgE+6@SH2Dd6XHwN+JZ}?)5)l6-?W1Q>U#3%Ul zFcXf8FmMNFHld8%u8(vkQB}pt@RZrj-@HX$MOn}xY(7o2l0D@r;pRf6KDNlMT&FW0 z2cXHKVxruyl7$^yZ(qM3aPDUK{`TCG%{CHHG3fbKX!7lQlR>edUM!T&oyP+A-cvkj zuMuOMX&MxN`JaE!r_K!&xKA%izntwRT=qO3SM8XbH_=CsuCbIz7kQvoV#S`HFyuTL z`aYwJuzh$kK5&+t_ywClWX;qf1y!4#es^b3N6nUl2o__26Nu z_vuc2Xi2u+$Qn&_dleeEMo~|Gi_1%=`hzHqZZ{W1G}0>cvcM} zmUR{ppXXE(IZ|MCvHhEy`; ziP5!3wsG|8YxaByw@!zGe4%1H>~^yh^Tw`zsq$gBOxO{Xu*7Q;P$-9jcqy)7+&#_T zuT`h-YFT1tGqgvca3} zj7X8YS`YCJE+b`fT&ySu+DBHLFbA3xAan_K-}*b$x>eS-cmtfBgPd_GB>3rV%uop~ z@I4jd_x`M+TrP9pnPm1u&-7TL8!L>`Yatg4=Fjr&*`m_PhB{zGfKG7xS>%&CS>*Yf z;5Q_jPPkZMTZ1|1Wj2WwR~^}STl9zqoAnwCzT-}Huw3g}M};gO+~e2!`5_^<3H-Hs zE?Mxh!V0RkD6pd~{48KzgZhIyZ8pcr`lZP(8Y_D~y`w7p;g?ui>*DM#lEwMipbS75 z{xx1>U+?uf4KDXE?#lYT-PPPTr#wxnoJI-4@s_gymjW|RgiV_3E#I$6ALLcXzXlgI z`u+Ua`z()`7F=H=@v(u{zn&+-Wc~KDRkJ&(2NX#rPMi<4IBW!#Kl8T-34!mDLNLE` z+6qw%{I-J}9tMujqY@l)z@r^=4@FS&F^NTMX81-7&8Ctbp|B0XFCSNAp^Ihgf$5}_ zgPND4!8<>}vZD?j`rM9jX% zBqppxI^hOgiGq$lM-LBY@8ho$LI1ScUMNrCNO=jZlUR52UdC|W-N%=&BW7Shf~iy# zH${7JpB3y%HLeEMdv##F*Ka@FL_S*DY9o{J7hcSxe*+nT2W72U@jRQW6LEhGaaw0h z=xb>%n^xb%koaMsy}0Vi`d!vJJyy&t(e3Ja`}#BLA#RcknnR5)(2l{rk)Cb5)k_C+ zt#mE?(QmbEQgU^SGqs0jq(>s@l$Ed%)Zmd7p@YzUela||1ujkI^L^5fW2l^5`E|{So-gHrPL7e3DJ?E zair~EbUgIagqy{c`p`h3livxCgB4i!ECsW;B>aiPVfY*qV)HpSpehVqOYzwG6^^JC zSDMm*NU?IGnhf)wbUxUTpEwDV?@4#QJHT1Aj>%ifbt50x_rfPJYZ#>C@kNmXjeYp3 zr!rJQyjf96#w(WL$!{2%%d9*?x9Wp4KdyX&F0wKLu1Fl%UIRm9vP{7T?utRWBI1}( z#sb{MC`TELIMl8UW?Bn?h`X>veS~x6mF&0U9;&bzlvO*e10@2PCJt!9xAeP{!UXN| zN*RVJk>$c^8ar$({?M2kGbKwsovOA%wX2@}CY{$x;#(0l3fxjdlnA=W&XxfJh4tx~ zFHH*$umn$uAZk#@Rm05TY7+aw7*+5f8BI3w!#h8j&Ytiq{MxX4>mk(_&ZUM^>ahIt zyl^A4%s29JT!mlUeeWv=K~QE{tX{jr?45fny#>T`cH4mu-Ab25)&J(E*nU4b2G|*= zap5I^ov}U&xV1C(-l&-2GHNL`#K8_zNSx@rp;L@BTUVV~Ye%G#B3>SSi_ootMtI{D zo2xyNiq&kk{?+C&iumvis>i4<(nj0;=We0(@OWY1Pb9{U7BAYA5e?HFrx$g0IMC)f zjHSERxHmtaeEI&=W_P|rZZC^M@J>B!38n1G95;#3ZaxH60hN~{%pQ%Dzxih%@HlTN z-*-zSswD6sG^TxtlejX7hhaQPzG~qD!>a<6z?7aX>FxG3Sd>e}=n@Tao zoSvKU$}b(SSso=u=>CKaRJ}}_fT~xIpWfJ+!Ts~XoqYSdr7@mtmb-6FV#CA9CysBl%-)0nYk03 zrAP44eZ8k4ah^k_jh92Rw;(EEd%Gr>p+3P2 zvgF?ipE=Mxaok_}c@GS0T3jCY-t^vx58c&b=_R2YpL{3StfqaQVFvXvkXWXZZImNX zfDlH1_r@rh-?T=>b%FkF_AX!!r0L;NO6lP-b9RH+wGbd)Jw`v8v-BEHYpON^UWRH= zXyo5PHf`TnMg(ow&=%(VTM_^5DR<#Q6dNU^V)B4kzqdXHMoOvBPX|hxCh11&M_Fw}fl{Uk9v6{9KB)=Bfj8J|&+x~hG3GA~{2w%DAC*|nbR4D- zs>T`currL-)WeN27HEN=v=R78TmAHUPWJDTe{7D?U&JKexo21H5)FGco5bump9~zS zB0G2%SRSv+xLe0gddRSZut!_Ck_beGZn4(d1DXpMbOmIk|0-lK+?**<6i_e{VQ@BkTe1G1O}rd~-?=Z)g7QdG*|EAlz5;KefH2>?EXMh?R=$ zq38YFoqY8c2iG4{lT|T1)9ogkBIz%&sf-0lN8Na5F0ll}d}m9?{}h7*Ns7dUo5}Yp zp=RKX&qF9Un>n-Ap8C>THzaDXPvAr)&&PdwqTRRkz&yQ9Fu0hKj+$>WeKWtNebx|R z3Zt+~3zT5`&~po8^l9w1vd5kHPi4<5_Mgh$9dQr%J@Buvos_C&o?gg0XrcLT{~>4t z<>|?j<8DzM(6_CTxX|7RM;lRfDD+AzmD%1upBc%PvyEs$Q1f zNpK$yy_{m(wCIy2BH{Uz1v5@Y?3)*=Zsf*S?31y?bSxDM7q+?aOZ&3Emi%Vt7Yd(d zl~RRa7<#olKc=mEy59yIJ=*)|auV$o9#GmafB~=h@Iu$2kK}@sRN|C~rP})%8~zcEmLS0m{>i*_Bmxu8NxW!{d)~ zCZhEz+r?qE10H4BK_^lJ-DE8`105PAQ9&@?hlmmo$x3$Ugx&sYbs^u0l9UJSNhcs< z&FsA$L3r>O21~Vch(QJfC@TDs*J0J$aL4EdLLvFsDKZL2dNG17nEmiT+J_6t1Ae;L z=3A8IJTvkZ<&D@M8fmo^b@mN?(+@*U&%s!mzP72}f}(;g*-!?m_XxJpEpzs>3~hGS ztV9v^6y=TFs&p3t@B;6$GCOYOcu3wTB( zjO5uJJ*!=&Hyeu8NwKjZ4eFLTnLob3mOu_shb|8d|5M1=Jr^Ikh0$Isd=ek~96f+L zr|38xymuRgZVepZC}n%f7ms{h%IHU%*#vj2fzq*=-zwe6Z__%&$kRLdjc zGtk*zwSPe+EYDbTAW9fLbh!9D|oI-x@v)y`|(XpUYC6b zu|3z9lV>eM57!7yTU8v(06hO{T2!@e=e5tc8g#nqJS?0Ic;14R>CJ)yO&Fj)bV17q zp`X<#yy6kZVboB!J4T?F6r1F`JpuQa#1Q&W)H(roz#-Jm@|aV+19!!G86av@G8(>G zla6wvhZpygQNkVXuK;iyn}RG*hg-kPYvif=F>@O(3R-c2ZpDa7juA?{Mrr(#JiqgY zcB}W}B&6+vJQnS@CVr`~jXZaq>ymOq8EE$H*NBj|wyL=jtV8>{?H3?15uA_^K;nTPh5O^;3G!)U5<22Vd$>gu?yhqbrXUO0cO;8Rm^ z`Iw{#BWO=I0mo#mo|dp$eqVd8F!sYh)Uou{f+bt-(0nq-yX2?>mxR7Ec{Tvqy`bjb zQnUAw=fk^$8}4j{wM(4E3duhvbPpFLH9d30o*$=gBWqjmXZ%Q!qdLcUviJoZu)*m=vgnx)9t25S zuTfUWkQC{a2Amz3?h^{NRsLSKrr%w4yLx2vNg0Asfv>fWnv&>i4dw_ph-CmM z>8CF&o}7IiN6%X7l}f0kqy zJlfJwEgGk*H|*v-(E{a}r&|{c5&ha}LT^1jF)If;;lVw5z~^q`RTSX?8!pc={EbQR zG>5QLamI6w2+q!$yOtlNt3kp4sGVEADjsgP4@9!*GSX7(x^u#yI9#hGj#53|LvUtHbbi%rUpWPM6TlIWx&ekwWtg^fhVxmF`LJ;aK z!Xoa3nhyDNkEzdh%e@7#2#@v$VMycnJ8%L$JpFU{2KEMvAd%%%|XRh7S^qcKg`IA+du_HLc zdfSmnTw^7fRcoa;ouK_l*Fe5!?VP91^^dfS%r_UcPG($N>cYs#4lDI>j4vLWs>+Bz zqH9pbmU;qx73o%apr`g~?O-F-XS0wrn=I_T7{`pH%dXDbr=-u0+#MJtk{s;Oo*jq@C2XBwB z_xS(A{h+p_{}AkYr{7r@3h{q*%EbmQqgXMQ@1Z{I18*~H?BXK0E9`PKWh1!jtRI5Q z>_*E7FAq~I&6aidsHJ}&3kE?|ws8As-;!QE*?bv&_(MAadFlh3hhT%URO}5al z5-{2SinY!E;-H| zq-beO32YWd4|>+^g_oaJb5l^A4(tH3>Sf+ue*M=qg_0Ixz6ZW~yyG-JlR=jk>x^gY7%CRxVFsEkH@op?a3O;h9)x1$ zKWUB{E%nwsS zrz_ke`&#)9nrk%aPg?gIvI%ivM_&AOmZND=duwjMhLyh2wBT(4@?VgB6&X%$`z~|Zc=g!n z1(ODCR~K~2_GS*mnyVQ7vHafmvxT z0L%)7b9gA{{;%iZPp+rByw}X8khm8>IbN>pdY~poBu{$4ier`9$+FVLGR}#MpJ$xq00;%KQR&Sv( z{VHb#V|I>xWA$0{1set32lH?Kedrxu`xc;a)UL%Oo)D}mi}x8rZrmfzDv8}W5+cpxv*Lhb@#x0M!N7Y*yUfaA#EG6`@I7 z^^W6pxCQkpCEDT$`2cnzW2W@5(f4pX9Q6j?GqU1 zV=4VlJ%Qi$(r%dG92Kz`Q~DBg#R~dsdy37VdN~>jGj1xCW&GP(9+qV{z3;7sKjN3Z zl=&gr?|zixwY?#AxQ@9n%z|yTpdqX^aqfg>ah+$dv(Og6|?okqL zPz}==O+gvz$Qi|KO5Ky4AB*4Y(n&);?hR^*>eK;tqcNaWg9FvZuOGdG{I>h9TV)@q zjBEes1qXzcmvS((-dWTXvcbNYSS=Uoy!3 zRB)#ZO+z30q8eQ9D{_0i>)S?I_^)EIH@-h5KS@0t^l3#y@znGG)!Q66qqUVq``#d1 zL`l$#Ll_}}a~4x57YE+0ZGLbJm%=TM5)ekqX>;S;YFNge_i@HhD~sCVZKajD)W@a&VrT@bg8wguW@WHpVOgcg zJ0mhN_AoAnHatFNsj?Ul3;LZDVMm#U?|USWM)*=byS!=TmR=jPMusmK#|E;7PQSY~ zTyCQbGiGWje3C!D+EQb!`svaUUs-VJQt(Hpo}a$jJ=Hj!h;s_dOp~$RXr-}Qd#s} z&r%8Y;lr+#9(iTIZEEmtg)|k|8-sKKg5De?jCUw?zr8_gNr!$^M^ydwXWt0W`W3dMb_+giJ!Z_iRh0AQ zma|Oy2w3%>L9%#VA$@keRH-q{;~eQ?zIwRdZ=zxA47*KYW;70M=g$?^9s5qz*j-N7`&D{pIzquMx7YWN8P$)EI!WMn7O}zKN>__ENktwko0!z?#ypsAqAiR zqTW{c{_LmaX*It z(csnAKRR<&wwp$Mg?@hL94EeLq};zvX=dqr$-UAsGFB17N`2ivQ0Gg z-Dg=Mb+!yuOHe-*hJlX5yCbod?KAH*4|F5xF3L6Bmr(;!HD z9!Y_BMV45I%AaNX?=M8(<>#rIWz;F^oHiU60k?`jO$XfIRXdCcm!WZZc?CI$qo%3SwvxeXL?WO& z5@6I)X)4V5OB%PBHO`Ot0#>Bk`^MJf>yGAzK&kdC*?I1UJoUvdzFWZuCrV3VLcDv| zG{=cBvs#Z;tJ-U?TG|!^!Q;d3*yA)CQA^jn&N9kc6OX5CY|C#W08;Wrgkg*Umy}XUxW<{6jIGqVtyJ4adTw z%<%i9Vs+lXZ!YCGOQBJx81u;v6<@JvCzk9WL8om zb-+!`=XzQVDk?t2%Phu>;o<5YoP1@Rs`K&y{Nb%woN`1~ej}1en=(uXn`zcjP)}9N zNmv20=kv{s7GHndaq+GP7w+^NUx-C@fD1^tTXUbUPXHZ+59%~zI1gbalWj*7c*yS( zK2~|{r~CG6z;7}u;9DhgwpKmC-FLCps-LCzpO7?lw{mKA;sMql8u;X;mdR5k>v0qU z>%S{$jYV9yf;Dm(3Ao!(wZC5=4b|guwJ>MFz8rsDW3YVPSs;&6FIOZ`-0dh{S%BI@ zQ{Xwx(Pah>&zUMQ?#Ww{qizDao)$-^R>`+S@yjBWy~%$!E+2J+ojQKmXWQCp&SK|> zbR6A`zKmL4u3mg)!(0l_7~)Lk0r}zrp*5pJ7$pbI&#yi?7T-5bxhbQo+VYDnIf8jS zt=$dA@36;U5>XG-R|=k6N9$p5<}p$zvHku>*&u43^DLqZW_YU}Cdzu6zio~CE<?FoKGI6f_bb0`-IzIzK zG5GT>j&d?_`*Tr5m2;1{`0EV0f90&j&#%KN7T>9s zF6oXaBX;Iuwy=85F*@l$HJkRYntg5llY$#1C%H%>14m67nffP2Q5=8}NaTrUxSoO- z?+dH6JRfUItEN^H&aC8t9R9xnCFQKww$2F87mbmV|7<`XXmSMflFCmv8&FLZ$SHi$ z_wG0FdJxkVyK-swT;w%$t`h!^v1ko~<1J!5KC|5bV&iP{w(5dZ5u^K)F`DAIIF%Ko zEtT^N?`UJ^yf(9pTuZ-a-u|2AJCt&8`H5eSMm<)gw%?kSSyfV!FFqjcm|LvbV}7u& zqHuAFF0AaLiyKQv(74b8oLhX0_|oHsK|8OIPH0dP-XhuK)_;s@_OxHG%U8Y&GD*8C zRoaHXur}#1V*`gih^`Jt2ZeG+3*+f?9M9e*01((<+*AMi-Aa{#ny=(uo{jrevf1m~ zG{nK57`H$NXNa)yk4coO15DyRF%$b>UY+NQveQJSl&;&F*GZi6_9)v!QKdM2eQk4^ z4?;^<1d@-jA4wTbZmgS;$8^c~#Hw#B_=0WuBFq^IIrmKqHkaS6iTj%6Zv;&en&nek zw2iBU%|;j-*zsVDFt$U!`Oji>e4Sl{s+iZIiAm@a6-^VLFMeO|&T(IwB6b6X%l1Bt z8fRm0^ZfMsjAOO?LQ;2Z(o38A9G~Y=D{Y^t8hW3_#J;IdXi=`Zd4(1Kk)LSac<#&~ zV|{q|*1K}aMO9(YK>-X~=rfs1=J=Q5g$DC=WGmBx_ zo&KXobbYaqnzAg}x)>IpN$izbwH~~BWybQu>SJHQM7c(zx8_V5KcT3>B_qj&nU%JT zAzA-{V~CHU?H|);y@zc>)RU$hhh|^U@_4VyIE7&)&@{)&lGKrgWUtVVS?86f&~>jJ zYC7Iv04a=>8{Ggd=?|=L5Wp)Tf1PpQWyF;V(%D&zNvVpTeGx}#!fI=XDP;6e7i5V9 zg6-`_S5nR~GPMlv9r}S4)|A{Fy5&(ltnoq-64ss9ygXfd6p30+KJ@ODW|L_)b7Cyf zU^vxCn2XXDL+aLwC^`owhJEGqxySjF!@X!FAKO;JluP<>3P^N92#dXZ%R5Lu>8S0A zMScUuQL{gc3)~+16&Ie*llfLr$86PIz3E=S@3k6g4|!^af-z5mtxZxUw$rM?Uag1A zCa1g^`HWENX{{JL01LtfNWOQg7nyhNn(f{;-Y1p|VLqB)2%)2R?VE&(_e&;$UQZs{ zQ9)>a?{|MJd>{OFGwc4Y=cEew7u0MO5WRAnZMMfugiqeg!zW4B{7YA7#15$+)j5!k z@I`jM{~>KQO){@V^?g4<8J7`BUk=aOI>FXv2=tU&y@*KBT24-xV}kEoJ0#Mx$QtFA z?tN2(e#_Y8V|-2UcIfMksI8hy)TS|7BFW%zMhY9wDeiU!jHRz7V+{Y~P&w!=&RI~yG=r0bkp+Qs>f-4_sN~Tbuxygc zjBbC)Rl3c`Rx`(ud*DBD*poO2rr=#YCn0YLn8EEPidmQ)1P-bGLl55S)+F|7oupVn ztg>R8OWBTIi!65v{4izGkvL-t<-slflxNXyp~N;qA@CtAryB4?&E?FX~mdp&t%h zO-s0sOLK;>iLc5{Lzxnl$hj)6LqjkQlB~LrMz|WaVYjZao z%`9HaDid)oG-Cr;B4qv?ePV3^8|)5-3DY=n9z!m7Gl8+^cY7*NFCR~xiyl_HUgnN;H`p~y+gs9_5eZKkdlzRG9X*W^3E3V3 zF-d2^n}-Q=VWDaU6Q*;b?8^3}WirsrS8plcGxzQf%GJ{2AAyzAE4Eg7fl!2YSZWHJ z<7c7f&l>Lfs)I$S*!y3~pW5lCeCGbG(chuN`27*E#b7P1DT=#?cO$K~XoZgnD$`$F z3-J6l59Vi(p9!EM8d40Y zy9h6GE=8tmlXzu#uI>S9=^dmxdM)R0GrTbjZ_hW*pFNYTc94Q4A_h?l8L zS6;cQ2bfjJ1es#NttZQ4!Fh9~)+IIZ4>zlexpRRMzLusyGM@xIVKYU zc%ZN}+zfJ(!|xpTNs^j;8XT4m&#JD}@6CXgPt$DXf7Y} z(zK8uFIe@m;51E@)5|^fP0{z+neTj{fSd|I$l*iL$njhr+0}9#?S||~^6mFyri`nl zK?Ui_er<+ec$-&saWPk0K1?x^cIZ}3Ro0134dZ^$3}j9GkMdV=t+&L8rfy_Fkcah^ zfEx_!>GNt-lbWoX?6g4AUdw?T;O|f8s`xlSdGPyyJ0#JlH01;*kfCz=xO%z@v{_+i znSA-qz;^mPXaOju8>6P9(;S*I2_4j?c#r1a8X^#0yQP3Qje7faJLy-Ab04t~+t2o4 z(6jyj=wwR5XSa*5gMq`0a2I;N*_-6Ss|q!$v9WC@@hsb($jT zB-(+{Yo$~PzM#yk^zF7tszIm92!v6fOcDUfq*Y$5+kovC-3%e4f^WMdWyYg^Y4Oz5 z+Bk)LuD@cR#3JYoA%{@B0LA2L8-GfdFOHXza%3}a2=Yc-8cR+PvogAaLkVhEK-H73 zck2`(fRQ0zax?Qxd}V)*n{$$*9HGVHD;ILMN78jz&mItg&;`cD0^V#T%K>ZlB9}AJl-&V?GYop zTi{QEGEEL5)S8naQ5l$1#rdz+>%Sr0ebkySMZ^5mM#j1@^Po#g=6cX2xqe6^wVeO( zviCb>l%LZ;m0K8!1Q3 zBcBdj?va=KbrrIFk)Eo*T)3;n)jg#U64bj*vkiUKOAStUsHRlrvN9k2Ez&39-*D~= zOS14O!B1CGbn`UlBICg~SjY|-%OEe|-9nVzB!y4fqqSVy_`v!ATkzT<3$q2_wcjmd zDoySaa|#aTJ-l{7#YMd6g3K3i>i*Ak20#BRAeM9Th1YSvWj4K*N|{H#5IGsT!RmFy zfP(=l7i3O`9xJCHdJNL<<1K+o0TdrW9KhvF7*{o1# z&_2eYaD!M9P0;Vliv`5Q1j5erZ+wn_*fq!)ZK{WJ$e90KK)F0j7gi|N$li1?RPyPKo&=Rj+S#I=|bUwP!T_@?64Di zoTkh)YQk=ZEczePWlE0;=r(vlI9GU-dq^ZBF?pVMeC1hk)456Xu~$l^ZvVNcxByiV z``_R6yUg`PmgRs+#?}(XKgeOA)fmq=>shd#P}04m8TMjk{^TWG40;d;a!%v~U}Bdo5Wlz?a=!8rY`ufFMnl$t zjGxSIO~!YXv}9q9F}roT86r}dyLEaQQWfSm*9LZwjOx47)`BRzZT$gA8*7i`z2J0(21hZz0Gx!UTGE!nXBV=voPMjR{HX}jO`BW zEHo$@ARTyc7nv&yTi8T2k+o*jq4QO#>J)EOxSS@4OmjNYEkEsE2L|7hXIDUGx&9!t zeCQK!IR`I>U2;#J&B2>YwvB&k;seoTHH?vqVOv%SQhe9Py?JWXFrr~cvTPUeZrr=c zTa(~2YI#B^$5L3C+Kt%2!)PbIdKZXnF4pjKELozk$CqeLEc9+y%{7-O<=I#)UA0!p z$$rO_o4EIdm&>DjfGubPY(X2{&#+F{?5X-LTQXbCaP{`6m2y_kz3+8Tz8mZQ{nJdp z2Y0CPVa8W`jL@@UtLDD)KQ)3YPzQ-J_KJ1Xr)(~-U%9Tz<&Qmf|EBRMsAJlJ4u@C# z%>a|M8*UrQ;2LOn>gXcy6CTd()){a7R$!V8#D6^Y8H)0(`B}i*HEz&J69y^v|Lf|V zBeaVvw}uKQ#iMp0@}PTbCQ2l(VhqE#|GK9Cs0M?)rIHY@mi0}GAbY_w_vf2LTh~GY z&$6C3fBbMKU~eN42&pCz2eV0byWb>AVWw9J$N1hm=p+U4GE8?zW#lr}iR)Kc{J!$7 zrmqX% zEp~d4!cpK|qIP8O$@0M)!B z2yuwlVa$6ESs89hQ@BqbJ+*ButM_@_AgD}wu|k5b`hejsO#hC^;ip-tdo^01Fmv-{ zA}O+G%`f z^UZ`8ge9ET00AzgIbs%sA*5*B94==k?PB{P2 z|CSPjsm%7CwJ|fDzm8fUs#A16ezH+#f_5&gL;Hq%7mcdlb_GqmvaZk821gu<5DUwc z1`2#J#KDWE8;^0#j;rce{t6Q`faY%`#>P-{W2umHEAI8REchg*(h)NJd-vEMLe71* zza69@-}$+RY#HXb_f3D*zfu%ZjDxMve_4>IOstQr!gC^CeAZ?QE*OWcbQ~22RmE8Z zkyZA>ub_vsB7o6_0>fSd$P!uQVx8h#Xk97^gS#;IAH_OW-am6RWJmYRg@SX@7Q>IG z(H7w&tne41;*mUx?ZA?>D6DM>1hTw?&F+Uno_?wmEVmfD^h636-u@D4w>E~!i63l` zB;GXJpyAh2tYEkEM|E=RH-@*R@{56dDT!yxI5^PmB29F5of7hov_uQWyhLLZRJz+u ze_F_?xqGZI9sJe*0$QX8<#@EJrX!5s={cg>O1ZLNJ11052r4!C`XN$X*>$_7+Exw;eKR1g<5z`Y{V_(Y;UXA4j&l&$y@-ij1{@I#rA~W5#NIQ2` zVcvUN@ATFWzFMTsQ-7sCRNUmKip_Z*CE#}S<@j%XfzJ);B3eYkI@4Y?c@&!?cj*Pz z4BAIc_IE=kg8N!CycF6e&HBtjlb;XW@Z;QpNa7E2AvY>Tkoz=^n10VWa-d{&)GF9j zq5**Nsyxepy{WJbW+~X+d0noleUKOK*gm3kSnqzb|INp*#M<%TQ?(ap`G2VuwRv=~(Lw_H2pJBy4* zm8gxqnYA_ZV22doj$uZB#;mYF<3HOj6wuRBX$K4?3$Qa=B%ft-!zrfTo)66My8IJ} zYD(+heeZXQysv}3Dn(_F(mpke1I2OXmGN8tE`qG}iL5M}kuS@HLIRM?)ADoqPa}=) z^Nh2a^)GMmR|D*@DFm?>HJ;8Wymxew1K}{QIc~ofeECl_%=!v9%KFBG9D12N?&Dg1 zz-X(L$3gHu6AG^7tIkV&Bx+^6;#r-SUg7}=2TTVZ;-7&=pu%A0?H|si9^d7mW7q47 z5w{n5WrR3P-pDaio3kvg9@6ON!#+6xDO@24$Ed*@c9SkVbSt!=7Jq&kJtw|A!!Pdn zGd+`(?D}K9uyV&m&!1iYLV!cJ>vpP!L8=Yw?GkgV<^73{fX_> zT!>5iV@M(SmGHI6cOW_$gIaK4+(=Bem9+zRE29f%Vv7d%n(PSa-R{<|<*0-^XLFro z>v1|B+MON3X(P!WPTNl^FX=?RD#dC$)l$ko)`g2A69t+#bs=lnxlTptdz{sC65BJK za>A{*P1=1e6jU9Ky-hLaTB^19!+o^W14s9_Gj34;S7Ro6%Beja0bQeiN1&`sqr|bzGd~Ytc3GS5Pd(Ohq6X}x= zx=}4;9&_x#2sY!TdCI+?Q;Mc&|WHm za-S&vGzF%9YhQj}XAf_70dz9D%lXQ>;~$~2<({CHubH+_-7_ENKkU;Y@Tg$QAy&v? zv{e64MHV%k&`|Si&C=G8`DrD!7}rHS@aCF&`A$?E(_k>cuWl)&TYeK<5*%}e9LP6o zymtKICAFb=@T9YvPDI4q8-r3z7b%-wH;62kS<|7BnY&m`ki}6;!1k}~hxN+SGSMrZ1nu!5a}9TjRl0bBmb$hWeG#RU@5?7&PuIxSDP%f zI@qi$vr*-2a36KH*P6=Q9q#{`nEaQnQus!5w11F#CqQfpF-*+5^{H0){k%gzS08H!oFC@D2so+mG`S02YZk-Cv+4kUP^uF4FH0nK(U>W95oC$*t3UtD@q0%) z4Zs+XO@N%hRNElL4=mU7pz(JCs8!DwgPWLio!?;-bX61U{)ky5zj!gnBvg&w)D1=k zw`A8#!HR4%zi&x_WyJHQm&Z)n7?;#zJdb-J8~h2T(1w$#f23OK;sEu?L!^ryH)&8I z*`(|MkT*4PMidsvJw2$4)doORZ}*0DqI?zQ&|06uET-^L-fe*z)+hu~m_E!$+?5!n z4D51HK^?1E=#QZ3Vn(Fw5z;97_@&qs(f%D(lF>uemrvPb&i1+JBi>+NU;m*C*JHM# zi0|*>W0vsbsa%>OJRcXhky2>8?04jj+*zCl50Kg zL5%mieBXiR-X|o`PRI4l;%sx6HnGdIi=kqpcMB4sl{F@S@jSC-nLKn$h(ozVY4?5S5$Fx-iDB*Q$&lBOKOMu*z z=OB;*3_AIC)mhx5 z!!Jh1e0?Oj$141u6{foGOTCA8ZPoA^!wPvoHcklB>j3a%zqc{WZ)$0|X6F8R*X+S8 z^wUGq#4A_8d(Lvv33*@CD_EA#S2Qc3r><^&Qf6cr{OE8mXd@>m!|yun@CfuGx=0Ve zM9-4u577=NpxUH8bX&lwgS(E7xjOV(C4A>M67p9c^=b*=Djzn2$+s(!Q+%;SMGXYc z3mZfgEB3L!*{9eThp|-^!r!R5%>g?#HqGjrlZP(?lMfw_VSYPd+6I-vSv4Ufi$P&J@TgLDzp6OWwSrqkU5F62qQ^R{G`ccxDJLwl`xQJ-b zEE|qLc%F43IVLSNf4T@xTR$s4D`wxm-8=eo(Rn?05`4*hR(+`fJ+{l+uD*2ZW#O;T zIFEgPDgP(>o~QUyzL}5OLs%UFI@l*zeySeFFq9@5+>Bf*c1pTfV6>D*vtKfK<&Yw~ z)g9kAoU`?c>N1G!%|P7rTattJ7tf5MjhWg>({-31~Rm_+L1@vBzO`7g~dh~BEeG@s}M>XGEq)m1SjCd0Z6?ObfVaMdB3 zMm)N18$>j~;&$7Z{G@Kg4Vk;RO;uVhCwyAY`q=XN@JCY1TEw&b;kU%ewWcXdiLu6Y zflt5__^i6y@sQ(+ae2$S{Zo9UW5wvE;mf(l!8RxPxv?1FCu2i=4SdAEVqQs6=y=B( zn|{{R>BG+gzZ0PAHhs7OFG4LP)E6BO*K?W#2S!6}R>tGR>l%1fB>wXgfvCBu`8I;W zD?30?8R?=>K#{UcsOzy#XE~UqM>fQB4+Hqi&2l39+ZxV@Ro4029t?}QAv}gjRy)z*Hi9b1*1cDQcFVvqO-xkkMo2Tk_wwox;#-tnL;o!M%YCPaOqkBGT& z_-DUVT@E~*5%(AhSsZdlIrzCSOyQQPC( zlDb~75NKg=2NJxWL8y~5NUhZr?BK)PAXrLL56~JJutrhfrc30pusWH3vj5Tg?YJ+( zhJUpvJAU)a=K#3pG^u{tKH32fTR?=Wf#FeKLagF0n#kgq`N5Lp6|sf?D#hk1T0wA8 zBf!Oita;d!OwfXUyON|}ANJvyq`8_Z&vMzDf&y@s%hfc8KcK>PG?wuERZ6TGi|*c+ zO!f9}WL(|+OAtcl5*u~e*8>6bQOLM`1vauMxf^vyXkk6p$?X%h^h{MoCVT_c+ zWXgaDoD^Ht5wSNDraeEH8(!B?W=hKR5FiC3PLcr+`6$tm^shYx0hohA&*v{p>wS?s zyV07BRaEs-Z!=%e>mUda6H_XgPzb=-rFwkHMiW~s3yI;eC+L#Z*}`xMfyI)2$Ps@htPR_e|vuOfn+unPicYBIj8lT0D?SH?rUrnh)n7#5<~`%A-O|+wW%@%XA!l_ z&C7hC-Yzc!aX&izBJ5w=o`HFSI2uH_ z53r8(g$r|Hc-SL8iGjw(g6v9v0XRL5>AQ^|x+k?<5*q?nzwOWRn${SDPi%!lkQ z9^KFrpGz~FIe1TIBI`Kgn7uRXZ7$P~HiUHo8t zDnuR6#$R{*ccNBfsS-`U&&lpyk!9q~TJi0yZ?2fHk=NFE864=Ed@yin8d(qyU~e6I z5<;tcTFJf)AMm#O40KC7Ew^E036%=8jUPqN&oDdz+p z_9J})r7RrH?oW398$h{^S}fjeWlRdcv%23{s8rH+*a!-O_gSR}bk@F-q=|`Ls|gIe zEg%WWPW;aMdMliwF zG|ekym4a`BAJp$>i>;>Ku!`V}#YX;%7x%3alPoG1z0qc8W`5cUP5rTUnng<;s13|* zQL(sv6(yy4?^1Wqt=3Fx8IjCq0t91xOsAvAW(k7nx%91n<(Hi@@lE+Bo~>5WW^pNq zbEf%K&nYqjvtEGUAF}jQ<=6V67stYj$;vFg z>4HCF3w{pR$L$`tK%X4;ZDIKN_qS&){0!o^O#031nTaHAqg+9L#WqSLJZfyV?!3%1 zk;Ap|4!T2kz#|=k&AX^f=lvLL{*^T~!`E#T9P@}_>2A{T@V3(INfYA{gZsoQgqYYA z!MNB*UTu$17Yr%y0_a2kR8CZEx~_oypXhsVx0BKUI%e7}br5BJ`%uZS{b7SxKE1RY|ae0`LnhfJ(Ls)QFoyTpp_AJ>Ka?@^OhL%62`k$ z1r7W$G)o|i9p)4$*{MUv92-8fnzsBMe_KXY^;tUMdSOK%miZpFO!0%Q&Zh7_cKxGW z`U~|urT}-#rhVe=4es*m?nuie1`mU|O+6p?V>2bL7G5L2*iimQKbIfRp5r%Ku5<^S zHt8SlxL494;r^uDxNQRVD1~I@pHpBxh)d! zBR7}FD4%1+88-z63c%WtJ4+=$8^~Nplk*E3*l3d7c{DJeU0;{WI~;eNKhe0{1|e3x zY49Tu(X`hy?$aj~y5x*!q&=(?gLVi5FkX&PjyTj{EO=IW4FvO##RjfY4u?=BqiRKR zj;eDl&pWKk|y-+y}a`V;neByN7X9c*=voM2_PFSnz91S)Ha+vh_?p}|@~Mx`GluVyBOL}8t*#qVKf;)1 z7Cm48B92Iy7TlOT4hFAeM-CxuIog4bp}vmCYgV zQw_4Oh{t?d65rR@n0tvw5y6O{(Y=0&i^$1C7K7p17j~w)EVS*JJD(HiFu?`E*}jv- zU|EAud^LT>;C{tQr2~|EDKU_uC_ByU~QSKXMJBi#T7^#y_(v>L0D& z*|p$Qcp8`GW2J3v=%XgX+{`F9_)#m9cfR_6*cf97h^?yWc8R;T1o7J-bOAJ&n9hN{ zA#ZTdALffh3_%{J{BX-y5PX!L#qheg0I93W&;E;X2(0Q?js`+cruMf-v5--fv_FEi zp=!jGgFzh9E-`=W`k;f;I-@W0eW3>X%u}i=Ti?)aV%fatA7RkZKE#NtEptd2S9TZ@ zkK3y^kZkA7sueTtE8Pm;Z=VtO4ldm}aMte+Yog9U{IKAm1QYxe|Mcruj!K_VcWl%B ztL4`X*`ElfsCqS2O7@Pf`G4nL?E&FNp2YPIz-O33V8YF;=>NNJyGQN@vd~r5AM0Z= z+|j2Je0lBSgf_47207UUF`fzM*A#C^xUHij7B_Td07QzHbQ^b2e@}V-^z24@L?ep0 zS@6!qozyHh{Z>e8jpiL6YqavKwX0I2W^t%|o89_CnhVh_-ZL-zy~B;rSDUyK&a(2^ zFOwlkCGB`&l~B;e-V}B=P3>a`R*%n4-qhjfuh>N$10U!Db8!oXM)B}6!wm;w-FMi7 zQ5=T0KIa5fN3_WLLUU9nTV_hYxBcMdNL?Q|8m}IAtnw-)Y$%jeNCtCZYRzK|wEX1% zt>wSW7^ieyXLO2>x$8ar8WZE9C~7s))rK8zY!!!&a8l-Jj){jAL>U`I@2w2ss3JcL*#r0VJs%TbWMJE|5b}DaZ~1KNGO;#OIvcB+ z-9Z(ZT0pBPtx4ly&I75ZzA|M!xF_IN?2ePLcNQKd;QaY0vbL8M^-NLmqb5(J=zdlxd$Jm0LnLv*Qg5Cv3Lnvbj0Ny@tBTU*#_b&;xWKIOM!Cb>D+ zYR$-=kS2}Rwrm`ADCHf^+Qo z!)w~f)@Zg`9r-E`F^;?}KgSwGvagKu-E7Z30$1R7J)qGz6!{&j)Y$p*m?Of1{5}n3 zgTl-*YkFfX7Q`SsVmN^T0~RE>K#3|I6Tc}h9Yg$*5sc6mDfktP(0AxTKiQhkR(ohr zOo|<;hvDZ40w`>rnc|6ncrWAzkOkEjV2E-0FWxKC=U1<>%kkA{I1>?2b>;eK#&;J3 zA9^q6heUFTE(iW8Ih6^EP#$?ACg~{RmrP)o-pI&AFih_uA=6~*I9siaRWTWMWTc$0 zV-$=|0SvtB+y3zZu0Qar%&yc!Y|W3~5k^M<{@*?jWkvH4Wz`U1$d9m0 z!cSI21?At)(X?x|Nl)2+ofw@^;A3df$vDcBXbom0B4pDw>~mg1J5E))qvix7x4kCN zDJ2r~(<<##B*L5&&3%x~%;!oI8>JJh4lw@yZCDfS2916H|28yl5Jt>eOX~{wvszt> z=DUj1U;SZcAB~J;CuI{x45F9bLQJ9Sw7mA&KYCulaUSsN@bCI^ShqZ_W0+WiPTT=f zn{?4tCvJxBtI^}XYr~7bb2ZT~5KMl!H`P(e7rn9Bs7l%zGh%rp#50HX4aT>Cruopu z$f@Fh3M5v|mw8H4KrRy^oK5q@SRR!r&!T;+!;U8v^h*9y@a6F?SlqktvVkGU>mDoC zgdIjyKOg|%`QHMNDgPU*v+hURRaGR_0p0cu?nA{iYg~SRx9=+~*0S#9*kKDSz%tSD z_%#-ggCMcn=PnLgT;COGvZ^*aFmFRO^j?vr_E7vVvRe^U94rOO8O=_qP)NFe4_DlS zb;HDw1=YCxX4UXR;*%di8vu}Dty9CnQ-sZO0(U^|VFNY$PX*h-ADG3x-80El_qzoc zHbGUtxGq0{6IbOy|6yxrYx0YkFzF&oXl6mk7r9+fnYwjs&I!4F__@Q%w7q(c7Y)dz zzXb=&hN;Xs^1$P)*e^WN_QWq40H$tF%+DHt@B}J|Y(DK~XdZCa(5q;YGJs`7u`LK+ zvU|0V&WH@DM3W_2z|rS;0zpOfun+H6ZDUe5UJ<&kqB}!^0U1KRu~l?JP|I7+7Gkyk zL)TkI)zLLkgSZodL$Kfy+?^2IEd+NB?ry=|gS%UR3&Gu865L&aOD>m-PUm@NeQVaN znIHXopXxq+PF3w)RlbqM&G&P^=aGPkH1;H8fV2X|Mn>mkL_Di3=cqg`sqkNo$~+RN zxdPMWbMUGuqO84hD^Am+;q;_Ok~r_^FUIczp-Yozxn)0@W$Zya@>#2gQk;O(RS9S< z3VG`X0lCd9h;{tkD&PjnaQu`R@89$iB-Ib;UzrM&phydEZdRLvBx#@k1$}k6R;d7{(0-;V6Ks&3=?>95JUL?q&xz~Vl_rNbd;gLrM)kG^>?^IB`10wo(@pk2f2J90(0Eri+TBwrvE6XC(#ne9nu--kfR7~cG& zKMiJeI6(0~hy-9LRYsi> z@Ex?#O^Ehpm$U#W-F(zF`LH=L+5Lk>{`?0ebStEJnVJ^U{+22YV8mwu70*YK*5!*s zzM&RP9RS3&TUaj49a;r!BYmxkKR<1-CS-wl(4BiY@Gut^luf~| zD{siZr$%%_MRjKMF8C)L*?5QeVMM;QndTFZm-6Uy1rWmJ^C+eQwT<_7<;E7$84Shq zar8RLi10j4oc$6yBUgUBSE@zY&zu7vb&$p^$>jlNX}>#yv(ZNBwvomdKI5Lyh-_>E zYzm#UcItjnxAUBc$f5j}VSksq_bd^iY6L&iezc>?;_*pNGY0vcdJdqXp#Z)u4N1Z< zUxmm2J@h8fLZr_Iy3&?ogs+l4NuLkX z3m;RoH*^1?NDP;JeNRidCib3V;Y*1inp?a=U_gU_)&=8XjN?#eyPizaC1R!Lew!;> z0AxfH?CE;KC`5Ap^?p;2Mn|4C@GBOX8%;%NMLa^YgJA%xN87Dcw^s>E`Xw{XUCkW- z{hK876z;zb{83eWRmdB1gt*Qe5gVxOpVU0z%#b^9tI9vxw3dHFD=7cCBQFxRbjirP zcBC#AXX+T5*Y7#?rB9oma!CWmadn`5`EYtF06LX<5NKAM4BI1$lYGL;>?4+xk$dsU zFJ2s!t{f6~lXmKml@G?gjIRq9ekv~Y7pl$=7bl$~$>ED=WfkAxL34y|d!p+_2?2eq zx($Gc*Q2<$VQnWzoezsQJ|_y0JYVFOK-${$~iHrv=*;>^FkXuh4pCh5SYCE&ze zI$w!W9cy5oBm91FC;3+lBO{olnNb}!`J&b*+ds%Z+8?B}PLtuCc(fmuak80}hoV(F zgUs%HKVeSQBkTi8A`hW-pydg_a`oQwoGLV8ZtWBn+asE%AK##Np=U-UjBTewJUNV4 z|0`!(a6xZ$)Rl+^W}c8D;(KLKL>4K1KX)!tYR&9Ec6@xs`hbSxft>2xJLV7_MiK{a z%KrwXZi_ap)CI}dgzp)wTBG&2Wlj-b^gU2alsgF=!{-t5t+17o>ir@ALu3Kr$!0B; z1f0~~Go)elNB3sPf*1#?fn#4WtcyZ*gv+xYgcgIfr|x2Ws^QF#4Egn3<(1)u^l6-s z%Fp+uFaYf)>gTC2_1}C3vyR3V^*maqsiIoB!k%tE|4X*W8+%pyrHi~ zmBbmp(P3WQ6Qcw7MVs!IM(#d4%0~k8bY45f)}MI|_3$+5j1B67ObsZ2DWuks?pw+q zq4-hE@vG0OtknZHTZ$JBi$jOZlN;kvI0*QD)VuMz)W>8Ra%Ty(d<}r|8LdRVnl4mye`-3fxy$`l>o%A7J9|CVC~CcZ%Xw z20DSo$l|;xQs7w3W*Nasq;1PigJt`jl(s z)Dbdtx3g2P!;-zSalwoSPH-g@)^Nv{KYcdsnfE2%B<;rEN;g~E=0N=&9Amg!wVsOK z+VX^hPWFd5V>%L5{bk+2@8R6Ji;=H-+d=OMm?bLIOPa^9)lLkG^q%Z3O|F&Osc&n; z^PkKbYp{)<@{KC~%4yZeAJfk+zpqV=xBqGQx1h9CZ5IeHZh9zbpez-o{Z> zLjdiK-1*WDeIQ+(t&5-Juo5l^Et--@;cltV)o*#D|Lr#bOUY#LWB0X8m zLXY3yq}^iFsQ%(%)aQfb7yT*NY0r<%fqWW?dH+jMk_sJY?JiX{OXgCr$icL6PF7)k z7Il1KBP-SOj%cHcSUrWE?Ds|;c4CyUa_bNyoEhHXudjzYRkfcy2f1X7Se$uFO>uPF zPbK1x9jJL=Ud)i6e4r&S9;|x1Y(l%Pzkc|#dCfngO20@luFWiYlSfc%K+ELByW2eR zr?4?^o=g685(<72ov@NyCc7vly<8X>l#h+}^Mx?I^QGGF$kO3J#Di{5*2raGCSA6D zG<#>^>;Qsq@F!ZEO4kI>7EpO0mllr0Dc^ z!yqNt!PS;&wfvpiqwEiFHrLP#;qS-sf*v3Ck#Z|JC23o_xbWjdDBBD$tAMTJ5QwD7 z%U!`a!-H3>7=YQS+%8n_LY^a*m%M(07(X`kmYyVOJrW~qeHtg729>D|ntQE_ON~x@o3>i)jnh?qKGN5?)3+AcYlX!XUSS;x`3`2wjV*1 z@YHIf$M;Nrcyu2$V_YaHe&3NY%BIm1h4wxg35?%TJ-wi`w{2$ zm(`ucYi)MGZef`m>(6-|*^;^c*_}s{P5#gBm-{+~JvhIe6&^<67Iqg?e?d`PNV4v& z;h~IHV3t**@R&}T75JrZ&+PYOfi|l8%DM60psC8JgVh9mQBcEL{z1w$WrzRTp;uNo zLE6ls4R{};vx{w_t8puZp^AMqeFYbrN^P}#C57hB%(JgX+RpZ%{b?08@bSC#cs>($ zelCPLZdei8AZOAR7KnT5h&ka83C+Vykz2g58-JN*#An_WUhL6xbEm6vSu^U^IpX@Q(B-c{@j@79Z)% zZJBFQDbo`)|Nw(r;T5Nvk(M`f|VX^soW$sNR0q zD4$qMSkgM8*b3Bsx_KEG;aj?W$QYVvA?%qiXEN;WP*>KBb!2nQ(!k%!9jMP|@D(cJ zN-IUxKdrD=H+I}P7|csXx|_}vyyOYc_e{e5t1~%QA|$GiTLnKnMJFrO72=E=0}k`C z3IRS^(Pn;M3MOXWq$|&ekEOX8$?u&EdWVDf$)EW1zLl)eV~N%(iM_zXUMR9#*3tFs z^jNY)Q4ZF)A~?L0th^V-RWaq|l}lGbYhmfk*ABF8Juj`dW`kG!Js=zwLk8wZm1_@q z1@NRCtOfwQ#x|Al-Pai9;&9|`{bK@Mk>wNW4 z?_t&o<-tp%ru$*qSk??ta|-ByZK z4ZHKwxc$^Z%)qD@uZ!jE7fEC`dV(0uc9M4jJbs>c4yGz_dmUnz zbR<4}nMUXa&+bVf_dVQO*z|;^$wyo`x0>;a}&AK|?zhy^Y!U`87m@a)Ak!mbmqaVs%Ip>Qn4`)<|3BuhGN4fj=!D8Z|{B35S7iY`{BGmLw9uT15`@TrCEu+ivi zt8UiYfTA4#ey^ONZRO!wIm*s3F}%|N%pL!Iz(`n>{PK;$W~Lp=5C%mrR0&OhtUI@6VH>0te4ceRAGZ6{_f&zQN zVbPmH@iVg-3(`kJ9QVx$nB^nq)N(l_fIYXS32RMQFHL(qe1?)gZ|>lYJm44d<2XoO z7b2$mdhGIOdYCoo3x$EiCe;2;q!(0b-%fxLnwtTrh6EFu2Hm4IKYtpt zv9fs)MT3+QH7uU%gScDwx@^@G9e2c}Oc|O=H#B@VZAll>ru#ET50_*{Y8ZH-O!O`r1hyhNgOV-@au$TqYn84oq^sJeL#BW>VLJYcBrF-- zlYlOC_SbmW(Ub#tg`D@U;=C}K$P1WM50UU{(nY%i4>zhTS>+5-wXUB{oPc!C$F~Qj zysst*05Vzrqw$w4)MZmpUH=YEbvvnjQ?qJ|9H9z6U321T3woX((FHZUxT~%k>Si_f zsHj@FsTUPS$lq5vyJ0r(i*fmLg|o1WhPLpWp@dD0Glz=vmlj_V<5VC68rgU`x2>Jg z60>&t@{=v&6u0z`#`mL)(rqLN;O(}DLGe!AF_)e*R0OO=mF}741qi98a7*XG*`krE zSHx`!B8wtzDs_&*?FC=Nm+3z)q^fdmW&m z?LN1v154ON#c>;?HuZ>tLc-)oe3@7;y>U(8CHV zkYSP5w+6#`bydbuEMLz1n=!MWI-&8%ukRfkMfzIj@;Fck&uZshBI$Jzk) zLEi{-bRz@bh;K*vBa}3C`~1s`x84GJQ-e{<_eap_mvmK_%kotQAgmJ>hZE33O6nED zIBb{N_*MD4-bgH=kp@BGy}J@xAIn+!GW_qi>na;+Zx+eo8gytHxMQ-Ydq0PUgvn4B zm?L?l>xNQKtEMctTBR@o*X&CESSprM*?P4}!Vz=4PKAz0&;6BY@6>)&wo+w|P!y$H zh!6cLbg9a&-fg&llZfW0`;a?cH9W#Mf8) zv_={NYSEIYhPFCC8mntK8o#BIx10R|CzQxWk8d*}R3i&XzjgYHA6m)6Zi0}TppQ%k zWWp8N%!lF&AGZcQnaZC-#e>cyo*9YQG03s4%YY7|Vu*ASp+xPU!;D;wav2FMlJ8fb zE;^zYF>!;#cM4Yn>b-0W9^Qc!!jz@;yzYPh2z0)5le^eF_xEx3*gPQQhM+w44`|C5EZjpT&gHK12Ot zlc<0r4R_`&%!L{%hT|~!P?)aiFL`e^nYL=E|@w#L&k!(Mz&KSEi5ZWA7wJzxxd ztwZGt_`n3}aKM6|#&`M{Qg|K;7-)<0@1hO7t;M3Bssj!ye7vq@ZJ9opCEKP%!};X3 zKvIuBhc8pjjYDhdXo0KbX^`h}Kd|Z-_HO#|3D{z4FKV;3l5M>$SoZFu^2)vz1-j`+ zCz!2ZsWz0o`}-OwpFalT)|hTX z2-}lL+RihDK`L0;ZjjYV(ylA*lO5u+Q0y}9!2!$!qusS*HlC@Tmo%unlCt?fn8;;0 zIz4YcyJ-Kp5!J}^ZM-2ES>{1 zCm?J+hkWjCdS>UtD3*mYMDNyfp9_7{E`7@>R*2*yC?eQoJs8lAxd`3HaYzK)5BaU0_=@14-Euk%YfX0`DCHd)Y66(O&-+o4Wq&i1=3?GnZr=@u_ zxRuamSV;4iQ|7PMY0;1T`3G++bPkZ-2oV zva_O~73iwIcT*Cmou^SHX5)2naatlf>s?F8wcln~vjbf-W$bajIR!s>o5m;l75VuM zyAMmJb!O9r?GtP&pAp;0UL*(Jijq=!>ovkr2^{}Hkh|Fa1H_ZEE>^bmcdG2kkBuJD zg-se>ck^SE5vVa!J2z17gaTh#G1EV>77pBenp%;yo{mY%95URp+Vrxsp!igj1$W|D zkI(hi-RmwT#yT3grm=^(2m81U2S!B2-Ww&e>-|SjB7&Gxxvq|zwiU8<&%#tQCpd0s zzr_>iBi)b_fDodd?!pc#iKlA**ytBsc%b1``-|a*ACrY{i-+=VO&+c~pljiR=MC#C zNceNdgNhg@?|vWD%%W#+?b;M=mhn3okA_>x-$Nyh*FygmZ7o0TI{8*OGOBrh^Ng)y zkwhVk;Woq9y+^E=>oXt=q|iaO6+GeL1nRU^fA3%dL~m(GyR1-N;0)sp;S!*=5;p(z zayXhg=ZL5+o+|$2;p9jK60^hmxlDASFMxOI6}$7o6d^64V!7Y8ZTc?4+49=Z)ffZ% zbM?nbd&(*J?h=e~qtv#QzObT0)Zy)3!|FVFIy#jU6{>N#31lKN5LVURmtm_x%3UAt z<|2kB_y!^n-~y{sFIa#Em&C16rM7}dqQBMNUx6aJMLrKfwwo)u@n`3}&(m6fV{I8B zbxJ*t4)d;YZ`|AQp}-9HZG9$UM@Q8?oW+e0b7H6ax}W67T16u4daSru6w58X=SX%p z2kC$*R}&^GXka-JwnLrX`&QQRR(&~Q3ib~)=YuSg;oQotkAm2!6VCn1PhLDa%6H(f zWQH*+C(1H=^+X4gAg`BM+(eW&qmE7Iyh++x`kw5@9q^QYllkQWCw=9G z9gGy7YSklGkhGtyd(W44A9b3Mn-o=p+{4`HlVUCPig^C{iqD>P6erBiQF7Yq8_Q_k z0G#N|a2Sk&kB1W40?S$M^6f9x4H*E7*tm?<>x)*(gmy_MPu%-_dSMOED{oT}{a||| z7+38h=wjx981qMd($ypW?$^A=Ia84&KNsyl&$i@X_rW&lp?1UYP= zQ``gd5r=8qF`l=l_9?;cdoylvq7;~m{`<>7h}iFwF`dkRp<<#&Xp9gFe#_5?-J!s; zn6!**Y7l6Fwg_Y!7J+PoHpPPkb&sepf#ugUqVyuJV0-dTW-*mu_XByfMQmRZ{L>3% zb*ukj4vUUgkGV9Md1gd1z$XlzXW`Z8c}akdiu>9VNV6fFGPdl*`4${8t+E+UGKGT2 z*i%6b_{&N*l^2y+6^IMDA|;V<^6r7;zpalc+IsB)R(k_&TniQa?Vt!ecW@q+1 zj)J_|Zp~<8YRUvDHn50cE$8T@OWQ+M@PIRKA$O|mKZ7mjtgU(Dp0Xab-(54@iGyp& zb0B_VNj?ymc(<3-|8-Peccdc6qdr+3=gzciBd&gN0wW9c!v|G$i;ClDKPd)Rd zO*OuJ9jHfCqk9Nw;jgN$C*UYi(>XP4o%{DS0VI&swM_%Fua6v21P6(Cpf(?4P1BW$ zsfyHqE=4BKrA7P}MRdD0=ge=_lEQJ_(FC25iW>JTGxh(#dT9Rx+u|gDU@@CHP-wC3uOKta0&)%fO5y z+!5Sq4&*`Awoamiv2Ri&jxq-eSa5V-haA*LjO1|=ZV994t_an7?_)wqu04+(Vnx!C z_H}TM2u{&1o3jrYk{%b#Fq8INB}lah6&LUcG~|&8`bMg1Z2js+&=#pV|IW$1Exg#< zl~MZTw(StI6N_TFwcf42PA>ZTL;oVg2w(sjR$2PBJzgvP{i`s}A+qRs5l+|R&2lC! zVN2Liza~?<%y)s`cT+TXs)#v8+n2Sb|7(3XZ33*akQZ6fGR5YQfgM)1KUmLq5zprW zuT0UnH9H*}mCux)f^*$hruv4^4H>Qnbuddu zofvrij2bOq0iCg4`PqWtd1nzw7Sz zfwOEAl^$_PAIyR5yq)kS2=^A5u4E=OPdmL-o^hcmCe@B-z}1fbD>&@p--t=Y}Kacu0XRMbO3-(0HDk=2-!N`-q$a}_u7s|8)m)#T$az%G9Pru|GC$- zQZ&-Yb}i9q*Va-K>=qo3@*Y(a4ExFd%=;FXfkYN`ZYKkn2j46v1eixX++B@wBWX^s zCi=47>+!)J$Qi@vu}LEH%8ei_M{aY~8;vFS7}Z|FZ7Tj8JEg}x_`_A6;)S=-jV6P$zC`;(Su$6yvi1Sk|zkfRHt{{&-aO^v>6nM(qfV)(<^-T+LC2f3idUMH3oY+eJqLIZo+Yefv5vA+TV9E@i@DF6xM*^CE3!mj6+ zvXkqgnazOVZW$6J0^ov#?0b1NwP2Jhsb!brgH!!VLi7PU1pqtuBaP8-x=JRxYs3zB zPxhupF8}NvF2zV0$jF4&#Z28#r$!|=g}9Rs$zkNdEbuUrwm8vIaR|mg%8mmB$lz`0 zjHv*HBhVE0=wZk>X##;C7OhQAWE$JC5Pmw>AV&Mhj308O8yitOwA`3qv(jOqrX+)< zKdju=p{l9n6u(?h!9Ow~jN@EOShSZ@VixQwS>Fc*TY6SRPc_)J`}LU#WW-bZ6(Nva zyhqqF0xsZw7K{X78}EqXIB!m5*t3RWBwQVSLLQ*TISqEQ;-XoE67@f4QtlNJbKco$ z#F!Fr#Yl+09Yt$lN-H}->u0n;Kt+LQcH>|dQUAkplB~~7GSUxBu(G=@yMJn4Cf)CR zGSjT#y|Hc6yOQkC@hh@B-w^&vaFew6m_-+ML{KJABR%3up#$VjeES#SnRH#6GmiiZ<2}Ow9)IEsx2gZ z%Tqmp-~A|Ke*94;bo68SA0iks+$WPCe$KxBuD8uPx|QkLL~~P9dWc)+f7kbnZwaT#X`-|(EGKk zhTz7CBE4ffVrmb)w#iNTd&~20`N4h!QOhcO^-%|tKa!?y<`A<#iXRo|&A5`d#_n1- zMQamt?fytQsH@zi=m>IHz^!aB=K|Ez3N-O7PXX4_>U)_oBy9K3*?lOT!F$(Cz4skvK*Kk+)Er z!R!*Ak=_UnHYGudh4fq9s{K49DMP|8qgZCwFn#Juu;oN zeWj9GSs?CT;rh)D*pNJNG0eMu50wuc9G?0#br^NBqz%;UI{b@28sI-PMi$%X?A10CCaK zDsJ8MWAl7mSTgPT;bA50sweH)nh58{S5A-Pzzvmt3jR6PVi>yW%)Sd=r5N96V48UF zw^rpgf|zd9Ov@9JZRsRW=)Y>a*EGQhG@24^s@gM74q4K z`HhAXyaGV@t@f`+i4b9yJnr``VaETP<7S4z8|^+0pSgs z}OsyoWcY9(MuYGJE>(#c3chj@<0l#{~rE7z1fBxp6*~dwg zq;~-EyIP3p*&OqFDht*1U#8Rd*9zsX?wkw4?P z16>}2bx+}B)#g_QMN~uGx05q&MfF7l-cP3_^3=&MB*D04eWLGq&sR=?nz;Nc2`0R= zu>x8WAj^yAa!f}(gTui@iPMr*Xo?Lk1)V8zX>G(>40Bz<8lWahmSUik zBI@-iY=(Aq=K(bA;ZL#|49|~7aFi+|0W{o7!N#wX(l(3||$Q2dtlr_=XbIU0fN2GAD;1nb1hZfpvxtP=7aogGa~ z+%_h){J<^Ux)m_A+qcdD+`PsxEPP+Ptf+Q{@u^3r?bzX;FNnoXL^VgK)4#}a%C(u@ zn+}hERFCb(HA>+7vJ!PX3w)j{l;8o|KA|_##B0QOKS#LekbQX^7IAH4%}QxABqVv< z;6~^((=Eqa+v5L`bai20M!rN7w~F>t&%Y~TB9IDafIbjiE<=gL+w?HUYWIHy#&P zU2QXiU^_?ge$RJ{RCgrWR;M!Wt4eOs0 zlwZZ@SIO#oRDrST`LdUoXrMsUU0k=aBGcUmG_;q^l}n}&=%*< zNm<)#;p|#&@?`l@mwixK>cNH5KwZd!Or7vKar#!<5bP5gz;JzicGeMANkI^mtNyAE zV{bAuNZx=n>!2y9F`G8#BEU7BA-n4%qO-$wJZ>IDjnXC{k`F}N*DEViQ6g_+XI|EG z{>)BgqV@F9yQW1h7X=*=$>^N52a7Lg-pBH{vx}Y%$oVZQSVL>Dcy=2NPb}A%_3%!& zrC;6|EL_r;UN{(?VRdZ#>MU$NgNClE$9~s|d307L!sp9wax=~@26_>#j;1VqT%$cW z^uND$kru?28{Qw(eJQRH@#GkpAnsMu8J+r57&n-QvieZ1UJxhz7Go9QxU8`Zaw{*h zBAwG#KO2yT*&g22Ce~JeT$^f)3QZ~akv{v0#8vIx$LuTd>Ga11$l{5P=qQ_U{mMnY zHJM*!Gge=Ag5xV`y<*FNW0n3Hdv3ThQ9t@`AX;}q&!$`SeHYxZ!mTk|Ha4he?yRRQ zFpa;Zg7&~|kr?fSoKHvKOBE{g$PJ_@ zgQk{vt6rBfO-`s&S17^GgDQ0>^|RBnc+KG6$%1E#~cGT0zy@o`1|t6BTY(9n#2xy{bZV;i{K~+yQPjS=4&4|1p`>390N}! zv|1MCNbP(Zr*rD2!>-AM!vWzLE2;!Ujb~QIeW9Ay?r1yYElL6faL4~qU=4M5RtL`G z_YK$>T->cqp)}`;L`T9!+Xs>lxgD!1iV%LlaK%Q8(YfQ--17MBz8-Gx42!rHxe*<0 z?+Gbt9Hf;CjZKG`hS*BmB|e47cyXe*UnY}t!t9e2 zo8&FgeDJxBEs8_5uz^%f$A56+4gj3pvD&0C$;dv|0)r50hgl15FAJ;Fzx%NY^FAh z=V4Xvj;+nqccDJwza)gBg zAhSA?e$xBw(eX(6Kbe&W2?@e~@-mlPmo)a)BImV#f|kFLgPj639(~?TVxRRgZKO0` z3}5wh{KBvtZ;~AV>D9561;JEuz36ENG~YCGvez_&Q}&=Ogc9e!oV-#}B;2@bVA*Ia zmiNU<)tA6ZoS4QuhE|bt!Dt`Yu%pPWm~mInj*|c0@1(1l*v`NAE3|Oh&*`L;3#d}s z!enqxHKz2}Wo&?4su`EB2;odhr--kLIN$#F8Z$s0=S2%z#w}V~VFSFVyP(DeNq7HlY zS^KBV+Fzmz1#ADI6@P7swBoo__)yX406W!==w!nLWT)JyLG+R>FXMP_r}(OFfP*_L z;-+M2m}?_^L^~U1g529a&swyoW2TW$BOJk;f;+uA?&?PzHRHEY8uVnmc1To?` zVfEE7P8jrHvW{2XcBc2;DLApV^|XCRJJ_{+R9z>WIEU<(Z}TXEqtqMn-OJUucWdmj z@v8LrKY(7AR5zw{GQUlaN6z3Rq4a&K_^E^>_FR<*wncGvT_G+n$lZkV;z^qk^+x^Wia2FAR5fcv0IAa?Q&P5Q=;@L=a? z$dAOg%smTMnf(g|tn8WS-ZGk?i}7~I`!MDNHulQ3fuo-96J1~Saq#;d-yn4w-pzrB zCbmz8rXr+n@pb(kaP>lyE=a2?ahk=ZXyTHIL|>Zh)q5RG1_vJu;XNqE_<`sbOIXfQ zZuCG)W_}H00nueNX^a!)>P@^NGeNb4*iSQ?`-`*Q!90Xv&%ig6cE`PwPw#e4>J)Hv zSu37WuE?&<)u8bi1B&kRY9^@Vvi`ZziYB&R>-NfnNgY<2Z}_4W(&dm*C(d{NZ(w1*O)X^MqdElq}d zOiec0vZBv@ezN7tQ->t9b3$0d zEiasx%exZLrabGW@in%-3DY*+y1O2p6zI9wn~tF&Bf^QT2`QjVC4(yo#6`eLBo{dBna?KYr`bXqGmT6H?7*kOJq8&c}E+&z6Y^A>><%VVWWXGj3KOO$|>iDYcLU< z+L}9g6i}fZk8aO=%fce7XuEpQ5K#1D(zfQ{w8L6xz%ayn?0?SC|B?2|XV56zE<>_k zF46OQt0ZlnFM>2LSA^2#kY(;h_3Me-Kz2FXTOZ&)i33-lz z0211b?qkMOvM^d>I{}V{t+R(X2&d#mE6~&Dg$mStU)_Td)-y`odtZ&kw|hA&o#o5w zrJYdUZ)quNOlS6TUv0zqw2<8?YLM?t5VP&l$W}dK)AS((i|?q9O^-p1m7NDCenX@v z10mdu=4l8#nmj5wHlNb8>GI}6_bdzVSXWyD)IIxg$;@=hx5*6YR%duOGz!HHa%9Y* zG)fu0UX$0CM_NP_l6zhNTzkfW9$8|9wtniP>CZ?9aHl95hTZDmnuXuj?>+6II5};IEn&;oc zl5#65rF)-?Nb@ZCl+emq6!Y_NPMX*Xz1iG^x8kj^2~Fn7MH~$dtd=#Q#%#DEYqqyxTITGB$vXJw|Vbo^$k$SM}4Qy2n zC&K$QnTNOAhAF_mNdfoQluiQ1w8fVkZZlBi^Te*+-rsyS@~FLD$xMMDe>ex$%PgR# zrl0zRvD)wvCkyham%n$vA~TYCB9$pmKzj(66q!`G7+8yQ?;y843GyhNdO!b1*VNTG zc!`*=7j28CT&KS~E1t@Uk^g$Ig*f+imC#ECi@rG?QXGaIOoj-*Sr6C>*xck9=*5H{ z^-4wwJB~Zdi&Qk=(cR2B#up>ixH< zaq%Me%FR?wXp^q}>KwH@{E+z{L46iD&st9<8F<9Iq{46gTIyYQwA`0r1z|J-g28tS zqDT}B^=tE(c-A$q-{7W9_rAeta1%4Iv$T8*#zaP&A^(Jp?%?|NNdY?hC71AU1U@jc z;Kv83>K7!WE|T-_lTAw4lS>B!#i0f~F8#1TRR@9W;<9@iDFympwBikf1Xv%?X$<7D zmTj8Vkom<0`^n4EfFp5RQ`3*NyRW!UQeY+X`>wE@Mr*gsT1hO@VfUB6&^QP9o0Jg1 z@g40OTwzxF-6_(!eb4fV0`~(4)6@BnAJ#Sb2h?YryuI{#2B^K|P{Z?}nTTG9UIVA1 zH|Y>TZ=hZc?_-1LLJ7vEUC%}E>r2s7w{F^NvEh6h3&r_2$D$gT{9SySXPjB|u_*a- zE_=wA#p&PRDujfeeW4BqKMmqZ*snP*_hrTU24$WChkU?oLVLzgztqmjnvh0`g=UKbxx|q|IKKnbJxRb-(a}mt{=5Oen^Hu7aod zQ}uOAE&~DFgWZl|G%5m(6$GW;vcUQAM)&P00V3w&Pzu5bWHsN;4wvvC1vV+AlHU-&>7h8Ua0= zxn^hiu`hWw0~v|1&)D#w_?HJ&i3jTN3G4?WJHAKLHly?ogRATA8glE9UP-x!&Tib& zE2#B9x*;Pw@)vR?F@kVgxG$yg+tECm(W)L;n6;}>24hDOX|t|4xNiS}jG`3=C&4YJ zcVz==y^TU#hdQIo@qJ76f^Vj=j8r($7{uzqWkICj{_tjE!oz07*}Wlkq#j-8@mt8t6dN^Y<*zm4&6 z%bw3FIj99vJ>o+G{nh-K2uW3@DQ)9;Ra*GY(W{`Qt2k_oFpKU^k#2lP^{00O2@5qc zU0oDwns6X#$CRBD<4bUG`ohT@(!pA~iIq1`0x7O0UdXDzNrHMvZo(|hN9V<;x;8-NIA z^+i4pb>sT2N2+Di8sl`?$%q+D@n-}w7VqG&xs?Qzq!pDp4r4JoFMrp^8|1;;kpqXm z-C73wtD_*=EV!l=K%9-5niD}Czg70nr9MIiB@9~EU#7+bIrJa#$hNvG8zQVK~~0}d?hF1?j#;rZ*9KU1ggBIQA+}n%u3F4~xx`KLNz|J!CI>AE7HoDn6RL4bJfp^S#A2ykwzZdU zs{wC_&FZS7layy51hR zkw+syXL%)K1J1b0xcR4V_jU?J%6?RQ$dSNk&tk^TKRRQc8Y#PNkb~`bnd>)}AdxEi8@Y!{1Xn#0LUt{hBSFS%}4;g_-m^%^wV%uO*}-y`$3l`=a34{E`4R4`PyI z-@iLlx(>4x4^F_4)kJH9(Y(31AeZJwb{B3ItGzAOS%^ihw9Rgc^!;LT}+a=*&0I z|GZ>2nMv;N>^<$Cdv^D?_c@@N0g=70>FT5Yi)%);g@3b&VDxQ|q!B{or=7bw##@GE zKc8#7&bZ$yODc1CpL5)g+E3p1I;i$C;s%#~8fh8DIV$Q)U0vycBfV9hRSk`<+AN4MwT zuNsjI|EkKQopqkMU0^fx^v>2lm>1MJJ#Qt< z3gl#QYAdCTKMa%l*Zkiv53C@w>m9?WPYY_$A94q1bCxE4IK|ZJc3RT9Bfaf+u9Ac2 zokuAX-IN7Vb@{0yFFDD!rJ_4R>6Q1i^1Y}LdL5_8x&u<%K0axIuf^V6ayVi+iEv7> z(@UgAL{rluz)(2Y44^oe-EJQ1*P`K{{>o3v1m2ZLF{+U#8a_j_Pfyx~LMt5ySjW-_ zo>DpDJ?3+Ww>Ysa5|H|C%1=`2V}{FCsR!QeGlJ=r+VzIppb_IEH1+Cd_X;;r#drcxM!!9+$Ngy1=g=q@nnElj>e^Gn;Y+FRuN2EINQ$#Xhr25x* z=l5S_bqHXgYTYafJ>-JL0pddfXU?43AhgofsdsxBr+>P$7@@Nw#UBo$>;h0~T9>0-;ZLS)8GB*G2@b3?HTw^X9=4n|}^+j$XWwl1y z4djAPbB5tgF;QCH$9=dF7?dy5+Bz_n%eQ;ARED@9;}#PEt{^0E1!?6U_NzgxyJZ~S zG24jb2>_#y1V$eak=B6@%GRRAiOjzw=w5I2>_n5->Njl$i{iau(6-IA`=Gn>Bc&&Y z(b*;6MC}65_+DKEuZeWP@pO7i{573!2hDOV1d+(n$>ussv z&Tt3nUPQCWOC# zQ1cT%o>A(_^S)-20bP1Sg8~|6w@x=@Z{S7Zwm3!XOBa;hhP2fIJHtl*&DhScojfmc zku6Ns83&EFZc(#^fqp`5`{J7UlGvuqy>QdI3sT#TP(>H?Z1cIKv4I4RXV~X|OQ5zP zIQ`hGZ$q%7mcpi9nDm(bl?Ip=Y$dDh&}=PI<8n=|m>gXZh$Y{6{>)bFJyv$yH4@W^ zlcAF4mx#&MulNfWukXRp_Da!+(){6QX_O=z&{OUaY~5%^ z`UR!Mw<+u29O^$yE8S$rEypKxON812i+k>V9Ql&_iP6q6-0z*Gk)3zlzY*QJOwV~T5-OM|^?yBZ_+OAH_O%6S~g;=vh zx(Sjm8gOX^MY8e4^w9X1%o}h;77z5$RQgwUFC$XzSu8rCuXbb!n~j#c0%FwHHyNpxKV}RhoVAFY)8=#} z z54GGJdELgooYcWKJMO{`h%-J+aJemK#nvsf{ko%pe)U13_qn#8`)e{!j@d#(%rmZ% zH)DK=or?LU+VXu`>e235kc?Pjo~~_ZkQ?cr7lP(-s*mtvSAQp}AUpGSh0Bc04gl}y zIBJKx#4k96QO)GHZ?wn9Clhz<8zmd?%$_p{{89LPsEHN@97>(P97+d?Gm70FVeAP; ze0@h^Uh(Q5gHR7V=vZVq;Y~wtlccx}RQhPuqkXg1(_@$OdTc`9-Rv)@PV8g}@oKAO zl5XHy&|Nnr1~Ms={+$N__%R>C8p7GW&L-1v>~H??z_V-8XRHg8b5;@?@2q` z`<0$~0`;jN#fZG&<2B)|xPL-C!(V+)c(A4{$GCR>T;mL3mk(Ka>+t0;yxDIPPE8bj zyZs;!XA>G^L8`lUVtq=rpzUS@p}eqyZ|$OG(a+@;r(ev1fKB`$4IB_Bf)hcCXSvXa zx&wvZ@J&NV4gOQO-)x3_l@3n^PtsYA0mIA1D>?!pu=9nJ_(lSOU449d1>{P36Bow`ywh2~z0;25r$2tG&w772mw&BDfDU@TuxhAL`?!La zp{}puhRl?DQYx}%vR_oF@eaESVXB+U6^Tmx9HS$^pl*XnF3?#JEFqo|QcuGz*3f1K1ZF~l-|es8i_hkTT4D=m|eFitOf zV^0%$CFuvcEewBG{loV*q+T&km)kGhB}ssHGoxV)tqJwMnl$4Exo z^-l65-{oexjWMrZ4Ak?#w?FYn^=p(~hj*Jg?`20JjK`H6CO$}Iv-7I&2h|Vt48AKi zsY)^_sc$N?n(?nCVxswFBm{Ls&I;%dzBH%Q)CkWXZ|^x0$2U8dI+}k6Yi;U~;~BRI zdFo8kMBU(5Y?V!HIg_j*n$EUR za(#OQ-KW3UnJ&lkc1?ZVUe;~qi)C9kpVLj=c?e8~VN3DRX?3BG4=SnyqEE?QZIprTf~Rl}@f~Hd z>A>82&p7^=g_J22vF<10+Ou@i#&h{Zz6zaVp{q*C3l(;FZF4xW{q)Sj8QPKiau^ns z{Jn2`JiEb@&5|xHa3|M8@@d1AY;OtTmfInSvm^#rM+q{%ggddSau0D_wC{$r)Nl`B z1{K9yt1Cdp2!j|Ot^RKMw^8!SNWDX5fnR8v^;O!_&;o@v3R;i3m4#1~pPJfu- zmhChz64%K&YF=utwIj?wXa@4d2vbD(F^BCM`Sd47+wM5Pw$*+h8Kp1OFM!VVW z?yrN!T=66V0%C(fm9`2==Q|n?LcQOLPb)KE)Yt-r4}*#v6UnuY3*AVy9Bgk91XYV1 zP23M+81rMW#9f6=?1EV4!fkXa=)F(^k4N3JScxDV!Efsf^`yJ25g@W2qmEP4txQ<^ znl~}ILqB6acQQG?>s#v^CQMkW`{Hh@`O+@7_MQ#`myA4U|3RQLMqlBy_M=(1$q6?b zmgwfXQHjSq-IhHRZSQY+5R}Ah{PY1&k}CX zh|OWnu~;WZq&5%Udp1ulymuHo?NE@XqDX@FA*agVY`O6#JMW8Szqke4wb?HHxMkr* zLuk|lWPHEOmLbOnVkh5IxsB%H6nTeDgu11*a`e=zp4V=577Bd5 z7;6u;LE}o>1Z+-MwZ*S7g7;E?o7_?#8RDNd+w%0t{oqBR0@^GsHSC;_W}U0mGIIRo zPQ7$6cZa!))at(WkaBEZ`wC`AZ?LZ5I-WOGTXW(mr^aimzR(B)={ZT@U z+$|tA1B&HTZl$M?Lts|%T6`0+S7HLJywA%++%0UHK;nY|2KGH8W$nh$i|2X@%VI+Y z6I`?`s+cu2SB;JF$7X`fBn|pgi;;yO*U9}wEjE~AbO7WgUrd*|*ZFgR6|tQBVO@jM zt&%xKjG0@(o{m3nhe6|+9KS08)~4U`Mja`(oNKdkyJPx8b#GDB0z*ek`t&Ss4MXzJ zlzGN)ht{X`-RI8Qu?mn{II~h3TR2TCh6d#&>GtvtEX$Vb`{RtUebEq-w%?A4ztXMp z>baB!r6=?wuA@rg)>zpfaBY0GFV4cNJFR^S_;eMGz7#Xxpo6H>76Y2Cp6hvKtaJPJ zYcp+KO^=-j9ahs_j&Svm@2s%uND=AOyu^<>ScfolSUNOn{ZK{+M)oS*~%_qt~n{QS4SX|B$ zQn2@JiUl+Q~JYw}+8diz52?Mw_{w_I;LQqZ+wLaC#M; z?C@A#(Kgf=Cp>&dOCI=9*tB&m} zUmpG1fVdg`-hkYr%R<)#Z=%JcLE z>2lmItW+<2V~@8TF06(EF0s261f9U8*KJksOY!$$47DPV(8`MD@V2UfDEAp0YGRe$ z?xalXVG4^(PFb?GvCd7f(brU-J$(n25p*fTkU64eD6Yh?>bqB`9T65q(h-T|672sJiW;@ zz!{&QpkVp~9|4MW3V`?o0_y_!{9oWiM93f-0I)z<{{UuzqTFF_*8^aFfif)hJxbMA0>E!Uye(-8|DM~PiXy$+)aJ}odUx02Q-837c>MGaK{w} zyYpXqJs0we`v6E0G!pM0;0^j;;NMOD?;`%Q`TspAxc?}Jjq(3aBG3y0xf=)?1ANK- WJ{ua^CJmbPnC!IMUrM4I;F zp7)&Z+q0gDwVr+Ny{~&e_g-^d8Y%!JLIgB4Gz3@jaU+C3i~#=qm5htChn2I3iH}P1c~BDIY4cZ)3cX|PP*w;H?RS^fOaOKC-0%<+;b&PHM3D$ldB*UD{Fnt; z+6Z0ng#?X4jVBLr$=QQ&E8o+*>_b^o5CCq&=wpM~p!<{?eZ`?s+_affZtU)R?i)l| zUXFDcY~FywZ2=7xRJ246mM`mOP9NoFO9^WgHI+X#uxDh6d z-`g^skn!y1W6;{5KTv_mb4%5ks*3VU?QNYgjgC^C>pag^9(V`5BqEjCw7GH$LOdr! z^KIv@X32eo#48UZi8_CQVTvf~I;I^9;*()o`h%<5nyGj(AyN!W4zKql5mmaO=KCI5 z0A)`1DuQ`D|B1}Twy7&-z)1SeD&_{{6-3zlKne4E^8Ko4JKtNiZ_~Z3<1W%IyI%@X z8(l*3IV??7gN?oB0zL~izDVC?Dmq)?13i^fa89*kNKn#v};cI7Ak2_0Pc9hNQ@8g4FNcWyH<_^~b3;yW?mZ7F*g zB-h`zv?C=ukrIlQvnM4%^KpTH%u%{lSz;yY$NG1kx5cf)Rj@eL&yp33GjW89{IT&r z^~9-Xb{It3v}G{x2t>Z;Q?N9-nZ?@#JCd9+%~%!Hs?z#)GZv9{frMh-nVL{R*Tz5! zU*i(xDaw8$D_2|t^=+_7P?r?66U>`e2yZVjg0QavkL9cdc+V!nlWl@u|9-Ra{w&AB z#m(xm9;bvQ5mZzbxQ1)nVTG9pcQyKjIgN4lLhETtE8zS!S z1I{l>dN%;s)UnQrIhsiyh~=?c9s1YJ-WezKpjI+c$Mr^JjU_w1dO8&5+U(t%{}gb| z;8$rRc^>Yzarn;@b{@N^O#YMEMVp+MEuT(IQLa*5`#tt1FMO(-q{TM)9(A za6e#>0mDFW&S1d%M926wwbw^ZTg}3H<zy~3o!;^`xo5g-ax(uS3O_B{pK637m)(}>|2cQv~Qr7V${zCgW4}1 zm7gOQU||a0!81ig19!|a`M~pn{>Sad`hS^w_&Qqsm2#VonoA}Ru>DZqV7ii%!J(iM zAY6(+i9J`C4zio?>_jQQ0?ZXb?yuV#m6XdYOWh2xf1i^}P=671^Ab=Dp-QhYDx=`$ z(vE%q3AFiX;P_I_*A;RY?VavfV2ZD>Zk?75TkXw$Uu~-*o%3*rZ|9u2o&z+Ql-ldWeE$2AVG-sX`Mk4JfA16B6p!uknG845I$SR?O& z6Hc?M)^=n&>uy8OHtyH%u@1!r7VNuo5q2zgI&RHAPa>aKhui*s#ohEhWvxq)r?|yK zae;S#_n|afRS2?kmCtqm*Xf5k$RK(S@A5_D|J3O?|LPZS7dHoU7Z-=eCXY)TQt#%$ zmAecGC$&<^)(E3f)}qx-ZAJV@+&Bfw0qNaEIbI%L33BG`$EOB9_a0fSi5bvjZ)Dyo ze9mZDKnP5q$FSpP4B)iE;pQnlh=zDBG&H;--tT=k7BRM&b<@fi7i1~IS2JNy%qzRi zzvvyW@jH#h_8ax&S-L|C%1GGaU8Gs2{4}WHTs;}xCW=0sHsZWuPgLj4fH)-qki}mu zSJ_s>_lYr4;O47|PLtR+O9RxFV#Z1pMStoJz8pRr=4U0PVRCQYx~#jgDudm5QM^8l z7JOF^%Tv>!$AVtYdY1)hmKE^%)n_OX^{er&l3C~#ImX%Z(yW*0VMran2wlL_*+RG+ zc$Ks{pung8G$_2%S%+dM(y5I4@kw;Lt@uI-M;7)U&k(YIA^Wev`zOBt8p4Tc4&6MM zk`K}2fvyvszyfD(i!ld@py29MK~POxVZ%^I)#vVMNmP+DhS(#2oO+`-aS&n6pW-M0 zHC;%)X~C|H&1&_7k00{4(9Shn0O|WEvo=F#J4sfP*-NOd84~}h+(hQIqgY(Ot}5YR zQJk+V>*(Tk*hLiOw%qHEUjakGLfTGQAzxgvO2mG~_aOLx-|$LOA=5`T($mg=u(epY zNLwzrqhRf){G8J%wet4mVoyJ4Y@NNm^v!neoAa&rZ}*@ZhQ{)zzmljspUaO{wzd9s zOxf(_mrTJ+2mQyP3;et7+-_Krz1KfIzs!O#1Oxqr8{p= zwqC1Q=U31As8$4-;|?*Ogysw;=_gGN++G(lENHUqB*Y@)pj5ox7UwT57-H~r-riVw z!%2UpI?165d!f*5LqSV6n&b6Yjs;S7{!%;3%CG__&Kdc=WUzQ;9B4M2)x&E^lpT5bp%Zh;wxeszv|w zz$-7feRXpB6pK37ZCW|=c{0>mDJAtyzLf#!9*q;yG1&1Y;`DZVGSQ0gj`x*~Z|!Zt zb@4vxfsSPXod}WF2Ag{UUxUuHyp>()UfkfcmJoSrL7|%fo4(4XlTJ?B;7UmVClP;R zBaQ<7;LN9O{lQ`vW-N5bnC|Wl+Ww#ZUWSh5yiU^ zNA3sh$WZZG0|(q%9d}Q-!6`#DL*prTf*jJq3LR}|bXnba?fM-c+x{T(lSUvx9Pr!I zv^V*^MqkZP%5*bC>$pgnhID1!=ZUwpj%Vxpi=$5#MEhsbX}%IstTL%tgNEj@w;MJB z`e)n^fM;{iTR-9CnaT8&L`70ob_)*mj$2>%i~W<^9ay)-!)NsqlNeX2UKEtkE4Oj~ zqB9{MuAo5wI?Fke$h$Y+ljj0~+)3@w*L!5Md+Y6*N^hj5Rw`9ELTj#Wj^;s_ZUF%S zcq2g+%rVFreDl?b=oz(@>fJQLy-fahp;1y4XKU$LCgOU$;yGs|#mu9{H{XP}C1!ke z8de*2`g$4z`)aeAA|Hl}niNi-En?9Lc11^*(=jN=Q{J4bJ_JDl z9>c<{SLt_Xva02w2385?xOV~eLbJU7m1`CY`~l`SF62I%ta}k%KA%?#!4eBUFEhJ_ zOTfxobiqo(m694E9XcK(M&0HINRf)x?MdJF_@6n!NYl!s`A~L6S$mCaG|{1$PFE{c zt!sYSBx*Wg>DGerHcXgLh#9S9%bFYG*oDUS zgf+t+emPrL@rUGmcQn+%C0H9_DRXpnJ6eznVP9|%VI(R z$ASC-7;^@&6X)n?^j(WZK4MC079sv-w}6EjG1`GoY7_&j{4uyF?DKdiyX_3e>qBIB zTdYyka=&V2f1Q9wJpwP-VP-??z(6x-#4FX#WEIyA*4sN;VRYX?0u-S z48P2BJC~+jJ6@hDy9sT|Top^5$cWxMtoO&_EZtuEEDrK84eLX(!!UXTOh`BxJT)ig zN?TK950!Rlbscp?Pn8Z`I)ZHKvAddQg)!;IXW+T2@UOb5_3?cxsIw>N12yBw zszQkNRUw|y&(vQ<@mFo(PP#ktGr4nOJ2m3IGzK_D->9uwOWHzG4;9EM^Z`yI?DJWb z$)`}TosYVL$c^;hu4KMP8f(PNN~)Yko))D zs-oPgsqEjOd4lV$JF-Vf8@%<2HEJcRD&)>_xW#b;nJ>-KDz+)iy8P;YY2cybr07&N zKchIFf7Jk`r(Kkz!&k=EWJfn!8eTnExH<|5j(~7OhUz5bfF6cCwx8R#UiMf^;N5Qg z(A@ao)A4hVd=V`QQtdX>IjvNx$0pP4ZsNM-m6@KVhIVn;m;LRYb06C~4oq>dCCoxT<^Rde0|!|JywwCa6CwBd8rx=Od3M=B)4nxQn&paQEB_(JKVq88zafI zeXEzy*?KBbS%qQ?{&wFCR2{8y=0>4QYoSZSE8g-c8peL%iWg#&&TdYae8i!>=z`G% zFefcfsa0ivL7V1V#c|rIrasA|HZz}TRn%DoS*j@~jkic|LLD-#$g-+7erE-)Z;N#H z5%GA2HC-SVd7*b29_5FsT#hv#W#yOi-fxO2-VZDQEnyZ?t@r`)Wa}1q5hfbz&*kNW z?U{pS*4)BZ4FAV?e}cPXT1e<=Xos0M@lp7cr)N{dP6d{gTh1!>L7vh}k zDO_MnArHFoc|$BAZ+5{DIv1j4<1f_d2|Vo4CmU3w_`bS~+o|dXG&DomEn3@S{eX8Z z-EB)66^+E)4ra4I7xn5l>Z_YuOq9vs&N4H^`iOo>ulBK1EjWQmQykTdP*j$XGl?*6 zwwwlwdRlJ&E_8X-`Lp!Qpm@bb#B5}oA#K^XD~7)#9jqfa$VGp0`9+5{MSM_Zgmdw7h|$EVE0o@kqO)BprwTH;%9I=M>E14nt~fn@)b# z1R4@=MypYvF}Bfhkfc#0=n*Q1VQ?(U+ExzvV)MS%8cX1gT2S2Bb>kG_C;7=R9PGoA z?1duRW{C~GtwjhswRg52|$&CY4i(wR|9mY;YTsRk4xHQuK0@8PexuOVYMLjckvWiK} zW(;1ET}!mS;1~sQmX$!(W0d&ub99F3R?;Yy2<*Vxk{^{?56>q)Q5b?*C~c=OF`L(; zJz{){%+BM)(|BXDRb#4+I56^g-bg|EQqqD~nLfzlsB{(*#1y~#i2oVbqqtg#n^$WS z9j8vO6g=IFE>xsT9zWtTMl+fWD&oLW0G!2%lTb~%IgK2JIN(MOW>Subj(WUO)OUm_ z6}wm^D00bw@_5OE&|{WIF121%j}1yHj=E7yvOhS)F78kv7ZMw{CrWA?Dp|QTZL?@uQNMy(9Bofx~?1^C|u)nQQAz%a0HQ&yyt}K z41HyUezQ2_XSt1QD9Vf3-JWg=$8@kb#t%J|RH{1%`NYS4Q}Lc+q6z>jpmn0ESgtN8 zh;>TmLN?FJ<3eKYM&JD~a{_d4k}KU=kiq$;N%i)&SZu$!r?3iZ&##p4>O|7|+&m?| zv^`Hbh-|XvpmG6EHQ+C=;?gXemQpR(@ANVHbR%^wgd|xz$TV&g2fq|HmfRs7=@69y~^EaK9h;E1aHp0nNY zZJcS3CA+|}qSPNTEz`+P|5#sS=f_iH-b^_KmbIRZhc042c6gtSiMwdGAmd*N;uLNe<6MF zHNvUqh$7b%Cc^YqOrP3cdJAGJjUiA(>2Kc~>1|r|Oa-aZmk!+5uq%iC`NnMY0MkEC zQS?IR788H3la^+0AQreY3!z7^5g=Rqf}D*Nav-Usl^J#on@_YSz!46NgqI0edMq=8 zLU~Nc+Dh~MYS46VJ6YW}z?6EDhH^2(YohduYFVmvgaWVG8v6A$Nu$4GM(xZZk;u8< za+~5zR8KNCSG^t`CB+ju%JLty**zn7hrkq5+|R_%#c+=`=SLZ&mJ{fdLz--G_z)yO2rgYPSiC&I#gD^C-4UWN2Bs@ zF<551nE^KW&9S=v-Y$XWUe!^iY#6+^WtIHebEC4a7!-$@rGzWN-T{$~ zLT~pM_y&>w&jpaSn~9hC(Y#Wlcjs;8gg-}*$M(46R8EO^utq8oT{zE#KQ;0Be3Zw4 zEh}bFDkCPSB}9=m69L(cC9Ztqh4v1Voyuvn{QX*>a}SmLcmAnhft|5la8U6n1IB|f zHw0Dog9>%zV4;&4QYG7 zQ~P!KyFoU;yCj1?)Wc};z!ybj(aRm+I74j8DEPoyb!=bt-mQ<{7~1tHp~D zdlwXS=`RC0ytIx*3E=tE`*j)0TPM=2?b-I(WJ4#I8DnWaHQ`;Ga&7fyZ?Fji;)wh^ zTON}LbK5o(5n5>y$lAH+3{$*JMxmSRO3w%Gbme)Sl<+>z7c28aV>Ft(AIhw4X((rk zN#-0_h@hCsQ!1{)KVMiur~UB0pLi;3gABG_D3RT_r8Bb{9zPE~Hihh#PIWTH72xpC z?Vsuza&BaKEj|3!NY{!?Z)T{R?{UX=9-s5eLCGx^_|`22iIi+cI+Y^^$S&P95YW{> z4=$PXe*R0PD2ZRHMBD!WG9Q=B(CN{y|4cL?o_%2`K#z@Vt^#kmYM4l65^^QVvCK1O zgn|QNvnSTMDyB>-rZMuXP?xf!5IQFu8X}r!v&?O@F%2j&Dg{(-@_*fA$_Y%0PA z0V4nd4rkP(#&8frU#wu~Jr<4>@}irJ*7CItHky{ZWJ3JV+|aEq-)7zE-EM0uMB~cm zkS2D>Mu~CU(88yfIGj0SL;Y@0Hn}&EK#lB)eGabqJa+JLUeX73HrEh^252O3F+a0P zdkvt?$OnA=SFlNhe3g|6ILd>qc#I>zk9jImcK`yjjVZg5g?&w17z4*Lncu!>sBFCz~;6?)BGGZHc|PLntBI3 zGho>uGX%?HWKHSF$yq`#Wjyu_{^8f*B^`!>oM3o;ffNWI9!yb&Nz8_d(Okl(^a&Z% zAs$B3#$4zYR`UB)0kyAPU~D))Tnh=I%p^u*0pG&wN4}s~4?CE883`KS%lfm` z-}phqQwWOX`sF_gfQFNP)BCk87ORV#D^l#MHpjk9_c{@ruTKusv8|2rN-Ck7r-X-7 zbZCiGY=IVJf0T2ZS9%g$zaS&R8%_m?@+xZYmNel@tw;Zmy{GZjC%HuTXqr2hOv{K~ zSPXsImk+xjtB9pArpx-e3Pyij%v`pbs17;fjeT~OumLA|JS@+QrWIls%x*{yXPbQT zI|DA6@?*X%?xGd0txsNf=9Kdr5;r}#-z+9gJ|I4_k>&CUChTx|6*ujX=S6%%i14=p z`=>tmsKEYD`#<#9e=hK+g!U*S{%rwp^79W-@t=-=idBya+uxP}CkFqixBb)mPnG6T z(E8i#0DpM@e|hVl?te-pk5bOxRtXnM|1V+ZpDX-Hos>P|LOcEd-_Nq|7|B|e>wjfI{BaL{Mi(bTO@7$hMH?htfvcXvq$PH+pJ-~ocW2X}XO`*zN`U)}f5 zeW@A-s&=hj-Tm~_ves5tf=9rEK|w)*aUmJkh53&kT;T7IQucPvW_Hd7S{@E&PI~O_ zwl+UB2km}yf*wEj%`o#{s%zs1NKy0>lw88=dL`-H(p7#tz0pG!OxB2a<#=vlZejlJ z+VrR6&ks_PxZa&T-d)V6%$6I?p+2no`(AI2zUV8F2=m&Y^_frh8D5enY_=*5AWm$M?qg^E;ukdpE(|2rMXx) zq%gU>Pxb`Vm5@;qSQ%TuurM%W2rw|}|EKNI0NWct&1{@F*#G|ip4g!X&jkuKpc`sU zw?)LZnvX(hjhI3vN}5}$N>`SbUHaA95%tqXqGN-TXXS;f-&HJ3p;ePTD=)xhGBDS2 z?rxUE{f%hFu{eImuEV-KlB$+r+k)t1u*SQARZYle?5F?<+NDo=hvKkGoe{=I&KdBE zY)+N9^VnV!=|5Yi?-<}mQukNUH-kO~2^k+NpbsTIuL}R-j#KIW)5A1wFWGp|Qh@x^ zJ|LIX)Iix^-*wKrS@5S?>H&S>0Kt0|K5fwKq|R+B-OL7&$ong{4Yt$14Dq(kH$$ zeXUFT64DdNfhbvr5@MA33;bg?k~NBAD;ZN8L!5C%O~aMzF-*chjK|7>!C)m7XCJbm-I7cg*D1l9-VZB#J_ppM5P!SkVmYI@yfNw zB*>DM-6AS}zbATUfkBA8B&Qi~+^~Z8c=O5^^B(@MI&0o;vkAav>w(Yz?QHD-RL8^~ zYW7zj+ju>tPENeg7sWoG^t#Wgk_%J=;_9S2j_!nsCLe7?<#U&wTdgwjr$1de7FR^r2N{C0Uf5v-rr!?- z!;_2WG8(R#n$WHEJ30DH9y=sWwkTVsnx=mtU|p$-dMu!B+qPJnnQPc)CYXSq7h4=z zyw^<-;}gjKYeXGd`AQ@pVyc19|7}D(z=-ZP98Q)-P%~3aXQ-8(h0|X`A^hTt~Zv4Xy~uXH7=jxY*is-9Gm924J!*cUi3s{` zg|k2`TYN>ylxUV#fuqpyTc*(Sy`lxAz-tTIvRJRK`%9y$rs+51#L}k$=;OtcjOS3TY@R^zUTee!8+bhL4S*u2tJjK*_n(gcC0a z;SXmSKtfU!kjR!NP+P+7s1JQGSD_^|vElHcLAMoRXq=$mmHT`v+;=hG&Tp5wH|K#+ zxon6%bafUTf)M`3Ugy!d0mLDiX^;0_F2h9jbCrZ0a;VZu5Wbw@R$uJ7>eg?p?)&%@;VmSOpF68mXg;OQc^35t^K>Qr26f)QbtNxdF+GVzMNd|l z2*Y`;mF53V#^5f|`P8pRpSwJ0aT2*gN#2X1jWdfIi-D)OB-qR^&VB>Rr09Ugh2&bw zkvpUs{7prj1|wo-*6q8mdRZQ~XI+{Se%~T8p?g*GwPZzwm4-@cMKQwvi?LilGTIQ=Kt;;Gv;>ZujzmCt^xAAGX-GV&Hu_Gum82}zp3{>E&Oj9PEh&O z$%!uh5;^YUIMG3rXUAbO_DRgwzv{CfZ*@$;kHNOe=FUIj$ly!b=ujyh4aVCS=n+RuRDRB*rQWVu)>J9YU9dBgcwqcu#^5r2)+VC^w&|NbLm8B`F~F&> zC*yAQ$U8vnCC+cTvSzf~wSKYuuDi~tw&%vu+l!i8+nGDBx6g|=>BE&< zei=(oTUggK3mnS^gk|fl2D2~A_7qVQ_aP?FrT5zG^>cb>MrRH42DZLldaPo;^9%KO z*L>f{kIa9RJ!dX)45qwDxwhR}T)nihom^)>pCf0b963HTEZ85v=!;qVt-fQK*BP&T zE4}`zJK=YQ;kUa zxaxL#p8a6ltY2Ppz|rjE=vUlt@X(sU;rd`>2M)s;TxWlHMq6DQI$7IkD(Y9YS*a4+ z+)xRQJLlkk&Pll&KiR%rGituGN#8VedZ}W*?xqsk3CJFXz3|AnyYj8}TZF}2z9-YQ z6R7XDbK9k975|0x(A&Ihar)agA^X?J<=%lZi(1`zU75G{?ZJToyMcaYcI(qw+{?|2 z=i=c@9x37BVf*UE^K<8+6U1BJo84<=?r8hDd*i&@uX$l{nRSMOpM!BU#60;ICCB;v zWpnwnU+%du!;rV1@9*;raxyZ#axuF@e_F2_tH#zrcEW|Hl*8QDb+gZp;e9s0ZWG5d zY7XPFk3idMKeEN1?z;a1?!ut=;o%}`RF8f7s2$UBuWZr`)+dAE+jiy(>hI4hF*o>B zo>Xnxjt>W}NqPpl=4AyT{$^|2uJ3(9{5~FwX>ZgWew+OQ-+nzew>3x{+!XP9cgOAG zom|(ZB2z`STvu)G4#hFnv#bBtz53z+w1f$Jw_l5FHD$()9|FS5V?4}sV@t$dK1bzo?n*Edw3CFHkk%!|1{B%Z5bm7q%&{MeRq29wGP zWp7}qo{)2I{I>}fgDv~<%cLQV5XJayH#@(BWP>jxOhJ&-ZrNW9-!^Q9*G$~A-BAU3;E2rrBHoH|u6aEP&A zrym_NT5u%=B~*Cnk>2=rs~+ate=5p8`Kk19;`$oJ)zw#SChp_~vUuFeuKL6-xk9{u z@tC#3`lmVb%K7I{)obnSluW|xsOjMdv$;RdK5ZO71;lKkjGqjf=cpg{gqro|=Wefj z@6^jrYC@h?nvZ^`nf5kk9x)LfEKt|hF2?~Z;OhNw;CZo7+VG&GRl5tFBiyHAh@5gY zPx#bNEWB47=_!)mhVhLY2Q?x{B!A_&xBGcAWyqK4BEtfajm1nUj1Q6SSU-vO$V{f&2NR(b0#@d#=lz%WowU(Y2m+ z68BgGb}RDqUtv}_*M$`;`RKZne#8x~rnquNJ^I{= zeS9mmEjgUL892jp^}Jr>fK2dN!4C#U$Ntz4b_E8Z`Vw6{9um4z%`-r$h?CcU)r{1~ zBuh3*u2t(|NTea+{%*vsZ13SEbt7?^2Af}Nj~x=_w@|Hgp_wI;)4scX2VaDw#{XKhH4+X51}obEgrvq5qPx!`Tcfy^d&|-FD+ud;B}Ka zbK}#q#3vS8h`rW^pNpl|M!leL>DfYSbx`-#5w%yV$0Gg>nu94#z-N4`*&)WxH9bAl z@~_DRPXQ{1t&J~a-tZ)}U1`%vNz>-~Yzt|-PDdQR$jDoTiN9|LNg0Ho!# z#*D!0yWkA{Zg|{TIw*WOkNGk`9D59JAuRI<&#Ldz+K#FCWa#@CDInS;#ktdQflX-N zYkC!aa5XrO%!%-DpF`F&ZBnyQ%E8|%kw!mKJUlaATofx?fEY&BxQVWl?DGr()w!w9 zopoM2yyKbItE`3Ofzv@)%OgD}ls{|FyrjS+8m|27>J~hZp(&A9G>O(S-$n|V_Fed& z--QX0v~{nI^w<+l%rWNFLIOvX*$2jH@C$ET#h7z&nb__#|3}?S3>@PiFiD$%fd$X| z70E<5{v(@b@e`+<+PxdLQCDJ(D>kGdoLy1FyIMLpFw~jcy_x1|ifk|665@(fOiQvv zhMm^Bw6jo9J-yw;>)WgM&W!ii z4^~!8<{T`qnUi&s)H1_>Pa2BQb!%1ai#`sP6m|zwwFS+p_MKoH1lQz6Yu8d2U!*b` z?~{k}NW2NS#IuD|UYxZFPTk$I#m+parC+5S-aA&aJrByN-EnVuJ)-W%KmL*wqJ?*s zmt_PiYr+`3< zuF)HT?)&ZG1pxz+WbjMMzdJNb~|9W3P&iT;ZnEcqAM6EXMW zpzEDC@vBIwsGs%x30Iba$mG}A3@SqUzr9z)Y8~eAC2AFHmD0UjQ%UStIAKCq_QhH| zm3{Q~yEs37p*ws53;k+l`QsLMBd3>0K}JDAfel`+FGhGT3h}Qad66VWR8>sN6&-%! zILT{VIUhE5v!^h#C%DP6yF!1uh5M%3t_;g%B5a|Y907WIuV6Bv1`A@JR1ltgvfnZj zGER%!d#0ES3Q7se#O0EouSE~1PD8~)K6sX*AS27vn|E8X89dxb8osxCFEcdgw=DX{ zBJc8Nj!KzUp1v%-)5=bfL7Tmw4%<2Nn%mRuX_XM=z3d}z8<)Jwr2vYr9;ndwCZ(*~ z_ROlbiREW1+rtlK9lv_L#pnB*tqRP;ZtKssQ47P@b}1q@Dc2F-C8x*JyYGuhd4oz% zN^&blh~K>-)D6u2Sy+tqep5c72G;juAR2ll_JV&%dhHqeGH5j!!>$OKXE@cC9dev- z!-Phf4M`PD#wZt*Tkafu+qTz#H|NKH5VK-tFEAQQS+!Q*cbvik{yJN}<`nWc;-xHs zT&IeGE8=@Zc6jD3uzJ4aBBDqz)YGVSzkk1D&a^cLq=WxoR|$Km7kP{Mtxm;1A>Yrz z*J_US;Nv6x0g~n9*rH$l>+lP>d=$0j*p2D=0_}G* z-qfgeH8Vl8qN8qRZHNm}QTQNyC8{fnubTZzYt!Ar*>L|=KSqL_N8<^aGY+nd)HE(5 z+o1r;2W>0Gdp+sLamsLo#cP=L!_wP^I*L&}*CwBqwt9H@sw9{Z45O_N5k~WU`<#W( zjZ_GNpsuur_syfsNSNJW6x4xVjcIJ!uACacyP>P>9(LjDmwVnABj@Lv$w_6C+g0cv zt#Ymy$Ui@7r_kI%k- zoJWjM1&s(Zp6&Pm&Q@l-!L5FMBnn&FI_Xe&zA;UTQeQ+vK`lU4EePQlOCaZ!*Q=mC zX~;OSz2snA(Lz8`PQ=Rw3}u%Q#<0R`|1pA4CiMj9epYStk4UU<;fZtE zn_)UH&;E0eFNt;B68&_V^T9B+BAYk&>(G=;VY~Y2X_&Z$ebTi=$krabJ^75NgxafY zpYYgssYs2dg<3S^V>1X6`!{oFjp->2Vv8B&1PfdAEO8DW*zIZ$y2FfLwhD#A8y_(a z)tc|-d@(Gr+$hBNRq;N!Ji}3a(D@@?f}sM*Za%}&>Y`0-{>tgns_)DAbM9dHsIvS1 zX@lSwECNmuw8BCtMS3Uqeo~Hu7R+W#dWrNl!vtePiX-h0uFb(3`KajA~x8cy!z#v4&ldmouY8F7j5xf zD)xQXMy7|U^jBV$Uz*jruVuXcEV)$A+yCqqBP6KuOFOMH4aq=eQ*Wx8IKrmt^w??G zy}-oo`qpx>@Zi2vkG@W}Zp?ae32dOVC7n?tE2nU+vok$c^kkjRHC%!A1Y{w20u!S* z3}z1QFRAe(U4~tM^VLmV#(J?+zG~+5Y{Whi_=tqM)zLKODs1s-<4smERim*aWfIiW zm7jOCIO$$;SV@^`?6Lu~9IO-2AZXc$z2|&{bgqZR1G$0)P?@Y4;u7zsb!BgPA%NKh z?xKx#`^uB-hNo`I*J2XNjk?Gy4J$zq4z8kxupd{|pDwM0GR{9XNR`X2RnS0kt?(JO zK`GGRunjbKyL;saxp81=o#6Em`;*Sh6>b!_@Ti0annpJvuy(%l*DpbY8vHUoi+3c* zU1Yf>5uIe~=)Gh)+SU#?S89Ila{w5#*`qyiX_zR$FjPkQ6-0u4QO8wyEiImpx+eCFkC=b zi{B}smo|Wy-b}GZ^4`pqqz zWnnMZ^7?Uex|X?-I|}yO29JQ-TI1Y&2Pv1S08gos&GmqV|AIqEJ@1k7gz@BpUH@C) zSLt&=;00!U5pT<2OleWA&m!zO9uc5a>0-Y4A)9xDR7I?e10kzIM6aHlh~(sQ@;k)p zu^~d>CoN~ z#H<0UY!VhF0@6fx>oAUUUvzOM=CwWd#_w|0!HG1Rp0)ZHaNGg^3AnR{3sn<_$Yh2> z1^DI9OL$j~gdDZv%G8cwf}M`YjI6I0QKbY~9CrX0ss445hMDd%#ycI#LZXvjnZ<#w z()heSrNZAzEIN8I8A@j7AQMz z9CC7Wa)qA#)Dk+T7%Yn+=U;d_-d=ZY^Dxlrv~-7e%grf0OZiBSf?9FPC*#B2Gspo- zlIOn9e9|c&Ah&F8e7fp1MGD9h9h@%#TR|&oWXidsfYLPty>N zv57)i6T2Hor&7QWXl>#?CW-{dNtRxVb5Mya&94!QZ4(EBeTIu6-L-Pz`e=c4T6w5| z`OUuc)auqedT4EGv#>Z!baRX9l8WAOS1JQBCr&~GJ$E)*iLHP?&0%Sw<2j)N2kj<2 zWh~OE93s3M^@75lE6I=JLk5eal=fDw!6;)(qF4O^BIE9LWBU5C@%et2glQP%XYbg~ z4Q|}8zOHLm)>%v>2_k($tcM`p4948on+kN%{;F6uQTM#jgw~Yw3A~qJv~N`TQ=dRi+HGjB?;Vi_WD*w$*@QyN9M^gKk??&S9s+~%# z&V;5ILof7DU$HaJXl1XHPEZChg_y7R;t`f=bkVEQSDv!O!+iN0mWqJD6vzJ+xY75c z;F~R@Hd*IHHa?Gh79f-NUzu|M%8WFzoW-`U%4fO@uFmMgt2NH85r``b=5>C&vJ%wz z0~mLF?1UjJ6rympDtDwx5kSL7(Q!=#_vE{dO_U^vMN_4VAWb9)!E+Js zZ5LT9EFNulp9aMCi+8;zf~VS&>lPnQN9g!979&xE86TkDz1SM<8QU5W7cfroTSn_p zmb;4P-q1?(u55Q0cgT-vG?qe)-ZW>UaU_AIiLTRqH46XuF?a+@Ev}T~M(x@3TNt7zDqU$r zJ6aepH|Ps*V>ah|@+cDLG*~#+R3iV_Hc=S4SJHt;Trl@fUGSXDt#X^En{>wHu|J+b>ZA}Nj>F8P(qyHMVaS5x+yW6;!pDzC;t5c#cE zJB)n;J?%4mgSfJ+V+9R@kyWKKV-Z6nvR=iR*T$kem3);*Ph*!PsLP-aeP*yVVtvO7 zvy9KZTU~RC!JuUuo-2ZuVx85-6Rlsgbnp9^w5CHGJdTt9YG&(= z-Cl4hR@OCKh_$0EeSF9J4|FO%u1{CHy>g|Zfk)W)RKB@;VYg`CC<;B(nL~vZh#pVb z?ft$TAm<}e!co&ZB6MXSV#iDE$9aZH3CT@3$q&O;W0lMMll-Z2JFVjQb;prw%%A8( zHixX1o^Nl#s>@)MZLOB9)+O3&knKZb_7`yvID?`fzcKU~{wb)-S7%%qWpI+VtkmoJ z!u-)jcgSDJHICpc_71^rqIE(G%{p>gngVSA&{TMLWA$63Z8_T(|Z^9w6Y8<_VZ`TM-6L1P79+T zVfh}2niE?YFYU%^ybwI;J}kb`Ge(MImmdlt#F3=GEjBucVYt&C3eqs;IjG~toH5Au zqcI}|R)4`66a@KEJ+intVr|&x!t9%uk`Ao1MBU#;r9c5Dx|PZZS;NwBno?ku#HK^X zFN_nD&x2jZ!gF#kEClNgVZQ(<4zZrriR(+h1cqlB# zWdJ@C=LAW`O!x}|J17ZKe6Y*sesAifFcE!8FS{h)DqAHI+SKKV(Pf~+A4TYcE2D0~ zr{<4*2js=u?m<3)KW_`-Kb;0aF(AKw*7gxHPx~|fJ|tnE4u64R{})0fNNQeKQa@z# za1M7qyrmPFn7f*>SdlLQmhSo0r2#CB@?g_>x77rYC4-5Kf7pV6jL%~?3qP>1#rA5(Y!cPx$x^{o$-o%JB8s;pBf}Tn?8U9SVRu3$HzOnVb!pOsJ zTv$DO5{q1Do#|y-r`h~0Atbv!2;RBRB-Jx8(6bObVkO^+x}tHv=_@OdEdTOdK?4pC zr*4|gN4V!e7}%|F>>m$@-Sarz{?xI;R1$Ef)UImWM3<4t-#kJu%1>?ZV>s`r!iTAO z>*%?;{1;mOJyv|$iYnZ1Fb*i|dOnmppAYM`;PbDNJvE8AZ-pzGM0`)8NSaRVd{njU ze3fdIwG`wjZZcL)Wxl)9xlJ8=Hnt{vXFnhN$4FY!m=AxQCu&&cE+t=G$f>y>GosMape^qzyfXC+ajkdQBB2C_^N2!YfR;oO_c%QWLdVGW+ns}kV7Cqe` zQ@diLRWcg5iFolL^zVYbue&>y52FaWhi3g_jm+gjsd1uS@e*Day&UjNW)o9%Dz_DJ zn&11Nn{W3;DcG?aykL-7sNx%{S>oMMSw^;C4ZBaj0utr$cqu-to{WY>lEa+t>>P#V ztKCR!P+9=~j!xcfPK5X5dd}Su0$VPPCAJkuGNXym=|JI%0PoY@CD+&`(ES&#^cq^m zwzhXYuinkMxVAFem}IfLJ@g(ubl?B%tFRYXxIf+sf**@mKW5>g3vmqtXkKYUh7+K9 zB{>6A>h>sQ#V;CQ)k-z!Q664PHiD$pzphNCUTG6d_66HU?^>EjYgoZo*CNQ`9up@# zrsqt#EXb9J@rfZ7_^KH(UOf;+PcS}p3=g)EMNHB-#;Q&-yeiq&U|`4l%C?+*$wXZF z8E_TTo*RLrf;?l=CsACDSLWi1f%k+*g=(QdOK-cLM|(aUnYUS=G!`BkEK92`4(e!F z6Oxx83*{m9VjB>z_ffp(xiw+jyTOxHXp8Gej!s~DtQ`Sc_kJy!E8Cj?<(1@*FagaS zE4_%6XNSU7SpSsq(eH`+1YlPGJ~QMLN8=Aj#awqstFtB8UX+TR<8K+ue|Cm*m)L!F zzF=i1E$2it!ORGZ(&BSAOkP}5pU&)E4Qn2&SdVK4jhh$BUy?KN7FvCvAAS1av5AjM z)MTXNpzj@vLf5Z0Iy?8psp*e*N_Fs~^b+*uZ#i7S$!5TG&Ho(|>fX)$^-@`S8`(;R zZuTO`!$7Ly+E6Z(61&4b zPjmNWa?bHyO4`Elp;qzd_uVBtuH(s{+dRwNQC5 zyO=CHyf3C(`6C!8-R2W+D=Lo6UcA)H6@Ya?2^%nn~ z+S_zJSSX+D_6CK#tCk3L31#QA=`g&Oh+wXzSB}l=^*6`&T^DF5f#G3&p1&i)c0Jd_ z!&<(Qjj|qYnqN>ga~vOnoPlxg=-_(&(8%?%eHx!G?1WuzUr9m_Q-Wkb-KWU=x~POMElq~@B=|EIaXT^+>Nv*og~UPSyQq?*Am_JC zGuX%B`K7O9gL8Cq6~qO<=zu{<3XD4q2b!1(Gr{VZjdpYy&^{j)$K(reP><8F`pND2 z{$YzXcf2ERw+aTg(IAogk>bZG3*8oSWVC?47e}zp(Z`ore-17cJ;=Cv-&k4o+AD!< z{qJRQRLzwksZP`dhX%ZqFc1~9^&E_Hd0jK=b87uMs+h1GHd(t3xsP&sG>HSGHdsgD{j)=Hp4;{vHq2t;PxCZ{rzFz8XGT$R2npe|>bC?~;3K z)ngsXtw<*rT^4m89z{4{_|1XHF`SVe#nGQt7C8T`-1&ewUp-y;!DOmUyNmK zoD|^o5?Nt~Bl#RB%`vr{JHmcMB74u)4`PXS2_botokc2_vgM?Gd1p@tvoh0ypM~HZ z+bntuicmngjaSn8-4V8!i-RoMR!iV5vYYu!_-;V>*l1b0Lo+BwG2wz#NGX?XpNB&~ z4Jf|3M^DgKV&na}Wpu`d1@j~scjtvscU72ik=+et48LK1!l5{gx5tNTA)xWfK%mip+iE*K=yBq0QBspqH@Aj< zJodh?gr6e%(>2V43S`-|-*RBubI^SEF7IRAK_9p21g%%8lQofAyhZN((j@QXyI#F) zS9v%Ol%x1&_1{)ux}i97;LUDKvq=#!5lP{qbi$;vMq}dZ5i+~T`{XD>OF$|Rf*0zT z>SicRcgm>C`RIe9TQJ(PX6x$gRqLdmUQujG))9p<5jwF&W<$w72PV^+*{7YtR-d{=RV#Lc$IA;=M`|8}ZEfpdtcd2x!bghrg6+;?<=-lp6q5%ExY6s(-~px?u~!y4c!`6Hse#Bj!GCTz+52w|NX&Xws0ZaB{< z%E|iXk_^lRePlL)jjkn>axb6xZ=8Vx{)sbIe-Hn!zu}^X@zz2ucjfU>E4<#u6yc3ip~{vGr1!GwpEV2tp7TB~|eo{o0-N5DvveUxX5ls?%ynK2G9{heFe z0wXFiM5i**#c2IjUqe5}V~pTbmF)Mh1ZrCX@-ZWc9b__NGWe!gSIGhuKY>PS1y%m> zIqx$%x?RuX`y7(WOu(l8>;P;ZfiRp`b=B0`M%WS5#hp?Bg3g!6XLRU* zLEZ=8bLby@_5}b@U_ps2PZwNhN*|K>@fDJ#0e+5u75%YYS3o4pNvINC)vT0ziZb&z zAq~{e{Nt^W(+Dh1Nf&l4T5yio9nHxasE6HEs0S&3xx*n#-rSH_M{_Fd-xv#CR1XOb z#KYm+Og3%0-(Ve-7(kAPI>`7#JLzzAfTXNMpP)__5v-WLYnQAgnHC;K{Z;6FXJiiOR;I)23 zMov=p+^jnI>niGhT@^`NMToZO>rc2tADL;67)uO>2E~z8MBV2^r6?GFcX4;LE2fo% zO+-;BX16F#oWs`jcw7s?A3tav| zLA0iVzR{G9zqfSRTg99b+!TL>syp7gK=KKV;#f9<3Sf^#mo5;qt!i_^kgG6ikAqO{ zMSgO_LF2)OT?-N5rhw*TW0bDcty#Nw&sIKa8G|^Cg#QUy55_3E%-q9H;98Xj>n9 z?W7uTU)i%79IsbSDHHO=b-t{?vhWRm?RsRM@_QDTx(LHv5XfERyuT&Uj|pIdMHxJ-h4;_a(SS;a99z!OT{;7C z9kRF^>La(WeYR{yLpN*^9;w-_L+G;_BB}z3i37vT4RvvUl9&jWld7~!a}kpso$(_yJO|7Hph1)N-jAmD2RS7}nA zqbo$0u2`{8)=-34LPtt=YS34Wt^h$a>71V^b*p6{Mq$(dO&Lu>=xQSZaD?l3wvGt| zi65}+OHLUl=vhKQ*Z=Wvt@667w+-?Et4k=Pvv&ij91N(mK>P#)<(&X3J&htFQ{2-&`!ITfg-N2a;Hb9Xqn)}iqi-2-d z*K!^5ZD_K#7n`=!b^q*Phrdn+V_(yTw68l#|AS8SOfpa#=v;!Os!>>!T6BW1s9^{? zngs;?yVri>95#m;a-~*Dy9Lt;ongF++-_9$mr1;AFrU$*h}sCD16;sbi1&qZ>Q+Dc>_iT)P2rJSZQwkjU4vH#zQ^*D_=YQwZ6x*z<7wS?oE>o#tjeUcY&z55EK1!uHh^K}b z%7B783z%lzFggsmts;-*HJvq#BwYCEK5uZO)h$}bO(_R=0EGxruaYKEh!80=sYqma zj6jdc4Nn@so0P(M3UwrNt2@u&U5yh~Dg&+k_>LQav*MRfY340R{zS55=l<_l-+>>Y zbqr%~iX3E)$akapqOiR4q?yBA&~JsP@iTQ;b3Pk6d#h3vC}3$hEM0X7=;sGEgu@sp zCcIi7f)|yvi}kx-D>`sPo_5#lR)znWL4tv%0^BpYSP!8GW)~NaBfq~QmnbWbm`8uH zps-%eXT^w+i}oVxeWL>*xj`o`*Y@rsDd3hUH;JEtr0#Y_y!^Cvfg?WO>?5h-EES4!eD6!>80@c}xR? zIpBzpm_ray*fHV_S_YZaZ``D))C66w!kn^LURp-33duXtaujN(hI51med<2tLSZhl ztq6s(SL)I6y0qf-N}kgR2Nhw;Jo+Ai4JdN->x`JGvr#UtQfWyfStpT;rZe50%YI%b zT3lK@v9pzxoH;f5O#5qCR&XeO;R>YBAd4_J8T5Q6><`2F7%%(Ek1b--yzyGnmN)rn ze^1Dmgj+g|M@PXx%(;=NL@2PrG7{F{W<=UICMUZAUC2q#Cq=-cElMR!5*Z=nOAbj+ zgRMfJt8DxAzo6HTmh~csg=luqPmZAQoZ30+P3;)BECOKKq~2z=(XkYtQ)slxZO93P z&y$2NRq$8At;!`MXi6q!2Y396M4?OSS5=mCHJ(_8OVIqXuuZ0>FmB8?EIscyQ?%(m zhq_K3n8;+t5MEn_#wp@Oui34}b6}S73ek=b7>1sAqp1LO(K%hi`z~>7T$(Ociz~#h zz)K@p5dm7XvM`H5EKP3oM#JkH%Z!bv#$=tXv5Q@_s`o{2EO;db#Zs4l}z_o$xA^kb?;DV(N}tsKNaw@qYOc zi>)KL>2B)APOv&^B7Dogy;g5CBoX@`TlR-5qz@bHCnuBpu@X)n?TuTx?=&0$rHU!S zKcx!rSgJ*ao41FHYb>^X?ygmpIg911!H9!g(X;g*z@;hLv&Rv*aO4t+WE>ta0Zj(# z>bW3%gs>uRnET&RU(#*3fFeeqPA{l34~a{G=XTI4LfJ7VP)5s12%5NYqvz(c9`h~; zi2v{u4UE86BIt0R@skb#g^<5r>8=%h<%c;Ap@v)_A|nVZUw||02m!4ZBbcYKAsJB? zjyD!hcMow$@y=S)WCMu6ylr?jZ;|l`8Av9LvDclnsxw8>>WPLaG)H7R70sesJ)gt? zlq4&aJOK^JF?1|lcPW`AXPUoPB}x4F&?y;FVEXOET4rp-`uEIL>jyC%d|kq;Mj{R@ zz^0A6ZlNWC7>sEBM}q1X8n|$MlIXxc0gi@$$BLAqlCg;)K>ZSY*e9vHUjEFjsTa4h zW@w-$ATKFDqn91OVMYZ|sbpbt2<3<{&&p&91656Y30yJp2@^eUP`%)OuITwX@QecO zIS#NiC0fE8I-U-`PtTW)$l)SDyWsWLo@KWU0*d&6Jsm3ZUU8LF#)G&=FYp$XJX|9F zfk`RoADEO%f-K07TkrNrm)5^By3d#6r(VGKQcTJCY^-g&x3BR=xau_?3YcFaG@3?2Mc=F*#;FKOem1AhJl8TD?{0grtP>tA%VB-ent zQd2za4UC7<0U?^-qu;*%O0ac{F(~c}!zwZSxIq+JMCQPalU* zaUr`W1Uf+3PH3SyWPG97LI|l^yl&dy(5nAxjcKD$Gr87u0I9SMX$5T)cOjwdqJ+QWZJLB^729PwGv4H5-dL#8+-D6rejC{Wo7aZ z3cRqhZsM4nB(ES>OoHq{B^iBZY}@*oHvpD!eZ$nruWj)JZP!GkTUVR|xFvbA1AT8( zFLV7g@Z5Ivx*}HXuuaYP=gT>gs#0BqaefCuLNd0)bOjSMoS?G5-Nsv5O7zP3;~`Li zp%q_vOn$ievIDedSxPG3aM3@Itj#ts!WR%uh*aQV2y+ZP{Mv;RPBRutHDh9qD^n`#^528R>j2FH! zY`A;UwH5tPI&44s=YfL&YH;@R{mJ2uWpDD_8E^x*)r#?yJ~BPjT9PX>XmX~o4_3bg z55D#c7Apb)!QFpT5+`*udRw{1n&S^Fc}{+@jqa*M8k)jVD)Z}T{na~LWEhTAP|#*M zTFcbl<&^6m8d)c5ZWlUW8!ezU1f&*V8>jKoH-@WJ?@zKLr!!s7JiqA8pDb6VA2lhp zVwDw;JpeBZ5rl8KIT=t)9OiI*EI;8ci8hoyzbAIDm^Ou6@sY?tb-w<=dm|YA&MJpO zd&-miH5i53C?WJKvANNgg*moyOlqUEkn}RR8Lf7RuVuPB_Fg@ie;?yfkK42OF;9|P zYAP?)%JbnO=8!C>rfilM{(g^llk6Q%P$zdR|go3svTAbkXEAKexVCM^%Y9*** zV)h5gd|QeECstS6{W?mo0ecsC%mUX_mgDBU7n}UoPpCY#T957Xc&kkb@&$;TFJPUD^nqVqi?EjaX2clKaOa?CsR4dD2m0lYt^!iM zT(l)o3gpuQEiUQ(*$MuhOVARvx?_^QyG|zOLjeI3CoVbPBx|Y6R>GLnWq6w-(NZ`a z6YEkqu(3$yMkj16ANHBxWnDH@bPckRgDQUXG zXtMwOawKApux4Xr2hMUd>R<|-I(H4mgGmtElMuacxi#T)vQ{3%;ggBWbT9lSL4}b# zE0P2!$3OlVT~vOK6apMs_yuYME7-PbKp z3th@&oBRsL1}DLK1$u!n*LV30dJLFRN&T28o*Je*Z2z>ZAt09F(3g64iu$1|&V`A&X1{rl+saw z1HGJA0&x~@Y|93>$BGbQzy>Fq^K-k@B0SH+Daeq2jG*9rIM^7HO(qEyIwX3KEbH6D z=Fev)-<*+h?ZI3IH~vrVcQ+ITZX^CsSfo+$iQXl@iJ?_If5&>sai~=bywWEBl!B=C zQc*Oim<0Wi8WliWhnS5`@q8{?)^tr8%zn~1)v@&}`mFT{^*R=)J8 z_nj!h@T3S<9Y)T#EXOh?_{oV=5@iooh7*mDbWci_6OL{!$-Mmj@e9`;8p>~LnH|53 z*&J6++s-ig+Bp#-DfGJPIkM<_^}-xhAwN40{(kCNYd{uonKC88FSp3&D3i|OV?3&$ z&%0A_PGaj=d+9}a8NWx##4L*iiUS(8FqjaMwip= zl3H+SM)L^EC0DApj!ip^t{9pwnox5cJU*WPk`6i06Lf6~F+W*|db7*BS`nZc9uuCd z6qN`&ybt=U>i%2|v%{_zz)OiDDt!6yQ&M81HMvF(AdlCD9mhJ1sOm~lNh(r^?feWKr z?w|EdS)&PBq}=D5urxGoEZ_w{OJ7Lx@AC38!+l5+@(ty%(4^WoS zr%PC4=(ze>W5%Q+%s3gky8G!~V&<+}bJvv<7ftk#Wm<=r*|x#jom1B~dZ@sc2Ff3Xbe~m8xSe)T+@ha=*2zSxollqs3}t z0{hfbTE_ZJaJ(4lWqlKfQ(iH*OJri;2>NAWqBSB?e_y{Wy7+5d+4ijC#QI-;Y#y1Z zZbCZ!9eBF_`?&p8X}V6ij=4G0Gx0&K#v$2b(kFF+zxu8B>_h@xTQv=DYFw27wDNNl z;sW%6@F+V3|Hk?ib^VZ`quc08xUVprnb|~R3JE(014e&xb?p!Juf4_*TiPTRS3meIxN7Bk`b_ZWxQENxiSwUJu?S(qi2pVh=6_d7k zD%L)_xbHOr{K)IM1Sf5%c4x|)iNRcZ3`k2+spt(-f`L8S^-P(G*N%qWAAJdSU(bH( zeZfU`LF-c=(&R|ejDv^S$^u>-=y9EFQN|bIf}Nt_0WPs`_5pAErtsG)svA8)_oVP>FWCIVz9nj|4&+raw=eV&6-%oS7~e9IbW9VQ~3Ui)>^~B=#@y z*E!i3h(}NuJ}83dG$_^*ST#)V@^&jFwtfp~Z~d&-?Fi`F_{?~*V31xP;0SI$pPJ_B z4Bt9kG{0R&GH7S|Jqu~CcR=PIlmvdu+mrf{#bd4^58<9j7B?BkaGg^1m)BPhOASD% z*C6DDa`9yyMt4UhHb*&#O-sQCrX-qn=#uAr*(T@Aq)?8rL=V(h6B$9t`Irx*U6o4HrVkOYFo^mkB++41B#1F#RTOqOi3$T| za7VP3r5OZ_>H^EAUVFz(e~gdg(0%Rc-ee|yjJ$^}k7*=G)IhK`mb6koNOBF@fPWMD zeDFt)0w4TU_w9It@mdvacs7sq#F!glEUOg4?E-8I8R>02cXCK$nwyk+nx@iH9abzG z&iGKAA;*97n`ujprHVg+*zuJMPjy40h0A1P&>Uz+i0-uMsPxgih#7i(R6l%wTiknG zwte<~H?fOdUcL2K{dd^3B3Og4jqwR-B|4aRlC2>+Kyu-w{1@R7_k)HxJpxNZlWF%>0v z30y@1?uXLQTRA?%Kcw(nfUZFeGOfKsA+~j!rkhE3WuS$z(7tNyKL*<(>}V)4GImYo zD>Q_^msUDEYBfkMR9T(1>&XQPZT6>n`S-eCfH?Dw5uLH&X1~&`hzSCu+&lkvdG+XB zAKtH*NAlArI9(Zm^9Ymhw;tb7Hm&sIVOxDIQz!HMlo4@0RocgLj7?T>&05$Wy9il z$j3z3l#YL^h56O4*2mIWZpSs%X6I7q*hvwug3?VV%Rwx!e8FO_jybkmb4bRt0>yit zobE&F``UI2#y&K|y6+k7r9M6ZdZ5|%-&izXrLHvVrczDc6Ob}@Su z)la6RG`3}hOXD}$*y3fBi4lm7I(ve#uB%j;y{xN>!Zy;&`)>Ek~a2ovrf=HoT&U% zV|PiC#!J#${dWcZJQ|rII$>IQls}##K3&<}LYgQfeNwrxVp6$w+^coWYI%u`e&?Ib zTDn?eiyDqYBa7IKFmfo#zb_oVBaPw^5FYb}Dra5Hj%3Sy{8MV@1w--y;Z#*bZ5R#y{ zf(4iwwQj}S*z>XOQj5vfus=7p$YI%3YIv(fRbBk@dd3k~8)<}^b1S9==t}ftpTNI8 zjB^BPt#-CGLzSdX`F#D*$i3Z2P-@;3ckXy^=zM5!EhejmkR7)VfGl_g{OJV|nPZ1$zb6XV8UpM%h0=u^=Xs? zs(cLkj`;}h16v@2SBsNqLF?Y7(_a|orbIn<_VIj23QkS(8v6^u3cno2$|rUdwn{T- z&Yz8WKAxwo3m?Pk!PyJRqK#UNPraHu^1#zudcM;4-|u@2XsO!@M`0g6;NiRi)guX$ zMG|;wm%6?`WxzB45M+V5BtxQNN=n3D92Taif0vDu)=bnr8z$;Q%^YkOgZevciC3B~ z7uaH@LWRAlfd!`gCz|94*|OB)6w8rB(jJ)q|uM??O| zA0f0ASyb0M==BUbgKzY1U19ECnLb^#)Z1Voiz_H%i$T^R|DIZSnC%~;YbeI2jFiF; z4*(%*Y`QwoNXXp*n=i(@>8@T=t!Elt52`ZF{g*4ko9_q@Sd-na<$7X*kz!sgC%@%) zqbYvG>fT88l#dqOfL1Y0F(pi>WY`eI_h{q#f!9Vkt2Soo4cslJWo}ac>7a7WrvP9< zlqyq!!@aYAN(dF0!hm_Cf1esujqrVg*k`7S4QWSQf^HWO6A53XIdJ5Mz&=N))Yc`I_lE1hpyz!;Mk%ZO!<3O4<#&f0}&DucMQ+pd?J+L{>3C73Edbm16pD_9xh^T z`MqZf+k9RNn4?M!G^5k#DRh8@1QukAy|gff7OJ$y?aVIX$e9GT1;2QrH6L7D@Oi9c zD`5bH%#V3eB}{q@vGa~|6LahJq}F~Kth%v&qD82BB=Q$n8ZY9k_&I8F2$IEGk|6n# zkSgIUgCUufB}-40Dt5cE%Dk5}AMIqENnAG;^d{GMa_{28uK1q`lYG&N2~d1$A+sP!Qo^z^(CwGc zcTa|zhwz~tgav=!7D6jcI`|Izy}YSYWu{9tQCy4$uhbam-=w5c2ApkDd8*)T-9a=h zPKw4ZAS{s_rMs{;1n5(qR6+6r@}&9PW5l8rFSlae^Ck>I{3?1ER(_F&u$3LWhjp+i zR%gTa{z|mYEdiH5Z$zDu@CS5$t(b#z=*854w4@iJGrY7~1{V;-FQlz_(dqeYe}OqF z4l4IocCGp6Fo0;HWLu#n%&Xw*RR(FskU@v1Ta(T<4(g%}ZTqnokgBMLD9x|EC+gm> zV|H2L6LAakPb$zZfy4W$~#Q2T<29yIab)7<*`-oV4fLR|Of+tz%)e3%M)qvy_XCXgI_L=-?V zU=hLrSGr&v?3v#-M6xgl4PAWeLXZ1FcRDzw6}en-eZ+%!{%~Zq&dFo(=`c+W&jnLb zg7OaQf~AMK`5b7T_48y0w}`U0?sJ#raO4LmI*Z&= zy2=njFGEX*Q?`g|->(LV1Q^r0$$>Q-Sq=0g^!`fkf4AXC-m*z9uo5Iu$(<9UiU%>oBUL3CC8-evqNypjf`hYU$jqP0cWJ~KD>e8}HBO!^Je z(Xik>=`waxsCi)Z;Yz&m^LW(Hcu!tz>tY$(zKnGpjyBl^AZ8*Y+wT)fXxmRg|N1rI zn5Dk?e0fAGlNE;CB5~HGyiB#_@4iw3d0)aTLNA&Af~?`UNSIS{B#M4Iq|nnp{KeJF z=(3BLhq9qktOOx_*QA-%0s^>t*oRu)h8tfKT#^B#F&n`M8Lj_s_`vA^xHB|dVXX6h zr3le^@^ThsW%j39k#6#WS1A6K`>Df2_^2P>DM~DHGd&P#Ap$d0io0LQ@sc z#}kzkSHh2WH)h_lAvX?X;o$ZJl)L}nps1}AjlLTJ6Mu%@iORaTJaU~hW*&_m;0$E< zM_YJj?o_zX9cE>c!*Wtzv9b9w(_5f^$TGmR7DTz^47c;ILG=-vO-+~Du0y&FQRYN#tt~6m4)Qc+rNfIY(mIB9vTUI}s%~1c zG@T4DA5lD{bO}^MXM_5gkj>3CpEv9NxC?ADecd0+*JFcpRDAcuvEu5X;UG$6;K<{d z*t$sHNBa%uJaOpisG00A4X%GnLRGyv9-qkqWy^I7i*JRHOuw&~!bv-_k|)FoJf__; zW|ebxhsRl#=HUdkQI{jc^$g}ZKI!msjvNhQ-6%^fkE-L8EY(D}9>^YxoYpv9Msyk3 znRedWnf}&I5+=}t$a3{w&ej$yHz3TZ{xRA9g(q!I>eD*X@VbQRJZqfpGyKigNcm{r zI;a-j6jPu|yc5O*1q0ZURlS^yA$)#53?GE7JeJ$Kg!L5PE3@GwIRXii>uDNwaWx}) zwEEw4m0_g(PPL_&Jt+l416q`$_m@M_tox1|)9J4Sq3xA|F9RjNn(tg9&#>-ZZ%G5& zc=?6jUJk!C%_!jUc9~bT+59AE^Uo&Q3a^YMx(e`0hkCz?X()H)G0`n^8r_0 zLwk8Abl`ZB=({F#$Kv`$RU$wc@v}vp!~g@7vHYbf&D&MQ`$pDVO!*-F5-`DjfBkOA zZe9$$`i^)$3e_O9a*d5^K zrOkxMYlr9BvZXhlj!%9_UeggdwWfAx;QVIOrQ;wJ5DXt>EsoN~jU;;URQ<6*H~m${ zkd)cg7(+mHmh%nur-HLeEs!gWA|z`TvERZ1#v6JhcWnt?p%|(Jy{ufsL@KW)PCOVi zhRcG-7&Ypw# zVGF)mm&7p$T_r5LsriD^_Q~Dcnlp;X45&XiQHmE;-?rCLCm#Bh5Mxne-5YiLq#fZ; zB5?XDscAo{*A?Z$K)YSb+3e3_R>~qlIO6mY49m|rGawBL#-tly19~H1G{l0)U;W@Y zHeML}#p%oI=3oQHTlk(%wAV#rig-=lYWW7IBD}hDaphTIVyM|D5XJ9-Bwn51>Z7B{2oT9y*O5d^~N#r zmm$pWl_x$I>Z-5?xgl!k&X}T-e{f^UDfVukP5!lQY`^Q<^PCUGQ|~E8M)9=&WYXr| zK?>W|==&ofDDYJXT3qjUB>CMH8B*h8Oepyt6LbVdiffv&dJcx!xW5VQwXzriGFpU+ zq8v;^Xb5ZyI3kJ(R(wzpA;N$wQX#j($o)u=jvQ7LaMzqCDbdDoUT(&CZcp$i;yt-| zc&0rnf=K9zUF5~k6$@eO8H~qMH#Bz|qKo*jw$FJXzea=iK(}C1OhicuWGqNYnK#vV zwC`1kux>N3X-UOU5fmz^a%XUU$JPU0MZ8LH!CBIxjnyAXHqFn~&&VBz_~I+epJeVd zRNOxEt04VagpMrURz$*TG@>Jki5elnQiK^=54DR69G7wJg3nXr)%0^GvqnK7a7Z2) zfnY!%q{&E(ilYllOwumhqnwa0gQLPpPJ)I$qEuNx=?P}Etug8JBcjC-oh*4?!Hykm zVGr_|$4pa*nvF}Q!Oy9b@PiiQ_xp2P1-_rVrin;gVZoY_R)F8h73EMfFcQO>?2k76 z&LPiTXbRNOwRuI@Yk@YH<9`t!X1vl1hF;vVTN+R+O~sqIr_fK2z>d_qDJ z)j1mO^3dOtTXN`t(GNQC7S^y~-rm6poxnjrroVQbJ-9*N%8Isv6^<66G{Ph1P%gMa zm`4%??jv56TDG=&W~lpFmQU9(tzzyF1#!z}@3d1&APL z_*0dz9S-WU-w&E4(*-SI2h?TB6BE5Tt}Qm5okRh_vLEpRar15j*sF_`ql3#bPK3jZ zC$qh&Qy(8LJuD1GgKw|DcTqK!@;`92LhBB%JbtXE^L!WXYvd>XCy!-?`9TEk|NH(* zAcYq$?&s$Zk<~R?%OJi*0?Y9j3j5;Er31}fNbPYWxf}NF*Qm+Oe=dGswTCRDN3gE> zpH4v(1P9iyUt#xt<#%~UIq89UH8SvxvK*3EZ0RdIX6+ykAY6 zkZyx}(dQ;gLn$9aBl?|-;V#f_djE7WyX^3a=!C93@0_$s?7$fctMw&ojS0nIf)jSi zD9HYQOH*^OH^vnqP5l!;TKqfs&dLjLyb~p3Jm2>p$GZT>Lg*^T;9cujB3=}WQ_)KdRr407@+xfHu+V~84%XZrz;8eW*{1NZ`Rf$Y%x zJ8qVJ(19dIpJhxEjswanh&+}GgMv_79rTn$_H~z5&&}7!n48U9-5@_!&UYy611T)S zM9wBn>gr@uCgr?C+iV&~Z^7P!Pad_meGLsb`O*xDGB&L=lB40$7)xGsM$mVDY zJ*}2vjB~^+wY*5;w{Z2Sgm0aDLc~ok9J>RfID1g!z#tlYDej&H1k;E5nQ_@$Pe!K%?I{BO|2bI~~zoOrtJBtC=Nb-ZV4* zPj52Zf6y>A;uIn&aydC)dG@mhF8Sb10PPHn;+*6I+DD!QgH6$p=`>e2j!- zB%=0yjQ4sJjG#}jIzLlQNY!1crIaf(dHI;4_q~MWh8(9o+wAAL<&SQCls}+OXQwAR~C$ zH;57Of0woCf0tEzN%KqPU@L!GY`ZPq1TZW*_QBzW>DnAs11veGr~JAS%arEcR5{m!Fm{`nF{Cd&s%e0M>_zz+^ff9|3FsR-J_QggtBGuv7B z!}j_Bw<)4&yC!snfAfLD!i-YHdiWIspU!L4m196vvGwe26XzP~1K)x!Dui|>X-i4* zJra@P%f!0>&zB@7d3?LZ^~@@n(bej);wlcd&uJ%m*nES8g&{z3dXTUrM5Pd+IIr1u zT$ZWDJqT<|*lR+fkD1eypd$J|@xXM}AprOpQ5JFa$o!}GdZCAoJ% z5(OQAq*eXW2vxqXjwRYbR^bNJYA0Tmn@(j_1tM{g&+#e%icSmU4PFlO;t^Xx+g|(c zPGA4(hfU|L?TndhNX`4_?v*Lhk9GjHYfu_Sp5oc&NFD-A4AR84y*c%BPaf!iFohW$ z9_e5+g@K8|w%x*KPG|kChyy_lM|QK5gLWeog}s;i-=%;w)T$}OFzQkXKWg9r1@!dF zlNrI?1%p`By3ybTCw;Mieyl2#MYjMnFMiJ;9+APImFJ-2R*4|6!MZ9?Zk(cr6FgZ% z!SezX$%~Q`>2?ZGq(P9fCl?aGGtRHlnAnDehwcDT7Lq5_#J3WCr0oLUlVVhse32r+ z2cfbIO8y%Xksue!AzmyNMCCGDJu1?+>bR>Kp5pH?sv~^@-d|RCq&m$1;cq(Y{HmUx z8JhMOgiCuEVqZ_h2p}YIP4`7{O{49FtyRj%Rwl(_qh3eNt(G-I_n@@CxCa!{xXIDo z5g2-z#B1ea_?UKRJuk@t(VdyWP>51akYk`n0VaQv8NWclJD$5R-&OyvHsoiqB-Ajo zA|GhdktD&l|F;oq+}AHrxvAvh`Re51Xer^`_9wB0PMw3RX03ag!CGV1F=#<6HC%3r z$+4$;Jm?KkF*&paLKo(ugb`dBdvOip$9Ii)&QtqvPo5oroxRsiEEt@NM36$B#?8D~ zn4>GIK}fFMYl>E)%YPYiWsB=Jui=)VuIPfzN1UH#3!erLsA^R>1E!ybIQx}zm3z^b zFMLcFf(r>7XJ&_}lln%AI2_0WS(dsXsZ;;wk@y1nm`&kDX!241;|dr(nN1^w25Sga zN^T)$v%iO21;6hQ76E}Mh4l6G0O{8!t6ACR1)VxYM{V=JqorQ*WM2R!*kRJB*%=^A z2}|6s6>s(aOdRgats2KUIWL6{%OIai0k(p|Lek#%rYRh)NGwE3Vjb!&j&kFhO*Xqm(}c{^n)IHA;N&A!{TT0fu+eA^AAKk zslogXE^Q_`O@iz&t%r%zTY_~XLE%txlZo}VF3kAJPSaknBCFV|pJsRpZ4ZZo~hGq;Fl(2CbR%e0hEk4^2j zYba|5tDFPfGooLrQsObe^TQVUK)1~!PQWlZdNdnz{-lVf1uVaVSlf7fbhrKyyh@{1 z#~w4$Fm)0V(9MH~%Yc8whBD?WJlN*Z$$ic4`0x8@KxftfZ!VqG+9zH5%s;)CwVKJH z%@D;9HMfETKiG;PkfUKGyiwYy6zIQfb)O|6r9i?twcz|`ufx8X%Pg2s$yboh8hivP z`Re;Sf@c^XWo}@_H7vj4oU5L;)FDQi!?%C{ZAl5Yh47=gf6ICTTjV+@Hl6z@cxWb$ zt=VEltVrz6DKS#--t}5qY95H#2cdx)Z$<5YJHQhBnj$;)0boX6?uqI0Y$pjJ^TTD@ z|J!j4xkIEXV?JH4nUR$3AQ}Zz}j%b8EJ7F38q}&+jZ*0yRs5c^b0C1`k06E=IKXPd2c# zaKI${JexjvE687Cy`boS>G9%R4dr`5-SFOsEQ<|4#VaGSq*ZG_p|je|RPuNbkXawB zT)1?!GkJ8BOv-q0E%o^L=k*6W!&(RzmmK%SG`aY(1C8^<>-Q^hdCrZ zK$C3O-}iYEum&0b;_Ii6DsX9+S-W7341%-^YM+Ki95z{2jK~BwH^fMnbC;A8&8WW7 z_c4x{zl`WGa~RhNLonwe)bfoOj-oc9Y4!r2MhNfb$IbG_8vRuTN_`CSA#CG6PUboL zfkq)H5P-)k1TY4n18D#-25nyS3&b*7obvs$)8&WP3ij&lrZCBMM(cyt^(k$>U(=kH zee<_ihq8;7+RTsJ!_)WI(SXl-?-uU4Vn}&(Y26{ytT0>dvsipcL}WOC+r1&A#$ruU zDKt+(r=XP(@g{;*_y>*#FKX148vp0zy~xENP;ckqVHC9Jj8kZW7w-1p34Bph<*O?~ z9rr!qP~M!PGDR2we@SjwsnIJh*pvGDyq;smT1xZ!#}4B#Wlj(bwgr;Q-ytwSKysPB zhq}qu5(FQ#BR6BtcU^Z4az~kERk7@GkP1>$QJfAM3OwL?PeYgkdC{dSK^gxd0Hr<$ z`IsHQH7@rCQX@GG$xzZAK0DE+i@*Rxi!>?`dgbYRFlTscIFRh59X!{EBK^Pc>>x#~ zN%YOz>mrmq1b<8duje(;XOQWBXwLRsv-thOI)BJP0V`S*(GYcW>A!7P9q~iA()~^|+s6cwuBH6#E?Zd5ymo*cb6C%W!15=mV zGl(C&NxDf5O_s5ef!jlbF4bK;)Iws%*KD{b|VM|(T{ zZJ_u$>+zS^*aa6%)|P~FhBAwV?u?8GGs_l(AZJ=?T*u*WL^>bh`!C<_Ads5-SA&oWT& z5+wk2?G4ZmK%Th?6ig0QZ`G!mU50)TLl$3k!ChS-i;7q(tzVs14A-A10_@{o!PbCc z|M!l|edfa{#<_7~%-8L8TZE*sq2Zl~ACK370y~9ys+)sRcJygcMlk4LfmThT0c^{6)I>1HfQu3AU1XuzURQn(~ zkewT}l$9BArw#ERH3#Z%t3}rCAOa`HBnWd*dORXW15Iegk`x>)njV(rDKu31Cp=c0 z#E9j2l;k1ftn{-fdiRzniGMWd^aS>$~Wxt;}hm&=y*{;jUT6p zNuU8!;)c2Meg{2~^azegd0=?| zNMz*HQpm;rN5B$m&7|O4V%*8gt>&sW+6)b1V*Ttq4fyLXyBHtAfi03fd`ryMxQKul zybWFO%x-yBmgce3^1nYjOKWf=<*2RVT$?bQEjofu1NP``07%1$(x9zO5f4{EMilbi zahWv36Ndx`Y6AE)%YP{xW0$o1M+GvR$u=h=l(VF;lf!NiS=^nyU)rlC7=9^x^hdip zZ+)HOd8^8g7YEORzMk%u|NLEi@-AcFA{R|j9ag$?7$tJ1Kyqy%&HOnOV5eJ8L}Tv8 zAn`v`u@69X$DZ^bVmTqzr$V_&H}7r_@3>kHH#>(gv;BGGn$u~WV*qAw8u9;ilcwN( zV|Kt|+7`~(j<{}mU3bRwQw<6IzetAQ6JeEYi!~=oxT#C1Sj{~v>dPi}2h;YQ_G$5% z6v0uR?4X1a3Gsz3jj4@4G+@;9zj7Fj?`lxK}<1qd1V~i`g8^k##Ea3)L5 z)B4cmU+2cNJ-HUzUdck1(ZtZt5`wq?=Mz4c$BodLu}b~KE6&o5!ajaMeUb32L9L-h zxaoZb#KfBN$<-E({w|#pLX28N20#Co*L$Qv$ck|oTuBhJn&mgwJ20NvMk+%H)FYiU zEK6Fh&CO?ijC}&8A^n%ya~{LEZdX?0EmHk#F3I@+v&`8gZiLCI*T=;tE^H1>-MeXWVp2|XEqVjHYw@hYD7fgC zFw;XS-~eXR*LY**SK@q@t#9@}QCA;^wwtd>uZ3`uGJ)O zOmUzdiuXnc3@0(zazF1Z;`+fWBK{kfcUFw}IXHrz_iy0U)(<{MqOrFRhPbRKT1yID zE@%<`wtKmZ8pm}8y-%xK*~f#?2)f0Gx|vli?zc5>3#37~+00bQAb4k=1P{}7?j(A2 ziH|V(zZ_k`M;-@=Ezw8fk-D7MFa%Rfh2azIthp+M?Oomw$SLN(Mb0Pe=GUHYkk06% zh{xkl;!>?jsPMDA(Pqput&&Tws3)L{0uM<9JGxod7DhC6j_(-$9XD(&tyl0L9QqO_ zO!`;i988(!3aD(@+s!r$pyK+_HVNB{7BN{~dkJMZiWXhRs=XP#-}F2`G<1H7pJRR* z-JR_nD_1HRpEXZ&V%RMo6EkWvhH7@s-)Ltt`ZjH}Ma9#TZ)nsP1$96W0>?F>F3T>a zZi$JKWUN8My}MK3QOAElzY!*GPh8<)m0AC{K%eo)*ar)IOuuy%N=_9s!v4|Iu}zNZ zF0Q_-YewGbvG&%PraWe?mQdOA?5AXxANK~EFC9%}Cn&6e?wXtBOG3FE^#$Q1XD5EH zzFtmPpFWTHJqyxIN>T*{{*WUH;MHB+|H0%*5P8IVeOb@4UC<>U{25BUN`X5(r$k^1 z7Q*rCIt^mnZU(Y=hziZT{ z)uPU7J$JVYbi)_>t?)I-osz={=S$HU`ta~@mDLO%KZ8;YETYGj3Abp}WJgq7H7r`l z+0zd7PVJI1?xzp&e3sZZhg&DHdG42no8Q;3&kcnqDC$qT_^|E0rZu1Q+)2?Rj8!iD zP5Bgs&Whw@USC6_9nn}3Xmc2*Fp?V6%IVwqYjPQ}A`qon375}i9bRmI%ysNkn|58m ze~(~LL>sd7k^WS5`PG9+?r%94zwQJ5Netwb&GF45hS@@VYA@}+#Wb={i~0GSq7(%k%IMbIa>sfyJEF8WdW2(0;{ z3vQFb=2;?t$+=Pfl4q=3Wr0#KL`##?%u{+rm!Z*OG`Mm8`uR>bjyUb15(+{Gnk=lv z_tce!4K5hf*(bhw{XZK@9(D9X(G9?o|@LP|jkd?zK?k0wy) zo6$$v{CuBwuJtcYyVkriZ`dtQPDPw0*im`3+}_WhjxJ3)eh>T&@TC*3wW$d;JgedT^3E-04F-$WWXCj(VAbW|FIaQd`h~dAE z?Yat;Ag1`i!SM6|4XM-6=4=gUU{(?D# zV-N!rA^FG^HhMorGUCWl-k98ERAmhq`hAV%=@z? zt-z(8vq`TR#@eAw5^n;uP*Wn{ne>B(m*K%;w96WHHXA zLG*$u1uC*9B-nGqh1qp*R4qv~pG5(@AU+NR`9oM(6K3yc>ZE)SAr39X$SEV*JsG5j zI}VkjewSQ(Qb5Ss8K&ot%?rD1|GTr@IT=C$y$a!PMqT_L^4NlE(3-O(yK59>0wf!; zX)?wE?aZw^^?zOKudiqzREG`W7N}nonwdPR%Vw~ZC+%f@l z7$0oSjh3szp0I3>CeutFmIq(H97!=VnF%AU5<_0tEHG2x>SmtjgcN{z4S8Ij8)Z-i z8%^j~Z&j=CJ@f8jJ1lCSizo__7X5Sgn=wU%4PTDYYU1JL-TfW6XwO6O%a*W84t=&J zebHxc{<+C_2*rY@I}IKkL1Hp!QF}4(7zIYs0YAocQk%)E_qaL^+TGKL^mhTj4a71>T%|N0zo$MrWP~{7I7&(_ADOB{ z3m3J26aVN*Nd9HyIq-BC+?h6aeQF(hb7qwW&Ll#K zlX{)WTdFMtlM=`iiw{gh7;_gPNtVMD5X6euqJ3XcaG{V@)<7=3O%mC4ZljHxL$^)3 zc>*|_?_gWg3{4s(|C{E*+?mqh)tu1uILb!XX_;k*ShD|v5;zvA|BfXt0$%3GqEWzp z!l3LutWk&Z;k5oySv;HM@^4UHbh)V>q&kA6ZMI0e;r6M2>zh7Nl%p@5WcY2Lo zP}QbCkEAu(;IrY^7*wK$lqyl88yi>Q9~Fw=F3=&6?g)GRLrUMSh0^k)t{XdEJUFh84mB3)p(N*K7Ro|}7 zi>c!VIaK5EbfnocZ-M44Uc;un-TrqkR;&;EOX*NH-ru=~ibD1ZTZ_73;C+YU)p>@C zw6Wiy*y}19#IH~q3{mlvE8xb#K~F5S5;%%7N-ks=ESmIaMRq{%0H02EKUbVr%e^xh z7?}+gt*w?Ua<+i>W^kE4(XJfher7#5m|M?=`EmOT3l;Z6<-YkLJg1`d+(k3zp9eAX zw2?l`^j9H$mPzX}!F0sqL0eUxIU-wS@PlFEL)eRkBF-7Cj4E30Y4 z6MDR#Im0FB)NZp!WpdDqdhGv-j$@da-J@Q?n@0}A4vh(uBFBUV-g45lRErilYr-yW zP;ag6lbEaG>o#+YW)Jn;`uxYtJHX80w~AK7zg_&_zAe6+{Z0+UoGL;&*b(GVOdaZh zki#CNNeguRO7{=+AU7pkZq3x++}}xGD0{j~y21gaHe(#RcknIIXQ;2o>kNBMvwpTM z2U?n^! z$wIXjX(J?i*r=5x zp^oOx&vG2M!bwpP!A7+$pJ5l{%BFLjh^PqohbqdjdhKkTZTPSzj#GMh*n!aMpKn5e zmx?AoD%P^0+7<@mXc}qPMutDJWMhpGl3CKD2)d9utF4(|95J5iu|oRlmGteZRA1$9C-Iy)maZe%7J{lRHb zFvMy#BIzA^IA0o@xtO1*&!*~pX`)D`r&<`jq#((3Qnt*z&o@Kex5VW}gX`F{5wO-; z7u|=QM@(5@tT4nk$gWlu}yf-G?gggjO}9EO^MTDEvi+)0$RyKlSe0ru&_(SUW_N-@vAj7 zJXPmx^>-a5>l`&H&LyS|Q5S@|8vg?eBW1cU^ROGpMoDK}OY)r4&M zm~PSJz&jWdrX!VWFPN*^2SGzNIx{T{V{a51_aPTq%IzDJEh0=&;Al%iRgE02yC!^& z$kpCIb09k+A2c;Mgo@S2>zhK0b4d8~Z47((^~{8H?yHn9tb-J%SpY=O!GY=MjIC;Q6r0 zNxEyw0yu&cNHoL$0u!^gU9LJbSW^<{`nu;JNo1n>W1Ghj!^rqd0$_KMxTfb|mO)vl z`j@Xvo!t+8=QaYXB}F;50dB_BZ%?W7YswUq5Uxnkp`K2Y4$&@1Xy}|o`#w^~miU&= zNJ+4NoF?QT zc&^}BM&q9w3gF9eF$TJHsgDo$EqnC*-ZArr{i|9x3#I2ZT(nnpcyu%f(5@0!+A0rz z=HY5$JbgTEULOj38tvA|AVpo*j}N+}%wZ|*PX|@{x3$ugMlAb)p z0JxYx*?Bbx0hHIQxny75_aAi*oa~BZ7(Sym6l7~&!EJ-S6eS31heIE}{Xa~7by!s2 z6E{nDH%LoK$I{)6(kWfS(nxnK9V?9pN`t@x(%s!1A}t*PDhRxn@9%w|=ly&4xpQak zoH;X}`OGp=+#4tFH`g&uEED_JniN+zI zzvI18=J6tXQ=1IOU_OwUURh9svUhKhROrO{-@m6XTlo@ zihxSwQOFJVyqFmNXMC8rmn0+=^kmSMrm@wmB1a z_4c&c5xiH(!(xkoPTWwO1fthSaWr&5L3)HbSYP&fl4CD&c%FM@(vxxYg$Y$C>wGHO z=UO*kZh88!Q8W3T8{`uIHJq5{Su=|n%?%rRCuwytFnbu(BjDHCu}s*hU-fT)im@9j zxf=0Uz1=vO%cH^JXkuVvQc8q6P3FKykAr>c1?;cFHz2|&|^nA zcyP+$$iYF+QF2CXs)P!4wG&a`Yfcr9+Or!NWt8%%rK5<@DRJa&2y z34YNHd-omIH~THW)WEnQvg-P`8PsA%R@n-k*1`C;b8TiMlpKk75qW_ zwmE9`q>y~-8gmn@*Bf=rXNcQvCvxDO=4^tS(j)U2`lh^;B_#*jk5~vd71ZxWu0@gJ zoenbEHFST-%~P&FHAvFF3@OMZZ?zq_scj5JTjrZ3a(^~ zzNyo~-+wKBw0!JXXs8UK>?o`bZp_3R@c7m&E)EG6F~Q$vpA}gMbVNZ`-Bs;f4X+rn zT0?LFSrN6~dIsEg#pwOjW&-XUg#;jQ%bPcGB?+MTfr;|$2|Fi;r3(?fKF-V$rAS#K z?d-m=y4TQZ*`BMYI&yu_h##yn$@TU@qGh^1DCkK|Lgs}j_8an&; z7UkxdeUv2?@z@9?^x)Q5ppDK`?)9Yg@NbqLKD@(NAhRZy+I=IlSGE(o{aw{-Ogv8kFb3`j`?3Qe;^tl085#M6#p8`Y5vsh5tOM zV5w`qyxxZu1U;G*5~j$``UrU z(Uf_B!ppa{!>@-Z%|iEr*c*ei08Y2pz{O(OOlD!<6`TxB3+Xz9O`tm0&WluVwk81Q?=u}cY1S=g-|#c67zP9J zL~AT_K#R$x9ZyQalSFSaSaV*`$cta6RuWm&4=PNe4v{#rRmP zoeB}khga3;%?ZGMYL1)IN(U}%_X@c8Zdq(t&-@hc-D2Ehyo){C4i)$~l9z?xUf6ZA zAc$pCjU+{bkQ7+rt;xC+OD~<>5k5QoLnlmj7??5QN>71Liyk2@q zx26-6J+3#U;0qv)!n<2CgY@9Agg)~&v>oB1&@I_XkJlvEVIIfs%8ORc9Q}W9^S&VM z$WmJcG>TOHX70Lms((e5@-3v=D!igAR2M6E6H?**jaMA$rU`pB=vQs@JtJ%KHx-OvJX@ zLHCyD&}yozGh})C23!ZZ*8=`cR zJ5o2sFAePjC0@x9EJ*4vo zCZwBA$x#Pk0~ggC(Mk&(Sy%LVfAy;VV3qm;U->2owsAMC6x@9Gvdcmyg(0M^sA9>_QwZvOd^>d$V#Kj0HHp ze6U9}-vlzveN<&5e5$28+*F~hSSR5En=KJ*e>pW3_UmA9{aJ`efz}LII#L73X?s!q z2!+OS<;i2pT}wpvao3TWwz7v zQnLw8v}G&Fo#Wk8mP#5<{L2(Ty}n$2_jH}Jjv_S3qC zz+2HFPot+1GrO7-)Uwxr8AfqaO@FYw4?QcAY|&BW)$lD~-D;W=US4C ziFg?5Ii`T`xdO{C zQ_kNb8kQL@@&3Ayu4~$1jqBB1Ri~C&S}@8?rDNSsL1~+?a;cM@&~AQG}@zn?cqwC+t#E5_2E zLk9OC9E{laAe>aW=CEj8Qg@DtihITit1gr5V8LBIu z2ik&0P^yA>X=hWchD%CxTt~VqRn4&*W;iAp+!qyt%0pRmZH~yeATdRnuF=|;RO^PW zwE~Sm@cLu1U&btlR~WM*b)8Y;kT?;6E*=z*YzkjTXbRst!Jf@vLBHOVJASuny5@a7 zf+cu?!(nPPOBEw3d8VSoI*Wb>p%)wO-i;lwM#DoCx-3&9{t1J*PF*=)=lHuW0%7#% zV0gAGknOT+X3;k?T15Neh8r22&{-+f+Oz$tOcSFR$A?FdjYl89z}G>xQ;s4)8?WY? zXrU0~Y5V(d-?ua&l{sLLWkaM9hFkq({SC0->Oc&r{eud8yL$I2*crU!X>8@Cd<$<$ zM=U6ifNMPd`^-!MU<#yd5vYyXLO9eUgI>$8LcIRS+mYC?ci8q_D)wtm-&E&jHxRFa za&%;5F1hK$-1*oxJzGVrW15IdV zs4y&&O}0K4S<{^>(vbP|nn7mE2>=ivp&lSOhPZuS2^0@RPZFW)%$%-#Ebk8n(L092 z;TS)k^X~*$=oGV+v^W|;?JFyM_b&^v%2DI8=hB~8!4917ZQc>!6Yv(y&_a<|9tT;; z@vVv01Aa9doeNy3k1MtCm*-T!&6|S7>$!JT#u4=h=l=Y-G`>ygBZ4$FpTmp=5MeQ) ziSI6>`)_C)_oII(z#od<@~d-67t$%0EI}v;?kGG*zZz2^PQTCvgIj*&>-Uz3+%ai- zNaV_bE~(|Kt7T>SIV%gA&F$x=zvZf$lgW{kW_(qshGU}ihrvv(fycw){A2Z_D)3G< zN%8M`Dne7L4;(J=f>LC``#w!>IT{*Fi6_mRkO!5Po7ASKU^B_<@r(G8eYF6_QBTC< zx*XKHmP*C?MEWT&2S7`e|6^4q1hcR8|6o_$e$g0Twk?Vgr~8 zUR!B{pUOB_Y;o5|GThs~w-TzCXZsG0|C-PD6u1zU0&txei1kwJ`pT1F3Zq@6zftwM zzJGk1vZsW;U75wWh5$*gX%~0bWxru25^Lu~ z`G%JAuc4F$|0zs7mdatODqYsyR_4_nET^mIIWv2g{+) z8w1LQC{W}U^*uXy`Dh_LU*}-0FUaFdtiJwsq}8YOK&JS~i>y)F(@&NK&o45N&0}fy zW6K0+$+b0e{I=E9a?(VW@E65no z1E6ZVL1XZ^@Z%yc4XbRV{nUS zpWO#mb-y=LRBem~h0)=yBjL*k7>HIo;pA8OL7LMD9bw8kqA*=P_KMk!TMSA%##6Pi<$4TU{3#jgV@zE6bzx7d?K01<&)>~R1w~lVss=br;;o@S5V|zTtHILh z1W@{|tG%ONBb8z}@Vx_Dzf6G&UkNFgLEA>5>CaQvgz8vxKhGt$a`W&|UO@4vYS1jA za~1VZ4-@kY=6K!IK!Gj3N-YJCRz8C%o?e95u<~f(or<_1(77CFOWM|&2>T49Xjg$| zM5ERoMoyQnG_q!E;7PZmn0u@zFsAa8g3>YSV?>INO+bP`tOKrg5k0P{vYh&cvRuLh z$T$%m>by(0Q<8&(GptUMj;%{ApfQvnhl*%JZM9=TZFLAA`jGM?w8(}T<*>4vj-Db6 z4hPOfoo{ZKi58C~a)F+rH_+$Hk=ob25>9#jWx_F^zc9oA4d(2|r@FStV1(QQSRbRF zHyo+IIZlUPMWnj&L@vF#oA}$SwBx?BTeX&}iN-cM`DCkei5^{8(F&xbWi%jZ?uZ%7 z8;J=6nuz5MQKOv)#UbYtC5p1$>$?+jWLlJBc3qzVFlv8dtGx~rU4Df2k{;9WvdWcb zh9?PBRCHT>qVAhEnM`WvAGgnt1O^bV&&Se@_Q2lF_z6g9rVq~mv;Wg+A%#{k@^J}R zgLD8@83&(=Y+!H;H9oMQ)v25dm)-YHdZN z5E?X{vX(Kj@H*r7#GWDXb$4!VK;Tsn-Uln9oEwp(-X{0m2K+tUU79%RJc#qGFuI83 zU`J_ZuFM565N%32Fjo$}>spLm%6#_^#Zg`DfMX0tG>iY7Olu2pvU2SIoU8)dW;gFQ z!=5|}^O>(*5&W&M#hKQ7}9p-|R$H zMg^4W92`SpqQjg1K(KFDz^+sLWG{z}epi#=4DFGihbE?=0h=rxsTK`g+Z6(ZAamZn zA2T`*$7HFLQ{U7ShY6My!7d1j$I?GIjD&CP8SK-@-Z-Xlb#=0|D}^_5~Hn|(i`lf^o4+ZpNWhnLYQROeGYE|r*GNa-aH-q9c9W_q zYj=4E!i|MMJS^u6#5UJyu=oABBw_$ki%z6xaI$vsuj%vMty)NWK|o?B9?s<1sNUtq zznhZ>?>ezSf5S7Mk{l9C??d+H>wmgLMdjR68mwHtRf_^fSyXfk($0tq$WS5LYZ(Sa z%{dC&NX%Z_3>pK7?;NH3*svY#G7P~Mr#8&J?tDcT83=H<-g?MoHHOC%J-%`*Futb;0L!=Z^#n|fzX zfJ{$8Cz%JOV&s!fm>EMJIF{wS-*cJz_*1^7D^Yjsy6ptRsxpV80cV<=4qPp9m&jwwNKiNzd(;T{) z7wW#T?&G?2a-HKzOa*^7T0JaKFCA%;+pf z!|5i73%usx_qLRKH9O?N4c6`-@Yob-(mnJi5BOY^+`E;F&;iG*B|;4$RGN_veA#Wc9&o&=ca+*C|lK6mpU4e zc2qf3MvSZ^E;&gUG1w@|!u^Br1UU|g$u;5vg&(SidU^A?zlpJ@^+J0K>fmnwHH>13 z?1501N1q?zwz$AhHk^HqlImAWDwBYY4tM6vQkRtKu2wL|TLBX-(8PGFFSe+d9DymL*~AHBs^<_LY!3Sr#BV7<0O5$m zUFT#4_}2kloVP71J47*HAj@1VW^`i@`p*f-Z{X;BNc}M|D{J6C?!{&Ps^yJq)QwI4 zr7PI5@Aj$^0uPn7vEKt>{2F|!=;U*NYyYF9;{jazcQ)YKC1J(b0^T32(iUISEeeJq zz9J6QjtD>$({Q%P(+&VnfVM@@oy;b};wW9JSKgWHI8;?r=M$_qek&lA@dTo&tV_Z^ z0$c2h%|$FEx5Vzt*5lbSH;`z8%!Qtpt_cuTOy)1^P*C&) zhxt2{Yy}oxS^Tm!%VICn596)N-UrfIiTGT{DP|KOOXB_d%0xR=XC;1|$pOPAhthrC zZpBzV9(YQia5h-6F_gS5>$YyxP?zLK+xL^S`o2@k0K*=47afi8TW!u#Y%cu;0V5tN zI&DBI4;81jwuJ;z+T?74PJT8br+$tpiawii7$RpUkf6YtU*9?-q5xaQXe%NLiQr=% zK@KK?@srt(gD-Nf?Ylw_Sqb2C64_dRz<~1RADNJU_!z`CRx>~|2@_jDc0gJ{W~4TS z0d0jrRCIhGoDV9-;}Fw<@g4K0KIHdP)HD>44kDn)*jiiv*ODU?8qC*t2Sm?aLxXn( z3~1R0Z;A!3SEUp2(~KKQ2N@i2@M$#@5@#ss23~GE0Dc`PHb(k!;yL=M53vh;cv~6_9N|fZFe+7Ry{L0im0Py|taI~p_9V{==fRt6) zD1}InNb99M=SErhF5=+ee)cmtixrYDkz0#!N!?#xT`R3HY0fRI*F)d(7y6>a_T42% zIPlZf?h3gjkOt~=mmTk$kvwr2Gv*x3m5pxbyK`mQD8MT>-8xN#ol?PJp}Q zJZnkttR+47y1g0dBA>EO$JBgtH5R3bIMOR(>GaEIilCDFuagx4Bwo; zP>wByZP*atg-;J)XEVDsnqM5r1r*YO&A!oDt$xwuU&6Jj*?a6;7TYH4WxLFU?^ktU z1x6w6eH^~YMnW&@u_;hfY@vw}w$S3CS&o=%#Fo$eR1u?_*8i2N z89=FO2$ZT;Mg}}7O1R_(A5cGKzvgQPx4FE7bA(#}Mz&cY??JFifU7^fEe>Ii+u&;X z9%x*xVdtu9O0rs-gOAfrtaFEi>+uy**9?}H0h$iY(e1v;g2uS2=zL%uX4jGmQb+w} z7hHBEK03kbXSp1ZT8Z3fz|_c%)zNgxc@>gG>J{Br1C*M5WR4kMQ5w-HpEp5gYXM{^ zZ|h;v0>f$7xB_rg$TF}!nMK$N>{;k1m5lT*BhZ7ac6yf`W~6arQ9TCi<80E35ZO7? ztMDH$mphk_P{rD3I z#!PtbKbV%EwOvn$rg6&7W3peH@UK_f7aEzcyl-jdgjJq0`@Ib`PQTyXhqs#rL+Vt{ z(xjGPr+ZJ-8OhP1Ax7H%pOr3)ghYmP>x)p0*`tP=!wr`NjH;;UsDU6Fg|y6cX*3wt z3+k9mGg7Ub_0O(DKpzEl>rv0cR2)czWQ9YQlRy?JZa*^Rhx6)9ZEmD4c0y7h@;=2V ze)Db~Ik^JEg)4m_gQh=3r|Q1p$0}pF$>T1O0O=e<1VhaeqvI9y6F_swNs+R?%-pqx zi_Wj~hfI20`_*gUw(uL=S@I)F*ew3-OK7MKR$XE)m zBub-NNvCOO)jWKA-RfET@ZmjwRw&T~%!jH9d1_0S-W#US4Vpzc8TfqMZm?t44l$!X zP51239d8+pEq^J;aTfNC$O9T+p@n;zt^_3q0H^hM7OUYlhG=mJb^trZ6hGmx1X$d7 zvhiCpnN0t4KJS_U1@R8PgQc~SE(SLhs3+^xw0l)JPS>hk3BWFT-fq}fx`ciJ!QEf{ zqptzd>w=81Q3?a2Q4hP>C_@1x5=>(4%w7qMf-EH<@u|0;;{#GGhs6cH-Pdx<6e{)V z#bJWh0;xFyib!X+oF?&h1P$0g{yQ<~K!I;<$~$$mys3A2zfY9_kNqA(gjf1jhfBuN zan8olIW!UwYB}z5SWkvRjLndqqbz?;kv_r>IadIgg*Sp!?*WwGT5G#xxt@(2NbQM_ z*~zblFOTnpaP13YJe}peVr}2O<_Hf5U2YXElcOM6B`A(A9I{TuaaQ%_9PKr2G32o= z5~;iqG(xAMGY2*wbSh5sVVO(WLHoG6s@U6a237^k^buzk68}Xd{*x5|yf~nX_Flm9 zTQ9hAqQqM^kYwp&C?f+lf#}57+;oEu`QS9LpX86gR-KN2xMg+inU+QnUguCNKowp< zl|CNjT5bM>W5Egn3k)@Qikv8NmgRFT^yRtojsrF}gg&o(yy)z%{!fEjZ6gQPhWC-y zStM zR#hTfTFIGKUkQ?U&!2%YQ}RCN7;Efb)RDZi1BUC%Ua}%Y9M?{s^2HKsi@nRfaK!z- zSU7v?#8V^&%s4MdP1tRyK%T<(+Y2tyx zXt;L)BP$Wh#`>75fhGy1Xhog1_!G~|IM~jO;XAJ?tZ!otzQ6OVlebYkhmFMjgR6^7t~burKC#ne4RBy;aDv-py@e z{cg~uw)lLQ)19mR-d*tDd&u85^X8ZL+{Gmu70a3LqoYX3YZ$ptwk3cUmM#z&m3vnbRAnD9Id`;{q`iH$!Hyz@j9(g3*fsd z4UBXi%nDfK!&A(Ku#L!~U-vEDOij$@#Z({F5rEzS(O6D?_XkQ}k0{zWaaiFRc?Z*Q zMR#Hdb>rrkD@zwd|M#Ac48KzN#mK%~E{gaU!fL@)0iz#Snfw;uYQg-qS^GpZHZqS% zdw+UGexhdeBsH1_@Q{q%G~v`U3y4r?KVPjS)DPEq+t#c?LDSRK4vyXd_BF3a-NSaQUJt1SgvnIl}C1L+oD>HcYk_y`zrcdEVF#3*#(6uuwpq)-9uNJYr*0WS`w3iA9DBJUTD&YZ&m}Zp_W&Z+=O|+l5jV#MnKr5?Hh2t!XQ0+!KGoCezM+ zXYkmF+R*Vl+YxLo1ej*lITC`vujt5JN892fl|x&%ZlRm&An7%|K=k)Dz=gtEA^@IV zk+?w6KvQ65Z}RTkP-%MgkM@67ArxB3S5pG4@;T?|4W|>UNO~lNks8lJ&JhRFnHmte zoOZmCv+!6J6n~=gSXcU7{mqWO^7Vc&CxX2F?wTu3GvML9oDm;y;Ht$fxNseMV|$+E zEGa-%kXCOR=1l;ApH5q|h~v!H5U(mAdR*`yHY)=dyEutoNf*Z~h%$V2km1ELY)!Cg z+TA_vtYscG%=5cOYr9(OFzA3SRRn7@5x3gXcFnj*E_^sXC@dUOyNtlEAbkJ^7!V5+ z-dDFLOcU1(Y){F%4h8H(s6qQ}-KM!ePn#CXBdriQK$`+ardXL&fDbNE5`KBAH9Km# z`hRm02+wm8$AUQ%*H#m{TM>-jAPN~Zo;Ob5 z_Oqp5w1jMUVYBU0$S7O7*3-U$?%hafZZf-?o0~r(^%I3v(m;(SBUSxwywzC{Gx=&^ z@2+neY!8=pgbyQ^lM09cWM9+l1t>Oe=R1=WY2jAWlv*jeD3Bb%UR!$s2*Gj6Nkf{K zevA#bK%f50GWAa<4^oz@C7)Stj23JNoI~RPq91{CLtH2Vdw86(teuhh$7>T41w>^e ze^#JR!wQy_2QrRALvaGoVH~>h3Gr`#(y{4T&M7rGI>WOVD{FZm2g^78(%KyORE%K1 zFks`_g~ZP0Pr)2DPz$;OhPMZ5;V8Jqc=&zIPONrv*wrQoG61S5;~Yte0Dpl5cObzf zKSX_kmGykr-OW3CPlC>ynn!bnmVaUbxh}Tm1Hd3Lq@p7R;0ZX`SX`R! zGPJ-cW3JTc3+V!#LTJHa`X0b$6;lur<$n^p8Vfk;>KB4`I*ozK>b6~Pr~Y*E$(`7Z)c&^Pj4 zf%?fiC|u&ohyhkn6X=*(3k))T9a_Y2I)ep}>IYDNqCDfUDP*Vh@<=F13?JQ#>CFsq zzX_v`A{6i#H?t5c#*4@0T2C>P1J!_g)hlv3cL4qGXxl0b2W2pqCa+mi*Sl~gDd1xR z-p7*eVg$BA&#IF=>qrJmyc!hshz6O;e>ve_IQrJFGyMT^EEi}!CM5o?12@Fy&J%iK-T{4(7SJjP=!1C3nKw?2;(WlZ z^(t}D)P-PnuC=&hu%aW>NIoZf_U`4M(nrph}g<^xFs3H{~7u{;@ zduS&6ps6p%Dl4m$g-r?Z%RJRzw)9Ei6^Jf2^wp&-p~Abb^PqChN_4oF)RE2AkD-c* zQl)8_Y5eB_)87h-w@zh@l--n)%Ta{ogF=xY&DQ`rjzC6S(c$~{d+-K?)V|c9l!aZR zTIcpj`SGb2J@;q25Xe!LXRv3%XwHTnI1~+76IGM=V>%MjV{N;2reu4hrW0L24KYy6 zCh>xwO$D;;{nb+tlMREND&Evh3u?+JfCfD!_ZXO?p03^xRn%1F<{OP#ivHDP6;z7m zao;dxabJTv*XEhwmJlJ{K~OH|L# z!@pMbLB4TMA6*y69_-%v)ZSRTlKt9leAE5uJ8ecKqQ1R`;1DIv(N}f@H$&GAn?jG! zy64vFSGo2Mv*3qT^>OXKUF0zuWnLl@F<*8vQCiIV+&{k@hFkZ-w(kP!zp9So>oIOHRd9ok<+5fiA|@x!W` z*a@u{T!Q|?+ZE}T`E?L5m6REP3%FPlN+S!*ULq$_VrczJC}y8{RNeXPwm}%LsJNw- z#7V3;t?m2wr&8gXKQ`t@{#wKUvMJpo!ZsrFwmht&Cm-K`0V$>hn9?FZ8-4{u7=od( zSFF0JGQ6TXckdOvpK{sM{;3v##(40^14TMBEnyE_xsjiuBPiv4}-2b#z=0` z^!|K~_nsl~^m7nt%pxz0jL1w5W^VmD#4|JZYpnh)%(eJ&3@q~T!H~H#`&)u3en|}c z9M|vj$^w4Mff1$w2|!a5#!a!O19J(ta&9_noXO%0`#4yNhZEwc+8GUc7{@!fh=-42 zu{POhX}$XdP=W^&l>p<555nxGs|6wk6USNPi{JE%t1{_(-~0NCdpK|LhL`n?DM`_6 zELvYc|CuiGZp*b8XN)Mg|IsH!1I(^btmv%9w_2|a2q(qG_XC8JCXxAROYhRpit{tz zW&En(iR|!0ZJt;C{bXXvnQxqO^$3p*|j4 zVwyOhE62-XfowHrL*N-2jts}>fcXRj=s=n_VLm@Bp|Y5S?EElT)UCoba8et)NVj$~ zOaC+hAz{A{g4_<9l7oSW?3W6ZvivmF(X23WO7CCW_nyv;oI|8?8>y$k*f*CmQ`${8 zQ}4^VM#LF&RoWxueS-zQ2SgKEa!Eo*ESde`RHvN`fQ%L_Mq4zdgdKD)%cB*T)&eEBhCRoAyE4%On|ORdArN z4MlU^?w%0u^!-3GxpF z>BHHozuIG;;L8~0HjzPLL5CZjNl9_AkB~LcNdn6kOEU_bc+>VCbRCpf@<%z__Y-8i z|Au^=;r!tVgMcrHebP{j@NMi35uHi-RnMIp^8H2QbT80p$5`0k-*(LJ4cqdD4Ge*D zD1bdJNxtaiA5lUMREBIeRI4|WvMT2khFeH+QIP?%mRmr#$CBKHF+vzS+|q!t?{gew zS;4}gQh(HLvW;mfSz4ntRy2VCpSk3n`i!~lE5!0> zo9g4i1cq-t9?F?bJWXJ)Iy?}QnSq4z0}`xIZ6RvFq4`h>Bon&58@qIwzc4y3fAo2r)mwB8D}` zYq_nAdX9sCI$G+tc7bfwIg=Qps;eh|ZvShICB183k(@8Ll{#__GR zu|OkM1P0CVp5p^^ecj|(ZwP+E{Y)O~{c7hns@G2|_z);<!yZG+~Kob z;LFO>CSuFVH(^CWWm-d(<%hx#)#!e!kN>FWN3*w$5RGsm+#PS54-`A7UR z*hd-)^6UC4Ik&XeWczn&*GaERqh&|&!hTkXhug_tRCLfWT6g!N*%ZU`a;E|rnSC2O zSTm(MLi}Y&uy@c+rot6m)B~+nc)`?hF)G_!*Umyf6Bu++*e#dgU;rl_+dC&1|0nlc*ePWTJNPIzQxNwjU%5|5#Yc+ z)VvI&jz*G9v^O=$m35H=>=aD;h4K@817(jm1+n&DaMKF3m8)jwh=fV|6$fHPQFL%Y?RAJM}RE z`VZlx?k=#XHqa^&F#GZz;#z~pT*c$(X~_A$EAweRC<>Nfo5C738^}EGK0TG&$loNo z*6>{Ip$({r$&W|OaOK|ua|2p+%^nE(`)@F(*1k(Iovx=Ilb;5DV1}%=NXUQrc>k7N1DvctP4z`6|@Z;JpRE8;@VjhA^-Bj3@|*aU+S*xvMpmwU~NMLOia7j zDwV0?n|$!S6kswkkV_lj%@@m5d`0x?HFEOfdD}B5--P^qy!U zi@BRygRQVYvB|BvlS9J4 zT$JQ+YPiF6J!E@09swR&8z=|oe{SL0nJWhx!Cii_- zG$Y~p`sV)5C**O!71fZwssBm|-SP&qk~UBrcK;xWd5kXWr8N~@7k?Q!{?rr(g+lUUP;u`O|l?|GtYbUSQ`s zYRzNmQI|6_;)vJw=^sNQUlO)wFahaRWeq?E`?XV?75M~oY#D(sYY?&E(O6@;4Cuxpl$l58px zevo$%Mn9qi{o>-@dfCum_F^tgsZ3;huTMj*Ujdzyz+kAslu2STM5X^x?ag<+Y!n$v zO~Lm$^TFXdn2IOgG=>D^6%mW*t#%B_7&3et9dI$YuV3Y;q#ZRW7CO&Rr|FPW#RmYv z>}N!CbIfwIC$}@Wtz{|Q>Y}XYro@NyX5!BhUS*@WJM!6!wz_7r!Ukw2USvQgCN|y~ zjz@ZX6)01g+?_}RRw_Ek5#b63U?F!T0dgQ|a)*BJeFbMjlPA+7u`2(hJ$p2^PhC(P z8c+TEI#O6j);nw&IBrk;1?u?`kMDY!e>RNckKGQsW|i3o+b<&aZFRzAh1k!+JUg$j z@Fr0PYPo}bO?0IS6Q|a0J<*wwEh=-d0RawZaSP=@ zf@7>-F?JfhJ5M7f1FQyr3pD1^geV-cXhK0ge^}uTNo0ZS0w%l|fa{PW0xn zkqU9)mz3e17x=5y987n^uXvd5{z#|%tem-!w$e_y-|hogZH0!_X=IgFO7KvMREGEXugow_=J|BXdx03 zVGMN3-NI}?8(&EG_#)zdCvm%I-ujdFIy?0>l||0C0TD%RY>)vd3M28|#Z{R0v_aFB zOiw}WZ-wMzg*JL-teiuclaX1Wg=@#Fid}()HVK|R)eRevduR@zIEqyQI~_Hlr(60| zv$;HxN_P}}(F_k5O!y2Y6h3QB@_)77>|r#p7|z06Y26e1JVkhTVJ_PO?~XZ#Swj%FBa2>E_9x)h*Esk-0Bek2M!tV5Mnrj}Fw6We zMj9^>wp>-h4fU)&U}?|i{zhLjFEFPO+Ty#4`+dRZVtD2*tyDG6j~Y{?6~an$KPyu<%Qik|9lyVof%@^fpuWc?F0 z%_qWTG6^q{p}fLm?0R0-{l`+qUZRIZ+KhWut679MQ=3}0p9?z|VSnd-?{36UJv0Ti z+?&Xj(VTrJq}7?|+>g{QDp3^m^)&=$TBzw*pU=cdg$m`BSOnosw26~BDn|aTBW9-N zShJM7sw-syU3FV%ZTBBuAkyB%d^HFpyp?hD{Ps$6D-{J%kv0X*(>rr~%)`~j^6Q%u z`5Ld)xK26!^k5p!62+9ybdou=SX{{A%dNEds18}gd(M@a$xV7jDMMF2U25P@u!l^( zmQ~1Y?%D*qk!j|qroFTH^43nyjCT)69BDclOE+eEf<@J2dAf2PrVA+9l^^d;F5REH zcuZMx!Y3s2atNI)9*Rmv!jBOWfpiDcpq~oYpjH~HZr?w@SoLU6qP1Cnp6Xq>@+jbSa%CT zi*zQMNHf!T5m6riHZzmLAQlsw6_N6raVpg}AO~{+l@WEDHx+p@q7EQdBLF!p0+7QZ zfJ?3%w~|EXxXjY4FhBlvofY6WFYBRAYMi z(lI56&d)iv#g*5w4*`SVg26fK2?& z?CAuHz#HjwRrv}#aWamm`c}-cM`$Sf?9FupR8$FVa73lw2b*Q5++N;5f^j>J_Jh@( zx5AbUP0)a2K!Y%aj9SDWH_zF(@;hTAJe-NlTYHE1b1mkE-ywJtmJV?6z|nP52PVbr zyN@+(+_^&o1C>psZVV^o%zE`cOlcmNuG0YgmxV+u2uG7|r zF(FfmSLU))$J8wTTlYBzxhR$w45ogLElTda1VArn$XAqdW?=?8oC9^DK`ZHdMC#!U zuRy)rivH4-H%OLbSwV@PL_2o#@iCf#I1QXzNGk556Qjev$OyW;WCwWta$T#7vq3~Nw+1`$a!o^Iw(gZnAqPv`Zzo}u6G!)uU$x)YUE_ziH;E<`iJo-z1Rk5) zUkQzD63S}UR0kk&mgZ=1-h0Th86I{x*3}A2zXd+XS;fZp$xh-my%x3LSDl#>1(6Mc zX_eV2;!{^gG(+1=MOlCeSe{K_>Fz-Yf6+JM%T6_;w*qax!cgHK)UCb1FIgpjDEy=p z4} z|3p)loXC5^W5I8-RYkJaKLeg3CO!J>DWs{te`eR-b!u`69S4xtrPRf!@#-+xMy_Ux zrRc}JLa(*Z!r+uwD)Z-A;|;}`{rxYEI>;mGNv4%xT@N94m_13HOeDEZcW)-MqEQK} zhu~Toc)9S0DCtgg+&QEPq2oQR$;zO>tFNmKECXDA>ltDXyL)D`%`_87XaCy&-GHlzT2 z79)Z+UYkS~QbIF$3bf)+nSCQVhtm_*>27I|PU-IMk_M%_ySt=YO1kU2yr1{@esJ&yX0BPYX3aS(&Q;veKbV{& z+KhH$*(7f>tn)*(qf}Z$I*%YZu*AvpA*W-`dW!n+Kmq)gK#37L8(OG?oL-$>JWYQH z(}e@L1ZS)KXkk&KzUB=JCKnb&Cbr6nFwqbd>np$(&sQPa!#M@4p}>C??27$^76sO> zlgdKN1KV+q2%{^~qC{a++T=(Ql2KFqx9)ILew0>c8?tW>~ zHskv&+}E?c9(QAVIkq>>VsP5fC+;B1_PdYy+nW36iEui}$Izz{pm83aJXX9*-u==> zqJ1~ryKBIqdx5D)3&?55$>SrNu-B4R_|Af%M@v8r1FB+FL3OHOg0a&uHgkS6%x6i( zAK*rY!8IIr(5N%I$M!+2v05}}`%oODBJ+bIPn?I*Xx(^;B6^9L_D?L39&|%f55E`= z*v}0WkNCMY{ngR<;Qr_F6_t~?_yXYn_!ULk1K`LKguoWC^sOu$a zc5=*U$i4$T4~>9{qBI9;XmCU%BBZehu6w`gyFDy!4LK~N*J&mF-O^i{p}{R2)2&y- z-WXhB@?1bob8!M7fSQWszlp_;9ypSDmZanhz9!Fsd>t6am^MfG(8_#XxHz)zFpz9b{*{deiKAnh5m($rZE z^==J8z-<^0j}HOd8}tJUSFtfnCEW#spo1pExR^zhe$XOb?+%IvuIWdlc+u*Ds_^kj zJL&$!jFba5b33_OVRQ&BN;04kF_MI=)D#n8I;qE3$J$9PlyAnI?k5TwTbNI=0X8KU z@3UBAAtyF~-1uR8v znhBc3A2X#J8}mr>G`)K9{lQ6)112KRXHLhC=G*<+A+5=qWzBaq#wy?exMWm}<4L3O z#&THUC4?yg0|#K;L4W~?2GFxB0-f|*ikgI?!r_9qf^4EyI1nlIPJ}7@02b65a`6FI zlVD@DZ=mgAvC^ioS1*@U9I(`X6NN|p$}ZeAboy-LOio{1qgSuNfO(&r=A!JFmpUg< z1N9(GY#z$n```JM1E^@eipAxprMb~2H#ktpLLdk#c*m&9jsZI;z%*l2LsN@FZfXgj z?NW)-CAK^;^|NdviD*IqaLMvCze9br=x+QyytyipX)fbbf;zGV+@8ho2>-M|5!e`C zH0hYbN9w#N_|NOLt6u78HwYRZ#5@5>8Cb;JnX|~YT!4tx7?c&BeAev>P%c2d!RbGy zcBK~;97m`7mabbGPHp1UUhmK6EF7G@9>fn1+Ue5FDV%JlJZwY1#UoC_y3+yz%K-!i zgD6Y(83qU;${^Y*;g@S6DB}a`_!hABZyi%qeN*aT&OFkbm3#SU7W7Kf;ZL&fNJQg- zb*OMR(*x_sd3)ei(lIe_X5g;z*E#)K{Ot-1`eR&zeKC^VtqgBY{rHG>831dplKdY z6+3-P3bta)t6_k{HWW zPUAl@$l?@Nd1T^ zqs|D>p2AkrM4j)kVPz;oJlCNi_6!Q4FPFC|53Zg0fx{?pw7tQkiBpJ@Ap^;j$H&eK z>A`>_cdlJsG?j&wKAkg?RR>#6*3N#3TZ5mBibl-J&bN)^^k0dm84?qdsWu1D(#=5A z1%eg_PfVKrT~Q$wo;W#H%AV`&K0rL=hziL$P@Ji9B|mMFv)}tkucs5Gn;O{K?^A)| zAp`Wd()rj|&$5|(2ZR~ncyjrePej@c#Xxp7zX(sjqN}}qt13iPIX5lbk6Vv`kop;G zRN|K}&R`#o3^ib!3Af*}E9;QQgq7{GVdOIqk>{?;8qNzxZ@&e+*dmxQx4@H)A=Ji}VrdOuy&f{H!DKu? z+fq9#gjOzzFb4&Si~wAVI<~KJ8zAS+$K7&B@%D3imvT3Pnj4upuNnv^*X?-9&lJH4 zYpVxi?9U-Z?{=W>czN8>#Tv9ro6_6;AmO7;ge1MW1w^tqwvb;YkQ-c+uX!( z=$;BjZv@(O{4N0M)CEM2{1+Pu;(@9`RM8bY}eVgVB@zz z_5F(IcAh*@#;D$l(7j#$LfkcmlQ0=W+GldOFmHY|(kOV4&?4l+#-IAD@3aMLC7Z=p z&9Neg{`dt$-#1Zi5H|V6+WeQIz8kgriI$d)DJccw&vAcYk#xTC!62hGcLc5ne#wPB zDvGx1n&3G5JjS^$N>3y}M~%sH#sK(i{7vg21}AQF)))jl_+F|@VVEHX@bNgusB!iI z1jv9L=ywhDRaLXd&tn3WT4dA^mG=2y5YxW121e$TRQpXuVViV&)I0lfpO-m@E-0xl z49k%AL708uow_oBJW=>XwEZ!X{e1!H!HIoH3-jfq6C8_(>i?t|u*1O)2OuvvDHIC; zd7(t8HA^{}a54eif>3C#)5E@tWVL=OHEt@hpP`P2O` zfFSnZq~ayz??;vo)GTf~s%0XZBO_F{1k5;fL!bL%=tEC7&+Y42sQ+Zi6Qt%z=q_(ozc9ip#jS1mHy`q|ree8(xLVoRUOS{<%2~%e%)!j*&S%{@j2r&^5 z^4Xz^f zh2Jeyq1^nBNa7tCtG7Ul=k@K5VN)qS@?6E{5}X396QZ%U!%w0ckOHLi}C$4R$d2k#2g zWUcA6B*94Yb^sv#f~na5&mTH;PLoQ8I|PxqR*u`HLB>3iq)80>1985FH*I)pC&SlUjqQ=SYu$Ic zf|+d2vI4WD7HOG(ri2cJO*71yc+}p5Ml6ub7E1obekXhX7yA_k_~b~1M&kIE9h#Wc zb_oh;a=zn~;MPF7IvD0ZA_u%rjFgkGMMb~hwqg2|jeulN4(_W&ppRzJ$N`@^J<0Ib zQeGTg_+XA$*Nu2E34Zn>Qc&h}JtEthrD31}pEEENniGr2_tHH)u|w^D3JYj>(vBV% zj{VH$o)K>@=G>YzNcmsQuEa5U>!OC^Y4 zu-_II7&^iU6B07=U8J{-0ycI*aF$)w9c+Lu&t3O*UTHXGxQnX~sQ%f2K}0vib1(dJ zbK_paOxXdlO*(36{|o|!;ef}ChpXv(D%zTYYFXi0Gm$KR7fi-(p?pR+43Fc;x}ZB{ z(z_U>11AW)y$wHo0eZwwW#7f);8mkj(QY|V5&O@=nrhKrvS6i^Xa|Z)IVS;*2B{knSsET7a+x-GkN^#~Le|76ANwzAv0+S+eLgm^IC|iD0-KxKecZrX`V>+znrGuFirEM1h42uu zk&-|$u+LVs7<7;mCJ+$$yKf#sH;s==CKs_+D-BTYChrvvM}A}=qpr%%_YkqlzG~7s zR99F$j?nQrL%DAz>&Of;1g9tLFQkIvN6XE&xM6@DQD`|d9aY))M0a?4%+2FItB#HD zFJ32}K_U8!JbnrrOdcqX?IeKWm$J~FZgB*)Z@81(VUZ&sWFxE@XqiBbWdL3pr*&7x zGd~RsvQ*-}OVp$n(n1a4;SF$sk`IvSL4&bX8`*nefYlw!7A7q*vQ2b4AEG5W(0F_x zeNsknY_Hu2MxKh49Th}LE(jlK{49__#bV?gsNFg^k9M24bum~HI0AtqoSnkfc1P2O zvnMVvkJ*vcPWu=flHyxjC|rxAK-f?@39M|2d|9@!N-*hp}r*#y1!< zo@{ZJg1+P6F-r98yvM8_;$8W$cR20vb(1r05z&boAvw!1SwwqF*QY)8<&FUj$w`4X zJIx53wa1O@G6w_@dh9~qm~LybHoyPb&Z0IlAoVhIIP)L%3E9xP%}bnmHJMvdX-v+z=p;#*$M-%8Wo){z}7y6LvzkL76>ON>AIX%$ZWC@G!w zb>~YO{z9p904j=1PZ}gLtc@si8k#Pb9chF^WGo1M8v>SXQ?Z2mMH_UuDF0qla=Irc zDrj_{~d9K>=@aX(tahl-mKO8F-^i7lln zLY;Nj`UiGmRo=wM_Ocb{Q>S=hp1;|i*+J6;Z!^o>DChyf+D`4lYK-*a^CzGwQg2nKb3!Gf7Sl0HReq7r5d`QL~%T`9ZDaY5XRx z?d7bVG7?Yj7kvZ5TQPgPnpJKMb9BOfecoJiGR7nea!Gq;yQz&63of5RO zDs1eqf|!IO`t|Q9@K2M4uaxh*`cTDrU?wrWgP!mT6NC6gP0Al!Wk%FIs z)sZd_?dhfOo~|h8QoQr+nyZHjHRXC#rMoxNPXO*JlSXG?KM{W{r%Pdm&G+Fj)u{fY z$u5{DV9M?0AXYRiEMf>$6wrqHFXa_S&=(F(w}uZFy9YnibA&syGX8U;$HLQE7ZEVg zhFT~}i7Vcd8Ip`zPMF-HCX`Fn4!NUDi9aWl4`_S!0RBKY=fAa#8NZ5bs$oc28@sHu z7glX#*N<#OTxPUg@We_q6q&=5ebWl}n@ML^A@5>58~-Aai$^4%f8#4CYoU%E@lKif zwyUPl4{y!X^iH^M@5k;{N-`+vFOnm-Z*t0rK`XeG0y(awqlZ;Mx_x(#UP`CcbBehs z_3PeqWBF8gRJ#WmQ2Zfd3>8rXz#_9;FKIg+gMM4;Aw|*9n^eXlxC~zt;~XJ@6)r?p zhhO&g-|?#YI*EDfRyU5B>>$RX0Z_Th2lb87Y|-yVAL}}aWxx9ikidKgzQPa)@~k6c&5L4-uB-0+${Q#jRKhrP z*$66Bq~Xvk5psmD{v(PQYq!TG1CnCAbWkxvOTU}baJjPF2uZz2EtmAQtK*W5PGR2& zg(D!JAKH^J5+wXFIBDC<`kLj`?a8mMlWS3(!Y^V8xV9^?aftETi;xQVbU%Ow&+>eHmaJTjlc zul^lKattq~;?Ap>4{w;DyhGlqa@clvu0Zy`MSKhG;~))+ zu|i@hgt<*XZyc1Q=)vf*ha&|T+JkhyV}vq0Vk`gA6PT(Wp?9}`>oH_5P^V8MtN(Ay zddzSZsdT4OvikZIY+R?qS}>TL>^cgEAhav1q!HW$U#7b zg%FJj1d8E!wif%hW8zz&9ezf+MKWi+YUUr*O1qfXwhp*uF9cp;r%_GXwHcZL5p+Mg z$S|mPY9JPZtrWmzTC|%tDgHoPfV{U2t|?bB3BPE+&J+BS@)RZ{JSqi7+)`(2e&049 z9urWg%l2g{!d1SaJO%-Gpwm*axX5slV;hASgV&b`XM4yTq9!R$Q%06T6^Hke|9thY zB0bR1u&=azR&bdWXqDZEnz(95`t$4zMvvfi1?P?j$dYYt{CNkLKQS=SV!P|y(E1A3 z#6O^Y^@$qF-%#UrzMgKa+|sK3_hx7-|9+}g4GrEpPkOria5_U4c8vzOX(y2&20*g) z&q#%%`$eK7eb6A$=k{-c94LT;#2rk{3jcfe}lt2XAY{Fzuu2TC{}? z<(LBEd&CKjL!pOuf@4dC-W1Y6o2diA#SfIICe!OVh1UO5Y zbpsa_VY-ZnHa$^afnCHSpc?o*4Pu2Qv6f*15;eWf&-9IF%5b^_*}Th!9ZTMP83HL1 zYcoPW*O7%#aAb|PwM-=-g~$ux3Z1Z?@Qw&AGrixtIh$nd6v3y- zDmO#G3E_9Edoj)0UAvS1Kw*oCh1GZSxV8JVd$1mt@TclX2UniwbDC3jC|yul2M~;H z6%T>|*nhVdacPtGcZ=BEW8(F~Pu{y4o;P3H)xzzhef<1vg=$>%BPJ=pUY~CTNOId0 zr|3oH`Twbz7a9sJmp`(&M--4RMekmVJ(lSi9Y8vdKX;0Z_ERvHa$OFN8A#G>&>S{I zCL&IXs*h=q9a@UJt4mW(s-DlIX~bYf8;i7U@p}C0PHw2~R|CYHs2Ocso-M>-qhrS5 z)&yw-8|1Ji{qB9@!v0YG+PZwe2<(I>fpHC36$VJ2Qpq;@5^=v15*{=RjySDP2wOWx zXP;Fb@vd8i^V$B4KE?Fn`27+u_3q`@^VPvihdm~cxL??psa*N7<}Ya)4DuUXXh_Pa z6J>5v^WSatw9uWeN9z`^gfKT40Y*c#xSH^KSqG?Gcg{N-U{vYedF*N(G_>rZoU?jH z_{;?Pp#rvklvS|J`w)B#k-^4Xq0|`Qlf?QHaZ!m0yHM_TPIhfhlLd=Jdb4#unU%IQ zqc64|KRx8OcsjQ(=}Fx+PCubidcJj0-dO9ZLOrXZ+6@Q^t-uRSh*u?`abp6WvxY^suwW!}l~Q)1cR^+@(uB)88N7Tpe%OF5fT!Z4hTLC8BIp(pS2SzexAHusixnb1_cJi<}IMn-T zRe0yrw?etUT0$2%3I*v!y(FT3#6#3oZ+26&)V(COq_BH@y;yE7Cy7zoRS-lqnecMsXME^2IZI}1@ssYp+5OO!K2^@J7t+pXXeTwu4T0~^|W#JLtM zO3++p>${>z%wfp-BaespBSv;M*eer4dRRQXJAAyiZf8i{h1(8{HBw&#((+jZUxuKGAKxGXh{0U)p!_*L{^ZPZ&I7zghP*JU|RYNgZsA%S3ua? zPzF^ijJL~lKhE5g(QGqpCl!qPIxLy`E6#>gfhiR^Dia`mEdD;2Z}t8HyeA_weX!9u zA1b*kOi_CI7IIN1s{lsQkkBa(ic~SFtB0iTQ7V{ko#Rpd9z_G zewno6`^Ob+a$bd-g@yD1tkbB57d_!s;S9`lJ%z{ZF>^G^_Kv4Sy^Hba{bx7yN^YM* z5{w8Bf{k6$AbQ^}KPv(ndKU#9AH6pNoSG4nS~IA;_>#txg=1CVx9~p&yh3kPCm$PW zrRdS5XzG!oPFNi`FO3P-__0LU$K*Ee4ZU$?!;pN9R?xH22O6Q6WZN>Kb`jzF`{D7K z=dVInZYyIo`O~^NJw0MyA~`E~ zo>(IHe&m=%4iU4=Zh)sCz4JL$I?mxKW(^_rjBlQw{!S13Q>%~22g^^X=PA_=*-#sE zPD0-O$c@Dot%!J>Y1w}H`tVMOVMos+`*ykA4l{aBs$f2dqlo)VhiZIU}oIL1O zO-cN-NdGn{W+>MvT$M-+BstLV*g^UC6@`o4sz?aG#A#cT%PdIP-h1_3XLBqOPDX^B ziatu6F=v+C_k#%b?M!cdh4*oe`e#}1NSGb;ix)|_>qoxhT#^w@aR(c$5G|dOMp`@Q zqok5?*AITD1{-=D=E`rMA2xO@wF-E)KDTzP3APA%wL-VHWoFFU-6YHQ1L!*k{P2kY zIYwJg8zLkTaQ!VyoDMRep!mMqyx|J=$a5_p49hjNJX>UCmK?1y1aFrIdV9B=dg!gv zGXqQMG72vz66@XO_#P!L@SCBiCq-6>of9#ZSuU3tIZ`kjLJLdt23Id6MH}2d7l#vS z+KV2-y_%{p4>#s0iW7PR#?gqy5$~I)s@9Q=NHOaTskguoufva5HAL@9uW<1a$M7BG zCFTf#V$x_C_hQqi8f4l!z`YvvSPuqwr8Z7yq$W-&nZG@mL`YGOK@;xcs^%K3B3@)tFr*j^^I>x^G3~E)Z;`w8ld`7c}%9eL+LcG$!c<%oWyx#XR zVgi$g@AU@5x1AT24Vdvk6Zm6=xfZ8(r#)y88OMA`Z3B;Nz{zPAds zvyy5eFl0yvrhiUZPylYko>)-eS&oxL@5vyQxtI?5q~yKfP%aX^Os9`d)Eht}I^Cke z%`*}vAIAb7Dp42d2LfY;sP)6i2oFo#;o93C>|Af{PWTL8Enm-Pd_3>-t=Gstt*()q zy@rBWE4f`v&$i7f(@4@_2;bmp0&-=Y*ZWEHizPWWoE*zWqEmv!1#zEd9&g`JBI(Ur zt)4z-4OYXfT^f=iTD!TSW5=Ejcg!|Ytg`m5LE1v5!wJ)3IOqDI0BU20#ncQ`$G;`^ zX-T{NPv2aeTG#c~y+51?+ju{mKK2~!Ekjc~RmMLHet}#qm`D&D5*sXa4 zBR8c@sP27Ex29s=y9yDM%qVmsY}pw*;pf;-Wy`bQ>t9vX{7a!cg<`Vcw zADyDX2(K5?^ig;HPPhemZ>*4rhBr-*AQq!XP8lNR za_bzG0o}ok7GW(kysqlOIGP8KB<^jh(aRi-Zz{7c=n1RP25!eS_JI6kX(EHV>Ac~g z(X#VeRF6I)*IM7#Vfe-0!=jBZ$!CY3SkP zY2x6Dz+9H@cAAAf64NjlxN<37oxn-zk`|Q0&zSv#voV^!Wp6h=V`jV!3Ngsr+tcy! z*|3T?1cd0zCD2EYm7$S}tk>n{aS<1}kY+j7OH3Ha9}cC3;e0b~ACf}E89GafmTEpc z<_oncI4iSrm92xe%I?vv;W3y>^keY2;&UvU%niDIiL^>5Fv!TZ36&jt893Rslf8em zZ4boga9hwL<$vtV1dmurh{$Zo$8zxed=2yb5IqEnM1bH9@tz0w!4fAwUDtLrJ-W8G zkg{%E_|yisoRz0bk-7r84ixvB$8Rz>^~M&`G->xA%1pimSCWY1iRg>=V_ZAXqC`kh ztbJO!@94{3U!h#f?tW`-RM#}NT~@Y?eAT`lE`6=V`PHOBj338&(>FpLO^yT_rKKH>0sfgKU zQ;UIIjAA2f{x_*ES=9L=0)M@1VeF+b$r3L|xAgXFnrX$xo!zSY=3NDiFKw)HEW!XF z8-82?UOKx7S%S{<%@5Uf+7@3U5%3GQwR7yy)Zce(T@_|o(GtgdiAxu<8m+A-Vkfxfff51;&SS8|akn#F|H{SC$u zVN{TY@mR>3NY5`GBf|;uYh!y>TxmmY!sXqKK{w1Ot8}T&@_Efd0S1e(z{7Qng@`wR zE!vWa1+mgwfb3!+V~m@I+ML+T5*B1r~-nCU* zo7Z-?$HVK@y`i3iS+ijwFaB%cqmHbo$D=HhTmpp;MIuc8TlY?n(eEo#s%1DB67Sfx_xq*|M znt>UdzCamOWS=T5Ax16cTCBG>M#{JiN;l*!sQv8Czd6{$ zsaGDWH5O^mlZ@L~*@LV3Km-xIiX)oURf&BN!_X%Gcg)472-t@iF{D!8TB0yinof*HEEV z@AtY@%N{8D!d(+z()kQZiUf(yw$^h|sj8@I0GLV*z|>kaaJ3ehr%m6t{(K-4uINr_Rf1A`@sll zz9IHU9way_+$c1-(#$4ckg{XtZPE70-r3IFwyx_U>2{-*#XLInQj2tZUpT0x1a+g5 zYBeBa=|1=V=kwmy&E?D9&E+{7GG%Pl`J~VE?F|3n!)D<}c3yFO>$PBE{W-?pN`x0MtsMlF`w zRVq+qlkm@>NTgNrQ5d@c?As8t|r>XR>)78N^-JnzwDPq8OgZgEc->%gPqy|jIz5OiY# zlo|)Im)fa*#?4wXAAdF3(v%Je>Hsw)IQff*z4(SROS>*A76DEN|k#fCyMZW5>VKB@xr4tleaF z+7xHD2~xXqATnYjScKk!S#7Da80BRRK{e*7iFC@cBW@I-Up>QvjLXU2TYKNwx6|jC z_zT8?F#M8U!vt}~R9}u6j?ed8cVEBRdV95mlQC3sTl+btp&qel{sc@uH^ELUU_`lb z7hXMy+SBhk3bM)Mvv2usgImVfyp{&jU4nhKe8E4BVpr#hZG>nu_b^!*rXJNn^*`m0 zoAR?*Fb9J)=w^GzmeeL{WK?H%d^aAy?&J{YJkEfNQO_2r%0SZoo$DPmWgsPPqBndB zy6vl;*ErtxU$UvUWVkF$@p_pX0l3)f$BhTTMKFyIL!W3!K`H_=H5FwXmqR~)$c^!$ zWHU`m07(POMO}-D#F(R$>e2H1r+~RFWQlm&hS#6VGkezuH!nAbH}02LXZJ)hyp%70 z2`PIzJ_(SYdLR$vkB_Q+QiVfc-i5_t)M_QX^=Z;GP<0iP5N==6d$o7zHOyA75|{{` zVLvTQta$|-4b^VW9uJN8<>Ou+8W!DwP6h){GN^4o*|=dv2tb*N@w9M|tq+L^Y#zun(YaEIYwWl zmB09FOg=OR%jpn(8D>i@W;F6l2nBxweyn)#P`&W2EXUG*wazGOhWot-5NFaWv?Ip$ zPH-^HAGd~Fh*h2;6VT`7N%CUz^z@@>f^y_h~;9<_F9UaAQjCa(zn7J8Y; z)xO?6((17AKH0wrvesSGeU74a_))@VugGCA$;JrWFV$4*0crF&VCA3p;@KtD%j?=+ zi?2}>CfZPvnE0Tw7cHDG0iv`^w6t2V3;<*pJfPS$UL|J$yAm+$r-GVKB=DQLUTjke zK-(N9uSdjBmkbjWPG6Zk6CZFua)^r2jb98}uPp?%!zluVatqczJ>BR9mpv8_s>mR? zLCDcdSB)QZPl_s3!Lcrg0>F- z>>$VsyM~j0;dy&Chj*NR$ENycJN*%>f$wGD#=z&p)67KOOVfkYgD^i@s9=`Hkmzgh zVG(+kb5T{eTmX;Ot54&WpY%v)rMl5=;+1GjFaYm%&cJSq><0mp!+zU>2VlN2+6~PQ z^Ci9SIsJIrnp_7jW(rDR`1@B+H0(goTMNLE0_x$=+T$$0y5T$JeY&_da=t%`A8G%v zwD;nCsc~1gx&A1zV^Z`Sl2szzHjkfHYU4D%^*^v#@@`fuk_BlymQhcJJ1#s=FuOiY zfiT&3>xpEDo!F4-aWZQ$lu#5q+h+jL>~Ubu^@F(13EY zR>4S58^LE4~$YtdQU}Nb9V)@1~@vi!-maN6&`U0w7th{ zPu!bOYrbFb!SrlL_5Dd@5#as<=d6!5zB8CE9DM^1YR~lqr)wVh!*^px+#_$N3__4A z$sX=`Qi(rxsfxY&d*;;4Ml~Vt!enH0h_C#D7qzT4v2ZlP z{Nh+COUwKGDU}3~%(>5k3T%vfJlPu!>%1+cbNmi#Y)?cZc;8FEyln6>2Z=r0>Ezw=-qifmTjhwiPc{^mvq=TWsun0mu>LMp6W=IRuH^PBw;unyl# zs;gyh0aCtB7()z*s_c}VUO^s2TNO#9qGI!>& z%mX;5{EtsWfI<877G$mXlMAlR)mYO_HL}3w-LlaH%ECf454rXhwFZ#k)2sVGfN{*z z$_yxcS5_*6V@hHDll@`g+kh7r!-?LpZGlDFg6UsUAq9qPdV4H4tN_G=9+v{+{>h8LY!eXsY{qF>{PbS-h!sMDn!rZVV1O--#wgO_}G-I3JUhSG! zk11@{gfkcuzy1mr4Vcn8xoz^2^DJO$@2Y(KV?>2^o;BDR+7$HY zsjXYXy8KdeN)dQc&4*F~#;+e*qcZ-TcXq9EjCF2RN6a&j`B6a(8KQ0{fpQ&33j*Pi z;X*?8zG8#GcgZRhzvMU<^jgUt(Tso zGIo$osl(N_pctbXP`q_8hkIfkT*%S24)6iTiNn4A`i2qaqmGL-F5Jq{-x2l={Y_n*j9>L4+A2um&hd~yebN(kEM#4`#Gir}{q31<+{iP8FW`y)4CIw{Bo->^ zubg=ib#NG4!QC-Kc5>FN5PZNl;&3l#;bPj+!aYIXbQBx=HV6Z$8jP|I7;&CH@7Mz( z3hZ!pBQwn!Fd)%eV;^0 zg?ZQ~`A5oF1T=}&cJH4<>7I!!1IS3SBTO3;kkOw7*5sa1M**mjk++_2$T=mH`nh+d z-caTMSrz8__pSrBa_E(1{D|nFK2JIQ81?t$?Yc64-6FS&5-v8yK(@PndS5|9ZkoEX z;$#wPJweVU`NXb^kL9LX17N#X(H8>^QZMu!y?LCgBZEq&}#KX zR=(bGM{z5yvW{wU!neWx%|n}1iW=3E^&=S61=H$~kb>%%m=Z43!`V}irCbTyz;|UQ z^VQ_ZS`dgs<{foOgQs@~6ilCiugT(6AbiawAF<#Iah3Yj$0;_M-_0e2L!cauYedcC zE5I_EzGqJ`?kHttln-1IBi4SFRljupqEIIecJnsT20*n4vL4N==OfZCG35&0$iW06 zme9`1M&{u;L|GD$IZVAYF|{!X%-J!V-46@y;1z)h{dI&pwHOYu zwk4F;QZ7lBG!C(IEI9b0HXLH@snlaf5`^&xC$av z8t({1+t6!C06rBs+Q1ydqr8`Uc24g6YqvhNQr=8@4K8sYJNSGUY zgj36TlJ`uBpG54e;IKhK3|slRYYqW{=Yz(Sk$rKHh#jpl79%l-UH;-clc^Q#<95DU zGd8SH^;iip3?l-ZWs}%NH-b=W%h!fh*6?0y)*HUM&$T&dRE8}qxWJc$SXVP69>~QA1vj|RIWUm8m8^bNZy54#@G@^aSbMlljjw+q6sK9pj@|Muub5;%e zA)u(G@pJvQuPyxY?~n}AQyV&n5~;}|P$wC4`YBrMqVJDbD(ONw7|8&oB`b$;=6Zvx z`4?G-ddK6T#~m~(zRw%O{O=Y8g?isQV3)#R*2{8I7vKsk(hmj1gwmx7`Z0?=ReuXs zu?IG89b;Qhwx3?4?;-&25K)SEI1*Q$CChHBewcrtyawurR!*Qm+a-_r&r!A?TJy`G z8#OnvuiLFV)Y|7Gf|-D2x3|H?-r2qD-N2b6KW6c(n-B2NQ1|YF6f)_Xv;^P-LQIrS z1yu$2FA*m{m)`aezV8Tnx;r^Z>%nlWp>FfMA?Pr$sVD(@DD-A@g!GDd$cgHr;fU)o zT(s(L8OC+mfRyB;_)6f_>DM8Cx4kwXY6?2ck)V=y0bdAM_DkN?Tl03Y`@6|Iuic`K zIF~R5sM4^+J3ucCh?66G;(WvhCwdf!g9a1n7bE;#r_v@7ur*>T#d<;1)nEP%k8Q!N z@(0n0VB}-h|HX`Q#h$+zQ&;N*g{7MnH~Ms$;5QS~gxhirsp`;7*Nx}{CIDMHB!Pxg zhoG^xL;AesshsWBF(mJowq@xUE8mp)_nyhx06GqmcPybP368z{@4>9}I6G+gBUg>D zNWrnJ_h<>T!291Iud~4Wi-WJUxe2UeR{z#-dUEud#l3LtI7;HV2MS{RI5XszN;d?UP@%Z^`2R`Dtro>PEtv5+On)6U zxyuI+zxPuP=hs$COTN?$+vh}jq=#AX3m~T1JJ@W%YAAZ%+kZYltMd{r!pDu+{;RzO zEm+Bu9ZwgS!DDQI2uUZDVO*MCcq43SXYP+R)}vyHyWv-)*?%UO|2?FNsBN9BCJv!< z;9>kppItUoeR(PrPFMWojM}_;;mMIzXS%!)_7R#-SPdZf5x*-S-ZCQzE~cxLt}0K@ zC7Mv2s%}vEYBzuIOPi#YL;*lp0=!D@yra#)8{v<@M6&ALRprP%uEd@bbi-<7#Iz569BZ1Yu`cIeg6))^K!OjCV z2jj>4LrWtvck77HT1Izvf?=64dC6UOM1!Ae8Cvx$|2gH#FdRMpPo6i8dxYM0UB4?N zWSI?(OW`W(N1lNho6-_$<0s}uEltsy++RGNtGkh+7848qv<4t~QywiMU~9!lfO`w5 z>K|-KT>jdmsV8D2dkT!DW*Vf;MtXL35`3~FfV~1k z=s0;9f4OuPnQ@2lBIzmz`pKwY+cg3CnFtU2&Ac zlnY4TiH0KaF;=kHR15Gen`WCY>+xCn#GtMSwvw)_v@EA@Kc5`9UV2|XxchK1GnYTB z#xs^fzrcA$6p2S@ubkN4oMH*h+OZd!w?26Cuad9(bb_*!am})@qzuwjJ1yC2?pxn3 zkBi$ARg_`%xNiQ@vZzE5j<1y`4cE*BfMEL*l#Xf7lbVhx4rl=mMO$Z==lWY8l&Wu` z>Fu6vh#&GjLfpeS=iPafdmR6^a$G!(x@A&y!G})+n#-+NmgOd)ddpbBk1q`08g4By zU-Ms!jl2;ZhczFkaAAzkpZxWN$rQGiexKW!x)BoI-P<{yF-v6Vg1<~{S=d?i@#y~b zX=xVn`u%ibclZ1dJqEfLP9IRnw$)v0AF!{RCPP_@e+iEHh_9B5y1^uT8yq&IQ}Wpq zR|kqV;&9-6lwv|&GyDpV9b|G#bf>Xv;sBTkR;2*Ceb`MD%cO_=4;)hJ%f{$Gn&LzI zd~sfOyqgN?V7j-YVH9p}JscPbl0(EI2J58#h|UpOq!gUf2?xs7Dcc?%*E>XxDF+_0 z(itY!Ufh>Bguy*(QLE>Bn-p}{HFJ9scWKn0eIzg+a*eFu)JGJia}6D;B#XTS$)B|! zuCMIwP9AOu{JZ-Ks_u@v`sPvl5|35BA;6F(xy}rT{Gz*AiJibj)RGC4H@2QTfw4${3u9$pQRWIA-ai(+RXKVYv2}b`&KoI;2VLPWpVpaj9x>kNWv<(sU=kzD?av525OkY;g3ux<{BCf z7=b?x^pvb?zBCFy@2!6rX9aOda48U4mm4eRc*ug*jYGa4%N#e+W`l++cSi9ubjIS8 zREzeHzaCx@j*{$s*rB;T4blM=3D5Y4h2}C*+&?|cv(@UJ+D846Ls7Z&Q~6?DcM?Fx8VIX~^#8be z^Khu!FMfQCC0nv&Ns44i2qD=e6k!quLuOF6u}k*#v2T@ZSwo01_OWkSD{EowTSCZ| zW$b?U)aQ3y-|zRYxt{BJuJ`@i_kGT}U*~mR=g_`KO?K~bmb}j6gnakcISXx02#nEs@XBuvGy9n3&NJR?_FK*)7|anOSeOUcDaA5bFayE9 zon8$jgV%(L1N|c#ek-b&W**Vkey2@dX}Q~d#TIv73u1OqK&7X7tMw++m0Nrvs=jRY zRd7n-gtO+;GtwZlv2(ukJm9ABVqE9=G)jNUk*A@0pD^hyEs~*qmR0$&<{?p{3ewlU zQc>_gKK;15Ko-O>V%AQn_6*9yAXGd@wMQnVtAf2K*c%{nNpDg_wvWePS1SN@@C6DM z{q)0@_2^Ys+hWqm@)YOYrc#MO1q+QMUjC7qS5WaY3nTa!KsUZuSx!jf3mC*awS=Tv zQIzI|+J6dOjeaOd?Q~Us!Ro1!xw;68JN4iWH<|ekxANOxs@8I~)0wf=shJta$HU^j zXHEoWi;W9X8+(dA(p0i%UA|T0LzGreThFe4n@Ce0WJI?=es6f)oVyF9@~o9R`dXfE zZ}P*wLjGhJK`r63iHWPmZ|vPt@pbpW0@ve);p2um1e8==zQ$GvgPxLRyG zf}){P5^L3m=>pHoWn0LCWwDvrQ6Mi%&7tRi%eM3F;heEl40O#k%qBS_p+NRj3>8;k zcw5VpW2w|y%hu*_;oGErLgvhTp`B;fccPb(u}?FVRX-tRB1in$y>@qCTzY40GOItO zu0l0GnW5anh{alOec&7;#2QEEtIS1RNdbPY3w49+#CPmf?|c%NKI}E>pO*OiZYw+m zdOiO`x!?I9zYtK#HzTL;<>sq8F1#}@-V?o%Ho7-ciC}@L|B0Y8v(y>iY~f@SEI4oOX0eVFMHQYl`Ss8EijR$g z5+n%b{q=}sHf*>_7#YHh&UBfy}>PUp7G&H|XI#rjwKYOybh-de?0&_6n+CnX8l z(}O&h{iB{8P$=HdG-ni$lDcGMT=K%IX7el_dQ*3Ya-t}dBDr5oYZn*|)Z-=Nhe2?E2=;5Amu9r;L_1$%|N%Dk<pB3R(;gAu1ih4OHPb-9IyB*@Q=;eZ+L7n@F;!nN+O*WtH|0(})0s6tboM)_oR#~zg}hf$mx z(_k{oP8cq4qj3kd!Dr-Gy}0>UpE=`_On;Vo*82O(rD=~|*y{LD3VD}cJfG&mSkK@c zsl!F#Lc12>Qq+16*8W6Y2~;+^7U{h3c*Qjj|ET+0Ht>g%Mbh5LhmhD|nO{_aH#*qw z{-TQccI0IA#--|b^uQPq27qRBY(q^H~g6Z1RxzH9NN z#h48Xt`0_!OFoFuE$UN+^-gm{_CDPy!iJ4I4<7h8Sws%k{rh|k_`K6kT>UOh%&MQl z701x8g~*$YenvTsjS5Y&y4`53wAi;unl2quTaYFTZVu~~2$Mgl3v^4IA9V`E4m z6I0HaeQbxlB$`mZrT5)qIlRm!Lg+_?&NBwFH{w3rx91?yIT@bwRXrPQ=hw%6d}O*h zowD=C1omv^p`7|f_|QH>DR*lHN|MmCUBzNEA`)P~^`LX=^wl`?h%&UL5HAkQ&uq9w z9A>R@yQII>Hun-ei;l9>Sw%>3Nhco!1AQyU@YZuv^-}O& z-khW)p?eZ7u(Io2yws&KujCjq$V+P&XC|mlfaK<9 zCiat0BQw(tPc4OFE6^He5$WDoNzPWY#^F$bzLCHY_e{HziPU&_wsbD6J{c}W7apu^==OX<1Uj?w?!67bBNz}^?!4@&`tBbFt z6na^HH<2;6p^*0$Uqnb&(_7EA-wa{I_u*|Lu&$kK@=dcIIIz?^gg(wMWfe zdV}xNTngobv_Kyz?t1CI%p6wmi#^y+|6PT@S&&?cmw_ntq|J0GLCocyA@I@t2t&qz zHM?UUhxsM@sR{f;emk*^)|he02IGg2>0x{eIEV%`>Ic6Bf<@E>Z5ym=ycGSz`uQ@5 za&XjdU{-_=yB%B7i@&A((k;{GweNQG$QiU9A5uJ>$dbRb7g*6c25XPA?snNbv&o5> zVY@5bH6!Yb@5P=r6jT_$2pa2S;j9elma#Rgehn$Y;10oI;3Z2Bnb;#d=g^J2r8{v& zB7V`uUjfJ}gDNUAFm1;VPwY!u&J&IXu;riPKF!+FiZ96)v7Lf!7jYL<6rT-`?MG}D z4UbNC_D>+Hw5*tyIxuCMCuNgwNq8Vxw)V%tO7V}++a1TNec|s($ZL6Fb8fy|)-|*1 zZ|EKen=*L1OW_xLX+Oc-I0yUMLxH!e=)jj&g>77yE7zbPFoL_NuN@Y=#HHDzb(~!g zQcrL^TJX;jd3ioK0>Pwsjs8A}Gr^)7^R%ss-lyjR(Cs>#q^MXBL)pbo0Ja46rk`YE zOC}JvR0Tf$d~xl;!5#1r1r5s_fk^#{{q7M}OsSTScTH1sZykpV){~yD_83;&vB68N z6<|Sr>IXF17Q3pOuq|`o#^-z!G)3?(ym|J?zNL#Dlu~eW zhe@oKG76((fT8N?7s*|IgxDci-#()mpb=jth`lx?R-geS)VEp!xa5~)^>$R1se_{X zkswEtg;&Q~hX8peWyFnUcD6&^42Xy*-^pm2uxJ%tWncNG#a7giGE;zIU_oa1mk>h} z;jEVAmft7xHYV<;p~iu=d(N+k85TfWMv={DJ|SYdy>&)4iu z%^kK`?d7N8(m7AFdXe}EaC|5uY%e&zxT3(`%z+k+sog1mQvslwgM)eUvB>}4*J@ZW zaTx~ogQa*4aZ5;4hJV{wqK)TXm1Lmw!4cPI(FXn}meK6VH`-R@&cH3TEwcE3tNK&7 zHQ_T{@FbM{f(Z%`9>Xmq@sE2 zo9!S31mq64YTsRh^(?-DRR?m*-VwuH1JHxOfNgCDUaNw(`oZeT1Ws}24*tfMU3bmO zzt+u*AZ1d_VrVjKI{bM?pHuBt*1;oRg4POG5}rHzk3ybsK?`C{jt3x>)p{528)!tp zIT_nuyu5vT?#(63&j23`3}oCGxLI@rp6kk&ss|mD1tQ~k6ahV3Y|$~%voiin2@1jD z3&2Afh;J!?SxZ31HJHo`l{ycNv0Fc$-DiRz0wcglks}(*kf=_-X5mTp<_9C`GoH6= zmfC+G`U3ntu6w=q;ZO^B)U193gA2GLwHH-YynY(Xfi}D}FhrE%$-F0_f>a_bfX9*} zNG%kz#D+WeXWSbxzhCTcob;ZYjqS9#NlW#dTFAlcSI$>(=9iFuy)bo9LMqt%79##! zc<|$rkOWB|bIn;qvPoaZ@RL6L<88%}i9TAlo78}(I=}$rg5^cA4obS*DkjKvY>xd(`08dQ+0;_GbTl@6?8sQYhjKJLUD529xmSiqkvwp#jG? z^$D99n=E-m-C*pn(OJZ%P;4*utQH5((PZpbS`7B~UBDO

!Yzz?+rEaF9nOK3{TK#?+j6}?~zE1X@F>kuv zz|Ta9yXkYPBBYLeso*b7IOy(_oWz|O2Q$}+>NQHSJcQT|;eNZdaFc=Jm-xY-83 zxq2|Jg3w*th`e)aZaN9Me3KsTS-|@mLW#i~R9D?mdGz7rFJvv6(t7i?SR0Irf#=>d^@BeAF68fM7AO(r`MY(nm5rxhgV| z_{{3-u0L82id{tc|3!1VU=IMz?ea^oL+o>@7>XGT($7LccS6w+e$wen`N~JS^x`M>Opcw zshT{&L>V%=BdME?e5#J-eNY063qSIs3<_5E&JHfzT-GIh$WWLLL-zR|mfPFA<&n?V zm74C}3@+SV25TrwZZ0#ilQVbXQ%IQNYSwtXmW{2Ul{W#v5)(rJ;dS2(OCBA1Z>zR&W2ocu1%QL+7PSHmiBhB}`rrw?AZI)%M{xRKQ)$O@G z#!$cmyyc}Fa;_L$c@WNZ1XEjYira-O{d%{KmCe;f^;e7e$;`>FE5D^w zv#zWxD3+8AV#SH44_d!zAE;EhEOzn6_{Zv`*&S{kMwVyPu2c2e_US2_gci3FQ4wEG zQYWIaPG0?@m5NY^IB-fU*O5kBW0bEZvw+;p_uVhbO3>LNyc>wE&iEELm^E4b$~s;| z+N&biQPFg*M5;uAQ`^0Zz`5QWu(r0lHFfD+2g21n@%pp={0l~?YW_~hlHp+X(Gbr= z!)$?~Uw)a)&(g)7>@(=j_L!O_?0nPA29+<6+-hPfWE1;MX~rG@IUYl-x36~_Gy$l{*9e`b;ps;AU|y0_iW91dviH`BPPc_w}7FqO(yre zAH#ENsI{QzJd@a)oZBmn`6ycFS+wF!<7OP*>SYS`*6;-}dJAhV#nR5yZ z86jo0q(~eNX?!h4EW{w}*R-^0^&lA|!~#d>qs$dqMnUJJaoxj+b0OJiB!$$h@%e{m z6eZg-cSuZ`4L2i_Cv(}hzUzX&y}Wfo=Y@$Ezq%PK==83*)ntzXp6n4p7-HX=*Cl0o zZkWyqV!HY0D z@I0``0s<4;k`GKi(Y!t6JXP4Ua9*VQB$N6L+3Ea=Pgi( z@alIiX7~)_gRmi`*_A(=GH4kk^PkaB1(YFRV3iI-QW&tz%pqdB{%#^&=lh&wD@Zv@ zpfH8qz9+GVt17NxIQ7kU^Vc7{ZVl&MScL3oltz153D1 zQQeXdnSM;Mq|zJea*gB$9Ni9r#YHr#onNAJurwbDYrFMH_~G~~dV{3QFxWO*Cp?A0 zEQ{B(Ycu;OiwafL5&?@rJUb6ZqL60fd+B>VW`kiGB&=qJQ$G0&OR7Zil#sK}u+bI> zFioBHSuu;{)mssn%-?r0Mm><*qZ><|{auk`?k zItyDO!ST`SBX1+kc(>CBjD?Mm*KtzwZOklis^$wp;ec<>$>5FsC?i5Nh>x|bNSyE+ z1rq~D8bXBS_P*}(11c^Odi_=6D&e-XU={Y?Oa>|R*Y2eXSdpi!u%$p6sf!L&G}jM& zeS3XEhIs&)} zYnAJ-C zNS*gQ#%MmW<|KMe_g|g2C4|-0iHJk8xW!H zH~3*ITiSxDML$pgycTnXbremVwzJ|6RnaufI_sqvCrS8dh8Z*MR>qB@o5zHqeVtO< zrREXWvqlHwt;s*9bn&e`j^gi@(05`0_l`lFfgB$M*faU8IWsqMGqRFs^~%`=E;jggQ&}Ft+r%nf@{La`MZ`4! z(<0t`YV_q46C5WAZ}AI?}5xSKI>PjL zQ8)nnsN@Y(G!9oRk~WpE6qJo(cOSHXw0U!PnGDsakieJf0kVYLAxy1SsSc#Gqzmq9 zBrj8E-3;&*B!R$J>w#54(6jXbA*{@nNRqcYH!z2$*EWI*5}DxUh_0i+r)-321(W{Gv_EFAuB-&%rtRLbWHR^ly-SY# zYsh4wx0&bk3n5VP;^{(Lny?2SIs+yeJx@9a4qMD z#$MNMfcZyXQ!|W61OMl(X+XT>8>W8)#7p+*q;*N^cwz10NsNC70B|p^aS`3V@}JvR z0y0E<)c_EkjPzD?NN^DWSf~ZKh%+ueBS1+U@_wwESXLnko_u^`?^Q{NZlSQu_ z?9)Z$Q z7vMo;bQL6Dxq94@T3GE|_?A0EUDL{bv1(ctqzR5UgfCJ%DiZy{)># z%(9ui55Ooqa62PB;(&MM=^i^avj0c}nJ6yq;}rbpR^_Pt0}bEYy-A&Z#s_-oz2LBv zhbApcCh7_suT~TeB-rxT-#>_>Au_{LjiAnW)H~8aMOOeWi6Moepr&)XxzV$Jnbl;Y z>%Wrj%*^#$nF^=N-w)p`pQEtCYYd{ubn|5<=B}22K4g6q00=Iu2xpukXNljL#rB~` zUE>29B~wl4%&m%Gl<}I3)&3@p60LX-h!5rd%GP;jXVw@QZ2fz zHqxh|h||yr^S+*5LY{r#3oQ0UZb#nQj(Qn|D@_FNq9*nLoc6s~O06J{T(P5@2d}p5 zeixqIJP`Y%?}8PezZ2bhx7k~n5N9#S=-hriCp>5RNvo&AwKu3dQNtJ?n-2U-wbeN# z&47h>pEPC&_X6y!ytv){=wC7NUS@bC+#kM~w(#y<{f5>=&@XMV>*+;5;kBvIhY*M1 zx(&cuRI}G?P@SKot2)U16>*Aim*7h2Slm2Qmu-zKl z*=8bt_4Fy)mP{|AX_3qpeO@cToV?SAo6j{&y*DKI?d|`hw__}>+QUN%_gfHVqRqaX zWMiRwmErfI0WUJKl16-cCl>pB28WV_lM_3e6Ev!ZITo3!r&17B#P{8p)Jh>s%wnST zQs_K7w_5S3)v8qZ)I0CmFus5isDT0llX0-V?B@9&EhCzjnr(h|%4ErvLO#+XPv}YS zg%DJ<+rs%H{wwSYgaum#+OD@q*{_Y9mKdRpwhX#fQXK-xAo^HRBK=YrNSZl7iM-M! z!c;BQbu^(Xal{jUU^O_e?Zg3xf6H%^$O*X3ychZckqAoNR+M_@YUWAVXFpUHc zo>^-Z7q0%Ro>&P|K3CR}*c^fq=zuAOZh!#rsI&(0m73Od?npJ_+^FF%8Uc4lQAYqp zNfJThRqP|M!mWQRur}G4Os0uh)wl9E7$Zg4A3_3#>o$Qcw6ND~QpGR^fY0Yazdd=> z&~9K2g$O#$F^QF}nakZKhg-XOn^mjrT3da;1=|7AxNfh3&r=))f6c&5->MFn0ZLM8 zDz)nB>Rfj7_u)iLbJ*pF5X0e=b@2Tn_T+Ven7Hn%0O?g+z9Q^Z$D9HwrUtP{bKMIw zZRIGMdEzvdvwjGT?Ky+ew*B7z_577JOt`e-;BO4RU6lT9x+i8Y&%VqR8-uSZHLS!` zy8~9b6p;g7ECBCviq$~9|C=(x&<^Me-&ly7X>yr{4g{$#w-%46% z-?75mn=S;A5rY=7J}bis@QG?^?S+|2Nz?^NT|KjvoK)Kf@s5{>kClBbv6fa!amz;| z=e=DYLU$HzpVpT}&acd*WEglZ)9aA{#qeR_9!16Uh3Bp^_BDEq_nCueT!(VpTsJdl zYcI!mB;KuA`8v)tCp}y4YSn0O(vzm%`65fW^}xTR2Xx^*avDQefsK%|f&$4cjq3tN z-ce9HYyo{VJ&*{_M!W(c0M(w80|CX>Fw-G#?b*bRm2vmt)zxv=t`}!C9NtDn2;eg{ z3B=^%QM~aGCF3NhlGI4L<0m@xd*yE*kDtjd!m$+~;<#V}D>4SGZS;XdYL-6H7T8&} zu!eF7icW$IEwycQoyA*ed;^?cI>CS|0u}FanD0vjOf%V!vKlt<{L1 zbX-sPO_hL92IxkEc$x-J&bNJAEXkx4V;5U!kpp*4+Vw$`z5QqWsbkU)=5cBzjN4D}w!fEj z`pLvTx6+l;8j9`>{}R@pTM4cHbwMk@nw$kNY)RI;EWS~Q9ohLL>sCj)S}}^rK6~eR z`8bQx}7ilth6VHC@-TIjeG${1jcV*%Jyqmlyr{3n)o zu(-DS$@OGvYyEU?#~6m|-Ljkyv)}&Jt+D36rsxN>ItoQ2r+#%OH3w{`N7Yi7@l*c4 z9xy(b*3h;5(`d`LscK>k{rr~+F4M)?o;7tGA8EfdUbU)UX!PY|$*xKk2B6%d&5J$R zu9ldnRm+en0$g5Q8#q%Xob6Cl`qXUfN`D>#CKM0xz({U_189&G-2`~Ex)du(+ImxS zhdFPH<7*k!Kw(P@tnmYxIK{O$LBc&>Nr=TW@_Y43-()A!wTEP(tVK-gpelA6&E9CQPiN6*;de%n2FW zz%^USV+G{+ZS0^zf=)y#{lT-{++AVIWy0MFTdP*p>2MKJ@fE^7dbBm{BAPkTk2|p) zA^WH~-T2VnSh0G+_n^1@15f{l$E?kZ(SQdog`=0j<7bFQE%Qr2@wRj)Agv)W9)GEs z(*zi*a5!ocJP#4@jos?x5u|MOa9;C&OpPYr%_;n1*n2lK9_HPZ6xDe@Y;;l(kwzjR zRee}rb-LbX!(Vs1`?mo*v$17XJEL_megzPg0cyc~BryXIq3qPBc_Y)Sn`*%2<2PhCcE-5yR5tgF{ACgyZUf!!Rg24`39B^79BLZnnMp*h^shU^aN~;7|E$CWkeJu-?#?cA^fSY!rLqQV@m;)W(I}R1#laH zYFpr!2ukvIU-efzSy>%ktwzF8uNLo|_MR?2)&8=A%lpEbNX7rH?R0=l)L@o)MPddU zo9@YN&F9`!DBlo1x*Z8|O?Kq$G6B6B(xN&&!_vnff9~nMa#~!F={;$ld^_ySKyBFW zc7&aa!RjVhG#L%PBcXBU9nkWOX)`KLg5ZH7j|C;6sxQ$G^6YLiZ2OHqv*kOLg2VXVseY2 z06#hJ<#rL`T$9W8-m)?XTR@B(GJ9+RB4vRk>t&t)-6@BcK+40}M?$;3bc9=|T8(F~ zc=cM`x5rJ9j3j7IzRaSW+Fya;5o1xh;!N+!K`~Z#!f2gVI@?rvwpWHN`v47sAZSzLpR}bN`BeK!5xUXDXl!>_ClW z-9@N)?`PZT3*VZFB5lT91!Nv27CW7wAxY`%3pqpuB z2R*)7x&lJRapb>5EW`9~9;Pg~Ay_*+=`1$M0WGF;wwCq{vF9cBw%&{Qj_Jzw&~9>=8hkAPakxIlzWCluI8j-Nz-3%MoO|2bbpOINe{} zF>|av=+1Wse;S9$KG$d~w+}Ptap-OhRS_&*(Y?+(1_P7jw6_@yn%2{%WP~fXC)Z;d z0#M;&S4+;k^7vicC_$YzXn5>T#3pUfvV&#!#@U0xsr$%Bg{3ChU9dIZnaAe$N|!yO zsMM%bDAhvp=%a`3y1IQf{KTF!Y%4yC{vtZpQ)_G9WOGk&B|;3LBj&j(@+V=C-~27v z6Rl{fseHYABdZth8!$auC%UDw=*>hfHs%af(L4Nxy8rEYnEB56)~?bQeb0tbsZhZk zzvW95(liy{xyEO!K4{c%*f&ZRkhn3LZ|)MP))R2?{k1!OxklBv?}ev=p=aa)p~>4} zY?Km}{M3~$mlc^GL9y>*knTQom3hVX->631LXx6wMUqZ+rh}@V=#&9Thx)Ww2 z(O~inSHPg~K*Pc_%)bCsBgX%nKhf(sNatl%-w@&tQN5&+Q`JXx1`8X;W&~ZN3}S2Z zZcXO}V=toh-w_Hng`y**JICwFd!4ehw)*}I5BsjwfnYBRx0%i-%Vxt!ZRoPU^;C2h ztNJcP`CuO|&^KVW0iu1vMlaY4tHtp2vAVgA?@W!oqKP)4!-K0sw5zdvQ|67h{P~^5 zx1>zDh6z%c)cx7XX}U%BShuya)?JaDXmcMIuLND%hmc5puWbP!4O(eDh*!fI+2N=d zKIT?#D%#x`06b%*4@QCcElnlj==4MB?4^yW2Jtwfu%GN&V$|(Q89)!vS>bY|!2IY> z(K}zHyKP@Z)#6&yK&oztTZc#E0rNvhhWQ&&v|9oQt4sDi|;Skn+1IA zppfqB4PCJ^`DgY5C+cQqFL6HTnBRI*L-)u^TaO98w86|k*~+d1V+_+z&;^?aO2}v{ z#ER9!ZX_&3l{}Wox7@(0nY~cN;J9Wv?-*@*gDRbKH<*S*7mP?_R_CiFB zSI;aLpyIz_#GQuD$!DoX1D#3R6WSxk4T3d8pn)DJ*!HBEX|0U~xmB$i&Mm2%BJY6% z4b^Ag13Uh-avtpXcS;V|nHWcmJT>dplbxjAx#kmx?R5|DirU&;En^Nh!QS}U^Q-Z9 z=&ECY?#t~!&F|0i@4JN6ztWn(o|neYJ*6)GS|*}R)Gh-+pbgWZRI6p$86#tDJo zKz^jAZ(|F5jbEr4KaY}%XFWou6h!Fn%)%RErh_Eab z{HAK9+s9c9M)J0qN=l)x_y^kD*3?{y`kLi=V65~Q!j>-kdAVnTTH#LdB5B*Qx;ydy zpv9}Zdh_ju&~ssyBoF65t3ON^d)pLWNx3&?N{hBd{(gk6{w{zvL0b45rCI$GwSi?j zzfOT=zm&an@Vn!_T>*pzT_*V&f-Np*8~#HX>modf92PhSKV_~?F>Z+ni+HuBRDbLx z`q<6q{+Dn0)hXT){-i1=MtzH$Z@VGdYk^8oEVTCE#K9YVcSQ5u>ER^rC$`0J)ek+z z8uH7yTx|esk4C8osfu#TMWI}!6w&DEmxWTei>6Ce)SqmphyoMT`N`v8wN~t`)duMj zfwL+4YF}N#q6Q@8o3f0AtDFQ0o|)~WU`y_d_iec5e%u#PSaX8IYUQ9+aY0%Ti-|7V zNNL91k(-()Ly#vXXsZ<~S6xN)@5w#?>X+#Uv9)mY3V7O0(5MxD2{wxqNA`j9=O#4X z@}|8#kc?_^`~d{QcI0>bx%nunY*Q8Q+n<(CAiA}r^!_84)eiL{@ODa8swjTNQ70)% z`du6uuRR`{TP6q&W`IQ5V9Iq?T{%(9Yi>jrt zWe(QO?)nfHvRl;AkbxFx0cv^_E)iTg zbtwh-x$e`@zM-i6sHON0X`W0;m8@=yj08ylv*95qq6RRO$Sn+TZXck(RHuwNoiUUm zMSB{7Oe!c#p1dleX!8JQxju~_fKyuPA5UpG;n*qp;KU@rM{0O5$MzaRhAH|?d`R#u z3oz@U2@!k>eIO#To(}m2(AAaD5wH)M%9WcZZ`+~PY98++zG-(VCGxfv9TSBL(@gMX zej;=%ymel6?r?cYDpV3QU46Gw1Go%*s8~`KW*Q z1W3Sa*V0by)_1J1F;k(^M*CE{L$W7Rq)+zCY8l>Wa)*jS#K|&>ocOOJAD$DG>f_=V`BhB5T(W-0nWq zkO%s5QBxxB{{O3~(XnL@Qlp}>xPDuSES!xPog2ITuA!OS;ZNL&Bj1MNPTPT#l->uu z(N~0uVZH$aO!8TT;u80^)*}cbX(;q{ctjCC{4?38bI-0~-DkVZjTq)Hv&l)EZf~;W zu^|S3p1>HNUjZ`nRiM|x_dY#qz`mWJ?)-4m^65t>owm9VGSpM-Dmc*c;=t9+0c#i2 zDtuZpT?ZR$aa(_PD3K?0Cngzw*N03Guk8s<$SJIGp02VyU|-yqdg`y^$nTNaIdrMi zZ~o(}=KC&Rfzo>gNvuF3(&vd4$nnXo{?wG3qXYEwEnt)WLndft zpRB~^v{GL|54|;cF~I+<*6p+p_aQA}nC6*a2e+QQ$vN|p>q zo#vYwE2l@>MntKbzlkoW$Id8FTe87<|FcjyRiFr>T`LfMt$+6v*x$1?jx(S2{U!U8 z>G==Bm8n>0Iiibb^hTszKxw3;cB>igwTkrMk%{%cz?KRrq&7KK(foZk+9OvWxK-%n zdRFCY-!U{!i2J~tTI1eDF#SU>BtP??g!{y2eR;|L$`s;Azfhoow0NmoD?OhRaP`Ap zhalt2X7@OxilIpDO5khPb1M=l&fN+E3ZwT1fgMC`3JtbK1#$0otn^WCnX&yS+3gmw zo)QolVzcC#<5E@RG}A2H`usqEvv9RibVUEe2f1FOwr6ws^LWS!AhWyh)!!gcbD(E` z^Gi_6S%B14DPLP0pH($7K-Qv(a`e{y$9Ee&~5V0{j+3OfG4xD~% zOcc*KsnqIQ%>tscMp9~XyUNnO`RaPGz%+L;(8iL2(*oL9QpK!qs1w}x;AF$+w7OQJ zcO*!nnQI6I?uq56h1I`Zd&)QXckwT+92u9AFM#y;BB0PNVw`@1@YXRdy>~EK)_?g3 zm-|bkQY6=KSL=ro^l=fs449DszNHLi9c@{bkL)$qwK?r=%Xe?g6dGb}BdPjsLJ1Ut znqkNf7gHcD)D1^N9;&g;g^foXTkC>WV~MHSTV)^FOnk2;9$%w$p;@C6xis@n@9RlS zc<_@A{i%rR5ahlwo;ky>pnyYFx;lVt7LN4<<^{+?Paqv?)_n##Fer0RUWvACT)dPD zX`lvyLKM!~0Gkog_C1vC3qZqc&NSJ2GD%W3|VW zTwdlcyrKCQC${Ad7wnoH7v5~}^ zsAw*3u}YFNTJwooHLcrpUb2e3Y@x(U6L_#DsRnWY7s6*yZDjivZWw7jq}g|EeDa-0 zN?j>=MQ3gCrk9kYuc{F2kb+3I^#R=hAltxCj-NmksL>nfuxDM#AibIb8KAZURpw^` zYASK8ZJ^a{rno(MO;O<{K86{f7)`Fu!)uhSf}n=x6Mv&&MQDHMLvP^7WRS?XOmX^P zRZVg7c!Ru8;nag$Jdg%k;e8NSP0tJM$9KM4ecgIVAr_O6r!;!?cCmg~(sz)c7E@~y zhKx1tR+kV(WGv@UJ$90-X~>*C*4n`TyaVCGT^e;j4#N?^(9d|zAbl7Vyr3hKwj%5k zh3PYR%n#C1<`#W44jA^VEegjkkzxpj+A=W}t01G;`NzOCI5-LioS*v33U&`#F)oW2 z`4oNL=(Q77sPwNRu7^NirB+T|0&1IaMd>4^J&k+WWvk=;h^GiDXXdzJuQlM7U)Vj? zsA5z~PC${4f+vcV`f@4+L*1}91Vmfc-^yHB}2&$+zY6A-D7!J&%|5-0d##Kt9+`?SXT7a(;3zSnXaJQI-2Jx6du_U*ijk zd2|(U6&7B~YyZcT6=zM#9!pUCMO<1(-REF}y7m+9y+#q8F$biLOBKKwDen-*qN;AK zo>EZGQN!w9oLu4hi)^g^AsZ_Ye2?@;Qs|KzC#CF91OEbo2_i9Ec}RT-#lBZGp>jE` zzm8z#tY`e&eo9ml0F5~j2~hZa!#l1mmAK`yl|cJV$u2DClyl%TBWG;|W1(YI;0rx^~ zNNNluGpM(<--9XLTwn0hKIkP%W{O%8VT~2>7N=hRO)b=`#K>Hj_j)MRz<_|GH-0E|jSnq+7_3BVu42vDP8pMx zd}{BXFgP_e2Q(oI-4B|t?s4+RXN@Az)WNXV*{<3@GD<;{i13d$I(9ma0wl)4D$3d) zR0Mxw9MC42>GFmGKzwN(;uCTaNdGl>D#AVDZd8REQX7LytXfp?8LMKiTP`w3B$x{( zbJF`WZt==q+b$TzL;qEiZE-933FyYMWoFxmNbd2y zzWbF4|CCWMyyW5pdz*}`2jUY+a(m$RV8fw>R*YUGZ9CeYoppg51IAsU8>HvH44pj{2g(D0Y2hUaCDBILL zhMcjV2DA55tNkZUgdM?j`RgIq?Q;dhrh?ElGlp5R-DOl<*p?hn9B=NDG)5R$sy?72>)O22FLW# z?pxQBkQ%6LW0D8X`@^l(cNyWjnI3U>aVu$uD*He94`G*AKj=ogpGqBTqMW09u}9@t z=Lw^(=gYY&7*r9y4mi0OzNHRkebLMgkOpvgx@GH+t^=TmF${DEhdcEE&obT&V(f#X z^hsMY-0k~uJaU)XgbsY^gW2&+VTce1F`zEz;lb? zHRJLE&b`FA9_bEBowIPQZni`JdD%*NO_0Sd0dB+v$SPyv z!wxjTBj90&ArZhP{S5geP5r>Mt4QXW(}?6z#%PZTfz4K-(?ksRd8=+`wMh4i=4A84 zPJ`cVU{nKf4y?y;!puLZse=C)9*+%KNVm-0ENnWad7&#l-^7^ zI?=bNmYPpVYQu~R(-0r>lheNs`SEG6+NX|MfE~Y(3Z9s#U04J7R6lSA*w=B9`bS=l zpMsO?j@4>x9pr6y-cUv-L_GfB|3F?N&DafO6mn6cDe=o<@G5BHTYMb+XaGHq)ClQ>!Ewhi3HLDFfP ziJdp!RIoPy75eMqAl=Cj&<$2m_W*#p{#~#*(PbsX^FZtDWPpxFe`knB{MY5*sq>&+ z$xY1GBpZUMAeJa0sh4;4jq@eN@n4EdKZm6ITv!-c0GeYUF!=Wv=77g=Hg#TuiF+~v z<2E9FTsH~+;!IJC7f?VpNi&AJ9oCtI7;Z?4yI^|bL&?z50_{4AWcNI>n*t~043(l2DDe3gEf zdbFu;Jb}~EEcjj?f#Jg9!@$Si;9J4~8ZriQTY9D{P2?38{&8X@a<&b88B`*B4U(mh z;<#b>9--Kf?^EMLYS&4$2gyRWtGw8IeUELBC|a*I9N4b+8falhv)?M)8vW|6-pzw^ z5gQYG|6-%rUVe$M3b0~{b3vZjis#x4o@Y^s7PZ8JL)wc6RK>PvPw>Vy+^(QD|17qS z+I5(4a;!MHcM9}AlfFFzF0$wi+K0A|n! zn4yp|CaCQg0LY~JrWhyd?-tgGphyq%i+U=WWO^#kpdTexs;#c_bC4&fUD+AkogvCp zbXD%D##|w}2}=EXt|g6t>%(imz+c3tfmt$@K5r>`ARlcTi2zmae8V1KzwJ+OmP(>S zg6Maj8ux%sR6lS8h)E`y8EpkNl^gd=9Az!uu}9TH1G4D6gv^dKVS$jMRy1hafuNUg zBg7R<)Ta&f=}Me3b&Nq8$lm*@Irc#dQvb@8eRkK`M@xZxF#~q{ zpsF&qas;X>4g7H@4}mVp+6_QjqAr58$-xAXZquPMC)Sv%X|iC2{M#NB089$B2L%uT zb_-zKJ~iA78Dx>K_}hK-@*f)R^NEq!PG9RaW0AgkAG=2lW|W#KNTdt}|&`dhPOrytZe? zZqeeQvWPG~rE+K(PZQT7HehDc)nDpMsYgCUr6dvR8JB;h$t;&2g2kYwq zwiL@q5n)Sl?Pa7?v3GIJkKA<;1II)NV}J?HftVQ6#G1%b|9}{tAA4OIxoL z^IeOC7gBF43_K+M>3JbSaObn5!v~>jAc}|@@kI}^;C%locVB_b#~ZJ|Q8tp?Wx92$ ze22eH#N$VZ(b5rD_}{MhXW5h(@i7n(DN|E_yG?j4oxU27)>+KoJT4Hv57ub4)gn5H z*?CQn#qD#{*6%8QxN1h!T%P)KY&gRHd-2oZ3(m6j#U00!Dk`lRFaYm4Iox~YIj`Qg zYdlYSE+#KczqDO799e#Y3NTGhZF&{B)9S?@m_A|vCLb8anXdT|EZ6I$?7P#%CuWlL zU#>{L&tGr2sv)%eoD#VU#u7hI4fzxGI(!Sz20si6)kI;($1ezNZ}VSC!5kbNj<33G z?{p=Rrc2R2A4P0mv!g%n4sG_jAt8K8O-}x+D1Zd+JlvVc8L#8U=^2i#`y&4tZc0{s z6{$a_T}QLHJgywzT0Fc);Y71h@FwQ^7MqTP&VN!)t80y!Iyb5Tv*^%kzn@n?HPNpt zXdh_3JW+n8&{$Mu}C%|pOnP-~%{1k3|1YU?2*D*XIR+h_ZbxWxJVJqocA&{Tl}Y7-Rm z9Ut4x8v(eAxzyV8GZKeg>aeFTIk^PNf;t)cHGc{|<#^!x z5*!zcfyOdeSY|O<_c@z9_h%mFPP-Am|8~R7k04ylf|#}^ZX9!G zmr*%kT6|!Q#lgDAe`!uC(W?LD z;;p6x@CI|Iu_SQxKaDu5o?l|xl#?#=4(ydX;X?k*VaLegh^g)Nq)4ZB=BqG&Fy=aV zVRTU>bNb+nF}6Ixvg4T^4ngHZ1vMH ze!G%CvYeVzLGqkHJZ>A@;RSGqrmm|zx*^L`Xy3Aeni2M9v-M@74VTY(KDq9J& zy`;+|ea_m|zsbg!b?PR@(9HZzzRuc-?PH=~F7sd1&IDv)YIk?8n4Mg!Vnwcr4MlLF zjJ8ep*6MI4vGj8vj8}P7diZsp0u$|M=s!6A|8ez|QBinbv;%@tD%}VoIW$PAq=2MI z%+MepNOwttbb}5cASgWyDIEgRsUY2rba%cxzyJI4-lthESzPAEx%=$1&%Q1r_rL?@ z8#6!wWo)79!9Im<G(IHJ+! zTvf}U%+OdT?lnW}2i~im&f_W`5Sh8J}KuA;V$=!?5RUG-Vbr^C&N=YHaSf#l0a zKe>swk;W`%=w5=>4R7>Ft*hcbLp6kTB#G-kT8fM?H0^3Y{5Gx>2P&AJ(!1be>1sjz zbqQkDS7g_z#f8rBE+}apLH9uOSy@SZW${g|k4AosG zuDi@|Tmlf$qU;up7im$bIFOV$+Sv71+iqrY+*T{Tk5H|be&%++6L`m%9*=rUGb;YL zjjeOHO`v)8*X0(kKW1Xmmra%g;#hw3IY*Bj@qJhxHZqm*H&b0LXIjy0ZCO^p>bb;? zzZ7qK=JSP`aIvgy+f?#-Zla)ctmac!&A3$((bpMGp0~vxs&D=1i|u0n5Kcpjk1y^$ zt<<%w-fPZZNrhDMlb*^bFG^9wZx_*ouWsMC`BlDo)A_c2KbV{*YgjuLvjrdZ0Tj5eX#Iq;@mY>4oKk0!w`KfdjW;{?#arbV7AN6Zy+i$>Sg>`km z$6c;`D$}gt)O$hBLAFkU8~6^z@R!v|bKJ1_>Ejm_+M7c09zVYV5iI9Rq-tCCL7{$y z{Q&>@S3MN&W6q_R_grjr<^#lMduKN`-&qwaFh|g;tfF+QIc3;oZh`m|MO4p`a`dSamTT7X=2xRVrc5v47HB=OV* zXjYaA-GMED?cPzP_-s_R`-5M7_g(U9KephmDB7DlA|c3K$C&TWd_J3EKLh*4J(oTIZCic&#Y&i zEQS1UAGm<9uo1$aw(WAdZZ&sRQGdNhmPe60xEnN{|C&CwqjZQ**<%j$JDPggbxYy? zMJZ>h2C)uWLkERjS0)mzXIJ2V{bW=ppqw7z+3bilun0#541=sr&6|-gIz#lLLSiA; zW^xouA`3D={dv}&xU5cnWTiic6_)rISWu{klmC{Rvw6qc-Dn*1tUxf$vak#FE9fjF zfamjj57p(#ZZ1(ysa%A@3D|wPD$JL;#TNB`6!3TW#*x-cfu#PHISD?DQgN1KOqVhb z-i$1oxQV;{`a<)#m^)_0fHw^+R>$)vvSXGF&yIoZMdJ6xyt}qK?W!^zTP%D;5*lu% z$s28s&v6wasFYLw@Q$5ItJ;Xc85Ys(k(L-y)7OYITLbLs9qZStQ_OqRJ5-eB&5ubx(ak;)kLr=lk9 z0E?UhU-0cL$d<2VVuV#Q3~5)wRejH27=8@XU$>YwJJ@^MoY-fn?t6(D^q~_N?Kyy?vSAdY);>#6N$y zopO^dO%N5tExD$tRotBW2vin_Yp{&9%!Y&k=Evl5Z(fBSC2RhfF)2l!$KnstFzam_%o-fJ$F z)7`>J3$vM%hIajAa*};Ch3ui)T*oEKEft99z6RSVP-W$&%8t%0cg85I|Fh}dL91UJ z&}wMzfTbla44lsB+CQ2(Pdz-P_>AdRR4x8!>9CQK)3*iObOSvDK)W13;>&ojyioOT zD7JoT?gSsM6xnr3reQv$lNG#PQ}InXR`%(6CnXMB18Y?q^v$lu(kqODbkDihBbQZn zuCC@T9Ihw6PS}z}(5>X_ca6RoIMFXP-^FNs)SZhS>z0VUbCCVvcB`TGNNeq)cPjnb zBjkxq&WC*u)nZ4b`=rJolhFD!9l8x{!EZ`GCtV0B-|AdT1mBI zwYt6W13h{b(l}qdI%#;C{3x=MF>JhNZT!`6F(FyfrVzQ6y`A1)*5}8oPKI6o7O&R- zD5dv~tOhozW-nElS?KW3J$*@ayhYiQpS;4wN~UnZ(TP=#azjjLKk=y?KX0*#if1r? zT@;*7JQ|Vnh)IUa>8xcqv*lBMd+u;S!5X<;acxHWm*Y<0s zD%V)~B!S290!Qnc@4@z%6^cn~8hn;sa!?wz;`aoh7v4p+mU>fuKe3J?M*h7zolf{j zoUIilE+JWBb>Te|!Tu8(Szh$HsE;&O^ytNvnsP}~F60P0{7(biX3(*J8luqj(-I-U zs}D(5(H+O8jks^Q460SzvrURLt0l~n>4I^Eokh#tYPe|Q?rSX3n?fcA(rF(B$1f2x z>BZY+;Hfg|2{Y?~d&G-KdfeuR*pyMCEmR6mvPybJ9Kj%8A;VIg=8!P~CLS(p=`kEaZsH(L)rbz&->w*VB90%n8R7Y`f&q) zL!qS)nsA`8pwO3~VLnn+KRdRwT+3Y8?osBBTW-z{DaXU#2VbZUN^zhe`nO2}2*er^ zq${u6$MU;OEHFzIDYiBEkdeiI8Lv!3zI3$YM-SG40(toSon=ZUssCIyOYM{%D962( zl|4g(@QGyqwLz}G+uvxno2pW(-XtuKfdkhL%1|U^(ymR&=!tixuKG)Gwz>|dGi>m* zz{FBYLXUvOQPe15F1a=9*--6N9P1@^chGltEnUy)Z6Fp0v`ICXl}K3?7hZjKvEOq! zy*bn7aqK=wz4f@^E(d3mDl-Vp`hBXa$(n_Gq|YznFv&XLshEvSl|(6(XGQ;=;5zLL zZ>6K6$1CiwJ4wqKM-*)|QPE;>&tTSbZBd^)z18VlM?tKndK+pj(@lxYP_}sO|wD4~*81{jMc$D=#l)6b3z*+uMvsun@pBG(xSS zC&>1G@q00lp5{cJAd`njw972~l=+^w3!5*w`RMk(-aqeGE$K|IRVMosB6~8OaEByY zH{LuWt)E@9T%%y5sAAR+PINxU8i`%Rfc;JPJ0qCDY~5PMjGlmuFu_|Rk5{#SX(^eF zTCV+$l>3A+LUODRy2nV%X*pCJpXDa^wp@6{1=-w#aX=_?OF)WR!{}v)e1-cFB_FOD zoaY~@f;cOzx=1;#_P9R9rr>}rlHf|uGfHPQ%P#x7hg?nPSsDIx6m8PqzCE-Xt`T~e zAyFf-Hpp{>U1V1_dFAnWzPj(*2HxD$P-?zMY{U6llo*wZqzF7|iv z_^h+cy%Cn6xtANS-H7K5fdbitN*eTfIeIDd`%`{1Ui7KHGtG87_wj-Z^L|k&PyDu- z%^xmNUa4=0aL}y5^i8Gxvar}?s>k`!3z0Y3`A@Sn=Qk;rqKg65=uc305N{F2)L)Ebm-H!NY5#W?fgv zef`mRqIe>DKC0Xe;jc5=T;4^I=Q;MKeOp2FhfLqaD&-on2~~+ZbiWj2;Hb7tYL5IV zP^^~i4f^qH=u-vWs3PoICXitintu^a8^zb2is#T;TlM$d{*+2_^1#_Xs0h>~em`V2 zk=ExJJrYnJvafeD?fWa+U>b$R7iX=lnr4li;%jxqRy;CvRF2HefFYcmpJ-Y;DRH^= zM_$|K=%?mD^f^Y30OHn1eOqUBID_$o3R4mEN8$F5pN(j&=0P&vpw2kM}8xGR~I=C z77I%k`plWX45|wtyCnnCx-blCbI3rSoeL@`A%8Q$xB#f$ zFz@e%V-!i=0-jzHm3RAI<5~ixU-1>U+svFj;}!J^MeAL5$bjPUEtsPL=-O>KZN=t6 z`yqYo(#Ij2oQZiQz4Fm*@xecL8gU0WTk$2^f~pc10h9^3iexIL114-ms<9{u3Tw_YD{Y`Qc!diH~n}YkEtG zo$JZXS%T|?(|!Bu~2y z3A>z#-p<{($u!Mujf2xtUA7r3-uJFOqrRjH@Ku1Y1DkE5znxsRmr*MfOD zbLh2tR54_YYd%o#`_-;A1Ca?NtO*-nb08A!GUfZMZ>`SPC9#0{!*nQ3zwKq# zGCHMsFC%mj6lFT;H`E=yBO>5z+r3%VgmsP4xR;Lki$aj;u{Ut@YYf|C@>X%ZZ7A-W z`iX;5$;B^szI884w@JjDM`@md8CygJ?qqZ=xKc2aT>$U4N7{u5JEts8z}5Eh2LbOY zXm3yOEiK8-=4+cMTIH1;2|~-{bkJBS4{961J^Astj77@lswyj_*(!+J2B*Q37)w)u zBIOy66}v_RZZ<@o19k&Whdk=r6|2+mi&uKqRv!O|H=nh>kt(#uwCM$Cj1OtUf%^An z(DR0F%7VF2PqWrY((l(G^qNlnn0l8zZo_Q&8&(-S_lmXUQ>hT_=CH?PXEguyJNu`R zCF+>$kWobhdIyg}*}x8V$g1_Gn7;gHpVY5p-5;sey&K2sP=5~04iX<9u$o{R35R!u z`LGo1yVpy#J|C>qx4s|KBT}#*`n;<=IGq+5pz=aK`K=i>kdcSK)rgiT;asm8?XOXe zZsI)U4j}b^n*;s}$g;?u-pIr_DQxMIwCu9h+H&piovJ_#sK9@+xQfDy_y6U081+U! zO{^vmGW0PRQrM8-so{gCF&IUfOaF_S z9bgx`=GFck_E^^XH)@1$u?gCD_=kZI6*?J#x^`CHnxo&>>#uxk_fc$Y^5-K{6LI`+ zCVro7uuc3J6PfhH$|N!(u0PDE@9vZg=q9pvYMUY9&=bIPbi<{#RG0UZD&N;%8kCDo z>(9{JU4Gs@$#__Oil6Zmcy6Ste^rxSK>P@0fs_&iNE|0Hwo%GNP+A$2-KcElkGK_- z{O%%nao*W;LbKJQRKfbX2ootmq@<2YAI?zCxoL26bzkyzo9t6cT=pXaa#7Ze(QT+!Rfz;Tb;< zPW&}*f#DZP1iC%w;>kQ9VcH3Ak6%E%H!$WA!LxriUYpa$lhtrMVn zM*Vuh7t+=dW(V02yj#&lOORt^7jgoepN_x<_HRt-DrVOWb^-1k+N?IKIgUT3y>Znc z>4=^SkW{3@;*Lo~ufz|Km)EG?8CT~UGe0l)IM_tcnYhzoonr5PUK$KcT&-*3u09bV#zm-b}0^+LW)? z@RhH-u!nP}>29eEG7Ve^nB+v%*qn@^M*dt%9D%ajqbUSg&(kbBIPGX9g!(~)$qUe6 z5~9of6RP6yj3s%n_eV65oU<9PC$3DEUlhhsix;p#f5aru!D?6(u7uttIM$5@1?O@T`0pU&$3kR+{@Kl{r~QwePOcr9gi04};#rMc?=? za>qa(-hJP^zK&lrT`}xAPa%}KUAv^}?*OTHw-ghks!EuJ>25~Km6w@r%qOGQvi!2e zKc-c{9Qq@yPQe`d!v=OpM2TgJMf%|>4`Npp1{F1@Hc}z|{6~NugZASbV*R9UwLY%@ znVnU=wNm_M7doJOog9Vmiek-kSJwO+}M68a81~Y6U193Az#C&XQ0kRV|ldEx=h;L0p;_B0G#Mm;|2l^K#~O zob=tAPH%*iFy`UVRdD7O;8K06%l;0Bsjo}l*4I0{@w(8MAGXQ)vJl%*!=H$IG;Cvm zso(qN7| zsA*+y`^wh{XF45U+CMPrC@DjXn@tIBr)^|Pb%c5#5 z2L+SuF$;U*)%X_$_q(I&NX46Dzk7z}H^@zIF%T5*I4x0j812reKJ| z6*f8PQZ)Ldz34VDV;VNjiOrymd<_O+(#HNOj#yez?H|gRYjD~uW%a#2c5(Ni6Mq6E zaUQR6XDjb&g`po2_zzf;8Rz`C9pY;zFqXERUbG(2W58+6KEs2fMD*5x*R5m)Kr1*X z)=3JD!Nz>OuRjsWc!m+B2^v3i@cc{F2LTBjR*IMD!+1|evTS0;+hW$p$Y*@cph5K3 zwYIcfm!uVSl%uwjlZkl)tX;TXHmkM;oy0GIn9r0uSq-LAOifJnw*7t~s93spzcJm~e19Jq4tn)~ z18I1r=b{fE*=}Ur@i>A|uIh{KIII*7odtWO3@+86y3AHGRz4cEhxY@nRBiII-3)C- z6cPtYA4G{gXuuyq)m}5f)~@&c^0v913hsuM)q{6CNjcsep=I?O>=*UO%qEmxs)2h% z?Y5*)``uUWMC~^zCa=qiH3vZmR*S-k&ZLabx&r-)ENvd8yNNdBGg=q9qU~WAlI(JA zOx)f1RD>864>-n3bbT5evsXGdUO0bq)qV^BCFK4#JGS~<3UxB!0Fazo49mR6nABXJ z8$o#JEy24CZhjP2^kB;ag$(one5C-m)UxWb{4?I?=PN4*0Ta3;rkvIbRiB7QZZ26M zRRr4r^NH|2VO+mc{@~O3RHA+1fYm~CVQbqZ+W&ZzggvYba2-*l{9gc`3@SzTHK9ZYrLBm`+i{q@@Ya_vrKU1wt@y-sto!|2vAyaQ9fY1i%W^bSC^Tq(VdmDfD z^{^y1++?AP^6leiz9W;fj>vaj4ZI2v!^a!m6dy&n_tUA5ra=SGD(p)PNLv<1G&|=; zihkK$&WQaf9LVaSOJcyDhaqFYrdx(#(@DhNY4SK_d`D#jPH=fVzrH(Lp*Lt+3NZu$ z%D^$Wyd6To(PA%C&39F{iao7tQh5w?@16#wcxD2j@oXdijHF9pYg1m zrc<+o5}*nS7QsT{!ll|(m%G?J%Rps95zjVgYXB1vEQFjd+d;{Om@_S!SjQzf5Hzl; zwM4)l`C)h(*8wxSzZ^gQCDMLo_}N2x1>(`qT)dm&VsE`ll;fD36FXR zH$fy+D*gZ1@;1Phi*{|vSzmiti$JJY`Y84sHf@lscYk2wN)TP1U9XW}jyb;$W(}}` zF6q>^mA9%{cn`A?0YqE`kBNhMmRCOSzxCGM2c)R*I;MZ2yr=qZ# zu`>s?`nsb3_Ke@8RGq`tN;)ZVO&F>N(zSodEb_HXM+~mrtAVLz&8Y}p7#Jv2x%sac zoc!xBxg#QvQ3ER&1Z$0iNo9ex7QNE7yz2qO+O^>rSn`^~l1Du5K_3>wm5ZwfL;vdg zmpUFR;13*F z7+xLd04s42pC1B9;JI&YoY2v6&2`V3^@z=}8{NR$gTlfX4#QW(gc z(dGDp?DEGZh2E=IgQ4~@nX5fz+Y{xh;S$uXj#YnMD0zAiJs1zK9|6#sW)^k?Kr3dH z#~2ao1u+L|S1yM~ab}EsV`j!-EDY8Q9zCc>b6)Rp%Tdbl05p_Y7jz}L9*>78aG04Z zXw9VU;EBmHV87KuGNO@*7Pc(7OdA}=K?3C$_E`?^@u2-@bSGShBs!`^A(AGNEWY>* z*=qJ;l^fjR7k3P7oZsE2YzO4s6A~ufFNz>?GEQpd@N7nu-`DtRCt#3(A}rF(0bh=| zC{PjPPlhr!MY#K6T$SHOPl1IIl@&Np2#XciDYLF?6Ke_`it)G3jVD3GW8HUv(c+iN zM6jPCzobc5Af1fh#l?0ATW1(WtO#_%=(jo~6OlLrPER;os#mJx?*qHIdW4v7xQi0@*98b2^601j3!Ot&$5 zZFc#iSh>EkiYMxFF4-gpfrh{lFv4vTQF8n5w42&#=?yxK9!^Ewye2&^`dO7HKEUED z#2gfwzQz+J(GJkF^NskTjymL95xhGTH7~SGbU{Qm!QT!yK}lAs-lq>P@+|NXg>CoN zrP%gf#%fGVDcF-iCtic^VuL6+0mIqA-hkowBX$Y}?|7SieNFS^4ID7t1q7f3|EbQ8 z;Chg8E%JC~)Q!O*)O7+t`&8>?t#S+PzG|fM;ot2xFo&EkFb{NDm_z!Vdp* zX=3|CU^7DO0Qt^dLAwQp^g!b^ee8Yl_$S|dY*){BxvN-j^=B=L1qB)wrFBN3F8d%( zjPc7{%P7CiQjn43B^cc07^PSvGKJwYgu=q0AQz(wInnHr`}F?;ZWye3CW+4?r+;*} zq?tEU$TNsGQJyGU8ynltCdTplc<3^ZRYF+H-TmR^s>0z`XZe#%nvjpyIqQ2xF0#FY z0={!t&4|Z9dM-VW_evecMasBHU!YqtIlh!LPx}^saCHgBwU^FTg{OHnJWsT!1u%)8 z23b=9be7yU&r8;byXrU3u9ABaD5B{Z6FIj1u z`o;%|FZHeQqO`p0=`!0N9s+Z~0)lJt<3vXBSLFZg(!N)6wo%)hG#mR6J7ab4WzSte zfe<4Z+xk?H#?!yEsRuTFAMD0UHh}Qog!;D4%Ep3IDsQA(BK4)4e;426T4e0>%K@#X86?rg}EJT~^2(sDU$A$Dh~; z+{kCq-slqn2hoCAyB2O_tm`vWMbqEzL65^g$pSUZ5cd?kXzi6Vv#kgic z$p*B1#^`$`XZh-HC>94|10WPoX&+&A@;DqknZJoXIda<8N~+&nz3RO=+1ZGVJ&o=C zu@Ir3X35bXPNXk~TiaY=O7d1WL^s3JmM^v2AtE`4GIwB?nY^lLDlH4aNy<_W2JZxp z3Y~aZprxt1%oEc`kZcWA=V_BWO+RN2&-M*^b2BI=4;psSwas$~vk4y)i_0M}_y1=0bWN!y3ypQh_sRBGpN&=erq4wz+m z6vH&D6V_8>W7MGTA@GurE_r@{E;j&-#!`WU|4NP!Uv0w+6;G^7Z~f+u$>RgBX{(^q zAhOP?;g3P#FqUD~7LBl+JZT>TosUIzG5cG0u7^T57iGtdH2T7Gl!7k+b6N(NQxhW5 z9-moj6&$~Lvu9b)E68K*Q?eo{A*2Q}$`FI$sTh&ov3x8eWHeC`@5_a+q76@>g<4_h zj8*>QRRmW0* zONFQ|dmPg@H9oVPm3VG%Xk>6Rk#>7?xh1fSEo>J>j?yR*eEg#D*~9@k*&?Vrlo31z zaoht>?w!}IqxZ8xpI~Hq0dAqbSipP>;N8a_TQ&;l(HTo~ zDFHJmsPq85J~Weu@;MyZIce2OGfa+Z+MJBG>+B(OXbQJHe4d{t61h{$e2-bagr5u~ zkbvTfFd7?iK*fBi>K$z^2HY0e|F|tE;I@LDfykjvzOYz;yh$FIOY!y+9-~!d(}nuo zC49_&V`b6Sj?Ss37kts{XwN@B&{kZA3H}iDeV$;XinyvPw$h_1dY7ux&=N(yLmbhs z4v9cO&;PsE-+*c_d4v38iZfk}W~G)O(j6nt0&+mISMvt}25p0}u%WL}u6GN+UM*Kp z-E~cfxacd7hP(<%&U)s1EMcYmME}cz!;G}ZtetIx;RaP=7IdCgeYzB-AkcaxWVq`M>g(0`8fA@bP`fT&5e zZqrrNBl{qo|3N?p()omVgw=^)?nHHuP2osG$-V_8Z;-WeIPfrd_g##6trnfn7xMR` zBSj(7+(?VNa<(ob4O%|l$R!-~krbknlY++eI%H1)Q5ReI!Dr)KdTY1;ZKnRWF-7MV z4ujx%ys`Lm7ReHDl>wAO0RB4b!iz>BZ__UZ4k6ZsnZERx;E}Q6WN4M--~S3z{ht*9cl#I^nX5@Yagrg;6@S)}G$Rjmr}mBZW_=0F z(}Mk$ptDXUxmB%6#lQ6kq@hD{9(%U)j>;Q3k$c2o^cFy`3p}5 zWP@10TSM1`5yw+S@%*PR`eIf)uMTy4p6<;t)zY#Z%xWsa_O&HxwT8_Gfv zU-~=7WFYwyQ=o+NQC~v}H!OhwG|RrAr&M9BX?Mq)Sp=`6wQ)xr74%TEr#gqNcOldQqi1N+e& z79{cU?>sqf2ye?65eBbJ@GhaLknLE^lq@z*NZ6(U;Ud58S~yXmWQgj02H8?ies2N9 zLTV4AP4!1D+f`WxH%>9N3ZpA)bTxqLe>WVzH)Cjt;h;Y0aEZ3HV$@y68L9v!9kfp} zfdM)?x~TRC;9v(!DQ#7^Y%}PfVw3#tfPZeTqKl5RB*;?L`^totW|Q7l&^!j)f_`B{ z&iEvCyTDgj&}gQa3RaY{C{PG3QuB28a(|GlW? z2ZXC;R4wQ=?Pl5$`6i)|>3ZT?9bdInC)je0IUv2cWi2xpaT=6ES`BX2?=Y4@uywu( zBGyuSz{7i78WW-K+KGMQFeOo%nP4nwRGb_r?#7G%oXrV1)y^2BA7rgQ-UnN|^o&(q05_(IxI0EDShH_kX(-v7FkY zXfw)hED*^wx!=*102|}PhG-+10OG^a##RtVJZWXA9VOlSccNcW*B*NW`kzV(_yBk{ zc}JRqmXrt>G`^u>uCRKZdtn68&!0AA7%|vSr>$K{^+@Ec=?MZJ+Qc=vE#4YhK}9tV zrb(=KNw(Rf`wc(*B8BMZw4m>BeKPPeWdE1{ut|9$kU)%0>N$bLn}d@Z9KvgElaxx-9kG@9 z@{+h<3m^po@62Yc$u3hC&QQFh>ul{Gxn8JJJ-53(ckqfWsRK{O80!7`Y%ROKlDc}t zm`<5P0qD>rMn+Zf?Gm~I!>vb+Tka3p3ORG@?TcnyMs1^Pn@0aSYwKvL%rSb&RJ`XP z(gyx>fn>l1s1Ve7wN+eCtA6~xI5T4}`TSZnr6o3o7uz3(+(`#o4;c20So{-HWF>fi z)myU74AqF+41H;-3i#g2FdL#!ee$6h`X;UjUNqqH7Z zPUDW=zrf74@@E6ZyTvcEm~08CZsD`W!3SCqsSAsY--1fD`!4~Zh_{W4(y&3^!yPJ6 z{s4v?v?^$*h6#>NyY2k5O?^Koo|(I~p_hy~P@wq%?99Iffd}bbYQCG3fJHb|&}l7_ z`%l|u76#sxC9DgprgP-ACmQ*wC-^0LM|UACh}K3&M!}CDU@Ky)HYc5_ub97IOz^$N zxZue2R2`;uzl$|LcEN)eH>Pj94IL9POHrE6V3;4Mz}57gvOO_J!raADz?+@j|1OlU z0Mqh8v#@RH03dUOl(%n@sRjG^m1I?1e`Ov=RFjYNn^wyKaV__HZU>rf3Ksj1Zfco@ zBh>08rt-OmvaX}WnIn0m35}J=PCyB}8OpX5PFpJeyW#Z$C}H18?Le5fviZN&rKxBO zvPWZ*5fZ-d2#N*sZ^F^ZzO#6Ze9G+34Nk!5hNK;cYr*rD*;QEk490ed?tdV)vQt?( ztST_qt>`N{ww>jQ4@A&Af*Q77&cTQOq!`PGG7mbE7yCc09v!U_T`a2C-U=qyNGK~$ zqoq0>ukw8kE-r4WD!-PnTsL9Y*WbE{gcKurLd1y;(vQCgfUN6b-m{DWW)g6fcKv!e)on%3vW{5eK_ z*K=lqI>vbZb?Sp+|0#?!y`Zl`%w3Dv=VN~+SLA+L3m*rvam4pJz<~*WSwZY^vDAh^rW{LGDgO)@q^%UWGdoIVAn>?`rcOF!1;1Gmuenqm zoC1cfQoK4Z#(UG|H!uT7_cE~$r$>1!&_e6}dnMn#oD$?{eiV{B?~bi;w*{YFbx>Z=<+O|b*Q zz6zGhw!$MJ#$=O@vi%R`qH@eQ4pDf~3zUdfXHKb)O_KzayVT$X(SS#u_f-TO)KsGa zBE1!!*7Rtk#jvjm6I)ih+6WGfGh3PVUCA+Ok2oM%3$5hE6mj%4IRm($fP=7!DC*I* znYDWIiIm*F#9dgmrb|$aJLrx+5%kLR_^&-CG);R#+8gR}!7EabN|Ekf=dTFyn*p9;Yqiw5d=h;Mx(nhqp)%UFpN`a;+qS>~e z1LYr+a@GD2t?EQEN;H=<$=*EdH}d^hMo&F){2r&T@pffopmqGWVu#+?$LgP!Pl6=* zWZxR}SGkp_j@Ot?mY!3^I;Qh})u)W=gYe4BpJkC-tEpdMZxNOG`7qFW%S0Hva8LVn z-!vVy54r!d|2-$HI`>tiVYk@sVrBZ%YCB4p^}Wb8crxk9-_Le}p0?RQo~xv_59GOX zoJbor8dc>9o+7t-dJHGus3Z?@Mn3PooFTGlnSgM!1u-GZHwjaLXRhYVcIi$r$ z0e5Y+?>e_%<2|ZlKY}J{CF$4E_u&qBO&k5NbD?9F=840Qj2*anCB?(id7gB=Ju^a2 zUq<>TpS1j6%LK*i{gV?1znT~N!n+c?JSDzOb!m@Ee|pzkl@mr%n4Lrmr)&ue?<5*t0!1T)nk`4Du=PH+t;ruBQM9`^nXxMnroW>DCn@o(+6A=~74cO?Z{a0q3~lWDQ~ zaa1J<`dirLQp6rxxb1JsaSnpgJYO9*^U&GXTD10UhFr2;W-uylWaw$@6-G#E^un}l z>mCBINx7sr{V2k&wjg#d3T7_9wW~V;fUd<5Z5=R7ox z(fGXbjK~Gdv1G(yjNZpl=0g>KqxBv?D2vs(EY836pG6Nyd{jQj zAd}Gx`;a(DC+ZFZq}=KOWN4DTZv(Fph=^hn+3u{Sw)TJ0vQIq);#ng|j_Ix6y9xqkNaXhWyO?tOtIzYAcSUn)42kJpv!()9e>G=e$+=r&^E4>Ra)sb#krE7`QqMHMr_YX%gm|O22Xj@9bC&bL%W|&b6Yz*59|iLnr;WC=~E02*L$L8 zt{2Ru8uk9THs==Kfy11C&xEwfDK5>@+DX*Th0Y6Il#1cmKMR@73tj2&qS` z{`zcjw%r886b2z51AwZ>KtzvVi`S?X@_cqO3)k21sZ&&V0No#dgMe1>%L5E5FL4M` zb*Z!s7V7v6jGl7bb^9mmM|<(<$bR;yWG?0^qarp##Z>i1{SZTjSm@qgY5K489Q&3Z zhjhu7^SM1=+F1qt zel_)1XSiamVsxMSHY<=SeopUWgD2-ZCvpDnyA6}K z2##^*$1~6KTk2(=XjzFj*SAdFUnGfZz-R55HxT*GGZ$j|Fmy(-yrbll7JsJYo&g@P zCUB#Aa1V%u-9Gn8;JK}h+|xY?cGVlhmMZy@{nJz? z-pXaU2iNK;uA$MQGjn2?XHr+H&sn`w%F%%PSR4bl-XW7 z`@GuMXzKs;AInHY?e1BA%f&uD z4?KnY#@VL#^V&cx1-KQtS|g;|vj0X?Z|1MiS#{2vXX#Ws*dL-XTQ+!wct2b1B}uma zf0L=s)|qFHXQ=g(Cwkldeu<J8b!D(`qZnuE;Hw$godL>{0!3+TzMISi#dUJw}V2b{2+O zir1fi{d8zyIOWzAOIzh~u+KSPT41T=tvLlf9y?|pPs5V^PopBDOleKJ-xO8SAPe_j zxyLz%vA*QPnmPvA&l-CaAZ1&+#l)x$KF5Cay70idg|;w!J4aE-7U=_4IT@#qsk>IT=|-jDosM%B)7tj=b9!? z;!_G%x5|26ZMf2TiN9d=z*+G~iqOMDRmK9$DWL~dI`~Ok4-Hl968+n`{-5xXII7eh ze$%*zkdk2yqObl~hPJBM@p0p2)WQzE*1&xH4;#&nZpXeA`%98}!;pG#-d7CoyJNp9 z`802{bc36pZ}l!u%86(;KT&|MAiptk+*O>d2S$O-+8ggP`qjU zaP`hOhpUzhD?^#qlz|kJzV^Se(dcphU3iMfBP(gW$X#O}l6er?(WB4_Zm2c9{7Nck z6Q$E25TC`3`*D~&Y#Y?5Si0&7B)}ML^~j9CF+{r_$LBSucbu!YXVa~|y%GK)#w_B3 zJrjgc)OH>N@$X}|*zS6Ck+eRI+8^e$G#Z}W%jEhx#NE(W-u0@2G z6sNAMmvoW#jL$H-D<>Oq85h#5!Gi$DnJMm zr$~=^G~z;dS~aBFg8X0U6G&q`bbd|Hycr{yDX9=NW~xlE53CgT@zO}v@A#&RShlvM zK4bM*vBr%`c(!x!GVl$$zOj0zjl=adn9XplDN!(+leItM1l)?kmn2?>-SluAi327! zKhgLzgNeF(@o@gDZT-PbuAqsoM#6}-+dB@SvpV2alznMcWi_q&BzZp)^hL3g>x*ls z1u4-Rp`k_1|K{l`Sg=ccIA1)>12#vSfo&63JZ~YBdEfnMegN(zZr;3}h{3(`-2`qQ zJgt%-j;NP}1O%Gi#hX}<*8Hjb4@dkg0P|4xNGi_DL$!@nE?Ondi|PT`guz}W8{Y_B z$@XIY{Mfc~h#lj?fgJYNvMSP%4&t)y5QYD(eZ{1Y`RE}TmbUd`RI#6FrEE#_iHh?) z(Vr;H*f0gGN1_{i%_PaL($(7?Z1$0|P)wXY!ohnO^Jr;_DG8?GMLjzH`wLgT4(k~s zIT{O2p}y3eO%tEi)L#qmhIr(RhOc2U?OExuh6S}r$JPhv>8}+D`dwMYICF_K4uGo8 zDSsge5Fnjejk9C9wFc`&9!r02+#rFUDZG6Y4pbUEXx&^2!wLU1sSM~S%(cT)JI%zj z)MJ;4epud6tO1q?Y+UEKz={^yA}i!+5OABck>$Y)pW#5re0T*ZAkgF!YjAA)yQQ(UvPtyKv}q5&p^!0eHo&Nfj>2a zVEL_$ElVA#_4Gu=-<_%v9|&sP1-&US4-G873)xOZyMBZ0@(Q%`-Q9bzjjM#T>Hdy; zz}@O5)dpaTRXrih?9gt&D1-d>5JZEw-dl4#>-uP?=i1$G9Lt(HiOD%u z!CT4Wi$%@K@#4$qec6|5j;E$YvfK6Neu;4|p(_Vwvo}zKn@4~Z?6XQ`4-4XJe{t`2 zt7U&i(b)v($VJ+5z`Oe<6 z_h*0ho;@?d^-A?GDLx|hb?Fl#MJfGE@iyswi|QA3q~-Kc$hNC5`%Bb_t&|!2`3Tt zQ^{il0~v7T<$tDf3H-|EmhnQksf9rf{5d+^;h?HheWm znfq@AMVHsumio{=+2cFlH0H%Ri~#ipep}!$7&kOwZb_0HPNa+dozSYy{OcYMGJrnp zAwXb$^ih7q2{d&1br9nax-Hr`i*!&WUS75y&)eszd`4rYfU6Y$fuaD1fyEjs#BU!_ zlIzoK8g$B(wa9E%Gf*7#eCpH-Z5h0`HRE$Rt+g)Z2GFyBn@u*(4 zCKtqUKlq((E!XmDeHf)Eb#a=`L^4|>!nr`qgKi$X$E;pO_ad%--xbZILFl`9Q;z5} z6FJ6*Op5i`wqTNy^$s?J>+FxWb#9-Ph4D*GloDVb4sJ{&>+??H%pZ-BZE#y> zmExD2Oc$E>r@u^%(c=p%cs3bfDbomgAS8Am&FyL&}6QeR*u?>G%pOyR#?H}TPvN!yzf4=Mt z0*K%|s-dbhA1;0Bd^Mf9w+fF(7iKkP#b(Aw+-ZiG}`hZQUv zQIfdFH81AhtWWP&>h-sM(xrgYK^RmJJSbSe5KeDi;ym$sGihvr_4w?2soMqZ1FOLn z+{4!(mVoE%!ZN1_Klxn|Ob=m3o@ni0^C1h0O$&e_JBsfBhTQ43{=R*W%V%~(b|fo0=H2^h`$-0> zcQM|4wUn9n*f5G$s&OA3JeA-#bJOTK3gV&n()xS(g~FU6xvf3uU4Tb^STy+3o(&am zL9HJa_V)sj}9!X95B0gJ^Vu9APgV?Kj=xVnAym zYkwDDGSDwF^W_ls0@S&f~^J8KFk)%vItyP>4t1vsxLkvJYUBw!@X#pN?nO0Iras6}B0V!wLDON>QhI^LF} zIz$}Nixrxv7O@mMpzCOjm2uP?#4IUi#t@fO`-Gmaswd?;fR7Q6M?f~z840<*E(uXx z-JaFC1AcZ|Fv3>t#5XkjbdB-=#x@y|)~!Je*vuE9$VPgmRI1UapYlhNypdki7v$fX zr$ClxCE23zpJd>38r@vF_5SO>F&)r*S@$MN4hfJ}ky{?SO97_gr8R>Cr`A1Lp!4(w zy>g=Ez?Oezz{ojf7Hqzx8vD_iAPorF1oWF{LSVQhJIa4iETtqwBKW&IoT3A@LHlu^ zF*VqF`fBb;6OqRBRjC!Xs?2Oo`>~!LvaQJxi~8@(pmzwi`G(;@l@m5TG+@C7gns$Z z><@0}j((riUejbNdr|^gJ8H2DkwI%m#Fs_4__R?8+xm#D3+Svdsyvg0(Yh(!&i=)n4& zqgS5pPLCYkPI?SBCut3ZCC^r`DLaEG=y)ZsWa~iQ76G{1E^jn0*!dyQvT=)#_$5)B zJEz?x;`-DnkQ>>2*G!AC`u6%{`%DP`JgV>2T4xcHjDtSt|jsAyr9@8irs;@%?^^a-hZcd_c9Rj z!viZ8JZ$BOT5WI^kfVHh%;dm6@Uu`s=zgG`ph_+E_(m-F3v zW2cibNko5zN0up+##G}NuyPH8wK9E89w^i_kyYQdBFoAWNLG<&AJ@u&uQY1SP)aai zXN|Uc-kAP*za^h!xv3+Kw*|HX48ynqMA1xyGBVvD|6srK<3i>mCbe)&YlW z5|D}T2rcx&u0g5KWM=G!ZmVRf)DFj#WcF*UbRix;-j?`_Z*{7dQf^3z_O&~BkWPdd zr@YdqmREuroDDVyGi9Jbqy~EpZiTT}mhZn&uX;bpnr+~GTutpRDhnGJ?iGjSh#Dss z!0*L^nKwKHDuXE*;8m5qn>*6l&?HFdYvSTg!+TRUb_{H=Ti<>XIbqmzce;6PsD1%` z@~V}hB!S~ylD73yv?f>nT)Wfkin|@s*MWUe0E%B9A4|%@uyPtRTAIYXO{WI&30;M( zVtxIkeRvfiT7N=i{c!-d#oQVj!^+u||6RIGGfqNXiYw=y>PEMa>0UC11sJsnO#)k% zJEU{JRgi6CB3Qp9>C)8#c{!5g|^8 z7bi~F$GiI*tNXn>yNA8y{yLlX%JZCD#}nyFA6>q>rb#Jpz9T|-6D9~u1ocg^k)&~| zl+`qNhsKNO#ngmj=s7M|;4LEm;WI@gX^osNfhp43NpKno<+TXKR6Q#dV z4iS-3C|LmYK>2E)Mn_1PZDw9%Gpc)Nshf`B{t6V|TCmpu=>KS;{D~3zjP>0(OBu}` zPViLM6~5K4g3yl<%dwR3Jv5xQS9vU!ySsqYte@Ycmt>yybPS zL9*m$HorpHp%yyzoLAW#tQ7UfarB~Z=yJcaTuUL%4P zsoX5+S%%D;Rn-A%=e$NN+|CJNRGqGx}Kl7MgY zWAUk;byGAgea$ir7c+RJWsvtdnBXQ-S(v4y@yEy;s!;oJ?YBg)aa|>;+iekkfV;Ni z;044V=ALjp{ZJAmDsf5h@5(pfFBuk{Z_|}i1uX4HvNv2+AHM8B=?KG^+-H*fx!5-+ z(nSmf3OW8Z%q$2ZE}J*7Mu4*&Wk*5ip$7OJHPh?n(pjAjz5r~04}ZjTmczdjMB!c# z<{b9Pb4NW+k!8PQGvbXO`B3o}0d=aW5RiS?*BTH)I`MzMQl8i6sJ74V=OZ<)%1S7j z?G{9=GuLK{NW-6z=Z<_m#Z1sUV=esGzr&o$`xyDFluO-kwbTzg!aKhu0v`f?i;=TQ zdahM+3;DiPVILo)eld&i53w#;m>$Su_hlypaNY0!mc~a91)g8ZsQCElJLvqQ87`TG?VqL;~U>p|LN zRGa`W7PbGD!DKMD^6>d5;DoxQo777?BvL~m}3z_y!V?uBQ zp#lhE59wqk$)YGj>N>3e)XJzeZ=rheq5s1FQ4n`H1)(+Ox5&m%bj))esQ#=1L!ij| zu20~Lk1#K(jN&;q6%vqo!vzmxf0V9?nyQwvT#LJv>f6bbEKe=cUZ*(Lm}QZaZu=uH z8w*6dKxe=MS95v6p=0^(51E#gaEO}9{utE4F4kyHiqW8689ZRan8SJ{(Alvc_~>1aP0 z78`-3lWYC$2kLxA@<`OPVyj!_Z!)N^bSo#A(%&V1%m3bn@r1ie2owW&%f}RRc=&n_ zY^5JxNOKiv{VI}1y3`FkwW}OA41_XV^JfC?J)4pK$j!jLWkTLb^Rsw>^*nW(y1~xi zKg8YSba)YS_KST19bv9_vT?1)qLvSt!~RLO-^>EnfciwboS)PHiK`prvuWJvIT~|J7^UV1Lidpgy9QeexC}~7@fXR-R*`RY z1~dOCMYQ$KEwn+&xpYhem?w&^y%uW1Ffyn5!p8EBi*I3VLHt4O~CFrl)d8Jn`OE$}zLgC2$nr>jrYUNN=_F&@ztLdWRWf z8_)i2?bN)H8{w?mls7N-jR`t>gb@@uP z&i}p*!|6$vGgv^Eif-o|p59Pmlh050t}IBouAeZ5hSZ7-<$_KD9t_DRT`ma%ab5VC zx?FA=$t`bMNK(cFKWQba2mj%q4R}+$0&E4N<97-c!{V2W%bBk5@PUV(uQM&f^~}kf z>PL(>MTj|4fO9CR(B|z&y2k%gAZj>qDZ46Ssw59%768<0Adno&1e80RDC!zoIDNo zEqi?`rEQtHIzXRSgSilUMA}#_HK?zD>nbY}GKAXKret-N{rxr7L$sbe?Wr8RV~dqZ zdS9tn%z_GYDy}p?aN8oC;Qt}^?1iZQkLd=@FF)y{)jt=CIX+x%$t%KzEr zTGfSF>7&1K>(Tu3R7Xb+R_RHxp1L30zyU3amyi)w_Xn*}lBW>xhQQ(kO+^UbIt~$~ z1bEMqlzSeez7XAuGNV z|C3K>`RlGOl9RevAe&Kdysk7yT=4H0QBwZ9jXHA0XO29|Ba3r{Bl$T{ik4j;f2)R% zVS425u#YR@HK$9|KRVdtpG;lqvzCEy#(M=SzwBr7SHurm{X2K0n}62z`t<(kF@4ag zfi%^H+21&`IzN>n|6VRD6hReAJHGi4H#DSYz%;8o01n@do|R1@oo z(^7uuxJbdRgZ*P?B3=A*L9C9c3OCrVXc^cCxpvN+U9n^5n>LKCx(rP|`_LXY)(5Uq z+S`6KErpOPlkVV<^OVI5z{<}Aj+N3%Y))@J*SqiKWIE=S4hW{q*2 z323@wWlc3$mLfBI8UEYU2<=O>tk|nr6%!88KKj3$t=ITBjqWx_&vHa72YQMmFgm%r zL?pUl+WS(UYmz%l9L{i_-QrwJnc7)0|1G`5nXlu34HVCHs%s9Ny3VRs=v`5H>e$o+ zDEe1bHwUQOkix>&TmRE@C)YJnfz$BSqtzNO@3W(R)L9jA1M4cKqDT9+e}_>5(v8Q# zZbu;HPZ=ZO!{AKo(tYN&VH9-e;t{++u%)UM z-l0#Ux&JY|PGsKi0a;p_*5|lDp>7`&Ar2?^`_Np|{IN+`(HybO8d^otmX0n^qOtjo zKkyusp$uq%an+5#b;rj*Hd6Yo+yjukjmw`$$C~hbh+&s|D+O(xED1bB!qwFSu&4}4 zL7)18yK~K40iV4k@s>a0YR&|ybmZ5`TV2!Vn1thxH(8%ERt(S4*2Cug z5xG}hfC{-#1IWffIrbJ_jujL+cAP3Pxw^qzeTAhF=|EDx7k0ktR-JzXionEkpsWIF zvagQ0iN*&`ma_-6^=#*#&kxOEwwSayrkloq>&$JzF)`aQge2|ih{(U5IQ5CwXrZR9 zBo#K*5&X#Q%|1D-sx|?hiFA`Ay;ty^=HFx8##@_v`964ADgIjw4JTgyJ{)V6%^&x} z53EK1a)ntYcp>zn5B2OMD>Tf_ZQo3tF0eU&=vk(tlMxcADC}C4o^AQ#_jmK3jmKyU zRa>Xw^;`EVv*x+E1;cBt(KwZ^2CAA+Wo+9)VxyJ0QWeq{ouHwi3cK(D0Z6(wcW*qc zPVNtxc?gYl${C(u%%&Wj&JEsNTwwN6T8s{VKM}y0@VAe5?O594u`razJinrx0p~g7 z(`+cXK=nM*MlCh0^l_QsF8AUIk;<3a{`SfG`tX74@bDSmxP+ zU)`yzNo&o|Si~E#^}rf=p2?WKH(uQUU3e`&9cG76W`0Zr4aD3xM*M+yc}WqW7>0=k zN5~<~k9{=$QnJ-ZXfRXU5QifnS#0*$L01^zd8Zx$Y76Mz+ef#Q;oa{%H_UEeO||zp z_;;;PkTx^rc9~%`Uw^d(+B^4}2U;(sxOB(McT!#mf8`InN)6StEgQz70lUU`pTXEs z>q<~j5QcqPT)q76Wb8eZb%}}|KFxJOE-O^SD)ob&D2|XtKTHD5h+%f@lkt|}%TEov z!XzH9rucGAT#Mqu;zFGU1kw#)LW}5*GQ5k4c{_unb35T*=FATV*0#EKr4DKFv{L;A zxM|B?Y-dd1X8sjg(@d9Pgw3|QMedq_spy9Z21h)bTbR|qZfm#q6V|_JY(L*wJb8>O z$}qS)I^K5PkMo?=PdIESpm+9Rotg}d0mUbi4?SN=!OIVZpkL;g-1v`q8t;gO1G%SK zcxWlR_ga)SS98O~o`j@mifuXa^LSi@xQdq$L~a%|#OIy*3E0nn>m6v>pWj-aSYFQU zfX>S6TA$WSL=UpK2HRPa)x+amKmP-B|HDP6nb}=#F(JyPMFYd*(x<&w9a$v$vR9OQ zIT*uFy0ifl?7kg{CL!h1bmN?1o6)g|6)m+7dDe6zd1 zrhK~_d;9mg|NYutx|ZPSu`BWO!FO=ZW(~L5pKPz`~=P zo{vv7QHPayRo<5V)}dEKdm~HEn)`-4DL8=MxLG#LII*bpKzOBIk72vgZgy!f|C(v%! z5vydZr4{UWnLhqie{y@>?IQjyw;2GSW|ut~eO#os2lFvPQ=x}69<}cm!Dcm$;is>) z#6rKo;dI?5so*F%W=fuKJfXmUFE{}P1PJNlD@-O4r0YQ7S zmXO144C>X7X)fhetMf|Q{Y&fxSEoycjn<4@XdSIh1vu=q9j)1?skF2>&Dpp{v)LDJ zpfmLNa(v~$@mGt`tY2C_e3N#B2^GZhMxrmrP@K<&{6E<9|AIPPvt zb42a;#8`_YdJdC*wqjxc_48lMF0Ooir4W@IAsKNB zOHQCQWr_%-?)J9vy#1a+okoW?I!LRI{luSX7HX`=k7{aQe&bAf=tA)4;thDPs(Xd* zoA%_E#0pkGC6t?G$g!;5@ajjZRl~^hi?HY8>CBW(EaF{m;bY_ZZ0vn=_i5uLs|0OkI`F6%P4lU&q^1ZpbXFvv@owsbPb0f{-ZF~GO)#p$j1td|SZjOiG7A|9WSP?QNF36B5N~;RZ zfmT(Pg)Okp4-o=d^kf^9E6AAfoT8i*z=X!i)d~L1;olcB$ z*#U2I(!qN{AiMpz87l=%-`>z``I)9om}3Sw)z{_bh)zPJfl@1zILgy+7g}^CqccDu z_FM8()dN=_uxI-o9331R4QWi<#mX^BOo@0K)$t>hy(Y`fT`N{%y5-rs;&6$0+&2}o zWQ3`~-`*G)p(k^1b?<9chO{NGCUR>nxNr*Dya(5``ELBgXJ@Iw$A0T@NPux_a! zOq90Tp>(Wc=gHeWnJ*-r!Z7rux6|lb|6=GUO#NQ<5SJoOk5P288?`!RR*;y5+IGch zIE6u0(7WPf6R^b?j5=?GJ_gz<6+c=Zc9mRsYDve#!iF4~hJYN|hyH+fTR1K-(BSdc zbsPp)@LMeIhd{8hf!#?c6lpJ3K?$D%xiE}CbB6E@1?>LdSzFjo|n15XMNz7UF!gbXa^YXb!z2{k9N-y~}! zR{x7*EO_R1_IbXSARafMJg5+S9I@>O_(R$YxisAqeljD{N#DnV1qXIRE{|XLd~!r; z7^q0W=NT$H0Zq{vubh_%UM2SJ(P6uOpl%O7B13ojO5RCMbU=f$WBpa8Nb3)q9POnm zdx71xU~O7O6K=rYZu6CKg0?vdL-T92QABLbiZsXy-4pF;6UpVS=Wf=tk#RN6Z~VI+SA68%NdM&{qGnW7dE!c z?LAUy4c49d_mY~2E(hj~MlxwydY8wmo8NzzI9T+ihibxGytSZ~pil4&3bCY{r4^{u2k6IrADEZZUoYmc?IA@h$EjC_kNU zJDm@k61CoD${*h>*55X_x8SjO$uLLyx@6{dS3fK(KW!F!cruuAeeM6y;dYx_XOG*g z$@6A)rKenB1X^p6*8aNNs$WE1c0B`ufRCDW>#Yo5 zXV`ir{Y{^sFnE`vTU1K_{i!|*=%Ox#ZFE(Ozf#L9^NkP>|{>g z44zc$!olsXzZKps@=KeCRR#OgKnE;@Y$d^%O@Fn_W6{Z&IorM@hsEHeu zyDrL9I&U>-HgoLKb)M{Q3Zu@QDk0p8l&blbAlc)`8ZmKLQ&C(Ps_~Y}s{WG4IjqfX zM0#)hPz^aE4E0D3pIHT{au#%FfPZt=N=oSM_$w1_@so%C@l0k0y-pYPP|IC6iF zV+Gg*!$!tB-bL!he%UrZw^!ai|I{)(L(Iv{L*f z9Mc(F5LPZkLdP8>EA2MjjWt9ua#!>RE?}8yXEuDUDU?r=8cG>Lp^NGXFeca&X&94B zFRyF#&6~Nm}aS*`jq=zty@G89X@nw9-|Hp0Kyr41vp|p~ee2^9BLX zMcH&{nsvAt%Vv)R7(0Y^3VwthD%b7DYBA9)7p83gqNNJ8OUdb!aEn(>sWi$RilK^Z z5q6C#2V=^lcZM;&6aU|3KgNlsB%=gZZo#m%@cvr~NQ@}1f76br=(T@p2GIAfVAR#a&+t=h!HCFs`yW#aU56dkEHGeU)pfLof@tOo7Z&xuxf}D0}RJ`1B ztn{k9noVa>sPR^YnV%FTKMJfs%5|Ee3|(TQ*13|5#xVjA*zL+ zz@7+Q_(cL){+P=84_mak>D={paa`#T?A@*IIyK)8w}{T>_+OKKQ4+*cqE~wF{~BE6 zR!DI|x7qr@lQK5XD{5Z5Yvns;4s==Diy;>L!jqXRI6-bVY4`^(*QA~3)z*3N*%)p2 zm-J^XPa1_^wP#Gwd z$f%ge`b#!Jr|Z#Dh~PG-3brR#+k0psSH*I$%!^=81HN7rv%)2thu1?uApidnh!(OE zYYtaF!_Q?acg6)^K8tv{aPtYhp^H5WmYriUxzHK5Upk?~hN7O(v7d<0SAP_ZP~MSf zDNF6To^>s+bm7FC$=q#AdVrDlpzo_Ce7+2aBEN$pW)BT6>o;ZhPTKbzFToL-g@wJ! zP79EESRr$IS%!We+yHFgY1dOo>n{XZEF~#wKAcCRO+AIdf1QspB%+=L63>Qaa~`Qr z9asih!dHl{bd7>gZ79CTX8+G`t9@kfZ_Qt2E-fUpS3 znOM$#Ovc(MhTJchEKRwuk_?Gtr?~Rct4IX{F*)k`g*fvKc+Dou#D<4Zc+K2kP4 zC#@$!n1CeB8C{g1$A`DO|J8F@^4wd}_XGe}O63bl8CAydmg34c9rkWpVP7qIfL3`A zMRcQq6~OeZ<(1+@Rp^uMK$u(wfG|w*eS$cL%vfZR_&ceyNVW-AL?|jQ4uD(#PRM zu2Q*x0X?RcG1+`Vc)UX=sWlI+-m@?ZFGl3udIlG}?P9&Fm< z3lEwavc*I-IYBW4^qhuMMtxV?qU>pYLFjUd$12h;j1LIgjP;~?*n|oHJwYSi%Xd;( zBCaswWxp}-#LfSEt{R-Qetwhg<~KeGIzz^gyeP=3ha0&{qiI6p$cJ1C*|9zZQX*^S_mYet zS%eh&7;tQ|Us;Xd^aTw3;~rN4Op+`?Tpz;3OJF;U#H&I?&_eF1Ao`LVdP_w2S4&EtV|v z^0rZAX1C6nL*kZXH#KXw+MGmUDRld0`Jcj%*yM(tJa5bP^*#YpTLy)Paj~*Q2PMbSb%R8Tq(EDX7bJ zuMArrX5g;3lEMSJnqc*io|BN*!o_S{3er5zfoa;^(W4VXo_Zl8a?-Nw${{CgB*u;P zea|oJuF^NkuCA_{(&p9{%xI#k!>6A%d{oX!uUiW~t_n(KNS6QhWphS>R7Q_nda8Hh zo7KzDY!3$TDWc^msvv3pcF{rR5#rIEob=IeUq@9;eS9KcNPJMG+HGALw<9ERP5sNH z20V4wO)e_y8=>;5keI&s>PZySMu-Yiy(^P9udg5U=fmrt8k8lY$ugg?3pP(i=rt11 z5LHPo-L{IOAi3%*@tPmH4`d4xyu3P&vZab#UO$dPEJe2~R((@W=tBFd$fWXGyjCaN zL#oz}z*%?2^ztIgvs`s{flB3ZEvkm_dvv)KjPZw@3>@`qRKIeX)X!^KwcS29n9)~< zN{9Hq#Wj0d6Cw15z}OM;?9+n|M@UWzgGP$O)9<@oF)+b|i1@wV=uq>>h*3&fJ%w1$ zInmu6ZDx_$P(|TLFmfd9Au|}6n-^_U)x4STd299Ez>xcaKST(r7orn!KU;qwvBV5s z3i=}37t;VeXCWo{XF$bMZAWnM;sf52)~6P+_kHsAJV`$pBvrk5t6#oHAJ`dy1vaVc zkd(|3mTz+&^x1d9?Cc5X6NLEmv>~%I3?^{hx6l|2IzFLuh0ujFgbzWcpeBvB&xeTk z*}u~!r26G487tQ=FP>fQJN%>i^6ZmqkzuX0X&M`WGD z^+}t*Se67;GndDrhLsC6cI3%oPO-EZ8RJqsb@xu^H!Xh7P^3@O5{y8kAeJnd?g2^y zR`(Zmg*;5%lnLlRtDF74Lp5!%(%mQt5`Pe-i`qc69TuG7T5^jDFA*h@GpdT1mSpUF zA%eyuVgsROmkFWS@1Pe!e`qDisez93RKydaZKn*&JB;w0W?ZUC2{&Vqms}#Dqo8j8 z`u4Mgu7z$fr^SdD1bCXo$vOdjqrZ+48Q!$izF!@NpUw>yg$?dldDMZ~kE1>;{Riw^ zI)Chp@r-FdA!kMi1>^A3d$GMbew~CtlCP-yQml2MhZ>u1XEe6#Pl_`pF;k~QSLC3e zb2!{CGt50Ai1cXA8v@SG21RGq!_$FW8E(7yK&}kYCMh6S4qUG1A5mD>dYIp*aYE>~ zt6lM{KeKg9sGw8X1YO_>jfLp4W8m$n0D+yhM#k@z5zttszAwLh}NIr*wA8 z%?Qg6J(WeKcohQ$)BAjd5+Zv}f)$sW1tcwWkO@VFsK&Y!Nir=?ud(^=?BXfion4Ft zRLr*ZQ5PvBH}rL2ruHynK{=n&fqBzae}2HEYbD;Phm52bM*oEG<(-fI3b^-C9NBnb zDm}imi!-J1h2n=m6;L-yxGJEcHsZ3olr+AXqF?t4xpm^(_uX>bK9yapcl2gj>_WZU_L+j$e@GIW4tnNKIK{ zYQNFPK&pVdJI?`M^F?%HygtNN-Ek76;V60N&Ze>~7bg&u9Vx>2v#t($wkckuD2q4s zi_5DSY?6H*_T7V33`|zOxcw%gYVuZsjwM-KuiCvvcA0E8d*ON(G{GFqL!m|#C7U?BVLQmaSQ#n4?;YY-$g@sO5+L4>m7s@iZ zUy`_N##Mlpc#Z{>^=?}<_-16Vf`yXi-SM@X`n__k>q4n5(1 z>5lnzIF$ojP8L-$^pl5uXPr1wxUjDlfx9K2 zp(4L3E}P0!aLHmdLsl9t8LUd3>4J@su^2i%ljEXk^B(G^3Y;?uDk?9n?O+KUj7VI&BF3F^YeHG+pxQzWliLN zvz*tKcakf*3oT0j6SE>AR2j0KGmtk5s17lEZ-|U5MM3;vNi@%pJ<0JKCjAzz?a$}> z_?VuLIZG)d@1H44VjdA+C`?jr!;hC>NUNKkP3I#N^-g$Z039W2@+UxmDz zl!0+vk#2*vZQE{lmW6yjEDjyh>GA04@wQ)qf6uI$ zQB`u|j*;fTW#J?VLkZqEcsYrw2!$k-BdqRqPzBy-$LsDe2_|_A3JElc){2$CHsJR!rllK7-EM3NgJbULI#W_Twul0IiX#HWHP^{RU4`9whgywG=4&^ui& zV}${wS;=9Rg)JpY!$>9ZfzL%utDq-xhR|(rq6BhEJplXz|DJ!)%cg|VO^3HiTsiQ~ zlOW}07wHvqnvGycfDmYQ!iHkp=$r5i;DV!Zxqp5CwnqjSq!QBa@m}DFTky{4 zqT$hp&*y1S{OsEF(&@(OpGiC6h3BYRdw%Cfaqs`$61~&qS~IfDXh&P98rSuIc}*M~ zvDItyksW(H@IwDUhVO&(;8<&enM7?UZ^&_ywV&O_)vgG(W_OwnOkniSnb*aW;6_Xx zDd+B&`gXlJ7w6jAq3WNe{9?Q`MiUWP>5S_ayEijrrTRQX#RrrFe18&j4@{HI>QHfA(T59_zl5J*tR`;A`P+V3Nx z+5gJ7&qmsk0Wfau7^aPG8$f{1-WG9b_-W|+%b?f)M3-A&rJo7Q^yrM4hx2NwnO^~5}{v@x#?4UX{CB!!# z*RP3@J9TS&Mb4vO<kfbERXsWd0!`GRx*VcePQntM3VK?808I0o9<8qw9$km z3!3-CB5_lKF`;{Ad*K7r&4TbQ9HqY7FUIXkYTH3KBkYy>KI=OI=s|9MCZGin6zIKZ$i2=5s7 zFGbbY_PIMx)cWF?3xpCv6^oYepZ^HaWqA|=!?hp;-psoJW6}^vA};1v-40|iY)QTD z&%7f)@HqqWb2n!*cnJOS;+T~Vnfs|;gzS{%nz%*pZwTg-gkcqyKV%)etW&(p-xBEi zd>g=>xGaSCu+Q*F)jn@(_+=dIV@ci2-Hc`LXUy>5j2%%>UqbIlnj+J^Pe$05}d z{tKOr+D3>;I)z>g^%#uRwNW9Er9L~A3|X&9mLR>LzU?;*cYyN~qH0bgm!M1EbHQ>B zYpG{;y@PfljJp(1iRpjQ=HMa~nsCiq9cpzShrcT2Aq=2Pv;4swrz5J09zn;SPq=hq zJXGRf1ZX2+p-LJ=sOw|e9JA|>&r5U%U*U>Oa;#=1jiL$9)Bz;6qYR-x;-X;y1R5Vs zpyL36mbO4bmstM^Lpgf)iQlz>xm$5rCKCq2u`xUxgTxVqx#s)#w~F{9ylTfAiy5JGVHh{U%7!=X+CLZ~41L%2`<5I%fB z{S-1WF?Hg&G%B({40S`g=gyeoU{&tSNB^r>D_>PC0>BNxY!L654Z1jBHeU(>vr)i@ z(p=GU)Ule4oQug#-^y8;$Lu_f^1Oa|To0X-hqHxSi95D%i}oK|xG?yfzLv^iR=4jD zXks8N_C^`$OzaFsJ?8xl`fQ9>4$i<30RxK!(|N5*8bD~G$C%7u-aQko?$7!V1R0AF z4Dq`>iw%Lk5pQVoEdILfqh&_SP1sstZ^y=g`@X}ota8?b5xnu|YUIVp#|=Rl#jeozc0QaLG`suZ6+QMv`PzMJQQJ!VjlJ9C<YzL z)!G_Ir+2+nDCdGD>UA~lUYLyzfxP$rGn9i_(GAC4hy1!v@`dPtX5{?-%m8QxO$6NQ znqxNCc3~fz>tBZeAteT5qh60l63B~7qh~hz{D7ElznJZNMNz)KH8D|AGIhr?o;G6tGgQt=nD*$tF5wR@D<$wgP}T@{yrQ_u|1-al*1Da zXZqL#cM5F!JEwRW@}E($e zlkJ}W-$rrfDJ%CU&^zY-|2G>>DoJa+V*|4bF*N9-EP4R+QgBks3rKAroYXeYPVkz=?#bhbnmm{Lmeh4U-#mljx=bKBgG1oqek}{1< zfbKTPaHH$o(Wn2<@n{6Te)G7;S`>I94-#U!50XLnZ*iS5ZN!G3b-z)_N02~oBoO3V zfZ$64DJ{VKK4?x(O|a0-n}0ab+U>O;w|Vmycw?%0NJ34>jd+5*3y@ohyY)EEu0hiZK3k6! z+P42-U04?{S9nWzSH`*t{+}||^ABGa()vqdpm)nsdP@gimUXe>!ZBCWdTePFy6WJY z;Jb?0H7nRj?+!XsCWbO% zWz^v*Fo|x+RrSZL$vZ&xBi=-FT?BR#Bu=ga5k$gVODrPvOLUqe2uIp~H89RMo=6Pw ze{v|9LAlk=@JxpEIb!Qerw7zFD0R_9pXiw1QoZu5BMW>jIWqmidiq38ZaiA{dnKV# z?Baf~Hg$C2!X-mq@+<>W)Wbp6y;AIgMvoT(q6umQ?U*_<_W+sJSC zM`_L->e4oQGku|4Rp;*>@DV==4!Kz*-*C>24`*FyU8p6~^vTG6qrigT_qHOaVv6gE zNzGrIJY_cfs@>`(Vh;A-wDeCcLp%k^R{@_c!yy5$pQe&Y{o>%Hk6PtaI~tY83$u9N z`)BS8g}cT3q5338Y{?a;Ry)B@>Xi}Sq9l6qku`HqaXJWbgbnRJreIy0UJDzT`>(f| zJM_;E8qo(WiJB(0K35{E<~TF=zCC)5ik5rHp%L}n`l)Rw@ zwTYvAXLcNNfv1yCdTwLJ;s*^Uc^hX4gG!>{qu|At&nq9d&Y-<2T^4xNzfJcvmHU<6 zr3Csbm21;ydUh})j)wk^mhaK7?P1ZrE+>lyMgNS~7lL1}quG44#L+|BbU_u*$7IB) zcK7MGuyu7szty*WnQOHkK7Bpv@-Va1sNjoO0Y5(K5j{Z$zjMFmiww*D#qU3T#}Fy= zHGZ9zloca9`fW(x87!jm0Y*I1n2RYb*Apu%pYWu|Ki29|$y=&$>~#i{DBXVhs6-4Y zD=wp`I?XWrsHVddw0yy7@AIanp}Jtz;9vcY=WGv{*2L$&rWN#hdk=k!$?9Rw$Q(pv zcv^H&L@c-F$I}#7o~vHu_JOT{mh8PM#S9aw9X-9O&!e`o;;PA|13l-YnpWMAqz{U8 zBaKU#a@M|aE$<7r{VC=8pECfx$mwN3(B8^7=ng+fc$1C zg!h9CBg+H!B+;_}hpMlPs`7inrMtW1a7dBv&OBYO`FwS4?7&f}I_7xdu4)p5+ zH8l;vc#0S5nsz>s^HoOX*h~$HOHA~a&p*a@9c1(*BF?u z)!lEeu#6C~tJUieW$uG5IDb`M9VvCI+|YkCk9vLsd%0EfsDwD(AEer%XZFf}=k3*o zK54k1d@VgZy&oY%z;$0AKX}zy$eT%3YDmmM6p4!D+FP!_E&^WwN<)0x#GQj zzSn5^4L#htR7C1v0gtBfuhCe492nkpfe1Z4ui~o1bjL4rMOyoG@vB%W zVO>HPtd7Il#F~*D(L?;=LX={&$#+|NX0Q&b5}pZaf+`X^aVG3GvHCYaDF~g;zQHdO zn0@t%N5ekt`@m(WxTnZcS>*B|Y4dY}rd?;G*_rYEclKGpwPq8TwSWc8-hfm#+#U{Y zj9b!HRp#E?6CA%*Jt&c-W-vaRz6{|*oHm>d}0%X89 z??*(3JH(JK{_kBW+Tq5=zx946SMaMe)E(YuMsU`Q!fAl^x~$3Ma?EF(pLlCJj`1h&{Fe%eygcG4 zm7Au;7s#X^;$@jM_1%uxWOtpoE?p5WJN^*E3Nq>&6q+o{X--cylmp;3pY)qA{DXS3 z5hi_gilwP028`d5y0*DlMXYQcqH(R2+Ljn{i&G=-)W$5g zI@BnSB**u?jR9hhE4GeRC8cnyR@sJi3!x%Nj7y8jFjCUwHJEj-O$l_OY~LzR&B=rG zDQt-=n=b5xAa-cRALACW5?V=@SQfDg2${8+icAbj9M$V%)W1tQ-q&K{8ZFygqKmQM z5P6ThJDPJ*Z&S$FhHqZq{@mjJdsZ%NJmH*4y8(YX;6WOeH|-Y(EPp>iip^>>bxela z$uk-F2kc*o$$>TpZm<4Jzhf`;*@>pf3HcFgCqDv0u7ow0aAQTjU(bG5M39JIxS3BW1Ti_3yIKkgBU>6-WVk1sXM;^t+{ic5L*$oHMt`F!PZ%Yg5!)U}(L zjy|I->wU4yqRGRoK{{Y$iIoHCX#6U?H~ss=6sl#C4^!pAM_IrhV*g$48DV%O`U~N6 z@TBeZ+_Ug*ZOX8ms5HH{3{>A&-)T>xX_vTd>%-Z};PKTlH=iUSXIy>@u_L@onCP@g zRaYW)q!Qohvf4mQ>&*oc-Xe?}w2xLxETMKi!fZEAMOgkfha}92$bX8onk(oH*tUhV zM)r1F{TyP9=MY!6lN6R3ha29J6L!N2c0FBxMj#{`t8Lj>?z3l8{eo3TSx$Fs#IO|{ zBrF36+JjndZtHuQ!=Zld5|qz^mXXjakTFQ5OYwBoVAX+?31EZ(c(^LYnYd4*$+_ZOZg@{fnl(pwC$D_yyeP1dJX?zio@u8d=k2^~N2nh}|b${qSL?hK_&;5L$BtVx{RG)A)3v)Dp4r3GWX{jkHTJ z<&0*Tlzj!j% zyEYS4y7|ntp)_-EM8PxIzEDuS%!Yiq9up~}Lc-#4&<|vMgc@v{U&rNB`zJKVN0U&i zn|lA6Y7=>xAFbQd;G}r(s1y&}JlcTm3sXa4X*g8d{*J_@>EfV{fCotT51#nXXs2q- zYzs|av>p*q9XH1)J=0f2-|9}UuQ0fngwn+bc8FSH3p_CgDx-*U1=}O@ zsjzazPA*9TD8MsW`AFAPA&-xH!f?-{dE0%GAkMJYlBJoB_g9zVNVwe5S|{grtZ z;%&tO!?d4ixXbOOO-t&s1^WZz6C3ySg$(9B(jmjgHU}bR(g2r?C?&r8Wwpvs?-P17 z@Qht9@;yGY7F|Cj;w5M(Qa6LYe;XBe*eb}a^$M=l1mSF1cr-pK2^@GSvC{mB-As8mk&kdOLxl5@qsQSi1A zvV>=_o&8m4dwEDB1T1O^ETS!)u++g|^ls9(Gd#+YV=lGKHS4OGbU&E$BUNzYPs`&- z)p~d^*8-h_`4AIE;+#I&pp6?b?wuCj8dB?y%=Js#dp|HwO85-uUcOhZV~ncq_4ybuM-0FKJ*|IozTq!+b}D%C>u zj0Rxel+IIRxU+Qo!6;YEn#rJp%)TzLP5HV0YKcG%{C8`ICZcP2f8$CD46ptEblK#_ z`KeXPV9Qw>S+Ff|9Ib27)Mh^_u$AI{I>mQD|EN(YuF7WeMQiNQXM*;qi`Xq&WpH1V zw(@AQ%4+r&cUI>(GQ0^!5>xL7A5GvLafK6|fW`NaY!i&3=&UIl=aQt>CE&$^`xB*|p zY?Sl=0L=7A1ZM=kA^pUP!P-O=&WiyiV9$?q$DOoo<|mJmIp(c@9z1e>F@4wgeXAkE zn=(X0<29uyd#gM2zy=0X*FSA@4b`Q~30TrmBQv|B^5&7_8Kug}HS{R4Vwn3r+clnb zmNVG>*}~xRD>qvw2^!f`+MKVYE-@_r#`9Vb$6~T(#lonFw(jEBMf6^t05@(s_5~3e ztynlz>kqMT3VZ$X6RYyq2z=i}Mz1kHu7*p{(IGMpNlfcGK;u7cV}ePjN$}9fG-M~j zt!{Ue>b3WNdW@@ZYD90P+QH@kYh(gxh9VRAaIdR7TUx`)y7koe|6JJO5_ru1O099w zx%TN(Mr;|fl!cGkBZXYC1||vep=xWvMLvg$)*V6nQvxRBHn9|z4n)U;SRkCW213>A zlu|26{6QiD=^7rw)%ynL>xRN(t|^Jfe&fDuB@-EtYXwdc+>HEoaEfzNC&xnMR{f2#~dN=UT~d@ygL9oS8M~v(9<`zWeH$gQz>*YC~m3((#)Y zk1=m1uBwCTL7lRc#-Nlyshd9<;PXR=+Iu-<0#~cA2*z=acdz3XOr8nJ7Cz;^ZzCa* zUJW~aDd?jJOQoBjq8xyZ7zf%Q^r)P)bDLhdE~Cf%H;}cp(B7+M@Dt*JGeHA;*G={R*NuwUj^NN>Wh(x zA+~p7?q#XeNmpE6XNCl!~7T_YV>xeI7ENt_U>Mwc5{QrnvNx=fn68n;~(i4K5%pRHcz@XjEvgo(EiZ)_EmKjzY!$72-fPRe6g zZyiM1URf2@lSbTusiLn&{kf;I$`I*RP(Q&BtlxYY9Z5Bc?yKJ^Cd`VLk)gJUxUi)nRKYtE&=7d25ife2e7U}yEs$RNDw zcdkQz4NBFCe^+3XB8%__#5t>G+C^|4@qzrH>(rFUp zZMB121E75PJUuYMyUoZNK)V0XW8Io@xovDwE9yt7K-o80F|sn6=Uw@BNEA`0%5Q7J z=SAM?nkvRMgeJjXS52j(KmDq0GE1C#HnNtF*e6p_I8fb_Q!E`Daup06bo_WnOhd0N zS{RxHz(t%At){DnG1MqCDY!*RfAW*b2V>g5BRxl%WEfvls-2#>Ni^dxXtGp*Cn?Wq zitLawlK_eG2dd$iG(rAF5BF(-O!@xIX5+D(a-gF*kA zU7lAUH5uT0LC2d(jXrhuH48>a&5U-S*a>TeD`_2o!e~iD&b8+Lf-yCvPwbNX7Tby3EzNkcegorxeA#c@w7J1#H zP!y8d.RQ~FT9!SKj8;=7iUUL!hB8y&cn^5?|}*^ug?q~3kV=T~xcNz{QU76wU# zfdUQ*NKpS4wHN16X*9e3{&wBFm|X;^;@G@-Q8|?q`&U6~Oi6{j>hGW+4FT;}=CQGe zLPah6kE#yCQnZe@9BA=0a~imM`&xXRk5u|9eum~})zu?Du|d5~B-G4Bg^~1n>8bD! zid1H%<3A5b+9~;OpzDb{M<(?TRGGhles{^bYvb_EYc@XTD|TwQ{Go+Rr94MwlMSL; zu*r*)C2~)r-782^rZ32u57);!Jy+&RArN=6*Z(s_2D~w^d&jdNvBpucMAQ3>L$gldu;L-yaT$S6JDePyn7QI<@Jl2q&-uQ*y>=dN+ zytfFBHC+)tNPXY@ra67tZIwY%?}(N0SUB49yX-d|iR0z9_d6$BlfRsgz0d0|{5CdF zsCJJ}kSM0Wq3n6bKFSfng!bBmI@U2t^;-a9IXW2gkxA8dK#p;Xj0bDR&b25fb=z1) zr}QZyW`M68{iZZMANO3i4JqE}gkS*jIf)~_oGB8N5o;t$P@|Y_H_iFtyzDHaNa&JB zmxt8*h76;mfv~ZC`IRHWk4^}L7e!6!lVIe0Wp9)|iL0Q80rG(gs9Q2SVT&2qcnw2L z$Quw*t)pdR_Rge0g^juL!86HZU{5~EEw#ZI88>@IFy06DHj{Sy%}vslM7d?ZMAf&w zeWwx>>HIP8gvcYrbhOpM58!U-eqI}oG^o5S)4L^2+faZimIeSII)+%ocd>4<@YjVa z9xI=d7;+yp_3JzqAU=|TnSUu(@=~ggM&0TcFMMh%1*8ijf%&ZWn8Wi-O zEEW3q{6MK01jQ|Loe7B!enGFkW6yl|L4Hd;0*So+iw47I6DC2if576`sM@bH|I}JmWB(~A8sl`q43wGD>ajuQ2C>c1t9K`@9uw-JK;g_ESyq$xuuL!~4!a4-`1 zUIcYBgVczKijeuBHRM_Wrj|D;?f*G+z=F^ShKCA+Hp_^jRQ%h1NtftqKRtQ$*GgjW z5Gus26q$s!y&o1b^rZ~8;2-5fj6#A7Ux7{nOx_r17zli?gr=WpN9Ica049h)AZR;y!#tRe9%5Z^z z_PQv*CO=X1a_{YdCiXpf+-<=d>n)?9I=Fe6Q7|_zp&+S*C6-WoJ4D(dDgqX|57daa zRQ!1H=?b5q@=O3oT=hg$IPZ77ZGPp%dxgl$BoT`L@1%|Yopgfz&)v=Crpt5WH*r@5 zB90S|xl}q*CUDg{Kx+8IW~-e>a%?hRcqTC(x}CtS*{8`+Mzu*f>*>=OcadNCZ`;x+ z^ti9(==7+FBnG&EK3kz^Dp$cqUIqCpt3W_wj@WWp666Sa{XiC=uE*oIPSi;e+V1IR~%Oe2}VR)1WD6^v-Yb6Kb&daa<^ zC%)1bO{KaYnp@4>B;TF+NSOPGtAVpF>nCP4J_$X27!{DdPJjFC{wpM~TTj2PdmiE< z8L01M26h(75@*x(19W0h#SXEED z`gNr91D^qh#gJjy<1wN!swKeCRv<%9M)4YHgqcYaLIU6dpo2JS#G?=uR-yw4qhxWS zP^HA*%ho(H6lJk|Jg`C1)MGVJ;6T#+$g0;v2_KX=m#^7<{%mn`GRR*>yD1@R$lKOVieGYxC)fqL=q!3r3j1Yo{NL{?>keLUxo7RE1C>Lq2gwAzXE8^c4HC0PUacy%gLr3^|Y)aYLS2+OtT zjNs=379i$;EB9Ff_1HLk^j)b5J77_noe6=%LM?M41aGt^#z~&E_K%YQ=qX;p=c{}}cZgFaU+{bAx;ON8kCbbZ1Epz=$!^$7; z`E`O_sOkQbv(NmWoFkwcQ$M^reeN5r7t|ZjGW_z11|MVg9LT098YeYs7^exs2uvbj z`U!%h`|-1Tbd(WGGrD-LY=j1=<1#{@)0hD*@l>WV2hP*s)S5Zm7TBfc7Ug{#E2a%e z+x&)5K--WONM9L??Sr3#J?C~)Z%R6Fwqf*N5-z~>F9`=7Wb4+CYSUftwq~%W;Cx`a zRXE=HmQ=6qc&R!m1~2Ddh1%A(32bUDjy(SP^FMjvl~&Aw9|Un8a!!}NuEN9M3yVlTS?B?o&X^|Kj6hslsxQQ zK)aKfyJq0aF#CIVnNzX>I=mTzIC&v)5k+-d$ulNNW5m9Ke?i_o(;Wbg^?$$-NBC0~ zk9d1RE02l6omx|S^Ef^!Fe`yFOW&(TNu(2?#u6F>C2 z#JE9mME3hvabXYLpz(l*KXIecWPe>ADSCUSE7tPVijZ=Cgcv}b8P%r$hhAUuRMD4X&sMs4X%E={(!`f&(`(EvInr++Io{7`OQem;mIR1Uz1 zTs1Q|B~kQD zyYMi%Zj?SF9YRb{diH%x;x+ES1c&efXd|t6`Xf~U!jj;_v@UVI5$dw1;FWd>uT)X(D5upxh z1~(1SzjJ+bFs&6IMgojEif|Z$7lr45CyUxmloR|zJ2z`=02E@j^$npH)L=GEyKxio z$1aGX^pfB%F+N+Yx0)2_hj2C4+5lDE7R0S3<5lDZr%k-Iue%2 zn*3YF{Ye^qkf76@1f#hz@-t{p(z#;bIdm~e5>LqW1ff&5pvJ_I+!i!XQ7ZjyUQf#r z=ob%Ikjn!08m+QTcizLmG)!Wn$Y7eB<8D!H_D0<&p!wimh@j%-{^VA7E9ELH;aZvCI_6r1u+vF7YCM&c46PnEOCp5MModGp-=$D+p?Mo@ixK~vod zjRg@7xJd+G7sDKc(A;=UlSe!)YoD#6LiqREqPcYPJE68fC^KI| z7=Rf~K1v#ei^wIp2VX>$53xsTo6O&Q6lXtM3vxe=x%BPpbrJ~Q!?K06L7H9rgoQo$ zBZB$&kPg|!jgo`c51oL{i9Y!OBC4a~80F!xpo9anK#A06BAwJvXp*q2ij;f*I!}+1 z0%3p%r(mk6a(C89ZOQqYrM@qar@!5TGHhp?6xqGqf^PQQW4yl_ww6yyhKC(%IbQ{h zmowbpuQTvw@(YvQG)yk5Vp;+b1U&!_dz+G`oS;pqS7tj*62=Z0_PG$t{U4=_N!uk& z1x6E*qLkHfCXhWOwGp;`V1&!|`q@f-c1D4<-W-$xTdh$=dG@k43cjMA!<_k~$g#DK z=kVV)-u}OBbSW)3vMpd9!MMGLtyB2lCdj3LO~?bAxQHkpVvN)#8WOHTYe#$k>}8LI z%iSgrwr6iYM!6jA6ytaz;C4L%R%{pKS9fFXR-SQEg~|M~l}sb4I@T;LDu`SPM%>G< zDRsn--h+`WjCK0o+B1Q*{}PlkmeC2um2Ei@|J(F=-$ik>6M1j>X)RWLC?Oyt@S7Oo~J=)`0F&hi3HDC zdYGd{cWQZPqRXke+AM6bT(?lwrd|lk!&@9aQuvEF-;L5qLO%5@mu6G|S^u<;FHDLTyNTD<8e zSxa-`z8tRyzv1dZXUxlmbE4?jX^`XY!KUQvE#$Q#FXvti|8kyzc5Zx9WMFb+WY>_l zkG%BArq;s3KC=Yp9B2caFQQP&t8bmS%L_d(TVQwVG^ScqsEm@LqSXnRk;FEsYxw5A ztF%FrDi1}4WBQlXt;J>pp02+|wBvtBvB5+nFC!O6)GPwc`dI%r)o`r^EfgVSMY|@> z=PuGg$Sv&=ihcx zifC)S01_*@VX0}hB&O2tV#PB=Y;0gb@#8eM)!Vm_VGzAr{2YcYOv%gOQLTSNz*)rP zv}JUbba9vP=2zl;|+fq%*!w5TAKD>%UgZ#2}aSjTrys37B#>f3o!1`25m250RNoQ*P(zef{%TT6UmiRol@LjkfRmE5j;b}~I!=e81eiy`$d$><9!vMobeBFhKC_?7nQn&ncnEgPd8+%_u7n;Ie&LuZhuY{ z{2)8Ne^J5uTaV;F#P+(BQSj8g{~9$tyc0Ge3d?w8Q`M<1XzRX-1%J zE=5>^KyyU_0l^!f-mx2q=|Lh?u{M(5j|CIDf%D$-&}ywbdn0=}Wyxckt0s?+S4S;8 zH|h^)47na(P+#6#)X|1(lX;|nr-G|Lw?#^Z3P^IdjSwxMu?9Ow4$Lm=VqPydvt9E0 zq$CEF@Zal4G@$5T zSLy~BO!u!MctBmtN{SmLqPR$}9*>7R9FGTzHgO+xfzzSFU9T-S(y9^&?q)MV#arGH zUl zQXcPE?gf+pI0Hpoiu2v)Zh{z4XsDM7%B2IB(WE+F4xv0pvncm0WQtOi1i@SywR=4Z zZ>!1v=A4h3CC24Hpd|ERiYrroh7)(I+6;Jpd&l)rd9PmlLfa2LcHCD?thN0v&ZXwp z6@rKt3g3v)vrub}=)Tw7R_@$j$>>9g(G7G5R~*r8Vft#xraAD1Y_Hd)OiC8DIdYv& z8>s(imh@QUq4-ew*VNVT77vriC6{v#@43Kb!7P;L0y(t3tyr|zeF(77;9v3K+LF*? zlQNp_EE)x-8Zco1J#7Qdm75wtl#HCbZ`&G=pwXguBBlab7NWvtD7d(mC!kPxF6{W$ z#lBtNE*AK*=Q34UC*tm#OB++y=}ghz7jBPIuLk#`0xx`7qa|*a$9~_aO)&A14<$dI zorlwlAfy4rPul!|DL}+1JBMXg8BnX$+jXB`%i4SU*_EpI$_{;0*s@BpqEU?hD}X?h zLQ75`lgHx9tJ2-S!?uZrw~QJcydysqnVT@Bh^&A&P)6#d0Ad{mFCx|}}rO_7elYlA=Op~xl zrAWz2TGODAF&J^uZztoRv;+xDLe<3--drdszQHRjwkEk0Db6GMgn2Z6Z&^nxpO;Ug zu#D4p9M6E`yjM3E)LnA?a%4@aukyEJjIY~ZaEUtfoo67gIz{Ot0lukmqmO@yCt->W zQ{%ZhkSh_aCtUa$@|JT z^ofQ?CeW?Iu^GotXu93P^|ocDX(A#ixLEN6r;g@_5(!ApG4j5$V)|&`^5m=v3km7y>1WYEMVqmZ zU%3;~(FC1>PRPuN5nl&H{{ata$co;Pqyn1g!xP>U_ejTBC-N3+g#+?<*wI_zE?MPn zF-IU%F(gMte0=g&Ek4NHa?I&n_0K9a=Hx<%oGHpxhdb@6`iz!P6Xg|%;07|LyG0Oh zg*7(sS5^3|q#vA65A~w54abdLf8La2$oLkXwK@0;D-aEDDf-)~e%E7v#ZG%iXT`ya zW5b^Uaq}+Eq)dzgx121U$U?*%-EQg0~9u)D3gL0knjcg`rxL%EBL>0q>=^9p?Tdo7}Q@51rE_ zsz{@m0x(ugn^zmSUHAEJe8<{0bEhA&w(~!lNj0k0_5R=wj6-hKrD;qW{rUkW(C`TV z`kMe~c*p?XJLAWZ6h{2$i*!Oj5}um{q7_C2%rpFX;U94)Q8^E!jUS=6hgak9GHAkp zAS6&;79c3#&Z8&;VHcUVsol_g0dzOAH@(zpYsluy+>wS%ihL+-{uF@z78tOP{`v$+ zQhjixB@4kkt@{9I5X0AP`pn# zKL2ul@)z)*G~Q1%Sh5C@$2n7>Cs*iw5nHt>zExW)FfTc}{yU=M05iYiTx(#7ezab5 zclS{2IwPR>mw7Dk&rs5t0yd!3$hVn9tV5`>ZcL5f_9$@yBEA?%0)2uVc5m%_6jT-l z6eHSs9@yBBep^IiV>>qVP-ziw!C>82JEW)hb;?Qs_i86K(@jpDd#KkE5vKUR&B; z)8C#NboYj{-+ExpmKE41owbFcX+zA3!Id=rvFg)gLatDKU<%B+Fj3z*u6!bXMw993 zk1e^Y3D?2GFSF@*3CHe)CRhc=W}{|*+5Hn(ob!_xjPP~pdyV?R9ZTJyp#UM(VOxvJ zcitAiA!g|9i0F=3c%QG5KV?HUFWH8+{($BQgxE}?SMdUSSFeazUAQSO(6By_26K!a zMY;7E)2`vIpV1`7NEc#74jR?AF9-JXndSizSZyy+O%`=`o#FBC+yV=7+we2jINt*J zFEq#QJ<0570`egX;*N5F7pl@Y5NKdN%CqW0@%`mb$ex}uK1IUcD2OTIuZ$Et#f^$h zsK-k@6Vw0~B8>(?uKXyE%iUS?bMkuk%%$D|4hW(7aMGH*lDB6($}&G)lHCo-ii9z+ zxfVE%t!s=(mpKZ#^=kByLhpT+#|@N!MQLTZH2k`tqw)3UFqs5Lvm3q_bHIA(c_Dk+ zp%-V^tM1mQ$rfenq7J*<5Soe&Q%F6-ftdRaL(I_!0p;XRQ67dUN;plZBl=4#rD)=68FvrgJ@S^pN;T4=9LPb-lQ# z5U1zDNO}5&sjD87@{l_WSpQ9^Y_uCms#3YK{isudJ?BuI(&KpUQmU9K)+0c!AoUq0=wd6jxP9!~CnDC;^UWyX6`f?n*UYi{Yq!#g;~lY=b(|~#N(F-%+t`2& zI&ck8aikb&A#K(L9R(t~^_bJmg|t+0qbH&nM^xB>jgv~Nggw#NT*cf50T(5Tr!6+D z8+EfRo5JUbAg^=w#7G_y2~+Q5RY_0~Xr4}?u0wX>*mA62d-%HFa?+){@Y9B>t?J8I z3Q6S_0rH`Ie=yv53KQD`&sW+(Bguu6BhMDJUm+QG^?!aY`0VO=HSaT??1+7JvH6um z(XUVFhezHBl`{>5ng7>Da|`ckbFXC?OLeuiewq(a$Qn@Qk)K-JyAAVZMC`%vwA13v%K8%P zqo{cAvA19jyPx>O6PKXRC>(bzCdr)IyvVu+rXlj7!N+h&nS2_|PVZ*I=p0cbCee)h zkH{h>! zX(?ICvWZJ`t*^gM`MbeP9e9Uf{HSa%=S%$#_Ix=2jbgF8e-`*XaYaoAQ#$PM)1x%? zG=hO5aN`g|Hk0LFy%dLr#nx>VEwFl`(V zfq3i01-|*3(fz|@kK;opXmTqg*hQE$A@QX72jG_{HhVOr%S`k?oS^zkhUgX}_v{N- z2H3J{c4K1$-PI$b59XgcdN)Uo&s~J$D`B@JM9p>em1Lp=5^w+O@-blH%{bdf6bgH! zSM4qc-MKta9;>B1VuYFhoM-xGZ2V^N(g}$OiaSd__U84!izo^UIXOXvwvgV)oL;L> zQDBS^s#xbjTAlBtZ-Ag%_$z#FqAn;esE=WWvIlDTYpEKND+jyUk{25HV6<;&( zzVjx3a&+>3$YC7hFCiY}wW2CrB1-h)CL~;+Bm?5o=vM+-V2Ce0KK6h&Hsp$ic}k;4 zJDnvB1*waa)rKzDLwuPh^rqJouo+8mQ?)T`o=_jlAr2j{#09@0%c-j`J@#0=aK7=e zBm?{RfEp= zowd83?jX|X5uFs(RM&}<7^RMFO*R4@1$QdNpF0;OA6KW_cx4u{Fmof`9;JhwB91kem-rbsor64VwN9g3nU;~ zp3_TG&o&|Sh@5=qGsztyaN=IWIcJ(joL{>SWVjjO>v_gyX~Z^zg{_YDF6hRTJS^Zw zQt_4MNYnk_{!aX>%Q{Nran(U_S zz|7!d17<7WDU=BUF47`Sd}YYQ7z@(9Is+07{rt=<(!l--P2sUxmK4woGM3FU`SC~p z%I=BdR8L(O8Uy;S%!e6Y$8JzCgmpmxq}zd~`i~lgr@bTW0WX%{RxImNM!|P=AHgV^gIZ7zPUd*TC6f^J+L7njyPa(vv$sFvCwQv@EX`?V!o^W^R@ zjATw8g?7ZorvAU82#bD4zSKTS&We#xj|7EEu}3BE`4K3G{AB_k$rPsuF-WH~o~ zu{#iOE__8*M4(PylTXgAROS;wjYKk5SiS=P$cO6R9Jm0}$kp{K_K9zGvB@%vofqTe z-of_=JSZ8@IVG2-D@p>148hWnI>2p2@_Y+)^}vetO0iBtVWS_v_R4^&-{%leN%g2m zO1W}oLf2IZz&x3H{q`n5&?2XNK3v!emm<6`q5%L&vd{ivUTsm*PRb;MwkE!lb0K@R z%uj5T!{Iq$<*)AEoTp7G^~V+1ztS$LE6VTVV0A{pLjR2?)CVI7a_(dKbf%{*W=^mF zZydV8wjGHpDL7J&i^zhJS&alnvSunSP|;w92hokig)<3Q3J#bjDL*ogAYKR@kG2&o zx3bEDR`)aV9RqqGZa`k}w!H~X#MfX+@LabO`oLdbOjR+TCKTJa@oS3v4t>yD_p$60 z4ur5n4#a~(O%SYZZIlubLi`|%G!CkDOJq#p<@^5FTt$h%%lH?R#Gx5jIKDYKbr))U zGp*WUW*OOIfVK!nyyfw*z3KJGsn4gC{o$za!jk1C{NST*0;-cqbRhw!WMl?Q;UyeF zGl?zlJ96IgV=@C5lLz1N+fbDEKIs`nNS}Q(aTsQ>ASXvfb;KmEja#uip$}XxI9Wu; z-Xh2rl!K}xuy=H+7>l?%#MMxju%UpRPN`##|PCc3S#X&GY}uwJtjhzp$7vA=$(%e0}@d&F}nRn=-^ z#`qRL)twR!7y{B#s<@t^z3~L)A+LNeIEROzU?xdE$^$$#WMC3O zbV5VoO+JEr-#Ci%zSbM`!A*)DRW08(Jju+n7$8pyy_7lzM`Xc4|s0>jO40iNR>0v{-x&gA2O@@9zd0t28bMM3$|fAO3VX0gzwaTB9U9GI>U7A!z|!YGv) zNW9-oO^81tp`P~jK^if7`XbTs<0H{E$SzasZ7bLlj$z#2B#!ot6$L^uY-#Y)IpnLR zJpLAUoqD#0oG;BfEr^(R|E<{BbWj`a44d+pc~oC17U+`)D^zxsIRp14jmg)58B7s< znU>JGj}VDaTm^zyGtJ6witOJ{zSKZP1rrNouUUv;qLlm;j}=70g{O~Ax22myGC$IT zUb=CB&s!W(K}+NVXgfJAkOh$#9oehEwSq89r}mJUoMxeh7! z3c!t^0bEjgqk}1wW^V$I`OUWIkKiW~_#W^#DM*(#IV%x?q-Afnim{_>yeZ&^+u$VA z{74G?Nkt5g_ydlEaLMxeB>*gu;#;JANsf&MX=+C~_Q%Xk&v-t1k0>{U*oFGXO^-Sj zA!j$sQZAd-@3qeT5$gPVQBX;{CGos3C+kSs+u-?MBR}34;Il{pKFbVYl%!D41L2VE ztdN|At`KBDwbCCAPZQR z&At=oIScxJ&I_+o1(hqfE-rRt$cI#3b(}@(<*k6_Uo8%?0TAdZQ>TRR?Gm-uEGd!$ zv!E>-n}Z=Z@`^+oZYIcv_?wY;L{w zkRi5e{BL5D%xI&eo*B_zE_}~h-m?==cr^m`-0bPR!R0hI79J2%*_ZSm?K-;ZbnxVqXLWo6z|RNiMD?nz0#%; z$m*PBnddZ`P9+ngEAx}xr=?Lss5g`!@TW_ZgPjR-A%l8;awY>e;a{V;q&MYH_Z3?7 z-SB!%eI@IaiLXtzSFN8o`=)`JiD0;0{I$o3a8ORZUrx=(b!Dotb|Gk-oyt!Md8WnZlO3!m&V4y#%_N}i$E^C9phtTY5!-&*ppJPSQUu5+up#wq#{M1{hsvoq z#gxqYY8r$MHM*dI@ix+`aTRbRM!9>qGzZ2tx^&OYO%@$#ch_&!ov8>r#1ejo0PcCm z{*LchCd3d^h>40pZlCvZ%`oN8$EWKVJV0fJE;8m`)Z8vPF5De#W<> z=>_fEk@_~bbi(8^!QVF?jqXG5b}aRzhXaHrY#B1GLuZdqhuIgBYzoEzDsv-Gc*ZXQ zV>X5}aa*Pw+OLo>?_z3FLxLfqfTTl;NNFCmj2GDdqD>0)vsmA?0oOQ;<$Lss$}?{B ze{VA35&_hUUg4Pm6l}|i=gBT#HGXtFawO6;L7gO-lSaLknkBXnl*Smh_Ux%GG;_{( zYaDoaU{f_1)3V`=>9+VHwW<35Vd^czvU;+H3EDDiqFt*e;E3 zHnRbx;gX|I@Gn!Nr~{vwu@E%!@p?$%tC2uVHAl#&(Nel1#lMaOa;~k^3P;0`Hcx}W zw;w_hYsqLw;4|+u)Z=fSHXg?hSGP{)1(q!}kIJ6>TAvy=4_Gw{?LC9CUuXp}H$bf< z+Bw=z&)1Us=9d&(%yDfo6I9tTPy)CQuaL4)5#GNV2K7@h^3HF`dXqk^#$^z+(bIcC zb~se}=?HlS=rRJSEE}R%+EUSz`zDnnn-NEEw&(BYdJ-R2VimkyDjRE*-$~@UCVw0< znW$(r<3aiCZ7(NLt}K)JxZQO$60~T`Bjr)Jejp>VY6+1BSSr10%OekUV>!mW(XWJw zBOy@~RP>^eCJ!F|GZ2K3f&|kU7M97=Vo#7T+ack#Vqyg*h?f2`2ESjyDExio!Fovs zb>_%=_MS*al%+El4!}`qI$a|A|4$~15T&Yt`&361+;|Gwd`j>2^-4>JfOh$k{!t?^ zwVxs8Sx(d3Xg?PnFa`btWGm}C1gDJxSnRjh$5H6ZxjS$2@xLs>$`I9go51uQw&i2-w694>E^6U}8fBbs<$ot?6b^OEq zoiR}ACX@B#n{;MBgc=p}<3Me>Fan1v0x(eHhs6vJ*zwGzPM>0&1Ue#1qQ;`YLXi2x zV}>CgL&fXFR)J;vubv!y3ISEbybfxTtgL*;mpMAiH&ozF=y9lq;8G|oiNTxDlf8pU zF?qV$wfkQ(+P{4)1W0z8SEY*!OZV^b<1@(XUux=1JUx(#qxx(@L3xFA3yul2p!7FY zlDqM8Smk7t0Huub=TT3wR+0Pz=sL|ATyO13){hRl;lJ}PZjE9%rSH<^%Jp!}1S*!H z9nYP+Z-yi)qRzHIxQ@Ulk59@;QX!67QE}A^3RuyM95fEEtUHRX`ibcitOh-G2;B3{ zV0W3YCFC_mdYu0{$wJ^Cmf-UtKUSWeAHF-a27RJ*8yBB8#U^zEE!pQEHybDY>oNlt zHH8A}9$-jm57j6pD4pdTYOZt;D&;I-qtfHWLog_;)MZigm{%vTpnAfr{^ed$2Gr52vhr@$(YS5 z`QU@j&)s3e{HXENkrN2P*2Z6576X8j+5TqzVNp5p`Nr|zOITSHaD+@MPE9q+VZ|K$ z@wJQEDN142PgBjp0*jgY!(Ca+Ktybig{Jur5u1U{?pqO$xl#I7h3D&cnU2yL#NzU} z{GiwaLYMyj)xN*;VNC7S%FW_jPLJ>7`6T*(@y5mhF}&sE84|6J4QY!qBnU-KFj-pV5pD7aGwbc$?L2QJT+Vt%0J)o3u7BctSO}LQ@ zfw5YizR{VY{&mb#!#`VscQ9 zJ7Z1xH-E}oP}aNT$b0AK@AG(EjTi>!k-1(ki4q$g^p<>#eFfsU`w#e5hvVQkup&FD za4yto!Yhr|VXX3y$vH!S#mW3^=O3^x^e&J5Jnl59Fn@O5L1ko#mlTnJxSGrb&1p&PF&7LJ(Kb;_4{noHCi#l6K!sx# z{Ee%C7Q0Ocy_07NoRot6VZ}Qvr0j14XXa0)Vg^Q03bs#CF?Y1KRjG6|vyC}U47#P3 zWjOCLStwBl&d)D~lgL#uY3kzzqV|{t{@xv|uSCA>OZw&1D5E}Oef!?$S)^5OZJKf- znsm5I?w{EGFk!@wno+6Oa7Ik3!nt0{PBMbboy9VtrwM z;~*iA$j^$>458DN7_X`r+IDN1YYS;U4!$4K;f-v-SmgCQk0ptu7y*&&Am8oFB*d=A zLtscGVvb2XM{d3xqAlGP#RUmd;UVXD&XLhP_1-r;QP298=#N{6qH-wL=Gjg~k&te7yBF59oU= zY3t*E0eFysMANL`Wb7V)EK;}v z;%^5290st1C`%qAjy4Zk@}>x8xORLT#z!!42oqJ+#X^jcsi<3Vv%Z8cTLJwc6|hV1 zlfF|ma%z2KPBWII9HRDm)Cb(vk_^P_uCTbrWX9}dg&Kl}jcf!OE>?=@Ftmyze%l<7 z7yIz4#H*EjIv~I!j>OQ>+VV!ePyE%6$_;@qDei-h5JY!v2{qJRu`Vu~A&n-A{V*iq zm*bT7UorK;^*AMFL2I6)o!;=b7vsAZdJSDmmt|vJJR}re@LiNU96O<;^+Z~D`?woU z6}DF&ax^C|3n&@^UQ;u(K=YT12DJao;~*_$dJ|zMW8eInAEsD@M=Tq$aV&&&^n^eR z=*W%T?q+m=(8SIV$$$o$?+FWAT}4urq2;m#noOk6M?U%$j`GuLgz@r_m;c5e(F_Sk zUHfHZ*kHFj1j1%g_CEKTSX#(`vQh4I{qix`8@r6+i!wn~^QM}Zi-SN)nH+wqCjOuK ztD0D%l1EwrG_m-lbrBr?VE>2W&eo>kE=rG+((kNb05JEzQTz9N2H8iQrJlw#aU?d* z&3<0%-Oi6d4W-h-;U*i@^&SDeJpxV%tC3C=23MuiWX&={*hv9H)o%eJLcvgzbQnoK zg2Tusbs7>Tl2ItP-P3Ys7&EDWjw-Y)hgaB z*TWSG84AufDU(X5?*L_%r7vW8q09~;zyz_hVr^6@^xth_bwmu@P5OH98^usOjki;dpK^N|@523rM{iHdMPiIGD0RjhU4M_`Goj4K&!xQNtyUO+i zhUhqwHz_h2(F1czA<6B$m$o(lN{q1aKn-68 zfsO2342~Unw3fTSg+i0b+>|9=Vce_)|P3mW0fTR8)r}n9kt!-Xz=}C6@acvG0!umhsku0W#0Y{nMN5$!p?7S=# z?+JI=s>Ap1}(Tl0Qif0YPY6k#QH&7W6Uub$1@2K$qUyhf_hq zuFIxZ_IGyQw_FQqv@TufqQ-%Lb)2sf6Ucu)xD`ST@s+gyv?Lh{ZG;<%MU z4MivN`stEGaaB&k21iuVMe(0J>B*q@m6!meA1M1PGoJD$2&lKgh`0+wXuhNLkB#PipcE|21VeT4SMD^e-K}MP|l- zSAT{0-?S7S&!CY0ig;aE8oKx6m*g{3Ag|7&_mjnxT%q_827J! zhRXb_OBv7qgben3m@WhPW2JxV+<(y0{cc@e(7AsaSUu4?mn{s_DCWKpZIPq;q?C`%-<@uyZS~ zFV?RWNN8rGGndotVAJq!W#y*?SF41=(JiD6_3Lm}2o=KbwDIA#Uomg1_T2~{^Va>d zt$L7Zz5ksn7>ljt!0Rc0b2C^YpK)maFiC$~*sj%PFTfHCd~D~A#gBkVZG(;#jnPIS zQ;AHBl;OgY|IXowEko$B^wh|m#(E{JiH^ZZ3$H49ET>aKrBH28d{McILQ48kdRX;G zrlYfGS^!|-&bW$V@->9Rs+fzsiZ)8$wcu8b8(@})cEAsYtLqq~m55~!^GtqS$PxJJ zDcBm*>x6DOl>vGkB|^^se4pY481-M>Brm%6cgb4ibji|>v>BEbWvYs((MSLiA%z0~ z5{cTcSU(NtJ3ZlazG-{9`+Kstd(nq^bIDy@xF=3go*`eAih`m6YHc(d;upahB(jgH zrbJonnC+3iylbMwi>w!V%smgF@~E?AEtouV)^zgTwYbj1X1guB0kiE=Uvwk?1NOB7 zu`9vH{hi2t{vwxckid%#+joQ-Itk;F zi>ZU6v$~=9<_TVrJE>bh@Hx?AUH?|xzk-<6l{#FxH+b)Vb!qJY0lXjzYG<;NgH9## za*AR1HZ<|quh!`4wFYHFhHZLPq@1~Zi2RWrj!z|(CH>{JuPI~d= zR3_vkDEhs{ZATZHk|OU&t4h;$%YEGOzubh-D*PYop1t&SM95X%?3yh$0+mTaxLxMt z$KmS);)#($pJ}I+EQXL!C0@{tH)%vOm?RpW*NQHA%BJB|FKGlAtc zvQ_Z!XU#vJIeOGbNEPsW0>mC;;9b!Zr zUGi&aB%-cgqzW%*v?pqnOQqGw&?WD^L#Ded&9{U_M=}NTp%OV8q)`OMgz-$F7~QGo zF`V6FKYc&eh1o9GZy33@-Othn1wcEhWLU1`vxRqpt7Jc(IkVV-NR+nm-g-E)c4Lx)^iUBgZ7BcF|wuK^h!31H=UHQ@R_411dzl`SGFML|R%WWpqX{28{ zq1Un>Pn;IdLnLyMV&sMVPHB<$vchD{Q|T{V!g1m?E0;XBpj^d8uRv3z!k@y+>lrv+ z!X2Pm5F;3)BjTZ%YEJF;3Z9YqIq*MNoQ@&bU`%_UvSI`u7!ts4y7!MhpmB+cpoK!9 z>$MpH58Q3pU%HbL2k+kp7!iKY`*fIH_1u|j6HBOtxe#kl*&u+tCFtR=AZJAtiHLF% zr|2eBCCFQ{$bl2TCo)fmvNcOnGL|YK#N1cP!E97bO1F&iiSi5SMxA}D2|>}>-WgVy zVhMZ#0yD(`DfsowlWja&X?}ENiI-%`S5goicIw)I+E|Ky{y;&)-z&S2P9GzaIh+-_ z5{VEY+PR!5)Fh~a<{TRe4XPIME|g?GM6Ql0PL3!V5ykUcv0QWnKON~W?cj3EZq&7e zGIIPxQ94q(=u9Z(Yf`$URkGo<-8r2Hxyp)|82i)dCrwAQJ#i!3-$6~tEZKS{b0jOn zMG_%#A4o(vFN&Dk)6^Ym4PACJ9eyWhZ|R!+FE^)KQOg?Z>QU^L z${da8#jO6o_eEgV;Cd>=3C6edh$tk|4yQALLTS6hU2uW1k zld`gyjGQd;p*UqHo#z6dT`KXg&ke^QK|!XPMje#JUqi9ay%b+w1BOfy{f|MJ^yDwN z;YKQ{=$y|Cu$163o~UxHlgKdGnZ76q^A4Dq17oe9{X?)y7vXCovqj`jT~nokg4BO_ zAU&hciS+L^_k!D%RfI^JbB8re=BStDLi+OZP(q^MEw09}tL4KDyM$kE4qk_(pV{0 z|2=wPI<3N=)N1sQUDIUsDyQx;0D5 zr5g$81tA_3TY<7+eq^eoEsKlUV&oJ)=?q{}fWYDmB^gj;JNp)ViR6z(%H$C(6+Kyo zD8vOxo4*9U0!-4^toO*gFgi^cCbD$>`04JP$ zyTe^uz+EMCnTXhk9nW=1?MDSn)in9Rs9}}_+$?&n&5RUD*jUs#9J`mwR!Ul$BvT@E znu-oHP^nyEydQSC_R#B%wHriyz1|ABY6o;KvZqQ94 zB=^T5$eAHdIeqe&c5?kkhlq-OJaV`nrl!D!IV+6Da@Mv zIR9PCq=Isn-y&k?VuFaygP)OaB7LE@u@_FTKiW_(zB`7_Hq)Jv<{);xd{!a=EG(DV z95iBHz5>Q)rZ@XW-9Aa17PlPP(+ljO$!YcvJB#K*o8`3M0^9!T{`-(z^!Dy4)QS37 zyvxxy=*yNFeBKCHYzjYyLG&k-g3oDDjRbHaWx#NBVUg2XT>U4$t8p^%kE!`Ne4$TB zzLM5?ly4IyG(PUyNhK=y>!L>6ep@?n#~9PJ5kVX^ji`_VgNGi??fRxzZpy>X_xs_`xLTRwq={YwT$3!4drkkIk+Wj65+bRJOtXy=O=+wQc3DysBPXG}`?(na z9C_)^&@qCEan1Lu&ho}^d>RbK!2;yvWee;?i%JTA;m_}r6Z%CDz_<4M9VL8Gn;Etl z^O*JT)x*>cn-rdZNCa&j;^KFw-cPF3Niqm9dyOx_HzM`sMb68Yxa7@AU-+Par7APf zwmRm%_eC)-O@V=`fvRV`utlDY8&0GWq=@e8hTdlqH-k$inBKjod{SC$z+50=pW1j9 zWA(XKqp;RhR-9oo<18N%H5PQX#^=Z)~Q8 z60J-KNMUSaXty|SeMNHnuirDWS8PgBX|sRyJrrOhOj5betvfR92K&0sRvQDjtplB` z=RcHGcT{drkKvfxy$u|_8je&pzSEdE9Q@eqqtcIeBT!pgJ7hC%u3kODlP&efP0;Y` z4_Z1TxkRu&^ZY?nTh1*kvdqP#C0-h0LtgI2v=2qiP?fSW(?3Gt3qL+C8aK_CCi3xF zu$qftOS$);f=!Bocx0<$DZZs5u!PcCJNjH(K@D%<9=H)F^3BYjLTJH_1zOXUGPp?2 zpTodMm=LAJz_rYArlp|u)tkEXmYq7xUi_LCzr(~hS0~@~zFMcT@Wyc_!E8p>rQD8; z!blpNq0tGHR+&xI<0W~MNP-q$4lmCJI6N;tcpXK0pLr~nmeu;8ODtc znlts43DnY&+`)?(ua6h139cA3sT`CnSmHk2Ib7s?8HtCt?RGTV2AyQkI(hb4hn2L_ z-3f19tib_*ww{}b?{4kIfeMdDWBcwSj0`biO-HXv;SSQsI)qW!I2gqK4EQk-M6{hg zSlW@EEW84AsNrtl&!ITs@{SDnG;KnK(3n&6yVR7AcR~irv6Hx@)Fzlq-nUSqP((9- zg<|SUHB(X=33^g^2H+On`Od0PD8v zwug~>G^7@bjSeT_cCarjSe%a_z)7+095q6m>rA{kme1bi9?e z7NO=dDw+}b*4RU2pWwV%Lk~Rhiqo&q{a$s1D4p+FRHksgZO&g`0 zjrbNUG$s1m)cbRLNpW3bX9zrrdeq}9M>S*}M<#XRh!CzDxmv5&y~(T`sN1CwR3p%q zXc;A(@`hk`MmKCTgiJe8^;v*XTCqj1U`9e8AblY=6aE}RIQ6qX-#@;T&5!jH1sef^ zhQlknMyTK8z$wmnR$LGG6F!aDD>D2L8GS{3dP%zT3QXAQPS_OiC6Z?b^}v^qKbqCU z!LX3|%hpc)rpcLC2a%3iqhv573^NZD48?~X80N|o&sPo7&<1X@1n$-D`Ev%^8%a}^ zKb%RtZNkF9O1ub66ip+fyscdc`A6*Ng`DQ7E{uK}!irB!^36j}oD!@m%63q1SBHls zBE(pDg2ffDg>#XN0#bltiu)nb5<5Ocv} zBPe}{bxgrq!N!bgAO3$|#y$2`Jl^293|WQhgVEk)Y(7@>a@A4hULqJRV(WW;i7n(ucmK@LwZrAMbFQ)Wpc3U4uqozLv$NU6uFAm|dby zD7cnkc^w8cKh|(b$GR!fxy?=CZQ0YCcn~TMY0@EmstZ>P>0y1{hDA@~fr(H3XL&0d z0f8rGB+3i@<{fHS<5t|TYjD(WhwpYBVSeY3RL`F^)@au&c?@Fu5K;!YS@`N9K~mPNU-O{;?x_u{E3in`4#Jyov_{c6>lR#?EKnt zzC8cqHR!Dx2))Vn|Iu6%GomDf>`VMw4~i2uB|FN80ROE{_>@54mj{_8f}}$+djoa-NL#!F|YWM33`;>^)O6fm3oL3N9atxddU6>vZTcC9%~Z=&=o9w1P5xf=3OtE6&(YQ2bR%ljA zgBZ(gwSPfpnQU2;ns^bIjvz^9dbEU4{on@g|CbNnkynm}GE8AY(!~}nU|Hs!*^E9#pA%Bw*6acfm68sssp*;%`>-u_J3kftyUp#jeM58skA6pp5e`ds}d zdTK}B*X!r|33YXdZ3ogHjtd9U&x#06o7l|f`1wqx*ET-Bx%0oxAY$N2`ubGt7r@E^ zy80{(SV$7M!I|k9&6zFt)AWVJaY(Zy?;j|L+Jm+=GOA^o2w{XYAm9bH}~ zl$$feFdl`R$jBR{*?yKgNXnGt07Jb+VW>vPfTu;FVEUBg%_r|}<3lCa3xWU8{4bNE z%4$~}^F$`Do|gloSPjX`k+jd17_s!=DZ8{y=GvBr*}#cxD1CF(Dz7YfjVgqzKJcYbfxr?kndMJ(H@gB!N)cMrMhqKcuZa&|0C zFvRfLh+F3~G92K9;#gMTxXT==kRwM#dDC?ld3K7wZQd_XXnYf__GF(t5BWN{@6|!L zGa>U5?c40akD4A7$$`P+c}eMVsR8lvVe*W#_E<0EQpliM=g!>q+>{|~D4po{!n{M_ zzPM4DqC*nrX`B$+oF^+D$sqyLHjDVaD)K; zsvb>BR=BUsucPw~N$j^(8XKX1y}n7ef-GA3J@#8_TWcj-y%` zJsa(iD8NC7DDPGiYa=L=mdl!78;cuQHt!1SpZ@H|ZE%nnNN@8oUo@bdAwPY^k<&o9 zA}})`Me}Dzr(wt_Vd7px#&qm&hMq3vDSkok2}=gd3cs<4ub?MsosVIrG>npXcw2Xg zR8wMW2)suG<6O9Ptg;5pb297Y9k~$Cu21@|>GEhXP9m&F5o@ch3XIHWbXWmY{%{@J zx-yG{qYFnu5ZEN}ITD^|tCah+IXAvT+-EdzTy|NIuziUw7jhi(i!I-zR?i4hf6VmZ zznfO!%lEJ70XM|&EfHSAq?#B%L*^xKx6D<$CkPXh8{fO#1h+3xQV7~Uf+gU5TWhz)!6a@^x`L#rstyF#)0TxI0)|gpCb*>1=6dDEO>o!1l6Q*vS8zHny2O5k z_qVI7n9+f^ApXDR46!u0nV#?HUxrHt)4OEt#UGg2Th84J5_BZEW9BkGZ#i~%ms~X^ z@`u8E95BtLRC}S0@SqU64En+lhyb6-h1^>KWREBJ2?3EjrO=XJ5%UpBQvd8h zV{?I}rCeWZck(Cz7A`TZJe~p`Gj<>V72pMm*D%&rxtDj;46oUTj)~uvu{++kzaL$m zS6a5*3KE)o{2Q$J)x8ylZKyU8QMhWdXuIQYDg_zWA#eTz(NAwjbWrL0R(BUCs40V? zkGqp?e_LU|K8m2WdcKwiD1Pu}%y7=C~SN-MV&y0~Z^(_6@8n=PN-x#tJcI}MgmAUEZ{ z$W4~K1g-@|atM)p_~a+6MFlx%Uo}a|Slq~^!OT<~>DMBRn_3siJp)_b@zd?Eo!@)( zz8Qq$M6NdvcN8m~sZ~N^>j6)Ag49(+nFhB%?B}h}K%air)om&)njbrBsp;+D_QM0ezQUdLMAc@0sPQtK%Hwl&4QN>tkFNO`jTsr`H<03LgoOB-aT9(k zfkwXD4(4;LA5bj&>Qel!xVJfN6!4Kge*L|eP?WDgDo;1V*yi<-(&UHfg*;SnTdXnLmY5@CC9T*4~1^@4w49 z({>sOBNGFfW5?9r*iau_!MADi&OTmCRGyP~U)of4S3$b6p7=NhzGH?!Vco8rgwH*1 zrYa7H3ujiqvnmb>ou5o0(z4HV*AhyPe2H+5XZIysjh=08A1~7#-eVoqx?(=@=8Gl& zp9a&Ea<%hdZfu!&<0l*?8`|{S?`qCRJ z|3&(+iCjYZ5EV1}c6m`i=kI!9Z_uOkItGPd1JfPtVuPB&l}6MxP9BYDFEdo{Lv}t zMw+Zc!}P0H!l1RZ>SBsavBhDfxEex#AxLrvFkAnp_rPpkxKjXFJm+=Ko#{|cYE4U3 z?R?L@#C5!NRd@=t#jUIIQ{Z>)@C~3}{V76}ZFP}6ZsXqUHK}{LqS?Zhh8ujR|MPc6 zMASoKeRwq74X~HGFwZVE)EXMiWiHE&yl6hyNhe$_*}mWSm>5)cnzZ_Yi$f%rn_%ov z_!osoIG@5MnuPOG0p`e#N2KE2^D+`2UZ!WSa>YG5J00YeP5}VWzlXX4twrA_)fH-J zmH42?qWa5f&ffNKz20x~oY5vdw*941``j=5|8W^W8>e@DFV90~<~KLUbW9LWByVyA zttIe#Yl#6Ausp~M$gA1t`9Pf|<-bLT6LS(aG?D9^G`C91SF20BV(cre@SK<-4ivIh zqnz%O&^V2>c21HG8C)bv?q_#~|BRu;aQ)v~t$et{;6rD|8?$3DNsKqP$AB})Trj@b z)xf0B4{#hDYRsPRsCtVhcx7xee^bKO&(O1;mmkn=D{&}pWSyAE<0Qin@8N!X@gAHR zN7q}cVbBknh1@%a8{W+MK~t(DMRsNk%lOu1vCd#m*Egm(?@mlbB;)z;GDuSIHBpzS z`cB}v=J$B5Skzd}tsEO}08J9HOpXd^baD9xuEsiLDJUM+df8GGXsrCom3YzmG2ljM zciUUg84|LKrnHx7&{+rnm?h02iYsjODc;MAc_h+Et4IdM3oL%yKXk7A$dri;%aDqW z$v(0Wm7~QhWRiH=m8x9Cgt(k;mM(O1utpzqVt)YAbbeL71Zl&}%le@iPe*>kN>q!#Vp+~8qxT1Q%szZo?yU7#D7eah{{Du9PEBs08(6F~|sI$B*SCR#WaT}xWn!yw*lgOAHTlZRe*v7~3JHtZ+9jL-KK_v6Wd zP7BF=k6+j#PelxtUd!8#cMqK;4@vL6>s6KxY427UxDTIP9YDS|)e}nQ*4OSWe3T2d zgco8%Cl&anA{Ad|@pwT@9qqqG4gpzC#L);$yt^+dxOMVTBPx+*d&2oXA$t<^6v?8M zt6&|vU)v6VM1Z16bEHu>voQ5q`TOx@OOhkO?NbIS?1C-9a`F4GbD{o@ z#B?J(_R^AH z4+(*$sAm~wwlC-<)iawjUb&`Q{^>!oO+XFnM<|s;rb>FcJKHU%IrzjxI1htau|cq* zZaC-qKU$H$w*|Ky74-t4!SK4gR~iF>{?eXr#F%2NqGwewu>-3pl0OdYcQzVS>D$-r z(-MA63oxv2SqvkX2-jYWV%BQ8f%irQy)gd{AlnC!dtM!X{CT%`fON)8U-hE?Jy?vG+xr(2!2ix~%r}uaQgu@x zBybpA=CX&~d2KcY=DzdVb_&vV?Xov${%+#%WN56}Q*vCCF_1k+t=rd~^`&p>*-?6F zla-E<@m$~Xa2g0&Os_46q=QH_lcD1qluKn<#{%$v>8=wfTR^|snURSH(Sh@kdVDmg zz4BgLD{{QlNt~1kO(BRb3$b_+!NE`{$BQ_M5FKW37SWk)Q`PLFmF@U0_p$5wNZ(mN zt!ITaL|7iaRjj_dWVbF63miqp5u9a>a&&qb^cafX(AmpGRr$JQWmE!^jzfR( zxbQB$R9_N()MP_Sd)g+9{AM%D9wGi+7qTN5lJZnTXvqW0@`+$jqTeD;CCQVm*Y)m3jxqXG;OC#Y zv?c8&)b982pjHSsv8)~740SzqgY=V9klJt~DUwW4;twu)Ty9*Eb{1d@p?fOg~e^Vv8zi3L_g|dNY*i0)%31i-H-=+LluzdX~6QH z?+bic-gr1%l~?a;hfdrZ%B;HelT7%rDmT9WJQ=<|UDX{&;!As`|DDyT4Sk<;+(@(8 zLns|UoOX2v_CDhft3 zO1I!HUr;nSn6b7$Z*Ip}DWauY`ARR3_!ZG2P*feyioXMV*DoBO=VDy$AN+ za;F9cdAuK~ETnEVBX>fj2nQbC%=qC(`}P|jZnE77Z9Lx_nv?bSPIB9>A0B9%l}X7g zN*3Y>$dc&5|EkYjj@pytk4tx0rM`2Q5*@kwb1N*LaF$43iS+XWCeo?-QaTSEO(KFU z4X&jm4RBiAB*3H~u2Ye~c`A=DklAO|5$ktLIE_xo&@G3@0*{5EV-!!l30VkY@Z_FOhIvTz-@Pi9wh-@p9Pmvri#8WsOZN#=;+f!_>TM zVaU7KD0sSr#1SsG#9sV`h3pBN9xm>4uk!R>Hi8-9RDP zdd8Bom3dF8)Jic0mK}Mjx2Pc~Aj|ZoG$NtXCA-qGRImQJ70TZYQXlHKe+m1_;qj1pJPj4L&#uzT5(X{moGJ;C zJa}=)t1bPDmlt|K;ezxRJdj!Ry4tO5BJ(evGR9pnSRx)=gn@JpzbRi>#&Y8_Hj3bb zi$V6mp2fupN(Mk)(|c@lz_d(#@Xeuy|Ccu#w9lGs^mvjNWp7+5@=vlXuTf8g+2z56 z7v`>EJH|fS?KBl*agY1BPd$9YHr%Jr^;RxU$Ht=!pO{|K!&nPjTx1+{_w>X*p_ujs zi@4ah-#1!h=?V(>klLY=r1@cZ7I6C$>J792a@OR&IN`)OwB#z$(2Jcjk+#6mvJbM? z|8xZzbD$lM9xWQrtoqmjYGNytLP|0jEje-q#&bB!!ys!dln7Vv9_uJ-u)p_bGEl{4 zzLr%09<2wykMV%XR(ja#N#hfv=?VR1mv`jXqj^%QXZuPMkU4p!;4P);A-o%7m^*%Lwat>*fdDRW zN_tPCofg3)paY<;;LM^OK%H)M)Umm`flvf$dkGU&G^7ZpYUA~ZA^hSed?BW9E&p3k zvBQmqU_nJhVT`}NH3$if%@`7PDaos);MJ$k^@(aU^=JSVN_5f0G&E1{kx`+GUzWM8 ze@2C*Jj(8y&B()2QO@JdJrs~EsTvV{>*&R^q#p9B@uaMb^>X5hqRJ#@T%F#dAOFV^ zq4?zo=$rF3O8m;J6b;}y4_T?w*^;1qN@`i^8_7mvj#~~b;gJ$4yd=B@EENCDBS<^Q zv1QmzHH$1f{Q5UIJiYhJyhuk&r^-(P^N-Wp5fKd4h2u>L@{#BEE}DH%;9x85)U_H%;7cc(QP#BMLrv3A6r`HMk!CWlDV zd-GJ-*U4asqEx6MT-VVA|Jgd*jmv^ z@gOD2N7J?umJwTJa5=wd64)d3TKCV_o`pARPg<*U{JXx*dtG{;GE0#d2WgmHs_qHlmNpDW{K; zH3v-}o2j(MM>vcAD22{@Oll(6>*@8A51;qu-G3f;9ROk&H|9E{t=FBb;lLD#eh;+= z7>DbVY7b^a@8ay&{P5d9c&_P8YyaF*CO6YMZP4zTW!_b42YCN0UO-PD%<;=)9i#pD zqfS7L{YN}n3QyRQL#2`s;e!CLyxJi(?VL)r8p=J7>-DfXPIv{mz{xKUSRt%#p z25jb+`s){0oJUqk;XGaUX_&JF#WW+{#>qH{WVG&qnnq`><+A`9GpPAz%6V|CY+gCG ziTrSRE^Ib+DWKHELh&Y+MPV`1O?PMczwpg=R?{jIzM4fU(`TG`P#eV|H`KJ581*Np zxIq2MEa!x>y>$Uk24EhO4?cUKN}v$a6%%&&8`rm0SqM;(C8)x!z%wy@+<`4s2x&Uz zuJZ>=jk8zYmqu5m!7q>WmABuGM2(!R9Xxg)rW+6v;XF#dHV!8@H9J;ymh9Fi28Y6v zTpU$YD#If4AJto;n9enkDWIH_WN=uXUe%(mdaPB z1ZZ913SB@~lr){$n9(Nd_XkN~DCl~pDoHi?V%;G2SpdI3k^{IM8xh(@3Ez@w!*2&% zJytVgt5$9>vVSQZR2r{{m-5K|(S4w9kH3Y$}zl&{>Ioa%Lsi{L$Y* zk1BT;CIlS1$oGucAexn$0atnL`DC+xAj(~&Uf&la=pab5Z!o0T`Ir2kwCJAOtvu4zkRX=j$ZD`n?_at=qxbHPvaGkakOWmzH*!oj3x+W61)rXN+kQ3T2iy+0 zw68!U{R-rss+fAW)B^g?tX`K*%=;B$3K%5)8%E}KDHm-*pt50lZ)WbTU_oMPOSx7Y|C3vKXg4qwRO_i+(wT#xY+v;N2FCJm#0nUg6;bu@@|m_JbR!w~ zoc3}fB}hlb?sw4OJ`*6mKa0o?39qOhwir6Rczj7p`0+gw9(;Wj_2`1Y>E`pBu~0XE z;y1IxX{Nj1eK|f@8E*5%J0br>oWwShbp`Eh1$)jKrFZDi_h=o6iXug_fmamQ)A#F~zsRIrA(>hmYpZplp zurh_9${X9#xr(08!DEHyTy3?oi7EFz`_E_$i-NdBS1a>pW;!u!Cr#&%4`IZjIO+W! zH9u>93Rs`dx%(@WSyD|SoO07E`Z((oZ#8iUa+6+gVAI%TTEUenlE81_ChLb8t6Ilx zV1_8s{gt^o-5!%l!IzAX_+O)*mwB)PL0$e^<{Ofy{6 zEho{U1Ikla)Bmn%%7hNj8vzJoT%Iw?Fi{E~3l_r2)hUnsT!6I>9#&c)w~jE%%eGhM z`y|EnyWTHd4+C}lPprxQGsBzP755>N)Ce3qTC|WI53*9g@hKeQVoa7lF~=X^)`}5!kO!;bX-)IvsrR zxHFmeZy7@Xf!9c62K_X4564Ga?kmY9oIw%rdI&_r9=B2W`8m-22`Cr1k9nkfe6mS{$90bBd&>%2DZ{193zy z5e!P3_@V*Nr=u%}iMso=LQMRE|MVwp5?8P^rhO`3pZ;T5`8F2ZKD$9}A?zd)cve?% z?0db^RM*h+Uuf8m-)Km2B-f9eh_)Q8hl$NR;i|u6olt^zFXDjy#2|1P!PzgeiYbYl zCqO`xN+oUbh71JV+NBPkB>PcE9a1?hHXZ4u4p%IwdToAk5P7z}25ADqZX z^G|#Bmbq4irwXQj?K`jAya`sFPqX-VqC|?HGz=?+gTf_&gVLO7;8uR3)H}eqZzxKc zMjxpGPLi4JHBv6*?NU=Sojs=sVNiPE6$MH!`Xd2z|&Xg^oah zCO>7C+s)zjTlSLylzRr0p~W-1*_IBM@`R?y9(Xn0(w&+P&f`88%h-;h@Tc?P2ntd*?+0O|#<&pv>=i3@j0Yo=vY9oQ`fzo+^Q%^&hWVDA)qtOPclbUUMG32pec`#7q- zlb;u<|7b8bk|1_%BJ~BAi9T(-vC~z^_8&Ad6Dx`QjcisF*VPxUK6?C=5)qAphVnL92)Y6z9E z`5dT6Ld#wGG_{X%%gK8Ae>cqR0rihy!|YE%ZwU3$q%VKhJNo5w_JJli#CWKc#8PO0 zVcSB|ll$2SbyZHM(RA_m!HE4l!IScQvCVrdd1A3Xl~B2k>Al~VraR6N?d_7qO-(70 zFMei=f1H{?S_)~JVmrVGNwZCle2qh66n33EJPsyb2p^(SMq)EX z=228D6+pjs9~~6Vo_;2?e}zu>whIuI@8W#Mna`2}DJx);7?diXSwNS0l}Qe8m5*c1 z{#*1Dr)+HfR}roEu@wk_%=&U%vq`;9CW2cEnydiw8HIF(u+% zI4~4geK2RmJAFXCODzh)f-xX_1!k;2xiH!4AII-TO@Z_p)m?Uz#PKsJMJYQ_)rD(xtosg11zUt}G@C-}2IxbM|%#)m?T)t56I7#N?DeHReubg{(b zpP`pzEM0QtU(e8sdGE}IZ$(T}yMT)xgd!C>#>G#sGrC!V+p8GG@~t z2oAI946NM$nv^A1o(D|^eUO;n$QF*`#vpQD4j}ee4k$C9rrMX72S^>&zUn+c>KaJYpq zC-BpM*i>LK?(_{Ye%`8$OnHFgz|yema{grZpLdKG@K8mB$aQi9#FJ3$;USZH3}k&3;6I;1&*^P*{p% z54p;4FN|?1?f2DyGeSM&O*eC&`H2Tl0p+#$L)Fc;E&=Y~MiQNJK6<$260LJ(#CYE0 zcjyV-0KNf#Mu@%Pt`dD(x;cRj1j&e^6-XfhCsw}6nY2m=u%kC4A7szqPu0%;iog&I}guDdL4Seg&{F$uSJ zGeU{?@u#!&G2Sm)1sMI6cMX~A6-7zHLLJs`nM)6f=DeiNMV}u1KB(WKiSyix==srg z4l|ijwKgd@X=N+Y%w(0#4Csx&ASvIPLwYQvMpi@3hS4yXR$Y?m=)OxtDU#)_T}(-Y z6e|uFV9WRTOP4(q2>xO!oG7JyQ3Rs*Ui}UFg%PL*3N<7dYEYG6Iq>^k zQ{fGYjl@+6NqlrjbPq!*08u@!rYW^m}qwkRXqZAb$vOJ$0x85IQo3dwv@*TwiHDTQ_V#a0|on(A6vzqS!LzE ziiRWTy_6V82TWJkgxrNp`bhsHW>|tA|4zQY{1Qes-%5sLX((x%gk0n_tx_!;M){!~ zbaEib$|@?30@(?I;*$lGi9GOWvkvhI!*I?ke}0e10SF9Bvhnhh6HdIo1)1k_Dg%L% z=_2nZg3WCMp2zF@q?Mca%GNrnEb$_XCl&)?P;IOn*h{~l)ts1y zC{>>;(h-I_$+Irvu~@^kgc#4zhPc=t?Waz82-Q7X471Sd=&x+VN)5@U`mUsQ{C{7X z`~-W*=%v+9zyPOu{2?1!jNJzmEaB6*VKS$h;@6S+W536VquU+!lI>!DLw^APTXS|HuISHmBy=+E$2L8!HaFfu44n|0^;I zewQ51n|C{6oC>D&B^!6$HcT2n!R;VCI3qCJMb!rAl_cHNZ1gd; zlH*aQQ6BNa2{wuh$TD`CmSG26%RwW==ezD6FP1~AErMl9QITuGBIQ{4G4HSVq8lM*J8I}1ycjLZ3 zkQczaw-N+fZv6u9^VPMwHS7$VP+b2Diu@H*!wa%ZPSh9REhK@zFPqWfy$5DoL9x*_ zKj|90mp~UEF0s)lgzL4uT3|li9j4J+LxdwRC;-Z@1FG_FFR1HHS{wV|*pcS=6am`e zs}i~~d9yv=i+n@WI3v*pEQeg*+U0Is^`DK+G6vHT^8??yecgF7yfU5jPocjvyr!%5 zT~+=3yD4;v5r3_i0Z-m4W>43aW_`DSI|Cw*KFP+s&pJ0M%?AC)fmJQTdIbTvvHN3I zB)|XC4bg*k_5VY-e$Q;I8Ip4?;*-Kb-g4QOec;jvTdXWoA@?5$oKJBfx{fyo1)sBN zp^T0bcCGnr4@x30c^@ltlRp`ed-D~6!Xu#qdLfSqW|R3Zi2@G#O zH#Wn=!}w(1=1Y~f{kb%@P%QsNVS=*|mg(TNe?>`6{#yrZW{-7X=O*cHJ5 zvQ;&pqU!!N0K`4f7f|QYE4c(%701cmA%yk0dJt0dR#6Q`^Q#m|zsVtO$MFn|T4cUS+)ged1?zp1EPDuX@mzM1TsvMpx6;@*L<80PG;zX(1cB2aCP z==e{HCxe41VDeq^K0;4G%OLr&u6OD|0!ELB2(Sne2a|gf!Q67-BlprqujdEDCg|&m zA@d@L|K98cyCCJ|@80lGOqvG)^gt*6UMIaTa&2})0Ai=S+~@^6F$?&2AVg@2y$_Q% zB+S^MeyZ`&D^2QdH5Ex&@o8TBcBY}%#jldGbTYQ#1nHJK0)^bTNcv0QQRDVv=BA-! zr8hTCLM0eDe-nYV&;wV-#)MQdZmj<3xC%%IWX4#_AAqO~sNHBoo;ZL|Z>F~3zn5*a zjOS-J0@%9Bog;{lv{3PMF|5uIS9%-eR+9dsT`@JUMZG<+Qa}to8y-v^s>Oj|aM+?G z47@Rcx9X9#ke+hOMt{jB-X3D@x&GPbzwM4I_W1$jRt|NZ1+(Hi_NT1Of2yg??LG_^ zrg93SeWtA(xFaFtIfpRmL02U{oPjdpKT|OBB7|wN(ye%{!{`Z?aMPFTvvQl!YyFE| zpZ`l~E7NX_$v#k((%Xs6IM?9Nx4LiA57Dm1OaR(%@{)4MSZ;Lkl3~cW`I4Al)hK=M zup!gcs8TB}&}gm6^mDlQ zz3l8h?5=lRjz@7CIn~dsDcJbT3Kc!Mg_NKdk)XXCyH;DKoS=k;z$eSG z*nGMsoRQm2=g48o_}Sk$US#GJ8%Y>j2c?vNVYC1L_VFTBWaVan*bsURzSW6~kJ?r7 zVuLkQ9FiKgVi~@xTJjpQi^C_Rs-(x(1;1DxnJ~6^&bX}A>5Yx!R2>~QEtR>w{)gqU z&~bfGHRyAnjx?3QhwgBgP333??Fb0%pZz;Jc-TJTN*k}+S^jXx@5iS5msdr(tYi=e zs^3+&caSjNNiG83zi<*KmA7>2@8kIqpi~fPB5zeDI3J6()=#VZQcR-S8h(0GyjVOa zR(-T$E9?c8`7g>MOFQvFBk>-)pqt#nOUfnC)uopVOUBJ^C96CC;e|Xom42Bl7aon{ z6l)l`M!O$$S(LIb2Jk)noaKjBn1*DOX`nfxmdehHX%yzM?P;uQ|F$k{Z%-fS)Stx9 zuadsjIo#$yz(26&2>Tc$W|%hI?aWAYB&@|V?w^^}(4U)KYyM;Xxh``I{hr@f%Tu3bS9K*GL#G$CaPO8fpViG*c7jU^)->b)rh0R;bIEw=tj+$850g1k`WGtQ)R)brPa|YdGSMybAvy zbB?Xa9RHvlHK2jb6=oz+3gb2d1XA5V2c8fyK)TFo!eWCET>JC+v+xN_UdfoM!Y6&v zfiFI;HiI+8wnsIc5+CRe1SVVMfe6^uuKZ8)fhBp%={LDL+zzKrUJ;8%gWX`?ntC_5 zxc0==Eb{2?=Xd4=bR8=;I__mga%l=UA zWSza#y*A$m>7+i!AM@Mqi5^LquQv8T3`-GBR``m6`TQQP{j%oqj> z@p_&V?0tngy;+Mzf3BbAk8F4zE5YF;1+i;@RgmsQ1kq8kW*h} z=TH)ZNwrtPvxsxsaqx!lnfl#lm69|G(=;0*Io%PPQ!-QNDH_>!x6w1NQrGT z!M)(neWw0{{Lie$F_T+xiL85X^9)~oE|)=@=gsU5h^L-&_}Udt`z8?7jPTO5DH#1x zKMDj4&rNGsb}!D|hYqmh8~A5l_T;sUksk9Qq;wt1lOV@i!USQVa0XzZG$2wT=#$eR zGg0o<`%nI-Yv4i#_FXJs-wmkVI8&J*k;eI>@_i^a+MC5txP1ob41%!E-2W7j1HWP* zIUPA5U2LgtnMSo=LsL2l)}XhdJ3Ix+ykQbopFOpedk_@63dX=NAKx(w086af;KY)J zh(aC?FC@4isjfa93$8vWlN29*62mq@L&{FNO{MFIJYl}FqWeXtLm9tvybl`_^nJg#z(u;xTRggP8+U3SnX>ETMfjSY{J5$zLmR;;DM|=~gyNQ; zBQq4rLrZ#~ZC~phKDehlgB!%Vnsu@jt z%nz7=7TcU}G#R%m3g6Lgs^W0KOhBnn=+NtZ#(A&*OAsj)%&rOqa9~Sl73A^cVK1|U z8hWAm*G=kYuV6=zg1|xC`5U)VXDlr+B&BsYTKy$^pKi91Wfa5ylHSVy0!qz=%hE5Cp<0l~yBFf=i0AB^$UhEkH_UJ9!6BEASqU#^ z8Vall@IyrsXBS8O+Lct3Veu;Ss8t%bVW@~LE)d_O0P@3-x)~U>&Mk(^ zD^X+B%_&FNS-2W-F6z^SEuyTIwkM$Kkqn(9NLs?3$y;4v2Lj8HZ>Z!GlTA5y=st%H zUif>2!>752U%_QmhEeJ8hYl1-s&pfmNAEkIV6he?Wdzpi_SA|?m zUMGbjl$KsrW zII~w$3_nx8hNHb_XW68oXGEWKAShR!myk6F-UX+;;&Z}RlKO;)2xubHQ+$I>$2{D2 zL~rse8>qHx*;^wf1tFg9oj~GhSs5Gnd`+|!eh1hwA7;PC%u4fN{^m|kQ4!%Xtym?B z980u0=ZeRT9a=wKmO1FO!N0G=bZpu-#Yg4lB6IF?^&j2bgAz zp756%6mh#y1R8!m<;^73TNwtX(jE>wG0&Nw+yUj}Ak8T5(*5VNx|o&pr^4^|5ymxS zz29$xAQ(;$M`h1Su1k|KaD}PAv>F3CcHu8(9?Iv4eq(jFcdz+12e#N|%kRF&(Ud># z%?E<4*9pD%y~wM^0KAJ|7$^bDUl!1ZG}s!}agkwErPKcROnJp9dy_oQ;K5m1a^)g$ zZVglvI9JQ_E22Pp`jwo6tQf5lfDqaCosNhnD!Ffe~ z|Cblgsm4LJL?YqCX&~uNpF@ib0evrR1a!%+!4Bm*`F|Iv|L(PC1&O=55?uM@wPzlgb$<_3X zrmYuc*1*`zeEj6Y0Dt+4fP?=4O{(9# zh5d|8!s88GV98WZ0!;Giyg4%Ng6#?*{$w(20_Y*&rV1v2?_*75I#*!I_LKK}*ZRfB zVxdW=r`v{gr`&OME{;O$*;?H8mS?rn%(Gg_3ZudA9vMZ58g(S=_Z1akmp92YG+0Eg z!}=o$1Ro>L3qt836a)wZyWoXC&X9?>f;jYkE=m{sj0@l3zQH0TWHYdLny7vj?Qr zw4MphkkVbW&%N>C-%D3HU_Z{PP!Zz8WBn&vqYDlnNOT6}Lij=)_<$b*8dWh_Zps+) zk`z#&1yzuY1%KojOf~!O;`Or({wWxuP#_fE!J=2yg?QTU+&WsYV9W+wFCaNY0yb0U zs9+s5$>OQz2&rB|3ze#lMvIpEA2-ADpR?&xkLj$VBXwty;HHv1l@y9&QT zo&-HU3}yyYhEt$2EH(kpvvezoN9F3W{rLt$LwmX)$b+nD)?mk+!~!b8Q1l=4=PV*B zfbl0|3d%yq>CR8lH< z&;D@dVY|2K`p6+!Q_O=XyO#9Ng>~=iA}HtRO>FV1X$i=*?5HPmOjO>7Bo{9!0Tjn^ zRA1OI;Mw%?jmIT@u;Lmk(qElG_axMtDfy#Z$JK5~=DhEj99I0{SR1M4@%e8BDflqk ztPQwPCH}#ZdGF?QVV{uNtb)ZZLAyL#h63YrelO1izV^TKo@t8nxL32Vz6t;ow_udl^CLA^lH)=!{QwV74sr zz=a1Q{gQA!71xF&NbpCEAZH!+S=_r9t5sZozTPVv+;hQpg;L?(ej#Jrqe5R`k4Jwo zqU$!dN{b7pj)R(1S~fg9)8B z)B3SL5@ROHJnXEO5=n$d7J4e-v;P>Qsw|8&Zqp3T=3Y0X=utI#k}mcvj%>83e{PB6 zMAbG0NF&}64Y18fqozxUvH)ifj=>4fQ#PxvJce}KF7=ZGtthOx+T#>Ia`S6u z^3(MqY-Gk18U~0W=QTx4A8IK-1y^HwBrx6!X=Ox^xV_tMvO+E>!%8mU@$H~UEXVv( z@VVsRcexSp5BzwCE`DNkzW;6W?11)Vli>PSx!(`3T-ef^`ixezK342JT>D;}b2{wN zB*=a4tljs#PIs6}u7H*r5&md%zng-Umvr5~7Sf$ultZOVtZ1FMU;ApfyIhB$J?5ZC z{*6?j=g;M}(j%>|zo1G}WhqH`sub1VcYtMsYlkTSr|YD-=!I{#51 z02vkrBNWsV8TZKG{_DhHi}C2gV?bEjnt(at-8j5=TN~0BmxEhqi^qUc0?z7}?|A`H z^F~8BEM(nkL29y_oG#KdmOyE?+L5{nN2*k*(6YzA^_HB-9?z*UaU80dFF@Fu>7N|N z`k;8cd!Ihy!G*3b{lk7uPNr@V?suRCtvWk5O{8+?-gKbV#Z61Ia3>s8an>wrvPv%)Im&b5XF zymb@XWh!{F1W}}c@ep0;eKSL#TB@?-ndG$@`V05IGNH#>A*lYMs|gKmhp6<>?UTcr zT!EeK^-Fn*dZ~{24Z#SlyHIGHmmjE>UUf*gE*@v!NM_xlIfSvZTmO+F zM|f#OTl(5N-i6@L=R7r06f|j}2pob6xaiAUJ=p4XKqoTSP-AFDjc1Fy@yVWtvgQ&yYoSD%%Rp>SCpW;opxPRy`CpuNLvU z3wP}^#>}Lr<&7(dp)m)&uy{skJ_U2kkUiAsB-%DG7uTH!2fK=Mf?a>F!nMX~k#4Ed zfdlb1^8HTM4x-&`)r!AHUAY9;8#ZuQ@*HtPU3t;WhM1a@k*>hhK|XeQLaYY zn)XA4r<{Egzw7CiQJwW-eM`mIWgg|$k<3~O%nIkBzZ6~qhQAc&6)X!i;i7ODLBAVR zg#L3q?iV+l$g}-5bmxZv&sDcNW;1KliL(lM0jc}n;H}v`{ti$-lTpN_CZvYYjOQ~Z zcY4xlT@ikLV@%)BW*m~yzwSRLWeN#Alk1R)V6vB0sL^JZ%0fv-tiSl;H(mD~t)=qE<}W8iF%!Ln&8Y zk9Rhnp@cQ^YbjM;P?sF~t?Cm=dZ2zZry0SBFE@A}%jW8@+UQ{8Nn4Pu!%(nT{~IC= zmKP_rMG_jZoqo>w_d-I=T_N@+tt>pFjwJp$hs-%Q8 zyEur`gQy%>DN~)Ts4P{Nn0Dgpmre`7w%Uj$_iYV8%93?t%HIF_4MZI3>`BznFKF+^ z%06n4|18cdb>LT(*)L1~cxVc3Wg+LCfgXHARag3^EV{a8)xDwike_x5FKHfsz3QLk~s}PG|z*>W0;E+I&Tt?_} zOjkKR`L@J9V-bnfk*qYfU2)9}m2C+iqI}m*UxC?FYv%!{^QJ2^;lj;TgT+TjEbG(>#7 zQa1kKs4zNiXjzOinory4d%}vzElcOnp1#j$&ahe9&Kl&EbjuTOMU0L;)q$8#U5^D3 zJ(M2Peg#BoNgkU?Q;BD3C&!%&FRJ}}*+DSDUID91)wXJG^^K)Q1(JMTD!}`~pM^y< zAg%%Ej&nW}*T!UPG%3Z3HEziL@QoUS7m5bkVdhiQ7x=E#B1G55F z?P)4H#fG^Jym<5JSR^M9+A0kG`~Fh*yuj|^uXi&SqiUMQrM+O`Gb1z$yATNw6!OxqR-t2*+@~_ zPg>=Pu-IDxal9NT+MOr z-0~1A;arD~@kA68iG;E`ff%|Wb`ETKVR^eMhl|3wZ{FzIC_p4(+VXQ=*r*Z1cg;S} z3L5z07y|Vs`_EnVCU5AnD-MIHN|Hh9as-3E(#Bz`Zde&_B4`t>_?liFGc})0-I=p< z<*JbF!7$yQ@-@9JhiR3> z6*EW>r{v!#j(ds_CgI|L#mYe2LCQ~>tiCzVjN(p)I_?u+Cvx4R3VWPw0DkD&|9)r( z?m3Gt*3!^R)oqpw`^03l>$1!>($H);*WTlDp%Nj)HGg3K%e;=y07)2=xJ)lY#@EFw zm{6sy;}}u29$^r(a?1<#a{dF2+bMs$)Tg&x8Ng?uS1_H~hE8&$mNpST5ZH4I^yjO2 zxxLC-eV}JiXLnh;SA3jY96GgPVYSE0r%um0Q8e9_Xbu%DE%5h%ej6hcIdbo>hPD-M_ z*%YljJT2=Y3PZ9(DcY~5?&X$MyBhr5@bD6v;v?ho5Iz%9sa^|7N-n(~Kesi^fmoJv z>n0vjW{`sdC?Qqu|0;tcwduvK%U=}&X7(QiR(;!I?d8_6b}@mG(r3ubXYO{_a7SfhFOBefRj$8ZM|^dFC+NAnYqIFDe+_+G~3a(ZTc!35oeT z1LnM9-ZHqW_PZ`25)MS=N6@6iJrQWqGBkb0Cw;=ulK8gauZRJG5v4a!)sVF*e3ASR zPo|n2w(sPF>j#^r@McuC+8WuO(=|Rj&N#Dxyr`s*N|??U?Q}2)#oXkNe6;iBze`Ah zsV+-#-R)PQ!E@U1K@X9Y7!oryeONhDbo8cez7FIhe2YyFeneJq zcI?}$VHQspD@qNPm98~YcSU?7BprP48pX%W=h+Rg7MEt{Mgb31SLl4y*B%zmAY7N( z!cG5%d!W;+ZR$JnYtWah&<#getc-(tKEop=K2H+|-F5UUgHGN!wT$3FoUz_4l{Gg^ zoj_!S{^-TN=X(|lb!dY-BM-FNE5~POzFeoS_SYQN`Q7Hhzi$z}L#KtVm%JLhOK)OJ z9Lrkn5<(@mRlE5>h)B%8YM0nsvopIo%5$S^%ZssC;+JxWUlca2IZds}=*o3h@>H+> z<0J)Wx{GTj55i;41UWgU&v8GD4BAs52FIiCg?n5J@X1T0Kj2)OeQ4?2;XE3WWsMk@ zt%Dj5$O?r8#D{a4jL342eOQ#0*sZf6c)XtzwZcN2vO_yZJixzFLyKaH-N4-eZ2I}# zg2=)aXY`Bs$(uSUdeI-ZDYo$wdv>-#!4$)q{Cx4DJAqA;i-_-qn30V$o*@81^83n;0-2yb7n~%$@qXFYUARM}L@pe)^@e^(j z^7Ya`-GrHx8!eh+RLa@stoFuI5O{{g46&vceK5Yt?M=;^psR;@%u#QjQs0(EP8(69 zO=~7r@a7+35H7)KevlAcmJ~RP6MjOP=_J^GPsh(*OnUX{c5Q=fB7navXF&efDI$%2tJ2ety3+V0~mxXw7l$3>h@AR zl*aM?zAl|b((Y)_5UhE%u~;%)X1VGB(j{v(_JopOx9izAuv}3${~_D6ib>Y9gUR7f z@nnO+q_G>kA)%vAZA3l4aTx@zW~bXak%h8OR8bTn36yE5uaE>-JGvFhl({i z(+CJoG%i6~I?=p56L#rO=iOZ%D;ncp-HXzPwuF?0>r7r{>sc+!iBd9bKiDhSpNeE9 zE-%+P-lOY^396JVv&BhLV;LJX0A|nU)I1wx^9kiF{m~N(BN{{g6c;fmipO6=;oTTK_>Cv0hLw#9}mF%)}vs^dW^4*`INNd$#z(?7?>w%k|Q<<;n^^ zADun)RufahXgAsU^29%CsAT_c5Noa@3`6zepNC+0x^pU3G%O9_sK2`GN9%5;1?~_x zdo$h-{bdC(GvJoVXGg>_S``u($`TE!*qZmsRkEF^;9G?^d?FW68e9H->}WG?($AC+ zY{N4<9> zr9nUE{D?4nuw0tJ@nCmv#R-mwC2E776NDE!q_X(%817iXbanywZq=KZjIOVMGv zqZopO(UTg9BCnQO*I82A)Eb^- z?QCt{Pq&bL6SSM3PSk;4kD3IL{rw_J=%Cv^@4C3jpT=1v7EXmD2z^tkh40Uc6DSCL z!3l2eTgn3p(zFY1KlZ;au>6$2=%9^7#Bd&^QGQLRBvxvE#{*I=DD~m z?W1c!-aZ5nTS8=Sg58;aoj)Rw^_F`1to)F7a&j2kN!mxkw%R6fOGGUXm{eTUY!XyOZh;R3f*HzUKS__P$#=CzegxevgR)*fgly1zO4^ z(q}4JwIUCkIM6$^{O=uwc|;yU9FgGt2}bE@gK;i%=bUFl(TLIQVR8U-m^b-t>qopg zzUby9l%i9Qy|}_&#%-ZMMTyD1e)72Zex2AK{bjNbFowSL(NVNGEZ;if$b18y6x6Vz zfxfF^#3 zjALHcqsw2({th$WS2N$Xzc^hqy{i1|Z=9AR7QLBNGi*IOf55NP%HTg-{Okqb4aUMk z;fa=U67baUcb9 z5MuDa%>m~=ReXVqiwc`*$t*&05EC`fxKBdM4h8*kSeOjztAXV&`FzlXV$o7}E6HB| zMm-CC-6xDjAwIgp?)i~+bt0Q!QP;P6=y6`isDe{4R^BxfV&&C}%p}3O4x|t3E;Uir z>s$Ua1=f9}#n?BmeHhEcC;t$>vzzyMj+=oDO`z8gqEI%kw&73Z{TvZ`b-vFbMTYb` zRd>5|yyh+CEH#pM4lC{3z2zc-*GYfh+pT_$`L%MFW0d@ZtC@H$@#*&TNdi1PSbksb z?5Fp2Y~xN7UAbSKJV2%fM7Dmro{FfZ_-qY{A+i}6oALPfPRXHa_WiI8)Ax`<6;|?L z^#-51D_danoCox}94qh@=|N;8;XhHAp=6Vf(X4XBem8;%rbGEG(JB!|f=pz2sNaq& zgkm*MGggTUa%A)oU+d^@isw-JVn>3VsPc!cm^(xzhoYmZ zj2(&h6sC=o=Nrl-eiad(UBU2q-rJQQh2UHpbS0E~XrsH{W`pf=LL?IFx{m7%cWS_v z#{@cv_^xaznD|^HsbckxO#y>Rq-?w|<7e?YPHYrh_V{uY`Y6YoG#CU-LR3hm>DVuc@+69d@W`6Lz$p$6JfEJI% zz;xgf`c>zm>SoodF7%Imozk>l$7zxpX;?gptdZ=9mO1X2*qwJ#qGt5x4>dQ5w@I11 z6)`}3M{zvGj;h;Dgdjk4KPb3>*$*%6T#8OarHF(;v%OmHk8O(@G$l0yG?ZPxr$*#R z4V4a>3sKM{sE(9&yWA~~qn7EXyHY*>*xEvkjq8U@P^4++sED?1whvA&8mCP!NXvvT z1<4yn)4~o!uKM`CXm9w4U;RH(%A?RrAxQ|UdnzPffqAN*DRwDRqA>0;Ay5cD1BzjX zD`Ve3D#5Z461L*W-_sk4{rp;q8p$w4%F69ND^b)nW=TDPnJvz~P(7BK3i*;OD-k9u zbm4q5^S~fmaqf&{M1PaLg@KUp^vUmFwShl|RDS;PHNF$I+o)uHIqs+RQHF*Otx^>% zpSQ1%9wStX%UNTr)xrpsKl(n3Yne}t>b^dshT$k_$}cEbj%XNd`-6>h`!!^4s3$L7 z%`4ecBUFi?y>7gU5F?E7{@w5gu}S>~q(ZMN4=*o#h7G?JU-OUX6>8-u*4aabDzDGOk=5PCG$wAP436lCBT-YWKSeII5Hu zNu^?xyGhNIlos2A2&MvafAH_NGERBeCn%ySDTD`?AH(+VH;k@I=Kh%IUgc=g8>Xdr z`jf9kZAr$Rwz=_1zIm@E5OgAI6S+|6($7`I6*e&~pcK-Me}-8^t&Yicwls=4r@uzw z2=R}c&=G)xP84jGy7cpY3;RuBlQ9o@%<+#zAGU--#hAed6oC(jkE~j4^EEMSyNjpV z5?|zh>vnCNsjsMiz;q`uvj4ZdX9G*hOimNMg_ViBSi*T~P;=^NY5^QwJpc0a6y3jZ zTflxkQX&8RR+F3YJL+fjDD#I>9nhdVXi)pA%v_F}hcR_%2xclZo`&$Vu~#0<=Ya{P zQ(sX&fi!si-zFY`{BQSJ`X!S5>2}`yJ}5y>#TcWbY@Hv^_Wzl4^7{61>o3dS8VQfT za~eIl>&$=OvbdiW1QM<_a+sX1|Gedq@2L_GkXOP$?&L>cd*QpUQDyJ&&Ee!O3!mLh zbnUCi(MiWI{hL>wTbO)FNaLBDcsx>BbQ52fBe=SQDu%6}>P)Idux3~Q@Y_*4A)zH;@ zwAb1_&T8f|&LPT^xPL>KPK!k)n|0Kd1MTG^qZDoQ9$f6A2t@vNc=7!(^|eD2O&Ty& zv_nJv)??bcL?BvjcV>r%aku&+57&>tfS+*XjP$G{rn%w;&6woSLT(!!0}`!S>p4N( zfkx-;$-(a4@f?Ms9mNxCSbIyS*VER$pTXnbnW&YHk7+TTaeJc2t$c25hAaOzmDZtU z42NzG)OphD1jVZ6Xo`{>3%RwR6N1fJhY8|r zlDk$2>yZ;#tll4-dFYN0+}w$f<;SrwS&84!yjA_mW_3n~z$((28$!W6q!mHx&gmaE zp)<*O%A|b35sj(~S&oFKu-wqvySXg}FLyij9u0?Lb7OCqSgA}VB*L9>Fv!qjikH{b z%~cRmi2D9@|BX@8{=M_Tr|GWx{{F;mjcb#k`R;lQlYOlte4f>?y-XmvC_BBN+HR9{ zD|n<`RFVUk4K7yPg%pPfJ}>PsDxlIF#ljBwZZbOH8r#qQ)&*Dj_SgZLqd$5{0;v&#Mb{5LP1bFf;Hfg7;0oU?HN#`-)-Q(!G9A z$qsu<_nPs0WEi@k)b-kNE|-{EQBrjwR|(8xNt0Fq{5YH0hr{ZLi66&1geSi`3{E!quDNDK zkbfqDmAd^UDL1zw3qoEB+f&&NtL?j4Y2dXL?I9S~CdD2aPd~bFxuJ52tcO%!E7Y=$S;(T7CP*{nA zpW{S6zxSj*p24=>M{IE0xRo~QQ`oxrOtX0Rli-454^8GReV$#7e=M%s#zzuQDX8#b zR&!_wEw;Hy5J_StSzO4mje=PD*6e97@0u-!dgrHk(KTBK(W|uk&obJgCwGL6M&o`s z>Q{8~!kj@wzoWk-7+{cLsPZJwrugSB+A5Tcq|rjJ=#&OsiCW0|MMnkSXmf-9Fdijq z=_X`A?+0^Iv zgxa+&I-;m2ggn=HdG3^UY zYy#sP6CLkzYwKV88^@;B&Q3j_rqjAw-II|Wp9hL6(}$fOji;wrPoFC&+-{y+ zo$n8AydIgd)iW(tMf-A&j0_+D_Gb9K@(VMGXj$mxF`i+@f2lm%o2Qs;9J)k?_<{tZ#4Fg<@j`Siz<7GuGRcFM!V0ZNHLWR1Eo`#(E!;`oT# zVy?SYsQ%?d;td{5fo~1|4^!72PxbfzuazCyA(xPq5eZp|%E(IgxX37*?47b_c4msi zwPkaWO-9zWx9mOc<+}Wi&-b6-pFM65=Y7uWbzZOMc)joKKhL!}u}r)7O{2IJ*3*lV zGgahI@MFq&c7A5}vON0zA6>C#zdEllU#aQ@=>i*_p23kwX$f`IQhG%VMm{l);Mx8C zbJYO2T#l!|*B>Ex;Tc2Xfu*)mH2Rr>z9;oRs=6`cx~C;Os&`f>$oup$_El}KIfz+zR?tstqZBP%n% zFS4=JPh3GsPop^~$f}tue`NI!S)Dgs*`X&{ub$T*mikuYJ@W1~KI<=M6L?QHZ?R6( zaju(2r+5W!`+$R+^Fv$=8*=ET(1*sL=I3TEPrr%0s4p;jIiT{w?8~DS*=>KX+9^k@ zOlyxT+H6&Tt*3>My7& zs?x||J9n^cJN-6CPT0OSPC+NAR+K(>upZ$Q-huc;2ALICI5-Dm?jmk8xz&ShmU&`2>sU0J`Q zgRyjChzsp~<*h2Wb987>99((hBLiiHeA3zzJZ-H&t%`&Rlj zjbJW@=KP7M%8m0{o8&C>0RqmZt=AV@A1Y$`G{2a_{tb~!F}27z@d!^KORS!GIJ6_G z35e%Bmo2hlQa>eS+uIJRyqHYUS!Bb2O>g5_QXEZ+_3g@D?T$5!#ZEWCbR7lvb_Zh{ za@$kxZk-CdIc-eniO@i>(b2r?}U^sR@?IteT0aM=G~yp z&u<(`1{TJm_L~x1JkI*8ckeY1sJnW{P;1~%njmD0UhMJdSIZ-aNBNJVm_4mBHXAJ? z&qCyB+z1Hx_Hpz6`ECqRT&=BA!1tQHFsD~91EULGmfy145}y}oV(Q+`@*orD2wOC` zK1=Er(c_kHu}nJ=>aO(9U)vf=4yE)16VWM6Ay#tQQvJkg<=bn#JZP9r-C~^0mvG?% zomBh5dK45?y{WnPD*N*Ss6S-!k*{?K<^m*`za{eh6qA!vdfik&D(gcg`{lPp^Qm!0 z^`X6CtlS%4x6B2_F4`3Fl1H~QiCOP>Z&PkC(#3^o;)K85Jnm{Xv9wm5>xvGb8z$C3 z;3%ftiBU{R=ZO7G8YnBM<%5_cBpQJZ@(dLmyCgc6`#Y(Lv+vO~ZAQ z+RkwOodk(@?^*aICR9Grexveo-|Fam79L9-rqXpPsgHH>(c_Qy(kXSE;963JD_F;d ztC?8Z*Nm(2J~-gzOO22Aqx{(XCx^*X4HB^4^Birf*UI*smib#ja;XB>a&{vH{YW=S z*B}`=-MXScgzUmT`^9RA{DtMc-gf9j}A<=*KJXeBIIlb*MW;i&EtpxKmPs8 zfXHx)Y87eOHWFi`#N+ha-r)xJHiIQsyKM(`bP#_tDCbe?{V=J28HjMwk?r8;2of}r^U3fXVfeX zbL8e`8@D`Srzc?9Ke)B;(#EzgOl^rvVWEOJy72&~F*qwZ|8@FL-D&8z7Cg>JN()Iy z%fO-AEz5->FEwnJi))lss5wN|mTd&jxkEg^$cydgLJo%7qQa16it!x_`qAp72CRYc0B=KcWi+ z!-Z3nemx?8J^ALWpKopC9*sI1s@yUBeYs&%W9@oUCGmK+a3r z2bm{b@|7jSH?nw5O-!D3!r|$XB^qaU{s_f-e~%#h>*+`&ScLT2(Z3`tAhf_pZLW@* zTD+pTkRljWvEH6Pk`!#LI&H)oHC)HJ{U?F4Xx)=%)hX;%Y3>ZJ@d3@ra8AeQ8xI;{ z;a8=VvzO7yst;}u4YZoHnS-cwQmW2+ar#~~NWC{axsu!dP!TG% zy_yKKFuz`E0xTta;QBm#0qf;)`JT#$RGPIdg?KC1H6HucSzMu9_mvS&P{hQ^Kd<2| z=^xT(zqafYzKI=(<;**z-u=u|FhTf0(UnuNsGtqf3SL6d3uSxm#_(oZhKvv|69u0TXbH9k&J>~CGAg}Ko($Rf{uo(ZNPv^IqE|Mh@9hKL|4~qlF?+CPulvt@{6m@5pLPn5 z=19!164&^p1ftcyJQ}fHq+aQ5w{}Q==Nm*ufWDu*`fBj67RMo`4tn#JK@eZZ2o-*R z9;af8oJ!9Q7w$Wrx~W@P$#vJ8;dmDwWcyZPF9mnV<#o_qCP&ipfZik5jE;9-=qA_x zQYoH%`Ss^d{MXg{5&`kajwQ0vMz0%F1y5+CalUQd(=T}3+Z*5i3_P|Dc3iU0f&p(+Oapk7VcLxNli}5tqA?8fxc1>Ju0L2r98_QdUDxu zw)cNYhi6T8s*&)k+PbEzKiCuR)6~Uw5#jp1BPdNJTjGk1**PSnep^G;HJ4oG^Fuc| zr=a@pI-wGj4ti$nFK8cC*!L^M<#=rIvf9P?k?^s-Jk%ii*u-ch$3R14@l;$;<>sfg zUEhj^hT7SkQzi{;fc$yG(LlSc`0Tk`f%RJLovd3=D+LeR*g#;(HHK6b6~C|^pX{y; ziq%Yyc}!177LaRj=$bD-TgjkW(lBd#sZ>{STdnG&(Eob+sgJ-k%JKHd?_)scp8pc0&?{Sm$T;~Y0`M|Vx9@oFK*qZ6B1~@it zeYPyAC2)Y)T;O<}j4!?Z{nLtcCBStas3`k_YheCk1Y0$)zR-5MxJO;IQs`rcEM_12 zl;}4|QdprsmBaac|8>w|=F8XrEPLcuGlq%0N(TBjJ2qFl94}FI+jC9lnrg?@dYkVg zUNSBl{t)YRI_g=Z%zLB6NlBEZ`of8RZ~2o;Lxet1UJ)}=Mzc~co#J`U{ys)miPk4L zT!rd?v#{|$)ggylDUK|NIL-e;ZiB|2Zy2dja>YRQYlvRPfP^Vje7Ys?R&oO5)^vh!JZgu zUSVbl){5)_Yo)%ljzFC@G&h~0m(z9O*(M0Tqcq>mOW4(*Z1t7<#lYq4SpVPwRpZ&t z{vGT;Z?_}VSl8@c!*m~}6dvGpHJcvGEDVI44etxI{o_`hZ=mAps`P#Uk69ArdV9X3 z&V|+SPd)Vjg`XRbW*t>_xZ|>&Xx#F7*!Kh_>Z(S@w~sWL=m-lmo#Si_N6Q2LiJ%hC zvhNkz=-tP6v7{0eQMsWh_v40wA21}aeGY>oy3|s}o0Hxo{XBy|WfeS0N~i|4C?BTe zbKm(_utXAaDwQ;XjiS-TZ$C=B(|bgd`7%DAyOvG8wb_P6{l%($;k(7q&7#But{z*D zg*mKuK ziPba&*p==LhF&_XWlq{PpCY%OCb<9pZ+D>bUGYLQ4=QhTUhIP4(-Mp%7^|H(}esQU3OVWAN|~#hNT07 z@H!t4{PVqNb~z+ z=vZy;Q;=KTP*!#tT2*fqykkHnTYck24^cCvU|L)&Z?8;s?Q`cPi(NpS%nI5qBC*G0P5?g!@6tuM~-8mS0QF4x$)o2Y+@lC8d6C>cOz|%k}-a zbdOI8{#M#y@`$zP{&7x|oy%XsL&$N#i(}QML!iZy#dtLK3{*l>0o3&4BoJ9I%o{>U zVWzm0QsXwtcc@?P+wca3{Oys`j`0 znCm}S6HVwg<&$>{#rl1(pc`}ViyzoP`y`0&V4Q2P_EnQRHybzGH&;`pCHCsMvknEU zsnhyTy)k`=`F{MpVWk+^LHxxQ_5I_hdlSh6``$jy##l_-X(0*^$T>1szLibbQP`J0 z`OxpgU-^$I$>yyyw}RfFOc-uzeocA}5B$n8)M7cXPL@;a_xABvu`$;t=f@_wF=slh z_6j2}9vqv8bT-~^vWa*#WI031%i}Iu^icD=GWFOm&nIq(t?4G(a@!wiK}$Rh!z|wS z8iti14K3<%ttGA@#O@t@m6)BiS$h%~sWc(p_r}-bLpIMOjr(mjp|FH`0u)^#YFWHaVF%XPey-26hyU;lZ1LDKaUlM z46WHU1Ze%rJANFVf2=Gy|K(Vj3+EVDR_;dA@a=o+w55OKn`zAg-0m$@4ZRVvBl{U0 zc69Tm2@rcr8N!h(#65nimtf#V z3#rjFqSBBmI`7xEIZT-SDW*x<-?k>ydNk?_c_Tq?ER9d%A2trD2QCr_H~O3{E}#AT zcaH_VdW1d0#LgE9IFx{{j9SYKL*_S2Z3)75uUgsd3PKn4aM)gRF~gY4WfdrIsAa!k zAW~){`-Ir`yHbbOG;Hm}?3IFEyS$QaZIMcTKD0GO{9C9$`RQBm+k8-E=bG011Pg}x zs4z3u%N6(Jx8MjQ*)vSFhexn)^?B^AaGv zAF^3Lx@?eXY5fX?mxibG-fzMdY$>ZN66`qgZ zS0EXPufm0cj|T$M3Iamp-Y85BFeHBetnIXj41xg{j==p_h^Ua|$z z$`matF$$h075>uD78xVJaEBOeYxFmn1&!dW;HKP)hnw9FVo73K|6y=;xn~UT`)306 zfEE5T;W|h(lF-JBGuq$?G+N;5W~JvAS?B>dAZ;)U+m!PZ?sF-6_lWu11#f}i6C|HC zuFjXG?FR%RI9ov^h`r7~rcpdJscC`Eq69h1?FLSdAaA}J;F%YhJ^R3-O|xDdQCmIr z*zhp=Rf&nr#qd>HfpFAk&xrC2Tu4~CD^=iweQFC+GKQ)7OZ4)CHk=iusAq3wKi4wW=Y{pErC^QHmwcBrf0eU^ zNlUoEu--7-)~JuF{$Pz)M!?I@TFt0~x2`D~=m7U1+{wJD|LiNiq#GZMBg>rc#a!qF z$oz@x%&!hKo_(`bgJamtSza~d7hqH>mYHeLyGNmEm-H43m{>M@oIs>$#`wJ8Xz0Qi zBA8I?Z?1%HfVrFO`}G^JjEAjHTJbsbuGGPtv-?sv6@ z{{Nu9f^l2AAS?5-J}!@28DCBJQSCT|Q57qU6Uz0h3VyAy_RCoL<11J%jw3Q~d-f=D zDRN{7Yz=nJ^IXB#2&CLvvQ18bVVzwpcDJex$?!RsBE7&XQ(th9zh?-QAPa^4esPP~ zEwOnEgua05eC%k2fM@mKlv5b)e~WlICRa%eu)NQR?=MC<{>AL{NO3adFQMefCeb7)z0!#Yi^%_l$CTWqzABp7dw?XAuq z)q9O_Jlz}>xh0-j10oD7F+{hjj6&FV=At}4+l0z+y_zEaliN7A$&f7bw<6wK$A8C^ z$_q_~kVRkjwjU3azqCeS?gV~$@*_^6q(=1>)ttJ zlEM`IUz^IN;%{S0QaMTQ%+^10yfetjhK!I{q&{qR5R~DXDa~UE;-XbBudh|qaQ`s! zZ;~MB)%MdAiI2u1w~j)WzKMT1F1(T-vSgU{|5h7zhw(^w9oIVHIemQukui|?>Yq5SCnYO*LiECB~_?iOlESoA%}$XJuls;)DOmE0pp;^$=sF5vBiUrcl z54MdfHj719*^Wr$R6Kf<{afuI{Vp#n_*QwJIDAvMK{Mg)xn>{C(oSspSZt{nJaT7j z48MY|eyxjyjq~m(dMO83$3;|QEcpEX{ok5M#S$@l$!{oliSqeV-?3T~j;tkkun|Q(#8yu!Hq0fVtRga&c4up)jE@UEFX=M{L?Z?DV)`g!M z^}B4YmAFQ8_>35o={)Zf4qggPpNIc|fer%W=K%ZKhZ|H7-oCe8>S?KQlmTj+?Bf-N zLA4$rXIXQ8lddF)i-e>FQNtL`Ue9?lpiulelG zP3-RJo>JuVX3`?yH-T)I9g&WQZPM{;=2emZNty7C|^F-`?~XY{wF50!eirQte?RVmGA zovUR9_x7$V;&NX7zIN7YmD$5Zt#7&}20GP1)Oz(HVMU1`=$}A9j$u{P<>1aHYUgBg zWY_!T5DD|Bk!rnG^DzO>mvx74u)nO%JgLM`|?`SWfxiMf4ZnB$)d z8QbJ7+j+tV%x^*unc<&z<%Is}$#2ZXZ}@XTl%0wU>IrWj z5=7+fV!n>U2OjqrqJSJ`#yKucl-6J7y)}0@-ee@XI+_FJlNXw+=bDy9WHR@PW<885(KINunptCzxCJZ+U+H3C?DWJw^nsiqtESs?G zvxnpKIZ{V*{){SA8)_f6#518JMW9Ez$HIXFfuHWmh2%q223zRrcRuFx2BkE?#`t(45q+zBTy=&TIH6JVP@5%~-NGcqMmr4!>VDPpe@*r? zq{bl&Bq{q_jI{Bd%Efg5q!n?0YTM6!Bs-JdPpRMQ5-5C5)MZ-)K%yb%KX6FWdxa_c z{L^@_bvNr`HpJgsrKj5H%Z1!lfsxLl%-lI8+0Mke{wug)pg`R-*;V7tTNNxp3IqgKT-I3Pfn;)NB(RsX2oY(@Aq!HWL-S+nbu@|T)UQCRoouvSj9GH zEEcI_SA3ONe^9^9V>dbp5Nqby8%heap*WJ9c@7xHc#ds1so29$hA~IG81CNU@SGVk@(i^!LskYC()PjSamBwL zgF^(fNzS&E4J7ovic+gOq|d-X%@pb!%Z04zaT{(DdsQ%6 z`lji-3GN1kQM2ynkfeqLu^@0s_Rei45ODmjK)?2I+)I7CU=tc6DWVUOS zRB4>bQMFXrSVApQA3zP)5fqBTzk3GCe?7jAf#&J|Vo($;+=V_nn5{K5$_)PVjt8&tQUon9CuNIBtJbO#&e#w?;p8~?$nQJPwnwcC4OS=Rt)JDT8?(h!N}0y zb5GxPoG|#%#-`j9Z-7Jj5SWEkxG`{Ar@5k!OuP@j*l=~xLd0z{nm~!IGEe}+OijJu z|H(SO5(A5Rqo9Czub?HZ)jt3`M`vObO7@L8Ty3>zEQ?s%6(nb6u&!U`ZQFV@ymco3WW=oS?N?a^CEZsK14}F-Tu+|i z#RxL4&pynla=WK!RnFi1Hjv3iYL>thZ}3K3NyS@8`(S!Xbi@rKEiWU3G4;DDxrPD0 zBKI$npMW}UKtmqL0kIoSRcSN`Ha0va`3nEMuj-|t^pw70ZZ`xuwM ze~M>^0`}r|kaGu)AEi8iwvxK=0(QuCl}$%CXikFH16yZ_Mm98F1@FdMssy|910HUx z`3MpZ3DQm>4aDchio|6`w!$_Yb}Z==-?SSH z9PZ&USd`1t+PaR?;0KyU6@?JsfH!0orXv>Bc$c3}=5B$xva#GPjx5%`8g3$p(s1`v zS)Au|-Ep&Jb_LTiFN+%KBIfzui7SK=s3mgI5v574;cmDrtkw-fmj65^TI(;%QYZR1 zxr>cScU2`@J%!5Yaw!QNFR%rDKzrdcCEY+*FL@w!tI_eh*jRjC6AH=yHpBS8&D;ni zJL@}BnMLJ%H8R*^HVgz+mx%AyrJRP%XVOnrixFFYp}!0o)b=n~r#k^sNKcU0Z#!;U zt{MIp_TT_YSWU*>3t9-m{>Yv0@v>zPvRk9>j3_)GZKH_;*6`KVg@84v%Yq#+&hKyK zCz|`5g0kDBOaghLG0w-{?OcuB0W*SIr>7%G;t*%!bL}`=!Nd)w#*Ql?ErAjg;#)C% zUhU@UFFhv#h7_T_lvHNbG*CZz)AeroupX>w1Za{hMn&4F614Evww>{*p37}gNe3yqR2W@EtJ zc{}_mWn)d*%jd=1YPIQ0D+OIzes9|O7%v8XzP>c(vWmDwI{c>}$x0tx9n5;osVoC( zP)l1YmONhvM*oO)mUaQcRC)9GI2~@BQGxY*k2*v4M9)fn-l zvaTi`U4Zmtm`{I5W%?H*q8*iWsfi5N%@}N=ERc0EnV*2w^IKWLm-3+x)s5{V`-~4w z7psehHj?FAC2J3T`DP5f7Qe*CWQ}ZM4#);;a}MmIm-VAR#FpT!=*#2H$CCNZPqfns zw97t|g4_D2F7XT+0DefkpkMWYLbx#i`!D?ustepS)@%~~mt9O~fM$$2Z^#fS4L0QP?k%~;rTAIfS7@6(L=5@TKxFs%G5pYfg(^nOb_HG%1JXQAv$@V0A13Z+`Gx!r>&Y;!sn%v!8*gZjtbwsv?lL?c(Ag~ zf&ApN62=@BV|m5mkf%*h;uA!%-cGJgrr=*q`Ml|8OFUHuL?^7oUv;W90P)lN0b57N zG8zr|AaDi&@zW010BxX|ZJhKZi+VG<(iU1e;m`DWMEK;|g$U*^dF^A)ty>r^pq6Hu z^i(=5`$gGjjlJoJF&#yo*R8)();Cv(7}bf#pZ)|ywzV+WJI?GzD_#BG3xaQ`8oeM8 zxmM**-js>fFGl}cLEHD}eI^m+>GL*UxM)-EnvLM8TALN+-2lFx@L@#rRITb7G1#HL~kL&=%>mnk%HLfh)B+GbfKWH( zLSmWJg1d&+`y{aQE8<1}8dNg>3mFJs&Z?{Yv zE>$80fBHqmF}lCw3z<=p3N|7=0Z$PJ*V&T`u{-exg|)254NJlpSqw6#nCb*j31b$# zjYFc&FX-o(svUy4@Ev(vYb4W@#nsM=Mo9o){o{8*+7Z`_v_8M<|CY}p^sDcMVQq+M zhhW;H_s`O6pi@CVMfwuYL$FCgV>gl7+`F(B25sq56o}{v6Hcgf=`m>yw zE=3^4!jkA@!b;nbihUHSs@s0){QwDM(!3}}IGuu&M;N?4VhSm3(&xIkxW^wggugCY1Ana%?dz5Dp+y zo)$Iz75<4OxxETXlggzJhh!oQ3O_jckL|)_qkOSLGtswu;26xAQ91x>yfr0{ATg;_w$r4NeJfTm6{= zMFFqVJM5t13dq4F3a5l}m3~p)d$LY*S93+{_iAiNGx}uB-t5ck{~LRI#mXR3ntAG2 zpFb6Fb!8xU%4_%y+c&l~`>X>6p$Z@=TQ1PSA>&lSCA-9@H05q9+Qae6#-sCjdZ~Bh zk!;@}%l!D+o%(zCHy464vi{@@krmz163WJ#dDE&6_lL?mn8|dYm(0Ejp{PDm_L#cn-g_XSSF7zbSP05shzwy zI3l|D0^fGa*T*)=mGj3JDgU_p_W*b2)WaKta)QdDjnxdX8?h_L$c!4e`@wX3lFe8E zc%`kqJd}bFE|J7w(LfstTJfx@bm9v)S|0`P%vEGkS)Lm+vf57g~?2%xdLwK)+v>k_;sWv&@&e&nD5tO!w z+YA`tWq7{C)5eItNC0K@rATYFICD$0dTRQ1)p=*ZENpfpjzOO z_iss=d0MW_-M$?zd!u|W>Uy*gfbdP<>z(LWDZo3U$D2l!Q|_<9mtA}pQHoUR@5Y|& zy--ZJ`Ab*Qhr!304^1 zqT|+1c(jqagzr72u&%^*9--5A|I34l zE19qlERu<#CeMr^B%MRH$f|i)2Zgd9k87z0Q17?y28~sjaU3L?lJ`P1fFv{}3`ty+ z*c74nQHU82{;X3zQnyGMY%JFSX^bz}FmlUjdC*Z1$2Oib?RcY0`x|J>eq=vB-;f;j z?Aay^9k>x#T%rN#7{p75ekd-cF7c!13MGifvZsbrUHm@3N2T66{#66Q3B+=KnkTod z&2^=roYy+n3WLnGC|eH(lE^;NxrSm_(LsoG6}f++A) zdldhxX;iWM?1d`*^9h@oG3iS`s@F<>2{Hon^a#y(&xqn1K_J7*wE58A$wbP4%>=!F ziH`q%2lE`D@CjbZ3(cWzv0j_jtJEch{gm0qS+!-D>WPT6pdN2bknxM<&Qf)&gUwVXG+p3XQb;ejklZoGyajD7W z`Bu!lFDi8{cXVdMZK%yXIrF>io1m>JL1`3855=mxPEZOru`nf>9FQzO*ySEaR@>A# z_j(#1k`%-$`yUu>b7Tb-1rLKF9jDEQWtG1)vIBjxrT49^S6+a)f`rbudcyx7+VM1_)tG7VBe^ z)mBQ`|CMR!lH-C5m_$D9VoAZSa zPJt-)E6s9y(6;z(yW%3fy|zQXpKpxYErfsVS<`0I!GB`?@Bca)-vw*iCmPH@EH#f# z*VeD=F#vv{H!0r2A>n%Y#$EmyQY_yB`95FB4Q)#pJf1~OV`j&YTVvBq?spEiAGG$6 zsk+*hMv)TgC*O^If5vZLjD8dVT*|bEhrCq*lvgu_MGV>`Vb#WSlKj3G?`*#6UFdjI zspm|5dj+VwMo|e31lSY)N2>oa9DoY(a^__|J`4%Eb~hi-4Tzk?SSo7=swTw)g-x3Y z4ZT7%A~0??-d#xq`1Ipyg#xbI$@i|`7GfAbkpF^R9wNpW*G?t~M0*K-XYYbN+(pfy zzQ=QhY~wE2ETRFzF&c}J?cTp1vi&Ny8|v3nWF^Z$7RtS>+>0}m^s=c&$C23SW$Ul| zB2&9HHcKs?CueJt$?g2?r}e5_4H^|yrTR@5uPQ$fhv%Ex z=3IimZ#T9n+Z_jM{59$ajT_x_FrUl>1MZ1BoHDXR%EP>O(zJeZ=w-tSs`gI%;+k|j zCm4!`O2tKz!Hb{~Gr&=7(aswJgk{l&17x^)&0bJa{R+YGYyWYM0~%faPyV2P7aFXC z{ylMBHkP|oI4u{De?WmPQU2r)_*j3@+zx%lv?Hc2fh<$H_yP9v!NRd5r{v^PsEdhg zz0f;vZEq~d@22M_&2Kk7P^Cn#+&TMcRq?x!g+1d+QhB;rD&O3@#l447@%fSF!v;x?o3FH>t*(ul3kc~2R?omdO zvy_4pAOT&pM7u?&T>&vt z%-=?NoiV`YeOdA3EnN{q-n@GgMNWvc;D(xW*VmCd^0kg})be!_bmB}9xN;t}eemO$ z;zo-7>@ND>Y|ppOad$9Mt8JF}*^>lLrwmxTsdn-4N3u!ft5-FCKQG4bUjD8yWCMh& zNIB7;GEuCf5QXMkJJ_NuppD5a;>@F4`)51&iVs-&0DtP_b%L;K+U6eg{dinM*4bI$ zKS^WzRqcQVs5h_R!JXi)+GyKeu*xGkn?Y`!YfF~8naT=*$X6>r1b;r`&6w>){9kl* zte{;^g0jJC6Gfs<)U{OjHtBl!3V5HdmI)7z-ilV7T55^;G+!9}kgrv~6V$F{P*nyb z+9z-uTVVJk)1CuxE}OjQW(s2gaLSJJT&6yrr)&(ho)T3QpqCSSB*cFnBb8_y6)0OS zGf0t#;j&-ofs|<1pM$(YK3{6Gn~9eGIcLqYWMCX?L#19f{6AwtJGcK?w&G1Ps%5uu8~ssEg#*x5$JW zdU=7@MBa{Lp|9HAt=WR_Wshwx+^7HmLQ{Tx-#C0okwFW%7md%s2tsyImo0+v0w9B; z_CjDfPUdZaDmo9(^Y-UPVktAO;lDP;(pF*Xs$yk|s+;Y* zm%g)NmPe(nlKfc#K*aW~8rlYRztpB5SQU#e?z_&1>X`LD9<)6L46l@`p9O!Fe-4Qn zOo?)Id_DL88Bnw^&sdj*j_6{LP3+K%wxS8h7S3O?k#w)I^SX?L=^IvG~ z{|oK(DIgX$*S7XNZQd3$Uk-?Dm9m`=W#Wrs?+z1}h^Ct^J0Fj+_u6!BbS5sWoXJEi z(#a-ny~I%?bb=38g3#8A9&TH{2{#~FwpZE`qW`Q}6A=K8f9!W9IR2VKX`eVV*l6lm zb?s0zlx`t-3xr_m0=WOW;nKi6cZ}Q^$|!u^Gj(KK6SEgSOxUq|%CFCkSZ3TPlW%BI ztF&41a;0S}VeCD!;TVMfpgKXk59GdBNAE5nZ0tdnE+|*UtpTT^1UMDW1j15h>l54Q z%fQlsl5_mQN8Su2Lbix5)`bXI1lh7av}XCi&~Q0q_|zl8NGnQM_TcYlCYzvtpR}DG zy(`Iqht+~U?`&^@gje&A7Vn$DCz| zn1_}9AIeTf!aIsAIU_;`)T<0PiA zxYK@_09BC~E_w<)_m_5Ndtl-xeC$-FJI?s53DoNDd-fSW4wB|U9rETpl_BaK7J3p> zv>Ko`iF}06n`l3jU0by63ljLRhC+<^Lq0e_-j z9KHtJU=rBLNm$?nYRuVVrtTsRF-~FTaD_=ge%EYH7@N%>`Y-1hlJ59urUuZjKA!WL zdU_5t8V4;g@YN~!@KLnfg;Y>A+(+^HJ3@u+hbRJzPO2-FB*C|_66vg<0^o$bNz zI!&nTHm=+=(D2^~-LMQ%8hM#_0L=Lkq2)eXilxvJvbx#%?kr|k^vvCb8###kA1);S zA1?d|6Ma;t>Kne#`Myl!>^dZ^1`HRh#H@N%tso>!7b>9pV{$}>RU04gQfPik0v~ek zjg`+W=oYm)o*0Co(;Blq{uXo6+O8Tpq{oKm7=8BzGL2ypuIzvPvZXZ5Lyo?+@2=e# z@dcPrg9o>OI%KC!3gBSTBdNOQ+fRWRt0S2;-@JZp#a}Awr2FyMk&T0^Y1~kF&>dR{ITX8Rb7cEy7H6e%bA5RZw1b`&H?ly+g z|LZn||8<+(&8^Pf>X-lvrM@zaI%~1;e28t%Cct^7V}&x^WiU*yx2Vx3f>P51xNmf)SxGo|`InzRZ4@Y?3%v0ylaOI;#!FylG}>99x2gqd_Uh3IG=Zw_ZcRVm zU5{(E0c2zfe{=zyajIT$ANJ2D_V{-u?$H7J4^9;d{m;~L{81_qJfBwPJ|40=6qOcX zmPUPq;l5!8rai;W);Du+>1^zS+C{`fd^Z z`3^JE3Yu{f44qYiP<*go+1{$&8Gm+F^NUx=ggv#eosEDx}w@nmgf(b5XRS&2QRC$FQ}xa#{5-~8x~8DN4k;G_%=keQ5QX&x>q5pmVyDiR#ag9YJdoWDQt!{a~?e5R` zxd=Rg6c~LeHqqtFVY-gXWXZd5|}* z7k)H&z=0$!V|))aeoj;t@(;oC1yf&;!e8vtnWXpT6|yTi6;H|hdnN*sjH*R?`^+Za?#9d{3&ZXlCEhNeUO;$@_|~p zk`!Ow9k`F%jN#`$3d)mGo88&&>=o{OWmgr1xsUI{6-*|S2#h(7F8N;s4DxYHp>(nM+sgFRHQq$*b z+8-E32X2YUDLDP5-pd4t1=pGZd9{!@IV8wmk(3m23(bWvbdk?z&|5wS-0=3q(1{p3 za{iYa0;4J_saf$yFxD`bMj+v{XKxE#3E&3|dOPP}P^a&@cH<}+klsRTSNwO|kWhTi zciMaBOeI{+8tyxvlCZQ90qa{o79a1BR`UD^Eh(k^D#LpSK;;(q@Fw z0^)`hf1qba`zjsGG3{FZRdHB=NlI-dp%&sB?%2y^=xj+|)b&g|wUpty1jBhG0rcLZ zGT^>vB{5)GxqCzwTIMZ}e?5vCcJ!sRofWf6i03yE&dA@J%o@LbGtzZf3jX?BPHN#x z>g4aKsN8@Noy(hkFe$!&j`CDEqQ6$fo=wLMd6Lx94TJqbbosF#$<&)kbJwgv3gH;Y zPz@eQNiu(v;&Z-~qs*{q`oL4+ZOWi_j2bWY(bZFPj!r-UZ`2lequkUPHx~@@*1%P7 z(ut7@7^%f;AbB+zpC_t+CYsQ$WmC0(0lI6k%^>Kmj@h-NezN|RiLcausRJH2!CQ`! z(->cS8OOebjo)d6&eIf^7rvi!>(#U?-#I=*s`ztby!GE4d<2?V2wn4S{fi&v@SUe? zmbxE{m&SxRqQB75fen;t+aG)+6O;wtcVd2GQz`L7Vm^RYR6MeJoOm~>Zr#!rOmR5dN<~TAu#px_WU%1Ffj#fb6<)?qE z0wK05vYQ?vNBo>CPXGbfa{Kba#g!rF3^ncS?76cemVie82B`@BM4b z1D!&kt4Ca$06h@y}lVCO^qmb(Yi_HvxBLU0VT44DF@nT0n@?Q3}ed zYhiTL>WdWw5cP>#XbD6=Tk^p47<5=g5~2BcLffLGzG_=~31&#`N#VQN$1;B4@ldPQ ze*UdTCUMbfW@#6GcPkw$mKlXBx^9mLDa(@q1P7`}7XZOAo-#Wv1{bQbEV%WIG=gZ` z0^A264L&SNx@mA=mL@J5s_hVgQ z7o(@GIBuykpHjZH5d63e>?v-JBS_c^S5t>67<0VJQ}gLL5T?GN7f+-fpaKciz~n1 zES=oE1yDd&y<`@`(Br~^6@j2;b>@#UIxcTnNV6q1S`q4u3y_2pl^Qs@Lh)qLQ+jIY z7}|cep5UGTcJfFq->w$n9hMsgMZ*eJ^LvmF&xvccS`~efu?WD^c{_LTgb1O3g@^tf zTD2ZA>(j$Fde$yKU1nX9+D_HVS6Z~MU$zeHSEY~oM(dlJMmg1gp0IrZQXzsqE84`W zC#H1}F={X!!11l0v1||-H%B8q_5&-1=MERtT5}Q+=SW}IsAM;?!H9wE^fie6lMOt&XQp&sAa;60ODV{{bNz0CydI%7A;($Pya{{V2-^8^&)XBtX#Ya)GKm0$}) zF<@K*DyBtYhI6Gp4bZD;Z{AY8IquoRlNpk_5vn?k2SGv(?H?6G@{fw?@2ih&v80o$ zpdz7l+J=|L{Lf&zvkyGjk|IwJu#FtSHu8Ex*-uljyxa#)P}R_AP+0%3{$Sc;sOVm} z#Oj61ec&d$uEd6UF4xPM_POjg=+6XHqaVS?Q_M*Y*GC3gPI5k+!8*k}m}Q6h@qkhX zsH+cyAv%htA*I;yIVB+4j_l;J`rHQ!rHE?e8$g-i!9bLv3T38&q32>@<1}kFbTeI9 zqEkMw+gqr_mI*P)%iV+5t`p%PPPGNLVcPXY$B@w zMyEx1N~cETW(;7Asi8jynnn3}4#`*v#g7Bw-_~3xeXp4uFRl(g3=?C-{I7DlvkTl!T@fF6VB)i2 zP5||-G213tB|rC%7XT7ZNK7cZ|BiLuqGZ9~p*PF4K@!F=Qg#b0U5f*mX(4DMaBD?M z-GF|u{djR=rS*#U>*Txw$B>(|cI_F&kx*=Y3KX_KO+Z2vEgIIQ9Q7OmTJBZQpF`BI zE@<|~j3#y~E$VK^A}n=SD+r?{y$&2LUs8AeLoumTrC7<%M>Q2)?T>Vn{WW<^RB0C^<e_fD4M^CEYWI!dCiV85%oCTlq-FPz-0#ryWog0vE59?)0@W$+HoPJpR{o` zM0xQzYHvR9hmhg(PQ~lYaR8G8q8i;Kz|1i32Cm9VS&sv7^BCeu;3kWb^+BGh&uHxS zZH;+T+Z&8gtI=ks(BN|RYWVNHJ!lx zv(I$@#olj!C=1%5rr7tV3(}KhBN3$x-}KlM0~aVWpi2VZgIn=Y9l8KS;$sCM5^<{& zj@1;?_KLQKk zoRnh!aZXBGI$G+D%&jQ&lfmK$#ZNgmimtaiK936C++A?P%oZz*)ToW>~+%VK*Rld zQ8M4fs@B}5M6JkDm}5?(M<0YNz_?F>jbb^?!`IJZBnJo>FTpsJqSNp{a6wl)o&SVFdklWye_R80L6_pU%Q21xODM?b=Vg-+MB%&e;A8`xu#gdQ_ZFsp?-981hub-B%|`bA2G@aIm$S`Xtw=%@(^jbLXRTM@T^&o?+*W|hZm|m^c2xO3>MRUTS z;31=zViOJwP6Z5==i`a8nPshvtwxqlT}8q`;p?oAn7IW2F)AA@Lg{l;r;JhdeVrwNCxNEiJbo`Rw zWP)tqFRS;7h&PmG>VnbOBZg9r@d``d+!y8E0wN@QB}d*$on~n*OXpzJwHDvvg06#2GM0!GUOH&NA?4?*FUj&xbSJXPd1A-ZVp|oa z--B#Wkk((%a`lh25dk#b$6IME2#xodee2qoPthB~9*@Bb71oQQr(AyDn_sy}*XqL) zwQ1fY*mSL{_Ux0Z2k|4)u6+Omhrv4_PUij-edMvKGO3n+(^8-#T5d2jzi|(AW}vFV z`>(1}cM0rKXt6RN!O|#Vosp?i9Im#L%g9get26b^ z&zeSx*@VjT?w|$%1TYYW9pHO#STK8l>`;IsdGE_>tQH!;6=+dq@F5JkahKSro^sc> z+7Mv~bJe8kx6-qG%i_IC3>mhm(Cj&| zZS??MgFM|Jx=h~Os<`U>8HnDnycrs5(RB$518)2XZZgJqjIeoEL4l443FzE4RS9kY za4Z!UZn0TvT6$;UM0+MLQA2ko57v~Z_P}Q&>gj1WK>y|@4nxWh4 zNzb+rI;|B4q)&Q|e5?sNvE`N9LM+suMYQ-MEbqr=QtF;5KPO=`FJv=lHq-&+-XV;v zMNBD$g#wVfK55s`<52i<(&F*;vw4F;u>k7JP-)%l&!88p5j{u?$?4luj@^6)gW|5h z=DX&$gip`k-Ato+hkN&v4Q6|SL;}3l=+CcS3l)ANXk@6rMXTp59`3qkMpMo~PE#%C zZMhj)D7#gmI6ypr-W|ME#CAGT=s5`tlBWsfaeRw$Aoz(@wG>$#wm6vP@rr~Csw>u& zWT8&-*3*VV8MbRAu&)e!WqaE+h{`L0pdcU-_`qoUDxm19%&|Jnf2NWNre>GyhS$Uf|HTR6V>U z6}kCN41$kP_8#nGl#T?T@y!$aAvAtBLpqbiMi1h>_<$4ovH=cbtAw(jT}n&lJ6?#R z3dbtDIG*}*ZY;PHU>Ms9t~0$^*K)_{K%xQ0Kg^QASTKU0>brZ8lI8mVIuR?@Fv|-N z$K)m5{h$EXQ{jdoU`zhDqjFCVgG#-I=#KhksmL4BZQ?B`u0l|%|8##B8bGPj-`)*s z;xmiE7it01pc+YXYaP;Kc}XYbEHbSXCt2C818!Q{?u{&+^c6 zEbD>GYgB^usRTctABdNN08e@R9S-ydC{k(zU`7Aq#HolfDldPnyqhYy#(St@+z0UV zLERQS{l_5PAIilbbjC{Qc1vML7Xw#hG3E;~j8NgBoM%{dA2zmD9+r6Ea|-UIcz^O0 z{G6gSX!>nE4ay)O@y>K45ufnG*?ErJ!0xH#8x9^{?Bdqx7{=yPKK11YTy|M!vqM_X@f=hkX(K-7#OuYvKRU}`tg zV(792^s`nRF!Hc0#Y&^_=MKpxP5EwKFE1&7#fmpXXr+Br}la6NtrA{p--{6^O*3Y$R;d=Ma zF0*CKdj?66;%Yh4);CvGC7Fx;F~Zct({z@TN7>SL_0f-1XhT$#oxge(kiU^1BZn%9NPhAQRF}!Klv*s=_KoiY10M@~g$# zx7rnlv0zYnSDxcQl{@`+j;i*55;{~-w*KBV3`^WE{qk?4x)y7b?ib_?ag zsC7tk2#^%MJzD~#@aBAO3G4ZH4gyQoqpK}XXXhRc4p{I{7x#akp8Eg=&N(~V6#nS2 zzv*qbn>E5e&OkJk?fMh#zfu*m=G7i@H0W)dh}IVr1eT68~=&*0nnrITG6 zpN>^#Qz|yzdw*^@yLSXEaXe-<(}h>GUd{~D0;L{f&#gaop5UtvVSX9lk5@PiIofRM zDZZq!Tk5Z7Q~Cte-tY~w82#`D37TlC-O7J8gR3N2Qw$ZSiV7=~WgLCL;ifzlSewKT zGyUT)nhDYBO~y4nTk5{e+C9|FG~FGo*9^OS1h&U`-Qw@0^bj;djE0~ajGi@~P?|MN zMr@EJpfZ6h!PXb$@ditS{}2>lektqK^)cLakwG)r=6z}q99!BakWAXFMk>2(x%RRO ztZDT|<$Inve>RFC`$q}>=#+4^i~C=@fpqIvbJOCHN3L+DM+J>p!C**%R{``O00mwu zKtbyXXh9(Az%rmEgK`p2eXDgwBQM+#2rxT{gwh`6PM-sJvdy0r!#5ifXaX$lD-;KqyxG3&dE*`I8LhphmEs ztE^GVuB8VwsW1$zz!?^Gj;6Gw7=HQek7!|3Te;k=9T|TI7-&sE|5d|s5eb$`uL7`; zJ=1@S7ul3A^QH9tC3i-;CZh+Cwks4b+yb!nsKD&J8Et!E2g3`=*R2ziUr1?xM}2=Y zta<&V+Z)SLV4&(8dlOrE?DV@|>^*o?WpkOI%FLU+|LI%YUJSRM!|VRKguFcbl5W)s zGWw=SRtDr`s>rARa-bV<2ZYb>yAP-I@~)GZZ(ouH=Y`RF&hiR)$Y6P40jNqy#D)c} z`Iuu#b!H~ss^hGs=`@XnWC1{G9WNOKjB37_Kk$WZ5_tJ##Iuc+$^D50dFu!7#j7bKf(gR z(OWC9DZ3Mn{$O|9Kx)_K@Sqi(U+$zy%lE3>*Gwf&9u$$2Z?<_BP9!R>p|m9q3p3w$ zm`lS80;J!>^rRMX041tL^2s&7Hr52Dc!4GfvP}wJgYVu^bO5;4sjp#4cpd^ z`!3@Et0AJA5AmHEB94!xwSOOHNL|CWto0BCXNQcv-nMruSnmXu$zvLj;*+CvkBZC{pa^nU zk6ByMh=p?DVqDp(23OdDB^%BL6$3+B(ue|OoIL)+yYQVrGnpF$k-#-rRzZnVuY7(@ z-O2!RAd7aM>1n3i%7c%iW8f}$Bh0GQMnfBPi7A=`;=XoO6Cx-ex+splVNTUtc_#K( zayGHJ?h+>rRFwfr+@io6fS$EgEnYyC+*0KC9K}V$Yz}+a^1Kz7Xos2-0!3ZKw8pA>!iP&1@vYt4%rt^Q?iXN~oTE<%8xYNs!dH(2=Xc^*jo{nT>6$A$l_Bn?`z3B^yE_M@IFeO6TjPKilF!eK|BhXzy6>H7{ z*0MAdQ2PopZ}k{T4TnHy-~@H5Mi8c2uBHW-lPrt>uFag6_;1yZ|5LN0gH{SSgqi3Uf% z)1JpOyvv}eE_;T3abOpi2WwScP{$WPM4s+}Z18}twkeVGxfVUC)(GIf%v9R|k8J+3 z3hqr?+QE^{^yZ08g3W#Uv%|k&d#_dq1QEMxciWQdNme@6vpsF&GATb8eYPr0q5LTaxDuju#i4U3jd|nUVB!~wjQEg!ulvf6c_H` z{YCB{aRm^1=PbUS55@K{FD@*VAqzXb;AV09)PYU&|5f&IL|7c1;$TG3h{^H)StHxZQ!JJiTwtjrz0nK)tmZ=~_9w7d z(MuLq;oshnuvWjH1?g&bwv7m9?&&SW*Lnr2lqt5pV`(-?VY9bgjn$f5%=5D%iRGue zpsipvU|*&{f%21PC$Q zmjKc)H^i4vWAc6PFsF3yZPSRFP8aAih1d+EgG6@s@^&Hd6mf{wspNnq=q=5zYbP^4pxb z{uaYXf4xw-PJSR-tIdDIC8lfiU!AB zyDI)B2I7;3e*`9!I)uRdlWYT_k&91+kUCn4!HqOXCx9D)FLR^Pvy*P!|HCtPw>olp z$tYjVNu-X<&6-e6475&`ssxZnRVOaqYQ7}6%u}e+F(c-!pYPEch`X+Z|39}7i^fLT zxX*x5j<%QAHq~XT?d8JOs(rz539MEoRMY^!F*$v#IKla{d@FM~Pt`>q>?6m zI$x9p8v6p&8>FgvOGh z=*HxKtsUgrrC$LnpUZMA0XL9JHXWy5b|kcvt9|VFb&eg%mCI12YsgAd8CqUD=08yJ)!_jO4rS$4W=*cn& z+Bk|HM#V^3n+{_Y3W*-3dlHoynI1;+lbC5Z(kpN~)s4bX#{K2!z`co<68wFJ?xq${ zB#7!tWKe$gn$P~&-+ofhslCjUrz7<}$RcsnO$*qRf$ie_1q7EldIng*rxGfDz9Q@~ zxy19kJM;P9e$HQvj;8)xQ77FwhD*QtU&K&ef4ex{CSY04blO&?`+v3HO#SH+OjO_+ z#(0fSsF+*ggoV9GLXQ2KW<(hU#>BIr;9qGB#z?+o(_@IC-g_t)i+vd970g07#I*d~ zXw74S5O|i2z-sIhzlLrszCc;@voHS6fvJsb*0h@Wk08qzBRJ(!q?-Ljfv>|4d-euhJ%vAdnp z@Wr^a%XmN2r*C|eW&IY01ta_Auv}s{$IZ^3anyTZ`DTna+Gb~6d$78#0WRg$5Pc|fC3-I;SeReI<-NIF8t

d5cMOF#vJ+w@`=|X*$o%)+#jGv*2sJ0;!&INRbdUcme6R>m9b-zg@0tvWzkX{ z(;aIFA|b+N^!O!xccu%VTOfh4>EL|9{D{=0B_X6p8I_YS7OUK*uyy@(<8o=gudP*f zog#AD8fBkCBv9t>-0o#Rv&dj6FWd|Fzw*Y4s~yL9s%Vq7ICQQUoskqW{fdqq$Y2q$1^c3oMUsxxQyZb{w zh!&sKa5Rl^US5BBzH<+Oqh*Gn8$wiu9Y&mVck%h^la|E+9RjC^)LQT^s~Mr~I;lVr zf1JlKjNEFed16zpV2J_cO}9d<=Vwpku%Jr^qiPfk4%Z5lfiI`VpqJg5>5s+n0k>Lh ztE!!TlUi*{Q2MR=HZz?28vAi=2s9BWg z7|IA(vx-Np#us{RxD}ughXe5OWv z$JF5neN!PZ@#*zSwbwTecLxEzzx))kHe+-{QEbvzd`F&%91{)mEzAs(Olt{t|JJ!D z_(m`*f@a-4D?J^HHQME6qVd#kv|EHU1EFO}-slbr4l_)=3vhmIf@<)3L5_DN_TyRi zk25+(9AyDkl7)|-3TLrw@NQLa6ki&Nw&{6Gtz9fwc6xaKlfXT9MauL~!rHop5XBLfoG4FyS!PC>f@cO9araj zuI!epcV>jgmz)@yJ{HY&19^H8Y|yMcx&n;VdKtt!57x|WpG;=|YfJUMT4PBp4{s^= zZz+3E9jLK}>(nZj8m=D+tMFmmfv)DEt8sfLE84WPrzao+4+|Vn2~EW3?Tdyg;aE(i9+m%P+rLqtE_@&G`DA6PA4rMs4xu zqJj-up`E+|YU2nWXjUZDH@!=+LYNbZ3BQx~RwI^4-o?dmWl_c$;x?=Jy`uSCzZ64Q zkS%!BMLIvOcvf?M5=U_CJkhgBf+$5fvWy(pfCf*AA=HB|*{E|X97iB2Uwr%||H2MW zFF~Nrh$fTw^4ba8Dn4=$p9t0vJ3_i!2c4cwNX%b4-VuFf&0dm9(eGPKhm5-dx2S?I z{$_z}LFpQi73_an-h!CDlKV*llAAzsG(3beeH# zihhEEC5i{#=M(h9@2SE3+wZkM$$x_7dG+(VYe(a`AFK_|tHP*f#`hkSSz-7q61&$L?(@E6jsx(x&CH z>OvPWKo<9=8^6z3*a`l$fY)`Q-Lo2NqxlT^_j$I)+caJ7naW5h7lcLUsc^3x!WBD()5hiy zH<}_3Q9OfNIzD+`qWt4kogpA}j)3R>=)WOSm2BJ7phO)3|Jhi0nyVo_WzF+6ca3ZW z{T{(EV)8>~T!2dg<)>21U&Or`Cft8vt{j8gAIGt7*MH^zM-?mSmbLzTMa5^~YRdTO z19Hao!lh}W(eB@on+k^qh}K45++Xj?nATgi1M* zZ!(SrlfWN`xWcmb&i_#8>*VFZ%}~qzg=BuP|E!W{lVCQNn~`|C%+Wz zpUzJuK|UY4hgP(mm+}Yi8uz&?e}%E}XgMpIy<)+Zlnmc!ZK2Al>K>oMyW=F~u!kxO z7jYr>H95YJG*7H)EO^VM6%+IzE|xKx9Y!lQJ!zEF(6AT@Mnrfxq8Ljvh2Oea4~pBJ z^!LdCZOScpyK!er2Mlm(*kRnRuVqCm(Zq#^C}k#vH)RuYWMa*9b;rU@BcItd^eRpo ze_$0S^IvAg!@`i0LdSYl7-9N7WlX7}neGDFvgXw*Su0pUFyyCY;;h7u6B?wR0L{1K zJ#vv1^^ z@iBK96#h}Px<=h-R^=1oNC-!6xCKpaNB|@HY6g?cz7wfhHlR2Ixq=@dP`-X$<`{pF zZiSHst#UE+9K8~4(?CL%VxoxbU|nYZzbE+fm={`N`Y5p+9|pz-}z z-$$S}x);y=*(=AYst})|N+=>tMYf<2BPLHAk$-$oi9U&Xr%#s}si6@eL6x8tyLSU! z5!G2h@jW&6bVyWzIAs}G=I0;CDQBO8Le`2XE2FI5Q=?D2-r4G(_l26H&;BghUN+}z z()G|#bE)pCwz`Zr9sSX1%DGBXJb!=xN5QcvC0$#`tD)KJ)#TeBrCzCgBrdlVjyaVL zLv95~o%-DJlg8ET;!*zify9%fCu2qgucU0baIji>6XdeI3})FdVk&w+zmkQu_%YXX zMdxL)BuiA#A#~K0yfD5NQlp7Tb}h2*CFcJ;CUKcQ(kNNnQAxBYEBCA8{A^wSAbN6* zw2Umw6drq+Ak1`8)l`w4V*a4MB=>8%(wCC)dWPrj0`dx_e6uP#g6t`w2tT^8!d#Xx z;RC{v3n{YHVV(xPU`ozj1Rq*gy1*4ZLziCEao>Zq3XEvMn(Pq_vmWeg7PYN5BvGsa zhff|{qz{`@+#wd|S+oBg+Dvc!^=fS{eK?nT=dmJNZs8&S*R$>31x-YPz=K(Eo&v=t z#WJXu_8Zt(L11H{1Y+|IOD7;s$4f~HvZWIT`6YFt5M}KNMc4&Vt6YUdWl2yb=_-6L z4oG#EYq*&<-WYBv~|L=&kOAH+L7bXWa1s#PEB3E zk)(XM)Ui6Km=Q||@nXt?kz-@z3!9pL7!FBUM`h((KB$_sd)*jO=s4ZAo#&dOaDl@mp1@s86l0piUfBgm>2`4 zDhyZQhuv(v6Rm@);IlyTF7@=8IenwPS8mRiEwe%oKA?i=M~r02T)_tis^w>wBIcZ> zXRRo!PU;v$FdX_#-#`HREb}CO3){#S=Or>?z0Dkr>;RrwDy#WuMBTph@ zW=usgai&UvcUi7IzH067W#Axf+H}1kQPq(s0(2p<8^3F3aXSt3*)aBRfHdc zC|m1YLj5E(aKhTRm=hny7e8;B(}YaD(5$Qfl#3r8z-L4^#O@sk*dTqS)?dh7XyXI( zW}_pHljCmXQIDsmY0Gp=&;Z?#q_;ncMKWjFwm)sq@2n=m5(_PtU!;m~F+!FUunnIx^?YU?LKOc9D{n~C+xT( z%qYatRLg)~$zb&CHMxdGqE^JLYY@SpCmUDvAFIMKSQvCfqzjFR9UjY&AqxWgVnCrA-{k9@j|Bb#2GKyx z0lGXs&NqXp?pExU!X32v!oSm6OE$7dS?StO{V{U)#Y}br92B1He6*CFY01p9{!)6E zI;(Cmdz(APwM!#5^-dpqkKXO0I*`~X)b#Y(XCe3x4THpI*-%s@Bvyt!Ao*d6D&9w} zU?iFBTB+iBls_TX2daQ(RD3j-bU5g1V8!B{w%57M+o-yLPO^E7Hv=_>sEIOpZGJCr zU7uy#Z>;Rp8EqIG0*aD2-EgX&3n= zcRBZtjnHnd=SS7-DE46Z{ zJRn#os5GXN7F^xKWfnL-K1n#0|1?faXZk*5P9!%FD?WjYEp4m5%rT!3fpJVK-jN`x zqQ{>Q;K)1d7kB!1PJ^2=r+2@D(iMW5I*Gcu;NlT;KUGm|$C@Q#4X^EZ>&iZS{h}ZX zhDe4Ck?i*Z{O~Zo;u}NkKXRh`+g);! zNt3q9<>fHiDH6hlsl=8be9jSO4GBdURs2vWq~Mh%`k{t49&vmz8ZJj-h7u-Mj|G#; zzesQl6o#AnmtYT44sK`oMXNqB6b#h{{qo&E&hT4Yz|cVT=qrV=bw?%k{>7i zrO%Y`6GdP+LhMlJv81hyCG06Ckth!;<@$f(CGr#CVJBMCAkcfZ3enOp^Jltz$HUWz zM`1!rra&!9QaRGo`rf|4Chp{q5BnNx-0&U>YhsbTU8QP|u9c!=gO`P+L&iY=&G;f| zFKfGOL3=C_Y?Q3_$6VsYi&11*k^y8SS@6Y^AzwT>WFc?G)t%g4+|@bZW4*m1aw> zwAI5dYSnvBQD%Hb3>s@qH&1^-O>%y;H+}Gx_9f?6m?5^AeR%_hRQAmJYUJXXC8A6B z6;%NVA5j?!vHko8Q!wL(+DihMVKqXR327KGHWAdwiMu|}k1r&cncxi1y(ut0U-aIqRT82K>Z{)S0u%2 z+BWn)Q<|Ue3~YmSZqa_Q4cb3srsN+Ld>gznM8Sz0zo_l_5SRjQ=huD-U+@k6=NR`r zi+&V)fv!^JZH+ePe0zlA9r)aK!m=|ucO3q-U16Mu=yb_~EA_kfq|SE2tTV70eSRpc zD?4NJn`lY}ji&*4qq*$M`MXQ&^T{d*JS@tz9_Ta(EZ#ny@aNx>5jU3`i@rze;T@U- z_gC|>xmQXf_WZM9bvnkkoYPzi|I^Q}i*bC4{kCj(!a<}ljhKOFwKwa+P-YesZp4CT75i&wzsPm9fOEGBr~sxr)Zcm=BPL zWr~m1v5}B$i@rR&QxbVD&3~26+!IP8{d%Q#^_l2sJ!^5jr{}kZ(29-v;lb+VHU}@v z_WAJiYHGla4c^fG^Lv^HYMvOb2?g^He_6x={49<@;Knox-~)_RsP&}FL!RmE;z9j= zRb!jp6$^&aIkwv~%|+H94bKdt4;V^2*k@T7%?Uo?y=3IXM;wN4+0Y+Zpq(jsO*C}^ z$6TVfGG8S^RejZj);zI<&O<*Wl}Cqm3wQEB+;eu#YO0)JS{)TQtPS1yMeH~Iu((mT zU~I~A2)n0qbMHPweK`EbbI5){$#%lOBeqw0h-VNPsmtJm`GQW5`;BXt}@-h9u%0QPBCa3_n=n>vIrk`-E9A`0upFJ2p=v9Th?|5597!>vFf% z4F%45m5A6aQgM0uM!Dw#gngSoJkiBz93MMhy%)|($>Jn>=`zQoou>Gh7ZGN>{@MZZLF3^Q|6bBT*JZ&td%KB!!ow z{pN4YqgR`f6h}Y2*n;)mgJp(qgv}0?Sp*n^McDoaT!b)Z3JR_u0#}aj{woSsI+R{A z`?p6NS^BcHQHn%%5z-8%EL~~>-v!7($1M$%jc!!&avOAL@ous=y_YVNn?eeN7LF~X zKmEd8Kg!`^$7;cdV6fT?VX$8NW%)U>e#CZS#u?%k(8hhK;=J%B_n<=%%i*=AHLS<* zCpRR4>xn`Vr^2O6fW>&v9`o)O{%F+CR#9=g$A;?6WZ@S-E}>t0rQYX(C-ea%jsWF>+K>P-9AOv$b+_4FMHkgalss5}* zct>iDTzeeXo1~O>bcx9c_ho94RjZWrk`0C>Q0RV1(tAs9_tBt*e;R&dLZ?=#DTvAv z%f%r<(3Kp)EO}$HFrB$Q0%w54h`a&wDzpB34_<(EFwO1dwP9jxEX zV7KvE-~EoXyMrxM{`(!VkV`r1EB{(Bi6l%k(Q}ye`w#s?Rg%7a_CBsXed&>X*n>FT zh<*|_+hNSa{(cYD*`7<0iruoiFQew^>1xpy6tA94FXS!N4x7xEkqY&W8o&H>vmlK6 z*sNJ7J&^2Tm{tSbC@ow_8rOsSzP>~ya3f&nm>J%0BI-^o7mop(o}IgFm|r-~ zy3NXkLs~gR51bv+%HewG!A-}vo=#0V<=?{>k3{vV8m0xdFU+)d*?3nhuMQ@zI3H!4 z?7uy!w;+^yyVgA~w02D)%Lj8k9=lQ;XS@T&@M6njZ~xm2;}jZ`GwW-Bq^g^Xd%*@{logw!m}hsb6|fCm>M zTN)umsQV`=#b@YfqpRn{+0^@6W%XYRXZy?brL@r+3C;lBr-jy*qfl!?3-;qTxuNu; z|8=`88*j3R!~5fNyDT9(vLH=$NU~u>B!wvy6!}5dGGcltBI*v7itS+^qjt9Yvf+30 zNB9!GjgT%@jtTs8EqzVHljcjJw(2~Vg^2IEHe#xe^cH0U#z5a3T+SYzl%4NCfBZ7q zdp&YEUp{|)VD?*wnSQUhmB?m_U2w8(JD`xzP-oG&nn`@w4<8o1L2~)IO4qV3$XETp zm*1bQy-wZt5zKT&b>*eAD6Rg^Ap|(S??n*&wVSK_^tS;+vwG31Zy1 zl8v#_``6{geF;PDuU$Bxl_hn-OhGHl=%NP))3DMM2TRDcHd(fo=y7m#gfA|SKDaJ{ zUN8Wa=Iga3*hhMAF4 zw2RCfuNyz#K)5#ipg>1OlhJQWjA>|Hf+e6uy8|^J?DjkZq*}1sGY!na09ylGThIa)bDWp31>r!Yxtz3e)7MDYWwz|@| z26k^zq5Ffq-ff-z#w|%!-raHf_1nKqK;{>szyt~5HSwotj;fpdAu+PYHyLu1WayQP zuc0wMAZZh4ot#0Xrz1a-YSN40C@V}Kq{sFN)!gPPH*+$H8}{N;us)J_pffs5beL;C z3lljBb^pXDMucHa#)2shg=O8VmqMQuX<*3vQZs(dW()tx$t=~fM!dj?g(5nc_)4S6 z$jy02h?S3*f;quWm#4=j=v{8t6>IV{ngrePFZN1dVaWkizt@N7iYbCh{@g+eDWAcm zq&CpoJ7x79j#Iqf?xbP$oT>Nt($nE3+I>SAM`PbLj`vWCmIj|k*#Z6&e-NOSo%<%^ z=sVZq4;u$ezXqJaeYil}dV8{Ic)F=zKTMsH?S?ZtSXHB|aT4){Y8IQE&e04_3O>YY z>{VDCd*vK;LQaXuME3tQnc3jfS{-j{4&oGNGFCuN=rm_?7su5X=j6&PSI!SH z>CcUYGmn9LM^yhUHsd%UAv^r%AkRgJ!oG0l7CRboLt1NH6-z+Y))7HiF374Z5GVYQ zO8sm^r(xz8-kySuIqfsR;Kr2OzK%9S6p+((#hL6m$1s-V-&2ExC>03j^c7J(#we+N zG2!zk+b>3}zJK8y{PbBX!NnCHwMJm~-l}%wM4j5zqu6`Fl%w=-OM}id%@*f>z>{;z z2SaE^Tbs-POGicc20(I{2=qmL@s86^%O_950nWN_(0VRIm$t7e;~$P9zz@EXcBeA= zch7bXcFBL?s?j#dPi5d;L-J>E`Sc09t(E(4a!cEf z8K~xrRxa4Mhn;KFdVDK{V+;75A{ewDaDE13n7{qg|C`(~)hz*M={M9MQe0ekC*keq z%2-~C=qkUnTzw6p5>AA>ASq+$U>0cp@mG3=ivGIa7{0Ha0T32jxir5fLmJzWM!F{R zKDL9f4kr)oo>PYrZ*h8|!TYwRp*UhbPj%qwG$Mg|All!LA~HXnMFG9jo!#FlUakWn z7R7Wc=hxy?xZf{v@fax$rNPvT$@T}dgjT_Qk7nj{0Q*?DWU2h;gAEj%S&|!4;F*y- zu>#;CqdQ>e-~K`L>*xlTb+Q-hqQ%wO;^&(Nu?&A#3e8SM3#1*r#~a@LxFRF8hC0^$%LM~gmq#w*&(NDQ%%p=gVO#}_D?#D$ zPjqLNE*xi=UkzDk5Y8|y3|WGA#PoN!SIcLaS6=p0O>Af3n_`28qrNI7K+klr%W)i$ zJF@JdI&_R!9X$G>m7J4@Au30(beP0yvF)XglXbUyGI`J`&=VY@cQzRm;r-!{a4G6) zs)-9!Vxz)*f5!eR@6xHNWEm`M7ep0iu&`Z1Rhg4TWL`JuS{`b1Uk)2NH7zHnMNrd? z=%Q}^3Hz`hY0lMmp@acFV-L18jChD1OZJ*W^txYidNdQZNoIXZ4Xr9x=2w%-WevL_ zq+jH&bg#|d{;Kbj>oEvRZa+WHBj2YrlzhM>WD|;%2Eq1 zcUi>dI%p4~+2|$iVOcggtXJe4<$H{$`KgvyJzrHohVl@kZaaVPGx#`-!Mqb4$uH?N z;m;2k2~QCi`Z+7n@uV`Ja7vRbY`34rV{x9+q$O-XVwomst-k6(Hyo5)q3CK2}hCvz118Z>rE=2 z+1DAuD*z{)f=(xwAzFQvE9O-I`($F%&G>(q`pU32o2G5t-QB${AwZ$H2QN|zl;Y9? z#i6)sDDGBViWPTvcXxMpioX~4^Zoe#kRu#PW_NaWc4p3V_M-O&^rZ}DyE>^O{h*8w zL;~QlY*g9;qkmsmWqmbClbinv|M^M?;>ITNUXka}kbwrk92Z89Mg&;+DJh%qb?{6H!wx; z&OmYdG@RTE{wFQegXEdN0Vld;3{hS=qkgbx{fEe4YFH~l1E5#m)+yj+eSP87p(V9- zj~0(eXr|4D-7kxzX$6Rfk$PApfPy3vR%v9#B`k;XUQ5xEsg!pc$tfP|O2WtU#m&Gq z(Q=tN8wkxDZb)R;^}8H87qFl_(YCC74loszJe&|=-5!yKU;yMz8XA7Z*8+r7tJQ%|?Sh4)YIfqq^9*WOP)!ZV6LWLVNyGt!1 z{HJR`cz-eaNqzRCflCTy(XPjurr(ZK_rE6V2#e&m&$L28cR|bSy$_;*YxqeJ8P8g5-YmfF5|RR+-XJM!wM6e$+0IeFN&uldjJuRb|G zX)X&h`+EVPKgG5o@o(Kd&xa2ayj_SdRnohbWEG}L!Ju+B{rbk)}IMdWk( zsm2>9fO<3QRK>Y~SqTRN7}QV&u!RGvC>VY4sM``2NLBwhdo3BGd(tFiW|PoN46~z-Hd4RFN98tgEN*d0N}KSx4lp4dJL;*V`SQ+;~3GZ~r!8yDR@` zag%&suO{q0$IW9FLl8CyATwElFEG3M>iMLuusliNugK|Uf4tMZ(ESCQjA04SSbb1W zpq-8xW$nNE0C3Sl4Jn6_6t$gb|3stSTrHq7-#1#|O-R^FLdcVic~Ei<~a{xi3PPSHJ{=w(3+t`7Fzm>zJr z#L$kvshJZ?H#mYD510}@6HizSB5qh>?-&d4qP&H(xCy(VvB&|JPfBwn6KALuTUMYF z(We6X=Z%L7v=Wl$r?TwlZ2iVXYhs7*#<>wFyA?{ffE&mQy6(oTS_`rbCJTW5OCO(M zwz*`&D#zN4#|q!tOszhcZJ;c0rtgQz`h5+NXQ_AhF7H4rd68sqqT*N;duHkR{+F!o zC^gk-k%cby^qq%22M4{&r@^MWx)ZTwne1H5YketJmVa1(Eh|)rvws2OQ3(=^-rS%6 z>G*VcKHW<-AjXE;J|O!gdCa`0-{5DC-VJ1l6HW$M4=vgXDns}9MH^5;&LIoE=>&^Y zy!`;*y0CPn)yF#upA9OD30f13CYhiIo5&GMijVxYt-RBZ>ZKFH?#Zc7ZeRZ@Do8K) zrc^`Ltf%=OxLfs>s(Uj+wo_5%3Y0KpPG=l)U?*|@uH6SG=*#5;l~I^D{xZXT)hH1y?L$wx-FWDd+-Xwf3+dM*d{CcYzDM!0^ zw`jkVn&#X-eCU5W7>p;k*@UA83u_(;lZjA`CX^s<=#j&Pl8aUASrTUmb?Nc6K?2UycF{wbGY+X7V7wCd>rGuuV%20|{qVNGHgFlAS0w-9(w;kWU?SdB%ydaIKxQK)?M{NXNO1=C*- zIOSUTRbk=<>r%=m$8Tmm=GE#gb^GnF%iv?qfntkQBRf{V8=F@53KseK0a2VrxeN8mf>b4 z0{M`&bxOYsdUlZ<8)GBWH_b37QD2u0$vEEccwpm5lZj(q*D*-4;6MQyVi(Cf7{jdv zAG*BV+oEml)#>f5?=St{kzQhQJggtAYttR;NZ~jB{h;@DJwp%{N9F*rTX%FM z;cK?Qa!G|Q)yRrs>Gz!9R4YNjmjR6R7UBVpz*Q(%eaC+90*co(5njiwz1hJU@jehXuH92PJfEOLr zIwc4W-4Pa(JSOdyvBlk2(EVwSLV<=`)ZN+Ab(uZmPxB ze3iV)eET43^Z@)h>}^?)GxWpy{pMvte@QwO)z0DRd~Go=fpIZxMG!G@)zNygSw%e& zy{u^HZ*6(ydLP&Wc(DsZ!-@C=kB|?d>dNG>+LuiZzZ{X*7up6e0mGc-H$;f%Zu*U@ zn@DbIEsQ{$s~??~nieC-OeXE+HE|ex?9?pqP?P^Wjj14%WtSj_xw3-g_??SgY8wf} zOtQHoto?LEo4UB(e=X}+>70Mk`W>Kj{%ol=Z`56~TA&8gdzIFfr9VrrKL5<2ow8C@ ztYU*Vl3!p-aR;LzcJ;{$ONQzHf?FP`OxI9KDST0bk7Phm-NH9ub+$Sm%YIf2;DnZ%s)r)qD~Y%XP8ts6s4wr|T|yNPV#ZKbUh@ zu#Ek06)UEn%3V}u*DvdtwTXr)v$^595lP<_0w zF)F!x^V88}3-qF8b#0vRbnnc&s-E%%lfph!WH7Gf(+=c%$c{cN+LevIKCcNzqS;CD z<}ES3BEV+CzFIz6(fE85apzHex5B#*ix=lRwvwNf=+V>aDXXwg9gCveQ)tS3KRq-7uPzVo^tt4{$eSLe8( zJ1(XA1Z(6wxOw|BuHfezS2!ep5o&?yR!}$fsrMQFI4k3NYTRAl&{XPt<5!3AIVjm$ z%PZs0_a~$DR5W@#{iDZWvj-m+37HVXm+mW!(ZsaID~yi^^BM>H`D%BU+F91+`h^ya z)+J+p5iCq8Cx>5I&@&0v?ONYPO7#ak&p)Kwx!c9sdv*zC+qj-yeNLgmh+b-%C1=p+cZ9l~^481l+q>^;yrNpss=6X`ar~ zhv{%b{6R6HH+``!S6vhjX9Vdatb7jW~bM69NZQSX&9 zF}};!U3YI1wz3+(L{1n({_jg-=a22B%n8Gav5awyZspT6ylP5Cq3ORpjZ?AnUfgFB zW5xH)s)l~dWdw@`nG)uTxij>7F+S;H#YmGM8oyL1UgzJ(EOW9@tRAd zka>C6D+%*-Sk0Px`=Rn)p5ER@TCEokz1Ts7kl^%C#2&9jpofYdc`@yXkA$^h6O2qB zp#9svY>~$T3nJ+?YJYZhpM8^G8#DOlfc@cTef^Wxve5EjtI{qyKCN01RAi5pZxVg` z&Z*Z}aAM628>$c&L@^Sx#62Hl8_JIjw)@y)^~s$xu*yY>_OLL5tkT3KadADN8Mijn zyPu>f))#kOBF6=Kp3(n7vif$DX>;n+F*Rr9^Bwbq!DXIX)?5DM5xT!^O7Zo&O_<3n z<#a9*f?x1Wd}8%FnB}_s?6V{-{FvmrX04*RCs(8T?YJoY^$+mfC9+XL5pL1x;jfR$ zh&jlFZ_^W<%n>Ku$GnQaR03g8&p_IHfDgp)ETgwn$;88nJd_MQEO#ueTs^5hbE$c=7hQwOcW%MSOec5W|$h5}{!N9ol|B1#wgDD}-k zl5r)Nu>Bk$h zW^VhN(%JbitGi>~%ZT01snD@+y@PH{r%{0)Q*x718cg*GoEMFiR=^jgT`X7JgtkFS zdyyOs40fvKa@0SkPlH|kgYR40 znwlPVgHl)}HdB6uJGaUdH_gCDc9iBdGi$tUaPnq$OLjc;^T;!+MZV=euE9*ni`wuR zEzJ`tnOWr5zPl5;YCJp~+&%l_`nANX@epoENcC@dk0NOFApGj zYj;f9xCH0V?Yat&n9Vbg)=py}vUKjQ4-6z)ShR^^2rQgLz->Tg=1;6#oWj8E%kP_^$y~MoR)^>3 z*_+fU}<`BlD2Kh)#aO)$ahZ6j8akD8Ze(3H40%W^8JU~Mp1KuMz(d7ZnRH` zDj$Znt*}q(mn_M75*j_469-dB3%C+yzgmPv{{e+l-pJ7B4kx5@EySExTULBOO)SO( zYBN}i$5`p(J`DKU@ZVH_Y47vFPw5bg?m!n%635%+V-~pb8 zR^IWK=HQz-NvG&k0@+LTvfl~6KXLRdxHYIXcJ8#}mu~l`IWGqjx-;nl>h3xO)a@Kq z{Kj?TueGGW!*l0Q!{O0zL-Nb>qo=?muNfq^FC=! zrt@%3wuc?Am>27j9DDa=IN}0#0k4am_-fulk|D4jNqo7Zl*o@8a^PI{~n4 z>pzb)o#K-djhBT-;nSqzOxO9s9Q;pjQn=7|(m)w>a|0h)URq97QPYgEWj_WyiDM=e z`4yVOvple6U|bRTo5hdb#^|BA930Jkv)gb682m4A>kX?k6|}@;|}3# zcMo$Vp=1;s+;gd6S`2TZHTXqA%rg9t@~I2-{Ufp%rpI{Wd$@tedO; zVny739rS+dhv;hYZb)wC!BLFvzqXip7^NG*KnCfHlwSAW`j?3sLPs?@ZT7o)uIJWE zw?ih-NpJEwuB0$-*M%!|*T&&>ZduD1p``8{S@F;Vc4O=iP?)llT@h%Ei{J`lMCCj2 zG^bmw*79FsCp{V)y(1w9Cw%R5S=KN8*QL!kq6C<+*!?81_TU1DFMgo+yY$%#~WXcIhcfEH>b;`blCck-+?1CNxB! zZ>&6DFpCGB!bSY1U87R>q8fCs-d$&Iy{}irXGH5?u(0F7&Wz=b_7QY1~_;Jx)~yG)pe8?^iXFJy?zKdIZ=R#XI38pXIo)kkIaM zRT;QJyg<6=MQq2{q}U?DLXUgagP z9)vf2DZUy|_exN7w0k_)Ty0NtqBaT(xIskjFJRN}SDQ2z13xl7g_6~;c+liA>+K%8 z3DrIczF>VcBX+|^1_=+?(OuzveCdhL`JfQ^G`RBXt2z&+K*Ie5&VE8l;5zm?&?~CN zeDRSCIZZ8O6vZf3MnB?m0cK~$>j4HsHU$T*Y%Lc4d%g;&%``q{GeYC(V6+?}HTZ^2 zu4lcFT`?xCA`t@k%~%^r?g5}W`}u5b0X7`ttWY5^2U zxoSncO2ougw!(Qbz-shC;vhvr=h#3ylEqnlRz=|c+V;l9_Nuh-{^{Ax@#oVIH&2^S z!_=s+tsqW%0)wZy)YJABnBAb)|Jq2L*bJBN=}et@S?)oS^+8lZ>xA zd!3@SK|UA`0@w!nk)d`s>st)oes5b#s3<8Y%p|LsDJ!-R*p*j#<|#s>@aQ2Qu^JSW zihzeZ9lG3DwX_^>)8tU>h%4B&OU`dCAk6qiQfZQlQW%3NDCp?0ywDOdH_6uZrOW&A zHONNmr}TPK{3x&d&#*bG>UW8L-r0;EuWxvbP*c6!2FTjHEN+y{j+?Pbf6vdJG`u;t zbaeN)@%r|i`kVF2@W*E(M^CN?XRgME-#Rax0*z@p>BA_^iJgfXQC90CwM_(!(WXI%13!i5Y!%6{*-2X$d`HeiVBxD8CQX=IzAk&Hza}cM58XSiFu^itdU7SRHYdpP z9B7Q1O0e`U&NCp-Y|eC~7#q0CRP4#Hgtjp~^1aG1J?sNHFTmWpE+PHyd)BY2H>&j* z3q%-w$bJ``%{8SGQd2azfA`bTBRS4~7b#9RZD}fm*RPJMB8*!+?VM3_l=a85am+i2 zp$`dP{|?VJBe`Zo15?TnD@eb>M=H;tA`Wa!PFITJh4tF$JkNiDmR4t4L{;kxSC9Bi zQh^ySPeTRQ7vD8bdXP`McwJ!6E7#Y3j+`7b@ne{00>#A#q)b=-qoSXPJ_@K18QZ7a zM`KP%PZ?*s(4xouB!$xWY~czSheS!!=t%StJyHOW4NXOGc$Qes-(ps%S~M)$vxvWi zVVM=|`I=GS^WY^Q<=zRpSZE-WQ-0k8i~jQYr09ny)CpH&F1C}1))#*&#`QbYgW zB&Yc~k)vw1GBOacqxc^63o(hffH~&>Z;ru64#(87==t65>(D#FOM*kXagVtM9mLfGX956|dhP0#?FV4XYY4 zmLd2_BJ`lZsE0yf_Q~LiNpN8e36P4zp`r{}XvFo(-9PwR2>hfF06F@(c(^p-y5IZ{ z^GjEXHEQ+JXFfYRCg3JpYFz6j_D488xH)FsO6cEI)NW!%#p{LQsJ58`Kx|d_9#YxE zp7>Y1Wp8f>c-K^OHUYx=0~czfeWXxa?;4V2n2GlYmf!~1E*1<+%4KgE3S@Rk*-MSe zMv7u`Q9*=^cX3uQwo@k*A|)D&)5izG0%_3+g?}tDD;CL&=l@dW9v-!fWUNY5M?reA zbiSdZrRe|-3e$#aaL_31j0&mh2_dG@2-kZP*PG; zKbA&}l#E0`hw3Mk%pqM2>C@8iKMgllG|YeioN{4wf8l0viA)9KiRmIo2rqhF9>wF!uTHfnj{mPF8af^=S|Zbnv@| z2XsG?JAq9T{urwgs<6BIDAA zjLbVP#MMiaB|Wq>^P;d!U_5Ze>vYErjbG)A0~kou2bQJKuh-^SXh?%dIM}d~@{GWt zbsX%tAmZUX&^<{bnC zYz;B3P+b@>nuL}#2ryBqd^=eC>JQSzL%f3#DFY&a3&hlE?z)iy$%|MbK9zwi%tMRb0yG6h!fs zRaEd_CnyZ?vEvRU#0-Z=TP+0`ajEG|sY%?sWPX={p3JV8y#2#s2esn#C%jMc&LY_s z*!=M!aXNS- z6Z?-nP>jfydOqUk{}AnwpOQ$Nmc=eYfp@vyIge zSOWlRXE6>mVmymvi@I(o4i5cn4I%iNk&Hpy6sk@%AS0Hf!>=q(=1-N;ZHg0FLMs|F zPD2AR5Y48{$PMELnU(P3ly2jE#+so4+@E*6oS*jxac}i1!Oc;59uvHS3#!5}ZhkTc z6){Ox(RZec#-H9ng1kxY*yp2V@E90maZLEui!t$NZ+`Hh%HkntJ{8&*@U8{Q;B`>< z1D94H)rB*N<%KEmO4J#be(UDZjP`a$fzf7@h1=-+@ty2feN;~$dOV?isLZ0V5j&(A z00xPzWv9^bR6*PpG1qT+_x`5%PoWE0gs6akvty1ZTURu+V{S$T)K`_cU#MJvbEh@O zquC7ns{U6tz@P3t4iDwy{hIHdtQau;c&D-(yS`^)vowBwevXT)9UpXUajQvg=FEL$ z7%lVJ8?>~*ME(Oj000KT)eHlOsI0^Tz6!r8EJpE;)^LD#fS;)**@grB%zvL^!T3SB z?W;hZQc~AP>h)feyjUCXGy3o1>|kxDT8+8h)DSm*T47)8@|=hK>z?#Dt+33ot?)}E zKp1&D5AZ!g#yMypEsc{5WJsuHByuB6;_+mAcvIlhXgQO$_S z+6pQ_B6a>b=tABhQS5-)V2J5;0JXu)MzQzhz#fF+sMy_`!|-Z0{BJS#0kzeQXvL-; z3e7Nm)rcs%t_jki7y4HN6*TbY;s{UyD93LgN!}#Qr8Oao-GUEQb*<^EUTNQZ0jv&b z;Hy*G*lhQTM(ve*$(;YbiI$ivwDq>fdqy6ttmm^`_O-+OdukU>B^?(VYijW_1LfsE8P)m9j{q@xej4y6JBZZ8|t zgCGsS5V%5$4=t}3-M=iaf?Sn(r+T|rdJR}m-Xs2VET?HxVa?I!P>0ztB*2gv#p&v1 zA;HP!==w>3!D&n3N~`(tan@Xf!q)FS1~kYAYA$&E} zD^vR40`3t;hQBW08~?EHyaxl}x|s?TAyyDeQQHLSum-y_L)dc;jGs_@>M2_G4dn!4 zfDC@G!aI}U($0k{-3df82azdo*;rt^Of2xVxDKir5!sY&u64w-(QE{WwjVCEffG{U z?JyM9aQ4TBls^r3>L&xb$wr?8mwA%cuR-eYhW0GPu1?XZ`c$_}c9wr`L{(9#xD#~N z6P-;_kWuuqI4RKOK*u-T&=Mek;2gC)=oOTi9^)u|YySnk`l$9NBg2n9AKlPm*nLvC zW|A)wbA6BuX@N0$@;Y`GcKiEZ8N8Zv-p(W_LbdjwJz60_zJBvQlUCtxuCz|A2QJLK zGoo{1a>|GrmF6iHp0DbsXKr1}^L&JpLeEJ==?>AI7Dp{4LWw>93;2oFzQ2B< z^pu91XDX0KSp~ks?E81qdG}tk77)`10>pSCB6>(XOcIk%lCnm9UXbZDiQt5=o@V|A z8sv%T^?}1H76>?1uwp@`y0Q&#$}D>C;xpV~1GPilVfRVk>Phaz=VTx>vr(W}v(3re zw!~uUh$5!90)D^G zJ|#^(y|rZK@@U!Jqj4`d@C~hrUxtIYX~9JkgsQB>F9*{X6~zTSfs|u}a$%T*X|PEq zrYpUmoQL^k)`p$cMXHbdt(B-ChGg1eJ@JLFcsqPlLeb>Gj89V(lG5ON`!N<0=>HC^ zmDj)ySeF1nnRWd&#t)zm1}0w?$fogBKV0E}AnV>&=(M__9kdpj^j(K66a!V@qvT%1wU88-t*b>eSxw&GypzxHP<(}6M8Rr8CJZ1HY zPc@~HRqdj3xYAz&@g{h#GTuQJy{|CDzJ}J&T0GL39-5L5RQ2Chi{M6UZ3SgpmNfw8 zi(_fEt80q>i%6--i_+}usO?)J*VWsd1Ev%g@I4BUqX`1L<1(WG)3+d4nR}F#3mKp1 z0(c8_BIt&q!R?dyHjxlY&ecI8XH~>vgC&;aSxH~@Q|$YypA{QIgblj!=W6Rz-if_= zzrQp>?F;~2p^3x?!Eno17fweKb)SxGr(YHHJ@q#^5@2h_FbGM!9>?1A?-WN?n?Q{dni4sT#2VbE!8B&c7Wv&W!Yf^PHQM~z8xCgm?=$X0^f%2H~yui=fS=Ked+JeuDs}c|NMoO`E!noZX^<$(| zI=-X*&y;`*ri@o?eEfV7u%e@7W%+)L${i%Ni`=*H(MeIW9p1iXmCUzqZ^54YAv~4zF1SlD}$f(3uWH{p5p*Dcq_N^mX z7oYn8!I{Nn&#zM1&m9QaAl%ka^$P$Z1s^CmySAt{#Zui{j!SEwcI%w=Nxbk0@$0vT z058%LoP`8HYsKX3=E{-zV!&o5bFth}NO8%?7xVr)Poe@3Y-Sg5R$!UWv9WGaE5Z9j zuUyKi-?rE0iM5Bif|nfFeu+VRxB65&9fypR_A!=KVilbUk$5A#6FijBn2o43^FV)& z$+G_I6p;O6?j#BMGACrt_G#B00j^&K%53vgjE!dNZ~qWyl7!4o5?YFV9CpjOhW$x(C-T*}B2Rb$E#3-ZBK}o&0d@> zseF34-uJ#uS$<7b>&L$mE3-AS!{>m}UwCHl!`Yt%G{GJ~mqQwsFoBYpjC`ptSbY7j z`Kz-QhxH+KdAE=BhSrfC3znJLq(q~|rT>ar9<{uZAAv&Ix6BR5L6BHz>C$>k_E;b= zy#n6ye}T{hPvBs9r~;sbJ{C6Q>NYsbF8ZZTMQ&l>qE*n z>)j=z$BE>2V9(WnJAq7y2io!hS?XsHl7I*v;FQ%)p#3a+5e_M4Txyx(WEZ7w}s(} zR=RThjc$@<<=xDd69L?hI7fGdtJ#WECbdToCk=w*nTP$l0OQn+CN`+yu*I)N{W^h~ z_WRcf%-Zw$zJ_+;KiD+T6m%ze=KDe-0sVj6!i<*&R+nZ}=EBVSB06;(_JRf4gyMoQ z143}Yy@0mahS8KB(SR(s8V#d&y5ESeD7zr+7|>iG4bpQEd&-XD0?r?z<%-&YhE=)^ z>?;f01C*gY)SC7}XljT=*?I7g+aWH{64s8iHF~6bfLQ~Z1%(CyQK>6#SpnAE1f=@S zr^nlCHT%~^o%76K0Tvap26md_Y}O7#Y(*yfd+&SJ0XR<(5R>$Uj7k1C<{8P?F-H*M z%iVZcY>6d9qkYC1ag$Ms^-wP8xN&_p7s3Q5#w8-zI;~Mk`Of6OHqse^ z+1hT0+U0jBe+>ir;P{B~p8v_kkw@?F=VJNE&^IH``yoF48(`C!PMy*Hy7=wwHl-6Y zTuo9BoI6@&w0YJ$hu60NXsyM*J4p3g%sfbY8^1k=PmG4KmQWW#RbWfslp8`>3&jHDZ~ukd<#)Mwt9FGjr?#Ygn?RLD0l%m=MxGE?xyu+_tWF0N8D45*7rZI!nz<~5liAXrXgOW`~$eg zj%v6JmimpPgRzzAriR87Q++u!oX9^|aInFB3Ww(y*UpLER*s*SOWtz~A5`CXm84(Y zX98%whP*u&=TnHy*JYuBjSv)H$*fsY4e`@o+dOX_NdpuCQIe+?DGk-vxp&>hOSg%uhl4dm=Ieb!dT%&c{ zW}kCj&CIZEL)imx$-jrX!n?7Q#N{s%=mm>UU{>bGs`l$1Bl%R33(1d@93xG127MtkVp7l$5pssA<)Wn+crlB&_Pny{zJvhgS2Re&;&Fhn9wYfV#M*tN2 zn-6-{#I+&4cXn=7dOkHjM!(S>==y|npXf&7VWn85SU`LB#L9xUeF51)EDT5mv|2>5 z2dx7XeI}wb?`5zhjizX1N^zicJ()O)`S`SysVK5VuxoM%sh?Xpp;+p1fN+}R|Af2W z{he6s0$m=PKeh7AlQ(~PDZD+XH0NvlXJcE{xXqRPiKplUCH4O=)2h}dM`<;{bO73@ zp*PM%IQIFzY~0BOvG)~XAQoKC`yfc$jv8aE8t;%m)c%c`;R6@~BVdHUEb|A)5g5^t z0*e$aB`ccj8>X>V{#b;mU1yUcinrQgf?Z`?ud6{{1=FlIlu-NmrmCP~G-UeeU~oen zz_9I?v%E}ihncrae(uV2TJ}oIn#^DBR9aPxlV8=EXX* z`@lQO)OWNsjWR&$eXr0Am<=fgM*NeB7RIZ_s$3DwxMZinys>n#KNNh(;%b1$Y5g01AboEKivbq$)FL+iP&ZL|92jSY!TxNj_CaDHgO> z;CI1`7mx&_8cr#*aV^f~t~7XB_s6P4DekW7=#w3yp03f$!h(tcfKVPxh7WigM#<3i zPDW8`qgLV9{Bj}@LFO(R>DePK`_`r<{ry4Hyu*LfYCjucdJ`!YZZRSkX;mrmR2ve| zLUGv-KPasMUEJ9Z2Xb3?l5A%6=VHYA7&|ow}c@TgSPZ`j94B$3p;XM9%m6h;;jA-(Dr|&(V^G^pK9UqK!%T9sjlA5C8kxav=9}|8h zQB+Up!m`fo)7OcqLr%(hq@Wtk&GBvRqHBb7$Z;tjudogmQ$j3}%CGZ6@P>e}4 z98dtt-OdM43eyFet8f3F+uszmt0H#6`~F$WzvG%hStVO3RiN=Zb+pL|dd5@GU(#3v z3b_y$?`4Tu`M1CUR!DO#=EpXWsCKqa%^W-Xc#H6ZdG?ux@D5g>@SLTX)>lh zP475GQ`<(j&8uhvN8tVrbATTkoYakGLKGU2Y=sPS8 z>E*YUrcBo-nMP2#);BBOZ8TDnWzZ%qvaBd4z>f+iaoO3BS=%-|-G))EPm~$S-4a?) z74>(uMBrd!5~tiJ>&Q=BK!d8_WNR{GrRIjou?HJ=L0#zMl^MRFO0_W(kW=`FJKJ!f zfdfecNRIUqYKxPX-@Udie3O1loDXs9dlz;E`U+?s z*;QyIFS$vd7MfJgysYG&SWkRJ6dRmP9jjz@91lcSHPiXz+Wn zv#Oz}l3DxnD$#T+=Vk6MuadNi%1Qj=+x2y`f)ux{BY6bteMs6hGRk2sM8B5^(GQ7>_*|_*#^GdN6|1Lpvt)E3to)#`)ijdX{4wB&4pt z=&GVgHEZ(61Ph;BQVtaab(rqtd2@Bn<4O_l=KHoW3d;V_r;u3hct(u&2k??Fiz2Vn1kZpn6lC^SF|-Z=bYax*yD zsU6X^o$%-Ae&6Xbf@%&{?2Jysp(Bos~E=0l{QA$qDu&7go~qhkBTQ%znEF1PbpgE?|Dlxp(N^gV-OwuS%z z2V#n(0$+TebrIJicGE)^&{9>l-G*KlM(8tV&ic#8GHx-|cN|ID|LaBm6W)MS8>-1YchJ6~0+VL^Q2QyRGw1)S00& zn|`#j8J^{tKMO&fln(7!OBet^q}lfK09Aa5{fw2%@g5h__BO9N%#$E+_3D$|B#6m^ z8jO~$$83?Fi@B?g8245~=LxCz9+>4`&^{u^J+05twB0AgosjGh zY~o7n^lyv9`@`o)o9@kwMXP&97q&Ag>|Vv071_!97$1`sc;?$eP#=3w5`M&lboC;i zW2(Yz<^CQMFAYY0e=oZhMwJ88C(qJQv#V;8Ai!`U@<{ti%W*&KdaA6lU1!RtNqElP z(3@s=D$|5HU+d*nu<<@0wp=YfF>gq1hTl`any}3Axu7u2;gW`6y{8My)X zpC^|LtYVu<6TG4+Z=OaO1rF2@QEJ@E?8 zBux`x*^TICSX?7#H_Xb`didk(70$~Y=|CGD0i-s3BSVHfTQ}m1$}{Wg z5TRcj8nD|M49t;3t*qQ6s$HLMhK*$`)*MmmT?JO=oMGQ#SwVn&?>qP&z)<_S82Ut@ z-y?rz?j%u7H^rWPtMWF+5E6wa#KuEdz&RKHAOFvL1{XxIPrpRE?)5PPlSqh$>d`w8 zm6;=hw*DraH`_Wwf+yPuGxocGuqUfOOb(7ruiG9``ZsDYW;S`g|Ja!U-;ecgr&8$3 zs0R3l9;>+>8*2oo@#I$Edt`tKVnz8R5yhR6y8UhINp@5AS34R?mml?#I{^-R9imi} zG(y~vo$Yy5j!Qa?MKSJl)(FAb@Vd~CN#jo(5IO(_V1=@v`m&(x)2l@(Ay`gk!X}lX z%UlEK9-1#4Dn~K`aC^Hi7%sRhGfcURK9Xgkr*YQkX7nCnRVE2{z9ub39qb?CYxR&| zy_IKRy#*m-1>rEY$yo!J7S)oN02oFNIUNHEu;z2EdF0u7;#MOJ<@-q6*Qc4}4h3(; z8ZgJD{r_vc4Yi{5kc{FP5!#(Hu6?kduq+dP{ry@W0AzVqeBY|`PVskN#)tLtK*d3> z5^7EgKA`rK|H`p~h-KRS?|$LH0YZHC01G-I^ZU!bt`@Vb|l?J7YKkPk^fd1-b6 z%LGy*dOr$o=EQ8^=V1TRI<6E~zc@T#)ekV$>b z@%d(O19+aut%cU-uVHQUpX_O7$@7zBxy7bc9`5YZmZ^lpxvOq+xjxT-{XEGHTy!w5 z0syDEG=}#-TkabEd9*Bjvo0)c{_+!DhC_vg6F2CKpVz$J5H|Y`4otf|BY}ml0|Kmm zs4|^}1wG6W3gfS?;C<3K#y8pG0i{aTc|>JdzW#1P^LylP!vTgyrgg>#xN;H6^m?Jn zyZ-6L`Rk2AySy*F4>_kJLtDtBX6bug#ZeVSS>l&j-XVzq2Xxdh2NxhSeh0{mJBP;` zw^ELOze7uf-uj`DY^f^d1bX0$B1?`DD#Q9UAvjg7<>F0<&@_u>5M_IzkXNHj@!tp0 zSt>WWSZeikxP88jm~QxJ*-WoIc2hk%2btA3f!}DqXA(O5#roZwgc9%2R>$K@a$I}% zbMC~O#iPfqvSi`JgO;uM{S5=pF?DpjP9-oXAI(l#XigR3?*x;r~!2qVUHbH{X1h| zyYx>qZ_Bkz$Eh-fN}8&DZvp z=ZCtAuV${VIAjZr3X*%TD|ucMiXG!g`Xv#e$h?ayW4W7~n-sAlqPA{d%?f7@bAe8! zm+z~ltD3!EgX=^?GfeenOlFuQPk>sEMXzL*6jCnJNuw3j|TT^@7d^{zZ?aV z>rpcbAb2s4KQrCijr;L;RB23x_hX_EPCOgSdaiYiJyxzhko;>Bg?#pQ$tRp<#PnB0 zkP$DIAJ^A51^f}h#0(r98X8CO^rP+g$Y0xk5lSF;N^p1h0v(t{3Y`zl=oy1 zP~6+n*OCc#T6_5=5n|E_UEL0OK+4OWM|>Fd1(Qi^fV-z5GTx6GS-CL(rBf%NGQ#@1 z1h94KH^9JoWM)eO*CDFikpYg_rls0Ih2ZRL(?>3;yvDWbnv<7~7S8n)@3{6bpc$#V zg4lpoOR4+KZPf@@21=3BBi096bkSnyFh6&x%A2E?)e%g%I)zt6-orRKFqgIRF zIle8<-7FgYS)R)7b<>CYQtedaL^4uhuX`-QGVdV#_Ef!z46SR!dflhF#NWfK6>}&H zjqqfGgZTSXo$Kfjam_$lvc?D+E+oc`_3oc0F)NQy0cI1%YRJ#}(GFR`dICXuVq35q zQCmQhbFPMzO&7-Q+yp$1{L3%c$uQ(>9H@OxO+`Q$@-^)8fKUw6X}S3icm+6c=8?=b z?Q8CM#3pJEu}c74@L$ju0u3DPVH>qRa9xL&flh&%SRrYpqYM7~>N(CYfz%%q0^5`M zPr9Ny(%hFC8OF?A#zDe&SUM@{t1e5YP?=&9C$C#gZJev*O0yk5&EDyWtKU?t^U))*UL1JwEx$A?s^Cv9zW}Z!ZE-osJwXUVJD<1aq zkCw=o1ei|bR|5T->EuHNw4E6}AGIxTTM~6&%B7wSPd>7J}G%u?>m;k!)~D@jlLgoSV(=&)xK| zye&9bC_5f;stueAP%zd{@#$~lUiCpN%S4uahGP48rg2Ln{cP_Bnl)+rM^Wk^GMr;u z(k4N%zx&|DRfSfaTq+S4MTh-zj!m?N$Kd4Rb@^z;F!6n3sA-SKb)+qnt-9zx ze>cdr?mM`f#^b^DjVEJ61|BdS7fYLhIALrFe&}reEkj`(J8Vh9saAW1p z?9nQY+4N>gh>_}YX+a1_mBu*cFAE9&bMgrMd(`K&G|&~4SHKjC-GR&gXc__C=Mq!> z*y&$w?3FDX;}FK&j_*@oMxJH5e*0ODk`5Sz#Gpw*=3d}cOLBfyHpZ0Xo0Vr)KrdSv zO!NC*tv2>LJRw5CIKiA9GWaTkLsDr@sFw7r)412@g1C?Mf$=Y)S~%*@<(*0%izcm6 zQz%c1JD#6Om8hZ>$*hT$xSKhK7aKN_)0FLBFh7Ep>Heb5eM=My#h?peNfY^$djUKj z>dG{ZD5o^St96$g!-RyWVTycYW-+JlAnNFhqGc?jp;hcEeW#S@-0+d8!+P<%8POQi zfReAdi#=pE-Xvo{_QFZs2#htvjqudx@{f3;w2BdkGc|H>E+GZbDQmMfSh_YOC_dl( zxU%T&eH+ft!s8<@Bxt^Vg(qUqNH_G#GXWQ~U|B-ILJ9MWD?;Lu5zA4=UL9YH_n^OG zr*p*fd?KjRkSJuhj;wB{j_lEN0Z(mdYk@j0*ZF{Lxtw- zC+cp09iKFHjX*omtqy0e=cHkp&Mu1{QzZ3DWqj#c5gOz?3suITc-R7t$$}Y&AXBJ5 z`<`Kx&wL7Kg-zkPIez{3IQv_18C>gMp{%(mWuYoQ{;~KDfX)7eu9-)Cu`N&XYmjl(P7coY=OyMV2fSqkc@k|Imnz z56h5{=$6Lo$+Pu6FArKQTfm4f?dIkmWiWO0v@*D}Stq-ISHdQ;QkumKX$ZHKg%hBG z-y&JJ^cx_G?pBsv!wz2}KiE`M*28eya7BNGa@NXqjKPV{-P*Bs|5UshpT;q(p=UuV z3uV!f^I%8*LH(Dy9)?bPj#YGKzNIvtOvsZVFIeI?Y#E0+)og|sI_?Nb>d<|}qTTt8 zs&&&7OGgVkcT7^jLgrcm&f}k|WG408zU#hfvV4aDv5Hp#v7n%3xY%lD=*;v^dZ7*j z+CuqX&Ta_J-U=T$4-px+G}K^mN-9Iw1qx`5I592}G^JlYcD9wbRk<6M^{rHAH=}r3 z02ygfrs7{mJH6Fp3NRZ_eZ^1e?jPvxJ)Nvj;bVjj*>(eEGo zOzd!F8E)o8)wJ>>uG08l;91xA6P_*T-FS1ZGXUcK?UURJ%0Y{>2qFgSWXKrie z_o7^;F5Tac-R*2XUTlBr-RixgV(PbNZ|0+5BaIun6T6RXJ$J@RGvju>z;eZjJ1lMa zV4JLfsyKd9v8BPrn`#h?ZOyYYk29OZ@k))Oku+OR`|2(T_PN!+7xsIE{!y25?InO) z5Q?Nc;_bgLRM8>$e0X)`cQLy&bE9=4kl<~m2j%WzU*E)-NjA{Lw>AK-%%VPhc!o@x zS?PL&VN%R`gz>fGIRg8wSj>klI!qX34VJPg#3jp_;KeDAFg<68gj5lvkSr1fOWJdyR?6Hj`9>Av$(p6WTF(2A zqr_Yh1A>3uYKm^i27*Su<+K^uyDqm3?#0XPC8e@H6sSnn={)y0a?gsc8qa8+qUC@0 zI@V*BYqiGr874-fS9~3?#fQ2L(a@Ov_}9!9pT6+BHGX?zfNXX2>P^V1wx~Cp^!69O zyh4JH&T?)o8;ENo^;Rp2diIz0(+w!!Y}&)M^E{NUw66-!DZ4SN8#jmZtx#o%y|=?5 zTB-6sBOW#)z$xOz&R8yRelmlS9Kdj?$XhwlrZpG~3t^ZGw$k5yKoZWi`=qaY@H24_1a7PBx&r@56mKJD;c{XlrBM21?W#u7i*#MH% zn-Fdl=!DKxqwDoWaBy0D)HMRo{+H#vQ9hzptKtx-v^MsA{}%ie7rW0H5PJ=XNBcOAlO zu+ZfXBM|Sejs~xa_FmJieS71`j*FGr(bmUc4Oj5Cl+4{~MVbV&W6ZRl+;kOjukPL8d9!_Yr0! zg~dMN+C7e!4~@>vOD)OPOya4Birx}`djB#y@v4{W3=={go2kiZuMcE$-ftM+op-AK ziM-ZcDf_KQpjgnlV2!f$SYE*<=pt@>k9elMN3J6FQSoohA2iMvm+O74SBTpAEr%xv zM|;R;-vw{z7hm^JgqJN@jGabM5=)_JBm~!`pORkau~p?zSnzG%>o*Ya@=uiN-f-ht z+(%zbJvok?Cak)1qWCX>EBoB<_Mn>pRn&di}(i_L8xo+@hi_yH!c%sttCXx24<$_L zCS>(zpxm|EfdP`KYnM!KU2jjzjii-6tJGGv)N&WbGq!}zk&(E(cjpJ;l03$Rt>sYEU?^zy5RA0o4M+P1QM>^VOOp1HIiMs5~8s=Z{q ze}6mAV&uyxyfjKOKGV8+n)!RM^VQ{x=#2C>#F}QI2gxVEClywI#ryOODs0!^&Jne= zERW_>=g3SHkpOODig_tTRlP-Fx#+-|Y`!32SAY3_nux1K)6?$E>=CE zzME0+XHqrR5bC#hI$N7S8Nisg`FyMYA!^)?aH#T&x{$gkas_Pb6zzgkvk*0P+;OAr zVJ{gw%nk2eFGmM9+al45jgVQZIqQ$Fw;HLvQM%aa5{;XoPit{P`@2?H)F|9s?u=Ii zH2x)0O6pYscuK~VElv-Cm=93lR*={MX6Q_M54x2A>w(5 z`le?wCQ6k1##`kK)J2#SD401!JPS*C&yp4=^B{FTi14yWXd@W^g6vTl7=?@iMs7#m z_kIP%tMC{FOD$c=R+DwwLBca9)f609A2?1wP02=QG2}lfAcV1Er)DPvskH~aU zx$Y8lA(lXqsEKRF~6U)*-FHbJYHS~#blT*Xj#r4`c= zSHG6NuAb;Q7?0PU9y)9|W;|D~mW92h9nJNv)Uq>B`ho9It8zVwVxxOxJ=RF(ZVS}n zsI%_fYCWE+^&1JBk#HZ8>I1X82;w!Ify=4Za7;;w8*lZuA)Q@ACeg##K6D^wL&0eF z$w<=T^h@!7N{XCBHN?S0Zm7>*apKF+WytA!JU>=I@sRbJH`Ri5Rs!`1LZ1`pU z+Uey2+m0DY!`gNvP8>GVd(6)tp8n#FjHR>owH-`1Kiz)8P#ogaCstR{6$F9M8~k> z>Stt}BR`vu!7d&Th0BXpn;T|voFgJ1xlMJOT!c#yJtP*rZ_V*N*j(gm2;TtnU+)1Jp{Zd?xeGxe!wk5eO7t7S3TF*Uc!B$6-0|=7K0FTYmJ^Q7G zIRd(mij$HNQLMnO;z5Rh)%9+9Nzd7pwOp5@DCr_5i!#5j_~S$NM*-yQjK(P>!t4kS zGCr)XB7*Axavikxf``q3;We6mz5N@_KegjT(Qs~iK>}UPa2Ft@XWOWxY8tE$j0YXr zJ!O!TLvqxq+{30x{fg^9elEb{HkaYHwg5|oPq58Fv^|k%C-*)g1nSSeEys7MKjVt8 zygwgq3tD9B;{ z4n7$a98K@zr|m6F_0_pdX}XiM{Vgkr_(~H=CHkB8MUveu0NcZ3VrZHB&U-%; z%j2dLR~lDtng?8d6>za;=&>m1lvlXYj3U@ReUT){AP_fl6bF+IC858bwV&G}!tz`X*3eu#4-55{06Mb?EN-y5p;-vc0P~gi zLUECkc&7tG5HuN5=Vup}&-(!Cnp*CJ_v^(&f zNxgvz5^eE0$?OzJBTPg=WORgGgYZE_y7J#}A`Tku*?zc(^B79M>@y&#Y}^ryt)qR> z#LekBM>GX_|JakfDh)Hhy~OQYq~1)I;PwrU+&ffof^wUto89^GTpOh{qI6i>`E_A_ zfJEgH>dfiMM4R+Irjpc|JzC>(6ho^MRnVRlh=Q8RWq#pZ+;|W<$6x4yi$;o9cB=|8 zC$2Zq3c;oUzVqZy=$k`ciYA!pDT=Cq=3cIRR8|Zj;1pnFn}XjJ_c^Br>xZ0p+3x6j zEQL?`KX|g?*_kj(nTSHk@ZaVWy28oRlh>WigJ(~ts>6hVOq)PPPWUER;)v*C;yhro z_oOOQ%OM#k&sh$&ipUAsdT{9ch&CV;qL@Fa>#%3PAwsLK-~G(a*>_V!BJc4cs6LpE z!6lyrL^k@*KUyJdBq}BCfR-IFlYA(SgtqrDuR?(DoQK)*qp3+m#of@y8-%kb;tof2 zAdnZNU-S3|+lWJ_d7`47VJiO8jEA#oM71w6FR7B^kyYDd-!GA)Ah$Cd6^9Pj3HdYo zrh23~UCl>S37v!jRD5VNs0$IDQ%J;y{Aka+CMN_NAT+E5g~iG{zkKNIyLy|{nQ=OT zE-@+cn}Qk$0cTB$g3a9tZ1VS*3IiBl1G{huLN#6X#gSsB0r3()V#=3MP)&LA)x-=t zP)eH4BU8nH0`H`21k`#ug$Z4zV@?nXovjKXC)mmzz8YfF7^DAUi-7YP2%P7kzM7{rC z)#yVl4%d%|Qdf^>wdhQNiNpxsocCa6JuV9e7C6tyb{MxyO^R;%{<-^KiSM4k6u=Up5bxW;zwa*e~Z$$|J``q!^u`0-#P)gRPixxJRC% z4^9t{Dj6s7%{vg;$RcrNrhkFTjg#J&qv9bLTs>MQS?4UxMkUS+Rq%Nx&kZ@G=3w8g0^u!!$1a9TN$a%$EldOy+H&~74yGqWg>3o`PT49};L z`Kv=x2E`~oyJ5=#C1novC8VU6IRhe#wj{D{cZSI=MRfxld`xZofxnaoghH%6q(`Xh z8|hH@aSmwvVr`fUz_YxGl0Y&dOhpl`XmRonG-mMo@lhY z{hZTFNidvNiB(lxVv`jOzy)lFT{Kr@;5$|jg-|4|Xn5W3CA|qH;>OF<6}4ko?HT0R zdUy3d!%;<*u6PhU@3z6{Kq=fJrZ1Kt0wsth(Rg&<82Y9bPXM=*9qVYxby9ZCC;XhG zGwu|>+`1Tgab^hI`xvUZ9` zaW%JEL#zs`sH!ML^N8#ud|AkcVit#kzc?=ci1nNPK#6Kca|B&YrZAc%<*wncPy3YDwu3&t3{H9vogXYXu7P%wkxm zy@OCnKULrS)S#dJfgBMYoa7h!O~@VN_xSg$?`gvic~J!C4G>+^=ap8z6T{61+Pk0- zhadJ$!R+lFZ(3e*rY!3_makjclku$;=@q!V@l;Whs)X-%>?&LXIX+~$lq|$F(l1Zq7`7rKCRd!HM`2=tGJ=rPu3v!Gg1xa zNG4&a`Awy`;}Z+__6Mi-L?ms&wl&$ABa7B=L({kn(2;|GLw<56e@arU1vP_Awq$Eh z^a|>esKy3EsAvoy#_DqYs0SgTp(a7rq==|U!jfQ83WUK2#nZ3;_RW57n=ZrmPiG&# zQ9kfz*x1zlR+;-m4sze4MDtB6HMW9C{Wg6i=B~PQe^8ZD&Q&@g0lRo%-5?~+-J0-p zcdO;p2wr4Xc`$rzzed|LKyw^@FryXiXLI_LG~Nyp0jME;w|4|=^~#|G%51V~F;u2R zeCZw#9=^cr0c(5>c?CMjJ{A=$QLbEjvK!x~KG*EP`?K8yX8&^V`>^DlFJLn>R+=%c zpCa3pF;ym%P%hM%jJ+~ev{|^7L*f~FHE#waSJYZH$EfJ4WHhGvG44ywN>tsCD6P zHI>L1FM2a*13({GgyVooKvZ4IU;vW<6_{Y=#=rYomgLTH0d3$*1woh%;|q}jJwXEp z8pHzKq$V(hAW5FQ5MCETRh7~~Tuh?*y6h@~u4FH7ph^F_fZk&YU~RjB*TyM_`CRrv zNYNa?3_wR-Wxu8Z5xR63NeUT4X?tmB9JeArXFwwf*0AOc0Zz%xrQ zahKm$5WSw9AYEqJg^BslCr_3`eZkbycj$Ihoq75UNQ5+AvXk5QU88O9%37RYVT&k8 zfhVlGe3bgTm(wjAOTwLK6pz8eNy;LOjb;G&@8%)~z6?F=;}FmV2#}8oZb?FFAydEc z{2EOw#NCMx44vIpJC%FkLf(U&1YEEbgo&+4N?<})7q)P+rtTlN`z)zhxf8!HoQCZ- zlIL6a+c7YcMjBsfU;eNRcI6^)Lqvo7Q9$RTsTzf7BhSdx>O>AZ2x$Jk%Wc)7xUGhd z_A%FCC8PAwf$^6|^E@mJK6HC{aS9Bm_p$F-Qo8NU4UK$5AlWV=_ttXy8+#&E^7fdN zJ9)2VWbx2W;O4NUWY$dAGA;r&;L}_u4ucswX*?}dD)I%~4mOpc=nu+fKmwXV=|9T^ zJ=;KnT=N;S8{?^m5_Lj@u3E>$cQ-q2T17i$mZqOWbb5(`dV)>oAJfZFrb=ND{t4oRtw+=(~OQX!+dqaFvXu zntfT1RCHaqo4A+yD9PumATjLcF@BtcJ3#3ZIk?>9-l)CeGv>059>ZHxZIO3bSsMg( zX7>cmSahlA@wP>B5a>(HFHJC3;ajRkNuwjxzZ)H9O8-pu1G#I^6zGElT(xXAIaF3z znIG?DY4bgT*b!nZ|8)qHvB+o7!oK**Ym%u=xIajs?j|rNYs2$lu|;n0rbzPrT(XcV_DKG~KS zT0tR3c7gb>Pn#yXg#-3O?2?Jm&jQEoOeJn#iKLiK35R+#Tq|Ss;+6`ioJ!1N3pB(o~@_iq@>$f z6+%YJ`i4`r9)E3(`h0u4045sJ3oel>R0|n}U~y2d zzF9Z@;%UKxuz{wa>F@qR?Ia!;LIebE>!j8p2x$BuNpOhjulGf3@;3spyd#&%=-jlW zJ*mG``W88+X=k-IL2e)#EIS%V6ZKCequ)Z9*DBuM>gNm`ACN6!-Ll;3&na!!>dE&j zwcf->bQiStt7W84iB`19QEP-a00b<)I%_bI#yR+1x&_FDvrva1>n+zaU({Y=j(N_88%HG(ncyY5!-`O@94Nefv$bKZh)LF(*P;(mFu>w(aNXg-37V`M6xpmETh9 zSSGi?G3`F9WeRY?Z984r8v>v6RQpq!$53JEM^#LXdS~srv+oLbXwt<`LHL}Iz&=!h z8UZrcYLPoSdE+}FjO<_t+n4xh1ywOvu@L1hz^{Hk-Cu#4?W?Z?b)*^q32@$4G8$>; z2^@UuKu>&MS?@qVq?6tU;R^@SS+$tN$x^}4nN0*5URRDT^Gc6T&T3ZqM3HjOFU=5t z!KU1o@TjD%H+&BtVM;e7<9+d++P0~W!Py66DQrof%r8AYG9O|`UT<1_@w7Z5W+kzw z6L)XQ&|8HHGaVy;eo9 z-Ta7C76is<-8ZD6zF>gUpQM>O^eLAt0uz3DEIU?vh^l=_8zPDh!io(vmG0?DpV@>! zaZ!ip|Edlld8O-g&8YOX$N@i*1V<%9wNrnbJ7$~ruX3$tKvWhj`}_@4D+klPe%Wo- zRI8VMBaews8P~$5@kmQaZIs1v?m1G-4>Sx5%a0hR=9`UK7l7AEQAaxLqq<`U?MWsp zV>Ix*!|yn1bZ=;aig60_Nr3zXv7|@3P<@xur3*^9I2w2xtjZc5ah00zY)0`KomUA- zP(sn3Q~5sTq+7zp>}$I9X(9iTjN?lxkkTV1*(9QIGRpQsrk0(D|>H^rpwMM?EU!BzB5Hf1pHltv#yJUOUa@o~mB{%yO`(v!8sJribEY*Gm|mgJL{> zngycF*&p~uFb0bdj-W+eu$*@G$$6gxQKkYe99th;)={3}Qu=&A=5cG<`Z^6+PrNMu zjT^ZEOODsQ8x<`_>)ple;vj}~D7^JWI+8h}V)<=mOtbAWq`8{vp?xRb94$_W7E~t2PZB3REWZHjTDxrkaBYq>{vU~ zWgQOAzuhy#wt#COBkizdA9y_{@%=h?haIrq8{gOU2|j z#QHQJjOJijrgTEu5bRe{lagz9@nb0L+azuA=;D^@Um?5)^gIRn0bdebYgpmWxAHHQ?rHtrGvb-h` z8^w;pzxcv&gGI<8lJ!^jXMtqJ3w)j%e`gA0w<}q$2MRv#Whor@%wmL}zP}MMB2b?L z2U1?qOM*K6XYQWO-q>)CNdI)eS)KYz2A_Qg>~TuJuCW{L)AgO8lXMm|%6#f|II{7z z(;qX}ykN*-g&RIEw-A^LRiiB99!fJB^^ zI#vj+X9wy-je%ik(b!XxNrZv)bEoLV&3_}cI14*Ni|N{7+|HAcMi*kGJjXdTS=X>b z?|cm(6`>FU)5<*M&FdVq`TG<@BTVy#zDaWBxXhDpFg6&OYrsQ-J*KmNhbhc^~H z4E?4Kl7EiXCs%w|u!F>c9$Qk03jsn@oW0GA1(pkr<-;dnxdIgas-Gq2=))VNt6c;7 z2s%tFL2;W@m!@oKb0etN*vF$|q4Ukx0rNT9NG#;nGE(vbQv6k0XyN{sI-Ss0tN5&v z8clg85#W}^3F@G$r@!S$R)~rdz#z@G>yTDz)0Z-p@QbGJs5^iEEpznvxZWLMoj!93 zf%0NSK*OR4k{rDq16IzO?B^pu_R_=9GIh}Cb1cxhWFK}B5@Pw>9Old4+`f@xf)NhS%+!sfZ2r7-G%nqQ=5!ZaaKs&T`;T% zj}qs2XA?&?_=q<)N-VI;bbc+*!rnv19_=61S zm;oO2CjGUPptH%IO24n2LFzybTTAxM)}qP)Oc<>M1C(hVWNyV?ux0i-4TJ|tLt;|+ z>UYP2{!2+IA?nuh?0!MZ{i(b%_jO5x1`#jc&1#{8+{`!Tg=_Ui=r&l%`s3?L2QtT-7UlKp-vq|8k00#V++ULi+!(xCx`#A0YmZo-#+Hf0YrQ&A+4u~^_^b0>^J z_t5iyQA>F{qsQK0pMn}h<4)m<1_64E+MP89OEx^+8aB=*2#R9^nA? zT;SF%lq9%J?c&j*GIY^&l^vd&g4MsSuq|1M!rrS0jmi+6M zLpaY}8Cu)~%u{R}Xvg8HTO!*Pf^(c4L~)Rv_L=^+*ch%Ai*S<4p`Ej@+c4xp@13yi zK9B5DkXzySS7^N(*_kQymFu^=>1Qd8RIwZPB(>wFpw^hGu#*?3MBUZ#aa0+L<(_6g zqn&r`qcJR>ae?-g@jz)9Q10O@(@4(Y>=@tDvHZw#>B(D(lWOx!dYsS{ey%j)Rgd6) zB}-1e5O(X-BulqSyvv7br^63vQZeQoWjj@<@qH?V5X9rG`Meet$jvS{Jxsn!lE3wN z$;!ENC9Pf8_V#chb#@cX8^f%%R!Ka89lRS%Vs;-a;CUZy#`~0bFWVI84mip63JGBo z0R$6BKowvoa1arw0z^HNJEXZjzQ1HBga7K&nGT!=#bC=C|KmWYSb# z|A$RcEK&&}DSG~Y`jp}oI2XA>?8A&6y;fY43LV<`VpldAm<030JOU zTUlGNLBB!b@!7axv5v(i>x{==-oR>{ytu`wKX4EglzVv;*Tz=5w_@qKHr(`YVR{o4 zFO*VSDmQTqoll0SG(2~Q9K zkJFy!i#72Vk>Ii{0vc&ObIIuQcM~OYaJnISK!OBP_pRm=2=7E$JkB&Jf(6W3Y-x$vnj2Qew8(xf6He4Dofq8*6xFCwcXN!O8 zO;8q?QQ{1!bBtjBBt6i3sKlR6JbRw}4R21r`wj#mG5lr?)6tD=89}B78DY+n$UZ4#>&z zh!UKMZoLPKpn#NO_$i+Y%13a=Gi}r4I(tU~u z>Qb5#0!FAyVm-=`WkY@9`-TTXsW`hFM*?z}UK{ffZcq{(teZJX)E%Z*tUz>7P)1;iUdT=#Bn@3Wp2{ zjxnPLS3SlWu9YJZn7`1|;{1hltQ{^r zn#RMhh`kYz4$Q?;zF`aG8}I?59__Mc7yeLN6UbdU&hj@jTy zT$~^zcVsh%d@docnAXaFjvI+#m1gwu;0qlK?Cl*Y?oukpcRFb&9>rr?K;(~DAckG= zn533EPJVhc&_1(p<<_;n2(+#nBt}`%z47_%;O-{Bnaa3@b9cYgIC~;>1rcgGnmcl& z=JZFBHBN|V+f?^6iD`|8S3Gh}^E1t3w$X{Eh%VSWz+Onlc^?T`#Z(x=#JFh1sqH?c z)XX;LlDX9OqR`{jx&E79@x64&UumX(c(Dtmi4$Y89HhP?Fuk|}M?FfV@V<}PZSZIw z;tNP$D>_5al07+R%s`L?BU;MAvZ&@bjQ@)dvuAeUj$$FT9i=aUpzgSb9niOwz%6)u zvb;Z(bWyk`&|10o)A6^k(t=g?t}yGZzqI8z7Er?R2$B}e0@X~-*c^x`UHW123StZ? zI7-lBlV2%^N1kGa{eo6{+%s^4#K8_Qi}FAz*b~&8kixXPe=Q*T+y~+;p!StNEH{i&LCudWk^7V-*;sN_W1)I{!z#xf!u8aXCK*w9prj+E72s^mN*oUquT z0cK+d{gOf4rU%K)gwn#2juiz7?{Jf`CSPxDvP-pfwUgjbEOP^q<$D_Edq=+wJ63DyOJFzPVtMiJ47l64vRq)vH+7* zEM0fo8VAnV3i_;fybNUzMoP{wKGZDKG?LKlL`Frc2B=+%*1a{dkq7!g4oWHsLvAW6 zeMb!hRGuWn@0^W!{de~#PA1c&^4VsO@q4q^7A;& zPRx_&t(4MOx}uUNYzGA(B&YvZNKV6RX83cPI?Ct-wX`q_BQl`+mWPg&rXO@dxuX8K z!ReJ@dq6^%| z)R~$))0;)#W_-ze6mw_r@TRG3omn3`9(uAlgHF5a!m!&$RO(9S7npg<_Ie4g(D5K< zE=5pcN?qFERUb_kaF?pP&KAhQ7w`)+4Wh;r#&&}&I62#b^;T@QSAvnaaE0VlLj_kx zJgpBQOC_?1E8r=1?FqYy;$Ztz8=S%^Nfh*Ye$tLF1%`h+PBl)jw`OU<}d!Cb!=rqa(55feY;W6QT?#NdTZE;^t9CB#~GFH*_~NP|d-4 z%ILQbm@=+~6qr0{y~x>$W~ohNzfXnjr<9;S=0%7

INF7CRY)pRC$xwEGa)-w(PqKm+OaGcj6p=)$jv2*-`0Fk7ouY zkQ&%|mQfcJ6@yW3mD6aWf8&i#93?LfUcNOfJ*H!o{MqxWJ47dhj`I!Pgfs8XZk*eO zdn(%(pkDepvv$Gq*1df} zDzhQD_h#w!A=vHLHs^zJYXbIt=hp6B?Dkst0ZG&XN$}rKuc*g!nVp2Mk5%3!R{3k( zJ}W03*qIw^uguDFaPJnv9w2qM%k=fAB?tdFrlTx}878sx!c%l6Vv<1}v zfHt;uF#X@a?K=NZxdC9Izzg#~z$*YoxLGkfnj1Qpny5KBSlF03{%;uIhA9QEfx(wy zKp^D*z+evi=M96CyOrtx3aSsc=tKg5ZUHZp{{T&f`v=t3*5R9xt?jq}ZCta%oT6C( zhy!2}{(k^pz556FUzYz*6#pyx|EEyk{s$g3g#RYO(cIM3$q`@%@W%QtH88MmUxo*M Ng#Zd_I{w6gg$+PKK*QGY}Q+CKYck254=B{q!_ADi1FKD4qMKRm{P#AmtQZ|O6=Xy zB9&8T$x+jJ$SlWYjRRG)!#=&UK;3lXZzW{A!;%2CSl2?g(Z9CTw|K2UNT5GQNUJ{b zYH`%vJShHN#k@drTQ>&Kt>OjhOi_GV`XkH2>-4kF$wXKSLV?XhhW#2ryu83NEnP*K z?8s714x}Q)*Lq(&C7jCIrK}JXH0&btF^<2h|B;*c4MCR0moO4xYS&1fz`u)#=2pTt zyn%jG;f8akcogh@c-3k2fa7r1BsfIp3H0gFZ2p&|M_t9SDZCWWB^OTL3)dsO91q8q zEDn#)DO6BX1r;rxgQZ;*9uAHQ2@X#4|H?fkjC&(z3p*Ds&VSEU2|db)Ja|8i7{@y@ z?UC_qmLt(R!vCU@CN4p0GgTEoKsq~mA{*_bd$zdw)?Rr=+$2MlIAFN|-2Y(9|F+EYj8c%##7whDWRU23sWSs%Xv>dh>cI+GfiiJqYIabqvOA{REz1sfTg9}sh|9C z2joCnZZ;_hE$2vDlC}u^e%el^URiQ2>+jY$cWi0vM9pS2YnxQn3MiUL@qJXx?q>-a z&;f&Jhn6e`KB4G%0VPY5vq_9qfE~#d6Ud^ZUiGbKA7cqwFTZePs<9Du_{KE9LU(lh z2g-^&WaX*{Qe7)-5>$wSR-9?`8qw1&h9AxY;y*YWKJJV0FlU=!kNJF)+#YJ7ZB{W6{dDiJw7Y=cclQy-4-$^=?ydR%-XT!~GL^qDMFn^85$lt77w*sG zpnuzvKpI0kFF+meB}b>~)7>J%JwFgJZSmNmip!c!U_sNr=pNxvJ^J2nRZLVd+u7!X zuPAMdge>BbP)v4jf+)1}O7$fnS?s~2xWq=e)O2I>1DWv3nmFeeb8yZpC!FBC-b4r@ zwNwF%@rJn>~ zKVDKmF!vvcmdO}zQD7^k4)*xJlSl+3(Zi0*#oEN#!dwgJY~x_%@{dRHC~2HtT0FSZ z&Y&X*rx*8N(v9&Z<`sNM^^YQsB;>8jooy%HM6x}=%HPn4kbV^PU=;bISppA%GcSo4 z-L%p^mQTql(G`J){5al)kGYS*0|7MxYj^{m5ubl1g|~T@64)Pq`JALb%()rBBkLN&7JB$Cg+@Y-o$mAyNJk|ZOQ2maNw=XQ?=y-)6a|2c_~Jaj7Ku<)NcdNx8zj%=rt>-8F?IO}m)0o1kJKb$XqC1tk}! zR#aL!|4#YH`K_9#Q}Ahod%A0(G44Av9C)cE%BD%zCMDB~6eUwG*CC=OEnE8V;3^ve zFxiJ+*R-q&78%t9O3l6UC0=^URv(MKcbwZ-nl$x0Kh@T^_Oi@EY)74+E}!MSlKr0K zS-;kRtV3wN1B&J3n6l+^CAPL{C$5z;(A1c8a8y#RerJ*%Yu>BV$dNHzpH zq-j|b?Lgft(7lR|u+j~VyWQsb0Jt|)m_0{;F{)Jf20zC+Gz}xKDh&@;VpZ~hWJOjy z^5cPQ(G4SM#;78pV2=MJaf{XOiU#W$&C~nXe3H_cFkm*R%5ikaFcBF;;l~8l&==BK z`^9xj8}frK=P|zRmyH+fQwc%v_r6@X1G9s!CzG~0+^%mLM1y1LprHQrku?+Sn8c!g^id^qy@t&Gur=AyiHvtLSi7j{af3NR4<*J-wgw9tXeY}!`RFQ7JAh`%nn_|I5ZO!=cq zmPC8Xu}-Z(LvF&Tpz;P?`#xg|6i*v>HnX1F4h(nKo^+U!d`g(CE!Yjt;>o~ef8t>6UN|Cn6KpkbuxMY z+(?I|WhjTySI#x-7Vm|OFv2$$;f=O`^mhz&oVliIB-@pV;^gSi!+f29KrnWf9tZC^ z9Kt!>>x2Kx*Gve-_G8}*hB52@4F_Qu_4II*u$4+r&s9A#$l(vkw5_# zDAt3rLcwSu^EmhA1ynJS>io^$_&1m2%dtl3kwz@+f4f{Szghi-vHWP}b01Bb9$Q}e z?&sHDv<+6Bo;M2GIk{pjuJ^WHN-F1LvF;moKdqh=R$Od7>^|H%+>YVy?9T0(UB9!q z7GR&*IeD0V5`CyI>w3y9;5vMDfT7zxxVs1VD{nsd>9118v~j&!zv{jQHnFXi-Bm@f z>NAQY)0QQuC&y{mYbhltyRylDD$ZtOEUQ;fj@R}q9aUl@zKsaY}k@<{c7- zVDrj}>^~5h{H8SVP2m2TQY)cG`cC6ZE=yDjYo*4U-6Zzd<;i8>G4tV8tLd!Yt;+A3 zHrwmRu?P1ziUqQB{uSz-ONM~PodG8!cq=W|SbzWew)V1amng%Ut|Wh7U}ew(b}Z-X z>L?9($Lh@_+pb(}7veHs+s*TB%`~$_T?MCu1f|J_*7m0wP-x%o)~>T}B@5<$?pybA zG5r%kBZdAc1Hk1(D(((7+F7u8_uQ*Q%H#2aNb8-SP>RtYHK;{=bnJSAw4)rQJ~p#1 z^rn}3qts11suI^vDeU8G$*95pSo`l#;pYd}uE)=iga$}z4QQv1GV*ftd`X`YG?a;m zxBf@G8~l7yFGe|-GeW_TA1kQ4R&nasAbygcc~2Y<=swjK^4a%YD#W02hueVtsxhp} ziSYACygY}#`aE7i#x6l)lCM**-VLHJ-r|?S+FH4QAubw{wb2Xk!#DA+FZw5)Vy#PJ z4>Y=MWAm1ePPbuJK?7{@v3G^d$uErGUo+1*lw2l_#69UYzhsH|y_{?p`42MJg&9`e z;>Wf`y*x#8ZTj2lyxxEmXkK4H0RPhR*N1&@ob$0e5xslGEH!9mOU-k!lFQ#v_E!U{ zhpu01iy@8sI-;K`sB;ZaPI=me(J$V%THs@;E5XVosHX7z)&Edqr@YmFQ*O{RYmiwc zyZ`*)>H5Il)urH4;n;t<=U2aE6pJxx~_lvgZC2!66}NejqnLfQqT1A^X%rM7e7otp)<}gsP8-j zp6ZhoWeL_^y=(M8RkjCBhqH8534#uBK^EH2NkrmH+QN1Bj#{`F{^65`Ij;&=c3Mgj z&&7LYK(`LjBzOPHxDH8~@jw1YTbYL%hvh~(fiF6Sele@bMgR$Y0Ou<~HVp{0_DawJ zF{o+Mz4pHy%G5YK?2k!MYXXk8uyB0uSma#&-(N@12I=(B`D3=#(&9w!18qgOl#+MX`} ztZ>d&90rQkFp3SW21cfs(+JdA`wqsV5hN+oN zQy7#cY0$}A^e8)4eGiw|!?xegleZ8`I)iuIoWXyDT8_OaT8@>OtuK?oQQjq#-)FKM zlXvy7KDOD;{<81F$NLkXsb27&;Bc-n!~XSf&-E%6;!g#dKXqe{1-)Kh;?Q{@;E7Gm z$|o?Y3UqzKUPp&J`Ce0CNhV8Ris%kZ>K$DL6+@R7bM*%d#|aWgoa44|p*i zc+O`yhg2}U185Vj>ChgoiJc05^;KZMQ!JO&6~%F~;iJP|`k?*eZD@1!iY-A?{1+mJ zv5yX8`lMrwv++xu;mCXxA0>zyj%h>*8%C6L7T+LQR)|_wpr&y%{@o#9DiBN^DjQ=g z`D)g9Vb*BiVAW_4$p@}(;sIAPsI|rm->S0mXMKrn5S?4H@504vi}zMHZ8AD|_on|) zj)O>r(d?SM>BiNFEo>=S#;Q@pv}gQ767GQAi=lx3#0-$;P*%<$DwPVvo2Mwd*M@ z;b1Yr`r$~U5@OTyXQ}lM4x;EQo%cWQ z>2w`IkcvB89QAOZtSn*GSL%-O`ZTs=Sr z!%J$f`>8Q*MXj>%WPkzbD4hTrGs;1Y{C+MK!>@J?8*Onon;9O=1)nO6bQJQ=JY%ON z%;H%^)*UCmEn$D(ZG?*y5_XY4ZU4HMKCL!c(pycNmpOp=szCXBN{5euF(FH==W`#` z;x>9?{=z!MS1EQLpCO29J&crDh@ktYqufEG%Y;(+N=UD7Sh(>)*b?<_C{M{4mq~6dfc)bl@uf(w&99l z!?$CjjEEB{yap^~&dH-$Dv0-aOP?~@Q0ut9%XWrBoE1Is4!h7b7{#6b!GGxfJR-M` z^SNgB-b5TT)RjId#EBZj1?px-`9OO+GB5VZVNb z=G)&s!h1rZBfcHTyAGF}VtV76Okgee6b;RdBU#b-c5KX|6x5UREzX+E=YKBmyaef&TIjbTC$i-e&-%219Ci`AJ%g z>u|oF3Ra~?leOt5uF6-YsI;qoRy=g%Lqskn%!6OH{k$NT-#Hxj6m3KKZ~w@Yez>w*Yix^I6_-t*|zx!QnpJ|O-OlR z8^q2zhn<=BH*&oT{TtJNh<$t4ojwxuaNxltCm`$m=e~Q)e z7HrYp5O|Kdy!3CgupknD6#8hMJpncuY+71>N@;B7OV8BMYr<`c~z* z_}DCtUx#>PAW0S6A+9c9KvM^$=etgKK6H>~48+xiW&pkBqI1GR6aif;-*|_iOO=26 z$s)mJtvG;TD0=lD)g~_(?;fvASlR#OeHBrI8Pj%LMJt(M_Ii8?e{=U)_%o7wr!5QB zYL1_VTx>TObpDTz_G2d>tAq1tN^%|lHw@3J;frd6Et?U66f|v2*;l|w7P=PEr-RM0 zlh&slI0s?>jr4pKlqK0W8V7{7I@gHkQ`d8thP=ZpUsbUBHQXa$Ui7~*J>^|R{fquN zq6!P9?T)S2=Up%L1pwT6j@w7MSlU$(_W{iG=CRYky>NTh>QYQ61o5uCPh`xf>%Oe> zns&x&v<<$|WXc~@M3{Z@R-U21rL8nFN&5XP%29Yk@w!qLIVM+JG!fDxkcO4%8sQPp z`%YOS3n3n_dlJ>}BlW^bYGly^J_zurBENMa)`w>dl7S`%a06)TYw&02lLLHwizahp z0;s}+k8Go)7I9x*^4nMJYYKel1@cc`e5xsrFqO^OCPed-Wq(CrB z-<>R7={4V_TeKwQOTzKg=wdBUpglblbcJRA#f^{zCO=7y>B9IWs*O6uc>&s5$a2D<`l?kv}xPwf2sG}75%?y3>E$1oOa8N{lnV-LlXZupBt}7M9 zRT~sRvxH@%y00r%lheJJFrmK$;?2^LN+ej}m=l0{?dTB^1jwp^{ z=Ivy!srUjmGw^sEn`q3$qE;u3G+faq#I*+EmdH{$_0RjB&0Ai*StKh^$a5f(o9stLS@mh&{J{T`qrq zUav`CM}?QvdVez%P$s6+a2uS^2I{4T10N}rt(oSR1A%3P`$!w(-sK`=DbNA8ni-z5g;3&7^^0uPsRQGhXk~5{E zl%yiE^cn-3zYSGbQj5v0;hJMoo1-V(2VCTmbMjH1L2i;hXJcY#k8OZ6W`|MHb2vYP zX+%bQO5Pd%P2g^v{GSEVv|NXe14TFu50+nN%>1twxwnINdnF(>5sEB}GHAa^AmX8`Z!j;j`B@Bht)Qq$gF^@PnWlG%)Y2`N>)GR<>kU&ST=Ng*xDb+8yH z+E9dzU4LfzN~9QwW^sM0#46J@2g*n3K&f@7w})f7f?$mqPsUY$n-mIl)7361#(-6x zgh@{gUG@Tn6sIFoFfYz-sK6=mu#0z^1GZJI%dUO$J-s(;MP^%sr)!e}Xv1o>fq2e| zX;ugYeN_O8RGRr2AKmHU#OCWxoQ;lod4bnT3X?#iy7O=YOt#83ZYyU2hZJ(WB)QPf z+Hx`*m)#Mg!C>S>?dFrPkg^O_#{!WLv-d|fa`IPbxyPmyxjdK^^ts0-UnOcBB|tfU zb4k&5(i09R9odk4vdq9mvgs%Cu&}Urdwsl5BhlG)6085Uc_2T~`3rk=8~lJ0KaOnC zIzSY!nI~48cF{fA`NjF#;$ zAdb#K3a|cOqpbfi%KhV_`Ytqgssz{dX{1-%|;kE9uW~=o9a#Dpb%5{i{Lh`8 z(hPj?8Gaiuk%aRyo+mPyaMEGx7ry+u|I1prX6J}h3H5jBN5UEUfW}DsfI*I&n1IGm zClsKs+r6OUwP*GA0WK3sr83st_(h3QDKEqm)(UCg01YvwJ@rmkV$w%5%{(HHk&*n@@d|6zCO$#N)>V<1Yy z9Z!-$@<+}cSs~fg`drOA155*Vs0fW8dm-(*)gg`_!&`GV4Uq@mCj}4hjkfpLY$1r{ zG}_L_+jkMt)*lnl)jvBsFG2HzhxK|rI6ggBrlw{itvv<$ex#@yX}ZRyOOIUK#^l07 z|FMXuQiNtJH+CS?IDRf(_@getFX#J-&c2GD2jU36GT7+~#6AEVaN zii0FPEb*Z9%`c)jxJb9bU3JN$w&gpu&W3-Xek$=M#z+6LhB#G#cF3rrGg^EY9<5m(YdV)F8Nw-G>I>0`+dVD&SFP@48o1Fz|cQG$pHGzVMm7{ z34fUurAbA&;ATtVEGGlL4u0Ab*fyzTM5!tDCWX3R{KE+X;=*vAd99lenb=#Z=_*mN z*FU>?*t^rUoGlMcgoROg9B+OA?)(ua4hJoNQ%=#1HA!0HW89=lbAg{~0W)PU0lVnw zoGOQRvolrT^{6P^ti;Ahf#qQVl`*t!rQfKa?pOZ|L4Xx7L$%(qo=pF)b4>kwVEwjda0&KWjW6(1IYa2_b| zNlXeNgWS&M^~^64-c7amx_F$aHq?YVAGla@=&I@cc~I`EhP_B!oU(jsE#Q}L(0()k zelz1}((9+n34f0qL^>WQyb-RiQbe> zG>tUs@to9tR@nmZ@^gv!PUsF>NG#Pz$_yoUmaNUd@H1h}akaxLBo?k%l#+2~I$qtU zZrtduhi$?0D|R|B%09Oaik~A)6;@#(@9!<_T)+Ab$$l#-(MyEm5z|t?7UlPtMAk>^ zw4dcsZQ`U$IEU6)ExaR~E+H+&9C*k$eb}Hzx7Lc9kVoBKwwr^M4xeDf-AztNNthzb z$`0ZQ%AXLO+^h(W&oQg#e&W9+5L-njW7bKUe!1>?E#u*L_*#(SZ?X3&!bM(@(fNKd zbfBbU3q}Y0*c&^{%wa)_K9@C|VSSjJM zXo>_5lp+5U;|VcII{noV@}=UT2S}>YR8(H>D9c^d=W0( z%_9;HoLjiX;BjjDm^yCzuF97Zxn7HE0IL6z&DpKb@PM98tfH^-9bFw&*ogo$vy}p@ z?Ng=kAW7`b;py3Ah=q&_f5myk>q|^qVH5dO05!k8;iSXIYkc$~iH9qCrc~sZRTuN! z*cSUf=4T*g(BZ2Gdit)8k3Thv%PiI)WVWk3EBY9zomW?9JNr>X@I7o9=&ykn(*g!R zq;L_P+C>ji3?cEq=e;y%IjUH``}d9nr^;KtEBO8)sM_s2Is%Li)Xo8hN()sTNKhG8 zZhY?ZC3Iv2I^Xn=wJp0;Ed?@jG!k~yY-lTk%9O3{kbGlqgE(9rc{Oo0rDnPUy`G(# z!~;r==y}loP{b>$!=6YT1aXkM#Lp6Hej8V*l)Iyb~3GhWX! zuIBsnZE%}8&qSeBQ50ASR1pK6iAFVEU z1F_;<1G)6D?exCWQeQ|!V5Mzp+)9|v8tYKk8TtT(;PN#DMPZPxP%VcTfE(?t{z8;^ z*N=gnkcMp(-+n2@fKKrQiYxqvW#B#-(QMkkea*nHb19YT_PJJ4>nrXOPW2v8P2>i8 zqa?Ta)Av>1kjbo=mi-6>&^q*w+M#MDX6Sx_N+_$6$2==q4K8U2s>7^3q7IHQR2o%5 z8Onn1cW?Xr+V)1GpTo%FyZyWw1aIgqo1jNcsDq2IZtg;>lXuUDl8r%+H6&CJKLfm z2%sYnJb7e>k?528?v`)nnfJ3d?G_W-3v^ITl^o|uQDd-2!~Hu9&mF4z1Vd#_^)UmE zLh+MdH=yY|?AuxKmEa^z$$e%{8j-(#5{tVR#su1SMFfr<)qPl)9i9QJQD zb}SIm6-2L8W{7`IkKm>&NMC3O#=>xHE41>e`?Y=}ipLw~LUs5^*8IU_PJuG!%_}6% zXc=OnzO7)2HykVHOeaZTCUPI&eZu7qi;J!@?qW`Wgx5+A%w0cxzqDwGrC!ta#aXQh56Ls8sZ$a$p>bkVAL@i9Fr@DV>SqL4 z21r=&ZdfU=Qg6vz_=KFPC8~S0;u3oc6;)-tl(i+riN6nDl3`8%9ZI-gN~kzY{Y?dH zTBB(QhB;56l@rISm4-N8Q)&t|5BD1#PX!Zyog<5zMo?YBeBN1PRq(2VnG1sWC(J}R zFIc`z)87n0^O{f_10={9#f=6Imga`cGB5TN(Ma^(~=8gI{iR_6g@(dd_A)Nk|xsRGu|Z zn2JUaLcC_0B=_cMcZ__pjuu1c<#d?7pOecoHwAEfQREVl)G3~nXcv`xla5C$O>!iR z!r+MW@U@+-ro3%2*9vRuR_|$ZDD}GGD^J`LAEQg8`{!s3UKI8XS2dA)=*>5|*}jL| z!?7td3KxVl0Hb-Q8gJdON97mq#*7&6VQ+RlyG_5=TjIo@eH}HoDKFcYu$|!NZf|x( zFi}Nljf^*d%)j|L&C-tQ7QVen5ewr4(E|`qO5L2h-4RV)(*$;28$V(nK1_VfU5s!7 zZ~K)XomicDrYPZ^8zjbfv`!Iw4;C_8qA1Q6BTfAA{2HHqt8z1_O6?3{LJzoso_vJ~ z#&PG#*9SsaPmX+y=w5|&BxlZR$${SPl_;@(5RLy$p{=X#94lN}+8fUO9YG)Bv7!wK zJfFFQqn*j#Cfd9g6-gwaS!EAXrrRY`+}OrnTe)BrbTWrTAw$J7g5*7^2?F$cd)sgx zBGp?kY$3@8)~u!EAi*XrEM&wkm_5}>QI(faa*U_w7%N4rQBAyV04%Pg7)OE3Sjagy z73t28F*i!QB6!+r4^mR@5YyP0_jq?!H=kr~zz($B8jDGBm&BBaC87Wxn`WMFkf)0O z3o_l?DERN|?K*+>5jv9i39o^Ja66}7u)M(=gkwmUBMs?8wHnN*-7FZK+JUUX&nF51)G&&L~hnMK?S&UoP zd2K^t=L|EjQHch9-_qb{Y32jM>t92*#j0=`^*V6Tgw3}~J&FZ%bs3Qtje z-z33IzTA0_o^?YC6j)CU-et710725LJ?Dd9c=LT^)L`gOLzn^XGl8rB8t5@L-q)e? zu~K@`WS4WZ$_5(;2qB;c2Z|?vjg4bBct{r!H7Kye{JGOuJ5alI3nfX-TTu^Cw_^g$ z;4iMM%>wOUI&c5sD=N$albx=)&2mPsP|^P-U9k2)2xV(Yr8J?xD3@0S|(+edRW9AarJnA%YQyf?5CpJF7p>B!v|3Afay9XHeT-f@Iuhb>WxiWvFc=j{|pO62>+ zsh!IKFD@MK)+v&BO=HQk`|@d&kt7xBWu!RCJoN6csy>N;DUxvMKwr3AE?AD=R7)6* zV{^YBYHEew9o_b$<7&pEcX@)zia6vTQk-R(QZis(H~OouOA3<>w%;>{-_G~zfzC?o zM;ATcI=?8hT!(9U2BIU}%1*Xg(fR`pWfY0oJf7Kix0}ApZd?gGa?hzQVa8Z!? zvGA!${l-ceDmu)JA+}Zun}ak2pG-BP2K`?{4B4h1zx9YkKW_O(@j-~pUyxA)pu0w} zxWSzXyv{cKOAL5p;};#1j>P#`-xi`JdVFWNb&m4cdP#RRBr3S^#RoWJ!QGauby!(E zlMJ{e3E$}P?|)R07>RDsEj`UhTtPy6NdMGS+!EH1Wg1K(2t@CcxSBitO zx@~$%)X<619d1LSy8rZdKLP2vnXp4Wjp(_>QU4uXJ$0j1_I_mqcM^EKdzFajtKP}1 za~%h(xvQt)?jnAmYcYAr_vuz#zqM+-1P|hVCw6Z}HIdXpzzxT#K7h4pM^HnfBlsEP z)9g+aWIf++i7?7Fnj%4=SdQO26xoVr{*C3_o(Dr$K*IpubhC`3uZ5_ zkMkg{&UFzCaaFIy-Mx~hYw3B(&+1fMud5Q}5(MXZUP5qZmL48N%1;&ad=GZ~F0U73 z;dg=l9ROSh6b_H94`#E*S3?hc%KlzBL}4K^uYoOs*oXd=4-wjIj_`vLhGjuTxQIYouA6P^J}Ed`0EV8o z?XQaFnq~*eyF{5)Lr2=QlVey3MnNzFaEW8W0!xN=XH1KxKlc0NUD*>oHWGY0%*v<~ zUN>xvIwM7UYVWv3LGVzs?zQID^23e8)wMXyxS9!oeG4^>JwMv|vD#YzK$P6P{vb{` z^}%q8=;9_QxCaRM#~~|SF4{l9dAySwg^mIEE_F>v) zy~Ssd{U<=0{{)C=5z(6nAlLXbp4|Ifv8vC8KJ^0IsJOj(M7W^#{J_8Z$aGd8Y21nQ zSxo7WpgsJ2bIYQ%XAQw@ZT_dX968RdBJQA*#$+I@=sQZ*o|Xh2W-a(KZuv8;wCRZa z*^o%{BnjXC`54N3N*74e`4gmHCT845KGexut8sg3Iu-HLcTEl!q}Zl`&Iq#oEw#5a zT#C<737Cq;JakGJdSU#F&U0WaEINL6hKb?R>=IpU*T)hfr6gTFcI}D`f=7}`(In_c z7n`?gg%RpC)q|@KY}-|*s!%bHKbb+yg0R(a54AKra+(=F%^n{ky0~Zr_*%TGtZnDY zSQh_n5{lp-5CM})jC({OPgrVi-&X8XL}SBG zdmC7+4e@DxUbA2LxU^qAS*}C_zkgzQlt1$!04~`_YjO44=~j4RyKsY=yFiz!i9Z)N zit6nxtp6|zsOd`0L52xQ6g;9ofP4jwH5sj=<5iam5h3Y9-c)li01m~7;pY(Py6))h zDk=Au^K@>c@ua`O&lz?;W|DkA;ab~Bye)sfrIo^71CFm&l$Xw)9P`{MxiOTJA%(9G>=49s_?g6}^ddzsMVuGMMG(x50MmvK|Fi)g4qcTT{-o=) z7#G21=Q`kOWcYBkM2P|^?i(^T!eZg;zf%+1b=2W?i}$ z#?3_Pe15~xB%&ZnEChdCpQG`BweQ_DLS7BsjS2$?#p=52f>X}Ez64{eiZr^1({6lR zU*DV4;jbp=I#h#TmnlURZQ7c5d|vIPCE=Gm%ha6M7?~WXTB(#BA{q&Cnk52@KBtiFXYKgB zP28;Nc(GQVpDSPVG&tR z#XX}~uu6-x{Pylm7e|cYie2d@Nc-^4)dh3;Eb@!o@!g+Dsv`atEHa373#OWqgEgtZu#jT9cc|-3+HGIxlV8e#a%u!GYR74MY>5$%D zW=s)4TD$t{hJUgpppo!nyL^q$`b-DTXChF*tn`R%gPqQoyK`9*6j-x8^l!{HLcN*h z_*JT2E3~5;SNdCD9=1Uw@OB=lGvj-9%_^}5146HE+hSl1=V}Xn=W;Q%4-D+ruu-9r zOR?a)WdW#9aV8Ib_>Y>^!7(gu!*Zbs64qF=bW0nKPgFGl=k@WV9@!4<{YAJxb&Y74 zo}naRAwi%(Tt3Y2`h-zBb8&x{d?iT?kKdP&2!?Lm9>Z>Qc0#02e^26xBf!kUS99+E z#&2FO))*a|$Vb@+U++vEYCL?ag*E#I?FkjR3!u!3l;2iu$2-?*ReBv&4H0H zVt7M*j9;f#RL_z4M`0Ql1I1C2GwrD}65-_Q#?Z@k{xjUHDwk8oz?TAmXEvwjF&2ZM zhbz%w4R#JHJ~aFrP6iRp%!wCNQ%d!c538Atbe`|FcFXNbbThYZ_pjzU?N(=V`#HSo zRtYdOKlMVJZ<-|O-g3Sl;`REoS`F69k+Kt&Yi6k#8>7c+FI5bfc|>&1BDRGLMYz!v z+W$C~b;;k+(LVK#%sC>N8Q2}GHXR3FgD#Bb_wfgg2B3#^pNd^}ESiwA*weZ1?s^-Q ztOOz3Vd4-cw?{Aq-|%Xh1(a^Yl-jD`rTElwlGfX-isw!ovKprJ?#aQsk0sCdIO+;j z9~R#{RJTEnO2o=zwCV;6OxUTh6vYNm>M@fz9*;A?EzB5|-?WhqK7)7+e!3L2;}5$n zxg+7#@v^grF};GapMK%2XyP~|2P#6$I8p7-IT6ZxHV7lzmg$GXUc!@>(r9{XItvZB z`9n2J;|NoN0P01YhFX-WM*8N?=tpe$nz4_TTFQgf!la1W);j!i9c9Bh_v8sDs9+4lv7$&gleX< zTIvCj6Be8qL|tRz1*v&AB+$EF;*yBku=l;tu$!9W@DNAo-?B)e1^5*N=rg~+;DkwZ zRfB|b>^kSiz#lp6JaSmsL$Q8RQQ0TPShZH+dN*!)+;B~&OXEmjO~w7d?Y{(K(lBMm zSQ(8`Kf}YaHDJ%jcxkNfYvyvyx)*oFk5Z*CViX(vVtX&Hg7J7b9&X{r1AGJlAy%dw zsA3?E^-zfG^{G%@o@aFw<%J-bLc?GcP23|wKACrQq4mwws0EJaF&_V(=DjM~#PIdf zbd(ZvA=%hBqKW^8D+6`6RjiV${1|PNWkn*tB6&-1gQzCLpkX1F zUpZj68w_dy2hM1c$JOssB|(uCvF?vI@+OwD*Q#V9+dMuphTx*YjFXkVoJ*ndjs{@5 z?0a#n`8W++xoco9H4Ni-Bl`bh4Eio1?Nzijf@w6q z5NEIY&^^d0o&&#t)dbaRKa{J9bT7kvSqL+*xk3s2-H7V#=Hg4`ODWg-l?J4y+nW12 zlUpHnuNhvGF=*ypFMqpUa9~vbqKk3Alrxo_csJwalJp)06Tu*z#aE$LCd&JA20H*symU$rR+>e z{p0>tMAG{+q!EyLk!s!1(F#GN6bB!7{ly%<;^XjT~xHg#{?MwQ7Hu26uN9e#$ohJY|?p9ZBGSu>9E&Wf=Vxnr^ACE{DiT!JxC&GqNK?8f%;P zl*gntN_B#}+JmB0lc;H|j}LS}(j`?`+lE);uT0sOx&sB`bP6rcU$f@#cxojfXJJZx zCTpM#MgMhJAvE@1cO36a*;Ua?DYbbB)98Dta83U6NdE5ns*T>UV|s#FW|dr1p%wCH z`{$LhJY&3~gQ7yU<ooPtlzGkzi0(!u6a0U43QM@YT!rmsEOF|?|ak)4xsw5CvH zkFVGU(A)inyx8v!1kzJRAlN?tmfbzGL zf|;jG^zV5wrBMxoIPQNhEV8GEUKjm&W_T2SzxgMpb#gMAY1Db#3~mB)CE!9e zDPg05dM}1TmRweWZ-zs9)kHq}MzFo?EQdPSO}wN>FsI9~8|wuye$cbB8Qy8wN$=Ga zadVC;HI1L4-&Z{C3JbQ2gS?4|Ye~HT{d`UIHr>|qc8#?E**8rQ4Wl3NuSb9NPc$d* z-%4W~q=QzisZ!&@1MjU*uN*6Ytu;ZQt&mLb(ij2LrWg5PKE~u)K zC+u`us(F#aW`o{~Ks`QO+ej_m`1#m^x1aU2jTmYFvPI%+TD5eU5TZ+)cm{lpUYy6% zbBKK(zGM2PfNsrN*#S;5(Y>u-SsO~1m6&8m#T=1ODJhV! z(S&k@`egkXG`C1?q^y$1-wAU?QJjW z-WM!{sX9${DTSKQ4?vEU5CLMO{RYN;I50+5w!0enOr0pgTdKL~G-_J=R9~#*yzW0VK=ptqUjA{?h-@b52kKyBVu^V z69Fj85R7fTwNO)OMLPwt5C^*y{7e}h#Yf~Y@m(e z^scOR=${SN!OOIk+*^ASyZvNmzC3vQCIWA?-}t5E$jf0?f3cU<@!F|zc!}cm1 zm7J~)g^#MNUTrL#&UfZZ)gyVL5Vi=LU%*?96$_eveSQt0*uzg5^$$bcqT5tIK2OX5 z>;~Et!WDT}eX~mlFY>$j8QLS?uF6k$CbB0hC!>B5tFeCC+-<#mLHZ&lh)C|y^sRLz zu_^RFLZ2%r~N2P|xM{!pO@c z_e~;~pU+ZSY$q$}BVVzDJBC!r1%uW)JiL8kpzmWxP#plYt}|_jG`wj+BP&Wz`zG=L zWk-1-lbA2~3W3(Qibo01B_j&Ox7VDd_Z^03T@!3)aboez4silWBuS{C_pAu+9t~rO*q-1<+=phHZ{C` zhf_T!rT&q0Z?3A~*L#*p-{S(pPkAsdvc}#{_IaHjoFqi7u}>bKyc5hqy^Ml=w-fbW zfrua8{y&8xnecr}h^UN3L#NmQnOFsL&jo3N;rpvgtw&}7ay7AM2|bk!JK%=e zTV^3$rSo3JEVKQLHMh&e%A4zeSwP=^xqkmhN}P| zb9Jv;U`^r#Cjw!Luu+uK2$jOsKd(LERLavWZ9s&qu|*8f!ixv!5p__rO&@RAX#r_U zrjm*f9b^BhIb>p$%&8T^P(WV{XCzRDucEBVJlV{+oTMLsLoDUk5kRA<{Sd5wYXrK4 z2hC?^7}Uof{r1!t=iu(L(Q$-@DNW}Ex5wfou3Z4`6V9C%2tVYr_>Oxjw#6IVvdT}U zU)rWPVVTS8JBVRfym7NKz)QLvmxbn6Z2IVCo$mL zfpS36`DxOo8%-+VK(OA2I?Wg&-0$QAy~5NJ0^u8cJ5ad4-?x*k=ghgYPN=V^n*P;( zUo^B`)m?gkT+e1M?R;t52iO`be|-4BY%UdO!=h~^yT^iQ5L|ci?rm0K7s7lxq<2Tg zl>zC;fg+1wxfw{dNQA&4>HxQ`*r}R`TGQ7~#cZw!k*39l_N+te{D*&-1q}ki%P}kb zpjb|zfc)D{dR=Qqi4trjpGv}w{?byI5ygHQa%H_Q-*Qcr44;c06z>QnslJBG!EI8& zV{e9XC(%hOj^moJ3{;1X`gjXe(fKO*6>6})XtLMS?` z$1R{iP2^0fR9G!qB{vJA=FMk{Q$c?m{5(BnEi>Tte~9|Zpt_nSOe{zOT-+T3!QI^< zXprFU?ykWuE&+mTaCdii_lvtj&;Wt#$@lKo{-P+T={eIqtxxyF!XDG4Dx;$y-T5Lu z&!BcEm9yxW+{{p`QRYHFqfx6-AtK$8%a^R&D~mdSj$G3DBA?P!8ZBD4Wnt{S&(o17 zlvsXJ5YQcpr+&dVl~OQnk})BNys{0I8g$AKP+;DYn5)SXV%=_4ns z9#1?_0d&jLjsI-@S7^m(w4?!ruF$-R-a(tU#tkxARolPwC;jxEib>7iu3%6;E1m? z3V&K!lzw|af>)Cem-K;RrVH*UL0O}3@;GCshLE$55Rs+#T5I1c~3viyObp zM343Hy{eUYQi~_emmscp(xMEyQ|9(QK)sW%C8KHqJN`6Y77u+{peRyMOM&%uXxhun zq1EC~rHL5BYGJRlVdD|*{Sj$dk_l2CX#l}64n%pM`Mk!pqJg~Bc0xTtaR9;h-VSke zf}{XJnAe$~06{2q-B(2VM6_IuZ*kY0umriF?JttX@jRq`KO^-($+zJGNt?-k$&+SCFBGS-hUQsdEC$XvQQ*gp&wf@OfF|kZC(u4|^Woti4$; zIU5DINwt2K8fHdWf%v#ybYk+m@1pc8nxP++(xFkB5NgUPSY>QMMjHPl@gZVS!Ok&- zzE?kUsgaus`7uqU;UkX*8xGMr=_)6_V~*ihNe;CZgzHMSk>;|S0-@vP@|YAtM{sm` z<4{OD*a;vT+TQH+AK6|%OIH8{(j$^-Cno^PkP2NNyVX0w1p%jMs7lA0Ha# z>i^lS9*|%qLxo1o39r=y|GSO=d^HAmq-%2dNl36itMbkj&~c#`zQ?u)Mt0v6 zmPf^G1O8&KOu;Tl0O_@r*brwEes@8MCdwV##76)^PA?5cM%XF?D%G0_88ExVvuM9A zb6UrR;KLsqc)v`nLYJ=iVibpnaovu{163d?kHSfBn;?&VzMC3=PYi_|Z9rMgT8{UJkG7 zKzWqK^l}D+hziS@Usn+i>haLN-lZrj?NNEe#IPpVrw)FuLeJ|z!321bo11%!) zD-B*#y-?^YBRybo=qo$DLYjYz2a;-Qv?8`&R1ie$u6x{0K>VJp+BZoEKiS%BtMxt_ zjFq4MvISvJ=36Y1D&c`V!+ZCqIl_?IL6df*f*2tj$}8f$s8}QSo*QbO47CBfE1LNM z`F6rZ4Hv_iDV@NPZ#@f(xQ-dl#X#B%vD~K$%r>f|7higUY zP2MCP(XarxbVK22QrhR#5z!=c{$T1TAo5OwN^1N{FXsZ zLn$W@O{o^G=k;5fE$G(PMXzgMT0XVz@_OVzl;f!p0tIYf!)F6Y_-U5P2Xi#WiG zU-h)HMIrUO?EA~flXPSZrJ4Z>0=ZhWzoxnmte2|XN2B@avGqJQUw=(O{qez{_CyEr{E;~dvD=x=D0b8vv2(A9_V5zu<*K5Q|EuVA0*ME?^;4z$B_9D?P;_@nelr z!^D_c>+A_E^^Kz_1>leO7aIi13xqkO6aZdVky z0!k(;)C*krrdivtk{k=kuv>7t59F6hMygdfb=JmSB*hV4fgixWxs4+Om0%Fo?DO^# z5#CNo~6z%P}o38y<9 z5)DE!_YYcgq%OdvlOcX)@Y+s~790HDdbvcx@))}_+%}q1`4Nv95nqK8X z1+H`i*F%afIDt>~&DCvPje!a_MZ29EwiMGg9*}6ad*-Xr-ka?EQyc9ZGNw8Pc8`^B z2ZFtW8X!!n{QKUD=7WT{V?dsJEAX^QB$fHo40R)@uuUg!25c@Clg?7Hq0gg%vKl-* zRT4^D_yVe)gzi>P;_1WJ$N8Jx^36;~9bzTlx3}Q@5)aRXPa=6;j+S znh>rNU8zg75i<#swA1I}gSt4UfW{w#_gof5->uI_3$&b7q09%ROqKCkCFnzIN!YXc zG)*)6?hy0i!IRcgXkYwz?r~oEG1(l4vNv$I)m)qoX7blfTz`KZ3l%qNTo-S;)2=m*%%>qZ@y2 z1V7Nw8-H#GS5PeWPk=}WphFS2>@YNnAH~U5FGHOq*o^n`$W}?lkVYTS5Wim-BaT{J zb!rKys%$`W$L*~BvPjNUv<&l)_~mo_+p+f;`)3va?Y z_k~zfUNIDAK3-Gc4iZrV|FZ}pqtU$~UbAv3;AHB=(@uyn7BL9Wh`QMIVd$!OUh;n} zbro@%tI~;XVKQDWf(Y6?=G4dNdg%aPCL&s8V*F9jG-xt9!Hp#xqA8K zL2&)jq@lI5_r+P~t*)zT^v~VB%ZId9zwZL7VJO!hmai_-k=c}3YRL)c(!>|su;S}0 zKh~SJ2H`T0nGhnIgG>mEP~goSQV0dH|M_yaGY8atI1}SMxTVgG#KLf?7fZ>_#aCNd zIaxVU7RADuUB1sbEGhlTW)fn&POBs^J8Yw)^P9UKjPV!MPX!O@O83=Isn)b88M}v{ zo8Rzw^Vm?AEC9d!vl7c7IRQlI!bk+gW( zw0W1BeVNul_Ob2;ku)l~)&BlIFK^OG&;oAL^iyDlSBa}F{NeaIkt;UZc~?&MD! zHcf$Ef3Rf( zw3RqI{#i9o!bw~wnL8tY0(hu{szmFvnlRQ4#~WwFxxpg{Nff58n-hfe4QiE%x)Pmz z^M|hrJ#@c&k^HGreza->H8Lo%#WbsEFf${aI49d}7=3>>XO zPpi0RSp_af#XZ+5AQr$`Rvd^g!E=f=3WmH!(xXQNyb4mmMKr$Q@KeF{X)8r-VC_#O zDZ^HMuAx#{HYM{2sz;q&i9a(?W`-7UC3e1jp5U!vaED1fmWn?!$_Gv{{>(1_r|>;+ z!Q=TkW_t87a1~ z^lbM+@8sz;%ny>(&EZB2Dc0R7E^Wu(%0`thx#wl95j}?r-HykjGNqIp$b9cjAxdOV z6z$@(;!!+(n!4CuDkrko$hZ1;_e+KTpWogKV%!?$O}16jBT0^WF;$~I4{#rd^T{t` zucxQYNcY|z!X-%{xANKxW288%Zz#qY*(RqI;UgpwnxA;ac9tgR= zgIylUfka7-Wi&;8gy$q#lLGc#a?vI%OPUjs<_QuILQY$5gt z`ueZLkVCIS#-#%q0GWdJJw50t@KNFQ+e3aomt{=k7>J3pzMjK@IPR_RlJ`aGn*q%LS?gtst^O*n*WPG|?Y^ zXm*dXQ#i7mR3Cv5W=ry|?qALYiV$$IYS1q_^{D-{y5U##w7Q*qO%j}Z=X1OO9rBxm z0N!ln)LJWDwn*1Q4Wc!!Ij!BdpFuF!)0{E;p_kkE#$~u!FrL3FYghT&4z#lOvP;s{ zO@ceS{A%vQPz{WmGPxBtvYbvz+K3>;E)Rk8KmtUffyNVrj`HikERaL*L9}6y=X*uE z13P(H0#o98F1Ol!^-}8H0}B;}HmSFd4%!K*8?g1>x8$AuOUC0#W6meqYVSoEK}rsk z1)^7IZZHXCaNZEu)_DjmYUt)e;N!8LATI3MWYb2q`XBE?n$xGQNHY%@4rE{eL8Gu# z#E}*%!5H8SpJJ}ZgonMqM{|SysK(8L{Y%WLH<73EFDuR$Dm9)OoHVt^YXM*nWj^gh zCrbbJPzKVARe^g=<5YC%^~&XK4F|F+ug}tWWrXA?We`1uShZ#Za^($@k*rfir%%8y z=cWFgyhK-r`wsjK%~7;7-2Os3LJwg2T8Yn&D1|m`BX)mxSz0d$#y@)m+Uf#F5sI0> zSb$M#TsPDJZ3WGkiD-Fh*Db+caG^~qLzzHKrr)@Ywg;EmGjB-5Rf8#xgtX}Q#bfinR3p#L8q82>v1Z&2kAwvxO` ze=h?)*;HDt?#D=0#Lmfh_)c*(Mu{M_V>{5kqC+tc7Qm8N`C6Tz0C0k!D#fN9Haarb zK(hjT9SsjXdW@YtaXwleoNdwt7sijfZe%`KuFsyhNX`-Ne3VPlAU>ZAx)V?vaOQj< zg=98I#+Jj^IGaLxxI(S#)<*ofTy}Fl*L-#r#+j_C2a!ux_ek+Pb`_54+roW$Szg~; z#Ox^`V^Wa4T_VA;FxnW9&h$dokn%mg5W}DL#HbVqs_q`RH0MbD0U^I5Az%Q6+?h_1 zExD~Kx`WrB>2X&0A!Dz0UFt|Z1AAufv*WwxJ$s*(UR}^pvxHcy-HlXG1GjRw6J#eVc*h=;A)9to-bMX8W8MRo z=H&ET!SDHA74L}M%u3^#e^0<<`)mZT6i;xVj}LzsFdhEN{}YGz+gf$Xye4$x>_1H5 z+wy|IjYAU6U@*qK_SDZlcNde5>2DjD49VeP1DAP)Dq)PW8uyU`M^%Tvw{Y7pvOh_? zgIzQ!@`zSrutYP*fX&Gtvdyk;5IGyu{FZO^j$Hl% zilpz?Uu0Oxvh`W45yL3Z$MX|wC8(#9G5Nm;tOxw#Gk#O7p573X#VF-3D5wAx{f9to z5VRv>7qnwL`55~44$+T)I+gMsvlu4Rl%za@xcvCf{R`%%qpwTrQ`;sAT%d8@6kqUV{ihlMkD(^=_*Ot#KZM^^)mJ zF1OF5^Hs2m25R_sn{)jJ5mtV`FYTHOginH2Oe%ae#M=wspIVg1l}@W36*|2Ski09( zU+hIK9Y@34fs+ zLt?(#Cwc>U`)8R!QSM_(Gty!)(qCws260cr&pK(E%O;0obFph;byVQEOgo@Fq~vI4 zJni7yM?!{~;)izOyV|hp`1MtU63ex#B8VtGX2`G^ERH$6t03-_{vuCe?{cjC_Wr)6^=Jl>o4NMgp^Ds3|{ z8#4H#rRP#zhyKkQ#P;0r!kulcwm-Yq^fq);%A@w||GxIycXn(0(LaLQK9+^et22~a zaBvyq&?dY{;*PSnxGDi90KcFBOrHUq4oLF!nM5bg57K4G&9gUbKe4OznCF)(&3Xm5<8a{3kAYQfMc*N{=jj_K!$VqWxzI4MZ^y{R|Elx4%8-mnP5xd7xs zJAmk_LCcp3SB1)n8oLFCGFQtN)mCP>s~Y<*dNv=mpd4EuO=qh3QE+r)spG4HhB|oDu4&j@ z=}-HO+#V!u>a_Gv*Po%U!nFyHr7nfn7X)df`aZCDpe-gQJJ7 z{y@1?KJ@4;P5y@O6+fK%!yJ7>tN4*8( zsA8{l47ZHj2vgsRYsv$J4#7346r$AZq_wGvnT^v)<;}-aUP4m$ZKJu*a6f4uuo&wf z(4}-8N6WbDObzkFnlw8ENH*cxlH`D0~7)6rvDEdRfh3XM>QOcw#8A_J5Ti84DJpPbDEF?Dk z4JNM6ytKPl|IXE=BQH*K6})YrK+sG##iO*{j}3S<+n5XmE9?zW>%xTp6vFn61Opqb z>JKhv!AXy7<(MgLQ<(LBao`A`E-%Ong->DTm7%gx1q-Y+kFq|S(fx+)xZU41+VV>O zL|r5h#FkBwT&yBlPj# zyGD(V7#9lfLjS_ZmQeKBY1=ae%Q*-b*|9N#tvwrKB{&mvFGRHQpAl&TE6#9K3^SR@ zeno+Rf-a+O&VuuGq8xG|mq*TPj>Re)ch z@st4kN9^K&O{N#Twxb+Iwe)cLZ;PQSBV2$G&G@WH0YY@#Y4;Q8!vuur_zCT9o;NVBNcG){$PrhDTmwtalV&9w$!D4|};NK0FrOY+FjqIhYJlwV@%O5~x$ zQndT%lXSqU((c-C%EWwLi_b~{#?A}QySRWWq>=t-u1WYr=WE_t4<$|}+@9caFOn!{^!o5- zPHH#NP&FD1-u%-6xJPA&r3%?~wu=h3~lZz*~T?Cn= zOur+0U2|w@uk^-`S&#ZMRg_rVfC~JEcq*Uj$iga-OLh!%q)3tCb&|{Z2c4ZuT`nxC zhGwV4w-Dg0#O`KV(!#3RG;_#Lt=HjJ(v_|)+Co^-?3%yuQt)M>U?LraSo$DJO8^E? zl;a3MV58)}G#Y+P6d>)tl}GZr(%$}fRy5jk3+F+dpSQaz>;`BEzsa`EguXJX=8-xE z?rUUzt~_E|l30ZbRU^*_ceA-1N8kiJN!r-vdt#e;Fxd_he@*-j(FXDC@Z=)fgKC#1!W{Hs=ZvsG#S3LvP>sMK32Wkq+Q{_H_SHdlHgEd@u9f@%Ki!& zA9Y4JIfIQzz@g-p798RNfRS**nBac4gd4|1rUn0PqCNY=$-xqVK{qKuEc}|6e zjWJZHGs<}}g}Ay71nXWjP0M=hwaeiVPp54h>~q*j87m)0hdAf4WAw#L$;8)M-5zv* zHd)K;;`7rG4)k90y}27s^uJ`-<(Ot~+$GC88XNXmhUxlZo8ihw$&FaRo=-lv3P3CU zkY7V7bP(On>SSH{EaG$OaPVD+x@uykQXhKtKN)x8AMput1L@}7=NY@SP`C2NSD9DT z7Lp$RhygOE4U(~lvj?;E z3htj@l@gPt8!rE83foi27G8_oCLzKBL{GKk5pRYme+jjN9t~~OUOr-{4w#+%8o?yY&Ku)`O8ZwHKZ~(u ze>3fcd$?^$K&o@AUtjv~8f{AM?x!crNZ~$t(1v0lX<}E-^CYzobk!tx$>j7NM~x64 z%lY>KT6)&wSabqr8Fv338urQcxr|Kb*8~f^->aUUg(ez?-zy_n22uLic$rmd%j2MV zaz`jkHABv~YT(Sg&CBJ6lm`g_P9ZC?-~+ceOdJoyKH`}=pk*guD@Vm*GOh=Y53-4g zFaqt7FL|*b`|zWjD765AEHWr7Ow007Bi}iW(F0o;A*x>pZ>bLt&;8c*)y4103#)I( zH%#Ue4I=m&pF-50Til0%W2=(=hz)&p1U{~H?q;*G=WIeD5&8tFNJ2t9w7~&}89-FA zu^W7H*NL1E;W(FpQ@rWvs=}V_{y~X;HjnCLq^~NNr7u{ z%ndt7II5?0PUT4OlHkuIivk^pUi!X%e$o2C+6rq!qxk_HC8AN>#t3I+^dsiz{@tP} zI;gx~-nq?!sPkn ztX{`76Mg9|&iLh2?v)&>>lM}9!&j5frcdLHE^DeMyE<1$Mp?mlvt({iDdZSG2hYmy z-Cs*9m{Ft}t18e;R5h?q*#yk#fJ%mfV-QU=;(HMqcl}IbExj zO3i{G)|MpsWm6WfpcJ%OE9ft8HQB_ZZ~G%z}ZB||VeBzy@x zxk(}pw8jHymdU3XlT`4%>%r%P%PXX<^(VI4Zth!@uMS$v8`3R>NHpM=z*ddn zE_O@mgP5&s&qb%mT?`r7!lQKalUu@Z_#;RY_zjcabOF27cRI71g7BcKF1%GZ=7zi8 zeltIL|J+i(6~5{FyN-7OQlhB2-p(Uq>-ND6YRSIF%gKeuf2%6vql#tLJ@N-f4?PwQ zy$U}&uIg%|iZ=hZ?XDhM$ucr~)M3j$jMo(+gBdW7u;Wclhz(Yjvx;0lVy!RxKGo=H(GQMSM%uzsK0YtUasN_gQlL)1R>YTjv-CoI zmyIVbm?Z(e&L=E$eY+4gJUfpI9@aGy7?TFQi$2TcX=!{r(4BjC`QhTCu*34!+3K$q zp~F9S!$*@shdOLg9qEbYw$T&ph1A)li`ssidla&ne+K}^`;`{Ph{rD zZJ`zb?R*870SF)_1FGtnGU5s{`jckT^8*; ze0V6m6TkvLnw7^IAM?CwgH6U4C^SFy?@^jSrSBD!cYA@bw;HSp(Arss#7GDH%g*k2 z91o2LKNqek?)YxbI6!y1AH~4>UqG|`X-mC6|Lykbi`5;@Z0phZw9>g4RW;TRbayv; z^&_yaB8{*gYzDTS{C4HxEbhnb@CFKgrrkg$5Sona=+`j?tKk?SbRC!$AP2n)sr!!{ zw3j8&T;yHotfj!IvP=h|#4=0dYHAH-3q1d-J=q2z{l1Z}4pvx5*PR{xlxaes=pNat zfIM?)GEEsLgtP8#{!i4lHyjlbMURn&1SL!;8yu_wu0-0BD`ydMf_i^A9}tHp?Dt}Sw;t81QYTEuTOE%4z0HPAMzD7ZY#Ht@^!J~Excgpd z6?!G0v?HG6GBO2J)VzIGo@OR8Z1H<3_;Y=NvOu%(GlC7b2cjtIix%~#v+Z4{Huf*| z&VDPtD;(xE|LQ3$D^=Vtb?_6*XE&PqS!xRxW%U^5>m;)%EeJJFF8b2D=GLa12u|g6B^({|4JPl!4T)Jd=(|hLEmNxyLxWcSQ7sro{EJXA9;NW~{ zEUgwAC;wW(-{U5ID^Hh`QsO#$eN5y@tH}-uW!biEhV9e`9$?5g zHrBYuy1u8x39JbT3T=C}ZgM%z3|@Fd2&)t9c}l4^yVVP`xXMX>iM=mmt*tuyG8kcY zV%n71eqc*6*bwNE!b6>@ z>P_N-*Sl=LlxrNQbH4~#8FLXzDr%zaCvrUol*Pf9UQgoKVjnRp8pKh07ww<%GFU^{ zqmO|dacn39I|_f0TLyN-9MgxBc07d|5JuCM!b)4uprIEtBtshOYp}O0#FOfN% zcr@0MRieQ&P=D9kez^LZWjpZ*^lW%kM35zr^_1X;$Cu_9CF2aT^mp#+Y_nQgkT#tB zzJw+ObCx#eC}Vn!SO}Q8##idznkJi)ng=wn#T{TW1G}+>xNS!|xG^V8F;fJ*(}cW=qt>8))kphqfM_#JwpT;VTP9`n zYTda?GH%x?BN$|pt>pw%dr;GmyZ8Yxi|)KaL~2;1P4|M{12mK_4Qt9a?M&y;yXESMZbKCCWu7%pyTe2(~?P5~H#vHnJ^#O(HU;mcU>rg^X zK5=!TD6MwZ?_iL#7eZrz=98ASWj%5=S&J3u{$RM3#Qcn3n8 z-RsP~mDcFYfDnCJ+@mexV~=~ICN;wk=)XJNdThRR45-=9w zsoJV*oyC~`#g%uyGIupNKso$WrQ`+H2xeX>kz$ZN{L&$Nz&JiUwq;;F{1Rs%`S`(d zPXZj<)5WORW0XCel+yeTVOKtAd`~a2*QJdUV}2VUp#w3#U|cB7e;Z53laIIW}D$y)_K}&Uvvlu);Sj>s5;Y(evdqY*Tax>Z+^`|MA6>4B4RwQNK z`ln00frMR|hDVDZi$9Raa_Bk14e%+GzyO*3kqao%SW8`z%ba2W$c?g(d@bEa2H+Fk zJIfQI?rT~MiYiVA0$F1bAr6(g+@hu;xJ2Xb@e`hU!h9lBtO2oj9+E!O6TE@sJ()%s z-wWUOlNMvs?RSV-mPgET7V@}UdmUEa3#K-F0 z<48w`;g7Gi|B}RxLK2>u^Ex=UZQ7VlF@H9{$oH^-_!gAyY8N`06g<# zjS0L@V{pY35LQb(^(`XAd7w!r-scgCnrkv*bz#LW@;qB$)3$o-)$r%e>BR|RuEkha zRlNQ8F$RS4k3cFlmqwEb9mR>5DB{8Tb!#^9{vKT*&33iCF~6Omno-~)Pi3f9rBjN4 zAaR+*UrwGdetGjj&Kn17VAJI2e#U=v0QN5RkH>&byXx4t9@ag+U6V; zZ)$5kQDlGy$dz1dYP*Z}Fta{t*8BC-Bw!wX@iE7s-|} z3EFm`*OQ^!U*Cb-?5^dx^>&=#6z5+o-ypuiMjXr|0_p8`cNX6J`C}bC&40a{J^jOJ z1NHl}j5WN&D-g^}DP3y=!Tirx7iR!pUd|96s+Kv5t|sn3u5FUP*6$Eu1)IMH@t0K! z1Ng5j*kDjsL)~oc-={)LT1Zl2ZtHnteHv`dp7hPSo$(a>uYjhruN)Puf1LPF9w#Zb$p?+r1PTT#KtWyOHD6ZeAaQzq#`) z-uIZA9?ne+=b96Ve3T;c0D_>1<~JQWiktRDLh-nMWu+N?>&V(7y5l!EHnpz-=-W-; zJdAnx{if!;@4(EITFTW{K@PRLnx;nik(Tsq&raX{immjc*PB^nGe?NMO-3E|7&0w2T&ByR|zxY`Y4?h6Y~<03p@jV%&MKdv`%)a2O6NEuP&+!EJT6yW+3S^ zy_Pa5;qF3(&%e;DK zrkcl%X~o38E$>PmuLi}ar~}Y*qwEuu0&KbTA_Gu%Az}6;%v5_`z-usado`Hwiy0N1 z)NO+D$#;+!`1uwQ&mckIf5|4m4>BZ8+6GLiky%mOJ;xJ2ak(L6Xj~L0Xop?)jqD6? zFh&w~!7LPRVJsLH6d}y|SqmQ>70VD<6t`NxSL-|h<8j_~*#MJApDCK*3z&f<=rX_P zzZg<7qwvGWn~q8~^K7D#Je7pTksjs;KfB+BTU*?zL(tuKN{m1YVz;;|B}lh4uCP`4 zCLuM}U?`t^5wyE8h4Sk!w?|cH3`7&}jb2Qc0cWL_USC4CeFLU6!)Ctn|wOC5gV8(QV#wh*zB1^D()?uLGo>Y7*Ighn56%q;EUR6i)Hdu;$`WIWPi+aOr`#rjb_FwdsiyKX9yb|dHLGj!@(7JUqeJeK+`kFWeDc< zJD?r)`VlhWfONl-X@oBe%V2(72UWof2d`PbhNxM;KvGj8jSgiy{K9Ba?}}f1Z;p)D zNcmB_el=(&q|aqlH8D&Zt@z&>M=kU4`DxAl zY*w^Wm4O;5D)eHCBh}BBCDJ;9BQiaP^Q()h3!<&P^;g1QRzKGE=81*_E|Qs$9Dcxi zAC^;o+(N3%EJ8XmguZE${aFQe0?nqD5T-}pQV&3$tf!vT;?2A0?%ckP{4AE>bAuJ| zzV!Qd2qpK95OM;Vg{BR6S7i-MN~iBgXZ4vzB8McyLt0XE$~H}19RYkq23(SNCua4b zau(#!EHmkgQZwm=54oJfrM+wVA2e|@rs#U8Vn1pp9lvAUW zkPPukn7~+Tj!kAjZOm`gm3mu$LbXkkxT%3e{FunRsEFNp3mB)q?3=K?m~AdcnOAC zYWn;Wma}Iq?EXU&9oo5u%U>1;mKaPOh(9M^iE21Hg=RKAUjReDd0%%HTWj$1!%Og(W?@1SbnM#WHmsWb3DfC z<|0{r(*Wt<=R5V;K)y;L+@Fk8TUkl5<+gOdV$Jtnmr2fDM|wFj;OI?~v-AK==>eD$ zC|P#p#oR_Mm#(;vkc*@DZelgzd$ks#3`TZOrXZ(P<~>UUIRU1Hc%l<?KlRGgtk=JjmJp>$6VM; zdpsJR)hjT>W+A)5GDfhxQo~fX9%MoKLTVP1WO@Hq#xuT)C8V>nQ1E53e<0LS*P}Ho zqvez3?(PW(x?8Vxr!nU{1zjR%bhy-(^>&YMR<<%{M!RAhOa*3kn7D*3@p#zLRHy}Z zQ#cjo5~K&wC2hsbRD{%25u3u5gqVSX&RJsatK;w`uHXSjUJ+=dP%zK1I36Fe1UrVZ z-MTe`x>H+nG3CAVGzG=zOTe3EOh~(NK=g=#CC3Zz^XUaD#a(dw~F zH@BG#)#_2BvzJ3L-d?A3rRTo4%(hvO=H@T@ocS=AxByIV0uHGQ;;=??32optgetIV z*pT7VarQ2luGQ;4Idgf+3oCx0A;VCQS|H$ULJL4C zh+GMO5c6r7MvKABgIux?y#?BmdbgU$i)Fmhx`#+*ax#T*f$JzZaQf0_4g+D)pC7e2 zkxvrlniPy3)7tFk$m}jD@#f59kmh=2`5lZ~MANmz*L*|GW%wTtU^?G1l3n~M1I!uH zoSh3H;gW%xpH=iAS^SS?n{u96viK!&>v%4HopUllT{AwaBqIyPI&E$%tcUAP;PXO*>zy|Tpgv7tWTU|g z;+qCuRf7AVySV=`>@oFSsGzSy_)tWj-4-EXQ+i6cDvpc2g3-H#t8Du#4QV$Dd%coA zq_!bM0+UI1T>c@7AH_Ev6Zv8{`jLxqzwoGtt0+pfUqrSTbR zuT+0+fTmmHr0GDbkeopi2;@eMFbdtCK|9h!Ba(~bye(bVO^k0tJZn1Vld_hO+sLW~}vq;?GVvR-I>|Jl2BuFYDb z52l5>0~GaloXaFtXRq!)#T|OfgL3Nd(ecODFXv64j7a4uU0R+{k-lk)p*4zeRt`QYbI;F3l#b`4z+Kr~w6f%8;PycsQ_k+xyYNC`0=!!Vs zsnDr~G)`1~O(IkAU8S7Dv4uQK$>)r@V+Pdgy;hGaK<7cN^v8iMGojWW_G-V`sc21A zoK@b7u{%|V*pkY@I=0XN4JyzpTZv$qEGS!4vk%+*=WRFpoiM3iz8BD*!CuQeJsxU{ zWNeno!q$KlK!6v-vtBeTl98RO+AI0FyguN5l*Mu$vu74_1;Pol(q9C&w1ql1niuC_ zf;zOzAR%p9SEruKT)kwt3^hNsk7$Zpe8&Q+ZVn3(fr>6sfRZX;f|3%`v(IimNKseo zS}QM4j<`(|`(^D?oySvoG0TWmE>0%9rR!NC@9V-?W71}QnvZuvhBg>Jgg)4t#^)gB zsywlhWHA}n#2h5S6E353zuA$VRY(wG|ShsK4QFaP{~TSUTU~%!oKWQ z2LQeYwy^CUp_&M90`dWlKh(*yYAS;)>lK4G<9$L7s>SjdlGFbfz=L|d-s*Av&k0!R zcL5mSC=cNwS?R{2(V|;-tRR)zbGs~*<3JfT??(2Q=f{BRuZ^j{tZ0(#QR9+6z938; z54R|FK{Y2XJDPCc|1(~DQ|%_g-@&EJZ3Wz)X>x-8qU|1mOm67AdPwV^xbt+~8C@Nq zm&FHFpq;o?h}}kT-9?jHyJo3h5FoAzai4bLI`tkYLv}i>uIzaxDeBGp&uHOWCeRJsFsh5Ii$IsEkiITchU)r{ExV}K z3uoE@?zC5q+26da9pC>>rdZr$ku0cxUbu{#JunNQeiN3GYkD5l{%ncUuS2G&K%klR z@_;d)+C%Uo{+3$ALY7>yNLFgEtU_m^L9n~=)2sxa=H#*ke7TDf6H5$=W|qM{{5;RM z#tYBAV7{n@reuLB)p0xX`saqVD0Qb#!YOArzw^EA+l3X4N!v421yDL*JvZXco9K&)E*2r`zeJ?n#XD*Zcps-lpZ!@Z_;*9BeeJv26XJQtot-4+f0?<| z_AXQNZJAe}oWCS)wOYkGbMxcFS;ZYIeguEq@mu<=UfBHAZ$*#3&0YCO{I&UcW`2I5 zxa}9$KmDj^b>f|cj;E6Sl(^&*5s{JlwJN|;HKKZF-X)9o56?N9teeAs>SpEQ_ivp2 zUQSuQRn=uZ_aVphIIf)L!}nGTe(d-b=_lTG{&ncr2|s@arMdt7>6tonNpbK0RYLc6 zuh{i*)_-@eCyMK>j_i1l_`}(Rxt}}NTS5NDEYasN5#l#ryY7@Iin-8~`MBxki{^gr zhiZ;0Erl@$Uj4D`;eHlS6tf`7>2j68geUgB{6`gU_ztBe6u<`B9BV6}*CH4=_92?mf|7+Wa(Yy4p!y_J-AO(~2r(YpXQMuQG3a_A@@V zA?oej>OvW|80W0!#<}0QZ}MgEDXsUHWhuYq@#$se_UP%_KT51r0{*7m-{W2}VM7;l zxs*+a!o8!r46ZFN-5DKc_b%*e^xk{Zr9<^UI2YRdb-H`=`X|>b%J)?lep>ueUeoQ= zL zpM}`{x?mgG?VFUJ*owUkFBkgsWc}6bn!j(&tt~mHb{52+(*HVt`|-!$KE97XdO4)7 zsQmU?krnkPPgg{UZr}eudG9Xku==l|TlC+{&-y?8^WG@!$8~>Sm;LuH<-GroKfs%v z!{Xkmb9d_*7+NQ?G6Z-tGKnyVFmP~iFjPrjjG3sTvB#Q`fkBpqfkBu79Yj0l=ar=9 zmBfcs7Ni!(>Q&_Cpc??(|KR-;sLzXufq@%Ee+|&s_#)s~m%bi|MA!JRru@c4poZ;0 zEP$eM7SO1a{N#Y5{DNZr#DW5B)}~G6Qe*>Kun~v_QFLcABk4}gFG|IxyKc!;x6=?Y#Rt5%M6caLlA|Mk=Dsxh? zYF*3pZHXLE>ti71N6|Wi9jvuHzbHE?KR+9rz3HzPt+)!*WC9E%DHP40Il!7BL5^$$ s*5F4@6cQ-r2ynq2QJj&QT2c%Q3?O9)aSbaQNHHf6+5=r++y&wR04JKPfB*mh literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-28-04 site Document Inventory Report - Site Level All Sites by Country.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-28-04 site Document Inventory Report - Site Level All Sites by Country.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..b5560d5d5dcf4a8be6bb9f957fb7f13f46678409 GIT binary patch literal 122692 zcmaI6b9f}-w=EpoPA0a^iEZ1qZQD*Jwv9<96Wf?%Vtb;ACe~LuzjMBO|G6hmch_5; zdb&5(UVH7gT1gfh0s{mF1_mVP%P&2U|LYGOSnG;9I=GoTxEZQ>JDI!cGkV$EeOH}y z7+^+uO&?pP<@~3lju|XUG>TRA4_wbTRqK(Wq3G&CADTN&B^u88#?->nLi66N&AClS zR0Q2`aKvwj_KMbOzca$0-r&?%!#Kl0_6r}o9sHQZ!nny7P`c{7l}3T%M`DO-!dx*z zQZJFUq}(Ytxx6S926N~=5B8tvw2ue^%NC!RoVLR93%>QnNZo3_2V0sBV5iq{K!1h{0N0qMj43!%ugjuEujC zKu1;OY@FrEr0JEB3<()?6;V!N?;Uz!#==C)HP?#5<{@;CWeNVh0&Zr>bI%$aFdJ>K zaEbDTE&!$e8=2!pG))=^xXU!`+(aJxd)kYp)Z{Em#_}x_(%?JO3#b?i{k|v?i{Ir5 zmy#?rOfo%n7cVFX2mu5Lh|>Qv_V7UL4PDIbT$va@U+Yr(Wx!cbA`B^}x^wIyQLWcv zVY;J#L*t~bZZ_t~Nl9$>boa-$*$MaWGqY`fu#9^MMoM?9GUk^AyDx+kTdh8=eDUHD zsQ)X3+5g9BPYOyw&8T->U?EIJb7DtTIUO}NSeSg%R{vZGRCX}h+2O?{9nx*U%&+hEG~*nw;^-}(bLQ_Pe+5Gjzy&BXh5cJ4 zTJZ<_jE(~79AAe3NuGjB^O60S0-a8r%zbQC-lPsuoSxt5FhK_JQWt3 zPYZ#`KNl7xE?wuGvlD5S5!}xGy+6gASn+eZVK1JhQ>boZIUYlbGcMssLx5=cl$^I) zRTK^top-7jpSs<}IKeW=4*MVFvUz#49EtZJMLF&OJ5Ow;ks)F9?i{;hUwpCze$6AK zOx-h%rX?aa^rob0lF5&4jMoRa0HkN|Pj`0xJXewdW7~n}|2x^J|F=7)jxOe({@5q! z%MLPQM107M`R9~|e-&9LnGjOK=T`25A8%sdBqIOi@Uhi819z&Q^1y>k<=D-Cis~PP z9Lj-c!7~gK*J{J8A4-JWX&0&-H9*ax1CA&l+_&DAksy0!d|3xh1Pw#&Ew?kz@gwn< zvq;FfaBLFQKFetRBvV6il4C&6(M+*#+T-mS^jeYEsBnfq`tUXRh+^zc&K@ z3lqs^<~&e9#WVrW|922EfFOF=F}Ye9yO^7)y17_8Sh{}3kv~otX@D379X-P!3OL|z9laOFQLOh4IJAj!`?9(5oyt#-W6!}7g`!=dSi@x(KZ`bwReyuhzQ(o zfThqdPQ5FXUVvTE|7-dY|J!mmZ#(ny&8NbM%B1))$E7W z6$tDf5KrGpXT!)-YKm*v-r4;HPlzXNQT&q(Q}|C6OsFiJGm35k3QC4c zxIhX^aTC42J>tbeo*diMj>(@4!Tu{%$2{d9$@E9QvD>viPKUgcRd0xfEhE&ayX&}c zh$tRMtyi}nC`yuhhE=J#<)epAj8_%lweL3 ze1bjeNYQIOK$yF%-%j0*M@#Y+(BLMdOE6LMT_V5171n)2K^E8&JjLD+<&RZ96)nA| zz{#GFLg&g4oWbg_Y^`ar`lWRFlvspa@hi$L4@dSQK5PsFm%Kzdg(mVHXWo8g$HE%# zbl+u??cja)9r03tYu#qB0OZv4wD;Axa{=o$0bcr^iHZ7+|0xfw#8rsjszd2F8NCO*GoF2=pB@PCJJFh8PN!)mjdmN-oh*lHiYT1{p5tM%-KID;M^iaU* zT)(jU@8OjNvypgy7_XEkb4=THFPIJB?nxO(8T-@mA}=~NbB#hkP2?{`qT#9K2Wg5M zKBc%_1&$c7)`o5@K-bGk`4aUq=d&VHu~k-unFl61?z_;)IKi_(c~mnMPbq{I$t#f| zMlY{;)&(fll(71=X3JuZO*8M{nQD~V#oO=@?^kNT312IQtfQ(OgS3y!rW}s@vU=lV zzlP}RS8-<|pJ{A=mLka8A_^f8+Wr5PMDYF-+W&Ok|2x3{>B7nKwu8(FLLV`|{GI3f zaY`JROy_I`1A-dUx!IfI%f3(cHgpay2|@GzBagfCMQ+s#j1T>)d?Ww`F0US1Y*cb4 zYPr++;pGE49MZpw0*?DF%D7v{!CHvMaOELd-57#%M|?hK$&NpMOkECRqCDPPjAnM@ zB)PYBeES@H$o`!1ihn4C2ea2SF8$Qh# zL1%uy@OGm1#?To1+&*1TRp3cM;N9`J#PjF_9RrEmKPg2091^qj-9P_}r!3EkD;ELR z+5gwBi}QbQ=W1nc?&b=REpTA@1mJo1y2}Q48^d!zPe{#I6G_i73UuQB$wiFNjtGon}M>`x4&3k8?8x&LrVslJ}k+F%0 zm>jXqo%NwN<%kxTcfQ{$zTRsLzf8L5Bxq6y8Zi8wpnZ0xd$snbJC5D?`Kq)buZewYSdf{T zSfKH$$@!bNyF$aE2 z@)u>ymSi$SVoY}B7&Wa!u}KN_k{C-#WofibT=6_5El12mcI6Z`tz)rE2{oF7fvXjk zry=3`b77OjM!8Uw5{Vp{gDUAzt;ATlRFrmll6)3Q%U6;d5fY1Z5zaD^R-41?XVW^t zi&PVJCpn#|Kt!y?Zra5qdjjvH9z-Y@!h>20?Ls1#2wsq=rdE1 zQ=OaksB5AEWB96EcnstmctZ+K1dcj$9u7s4cX)Dl{x#INu+WwFA1)tOcb)j?TRLTA z4!dA>?IEs4N-xX$f?9gDJ79ue4JRVFsC^9BYTlU|3|J>PIAY&2y(Z(&IyzJwR-aGY z%G_@1)yFJuswD4lqQId=-7e^-=5mYqN0_ z|7#nFNIQtgnOy5kYptu_l_`b(_TR<3y`pfyvuDE`Hx<@W{=cWxO@F=`mM2fq|r@g<%M8mJvQ4%r( z4|a(_l*2A>;5tuH0lZH$hN7X3<225QFRTvV7Q14{CC7c=z>+w)7QJZT92z z@qqeAXWmS#EfR04wv&gS%kamgXBT>28LG1JjZpf_-;0_GX!f`P_V}C4`E{P}y1cWy z$7Nui2jXpIHEyj5iD!>7HCKu;zxV{@Nb!!G3Cmel-|U%|QEM?#|Gsx?Ugg!H z_H=0ov!XqfeUpoQSYX{br{m7LY8Uhl)bxi)47rnRqQ$DF4G2}c-k!Lw*eUMn_7%*F zBZ9nYf}7rb1*5+C|2r*44OrYxUdiHJ+QLpf0b*0!2FaBCoy&QE;2O%-I%hq>arn;xycRmG(=L*i5m3i!c((dP~h$5nSrN!p$%lx+II)Yo!4$% zQ0}?~4dSgfu%`9dMAYn~A$>X_G+v*=0!M2z3oe+uM03@`aK$!CL`318 zpA8=P=2MU{>~a&JVhb<0ojzHOVlix{yfqoR3~h{+o3;d@Hg|tS@co_IOOx@aW&C)LcIuI>fv}@G52sS? z@=GXvk+vkSa$d?B>?2pr8tf#Pk1?*G$;3S=ubeiH##e1L>1jw+PHgR(jvz+_8%8&o zpR#wsrWeLUGuvP8cUu*V1y=_G_U?5jnwb@>1y=&6w*N#TtF&L={Jr<+(UP|y3T;{S zxfj1Hcp>e1;vjEStX(AL4u#sVCI3OM3GLb5Z^2$`oAytQOr50@=^s&cHEIx(OV2ky znn(Bi%we~?lOH?s6ALC?4%S$Qqt$djdUk4VvJHLlU_=r6g&PUXh<9`L+q=eL)a6Hn z%(q(MrST34N}$hFRZ>9(Nz_w8CGn><3XWPDUJ0&8pSTRh789!iMv2s>Bi*GF(bT~Q zZU(u>U7O4CRp3)9bx@WFRfPhm=0b>*QFZ~UYUo!r2yRJS0Ri_zeJO{U+3u_gUifNn zGjFe&`c=b2dL*#WTh(<2_2|N6Ao&3E(zgC67H;5CcE`v=$c5K?oWA{cYpK()!M2=5 zKhva(GTE+slS&(-6I%R|I2ouE<&M`5XjL{6cNW|qXxip!9AUWIrmnSZibt(1rYHtG*Dp zGqy;7oO%d^B$@GN!i>2gR#&l_*^W~go2fa&?cn53qwPS}>02O{v&zoFM{S9}OMszN z?Ru4*hk+<+ttz>b-my3d{T&Q ze26=sxFlkd_r5zo0i~YvS?U%+VIlA|ZhRn_zrt`8F)yI(Y&fLH$Qyp6up^I@QwXV8 zu|rBh6*35sBI1FQr*7$yz)fS~RYP&vAd%3kw}SzYq6^{!DO-p4zRkM`@?VV4#!!(J znjfTAgdG7S@V~R zhQmp`l+H&=8|spF5E&;(ol=7^A$F)#FQOwa6&TBkb!s7i>VgSvA75|2+FFM@*CGe8 zz#5Go+pnBoF_IcX&3#P;cX2@7vf;8G!p(SRfk~q6mW>^cz&ss&zT82g><@E_??MBo7u$)lu* zFR~C>v@bDVt`qbwi&CWO>J$rU$l*8cdw-YgEEQ8^k=Ax?35zWA*ESA9GFZ1lT{3Wl z%_!6bvvTEaJxxg}8kTI!G|I)DiedtsO1<`$XssolUr_}q>!7X$toI?El7x176JqA- z28x`dt=ZN?AJ~&l4XkuE7GFp_p$Gf}J6XXVUhc`suu+tx&vztEbPH7!0wr#KUhKfP zneDBeOF!n}DSnOlnTZ^8kq!0M%=7`pxfRU_+ z3snimxn3Haxhgq`8dhh!y#oR!iTDZv@#n$bw3RqET>yjh=k}9QaCt`}lRpryVd5eD zC9`*bPui4b1wI*aw_^6Mx(U#M$tWl!@OiU*req=Ac+3GWzn;40Ul<({Cbz zE`2AIqzEd8id-A2bYlWeP@Ddr-;Hs`L7G6gRqo`{R^q?0PuD`TdprO8nF^1f7P?L$ zwIJ3lw)vcfaCY==@`C1LTwo&hyL`{4PUSsJYQm)h)>j%hZ9@m`;78fv5I~xq>4{I) zg1>Oj8!oqUJZ9q*_3ihT(_81cWuNl-BQUpPJ9aL#P2V2(7Db`rYP7r-UYiQ~cabbY zeK1(xwB(|tNXCAFBrzq|t(Ho&AVqj{<7-^lH>C5Qm941CPcbFTUk~DmW2FZ^TA#0I z4V^LPLmuBpOz2yC=N(NMG)TMZGqu2fU%U$ zJh1=swOwdbfWrBSx?TFK&tX5&!Q%M54wGj}mHhkc*g%zDjqD_w9k3)8ZQg>Cz|@cYpZf8Us7co=4i`$y9z zXC>#2g5)j*-&Zv!Ox4kZ8FB^m+e3=IzvjeI`np90np>F&_jh&visDy(J&&W?H4T?U zftnoHQdoHx<33+vlchp;4agTvQmyGNetxAHUEJ_$upAhf zRGp_(Eg-6X^!9HiuBp=W$kJVA%XezSHV#wt;jby9jk8#~hiNt;rL~w8hH8eY_ZqVL zbG)@LK2C?Y6H&9{E|&!3sZl1Yes7bpXz+pix)Mx)>FLUlwj-)}m!v#b;d(sew}bRA za4T08Z1_Q?bJi3)2ugIIlG&|jQRWM~QGH6o)DAKuKP4boy$`34$5NHr5T#(<+7Xuy zxr${zn15K}sy|0!?t_e71Ydxm{Veb>-tI9y0DD^x2lXFKgS!YZb)?+iR!hrihku?F zZQQwgmEC?4*1%5DMOx{pkYzdd6l&W7(-29UKYuZD%s!&>6ij_S7?di`Ms}Y=f%S z=L-1b$36HSqtli2tcbYb5fkJy!o_$yPBP|kIxfUUUPW7!zBSx9vmhwYT%OQmxpH1K zvAzTdQOtdd?O>Vnla-W00SdC-4sje<7G2Dl9&#Y$_z5e;79*{fFDP|WK&Tn5mJT&MAE3&-Ni}=gGpyl+N*1(U)!!#c< zF-mCrCb_frnWRaC^z4slo!S5&>GXR1;e*lD}pegyn&lj3fdv+MFYyaz0k?(l|*>x_e2?)}eYnwiZwL@1^(>?X`lp_4fTI>T^Ot zFGkfGiBw1P=h#bWE=ZV!OS;->`{~;eo)ykNA$HLIornxpPBLlwVpKGJ?X5iB8n4Xe zx>A5*zoX*~rv{OY&vQ?pT;{>K4ANPnuQwsLd8vLx&00|7+&y}eH0<=Hndq|%ch$cE zRQO;iSRV5B?Qefq7T%?3>iKklU556EqwWh!iV*Zq`-@R2uol#Vp8Nfl<%;8e`F&x| zTl@v3RYC-{wgD~YdIw}ccii`FxW;w=`D<*ZJIiu$k58pN^<{$H{t4DiespX)xU!dN zfkk8Z{>@K+!I|{_7QIPYiJ|(PEoIqSP!LUSH2KWl4EAFsuG>udfpt#9HBRnE=0X%A z=jG}iRJ!n&05NWmGbs7Iksio+DHo$qp>uE%ty5>xs%-?Nkf0qg*GZa@49uEO>@oM?7ygxs|lQMf5;ylNcr%f@U7fIjL%I_hxf zg8yptZ)xCXt;dk*>$14`8g*VV*bQr;uD8SgY%^K#Fc#8v77O?2?@&)YnDR2?X2EHc zx08sdVN^fZu1E#N+*n~}e>Wg85&tIF zSUEa1;1m-d{CO>ILB*}?Y3E%XRojdL{Edfs)k=$p!8cin($c)Gl>W7KAOK62qP$3p zDG$>#&VR34WB~!|-ZIV)$jS@EPkoE{sc*@&ipWMs=EFw3e}@JKp-0r-_p?tkv@=C9 zs5-KurHEHVH{FSm!6HzRk*uZxgL{?zP#L#uNdlt7sVeKg9N%xrD1(RefTpBY>Bu3& zBN(wptCJR^zw|_}I-gdTga3G0&uN<5+Mk!&BSdMiwOkT%=Y?j2*$Xk|aXCkguc>Q_ z7v|es_rU@bB}n_`6pnOZ=q4Vn(Yb_P7G+EF^U+VAyUFprq`)|?MWpoOVf&|o56AB+ z*}KnJY8|)(N|;@F{zIJ~`sk^TG#&QLo;;?PUA}Sy9%KhnhnDqJlcJ7rV zvXBBr+xzkhEF(D~&k=~yO3r$E)AAPLeFh{~Oxnl+GjCkU-2~=qV%(jKX|v5-VJ{0V z{O0V{ZBP98802$1I5=J^S^qcuj%^oC)@?C{^@UdQ)GilZquwW$6aW!_x}R9ktmo0V zH$QOlGuV|_Vq6n{r>XYoExHV(^p$*8gDsrI3PoQ0oli?qkJ>x&jx#Yvm(vGtp>!x z7kJ$->?uMOO^x4$&&dDqiek#@Pb(2jJHB5(h(A3kUsg znFIs8dUxS843o-iOsv)@-pI5knkp8d{FG{zMut}GHdu+K2?%{;2J|g_a_vQ&G11AU z3CKD;9f`k4Hi(ULTcVR%47%+YpVKV{Fx@hQ@3>oUNEyV3(7&@4&L=sA}o zY$_ztbQZ#OW0>ub!gX;wQ6q2AogmiA-yh>pP8`_qVpzma393b~vdB6thrEZhiIQ~! z%Zm^v1E0d!fw0(90pz_3nKR}H-kOSnYI?)*suD#fW>Pcx>3jxI_OQW3Db29L1}?`} zt@gnQ*$}jyBKdRAfyovU@ z{Yw^yglx71&Mh;lr42glgEqr;S_juMcJpP}riGPVmP5lgeZ55uD7B{EUd@h=-{iGX7weGvhAq~e%sZUZO*=jb z1ilhAJRwsn-E;BV9xZC}Hxm~jb^Ex|g$uO*wn}kmX)!sXy_YRI+SRq2iqrcod|PPi!f8(k#m+Mt zGS1_1!CFSXoYz90$oz-FI~$Vf@WY-I6~5l+n>Lj1IzvV>#8)H7 z&SBP+KD)3Y%laBBY)Q)oWXA2+o12TfP#|^|w))rUSXrOVN^2==VF^agb=4nc7(? z$_i0LaLf|s{JADMm0BH2SZ_3$gUhqvHl|+XS~uZAQA8Q+R-4MAUU)qC&BTmWM{IT% zpq~x|G5*nV5+1FOFAFo={0)h?)4r$_s%+4q-+0Fj?3Cz0a{nJH9ab6?!laI)G9%#S z0+@TGZ(}X4`|0mU-_ksO4a4+eqeylbi*$!YHlY*lJpIf0qcC)FuYQ=_Va9`fp^jvf;B zEuMWv<2b6yGinA&bwnklIhWO%pej?YThz_B67;1^sHIr_Mjs9h&2F3TQ?v1XYBuDM zk1QU}vLol*2>zVNZl7ZxLs18ebI%|Nl|St8Iu=&^m$?dzzL)qem}9)2BtFMKp%}o> zy1zbi;b}A{7SrHXPPFTOKU8CouTvbCkM6j`gJrRkId4z5kXd*C9;^GNzI5g@dB(_6 zcB#`8|K;AaXlcmA(ApoF08ls63FS2FKUQ&_$gCy8Ek>IvzU!P*F6()izDSMrU|F$F z(Q~o1>52mx!NXavD+Z=AvJGG=>;B5m!z;+DmnU6kiKyNIQoVmc}64>cCNTp-J12 zsvQ<)0j94D-D$M=MJR#BaV!{(^VdbI)6k&9JcuD)=Kx%xXo0g2HwY8~(9R&>;|DHU zzLh2zqxFmE2Fn#@2ayF~Xiv%i%`_Y|auMHiQ2eyM0Q)pA$#dOt=0@Un+l+m{Y{b~- zz1apI(vr=?*`g5|(+X|t#8bP;)Ud%w>`Sp9*T1G2Zx*BjY1v~#o*HU=0f=*6k32WK z=N179E~q09oAYT;E~pF+E)y9xcmCQu^bwK8$IyAXI-Dg52P8YVp71QZj>^z-p#?en z4GaXUa*L3x?2fi(mG^O52UuE>w)cDZAwRA4U*QKM14|C^z~(Hy9oIKNID2Y+k<~}E z?WMO|Ubxe`r<-|>r4uPkJ`avj$Emm2BwM}F@t93EthM8yxBU}tAA+jtTUYbzjC#D9 z;zh^yp5^>R4L$Gby&+OFqRF?hU6ddL+hiKyxBL*#1N|3J;zjs1;cF|+I zN65|?#LnLJZepcY=RJS#Vtf+Ze&7Ev@XPl*>^;DKf1mW(+OAgfPdy%UL=|${T&hK` zbZX2hY86=FL63%R^6DE3HS@nZ$V&3@Z*-+ZM|RmYa)mwvXX!se%8&Bw{=6&}I@&8K z20F_t2_E{vlUN{>3j2mYiIkAtGGQAg(bHdOI5e*pEA}i;>DuTRVSRPUv?7z3kR4Wm zDV$e}=sY)iC{&G`*ktO6qaJyvS7O*sZAxMoXKg6A8`HtkA21-VHzOLl!>Q4m0{G(f zBcKrF z^#v6@>AycoXc!`g%agGu<*t7Qmy*zIp#LZ{Kh|+q&kz1AREp0k;3WK!K`&~1065el zvjQ&vx&uW;94hr%|f<|wDg}?9wBYT1bt|P&9r0J{f}4hj^c8DbS8VcO*CF~oRGayivO^$ zqu)sd+6~3TbchZHKv7LOvGs|fU@N^MVpgpv@x}HGV~4)Pivm$N)9MQKqLS!RrW|3u zE|#VzjPlHj;>wQkOo~}mVWHfNMr}xq=E{!lWkOg!-%m5RyIYlyUR9ruai!~PmH#|w-#M;Ri}qYg_9BH%cl%W- z4bq|?MuvRRiAXWevMs6+*#abfwxJC}lpz^+5FUAir`4hji6C}7j}I#|NV6*;PqVS4 ze0@GnFGKRmL(s1RpDCtr|7Xw)9nGHnbw}>2%II|(+laT5pZ9>ao^ykOK+eoI_QHwg zbvX5KLhxy;GP~8#NvF$%sjCbY@08|^ut<@XxQ&cJW0MjO0>`_Ux#Y&*TEZHywXLzz8V}}(MtLg2MB&HM(_J-@c(PUrNR@J zQ30WjWPB}sHKPT$6;s)zg4#Rxk@qsGXJ-lF+D z6p^FHOv^<1lD7%HNH3$ioE-DVd`S&GvH6o9!~$G*qPwVWGGEAUqyneI#^8B7$sHcL z#-64}n?|OX4re!QU}Tnzs&K7e(ZlPBOrDPr&xS@1j2tdjO*y zLL(<0I5wdG-M4-4(T{`BRng}QN0?&9@}mOeq%S)PR}F=2!=X1Ll4d$;WQGW;c(7*g z%wPzCrh(p~PuJ}v2G2lS`8+VWlu00`;nw76OG227|{4 z=K}2iTbR!^8i1#WTjPxLe&Il!FGY}9bAj>;EzAXt)EUDaFbq#3mRau@vg=EXBOiMtMN>l=a1&}FqN4lmsr^ioS%EKVPV)#R&z6OJSv>!(;O zPS-%MGo&B}&mEg#1zHgVEat^pgV?OIWEdyDC~TDXzlt_Kt7)V)t`hj%8qP3nb$#vR z`@shrqweI*_e{RZ%4>KNn5>S2q!#i(Q?q zPqS~J&<_xgGBC@f@hX}`y~z+0{tEmR-m*GOKSVqd+X`y28vo)1C$$wsCVzm)otn|* z%xb7%Gdy0p^Y6BmvPkh5__d=tEKw?Oj~>M^Mx`I8QsYZjh^tpdnGB?u@vf6+s9Z6uu3K@h4cw5daFxWCp-8 za3yO1_i$u2F3Y6mRU|@f&ZNeTPTON?U#y$(ID-)ttTA#<#_*>;>nU^`;zb2&r@kqtkfjK~zSjguuCy%fkFL%R8thyl zhRoMx!lbKrNNV+<;M3-!XBtzQ$u!!&=d@a|K4h^fus)I?xSe7&NqH=3$fy<{Lh$jM zIMeo8FmhT<;+b_?5WmPmIFLx4N{~k(IS2Y{po{RyPgpx;Q>)q_CWLNag%fTT&#b=t^(RUN8H5T!}L*nPUA9+`0p^1v#u z7AdDh!1}=XxKehC^4F3-(!)U8eJr;U31FE;PzBH`B!Fd3K`iH03CeT3r$ZO^E&HXL zXhX*7xpU%=W5sz4IP999FE3-wJ2HrZzJGzD)iDl^pg+~?B#AY90u9iSc>+ZOJ%GkG z|7z3xt#&i%q<#}*o0wXluLx@o9NsY-A)vGDD8UCzvbDL*d2ui2MW5H)& z(LMmts4xLU;{y;)B{o1bcYDRJtlAn+p^HG7`uO;uChf#6%s$=ecT<-=%A}s~Ida0op+)TQOscOLW-)nef~^+GG0+BmSGwV74X%1V zdEmczNR_j24E_bZbU+nL;yH*TzhBlbznKyuT#mv;#613rcd~`gOq%udA+$bb_BNOtTbCIHG#vqB#v#d0k?u zf*cjX+l&?!0`>$;IQREy<+w?+i8*>mgI4qg33&){(VIBRc|KtZOh`J?HR;%WUo3IJ zu*~jOm+}Euz3=Os$|!Q71K$)b?sgXUu4e5k5=I!mG`Q5|tQa0~2)ob*8ofvhpRqz& zu;%b`w-mUFfi@noLMbRfoa`VKLBL{O3@?c7L<)QqIx`bHvp>~DTVpq|T}8Mj&O=`Gk^w&)OSB!sb3Xku%6eZTzMIR4^OM!NuC1i`_^+@qjOpyeb-&=_)1v*z;_9jSG zC3t!LI8JyT!Tej)pmpIK_>lI6?`r(g0Y3VJ{OMUL4APXpyX%}Nn;egwe@ni@C0zg zJjc-Oz9>RE-sYg>E~G&KUqYa8Lju<(Q-ZGI!0|)v*4>auHIv-)R(yl$B zV90byX3M^?%DX?R?++?Vk#p1FmC?WBDtk_O&@vCA=j-0)CPcg>_Wb&{rOw55W8o-75F07?Jw zGP6yyl&$cQwYiT}3H3C3Hk-DzQS~tKZEYQSUpovftW#xpN)X_z3R=<{iGlPAp%+Cz z9qd52_vZniByul`U@wZ@=8BY^OuvnS5s-&#Ira##IUKZ6K3YpuS$rFW)qM5{4Fhdc zsaz`rAP4aP^;;tV)IS1H|1X^XU*lAbEwtimhDmHdi1?Ao3^og+^Grpzf{PIGw_=HDP%ZI3T5ocq0uB+V$*Df0C^(;^r$KcfK%}PyGKPr zVi8)zC9})Ge2~SWX4ynSO01bc0Qv?8P{vWHpEk3A0s3Y*3Sbj5x8bNu`M|=xekGHz z^7kDI;I28(dG1ruU8EY{Bj^y!_1De`F(MWb)j$-c(+B0pUmUTHy@?{!gnsZGWN5=M z%e?f|Wr#nxY)S18LRyn~4UQOPwXk^7IPY7lM0gwM?GF@65rIC?3J7RmF)z0E*$2Lm zBP4A12*7VCIAq@C!(~b;Dl&ykc3%I```d+FR?ni8#W@0tgp5y_o*x7Bf#slrM3rTr z2=oWVje$OpQbAhnnIPwV228<+HDl^MF;Y#gKz6NU4lBs8C)ud-2#I5FN!^#n1&&t`u8TMOv3WxOk31fCVO3;zHN2F}W&aC+x8k&AAy}DBq4LO+TXL)GH zsxwX#;g1g<2B|Td$m-qGzr*P3G$fQ}bb#O0tnlBgsGSqSo>)96oVo)7jt@iHz?XW7 zj+~OU+tGv^SsbtJ55G$+O1GrQ%YyHDK7>z$;u&=DtyWzUQOL|kIn6Ej6@^!CpJ-w4 z7Sm1#^R?b%^QF@Zm!WCj?A!L27KvwN%BgIasq7yF-f@qq@dOU`D3twYPuLIO2Nzwe zEtCr1IC8~fwFha4Ef6KMnQggKky-+@yFU1|ov~OA^)h2^@`QIWskLu~(pM4uM#)QH zl@p>H6vu0E1IT5T5F$ZpSH&4V8}T=<6he!zBkQSR_B3olE0I!`>(cH95SK_|>j+T> zDK?-JTg&0o5!}d2w-P~pTywuYNbko-^!L7vwWmD4T-(o{jJF^B%O6=^c)T>iSWi@6 zXSMmEYCcd|)mK@iyOlB&*5S5*j+dKe`VjXsPt)S}Z`hKE7AqDTZpfj^T`6=4M9b6m zABLpsC*hvOr7Pg+HiIRpd{Z}a(oMkrd<>!>8O3mfC`il&ux%orK@gL76%nd>E)x_r z$ewZWPab9+ktD|18jx-=h>m~}6I{9AHX4OLB>8Rp;oZ%K<%#5KvjP$-?`H7EIFHgpYg8e~*vm@~!V z8UPn*hm*;V(dJ4=*5=P(-JY~=ne?oV^^jsNGB;k)rs2C6!fm4c%Jpzj3y?Xgyed(4 zQR9Z#sbsVPMqHM?%49~#@Jp0~N~cOlN%6lY!p>@dI5@6c2cK2um&9Z|<*ELklRNxH z4$1INDoT6~EN+|gZ=j{x`Mevrc?Z6Gm33XLlJR*?YTU6{lHsaC_?QXoyOmCqxg|^f z4<^sEpvTqAz$AO+Xx_9#@Oqf?;c{(Gt$ixQv8MDZO(i=_CgZ07MT^?wF10o-K3Jm~ zwmJ{chUnADIb_R>yXCW|R7@#k<=5#kdqk7U28yugF+V9?C3&7Czsv!dPxg*p{YRx` z)&HC!)3OevC1{?dBQk+)$=B?~HnPYySh*7 z?f#91b(M!W%Kl*vqMbeZ`|y5N`>OaGB*&ohgr2Uq`B65vaXru+kKihTzR}@Z59sa6 zK~3FV9F*4%WP)DK-x@rd4g0>=JOQ`OQ^$+(8$uSc6YwF97n-#)a&i5#(t6)hALrBT zJPLIjsBJUK$TgVoz5_AVek7q?r3YfHjlIYV#Mmwa)#_KJ*sukzJ@7vyVNUo+oks0X zsOE?RQ0468zp`5b%~>RC?96qKbn#*R%7=?NIee=)D|m^__u?;T?cn}cXxLJgzdby@9h5JT;|M~`*l}+RduVXtAVco0T%)ga8UvQ7XuJ* z9n9?ZoAfiYqA*Qnw)641IXgMn;}Plu&wpSTxZD>k>NyHjX#mZcjy@-?dS`8Plo^D@ z0R$7c1q?_fu?m%n!%pZvPBMH5p+G3K7&n<7Q6)2P?Yo`t0K~oSlsnaA3EC1jJkh$V zkNG1BVbW=8J+2>OWq9TS)X0D^Sc>vhm(J@he`kW6hjQoA@H@_hTFTX>+}37_?nA8ktLG@u#d&W)(Z1&+G#D^>?-S`)wt(Wlhp39Y z5&(+7X-5_4zkZJ`JnHGe*zti9Ok6BPfS6H4h!_8|!&PMBf+CDd2@VnU>(;@+`lslD z4G4jS#O9^lD-@QuR)7=?0E2O5^-l^_fWdgBa&so3ds{V`^pSditkDssps$k`Mm&`? ze4{DvgW6{DLqHmX#ZCrano^H#-$-x!XnhCt9LkZJ;Uf^QKmj%aDTrKNi!^=M4>ogs zP2+u_%Ht#9?YA*o!RD>@jea(_(MxlIEN>c|{U2le&;3rVuZLUGEqbtrkw$H)KSxck zzD1<13d7mrIBpOzCuJSns<+G7eNY|tkI>tSwBL}X+|?_Ly_!{5k>-KPj%6D008C46 zYztFD(B;ScSirO-hykWWSsE}cMX`_YnKB-9$0hmyTRuZ8NjD>X7oohhlcjv_1fQAS zCTTM|?);XKNVjBs5TVp{r=(jJz?G#7H<`|fl|uBBA&Y@iLm!^AwVthSXgGezDE_dm zRM2YX{gc8yHJ|S5QhMx%&o@8Sf<7V~Qw1qR0GW(s%AnV}k`IRMP8jdx{9n>=srpSA zCBoLo`aZ-={r&k7Tol^(p=RZC=BEu3H;E&>?Ovmx%t!Z)$M#zx#d{AGK`gLnsw0Mr zB#et>x@(H+jzd<$55=>}1Why7J_K-Joka~l;5RO|q%d6I&Dn5i1O)lfe0(2n!F73C zXE(3*x47?9$PgV~&UkJ5n05R4tytHTw8tAF4d8tz?LrPKKrve3g*hnK14SWP4|8<@ z9cFKpbUG&XiX;U-V>}}Mm*u_q+#o8j4i>(0nw%9>eEi?C{qpBU_jn7!dLGnzUNm@2 zn^SDZ&Ni6QS@VW7@M(d%)7(0V2RrT*M zwWqEdHA-3TMw1#o+xqCY+)_NI9M>PVEZ#bX3iyfT?i}nf)PH{B>^I;ime)z#%nnmB z%w7JsTz4Hf+d5baTJDFci(G$5#v8tw+s8G)BwW7;TyD4-8DnzkIoo2;8ADZoWaa0X z30m$>xl36$Go0KKF{t0~_4<_ltu2OYohSS5uOKbLrpW$kbt_KNO8Eo^ui~CS%&pi2LQLSQB?j3b4A~&zV^AE!Fq^9w6XK)j-io^^*k4{jJ+( zma(%+@~c3fqD^2{Y;0rqX9ycdM zasON0?v4Akb)VNGxXZ%cB(|O-QoCapFu4wtVfQ?>hQcxfuJ#7bR?^qw&AO%;m8k=p zozgNeuR)3+9g55b&_c^V_KNW3Zuu6y8xjX4)vDj>lZn6S6X{D9MeY}_=o5n(6yxWt zy=4jwuFy18m;v)=z=g$Sl}kC2@Voct9zw-CwXMQpP_>3sq(iqWoC*_w*Wn*t8XOh2 zKGn*XKwHrk7p+89Bh%gjALyS5l+u|v?gmc2S1j(+#3fU%<3273zhZa0Q1TE4hhd`Q zcrP8z6mag}%?RN)eh}^Q*wteX`U4RcJm7eE?5KivVLGXOm2T4gtw6G7Gc2b&yd`aY z{f>K*^zNvHP*;R$bOfB!h?yAE3`WxFpQvur<&qA&T;XmA0bqy!vO{jD0I=Ki7wAbx zfyrxu!Q1q4|3hA3wn={i35?7*BmrvIwZorZ2M8;Jz6@o$DbQDqIc{Ziv1UR`T3-_a zCeRVEFqzQitqetF?$z#h-OqcY>5q7Uo8mSnqEP7iHA>Q+aCF@$O*xig^X#X9Sy_P= zhNe9KLafVuUPIfejKMffj7?;wt+2~6jBClLn_OmrhGscU{4^o50v)O|Mf{H|=U-$( z+*TZYukvPyC!GXlmx@FDRdLE@A%eVGK-y>&V4oA&bJ+h|`PQ7T~sJdL>zJ(;^L6j8*TdXjwPV$ROD)q;f`JU?@573=FFt1X-=wx*?!Y zdE%1_r3puo&R4kC`nj)ggtLN(XN6jlX&kWupUe^hzT7f=epQt1CZ&TVAHza~^NOnu zfE-+*!5z{UWPpV(A>G0H`2t<_-3_*v9@n6o)S!C_NO8dKZiitTasB&v*Fg$)*As(r zjt_PXl5>W(xL8%G$?4YsgDl|$->;r6aaPAF)%x2;C&UwpBEQ+AV@x|#r6NDkC?`ao zghmBruQqz#ycZ>=CwX}0(fLxnuuD-!S!A`MsE6My3#^^Fyz{Y?TcLT0lv}t`iFV3q zdGe|H+GNAKGKpG>Wfm1*>%$FI<00y_SCXL96YpxSo%>JBk1RCjM`)l7W|d_Z$L%=VvYtS9NnyhM_8#wCY^fteMur6q%c7P9ps=$X;9=0q0Nj` zshC*TFnWwkLfFd7^mlHAGIYE0C_4YO`Cb*u--u)e3C+SRYLsmsw}byBrpR0xLJb^x zn>2CTim%AS5Dg@+_!3Li!fURA`~A1#*U82ADHyVw_InAC;Df|)hB|QBa7!L^zpx{N zT#oC^$!IFTVBzM2OqWok_H*C{yZ@-kiu;jd>xlaqlVWv? zzeRIdQeb_KvO??Ak+7KL`c4P@gGC1gFdzbAaHaUeKL%hy0t`?O0vJH%hSgp6VdFu> zuBLmH*oS8y_}hkT{|r6y5%mX}l|0miHohf#c(F7ENHXx2XMcZ3DQ;SVw6IC z;a|P{Y|(-5Xc1gPwv>fZ3Xx)owLRJS{-=ECcHJF`))$Ee)NF?9?x*iK{DUEt{t1OFZhfKlSOfxx66_v90+e#MoO1>u+n$Vh@m(=yX zngTvQAS{XS0+V4-nYY>|h4BTBcTn^9< znrN~h5xOw9mhHb?qbLTTD~G@&g0Lh4paS*Zb=%rhBEeQ>LCo6kNC(jipQYrMc!C+h zaXSFxFiHzS%Rh|V0LGSo7zwu21kHHTaU!j3hPasnr%kY49X!Xw6Q0cGMu5(0`Y|&p za66XesxG83Rl^O$pvXvIBps2>OtQSwPy;m|z%6<-fLk~JxTQk;k6Z2lw?+ariQ8_r z65w|dLV>FMf7ew4^$GCJ=9akvzm=4TpZpz(am-K?LIuxtmM7@x(Z=Iy)QNv{=!`(e zLIb~~gs~4PU63c>#6aDGnUt>QO&6Hggd-eTB}MxMS-mx2LL^QB;cF(w6``kr3<6X* zB*h2neZG}^)>zV1ToeST7HOpb5hF&54`-Fc@i6}CAFt8--u#nD+hDdS!@Q+FqB(&P znK|5Y{M~Z4XOK`jwR0ekh4B$k#4z#0bQ=>*loJb3gF_hH1mA1nb8-@zC^R`M1xHtjTp^DdJAQOgda1WXC9YR8^M$#Q z7Di3&L$Pjv_zg`&3V$%^-cS2BhpLZ&&%=Z|k@yVoh!zIm(Pw~1m{0(ZzFslk_TQz} z72p-gci+|~R|>&Wi??5VW#~X}z-Cb@sYDPSc9X@FpkvJDou7f)I?P*u0w|AU2b^*M z=f~(rxokLqD{X;WU^uq`Rs0p{yL9Cg)D}3X0fJ{i0!ifJ#LyB_3L$1Q6FXb-J=E+q zbMKu>>aSAUhN`>belU0gJ^@G7)8IXA=YB_Vit^crYx2o(po;3*PIDq`Pm*l-*F#r& zEJ?tgBuGjqUE3pww# zyjv1Vhc?^s(M`g_Wuf6cOEK}57gZzcx?v-?svh1IG08H!r{!4@{jOzD1P8eu@_Z}4M#$+`EyPr(f&srkzWC(NjV8Cp2%Z4s9e8cFaJ_E5mv-9A?c7zKI^UF zG9dv>srW+-6j|mOP>x%EH2EfVKHNe5vI?#EAh=AOdG_sr@+EWgaqH3Uay)F4J!X@= z>18sQclW-q`!Y-aDCII`n=8Eiw(&{OvG;PD!{e2B0`kU_XD)2Bx1_#Nx=nY?R`&1O zq}jKTeXE-qt#O=mgoJc)@3zfmh-EhW;@I`GNZe1UW!y|!SynZkPrN0|f`rgDofu#TFl&iVLZ(1>p= zHV0^C+WfZ2kE5H5Zy!79)5u&f^Z_2w^K~-z$N!;YPTti7esHkLo zEuPcY<$*g{X)T@uRACylCI52(v^6B(1AM$tXpLn4H$-1IAKzIvz0;xegp=?1im*OFS)JC^Xtwm;vZk)39q=C+VrvN?D58g&mO!o84h+8T_bNu zDV#$?_Y8-?dE1}Aw6=gMr%!GQ?a(gwOzoV!*;7jRTkY)D>5Sj>qA-*8Pqr?&cv5~{ zmI^rgs;}P$$5{%nIy2)clwDM!s)e5lS>hH^49DM=r>a(5lwRBNiIQCYxVIE~!Pncs zioCIH+bAVbdrK5923Nn)+twp&oHt8w2=0-{{dGRFmx4d_;ppl)9JkJ(jl2_F+ip%gi zaYZXegx4=!2o-34LJ-VZ%7?RMVxgiT!lkS=#%DzxCSLc-!lre3jc<#Wd&ge(#wf>y z%evoDFSnxocnQm459|itB!sq^4$cyjRT;Y-;*r6k~sI+nt&40IkNSA?gfk+~U+ zfkt4Xm)=IL>k+ub&dTA9dR-C7xCl$bm#j=eR8L9SZ@i6$kV6SRJ2H_uc7)o7q>$e( z_s0#I7Y%mnsM8fLd@qlw4(_}XO8oG*r#o$x)@-rc>ptAKGL1l0x{12=c){q7Dgi(B zo(+;W(};J@LI5Z<{!WWi;Fyp`ii+}`O_2|7t41KU2|&5#zVz?B(hqn-3JrK#{m|pQ zxl}%h{7nr$WgD4>4ZQl67y;f?Y0?c_*i?*vlswpd9zXZu)vl7+`H;Sy&L*U45~ukw zE9SeZ*MeM;|72=PkYquS1w|BkZYW(1BWls-(*O$}nGlQHO(!!|3g#aHl4;-B!wPeF z#mHR|zHp#hK}>&OAjg^U10I@%8d6;m@&I|os)rq49BX2xv>C&A#&Z`!C+)YNIaSvmHmpOy1GcZ^3 zeoL|S78OZ&?lOMNMA4|oHOpPwsR2N|5U=umcQz&k>BetaVEhPstA~F8q-`Wzi`PpW zLLMV~LMq&G3>Efzf&Hgo=W8d&N^es?`}GU^aImm+8i#lsc#fbL!#kUDzrohdt z_-|CZH)so8HnAJjMhWVpmHQApRb$nYQriX&K|!mmV%#Z4I-|$ zZVp{>G!?%Q|MuE7nANqO-A~Ygh%Tp5^40}Lg4H@~>nm19s^^3_^jTKTzBS6*M-+%; zrQy#-CFQtrX~~0r^M}_~8-I26E`>c2OkC*NP;7dil8%bvvNYi^54A+!x6i#JQJJ5? zSC&HezQnssPNo#ay@(w-BAp1u_@}{Vs{hmJ`S%hGn81=<-f2r-6v~5nYmP# z8+>Vp*V#WzoA0p>w!ztV6C$`>Y$R59G@7jG&_g=48B3C?h8)NX=eQ!8FnrjX^V{qV z;#JFtu#!Ez6Z0vB-4&Eemik$u0W$8%_m)ep4@JOekyVPcH|aT>{?+tgM24qy=X%(m zpNkWB(M^eSpWO9Sm|5@Y)ubgi;5rLV+akJLTYfodm~EU|8}JT?u`Xc*7y!?|ZE_Nt z4|hQOx5P;I?A8Jj|AcgJ^#CCx!oKUiGi@tV;_b2hbOxE`YtmS zf63F0FSJzVQ~NCFyP|H_M(=ERUosRpYB=tJ)qRGTO0m40^m`MF`$I;kh0S$ehcxou zy0!rM^bX#6ukWIcw$m)lo;nU;?{g>f_ZK%53aY!)ir z$ClWK7t_?>-4bqCk-VTp6&t|4ft1*X@y3&hxw9~F{0U3PQg+-q%=hD0<) z8nKlfv^G#BXx-P2J2XM84uAm(cGpWp)GeEE9%D;8sT61Z!Y}b`W)Cf8pSIgn6t2YftgfuO>8>2)4iJ#b8 z=T8x5_r)4c%A%|Y>ZOU!XNQet4E*8vfpnNSfi)l1Xnh^Cv;TF}WNrUl4BgWChEwIp z_2!eW!DQ6(*o;t%N57{bFvXPv%!D&qX3D#-N%O8VUa*~Ya#^a6?5p`k5FW6T`cD32 z{PC81;TWB$v}@5uG+shGHMrC)k9XdR%cEJWM$&5OM>FlwG}SZ+Bes9oFx`YVC*5MW z;$T!B*}A`eP>=B}PwPyGC$OOk^QF0Is1U@u_AEm_t%=Wje=7cY_^Ak7gdLdAbqaIW zE>YI+CurbN21_bkuY;7d>P9x~(S$9v^4zaJ%ch6O*n50$D6)gduEy9U0t?ngCY@9% zr9d4o(LkE&{T|US^W7)Pn>CtCIv>cr-Tf{II*@+r#GWZa%&#(9k@__U5q8&mc^Iyz z0)Ol*m`@~iIU$N4PCPSI(amgLzrr$2cwErXBn(qD>(Hh%W**1t%S~e5KxH_N`p2Lk z_@P=;4&!{Ag1SvHBv;T(NI-&Gf~=801HKT>y|-`QyA|#=P%~8X^V&H{u?x5N3lDjT zLx2|$eEty}E0OwX*|gcAAelztkR&W9r~TD3R=rfY?DG&N%9p|)AAXY{bHVg#sn)10 zK=|rgTfskp>k1`uIXNAyp~{6x&Dz??LrwoiQtiI*(n*rwnAWkzFm9YugT4ryVa^7* zd190*Aikjr?sT5I=~?*=t|dC7{q<7z(vwfrtdhyRT7Lz-mIOSQm9{$syw!D&s6bqb z@xs>e&iC9CZ>XJdLS?wWd?mDrEoMoNrHGEl&9pY=Q9&dPd34P&sNmiLTfG=7 ztg+yV%D{&vN1tYqQ*m7K;Y(RJ78kUob8~D$3`+R^+?&Cyk&fy3TUYIS+TGXdzl$+n z1SQU#QZuP2qEO3qi+K7~EQB~I8_7!&iUrlwD|1qm6NAN;32YUHi*5dq0aWU~@+Nd1;|!6BI~`UI972bpOdh0}l{6DjH}e_FEQy9Vx+P?_1md|5XKeXx zN=Y})a>Cv5@NAhfYexyO@-@wtVnuo8%KVBhr}%(OXsME+NIWf$kEKGx_tsDhtZ-IL zc|!GLi#RDxjZ~!`ZG`vP6X!v?z*2{5%$IpmuSf3Uh|*_qZ9U(LcU0ek?$PHb_7!@` z%5vzpR=9c8BUf{!sFDwFps2vtUL$F#u^eA>!i(HjH*WpQfCB~fW5-|(RS3^Xd1N2_s)j4h;LhxLq77D|QoP_r5fRb8NOmX)UW>h$QBHFwah$Z2pnHJDD$^P-F> z$?*nS+$`8BB8p?tfa=T?sxTa9eJ|_pAG?Ko0KQl|jM`p~G1{{C#TBKJ@R;~CrQn?_ zn;x3zz7sx^7|y=mqemiqH`uIFp}kS0`t?Ht3g_YD@UzAPW3DjA)sEv3Gx|0<5!5q& zP8^}U`MtE8V+-^Uv|NY3nbj+wG+XwI%;ztAFBHMaR7*;Yl``1m-EZwPMC#P*EBZ3N$r4CHEZxts{=`LZ6Iiu!0Sp?c0B zSFb0$U@7MNpIe|h{s>id`R=)HEUDy`or;;wr%`D*n{JikhNj4X4xQ7S=0ON-qbz`C zZPU@UU%T@T&I=pxW>r0?I{u#V*!i5mv40}te`bGm@dDTc|=&EEKqs3|-DuDgM; zh!6tvbR$bxJa~0UQCIs6Mb|s-4Ec4!--? zIe0uj?2!J94FnYv7vJCuDBJ`o70CTN7C57k&;gg;AU+?(HH|K0zQ+_HHnyK zNi;iPj+94>UB-Xf=IHOjsi*5HU&9^V-N0XE$>1Sx+~g^GP_8qYOQN?}m5sNSn6x?0 zI4Flw*F;MA;M<-C^mnBVlesxOHW~eC$wLC!GS5rr2&+Y0xURen%@s#q_UZU8wdIs5 z3yytzy{Yw_a?I{&%d(z`6qWq@YaKKkfG5--WUJPmDsMIi7ho8x+xL#}ogB%O6XUI{x z_4At^V|D(S#XGS-#01Hx>TzjIZixrlgYkWT)R2xnlf`Ntq3C~F4!;NY@#hk4PXdiS~)m+WVO>?8-TR6{x86s)USq=4}t-o=$TMcY( zCbj2!9445knS;vnrSOT=niPN|*-_|;lnP}jntI&0k-qd;XQfz6^x~iRpC<=Evcy|> zz4#)3Kq8F;?CtzlkZ^!QkuTq=&>=>Hl~HXFg#Oi;!Ns>YT2C8#zGg8Zn-3inbdn35 zz`J3|7Jk$AE4|XcLAa`h3(@9*uK}!rG{64CBO-tLtMiMzVhpCBa{J&#k?8!M+4(~d zh4!Gr!hH#L>El(p(IvcyGdDPkZU3Suo@j=Hf+LD9PYG#00h~3X<$r>Gpu*tts~BX% z)Neo^a&j?N@H3+LV$N^yMO+z^N^k+o!f?Rs7;91RcA|~3PeRVJHO$7Ayx~6=>n3BB zeo^yytfao+RD%a^pG$cCL!rU0HFO-qlO93=TwD(1>*}LH6R5j1`J6I?Hp;;z$QkNN z1jUTV8GKl)g5Ck}#-u|Th3;f7ybyj}j%zS467VvRHV`FjpT zGt1zLG#V+|Jiif$4(0XAb}5})mn%#>6(jbdY*jl1LieF!T3jNOFZvX(kR}Y zA@80cl)->oewNO zg>A7v)s+d7Bnv1r`b5kJbC>hZ1($QP^`5~PJ_Y86m+lKLI5Cu&Hup2^(6F?Loz zgk?*6v=GE&5?2ImsWYrb^#wpOs}2J7ggSN0}%MMI?u5<7wcv3L^=XE z{8(IWABh=}TDa~Xndk%aT%&pqd>Ks^U7X085XkwB8tT8eSmRJX9I%+U9`2arM#k|z z%v}GX7$uBk*~DGew^50pU=wlSi4m%`-k+9q33Sq|nlKRdalWhSURB)RG4oNa9Dy~O zA}LjAV)9Cr(1-H|PRWOYdRbD)Fo%^c_@*+@7VQBVZO5feo+mQ!#psiagxON%Sed%3 z0yUbU+b#TQ)EG9IW9O(*_nNVi!kC%8LX6M?gEqfY-B77#1|2H|{gCeM_)yRH?3MLSHc4Xe9iz9hxdw?cI9M|JviyL}n zBVtwasa}vQrdxHpp<&RVLw7f)S^e`mh63T}g>#zmiHejzb+v?IwCHi09-NG9Q3LH= zGZm;j_)=8g^=@PCuAF=ZSx{dpk-z`jWEa>3_unSFaK~ID?s2a-vwMvjr9BqXeK}T| zV%HO#qt7MSU5{5jzy)=IOMuEp4B}Q?*q;4;5$qM>qd9z+ZnH43nO{?*E3g@~o9n}b zSiLJ%Wrb6@)eaGK+kU-$-5OgLb=ax0b)-2(xKJ~Bczw4%^DnMu^5fKu^hMbZlfq}k zOqUnxI0KtvhkUxCSSJHZ(zSBy`ar~J5iI~onM%$Ik;+dqGEEgOa3~;b@=2C$!zlPB zC^IPy*L}o&L&9MX`wPY3$S~A!%^Xjxu`S9M2a2^1!{V~$J07DFsjLJ;n0#}|U~(@c%J^IJlBrZn?$b**=@2<*A=I-6q_`8S zI71!Wz$)Iq^ZL&svH|dhVa*@2KWM*vs&Icjk>9frFUzTt>;k*vRwWF=?8XF{A0{bs zuZqKW>Iu1H3Z%>t1Q>M*DaAw_Rp@0D0016{|0+?yos_KN>{`V2A@|LLy-P*bdI%%> zR{WY9>@htpf#`xgnkv_xBb<ZktdziU;lB) z*%*I*Vgt%)Y3<&M?XOz=ELk%H=>1w)c(U_#_tHwr)f8VG{aCbBgBU|f5`E##VFT-M z=#ewKRXl4O>N(doKI`CQxw1jYt_>m16-{jWB-u z#3HZy_gC8uX2Z1JK6XXGiUnvJTinQIYHfufqMaLgd_6@RXtqn`xnEbeHjj;eAo+CO zv+9(EFU#+VG;S!GWcIk0pp7Y=|7%~zU9Or?x_Ln>IxFPtWO?{mybIF&p{Cs9r2qat zSC6Uc17t&@e?-G4HMRk_U#cYy<%$hgZK2Yb;r>@^9W=lZFm@p}KU7+7X@zt}2cBCQ zSL`&ID_Iv;EJllfrRgEmh#3Xi(e>|?*j*?UNZ3g&nO#u>jXqfs(T% z+Y7Ol@tNZjN=~?S9TB&`5Fh@5*akrK@On8;`RH_9 zCMv^~j*P!vvrLHYe>8V24PFss$d*D5T45@+1)6CT8GfPR?dyYpl$K?MUs^Frb_AAP zOj?jVI22M1qp9L8YstFTZZ+eb{nJ}kxUQ={ZeiOss{XDECS20~c?aJHptNfeE`4*S zZr~eVvhX`)UHV@LR^$lQb3*TG44{azI%-G+wB9XkclONkh{xAUgP5P4p&%5~Y?bx9 zx?TaZlk0K7ASXYv1OT@qc{OPdxE&_}l6x$sw7~lx6mzj-=>@W#r3i)@1pw=h6055# zQsWx(xrHCef=ovQ<58D}%Kg_dovlXJh`8PVmo0s7lRX^{S+UezIv;rorMo3S z{R>jy(JtGleRGaoHhG3}F5Sw|9c_~O!2y!Nb^lqe)#cTMK^|Yd4fbe--v@Ax(5-ny z!mLhB557jWpF~|<|4ypi`4%eJIR85(jb>k>tg9{+6#Tl7A|rBIl+KB|kYa;&l4L_T z`dhjcCd4Q#jA$T-9amT+bU>2FRF0-z0Odk`VmNV6i?%}(DKJ>KOnrc!?c&G_>(9cfbUm%s*82E|hG_4HuJEVT>Z1?~ z=iEPj?ekv1Er7-pbBh5Yx{4os+~dmOi$VueEq%7E75M4O-o87B0xL2U2la0I-9pp~Q)5XNFvH7Ju7ueN}p2 zkl^?ESN4`{$Yyv1e%>&Y<3#0Dw8y9fGdDzAa(}|^P-Ac*kq>Gx#CnOZq3X#ngdoQ3uqIX`XSc!W zt{#+IDC|l(I_ac?gP*Y?&wsGaMfo>uW4-Xz40L5|16Zm`RD})K({}V*An^kQKf%W# zHR3}r%@z)le$>rS;Lncv+DYUW*J26(5r?{+FD2_d6lnB()9v{kdIGr*Y$`h4D<3H+ zPsC)XKa?jQ&6O0^%M&4*dLw*p51&w>Ay38dqd}|OaQ3@RLBEhzxuud}D>WP6#QdW@Kk#XqGx-!>sqltVdbSJBVN zf>lX+58J$Pc3!=^K4yl;JpF^FR{!-~=$KGot4Jqoqt`OBFWKcy-=-^-?zKsNQP{M8 z#W$hPCP)+4j-T%x8%~cwLz5|%L7(a*ra>9!rMgC=J42ZpE2_0b^^yF&%P97N72?%P zQ;xc<>I-MF)?d0RKasOkxZb^rhwgce3aQ)%NgQiZCx^D@p3kl~*Ku_Hw24q2Iwy_Y zG@BEtefL5>l683R^k1$9Aq>uc6zi;$`k)Ww8%rpAm(Jtf*`1KF7DoA(+32Yz1ae2- ziY8Xms4x%wE@fy_mjg3aS6`9U+_)%Vm0N>Qf=w5?-1w20frIIFZZNm=dBjg?1<$+J zPV1kpriVaWVc4dC3bVV7d4P*{=;`uG_1huSCq*x5KDG~~E$>K3DFN|gCe5NDa0Z)d z4|T-}XBBtV^x055KCGB(U$H9C@y;|kk1;IB(L}h!4lw{6=0=5Jn-m=8#=5&3`*d$w z%Q}8spF4VCCHN{HMzRT8HXn~FXPcV@M$Z+kykyBY@I}Z>!xjVDd<+fPA828Ye*WA4V17OzVHSSd+4`+>BfR~Tu zh?5&4HRwM(#)x?oSHwYovEd1R4Vsgx*v05z9Q^mbKT@-DjoUUF&DU@AbCoynmr@0l z6u(>9)Oa^^LA?~0N}4CCj6)aO1O3FGA(kuGnp0My2uKDDff=`{)b$PQ)`c#+bd5e= zK^P%F_O|Dm*95o1gHE?o=V?O%sn6hLPzl9*nq|AG%En@SPmIO-lnWo9I3E zB*GhlkS1H*b!noswpxXXj5$<{H;`g?w0Y@q`qiQa>?{VMl>=)B(0K8ysJ<=eAKVls z%LOibsr%pk5uPtxPO|-`zfX#frWO>Cz23m}6$p?At{j!}>?d#Br}-V~!++TRB&uUk z{JPI#igEiM_gJ}Vf4Y$RP;q7cxTFyb@qxJGbtcx7x#S0Pzf4T1YG&F zNh?vCd`1?lwBC&3^~dgmdZunNS-i*V?&#?R%IW>%n9P;dN(r0En_~)n{;sy0hr`G%Ebk`W@h{LbSgsGh&gr)AN*Zf^M5&fCr zo846E2nwb-!z9rqe^F?$ecZ;$Qwcf=eX@b?c|60d)18w zY;n?=)bk-wC${+2p93wh@}c>=NC5x{OWhJG<*Y2vH z@$61p@vCV|3&_Yc&bVZ8mu*m;jkt}HR3}e`JXDE)?fclfI%Al!FSYWjcQ`{I1QhfS zX|)RFe_H8n4d<-&pTZ1QavZ8n!TFI`INu9-0i7-yJx(WK?(Aob5h;jK7MPKt6=+mm z=;(6bZEmih8_lLLD?lsY;)iEi8fK7K#$K&6JFj)FJ$Hi`RS#LO-Sff1u^1zJT;`sxuuR=+Z5n@<>`bDZ_8x8T%4?i>Bj>u{ACB6)K;6DVQ}?of`Oo==?KaYqaM z4jbY^-w@I3OcM7}wn~O>^?a*7V2M^3Ik~{QvDPfH*YGd-hBv?tfcV}`Hy*zo^vzSp zrMnmfQBQ-{o7k&$XXlsBwR`_zF>KQA83F-Vz~d^D%k3x32dmx@LKiM4sONdM*3LYC zyuDuu_1`;w{`G!t5|zCXYv|$`rj{AQUaX~o2^`Jk3gw9POlI^}J^2qR)IzzNABp|x z1yQRK=i5|-hN>V^cY;KH& z0O81ana6FP4x?A;JB-iNpe(G4;+F{ij9U`q{GCeHaF8+fozaDGl1;+|R(77*hPsc? zPHKUbuMwIsR;&EnjONm1(88VPOyl&AZYI72LtfE+p#Y)l>L(|7ewrGy{wevxY=%Fm zBLU4FCMw0uS;VL#_O%-vCMfIVqq{JoPB>w-W9aK)KT%o(DJv@|eoRMM_#b7`UAOl8 zFeo}eRza7ep-i9uO#w}L@|h1P3!+2car8+^i0lPjrOU~22wW0YTS=`95f4i!ZQ zzraFitFyd0;KE2ECu+0AJWvnB9 zr`YhEL45+BxA0h^QkS8;Emyov$Fn>`IMa2po!6(+1>r(RVhZ_0qdL&X5M`=|w%joJ zrw}Pt=eNQG1UV(PCw477n7M|le@Nl5gW=D`=+}?GB27MdD#pIMck0=yuOf3J?M;{6 z829h=`ObkVD(pATvK_VrcJ^ww+k(YZd(6`>u+gvD13ud(f?Hm1O*bd&p4!%g)P8+? zvm<^SJT$C1K+85C0Jp)9|($4ei3lC*&L!6KPCXQIn1<6r_JoU+tDDt#d2 zU5ef4l{=LGy7O|EA&k*+{&8o{Sev)!$R%K(;g!U~`jwl%n(&DPbXgzM^drmjmJ3oyks%TBsCz)6{1a>TEFOPkM@?OJ)p)XdC*Rv444=BZve*#f5jHyR6eES6 zUo?*ryhvxK_E=I`(TRk5p3{BapN$-~EE-wQBVv0T&QOk0&nMxU5EiA3QXLCc9Yzjw zqaW!YeI`smQ5K-rvYE8d8hwo_!VEJe{%YTyXTg>bDfTfKyHC7T``8~fc7v6TUW#sV zbmEkm4MBA7BUer37l%_UiiSwyVwH3EXGv+r%X!s-^z|;UlvK{Xf1a8goH-)&^2nYt z0&{E=+gm)a^o0cCS3_rKzcwuF5a_OzNU|8c59GaH+q)|rF4^Q2nYMSliLS_9cx@1k z998?QmFAJ`y$8MchtIUKzu?IA?C-6J>IiRbv-PhGO`$0@%OMS!>d<5s#qN7ZPeHLI zW0U@cMlRGUhkTzbJpS|tojj5mVS(S_ zfGXQ=8;1W?rfE6N&X4Ady)>o)xJ$@NHHO3wm)%Ti<&dmxvn@)I9Y_t?oX`XF#3L<- zUIHNoOt~*N)=O<|FT5OWY4WCtZj$BpOm30_4lZtkf+YrS+@l(9mrG2!i_DiBy#iS@ zlDZaUx5F@cgqy@OZWo4Hlta0?h%xTeY$D(=bCrXi;Z{i!-g~I?59LNq_3%8Jz;)Kc zgVkz6;YImVWD^DjldSG>ZU(6y>iGS505 zZd7pVIIzR~xvL`3u~q^?JEkzi&hXZ06=%Efe%pQSOI2lTpb>CzDZ6I=;C+?i+OP?dC8^ zW9$TVfBjMOfe9QBVxEl&YF^!%XGRA8Xe``SKgsLP#*_#DPvx&zga};V6;EZY2#k8X zeGke8e4f#Lj_Kc$@9Ok*XS`*6d`%FK2|vNc_-ld&ibwmB?Kvr*mD`;96g?bwS5%eI z0M>F{Q^_3YKThKOH8;dGfYLd?f{gx2)EIBaZ7!HFg;a`^pAC z;rjket5NuVjXZScYR3~I_@j#N)to*(MKn~DBU%5sO{X|mSZA;?1adEukDA!g=BRJBPLu!3E9tBDy3$-DmBJdGT%m4-yXLL)>M`ZdO$9ycnBT*{Wy|Une;0R}wlf6Zd za&gh}qu~avMu_4K^8QS*;FiyWhCrT>E0=qn4u=oIG{Z%+w!y>p+Q(HUnfQIOKj9zb zBp!b~#>_J{dV#=%Wj`pnlMXWatMxb8U|y6&DhGMtM7QXqha`U@!RGX;8}BS5#3_Wz z?cTHXUuoPvAzF@5PG}4Z+%m6Z+?KI=Ht{nuY0T?G55X=eiqb}HOKGM&;W*Zw=t+$d zAAhV95U#0hxp7V066>)`=oAkQLWgR~oGNH|0wZOBh%s~)q;|tdw7)(UOJU2%9Y@u? zPCoLy@cgJCaemI2r|+s@G{IN5b<5^R!$ukB3B6OHs1B@GD@i)(WSmFa`(|CSXkndA zYHS5qKRf+4M@Gk_W__*afB|~6(>Hdj?ZI71kt8{%re5^?qm9=_PJRjrmeG#3!MnJF zM%+1e%L>gvWv2WRqAj%;y{Kqc{;=K^Bf08FfxoaaF!p#swA_^)C{R;%VT`=GQt_T_ zO`vL< z_CvGwp;judnx&a11b&`yVr9}}`JUm@b2l>A2;?iSu2qGtGa~d^VB4=Fqg!zfY1Z-Z zhifuwRw|Oxr4EBawqG(;+2?&Q4U<=M3RP?ISRCV0)I8GfhGd~|<*sXq-A1ATLP_%a zBR&uu4_M=qJ@NcxvGr{*j{=c{@%o(8%otrVK#PMgO5%5Ai{K;JLHal6J2mP*ojs}u zI^&!mar{tU>jQPH2#614J%+Dmm7#B8D)ODQn|HODf7MIqjA~?__Rih?<8Q5pyLpv- z8zbT5=0)e3gw9^{ZPkM|e};d|k#gpPnJDcU5VeE$U+`7SaM{1|&U%JrQUtQ6z~TqQ zDW>!5+fBKwKli+Ub}edGFB63II4a|zDU03rBs}g6+?}^=$L;Z|llg=CEbo-oTjc-8-MP zq+n4O0r^wdpBld6BGx@3KTsLpooA}Rv zX8UZhF{al2e(dEpw)u7YYoKyw_2WA{6Btu@WMR8_2llR4U$^cf-uzt~>o!%&+{`Y- z?2qrSAHPygt!|%DsEjwN-is9ec!OMUq8_6h3H!1(F%o=u=lFd8P~4tMUlvvHn2IY9 ze~g$!5IpCoOrHDXSQnw8Iw1N%yz5#c_jy!BUZRR^Xy7SD2Wl46f_TfOAsBJTCe|bX zyxWgL^Q2uXI|M?FufX?xV@B9r*)&dGuc6(3*jz)K@0Q{U{K@CS=7YqT$GB8NUU>3% zs){M1_!R@q?&R3}_OHrZMi?JYP2c_9(cn_{Senn0i#EBj^56$P6{2C|m`L+x{g+HU zOy~(2@qB8Me7gA^CJxj5d=TT$Vg(!8*UprmN8*yrj+5#Y5fHx21^7t$#Sw&OJ*p8{`Q}U4zESxv@Q+{P-lLEEMl^>MG)IQ)PW`PR+M^Iq>JM?D zocXHcF+YswFwManec{!}!XJI4-UGiY zMrmY9`Sk2X7DT8C)1sJu#J;ZZf5Oh6Lia(IeKo;HSs#r%+yuLCY(wLl>wr9#-okWZ~(z2!s0Gy6C$-?TG9AB${fK%h@8j6cGHcIJIPcsP`^LOr^HR;KEsvO8#;P z!oEijj6FSR^byb`b`3n>k6Rkt_4Sc5f&_;XTD?a|`~2H_edzFZ>-d{tDBO_sDLGIC zN}2Y~LpR^`=hF|8?!S}h&KO*Ed&{3moXZS`?uq~;PwsTx)_qhU%|!N;nhvTIzy zkNrAmg<*@>J-3`#I(&!uI3F!>vvSl}4PKT@P!)Qv<$q&^R3FTa;iX{%c4f0q9=06m zuc#NnjX-$%$ZS=_;Fw^FBEM5BE@vdV#azUIeI~ZmK9h*Gusj;hF0B(T!{VxFqjp)b z{P4%}?#6k!-gUf3d^AsePjceHkXAQxH8XMW3;Q(UoGJ27dNq&pZct|@r?jq6N$?lm zGpb+5R|;ld8%Pe@y>-qgN97HTZN@ z>XbA5c%`d57TxjTxnuA}|7u;I5c=07Uosm4t7)%D!cvFsYT_3~R7$>cxLG+qlM;jy(-@IK=ugaS{0E*A@AGc4<*O4bZ>^(LDM?$4NzULq+kk^?F7*t4{p1W@R*-%=B zV(`JA9jUj9P&4qti*?T;zt3UJfV&lzlb0Vkp9{L7aBFEUpKGvWEn1Fx@pLGrm^h2Q zzvQl6!rb;P)v+dG3Kyv%?Dcgr5Aoe~^}D|t%hf&~^dR8r^rggmiEGU~7>02rkkZp= z!)?IFpt5aKgbQH4#6q+-DXh>?|A_MZrIlF>h5F2VDXROc$}xB~`ruO3=&s6$39bJ< z1+nR6)KCx*;WCLlHBC!at-}`U3A@6_z6)C@oBBu_(tRip;9%##6MW{FdwO;cSw)VM zeM7g%%C5@Fc@xE!IPzMDZjt;S+#oIvVr&?gXgR$*e5qYc@>RFc@X0=g{Ba|^?Ly`` zXU{a!kGwNe3US?+EE3$60l>6lByMG}M()~a?98IU`n(UFLGnzKJkNPg`n)4;9J^sC zR3`G#%dSi7diiY57P9oLcRKb`$X^P-+4r0!*s9;^shp6CQJoQ#@hwnbTOXoh6f&rB zDfn;4emy5a`(ZY+3mtN-dDB4kgFKLP@;0X58I$DGykJlluXxlLU&_JT196rS_jQ$s zH=H6nF{rgD(?sN(ulhhXL@%~(5sAS)wsn34-DM>9GxH(QvsiUh zKN<&SC0<=7FH3bcAWQHn4JR?^>8}||b^N%~66O7pTJvQx?!vPs;u-l=%+JmfKq)5# z{s40WQ1!sghzvJk-bI|kOVX>7Zhp**5)fGB96msxd{H^bKXbfi_=#LiPWyvO>9{~b zD8=F5?6bc`@>5xIBV!W_esi`OEzb_sIH6n@K;`C7!4jk8FSLqcMQtcF+wiW8^An`Q z!+ya)aE!0sU0+ab!aT3_3AatFGF5$SP$P@O$On<>RR-Nq3s?7Ci?Mt82I=%8B4!{1 z_RccbYg!m!#ddl|(~?iKjUB1H*jlvkc>NWi8#$^@+weXm7wj%q?Gv6}US!@DhVvC0 zo)Q+N$cihmW_9Re((#9PRb{HQSZB+1vDN1v=zBl$B41mm&`#;xTKMSHLt{#hK00%L zVjD-4jo(^Rf1NUDy}Kd`U~H89}|FQ+m{rDf8#7Yb_w|gehFKNilWrua<3e zc$$9hm47I~u^Y@+8n!|~O{0Pkx!hkkeBdh0ra2hjGgkw+z3-+W8O?B`HeHSfE&Jk2 z1VnTAix5#DXYqj_xG`$#DG<(x1>Y;`ZnUcsbi(p7#N23?&GzQH{c|#oHuJ9#w!6gQCr@vB3y)Tq-q*C;h3nt#%{Z2M!Y7Vy4?j=3 zpfNwveqWd;NW5Uj+9b{cPWd001I+U=L8`@DB>)-{w7=z@h)*wlOcsI~d0p+sjl@l{ zN!AaV=z1{NVV+MVJUH_1$UT3;>&250?;mhgy+2ZEV#S->DxBx>YJG{I<|$ zoUV;m-V?0GZOkpO6OHJQRuyX22v|rjY~;(Rq~9lvHRgAhmEC)oO?_2+dO1SPnGB;l z&n1oxWV1ywpOXD|p7$r;Jq|L!P@+WMO42z^imw9YV3mr_5P*kGS%5`)_-w-&0nlg}nNg&7|$Q*)o-*%-+kha&vM$oyx`dFsS-%uGw&!kh%dE*fr{b!Cld0e8oYNX=3ShbcGcQM6UN z6zCVxy=jWMc))R$Hux!`i+>R>LI9p{^hl>G_Z$U3!1=o}I!KJN32AhpG;;kk%49-u zPq}%bJilxCB+E;;t+ZJvF)MM!5u({s&MD2_qlY#>XhL|aFDl}@ik3XQzX?74(XgbV zPF9hqp9gcTt14t6Xlo&BTa_HECM~=cTbetK%-ZwdSE{QL%%58FMlj$_Gm>$l%~|3+ z|A0uc5AmkCZj=h+mIm3R$dCZJ5n1m(Dtq7}DM@t}aiMjWUj7jCZE8=(;)>f6%64iZ zeI$?5I{GycOL$C8iRs74HkCRhEXuN}8s7?)54iBvJdI)DFRf*Wp8?|Tlg(O0^~#vb zF{NzV<(|R8Q@6^HacRC)(};UrBZ-)!lay#pa1-7L9K!DsloFKU7)zZC&D84hN#0~OAr$OGyyrjt-h{F+IdWvGb+C5^!ZdQ;gf0eizFOZnSk_Ow zYS*D#R{tweXMSVa@E9-=_F7vXd_Vw&J1notwe!KNt?U#LQ2Tb)s;=dDXKO~i9X9V*_7S*ctmu$YW+ zTV+s(CJCQxJC6N^Is^Ac~j+p{zWg%1g&+SMo&K8gCRbSJ@&%Z=#(;Y z;UB-YzZdFPp5`_cxR8OI2EfU;B=ZDeqA-)P_ZbWDoC@@}GOZY{0U+7X%hYjXx<@$$ zVXF$GCIg2pFvc5DSxAps{-T9tE2kHjSuZV*%smoC^MZJxdb>`uzZ3d_?ZPv6)G8+( z|1-`7al(E~zZIr3Ew<6N%h&m_mP7a|Cr)Xx{tpwgRXRN!oBQQP&N@hqJU|A&#k)8e zTK6HyidWQZn#-AHwy@C>&)+Gsn7G0Pr`C=osH|?LbI3swM%j%685*`^;LbHSG?_yh|M@HDEi# zJ>3JbU$;Qp_(8+=nK!LnZJB^G^&25Xp?aKYM+%vfYq*!-G@w%HiO~4Ium^cmV553Z&xqy8L#=PW2z9Jd8c1elMA!bS8za{23 zYvL9@it#L+x+c@06?%F}<)ntat}8rXd<(^Kli2>$y43f_{~( zoOtW};WpwcSJo2Zp;S2NE6^o`Z?k)n2_bXWOf4NhNdIak0|2PFJW|^^pA&b^MPX>f}O&_icImM`UNA=8&njALl#As}79tOkJHwVtlfx@iCZU!2J3G`*d#g~=!E z!7|OhfATE9EA)ThFF89&^A^yQt4FwE zH)KV0)3(60P`SGZ0G%3T|5x&Lp~;Mzg?fIUezh9G@6Vs38X*URlmCS8B~gm>Bmxi; ziscSaWgpuof6itM6pUW)%1F=sWlul7{UV60CfAWMwkrT(lWcJ0M+g0>u-r~Ii%HC2W4M`yOCE!DVAUHa)wQd~`X=YZe7b_l}u+RePgv+A3|Hmgrpc(psO$~(!*1mljS)Ow@Bd>*u zb!!1YRGkl`=mW=ms78Ld6u%`?G;6FUzOjnB5kq7wPAnK?(+E85K^4J1PNnqFM4yqL zCKuX6KycN+Jmb?y z^RH=soC`H2;FPKx&pJZ1!9%e6{GSdLt}S)6Ygd{rt1gzax2P;P@yJ~hBo?)d%i-(y z%}Exi4h9UYFx&!cHXxrYo(&!7RdJLTwRr(Xr5E|!oPqR?q?mEJ0m+%9*oSlj=$1%2 z-H29hO~4+h&g%v8>3@Ie)#`)OCML*ztrK!wkDFjv@Klgc81IJ(#+WuF*%YlE(m=2d zZ2P(Rz_K{)fo!rN{mH^dTgFu8d$;CmfQpybOl)o89S{**+jFU zocl`{zrQ-^LNNQHXCnfj!Op~fvQLz5@1=WX4y~p??4p#vRE#gesb|aP5)+b~ob-%G zvm}l$(LRj}emlwiEz&CpYn9M+FKhtae>eEHvn*;{PDpaLEczjx5V|#&MmMsoSVj+A zzr12u8_eGC=?<$_V_{D0FQXN%(xWVcbs$TZ>8F;72I#fDvNtdyurRI=|DTx}06~D6 z>}a2U@O?Y6!Tu$aKOl43vR1!7{rCFON>>T?;QHdQSv;?*yTb?)*FNirA27LrIzHX) znU)7IQi1eu-(Xn^(d#jG$|1E|Fb83ErL{b%hwJ}C^n4rLTXeoulv;avI9%VwbApkjahYSeY@r%i$4G*RMd0UdX#2;?K&6dvHfIlpiO zcrYSrb+jI_#|lU`?mPyS5|z_vE*}bBWs_S&dX~`xc{9f3Zf#tDH@?mE6m$Qhk9iz| zFou7uQb&YE=~b+K)cBPQs~qXbx9RU2ggY_Kr93w4S}RP8&0FSWN){S>W#f(3IR8#E zu9by85q(uOJd2-QWSh03Akj{;lYBq`0#`;H<0;>f5-3`km{wCxsNr`|1)r-bMF5|8 zgn8nogz-sNhLS=LFHe!QNs78Jb`dVjXqdYXY%2OG z>L;IK>-m&)$(k}%Vo9(h=AQK=-#2xa$nB86G0PxQEC+)|&B4qqK<#LftEy^jbOF!x zyixdz8Fc!5(iHOIuP{adcxXys^@mhM=;4+J&$$?)9mkA!;y$w7mlI2Vq_!V)5(gfB z3z#ECaG6L?aA1iZcew)u8IP=kT8xV0he4Fbqj+ET2`rKfvWYP&41O-urR&x21HTSJ z4E{zIdG4w`)vT5VJ75(ZzeH1e=i)vOS$vj2TY*ucZ;{i80KRu|p#u0GZ#P5(eHi+; zG047Cggf8@4wVv{B;dlpi*nwau>0ubm&Jx&GRiVjg=XSFQ}E6ke{0wIP&`>((Z(e^ z<4}7@2txOm$nD#PX$Rp(%}HA+@-$jan&E}<2L`;$t)?p=QafEU_<7hyv0U==GaY0M zR{tPKD+mqQ`p#tY@8{|nEXQA_>C{KKeokUbuMVWr47q_EX{*)FKqeG*buV{0FNpNO z!`TbvBBG_#id*uJZ~gVIDG^e3+OHFT+k%}}&b?lyNH<~}1Kg9e!;4YN;)yKobKjk$ z5SoLDutQnkGpN`OGDhK!nnZXH9P>TZQRai zyUx!^`!N#Em;)cNji@}`^~U*PyW+!l*qSo$8#=^%5 zJZg;Xg=@*Olh8Lc;^@NY4m~Dr{VbCi5`xegDwFBT%XlF%>f{=Dsl(CFJwZFXQ2CN5 zg@V}e*BZlu|L($riiIXq`JP{S@PKH*IxT4Q< zlGP35*{+6=WGFZB0g)(PxrGl)xMhk5XKZ95cIrXwVc9@CKWqj0{t6k`PIq?~pU z{n#b{>tIxD&ssDw{jI!$Jbs-sdpLi;h0N-*9?Fd+h(MpiyamRzrsBsY`RXo1M9ZJ+ zheeL;M&-SMojRp;LO60wm6Ih;V3zS?YL=s$dY*6Oh(N60|5B__fsc%!pE`hYhDo`= zl561ir~ByHr3y?7_dEMQDi)w6@$LIKU&_{vG^ey?ECDM4=rF}|rVmYxuK(RA!k=s@ z>$jtU&)FIfL*}CEK+{%CClEw8ab&c}8zW$)Gt8v&n0OQm2LK04NOMABfGcyzaze8A zUPrXHd2@~5gtFFuvBf`N;V)PxpH4nA#1sd~$P^8ZdeE{NG%Ls)lsko3$^=`=sIl;$8WT@WN8H z`>qMP!j?^_dPc7|pf-1sqHYex0^k;`jPAFo{t^n;>)J%-uYcXHi!e@&UPFk4Sxitf zgNcNJ$~*HeGMfmzP`R!b|HDPvV9WzJ&JJ)T6vTS{55y$?xlSf^6kp5G)&CbHUNRdl z-nQ}NU#|9$g!PUlp-4kdSv|{sC|_t-ZKAalNX>ZAZrAeJB5H{Xw<2kXgKtney{c7l z6~A7}nc7*$LG{wn#!tf`{RyG&;ftTr8{ zyA5ztQm9g0n!y&&2*~}cKrlact>jUMc(&GGnY7N!-;T^6TG7ux5Sy7<4C5?0RsKVGZO)TTVp+C!k9)35{bG%=WiOL z3^eXM$TxBOu0H!6bjc}}&oO7t@Q6d&mD#CX*FUEBr65iC@|70xH1nR`LFX)-Ji`Rb zqerd+fRT;`;<`|R!3q}dM@s|;2%&e6 zfhV%4;_LBPLQmT z%4zya3FH4=}R!L zB50hC^6gPxf~eCZ4GIfclMM9?KqDUtq1d!P*-^x7{_|tNA`b8&p<*l+(@UpHEdIMX)Ue$g`>4S1(hsC$W^}9WHsvDZzBF7rYiS=H<4w zJh2C!^PkSOwBoUEG3FVEbFOlkml0O;H0be`11s`1zJSb&Aiwv0zF07hGvi-rykqM& zz{+}a+FTyw3W1KmpN2e*BAxk*|YvuWoD@kLWx@*lf%`OZZRjw`1fsas!hI2)| zUWsA(_*#K@+D)okfSl%Wo#FpEn!U#VioFCtxjW&#NuA&sjO~o9KiRd*u-Yh_P=`cW|)e40LB;wjPWU& z`|c6p-YzZmf@1jDw&f)NYrWQHM+JGMr;(6i0M&=|+>pPIc=4-yDmy?Xe7Cie4w1os zbW9fJTE0Z;S& zzK|s3x>if}E$rPXWkv7>a}57xtkGMw?LkUAE4(~6Lilwx z`uX~v#wO*~jrbAKP&e|fLiH2M0bWer8LM@!w*7n>k<9+j6DZM14b(cG1wkCg2gd`Y zWa?>aTeVDi>MhSR;-vRlNt-{l+(53COD?n_9^-|4;F#)jxlvH18`hcnJ7B1-b#-mh znSNuDinHT==Ap+S?>kCylyRoI;M(@S9+mJl{czZA!|Ne|b9O}C@0sJjHE6_listw= zc#MlH0&WC9b}EGTMcsb3cf+#I?IQ=3w`8+T?fc-^$Q{e<&Q1HVGte9|ii8KeOILt0 zj;?bD6MgE?D39LXVPa#72FngZqxTYVt8SnM@ymWSRta(luGHc z`U4b_F9PWe|9au5spWvRdzvY&6R#TI^+dlEKHc@CQci*<;g}flp^KQWpX|U$I8da+ zKMfumzG-p9#Ayfl27=F>XN}sYv-ft-jk@Gtj8{L8V{NXhspmB>Q67AC=`Ar6bpaf& zG_6nKj1bL^sibdB_9o&e={SJGGMcHQ@dY(np%L(VA>>L0PDD4Cf4d%)Ak^U(pX}AY z0Cc9A-Y*k*Q;uM z894h;zG%*ftzziK*&$swhX?y}{YDyrbiZ6p!t(OM!}N>2DhDi-UBY zUeU4HVWfJ*foNua_Ib3a2MR(FmOTIt5Yg*JkJ!biOZDRw^8wh|#MoodF%$D{AX#h3 zD-;i2B)ciM3;f<&DcC0NpAN!ZR5~suV2H=#3p(2_7P8qOwP#h;k8s4)g^hVk6IGn* zJ-(p3lA0UZ9vq$;nOZ^iUOq>pudP6r)SY&C%7gaxW*f=TLC?hBLe!d0zS|O6cS#V! zMbzgVcS&64R$!LN{XESB6%?2+wIkzs-?pAq_H5x(-m$h}lPKF36GKFXDvZ9Pf~Y4p zh_S;-{I-7#yNB;}-b%mJpE{iip$c_Heem*!GanBX-}3(BgqLjuWkPvbHcn*|qlPUJ zoh{<^@EpN>!_}V3@U^bXx@@rrZeTVC!Zt)7IRomQQT21x#VCIx&Nw4uy}LiFL7t^0 z+-*}$YT6^-ol!mdq(Q?Np?Q&9Kz@BXN4n5Z;F(_KDi53zo~oEv7z8ZQdI=QIZq2m| zbMI|j2ihvhL!OKtESea&(l{ax>`@tA@%HLhnYfq}#&W3L5Q89fQ}zySkYd`Y6(U&Q z^U==6@SMXGx%%I@@WXw1fX}}zhMLstzfzrat z#Rqhq6|&61Yh-0C_tCoHm}NeiwgAWbSbwzyUZpqJGC}sCy7+JZ+)R_Yz*m)d%)PU+ zN11<9qRvb*+9dJ`;M14Bxx|!sM+hb;R!u-?tgxh0Vav|p=j;J7Cqa4-^vz0dpVSy+zz_@70o%1)noLJ5f zE@?t6I}8_*R?TCcZ6+aGH_MCm(8?-3$)~Gq?A>YwA|;>xz{f7%blfSvpftK~vI)OW zv(qnCm>bunoTQ8zgZJjSQvQ3RY(3m?GgfH`{rE3JH34s+d^r|pF;6Dn1owd^dM^w{ z80PT_dyeQE#5WwZCljZQk40uhMF;Hr$Jxm8pq6NotsX_swjB{aG|z%RDa0yu=hCjM>u`KF|p+GSDMJ_bov6LjJzZ_RoNhI`QJ=$PZOS?vQ!mkyZ>$b zXSfv$vb;QjPS<~PwWnRTD&-8!wKGe~;q3x-?-|oSD`nb8SJ+Enjpn(v*xfjNX|4=% zow!Q-H*~xV3?0`38kw|B^o+Vq13qn`I+5Y4T}DAl#TmymYi9w|#y=e?YR-fjUfy2q zJv|)?!(O9rX;(VUk?&kH;1pP>XKK?Bwff5f)Xe7Kky);;|BPqQ{t<^QrB|GBGhy$| zE_FqKb2ZYv6ws*f7g)3l<3L1oog$ZPiS?C@^CG z&zlSYZ|bteaCz0DX?dYn`$wR;>5;?J$Av(*Xvzz#V%X=Yw3c){6(Y9w><}RzAAgG7 zOEvNv3sccas;4nHYnChH|9u%A5F=2`@kj4i`T@fQ?BV;9udd)AK%<5x42eVxT;KUg z&g>n-BjQxRqBHHZ$o+{5&-ay0j{W*(;yx@$lK=MBFI_BT>b|iYIoyW(_eqvgFBO{8 zSCt*@1wk%#m3yX&YPI_BM}}#Kdu&g+jXcm=0#ika8wEzQ+KHT@WIX3o!O+1yneUlu z;n+DQq1j;NzQaunW>=sM_R6jL2*(N)ZPmC?-sKN%V_8RxATukDg-GL{bQ8lL@?LB3 zjV*jT7`E)#NL)0Aa9sGuaJDkX4;N3C9V=%TQ**!v^~~D@)LJ-8;U5fPP2Su#rE{SP z^2Mpjiqw~?Z61Gi0!$Fg4vd=~jFj)w3oa6M$8z9D!7B(|t9)hu>Bm0Mok#i#agTSj zC3y?+l6MpgW$hx36hIvXL$;YESGv)h=z*H69DoUwbz@7VbJC@U#vyQu3v&i%7Go_U z)HVjTiOk)kY_7bWtMo9^eLEqsvULpl)AVnq8kXFeSI;`~gW*#JLB}x?R&J6-Zp*8l zlH)CdTS`6Fi5FsynsyU{>5pdt7j;34zfv5?6dXC=7INn0Ygw3e;xvWCN1qxCIc8WA z-V+tT;;ygh)u&uIbkbxsm`0+r%2f5MlAh*>b*w@@YZ$JqJcRz@HC&I#zw-CsJ;%N23uTG>y?_dgEOR#} zZ!L@Y@QI&1j#mGb1m-Cr%bkLQe?x!qb?Mz0GMTF*=38XmTjy}2m|(ThtKS$o>8b;a z(S6p4u~;dR!L*MNFyl%W9@!cIA=f$t{O#ZY<}? zEvG9eNAARx#kGCehO=d(%w~ye?^5F|Z?EY1u7QGzX0D?0>;|N-M|wBna(Y;mIe|IH z+Gm*ns{J1%!s+jtZWm}UE+1ddFbX9W+SF(h$ah#@`*W0G|KHnoK8TGQ=fw2HaZ5Xo zBkWJ`N&qW=z=;&VIS?JoGS@apr)BdE)41i4KWQzapAh8RBzE`CL?)6|-{IeG>Al ze(@oCe!8+-Tht|v5R3b0#`iVp7x8d_mHx6Q@%$Qk?z)A`|28?2o$@s>PtPCKWbkeL zrlCZ^a5~q|{_OmnxY5MVYlYxX%Y=mEL!`M>7(w=L2N}Hv8cf%ksZMIR4vA=YwH`BlQVbH3Z5?1-z~slGkp<>Xpki9K#IVN0 zyv*6jqHzXg7zyR^%r(8mf(yqi^|~C%EE1p0R2g$l=BQ!VHv!2uydxgD$JmGaQ0#hb zXr*I#7n3fq-s3egfFS8g!pH(J+C~rh==a1kagU{C=!4RHT!fWSr*qEjz608Q{j8u& zhXRN8=v=5W&sD&xw4>iP$er->iTmn=->dtuS@e(%;xr1PLsG0Z6r?f)31T02dy5SR zK8!j!3#m50=-g)-Z+Z^jPQH5>%y<0J}}zp_fI>vK8;DEXeUTPmI@AE6vP(J-5;5qq2cJ zx6=?8$$&ctX;k3%ZJfFdtXVdMGS1O@69AVy7QWN0ZVpM*OXnc{L4ZF=FW?6%Udf7JFUzkS;+6pE zy~~!RJUO&=*)#h=euvZGTScI=Es};3SOceFWA)G9sV}e$+o${7Wy8uVrIT5Lm|?!6 z{&ypX7Hyv~2i9DFu65O`lx_;xK1!mfcba2ZoVdQoa2*P8RHyxSi^OOK9@~)E z>KRQoMEk4J85)SoF+t*A=rnG482uMI@%{^)KH7A7usd-2M~7|jHkPE-I(qm-pY7>C zsYU4wEj_wr|5L{Ni7Tfez^b{_`dY+e#KJEQz|f1QhVUi1)_M?BS9=0vbIs%Q@L3Yz7<3~~yV*wx!%0$wT2lAjR{>2|*0z!lnM<+$) zc0wk-YVGWdt%)4DjTO)_A0g@q7>+r=WUD>!MQN@AfZC(|P2+lX$?n0krq?QmK^33b zo*ba|0En$<*qU;WM*9EO?YH)gWrRB^@={8Y>yTPDJICEG`X7m?Ij}8X0|GiMy#8I& zo)nL@0;{Ptm^M1lO)qCXi7XsIW_PA;=hAi#)|LgBHh_+&PEShyncjuO6)%*ytjEh^ zE|}ff>t5`i>AC(hJ$qOTL?xe}M3_rMRRvCh>Vzut5aS{OF_&+V3!tI|+463Df<8$Q zm7rEFH}Hm|M(ese)a)Bdj{z5j7v zYWd5C%t3C#b{H0iw--(TNfc)j_kYHV`xG!%6JKKcrIKIhQOUmZP!s8hACuV=NZNKi zs+VxQegMF5ih$JTc9a3uKb=1>-dbNw80REbD--OZmKwPwG|*t z%&po4AWEUFIVZ}lH&{C^YelktHcpJe=mWS!S#lv$0-gbs%{(9~h!_`@QQ(-|{JU$#$vIqObap1T{$f68jg*c^ z>y5=pf8})VzpG77fU8ZqY|C}ATmd-XR&!==|;c(B^rPSGSw!5_+ z%j-vrfm)i2USir682-iduJOKhLqPnFivr(`tAhHkIAm%Y;P2bYuT1&a7Y&cu(&#v* z^gL|>B%W5UMiwv)^JWIkmxGK+dnP==IFD|klgllGNJR{Hw%8H&Yk|(RrGu8U(N=XX zq~X1dYNutOgOw8clP@;oZb;5LM!5;=3HN6u$xblN6Hz{+hKRv%?fg8q-K{E*z2IuB z1+@c2mtq02SzD^}4kd_R=@smlQ7hqT=TX^Ymx(|<>u#inz$I8uMc+R$9OzU1dQ9+? z!rRB8-lzROJ71YHTprTpmIFBOHMyKzIRjd9(YIk>*5JYsMNO3v+la5kesTm^Hj8?} zVxK=Y2|`pIkteX&7|KB%DnOVY~D!I~O6Us_VZ z--?(2H6EF-EoxlWk%dRA!fh6C&WW#oaa_mB+ZYRCOZRzSTUaMY^IH*K110|GIf)=o z$$1n3m8yQQPZC{}0}mhdHHS^)gQ-;_!gWt%CMP!GHEhjgF6;5J^b_nJRZ}iZF)rA-;$j7Au z-3vH(Ml+@14~Z-)`vC}<6#2T}4HcQ7oqCQbEBYu8%I-Nq;H&HF!D~Zt zob%i&;_LGFrI=WlLwpXKd6{;2HgQ99{56t|Bw(&n@+ie}7Bussp?~K3+9G2bdVIgx z2PLhJn5X1jLZJT#;4cL}=V(xajEk;=uiAy;enQwn0dR2UR4M%3U%(PG7nP6_^^5-cX1IuyECbe{TSVgf4h}{O6v)VnzauM1pI=PsFKNcMTr^v=4L0*@ zE3D{Rw|@J7_dm>RB&9J?r(<%(E=w7t11|IbuyvL}aW&oA27-hnxCVC;+#zVt;O-jS z-DQB_ZoxIUySrPk;4-*71Q-Sh@a;U$`<^id;SQ8nGYyZ7$yd#&qUTOC^Gj5?|% z-OIl8Xv2`5s}hnPGa8zN$g6kv*xcT9Cgr4zOChYQ%A@C8ADTaMjkEOPrL8zdjD2Gq>L(Ij^0vIB$BjaL!A> z?X(34ys_R@QSDsSOyD$XXU^$&@8U6j_3lZ{YrL-(i*zby)%5;zHHQ0gHg0l zo`9$dsv`bub6Tc{EUtX@S_!JGaTFRxzwWb);ChNZB)n~;iL=L_=Nrtb~-U%et5N&yDFHOja$};yRoz_FA#w7$W8JT z8#@-rJ8VZNz=$^Amx*Tigib1SfokfaDP%W4jdtZ1u-2n$xu#v<(QEQXoyHaor5$#6 z$bSt+czaDbY@9FtTR5GRd8vtK5y~aPZfxaq>jD;;hWROSji#u=%-$2k8PvIv(=DZ=n)jEBSRX9Q~_}@l5IN*PccFr~b zG1}P&9EAX*oit~!`FE*Y3`0OxR13o)Z?tsq@k%ybd z7crmTcFC2O>$Q4f)duUGp#ZEL;|5;D4wjX0Ybr&v<~s560i7IrX+a29qyiF($;zVP}NC0)N5EXVANsPz51G`Qhh)GI2Z@S474Z(wD?EX z-sD9J*bS?+oJfG&B?pq)?PW(2_Yp70b%t`sb-NI=yu`Du%;Nk4Ql|@zQ_=ncG=;K% zeQn|dl@ye;sYWmP#{c?Z+`#VtZRVzTUGr3{Pg3C^8V6)wLB?dLCBQXPe+n4{4JR~D zSVgvj?pyTe5>*)#4^i|rkGv40ugqrCsrN7dTa!Huv~1!%$L3RopJ*34gZq^a-(EdU z6qg@vlvQ_q(WCA8y04JfAy8w!Gd|_A?~QMUtbCd*VzM6od3-9v^rq)gV}$Z8yHF41 ziLZg5Xb$h&fYA5)z-27}ic%f0!0_Rk9~a><@RIzFR2A*vNaY47H+Aj2SoS!(Sl#|q ztDX1PX6LuxBTWbXxi4z;Haw!HSic#l1Ax~iueglH&O}Z8uD^O@C|t)duBXJ#la(v2 zgCg`9HGrVO-P&$kWwIVBaoxsJKsX@1@|#^U@u=*9PJ-mv;WyF;aL!yP$B zLk{jcWDM2r)?rG})FA6VG)ghk)LT#gxWU^VdwfD0)FACikCV+f${u@dp!ZpGc2+cBw zsx)gnSC2h8d8=~Qf{E|NZ@lguyP3Gh{svma{T@liNBGp5n(g$oBtO-K0?^nABY#wf z*u94gH3tw9(xC(JOoVFN&Idt$IF4JVuVX&DY!jV>97FoM99*5^skL~>?njIXUA5e~ zjA+_nQT0paxi9Ap21(O0NeOte@OJU`a|AO&xh%&N6kNM#$^V-9#O>T}P0=kdr4v(d zk>wQstR^K~jtmNq7dS5$6&0k+dB4lrvd?Q-BU3=yCkvSOYOYR0crp}5q;m;-5%w;EFA6>T&gAf31DuLdVWL&b$7G|_3|mPJynqPNi;E8qgrl4 zSh|d$eK7ic1L^Koyx+bjnumv(?)lE+zq{9WM#ayMi{xZat>drw*4sOzQNhTHIQ!lJ zYu%j1F?Ztlu^@%r>QaE`|K_N$`6Qk?B1SK&&KqKo)2r%8YEET-HCpNnREk+b7GkJs zj?I8<)jNjlei69Tx4eAo9DiAw@Ngh2`Ezq^5`brcFlO|i_Q)?hMYUMDp5t0bMcDW@ zaJOw!(B_6wj}0yok2~RTe@@ki>? zNR3iU`AYuH#y(tfll$E{@^~4`0IhVt-CQ=SR@8XGTqs8vA8@~E`1TIHSh5aCMq@yv zpOfs06Nfu@_%-y-y7!I$=7=}}vR#ZTK?S8Uu8G77GG#p=ppJv8twn5zcNyeOwx!KH z9b2`N3}S)3nWX#irsH9N`El*|+R{M%J85@iOqa#2K#88H0#?=%U8T`}0+1mFDRu#GT$IjS5b`JY)&MtTWCd zus+syUpj?`fppe{VlvO9sKgFHN5?6sVFJD%eO`JKa{jOENki7B$ZRwAIPmSgn!KQ*55f^M^|CLMfwWfd-zfz!Q zJ2C>Ld%)a4u2f$>VW@*QWn%XZjZLl?VHgFX- z!-6%ngsDY#fD;PtVRPej%#WN&iHsZD2IR`D8ZZBX$DeKprjT%}F&Xwp@4x7=e(>zN zzUC`_W&C;6%dHqKLgYsbL8DW`Ry~&W32lh%_ouQ~%KDm2RtZ;IIKX+Z4OA}1&1O%)@~v1u6^$B(mZoGgOXYr_Fe)s89)cXD5K z#W^Z2ZB2D6L+0|wx#*+TDe+fuQ=AW(Xjjg?C|zha^t(tKQRI@MD!+3Wx5{GvGFc&- zu{bki0}kWE+we5A@EmDHN3w5v%TPxB8ApM?r;D(&!P2NOBwGPliEM+}Fz@zVXl4uS z+2kZ`-2YeZjKJh86uVO|)l?ukbYs~}}pU{vsZ$|Mcn4h{4h53L2x(jhr zyGU;ltWf34yfxJ^{OE8#AnrM0V#(#Q+)W`KWK&`T5R=~m!lKvN<3_@kCdyN)aiIo_ zU}o2k=k0sk5au~jZTAni$}VN^p6>VAalYOc-TsPO8!1LwjvnBN840fga>Im~rA?DZ z3s$(CB<+#;B)=Jcy3Lil88SlYzj|(;hVET$c|X~!MoQSbl`|ho5`U^kxUWURBNqaE zaGtwLRWTo7upnyOj{2QUIbc&@=P#Cn6kl{o*^z`oU+9%$6XxT-cPE={{AsC z{HiTO)m$8LYO^7<;kmDWBVwTC7VjV9u8`|Xo8&V6ru)L^Tk1nMIhYKr+uZ0U@vli5 zqJHQ$4ud2H6+%DQTcp=7&@9GG%9tG-GkF(7l^ePunKa7REFX=zd(F|WPhcxJIQLc3 zG%?6sUFXeoCR`*NI~UCK`n-pBL~wh)aLP8n8S2!!YPRhp)wyx<^Qu_Xu{&WZco^?j zN%{i$N`i}XhsSSw3zaq;S4gZn>p(fs()Di_ZVKfX_tw;i$M3gR%Ton%gaVN>c`^!H zN5G|?C`bOzjWN^lB%8W`HA-YKk-{;3&z&rq69HitxJ~WLo&14%5~#Thdl&7U%(npO zi--?kx=3_qhwHS-M`zOOuG*ha>5ef2%3G^G1caHCm0?>za&XXf*Pz-A0fH8j zrmjatdTDAw*Z76PgmR>rkpPN!sa0|5*6JxkyB=vbL;k(pTk4-UxMw{Msv`kgEkm2n zJ*!+}H=JeBKKbR{`W+ozFV~Nen%HQ(0QlAY}9 z-S|&^%Alq&P5|7+)bm8)*5?4h!`Yu3C$drRwX+%u=j}$${4x6`?^1TeKQOU(*(q3s zy0wuxvTzvFH8=*a7}B8V-wPAplx@#%3vsCD9=EEc%roTdl|PaYABbvxSJXB*uePT4 zoi=;lW86GgfLfMdy6 z&21Yg(sSW|(N3ugo8G@@=d}S(*0L>t< zWB|_B^RLE>G*91`lAH<+rsL%EX1%E1J^^!ZnlCG^ba$t~sQFkN()gyfd93nf9}XC3 ziTsYRxJg9`$+@ujUxal_FpG{B9Q`UGvG7uP5J(brMS}w4L@b--k)u}iRCV~YlNLAO zrvIQxT*go50jDU?V+o8j{3$Ni$jj z9LtD6wDlZgp79!-Flk&W*>FWOyppdt-I8b&!6v77$~aUja7|117)ume@-=6KqAJR- zvchJ0WU$bdy1=%~R@djh8#ay~&4AGR^EKFRg}`M3m!Vw%2Ls~~Av8?!QR#Ouog42j z#z5pK{5`MWymCEf!nFfF2BvM1#(~4Uq*BbrV5f8^RyG|Vh~sg#bt7g3m<1>Rq95B2 z*UU+_G#aTllSu{s`Smf=hQynP12dxy`{-JfF;Y5l{Npo!b>vK_l>B+TjDS^gy5-n+ zJ0!90-1>|r2`9QpT8iDz&H%|UQR#AOc}~{c@&{^wt3l{`;5H4JKN0tYfK6|-K+jIs z4w^)Q)!n{o8|I!ySFhxf+Om$ml=#7%Kg^KKES(!(0G+Zau5&M{>15BLwqnWVda?8g zJ$|QETldgI%?T3{+gt#5x*f^-7R&^k0p}*TVME$J4Z*vnuVwy20El=+ykklla@mS4Mj|bl<#v zL0oow=IKeKt@JE=olm)9fBiXrWN9^Y&ZzvNc%yX}KgK>w%xWF-OJE5pq7h%hotM;N z1^TV1K%#wri;T4H#rQ~GEg2ib>BryEo&%$GagWn!D1+t@HlQ_ITAEoS_Jke@D#1a~ znKmoufCJ{5KxQ7m>Yb}{N~`n`tjq{lpNc)qTw^O{g;>{mcj^`e2V+SKN^lBe18pYn8lMt=R1q~+>GK+c37RWCFN_IXmt1D$k} z2;gbrNKfAlYNLt@X0dae@rkNv;{n2rx(Uf+4y7V$h1)?{75T>Lrqkyxtr6IJGji`; z07xYx#ZVnFSY7Ro@YS*>or`-CcY%7A4nfK<&J^^;08mw2Aog$4B)!UPtltv9iTg1| z^ipJ4GZLsUxC-Je5|9@zbjgwlRJnQfrzr%YO<&#ddsY2<>c!^T zOHZne$fqoE3ZO`^*(y|A1wyZH6M?r8g5;7tQ*rTeBJ4!E3|_JOxg3J@UJXH2Y@|!* zb5OE|{|R>U?e>cb8!f|;zT z8J^LylsR2of;IMiHmUp$&;WP)*WXN#qwJDAt5FTXJH2_aLR6z-EC^_cx;6`R&1EGjlLTyN-l1Jq zQ`C~bLu;xwiVk7Toa{>fE!ZC};2%|(`BdV1ys0jeD&Pd{Cq z_&w(^x7)wmcN<2iyax`R-VwmGDH35+e5`uiwOQM?cQ(MM02b!tfNmM^Ds5t?0c0+1HLRy!s3T~Y*k=v3#2FYct949?4svaz6nocY z$Wk>St?^$AWzXM+_my7W4-{Ult5rB(aVK~i-HV@cbysZ`zs#FIu^Od0Dx2nsJ+U%p zL`HUo7wGAhNAKK6OLJ+KG0ebhA3ac z5U$0Sbd3LKzd2SCR@c@!__6Pk{dgNxT2%n828jPH<*za92e=KaEs8##TesdT_dlgf zI6W2`KhE1V`zdl?wt#i8eDi$H42jkmD**0sy+0W^S0%Sl{sg>=;gy7B${rCX`e2gh zF%FS5)q&8`Are@lmKHBiFbl+a0@kQ!Z+TJf`|Yy{R<_ncc~C7<18NUEB+koVu;Lw3 znsw*=dNEz2c&RS#E{|=qSez&+Rw|U6c=#YU)i9*WQtuyEVxy~-jU2#cwkU8~rddzWB5$fO0n={9XEb$^wdh<_4T3!_qollrX{W;lz{0O5bPEyq zi$@jZS{rTY(+lCUX(QiPjR$;-F&!J9%ZBXc7byRNC=XYtQH`cwOuC&UpAV)->~FKR zRDHVpI4XVs^a&d1ANs@_cEI#s`UK#-iVr8YueP7-ABKTYTG>k#ULc}A%km8p@+zrp z;<_ztA;o?k%)uG>uMgdp3vhckcMSkkU(0t9j5znQBYBe4NTE-PhI4ch7bI{U)tVKy zP{oVf+K(v^E+k0}44a5S63dG6AMAr>AQc-4E6QD~rJniAh>CKLLPXa8&6}JMD=-;3 zCJXlO1!*4`y45bbl57ns0je+`T7Bw?UXV9N0XF?#*yQt?WRMFbz?Wt-%k+P6pQ zN)GizPXN(Ag>A#U!SkZQ^q)Ebs(<5ss8kB(6moU(XA^8aQaZzj#DFO>ZY1&9=glti zC4oqRTFs5m2iX%3=gUz`${(DV*xITwc1ln|)Sn$hD(!z_aZApi!C5#UVl;Q7pJL$OZY9%j~iZhXqXB1A7YFT8Y^T>m%EO37e} zq+Wl9L0?v|nEV{$au-0A<2T zP;u#=`dOr^C(pPi+qS^?b6*y3NY@b;Ehop72o1v+|2rK&UPkVd9d}o>?#i)^P;U|z z@!!#Y7n>idTrte*Gez+Xaji17HAxNge}kKy{4|ApL#*8>F^k#}+|lH{rnuBf+=aSU z?dF9_7m!%zF?aNO#Y$JM1Z9jliC(n_?8hzOczD>y<1beE(_~9z~-I$NNOFzPQPp`famRa=KL;59)9Tk7&I*QONeu) zwCpE^h+90 zxlpAxb?&JGZwl;G_;OZs6HdZ*pTAyv^`{L0kJkd9+QQ(Z-Fdt1)}bf+0avXU3_v=I zr|cO%>>uapqK%lhG1~-d6Cu1vZ2+f#XqW%(*BZl?ygO}Y%<2429hekv9_$}+vBsw8 zu@hW+)u7j(^C50;lkKl1tNXQp|2<$)!0?Lt=LitS*IZ{Fkgai>q#;qC0L>yuF-nHE z-t$hda1V#{5GghJe*zA*tF|DM<$pqb{&D8WGO9K8SBT z>*nSNUnWx_u~aCH(Wu452FNgP4dn(3(QRe^49y6nHnz@;r20sgc_Qjud1#NRwIG+?=c@{=>-Rkn_Yfzhcb;m4Q)-DsSvhltqlkF#^;UuS2=#f-z2NYrC2M&ISLIpXCn)6IGH&A#Ez#;L>=D=g$pr6>No3114Je#o&gxNQUE~QK znuY};vkMKW)L)~Bft=bEIKV7Ki|Zo8)Ooutjla6divj@(l*fw8ZK?!%Hg)_D&d>tj z3=RO!&|{nIg?gT&mKAeS9hy9UOcIM$LMz>gI}$F-hKgDOsPE+hQ59WM&i|(E^7Rx; znW{~wsK3l;qG+i_zB6+5SHtbmo#~O5t%U8If{5RU5y+3|gtH9?EPs z4rBE%$qe#Ft-dfzplnzXP&O=d?*CI%ZrF;~+f&tNJ>|tw`(iBAtYQMw6*`Or#-cXm z6W24*VynY*01))XQ1I;kKowTJc=cjewc5m=EcV99m60_6df=fn1v2IUj|{uG-Uk;n zW-ff3iN*TeF&T5xf_?=NXQqCUSh?e}LKmnlr>#g7&!R+x?3&9%0m(ZmohJ#aT*()Y zbWuD8W=0hpu+cepVqdLmHDc~mOo?llU|MJzt3Zd^Yc*KC}{ z_RgPy+rQTHsfC*5Za6-bdhytwASZa;kCYcrtw+G#wSD~g+ffT|JJrp3-zuZi|N8-h zQi`?}niPw>BD0>({M&<(x>zEVuJ0xo2OZ*`sZtrYxYE_i@S_~iOFE^~V2krJ-Mox% z7V-zWxIU83Mj4Fz491DhAJ*w%?aeMh0NSUi#9rgm$$ zA(uAyq6jJJZa)jzS`qhiZtSn-t2mJ2t(8)DmZWG7R6AM;(C7J*3@YdVx7}%rC(eoZ zkbl!Dl`V7ALCTRqvqSeLckn(*Jk%$1m_14yR4itoSV5vO-(IF73UT&L8@2yb4R6a? z*J_j64Ibw*YW?E1Fw{;NkbbR2j4)LOLC|E}OVT{EsMG6}#QJ=qVgXx;)(F=inDi&_ z>iPEkTRMx;KxR zc`q0J7`W=v8hknk1ss&&&Fw2B)(KYZ}&PI zrCmrd_Kq5U8kMNwHt-VeFi0DRPL!@>u&y5GJy|~QJ|C}v_vXiF`EfqqXg-`dz=c14 ze&_A6dK%D8QZ9N~=Cu??emw9lvfK42YkTEG@U~MaAFTDkrCC$RV&%G-Wj5`x(aafn z_&h2Jbz2dEx(Y{SodP=(H8B&LI<_Z?^ECZvq>`$-DKV8ZxW7!Swn!(adp##${&$Ok zeR_`nHgt>5W7Vd7$Fe))Yjd+!_&L21uq9}{oA?>fByX&QM`D6Xd1KkI-edt`B-sMG zxAqyE-L$#eM>v=*h6P9-f<%tw_A?kxry4E(o2i6kDa zrVn*g`&cqPNl857QBihit(b%Q=xgg&)NPfo*IcelSreJxDo@G%ahMQI9u#t-b@8J= zbbTo;lh2oWcOGJ$sVc&u29b*!c|DUj&mElr@@t(dSvc@iw=Iulyl8%mJwvP>Gvi`g z%2ANXjyMr&rJUDAsmoy6;x{h!+Bm8n>?4GVB;R3Ym9h=0F_LlqAs%)uTDhT+p*YnpQ3O<}YVqaBs@`{VZn2s_ zG$}m=n#0|`F@W$$-l7A-=q>Mtw``B0R-g85+JA6W@=)Kkn&=YX$P;KIqFc$wZ8_BI7$&Om7=|V-Rz5HdEr(O!TB!x+dO7ZXpiMV1e3q|5 zX3nv7nh8WZ5$!B9PD@uBj`^N-gABo_OZW}p{wwbIq@&+V2g#T6 zs&ZJ=Y<=y*Z-U$dvAI0HG;(y4&b&O{*F02Li{8y&ozEU$wrEElTrtDOt`G?P6hErx zoU;!xADLhA^_HY)@BD*&5gc+Vw#WV`R`$(1Aq2~W+f{gac<%dJKSCpUdo}QP3JSio zKkq}Q<4&g$Nbnb_nP+d#)-CjdPV-kWmmzd12+QA;%|zS+vBORgKiZ5`DR9#~wm%(M zfhQ;bH0YiA>M*tk_dS|vBzwUXOLVkQ&xYlc4x;i*Ce~lCkt6?ppwE-wZ}~_tFxxO$ zr%)i`lQ|SM7HRr`j@5S}RG589mK<^UFq?`_vMMI#0cye7+9BVP5)jA^(b6G@EDqa$6(0!ftlCnQ6a;w zXKyuk!+gMhS1M18ySjg zYvMq&s!$w-En+cMS}X-|JpKY+M?LZ6T7LJ;d{3v-lj@BKlhEPg+*|W>l-%q{Kc7C# zZoTQXNpdCqi}?4p6JZIu;Zx3vSR53#iMF$TR#`?N%p@kCj zhlE5BCeGG(stJ7N8Ogp5=|DB(b-lpgTCr59n*LT`5Q{=l$B-fG0Dq++khU7X!!Y@R zK7L}#DLVdYZxZpkr<1*(KiM#grCOnUh~HjX0%^7&r*st6p=v!37-{^veng>#>VKL! zs`n~q-3#h0lPFEUIk#enqNeDqe)l$qTFi_0eKLxvri3mwo9qt%6tk!o34{>RCR2NR zfd4)F2#1q>CJ+#(kxIuUV-t81ND3;YHjD+|*k!MEs^x*IxK@7aY%+u=MeetY8aD*m zmx}QT(|i550t}12hKD&WGDZjuuq9X133hZKhai=!FP;L0w8;r3Qkk1|(@`Zgc@nsjr z=f8IM@}uT|oE$c!a$FbornXT2cd!Tt`TXx9y^1$gw>y6NsyVOs`-<0!WkQn;roRXA zDA0DZ3GVWjssOG15n(oe5$35*nSb{QEs>9K@)dM4>RL10b-P2ba=ot$~m5=c|{=s4KEj z_e4^I=JW}^-^>h$)k1o5FHDaQ&>t7@iKc4i)*Y{E%xA}^O!iN@%hKe$|al+S&A0q+yGU5x}dMTioc!~_%$bu13$3Z9D1I(MGh>EcI+>6|iJk2}==q3lv zQ&0}Y+rG+&@LY;9i_U%y2DaZg&!vyZoxjW$6z;%vG#|$wkpoSzpMst_@^UPMZatl~ zU2(KeNZ%o5iD@=u{jFbaJ&l zJC74HM-s->E3_0&{!y3&N{A;SG>?obG{h|ZDFI;($EM6*5{(0z|8R?IGEFS@p$N-l zSuxIZ4uS2O!JKLAL+BmDYbA!g1jP#O$@MkCEr#%bleJP_A3>WKwaeRc%gb5)c}2j? zhLXlRMKAax`gh^GdT_DT)#P02!xNInkO-$ISQOKfxIxv0kz<$IM$MGNfVy}x-RF)OxOdEok237j8_SqVJeP4Fl8Ih_d zLxB|Lb)Z6_`!=4-p21=N);r89$bRZQ69-v5Mk$JN>Qvh2ZZ*HNIVz;QjrKjr`Hq|O zA1V#^J+%;+y*~6p!!$JdAODER54R!kO^K9#w^j^D)p`U4M>v9KvGAYuqyDpp6=`1;R z3#zKsqb!U)4J$>f70dU0D2MmW`&s!R9^($AqT7#MR$d^{A)2=r+GbZy*50IlVuRwS zn8>MAWqpAvW#X==GQBqwbr62scpEMO(eAg2-=FZp+e^SRZCz00%-G&4$kTjus&FFB-l5r&ixohQZD9j$*IUlfejbTmtq&BD)CmHqj7%$|^ zY48DO%T1+JgMM4gg8|hkiYXd%?9P~I@Pqyh`dGj33w|cz$M#pQ-_CXt_STjj!?Wj| zIXhwF*!MzM*K%3Qdm)N-=_QVxKcrP}!?6#U@>s^|S$>LG!cXGNl%}t3I$JHH7{Mk8 zH^3%L-vj@);3R~yeWYcQdha~x6k2#7YSyt5nX{0G1ZrNfBO!S63u?};Wa@4$ z8FZ>1#SOrct|_K#e1oagLy~ICC^a9o7^b)+a(*RL=u`$P{Y>Zf_AuRW=aN)r>n=a@>piFE+Gfo;I4*28$js?6q*#4Ci8hjh1Di zJz^Zgr5bhg5G_<_8fST@m&4O0K46rkSCPew3&C}K(i6%5mvzHu9!bMY&W}9Wk;}b-97E6J=8Sm`D-Rc}yxx`3RqN{Q zB{9#mxM>?FE&iNW({IfizP!{{IwcYaX}*a#XE|m)EYJ{4)b|t<`a?%_o7aHkfy-aL zKDBHtNt@{P4#<0(Ha^7Cy20<6orT~(D9(_G`jv(2j=9<**$ZY0MdT1ypO6xVTlhHk ziB5kr*;bcxCu48C@4bjP+NKKD&4kxQb47wXZzy_|YuRX;BMJGQKe9ui^t>Au<>z!L zRMhnfw$|B&>_;@A3)v=WKB^e0-Tb$ASvvA36kKR3ykiP6)#VuiM-&@{R8blAWX zMWxy?FJ0T0%bRx=xAan!nDx9$2KFify5TXfxGn3%wsk8(EE-92f8JQ4O6i3L=0u*? z7M=W{^BtQXw7;j2J0=Zs>~xUI9#+=qR+}*P#BT*U($x=M5O2nZ5W6%nk*>65&K29J zCkKri^6eX-mP73GZDBh!@(E~?9$?C}Tgc)^ja1{di&l^m%2b!FvCGoArhhO_7b| zsGZ;My~%esBK{saZG9z{O0f)H5hq0?Pn%rX6SYpkicHQsK~)L03OQT4(aAmYjnWi4 z*ls&VqqR?4Ji^AT`j&Th*|Ln_C!ij>sRmI*v!nfb#tcm_fC(NGe&f?S_qy55*xt-K zHo%H_*#U%Snn{EY&Nk~HE9HW(e zIti?tjstZ_79SZG#k(G5$J!O>S@ZN?NH)nYWf`qlCMOaHyV^xDO^N?#yG(H;7CKqB z_7$EnFeIBA>Q~n!v6MSl(n|D@Ffm3@*VXh`%A%hhOa(a5!=pWE$yYOm1oxXjgE3_H z`hg~2-$D(A-}rw8UBU-s#3CH=sTdQCsQhktMJR*HaCdC=z{^)77F`A0Jq|N)JbxYw zVS=KGH7{8qH(A5q5QgvutRte)Z>f@wcOy-~x-ry;7?n`1DfK1KL?M@h;a-A2Uz zJN6KG$=?J~LsrToPCfj*Rokc;&tBKMI@~E^{q`6B+U>>>uD*VIv?af`{xVYR?ZMu% z2tSK>dnn)cH`n5#cngPo-6A~XVT(Cn_`FEEVI`5>(CrXzbEOEU zkAo(521LDUUR(qts$KXO`1-QB+MPQq-JKQEDZIKQn#AjA}|*X#06?|G$f=MC?2GP)mV}?(0#Sr-sAx@)PV&*X~tS9 zB6ZHR&NbB=9}2eF)=~`8gfw-qbaDd^W9UN)U*N(q%S+T2P@beGOO=?GPd!wp?TKzrnE z&So82(=N07X7#g*)%}TKkXz(IdTs4m>M|G>;XPT}5z#M;Lw^a3r)#XjbCa$WA>VaU z?g=_>I-V0}X`h8LW&f#%uhxPYh3s4PT1CBu%9PqU648fg=}X+G2gh=Yz*zGtyJssE zC_T5Zbb%p;#So!az9edkorp4`N7qyc#Um#}-jgLmw$wFA(vvV8lZN-xMptWnoLv`d z4BIWuBnF8;aduyh;@djHAuoARBf}6bB{TsQM$O@D>Sa|H<>c(GDFN{uB%C zp0vph_Ku&P6}!hDKtK99sUr}U7fwVWHI@cho`GvGK0uY;2lUMjKUn4O*!%Y6kWq%} z?DX3O%#8_~N>?89Jl&tb;o0JXj3&>`n7#FE9ezx3Dd8#n)gvTFdCZqWZaU=8x;BLu z3&#CX!+=EzwM2s{3E2E24cW_yb`luTUZXvBKAz;}L+5~NXCQpbc{Oc%0n0&~VA``$ zDXSgh<=Xhd4PpgTqB1bRzLvnm*G4vY$t~P%!0b_Z9)EUvDxOR5$!^OB4&^soocOed za^@@&qJgY=YQrmEKGYUN%jeD9%iJcaA5$JuZ&MEnrF-mZ zO3FV{1FutIR_2T|VK}me@lgbZ!kWsA6N(J6b!0f;@;6TR7FIpFHte8&)uEBh<+G){ z{H-tdfWUm6qTsQ5!FOJF@?#^7%KugHm?967WmL$UJQz1-&Cm&BMjEyVDnU(A z_T{6lN|@6Lw#c^5)}F5S*5=R9pv~^?)xIsCgj6AZ&VROU{W?1hLc&|#ekTl{npf1x z9_D8-ay^;`q6}V0fScK&;>8BpnBXY%2Qx*}NJ12MNy?{c7N!jJv}=+f>M%9CU*;|T zgF1C$(07iR@^w+638p@=YX58jVP_YEX zfk%#=?8DNRPWayapy6GB-Lc(mF-MCi$HxnoNFxUGp90!n zmyy5|0|TgUXzmi*((qkcnYbg6%(;FDjrbp;^;I4Uaj@>l@HnB4;calp+*bYfk}-Jk zGW&C*j9Z?5dUY6Rj>egh=3|tBYk~Q&Hx}03;<kiYrq;;kVQi_eG@*`m)B(K7!nr!nW29%v65$x)JU! zxe3J%IFg29!4o>Jk_CSn{uXKOHb3{(orU+nDoNC9c=l^7bqybW7TFN)sbGZpX`aUr zY6Pv7I&TdY&QpVC@N0QXI8UKotRNj>-wz%`7*9LcpKKzOH^P|9*GikzNT%BDsOw*@ zM6WwA2O#IT{ydjMvSd{Xx!~6bLGrp-oOzJaxv=a~Ih0TQoe0w8o%;)<__ zz*Oo|rpz`KW5pOvj}g^_&Yq(01gRBsGOs1qKISboQ=C8 z*MXG>aYlZ{SFNG}H*d+lrog)Js!~KSwp{t?Y*fueo_J=XDb@X*#_*URO}vqbjW>1z z(5{cp5u+9GcK(v1wHgvtV(;>2#QStAzw~1}rQfQ)JcZ7$o935$`T$ciybY;1F#U!r zWC$Om%@RaFpt%CK8ny!~^ZwTOqs}*PJ^jzVngU8fnk^|kyIU=rF%mtNkMvo^D8D)l zPc(AbQw0#%2tLkDdT-E^9!UgT_NrgL?;Kd^U5rkv<=}Ld;2#j56pm6^BLfm>E_iqj zzSp%kz26F4Np_n1sWu2*)8qh{kxGRXszny$E+eZ{zPk+P#sTu$Vt46}1zF0cf44oI z|7?4wZY*5D3a$+uykG-d| zIeDVAu6=aO!m0PHTHWy$;WP0z(=niDEy@gV*S0j23!j- z!U>@}Nq1mqsM}TJ`WO2xIS=4&*|Qj_33I1PM=MzXRze8U)~|D`?hj|I?J1o*%qguz zy%%iVh~S~h-RNBeUgJY|`)|Ou5dPc;`vhzY;zCMWvZ1BU_7hkFsU=81X8FJ8?x*Q~ z&WWr@i8E)Pn{g2sPQ4C~{e>JLhjt=ik@+uz5A26I_A&bntA zJ38EapcbB{q!s&*18=7XdUxPSl|$WK8ktz?kcv4rdA*3be}5TuMYkJ-k}Wk| z#v1Yl_6dcgH6(EeqjE<5Jz#B@En+lwP~1}iuKzq_^ATL=7ZaOyIXK~2pZ(U-GjTkd+OQ#Kt197E%CA!)o4*9Xo9PtJfLD4DZs z_&?^=@Gpf8370cBf4%PRb;s>Knsj1KmmxY|DEvtQ-LS)^jxXHL;~50xMtaO<4YA{*{A*$S0)z>>UuSVU*Lxps4;Ji&)IrFIroZdUd!k`i zYI*VBPYm?^zvm{S1)%M)P(K)Ah`N8JU~2>{M3_^y^UCl-N)~D#rT4G>;zlBMCAuBbYKCLK2AnLTmy~ z$%GJdKfU+9I9>}--b7gEQ}>j{!*N)C;aSeXlB)2i>i~kzhWi1LW{yh!I(Lf(rfVOJ zjM;D3EAbEg0CT1v(P;SU1CG`ak)}?8NR+fr=sLeYIW)U|Q|osaA*(O^zDjRfUGM`d zLxmg(1j_KA2`kFsrK5ud(6W*4jiyDkz1-GAl~->Lh?DPCfH1G2J(-q}}P z1!-Jcy{22sM;zZR4lIH2M@FZ+mfoDv4$)!C$$D{dQDhvEggd=48KHgj>H~$=M%4$; z9lCA_8LIP@fh8c>EB!1;vg~e$B-t#=$r+#W#8N+#9W2nEk|tF;_!e2is>wT}nv%Ig zQi}tc08dPK^3kx9wl$7L_&vS~>@@!GiB*spc?*f8f{Geu!+50gsqu%d-2!{N4LO|o zYdn;lYvx%VKXE2zf#dOkee+wQVDMgs!XCt+76;=A%RiszM$2oF?jj?GCv1Oi->F7mzB1zcyBHJ4M0OZHR`8R8i zKz2_3#wO1wbMp~_c-Qk+4eRJ)3UcT)>1X%}y=WyPY&Hb#cq25A(9Cx$C{!(}tK#`5 z@At?i9I1fDp%@*snlk9xEg`Ang9yuXZER@y!d_B%E_+BUk}BTmWUC1#%xC2wi2tn@Y%TMK46JXi|#0p#I8` zp_C5hHj^yfN0;v>*|CD-Dy+F%;3O~m8G%L{` z3;*nS(O{kuJL))A^ouD&OOM(U`FjD?cbz|f`5{`$(Vc~Y6d>Getk9MPApp@VR($hZ z>hh^MURu4KcW&pA?1zu6H z@jva4_u1r+dVrHNya~%$O+wcevv(|yAZ$}d4E#;p2M(8=udCda@cc8!Hr(!|;ccUP zAl4|TPfFeIctx$E^)7IztF12Vem)PtI6rnVW|CKCbd)nRq0Bn4^`Eqx_g|2ySV$gc zGnI8=s&?b_s&&|3+e8~>8eHwLNn=W&RU4leJ&o$#yw!ltalLf$JLPG?-|^D=-|g(d zykmq~S79V9$;B?-q4cg}J}1gUU|gMEd}4!Z;~2Ph_9>gQtqUKoHC7KN`g-umA$$a7 zu1pV@c5z{jp=3W&)EuG-f~l5QCMy0$i~U0LVigaVTuIs1q|_@St&RMs=igonKMvi9I|faL6bI z;DwwZ_tc&cb z6!4J0C`z!|)i}$SIVqzbRJWMQ(h5nrTA3p#+gaRZkry=Q)f3U41;&57xTV5G+Q+S3 z#5bA(YJtt&)qG0T2OO!Ij~>IWdx`{oHC^gduvRU|8JRQ}-&2onVL4t|x6UKAbZ=k8 zw2(!$HoG|myx@Dxay`x>Id`c4!}PY2!aSxM@A$zm!4#_7ie=qi$43K_;oXvnd5Ew- z4aed!fDpS(C0Q!kL>Il-w3v7u5tV7dbta`V0W|`lk?km!K!{hsvF6OIdobBkHbJjfrm@9-I z)FIW7?LIxUk7UkSsv3oo6CP@XR5$)vw+XV~+OV&(l$plD_pG^2_XqLN)P<0Ih#9J< z4Ao!7#%TR?82ppzqR($Zz^*yyWRApKW(}E--p`c=2hRi(`gg)}j`sy+>fo~|rsC21 zQOA9JIEn6cgX%;B(vX!_?F27`nS&%+DMbRYWD&O@JML=E{vJ-zYRtU0M%S=6!)Sa+sJ^u3x%GSmw>04Bm`hyCVkPWKvI5?{oVFiKpto)qtVmBVC zDHWj5d5iyXbDiYp1xW_hE6wyYh1dx;@3azi$n3Eax2+wo6E*LGAL2oOQ zp#;D8EAa`7{3USp%I{}hz%{&MVQ_??b3y0 zYUo5TO>qEdY2y(2;bgmd1Z+NA_1u!xY$~Dh1o|{#PMDg4#|R3rXqpZR ziH!Pgz1?lLd#ES=CjLml4i>@sLor#ryL#-A49J&MM2`>~UBhjQvOHxw&bC~20I9-n*zBi8(w}#8oWaNyf_>v= zTEU^8=2+_6eh$)x#wy)s)bo(7FLcR3GI48p)V0(^5scPg-sh}LGts7OpP*F4Bb0>v zvO8YS%J~bozOX1D>VmSKGA1y34?Gt)tBX?*+Jn~m^_v4+%Pr9+ypF>7JjU=5O850p z68MIRD0q-8Tmp7e0wWsaF*vOh45K<4K*wE@av%Uf>vcXi7mG^aP(QMw1e>eGC%u9n zV|%ien}b`_)$9UC`-o={OszxamVhbWeIfFrWkDvv_MTi z57X2gpj-p1`i8=PbwQS#M8R1qa#$Td+re=W>@m$Y!+9FV_yQ|0dDVPv`T z!-A=~K)#(CR?daybJO;&&9APXU$)h+jcO}it|ip&;^(RcX_0kKL$S-9Ah>9E)O;@s zsB@r%C>egG?EPL*OkC1rXKUvm93w0>QrnX>8<`>Vp#LVy&cw1p5EFe&RFLCQDA?eF z3TzgsVXf^i3_Zv zITZWEtmZS*%?|2)ezcb_lg*Im=C<7cRiD`8{u>pq+Pd6mWn`A3mD^duYLRMS8~Cao zB9u_K2;h_{)>Q)}>M!<*wW11tVyV7l*U8bVpCd`iA3>U((8c8}hMLMy0*GlgD`otx z>n}<@Elx`~gRZ}{uI?|KaHIJw60A@ssnny->52dqhAN13w0wIwb$-Dx_$WF&cZefv znK*O@LFjF)l>f%U$-@MyWOQ~3JJ*_Wp$8=~`A!iaCqzHAKAq@;l@HV{zgT8{_}5r)?*GT zRFu;|Eouh;O2*NLRjJU_z$nw0^%8~L|G;eWN(V$xTFN`dEmqJHJP@kSAns%{j=HQO z;>0~(i{+jHS#32CCiEoUN;czm)Yz9ep4_j*;M->`?iAf0c(6iUArH$@5|AfZGCo7m z=`Ng%H6}|XdY#QQ^AErhm{OuN1BMfG4u{PMl7CFRN~x1;&XR0~_L9V(l|S09LKw63 zb#l~wKMU|cW`p@n1ueHlMZ5osQqJDbnNMO4v^Y}09R7A@>1*++|DUs)EiWH>TU+NS z1_PEN!Yr`1S$vQ@(&a@P*C$!T!b?5EHq%=J|c_haK-nuHLa?HWk_ zv@-cWE0wpg(t5K}o(xJoZ&8OzWRl`- zU&X`z?JF4V-@bzDu)+#NMOt8qB@D)ThUK1jf7a_Z8iq26UJt$R0?FWe6vLk31bLVZ<4A)PF0bsEEOtnw8uJihO0d4r8$F^?2=EWO@sNsG=^S0cK$dKr6x4_TEM^ z(kny7Ym5?DNV!6(nI7LulCB6|xEzLrPyD3j9TYobXp`7*>~WIx^>n5j}|C zighFZJNYM_C=%K7d0QsB8@2&Ka#yRo?2bDnt?b&F0(_5bv7a`mzX!sogGB6Mlz^3CVp(GP z};OUmgI-rAl+?I|Q5HV6>hFB!wDKaQ_WN`$xz~5TmUq z{f2fOIkq<|(F;V<_owW-ib(q3dMHT$t!Gf}vvj|IlPM9R`Y&eg*_g_pj1ijZgnk7G zvk0|A8)|!H7|GKr$#t`MlU4QUB6*-Ev8rcR z@gb-I7FX<9Qnc>%TD!s^qW&s13kEj#LtO=m&`gutrrdF?xsD zpHu48;4Rzh1suI0G?|YXV4xOspAqw-1Q%!ri391bQPv0BNdMlb_MAH1R;o%bkN46(Ozlf<*>U$Uh0qKJaLCgkGD|ZJmHEP7iSNT1lF*1%ryYTY2|eTXBASYR5s*;PJ79p7>Jp z=l4|Y4f=`cx02@6m%H1Ulc*WzoIGwxeJzD|&-@L%nSf5~QPERr!UT2w~ z3rA0~x$zQ_J?vIwl+lyQ-EM}_daF3(Z6ucoVu-9Nx3jVE^PW@nfa_AZ?w?Ij9CF(7 zTT}Rfp7noK9+B2Z7b+F?(rW4#f7q_yBcJYWE)M0I&^zvtR_o|vP1hyxxM>$4eMbXK zW*+qK5^ALGJ{=@uci7Ph3ws`-CT}iMMZtFnc7IyMZ}fpakqIxIS=Ynf**K8>=vnY- zp*>0}x9R)P{w4r3*m}$(^zFSnSw#Yhs-_p5hT*KVldRTZ>_ZT$&CX8IAX}F?guVx) zrMdh77kK2fk$kCcQ}MHqJ8kELg5n-yEZ^#&)fSk=Bb2V|$#CMXYYAHD3Ry!L+gx6D zh&jr(g;Rb@geWWE(O#(YwzAUE-Kh&@@{aS?XSe5Kf?vU*P1sXkGmG1AH0Nf*>NM7X z~0gpL8`%A+dEj+Z0yjb5M~S^@{Jcfg9{sDEOg|dqlPG zC%UwSzXHkEdp?2>>3?nY)ssXJwx_QD7-j2vi2*a4khc;h%|b;t6A2yhvyL11wD;9_ zfiNN@!|V&k*z9)?OHAVM88*lTVHEIjJTF=PCv-et(aFt71k|m zv=E4ssQ7hMh&hi#?q?OmIkAK85=oy!WlH2l%e+xhxS+{i*F>Ny7LA|Hl&w^|o)0d4 zUVUPNT;y@!3V@SgSq4sKO0e5FWxMiLfUZX?{5V;|=r)Eq0+zp;v67EWZ&Bw&n2Fm` z5x|XQSyD6yFGTT}5;(STP~E61svc8_u$NAp3B#`6H&)(5o#KArNWM=D+(%l+M_K*5f&Uj*L*&KZ@3>@7VaJPejk>GW%oOx5tlcK& znaeaIap$ZmWBHE3WPyu30aRkawy(|rR3~P`;Z`HQDWk7f{n=JIv|p>*1o6Y$v-GHQkYR z9w_a{1AgV;(vH&iFtMcC9(W56PLpXj6uyoDOWNtF*Z@rFDc}(>Ex4gJ?EjgNmhqv&G7HgJ>yiL%28= zj8O}xt`f-g>@j|o1E-RAgwjWyCllT4zb>Lss7`?UBUL>8w(>4^F;nfS=XmDQ@xJBZ z(QYx$MSXTIGl*8ZMy)Z)r~>2BDO)cAedvG=NSF5!GJv;TRq<6eOg7DY_+|9&Aw_ZN z9?3RmLgq<+l8%MDv*}Y*Ya4k24Tg(+5wb{!J5TPUcGRK}df$+*(eUL0WE1$Z^ zV_>gczeBK9`IY5%wr(;V;7`rh8VTz~TA986iw`0@OYB1iJyu>qJ*t__KoB#yNM5ke zjSAn*ZXp8zN0OEol%mjzC~DOYQmN@!iQ%uvXNzSsbU=dx%iF?Rv^|k2&A?%qn{-gnn~mJ+&g<9_17aN1jYNKJ?z+)dg^0@pB4o-w7C zNfZeQ4lR?dya1mVnR;72LfO^*epVh-6*ht z_Ap+~%nOc%T?nY=3qR|NQ4LwXa}pp0uI++erh&{0U%Vn&@e8-)Zp+dPQnmfL8P7r4 zGTVXvB0F-0&O-9tl`>TCZb9YtYlnqH3%`Kt-4X%;RS4KGHRn3s3nzYv&~7$i9vk!E zH~{qfSkK>IjnLL3HEXYf*mf#8%hJ@JS--mCzFtxQN0y$umBc9Vw>0oaWEg)bm<31w z1wuS)$JVyi7Wf)S;aX~z`tkL+Q2V20fWmb`?C3wZiOESI~Jyl9@I3aTF;PNU#=$g5={aZG^ zcxiBE?VzD7+fC(ax6*?6J96r0_2~7N1iv!7Ap4}a8CD59-Smt!0o<>+WQw{p<7lksk;rOG$;OJTG-L-kZZdq92H zt*QcUFYj_X|FMhzx80fS2jRM*2e_HlZQXdXTboP(m#I6KM4sufOW+8K-d^Wa70-~4 z7O}qyaw7Xyt*er1)sConrsspy^Bye1emd^dgZZ6Mf#5rSy+MT2mG6f#p#EBh7%3~G zMaeXzhQd=um$_lHq{?2<*Al1F%^kD}6N6>9450dR*MpW#2((;X*K-`hjipd_X8yXE z!;hr|d*%`2)3BWz@vJ_tYYCcGr%{r9o>znxbuXxbkDSoqy z>mgWrG2?#!$W`&_<^p&eb)g~^`EK}qO`={lD(9|w^fH+XvDiYf#;qBm#F;Y^r(nb} z)>5k((93yVg4Xco;MlOGlPrfOehkD!{R+D7KQsns+C4=ZkWOFA|nNt%=Z(+TX_kZk7b4kskkpaOt^Q} z#v`8=5@2e9|IY&a{~z;T%`B3i%N9JLtxKNQHw&1tEykxYplrtqVVh=x$*g&>68B!r znvPdL0NF^`qC8F?FLjgQv2Bnw*L!QkWt2Vzzs1FN5f>!C)Uoz0;oF!gRh}*E^(W}l zaLx&TO-ULcLcLIk>qA%rtOEdjtbNZRw~#`8`gnXWY^?o^vE-#`Z+~m%KP7tmzb zRu0Eh{a{$|FYB%{#CrZ@V!XhijX3~^mhrK#96zK}v)m$& z68L=x7Q=#)05Jk|2&_$_WXOKO0-IAd)lN1B)@!uPQe*`A@})#DGjf^(e3+S1g&p&l zbVqDT(UOFH01=zQ_XHss3_E@xWKpoedJ9`s6*eBqp2+P-R z0Zbu7rq_|1kOk)`&G-*L?$nei=LP66REsbYMZNt?H6=H^P6 zkC&tG9#n4k`v}zDZVAvFn_oOi?JAVw-WXITaKF{$N?zDvO-lW zu|kc``R=SWi?9NBJFsVwxmaG9*5i|H%d>*(y6SxwXSs+&yRng&gO4J>{^J@Q1W891 z6J`^t_|)}Wo+^!!GaSSqqVi@I^C4uV({Q8!#Y0|zaS0R;$J;fH=Xd4K(JmP?35US7_1L)yr zC*PfOT8rI~C8sEWQkf~kc}t4%q*6f9YfRyU@(gQo2^H>LntR50u1ijX#cv0Jc7S<% z?pfp_HjSYj^CLL`!I4s9!~Ig7ceAmTVdlK*1k zm4F~~Pk3QLrytTng7MA83?ar989yVGUC%uMp-~B)M20mpCozkCQo}cA`=748E z{$y33cOu^!+T3rw77A>jz2Pf*eLPCSspu-b(S5WTzTLVGb~m(!%q;hT=-Q4^yLstq zu3#u?Fi{jKX8X@Zk3ZLa*AHkb`>w8x?J2YYGM*`E@0gY>6 z1ZvZ46EGEEIorsh8KLu9UYEa|BPr7n_s5VDwnD`g6N?tc4$?0&Wxy;d1T!NFEZ(83 zX9{?9Je`Q>Qf76OBj|6efX4Yor~hI@Ko)3@{ixpFMmjAti#=;sVX zsB70~o_wBuDLWVl3>FC2r{no(BaOkAQ^b-rWw@D5fvbocCNTsX{AJoD_}Q#;#ikFj zA*ywz_{Tsx5yAUQ>C2yB0@OH0NG{OCTf96bn(ysXK*7sz>3sZgRJftYcSbqqv+cX! zP~ZPPrP=-C+Ra4L!kQFKF}yx)@$u@HVgBH-1<{Oi_jqrnAI@bersxx5tEx~|XcpWb zSxaQBn1~_x{oe0^Kf-+l$n#$X>MRWO3zp-#*e-cKs zZ=R($G;QXI^RD|^MY%SgD$g-zX1-ZbMJmvi(((@K7NhsC^ZS+Zx+8~(7T-X+nh3iU zcMS#1EF~LM(Rto0uX^oww)#9Zx}myBe4~$@0_lV;AI!Rmb)UOEstD z4>5O0wm{>yGn?L;Ep&IT@So!6^eXWWHgA34`+MXs?DRxCsXX9&O3>TMsT}-iAF)*N zvGn0(|MIZ0%e{X2laDTb-zxN&P2)^YO|wf`hfg2#)&{#Y{Y_@+_04tpW=JvSqf0Q^ z+95+K&fNo+=9)+2M$I_W7q4{KwcVUtgHV*aU!R{S#6I!gb!e;ws4dg}{AQ9RP%2^a zuF04CqgRu%38Rvefj%4aNbZsmb=0SYWdvhuQjg0v1(Ph7eQWdJofjo9wPT2G_JfY! zt23gRLUWjV!sQPiyh>UZjar>Mwe@Q)3Cg$E*lAD4PhU$lG82{s!e6Bl8U;FAy>PT_ zI0!jTIRbRwNsV6muxJJx6OA9jAH+-9vU^C_hL$Ph3}9b zx@H_05yk>6z5~88Z8Q(!X%DHkJ!g{XDT%goxs6COwn5{qUi_7Q84|Aci6-44nrxlQ z`Q*sQXLy}xp<#EgBJ@K)&E|51!UN*Jr~cP3wn%b_H^IRNNI)dmd{UNULtN?95@?0x zCuH9kMC(McUVXW!9A@x4J?_&&})&+}MX-$Z*)Qq``E!6vb(f3@WW~ z6FNgQ;Eb>9kX#X_m9p9S?SMer&4beSh>nFXVmI>_C+v48w_lS&HJPPfk~PeuZgbX( zYl@TraHBI|5C|`WvfnTIVPiSqSsKJ^(?rc!a!F%#^)A>2neX{PZ&SGN7;c095c1^6 zY{MJpW}q-ry?i{B&l&n-qViUko-vL5QVz{w5Kdv|9c9!%6p9P4PVe-_X zdqPeg&@@^Oh0FI4KyyIlnU8>j&}By0_VIxJ&dP!NV4h#m;0e|?!+5BC7BJ#Pd`DFv zp>zJQ%%-wm!B#j$_H$vGefu6e{HyKce8l>Q05Jw}hL?v6t^ZJTECVymPi!f&H>)^=qehf%*$AV8RgbvWeBKknQ zAM!X)OPpgjJ>yinx%|#y?XlkD|IO#l0=C5$q2tfY;^E<3W2H?()J7LPKi*AL*YZ?j zCq!9>rOnGv2B<_W`19lx{cq+NJHOmffFwe2Nzew8DdD5jD~0+Emza%0xb3feUIS4B z;XzZ?yK?F12xr7j^gbQv=lA9G=KtKTRWSoBMb1H0PCD#Q8NYdwnI-i z$xqlFxjE5qt3bK|fc3(cKRfo0FugbLUxA1CDnl)zxkx zhRkkmq9NR$^A!SC8jIV{WaWX-rg#{^Q1d_?dZ@i`wDYZ`*r`A+?Kjjk3t_KL$o)fY z3L_!!EAWFY%?_f~Y@iB)A+dqm#dw#e|70yuF!I&1lM0eKq?gy15F7HVf$$aV($ylF zV@(!Ssppm&zHyRm8AAZIyFtLA38_vmA*PZ@rCOSG2793Oi_Th#QuyhvHwxMLd(vRlkCcZx6Xs$cztQw~vX7d2Fk6R+2i8fRR6-;_bP72rGZehfltp|I5OshwVSC@1xdYo>{##&L3)SAOYGr0K z^TQKF3ZNVl=s(bd-w`|V&w@m%!|CVY0Z0-(-kKP%&D@qZi1kl(%cuP8ChFcsZ8*C?nDx#eNByf} zL%T!(5VgKn0hfhyF2Al6D)?DWjLplYMRA>lOd@%lG7_;LZNXhYd;uua0qA@b&=-!M zESOop}`IRRv3&kGFPb1hvN3Mu*p& zZ*6rr$TL?ee=0xg2B61-q#u$~j5{r3C?#^1gqq&upt?*%rG;2*Z!LemZ9)#S4w-05 zo|X<=WtB?mtIkeyaQ$19bFi^MUzX@~;I?4H*C?efC;Ho#Jw)Y}@fh#RJkGP@R)RVF zd8Nw#GX*acwIeT7Hajm=G1W>H^8iPgL;dQyh0^uG5YQL@ur^7Z9knpZdgZlfId3A@ zrZ=jdwk7}k4QH^hM5uB|wQTL9`CybjgRnP1&b!E6g!u#Huzv*5v=sGAtGw;D72cl_ zMn6IL1E$pL?a~F9Qnha8&^9_vtZwzrM#2;S{ZFTgf`?<#lDp1gm$HplvOhe~RYd*v z2m_siZ>&(BSu#VD%2cNJ<*fDbn_! z=81i)JVqnGDzDS#|BIr`#YIOD$Um-&D+v2)RZcbKY%tn9uTLKBmlqEl0Z>=ov(I;6 zLtpm9gi#gu$k>2$*dF5xr8!U#9mAhiotwSv=Bha&{f5e_*AfDUQNQ>>%0@*o|MH8z zp{WOFCDo14#Er8Kxc%!yfrHLe_GOCLm4H39s&Lq^D^ZNTKW^lvhmkC?5;$3H$-gx- zh2U&}WT@@Bn2N%z>5yy`bnL>3$|Ap1$wl^F*JpqFH`KA%N6&F~%^Pf`SXSck6oHu6 z>As{9@SZ>>!4uJq(Ar$)48+r#HOU#E1oc}0O;^!9ospWVD^myhNkIqZ31Z_vhdqCD z*i0SI?MXa%S*PK(UGw6A`jdmiN+2$sBW%3Ir5s`;-6@Il_-b0X)O|OYr~VC^hYpRi zSLzKK&Qh4W=U!Dn(cmTfE(Ik#Ap6b=1+^l7tIx=pH~La?4Qi~oi=Klh2>Et-R29j* z4+w>c#NJ`ScW_QnjEdpMw>8wRYDIiSH__AYIg2V*td4_x!fIrhaE>qaf7vI5b|U*o zOj?x0=`@?yof5YL981AfO?T0EUndGN&aTS#-`ua`qqf0@p0?r z=AY)MyKV~RZaU91z6_Dm$FHsbm+0s;dfAM&Unk7r{}LU2gs@n>d=nl0z>R_^heJ)d z1)x5y_;@Og(rlM3|9VY5qmI*z!dWF_$;z7PqGr&C0N$y=qOiJXHMeDF+p}($0~76E zuP0*Hb^*xJO}oyOvV+O<|Fd6w;<&v0Uq@ z(`;N*mx8^UM)h_@E!=!YvBvs&Hx|vF!~R+MU*WHc2(634C@uJw%D}Yt3QRTLsAn58 zhhGTo;y6U>x9^>d>SvUylNlePH5@&tN;CFuW>o;L+g`zx%2akk3JRRRS;j8$eo-r> z#ewSY!F33f7C(?ln6*#h3{PLZJgkAEre+#PEnC~qadk9|Vtc4NpsU;(iUnO;5x#{w z1z?O|k49e>gnh#c3cVwhO`sA1sFY%j!685-39+`pMqgG5wC2WU!yhW5EsJZy7i?~o@fO#0u z-@E)@e=h}ynaSU{OnfofI(fN7q1de;S_b^q{VL3TZP*AfzW)ijx~9PQO+_dzZHf}R zAB|)~ql(ZBKkGPgr+pte`J80)HW zn)536Sz9IkEirLJ95Zxpaf8>$vhDtCnBQ0{Ot=~i-%A|71t8f?zyl;ZYe&uZEkO3w z61-z7R=(NCE5YDrO#n4sdW#7>)+`I0CJ{sy-n)?#0O*+D<8q(>OvcC9GsN2dn*OJ{GmImpH$hPk44LD{ z&{4GI7w00EFpFHY{=J49Qa~ESRkv@9N|^x>D7EZ4+wz0iX0lRq%z)Z%^}7_-*ky^h zpbZ9z#qsG+MH`~z4{;jK9#~l!M>h>$!Cs!Re^am~C#*(lneGrT*f zTJurGk3JEkP`CPF7BZuxX-EE9X%Ilj1gsPlAY=koipqkUl7wA8N8#P{gV!G4NuW|? zU}fm>p4K|J$*FZ_M^1R_{IUUs;}9nN0rKxJp6+ECpjU)JvVF0FfITWz_-yJvYUZX9 z=I7&Z%3F7k)y$D#MSqjvrvRyf{uaR##DJyO$JV8spmt1T#8K4c<;k_xmQJaT7j2BH zz3Wt$>vn~=PJxR`2S(cPf&!C+w?={QHaT#m`;={qR`a{jyT&nO!;?ymA<5IzW3^r7ex`zmLqe_h_D0+`f3ZN}-Ntg@3k zNrqWvyDfaIB8%DtvaRk1e*5BWs<@tV(mFinv1^MTvpI9!!S7la#a1bPZDh>YAco` zdx_Dt`NB3LR855EDa02N$_koKpIckh{4L^wx}GZYd*sIlW3i*IKH6c@;N_7*@k8af zKa9nJHtkGCKWu!4CjorALpmmTO*7NP_q6=??cu@cXhCDwdELWV_KO*8^sX-<4|jUKX|s0sl&R&ZC!B@!-8WJEk0byfsGCA{ zL*jayzzV($I+LL^GZvO$A$8jBZ3@}mkV0BdH{?M}Q|jgsRF((Ys7`@$&AD~V2*l|F zZ!Y+Lxo~D3c;Us15o7|=dfwN20F71?hGVM7QI{e(1(P-K6s7J>TKw3DfD~a-eh+R7 z!7u|pa?@B*+jH3^A99=`M(hx6Q2TTOH&^;8T2ezc9s7;hS=m`Oa3TRU!qCG9VVLH$ z@6DVtU+nOdhFLe7Iup!dy3;l(20@$^<1Adm-AzqXA5yq_MAKvXQp$q<0f3U6fulKvE?A=w8JqH9XjkZEGaD;=N1Qu!`FcS3pv@WqAn`} zgzQz8UEz``a~Hk19Xk-ajZAedtjrgA?NgIv__61F832I)${}I=!O<(@e9g1fy~rC5 zki=Y*^c-2%d0Jc^I6&g9d)2;1D*JgH;EMF>$VsnGZ#~wV_n>7}??I!{d6D{esDY0x zdqof#xI@=6ztA-Tkg0BxSU8DF5dOmICyiu)Xm8jZDU#YuF`>nCc zt+FLu>j%GT?r~Zk?+%Qr%CAE}dCm7_sHpXwSA-Sj+OjEt(f`pMsufKOI*!4<*S5d} z5I%dvcO8`tQ17Z$_G@#v!iulq)wyD4_xIdu z!Am(&M(>pR6B4HYe+5D(!>aUepMw6yM4T^StnwZ4K)veB#a0Hdcri}E>R zi@*a0Yd7I5A|5~K#A9nA1vSzhyux2!0;RmR7EJ^gUD=~HjhZ~V7rfFzK1GY8vk`Ta z;DhaGK$w0B;f4y3&S>yx?5`O==Nqk6n&1U(Qt36{N#!(`AeiElPAv&j0}7k0x6ZQQ z+(6*9g^V5HTh_w*mxBSyVQp1W8KlI*XHQtZ(d{LaQ5X==$Qc4Oaw3fa6PVBf6n8G& zGmKx2(4XqI%y^Jl1cAHm7Ki1xW_uC6$@(^YM=| zP6<{c&DwExc8=N?SC7=fy%%EFsbrwJg?BWRPvD^Lz zc%Q&*kMXG&#L+l$mli{4y9Pec-(0%3s@f``vN%Z2_SFeBbGK>%HqN^D^#+fxq!=Ns z@$&JtWR}t@#v%zqmy2!n+RUah14@>Vpk%q{-j4cY_5x0GCG;EP_t*Y_SJzJNFoz?T zuFV5AS#X_R+RF@m$I(bErA)n-=NVJkL@A21jC^qj%DIvDBB5D7@QTjFfyY| z!z&DS8O&m=-YBn%#Alxj@z>@hR9CE0DwQcz&)Xq%M~Ic5U)-nVzJ1*-+7bT7Mp?1@ zhj}b{6L#p87~gM&ndJ!Dm&RlY`JLHV8R>7>QpImsvNYWO5AmgUJ{trx@mh~M-|r=# z668?53vM3ZH;dghR{^epD^zHFmS}sHxWbKuQlM-Mt3jJMDa_@UY~@Hd#BB6F6ulKq zJyArIZr=3n6h!pdG!+6%g493N58yZP=1~?vyx9j3Z~mGGh&Quq{f~Gvroq$kX&39h ziFwV(G|HhC2>`UdLg=6o%>7SExkx?Ysn8rN;X@7rY zR^PM%qmEe*tH3UUr=ma*ZAZTIXxYnsE2s|9YR+GU#*zScr^)-19*4fyV8k%|#44^ya&bod27 zTazEoM_t_6+L_L*{~uRx!4PHCHSB_dgbFH1mo!L&bf-v{ba!`mj)WlHAl)t99YabC z-8pm&L-XA}&wIY}p7RH0?R)P%Yp=Z44}}-O0AQKmh%03K6u(Tt)?{nr4+xkg1p=>Jlj;Zp#`xttfE zIJf_!ILG||DbDTo4glu9J@}Q(WbyyV_&c~s_wBzF=g_}?YH|NXMd!n>b*Jh=zAEgs z;)t!)|JWx@58;b@>M$QJbKB@&$+>INMoXAsxcTn6Xk0pQ@#e!0>_ytAoj^%*G0*ks zR3#G1+vtm}!|!#TG*6+(kFcV$gEdqAXOgQ-1Qm8bVeuh&bB;YYZcO=0>8p+TJX2o> zkxK(T>#RbjZmqHAj^xI>heEkow{sBKTOa5fRE#VvaR;Egq#JZ$C8ATtHlf)=T(soh zW{)oL;G<`YLa=pvx%arC$~hcZhA!(UOkMU&Z*SJ=mcg7)%d zmEzWq@!jR=L)m_Uvfng-sW^V%bPl6XCw8FnenyVlqMmG^A)SnNMyvSGVzB|>eYbp2 z)`3#1YS|J~xMPuMF-8!?bKgbY$5_H1*OWpl|@NoAS#;iMt!`nLMuF4*+&!fw_jtHjln#Ad`}Ao26R zTvsMBwx&yB;YZD&r0>_#1NXC(k*ZPMdDjxpG1~*(Tvd#ej#1^{VYjyVDyN@x!%kF*feh9lpq1eqH%j*ZcHmuH^ zG8)4T%|FBc5YA{3WkE!ezX};DBjR$vg<;%h537t-`po)OBqZNS{ZOA8G$QI4?Ct|$ zYz!{58M{`s#AA`ULrsf{wwTht-C0y03Flr15dn3EI+-zyY^xPEd*N-nN}q~>B-eoe zk{Y)4x4R`iM5t{&nN*yW?-c@JTNviQ ziWL+ifWT|6pefz=gwdaOUANZ7&vyQIk9AFoWu!r^{p#CwipwFxBS0P<5`Ad-Awsf1 z9GGVz+7Vp(ugSg*?OPqr$lr3qKVNe#oFt-ZIjoE4f4=e6XS@&pR<~Hawxll+gJ&d^ z+DU&h$aM{Q78Vd2W>3Dg$6~u5i{Q&J?0b5$@*GRdqkMJ7_0167KV=m8iPrMvbNbF0 zpb2=9>~UK(uND^f8%r+uRqQzyNC?hJeAPdmDn${W(k+?-|Lf86qTIZ#)Ejoa*VBXR zsjfGnU%EgwS6!fE+!v&R-@VrJ96qnteL9n->fSYsXpWqXa3u0Sf-ps`9*_akM1gogOxGE2O-3nWt=`y=VKXt;*ni)97LURi7b7VT<|xhCIum)xi6GdNih2VWpzDKT z>nf0za;a}jm7fP3SD6!==MD6DgOPmNrOdcf;5fQJl~b@tDV-?<6`vNneN?6~-|U!M z{q8+)`6~cOHE2{<-S`LzSm{Irwzf5=t%ab>iuUv*uV-H7*9t@~6hN^gPntXNB zvaIrTV5(gYyOdFw9y0$mRH@$iX844$kf4BthVSdHq?^G(y~*<->5Kg(fsEqRl30xQ zmCJHKhGJ@El_6AJSIqrc5@;hi+OPckb=Jil^40K&YX77xp{F%`U%oJ*(2zHuujC5y zw7P?vTD;+Tc6BL1W3|ox)dgO)7~zE1{jZX2S%i(N=_SxnS^PflniOhyzhoB?=AMos zJ32Z#queRiX|k|A8pRFdUi1_~A$q|c&*+uD82zKNDdB$Qx9qEYwU}(FX^s#TK=!-S zvQj|yJB7m1LPJh*{u13GYY~48% zsbtS`fAuist1k^u--r=J3e*$C|15YVC%YvNd+8@17b@Gag@0IyWM*i2{{;riNlLCP z8>qNTn3yV|c0z_9&NgUuc*3s74%hwQ&k?OX%8t(cKYvcI-(q(6_L2|ztGa(=ufMS~ z^i9FmEM3*^5TJDZcrD1-21%<7`rTojZIV9~c1|80>0%`vt(^Cf)k%G$a;isTx^mOX ze>D@M)4%c9;Tc|ZDdsM`;(9~haCVYg87x~P*XuLy`s*%YYyuj>Gy2%{tF7z^du+}% zN}kr07^&V+=|g1Y%X#0HN-@%Ji>?TfN}1NTV82HHa_Gu0i6W&CC0~VwRzg>ORuwGL z@+pRd0wiGefWBeXb}rr$><($x_?|LiA-{YfSfu8y7^yK^`Zm*E&pgi^roJYw;CS&f zS-k6XHQqI8{)I8zVMpi!3@5d;pPTDMx_R>mauF?gCZpwzjMKOx?Rqx@BLxuSPcKt` zVLeJ+PK&K*kIwuC>GtHWP+>^7hqjNswlCOCMi!}G5DbSVOT?AUt_TinCx^DSyf)t3 z$M;dw^Ke(15H7l?%^3mz_%ggp)6(mWqM$f&4i@FzXfijz&Sm~;w8|bJ-janFqI~^k zUG+}7%Vp$O%UJTe&p}Ak2w&i+EKJA2)J%8LC#>TAoZjJGIY#m@|O$ z3YwVJSnACuZRFbS>6EZFIaq0CN#gF%Q3~+-G{&WGxt0O5B`uCVS7IQ7LEUbAd5}^$ zYT4IAV*tR0pY$&AO2)851^3I12S6(*HGdcQwJ~yozKnTtIKw|>D?$aYu77L75x={q{hh$uGFmi9nkc79g zuY``yjCR7X9Jv=l`*M~;xl_P^G4uM|uFW)CY%27O8*tS^V;^3N)3JYUeTSKf-#H!|xkCoI#&0HQ0b7GHVVnI8qew!&U6~7L90!KNkU!WB*iJwvsjO!l6Yg~O2uAG5= z0@fuc?oa>lo&Pqx;FI;W|94kn_AjU1kx@F$#+L41p}bf6`YWyhgk`BE7xuq_PA}-O zJFfBBHKC8VuMncq-ad`6Gv_`{*NVhrh~RQ*HXiR(lpc?q2CtaV`%re~wnPP57#8*b z$5*2%1q3w}hyp-zzeoF>zv&lr$%1zHO${1tRCq1mvsJ;M4N#+affFED(Ug-C$x*G7 zF3_4*!uveCP66dZCofnm$~*gBKD8o2jGSpS78db^qF$W>M^XZ>)dd?gd)KIhwm=gF zH})9xq^ZmQa3(^fn%7L_A48DeRN}T7T%57}kJ-*-6?J&ItS4aKQXy9V@yZXCgm>!{ zuWi|12ZQNP+6McVcKOV*y{efdHK52UjPJ)Z5GTtTYW)N}B969cF7JyhHL!s&_*4_8 z94SYoTs(c#$tRU`eu_e$>!kcCkcdwqKsHs3GwVxK+Pd>=WdJ}qg~x)ZW7QRepXRXN zLtOp2J(IUwc|-f`4D1E@?cBQcV~j#>OTCIg4OqRd{wj-<{f*3J15JX+9R^m#+Dkn^ zN~PCNkuhuwdT{`_db1d>I9f!~&N(G0KHqcXy?4h(x;>O*W;StHEkacuVV60)C#BEXt?s%`6oa)c`u$^f3XO8F zz=${X_v$9J*u=T{QL4o=#;!+rKZhNpk4%0UQi{!vG^V29@nN!Zp1Q7c4NKSz_WabF zEf}vHk)6@=TY5qaF*dY^OiiCS`1pB6XI&p!v_6n;T$(oDwHef1DcDeh>g#;o0|d9} z8xODCkfTFbAvx1mNq0H)JmT^};AHrZGgB`0woG=4Xw5ZK`!3)pJNO3qgqj1zlh+Ou zc^WGm;e(?;8WHi^p=-BH6T5uB!=Ae=FF!BPYz+*rtut;P5|90>M!G~@KbWU-c&ctDIZuHWd`_qO_-w-BGk z>ApbaJoq3>83m_DHhSeAb;J_D5dKiYR`Wx3k&Y3=bchIU>RD-fwK+S84EWw=Oe`uDR@doOuzO zdXAL#~b>i?*x6l2_p3sV(zQplF_0B+g|EnN$KbRj|fd0Dk zv3yaM%_^}FxUpV{)eE^LN2isyAUSu~rZ9iXBb>tmPay%oxyF6QY^6pXz`#(8dE>c* z#eW)ndXKNs2^-fm|e1YW5jYUtIrr3=7e79Z0mr~^xqtM#h zqPapGG3F(QJmE!%+f^qxPcUKTMD4+;La_dJ zSmVn}LA+c>jNfNkr-d)tUVWF>)=M8wJzJEuJnEP_Yv5#Cl}!SOuX|f(;~zcvQrHF9 zb`urO+Ate{DM1MKkJ45f$A*(Gq<&!mqn;iNPu}%i9JphDVQE^yBS;`S|74CeZtl!V>AYfbg{-%spmiQh(UhfJ7eHspqqnxZh1Anc`MC4u&KSyCjsWbrk)cO&oF4szl}ETF<0T+ zL(T3@<-DEzGu(@_B+IUpRNxAP#ivfaU3@f1=LYw8?CKUC>q!_oDx(Lj{2iYULGF>s zRm|M>#n7gYxoff5elN3AHyY@L2Q1ExKRf=UT=&gOwX?NuOJ$((b}(nileu%1L!Txt zPustZ(*6>>J>Qnh6Y9yk#bf=I=~;O>EyKwgU4F())V$;p`ddTgN9PK0-p)p~c15}^ zB)ZiCU!am}cB5%2+F)g=COqqNj~BN-HR&C24N6nSs%f1yA}_$#n~HgR{ZF?l#?SMd zopXnQ2d!51OO@Ms*5*dR413pt8818xbY?Io#S-26MPFgjd%bPtlge9N{OiH4nT0X9 zzx7(HspWTncOjaQ4UNV!`@ehea~<>~JN>>5I3$W2VJcnX^;6q9B=mPr8w{yN7Q@)) zEIp5YIRMtKCbg zxFwZ>`FG=6)|ySVN&Qc009KW%Q6SEC6-C=oo7;o2TN>K*^W^*Qa7PEcmtXT5F@y<# zeqOKrD(sw0dwx1BJE3!@#;TT2#Vu9kr>c>e4MElh80;B3h-{MUoWGi?IA^Ug=DH}j z{PHYJ_%s-czBOfmrDG#wQ!fgoMH+%pXk7hyD$&e|!UeVv3oQXcX9 zThg4!NI5#M%t|?W#4G{<>%x*&cow0N6SsB2x)^nKH$t-Gec)xL&$Ierks0n`cQk&t z)ZddqC5>a_KBR8R5YAsLq*^bfG8c67x{nRO8T6k)FQG<0<+`-%Zq@$)=rs*73M$+; z9HGGqSf+_~<;2A<#r;;I4qveb?wdIPMZE=LlKV7%#>sPJ&DIjrL^D0+`Z4T~SR-Jg z>(R8wp*_To8S9-@o!X~gxo84P@^6p%wpvqAO>wdAty?5mnUj`W>tlzS^+yVUsTST& zV*of>{56XBp@MRxh3|gqH6fDJmmCfc`}YOFjE@A87ETF+Djj+}+&LIzB=XwusDTus zD^N{3_e1BlO45-#pvTsLojsEVv4I&Y=>D4yq4c}PNXh14Y3I_uLk~taX=bnL6;3)@ zcNWWB@6uE%v{w+EpeC&tQDl9`m}#W~?d6L8pjq6MTCKS4Qw z_kNP2ppwyjo5XXZF#CJ+(XZL=I__yhy%SEhB(IIw5cB-uA5&iVMS=l)?C(=dIV%(p zFwCBlNHga2J5_>O&@}`Yl3-IL;Uk;W(``aWB%8EOS#NwIOfAFlanrV3-2OGWE4Oh0 z9>M2+{AJtJ;Jl8GXIxN`mD+u6>t<^$R$^~kaK2DNSukcUZBI(= z<^OJ~_m-u95=1BJy$Wp{?xuO}@bW3W25((J-8mIXj zm#=&RUedQg(n}FeVcolh#ANx-v%!jB?YR@TFSVc1xv}M*!kt`yz#S(9YT_olvjJr= ze3}(_DL5bf5c={KMpHudyf#{c7H#tv@rH*}q)82h#lM5}ab0Zn}rz4)2>p*(jf#tPhJfLOz@dX36H9n+)(X zg>Yy3d#wxtZ0(i!@RK>7SJ$g%vRAx*dzfP|2eVNViviglz8wuaJ~fKx`zY5Lq8SCv ztQ!q>k!mz>V2IuEC)E0?yjMulW(tX>z>r^HIfW`_OZwA{qiB(~)%<_00S$x5=g49l z6hDJV7;-nG^z!d31Ia2H1a{QM7nhR(sYtM1v?NMa^9GqWJN{t#+6@tiN>(|wA$g0> zVk=H{qq=%md83x^JOk-mj5QCs?~`%!ZKj?kDo50f&2|?Dk@ZW~W5&Gjx5&x5ff0Ae zK2a%6KwZ98i(hHq5p+7T{9V*CR)Mv$#)-j<_=LR=TCV?#aqpj`;2HL;ab+AxBxVT= zgl72H#wY;>T7Of2h^bWGDvd>(?yxkO&oglBKs^?M*-X5OF^IlYQDIg4s>0urx_EM7 z&L) z?T0Jd1Z>#MSkR?oi)!lwvlZgnF3_?7GcW`PBLpx5lP2#b9bnAefwINr>H(@iOSY2d ze!gsvIuyq zYT$o<_sp%>A6WJ4(@u#;83#qIUxat`gTf@^>Zxyh6Qw;m2|wGoyCyyhSU!Tu0GsD@ zs}s=2@e7|0^aCG!{0nascj^(sbj&!xxlwWBF(Qf1;4fGi z004g)(uo8D0Qfm_&Tk$zY|@4&3sXb525WlU)J4(z5D)cRhCXY+Sv@u7hLpL!xfKJzD>`97)T>zdwL>!d{=q0l3!Y3;3D73b>nQ6vn z7<)6aVe(^?Z8Fgxdq`HzOZ_cN%E^`nQ_+IPGI@o+?#&?PxB**@2W<6)^^XmwjL8B~ z3lv=H5%hG&h8Se_DGe5>^CN?9Kq>TJiUS|$D0^eG-%7OQ%)MsHcBM;gUi?L4ey+2e z&PpdSZij>q!;3_E!#(9L`9D^Q{_}^gO~8ida!k{V42#5qjoO|}bB=6G0j+a(Yk`9h zR^p!;HP<&&Rp}o-uH1@xX1`mAB*od?l9TTA=5S*G`kZHTG^v%<%s*C{lo{ z@LSx;yA+$S$J2*VrnKC&2GGga#>2KTCV-dpeOaEEA$gtBby?E=^JE`4cNAj&lr{<( zfHWl&_@iH#1Abo{)ZgQ`DWRVC*S)k~Uc1}%KO2O)ybA1nknN)knG}V0Zpi)j?YKxA z6Yco_SP&Ke9}8m4yx=ST1hNczVL%#_|M0BzN0+!3>5tflC*?>Z)L*ZizXQNI%F9o2 z6C3_@70Z(b&OsN+dV@-e$6LL?6%D}9eERU?HlY*gFGnNI$jF9=*ProV8|9|s^%1~U z7PBQyH-j2X%M#n9(U!T09Up-8gT&HURwwd-vNb#*4$H#LH}>(pZmQ;V{+0!0EIRgG zFW#W+GGm1uQn_d=1}dgsBnwASUy1X4={vjGRVk^xO#oa;AhLRqOaj0yfgxak zTaydRF{cL(z)IBeY?b^QQ1(nKz+qb`QsETD+Rc_UuMi#emm`+raz1fHM?L4ys;;X_ zXB2!8y5;m)f8xuS)w5{wK7&j797wBXai(}6SHi{JTWM`+i_J^d79bfh%iJ=z?%t&` z*!e#?c;oBZ&t=bb4kJ#Vm-#q%l$Uifk&m4or4K9DFU8R_f!Sy_*1pgIl_{>dK+Ns? zx!i;&^ZAyUnq%z51;?0*yh6#leztTx*KhrK8q^U2SljJyGY3wGQMY^Xd8c!7*x%a3 z%B22?oFTcWMyfgGXzE48K6)vXdZ5$P={c>vx%jo`&j9OWZmfXPCM+~+nwt>6s!5s5EuW;17X`GQT27{(hH0hqc1Ef;!SORje7|s~{X)^WYtdRB z8B&4afGc7$W?rxKbq=agHWsXiw5>mPU9%bkIzpE4YXHF@^#`0U(SbyA(C`ZzZeO+z z3d7Q)uNMD(;7^tY{Zn~wm{m}osko(&`$jmPWE}9Yl<#ku0duef^aQ?o^VIa$5Ry;_ z;dT=Y6SX5%0A^W~IKIgrwIZT;KS(eroMd(@p304MeG^SvQcDp5obTQC$mi^JPf{C@ z9g00Qw=`qRN_#4>h$%vIVLKsnY5*YspG-{+t704a2C`Kc*V&psM@6sqwbBEg?ehlU z*+$1E+g07d`|)=)i}s&Uvi3}=b}jVZ{}=yJ|qVA+g)FFo09=dwJ~ z*{1G;e~^qPq+-aW9^jAK74+)SPS0^;I17iu1qWo`+1QODiMC{_2wMyh46ZA3+|rE9 zep(%bt4SyNsvT7w;PlVOtqrE6^5U_ppcwyK`R%jWfUJYbzexxwXg#*P0X7z+qd_gZ z;tXs_j)%-yqs31w;5_~BgLmmB(6cFEh-gvD#MMa|7x?jXwr1h&L5yj8VQ`gU-i`ao9l&ig8)m4KlTmKCtD^E;;EJcRiM$ghuU_B20m3fF$X!(N z?Fe28Tl(K#Qf{^3-o`$dGMR<1=gLZ7n2TBOu}I#^M>q+?GqL-#42v-_EQP(UI6ASy zDFuKXew%j(pYL zIXf-hLv+;@yoc_kXy;7ka#MKq^HE5`-Yo9<8Jl$q7&zqPky6ud)O_cwojuT@rFK|^ z9J6z|Nw@M@Hes3ZPGWpS^w;ilrS!o^qKy1~rG-b%GlgBxs&iv0B}$tlxX`;F(LuFI zbF5ZU8-|P$HGBKCZ30F6{gT8I+!K}qAYutc_iO{lM}G_u&>>-hKHV<)%Aoctue$Uql1x zk3p}X@Y=@v_lik8k;9s~z`D?g+Dga<0#>R-xA)p`c{EY8>om!$RJTiB_*eFH-maCM zp@b_V?E`t{H`v2WQ~*Z+cT+Fk8lvog&}ar0`3# zw&v;}*Y?cOcZXen%`PaqgnJ&O0`zQ-+@=&E*1qYhCF)i}v(Ho?g^se+vp?U;{MJ@h zV9M`IWnkvhtBW&rDT%C<7HNL^Ync$dSDXqxpXl>sc4C|D1#70^q9Hqo$XyOSx1&2e z9vmQI7_D%HiKNr9QIbWay6Qy29SwAuZz z@km?&giwZ1LK)NfL|?8_vgOu3o7FNLvoa!?Um3L7Dx;pPi%Y~vh&i0LrNIek5X}1- zhNqi;b*d#CJLth#OFra@F84-67#&0PEPkEX3Q8!v`y`NY%R!i?P}fD$rQ9dceH{B# zt3~3~c^gAQk#y~i*wiF{obZwM(ASuh6AXfFd67OoFo1+QW1@N=+Y6~b-1*`L_UsGf zZrC{Rf}UJ*kL_5xd;W4IpF#=c$d0>YFnrh(6-&m!eHuDG7UoAWv>SE6zW8W+JvhL1+Wp`-6zP z*0)isC(*MKqrRL!raseE&uI_JHiRI4I2EdbV@_p`meqv*+9%>5>9$4CdpNMJ=XZ|eVO4j_DMQt`wZq**qqL^(SwVWe8{iGOOdQ+c!j^y5&K%1v#Y9P z&;_Y;gTHWL(l`y-^?J4nCFaQY#Swl_}i3CXYBhJVplLYCn`J}@?Ao)qenn{b;)+Fu>Tp@QTF#3v!dQL)? zXd+1PbM3jaEjX{j%|ryej+c~LMooOo3sEKYC8TqzR?AGq_1i-beY<(~_scMmuaG5q zwC|MTe{;p}KoDw>c`BB_&|SHn1puruU*AjHRhf5Jaz^86Q&r#ebKmWu`U;>s=7wDS zu4*j85?~WwbI2OE**_TV0bUQvNR?!mH#5XF5oV_T{@r7K zGK%B+k~w*pzZQ5b1_j#Z_m6YmV`LOF>$mCn+<4t=H9aWX`bGGqGA_!sa#|R!id!yJ z^p1Z^+S!hhfaD7=b$0;HrFlZTiu0;<2E!E2K{Z4Log3QMqxnB`Z4&7P_t*u-j zaP69!%rNZEpCa4r%B%5?c!JHlm22uSLXmX5Jr#2$-E%$-bj+9dnD<){!dDWdh{++V zXish!Bdui5eufuCErzxbShY_In3puEzP-QOoHH{{w5rgJwcKW4W zu#xZLy`#KRwn~TG2iU%sYq3<#o|pi4Eh2R45M2>ywNn)OW4{|nY?o^wUu^HbeaKI+ zv=7+>F1I0^)vLMub1g*W1Fqv#>;4K(1UHHJ0m2JB?!Yi5ly`r-(E4Ogh*oeB_z2ru z!JF+Nt0y(Q-|r<9 zL*|~PG!yYr8a6QShXsJxK-<~fR;}L^!@cYwR9>v_ zp}oyampO-QxEuOd$uaq6*yBaQ?N0BIVP0H`_|U){FcR$5huvaGWOJTg6<^q$na~Yv za8KdGWi!qt*3PMWk~w}eQlYgnOI4>I!6m?Q81*(kY=it}St}2Z^{1P@)r~^i?S@&g zVj3~BV%E+gT&@?0rvSJfLqCg|(U;omPza^F2CAL70f|C@CyWez7l!efee|A?1&DaF zR^d7i@>lo%GGLC9JSsj*g`KV3fr?Cm4C{DxInuvOn&c-~f_L3iu8$_A6lT)dnFH?zhGVwj(kHNkVt7_R< zT(C9Yw@tkf;P=?j!wQYd9mnP>NNs!U^CuPOc7i24WK{f|wV_?h2)}l`Hg^sOa{G?abp910 z28Pl*<0X_3>3vUTmzGl_PMJ$eyX3(#VnkD{3gemRu3qX0qZM~M#1ZPuplo)4h3JYd zW^O?;->i;`lZ-K!ztp-PD&F_h3=3;4*#CewP;~;{9^?3Ub|`01H8;4HJe9GU_6!V~ zP#^CSeN{Y2Km!Mbwd$D_D?Qu%sC;rd-@JQz1?v%tS!}uC`IA8k@nVT5WUZIrJ?~D9AnL|q*Z$9a% zc=0BTJ<2hV{9k^XpF?avZTj^e%s&h$=mYV2Ngg zLhZHY225RUw`-^ZCt|TnUs`7Y$bH|M)en%bJ+V*>WSOFoVLN3iX^oMg&|kXoqOK@| zpS=VLNY;EB+^S1n%oD!*~N0?bie$c$gO*oRwFZoG0K`v$;KGLDLg_d>t! z`sC+BalAcq=GR`l5^X=rh@(S($%gUQR% zyg~G0jGl^OL6;gF5!--^c?s$pPilRyx!oyWn9JO7@)QM~Dhf5PO6k3}Ry$Q?YzW0{ zg>44#-kGR}2i5U|hXFY3zwflB|9`(zxk&UZ4Qd&i46AHGpQWR*BF6lhYV z+I*b$)Zk%^75pt8nxdIj>QE>K6EGi~L-oH$83Hxs{2b>Oujg7WpDKTdmk1>(RKfO^ zEcGT-oidhC#WV*B8D7nbB0bV3n&mR+zA1fG{#b8Z@k5WX@nq@WWy;~L9!ymxZd#Nr zKKYkXA}XoGEhrIGl6R{IQMT5_5tRYi|Je$_UlJsJJ1h2|j8chc-*oCx<7UQ=ncccJQfB86OLntyD zO5gXYkW1Z6=JpNg=JMFu76OSZ@ZD)T>sFMW)hZ`lh8xR|pcKf&p_ogvkl?BN zRGFJ??n9B)ZTPo%b;DZQRd9w6M#XF1WX-ezDw++s6!CPjkExl>}R( zK*qhYJJgMTVE}~hyy(*coqmj_!P#iC=`Vef3Z=(4&0dLzG8*>T1gXw@;jzlGeSfKK zUq{6&7-Y*`XUfWp7VbBC-nDjrLNmfSllyRgzmMwBEMHKK(H zDv<86(l|U$5FeB(f4i5!5GFrNZX?&n{gHe;!lC@_)0n-gx*?;3Woqr*8ri`=wNS2M zeT?yMcX@vonkuoR)!WARXrT;J0J7%(N0u&gCe_7mU-{P^eJDs^WJ3d`q#EYHon})0 zs$rE$(!~d9$$@FWXy1sTCrLQUSubf6vBBPbX@LL9^Ks^g*~N%R;eNuz&Ka!%itZ8E zZQuOd&dZeNuW$FPVK>ka|AKs%FbW~(#HfaKMHbXy$pKP|?LQubHIAVPjlfOSDzc*^ zxf0tpFXnavJmrL`_Ms%lpy$T+@7rfSAVshVgcVF*~k5V;{Or3ubFd;!U9Of zJ2fyKBTWseG?bH;`#Vv89X2oae1F8=r>efj2f*AZFNsm{U#`dwzStL@e6!Dx-01A$ z+*NW>ubxVTISB2C$#q5W>8~CDX3<2ZI{#(wH3nI!Xby=M0^xUCW&JA zj0EgFP$W+$-nx?AvZgPchD(?Jnp;AkDKK>M0}4E_DLOZU z$197madbNgT|}<4WOhN9K5&M@K54I@4^Rg4r2|rIo>Jvi~>TR zz@cn&Y2}%YJt^CEvtD1&p4TVmEW(5NGa^*Zm*@9f51ZFe)9dLaXcb7#*y5oCKlzYH zP$>%oWsTz1RiX4o6X2#t9~!$5!6ybinT@!Za0j-W9_gSwl`*glZbi;@ZV!teTR;(W zH0IAArW%nNqn8ZKK~)ClE8a`rbvL-r&Ql$UX0kZ;n)HS;wt(*>La}45`^d29Wv;Sg zjbf|RH#~%%)F8dl99;0eZ{Oo2``_7y?BS5{0qyM8|z9anxa}EdTXxsSt$qq3;eDR8195 zLLlnSoovG6BApcY`ekA2P-w4KqJFd!5svQvlY(cxs}^J`i%hv^RAx<5GpKO?hCiEw zLO@+ejD@yUY9<`jq0W&P7<=5id3U_|1a|7QDnp;Z5n@*FgqYu6dD5Y5mBBWenpP@f zYSXp)3Vd+35VC1Syua=7la}Z#aMB^TvuNZNl_EB|YXRviEI%5bLV|gjS{qYQ8!)=O zY|OE+>F4*o?JLRq&7ZD2U@w=I2M21>!X$oy-XRBp#M-4F!X+}V_z+$2V~f3q>}-3(a2`(d(}I*Gpkr4yW2O?c*(tA z?rjzT=PcE|(IKt&^Vh(~I62~XP&fJ5bhx5n<^X4wup~FcaBoj}yBw%l8G1i)VY_In z{ilGLfy63vmFPLQFLH@pyR%!3 zj;q{a4-`(*$c)*I>m-nm9UNRW9E3pksTEa06V5KY0>Yxeb(pqoiqy*=l_>lbmZ^t2cTssG z7NxuDQCh-k*Q#)Y(b2#SBAe%`^#k{S!lnmxM3AdC1HAy!4jtfBk@T#npc~71|5)M! zYN6`+Rht^mzNGgw62Ne}M+-eiLG2P6mn4xq%$LsBI0b7}2=Fc1_Rv)(vpH>#5Qv=VZ&TFeji|}%?;UMV&3=lJjma+ltV+>v z7{#XOQwy2Dz#qA9{)YC7p^bIgShvYLQ1*863$*~GEI2_CGWAXQ*VnfJ9!$>}l@kZS z@~>r!51l9Jpx)ua$egxbX!@@|`=l!|zaQ;M8#J1i`BA+#`XSc*9N#;9vGC6oi%2u6 z)B)9%8AshP#X5-nfa(q9s5e@BiaK*nGKmk>ezJvMx^To!Jl;J6i{=ZszMC_Nxe4y% z7doK7x#fUKnAG?_zMD_!-?fuk^ZF?;ArY%suyU888m`3m(xH8E9HB2Oj~$`JW)eRj z8OQb2okQ6;8NS=AK;KZ))a`H}xMKV@+0VPB6nV^MnHP8tLzm;M{~Ai2y*ml@d33Zx9&Uaf}n0?wTufk{6@ zxXNvolK1@8zc{Gds}ns;t|HgJ-t`+l8|2CCIb*3#3**b^lHplh>CM(R06tIPeho_ym1fwUfhV? zZuXzJ+1Szj^$)-4!Ks<_i%Qu?-tXYXCO6GkR`0M@=Ed?ZV`|HJ6}F^~So`m8-2{tb zFUXo4o4vl6IKa5{RV+m+$^6l3jXMzSM(*;wemE0q&j=+A;&Hv?CcMTB{P~NuO6FdE zQmA^9fs_DP%N1sqq~(l|N2~Ww%F%n2c8!!LL~QNZYs~c}u_=G=b(d2Xr8~?H=Itv< z4BPm>eDn7K8^;{CSL>O>K!oe&>Q@0dqf`B&6{*q1M)wNd8)HWASNhM)KKe=%??#`~ z2XCv*QEh6yvuly%i{<1*vUwDPZYNTX|_(v@zGwVhB+2XBv z+SblIJxK>rnOMeEO6PR6d*k)b%d_0Jg1p~uT8oi0r=4qTe?t*Y0}aQ#J=rzHvtB^F z@e0|n4(AOpAlcw&3L_RapfGz(+Ll+5YTdG{UlNBODlF~Pyc)>N*FhLhhthMy-O(uC zQe>dGpi$Jsrc0<0ekDHf3%M@fuLGHpaz%FuD1F1&m&HW`;#Lkz-oZ*yj7^X2-R-ZC zPs%&2yr$kAyrrHxK6x8fQ<(iq{@SwcR(ai;FszEP$CqWvfh1XM8O7D?f=v!Ri)S9} z=c{KoH&~_gSW$gi2>LP}n4J`;5eOhz9bZR3Odyth~)Y9u;4 z9h)HBBK{+05=0PZ?fl~?Crk({{q4$1FKq+LUE+iEf>_)0{amTu^Gi7w{azO30C7xn zJTtLgmeyIlqSL@%OneVOKe!yzHm?4zHkiL9cJq$B%asIBAZ?T^iWu2 z3^?L{f(b=(iTgBiSA=B#^J0nT|Iv?nA8kZ%3`9CDP-;jlq(<$$Dm$AbX%PC!>lVy+d%CJG z6>R=NR~+vDbUO>1y)VA!x_CAw*vB$8e?H)t*r_tQE3=x;M_B1bh>A1v;X^%*%7A~M zSyPTQNxI~&P{$b-LT^Q@vd7A+UFtoIG;+maBhi63+~*F4H<65=fNy>s=2ZNON^b6z zf+#%|PDNVn2x{J*qd@IF5arY|B+(h#d;H#EGBxc~pM-ni|J>wlc=_Ag`F3`vRqJAdiAzekh^S(j`N5O` zUH>qz>fm|yKwW=Ttm@#s@UBYC#uxXK-rycBTulO825?Z&N?AlxbL9&+1E}}v>2~DR zrPFh|PmV?TJ)d=82+ko;b6@@vz6+R{k_=kFhyzE~j6fx+<3D?rr3^N#92uL<6QA1kVaMZy2LZk^qsI_<3;e%|-j)Ga?q zcFG8SmrqIZTEXt8R5LNH*QYl|4%3!D6cVC{OEh&%f>u9P*ea8q80Y}xM16_&cwkR5 zqDH|UNy!p)_mHUM5oIaK#LNm~)dp`o4W*;h`4d|g340VHfGYBtkU&?{ph%y*mSKC8 z_p)5ty0WZ#rIVKNFALC|DGGK2ma_y?ZhSsJ>8RxIsEVGrKhB|x)bnSn(C-=Caddp7 zT^k{|fHzKosz5@~VCGq~?xsSVW0TZ{(_h)9Mo3q-@h`kkFzH87#w=DkacqH$5hu7k3Ojp_i(rB1QH?4!Ew(h1U4S9TkQU zt@7It$+bNM2MU}|@yp(|UZC2&w&@;krK6e8#l^mxNmEbEzsAR7UL7O`Q+!SbJswH5 zt+f*l-iz}rPBc+QnO+&CG)Q;11}|WnhP^sPj4Fs?Nivf)smrJbgj2 zl<6LciqC^pN_RI0Bmc`Of|06!v-Jd}^-J@EG-<;?9j4v*YW)EutcLPF^;_jD}~mY?=N`NC}Wwk9C*?ZQP}Cf;f$rMa;faK z_epmzQYMStRpNQ(GX45gHaCKo2q)Mq2U4ZxF5lu*5Z{Tp52k zqhfU0HdV+2QhIjyV?Do zc8@u8Y65xv2GURC51mv0JCsc;!B=^yY^M5+ywg_s*XjDdKhY3ee%7-pC;D1tbvFMq`m-#kl{F>vGAmwnwqY`xT zo_b`R`%R@n;)CHeD6#(4?JT6rcMz33>$oMD(EL$!wEdfw=+4uJCS3~RTtOurD;u1HUqe<* z9TPePD|sH?JvYf6!d>wsox)vxXc9r~aPtM$BzLsXDfJ|U6`lt&`h}9Vg1N4ca-vWc zT@X+3G6w{0bB*nQ7>ZVPqX47%h&Ym4kF@2NHEBB2&NE_;l#`dqWzT1Q4spIPqHP|MgTx(kvX$17P-$n z5}r>i_^`UL-%X|5w>vfeQ7W2*OVYCWUV6Xz1~UAT?QPeqru5}({|At~9VYX&^Dz~$ z828RY%t5{<)0jN56&5aN@J=a<~@I$WZZh9Kq-!%`*Td&z_&3;|w@4gKW}mEGo}{bpH47 zE~_YMl;LsTUFNr7T%(A)k6ip7csVs+q5+p+rDpPZl>451`i-Tw9q?b>69O-tW;J2r zJ6{2{E|2zsbeb`FU#dIctlSiqf-ht_alR@twAVR2QvKJelfNvG&-+QnjLWRl!CX_@ zPuCXM0d!9sN~JJx>-clNreXZ}DOjac_dH268!V9S;zFy<*oIOG+2c-OZG4v2CohEe z;H6^zf^u1!)*ARdmp%+J-{SHwYh&wu>0+-<9J`D}(A4V(+Mm9{v?Z69geSqP)%*2X z6KvKXRcCG9-8_LWq}>1P%xxh2^Y=wh-eB^O)NsHQb@7yWgBAd2!v0$l!7oN2 zr0i-x!4KERGGUEqRl3N_h$Fa2?>k69)t~`4Bj5N=JP#ZCua%gt_u8WZjuG3int{9F zu+5pKDk+w$ky5(OG9Pz^m|B2_&TpDFDbdMqqZ&423*mL(nz%;E!ffv_KCBS<{>koD z#871u6ZtY-NEW_QKqi~(R;%I(qe0`)jq@?<8**oyKFECqIru@!6NX-IaOl1ZIOpLh zHxFAj)YETQ7Zubms;gFm_+@*Ac*U4c)sB6fF%mun`(5!up91U8DbO>l7Q!;Y7fSS2 zbP=Js{;s0RP2pfL@TCIFjR)|h0?Uo-Zxn0m)%)wiG!_j}>a&=*W@VNtrCv7r15gt_g$9b;Fe5dKi;xwG z)OvmRoKlNlb*yN|f@cK(1YI!#gGP1L{@?^ShS>vjTI9z5S%{i!-8HN8z$N zrV#(#Lik=_q&}vj)Ma6zcJyXgan+mF(5`p@?VS{L17fGv^=}`g-8NG>3R{iE72JSu zWdfpJ4D0i049@(~c+~oX@?(s;JDcpjg}}E3C6vDq0HW#=9!$Gk{|=m}qyGwkE3?@= zpjhJ(&o@IGhY{Z#obdzvvUYzCZkEKF86 z0==7Ce2tuZ&yRe-lYvpN^tn*yU|>ORp2^2p5cbs&sv=7pN+R+Px~XdJZ%l%7X+J>k zUBUI`(A)MH+udDmU>Yv;TPg`&?LCM+{r<5{Nb=K!UuH_W?+|SPl$$5GhV~rLKFrN_kueh);{^b8Ivw1;wI_9k_HRi4b^!u-yF~jDY&v0s6id zoeyF>*4Hh5ct0s*Uqyc%&wJBUU$lg{C7AP7>&=fUO6R0WN;#jb9O(UHkm#KvuMS4R z<~!a?MVC`2CrDZgcQV^xYvar1$NGM7M(&W0co6nU7H*D!w?3fHn3O010Wevw58zb& zIB{B19ZgX=h(CY6+IIwmXv1z!?Ti2@0;J)M2BuHnhi1Y1=&|ReZVL)_*W^upXkhn+ zir6prub`NEGWtK=6>Ro&f9>v?pmz>|_!m?npt`w_&Z6b6!o|Tzp>FqD+=KlLr1%DG zo3qr!cn&qcet6#|lv4rp?BLq7vS=uFnq>0F`$$JEtd(oJp!Ga!`pKg71*iRYv5bhS z(`f!~fUE1xYbljj4)CvC$@T#T9FotrYa>9_oPPM40l!t65n3n^_;0)uGl}wPd<>f& z#+(PdsAcDDrP11j6w83-j<31%iuPldNhZDDM-FOWwK#vIjQzfQ#z4yL%VMq=4#*&;gLV&95Y{AAiCr`F8+83zTerlw)U1 zW@60JCm!ueKsI}^H^+4^PMI$x9>~L3+Z;wXkWR!aAO?=*em2lbFrcGkUn=sb6XUm< zt2H7H=|lUSkL^=h9v#tRP+*nX^3VgQJryA4wuX)I^AVd;nTcCFYF)G?S4dfrJRTB| z(s-+B`h$C+3?0(05*O%jt1^@Qd;9LNFmMguh2iYwAdN+X#XAGG$Ue=M^OxYFZ15R?WZ|)!JZlKx# z?&8k#hb#V;|J}9T05fkWGkU~<5a50H(79DGEo|@qPE7;n>UwX()CNK3wps7@n+(}y z?>2FQZ)$ytmK&hfK|3+)Y;d>Ev{RNg7mAY8=?s+$@yLiN)|YJSXX)S{{@fxk;Lw-@ zsm6*Vrd2+tsvn!iXN~{Aw6YAXcJSI5+zkTu29~_Ux@c&Z5+@kq>a@JQcch#*M{tMZ z&HTL^6vUcy^DUFvTc4%+xxOXPuYuPm9F=xQ<2xD38mwaK&oxfPq;qPjv270}d5nT? z4tI=##JUscjub#om819@_pa*NWl+x$B>a`N)aW%2Xav<_>OcTx{-X^F4FZY!P$=xZ ziwOa$_48!+f+@8gG=FwSs}L<~{`V z{=0E!JPR4ACC2$9eO*u|kZkq3z>8mg*_?T~1YM9P)`6rG$NK74WXS6GXwod!CGbcV z^PB1+68A5&0lkv8YXk-r3O0%JW}mWByLx(q-;)0|j=;>kp)AwNtk+Ac7hfwBqIgp_ z@nU#_EcmAE)eiBI4GhZ<nW};M1H! z17+y=kp#Lai{AszSMN90d|%+5$pw*7zux=}OdQVz53JH{%mqYXkVBdEn|(I!F9C0L zSj+iJOv+2+a7zEIk9>c24`*MN0OzSaA^&oEZp^(-K$I;d4rGY%meIU#1t$P7ejUgB|BnH-|MI@kr|OJBXWmxc*{c}$93W>r!FH^j25$OMNJabLvd zPr)U=c;c4pajGR#ZrW)sdGy4gG$jsSsXL<_@CFblJDa8OIu)X?wwNkLri-%RJW&Sq z)KeuX?lE!qif&%oS<{f%~tndbq76d^htssD!wy_>+uT4N|&>I-(toS38Sm zgw+x}AJce=zn9N*G1z!HHy{ib=}<@lAvW@gl%T>~=!YcdI}DT+WF26~E?Vnbh&6{T zTm$vS8k2@!JEJdJ9+)b@5F>+^BI_;-fSst^y-Tda_YM4suS6EbO305%gp(eVS06-c z4{?F=mis^C!k-ms?P%qf&)8J9-QzFo<+eJ)F1bYIJ5eau&!mthfjdkTVtlIY2lBq) z>n2~4;_KoPM_;ac>Ri!MOhz@df0Jmpd)u^WdAV}V5s>rru<2jnRg>vL8olgHDhvD@ z!|O^q{62>#t19!o6(aBcF8!g8kG!w*4D}%_^}>InM;<`AQBTGp6%r93;67nkI9`b0MRw4+z9**Xksvk8PM2mFx zD)u!$?_%MOf^!`rQxTs9iAQ0J^N4oqT&@LnRn811_I^AP;9ns&YSTOkKo*wD&)~|_ zw?EeJkOT{nSqE0LZ}iF$lMnp&MdMzgCZ!WW7`SN+8>z-`oEKI$mP|GctVNwgbeI4p zftL(hunP7AGtS)~=7$t#iraikjQhV9SKv!mjkzK&oplirp_A(&PiRl2m}`@lOM~ohi zhc$u<)}IOGqYAv5GCh!b46SD=2xT+8kPyr%_~D++ETg9Lt}pLfj^(QtyWb!rfPC+s zzW=#KHK_f$CP7#D5EkRw5f;ecSDBi#be5I+EE;5R@C?+oY}+7HhrniI-o_l4DVtK4 z6=0-T(O(__*JA8I25l|@!Mg9uxWd}xk_>qD`$;79b)1`~VR75)!227NA`H_)q{O`f z{Z=|4JS5zQ%#0krC~=x>@A_z?IJ>fa0ONFZy#eGncB$dsZ2CKUcj+&>SyA{YH)upx zJ#~lWjZw-h1+TaB%%7P@(R1ZR;5qbbxpMJr)$!q5qv=Xfo4&z43RN`&MdruOAI%5Q zl)&L?{hI{X;cbiT$8n#-Hqpy&{aYB=O(OM?P|04u_IJg<%IINwXN$dH1IYV#r8Sqgi@3G=fP=JR&iI*xUP z>sy@$mot)+1 zAf431wHti_3B;T!HFD}@9y%0D)x0}G{q@^suJAKA+9x%86B?JauHb>Ewh=c7{1H}a zm*|-{2N?AcwKGdL;|6{@5a-%_7Df@l4h8gZxip>}n?ba5x_VeacAXrrw$NN3@hmpB#G9ZU@K zPWABp)i=I|Y8YLuv#jrzp2$H$dR=-tRE)PF(5l8Y$4&>QVq~9u_E$y%E|^S;BtF|P z18x>aE$KtXQbSV<&n`E*3wt4BJR%#$-2vT%g74c9GwBZ>977vQO6)3u;y1>&={k^d z6pHqGKLyAONU5`TbJ9=Vl6fRySZxEvdG!9i{y1|bfiIP7m)9*X_hAd*D0RjOk!h0H z=01YX&2kCk{qu=P^bMw3qk6?rN|)t?6S6{yk*jsVVsv<$3@>_7*`>nZ=`SQGyz{Dd zTnDPgUF}`ZV-SJgZo@L{D^7}EL2HPS>~do{>xB&t{3kp;11V1k(RIf>kFVnR9RG;n zTc!yGe1gwn$3HiQkrbS9im!-)vf2|uY;M7Z=-uZBv@6oEK-h2t2(d)BGyc5m$XIGA zjoTs5TkOCZ?pd7g#>tdtV8=6)q?toZAc1F}5IHa%5Jflf9AOQi&Mvij|IqW1U5XxRGsVHS0 znB~0hayYE*MCPWZr!l7h_JQ#7AaCv17lC8(XOG9HWq!^?#5KylnI+A*&Utyd4J zLe+Rp5y6o1-YP;lk(;4=cV=*Gh8$y_Z*LUci-589Iee}2zPmP(g^yXv59j&-^|15% z%2H^I(=WTY@j;HjW6WXs36H`5AyROw5H=@p=eMM**e+sROeX8k3wykm$ofLoQ6BvW zsK_ob*4p$;-7H4IFsRo%FTy`S4yWw5Jzm|1)*d}M<< z`yp|RKO@QL3D?-(-lzRq;Aw5*h-R@y%{#;oSN__zVPi7c?jCfn?XB<#{9p!5=l?Z;aXe{FsQOiO%RetDfqm8&kPcQ&( z_`Ab|cjl;oavZzk#L*MlWW}A-&~mn&^lNcaV_J#Q3-fg9WA+unTInNlY$)8~MmV}Z zE>kzKwgs-48arT%yKb=IF{srP4!(b8tu{84o>IwPyD0RHUIZOn9}S2MuX}U@*ma zc6i|ulPtbaw+BB}okF3kLf2C7!LLCprj85k`Xswt;5aUoxI>{Un*eAAba;7kwwm?^ zC!TB1R4nh07kZi|_EE5c7Zj@9 zmKM0OE-1l$pBe<_71}@*JHMRF5|%Ct&q%9EpD)i{yu9FQhT5Lk8x(nLeB%kCV%zGVYtGsam#rD65= zL}s%N;+nC38SZLTk=uQ&4QCa*eM@@)WM%aaveH-wRmQDrO5Qmeuh}0gOu&HfHS(-h z%?1N=2D&t^xkpiUC2;$Jmz2Ttg>9(AcpUq($H34cu*?5Tx9HAE42$3793WI9=w@vi z(U?V9;9_w1s+|T>nr%_^;n_)~E57=|$`{qR)otieoHNOn7o@cMK&GX~&(C^BAQp;j zQXm_nv%yC-sL=m=J*C1$5N^*t^lGhWU-%g<_MktaxhL>L+t~Oa!c%G@(2hl4} z@<~(g_hkp>VFpcwEk7WBwa12#4`M@}|B)ZE`Lq!6>`?0>dXxc3mPUj#m=OL7Sf&dA z&I|UH^E#LrL;3GoV9xfvEu%;|TO*nXlgHZF2P4R#kH*W|QgEEJVM0N$iIaUcs}+o# zs=16-S`AXQUo(HSv0^mO{c_inp> zjWNHJ&xyeD8P~|MLgLCPDNt)qGv;ZHDjUT&dlIM$F}^!)09-C>kW$7kjicEX_D87zV9an7rf%ezdI<(L_*KL#5Y~?YimRSP^t*^eZ>RyFfQO ziM}RfbpQ1kewv#>)603G2*i0>0h#&*M4&KdRT(2LfqJof50x-Zqq+u`G|)~M7R<4b z;O6Ead?60Ny6gG3|3UtQ)HJIRlZvi=w+C9ccY~o*;zCoMP1kw=zvRnfQ8H}wkqL`A zerHvn+Ye9kvMN!7Gb4`drWv~oCv${w_w0<2=@|n_34K=X)GJRnv@m8Q ziv4Yjd;jdeU(vqEM_0I;+x)&#6Q>E-P}Rdw)JquT9>U4cC210dFpKl@~4Rki6N=7IDYYackVu2BTfPrD)%&O6?jBqvk_+zufp1iSh(tgXl=W&qXLsMroP!(1?RQDfYOh=zX$is}^!wGlaNDK`pFA49 z2EVTQOBdygk20pGW?52oy{4xpSpeYME0|-)P1g4DvIk!DGQ3RcE#aOqBeO#)UPc&y zfi&Baoo>&&j7xVmnKXIEj4;%dz~3Xw0~g&pm2^?(VQ42bZ61tFWupU5?ksZ|KL-I% zxE7MCx`RU7o|9ZZAfSc!BHfo_Q2*2%mQx|75C-alk24Po0fBJh^2lMlcvb9$ulo1Q zz>(anan2cLWJ8rDN14)F74FS_y#^&THw zgZvF0n`a(A`PtBd0FS;4cp(<=744R{L`f>Cl^ci5uC6H!)pF47VTkxbnt-Ck4d6uq zMayVcOG|w`d)a%?tm#c{d(pC~=?!;x5nXf->EvS;#zc*eYPacSy`_t8t+h35dr?)e zkSK#eff=;tX5L%~i4Wh~h4AqjUh^P=KhppA~&mHeBP*x@z z*v-OWS;9K?YcW)_XFK)tGoGQ6T*cV;nTX0;60GX34KR3jUHvGq8wfSUI9Q75>mclDho=@+CC|JfQ2Oz^oB;$1l40ftyJxJLa(#!Y| zK{F}6+7i{M+f=+X>CPxT`~d`s&gQ>(LgL}~&Vx(-HvSV~S!ke*J~K5|U6ZjXhah5N zD|iU>=p+mp>U?{8E_`8Hxfdgo9lIBmt^pNW;fSzWH9D;gwlKd}igUy<`k?NWDwidO zsth-sVC~7OQc?r2f=xXR=`vQmpSLN{xq3f=*UnjD?0YjuCM;3@Y-VE}9k)8%xe0Y8 zTa1DLSS-liGw4UUbMs)v|Hb8qi~JMZ<)2}AFW=Zf!4Rd;{Cx%1VAgr+iJ^+9djV!` zyWw;CYeXD|x0NmtA!p{zC9-dw|nU>FMIbl4w@s*$xZ1ca! ztoX~DEDmA&Y7`QWwGi+hSw@1=uKYD+ZPNhPMLQXk1dPD~NzQljJ;>!frqOBQ)I;t& zInGnfJC%hCoUd#(zjoGuS`1P3rM>n=lV@`qm7dtLdNwBB6={vE^1<+o7cY1M! z`Hh%nQSuS8Qpfd!YXH`2ws8 zc^tm_own-bjsgFi$Zkm~&t6X%=bfevl*$$?K{vRHG@S*5XYgtl#JMGDSLE06B}-(# z!>=~ABufB1H!09YiTRiQ%XU$G>s*wU+jH8}{&Yi%F<-K{ujw}q8X@Pl%rEOY0OG}) zyuQ)~l!275v-{HZ)RR5u0hY8gj08`JY~of(@^#=-9JV!t8Dram5%mTe3*LSAh?n=k zka-^~M77WOVHJEEixSE4%*( z;d|hJeYsAh*+=3vxC{RfK4Y!_hw%N3)L=nslX4dAlV1OHUhRmh|{WDOwwD3=nxP`e0%iAhM* zC7y)QLudYCrP`ip>hrc?x$t105Qk4-N>^t=$jX7JV3Tf|4f;oOKUZ=sH1ii<6Niej zsdfjvAD*B;t{(B%pS2w_ofuo0wWkt2Xj&oZpL%C~gMI@7v^#of9>&b~5)bg6f+;Z) zHJx@@%6w>!$RoB_szZDy`CkD#Wq#IpKKpC!$Dngw9qE1=vncyeT=_7KdG!@)&=3P! z5gPsH1Ppq>nTlTMCuds7i3Jm5!|WCq1X^oiD82?zzEp?Dy70Fafdb0ED;WC`9J?V$ zm-Q=5#Sgo4FLxVnZNjkA2HTSWlF!v8iJODuzG(&*F|^t1hLu2MET~=N@roM9rZwo+ zwo^#(41A)3&$M{L%%xS~srWGz;P2;)?9`o4Hr?Sq@Eban*8UDw@sdz5(2pHs`)X7UFeu9pzq3m=o6d z;$>Xkk2Y~P(?f&Ppqd0gF_jJiz>T`BG130eU4Z;b1IVvhfc#>5xqOPr|r!R+niXAbXvY=|8v=+c1`yi7P5|Lmj zCc zv~HW_;ybqViikbqPYW&${SPGOu4+8K!3; zjZXS@yH)s=d1N&wYI$Rp(~u!B?=p>(j@m6h3Ov?Sh|-jMB#q{PBDtlqJ3u@Z!S)7f zc5T*m?Eab0qh}Q09FiNsZljd|m8gPxKO>pD&!Z;=y!vf|eE7za*&Wlv==~(WmJq8A zmahW7-=Vr>j(+WEGZqr7==*{@_bV0%9OGkNc48-ry~q-2=?|ozatOIkT291+0EU$HaUu z1GzHKg=-NW0!nY;U{O2ZNIh3_{&SPr9iSbwB~)H9cIu-~w&4PM9fplW}l z0{3OpMqHp9%VHK2e~%g-2WCT?aL&YReZ0^5qgtWz*Z!(7&2qmC3N?8j(KQe~U=a(5 za*HkbIOWsKnC)FMQ>}G}DYxCkjkI(M(ETI7sbXkh;2>p6tjP``9EsKvRhy8aH@vt6 zL8{3r;&f5}#<2gS^2jW)RaR~WWaRxMifI7T`4=-2@byq8&-<(QUUyYXPnA%a=>4B~ z{rCg3a=1F-H#gh{MMIH}+iLiM!5?5)D?MEU7=hqv}R9;!)cCs|t$QrSeqBZsp(s`vUYg?#%NwX)ivH9saA2xSdU<_mX;dBx|8b8)C2Vz_qpt zu7!ff8StIG#a-CdiZe9&u^g2ly0&(QY#|}GwuFFUq5=mo<({V8lPE`QS{_-FNks>} zNtkI)y;^J0kzz~JDyVL@&lFp0e_xsu&NmM+=T=2bXv2sDH}jkrGft>Jt=YT0TnkJq z_*{bhRA2*&;@`y&WD=5m<0yn$Tfd4iw+}hZef6e+@@0AuaXmW`9t=M?6;>rAjy>r5 zrh4m0S%k{S&E0_ZCMh0k z9gX_5QmOH+b(^u6Td_?oc-O{MCDl3L@7tt32EH1=^StNP^ZeFSny#;pdI<<;f7qo= z)(hInqg8^@A2R0JxIa0-c_-@&hv}l_V$Q=kpvJ&t&X%>n@90AiIzD;w$f2sMfd;S(t|pko;Q#qdJr22EJ|LBK#wom&%fRS^ zm`Cy?4)U)hTn{7GgV2;^{*KJvRpNWO(U( zT)N<^=5Ft6c<0sySmsYHd|n1BASzc09~z$f+pB<4_6aH?Xy}Y{AA%7~_Wx_{Mf}bB z?w9I5;EQ+Oi701t^9jflvRt2Pc?Y%Aa0cmB3(uk27{kk+02NROy%lykUwV+Tj@Gpp ztx#*P(7VEUSd!D5QmV)Aqtn}*q*Glu6!q0;1QUvxH%h~ zpw{uY05D7d6#&B~VZ41!y1ah}65lekm^LjFpih(LZsZR)=%Y~ zw(J^|2OtdWUfV3k%ngh8<3o+Y+ zdfuW$z^9jf*6Nq>?z-$N5v8;g3DFdIAz-?#UDImgT8ufKtpd{xu3gVSN#eP*AiLsR zt{Aj7573u%VaoVRpmDUjER!v}IA^l)NB#Z*%p0*E5gm#tq5J4|>_PvbTNk8(dOATu zYehO&l@6;JP7KvR!cLz9w%fS)p (_8pz;@EA(QW7RLUTzQt_oBNnzlvx0+Ll$v z-51MV$@X$<%Uggxzc!e)^!SYI+nn`H?hxjfxt1Qdgywv57RZXt!k5@QtJa%CW!my%`_@L5aJZIgUr>cFlGWA>SUp@g>snF&>ZTR%3*#!+8V<)? z{Zflthlch~071)+Ggia%!*}BG2@e&%$#-^Y#=Wv(3`FEE8V1Vx>VHu#&d%{NpaMtR{rYlpHz?lk5vGr z^o8tit2!0;tgu#bu9S_=IpzlB4C550Z#FBH*&sH@O19fYcDg3y+$7P(9Rv6HPTMvU zjm2qrbIhU=X_U+N5W%P3xgr_!3y2j zihFG+%di<1A(2?y5N!Q^0Oi2MVA(lZgFrx_W}X?TD|(Z)gFk^cglk4!eq?o7j}sez z2R6UWUFFdeJ*dmOP`I{fdw@!&LA_Y0=1hot&vLKZ3o7eCLk9>iL$_e+z`XoJuP25A z6W}lk>LjT@I1vSK?k`sU!`HQelK33GnSHTY9}qb9bP`4kbWUzovoP^IUr~zG==`wyrqQ>80r@ zI}reI>w(w#s|ffC@qCi~mq7LaU-qsdu8Z+bood%l;18hw@`Ic6Nq`J0+yKeP(FX&3 zgZx;ewmvOPV##)@hSkmsagoVcYP+6OI=e$f;+R9@?<(61*qS`#yI#G6VIbv1Dbn?Y z?9>-KS z+hoqCM7rL+uxIS+`9}q{-PQ_MCB_{%wu(qIwV9k$Ry-LSc#-V1?E&ZO<}kle@4S?3 z6Chc7LsC^sZ^yZMGrsIo;~e_Lndg#MrljU*{C=74xF+*h4Efk^*#rO!YR?=}q*QRs zL~@jXSz6Cjo~v3bKA(TpXO=&d9BV~|+uDZzy5W&zH6Pdc9wg#1-)Lz*EzS9w2r+pxbu(&Jw=_ZjIG^ZIH-%{){3e+6|&`k4foRQwyIA|7Ub4zTWo-5DmlmII%MM z79d@0b=2A)L|BEyS-bM_%fqrX@8m&B#y#+c!6!D-4Sdhqy6*V=gTSmK#E7qHjwAc# zc$DjyFgz^M`p>o6+`VkT4rvy_ob6^$sN#20iqvYtoa&8T9; zf8(DAT2{rVSbAGCa~E=*V=E7@oR+n*v^K0kWROgijav?+XT{=Al5?OYb)>b!CVn%G z>1F;5nimt&Lr*hI`LpE@&==yJ&5Zb+5G2T!VV(U!tW}6ZRD^$=RL^ckj!gPg{$#MP zl#W9}WyTYPVcs>>~oOfHgB2!cOr*4JywA!)Qf6yjSCDkc6y^%>zdp3LN zrxHpxiGB3}g&o2!w0!3^C0*X4`Y--UlZ21iFcAwSWsN1eCtJ3!^haa!2A+^=|B-W` zj__6cMUU_=$w)f;?x%A{7s!gA4to@A&TKZUOdfEd9=XLYC%|=! z3VGWzi5yX%`e&JZN1#ESArk4FKmwOi*>n?Ngzc>|R7gVoYGr(gU}2ty_hHPkCT(a` z8!pGSVetb>6X3j6``KKHhtThTa;L0`3la{k2GWUOB@f=yCeF6rB(&+zq>Q3G0NHRe zJu?cMjRbEUx_>WG9N7cLaTmY2d03ni3!~LOM7qF@NOdUVta54`hhW@tQ9p69X7L>Jt zXyMn;Pc;B(_rZVC?j7Qflry>MlrembQE%u_8)mcWebwVjHyg)E-$=$R)!?hd{VYf)YEnXJ zdo|-)*FbBNC|Lx;W+SD%DQ}$|fDI0SY0F4a^UA_HKmhKC;E5KZYJ=iI{XfefRWx-gtp%^!GnO)@;z`zq4Qa70wCL zi8uqR;}uDK{&VKl`{2QjCDpisZ-$=npHVgG4|u9WP$pFq15>EUm_y-;l+I7A_kc9g zEol~?k7;5Ky&INw!tJy1r;}$lEfR3&l!+$el$;||g(+X~XB-1Pm6KvhZ92|r}~Iq z&xslL{t;dE2d)j_UjfTTb*c|IfnX2myMUkvXwA&L_c-myDU!I9G+xSp9YN$j8_iO^ zp;v3F!4bL%-xtHAv|Lz|UVhuLk`8{rpGFr$^ZPssc>SB=l`%zC6o=JCAwx=3_1&>y$R?D+4aY)6$#KPKkm+vx@4z^ITc!QMRWa`4f$NJ-AyLp<3XbsmGZ%|3WdT)9R zY3Rq6)BG5~=*Tj}J9*00$Ie@SF^IvCt}+qeS;3^FfZ6AO2ij<-Qu+ZhWoi_M(M925 za#S^h-UMGQT#9e(!Mu>vZF_J9WmF=AH6$8q6pb1a_}Qx_$QLIRbPzQ!^?5Q6(8-Te zRLI1B;Z{N!AX&{kc($V_{gpc+=S5qM$g!f~h8$L!$BKB!jY+ zv6|=tQ))RtcI@{Z!cN6C!$8Ekl9jXzxw*It4zeilLyd)PRf{!Ye!0B$xoe3r28#)6 zIilMtomzspazo!4iXgjQAq|R=l4I<5M&k{`9|HEX=*nuSuDHZVJDY3>j|u6zhxdZd-`NQKdu=ZNotJ! z1zdmGi-NS)YpX5b0@ooM;%(G&K+W&kxiI===lNL?Q1iP2YW`&KZWn`tXTGngSH8$$ zV!p=iwimx!o1;4bMg6nSWfBQQ7#{Fp74HEy`J&#|`g%jvNaeSCq>;+F#3*~~r%G3p z6d6%&PO*i48qpk&k!Ww+ux>y|k@++_jd&U037tqbLPzD3j57n3)EWidae^Qpn(S{>CSHxVR0#&{5ecfS1ftOfJfF-Im(kZ5 z`#piH&_Gew%2>-*L$2Dm=2 z@&?be<7$}w!eH;%0Hj@bTUu%wM&yxoY!l39k$PSQ;A*;r8` zO2KfOGGG&e+@4^vfkFA4&53&Hex!IkHTw!PY12eJngH$8Wrx;b>-aOjtf~VHb2!&y zg&8DFZ-;m+a@_1JtWEm7G_2u1SE|kX?#-8TJ56S`6GKy%kqxpQ6cM$qu2JvJzFp`n zrO;n?UyAVAKRHs#&ccV_=GBp3k!z=lR?#zEB2>|HFD8!@bCfPi{<2&r)sVkeWT;cP zT$qz?em=pVymaMPRNKQEbci3Ps?E+C|1HK7D_2uRwL`39hxl2l$Ly@xKh70tvtxbQ@*5+9F2XrR z8$GiCLeO+Su^T@_n0oy&h5Y2LVMPSff6bzoiCS^*WafK`N*Q(~rYVQRArTOr7@q1Go5V z*fZ^B`|cAfJ+;?oIwRM3bIt+ZLJICq{DYxYZt;{B^HAX7u>iU2rk+Ux5d~Jqq*s&aN z6_aOo>B8s0#>b1zUpiwSI&ZoCNST&|wHCV!Kv#9k35SNM?} z&SiFL%k}plrr2fotu2$7jRRDTEGA7I*O_f>L{GoA?JZ;=yQ_Tm9$v#rrv~aX;;1t) zRm{+o@rXFCg_jX(H~yMGAoQUsj6GLp_~ou`HzA!erzZ-T5U$W=6QUBm?HNRR&a5H(MA!0#H$>)Eis*QTN9(yMRHb8@ z#G7)?9=k&n)=g?K9s+~fslyQ6UO$Q|uFnVk!dR77Mt(L*&cU{6R9Cmr_a=Tz$9~f6 zqbWvUX~6AQeR$Nnha)x=^Ur16`3(~sDr0Sb_pK&9f=$}m-8p{B|Z-MAEw))h-DZ6?Pl6%~A8p$m)WuO|6hc)U0?zBj4#*XI1HU%S?+TOtv} z?DCx5P(LKI4EAbJ4SsaNyruYSL)~=v4O7J6GuDq^!TAG&75W3VT^nfw%{*gg8$Z2% zbcg)tBdi|y#{QAydQ*QT%I^CKLY5isk>>CnLzRT`;CDU5(BcXMMDe?kDp*_4r#XJi zESDbs$)(@*Oc!YR9*1c!HYdlo>Gnzf9e_*~b5&9vFowr?I`s>>H0v8yD*W(TTU zcc{$%%qz7KehE2`6Ez%sK|+AxPJl=24;~*FR5l|YTxRif`2brNbuug5q~LIK`i5%s z8yn`fvOW1WIy`I=tk)-m(BSGLgwUQac382jffY_nxa3q~q#N`y|It__<8CaMK$EX3 zlb`%@p0J=)Fm=)C_CDu3DJL2*6<)l7D2;W@R5JO{iCVe zMi^Xp%XwYIyL~1HCjsrZ92#j31!ZAT#)fObPuSj)QMgN;HBWXL{&x~A zpP3c5C(7eV;o?X$n|;{<{A|V~+1DpBR6VP_AKHD4%NAyyfcF zm&P1VZ+35e^V27GW%Abz^=HK9cNzJ2mu~YGmn%#blB8d=KaZO(tLJbikuI+ znsB6jzB4Xk4b7M%Gcu2*nLbncHY4rX_t+z4 zyF>dw&RqCVX{+A8GV3>ARyw8rtUTL&X~yCUw^|>FaBx=ckIbE0|K`WqhcoZ37Q z3W*_N$tznNcDXAleh_A}KAa)-{V;IH#7gtd!vzoCI_~upDC0dOvD@J=|NJ#7k(XL6 zpJ+5mb~DfCG5MKVFgbofG(*{xAWwIX`+{p&#Jn75on4R!tTr;=IUnwcm?u2({V^%; zl=pc%ip5;FtubA&@?5^gQ7=W-m##NFLSMR`a20(ywf)D0+@HMSEfeM@J0BHh_FiMd zrL$3Z>E+YBM!km^E7smq@p$v%dP!rPcju8?9?O<+7gt=CIg|0CEiU5wEz$S0I4iF6 zcC|YN*gSD3D7iA~q z=VxQHH~saZ6<2|pOn`wTg`)X02Us&C$dQe}8vMwKLITAc0WP>BiZfDEONxPk0i+Be Vu3=>ZDdq%1d!P&6-vRo80RVZ4|Ly<) literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-28-13 study Document Inventory Report - Study Level.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-28-13 study Document Inventory Report - Study Level.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..b780bbe9e2e41ad132e2bbe31a8e2ae13809d3e1 GIT binary patch literal 300515 zcmaI7V{~P~)-D{|wr$(!*zE4uwrzH7+v(Ulww;dMvF+sUKIa?XegE8dkFhq!UZdum z&wOg4s+O`GI0Oa=3=9lNDE^!d$p3hu1Hbn}%AufjQ zGcfEkNOw(Vu@4CIWzakI)-+7jlfxI_uz?>nTNpFK2c@rkSg8{_dM1IWB+8Z`BJ&Vi zi_e~PkaT5h+fJNXOyqrIWsYhx4pBy0@lw+fpYL;d5cbki36 zEri>Sfj!w4N}$FJzUpeTI1QU)*np!Uui7R)A{8#;R}|LTADUUw-vlWRG?jQRgy^Vh zTy-welwAJ3s)%k z^nNHc>E!kok+jJm;7(Jpv*S4&pUH1p(i1Z%smpiFNCThDZ=e#a4Ey3ptUgyK+{$v$ zFbNDao&2C6AcPPgAjpPj+I5RW-d;gu-CkxJs5~fc%*_CAriE6nP4bv65 z2#u4px>=VcFa2$^yQ?p{#YVJmpM`zvv1>b{LsOC}x zv+vkpPZ~;5-JoY(Xdy&ZYkWsdB?UD)P?TcRTK8N8RBj;B=)xr%T$a(f7JUuXdp@hB zYw3j=d^+QF2jOq<&tN{IOBsa8q|Y6JZnijup+Cd4bM|8GXPqU`E%t$h3?};W0eWt$ zJ^-E;rHnJG()(>T4tPl^yA&%h)0>AqtzULnzZlG4v*sV9<^mxI;rvvXL+)3JSA4<# zp<~AeBXSFxEW42K%0B*|fAlp44-IvJ|(UgEuuM` z5%wiJ>YG&@$|tr?IxeD2z@yR$KUUAkMNBbg_qEkD4R@-W_{57$ZQmt$is~DH9L$Mm z#ybS_tI3K*H<%b1U=yqo(NDwr0~}FEw0FHFHCFD-@ai`>F*FQ~r~J-5XItEyqgc?n zXmmVvfARH_7o$eiIp9p)wg98$5d}-p%)lzm+amemW4cXgH$5k%4vD z3B+7M%e&iwl;6jUaWt(mOMU3DnQR9~?=~+68hp6YU#`#`e&#Ldc%h(T$bu0mF=^c9 z2&8B&hZEYt|4_&M&F1EqPsz-cJ(rgGo|zY_Z+^Bup)QSV;qTAxeCDk1xwzr?A5O5L zdCEZnXG}ft`hSCn0R+**hS}M|(8<(9&Be*m&fNJQj)K2Lk@`tcK(4xj&NrF7Sca1y z4ff#gK|^Xniy4w3_wNq=I8*FSIq2bw-)?BCR&As~;eX5D|DjfSN+X zIP|Pgc>wi_{9oOV`2T6{;%Q_0ACr@diGpYSbujDwW9J_f^ z@N^8migM3zEiyo6G)4jyStV$lc5Rh0s!EkHVs;(DcvrI~j|~28iMEdWt^9$6HqkV* z22G}|U$WHeyR5lNiT8n1=SHitPPb}ZLq|W&{HFD|)BD|rq*sdHyCm(8+GUFnVk`R+ z2??qki9DhGza&!+GMO+6R9cdn)(!L;AtHF~ zwclOZP?&{s>@mJeWgCA>sS{P}!sW+lo3|>2JyOgr9en>Z8s!lWfedL~Q-(QJ^a^zU zO@?0W2Ex*5`ElxUG*XnafCe`%Q-q0{>lB_2m;XB*1zBiI_!N6XTrgVYRJ{0+5+`$9 z8l5}We;TXZys4_uVov$$C9VLwY%anj2S@HACS()?m!e1|kv9AjXWn*Y$IKG%bl+)$ z{qN`QC*qY5_qx?U9>}TjY0tYMU;*;hEY#xpCv)p$@@_v5OIf>%^g8Rs*;hr5Ja6#n zOCi(ef0zzEP9g9BWcdc<|HgFW|MJD%-pSg?-ro8j$zu{G6bD#PB%gdjaZTlNlEX=4 zRY^5cIzWrDT9!C+IW#{aY@Tjjco+lSM#j4{`OPm^hW?ggt|#5iXQDNz!2Oc94duu} z6H03Yn5V0A5A}6itgSIdyY0(ah#xym`)($F6K){P(6+2zz$tXWzvP#q@sY!5+S}*w z-NP#hWG8k1GF&N5;8d{fS}^Iy-IF$qF!ZJ8M_#gTKpugB8rPc-N5fOk4bYO*e@S$? z_8-<`s}9~+KwG9P?uygLQOXEU!d+DFFYFm!)cZdX{%;yiP_Q0gK@j@53pw zV>X_(7WNCMOX1yM3K%&3Mu#&~Irrv&ZH#!1Ly z1mTIKZqKpLL;$avZFXR%BVxJWVeBA?_vBxQs^~cn$q7MSvQ9?j& zpXhen_l?0(j@fOFU-_Q&SgbV6+8(u>NDBq6V>oN6J@ zQ>gRuXnWjp((DQm3j&@hzMkW?Ybq@>9ONxoc}2E24|D!KOrNDaD|0pPLMP0dPF+80 z?j}Ao!3`=HpZo>abc8KX&Wl=Cbw7`=y)T+9JRCok$KOjf-#=QtN3HByJA9to!V%-n z!|pU%))|EvYa6?$unoT8+Sh#CyL7jnaEJj&O9PuDKJYvqw(i%b#BV-;Y0bHV)=iQ@bA@ zZg(2UV?NIAJ>yTFd3o$3-V4Uv4jerj=5OJIJ3GHO`-a?{bFSQcTki>8gwBcW_?~t` zKgooBb50hPGg5OcPAs)vpYNB6Ki~G20F6nl_I_V^Uw3t@Ull9Z=l8=qXP=h~=hnIY zQ{7lqSLa^NPkV+hd%|{H%UTl;WmE8(Fmy(w`tjI~rmrLAul8aZWNNb5Qc?`Dt9^Za ztEw}Asj}nScO&d6;+A!%HsThqB($z=rp6^unZkka^@!nQ$)2yuR#yLVpO4)cW}%OV z8T~K3;iEi#AKSYMJmfzkW&JWuqkmRy^)?J5G?<8{CpI&-+C(NB_(f__`_nf|hIicB zBX3_`40pNc{2&G!BM-;JpQ87{6P+@ywFP<(W-@cP+m|1$LwYS*wU0$#ys>hua;v%Z z)0R>Yhf z6TC6T)6;lnZi_%P{!B%PI;@&v`Z8Ak5Fc=WpQ>^Olua+c$0a0l6ok|fA053yh}q;D zE9D!DQZp;@7BG1BbtI)lrza+lN5Am9(+uI!u7kK)e;ypuHdI!|KdidA5D$ zjBm_5yL7I)8Ay*;FXHYVE^J#C!4WPZm2gD_Xb%`rvj<^Ohw_kaaRM6pi=zeVh%upV z<9Urlb2sOqJ>8TfhVg6|d_B3A^*w-&6b}&o7KB2XUTn{NMno2AT!B42wAb?hUHld} zODx^T$-F-v&XpifNnxt`Mp7aJ{wI3E`SCnBv&sM0q5XE=*#Y+w@i9>(V%HeDS5m${ zNdjHhEA?S_0VmaKYYAS`)oqGfaeYA?xI6OMYj!JtzGWl4d~ePHjuPP{)niWD@C?^a z#;=Mvg{wQGRtNZmKbL=9yQf=8kbu)l5F65Q>9U+%Ps`l?;eJ2r_)czDr50S+Msp(T z{O3JW&(9kBTibif#+bvrv@?dn3L?=iHM(Jx{ws;bG9w1mUyhk#&%d+yo|};oLi7Pc z-@BKOrwWn17SewUna%CWZYLrR8k$)7PIsHmP0Zj9<}E<SM5t?$l^$wTvxbcg(1Y(b+9H7W7UAhvgAVEUOaAQK z*pk40r2!TGmbpH~2-Ae`MKXJNy!8H{@eyDDZ0fe{HYX~voEdyzO%nr<^lM!;JIe|O zRHdKQpROY)a>!(Yx6W=Wp*Xv$K|4RH1hAO5mg}91gfy<_9C+TVwakMf=Jr7b@KCMF z`$wvYMt`}YQiHf)V(AVBezbW)w0^yE4X!eVlTTkhy|7FBqHqz(-b%n_#Q$};+0OK| zdge$3cQ`1~=Qa z^yrkT88Dc_Lbxi49n3Nek%U?_lZih-kqo&{x`+Ue~Nza3TB_V1`xCK zSM{6~6b@l7`kPaH8aMIi6ENHh3e)7R2z*3aygk8pb&fY`9WdMeR6AJ6q#MZ1dB7}% z^Dy4;MoToJe8)0U;1qQIqt0um(46)2k2;`WB-6@$@rN3A8ur@e58`;D`_;V>SJYnD zySjOQeUpg?Az+B$JGV~g2AL8V0f2z4GGmLW4#(%ljAO{HkN|MP4eOABytJ+yS`UOB{hKmQV4 zo&5C*zu)FM+j3n|7OE8LOHgRkg^1sLtwPkb>4R8*osr82pNH3ay*kARpSL+{yxYic zh1F%m%O5e#)jF~1=h+oKef7Ys`N|-AU-vtxXS}GCs0#a_>iUp(-8A=NC%-GwOtE=h zC39F1dH%F?n#_V2&jPjS=RI?f8@~yvdM_D`w!p$-5$uA#|3_IP9G!tHy?jR%$x0lW zF=o@(XNv|(hF`FjC}6unF*%8V#8p^vkGiav??pE*E_}9-$8NP+2qo~(Tp4ouU4La+ zJI3FeX+)l&QZL1u&8NaI&B&8pTF;mzT!7Nr62;%jJA>U6P3CWx7fo;nT|%JzuUo+LXpAHLnuku~A+DwA-{ z6<26-4u^g|N?Y_*W%0oiu~FpznY43i+w$M4ez1#@R@zcvy&Hbbq8M^I$O+g?{55R77Lg_14JDhYb^zz%Azq&(N%3(<|tiR=S zO+l)YC5{ihG;CRexh!-0)Rk1?(c%z z0u*it6wYSzv3p0s8zU@wMRx%1iAP zW+hSKYgsvmhWvQrm)?E#0G&n<+SrU=wZ9D>eNEZu!sn=Vh1#^5@7Lmet)UD(DHLqh zGKq$OLXx9WwP_JHfv*Xdfa|gqg(qZ(=K6)Lb@S%D`R^8QtKUnmL3NKmbcqr;g^29D zl}6F0;;dj5jlOYS=P$L}oz_f$Mlz$I&!Dp_A83Fouk7-^&h?)jT?2u@wuG zVy+G=yX?1`DGXq)4tCBVNfm;x+ElBrO9fZ1tr5noI_2_epK4@Qn#m&<c2_POe& zEP`Y|)rX8~ffVeIN>f%_+^W2Xbr&Iyj>)Sx_Jz2cMcvAaNJ~YgLK|PT1Mxpi-91-h z970m>E2-xOGKDBgY1G)*(Z{}iz*c~Re5T>yLfkD&tKxcXy6A(7uN^Q`^F*mokmo9} zR9wM6Uqw~}8+B!s*&)~BUrA$g|GLe%j)+ZduUI&=>)mA)Fu|V8D2wh`I@gDuN|#uE zd5TaHNGJbm3HMZ5Rc$g_C&<k>fgD28$T2b>7!9#vv9ttP#MDt&iZtG@--fB6E!S3 z=@$>Z|4>J=KCMi~n8hZ{F|(csw5$d&MJ49QY@E_E;ZDnIU3I8IQ%Oe|qKzYn9q{{r}`U#PM@ygHAEVi^L+29{U zIye|)0@$_eUO#DOdNsVOo48_oUV)&*L!-?qv8<#?w}=qI4S_=so-mLyr4vjzt8;qs zro!qQ^<0vm?VJpmfs_42r9}?+rqpoWulqOXiKQ z!4pqcE9^;6!WP6s^?NVS*YuiM&r3Ynn(p7IBu}R){M=RYro*x|^Mrt+>UgSZzkR{@ zhD8%&d)MAERBW*dzlr$9p)(WTKR&%c4=JfsbZ_v?;l~UYzwV5M3r%6!5zjQTVg6#5 z%_E{0cniQgvN|&>NqLEcP~1r>u1KELG38@NT-Qahn)%{b({*nQG6{5At!`_pv)4Q) z>g1-EHp~5-lI_ys^=T92SuPv?6B{~v+RmIFXH?m)ZZBulHO$5WQE7L2sr}w4N=lVG z<9jik?Z#?QN+V{@s)U{q^bi1(4hF}k7ep8sg1J(@(!#n;{}W?xrDb;M*j@XDNZ6nk zdeNFT+vgbZtepOCpGB#gIY~jc)9?Iica0=WC^Q4)>x4z(r=6uJh*` zHuhul+-0A)t%T|kj`cp-wtaL{zMvMLf@)5TApdHuss`jXT;4`9`ZlHH zMTRLfi$~X*km)N=%#T$5_}wLGXyWo(N0&-l`66apmD^for*f9?l7ZqqF(E!Uzkfiw zSAlewai(!+oC3weH}NDnI>Xg7)xtfL_+<6T*D+BuvG!A|USKxZO&I~NX-|PuzcMXE z)oI%J_;{JaHCp$r%uG!Fl~|KJEc)Cq>*(zG_VsS_7OJ{JGEiMUa=uKU>p>w|r~`GL z*7_|B3^!F4y=azmQ6;ZwN_Kfbjn&ZE{(3Krhf9m@h;pFd5zF>qra*L|piW!KO)Sub zCMOhQb9|!QPY=9j5C5VDUX~&$c3`Y`EcC%7z~fpFm*lc8Nz?^}^=#FkvO-NtgiSFC zBb8NML09$Fd|p(ZpyiHwUpHHoCQ@9v=|lSt4qM6KJ)bK@l+#+c$aa_lxyZl@G7 zBVcLYtwh9$DuS{Jlaz z2dO1jr5C`J#jvra7aHhb#M51v8xTFrwhmH1J-x1u$iICzbA2c43nP8}JOToOB$k;h zXoLsLFTjE|O?+%v^x!W;&p&gPoBAYarn+Y+3$?3GDZV-yebrKO zg3+nO#8IGLEi0T~Z5wBeJZ-nD{*xObcl;diSb&%y-sU<|Zw$ zKu942k%Sf0+-*e?r?me-*=*#X_@fO^(L&CbL}=IHlGB!TE=IUw!;!$t0&^+Gq<;ZU zE)OI-Vzcs!|0Ki_VeH*X)V8J=A|8hdn5pGBL`m-et-c!=a&cJO@g8=SU7S_6~XJdB{KEz2547Us6L%?OUZtim{ z8p&*ardwt_876oB@N=^WCaR^k2&PQ#4u}R&gK{#zYGuLDr$+RtsLZsX7S2G~I!*=M zWU>=-1{%bSYmlzMSPw`x;%n`B+ygeM(4dj{Yh{`|QA4Ahl(&6X4>$;*G`$O9vv;f| zxS3RnoG=aSJMB3NMZd0V363VB>n3lfKx(oG_b}?cG9QO*fd=-%-qd6m8Olz|9E+gE zI{9c4)a!PU&BX(n!jo193>Bj{M+`t(ECD3tsbsrliM?jZ`ILtMh}B}C*TM`RUyw`N z4?=cCNY%Hvm!YQ$#v5M5D!jwcQjB{e zFW3GLep$cWs}f;+kxi&GnKVXa2T1+B7a?nXX>4{Ri~soT3|&@}dypdXEroxC zuoZae?TD^9!3mPYf9?=6NsY*h2QGgaci$nkP$rcamc-Cv(s83PWll529B~cMPu*^YJRPD&53}P@0>v6k^TJ?C~ON+}I%z2-{ zs7gasd9bN*C`1M&GN?#z{7A2B1ApFwTUfS%D!&UVXP7i_yDxKXo98Un4iOO~wH)nLLuh@_H7bR0@aHsC7l zsF-knGgx`HYi;V}7`QAVp8%z#))JeN&b&@%i*YgLWxtu%JUaRHkCu@@5+i`0}~vQM=~luZ|lL;7u}W^riQEo zD@aC%G6WRDsB{YUgkc@J{C+I(;*b)_wEh{s4iy}HT=-Dd1rdyIev=k()a1D9s`L$Y zL+iL&ulOXdd9ce-X~E!KcdwcDPZPSdU+XF4elOQIS1+y!#;0CybsN}-uX4nU4fYB@ zjy|b}KndJEe?`;?cmR8vcQ-dO@>ABbXeiVe9>2HGaINUz7nKY`z~^$@okjQ51JtE8 z(G>UD*}GrQo3TVP(X5exsF)JRT&25f<)j;B!Lo;|TH5UA+PCwX$IIAyRQ)YXQzEXP zzHFeD2o<=-1(pO!95Iyf+aaQOL)w{2QML#N-*4d29$lhH~@A0+vT$XZW= zI4AD6u)bu9)wOllnsvb)Zxs*}gPt;ZkCmjUb4Jx-5FhZHg|!^Y4Wfa|@NVcEr^)d- zpUvRf#zg_x-Vy96I{oI4R|YK2P;qHouG^qto~`MpygOT$!iyI7rN)9~FMpMka*G^p zcgf30zAm4Hl-OaU4g7ro{GdT1(_qqi%k1UALx-q`5nnC2U|yPJX~Ch@*PZZZ!iQzT zm7C=61U6Ff2bFr~_jP|W_a}co2wuLW>?(`z6g22?2sf2k9VE@j5HPBL|2zgS+C6jq z)c22O;u1dE5#%?`@2HB$rC{Ao#7)^l_`!*N| z$NbZjUQ0lj&-YVw{v*I$SULue!f(<(vR`}UwEguBdtvZ4yLqe?#8#^Qy+mBc1yrb^ zhRw)+eQu30$F0c?TX;%esut-8@AB>9@NoA>|haU%gdYh!nf*#;v)p(d;N4103ZYS;Ve007oqARA+O^$kcO_w8k$vf&};4-0(N1Hkm3{mjAnA$O|#lj+FmH*4n z!9g%hKmoCKUw@2NfJvH>502A0cTSl9sPwQAEI!!sNp`n6;evaFA?B zr9Eb&aNa#{2)YbusJ)uJbDlu(43_W zV$FRI&Om}t1xjzEAwUQ8#hx|^)=olikN_0*Ca9s;quJXcq08W~+AKlG z#1M&`2W-`5IA!m#duS#bH_rS8yXJ%=H261w9enO(#}1)>?abKFn?P{)tW-q(#hwTT z`C2owR(Rf3L)P)dfUvOn>=JuiYbrTta&g+{F~-J1X}O z)l){*i}{D{Xsed~#8krAYDK98xEihY{J?5M#lZK!PNdUhR3F)r2ueiVOv~S060V-) z>L7H$D(anq-EHRUg?+s%nFu-^&(RkBC z;BWq7R7F4IFzt#F5Hs4Ry%nl&4fti5FXz?jb#=YwOP$Gfk=#TJxell=RE|CA&cbVQ z1FLhRH~1Emq@=G^vpLh$;6*-MW1q}`M8*m;+Q`Uq*;!Zc9yH~slF4vn2PsR4Yo@vv zbK^(#Ovb;^o)#^Msb=)B)r*ms8X-LfyC`Gp6vm*amOPhaY}%CUgGu;gsG!ph5@fN< zZ!<4BTPRm)YoadMmT_so{pqXG@yJ6ha0x`!Ap^}+1zpWo`aTr&kQBH5#)DV0G~Z~f z2<(W^^2`V6nCXnT+Gv`I z;?cJOiJ=gsG?j>c$Od?^fL?^sFEN33P;}Hu1Zb+t&yJ22J3HW3ZqulJ>T7Su_#aHh z37jD8`s0xUiN-3d_cP1hK9r!+ifB3iE^MO)?L+|ZS3@Foa%mx3B-CEfE!@XbW9bk3jm}bxPT$r{^2-I(47AI5>PJdQ^c&;UC zQyQMp-AI(O!g_u4_i;{!5Gult1qdK&76BbMtR_Lgo?RBP|8QI5v(;=tFC~=Zc-K-4yzF?w z5nVAT`nFIHCvu8HCtOA8&YEPQ!Y>|wR^iIBON#OSZ)ijW?O^nh~H% zhrnVW7Pv}zPV~4iXZJi{*8GaqHLY2N7$GHMlmhJhRg(+UW`9zP@RTS7fb(vk^28%+ zX&aXAULR8pJM|gM?Inl&4pO)HGGP!W8YMOsO6rAn8gRsp>yx!2&E2?;uuu=%N3FPa zdAVfp`dY{$W1P4-{n-s^$uq}LN&Ib|1B=z;x+bfG;~razl&WksEj(`SU?%GV32za7 z@Ll(D<{*uM@BIjk?9>uWV`5&)*7sb|Qp0W5LmC!y!U$o7t)DO^*%#iXe>I(_QzDfb zee+&zo4QM59*vFC&>ByL3Z037JZYmLasK#v_mTgcO<_d$7ZiOO5TyZ{LJ8bhmA`D< z#KPaG&o=$q{a22dx2m~?d)`JwUG#f!=-9reWP~c(-3zDXWnP!HzRW0)smBA*6#!mU zv>f`lqnp4ARo8zC!_B{QUd{LkVumOk>UtfV1CM;bqCkkKn|9sIt!@a5;LaW>!YSe)GG}Yu%-9498q?Rcm#%^fySYu-};- z>JQkmhVE@&HgOx86eTWTm{W9HE%2IY-&v!~D3#|J#HRjM2@*~@_@3k0+!N^0O(f;& zHEzhxr1H?h{uH4}AXAVTHP2gQopS*h(e;9=QUn54L|sUOtEeQQu90)bjD1za?U^uJ zD_`GH)l%dIw%z&OGUJZPX6*WMS_qwvKGm2R)uAEFBVS>43bvqs9+GZwwR!PJyI~1} zPN}5UwiJSP-WroR=9dDsdT!J(2vb*gI^1*&_Kgh5`QS9$1&uE1mHsl8 zAS2U{DO(bpQTkAHNfbr>-9IsXKAneG*xfwH2_9xYTby{ zqQAN%W={q(vtioZe3?>*lz}9T{9gRR5$I@l98PYY0!!-UaewJn#>GOz2bKnmbM6G~F!2s!$n#!{1#n0}w%95XfH>C8db-{+@jDf=Qf76#v5 zob*X*yp>H)Gny?CH4J_=&1CBm zC4%9_;||(Ijc3nsAvKSqa}V6uapH?8f&SYmw(m>&^tMS{!=$t|Z9I&=>PxBKXjd4i z1{y;pa}$JNq`SFjn$v>^!Fpqovzf78iZmPP&^N?TV(QCI62}Yum$)RdkH5~?s2hFg z+t4t7nykP_Cp^{X4&x0pGC@nN>IWgJxM!JG-Uj{ENB4jng8_El&9R?*(c zcXh({jzRwK%ukXba(6dZ`gz3JIX)hczA{Z z4_!AWUY<|Mrimhbom9fyH4<#okR_8DbPz!A8n>)xPh#emb-w%nZ&N?+_I>?6JiETz z+7(#5k`EeRaRws{`T@qLFjc&oUY!W!IkirMEfUfC`@EWf>Cocy6?SmYdE3n0tz-4z zDX$24Ko5}yUf>|WE9fqLhNCC6PV_7SKnz4E83!llJrbIu|hT_?uw_^R3Y}^ zcnai}7DID-szF(Kw|&Q2@RXJ(9xf-)AhI|69J{-_rc&ot(fsJ)D)6JuwPB4zV40Fu zdhscK(8wcnHuLkv41=}f&>!nq_1<6Y2Ss9g$aVG(K&5CcES-EDCu=uCvjB_{ANJ!o zgr)C@h!c>ApvP5tm2JC;cNNVm$^Wu~K*A)S=o+ZHo?uSTVDMz_A!7JX=RcaVa7$zzIF` zx_P|7b%D9dtTz&+H@5=U5@{xzrI#-N-2Die(l-c5=Lwj)1OdmVpc3hYl7SGZL-nsi z)WRew#aRiefRm8Z04ksSPkAI0**ek`ob0}^*BfYjP5wbbn}{-|m1FdkVyG;2t^V=m zNGe%;J%g!NV5Pw6e*ObpWg?W3Jb$0;D)NC%#Z7lm;w5C-3z z$*2;|h*lFJp(3Jc&8BGJ?9A4$u^KYd5s$G!H9v#Eqj7r4IL-f&=Y$V@^fs?O%s{Uc z3GBrD$thcxS!?2h8~V_&C-%Zg^qv&-*!Jz1VH;b6Yo;OYZtAgnw9v)1qLv4+ZF5)k zvMYIiO8hioOGJn{N%<}kcOm)$<(0KortPAv`p;Ef{YCruhs)Pb<-{{-&=8d)ackTo#JG2Z;Re%L^hKE!} z1Ng+jA}I-_xS_EF`Z>*{g@Fx;O%nm7r$}`S2Z=&rT%}7{!(L-aAc`URS~M7)m_0ke zV5zgO%qyU$@~&X90M$-REz1@=vQO5GB)3u@EP2ql2i%2|l1R|zL4S50o$~-cLN>v)XcOtzns4S=XUrrAL6$@k za(5&_VKwZ95R~;l@1>E`v)%l$)|nQAG}=W3R`bK&k*1Z!-;D zbUKPd)L3ApHy1(N&rAb* z#R;r-I1j1LLgX{RlEUOU1&Q1(vxf|5bb#4{&KPI|XYS6;%8s zef%OLAXgW~!dGE(#IskS=vP4}gc5RB!0A*!p*>FFCM$XSoKw^5>n)(4lbX0V|s1UIp7|Wi%fb! z9UX`~RQ`RL$XW*XtEnohLqI~EF7)0`cMIKj^-iIF4U_h;(f6@l{pPeP%*{oZ#80p_ z+|69d3keGr@+xh4d146;O(F+QTC@+Hlb*<$E_0CWjnL`2W3!W$s7KBE~2s)Jfxd{{I?%Y za&UlzhD<09>+ZPb@v&eOs(JEhXq)@#=>?DPl2D1$^|XjxjdkCEL2h%=kie-6WgjK! zvoj}R_k=C_bH<#fy$(VGFG!hHP4$*2Sw^HpWz9te%JuL3d7B7RZy4K`qmY!mkMbWh zlhIzo$86OPZwN8m7{x}{m5-d0#%MNgk2dsi9i0`Gut@r_d<57w|Fvz>w~ng3)GB6Q zk1Pwmr8kb@6tJoZE(P7rmnyD0!@IS9(&<^o><|tD22FNa+yn{d+N?JjF|^qJ{(Pd1 zIR@xJ#E2NLtpWeo^k?PTl0Wf*!Pn82r>U9G%d&#r*KOzzKzSA6w9H}3$O)P0)mi>^ zV0MKW3xzn@pA~keVAJ~Df$1J#)0YU)1QdtmAZZS$X)^o(-YClALl9JGcL)@2oq=6{ z@M%gs++j`rbR|1_Hf6KjO2 zbZ_T`986bW)izszO_l`{CxBy2Vn!~kvSNbk3lDuI{l#|YeEJ%ZK;1Yf!6S9P_+`PA zNS!YTl#@yaxcQD+&pPA%J_EGxuvr3&&BiytDHo1AVW>9Q^Re8X`mnvNjvZM=4Z(;A zP4Q~9^OTW3qBF8oHQE|2*>X`q_wP$uW^dRevZtFl&uu;%I_7PgwBcXTC32C!yukj8 z+(G_{Iqt>)6CMzg!PPvuJN(X+Ze^-Nha^jEn`eOwolvrUrrPaI0Z^xg};yuu( zin0Fe?C}BXJC9FO>N?ar^4v{aMFHtt6;ve^y=A#`GGsK%fKg{)!xc6dCUAxC0Q5dd zE#+XmVHGR}x<Cl#j! zH2ge$;bg-j0ToZJ5Xs(!2pLyThA;_Hrt5veP=0}p4~PZ!1@S8|$G-nz0$58iE}KJS zpi^N-3D0K=+APt?g@g!@0$@g_lwl|+kv^>u`5p=Og|JJ*_}QrKR;P(GJ!X(x4t{?d z`3J_JPnhX$=Oi5HO3pRMQ{$__Ao7eyAi2o6u07+vc#ZbJyHgv)pkm#QREG-mtSq=7 zq4Q1};k$3f;i$3Qu6?0RA@>%Ly1_qM0f`>KLRBdb9#*-aNZVvp@$1 zi1R8@+X+h63)UTCOQ~p`gNt{>HM7j zcpzc{F`<+!FNSt(Q8D?2+-X^_7Xb>tY3kNDrKCec!7cMOU z%Yu=RHldWK`J#YiEmNB5#fZ}IX={>(U7H{ZiW~W>h?pGJ7j|4)#6*>ytw4jXy6uhZ zhv*t=e8PVziF3ltCMxfPvx=5cUe_OBREV~hivFMpnT>nRQ;ne{XDb z$P7Me5XgB~MkuOyf)dNqy*d5ZARs(MQsXKZ6jBw}v! zDW(pO`?MMZ@#FB3gn3Lz87(>iEYlsilc;*{5DHq7|BF8$=pX(ix+;N~&_h22SSa&D z4J=)f_5GOz@TLJC1hr<4PKF~zWtl_BaWxI8ege579`Ce21Gl$P!>Fn?7@LS}e86Z_WJq4rGYH9gLke6BEd--S9p}Y+ zU)^Vx8@?&T2D+ThD@yNu^tjURhGPHV;i#I1tP}EtXKvD(RJq?ZxT=(i@Pm^D=VeYn4eI=)Lj2bjq(Fbv8_VSS3ovPnT7g zNPQ8mf4Y+!85i})Lb2W$8p}}@fyv>Fdsh1Wv>~X?0^(y{RAx6E7gGa^L;%Xx4xJf87E9#3;bd0LIg3;G2f-Ko=Scq}w0ep^j2n1@($^m8y; zO`!`5dUr6|RSkH`1r5)J-~)wMRV+yiEfXz4faz8lq=H6O8V8&V?Hq>GsV!*uzhOh7 z1%tyUwT**Mqwq+}$Z|#hsSoE%M;*?(Xhxg@Y7#r<7vF z-Q67u+}-aTYNL^8V=P zd^8KKnny)?Q-lw=p!vP6!!jcK3wS`wb{}L`t@Mq#Io|=Tfksu^; z(xeS;s2P{_&|MGoe~$EHn5?h!I$m)gEw5Fl8Kk zh&Y-ElZA^rrN)U<`7M)aa%s(=nXw`ox~i!aFt?N`Y)MZ5U~XvhkK)N;sa!}uqcc8# z5YPK?dO>lI$T^$w#Aj2tcv6Jgab-#fV0W=C%A~3qCh?nlJz4`q zYj=@3o(gwc$6u9D$#FoR*zk$@6Oh<#t4C~Y4XDI_y>0jC&yqU*piK3oDEX)~#92M) z+b~WipOTajIq>^ml28q)MZFD8&+#0$4HoshwilhfD41;k``sy&6ZE&F#m;o#?EtTk=_Y_MJA%tpi@M zE3ZGv5!td=3loWWk}{7blYu&$r)p(Id*w$i|0`smvzxhgDPSb~p8MTiB20o9r*M=d zQL9Aqn8xx!+a85c4j3UdF_tsYxs~?wXC6r4lp@4evQ29KLua+v>Ys_kr2ia*VUl43 z8-Zb(u~jqs4J|ENsa~W1_kng0YmcX%k7Q`lNvtjf{}BVN$bRYwr$hTyUAs8 z>3W}zr%yH-5&_CQ%GQcUFC)FhWu@z;pL9BP`I<&;xTmH+U>`n*PRPRS8<~t6F4e1#b2{n zFuHY>!F+hmpJI0tnRBt6W`L)~1sqZ94TJ)8`kAEJOknW}QYs`;XQb0oQ(_2G0$^b1 z@W8213cLnPf#}4NRmN43O{H1#!C`gW8e)WhwUezo5&8ia*QzB(BB?wT6Dn!%+^BJX z=JBYXaDQ%i&No-)p|B?BEVak&EU(IHueeUNgPBLUF#1(FHHhb+*fS@Gg~jEQ>23i+R;$3-$K1kx=7*n~i7rH8Wf@jK63!l%xPb zkuwXvsO!!1vQ0o}hWrO{L?sgxZsl-hcS_`I3kq{zNdBYgeJ4+b7hn*E8Emi<3S%dR z<2iz`SN`brvF*p6ng7fbPxvi zrBdGv)PW#epO82ZfyeSIf3Qiprl4>B4t!T5D9BkqJaX3YBp$Ix+-6Ukwx$rSmnL_b zJQ2*7*h}2znheeSUg7;~7=al)ypF<5*-ajbhsC!6%goVB9x``{VfAx{1=O?QdUXiQCV=6A4b% zQ{kgw@~97?Q&fxi&o#M^_dUSt*Kos*P@fIK(*5UK>mNTCrmyZzS|)3$tlq44_B}7t zl!lblCABrmEKkHH>|S5*kWvllu{Ls&kQEyN*-)azoHo>F{=*)Q&Lz%aYO73(DjRIkHID7-Z!{$D5fPHB8 z+E}B7<*%*Ecj@GBS`#jO|NiD;i&C zw~s-k`Ii6>gPp(B10IH{XWS%;#KN#jjxc}e@y`#8L!(>i&mz39$%3kVnXh>vgOT+;a*O^WAac>iE9S?WihDmP0wX&+)6}|bL79!MuA~xB_Y%? z|MAA@m05uQlkX-wKOW5QJEuosL6H>NV^P zT*QFW+uU5lkh4*8N1`JCJPE!IeA;;Ay1y_@{f;_z7oap#ffMWuy?vAGljG02==eh9 ztTsxbBPx@8$P}wC&ZuuS z+j5^LvY-@;)C+xyhiH`qYchWE(P{GhOo`p(!`Et`hwm2lh^5ozEO}#1V@3AoX9b(D z{lg{Xi`->Ucd{W*G|dcm{h?3EZW$ktiCey7Vm~h=+=dcMi}q*9*HOzFp%>>J4Hg&% zi2Ku1Al+Sx`x6{f88Y?n-P{ad?B_8&NRUZ?R}UuQpBAZ<7_I;@A`qaCQ0J9i$Y+Jhw)~_;KP62uf}2CwW5)%>N0~rTUk{B|KM0KgcZmub z`5O4EwTj9H3N7L%yRA}ygeWfobU#@^T$b zvI!J-E+G^uR^P=gEHoi`-vtcE0@mApWcCsNbHc5tdA6k+59f1?A_DwZ9%Y0Pgpdm} z*nQ7MQj%`f-khhL2{>)5pQgXt#`ri0#Q2@I^6&28wDuMudP{t4J`|h}rk{m<@uZ$?dS)*gc=c=ia81-K|+E>WojS~OV;ItqNMSR*fG)AMay z``$5CE}w6uC~MQNt&AyEGMLMffnPj%4Hml*g^orW4LjQ(fuf*B ze*E8xxL+@h+xfY;{mwt;Tr@^ZNe9Y+EJn2M^6YR^Jb(WD;%>q5W!Hni_fze4w!FW# z>b@MuJzW-uYfeOrptkY;Qu|mhc@aeK;^wT~+@EMwGuF-}<*YG&i7no*u8u^g=`BF; zUKD1fi|h!GKg;6bVf^I32_;KZzvainkSwru8p@|Rc*>t52*Hf+IO0R+%g%uqv3Qv~ z(x`ro>%WJZEd$}uwaO#ADUvD)eg#Hf#6^!NKU8k6NSO3qSFtUD|tx5(t}g}z8tiP4tFE;{{J^{P~qS|rMP?b@*KEH@$>sO zrWgE14PVO!IqZcgf|PU7l9oMEblr#0YXv@K1Rlgua!BIsE){iXF9kA;7t(LS{79`N zo=`<-e!exZ^f%Vc?!2j!IBYMZU-J#VIr+JNFAhB_mF-Tt%L3j z^;!^r5juT-EF~08Q-#64egq9?BDln3y`E$#=5Q$EF#D&JmWz;*6`Mr$6ZN_nOWi~E z8CUdg-SN67H&}{R#)6Sejca|y@l(5@d^S$Tk_HAFG}HEbg90ft8oF;J5gC578!Eq= z?SjK%M-CjbKv~`LUjjV+I6in0Onf+4Fmgk*7~g*Sb;j1-Ia!yUe_U>c=(v2yfihpJ zvP-(ZAYLIFwu)TnMo<^G?}jOtfmr@usN*pnmA`8f!!WS1KhV+dIyCiIMc6eS%*?h8etu+^=koa-n;-loB^D|(eq&D4M-=%HhCVO(JS#DmIsxN$I#5`3E zFTKrAIYyET1D>qk+Y5%>4$@a|>XNfLU@x?CwTSOC1u=PH*;6dB!=z_F@DkL+uS3>R zCtFF{;9*Dq-4Op|eemovvz7`iQBu$+s8M6*@>?G!GT=3b4C!(M8UqcOQI;@s^Yvd0{j`lyNBbD z6w)(KH$ka!o5x3Or2r>~yAQ_S5K<#4*Hx+)MC{3R#@9aFv!r>QCD}b2z5eh|uRA8v z8#A!KE&LN6$L9?jd7t5e2`-8wO^9F+ey&B|FIdx8|4)?e2rpWpW-#y#lNROMx^!|O zMw(82%vOmSkdt;oOJWTUr<=Oj+jryj%~9M+|7^*>d+4#)Ktz?^Wl8jko5hW)D}$U4 zEKcMGih4>?hQ(qyB@way7uUb?GrM8lyYAq& z-c?cI(ke|}Mgrrp5S3Nif8LeKS``sc`3(Ac*Aud zBB;w@5K6ny`Vlq>GjlL#`)Jc}Jafw+Q#3BEZXHBgg$f?f5luo@o zW>jFgXm)R8nR>KCl{-#FHrgXPRv{%{_hqBEb1+4L6r+R=DSzm$S|K}1#YeAA#3ME1 z$JnXD$BjrpU8sJxSIFqhOjwGgobJo8Y3#Uh*Q(=p4aS4DJ|-@$zjZd;#=j7eH;+dr zWDfF^Z5WRru+{HA5!-dVf>;#zM{2T-kiHeK&7Yx|s4a`WOCKf|%XCjh+4ypt(`5-L z-&aW{L6_OpWuvW9@n38^V0^88g6^^R`!%qyR;$`Ejj5mL1{4F`Z`YWF-U&LPIJ`SK zLy{ndWQx!xrqI|((UCk<7l)cf=Smq9Pa0B{1j&^kTw)zlw$xmn9DJ&|Ndb)cXf$3;wV z1}iB~zVDj>g_jIV0ZTdVOtL&OI6crCg+_Y-hK!UM{YwfxK5>|4-c<8-NZ1@o3Xb6G z_bDu9LgR9(GCj!jl*BMsLYUj+2fV9&JB!UoIu%rBxK&Kx6zIh41=ZdHMI09lK@iqV zwicY0%vmUi5$4`PlP@q!jDk;H~FpMuMNIYcj z*rN~>I2}0ZdEl>^1}nmY4XXmPZ`!wcO%9x8)D8Q@KUZT#Ne`m#`_u?@ocu?%gAS!G z(g~iY+IGUk5K!f|i4L0BheU(-D0}xOe;fcZkvvTmLXt5#AE=E!WA*pTp6NOZ?CxKr zgDLP!?C2@V$RLT65;0r}K5mnfqjE1}{L?j7TgrFIs+qea1$W{X=@d_pwjFsf`4ja- z_Q(@U0-D44KoABB99yuc$!#o_cY#@80ejA3@Q)#K7Mlvcq%yDFoCe8sfbvd#D~(HA zI^*kLo++H?P$W&3?0Dn|_!f`gKHd7%Chk<-F7TfbwGxjiy}It{ed_(LcCK|0Ps5K4 zEDU<}iY&CB=nUI|i+UhCs#U&k9Ee&km#q4THrFB`-Ym zONxcOJl*h|MMt{?ugkOaT~7_CbNV?a08XJ7dKqJIcv!rnv^pp~P!Xf{8+BUHK;|`3 z#qMTr^_K;p%5pjdOCw;@mK=c6U&bh)ON4uWYPf6>1N` z^hPQ%^!}qu;#uF>GV(Y7C(jp%k?cW7eq-JldBN;0R-Xg+Bs3^by8oMm7ZT86h+_r^Wq1Q?)qBPgQrFR61@NWO!?znjwgZKh zt(*mi1!=tnhkG!=Mfr_>4AgiE!%|n5haAt7r{`~~(<=k%p{s0@Zclh7UcE2Cp5a6T zN_Y-f^s9UpU2qEQ&jd=oX4v|*narqw?qZhn;m~1SjW^B;qzb-*AcucG32bp!9u{3d z)HrjxgMZwSvDi$BSy<&@@nuA%@VIWsl0_)Lr1$Uplq zfLuukJ}-#+<&njtjnBc~5}05fTqe$>)mnaU2V)=73R^D|NT9OXx4eyk-)aaKO%y-N z*(=<$?mfQXz>jcAx{E`22|%|OfG(y;9pr)8{Iece2y*Oi;HIwHPsJ#(4n=KRfVM>9^mdH#N!iSp+Z5_(1j z0S~C!EHpX{2G*d(MT}mzj}~vx+Zfp6E_5K;5XI;co&9l;c!N4|CX~x*TW{?MhB$#^ zIDEj?AeqAF)kHY93vunA(#IP5mGK7OB^}vlQ%Tocpfh6FQMM0YpbN?y4WX$0VsI|E z9B%{fLLQZQ`Lp^nqd3+2r+HjW!VH*^xCe)wgTp<%YyLVSq{n=uJVGEar}ILk_$$pww;PdMivl_^ZRhOe>(&a- zM@6&o`~BRvuU`Ut>3vt|Q&o;}i$#7bwvcVT{l_xdim5j#OF3Dh3;G&;5W%-Le6hoB z7bFiUtaGM=-(vYHlc)sio`4cO+?$OCvDjK0Ttn(YFpb`3%Q2*}I^j)%Y(3^+3Gy`A zcRYFftqtx+9-i%=Fq|%}5j~RBZC^SEZcR?=zgU}~dBKkv&Ap+xs}s%DT)6||_~9GU zvlV{M*drpen@>ONxHkF4=K>cuF9+KGe+-c+Okw#{RZM+M?2vB3)B=-}-CDR?IM{bC4ot!i zi>lTm{uHfCc&vy#6!!AO|98R79Gl6uGEZO@lGxa-I}XMV2e+Dl;X5FvRAKoWtW2S< zxev~!`<;!u{L|B4U;B&=E$+(o7xka!C}N$)PL!dhRx+dU=XnH=>-rP!q zY~T{eOymu=J`dGgqz^0;4tCucA_q>K_ly!%oA-nt_#EFOY9C0SC4bk=wim?-@%o=? z8~(p)`x?l=xs0@?zb!!@Zyr(ccPOz?w(_Q~+(T;rr`v_ZCRZ|r#bZ=t?Ih=ibn0j3 zmIWihuDJ-6^Kk`}>$Tdye(!IG+q;*Th~QWiiuv_I&H)3G2-3QDaf8m^3s3mJ z{9JZ#XUS@D!iv`(s3+aN;_Xs1-x~OHyHAf#+|zByUbHNEJuq$^Jasb zK!T^dS0_11D4wsHD}oU*R~NEvA9g3$B8sepr0gfwKB(f^;Q{CN`V3rl zL5)n1+HN1!5kfR{BI05)lXzFym#A2~H!1(PC6DRv-%mG9U~dH@Qw>cFvCbn}dM0SP z+#gp=Tnm2A^8+`6mHVdC&MqHSv@*|iiV$;_JU6X}IjWHEO z$%ik(`34Y$#pLnRLXjkvaXU&@{jT3RX0jj{x>w!L*4~T0v!VB=QQ_MQ+ zwo}I4$~-2=Jggxg#=Zj|*W|z!Xlu;DVPKxVlxCf>QtoGRX2ebiaH*3bdZz?TTncQR z6TlSI@dIzLGhz4QR!lIrX6M}Xr(-|cvL~|P(5~&L`^y9|o5n7G;aTs0(H}e(7k#n0 zhfCYzj*A^` z#a4Wmcss^kCcIkyw*Ki5@x_=;2QET=$M&TR-Fz5J>c!2m#GmWu>*|Zdxg4@zGgos6 zfPt&8SI4R!(r@SfcT!CT72;%1E=&rNly5twX4_x%!vBqf*u0t#L`&pBx;fRVDa8>!Lg# z36pm%C>&E^bu)|WT|x+@y2ea(*QP9m!N5RRJUB%d1fp4iIs~N0+I8eL`a4M}rV@{L4@rugm7CU_|tdh1t|0Fi{sWsn*HDQYLiw74<); zYywb$&(}@q99MsQ+&$aUZ=5{w#0Pd6tw)DVCu9h{z9vI=K~n>C3_=%H5GDqaSd~|I zR6Q0sLN3f~yOQQ+@~;`m%PZw4dA&Mq|msF*k=-CGT>ln^}4%_aIp z!hR1}U{VCI!2T1X@G3?(-hC8Rj1|lC?=Df19Lq4?sgEF(gGPWVAjePxoRyD!nf1z< zo$?W@zJNQ8V>(vgvI$EfiWa&BN72dpxM?zQ9SRyM9N^t;i#N1# zd30Fm9B@TQb%uSp6;gx%}dNmR&@fsaJ;{TRs>22}{ zdcw`nTtF4|@Ex(}VodD#Zcq9ClJO#ttmJqzY9W9OJjY<8v?vHLlEtQ> zxgV!7P*3}hgrz@kQ1v4me@q2CO3IzT$ghsFbxIi-)Ba2W_2LXa864=&m;XpyRCMa4D=zSDNpEBu{V@FE}^zANV7_D$Te z6Mqnp92bzh@URZ{${V!?)4;EMtFlZl8A00~Z7Zn<5PB5a2{0}}f}6bnWg!X`*FLvw zhEnt@2M@0kHB!Z;oQXLM=p4C|csOhbMV`Pj0zP4Dm#T;r6WgTtl{Q|#CTDiwmNS+Y zPgL@h7~KMaawJ+BkQR1E9lVVsUkCA8__DJXe^JX8^)BqGZ%YxmvhP^5qz%ilU#aCl z{#y0#JI0D^x-%}@!JiYG&?KE;t}_TXCuEu&n_ybP!L@{R9}_qd{;%zFs3AMpKkT3g zn$}5*C?JONl@h=nTZ9lL@u>Slua{)}M&pZHNET>4v?wml8%&Hf#D1{lBez+*kEd3V z-zJa|m}9B_2*s^$X-y>y5GOQ<49Zv}<14s>paZG`9_)~)%uOxYujIZoMW3La6K948 z3xR~ujm(Xdx;T7`Bd1on$(5G6hEAN0iS~SM_Zb=Aq1sY_+d;rkcYCvlB3#0iHiG}c zm>6ABvY6NnJBRVVDuq8bFQ80$0Y{fP^C`Ok2*4JuVTWO*A<64e%Zq$88!m;y8-YoR z#^s|!0KU>wh4rQmIgmknw-wGs{Im#&`ukkwz7cxxPADw~+cPJjmR^tt$)kMYl-I|K z$)B&E`^n{1c!oY%>@>YE=46fRL-&IKQzp?2(ZPVSwMM@6;Soe0rxE$iF1F@mZRKH6 z$VDh)eNKtr8l)>?<--o7g;A<^`OBOxR}$*6XDYz`C}3y<$dVr~F+>;9!l8;QD6K#k zhci(pG{}({)9YCQG*;ta!3+_xXPq`JgAz#EL<+R|SFMcQc6sTA%T%GU$dUkIcPeyB zNlGtvmA&DH)jUK`ZF3f3jhAjFF)C$;3qS;EBw7`KNH9mmBit3fY4PX_Uz9`dww7j1 z7fH%1iHsG*A%F`WP!+>+*OpHRQ?eF`OeGR8f27)XY>#B52cD*JR2S(Q8&Z0WtL$qx zzGfLFY8y^uQAa$ScWWC`b`3`$&I}h&;|;EiT11N8W?O=IBXE!-`$)gICQI}{3*iFX zvL6*w5>f@VLLiTfwqm9%J{1B&p%4uR0-z-XIV3Ht&$z)`a7;z4YSRvp&{T^P_E1VcSm?McYG(J2n4aYx&(zJE(9?}Aa9n%NN56B zfLSgLM1(bTnCn!oMi|&Cv-}s>;+ov zy;vVx&~xG7=!v-%HEZ0Z=%Mixtjxq~%ITpvcTH=s2Ewoc2~E%8>zmi55%6F+d@Hbm zVlaqOpp)4F&xwd#$Ob$oTu-eFdE3^ep9qE9zDWO%xw?FE#vM3^F&k|kJs|}M%KM=e z9Mpv2Ok2ZgjMu^=hk2<3G@b*`z;#YekcW~&= z95rx|KA{#Xa8SBiPq-V-M4?=tLl%R>jxIk@6G;KQgpJ6CCFMFPe{g_&$hh7w@RkRL5M<(o^CEF3>&$QIAx^c#mlLOOR(>P`hor?eBDnf9T zG?qOT7aPN*=$5o*jRci0SE%NUmNEh@qNO}gvM2)ZeUXN+A)9cEYEdhjWgfm01;CBR zihH(i=22409m)YHOW3-lY4}c&7+5VUpTr=@N6#CZt&0NdaIY_oH>+JfFBT5;CJO;BjBP_IRuNT=Paz4VioV~iAn4h zGkk#L#D}zyLc&H}ENnJ@wAl~P*#$dYo#NA?^X(rW(mINN-ZE0~j6Jy0>g<9E@M%)$ zd*(S&xCq8e|JXFye~&kgn4txM;&G*MiqJwC-!kfSD3y_7BwFc1`mm3&2l0oD0mIu= z%b71u`KieCKP~c)Wf{1taia$H#c{(1|IhkB{1V+hMqkC3OcIope;>YlfO}r2Q04o6 zygd}cSt`y21Z5&b23f3ZiiWd^>wjdTbA`|qvY*BLxDTGM-g@ngFD4RIDiYq6(lpO` zBF;zocYuN=h4YsDagxAX@9dDH0mu2UZTy*$8W!=1K15ScM@31&#jgvq1eY_Hh?KMr z_n)wR1&V;M9HpbhA#7!`-z2@C=PUPha~D4-M{aKp3<47|+fdlRC#gew(C$N=oSFnE zIg^g&BOde>(y^qeWj4~?F3K`poLT~9GXwbmqrCZN3F?8gnkjzCsA&`sdc&*@*>RJN z0QaSUp~OG?#Y^CUBU<`Yaq8GGHo86tigdJlXo_ls|FCZKYjM~3mGrrr)JeMd3B7%Gf9p zv0!%9Q=KOcV-BHL4V>lWW8xE|ZYHF7E$hmSx9y5T zG3X5XSZhC~Cl(en4`>vCkM95A;{^oU)^t{gqO>mQRr3O~K`-K$4D*BKXlvpsB-}i$PF)6i}IlQ%S3gM5!8B!GeX# z>m&L+zP6fga{ury%_`3J4w5aZY4kN`PP5F9AFNC@Y=s{3c`8r*J3f2-cG>$E=oM!vB*D-EsxO2g;gkF}dlno0A}` zZ|=NCUsv|%ejXfzPpj7+wa3M^c)m@FeA;yRGCd6;Vk;LVzhVBrpx_kuj7u=O z^yLSYuFuN-lTI@0wB>)XAhedsefeMx1wy^YRx7SUK5+}+9cIwg^~_h4>R4JxM2|&X zV87BS{*EG*k{&X6=Y*-mtKe3jf)#0{Z;B=<d($d2drzX^{{5+ra zch;$kB_GFDOy=hM+lgy)l*+B3vAeiDP$`}KNWF2kD6s3C9|W>pJ((Q+T6}~8UCOsP z=lJO*r75S!}cLcJcvpKEhsgw$o9>(vd40$ z?auh-XcjLr-l*$zZ9{O(J=03xypC^)3C%su zt9MCEPeE{Rnq`sCf9u&ZCdS-8gvKOwS3oU`$u~HUZe!SYp&R|TY&CN(z}xLHw2*JQ zrsBa^axkZVa-)h4)*9A@G$MA-6~;8u{+EV)U80&V#3$wlcNI%%0#b1k=Og?BTz_Ic zYW?-NOs&b5u0WgYa@v0-CT2&p+P{9-l#P)ek(nKA4s0%XIEDd1%8#nq?(a2<%Eem7 z*v-?6X^C-|G7tB$nn`Iz0RJ~&b^-#;ggQ9vZuaeAzmqd~5Z|DlC|!X`AOngw6pR}h ztH9q%4}ZufX%o0u$?~(Q-9|0{D`P zl+D`VKAzsX96x?Od3R}P1YXgKG9TcR zguIdb-0~G3JnTBozlxRkgiyN{!cJ3_vItOY|$BcOZ$&CRtu4yH-txO^;jv= zfDnN=`cws&JQ{5DFEFFd&;ht6`}y3J!Vx#tjov5UB`{hsv=d^vCYcWwUt87p&13}B z@F$~2J9MPUTdYMViLeK6kh9*Lsz01p%Wae;{3J1Q$O&a}FTAa;E?Ha!Q@AmA!E|)@ zbbPMsP1ms?kNn*-?mf`eow_2JHqcH_Xe>YX-m|FRS>LGNDb2$ee}P3|ID_4;}kl49$A1ox7w>AMW{ zeS%P-+0L@)qE%q6pXz}ll7&em=__jU6*-f=PWQisD<`hl;}kadS~Dx8uj~Gv7IU0o zeB|~BAA*~%{5+R0CniUkEOJ+K>~AO3RviL+7(#blfTPiKAxB@b+y0ThmB+tIwL>DI zvRij^Uq(4urX0HTNv{rWW-J%I5JxL*GGxZN+^~@=oatOS2Av)-sb#vr7Vcl{&H>Y) z%|EQ8lQb7cbq5}jPq`8=s}4@-4+y=0vY_cp&et(j2l)HBvbQRUL=&tW+U;`ZVuk-(Q=>lYE-#)0L#vqd7hr@O}qOGFWPd z?MvPQ^+_S|di8=O`(Qt*1CBr7qa`&a8x`-BpMm6YW{1HsBPjQ9*6v|%Oi;DZ>7jXS zdnUliy+#+NErc{@b06ek4WqsvV@;j?0YA5Q0IT54%d0j7rAAh(JKP`P0+InGbaXE# zl<6P&9H50w3;bRyqESwlNYV|t-%nKyeCx-Mufo*&E2uQq*ghJ!bJWK5ao)iU`-#7o z!)hE!>)clSQ^uvPyZ>&y%+=~7=K1Xn-G#efs2X)wgyg#+BneGTh8gj_ z!PuFU`IL&|6jroM6(Qu3k|T+Y(2PJ9r&ObEZx<7Oc$)TBjPbeeFb*AoCd&?vP<12E z@a^?^?gs@CJ@J<>fBQ^5*31(*J5R}@k!g#CNfc!(uzKjs(q@{3DwnBgvCP^RBm=5!p&vp}dG&X-z62EbdSz0uX3bYGs(93)vTC49fm!2KU;L?DV z%@XVrnBMeCh`T+mMU2r-h9AEC&TtCZ4AWJh9gK< z(HlC}Eea>5*!r;^kfni*uvo`h*DSr!;>PKp&s19w*=3Ci58=Zqw(SKR1H!y%JrPRnW>Z>0XKM z<*J#W)f4QZU@flO$KV75{5#ovzkt%q!aQLq%DW(x9s=9zq3=tW?k`sAEa`h|g^MiX zLme&bhKKt&5)C<)jgnIf~a0CM+sEkSr8}%G(%B5rQ(S1_+@YuQ6w#o^X`rzx>+|~8D zj!C?m{o)q0;;l!u!|DC2qoyC%$&nYux|iG2;xq?6J+Y-NEhT{<;@Y3Gv2F8KqrjmM zCy<~R)B$)`4~f=7lCQiDCLV{%v43zeBc!g$olvf0C~{2Qf&mW0m!D3XAldQcqERb~ zhb&SdNo50H01SzZlS2UkRWyy5Oh{it_l8njC_Smgti`w+HdDEMTrz|7%(U z?rM^IL*N`Pb(9tpbbgjLzrG$CfiNUPjfL6*V^c3=7o&29Xra+o=GVaB4%g8CSq{IC znYO8loXx!;H^785>p)_*CVHqf^*tgLjj&z8X>k`ZfiQusGvGq%?CGE~r&vk+6MeA>&`%77H)h*d{ z(J@;($oM#l!-)sHO~`R>qra{*f8FfUMt{kGRiL38rlavGJ=-l>+XnAc>=47qb!5kQ zrpGw0!Diy5aS0{GVA6(Rk6P|Ej0!v#Ah3jD60H%zj2)_!(NDejw$-mow8WDpuig7O zCnx-QJxv7XcIV!GaL=&};6?j`Dhk~lWS7k%5;o2XxD|P#6uN_mWKeX04KRFWwb#mk z8lUikI)EG5yS7O=LvWc@MI=sW2^tl%kLIX~4O|;b=}K_0`d_p%{fyy;ebLqx!vZJy zn8yUX!d9RhSc;H5(OlF+q_SIFI9S9tM?y>que#J#gZ+E5YPJ8{Y5-4l%CNyCr-Zl) z?;tUX#uyPIzl&8?9CV}$0g^nJ4l6;Pk2C>J!?3l4yU%jo?!-w+9ww88Zj>7AQwsId z1>)z34LX4jNs#xzqU!jK8finjt1lZ#svy54w)4Phgf{jS+o|&+sN|CBA3~_s##X-y zNzcF34&X&7D&G0sRZ#T$=Kj<5b>h1IO_tr2fSs@7%*(d>UNU|j*kY*nzV3e7 zk|_F_ta31Lnqzs%%bxCBhI_E-eE_`80aWn6x1lex->fzpHBm2FzSg>WW=G9U$SgY5 z-~76fdS8!k*&;A4_}c{e#nGX-@dT34$`-WCg10(;?z~;=jIeF#LcZ59CAj`i2L;?^ z1KY_pKko}yDUx2DTH1xdG9A)Fe50eaG*~D7Tj#5Q$5@svZn{Z31z0HHgG|@T!&AaNQLkxaA<*7A^0c*Sj zi#>6a-?)!lxY5QU!}O&jeg6yU|GMIu3_k|#g$lw!8LRg~g}%dAu;9Y$x{;pJhc+q- z&_#J!#Q@@Y0;xp{<(5Rk=`t(0!KJr^@@bK_Il`i4v5iGOuH|zAu2@2hRSV@Z7%jMODuiLwu0=~31HXVYCbGq^d z6fo2Q&J^b;s|f-N`;GnGUlZ~4>}h9AP7c{G@98=9ZxNX`_FNo}zC@G!vSMCn7vLK- z7*d3B8S? zdRgj|;lUT|xAv{C$2W9>FB)t;wYo3XsYd3nHITmWDnJzqCMW#2c z?~+o=DT!C;P-9_#;ehFIW6y1LSI+Dj+gX!NzUZ%8sszz*cG}I7evg=l>}JH_rM4CC z*FmOa8_434V1xX+O-2i1&R*juyN^-Se#R`)UppK)!O}eL1;o~tn~wP`!yfs zd9Pkvz>ppJV_+Z_w{oWhp;pNSykwR2gEUX0RNg^OZ{t8Ef>x~9?-DiKRm^&;h6(|3 zX$jNXo(s%9RwZ%w5`Ji4dy?QuNj0ysAm%bg4=N-iY1Qw_d&!*^t{3|lc|MX5YNwLE zsXA|J5flg_GUO@Ge~Dco7_0Sl6F_}9#xQ`m_&q;Z zcdgbWw&l6211k`*Rr4RltkR^ua@!`$^g&yrfOd)sglDpY5@PxVbH9cp^Jun}v}rR+ zQ4NJS_x7H&fhsCw&qreW9Jv&Ma@GvOTs+k(24x}bbmW?#bqDMIh5Y;?soL~OyRm2) zeKVx&3?JpKPS%H8pMjLUh?3DTE!#=A#^llj0mb7p$8!QnW=r^oizNQ)y@h1=e6cxi z_Kat%gH5YGzG(rg!yyglYaAq?u!LEGvWJU&`o6eU(|z3iA!X{|0fj;|Tf0p~?0AEL z_R;j!HG7M3X+|XfYuUcKMx$%>T}8YkLIiTd7=jV9@}+DmwLFVrvqvq`Svxh4UFHXi z=atK~_B%w%6%SQ7g)K12z6)FeYen38&ZEmBTg%DrJ8p~nd#dGS=GZ}t_LD`!)VtID z+ZXs=X;=q@V7nrd*_oJcAQm6s+dYL2kxC#Wby+m-mq0|O0`GZIF$;WG6{s(FNH{PF zvYC?5?JpoP38AcKINTishv=@tOFpg;3B7bY(Z&1 zJz}jh@gVnDpnGOgBl}2Ar+Y5PhK}EQp*)uv*@1VJPj8Og!~@LDacHVKG_E?CA2{o3 z=M;0>qT=Kh_L;}JU4oEnnN@FSoJ&gJ3R06>=(!cPCKO9+uijd)&>&>9a^YJ@jQ+d1 z^a=;A{Tv%5r3X#S;N>jbNIm!g_dx9DWpY@>-S3AE{ETRMEt#gc;*^jasGthbBQol1 zXdFhs;%!fx*yg~A0 zdcMY8Tbcj)q)hWN;ZYIISfpXyQXq?`0!kD)aii9W!@^rnW_^ZEPDRA>}mp!gCIzsCboakE8MJxY{0V5EB4u_86dkD@Y`G{jN z4Exlhk`f%k7?(**&W{P`z?-VbA&PJj4!JF59~V~vN@>FgmW*Tco~quF+Wxuen$45t z+rHQ|^(|?hs`C2q>`7{}B48sfAMe(VmhKahcu|v|JJZ`U@1mxkv(`?D@IruiNei9sB0%FZY{~C|3nvTK7zm0)ut?dp??d|J)kD&#E)3vrkCDvlzI9G=Z z7(NJBSb(qff&O@SGHp;as{VPTo%l9e7h z7?jxeu*vk1t5N~%L^_;RO%XaEOeNKDISp3GBXoe!koKHK(TVy$Y&H^K?)?2$lzq#; zuBS)ql9#m7kaMNAUHoez+H*UC$OTd9TUnXYoLuVjzFqv$h86@U!aTtwYDj?LX{L0w3Gf`$ z$~Q2CWA3ND`rtfbIQ1lzIL438;)%^zwo-svw$fdbvE1wM;NGzGYFP2&LfggXGVvkD z>Z2XYRmN_B@l%N3^^v#6>Te@sn+^k)#cbo`T^j9{7v;a*`8hUTb9@BAyV1;uEhWS7 ztDtfCXy@RG*LSBs7U^~R!%LucN?A`iGTc1+g{f_0;mI^7*%I{?UGm!hE>w zB{t@9sh{&IL`TS(#L&1{_fu%DdysR1ZQ2Ah+m*VK(d~wY@QkSfOzyFfKE|R4GZ);7 z_$=yydAv1DQpIXs+oXN1lobzd=lh18koo-LNX^e$t&3r~9gaa4PGEJaj%Z~X(|`9^ z^%W@YwY60mZC1MnqPrX$5sZOc7H zF@x|Tn(8Tjd=EtSf|cX@jFp<19|^ER6@qq|bu}0G^z6y=-vYNGd-AXExS(IlmNJ~> zDkTIq!KUyG6khbuCOkVNe9;J}^D2y=4IH{V`gag>VXV*XmIb1_&1UR9@qby82vvKU zW$=2!KgT+Yt5IIC8+9mQKV0IJ4mWmaG?$Ct4}enRe$$gMMFN7IN4CKSBL4Z6rM=2s zVlf3(Bcdb6N*HnB1{#UaG?Qk(qW@ww691VlhHrs45Pw|7n1+c2_ay}DLn=euzoHX0 zA{#j|H=St=k4>(Z_`Ct9EXXA>9HBNO?Ntxnc>NGq$&!@D%Qt1@WgDOUY?x(mJaS>Y z%W?N-_F3=?f&Wnacz&t9H+Bb;O*We!7VhgLl7(L0BI|Q_LF8!cxw-4TG*mHL?GgD` z7M$ufohdL@xQ17)1dJ6cb>`}?)PhY6kwWCEbxP?bqaVW~@|E0UU2JhHs?;&Gfyqcd zBgKlEoy>k^L`T6HqUi+sfWGyI*zFfo>I~|i(hNT3JRR2Fzhl_nJ$Y9n^rxdLqk+*` zj}m(q+iFR+F#qdJu@;Y)bqa7dTLOK6i*~NVWIq0DLb}6LM4GqDVl9h@1=~K+S^F+E zNZ&NoHhTG=i_A3Lb`Tod`i)Ul$yqxzhzc#v#5cXHZmWD3KHdr}%<8md51iSoDQp_C zh~|(eNqw;ibd2;f&Gms#-SGLlhSlc3QcEDuzt# zxj?avAx{^Kp#v==*MXj$^FF8U=`LOZH1!z%j82v)w+0*rmcNWz)kOaKG+%P?5JQ}b z6}~qo!+eD!;0HEab;INz|nM3*Y*3O!aS7d@m}2GJ?aOgRfkQmvJ6;5--k5pC_ZIcUT>- zj(Z@e)C9X}$pnw?G#SASx#ryM3`;Mr?1y6kg5rFh+;jcpw?y^ z8urSfcMPx~4=RUDu^jFo3+xcR1(c1qtli~l(k~MQQZ;Z)C*sfOK3FD^`dl(2+5V;i zD`>#h%4`nJgMu3BI+_+w9j;%0bmM%|T%YfEc;FP%1dfOHR{W=+4F!M|jIt*u46 z9HXtFu)FlV&W`FI!hu+{0B|%TuFtEM>H}-hRw24TjzU<(Jel3?fzUU%b6+b4gf@AP=0}!v$xBo-MeedhL9^3-|u~$I$vcuW|$C<=SAO z#9U8atN5M&-CclTX5eN z^X_9Nd%NoOddDA~hYBS-W6GPgGZ(q{k39lG3lh6NHXOcdfoATz*Me|`7@DB2wSo2wclWu0N7m7T1HIKki`O5Tnch9O-FW`w$ znQsanyrjJD>pJ&soWJ%5mB{h)aJrFSUg7Ev9RsP#KV9E$H9C1j3vVu!_FO2lQ%W4WDZ ze)8$5%ZN7zl$lcLlg!n^?V#}w5v!++hZ)HZDUsB&%nMn-F`dZ;lYtuW_CWYYa1CA| zpg-vF5C>Z?u`;oRbOLFt<-}Die)~{A;yEsUFv#vyE0DLkV*S|u%Ve7jtJC_gAH(pZ z7q-`-Y=?@-2l?lSq;wc_U;=4N^y>8>LQtl~5-25p3OPv^C#C-zg4Y7}hVz^L%C{;3 zZNEu1APGsB%hzjiJYyKBV1N%OkDrgg^!~aW@$F1KaLnJ5-t+Ar2`N3NmF$)O4zKwW@0Q2g-R)aUw|-#V*{^&W|yy+@$>S# zc^TRe4yfQ}M@g;Bbaf|$3_n%|OA!~bp;`nW6r~fI{p|FOFPJc%R$T`D>u2@em0(aA za7g5rI64FxKYy|QuXAVI58Hn*Y?zOZ6PHC=CAmpyN;d7>AEP*787_@B^Glwcv^ zPJFINbaGS+4EGk8W?T=>fd5Eyz*oJYb9AcO3~h=M#~S|2gdaC&qaZ;bocU#cU%lUxv<+?|ClOt+qef0X{y zL;UXfPduk54aoT5D5zZgFLuoa{`Zn$Y0``G>q54}a=3$yb6HY4q&X&DvBCJCwwxRV z`hl62exOnLTR58Fuc^e#7)8 z;F{iFLwfh8XXY2<3;lih^*6Rd=6@fzAf-c{V;c>JW#c^!N|S0m;uI=lN-m+Af=&n# zEzhe!(+%*lE9mDwP@Hm6U-7hf9{401!I6+S5b+2uRX&cT8tf$}KGbI&q|Arjas{te z_92_C7V8>uDv=Y@-WdW1=MDdA@gfcGG&P6Hau0e4SWp3a)+NvWWh9X&IL{HBRUmE za*t?QN}T`ofbRn_0?*Jf_SLFNfr%zjaSdrD`)aTksK#)R>fQ=~@J}Lildv{INVeeJ zkQmodtO)#1UmG!>b)^DwUQ%ZTJ$3b{6Ahx{`o9BBW_{t|RVZC1;BjP?#H@v{4REQ) zJbD!d%;W$~yTi-woNUKOLWa=1#53YA-~d64hWLSqM{&u!tVqXdqQ#FAbSE}cMgefc zSmx+u8izT~*!l1UN$bT}bU&9%BRy5`HiQB+B}|M!0jkQ$z3mY}>ehiENP1v_NE_h| zaBRiOA|Z6Gzp}nXIG|*tyq2S)RZidmCD}0cBrU?0LDUgNKJeTMUjSEkiCw92rWZKt z7RP-&d)QBMFNI`^`I;|)BvpMrFq}Jscep~N-aJmR?2xK2lS2JE(LEKz9Li=S6G4Xx zuh)2JEG|%y3)WE;WBkeH`c2nN&N zKWE2>DjM?^j~c`_LUUu~1JWqwMU7i=RF1~C_)mlnXvErxk|?Q+oAlb4Sc#$| z!NzcUM;N&&Jm40>V)x;PsxiRZ3t_z6JM(*&_zr0}fHk5K?;tdx5t|@F=yMAbJSrwT zLpgr2<{mM`+R1zdUCCe+>QgXE-U!2mIF;K;&4y$HZv>+-!RZPL7wjcm2kAqYB|VBk zq@6;!SSj!@V!OgV&_8*Axx26$K>S@VOTT3E0wWEo0xJfN%YUg0gPx{(@`)6%ll)zR zz|uvpW{(@n8Y#|pl#I*blMsNTq^y4y!9oWo=^Udsi$bI6yiJ|F7!^G2P=>?|5Bxyk zPX+S`{P$k#cbB37z|&B~2_~0Ptb8H9Afehba1;iP@js_B{CFUTQ`UVMhn6H znGR?1IO7Dv(X;R1e5Pn7#!c#$USi?~MSB#oK`{^3(BpU?4}y*^aa{fM1*QjIqS&N- zMs3|w<-QeIf$sIfr`Zxn!MBr=~6hLn;XioFF9=AvG|duCfPARIxE91`38Wt zucNzflDlVs5^DrmIAG8Ck^B0AQovD;hT4(?>*7WwGB;@15sro5;pl#iH-bNc_Q?a% zf;P#=>VVq`cGZUY1Q3;&%f!Q7U7~I4QkYBLz(~5Fu)UZ=iJLd7z^t$xkR|Adk#T5% zl01kG6)x*g34!JL$GOXtcTQ@Ma(oI3u=|FR7S)ree~S?C|7~%tNCd*MwO@Ruv^HOQAub?^g^LO}5Gkza{sLgrh3M;m)z2}8ELj3| z%i{6T0PisuA`4GpcZ&y~SUFkw+!J3e{*2u$`x2w63m{ksN0ItkfuPrdF!iHr6cU15 z=;dH`IkRK%|9w~bW0fSZ;1IGCY4!lpW;z+f5ZinKB|1R7>KOQFPGy@sQV0#=fhH9= z9ldPxiM*EE_GJ=50ZOJqvD-LhMu9=mx%=fIKd>~`p1V?6{hbARs3gtAoQNi=)C~hA z`@fRbjPFu;ZVHdk{-?1ERHs~O4ylKp%UO?4>gT7&G9g%XvBMEPh2^R)wNpQA>p_BA zRFV>nTwVRsD1=2gbNH?R;Q0)Q9DxCFgr^gd=BJ><;qxn6Ys-F47Dtvs>Ac*?^bHr1*6$+gBn zhR)xMI7-O4@%YuY{%r3QA=4f@{qpyzpe>wvFX6FCpYlhmc5>VMnvV2V_N(^??m0VX zy;r&K#(4%V^oeT^?OuT~w19~Q04{7UxGhgS6J9B!=SXwq8gjxER)ij+t3#yzHnx9! zNIMNlMmZrQ^Yuq5OwJGT)O*Q2XxvmE@~Ox`{0yZ9qB1ncN z)-XBuQ(j}M%o2j2B-zw0HvykmLwZk@#ucazO5dyZHwdnl39d4bF}x0Ac5?s4r|0JS7e`sJ z58Y`BE4uGDawa1Gs#l3)57uIPXDVcNaFVE5Lm-Z51p9Cw(FJBv+{CHvd6zKz||1I))PlPB1>2&TR!k>1h-a!wh`BID%Dn;o4B6*h?nZh! zsENOasH=r5?EQHg-264N)|{Dh#$Fl^QElavU&DINzUV@@_gP`!%;}Y5eX156@h;V? zm=K}8obfF(qnkLF@fsI0tL#KA&>A^rb3WOzTwS=q*#H~!?Ys(C%&TpI&^UNN(^+z5-4uL6ai{PtvM;mLW#`_7e5GfSd{Y);kLzP3Ja{^Y)#JQR9ERn< zi2AKMCP}VZ&YF&q#)LSL(#`V3Po@u4kbXiEMrx!LA3Q}X#|ex$SI4FK?I(HLSpS$k zRVBYUpOX;?zAPb==3gwM$x`YLcbs(_gA|EM?oo3G%h5pvjIpiqhm%IK2y-j=%H$xs0 zbO+Xyv*vL;4AVR^lt+%j(T*FJ{8wmt(nK1i2u4NN9>&(w@ff06XshH?lat&6jsQrp!wzEAaU4>Z>% zivLuWr5tzTzR9*e>EM)uB>HVUI$e$+gH&P2aMn~`MHG6cL=3| zC@Z%-ZQk8)Q1H1VUf6}5XQSA8G9C9$o`eWUFm`wa$o;%#t#8V?bd^HVSwrH;*&Ru9 zuey2Tzx}tBrx}1})XJ2M)^*Y?*n)gJn%NG$=Mv55E}_nbl&V19^z!6lZHF1VlAUjH zvd*Ht5nX2L^YQ%N`(}wMapK4mj^E=|j>epDp2LwEwDnVerRSqhwZyhVl7*&|Dw-5r z9JE+%a3+2XOK*YH5TeoKfDDOIAVbd1u3fv)wbqN}6f;iPxt@HnveX@0D7H5jwE(Ud zkct!BLZrce_^SIgR^q2+vE(71_u|**CP4{)3C5c0U-QG0_f+Uus;=?RW0gqblZsCW zo=ja?-J-{=D0SZ}y)B$45zCOpQ#;jhGP3h#VlOpm2*niBpM#&)sw2yB#8)?oxW(*d zxXpZu&KMcY{M}BmBZ?H-&>Sk7IYu3K@8Kf;RiL1~o_Kq}ZMtkh?G!W|+!sbO_4#D= zW8ItT81i_@vaL&Z^1$yT6SvCT*%!+APlGgIFB)K2(-g4vf3d2<)6`+Z!wfs_sh%+2 zNBTK9?PrP%TmrA5|4r@}6V4~wnQ`0?=BPm)BLWt43K^N>UhytE8+`pGIKRntP^ZYZ zVVdgTX~qxdp7CC_Ce9a_U082A1($u0cZ%lQBG`4*CC)j>iq{u;mibFcL3U14)C!is z^YlrZELDn84hmm@)q)ROiB}h`UDUOSE%moBJfV&CiwhbFGcj7OetBo_;8t@=DRega zFUeR_k=OT)bNAv%|L;#lC4JNJzgQz1eMH!+^hZ=4R!Gt3Q;dU=^+5px6LmJ7qT$md zS_wGUhiHqHbi9AmGmI+&4BKw`h3!*4b+}X+$$Z8|38d2r@%=t)2=2AT?< zKZqMEumA2Wm^HHEOqD(YSy(>Loh9YNH6_ins6I?ctF&YgQq7Jeo&Zqs(bZzU?tr6M zx9<3+jL$deM3;&bJ+st;c*oD3)Z>as8UocYc!v`nHM(AoCf+X3b<8VvB8=@tdp_w?`n$&S=uST?Tdy3pe`101Y zHJl=G;d`mW1WE*rK6S7EpInr?*z|)z{0fYL=emSfUp4kG%&)~Qk8TC%WOl9-3RbdX zPDDrOYW6UtD{DHPF7fGYP~^9OxvPuYMDYV<(S$iG+bCz|vANh)Hb#vlZ}D51r(E}%XV51nRmLGUx(jDUvcnapHr$PxV~QhE&{k zX-Ls)8o}JTPR%;$>ha%GxDy{fIL|RENGPmMn+wI<;+(`?0#!>-Y|VTRW~&aK#iR|L z6O`}vx!8f?>Tw298f)1g*NKwhFT0?x$kEPK{mD=_c9_hmGVC%dtwFf(rQWDwKM0>z z^Fd{T-pew5jbR(r8#(&5kWeJX5w0A4_gj`&IYK5DyIS{c@HVgW;~ zJ4m1mmFsgWtG&IoxNyn%{^kfd@+8F>3kXzH*6GUE^@?x5slzSUNs88Fn?+< z#6Z1V!XltX|A)KA75e3E*0s-G{U0ThP;>w;OLH5<&bNTXGW^l!^EU95o?#m;`;>fu z@vSOc?|3j3P=3m(Mu3D8p#0JzK>73tygEoSR53Xh)w(r0^W+Xn(LR&Yd^GYa zp{g+PSje)2KxMs=Wsd2?^Ya{N1>hfAfP*v+*lqH4dEz z?YsTw4+Yj4VV@5;#D3@KsPfJIGS9e%pqE$xd%z{A4X_8M=v#J5SLo0jp6qxLVa%TF zp#%{l^^5%CRqJtciln;~t@3NYCK$J~M7$T~hH3L|3oiI9xiQB0Cya(uJ24^sF1t1p`ggVIU6BlDWWJi1=k_ikgBYj+A6Ga zzu>z{Vhm`*`u#Xnz247nxAsqM^eKF|f3U)2e{#8+#*d{`eZzLyJ9kn3&D`h#(sp>~ zdq;0ubY9KzeD-X>xp)_Sx&>=zVI=qA=hDn(VQ`HqR++_nQ^yga8`B?FM>x7y9@A(G zgV%mJ&9dZE^TmF&3+;QG^n~61N2zrN_2f0m+qy-QFJ@?=QA#bc@s;`qrk{6t_MYWl zRKFzX_&vH@5nMMD=536rnf{_b*p784EFg$)KvA{2e{%z#p!-o?hG6N zw#B)>P<>jDQE@3Ge}0!4&mJwABs>lN(9EQp(XGY`_{FTv5*#9e7-dfZ!mOkNndVGq zRV}4_EcRs*Dhr^LmveYp)tQF3{s3TGy5xX{w>m7Dx4#~8_{L@aRFqUN@;kx%Aqvj> z+uZ|&J=bXQwJgysbM2zF={{2tRX!Nm(%TwzX0KD-Ws7NUgF}GN-v<+WPhfl=Umn;5 z$tZN9Qi6z{+H|mQF%7Y%2$w#xQcU+4q$IEDtIN`w7U$cBUg;SU^JaL@?_iMtcOx>*2^ao$BkZ#r$jp8!gb0xTY`I$zSdUR zhq8Y^{$c$bJz(JPkSP3>3nB3es6b4K7!?P)2NYMAt`u4yI#eqHBJt2)U!<1YDG#-Y zx5eQ;SYo@mCBo9-F_CJNKO&%>5HZTol1u9LfFmk6WVY={g-1yU-jZgEEhx__*>k(K z!R>r1%qy6*1bJJZPVij^@`^fT_Rv^xei@F?7OgCbd*iho4-`;aG@XR@hndZM9{24* zvy~)G|7K9!({{ZO$fhgpqK0h$Vab&~+~^K-AqcSW+PD(9I=-VGp3~pVSu}hE+<({e zZACfbFyDyQA&s7sB>}?F75{`B7GS)364ZIF*W%Tx?{KYlx;+fRF@6k1E`2IAEOc*Z zUi!37#lmM=tICH+?o*;MM2P%h)gqYR;0aJl_u)juDd7r((65=OVZ8xM2GY_lnEc17 zX;rzgcT*45VVNQ;C_QERNMeKT#Nb3-VVOx1*wX1v$J7176iM4E#Sl7P`=-5ZGG zX59VmAWwY!u6m^BH^b^}L+{PKG-ZdgSFp#%SK9=%)9I2rAeeGjZ_%*1JndINt6v(J zpPe;NO?W~EZ-(p#cvA!!&-6{gCb#P5^I$+b3lCNGvq>F77m3;vwc&N7>1i9~wDZg&vbqo3ggb0%kYHPZv-ac}B)JGAHTz*1;C_gp`7@GC_g{Xkv zqGYX?@y2xmUvseZO9QupUGvv-gBt_pV|Ko22WJ<)A7=ytr>hhv=n`}lMFpSGlway& zn;-CYC$AR)^K<44IRj3ZyuwL_M{pL^k11vGTw{jL_V;7PM%kt!o!)5XKtwbro;QX% z-2EGfJ%KpvDAfHem}qqgQj7X|x6n&OQ|SjsbGY0=5G4|t`QY{wZ#xR9lp>BS41O+T8QO&&L>&E?Acdy&oE|`pY&yaY74YeFr~r>dj{TtBg2Ig&)uX}nIO%;HUNS7ylr7+KZ>GA(l=JUD??LBBJI5Cc{o{l zc~m4nAo|qXZ0!H+QfA-!(!u$&ve(mfXUhEcBG9r2GNn@vmOJy=|_&1pUK z*_UWcyz;uW0J>yJaz6hntIBcyM)14G&bQ~=HPIuScVu{EQi?|d6`4-Ykg^=w-(T;% zK>b>*z(6^Y{#&xaqM|6SZ7HQh!uBFrv%ysShrPAQR6Fbk+tyb03h!fu&(9^#gMW8d zJv?;{3_qjcCTLSzhR?!{~N#!Y}KZ@3W*-*nvGTc)=y6n?|$N6rH`Cjk0IcB^W{l&Oo&udnLP&B{Vp3zM1m%39Snqu; zG<2_m8PWlw)78$>1j3AHp;nNuksb|{WDDPMb4Sz4j1Rs^^1fO7oi||BqmYM^{d1u< z|F;KXTYhxuL1alHBOiLU6t=9!Y7N8hdEkLG@psD$lKHtdnGGnCdsYh`P8@oIdifOK zD_{lrZq~k_U3xw?qsC1&JZ7HwAp=X5=$7lG6zPlvw0hFt-n$ehuNY}p>zHV_mqfpR z_%qcMBBzQt${Yxb-rW}XFezB~y)&X8+DN+54~57{(E7XOzm3D>p&|-o9j!qdCtAQE z7%PIA5bgP^iejnwOvdNhfdpI?CuX#|mrZ`E5Q(9Xh(qH((4Qvc>eLLb5kJ%*wbhV^ z8&IZKl1?^j(V%#?6(xN!53$$!2h}_D#Vh4)mr#_&m7Y#jx5&^^wVTPa_?GbB;)EzQ z5^sbn0c&9KH^_fmhIv7G|F*eJJn#h{X;-$lMy3~2{I1lYUQ)R0RLaaC-%VjFKMVpR zOKX4lpguGaEc}nxRvbabLycpY1tLrl5F#0hE(EH4fbhmsU{X*tX}HiroS?bG zHYXz~rw|-F_%F%8s;W=JKp;QrHGzF10#MYZR^;%$H^5=@epA0+Nm$<*A@`;cZA0!K zMRtF>{I}m_JA~JjsL^{}zMTJT>lsEGCPW=A`R5vAQKFs4X;+hPA@~~ZUM$uS%W|#! zH7GS45Jj8(L-$uB$>X4ZOikh#_ok{dWeP{|_%sbBkJ}U0NfEzxeGD-7!@`K$?x#p3 zd@}KK;6{1agN%;Tj{zvn`_^g4>M~HHykj;S2ey-QQs$H*oeKxPz5{ldu(Y#?W=sS5 zH@zyvF!I+3?bi`CVI#~6Wx`Olkr6LD?4t@{wu?KaG?&fB_XFUB_SFCkU=osFy!pHO zbGrnE7^8PIb=!K;{;rf&h}^>S&<}f2wy;asR({KGlGGvp&`epg09Fsd%9>$qXV4^4 zV0iySMh-7@upnfztmAx%Zt zhh+9&vz>X)$shf(ViULB|MBSO=kOZk4&Enw$S)e`VXmkvmCCn4SET^*@KFeJ<4Lgo}I9C5R8@mQOK; z?};?M;tcg8$qf3hpw@}NDOWf&3NyC}GS*MlS;>rt`!a}2i_oFcuf2<$8plqeqH?7$$VBNs0S+ac|~$O6-) z#%U%m6DSQuadQi>Zn83Wjo_VP;>XtWz(jjnPBCNs_!N~c*e)y4){p;OPp;Ho?XFE< z6ZNiWUs{u4i+-#8h(tilF;T1K730d*-#gybgpLnVUCRg*XmoE`|Mbv)SB)QEzq466 zmeRPq(=YMoT`QSw_P{PCQ1H54umlp^HMq$=0=nb5$id&h-244j+9#I2U$Z)yowA!} z4L=8Xy&N9T+q!t%FaO?+?d+8eWg{Mc%2H-FukcYY!^3jXQI1pL`{xzfo1!E70$AT2 zZQ-oeSTVtlt_L0d_2~rsuTMvTQ_yW_KQEQce<2dykK>8sth776qZ+%HhKfJMgSA_ksT%-p1XbiBAH zzc22+-!UGd|0yBreNxTK;iH@@RpRHF;I(;XMWfZVSEI1TRs#Q>#8T_uq!iG`mfyqsJa2 z7HK4{{6TWIucl^n3UeACyp(L(Qw?@vFRM2CJO0O0aNd;c)Z4IriD7s9`$QPqm4a6z zhl>4(+8>X-XhzK5=mAB|%}?A&d7xPVJuZrk1mMg|JYHFPwDL*P?BQu2+EqrseY8W) zq5%d5d;!w;->q|HWzE{7n?%y82Yt_12!6V&=^BtqX1|vB7C0$8Y3NLeC`;9e0QW@{ z3BE6X>kcYeG=tU$(D^Vn9Or^O>IO{n=!2U<1sb7cJq0Ad(p#u%1ho?OMHJ*vwx-KeHu(a8nt3*MhP!VmyUy*Oy~fn>7L}1DZ1S9 z<-{!|V;s*})_Ms(*(&)>5(WJf415DVILhJ@o+eTmPxY29Re1OU(}!q?`lYu|SMsVI zXo8Q!h|;yE14lf?H3cv7D|xL{1ZKo4TLt7WI&`Ez^d7oi&+2{F^I@vY+pn~vWnN_- z{=ILgm!9jz%PUkIu3dE6`RLclfxW!ynOP*>q9B%wKGZET$P>1@S$Q|ld^P(3|G+~P z7?Nn6W%qq95&av4(I8}B8A!epp$O3c{VBlp&S(J#Z+)dk=OHjX@U*iB{dMGVa$2lj zc6KO=klQUNaxN)N=D%~}CLSYkWLF;~*o6tCq=NS+Zah_5w38q8518)`m!Cht zU1Dp?=iZ&E63(LM4jCl-sfRjK(CA3#0fB3fa}ZL9Vs#emijDkic_+b z5m)36CV~0o#6JT6n6RM$n3xsv(%Iff9=$<(d#}@PoauR*?HuPR{v4U(nfZ(t?Rm;s z=)E8@oMY3+XF?ly&`dG(zi|rFK;qdFCYtky4u?<7qMFe=?kE~&wERo$LNXBHm-DZG z5yU?(a;>+5j3B|Go=Dh~%_e!4R?7vQTvsdeTO?P0V>p6WT<5g-S1ZPQ+iGHtZj5B? zSo4`$Sz&7jfa^X(K6nk-!`aFbgwZ=`O$zlhceZ6*5#8)JF$}My2B773qgw|)0OhBk z>c$-fbPHqz`55ZifJNCDVGQLczGdyKbpMoW-gS8{w$jz>mI&>V!EV1*?D{7zzHnay zmVPwdSslTD0`vPPFqxeKvqp}T%GC;pz3ES>7L-Ce1{a$LB5YxbJ(nDpfAKZ8v&O_e z7!PH4OOc|D)%mQc|4y2DAZwjcM}lE@rD2m~*Y6ldaF^?j7Jv6Yrp`S6YQ|?ETT1Wp zg)#%Q(#Z2&09t8)atsGUcu)k3eJC`Rh03gh=9&Hx2ypJ1*muH3Io?7eYh$%JYYP8M zGdipFly0mAw&n%bUUG}B)b{ozKxi*Qqko+;9_tBT&t;K4dG!Zn$<-(_Xa$|Xd~@QT5%6-XP}h;10_XUO`w2Q;qmg)N znp1zkCUw*DY0BvQvs236NpPA~jRj?2<1+=(l>8k5^gGU!-&6EnhKT{vJdBZ1o8eo# zi{MiSPryX=`q7PQ=fB3r-0zHe);yYL1s{P6S__;J68`q00co_K=lkO;&itHtpH&3D zE?81niXJTFfd!*0vaGt%bnjopjv_d=QfIyVFmAfvrw8$rc3VZmyUPtr+lSz|FAAM+L3*^YA8L1Ax{39(jr>%vq!Ngw5XxL$$8xycd5+)TLCMJ6m2}6M6Mf+ zrLIp_K=Ob#fzhr0@rn!Er7yGQT=NWM94AIBS~z}X14SR}%LF80T_Tvvbcgc?m^I6o zgXEQGS(L|m@+>lAK7%Y^v>wEzq|lo06BW6Ijay;4qBkcuNrVqi9?ccXe|iO&Qa!O`h$TcY*eZ z(n?`y^>_z>yxLze!UI`&ToScXT*J@Oee6k}(st=^*f^1!uEi+fJ6rJ%XeCWhF-3OZ z<@0OgHiIRLkk{l*+>Zw=^;XhaC4Tgu?wL{!5r3u(3l^F_vu#Wo;h`>2*#)4dD1=A! zDg=b!gMSqPjWd;&-#-1$GP+D}JwYy^vCwtuvCntJM2b#z=z_dAmL2bKC>l6d9Gp5qwNFkip81> z0jTp1MkvCn!a>mKfeIuF(&g7Cmwt=OI=L&?7_=1sU+f6|cLiLFCWt=$*Lqdz992C) zO_P@g=FQkIOoD2(AL}bf(IkyXe@XNTrk-X*36VAS?L~-&o`}Wt9l12m$8Mo8c=+I1 zZOO`%=^gW=m-8VlbOUq4`rsT;entl?1NlfUJV+3&IdA&m%kS$z>^45+#QEAvQ;v23 zl=IxO_#)~7BG@jctgrMLYU+Q;8k3Vp&`zXHvi!IiK{75YI?qi|oR}NTHO(5C6Ag{Q zWuPfnXMh=0#mUalBwMs#sNjS^a_w&U+$YPYDrM0!WEWHhA+jO}JJdgeO(C-N?Nbsr z>*F5mqN{gcYicET?kHl=aw5fa;QuHBbC%9=qp|j>fl`i0Lt@#1 zuje}Vjjztd+=!o@i&(r{pNK3IP>brl4z@jjr@)4T&$uLUyS<|3ZVMrgK+CmnE{#TU zYprL1(EOQgm>^4iT1X6Z*5ceLh$h6{1dIdV=3c0uTd0|Hej8IX+*H2Qd!fEA0nSlM z04Y&;=pUBxJO)t?q$*nIFeE#lfTV0-^&2gR{ydzcp?G@l8|SM$$usJxb+1Nkrny7( zLw5cjS#KE?XV7eo;u73taJS%^;1Dcm2*KS6?(XiE;1D2$5XfM`-Q8_)26uP85AQkO zch0@{*DTgzJ>6BktGc^nw^i%gTNnYlS-%iYa=)46sjI=I$$j1P{aW|vywj>D6U`>) za*k3gmxuD7Q^lMdjHCu5A<`mJba3EWAZKlWnW$31j10IF=a`UsD>38dQW;}3Jw$fb!mFs1HncNyy&E9iSffhChjU-afBq{TY?KL z_z@JFH_2TXN&$>LM47ENZzB8qj!4`WyWAV}8H?{*9sVqnD5qssco%3Nmzv}ptgCyC z(|WcvPQ3KM7vo_xf6usQjO=1JTsDKc22KaNxl<|2ete6Ytb=~#Y+eiQM;M4dNCEnP znOHbpK?C?_7Totpf6gum=Vx@y^u+Qh7CRgq{E2_dBkvhqr`t{oZbQ)9oae_>an6NKrw?msSoe z3+8goU3P%Vub}Z3-tdT5iI4<2k`riXjE$sQmyqfAkQhMGX5%DzEeNbzr=tZL%wx}n ziRSqX&Gg*zDf&7bT>Xi;WloI%A-M0+I9tuoRc+X~TLIoaZpVVkDMbCTje$P{CTlQ9 zh*3^ljz2js8b`4E#rq9|Nd9}bfKP&Op~vnt_k%BJXb;e51b+o+Bgt^Sei7-ul%o|L zJ<*yC>A7)Xg|Ml7i@kx}{v@`$QonqN{+(F1m7*IgO6$ITCL2Gdsu@ty0KzHm4v9-7 z52?aQHZbCUMXE#3fDD~GI%p$`yNY$Nzuyvg1Xl2rE`>5O4(A^UT|`#gb89RI2p*j* zCeHG}q;7#>YraXH5si^lN`I}xX9p6Cd>-!0+&V4mXDmLoG71UORY;%iOl%zA#vg_;o&N4*~Jbe(8$qR2zKJ%eNS-*B^l zp{fZRMiSey5(UvehNy(H<)lrJsko>LI%HR8l={e|k102) za5vVdaQ8YS5cfEVkqPJ;0?A&lZ7b0+AzFthm^39Jf)E1J&wACsVxDshb)aOTCwGlV z1c>#fg~0a4jdVEw6(laSJ0RSk&U&5cEttq6`ng2_*&;9WoI{Ojqb&cQb!|ZSPZ_HrVU( zSj+Nq$+4bm6YA#Fe=k44_6gI`q{0A$b-lOBYaB1tgwxymp8Y>Ws=7{-7k9(NbZ*!p zO%}1l{<|D)e9kH*_CRvU}?cY5$HYn4~(+nt^{pH@|y;Q&SZL3%BAk#>h_g|y! zp@(7URx6c0yy+DAMy65xwca%L*at5k_SXMW_4%DJ5%6)Erra2BBwFf+17%KHPj)#> z0h&S|cCFq9j9!a<2t`R|bNx&gVfdPKNU_wrnHL%zZH|JZtO#mBElUX+KPpIRwOKN% z^04vSSqr>DUCXooXd5qhthk!0B!mhwqy5?JF3=)6++p&mOPn)!G3v- zA?#X*#E!ky`k&|A)so^6C0xFJC|Mgwnd>>-FnHwFS&KDlq7qtKi?wf}BFTBU8h$@U zMfrd!vo78B8%mKvnt9684>Sv`!<-==G`3qN9^2lw3cqnS*2*0FoEejAXHP&^pH2)) zT>FLqw~0c46hjW*@5vIo|A&*Ms+LM?^n!_HxD7E8=Q98bP~wCJF`X$)AZ1m6L`8B3MI9I}WYqIl?0zOUOVySt#u3vmV6+?@MZnfUITK1GbQ>|NDbYd4 zX@Wq%{?O5=KCaM&;J!09dlYcUlg6wt2hKg-KL6epwo92|lLgCm1qz0ihdK&Me(x~p zTjR`SD{QQajkXp1+$E^+VY3Y}0taa7i~vPUn3K>IQeuLFPJ8A*GU70jD(D|xvDKBn zhGBvK=>5<=Q573(MiLvD2n&yg(~3*8j-m<7R;t?*tT^jtUeynl;)^Y8ZhZE@=89Px z1S}kg6(M8e4D8BEKXm+rk5!NR&Hl7jkP8HqW91S8jigP;jHGEq+S4Vj(cya0KbeSg zUhAO-;xyqA5m!QhQh`s%L6xjyW=UHSHpH@CIZqC-rU+h015hMWSKwz?msgbIGT|8v zh00^7V`x0OjeOoH9g_4UdgZ~}glRxJn5u|~*W$-=mF&a_SMDzent08_x`aA}^u$Y8 z3a>I8-1BRjfeJ_$)M}re>wfSAJA`aH7VS>)*wbLBq$>j zD@sUS0CRxJp}**u<5<9uL66d^k^{F7X%k`{T`5W z_I?qv7!XRFD6l{{0o3%%!WH;|EbpDoJf;QGz>+3f|Lz|C1^I4m8 z#+#QnX)RZq>Ty5cgwdsOk93rnFTNK3g}xTQ;@+{f;y1Z9sQ9zC-bmn{J4X&%D#%NG zyGzlI4K)Mdnew~_umKWJ8PUA&AwMxq%ru7v3Nmr;>o8Tkwl!g0zh$$h0r$^*tL`Y)3~$5%rZIP;y8mNTdwP}? z=QNLKzV#5|E-Akf;Wm;L4-h8V#@_jJD{Jg;>9_h)`sngf6DW`D$;++b{OhF`Wo+1x za1ZAFujoqoxt7V&gl#KIp$vh}-`eDZo3<^>X>VWt1O(j?je!Rm-IWM6WBPd%(s#DS zGBLb+tDDMiw%T3^C)yo~ojUUZD74w0sR?7mUI04n$1WGLW$IyJkIXtscID)v3|xPm zw+E{jiz)-qF+1m}fz}m&W&T%gDsRmDo&8gKAz$VczkJQ92b;i^?*ew0&P`mF_Bn?m zOwVmXB0>*sbV}+XFTW%`+V=d2tMKCLGk@v@d<+dv1bT-0F|mQ{j%t5nwf^_4@(<26 z?B5N&VbHt;wMQ*!hCZ{G+zoLP@W_>ON$?xLo^F=cH}@TJb`H;HUg(It!4-F9FFnI# z?yHo75AAxy)n{ZmWe2-vPULUcqjITlh2Cinl#X;^-L~$7S9zBePl(l<^!Xny_~~*G z4Z7pckU28@;hU}ES9HTr4{7(a(~HyJUG$uAk~5MrjX3M3UZ3vT2 z|7=qvs^W6pMxB|j0*Mrht~cc5@_}>%#p~2O*1I<@2KeRnsgT^wv)I6N9R%O*LAPP? z=2Q+IrEA`Y6BFqFCbiL}d5Hp$3ZjIGBezk^sMcSEZDBt9vW$Fc6~rH?nSX}+1(lZC zhC*qQ@ZTi??Qm9t?WI68(>jt^`G491REgT`@r1+jH(kFMv8kxr|B4|*rw;1vhHwHj z&Z{G_s&*9+F3#BE1vC8_hL{6c$8X#s;<73z)`V`7R>jpuk#g+MoYHt+?bstYC{kjq zQ0p%(?JEAOX%^w>!mYR9UgqKcD49=alFHne8VW$zjuttcAHXB6?4kgP*(x@(Wy7R^ z-J9G%657paU=K-tJqNval03gV1dTZz!w)onUEOrjN4+@6W4c1S2;K}>C7M}8sy?}D z)Uv~zDHITaq*D^)ob?e8<5c&6LOf~6LOd~VSHzKM1}KPnG@Fj%ET|G6q^zI!RImM# zVg`^DEVI+d{TxfDiU|U` zq}PU<3jz$Xp}rjh+Iy~=~GeCc!A zYMNdYY4KA?`#8Gm39PuXOga3JbJMe39g~HJ0cI!5_oG>4h{=Ly1JN<0W&!S$tjbn# zPw6`sbM;d5No_r91CNoh%GftT<5vz8YoVnouXAoBuZLiO>@3_pE=w3p(viXaLAw>5 zuj0;rWzKHc`}XRIAvJjvfe;xduO~0WiY6h0F0;_Zh4Y*f)~qDp@>0b)Yj^qh*OE}6 zz=WLD?_Ozkg3rgxuTkW+{vZ1INX--RikL#&p+Bo*KUO2t{lhTB%;4zuSN5EDF}FGT z{a*H@8?|}I#Vm1JBJtoIx0hZ@kR`KPuC7M&i&3uDkz$U4mj@I7(5LeGYYkYS4C=_P z^1N$-KQ zX@&9c0tGHlasvTvPjaIvDz5mEw~751Gx`nk;7d3>mXm-o=-Vr4!$Y170t#o&!YPM2Jc(WK;_@4nlXg{dSsh(~ zV!F;H7;>a2)SM4M&9Jb2s4MZn@K@^&?qnDL$6tF&|0%Y4O}PSvbhwW7n0Wte;){DX z_4$DQjz~F?!Fj{@)XL8!Y!ld@XqctsqkbOHo4+{w6i`nWQPL4bKwYvlXtvcW`#jc1(B=aqDLzA z&jYOjS+e8TXFpB}OV98LaZTrWvG&(TZxuUhW)|J&Zr6g5- z^7n?bZPI7AV?-U--qc}XOVem?ivKuHMggOUa0<^sAlQ~B<1~4mr@+)Qh0$Z3!^mHwbk`^SI zydTvsk{A4CF&Y5YZ3cQ*`fr5lJ63Ii@=;{tArqXr^T{3~--W>msu+gQI-Yvu`l^V+ z657de1)B-Z?_0t2q>@r}TjHea+6mSu4&#C|j{7uNqB=lq!Aelv;dM&@YM3RY`t3`s znLgAMA31$^$l~us4j=!P3Mc?x$Qdn%wIN6ht+yRtK|l4C^K!&!+dB32$m-99v7(FJJPfj^FH5; zq60x3zK(v^d>wDps3$v0~`lhWa45ns!)p8uVDj|zV-DierYXgeoQE9zV)VK z4Pwj(Ct@XSXvyw6XO)9dILC$m&10ojx&8jg+1TK+@uAH-s+_QPxyd(~Rw!^z)qA_@7 z6EME)a<)F#dZEk+qCMhA_vS-WJ_Tx6ouCYFfOZ2xpioNZkbgw&ZLN@*II84+6={r1 zqDg0<6w*ETUyJZRm+WkpzJlx+hV0$ZeP{M_5)yC!?4pt}wv!Q?yDPJYJv>KS9_zHC zR`q7!6^fmuZ-@TbE<27n=FvUZE2QXxKi30VxNj=%zc)9&70t3`@H+>mJnN_s4KcF6 z8E%d0Re~2(cFB~WP*^mp@f{~%OkibBadMT^vF+3yq% zwvb*F*4|el$;u(5iL(tlvPnN;XaNbm@JM55jPG$6NlAC5QrEX;CiR=1G%2{<2YptF@USxs zn~lL0@nH1-zT~n}?Tm=^K7WsG$hvx>P5%O!!WhoBaNLEyQl&uleNR-I+B+0NieRzH z840;f7nXY5l5_4b^8R(4Gs~@ay_8OK-+iE11JG_tTu`_eT}F%ZQ-Wrj;mgk2)xqb& z;vSGC?mw}GU#92O%dp81M%=-jMH~Oz;hcr0=|#T^I0xT$o>sR{vH{u3IQw^vLULmeQ0Np8)bNd z=Nsfb7BaeXYv4wyyj^#e2d~6Jvt6b~xV?0>=ARCr3drJsB85D-t@ysSwx>Mu%@ImB ze6LWC%etoXkU>2W+HA3@LJ?@65jTNLtB~WjMg7=LD<_zTZb-S~JQ<(} zM7d=k6((;)wc<$w_}x}v2H>Jl5%b=I-iY?s{O%||Zzgnqdny5kh%O4W)B4hWMx!G{ zG!&i*cGW<`t>ewLWd4YH_W`=r#P$pU&dKgKEz3o`e!pS(aYN5xa#b+VT#s3fc%G!% zSZ7NEz6l(8Npl`7S+hrP{dspvB%+KtWVTGJ*!*MRB23x4c6pip{w1qyU~gt`emyH) zBZe%}880q1qA;GjN4>rmY*WP~AYK4aHlk@sr`NxA2kQ7tse#5cx`Q?EZmm!l( zMVH3x+Gw$87UU2p26V_;i)H+h2-cD?AsWdt+;v@>=1AbYs&>|5la5~V)819a z>y-3hP$5Jj_$j5{Msz_`9QAb{IQ#F7o~$9-1Knkgfd)a{^}qc4^C@fZc(W*qZ3!L3;bt5iM8fysUT3LjlN#)Do21@0OH}0>Q+5U- zxgGqzEnjyk06d;uTjai1Lb+JV5YE_9cCML1TUea=HLh)7*P8KgZ|lqegc|bq2WCo# zz7l)l#eEC6;Vn!RKUe~Qx&pHb09Aj7X8w4@Q^CLnrSrW?vptWn{`RkidAbj^i!$28 zq0>NFgDG}1cL=ATWM{icpAl#74~fQLq$oZ8@?m%@QQQ4u9DeV8%bg0&UGUX)?+;)y zNJ-~@V(3U36@a?y7MGzPoxOFB75y?U{Q9I#f8}iAq-Nu>F4Z9TDB}u!h2XA?`Eiqz(0=v@B!O9P^&1 z<~Z$Xuxo|K>kfve)YfqA5oYJ`l*!#LBR@YIH0I?%Y+j|a&HKSdZoqz|oYG8#A>&UA9vZ5+ z*RX166YAkx`ZvBPRC5c&54_UmB`t2htThyRn2@xb?Tdb=k|B6IF?(`fu3K-5bL2AP zc#G@4>_4fD@s}DZk3DQHJwRnlQ(fM*?!gLI7_FX|tK7!(5Lr@4VJyqmeY9kS} z2x479X?@_~ZXG+NPZDqn<)=Ki_v67MQR>vtn_9)tkpVj2wox zxh>u=>vN24*5IR7-wj{L zGf}X4gvqEF;wy;Ep_Wp&Nfkv`UyHw;W9V|JIDSEwC`D~nJZ_Lkz+wEaiAhBegWgG- zE43z1`doz!Q~!AU#hyA$L-jf<&B*^Vt6gAL;z05gKHgCvWB<-X-K1ikKfcYy!-~ds zsKWXOG@}6mKY#jw(ILbq4QY8dZ*@?wF4{5A@pGNOxlApj!G%av4&R-s7Qy{Wk<7$) z9owzwZnUxXeT}^KahR-DOY_3UW>yCz;Nn?+D*gmsLFaK~R8Aa4`e`xX7_M#QSaf+s zNu85f77jkBj`q1i7-xfdb=A({Sj=E~)kC}U^W)=IYryPG%FKkLN9WG9Jn<;wvg7%< zo|O$b{%93}!dI|u$GG&54CuW$rTwNjCq;wL&6dAU-TpDwt)mB1@RPmAO`nFAd!C-& zlE1NCilx-7L%#Jl-H&`^c(@#qYh)DPS^s1&xP;`gD=V%2*{2YF{3X`X+Om3PTefqH zZQ2*{+xH>p>*6o@#zgKgGec4IKJOaHt({D#jOvD1RGhpJE(ArGOvpC2c-Uwo4NHZg zbd-ay1{22iTeU(p(br3*&^VG_>`SN&gg9Z?oOTCoA`a8`Ql_S$Nh>n42+{IxeERvC zyI}`O#DFZmJtPdOH3mo1ONgze2|00|<}AD`aWj4(E4Ciii1Se0H&hmuH8+9SlD_3H^b*ExkMUF+EFJq-Dvf`okJ zh@|GzA+OSo%B&4^+Ll=o;g~i>{w{r~o3()^|9PTMJls1jIPW}TqBW*<#H6d_0@el; z6hjvgx4WOzV2j>GqAkeI3kZncSqp})RH45LIE(v#1@uUWz;SYnon(~+zBw@w?qW5Ts6f6Tp;7<41re-UBa6IUp&IMh%s__SF0pBqq1ohPt zXwStO`K7nnne%_q6QD4svqeaw{Xc7#MGveQ!#73#^Ml@^Utih;(Zy;eD;@qkFm(2! z=b_y@(%Qz#ZdWB$HxeJgf&8ZQd*>+f=pTi;0uir64gJqhTpj5${Vmab zlzN=_@v(L0l+w^wG*WP2${KNXIhO6XC7G7Tlzp}3G`=U*__z*f`eI}Mr)@-TjhJY@ zxZ@RzWI>1w$nj^XB#w{H*^`M(en+s9B*nad{=|Cg%@9MDmEie>$^<@d4t7Z>#>z_@$g%%=Y%L$xh)h=XOW zo)@evF#yEkmRUsUDD}L5mFg?{s{$X{XNd>2O|uUTdWq+cS9=oExRQCA|JOKdHNAld z)eynj-u}U7M0%xLbB(yT8N*)RsJ7S=qd57Yr1swXS>i8()}TwSCgqDv^CwirGc=h^i3E_?Om%qJo)-H)RulRc{Z4A)CPiesuPr%B*(hfOvh zB($uHM4jdC+DdDXl(PLsu4nFF!8{Ca0Si8OZz?`$%dcDpBFfZxT2~eLLvR>mx+)Dx zhsFZlA~bHbhlEz!QgNe+XeQ2jVf2%dz)Tr5Y=!3Z|M;dNV3tONWPP*5+H-Ad|E}y7 z>;_Po7Hz-IWeE<-t!Z_TrhKP`jlcTK1>jpS92(p1lwUH_7JuFNEnHKOA`^v-r;O|M zp^UR8EmJznxXQoFl!ByvD?KzqZ6E)~E%kn~M3>`?i8Hl~E%S*9$C(6ae}&f1`~Ph& z5d}CMfPIhl|P_6VxWdKLaSupcm4TR@2;hHvaz>NXSxA%Lti&VU~-dM5z4Z zT%PlPT#9n*;<)5#;$6@y;(v02IYcwk2`3v46K1AEq)Z?Kr7q%$;vlcBs6f}==zFC3uGkdI;GkfamtD(Ns_IP*@ zSEtS0DD~MQ6n0eM_|;F@A|z$le$Hl0h>LTg2sLg(O$r2oHI0HWP{emB;+L1q=y{~mh; z7=P?>+faKo9Pob`&Pg;Z^G-Dvx~19jt6L?CnAI-T=Kuc=)I=%+s{Y={HMu)VAjLlu z-E>xjR^SMnup|lgpKB*ddf`F@YEPK^o5=`Gcu$0`O zcs#VeFu=>bI~3-5EJE?a3o`w$RT6w%rFA_ngWBbf``1)!)EuVxJ8pX>OdvcT`|+us zd9D3uSX7Hjr^9G9x4&q;?^o}2I85)+a#`8Q61Z{szc}{%+>$dg_0vR`6UvJ-7Nq^} zfp{lvMjB22;|w(a+Zlj~dm2ps@#>dE9V^TnV^#JrjUG-SstLXtYF|uOGQooJq>|BbsE0C%r0r|0*=3gQF{Ycf~^L#(rOF#w#K z^L)B~l%PT?rU!5J>E!bVRFu2*{kys*EJN_kP1^aeR4x$IzS`$Rg*+(a6`-$*Vqw*3 z-@mk%Q(MY;zI4S{7T-L4WLH^j!LYh0wG%TCULedQX_=G}+F#oDz}|jOK&xL}@Ld7S_p25`=tiiGI zbW;>)$iDlDR)F$)0k~j{7U%SSKr6f%67==q?dOXLH|>l5^Obd1!I_tTqB6LDX7H@$ z#?4C31(%dYSN08tx-$$ZO_u^8#)f=e&hycumFk#Ed7X!5UFp=(^483?i5mo*7t!Vp zvCVs7nH}+ZUvc)>nl+#T_6RrxYrZr$uIPhxNWy(Hv(QG`DdPW>#*bGl3G?FETM+At z4-bs&tU5S!COo7aEg!#xdqG50Z`fW^ESb~aG%fE_E*>mDX&$d_+MSLQ*n~Y(QePj9q7gw)okkq~fB~a}3aQbQu*h zo6-QRRz&xCQh|H!+@3yaXO!)n7OZvEnLxWSN}qW z^n_i;cvq*mW?aY9rBP93j0mYMz4V_=-FW8<`=?DWV!#KgyMJ~y7Gu%GmPqs+?&Mu4 zXw_*W~Z!yw2H5o3+*aK@!-w=(6!Tn)&T zvB4mUQX1~so}+W@Ic937^rk5x56FUgsDzSEPm`xezuEbej9me{rTpD;u8>x#>j zzbs}AQ8q@Nime_Wdn`7g+5bI5f0E)~JjHvl%On8am+AvBU17gz+%TREiYL@(ohQE< zmo~~Uc9OuOhWoe%D<4R2X^A6Q-g101_Ls42Q<7Px4HtBBE}h4PG{`8ps$ulezoD`N%{Cl}>eQxG{7z^!r2FQv`-21W#x8v@e4-JP}_tGO{%IEKPvT zKp5Bz)>5RQs3xqP)wvup34UCSf4n64Tdh-7y#1=@pHDcM9FFb9Rt=Vrt#re&UqwG_7tg32CM0!VnSDyuY< zk`38b2u(ZdH#6Yw%@F5pbFaD?(JH8$jwQFCl=8}exWE_trKas7W1d#!+Q}r?@ic;k zI#Ek)Q$EL-5RNan!|42x{LLu>rRUUxF@P(VOieq3I2(*saXTIi1{}J-=%9LZ4@{(= z|J1YE##o@5(|WGTXpKtb?)nZdw&PXayD^`IFA$dH`;Y5HViUuWb$dj39}^2sj^D`54*OIr3z zqoJ4MZ#^q8#yeW(oK00BUYySso?he4k+vfnNo@xDzO5Kt4c>l!SAECF?(56g8!KFK zykF<|86Mg9-aKP-bAQkFL#H_fL4r&gZ1T z#gi>^ikDYcA8YB;*wV0|U+#~Q*Bh^4mW@FY@4jOv{u?XLW+-i8rp&r{i+J#AI#*Yp z5aP3jMQvo&viNlv(r(Jq#F1)cwlHGQ;=jc!Jg8BuBh;{3YPN!ea`=2G&5ecV{$#FI1N+i3_N2~Gn1&L58$&~tE(n_nIbvPEB@ zi*5T^ZQGBUPNG`D?C*n8y>P>y27Y$|TU_i){S+c3?r_K$KaYph|#;D1xaJT1O&Eht1<6A5&%A^V_&ZK4)oVAcQ(a zdy;fEt9$QA9dKKP(oo%rEClC~;1fue8Owuo{aPD6PxUB>me4(2mH8eYu8J%s z*1*%V0=`iRQg|J-#Oc6m=^VBc6dUuCXZ`xMF72i#G~D4}Py?&0rzmjHZ-+*mbM?rk z4)%HfqT%5u$Y@L}WcsT!^LTZK0=`f0k~Q*|+o0vfq(A4%4d0;6H(GQx6ho|p?e;|az(bY8kQPFBYCdc)4E zEmItfM-U6ZE0|=P;_~i;!PmkGW&gh;+FsWVzm*u#MNK>u z1{fC1jqLmKrV2k3W{M)anbGR9vK`nRW}!TD>j~}R#jSBr-2HdRy}1#(ED-Lp+W%`_ z(*f=80@^))2G5M#sDIZrezqTuuuQfWfx}{kK+eW6$j3=hKR{Z*+WZf}V_TA!)6+BC zHY}qA=|$oyLy}juEo!>gj{eMGfLqZj`$NF<8%f9fyGyyoQ+QECiFwr$rSMfGziu3q z;Kev>ga#kyYiwR9JUZypmX3nN@iiznSWhK481V~;*SnfYYs|y6w-uy5cQM|wsa_Bn zY-k@{*FcAsPgT!hfr%JIL=_j@ubU#*;hDMHlo-*Na#Bkvrhk&INj-?N<8}F#H;Td# zS>R|hYkgdL9J!a?9Yt$K48E#}63&@Dv)7Garp)fiz(ww?-^;X-D!T7=rxsQd{?bf` zyqOsy`@VJ>GUy-nG_2f+xZZ}BP@Bt#^i!dWRxUYOHj!aZqu+p|OY>IS1{|x_r@1b| zORkPB;vX7J<;s94QET=_XY`6&Rn>zM|LtdEAyzcB4j_am_>Kz&UlDgH+qWt68}Q4;7@3^95UTU|O5U9xpxZ>{<&HII@Tji!{F^jYwusI{cXFN#uf{eJ#a&qdyy~6V(_OjI{iPP2SDAnEk?JBH zvd=YQ#(-x{*xBtJkC(`j6y-+7Xl+gLB@E9imxG_#`zPND+J@EwkXSid9~&?Q{|Q1c z@3Mb4q%BM8Fv~Aoy+Ra7RX3|OiVZ~C+RsD~;p^cJP%2lm4?ZuU6fq63RuMGq6t6F>%Isc*O*p1#3m zxwnSece9D2Y4j|f5;R7>%AtOa!^Eu&sXF zvoU*JfLG^CwP)bxsL)c=Gr5l`lJ#L0J;bKIBC}F>)Oz7A@ZH1oWc}a81xLp#8M9OU zJI9TMvXE2+f%(?MNg-!GR-?I8e>8wZ{43gRAiUUpmbjaBv1Z#_-*qTPs;?)6!>-!lr zOAvf03+v)d8+gl*!s$v82iU^b_tR;_Gle2`t#o3|9j89wcw^waesV1(b0s~vA3wX& zKOBZ^_1&UoFRkE){+plM14B`{Y@=@;(XAdWpk=vv9dS?S;3`-ByDu?^jh+R6)eurG zs0B-REMZD;oxb#q!Ax>mIwlMXZu5dm(Z@7{b!=v12iwq|i}v%Q#xc>QH+eDra&dNh zXj4=+$aY+Xat??>CldsHu9!%90*h2;fPu$!4-t(8+98iX}NG6G&{sAA%! zkQIe$?8_OKcYuC&OE+9$tXGcN>xl9^(y(6AH7-R$CoH0U(UdYfTK4Ux&JUUa>>57j z5btipCYDb=5yjVuBb-~GOm}R3SZRK@0%_0Zcuj7plKBz5#RgX7GVU!lxT?ZWEM~-z z!taU=8_?MOz7~~u=CC&-IozF&=SQVnuAN)WO2CZUAJMqR`$#2>iiSAI93lj%#+f_h z_sATa*HHeGq+?WWk9J2%{7MMh=ZGNqTcsbO^O<&|a0${)G@7yC2$J)d@8D+6bxWmm4@x}B7>AVF?w?o8T^oqf&&+T z;5IW6>nlN>ept&*cSG>tToBw(1q3~E0qJkNV?4bQV!uw!J4bBzmj61>sgE##GmZNhoY}`Myn)09=$&EWcHa4^d@|GEA`D+;&MG8y3Cm(WJUj4bzyPeog<-c>rmD*`uxT6j29$l)nVRN+GHYsf+#>)hqh}_XxS~< zU<%2G46sLsy%l8*$82Cf6;0sK4HTK`ETq*v6}Vho&kSr_iSfMD?!+k7NKCGmeMKmD zpBEs9$Bjiole^qghR2m=V51V*>4k7m)y(~Mg$_~DPP$N_xx)%gq-cv5Fh)`1#;uY` z2kTX13%Q%#HdZ|-{~rH0LzvhZYy9Oatb8@D^sLKQ0LGDu&R>URH*N9c>YNWTHN246 zdDFbd5ivcxSf7DCG>C){6B}Osxn@uO``M2Pn~I^TPDeM!O11MVwql2khy-ILsbu9Z zkmY4VzuTOTXZS_wo}#(x)zgPN4z(Ul0ViNhynvp&i_!|M4QTCnw-9#OOz(ZTIul@1 z_9Sx}f$13zK@zo=X_RfQtOreFZ2=7%C4Jg_ohGj2NP~a6{DcvFvR{Cj6Uc_QLSGJ) zK#)(It=mAvC7d#g$JgAi#bt1T*Ln!QY#T_Cj!IV$5&0GybI>EVQ=D21cNpmW@t0jJ z(tf(Qws$-KPbrLwzmUiwuIKn$UXAi>A1O`Dy+$NFnjJ>Sl4W7DPEgp z-V}Siv3a&m$wXNF*JIpwrrl5IBsk+U7e=?0$X#`m_V0%C60!>r0v4AKk0JCE>iFJ|yu$tKLjJ7{PZvjRnjHSV zjoxyAqPH%NpC9M+A^j^DtD;2yQ!P2@j#2yyB5Z!E4~|d!*ErOFgvm| zKkRK)zv$R0ue@9ayVT@hpvLnux9WR*tl2(|z*j%ZPANbuKsWWNim8DcLnLkMGv&)Q zzOp6sx2-;PqrdvqR9a`u9`G{6$p+q0HqsK7NHuOpOzP(R5!2SX|K%IdEo|Vs)C(J~EPqqDegisFTt~5zn-|(vPq#2*tS~fjARG=6<9oc)lydUEn{X*TM1)8q~ zPb?Ej5bu0X{5N_3y6tto@g<-lq$$h&)|v1ZzZGn;B6!qEH!K55!|FkK;763u(kssi ztndtG>I^idK{c+v+}v`1kHeB_m{@!#zu&N zVO|1K^v;~*l!=ye6laH*SQilZW9=G)F)?{$x#01f9b21T(DkS%?&Lz_0RF)5;;3b0 zoqc=C^J7Bl@sEY^_(*@}_*34W;<{fo1p}LD#Ipzk>uA~Qk%nCt78hvrk*8>3zfRG% z1REOa8!iTd&Sc@|RwRBjhAMWtF5QT=xYOAvuJ}H*p^PCN@t?)WwCf$=n znl+n)2WckC`ZnvMnxd`Smp_M;++^e-0~SY$rSG3OLU@$_u7;^*S2p^q2qc|K6bOEt zy}A%AW!RdFBikqgCob~YmFizFl)dCnZV67Q3&zC6;W-kjVE2%y9x*~~ziZt;LeUQ| zm%WHH9v+rQyb3i~6>lgf_;=z^R!@*(k>@3+3JnuWP7B$zm~B_3#rX|)5==~}Vq`@h zJl&q$t~RcZ?Qb$tBwuZA*8GvdYH! zrGketr3`Gd_?7(n|6%K|qoVrWxB+x1Y3W88>FyM15J?4OhVGIErBhm3x&)CD>28o1 zQV>D9q`SNC=KFi^y6?Nz{p&23!<;$iJo|}H?1O$uFM1Ig{_4yQOPUut)I%S^6c&e5 zc%|{`QSO9@dN_iy-AJ6*;5(+_Nb9Eq>(&o6kN^H^F@K@kF&`JdC(1G2{k^b+p`d49 znz?;4b4NtG)tLq%9iXYPxBW5(6Q&u>p_`}krLAVx_FR!uL$W-FILJuSG6oY|J_EV> zSOGqJ<}yuzpRSmwh!}HD*3D7jHBDCAtc2r^!sJVFOqr8hD%wm7Y?UyS%4(dV*l|bx z?R1R6we4f@Bu+_UZdUIG>|LDQT<-l^cf{Se7#uh|(cLbCeRxFZuR~1on?6ig&83uj zhN$;&F@{2Yh|MUXoy4eK5`<*34ppqA6S_y|VIIF;5KmmRype!)3e7i*F19}FUU2uB zT^5*-dFm(g#7~CCuk(d(PUvr;h1l473+35HMW-UYi@Yq?MgE9^vb<0ac@_+(W!|-d znLTtS>u70~Z@)N%2)sh`4;$?BQ~5H@!B2Jd#4e}UeoCXM_0vDs zRtE^;m;Q@ym+#-#G#T7ZYvP$JRsRRg{c?HnIn?G?(FDrY?mg_Gd719)gsscIRP48>CA=H@8s-6&`Ls> ztM!fYaO<>ePV3M}*UI9gu?A+nSsy_a!iZdZ`3U6#Q*ZZ_zPkB!_sy;=gK;QT{} zkkWL+ewSbA(0S>qMdOzIFKYsf09$OnWJD$Ab7Kju)SutI)4Q#{y?EE-<83Jukdv5! zZ^M?cZ}WP@jUr?5EB3b=Q!Zzt%VY-?$qGjn_+Z*sDhaUUaT||HY^QBg21__TY2c@j z=n%aLVD9fP!DNTt3aFYtgwx`v z^jM*owtvIzk~OgPf5p!BPUJX1&~;89#p}D5mv`PcevSf8ww5)Z2&8$!vlmf_Q5LJ1 z1N7PHxWW2zFDc}>Wm`{HbDcYW;a?(S@fRe5V*Y<*_Tl_adK>E7Fmuf5T8JjB)3 z&T9L|coXK6I|@JJaU=y-!tJ9uTqu8(%fCk<+jqW6Zt+30wEQp(HXjQgc!NiDV>Mf zzR?{T{)rO1--lHG^9o|Z2hsYC^Cx-`-%h{g+F081X%h#sc?#w{s zgVVXO(9)yx%cj9}5{S|ABdI}D2w57JX}{CHW+)@_PaHSYuvBcxSPmrr40B|p*kh>! z$cmRUgxyiue-Z~We*C7|6i-eUF7B5y?6*3{i66j(#J%tmNqQ7Q{`-*j&EDL$kV3T= zzU}K_`|LiRmy`uB0rs@Z+e`wr;M|q0MV)q9!;%#p;%f&A+`d1hKlPDJ_^jZ+9sWe$ zlG?2vonK>qaV=c%!`t=Od-2KjG6@?$?PZgDbm;1QQ@rK%^-WxT=+Gr;8l!3bVI4hn z8pb)V9y$2xbMV!BP80OdJ*Q-vgV|*-=UFyKQ}C1bG@FE_>P#nObm8m1DZ{DKi*oho zC({bE19f8l!~A<6fW1zAzQ) z(i2Pje;xoRbB7xRLMkYli!39pdb-1EOK)zuv**BWlahbGbTxT9pkk;j>yOZ7*zcb^ zCq$@jkf>+Q``%pS=|WsP5{QYhP~OxJ|Dre^dYv;&L~KFM1fDE$fGsBTiZ?MvaE3^L z{Ii948RL&p$Xym+%csq88=o}MPd7GRbOsIaH**F^f8AG=Hf~h`k2ITmlOTGP&9bho zM75N2ebIPi~s9D-9M!PA9acl+MCLPk17(1iYL{|gx-$Kg%&pG zZzSd>C+Z5XP7FSs3nESJUy*}ipe`xk{}R#ycLt;TeWc;Bfp5b_^A!+soNCrdH{V`t zdQ$mb{CEPUI=AkwWvnG!71R)ld>k;4hk*NpBLaUE@XWI2pK(nQMR@g@-U;n4U0zx(7`XuWl*h-nlWHLU@SE<2!PH z86-K4&gU~^s=CB@`^~9J&oGKW^yL&S>kMdm)C^LOxWIt;G(RJ`A}e zKp$l#rPQjqZFSq5U-Cs0Y1-qKEM@Cm;&VY$E83lY$9MiIVPiP5(zZ^nIOcQHm<3VJ zb{8^976I?I0obPN{aU&n*E3qUuAeh0MaXb@ma>UUR$rh6HbRx!g3rcjB(08bpJ>32 zL@3*!+3tztobjdE^L%fr=(yB<)R>_5YW2js{#gMo9qj~>*RMPa>9%~rA*}f)GeQJr z<`=9$z@+_i$=S=NWoE9}cRu+3uC-~o0nxzRi1zujYD&xC0+H?Eg!Hg329u{^{v?xo zl5lN5XDno~s$AeqIjo=3eL*W#S6U+}ne`b9M(xtbHmdC^6(h)swf@mQ^>QvQDQ|A` z2qZFE_mj|cJ;#!9mIXX?YX7ddf7ckX>T7#0%uf(!PEIeW9BF2>Q6|3UTI4r7ufJ#S z9_|DS<36)le{1O27a#sU;Jxq%DPq%y30vwLIZ9_JH|+N%w0j6$4L)n{Vk(#3a>ZH- z12-cQAuz_Wx-1#a+{;Q%BN?5ert?JX&mza>0a;7i?FW~N(5cPqLZ20BA~R+xOS73H zp+&IH`*~;apcZTG5*g~{!sY*F@$xloW)#O*`!d6wG9Sq(-L#vb*VRNkP;Wed=9lYqM^*<&J}I)kfa_=8D4aLxgiR3zek^X#3glh-*5 zu7Q%z)ot{j-o1jvIc1O{TX?-Op=+l-yZRUITuo$kFUrD~eurE*IIXs5Q_UHAmMN?X zw>MzFxPBV9Ur3=ta)B?&o~tP~@sYggv8?`XJyAzBqZi^~mYVVjqDPY=`TjktGUu1j z6L4OwK|=kqyNa1x8;04flfA8D1MjnQuBN6kJa!w8a1MU9tCnw{hpKm`d>3S)NsG(? zZcjGqy*m8=sR@>>1FSRhe!5rG8c^D465S2Uk*^bP1Tc>i0?M~nwj#+{K*o$t`?nOd z`!TYbCN5`s{vqvoW-vPAs-gNTb^PMQg(`@;Yz3@c65?ErZoZHay(?uox3w9=<&n?9 z&+z!4ddWMg-}Y>v9jV3%goJ(ia@0fT*V4G*O*u2RyQ+a@WE@HJlYiQUi#@TL z*dVgQZy~EAV!!Y0F&Z9WD152~>p0(*+Q4+R?R(MuxT46YS!?mzRTFqzz|W!+1GHFZ zcqvw;U##ht`RaD5?nU?Y+!>vZY2i2ZiC~Lf$H!|fMHfYt0HZRexbnp(GNmB*yXcN< zF??nV>73W4e%z@Ozgv^ZzEYcvrs&J>Y2~H;x{j--(MKB|KR5Q8gttn|;ooqw zbAr#OZ^}tqXHo&={gPIM{gTlKTno2eZYuWb8*j=qJNamwHk z22xOpL-_E;u`NsoTZ`F7#)p0!6bX@8_>goFraZ}maNRYf>?;*{S#1p@i5jH=Uw^4Li@|HzyXDqoxQaKLxrmqWYIuo z_F|H*F5KK}M(HXX0tw2>RDP64Sjv2=V>E(^+e5jlx~^i~3a3r@{k*l7GBA58VOF)I z#7|dJ7wkzx6AxdReNV{9HMFTYt5h2~4pHpGJZ*wv@zfU3cU0nL zNU4P-Dm@W>}GN@dFImya3v_~k1KS|GfCm!8i zO!UjrxO7!^Xnc~Y=N-vv_9sU+83dk*$*lC%{Xo-PR#6rpc6aMzwrpQHeqdzWofep$ z?5rSPBxULp!lj$E^g5bl#ox(UL~)J~sUmT*VV_KPVVDUedy|^yPPzyy)S;mdQ!fh8 zp;_tmmcJCXeK7=P{$==Q?~j>4SfCwJ4DO*L%)7>ah5q&*2SdT=`hvQ%m`4T)^VOe& zY;!F!xi)IHD|7u_*9$~Z;^2$Li9maS`?ry~P~ixrFe1mKvUT+Acfu%JHqIUQ&Tf8w zUhiq{np&Es^yB8t&WqXFHEgpR4$F@!^H=S$$kQ+oydQ1>BlGmUr;364{QZwR`)rG5 z&5{|KB!WsO^;^!6xTswg;ajVF}i(zJprJb%CsLx$=Rn>dto#k$tpy9l=Oc9mH zpCrP9nTwbXlTAOh6|?_4i?WwpD^k+uWT0cg=vQR8gGv#blhEHmd!Cx#t4eEAz1&(l zf0x3+&+`a3bpm$GEy_=jV$OUmrEHspNqo5P>v_4;21}1WmuPYC;fstvQ=*#~s)@2z zx%hUitXjT+coS41CZK^yD)x%l*nGqnUmV@ontd0(AXE2cQ(Xty_{ZC6Ji;#gN7C{5 zkDSeD(s4Vxmuw3ac*Utqg))3bd4_&|Ef+@NA;|dH8)V8SU^rVAhq$$UO=`IzWg;xo ziSGEQ!*bDxIihHwKP?NlDX!~Y& zh~>C6Up85*Cs)v-y*f=AMinpd9oXfc{cXhk*46eF5MIvh@tsfa*}gj9s4U({GWsF% zcbO?18=-L0MBdNd%JlvR#=m5Y2n2!)Fhhw<@XmXgV$ zdE$a!`zFjClbO*he*;4p!pnJaB`~sr%PT?*$Hv~Vl}&e>(-qfqODIU;!+tD+yn<2m zbrD@em6NlhPC6jBihGWvGE-fTU4SoS!$BDsEj=ft=g$0RD*%!q#38|cjj6F^uB%I4ebTh11#D&M`OwlURg z`(Y5Oubaxz!CcGunHbe(HTX&@oOzOU<4P*JSo-#Au1ZJ)-4t6THq`p2L}=$ni39D2 zf!Nc)l!l_(CFxu1A8*>uV0F8#U9?CB&e^`T1+d6d!YCzTck|$@^}#LSg>D@`P54|% z?&e;7|8lza7w<+k-P+H@K@O6Q-XyRWVGfr%e)wtKbwNz-tuyn6x2`p9@i%kHO%kq# zaG<9hYihf1yt+IMS)Y_9$~Fw|D<_V>Vci{;6;66~EH6W%ormP&-GL-gaO^%Cbwv+qCORU7uJ+iS zNBr~Xx{9BMW17xv3^hlokDaTYUpwnJ7QIlEI)JerfRJ%4f*zoYSS*a#bhxXu;A&Y} zpQI~{xf>+#@DtRUhuwhH9rftZ)5P{S8P#oex6>kJx_9|bh|NWx6ZPT|lboXQ z+$rsrGt4A%x6hIkq8cQ!`P^)#| z<=$+~yP^@7v!lN@`3GFMiHoQZ9v&+sBr#u}uOe)cMg!9x41)%*lo}A2H{kAb z)E1cZ_X1|qx#$-bq{Gt5#ujb32D`xx9m&t!9&y^s;_wK}C=IMBNRp5By#Hj}9$7C% zt*KWT$HubQ%zUc6yJkc##d!@0OTA=-4AFe&9QD?}x7gJz>gX0&JpgSOllB8ehEWO8UbIhm{d+Mm~k&V{YmHjxO`xOmu*XRQ1( zGwv`x$M_R%@h?JfInQi&Aj2+b^Q=2+&HcW~+P1c|EEpY%+gBi>f;5Nk1F7XrKg@F= z>>G0zlb6@I&VlpeG>3V2%+3vZw&EC2yQMnZvCz~cLAJMO*Y8&hgbA*2WA!q7hsKJQ zTRS%)eP7qYDSqM1Mh+fJGEl*>`F4<@jJ_;=5tRp3&u%6k=S_5D6gDT-K0^%h>&~}5 zb1^q$JO|dJu$;0TT7M4>@#xkH5lQ%XklUjgz2i~ZjR>V=qTyr*TuAo2jdX?LGe*}N2~17*VS9Gl5?TnY&FCnzFIZQiT$Zln?{2f zr3`gttW4RPM8WqL^D3iQeYMzAU7jLzEy#%ZN!cbyTl{CXb?=dWj?vn8)l z(EY2fVYcJ5wBQS-zD3?0a4EIaD9+bGby*qjq4p6Y8C3o?aus4En(Oxe0%eV1t~?No zEVQZ$2T6D-WMS@eir2WsfFW5dK)dr=kz%1(RaoFaxBpmWX70UsMTMS~ZzN~GnaUPW zi)e>if3CjJBv%=mwz=b1n{WgRBUP3wwDTEp4{m+2R%T1p^k&DAwwg!$lF_ z^}{q#2d1_~)~BDahpmSghxG#~9?4ylUtk%cYGs^dO}r}?qf+J2{YNO-8S1aO{}{rT zbd%or!=6oNqB<3BIlbuEfT|_W68+I!k>MUHg`)-K$JBzNzre))hegMaS(=wG)5h_k zqdIzl=V@AWJKEDMG&0Ic4@(m$l{gXK4jKejTJquLJEl%DwJ#KBSdf8)(aep$zv$A- zggF#pa{K@`wh|n_OK)^`SXCZP`9-C&^Tw&djLIV+V7U10H6EetJDAips2qaaQ``nw zObe=<0-}#{@=rA$=gSa%)D5A4bjiZZt#f$BNA3Su$NZn-Dj06be$@Fi$qfD}00&8Xctf^SP&U zp~7&MjR+g^?@78cAY;@FL4n}@{gtP+Spo^+gS_HG?r0o{nmVcs(KvPEAvX4Yo!`t( znZ(@DZ;u8*9(=*^`}D>UhlTK$Yfpn3oP*K+>t^o%*Uj9ci$wQqs8O7q>ZH;c&6`Eb*zI6&y9mr0!|gxBYtwWl!oM-F zVEpahM}@F_(<=Ih2@xrm8+AEPdYzF7XrPdyKGBv0BQh(1H@Us z*Jwkc@^14>WoP&s?b4O=5TJr4K2*>E%~()D@#M|$_8H+mh)9|;*#AQ*zYH&!l0G(> z)WBLTS*%O{Z(iLL50kpf{q~T`!c0_4I!AGr;K)2@Pa&nXK+YGe_0gB6t0P!T?6#F+ z`&>nTvvyn>BkOW}#HD8>4Rv1<*LCQ48$9J_un=Dw z@RU(1)o)uDPp&JSY;5fK)Xc}rS8u7*=kFO7G~8bvhX2>IUW)(MvwAQ59kbZpYaXfb zGY(4ZKL;Ig2W#)SRCJbu{k`{f);l+g%rDJp1|dLP7xE?Nu;YM%4+yZVDdK$aiM-@7 z?PGqrSx~B0awY1`NP&CV6x$y=ex|Z6>BDKH@jLPROgpX1U{^GR-m< zKarjcqgdTX{1v`A49!Qp_cPSZ#W*Pc zNu1JPsKH;>lDhCV;k{wm-o$5r ztr<&!DYJJ05DG>y?alw@m=xqUgD~w{*R~BsM6JP-*03KPl?<0?%hw>gHOI;>6PjzK zn$QIOHks6_a3~6|F|Xp9OTU$_JeN$$2nHAsXd)jlAkaht3@8D-r1Ny3U?4UT{Xw}T z$-+==dl7iu`U%1=Qwq?9ffDt1t*g1023IwQ(tR&Oxzullodd2pLn_1f`}Cxu85I*W z%}2cP#UnIL-?f&oHNx_178gGEu(mzFJj%A607xG!QSlf=N)hX;W2xx)^axdK-#T5~ z`yyR+@2kI>6*^D!ohbA_f*`$8$rc1}o}Uxup$k#xXJ)cB*3HI7umbb=+E#8 zJ_lN$M6^7&()xzM##Vv%&^;A*)+L^fUr%SGGMxEbroV~{fEK?E1!aN&CKZb3Y?kD3 z8Yd0gDU_+kvp z@A=>OvOLqMZp#&HZ*C#xBhf7POX3dnXTKCrFTfR8keobRfv0V@!mwy<=i0Z`h^J>N zsBj8T5E6V7rg@&;1Dl8X+v6{>@;uB_R^OiK3Js$(&aHJ}a4~L$Nw7m8Flu zCSk^tJmKzCw!}@46f!_k$oNQ&nNPPck-gSe^VfSrD7uzl{CNEeICz~uu3Pp6ciYZy z;h1%zn@4k0mNf=e!W8CQ1xrlRL~5N|O&<3H*)+dQ=l|7{ByBe}D%vs0&G37itJV%e zGkV3h3s^7)6<4pIQVA9$D_2nTeC?Sag0vG~E`cXkHA%Rl{Yk;v3$jK@&t~Oi1c@y2 zI(&LC&+SadODl|br_v7OYSW_Qm)*c$>%Cs4;9;js1_>_+Bs|i=?hYS#Lw_UbbnO)X zwxOs+*`O7cbd~xd$gO$WXp11XN>_19H*MB{f|zaSk2zKyz+nzX@(lCdi$5uYUD}1! z3r-_L+zz+C;mfqB{&u01~Yyi9NYoi^mnrsh9>G-Iv8 zT7XsY76;VQtO&PCpI7uEdh1WLtZexWUd)oFJ!z?I<7xfuoeKJ6(AI6xbbaL=lY7|3 z>W}%qAEOuNalATH9Zvl|QiJjjNvG8DfZQn|@!ie3%A#<8H>DpO{JfKyEiP{n%Di zv{I|@Q@eziJg2Al{w4EkEE>xL?tTb5%9rn4PGr$*cK#1v_vg!9o4AhzqB5AV_iLoU z7pi!&!M${h0p8p@sKuT%t_lltno9=C&uZ)4>T_2^v2*ez2|THuAKGi`^tDWQ^~l(e zFu5O79;446*H@tZ93$~bhq<;cy!cszs0$e-Ms>_Py#Q%zo|POT8NF;iRS~o4EkH^8 z)C#Dh7UudO6{B95z>iF(9dW)g zuS42<`{!SFqPAE=8`Z$AzCJ^p<`6{|yxWt)5#iFUz*gnm4nTjI37kCsb$#oZcp-;^ z?={1=?)=OGArq$n;;aEkHMlNboI#pq98<)dU6re1!%M6&twt>HuMD?OyM3L-k~?@N zi>$?&lM6A3yVlZrUBEvM5hn!Gw9Ls(rAjC`;qV!$q}(M`vYx_5h3Fl<^>KqmP{HkAK%cG?PDy zI6=PyCbVYux5FDs9P}s0$vTS67(iJ5EP6Ww!g5hlY6j0)w(Nt=47YH+SI+~>{5MY3 zvwgf}BORli*X$O`Sm}oP`NC-7J)v(-zAG;G2qvca7+>ZAI{qp}5>S5=v`N5c&^si^Q~w$g?Boz|2uc7 znfVf`ba{rZh9jZ&Sfah1tCUvNgAY?(_7E=Bf#*!$oVpV$gwz~t(b-u-%Xw2>^%IoE zf9A}WQom+3d=hq#?9bP?3U+&5i|#FpQV~*riN~y{Wd(Bj9g@V%(RDC&`suxX>IWE4 z{0IZ(q11M(XF{-}>qd3E-I?*Vflg0Tw?64TW;A2%!Z?t5)Zu08aj;Spv(XDFEUymgTPcpq9=ygMx%7$ zqaR#*r1~nAgP841BaRr=I8Wf}zy1Z|LhA86rSF~lp2X?Wk@4(9$ya&=&)e>IJPaA| zAu`qri3W|>xJ}*`|(k6<{_k@;pIMfno&?bnm5V!R37VtKT<3x=oP=KqCGt01|Qb zf?`E#mf_syGM8B?$}*zY!t;CcP}ehkW}q;Wx&tfW`ai|B^FmDG^_|yWqu<^>Ed8e@ zfT7oVmknxRcsW)h`1-Opelss{sAB4a8T;xfB@CaP4a?#uKifd(sW^T3V3ykV1tzks zbuYzya(4Gv;h}!4)4&4?VZOmvO$)bKX?!(ockh%fE@jmWaFTL`JEjhrr-WrNX@zC7 zS%hUozWeVuk)>7&>)MLHfO(U6+ikaQhUslwia59P$e2WsAt;7IaFo#|%MHf^THxLo z9SlYVp6X=6-U%3;Z`h5mymPd|2ZDJWw!8C2%%k!vwg*FsUX<(k6}vocL-9w z4~OUCyWbC{Q_YU`F!kbBYcU;`YRb_pF!;XROuiTN zbq^OOO%dzf>HT^M#xh^ag^m?3j$1Qk3A-Pn7r3KsS}$l2UEfJ!Q1_Wa4|2jk>Fg!m z&pVlWgpjM4Fjr4zRu7#%5_?IlBiDbQ8ZYpeLm&jE?^8GSWsT|hc7=8rdC895SB~Y| zBxC7Wd{Vw@j&fc{-pDhX`1 zAGmnWzMQ#xK769^+-qx?%cF9t+BC zT;2Ib2il-?u3LGY3OlAZJxtAAW;Uk-7Ec7fAejfugSU5B5lTCCpP4x&aUF+th6-km zncW$`jC6v*f9{&mwG6yCPF@v?1fzjvFs~ob0#`YwO7!#i=$yHu_x<@oSJ~#|eY?MX z?RU(tYZZ;-79ljP-KupD%zU=3z2He&g~;9=;4(5D*F|Z~lvC}5$N#x9llgUsyZn|; zbSz%<`gihW=b{XM5#zB?6xC>PX~#^kA?KnzL$XB+Qge_6kVFq+ncp#k=6e;KpH6A5 zZIXT?HMisxH>L=L=@hGyD1JbGYvH!G!{*9X#D1_cK+C^#r0Pq9-E<$m44Uzf1#PO6U@JHi!r zi3@gV(xMvx6uU}FdFFn~OYD0kP`pukrc{ns=VqwwTa!`Q=3>3;tyLc0iRRD)u@M2S zt}LYcd<7C>@fybnN{WON%i39fj{Hs!xuy0(Hi-*Dzidfi*P!OXxVbBbqTVK2RS^U*UZsRp@vcRIxtPa@i{ z_-B@)so{~BjA4i$8VrITG4DK-+F^wxREu2gGB!UH!j=3^Fj?lbA}+A{K{=iWgZwv0 zf&<+$t8;^hhp6VUU&W@AWQuK*GevPg&I1L@jpCou`;u68NeG!^{ZV;;$d~UtL!v{t z!_Jg`N@HeROrBWIG^3BiUQwHw+e1LRVrD8NsSAhLo7u?Ty_*J}*bkbZFZ0LQNUyt} z_1Sx?lV!i(`1i%Y5iSxC37ad#I2PyKu8x|&x>}iAQ@NMu>zg*H<-wtesR?FO0@GTx zYf=mAR|i_H0Y_{g?u-zO#Z?l~8It`PWN*SZO-4aN05%fW$h1O6K}9BqeYw_17lttcY%-J9eATxWDc64`ttS!}=b!B+@g;`ds5Bc%mNvq|?Rn(x> znMXj5*kQ3*`rFhcu!E5wXZ*z4E<5$mF?yVXo-ul|k+Gu&hYBg|lb!VPXUz0BXV3j> z^>ybicd59dzYt2`@vs!Uv;7@16GZC%X!zh+$k;JXwdrq3-3CH$I22k}9>UI5EcL*~ zcs>FYTPLggBgtsf5V7l?OMkT zkME+4)_CNk(trAwFrk)yNSmMNp)UM~v z`==_e?h)X+;!A(2ayx|dC;IKzSzYD#FqY51?-Rlyj>OItXwwE zSc>gV&7EnEtr8=(Yb?9$o&@#-7~su7g+2n>i6Q@IH?L5a(rXg!wozQ0KL?p-$bF5- zW;gX38JVRzA$LkjOvPLqTofMYwg{+oZn#jbq33nWv_7C(s{*7uJDUIzpuCbaxrzL# zwYqApHOardbLZfvd8sbIhg1f(D1?WUL83&}D-fOWZ*6a)kiLYgG?h#4y`@Gqx)Fn9 zghlNZiujWVV@k54PO>vexe&}udJm6lrr0pF{7H2Q`}=0AHR!<+a;!Lr4jN?-l3(c1 zo~gbfxBbkP=lgp!zLP$g5~SXGb=G2XO~Dq@_tuiaY?A}(A&k;ZIA!4Jekn!Jy>=)o zb8AW;``vV~u;AwQVpF*7`3ck2yA!D~M ziW=O=_j^T#$ItwJpDcO=Ppxd>0wAu8v4a?mu~&N8`wxX}+5aQ~jg$4v&2<3S;PwxY z!^i?T%(suPZdxTB&rsfk={ja2*WwE;jPeS)9zfMHfZaeC@J5b;wS-}fONV=$k&NfH z&o%8Cpez_e{UxYSIbti4VpJ$P9QUYh_tyT@)vaaw?z*H*Qso*eDUGsIpV@fKLW@WK zKUpOkprgZ{$s^aJ_`H&IkmnKnx%MU^kbDYlALk$QL%qzRSFGU0Yj19N*n3b0x)t7~ zLRE_|K8pGS&Xk44CB?*oflw4f1^3pNi_*oJUXqb>DBmif%>w{5c9OT^8qxacD_bWn@YyMqn5?!LCElx4x$b2* z3oa5DtvjT^6K!8-YM}M|@%x5poPM}7DLy81VVLh0(uw$mo5RVasHBdsnz(fX+V=w1 zjT^urj4>8jKKP%6h48poXkwbW15Yfx{O;H7+*kg`>VH>Uc#`s7S=Z_t&S_257{|Wj zbAEz+b9W?3=suo5`_K3w>t-gW`c^HcdWZ>FJPf{^OVtez)4++@b z6y5)O@$t9{o8F!H(RF9Z%@!nkI0opH;(>uCKom{^WT17zsES>M5??)qaTez1sO8?NRa9c0(vx=Q((d10`5@ z+9CgFx_$*y^goKZ6+xHmVJM;;vl`!~7uJ{f%{z`{L_zf2GnRQkof<-rH1-}6R)He< zH_<)4lsD4O8E)e<*Bv)Dt%lW6sg4eKMFwp&bVx7K>syrm4h)|!25Df0U)kl2%zK=n zNiG1d=Ceyck;Gd76r2kpjOTykYZp}IyYv#NUEvxi+xTh=O!s8vmkANtshEHi?wFcH z1%cRFBlKg;j&taW)dE;}6r~(t*2oadZ^A`J$Pkg2!q=;FC?oUxdlI2p;|t;j!8A29 z>DOZe2YhZ9`)7L=ZX(<<=(Ey%xrXuD=3=_Du2!`E1LbI6)iN;aN46iKt`o%8>d%ZT z(zwp5k8}#CUUC)s@2twc?j-h&aQ_v0|FSWO%Lm{>!~?O{ITecTJa1AKZF?Q{_I{PM zBpNGycmGIHunMm>Sq5|3tnP2*F(BvL`B89{Y&zCf%(gM!LH_4L&y@r&M8^_6#h|1K zP86vR<^QA)?fETK=hu4sTXS7==}B5=-S3&Rv28;ppEM zz8OBC$A9%lq5`1mSNBU~Z8*(dS~Nrr22izYFSh7omlyUEI$=N1=Y_HD3CQD%m%gE|W z7GM-pZBTv&c1gi3C{u(!E<>r(ADQXP)e|Zf&Yq`PxU*&}uMtPCWp3;gaa5tNll3MiXRdy|_sZB=G1iys1TJdug>)S#!}fwhxCoL{t( zzw#J(_sv0sER7-uo|@TWRPR8GGvJ8%^);l04pJKz1kczRgj~ZjzHDi^`h|@sJ3IT` zJz=uJc@sH;GnfM`gQbrkiwoCJ+9#Eu+txiL&anO+H&pClE>08GL%EN{YImBBprM!~ ztFfF%Jp}YlV7$iWC$Al_FJUtd6H-{JS7k`$GsA?H3{)?}gz`o{Ii6PLz9|$fL*kkE z9>b5HAzieFe={f|Va}#>AB)+E9CY%Wl`vC}M8Cdz$Z2#)|K&6~B;eA(wF52q_Xg=(CEBKhX{5-jWt#gdO@xM2jab~cDJbaXak2 zq{#2iMAFox=1dqRBg+5+7mEC)@KrL0hfPbzt~qrtNNzVrg90{)8Nw@o zYqA1oMVOO?IMe31JkQ(b%J&E;&W;!TnHW%{7}zE@(xdy(GSeBz!al`f%eLOtw_vv& zaEhAKU~?k0QJbB&^J@(1MnvR)<_Ryh!G9f2$-cI@$H=6^;>7>Ir-1GMGX+R4%=xvp zEUF1QY;~&%3gUimWIZgmtfM6}cg5FP;pzd)zfyhlVfkyJjY4{*h^z4iDlVREoqzlSpr*<)g@4F&LrcY4~t1-Ec_9uT%V)+<&MV2Qs zaW!mFUdU%SnF|JZ@QJ8aS1?Ixa*~z>yZ*S8vLM_&93f0qs&>%8|CZ?aAcp(H>JG$k z9;>ysfr9QhpoLwwtAuBR3$!#p zeC&6y*T-euY2Yk>eZD8hzB8&^bzoF@Al3#Y{v*}~C3<;sB142TA`hJ-^70Y&u$HW8bV@ZST{nB!+mXSb zK(gcr`*90sC*h*6x9B2A#HJ5Ig+hkhu_TF~68r>u=Djz6BnM}8x~mv$Ikf+@ z*^I-i1WrfdG>=5rwisIrRv({WgP#WWotQU=ShN3w*D%b8-zf3o_3K?qfv?AhasESR z0ZJL@KXj3D{{@u={no#>?)Bk?RiekpcL2`S4)F&ak~u}1#6c1xg7sp?)vj1zUdvkV z!Xr%K%|Vq|qH(S%@TqXKX&n4c1?F&5w6?3K!Shwd0PBP(NEyL?`~w%jT=W&3fp-GP zssq#%{N~EHD*&pc6%qiXILaZ3tQTV+YVJE3+JA|)vo=giER1rK4Q4+GDwW&+Ckglm zPb_K{ntz_vlBWkT&cpg2d0A!4PYQutI>$1Z@8zqzp$4!jbRK?smny=4 z?{@ArSJv%>_4}i{0yf5F7Ub^Diz>i}`wDHUtgpx;;RpzS#4 z%0~Y*!X{TL;R6-49HRA%TD@v4H4*&a3^xVri!mtO z%eL8@hd+MX(1xd0bTN~>{U zMhh=n>uZ3s^0OtLfJ;cyj6DI$o-$TI?R9E8wZMl$E~c#viSiBN2ow(-;z%ucDC7H)P<}_X+-4YJ_uoApwA#HW1!oHEJ z0oG+4Ka_``#38c=ev%d_)J9PnCo|n;E#*YMPJ?|Xovg{(lrvR}wJB%;z`qw}eTsVP z$-Xh+QZuV4Vk##%Hq@$@{3Q;+kJe6_P9v#)t+_No`A)cOV<;2R5$$_4JEI#r62$`@ zZ&cdq!Iu3e1*Trv&*7IQR;!a6AJQwneA8jPAySfX&8F-iE7&*FCr#Bbz zDN}h4`vj^Mo%j8UuHg3c?X73=)`SaUMn}PcGIgM0$t@WaCauCBpfITy2mAo?1yPUF zy}2s*`j_JSH{h*S1DltD)U`93nXf++6?axT(602y9)glM!uHg|^Z&I9 zS0Gp}gW)!GHD^&6UP{hi!q!dz+lC;WiSIWP+R$E_WYstdJP?`WHDzckWS<+4vioqh zsdb16IO<3aA~J#k_BP3I@_OK6te1T3I(K>@i++jtKg>UY_i(vuV0s z+}+(JxJwAGL4s>=3-0djPH=(-cM{we_XODBF2UU`-^KmB_5IqSSZe5**3+kF@{D1I z>4x|*W793JEZuV*&76VN|DvPp(5sU(XKy_U^T2I>w)TG`i?qCvMMB5S?s6s>%EkU! zZFr5b@+duqXW@cdI*XrwNik*=J|b`?^O8hKv2&w+{?=nXKgF-!RGE` z?yWM*41PAgaIxaDUWJYy0LOK6X#fLG5$pwVkyFn7AD>Gcz&?s?r}ai&)G@rdPCc=O zptl+%j~Xc1d&hw3FF*X=A?!eP-8p-GX1%9SMrfToc(t!kc5>n%Ew&3F?jin1s#tj0 zb1$+t|{$iQ#RkIyc(@%}_f&Usio*unA=%$;( zEu{n9Ep##&2lH})A!%EpnLuC;>MJk@MKmP$qEx)IR5|py;U6`s8SL}Zf5R;;9L!0N z#Z*$LRSY-$W)(dZ%zw4ovHn<`u_(9`{zufA12i4GI%JMwC-XY_&XGI6S|;Ff+eY-; zj@>b5Aa2un!Dp*OR3B8cF859i;DI2qjJKhV5i@i!jza=>E=@t&$@^zwj`(Fqi30_w zPx}B#=ud-iMWq=G1>IOXmqKr+Ao-Wo1#Dxcc~|}!qAvkXZPmVvUrriz@05_i?P>}@ zZfjuxrvMspzI1VQ0VW0V9oOk}xiTKFBZWMbis=IX1X=+jW-8BsakZny*+W+dj0RF( zEHypl$S$;GN880X<-}($P&>j7Q|Ffn zE?UO4foAEZ74^JN)9DNZHW0bGG3AZyQ9rchuikOl?y#(Q@ygZ9^hS?WHP*yD3nh)D zsl5UoG)!hK zz*Hk5yvq(A$!8mERPB(Kp)0+Y?t@I7jY3`1!r<((@1RAe2F~%1H{l+(IL))|7ppbY z=6IHZa6rR}5V#c`tEI>}niBw3A^=bYmBjYO-T z{=ucF%#uw;q90pYCrbpN(ps9N+!&@*B6u&Xa!<9)YNIwoU-Js1S`y(SLnNEU8eK zh}ya&uOF$A=bH!?Ic#IYC!<|_i)ABLmQyuag~BRR~~tTkS!25&92#?k~Wn%s-jfLiHCjo`0DS9J^wZQGU}{IaEudl6UPe`)u}0cnR(<`Xye z)>zoE282Vl2<%J9hfs%6;@(w*yL*{#HiUWAjN^#$875|IE^s!*IY>~hH7(Pc(k+O* zl}hMT58bIb;DU53#q#Ag!gS$-MUu^IY`rhlpP=o-3nmlh=W1O_D>zqZixf4L^tl=x zp^alPH*h#>@rXFjcWSXU*FKXs?fqI~LQ1?>6&6P3>}2p5$S>$Di%1O75!vk`W<-pHML-`3to76}4Qq;Qp<81xH`HP9 zTG3sW<%3_}8;!pG{JaZJX~7z7(EcA$*q1 ztst&xU+0Hvlt#R+xIm%J5z0YW0+EQ;8_RCtj{`NDm_GBtr=XqaQZ@S9=;WF! zq@Dn~X-+bJt7*C0oRY?|m7i%>(dbVdoN7m8{v?$Uv}L;Yd=I&9SX7)XV#r8}u%2_D z?GUtqq=MIA5LVQ_)P-!c*C zwamtoY$7vjk=U=Sc7z7SVqW5KvIVu#ydYmNN{zBB^x-#F>jX}d7!wvvuMdkw6bjqg z1!fiOltm;l4&d;)enXuFvZg8Kt!8G^;=_HK#SDtnBQxAW$iC;`a>R4;eC4>xSsYap-#l&R>1jJ;}KDbZSalQ-G91G`)$T0l} zH`ZyRSg;Nc6;&v#5V~(%f#572M=WAWB@>1qZpX4a@2$C#!mODi_fGW3zgIeUX74vk z&>T~yb&_BS{hB{=;U>4|+ATUCxgPs&DYl^q?`BX2=ds{4q9LPuS(`h%tkbVatDrg?#Amt*C7c4NiD6Y8i zs5ahI5~2~Jw`7$L8-wcNSLwFa&i!$MK8M-lM>(I6y@PajB!v(0JmKG?lr(MZuEC>o zM7+Bo(h@>FL&6wKpEGOaOfOx;$mw>7i|2iMUnjRb)s#I*oT$@2f%hFmr~r9ek8r$T zk-;Um_VhH?i1XOc)$ z9%%L2O}JioZ`$bB@k>t!*Olt%&u3VtaO;z0!YJlWhUPtam0k6I*-fT=CZj~nhxe}1 zZiVu?4UST%wfFb?@=}|~-$AYNn!A9stz!ja3@&bv@3FI~XBdJv8C$c5r>BWE{+;9V zb&2vqAuAm5+qR`2IT5u^jKY{0lX8 zbG%ZYu+&SlSjI6v`e>ODk^85Q2=WhDA`vVFq+W?q4q#3a)#xwebCrDT`({F33Xgzy z971wX#_3G`faa>Ei$^H$oR{nMoggY@)MVOcn@+&+pVgGYa$0^b=fqz!y{95os^-1b~o?g`1YX8Q2QQ4^U}S(pbZNqYZ0 zI+H@HBj@Jqwq@Qw6z!G>FR-(1kv9-mv|1!U0w)&(2|c#0F}yOu6wiq&LUYW~jI#ZM zFWV@Ba}l#rGzFi@w|$^)>mFrk`Ey&WlH4&S_{%~q?OqC+pfyT`-3d!Dp|0+PVi6X{ zW5h8w-3a51;emJFkI?48DL7-EA{+fd`h(~gyUoh{V>71@s2;VBDtICu?-18;U4)G3c~^kn;(#|% z7!U_q`7>OVLSDaC4`#_YiX7&E_Nif?=fuKK1fuP(6K0L|0wC!P#&Mb!Pw#OE8PQ6A zY3mT7bbbj}Wfvb;9!QxRFWcoeW9=Db-o|fCnUP`|IlSh=r-T#JsZ0k#wv-M$t7tL| zq6r0BnzCod%M9KR5&il2A@sj1irf}niMq>h>jO#~PxQTQh<&11lB?(GxB((z6k2~9 zI#lW83wg9AmW(U?(Mt#jaD?H1RRObX3gdJi@XMgtry13N!T2fd{nO&wtOV&7YM*%VGD zuA8eDz)CN@0iqW$8vB^jdFap~KJSr68p)9y5RNDZg_*7w_&<#(5l!B{5cpTw!iv_S zBC@LL-PPXJMT~}v-jr23=;Rv36;hbdaiavX!72)*9%?FflT8`E&us6hW$MW1u{k`U ztz4|DZ%MV9#{L{kSN>GdSA3qPyy`e~7?7$vX<%EUN#q8^ci;X)iah`q?LeVQ|% zvpXO021X}{i&%JwV7P8wQPs9|@q9hup|(`6_8X7<1~?(=z2P|+k_O1F#Qe+RL+qQncQ zn_i3sP|qcrpOTjKrO^-tK2dmUiqwqA4yrNfV!*4Bs@Qm~ zS;?y+k$x?b@Mo0X^-8($U9lSo+qNuTv>c+moJrZ98tXm)na;@>W73F1wG`wdm(}qT zbCJsTUV{k%T>oQlM5ZJXVW*Ev(HFQn5JOpVsJRAs>LrStXKjl%%S(Ke#-Rbcf*vtd}Iv0o(4|vW#vyz z`;6K5YQYyH`QLAr=Yjlq1==(bhnp!J$Mhg3fGKh~I*Y8Rf_GW*hlv0_j>Kk0ED$5(H{@Q<%w!I=Tr5YIOp3Gp2%x*&A!4IM_6Aq&~SH_y%1t%4p!Y)=xmL!SRt!( zY@227LhQ$9UVW02H6O!Y?si%-03(=KVKPm;(fJvXk9;FZMAe&sWjw)$^f+0<)oJc! zJy?sx!J^-(jIKf1zp^L?HI%erOi+0(fux0GIiGW=BFQ&^hzWxgaW~*mcmW;2l&+s> zfpcEfNKV7@!y^Y$1ItBjVx-pc^)2(qhI`fkGXELiBVhxDDV(gXf|%%sQbNFyRgOZa z?r_|jpihhP3T!L5T114D?F>$75`8c5*jzFcDfR(O2TyxAP zF(MZ>DlUZ8lL7lC$Ke0u06x$$Y*UWMQk8P!CV9wwo|17(_wJiI3~+*UTdVV93eR2B zvp4+YoK%QC0?kTRt&n$_Frgh%&O7sOwCzFI2Gn zYsk{`C}HyM`Mn&}eOmcW8MeSfTJ27mixgX*B`~%VoWXL^j46t8lnrVEyFcxS!LjwN zEPlX@sCe+U$CuYuoVOq3gvX4qz6P>24xskSrKsC0GyNE5p?+1RmWY+E*<&A=GnWvxCp32;mFig3vB2wPvmF(z4) zWZ1S{DbjCF1t;r6V%Bd9{7|{!D329{^A8z9m#eFi>ZE6Xfcv+smNJ$m_l5$T_%X`g zSK@7OF`z0NcaUf1iGo5KQs14SNNEb7f3OP|ck>{xVPVYV;GTna&b?fA2 zfxSb4PTmXK*hhUB{|ZE&VVv&~E)OvBa2=Hcdp~Yub2@P!O)ZmTx|=)8X4QUyc?WXB zVMPG+%V`$)NGQWjFti=a5_vA05xcdmv`Kn_c0%JPQ{iN5EzL%cK$Tmhd`B`DGbvGa}%9-B?L`F>$b0&74E<@2U4?8a?T?aOb|CQS|{fi#G5VL z!lpc0$su2Ocfhdk|Z65KxJ!(SAK~MUN)kvjH^bYowbDt z#s%qCXhBg2O_9(w&3X&GsT@&kcGo!$I%-+IAq5HijS_r1fF zX%WN9E?dPHXEWwWaA!*~hy~IWJo!RklFfJ6aDSF*!aC5ws^7lN^8%l?y zl0~SfbIPRn6Og9iU`y?>Po`|%NL3-94DtxN8Yrn`2`UQqQ<6nJ45r`*4Xd$)Up%dr z+33RG!Zyru;zkZ(gyi@?t{R!lVm7}GA5hNdh}uzpk-4CrMVDJwU^%<6 zOkx6C>}+R;Sbk~K7ha)YF~`3`8(fWN>Xa(eI7|w%a4>01oXwTn1h5}%P}=rQ?AGz= zX`fnEmDS!wigU9!hYm+pia_5Zy;wb>Itc6P>hUqa7NM=R(;(2nV>x>E>6-ShWJ;YT zsf9hh+E?Gt^rjQlm}&n+;IZF|Cm%xoKEG$s?3xRZ8X233ilu3T3}f}K7GV6+YU4rg zK;3FDZ~NZKbr0-&-;g3iYcf;dcfPgF^(CSzQ+!?wno^K8)*5icP2XtY^BOI*G8qaQ zdrUt&w&B;X{)iaoP&{0R7mwN$Zm`e^c^5=1VndWZjjIx`1f^*x-1@?JJTJ;Upr!=% zUm2PS4ID0n7{i(OtIcyW!u;1_zgi?tLe91qq#zC>9*#=AX!R z-in0;jtLx<#hN@m{ZX5?udjG32%P4=MLia#VBVams399g-`%Z;KX=pL+=Ht#@geEYF?bgG z^RR>jo5Yl+`s3WDZo(R-I+On@nFzA8+Mhy>xT{kFNnj2lZdo|n>2%=AFN*imYxa67 zhoGOC>fk$SdI(Ou)DFN}NzesjteCg&X<{=ra0&zJk&^_9A%u{Jj%eGFFF9z+bOa@R zM(Q3)AbqSDKWh5xpZVFM=Db75>IY|4oar?V)lbko{R4Maf-*lDiV_S`V79+!B`U5v zo2M(6P7iVUr)!tiq^U`q>tx?F;i?-Nl7AQYPNa}_fPE-~eHvo)ur|Z^Ep46F;qcvzRPgisdhvI@v|EsQWO#fG1y(b2$EAh-} z1wK{TVq56)m|w>Lbl8kd)A+j`B_ifNO?P3knRBI93{HxWX)?0;5@=RJuhGh)$Kse+ zQwLCgKr}JK5*@Ev!at$q;X2h))%s4II~RipJ!%L7CR9fXPMX*tLgPI2e?R?Ke&0On9bE0d>Y#-X_Es9g|yYuK6{D<6xTo5-oy z2-ri6i7<1hDvS7vG8%<+gWpyFAO78siQN^YLEUHTf2g<$cz6FRu1*&pBkC=>a zZ?A87`YnN*D$8xm=3x78m4Zy(N|A`p@jDj5{)eQ^B=ZydUXR~kysZv%9i_mjdNg{& z7YZ2Nkfr=6I`MSnlj$Lwz;xZ28u?OYG6XK+ucwI!L~>AK>6N!YMJJvvegeRFA8zuk zv9Ik??0J{42esy5>+uSY%HWyK=R|LyK@l-8CHk2&Z0ZWv&^QrH_jI7yaL;KvL6%Qp zCDt#|=agabO|L9Je&#UKDSrQBR5or1)H?MVHGn+P^{9G)JaV_~-LGA(&nNt%5tBS9 zGRWEqMnv;(@IT^nMe?Pb$h}>U=`Ngu!LG`9p&I2O!rHR)m?|6M!={byv!%KYM_u&A>>8B>FAP3Y=4g5}VUxrI}WZH?U#~?{lPgy^FRE12mowDC&ivvKaaT>lRh?*ng z03`sK=(N5=*SB7-OO6TL;e2cppsoVPl^p^`#r73|j~QuP2FM~Nd66C;Yb`9aDZLKn zYY&o41|*A7i{Y8#Or-c8IpT_U@0foi`IP%X(bki)RvJ-ZFGT0biR;+t=pzCk%?%+I zd02fzO#WXyCuUXTC+%n%okRO>03ONwEPwoioJLK6DqVb7c}IY-WNRb3y=n10K42+8 z&uATQg0$x;z$H*{9+ybVw2_OnW*q1M^h#Sj|9|94d(l7CAMwjI4|RqGY3j{*r6FQy zdx`-4+`LY(?a#7a2QlhA@FX|I$A8x;EOz)E-hAoTR}!0bfzR`zgmVAa?s)#M-9a3Xr(MR{WI&#?Pp4}n$AV;HR0crIkaNJO0f>2% z!Nu!qGoJxnWArYNE)}jz#f&Z75ViLlXM-lF&7bCy;J_2#CSfcy(~TC$3N*+@IWkS4 z{h>VL0T4)`-sN*j|5ljpf5=J5qR!Yfchyf@HXAa3sdScRAZAafl{^FCbb?FnA)2%= zf;P5!GVI>Hwt`bXZ&@CLqaIBOWQPR}_^3_UBKW*Z8fV2$BTdV~rrN5hBv`@-`ODwj zTtB}=BMz1Sb>d=C>I48}PCJ&hzuuZljeG8cMMTZ|{vQpJ$i9P674Xggkx<7e*BD$r zAPwbB$cPPz64Q|ya!*DF96;6(%2a<#zh$6>D-5Rk=Pt5pJ}3#JH>}eH5m(5DtYA*4 z0JQN_eZ`xBgj<~Nk8`c63u6qBzh)I8(^WJ06JMK{%o@`43xGb#f_&N`u+#zoYy(Xc zBY2Vdzv~q4ni4kQ4!}zyLFI^PB3RoJxSZ`j8`I2E{OAV*!Uv_8?ci#u6Oi7ZYNnrM zVqv&*sRF8L^rHYqqr#iMb2VXVrw)me{)5eZa4QGIW+u%Ppp8+)6iS;v;@sZe!5(0J z{4dvzKc}>RZgKC&OX|%N*R{j2Eggx60O1>Mb@fm&cRNum_+!j$PO(|v%sxpIJwu2kV4<$R`#>HhtK6@B_Z(?Y^*dS^U*`M$3@i=p&Lk zD5_-a3edwSi=@9ef~9q^ft8n!?wZ<$?X~4VtiIMm8fRkVoZa~aD~C@t3+yIsG47*= zrgnn$b;%##^2o-c+fI~IQqBW^64;LscT$Jc*vebLUwuL_)IsSb=?j3z)=d}BR^F*cscvypHZo|k=zm{} zclN0k-bxb^k`epPa*_up!t_zE0hyQRMkz=ai`Wk+TUb1IMsIJMt@#EM<6r(^OrrnA z*V9^`Lm5Sg^@RHbw)v^oE&d6xe{9uyY>e$aEjTTTWD<@{n zFhHwZm_rfYnqxV&vVD?<-R;lbJ}10@3VmJIRx_r%iKOpsK(r9KLBgCr#NH%_pxf%l zI(nw2CGWl(o=XOgBuXa9c1iwZNN9xR1X>P7EOK%APkO69)$4Uv$jv7<8O&r|Fk}Wu z*a|(NxIqCGk8cQf0MRvoa0{T!=%*UDQVz_;ZJx1q(1Y3$AtJmgCYAowBsEKQoDh+1 zKPq{Lu)Pz46>n2hKlsUHz|Rm-j}#0IMtAWn0v-6DAwVPbXky7uvxWWJ7NHhhhIjZo zP`{eR6X0n2xkhfINedhO4Hqx64F@K91S5#+{>c`I-OACEtP` zAjf9cZeoT)J&L`cM^`&*`tsysK!+*6~5OyO8uH_|!Fe<-7u z4CAJCyl(vH0~|Yno>sc>1e*oaFOI?h66oLvt##Spbjkyu6%MT@@-a|2{dzu&ZdD?! zF>ZELkGRXKRy`Q#@`G44XMp2_W)1zGKk|FtUs(8|+v|tk`p@@q9a}A{x7*j>zPe5Z zZGNq;7RX_=Z*YXJj={VE+PPYEv5&TjbJNTXze;NbmwWnQ>%re2?NP(iZS*Q@+1#YCyWd=z5-yqW{I= z?>$phi?#L=I9gprtn;24F*?dKQUYQGRJ)E@;%U;fE&>O;WqXbk@C+GW3SUffEABh< zPY8clKF&o-vKVj%8+~2og|d`pys4lz1WF#*-u zooR-0!ua&$sl&@FO!^jF+SW#!Q=E61*T4F1>!sTc(|;LD4#+}0(j^@zuFh!x^k=t{ z4P?^Pb!>A$f2et$0VO-yPw0GZU0NJ`RI+UwhKl%juT(-%I#=59O0wdrVFvc=ug^%d znnwQYPA7L?@w@mwO&QESgdLEqU0}bI;yH1&@CvyN@L$DUUO#3B8=akMdvuruo+q;M zJLq}*OI-WqYG!%x0Uassom2h4T`w%Qv&j8vMjev>V?TXQvhpy9$)jw(u!TdXom z%xnC~5Pl@QZ|LAjVL!g;Ie4H%6}z27vb?)#riypeVXE1=4JE_pAD6{SsC2d-+!lKqs(!4~|m|TvVDJ@pzQka(Bj(dypRU0?+v?m^_ ze83m^I}Z^r6PpHh1H*FU8sajtQGJ`;pc(+B%^~FML2w!9Q8dbY5~K1 zbV5R2=gElDGQ|H2qU6sn;m5ww2u}S;mqtk(*WBc}Zy=vDThf`x3lxL1U^9JGC-il8 z+RE$LUEl8R-it@z-=S^aAa>=?W5p@qKGKp`P%5R__?DpAHY_ zr!na=j+CK=kNp?&s?G^r*aoR`Z7LoLO5;lBJ|U=&VxC2a(Cs*R-}Jj}FgyUxZo0Rt zdZ)hQG1Ilum32qQy4jiavD5J+Ph`Z5ZRZSKEePjjNUbwFVHKJ!YDc=eCv4%F8aAED6gb!6`7Q$@vLano^1~^=o#}J`XTCE z8ade67*6bv}1cOW4Y=vd&|r7#pI=}!MM}mPd@!8=r7q?FV6X2tH17(q;?|}aDdsx2U>F=1Tk_-xNN$d4x3p*MJc+*Z+(?WK6OG+aqF(Ww zswuB&6@CSTP&V*2a2R||Qad&+jX38o9+6M4Q<1Qd9eQ2$a?Dl!XrTQw%qUwk3fR#- zz~u`^=h*d`1$-QYO}4i?#LR*`SyT~@Gz_TsOJ{i-8uj`G*;TagdNELr%6K7yNB2HO zA!(CKKb{=L-BL#uoAQJS99m|}zdXfM+9{v?)+PerK7%lsJwyd-fz24Q%i zq{SS+uom|#S+TE7H8k6PDK=Dg*g&_=(^@uIg;E~;%A;efZlR?Z{Me4j4g611?F~ed zmiROCCCSf5scsdPsDMcwxa4p~g>9<~J7s^lYk7QLts4E&*+&1X_*RE0UWl`uUaSj| z0r+EiVbkl;A0MKLIQ7CCw2HdqYPt*&BrvYD3mVNk8IZeR8D#GNIsqCZ?sz-$*<6*Hwr+gtE&DSF>e=rklkRrmW+*V$K?I5)C^L&OJQ8yxKVlCqjE z71P=;0a~@W`q}w}N4jScMm-xO1X#`7zySq5`Fu14%9asGJUZ3`^cE>DmrtJ95$NMm zF(z-$TAC3)^=Fl8u`6s=@>yB$79#!P07r=X^Ehx1>Y6@3U|Q_7`9I*)A$HFs7^aPjSo$E9GE)7^(PJoCqut;G2jMW)u+!U;;fZgFa73b$Ve4aY#Na3x@h_lo1KjW#?1S1A1SXnlQ;465}~mG`LTe)@?r%<1CSs6ElNr znm7Nk9Y%lY8->m9lN@v+IaIhYF>3mxU@5-rVB{YzjI7HcuzFjOA;{cTKyxtIOF5hr zS*?Fd!uWpJiAW%J6_NC_pvIa44wI(slL8|Hw1p+?*gM!#J;6?#B*Y2(T}o{7xLpX; zZLN%1q?u!>;9P^!LJ3ud&hGC*Bx81PpZI_P6OKwU&sKd7KT`$430&U`L4DP`W5akp zL@x9bU7GO^TOU{AVx4Tml+^jRhaAw-biLNw;pzTG>>981KW#!-#=)(1S5QMG?YzL6 zapNa{D6vJ_co8#(^iwTbt<~iF8vFqskTL$|4COGr9a_fmj7qtJWEu)xBzwW8dghIU zv9@}VFcvP`D1$RJ8~8h5notgQGb-M^x0RJudSASEzsYxCI23su zfhA2cmpjF2Kdk%?C^`3C`eV2V)tSBaXNo7;C%&GY3LKD6{c8? zmrQ-kvHuNtASX6RD`1g3`VQOh$xb%EBXP|Hb*`H{Q3bX9xhHD^thImWW$Z^AuEYK! z*nGU{6pOIjIIQV z#F|0}LPli86neOzkc|SL?w<*_v}zCesvx7m zw1QB1Dl@okPs=F3yEd~Ah2mN%Qh+uBZjcHKCrXl-;xoiv8QYwGm_ZV zS+4b{D|3G|>4lS*g^e^K5H&+X5fgnl0OQ+TGaMvOeTVVx%LOFk?|4K%aD0&!0dL2L z?)oGg74}ZxXXyL*{;WN%>CVP3A5;kP?c2tRVE(tUYnbt?J5*IRRAa-o%OLcIBf&SN ztS*CN4e5uql>^)u5c4;k?9hIDLtbOD)U>>%c>E#Vb^;$p5S%h?&@MiSZE>{lhRG2I zNk+yjp`X26FK+5zRf|&2-BwBQPXPo*v#=^4HIyy}MgfR9)uVs;QMJ8rzzxIl67!~6 z4QPbieI+EuQKb9dDTWO-R7ic%e7#EH9JJ8lu@n*l7W$QG!vri;#Mx2-EW}t&G=wF) zp?GD@_%MOSUtU`82#px$l!D2LF35}baU0z=o=}zDyhO?f4SoZiJMHPlv^2hgdSJq@5QE4$6{m`Ds~&jJB= zFXnXnZS+&c%&nDZhDhzU(E73U(U<`Lu47I}l*i+*EZw9;iv`$iGR&laI%KH!vb=tL z%pV}&Iy-~ez(NuOuze24WWTcL)}XgN&^n7hz){U^m|#D(1@`Eay%F0q#9|s8jL5?>zlq% z#MXz4EwYmltPYuMYj`L17w;lAd%kIG6R!67L+ey~xzGrLK!y!6uzfCUE$_nQ1RBbp zn!TKTxVp-7thcV|6tXNO3bY9TAk`M@6oZ=HO*O-(D{^RsV#2AToS9kmG>t9DJ+rJh zKKLy`!#nw3g7)%Xf_D7+D+}^ivij-#1Ia?3QkJ1bkYA8{#p#>!9l3OfMumygabeJGT>Kmrh9DfQVD1#b8Q9yzc({@5B zCDCKb0ZAk4tvZN5Rm7=SpR~~=8T=jZFb}&yVDbu30!UUhiX&y>$QyC--AZ|pnt8#L ze=(niMBrV}Pew6|5iTelrlbjl!KIZsu4cuNQ_K?tl@4^bx&reA6=Ti!|J%-Mz{Y{? z{0*dlOZy2Y_Urh?;{A(!vpWZ#KP5PHw_DOZm4fWCY60ivW|DDu_$#w2bRJT~SDkVb zV1nS+P0VczWME!a%D7%g%?bZ2h@kR_mftHH9&}meTC{cF9eiP32A@){Q=KbT)&Oo2 z?gLN~okxX@b{GgXrlNGW(d+b-G@){!uAg`)MXJya!G}|0;UG#=lb}h5`Us&KMKw0| zNSIsnpl4aB48wasN8QcIy$}H1K1I}j|JB0u30-9Lb+6rI^VtU<6#ZH!ADg!UuWVY` z^5&HXR@Ts|H@}DNKCce$EGM+lf2vc*QnX6=cojk4+m5&m#P6~9rgNh$WboV$8Xl}) z6nz&tndZ4O$za+lwgGCA)=>=5Xgi{gBau?XJQ^B8OVw6!3}n}c+ijiQPF8Zy6A~5^ z>2258e#`aT+v0&-uQ%n6f@0oZ)p^!*i*1pgqsi`-dJZILO9B` zi`7u5+(vbMqe=813en?`+xiI3bg6mI0Og$F09OIZ`P=Cj!lB!AGf|$B^L`kPGVyw> zh2-@;MS)4BHXz=|{uM(s>cYA_M?$e&e{QAkg+GC&TVZ=fH&Q+OTaFXf$PQ^W;nwGs)jdS#ewuEjHC3Ybd_{;K*`)q1EK_@JzbGHg&Z1w>ITS z^O5if!a|143ZN#9>@CiKnylTt&hYfC2Y3&xTjBV5U(R0RdzI?Wow+WP2*=5^^a4aA zqp(;Y0e~~AjO{mOLmwIsx0W99vS1F?Vfsx2p-5dl@fw58E84wx#Mde&A_I_!OKT zQrHzB+rM=amGFsuAmpWi4`;unRZEV{Hkd0ZuodAX*mhPhz z2~06HGVMyZC|Gxi*1(WT9uqtfj&N3gsc3Nj9HL6&2aKbBsmL)iD~=egDy}Or2mjcc z+h@4GaqwMT`EZ<#Pl{2sT+G$^OHAjz7%$jjQ<^uQ6c&P*7_m*|+=?~xucH#-J;qc!T_NxO9BV8BS%srjjjNzv04ur8f41vfLMLaxQ4?0!_ry) z7dR|(lV6CXc|D^2dmY~Op>v$4Ehn`C4XY>0+b03z0}asM%tTYK`HRD{^K_8Lg3J0g_1|am;|X8M{`2O#+AI0@ILEiFfPPfZ&+d$S&%f!fb@vOn*e8Es|ZdKNA962)puG+N7QY@yvy zJ)KoJ3*Bf%Sh5o`V?!%!3R|ngfu3U!&EBMy86_#u2y7PsDA!=ll|k`A*uLb%%}i}S zBU|eh+JM2zT%OtfL3D4e2uiXb8k4^BkYZ(Y=!CFf8p4EAzcPk(iua4PYkC|@Wh*^s zBF*dj+UbL%Hl9BW4G0{ydwB1RV)8wh73LoN3VZ1aW%(TSRR#bzW4Yj2;pb)Z)reG%Z4lqDpqL>_)g6gp5uRN~ z-Q&Ii&9E_?&_9^2?zpwm{>32D+7TNfUXO}XCUJPf(){{19p3Ai@6b|}^Rl=Zd-HVD z^^)HFWblu8_hRtkucfP5$8q*iPDs$UqPo45*iZb8U$7g54$y_B5}W%|GGMG9;cia2 zypHQsWNW6E+nC$^GSv)ILtff)1Cej(dV^}hV&+|G#7kJsGcwexYXj#h%~nRJadD6A zKw>-~C&@`Zo+$4;1>e!pjg5NlaW(^M{QRR+DG~1;sYm?7FQB?}pa53G0#>8O?0PUu z6w_@1{rm@lExPkAKpgPdLX6}8D&>dx=F6ZVguz+6|4zaz{>6;pC-U+a+PFPqfE@v;0K4Yi-ONdpvV)lVCE?Bt@RvQem@)jpalx%*QxN zMx)}?=kVd|64RiQ_5&HCU}?@_6LU#1L1SqcpSx3SCAYN4eX_c=MPrHm@xY4uqyU-go&U=ERU(|ve>|Ir_1L?(%$#V;?r4xfQ- zB6a{t2CJ3`3WbyKbGSDi3hcM-sDqp5c7FE=r5u7O?p&E9$rD(>wf0B%#R5D)e}E`p zPQ1TK{5}2jFj`ry!U0BjhQT59LUAfQ{s$*;M_ZY44n3$9_{ulz#UT6%Is<+vydL4lP!P*e)_q#T z?graZw>aTR-xV2X!o5s$<&&2o>T)aJ14Vu^1WgYz!uEAdh+tBX9&=hTPIua!lZs%E zAMD;&V2q$%JP;cA?QiKfSV!}B!Wl0@!QmM*k()@srI4yHhjw)(sn&j@KcFlgUZXo42X&bxmZuubEZ?$meZp|KOL67NH(-jT!TY+2Z}q zZJp^e5I9rR+x6+JMyxNYAluUsT%vlPXK^D;f#LDL0I#71ZW=H+(wOY5Ka7uH+!fX{3QY?@tJzwmGJ6U)Iqru40ECkJimnY+Oz zpkANt**-P9`@A@6WxefoFE?#kmi=5n)Vg=0+fK@~VsW8kRMfGGu~!GGIose+VY&SS z!ki->f|1}+48F{txj4C4VcGQLsh~DF^>Y0Ak5jFDPq@arfF1P6+w7$7;d1}NuUB#t zm#p&yI|u&utW4Hs!cOU`qh-@H=vfT6~mj) zlw^-$UT``^L&?(MTA>~cD|ljjowSew$<+KV`oV~# z*B>v>(ewd&yeh?EA40zbGd4zXu@n=f2r_tltNRiFBum3f;3#g9$WvRFDFo%3(iclA zMxe#B(*YtlicMd27pJ+7@|TAyYLouacXA*%`gTpJI+32Af~e%gF@xFm9t3!PcN9#x zfaiBNoPwC5LsJ`4?%uxNZ^BS|fKmcEKW@|p?4!!supc28*z}ZocK*<@bLYCq zatL%Jx1eTTxyU()+VQ%ru7B-YTAf?``FppGW&y0@uT7-k-3&K43gB-5LI$P8;I5DD zLHgTqh`MXosvkI7!4v|d{bg&~F}yvrPU7wklyNXDfGvparJ%m+ihXKE=y7m~&qRJJ z-@L34=fKg-FO2}^ilr?FiSJPwuK4;X^wekDAl!wy$>6=x#QhhEcl^k&wg$KL1NSkW zifmVp(q;HEc8`dqYn*0S5EI~dbJ|8_5rb)uK7|0ptL;rKpvM_QF3ipESm9cbrVs#; zyv8BO817BArV?xTwfi~J;RP|)fJ?S{83v^#cXvM1%06Z$l=uYb((pv*L8KU#7TzgA zp}k|{g_ahcpbYpj4K#sdsi+)Fx6%X2qT`r#ET)GAcR8~nh*#E7yPjOk0upVO<@3mUF0`4@9aTefCx73{5lIUr@_9J)K zb$FMYbdf(#sX4#iBs8jZNL1!H!!edESS$>9WuTUT9{ac@iQ~c z;>xTh*KKq#Z|T9`dPXB)7H(2Z=$kv*jWO#n|C7-MGNMv{m(N%Of>*%qc2HlIRJ=1hC;7<>{Rh4~hZ1 z!>AcVvjOhf5Qk%l2PX`%0dB1g1X6UJArSjSqWa~*hIVJjR?ntzl~`E3jc;AypSTN@ zTPz8%_4)q)jhKVt?C^zdh(9(`!>9Yffkq{0M&^dtFNr5tbZttOKm{byn&n`oxE+S` z2DO!=HpPY3!|M9_XB}h< z?P*lcem)_rrQqR}Cd~U)@+JH*pjLj$ooRi7plBbt}<8FG_ z$*+|T_V+ufK7w;YP0ID%&5$=sx|)XxSE9yYCt;uFB~e|UHPXT z`TUZNu=SPUjg?Jx+7yCGlm)zOR4WvNiZV}Qd4VLy0J@sw}tOMHkkIj%2%Fu-`;u8BiG(LdlrHo zlFyw0d2sSPRKDd}9D1?dK_j*ZX90hAC2*wR&ia>h72$q$U70gLV_r(Fa;RGyuV!$& zj8h6MYHdhrn&2v46=;ZNKz~tEpFEVC=H9A^JQJ=MtzcFvp`7 zFl^gi7BU!rkuRtaeE27NT3EyTV3(p?YODKh{%-p2a~@fmY%h3KesTZ3Iel^WOY_jJ z(=Q-*U4?#teN5>ZpUmd#e)`6asQ7I$NzMB6*?WNPP&7SuyNR@yrW`oIv3!;-wMlM7 z^^+2tw{76IM+`#2ylbL`g^eYA?c=Xjv_j>C`g8sH7M@W%QB|T z21aNIb5_~<8V{DI!DVXWzkj(S7Z~_k{)quxU!O&Q5+vIXv>?m0_ym$jp z7c|+-iXTepT;g%(Ed8~Z)}gjR87v=NhKM3mUnA$g*3@3blcKGDygrRF@o!SGs}6N7 zYVMzk0#WYhRDv<;r-T1^!;pyZTwZn_M6Fm3w;I|>J52rC@os{zXu!)QAe*;ihLfP% zhQE@e+rE^Spfg@wsZUy|`^UM5$- z>=aQy<;>^G)eDbXmk?@LluVg;IL3C^NI&#qgjR!0I{1NsUM}=m!QC%WRpAwS_22XE zbN8eDOWe+?gdZ>wa$|a$t2)$8vB3Q3E0ZLqzj<&-c(_x+1rz16=us4HBW>dsmhw`^pr7GBG>!+HSXcG=;TGLtK~@H-6c+^ZSU}J+*8&+q4HEb# zA+U3wd|FIm@4qR~c@Z;tXSYqmo7uySAHDmN^@|5V4yST;H-aj)LPU21X$F`OrI4)D z#P{{r4Xlw#6wvKd*(Gn~yTN-mL+ra(OttQG*k$e2m`7K<#-w_A8wi3&F&00}J?0AY zY^)yl0Un2v;XeHl-%RFNF~4!UiN%IBFLqsCs9{_RsLp(4X?Q3$&=6Twz$$?en>^H~ zQ1gIDc4VOjU&wyB4dWeJotoW9Ua`|E)cB_zJH^!!%3YeIzjX|%fk)%+?~@u-9iIt4 zx*>md*GTeJCDR?giumZDUF72yV z-uq5kMwUqHu1NJs?pp^vF9$@+P~XKwKz(x=PybN);6e2Xl~dk+k>$u19@x4IH&*aQ z)?grS85W9U+S}ZjQRzJq-@7@~((yt!+M!RCtDAb#eJ5w_E*Pg;f3!qfu%AzPZHslW zTLuK$QgUpjkXgHeYaRz*>U=P_{DKXmo*hd!!#)?P@FQ5?dgdrFHL|qTD6RW~uN1bN ztK*$r<%GBUd!o^vy<-*PTzw7FoHZ@f%wFc8OkYRc_o3EYn07-0SA#4&;Isyymj4_r z!+gxznp-mo8YsOImlF0tV_#e&P$5j(g6J4?wS>5gt}{hv9~75TxP3zNaYQ3u>USK| zwjct#9Yod{8CO*?rtc+q>-kq(vm`w{tqk!`DLf)Lrw2skp-a)Nd@ko zq6^^vG6KufWlVcqp#7>Fvp^alciQXrz*Kl?mY9YdrMsB-1rMau2V&sa1Xptqq$ zL1%S8ckc`>SLVh(F8DIUAs#(sg35nS|4{Cj8LuPgnE-l9jbiGIKj+q(I$XrQ8aFLh zi7Xi!k&3SP4fI7Cs17=NC9X0su1GL}RUI`+B9&>gmUu!yu>#HZL3f{=3`3MXd9_E* zD+L-9OR~3r*S_WQf+ij{o2!az0dD{GK4%2Dt(`mLBfU4=t9x(swTAcPo+t6;?C$>l z*g|AzF5P?;E(7x+6Ufb#qUSIjo4Q=i6aO3dG7+Vbde^_CQK9N}1}?-rM5M{5I+H_P zunWj>5H!`4eEWIUv3GglkzP;CFR4@d~gvj zV>(zPPFdT(MfKz9@V_MZX~E?D}X4*nIN{WQmL&Oo_MD?KBy z+?v+&F3^mn`dh;35(tp0aXW+ixjWMo-8N_}Bd%2fE#E@R)iiWAcR8vwK)HRB5V8Swg@ZfWOcS$oUJfPvjB6^k>4YjiO5N_AnS{h9umP6y?Lr1T#BRSST#F+7F%Fq72R)* zS2yqtoDX}&dU^#&E9wh~w@3Ls->wyIpsgxuE^hMNXD%ZsWpeTjA^GRof$z8X<6Q^i z_W_mCur3Y6S|#Dd`IFSV*+xQFXO|Uj;{Iej6s($g3!yH7Vw#M@7zPN=Z%y6w`PTXO zxC=qp6_>ZVUzKiyBj2d+_*DAU>Zc{OcRFCuU2T0aJYwi{HQFm~?2njXy!0wYyYj=z z!HsXybHmkhf_-FeFcUhs9eGGsf6godRs1ze+%1#GHGTj1=NgaE#uPO)OZtzNdBHtp z9y5hPX?r&n%qT(C5H~{Q&7NXShjfu@6QlFPVo5u~=xy}e3@S-)^eME!*7?r19vJC% z^utNI8C9%T=_FkF91n`#X#{y(x%&}v`w_DijY8;c)7@T9O}QmnqSc~2b|(vL?tCg1 z8M*_Rl%}c5n65KEn7vlPyAjVw#8IE!_NGs402^Ox$Za*u>-O}?TkZ;5_*?Ps5R;Xf z))_T_2zHKTJgF*CAT&T5;*P~D{Ejt_dG(cc98&7(c4!HU`kFw~tlT|YXKH%f!mAJU z3uN~Jr!*idpPr*j=qPyA>YmHhU9KEXS*1b9E#vZ?+IRYx)tj3q?I}d8#DFWbBEwf$ z_Gw;R&#h>L(K~>@@HmqB^a8`woqmN?OmE^+U2CbC^dh2K1GDNgV2I4{%SSAV9c zm6b-Abiuwfu?9RryQk=45WSs;vwHc?EBOxI0wwxZ(JJ=LmD7J2P3AR6vGyO{o3;ew zx%q(fL@G*;N2))xPu=g5%o86W<0@c zFA2f=MGxaOAoNXtAEOTB)0T8M*Csfswm+T2nbgXT8vyFrcOo%(I5|f@@rARTsxaewLLW#d;Q>T8Y7vAVii z!ib?<8E>B990%jJD)PC=Y7=S+f18HF#G7Y50)HwD>5_qtGUn7U7ZSCz*TG$)G3P%A zmXDmkfti9lV_KAI_>DYa@n&Yy;!PB(;7LddkoMs+Ug2wK)Nl6qbH~{d=%qacBEn(K!^W4ArmY)|G&YCQoG2qR8lu>k%LPbRKE-dO%H#7J{HW9 z{%=9SsQ(rO=J{oYtsay-dib<-Py5fNmu#e^E*T&Gfl?(f<_Au#nvu5cJ&G2tHcgnr z(g{RnWt|GRHoT+?xN`gCVv%JyYR3yRr@K6IEgw@LaTUs!ppr1kgH#1vF~&MmQ2W}- zwf&1m<6Ld^`zU!8#J~H`dfQU~`aq#@T?%lG<2*W6s#~OgeD~1rY@T!W>3VBiS$k;l za~8$De==OT5a=|jSOO+hj`1q}Q1056urNKI%?q5YfzRXWx04!#>JBUwNkFY!xBH>> zTKCK$t#KPkJ%p>4+HQS!E$4(DVUSf6-=cykoY0~Iw9%9kT<}tqXH2V8jg(NNFF)lg zYosotDpA&!Mk%2HE}gbi(RGn^WBsVIM*l?sZjF~+k2K?>_pL99 zmHVu^qmuWQB&lw61+8^bmB!ZilBe4?VaLE#Zl1ycQ1ZpxqqjLJ2pw1^So`HTh;X&= z4t2yRcXc#O3mdeYmpYY3daiq-ZeD2Sid5C=wf+XiN?wFLml>VDt^@PK?x_V}R?^K6 z>JAsHT`@#afLTy~WYS{8)BbQXT?Ne8XitQxM|kE}w&S$^`(koXzyrgv2tbSohxW&= zogCGV8;_X1B^xTv&9E;Brnr!A4Bnzl73?@5>?h#e{J8l#1W?D!{#HZD{^0phD)!?1 zwDYT7P3F#N_Y)tJ*0OI~MNfH>X_LU5`iZYe1xyRSo2@8{Ig6UKh;yl&s8 z$HV`GG&|@p`%q#NM~W$Hqt2zo%@4aPw}xjIdb$Gs{BuBe#^bO$f*(APMKO{|OAW_E zNIO4@x;r?qzbn=@@atJ$=QVV+HSsNuEDtfSz))&3ysX1&AlD!&AB=u5lgk#|F6Z@c$2QthN{@ZvX|iDhWZoI_JETU&|dXVLgq9Sc5d39A@lH0 z%NWjjud9PJJ|*yfdz3jsodP_8VUqsiaEzFD^eS2~=GK-STrJ-H3=w>q+Mb?=94qx!QqOPAjv9PSdl$WN=qMI44}N|P zR8n0a&amThyqEF0d3X1@x_@sJMas-ds*Fib0GyML4Ki}~eFYNZ>rh%6k9i;cXKTc(#byT6k@Riq$%}&T-jAjlEw#DXK$Z&6kvDe| z@MiXE1aH&Z2=6Ad*L>F3E}Ao48mwe)s~w-GxY}Nkd}FZc0rO^eOAe&|!b0QOzgmzo|Fdt9k!?3R3$q?Sm; z?iC0M9(z7TwoHO%21;cg&!P4Bq}RuUNQo@W;$w>Wej!eGyx{yvi7IsXQ{ker(OrL5 zI5RZHH#c!|rDapj?Thn=8=OOiucZuiRa~aO+QN?#yH<<$WOWsLN_wz}no*NkiC*1} zlk^vrbf?w}8Jx^?j^eTSno+cyRknT>$l~g|o#X}(qV=*{gniL-9a)sw)}K7wP&0i< z`E6TXZf5s@Wx%+ye&60@(Mnu6Zg_DvTT%_PA}^kqd9VA>aes_yfPx$M-2SZ)6SATm z80nMofZD>`%9i{HkG)=P8pcho^4Sfh=Wvi*!R-7itV71h`oOcVU*Y^)$GXtzC1US_}=0C421$`@H>89uKQ0XVuWLmz2w`f?HoiqOcMoRjvXR z*o6?MD0`L)Q(0qUR|T^Xe4Y7p6Xo-1VzDirJ7FElm_mlXssatWKVSZBW-%M;=X4I? zC*RS~Qmif?bbIui*b>~cE=+~Ndm6*g3tA!;E39vvhgoG|nR{6Wk#&D$fVZ7?PM(m| zq>jnzVvyAs9yElMG&VPOcTjVF7BRrXn$F zMTuy8^7bEUtV&7pa1<{v*XhTgb}O6gTG<|KNrRHdRG1KKhqeK0kx_e35&R``J>!`v z*+<&B{Lty<>?v9q*t9z)Mw#KpgfFGq<&0SGp8H!pF$qX9u$G|P zPJ_h$K8f= zkSE(-TYiNPGq4$ep2F3pNE{{eV zMycAYT$MF@>WTwZ2$JcGa3UrAj&clU9g^qkSu!4Tb-5m>qztW}^hJZQSXIh>Ql0yy zrbO4dwhz?F#yC>8E#cT1l2d^AL({d7f9c}c^PXi#ppn!XZzS=+1^zd-j*NFS=Yofv z!Ub;hcImX>rX51cO8uW!mGFg{@*!smTDiBFOp#+?ba=>!P27uWc*Az^J`srNGX==v>Fb1yMQ?l49m246Pqt2(>^GOb-$ z(Oeo~uyOKV@Bi4F7#pcfMhx88+0-jy%6m6*9Xk0gw~l_{sfq|7^elP}0`0$76WDg_ z_wMJ%f2$_$nPRqT%-2c7o7q#`m?UlHt-Y*^Kt$ylE-VJoiP~uak zWyFiFB}ld{9Vw<+n@>LOvBnsS@_Y%MYK15U*}WZUNl@0L9@z^vxIS3ByA zyubIIS<$=6{NZx=R|+J_ z$)Eru{W5C^`xhE8-iI>2Z5%sCG78XkC>}ACg>B!H>J`{8WGB{BQ?k|nJ)j2WjYF|t z%(=PZaUdjtTC}fAhT_FZo1iP7NWCQ@1p2=?_KEO3=Ppab6a`a-Z@4A?rfEHSq4)EM z7XXn1)`+~i8BG8p6A^l0IU7v2$Cu1XOuo;mAKuWRm3Q)`Y<<3rF6Pa=FNO895?Hj@ zm{UkK0zc1 zz?qqT3Y_vTm02cOcx8Y(Shqd6p#qi{OWBgYjJ}&|VW+eXI9WY--t#iI(o|IM6XXKV z8hSww|Ffk9n{EqF(BV+bEt5V=_x1cjKOlPq0+Gg|r$w zO9-W?*5Kf9^7Uhju@65Jc8_CULUT=ouJTL-(;u+`3+Q^$xBL{-1uw@&s#;IK_1i+^ zkLgXo6r=b>$&Wi)f5zM=f4P0=8mOB9iz-C@Pay{ewHv$p0te4)BUSxz6F`}GeYm1< zI38&<^~Z-Gf{l@Gkhkz8y$bLY9r1t_@x~9?{+NaZOjYuvYK&E8yu+`=c%wj4B;yWa z5Wz@QNu~*EEbsod=jN`xB(VFT><_N{`@EC}nD9>1+u+^-j(%+CGyU_>d-R5TCmJ1b znFPNdlWRihk87ASP)kt+q|jOp8;H@$C6CO9n<0N{xv(&P^NXH;jpF(_?J8Duollt1 zFV8!z-Gj+xkfFQ73I(ttOfigq4paLi1EpRjItbB5%JK-FAYm%g9_EIyaf6n+HO*7e zh>Z~3y88MI*kW{ykAWw^36TH8G03nqwG;Z9x_@6kxhoo719Jz}4WbpeP@>SF^#r#CT)T?&R2QC=Z9X9!v7e}f4j!Vo3Qxv_hqXBLw8hnK%x`o z2kQKia1!8EKI9MHw8}qti$GGip#2*b0WR~I#lx%Wk~Z8yStJ)65V_9qB9PNdu2BN@ z+;`Y(Q+La5RFw+V{00g@$xVEe8zx%*xSf}P4wDwI8}hyRezd|?9QTB}>dklK^1sBr z$$8NUeOVB8NP`*w%O+O|=a%}*5eGNbm-g;0Bwmy@Uv_|mSpQyoAOP3WR=mUlu9e-X zjFWvkysGrWXprp{CA}Mdi+SUdSg^pYjZ~57BAclAH1~{#MG&_OvN>jN-+zMx;t6f1 zE$9I32H4rsv3V@)uNS>>{wU4g#U=#d){h~t?BF9w7=Rlk&tu8RJx+&S}e(0q59J9Pv)m0)%LSsP!`KDfQ~ zMVTO(d|et5L-M@WSBu*jHmVu}r!^EY48ngQP�E*08Hcgl4{0ad^-g-V`p_$~<4} z-5>CINz0EC>v0D2dh$jG=zIF~L{VljgpQXJYd;tal->A%V08vm3^jT+Ik^K7p8)vl;Pqhm#-t0|FJ-G(KUhu!QH5bn zGf|A>gzHRultNTkVaw$3=ZrY!AuSQxoTQm*N^n}Uq(on?yjNsSn z+nuI3npipSr0!n-Xz0-EdG{}N7cX`crc&w5^LE92UG-c7bvM3jRi*;fCHEBqzY5*v zV@Xu{(hpR_1js`e6m5BhxWEzGVZldo1&2dK-S##&K<@fPtZ{~4cm7BcVf|9O3$&_f ztw{&jIk(;t213CF&i@C>fk}b>`bM8R#Yonnv9tS{C&epQpG~2+7m}ct_g?n2NpWKZ zo?#;c?5^yPVl{(Wk+n6Gq1A&gu%v2h2KsKRaHLYR~h($7A<~ z`pqJ|?m4Z^g7W0E)6dDy^N{{+`ztrEz zsHqn!zJqPyI&4sjQTGVvhU3>&at+&k!D*g`gfGRSWk$&V*da}jvkR<5=GUkpfDs3QygsN)rBu} zI5O=Bvoj47@&QpHCi5GIv|l8q?3MPpTJ7^y*X@l9lk7Qeb4at`OwVaNbWG2CWOYX> z=&?g&R<8^HtGZWw`%`6qA&T{pUqn>$`A6Ia>oN?K+) zC##Hms?5Iqc^(EL_k~`TjsnBF;$@>zCG@^J>pX6Tb<{hQT$%fXv)wxq z0=IWYN?gDd1$obRdN(vi+0u+x?)G%IG33agSO9&m7TPes)$sK7fcg}ec33bAGUFd` zo&!qXynrZaB<`fw%L|NOpAZ$FHqYOEi80w_axlsRSSwR9yqTOeGQfL{1+=%(ggFs= zF;NhEtyNy;5-+>d!xb zRa0c?@5!hNPGVDBF#-sGiyOtn5LtjvDa3DU*#Yez{>~OR;8f;T^_i0)Kn+aEr~F=on88#*vvnl;nvt+L;mznn=Oln4dtABSl1jmIKgE2A~}re-DOl z$=R=YJgon`GnZ!rqI6g3hh=at!NS$8vVZJ$4GzPw%cGpsY^Lq$PAp2WOSO{LBYr$u zM;s(={)d{Ovd6$UuYq zOApBO?#y6escWdaBJLE8M0wY-B;s~ds6#|T5%r@vds_vUVK_w6Z4cGLfyGaV@y*rS zw^?Y|Dcs=tbELFJ)5Q+ITAWSzRsMgwli3qsl+;5J9B{U&oBmWxUdZn~+sRJ$EzVzm zoE>^%*sZjVKaUShj^hl;%Lht}kt4ABxQed3_?J&wqf|zH>b`XoR0-RSRlJ9U-+fIAV2)<^p{&satw#WkgaNI=;B_7nTn8?j1z}Ijs44Harx!Px-*=_9*sYl zlnDfx6b0+lMwg(U%RRdn=Ifd}1!*CK7Z=vNHK-*I%u%tXo83btBB<2O)m4{Q?$FVuOz>=^#t@N~o*uU{m82 z-|NrTlrjP(FTZ5Mwp*C7X3I)ItWz_RODy z*H_$RV{`KFa@g{jcYRu4t5Rgo(h#YTIIgD}&i;L!)_dpT*XU~#Z_PkqklpqdXLo2F z4=z}kv9+jVJJ`?!1Vj_BOLu%1B`Gv}CffDWv(g)F`K?~5eKBqM(_XSCl++x%w>!xu z18>=TkHv?E-vVx)aoklIXKNYoIgE~_ZtHvC-~C~O27}ELBS?@Sh0+3(P1Nev@kA|)f*BEmx>0e+tF;El1u%l zh-uwvIrO9xYsc~VWsXJ0gI(l>!b_!I5x(KVG6gZQ4fkaw1+lORYmJTN+8Nf-`yO4J z9nx2RtIksIaVxJsBY)nR%m9)nB+Ft9CQSHJ{u8!h{UMP zazXq}zd=6Z!oPg9Um8YOGWS^~sTeZbGo3h8KUlGvyKrPGh{N@hWqx2_bywNbeRhwZ zk|YmU1aKuzUcWfYy16X!@OlmT&A@TUm?V}fK7%(Xgh>fL2YH6eLx@OU0~#?#2@=fd#iy^f63re_f@lE1+plEO z0DxD3_|`~xHf?!%s`y_8fg!JlI+4*YGWLAf6URMK62DyL)P~dV^}18OtFN>5k4Vc* z3OJa|#aJ#HBB;Lc1v@6*kJ13`a4|zSXUslm_t^9eN9KfV9#ZEWd|Q^R0l3GOEK>v7 zlZc8T*Q+G1h71AiwE9neefe(tYk%He4d5yEBFf4@pk8ZOZ&~$i6=LI?<@feRo$?Q{ z&>(ddJ~05MT<@-(VaS~3yd&hY>S;4Rp?g-ZR>W^~7?Q*S-phDzT0aonj$PH~tBJY- zu$Hg9%3qokPY-}V%2tp*tKA@!cw-0kv1}YZE2)eK4m~0p zi)u3^{ACC_V}4zT$f~z7uT&t{qv<-wBY`p0BfJb-*aL40XI!%G_IFBH)w~FNpDqI# zJf)Y)%qj-e_DnP;z!i+<7)+H4n9F{-;-<$aIqGeLbgTp=iT@=<|sJVubFw#cU`$NF(cxuNfBN$n>@ z+9>W+t9Ya_j-T?b5nQRoxkx7Y0PsneuJUa+UW*B5%nf~$(To56=`cT`moMUXKwiQU zpZGOD7fDqp((sNPWcj3s=;A7;11O7YGa%d5@p9g zX)36r08uMVgnQ;ETBDxJiptJWCXN==RaOqDNJ``qo~NzSqxP|&9sl19a!PQKa>bc+ zbp0;s{i?wyWn!xTTOMhs5S|Xef~qYdU6v-U(YJC9mAbByJmHC9#Y6D~F)@I8VhP$} z;@4eSp`WV9-hOwWR^i(movIWkNc7+I1Cnmbe}x`cKVW;bXVM`HM`V11^}rRXN`NGT zyf8S~Ty5{Z1#yC&`wHGAHf)2pdDLwj$}SzmX_eiiszW`$z*Cnc8J+g5pf zZ`;9NEpRaSGE7QDy+?EWbh2tieSCG{`XJSB04%sDQLQ`z%R?uL-yMx7OdlP05A#3G zo5KbkXPyjbUi3P(drp`5 zG=MYNrGXNs;sFl?*otQBMHkqb7eY929R~+kL4X{F5H~@E9(zFQOU+e9=|>{6dTkUN z*}Aa+;2H2AJO_Insiwr_gqJzu_d63}yC}_}sFHfopu7UnlvF>(FJZyWmeUqg=fLfl zVB4eNLMaXvO2&%`e*h(3TUh+sWeO@cC(+P1aG7_u&I(+me+2ulGRX@J934OFK}jwfUtWB|CZ?c6qvk|?qPhf9W`|pU>Z|o zj+)ol$+h*xac*zM(O(%rm1Q^|-ut7oMu8yZ-yK+I+7IVu9s@B?#t2`c-M0r2S*vYvl z5MWqV;8khRy-ix_B4f)b%EICDW{H#l=?b4;tF5WHLK=SBBDyEj- zFj%w0WFXRky#r-T(xJxOj$&Gcg98S%M+le%DW&+r@KU6kl}WB)Mk(Z!rh}~h*tXcb z{P5!J=%~%p^R8EP6ceYW{brR^HJFD(to@;19-M4l!5c$ zj+Cox;vAAh_(4$5a_T5hL4(h7J>C}Ruvc;1MmZj()ZS=*>wEc*{#=2Bx6J-L$6zGEj{`881KD1QilkE|yQh`mXVFF|5|tML2WUf*|rlfXf#vi?ITeim1L6iw~4 zbW2SF%I1;?QRCoOKm?d_d>G$pY&3D^8MlNN#!Ah~nBukwwqacRKW?8amSs92UcT*_f&QubhQ5>zx`5>(fx=k_Vem8(w} z8{U+C5OkesNkB@dRW!$)qVE^YpM%WU9Dkp%m<%)sz-55~To&>=X5bjsICp3&qGK-J zP#EE~fP90(h@zDfL2N$DswMG3d~iG^mbv-X)jm#SUZdxRKD;ewT0SZCINIMnHn0r_ z57@KYY(x<|XiR>ATWD2Q5Ibn+z%SzB;wE1lK%{QQLQ zLN&n^gs?3y#|S8m#}Au43O?w<5&{8G8jmXwkyP05#{o)p4d&jL=x`tFU!o(@X^Zqs z$wR%!5O6T}_R*sAe2AS^+7Gd_Jt}uE4iQ=SbIPM8-PI&wL`04;U>SEAa4wY6d}J|I z0XuAI5l5A(n#V|Cm`dEmZOUr-u=r+4mMjmj#+GE6^2nazDe^8cMztl)VfhB2ybqM- z_Uaw{tpF&msRo&4PQ6)?`dOfEo+P>vPxr?AsS)tdU#k(;QT+-o!ob~``_MRD?BWC@ z%Ax?S3yk$d6BAP(3Hm2qTU7iS8qwdi&anu54uS;IhL8J0#gtLY zDH-B~HVoCHVW?Q+Wc*@rc5^2<`_z$#NAO|Qwa~~76ynnYBA?5akTy}1VhM+ia>-~E z`s_J8b*hj&zzKLT`Q-IZf%~gnXcH==i+AYyw7jS{hWV5PZ;ZSB8-wQy2?;W4l{v)T z>XLwI^xZ!ect7f3%99_aSF36Pt<1^#lnrTgo=$(4f~!LzVDKrz2VPmCe6R#>6(zDr z1L1f(%h&zx(TK`X6?i;GRIaLZ-h6m17R>^56j8&JF@-!YTbzW)G^kOK^MECEi-TUz zOW_FTNvB7Y@@sTGA6W!hyhBQ?7OgLb3>i}hFug)Tok=1AEtdEf-?4CsEimk0#!7B0 zAK;0l+-bhiQwAt#QFKa+Fw^|!nTB*|8}DqmM`)(q`A&}Abt`W#2Vm~6AAX0{v(FlLN*-J~cqWUK>K{#J}Km11+QUf0bll zNdi6t!~-X({~Wj{_;fO&GGjj?mgY%`oQbo7RTj&oOmYWPM!D2={8Yo1#VjW=O0k?+ zN0%XM{7F0|p5T8@e%JpAH1d3FMXJcw*Wm18#lXTB=5`iy=O!VLa~PF66o$NdEE{|R zR+oJE{)>C7@$>V7H@}{~8_p$>O($2R{=brt%g-Q}IdX^uL>Tn&K`0tuxjpCR$9CO! z5wEmw?`c|YH_N|le5AmiXOcvUiAR`}Tb1B#jSa};@>`)Q#2+6!b<^)iC@DGWPkxmta`F9GCGn?$Rhqac$WwGcn@dZz_AZKG6~&T; z{bG=V14sP^?WM50?DFMSAy7;xLm<%X9D1->pg>L-Ea9-t1gn$|Zg$|?t1}52{QSrH z(IOVmnR4I3*0TOihjbaEX0HO46i-K?iF$e}k%+YU>Rz9NzewQVpvu|QmDEY*0*zOf z?wg37dXI&J*2BUD8wPpd;Ep3j8y7LPGS*&1D;{aYhfIeKNpR;X1Y|m5gk7Oj!ZG;W zlIFkU(_vYP|M2nu*!s$_DxWV}>Fy&S(i}?Z?(QxDr5mKXI}Y95ap(pq=?3ZUk`|B> z5DD*#zyE#im;0UP3^TK5?X}k4Gp{Hm5Fh(%OX2N|iS=Ql?1x|V5dhu;i=+((lIj9B zSO*JJ?49g{Xya~v3$v7HBrBiP`E}0E zr~I@@IEp}pm-wToSD0na)B4s5vlrFBHW8g#2x4KECQ{`j{LmXI7F7C&TalE#zh!Ut z{@4D)oIGL9&h+)Z_)XJ_jn!N$8CFMWCe4dG@cbaDd4$qfH;&+L{cf{71QlC$JqI@Z z%?lK&q-RL0D*;fLzM`oFDyN%{b_gPfE@Dp-;e8?FN!q-}Y3JM8VVD|j9s0ypUD&& z{!$R>?V&v_84ccj#g5SKD7Zs78P<=ZrumsCQa6o{fbWj1iUJQI%;bfy=ma?kWH!Ep z=5TXkq0By9!eP*5;&$(+nVN4N#{xXKJnw-V#e>WLUPdV0l?o$bgDpz)>ydWICYNW` z+wCI20U_bp8Hu`Qco=SZ<8sIBRu4gA_+03!Pc%d__lQEKojxEO_Q%!*a9ePUN=PPz zfE;4&GcQkW9~F2!8D5Bb~>5w5L6pamY6B1GZDU(voU z{ncFj2>Bdp85m{g3v2}kEF0sCwHZ!67rzW&LXqLkTFsaOns)_9>V9L(vC3Rzyq)z_ zpo*6R&|HBkRj$ql33B1=dv)B@F26*!SXq0rva#WF{~B>iX4kyM0`T?RiK!cHuX?ye z*a76-7N;buFsL-UHP^JQ*gyO1c|F!`gc#&11D^%*((%LM(=T{c8HK#P+`F8se(KbR zERbmmtYK(Rv#FX&7K|MoUX@LBtO)Gr3w0GS9)%iom9}`4ZdGI%;9pOOH?MspoEl0% z)IbZkknb!RHQ9Z&0Dx3IPDHdB)oE793i1OD_S+Z1Ifl}BY1#E6INz>y$%?+ibePcS zrB@=IZ@18R$3+UgUY6O;ddc%Lr&;9p`gvVbuMP)%?}aCY%u2P${yu&=|FmSbxwFA) zf>DI%eLKty@AFD)V-LqMz#q^D;o-mEjO{Z#SgCG2VpfhIKr@!#vZ<~nOQrNZU&*$kxm}?mt6pAu;F^ zJj*vr*x^a-*{b7aS?^%VhuFm=0isDdBJ7m2wxnqfiU)JIi*5h z!jQ^a_w8BPxxEAj5l2A8Nr*A91%>2e)e# zy;(0VsChc18IF~pQ)$2Z6Jy2AxS)4u&ejAO7qhmI%SSL}3Pc!om@8Wy!s0l(Z=I_ z_w#XKW%%^wp)qgj8B?5@b8wJpaHj$}>qsq2ci-;AKtHLrF*M+INaCMAJ*0o${+BfB z7>;8DUy$Rt#;-hh;u^Ydm$ z7aR`PVvi+{S@Im8NXUXB1X;WWSAq~1FTI8$fpu>-{-z*0^C&xQO}rLU>$BhLARX{^ zcY^iCSDPCYX}Dmmzgf?~z>+o1lLb~S`|VrxW}EV=*N*Db31jm62~i@u;okz|-z)8g zQxSZ}_j!z;NNsVu680WhyaAn-`2IF<<<1gUmIs6egK{I&gB4=vddXXq;-9x}B^s#>49mB1((KdU0uGFTJh5CHVzu~C(mibKHB)74Zn+xs>((MZE%R^a zF2{qVF#lNX%Kn6n>WXv^C4Za2d22rvcG#fzx|my-j%GEZ>*w3kOocTbikFI$=J$sfBK`aXOUCA9wjc{!8#+;LGvhQhUr-8Nkx7Wz5g>n}h2 zE_ANk(B3tZXEgu9RUCx>+D(yk8Zn$;dE|FYufegW*-Dt_@RD@*Lr@?C&!7DbCWY4cFU^3;(CS)4uD{=@hwNk5p$JxE zt*yT0EaNpLcbg`I-1w9B%6$d2ARv))G}8zM;Q zZvnWiY-E4=FMueW_h15GKYitX%OpwK7H!c=AcUa*^Cq@WzNP!go|LjR0z zV2A!I4ngc$XsdqvWbM|o2XbpDTz1`E<#l#PeVE(?bInFS(eJWV4o}OsRzNb}>MEXFBwfV#4<&OpBdTYBgwb&^O$9@UA@BRw*9k}?IBVo& zp1`=TiX-dz@gztolMF|SoT**bQl_B~>nAW(g^QHW{(&7AT_<#Vz{C?E^WI0n9e!#O zhj=#WZd4el__N!=zcOj!+~AykAKSE<_nRt`l=F4;)n9dggY$1lVD;*AU+eA7tMr=<}0(RAIhyNU4W@P6Z6%7!v}Lv$r$EZjR+oW-fV0;Y~mK2%qaNW1w^6Ym1d zExJuHl7P0cq+`f++KRuf(p2qcwr|Jd_04^;30W5n|19zA*Pcz%Z~m9xsP|V_x|B0*MX-C{FnQcL*;b$vC|i(ubnSwpfMGjh{dLeBY;h z5gFrIQJ5NY3GZg>kmg79$D!xDgbdvFk|loA`NHFiA-KRsn)xG!Q#1F_8C~dmqZJ=K zi4&H{GzF_*sh3Q1dbvKzG472ac=Dei#d|B+X`^tu9(it{?F-OGfOtrxP{2v4 z=Ho6EGS5xlW*x!CTw4O-*j#q?xY-PAjZ~#)26vcZ=uRWUU)6;q#?R+pX!C$aeQEwX@r3PcC564>I6H5&NbjpK zPC{Xpo69qN;=9lGtQG{c=XERVGP}hY4Jm5Kh`9sv9G*RI$&~>DzCs)$pc-@)l8pDE zu7M$0C-XvoG9@36A~4OFL@wBlzYvh3#4&z*2nw?-s77dmo92gZax>_AfIljNLDwN9B z9Ji5I`yB$O5RTdRQrAqwqtVS|pRtFBpe(u3$gL*Ac+#U56w3W{af&#N0VYJH`<4A= zLJlsI@QFX-9n!SOw^Kg|Iy83ibEzYMdT&xhBhfj8LZ3+0Y~ zr6aaarThOjO`aY62VvUcy}FcZNVu@mpLR`mZq37Bb}Jm@s$d zU7p$>OMIuEO}w5hu-!zpjH`_1a48j9-Wzpb42+xwuuA`sBVQ@poN#T&odrc&S9f9z zn0lr075$uMP5csgYQ5qn7)FalxnT?Zh}z2Sj3B+D|zN=+O{q&ig=UWcJc) z=2Hwb28n16?N5~$4yLS*6yNHc-l;@K+n+%sfli;=JOK6sz+%C9L&Dh z$yB;x1^mvzIIJ$8k`RQG%~L}f4=lh^{t~iJ8&mVjki}tF=o|R}0Ytu(x>irNJ}@cO!2$|B@&w znG$$$@H#pcVe$5__+{4;Ipo%y{vB@_rdO_PpIY$preS-==q9p-azcWg=;aXwRn9X7 zEHUFb;?ujPB^m_3s-|@2GUGd6413g%)hR2Q!)Rx&v(T>}!wGQ~%;KR#X_k}Vq#;1l z0+i+o?eWw}7VB8+a~LUxL5c@-(dx)D z;vKxL1Q3J(F%fh0(yRWDO?O`oY{%;?8}*WsA-D6U57~ zfnNh}6B%z^OyQ2-j2}gq-nxtV9tE`IO^M8gqFoUp-7y4aP`J5^MT;9-*Q{(+8Ac@E zX?rl&G~J+!>r{!Xl$MK0EbLw84>TcsyCX@aBul9WkuD*>`v}Oq*09JoIJ)8k@%Oj< z9>4XsGPRfuh&M%2D|JaRQ%TmPhzKxx6__M3r#1kq(ryGpAg{~E-wTD^t}Z%IBA1!0 zqW0tuN!1hLI{KU3FK^275iGonHLOmlgfyo6M9kjlMo+PqS=0ndV()qN2}ISi!U_~M zvMQ_%u?)ODb#~u#+Y8J$(6b6%SoPa}(a@h8tv>6wsYkgJ4MtghxfwlB#hjyb8#U?* zEwb)vgY*n<+`$X~>5Bdok#ebcG4ce!0HwSn(gX*TgzmV7}h>x;>;t9~<}MJBXsi?T?x_!6?r;2fkvt{q3!5 zlJs|&D`dC#-ibWfwtU_9&AwgFRyS)ltbY;0SS^zr1Rd3Mo*d3T+;Qbo_7$vHzWnzV zK`g-Iv^_jZw7gHhui~p{rwM+;cQ&x8zOia+~Le+>^xq>_1;Vr;6PQA5^*4;q%L?;)HBcd5WKgZ9fjiZjjhZOA{%z ztEH{_$!|w`0@VQTfY-qrL%FAz7EvbL8afiMeJDY@=$lGb`9Ty+Ll)fgNe|~LrAIj^ z4gAD!dw=q%mISvK9%i>x&l0X0@VVF+!c2})DA|;~6f1Fse8NC*eD?|&SxiWequ=qCU z8rlPczb)at*=q4OK%Kmz9F+AroSgn6ly$PDTj|YyCYFMz++Ap|+o14$3P15faSM+2 zFZ09On2qSdicIneAMT1&2GEgSMGB#B=_yGL&Hvgv-{2s&s^S=Fbfzrob*~2KQ$Nfk zhTApliTuup<&|h`3}_H)IKFq|820SN3!Q8wC-XH_#w=hKZRjcAi^W38##(csA?Bd6ONW!D~h*|0{dae(L}v&rfC`>o*)Al4r#GEuwU&WiM5 z;29Sxj%Eg93SNj3#YA29z7&e|WwCu^Y>0jzxe(7SI-*yTsU|C=)sOu|%d))RzNOz1 zWIE(tQ$9G5octq(%Q{l-CoY%MZ zdZ(w^Hn;Ilx*xhbrp<1-`BQu>w~Pt1sW58I&)P@y_*)tDxjnauw-Sd23; z(Cjv+C7bMrhDZ>Z%tJLMD-f}W+2ct}$e3W%`UC^nO%ldXl5lYrab;vn7I?O9-=wVl zrSyfzEpE)k{kZZ_z{@oU^FEJB7$Ma%@fG9DGHI)XGs$}E->37xYXNM|`5gvY25F7^ z6L+U}P1$SGuKengqzCQ`X*Z`e-?)_cIwnrxww;Hs=d`fNhu>;U^f%H;)D+Ayx+x-s zNSuR0WH`#Q5-g9_?#)x5I{zRhT+;vEF3+rwU}P>r+qevn_Y(;oR6Glxy z?Slz4P~z45e|*hBCnGVC8=1u=w9mUNn2{wr>7*Av`^?Mm{0xFVl9R>8Pf#`af5Y;U zMJDd=m306+``R#dAxW!!FyXI|Jk7mUg5K!c#7^w>vr5g2?hq>BhEW~d{R%YUSz;&N z==S|M&b8$?qF+tAgtgVsxaRo;>*L*o}67E?BZF^&@8z-#Ay}rWpf$_U()-QpqJIEw|01!$$rKh-6q4 z#9`tP#$kbC!S&ke4Xz9FFs+Khvz)V;e}R?4#PAjI+l)vprVkAr%~w zFhA97GJW`N(>`8YVi%h5xUi5=WDOGX;>><%4zx)v&F?RM?f+NFXNle`6q&@EkkR*8 zMiVr2pyurYeT^3>mePS8;R5xVIWoIC4%bFhH_q8#?=v(O z{mHY-_#=7S^en~B&vV|qMkw6A6mu7~64MEn*UkOJd|vq$Y2LO4(<7FnCiA{XB{d;` zV1wiS;?%w)UsTj1OnmC+PxF;8Uz=K5f)nGHDP4K#Lk}33btk;?67y^Oo>sL<^onoY zZ}QWERB-PHid7O7Z0p+q8wD2)ZEYs|cF0jfjxtP)gSy|dFL{6=O(^-48dhX_j4Lkh zEL2E9NW|oF!Go#{P3{os^S23oXck-7}_)3c_<(3dk-a&V4u7G+TBW~dd40_i)M%`MY$YJd zTzkbgCbDCDD<;KtJ}06Pfd=$>egPjZZok&DAZuJYpYjuW@J6~KFCRn}qL){7z|2K@ z1{HVE1$ZXtl^)%YkMpOl1eN?87HAw6Sgjy6%Q#Uhop>eb=Csu~q-jHw=c&z^R`wye z*9(nkEzWaC_ovXZ{}%v@Ccu8?YN?jvEfXC29&*=n?d0w0@%YIq@4 zB3MQm+)O}{pli$b&6F>e)8P|xi2F8B(}Pl~xR!<*C_DS#C++o4l6|5?t6Ua%bgR(CyN8_IfYu` z)0ZB0Xo+9RNbc70r7Gz_p)MBRN@o)+4`b3sOQ}NFg1{(q3DdTsPPQBPQRIWy)=5gk z35b(+X)z2u!5gVxM@x6HTM*u2QSgxt+Zx5MQ8qd2tQ)PZ`TOvR^+nFdui>u!2S~eZ zj50s`T-Kd+2yNS9g5D=Z&9_l4bP+QHGZ`>*5C+>&5RKx5Q5CEP?eTegX6jX2To?0` z9h%(K4&Q&>jA&eAYq)cFA$Nq%G^{x#z1Md;9a`bKmm#M7Vi-&wA|Y`n5|`^M=NKSd zLSt6rWO5$=G(1dZ3T-8Sfua@ESo(h%wq4o(^GsKu=W1w3WqNY^2nH zMtBwvjW#2&aa>`}O|-G)hjX#q4!J7Ygec0yCp3A9;^VJv1VZTEV3G(p!iVA?V3sqc z;7&RVS0O%tK$4Rq|H96RRM}Eg?XGAyce>B=2APExL?Y z0mA5w+wHweQ`Zy|+4(tv()Y&ekusEBnIh;;j#1$rx`ffjUXeriKoEREW7qXB5P>p1 z=41%nn5=4gko{kn&38dU^2a$Dznd$qVMuDj^%M#Hhp#`z&p%xN*LPXemW<;_LGTE);Sy?Sa8UeT*sO@@??@owqIxNGy;>3UYG}CGArfNcp=Yv; z(alWKAK7vatEov4iQexWj^XQVLHw#)L-#;iAr&nIV){n0A0&kHTuM4j<0?=7{`wt~qk z*{LBXRzD>G^Pt3r+@ftY8t{}4kULSgsYy~2mn&)iV)Jy^1Kk2ki~Is6#0k14t(f#K0*98s#4pmG`3=;XxIMYAb#%q zXOnx6=rcY^X4YtFFb_f;FjRK^0K(JINnOoD29;%t>+5k)N1k5?M%5ZV13j z*Xx(%10OU6^YWc{!?tW6N?aWrp*W3e`Pv7%0rrGhG^Mq*q&Q+gUH zx*URAm@5al$2s-sUNI*W5=un(1)}eUkw-!Bw2tvAE<4_ZXr(u=QQdhUa%&0Ky224b z!DB2)^b!PM+4SI$LbOEdb}H%m1{Lbw*z9^lrG9~f$f16V(Z!ej4F7LGc?!`W5(M<} zr7)?)3}JsjE&&3^6z8`8qX}`eU;jaxvda#%tIzGjjL^cP;}PK|6&bI*0=8cKvY!k3 zp;s=oezsn&|9DMJO@p)6>s7rKF8haAR~AR;&g{D_+OO{)NJzPU6LlhyC=l1QkQZF4 zOY~TX5)|-~m%A{CiR-nKr+;rG@0G;{|N8hlcdE|{1HlY<#?KI!f+t7yY>angPn@OW zZP#Y=m67=&WV@z8okKi5AcPAoam>%O;e9DyYbG3-X7`7a)8ZtZ1}oQ=uYQ~ci&@MD zrVGapcx(GEtU6O#Bw%8z@%h#7 z_Do^-X`D*fFS%ySm9@7sMb_Pvz!IsBL?GlO_O+^0K0d7y&uZy{UP;we!fsKNq%+Al z;1Z(P;&)jzI((uRJ!EJj{qhCt^__$vkh_Bu`piWWLsn!g8_C<6rzVTPon5E;x{*GP z3(N*skw&9^kU_NHsLAqqhgq*(=ZKw2MmlV~6F*pJDpc=my!i-IhrDQpv+cv$a02R- zfR7rU(+0q!uC=t@;ge|ZQ3r!Z=HIG@q~Tid`zZiFqGWhuc^GJTUa}fPn6oW6<7ds) zkBEccu7M7f6&n+$UcwHnQoE~5o&lTQA#vomo#|eW5Qa3h_Yi3-VdVV%J_^_3`EBUG z;lx5>hZ}W);f`7@+8nO|lliJA8&=Tp;g1eWethOUFWjU4I1>G>RD&yU1XX|G+DyrA80hSb%kWYW_ashBi1 zK#_@t3o@mo43yxRCRY1oI!g1Wtq`q_83*?RuvH>;@6mfer3ffWu;c}EeRtXTN+*=9 zi6**@!kDjctSAmHSisWh{vmQ`i6`SJHD84otp5=38)a;0{`JaUdHMQN~idIXfmu{XRGa%70-Z4ZP8Ti?s(~XRP~8Wg;kV3iB!#~%vt^{< zlH@f0X}kb|WX7MN`jvN-bop&*qroL2>tTeJl)ORH62{)5c5b1GPhMsdQl3`mbj})2m}Oqrp^8`z*xuYp(;SaEaJIfa3cS(~J`jrSQGHCkwkL zDao0snG1gS1C;6aK72$t0$D`(h{0N1xVKjndFpHEK^qr`1UN$~jGGA+wG%-WSBkP= zGiVPsx5$4)f1+DJSmtlMEf%MN=EO%n)RiHg#qE`|Ev}A$_Z=LHLhm5J*-*hwktm6J zrAT0vja9AC$#J%eJFnFfq~)N6qDY<~FXrGWFoz(!ffeCh5|#fNf8Do<>VcUOC8Bx) zLWvOpNK&wI;po!v;Hgp5^CnC`{4l~(V{#QDdi`rE;{>e-Uk2y0&N`#4{p@oCK^b+-AnRmOeU{4!p)GSL_siGn>%c6}~jrOV!8MiCV zSc?*d!;_t`W~s#Bcz=%0Um#XsLV)}z!zv)^)f^615F%p@q%dd4N(2KehaYjYY2yc7 z26i#Hu5_4)XTnd40t7jE1MDFc;B{!HO8zuEC&zyz@g-3JGYL1x824lrd%vXbSC6@c9KO@&wOc5 z-6@V|%*^g}CU6;Am+vR$zA*5SvnOcdq%A zhyS%I8fxDD<(ted%kmMxR5h);#O~X5eAkOClT}Y(lUJ;`+17%jW(0z}yOsF2yMXXm z{BL)w-iTTY(d{%Jl_-)%=|u$X(SCjr1(9+r0M{WwX?g>29k=1eI5OoLAw?2Yy{EL! z^;>r9zkG+-Y~I)Foz`2!m};>c;hDaC3TT)FnzorfYM3(?0I#Eu_|}6wlC=|>n=F^= zDXnS+Gs?2gobso+@qKG3?O>K@P|~!_(a?w>x74f`mK+@;US8#}L=n1ueVjNT62qkc zUPqLm3&|oA?wHurS2W1hSKM&RHFMp?bj#LE$)d0rTM%!m{~KfMSOxQCt!pHi#c(6I zWVD~sNz0IdQgp{X^f2O*K=~3$VLtU^g-|n&K%1(V5c<;e9LM_W5K1RTBRa}ndX-b| zbsV~%$E=Bq4h|-(n`^?DAo^c~U|GV*5HIw^69l&pInJqVISL{aLaETE*i1HF-b$J%;*a;*{P zrNIz(HzRG#Dw+%gvk`0d$vx{Ir}tmAe?9H*+IY5q&HAe^Eb3qNb3JRgsnZo*d`D*Y zpu834Jx{9vaIIUFN5W4uNKAQB#`0HEBm7<(<^Fm z<8FX`@qoV=?BzaD%1R<8SU-3xKx^7`$D4oHCB*gvXn~2dOYwOE!2cnNg6E*U)l?PW z=>##ns9J-2TH5gVGV}GrsYY4LqSTLb-MtyklE=1j>^j)07nIbe_bdKRY?@k zvPv-`c5-H@7rkv(FT}$4AF&vAGyorUIT#%;mocxuN|K(o+=+kuCuJ#vhIdC_ z<&;46Aj<=epB8J5Xf3HSklY&&V}>@DIou1yH|jgp#xyZo}l6*>a-x1j~~4c zQU`iOmDribok!8IA%JnyPf>veKp~HSk{Kb&8x~2s(&)q}FV#$#%Gvm(?;K*U;sBX^ zL`~@-kP90O{RtTsM373%L&ndrDgA4IYRP+)PG_Git~;ahk%=Wq*)W z*~57+LJIOb-fwiI4h(bTnhq}bAUJlph9GN9F7K8+T9OpCxO1eD}l|y!TG;l#GC)T2=-6l>S&czg^Ugbs7a%7cE{K6|2Qb)*1^fzY5#a3jzIhk zXaZY`s$dduCDt3C>b=sp1ei3rw>G#W9{ysjOxSp;GveRS-rd$aL3Op<@K2S>eLK1h ze5ULUvu<`fPo@Kb8|CWGCFyWQL2+*@vwTc3RdoPpV(TwBKWAVO9=AKZZFcX$ar*S7 zL7iWd!v=m)lU!9YSeh+JFAA3LJ!~63eC#mb(Z)Qo5HIA;6Re)J`)rJ!6xZ1 z2tG#UWxA!>*8F%XhX!!C_k>B3xzWSt z;P$Vb3PPmxU_f&c#)TvT{MplF66kn$KP+8=+JLg(Cxjx;y&5LVM^eSyVwbMm< zD^0}7`D(+uPAmxDWp1z0G5kB=U#!SLTj^vRjb;_1r`^KP$uJAZ`v(zV7@|)Bv5jK1 zbBRs>Ocnp<8>UDNjqS*l<4%|#rFWFtjY`=JkDeJm_+i|`(hV%V4gglxvt*xSgw{5@ z)(CO9*8E_MS~$yF<*o`2q>4$EvYu?K|BFR5<(f3rL-FZFHW>17PZ`G4ruvl3H$^Uk1Al#8#j) zWIE7TFC(B{u!bo#(QrdZkrF`ummp@rp_R6RRnifRoY87>*5cr3L#^~^dQ8B@k&qID zNS^UBL@tUsn0!hukD8`R#BtQ797!jy19o|2*;@YZO=;6vyy7AENlNi{bq;L1{{xGT zW>lwE6pjY56}(_k+~LKJ5x}+vDM*1a)mf>ZzteA)8fS>R>VWp3F5B3rsJkqZ20*%X zkSVJz6ZDnDAy}U_qqzR^wBn_u9quA665|Mi}_-C#Ubhh=kuVBx^1sj5cjt~NM?3M01!9A(b7H2vtXw3p-%-UsYG zSuS2>6Wz!MBkC+mM(9tTM^Vw|2sBs~WVeOs8J=ZB)S?TI3RHk!qTXq|meg_Sk1-!q zGa!x)7eoEsEY(9J4>BJx79Q}5Lo*o` zjsXCoiwm{aKU$>Ly|vA_ZwpWFQUx{GEt{`Dcfiah{sL?30&SBS+!CJvH8I!iV42)q zN-l18a-LGbAooC57LXPk?*{weZMdWstlUo@hRXF_EneEPtV~cG7#-o~v~o#^lEmiV zZjdQnGvLgTN>026PL*d!A}VmI&X%9n(gtm=Ct~~jg?+{*?GBmFuztFoO*VUWxs%Yn zILRa^){aQu=z#puN5O`Q3zDEv&3TQ$Lx0m&TgA)wmWN*lrcid+s9r^j`f2n#pkLr2 z!_I2)^PLXbr@ZtC)t?O4Jr5aPLnd;$g5GS4(qKUlLX!Yf`8#&RS*SQz>w!li^(T8A zrxOvJGAR3v!{=q-X%7iIq;YW@5qOXA5X=oXJrT7?rl<()uPP+_IcOss^~&?FNKF7e z@*aH`2Suru3fM!^J7{vyBI7dV6`SpusfK`>4E;Z&tQZ8=(vhQYI58E7<#5VWxz2tH`P)L7f%(FV@{>`@k+PX zRsMvAEM6SA`$vZ?L&;hEY92%#?O-ujQIj}{prI;Bc)lIhlA~8}XtkG!O-ZV(2rzJ} z@41<3@!t?90^O~s|BTn5r242^iqDgnQbi^~W6 zzO&l&XSfQML|Qur;*^jbl2c|2EOz1$ly4}wYgi$jZo3BEk36o23+qCgHnfm6c~}1} zz$%{mVVC0j+u<9ZHqUInmHq>Ls(afAfa!e{H7Ee4Q{euw75r=VVDe~g@x5Ck%l;Y@ zUu-g>4r?rWjZAMitREIv_ElGB%=t@p5#71WPVy@v7Tx*ppOGU{PcEmk!EB%r*%757 z3k6N00Is~4*dhF=Yu97bs=#>nB&nt~Kd-Lvvi!rE4?Ez72v6Fd8D=xukrJ#ejy?Q1 zu=>z;GPol{RT`L!9o9Rj4lD;mJOo&d5pjuWk1yQ*887{8b*p}t$=_dvwxuTrMTl8l ztk=Lg$>?GSh_$|V8F=r;X#^rw<_2O+d?(jV4SNmV4y{^&zhNl;tn-%bo(?*#2t*hN z_Xmwk&Ees0+(OQpY~$oJP@$)NXshrW)lOI;J9sKwoy0z)y?y-a(=pDqhUNDlF8j*ZUQvRWJaEirWXgbJ_BEEHN}kz1j>D(Rhy-}N;fp{w z(Rlk7(ZRG%KLrzjN~YuqQEEL*a=i3SDsnx;U-2)QQ0G5f5?3@v>*DtH?6%R#{Ln|A z_hyPL;Y9tWwu0h2+os2`Wos`o;vQX4Jyc`O5xyr~0~Ssq2oa{P-;dQT)-%_`u_oO^L~OR>fz&rZWCw^Rzy2p2Ea71& z49w(39vazn+x&fC#W3ZNU_|v0XbdB3fVu@vyo%P0_t(f0Mkk8m?{d&CZ5vHqbpowN z1tAz#ojvPL`h9PtXIzQbziNL514VZ&X64&C4ywr<$4jHmujM@yPoFzxW{5Z6wXG?@ z_1G=#_1lF<1GP7Av&lJiU4ddAo{bcp(|xwuQom;!8w_5W=-_3zb~bEpdOlR33MME< zB6)sHm)RUCshWJdq>&i)h+a8=#^pyt<_+RQ1j#2*|#8sd3(kku)DLez41#CPLYm0DAsHBmjDjnrN*}5m1jPa{|qT^`Tnk zxF;n3UI-{!^f2)v%=(%5Xf*;@mclAqkiqy|yfG}9F`V0(p?+jc5Jns50B4oXYf5Sc zN(rM?Mc1liMyi^jBAhfOfch5TVCJL+F+sj$TK0{VH#TkMWZ_#HW3`yx_L_I@w^0-1 z9Ss+a*Z6B@%?8XIV@<%Nw)XmABANEY{8^SwRYSkE7Zs53q5=ppefg)DD*lvC_ez$D zpr!#2Dw(M!lRThPbPgcEXos|mC6YSPBjf*fn2a2!BxVNe0(~9or;H=CZCsFp$^qs= z78M?WTd$j)UjWeJ^l)T&*T9Z3?<~WnF28nP3y-IRNBgC$>Tos#zs_7+uEz5v?k)4N z+6B(Bvrgxhn&2R+m@IRmqj&u%)0%dfKB$$H%{z{*oX_%`e`rA8lN z2A5<#c?}j~W0M~o+qw2{t$lO!l|EMmUPp_dF!OW2^dM-z zd+9;A5<;h>n19cAeZr{kN%&5lCs0O$| z%hLV>Obt<|r|M6eHH$wRwQad>?hQz`-&!efc%x%1(Li#6j|>X^4g;PgQo;5KH@&nK zZ0U^(JNgGNou4FhrZ=t710`?vn`~-@3p`S%@6IPRvrprn8 zo|Tog#-@8%lciy*snfej+#7rixRHDkd=XT7LGFO(PNgS&zBf^NdbaRu@OWX~+<>Vv z3ki5rOmksT>|+gSMan58U_K#D)3fq89G%?B11jhw?`s zwmpp>2h|^YzeO_9w0VzFw79B2zCOfFly43Dw(sf^8XF{8gAn-rQXtu{pCs^mE<|lM z6OnqUc;4!5!^%$v>mbN3;GuyM{t!B14Wn?qz-#1=?hOv6=f{K0?+ZIXHsLKTpp&G3 z?GYlrvDfbqUI^rqX=0!g<5=zL5cf^$8 z@1nc|FzsRuPeV>^s^_`lTZ%?G*7yXeSWw#wSMuAbKEqkFi$^!Q!U3M$sxe=ih&ru} zYdp)~ILw+bG5f2NA@Jb;H_w0S+1kB@?{+1cQ-x@VzM2}Y5(?BCp2LvofuQi;QStFt zL@B2ox{xi9GlxFFDf}VN0fJy1uKn}TwzbVgNSnLBH9XMXk>F;k3_;I|q2q_8?FU5YG-rY+8L|ugie#*Y1uGUd;+SNA& ze^2<4Qjj(}Oce?Rf_^taMNQO6P#Dj?5_;jJBXHjMKKsti^?EFC^{x^w0=V+F(JoS? zh(f9h;4aV$^Mboz+!QH#3JS?X8?|>URbaSEns~E9XNNFk_fR)OsZ!R$mG(uRM`J^=Ln{A?xK z{T9|oyJC~&L;T+~`;35TqT^htn|@RXNnHJ4)b!H(GaJFs%entwR}3HNlrlg!3yW6f zRMD$HsFbZ+=DO9zm=MW&stPAbOXF>hl5&emB*Gtu58M_~d9gOO&0RHUU57s8%?;W- zMGxMyIe!UM+OO}k^AGOxkQ~h zb9{yLs?Rst7TnNeUjmQXySXUwvq<~0uD;Vz6>VZ=$>M%_Tx^HSnlxNfh zBTA&*i7eA&d+aP7Q5&6-{iOjYnt(Ei3ks*N(-C}j8Fgw&D`Rp~n|h^Xz<^eHv%Vnm zk+FMx$(;f@mcyKAmfniP|J!j8faBW3(Ata$QROkw*5z`+Eqls6&H{Y|1KYwFUgYPb1E6;41XGI>v6|RpJ5Qn-l6`be zst-ulD#nn>HuWIflrM$$__uMnkK`Fc>KD7+6+gVE=2nwq1bhK0T0TDAcN)^?Wkj`G zZ0J3<84JXHk; zG&|lclf|ekS67<9@QJ8b&um!;-5U`=(d$dSO%z~fU}6TbgB@z}Ej#>yDOT)E_1~Ii z=(jchvC8q%Bfn)w93-@;5>z8GLi1O+*-W;-Nj&91Zc#=3VD|IHivy+cLGf4*5kfd1 z^YVEDrV8DYMyDM=#uBn{mc+w>2`GX-$ti?uNr|uzMxOvs2_+u+>|_1ekmKTT%lfLW zx8R-etbc19vO=wx$@6RThtE*J34I$<#5gnSWo{z>j{QMnDuNpTd#^r+?o|A-*X<7ye z2?$;erj#+M+o$s3{e{tS*RD~2E zxFHTab_C8~!2(a1ApB7iEZ+mFGsFxjZC80Dvbvj+@mw$W!IvaA34oPv*OOeZTg+LZ zeKGE}j1&FurQPSENEGCgNs^4--T##+!Jliwq0n7UR$qJ{*Gh{=Upp$y<4Ttz428`f zvOf=t)`^EuRL?$h?Q*uq@#sr6D^o1oumV6Ukjc#f@ok^dlB=BTp@W~RRIemIMfI4! z>tepB=Sophx^RsI`c8$XEo*a8CxX4-yxKTieL+4AMPgjVeF5;c9ZpOaFNf4?0bLo8E2Hada1aW)KO%elmy55J#7($d1o+1j> zi3anXE>uC?x%hhMMTt}FOzVrV-T#me(xY{0!! zpoQlf0j(@=Qm;yX^zO^b(9v<5W+2pYt!OmZ)zQo4F;>pv3 z1b?x$ShDcYk9)J6NNDHmWbN&|mbs_0obG0d;4;p8?nj5c)V3?b{pk zOK@?YYnk;iH~ER`K-knLmHBD=5&uHlF)x4gISIGoE~u zb7+x=NFpfaCoU@)8mA*ql@aIndxBGqdz`%O$5Wt>Hj$vY2a~26wPm;Wn$TsEb~=CV zmD4M2XQB_6dark+{36fu&+_Qz)A(lUvgv88& z>SqR*T?kR>VhTDg$k$O(BSazbY1m&?0-h%Qg2wNLa&aW!NJxc+zA7NC=rF4OEe7Pv zXMTKb%C8GZtyd3~@e_i7AW-qt+n=Ech{cKbN{0G@^l^|Ume=%#7gr%w&B`$encFz; zk@8&F5db(4|BdlHQdYO;0{fx@6HSl-tLp<++~~=T&w6i4ZpnLE(!T?tRz^8j##R$F5(ue=3$@=qwFd;a zMkXYmn3Kxo2*j!0YJDCA0%8eZ#o1S5ogF2cplC zDx{kij|vtU4w@?|t9%N~wFxuXR#-RDfsCs?S|>ql8q$rur`_XyB+KSh zg6iZI17IxsNJcJ2)J5P{|KR5A!!rv5O|~yWwt{;<$Y%Y)%Z*0+&;RjfA(>KoMv3y1 zTSo-~Y;-^8pgJwVA1d~1O^`-|pDos0OsY@O>^+byC}lzIMwCRxP!53R&~#p5lFG0O z5d_F*H9bK&mKw@YotcPL5)sHcSH9rbpJvW1M#V_kjF zp*fq%jEXw=@RkmkeJ!DC6ZFwxXy9(Fg_y9uYp2T@ipJW-p)WX&Z=PUC+;#o3aC>jr zmhvxgyTh4c93;~o@cp4;{l?RfFmPznym0qKUwHXad;sH7_PsS2{ZaSE949yrR2FNEN$gvqe^?P&?{Gz< zOQVw^%j1PWbFcz^seb3oCW;CO`$nlb^%>bMDbCNtS_bjDBc_SxhrZdGdZiA7#M zuW_pLuNC%E+(KTCpS)*UzJNM{pmxXIF*QM_|C z-@?QFM%MQZxfaAYj1BCRyc}Bp?*SAFJrE3<=xDUp7-0UQ*Yp=8`%{34`MZ}8h3sR2 zmy9uUZ^%Thn&Dec%Ie-50XJO+nGxp#NhV({pwmUR&&Y`}^`R?VRIP;MY@C|GMOC05 zvq#S8j_LQu7d}&MYxAN`69(l@dvY|*_cn|~gIN6^jkFKpPZ?&fkDi8HBg{=soiPy>?kTRvOce4Ni* zj(uyD0y0qQ;BO!+bct0l0>mz5=s9%3u6JqM`04~T|1IzGNl|}6oml}Q<9i?gx6p(D zW;}?JsOhKuvq5&y6X%Z?MyqCn=Rh@%h*nw{fnGxbh2I%lGxZkI!*7Aj-dmpvcekj& z31?+YykUa*_g-%jD3=iPjA-t6#V9DBa(jK-xQAD$BES}P0+bs3wsYZYhsk^caD!*> zO{Y7yP9R5fDIb|nDgpTl>9>7{!80r%_mDsqj0CX4< zA#a@XPT|i58v(maF^pbdPTkF?wi3z82ICFu5fu+sk3dSZ24@2~ZWKWPJnfN@5J$Ru z*72(Pi}Wjt2r7_}=C|zb;G15D-WW1b%05Drg%%I zp$Uc+XYw+j-~Q^->7DSaTTv@bx%76U&#l8BtB={Sr6%ul#Snv= z&=FdqrP$GEc2Dbwz=jPtvS!PeQD#cv)5|Mwi&PjpiT)`Uz+eThi3u>-7Gnucf3?g* zd-jUA+1KgT>303cG|wyT2sQ)zJ7@F1gPJI=sWms;J~v+muah$vsh%No3QqXVSF0qd zbvzwv>hIlzECGt!1n;K!?WVn65!ch+ToY2&z6A4W3&3bIOG#&%%!S zjc)2QLIU$U3?T)4PWjz0C!%e^lQT<9N)Bp2+87(?@7TbOOCWd$$}b}2CE7rKy4*gj zaYl4hEu*ZS9PC1iaT07cxq0pwx(Zi%abjp29OWFxgEK;*#FzpB$&x+c?Ae`-a2dH& za?Det5uQ>-`8Z<~x&fUp*vQ)X#c5rB%7du8)VDk#*WI!s)cBil(f%>+(~V`BCI#E+ z;kO&lQm;PZ#C#+cW_nllE>pX08fWGl_GU#3f&M96BXasep%=`U)L}ZKKM>O6<%j!nm3ZfzOXCYaU-f}jvy35Q$-8^w%tWK`o;G$BJab?Stmq&c@q#(YK}C!g*9${H4>;FH-E^ zbzXI5`lI}Ry~`*;*{I&~h-Jh=uPzD$O;nF^8sm|8!$bO$NUVOY#y1G9a4okIb8Yif z#95ugTo~|dle&-6`q!3UL#TAa{P344JI0`E=BwF7~{{h@)L`X#FtqOA6$gJw?9%X z`Te1J(JpZI{VMG!T=YhE?DnzySE5D*105>dXo54~;Rads4NCvz*FYCxf;ZZ2Y_-Fa zTqG}v%=~p?O`}pm{38iv+C2diCW6iN7SOzuojK!ooJeN3ayj+j^Ps4Sn)tZe!crT_u42?i6=l=e={%b}>G;Oy*`LnGlGvMI)=VMD0T5yHN z@CdXxv9CRV2h?u#(WK!3S=bDiu;OBma-*Cg?aZkDX3ITf7BR=B;Kp{JMxM70(#H$v z+n9R>0A%Q5tuJD^zj5JjccaoS?cDOtH~5B80I%SN6+On`OY+5Q+VkWH4}z`9?cPu~ zK4W{{Y!2n8|5cU3hO^S;dg725H?H`r&R37%q@M&B2AXLcu&)qsPT9$CH*T5_sg9q! zabll2Y4kJbaSk^KQv#ffNH+&)LMOQC(wsU{I4cI2E_)k9sbt6Y@p}jq_NKZ|w^3gO zSOe+lqZ5I-1=xe&(hLDPb`L7&VFld*+sv;5&t|?^kNBCn+kAL&;@Q{KFS`mkMg}Yj zB4y!Fq#qA?XWc9EQQ;Lj35O`-RY~XnLZ`yDd+7AC6L*RmiA5>3zFIB8S^!?7Nbnf@ ze&(@I`akFAsvPBU1wi$Ic9>~HTeogR6AX%wHy{`&|LQ$EaI1oI^;1dZzz@0zH(~HI zwVTFBBr6EK3QCVCnk?iFUrjI=iW@ns+-HW?JGdE$8|QdpAPLNEglJggz}OvTRk$-b zcz6ib{@oAs^M&c}np!xAb5LM|u69_kC>x((;+@FUemG1B)Ez9?EFU<~L&EB#9@vwy zGnP$t6sgTVe|9Gp91?gKaVXS{qLSj}kGxoxa>T+EaEFm&TB;#C{h;_l!M$O=9xjds_Ey^?nk`t-FfJ0v zoT%+Q^2|YH=Ft=LcK=^_?!rF|T8~>d5j6CoBBIXCyyaC3T?#22>W22S8!o9DmtJ0D zvom<|?HVq@BG&YY3wIpOuIWtP@PF_S106ZW6i=K@ozd8m4%6Q5V#Qg3y>tQTrnB&% zp&Qz~D*jT}Rvf8Prh)0njB3rvj!sR!NJyt2&IR@pZuD3Ru1`-S^)&fDmT_9BWB)67 zTD!)i&y>mQg?t05_1HkToU$Y|(l z9ORGNXpm!#pnO=5EM9ys5U(n2L-PrLjUUjuArCUF*SiTmHeq>MNQ+gTn@xQ#jH8P}G287Y{5^9=-91F(SrgH9ez+zV)X373MR0{si? z#IeQ)R;V)pr#OT@3)7ks4m{3Es8}&O@$flw9Hoz|TlmYnk(SOK7cxBaJir<#O&>!- zUj$Sl(~@>D(GkeU>Z5r45V|{scx0tzPImjzSX+ z3qL^Z#9t%cN+87xNeP2YQ~(PG?s#c5WpLOTjHYFv%S&g{RE~sj@60C|UofK!(y^mv zGc6`b5-5!;fxIys_;Z|J^2gPwiMNM;Rk3zMdr>oi3byd4zAG=`m^#d%{l=}q>EYaT zUH4O-c2QtpJ>|(b=seoY#P?zQvf#@Ly*oMOx$^>)nx3V<_#d0Er)L^SA%u_hm4Q5c zixsC5OYQ2lDI(haw|9x`Qm)1nminF^5g~%~&~=%b)GT(nut{_J+I?x@NK5;=g%VAI zruj*e@RDvSZ>pwm;U(P*9O01Q;D=sYD7MCA7{}h#^+tz}F$R;@V80nDhbeC4-y8Rb z_LW3#qET}9VfxgM2ORNuDQik`wLxiro@R*VRoQkWCI*mUV90SZi|vejIUs1m<445V z$)zstq@F!h4X@Ml*U*ro{8E+N@2>wU)eg1bL^YPq;g z!Lqr$i78yaL%8CAAw5L$Eg*m!wgX_Ns_1>P%)u#~1scW2q;U@@X!`RI4Mp$%L;pHH zLys4VjHaNW~#T>D=8N`Fy_LSWKFd zIdo)EAf)Bq+H~9C)9mdhFri~zBpdP7jJ_zlPKgf!V`7qv#ScAF`D+;!>jFi0$l`s% zj4_bZa?=E^S5fujc)eONwrvZnfR8AZMa0!$xK*@S1lF35REf47m*gH52n{U^nBha5 zuzzjCaF5XN$YjJkD(a{F*9$m_!ah<1pJTnOySgsq=TJyN|MnUL4T%iGPT3@h@)APB zpRY2c2+hQ^Vik>~*r| z=$1=RPC!@4_;}`l)6F8eUrQESr8fWhN~QYIav3FgG>_UmDGl$N7;*A?B|dDJ4htAf z7#Pj&r#c7HoVE7jjsqE1s3Ol1SsMI$`7T_M3SnIP=y>Ev--7lP##Ob$yYvE-nXFhJ zyjl}@_~4p*?m;B`Re+h}BuCB{VE7gNv+w-AcI4EgKI>p_m47s=?U~R!`+^X|OpC&Z z{e6d)rV74-_;1cnD?OIU4GyS0W%62cuw|loQtCNU(Nxh{W2X7$BFWbqsKsRmn{i6F zb`ICyfkI$I93B_>ZJT$Cok|`}=OqKJ>1-v#JLWhXG%LZ(ytp^+yuF`{=lij>d(QF zN&QW>wySpOmYch`=omX*1ZnzGu>OAJU`H2ubL^yVj@pE)QAGZPzz(;}F-LZ&+V7 z_?%wNBv#zrY;~9aK`*`BXf!G{=WA;;m};Y-w875$`tHW;_AH*sw~*q5+&a;|FxLB0 z-p8GPMu|@ZR>Tb^IO|B|Vu%wv`PKNCSvX;Q(sqXZgES+oB=Y&irAb0PFWT<`V&{(G znDIiGX%x~Sg_@wcisyqgE6?#tVSojH0@kpVG;;r{jJX8(xb!qyujMD6yZX>xYU6HD zPGx&ZVc@G@(Q2sieYi`|CqA=`aqc*UqF)qr@cLPYLosZvg~=|x#52c3Zqj6Q&Fxqo zl_v~{j^DMzt$Nz&IHHk=zljGJ^i`G9o|Ik<+G6Xm5eNwl!6TNSgAApzAK1lQHMHMO zx+Ek;`!=rL#SF+@7kE?2$XId6*^$uV+UIokS@PFjhlClI{c>piDS*=UXYv$z0vivb zicfsOY|=TDG;nDe$On@*V|ejqkM+1|^0>Q;4=oeOCk(x<_Q391A?Ihqu^a%w(Q1y% z+*5BYhjR0YH|aA? zG-+Iv+P&r)TF~W46c*Y%QaZlKq|lQSor>(O4M&S-ErxCB<=UcS=IURfp8`c56yIeKLZC+!fi}V4%*FA(Xk5vF7#EdY zpiG0Q)f4^*&Vrkx1RX*-hl_3hJT?Db#}ocKpT*kgwVkAEWV&fh^nR{!Nqhze$jR=A z=7#EK2A3OYrF9IiBPFSv!Z=K}=5PHq%Z0Bmshli5TF;x6hSFExee ze^P7#929v9nciqv=VS?fcyat#gYOoOV#G{cxgsA$oDlS#Yov-(>@24cl-T8T|LpK) zF5w5(SG$K^siixmFNbBE1v7msj=vjOMe}6oNx$N3fx=iY?x(6qU^dfDe3C+lBrP_I zws?xg;kEOC98EEnQeRcvl#tM``xlfzOoJsj#ZHNj5m1oI=CRR3FCp68SHT`7O{H24 z7-`Vp$Ur(L2@tUY7~)G=HdsrVn{8UA9c$JZV~DU1ig}!F1`z^Gw2G-o$L40K8xkP3(T6-7d7oq z`>K1?52jLtDllj4(-_j@C0)r5N1B-SuqlKB35;?c%QGAr57MbLY5GlD(z!M@ytyx3 z;>EE9IaFuST(zT=UeqVjE!7>v$QMd^HKA0zv{K|?6QmvKGZMdv4dz$!AC5zw!Y0E| zIdw?4v%@}hu5w!MC=hn#_7TO!cl5{&E z>{G|8)74M8;4u_5xUvN1zMBuK%T}y8Qu*=syKtiXaP0X9CH(R zA$~tVkIkR+Ub7ha1~2D>Gl9b$to8y1{X68Gg7-hjR{k?G%6<1EL%SJT_gY$2j%Fi> ze7LEePBNhIgHNiR4Kz)xuiaLTonHjsTM%Rqy)SFe=gxlrKJ+zzS31Pcpvm{@wdJK# z>noKjF;KXmmJm}E@HAEO74sJ*J_4Ah061yFL-W^FNwma9uyVGfxRhOLZR5FCe`A?V zKpZh*!Q{UabO5-l=^rjz3avYmdiu$9CyEvi!u2o!m1J!hL|H`Fop8EUxeaq-m$6qr z>=Tr}(NtjJZPHOgKmCM2&TJeXNz^FfJOrEfbkGU^#PKy2h^KxOl`?cQv?(fTkEB-u z8+bE)mFt|B2hH#~gSEll$>qq=4&0od#@7ASoB}F4Sw>?s!n2-^r!kNPOMZO}@T`g_ zNu`Y6Yb+K9sqjy1b4HW6iRL7m(?9 zZZ_viEfx(dkF^dC*KG_mw|~_x`Jha~OZTO-|6uk}3e6}H{p-Yq<~)vzcBy5hAeX~T z!aof`qAlTk&q|pbOQO!X>#OimI~1HHjb5RMy(bWPik{ABNp%KxE;St6v-D2MYd)Ws zlrjQ5V6WgTHM)Bh!PYPL@67Ax9&t7o^O5-`QBnhO=5QkVDlm4Qn%tzHT3i{@B>7t$ zm8ei$991jBUmVo~Nt`6No4Q?aXyW6ww((kgPhL&$$XOXu&yEFoq8t&%g(U>D<&;i6s1}ox}i%p0M&E6cA z`Q~fAPZa<48nTE7(enu6a_z<@YkOONhyhV40Ix?r~97lo zPZDFt)Sm3x*TI7r(9m#pTJMiOC&K|ye>sXqYr|a^SSL_Vx;$YE~2IKL@AtjkpVbN%I zBR=E-2tb+xDQ9i1EV(KtdaTOybD}kUkT*}SW-952ka10mSWJh<3>tc|`dK`0omCB% zDtYgsFNxC(wTH_rTy9F5O18Z>)AwhG?G0MW_wk2xaDX*LJBEn>alWb6z6S8`4&nie zMLtBN@2?;@IckZ5#wRt8&(ytD;5h0vdcZ(uF{|-M1jHnYBrpLCDKrK$rL44{CR!wy zQIc>UVc?O43}mnfW`|(2nVv!It9H=*F$++kNvK5 zjDtGinH{GU$6s13jumoC$%!|O3Z8ROX8uSmV+E%CbmTJLZ1%< zGiEIy1u)K~^b%-U57sRf8Gi^IoBoA*nZI*9NfZU`SAlTr}&MEJ>>?vr2 zAZxYN%-918aaCyo$o~iZ3X$%i-y{@Ydz&*NoBMBo%(zow4^>p|#%qT3=+Mc4%A7b% z2Ob6juw!N(-`*TlzASuMkFnc3{&TbYx53r)?_W&=f9?)1EU(XBJvE$Zqdq$NK3Kno z|KpW<3~z=z(MZi-^V&K?KH4wEu+*dM$@H6bm#ZzimWm_l9?^&q$E#T5HwYf8$^#i{ zsXMDa#At#n45-<3v(ps<0@57FIh$)2$yG5AB>JP5p_6*(pT|l}c4CW%o&$(2e?8(k z+U*v!3>Jp}1W5UvS_0)(1wvQmTbx8W$*rdj8%EGY-~(?g&}9!60lu6^(O>V!@wzHl zdJ^I2W#ZSa<`7I%J0dy(^bpW7YpziM zXS#FK^cVfIUAjC0d#^_#R!1TMHC^u;EnLV&l>SqiX8pqtnvMjVN}uZp}&V#ZO6== zzq2qLHvmKn8CehZbM}jQ{n667!jg9=lQ(707VM5nZ|R3hH*zVV(L7r7*4a=+?w@sY z1^o=`5OX9niI=1Ah(4|#(nx;@&>sk6lJA!qeL>tO!zKOzajilHi|Ej15h9Y&5Riu* zXe6s27iMcC$4;0V2l-m$kYG1l%{>Q^>LP4IasghGt`JqoDWamUzor&No4~;9(Pj3M z=EE&-x240jes-&RYhXGrOQ+j4CAz zchiiZ}YWx`y1{NI$?OvQ8-yN%mwrtGj==_VC8md#CqBku|h2X#g3pNr{y7{<3zOjA0}Aj09Sx*@BVLni9nx|;)n#$>)VJtazq@g{^kf? z(lJt1ze*T_&>IvUamd8Z?eq{Engn%vNo?)z+N@mjww`;=QHp^0xqyrgJ3s{FxGn3O z0>VwLS?QQ=q7`#rpS?cSysW*uc}zb2vX_i{xI;iYcU7S1)@@>I5tmZYa5 zuPi@!(l=V{yffMU%&r2>N1$ckSO_DDUGlhxoN? zFWs)T-nup4WEc!NI1rbQdz@Y_-$$vd4ksm@Dm$M34|XV`|s zf$_q7swzl?l)?gK>`;XGjCQE{MSlv+7M&9{$gvLvPMax_j7G3^axHrGRjoA(KEo3nx!|0OO$lp{JIV;HYCEi1}9dN|0uCK4me9O-b4 z&5)uFr;agthN%(|cWPLP*ph&vE zv=(vE|3#zeftRM)TP8mi436Z~1#d0ai8=CY$7 z+dR*I{hT5fzxz_#D+zUXzu3h&8BG0iVPo>HvBHAt@=aLj^sV>#tL@RFr5|fMa+0M> zpJ|J-_&UhE0bB4<@{pLWum2@DlHTH-8IUku3Px^ou`_u-*_Xdc9Sx^O5rBD&7xDKYFSeW(6oz#XK|EiYs@AH{gN%_C`JnXVRTc_JeYp zdh9w#FQ0yHm<6DPdZ|0aD@?DfskSnhibKBL}60uz37pI%lb5H`qvwXZ1_=n4ZX zNJDY6i>WV+izHFOQTMqEs~;>ncDKWR!_q$QJ3qSa^b#$U1&STrO zE3eQctXSBt=k5*-k&t6@gHkh0w!$(DsUHJ+K~>6k!DofzMV>IBEBGk&>L~i2StobjwMtl=)swwFjU7H; z2ycN$xnb86VrY@>e%ydYZ{Su{FYY5N$MlWi0yweZyQBRraAK2C=)$7qKchTpFypQ% z5|1lW$WH1npsk5$n|NL`XY%LnF>PgO6hdrg5-BSmW~}(Wn0wva(6e-ezU1^Ctx1f}u_eAtj zh~nhEs9tWBomoIbZ#R-({HAC*Zq&Gc$v1t@C(m(Xei7*m>K+^xaLtubbx;f708uPO zyf@HR#w%8WbD_>h*gIv8nmshu*E1-Oq~8xKW*ID8cz>&u=YjdyowUcRT=q^l?TJjD zhl$*p<6;#dqC6?dNKxSynGd2ClI z8-Wj7;uy5$nMfYTdE%LHbcObQz!Xe6`LP8?!-YGOLA%ML@i>BQ13vqhq0f7$%$)hY z*&B`T|HBpBKV_Fm*i}&xGNn6EF@2p2J!pzN|BMe?SA)Lom5t#cmiy|@5{^5 z@r6ducI$s_67hL=W#)tMg`VgS#cg80e@aksxNHM5EEN${^@DKgVbF{x3G7(*4Q5G$s{bnjHo(x`k{xjWrfp z!A0iq#q9_-QQ$vb0bI<9BkQ@1wRHpFYje4crvsMQUIlEd~5|X8H2o=-#i9 z-L2lzt);{LqqBp**MGeX*(|T8Z{x#rKU8{`YQ*qaq^V7*^{e4lDYz||1v-Ul24W!* zlPu+|XxaLjUcSjWwxsfbpx!+7QdJa4kW$m#9;(Mcqw7wge&Fw@y&Hw;%!c|XZuO-% z>Ig^+4wr1~6=;^qcitQi$NrHg3hoVZz}jozr7MT3;StOcKk^#S~0W z!{(e@8@ben3Z5Ot)V|sIK5cUyaz*WuH$L^ub?7|9`KMT4LBGs4q!Ag-8TwR-H_bjv zR3^TI+?T;w6h@>Kc4$9Dc^&Eo{pn?>O%lh&j)g}a+!w?S#*&Aw9M3qKSBvK;KT1x^ zzJ0)qcA^Dq1wRfKe2FYXuFFlp>*|THVN2T-RgVqAmZ#9N=j@C)r=^E~GdbX3oFxfJ z0S6=Kv3owZ1e-H?ZBD#0N<`?YK1%6)m?X4B4@HpGcb z0u%fT4M7r^d#GG=)id9`*u!UajY=q1z$$c-6HmoC2Uy#=fVgk)ENE%eSq?h}jXrvBDv1MEjD%T_;Ado?a2k|@`scm&eE)0D)jpF#25{J2IjJ7O=iM>&6(FiByT--T4>`@hpN3aOdq4VOba7HgcZJn=s zO=*hV5c}mQJs5K3>eYb(!;~Yq7fvT|z7X)fNk!=^-Mb0-}ynt zN{4-_1B93~M9Lmh8l&kCiy1mB5sOx=e!UV#f=K$fKL2IsDKUTs5KR#iOgDooRq_73 zt0GkW#}r6fT@}}=0pshcxLZx#=)OntUZP6}VaIsov&PAd3D6dLLDMw=3|&PcdnLqT z@`o6ubN;pwNd0~Ink>*g{K4rxK?b^3c80Oa?Nf_PME6M~grl%>kXk~O&+%^&?wH3B zI$IQpD2sh+n^%N!>B8`1Ex1O`UhP*y(2`Z6HiQDR_r&bUNR2Q1F_Xo&=Lu=ICmNuZmT zjN7o2cdIAD4 z1un*_@pQ(pYe!+Fp{3^Eg`H|-nP!y&sR=bd+ueJP80jBJy#K{D=F&?-~pJ5VEV0H|K~ zgNlH-^N-{>Wlnt19L{bf3xZ9xS7l$LE6~LTPt$^7%!?A@(|L54idEyMDfZmzW7Nzp zs4;Mz2#&lm?BKh}RF*F%?BES*&qd4uKT1sBk=KfzpByDW4gM|YIrUr5kMVqX+NPM} zp!Mck#j?4f_LtkXJ1KaBBI-KOw))qc zj@=Kqa?&J(ZP1m<$P+sh6`=kCnfb-j zCgwH%DW9}3fY#p`r8Ue55>AK@Bvb;TfR_>oWm*;u$>+*Zy zQ&f**T^u6W$DFUO2p>NZt?g;*?^%a5f@NU>SS8;8tYEw3_?=5MJ|#gbqc*-^ z@}&4cAD3?xoG7NQfL09;L~|pWAJ?_gV-Z*A2~%kkB$v8Cs>F)G<%26B;vVe3jd@(+ zwWpVUdpC|xb^>S3!JPM>qa}vPzqf!;(;I#Kg~9cAaF#|dN3^%2z(m6w_shO`KaOm0 zn873gbGvKhb#46lSBAmj=*;x-0hc*@zy5HH4ycR*k|}@65KEPZ=`mG z8O+pi=0j-BionShZKO>S&BcvD^tLD}0!^BD2G>Am9-S;4k3mD9O(U>*wEx@99GY_S zClfHa^2z|{Wq|e}zHCF-se|0!zTip{>rFqJnfBA1ye;8sfxC#hvxk+e$v|v&AJylfQBewulEjmWV5g z>?vo?c85?J#tR#ks;?^EEs3EpG>eE7qG2^FcAzle;M=gvvAa;A;v%ty5B}ozu7}_7 z<>BI@8jm-nKM$V+9%2xb96d>fgT>P#;%z$6O9Z$UydDTi9EHcLlt270iKXmvPh#aZ zR(0_Ol5TQe8C-_CO4Xq}7m@)_0>Nmh(MD*$n@4p&z88Mw(RrxY@1^T;Rk%^+Q~Upz zs{jj38CjJ`|God20>ilOO@Un`$y0BPytn9eaD_eII=OuajRsttPyxgg*gAz62uy*k zGeO2>pN1CA{S0)8)!c0X(V*dpWY^x(-Fy%J>A{9WKa4}XmJFy@txZ)a?g(>uFk@uX|r1yH(bM~j@J z|BzeZuyX@IZfP9;WM_3E#8#GT*POCbIZCF9O2g7iwR_TZ-RU!eOdA9zxWYqUtH#vq z*|mB$-+EoSRxGSM?|=PXr}Aj!eP7Ykb&26MnQca0S8kn#=;tzEq6m@vMRXY5Xtawh z+LFrg%+hdV=3u`f#wUAFqAQOzpY^T*<(3&y$Y31Kv62M&z)A_yA*S~xgAsqr5JDe-qFVGLjT+|J>pcl{#I%)lh*c_Exy$>O`x zI(6Q2`TLc6O@p3Ammj`ej#AoS=E4%fR9ugqu&;)q!q1=8_5H~EkaoD>Fio+~Rm=Kq zpFLbD=+hNK&!e*GPuaAtaQ&-PEZa+x1n_&bsJoQhISjH-cMXb_lwEhZdPw6*i=5i&*TQL4y!ftMbd;}*W>`r{wxYF8{ zx`F`OK3G3L8^}IxdZuZa&@!o^-|~^8ZS?4w#@w%McU4jHTvO$PXM*qYZ#*x~lE9sh zSefpEY@ts`8h!(+$qOz>ALjB`=9XWQjHh>@reZc2~d&Dal^9dW`bA2DQM&c-&J2qT0*1NvX7i zwH)tn*Xh#R8j4sXsMspMmo^G|pWbbm@HUSWOb^@ST1LEl+2%R~kc1!>f{Q3U0r}$p zVd|@c;_AL2aSg7)WzgUdT*BZ4cPF?8x8Om7I|Rt!8c2|!!GpWIySqEHkMFm&wSPek zRor>^T{)*ucc0%to!X1cw1P@J7n#FUED@{v8mzq1mgRS{*sAm40&UZr##$HhZmdKA z(Y%1;%t;TpN}g8!?tAfn`QI08Rx2RD{mX(zy|L7)3V_E({{xSW0C_X(&JM{=cGW8{ z*3!c7$=-YXP1j`h@~9(3CUz$vYgQ)u8n7J2sRoRtT@jT?fap3>0-x|`B~)!Z^W^t} z{naSfqpjg*(JK`kTs`95BsKgH9L+tke^ErT>LzP{YD8WOXT<+2oRP3f^;$FGYVT30 z9XQhCMwOI;_0#QHiWrZ99M6n1cRXl|tBnHXJ%QXkU5v3>9FJ379L{@$x3ax;uMDYn zz`CZK?%G7Y2|xalreJ=s6Xi;ptvYDG~yit_Xo08i;yL2qIGW2T*uc%gRr(njKpQ6|e>& zG3nH;WmWF(O=*Vv_nZ16f`=zlH)wnRZ^Y?*+@U=te$KtV2W@Ju*F z!6a`6WcohuuhY&E?3hI(1tZ7+SPxRC5Xl>5L*L+1wJw4ft^U$F0Dlv8xyAGr6Qz;M z@Rc+Tz6%HP!0J1l!_%VDA=PXn=|CZuhMuY>9%&#~NVjRQ(W0W{S<@7j;jBSZ#=tfH2=U)(Q*t(}uPEY@QA#SUAA3bxcYqLTiq;^bgn%l4PcJRN^Q1 zE7g5>)nRvRm^LK|npY<~JMs14k9&&fODX!j(Td~m#KXP#yXowI(@Fy6YT>dxl{jk( z?X*uCG({?}cP0%G!UB8^mj_Q38qt1_ll6kI2-=t&!?Ukp2LJ|!7beRFm{E150b_Ut zMl_2`cRV5PM8yA{kO10$D0CC|BBI9TnSy&mJ;{i&v@|%(e(X9kM8(KUbvd8sn}+PX zvI01*H=*0Jw}ZFbB2>X+a}qrX(&Mx*Xn%v;7R{5K!%u<`*3F|M0Pr5UPlx1XHjW6E z3yky;>uq~E$6GVN=7B#l8r6bmCBe{3&nlN&+F5k86XU%yu)h9D{-P{kjoI){!~n3mG>9HI04j%U z^iu|2GOp`37NKC(=d!NW?+(f%O8;KB3z7PNfi2N%U|Zfh%ci`0s90^`lhpFJ?0Z|S z&oA#Wz6t)4d+B8J-z+)a{y>`HCs6?0CHG3*KowmHaYDy>g$#AvVUErIN!$f(So}%c z5Y_sgdNyS3)aez7c@qEtF$}f1I$7v?eRDP@k8%oUGr(mVBUS(xHv8=}C;|W_Lnh`{1`fL=f^1RVAfSrjQcE>Uo=ma}XF6h?F8x}&?eSvBg#HIVMT0&M$ z6~A882U>%UZ4)t1R;t)j-^Zg!_7KwQFjZ9XJ2}R@gzt>oWA0ayI zwL7HAr=vR-;S$I{7uEO-De{kx;nj0r@?VKa{|$p=_Szqkpi%mkvZ)@N7`eIMw*Hm%O^C+y>0XPYd!d@L&0r=^+C}<>#r4mJM1sU*^)lGxAzJ62t#}ikTLb4os1qzDcYf=34uN&a^eSX;XZ!5_KJnU6 z@#5HPx7tz^rE{N6`u%m5w93(NNI{-idw9(OxTGzL%RzthCy0QFg%}i(Q~-csatQ`E z4T5ccV){d;qKBGm4C;gHe$|-5x`xYQ6grQKqgmlu+B{}4nS?=fn?e6H;UM%;aeWwH z@57h7KZw%o3oFgx#3STG6+-$B;q9)CN#o%r^!dFyFqa4rKpw6cfk2f22B;FioA-v` zMA*6Q&5OoNBD|j&IZ2Ix0lKsynWNzWlx!q(Fdoo&No?9)dU=1?zI85*R8wFl(hMW% zI3(T`wxSxi14AW%@VBpaL>e4-qIjNj^y}UfHXG`H6K{&;8*0S*PCP`z(zSkAq*4hz zc%>`QFbbD>Kgci!;seCi9nw4);^Ey_3bNSU8nck@!6FG^3#!inKj>{!QtzBb1ZQ1z?sH^;@oEj{~7(74|vU zR|mz0jl~Kt#kC!QJ*pXj{%d>_Aax=R`Vm!0q4>&!?mTn)@w)ZCkq=9O2=K440uLNP zH??m1`fTlsslcv(^S@pH=6}1so?YwnzlYC5NqoKY{YMTr9(5&Em($a|N3}*;5SC2+ zdEhYXQGFaJq^b&0HUz*ME=(LlAeDN%oV(&^hOpJhsHy~F4`H;O?JlC-s$hf_kpOOp z2~KHuAg9?&Q*p;3pOymE;UBEts#>ugV43EzE_=Mv2sHjjBhVxQrM41z+U!Qs#$+y| zQhV)~E}G*xhpz`MOA+DV&~{msqujIJ8Q@fDdGAE3Xy@gyM$c{kwejL_e~o-PW7lXV zBGKuXEZEG5Mp!#>g*lc0)BqdD;H)Y@7KslHZvn9VxgmEGnP@dG6LYAVzjm)}Zf)!L za8Sp(mL{QHoTZHnZ{8i2TQ*mB3||7=hS~(g4cmPd!&Y7(B^CG~5*3ag z#j|$hj{>mTch=SwURe^zLPb%s1_Ajm!xVH6oK=35WFqeXXpsz{{sTvjv>OddtcM!Y!W(>{ThJc>IVTn26r&_LG- z9}Q2BHP5Uzyv7B5>B3Q3vr79fuQ&wA2|`Z{&$Ae#D*=NX4t%7~=cla_{#)j&%}xbh zs~$^9^f;X^(1W4W_#aKo$UStSuH;cSJfX)ICO#t*cjbc}!6W#Q!Y=xOZGUhEliy zvCx|fE~R7Al#KAEHJK3<*H`W_g9|5--&)3qC4Dcl+;}Rw4{85Z@~Jz9I&}dH5e`d_->F=G8dV63zUzayM=fpaU%>!{F7I}} zQ>wQ>DgP(Xe)Hy3&#$yARm{&hu|>bEI)D4x`+eJplGgudh#qE`2|0Lq(1R7>#fB7- zN-`U=T4hFoVuPTMm;XuC5CPr#@>+1g<=mQjkd}ftJxNNT=~+`IZn7!b;oEJX?3R|o zsRq=%x(7nk6y_652MV|(M0#{79{F7*wP@5{uJ`C)&={pRV&1v>J6H^omx-zeZG;Uo8eRsFjpWz`5TOT@qonoKt$N$@x+{yA)6%$KdU8L|%VJg@_aypwLHJ0fBXm|(|!>nhh8uSF2 z+4e2`-zowW(Ggm>k7%tqHm}kr&d;yXr%jWC?&NsC;0YWxTkpO92Q|*~0qaxH;|Rj_ z`5a3PUsCyTa!eJJpTAc~Yr5(s>=muz2pms5jjq!lHwQPTFP44%CVly}Ppg`+G>gKn zmJe)e`@Y}y4A1WcWGqj!ewIpC1onNx!D&K_wg)7e@vg-?PQGJ8e+vEbaTwAV?i-EsX&RLvxy>O|jO z{^>L8RtL7ie_}Ale&?ry5F3{#(BezyU=-~h<=%-{^W5n<+(G*dG_)nyh)58 z$7Fu18KIN*X+JKr|DAfcIH2@F2b4a9GyqwW~Dqss?!3VmK zNmKJukTC+B3ASfCje2QRL6e3T8$wAP3+C1@C<|iNMBaucud#71Bv#hx4SB*Vjj>OR z%UJ|h7rWz<{U;VVhRYRpLsOgIPr7T+?xGs^H|wdW82>N!T#d&tu3mhCa&HC`TJFp} zE}Ee*7DD3HU$qzD<)0oK)AtRE#o8v`_|_XOn-??mvKKu-T3SBO-2Up`uD@=?GT)T# zEP|!7cnBL2=LL2IX_&02tjeAi4QRPL^93;(*tv((0a$NyJ9rcOB20(%DD{p%{?v;> zh3f)YY?<< zJNR<+Ru@k%R;J1ZPb^%y3Bmbab-D8IMc9Z1@4qz{3mL!M_Z84jgC2|l>$rxOewi?klKz|wQ^9m%^pgV8J;q8}^Zx`Jf>Z(% zI(FKt;KYm|2Ey7`E(kyHn$DhZU42D|zYorb*?R}Lzd!wg$4)&c!}vZyGFgfV#4yl9 zZ+?Q(L^bkCXY%)4nv*<1j2sT3k2^{e=K7PTD%%HJIYgK z#IDmPJXc>NGj4^u{obAa)C#sX+NmMt#cTe<^=;YU-=U^PPHI7i=XL!%+t^qrsAxNd zLYb$McoV@0{nwI7DGG$i?>>oO3W(98P!$0J8UKK#E=kb4b2{r_>Cje)V~ z0Rc5TC$)tvHW!Wn!Sw(cc0b(~Y&un78c=V&dv?adOZcN=N`Dn(-iw|nca13>KJ+m? zK8?ng^eLx?mvg!5D!~d%qr_qLzOVQk9GH(Isx9`sl*Ok^_7drJ}+t}R5sAxu>O_TQ%c(@(|20)6YKa88h09sF@3e5W7L{8$3XQ_D8C%b6K45-R2 zqv@$_vv1#-lwaFUh?dk$=v`^Z?vqk_dvEO(GvEqmWXYO3di#&hzrQ*gyC{Abb@O(q z3aHxoUW!n3pacI$jOQSU1$Vq<4dVrdlBYkua5=09b@rIWH}4G}O+md)5u_^*ru z?^O-YOO!%@Ot!lwt6di3f(FUa;`9p+&rG1*?XTS+7sS#HfLu62jfstmAFbpmIEq>l zB$<;KfvQ~-FH$i=V1E1mJ@=#xg3CB}E=qwQO}zY(#aR`$RO7Jp702Kgp)$o$1e$mm zOk@!(Iyel)=&`C@)-fIU--h|W^0v-St^r(h8~YrX+ae3xbD6IjSU5>se2ybScCMD$ z^|>E1!vg=lD*YYfNmCPcuy85A4aVN*CpHpmKuZ%Ipo!~=+sL|Yi#DGP=s5y}UHF~8 zFkUi%&Qo{aHp}zX$8NEl>KEP$Ka$z~t^MfSjsD*SWABBj8UV;cyi7ZL%u+D_e#m$y z%7or@6bILp)yNH_02Jq+ivE6myAMNsZu0Ml{{wSbs_K?}oJ8CGw(q6$?VHH_;i3im z0|_q1X^iY(Obc{5%TAnTxy)+5zS^QL zjdc~0pH-fV^*k?;$9CnCOFx|Dc1e`R3igf#Ryx2zLXh41fqi$MCLF8I8-K@f=dM7J zqE*F+Pp1&i9_e(~G8Mco$5xg9c)Mt0zzO3cVq?En__Jp-1p%JI^ay5lHdwGLLuW`a z=)U-9e)y;*{Yku}+A*p%IJAd^nRNz~Zvo4i1nlqgZ+HB2hUl654U?Jst1OqlbZ@2` z7kmNcxK3$UWke3wsZVFwzXzckXYt(@!`x@_xfW;c(cW%nPWIfWd_lHY`CoGQkz*Mu z6~WU~I^({#a@n&Dw*EHuI}Ln?K3t;=s6E164d+%_LgP<+)2WlKXT_T_A*}V*)c6I& zfF`~G1IIExr+RXCG+RW(FU9YAZX!F=UuPp z&Qo)R9p=c2DcM^PF@r8xM%tb1ZAu-2yed~m!D`g@bl$>L+@i52WO3SsJ3z>INbxPw zb9;;aXn+H+UA-&EDZx=-2JhyQ&xr`Lw3pSL{fLjROTc0$e^+8VTOG33$?xJ`W8Kly z1(|pM5icDkvlx8k4*Z|&#riU#bP7<^9Lb~RJ{_$I}6 zM#n0$Ux8n$hzm z$!YE%OnJ2==hZEYCzzq;dj>6M6;`gmz!AKmD=E9Rq{|115- zaA|erhU`y3w3Xh9rX5DneX;Gw4rU)iLqDBz!e6)9K68<>yzmb4SPq>9kbML8)2o4n zm%PaX%i5XxqZdmTpXc(h23m}nGR=G+Y^PbJMRRV?aHn8|h7eNFRI_c?XjO&ws&Se2 zsdp@gc8){mHE8Nc-2Me-6k9w3Nmz3D6uKCI{E(_sfZhJ0dr}hGMvL2L6xr4|OqdJS2;H{G}QVFmbwe5c^2X1n2miwe(*? z%jrdZ$6-gL>V@#k?anvxxk8?-DCx2eN)+!(YRz5%$*lv>;wiKd7l}OZ>oO^ymY*cq z?9%(p@XiZEoZhF3g2f4WDa{j4n4Xcar=_vYZSQN(U%zf>?@M3xQ5D&xti$HJP16sX zI}(Md9Re7lcp~%K3%y4-H{E80!#pt6IwN0i5xZD#YDbK-n!Ocr+tE(1-hLK#z!JCm zjlIU(UuQ%4d(J)RQ+E(tdt~8ddXi&5s0*l*EqA`Jx3w8++iIw~Br%ll6| z+3^LmB?1^aDWzYy5r@R6FQq%u{yX~PNRv+1c7F*~&wIMR&tBG?Eqd5vX-a1=9bUFY z6_f1d`t~)+{a^Z2J_i=mReYa_1&3d^wQ0?=ZerN}yJ@H0Tjb_TPF zjPBB0)B%1@L*Ek_wqx#yI<|y?Gz2!ow-v!PT~r~A40V+wo0JQAp}0<_i?Of^4k;cw zp**j@`;ui}HPClss5U?+7C&QIzQ~7S!j@=*?TRC1&F{J#A(S-zQurhrTv|(kuHHyS zNCQ-~BQj0fBZ5Lk%S%h_^+I^0Uu3(Q4bcYeJ1382LjK_adp0Zl z*On)x_g#c%o8}b}(6Y=&pQbU0CGuTMI`np6zV}geL zYj1x1Zv+Rwpe8OjwrSdCdKTh$_b<9;!l4qm8Nduw(-5Y6K;X041dzm_bx@7tsMglO{5N z@C!QTt2R|V_z)K(Q(1uZbkp~md5|H*Icwn&Qht+}Z#Oel1+k}VbnYfO#u`}-mrXT) zY1CU4?(e_hsiUr#55`?|Qm|mlO-E`UUo|*r!w|85X1Z|GS1`UkxvY#{kUnHtdwXs%OXrWt#y7`z;?$3J7? z0{=tHu;3IZCHfJE+`i!g?#XF#nb_Z5JN}}qq-<@FEN5Q5KKmS!B{L=JFb_)Fi>Mk0 zM`t9`*MA@s4jB?JR)PkW0Wu`ZNppDDz~~S}fv@|R*YNZO6inUpG*+e9g#yHwUf)nr zrRdRMUK0;*5fqNirTl-eM@aPhe`P==hwUy2=+BTND8oNc{}2t!B=#p70kgn}f|b=I zAYk>KmrzXmZWhx>7y;f(C-~b5$ndQrmSEDp%f?52m)(nk%mb8)CZOBsm|TVx7V6E+ zMuULkG9%n4x|Pq^^+EP(U_&3-2!kj{@|;MQ>|0(J95oLGn#8H4Pu{wn$rnNn%Xrq? zH;6;=+)_cfiv%Uf#MM{;?%XXe;zLG5O4YjzE zPNPIi(RT#w5J@F~Xe!`{rZE?U4f{J=5M{0K^+5$t*l7`SE6=0Os%TLXrU;P%eSH7N z4paQxoGxDWBss87k$Ce}YDmzReWe!2_JwBcPfN&w+N$_;8;0v|=Q_=xk?+vGyql1ww}%l|W(W8==S`c^Maoi?L|k~K;syCg2?ZTe zEoH&pgg?(fkUqB3#oS(IM7p|!bOo#qE(~x{8wGx}g6Dy#`3|OeEYFBXtW09dVwhV} z%n-FH;8zR$O)&0Q0zt)Z;aCDOAJ-^R;s&$X2j!^r?VEEh=_~OdXCwM4Z&{f`KuYqa zT;?K>?j92J!gBh1&qy00t(G2)x+FsREkW zNd>9lw}%fEF^YZbxo}xD){}s~es@!^5(uC=pnjmNIZOHt3zQ zE#4Ei>;in#)D+G)R`m_(3dq261?CfzCmM3{BvP$3Yc>Kr){QRxt{U1Mr`57~r)xND z2m)d!9*)VGE<*uAO0=@15>rW(C5)Yi?B)KK0aQ;!> zUWk4``jfKu-XA)Ts0@^=r)KlrU%%qS`YWqaze-S2oAy5C+St|Ytq-G~Ck{}jCE!ce zB+f~?MZx+@0{B>Xcp65l(-EIpz6j+o{bM z+t+*U75rEw=OcXvCdXdE`hF~STVis7sE}g5`Am?JxI^!c2v6Uw)5i)BFX=K;ASEe) z?(ou}1+$X|D|}m-H$C6Dt8FkG7EVwRQ63`n{&Z96RDd&?RZs6;O|zzI4>&w@P`6^@ z;tzp61)=>kTSrcE^rcG_Ik`vIT%ihN3Beyi8ZU4WOrvWy@14()Ou=Dc9%K|hX37}N zjp9wu%>SVH@olDbA?5i*wNYXNgHzGO2C-uYYlMFM6nXdJ?{Ap?chK=VbHaYAeq^bE zf-sgxhhnAlXW|Fj+q&0kF%B~7gLhqPR=|;8-|ZWyjla(7>Top?xk&-K3e9tuLkH~k+#tgzH8hc{5579V>Pyt{Vvb?U57dHFgnSgG^7PN z`-2A0y+>87(e)gPJmNbw_C6jIJsM;G+n98$y2GszuVZSUU1v!qTxkaOo$CMUxMl#F zI*R$nZT9fs@#t`V`17hAJ{sY4f@z*C+m}oHaU_rqqYSu072rdjM>)e!oNjJn^o5LI z9P{(>lpwUb=n_5<&8vJU9ZL#oPMiyLbL_r_2W54_%68G6A)3dl#f$WNXb;4pTa=E( zWU2h(3 z)HVKSv-|k|%E_^SdUE7MCwCnw718d8{RxJuQ6*(Wluz2Us$c09nPW?qL{rrW1?~~K zm}+DMcE(=1^JtW5rLQ8Y(#6v=;g%`((Y+sI^Pf}|&s_55P;XXnD`_W+x_9#1{x%utvo-mk|;3*?SgN}>Ll9XxXA>Wnv36s>JXXbd->xw0|FMM zTylX>`f}_%87=~e?7NsALG#l#qC;SUW~d=2e!4_j;`G+)L-6Q6D1cJoOP7J}4Xz5` zJObH9+9xq0B3M9IIZ|<=b$HLhZN;N?sJUv6RVlCcBBzDV%#QvjtdI7S277Ac8DPnx zgYR~4_s@2W!Tli~AiN(QO##%h>5~`eJMC?jDc61JVJ<;3^@qpk=sTSsRwa3n6P6Es z4*yYLd(#O3#1hD9S)3(9Ys3v(HF9)>nh3dLU=6!d12(R(xif(GJA`As*8KZFOe~Wo zF+AF~?j^*HP^cZTx-w-m=3P}F(U;jlcc`r$Q$A8>W1iS%_wjdE^eDE<(jr7)fyobv zsacM1Uch7EbiD5^I#%>V^MAzsgOhfebso<6W5qa=-is~W?^cEPE;S9ty+@z%UYMM7 z(YL(bbCG2e?nV8PzpH1mN8NDa*`m=~k!94XI}+ewY;o!~F>K*CdhyW}Ic~*Q%9S`A zXz;{(BVQyo&Vh4C9~Isg6BrTx3?fq(15LRe^iokva`NI7jJ0tNQ9c^7!5=noSns2I zOsgQmgd4<@2I`y@&--%vH2p+2^x&GMwSKu-8A9_&E$Vg!Nde9Cso2nSAuU02_^k zWlfzJ;C?4bnByGnu5}c=)-B>mCO#!5Td<|Sn3>^Th&^pp9Z19N~uB~Vz%(w_7e zNL(@{-0+SV)_>?WO85z&&d~>LZ5QB&@HLejABVnC0mOqaNkH1The(|!88m6al^fO} zNP+h87Zyrxz@T~?IX^>1@%2|-hG`)`k@>Ath0$t&PTg;Nn!fn z=h22Tp@Hj*LHZk&g%H%MJzb?2tRg6G7F^MQ{6}2qkzLtHG1GYKVta6tqS)~__21>P zzO=Q<)g_+!cyiOqPhxaL<_TP4)p3+N^Y27jd4Vhxt)E${pP|QmBmw~)i)-uyHI;F0 zIlb7wSz=wprZ7fcyalG;X2q3Vbb=uDp!>`X?AV$MldpdK_Ik#hJ(h6wi2dt5^rjl1 z4$F9&KvV9?xuf~F0yEh5M5hG>&4ItVcocbg!@SsmI#VMB({pe>{%_pQ?vNC<${-i1 zuLL4G_n{K{9e@@?%Cu5{Q`*KnA+6FmCZ{I9wX%jHcxaft?CBHZXHQ`Y{6Zh&PH7uB zXQcjhX(m%W5V+*=mo=9Q%OJp<()KaX$pyi#<~l;`6)?xm0VG?2CdJ=L0eldRy3HJoel&dGBU79ztKcw`{;ZH7>&oP)K@`VB0lt@WiCT4f*gayx2Zxpky81R~T1{6Q|HeAyApa@R%Ew<7nKFFYDbpsR} z1oFH!fNg-#UE2A3m(psm>FBQW$>BxS)ole{?Wb(?ORge6>&LvIx~t|&IkXgiPE{DW z+;WyM4=Yo^HfW-cnN!x6SWbur^P_%EX9kPBu;HQ8!1&Sq!Q@vtTR#j)0V)p#Am=Oy zXH5k9%2nhsWQ2}}xE8EWk1)HMFk=Sc0oi=dHn#C=W0F&Tt9Fh3rep*(*clVBYxnbUN_?38=7o6B%} zhv=W-w(I1It4f3GjN34vJsAe#JLXnc=p0D+rlW7Df@;L!2eVFG|*)hK0tMZf_bZdhpM;l{(^g3E=A~n=%NC0Zlzj4;^ku zwtp06#db57Qv0I?qJxrTP!@Bl8yfy^5!8x@H0P{>W99a(9`$b zqaZ#HImA5)ql0<{)58iZ9*$y4IrBhk%xcSI=cirPP6?ft$ZGjwR6?JzT{GVGS-BYo zKT{CpAN3N!!ej6~IOm zoV^VWAn@X{`_|B)bJ>SZatw%F`I^W=l=Xq2OA_;sLuC^|q^zf4fFu~K6fCQT{i7Op zZc6>bcSS6k^>Qj2vk)>CezXKsi_ARQL;Q$$A@~J3L#Ht@_rD>^>qklfW7Sbun(ntC z2CQPZdr`xyk7mI*^H+`&d05yYE(Uv!yDu|QF{1O0L<_-EUG$}d(~moUm%9(1x24{< z8EG75n>*5{KEzVA+#f_VIEt8)+5D|3KKNnFjj+VI!aHwHMl41)+XW*LepNNWQP7oMm2Sm#xJEunTH)hWN{v9 zgyQ9LdF{<>{KHn2yj-~d{=1L6z_$+49N2sNM4H8?7TJS@&3PC9S^b>#E_P(!Oc7%D zT_4$6^`Z5RmmSNxm8^}d7X1o`s>^+;n{4QsGMDR5i)WGMdFz6kO1B#4Yo{RrqO~Dc zz@5b{+$Q+h+JIZR>$Bc!n^=jcg$#SPg^afLFCV9nOp&d5A*Y|o0Eiso>ZNTCt62$9 zhlE9d*z+TJEdqfd*b01KwAaTcr6&|b6si&Jtt>z(T0fayQYox2+^<{tYY)=*jjn2T z75zJffQpXyRwY|ySkj3GQk;8XCy_VvJs`kQkGwTy|A(-m!LGx*+Vk zJ*e!KXuR{gBv$7t-lgDtYC{G8_u5+i|El)^NRO}$^wB3{)$*IpwT(uj6{`~JK=tj7 z;Rmh}hRDd~qmo$l4_eWva4Qon<*Wia*>=B7`SMKp{GbfI z#|k)WgFc8o^&3Oi#U8IIUzFQ!`2y~hhn^p&ji2-{Ie$_VF3g-EH0c5Bc|<~8B#7`&UI#+XI(q+oHC7fZMewi#HCAj z^i={;_ItM*zhy9!t0@G01xUAu_fC(>x$LAwko~I1)W;QL21baQpT19BD*JH{w;Zi+ z$aek=H8%SGrkr)0ciw=E2B01iFJ(zt@%!{uvV(T;sQGb3gud}xcR5+d2`o*QPjUku zpY5Ax8$$dPc#-d$X=l!AXrwM5MbY9+g?ysB^HchI^23sYHpXS_+t2nAI*H=MdBGmd zX=S^=j@$tI-ZE`%=`{To<57ny%1nxYYcmnhb?LL8<|(tt#GB{lbjOA5M(d&kzrSQQ zI>+Vx>&OrQu^goK$GmZMQKVhY70n1SAaf%@MdcNll+CfrCD!O6Z6FRwLUwcRkQVFc zkB#cY^C2u0P@6vu&!K2enU`{h1SM(FK$0jH&iS z@Tt9t1wadzZEE$v@Y9t9O=3kDX_9xKzrEygVV6-Mf}*v|rGLo{B;t?nfd?J$nx#=NOZ#XF;Gnj%&!#wTDvgQhZ z_PR|;^m0a|{p&mL|B5?K8^(^)sgNM=7sNHH-dkRGG=lVwLeBjH&p}GA|aA7>yVi=?ZTat6JR=oF7y)xIE{AJ zu#=D;ssHkaPjOysQfXu$ZBuDD6@>-AW-HfJWMt*zYh(&PN6umeJ11>%hSOpfNCoJT z@qTiP3aDTfsawTsH2Kgb97k&(dq~d)eJN`Aib{Hf$!=uHEEs(m)C!JYr0@M#iwDPPk@ip160 zKllPocBw2^xvJmEH1Ki8@l7tjeaH%~E z$lqkL$+Em8)s8D5pO-B>D{ebU9^CHzIaht1ei!zV$gm>3O^W_^@p01p9H)VkgYpk$ zwAn#;h>|wCYmnFbU`#(TAC%R_sp~k-@kj9QVl3f?C*)t6Zr@XLt~`+%=X*!UN;RL3L)0d=8*sX|2FXd@ih7eGI~w^ zl%e3ob+<_J65=tk122rFNZlx2gW}P7@5Mjkw}%1Bv}d((3WXh6?cTeFHG!kQK(a;< z#?Ll~)g#qy-76Is`%#V|2v^Sx2Sm%*ko>*DWo1?~&^$W9pmL3oi$2*vQpN?xrX|Eu zvRBxWEF~HhM3ha&_;yl`O}3O;hydaW;^2zqiS;-~)+PlM`CORifVp?vZgj%i5elvl zI9x7mZy2DbJM3H9hEMIPfeMTb;jvpZ69=fn|6;#ziZD~*$+7`o`$JKZLA-{K=V_SO za}?#vJ^Ran*z-LW^dVpxD&BVYE8w;w;9B`*^F_?6?V&i}d^X^vBH&g#;H6jWX%u=h z8vrG0v&x*`6hjvAkL~a%;B1hX%If|yY2N7(&K3L|Z#b#q`4h{6+8C*r#k~DWh42VX zomV=oJt&_MqLPL~ZX#WvNih_zrD`P;D?g9W5e;mts{N3+plMMHXa)4l_+>l$>0lJP zj}`Dh34Jhr*_egyi9MYuzbs=x_t;;6Pu44-(`|V_ic{O3@{OM^;$EiNfxiUY%Rtvs z1Fiy~7g$imo58l*fS0pV=v7$2*(jT0v0QnR#WAYwQJB~xVy@WJX27{N^nBF+u3K!# ze>SN#)rvhEN+G|R&~rd*`q7E>0XT3^u|<#{*PHeZF|Tvkw|1tkSka{AB|bF`YB9XJ5iuHDlWGu};P4Ci1&U{E{an=`BncG{@}=PHvH_hBZ8-M2plJ z?r(!_Kuj=*74UTXaeqeh7&jgnJ!Gbc7bn*CWsol>ZMhCV)%6 zD+`*DPG+_^Dh~t<`%&xW79;G>=$&GHU2@hGcgd(rZnFEbfKFsWscD)3KId`$aahWa z^pS5i?tP$MgY0$);h0At;PcQ;y@GRt=PZIMyH1W;8HvTj5JV(ZE-!x@SMj(*9j*@; zAgz}p1er#Ah9Js_bLM)21XmJd-$nDVkwb$p!b}q~HMI4=|3P8Yi?C;;KYJZtMPZkm zx`c(g<^D!A9d8Pv*H9g*+hM$VxXSPVHP)QHJ+w7D>1c7dAMdVCWiJ+6X{SG2Ru!E1 zxA2~G{UHvhVhvK$; z*rGVedV?k8Aol3mA(X1lEi%2c%dyk}fR^=_>FJ&DPbEdrVTokSJQT~sRK0_LsBS{e zmRYLO1CMgy+>;~bpuu+uSIAO>br9sAB-X7DZqwCDl(F??c{?^mFp%%rI%60lrlM=g%i{`OSC`3FB70(!=Fe zR~zec-l|qI9;MS#(f5c`2;@@gcnI5B;+PY;3%(x(J}M2C*%h4k*ed^Lk&^L#ff3^~Vpx8SQP_;HKn6_=|*5L%0(81L?5MA#6%*5*cGE zYeI$FT&69vh$e&}wL6_M4qbT@!LxDQY2HRCp5W>Ci$p>gIU{-aDnN494xGvwX-5hs zRYM2;>uV*Y78&nh`*S!7w*mvV)YCqccA)v?NkXB|x6qrbDwE^pW32Vh59(gsm0teM zW36uq7Z9D<9Q9I4h-a5H-8PGArLWJ&o7`fcWB415l0V_Znf{g&ma;Hud{v)jVUkNI zE=@>f8*A(-21c&2yec^wDy|wj889)>MlH6R_|aZ0-w$guysQ3IBWEF^sCKSkUC+0@ z_Sl;Bnx<^AgykUc<|WWQ_gfUSRUzUS*Wu-5el+!&ml+D9+d7dZhE%6x*?^*Jv|;x( z2miaao&NW!I_yC?f+$M?_kFlQyWgz%2Hh^wc7r3oSqJSqP-f>!@wh_QO~1r5nhONi zrX<2wWsEMsm1G$i-qgF?AMR}TMrA*^u?KhwiM5zr-W*(XzBpX=cE=RXkZ?~nA<NeB5T zT=YhbotbzHn{QK?%ZK@sdI(<|Ssk|ser_y5F;=$4T*c@c#0T_^ z2|Zf-z{0Z$bSY7lK!leSy@PCY7Y;=A$ zcKYG+p%5Zt0xRTqZ?y-v*FoTU0O|r2@8`s~E&aDvGkp4Qx!#D8#uPX0yjC_k5 z@+orsO|*l?$|x4q@lZ_F5Za)Lg0{$Xg`6G|A2S^?h&7uOQEhm{{2>*(9RN**9tS*( zLNB2N8&{{$$$+Oe;P>;kmtyG4>hmD<{`92{dcF$Xg|4r@bha&!<<_p%G<9CxP!f(c zPH+fs6c@?E7ZqWb(a{q;7@1kegwf}vxc$V|lVgvRw%aHa@)Cn7v(ota;e@58F&(^} zCY9Qmrq!0zZJjdwhn0D7oP-{2?11>GB$*7Qj7b1@98E2=72V7G`h3Ih_P#Nh=oE|U zY4W9a`1Y~M*rELN2C^O&a0y8bcz8K>q*UrYw9G!0Bz=E1OQO}QuBazS{sT@U$Ujdt zqO}->S=>6({(#Z&fC^%J=oau@?yqigK0c$~d&9pxUhI{fe0bX+wDNWHl|AH)jCr-# zSr-AFsg7AEH792-S$vno_V2*n6zKmyTwP^YRa>_PX(W`CO-oBiY(k|wr9`BqyOG+I zNJuwGNQa1YH%NnYcM5_u2uR+!;oR?j=l(g*(}5HY7W>}>TkBs-yTJzvDM}64kqt1)D@e#3vW>p2@Zt(379PL zpfz4?R3GadnIgDX-kvM^IiOe-b>$pLHTvuW@^H_Q%V{kG1f)pud&pW z-Krqhyn>F7LSGYhf9@JgRQu_Ah5y@n6arLaA(C%jW62`ZJYEw@zZ3Mb@j5ynmOxzT zaQ|Q>o)evm#40nK!IW(lwB}d$JR$SI$tN>*+sLUrZsPf(g@gHmGHML<_^WdjNG5j~ zK4y_GW7hVXNmsCIA@k!>UABj;LbS^7!kZ`S28D{$DHn7f?Kv)I|7z{?`5>1{<#m;Hs6X1`9DH~}^n^YzH}WGL#e?(b z2I8TC^mtJtUQ`d65=`HJJkFtgXjwr?pe-RTxzp8OLD|Lp#z{<*yKL*A_OtNoi!(A> z%%JY{tL!x&@wHJe;jhtojm=C2YwMbPk0G^3ry|FW0M;suop1(WGa`05|JZv;V9vPs8|mKX{?o&kFM@8qLNUIu_@v-COkHLcZm1e^3`vfCyvt3u(okRp4!+5*<`z2T-F;K+7~|L5*>Ulw|61P?a$A` zVK1z-`wGt!TS#wC_g!0JNFMA5vmKn~72!K+MPCPnkON>DW7Mo|{{+ZMt^)tKS^O z^Rgoj^~XoSNhj|w39+iG(j9p7sK~~u9I0&n!Lg2`SMby zELwS-C9!Hs6t=-l+3;(9*}5M!VMO82d|h;iNM>XR7LkH1PPc?$2x|6o&(pIt{mBqh zJr|_?^(u9oi^B0VT|I5jruqh0HSF9fD@}ZXqX_B~!2PKzS(7K;y^D|A{}YR{sjw0c z{p#j|M?=lLhs(k8;ntSH`{-B&!^WxSrrFS|ApG{VC>5h~s(aCEIq@FZMWyCSc7(Jf z))1j`bN7obXwwvsR0v~{u1qS-y)KG`8n<<3of;vD znnlpmrW6d8?e7l>Kq4m6$zpG*d6;Mz2dLwcd|dU7Q}*I}%C|=AHiwgM6qA4{#%lB- z88L-FO9RPa!`{JU!gV)Gt)aZh1b0#GSwrMsu&I#-E5ImZmq4LB=Mo5~rH9~aWvRk5`d1Y#kZ_VbYv>bFKR zC~jvwle_?O$GKY8u>>gxV?Cc>XEI58!DzaES4ON-e77 zh@FO9hG`{R+g#kUH6s`Ih$LB5C0?4JiqSuIeB;zrcI{c@2)A`Xn1k=9C>7^{dran0 zU8>pN9=ZW9GLcA72;sZ&7yH;hnyj*rtfOZl5l;o}B-Z0Gu5^c|*C3zB{G}&ZZL`}! z+waM)qfu|y1myWR)QyK4CHa#OVD+sl_Iua`VBu?=| zY&5>k>3tP9=L5{5Ox7%{HB-*W4K;4}c?GC7xwQ*%8i`RlyRx(vDhVS9SJpHvWEH}0 zVeh)ytG@X`-exDW?Q=(sa}7&c&r%vKIZC!?P=7O)C@*29ldmeDk5^?j^N1Px+c?&# znPp-E2^f0h;vN@FT4sY1+94~rDaGA2qIhHbt@*NY6V*a9asBDV>D5B%p!W`+Q+4g% zBRd}OQQ>QuEZ$7nC;j^RR)%_t(C!xi$OyU!$4-dB*vZ+Wt&s-Men+h+;dFt z)Q)7jzd<9OmEO%aXRFuFpW63MC~-(Hc5R-wEY9JmrCcfV(^9LG3aw(5UR->mA3rSJ zjE(%YE+d+mE-#wtG$`b;z4%oc}*JNbEnNl4uUu&qgL zXDaee&Ju9OcGThk``iQB#k|AVoJ}>POBQ%vXtDAx`>R4?Ey_ACHpBI4~wrS z{)Q2MjbDt%*9eQX(3pnxfQK(@+A~j#D=@&v_H194MaBqM%B&jk%MdZNZuI;#;-7Et z2%HW5@kkxQO0(nfyD(jZ59&|FvhSg!#Dl)NsUj@xCU~`8U&Jv`v9;tMNSnP)ZqTyIyGFC%`3}a& zi5i*C>FUzi+vSvUHVG5Rx)t=egovqjx85s7J9){52A1QK4ib2aio9-;u6?Di_l)MriYsrD(^=qC$d!3J!3X9~w?e;?#03J|JQnKA?nK}9yIa^ygl zweNB_Zj0QRdp!)Ko4FJ^Ek9*HSP+ntjyii#k#}b>wHv=5L~4%vDM~?*_ zv2M3(s74=_?s?|<;JxIbibzr2D_8y!8qA??)4ea9KZd$3YluRz9;hp>V*&EOBqTHfHt$cn4;*T``!?|!?s`J1q#j)@nxJrYT!OtdEN zKO!|JOugcyNMeu6Mo#e}#bB)3<9obGI^OLKnqw?daoQNGmLHJP#p2`ySOZN^|pHn3!eahc3e?y}0u8to*R zBIuXSO@qamCl2(W8rHBVnJrc0CChY*;SWh;aJ@_}G^3AuG56gictnJtRq}8o{@Zpw zyUANcf|97=n1@`7lI$=XYdw#pt?9F!{$dRxmzQNeVZLoKh%ydS9|aZZNk!^nlJ@e; z7pybeELN5@k<7kXZ<_>)M*b8uRBaKlJB6Z&DD74}%$9RSV`5a6)ST}p)f!KI{mk>| zLHY-u$dKclG5yLCy-aQ7RupYylA{_vMMuL z?~H`&N_Y+9Lw`MY+8RVrDS~FBlF82V%~udGb>&9J(&b{EzkJLk`5;MDqBoeMYB8cL z86S5xIZz_f*Foo;@m|steLkcTvY0wvA6`A`#6SiNGq35t6|YDA)Dz0sl*| z;&69H2UyW;ZQMY(?psb`6Em(Hmuec@l6{UoH@gza??O7_@~+$m5p>sB=eh>2$iC9_tmp(t`{|;-#9A5{PNw zh}`d~Q z^0H&)N8-Z<_YVSRH{)*zLRIuXv9v!9p&AUk5{=x_f z*MFevwzk5k!;0qLZ`|+aGYJ(bdk{u8fF&L6FR5#an%!4$k8=8KDDS={*$dnJ0B-vxL?3lRBv9XhJSQO};ZOwu z*|!9Fs^dvmGv!g~J;-YdQtf+`SQMg6*;02ww~x~^<1kOf6RQ+=Cq%$Gznar&x--Z? z!$F42A(I>zwhz5w?nal5aZx1d$zu0TPZ^i|n5ixl!Y$*TMK zU4XS42GPJziQLljk;oZ)u6h5&jLqwLTLb5>ao$G{vOiGW3t!9ObVXQfg(2D*o$4P3 z@cOL&2z=PE1*YJATRK1L(i-iv%qidtE_W}t-3H?yec?J5&;6Bj+~9mE;-Q+6bPyPw z@6r|`;cJQ;2H}2aihBfsulbj~^Wr+O?p**+0m{#sV-aLXj~sbUn-2`p%xF^o5Y>e& z%ptc;`gL-Kwa4j2pBoPp@)DXv2bIMkN2To%p*iPIG(+AjTMxr0r96)fSk(kiM|Q%% z2&E4!Gs)51Rb(UEn8aqLLaQeuIn(di5NhIz4goaEk=>+aX zGWuvkZ?+bP9BOVG)@A>R)P;8jW|;aKk9*ShXnCT(#Tn7QOARd#)ReM4r)drkkpS^8ZO`jH#;@7sVu6vcTL2;dJrv(q;Fp(umf$hj02~oScYUXM%?5Pe;^? z#pr~Y5(f{oJ(QNH`RE?f1%z-eIY~}R9D@q$XYoaU2WBv1{O#6CjD(|E_zpEWsdQXB zf7rGEs4tp*j61@NopNAayF;-Dea1_cEP5H|%1*_2A@V$xO@9zWriY`quJGVH=CtiI zk+CCbS&z*ubjIj}Cx`upVKhj-a_QZ_y1Nr;Xx!eRE>^w740x9qWvI>7Ie0)q6G#Kf zh)C3A6yheQX=qv=$?C>bC@9H)*jcR_=^8<)5;qB=14%FyS~?LO6-zg&crC71%xZnZ zFlI#ivx!BX1e{mq0eJ(7u#~d`y{!k*^8qMH&u=a)*gnV5LH`A;NP+Bw5jFWUC^)c? z@P;HTX_qp(=`oFn1zl+`Q>8XzjHrp9VZn`uGz5TXs0}h)OuTBa z-x@>FE`k_IY z2@s1HQg%-f!neQ5FYKe*rQ~x)Pgx0c4~k>G5&N6cbqR@V&(BW&hC-iFpbT7Y*hyauy%*R$cS2csfDKiS)~3^)n4_aAMLuRNsqS z5_De&l8+;vb-zHW(l z^9-pK;|z)9aGw`nUsKm~nLS?B<*%3aSqSl<*kz6xJA${gcTXp!<#*!W*zq)V`NsR7 zDKbvE8&*;F4=~vnbuiBuJANWG?IJ3t*w7vKiwWZ$|B{pWHU5j0iVwv-^ts%NQ4LMq z(-!on3VrMw;9d5;&EHHKo1(uu?ypiGs~8a>2+)=qi9Jo-A1_Zxu2$5uO7)u4^Zs>x z>P5qA`_#LRKJWl2)4erj+i}0I1GN-8MNpK4shU&~Xm*#}V z0?CWQld1Ac=q`PDqpKa}$s^-9XZnJQhS%@SvlBRnS3>M$&wB#iw(5RjYu9a9BR6;| zp@ujm7A(tivVws-r6qk1?iuzT+(TD~@YC#QXK9@)6_hd|>jy>O^DPrWAIb5F#8cCp zv?_cs!S*ezBGz*xx~n!DjIvzt(e(NGQ2as-WMAN`YOXu-XwE;0d#&KOc=hAmhjhId z4|h-dKYw=*ZI0&0JO1EPmqlFlbrU{*U`C~CV-YLZhrZbGjD_j)nClOncUN>J^wbt3B2>nd6^_QGwBI0|Np-G+M~><7&9_ zGjr2knLZESfH6^C^R5&&8d>8>9FsLndo=NTe)VH^AM4x2gKChb1>co7cnX#OPIyK% zH5vATDSq7pl-^Bo!NTPDg&`9&%xU61AHIv;dAtWnt%8TNM8B)6fMQkmbgnFeE<(L@ zOqVA=VRuOY@gze(Y^sYfwt_1o`{y6T0P2*grUSDnv}5e{rZKzjCa~N#(ln9%q-Lqo zuj+|6&kT|t=edItRevVXWv}j)i;3RfLT(%;Uqd?Zc_hPbPDQZ$-X0#1T$ArLh>4LL zgew!6n`TP)X$=(@ZV6h=jC68lUBbl&`UR9)(FH_Sqysi?vO_iw<;Q!%RVWKGJDSwQ zuGJ%NNET5F?Hr>dxXMIDfkQD^4HhZYLz?_4&dMJw+fH1##(d|da0Y+IC8;k z5V4w$55NO#>4@O%(^UKR)XB2WL*tF&Q_K%Q;HQv@5qf*lMQY%2!`;O$hY zN&b;wHk!x$slzBzqCrg6#y1m7Le2f39dd|kfw=!2}?emY)f6?Ye%N-X{9*l z|2u_55>d*qGNond6S}vVlzS81qwWf1bpg8q=!sHTxlL7w;0A~|4E%5exUbv zVz=N!*4XskKPCye2Do#UWH2f|L>QGA#feFDfPvtf%($w99m6h)u1#9dicVTKm|ArC zS2<2-TNY%Ij0}=Fro@y@CHDB3MnlQ0d^4DRW4AGT{?o0IJJIW2Zg`@ z5QNb&z|tuq^q*2_h6?m{DD}RZ!nba&5)oWe@%6`y@C3gJ4tM=GtXtPV73*)n>d>;Z zjU5g1J}wss{~!P`;P(4LRi8%JPDI$mqv7v?@I2|}nP$u~yYoEGp|Ai&n=XIFBUo%q zM#a=gl7rswsVjVgh(ngx+!NAII!U38kY`B9d2b_>2bH)4#17);Naw5OV=qe$BUa~d z{xALyd;~_F^y0lI8$t}>CtRwav8?&ebD%l==Q(8imFkjr%pJd|<@UxA=4df044hbD zoLG?E1(2LrKMM#Tzv4>UA6a@MOC?bFLzHR(Y3!h0;Jyir89Oq_x|39)p!znw`3Ye7?*+=hx)Qho93C+pa6~n z5^c{4MSU(JCxznaP#^qQiEA{fyBmv`)^vk%-@Eg7HXfNlg2$k!yKV(er=R4$nMWp} zhBe|TAk8ti=vIP%X{4_>2*vK#_Af3ZQkbDf_7>PSzcu`yl+A;&g*R5hBWBWhloaj_ z1lZDR^X&|Zh_|?Y@dk=9Ndd!GNu6gl#Ta?8q+@94ach-xeA?5~udSsEtq_bk~14EfAIDx`zS`W#|r@sAqO4^J$PzeI_5P=vFF+Ykx z5}2n=S7*vl5nn$6LXtl8U=5=Vw3Yv@Xa89DVy#Z5cbG{i44N3!$u^T|)0g7Oe|3EvjafM-4| z;XQ&v9Z8z3>(cVpL43E3BFL1LbnTk^gm%f*zUA`0JxNVKVJ1f@f(39==2Bu$luyNsb3W~us$IXn&b_)`Pu1+e`DMn==&|L?!Tq5p1+ zaYGSaS<3y(=J5JtcnTHnoWAb;;%l7qkh4|cx#=cmJh(EZ8}#LU9Xv@sLXrr$J!Xr| zKP@#iyP@;xr{=xH9-#|Itx;@gu#iGB>NZ^XF+B8x?rh=>17&?y#xpW(z_Q%7!%@3k z-=^-kFsqli8-t2ruW-M1$qcldLs>GoXV*S=4G(2!Eni^2ftYHGQQ+juNVTcT7O~kw zTN>|etG$3wi4mRr_%X~5w_VxfxveVDwru7@`)o=qje!yd!U4Z1+|U*t4*g~sM7rDH zip%zUt(?+8cYa@i2b#eGV$UFTQCITCG-(wR0SxFQD#QC@_(e?0V1dq3G++D@G|n}B z+g!6p>zE!4DUlHrFtT8fe*OZ^5+MCjciyAT!DFH-JSa)GlROEu8Ab@aAH0aj)Mu0s zlz1oV_x`CTuYX2$p@o(b;aS!$R) zHZw!wCi1tH%iggVTaMZBH`)^QOtafad3{?r`U$YxwBPUHM!bw5|CdkR4sJ@mxhm3V znU_T}G)jt^SLAJsGVwar@1$Ud0MS#t0n@Rv>l`ckt9rjNXv%_Chsw*Zw z$tVp4&Rn1{E%eV}wQ0HAl2SLgA2+Ppae*$dP+CtywaT&AesAwJ%zs*wjV#I zMcr5u;f4L7tp|9-u4~r_c;uoGfzTQROIiPu4MKr_QuuN5k=z|;j6NfSn58!#XE*t^ zA1Usm-kzZ(PCJF5n7iuHb6Y(eIk9Ye8VO&bpH8_OZj<~ONkH|=f^4Bb z?AY?re_7rxWk~9TOt<9B#=$##o(^vzO(`$be~MX|Qz@dW#D#*cO-VMuS;1Q+>7c3f zD>a1!6RVikA$7HQ->v;Z<6HaY!2Z@kRoPPlcTiD>IB&bICGhuw6)qV`#RLM$^tyk{ zeKhgg!dGz%*gi}3vB$<|eBS#VW9;ZUKzD2U#lKB!OqFx7wjI8npWSu*v|c)E7BAKZ zpnOT7prYW3aOdhY#gxunf}Vynz{3#nq@{3VN=$&Fl>(i$BQ>W2%W;S^)Ec*5-hWnJ zL$;3{TdmYUt^&)h*nS&y$ZgOer;^P{;=%5}PE1RAlhyqEuig6y%wi%^I!r>SkY?+O z)ijKmw!`3+`#%p*5*x3d)Z`%XeDS1fCE!m_{0OJ}YrHAuVb0qU13Uom@){PbLGAQ) z?Q21BN-Tl#w_Q@F4*@{(z<&^lY*K(nH#r<g z+##P-#M`21`eyx!N3nz@g}@2lF%}#MZo7ku&OeXj4+Cu{%KA$GWAL2ETPx6cGXLp3 zNdY-f?5rQl9^F;u4g9Q{m+REOkYT|yj>i9D5p4rd>^^P(z4}G&Yw&YwZ*D;q01t4q zR>DBK0dZvkWpVAjwXV$h&jonD6#u7RLb2t{A(GQxRg-K*=1NJDgR=KvbV;Z+>OPGY z3ZNCWEy$0S{7^evcxFm*5hM~XcGu#IK#NB@(cH`aa7W;N^9D0;hn2$70~`th^k4>w zAAyFxzOovG4ycfBYxIt=*X4XsH!%0nLK!Qlf)~Xt0A2gE{PrLjIc~@AU}W(i|0M*R z<&ccXzL-AWH@GY}!*CysHyN2w49x8+#lWsq|HT=Km^~Lt4 zB;&ZJj#*VT90ab5%k`NX{y)mOAuZQNenLn-FhF%e_%1tVnNhAS?hRx~cXbK~W`MN< zP*n~kvwhfvKj6}K4hK~uw>`)P4ytf#-@BzqVa1*-Hmg{u zzEU>V^oL`5DOU3uIR0i?y2an%w?77Iy0rZF&Mn+;e${qmzyZsg;Us9Dt9jZb#I2xp z`f4?+UEVtdW$RQH3h!^bpQT3avU8V>o3ritsLCz?*BOI$$JqayWzNZu+BK-1z0`dA z({RzP*WL^Q=g3olNgUMppp5MlatqT}JD=!@p#lrz@= zP3YetxN6{#wj{~sZ`As=hqrKIF9M6fC5{qauipFvSZ-hc*ivXWC|Jn6^EL5RqaeWHi3bAw zbRf%|Pj<8@(enFGM718K0_+Rb@vdVa& z-{>7wF^x_Chc4V&KKaLTnE+YXY#O7yb?XYFVw>zCQ}zEx$lxQTciar5)PNeNGfeFC}xmr_y#3<1gc zs(e^#+q%NX50EXWgQ=+9d~XMz{M@&KGvSg#>!fQwD@@qG2^85+^Ec+zWm#8@7JgIk zm29N-0q*|~wAYwA;!0qsmeZhk=g;XtTi2KJC8Aeq>082fDej}Q-DKgC#y2LLsca<(5XpgfN4=%^?dc}&YmXfZY9~ArOdAVM|jYmPDy~E{{+LdgFnl61!z%5bt)uT zbT{rJJaXn~O;ooF1^%xraJEHf`_u)Krx8Bi` z;2FQWCiMSoFNRr+@}F?g2>chflG=8gFE+muIvm=0%J(B-|K?W=0@&}SU|)wPrgO0q z90WGaho+eSf83a|we6u*x@`yMx&8OP)l1U3!$6~G=PAt2n}q(G9J`K;4qcfbk5tXS zib&asN26?ghr@FN7!%zOvKi1Wb1Pzxzjh8e z1q(P8(4M@Fcxs62Ph?;#3kz;+BUz^T^U{S3pr5T+SUdIdksN+)pbby206}PNASY;R zKWe(PKkj`#IE*4LmFLyz5#Uip@=Cq8OP2^~+f_X{g%yNF2H6zBzG}Jt5POHKm9ZteV71SLf6vlnh@_b+zUpx60#o#C?)XGwehL{5Gc^Jx9)NQytlW8Guu2`}$ zQ&ca$I%U8lp#8+F~*KPsIi!~%B= zKPO7wH$>oD+%f?SBQ0uJg)y;WG)X*j36{O5_rB=84Utdr>q%jf!bWz!km`3X{MU2p$-9ooDH!dV@OFKJs=)vaAh@fD-N!{(_Xi%U(zkM~=X9DzU(+ zxMhV}p1~oQATUfFVf#1U(?OaC3SnWqf0T4-h3)x2)Z{-$(?Qiiq5~>eHTWxv zl05$%dJj7R7f@Eq6e>G0H76ed%6Vsh>dtKaF7<4O?+}fCx?xjxy-d)xt1-1sx6JkI)-Z$?#&?96PHXvRgax)%`j`# z(=A&lBJB5A>N;bc2LvWRwk=0BMZFq7B*<3u?cUUVU-%v_hD}TW$CPZCOsy7noT?lr z#|t@cb40;sLrTvZx(LlcCGA3%KbQD z)M(=tA3wYV3Z5D`EHLWuC=0N;1eB`sOt*68i&PU+>urF<+y%&aDFnh|@eL|0S(O-W z6|dV5msJS6;Z6rm`39Wcsyj=WY4XbDXsi^XI)rheSr(ilJRuC1#F#D9u{5UexirM~ zCstrPDOMDJ1F}XHCiQXuZ;paHRsNlc#qt|BSmB+b+4tco(*G|DiS$5To=UB6nWXHZ zOyS2CEJN*+hAu~5ZNGD>MbSumUj7A8}^` zA3OQox9z{&VNW&ChJ6Gk(-c>i?_h-jccJc^kw>?~jekJgS87JJHn+w8lN9_w>@VM4 zV7@BcDGWU6NqTS{U+s=|jz8d16JsY{x#+ApDJ@>Z#8JCr6JHTIai%OKMltzjZ>L!0 zg>h?9wYQ)}^-gBz;6^sKaQa+n{b%J`RW(u&BXcY64mXe8&Nv9T+vUd|{4hRSaBA+S z1Ot?%2i&(xLdcyq`=;mCEBNzmES^TY|L*l7ZV=t6Cc8oI{tUaPa~~y?QUi$B`rv}| zE!+pX@tVEux;gp;=Vg^SgpT4uuQlIJMf*D_S97P*!bN=FN~~t< z?4bpr^Dgb%h7ZOM;HggL@WYfu`D(s^;Sb65MDMP0eCI8t{XYp9?wZrt-DfZ#-I}Y| zbSQRl&om&Wh&F^u#hP&8`U~$U6xou{i}y>M^ZKyR+8r+c1IOj1La(w)tCEHOx_n32 zE`*BGSDF9hzH$cD;1=kz-RZ&U{Mg0wRlhlfUX`F5a3tVyH{@1mD?hdXiri8G5jP;W z`~Bj;JAsS1mWEeZ#c$Sc4|c!w_FxTcF4;52QM(_`X*!(d---!e?!<(T5MMlQ$=$F5 z2&mZ)65!i(}hfu*NrzGLloGqRX2p&-sMPwIG6z2qL(&rE~+lx9Zl8#H&oKEGkwJy=swxb zo2F?A8X(t1MMVN2yK?{%-N8FmvFO}@-;Hz5r3M<&nE_c1+8Y0Lx?o@~j@_djxENt^ z`b+O0GI4TCCR`Pew&B41nL%=Hg2U~k^S?JOJVhgc4S_$%t!$%wC)TO&Ifo!8AP8aC({hxg*B zqiaq#yS&T2y_^4Tm0h@bJ)SdhIdB`j60XYcMmj*;(NyAX+H3L$9i*hG&h2K?@N{u* zcnGPMLQspgPkmG4{6+R(RL-l7AkE4~t^Oa!9Sxv*GmZ!`9ufHpE_o%A+@Yp3l zXM~4Fe_y28774jDE3w&}-pqw1UdNx;|78t(5xYC8a|*LQ`tx&q{AcQUot{AUC!ubh z*H&RdWF%uZ7~K;pPb4V`qQjcTkbm~Q@ZeQW%~;ZV%2v$g)i7gw?cq2Z)?_2DbA6V7 zgT2o?&%ZPpICy2{bLoGDx;{WNFW+zG79q_(;6^5W3yBG*IRSQvHW53^DVdd0SD`=FtuOc36l0cgDJ|HJsitZ3ipN_xI~=>hlIu zpDGc1{!Sc|Ftoe*eeHg95pp$uecsmp=c4)2<^Hc6rw6QauM2iFMn;)CS#v&sOQ-Je zH}@%mvxxslMND>!OEW`>_$Q_ zPX8hpuDA;woXtPFNi4Y@krD z_L5|;p5cUkjADy$k6sA=nP0a5eM-(!-<`HFzv~^hcRlrPtv;(rXX&S`p{0+(sOtu;Mxg+>c*Iir zYA6BUtr9~t&HK`|bb3cfTUU=|DRM+P+orln=vR8wS}irJaTf3wPLCYn-*mmz^z@~# zXr7WUaz0NpvF>p^l;!TMUw7dok6V1_;`#UbFkxBhdb(pLkU`W|*RwA5jGpUFVl0av z-IuIEU%Gt?JpIIYx`ufaP4NEDWQR+dap!_5ue$ohX=wwvYACQuI#`uVg<(;CmCxj- zA5`c2TnJSx-7&l2EE`HlJvQOmSTk-RXa2F@=U2tMWdCCo*02w9cLIWA)tHfgw@C5h-b4#`8bt6kjRc+?hmcQCk zfp(Zq$BBJzV}J}kihv&*YkJ<{!rGwy{AV`Zb|Rf$bY>V1j`(z|);)BT))aK(Sj(A2 z?a{J2e3fUTe4k$%3mPoxxd{1t7HjKiFYKmC*Sgi;jbRQ*uQn4h4zI$NG}d3=K8+29B9bK#jahWo{qD_Z@nA;ns~pfY}QGq zediPW(8iK<*0!@Cg~}r6%aJOUj-0s8lkZ4tE;WuTvB<3{u|~(vGl|usWfmkOW}}*) z-;Dq5d#aws`&8)Uqz6f;^N>=AgRRkri$P0TKK&6^d&A|%RbW4*yEtnPKhk0_pp?=(6u(3SvE?VhYzUc8>C{~_wZ9 z_a2>GxD+>e{xRC>GFLBi3A;I2pS(V8kLlcD6Fk+C;<76|;G7Uidi_GCXf#v-5lIAh z2upmPNS_LwwUUG|=aO%;s*qFicU!*dvXQd#`jcX>4GLp;G4jeI&Q|WnQY{oh9D4cFT>+ znybbv7O`J1V%PMM4OP*bqq*KFRd+18q;kC>pqrOwIOlo;8LqoltXa!sjFYSj@YREV z0VD*$Yh0=rOlbF$-FSo5o%yiV$Bra!lJ-~mJiw#-Qa<;fBlJ4p*K52&l)s|QUX(>z zN4F22>ju}yH`N^o?r+^Zx*BjK2+2(O6y&A*Mw5Qn3DDSodACxCDM^4V#R0_p?$aLWwb+<{>#pwGTOU!I*)q-)@-SQg(5$0IyvPaj@iXhitUsHxrEjsoBwwuUuY8Y^b>1O5}<% zYtaqISUGmbcT?&a%l%{c_H7>y6`!+!?MHZVg-DbJqmGyrTl~r^pM=Gf`5mwFg#ia; zQa%r(i}Rww)!a9uB;t=>svdDAQForrEe&6AFg3$mR)3tEZWGeF$1hdRxMfCU>~S+@ z`Qv+0W$^PP36igT^zaM7Vl7QuNE(0xo%CPgcYH&i+SSNT@htqbZp9tas2?BcNhVbW z;N7;ER9SY})6@<2qk0c-M{n3sLf`M%`wpcpXE*UgFm=e&(d&w@7kUa$=)gU#CcGTv zciy3%8_&`t9tH<(dhx!)7b@QI&CX+N%Z?hO&V~mb`MndhwBCE1Yo)gI;f(8IyyvAU zHF`UGah_xwcS~;EF3Aw+nY_q<^Zv=XXX!%vv&^~gh-%;(Yzv+;vL_k`Lh42~k;ECz zBOgD4GUOKUxs-hzM1+DtQ$&(O1in#Gf};b{t2fR&t7ueR7_8tZ5QZ^W^AV8U7T6AK zS@u3SHpd0@5jSlH2u3@BZ|A5#_D|Oh$=Ku1t7JT^Ao3Fg|ABZ0-EQ|-Eo~TVH^X+_ zopGIpuYo`z6YB9uX%u~Go2>{|=xf}QbI4Z0 z$?nc3>*o2`l+1wpS90QN`DEov@Ah6sjm<^&X8JUCuA zr;2ClzsWA}SJ3b59q9$omw%GGNFpoqbWP9*c1PQ!ElFqZ=|nFcuy^bxl}p`m+Q zb-U+ehTy)9iFWZ$liAN6shLtHBb}foMBjA3i!#BE0`O9OU$w4Pp}NYG`I+@G^}p-X z;1zY`ywd=Wd(h0n2PBuCUsgkMl`XAgy|Kv8E%b_%y|{7SMKLQtlL z6QWBBl%YybMW;A0A@1~MW(&a=ZH__fpXPq#&GAgtGXRu7aDAMJCa}WBD+A9LFXcq8RU=;>C6HBccMicAaTTZsWkWF^#MV#p%O;eGihS!j>yd)RDNmx{g~Wq69IGQvs8J^6-DS zddsM|nxI>F26qN`7zmo+9)b++7Tn#PKyY_UummT#LvVK|NC-{{9^Bo@Jv{Gw@3+?X zhr!nA(^b_aySjI?NCpJ@#xQ_=;lDwHoN|QynwI`hZktC?07ofr`=|&(jZ^c&BiKSK zGJ!y0-!0dU0>L*>ii_y*0Vm(9Dr| zT7RsgRL{s)(g~cCTYdHnt>TsArmY7Wak_L$@F>w@Zz$7GA7%D1mNNnFovZt5X%125 zAF7ao37A2vLQXpi#Qb9zJsi1=kJu*pWBYXqiG%Y!V7E%LCcUEJE z219BMLLx!=;pZ!{hf7I?S;%&&96S}dryR&9&V+io`O2%bwx{r=xNZ+Jj^u-Ui)c#g zF!qf3RXG`#i`5>0;VJ+2HQWYEHo_X9bcA+`FYZqFLn9|UpOdDIszHrk!uw>{>?-R2 zZtnxxPa`fL7{MZhC7X3mby_7)>}J*RLEJZD{}aSM*=KSHV*H8+k<^|i9S&vC*lY%W zOhJvk;%eLB=5UqUCSwf8_=oPQ#2NL%`%giE#(XD{I(=^>wN1U%inWyz{{g_K6 z-4=JHeNCPBNt^|Ilka`V3W38hfGK_1!0fjk*u_ju<1_Y@@5Vk6Pfr}td?$oRNT`Ew zMqT;-lVRZhXHrZ8Fup}^=?+#Oj~Q8Xh@K5Mc?aBd{XW1a0C|H0r&7EnED`L+&>0e583|m$$sP;?eQ+_R)D62ZK`)ycm|5{Y#(yO-7bXA4m zp=6_1#p2d&01-HB8SZmm@I}y~XF@F$(;pAbo#=9Vm z{;0dBCjyhZo%f6K!Y_V}7<9$9qp5pM7Ot)%+t4fd+uPFT`Jq6LAvhCh|~T1;p1 z6w|Nq{xc1oZtRVVQ=T_#d=+$mrd}6jGI?dHx4iStzl9i)BR)b=yS3cGBEztm2$oa3 z!tZ{9#w~Am*JmE>?9uKt-nU=}*WM8*r!;EH;$PZL*XtGU<)M|qy1KFhiTs%E1iFg8 zQX!ama?G7C>9BNdu`C@+)ijC;$$9F0()Ew0#bUceWp9UtM>w$X{sc~Y9`mvZ8+4su z3+_AGH+Q6w2@82sUQxugHXx1kbN#9}{8jRf8?gj_Su7vx%7T7hr8TrPz0mf-$JL8T zF+Y@pKC@isycsMiWDA_zZx;8!8=yc5Z-zhfYR;Iw)>|=k1kOOIkL(v#`6dwdM>KDi z93jhsj?3&GM8h|w$9Ffjbd4ThrBd3(x~|`|fun`mvX~+$KajMabl|_fUQZcxsB{>+ zttMeL)GgyQO0*ha)0aDvj&WpAs{TRa5BVltt%K9GwamSucOv=QBv&5cb!Ii<8FdeT z^etcs)%!I5@#}ZrQ>d<=9-g0dE|edhjCiLg8mS-7HXOUW{4So^GMrWphi#VN_B2T; z;U{!YTEC~#0+~o+RY4UMf<+Q*HtX3RL3s+EwanG~xsk#T7tHSdFe-`aPpvccGZ{QH zA}(_pnvWs3f^*}qpIPkoJZ?BzR|zEb%yvsPD?A%N;!@Rq%HN=(1y__;-6E5yU>>C? z>B5%e@=f#!;^lP2qf&u-zY!M)Q{ss|+%i`Lip-MorLNt0$iZ=eEe=Rf?u8ySUyKwORT8HSqqP8M27i7>IxK z4yoOkMHsUyvic)DH{;P@xPeW!r6BWe>|8Yl7H2?8&KPXo8Fj#U2i+*8KmnE%yDNbp zmS3p$tx7P%*CVg8fK;SKvlK7zRClCa7Qa^(O3Z8jaD&J5XrC|oi z5f1G)H`O2mp5OJ{cQCG%;&CFf zylk+d&+yfuf*Wp-&rIoZC?lS29Po0wbeur=dynon(4_Ui&=#{a`n0|Gv+3cWaFK8e zYgo!YZojB_+u4-;>}%{496-uqI8)f0h-kxu1m2fJVUr5!9>;(i(j{NP6sBuuUfdnq z&Q6cofcJch6#}A->O=Q~!(fXyQTcZKYs8K8xInocoN zRh9v8Qp{;t`9_yd^-}c4?6{uIfGv~dC483s>o7j}EQpi=AF0yn_l4~j=nsnEp$ktk7-vha_3 zR66~;9f|k7CQ%Tl6Q+b@+MZp6Ja|`6P2CU~Mw7Ugq^U#3y#bubKaJt7O zKtpS>Plw&|p@j(u{r`KC4!g`?Jav^5*>6!B@@zd3S zd(w?U0tLISZifKmVE*m9_m6#BSGb#u;GC;QpXU0hn@0LvJAtyYE^HcNX(PG4^b)I$ z*m8W(c{s1}9|e$eJKbu8B$G~_T~#+fP@L0(W6KFau<(8~jN!&FNCUrI3yfCemm+*@ zLL9Y?$-W~8PSI7U3;clRuTXCte6uQ)&S%n6k#GC3_eJh}3bB3G8U!WYj8lbo=ECgG zGSj+Eym@wf?fu&KgzCl6Cqe%iIwr^*MnG&NU=w8bCN6x_fK1l?gFRY{W*!*u1zWlu zNNaKvD9(FU2=OVr>Axp&mK8JYzL0_RUOc<(KzD29JR2=b8jYY1!trf~abk+GDe<>Yz+f1|P=9VEKw8B^T%xgZ%IssT`P zx=VSe@tXd_l-9Vv5k*)Ume(t@CA?C|bolZfwi1tIpCJqW6!366mm&jpENft_UmeDdd zFMK>!lIi;Q`8VK`%MyeAA<06k(Z%xR6FIN%UswZv_~$o2e~UL(PwPbGvX9|MmTUVJI31L)J;Z^Fv07pp8>}A_+g< zI0#|Z0N_ncqOJdoXbU8!*ykB&MqO+>u{k>3+{^@eUB$2Cn^+!Hrc~;9(n-x8k%=qy z4$Iqw&L-c67{{^?;s)@&IrC^oTnRDMdT+GN5KwgbMH@mz6Pw=;L>rWH)-z<1$?|8m ztop!)FH(Iqsafh3_>me1VMwTHZElfV&lR^-D$b$u1AKIXP;-Dn(0kLMtJ{02?h-&H0gG)<4%d!D1_g8U6AOVvEu-1|X9s{ypI*<%BtykZym%nKny+mJ3u!6lC=u}S-XqLxx5iepnajJ zOZ$CuyH^(tO!IvwknviXUuE1pB#uA$0X*b?3oCP#bj1L<=vk<~$YrUbWc9*nenser zXuZ;Qbb(#CpG;a6Slp+Y1~b^4f!?+GO1f*m-fTz)$X1H%*Xvi!I<1_@ z^Pb%7W!wM+qTatX)%LN2Ip&GwpPnjaRxb#Bu`}9|+xJqYxm4HdSt7Ap237X~L04&{ z+=pO9O*gXruiras1U4%1Dl06>F@qqa27yR8ukG}Wf6MimAf)hU3b?ue zr)$zQ^FRP|Z_&VXAq!SKRv?a^Re_V+W+6S+kIMoC&VkirLM zFtCTURlrG?Def+764BnL=HJ=+RVQoEl1;E$tD=XVBwsSE9N#S}bXg@lWxngUZLe3E z=!Rmnv#q7$n($!Gn((Rh#5$%v*%6&rjhbZd z&@y_YMAU$L8sJJ;4CDl(dMBbpF%e&tx(c6UF$74c-Ua(%r;wc61R^fe8E2Hke+1BdU!=<^2K zGSBMDrPIdBRhzIcgZX@E4BKB#GQn2|6)K&xv`D}vlMqBWFj{m)YTjgV3f0ZS z_&0zx`0zVXq;wiwZ&anzAmX(1fE${C-!~~ZwzDaU&J_OBeTASg7py=AtM1K8!jqwj z8afTzH=xfw_%K<}sjVV7*~DS3lG~HAWbVoSeTFOGL{HJw;qmbiDNFi?y7Mc7;ZI{{ z#mKK+F|zfFOVnZ!-{gNMVxx=F$|dMl3hm#VMpKxch#b<_IKKb(Sz1mIsS-p7?k}H3 zQwcXqTRYM~ZZ5Q%`Onp|0r_-I>kos8YfxsgqmK9V99Vs zJw}WVpN!C5p~(RwK}zlLxnG{PItdrO+VbZe+UxP|l?&NeA2a^WqjLw)z`4C)$5v6f ztf`$6OvTO2q&u9Qt=ke&I{k`}MpmZcLu5u=sm)j$5i?Ya+zDH2Y?%MQn;*!gyt zU(XJc8gUGh-u(fPhIO=LgoS*LUX5%wzSfq9-*&I!XvPT%+Z;)IbIA!*wfE3i!#oF;mc z0xC==h(rNYXoFwSCl8+-KH2rxW6qPQfNu&fG=B@u)du=vd};ja`+}ikL6|5zmZ6(0 zZ?&XI*X2-(i)@#~dVyiqi3Jgo5g=7_;sCg6RM;vU4Ra{0VJE24u^4ukDJp{4BHn`! zYxPSs4v^KN@hbMP>{?wKBYy8GZLJC->_H=Qbb&DF%jZ%y`xb>!__M9Q6wgZDg$XSY z`B)3mEHOFobd}0EQ5cCOa|W4)(Y+Pe<_%`3nd7gEdVpL`H^?tAxHdu457d)PgJ+Yh zQXN?TKP>z*2R`{6_;t|#=e~W=gY%71whW8QisMp8LS~^mh9D`j^WNeZ<-Gc0STEQrT=4LaP{R(`Lv5e^lO;0s3UZBMxKi-2N z>MO&GwG3q9=H+vkuy8AA))rFecTsAfl^Yk zssOYfM7tp<)d?w6#^tK$Fm@!ed|jxeZO|Ian-f0Q(<1Xim{t`&fH*Gj&%nha1Xk*@ zfJolYmNax;vFW*KE9zy6t3_7hrU8}qD-0l8bdp*`5Np!gnaLYtWt7aprn&tBtP@~g zi_sTeFi+QveY$O*>P-dr#g?=FhU{f*^fWWF3<+HIw>h$K6WhDE)b}(Y-ix=>~lh!Vj29N>> z?*$6Nh2_=qiQ1bVhVdQuZW?F%B9YiQgVZ=cx@aznww> zc1{O>AqGPkGmK{=@D-T05!6=fJ0P83CU`3`QKhm30Uw9(ip{+zrkff*Yqphola%GPczWI#fp(7n4S8Y80KgY`>WDOn}-?O`X zuOq-g*iU!n)2VF#cqM(^U6kYIhz{aP*GXn|wn$A%hURNtI4SJ_>_LDL#qYZ1)xp-l z_QBGVGGEg-A{Ch^M8#?Qj%0^vR%W8f2(tK}Wiy4CEjp~t6oI{RHK6{TTxWVhlojvu z^%U<#*Pi2z53>pZV$qk)o8ZEjL3h#6ehip%LF3Z1(DiA8Hwzn2JgWcv`@jEXj(DP7<>Lrd28Bb zOs@+uQreTH$o8`tf5X@%^j0E~tTRxN5}We=lpkx=Gm2&`w%@DQMVLdV^5VqV0gUW- z86tdq5Nr{ySM&b&P&D`E-`+u609UHUO?a{PSW(*eWSO@4aDE zlF-<8?#$sM=bL^UO&eSQ4GJAsfE&?OUO}7wXUpV;-2~UmuK=tiXvJ?@5DDe=J~6$i zbXG0w1>**5Eenc8g$q7-+M~&8n&JiKERbsgqQIB#L;P06hP7G*=+)WsSeiVD?i;019C zK0P~mWDup?L@>>J08V62YG!-u>gfp6GgjXQKlaKx$Y3fTPT`UM5Pq|SB6_{?qf z=){Q)*wE9wqHm!8ul}EVz*W$_jsI2rt~pNkt%IE}UxUCSYN=Ed2&fWx?%)3)ff?Wz z>lShWtFeUl0}`#%Rr6jGCX+zhvJ$7-x?U|*xPUZ*3owu}jd$?SzHiqLU6;~z0q!mV zXPc7J_49lu|7!2H$63uDjvJ)gDOlrrE_QMFF+WPUKHDAqOnR%-K( zc$1k}i=f_Yf9JhEHHS?8XMHKEukt-3;8UG5P!SWGs@jdlrt+AAm$Z#E_$>gipxFfl z5sDh9*PsI8%)zAYa+`u%&?Lo_K1jK&TK=ymHTr_IF6^_w%jzIm+o-+Y2X)lT8ou6@ z{zW72+tC*{@aO-zffOqh z%H0_N?vN0Dfji2zAhd;0Si7oW58R3jVvkCg4bX}4ELVrXd?{Bf(SrYe=bcv^sULR$ zwiJC&Z3N={3P1jT!A(~bM1p&EUHF~wv~enj-!fHiFa!NeGY<+R{_V4GP--PaS~hA8J(*f*s^li8#PB#8?t>KKWk>TXe3&u1i%CbXY~+WM_yY?&KpIv^5k9e zF29Dd8La8WX~c6goB5j6qy0|Pm^}ZQ;PXph@$2rHBPTxk!Cdfdpc6}k1}L%rE?gMA zO*VXLA-jI`)S1!fuHy6Y;%w96#=I4qkht~P`}{IxX{)TUVQ^48wEVtqW|+^}ObzyS zl8k#xg~;+fRzcqvN0u!j?SO@dadeMUbhyEWWUfi%u-JSy%u!E|X1lyt_?~zd08Vh> z>d3KJsqUOli{a&P&2Vz^uhcdKR^y<{E?|7d`VEEvQZ=_tDPZyMZ0O0soWrD&n*CHx z&MrM%{|!JNk^H3usifFdl~DQSadT^SXMEN0&&u&hX~M-mbzi2%^7P`I8&~z9{E@{j zNqzE5fMR~dMnF4iD+mvX)fohS$@Md5Yq`nL<6C|Lokm-yD+_fbw$9)>2@q;6X0w4% z>%D*0-KaR!=-)Kbd0+VuMfNY;L)xGb)ba(G{sg^)+3t83aE`#0jt~yzN4UP=^2KK= zwpPl2&R!kd2Kf_Q@e>YhtEihj$Nf^2EQMsl&iQ%s@+rDyW0>xWnJ!-}#a1SfVl&cE zSw1LwFS&nX@}j>|ixT75RC3(_FRIxR0v0^P#2|C|jMp6;B$ zn80-xZ#7M+19MWT z(ZujpGH^P<+!A`d)Y|M40PtQIrIAneAMied`8&;VGCQ}soypUQK4Y&#Yf%sYx}pYh z$pC3;&$fbx<29Q;&S;@S{|oxXEPBY%o=KXf6afDzs!oUdQNW||H3p#C zY?3F|(8d4m=fO^(@UO6)sa8veuEePZgVsel44doE)N5FPeo*~u12~`` zRGB6ZyuSS({M#c6xBYE%QC}1mtP~)noh zC3pe-I{z=|r_{tkhrz#SU+I+o!iq$l4P(O0`Ah?mGO+C%U-;PUvw>31jRf;0?421S zR;kcf-;|r%lt|rRM*_A^^a98w3OtF@9LHyYF#1K^)#o$QLS4flb?`{{(-bYdXpOr9 zBzm5MK=mK?%h#E%>QAx;tuSV8&AfgwzsN|$jf+U0@_$hS8|gUIXLJ|YoEITJCA6!qtH(OeYmL_b)X%|-YG9w zrpY56C*-#2C2;MD?ea8gg?-ddA&+N`Ft8V z1}jst`KjdbsyAy4cADaH*7c6pI@^w8EUV8lQCv5W#=$|#D~u=7P9;zz^I&e0pcTD4 zdvKy5TNl*7^4X4s1tcOhcZcOtize-Kz8Wp^b}`N_y%-N^UGBe0~!g+NdSK%}cUMbuLd3=8h`l#Uqiq!U_d8px#h$3LG{nkYD z;5BJ|>^<=jwZ%A2x1Fm7>(JdaEb>q~6WYH|vH00@GHMnhI!GJd@8LlkPPqqou(pBe z9nPyaHHSr5{cw5LE~enzTYA$VgC2Mv`>KVgSuR_unwwXeZ*0FIPf!{e3e_m}r;m9E zU4KgNP^y5aK1AY$YIo#c<6tkWoLR(UAdp$}9#v8%1itRW<4jhXx5S;_qEvf{adfBK~7908X-r$&J8iV_8yx#bJi@^MANkUh%8=s~cRNTpV(9Ah~=pGz~ zvI@uu;eev^vuC%aC0mF&XbD!AE6}RUmEejxS5uzhR_%^@FoZNtWd9`o_!fVI>cTUb zKypp3IhX>u@A@si(fV)qSdq9aJE2#PI6fj(4K$B;IHoO2B@rQK!JQ-^ttvX(#9!tl%)FNUW?^Le& z`-fJXx}@-P{mP7T*Ke`87FZNRxOt@nslCEFmKHRAHtPY?ymP!Z3&(UpD zk#QRpTz$vsR^)-J@IXA~f$OfKg+GBkNIbq8qzTnv?P z*RQd;CY_gvj11_H%CcK<3jBb12C7;p5mXibV5*yq$pgQCS;I*f+`}_dP9JA6%+<#% z9_y9YYcwR;Iqg|Qot-W7@{py|{w2s~5?l6pl552eHspEN`o0M!O{K0Wbsof20%PKnOZ z-BNMXhUHKfd7`9)dLMs5xWWC$WMY%uRU8Tx!Y0oP#CiQ_#M^ATCeJkXx;Oi~O-twH ztBvpL=A#H`#;9C^A>|&aA{#wdVlbMe(Ok=c=hChk|7zPQ**UsLDvoo*MCxPxujVS9 z0f%BR*xSeTBf5nzyBt(zk2Z(C2TW+N!>8LhT*Sy6lXdkDkLEQ4R)j>$vq@Ezs>K6e zbZRu%i>g`BV1oP+d6-uX^X@4UMZ5yWjJnGO@D(wnAdYjS)a5KS#&nPboLG@*azZFt zn#+|k12N>zh!l(v(k6y%zOcK1I;Tb(xbT2eL5B-5>FZUKGoLGzIfWpgQ{w_7ARMsZ z0wWmOd^Ib4j&;!a7m-fPGfW$!!8P1mCTpcn)B!U6JI>$sE~54WTq1f2!4cyZrt)ac zJuML26bN4mwBB9CzJ5Q92r3IL9*FM&`emZ6i1W3ZHfz0;_E<6(eD#k4`}dqdf{x2YYd1cy&3jlccay!E3*p6i3=ijN)D}?l@8z66~j?3q%#-J!k>`% zS0LEOp5;SmgG(w&rr%7AJO8!H_K|U7u&+Q~8MT`nlb_P(4hLX3;YM#qoFRF{<;Geq zOlzNo6X$!1A3mMVp*^MqU34foV=$fW41Ts5$@0kq<1AmDVRx1nfPIzkhjy`e(k; zT*ia11&CZ7D{$B?nSTGXuwrzZf)IwHnC!DGTvl0+L60|Rp>F|oUX5{$uLh^LAry|& zUWVUFmc|_Usf9-Ud+>Jai|LE~kLd#+eWRtnAGYipUZ=Qx5rH2>y1%y57<^$!RX zleUuoMypNM^kt}%un+@CY(9!nEnw9i4gl$h|6T5&z zo8sk81|G$o;SY4|n8l%YSfzYGX(*&nXJr zwhkjhUOAmoQ(qYIDYr>-FFteVk#-|%LZN$+7PMO&iixzdJ;+}PpwL?&jNnJbV8&7S zvi=TgTegQEUynK=m+GFM!WyoAyEA*wk0bjSeZ5ZkSkR+ zNI`o|TIl=25#iMgRI!x&+lsEEI&wOXdoOpxETQxAM5}DE5z#o<)Lf{zFPi+1)453A zH!JMVEvW7)s&G{+Fiz@V8PYn0g>f-CIHm4o=9w>aYfJ`IzrehajQeoWSmyF>Q22=S zVx2+q7+hZi`{P;MfI79&rQ&f*jsRU@A&GBjG7RZWcYPwiJ$e) zNaW{Q_dQ?Vc-}n<8=ZnmwT%37LH_p`V=x)dYS_2sWsT0|GA*6Uk4a8lq|PXNMAj9~ zsnN;mZ)4oZgTqiwArYSphHe)YTy~!v6jWXT_l--Sb2^`TbNJvj2}%ZVBGClHAtSYV zca!WMk0b=i9Ja#44;_qSLyn%&RB>ZbN}qb6n8nEN7vEsaYf>y9-JP zG3XtV;=6lbFd(-0+8-iZKJ(I-Bv65Y1Cb=Wa~+u-rFwxQ-(mwJ`Fnx_t0o9H=&MC9BwvPrqwbIh>#moJa`QaBJ6;?{ z4f>y1;QY@l*bwMh5+rbWDLXSe(v}*Izo7@A(inH+>>h$8b0Qe{5NNOrApDDeeqt=G zZil7?iZMXXZ`r{$92d0EjftQ@RNB%Kl+;oYBs6JqhIkb?sT{j`4q<*xg!=#r zyqRI_AQoy#Tz*4CMWf>qyoV%e2+mu6=;SQ?CzyxwClm?OzZ4M9rrSrawAGy)+O=_K zJR9tfxD!V2dG^Q;Y1+GyCQ?E^da#m*CKJ&i*EPRh7$fc$l~FQT%Q1Ty<|CH(f5UtZ zVQB$|S?f&g{M$u`jKdTPk8B{cM(%d=cUYA6a3v_D>A<1$K9eoi=E<_ztA41pKeh*< z+n8t_iPy1{xW4T}542#bgx&g6ge=rAJSg~od@{X$&!=>aqHD-PB6uXOj-5)5IYf_Xu0S4WAk97ZSQ-s2k5q?9zOiCi-@t@$_r29Ab`eUpp&1#Wsu|ClgvZ;AY zpp*g|C8gyr{w|{m4ALfqMDNr3;mY0_gdKHrg&mTDRmNCQc8@{sJ>LR(?ZueS9|mAG z{M5bwL~CCloI--f{9(!?5Q_US+mcy8;ppg=P3?+?oV_Tt;1xbw>b#w{{Ojtl>CXFt zn1v|XGTNZd+fm9R>82=SDacYH2|JpDY3;P5OqM~5=m^O))Y_iyL7>_Dqce0$aX`kE zRq@Olwcy8aH*T1*RvK*aB;HCCv@P`bV#>xWvr@R+E7=3wQFI?hD@~!w2Ga{~34$`n zD2zKaNF$NobywFCOn}7mfPx=k{(wz&%<`lv3g_l54S?#PH4JOjk2nD8HM>*Opa<{I4re_ zs*Ck}ciFTqD+6nw`yMBe0Nlr2CASPe5AUpjf>eWkD3==w9-f9C?$e~hVjmY~aTRGz zHkT!J_Wm3N;|F6E{u;m6bNaaF==Sl7P!>vgc-Z?|o4*b{$}nI86(GQ#>siZC`iIfD+nD_6k@l%*spv|7-x8cZ zrGok4H8631lwf%ftYz1J2K5H40R}=eG4&NhgGtuTI+bev=~ovt!u*o{U*!#T*RfQe z4r!hx!bZOw_a%`t9qGm{-I;TO_txc}e@#sCg``WuT{F@L<#rNB!cV)<-0G(4FcjBq;5Gf zie}b^SlyUNlWR8jlDNoZ-hIg0jR`p7wWY2xWchfYxPHH6+P2`3e?>3w&2LqTfz5<$ zOZg|CB)^{UPb&X6|H@k$FIAFCghe-LH6K_{ohxmpf)*r~1IHnw(O4V<*z@mU!z#01 zm1@tUL9KK$V3*+BM(zckqRD8i45N>yZy&#W`SZZkOHHh@65se2(`KRCjoM}~apPZblt5|jibIM<{Ei5Q5_ z{`liCY%CfWFkjp`=706S=vA$`eRJ^2aodP!HTs_hf42WUHrFjuIvdY2Bij%DkhSu3 zw^R277O2$9ns_JtAvqhOB)W}iDb1&Y);Z7(j7ba)@t_s(lHz7N*~`Q`hA^=BZ(Q~Q zll+OoNVRl&M;FHds*7baVIyD7fG~?zFmOgFdO~B=-;ZJeU=KKX8zUGS0^P|O%Vw)oeyF2{7k1kOXPs#taF@7Ta*+EBG&mya8z_Me=u&FtC{Ap zuh*_s!cBv#sXCbuA8J)7NXT#KmMo>8(HgAtH$hqqvRG#vzUnIlS;SQ@$d#umDIKLi zBna@AKw>OhU+W8&QSkT$pWsix1Cx-dhuAbzyXJT`{uE`eYH^&xS(GdS#>27UbC;&o zw$7KJ#jDYkbH#$k*yXOymB1lUsZD64B?H*5QEM3kdbMRFewZB% z@C*si9D%nTBm4cdAyG{4yrENXJSkUWl1$lzz3h*A3&APy<1Lou<1_!TSJdYf1z6jL zVUSlR2F=S^o2=xC5%^^Lw4X|u(FrIB&Ao5z-J3BZLLH5@1}so={4S{@Ij|-J-zU`5 z5yArnF*rq1E#pAYf$$T zLBCEKO3Nv)g$AXEKPgHShM02Y$k92Js!w&_!zZF#6<@p-!sVSdGvPw4vH4u&(MNyW z7p$l-HU*zyC@BZBehl^kx9nzk9LFJw{XDVbF?CJTbzAmz+D%#+1B6-ZJeft>=eb2XaZ(L(8|1>1 z73tizG<{$-JdRolYnq~o&@m{7VtPV?_uEN1x)Nj}i+C9QEZ-ua==;STVn5n<)HS*N zD0_TaIAV?U+&T+1*fb+3W|!Z^WPC0=$*5hZ2*pf;GblqZ-_v)8`Wk9?LZ(WZNNn?X zpkoMhDvnh}vR39q9hjznky=M#{#Dseux3ki`98qAxbZ@et_@U`(mt zFg_i5&!n(fHTR{Kh;|=bn za8TX;{^DNGKx_Of(G9uZcnks>)B{Q;2r9EL$s_AK4WDSA$7cjcS!2JDj&_Zds_+*& zN1c0$^`Q)ehul(NVVBy@6E>?7+?eE+#q1Wp(&%u*n_fI$|NE^xK&gvaiBNe-D6`Q< z&NekMl~_q2BHfvXqfWiRxN4zDHo}I;9b)TIgR<&QH>^ z^l57na;SlLiH`sT$Ddne>jVm_`z(OMG1x<*LXq4sBdVhv7p_u{J+c{3cIy@}OY92& z{q0;235??JS|8lRW@!jy{uJri>EFe*NU_IG(%#+e;m4`p{QFp@p(aX6m6f*kZaXyi|>b=wgMEK$F*L?PXE9d zSe+ojL81aqZor4>Xj_D*`=oh$bZk&_=o${beuHluius8mRp<)lUq=SEl*dj+oU=^k zdizig;tHf3?ukH59h!!xu6hcTRW-)q9=|S0?R_{dlSQ^9LVZ!NLfbnAV==fKv{b=2 z9}>k!e7IC*^R@h1ct0XWElPtzi8uQ(7(qXD;c}QO*u`sOPid`XEPu~@N9)29ajwAQ z3IqXTgryGQfvBsnqr7ga7yQQgmhR!6&K*yxc2opMHe(BrT(P*9_uI(DWM6krjsg7| zDHkbP=pVu!JaHv+k<}SLP}VUgVo4)n~bC`gqmB)^_e(ox;7-qBaZ2ijToYC;422*Q>v2PD^P{Zk>3v{+X0p z%pyr?5Q~(0Y*}_b{+IolP^TUgCwKFMu@3Tg~F`D%-w?NGsqu~5XN@m8qwL2)2$T; z^VHG6tLa*b0_^W(eA!<)8DA&ga$|vvqa~tK<;Bmm0=g%q%kiV1hVt;jDxa7DG5|imy+g=%#>7`|Q-h+k~ zyfxm(6rabR6fpf699aD=8oBNUKG!;ky`nlVwT>B6r*9`BxVkHPXdnVHR9fxKxXJ{A zD-FToF1@x%Nf%AshaTq4^~6>{>w&@!GPS1;Env$1P2q0lj3NpRoSGyEH^z>`67Xk4 z=(BN4)NX_lYYX;pl5*j&t0B=vbFF@kXA<|Q5U=i%dKn>DdV1Hm3cKlNid9m^-iK>y zsAug+0uH(yhBdi$nGo`&3LJy#_Y61gkCS`GQkvYq72ge9aVudvTBrVo)isaBgAwF- zrI2q}PmxFue*{)j9^OIBuhsTEC!7${WYN=tw(tf7m9~r!)1EX00DTP$rpp2PiXIDr z$|5^sajzTh%7ih=)LKvVEQ)>)A#u-H-QvhJ6nYmHubXlf2uvyZ!EdWlk&HOK^0O0!gmSC3a`V4xk~V3z8sVt?yX@^R8d za)d;wA*o*{CbI_-Uw!KEyV%5Y83hp)p(~|gLrBXtZSlW!w;ZntgviWc*TF5_ zg_CYWq$0AQxKAP2Tp~D|!jBUAWbYl-XI~rQI;xwb)MK?NC^m_SkJs+lTDc6a<4bBJ zNy(dY8|%_Yb=HVSzI!Z+gwM}PhK?(*iO$YXQ*;NWAZ0LPSTj*g~N(`G6c z)=7Ukeb!flP{GKA|HIT*2G!LB+Xe~l?(Xgog1dwSx8SY`?yd)S3GVI=2X_hX7Tnz( z-u~`=uj>8URi{qP%$}K^-P3EWZd=;u)V5(Fc+K46;We6sImO&!c8oOiZmF8`=xO$6 zE;vHZQI}U5j^4p!n^0(V6}X}zyNWeFmlvr!Zk)5ROGcN#qx+23Vc{O*A)*W)hGIn4N|@Hzs8sS}BBYM%&z z?45uoGPN_}hPIgXiJIgSvBlt-5{LiiSRni`#X>;ZKTMb-D)-3si_Fg~D24YxyXtQ6 z@KZRJz$i4h_w_XYT{P0(2S)WHHu*Uenx(vV?sxBY>?_vv{OmQ}>m1R^D^kw8{iWg7 z!PT5F$T~Iqw?CFddn?rsB(+i4bYpHDS%y~sRJDZfe_4#kfID5P_h&I^47jk=D5@lY zM)XKzR_OU);}o080iy+vbM24H@d640JkTTvNwETI3<|>}!aafgBmLkc2njLZV^|@O zB?D(4RUhA0?~wDQ3AP`p^R_h2N!>*WmR#yzg+$roW<}7PC^n;|V-0*a#>^|0`X?q) zcQm9ip=+{!yiijScQnh9KpBHZ7+R}p%-aQ8L3N3uea%qQPwugRuf!BXiz=oA+j)m? zk<2ZcoKZBR7?x)Rh;HJ-#Ag-l%m)*D4VX^%m76k2f8&oHB~qbPUFr!)S+(7|xIemqHPql?hdWUtT=Z1u#O)SE5@ z2B=|Iz@io11)fm0S3=~D!$$p!mJm_D1ShnsDeyCZEdcBJt-7-QB?n{XT(!g`5-UP3 z{-`7f`U{NefAL~*V`%nP{@+v*4Twl$;Ku#n(0Ao-pah5F0 z=#1B%_Qc#2+N}>g6xbNY89RfI18lp@?~j1etUQPL_q<M^gg^$c)H{1 z(wrhwKY~?S1%Fn%aNg~==-K3kdU9^Al~}V5%2M=v6IDn+X=R}x1VX)7{ohi2narlw zyEN*3{}DEi`K3w4a}kDVQd!1z;>zSpL4GjO>!6Kp>tw>%-|e3klBH#q`OtS;9q5nDgD~78x>{g0vQs3JKwYXDn3_8zjK@ z_@8iIl*nNCt-qy{TSiaC z@7K7cQU#BXR5a7`HhW!$E-uCS(~@lgdFYsun$w5Zgx#nXn|UcUWM$>kQs&23Jjc?y zxaJ@A>mK=dvA;W+_n+?fXnn_cR|m9_OIH{#qN@C}p%m)0xhXjtQz0q)PiQi;b)mUI zan971yd7?Csin=cZ${jlu^2NGY>l(B9E~URh@yu%LAz|h$e-j&7{|LY2ZToPZJ?)} zjYam5Z0XG{G!?|TjVwA4v$BemG)wDb&OW)i%)c&;jaHVDtcqtRGZAK<2_RP2L-WEx)$@Z?90BAe4 zOOkwncv`gPp=P1`QB95 z3i`hxo3SUuz@cyzX3ZWJ1r3rxm(vgj=wfkz;xbKA1kb9o&Q_@kbRs$aAS6hHh_$8k z!ikVCVOK2p2_OXYW?|rW$wuYWP{-x^t0BgZq$S(2RM zcTN7(9`B_X`Sogr24W*K%WJ#0_S%8u%fE@#^nO2ag+I?$sqFNej|(kUGfIn+hXHt6 zi=H5)-BPz6iQl+mdlaFaFXiUAu(jM_ki><@f(CF^5J?R1aQxD5WB+m04n4xP(L7nF zYLiQXgVl&iw9?(MCAi{bB>-Aq3wQSZcPL`V=@^3?@r)(WgImH!KNNd64?!Wp2$qkN zdzR;xab8bUb8wtH=URsQpcVn4oP(MI!BH%1sB9?SvP>v)1Jn^-f$UZo(KHpg77Q(< zdF+%#6paXf4Wn$1i1n#uMM0kwIwi5ug>+joO>i*FeQpzl{ihjfL)YfCubECP*Qkk3 znrdi_M>;-GtTRt)QLX8M0xUO&HXSiv<}Elx0GaG8v|P(}(b8P8 zJa<}Ywct`*F@*R~Uuk`X(QCMw4Iw%-$a_7#AK%JjE&t6S1p|Y^m41)oV)rWq_=X$c zs=*lrRX;s1=?kukYv6yQiZ49MmAhQ8kDE6C_KaQIR1u$d7A?hgP zXEc*o8hr?0A(119W{_byB?q-APo3KdFPT0QopL;>_rL7eQoYHfJ=hghVIF!m+Qw4)KfEAi4b0`a?PQ?scTd)Vsk6}HN(Cri3haI9(qWl zhqjeP4a$VF!In3i*F?|o`KQ*M~d#<&Uc)$u0Et6uH6NoG>*` zR_Xy;GEiTc?2sXDCV-y~82-qFg|aRfwkhE0kX8E;e&YNIPm@wo%)zjwyieREGfHd^^L82~TxYb-vKQbZKa1mvNkORMC28HB)CIN}V5-4Ye z^oNB&jhA`v{$Z8E*fc7L7=&W)wOmr!>4_vjjq9J05O<9V&1ID76CyzE$164ziGsDZ z6wqAq^X^fOGkL2H4FgTwxbqQMojVbPOt}H%AA*ntH!_qTzlC1C*oB_laCCjzJ+Iu; zCl}K_9oKF|FpG-t)vU$bpmcbTa!&FtMItK*H{TIZVdw=c2x96YL8Xj)bTEi|Ny5~|K zHOvPoq0~O)>&UP7^hxc?CsP5b`=?SQi(|Hw+YZm2MuQbyfma(1R(B;snM|%9HzM9M zPngAxAtjCY8D*PPm*cU9eEZUg|Ld6R&&5t;&&y()EUX?bJFHQV@=0A+#D8b!Vn<|5 zUE+|X*3l!|-3i#7F;@#>7YaP6sKtM3f4X~8dIS&|hZkp@E^BI^)UtBPb`k&V{BSK! zU=1pQvJZ%5Z2%r_sf~L^&Rzc|7GpN@myd;>-D}q?NzK94CwtFh58**y$@(^ARgun* zqV|qmOTIK^*Mz4#YS|M5zBDQD$yKo6mHhF*NA)h^pk*&J1#wUp0LCa8WWT0@!}hci ze%*fTQ4p>+@W>E2$3czo#q|l7la6@Wwl6BtV1k@9 zOMe{`tGv&P@D(h}R@`0NkUFlu`}RfaZ^TCaW9{nUjR)r0k>~`2;P4N0g))wekg<(i zGhJOqDojhJ9K}=sTrkC@2Tod3YKm-4fnE38F%QRV!s8KpMMSYZIwg6tcr&Y^ii44Z zoX$Y2f#|ArAZl%1n^0Gb1r5;QP2~}K`v&hcz<=KV7-%k4Jhpw!Oe8NL1I#Hgw~!1Z z&Mel(|FxaYf!t={27m)=-|Liw&wt~Z|Nc->n7oq`^pc&Kows@N1}`*aW9e|$Y{X5u}Zb1_G{ zkC5D-bC;_<#@#cbJ2N+RC@ysU`tg+ZSkPK!HqT8v!}gP`=;QL;vd5kK)m|yaABpCt z9gq5SpZG!Kdy$0FWl2Yd0#Qv3o+FvlJSx#h9~M29uJX^%ETR8&Q%VBCx>Y#)qvK|V zD<+Tual z5ihuua*hj=?7dX%KC^5dBkgLOor0R^4NB~f@CLCadOxFvGwl*uFwA>y7toa;##LL+ zj4Voi2>@JS7xpuv6mk=oZtw@ zx!|o_q{JJQP^_+hww+AQJu8!c{;liz;0u&ebxoeaHdUOVBIo&-xY__#M)BSZF3vB_IWn;`{F=f{5Xl}xfBl=m9}nK_c3mq(T;@tCzqaA zDQ|7TAQ5G}yj3?KTqrV2eO^^RaYFkI44|1M02n|xZ$H)$Ar-74J)ta4aUvB(zDNrh z9jt6mpg@f^BsRQM*5{t|hwdL<#dXBL^9mu*4UL~MML7m{vr&HclIWcW@%D!z{zJpn za}y`Ee7S4BvvKUIL|sR5*RVPLVdNr)iDxK29@*CGo>7CRmpiXO&>IWkhaLieX)^4t ztJM)35&bKx#V>14m5gNYASwq5)1*~0L8fVd0ap@Lu4?swvKUguwp=q*8$bT>^4}7f zSRV;VEN#9yygL+w*9=F@P)S`W36-;Yf^A%IeN6gDM#5~igUn{P58@AR&7rno(kMKM z5)4}N+WsT#dc*z?VK)0-g^E1l35=cIp}_98GNhZ(|6W`&wK_ zev`ZxW+UZBgKv)>56Avq(~h^F-0+D7R1dxsC%Tu31{vG?^Yzgu`u*Jm&ID!cv0;p@rG$79;0{ET_Sb6-gd{Jof}-`vVCc83m;{=CODNJPBGt zsyMb-%sNEkN~c9HoChgfG%el&GoxUAQdY0GDe!Ro;uRvh1}-?6SkcHIw(nmxfgJ0 zaQ7wukHcjPlv{z*+0V)7-kl6>`V?3>avErT=>S*rbMvp6=>^Fq zKRow*VC+FWibINdQPlBp!8`_E5yCK$OrTDT(Cnrcq=z;?y#Hf_)-^gIQP^C%bNhY- z!P-LHB7pv{;UIfb(bk#L(nK9AavG!RL(i1}Jl^HDVGJPpQb&HCF$_bG$xwIo*KG=> z6d7nY7#>om{tlhy(U%k$af}VKVE`PVc@`Em?^AZH4MY(9e+_@eq9N-<2|eXu9ju@; zEq^z&UQ+T%5l-VwMB?Tp@GI2Hz~?D2O_*q6A%F%#i?*rY7ln7}+nduZbgXJULC>j? z6;WGMDq!F>H1>?WQ;vo59cO^H*O@#^I5YzrZ2q@Jg8JvQXd2_f7jcm@^ZQk|N8 zYpn(f0T{s;)(z9+Cn<#(7$n_(f#3k{p_+qQ$cYccKYR*iuHB7X2po2wJlOreyxl;s z_(?%rZ9%vA5q$1n+#;AbBdYqOSE$9d#)-tOe_sk?_7i|pHl5L#0RBZcBAI4vjzKOo ziFIso^&u4%kYoV$6ai;*Flz{O##}L-CpVL=60or|2D%PXmzKeeiA& z*oY`y6DP$3*PVYou#yh!%6s=@ot*96T?qw~OkML7Dr+_>^V91SQWG>yU>10N;T4SOjpR`AK@A9&gVOOu9GnF|Q*uj&c>C|ErmZkWP-Kq2_%`u-i== zQ7_j1lnIP8%&O&kt{WB9;OU@gY0aRx6WB+4T{`H;7=#iX<<$)xeh&8>SBYceNMr#K zzom7Wla(_%4KOo|TwpMG*$gN1K!1*ZS(QsntS%_1J}z-2LZ3sf9v3p3QQ}&PXBV&Wh{IFara2 z*yLy`^9*y-*eVpZ8ZoHAnMQxz`JWJwnxsz*BB8*Bhs3KAuL06Bb?Oh@4b0!FV7v*g5K=<5!=%A*=fds4EQ_ue z^p!`P0!k>oIP$&EMCvB7hh(x?lXHP7rZ`4L)|=D?R5BQJ11-6Xa1BCvP&RamIiKf9 zhm+q$LZUc+&~M>8f>Ctein4Zu+O#h8Ftm9`Fw*7V0l8+@LkvsC$)?JX{-?@-z?coQ zpL8*2U#ud93j9O$;{HwVS!wJ_ZB$ZT9^m^-q;Hw2dRvlN;t-x=meFKJ={fb@z+RyGXO+N=QPg)$eq^;Y89spq}GfgkCHAWsMa*gaNI;g#o{Q~q-NBK zgpf-Q5{%3Y*VICY42Rf5t)un@EN4w6?V8F_WhWn+lIt~I>7i7G-A}a_U>JmhWb!Dn zJ0Qo$5eJS~-QPVWW)ENQ8X=;g#!JmiQ_VO+W=DazHW7H31~^&yDE5dlaH3-ED8jHw zw3OFodo>zk3G&z=FaIY%8BH8BteNA6RFWIZj2w(afIGRJh@RGxR4J+?WvNoA2Gf^+ zt}^1C{;D$K?LBBnN8fmv4}PL6koqd|()1b`Mc7bPt+ zDHcQ86w!7aK~GC`rNN9C<%v4J{m&TA6p-6tGjL>i0B!wQ1P(pU3XcvQN{%Hyd6xp7 zP&u2rHZ~V0(ni?H%#4wMQVYtHw`hKbI8E+f%jeh{F<+#ZEEn7gm~xeF3n3!!ZC zm?kP>Sg~72BGL;t67*GCgeF#zQUQz1Qi`4xdlaa#Sd%OP34sAbxGhFNQ8C!DfLc-J zzw@b%dReA7WOFQXki!LXw|LpXUjJ>KTM4|1+54YXPUxGHQ@$~q9|-Dd%V9RM#V>23 zTezC+fle6gt+MFm{e<59W9&8O?@6-_)=*)_&h5@mqp2Mf?yzHVi8vE{9k;w+Ghs`T zL%>HLlie?x(jU-IT*rOGLRXQU6aEB><;$;u^n-JuRpeC6V(5OiX_C}glb|APtg zxzJG<5nutkj!ae_B|c~#!sOVrut_jeBP@|??CWAVjx;YnI+TS38tHe52Jj^r#kD~8 zFZl&q@X1<88pEVf6LgW@Y=KI3gb_4*-DeHsjm(|zc*-EGc<#7`JtIjN5tMlEZZTeQ z4Lim)Y4U(5Duh-)gt&r2G}&ID0*q(^lk=#^9lic~HLoXDiGoQa`7 zz+K?=8J1fmh3`ryl@{xnOMUx!sa(OChL1-Q0-N3mK@Te}j*cRGo ze+^IaImaX%h$HAJF8m_kSt6^N{fS0k9FOj%GTrIbc{&+5rXz&F;E_HX%#Q4J)@1oU zH3!I21?8;B8Huu#1l13xMp;N4u%gr_q^&ANekdD@Q?}Dm9?{b`gC*s3DnnD4_@Mx0 z+}5>$p~KTY+biCdccRh{PvIB6SNH5G)wf#T2R?i!*8=e=k{h3NUw7rP+`D}+gs;m@ z^Ap2{pYztF($79|{1)>E=R+#~m+ZopONo9Rn$w^%=3o3mZ;g1RN8?8gLPnI4@bTY} zzf^>z@mA`?2q09XIlVi_6_ZJ2CnKn%Mkw4qA8pj{U7$6vi1W32xXjRy9$bMqjoSjD z1HYprq^D=y1?HnA^S(B=_FMhvWUN)5d z_%nB}%A?H2TU%4indu?J_9}J;HJy~b9!l)(^0O}ie<~E~)Gd`cdG^GsSl#C{1gl1b zZY|A!_)h)PFOPIq^@y|Alf=>4hvxmnG4b*AVMOzktL7Y8lyHD>yz=DwmP$%U=$j z4jdCV>qd8yThebmWx{g_ni3j67+rbVJf?F&{k>mBr_cLPB*AA}l=v1PpnUs(0kdeK zEQO2rEBdw$K4HNZJA0w1V1kS_P^bUCxOcE9zG=u`HsE&G$&!X~deW4OT3T@3@ciUS zqI)oyDyrRAYMb={N!+DK<8!z(xX(+A`1j z6r-jfWTNvww?heshr#7r8%V~6))zvON>*MXK8U%B47AIF{aetjsI%EJW38f#*gq-u zcV_&(o3pfB8($Ay*f5$GT^JU&eGwHitL!m47r+ptUoctTh7V1m2AJ3*ETb5JYaQ?6 z%0~?_dK#8w5qo9GrS`jn*;W4p_I|ajVVtc}8GIaGl0Bkesg2{vX`!+Wlb@*(`xHMl zSJR|gpD6F)Aw)Aze6i$5vM4iH7A{NjT1UEE0Wug!Ko7I?YCsETeG2l|U+kZEOS z4-`OQD~`^`PvQ_;#gLz-># z$x|NuYnmi#glXq`rAA1f^sY4HUm4Na+tY0gN$qD9RiAD*ua|dbl}&mfnczg_jOc3F zJAY6;*Z#8GtMv^;ScLXx^X7wbSV{W%Z)+L<;zmoK$##NbHnIgDWC~U!GxhXENE2xy zi;tVT-ko(GN;cpxE@+%%7GPiZ0-r0Dyru#Uw_qFY0NJxY$?0BT_T`1TdI0 zv{^&`DIo;g_A=58J}|tofJ+wN{9^Lg$>P{9d$n8#{aU%{u0WUXN@8)zkAXin;RVBI zC*OU)E;mB|DtD))9kwF5GW7i3hX_ASo7oX{ed5)mg)KeYwJU#Dxj(&1+gOq9Lpl3< z{@gHO@*Xk+u}Y6>@3zITK`&tOo!% z5Twf`0=SWAXXiwV7Y5{bErVEN3L@sd+x<4>HLM{vxDs|FMpSIf! zi?wy?1D!AFXBT^@etFwja7=&G>?m3P@FVphLlKVMw0e1ha(RUKZT#UJEL!DD)sP~7 z0tMrx`1)MBf>tINMo_T-S;hPEdd!ra(I*{@I<78aOZ+*%VP#-y0rs{=`p$S((>|EZ z-sQdXt!Lnb_YC#lT85sFg)i6p9kbwT&ND|E>Uq`q3XSU`F3L-2G7S?l!>yr&U1O5} zIsB`hIhQ5mI+Ake_km z(b?|w)(g6b!4?B(ls}Q+jgB8_pbL!RFE!6l@y2B0z)d?JNV zu1O?l^s^tx^2n`GK!b~CuBlrCkAeRZg^vehjvovTc=yKGtg0tcP*caia}RrRsGe+_ zck*$~2J&2~FjdqA?|fQFS$T~iave?IFXmSbnwOGUlWg5HJRfdX|I>19xpum1pUSn$ zf6Gt5<6U*vW*d4=pJw^NukwrMxKX`h&1Q6ub57%iaHTyXUvG_M{jyF%XY$}UUrgTn zp+(PjG5uADzhmP&tGa&Cz@dV%2j`PXCnu>@-u!_%enNn_WO*9Ro9?otCdj+I$(35U z;dp!h`kcbU`)g}!YYTTf{Z^iuY6pF}4*zlXds$F~x+sSjuo3n#(gp7|sEtn1Z1nVU zc&opU+45iK`|a?)xWF6Q$|t0T%qQ1=bHE5Zu-A=yWMW1d*B-B(&@R|d#I=q~6OFEr zgf{ZljA#kb`YDCqo>i%Ch07f!cgXO}g1cHhtBPD5+ySM~E;W`QOWs`qsE^Hm<0?@C z72Jy5hM`}pUYX6NR~3|85tS$O1Yh{z0&u+&mFUaLqf}uz3bZ0W!4Dd%|OQ_ zv9Ze~TT9N_ZteEe5`B^xGnXP`mx|!pea)dN-JkoRx)LOZAYBRlMOd)QV#?0dZOZGq z)tj{F##O~-%U|==cK(22DJwSVLA6Vf`U;p|f9t3Mv9r|@Cbn6^f1Hk8n%1soLPdxY zmzYrAy^~Wge!lD$A^d;^0Oy(W&~DbP)}@WlWjtKWtpj>EzT?h z{d;fkBOmQRn=$ereqP0`Kl}C=`XDGph)qg|5&8!qbXWEnjwDW?edqc_CzHB;=`J7T<1fEs+cfCSm0<@&~8gy z0+j?LxbD6{W)qx5J43IUn)$#8bC6J^_e{*saRH=Q8LJbk0QAy5(~kb&^z z9GrLE_gm6rz)^w_-70as7)N}(%j3&mOagN|iJ$WYoUIX>STA+V=(bB4j$t{&WcGCE zHi>9G33W#MhDv^}lj^W0*xKJ78fzI7$q>`kUEnAO$;nTd>5;)~zrw!P*My7asuSA7 z%-dZc{lM=S@vW!YMm^9h=E#e>$>UJA9g7Qu7~KP zMiN?6uSSx~KDtKo*2LQ&;*ho6tr2w~Bb#**T&)tnuG`MbVhamU)T=bI=;6984aR7Q zD|CaRmQpOB%Ga@kFULPA<&zD#+u+=2SL6m_$1)%gh%Y1cR8f8IS&^Rq@5Euua}c<% zYbs0_>m5yTqo|J@(_q50)IX-g6*1Y8DgU}4OQ=X2`shG?cID&%I!S97NV|6`^%=h1 z-al)=Yod>euo|P;M&as83m?@=9%QozOsGY7*M2F*lCo-j&c7vxk7XyHVv9)DIQJdG zT1)17(1?zb0zk59yNtc~SK_{A@S{8_NlX8dXG!_2&P>gIAd6vVFCX!@wh2;Wi|Aw+ znJz`#tCixx&Ed-_u1(l3!Xztgrzv#5NBv8?9?QbC`Wpn(wXJi5h%xtY^3J+{k-m3z za>;#afW|L?!Me+m_r-?JRsw}Ac1*-yhe^s(n@SY-5}UBZgHq9sZB1nZ+Cj@eP$dJMT)ZeE=T=4zdA)XG*AMbbe+pwl3~j8qj(+6E51-bSs4DaF zm+hjnw^MoMnVh*YH4>|k`Ep&1vBUt&z7rZ^ur8M467Ck^k>6h~TCBh%1XF%FQ>HSB z3J*Rzm}Jtqu`xh&D0eB57h{3Ki4wL=%9u8$o!83LkRkh)Td-Xnu1v{+~AQVDTeSy{W)`I&H5q#bFs5*+nva({h z483ki3{io;@ULi--X>0|_A&w=n)td4@zbWc+zR+{?5TRUU6ff+qlakvRc=CAktmLp zTdnYzJ{>x~meS$|b|e-PXXu)}{B32jp^mu3#5_Koc2fIUvn%+CGfCD5i8OgkE%|-; zb3;9LFyLOhbIQWLNb%mMA-SWvf`dg6WUz?;3* zLys$F)^~#aAFFi@+G_TLF>_D~-R4BJ_Am#Z%hH^bU6qy%1CQjbOepx{2(VV@uD!zNMj0|cl_t)dEEqWGW}v$ZjlYU*UG<^M?kl}y)35RpN<%<(_8va4bevEs z;P&~rdvRgc$NIc9Z{*Q&7kDS)Xcsdqz}}li%U|)8?rQ4lHrUzMS#Jl*kDJmm86yir zA!8BmOAo;*LSI`bA1XHr{0S+;guL-efU{N=V-SGOgUMbOes@g>^saCIJO1~p}zeZCwDr; zax`Kqm}ZpIl^slo9Nx}O<}az`p9-}j3z?Wof=K!|tz{B=X+R(dyen~U#pkW=ZH7Ay z(FoND=>WU#IZ;5n(z_+$33Lues?ZSH#*+x){wgQTbdBseqB?Ddw;+qkv!iEFeqTa^ z0+@dv@vhh5qV*0N$5;j*62mhz;m9|L+!ly}(1YWPtV)#GAD`ld#5Gd;1gX4B>}60s z6lJsPtnK+~cEdSK-#Nq_G)W@*(u_0vwy3;;K2b;&Wi8g(!rIDv}SgWqd)xBsU>h;#Kmr2iD&bRyOf?InS+m~)oR9aRkSwLCyr-j zMS<7?apX>hM!Gc713RYZ#jq2B44H7P@e;|dDO3?y>5*kphBWF%A z{UOQzq#S+u6+~6HgAvoHX)?B^mR(W+CkZbKFKcX0Ptjf z!y1x27p^Qt{H?rm_;XNxs9W`Z!>HMHcf33zib0MOBOym8?~X1~5sb>KE>;hDc>?fr ze<*zQflb&l6h1zDRQUOb%ot{*HTcI)*(36XVdzn_vJ$~3v%i-YZM-KqS`|F8-?uoh zFXU0(*)I7DvUI&~)hmgSj_}g5SBV*(`xy3`|pN<6(R$`gvOHNC7)vG~ZR*^H34P#K{9C#dljBWhaop1TZN zyOYO>`4wvOlsry6w6#Tt(j{=n+u8QYaYDPO(Q09*i!Y;LRd%}VrGa7 zeFP%%8ObSE!z%yGlv=KfOkYXw)&?cT9Gli9?^FR$<$A0?(Z1Mf=4w$iA_OJ<_pOaD zv-XZS>vJ-^c8RzXQLp4$x2?b$b_sJ(bR=;oC#B`+i8AqqO}c|_m7W4tzQsQ7rCln9xzWy!S)x22N=40I7CPk5G- z#M+nXI6twPplB22cEwTb{Ad}-Q831#73n!cZo+pPw+fI%q>=>1y|lE6{6EQFIctfs z_bHGHhF;Wf1naC|Pa>T|P{Rqg4w~hIfpo$80(xAPSjD!(y5Gq24!x=58?mv;k>YGV zOFgCW1gFK>64#N_X&pV4K{io)RD1H=w8GHQ6A zG=sp9^p4Z8wZ`bvta+NRwPFl27|L-qqd3W7iLJrxN8f<_dD7JpPO!NAIA;h5xJ)a8 zOSKlw&i#4iyCVSu9(QgS)2dOart^GLuO-zwb&(|>ud(%9OO8FAzW6RUla4&zYFPQ50C$nrMDzd*zH!6( zg1*Lx40r&+b6Q#7s?CO;;T@pBH)YBdGt+sSt?q=U(he_lL2nCz^;G?_0qa-q5c^ zRq?&BWT%2BE;r7r{@sO%inL`Rj!2O#_|ZYK4j2g4Y9_AoTz!29^rx=frwb(?_1)ew z6vo~0-30U@D21kH5~gG=icQ8kfZA%0tAur5xnc*Ls+z>&@pPjJO7UqbgBUUg5}(~D zVO;iNd9dAapa-_7l=SFOm}10+SCz%%Y8bG!{vPom%jq!?zLi*~ilQ#^yF)SL0gl#g zqvw&VUV(D5L*p{e2(13*SH1E*ZKqE6XNN3b>lw_6F;c-o<*18SYxeF!i&2qXe;UK6 zbt-K7)Z`k=nXolUhG6ei9*R{3Umz4wUp+l=9peR0jHoN<$p@z>6R$K_ie<{rv}uJh zBUB45!Lf!dz<5rX&>I;OyxSd54?V&hj0La56+Xt7KoYT~&l9o!9byNK{IjT)L@BrR z%vnQAz9aG27D6&`@YmWr81*>Ztie!#!>jc$`o3qmq@WO(66MEP^~p&ON>EoF2}C03!p|r2 zP$NRUo&-JWHIs8KTGJ+OY~Lu0c1Z_X6olVk+5Mb=a2m5Ieq3aLtbRHTae=OhE+`JW zz-5-Pu~qQ}ba-$#%j26Wy0J1}pTHxFsnnmN#KQOo(hdcwv>t=)q#Vd724JRgaYq`} zW@Bs(9^9+1u3SRnKX)V(67BEb?_TPE=E<}^C_O<~dv_CErJDe;!4Z)|cy zJNmh(7AH_1OZm^WutAVjN{Bt7J6ckMbBx=P7I%d(=6>OjoTMUd0aW?3fO~uQ_;&yNeA`Uhq}_76 zd{UKGa>ERfd*TAOp8gL8f1wR@*Jel>zB3tjv8poPj>3FF$7ZadpS~R^?(B1D>Ne~N zR_tbJ*Q-rpziQME2=TLdDF`)P%lxht9RMqnuI*Z>A@BdE5Au%56j2E2Lw($W-L|{& zBd;%9&Nr0QiX36WuEXSr2uBr+D+N!*E&r?!b*rJ|3^GG?ynZ{|KJaQ<^Umx{kBsm@ z<&=jWR>aKd(Z?r)OsKV)8CjA{3dPeJvEX$kqa^EQOy&ZL3CEcRP}g=I7yH#!aY0VO zxduaC18KIVmQ;d5m%y;xgfet!6O9sXTouFN!;wJJ*zDt2hnPkXp*NiKu0CMmxKQd` z;$B~}v?=wTb!jLj^jR=*%ddml_^#-GSbx`}IQIz;_w38g<14Qd!=s`TSLi^zFwumJ!=9xhv^lh%k{YtEf-) zgy%9QvLSimeKqP!;=XAWlkhoJ!mYd`n7`>yZ*mIaswjy-XP|OiIRIm(NF6-A^06)I zoUoymP)c~U_P(a_i}gPNbepV?CUsx*R&BNNJ!gAjt+l&-HHfWj3b9Gn2_|S#i_Uq( zEed)9!%YIfzlHxNDFFgP8vzg4NXjB?!}Tp_Na0M}86<#WH4B~28+DC4L`)=BTJ-VF zcsF1;hS+Zduj(g)IDtBB5srw!gtFke6KPT1+vmEhC4mxa;zbDT5D=?|4ylSEh)-Df zqcHWga1}g|GJk)8Zg`Jj{&v5jO~iHflUp9!z#9E<{1J`!=KC@E@pG2k z^NnVM$DVcC#(6{0_eJ=9N58&nLvX)-W4`+J-mtL=yFW5MpaAoY*i#ZP2ExPaoPRh!m1G4be}LJQWL z7IK669WdJ4(gf-;ML6nWpi}HE@(rkVc%;P774B2G{^vh^F`?&#DLQpFpof6xL`3~H z?=f=Cqpi{)ACB-okiP8EnVpx-vxNS>UF^W>!$z|mSAo9)Y(Y}{dj`hVL=50JgVlgw zmZs0o)EeXx5^6())gbEmYhuj~DCNN!xNe@MB(XB-T}w2Z54?HGYhywiVNT71$1&I{ zbP#o+1;q-H25I|;Thowzmb#EuwMg7?Ab@K^pBs> zQaa6>;EZHxn0IK?189A2E0zS!>YB+gpDH;6{w^o<3F*IJEKx`C=1=I;G!e^hfSvxM z5SA(ldtDOlq4$4zHAjr)uKgSXrBV-&#UWL{sw1Lg)aZ6)p4g^-%733l0`bHl>+MP0k zdbNIsMY1ZJt(%O9VZYWJqklqP&)+u0z9!pDU#;OZ2G|UgNPxmyHM5FNshr< zzKX7N?+Mq9u@7zLo-ys&u1fRtmu!mBa)#NW*++jfQ)I`qQeE~IGJpy=;fkJQq~8^F z1A@Uk5Fn%5E2RqFr`ZeJ;vzu{V*nI4Fy{y%g7?!2MuS5@O7CNMmxW`pRC8u`N<>B@ z#*Z8joQIoOJx#FnrM%X9V~Bf5V)9Lo01!mJ0j2n)N@o}w#@HsCYmol_%S38*dwuFz8^yWRPsUQ5(DmqMvYpIikhc_Sa!@Xvb9st z3Do%5TQHwyZPTxr)_;<3VG5rJ7tsf(CY)v7v>Y;vxfG0w-hV98u*=L^e)_tG4ed$# zL~G{7R6|{Q59(-MP@F?7X9B@)8;ob}Il3>&A(l%?GEiJ8j;JbsW~JWypp zXM}$;8@D}y9ua-Cry1%YqCmerhJ6g$oH&|BmT3mFV5D*l{GBixGgTGn@CaNR=ZzRz zzunPwvgds3FQ)R5Tw<)(^DTkbFw`2Qh{M3!(d0eqKhL8X=)|4O;|GEHWzTfqFLU10 z{dW{0WE+`Cfdpic*L+*GK1CBbb+L(78fidACke(L&Ozy+i7Pt-mBe-Fg(Q#swn73^ zLp860l4>d{7rArkIq+*OIfIMTzp>irW4~}EAW&F_ZmUbGx(etI)UD5q4(C`~%imdm z0Gn;=Uti^j(<7RX4<>;o;n>R@6cQOqxzY@rGM*M>>HqQInBbOU*(FByOLeF(k;f3RET#{k|S~K~SC>byh5|36G!WmuF^(_Xq$8U+-Qk}jo@bd``=q(MZ&rMp2IDFHzmX>ci}J4HaG zR+R4UZoaelzVG$@((7`aXP!B8X70IXo^vu6in||}zBFQ6HN#kNe^Bw*B{15T#A;{m=N-@6&#^*IuxmmwQ9cM#mh} z)CXoGyr}}=-87%yu5(g|ofIqn`K|6sW>oXDVz> zZ@|>@C`1*WJxQf*5I^UQdJrwP$W@0LHR?3Lb*v|#wWvT+GvG5m3FvJHGx`?Pi`1Y( zA`O3kbp5yQbNx%=faSHn7nzzF?-kjVb$XC_iEFuMG@8EAvM2>aD&vznOILS`uG{HRv zV2UoQ-lD3^c2vQ_Y=rNLEDMD5N#ZD1=QUbr@Y)$IDUq`fQ(d$ffq*2{=jexj_v8g_ z@haSOvpr9W@t8c=w?%j82G_EkM-^GS|c=gxY5$!&H0T=i$7 zzVHqF1iQBMPAI(ZL}^69=dF^J>o9Wf#Oo(rzp|eF}KlUkZ3r^E?P4I31d~WG!zCII%P+Utzp@Q*{gjNAMDdMzoZ(*v*+7 zKH%qei0(QYX{-%ZA--i?FZK8m3y0fYqO8jn~@KEi_3FCW1 z0v~n3;N&FSsl3j}c6t5#HcP?Bh`(0ElY$MjTfJXQ;;2OQ)t~(=Zd&K85fzwzaP;U#p96v1>1Yaa&V*_bzISo8{#HN$9*X84`B{oKOzQ?yIJz9;>Vo{{?GfLaYZz$ z2+K9jNDJq@O}h2hj*-D^e~9e)bcUi;Tz&ZO3@OEw3;V{u%Do(q<>D=E&q%)(K?;mcxq zU|!C_?QCeI$Vf%vZh|$L49=o;(d?d+|B5M+3r5Ypay!s~SSJ9c2<7iSHR}8PqoP2) zSy&F{Abl%a+h|oOkDX6G%29d+Xz=hx16-3&$1AE{%MaTsKK2ELBs{|9C^X(na5DSb z3C2gwwWb+L_I~zy=imF_#6q_wzf5<}%x)%m^4%$npQ&H(hrK`DosvKOH=mrQ`PQWP z#C3hW^nW1dZKpsZG*fIdw2PGA2OmQ32C>Ca{pXCjzQf{2nI2>T5ue4~J|8W}T@L@n zQhFIrmg8aR>@2Cip6$DPP5z*1m@-S}*-%@1IBnqA6+!xn5Dno)t=IL%vVr`|R5>ge zoBcU#kEY)3);$J^wAJUbn1sa7zj{jh3Sf*i1l^`SDcuvTt1*gi4t(zd&aHM8;@&U) zicIvPCv#8##WnuZ|G~3JzGN~yZEdS$r#9yoO~9Gj?#kCS*--Vk6*9Tz8Jb&#nYZ0$ z@*`VAQ&i6hOAq(Q@c39E2C2y*m^lkIzG!|2CKhpOK9&Hp(NPpHK14J9O!&O6zk2-8 zir!%P>(8S5G5a>RgpsqaNeo^66DQk|H;wDdqVW4oBBG+8yCWWhW@K1?Vm0HFWf|z{ zBQWv2fV6XjI5cm@3PM?&twwnuf+B7B$JSTM8=$C*9Gmp764>-JNEUqTuBbX>uuuzI(Pf0-wsIb zy`6ciTJ!$ZYD0v0N5p;<8UIMl{SBEuV*MxLH9TdcioB7e+3jCT#46<*y(g55U!9Nd z`8bG4T%J&MA=Qk$Ssr$qeRzP`*AEl1tl4Ayn(=~}zJzqxb@8JeWg}-*P%y4GS^+WU z(-S5BWTmHB7@lZscu@K~Fhog7%@c;+C{CcuoR}?{e&yVS{2#WrFZFS*-R)jSLtI)Z z$;q~(ikYIg)f5*4*2J%?l9usx>hphc)ae&)A6gowI>NKDH4lQsz%R54@ZD`Ptf< zc+qtf>dL;T>NH)uqJpH(Z~R_r6Xx1Dog8~Y&HC%RdQS$$l)%MHtrb8SJH@YByK)-s zlxAUdu5tF>3&>PAWlOKKgHA68sgZ}40fxhx__E?}|K`LYo;66B2F|WlREHG5Aqf$Q zf88}0Se}D>hJ%YEf7uR;N0jsjuHQP`zBWL8aMo7&`AYte&er{Gs{;RvX{lhl#`y~} z5{5v6xfOKh5r)DfIon^~gEAc|5hX0sJgo(N;5_!gvx^9J&0MvmMlhYMlUU#b4x*84 zKcM~Z$1@JRUQ26#!EuGmZb8R?>3m>QfQS*xb6^^)9Fbl)2x{`ip9 z_{em{1=deXYkzvUX7)*s(a-;*XsgHfeP)Ja@r-;ckz@Fa96By$E!+LYFQKc_ZSADX zn{Nbn2;JMheqFgVH-OzftLnZkSgS*>$`P^ATd0qmKB|Z}j$Vy6#8}fF7DY42Hd}kN7*0p=Fs0M%x|vX%yK;ZrL*KS$DQo#64&S83Z2pLT(V?a`zA(Hkj(VO_-1vfWYhWlV4MkGhGgXRX7#aDD^by= zCOtu27dQUd>lS_r4Mfg6MobnFi`9WrBkzlo@7bkNP43q|y>k3=$4#q&kN>JDZ-N_+ zzueW`%V!FBlNb0#$ot~7`JDh^&-~w_=;?1Z<45Y&y;JFE#N{H^@5T9k6?vY@1f!=X zIPJg7JU7Z!{*`=vdUQM;@_lbr^~n8CBH=Ydzwg-W@a4%;GXvbHp&r(%pM2^}bM(+D z<64kHwj}2lBjzkZPx<1f(AAVsy>>>!9TpGyqbS;~k6=TqBve?aKQdrFevZW| zzQa}Sb>RZr) z_j%VsiFv-$c@p2RkC*1NS+6fnmXwdSxH(_-)mq6z%x3Jl)84h$e(72phfQBxEVy`? zc$^=Euu4ftO+z2AE9=qMrxlsI-&%W4{f))wL%%HFDijlqbmSM@r&RJ1$31;+e+*M( z6!X|HHrbAUii1T|Cf(bHjmP-?J+|+uW9^-go`gRTcXI$^y<0`v_hO(wdi%k&$tIStT&tc&hlB+AP1Kww+(GN!}pXv@Zb{ zn~Cj|#XvM3?NJX;5`{^@9QLtzMg08y?V28=QWLMOT?Yxr&yEx z6lla==z=rSq*LFKEH$+cGI?3MG%A0*tK?c_8AzH}*__oKO6t8n`Bke$z*}8G_IA8v zzg9m?U^Y4cycn9W=<@spHC&%*HO?Op-#rjQBfL12R}mYv=zUX}g)sZQx!i)W2h7LeV_ zmG%y!`isprtf?U)YMtJ`@t z2EXn;s1s?vI&;BrjPIHGBK1k7MrD9n>Sd1^%{$yazWgJ*#}G%Bt0#s?^ghG|*7!Fq z17~iUPqRjsi@dN+F`z~tP=hzIe`m3KT+!E6PjPBXi>|kP!pBWp>weeAESgs=R2aBW z(}#C@#1(&%6Sq6zg%6M6PZN1^-fHHp4D2u#Q#O#2R%Nk$iN=Y3pYsK^v>L+??X>{- zc)Cphnar-9_vnQC{z3k>Ze&fF$t|^Od&EvxY5wxN}9&RiBnW zo>Qksb_OfN8BW80v%2ow!~V>{hBo{$Y);58^Zv5*O0%TT)#YaPe*X1?;+3W3nJEMJ z5;4o=%6t6{mGMKFx1Wl5a5xw8>)>SSg>}ckYW!?CV_Su{o{`AtaYoBm-z@APSXkL= z@vOTtBA#nDxlh~S`E|9VeU`S}J~6LR3;PQa@WBovi^e9tH#1e@@hj(1OHPb(?`(bS z#ljLpkD>?_52`uyOjkL3)a9jvGv1R!E^kcg;d!7_!{4onLzhwIcU6Q=Z`uxKs)|x zC0{}Xb;}3HGIS%TfgC$k?=L|WoUsns7Cgr@adp36i=Kc9Bia$!h29<0`dG?=JLhq= z#^giZTe^d9!u5kq`x8zGnAm>QI%PWH zb+mp&BwEc+t3Mv)v@SOOV~A>63dgBr%n(AWlZo+|CKH2}Us?ozyc&A{X*FzC-)<>k zZy_S&HQT*ACyy+K{4*(5rP)%PqMT?&z4y{~Wny3t9}TIl6lf#}=P8iXO6b2xc06Ug zeq0@hwye$Z&f3ebiCSiD$Yxq9%n^Bp-rX{ z>dXK4P|-t#~RAMQPqux@jSoo5EE7G!M}63(vvpUE`&Ce;6~&wPpDMAN2fop z?Yw=kBeGGh1lvSy=pn6oLMB<_)nLVRy{r$eY};Co65sVis^2-?s3Yvm;k3Ukt@gpG z1^48jwEB8?WwH4B;^1^t#I}k}5sz3qC{D|?jyqza|HbbBmh;7x!f^820}ewmoMgB6 z)~KazSRU0>8LTPPWZu7aI1x%pZ*;$2n%~LT{u<^z$0KF%zRs!=_*_~rg6bXl$T`fz>Y~$-BoVU=c29f($=@;sb+d#2S`sm|qCXkM zxC$zRA;48K;u~7U#7yn-&MUs}Z6?onYI7wwwC)o$e;H|uxON|zzX~yCc|d4Q^BOOHRnH$9WH2>K%bV5)iV-bj>RG*PK>`|t<@o#8I9CeF_O%V!FxOz2U3#P zOM}ztQWDK4YueKnd*Gs0W>2kO4oRVL+Jk8hy=r}RuLHYvk*3(9B@4wZ>^ap=MAHqN3o49i@ znF8DXzFw8?eX(;|y(n8pxwZ5oq66C|-}Gg=Qlx{;{1L*PO+hbg4XnR~b&lvGsB@W0 z#utLg2|@DdzcXy!U=e1z0C-|St4T;Ac27tNPBHpK+yrm0qt3ha`Cthlg<;b)<_O}G z9f(hM7_@G7aiVxAbn&EYmV`@*&zClQ23r!7&W4E%ON6v1I3<4rd%g3=+Ad+hE^kf^ zUx!A28x2K!q*!IhGiW>4^}f`yHn-n6)OH76KhlT`be#vfE{E=Q7n_;485j$pf z33+Z$d286`HUlz5>c=leqsFUf5k_0Zq)FoW>iHj3_lI4IVtXToX3=zGetibZ{f#^h zEcd71-DW%SKa3m2YHga>kYhF9M>Sm9XykY!)1hI6#!vk$S?*!r_PiQ{n(e^P2QPPc zLfNQjuPE}gtO-FDu|(1V+m4s9$4-@PYCePooJL)JhSP@6YTx4l%Qyj|VofaiyJJ={ z((bdFpeUnsk0I!eW(2M)@FdI`?R&fnTBsK@2Eu=ZcpxiI{9>iRPP9kkjifHt?%XsG6Y{ z$szF_weV(Z&|1f5!XU9l)}eR%9ob?av1{PG@O--308TgAX1Syg)4T+5Xaw7jZy>K) z##hY*ibW>U=sbNp%0^=H?oA&EC&V)^!zv&Fdu~@cH?S|JDQYm{? z2_LD;3=Fz2NWE3b^>Azb0HDWPEYf%!aFD>v_)&`I8+h5Al3#JvKg)0d%bbgg8i{{B z6s*%I*SC8RNc1h0mjooC*jv(S4$Hr#Rd(W2c{eOnRh*z|^};>EG#I!AD7eTDv0^cO zV%UjZfat)Su4I-PDSy$fbkN)jSXOj$zxr-iN!RioHHI7rqx) zr^DHa*B<*z$9g7=&0hO@a|hV~=X=CC(j48pKfRQdWXqz9jyt!#KxfcD!~V>qA>r@( zu7@YOTfB?(^vQD-q2LY2Vm^vJU$W&1E9@3MTKp#a;Zx0;kg-lJdeoA*A%g+ZArO!D z12AVIm+q9qnKs-Xc8}AKNpgqo6G1vZwfW4;{Ee<`&RpiV($Nk5t!mXa{w!!K2}uO* zlxe|+I-dx#>;=v=8x;AepH$XD_{%bJ9C$Nv_|2ZEazGkUWy#;?)p!!a@&gzdI7AYp z9l?fi;v%Es6bGpWC3#_))NIQB!3>X)G(|GR57~(tFO0e#SARx3&{mMOm_SHUZpRvy z1zTlp_ z&j$q3s`%eucMN2wh7hg1&`=f!p$&b2bC7wDgHGBuS23{ba!X^EVYMJv4WW3W@H!cj zEce0ffGHJc$B?%+p82lVOrPKE?EmpIB=|e)p8e0jfyg-W2e@mo9GJ=yRz>!jw-|J8 zWg3PF#lnXCJUFfI32ub~2)`aB*Jx!8G=5P!mJFd)OWci{mbB5m<%#UZdLGy?)wzvb1s9>()_O?Ls>w=-2;`FGn}AZ_lg0OtUh(o9I$PkW=4G*r~=@&H}Ks6~NLX-RrkSz3J$m^&M=cgnv?) z8XS1>8}q-KE8l4TC2ZhC?P}NSwtY@Jzig!t8vjm`HeA_{unpvbB3)GBv=TFonS$0N%%tw&StY~pT>5Dh+O4&b<&G^XR;3U;;0cn ziucEO6pw*H{CZ|-pJEzWP1n+7DmIhaWfj6F^vRs-7G;+eN^f76

gT?e$BDzO^^II*pEtQ|y0fv6YsYXw*wVdEzldMA+|-aT=b(39A*PR_+s9 zIMZ!_mqsyhVN8!QGsW9}P|l7C7m+j*Jic&tyx)ezCuYNlwyO-l=xMn-(N(@&kMc#8 z9)y@iKJY~>esEXH)}OHxf<*D-EGm_GEFpT2E0z_>f>1q;>O2M5*nu6$&RAFI_&u+Z zb@>o*#xu3jo(PP}Jwr)9x;*4L0UJ(;rTbOel7vv0^|mYLN6yyx&$h~dsHve;B47h+ z>cqBfAMZe+py2(OFAhS_!tmBF@^NKIFPbr@9R+_em7j8H%kQdDaW{brF2{nOx`=E) z{+$->b+$~xGQHz{sp>js*Wy@O-8zjl*9CKs_T9B-m@}EK<}K(MXFn`6%mhfiTs(9N zlJyE}XX%!c!JJtsT!my(6kic16xYcXEJ5=k<#9S?)idsje!)6;%?kpuIwWQnLiMjAySej?K? zEV3jN599z@!q*Jyqr*;e%xg8*y)F z-iKLXF<)R0JaIA{5U4pJ%A~BvXN$iMh1TNBIJ3TrAM&6X?U;%rC+%WFw_4Dov!X0{ z(z@&$EaR@W&siV@mx873@ZVnDmgHnIde4KuF_b2C{F)? za9oVsd0*{)9l9eL7Rw8ic_!Jc?^?L-r8V3pB7YU7P6nRfcmq3H^!+PiUbaIVO@eCk z?yMHY`J9|DsU;OxQmJ7xELkD2;2A-PmtWUMb+=y(0C045%z_9OIG}gYGZ0f=eAe2BgXXItc4{7B$knKrR3+baafKUvTG%@k;9=DaT zMAjPha^+7BT!36BWfk%WHL4m5JZS5C-Pb~puix$4Gm8d8EgorW z!!6^5PE2UK;jPw%}%>M9f zJxV;yi#9w<`!g>nJx0d#YwdnGGFojd^f@K=oydA^D|F*&P@oB+NLD;)M8_*oKdR}u z6MnXjs3XYR53wRIJfZ>OM~Wn{W3pBrBd5gO`Iu}YoIy-L7vy0v5a6cp#0M{~!vDPEY#QG{8=Xd=tg1E5;-r3%*((y&Rv-*i6A5ES%f6{tXbs= zK)bjA?c(C_FBrJ0#@UqWezFs0;QWl(#vL*UzBlCm%kRM*T&TB6$dl{C-TiG_#x$u* zk(Z*N>98J5o;&g5sdYehbaY&Ne`dF10^p}==qV8_M3omLSE+jC5G&4o@VxM8CD!Mz z_xEMAQ%C@4utF|jbjRRS>ai~~7+3mNgBHgW!ug47yJ7TLHvm&p&>S4#Lwea_^!FFV zlsHv>udC=hl}dv`O=EIqSLG?KTy^x?ogEF5!9Lt*@sSq zGz4Jx>D7`{SQ^y}>bhi!sozTb;=%}=XTN9?C+6;DWGYnn1Lt1vcxgcqCad3OGX=whKO*{hpi|6K2sq+;{MWmiGw zVph@(X(gVgbq*l>lB7z_?6m~1oUNKoe$h*{yj1>Vudje8jOTm-&e^9*Yq`{PF72M9auiv z0eJ>2fBvm#IDWj)iYk7UTSrwG4{X~-Xdez~hp#R?M@DJQ2Zv?iDKuY{<@<3l-(JBp z`uI>6YgCQ-5V!2UUjsS8z0!2FJ#DJMw_~&1k(9!r%#*_`#ay@`EHqdVpaUQMvR3PD zHm_L=eDnz)*GSi>{k|Gu4LJciCQG$_4)s-RCtKM85 zY%DT2dAagsyL;a!F$>pmW;l}%C*V&hW%5F8?NaUch8fi+0gv6?`FxGeWBQfCWYMR@ zU)X;(Tug)7H4|-L+vlCtc%h_L>7yY96|Hk3;5_a~AK*N_;u+>s!1y?C0~%cHXv06j z=0rfLy-)XpIQ+vM^QD*Y20CBUg%{}U*n8cD55~xjKB2NMZ?^U9qo2ji(ltu{zc0p zI;;G)oTJC+k2I*Z)xQ4(Rs2Fi0kQibVNA999nEp!qe3?l=abMP?K@yW_lmT@X07JZ zkzhzVeuUPThAQMojwDsd&Kt-tf#|H!?jW^z0zTPaIPld79ZHr*px#ck%69!Gp-=8- z7)B5a8-#dp0#abpDkD6xj{dTgpwWu@rZOG_m9YaOTnzJ{Si#FFQ-<&?n5itV#Q|L* zS-2+igB7g&<*!R~3MTUSB!Y+Cg;5>?1ivv0U~>u!34)nZJ&|hg`iYRWJD!iDLH#Q7 zuYQdLax-j@^Q_G*g`k$#A6yEY99xT&Y zG!7Yx2ugMHK_D3^{>?5Oyn&%idI)G3F^gODjo*jWo;Q+rf{L|pw7Xg@-j+{8l}k)w z&KxHHl!AVQIp1Z(#MxNc&x55&-tcLDVLq%W$Y$bk>33Q3XgLXkO+7!thim?~3D^7y zYp<%Tl^A!9I)rxIY@n8Ff&ZULwp5y!x;xk|5^pF&4si zqWO$j{>J^rC~8Obf=$;F9#J!esx~V02j!(kgn7&}z?9!$15!pVoMf>fr<42&1rY{hWBmE|EF;4J5sCS~-9 z{6e7olKR%cdwc%p2J9W$(GKjw1&S&O@h)g6pZ;uc;KuB z8`!$H{l?Z<@FCaWCLCaqLhxU}3Ler~QYQ~_e?ziPJDdEOrJJ3%JrrD2U-^@JVq#qc zu7D}K4{0RdyjP0i)5d_wC8a2~cU%WzGhqmW8zRY?nn`wRAK~t`f9j3zA%^@3MyjLU zN*e|PUd;m71Mq5NL3!UIXgy3GtIsrtkFj}2f6p4C?_#k>Dt_X zb;tl-0Xc@%-I8rs>4L_;AUOk-`)6cK_b;f4nNqoWzX==K@n*V1=kzzHp_AQn`mp@DNnh1QT>T%>Q$WMBo&oB);p!&7r``W4$+4KH`_g zcBA~Ye4O%zaT^6qMs^4`SKyQ4U~hM{LS)!S2?O`C6s)LKQa2VC<^jJ*w`$Pw2JNCH z1J%MTNN}TOVk5EQ+3QE@8|H~p*a|s?a*Lw2&xi>?)@6O7Q&XCH48~(J zId_3;_;QYR*AL{l&i1i8_=A?}uB$RYGwM8gLajbC5B5e(OO`xH$v8`N8%ukfXdDL50!fuFkL4#9>al!C*e_)zf}u)29@QxPPFewSU?&R zoK5Ile}ON*a+dWp;Q!nXtmXgXFX>DEf;?W@QFlX%R&Wzq8oVEHxACX$ z_mi}GDZu)fBl)qqA<-un7r%ZoOMi3A7yF->U2Hk)3R^C^7(4D2Vwm5c8#u@x&9h zG)1VBXvuCjS^`G9KcR-4DfC)%tUG}>p3_A05iMu@#|MNcg7^YQR=0dX^9~y)70MuT z3I7bjVKP?L04&TV)2CVdFYXtCxbL|UC;gvbw4%I%bqDay2{$HIXCcgm_6=z4@3MB7 zYz6Nz3TG;+6<)Qo#nkfE4$Z<=opDW{FO1`>6L#fM?s$HO*qo{7mo6Pd@L#I z?X0GXVqumWS60RYu{pO`;YQ~Vkqxb;pk#%as{Rv85v;b(`6nSvP3;l*QrGa8$_J1<*flM(8|9|mfyz4X_fayl^IFPFVg2~~H zf66DT>QuDewS5q(eXA$>PbR}-Ep+WI^xYiTr6$F=)%b zl!fatv!9s-An1Vg2hiIK2}u8@^78JMkF`NALJYy@@9Gaa2_;@1czy7^;AmI(>A(h{ zE7`;M26TN^|CgY0%i!Y+%WD!Jq|A%8@If!V(JBG>uy?}Un*>#Fku7!z+EN}Y9$2_@ z8l|z;CQnCAKc{~zN$D4QP@ou2fkJZ0q8yMfcxt5`wcVVkH0@|Iel#pLTQ@6WfB#=H zjrKr-Wa^h1;cwq;3#Im?{1NoZQ19z5<&+==bBP>?6YQ(#fqR7tQ0m{Q0W0y;{^D!> zA07nds(8-q|aj8(9NClN3mb7qVm6BnHb>%?tS80CG_Wg8q)Am)tLbZK+ z3d8OSZmHw+cW zBaJuHWfp2vw+c*HTS##H4P9F>dA3UYiqKyWMQ`9TAv)dzzDGIqpgh$rtZGGQlZvl25T zq6&DiFu3+no&N2G=nT#kswE65=?DPg{q$avg3eDpiN^^>{MO&A?O&x+jhC0vyHeLz zyY2Og(_U_u?tyI=9h!t(#gnB`qiGvRG(S@+QNF+PJ~OyNJuLSNHnkDy zE`~3Po%4g;lU~r`f=ogE%HZ^Wy;%`HqFad6I#}&w|7PAVs`WTIJsIV zW^OIUU437k7C#%`&tIlCnsl-GL;IkmT7%Ev$kj$Oeg!ctNb#<;BOD^5DtWoS=_~GW zx+W#%eRcRV1pzmL->|59lEtcd`yP(HitNN68>nN&D!=zWy;ar`Y)rwQ;%D<(7K|fp zHfeNGPh+2t-pwp_xeum3(PW6R(PV

6=8PuAG{h7tc**jF;mU#*0I_-S*Xoc?=V? zLcL~QW&XekP}h?r?eXb%jwdofJf`K0B<))5R~&GRpELepPLAr&qx!3;D!v{R3-oQM z%4|(5F@61jI>4}!`6ftgDuEfGtYeJR_=uQl4LtAJwo15V#(L$!WTz3XJ2C()qpV>i6Oi8Y zN49&sFmTHuQhdgeHar$)Di7GmJ-RT`DDu1J3!i>|G*SFPMBj~KIX^)5pyHvx=ezaX zNlV}n=bGT=*pSPh7#JMY0$tD=Cu3^&UTC}kjlB63Rvrdc5aG!t@21?>Dg*O|hGDE| z0Urje7oI-qiA%~7QR87_7BBymy#P9_sGdBkA)GE}xQV`k5XT#>!tp79jei;%7Q22j zP+W!DRtH6!AV*&-%>R&@2Be0RQKV-RD^JyGwT6(lOzPnz)n#y2k`Idl7A|y%WCbTx zgf^;z{lVVpX`as7l$;_vIsF27ja`SK17G10IQ@e6n~+}{XbnFKTpog_ zoEF_7h?%`|*`A*AIlF9!G)OUAB7CnXSM>@GhPPA}zwP{VYPz-XBOO%qP2|()nB`MT z+RHVyOEur6M~MiXT5%T}qt9R7wp6cCx^)g92XH8XGP$~L&ett12~MD?HWDqr&d|ne zTNw@(fJO&l3YOQ!_m{8x(@hA@mV|rk%#;d?Q&0+lNrdOTT3;hMD+cCn4J>7TDf!)8 zdV&hx*(P?O-oV7amzm(?6QEh_U7qUcvxC=fg?x4%N)YD04yu7|T7y;D(mJPOYQJop zuHN>&+*v&gnZ9ECd$g(f)ab}1xT)?9ZTK#1&KAs&+_GhU-5%T1CHC5+$ z>K&PbsJ^BU+Cjo2dUr~~foca~{dt%3{%4l;^Vy|ie?Wj;DHaw60e0p5I74aa(|3#m zb=$`-9G?ls%$Bh(KfYoBh0)ww;8TZmllrr4wy#b&X9b(4be;>%^-A`1(PZPUp%x!i zh|Vb(?xL?DI*3N=Mt#_Hjv=BaMV&-98Ox@0aiWCQ7lpBw!v}2^ZctUXRqGx0Wk+Kouarj*^y;N8T zY~npIy1gfjZ8*#?J!Qz^6k?scHIou@Z^56$Ux5J^dY2@yB6j(y>Z>Q|g2_!j<8fP9 zPsPE0En!n`xQGV(wZ_klQ@Oo*tDN!bBjxw)*SpAM?Cut3!^%7~e!EG*j)t`G6@1~p zSbJmXui4BE!wS#>{@_#y{%~~sc?)Ae7hynCS{AyguUbSSi1rDzhwe+akXtjC#-O3W zeh1r5I!IA%?;?nd;Bc^r=-PVpOc

?iUU`f7=>hWZtc*E5hJPtWL~_yTX8`9Ubi+ z-^r=wld&Bc$@4W`iRH&8lDIJefav33`UhbC>RI~gi3pp5(V^@q)SfyLzS&caL@~3g z5gGaGQoa|9g~^%63*+Y_=cnxh2AS2bf!zM62@LAwDG8a zR>|$D+sPFBPwGN~4*mO{MP}RA@RP2_qbH*C(Y|LDrBx`C?-e0{H9Y@#c_e~pZct<1 zwnOop*_I9j-_O>l;5(FMN8bdVL=L-hmjt)hwn1gr+O92)N+p8<`G}k++P0+I-_umF3%oYJwHHZ}@IqNE~5F z*bz5oB{P+{WVs)(a0irH;L}yuJb&`zY-Mu5#RfaFq7 zdFV)E1qkN;$>U3D%x z`EomQpr+NZKxJ)SYB1PJ5$t0!k_BT@60@0%rsE3VtNmv0^Wol7n~dh$B3^~IprkD% zSo}h&$4dTOmJHIG{{({+GZ%vU4(v|po9y|s1!T`Yj@ObH zu-^(66LwO+t$DAXU1b<&UP!e`KjkkQ8w379_yw3g*kTkow>U zq%uGW0;O_efUsWjA23w*6QyYv>3)KSBrZ*MNFI2go++ z{VK2;^d8e?*?Ttfwo3ZBEUIl<+*nMEj!AZ;V()%pj9*3sa4`YHmN#$lxP3vB?8qQe0y&|d^8Zf~tiX2peJE)I?ZbKT#>6uGy&~~(i6)Yx|wj0R4Hw&<7j?(~~>V^~sTX92$ zcqXQ>F?@vpX;zKbV1nwgM}l=~u{M5%In7S7)klYox0T!yT{D z=v*2vUJMK`UK~uuzLxsO%whGHPz#gfO;Oqv?E}>r%S6KG=?b~hG5?383%v=$7 zLt7YcnrSRf6da}Zq~ZYE#|9pYetVN+zRUW1>9m3(8D#K9{>FphL1 zlpezz%-s!j`O&(0|L}7W(;B#w15c%qBI*3rTg?l^xq!*FO{H6}a?&>RceDwmIuxQ0 zI4u@#U<}0llmoli;k0|0b3te;J5k*=q?zpatbBy2RJYUb@uTkEdcJo)@5WaFP!gV= z*@DTzzSXJ>uWgD`Xz&;=35Y9!yB>(ZRqpJs1w)ywYo;+S$UB3%j^?s*N zY(l8bd9r@I{ZCn5TT6`xS&D#)JwW*};G?~Gn5$jT4mR*TB2(5D*?!z^wA}_eO9L(z z=seK7&%aV#yW)ugUu{AN1Wa%*4`jhpLm>1X_)X1HO|+OZe``pl=qtiq{=|5$U?z0e z1I@j=)f2sJryHox+U%CKYpf^Kc@p@y&^C5C8iArA^-vxR^KQ=+6RNdIpW~y;V%O^H zUnwHjyGmz@zcSt$+vN|{RrD*#9Pa>H1bZJ&L=)d(EE?au&m0-)Z}rPslr;pw_O)BU!{)$iT3=rF9FTIHC3!9WTbd<{+Biv`^X}fPQ6-GV}Vn zVBV;R?DY}@d$)PbIu^y^_)VXPDzQmjkkZQx{m8`YzCpj}OY8KtL4>$8+L&)A?0G6h zNM^BYbDPivc5rnHZCeO8c+Q`n{cz2{S7+B>Q+Bu@M%0PhH!5tb=FkiCPU!-WX6{qm z&}5my+(m+QpLZy2I55r!*TvroKNNlYxyA*zJ9@@QBlWg&iO0s<_f<4eXfMK*3FnaDCn1lcV?<;0|hXU#p6#eq%IKV9ibYHo6q z20(Z2pyR(ARVAn}1#ccD{pKMv7nKfe?7~9D&~m|>82Z{W^mpT79zlqdA<9i=O8j%t z9PI28-&peA7b-)J7p8K1(F;vPA^@-WM&-+vEaW?;I)U*k4dnf7Tra zX{4t3x1e-z+cSHzYnP%zo)`g-cCD0P(<=bkm~b=h{%5|5Ca}wDJ?x57=A8OICcx(n z@q(DoG>H_r_V3oH3(2i>dop{wUI-M(RThB^%A|wR_L$K%0~Drfm*dCRUI!cVA-|f5 zqW_Pqw+^dvd)|jP-4dddG$@KlNJy8G5*Dc&6i{hUq`N^HL`3N>L8PP+MFgagMmnV% z0e|ys&N-j&d%gd2&9nAe6Zg#AGgQ^N?d^#hBPku;u;-W1tJ%Qab>d6~1i7+LA4Knc zR;cYeJ-2uINU|&0a zGewTMM$)a-7k)QaQ4YB&+%qw^7|2?CG)e2Jo`BXlc=pj)+<%_$G*`Kj?t4!!e%;Il zIP(tt3Y3_@=!{xZp$^3a#*6f+whlE^-QNkoz6%h@HGYp9a@-yo>7*Nc6W44+EJisxP zzunyw$e#E4@mz8G%@DE?B=R6n+pPctupLfJD;PQ#E}xa&xKV3Mh( z(q=ET!CKdP?{6{kRQhb5MC~i?ya#Yf#cDHc(4E9eHcRK1NU^6ukK*kY61MZ`paQ@- zU(5~7m0Etr1W=IfG$r8h=}T4TgE90MUQ5mleT%gdZeleQ zLpE9vr}wzI$#T2NtVhzba4q)-z^89jW>-P@lBve={?6#zzx#_?mD8+gF0Xpd*o@I1 z%s>SGSoozI{K}3{u^@+uX^3O-Lw7gX+J@xbmt==06)F$TSp2l${XKnM`eNIcHMS}N zD|>r+WrFZ*$GJRY5h;B*E9y7wSckc$dI~Kd@y8j!HN6J=-;dIBKcV>9(i0J?zo<6vE$SYfn7@MvUPFL?O0xdftgiAq zq7U{S&#cX5c4442KWOp^l;&b>{JxU@u1noIIlTBXaAn=5d*h;DNJqvXC?Zn30p-Tc z3YwfLB5QZBN1*ZDj1}%8r4Yf@#O)(@fW$+zwR~6IVDG%^fZQ)WaNA#gAZ}a8<|@a+ z8`b>f4TZ<$?oL&9nOk~Q7bhi`RJf-L|uf*>CzNoB1 z6IIFYV07t)ABPUPp+Qhm1J^_0KfNs-nxPDf1;yR-jUP4c{h@>K=mz1@jYWO}%QaPX z-EDlO^UTUOqC_zvM#y3oCy^SMv(CWfEn#CBzOn zGw9;}?kDMHv^^PD>D3Ia`aSB{yu04PrrDPY;N8fuG#hN^IvHg*QX;)_|7vF1t}BMe za|@0i32~A=JVq!+lq_#V!b2kx-#>Ni_cJg>gdS9^fS$pgE-)tRtLSjg*LFKpkh;f% z)Z?b_wIT_1q_qrsk>8<^s-fbN!XVp`TzW&3R=I8WNMvf1Y~y_VrrN4wT;p^XI)&Qb0?fb1wv1 z;!I{ic4LUXB{62R_#-2kM0dUBv=NWwD_nGFek9_Jmd>KAInA@15_aS>%$UQ-tIc#l zMX(C>;0ptzE@DT9RgfNK&%QguP!Hj9{M9@?BplWFmHuom$VL-NgkRqD zu!dbe)CKp^nP(4%GuyS%ojf;`kURgmjPJLd@R$MQiaRPCh!aJN#e_@V?(N(#_Wz|F zVb_`nTA@~2U~!W(N1NSj+T(a`WD>6zf@H4k6E{t{0fM#TR3tnC(*~ljKNQGzlbU%q zM-Wz13iv%9x4RlLGkrviqy|CPH8!q2uAzC&NC zn(88Go>#w2i)MPvL}ia7^UC3URjly4Jm>Z;firbm3txvEg${ZZsa=k89vaAnnOVaOdmv6|}*2{0ftFA1J~h zDb@a8QhFDXQZ*cn!n>rS6_!%8{Nwv;^*w!;;Goz{%?&6fcuE;v$$kE=Xh5oN597P1 zC!AX~eZ|*UJ1cNx<8(V1rlCa6QZXmaY1}5Ec0kRsSpl&nMsRb(18Z)i8?Q}2ho;i@ zmn&gQ@Kjw*XWt@F2#nCB&R7B?f9CzkH&_0=6ffj;eFpL=A9S9bZpx5>R#OetJ~nQK zuoIa1hFtW9-_;BKPE!wxqAG}QM=SWHiA8=oNpPt4*$N@S(c18{8Wv^t?aCEDZY6oZ zV*my@f3FotA*(ZfznOLmkCm#c2OvNellinI&zLh~xV1T(j zgVXN4KTp==2V~HnT(RW#o7wR~h@5Wwc8ZREog;qQotqq~sFBfr28cJ%vJxV_HKVfEJ)NWbm}R zj_{%H*akkkl(b6p?Hhq&EAEKBBaDK>ml%8Br>V4Da-~S=*}(d}nR^7B7=jwJzu3lx zb>;U==a=tZrzzHDox$G%Ozg~g49y@pUdEOHKpuPV89In+TvHV7@-!cPrM;nv01<>S zWy`k_OrvQ%12=rMDQjlJVJm*rm94#uoEf^`aOR$d`RN~XyF?&fo@DT*$nV+tvo%gg zPs;~6I5_PTMJHOc-G$|Mzr=(!?pS?=nPfz~Ds~%p7vF{o4WD(!!}&7CEm^X+D*!&Ax{KBA?SKDhO>pRjw_koo&CTn+ zP035xPjU#UIV3e6P*wfQC2usDw5#qU$wb4v8Qy(Gc<&@7K7K_@A0jZjX>IZ}uIb12 zN1o@d$M+Z@7KeNE`NOqX4)>S>;FhP!R$dZrX97Pm_KFZ<{C8v^$RXw(zoFH@s#AZ? zLQ;jspk|BT1?z9)m}38$%I}ks~-JQqY<#n1HmJ!>$#Q8xfgJ5;PAf=}x4 z9ZYDuyZG$IM8|U1v0ghi$OhB+o9WDA%J_#W=g1VuHYduT3ErH-cNxx^Ab;k%cMl5q zIOOhqVekzLo!EsV@Y*GOKS(lgk5n9(peR0x0F)JaQF?znK?{dsl^4aEDx=bT2Y<{X zg1iYag+RnI!%i$yJIvp5#L(KWb7k+3q(0Ik_}4H+f4G20xd#p_wESD=BVf+UlDm=$ zZpmm8JF~=)Nvi76YrPAhc=YKEk9Q*H4-!?ORa?aBP3LD2go1z{WqRO;KqZu1rn{&w z3J&apE=|W0;Nv8F<(iLFcWl&_)TYVg`8P1Y=Q^5QxiKoLDNy2~7|-vu)4T6=x~r4_ zYg#Ft6dj@jEvAm0xo6fKw$>xHF@2zEOdn`>Xn3n?xW;UrxQs>U=pHz!tA$^>K(%Kx zHjE4GHidqDIU62xi`>&0qt0pQ(iAKK>Y5rd4XM9ZvFa0u%~I~$G|Dp_#eu<~ zE_Yo8gZCucB2`_a8%xUHQn8z|y<@u+%$Y!cx`s`t<83L?e)?(quZZi>w?a20R*hH9*S}SZ?Yv#?|oyDQNpy z{YDdwqMV)nS~Q&C28>a1VjaU5oJ>gf%Db;xO#M7aaV&L0y*&}VUZ~dr1({K9PY)!v zH(L%=z!Y*Fl{m!Ua+lEe9YyIW{H(lBIWMTPD=?Wp_+O%cdy*&+fo?d|ylz~b+{-E& zFq1ur?42N!_nF!OkwX?${HM$S>8#V~$*__EfCiFHI)&nrsS?x6CLI=a{wUm2T6#pt z_Fqwo@Sma-=!d&=p;!tNY9kj9$^ZaGK)PYwKoKSYYZr^oG_xzfHXLWp+nDsXYlbeC z`l`3+U^`ug2$QAqFq@_pJ;uJ1wb>q@c&q!LpHxwoPPQW2cIak60Yz59HI-7R1^nkX zv`%tIM0^^MVEP&V9$0HznqUBwKA6m|XO19(6~yoNY~6vf1ptK>1SkkqUTeJds3}CE z>hOz3Sy(ZT@P7{%NOw|Ayn4SU*17LRLg_5l?+wiD!qf4?kt@rA;24X+rxWo+@wLK6 z7&4FvI6CM@=ksoyGcm@^QP-;Ev)E|5a~=NC^SK#as1U7UDn#{FRGjRE7FerVD*om} zveMLfYYC31>O3tZdadTZf~(<8%?LvJYekQ1x){Dd0y+8WDJ=_^GJsT%XvG{_*~Ms) zsUJ_nsu_RWatHJzbAq1Wsrfg|Xkg{Sql!$oE%}--t?_jY1{+N30lp3>G)2Gq3Mfhv^*o{U6`EuuXVS}hH2fc_?Zt~D->f* zC;aBnalh0BOJL1Ydl~IXI+DjfvcJ$lgoH$r-gM%Iu3ytog+^cK`jaatkq_l z09b4D`;dq$N0Ti&O62STDgyN@UWnrkp=~6JZ)jwfqRYDXll>DCS>qJZ@NlPsH2*2*=~jkanjj&eP(>0FgfU!hV@nlEL3ZLkL}4cotSuZ-5T` zMw<-{H@~0+?FXn;mk6+%4%2#r$&N7926vkGWBoa2Jar2Qpc?w8R$ zFUZGP%ZEM#(mTv61E{l-M|!;;&{MEz|BGo>*v)gZo{9u~l7k!BWl(Hd_K0^Pw|)7> z_SCAYGe&~RCK17so{pUK3h0Tm{raI{kZ3LOUbcAY-BdE5dzmi8G zlHwJeeOKaj9vTRgNJw0l(F}HEiMb)6AxbM-6-~^#w;#N^N7sMn@mJb2r^6x0EGeJn z{o5!#clHX)n9AohHSzgxkH}WA&hd`taf13OR+|xlnwQRzRjV$q?OaOX?ycTp5U&P~ z$b%qX0ISu2;T;u;X>r2*N3Chj4}Hb4WE5>Iv!s#Z^cY+OEoDtsns2v?Y$E`KmlPKL<{1aDJ2T8wzL>V|YWP7uGpkHMq+X z1uv1lxW3VJm&!qCdbM!f6?w7npkw;_eHlrQ z9WJGi^t{syUb+1Si7(Aaf(O9tPln$GJksHW5_>(1k?ncq9PjFJB<3QC<2o-Uahx&O zYbx067Bl(^!F(A>d8hCFK~i2Xdl~ez0EC0`>3jw|Z-b6MWR3%v%u!*-@51s+EafJ< zCbcJul!ZJJ3wJx)kPbC6P`dRJ)_%0rV8ocMxv(5d-qTL6>?1U>c76 z3PbC!keYi5pBlsHMS2Iwc&n)JaBv?!mb8ul^4%2E?mPMi!{gp88W9`m`V-lw?+It# zem&wngIWP+<}^c6QQpnxI>mJG;pyo5s^}&r+n7R^`h)zwtC3@~NI84_ym0SFC$8C( z9BCN*AGt&N3;xOWOIKYbv`)Dc$2p{{%5Fl_ZR5Q{RrBAqj!)3eDDS@FIu!xoyya;YMDyvu!AdzC7P>T<^4-z)6Ro9D0}!o zTlmbS@LzE>nE4e5k;~xvUOrxU4J7ieGnVHa%Vle9xiZl~j$nqp<}7I3+tsw5#y&Cb z_PmeABZcwEFl0UgRN?jN<~)5=^(#k8dWRo*3--BFIE8xEU@7%^XTef-bg@y6NL|59 zeJB(?jp=SUgG}gdfXo`3DWVkgaC?+Ssn^!Ub1&rP!2%tH7Ede?5$geTk{q=Fp_r{;J+-JiWKx_foR}f(w{n9@xvB_oWNGNGK=i4`DoRJ87$9B(oKs zNUn+|nhMhMk|2x(QcIZrV&dq#-ND9bDA!(;c#&F-b8${LsF~v*!(F2IIYxFuaUL{u)#)J4I_o9DIMPB;f zt05yo$n}EE^0uYqFY=Ce^f5C>*Y4RsJ9>Zf<5+hg59V@zVlLOqf>LSl zb3iodaktyKsW3sV6IucI&Eo(0O$$(l76!>fT_zMTdEmJMs>}vK!}LpM-&!Y~M@T(9 zcRxOI9KXe}2C^MFD?v7Pp_dh<(kRy{JxM(-rK&dw$<}%TwS}utV*`B_<$tF$EQl7|50n!GT>h* zE^FS=v#L&ogn8^t_E|1S_MQ7Cqo$-*znBi7hOLfI@j5HI1XYqtOd3n<0QLYYtS@cO z*GEZw!bVRCJ5A+_ABzvc`Ejb9`>|)nQ7~YF6^H=650B-_*EN9(@rB!lM^iJ(aY1uM zewkC_rX<7t`B|;%`5VieFt>;SG@6An70s8?GLogK=qaoHi3T}P=pT7!u4ux1sF@#0 zjF;2R7}cxR!20t1A<8bCXa+lnobW#55vvFkhT7PEf1c!YY+Pknprzm_|9gut^ieQd z9D>7yux8KD(!9waiObS%GatEP{p!v)=}U_nAA0!;$0}q*ueIU0E#*hwsi$!Qo{yjT z*g}yPU;+iSmyMTqRI@qz{rejuis)-(3=jDwj>EO>6j#l8Z|#aIR972fx)2-0AtXAV zbepdN-N!1HnfPaLqe%9BsaX2yJ_Z^t0s<$?5E2--1P0hpNZOAfC-8G#wjjFK{CWRZ zSZyI`-TTbel2lSIW5E00@|EEO+z4YI=9`P{jVJwiEb``pr2`# zp)PNe6<--)wHIyS`W4_R#bq0QO-(9qAVlF3F&i1ii0ane-|x9N$u0G{I4+ftPynK@ z8p<0_4nHe)pJI!fPj}E}Lhwm)C(PIqniCS&R=( zgM_k=l&;E)U)4?t2nx2tdRsht7AY$@;YHzN^d=qjCfw=vJO95AUnRK*(lGiu^WUKS z7v&IN4sGjJyQ-0YnXIeg>zMAv<#iGF)S+%z1=I$sfZA~A1|GO>z$#8J=h)0K^bI@N zx4UAUZmpY|*Cp5ZJA0wJx(L?FBhFd&dY-ZznJV-sz9YL?82x zze5OU+`96DRwWKU^(VqKYA}sAm^OySTSc+IioA6eePsj>SK-2@7C10x&SE5`#?-Vg zT4YbGmz};HN9io}nCap}uEm8D@CTJjAxzPE#yqg8V8^JYg`lV>ZwDceZ05Ql^nwrN zl}_94*T9a+`MRmzK0t%rcYj&s`rr<}?)^c|V37{lp3s*Vb8YW}Ai2##0t zbmeSUKx5%-6ug6bnHU@F3~EfG_1M=jYwoWfM2TLTHV3-@59G%2-mZupn5|;!!5<+G zx0z2{5OxpJzPT{tI=Fn4u)N#Pa&`mpxX2O?lap>li$6l*?aeFt=JAR(_ti;p!32s6 zX#2O&vpTbdXa3pBH47S>U$}3+-);JkA#U+>y)E z1u<~a;W5#)t%+6lYS+s`&F0A#uu*7wqRatJ(ux@#l05)6rS=!Rw1tm1=8!28gyG#? z7+J}x^g@0xT1$$yuqlbwJv}@naP!6>rm0j%^}^>?qw8KlFNj})L_IBRH805Q1*91b zg?gjV@>z2kl>WQ_tM+JNM!USjKn{Q9?i~Y}xi9B&0#f34+V)XryXu&*$Da1%-xsvq-oT@hUMg#JQXr z6b^&o1?WA-F(AE1g;{@=AE89fXr)Q7*YI>>$kPb{bsU}!p^hU@S2xz$UNQC3JauRg z5L9)ZJ#bHU3L@BkR3!vI^@`WFcTD7T!la~;NNL$2l!HuGgP6HMVcxpl(MxbNA~x=42rnUq&$FSPIJjOJDa_CgW4N*uwOmAsZd6lh7D zSqN~PfdJ6&GFxR`H>NO-<}9_bs=nFXIaksqPl??SAjb~eaSGs$6UL-}e0XU3d*s8H z==U6qr1Fe1$fE0+^mT-YqkFII+b@-VAYLr{#15USd!ehfgj9e%`YQ38ZT9EgU7fTZ zWChyCE)*;Mfi0{YHb~C&=4^F}hA}1?8-U*tRHabn&tXY+THXE7KqX8uqN$nv45|F` z9_ELDe(U?_ev+6jupk>O`HrSH4RJ;hM6{UcgSN0@y7;MyGvZn+hqj}~hZBue`l4u! zfr}p+0N6jp*BALcd7p)>^xruW$8qPA!s5Y!k|?$&X`Q?>n$n#};1&gz%(L9!_vj_S zh$z+c&}uP!)O}@!V$*L&x8a{TRk7wF)FOgM6vsvUUe{+~QKs8BYI|Up-)|VVfXkAkI4BHH^6>aGf4ETh zedE)o^E#XAz>b-!Vpi2Ri(2E$1OjRA-G%R~+h#GLnB7ZA_H80Byj=XcZ0T<2H;>oc zc^L0dWrlc%y4F(Qu;8d};V(mI#4~N@rfb$0j!lWP=gh??oRpps-Vo-Pu%w+C`K~fi z@^OsN+tW9MACD5(7z3!WRI5W_eHZS1C%CNeBhBj1L2D>No#m6^8y8@)t!kb%WgjuA&c?EU^W%clr;DxwQ|$W@n*EkMRcaF|!-h)iX1VgIzZBu0eBJr4N3K3! z$hkWwpo6UW%!$-SoIP;LEQ?=jnO|tcdHN&=A(g=v3^ka;k=mZ0B8s8S-c<}n(&rFi z*84QnPNaRvmIj27ro1R5AjI*|jJ9C;``Z~Sq0^7%DNi*~L$NGTMd%7;G7hLqK7xgqsvj$$9{D*AL*yp}*Z9;rsrBj0TU3B(}4! z_Xj*l=SxI2^!n_`HfMk%V=X@;)EJiMoZSd5FJrhHP<<g&9$y!hHAdFT1#!0c*xhU5YH~7RvBuV}Z^YskE zzmI&}817u$@#4%Fd=1Q==c=?t)){8mnQlAX^veld-<}v?*qQ?vZfSMlj<3r=>;i-ct*i&*(bnq@znsm(^r!0 z@?xR8!|H!N7y=!1D)t_7CooW930$AHDj{SV{l*ra zS>Tu8KDoI=o$&xh=P})4$kGHc^-hzg*=3{KcaXr{mnV$yz_xP9z)b(G>|C!+3sU7DjKR1-M&ArkzxQGaCq~E2>do^7~qe2`C3^r2P zVeXO8fcedR3usAEZlS+PZw%56RYsF-Y@GfWe)~!ji?*B>o= zf3p!CYjJL7nbySIGNd=~CwCdjdZth6U(yk z0`}FG-@7`~LSFL!uS3lC$h72G$S+!)N|%Go%;P zn=aD)ZlZGuzI)}|zL?KHJcSQeF(K9jB!_NmT{B^-cW}Y1m-kdioxV6>N-U+Se zf=DQvUe3)!?iUZXjbKSecnz0z=fFCXvIvBSUh&v>4I^ESX^-ORH2lYk4H+&5r}!9w zcjA64m(suT+6v|9MSQzyc{AhGeXRdaJ?K>mgGetFteH`p|F>hZU0~-tFkho;u?5^U z-lx%{=eMVixQmk-!XNrL^YjMKg(4+u3PS4Vr(5?lLS(wDk||HP`M9xM(3B#jsJJa? zH?`v2uMCrRvoY_r5R1XiI|CMTF;m$WsaJpg#5abm&Tc~=OsNADGZraqhJE_@Eum^j z<%K?17b{Yk?uIpgY!)yXZCsR2s`+#uKP({c?+kTW{x(GR&H8Z{#)IM*mc9pzVH6@n zq>{{3vxL(_WJARgGQe`4dW9YT^UI->o-KF_3*vo(ImVs;#hBkGF=mjV(sl`A%nqvr zp7t=pkoN4`0oQ!?r}5(3IxuWvQHI{8t80SPn}uJ-Ah=i`(+@Jlmx$m`U*vstO5szO z3{#G=W5pv)`eZ`Eg{<+eKbvrGnX=q}BzcQG<~Q=3Rp&U_8j+xLSUPXB3tm zvu_F_L|2fD5M4zCO|5VKe*W_!w|`QcTY8l2M+hawg-v4^qvj+XC@&VVn`&|qIlQ+V z{;N4ZZy9d%TdkQ3#N3w3v$7CM^qMpM_!$z~Ft+D%VtZqq={1y<(IQY{k`KQtfZf-8 zQ)9cAEXoiW^4?Lv40-=18?D%M-%F$2N5LWtYXA=O_mJD@ALA2A@=)SK(jLzrv=5uj zpT9;J^E-gZ1qvf;Qj}fT_wG=nKG$+uosypwGBw6s6l2A#x`)Qd*hyog8deI8iqFM} z9xu35>WzV6x8=o($l&`|^Z#OV+Efj867TCgVh zjDEOAUg;WBY@ze26n=*(sG}~gU)xxuMcK^Q&NuPwwUc{zPW@ub$&&;;4v;DwAeDI9 z*D!05GX9D?oDX!K_?6oEv`SDL6!U=y_(-r=7?=IzY93 z72~jKZ1w1leB)C+6{kJ2wbxNh4r--s(A;W=_pdCHCY z02y|2+>8ilST!=8vyK*NH@_JaGK)vsC~(w9$=Z|918 zxK7`zItTdHsqYE_@b+SeYkmUftv2F^wNe%45nrDmf?s^;wfr&{30c!irV=Ljx0E=2 z{Qs>{JhH|((3Ua20)|!j3%xi4bC|~iiVdR55;-g^C*++^>XtSAamenf0WgmvMgz>Q zN^|UZ^)SVbrTv|?y#Z`_Q92_ESs7#&govW(`mbhgW10F_wXmaT>`%Lxt*cw(-K7&V zIRM$UQs*da0Kpix=NZo9#6h;^$$0>}VfBZej=^6*7`6$GF>o3m_9doJhwyu%Fh_>< z5|6;35r*|oJ^=bPrHwvK>t2{Rjnwo2?{BtwukC%G^T<3Y8D4Esx`6}SNH6V4WGZ)! zexKfdLnx&4g6LsoY~$;xV@Y{kS_RF1OQgeqjIVz_AtLya^;CR!zXX)gWprr~1`P06 zc#>9I?}|yw@B*Mm2G|ANNEa~Vi5`^f;kOZmZvT|@P&&`br7cIci|cW!Z)h0~krkVt zgt`?ltK^zIJ-AJQDpk%LEaEs>`zH<90mxwMVIDFwu(RNL{GGRh3U?$Yu+~r=cc>c* zdf2f_0JT3YnR8gustm;?_w&3C_~qeo1nX)30e7bVfjgBUzEFmhZvgJXEBm_Pk^$Vo z;DGV=>I>GIU6?dou~@5It}#&jeWcP0ScAiW{Y9hZV$)5jtdT9Wh?WTHjFCme351!3 zY3>bT+6e0mtGFi1-Lc9QtdXL}xqaX`6l*c*aZUfS#6i>v3jIV@^T%LE+J_ld_|t!4 zz_cbQaL>gu`n$ca^WbPiY6MsdIn!f>O{2|!P2N2xp`);w0m+QJQq91>@;!TJ8JW_? z)~aG)Y251?#bS}Id#!Q6oaC`NZ{3lUXyE$d>(uX3qNAsdr`%&$rqsW_Xh{0tKGi%6 zduEM-+95m+Hz;4G)_Hh$FmU3TXG;aPaNeuHANqTaa%4}aB>lAJ5Wqlej z>jS7lS){j(qT3+KX2Eg*nQ_C{K7%O`>7=@WOe{pEpriu!L3`eQ01L~4bti86J@P0| zp<1I%;p~E{q!tLh_ zc1!zKP6Ypfc>KaZ2}&VPW#2A~@lq=TITNtYAK1B2==T=c5E?{Dn;&5&>~4e|^^8F6 zA78WP@qG8V)pBZ}b~UePQ7b|Gfsj@-ipaC{@3U6*N2PS1EHAh{{w00aOkde8`sq$Z0&iNn{+dWT7SdiXuK6>%Xy#6mcR!nCYzasuTlKk1 zR0+3S?O3cnyp$=-zP1p5#nsK3NmCL1!tbaE+WOh!Q4&A!seQ1zj4dYo`^LyTF{3TiEW=y_aF0$&znrA1M z4GH;JuM|vye@Tv`b~;sLR7Gy9MVqwOslM}Lb*bDRUzrX?s>!oegj;%16lX=v4e%|# zqieas@KohMbSFuyFNp52F`9ktA^Ej4(ZZ>Hg6CJJazJAE1`fY~9B!%caDbE z7_3*vv|KZuP6WS*)i>nsGOrj(+mq>EU3FC5ZZMjgzZ&(J*JH5N=N@w)0rwcI)Mdv2 z$D+I~#cRdG!`c**w?ggPH||E`OBmA{jAgh)s)IrA(uQkfw^QVI52zC>-&c&xLZfiyJVWn>oO7p zt6O7tY09nJ3$5c5&=1EJmbtTc(z$1Pi*USil>?H)+mPGli)!=n5g?BzFLtf#!pe7+ zUB>q_Gk7sVe4Fq3?8GsuNvpv^qan7<=i86YxsA81N#9zt42#;}{E7{RZwMwEDhHn1 zUj6eZ8Lc5(BG16RQEarREwa$N8R^8Lps;x3w!Mw!VB`~@M;9!8${a+q`U8hIQk7faI_C9Kfyj73{B)~g$arXV)VxuN^i7x>RjPaZ26Xhd#(DffO+ zy_EOXZfl=Qf`Xm>fGtSu8rP!c{M6l|)c1CU(d2i{>ZcL?tMZNLQ0$#JTTi&JmwJjx zgxR3UT=r`#&5Jd|TZmxShEx!2Qu@UH(PK2|HUWd`#RbDev+g%@X$vwTA#E?y7sit_ z_Zi6t!MemGrfds8R z+~&P+?1h|(QzbjEO)(OWRVqJ82)BcKF1`|_=i_4*dOzbsb6KY2t5cGi-dOS{J_K8m zxzu0(H(RH9j*#QXO_#)Owm(?J+Utg;_>&E%oEyx@zW7wRTMD>7U*FlfK=k>#cW24R zt~-XyPrp4^#-jCo5q(OInTX(#G44YSA_4-=b52)iDxH*jbB zPo3M$R3=Cce+Rz-n=k5}kI%EPcm4Z3H|w+LZ8ftZ~i3&yzVf^VN6C zhvaiI-Z~7~aStQZp~i{rdgc=KNs53vSzTUlfv^NL{*SRj@}C~sDg^=W`q*^&FKS=3 zyHtajQCdv);DT z>C~hWwQ8ORq_j@4c^0b-!s++!G@F|^^|7=8{A1jAUpSukF|;3^PU!X)pcEh3!R&ki17IvR3QAzEqUJI z<+a6596vg~t#N(XdB3OEM!tFcrbj$C{V7V(O{p{|b+o&465&r!3~(#?6EYGNedgbP zOfOxGvUj{=uD9npmZ^LpDcm22zxda5AjdpKa&j6Mfk`~g#heQs&hZ~nCiLCJ3n_%!Se<=x&W3@==2#?3S zV7kL0vyAU!%v6Tajrsj%iIGP%UTD=>R<6Ao852#|xyZF!q8fy!B;uQv^A zlP)(jkzn=bn#J4A?sJKOhuUPjD2AIoA90f^gR7<3^9@0Zpy90Um|n^QxwyHsc^i@k zzD_(h0s`N8Ch@nlyf#Qf<8q6E#^b%+8xr)@?UvY(w2%a^j_gA|-b81Uq7b;{ z8g#yEM9P)H4PAhD7MN!5imr>UEYv1D6f4vJywQNB{2x;>tWh8Wd z+NNAE5)H%0-J!m&-yS5Waq+UTdAuF&!TdD}_MU2T{?aU_>?y-X^{PWTQ(UsP{({)a zNVv2o@=6R3Yvi$~oG-OIXY%{pVN|AcJywiKQ5c+^pvI69G{j0iv7-Z-F ziP~U(m`HPZ3L+&duTB#vip10V0@jY^hM1_JA33wO1phn!Nn-djP;P?-g%jb}DpyuE z^K)(%;!yO0L6%@54yseJY2xfRLX^Hhn1DULyK*b@IK`L%MkgHbpD+&JMM*c<;Z^-V?eG_2V~_ah35Wl>zK&s zRpt1MX#&R{n*3jIJ(0XRbzY7(h3JUc0WC!htnKTcyz9R`$9UIX@UBPn*P`OneEZI2 zI1_Pk@!tC(mEd1=9Vb2I#1Hx-2TxXbI)EJf^t#Df6!W-5%gMph9wG-fbYtQa!25kM zFp=+Dcm7My%RlU}53)rm*r%xZP9#$~hrEg*OuYSGo;>!cCkAI?AkdE!2xJx}@a%l8 zv$C>*`%&zPWFIu#*-E@o$;7OgJDtOkx-diN#A8kejWL6*w+E&HG$ z70uFyl#k7pm|#Y`Md?^^K$vXDVGoj2(fr-8DSPp+n#zkS7i^48h%Q~b7Pn}D!Gx^I z;RB645uvy-BIhVHk9h3sTMQ<66FjRPu3uo8ZSePuBY)=^M^KetcUkBM%7r8ar)WKl z&T!POO~QggX7-^%+12`M7$A#sitoN3M$bx*a?m=9`dxXZ)7j8X0K0R_G~~e)EtcU= zY{O|mH@X_OBPEURj)yu&N%EIeJ;ta_ev9N?P`D_$iEUiHYWdk zZ6iE^na~$6Enjn?a|kl|7GmGE0v1A?EoLSJBX0!;vlN@eNSOuw(u=3+HST+3)MZW4?eV>A6GcB@6)ko2dT7`~(+OI)NR{uH5{y?YoR*Su#? zyG4D%trR*e+7oAD*eOpjN&ABkUzfxua&y;Ifp}xG$I!l!%DcfvmTTA6^9i0z-V|-k?ozahjPTJAd459^^^I9yc2q#} ztURieG9UA{*R~=82CkP%p1MI25E*@NF;aGK^33O|heQnzDP;k5b686 z{C0EcZPIxf5iUxX;G7G;`A@y{h0g>s$x*g7CkER3vWZKJQTFN1g=+d@|M`-9h;u&m z#61QwsZhSHFT3z)knPd*7k9mwkQ&EVYgRgPfwb?b8(aq{_{(nl#yqCop;i~4oRQF& z$n^rHmnTmE^&xM(mKvFm#7-N#@A=yIDt_y%y_O$ral$57&u0W%kZy&~$UT4>x z4)LI?k#O1XX}qi>=H$df~S3nQNn!@QHY9{`J6fRS9V!I40A*sws z{Q%`A$c_Ps8Fb&-vi`J=pOKbfdU!UU4hjfZd^%U*=+Z1b6=zqt15eF5os$wuHw8eH zMkgC`^X=Eb9LX)2A4-x-+#8lZS!5(N39;{Bl9khPlFUB>_1D;X%}o`Gn-`8R8E!Ir zIyb~4C*JlJLQae$z(2oDEl=>giu4L~4}x1FLolc_D#SS1__{1Fdr6wgVtaG&KlmH) zlER1_%|o;*f7A{2&8(YilQS2ZjT?dynVa5c*aHK)>{6WhUE|bfw4cdLU-Qmj@)S}|=&WLi0mx(Q&Pq351ru@>ZRH+mnLE7sZ^VO4P+evAIIW_te zwR22_@cSvP2s_qzirsbQGzF`4b5ptE<~N5<=V@K`zjx{uoyUdLw$f0IaI#@z?bqb= z@d$M@yVkZnmaixNIE_C<5xDdAs~(TOMXy>xCk1@)apH$dS3AQ|j0 z7$if@qC4$-R83v&x-VC8SqBR)9%2)0R5yHZm=V!?Ri-eD#jIJO+uP*aT{nxjcJuq$ zQUD*f*m9%J~gpzR|E&R4XJPlDdOjd>co=!-d_|JO7hZnjgXV4!@@oBY!m==CeAh!V(C8$ zyZmfNGRs7HBkB8diU+_VV(_-;Cq&1=ym(UF;soxqo=B(Q9bV(dulP6 zs5cIOWn_}ahd6hY+;3G?`z1K;DN+h9%!=degUL5HZxh~IiCG-?>7{KUL}8E+PRtOqE|A&KU9Ol*2jJ$OC!0hlZ+^ zvTRRAU#4<=ZI#{)#8rhKV^2yNYX#Zru9U#nnk$Rj)H3=dT@pN8Hvz}O>s!F}mb9i?)~$}4Vo_TRRQXr_a#b%9)S=?!k4Fo>@w z(Xxcvo%z_?3(k^$ou~V0aa46I-`Y*@2MUAAZm57;aFbN%4A!L+Xw62$5?NqYb5SDTxy%?yEW6T(|<2*EllIwqZ73=%=kA$ zz&?e^5U6Y-n!oRIp5buWKeMM)rWL4jzB59$3EUyK|rWCH57q zP9#C=vc@E6Vs<{B-Juf9fl(G6*|-q|i~P@&K0bCqazDt=>>Amg6+|lPcazbJPN0|b z=6F4d6@4-opt?H^)!hiF?p_v)f7N7)HsCM8(@%WXG!X-;ZNwx%%(qFwetMJQj`{2@ zC`-}c+=|H;wO5m8!Yic_y&Kel6nP`*oK_m8?L+V5I`O>04}GU?@J!CbbK|n0P9{97 zJi6#6{1T_O2;KNDZNlZE%)9$GJ1S7E?@){foe83mjg*zWp%8g$y3WC4>mn20i?etf zsvm1gKmReBO$g^`#18hBzQb)2s9C zWp$?VTtYY(sLIBvTYNg}r>Kp&#%#3&sRUD|PTke5uYf}4=PIM7gm9Kd9y7|3Qd|%# z?8cbKYv8Bqg9qZoNAO4lD9C>X5U|!ST?{;xgTFcmAaKoi)lfHdjkqyVxpr2cU-GLk$(Et}n^=dx? zTqtQFzYmAW&b!dl7j78TO2g4r=9_!tL~H<_rn+AEn=vdPtz9P}FU!5sh`2ah8;bD% zPXwVJ!q`@z@QDp%3x!E{7g91KF1B-0WrM^CfJH;WMY3U_%Tv?-?yD)0@-)gKs>Nxt zm}cH9m<0+kSb$`sBGIsurMds0XGcH!^F`4YGU2}>sfYlm=$keK>6R5WyZOl1^)V;9wLI>@}&y$ zLmQy&rvFP#L*BGKRzlDNjw9ef)l-;;(g$B&gRgn{;MghQ-O}$zP==0nv zk2#1e1{_&#p87{)j&|Rq&mhj6x(vyvkrd#52KyQIk*H^xa9S4!6?RgsSDM_Z*;nI|%)V8g zt@twXQksGZJdP4D9fc!P*cV2E!~t2R-2;?6H`E=ELC`O)dgpN4s4m?{vzjAekZzM~ z>`rXs^H{tsD-CWE3Wc_QT%90g>6YdoK7mVu1V`a3(;}ewi-6+SZRdUriiM<|VN*}w z{&HYGBAf&pfP~iFWC|tpVVaV4X$91c$L=VqEgKs*I9@z~43%a1%3naQ;r*ul+O>C3 z=l*%$jkj%*rTg9!njcbsxpAxuWU()6wV9sUDQE)()SNYAsQ`6WZ|EMEc9?{mZ6rib zh8+GHd%bY%&A_}9;Q;N!8f{55CSQ@nWNpO!(q$E zFRJ!uY*Kgg*h}BUTi+T${u?+GK&=)kiqH0>J(mu5Mcv<_Eq(2oTe~VDCt>8?lU3jQ zDpaq8kI(jQBdhI^^EdqXi4lj>exB9G(HzOt@L+z^N z670>oS-!YKYI8K9d8H5K7Ss5?#qrxG1MEOLep_txKygK{#4#fMdiv zZ(>}M5_{0y536+&XDcxEMYHr7jpE3x+u{T66ukxyK%hXo)*0&D{&Q2sp)`A2&L24t z#X^0}<)R>ES56KmYcnE8&>KxmI7Vf_v)T#_BLXP{=RcBQG0~=Y7uEYwVnQ+a)m&}f z9b4jf#M=N+8ytg3Q?fB|w3`gjKc!gzT%7n}t_E&n0yd}>c7zm&ken-aZLzrBGM=Zn zoersu(I6>R zy^bw31^CTXfT*7Dkh%k;+yPSSs2F^;4H(ce+v~G)^8O*zxkjbmA=>{1A;M?C`|Kli zVC?97L_e{scA(A1chxS~_5{KMayME*0+Li8;h2a_>pU`0C zvZTCq#66&lR4v~m$Me@)3=I%j2UBI_KFEV_a1Jdru6?p_)^reoAq>CXi0KL=>=xJn zMd@IBdK=MCob(-uAo9)XrEeLFJF6)P1TgPDM_z|6(r`aFr_Tv#v?-4d=g7Aje1`_& zIA;z5_{E+}*C;IM6mbLqV~9uS(&juy{7oy;5=Cbwq`cxSnhhX`H35??@)wigpnr}>r| zp@qLod=J6#mOJwz{Pw;=4vWM39g*yt7nYGU9`PCBZ!62QK(`vqAs&!37>Ii38i*dn zP}-vc7og3|d26a~XO4c`oRJ=DljhL$O^pSs&x^Nq=9|%iNi5M40xheGrAY}{2$=RU zNU_y%Hy9+ma3xvh0#V&Hx5P?C*`3$l$Epb9?{^2;jpf^%cw+IIQu)-$owkjit zXl^->8)~gq?ZR4zt@!X3h}SD|ruy%?0#(-b%Z)?AD>O4#eQC;lPoxad%m5cI;8^y( z$$(>dzYnDwb;Iyc8eSTgM+$ybhCA^r@(PYPD`vQd-WzlJrwW?*3d}Wy@!|-XZtW5z zV5E3H{0s_rw$%zfCb&rfZ(qfqx=b!$wD1@a!w&b~bpncRp9?(XR_7h2|6(T62nfpktv~zTIfkXr1&52}v zhxirD!+9?n)S97<=VGaqVmh}kh%(cf4Ydbh4x38VZZoa9OBx91XJxM#22N#=F$U^k z*if`vmfz|J4F|M#)d{LbntNjT~?mp2n!%=Y`_GgZzcp#3mN0#p>uh=T?mt8ax3ZR~7x{xT-A5K(Qv zv${ZqQMCT)>ilcDrJH~7A+>>Jl!-|XHFX}!x^99z7bp&3HJQ#{85*o}xhMs=7lvL_ zvmC23Kn`xN@>`|9m=0l6pgFP8Cz9kOZAtca#v)I!lml!5jUP*W9p6P z+PV3VKir74eRxor3#v-O7B6JuV-(GEoEHiU#w7pxyPtt;?R8sTnRCQ z;(-5e5b4PtD|r{cJP4S|mRaf2qzA=Ugzg(%2xMS5IQg0w=qlvZL#OM6zN11kUMQ>| zmz)RosTrD@f5`fE`<0%Q&~|fD%tdMGN8hmIs(&4BeOF1F2|$j_g?XU(iS?Ckiv3gFqJ)z<18V9^hek*>JdVd_I_9e=GBq!^uK7Em~H6 zld)kYqvrftU9!H|Wm}+$^tBqu7IsNZ01ZkN{p>I*Eb=XCLAry_?q!M^z6{HM!73%I zNkqCsN*`nR9sz#^3NKGb7PvZLC#S+K-{a*k6)v42uyZ8_#b5rvm*w}c594ngGvATO zZ?#^FDcMd2v}EU-jj-ISPEf0Wy%!3p8j7k9arG1R2=iIP5SE#^cUmi@a^h zNT|z&EvsMZtCwrd+5mZmLj4w=SHf2Ynk%{Kx-y3~_Krj9bXR*?1o)W0OYHkAmvJl_ zsMhee7|NMmv9SS#+y2Qi-1@K3_UMU}#*^~2-d0G6s&V5)E0;Q*gio5tG72TZ41QBB4PIo0LUj(E?#&a2}R0>AJ{T{(eK8~=q>_Rt*S=psZ?5`R+9roqQ9k&Cb zw8O=e?cpv1sT5K|i=J{gAOM?&Qbi4WKDX@|896>Y&HF z7+uo&DAu)jmb2gC`v6G87fk%T83hjjchS|jfS`s;^eE@drCy0V`coHK!M=!#)pWBj zYleWe0C|Khc=c-I@)*O`U2ih8U-k>_`7P+kx&`dey*^c4%jWw2UgJy ztO6Q6kr{z!o!js`)q99frE(bQqgQ}EFmJ=&e+R_}!Vl6G1EM!Do;#q8=@Egfe^b^T zQy>^Mx&cQ5t(WWHGwfSYC#db4J&t>5OgVhOCs|Q5^gH{2E|tphu6q}N)uhFUK{B(% zk6K57?nWWQ1I5(24aDP^;{zF&xrlgyP(D}~2^Nk~NE93C1X@ty`wGVV7pk*n?rm5T z&A7)o)UvJu@Z8mj!oAOJG48q;ym~DO5a7XA3yB9NJ^MgcKN9GG|JY89`yLRfDFoD3 z)yvkgnAjt}A$pQynjx53-XSyF(46_o*cL}V?t8W#ly;8@heP5*Ywf&aD$7*d|GC0N z^~5eymiY4uhR^o=kw=gJme)&6v(^_N8Coaw3}NIK zRo8pDYgOs98jteuxATCJ12|F=pEQ;?S zf=1se%$QItplg5aQ4%7nGI;kDf?FCL>T~bcKcJz&IViyT#KM-tVtCohs~yMae9~Jx zQkrL{KBVTzb|>$i7Hgv*G!bwF2!sIya7-qt5!i?Es8e-}h6NuW89z=#IM@Co^6nQ4 zsKsCVHwm2;7}k9y|Hd&(VH@jyO%sO>9dK1Y=oCKzPP+c+A_dOuG_FNM0rE$IO4>O# zpSIm{A@ryuHsGHizojlgq3|5~J2D$+iZb3y?&3Q8Lx%i`c}u_eMeeo>5bcpwgZ1g< zAYwAF+o#*<*qZx5iD&`bOG|_?& z7JXQr*mS)!`E9uMs!Tz+GySVgTSj-~(5n3Wk2cl8I&_Fo>NmFO&MNn0PoxqOD#VND zF^9mIPJ6Z>->BIn>8E4e2Iiz>YodY_i}22_6V&L)uR_=D+D%%hk|DQX6xy69zrGq84vm4S+bcP}B0fr%Xs>=7<+T@}hKE9M@X7A*{ znB4{{*VkLOeEEgJ=o%L3Y$`1=^B-mrw#USqBd6B-r^ZRC;mB9XeVDVfp=A2h)p(k; znwA`q4^!i`0myF@L5o90QU@bRN)n|Aw#iM011*;<=-gn0e%E-{32+%ze|9qzZY%Z$ zvxeqo>i=v=W2`wG=*|=-j8JlenCnQ?a{(%_Le+uE+?(rp{ZOAH@%3H!|wnM}7?E7fi>?XZ*J8H1NL9~D;iejvBG24uA?+6 z4mE(?_kkY>Lmv>iI9&z(0_t478nmx^VqtFKqO&cuBE{=tc|W6Menky*UX%orWFww$0fU5N>QNFR<`%Meu%H=vXsFQwZh zqbiF{0^ai1$%aZIZaL(8_|z2P@M}V$0s$dp@PL~i!PnU#RP!opZ%l4PZGm{YdIi{^ zRO622-zJsN^jwdh&JB>+cB6Ix<_bQxdOUsY@MwSCsm(pwUpysSg$=+ubCcs~@qTxP zNlNPo+lqIr3$bPN89|Mzhx3dE<#SaiIO#E#mJIag+2W18jz2HX#a9ZgdS+SvbjFG+ zY$1(zN%H-UAK?zT|H#e*T#vHTF0+Q3pkC5dl`w;DY2>O*dbIi%-Q%|7!9YJpzCiYi zR+gR{ZrCv`NqQwhdO1s^0l`b7^lq90fq;>*j#9eZgy00Ilf3J*dc`8#a1{PAe*^OX zA}B1gC@`hmKR=s}IJdzw+v@MpNP%`0GfsTu=?lg{Y21eat(H3y+X0ti*8&)oWj}8h zegQA1>&Pc>5t6;RC!i3aYiml0FI~Pb^Im$$;2XEb0Yp96jdRBgRf%#ruz_%kW%-16 zCV;8_dUtVmd#h;%d}hi;yeOUSGV6AHNX$7y4W`#}v@iZ?GY#HKP>aFC2OD!d^9aVl zkb|%1_P0{Dzd3g!N|jGUvVdwyC>yxN<;}2SsTsd_Q{y<(P9amOnfqaoq^>P5HMiHJmfreBV5}Z8N%;Y2I`r=G zJb3Rk+<>km^SwG}$@dr>r8VPN8}dtll5(vF{P=wbLOnIT_oB zWQlV%f7u$kdY@@IKAd@Yrs&XZIh%PlrTJx%cTKz~+7)!t;T~#Ed)vf!=|1`TTq?69 zU*`O)^;r%YicHrpW|f;l2e!uKltQmb!23h34S<`ok$j(KX`tFGe0R@+S+HioG-cDB!x)Z@p%ee^GPk z$g8=0T&z>WZi$=gt(RB)a1AM=_<<5nIPS?)Fp!5la~W;#wMw!9I*C7I`DOi{k5t!e zx`Ki*NuU)dY~m-Gy47T)K!LBFe{|;XJAX8#AtDdqk=47=#vT*oVI=l|v4?nmgVGA{ znd&`IQLjLK*f5cm2H?;$DdNJ&d)~wHTTh0rO`7zl#TAeD7n_zeW(>Q%3xZ(P zLB}FC-I;zLN1EfVs@+4+cbfy_-8uPAvpZrii3J?;OwlB*kb==X+rPZfZQ;LoMGPGu zDvv9ti%QP`Ub0N!0cdODmzlcl9brv-g$1IBY1QUeR=_~iXc13^)im0cz&#9THQpJi=YZ-b~(7eDN;3tWbv9VeS$2QX|`E z?h>f#Rsg@6do|TdBr%@L*7jix2Yk4F;mh9jieN+h{pM3NOIm~qVIBfFR#x%7vQUXy zchi?D4aX4lNc;o=Exaao38uyAUx^M$=pjQ%zCDl$yOEFE54M1l?0E5F)wfI5FJ`I! zlnm-(e~hg17$&1_G8=DWX1yBRgZRm90R>z79SbElY`7OaSH2wfb?P|RLP5AioMOa6 z&;NQ8s3FPuY;lFfvC55|SeqkJJDV$^$o%>;zFyxbE0tFe1yLB-WIBn1#lc}(_^{`= zLh@1AQZ_|-;Jslj32rdddv{*Vk{fSTwOZrBw$L%lRy~1XyY05nwna-VI~ep7^vf}C zpR2K_Wv`zZ=QCtj1(N8$BwosR?8jQ6W!IOudiUlOMr!>Zz!$H)Q#gQ1Y7(MF`qLlk9^x#zSpL}?&G7A8KW2dn0l8wO$ywc!=9wqiW@;+ugu}oqo%_9 zcnN>IN%Z-9E2nk1VSPZ~{Nf6zpY9F|QNy{{1j#MiDXHy>`v^S)J4M*DYBC+ zR37C`6Y^xDR>^q6SqBryia?-Zh zcSmd4m5-SvVYj^AJRhgbUH!QX<;V1uS>t3StkJDG0~H3be)3)Q6eshXH*YJXF z2ZZF_e^xzHOD!k9pncmkszY!&{kh3bi%MB>YJSFDhT2V3w0wZ-o-1q5WQ=E zFJT<^cNhp&bV&(>jb$BF2j-eel_$R#rn_gKMB`L9QO>5^|6P@HF`;Dq)_>L!xnFCp(od{EyuT+7R=m>;%A~_In6%$S#Q6Dv)@}@V7mChEs)c+nq-EkL~P6YBo zu7gIvF_=oQnPCR~*nqeXi_ZH1Vs=9Sx$QuJA|Kd`A9hn?cuA23wEk#qK!5#PFj#;G z;Ox9dwY;Nf<;(nje$Y2b@APyENq2D;SZbcT#}kGz*@fBMWDUz@Dp@N4nmyTpM~HzQ zgB+eSg_l#JkRj1|v_QEyjY&Y{qQvxNC^9hUaxg3IJ?Ou^0B->%SX$2G8t(AaZKn%) zwZ}o*>b9>gpX71Nzd1e^$ui(vB=F7Kb7@!ASoMR7VuOe?f;%?ESoyh&3xQ#qG0GYBz7lfGE=xYEt(Y^T}aCyIw#GG zKHuD+MyUy~r@&~SD3k}0)v?!P?U#uTqNMbN$ks3ak*U{o-jYXqcml4s5^p>z$*FcREdGGq!bldopbjL3GJb%=k?6`Kd`IN^jpRYAhyu+ zFiaEARqEoByL4=kuR%KINY}f;xO9wV?XgAFHoB81vA7ZQ4iL^(j`qX}6f~>)FMb}E zCnPmKLtSSqCi`a>EDF?0xLlha$vN|LuOlVM*A5Ux&RVsJ#^f97y;j^#@;T#pc+uM- z4^jd1urohk?A8u&mju?TA4$pt*qg^ zZ_7qgF(Na-TRw(s<2LY$9sat(YGS}1#ML+yS^KyUTf!}k?CN=+vy8TNP|K1Gdivdq zEPe>J$iv@Gq=nl^y3ndvj!Z|(%5YFmbpRUCB>q0bLuZ-L>qJ&}1A82Oyn(HNn|?{R zl@j;`-=(BCgChSHS5J3(o{+O?d3}?GM?5Y58Gch`D6FJC9BNy1pVcB;Prt)f;`2o^ zYx4Qb$R$d%5E_F@%5n|~Ap*nnh@Xmf!f~aUyN`r6Zndp^9`e@Nue-ZwW@mW*&RCGX zLAN0xJZ__)I0l2ce2s5hOnG?hrfh#t(SwMqcR(Y<d&E=Kp5>+9mOJ9B!FPCS_@4siPS;E!p;O}S-VVo+F#l?MZv8w#M>B9QZhRj)z z(U_7ka=9A9f-5e6t2Eh}>ut<(6S6+HI8IILF)p@bFPCPIUmY*;7=Ux(MNvS%9236I zH#QQb+qs;9AYF5@J~$j8SGLaC)P{T^nn;c{H@CbRQiq**Nr`pOidY~*;^CJ^w^fqV zMccTkgoM9^pTykNCdy#NqIV=HN!@i~BAn9+b0LzvOU~OiktcS|g2nhstj+g--J zd7|GwJLmH|sA?zLMQY&VuW)t4j`|UQs@V zdU1Zdt)t3dw0v>Svms_=)1M9EtzJW2c4L#jT!rLPFHt{TV{=OYS&TDna)#cdh z(=E^a@`2yWF zn0)tD;`pcfyq1@68Fs?hlRk)bLh}b-G^MbOWgCjrbpy%!2 zakpalHK6#%j@y#0&WtMczBVw}56&&Razj*(Q{hdIj(dt{LT}z!T6)|JVYxUEcD@WcTO7*4-%9U(%M#dZUQVu5xis4Fj zrD)ow-LlLd^;aGg!wEGZJf^YHpFn5d7xx4ubI>G9p$&IoGSCD?2@z&38a9qoA#br$ zmiaZaE}~@vpq9m~*Ue*FFe=bVUW1J$?7o&tVWjKbR>S^AeHo zssy@!%>0K~IS5HwN0|m#IcBA^f!wJ0lhI}J3RA9%j7*268M>VN%7igXbg6MprdsAU z$yx9vUjlhaE1uZS=CQq>aTPQA-)4q_2n>tNf3VmtMrrjVK-QFJh21z^$7EnR+IxpR z5SVTO-Q15xTK5Yr_<359Sy)jS6N*)^P6Ps#gjYw@FWJUMFbvCeHq-n2N{z6rj>RR5 zgylp*mW{JWbvj`UvchohjrJ8|1DZ_N%b9acBZ0u6ZGb&+ye?$Cxu12GJ53z%qlQY( zj)Ox{r=wf_ToR)7W1yH)<5+!zkh+gX1M2lu zDU_5qAbz)e8*cRv?RX1TNWbpXNW$U`DsodarL@+cXnuBoD(np%nMq4 zT=Bj9HWS)582a!bolbD5;!iSoY}JvSSL=)EY@z(&2E1kan32l&AC7@%IOiLK+I<$4 zJt6qZ>Y1N9VfSLI=i~^!#!Us_N8+`x;5e9_2NDGx3>h#Yu#|G4JOx5@{`5C(`TZM@ z`tWVY5;9t`QB{&6QtNM!sYq$-d%=-A8_CltNj`3F57nFoXPVb*8-D!?kMY5|t4pnc zFM!94-M6f|M5i4fVJ0%ucRNJ8FeDdEkC_VKt9Ou8;E~$hrsbBF|FhP~T@(MuZ=0kg z$F|t-^8)Kn%uSx=g6(AjNE?Pc7J`ld*G_8dEA^+(6bvEe3 zsg{djU8xJVxmqE<$;vl3yW&W%dn?1FO#0JLb7Y5R++!M*yVp-&?<`zzcZ0+xr3Vsb z7%RlaIaA4zItULFqm&Q_hQY_yNMNoBMW?oL*KVw`nJJ=+Rr~mr>?}3#i=?igtpIrq zi1Tt$M$VOEWXtiPIlbKPkHYEh2wLzBwuQF*j;5x){c(rQH0FUaBpfpfqBG{q`R+bV zOZ?{j8PhQlh2l|&iAq(2RUB19*H>qQcOV0(etiuI8FLo%lO)6h(~+hTITqcT6gQ`q zn-+B?PC0=Ikm=!=Bji}zV5uahb>r|aV~0bht;8REW7f5rW2PCs@7JZ1kGUl1AuTpU zB#FOhig(nBN}J!Ddp4$4b(0_CTY9Y&p{=K7wG*OcxW&|%&Rjpmc=-75+r=EPZ#n)@ zObZ07yr;f9_PIE0KFHNk2v91Zqb>7<)`Uo0X5UY|q+SWc%MvJeGD=t|XSl7jion}5 zYH*v_cPID7*g6S zI>zUylOGjPXln9(-w820b$!OJFC${})~IgVF+U&wnrsz_Gx>M;i@4g*9~L#)<@3Lr zbpk{_F|l?Ej}VmcQU&`Yi}Rs%c^MUggf3ypb5JggpE~n+Kba~Fbh;`|?r$xEPn@?` zF|T*^x1&^xu7;^$-Y4kqX1H7!w#cMI3sYL^%tUP^pdXn074waTy<>P(^}}r9FVbT$ zs{dFi3{+Bo?2`sdM2&Bg9BE(37MPvnnx=+Mt@Tc&U6XtW3&i}@?Ud>&5j`2~Jas?` zImzZW0wV`fYS2z4Ewlz7)HPp_OOz7zMJEDXebtLc%g)779B>GmzK^Xdk^V&2_$PVCyZFn~rkY?dS%1r;@;QnCRlirA;rjPRe2hqi@`z$dfR)&T8pHGHX_g(tC^?viGKhk|X zJO*hI!xHF{tmLGHWE%yR(dS#NaG;wV7LF>)c$dVr>unk!_YLY66keC-w#O6_A`kW7 z-GdI=el+I{YhH(ZtmDb}^8BSaF`*hiapbnVt9#9MH1>fXve^unHru+vd?b=6*cU8e zNsXToJlTfI3tIWtu#jxyv=CSqmzTNw{FoI-+5%aHE-PyKj4@)8{GR zsGIjltL=RLO?2;hLqtf=aiRXYI}vk`p|9?%p6TRWW^pPVN|E38L*p!iKlP7Ix()Bc z9HfAlNM6?2?5KEC$oPS`z;<*dUD$Z5wVvx89c z#=Iu}Q;*y1Of<5?=_pL8qy$9JO29*AyT85JNiw3F>Bz=~(o6Je=iQT6eMR%5-PLz< zF+_#=_%marZFDwzq-4wr4@=5nca~&i-B7o@n`~#Qbf?R0w*B46OGAEA?Rl%+)%Hr{ zI8#4Uv2>eN42v5V-wVy^^!T}>u30tLeAA%FZHes!PCHnR5o2P?{0vX1XK_8{g8^P{ zg{K&@O~=n|RwuXb6;OfCQ!#+d0Y2Vy+F_rxL^w)9nLGNxh$XYy*xozvB8%Z~Gyd^v z!w=2mZK15a{DW5{rGphZpJv2;OBwgJp%qRn&aq_Sl_;tXV)}j5a9RsR7Y_Up(Pn9P z7Ef<`>4zV;g$@a+^~YIi>tT$fteD!Arba$m0;Mz3jbBnL=&`p;+SF@QPUoVWE~~C> zuXThQzw&m}+%1~EY~_FM@yXLo7?1{#QSu}b95cg;|BOx{5sjIbOg4CKK6YF(-t#O@ zC?YjVgq$_j7ymA7physexnS#U9d0VM;^c5iQUqHdXePLe2eMP2X%jqj^2zCppd^!% z2MJPmJ?lsRnwtJDFX5!u`2l~dbJVzR+-$yWAwYcVY;E7O0D{Xq>BwhoT)@vG)iyWR zYfj(%=xzY!>m;@V01KPg9Ww4SZ_x3{Brid~Xi^y5VjAr+Kh1rUL4W29~&$N-b z9tNdpvLUED-9&!z6?}R*R`NJ^l~dg6LN0&v zo?}@Tb07jmV8?yAaC2O8D-dth+v{%EJALKJi}_jbc3o{+9Oi8Vt$-d&4}}VgOrhmL z61W6my~yP1Dj_#vKQ=mT&&;W_Dcl!xo4%0Tj@UsJB?`NJy)W7~g7GmBUgksEY(yja zfzQg|TxIb%B5^fXXf4`BgarR}m=#HCB{V+R6=T}kdSM35ln0C)KlX5R<9u=8`E+x0 zb$!2eumF~G@$}$U;+2&y&Xqo>GbgM)q8@J4rm;v@c6akwF6^C_qz%GL!wv|uVDEZl z^GYSJDM8oYCA=4cnI78GWR7+E6R(&I7UUuEVPl~ub%K?qTS5&JgTorRcZf8DiKA~p z38#%Sh;mHU?7;H=f^v9mAU|!?#A*F#G&z+O-HT_2Pb%M-pApNnlK38e_DVzKJvJnQE&z;FokpV-0T z3P9&pReZ0-R|+S=W9G`=KSVsXPO<^aD)WGdQH+dXTi>h(vgG8wl%bXc!d`n3lg3b9 zZe(c$F}*5EIGwhluysiUb3%B_yqCRmNf5)plu{TLj59}0H==VG#BMWE-`M8C;n8yE z6Ew@%A+=VK84O5P7wtR#EldG%|+q@YV^JWz+CW9gzrD| z8+~;-6@{_qor?D0VI@(^CAN>NBp{-7f%)z}Gnyx?YPj2|IihuFZe{-}(g6wOFHBy} z7^QuFPF4Pvw?o(Gwb6wP6UXxtQ${8W)!q{W1BDGI1RnbjfEcq*N=gQzW}-s(x{$$4 z$K|42Va8)fN#!?YK*D($2am%^vjb;(33$y7EP}(vR5Vp@)=^tj!I4aa|4ru?Y0NJnfxR z#+I6a8IH~GDdbcHYaIJqmrB7z5^7t>&df_~_GCE|m^9e&p~fG1J|XR=gnM&bU|`*o z42x1(#4%cCzjB0;R(^k^)JJJS_zOdvb9_%Tza=U#=E(eqPJMXdaPZ!zV54b6Pl4De z^=`U@G5+9@M5>FoIW&{_Yj4MY0(x?fAPNZRZF>lD82NZd*e{Hwci$$5s2{JrG7)6g zUs}uxdW2d+w;nTE%q|f#n?t<`^iQs_Swig(eXrqXXGI=Xd-&_)-rxR*U~kzixG~2k zUb$5BB1-1EB`N1OmpvBFA$H2q%DTPkaA5ql1nm%L&)5jO?7be;6nu2m|KWV+TVn-T z`F3QbLT^X*twN|Y1}PZ$iK-F`GGMO?N|+9~Iz}a6G8rjYK=hlSPh8E55%6A01dOj0 zLKvav0l$^sj*1W889>`iNzwx<0?DjHFXA&xGAl_x%_8EzSB3N6Ln0@WwSb3Acdg<> zmXWfY#AxXEC9Gho0?C$$xnAaxDOKr_I?l&DOwuC75oq;N=1eS z=2D?101nUJqbY;DUBften1eRqC8`nRG7yTR4IUXiO5#Qb5N1 zKJsb==9kbIywNF~$TZZ36WLkl0`wEI5T58|0GF^3o;L6j1^+ACXfM`v^%PS1nV*OS zgOCUXHz4?*u?d`%gaKquXpjC)a4{sX1GeZfrCvVbKX0^kI{WEqV`Bg-#u&f|09K4K zfD=H3rX9JV1?Sj6=IfRag^T`&XKz7y{Ub?r+g=Yds$N0IX|8@VHred|Z2p(n)n7Ca6Kufl&8v|EM838i`_IS{x=J|T?(DurQ{*e!S5k1gi#=gXH{ zWK(JEPi$?Emxi5dm4~Drk)%V5TKjaYyCGew@ZL3Z0kKRx-%3MEVkQGv%))!PEw3JK zE{xr^v)VtcWm7DSz`LkiITvAnXc{4({jUDZ|L2<+b;8(3om^o0N9x|38IVw^5G!EL zI8y1%n+Rs{i;Q3feW>yKh9Q4auQv#qT*%D`4D~K0GXPy2ntf-m<$!gtO$ydTYX5p- zFnTgHu;u7+Yj$CKp8Eoy9@esa*uX;RygZ2{Eg?Bk%U6GKK1;01+qtg-Kb+|}OQ~)K z_Iz=OqZ9O&QmbbinKQk3w7xMD5vzM`IS7@jqw`>Y6dn5-`4&EKpw1y+S@a0410(e7 z_j^phG>t?90rVrilzC~C>j*(U9UMMI8xz!-aQ9Pq2_ z1b^zZCWPK+<|y3)f;?SWkGMg(LPi;GVbhxi-q#cz3Hq%AnXIeU*owUR?bQO2{-qF) zQrs->okH6W7is*?euZcVJcqF3N(D3hS(y@_)$6yOtsS~l;6JaSq%?tDP+OxD1|N~a zj*p_S#;HmvmpK3sn39?SsR^qCvbx$wHAk0| za`L4BplXN~;gQEYvC`w(pKrPuELG^OKlKvF z{dEb>(iDAM(Mf(lQ1ZJxNI>B<(|=x>>7yboyh#PHOml&FSnEV`h+9qA}GsOXY8PA8LLI8Lm7ECW6W7uUpg5S|0jjk9CV}VM_fN9MhiQ^MW<<# z?tFBQfQ?a5zi*U|Qlj5EdOABkQVH!XrRbe4=q>A;R;^Z#8VnReL^Hhj#^Cr;I*wsL zg&c}%o^Vo!YE~;Ave+v*{lD3(foXMTMDdlYi_8+XO`$*&_)-QOeX|R%|#1N|)`!dmljLmu^U%eCVRvQ2JV*TRCt$dmB zR~Jt0nuHC<4(V}IHz(DgjvyEQelU(XUrL3plz*2MFvV5C4-nSCt>&j9Iu@q5%f;q? zUm5FUz&}-WHudR039I~1!oIuE?+ascvh!n!2;jZ%osDpzZ=VgzcZ~`{acP7_#=t-? zcx8Wn+7^^}hZBi@`6w@GR$72&%)RYGX?7WN`TgT}&ieh{9c4!set80=k?LSi_yJF( zfN!dNw1{*$f7ti&E|n;WBzhI<=QyvcHx5xejd1hcrgLqAi>UF>5_j9JbPt?l{;ASL zFcau|pf(*Tf|Uh!L^F8D^Jbu$)g0tEJ77W4a-j34GJ5KW$yzk6mf+j?#|ynxE#0S7n+x z$C`#vvBrNYIeczyatKbY2lRLXh8|QF0KlmyEu~Q-n$x!BAeLoOv+=ch0-^eXa2veE zV8bvGs(27`IFMT#MZA#wp+5(h&;fYR9`8cfusGD7UwlzFpNIk-ddRzkg6|QKSH9CU z1X29^js#CwLsmnvZ;V78GqXr&BdrV0um`|*2lY-*Npkt)1+2Gf43+%8XE{;zQ+UGo z9Q)C7p^$Y%lG7h=k?G&MA&t~Dja7yOi^l0dbN+zxxlZ=IeFxljG-_D}7tw6-*F!52 zANpYDm3)uR%3RCL()&!7Kafy=IHTT_usrAd!#CBIhZE<~b48mD zQ*CSA@TQI8yT-}p6&(A63%kCZY2?$6ib zP_z|rt3(0F^3sK8ZgGFEYz4*!6pRFcx^Lyb!q!)#AHvdzjE>xcM#1}|7vLi|z&S9a zr*0=K#^ALuM>eFs=al13!OT>8R9P@HRkME)_}gQcyq(YzgU3EY``$8Pqsz=KM?T7- zc2G@0!F#YcencEIs;X6b5TFBqb3>~BqhlQoSyG5ir|fs-th(dm{O{b4)?Ye><`hoII>r&o zkx$HZf7Sj$yZh+n>vdE$$aosP>yF;I6-r@!Z@fq;0JX}{(nD9oXlnKeS z^j`sDY1@0_QBn!D6{NTHjB7Y`V$VONDEIpR+WHE(Dww5jy1S9?kdRL4v=Ef;M!F@X zyFt1n1e9*15fG4;mhKKYNXNGa?t9<+yx;Zto#($E&(7}7&d$!xY&5wc4b*$7Y(NW+ zV6?x;2S2i1viv+y-Ei?sh+R|C58mP~?Ly7|r|3$@?nIK(v8YkaytF7)Ygy22pPP%g zHbXx7Q;x=Zyep3r5rsegTu)$)X7eHaOsbSzjTuaIeOUrLN7pS85?7-OdQ9qBRkWr0 z_R17GVqwPza)iI1;x~BVt>Z$svE!|4&gE|ldqf;=+^E^-g7VOzzX~0FL$eESYuYtX znw518n}NXm2V8A5cdVE!A8BtJG#zt#ic>H1gXgbaD}tGhSl>NaaX>cyfowb=tFz7M zwU16G#?#=Ru#Srj_6#c~$wz+Ot~Wilyl7}Be?t|2d1wyV-qDs);c4~oxJ8a+&8Y%M zI4JbRz8#0+MwjD&>QjDKS0o)&RF=95|5xqB@mn8i?{#1MnswO1uIEI4N56N?!Y4WAX8%2TPfrxRTnibA7wWJM*%=;C-IML7cMt(OJv_p7pwE?PQmuAcSlnydAk7Quh~V#^*Os@|LAG}tohUK&S*{3v_DuG z;L4&QFO@@FI&yQG)4Y}&uAy_^*mxAUHtba~p|c0E9rSWM0Aia~>v-V4hOpQCakN+s z?|XvT_hd7;Pnz~aPggp`+zB1VJDwC~mf*h+ZWVjr+sg3-KY7Roxr>I(A3rHwDfzVLB2U6e+tb3Uy3{ zrX~5LZb@r(iai-h9AZY!Ji0Fvs%PYd0FgH=ON<#_H8bU5RKNUwn~`JwL&shWs#l$q$un1@7or*E^Y~_7%>*+E2uuki z=ojp!R;6WlYrha5J_Pr0G;Mcwu30kLHD))rcu#aRX3?6W^J?YWf4kC67!uCD26{W# z#gJ0Y6I;Gy)vF!tv$gpS_LD+L-!ilolxYT=37w!89c77~!>b$i=s(@!d^kx>LXF-H$6%ZFHvE>ad^vnE@gs=izv8d}WGxBO~fHF!V;ZkcgU=}&~%uBcPNyuWo9 z_E8|}AH43oE*mP)EpB6=q9lI5V`u5=RMd-KQ>fue3WvQ-;2t`U2Bbpc$Y`{=VJQWq zb&7}uKHk0%MOE}dRg{oI>PNuA);rwt0>2pr`)3BPSB+d_D3O0nbuMy$&1Web(Tu-W zbH~6quuPzV`es*941`pXD?hUh%EZC$&UAX+G3^kx!!FOsKk_~44+Q3hFE}teZK(+F zHWz8%vFjw(mK>&A!3*UF-cf9`mFNtN&h zwagQ-JnY(@>@S|3W2xT2XBiyEsfIzHe#8WY;MFqSu&nR-IV6d1Dn9x_s=+=1L8@gK zBNHC+d$AGxK}NbJt7(?|mayNs`63kg!9p7WDI7Yck+38;iLOCPb=>Ql@f+NZ6=0rW zZ{Z|A*}}>5;1Zr4V7$w)6MH$ny=ocE|Bf{+vzg3xaXK@y!11ZD*Hw7C;O=9RtQ1+t zt@AqFgkYYtO3#2tnoDfZp#$4ax)}b;ZytF$j}dD2V?DCpxRrq}LWi_0;cx}Ao5Pk4 zKU(2r53lp|gDj;HzGY2cAJw zICKJCwI)ckwma_l9gF=mW( z2XvJR4CNiFMW@y*X2xX*DXqX;&rNh*hAWoJEnX948Jw&Q5F= z9OtF=GZbI8t&ezXl*RvDP3FXgq+Z9&be6m_EUsP^PMLbsW!;g4tA^&b0#2R{K$JPD z<@mvEft)A`E$vP@zb1aMJsw|qJG@0Gc8vI7L3@Byy@LFwsd!Fs-~P5~5;5tGEm2{| zF=AH${E1N?F^+r_+XAGVon~^VjsN5EvxJ@Wc;1UyNwFg(ir!roy*izK)V>aB6mVz6 zv6l=6Sa2Ns%VNOcaUI2DhJV~}hlssm%8Ci@m@kqNv7iMhST098z2}|OD;p`vLWR6H zdOzjE4KTr(ajP#oPFS!;Z zvU$-Np)EFFa^tb}(&Z@{!ihc~Ekyfc?Uk%ct zg5UhxPawEtpf{eN6Oo}PSXTt43inB(z?y7chGIStPPquh1j9Wgk-buql&?*vj1?t8 z@;bA<1cQhS+}WXD*6rXNEo?dYF{4t3ezoc4VA)#oHdx>`o`su*%!c2xBuBQ7^@305|oj531(?8fH$X5=Oe>Zw7i<3%$ar*}z< zi+pn2VnOiJAPR1!!_OZ~V|mfh@~q!d?dVt3-e>QGuVfcMWWilS7*tc~>o@fYYtI}j z3+4yS8o#VVDDrn%UOmbnB*lM+I&=okTWouELB(g=zZ-*r+RQ*R4NGH4Gp!g-@p4jX zo6hWBL8U2df)u)4pmV-#WAFMAqA_CaFg2;2*r1vsU;3BaNGsxTza-&Z|8;IkX@8NTed@HUIcNa66p=`YTX{RcTayi7Nj%AsGp!R5eK6@`G(s1 zdAL(t1m5pA(|p^^5L|X}*(lyQ-c9)?Ha6r{(*5B|a#b?U2uYfp%%5M#HXBu1PvY1g zoEJ|Zap3p1PptZgel}=syDL8XzQ21WCNkh3gdQ3qk&>FJ-GPD2JEzw7`TB0TaArQ+ z(XbIRDOr=1YZ$>U*`MpHWM`M=oO@wG06eg{_l4Dj$^9~FH_=BmO});;AC%93aGT+R zlrPCQ+)@S==GB5C0j>;haT)X^7HUekFf&(MSzejeB{@KM8Atnwyc9ZW=rn-yC6oxd z+i6+h->xzlkOE3bt|rMOCoFJhc$>fWKEtVbBy%xfbj#lB5D{&0&UD^s(klS`{lWe{d9dtDPR_(wH+h z;FcCz2zC)UqYRWOGNr}*h5;vwwV=z-Ai7bn6C|iEkj96m?sb7j0Jm+DJAUUWD#h@t z8iQ`w6`EKJvrRP_>5nM3GP^8~uqqL=OXhe%^G3=4(Y&4Z|7qS1%zg7*UjKN>2b!nn zaakC(A*E|J3<9AUMlLFkM{U~8RNi$L z_G0|l-)y`jPlxu?YTwA6!wXx*kB&nfzZRPcj1}B5z0p`a7GBcaS4>DdiTNJ zk#owuxTo=lHFBzl$JeMGuEEr$PvI6*`3Ze=o0L3{K77T7{}2n$mr=%FO(-Z#90z@v z=XWHl8&_;`3tOQqBbouNONv4pPj28YGJ3sTEn|Y+P)iRFDLCk3@>AO+Jl%Bg&5%NA zAjA!G9YTag`^F;c=>{xKg8Z`2fQ65}nd9XwUsb{GwjcjmpIaI}7Q>UhG-qb_{K33c zV;)_!SLuu21f`TYkfeGODd2aHL5mBYQ@(>}V848QtdQOlIrr&p%_jl@<+NgB613AP zDHdK;N{FvSpHRd(IbWkjIaNJp%DB{l<3;7d+mf>*%5e{+iCrHbTEmKRF4w15!r3>~ z@H$VQo={|3#PKL}G+6!WSdXKKA&uIIP^#8E-X)mZZAPh~+TWk;H8K@uK9-Vt{wk~H z%(m^Ilst7kjwI&qa2H!lm)k&Zlx9hHNyC?sJD>OFvvd5>>|1T$8?|d)3N1@C)o7@K;R=)YCM?zJBt3A~2 zloCH){K#pEzOmIlWOPf{ugrLweYn}JwBd2a(iSUp*F5;sTbKM$MaYELeREbJ#+11& z2i)~|`^~C9ZPOxpQhU$f)0@RVdmHoCx7YI*d+_Oj)yd^kkcpWP@}Kj`v2?00y)&8J zzb`#?*`dMr2t@K=+uE?bYS2g8K6r0`pnt`f!jJlU8efXgoZEr1UzgceL_6@{!gb`& z^UQ0cZ(YwDkzE6`+rdz~<~1dr;!Gzh*qNi|-Vk<5^@Z#g z_i#_cmWhX8E@k|VHSb2|^=#9-<S1no>7Q|GhPlh*tMF?^rkL z(h`5z-&j;(DgCEJCa}Wg2xE*Ls9QA|%yB3v4uP(huCF1qT%m%N_)iVtRHk-haSF9V z$?9wxS*O?D(G1m(QuZ5!G~AN&hdS*%N5XmEs%ID8f@{aFDWI}V4v#5nSxw2UDZkaw zGeMcx@!^Bm?^-=Im=-f)Z-|rd#UCi@GIa(mjo- z?9O19R}}q(yF=>5OP!AObBAmf{3_qbrC+>1fq3@gQ10q2!)8(@JSaP)t6ZzCL65-zE0Qrr}S{bGenmv2?OS8XWLSnOXb zE($56&U_ys9uKZfOkwm*82V!Bp(bvYvcCRQ#K)6owQ5N#x_&047^@-b?PGZa{3ZA) zkKRDC&sS8aRle!!{_hgnDQ!O%+^ONf2{;zFT_NO`xkR)_)i3c|Gd28DcCdhq`KQ-E z@-?XlAOjc5*gIL)9%%pIa@FX`Z1W*J#u|@$E93$nW}?G#6s_~rBsY2mhgx!Tch=_A z^Jw?_mS)!|Q$P4!!g4-CbWlR>H<@5u=inon-Z(dM>MRV&mADqzGj|2u2vQooelmkj z*A#V^s~SqFCw9XyeFpNP1FG#|o8#Z-?{L0HyVFe!;ZDcfZZN<=m|fxUOgcr|Fvb|+ zyF@#TkaWJZz4IqeMSh1tF+fL#dH{)SOyc?8oD|oNv~Z^TBSVP%*Z9VGv2~^m z(|h~HvAZXR0+PtFAqT=Mu|lywcPPJ(pZlkG^Y>4>^dA{Ye_GnJY@J6gfp@1%e6=6& ztjzFi`3blObVZC>l1RNq54GT>KmJSJ75um^Ed|1Nt{z8Q>5M<)+;AnDMMY#ps}7dL zFuz!l(sfyFV_7eGFGo~OoO)W`$#g-I=wmTlyE zGwh|OlueWHXA8X-(-Yt3%qt@`j3nJ@7Kq;JNBAgiChFh4iBzUo<$R|c8Kx_A z4=XVkp6|uTUWEB>+9*8laC^&;>XM5T=s4RUcJaK`y2VG-1Jq2;nmV=u5F^nkE|g0+?bc& zX-3uac}6$)l|ao#02q)~&EIxY&8$?Ovz1kc47!Sov`neb^@^Z(YmW9I{j$wZ6QX7( zij>w?qzr!XTX_zZeyh{5a&e8yC$=oSC5K%_!ziQK3cR)?K_Igbx z`$*8-6OYj6#fs#sz)A9HLxgJ;+<@nzRbtCx$SjZ6etb(3>j>WWshhhQVaTeN z@iVDd%>ZCpv5_H)Z+&`ut-JZMIgWJ`<=rDMTV?Fjn!IUzg;@6eSUU6)3uH|KhW#1> z<$(xs#(id1#DKTq%y>9wy{ti3*5GPBvNJ7KM6x=8)*`*`?6uFO_26RMiq$LtfP9v) zu_E#xxv!~*8u(l_n1|5L?k<$@w+;&-e`g>o+FQ&V%A~=Tn?Lu2+|5g}@-c~ty39`v zLcNvs`2f*yT|WdNnwa`MG%@Q0FV)s@#zd+x(Sv;rYSNO}khKa4%A^kOFH?U`j7okA z<)$OO7ylB1aYU1ifFVZTi|3_4^!Ug@p}MHOQ1+$=fvT{Vh&-Nssg_c0ZGOoqJDLE~ z5nlg!-BKt2Nb>sQqN;9e#O!)UP6z^|e>U14dpV)P59#E1NwZn#oDh>es1}~e}N{U5HOVWhC zYr)xe=wYXJ<)uKY{0Haid$?Pyk1}qILs>X`)aNfVj^VzeXqK@|Ir8-y?q}37vjjK-x=REpxYi)S&Og!nOXPpRBJDX_oSP6+44>TkCmchR!UWx@s#-#5zo1H z#(Jv%%H6(tuxhsH!gaxce2Ch;;AK|AJR+VhO8w{1xI4rpc?T}RHKR}s=_9%(l7oc! zMm2u8wxo!T5St=(e-^?wS85+nuA3<^=mRM3p_ApBLv6-OcZ;aJE*+d+l1}4t5V}*d z$*r0rG}pK;)}d1ph7nZRAJ?*}WM_siciyGJ_az{ONBwS!0iAp#$=q?(6Jixdzhpav zM~$Lg-m2h9QO^9Z&ki21%>r+#S!0M<^R)cjq|c5m3>39P2b>RifUst_%Z39@px4;= zdff<^a0ePJdrio@n}K2@+4M9(3@M3VZX0=f!K$HdM~Q^BR?go*WEb@-M8Wyxw`EJEA*SWJjseecFS;}lOI6wo4v=awu4V|fTQum^Fi*o zyO-@&GakKNCLT1OnvjJY$?`5xfu^eq{?Gij2Nn= zE3Cc{dyOD@;Qo~P5&1jjOnTC3;U^+=QvDbF4caYhw$J3cz3!I9K9gh347Z5`Ph-xa zk_W%oQ=UVo-%2(WL+&W<`THS#et|=zVl&-V4Waze`h`eU=cmUrn2^$FI_^?8T|(SHQRR^#JW{O{QNoDaLI~~7d+20A zUcAN2@X{(C+$7x`yJ!sYqDy>zW1tq4VP(&==Fv+})!iZCzt?+TvY_VCJ3i%{UpZ{I zFak%+a7ZBt7>JE^8V+YmK(-rH9mH>Cp10$4){V-?5nT-TCG=z;O>)IzsGUnYYAj** z+5ees`pCfT?&6@gPwwH8i8On<+1**az53P7b#^pgKn-;wT~?MmlB7B2EuYB}_63f? zHI3xC%~Po4bo7a-h-UQ`{bu65v*Nf$=x)b}^;2&Cs3=xa*3`Eth6&XOtx0|~!TSZt zhHUw{uA4V9Ymie=zUu@0Sf1VFG~17{I<>9VB)swP56U%e^Q*Kh+R%>YloRI1EDe5f zq8y1q-wWs6+GBvy+qEQ`x@NU%*@s+mfzaKB6C2incp?K|yi0kk`~ssMPOi5{dyTBF zSWk{7!gxmvUL5zLxdqDG2S7g;+)NNxYr4A-zfHM2%y^}Ew2^$gcz3wrK<1@YR<&f? ziY`VZ5_3RF9ARC5b<&{ajZR6WmX2i<{npb(fGXLa=iF=7vX`E*dkZ>wZ$oWNL7IXM ze2U;_j7K~Ml3YSsl0D@JI0@E{4Z~95#I5*T+KeG2b&vH~8KsW5CB<>MT3WC`g&tsE zOSxi)-*9|%RX~k!!Z#w&3}eo{hLU?m-a#am8vWFr0T}GBey2h7buaFMn>%L-2|ni$ zI$uA7x$1ou0v$pOkrm~iokI<^A)kNcD6A9?i`k8W5!&+r8SHQ8XhbiX7i`6bPx|+a zsV?PMbKw{92Jz3Edo6oqsJah9J4QA=8-rn@qOXrtElMr32W6;a!E2u*u=>miL0D&+ z3c8O;B=w(f;dJt^_X}e1Icwa!k`tTG_gS;C{*`_1YyIXQqlfO zP+)kG=rdryL?(5pYNTkaa%>FLS3;A5_OSsy*>ag@&ka=G%KdO*!8Xh4IVeFNF1I3@*>UIt2rpyFiMFJ^`M*;q_mN;1i?#LA+vD8~}v z>fAFSs;&Z8bLKQI?1q8f?AY{=>O$JSYV8oIiQ`^1KLv$QJV521r@Zu{f~@m^z!7gQ zv;ndR_YHXLFB6O6pBqC9#b176RVXWB=wGZ5>9$tcPcUaA^;P%Bl6~mxa34ApfPHu? z@$T%PZKeCU9Nm&at#hQ%d6qt(30^F%D=_a7P6$P474{@h6>vqgfSbF|=zc^6ffrC2 zTxB}z)`(S$X?H%Ti{rw!bVJANJ#@0b-d#PC(f7{*-FP`9@L71Y@Rib@d(a0AiY>@r z;cL7X=?E~F;hhuTI4Ipxw({I4N~saNP0If*fXBkQIWam*TCu~%S7E?Vc6qRu0ay!P z@0@NxLiEm~-pV0=XOL28=qZ21y)4fK)duGmX%x6#YVxAE&mQACq}m(IgYRia_7px* zikH-QE`h(zS(5na_wR)wiP`3q{BCPcEU%vdqb4Bx9(Mn9jzR|x1XHZ0=n?nm1KATO zSqoPK=uo|{Y4yKr$}N)Xr)0=ne7b$;N$8$V0gRxNd$9U~DfzEHVve~Nvb}pfV&y9H zX~r)n#t4eAc`??mKnw0@b)Z~onaT4WjbfNihoFqx=%djeS}3!lV-4CZE(-B770o?}I$tzDo?D8#Wxv zhY)RsGrHGx*H}XK=3>tqq9a0_uZJb5@800_zC?It*9H`LkOX}QB3vBCq-DCqmVg>5 z1rG5$Oez&UY|;~HF_e@Kz;_^iKMAwktkI*c(sS(bwC^SobVy72%l~=CcwO=9AUGR3 zLGVSkmovEa`guaWg_>TU)bqwJ_#?-6V10l>j_1vpN4@93PxQqMkEbJKU%aqP#<+I3 z4vK?cY$=apfr;0n)iNY-JUaAGSoG=&ijw`En4+=>eZDI}If6t?$wU8wXQkcHJ>ctC zlU1)yqV%>)U4ck{+Ju5H60!F0sJ8+=3K5O(h`}Puf*deu--{0m^&L6$KJz2_$0#`z znydGHYk~W_mKQJu`GaPyQd_d7hZQ*xx!>+k_*B@PMzJ3QQI_hSH!-cn|JD2QW&f|)DGBar!(k|p#Bg%xeRHzQM-vVv+xr4m3}?($pm`ln^);oX zs*rv@4KJag(aa0*G|{{toyW2bQ}KLj?cS&UeavP`*`5nkNWhML0F_CUVUEqkOJOxI z7lhlfeT-)?=y?X*HZinTK<{lq68Y%qtz>jwId{p{lJUT6sWI0D2Up_AoGuce?8s{XJVuABCa^um8%@zJj=j($0Fw#%j*Z<_ytqpB^N$=!uY=_vIvF}U>!tx&EIq=*GRw*g-Vj@~TqQ0v5 zd0>`(#rrP{>RplH)!yps5MhtYv#XEw1)z(Kv+qIYEUY?xF9+G1ZsPS|y_ab8k|~%% za${C3fd{OqX+3$#>_eMp^I(+=@{O0%i*#}un4iq43WLXsc#0qIxGvBz_qoZ=djxW0=otSnY!o|*3dENqjGIOgXEYVaBY1^z3pWY3z=4=~X{BYq4xV=4-H z0i$w)N#Bd*+bUG>5(~wb^_5Jnris{*DnVEtVIWK_n?u8}?2Z=niE6x%M|GraMe~6- zh(x{%c+g?~0LOlI-(dEd&MCfxMl<(FYS&Y8!zyqI$5M;HTyCWB3&Fr_jP*znt|Rc) zgBOV^0bQI}HrECvxgD+hHyr_8&Neo^TjGYBO?K$uM%jYGoa& zzAB0!z<yc%t!fey}3bpi8UP^unM^hd;`t=F4|ufC)6=>+Z35WW|)yHEULDpZk>s9UzK2-#fE!WrF9nuc4m2ctm{Zb>*er0UcqToaun6%acnSn# z>z1*}K0%;e5_r;ZihrKLVE4g=UFqbjnc56XFRU!Lx7;ZbJpYkZDIO5Ar?gB1@4m$z z3r2_AJy>UxF%9eMoE+KZKl(~T9K^M`KCUQ`YQK(!B$?^8E=UnV3DT?mj2Gy*zszV-(du2z|np4-b3xh|{b-|6`{Qf6$L53LiIpU8gm)p=Cl4WClTn1z)G|iheZ$d6U7XU1JvA#1yeFcoZC|C2NwD%MZH>D z#-)RK*VglRoA({nOZ$%X`eowDp?F+D@8|noEV-l8fC>8^f)kY38bsT$%Cg!%;Of{^ zSNF3$7SG$=+vUD$32-o0?O&$MimnY#cAAJq6$(f4NAT9*I8DFq#QrsLY*jbE2kx}V zHvMh#ZuQk;UAFBN=7V+$S;R0JLi%Val=mitUEX5QF>gPmBDrFCbxxOqkK5=9w_tL0 zhHcJ(=O|bDKD)}s{?HuU?91I!oUXb{)!1?)zq^Q8f>R<6PJ2L_7 z8KaAL--JT2J6y>$ z4}X`Ciz)KsTt@ER9EX`ICpdgqoA325gh2h|gpuuK>)u`PRAaB_-b|F8+F=%29rjP( z$}lc8??V?93)XwlV$C#*(zoxfr(`P{`ib=YRa<*8#cb+2CMFOM4Q3Pw9RxF_xd%nC z*jPheBq_6D(Qi3^8xmjJy*L2Ro=S4xhtT?7eJ~vTOl;-qG4UR^leX>zb|(H;yEsE@s>;8>JRNT$#=CEKZaM_AR2ZFJwI{ zx%-n%sv-3PJVYS))7@!wh>v4Qm#EN!mQd+S7K<&-IL^!nW@v}i!83(u62~VgYxs%w zny!@aO^|K^WV>NU)@=h@-%`Us4joYWH`9hS;RX7;*5upHI9+_8*+B1+%~3;E&oZ z`1ILtWMjnTcHx~acNYzFlf;`7^L0zDjTih)T7zxgbJnc`ts6)92_YdjR1{DH)v}7E zTkyOFL}{dAjC83b1+Mn2h^~bfZIgAU@*m>Z8a{>){1FJ_-1^F@I98us!av zoC<1;3*QJecNhsK%wbB-wC%_2c5Jn_0c~LBO@s&gU70Zih&=^KTY> zCch$$_<_a7`w-C_i_GP*P%z*6M5<|SpA7<~I=E?nhz5ggWI53%FGM4$6nN}xV1YZ9 zhs-7?#?1EDch2IAOY~<|acHX|Wh>FhC=;=Y+~Ik?2%512k2`7<4V1Wlb`XL2*~CP) z!y5#1Rb&+=RR~ThN;i~mcX_;|hOuhuvp~R+E;TA^M4nqfD5s(Bnz}J<{KwZ&_(I1Q zeodnk!7l=p*Wke-#IW_)FL(_;saLTiEi)_;l{?&f1nQ~AMc}UTz7N5D1}{0xAbU)I zIR0w=j>1wL!DQh#EUxb zU>uPW+TEMo?_u0$yuS#tC8Wh9VU>I>OtRad4z76F(8*)ellH+C*@>@ACphi1Okk+t z4vsNNtav6_kc`QFjW)J-VH^8Nlkkop5eE3R(#oHGl1zj#ek98<^6422PgDus{i3}F zWlW3JkFtSSbTkJm8)vLp6b|ii)bSpbOxB4tB z;|JE+k7NlX{D-FMXZOyQrY>%zC%bu}VO(i4%Z$FT4F{5H4My^Yll&sMM=FTn>TsXr z)DY)30o%0@EZJ27+y4%_mvpWWJ$WDe`yrgm{jO{N+hp>9OnUtjAT`qIg-?9J2--Jl zn&TvP|2cKF_d)$&p7*g>mLl?!9P7t4qYNe~X^}k;S!`E6fuZk3vj0F@@G>|-RlA5$ zu_%E|TOcHKHIrGMXU$f=<)mR6S(h=1FFGgaGl{UC*rp@!Xs#=?O(EdASCb2qqW1@TJIC z8hFQEc^GLd)bE@xZlH2j7>bXdQ}av^UI0gl`Bnn%0^SggqR2PVSzraaY%SG8aA5bL zCT)<_2^QVBB=sc13Krx?4UyJ~8<5GUmxVSwqfiz!y!`C_%*}QW(Z{Ky8QTkY3i7&S zj8)*a_vDGGd{$7PnZF{_u0;5i2H%;W80O|=WFo^H8lOjS@qfvSuM%$Lf+ohpDxmt-{mc9@obf8XrAq42LZl3L23)l^D z&o)Ah(0=>xKQV!erX~B7O^GFVAEQTTka3-lc`o4%gG7G*8AGQd?j`)0lDKTZ9Ly9q zX1w3kPl)9NjVGXaig{1-1T)qRxt-z0m+Xs4G;>nXtM*J+pB5?cP^@;te^Z4KGzjTK z7)Ldz@YDa9T*QwMPPj?`uZ znk)@DG0>5Y>5NjL2;1=hMTsn|!~+|KjI}57w08%xdd&ZL<&s1|rGuCHxe=3a`6Xi zm~?`6dRc3d<#At9<8)z}Z!7*)#6(#YKh?lMYx_kYd zU(Kl8zNz#RTXqYVM%dA*_Pzh}Y&%-lsh=jnj=&EVwMwJtVVY)o%z{PAewSvQw}p=C z_6xT8HQg>cbe1OK{9c#T8jCTT$dUgl1#j~5yEy+WC!z-yag+$LZqDOr`V{CS^`tcc zD_H2gYnw#C&SuUbr`hJPzCN;@Kz2my{Qm9UjkLXTM!h;-Nins4v^p$dMooC9hCgx2 z-`GC(@MK?a%b4!+=A{Y8S}il(UG8CmF~;sbchBz3nl*dwiET^3@$Ik|LqklMQOqOul4+?IBD%%#6TSWj}+FKeHz^8a*GVCq`HfQK$~fEk@Qw?|f`GJ7%q0^~^h*TbmEt7hb0p zyet@dlK`=jUyKRvlm%3hyB?a$GR@EbWC;3ak>uNLnxDQL~Gw$4Y^;Yzks>=i1j#(hPTlRTRHm3 z2@BNZ9o038B|Om@lK6uE;)wSSD*+Z6LllCzz6)%>0lN5R*&(sTNVjFHuC4zb?Ne;5 zAKSN}c1RSoR`Nb(l$r&wyxt;vL+D%WWyX+x;|yKO(zKkBf`$f*~sRv`f%vNN5Ys z+s8YF4h2gimTW@?-3k7EF_V-NN0#g`0jbld%qW*SLV5~>kfZ{mF2(5p*2fPiQ;a3E zCDW&Q+L~(U(KoTXA8MMnF~hsmy2$E6lgBO#7e;aWu97!31@N|X6F&@n@|mMaFzPMA zzON3GcK=^j7yJ!riyZ33?#Q$EMh<(;`W!YB>m;rI4@o6eY)K|hYT01D%hR>zrD1Y> zWGK)G6Q5K~k!+2j=lEv~(_6AlbM1zUG<48~xk3V-K>GDK>YKce`n{5+cQ=IHDqH9G zh`=eTj_!?H!`h5;;+Ybhs;XHm>!`Od4C!vnxeE4M9i4`~T||;9?f$n{fAlYES4A5% zZ6+a$@AVs}C$iUBXYDpSLN0_g2+vSjH;UIv0t{nosipYB@}qO<5z^g3w}Ll?K0QB) zI$e%j;xv%76-;2yz?_Zd_#A&>mzs@f-ueM9se{OTh<%=O8{D%9oHk99b^IK$ID3_XKRX&}X2PBu< z`BAO{q^0M<$rB88%@+Nl&1D<>a(f_IdpeAJyxfq=*W3apGfir@vL%iMJUVmJmv!>7f*Lp#oBAYZ3diSw7 z;~2^*EDey_0Ph!cZYV%%$DAYHfxUY@QuL8C*-~0H+dgaur_J+htq6xx#Vb@;8oOZv zeH**v2Bg**@ag1>i?9EDtnzq6(d;B5xO{VIJZc>~kEA{v;HaNBSg6!d=QSsEC76>lg!YC+0Xxykw!sE?zqnLsVhdAq@5(+BJdOu?cD&C)YP-KXUS_|lRP~|K#R|D6p zkbhf#P@5syglVp7?>LWpqhYdQnH19RA>yl^6~DR7W+F6`j3Cw&v9f-udUE4m(+g2q zJzX@8RUPw==}tzi^PQPn#8{-Qgm@FA7RpcM$9(N7;6rXwcM9{?lU7ZWaxu#^qLDVM zz=%wg_l|p1oWeAcB_BeAZ;KEEd(&QO*XrJn5kgQf&`w+6?6QmLOYUqU^@?rFo%#GT zZiNHGsjDp|Rn74>{?B}eZ#9OPyVaAGSe+k4Nvc10_p)PV zZ1rui@d7W8uODs9Yb2^jzw8cwobrAmwnJoXzq47||B}dQYdnYYhNio3Unup(TfCke zqHd}HdkkT&929O;^Q+Iv=g59ISg3b4)z}+N^JbL;J}nDG0?Hd5H;#!@^JbVgCLq{> z!F@PWCMcADPI`IeGemWkp4_iGI@vlXw!UY4r`*z8-FCMreGAD3t-#)$*JE*#_flw9ijkR8X^+B)eAATR=vuH=TGc9^py$C^+xp;bg za|i$WIWkJ3wZMPA3aPM^lqG&W`VF&7J-m1>~RfqJKf*bBHi7nE#+) z0ltA!aCWyg{jXWkqs!2#K-M+z!Tv|q6y*D?@9i9|jO^^J{#&``ySYUZAQLZO(xZQ5 zK0&$9{J`@6B=KL_|DQrZ@(((=X#cK+lZC0NvlCzj0IrAHARx=^l zX|mM)d6aM5M7xIf+BS8j*~AXfo+i~;ZIWi`co-P9|10)rQ0z_ItQ_3g+5SCOCG{%8abic9&`)#% z9T9Ns)?$!5qZg2fl2^gCKxKJZa93wtgfa8oFcKn(C=IF(Hz4;ICiKBw&^Lqs`Afvf&h2 z-D~jHaQxT{w$qLhq-N)k zLKaIC(rh%FLyNBIlk-ic=M@^UXL&)hmi`WiRYaaKx9jPuA?lGJ_ay`4}@%v10y%!^Zt5&zKn+pTo=Qy9jybrwMXx&pwE$QV66f>`{)`v?+ zSk2N53%qPGLPyRDgEU8OTA@b)l=bRLx5FwWu0S zs2q15bG0Os$8N2+7qRjIZnZS*^|7;AL9xQJ+)WSj?;WW)Wrv8H7r%T6MP{8*1sOY= z=8ueDJO{rp3-3`34gp4i?#)#RN*7P1P1?kAnEcMcG^xLBG7)!&K8`L~+yBuc*V zMSUDYL{#LL%#$Zj1>^O$L_Arm&=FcVum{khI|?zj%`yCzOZ_V{aH}Z1 zX^Jy(clF~Ne3YQG-m^z5HoI7kGrqoDwuNkJt)ylru`p5VoP8n6(dX>af#+BA5drCN zgz%O%HRO}ez9E1r8oWv`7>*9RmlKbp;i8;*T+}gzqW3ttZjl+N`BfR%SYn&vCxjc) zqA}_x(#3!1iL%Dz@%VFtrU=?>8Y>!XXVoqq;tL4NW}`fEh?LG_!$59~om?K|_ z<{VeHt?fuo_T0v~_g{BjF)qaT*X{fBU`{Mfx}VKJ^9a}0-)#RHvbRj6?DPq6l(l)t zuXCQCzLn=F3x=IM6tcbk$9_m-bRu_9FW*4;-#i`bfBXgD?Do~%+4<`~Cyz}W|J=`k z{psHS8?lvA4*meGq6W2gYP)1ULGvO{E|1Pjl*9eig8*xY*YH?Zmaq+EWpMxJ`}O3T zxh&jzb<`iqj^B8IxMJxIAe#&={=we%^R+eB7_U7gTj}3!Qvu*4S@C-EOg+2Gd7?rO zQi!k|lfM#v0PH(2+R$wQLIWzdi@S7q47Jnk}mac8^XiXtxG#w>;RBPyKRBo;cQ4zc!}RC_;lP$jQaL)US%j$m3w zza|}w%5i#u9v9DiQQu6t9W2=ZK?oIU2I9ycy|q`e@OyK_?GU+r5{$KQBZ7{kout* zBAkkLSfOdrskF^@?VGnR!eD6c4mKQdMwD5nfs>sCv&qVRw6+;M-}a|D;F5!A?1;89 z{#a?Oj|}tl#&P(cDDvY^U%G$$j|U5CI%bD-xMKViJ&YTG@tfH9N>U=xMKIFQEPS)I zSpSo@S@c52JVFl2?Ume$*WVZz;hEX{*i{~MoELO=lo5Xxy>DPFd-FSqvX@tOy1KLd zKc2EVE&RC%-8#?znstf(f4_6LwX*VXhmtLH;r!=-8=YXUb@{XlA92-?)J`4MWs(?K z|91j+u4x*t@|n$622*E{_Sr)E73(sY$ApxIFBcrD9Q^KVhxK`ds@==*$P%I0q;(dw zeJ)GtZND5M-+-nAL-D;5&lYdT-EU8mp4TNC5FOxMUXW?SZDg^LiBq-CX?)P@&Jkcb z?wa!T$>cR&{H1yIwf#ve?P=io=?*e2?!R^+{?;-a4@l1&10FavKNwZ3j7LuXv2NoJ z+6eUTcP*S`ds740;9sl+0 zxcm^H(Fu8)JX}7(D$@;m?KRpAe0c5XU}L{8dAJGmGt@a5PJ3S6(b#lIuDI^M{^R@R zb+fK|aI#m{>61Rzp+eifVRV7{2HdFp#s4Pl*6@7a|Mu40z83U&gT+<#xOeTY8e+6&CFY%1QU;Y5W9$NH+>`dCLO&H+30Tjo-X1!Pr=(Javn#8f}tXo+U4j z1Fu!%?-^_tFaKV%H$BU>JP&M7a4=WCaZ`*p6 zSS4G!pR~Tj8~Sm%8=&n=00p-A{rTZK@cw`R`7&9!XFg~vef{oQNbs$FJ)K{=-}5By z+O2J!v1S5kHF9w#ztctTZ^^5cayFbevx9FNo`n7(!Xi>B2lHC7zDatNld|Pl< zCpj!C@fZ3}jVms*MsDu^cU<-D@$h&(y{zWw?Kb{x&#U3hg7;=MvwS-JWioO#z5coW zS!0sjIvofcZmAf4b7^Yp(5n)6pm3*8*+uZ1peSp)Ro8e6N^>10#uLxW&h)_%_PxG6 zDk^HR*0`~<8yfm?HF@6N<^zyZW>6g)4=*#Kd%GQ+n0Zx0dg#xifO=Y9*E2oG3iRbM zS1kmV6FyCK{M@rmDbOI0wct$9b$rWFmm$)Gb$LAADm4Nd7mSmee(DD5h)DQNfa!re zAX|)9oxZ-vz^pnImkb!cKeSeUjh@bUNUfK8qt>skQNFLN5ldax%}G1M8htqIe{DHf z+5iE!mX?7B+Sk82R?m`(_JfsI4IiRcP<&7X*oDrzhABxmm9sA^9LCO1*ANCfL>cSvbM4z z>C1<2fyOnzrpMYIUcH;zLWrPXd^4Qg%Zs_)&Ap|8kf)&aY8@&({+WMfvOCl6}})&V{NAkqvJ)s#;d4o#*$ zi6LawKwmO10OEjIOJQ!j^aRFeV;fA=NBlgi%rqlg>pwst4*< zS658G?)O^*Mf5WZOgg)(t_KsY501O(rgdbm>tf8Kx*&uPbsev*?VWY2PYxg>lQc}k z?o}fo%1F`v`B0tZuL^d^AOK6X|&$K!59ov}YheqX5mbB5+$@E#4<^@rL zaclz6pc4V8NgyT>4N$vMb!$;~ZF41~uLYO>zAf{i6gvi3N)ZFjfvqDNCmPEZpnE#R z-ER0ipUDLX=ep3k6$2P6!c3>;$J^vBgkJq%3b@(;3bX`?Y_Ye@0Oq;x$3Me5xRJ1K zpuVeJ6s^_Xuv0Cakn{hH*i2E!wySm@T$TNz6VT0hKVjWs{DO+JUgd?iUNsnfz66Sj zWpc)FYp&>CJt4$-x2D?!kAyw@(xJI2BOM|s!yS&CwyI7_@MV|S_Pw>|{=%CVovF<+<1qgu66i ze)RsMz)Ca?m7M!ea_;|Z*n8^YDtoxIL1wHCpZ4I9ZzzvMH`BXMu^#E6P(@-wY*9-Cd^-X|8hy5tjEoZ5YB<9LoJ1 z*rZm@2tcc6OS=xTY#Y7SEpzFU=iOmmo}zh7?gp3k?y+Rn*9GOnmH;FP<)QlUzWszB zKtihII~Ju(g35%$GOUAl;q}e=XUS?DDL7VSOdu0WRHo#4>m42J{E4}^Q<_*mcPj>W zc=B-}A6Gw7lJT_m$b&YWJmS6VE#QWTgak7xnTT&kW7+1B*}aIL9;e1 zR}@V~s=#xZc6fKoYLg;;)OIq|_FRXy(JMyOHr5Cfv*c9HUX{arTz-9oIjEo2r!?)U znKuVvgJF)PM~j}L&g6GqfGM#m)f{bHdO0VJ9SEBf^Wl}SlOc(ogXm_4&+VV-Q{keP z_(aatksBM7g(}TzmRTgL2E(}8Rn|YI4Z^|6lTOUvCW*2b z6^r~{t(jXHz&v-eXAorUNvCMINy$+@=Y1X?G!veu{W+K{96LH5kcky8PqMpJh&+=m zL;ywK2v2XytykmvP{^2$JuULw)gC>I)su2k(pX9+HbHPfCF%<(X2SJ3d`W|+euGn8 zc9H2&=m6IkVw?4tQu>5CdrQp2TQ+D4BvLBJqHFFZ@yH%`%H4S1kp}uZU zrpkt}$k5@313JF3RP!pkQ=?6lBNLYQuKZ3Gbnv9y$uOCSy~GAk)BKV6>m5W*Q*z#S zI#pxlp_-yF$!34sJd88@3@>&NE{bJCU{$vx$@jHoG#; zOu*soebiBOeHmy37Lx3g_2^v+LdS`=c%hxp9HG*rZhnPrL+!nbziO6JCW#)|+R~Gs zPKEwDcH17SrE7p0u_iIzSn^2B`oW$3+oH!+`pNG8Jc^i^! zGBW4xDdoCR4gEV$l;V;&ximONFK}F7a>&D|e!VwP=>1}c}ZQ5*k(eM{BWM!clg}!0}oOfnu6L63mK^9mXRR&N2iKcaGl6V zebmoRJqTXkq#FR9Ydq1#SvBbw{1~#YY6^f{CdSMcEoRdLjy6lA*eaO{jW$f=2k$KR zUk*`3A0o-zcz#ZrIhfp_pd%Vl6N0GlzMD9o#KF7#(T$Gg`-agcPsHTI3uhhBiJ^~Y zD9=jxc^EzK9n|tKSTc9^uX;lmPH!Yc) zh!mp$b^4)x!4dZxOe8lTFw|*6-YbAR{QUaIEeOO~^NUMmykA7bF4sWJiNYAu zQMEj7REZL6a+u{+%AC|jCAfptOoy@oAy?=E|S zQvICXqR9}5j?)f#BXLEuCnuK=N?;*=!=$5ozU#mAHOBk_URc;|@^Q}MLz#t!1&=NO z!^~P{AsV?A3VYyfpy!WshyeDwYhzv)qMev}yQlT$Hr`BgxvG16D(-1VuY!->$)w;u zP(*o5Uk5*P>iwze81!v8!@)?2U>o^1P^RtW1)OvX|BuyLd?MFfzc^)~xMP@YSby-* z>5AuKZjrugBR?#X*+*`X4oKOoiE|~rLWtY-Y64@^-OHdXJE)DKrJ~fXD9uJ&}S92Y{LJo5 zcyu`YBvLL3KWt!LCw*rZ*E%#qPtZcq+h%wc;=ZLj>;j47uGQ%Bs7|>*jmD@?xxHDh0A?_ zCprWoU_lYaP*%ep2LQS0I%X-5B$vTH(Qij*$>_hnbY|T?>p|fj7dBR*ST+NAlcgd~E!^Pv z;RQ(F=|gt%-KQ3${j;N1;10WL;(9m8j}{N@?+SXo+_WKVEfv#|TOi8t(3M;!uu!~! zpzUvmtjCp7QlVLN8kLFuIoBy_C7YMq2VqTWu1?j$_Flsf7;9AJ=#(5Rp@Z%`s>}MsBL~O94p7r9IWn?T`V3Ya5v8B zsZm~_4;D+Ry}bsi`L3~Gqad7+i!;R=F{&xuoS4P1hJFfbC;x@ziFKcYcS2plgj0vK z5MV+c)-H_Mm6D52jt{9z6H|Z3hfSFDUMj@D2KeY-W+*wEO>-s6B6&o{qMLb~snJJe zIG(M401(ittmZ5ybn%FW!mcQmP`3Bo_73(X~$^&?ksiozxihST)(Uh7+g#y zfHyX(N%hX+R=}_kYx_ZmO5R(h0YiR&uZ*jz$G5z?`+i`R+eAm@K~H+ZFn}|wUI@$; zBu>jv{KBbX8TbNrn;6`YXy3n@zteX6EAZ=W_wuOa;NXu}lXzw6dd&Hvqo033juAy+ z^%!{Y=5*5U#>a~g^_e4s$q@J{OADW5lXsryP8|LBlm^d(JS8GU=Gij`Oh<|KY*eQ8 zCo@Q^Jw{m&Iy%xu2~zBx8OP?A@AAVSrNo|Of7}^xNmTf?!i;PBbt_^w4W2d*&PApe zx^r%er!O+n&Lh%k5Uw{qm&eo}X_nHcl{%j?A5FTpA1~90c zEv}||>~8T~r7!7)LGXo>xke|lysOJL@||%>9uwZzl$g-3nITxZQ1?DK*3smtlTX1K zpA(FHF7rv74%adIu9cZ5womp}~$_pawbf~wjd zG*m~r*V)*EzEp`bl*u|gdTe=r|1Fo}CwsE<1>Qgvr<3#|Y9$09gK~#3;6G4C zthkwRhS)r+x3l6Ws*OwtTgDkZ&ln*j zcQvbJlvx-RlOAchZQsZQsn#TNhC@L-Cg~T#69%@2U2(~EiSC!xU1PY`N<_d+S zshJr{)hW5dW^GhJcaJMEpOYIE{_c0&yk=Bu14)5afq(o*q&gw{@dBG-v3#6=gNNE9>bdQ`MgZt}>! zv4}KXGIl1U23l>>0G?B6s&`mzMDE#PVck=PeK&37PVk7Y-alds4wyzqeUTZe%*>VX ziloMSxZKB*xstJ45?SZIu`bvN@bT279P}`ur=e#10?)W>6udN6nNhAh-gxLvIi26a z1(*9Ad#^L+_Xle7P@8ru+(fm@jXLG;t%ps@wJC&>s;}r;$46Q|vL}11j(WbXp!J|H z?8!GZrx=a;=kT+%4qh=|9EK{>avi)PVORV^t4xA{$EAvO)>eh`o~TQXw!lZ*(kEIR z6r4#j1p&eYagBpj<%5oG!F0PN@fbykKO>6fu09>2N&mSzF5CQZvMaEfQDnVb8YXigRue48(N+MW3k+gtg6nZNDI2T& zqvyoH(<)i*c(Rw_WFtct_bDb{1c)}$HsZ!N?mhNhnwMX%xLD&3PH3|9;yf)l7TPftZ=T~Bx1th7d12i|@ zgw&me)7YbQmZeW{I4IvH$b<5uPRBGd%~>#L8sygzw$-@Sp#g?jAsRh`!x7JiNTcY? z0qR%lL7$Fh9INyK06%;;>LcC4R0$xPe+i5VkJ_tsOMX}XgaYkXa8nvp3T@L~%oEi= zY2(HW?VShS8jC_*X(q#IUz!e{WIQfWRknI>IEAgFLLQT|akZMDUCK=EWLB@;QGh5G zrwuq1wIXRDbF5@Rhi>)lT{f9&s{TFwT2nZd(J!DckL;$HjD?I;k*gkLl74?%IK}y> z^5u9|PYP4)XQ1#OF>;>L`x9cC%+R6R3S(%M5G#x+M!amKz5ijF2(6Hl)YT;d8nm(C zC1CP_m&L17X2(bN8l_7G3S3y&Yg;VJ!dpbH>(}A4dKk(Bl~gOcOv&fCdiGO<)^tbZgLg<&veA$qS-Vj_P|r3}QZk4;yD%iU_hPifrLJz?LoO2vx7 zo$sVbl$ho|$jN&_I|~=EruMB>cM|F~(4Io{H^==kqZJ0gKO?}e@Be3nW?=}_2+p3Z zR^esKkN07Y17qQ)!UNlpQKGfym=gVblV_2pPiDlyXlXfLAV{O4>Lgy5A}$H)-~~p0 z@Sn&-{OAp86ruD4v`YyHOI3V&1K*;;2m*4FUk6&kX8AvocANha45dp*9GcotlMOSq zTc)2F3z;=5-fdx9ifw=!h+O1%p?nk`HjZEZI(cw}Q`X0sHl}y)CpzUPMKUnh zOr~K<9~*^4q?DFVJGbj%Ckmv=g=)C5QL9o-%Xl7=T~OvxQ}dhN#j`5M1K{SKApa=K zuALOxTi^h@!i}}+ux7shwBskxfLDpLTzzgEpbWwgWh#|c4uMvq^AH#w<$3hb&&v0Q z%jF8u=0r1iC1$76J6R#0bk<76@{i*rWp-ga)VQYTEio6E6v4zm^K|F-%$4injTqyr7Qaf(LLQH$@?Tu=ghrNd4L)l1*(Mw15k$~~u z18g{G*I}D$73TLgmj+i{y%<=OaN!w^8z$`QJYLB*m^1&d+lBKQ>czJ0bx>@v$&;eo zQS^~3`o%nrUD!S<-p4N{Bz(gbqQnPr5f&U1NI}K^w@6WY3`;TXk#zE?HsSAt>qIE7 z+lDt6-l3fTfrAbs@5lFtwc8A}aU>NZTT!4zaLK5X1X4+2mNUMhy9=i;p!Z=<3-bal zlZhUf>0Y2oFZt0M8qR!RzbN@ARXpirPd4hO0_6(0q-%duc4SNON;-nk;dQKIa=(AH zEC>#al1HY~C4VaTZgdoTU}TevL?^f+T$n~hZxFvfR+P1VX+)|HVvdV){Z0!jk1uEb zpxIH)vXbNA&i!r?M&ftw2c-4T&_g$F7tvz7lLFG?_sC#dDfJohlpJ>iU6KWD=F1eD zMb$0d>TSiawLU&CD@=!Z;eRzyh~uL+JGAa!C(kSVenvH)nRx-v{w4nEgGS+99l4$> z_AKr8kVqs`>*#wp^6gSVLh!cE$n~98+j0tIihIh`#AkkCm>1j`#ej>l9D;!S{Gw`s`!R z(1-4}qg84rS(&qt(ZGSr-oUTHtV!!oO7BefC_p~Q?!G<3^7X>BD zrm!T}YAU&+6!TI#cKc-}N_pk3NF0f3cu3w^0 z`QQr%JjY#k+wTGg=-2b10eLmxn2X*wk;7EhZu*UY2^!7r$3s#wyQWTROOx;SX=F0c z+K?p=;{Z5w|NU~GQF{!OH8R#+ael1~u~uC_14cJE%BX0DGf$VEIMdJUd?Vyd4;lKa zdtN`IW4GazXf+Imx>qB94y*<~j+FSp;zYx>nHftU_`%-jm)84sXU7_i;2_fgI%pF% z!~PNC{v3HoRCwq{9Ie`5lerzM<?drF%Ixop}sDhNGpu3D47)3?)7$XmY+tyQmqr zyrFK}sJy?#C)685kQ7#@;jL(ts()vs3N4`WOZ*OSRGn>gBmt z#e4N(OT}^s{w!IZtr-=U03V?S{cl0})<~|I_x)@2n2+{4l0fSAQ}R;3&;ebQVSMsZ z)jciis@pAk;zr`1flq6%lAoyT7!`}XPBYa|y^eWR0_Ntv_(Gd;YqeUyk0WJe7%(WadkCc{C&&9PI|4*KiGH6$U<~jNGy5sUzit6$Le-|M1nJpBFK z9+Q2Gg@t_@ciQ{HpTA)KkT0TM?`V^t zUG4>VXWWjvc?SG-(m6OuPE`n7d|J2vYzouW#(TfCyzk$=0l|oc4xJ|{d*TuH#R4wv zV5D*&ozR-?=V{#i=ixii%%{QxvBA<;r~GR0CNb7eS{!6GIT{~H@@P(q6Z!2H)jYDi z4!_6!UCOtet@NO0f~dR?sfKaD=*rNIWk*e{EBQBxsNo?$?5kb{;pGIY=@~GU@uJwN z)-6sA^|W!xF)hWoB+@RY9nXLTfc3lgqxV1RyCToajXO=9llqNrAQR5Hu|ga-7ixXe zvj9!5@_<46^_??=g?!&r2>&Wa!U&w&fX>_U9j{cdSY((?&zpVa?9{&JxWsX zV8vb#xzM2bFMm5M!ZAA1pVk`ucY=!dOJ)H|*Gu1Q){Lb82#wxkPDCnZ*^U_NDzG%i zwJe)y5E`1~zA9ZiSkX~p=<7al3ASyXQSHqVUw@!5EqOYIYFXIt}S zNl!EPDx8HMo*{Ny)H0qN8<;Foo@wMfW3MsF_lPNxvu2kTt6=n|xfah#(p(QLSG|6) z%bV^QDUoqX;K#8{-ZN^{vM^ymntlT|@@g_BuN}Wxw&_N%#!yb-2apDHCmzE2g;kV_ zxq>f9=-B3ld3F(PHabvdx44ZaiVyABFvSD*QDNFr2c)W1#W1J{6J@jJY4l^@(z0Qo z4N6#tVYITn$F!4jh0ll%k`?`t#mhmG5?_L}sc zZFa|cG|8bwrrB`>e`UH|IEG4FTZF&MT{hpi)ezQ`%47JqA1>R)UL81?$$~o}_B5J8L=L*9x3dDp)&khrD-1;hMSZN>&!M+rSfN)5AOa~O>kiH* z2cf*Khoq0V0lpwGr}4Z+u|4@tBANN@wJ%+y5k|?A#35)8=wh86r;(N&Pz_PS8#VHJ z@!r2Zx(UA`6z`_U)>BOZO(yfEp0Gro3NNYzoXx8Mpl6|%ZKIs8BR_^^IPu!7$ts_U zskx2m>uSX}e?%&XQVj4G4^s?K1CXYC+F_x*C9uW0eLT`MWBEbbSmbak_$J%4<ZCgy+a^ArIXf$!Zpgrm7*=nbc*%>H9n92tz#{yeT^-MTOCq2y&98eg8446 zu()%bd{`S%6vF}d7+eN?!A8Nk>{Sq2HZ|);y(FG?*BLn}Q}wQ`r-v{^+Bvfsp^j&0W<@9^qfV-t%qidS3h1;WfF-IJTa)zm`B|K;aC0OelLohn~2vdwqnK6J8QH z`S3(4nk8+x&M6gAF_#ey$}i60T9pNHXM0;>(<^3a=05JD6+Dt%u(BMihzXei50{U2JD3> z=Q=R@OVXF@yj;p{laQx}WPax_>v@^Pagq_LDQSRw9aN)WsCwvSPlR=5SV$j&#u?#Hu;jcBr;_uq|jlEFI= z8E3D^N4#UWE(tn#FB|e8bAsgsZ7`9>->j)1le4MNoG5wtcc4Uh4ffH@cJ6BTDRY@nLvLlf&kw_#b8<9!9Qq=0l?J25hYIvvpYoqO< zVw~PsFdkFuF)dUQz6-!8Qs0PB-_vG)aO6{N)_W3uAJQ<>MkFe=0u!P39D4EY?z+-vJ&o!7r` zH)>kdiQlAt4cIwvHt43Ip70c7#0LKN6SYEV6`|}=Q}1Janm!pQ;^-Pyj{w;9AU{FPx|HE$oW z#JmtG2R_1=J#p2|k{L^*sEqm`8gkqzBWKzm#dm7YP=&E(^w5lXqcJeVqMWMXF$4@i z+oSJJ<50L`9IS;mh&gl30wX`+x4@1eEzLfs%F~JK;k~3HSK{y=^l*7&H!+S)vSk&7 z#yM){t$7sD^HugQU`|f@Ao_lw2ad8Fov6(x-WOmPe1MI|bo2adE7zd4JA=uqJ%{8E z^^_S%#)pOx2ye-!(tv65=bXt}Y4BG@d3e-DT7i#s71UCG*$rHMsDEXM*C=ePs#P$v zJv?nsihz)s0Ym^1xc7C;VZ_AlRoBjm^~Ya>kBJ}M&HaSF(tF8muap{o#QAr?`)Wn7 z+EVIfR!YxVTa`pO&U*!~Z_p#w41Q&-@r2lJD$*rUwiNk(OteiAY;N5i`!T5Yl2z_j zFF0e!kI#k7sR)FyYnV|Z%D@5zKNFI$5tAo5IR zNW{wBS^MAy4YB6*P|#d1`dP3D}4hm#{Y2f#km*?H_EH`i$ntk#z; zh7*O*B9jKyXBQAXZfM^NvX|1Cedr_Jv+ZBLIOTo1)pDnBUr{3tYq57+w&fjmCqY6p z=E05;LXaCX}tY^&9g@mxd87M=I%-hKIbROHBfW#n7a_q}>*Lp~4-rksP+l z9ByhPcY-DGU20)WFLJ`8e93y54!uOpl1GMq4&MM}tt)Xf`M@bX$TL(T=H>gw`gy)P zakSr?P=-&yO|5FsaT~cn2_*P&@Ar7nve!VhFrYxW2EBsfPvD`P z?PFAw{SdCZ@zk)rI_9tB*SVUm&G}gRF6(-@U1^iiqgE0x`m*`i+plxOx!FXL0W>(R z1Xp*!D{tO%U5zI3lg9b+xS~OBbUrUR8Q^@;g-W?aBITePWT<13fwh%ylGiPyK_$wl zn1h)34PPYehY*yCay{bdX zgKVMgsZOCZ&TH}ci20Yd?u8TO%%jCRf=KB!&=OnX__G`|iv%KqDBVY1erkv%msffT zWC;S^I?l=5By@1me(jMbMDf7rOVKobO$YBbx z4|dCq776=K+^7=JJU0owf5Rz=!FHP=EhaPR&Mo-fU^!AjM<6~- zdW~%dBQAXoxZQ!eJ*v1*WL{$D=Wpi9@3jKC5;IsxgQolewWfW+Zf_1qtcPH?Dw z@-0MW#fE3*#fHb$#fE;S`xQ6INJ_xb)J&wR>H-Y?=`zJ6Otcs?WdZ^QuruL6vEgoy zrNoCxQqJ(vKTH&8$$f;$5Hxr5IaZ7wI$WY*Iv-0YJBNIlISE14^&JhVZifdf^r|5uQcnMVgV zdLp7J&jOMx+K3FGZ%zE zv2Jb?nFU?5(+ExFM$MQZzgN zZofeu-|goa`VFx`K-V`z#pMe3fU3dY9-Y4!fccB^%ZxmsexhY#rOn>l>~r{HGNn!@ z(#cM|Qgo_mr`kS_hp$IU^Nj<1eu!m99WYfqJS`?6=D`bvb0h(;VakS-8M(q{tnynX0)6P9$(<2<*kiIVf zI!Z`8ZEM@9< z8{opk3`qVZcQ)-SuDc|)w<)ygfg*CbUdR1DaokxO@clV%e$#Xv7dIr-1S;YgD&p#N ziR4*~nY|``-S@@ghFTwdch+o_uJWm+tR@dcmF+fP6o#G4)Ff0){_{+S|BhPuUYHv9 zLwFd5DuN#59L6lSt`OSLWGB)Jrr)AMj^`IKo72O_Y!aX4{&!TshOFd$Z-u1x=M;AB zkqNB)4wuQ7SRo%p>VqIVA%mK*4tvrMz1G;o(#V{jlnWJUnz61IwutCy3AuHtXVC!r=8=c$9MD%?<3(y`K))-=jJ;De|sc!_R zERL$OhAc)J5pKLYzM?J4?z#Sq`6`3U!hsPz+%dk_DwgvYapl<;h(-~a(agacJq%GZ z7V(Od@cuzGBP8;=blRUxuTR+NauCrzTF3>)h_D;c!sLu@vL{KU1`;VBT#0dNk;aY{ zbk*S~)b{YueTZR89prB{>)H}>eF_}XAm#+A{XD}w_+$k@4j*&k6j6$6G8NG`@H7*y zHTSoz7dV5EXY@N^WcI^m3OO(GV4^u=f@&rw&16Vp`$sxYdd=MaQ?|c;e5bXGhIu~Q z&cuDKWt(Fc@UXmm5hx`3Inc*9&<(Xnz(9eUC57-im>L^D*XOl=aZiRmiLbd%jm^jKHaR|!O&BNm;sMrl2Ynq0T$gO$6$&dnU(%TMoXop zXhR9Ws<{;o3TGSXrdd-mduP%_B(&YwgNVA5K7o31h5D0}@e5>&md-(odw7D-a0^O8 z(ohQkGW@VpT_*N&`sFI!(}~+%+Xp=NZVgwTc#Ay!dN2I=OqOW_7{c#Z_--{o7QXpd zmyC#s!7SpMcd1MV=M@)5p4{;a9MjWZBf}^zbOi6HaJqf21 zbJP|cX#?VmUkJQ0`IgM6<-IYRp$oPMXb}7@W>i2_z0cFsNWx~dS%skNcvDze`p~2H zsTu>;)qt@6wT=Vh@j^m5o`1Vw%{BwGX*+f#9HErjOz6~HsMV6wh>}^il+1*T^z$^H@Z;cmZ4Uh=2c%u= zCyo^g4NN@G5u{QZ=E5j$=R2<`9Ow;ofHeJ0nIcJUWG(yp?jhHqZkylSjF3__+GZa8 zq*l*!ub8uA2B{4bPA8&px<<~b;i_cqja>78(a}- z_tP8mGuVf;DAI=eP1~*j%c+y6;Wzrj9lU@Ih4YGZQ{8W}lNHiLWN6S8y3dxl8x?6! zO#&u&{i+>WRrmrm4{e7;pFyE`80lu{ z27O=dUGIN?@4ojAYcb4PobUObefHUB*V&(ZRuy=CVt9Wl#u$cM7U#>U4}lqxgWJm( zxp2Ol9@Z%#$WX zyZ+qL0&vv6$CJu)&W>J+!KTXkBZ;>S zj=S0s$YN2+AxXf8WpuTrA99c!cJ1OStrR+=&h}aj$f*H zk+jqGgC1ez#t2-D<%ChH#;7?R7&C339YCQPdAUsI4crw_g9*KCrcX-y#67F^3*Xl2 z&O*8!Dx3^;hnIpm;E-97cDFVUp{@l@-p+eQQ7efqtJlJy#uMa^4+5f5bL(TY2%50AB z*kj1DES9aF(sM`*qzJ5KnPF$5Kd~T~=A02=xA9|J`DFN<29Fn;R#5mW`fy0}MaN>J z`FdBNiR9B?VLhO`_tBBvt1!C6n0}2Jp|Muy0ihQ!{?^`@y#0(lmdd*6&tK(9B2?I8 z4gZb3R%NWdTqT|;4Q*X*Z^a~?r#X^+A9p%t*O_r=gE$2e&UXJD+)=xph+CVT+1E8| z56ER>SZJlT6BgA()VNh&?ITe##@z6|gJ=>9PW6_u4JmunyfU4^S5+BYpEJEtN6L~Q zyEeiFAI>m{eV@<;rD$7(I4a*EZ*UB4n$zDH*{||lu3pYt#w_Q-OYeV}uokm)UKB~~ zuUzk{X6}oyeEt2`*thXF&DSzx=a}0L3AP`KV7PC;`!!SUD`MQ47Cx7i1)4%+TTokh zGYz&pg64v``GvHkbUGhvS$a=dzX=yq$txUFvY_6HuflvVt zxc8C`ad5ab@q}g!-KVBg;g|04IvYFKsE$^%)s0d@J)>=m%Mo@41z$P(-F6eCQX@&~ z2H4f1fwRT^t2ceAsqxQ$gFdqHQh@A`vd3I=An!w%$bx5JqY+ErES>P)5>`>51R)d2 zV9G^w(p%1hq~v#fTP*oJ2-ozzC2tzIwN_idZBlGpHy#7tWz3s;Q_?XneA?_;VM7l( zOW$s+sj5Yi+_Y0+wyA^uwUJPrqF1SbqbmQMg@gqAmTMwH zMU}-KGhHrD{-ay=nuTo_Ue;%912#TaoW3yEl(T#@V2}1S*T14@JX&0-zoK}~^*e9P z%{i5|Z%vdxNi&yP$>pQ9D3aiI^*rtixIJs$_p%~+%3j(!}l4Z+7Rc31&Lt*Nl1AcMVuI4fmT`f)Bd{2hwG*ilv zdwk3Wl6D}4&tzJxyTl~Qp^2XX?sGTF%XVy~h;S@_-Bc}+PtEx^1D*9d{p_}lSP{O3 z7}$7Kt(fpU)F-_m6Hym(($9QN0FSu)oxBq*FbUl`R#9Qhm&imC@MrBPlXuxwEiGQe zHqA-tc7iSO^#{IZb0$EK60GERmVJEQ0Q9Htdq$XSE4ykj(@$M_0ZQNQz4H0O7JFv0qQ__PX^={^;5qlJm+hRY&BnuP6{B;tUKCI%ga;lj0Wb&5?T1GTCuu!YnMM_@hvyhRBp;_vZc$r$FEB8e)| z)O(tJg8EWh?U~%Q#TWL#&%m21T*D?(VToFM7H zupbhrez~jXoGm?9av#)41=55FUETv6IoN!QRV2axlVA{=^`PYgs+QSf=FFeJ#1`u( zt~3#W5pIK^Uqpi-ND21F0D3E+GY>)zzDdB+HP|ix+~QwISMM*lxxm+qQ-$AJS&bg>~%hv(`GHY1JrmB#`x zWBCQt)SOa}=08_n?%h#cfnOW!>s?$?QLTh43Kl{`V5Dh%LXUo$hqZO20rF>U!|(Zz zbG~Ka0$=XK?wU?O0!U;3_&`p9`>fU$*jNYLqjfV`hqdSML6`{A{&6i)rjt3FN^fgYOycMCOZeP3zQsJTFS@s5Epa#-z8gi)Z6K^&ttn>PX!SF|NQPos z#X1DY+h>jDJD`u2y|98%jhfwj;|A>DR@2$<(ax(=c2*sRyP^@`S`pCVWeSlpT9Y86hU?N7v?Po9Spv^q*pouX1{PM-LK^COxLS`K>uZ=BVcuTP!U zTGa%c73F0v##O9AV(qlCjxo^$;PA;lFmOmlBgNz*qW$RBGp9S7&%QnTCgxkW*lW^V z2{MWXi&yh1fVlY|6)feq5FHT6D%ILcSTN>D{AK35tVKPUC|!f=*5RCgGy2_c$GLKY zJhaf%Nc}AILDA?NnUrpoW3|iyl7ea)P&n;q5^GQO?uiyM*9E@D?RsRli1huj_pvw=hJPsH82g@wf`UYjb7*Wf|VKFlGt-2JHRrZ5Wq!w-DUXGE$UT znqJ~>6Cwan4pw5wahK6tbtZ zzMuNL&aPTU=1C9b+oY2<5%*HQ28W-4+BvprW_X+$8mTdaFiewNST?5&w9*iG#m`}0 z4~B91dyg>3o>Vpk@0NT;$9`W!M;8_B7d%zXJO3`wuvsD9X+QwhpTzb7R?h(0^jy(| z(#TuDM(&QrV*bGVq{~yH6wn|a4vI;bFjQk2(w%M~MgX_(#&brJuyA__8;?Y@ywB=9O*p^3 z9i^iimgTs?3*Aj2TGA;_%y<3H3pQFl;Z;Nvn(Wja25j`!mRXbn>;`FHvGrpkEc*=% z99{6RsUBA~V|RH}`X)-X1Dx0CF)P8g>Q^;vTN!WvWvf4)**^VtS+ts_x3hAg=hUh3 zzHX5xrHz|M+VuyX=8IfnBHRr{O9+m}BkS3>Tc@gNd(Trg^oMTd4&b)lo%PovH6s_B zv@?C1eia0NJc6LEy$Qq1)cCoRV!A5A+AAhbBP&AjO#`c^IR5kn`6r@+zFV%*2!d_3 zvD(B;B13OjUaJPWC!QW-_84k{?Ea6=E9(76g@i|FQ<_(t%`hOxJp1EUmeQJI!ut%T zEx2VsedpOV=hACBIw=qXTfj@X>!T;QD}DB7Vl7v9Y^W$)Ky?TTB_6j~r7+TMAV!^E z3Dd;jv7S~BlmWG3pgo-+LZ$iCdMd0yIG#L$@%&L5rD)2i5;**eL2$=S_dds){Ds{^H$5 zBkBPGzum`1F$xXc(G*!~jnt5X0>$1(_;kfuB8D$$Eh!WPHQe1wgqF|M8+#0?v%UeZ zarh2DbChf-)}&^)Pma$Z@eP^~e&XYIU#J=*c*(GD(Rad{0d8sZNr1ItflVLi1IPx96&Si^?3Foz(EKY; zC5?`kWSFP8*0OU4!^c^KpftuuVSqfK+9y~Uu-F&t@lz2rWA}yd^nZMD=+*pFWT+zN|F6_Ue8+#Y69@- zgwlg#p++`c+n5mQdW)>9eJ~RV!Wo~~>jhKAbrCNH08%fiYbih(M}wfx>-2biX@fPs zht$>_yWuG;+*rhrlXhiUUQmZZ$>Zo%e}{gJ0f!+EwJ}>HbpUTHI(5JtO?du`xeg_| zWxxTM->|ow@>X42MS!{b?$API|6+;0&xGEIB)qHD9~c3rIgAPiPI!c*WCE+Vudi3U zf_6i2e!TdxQYUNEPQ|Z_g&-GvrHv`s>730;4Xr$2cshCWR;B>(v$u8Q<~jBdm`S#m zvogTVzE-hQFaPXvV~FqUaFe`gcu)g6P2sumE(siuMqAih8cfY9F3bss5;oi+W#0+$ zRDAu7BrWkXsV1yy7QkyF>K9drRwGzC-O%o&h2U-X3vue5(_>PyRd$Nb87T4f_5cFm{RyQ2U}XZ3PcLjt z7IeHJY%obmP8`8=lV2m54z`9^mY^cgy?M16|Aer05|v;utieLC5vpEknrl zMzKBt%aX`il>}rkA-aD-s*9>p)$WlB&YXG*=035ol)~Bz5@`wMEmu60sm)RLk^<(z z5-w(jA=>yIlp)#z{El~(*-)ubKpuD0?lxWPm~5q5g>GaXZpOJaZi>tfd3zi5?2S;a z%GD^PN+o<;@LP+pW{RXtXtip18y~(6A&9nMdg)*D&ia1sWb>460T!e#Mccx*9$kM`V6P5!x3o!u%h>b60b<$AYTT_q2FFWEQch?8E*)y;c z{CMk^yw;S{LZ2IrHcp$3R6wUUA6I?@>E_p}; zsNUt7UiNd~kG7#{_P|!tIHGHbM9I&9ua0VZ zCarWVWxV?{yf=!!+({e(wz-BVSeKY_j#A{Ni@$$ z`CJ4Bl8qr{E_dVXB5xaWR@|aC2gg{4%8PE^XpvD%nf`FB_Sg%W;&oeky4xuyb1`D< zUEyPsg*bP0P zeBm~kisZ!Z*$*0UU|yPUv;Fs{838K3T?aLbtDHv%cKzw#JZd`Nqw)!i_n1Q$ zhQx1e0LiUyXSry$$unAzn(zha%t_~mMqloqUkARPfFTWW1mvnC(g-Ah$n;M3dKcKs z+V5`rZYR6zZ4c#=RT1FX&E5ce-=7~a? z;#gD(2Uqs(CPV%(=f&^AA<5Md`A{J5+s8=q-hVt;sd;Q;W4CLUWLKH$4ms;Pz&)xl zM!1Ein~yZBzcKigo&MeYzgv(;Uq7ri6P__t zusWknE(-~r6eTD@gO+@DH3*}NjwB2t2*Rdu)Ew50-gfIP*D=Opup)NvRZ{2%y-HQg zb-X$olTX3?L;OS5<&I_C&#@-&)Y*FZe_NkOqKwSLQQK%{(b^VB!nqc@pJM`r6BK@kD@&|5n{OdM-ygk_ zwts!0kve-YZ05kcoRSB`J?}v-F$Rn;<_`7z)NdGg7)kwD3f1aNn{;KRx_5ss%n=?j zSpABgBfMaqjCwe1<_>R2bWKPzGJh9to=PLc#^fdXjJK-RjOL)rS_)Q)%g`4Kcgu$a zB!qvEv)7x$d2HVoUbPPTn6;nY%cu0*5s$tEW;hI8cF{?!NjeTFN_D#1N<%f39ewbK zOSjKQJAy)`=XR9oE-{Pp-Kxy_89<|#-Vg?<)qvlz3)pQ5%aICJn(ff= z6Le`3rl(g)vro|4d`Xp>yAB{IKUSo=1MXM1X2XW_IP#uVmg)?ldDg(y12;jE==^jO zL~yCdt#jbm&AX!%NZM$;P7D{8aq8DLbSxV~1youoY+lzE;4eh4H1>8Q5YjFj3xVCg zQR04GOn@oK7=$|hdsDW8X7+{}hv##2IDH@SmMjcU$67&8+G9_U5XT_m&BeCZWo|m(ffqp zh{?V{fY$q4rWbwQTN{Q&g-3{W?SpbZJ#I+pWocK^%eVzkef&Yc#$S5---&8@DiRFR zsDlwC5JxNpxD+;{j=O>tHH>1ud53iMp?)ZKLYm($dB>L_i&g*bKjSfh^DkBZ^o8kv zM~O*6-=zzsJJ#u$F$p5UjaW*~_Z6TWtVqhyhhIkXW*yO1 z$=e;@{yqO2z#Xif%h^^2qs^S~e7(x5vWHZokti;8tR|A~l#6rt77f+>@J4=yjjvn2 zht0AZJHxpZnF@S1+y8r(-H@dkF_>soF7oQ9%VkvMT~Rc=z!>P&ND{LW;R7YYS(Rjr zf7zn6e;gfLx9INncQ5#7iVt^AKptCh^XWT>l-Gc}Ffe?DVnXwpHox<0WLX2%Zw6NG z;Y$=&*sLr6@TCQuD=^@}EpZ83(ChPN`FRfQEeKscWwN~z*ZJv5G-qVgPHUN_ zD5zth#5)dDP%}n1reM^afvUUo%RVL*ZbE6yCWaVvh`Pt@^v%3|1 z0a;S=7+dpzwyi-Z`pN^cO*Mqq`{RwFBnwP&N0W60mjX>xg+$ArnmIMhv?OSAVHDRl~EPy+kJPu%Q~m=*}>^y z6yX$XriF!PvhL4yTJRfXL=x|vT*NY{T@1fMH-WHS#$sLB?i}(5$7w61_6`OFDq?;4 z=4sHZt2HFmMN){f*OXa6hb2o;TKrMcuMX+$wII=YV_ZeepV2U#~6>Q6W5=4Q09Tu5Om* zw*bo5g3yap76{T#L#(ZU+7MQtKn#*+d$X2S*u}do_^8yR*1azsJru>lathkD`1&!$ zLOwXWwXjC@u$WTv0yb7V@~KQs|I0@CO@BI!qh>5{11cGA2{j%{aiHHKaM8VEO3qo**GSJ~}*!N%J zzd0w0w<Y>OfSGu0;P_^GQYTmW)nVtfN(6-RcDRFB&1FXZM!I zVe?0l-MhcsF|<1TfT!3Xf#TrIveBH#JPm~T>Tt9v7VkVJ`7~isMfKaX7m$Aw7%oZj zjH-`X;#;Q!Rwn&(Jm>PMRn6J?+(3C2WvV4q7Glu?vS%!5!aAFn?4fCw_euQB!Ql(Fu4wQcQMqr^VO ztIl1_2^ucaTKX#pP7nBCELdaB(_#+U#m-`rXPN&DO2RvleB>d^+=yDjKWF*pl!T4@ZWL^l0cp0OtfiMl~td!CMgXi#R zr4ho026UEQ3W7RiN|mB^i6d3LerAQ=!xKJ_&}W0x&QY>KMIV&UEmWB#DJcL(JBKmz z$L$GgXR$N4Y6xGOYAv~1cK$S2)um9B^F3MQiRKwwn&^d9ef9##SHlcfGvwpdmlibC zq_d0w2Kk1~bkL%E=`nh(=KQmP-u06_ZNG~3nnXK#j3a1OVvgt4SST=&m6pBq;nk)| zGE&B^Ul0LHuRZA_ExNCYCw`|9O~K;=shDrO9nT#bTe%?v8bcM#-6N!eC=qLXgAsmM zzT+Caok=3#)9Wr%&c?L!PG0_jb*{nF-xP*1!FUi!)dI%j$T1v!A{qbP`it z74pu=6h{ZWz_t2HvJ({J@a>LZXx8`HGDBx0n_cFc^T9?_BDOG-6lxBf@K!_C&aUU7 zH;fW|HU<3IvqGUfQe-{dRc({muzJH z!u3feG#O|zl1_y~O`H1`v5ij20@`t#SZyC^inU7ubbBKs%y(&%;qGeIy_40^U11uxR@&E$~#bAPm8xX~FU?$Wn4GGraopPelY$rK{VFXHoL zAtU(`C`}(xHG2rgQ8s64A86KB;`!a`WX)8ex3?fUM+q2%x!?<9W!Or@2jB*Y$$EL{ zu%ckX2q?c%$Q^WM*AYAR2v#FUCYs`#S0QQxURRk5=z)#(=$Gjej7yM7qvywLP!p)% zXg)ZovrJ2^X=gZCGOm}^TK95vF-eCG9;zp%q-R6PbmZh7C%UCfKsV0$eSL5DPKGu% zhl2lTWF#Vqiron!o;qvh{to&h;UO+@j5Gb(AU!NC6A5kyj2|t~T@&qLK;<~BZ%X5Dr$3th=>z|A77D8GYb_isbS)TTXWh1G~ z7MUU%u6EMX-IGtvE7E}iWC7LdJMWY51ybgRsUIA(+;)*g3&2^ym-32R=F2MrA583w zC(GpBO_-K;l{AS`sen~vWj9NZ5qIUtbA1?|>DKjuQecSzXIKH&Dhbq|9=l{Q8IWLqq1J5jEN%1cKV(ZEEcL)dk4gb&4lh zQ5R0xyXEtk3Bz-ds36D;hTpmD6-mTC4dQ*N<%}3{f|p*zw(=1JEiBri;Atco=Ngv-&)TcC>?i}h+{d~QkmwSWnxd^RaSJJY({C zS^aJ2!rw=0iU#dVk?}!ck@2pEdbeWzuY=MWPM+*QHjUuduMw^4uwShP1NALNv?^P= zs!tY9fIHdcEl&2Oo4;wzd4p{HP8`PH^Xd`^6RvqPV1`962pe|OtZ>K+a<4{iuD9S% zcu_m>4H2j3{WHW6MrIai2(1fFODu0-s4_J=b2N~IVk*_&*|&Z|}=V*YE` zN{jy)HuKTLutM4!Nh4f}Fn)^KGp8#ba3i$p%t@(Q`I#A%05>G*XE`{T;<@dXsuAQ< zQlU_yP~f4@w2&4;Xs^mQi2_e7p~$tGUc6HWm}??Fk4(Be0mtZ>+B&~vYTnR3&7Z`u zlF7M5d=Jfkk17KWr+hS_NpJkFRZ~$%B+g=Hm>xgOWdc^QtJ!aqbd$)nXop)d)t*RY zhG1igjH}xo@~@_dt7&4dXk(${06}Bykl$P*roy>OkeH%kx=u^3@JT0+Q>U5fEw+;c z*#yR?*h*d6u83Zr2J*PCJ8FY1iDF@3EAsccyPvCMVomZ%3k}-n_1G1V9XdA_4?gzq zrlmT>%_V6>n{Qe&jgB|_7D}NTf7nJ|egY>bR8s8ci%1MuIQ$#(u$2pc;(nh={5BcWaHT?ZwfB+w4Nf_11c08yF^<-0oj*ffB4hy$SzZb-m& z^I?ahac}4idyeR6&3e`h+EaM2i$ph}UT~I~^X_8Z)@+9XN<7mp_}(xgI{S)|NAUFQ zsbE|HfFLmv<#c>Fa^f73sTC1;XKly?Zhq0CyiX8PHp=L<6&qqKHqOo)wUqyQ)?B!B zh~IFjLNXpUFQ7ZRM83)HDXCLa>{M;BhkQg;?*=$h^RGn!--6|kJx9u?p|0aFVHZps z<7EuP^+!vU%$FNaijEmLuXP{P>p56GwoIrVT3VQbK^EkAW^A2nP@TPmcn zJdzWX`u7LZBpBaJ(Zo8T5syWCET=~PolV&i&2rn9A?Y;5UmhuxBxs-mpAEyWaeNdbRg!46*xz3_otdYsfbwLuzG<8`*`maYJW#m4TsCUwGWAZu zTp;e{RgjnH6nY^IyiF8}US{rhIYKn5lUN{f(vE7z=XaTF`IHU?dK3#R?E7Z3Dn^(_ zu^-;9X^$OF)~6}S`ae~iC{edPi9}TI`)+%P*m2vDn)g%>^+#v}L`5V6x3}&7d@~%K zMB79vI9@KRw7+umPm)9?R7Np8on;bPq}7wT;4PY0t5jP*;^PDEFO>=kTcht=p1~eu za6FAAAs~Z$!3UO#CQ+jd^8y;u$iwie6$(BkjNZ9p3O)rDt1^4O%Bsq8+A*2R9Jar- zCIj>?2l9=HZXuS>vb1-cQQvhm}oD&C;J574ax*68vCa4U%9~0_@e=u zR-j_>`SCo^v?YNz8lb6JGZsKot>VE`LBdZnv4XT_2L=>oOE4n53fVur3J2Y##wwkq z;$%k#c=Tn;mYrGKm4uLzVPHJ;@N%ANr8#1N25XEiG8Ci6LJD)W{XHv8JpNdZ=esPr zvF5tAmwX}}1Bk>sX(JtQqJ<7Fqs#vgiA*$d28?}t(#;qbZSY)=u*#JX@4O7Eh!?kl z#Z?4;Pmw|*6BiLm3zZDKU;Gu|akD#;vVPWAtiLPAt8{-fz<&r+_Q^fYzgf}MCaf|D zmWl2WtlhFA=Jx_@t}gvyn<7Iqa^gd}y4&iRvw7!3HJRTPVXdH>OT4M&eVXHv2Tg-# zuUZ6Fq4bt(sn~9&?NZ(Cay1m5NFqj`?^->sCi2NLYh~WuB6QR^@bDc*&S*8`jObVh$MU}d6&-6i zcA%SMyb(=8jHv@#ARuLdQ1mc~g1#|fE815Jz84f#k%^j{|D)a5TI%|UB%Q4uWluOp zqP5X5i%7rpynXQ}SFkJZ*>s|vY0knU5XCXR5VIka=dzTi^uA<~=Czlv@l&UCedO+v z!G6>|I%&F1K3@%DeFM;|Sr5&aS+mcZIPim}D>(c+kUzb#uEex{3K5Z)^sjJP0vYl8 zO%-@k4OdT-^G@{;*(*iYW&QljrP`ghUbp`av{bBd*@BvmfirsfBN7BcV7Rr!a+@hG zDpUlBI$juHFY87v>&p8m2Jku@yK;tNTP~q?;_M|H$QwYyAAQaJ+Q>Ro9GQ?g$`r*~ z1PF=Om&OqtPco!=LP5g|IIRaY@nf;mmH9>ATGi-LqB+_*BF#RN7OZni$_tF57p&_) zgx3{p0U@^}rjqS$P2#bK=XI1Pvd~4W4Jo95tsQknp|V6l6u{nIeu?s3{QbFc!(P{bcG}}i z$<2E;Y2SO8rw7?4S`Q7X#^6EFxuv%wi^+^YD(lzA_X|TeL|xN&$JK#yJzQmxeKov$ z!hQ`R@hfhj>}s)KZ#u4th#iQYJFmsgL`pGhn0o`K{ksc*rowSQvO){)5(UgNUxDP?*9zpN^oT>MCjortFN%liTU(&;!F*W2%A5PEUnmgsh8Z+h1!L~m<%QpCTUB;+d`WN#97 zSsl?=b98voWN`&4#l2EO_g$vrdrW+Mm>~TAZ}``fXuhC1uB1Ejm?vL!wxCh=m!!;A zUPWPLUEbH0!B_gyObdU5Gk2cwf?oxp>hO%4+@IVPxKxtv z{|mc~T1N*Ac11zyNX7uZqoR?a{0GhVpIEaGXukhvGycD^egFFbZvTK|eSoC>PYVEW z^!@=*``;b^34Hp1*7~281z^nmH+JiP_x>m1=L0zEf0`ruKYIUfsMP=N{!iG=2UyVm zG#CK7`~Lz7{qHCI6NvEvp7TG=0f1(Fc*6gHb^dqPe*z6YAT|D{WnllS>px)y|GV=) zf%qP<2>;VgasJi$|AS2U-_Q9cQ#`=-{ihK<`k$Bhzd-ynRWY$1{u3AYkp`A&81nG# Fe*y6V9>f3u literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-28-32 site Document Inventory Report - Site Level All Sites by Country.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_05-28-32 site Document Inventory Report - Site Level All Sites by Country.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..708de0b1cb3e908a4a864dcabb83e4e21489f56d GIT binary patch literal 136817 zcmafa1yo#3vn>w6J-9<~27^?(=S~-%J5f0d(c#kA%-l@l z)}+CqL0e1|%e!~LyN~`4y~R#z@K;8?BQJHsWIZ`Tes*i5A+y2Ra|rHrFyv8LBSfLWM|lm$U0$G_5~(0c zvZpO2a3;pWP~ohe*}uZHyKBzp4V6$@(b3(H?faaP71 zF;rIX^FuBrIe3IPM%p$$NC*gG7zhZZ|EKMd0Nd+3np!)tFuz?Z;=5&`S_smI#W zZD27hmm?6`!{*@e5|-Ag(?3Z|u649`M>JTAbnk#ZZoIM%y9$NKw5u>@<@vkJ2IN{S zJ^Uhc=Mk(t6UOO2u-}%3Q&2VNToIfNRMr^TQ~@VpMEHwPt$oow5r&lO4Kq4*&VZI> za;m~w#_*a+Z)l%?_y9fe{b&<;_uJ=hyhdj-$YTjFoBSPYG4lNj19a1NqRq!`1@H}a z{<(}M`k(ytT$j9Cxf>L}AJY_GZ?Lf=Nl4iySwWdz+-z$^+Tunsnm?w`+(=FP!w@6- zfLQ{smq>qog?h7&EgOQ|9 z|5g_yT|A=VYgZ9N#K7Vk%O#?1bTo`M_p^R~O|xiPSo?|GqnEl6zlWVCBE>+TBy4Mn zU8*Z8PLinX9#*#E5l_P$A&Y+5dAn z82^1a#&(XTZ|kv%)s^c7VF$m;4t-6p58@SDAs-P|BGPnle;;rB*;-IKckQL!G81R6 zmFnDyL}A^^OO^5wVjn*5OGW`UoqH&jfcJT)WMK=(R6 z5;O89_}XGJu)={fz%ME5~-7 za=4o1##$3XJ{c$gikN?RCi1BoGUM_Um2p^>lIZN5BxNr_WYYJ& zU;0tGSq~%{85q0TzP2X*e7Cu&!_uv3*iw(C{!?v4GA`pr_0wemMdxqxt;MCL-}JaM z(91%r6RVFpaY7ti*>6S^rp|MK13ab%`2Bwy5gRa~yETiGg`uOViHftMrLDQsn;iur zMNoUl&>_w{0#4SLJwXGBw+7ot*N}mgLHUe{usc_KyAEs#`1^LNb0Oh@eQ*lj;3Q6F zFx@%+cnU^qq!#tkDksTBmHF$jqk852&HnqX->-^e1HIoPTs=53tkt6k)8j%}-rN;)0N)wL}>v@>g8MjW56 zo+Uh!e4Zrew5t{^0!gjx3dF@}GR3n6cXr9fZ)DOCDWDmt3r zy3o=4RWX4G@R3;lEj3=+h%^>gmhS{^vw3}4oyD}$`9sW)_eIm8&Y5^}r%{1J*!Wa= z;CQ-_7rYspUz=u@1V=lLqaSx)wq8)q1-VwNdb1&pjE_2>3|nVmFU^81?mx3MjwNpO zaD$4PouyY;Pmf=F|xD!@&@v# zxKV{(5W2*jcM!g*T;>$wG_6dKs@f5pzxFTnS@#*u8_L?X!Tp_jn33qDuN-a@t2Gfz zS`4mK`vn}-CVAL+-e)4^uj$INSO+r+ROOcLLKE}!pBxK zqgli%e(1XD7OixjOl#3kI(r@VB@wPNaP>LFFkNziz41mQ;hjb(We|DrO~nbns?hK{ z5f&b8dSL=4fohhYhJ^k@qVr|vfF4`FZ?;#2JbE-Y1or8@I&DhjU z1$fY{b17i6_dQcI#c{!XUrzp(b%4|B*gWgCq;ZDESvPTw)eEhotT@Paiq#QCE))a! z&{Y>9?uO;!_lCXLG9!_EdMjUwxl_=N)%D+85hv#LmIN^E&i@)j2>xZ-e`VhPZs31q z;W+s(y&z=a*YN4D4l~_&dA2OZQ(uI9{Hl|<*=wQ-evWolwe~Iu!}DEJMgH+ZtJm?3 z`o;_XEeHoKul6n1An#bre6#x1-4nJypnD4)8b3AEuwC2MQkYKv*Ik&JAq?lH#7z2v zwLsL6+9&Lh!YB`My2;hUz}rybLkZo^1Mg8k9u=Dm|27AdVu9b$eGpz_yRPwa1RAh9 z>MFUf7RD>L$?JK~M07*Mty$e78!=j|eM9V1I}9BqzK7YqH~XnECttTH-gJIAELueTC zRaF|QnM;^#DLy>Bp=fDN?@5gLqj$OB&0@ z>*1Z9o)GVd&ui!Flkf9I%KYQbZ!xen<-=V{y3q4WudCP9BpQh|vk>-T-MER13gcdu zTiMNxH3Qe;IjObnLjOrAVv8PsjzflEQ`UG&=j#<|)$hgrT7H9i=Jn^pyTRQ%w3nyB zBbFC_7M~^BSCXW`udUi&8M!7ZU#`78JXe-hu8hDswn)wGx*NEr*U(H)U>ACp#c8z* zTi4cK9oo;ADy+V*h748lqoau;DP{eIkFV1=ZEg1(Qj2w+8n1sxpRE3FDRwGuU;5~* z+cuOP`&PWFcy+OW>%(&ObEU(jYG}fFB&g+8x3T-vY0t2eIKd?7NkW$oj;#8)`zt@GGMXb- zUmmuOF4Zw7IXwkinP2V=7(_;i(U@O#LS7LqO|sOC#cY7uDcVtm~5 zMrJ)eVg6=3_ZRM8`z$TN^s7^AuU1wF{t!sLN{y6$v%2%|ZNhNZx3@=iZNV#ht~M>- zS>paQU!=VnIZUlp!^iWUAq1{tAXLO!1l5;-)}J4WIy?Bk-dvwNT$8>o`mR7>9x(_Lv-|P2&u)Xm^RH&s=B#DK0Abu26eXT-g z{}EWt^?}7iPdr-T#ntn=F=OPF+JVSis>sx{PLF9nW%}XB^{bY^nbz~4{knox!FB6h z<6@FMecK3mp8DjvhnCQni|ePY;S2p2d+g_(58ub1e+X`pzT9uFWxw7ZPC}F1$Dj$8 ztZHv)HSFVmO(TudoI02v-H9O8_-tjQiT8tuaJp{E@wS6jaYDQS7h=Ev_TZMr%9rNv z!4-CJ>3Lw7tIalr(e|ppu&+j^zu{?S)REBMj9~^O? z*+1*2TO5Vmxu-24$OI{=Q)jV&VSPzSBUOn6Jg3JCqzSo}= z<{dYrSodIb>k1aHod_qH*yB#^Y-bugK${+(t@Di_88;pJOPZTzPCZy9FBJIx4_Lv6 ziCIXzDm;CqG2)>>+;y3=hS$4IoDF;_=IlL2NI)SZJ}J>FL-j(gj4;yo0`d&G*gYKC zPk&}IyWGg?^bv8)8r3ad|9M4lw@@(3nPT}J`$eQtG6MRc@_&CLDGD_a3~oaPKjZM zg`3N7r2CdnSFl75ZL2<-Ow@a86AS%Sj^au0RrCf)KRJcm{Yqo|dL|u+o}iPDKOWfj zIkV*3p^6mFR3>liC`=(L)r{v6ZOF~A(NEUGyFVg5lSF?myv)APskMc5Ky~WU+hSxHvs|bz06%!SBiTIT<@sa}l%MfNw1O-Zc1w zeH-lgXNX^yg2<*FVuc`Z0D0=v+wH_zwbsh+51`u^YB|H%PXFr$WG)E z7ovd*O>8NFKhl`uAtYPAAOfpX@Hsoo_oyG45aS5(uo_NC{2eW*+ ziej&Yp^Q|$7++oSau*Hw#Irpy1po!E0R_YX1+WAF1s`Pt7*;LQ@uPc^9bz zfARFrjzIk0@Sl*;q?%aU_ER$o|KerY#}@_c*Q>Pf%QNAVG|T#J#SMXwV~};sgQXOf z{kIIMNQ2+IA+z+D%Tqo7#@BOa0~Xu;2bc>PnCm03SfhJVyT&^C>%Qc5c!Kb7qPpz$ zFv;^jd+7(n(e`<6laM?(UP)<*=KS((J$%>9jEBU)EbG85*U^#M=ALh}tOK)nPM#eI zAibu`UfN}?e^m4g*CCQ3~~5${c>eZu2?>{8MBs{<_}lU^ZUU^M(|wr z@=p{9Lx5;Y@;Xb*DeY9v3UipCL?nKaG3;$M2f#eyF_HS_xo`6v0Q2Ndo`(ve=@Xhm zZnXXmA@@XS5W8;vFx`8BD{cpAAa@N)6qxSirpe8gjqYUhSm#Y5wP2@rL@x45B2eH% zM%#eI>g~m_MLy@DDSFT=pi$h`QFzz+3;fCoikY@4>sT(NjNOew*Fw`@nPsJlUXIFOl~4 z*rrZ{V2ufcy5nYrZyay&#b3ox=2)l{FURgpee244Ux!=>ziQcst{`vnu@|BES)%5& z$zEEnXF{jpd1H1lP^RK0tHdJZls2?#veyA+t6^MS?m04n45^`lCZF=RxlI$AJ0xd}!WuNc*ryYJ*4?OqUZmT?nyj^n(uK9SS>am((FE zELqW4DS;#Gu1FOKVM{kTtfpQRGN z;BSVnQ9J$;zpK~uNwhq%ZqH<~i()*pnfNKf{duDC>Uq`1-=ITCQdDZn>^%H*|6tFm zJ(KCoKoQX+qSWPmc*NC%=gq}ce_h0fAXbf^raruQYpcP%+b+@}~3i9Z- zb1tf)zRh#_%M1k=Q!P;s=GQ~Vj_%FRK^7Ss8(R@UaNFLb5mj+lakH*l-Wt7?(EAJx zIz0g|ZER_d+h>(VQdJSh=|%!8>m$yO-#_)pb#Lu28TqJzC%<7mRM{=wER#`teUklh zlDBOmv(UCEj=t%)wgkyJqBSH2>RKALXlM(!YJYmVl}x4%dbdv=;Kaod* zW{%RIK5>EJm@lC8ezvG8hBli7<9n-q+lx|pmBwOFTh;W{4OQ+ntzx9pknp!Qt-s_r z@$BQHqI0b+P6*yCkxmFi+uR}UsH>LHQ(9CMlQfp}nDKk~GPP$^J;*^~__^{FLrJ0u z2$)uUVeAYSb626fMfGyhC)ozE;4{H)vXou6?k*)gtjO(kYQwd79TQf$3?cZ_?mH@* zhmJ|45Hk1^1yDzpK1`QSfJj?s7YwviaE1Z8SOJvFQlDzGfRG1qB%mIY`u&pB1OcI@JC8GBSZ zUo1)V2|T}j%86m;#^{4pYjk1VsJ;*j7wNua%N-}~3Yq4tKqTx`yZmPVKv9i&FV-E^#)L9EeSnnB}48ygIfK>WC$vNeR63fpOa>LD9c0Y>j#24Ufv zC)NlM`MP-$ppmMVlm6~nThOnboGiUdY3%$3*WL2>eI#uCYwf$$+1D>Q7g|>y3RgNH z%6YEV7L=}4n;xLr+2?sNww9Hb+~S`6z-n^>wOpGuw~G~xvf*j8i1-tRuR-?Yh=)$=oSNl~Ka4Lco$l5Ud7{Fk{+RL;VeUqPaMLZN(kJhEup zA&{A&8>7U?SVC%{Lgg3mGmC3fZRoF)Ui|y*d3G(qD9Nzo+Hw?V;r<6IqXzH%Gch*@h;@&z#)v zY4#YtgB`Z&^d(X!=K8EXS!nQJu;02);D|qVfcj~2`eCnycI5kBciGaVm5adZ&zDcH zY7PSWdN{|KQbrjFa0DgeA@|}+aR@tHk2jTP;!}Aj_R^#Fu@}4rg#%seI0=y;8gpU2 zm%|D8!i6q&4s0lrc7F^-J3E&5t_sI@m*zbB6F#BQc6&JqbdgVsq!ImpA5MQhrQDn> zK8VIwJ;CY^6MrBr?Oe{}CaI7^*$O#usOiXJ5_&~{c5d|+`aJ5(^I0#+&;0TOMPt^O zt(hZSdgVetz2{vBDHWK}ESt-;t8V-JYIGj$a`9(uXCY~>2E#j@Gw#l~ zhZVHxa0o6N74KqRN2e9fm7qcbfHw^a)qch+evDOV<5DF9`^(Ufwdy@oswZK z(>`G?Zp^(4wA z38^2PcKV(vAi6d*7xi0DNR`yMy?Z`Nbxp~5xvr8cw559v1*hU`WYPWzaRpauOI$Ia z)GtW%BgsPB-4RKz+?!y}soUEH!f||lWnZnBIeqo^nyW=jmv3c+B`xH0QJ>a^lA>dEDZ5ara4vsaAVgVKv`hT^=>*4;P48Q=o^u4J!sTkz^tLVkSV?Ee!p^(>2T6T?cnd{Q6t`f)p*4PEWE@@QA$NsaMDU4RAF=YAda+D zZpyzScBw)X>T#+-rXt1`?4vw%8q3G+Lf~_;@1r)yiFnsx<=!o-SJTcxYru8C3iHh+PQEC27>6 zDm~&(pR00b^OT=+6Rdexmui(y8>vGf%7R!o4|q2r{=pR#Y$m@8=#O=EpCLQ+C7&Tt z9p*?yk=HH1Z5IlGK0iY?>q-0ii3wc8?`E9+c!Ai6i?@_|Hk>0ZjRN}uBY4k|o^eXP z2@>l_ZbHDmO)K}e*YMmp&eNocKanhd^{*?B&`pXRp^4KhXP>6fp2V!olWw|nS>M2$ zunH4CLk9Z+x6erU`o&pahwS&Wq`O_(d54lz*e(KobvWPlA}Qm6ePql!f(jkAAo+P{ zFME!W4`5Wa-~P@7N)P#@%f(*s6cqkMz>5FGHX)ORI9oJP*pGmf%OV+?L0$|ZLxQ>0 zz>9Ti2|fMdu7$FJMR>8YH47623CY!CPUxq#q#o zIp;v#A0yDGRTSHE6K}=NKyt~#D}2%ZHsfC#$br%(3>t@(kr6)hBbMf!vTvP%tQD>( zaE8d!lz|7qP!V^ZC-ahJ37e&sOaKhomp1cUrxb?`JS$ zZ;JkYc{jwfCdLHWK}p>lt=&^htxA}e46=InP)xmQ6Zs~frc|(W^UqTWcQjn6_$XjQi zxs7zExV+Eh;?me-;~(i&B8>!#<5{%P%R-Ldh9j^aha;SQ1;?UGVUYI~XDW*oVXKOR z>Sb9Y5S~95ko_Q`fO1s0Qxf+(mzJr?3k8KE%n#5~L{f+fh9kHU{v#NPB9#aPiv!59 zk$@>u_sR*)abCzXBup)EpcglrmRxE1rI@>uegi2EgVM-A(WP5uEdhhqFDvdxPKE*S zatsUuDz3jh$7okK^U+=+g75J4zaY3x_7{^Qv+EEhhz?w`b5?AuoE=#qoIT$Hnxc^R z}gW! zDgIE*nwJGS0xbMt)#mB9XTYiGyN$Xg&}!+squ?d@tvN)3IkLowNp@@BHFgZDj~w8; zDa5Q*X0%)pXZuzHnAOC2^>2RQa&`nfs2Q?N>Gvp5lC{%hSs7W`?csWzKE#>28;s$t z!SW*spi)$5l&RlWF!3r1QR5V8y1Mh-?U3x4+r_+rc!erf7AWHhRM{r@7>*r7wT$Pb zsKE=d?3^u@nh2tn}>;hRK zPNek|qdf&bc4<6^`I~Nab}nqtZNtCPLMUYFAYSUw4PE`YiAFeN+=Qne;#jp6$%3aF zGQ=(mAPV+FbmX2XAPb2jT4c}YT+y0|O;XIY=y! ziMy|c7md}d2qj#_C2K`}e`rs1o`>iNoJqOw98>CauaMZrtG;jSqGuC1|Dc%({N>Zg z`X;C(axR}Z*Kk2CQb3*Oi8wEHdN>z3&SW=dJgD{m&bWvRUp&FFs^GG|iZ^*gBvMl{ zfq{_2D@8$E>I5@f!7G&gs#`I!XKcar>NeS@nuf-qn*Nw>T4K01Pu0SQt{GG{zoe}R(kHR~$uFCht<8f0jKY3gg?ut02&cugHjco)Me$T@x zr^oEM7ZGigbPeYI<)UvH4<0e4tGIjovD0l#gwsp3w^MMx9?XbC#`J|M-5YX+;I@% z7w);dYRQR15}XBK``@`TmJjx{EaM>^*Hljo_B`4ezX`OP18b^ZmXW@2FFDYamndt_ z{-Ks7`NP2xhNhx<+_ct{21i#8Yl5{uI zVXau2uPEATH7PFwOy$Yj7Ympw6Szx#epVF}Z<7C6;o~gtsYh667 z$+Pe}Ma0dN)a}uxH=61igd5ddUOGiz8T;o`9WrmLen^upTD}gHKGmGBxV5qK#Ur+a zqJ~lMQu!Y@CHBj76)e3Ih&;&Iag_+63OxYwLKrHL7kGiZkP97YLdn~vQ`Jy5Ixnj3 zTX*xM>r{VWSs+#%(_74m%q~kPLta!n#M#kq=jt*KcYljF569gHwn1Q3FG7*sKmAIS zVg+sd*1iLpwML#Eq*%H(!p!fL2{)C{enJ8kF6QiV%io;`+u+RyTN%GOKRM}qaBI|? z0B&y}#tN8b)yCV)3OWO^r5HsAOz3{k%e)6U59dSnQ>6E_6oo%@8Bn`_oVNg)!c&8RB{`oba9^D#*i1K`BiKZj zsvz%^2CS{14c$0T5IY)F563+x_C*)~rWMK`Vmd9CIReRwAIo?@gTY^hq$+?s^(GK$ zz5oWaLUAM9$Xb9X3Sib2E44te1T@@j@f9bM{sN?1Z7~AzFF+)%hXW!h0T4+mAc06q zV5PN1@9E3eNsm;0ux7jtQtTTei(2~K#Z1?_VAGOY=ojvENeO?Y`hP0y`hnAuI zal^7uP&`kPb?TRTU?}@i88}}?BhSyS6rATLM#K@0PU*dz!)=LOQX%QD!<-N9`awbf z`o+UUh!sksX>E!|t4u&wa>~p? z%b)?gz;h@-8Vz6t*8nS+fd*KCK$o<7nfyqN+mp;o`_hWUMeD)v)d#6P{fMk~?&z0` z?~KzX!}ZO{1xan0dmc~Zj~+g1e)upDLa zPzQb+C0=EilFz)mC7V3*t+L`~$`qkL@}M1?V=*B^JZUlBxDGWGz;*VcW&4W70j`6| zN{{hSEDms;HvzzPR4F8>w{3S;R46u8rzFCLaHuKJ^al$dlMrx8CBvp1fKf@r!vNGI z0{K^&0zeHll;q_L0)>W9fD%a**aOd^kNy&BrHUUU@8M^c1oi+BkQ9Qx1H>_II<)4B zOFsYs`~U(*px+SS@rHn!yh{*08h`-)$PqC?dcdCl2mk~mg@8TY5Rmvrhm}a;?-e{^ zUrFktjb#`En5Dia9wQJLgdw0b=JB(04XAhsD_JMP!$2vK#7e{OL5f_ek&Gykr-l3w z#7j5>&AC_f!(t-EocRSd9ioazp4N*T9-y)_xP)+1vJP{f9-zug zOS$DV7xEdTARVAeTllU)@)i9p;v;j*H~9s2!*dC-+96yZmMk$$B$!JDTj3Q1dnXc{ zadtqLke9bqQ_}vjMEGF}oxtt4`-OQM0^A4b=x4-WVm`L`csPQpQYhiO2isAcuIq7RYvyV?zLJg`JlkA`eQ*CK9o$7-Dy$463^Gfb`gVpVzm1 z$+tJ{*^74ePUAOU|NZ6-R|Zq_+{UMpPOZ(9O#I1WgeFgNp0QC6;>ORub!0bOkw$91 zz358MC{itR8=!dk=dVvsH;P4*(d!v=Nz-ccs~4kRJa0Vk7%u#SEmdr>;zx|uG{b=2 zXcD)#Z)6fT(Y9t-2wwRcc?tWdr?y?&QRp!OeE3mqn{l4OVb}48ED`EWabFxj2N^EJ zIub$v9$s!NA*jAPKcE>GgX8hiuD-j&_i&Nf=D1+|^|iet;q_Lpx0fz00y&nJO&GJG zLw1zKT}Bw6jA!hNJ8>feG?j=61ONdz00Q^`1mYkKs0i_eaUaSooao9j4jdbr+H_T= zB3|}|UXN{RmL$23m-bwJw8W3MJv-Xy7o-wua19g53pWT zG*;Uplo4CviPZAmcXILkxH1{Q$F{}2_#fxC0J`DA4bY8{H@dN~72+*|29(#vgPz{y zgJn^moBJmBSIrm(_-E}Shtc=fd=@(^j~6!Wjys)u%CC*?B8sl`H_tAeciYd&g&sJY zjaqHKem9SCfs+#Y(l}qqQS>Vu_7|W1P{~m9SpZ)FB)Kd=li(2w8S)SbXcBY)O@ad? z#fT-f8lTp*imKel-(~Rue$+w!aEF<;U11J!FJ>AV%6{k3U}Yc>QU{@nxd4Gs2C<|f z9|(k0bU+}C|EIbG?va)$%gYDJA_CPNU1Yqdpe!N~2;T%iAfyfgD+7U0n;MpT%P9^! zkb*9>dS06bGp;5ln~^`g0_}2G6uyyxE|e@DD$NaNrmiA^+kGBZN$oC;8BMuhK)w85`!73DThn5w!V#z z#tS$*4d7-LpvHKp0)Ck>tG8?qaJXrJ$dN}|iG`920NLIOx}?KYnmWNW&}}|=te8{j z|Hk_AH~xRDPXb_lJI%!?&AFVrhDh}~e=>Hr=HMK2Cf_@+RxZcFg9(9v`V;8O%)tQx z)dmQtb8uQX!@dbPQH&9}S4IN*Yqq&NWs3ctD&j@iyZz_<*mSz`=uJ+T*bcgPcyj6ffOPZe!OFj*NA*+8dB>#q? zs=PE%={q2q(nMN`3YNYDF!Uw>Ff<gWsu~y|`%zuMYEUvrv2c{ukH0?@i zE#|-<5#Dz2V$8Fr>+Lu?_IxvaF!cPWm$tK$INbPZ$7E z+C5xF)K9l%jL1xkWbd*gs)ex){R2cz<>VxN1o7SwX#|`009YL zUey5e>VX277h{(+XHUL;p{(2m&hzh(?tGT{3zN#*wr9bg#~^Fh=O;+)*x&kb+`L z!a#6^fq4tAkXz_IkU(&~;dEaKE_M=ZPYoPgPV=c7>WQpyKtf~1!>m3@>8p7Q;#JbNVKgBgUh zhy=40WEd(@0nI}pzMNym|pK~-|G=2}yrEOH6RA|;=U z_0$US!(;|58`%m9N7xl^MzEW8irIq11n5)u4De$iLN02HBO&LZva?n$@W6yy>Ov2|^mS%$mo#YXLYN zOalQpsE~T;!FVxmIXt6KODiKjQI;a1Z=pirdkL@n&HO=}3QU;_P|@>B0F+*>2&m{~ zoXQnCV~(5|`OuVIec+RRb6ufcGcb_5l@8FDm7@@U=@s1DRDiY6x;{;GO`gxNfiwrs zX?&kAV3SK6VSJbVmrZi_6-o1Z%|ZX(Ekx4y;FXH8c(NpXK>P3A=t`z=QZ1@x02?uF zP>GY6)L40F{T(WGiBUh6R38vyV;OXZ)od)RRE&%=oqS5l2v6huz`dT-1 zg{wzJRkbF|CGofKCH0*iuo{N&kJGAJDlaPaasv7_^SV?b<)Y&0Ib;bq-$gnp811h! z3Nyvkms!D8g4tJXqvGL8zy{c51hBz=R@gu{Mbbac+A1;IjEgHf4`_Q&>qji{#=lE# zwvN+Ux$*W;D|gF^tMS3NIN+2(G#7s%Hhxw^qMm0OU&-X?l^?!Mf{~Xio zKvwB^Q~H4-@lqmi98yM9oZt@*5_JfjzBAyK6ak4WZ*B<%xFr(cmK|Nv?fNzB5$v|5 zR=+(i?kYajgr{c~88hm@5!BnbQ0z{+D{d*D9^o?oS!2Ux22^YU8kKLLZZdIDYf_?c zSNK_p)}z{FBF>_-`4I-`J%9^)5darB%zrZRkWy;w@&EI3sN3|W+EzSWkR0y9cI=0M zK<6#=??<>P@S6I1y{EX$TCqK_k~Q=?1_;IW{*=0i@9|39wj9MTSpYx#feiQ=8&%jW zt=DOlMT(vHZ0%hd_RAFE zwQefDtyEZTp6xfNp#aV_--WKE1`Rk92jEO7ZFczUiyWoSBgZqc$Y=vy%cAhX!)9o@r3YBN}xuJ>( zD#_YF(~=S&D_57J54*|Vk3LYD_&#Hslq(P>PGCams2*FWbW6v(FmcOEo5Mn8S>9kd z1}i-W2HsX>S39)`0dGH)QtUI7WDmq2w$gqd&=AWEH`n=Kz-TI($i~Mp@>1J(BgSqL zY)>Z`s_Y$GO_xEI$V&1@tX^lL6`ocQ!0-hm*X>UxLBQ*_p@aRx(EzWz_lqOaU*gwZ zt864aTVEQ2C&y~I1Q*BjYuY2TYp0h|D0qxv8Fz!vk8p|p*s$Re0XVh~#LIrev3+&D zw_!q`>X49D<0e^Qz_)kpn|_n%jNF?_F#*tTjZOP5HzP*wfdJ!wU(W2hAt%w9Vd2#f zQ3*6ZMq^<(_OsHXs@NYitpz~a_E~+l2M9SVJTfE>k$t{gHzef}Hj!O2TSEN9!e#rV zcAhNSyt!dH8yrFIX=_9vb(n+cu9-&Th~Ifs&4{0vA3bGXP6j9K+9H9&jkcINq4>+8 zI{w_fwiwp|r8$B+zJ0M&l0Q&wm$Gg0v8v-6C;i9e4j986A%*@Mof;fcTF)MpabS?n zB6rf&**td`dz?78E4NzQpek~ zZTAv18q@REeE$@D44%!jBP`_${ePRs>K8jzvJ+~c@Gb5+O(lCgJ_Xf4mAJVupx<}k zGoW+B6bp+Y|9Z>P!k4wsX7Q|XMeK^L?OJK6YnW6KH@K-obOF=|Kz$SdJdcTyMZZ^w zq#n`?xTY5wC^atU?RY5N`NGJ4TXlz1edPB6Hl>sjTpC>+HF}jg!=JZRii%4*F#Kc3 zwJaLlW=s(syQ~zzKq)GKfg``T09E26N>*Gv=%~5Ea079ZzLQnpaRn0cJuW^HGLXwa zqLJfoxeO$(j)NCai2q>?rz0(Pf&n$|_y%@nf~1rM*z-rIw>{Sf_Pm^B;PF2$9m$W| zO4Jh7G?yha;({nE1$-$U+VOFI*>Za!9&vy|a^Yn1yBOGI@wskT9#k_0`G4#v?CvOb zN&;hF+ij=s`EKa&%Od^Z?EY3#un1AJbq*A}x|AW`;a*82D4D`ovSz1gkC{7YtK;*S zi(aZW4uLpQCyl;+&h!1|K{b~*ghx2mC^67DYw*HH%QnzrRL;;b*kZ&;?USy7Gf^O3 zt#@8Bb1ZE64!xj(we7^WO?j&%5;tT_yu#R)<8F9xWOyIkqSn-;Tt=hqP+abmFg!pQKz`X?XNTP4R7z~s_VbJ z((FkWOVtW+(%B`PcFB(nns|L`_~+6&Xu_vicdBaHkQr=aKBh&%meoYFa`+;Npr2+` zM>5=iWXrXLI%7>JQX|{o#kC?yp&M`WYPMo$yK6!Bo`~1WiDWp#tb>tDee{SGz2h0Z zWU?>S6^&i>cvbsFa4!k(J-3ak%dG9)#ESILh2vktpHD=Y8~+>tPfboy(Hka>EOC#u zT`eggXzpVeLo&PrlZ+22Py>;#q=i_4Ty*pLy z!TzOjP+qE!hvWdZZO)ICp*;Tmj5Hw?z`a$t?+SaQ5ppu%Ea@}S(h&DO*oN_=62_W5 z^GizXvj}H?zQ_l~DaAP3SkteXx$4OWNy%K3#UB(0MAH{L3gjUY=)s~an5om+m`O~T zWil#AFn?J0%YL2d&7b47{ZN1_vOGpX%Sp!p1(`nwWKP*AvZeev^ToxWPvj;YPTpE1 zQfA1n4t)Bf-#eVq1vBiJ&5z62W;>R=J4S0$*f89$C28PSqal+3YGre!oq%jCs5G+I{B~^vz-kSo={ z!d4;M%Pd&A<@)iIOh65YP@h`e6xFC^sAq4_OFV0}JM;N1?epl!9R~7J})Nl2QIKj6imKlz;hMe_^N#rG2pgX(l@IX(hG2_2;oQAhn z*^jz3W1TY5{Du9-+E2tq{k^6=-DzJDOHFzV`RHhP3Ic<594TTZBGNnb*IPDSKW>qY z3%=>o3O)1!?+M=hia>l^sQb<7``?fZrPov3d&2oYhDp<@1d^ zj{R_F1##4_u3Kt*qTgiu3g6C03VHt8a>u2$5nVzkR#BW;O4!6{`>@BVOp@BcKVSuG zrpA2&0g=sIX5mLxRhiuQH|Xjm&BPZ???cGvYg06^eKhbA5K&5)oSk?6^iyf0kT9G**Y?Ew=fqsp z^Un+=u19RwBZo+}tSyy?=Py4#x)>L+?H&y%KsH}(34s6Opi_u0A*&kKqiW6(zPF8y zsoT*~CZ@VBDy#Z4+-XwBzfLLHss8rLW6Rb<$GXXBE$b+=;FIf`&BXh;Q25V5r4r8t zYjY6~92;{S=|U(F4jEXH9bCl@{(*(VyQF2H9HgLXQ7L*wycmL5{RI+ir&gM!U{zZC z5@6!XTpBR5s!?4{BNGpLP!x6w4b7?&4AQ^>T1=%7ZX9)LI6#w04QMi{!U9buHNUtM zwV;$syi4A^*}WF$Fr8xGjX_>?LSz6V;uEB$6gxg?SYZy+u@kJ=$W2IGA0-mEN4|Rb@J*c`~*wqBeF4Hg(_f`hU{&t^&iI%uc;#bE|hO*>U zZ1$O1NE|Mpe?5BsH?9C9YNqS6%_#8}X`~n8HvP(oysJ?cu&P|3fNp!r-D}FheL`eL zyDm21ETLdyJd2zLQPC{wxi%%u_Ode8CayogDIbntGWqtPk`gW^LKF04lTW*Jr<^yq zg@x;LQ)JMsI?~46sw#FTz`3h|sj}v~V%A84Z=O@YU>w2Tb9lh9t0==cyhK7FE9ATZ z`^F0#OJqRlTvmGtV}unPf#F%Im@7X5u~paLcjc@=|2K+UJmwk;reD?=Xxv8u=Vqqy z45;oV-&_6s@#HPyfi7wJX6{E)7#u3D&y=OQx`6RmB`qNjDbHz`0`Up}3QWm_uB=5_ zY(O>K5~0mWPHgF~q^k`)d5*^gda9OhJylw!x1Q=8Si4DMrpF=}uOR4&FA-Og12FpK zTLbUDWiAjb%$?x}vG2|dC0dGrU^xZFWQwooct%h5=Q*e&7XNy`w&Rm00s?cBE+pjH zyfp(Ez>%SVru91nplR&~G_4U3UR$(TDs$^dNhQ(Dv*%ar5>bGEm%1^B4~%8!@Qs@~ zIU0fca|#-Pvk%R)MmMqsN)Fv6GQ+k+6k0{)w4&tz;}Q{0=~TmR)?G*PB?#1;Sd_N| zVzrRK0WlI-6KFn%t{nK26Y!V6nT{m1<8HFQGe?$-e9qe2ekoiut5m=I=Ab`R!OnHb zF+JQ@ojtWqm1S$s?J3I>4jNfs-i!Zh3t2{L$$vRaA(hSt8>jxeKdFgW&b_@-P&Ozh%`!+cSmG!I-Np zWjb1U@y$jH%`(QY*nARmH;lVY1hc7g_vhx?L6RM3os~{qzSzZ!V`^aDOqb-=S-m1?BkQ{&fMz_p%ip2(n&Y&m!uPY}$Z>ChX7*o@JEW>QRC)7~DlXi+gKUy&c}74J+g z4(~s8Kjner_kl^;x~If1WY^T@YFFsYrnZzotGUGHPI5e&ucg7m)6K34GiMvAXV4!u zwMGX!YUesX=5;z8Rzp`)#&I&8|L<3!aI4H{&tx=3;i?2#Xs;QMb7MVXTQ(Mpt`1P8 z77!!bO{eoqZnLpoiIl}2v&p|@_ArYk)cio~V12{`3+fl?KI5{-P3y;k@$Zi|!w0D~ z*_#Nbl1+ifpcz++(z-*MP0()V#O=YZav2uMe48+6_ zR;nL}h;L7;gMZ$r3SjD^yy;t35`iZvA=H+5{|0@ zH#>%R^SK(Xavppt0bABcbNE1^q|;U=?8*Z6I&pas@=|t>3w}^Wrbzt!ltN*D^;8~|wH?#jT^p$&!-FGEk^JPsW36-^Q@W3ACKPk~OEWj4Nqo09j{!ds zzGOu2+H<*V(NB|~pwHP;DrtTC2Dwt-m;lDmm}}{0eEe)kbwy|gwf|0> zF-8F~tcofqJ-c-g{rY^>MFUkDveL z!-EF(;wyG1_Lb09xm*JG;1oZPBtX@=lTb{brd-lJ z{;__sFP-OuRPuAW?oP@!XPfft>Fs}R0w!Wf4IqbsOr1MA0YSk-p;Dh z(Ib&1@S&pnR7$5xA|bG9Cc^-ixa~%qOB~b9bHPWSs1W*Va)G*;O=fx~4N8|t42kqIbOaK9*8 zEn^Xj+-(8&br}P3b9uNAf9$gr2}Ds2Xiy`l)Q?Tt_U$o`!CEsm{P#VPINmdc2{8oM zc=d(RRrugAwOPT7b#!X4C2wAgb@7-Ul2F-w{L^Z4R&;gUBlz{i&YR&qe_oikmN@_7hh_UoPrltOTt&jpT$TZQgW=Z%+2zl8hD|yJ+h9$3q~Ux zdA-l!i|S^-Y6vR5wo1a9b3dq}?^2K8avI<*RH(EHSE{>ri=`lX%+4Re=%@yeil|~& z*SAg}z>Y=O!R)Dd;_Yp}7TNsrDQX*MEglE9nb^#WQn_50Ioyi4$;O(3vZ3ZF;gI!L zMbFD2>ruzU$6vjos?>U7WT?~1FBw8S(nVD38uNQbr$k?}KQXa)v`$;&_tWSJUFPMM zo74S_Aeub7v3Kbpfx&~h@K2|jf& z3XT{F{J6j01Ui_Gx0-`q<^`WTZx}BaGj!#$!4Dsril~vkY{zC@Wda4yV&veu;(`}i z=|_ABLn!GNMkLzT?Br!cqLbqxX>Q6s&d}pBhWh45?8?CXo1Yo|e=A|p#)_K9O z?my&l{KgwHcBzLA`I!f>^Es9rcYm&IL)k`A7F6C`zQH3h(G`mD9Y;ZeVPPbnWVrO* zgpPC*O|szOWT-p7+aFwv45_Cwy%ZfoNjG%dd%JM&KZ3G0CrJ!{2!&}$GANf&{@9(6byOaH)wHI_HT2% zcLkbGzF%0IXmChFGAj5e1IjJzV{NL#CU<>b+T`f2U>tnP194zGc763hW7_AoyL9^s zAK#lNeB1k3LI>3pi$Ooq3i`<{;lki8r=<{@`^4O;J;ESJpm$8M!BOq=*7w>9#_&2F zO@Brwc|XrH7_(6GD>tR0v4|8y3ZYLlexlaUOW|rKV@fhb`Ak;m=+kr63hs4}fz=m| znIs#YNUF5$WM&34dF9u~f#W zL;qbAFk6&9JXtR!!W*`N`%Q#%G9|90IcRP&k-CZrchO)M39q>}8Py@|gk)pmkyqH) z+60N#t8fR^XW`jx43p{L1oi7Iim)jnUSc`!%_uN@aZ|^bOUIsMe!c9h=HhI7TMikY zuy#H>uh}(Gu;h`3eyK`I^lA$2*fvorUMs?GmNm2Ax3O?aCh;IGLxSPphIeS#4e4gb zIQ+CN0%{)Tl=^t#whP?7VYt+&h2xzUbM*b8UDFxnL>{g}6fGH{#k!aSX>J;3^Lp7K zGHeAy^x5n6)}!^|ZvFMNcPp7hju!b_iCXCFBh=2WQSX(;)7J%OOI(Bz?!fL zl}6v%a0ZLV1K0#O3H1Ti9DgL%ubfy*pgnT&R%$5So0Z+@ed*zZGO`_1;mJ?_OtLe*vLLh;7k|q+ z2FZHXSefSvh0&)2jc}#X_AT-ighodz3&?L;O~ze{AI_yuYD+3{8-H)|e5Zfs zAW_^-Mem!VK2%3f~&mR zaV(Z@TyB`UrnxEByIBh#dGYk@f^c$rMSn^Tc`uetVP||Isfk#&NhL_);aRRpy`UCX zi5u}&0k(}n2OcK%jc=o)LvL;>BD)|hGK-Ab_mvu*kzd|1v^v_h_eK zNI|SNO%eoI2yyt!PWQC*$N|%@vnSuR!SH`9)?v9u(M(q2qKsk&DDqAy=GnJ)5m>*! z&&G20Vr6ia)R$hFPXJDwjbtPtm9}n$uRx)a@R}cdULGA_ke`Z%Mv1OsNhD!sOBC=S z&8&eePQH6rEd>ru>Zj%Cx+F()6Wh`EG;t9aq8n20>6JfmrRGUfNfrOPV8S^Gj7Qm4 z)@edlv62EjpUaV8B)U7F$}cco__V*nlil_}uUE@sf|lL4I(rEG+23oyWNC*PG(_3y z(WQrn>lI^g(7hj%lVx#kE*9-y*h#%32whYdc!9H95=o-r{(u|{Wj^(gxU3291Z*&M0ChLG#_(8TuyR1*^IR~q{Q>rO2>5*4@a@iNN zx||+YR4AA`i8-!E8TkM5O%M1TZY^R@pMwcG^fj zxE#?ooD(0IBub0`w_yYmM)(9Rx{%9jA;B@TX5`i~OHi7a$c>yKclCs=;Q1$Qm=Qw) zuoNKy-RVKxUxT@AV?{r^(z$I9Muse!tUdX<(DXTcaO5-!PkC;(f)L=X%V`OFlgS$* zxt~TS$I;81UK+<=<~CvTG;H7N`<)MW?b>A=TiR%!OzkhMRt5DocoLB63(0GtdeS>4 zgtEy?rR1&V;aQ`$5%9RRl1pN2>h_=;itg&Zh|{eEk2HSS6{a@`Q;f!1>Rx{_YkPuZ z6@x^tHk~aGCU=t^Zv`VHu7r6UAxx^;r>i+Qeibd2CI>F3v)l^>R;=bj$6kX5PP6b#yJ_XE#+F`BS`eMY&t5I8@_63KG2;lI z<5m@ush^!=Abt-=yB~PR4OrvgR2dJm%Ja?uqvqdS#^CVL;&8QQHi&cm2MBZ7-@5sV zw7Tm=NsXpjXoI@NlQ4jissw*A5~fQ}kSg80z@ z2kNP@W=~f-fo=gRS>0py6L&m{tH7@@R7NP+?dmMaRydNzd>)=L(KY+zH@crWANsP7 zE$H@S!~Ctm_!d)=o6E>dc+Y&+MKGt8+~H2T?nxE&%80*_rg>_1SfJKRPFJMyv$B|U zV^hPq-``Gz9efJL*TwGh9YLc0=4RAN0=0-+qN-_*wrYE+E^6*^jaKY9254%Ee*!a4 z|1BqZc4gK!t{x&qfH$@q69z>vYy3oao&E^x7l$=b`Fr!amKY4^^Urcni|%+rDm1qs z!-IxFkYT$!_PTWa-Bv3`j@+9HLgY;NKX-Y_{46L7`YjA5d0~&Zp>@qlyU4H-FB9Z? zj-WYlYZf)oyto5m&VjRTOH=wQk(}u(!*tnfzJ?>+UhpVg)2~^JE%&xHkeTcJQ|3Ui zRFIu#he;v_dqXNwC4p4pIZ@5OO|-aX$o3@4Po|)?qHStM31D2^vO_AzjUmj-R;pDX z`oyG_vTO}Uem&gO(nZ_XH*hru9*p&rcqct~jYD@n&&J?U$XvIJ?hn%sr>_rnKYpr) z(wJWv)g3V=EE`y8pG=$KhC1Id^saB4`As$onjlD$M7-;3uHxgmU!LrqzMLPMl2gR->2Nw zy!2!r-xDEr-7mfA4k*VWcyCzg=4B^2FKu5_t}w0-SN^w;l1m0>%Z+@rj6sJI-}<*D z7~z*?rZA^<4sWtUjNG=k5zatD4;YtN3(+6*SnG(`=n>CNF&DI z+EM-4?BVM0DP&q9nTxsXYWJt$9^gMupH_vh86PP3u$0R~(|)s^GCV!k{M+Ez9Ee&P0Jl1}E(5^p z&`rz0MU62PzXVg*LZvgV%sd+dHCi=wmJBSc(3*26IHROm;Pe1v;t_7Be$M{RVK%xf zvgwp0k|HMlm?k!7Y8FQ)fggKrzE|by#=)^Aiq57f70}X|){H}R5v&fBRc?tA2WRQb zu{&B~12KY$B0SfKUTI%nS@4R|?9{Pv~fvy_!SZNkFnhTX?ZZ-$O- z8*u82Uu3c8us@1PsE@1&er7vo%AE`ywtlriIc8%2e*0HCSe%!M_nlGa5m&(b>Tae- z_E>EaxWYRj%JRYb!l=TgN#gaRDfQ++LL8v$!a5T@#@g{Czruq5C0}%;gl>J^92xT> zlhU+{-$J}^8tFj5-=qxpW)>{?xUTL-mf(XSumSP4vAI0ZXBV5HwDx0?RQ_g;nf=}E z-;V&YA{StvHUQ+G-AwcnYBIsdR}uEV?B=DG?I;SMvxR_(`or&$D24hv_s%iUD#v9| zlPOuBHDRjA*r)CfF7tIDZoo^_LSv`VYP;xf3=Q{XHUPP#dyy^JVj66~Z$}}mo_1>n z)u&L!tM_#4HvhzvCow0*+O}v<{UPLV(OzLo3boUx;ww2yS08f;5^+E@L85!i3Ef-! z6CVk^SoMCpzL77|)iOCppa@woLbla-G^aHd54ZCOwYda*@lj&RYfREpqH&n~GU!DH zV2hgL<5qwzmeBWF!9}+*{C4Nw&+WvbCmh9h*?Cx-kFC zs6z93Os0yq{rE<0GzMH?T&k%_G3s9O*YoC}AJH`bqssi5iglN&!2Y51vT72MMmNXD zr)r#@tc5h?WViDFE?irwSj<>iMlT!N)S_WET>kLMWq4$oY2*L^+BKg5RKqwW^xg`p!5?i+r429hK#KlL4yED)N+upAe(qt7KB6fr{lbUiW~bdj zm_FrUAI}D7r%pvm^^I%S$S9@bDVp}cSDawjgE#HWJl0!sPMx~a87bPo`l?{Kd6N$L zwSP5hmzUXvp10K_;|dEw1=En@zQx~myPdmg7P<4g>iv~HyVQPJ%aJVZg&7mW!iTQlcGbE$*VU__~79^!rw!X zTF2ye`im`xul#k=|CxFq8;a?iKpse0Sx0ixmPc=IM64NzrKlO$oo=S%6g5>LAdpd! zR0*8B*aP^YAO*K_xT%PM2R;lQSCG<;Z+Blon ztaWRJ@RNDZiH230qfAd4+b1Vaw+4K(V2J~~sbY76FO>_5$&K}X03AN@rTN7bp?@Qq z8%(T98&cjU$9*ZGo=cKuc<_)CHhGO^dxtT-jN?<8ZTq^Gfh4Bz?sRh2p@4bOV^w|# z&#rI2V3Z-e%e_ISat}_?HK{CP#)wr;oktpn=;Q7WJK%%f(DB`EMKYu^i)Lk6Erk3R zE@({ci;CVSw8Nv}VKUjdElU@7NPMH6XvuQ|!Wnmr#72D< zy=w*YV#%A1LfNPh6kzI%?cM1HM{fp((8h@|j4g$t&oUkp*b;NmK^l$D*{+~#+_|xxe&C1$u z*zOdI3DRfzJqiFojn(B8V3Q@Fv6L?=mY>lqpJZ4i9PAg2RvnUcGAYeVBGms{X{@f- z9-!HU2wxdFnQrZFb@mxGrwEPwWU6wjmNC2rnJ6FK!<2v^VRBkYCryp_;K=Eg4X5x~ zxgRrt;&#Fi{0t~=n{$qQKym*JWX=CJoA#w!6IQ%yOYBPBaWYsvKHdgHb|anA95>?b z(CQP(Im41-17pu8gvr>h^wKoIJBU5T)&)l!_O&#r)ym|Yfo}dm;{HD*w%(wBzSzKW ztliYJ)t))=jLz0@1sml*W<|8PS)^pWtt$nfO9QJ*S!U~o-rVYpxXMoXne4JfMA)oj zWYzCW9!&9ww%8`rM06}nG;#hzj-10%q%6f?rzZX?KDK0T^0eEsIGgKqYsn*;IsQWv zgQYKzURF|KycZlQE)n}h;Yzfu_jeZYx104-ni2ky2BgXH8W&4X_t$*Os{mjb`9Z5#mX zc5e^{0Bv3W$2{vaCih~$rAM~DvCJR6ju^rGCnHSW|C14z|H%l_#_z*ij2@o*C+-ayXVEDh@pNqF_=jIXQh5BX_HE!+70OG_1<{-WjCd7(IKa zLsWcw<^>r?)W2qWQ82mi3Q-5{kTDx#xtDxQ`kDNc*|mMpFOO|>E%Y)DDmk%67ROXn z#V|!SE~1M2S-Vc9LPv3|N` zf}*nz5oPhpPp2gT4+Hv95NwRd*5-u(hgdP6G-| zd86fSH|`l4OT2POnrY#APBh@Q*727l0%!vqVb?Lqn%)VX6fuCyoF@__yQQgwqG)J? zd;}IQt0ky_nRi?M2so{l-HRWSEi#P^N-el|q+>UO2= z?ASiGn@ga8fh-A)W-(-GFmb9HW1+LT_Hs97F#mgR%WeXSew(x8qPuZqjF(o0JcK$eHddEh^LsOUwa=qU=(bYPOG1AvO%0oHtKR z&1*pTJDT1(0dsLFY~k4`R7@+1-q$;t9{WVBu84{W*{U5vfn2?PP5LQ7r__+KOrp-< z=m%2R`^AUlXH2AzRmTPw#1?VvVJVksNyMTY&20aE(w*^6sLnw4NATo!Vt%Yx&8l&Y z0DSP|Rw6N8WuH9uwr1#mr|5+7-zhpVW__LysFmK)NC~1NpGVLW0dV?i4XmI5&iupj z1%Oj_Y|sbb)LI%yG02Y)iL}aWErCqm9!YsO_9$~`AS#>8LVb2;RR#bcnESYxIuR?3C>ix%tSf`Qni(O2rMu-1&30E{d zsxkGl&p+OHYb^bFq*x7bhO3;~@>s75VT_0&M*j@b!F#Kiil*bnC&@>=dgOyLU4tmA z%4+z*IY`eNBNWNyDEct(7^A$F(yB&KK+LooLe#yYx z`h0*8SF|+-=dxl>$*eK*ATp;+9S|y5xi>6UJOwEf%rXMidrEhDCM?B|dS@Fr!j@5e zDmOK~>IvU$^wje6nE)Kp2hz59n;dPKszWq?bCzVF@b=FV6R5gpn^^`&Kw50fj2cys z0!$sML71&n8rVBx((*?6@R&ptQ?Uqbk3>d!PaS)1no_1FtsgesuoK^QA+#8n7TqIw zV<=wxGR6$w6>Qi!vKHoz`|ih55y)58n zJ)2GiJ9qyOdAb#Unjr@z9=Vpy9)YiSj5XJudNxmgOvmvIymV|sp#GyrEgz5jC!38M z=hiS#8H0_?W>S2B#c8?KY6bh$Pfzgw3i}qi*<0|T3Hj_=y5i;Ymx~lU?X8U(Bcb8R zb_Tz8iCh@QWSdpF^4yK{bO}yALY*!?Hb!hSIy5(F(=(KzKyx!y>l4XBuJhVX{UtaP z^NN4)Eu2}kx9?PrAdhD5sy4GFoEUJ6LdX+t2tuYgnl8l|-p9u6`p$W=edpk~XKi$g zcJON?JP#>6{FGMmJ#qPZFQwQkXso_oE%U?XOMW`vG{qNe474!{F%qg`CRxV9HV#h zGfzUJX3SSsFATOX%e$Uo+l_XgYJlAAI=_{b)X4wZyXg>nt#qC~_nSb4cWR$HNB)9< zen$xx-KF?&t)1&{{IeX+x2)WB6`}BdJ(5m-3>a7ytd3s?`15{kK5&zH^B7%~w9V!y z{~}%@)veSVQ2LeE%D1zCG{X6pGr>T{QmO4xA!)$0!^QkgxgBjVU$7xjYOu#I=0&4r zLaM)@NbOb`$_o&P8;tO!hre&VCj11viJS~Bx#*35-PhA37_|%T3=B&nkzEaH9sP)N z>pTXWj!vM%nB6RQzo?6pA#}*yBLMbm(Wzt~(8JTTTM>?sWeHx&D8nMRY^v+7%(H|q z>(posO(-^Yyt&xiu;SG!S!+*374Uq}WZAruLh1{z;h$NsYUiic9{aF69#gENvm{Zr zDzz+yDzq%HWeXfe>P>Deo3!|)k9J~hW21Ry=e z=9#OygK`Fy`4=}w$A=INVvcS75;RHP3Jz4G@g-HRn-a9{ztT6m_S7|B^?@y(fV@f>x@8%*i2S^#HWhiM+Yj%(fKog5qdll5-A?(=4#fGs^GO;B`?O<@ zDT-f9Yh$6B9radxxa_aShvRR)%Ao1Dqua5+f|ENCiSkBWDA`6`tvoaqkEW1X0ueET zeUMfxrGSWVtR5Vvz*Q=^#OhJsFSpjtB9U*4aY}}LD88}QCj<|hduH1wR7M2Hjqf;3CEJLo5PP|wGyNJf_XgY@O3&sA(bhb5c zquoL`Y&Ji)L@tr^#V;A>dmneKp!eKvI#zY5pVi4`YRYP_8<$d(xOOF`p9mzl7EwRJtez~ze7Kx8e7^akX#33`S^ihBrKiHs) z(ykS{sMxJxp^y2w;v#tv8+r{=@ zVS*D4t-!4RNfTpwVl!LcsX-9{OStYeBCmxh%9A-`Gx*C#ax8QYFwKtEMuVcj8}-~v zn=!Ajwb8^23e!X2dO?NU*UQXpjEW~l#`)sgLrArG$uE3m64LgPAVGGVSE24Y6PGbU z8EndP&StjFQ-gCLU&Oy==n5RhstulT(Why*s@pAmzsl;6$-&j`h2S2d**oBAi&pEq zmIoKsO!rg)z-b%rP8Mjic-ZzKZVcwj&kpPc8E9kie_jL8#m-N#3*55&pqNDW01e!k z2X1xkA?f$-3D(-EhQ{Lev$&*`?iKG}%^vQ@%ObG~GeGRF_OB$#-O0>K>OQ&2vQ#Uy zFXl$OVju#kkCayTMv=zKSN#};1}WDJpiH$XX6S4P*VO}Fa9#N4C7UqD zTru8P(40r2@h9mRxT%(T$%wgqqEYunv1l{I6bvJr+HSinD1625`~BT+D^LFBCl9Rj zXM%K~(?{9lm{DPjf;k#@Tr*_-GWtPitH#_+>Vk_kRSYn-y|+xk4`D?gbtk7e+!CkW zjt^<4bE@X=V1LJOeq8>&X1qy;Hrv zs8L-K%#H{`o5!Xw@B?lL72S48u$Uda7S6XjygX3`EM-vuh~`*O)9_1!+Bx<)n3yYUYP3JUzE(JWYK|6&T0;5a!T~ zwI6AoP1>Fhr>};2CyF37_<@WjQFm?Tj+>l26p@|dwa3CoMaruCjP$%5*V@y8)H=-c(^Y8}=_J|gM!W0e8GXZ2h-2GLMI}Y0fXDH%HV{F#q3>zSsq9%0 zEx-;`rNy3Ua9C<#Rf?X~29%w%AA!27juaDA0MsH;Emf=z#_aoHRW`3W%9P75tmSbf zC|wbtjEuPC`oDo^t`)G$1=RN1=Oa&(?yWL8m!Jd{aG#3eIWQZ~;l@dvPnc|5Rsa5* zMO6`yL2PzcR{`X}H>6(Wy|7TBK$;4>N@(X!b%x&s*w$0>Ds#w4dxM^d;u{TECulY;T@( zuXOQL!Am}Sa2o2zw%V?1U0s^DEvbxqTF~^-&~FsnFR~{Vx-kh_JD+1|Rx#MjPPx*N zFV)U~y6B0!s|JAFbbC>iN6ly{ek)D)`IX_6!Sb~Rt!l#^gOL`nET^rlC4gnQ-DoK( zJTR8)c7q=t9}ok1h!3u(owl}=NY%itBVJT3Z8V&s0b6a5M`(V3VD5IC9#YMepW_MJYX~{!QWy|22#S2Ma z_gYAA00e4N4oF{>2Uodek(T0)`Ron}7uX zO$)EnmVSy}SkpPC{a&l>7M+TQwfFGU8{7tc5&v?wJMQY5(FFVP#cGl>Ge)|jn?O4# zn|xK=fFMy$YD+PY6W<4|setG9tc&Y)fYX-dOVd#)a8|*ZTTdLM#k6xp&Zs9#AoK5G zzhVeRDbFa7s^Jf&6q*Bn58M*kMEWJa*=(aF-M#5wn^~5s;Ze}J#Afn&zRq~1XA`Ia zhf>ye4s1%Hc5Djx*#j;p4@a<3*H+q2a^>F)rbhW;g7DsG2RIFq;A?$5R6jftAP)sqNQup@6BiI)VwC=mAAzxD41meV}muP5K29Q=>vuvPyq zy9&!NW`VNDdIC|xBPc)#j4-s+I+ELE#IQq{Y70V1iB*1?oOX_Fj!P|(9vJNGS<9I$ zGG02drU9g%0mGE$eNmQjMMXO*Uj7rzskE0RLtwZ8L1OnLx;8r8qC+E~juX4Rc@hQF ztWALizuSv;xy&z{@_CXXOh1ITaxSM6VWNT87l`Y|w)~L{Iop7=(>Czv3=TI599CmL z&_^<ImVm20@aqDfTP^EEn7VQ^n_L1z=Q z^p%IiZ1*f!<}BvgxnP)n!iKY}PYhK~(gw&V?^@kgR)@Pd%@JV9%;VzTAQi1nc5=fJ z0azfHK-P$Nvs|CMG|#81=Ao_|{!^!n}K zMtoxcQHfm2=x`*?Xq9xUjNv(`?JKzN+BiSaMmfnNC+&;LxP}O}iDsz`@CAt65%7CD zj+th8n{^tXYT?1PUZCiiLs9aUF&roQcc+r$gRxyH+@uGhP7aiDod($MrH@Aruw6C` zxC5EaG`%rA@q6aY>Mb>xQVcdOVi!dT>4em9Q9#4Zx!;Kb8cy@}BJiDI`7~YfZ)Q_I zoIZxRu7yK3R?n>c4UB)PwW(eZ@NJ;{X@bfHFN#=m4r)JM;=zGZ>%=zWovzQU1BbdV ziU4Kj;qFEMQFgV9%-rpRYuYo(vr>(@s%-hI*8NcRIok1udmo8|)%hTb)yJ&t zmE33#3>Ux|{c@puqG(_rs7m(PKI`K#wN}ABoH&LS4WMCHTCKByP~l|5DodpHXGn!= zvvN>U%pXQkF9-YEs-J)_ybT(_vk2T0IRPS-6XS!IEOqS-Hi3zxr>@zslzDq|XLGi- z?w8=6hN*@`D&-`)EGpJ~yDv^4&Sc?Hz7qq4e|v1GXZ^QFzBE=grSvQf^=h3Vpjpz^ zl*Slw=lnIZxn9Sfxc{QX<|h_T<+!|ZZip)t;pHdV^fCEiXJcNS6Vr!K5!I=>KJ!nK zjAhPxoojvC9TI%=6{PNZ7#)dhv0Oc{NI@$6YfFENMA8MR4)$HhF}+AcTgT7&1_(pM znjJ{6>~|YdBM|$sgdM|mJZy9Wg?|+JTT96!jl#D~=YkGIL5=Upx1$LZ1_Hr{E#W7^ z8Nr0(p-a~`-!(=)^cO@hD@L{|5g$}80CV&VTi$MBu%i6fCqEy`JlP_x`eUJA&+e3* zqtgV_zNfD$aw?J;k%?#XE0PTg9OP~JxgkF8i;%S@J^d;^nA_K@|MhhA)K|4FppwBs zV9GsA(?FI-$bux;#SzkThb=I`k>Xc3nKteZ_LWMh8Ugd|6a7?OsdTZRdSWa4y3NAi zkKqtbv7zgquhZ3k{YUy5jZ4_&+h>I@uA-~t9#NLK!8ha{;Q4~o2#gJ#rdVIe<{2DU z)KeTP^UH;rs2Fs@L}T=A6i8MD|p(Y3FnhMW8y zydk}PUG5dpxL<|NLE};>F5$nqLj{<>G48;-dfD-5T$(Gbb~LZP{M=Xt9s9U6NAa$u zJ9?Z&Ak86wpWi?3WUY)IRJ&YHHfQ9w%f^?k?;ZGhr`ZIcjxC?UjX>SQ828{bNnA)NoP!AY`B3o2w_oElof7R>ty}fdNi+gor%Q)eZo(I+D%#0HsGJ04?zY>;L z0x!W`MW^L`=Mnf-kHVAD7z+83t^GW9A<}`NbNB)7k}@q{DvWX0Z>4~HTcVUnZ@X!$ z@MYNbCPma)ncx!ES(%OlZ`ZH2Fz8Llz3bXc%c0!p7SSs>-Zy%GTvuZ$Bh~%gNa_K? zu3t-`R1M-TB~)qE(SzyqkKFT*48v=k<~0xc+raDoFUqZUt)E^_8hG|!b>dz6bs80P z={fs%T6Ifo&<{yFUd6aqm;|WAMw^75=0y=+B$L#l3G|*22{j!CCWeC797L;45^Off z>}w9lab95~RDor^_#Kx5%X)RanQO7M8KvY!;NH`~TD|=Z*xWf>kF+2e*aa-05sl{;v!c9HOeI4qZrNM6ntJa02x657S;z1_5dsl z=McD?@8%$PA)4JbT5VLjvZ_)l&-u9Zy;0+@(}SnGGr=h4oI+exq!8n`4D2oRp>fal=gw!~%EF7PMZwrlyWN)Oqfx?FSOTg?aHIm# zsKI=%4WDj@w@2-sZ;jfXBD=q>+YoF=dDi~1qE3Fu^dV)B3RUS(BFC_;gj7}vfsP>J zxQbEz4wbt)_?Dn~W_2$E39BR$iZawgontyn@0AmdZs7>FQb*WEKY!kVV~7B`WSI9U zUVS-x$E=z~y$a{wWVgi6ymN@xIY!Z6oYoO}lojGbbcFm+{*FdI=KAdEIIxE+;rlcqX!PkMyIR%PY76n~j=ioE zO?%3c1WAUE^O)0iZd^Ym@JcmQuQ2R(+xLvmS3RvdxAUK15bbg980-yP1pkAoAa-Ik zs_^h9ejj{p3{`}TExRfthz2Mp?Z5{76Ww7yG(dERE?fgL=tIWA@ES7{geXx?Wj)$u`9{tKV!Wo!}nCxEFIdTov6}jbJ?eUvY!a z-?}L}|AY7?il1Wb#ecf1%ggpI=aUaP8U8=;s^h0T9 zY$6lKUDs|DDRxIlSYmf4gxeMlYqI(Bk{uf~KnZo|G#IS0faRe%O_2^=&;ieK28465 z>IXIUnk#-EAfl1fwm6}Y)YNSHwIbX_y5r1D7DtKR?DEHNLNX5j0EYnKUd((kiybj> zJoN+IHsw>+LcbX-G|ecjUIcRhd6=a_(h2sK`zIIZ&%0iTp&j4C`w*I6B$0dX=$pzW zD9Yd>^AGxulB)H-I~yD3PHIJAET=yxU!kp@pqp+_?z4VhT~Syj=Ygm+KUS@Q+fUv< z>&CkrHt!gC?>Q5G%;1$;Nx0pyAlP(%I~?vSePSKil0vuf88z0o;7ezg+}3fF@IF?8 z!jWGkCXa;us8({mhrF?Xp)X5o7kn)(J$ZgUItwi6pQ|1Sy?0*{iPec1t|E0ms|%iv zgDKYhr+(-V3I`;4Tf*~I?GW*&-|0tJt1QH*7M*g?@LnY#{MIh|t(qqSiGjvI?c!ki zPs=jHMvpln@-4JpXXJdX^G@OfPeZ$mld z#JgHK7J7Xx{B#~hcd9Q#>l4TEK7Pi=F}^pXni%GT6BofC6o>d%1E}=aS&Mu&R3jA8 zxf+-Kbl6ejxD42^|3Wv_Xr!BDig#wwL3^z9O#;&tRgIC-nrAbw9WZLHf}SD=UcMc7 zhXmpj6Tu-pyedIS^2%a#1tJT%YI@f!FQeCn){1(Iau<+W*E*QdF|Sr4-GNM+pQ)|U zae2SJ`Q@&ozQRh}DOD=WRmu7jaIE5Ad{D9w-j`+RwM!@#{MqR-5L;v@yNl@ht#Uzq z1mos6#XFkI9O$>%JD1%SzVJ-ny&&YE3jOhQT{ke47T=E{37rbw|vy_tx2ZxUb$rRzw5UYgcvBU&ZF$xcpJN z%lghbQ~Y*8E6@TKZ|l~QoXKF%`f0jKsM>?tEIOoSqRvlO!_3ehYnl;d-@P{OEt_)% zozPYPjO~NrJEZ4ITgHc2hUcv%1a3pwXOj%ymq<^}yzF*6VZRq=my~W1Eb0wq7>X1< z=1Q)&FpbuZ=T`3gklcM*4a`D;s;u7ZLHl+ctZ$6p_k%^)jp7i!hUp&uV!S9Ljjusz zC$$K^EXtZhK5~Rxzz`Zag=wJm5gSdak6U0K`1RsWSYVDK7PpbCT42sQ6bRa-M4Gie zuV)ka*Vy!Cr@s>x+oPk#%g0>MMY_908flP}RJyx6rMpqOmX4*nK{}TP zSvr=E-^=&sd(Q7K;J{(-ojZ5pnP={Hv26EvfDuMKyqbykJyI{@bxq7UQmtp-Ou@w> zD$Cn1aP!&mc5i0kHqHsiHakIB_WC`fM$#`UcD>~$DO~S+zyDMr`HKp4*BXoI&|pq) zPjC*K^3T1?P~|$L>{3r+$UfkDt)xARW4wY6g6;k+YM0=;tQ%u6 zLVvZ`{dnJ65^Lo|SRvy?>L8~){G;fqs4Bn{tc>&72Xs6y+d~F(WoMnGQJp9${s<+# zGjk~^x`NWwj2$qH%)4$?oeeMw6<3F1O+REh){q!ZqnaJJ#hi{GI2GuIvW?`YP}xMY z87oZ3-s~6D)W}dkC;JJ%On<)IpH_F3rC4Ao^<8s-Aw0^y>~CNA`rM{`f9rdvTTNj2 zl`&5^I(Nw{5_qER;mm$-W&7=CW&|JN7{iVf@YDS^gUl9wB4~{^?Is+O8D)vxdGg1{ z(D&o%Vdt?oM^ycn8(((}Q58p?OXpIyl%9`IP%6ZuX9EM~fyN2)q|i&AXQn>neNL87 zRBFRc+n_8SX%cq&zCkbdn#HJN2d71!^7GYC4fhYd=O>vlEBWLG3h=wGT)3=?bu3N4 zmfw-8bk1w@Y~fYBu9T`*7B%y>&D=t1!eh-l)ZtHyd)uYY^~!&R?h*c^(CyB}N6S`o zS3>|_eNIMZ@2k*I}`(=O+^u6C}j|K?)o4V^o}NRrnR$XC`L5au@P%$%g3O9hEbZH# z=;gVk(GM%%D*X$o#}E&hY^MarZX^4_;wzsJ0~+;vD3-%NoKM;j9k+q`87skA)B3Xc zJ&v}!rcBE^Eb)2$rKB8eCw6ZA#?~abR_)6JH?ieAoGLq67>g4~EqX5h1hZ)UCwM^f zpI{-A4+n2_W%X_hk<13kweuB@hW`X)X543euUNXLD-WaVT=czjT&>WWW45iHbnrIlpb(9BUEn4mGrf{3(7(o} z#@E^{TK#zXjg2Nn{{u#4oB8d zF~y79*`-OXN1U8j5+(NYB1g^S8ix)}tr`AM3KJ$zVgYmj-iC-O?t|K3+77n8nQ=`c znIHVjU!xoP0)GU-9Ir&@wanoD>^}R_PCk`@C*u~<&YMa71-Qnw&mqcX$LC5zjq=(6 zD+nghs9*M2(BU9EGI#v@QNiI}qqd@>%d*37ksfzf$%mkmmSP_KMCAcvSt7?BzLvaL z@pNi>!Uobh{-v=ToeWt`e}Y5LA-I;O&@Rf)wcQ98c|ySHw#z!JjL{A^8*LPz2JKBD zpOxTwIJhRz)G$!DJe9G~HhsvWZ3^>>Z#$f%jmNg**oP8p>LrBTa;~{xC!pSQ#=A2l ztk6{ef8!ay$^w&dT+6;^);YZyRCTyNV`}*@8n)A0#r#rbz7KZnY}Yb`?)cd@qQaER zk581I61P%~ea!HetW?>v*9N?Wt zoak>bmNkBnlz`<+D=Wrojx)Z1*p{Y!6v0SgJq~1iBZGD3302&Qeca$(CMFI!YE^^A zOXv_Lb7+GqqcPXkY)6aE1=JTpGHlKnTW}PbF zpjT<4Qx^Aa)1y##RscwBiP;4+nwn1PdwJX47=FDD!bdjHf;sB-t!61z7fz!QkX?bc zb=YJV0%f;cGiEtcBpz=78>0`I>^nYR;GLU~@%%h|e7?Eqt1mI+9g42g4VWB4lYUuF zEbFv_9n#JmQ4)h7n0KZ3UeYOm=+tw$W0h`qoqQgA!J^`}b9oO^zRqnNd;stGq#xnx z3WHcFQoy_UZ7(TVPmLX&3zBYya`VT$-1pDAjt>|tXau{i@;*wK=&Td7lG5TNo6Azh z*2q+hx%)QWowP$b^P=DzvxoI-`2Zw2asST*5!l^6pw9#tBk9DSo!ME#|>9`Ni9{=7NTeNg{%C2b4 z#64U~eFNLSv3l}dFid>d?fv$U7iS0wSl=%nPN>r{V7dtGZLlzsp}@e7tG^&Yl<*%yk;Rq>#yo}C{Z(51efo%1WYyFA zH%^fwue{Lt$M=ZU7K}Xe3<)CKj9c}4Mx4D$h-Z#fxo6Nzc{~4deLt_XfX>}Ozp!-D zj^22#jHbeTJ0ac*km@Gf2fJb4(p2+=u-=NhuIZ%fraat_4a!L^$08*87znGK_2eA> zqCHcjDNd{i+dwL-c2viexeFbPQfOdWw^op%Gz7|`7K#mE=vle%$!LrVWRXf-aQrTJIHat1l$$BccnLgbB*2$^BFX<_k^>@og`5r$_yGS2RZMQ;mCX@ zWcy9CX&`gDEdE1}Glwt<58vtiCpHh7t;y4>%r z7n>`GLtp#IK!kTWZrL)x9u;wyQx)I=7RMU&Ztf+F2N{dx0ADOMt4LgLQ?|RUeaU zhYa6p4yA#qWaoDs`VQLit?VJT6uta*v2I&!fc1F**0+DGioIVKdWoBxf^qo)*1y64 zz5wY~@p{r3_`S8OwzD8zWj)A0f2mQO6|}YFdAtwl5>6?M|K)4XkML z(tChzG~7Scf@H{PgV1SbZpq_kUrzY`b$RRAYL)-RD)~wOWfgz2w97+jOPcxt-gz2) zLX*D#)=3V#3w938GvB_`I35)PDAui%I^V#Ef~LV;|2d^iuVcaPytz#oNM3cQ%}vD} z*No9b3>?ZTtS7$wX3FPpK5ZxEFcRqriYyF3-gDq^fM5t0dUj9iNKdyl{*nuV#*qR* zpE@qvFXI}90#6VrfTEU?Pe#ju&DGy5oDIs3I7!f`wxbD0{?S;-Yh9yry*n~<^t~~| zUUFao88IXPMGdeX+9vt<0s%et(jutE@Hi}SF3t1x-rnPD#T3|$qdwVW`OPzhNOAupp`Xh*q|OxIKKHBkO5BLiybtm6FXBwW(73xoM|_$q zOtp#Y{T4kmTBr8p=1@Sb<&y82M(`T_roeL{LTr%>- zX(L!1^iqlc!U|d`gf^rWSzPKAIBsor%#vk;!6vS;pHD^px=tO-BJwVXXixVwk?zoZ~P_aM`ooyI@k9{tqY$wIy&_#FMySX^{8@y{ZW?^P~-1=PA zA>Xn|v$4p)3k8XBaVAqyeV(58$6=lHO}n=3 z!Y7HjZiPKDJz!g^vYU3s3el3o%5rX4gYlz-Q?dEEVs6YyJm*Ww7fTmb#iTy$4cYf7 zJbhe}C=Z|cRBC2xK%#sO`<2qMFVU0k;+#HdK2$Mv-b|*Fz>R-Fv<8N%B5oS)L{5c!Z~@0{(pg` z4gEH&gda?MuS{`<#Z@Tb|Jfk>^_lk354c#pIry`11Qd7LRm?Mewf9lh7u!s%rg(T~ z3<4Hiv)piYH(~sWXL#5QL$SO?z^#gFlJC#mU`=@Yq`&MZm-7*KmzwHed%v*gVZIlm zNbZ2>KH34{LGzI67kTtqrEvt8&>F7twnzD&aulI#2Okj5YFXSi!`Y#tlw|0oMS9s0nb2ht>I!x2Uox- zbAn#STjF39DXeLvA_l!ZoZ*E%cH#0dqWwS=hjecatbwml~5r1ag@rL8frc;)!BOa?}Ly(adNSXZf zKSPzu71pwZCSy>W6czmRQTejrJX~CZfjmBAc%>Q|=mtiJ1UmS{5U?#UyX|IH0mDO>j>g~Kb1Muuy8tW?U5p92p?@nfMA9k#?_E2|eSY01MC=zF0mSwG!EgM0J+`IzxkhMj6 zb|dKmLUtW4?16|C;%P9HF421Lf_ze98n*^SECpN;_@5*81g!y%IGud*WTe$qi)g{D zB)9Ol&>n3EpQ0qgf4SrupdE=jcQBxx5Jv{El?t~r2mOXcYv#49+tdQ|vvCiHU*_PmIt zG6(6^Mi~aBY=r%BO3J3+9h9Qb%=H zT(P=}`iKt!^g6T<^oMQ5TA32!YdnJd`?8aShYNc~x2VIYedv5Hd%HBJe92S;C32Z~ zfe74_x2t{i4$ycIk@y%swo!QNIh1#Yrpui2iYNnh*_iZu)NViXua@tc=3|BKQ^ceB zg|~2q%tT()S*Q=jzYig=a5crk2KiZl6Am!t|=I2q$ z5QXUw|Djfd{>kp z`80h89#MS?z4E%#YNkhOv^I;=NHOnco@}`v`6DsiQ-L0*rHPu(P1W@wstOZ$ygN!IPR!^iJTG|ZhSz~ik4YgLPUv63BHpBZuJjE?L+MmHAtxd~{ z^>=9a@8Vl3y|hGEs(#*o)MP`di8;7B!5gwTs;Y3A`!eIFkpxY3@mf5YwM!`bDr~TM z=Xzsy?xPl?&B*rbJTSBK^5{oQ*;y<%_GVf_@vH^zZVd}|7qdzfx4t;YF64)+G!Aq( zkQNeNiI{vEaL;d7LaF38@~$+-`bxt(C1-WisIGRt((8!&H1LG{G_h$dO~}RrB>L7T z0@@zxV8f@^c{D{^erP-^KHrqArQ2+(tfjG{Cak5MvlgRQlWVLe2s529Gl7&8$DeMo z^%p6}qEJs*q|ZAdp0J|5wq*as)f_bI9P}}G3MgC_qIb!nPxr<#@*+VbJo#+U=2a#9)@LT@ZP;5Q~{ z^ngCtw*aT_mJ_<@1QSAL9#51rtDzI{ZhrwGtNH&E0{@?oI{%9*QZN7+5!c!}6pL@g4in2_XB*VT&&9o8 ziG;LIJ$g7VGw|(5F%C29xOxicpLH17OLsWq*f)O2vu_OZ>Ta>x*l~C(I=>#^H&15) z&L2Ua2xl65JrO=WNjee!lOQV|%z-gMn9Kj)R&ZJQF^z^jg1rbH_?Yc+6oGSs?@Irx ze>(@U3mW(LbMhaDe^xwdG_uCwF$Pkw%xzM3kA?8zU-wJUYBBL=*(K{65&jy|bGw#W zQimP>I?_K5#+;5?1GS`?|0xU3qStytfhU&jt1(4b$asD!za1SVk5dA1%Zafm3qPX4 zC_Epk`^TDxz;6CUE}&Aj|7nr2qYu0!ZuMnbYNwv$QV6unppzS-uFGbi>E$*#F_2H1 z$k`RmWh7KJ9~nCMv`=M4OTAHBBcQ!CEsN0nku905{@Gi-aPQo@r~2^eek$j?#!ESX zcN}{*Jw1N(Xy`DsC8Djw{T;%)q?jCU^T8sWSW-WyoGNI9hB;9tdY>NLrI+1=pzO9( zn4Tu9)08peN17G-m?$u`HH!@T?T-e4WY)5-bJiFc&o5@c_@}!b(np9vH;|%N>%6A=Ax-=EyM~;jM7ZZA zd`)dMP&RrtqlrVASaF&<45`I->7u)#RPjfv|3pZI)I6Ze&iJ1G4UyqzdeW+e01qU#!{mB`B6(L z%bey_f%;ncFW&q`^_JpKMGkc)KfUg4*f9N25_1M1=+@6^q%~fa;%@()WV^J_CS!P@nCRZTh|EM%iJorFR z^)ro_Z7Qa@UGGl}NvGZv*?(poZ3`xfK8e7u<~K`zjU2xLl>v@&`p)=$c+Fc7I=*z=u0C8*ZM~tSt~>w^{t^okHolof zfc{Tf`v=%&33VZ~Nou5ac5#}a3z9swS+ZDOA1ILLR)|{?B%A;cMWF8FvVUMQkRe3!-Dmrp@|ue2fXuD$X;2cY8f@daS5maRDcI2A=_uQ~%qX z-Jh=`>0d-eWpX6KbTNn4N=y`-QJdcaEqb*hBR87=b_Z5*UW=i&O>9>nV%}$0ruFFi zUNv&Kpys&T?B9LBcOoq{5HYiPA`MWMlw$39m6F}Lqvt3Lx(3C87FzLV;JUImAWoa!$Jb^zMevI2->C~;vc(Lr+co> zkh|rueRB;h{z}HqVw5NN6O0${AmP>w{`0Aabd6>;Mvcy(*CM`jl~D|MQwg{Y|49>f z`zLKRhC|t6nS>U_)kN|{8olZ#(!Y%n6bLS!g)`>;{b}Kzq~H51`cRNSL5^xy*_*J{ zZUJa|_c|0mp8zFBJ!(ze=+D?*ZkFZG_4S!4Q!@o|?!-J`nbk60CvSVcvN_qK1APSa zn7=|^cRS6UJN>qed?Kp{)oFhmeBwD^R9Nruxiyp;gBz?+gZs30l;BR}# zsB4D;03_tST>K>8IC8ll*%cnExQQwJ(PJ;99Q$0``nLw*4hN19fQ{w=DU;CY8yd4m zSI_>mltW6-Us;$TQE!BBPjA9y_^8$Za?b&aF^f#oq0ooZ(b(}Zp9cq(QSuZDk*?Jo z#v6e!3*w+k03qo<#)HTlN#jlq1l8F>I;F`bh0Ft?>?-3Rk2X%9C`SZAm_5eBv}5U z)%7KpkvDUVj>9C{AD0Wr^Ptz6aFT1}+hAY(q|AS4>z~X^(ovMuq0E0iGww5_{Pl&5 zbp?#z!A!5&R!gkK7WZb$bAg|U=IvtH>CeXq>0M9ATA<>#}D^GV;ZaRm;i;2jpA5HNW>0(3f$eF6E@(`jJ64OTa?TX!KHm zWMCsG!5K1e;})KnZkkliO8oJ+Lq$aJyHtSzByaz1z}X<*8V%9`9Ym3wZBM7a;BQDjIlIC+1xe7S@r^qoFtZ?D-|$r6 zG>!8K{z&jZ%Y4W#p3Y~t4Ieq9XPU4(5IHl-GZ3-`@2dbL9{oX2Y2gTR=kC4=OE8m> z=0?6J;cp&0Kkn6vP4yx(mr?rT%>x+wdyi9D@Jaf~XuTPKrmfoAt*_FTJGzy4>81ea zX-`_csI8?+Qzx~6!bJqfm0*>uNHf~6P^^SlHd}z}>~xifmECkM+)50iRxq#X^hcRM z`09twW)E;Rflk`||2k<_BUQR;1Ki_t1eAEBM?1kry!F^1)azOx@9H|C3AN9z! z#ntoK7Q9Y=gW6v2t48iRItWWeri1OYJ+B80-$}JBWd{U3=w?tM9?)QAFYX(qXQA?x zCB-Gy4e(YL?M>~xb9C&%!nJnjG_S=2cWL3847CITy;;Ss=*hhpm@Z;}Sa_xn7CV zo^XP_4*T!(isYOY6}$sJf#V>b5UARtf>96fT6j|@Cs-i{BDz^)XRFM@6LT=fwGzydZFk@i?5p4&4qdanb`@DnQf4(blJxS zdu?`Dk&bUQa?REidNZH+l~ueS&W#;?xYz1vB!`ewkT*gtI=7}8TBW>FhP00!412pe z*HHI3RzA~aS&Au0mPRc)I;A$R3pUFwvR-B|Ly{<9TJ@R`UzulhmQ&nZO$>+O%UwAi z4cv8nkagnSgn)$%o(15IYaXESQ~_kWgK!JI@$XH}QVqD8byY%d4+8HQn8;j3-&~JU zt^R=m^iA$}ea7n84`$?kx^TND&E~YftOlfHU!HEH*qd8_hece_{V^W2M!uZpr+u@k&5nfpFWyIZ8I#TeJ#OHc-It$#HHO+=(ITsSqLW~!= zzYP|BY?Va0kMNZ~^@{hjf9DJDX9N~d@>QktX!{=IZMYD=FE@2K_-O>jWFBOtN?_)t zi+yE>`yKPUpeZ5716d$ui10wumtgaow&cHBm?CPq8t+MVf0z?tq7Y$jlyY9XR`w%A z#Aq-dr8+PXxgytVFZQ-aep-mk?04ZWt5(kWDLitN`&)Za*h#6MdNunH*f%qFB?E4Hxrf1NO2T`TvQTo4vH>(FR{U*UZiyLhh+LY6BoV3FC!*!@B=Kj1W=o`7 zFCab9pjljxV$9Q^$?4=hy!WbW#u=g3S`UhjE_t)EZL2{)nG&|E^PZ5i6ZxH>-5f`m zSe_qogxh=gO>9;6h|?w{l-Ax4+AhjPFRdLPnue?Nk`Kdzo*jMo9*HR6K}Y>*na3SVIxSJ|J*YbZz`2l?TJDPR_mgNez%W2gl zBOY_hEazC*nx`SXo$W+oZqt_nJtIpcEL^*sNLeGS&po;NxxIh08PhW)w`5hmpxoC3 z-mIObqDdzD6idLkc3iiiSi6WcQ&!eVqpA7cL}Vl6sM%5z&7QyOCtw{Jil{3Nc*sek z=SR&t3qLdan}p;9%(3@wwjJ}zz={ z91*bf+}?^tVC%VH%@yXVauvdg4Z`oZu^h15=OfR{hEl_r$_OMhu|SOXB3eH`B5_1cn-dG__++B$f(H+!$uL8>wlBQq}}zD+16 zRgCWl&ghGEnS99n*Fj}&27>86;>TuE({3}4+`=sT5n8Gz*kh_q^xu9seXW`sOXMdm zB0XjgGBFDCZh%-Tw%)K|?(i`NAaDyWcw{Pi;`c_Iu*Ce~R zKJJX_J215Hh$pRgL_;FN&Y-F}p_~6K;4ZS=@>{B8$=sZ4VS@6|2B+b)*P!V2Wqd`` z0&nE>&2BA}J+LAIb;TZVyLac-%^nM(nV%cDG}}FiF|~U0Q&|V+THhx0zFr!_C}VZBhczR> z_h+vXX$mXSY`mwrh9w6vN2i&X@B*PSYrvRBaS-skAX1gC#pqzKnwG=#@$GvQ&Yl_S zN#mOIB1`GJsmA7?{pMwkqd_#S_|B^*B`=c0ZcOW2yzjod(3C zG9d0)qONEFX1jcTRK|a-Dp=)IeSbpu@;KX=*=}zcmZ=IdxU{0t_wj%ihUcQE<5qsB!7KT#~~4nOTjJ?VB}`Y4desx zukXkvMKauufAL2>BWjohi*~N37?O|ZuNCQhGbOD2h8;BSYL`4?8K%E=Uvx3qwpN*X zlWel*tAFxM=9k3nJ$Jz$FcVvDJ1r4w%3J-134@Prp6Q;&grV`ivteoA>^qM*%OT~p)^`RDN5fZB%fIx+ zthB_$t#EG;Y!*DzKg06o3wu%};VOg=}e>4QA`@*wFnZ%gU8#XKE3lU-L5hiGy9Mkx!H zpuOt-^`wJYYn|Mp5mwWT=(H4pe}wm&+HAv865wpQ24mty)Ufk#-2sNyr9C`dG#(P5 z-4)2^zX*p(?W+5#4@D3Yu@BuNIl84~7YbQZ=m%rIIco$*$Ms^yf5)|@=@5e{rBdWC*hhqTLh6d}@UGtH znxsN4T{7Q{8+Is8;J@F4z7Ro!f@?%nRGV-dnW7K`8XL(tKq5Vx;XY+V6{x>=0ZtWf z#DqENH`38^O`^R^5m5Sf9P12egDkRx_|+)lmF+#ygXVT8*t_ES*}m<;yd1N8LK+CU znCDqB9t%rppLw!NJ*%GAkz4}IKNbxN(?{Ej|6*BOQ`FWM^K@%nKID%- zkiHkFvzw=*v8e!gBl!oEOh!E9dcrVw6=a{V zf3Nr`C>?USM!fmEIPeNQpwXhD-4Pc5Qy4bO1;9}dDJLp#9ZfvZ>#Ajmd#^dYT+Q#D`sH$2~IC!*U68#f_mdZU6#fh*d4 zz8dYZFrGFD3qe;>qxx*!S5A7>uJTo|Wk&DIjSCon!^!t_DO}Kl2Er?$C!?N;kFBh3 z!{rxBlX9r8&=4@GK5g89Q#g`uuaSb6?j3+~^$xfwal(k3Q(H+nWQ2Nh!hOVu@CRjT z0rXH1`~9Q^X<@Y4-1Uzc7(xqyOI*Y@oEtUKTdRV1M>2p3TMs(X66t?7#%mfb5a|kd zeW$!iymC7K0L%9n8fuSNjXmjY1bKx{Jx$59VVVJcggs&~6Rw94-4}pXcO~pR4X!Fb zV3_R>#v zU!IEUmzH34Bt^ZV#vt(o*r`{p*kPaaRe=;CP-a)x}V%2fb(0S4;{a03_UO zP|#e`+D;oQ7qx$g-Av@et#bk-e;=pwZQOyteu6ebaZQTN%7wJQ2((uk1@`%An1+$L z*)ZK7H|Pv^keAs7V+L`7&~Dx<lVE~nBS%yXnu=Uu5(Fnwz;L~RC&`< zCeLku&G@{ibGE(aH`MwP=k}8C|3OB`(Buz{o5%t9?D1e~Qi>YQ3)BkAfN|1z_hJm= zRFLK?uM#cf8hL*8xVZ~omo~fWaOTcZKk)L&24tu#izO75*r? zJRX|$khT~$Dfd*N_3{Ww&LqH7l7Ec`k^~UrGK6j(IjK!r4ayu??ccAgQOzve=_AoQ zG|W6f^?Sp2y-a2P`Bv)i;8OHzgw10zJantqpfFDjc(A$}a&v2TD~9^wX-Xg`>=zY( zMW?#F`041*t-Y2_Plur9%bxAsvG3FQjQErHZJD3E`b%MJab_&tweGiqSsP37iAeRX zPQVO)DMYhr8_Sw75r`iM*ll~6QK!~b4AJ6|Dsyh@B_KFzLrLo7kocGZSWhFuNR6(* zKH)vyWVnuVOxh>C^^74pS+lV@dWV8_jL<3-Is{#1;Oc4guzah;zy4DF{#&YLSun|S zrG3iL$cqrvj9Q-|rF^nXl{QS-Ox5-Ts3&`SdDrfIz~J7I9;ue)XQ@{lzczjan-4K! z(g>w!r)ZBz7-@|lII45RkGmIj@Cp5b#_AAL$`|5r97^~X;ztRq=%cx6Q)4icVxH@z ze_BY^={q4xD_dYMXxM$#+3Cf&J&&xmP=Xm?!wei^D;p#=BG_{d8LX~PjMh*=<)fNj z{A>{4xq86xDx&os3R;0AKa9+Ibgud^16-9(4Z|xzSc5?|bRCD-uVF4C!m;TiN(jmK z=_xEy7vtc5g3&kf*=R?WI$io7mzYQSX>{fiy7kNgSH5!ODIt*v0cx9zFfwEW)Fyy8 zDgV{E{r4w5g4}!IG6QHhVh4&xPPTdS@GLhpcnu|VA;KQaNd2vn08pI(pgO43d<92# zr|(1YsFp=+lYHmJtwmt_XvF8s!P@bn7(xFdX8J|#sN4oA7PKQ6!@QJF() zEc~a%H-9QBn2)t}V4_k_Rc2DZgFpF5JZ-uAB{0kiuNlmJKOI{v3+NYA$5!Z3uY^E<{nxB$X@T#^*Lk&o0Gn z*N@x<+gGs<|17Y*3(4u~Clh6LGKrYBG>Ho6tMSuO)#XZ@__y3;)e)5J zH=w;?*79ETvLN8LhJix!wcFHOK=RtWx!!;AsEw32E^RSv2^Or-(hX@?bM;Ammx5a;vOt3JEX8yu0}GS~VFPp0aO>+; z(ey#cx8GcMc_2u>DI@AlOM4zKU3okM$hX_aBj5kgjx4nX2#w)IGbGas3osv>MWzCW zqWAF@o=d;G-9#Tg12GFubSyu*Ul87}UXm0OhR_iunU2wJB?AYkzxR(qh2d)O#%&uY z0@h>mVco8L9Vzp|F6=rF^L1LAw^ykjga10f%e-j#aX85T>+Aw(z^Wtqt#f2BrC7e& z)3x2s)eNc_vOq3Omk|1B`f?WeZ^X--o5W668n7g637b*Cl7I=s(lOPgN|gAAAA4Em z99y=OipOyVpp#Zu81l*}}+ua-v7uKfJ8eQ)iHIzmR*JRfFY zhLF{HFX_Z5$(FK}$Agzg*2@YAhv&niRx_bOQU&*^hnypdS7IjBFTz`|#6Mg$Nr7y3 zj=*#tNM`~g!NTK-t&0)a=w_kkir%Dp!T`e;*N($gBUSa)iJ~hL@}Hw2=JD1-O4qmJ z%!RZC+5UyYHg~W5=!Ryw<;2s-NTb}|BmX)c(k{_rvag}3Q(seR$FFY_O#;V2uGI`4 z9djNvJF4FeSqz3ree!MeLZFu)Y;>`jK!#WT35)|QJ_!E&BL(Ub8FN@2xFLU#V;{wo zjtmeMF~ZgQac$pkkWF^o8Ma9RF2g+P#U5k<#qP12|A2(}=;fMInZ+k^Q6EvbSq^01 zWVWIl^$HDWKOSF5dfd)mT?T1&<$imkx%`=v)I=5gxcp=|S!7_au| zY`48;e00VLXEJFHqY>cvBV59D;06REY8GD&g|&tN*D)^E{FV8SKOx?Fx@O(7EF57m zS)Gua8>0&4G}%Uq*>Mr(IWSn>7gDBta`)um)AVv+qZqaV{k;u!&oloqV3R}fU@0vw zwi=Y{YN@IUDJLE2cP!4elNdK-{X&W?*?$FFpBwejJqeRXH2zQ-8)fU|fO}og@9dws zxXRwFzBs2@Smr_jovBLR$@cUEZZle(jjQY}@x znzfL6YYM4E@`i|E#5+u}%wv&q_pI|r`}U>0!K2aGuT-d3XX7a6nVc`q%!~@qvabS^hLO=jvx@PFioX+_iT5Ox|E%o(K=HTtv_qv;h7-mQm7MXX zX4jZ*V!%C5N(hjQD9iVa7ds)>rUl_nm*1IuNtj&u`|RLqTy$$l$ov|r+^P3!$e_X` z+A*MAO}C}Xc$=%Qn`Qe<5>e%^5jHciOtV%C@P3W#PGf0{(ew)_+^@{>8}QJ>F7>L& z5rE0Eyh7Ytbo`d;^Ofc5Lr#^tLeg1mSb9wtrg)Ydg5lA*L9<|B+tbj{Td1mPMV=Yf@nq z#SJP!#X*DK5_H#03QdBeKT6!)0AfzR*e|_+1ZLJGxH=8`eThgFFDjCP`oyN|BY@ch z^PTU$U{f*RjU~c39#`xx#sNm*$&Yx^Sa63dc6G=RF5Dr~H{@bF>9&rO=+!^jxXTcO zazuChEwH_c=b`?6IRyfXtOu%OM;PB-Kw(}QVO6j+scR2MasEr!f|mHq!h58h85WlG z1-7!FHG*)BFnh_`s9-M_vBzAK@*w@|gRSWeR+OsL`0u(TB!51W{-H=HG7TS$RQXFm zXx**a-pBd!K{CoGV!cY=%`q z6K7&oW_llYcw}_^Y^T#3Q7@sX+hg0x=hM4EeVt8?ThfLwkO~RH)0j+~+Bf?+dseJ) zeWwkj?zyfi7pH7*rsSc8V+UC2>JQP&e0*K?>%9q7Q@=(b6;~eIIOJkW5lj(XfOJwD z3t}~)I5;zy19|@&nq(Me&ONsjuJjBx`tr`Ya?C%GIZn%>_}2Y_qmhu%T1A@hi~Zmw zd1BQ~nv^YT`AW&pB@3=0E$(8giBNNgZX1lZ8;!bfHJ@_rPivxr1sn0U3yB+#zn-SN z-1t3hcV6%A_venF!V)Q4zLw1{LuaIc_ezcjUD7KWmtATEm`^f@bKX&$G>wAG?sOb| z&aKZqdDZINSTHlXfzGy*t|I{z$#*p%XqCi*m}uC)cV@&z1L%HcyNn!N5pd^#(rxvC7Y?PR{eezLk{@XKJ8d4@i&!@>{{eF}mrOB6AvFW;@g1A{YS z6q^DABF3Y@{D$~`WtUn;F~HGNaVr=LaTs|O;5{fX5bWW9N)m5H*mSDQ1 zVCs=$?tzj;Dh~J7{8bszW{5J7Wp^KVM#$$6AZ@T?K}S;3#baezEYFsLz8cF z5ymHTj(<|Xe)0GW4c5YUT^^sv3%fyL2Ajj|b2n#gi@X{%JH199%pAeqw}UU51i5~X z#Ar@Zd-p{GhqVU#&B7u=tJUI$cbuqH-b=`TNLqC%XFgkgw4KvB>CofKjk|wQSME<0 zd{SXHI7kfSp-2pRUM9aD{?>l4SKTw4`!ITJxBL91nA;PWt1P?b9v{U1VDTK6*7SBWi#^s|XN^4;gWm{JwHbEj@RfdVSe9K> zCDcuurK|FGJTBl4FI1m)AoPxeU)au!a?FXkT$FwvKJ^4{A5pJ$u~HnEgzEr^xD$h% z>#EDU-s+vkPaoqT`fbm7SxuQMS^TjiDr@|J0DC~dARr)0>%H4NuJH7N-+Jy^?@kV* zMdvoZ@+FlcKoec15o(l)j#*`|b%u<M1fl$kb3FuL zZmruMrau;F2niA_K!UqlaM$4O?(Xg`!QI{6-CYvgg4-a$WpKjaaG$*2x##?vwP2uH zs;jF@_V!A9_IZA~er4$%_&DpZ`e%p4aO+PX72+l-)*3Q{`4)gCLiOSuMn|Im{OILy zIIc3bVk2LWffEwHj*Klqu+1WB#G50$4bNrI=7p>EiCtMWiJiqJXf}RTWh6ZsnK8?# zAz@v3)KtfSz>FP8of&MhWzCgO^YE37!Q(fCU;FfUuD{duMI2)o5x%zS(j;u{v~-*2 zCG#-if8~ZbLfu;1NV}zYaMeFgR0qau=ZR(D+kVFiB&(7fx~&->dwP=8lT7z_ZM2^D zVJX&t)__Mi0V)W!CdC>Pv+d@1I=Zc()9NWRN1Eh2l%swbo_^?)!~qOWSZy94jWB&x zozrZ6R@^Y2;I}icdi?KWx8HBO_Dx=%A za(iR`8?$YBZ1MWVu4l_nl|zbrN{M`2%bvN8H#Z7FJ?T)zb1l=4D(T}&Z8tWv1K-a* zpr}LcCv;5S7k0l$O$z2!Iw#z+AjOpjcpK`G&FYkm-JHA)=z+g>EB1^2Mf_uX`);?` z8&0u0t07N@(+XtkQBS(&R59mu%3EcquLS~BchEe*jVZStcZ@7L$lGC$Y2EQ==lv$A z{I=-Twy{+;i7ova!Q2vc2SsVYW)kloj1ClSkoy~;Yk%SqM!o(utq}eUHLXAg3Eo3- ziv=|FVV6tXa+ynN7w1ZZIHZ`gwfs$RjBus&U#hn+$#Eg&*^Np58Z@MJ{pR{&+R@Rq zeCc1hd7^PHpInBt&Z4J)Og{rOsNIQUi2+gQbJ*6}lK8M>Q(F-k=& zQv=~2;vpmX@E3zP>cRjcf!vW~H@;F8(E-?6db)s17IC$)Qh6J7TAD+zWnbC$e^e?;!f4AJDmE7Y#Q%@QiCkA$quu@)c zJ1751tQJ1Gd^2dG7Lz}+9@{Szi%&n{+CxFV| zDjBl}#X12CmX+O|vBK_f=l{Ubp|DNO^}U}~^<7~|`uNS|4yFBWMCDlb_p#@=61+Q} zeduEeREMg8<#!{x-^RZZ-GJgRZr?8*b{|rZPD>3Hz#90*$xs0H#>6|cC#@;U)TbA< z7m7t#Uc%O~|8+VNO_fV64t!$g-iCBB1cg%@g3!VIGp3f$2-z{xX?h0L((Z+W=FB|FPo!JXvQ6-kTZP}UZenn=L3WD=%O8_v-8bxAQ ztz8_s=GFR_p~ zRM5KX2SO3socesu5|GEOaYUlj0-0*X;4I~&d`{FVT|(d2W$~Bu6eIVL@nkXS_X@5; zk7yX+COSN@{j02D9{u}+H1@t_=_|8(Z9!-*_5vdu03MOjOj>`YM z&Oa7d!M0WRZd7UnMRj;=9`Aq#@TC)h@e-aA=L%t>@?Y z+kMf+BQxy_c^*>M&nI%3Fym*NG*4m*`NT)Dndv;E;yVGKyU^=su z4%G&*+9taFo_IBn@IxMn97{T8GWEw9E+%q@p8{vR%smKC7{@53rlxD{;WK>Jh=cY> zCvzmCZF>nU_Dq7raSx!uYDI>fnE9Dpy9sap7V-zA0%4<)at)_lqzhpgeI&c{mtQ_QWRbb1;$pWqeWU~*u!K0< z*3yu%`MluSp?*5e9?&aBI?|{HH);4EQaYK!RsuG45wNM1?m2n9m2Yw{ms1k_!w<*( zYv9b50&%wxow0mwBWvf9PGM=0=#v7pwDduVO7AC1pv!X1ZAg?sJivAz2uGig@)oQd z8W(s)<7Krmzszgh)6v4AdIceIK!lz8akYj3(1OcQz^jt87Np+|ykuknm=;4E)jF$bgQjeY0bad8%H7q%8b-2R`?U~g@je?l|oMZR#M{%Oqs z;A-ySvZx>r8lMSBM-FNxm4gv7r`kLDptaYy3@~eqWP)K=M1ce{910{1a20;;J_vg* z6OL;xY&BS_DP+W~u?@%5yfD4Hr^ozxyHu$SjXt+0&^Y*!2C+FT|2`wdXllG~rs+ zNcylZ3L`fOlzE+y(v|+dW$j6Vg3H+#U8AqXQVHuWiG7Usv z<$Lj&DEJ1We0}nvQ;AD3zELX`zfCUh;64;ODRPkoB&qx-DfWMo06OP?lKg2d9+f?H zn)Kv8Qs0N)VE1T%cz!k!A~<>D^3wCA$M_-^NQ zV|E++0e0 zxz;K!x*b)sWfDL#Xm%mmf@K%UzUtrA!LL|J#xF@}VhUIit!eUNNe5g+wq1;45s zJI~BK-9Fy>>I&j*#ra!q?d)&!^b^H@Qh7_b%U0^xpF(=6;AHnUvQb$lbFFl=)q5880-E(niC@A}nK5I!j3 z7Izscmy(2(?@UY`6e9{W51pfKDgc^N&lAg`@_kbw;j7nMAz8GtA{LnL{dMRG7Wy{S zCIB*u@iPec2k#>npQ^wSb|?P0qHBa+et6Bb2*dpQNyG1vz<=L^@)TB%aS&sfRw53b{Vx1{bLNYP zM*s)lZiieN*aM46!kf#X;?h$9l!vrv%_Q%8eh9A0>e#^F$$EfwMdBq*WmD$`nPy+& z(E#TFah)7%+>IJ*9NknCJpMZp@f-}4$tgho8J04mA5PJeK$D{HFaA8q-1*YB5GYfa zsVZuRgHI5W8U;5A4Fv16S^DZ0+WhL4Fz<#|@XD8j4M(!y)X<$-ai&Ht{s;NB18bai zGC-SB%Qo=wGpdD@H(l9O)3|xB@H5xwn%Stq85{})q(VajcO;1VJBnH6^aoTVn<;q4 zqXD2f(HfdJogUsA0A!5=TIe)!e~VLh@=KwvHl>!x^n`?0$DC#2EwBN9OBylC*}%R| z8X@7);1*6fFjgy}+L);D3@fpW zbaE-CHM9v|LxK&pQLyXr4K)V&zarS|Vqtu=(OAgJpYJBZX&tWcf6q?$J}bWg)6%p? z_@|Zzt_?R(BDFNkf*)CXtRTYSaYaWsyWG|`&xj5X(0zyLKXv;C`yXtV5 z4S0TTgaOO7GVFKOV^Sj;UOfJrO#1~OXDPJn0+6#5d$|tCK~k`!kbvrB`EN43?*E(2@0@ph z?yPz6ikHH>1 z1$FwajB}Q9iVOp@23&z)6dP3P&#i!hf!&iDiT*^|vMhwvym@zu38WaVh>cZy(i&@R za~fw<{|-8DQsd^?0b1aUYovc7H(^A$8GHlm0tR3gY?qHHjI$!)FcsBpj6rKKu1HJ6 zObx`$a@9y24a8`A)%b?GSu_(`{y3&Ofl+Wk^XVGu65FYALp^(}tL)Duwo;9%3%T2o zdP3=yE|_W(gSxp-+F{Wx{p>4=p;YC9vfOEqHd2~aclCITT72VUUSz`e71BhS|+6c*{S^) z<*mLi&BaB&yB`oyZGEYsO8Mf~ss>=S5^O678`%{97f{^*(GHKvNMw8xE7+t$V=Pr= zq5w+rEhSFTZ&rsO?Oecfv-_2)gAebbcl8gxjhOHk1&&3Y zo1<440bA%zH|tL@_TJ5~-Dg7Qmu_>8VQsq8!FMcdS6y3v&*iTh&->b;Kz|aO{Y_ozaG3beFOHe)urVn|H`(X=X7aUM;>u>7@{5GgQ zMuNux2;Uh2;k%Ht+B#V=H@to9sd-e&hvy#+w(cDUE3M+*1|a&qSX)YbcN@^YjLn7m zg!hq}u54;#ocVfFAy$A3o5^>t;0L6L20?D3vjbZf!a0{=C(SR^EA9$Hxg7Y$Lfri~ zp@T4j+$*2MsPf}u&BK#)g|nlrR0~Nk$tJ|Hc5pb?{j>xuX#Of>T2(ppI}7N$LNB<5 zA;MSzb1w(xp6@pI;{qevO62nK0P?Wo)x>|))~-)DE=uz|SO3+g^ny#~G~&8(*onrI zo~#`Qh;k1S7#0W{O>>0FgQhrA-cRU0xTi!sA|2md*D(%3J2`EN36yZ6J5ewbpRfm2 zbOa-{A6F8g??Tye)3ML3@&R$fcmlI7;h#P6n=Kn-<)Kt;v)i7;Vt9R_-_=9U6d^!G zgB{0?fkd0QH_-;LJT8>@gvFqbF{|!#nrxcIe@}-VtYzJy=6wsl*g_T@H<);#+dzxL zFdO0?ka#SR4=>SIAeUvImXpl#@e+b3Yn+x7-0j6ZO6D1$juP>aa<46H|9qyu>(Lu) zbAX>8uuks0gn6fr_a-`FDSOPnJsm%J5OPpv#o?a7be|0qAZ|h|P&_~(>)U6=yU_Ms ze@MIS*GiJqOT6mz+eQ}4oZ93YSv@t*-bVVKZ6EAUetBJittWVW0n9n}gm@BJgnNrU zuTi20IB_DhT^@Oq(ZzqM%B7L03?i=Inraej{__kVBEt_EE+~w!Kuzz#@c_M$2$ZNV zFJ{4MC!DE{f7+-CvBtBfS1K>VRvzMQXeR(0R0k*A!?y-~>qhLpz;k?`ze#UVnpIra7{_3#%*me_vJ2^Y%_{cV5YZh0F@^-KB zs}{DFg_J*VQCm|5LkE!#4n1?9~aCuO+*A3DPHv6|F`zoGU9sK zDaR5v{gFJS(Z+a+{fx1}-iF=aUz0oBdn&5(H>{7$(eKZqc3&zejsUt3$1Wy>U+usK z>;fAQ4QznHI=uz`FCWiF#3KG;FMJ9C?vu2dMyG{R!>0CYA@u6xY%=_t+tKr%kPOm}j`_MQ43 z>(r3=LJI{E*xpmcoS09a7s;P^9YDF6S`1=Gft`0TBU3?4~j(4HfP z{NUWJ+ z5Kq*~gJfD^(}faN;x)bNDS-|NM}ptznXY^V*ik&FMl@YbM-wMo+B!KVOLpbBoNd}& zjM;#aIM`u2jdTD?GJO^ZjZyS*+Z=$1++dc@qv8T7SASw=m97gzv;l3gN85TwU(oRp zG5tHQsnbU?0O$^9vDxk_g#?x$#dt!Sl_(b)u63qeUo^t<*(a*yvu!<{i%hYm726XP z=Fy`kLSb!^$4Xos6y{ixSpuCn6Fk@XtL@G@*S`qu)S<2Egy}i*$yK&ngDP z>~z9y8Xy|dbVHJ*5h@Rg+3!!sC#hf_WFWa(U0v~wYF{W2W6o^!-6I?VHJWjj&&X)6C+*GO zb&*6f7CA1$mFjdTwKQGNRb8yPER{Lba^Scz$B*lOP!m(V zXavjiwJon4cfGZ%OOHSu%#O%-r#4G9v4G95F zNV+AevVhSPjS8H;H_jt;jz!iKMR2I#?Wc(x44s?}+5nzRQr8~mGu2?^DWg05WKppq zhLkW!`(ITK34%RjfQ?6jU<@B%;}LekbU*q(=)EBOtg~N!HTgL?0C~+)qY1yFU26zu&80o42 zV0t6~ZYkJ&eKJg*TQ=njmIq?bmd$GI`U_0>ee**O`%v>;<$X(MENK8metdV3;@o&lkWzpP5{$I@otc(NPSo0tMK9&)hd5-m*(|VdoOL4 za>q*aq~9Nw>!9?66GXAhH5A1>8h22Uw!}DmHy3ar*4y{dGC}~_gB6rffO}x$mtQH$ zY2im&C*SVcZA{z1U{n($LeDC-Q__Y8;JeWX5Wwa^0GqdR@hE!JPQXijEBEJqf}@WE z67*aMYygDxK@`}4dcgMc1vmI6J_0EGO!?!wHUUb)zsL}i4sBm8f7LA> zwg!K_7u;KvV(+%Jis}O(+#34 zw z^DmC_9)4*Rc9*>6k^uGLz>S37KRcA$R)PHDZwM=PzCEY&f)Y4THl#&cV zmQku$)#Wf$_*|&)Nz7rV-)bNIH0lM$c`?nINnVlVqGiL8Nbo+8K>#%;rD!a7oW|lM z{2fN`{`TcoTFBOy2qye4o))I5eD+esdmyj@3LUk!$02fZ)LG)xHD?E00h8GOBf@m~= z@B&SP24*&Jhhzh$X7I&RuBrEs^#%mRY-%aw{08kdS0m}40M%7YFStJD94UhPeI3Yx z%a456na-WRZ%~I3@0jajRUK~qb5>DKZ2wiKOmoXM)ARfxojDOb>IIsg;9ePjGOkOvg}XM+ zeci;l_Y0#4{}P#II33`f3XU6_c<^Za+ZScpX?`H~N!}qqXtjA)aNwuS zBSt1ONA(=xMZ!h?5-PlaIcB;_Jm%b@efoT=>)_?AF1V6yJiv{$oG>%YNn#e@C{i)t z(KQ_+U^CEtuVnLKatpJKW5`LJU*+lAOmghF&VF!FzqbzJedXukuU}hPw^;d#Hn6Sj z2uFV)0Be7cHt-eURqqr!*X9mN*cQZo&Hg^~(dGY>_+ zPVlHX$tNz*$6qj_ScGbL#~$?TdFiEoEpF>h`{~!n?O9W&LpOeoRvry;9?T8d$3x>a zVYHv$@TymGREXB8kuY_i>vMFuCoD3};Zgm`9E3v`5uKQc^W>1uEfK3UTCD;=Q}vO- zxIeNW182)0R(L5-QQq0LI3vPx%y}rmuH&FR{!xp{2*72!b^Y_IV+$GT%*}aFIUnCL zaS9_n%B3QI@`1r!YY8KB(Y{w|@UHmYrc6TL=>fOlnVBT=oG^pLK@u`^W*{_V&%~%?w6TH4ZZ0Xr)+>VJ$SmwJn*fvJa1Dsxygvh1~&z=mrLHNzicO+WiKWZ2(0@ zsW>@IG>0AYDY8RQk?jA1@Dh(~4OxfmiUK#o@09X3XPA1?g22hLU})8u^#RwDk!aS|`GVOR+UQ~~piGFKaFFO!To#C{kNj-XtV<@4LCanwzMGn!F%71R&hV*86HO!;~3`U<|{#YLc~^=B<< zA$K7>^!aX^&+SadcP3nKcs>VPuKIo`{NMcPFFGJ&wgXL$69Ud1RpKY6mp6fNgAW3S z69ck(Xmjln11}2Sa~_q8qlEDpICl=sY^S4T$$i-SbSB z@E&mS7f5}5t;fjUQc^^i(GXBRUa`FV89+@G0)@aqgIKJO^{n;xUK#zS&VWU&4XSmj zeFMU)WT=oeu!-4qv0ni9s#V=PU|)Wa9<1hiX+bwMm|Yp9^?34p>hgO0Z1Zq!YE&5P zU;R-tH97^}QGy2jAXkNMxLKy10#cY1Z!L;JP8P{B916nj0~@)Vg!HI>jk#52(5b0R zf3L;Rt*KfR4*`eh>l-xDjv&0oJLpOo`x5|ZN_>lPB&&LZ8maBsvB(H6)lc}=;Qb-x zn3c`1Pa`Spg@S~2pXA*Y&XP0f@}9KEzROjd$EzSu`qpYhTXH$v^txTmRC?kZC=y(Q z$rs=2UeG@3rnDHKUC?IE;I#CQJw=A#F1}x?`#5>i$(D*pQY)#x{W*u7C4hAy=zcxLuXP0#2`>!XmcP~Z3RA(=WN9qNU{b`M{O7X6ov*JP&x zg;NbK%}RGLBlT{3P@2V3STS=!?-z#*g^~1B__7ax75s%yyQ_(#h`~(L`9s1q5Xw|& zaMbkuL+v>8kHOef_;#G~MVHDST2M7GCk{ncpKq&v=+_wz4z`M6L@~!~%SbNEEP|60 z$KXq>@*y3TQ{T8iwk>3T5dyU)G78O5~UtvpWOc`pdM;LW;Xm@MQq zv!s&$E6isk8XfKFJwlHIM!2cv2e{0Jx;Y5#znJ+>dfWAlg>h%d{#wzG9qQzM{pwMY)+dphOJ9&h-8+2x;O#8&zNEcmxh&ELYtUF{>q0w!dMOgm36mUun`a}=y`B0V!Ut$ zRrw|+u#&*vOxfbNmuht(VIdBY+mYr9Pw7@1q{kEVy8_H>RpgUUwM*#A5b&Rllf>Z* z`8Qb|XRH-;Q`4>pA)!XP;I;`%WXXPZj$0!p8iS{?K2b{66+>c4bEdaMNvZPg3R6sU zX(r~5Gus}GYJ?75+n)6IQg;5WdUI{JXmz>bSJ9W-@Gr&*S@*};TqD8FqctT36dWXm zGIk;;B<_q`cD-sFr9-#0AN9{?M$>XhRN7^CZc@gM zl%{hB??n!QiFL%G1>3cL;%$dlT%}d*KM1=j+o_p$-OBls>}P1wC})(EO3iMHz>kR? zDo9WmuK(nT8Z2i#U;5n=l@_Deag+iVHyB|jpw3E}{8wzf3i+=aWC(CtdR`uk;Lqkk zb#aWCPwT7QJFM@jFB00x=x0GSIkXsc;`aDR!JAg_&R(Qml^ymGpoub$sztp;7L&$k z+i?7=->JWz)LX;I(zQAD6R^Hc;_KF$Ozvkkb^3pUbGA*Ry*^%G6hAFPW^`w71;kCh zU~5Zmtw^OG4(Z*hGlo5=cC6u73HK!bINTie6f6wQ|6tpqix}3*t%tJ4jRV)bi1rHs zI!H@j__WAJmEgWF5*w{R16S^8l3(!~M>Y*K;qsU3ycW{4Hn1>S_F~%mP@q)S0XtG# z4{(q@I}F8==zdEKz9ra*+Qtt%37<~TMAXFE*7J5okYm&anYO%-G<9u9O?^UE-dWa4 zQVd&h@oGG6pVdF3)ii~FPVi8+8`o_J z9jivh@1SDLM}@`r-*NN#;LDlZwZH#NB4JK;uk7$@&G_c>b)5+MmLq9jUsx}*p0o7N zT0bQIgDHYFrQ5|57*}Ovl<;q)--w9gE0hOE|GF}|8Z}g^1|S<- zn%@BAM?#>yhorw#d4qMk-}V>DBWs4|NF8E=P(ZM0#4WY8A8gwWDmA(>S{KozY)D(B z&~2(p#(7=`KN`|`(TY+EE?%T{A`R9*nkc{Waq6n?c&nid+?{+redx>mFi@~g_@3#u z2kAWaS-&s&78UCP-PDRFB4vWx9;<3QqP>55u|A{kC}Ni(P6|Ah}?Z2h#u1xJpo2cLq;zXzGDY z$l8tu`hdT+qfqPrfzrQj$=dO#bZ@NlWgyOP zJ80w1!8Dz!t&7P|wqd89sp7=# zNnYL(My(+==+a0Zn{pDJW`_jK-J~8kbJ=uL?+HEeP+Tp)3Nm-&pJr>EBE;O12TRx!Q8dF*-ZweHsR)(*Ogqf?>P4Y{@iCxU?kQCn4lQ!72saC<#c_Hb)w zl_QWfwceTTi5k|I3`N+Qwv+DhwQD0;8ZE}&n@6>`HOOUrjyH7VVu~0Zf?=jWr#x(K zy6)sMJA@*3?#LZwnVl3qM3xkG5s$4hIGXOx7z7xLU{CWRpt8znGfy!Y5>uG`;A?Y_ z(nWUD-kvjvHv-1&?=Ge_)H{Rv1vFOuabc`WRWQ=Sw+i-bQQ`54d)WUH1q!oQWT-L= z=NEuKM`?nzUcQkIOtr2rJD=$fA}9ir(ZGx9h-Q3=^q-b^$WH*9R?k0SMt4ZAFw7gomJ0br&Jcs`fR*>liV%+j;F8o82>-~OveF5D++jid8!^|E6Dw(%_}SsB zkGI78&Jc#L(uf~ta+HA6fO24wXoF$uDS?L5$eP@Mtf?#-AMFZjO@r|yq~YFL3S6s8 zFPh4hTbWWlIIkL1t@3hw^f6?b%d$T&w6HbRe{vfo%x|(_qR#Df^@x9kXWQwDS-2K{ zxcj4fCF(O|+<;6lzCjmmZX(G%Tls#|Z>p@1%w9QcC^#it3k$<-(30a$p>VKzAs1&3rw6%}s-6)A2jP2>m{kNCwa@@t3}i;zfKBC}~sa zKb`PE&`Jy#W|JoyIY}(l?m|;FP+HMse@wx~%a@tG_($4*<*GskZ}?OJ9vAqjSM{Vr z7wCMG;FarFeq^p9G1ZN@wGvo8bahnTQ0@A&c-3a~;v0N-zNsoAH0JFOe4IF`+o~<{ z5fd zCYRTfyX-g`UPWH@-%DkkW09WbQAL0>-O+|6;p}v~P|gW8sp zcg9-aAd7gKE7Jn?rki;cDG=G3g*tNuUXG66d}MFv)E5?3qB|{A_V!kyLNQcz##X+? zKCyvWAVH%aNvGfoHM3YM&moa9hhfvBJ1woZ-*n zYrcwg1=akUdovG63%K6TUTtcs?X6AyVuCcs69>T`ZmR8Fmz@1C!i;h6xu#8v5hRi^)zQIu6|cqH}|$=1(+!7nG7* zdBnz{NUV$#zjNJ#m)O%!nFR6aEgHTHf>W%>8-wc5Klu}XWS-6zM zckRZQ1l-m1D&ZJ|+ElNl$_t~{O#Mf63JQBOsF)#)8^bQxD;CVJ2t&`WM~px%!0GT# z_T%g*qOY$+VdrCFzl!*^prC7+j1CYRA@<^zHr_rdag^H?Ddd74Ir==cNGLDs3>a~X zSd(U$DZq$N0Y;qlqDwzR-J2MJg-OzU@z1dx?PcqR%5z)qy`aFB9rDl#Q7z3|gujr* z@+4`)VCNM)SuZJaPga)|`g7-@jko@$iV-u;aCg_YB~9RM+)s}=>1)hzlr@G{kMC^m zh%s{M(9K2m1N0L(aReXReT!ELlRSqn$f6su3BNW5F96|OX!>PtvEjC$iLVhaM5+2` zcOX^OzGW_(Ad>c~rTy1;?hTLO@F(%BQ~f~VAfdzFz|@aNZTQ)FFk|XGA@82yl)^M< zd8jY#DFAcn_05BRb9NCl+MLT3no31AD&qbkow< zTbJV50>>;Af;zo3b?izEN#E}aYvtkh`V!QeRjEhuV(0CRcCgWj(Z$qW&_3we^83_x zh%nws_rvngi@@vh-PtdJSLk7$owQxj1KoyNzg_GH$!_2E^`8#ni1AbId_YZSC41Rn zCifqeOg3>C3ZP+nmj18oJWcmX3X zce8D2=NKyH5zgP>|1|brF3vpek5*0W^2eimC6p1k=v{ui~iy@-5CG?}9L z3bX4`m|UG9?UZQZ`Kdz&&!P@?daF_gP>792vF_F&{L{=fRZ)%;nK*bZNCctLdh;EQO^F%RK?PLwXmR z5}RTw$~@!Grh`F$ZZtqKQJk&oOtF z2<#2n1#-Y4y+sHqF|M*x7HDCYYS1!W-ZT*1lu>uaf=r^VRad|d7`;2>HuYVmzBxHE z4mQz5)2ueaHXrCVgc`#;)R~kg`ucA0YuVH0{6_2v-9O>Fu+g?@_5dA>n_IAmW_IAy z0}xiQ(AJP_u&zw!yh_lDk~6#PWsx_RTsb?TMVW#Ux5OuPUK>!196E7YGpbx)RsApX zbx0HQSUWdb#}$X7qhZIU$}hDP<%X5k*@N1`Iq-P{b;o{QgoC6g$nL*g(RCpOTHDK{ zx*@KnUrM;3+ODlokY;UPbLeNRxnu1ZDu9?i38_1sJxDVg8cH z4UOtDCUz$rBn6RQ1)qZQ{{PDqR(5n=|$~~&Q zX|N+Tn7usaCFZ}WZX0BpNq%DQwnmZ6Z@siJT2_IwBK%LLv5lD7^R`8sMw(3)ssX6l z*hG$Jg}q@V4cC~|d`Yk^%M~4-Lx|(72-GA=KdFSHrNQCYIGjT}GX2Za@jd)Tc%KaB z#<`l@f3vi8!R5i;l1cSAgV02miNmp%+M!4uwK|vs0)N>3Patl+$pc-qvD7uMOc?uu zyY8gH+t>0mdyr0F4X4! z5o|XoQyOL05{=QROFrE~);wFY6gbPLxYHsGCMzL>a+k6M#InE2VIHxm=7Rt%2kwl4 zavm9TPn?o&F(?KiP`t*cgs~VOG4hUt6-=_W$4TxzHQM|=wJ_X-u8W~)UhQoSjHEr$ z18FBe5P@Fe`W!r&)6Lh;87IM0VVc>q8OsIKjcGHWeNnVcpvi23!&=Nw*3L6i zBwD26QeQeGJCdZwV=79BQ1oxG5p#Nq@Mti7@YZV z(LX+t-V#D>At7j8rJr1$Bx*z{Z}2uGrOdgE$;eqTty{_6gf|35<0tK4QT~ZMb#wbi zkk<9W#Z=Ub&T?(-ExpS)l`hI*fmhR*i?`IeZSDo5nF7N>}oFuT*-rKlt>lr@hbHU@Mkx73%h z%8BD#u!fPzX#@Yvy7EsmVUfv)md$A6VXmB+C3{jw9IGBcmfZhjWxKhF0&7|J(m}G@ zOUn$gmWz@|FIN1E-m>%8)wRnKlGKH6Of?HBPKgOuC+0tQ!JHS0v-D|r8Q=rGApIn*>g*8Z7WRm=@nUh${V z=X?SA~Rwd8x#=E9?5rS{>aO$r~W!8_Ut*842+WERL{zBx$_q_Y3{EjEQ3HPDtesO`dh z4XH&P+l^;NGfhOI48=?S1E~cv!t-lMK}vQN&c0OrX2gUI&L{c*A5(7`mc{n{4=d6s z4Fb~XO?L=LcSv^$NOyOGbc&=P-AH$bgmiazcR$h;*sOef9`B)Z^8vt7Q)A8nPRZiL$rW86CNeGPSeZ7sBY%@x9u;@hwpvijg| z(U0duJGH^ko?-f)#aj$=0_hCp0?-#WeW~V@&a~L!PT#gfdHK)^zq(8Q`_kjb$|w9d zdUTeGr+Gb`ctjeukFzaB(d#I3obV%@!JCOp{l)or0;zLLyl~ zhki!!X-C#ciS@~=hW}VPgCfLUZHc~1|BTsL_ zzT6L>t_TT7ywDiR%x4?Idm&d$_p?Cst4p1AQThB&W8rjV=2!qU7KK1#k?p=>kMH5s z%07Zh?n6^lOr!)39HJy13_S2VWB`nGQ1CpHYFLN+J)iHeTVly~4|B_yc=1#<0Gxq) zI8ic(?`gL6((G-=dW0YU-j2MjD3?RlU^ejPRc8k8&ZG0S4%p9aPj?I(ttTwki`o_5 za+X?W5ll%j)=Tgg{4-=0(vQxT!2qc|(-MZ-s0$86Xp2?-PTz+6s8}q%H8ZtT%Q+(i z-?p2O&h~=9DUnLY`j8Bp%32*l;je|q8jClf*kH6Uh-c{$HdNzl#n{n+1NWT@=OBFl zZ;}jfWHt&&n=ICS>Ge*x8?G{H+O~~oRy?(HawRR2o(E4Ym@aMq7*&P{A!7d>29>hf z;FNM(GkgZ4joTOZZpH?E_oqy9kf_1>dC8ca=SG6&bZbc5Q=Jp7p44rIg}R{C z40!Qr2oDh5tCL%QNTTH--~|Z5!gEBr-O4Qf!_^EW#Wp+N*~5N(p3Vgf+)7MsZMRj8 z3KDTl(*qZ{x<0u2D+1Al zaD71qzluq1lvk%ZRNa*s8cJo9Hq_e#i3rl^B^HOVoKcAh08I*&ma9tev(X8 zo)l&C;2ebQtK)1agJZ7<9DB+qTAwh>b@>K->c%28K0oDKoL%tVZmE|L;KB2*U7bC9 z5AL-aICRL59l;q&yIeR(B#1w{_Z)k;(fGHWhlG(M!?rX@DvJv(P!y4?T3SOrS-^dV zx-#RBF}|pbp31uI%pB~BUS-Ec_GUN<@4DWsUA=3d?-A-da`(_m>=+5(dMtm;yx3Zu zW+d*9i>vF4bR~zHi3mGyU83-%L`TZPW&_N+iMp!-ctujyQg*`S*4^ev0*BU_{!FA% zNXAJSzd6mBX11TRJN4^{hJZ98FZKJVlHfO%u71mkVlKrib8FqD2sS29Im=X2%%EEJ zHntkAuztncY_y`L!5O2j=Opa)F1;~JRq!B~XR*NgGO{{MuZzsb`!~~zk^JXEdOJ<0 zt|hHv@+>`0@KYvHuFUQQxTzo{m>*w7tB^%?;Ld=j?yJt_44yjFddg|IoDc)a*u>l?RskMm`i>E7GzNX7np}xz-|TD5G)6JcpA$uWu(XY>Hr@(NrMO$+FvRJlbRmN6mn9 zfHe45P8$qZ{w+XlJ?^qjl|d9uOYUaEN_3eSVl19dk5LX|c%z%23=M1Obh{O#p5#*? zPn>p0P?`EX0<$G{rbMYRxXERRoK|{*Dp_A!F$LDW-nn{;>St+^aaHo~!135H+)=f` zfGr`Er=-Of%5= zy}^OkjvhhKzc@nd9z}Nd{=ocb7OvsJv4Zzh%h_Szc%Id2=_+@+CY7J82Q# zwxkfdG?_bT6QB5xOl8r)5!O~1YNUN4Ynew3iCTcjPkYP=m9J^T&W$ zmNnV4pqC0<>03rO4s75PZ1>q&fe?4JYX1|uGLyEoF{;V4UWM57_|3#MJveD_G9O34 z;$CD1a9#j*sfWM*oyK=o#YO>?ovydb)4#bX5@C?S8Jsb(jXP-5|EWhIIaLv3^SwPU zvEo+>Gb-p5Gca%tV5u#XPb~k6VvRPgj-;ht4mX7DY=1Y9sfu|vIPm|ah#NLjgam|z zPOs6cijhJODvObPN{_z{4{KrtvySQKsNs5hDa{0xL6lou7M&D#>DsY9iV(Bk@nMIX zV>UlsE!~a;hmE&h`BQ3i$75E9v4`Z`>#sfcSm$N)lQ_>V$Tl$g7aLt^RnR>5!j1eY zmn9vvk=uoYtuv96{xK{(uz=$B7LCxRCM0ZAFDd6)JG=!ym1hl5+1EsEd(xM)GI}|3 z-Hf`_IjqPBBKzZLI0)0U7(5vBqEMJsbQqz#MzJwVZPCVL?~}p|%v^QRU5{Knw4+r6 z3o)8kXmREz^Lg1y;QL|Te1LM^>HPqOQK*Ohxu1Sf85*ai#V7=uG-$C?U$mV+uZT>) zGJ_5(Y1dU$5Ub*wZydI{2w=c1kyaR- z|6uoDPw;XO9S{-pxe2kHVhbW(N97{CvV_b0_ioPq<<}8;4O1(SX)X28etn=KGm&6S zaRp;3^^c_w>EQsEt{~Ft1}{sFb0U{G<)vgK63l}*HtG>(*!-aHXYaATpC1)*IKJeu zp~S;4zHazP@oAxxIlLRMtix`wA5e~8g+w`Ic3l!V429IyTW>R

P!>b<-dy}l;N27%|BowEJ&GyDVOqJ z<<`6o7KAZsru5$BaoG1@3tQz!XgQv}%8GB+{nGU!vGA_?6HlnB4PyS|rO)n;QeUz! z4~9K_n~)s;by>;6m4i8})zQ_Udl;R*bW?W0%4*;XL#h9?*0L8XU)X!aX05Qv##8U? z5J0vjR)5^|NvRx`|ExJj(U6(?ys){6(WPgt{sRm{$ttpi1dS>|eYIi)8%ImY(@mzc zN@W?*%|X#(m!Mb>+p+#r%H=}(doHOfQM9H znV!o$fa#RQFJ<1y>r4+i6RK9d<9YPsw#u2c1u?KzQ|~mZMFo0eYA@tFbnIw)I0@r$ zsg6Yor@PGM#KKZB!|HKV@nx158{&feu68ioBkqT@z4l2}{J zV-qj5FWWO@IQbF5X3riQ*4wiUfFu1>Ue(P_l_kcAq5bRTS?i+J2CJ<|R<_8?_K$#< zV7KZTH1w77pX+K_Ns)_6BAMGP(t=nEX#aOjysz9234X%LD#H8Iw^dN}#U2<=CHB zj0k4$&xnx}e0Gu9-U^+-$D$RA9kIa*fp@vUiS;dbmkV;eCf#eSYr>^3R*1}}wu!7J z8y}$3DgQDfK-Z*nyqV-jjWpPnOAu)>?jNf+H!4BYcqt#=(nXAv@krW+7rL zXE{gS-pbT>#|F9)HA4VM;~mpK`T%i=j!#Bg$;sVd@(w~17kR^3?ZVj~?ZZ9KE^Z}k zC%xi{1sx5Coj@@DP@vm_)#UXTR%3)|bAl0&;7%6+0)ZdYO<6?*ktW_@%xpDkN4ACu zV~H`om9b)Fe(o>5Rid2sVTf<7F(1=UtUl^BRh~hY247s}Mew z-_ArO7aHMAAh1Hayx+HW!otXqRxGdaextB3 zs++DL>aaaBw;Z;A3i0D*JBeBdfnW0p@(|z65jl4_#>SX~=eS4YO2n$J&CJ2kN{_DX z$v{`uV!HOr`JMUQeLCx`&R+_@_sl$IWzB+Ls%=k>Nkk|{4`3ZuW;Jh2ey1J&OuG=U zeYoF_>9#;>B60S?YQBy&0?@j|k!KR~vxBH6ar!4K@*chKen=rxqLcw=# z-*#w7l=@XfPdt-k5JH;dmk=KLPGLK^a#Da59RAG{0S=}n0VTs}PD&H+R4B2)Erd#v z2g(QF=7V+r1pE|Frw!o5`OmIAvWV z{A+^P(VLjReX5Jz)O2JK=8MNCMh`|{+7EV@`_{%-HP?|C+QTCg&&7)aSd_kJ!f=h1 z%H%sIr?4z!Ru@PwwJi4`CyV6{M6LurVnA|KRP%04*zCqS{y!wM-Pq5dIO}S#QeA+) z)}tU_KBMNB_RRf=NqubPl?cKdfnYwl0|lVjXK*-#!I@!slvETh_v)RN>C%DpAFt$3 z$HK0TN2~l`5hBadiGqO=%fSb=tK@`f=uxwYETxx?a~Z9C?S!Aphi1A@$nnh@C+(~y z+R@j_W^Pi+)9d<5VneMoL7~=p#!EMyMP-*M23M!YQgt8Vtk$L)1#u|+FB^zO(lA|m z8%kcY?=xoGp62h}dkBX&c2FeFuV>IUDl%zww6Z4>6rkGLEm0*a>TJmj)#R8tT;%#i z^O^NM{+giYipL5OmWg2=Bo_ZHa4o>jMIbv0+TXZ4*|>J7TLxL%#NLbMWbmXz<4j=*B4G2PYJI&D zzAEfir(;#5g5NxERXe-unGK?aKloj{fp)RI_LSAoMf0^~9UtJuOg_kwT#)g-bzx#O ztVC6!{p&3%k|j=>y!ZV0&26PT`N7)kdle1)@o1t5jS@5zxBr-+2iCt9jNIUp(vD4ShhZG}!kXiZ+Cb1@Og$T- ztVj@k#pdOoCiZ466e`%3ViA7L%f;w;Dyx_Hdti6i+5X8UjGkPIxpcCaj80>+vy0fi zL;>7xsQ=!eqzLNvg$TmTCoW3bdL<_piS?==N{l9EME(bfGEr*QO$U~6p?8#56rpTz zac`3PdBnD>0w^)UYlv0I2Y4i=ojyg8%w;06OJu-T?!Xb!3QymIpnsWq#b$FJM7hEwVQ zg)%!U$O{GGOHSkmytb@KU|zGK$(NdWwvce`Y~rTq(DlOBpCt!dNASO`V{jS#J95lb zILuRseLk{$OB^B=GGPvrFagR*xtpi>2EB64v~T?Vy-K8efA-8(mWjU&7h$2D_G|-{ zYSDs_WzvgzosJjp@c<^yw;#`))SYA`Q@^q@(7hiu;1=j3lFhpkxMd}odGAMOGsu`_y^l-Xf6!ew5H z`|R-dmI*}0tYf;I#)jwGn*15Ud9vu_7b_jrVLkWn=6O>&(1YI3ug0y7RR6eNNA zN^`ZhzbH)cDT>SD&@iAB{&hs8%ECr*DGh5FSw)W@DtV>xr~dFdEWO!MCgD-O#t)<7 zBT!<{5#VGf90tEjLJ9ez=Qt)fC-HUh_=0{0r5^)v1_e%<2IrvInoA4JxvsXptqR=s zlKy%;lZBgaAb}a)ICj{eT(VH-E&l;W7{gPW$THtQA}|**>)OizyL0JH5x`7H-x4hK zJNXa#Yld&U5Wk%HJR7-H>e=zogISgaY9*+Hsn^1=eGgZ)^=pph934Ht#bdyUB=Mf| ziVhq86w}yD+zvy0^>fN`474i}F|9Mo)PrZ6)4*R*+>e$&Fo!>Xt{X&ukq`-q$RQJ> zY7B_Q3U_jqKd__#@`2C?*0^mia$wx5!==_B6zeTr!Y*+lIwOFWek)Gsp&kuKp^LNu z8ecr|LkBTDH47bGXwI$1W~;o@@|_MLi0zBjg97Aa!0@T!V_9orlfK&VNnNVfRc_Ju zHnb*@9O{9r2a&>sHQt=SsF)UhirA%2`~4*Q|EYLmj@BXsOw1ktPolVt1n8xp=%wnJ(k#ZQ}_}FRxY_v{oK6Gs-uehjJFEPAk{Sz{_6cCLyHcHl9 z6^*6H#0oJmG|eA$X=9Kpe_50nd!!_(v>zK5p}nnE2~TEtH`fzH9EWGMhShVNy#BF- z2ZO*x`285ofQemqXZlnauA| z&&8)k$omkz059ZpobhB@X-hFpA@j<)C7B{}P`#Bhxku`ASa_yAZ9x5y^+8AZt!a|| z#Zwal)1+dlfSW>bzVkh>4a@oSQg3EYyiy$vbn6}G%W@-=4+^MNv_*&vu)+$zV#hu{ zBn69;;&BnvYcL{A_Z&U~M+oL1-_L-w~C{;Rq{< zm&?{-Gr5C|*qiHPjGg4bZIyu8Xh~u9Ovr~+jklfIkRWP_dEqxDTAukxmkg1ptxsR( z0i_txIpNqVt!qk7B-jj87|EpFV`zoG^{PX%9PWksyG1<=x|uDy zx_Zz)Eq9go*G5(I{HJ;+y!<@(m9(z4%8AMLilzKO?VY(@*mXvG_?D!)A$pSe*D_Bp zW237+BJbb%>69+BI0o3v&R+iXcca%FJ%KAB}h zbT%QXKbV&hUp*c+8NjSTb7{+Ky?^~JlGEmHsgsELGRxNGI>TIYw@ZiK1m2}a9q#7l zaUZ_R=rpUI)~BhkBg(-myZW$$_nn4{I&oaR^)b8XNsi&>Q9>|K{gSu~NobdI;Ba1pi7CmvrflT=Wk&d$f9%JLc;DjJ`zFf9d5&OA9innkM-&9F?BX6| z;Lbe=T`ptVkyou5`*kNmJ16Y?E_$3Vk}{>ZjZ?-UU&Q?YuML=h^TZ{&SRy;Cf0R8t zn&**MGWI)O{cuVKC059kVV~*~#$IGRQmBn9$MOc@5th^J-IPxveowPAJa z*w-y7udwgvP)QBEZ*=$?U49%R;^e?d?M{q+!5}AD4{j#o;vjAl{e}FDu-e+6uddEI z8{ChB8Ygw0@A+bCYWzwk|A^O(7P3Z0{&si|47>k~X+DMA9s*^@!MQY?=Ec=oXtIb^ z%^%=k)KOr>^o>2ToS%#v6|dDS@iEhvB0n?D_Y2jzMtLCmWv0vOPV4+;0l3hBLmr{+ z)@U|^=B6=sl|p(~!sFY0OrVuRG!>3f?ekluE=5##4swpc38pA@RJl6ejA02~_fT&& z%7LSgsj$*$l@q(R3xC?ff(Yz*j~o{2kQhdUQ}67@R&*BqYwJ zm81bD$l^y$Zf54KEq}9U#N#%Vo0>Om1;nQO(>wB;>0jowG3W$|qq4lS9lb6W#T8jt zzUvalDcD%gi=31g1|FNt9IhLG@W!b13YB0mAgZ+(Q1v{VD6D+`>?|vz5wa=gEDKo- z-PFk3Y;CbOz?z4Uwbi>{P4wLHCEJ`F*FBzHciPa)hRvH_V6(hegLBC&m|cWk2w?h^ zS*yL!bvqqz(Q;9WHDvuUcRANTtTgHFbg!m=soGRh}j&0 zAM00oX%`8y+J+#^a7A=2qA*MX7CXfI-iBlqKalssWnj3F$~C4wCFtp~Na!r^?kkv} zd*ui=PkW0S&j!=Uo5k|TviA!)sIPoD_Ayg$!icH`Y|uK*J8eeR>Ti0Tij^em#qU|N z100>2na{2^9Yf3W1NB7e-xf?Q2-#-4z;?|uDfZq3AD;E+HC>SwawHRo6IGr5Z|C-2 zUNIcBiyi1h$OTongk@Jg(*+jGV<`!K2o%Vq*?SNPJ86wFgc!4GOknH`KmLAiT2^eb zVIAe`{D39z)UgWPWiB}B&2+U&jKDz;lVblaS5V39u+b0Z)!5++2HpgF*R!(OBJoZB zh5*7i>2)j;lp%4L;v$@?jZRa3 z^Bf8V>jMhYXD@QPGs|mfRw<+KX+qbBo%m7o7uEb2MBiWR*kLn2s$7z|`Y1}=rHrxz z7RbAvuFjUu@7Em^%5&H1g#7Nq;%W(cP0b|4w-12ZYM-94NFrjbSfh^ZpD0kR>J0LW zHf%r7Ev_ld*LzCh_(urXxz9&WMO5V`po)C8GMr|9%~t3q|ImJO040Or9bz?9$Q4<> zlUbfrzQTQiv|&$$@Df@l=U|E_B36vZbtB(H0V(#a48Ir#iOE)vo$Imqsn;>x4oIeS zpm7y;A^umB2YYmOS0(uLIm0uSdQ!&-vqRlyWM_Wx)LRo zys|_2jU|fDAvip2{$6}?t$qPHsV#6Qavu1<^QZEdJ(J6#c8Fz$#@UoU%=A4xIH^R* zj28sW+k};uj!pQL;mDZPXuI`gwv&8$q?_0ku}pj}8M%_Iu#j`)_jv=Ns-Ue3Wj`~I zp+dEAQ@qxBx-$4#Y$OA>D~HesnEr=js;aa~NVeVIm)O0(B#jp&KaTsqtBn6+`dt9i zzY7l2y?;!<$4au)W8rxz*#P1eRuLAuh}1itZPD`S78NT@9m zMl~>u5zL+?xgJk5RV;xCF*Iq08(2pRx+&;FRhBZ%Y~UFI|Fkv!cKUQjPmHw zS8^L@aje=sYGU|LY8)@!%99>``0zd-9z#9D6W10WHNrfed;Mv%UAX>A+-+dn=HGe) zB(c@0L8P5Ui1MS8Ar$pm>gut0O7%@_6i3-14(w|XIRbGDilO!{P@Zh-wl(+ z)ezJS2DtWL&>4Oi<#p8s=-^M6>t;}A?LN8bO0HZ;@uk8~K%|MNw#s=;HysF@js=X0 z7&>&1l)7Ng3rLl5ugpokCN1{b)sTW)G!@^M_FD&RsN}L>q zfs$+d;i5aPl{)E`op@Sa&cvYbK0SUpt9+9%oP*@!y2KP!OHvfV9(qUk;K9t`piR$l znfepFu1YFF)RO?r_olhMCCJYX(U#K47`^O*Od10ZK6x=`?{YNBf;!tlK>iiDnEB6( z3KyL8UY;MK>}J9!o~&m6%Mw|h`v};Cf}5QTO0OHp*&*eoyqs9P0O9`BUpC~cP;?dI ztI!=~f-6lPsseFni^&;Gc6pCPQV}4+$gGgZRw_40DsyE=2amUh^$^g9N=wq!m@6zHj1fy7rEvEa~-8H60pY_^x?W*f0RL)_F0w82%CN?t-v zC!f43d!?hyS_IU@g&5hy6rzR+J_LN^tNYQn`~5+$vZA{2gqG+f0R{K=U<_hvmcV{M z6{4R1vzQ&qWCchGI)Rh`;Xs{XLmfy7N&sA{e)6DRs3)y|^o&ZMG#YXGecPJc(Mkj1 zz?|TRdlwXidiWmyLjjo~m5lhISLXMbi57C5! z5ECWKC&WIDaaLn{x=3U<1PNe=G3PcIajGCXD~ZBx>vO8aY@_O`fYlgIZz%$+;ozgI zGJjL_`5I~@st1;peAX$QXC^7}YngNO8k<_5#hA9RQ0BHdGiFM0qVHYOhU~{V`^M)Z zX*WC$<99*#B4KwT$F3#xN?sEFjrT0=3Tl1HLQAxwxH`@FlRr2nV^4|#c`y!;_9dt+ z1a(S%g>;Clp|4s+6Wy(qH3WEZ%0+!#6kOQy086HDGsljN&g#drz7+rSdGEFbi&qsk zd|lzND3W6ujHr0_en?BKD0ixkjN65FH`_9HHG@zHL zJRS*=df->yZ%{IRI#hQ}^mbAI-}5tA`tSKcAB0-TcivwKS85@Y=p}`ub4*YV4D#2D zCl$?rN>yuC9-Liyyv{1Q`f4hHd*DyZ9_q6acxn^rPx(N0=;-sTG=G!%dBqAMDV7W~ z!RTV#6kJ|cPSW;sVQDR}o6tu9+V2PU>~J+@BY7|9@JAwaeENQi8cm(=#dg1ov9WLw zdz&g(&WFDs%(Se0NiZfa{jo2MQ9{p`GaHG&GBhS_4+OJ2o~ZF4n1gNed&o;H51V2? z2ROO-d1u8c)gLn4Lw}>jEv01x_etD?oZ|kB8*XJpURaN2qV)4^d69=)K=?2i?5QdEAud!iKX%nR>&1vBdaB0%cg;u!Z{k>1$%*2!Z{3`E*aB{Xph5Fr z#7K4e@9($|*u-WGJ3d=4X^bJMH52Y1B)pCEH{}yX>1Tj1Aa;rY_yF&4R6$^*qvvr- z{XaPi0+6$0^9>#l%?X=H@&rACuAkvGDoBl-o_V`8_b)Z_sy#C^;rc0O(t%YvN!0Gr zNBpDhc{16UX09NJ%fKq=Nt5#X|06^8Dyd`=CZkuQm0*wH=7{3V{eyOZD!mjzE<*{? zO%7&0K7n`;fAVLTP=-=HA(yKhIM%n?=N!O=w%Rjy60SeyPlA=v;I*ubjbH#m(ygNr z^29earpOwHWvJ6dumE0|5~SZ&MwuKh4skDPErohCSVG?36F1qT9$0wpbncIzCyEQT zS(5}OdDzKpP-2vmL1aA0DWQ7qADsb1alAArFY_yN$@0hiT2tvk3F60pu<-fE&T%5d z7{5yWlHWgZW-4#>h4&@%u0`u?!C^76 zQxX-Hxz>x1D2#&EM2s6Lg(lK7zg2l?GVyKk$Qj!wXjMP`9OOv?py}4n9`b?q#_@Z2 z?--J!sc(?fgCVGhL}>3aCOT+LB3Z>`$X$Iv5nx$qi*H-eV^|q%+&=dN7QnbY^C5A} z8~^l>UFJ7U)m&z8@&F?n$`^Z~LS!x;6A;HGv^v2Y9(qR$z3-si% zRB_{g5sN1ygoF3n>b;%<*mlW592GVMZ*=|(26<)or*PYEudxxMaq2HS;nKbB6g+Rxb}FJkR@C&akVbrNaB4L=Sal7nKjS@X4VGtXk^nO8aFViAvZ zq>82vZ}i0;OH1SFe|a1XE|aYcCr6)bXc)$p$2h~g>!g>_7Z1LAdeXQ&>|Ya503x!0 z0Yk=J?r%ox|+YSCS<-j+dLRv+a;?%YT#9 z0Y_RVAPqUtGW@ag_xt0RL}-s;+6sFM(NU#D^ZOQ%z~K%OIQAmBaD5syGX#`5w@g%O z-$U>>VUaUw6g__a?I8WN&-Png+d-wwxo=;=C35vo-&{)L(RCRqO~-uY0v$#< zoCOgI^t5@{T9DuC(sELs80|#3=km1cnrt>d`*F)-exaQ(mWotL0}YJ6Q)nsR7^@1R z#R+3h7qqi186XLP80|rf*rei-HPJ>$LV%9K?`Snf)R2HKdO<(dmWZxt4*Ww-cVksC zRAo`2%V=2{HmmZdPZP$ce`leoX(LZ_O1QCQmb)GOFW5i7ro>pUc$_KJEw;7j&+>rT z(-6f$gNVmoR-X?9F*Ids!cmlEd0?Cd*6TS4tw1-uuXBkWYTX$^ywG0?UN*>2F z{$lfkC*T_O097)f_O#M)?c#+G~ zpNawJY47u_GJR9d(x%!Lmf}OL<30uaqBl|-T@nxC zH81sX_Jr%-mr&6vnta0`#9>UTGh+J!FqRkLF3|j$mrI%G_QX;hRJzX(tR=r&4HECz zpD7{I7n6oB{)%!{xa(~>AI?_(oO1T9*USPV_-{QT^KNh8mQTu$(34|MYCCDv4G&y> zQAJxtTS4S^eo=jf|E5Db`hGH+hIsfQ+ZJ9vE5#0y6$qmv6Scf@|{X??qyjsl7zL^mJUsRA2?$j5irae>_w zwd%brh#U2+FmA!kIlO_Mo3q@YhxX$m%kt;LFo$vzDGKt0ln4@@d)4|ZS)KS#I8nCh zU)lctfY!G}RZmM?q|zXOP+iZj;$M4eVi^58`CvGUbSAd=jXjZcq+MAP<-ZU|+mDo0 z$+g2*@UhcL;xU=Z(31N9tfq&+YU)b_tfsTTYI+Dh_OlPI6aD26QPE$s`D)eISP)ka zgTzii)P-|RkF>=#?AWM(lco@YOZSu+l*fA=*h zYDg>m+(^*J+RJikWdT?Q7@XkGkXWqTcJ4^r^xmI@B5M$`CD`uq=PvXwAF!G2*=;Kl zfd^O_CG7}QK$<9zbMoZ#<*=<@?rwkW4HZ%Nb=uHUa!_?~U;fUu+vvUc@ZtXY^MsHU z#b{PKLau@&UPX)HW2eC=WH#LkM0qDOgvquof`J@xx{RuxY4k}%)2|o;^78PyOqi1qiu^RS%l^fXlY8+GZ!OjgLk|; zdqm-w629UQwkcjhZ}Cg@pv(UGXWF;?(aWa&@A$wMbHg@8l=ih24~TLEQPcqNPN56l z{m&?bEVd`f5-u6nZI?Wu{yvxWYeL4W_%pyRV&I2eeIXN-`_*Mu1B@*otS0|~Y8+sd zgIv*MhLx)Jguif6#B^McE4ci+&ALhR2hDDDOaAAiN#m$h{Le|#!7>t=_9^uq0IqUc z>can-TcRfc;~kL2T6$x?nJ8nqz@q)?vJB~4E(!i5Dvly3Y75ezvcax5_wgPpIKhp4 zoIlNGGGwdyTF3c!Oz&M(y&rH4PoOdYsW@(aIz33K2Iifl(E=NUNIrt| zZg0o`8EPi-W;%`?n&Fw*Llh?!C zCIG$E8+w$2o4f!7^c&9_6!K#3TA+rv*5VQdYTqz(anrBR+``=Lriyq~G`Z{1(02X! zpo$LVJkksa zU$*C5IIF$mrs!_sR1l@8ra7tdD~d{Xbtv*VS|$6*KMeP~`Tz9K0^fV?Ph}6I-#0U; zsEE1H8+5Vcc#fgtt zDG3!SWh1Mfpkv$r&wJmB7+j?US{tNbfqe5xmm;y&)X#YczrvOZR*<)y1)zpTNU@Rg zQHv$2RZCCj3{=F2#7jpHYk3sMl4J*N+lx9#%%Yy-$gnb8Yg@y ztUi#*Sqj2_NE-OeEQ_lOlsmbd!;`>^ocOJ^ko|mdm<6$l>Gvt`6XsK`0`Ew*w^sdw z4rmt+f`XHy-Lv>n7%_+Y_*FyJrIj$dTiaX>6mE1<=z4hXP3>f|jL(7cnn|6@0IWsl zYRWhWl2a$j)`;7o7#i0;3?NB_?zlpK78UtX6M0ita2pHN9?~^oJZxa^z@umW6 zME*P^!~5G3ZxtB^52cW}P?N}Rs2dG>KhSv7>gK4*Bp$T*xBon{YZUI%^wTD;P$gjw zuIc2i!%Yv={_y!3o~rW;WmAb^eaHs|x{C5*I&5I&{Op$|_Dh)rQN2*GGg3-)R8t#_xQMp|IhG;K{%pm%qWtDTVKkiWy4-2W@|4*Vzdrdy@6i<08g zAxYkoxSi|Svv5mY`#ERoI`qJ!lIK*+BHD&pKc@TNn{fkLahRGuU|%=ys!1D*2*SsI z&U2f2x>}?Ai`QNgK#Kza01H!G@C4T9Gm$v*ytF+|RPiqu*Mco}60fA_5oV&SRRJM7 z3Qn5>XxOhgEBm4qJ8j7O6L8cIVuyJz;Rg5xjr(9sP|LI%?c_}(FGbdT=P!T;X3vlP zdKc|1A?uJdS#F<8Ph)fhTL|=N81uECib%84BSBdq_0^|$s@_IB^2drPwQP^I6HXw% zH@92u#-GRf1(o8Bdske~ZGn!#_!utKD*C@9W7<~IU1nubAmSr9@Hq#GELevHNNdOL zc7UVp{IQGW_Fy=As*X4n`vspEa{KD+)JTbsqXYHNZ634|rIq*UG9+gnzvCC|4)c?OuFf zLYuiHlSb*GRET82C4^!?OWg#t`UAYq>XDybN`87K*LWylgq{EN!pUh4@B%9$>Sp=? zRs>{TcySyrm>RV)^tuNo^f7*N+u6elXO&2Bv1|swjGwNs5br&LmVdNAuG?q=i0iwg&+`uKj;_oZtWO zxc0~g)WumBX_>Rb*^-RA9l@4goInjO)FN-gKxGo*-o1MpdVllCd`+^YvdjAYcw^5y-b*blLCq zjtmE0tTD3FOz3O5bj}^XDII!gIx;i!&XQC0h|eR}V|xnFMn(O;*#gVnptlgjONQ&_ISP zR)OP=+17rfSO5DgTSgD9RZ91`wyr2bZJ2D9N&+g5CNR6u+t!W(vkU#HX;$O|&irh7 z8d{wF}|IC>J$wL8Bq_Q&1<;R=R!Gs%-k8DjQJirJju1%q3zh-uO z)4NNioUTL-897+K15x36Ke=mjK8!7lk^I9wwdk|VBO(J+*m}is_Lp;C=RVpa%J>x4 z-aHV$_SyA6nKB^u{8xH|*_kc239trT&SO9APdV-JE-@)Bc!`PZG$UnHI728#wQePs z#t;AF@`!(alsBa<1&G3o-|2g zZeK|bs3+uY+b~zfPfQgx3t*+H&|U|7)rzf8SvTD~FD6oNj)By}gjWj=5?g{+4?@c- z0M+UNsFp_uB3Yi@pViMl`hl2}fHu8-G^_zVoHYT4i7AL*JCGAzqM1nwS z?;$*9m$5xr%Dn$g{sS?j~#v}y5gBSqznz_)_ouAPTmMQXp%G<^e1KNI9pUG7jPff8a^Y+XkxTJ7~d+tLA06s89OdvmUzv7k` z4IOfa+o8pIz$kHX&H^RZ!Bc}md@BqC4303@rF5(gl-b58!t&K~k zFH#pk!1b)O=E{hA@#`@-3gVMV_t0bG0v1O_N$Ja6n7lAsER7u^kR#17pu~?r&ORh>2?LC3Lg#U}awrc+S zV~8>(p=^mnvugUOnW1QR$w8oIl0$3$zNY&Z66BT%WA^c7*IY6ee-B0jtJYhMFEu*X1f+{$-b4~<&ZgM*_ z!#MU*zhaJLbkUGLzO={`>XVx8Mt`TrKIhK)y!ItgG`j{dXoRCCG}$Rjkg(%j+XrO_ z1)t9&f|V5+e*WR0uwD84AvVGoUmY?p{JFA%Y0i*ytU{gZhb89d7Xo9}H3{k8eB_E$ ziHM^{1fR<32|)*2QvP}EuoB$Z=d}@|)XR^xVKxp%c;l0^MycsTcbrA4J&j8WtC!Ad z(-oW1%C_!pn1?2+R~>@tbcp65gsNDJR@FQh_oAB>oE#ybgf)MuKvZ!Y=xX# zH?99RK5ctxvwwLaeqnWWYQ9@}*|1rFdv5zbd0W|zq;0dFO*jGSgE^-5&`1)oGpjCa zHrp3lwT{Bybr-}jTvX&*MN=UZ$6D$Rv3Q<6MZ(hzjk^YY@n4fL-YNBR3wXXfmxbdy z^ZAv)qqb^8R6n^Neypy-##IztJ0AI#dR9Dvq^KdjMDZPNoKTm2MXA@r?y@+58mFpq+d zkRPHNINQzd^9tE&%?Q49;Lm34@oly2z4*kuFrptQpOAPIjDk)aMQwX=vK

iv-7v zVf4*5WJud_ETDBIVQ4*uBEsi@CJy$9c9R%~nWdBHu}i(=O=miN7tlr9`XsF-T%#XP z1^to0n26AXAf@QF;9O4uGalMy*}#i;i8H(OHMPNb7Dr`3eQa%@U5y1=S3Qp=n}aBG z87VX4G1{rfJvUByJr7gwl>H8IdBDWf&G7Zf!TEOW5r>D@<2k3UiT_~LOeA-`>oaFk zrs=2Tv}S>)I!rri{Sx_v!r@b1oF;-C{hK)86mvpqW5W2QzPlHf2o62`PE3rxs^k~_ z*ahEwUr{jJilv1J(y3l@z3Fa+s9Lc&hZRBd6LPcjM(%-s6$Bv)eU*`jORajebZN$B z+zGU4`sx$Z1|)5Ap{}frRd5Y{6(V*uW5+5D4ExJ&XvO~pC5bg?3i*T^YD*X)ij^`u z=jvxKn9-NtZPYS+KUzY_)jn$fsHj=%m}k(9x4R3n{8v?dyzmzH@v!T4Fzv=9k#~v2 zs%WBmpb@!3I!OXU+Do|4Ur)h{GlbvQP-B$7F{yz2##xl zz$d3K{loA~e5|LcPgG@}G;e@_p5oWGzPAoeG!jAv>2@H6jxYt7$WAqYkusH6K60?0 z*I4Y_QM_T(bI)tZDa2O2%xK=Alz4(Wh4^a*KKOTU-<%6E^{nMWnbdk)%;r%!aW_ne z9iJjgtqqEqR41Y4%?weTt>qdyD2DZDc>bv?U7t0XhkneGv@U#C&-f8MltU&FTpjQO z=qsxa3AiIshnI$OK!G*&e~)R;rfl}s>!_Raz+uNBs7ciqQvh6zXH6FBKZ z7qQOC`JOrH6@f1?A$fwYQca1-g%>-v3**}nIe42mL2AJ8^J1#mO3ROX_A2&t8wiAZ zeQ%|tyJ`e!_uC5Gm`PPek*!XxRW{^I%_{ISr>>BHO~JuLL0D*{E_HH!=*NqzIgnlg z^Wt4>BhalGICx&+acEkq?e|ep==z>s6pPRb6kHIk`VXM_AFI_wsaemDX^T_jF_KK! zbb}Xu$D$6x1IGWQ$EY%oAKSpVso-!5?6-BDd^rW>R8;w?!?iZpEUQm$3=^$8ELVq` z((r$b!oNqiDYf(7t$-i_oDHvg26SfO-r^pfUY}WhHV(pPqddAR5&^}}wYn*xxe08y*)==mIC25q$h_hAiSpk;X>EM>%@3_ zrdCxzK1>uTX6655>Mg^f?7lZp5or`9MS-D_?(Poh2I&xx?i@fsNr3^RTV&|&?(Xi8 z9vF}qI?m(!JOAsPPxEb_wO8#G_g;%`n-jYB)0N2x?F@L&8Y|l~LLL+59@{QZ)>e+P z%}RF7I~#PbDZfa^-@xtYYmM%`ofaG`Ylcm6l9>E&O2iqlH8g}g2CPT04NPgji^(!((OP(hx1yOe%R%_rwHSN?E>Xd2^M?=Eosddsyo#Jf0 zM%m(k_FKFG^IW?CTMOj6dRnZ9$2U)Nm5^TLBA>f8DGg3xeOUo-qMK}5hoR5YDfINe z@gdZxSTq7=<2T*rb{GI?1D92LB>>hDc=#r5#|9rt{o{O-*7&3;SvLaG811J+GY`>K zDSii_(!>k^_<;ccKR9hG<~;wB^~+oN=9hV;`_Opr?)UZWRjOb9w>6ABcSS~vLQmR& zcyC7WB43sd``+;s&p{y_`5}W`VHr&|qe|w7xXiy)aEh0yeCh`*gq2B2j(uE)ZgnAEYLkwyo}f= z(@(lXZfPEoRa6bVcJNT6UI9Y$X6xPgB%*w3jFfMNn%AT^h;`EUj30&FajQ1AU?wr1 z!b;&g${CsvYjD5^mOOUzfq)B4wKS2i3QVci6J&p8<)7m7N`X59O0xR*}5giVSX%8 z{mr1!Y!XnmV457z>zjX6%+p(!O1(kAfBU_TSU@-kk{m^mbWw0Gv^pq-Dm zU9PTGXPZJK_~>AvHtO$oL+Af=v3{E|^uGGNf>DO{hxy>`kgS-9+GmkT0b(@o=YcC- z+7UeksE5&nQ+6W~@8ZL1?`Vfkm};5x2KqHLme(YfUQXINZ2`sjD8PvT#dw+XHgm2k zhcR;-!bQpZMQc^Jh$mnRi?{FV_o4uNg73Jsauud2xxE*isZPCye*?g12j(@qSSfWe zUL)#o)AutvOZXIjp0?%)eOu<`4gKDW)W~JxEM|t^+sPaNH0?D>)cx%{SezQ`&hc;D zhL!?*eTrWWgmZlX)`!jhTOY=A@gu*{^CRdZRpiefq_%4#tZ9UnT9taUp4$^#n-^Md zu$BKlxn9+c+HWo79vhp^mI>5)j_OK2dm%paxb2Z{S0Cp_dpy?2X{;GBqRdsv43ZyH zyj@=bxrkvA=2Vsjq zOnX^OzfXV%_;m9DwsW|T=WAYO5rrPcy65$oHLlOnT~wf#Ch>Wz<6pK7d)v0uQkBbZ ztk(4C4ailt9CBnP*=FPY5@+~eyG1DReDCYXst-%%X+8=P;Y#h|7erNNRp@Ryh1~^}2QK^fc%Ehd+&7Py+_#v}wV$VFsCqks|XgVtYpu}JxqFO@rp`UNP z9_x=xY`FWjmVRY)53P$bWVnHCB@@ZAL3kx{Q*uu;|L2*4`lQ4QI~z~(!?eT_{^2pu zC7tE<_D}5ZREg<~-J}upX4o-G&f&k&EgI@IZ@$!tEPmA|^k#SdF1BpJCM1U6n;G+M zlm2$0O65F#69#8y05gHd5TN+YSXO;8n!^em8%sXiw1~|~Li#u)OD};)%~#CoDGNL1 zS`-!?m&7<#F5o`TYt*Y`Mq+GP5`LZUf-{CaZ^_dB;C_5F;N(bjK5GZAikHLcWMB|$ zud(NNOSX{&FuCjR|Cr4GB;n{eE-&v&>w>o#XuZ^vj2`n^sd53YtW0V+9}qe0z(RvR zLCI2owVcv2B`X<5sr)J8|5)qer#8KhpQIZhR^)q_TK@SkJ|nw_v2#-cxrsIyhJ?v* z>Bpq0GTEO9PKCJY7pCx!d)Kp0WeXIfOQ3O^u}&!k0 z)!K3tkeTHDQy&DE`$w9*eC-xpr!GcJ(DVliZms@g%@|b;;8^Oy`YO^K*_tX)=ul23 z!}P8H?^vzD=a;-b72202!Z!>}&NRWWF!ntKgqJV(KV_wig{`&i7BAjfL^`OWtFbvj z&E_psg*(LmNe=e^N)9Gug{7ye9k&}J?k*>|GjYnc5Lu%xY#@lxmx}RFgcYcDlmHBRS_a}A;)onUs*H&bf478y~{RQR9@{Aw%r>rABW(L|# zkVG>r@+Q(HJ-|xz|FQB-*T=SkFcI9BC6N>qXu#RfW1Lhg7c|jhc>eoRJaK`g2%9S6 zN$%G9&9~IEbi&Q5C-<{$blx&939o=F$~V!!oyENTfL$@tue&PqUUyj?#;;cK?RcZi z^TSeQ&~dy}boS3vq`Xr9GYRbxdPB`9O|8MNhPz;FUb8-QS>rsEP3xnZFe=eQ%fBfWJTJ3U^#$vCmo9cI>>dW(Kz>et4jD=Ood`Lw4?ZZJ; zGjb3MvpEzk8vpw4rZ`^pVSE)kl~D*hU1AB%y#=hVh>l&Nl1o`LhDV|j|EuN|uLN+! zmrYu~QU`-kB5ncYe3bcc`%gK|LN0AGHH3*=)G+(_e=T8f7rgpOG0RRn+x@tyhsr?_AS!a3SEtan`IHlfUXdo^|?q{y`20x_U+7b0IMHaeX%H)R2DYD_c|h z67MieF}<`AAtqOL3w!+D8_OTTP}Cr9ZfrHhpv9MrAZL)IROY3$IVi`{ppX%3pe7WC)aetF06vPeih` z=KxiV6jRtvH|Yei4Z5U8*AC7?23t^V;~V^S-_gykm$?B#UDmYI$wh8-DtJ<51*tNvK%!MAu7E=zj-l2>o{;#T7*VJ3DT*4qD500Nx< z_@#Dw%Vi!DTD(6UcwaTCikWfq!R%pZr7BL|66zS2EHL@9A)p7el*{vC$$r0u*a23pz-P~EW>|Q*g<6ePSSUM_{bEw z^#E|6V-ERak#R{IIA0Cp#V?;K+ksvCeo;wPCclHii9>QR2e@}@wVOU@HE)h zTeCSV{}OJnSJ@u3hYB69)Im8LR+VOSL>cYY;m5FFUp}=x>Oq{n`{>aQ)5quJ?|wK- z4>J5+$t@e~sDGgCxUTEJRvw`eH~@&U&tmKeB9hkX{J3riTq25jR3|eLZoYQ-Q;?Zg za`jeX5C@zqiCfiiDjUYR1C_`T4c57PSBOKsJ6j$=M683#cC;Hngj_u|P3qP;+4SeD^Rg>uS_4QwBmEjolcT%^qWbo!~9jsTH=QSjaMpl6jWt}aJ{tqdR>>3rQOkB=8U}B{$lNCYnP+)LYsZ>66 zxz=o#$J&wTH`@{*d22_NZDn6T@-_8PPUxZNp~@Efoumx#ByMgT!F)03&;4oqD5e1~ zYWKOwLzxXnHd(d?C3_vQj})uH<>Z#+Nkf@`nycE^;jLKdLUTobS=|IVyBTa@{Yrp> z5oM@uT#lK%`mm#7Yjn@>R%PmMV~5~Hk4;STI^m_@#Y?H<5s#s*F*{!YJE&>>WcuHO z(eIq@6GojD>gZ0+zil}tNKLFL*?HV#-TEv+!igM%L0T>A_SV_&6FD#fkJ0Jz!hcA3 z)>MXDh)rgUE#yg>$J2TooW*HzbVS#0a?dSY3=7Nf)?yi;H$kjD-KfITC*g_x#H+eZ z#h&x5qZ!})ytO&vJhxFH!aDtaMe$lcpK}E?<+E2ocwbSz53eK_%*SK7v#xg0?hF}V z%zui4D490m@m0U@w%4|xs$?JNQ{Nhp;V>DH>1vG?<`T6rqhs0o@}cZe3K;@^@V?6? zHoZ*=X86E`zcjY^(r&qw0eiV{MTHt7SeJ3u;faOH8&`pJHT!T`u=Xcnsv0!D4g;}9 z&VH_6pMP(d#bN~`R`m+FHpr+cZTpoXzrl?zhCs{@t>CS-Irl$%CuP|0LyDZS1v4UzZt{W3;3f5OWd}LNG z5)aESaq;nZEL&{i=)6t2b;5DuwjrPyxy>Im0S69+_jo-n5l;ssfiDW)>1e@>1zok# ziyq%zgkC749%L*C)=mXv;)Vkh?t`E{0EHKzqD){kz;>8H$V}W##`L;_rRfD=B@^qJ z0~wFX-hTUzD%UlBYa0IUFYOo|JsPs}vI>EzYpfrJ={_Tr;>CULG6LltV@_$nQpSdt zljc*A(w&$xsXv%^C0-)S;~WX~uND5hkh5c$T4vpn@bN`WxVUs;ox*vknmSjikws!y zaIqeJp+@)t7cPD)MOg5O3^XO^ldX~mDr>2KPxvDvif!KtR<>?4M%?hV(w0LElpRFL z-j*FRB}tzb%9Bmhv|)Z8v-wtS0Oy-LXcMR;70Q9&5tPKLQ&3mwg9(D)Hd;c6Nj2k> z=dk_zF?rBVB;_Pop2~J))6OYH>o4|OsaxLhx}Jj2Jl<}L{Sg2BvD+7}eS=bni~PY2 zzd+uIo@*D8A)4Q@AB!NPmYu`tnj1sH+i_j#F;4P8W|AIrsQ~0ad(+;(-S&S@)o39j zWT6S0X=DNA=`k)JA=Wr!bS@uP&#s-w`f3oVOj)ivIC#JHu+{M10dQ`P0TnHicsFwSLm4dITfXn&@%iowrg=g@EAZs4&uq?^)+XEe;=c z&o7J1qE68elg&Dg*Q@?lHpZY=hF|jt2p($4M5sQOy;>%H(M^o^^Tl|WO&azb+FRhw zn!Sc)!dC?(U}eS18Zhx@Mul+WG?5qySA5?=XQC|{K2Zhx=%1LZhTi{Db0!|QZ$%%WEu=+P~FjGd4L^dR#T z=O8L#wjioaqZgoe1x%$YbhDm=3L#mO+@lL1(20uNUp0^54K-8-z|8(ip%wws3R=c9 zgSNSSGPsbs?>Ao4XA{w|f{%%^hKmT13cYK!=U^i<$pyTBl&sqj;Qa;OWh7#5EOv@dcPL=R`+@9tCSY** zDtVcJ!R2@v{8U|&NZ+=aPddpD*hw!g_Yk$j9O6SFm@XR(^a?bK06f?b@w5uy!S=-r z#|SMuiIMVmV~vWQ+At94t@x2j7szxj#6(^F2fyVSh&Drg=*?}QA}ADEkj%dqdFO6a z&Ej6oXW!nek-^2id?`J<1OYo2iksm36Zt54z9K@ORcLj|c_KlGdl3nga`rB-u+LY> z%+nHNFFJr@W&#}_4%P?*9$Usfl@!AXFYQ+e&08i(eNnu|HJ9H;qQf zB669W-}FW7O8>lvDt1+!_p8vE*FjcIJQ6+tw#X(3`S8yc7v;M4insRClpdT6)*WGX zSGFGhuGIr_9xIj)MK=sYR(tI&RU3Z!%FFDZ6b4=YR`dZOrgtDqM9+c~+3)Wh6)pu# zghBxV?^abMiFE}up9^Zl5?S?oiyf%Srpqp80~)z^V5iDcBd(|4Sw{XPmT++Vin3)L zWkC6>D^>GX*XCb{Tj%Q1YND7>*5>jFByS?!=Qz1^xDtR_ye5@j80pFyJH54Of5@wU zTZSIs`bY%cGj$lB5q!^wCqJYRG|T{w?}R^lzzaV$)DAyP85ZeuP2US*9pYf!#4~)m z9k8pKgLTxZZz>Y=6mHP>?a29&4)<94GUsV+$w_Wj2VeS!Z3|w98{P5eMFF5#- z0DvdAgLwb0?hi_A^jd)Z)~yWNj&^&{n!%+P08K)a=Ldsk@!(D zqng!9XFKot;2Jlv1&*o|yhvcP$6;tx1%a*((0hkjwJqY^RyZhB6ZRlqyCk^6hXPDp}W+RR*zj5!v#E8?Jd za*;V=`gsKBsgC6b^2&?!^JXJQ=5a(GH&}*|;(u24qN!azH+~|+Nuy0neu>0ZQW`*tkm z>s1BOiS{36iI7Ph6v)-|TgS@D0@}d&jt^FVM_1++{&x69Y+dCLuc?y~-SF*2-IH-y!=m28=kR_)Bd{*)Xzv;{QvkP^<`bE?=d{LcH zdvBxHDMa`N?FXsYGiZFpa#5BKwE5=$e7|mzCQC%FXvyS)jGkCD;C(B}HVY^#-yHJl zenyMywftN`B71@MM(|GXi8oRizL zg@0i$qljo$q2pz|6N4*{+Hez)Vb}-Ev(>=a+s@C!{DFk4|J=20!*cS0UB~n-pD5a8 zxB1BorVBOC?EQ*AF;USnXSQa2sIMCMLm6TCN14RD*dRKnz)1`;AI9vDBh=YnJzCUD z!LaZiEg;a<^n9(;Y|kDUWf@@dG=U~iwm6RPm3d!7Woh=02+4wOK9%-nJ$(Z3tu5a*;>`DIm@&dW$`PH91ukn zKtwi(xe6d+ABv|JnKJ+oK{QBTdUla!X%S#CBA@MO!J7@z+Q1LL4D_e`@sF4bNXW~J zauy>p{I%JB@A_6zma0*ofL~9Ntek}bt7{;#tJ@8B!@J|r8)K${tip8<1E^xL3i;VG zE%FW0&_5a67YIO6boUY>r77O86pQw~x_QpzI`lPe4p4gB05W5O#we`QEk7;lmB?#J z<61djSAq*dMXdFA*75i|pm_Uus^Q`Oq=odk{%J1zFSvDa)p5r4OIUpC3jE|^@i*bQD-$6h-)tXvL z<>`KYq3wl{G-I0$lMXV%)_a<850p*WbV*J56XLO zrn#Rtj-LH?V7?=sqT)H;Tg7R2kNVb999b`tdyM9)VYb(M?SScacT5B@s}tqTWMu}f zTRrWBA~nzMa$)C9Spc+j2MWtZm_GCVsUmMYBa3MKz6L8^Y&!AmB6@L;Qg6$#0W#?Z z!lmnek1ors=Rr>wA)ul{%x+PM@Ln?&^e1aepg!0on!zy~I>e+>LGB34Z6VXS88qlU3*9T;V;uLqPRi-}W?oj5xgYy1d@# zaHS^pD;9I0N?{QxVOcK|DY-(dUmVm2jQH!e+SY$6irI#NAKZPPiEaSBs~_uMGmI|oocLv_0=|u~7+a$_fbpmvn@Ix#=ftHzKN0Ax{zVn}9ma_GmwQ4)&^A4MX3Fvs^ zkf?Zp%ltTJWhfpq7;YtvS~CB1JYYXRl0NW5bJC5XUJ}#OWjX#P_C4g8XbH<>lRD?E zB-Zh7&IT)36taLydB^rHCiYpIsT10~`j6wFVG)#P4*E59UmO&>__K?ZodhLxdd)PP z1@(1+D{@5{TI?dQ?V*3C5@0+k86Enx>b%VIli&G0Z06rLjrwD9$^2Hk{JAdLPUU{XeRw-+}>0w7?a7j<@kd(JUpb;>F!AqW}94IIu z2Yl?S;F2=%u?=M_=vhw2klxe}RLZ?L)x=jTLdqZAm2Cr;kALLsg;Sg=&v?jfD%<;V zfW9nq8u|^Ct$$8(te&lH;(af?GsfarAIf@2$N2N_L44;fEN1mMu_`X8>vuWOeO|rv z#Hn5;+iE?|grfB|GPi2x_EB?77XO~;bs*C1f(kP5P&B_QQJ#H6FT()FS-;uLdBuW&_bFyj_PQe*|6H{(=;{ta5k6q7BON8I_YDSMnd`FVYQN^P&K@2h3urqB^3Xdsh;lKl%Migcyu`F&M|art9*3i{{FH)1~K_& zkJEh+YQ9hyyK#~X)I!dmA@IXbd%ZRH3@%SUW4y|Frd0eHvQnYKZ;=&5!&kv;yW_2J zH&Zo+Yo7&tIuly0ax)>a6K<=v+rnVc#Y{hIXY?d3q!?v%N_mEm;^$afEruaInd z3r_K2z0X&nPsa|9^S(;wyAFk9Q&*<($z)W6uk9$%O8%Y?@Q0KzMl=a6v(yU z4Uwuh{94HzLE8zly9znGLO9mD2cMnarGeoCXDPQ^uNVG8*nrN%*)tvBu$JBy-WsnK zbKeeAe8T_i9l{KJ!_2#e8OTKSGRFvaBtIoUnaTC0)a5cA2GisIrG@;%qcy0*aDBot z7pV(Z(?-Bv5~&>W(T3qEJjQn#UbCS}to1F+Cv9Bsb*pxa9-xj_hgx$Q8MuhI`2`{x z<3|%2c(fZzOh7Fh@h=GHe{wSh%`M*b!yOl09_r1{f1{%MXkGy#pnAyC#L`nhJt7S) zN{6*OR0(xG2eiFXNdE??2QsNZ{mydE2Jv)a?fe}S>Mh7Vy&2>$?R06j{8mkJdTF5h zkNrDgT?d^mQh|4|g*XNtnxL>d_~+u|vtHxs!~DQtyRzJl1IsncWqo0)3P@GimX(_8I-3iik|YDBW~0wXwwkIh=cLHy@$uMqci2vkt=we zOYiyNuxC8fb##{TPJ?JTqT7-as1{B_e4pWx`le66AA!it>pfJda54DyoJrFsn`q_W zShMf$(rDIbq7jqy8$o|;>Dp07n`aR1@x>u+@!=l#p61N!(XzZ)^h?{J+u##@*?)uI z4;LXEJM}7@ruin=A1|LFM{Az3GdMEtuX`eTeEDo-v&-GpeYEon=GOpB`!wuiG~LVv z&e{%=Hx#R;uYS_nn;L1;OtbOMjeIQNq8~X!pZ~{(GwXSP4OK!Jhk8>K!|^cpRW#bw zldQ_0N9oh=nCcnz`G&WoRgwVvQ=#>tOc~)mUrjPRXDn#i>fSjs^MP2FDf3Hl-&0vH zTc`?k+(?-T5$XMD+N+B3G~{H>@yXjr<-g=9Wl|{&(AOm^4fxN}r$vWz9`&m5N|fRP zkQ0{)nA3MIz3BcwM*>gj;6C5E{X222>Q}wycz9C0%ac7m!x{Q<%jsov-QcsP2ayi3 z`u^+Z!bLGGcV6XM=PZ4uvn0Od+C@~Ag$2=WmT3RK5HKilu(!D=7Q?ePU51Qf`kiJB zzBt5-t_TYJScqu$OHKHP{&^~KJgG|??;w=^q87Rfiwy>cJzpD{;vr_kVG{>DSF&ts z_D&v#K&y168;^M9)t7HKLbM;|f=Nxttb%|mnhlhiZK)408z_!TLfV~Z2CtG%J$#0W zoHe)lFx-AWzLbUAd(eE>eLV?u*>q)BYSNnF;LBn0%D+nB>Q+4v-9B0Q_olptGRMPF zt|>S%6EEg&Q#~F4UwJkEIz=u{V=TwT6&#Or_-q`{mn{+H6h8y#XnT+CwUiJ>X{c4C zABv)8Q`Bmpr36N+0z1aAvfrfP4IXuE^QGZoT$!Cs>@vl}TvrFPk%nncX7&QA!K!={ zmME|K;m}$$iQ99W?sD^rB^Jv@lCZEmr$25AJ9zTDUMD7gzh3S48taIDxL$W?zi0O~ z7bb8n6A|RABAg3p`WF=s(Or@->&C!CfeX})fs%R2b$~H=KX4NR6cN@UCOC;loT+ny zpW%3j$mvr9+4}+-Faxa?9?pU5<<}l!YOASbyhd=Hd=v^*?v*Sz&t5yWEByNBBiO(y zz>s$s81%mNQx#CZf_l1031OG|0oWhOxf~QAV z+y8PAtHY%;t{}?bWszJM=~?ZgO;{7CZFNg)Zh`(9$QRdVQx?ivjx>axo{ORDIUx$E z_zN3u``@yVhijsxbW4Xw0nSrDCp=LOg1!G5qD;vgiffaiJ*$xg;-*9Ale{u^3acnK zk=wMPUb1nMqfen6%#}g&g%G|+$6)jOccoq9`7&PhN9Bq|La>;6`Xcv`kdF^oL<@(Sid@bcpNU3 zHp(bIykva5omaSS7GJgy6BRQ83adFF`trosmZ1-Z_>@*HxK(*uQz}5;%;81KN=$_g zP_$TysnY?97FW}Yz*4gEh?-23oPZu8Eso>%m9_HO0G%g2;pQJcLNRwu#aPTLXD>VV zg0>)Hz-aBHS!(KU!(JP4UEV@saW`vHP9_}=?+sfQ3{e71uNAbVmfAQ+5E%RIZwrWI zQSLKxY~JC32H;4cI3+lWPy4S|LzBP}lSv`zHl-1#xuurEWXvzN2VmspHDX3N?lm1| zbh21Zs$y0A*qA`_tO_L0sNZrh8K-W)qils}Bi+ul_hy^uti&Ry0GSBM(T`IOPDPT0 z(fZ)lF7m~!MI-s+Gw=Bp;QkIu2j74&Jf8o%zhjr0ew+6uQS^yZ{sU(d~9yd9HLcsua^e>(6$X#t>PZaOjyQr81 z7r?QOK!G0%qhwiiJ$B>u^?jn$2ejeG+m89qO{U6xTtigMg`>EYN)Y@>abfqc~zc%k`tLzS^Fl4=ryjNUw(={N#mR$PEj> z|E)f-6+>da#xkCWOG(c5jM15&? z( zr2nigz~hij>xI9GHp6e$jJYCDB#n$?l8p4NRY*02bk^+_4Yq&g3h>bb%^5qi{bsqS zm&=e@JrvChEh=550#|kQjeSle0;_L@q&dex8GI(1#|^OP+G*k@Gwc0`Z3HXAJHN0{ z={t?Ey2i4cgQ{Q^4V&U*${J3WPSNOAf z!thE{!K&BA$qYUE5D6F53|;#4!wO2)v1t1q`yU-1HQaz)Dl^7X2_$W`sb?{W3mJZL zY{V)E>J9tf2pnyYjBlgXP2-QWbl^6gF4LfOIr?G-`1|f05~*nWxQ>*fdVV655)K0e zco&0^qyDA{eDM^B{$Nehnc_KbK`zwc3uM&jD$_Jc;M~bm{+|X;`U(_jhLO8d7#qzz z;Kq7I`CfS~X%RNXJ`W z^6V1!qL=DO3;5Qb$u0)qTV4XDweK*Cwe$^RlGGzOOq3tn){a2+{hyzLZUwwRhUh&M zo5^!p7U5ddYZz0?{711e>QRo^=$~Uq4)5O2p2xt933k$=`pCLDKP|>I`k2(yr{iUI z`>Fs@WIp5*lG(fP(-mLbdDbNGy>$!)BjN84O*ZxXCuQWpK>XO#w^s6FLC!96=YaDA z#0iZFXt*!|4HsQ9hF@BLaDQ@GQRDELD1uOL-AhGwfMr_E{de&Elwr~_m$(d3|A?Gw zTO;Ht2tosLUF`XCLVwIiR77aS;SgEzi*K$D0^Dl6-W4K~pm@F8kzEHZ`VaR*2g{%O zQ^MMG#jN4E_o$IkIQS>n=jUis(}=A62?1e zfE^ZPMbTX85pRs5s)dpgJ|d6Aegz;5Y_e~YbxZ7dJzv!PQc|Ku#)P}&f9B@mW=y=4 z)KI6CeC3iJVmmp%E{APTRgPre%==BH2Y#x&PzS9rTPA~jv-d4>z%(jYmcL1<gRd+oHlvvS^nYM_=8IwD=Pt9U&{RDa#)ue(9Avnn%Vg{qazHJ zaP3p|Z4Qd*VLaxtx85)FmkH?YD9KJNDd|h3>O+0rkj6h;;0p;Jr_w-Xn;$3z+dr{! z6RocaugncF`Q?wzmj_M6sp{6+rD1?Pk8)pFBg)!E)DeW2b%SH&{Tm z&BnEUM@FG#R!Jw}QDY83FCZCXl_lS!Eq`j87Q0ZQ{E~;PJ~SkIy>r;+jwQ9xraV=i z0JtLoa0lfdcitJnK$JHrsaj9M%_8kHp!Q}v06J!9ccRtqV+X7GjP}s|x!==o&^Nzr zQK>ev3iq!_eAytmPoPma0uyVJ3NeH^#W<`!+J&J3%9c>-`cXAUkf#HCi+AwG2bc&! znI~JE1SH%C2Q$N83XHUE5InPp#%*yy71{|#WiBk>`jU&mXMuRdWbwhnOH5>s*=b8!RVx(t$`4|S z@fB#Sem9h%Wo8xaf_VD9EqD+xfzA1K<@}vrJ(jN5<_#9pH@rnS zeTjvv0^~M!H4~;jzN1slvR3F>eRB`LMhO}Mj87kWGLcTy@_aP2ZqUR%Fe_Zx46E4u zZXT$Wy7-)#b|EKSMYFBN17+*>;SWW2UlF_o?np23>D)P%cW<-j~(N}EM0LMwB(1&a?I z7)zozVmS4OC&LFPWhUw4GxY7YB2rxhR7Js+dBTQoQ9{_f0l$@NyY3>N52jr`r2dIf7sa#n+uXZM1*hkB<={*4Y@mvH&l zQ@L5ZaL?!74cp-%K3`X)&$v7it(qkLo_edFDmB17%f^C;K9|+|$}x|-H2wMmLv~C# zMs>ych~(mS4^b0!T578e$29wRq?>2mc!%_a1G4WjaXEyrSP0Wyx{v)IADk0|C8HV$~67wI~g#nMf&cJ?L;ggSlNVYm8nH<+$@xtdW`a_pjZ$D?_0fFTqZSM4s znf0f?kCxR)xV!g?q;=o;@p5Bv@5O6ufxt2w81dZObu*Bffr~4{I7Zm=fxh^nPUedf z8Lo_b)Zh)eDSo8zo4sG()PNA}#;vP>1oKzi@27=<5W(4}@bvma1HL`Lou}7BD_qvd zV7=ae!-6(h^OfI}k<+ppV+*Kp#qFJv7Yt?0oSYa{N-rJCGM>b76Kv8O`Z{SQ? zPb)8X1CMG~Est|)u$+JCmD1Poe=Vm= zb05TT?V57+^19uLXlF8js=Q=`=N4f$3;?8=h;;Dx3WTAYL&ge2(x-EoW?p0_h8$`T z{=gfh*-nSOjX!=fMi1CuldK>Bc}X}vNY~(ZQ?@i?jloEa4}p45LQ9#$4}dFX-(kK@ zWTnip&T|JOGPok>K5M4mrMJucU>@jmw7L4m;L3D^oQS9Ec2 zY zh*0e7wh979vc6DQ0*_aIiHB4H0=DJ~)7A#^TkBY5y`PenTC}t1v%I}UxFOUeFLga0 zD?~f3O}4pZkemI#mm_-aisUd4ITXE0^t$vudz0NHSJc# zfF_0aA~~RO+V}>CNSgDseR;kiFo3+UBSP2+gW6uSFLZMADI zS1?t%_?6r&LAYnGZv!kM#Ak9<+WoiU>X=n;yj$r0o2=ScQU9`b%R_J}kxSLCq|Ztr z{nIUNvzId)Z1bPqwO>}dBV>b;fkbKqO}D~X7~Vf{4WK2A7B;bDuqbIwa2hLsM+D9wN6S&Uy=2g11MwIREtGnwPZn=4UlO$F>iRoxhs4L zvulwxSLyOSD&jk-#6~}H3O|1{j>I`~mz4+M@^a(r>0M z@pQxG{+L(sPzwr|KE|9Yp`U$T&lYP1`bcoP;QCybQd{CBhLM(H{lOLdgBC=QT2U@2GGa-zdtYM*6(=Af?)Qjcmv@=f()0{-XW$lB=)cD?7}rjvgg=DeY?#;TGa+MM zTj-a*%MA^*veA*{*IM_`P`=&?f9AN&{me0G)u{t${5*41F-2(s!ic|@n&U%O#)d7L z^^Z{p-_pO`5@r`m>=+_qtz5wjh(NZ=o6mJdizl_LGeoZ%#$*9p_KN>UlVqxg&gbU^ znGHuUAd!h>*xz>v{V4Ezy;tHCR^T43E96<1pl$^ zluSGfX!DP+6&CPqe3S(b%xt}X?B5mY=_aNE6Ss*qp&0{PsI^n^f3*s)HS*x6?i-nU zwDQ-XDe`;*9UfWD8lQO9H>*s@Bzb=kGehkcycwbcm6Uv?S{9!h1hn6b27O5 z#gi4RU!@HGYE=y83zf-YKu`Ls@k*+#bx=CF}nfLgUs6PSA|} z=DV4RfbzmGmFg33x3 z)G8*J16iI@Y%h;F6uzjvq`Pq4?b!P8k`U|ak2C+avwm;|d5f8J$K1eW^Mq6X#o_MZ z&7$7hAC+#Xk&v#0n6%R88(W*hJvQ9B&!M&P3;0RO^nuIIgBK{~vp}=^XPWAWL+#Pz ztP|f8LOuTlcuf5=tB;gs@I=JlIde0%L@QYQOJ4$yVFk>6-OaYaj;i+Ah~8`E-&;P1 zRVsh|STeBMJ`6|5OCZE8x8Skh*StZB>Y=`6)+P4f9mMPtfL$nxRq383NZzkBV@yP% z@!_b{+BTEB$Ri}D3c;mS$9=f{(|tGFdw5M;|Ac}Kqas`#UA+{!+fhBK=0%KZpIihl zg6y07pbc&cnFy5c?(Xhx>6A|C?(S|xx}^mK-i^=i&b{;g z<98gLS!c)DXYI8<5v~D+-00I~)f;PX=v_7EP9Si0iAoNhef)HbqF%F02_@BtlW%zgSS8;}G6lYvNaO>Si23 zS^YV_2FbkH^Q}YR`i!Y8<$?ML&)ELC$I+1!TN z_cER1YX|4pa(GDFi(`L47hUW(=}y8=Yj{(kLz%r#VP zL$c<)HE}Y?uu}&sa@^*`fC4RD8dGvX@uXh{iQH;3bv2fnoqVh$eoeV6nf-8U)l_sD z@@#o4nFzwSlK7PXaWVo0)u0DBIn8YwGnj5NwENOibuR>Hp<>o!TfpNqxE?TIgspAr`i` z-y%8sw;ckOLi)b{a;QBEG2mm*7-wwZo zi45Tlb$NEw2jq86IA|xrUyRjZ4Rx3l%U!@pL?Z^I<7)>rqKvgfV$13wP($JA%HGs|i=O{l7CfhO9S0l`#_YIH zG^zpT?_|vAm#t{E+Fdd}6H=s%o=4?LgqdGU6A-?SdS@$s^B1ejqkhlze3=c_W)90o zb?3{P_3&4}iP=XtnG8kpV3ydc7Y3H5C|SS4SCN{WLVnaDW@DugC`t>vp*PfH;M$og z;t~rWuH^A1aA-q5xttkq#DdVs#13;AxNG*99cFG)YQ*v#xr%+QT86gm6fxqu;eH}f ztwNl}jY9pr;o?18SaH{Kyt_V~DUov1e7^rEdGgIoyRbN3o&jHT=07lL79z(AR2&E#vk{`f-ICl) z29t@^F?&Y68~S)p>GoQ0Mgb*Fptt^`lyq;DGl7q09nA%+%C zj>G6Byp$!T>$Wq%UU+Tf1k?;T`9gcGY6F+5+pLxfaWXbV?)-j;E9Xx>rY=PQ)aC+y|&=!9P+qR+`th3TlnHi3_%h#r@U%&&i`{->Zl1d5TG(jW`IOh38; zct)b=HZ?pTu=HhwQkA#ADaxR;F)F~_*7Jk(bgv;~8nR3g8+)JjRHf37-%1#JtI!Li zM|z-gsOc=~Yr94qh`fM`_jda}yt3s{oscp0@mhGJ4inW)>OIfAV?`AE7uKxr9IQnI zM9QGAq!?XhD@HsLhrJ^Zo*#!+^yXb4unf}|;O?&J)l=Z-RxbuKBr8*>D9;h#b|~+A z{{vl~r3+fyRiFs3>1~k+R>PNH8QG^Xul<_^;R%aKGgBe1omEOLJd_)1i9Eksv2U}e z)_@EuhJZ*DgcFS}GZX77NrIgQe-KTR9!t=$U{2>LNq~dy%AtfDza%N4;OSVgNixDA z)%epJ8pt<*xBl*SGY}!*XhnF4tB_c`XV6a7Cuz4?oEg==6 z!Yk29IilrWbgwX0u9}!-4ZebINCao@BIK+Tz^Wd{l2cRd+v@4U2uY(Hqmoc!rNJLh zk${pRlsiXkJd%)f>SCb+A;C2Tntw(n%CWE&Kr~aLZH?R%oi-hBaW5e?WznyY zuF8PvUC9%Y0R@~Jhg?ehuuSH1>jkeZslV}5n3M)Bu`9Zq@-`@j?yUKJ57s@VJRUvmAPaL`7f0 zng4sUnS1SF1bYvgSEpUIjkr_=`>g$0yV*@+(1~aDXmIqQ5CWdE z-ZgQ7($IbVntUN`|It8jaK^gCtr)))ckk(Bk?fxbogSPw$Ku~+h)~YHH|N_pDQLx& zpII~By2Bu&-;A`9uc1OluWa4t-D?tb7=BXfws32dm0850YcD}1Re@|;KZTFRVRF3l zQkDHwk^aYQk{Op&*yjp7ZWKZ>TUXYKZ!T~U#!TgRP zcTR;2l0z?FL1#(U)6n!$K#N3qEd41%1kosYE=GxjY}v5NMr@NywUJDMUX>`>Rb3?2 zd^V+Yyn}+AfCJfmHVjVPB6lXw14TtRC{A8V zzRA%ly@~d<9?XP_{=%o7fxkg@vUHGV1&{zgIma`B3eaz<;6Ku(RCeRxRsO3mg9T-k zhwmG+22w{l8?^KuY#fE*jF)yEtJist8-h99pHDTX;0`}vtFln045;As$?MXKbn9ql zba1WIb2^SQ4$tCevQ-#WoX*v-7$;^UmT3Wk2M$t|E&%MfI(DBn9RJ{k`Apj9hiy0% zLNiOar78w3Rvp2IegX>w_@zEiMJ4HhMtAXyShdB6KE|Y*y!?smyl3_N`f$@fUseE$ zbQfI8OyDENZfri=^1NRd*u7X<%8_zn(!5by^5s_ebW~L4ysr4OwaJ{($I|q|j>0HS<#xmcxo=1An3{x&?o zJ=V*lr>0i;>%$V<((Rv0{`(^ML~PYo^aBND$-cP2SOPgX_vsF~hJ&Ug|DQ`WqG_ zs2ygs)4*PNm$D8VyZxvv~8o`Qvf5D*QPp04KP-b5K$Y zk2`9n7^ASeT#y~and7JUK^h?kzNSC&B464e#}54_49vpey_i%Ibm6V=ACll_l#HyM zbx4QvIgId`T0&@I!g^ciIe~OjYWKILsL)IX_lRS&>!TYl&otEH)5qT7LCuV6Atoh! zKGEOrZ!1hCEw_1mX8TXqnCrGUKp)Fn`lN;i%PdNYZGwDfmr)eLG>v00o8{u7Y_?wy zT@J4)0(n|NT3}OH z&pkEQClNEFrfsr7kf|~;ckcF3Lz0+|!jwkgKMA2n;nYJLAbiy)b9?cjuMGXGxxqdAaD8rD`Kq>M<8Y%3WXBDxV-sfH&9cw;wj0fB*w;^uY$Iykzw{RE z#QYFIzqCbdP>ojfYOZD1AR+5k=|}zuo7hA|v#qP+t%+?bRE@4Vi9>kogu}wKn8)1@<4$t)M;BR& zgJ<#6=h#ww^ptn#v-YY7*6<3LwR?w)8P+AR>~a=BFRUN>;URbc+C5^AE;;42`8ZF6 z#Ecv(eX{kgJBCSLsvQAnzp-l*S`WwL^o8 zu-I@KX>!3Fh`h3z^3$(B1?8ZG~8%MdG>Gfc2N{HtLS%J1R3(IhrABy^2z6Zwa7sG9A!Wn4Gwhe zRVqW^L`1OtMU8g)nFg_Mj-(o16xPtSlfv0sJlP%@p&u&pYga}3R~^il<-$|{*Lr!& z&@b`%AyD5?CdFk!2l|P-(5Dm&I`?8rVxvI7_}35NAiiD&+%9MOkp1r?JZ{VwHtiqC zHWit@N6E=$Eq6L?^%gbiqM$B|%2g*EaS(pZDwD06)8Lep3#qGBskvg>dkAIISYaE1 z4W#d@CEnBjI$ycuLDlC^Nqu!EL8=1{ABI417G|cG%1=Ku7u}R%XJjufpAK>dss2us z?C$=n8p6EXWKZU+6#=1^$FzR7SD}@^We`w*eZ=A%kU^M|2VD+)(rK~kKG`tZX}2Iv z&!t^gpO14jXYO+?nfz{NVa?#OB`1ZxRkoNdfwT4M*Y4V?<=GD%q%d9UL%g>Wp_q9t zob%*R@B5u6HecmL*Dy9o#k#Tnx^v_V1UvGqn2pWsG5UKDmGFB8@WpU9oj zD%R4p`f^3FsG6%x{x-aG(fTJK_v?V7lco;l+2efk`f&5o&AVaULjyPMfNJKNiGsy+ zd^RvM>b_hQf^cP>1-JLDjdFFNAu*kvW3%;i0DL)18Z-G&>5VSLCALb@GvqN5#gN)B)GdTUxpZ$nzE0M1;Sf5Lq5 zs}9Rlgl2_Y#Rm%nrE<{kyE(snf3E3ab3@d$TIkRmH{_RZq-TB6%IhB2T=@B2`NQBs zliSG8d`!4grnA(3521D9L6zfT$;;2pDzpz6oy0UGXI?mE{kl6oxbRtBeyw~TRl%)W zSBP%wl`LXv4dxp*741Q+st35Jc$x>&x^lb37^nY6~z5}LU4Eg#N)>GhxXlI zR31LKb+iZKM$FnUTOlIqTQB^cvsf#}{z~={&IQc^;I>#hvwAZNpxUT7WmG#n?`hG_0@Q*r#`l~^hu&MglhkuxE+wqt z-!-bf9cbXqypFa>Ebg#zRrt%G5KwH*D6Tz=C;mM7xOe<_H|WZeeZd%|29tQE&~svL zj57v7o!Y`T!a5DHf8`8o)MdNt&eAUGXda}RZ~n^DkQplee$8>x68@s-=Dyvg?i$_u zJ=F>*l`wu;WI~jMMn=7{sU+6>AaGGzuX?#eHP~^Df?CW8(ka0&!_(=aH9v`8S94^& zMU_dT&wPvie8l@y{dCqV*eAK>$wuHaKtBT?j)8>+%*@Qj)OMM9_O(ydQpp|Mx{F5*g$#^WS%j*q|FEfDi6G+idEAlKv>ywC!?8P7w(Pn0s$zdvW;#AWR-_;0{no#^2} zKf1)v0)EmJYQ`sw`K34PFw!8_J zoQgG}40^drvHikuV_3~R%Ha8aGvan#-@an0sC-Rry>R<{`>X+ApaYL?_7*o@H?k81 zgjUW+Y4;Q>>&8H7N!j`~JYq1HJN=E`U!Xt1dmXb+_;C{w738ny5Z$zB{<3!iMeQJm z8Ym>jLWoUPT4HM$<>OG~0RRutXcVjJMc8~1&ia3l$M-97NU@p9VKgB;b&C%sI6~`d zkChtNP=AYDYPh}dq_an!M9=xYyBn}%TQ!_(^IFwA-uycM4aK8)@LJ+$uVXOA!r{Y? z(YxJ{SvE(1-P8wig{+#flhbTuLGR&~!Qrt8I^ z#VqZ$dfMME-&V;S*djcmx<1U?ICA3f3i{ty-8dM^xy-cZQQ^^cZ;NT zfL6lqgV7B;lcyw_13hvoc3L*p@WH(IUeAmzi)#Ry8oB)3{=^%-;@RWhgPZuc1XFOh zHk);>-Sl>NC6L47&??%inx{gpmovXnmG}K-;+X`^x}CFb@5)TZ8EaO9j(MW7=a0um zOL}kDLLL`2$mhqk=9ba#>pbsO2(fSzjrY#hvpz>>e;eyia3;-LTD!3^NfK=suy7xo zZ*Wh%&~WPDG(zT_%jX>&(7Gw+F-p6+URe72qkV#BKJ9udhst59Z2QQBd$gz$N-K`n zXpgr|#WL%3&immHt-Eubk4XGC9{jZ&&Q_E!ej3ir6#C57ya+DL)dQ+Y7y3MKATM;l zK>mbnsAe;rnP5eCLvO!o;x}pwd5|=33mNLTUO1D`P!&NkNICTtquQ8H1Qn#m9~cw- zNAl~*6h85bqW$LH1T6RXCwv(dA~omVrqL5rR}M7;t)Qd~G<^92XIkZ(R7? zjm}Q*=r=CGb?4gT9kD@4W($M(UcC(Q{Ya=D6_zX-5D+ zRXg+>V}1$%X($v9z8?Vp9}smC3y5ZXCKb10EYB%3mV9Lyd=3Gs;cM7$rlz7m@+#!O zAyWUIqsCC)x9SmAas6|FcVS3@R_-q1g8yx%EVOhi1nb|70LhEn(T?JUd+de!x6qH0Z65SnbesD7K=R-Uq93S* zLwZ_tXx~s}53!*u5f|O-AM1aD5OI8cg&IZeq=PakQu?C*bagO0V^@@!WZKrYODg-u z!sxG--@26-yDtC*LtdGXz)Y^#|MBIaNyfaQ&jW%J{(Tr^O)geGTYz;eLYU=w3poQ(gp-}riHP=vms^SiI(1$eiW!$CeVB8U6|G#k~ z{F_^dkV0>#?aqlP2#OCt^W4EA8BpJ|q2j}m1K)L(*zP1Oc*Y>)k$T7;w-ZG~DRY7X zUfxV`hF%dUEu(4W^y^_&6?qmn@SQo|u1Gnph54Mcv$xq=tgvnD1q*tzF=Gv75!NZT zw{+-O-#Xr8B`X6Ad78>3o{Hj7sG&akw93IMN%%TBHJ}r*qL?l36LH) z9R5apUfw+zS46xF@L|9^0aE1#;U1Ga5`)yBUzQwWSfjK785t?L^Pmp{C^1J0lf+~391e%(=Hvmei(`*=?$2bgtkJ{| z2j?kma`p#XR+Zj=jP9+uZd;RJMy1V#HIF*>&GRVTUWl_Tg5;SAgR0dgykQ&paBH+$plV=JbH5T8W zn1f;(OX20`zR3j)niEzf>B~5nGS?%S=SN}h8yF<#A1wIp%1JUt{vA#oaNINq0HItd z2!A_=;$AbP0VTMQd3?ANp1gFebYth)B4>S}`fQnKi8-p|cEq4&e?92s8xZa%U6#Qt z1)Y3ijkjCF-S6CtKlc$-x?I-s)e|J`;IWlX^!kq|FkhL1yqY+&SKVm2#~yiuRj=}i z^N`=D(mCx@QB1Vv64Y-{*8K^}x;}&@2_%-ALw?&r1YMIn^NU|5Ww%FlIchCQI2Hbs>&(2f zPj>z6rdoRQDxqsj-O-ue+-mReaqFhRqUk9u)#RkT;)nfbzW4LrQh%2kf0jdatTQDNC-1ua5+a+D(D>pe#i@ zAKWADi9RP(6V+mov1Vy~)Pu@{uuDmkgK)p~UK-p;9|eOI@@ZdFvFi)Gp_$m{c07DK zBV5s$Sl&UOf0o7VcWp?Ap3OT zC4F<#88Ms_qgM7?=>f{~OAx8#X!?Rq1``@LxS9Gbqu;vg-;IB%cw!)vfWUkWD2DZ< zWWX)x%VJa#6F4yIXNJD%eJ~EoKgBB-7b}7-LVzc!-&bjv8LJsfhpx{%^a4^^gVMVC z9NRVmEF^kP?CQG6yNdy;yNgWMEmkDuyAO&!+TauWinFunMM}0W58ea5sIySF&yPty za>Ctp?b*@luOq;ET)YrzoJ1sEs1Iug`BDrCEJD8yL;Mn4QLB{RZLDjA{T zLyZp;DsJ~p2nZ)3ME)N!xit!f0hkD!bEy9W?fF(|N*iTC-yh;7{R{%b)XAYPV;5e6 zx{LkR4e9#YDo&yBo1f86#?84<$IXM^)3pjut18!CURX?LW|i(;w>0B^RqVuTPy5bL z8SDJ^;$3LwG^e!goefvf<<=L%4K z)1_ZdJ!9;9x(7rpdA2jAFL7$txRQ>{ zo6UE+rM@LO9I?Ea9T}R(nWg$S?p;uZh?<;0O)C{f^&9xkEQ@&*YTmF5x4?_F(;IJL zsyd)AbNIDMeO#AOb^t7Xzu#<+05>AQhEKv}2`5OaxXtx*FroC8_wT{sMJ{`Z!Ge`M zCn*WqsxPTNvkLTR0UU%oenrA;Qku1=etQ#D(uD9qgM=cs8{ac{omos-y zCO%z9>KrIKU#|fNkw2}TgIC%;iPhXOA*OT26`6P2mkEq8BRP&z&^?eCFUv$4eV91H zvp(zQGRMK~Gq1q!$jo03(8!vm#Svnny~ZFZ6$x zEMy2@KPvm)_M8@RTVA_FMF$(0AU7xQd$ec;qHhqKNqICl(Dgcx1Z;e9A*wPygZ5); z_~?*18M%kUpfEv*_y&UpZR#_we!wGEmwo_uKa22}>n%{YjYO3%x>YIS?Z@d#AAo%* z{Sl2SYSGNl?M0l-(47e?na7*j`n{7^WkB(7jItmChg4gu6^}roh=bCiDFhboT6oA_7;%>4O>4INpSqWsve zIn>FU+s>X@9+GeS4odHziHit?b>GE{tI3L3UW`^3lKg@}6&D{Ku;Va1%*>6ZePEt& zUWozjAJf)R%qo`IHJN}#;u63c*4Iq3s&gk&aV&7n7K{P+f-@m5N7L|#z~I`h)r6UE zKTwspr#&c49h1=krWJbqP4a6wVZ_4MpjG?N;zT3m#o~mvIdt@6S7&+rKdqS`816h+ zC58L?pmcmG#$Fjfr_&|+14AbTfhk6(#9y*ZgCq;X$vnd;K`+?YNjb=4_lex_dKblCNmL(^CDdDp;ICG6Va-t_aV zOldC~QE?FlrJBRpSBVQYs?WRP(DSGbT}jP+erVo=_+IoT3VYI7czq>lTm$2ofkqQ%Rsp*yqL}p@c-M z^lctvy7NEC@pe?xpEeYeO^zZVW`0o)d1@lVMm%92Su=$ ze2$hl1afz5^wNFpNWlGqGanA3)}QPZekx8OY+xooN;moHhMtup+;~`TMpRNbVE{y0-Kta z9>-#B8W_w1;40wa(;vo7h|oQwh?W>LR?^ruC?;0)Ztn`03A%?kqb|R*-tkxo@Emh~ z2#=5EJ%WNbSVXVV_xI&-1sPCc#pZ{Z7)Lam-hY`9<|9Ai0{Iqpm9mu?wy)eQFLpI3 zM>qNO^8mrUcGW^-!p~O*a*O#FC@Qc!QT@+AW@_4#@ zqura4Mk3&FBm^9e5HFz&+itpg5+h@8=Q{;n5en8tQ*`HHrVnu12Hze|9x& zL+p)sZRU(91VnK!yYzn^L&WJLP{}p9US;)g0x#!2o7v;y6nGTaQ_8^`xk64U^oYzdM3$|MvPASFM8o? zb7Qk{pa0g*Rv?yH8aCQlAQrq2#AtdxQ0+yGp63R6SI^8rrd^TyaBl&A@$7Y%^ziT8WO|u4 z-__Q*uHVefl%R*Pc@BO^Vm2X~_cX!b86ht&L_YZofF^=q_A|lWr{{`1rRsW@*Q708 zj59Pxlb%w#shczPUR^x2iW_7-Rtll@FQMjUmNM;3+=ugx@DnB5V*ciDwvrpZ-*sflC9^X{{Jk0)&MK>TOly@k;IPsXrizWgm z9#cx8x(_%f<^fUOHpl*rs0Q6Enk5d0)mV%DVX=UiP(Rc=NNp^*SW`;~Npj&=@CU!z zU+-e(4dvy#Dj^SAmBr;5wl0>J~1dEd?x~e*3zOUxUw|*9UH)5Dcrq=5_x=n#A7h;d>dg%cP8;lwE;0k2<78h{J_IbN8`@`>&WE#<^sC}dW43Uf17 z?#ngYZC25@M$d9XX3O*Hw2oJK&fM1V#zWy+J|rzmy~Id-eCcbwOT*(x9#Le6zaiiJ zg8a+fF;!BwbS%9c;S)V@_+nm^NqAqbs*2ZlX+G_6+ckn=o;G6;ap|6xeahpqE6;qT zrT+Cu7OZ~Iq5I3~PhGWYE!QsUt3HqbMKaZqv`#hzkEp6MT zpObp4z@VYLgDu$WBi6hy>Ru`{{(P7N$#lf`#D~$*xyBgwLVw9cB-Xuj>iO3zvJY=Z ze7aduAC>cK-mWx$k3}KFX8xrfu%FiTZ!mop{|2*Y@oz92#xH}>S~Dqmf^Xf_m^0{{ z-!K;Jz(laf`(q)MIxdaQ{%u=eP;poBk>M)>oF&I#z==)HSg{^$)!W4BD#Q;KTVkg9 zv<0z^uVX~(ATVrc1+FYt+%BEIO8kN~7JY}k2>s&T_NNm|4656yjJotzXQTk-{VH0n z)nWJiGm}=%hB&W9p5lD1*vwKYZ8AEAf^aF-O74jIYf~e{>Cq}yQ~h#@uA3iNp-#HA zaS-~nKzDDso?DnCtE-=>OSD%lV1K0)3``YofI#rYENhiO5SV2-`Eau+C(h-m#9`O? zu;%fy;FjU*Mt|K13#_v}W_Z1%uQ>u2n2_#wgX4S5fRsKQ*)I0c-2a$?Y&o#*>kSSF zqP}cox!N-gU*c6T6f)ADYwbUu22Py!?ucUG#IXTCn|;d=H;bxD^T)>huJE58N`Mss zQq@3}bzk=~+YJsx^me=?!douh%t2!sA)=qL9%!oi;cXHhE&j!Us{a=UY6T2Nb#{fX zMv@WBc1`7KZOHBAxH-mES>y;|#<385$?jWq&1Il^obsv7>v0u$Rp4#Va;zA2j~>5O zOj`H7UcpKHY&q@VOtgibSsLxa^*pOf3#nSFFF8+Q{bB{?S64MpaMG;~G)L-y=E!{g z4g;FXk(@O#w%^^4n>8a(C&zNS&8I3Y%1sZn7e;oDi}SEvO>cLXrQ!%j z=D1w#|FC$gS`a)P@qS%jRw%k<(b=FNtRK0fZem~Es7%^H`d+~;_sE~+DS*=^?V61M zy@g%v$#OI?a-xNqWx-S08h+u`l+{K%xA)k{PSc*WvPQFW7(TfHDR~rocokycd5kZ` z|5#?lXu{3ME2w8ti&Q>j8lRh&Ipok?9MeQ50INTR12M(~SEkRmo}Do(`nk>-sb%r~ z{KLsDX_I%>>M?S|h9wU2{B#WBhyE>7)BN&+*rIL}3HxHNS4cRF8gh7zJ&`(AkXue- zJJ)v4mYI^9T3!Li!O}fMs4V6RVpTW><+uJ>Gx-xD(Kld>cId$b3w-Js;IrX*!l(G+;<`a8u}o&_3o*vm!QKbJDDP=s;9IIu2UdzR$ZBS%;(8y z)@cZBw!BU2Gx|KkyP%TxNoTf0!Yr(3l%SYiLwCHBDzq#f3m@Brt-(u@SXE`Qd-f_JRy_aeHriWJ^{8-okD*etjm5pcAv*l9}$365}z0PybzqerF zLT4Y@jHHYPOfHxZM<8vrmQ%-ODerL0uOA<=d(pU;PhY=F9HRuzBrh0MNAM&a{)wF6 zNzPn`@l8KEla(MAoFR{2ETWTj&~}_Wy=B?07je&C0nSQmz*%X^QpPx{$vOP4MAFL3 zB^e{a-qYp-t*%|P;x`$WB*b;qlSP9Vcc1UUy^DkRvVk)c%K`PGM^cn7W&(IMm%1h} zi>@GKt^XYNivW+R$fpZc|}u54f{9BwNNm6eTe(YT2<3;)p{^ zd88Y8*uJc%@m6}CXMEsR{>q}TN~4c!(mX4r6-7$;ewz(VA2%czV-svdf~BsK%L3E7 z=vD@#LLW)hKAb_}^)$>SQ483b>RGlLP$sJZWio>XDZzIO5DFXIq<61MSHhHV>p!e~ zYVfsaalZPlS=zGW_F2ax(6~L;1=$3=9D*z0<)}p^w`^0bP&T7cGhRJFCp|M#IqKV- z@#t8}B2GQ9A9@*b42p{xBL6>F6NHA=GKMZ z^w^=jKbwGa%)V0-99{tMz;XfZXXEyTT)*f1LZisalo8jxGpx^c!_UkX+deKd9I~Wq zJ*H@`OQXg9rE6+$6u*G`Moz=c+2Q3qFLN17T`$bC6-ZQ7VsF7{!qXWJ^nI9-i$+b+ zAJcbSy8viDc1rV+!ARjlzThDd`Yr?q85%?U#%H(%~j?o%O zF%aP?PCOPp?(t}vruKbWN^VsxSyuJp*tb*4wpJjlW{yp^?P}$Q408pN(7P*16p>~f zO3qQ)J+xyTN~0?~)QFeWWKzJ$YB%HJkM4RVN{@%K+*8)mdF7?IoX-5wr8Cxav|=S~ zI`;4RnE?v_D@Y5_DoDP9sN=BAg_z#+oApMVhP*IBK7iboqG7>0@E4K>KDGBQB$Srn z>C6{H)}|B}=>rtpt{y?I@Y88aZ>M2~(nV`w4oHX6tz11s&$8{uE9OVq?n9X3NazWR z$&P515U2|(2(ifJISs2K9Ycxc=)*aN3|+ixKo5`X zyU?8gMgAJD%ssJ{Ov*_2nsm{*%Esp)8e}_e;M|iWV#f_EN~+$AsaF4O{$^5{qa8Ud zR~4<8^|no|pS{th+KRE0hwm2D(z^)qedPC1z9@$rR#Po-mcc3z=S~uba14HN_jw)G z*Dv5+g#=(OQv@FD?l?q5|AcJnmD|!A1d@Yns{`KHTzJEHFn{VOreA zr^-^$RWOa&q7i2a;xP!~#MsQ}OJtN(}Cvue#bu(XUPxY@{m} z^$+IeIW(u=yx51JCW2a?JV)Ph;jXc|C-2jUz7@({1Mj*WMKdr0$t8sw>vFyLWoq5K zbQSq7{PI98lZl0NH0r(@zJ9YwQVglmh>OKhE?N^F0`Eil8 zrOU15Ik1{1NiK}c&bSS{(ZIQ?bm=lHb!_-R=lbX4Nt2=Hy{h3-y73V1L}wtKV?6)W zKc^RoE1x*9$ZHCphQ3s3GOD3yI-SD*f2A z_nuq51I?o2$U4$N!1u$~vE?f8>l(p{uOsmNCfgXV>ygwM?E*N4; zLq`O{?g8>R)6|gJU}q2I#V3th2%dvu*ch_XV?4w)1PK+|7Q!`AYyv-tDU@UE z9_~W0Ce8(_{}*|jL-3DScnF7GBtR}H(2XlLp-xC1Yhihd?4wEN`oZI3d4ZSHyCUZr zJlTd)odJJ6?e|U__fa$gXf8I~aS|_HOhS`VGVoF6_s40*Rdr( z{6I|wBaSav8}zgnVAu)(*Jh!I+J2eLCF+KGLEV(v?sXjgw76r4*v+eQumD0gy5(R2 z;E*D{T90@~G;307xt7UH1S%$Pc!zN8KBletE3v_c% zyr5%D=;wR9RmjQWuz@^_Q2@o`RxnYj7G<%nRl4AG zQzMk2H?-_Z=$pH~%IFcg3ccD$zvlP*=MX3A_dkcYEa6>%x^oUYKg?XGS$Lp+)N5~> zd$v+J!^(cLZCb~#zr4;(m#Yvyf3_li7QJ5isnr&n`PL2Os&_E^-@&Tf`C}+TQx&ED z`qh}O^*r!}cRRa#ANj>5Ty-BAOCG#?_giqqWwiM^DK#xBzpde6D{DsgNOox(h_$> zB8gp5B`L7iuHllu1+K%OcfN{Yrgp%^D1x8~$VrMI=+2f{Nh@vfMdNsuZdo?Ty`N~` zCVGWE>kntD34byrvgM2mkPZ&F?3`zFB~|7AUDjXL@eq9&mx-JmC$^JI%&%1irL#*r`c+gi3qOeWZt zvOIB_FYm;~O#sqEKxn{}*+I*@sfCq*uDz{DrK;=m*$C{~z3oH&_^x{hz|GKiy?-a4 zGDC6CzF?Rn)0kf?+J#TZPF4&)I!6$3)M$9We`Agu^Igz?dZD1PTgG!$+*7g*&HPCl zmUSAoj~_jT9`bKh1nuhWSfKC2#Y5)IcIe<_|L1B?{yK%1ZlNJ;V*ryWsp+O#{L)qg zA`|QPpTCO+^zJ^1FND$w|1w1+wcfAgHioIJ( zjTS2-)=B*QRDcxNkIGL4rd#|C;b!+EW6?v#notDY`*nLNkODUN?H^_>23*0k?!t8*P#^=2{{4+QU@d?rKP*OkK{qRyPN;;efR#? z{oQqS9nR9lyz{>E&g|K<_p_hp@u%-?sLSPHub?z($@C?3!h{uyV2Tbd>in#OBph^E zNx58`ao?y{3ojFST6zSnN_578TM~w4eh0TSUmb4h{X@+jA?wR^TRu5(O6h)BpHf7) z@%M@y>V7@1dp&+=^>fve*xT31`>hzi(h;uQW|Ws1;&5>+{BcW*-CwX+*RZ^Dfx}Rs zIHZ$J6|HuRfoFAe*7xmAD`Ww@x4|9^>s(+sbP|kTkah=pVD6Wz&;C(^nqz(~PVd6P z-wrTLU2h-m4&R$Jud0HJaeP&vtR zh;%4ZeXTdke5u5#vJ;o@QW;X)mRh3avHqZ?Pm6ITU&=bENVrfo$DiyC@6!C{;APP= zZ#BPtWpBHQdzFGH`{|)t4F8(!dskibJ&(&RrD{!voK1x9KIyE>z0e}l52?|t5%vc{lcK{-8_-c{56O>bn0Kp7Lo;W{Q27tCs20L+VgZx*7#st8|8L;m?ug zYSKlXB=7k2c+_sICiA`Dl3z{Fzr$NkxW8@|YjHU7?VxT=K)uLzgPyt?`^iYuBbCe$ z(ls!y!tX3h(+f#h^W@1FqipYm<={^^pj;O4W}1~meT_uCigW`Mp>6v?E^ zw=sfy9EDpZ@(3%wa$M=&7#4Om*bm2o-ndP*p)b18;l*vbb9N|t-?Pb?lTgU2lqD^?KHCqN8^D0h$=9R{9}L&LlqPW6SxDp zqZ|f$Bk~O~NX3O(Kke9G-$ZY^gbOrpx2zJ|Qs-!ML)E>lx|;5}a})~FOU_I3nvWU_ zU>L9!q#X~ta2V$9HBy+vL1F=ky247f*}ikLyrbPLSS-{h3;@a#NM02#vSZPC8#>On zXJwb(dVhLPXC212>nClim;IJYF=%r^cqfg2VH7$0V!WF}D7c|=dHcYlVfTHt$QR;1 zYPFef`7XmMPCoZ~gFn1-P{9gncWv075nJ&$P9J&T~5gim620~lg7fFa5`P-f}O5Yv}M{50=^ zZ;o%A7_se=-amS{i1a^yE%dBuONNNohV#lDUwt~|rEk+0?2qgbKqX3au7bt2&go^% zb}l&~Lchnon&Y_Z@>dN`{ATBSPu;cLZ}8A>QF)c{7bZIJ6X88!UJ75@Cvm{jCuWt< z5QHoU5wqI7>Ncm#??+d&9LN-xO$Nx)6VwLa^V%^pY2PtCtif1PEg|RJ;l7_4d!ap8 zR3BHv%ulMsE{3AchsIwGIeIpcG&RItLJzW`zu5?XHi`rjUsJ19jsAtReZJ{J(3ge7 zRQ6KqpYQU9AG`dRy|Qh%5v@Ioxfon7INTo4&TGh=MOW+0+xB)F-l^Rh{CVm`l`u5IO#bor9L$s84xRBtrc!%ul=-Lzu(O zp0g$d)e=~bX%UQ+=0wzV+t<)2tB3>j0M4HE;Df<8 z{ZpE@WIAZ-ja8V`PO9$+y^n6xH~!`a{A#ETzVIfPKB#gy7cy?5y%&yhX!L9hOZT zsX8i!hZ;-XYNG^j1bRQ`k0nW~G%cyGN5j804hOcTMGW4a`1{2lw!&9k3A1xH_-CV| zSE74R3G^Eeu6`Q=R(*eW`T2nWpHluSS$4{l`U(B>TYaygRd2n3R}tzL{ex(51)LX? z_K6X*CV_0>e&=y4-9OreKxo#VKJ)zJyLzp%S)+!Rg6Lge5U(t)9?W%^mcUaaiqU`~ zfKZSZuKgcPaLP2Rk22s}8{!e~#hckwc5>6N`+FY!eQ@6-1-^%&b zmzHHq4JpZlylnd2p4T)&he3UwD53dlr6!GnVN72MgW|W7*aPD+(8slSF+b?z^1atW zfpvHpec_Mq7SfiSx9=}b(K}P@Vv?5Qk9~{Qoqv5DPYC&e?zEd&so+kOGXNx=^zS5{ z+!=KSgVFZCWYtu|-G4gKl%?kLLG`vHu3+5felB_tlCG}7@OsN*wvzt+2#tIgu>if< zoaA*)E*@m5G;m19RCv{^#nxl0P0Cd`FFXA;0TmzplO(d_#b(j``>WdanF#?)7F7H& z^Co^6;5BN1jD}T>q<5_kS+%@`rOHf7v78wkK29b)vH{!+1D)W@+%Q>It=btb;v$+g z)uLw9&L%)G=)*6j_Un%xgH!ZAesXV768-?;1A9P{Axg zlh!yXA0ji_Ke!jp_f697DumJJ!|{7rGFPGZA+jdc{j->21k?dg7>Hg4HS zF#A)^@Tn5?FLudIhBuIDI6#N!F*cl}KUk?%`as zlztwH?XFHYWJSu+^99x}iK95E%o92l`Sy=>7YGJlem>wMMUb{}6dli9VkOp#+@8)7 zpLgURRRBZ0L!`rBvw|P^FRn;Bf0y_R`UU1-^KJ1KG!H;)*?Eec;go{gsQi2r4&Rxyf)Je!sGWmz(7oZfoR@|-8C({ zshgPidz96RvY#%X_T2L&^;0H`1z|G0_sZKcOp%u zuT7_WjJUbJX$WSHt}C9A6;*V^Gj;O?TQ6 zN;4ozGWhoJ>33Y!ms$4Fxr52;i>-KzzV@iNKc97Acmx`UwbA6xG+r}4+>u;ik>q?V81JbPv}6qe69E_ZTDlogISB<@Cql+XHIR$+Qh0nBSN=#YpX@i_$B%hsK@{SPP_}C}nM-w`|YVBEfH@+$l4e1#9po*L(a%H;@cf*a$La$QMWZ=a>OZ$=U1bIr>DrM_1 zB`p?G@zt%xm3^aCv36*H?ozGu(a>E+YD#;{ChbcsI{^gLwnKn_I|ZTOf<3PyWsMS` zWmtCij zJipuJ*T#k__3jb>&CY;lt2k{gubr*yTM`W6(i#U&z#-Gnme+!IBtFa;BCS9-A^kNX zw@5to#`X#I0UHR99-$0A1RV1tLBIcDfb*KNP@a~9+5HZsA2cT;UOx~0+480C-Uzyd z0^`j_jd!`H?}C?WRin`h1?*goVrk9dX{q`q2NidWOSXQ5Mpm7-^m$)_zT-*n;4vPz z;`mjnW6VL(X)gqtl=J)mQvH{ywkW9;WSG^NYp-Sawt6nlJsLQ){>GFwvS~d>y6NSa zB7L=fr8cneInJ}2WKKD(j0(h3OfZcp$;7{Gng9ta1Ie_K1gQ>7nKnkNl{K0Xp5wnf zwI5Inh(qr;`xO@gi4SL5mGQpm8q0x&$mow3NImnLI6sa!yn2RCr{-CpG2l~c9lSV8 zv&;Pf5a)jY#QB)sK6&04MmfE?GJ73r-;(mphYhv78gw@XYklQ34==A*4Cxx{Fn3qA zGDxjNl;eY!@W=cC-e&ydIr`yaRy@3-AY7NJHnCNAi8E==#1({qJd%A~iTE3Z1asB4 z;~;?pXwH>x;mf?#vCnDUy)hzzerPj)bXVxk z35jM67}_;aM#NSMJR5ouF}-x?;Tr!yje{grU_&-@+3r_J{37!i)$~HFh3R^HkorPHr{JF5Pf-_NqTc>eyf4(?fvye)g3?J>Sseu zW1naDwoB!AN1x712E_3qBYsS=xH=!jbqfjyN&ZuX#s})Xqs+6(sZqHkmXq(&akMl%KIwew`9oo$c2{LpuHe)zkha61d_(G zg^IH`+^}j063-JmbD{2H96c$LXC}4!0rEZP9>?_y=a%(Gg@m1r_2&h(A1=ZbzC3dP zu1vFNOL7c+TR&3i-YVATbnRSiep>a+QD&Ms-#F59qT`i10=GU^{0kI`J6VRcpk=^A zgnQw2U_Bcrdsww$7?rOg4pkqjWJY9sXowj{@k@IX)+TgU=ZNdwcXNbNFQS2dv1ooR z$&+uNZ*DZO3s)H};_JSuT3g{4GeZ9G>_sY<-ELpiZjh2CK_-vx1zdG}L=8A=OD_pK zlk)CkW|2ON7-@-pw85-J=grD6JgJ7>_?C7xhH#R6qF%~zyzCqul`{dr-=;33sdEd;-PC({lmvigxvbT zxtt^9(~nZ+n5%tM_)$Zz`O&7+O6R4s4g}@r6H%kJ$rP7tmaP~A_wkg*%e~QMJu^>= z?|Tffn~T-%oGgB_Q|rt@d+0M-1*&Wx3Cj&#hrE^W>eXfCe#CEl=Mqdi#-%n2sS^@f z4j|qng=&!ZgyRS_3HdwI7kbU)$d*|MYM7be1oXmo4kVT}dcV zML7VfD9cgm{l$g`%CFCN`uyCDG|GgUxMnY}8KIA>N4a>?vfFh^XSaxtcQivbMEx)B zqqqbVpcRgr{QRJRy8~6_bFYT!i+sJ*UO#dbE3nR1^6e}gQQ+pvg#@u5;;AMwHFeQI ztu$B6O0rEv5Aq25Ko+hKWZ}O5jk64&$d>#m+4cDo>3sKQ>jp+2kOJx>{ALNpY=to1 z5{%hOtz6m1{N7yJafh8=_jJ)|Bzr=@pUbcH*VgRo@7G1tSpTT#C9vT(H)EB6r1mU2 zl}-UR+Yy1AIo{sOk@W8`yYmt8Luh?y!V%>tpSHWE%NVZsqRgYT+$FreGXnN9y5tHX z8XZRUMh~1&0fE+5f*&4(c29&=qd`H)15th0YsvZtJL#Q?W-bN~RO}oc6Kf)qWJxu} zA`tzlJ?3TgFWi%6IZevgt!jkUrVl*}ynmS}>wr|nlU3mHffZJyods6d(+0AyXFX-U z(Zh*r;2BO?492_>gfb!{fUtxg?>)sN~aOiX~H>p6VAeK>bR|Y3g zXOaCVVg z?gdj2j|}zCEDvXMN^QYv7l*g!b)elgm8s%&C6K;;6~)?pSZ=%l6R<*;FGEW%!})3n zP}#4JWqMq{?>YNY|CP2wm)O;mwLl)|3dgEk6hI4Ex>hZ?H zE_^;eJbq&&wPeYoP+XY{NtAgkV>S5GO`X}YIE2$GuWP@U45Z32sf_~jeB1E^kHW88Gvk{Cf& z4dF4hZhnck#Z~t5ivMZ-EIF$8^CFr2KP%nO=Ai_%XCVIZRjkRseWQ&tkg(hcugiZK zDi~GW71+Lq$=I;b=!hmN?hEwfG0u$lLBIh`6n>^#-abxW$n{ivK<%Nk6xW-im^=n_ zAVYyNyOZRn-|raj*$X*XoF6~m&?8)GUDjd@COz0+(qcp$dsG{;?XKpp9&+7YUTmbs zB)QbiP1s{B1p5^m>VlQ->Wh)VlHJ(-nAXU=dCTD~*6fIH{c|!W}x?g;By0qTdYP z9=bP-`^5RFtW0y}I`m!3{0Q(*(yyBk80dwmXWVba`LS2$i!`6}3tSA-2*KQaA8Cgw zPzbgYnKF7}D#7mGfx=n@(88|TvW#oKef>Mb;PZVIv)szN&08n`Y~27QNe2kcqzWp zrd6A|o4)r=ThSFyd~Rjh;zfsp*j!Gip1XIT@BUT(9A)rsFIf%}0ei`tb1!(ly-y+M z!Fpop*V4}dfrHV9m&Eo)W-HrjhWGBe$6E#-d=K#8zsaikRe6coZL7Pw#@0fFbWh8FTSK2n3jxrvHC+CxeA(zwV4RuNm zE2$vxQQu|>-)e|kzB%nark$l7l)pOn8xf@Z1344boaasYLi(WXg0&})H z!XpEwrP`Hb#ZqA=>FalilnN|NnYAF4dyir-~>P&G^)EHw!pArL*TRT*)k4^QUQq-HgB zNkyF*mtZ~xp89|v@YH828}sl^0bpYX05+=ro)}x`$Ez0WFC}*@iYg?bdg<>ZLGSNi zc^8A}ej4Ia45s_3fv|R*W_;Q1T29jGcz0dRuhsmrRjZFf=061IF7R`E!bNs;bVS!g z`b9T&QW>j}-)fI4y?=6_s}qx*7f6RUDwD zu25xOXmZ5;MSFizfU&J}|MJ68GTn2DU@~*RKuNG2e?D%;1(m)3EJ^RTXs-lij2`4n(C=%FcXp;sXVI_r z&)@j}#;6}5w@yDcJjM>cKKP+dsw=N#aUg-%^e&t7JtsIN`5d_EK{O9XhgJso2E?d~ zv2V0rAcTs%)5{hMg^JC2G^zPUMHEwC5e#BzDBZip>iP|8mi=)}jzM;ywoJ+`9cDj_ zryDN$*Z_?Yx$&q>0sE^%)P$!uV%MQkhb{j%rtQS5e>0MQ3w*3;w?@IaXsYwj#$q}< zHcCTU9zz9dD|l2pezlTtS#y5vKtk-`@-N?N{B3ewLtPCtRezBD@7PPP2aA4XfLVLm zp0Jlok~8Y6>b=Ywxwcn*#j>ASVvAzsYK~9vwQrH=&ljUi7Y_PGr1-9k=jRs0qIN0w zMK}FTYT`vUee-Q}uMuK5S2rsMNJOnx_aH}%5j((|E*tutBoN5sjU2u+&g66?ARct* zI(s)aVeWPhJwlIh3IA;pgZ9Sl_(PZz@eoEixKK|T0F~Gd+}mmvogmDc2X9fgm@EsHZMxYRRw#L`zI+f z?J2;D8w>GL__d)x$V2xx7$n1dr#^aKV!xte`}HRz4`={L)4{Z`5>liCJHy*MHW)v& z8!)0z$+r=ETIkKhzSWR(AAcF^(iAbQRHnA)S3P0x=xJp$tT_4E1Z>=gtmZElZNzV4)q5%#!2-LI5e??u;r$C~Vx~N)Xs1|m z@By9=B{2QiEV!30yBoQ?uO8oJzvgKrqIs$RdEJctF1!YlS0Nlw@duE<9FWcHVJPE@ z#+7l!UIk0z5cPwDlY2dZ$}5o9k*ZcT>SpX6ktDH+vsf`RYC`-nRgA`}s?q+X>3U&H zQXYJflR7Lk_w0;ku#~BaApDDu3aX|IZ5ITbbwWvL}|AD1;jT z9m;kY{%fA;SWvjVT;9Yq;hpmLS@ZtyX%43P#lkbruklD)U2+P-EW}Hwlr&>m?aUHh z`*Q&zV%kB-E5IeOd# zDPM;~e9>tR{5~t62p~8%WShc^0~dRvc$wy;|KkF`K%&d6e8=Y$>l{-sXuzAb^W4J!2-+z7 zJbzy#^Sq8B0yh~YV?k956X$Qg~<*-LqERjZsN)uA13*cQM8YfLz@et*Zcz+er=q=cLGt zm9&{k*N!Ub!#l++IIjHEGse*8DY-_*^n(Y)#Ytb6URU$e)%KIGl_ot&k7uZj;%46> zPYAwksVh~%Ain^gd^!eGiApi;krty9E>PzG4QaR&mO{Im zGpw2aJ!kYN|Cuv~ew{4OqsQ)z( zwcFLk9x!#UezJUz-uqTFEQt2cI2nd@w{^2^c&iBzI#ze2ks9uXtE zlFHL5L%;BJQ~(fiHt=bcflteiBx91-$9tio6PIH7IEj}sEID#Cw$?{$rALB zJlINk<+C%}@|JuPwu1=sJ@!cuMH)pvlHE$w<^Ol)5M&FaVy9PjvX5zSdVHk+x}RgF zsEqXprVUmF79|XvJVy5;WJh>u%s#qY`? zlrVO%1Vx&>sPgx0`IuD%V)4f;K_E68Ty28qx07JxzFZpD%Y-@NZfytU58|Ch8;y{M zf=%vire;Kf+V-G`=3^uaZ*;|k+`@$gCY?9aAuD!&qWcJo?gP_?K#4VeQwC7_J~VHd z0q{$bgbye?pVfK4(Y>BxVXb;l>%fUEB5vPSm>WFg+$Mt-`X$|E#1-*=y_P@)Tv#xuC@d)J2-B1(rPl!-zyTzZ=F0YFQ7)uUp#GWQGrS6RVbQOK;X)4B?bPC z=Oix|xcwQ-%CFS+LjTOlGHUs055{4_kzPDOxA^UU&s$WNNW$rbxAZGM| zGzrn?io4AXW=_LONhD1aSc;!7BG6-I3a$7|cZZaBf}JHVm| zUSLxi*sbhG7pDnXuv80L@F2nw5yA)g+A07w{0JUZqDo{ioDaE3Te;loqBRSrSp8I@ z?uS{wdJ?G-)31Y>U|xVSZUz9idDBJcitd0~zr@6Z^bWS=BSFMz5Qw;Rn0+1!jk zrNn7d3>}Dk)c`J4U5--)yisbkrg&_bS`j4TJmk>)?Xw&$E0lPE|J>l(;R|UW?{5`O z7}y;%$bBQzxQt+9x{#Ce@VMHg>42$cf6&NxN)tmSY+qZLVF zxcl+kDc6^g_ZI2iM&lT}^PTAYilCMKCT-Xeyl;{Y((>(R6;I{OE^RMnDe~s8Ae^)8 z;`0%Nr}PGD#t{G@*y`mY7_>jGC2u9Xi+L6mR<7ji#AAXqNAV9-2VJ3w=E!9$)zQwG z3_e8j4YUev??Ce{wgPEPRNBF^OvqrgjA&<3jpwHw?So1juUe*HbW#0$H~IIdvp|Jw zZhJjV;;MJs<%jIvKj_w9v~#l0MtIwskxHOYe-Aww5M+_>NxTL_e~m(Tp73%G{Ynv( zu+0ToC<4=R=Ecbj>HW@KNUVhv`aqyRHiBg`3}>OOs%RIeMD+qRSm>fN_5Z&&qSft{ zmFxSQA644Vk1uZ$PNOzTF&#z*-Ap^DS8k;)_UBh5WX~ zH%Jwd$sio-pSjn${gZTH--&0G3A4i)Xg^WOUhxGj@@aMVp4ufY6KX z157;%qIkMx0chYcXrDL(xM0RXS{Q)U4&@|s2jC}4NwNq(BYYqT3K6&oEAEg1{fm=H zUiV*U!bHu(md9GyQ9DAy6LE-X zKlB<@mH5+_S7a-Ntr}p;AL3Xk{yAxM)@Kfm>>ZP^G$Km-3V^~FVa9eKMS4QIU-0%% zg^Z4R3`|q`6>ZhU^=?Lyv4k?HEE!R%%5>Uc){lO@#{4xN8gRaFwa~g8p5Ph~MI{sw zaM9T~Q2RUB^RXG}wb|g4@baS3Atj_TdbO@`_WL$3kH>VcMIq_^H_s)a=%_z)OZOC&Q`(|FM5NSmEI+1GNFO*W=>a&3k~uZ>2x!{41NX-h#c+Dc7Q9(%!Z6~ zifF%`p3}$INv;;KN963b`-&9}h>M2hqgRgoUg7M5Xdy%m*MnNMU8-l}r!Ti%w3v5` z24iUXRDb9jPbNR1@z-aGTUbYHmXo=Ygle6k&i(!v8JcB7Ft`Ft+YZ5=9(XUPo^7T{ zypw{im#isE)fe^7Gj&Z(oNoRsLA-WtqSd6m!&zF7dYj=Og5T~UJQ(|1M5`lxR$gsH zzlRQekM|AKmHWEszT2;Ae75N?Tu1UCXos;dbf*c0-$t-&JUnZ5Y68`Bh=x=@jX(AA zb48{wtvVLY8a7-y9TRCANqIpk;7rRYH7vv}h|`hUIm?350?&APrfysU2Vqd>i{jX5 z_;L=2MgKzc6$Nbi|? zPrF;NIALRLfAc?c^Z4!m)bnyV{@l<{i#%l8qnf{fz_Yt^+20VJ#p#41I!B6sgXLWW z;-R+yKRfvINq4aVNE?6VI&=1L<*D`Mv*YN5>T`1(Yw}R7T*+lk8TyPC)jpK+d@ah? zcb-#Yrws*F(mSQezVyc`Gy_c(q*h2$fXMEHWz?ExZ3dpd1o7$97GFJ2i?>QGwg)8- zq?FkOeJ@IrUssc=b>xrwzg(UK>9UR|-bAP-C18ZJo!0nzGIaM6kT^ zfa#D#4?Z-*l9fd8>?V!T3p(c z16q4!5N~mN9;zX9EbtL z!z*Gx|Kbmq@h(YOt($_`=E%g9vAu5gp71OCq_tXK*VW;4c zJP7;c$O#ZhelHHmRH8O(5fz^Tf<>}3?5o# zv^nsWJ{(cW>+(^c(5C5|8mZorD1W0*;Oh6t-c#NEaiO_gs!oJTvb9nc9AOB*6@<;G|Q+ zL-~C#BI7vv)z5~$zFea!&#jQMaaJFZ-%dp~%Q~N>{-NI@IdTG_nhJDj1)yJ4MWyaN z%G|(ZOt#Lrssqp`zp63 zPJC11MFyrWP>;||r*uc_Fa<=A=AD@i2(}Aeo0^sU0rs>25MJrn5qg?z6AJk~D1xtC zRtBWdo=_eS9~=CBA@+PN`u1IY2jT5W(dmYvmgjiID-aC!Ii>v)I zm}|FLvmN6u{+DNBn#-$x$CWp9lkAPYkQ-=Yb&;9IEbUF{q<{WwOXGEbssa`^mLs)H z2M!v_v^F`4ssbt+2?_}cHa0d&B;~Mv6x-7}AygC;Y77(U zWZ`PS?gg>`-xmN!WrbzX?hP6W3f_OT_XU?VaYE(;8Ny}W~wfZPOcm#PEP;3+q>4{Oc~DiKnEq@L-Zf5ZP5QmYcod|i~p;+Q{x1) z7ibm=J|zFqybuh8mpzB8wTX*``8zik8wV@b|LY1^J&eM~pz|3_6qNh_aRqDeKX+Gf zgW6mCpG`?&wOwU1pM%-YK9{)$fgJ;ym$A@IN+}sxC1H@@B`)l E0qO(;asU7T literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-56-57 study Document Inventory Report - Study Level.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-56-57 study Document Inventory Report - Study Level.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..d0257fdca1f5beef8581cfb1081f4adaca9a347d GIT binary patch literal 216948 zcmaI71yCDa@Ggo=v7o_S3k~iRcc)OK#l5(@yL)k`#ogWA-QAty4ma)ZzIpe}oBPj9 zWG0z&cE9~r&e@Hk3^WWD1OfsA1VO=+CdB{ozyyE(E@ExvU}WW>qvC2~WUmEsv9zdD z9XwqxcouSA=8$r|1S+(>-4OfvO_s&%G8rSHhRj54KkZ#wNyUcZT)0 z_1{E`DnV+66DFCeeABPm#8g6z{h5RG-y0Cq)z}zUwpe*$$#)b3R6s+ zE=o-9BD@@vKI$Nw5%T4e5&X6jTQlaz2W0+*CezBJUBquq)lF`zYrvzRA>1-07G;L2 zyC=!ob)+j8r%hdJ@^ygk*9n3zOLZc&EVe;CwtC#kYXm6Ncqs2-ILq_2lR{;LKW%7> z@g0aT(UmzWC%BX7I;181{08lXm15XBdY_qaurbn&)I)&W#E#+2zO#$ah9=y1EWTb7 zq1rPS00Me1KzTBS^;sxg0tB?(7~$l$l{i1eMw2 z;)qjG1|A`nfwq+w5(0t<1_DCy|B5{l7<(N%BMW;*(BIdxxGrgEWWG&9)?*yozqe3ja*N7q#I{Wu>3!;l4tYYvx*~f{-#jq55YI>Cn=j>?<&r z(cP!h>f7cXX`shbjyI8a{lEM3=$}g=kH)`k^0l)>%k|Co(@j|mH=VTphOf8w&1Epu zk@eAbTJmV&s#i!kq0YbAU|~ZNld$?}24!@4yR8;sg%iPG@{~4xD>3B@L-fH*i80`2 ziDc0e>MuH0EC@1tVBMvm{wH(*;9nS88z|aY+t@Se+1UK0rCe0k2QV!~FTBJC+t!YS zM5hz{5He4N1W13aa7Hb+d7YC+X@Chi*->NpwcWiW8PR zz)F`r;i{RS0O8jplwK8p?L|b0nXL#rfou$?f_|jYF_Os!x ze8=y_7uXb7r4^AV+}GxBY&+yYw3oi-L-2W3`4Tq{Gb-IIdW7fcRfodSnWE8mvWuxs zWa@C6V!>h0Y#2O275#L?+jDigO)fj1gkz1UXpuFqI`uH9otUTNzl4eX*jQsi`UOF# zn1f1u#THD$k*)l;;mfTt=zjq;BOGwh9MfE-4L)dD33h$_wJ@^*JDtx{lwvaoEsX)o zKxkRI%j^10OY5ScmaaNiwwh&V;$EzOp6Yv6o5~+^FAT4YNOO<@8ByHY>sarn3GA1m zrbn2+C>pQCTf>80rV9N0zoUo+M$yHB(cVo{ytXF4)!vcEYDx>>VhkMgkH+`e|u`Hmy#|qEV5HaeYhnMAZg{ZbK;crB~Gc*EFokBDMut1 zv+WfRUEa&N+WKFFIj1=0>7soyK!p@sB5W9UY>?6~NtDuObR58XQ8uRt^)LH@v4SUF zcuPtbXOvowA=TI|mhYw^ZKCwseb26SwLwv{{Yzzab2shun)$HZ%k`_6+fT0-F}iOR z3#I`iX4bz&MX57Hv-o#*Nyl!bQW4~+)x=cIZ!ONDqaw*`6b@q%vTu~31b+u|gwPMe z!AWxpWl7>FtYLOF1U(zeQ34Gt7(FSFEqQ2~rl}7lem?LGUN3iYSY;e7xx!Se>!Od| zUPc7Mgm7D{zc@4k82K}-u{0#o4a9#|3MseY@!~d4o8=-N$fxJ`zP#xVa)|`M1~e=y zA{@)R`8t=8W0pEWFtz@8J$5)4$jg|)_%JM$hmD?T7o7YdyDS-i#=kCb3|tlY9IkXM z^6QQYH+5JNlQYwM9H+^owxq^%O7Y?`ItN%V72=SAD{~eZFo=amnWq#-7yO1hZMnE< z`~&}Z$8Lmm_igJ9<$|Ac#jGa_;@IH0<3+D!2KLH0(DdOuW5Z~|RyP+@L6d{z3iH{? zdr^igxBu~DF6ixF_=6v&V8VmjJ?d~vq6GuOAaHvdcV$k-A29wva;y+Zv}-}ncZHd-tVU^sse>`N_d~Yjs5ztn~!S~$xN?YFJ6ZmW2-_RnEgQ0b%s!E@3XSYK6JJF zc__2Swu^Cd?q`_)W2N;i%3ohpYY3eu0b{%SKSmM!|FHcp_x_&<|Cfhj<;;7SkOkkv zraWz@yKwWY7!4-P1-yJJe{!)^MgFcE>8NPwnHPlTy`hZw0%e3C~s^27pP25 zatr6csOW3fu#nl~f!b3wjJ#OUJcR5*#Wozv6IYJXFkJrz7DT^cpc0+eKG3omO*rU?zy zd>n+3fKTU>!RubfyLnwLahye()x7s>7v741`jA^ylhi_k_v=;?8cp7x;P=W*iPN*0dluEDoK@|& zcKv#y)^B}BPr)6pd(>J~=8r+Di5_n!XqX4VYTnN>+Ls2Y9&4&^Rzvr%wM!nc?_6z< zCurL{XWI%3Lo6Dn7?&4X^$Ndk>HA(N-)WOl9OFHr?nl<<_D@zQ+uBw_RiAQGx=pJz ztghe9%f2i3G{*susX`KC`NMs&hH|6BMmlTB{$eDlhoG>Gw}_ z!@ZxXnXx~0zCDVo3jM&w)wrAvBhU!^{ngYE`=@Gb>`w!dcH`%%C|7)^=$@S)9=p(? z)x5}n;FKkzpb!HN@$?>2+fngQdtB_S5uvWu96#Y#E$>hTFkhD_^eQr^4IZL^3olG{k$|KnUKF=DDw7+U~>!W{!dl%kJ6%K0w+2Cab%Cdj*v@u z_I;vrV>|CGOJdO^SQ=%7Ww$- zZW+h!3v5*!or81=H14ISfj+?t@{G{~fMYm(aT0-1d2x9|`|-9vk0CCqH!mZe{`b(m zva7ieAW`YnbH26y`LA)HBvNuD14hn7^W)$S*LI>x=KFL>wo%OY&(@1A-Q8*orw6y= z>?dP?qID+On|xi2SNnjCVrTGgHMcLY7bYVHt7xr*Wvu`=K79)(2TE-l?|P_-de`0S zrBjmaK*4s>Cq-OrMudWN)@bf1-nKaE@foBJS;k!?T+ua}kmj~1FU~9B^E(Koewdr; zH`3y#5~0~MI3+E6sN6;ZgOKg>aVl=ktg;RgjfJ#5?Q*U9S5n7pp|3Wq5yChR=mE3U zg+VHMhS(t1h~AJr%JKYY22jwYLH3}>`K zqWHzbEd<$*!zfF0p>ZzaTYhmVD60-@kRjO$SR6%v_2h2*Xs)7Tlm3L{bp~sUWWy_u z+nCFKg%_hlARTYrKY0&W5U63s)&5SXRf4hX|}V(=)wJcXU2Sw-oC zIlJ1f34ycAx+JxE*nL^-Do7bQK{|w0_3kR`*qqZrNN74Sp~pB2@mS!09~dR0X1(~q za{aU$b@HIJ+1NfzwBP6iKva1%3mxB;Pk2YGDeFWPKL5UItkhXLX`Jg_R^!sPMt$N& zu&22jZNZPhIz5Pipo3H_th^@E@!gXA=1&TPOdrKDgZ4l}sE2I8zAzEmAwvl7LvpD# zhsGYOdeR8)DrDDd`al+kM(c{PY}z$ z#E5)#KQAZ&LO3BrNT-arpll7GVc--HklivCqjh16i$ z547TptQlje(l)ttvxUz%O^4mY7$=4=*Icrrew%&3_L1TGsiXLLMJ>^dwG|e(BZR-_ zF_3`ZPq@Hk_&p!3KU1Y;f)2^H!iXVnGym}sbG+c{NUK()Un?st7!52i8p?os<%?vc z^#R_c0l*a;z7~ABtaAgy2yu0NDEa9pF?W8$0MUZXU0$eN@czS@! zKDeE?umteF1;lP(<1i@#EglXAd?apgQTg(!LLeDEptKiHQhYH*`5W5QqFAWu(^^NP zR;Ntan$SBow3^4fy}zH-Jbc!^5O`(PI4vzPj6IvlV8E@~vc?`%hsTa>TV+vQ z@7!DOqjjxTPnxMV*KwF%0&tQ9kRLC->b>xEqRU*o}^nL3HLJ z3k}X`uUGxwtexfydY8`y%BC~;$W|;xFF8-Plgv**p-C;gTh`7ELtk9AA56kw^`YW* z7<;#K;Jj=psrSD!ejq%oEoCU~!hQcnii>Gbir(M2_Q+VUFu!|zyiEd}U&3}cb-@wl zyIW(fFyIPcI(_~S)aBMGgm)P)$Rw-I-+T0BeCyGNPrC1qq`)40oxt~*G3}RQ8Oe7G z^xpoB0`c-?DO~$ZZ5M&2o6HPFImU9$P1w7e?zEX6#QB=|$|odLk*NMKVCxf7``eZV zdwO?K$EH6duzsMIkDvQJ>-YC3i1Q^Rz1Kj5&vI#kjI;$mK8>$r@30e#mjjpAXAWp} zT#CtX7~4nGr@mc+^r=ANekVFvB*0hnQ06TOD>m*_Y(|gd^zh}YMk|NMuD<-&!yn7h zPiwrjueAD8^s2!+mZzajkAPPjPur%t{AY#{1L}JXVqG$t=~#2M0;BxV``3rku^XiW z8XRy$!9+Uuv7lgUzy$3mgv&WG#!!dUYk>L!o^XTQn%kw`j9zIs&S*^U2u)uS2u9^8 zy)gM3?=`XJs1;h*CU-->vngaYuHAsf6A7wRs@AENSRi-g$W8AIyVQ|wwc#%3Qtv^2 z`x1IzvLw3PqMo??Iib=dLajz<29E4%z(3NWcd+!OzdR>)8EMr z)UJRpqzL5s=&zfL*q;7t?yFx9-H#1CJ^dVyaE;N>4o-RuP<|Pi)J7f7)YAw*Aqey{ zdj<#$O**t~RP@>?EF1}&F+3q05tvzghCR1^p!>~G?3;Lqt@zz9O?IAB<7&>0=%SPE zEP;u}?^)WMw0Xk$g-`Pv1EG2CC(FYJ{=!_KSZw$AVkE$3s`CS^UM`cM){y(e{E@t8 z}nH=>uuNt;^SZ0+w5AkR-Vw{ZK-Ug~8dSi>~ zP|Y)FSTY2M^P4YA;hWVG>W}wYPx&_7hUfC+UA9BuMW(Sa1|#-dQ&xFJCJo&YILzCr zep_&kdr;?t35Pe@Kzw~tGXC*pL;1^H*!Wf$vJdMz4Ayw#k>1H+C8>O$eOFDN?Hd|k ztI>cociFb@J-XbR+ml%T^H3MQ(06{2^IGRYUprC{r~ZeVFx%r6rA;k`jYK}R?$kEL z^1|1l)7H{UhH(v7aMJavD#IsdOJ$ce(HFvM&UAl#vUA(pZPAEk++*ZYXyKg6leu3) zs_|~sy9Ey83-z{<){4<2@;9n`gl^o%D_?#ZtXtdxqF*VFhLd%?G12P)%=xmIm&Ep3 z0+g`A;D@h<#9INb`a?Yy%!b4GO1MnH&kATFPKV)S7{nwQ$K$o}M}v2s%u`Q&8-2hD zL+d1OXQF2lb0=nkG4;cUD{Zf*q=@5pCd?8PFE0|K4?&6t}n8~`=$$LDTLNlfw z@%iU55iiMg$8uG^xr5^}tBNUkCUU5yV^GK6o?F$t8EakaFg(gdkSq}{VVH_s zB-n_Lt@;4i0f$8J`hL2P-nTuZ@QTU%)Wf4FQc8J>k(32b&}mJ!GpMYb=MNif_9L5U z8&z40Z{CNamP~T@T=W8W%{+4N=O%kS0vq1RLyQO+zv%5u3ep>D(kdM8LV=MAP* z4p9GCoi>c?|C|$l!`8tq`NEo2NOG9smfdy5Mg$Lf;M2mHGcmI#W7X5=QpUV8*3XB# z8S9fJ8vM+!AU}7@OF<~ugsdUX5YW?{LdUIQxqWyWvdl7ff0SLbJ^T_qFXbB>dc! z@Z6_bOV9|lEOLS6>XJtFS{Q8dty9egHN9fE&AypuNS0QKzE34xx%JChu!7a=dH422uhKxjz1n>EYpo#H(N429W~@x@oP?NfPTYB zHTL&SQg6Zsp-mR69Y6BD+`6Fe2R^rbx;|iRoX}RBhuIsT>HauXRFS*k?53*1I$^I4 zBkMUK@qt^-_C&wR+)L%`w4DFeQEkJ#sk4B8)&FufxFs*2-`ue2VV84ql8!`HE6WwV zwFMk?X$0)q`So&{buyfsZTEeSJ+h)HBpBMYK<~;>PJ(Nn9jHseDzL$1T!;8Bc#Tu+ zJ`Y;#e)it7<#^iR!@gr)m{dmUIlx!VGEYeUJ+CJpsn9e~p1SRhky)jjk)bOdiV zU!u9RdGoOsNYagSxLwi6a`IDWxsYRAyx=6*utmmt&k{-@w~BuLa?k9|Bh6gooQm zyfy>nn2)0q(dWmQunyOOY)aH0toW5`J7E1;&dhTsTbOoWvz$Fr2WY+MfsS0S+UkHu zq1`_ai|H&zG?ip?{bEENZEI~pF4J9%=RzbM0VJUtN=&J%tCS~cuV%XtBe$LV_0ScQ z@c5*C{P80q6ULCWuwQZJ=wvn7{1lTL%eqc+gPuU_8pxV%Tfyy|s2W&ORq4tKbXVh$ z<#mH{SUAD^3|8LQa7N3(@XLlrPht;Uq;pliiq%fAy>o!d9j$$U5WA}`Aabd}*L)sxBmk6!K^q>cb${4)1-2afkJB$Zy)8JPLIgU$ipWM(9?aOk8wEwX3 z@&=qQwey5N`Ko`h3<;b;kCEGShSC?;G|WcR?~aEHK}1_7&40mq#+Mi(?`TxXcDn3K zUGF2i&Zlta=?S@Qaq=llyV`;cCxyI$yMIw1ka>L7Gp-R?t z0Hsnk~*PhiM?{&aIYHG|C~X8yjT@E-QgCsV)jz(MCH7M8R-mhJr>?c(@; zfQWFC)2~@|&yWZ04_HkEg&)^)bR_vcnWe=?YzJNJ+-|2iHa({LY%JmVgN!RZO-4U6 zdoN9nv-+QZhX6$j1k<}6_aTcCD3W64!`*uhLlCvK2!wK4_Oen3W$P>CUkHTsHIaPg z@qF`B^X{tX0DNxy^H4vb^G9)CE#R@#q>CLXj~TDzzfG?lLZ@0DOVgkchqWNYJHO-=8lcg>_&i$xB|KY!?p?IEeYxY$3h_I{ zYRbWer*q@L!R_+Rfd`|e`^A(aLm`^_dTCoOvD0-c2;VMPQKksNUzr?R%yGM6@MC1! zsJ?Ih&fb^NHku``mT(|l$UA>)Iy3Ex1EsxiupGHJoY{Sj!;E6zB)qXNDq_KR!}NYR zrl9zdoiM)C+hP|Zbmu;3%xYL)GK(yuBmIumiqhyKki58)soY(|TBYQ3DMd_->^8<51fno~4G`=6g zY$+E7zAyP?;|L={ygWi_$dq~qOP+pdv$r9P(*$kl9+U)WPKtS;V0Qs36w;gAMYTiA z%IXMfQNy!~Cz7yDw(nOety$!*LR6t^kDdTTlrF0~6J$X7PXID>zn|jzf>r@3r6x38 zAvlxOLjBIR&C&r-XV9w0eyj3=W$)8{6}f=_Z=V9v90YSQq3(hy;Xk)5@~kI(kEy~1 zjWi;W#UBoG_Z@YAl|qkQqhV6BLA5MpF$>0iC9jl5QIZzD=*GA*M<`xW|`zWW7HF7 z{b&52igCW}XSNg0OzSx0)6Ye2u11Cf1rVTb1 z$GG8HN!PhD7VJ`a0_uRImXRqpGmU`Ajg{)l&S7vjUfPa1f@Ju&5|%Lf)* z$1`YqLoRVny6^;aHd=M&X!-@`@;r~$)MHRLPceJCa2v#g(GJgKOTc3*W%$R0NT$*f z!qB@(r$0xSei#e6maZ&D2VddbGO&k&Kj zEnM;>Qib$e{U?Vbzz@4eQ0|9ZEi817>-%3D3aTqjHNH}(CO|JZKWhV;?~wcy9kt=f zVp~<<1HfnlzPOU|`o>I76q3HMOD$|$b{fRy1kGap@tC)v+GsLf@t{tgU~qQOy}rLyYCdDCCyaf0}Dt!#TM zyG8BQJp}4t;2+ zFD9{lhkvevYE%Xx{6SCeLQ&=Oe9oelh;XA|PDon45BU}#fZQCV&sY4*PY>Ni2Mv|r z+$Ng)OL z4w-uU74)`Qhoo0UiftRMRG=tXX&8Oju?_1&0DxNU()uWAG4&;}JK#j$bKlP`hBQWq z=?Y)=Qb!AI+m9t$a7-Fbb(hek-?9RpOg5B_A;6I)Imr zP{lzq#CD-7gDq83nb(bHa>MjhqJHc;pB$RbEjH~C2J!0LF zaKbnow7Omr6rov`u!rkg+Z-B>_}iIZR3GA4TmwwFQetA1sOnrOpqk0iDa*HA1)Kkn>5h zV%P4l=3;8wcj=OpwV!d!0?~_AZsdMDfC;Ee1w%}!ZtIR*8c-<+Un(m2KK1yrK>1kx zVq7L|tuwQhaZ9G*F~o8G#5;Q3zHIFr`NJz1p8y^`UA_0wCN3qnP+rqM5@F82p=#Ht z^&yU0X9kuMpN~pYQ=VTlLtcSq{$!^FZQwvLDvcF5%B);!$E(A(8fcrM$hu!oM zE$0bJ1Qh!#Snzy=POLTTOYaGLwZI0Z^{eUmcavvFwdy&|*};AEIFvApfX~7l-Cu$& z0+9S)#dL1IU`_<#qbo>|q59vpiz!8#h|&o1QOJh8_Q}ti5dS(Gyaz%L+}elD8EEjS zSLK{Dc4HG6`EpaF`UpiZQIU$PJNv1N?QPu>#Z7c~&c(G9!F*_DoWKG)hM?OaVdyu0 zhGQo0*MZk>M1l^11v8Qi%t$U;X1*1q&e8IJE;XnPW zNSfnhIpy%?EVF#dx_vRvAA6V0SrC*z=rhtx{P}o=Tyc@@b}ni)62G4Pyq~fC*X4Zv zbGiKAE1hIPErk~AMlDl}_njbZpYv@LcAU)mV@IcHd>n3L6;elBPLoo!mk}t`~bU%Ls372PuSSryK;OLfFZ2C|MA4ZRtg?Z$yPNemZ?4>I|JBpzA7szq<FsVq0*;X)$^%vdvrk5( zSX;x`dfa^lU$Xb4L>IMEa~capO7qzKD+fsDwNix|nOtU3(0}xUBiavT`O#CkXUE*a zaaQ{uaC*XL3yyKdE|Js78@9b0nwJHr%vwL-)MJA?^Q_##-%AUf?)}2k7E9e~6C`cl zV3DUf28}6d&XUb5r3x(?08T(-q?)*b48p(gL?T1N-g3zf6qWw^E}K774(Ys9>K3~U zD<326mE~*?#Aoo*np4WwxKztNUrOV_@|}xTfh9lT2I%lfa>c4{M|z|6@kp~GxJT%( z{l*JG+I9Vch%oeg^!<8gPcU!$2yYq{zdT|h{Fst8$wbk!;Myg$Wzww`CJ_JXGA=Ol zQ^Wae8?Ry^K;nvpxeC>%xR48Vr3@3%8s5K4C{N_T6vOGmF zMlthRg+h&!I?3D|xf}#$qAHX|WUb#-vF2=zL9?W?g@GF2;EOiu6^rz4NgU`)@it2a zM_uPLZ=@)84h=A8oFJ8@3u)6NN3O{A`{O3BPRi->y?lglC+#!)KcHa$0aflts)=R5 zte{=BXvjIevR`vc7Cuw=@?1AsTd8qye|UNxcZ_k)va)J?In49UR70(^BU`KAQn!5@ z>6lQ;L3#v-&+&8YJ-@cWRVl+^e;Bb_)L_nWd95!6-neCO0`>*^Iw4qzDIB)e4jOzw zvZVP2T?Xlv@e322feyc7ebDYm`4AQYS>}GKqF*&WMNu5ibHnoy3&9;3ToHT-K;m)h z)pNNS6g0@eAm8>uZ#7cNFx(G=>4pg#gDJ&@ zkbpkBMNpx^AT%$Mc%YDoe!$KN*sxb`?Gah90)8exT)f@<>Zk-=8ZBW(g6+<~D3=`o z4^tKJ8&w|>SVx??(BJ!V`f&3!+}y5!qX3K~&P>F!!{MDJr2~d#GV&v|KB{5O4a(en z5Y_HBtZtV}ta5BdA35nGCTH3sU16+w$kH#@?muxLsAv~Dyd}eijn1tC!qs1}T;6D+ zeYzyG4PYzE1D4|!`?{;h0B$hyd&{zn{g)zau(1O-%tu>SkE{F(Gq6T&`!;y3-snKb z0VjpIq^Hd7j%rE(P%Y;>!vJ>MY)Fl-c<&Bs7KvDPSS~~H&ZwrCP%) z`Rc_dP^sO^;kf9N2bV!$^E15aE^@ZIJ07f_Gy^H(i9A-xAnl8`$U(TIU$&M-D5k^4 z>)(t#uOtrU2G$8E59~yQdN7g}Ly8o+7=qI=y)CrG%A=aHLdl9)e=7}W{4kdK-h)=j zO|6abYe-8NS?0>zV*E68OF_DMDN!MH=UjEMlFfUou^2XlFPN9#TWAi`G3e}nB%Dj~(uvr3W5m1owfg3^pF3ZnVG*8{Pa)5STt5mRYl1n3UGJY9$Bm39O*Nh7KpAhs=Rb;HWh_t=nZ@~xx zO2DgU8m#Y4sn4Eo%kDezGkpDLppXBB>7RcMG}?zM0}oE+zphfPF)tHVL__2u$b!-o z0e>mxza0EhnZPS=`rKZ@x9ArJhoEmG#vac;1%suZ@eA$0LKe;I9r!2Q_x?FhUE&B@ zFIuRy<;K?r5}|QjYqa!)uM9V&#JBxfIw;V1DlsplK4jmo@i^1N*CvNz`6?}*5hf~2 zKxp|xlS4dXCpMW~9gr6spqsQokHU&mSTJombr+(alvP+O>=S~IbH&TE4X$9jiOGO^ zMIxZ?z^DriL{EEj(wMBc|mJQ*-j0WJxIz&~a*G%EduqVH>U1zVY` zK1T=m{}v$}fE!{;&>a04DUL(bmEu2qIQ|hBMDUNmg8$Z6Knr6q9aj7lehgquLIGQ# zmuCphk9tY4^O{gy5H3YfjU7VGVNQ|#AN)md|KKl#^IJFQJ@aYs2-;nnAjJlkH;yVO zU|RJym%t$apO$I*(a&bU?oDoE#ud*H23}k3zqO0NYtQ+REHWS@pV_svXOJ8g!*zzO zDqrjV=iTgr|Gb+Wa6?D|s;I2`F8;-#Ble5qU+-i}OY`c?6RWS1o4O`ZOTI5O%3kPFS+`K0@t1VyK`)q#4@u3AT+#;!EPr@)RL} zwNNZ6MDX)6=yFB&A;L{7g+Ay$+vNkxR z=5R|}10n0P3H=9}9%`W(y-aW`I8C1O`4&Wfd2i2rj_OU*2tEl0War8txV5uni79P5 z?c|y?zvf>Qjf)BY&hF`(7l!Sg4hR<=eH8xoO>M~ge1@Tk4o(lGy}0q6gaayBKwIbi zD*kI!dbLhj-k3h)cS}o54W$)c92B;dUj{ zuHL#XB`D81ViafK;ME#7v!|);GK<^IJFCmBJC163-VHMvehk9~BnMD`gXz_pgn`*Z zh*GC>i~1zqI4Z78LrN=Q;}b|uD**wr2H$RB#2j|t!FX{07FJaH2-DX8yQRM8%;(3N z=F;G&iDvavH?r*QB6&gKhHR0}`RTvd`7{j8|D`rnri2BUzGJdG0v@f?Uc1k+Od1^ymE<6 zRj~PP)D2rk{S`HE=9GSvJ7qtq!~e|CN{5X(C%f{ix^NW>GaLUIk0Ch$fIKb>3hQ*W zcHe^LR{6ejwa11oB!-E8LkP)uJC9|~Mrg}XN*xrHJe zQ)=okpp%fq{TvfjeBb=2mY>ywjaQkns7)($tLJ{$mL5c2XiDpsxpSCu29uMRT8I9% z?K4&U@;pTJUFL^LM12j|7t}QKKcRN!mauw1y7}7{Z+pHT+?Gsk7)p^xSY0?hK3!az z=BtZlw&NsV?NGedGR~)_c`)_R_xkqFZuQ%rH==u-g8N}oKg!3l;lfbqY=PGCH`H|? z&SxVie~ek9#d53!cCAM&A3G$1Mfre_!qw`z=(MzN1%jsN#Yl%#4Y$8OD!HPncNHxmI9DR~})!fAx-!c&}=T9m7t& zCMP{9ol`~Sjs$!q$b^BBe zm$DZI4!8I7(8v`iJkQ`{jK7TzWS5#gUjC_qOSdUWWwdmFGLk0E!svBLzx=QzpWr44 zpFP<8%A)E98W;$!SN->w0o|e!l`@S?%`(x@cCnq~{up^o7-)mr3Pj;PA1FDMDiKt7 zkM|T*vUJsZ<#=_ge#iZambr15{HB!mN4pNbeCKi!t+t-D!dWVA=yyb~#7APIxB~d~ zSfXzxm&*YaLFdOYR4N~NM&yWqByqSHp9s4inQK})>wy(~Z6{%7n_=Z2W4sFojcf_RXI>PJZpPE(&=v8deeyacM)8AsLrf3_?ow1DXRJC1?S5r4teiX0fZ#Z`2&lZ>eIs6-N6}$7TGKq>r7O(4D3Y2Snn)kUiYRA-w%ca;0gT$SIn~ewK%%WUI@)|bR zHxThXsgNedHhi`bDYY%;5NHX`WIcV(KCrpX{CA;}kywN=lbr{o;T<8iwBkvH@Yx{9}ltvPXW|GdS+Ige$FF1#ICCZCQfL^>}77BhDM~k%+d=Y z_*yO|=dQ5HB6s&GR6VotwZv~38)#qY!${Xlc12{nGyRRFT)VeshOQViJTW@1G!LCA zI8VYPrt=(H)UE2DWs&Dr7=|vXttXgzt#mGw5A2-TV-u0mM-tfb#AbwSFfZ(x(=xms zY&mfeL=yA>G`Qvl?E)BBdXe!}1crwj^1EGOZ9`xwuE_-fdCG zSHqHTRb!VX=G}oC{7jm$b&LjMyXScfpt%}56x1AmMYWaYm>0QwaiuWpcX$T)jQ#!=J#dm0m=&HlcKvtc9a5;Jf3j zyGH^(w>qzMVmU7s{U=3{8Yn9?R7~&;sw~YDj6RRv^r%DkWXKU&_SMIfbD~}3+n=ro zg$;s*{@7%Nn4h|{t=2EW+c`tthQ%F%5E9$+48N? z`@8?2)XOc>0RPyt6K)l61O7RvIcaO--VaU|O!{F?|XM_`yBYGimG3S7b=E z8?%lK!%ZveFSxFqY`p$gF=xoDFpE#8I+?rTgJS*}kOU|&c3>92 z8~>+!joMEB$%oQOUbA(<=wpII(E%S_>yjY~mrjw7Tl4w{h0Sf2Ww!XVDBnD;7QP+M%s!? zunNq%HO)NmK8hDgdAP#(eHh11wi3;D$RB=S2^IS5i?gqcgAei_9Cy6HExmT6LN%B; zy@@z3yd@;6^b4eVmZX4jOPkjY1)}3Ms>E-9nIM(>{yml%^ZUoVa8p>JSgT{4FZn|8N8SX*{`kuzwxfHdU%V5TA+FA{WGlIl@?Q5?f|m; z{OV9&%t;&R%+eMV;Mpjpyj3CNXbn39yidMzO6ik6cpppPF@7uv8f9YGZ?%SC;W$(4 zpt*@Mfk~)wJr9>Hpf|gZgNM<+G0?GG1Yg0X3{@pzA)!#ynh}ouKgZp46GO*u_xXS( zlN9jhj#6vjL@YDq5RvnW+R2quYN5>@^T5&1dBMx9sT0wv@YTYCF~oA!HLrrZZkgEB z=Bs16&5NFrNeX2CSN5 z6L@C*Ice@u_T&x|)5ZySkj7P^+|-h+47QSy2y+2=a_wMDWnP03jji)zxIWi`E!cT# znykR<53c4}v0BVp2BF(`J>Ls!tx>C^V{CwVFl14_LMhu0&mw`nW_$y+-IxfUh``r! z;wGEEFi7aAW@^?XI3(+GC~n;C%9?_>x2Nb|@-f9)RlC`7k7~*yWH>;I^(UeT#Yc&; z;gQZnpi)gCu{g%j2ga_j80}zFfVk21e+2lb7LcU$F3ibk*1#L-Q{!&h5PHq?vqgrX zPIFU*BSAe?3D0?5)+mGPEJs}ZtI(dml4<~W09#}c&WAr zgQ{@od7QK0v-&psg+ZY@$ATD`REh4hV&Y@2FrPU`vCnVqJ0#VBh^n=|5woKHiVSHd zec5jgk*lSAPIc7?l8?vccj2GGkC1H`Nwef0Zrn=pQkBwnVAMjbV9G+KuX) zAk`rmc|T@?qYP_`gfb}9KZG*hz56EKT^o0rD$6L@_@pKH&FE@Eb=Q40dezj9&0r77 ztJf1JkuiI=JcKwe)6w{9-@UCwry}mR4W$hQ(C^vN)#Tl&H$rXvDf2jhS|wOz7zFOX z+DNK%)FK2hpVOham+(}9k}j9=HKHPoMRCnERi=rVfSPbXF-M5B6Es9jL%h|zHzvQE zU@=etOW~60Aky#$Urhv?K7cx0!vYCL{>&KvM5?QLr(ekAfxp7=pz~X-&&{Fid6%5J5tVm2KJdkTCSZkQQKjmODu+ORB$v zaH_N}zbQeBd&-pWqHuaSx8i5@<29G;)V0(rjEGTaBW5JiX(RsJlxS0~^X(Uh&2=*9 z^asz6&1ptSING!7xF_t0RT3&(&F!O3SdSN)mr|%l!$aWA?g$N-o!z?Z>h?iCzsg+a zhOsdo>pbs1eM|cJMYL7@RJMGW$w3X?!Z{}+FYD=V?3!?6 zv$1z<+u3m%tFhDAwr!`4ois*c+iGmvc5?RjpL20;-rF^^)_CTbmt{qyzu;S14}MJz znuKdphU{(`v7MQ9d{Rr9^0#5ZAprwBL>ilgg#jSeL0A6R;$sGnQ`WA{$LE2gvIH^C zLyh4sS3>C~T9|^Nmq}=TJD*Ow?Dk(>j{4LDz2EhzXmh?rA+}=3(NSJiJ6+A7R?-h= zBZ7tgNt+AhWo%BwHR5EyrP*?N8%X+9CbY6O{bflMRl=&R?jgoTC8aUe;$XFxmz~An;b)hc)ea2#Tmx zWQ`kR#JGvGo>+Ssx+(>gLOOuW*9Kl(W$f9dZslht^9f&cRpP_pJ+B6H!z9^?UDb5v z1fQ?3+CY%4gv5*6?J((zdSlrFmn92+OEB8u+1pOD68{gKDZ#}pL22sW4Fdw z=ElYyGU>7oq~5hPd))X^erO)mS0R2?p;steuAk-YP^+BgYWyq^s!bP#ur$-LEOxNK zQiR^Fp8`31XF!KE3bqWDYpKcrQ}Oc2fvs5VEPN(Rif>7bbY@Xb0k>$}Rn0I%WS3&q zEb-KHyT7gO$2;H0?YbLLx}?%3B@3eQAxmKh&{B0svh!|4rKy!_&6&;%Y*@}8XfF78 zAaf3Vx3FVV{ZILeVGCdHI-JIPd3EPdQgN5?7U&3r#0^x6-u9w9wb9bmBiEWmrQUlw z+y<~x=J{^9o$}Grm5gTx28r?p2IU_jqTli&$00b>Tx-FVd#%L0P70(+t6R;Y>w6>C z3a!qzk;s_L^KHkS{h?cG?PNDZLakQ`wOyMu>=N~4z@Oro_pHEmn-SLa2YIR|^_HR& z2&{4}XmhycB$5zQ9&?-8dAc_iG9t_`GIy(WpIHA4N@Mge>e7h}agu9{Uijf%ajkIw z8sf{SHWuLq;ysD{MKc4E`^KeW77h-(|wh>a7P?vy@tUOJfXRwhk!i` z>TH0uG5U%b7;C;$#&$JG2aCO?=_Uk2n`TV6#{OcB!Jjq%@D5?u5h34FrS@)(-P28X zxnDrQ-YDM=?h~>4v^UoUl2f;R0ii?hAjcdSF8-Du*D@B;P(=Hoo6vA|s!y~B-)D|; zM~%bzcnh+Qn+Ol-F5402wCY=;mrmR$M+LR^uQ;?y2fh1R2rcr6Qfkqow|@oJOZOJH zN=MhTCXcFYZVsOfa-TWfae{YuH3WY+7u(=^?j=AEN*Fwl*96PRf8hhykd@@Q1DXg{ z5u2pf!g=(Da?@nG7W`A9j8gno$4Q?WTmx)AO@CYt6Mx3R5-VN3wrg^@>yy8!A3v3! z85yq_hXe1&F3?{YDv8}&eMJpit3-0q6n~54&Ws%cN!ElJ(IKe2x$RDaXr z6Luj6`NXgvQ%=+fan^IV)Q zf`<&IO`7APQkHqzG4y1$cO@C+NaWqXPV zSaE(f1RPpj&ZVeCJJGyS~MHJqwRxaxFp?xYJ18^c0_*eJ<#=NYH{Tif4n4`5`pZ4=rhcQ-IC{}dzMsHvZ!d>61pnLo2dJO;%Y365DJw}&p zah4sKUDTo5AJV(2&Mt(ig?kgBb}7h`*Tltku;zv? zx~Ah38Q-lYgJTscVKnEInJx41Lm{)ie_tlv_V;1bMGTNq4|pmMHO}`~ZLHHF8bkec zwo3dBIAqI|L?aFzuDAL>Y@Z&nm(g4J3}XDQr^YbCX5?RMsFfN^5{Iz;if)WoJm;?`J5+`{j35Y?g@o6Bw?hF^}?f+BMHc*^&0(NHX7HDnQE^W=K=&)7jX!ljpEv@s$`p>Ngq&(b_6JyLxQ`-Kyn-O`u6@osF( zEPQ~3XcBfBUQpcTLV*wWFY$FM<3w81YGxKZ#2&(BipQmp21)Qx>N{E(+t;8B5#&(ZOzUgn2oKAQ_XzJ#FUAU zv=D9S__Pq+Kah-$)1}?IvKocP^Em^3dk=aL#N)Y0Tm=YxZM*ruJhwe{wTc27LLK62 zUxxjD+ci7-nOvJOe!07L2X^(Vj?FQ2jf%+(h@i0v@)op2P&6!^StpJXe^c}IRp z;ULhA0R-c`<$!HV5YLgQfPU@1;zFZ7TbLvaS6bycr za<;B8BwvVj1Q@#HfomB3gfp|IiN=g+LMu|# zC`xMaBYe6vRGp?OiI|)sunI!D0LT{Fc$=2Z(hTEitC#YAM1>6`U>gv>Dd4W=vc)pidO zA0+zM=i>xAr{5->{unCM0>Ias0pR0@o26MJp0(s?adi2?sjtv2nl%Ey5wZ6Kcz2vx z$?b}ED2`MRC7A=y_QL-~$JZ%(^&qGC=%F68$mf!msKGXO_mL0|P>3djE@h-JoL`FB z#%!io$`5$2&^sb;wJtRBCDc+bm?~pEc#}gAK?!B-UW5xoW0H6Y24PW07oDp4rk(e!6 zNMLTRE_ZNGA6(~q^VL_Y=*D*TakxXd{DR+&n!EaO#sQKnt`;W!z`dr(rhp-DdP#4s-UNID+D9Vm1(>D z!9`f~03X&w&te{AY@Jg+Uc}cnfz>!!Xd$DT;yg~217@?pcj8;l;|spdHMoEt7U%(m zF3o_r!T@gtxPHt87I*?qB6%@+m~}_#SZU0X5ZibbTUx(=L6+(!`}g$7v|Qz0p|m&? zI$cn5Si=Z%Z*#cl)f`5z#`xrY?DuL{0G%Q@4Oo1;)X8ZuHL_F*1PvXU#Ih^w9Xh)| z!|Kw}n6JG&n2IlM+cMQ&2%4m!%D6Ojxkt#HzMQi-ynM>FC?yhX1Sd37TI$gQ`l8~y zkE65K#n{DBdwfz_{@N6Msl-z7)I>br8#!d5Xh^>4#&gUol}E(+)F{XAd%H@0i-p3I z@wK0fpgV?S@?=#9xLK8n|6W}y5VtiPkzn#1|wAoE^ai1J)De zF4yH+&EM-!hX6e{qfSIZnLS!QrQM(WP1Ar=X?{_qdyw7JQ`=O}uIYA>`sG~c>$r!8$YO>_A;L#T zpr=1v$}=(OA2vS4DS@QYcO>@R>j)r35e?Fiz{pbOt#D|ep%){;@>Ph{;ih_=8yY~l zNzm!9F!;9$gaplLuY?44;*c627zl!V9YU`xnbdt}x^A(8=^LhR$jx`CoD|1}G>W{i1cYBrcQ;<2u|be0~7=i^pG z%@p8XLbNw0vj_@hXj@enCNZs_Cwf$#)vgTS=WN?RhgnOT^i9&(715h z$|h8sN7!65vhE*JP17X1*bNv;gu(ljG^r0NxFrVl}zvw}i zHKYdkNAs?1#Jw!iNqj?syrm}8@+J;yzfN}Duxm?LR9IVZf&-!3A|T~C*VMwM7EP- z5G1@(<=9)0A6K~aN6&`ii0@%*(-r*<#}$g?1G}=tQn$A1S$mH1MK8GIJsC8MphN_A zPdNnIqVxBpnVrDRSRO^;34yuqX7bq446QQJxvwLS#O^1f_eoWPba``0K1JP>Dn9MD zBWS$E>sbTQF266kPI_WrMKq(0hS0}C7r1|axLaor=T_43AMJX6tf@GCO0{06%FwEPTP?iYbb|&)R5UklO(x;w+pp^f&Yal)m=Hu!J|-D?ku85}nCcm%e_5F!pXM{cT-BB2Ccw#Z7> zn^O576z{%=KKx$?_>x;9kYzp*4^RYxnwq+pw8z$@>i`>;`<=Am3YV8jFCufT`e619 zcIifRXdlAWOVaV`AU^3RQd_lokTxnK_bN-dkc9FHQcBWCX6mGxwR8^6;fO8u-T^-2 zR*tM9S*0J*?U0tG`~W78=){>T+^t!1z*l6>kn#vfN<2^t-cLLl_=?U2_W>uH;m1@o z3^+a#B|}W`YXg-r#FSo@H>76bS*|3z%a8jmIEA_h+q4r0x@BK2M;R<$ckJYjrF;R- zuRFwa;|+c3#x9iIPOy9+XC3K51t zOnoTO-6UNC;ZysV42}TFzoi)FQ{*R9ps>;v*skJ#xeZ*LaKRhR`^hNL>P}6$zk@fj z8*_N|TlgRe@t>+#;q_Sf&oWfgIN@~@_RqMdl|$k#HHR{wS}381rL0!bbxo)-h~#Gw z$=9d}atZH{A!x|&bCtY>_(69ynWjN3S3}+9VSN|e#+!AmM{T|WA8m22b;}2Mm)^T1 z+sZq+KiV)e{96bxK9xyEviw_y=S~LSUT$8^lCivW@$|{N4&Q!eY#}^zZft0^w-2=O zpfefg z@k5ZqlM=-%{o`E{)w|-3emcO??@WnSrAI7kfaT-(A2ZzB$(_=(utAo zgay#_%%Jokmow9b;lp!7i52!d=na`Q__HMCt5b%r*{^p^+AJYHOev-zbwfRg$dZrc5K@my~cX!j0jWYcB)TF7aM4QRwV{7ts+B* zcT;xzg=C}@&`bk;{d1Y1gwkhjKhC!cn>O#W9VuR!M{3~ImNJ!8Ff9w~RsMTq#Hq2z z6V)gZ4R*=5ld1=GL@Vx+dto-gi}MXxaEm|*XNqmUIH?Uwz-}6w$UGnRzOK%H@KB6+ zCKfRuZ&XJlpOfgcneMwXDMGm%1YCh3F_wl_##GtkHX7&U3*uPGTC$gVDhPejN=DM; zrFiP^qQ7hO=+!ZQ1H4X}`FlSsE1FPvdpoJ}PL=m23sL|#b&5W7eu+fUacp>1ID(k8 zmSQeOQam}J?DSqD2Gm1l^A?efiy{0%h|vo0%^1{sO_Ar;{DH+{*DV@iJb#*P)f}wJ zgT|2hq-+=oyL{HGG7JkYE6P7h!f?Y4Vd$AOc*e{^4~y@r4(P)_Dv&n%iTHwO6kPYM zdESgN1*h1M(%i@~G_5TazL-DI2%bvvCa-D&r5xujr#sK4t+&41*U>wTX~gL4^dwsc zIB^peSo|u4z;J`+E2w$;3^0@_GkFcB{FIy-yR~cR3^wAODf1>Hvu}}Wq){8TejPo_h0&&G#&D z{nzfoYM6ykNTrE!m*$93c&AW?jL6YWYD4uL0})KOh0x-AP*=fK25~bp+V^@7lGA;MupY(27s&_ zBo+)UhvN(2A5OT)rDO~i$Ll)PNhj9~Wvu?TC0pbfmk*A*<^l5D};5pQ}^gKF?R!GiJwvWYeKy9zm+q5rVIRfgUu(ei*4U` z32sn?zcWrM{$O2{xEZAi_Islaj{U=iV?OX}e0$&uq&Iq)dJJt2^k$NbX3YW3)}!ic(A zS>wCf>K71T(U14!6M{QLw@P=LD5T(^xl{0O{T#*Dl3H2LD2{IDNwkyIxkC z0qwwq%dHB^j;#})Luz}ML61<2`mX`={0{XG=YpP)bO}Vm|2!G|l+gbUY-0qgSjDQ* zfCus#HvY?fw=-G}rji(k1s7A5kHSWRFI{EnP|(P1d~kyt8&ZTJP{&&AO{W1RLNGdT zARB=c404h%q%z+FdwZIK-z&xRAc90O(1J5S{$17qsVSidjcbENGquR$qhxdhwsLF9 zXt*0TSWsI2uMZk7M{0(JQG$cE;dMYaBuYM~QODW_r9qVdBe+~&Aj}VFcOj48ZdyeN zwV}r#W~3u@tP;?YGE*oR20im3M3uxLf|UN}l~MYzoiO@J2;eF}Q01kbFQ<;C7=-ui zfLd6*$TU=lkP^0UjA-8!8i5|3=}hS-oewbIZ$L%0vhqA8F!CZ$(j3INPZ5GF30zkR z4oXNU$^)RD3#=;Yp#+_xB?SG)i&WIRXrUKl3#VuO*5zEJnb7z-=j3$lJ9b@-bEjLuT&>7slcY?3QOAoqqi$%Cd zA1&_ndRaJu)v=n%yJ4u5vYHgptR|Xk2yzf#p9(kT5G*F~&*$6=hq@9h|I?m3@C_Kk zPuPWfLDZ2XISyFp9M55cOk!;zxb4o6 zzF>z}+)wHNbNFp72#;fRU9s34v6x%}Cjt~trYOwA#u*P#I&=3r>+zg76wGfzEUpho z>z)aP7oyqN4uHe092GQ7mHG=Cu8)`)et2vH+gU!+f5od}ASan2Y@1^jCPx6LqXTus>Q=?wV`9jBnj*JL*V_ z2fGbq)R#rSfXjv~=Tcug!L4dO?h~D2G%-$$`KV^nH{iVlx^q9QrpgYt8Eo>u05)xP zwdG&e-f`RMg^QLrh#N8V)TbS9=DWH^MyOF}j3iKq$XKLd3NU zbmtw?fkuc%a7KmUf9L$xvxwG3Oz*{p(=61~$b`zifsev1AoZgGOkh(ZUYZ?%D=y?F z>Xf@rnVWrXzFV$qRo|xPF6{Ps;$L!CMQeNG``U@;0iYY+#487yo*Dj~%zr6B1<`)pM??9JPx`VLe+y-+mX2Ge8vTPIkOH%|y$Oz+~csF60R6)K3) zIhO@uiGIT@bV~uJEJ0#z-F51-mqr0l@%5+yv_y<@jn|nfU8BC)uo9VrYwTR!4~>ry zNtZSnv$Ao<8T9Cj4zd>y_<5&rSv|!3`ukG)P<_Y=R#0(X&H%*+%4)4M1I}0WLZ6~WOE)}Npcf)R8LyeEq|CWTORT@LC@VIuhALUJ4vH8 zqE6PuI9rq{V2vKy7$`XysKG7Cdr-(b9WL=wgcnkPyJzk|=Re+G zN3VAvlcIZ?3hPK(xlmg#7SoGC-PtbVLSy7=c<3CL1YM(a_0A(Ii_WS zgf^K)80%eNeFv&yb)zPI0JLEFT{&7JuZX+z1w%|SW7#Cez)QJ|NT z=1(o^F_{wqmX)DAju+HLUS1v_$cE+o5{))ezW`zJxI%i|$R-K<==?q2f`iOR5c<7l zBrRS5xFr>_B6wzLIED2b!M&U_hCB@IKE!Pf6w=B?0TrRAfwjFo3yM}qBr`%I-e5y< z9$*awWI!;9;Mzc95Fi1cknid|&o_@RF=z>K3=mX~M0U)ZrYDzYXNrq?D_u|vn?Wmd z%7N&WzzZ^EmXa+qg?Kwfk_~602kY=#20kgBkh?ZzvkooQdX-GLF%1P}aqI=1fGIcv zDD#kFrYQ&>cL@%ZPO$|0PSABrx_$>&{PkZJ>8+Hb+$nt>1InEm%Ew5Lc@;LycE?!- z&V5Xk=Y^`9SHk-mh}Dol8kciYj;oY|u8>2ouDHZK>RX>i>(AindE{2t`sFrLrGEk1 z3U|}nVEMr{??C(K(1F{f=S+5t4BCUy6gdPLMqoYZM-@z7Uf|1KPaJNun8v%ZH0&uJ zZmmf_kNE*ruzEotcVyGn z28C(Ub{p(T?BtD8y3#4KWY*ajN3we$Bz*suD|gTo0N1jmotz1)oD-okdvEI}B}1w? z;;nYi5YrwAqwM*NCw`mZey#hLM#W(Xv?O8Ku%(}o`G=#K-hV@_c>RBa*?#cs%CIG@ zS+5%@=lw$&)7&Xj{IB{7xh;}n0jt1Y@Ib>62PMZI3rE>_?Lsmps5im@ zrvvvHA_z5f!nzHj?S%|vb(!`WJ8({n>)3roDYI#4&VWDj4)#QuqW-P%j|`$8h}z;$ zu#r9bzMAQuHF=J514sO+3QBXdGrDEbpN+x`FfzFhVemO&DY4uIOM#9VIJ5!Qq{1NT zdUn!|jJaMpvE#qC^6anA4fPc}ZQ~&o8NQ35Fs_M60P{i|v$*G70{5T`uz1$nEK%W{ z$y?NmK_s4l6KcqDua?4dG6~W`^YzHP7W7oXwg!Tp(eCfM2&|o#;~LBIp<-2*aNxy0 zF4d}tSg~%pXWW^?^X@iira>F=0Nf}T9l2RRvANE*GsYbmwLl3Up19Q{w;kLBoB|Cw zZyk+r3~NmZ1I~zCI}k%21ja#|wAkJiuQ){v>au^up*O}p7II%S94O!-wJyR4wGgyG z0!19+g`6;a;&b2OZ=QSp@D%3?!s3&L!^-Ih_;T(CjYMN6G|u3IjKxUXVGtZ3HIT@| zM0n!rBh`Q2Tv1v85Uchpkkj{o)>X0*D*Sic1X$n-;uum;`2^tj>G6}rX@h1a1rN0U z=yqSh0kGlQKn2=+G-tZ+0gIgSSuekp-p5Dg#J537amt~qOD$U`@(njoMk*2oe-#!o z9*sm-J9)z{xhmOy@!rB%j}q1Lmb06|RR2`Q|94*=fkkZ!he_83yGL>rjf%*UsIQ2x zJKV8@tTqIR$RA=4v^a7d0b{AIaa&G0D7o!zQDsskd18^Qvpi56<^N#^7LVkqYD!jq zo|JaJ=Hf-M?Rig4H8LQknanpo!p{Kn0YK^@5C@rvTt*I*c@dH8NS)8=4|`)cZTn>Z z&4DxK%42A zK!YChe21(a6}{&94=iPjTbTp4Al z{DaGLW%>TFJ2f8HAW44a5IpSnrHxb1-+;*7$>F^#cQGVsRCr?^b%(34d#=G+LrfSJeE)9G2uEdY`av z|9-s|Q1WVnd`dY_edv4viac0(nA>UTCnR~sMD(##u0e=qEeokG980$A&rBrbwT%PB z<`451+39^|r|$MO(-Zqavot0+}VeHb~3)!9@{{jpqaJXd2P zTWoLm+!n`CndfByZg7E5F2U{5h&gv zdU%vNTHH5F?K^5G{H6=FPJ}p*xGQ^8QNw`9OHsH@?9jg6kfCkx6k~;oAmFrpIry$h zrdSCN|B1dC^Q?iTf2~h`5)DpdC8UW%lpuWcvjRfNsZOA^Rc4&`Rp66CVy<}=lf&&# zEm}Mzw;}0?bg*vXQ)Y!6@_an1Hc z_D&pjL;yn&6Ct6E0Giflx}tZgpaaoiVt?7%BNcM;9ic$%v+Ou^Go#<7y6m-+iyAf z@VqJ_dVylmb!d~Oc9&T&WwMs8cM%o=N1aaWzGn)dh1h5PgGQLQ_x+BnF{#CUnjCnM zt6c&fh-cH_D_nhOl=}PU8*|cPb5naN6qASlHk)4rwM3BP)tAUJ5)q>; z%%<>N$wPAa=Bufx@8YL&8N(w#tx|4KIHkW^te`ZL^T5>7sCX=j(u*z|3XuOLGv;;j zH}{QL>SpW}?=Xi&ZN#<0juWHawgaJ=5T?PPrR@rD<^HP#z)v;UX`?qdM%`7?A@6(~ z;yXa(M)t1em=FE#=h&bT=!cwc^f22G+Wq~z!7K+4dVabz{my3}OLQ|{WrUu8^6`Mk z6>S9upDFw=AF(^$JD4^mt*JFB3aE%ykN$^N#k0T<%f5R6SvS~8W#lh!*AXbPkI#^AXDhhXZIRC$^7%aufw5*`+e&X4L!Dk5H{ZB6O&Y-0# zuu^Vs&>7ZG5F88gL>8pPzp5ZP*m0m{kg_=;Vy_EriYTLf(=?Hzn_8`-?QGT!2&~Qt z0oc%li_2*eu3hN9;J2~0z-LKKh0ovBNeoRzLk|8VSC`xOSfszY`WlBP5XIsTUg%HD zKsyyMtLw@5?aSeHnIsxv#E2Hcp-v~lSmN5s&B)HVp@f`#Z`Nl}Tn`pf!sY85KH4yD z9o!LKui)2~ayP?p895T}>9ynAS6-Vd*!*T?)0HsN#PA*T$M+Af(I~m3a7#5VC z@({9fP85A4eJcB@Srjl!GHjCtS>Z+#;QaW&#gcWZhuFPaiM3@Z%$k zb=G|nu`3W}2HY`g<=RhAt7xVsGy&8y!uDx7$b6ooYS$I5+hQvssX0 zgGQ@n86ul^6I&wKbIdX?7QH%0P2(C+wK_JVNE#RdBOKV4Y3NC5a7TE2%ng)_u4j30 zzZic8-=H^BV0?xoyp!H%u|6Hx7Uq+Gse-}(!7oZgkglb2aTSP|}4mVW) zLVLt-nj*XTwco0pUh)nEl;w-(0V3K(NXu?6t4J*{RfN*x4y%11$KMW%w?#}&df1nY zh<#9ag;hl^ciGE@`@H_=EsvWVfF^m{(rRZU()&SBi6GLk~wD*N)r&X449sG5OCp%sPJLgiigwcO zg@^%uaOWe$?Oe@}Yk~EqApu3C&B}o=i%5Y0%mN~w8J7XnNl~U)(u&EZ@@LX>&gzZE zjTv{n3qT4CA#cv}Q}D@{{Mzrnrb|&cWSmKxxrT+GnaXM}bCc=u{=Dnc8os5whX|v+ zX9m@W>9=25T~mtOgu^$dT62bEC>%3ms=D#flmHqyQ0zz6gr)>iW^_l{jEDpuvfWRf z1X|1J5dn!ce9>|^%OW!6|J&shC;EU28u+}&Fj5yre{%FfEQDqQ~tq6XMEEUrrD7XGqO{#S8Hhv3Otk+MOi_C z2Mu`&j0=N4oE23I`yo0iQAx;NXdXh4nABef`QwPDVEv#|{?qLO;ZAYQ1=)~~5=OYz zGb#OhI+pF_2j6-RU2&VA0y4knrM}Uykm8-l7-_jLgoH&ON@VBQR_U>H#OzL^{w7L3 z8Qj0|Xr34nOc&&I*PV5(KQe4V=CDGsTAV?Jd|uC|QQ2M;l>(9DK+dqo(ABUxRFV2? z$PL1gWeb2D+8

S@vS&_>_deD~(SYt2WZhnLnrviw?bjfw}*Rp&X))4l;7O0yxBw zU#S(~tsGkd@po(P_WvF(M&iobEvivAIecgg&zN#S5`)Cm*R)B7YiXtuInID*i>O4! zy%VkL)=y3CaQDVIEUJWP|x1EDKs2l zZo>4;|Duc~d~=~c*F%WK>~s;U({_QB zc|2Ln+G@37?;=F^>V##8UEtJKJ8=9#0WMQ__)loCM+`sbP5C{E7Bmy_oxQ(&&T7f4j{|J_bt8(iWGx=v^-;Lzcm`-FPf?O68*TTJdvmKr1 z22hJQ~;?Mg=31UwxbX+){i#6io56NJg%GCMu-P!9+2+>96 z=i80bw&4($2j{+eW3opS)w?S5Y;xotYGFfpQEUhi=@@jIFHunvl_n%?bqWTAuq493 z2a4DED{^f2{CGb2$IsYZ?Y_1$+&v>(V&c2D!NY_z*BAu)XJtAjF&@pg<3C6k10qc) z@4}mzlkXTG+SP#UNQPfUS}9nTnjca`w~7Bk+6o+2mXZpRLpfOA`90!|VP<8p$q|Ni z7Vmf>`|iW@FuJ3?z_Ja=komy-f$<84ByDn~2_G8?iWqzn0$C}2%y7? zFmjP+A~~?5Y`%p$X3b}Aib5+Cg()fBDYsG99U%*T!&ZRlgNVR`qSn%+Sk^&}{ zdiC|??+n;`6N6Fzl7>|15ts?aSmt5sk90d5er;-J{0Yn$zPEIkq=Z(0`3~+y2e~s~ z4(U*U3CU`bZQ7MvPQZom9j`2-Lie8yZ>VDMK~kVDm@$l_Od2A>F#q7-Uc6IhvN*~l zrQi517*nq}zAgkrAaQ!nr+sg6dz>umWN~8G#ijTL3j)L~ma4bRPEsHam~o4SoX@`f z)=}nV!WisLzZ{M{BMmP=xD`QW7M(Un>R zPr62u3*daRcgxJF?H?b-1V0Q(pg(7J%lhkSuj}0*I8^Ry#BS>*I%l_oP9C4G-H&ib zB{U5D_8G1-gWyljO?Ym+hm6QwOYEp{LuDjMbXIg#Jj`p)NCq4__Q;vX|Gh2wXxVi? zCB!Y?=e`4!ZO% z@y!=*mc6{)gj?af`Dknks*a&{KJ8LF1i)}oq>Bo?O@09eS5Dw_cQAh*cM4~C`P4Um znSUOfeRXUI!wn^K&vf~_yHS0<(M-ORO`XMmF8SP4trKQXap!iPyvFT5y;yAg3DvsDH}G&l@@H7<4Yhh$bNo) zYQvD?>N}m;HH3AFqs6t;n-m~|mO%uK2nlI%@2ZCR1X)>M9lCY?(fwC*HaS&s z9_Wx8i-l=<8#|xA%Bq)kT+YaVFTh{rIn-vqZ%VH>=5(3f84IWI8-Av9Yj{S``@nnfJnWl7{1)V zS9G~M$|+Mb6P2>D8cY%+hHE-O8)8l%sCEGJXq^+7KOs`uK3qW#_rVZ-0po2%QPaMP z{5Y?R09j?to`=bYw9k%Y3dpUrmoVwMcf*#vC}*1NO5{_2Bc5iCqM;ghX-vm_MArDG zgfuLK_UA6DMz;PbYFd%XGC|T(5MjL;t?ie1q%yj6vzpnEstdaSMAdihylWs_j42e~ zW&v^W!bzZ4f6tloRmr-b-$V6bb1pRCG?ytDLhtoA<~ukDBH-_Xa0uswx$3OL@c?5B zpX*7j!G6^|cyUztlq=MzWOC{dyC}N~)H$UFPG>c>7O~j2j06~mU0_MB%vh%Cz55YW zdnCO8l|lk>A*B#@rNv0q3{D;zL7(2zKC-y@&V(%IhOj+{)0W_%%CN1TrhFVLI5?fh_yGl^==1FT3*x-wE6qow@tEzKa!_D z0O)f!O7E!9h9QEa8Ok-M$7$u}fp+1rxDg**1`J335!A}L?##SE|2qXH=Fb{;rnalo zPka5lxfxVGb1TW?Qnq8ls}g4ME4h1-X3a$`@Ue2W38h-rI)stuiw*VOyY@qIz$%s) z{4yRr$*T(iM-9w{tZSrIOwPy3s^$LT4La$`gO9*4-mYfnZE7ujhy3DBFhXE zB0v&5_?(ZvIySETmB7-Das8Um(7|2q^(^_xHkWmof*Q>e6Rc)Uu*setWOJ;;%k;wt zzuQwM*wP0g%@Pz+uIA|-New?`*53@2tFCdKt<`tjed?YQca%!R2@l+F?>^qyN4HnG zKfI0Jgu1u3Fly+qI%_jujjRqG6+R?fQtF;cc}~Bzz9#iG?=XR=eKy-uahdhD-z~7} zuR>g{d6tUZ9Z4Hd-aqE@7`dtAN^m~Z3h`qSo4Uw1h=zHthWK!xDN#VZhd=+{F86 z{O5=8*yOp1;^?ngJ`rv-`hPqpyxR3$MJzTg_<_beVc;f*(<<*3t?rFoI?PA8mI=zn zAqLqDCvO*?oo~=r?ff*d+sLA`HwP4&0uV&m$et=1EQ>?etW;^Q9?$_7HnO^5z(I%x+TNw&>%@TQ9 zXEfSTp=*fSHrA1)C?e_wWvF?7C@dzs%Vf$lm)^S2#CY*jyi?t~C^7e4lWZNgCWh*e zXb(-KsFOL|4);7O-CkLmR{o-67;4y0LK5qK9`_`1fb6%xImS!n1j_teq^yLn6D8QR z=nZq-o~yP+W5SVMR+Nz27|326>Z>iiEW!^zm4=IFGp_@^^eyaz+|AJ^oy2qj3-`Y@ z9UEf6v*L^d%*t2!E(BsA{&F50_KQ=9Ah)IfgtUQ%Pm`Bou z1jPxl@laPEkoAi|ZMlD^Wr2s+JfRk*;K6F1@NR!LoT4s+sPRdx#W>tQfq*yIz`5)L zJLG;MxR$X?mxlvaf^UDAso>d1wIBi$uz8V+xuzSiY5qGkrG5CZ)$?? zPQJ2?@f{?~*`5WXZNTkU-4B`xl`6=+3=*>&YrCT=;RTniAH(gPI{pM)+H<1?XmMLD zmD~sOqc@*Att(8IBo?WdMS#m#$&EbQ<$3bLNG_G7<5Rj2Pu!&b#>XU44oE$)0S9r& z*WvWR+xDk3p9Wg@`Sgz_*;)f*(%gM5SO0}}e^-?68j5-Pxt2{?1q3^+C3}c0{cP@C zB7irDz`2W^hp+-Q_kz}p8oP?z`?p>;Cvfvq=%z4SXCF?|j zeuE2mO7)vM#V=;RY#w*^W?vreN2d1%a(yv`5y$e6Nv29P(uYZ=EWqOCt8%yt4}>g< z{-$Gs;cLPk>zIL!NLhg;+#;9jneX<7xGH-Ze+1OSjbvN7j3=O#^u%6+aXcY2Rk!U~ zeNufIF^On3qHoy?9tR^pJnsX~Q?NpMPRyKH?QakbYSQk64=dVTT{&#Sle?GNF|ivD zJZ_aX{i=QP$iGITm-KvC6e^XlMi908#j^=X#&{pZ+@lH}E>przdnRIaz8BZf$(}DZ zpB;R%QnDX(#8`!Wyc=5|O6?*Z3uc&B=B!lBn*{;yW7=AawwFYLLAv4xELxoXKQw)1 zK$P9{wsdzRvA~kjf^^p|ozfs70*bVBcSuV&OCv~$fFKA+_tGiN(%taCeSYuznPtwI zIaBAFnRA1Y^qd&`CZKeeG?I&9VC6{VH^ZqqZam^aH?tmlIYKKRXDr1v9fF7-91f#a zRNt<=^ol3ON3PtLL5+KX9_p3YZFGb!ctde5$GY$*itHP5h%8Q(sK{;SfYL&sUMYWv z&g0qe?cn}tm)m8H{fzUbAtyckR@3J8(+TnuMEuV(;L?{1rtiApwZlRR5Z4f6)dl9ccpvA2F5j1BSa9oOmx*RgwBOjRz7M3t zPnFj7JPEZkNpj~r^-R*6=9N*d<5y7sDly3wg>u+odJNmJ!h`INjA2^KF*%t;<@ZGk zOo%c{rhZC!i@SjT@nwMNMgX{)parZG?{ZuH1Jz# z$MY({B*%5@^ovb`cdxlngmg)gCw)c%ik|!nB_4j61~h(|Ek))NZhwgjf2oX|Y~|!* z``VqD>q`pro^RU)4>QI`c~j0B{rfscP%f*BhEF?eTXPCq$wdPImcrOc!a#&&8F!TB zO71AdGayCL^u%m|<+5|#!C;padIQF*s}`=VLt+CnC#9#yPjbmww$Vrs;Aen73G>Uy zR^E8By=N_0&%}&6Dh;y=$2Tz-Qm^8L2YoC2Qj}NV+khvB(fll6WzVVp_F${(?tZQm zyUKrvY=yG2$Xze|w?Ls<+GSF(Cdwol5P4M3ds1Us!#cLs>tHjpa&`BLH0s@$E!yEf)v_j{DG=N1xlA$}@}8HWuXkfJ-l#o#N5cEZ;~|ps z=!qc@$!FuY%KFwn`(Ap7wYI^WMmoxo_-MAT`(ie~pD#;PE88nS{<{>n$>1&(E+^44 z>`q$CJ1e)mtypye0!##u4LlR^c&)}}ELdRd&e+#ID{&Wq=7PWY{432v!g`Sd2t(OR zz!6m56u*43WZK-~bFb~bu&kdbz^sJ$uw>H*8r@yj1+0@9Pn?#pON)4i>-u7IfxB1o zMLiUu)b9BT`~nN9G)~J9+5|JOD?kJqpu9%(i`gXG&TV1QQutu{Newor{~Uj}c(<^` zz%s6EiI)2lEgwT8hvwmUqsUb?lA3kdLd| z>0i%F<7UHXL-)q!I*-o3z6~E|4l+oA?}+E>3Z;?8QqM~6B=S=#2rB+R%xvrL1SK<0 zEVvV_mi+VR10tac_*M%|v9UJEdz^KQZfYlZP9MntqsERw8l+I%MXWXszX9=;<@L8+ z>5cJ$@%Z78C~?r)px#mGmyAQFFBkSVexDc*?>`>W)^xuc{^k2n^x=Equf^9Q@9EA8 zB?+UJ`2=25e2B<$Ccfrt>#u8uf#4mpz#+*7Z8AzYQ0Kv_NXU{IcO@M8z_i)v-dxb{ zv5^vTJCX+8E#KXxf6JVwIOL3dRV4x&>V4{EmROe?*MU}zO$L1}0<0q!quyP5YenNH zg~}_QZ(hC+f9@`BXYU?_GQ*kN%kjOuGSSbs^0$&?K(+;mRI$8l;a?Gp8bo@4>sd(N-3 z<>{gfn=7ayf_p5+Hu8GbZakc#rdgt0-mg>!Ag|mRXWT_kL7!UTIyBKK%4>ewiukIu zUuoK4sN>`?)C}{(wAd9-il>(LlkQ%<2wRC2{`%y)IW|9j9GsIBpB4SMsfS!bDm4FP zxlzP~q(r9`<1UsZrFSsoXFNaSmmJRQ$h=taP=(Zuq$txwS3w*F!Vb!L75Lm@9LqAI zhy+X%s%|(IwfGtn>y#1G_a;U7XNN0X(7zR> z(^7cbS3k6y3Z~?O(Gb3Wrs$#fj&ZItYH@%l=(?D>z4S?`W2d7NumFNTAtJ({v(>pP zF}}UW!<^KG&9yy!?@Ni-`aaa)TN#<$gmE)%Uc1%5z^cj8=HnTDN}`F|HhZ{0RLulFXS)C_1;t@geL|iw7FXY`+rr7cdjsME*8DSt} zVFbON4r1*6qI=3nP-ueDKv62RY{r~SdcJOL%bCTftvX9<3J1b^X z^LTI&y%f*f^LC9?ub(-yEyVur*h7WMQk%2zeAW;hH<&gW(ZFM;IpEs(`7;7MQrq55>NNvj;j?Y_SiX|Yo#XS zfs-pfxaYDM{(MrrYT~vDNX!wQRBPHKUBZahYz>y|YT+YLHAISDY@w9VwqB!n3<}J^ z&lzdG#zjm2sh5wYnq5erE~=hL#v9b{a%;iyC#@;32hW>6Z*0eO#`e6rTAeX7lF7Y6 zo#`qBjNlvEQ^6*}gVCRtQ8Jz;PPRBLUijX5wHHJ|Fr_SK(=;YH)v=NM>@U>~#NA_+ z<^QFJ^x{PBoC4vIhx@sZ?>>x8_F?pqPcIr?4}7*29E*25p~5Ee(vgmd6jqQTa(82R z!HCb#AP|ut^D3T}aFc4LE@kr?jyO5IOyX7FVC(vlN9GHJD zhJwk1mVP*A+lDNBlr&nsCvCLLIf z&z+Rvg=O%s#fy~cyN6MdBNsoO+fGZ?N9_9e3ml&4&rBCT-aWHnH%%yQhJ72Cz6Lz> z^Bc&JVjW1M=Z`RcA$lA(bw7s~m|DTl$6s5|`>4=|ei4D5Q#4WaxN2 z%e8kYTMXAb)j<&vK}$r!S6hN}B9KOEKn;-ug@*v^^?tEtr<2MAPX#fpjiV}mU0G?# z_rurTd*!CG<|gFCB+l2lF4yh0eb!w!O43TkanBZCw6BRW=((e{!!2o*m(Ev%u|ufC zq`<=`QzgOIiIGn9avvzk@Ii-aZ!KbagkzG@bEAaPE~Bt=v7xGjU4$g^vX*~BXPEqh zz{%kLZVyc^w-;}_tbR|ITams&0IBTVo1my%x@TM8J`SPieD}2MEmX+fwCoE2y|Iz= zuxj~FxnKQ%#_fhKumTiifAdvNroHNr7v;*A(UMbxdjLyP- zAByJT@1$xZPNWqY@sWz7*sXL&((_GlX++@e$YIpmR@P4@x8S~>`0fJ5^tr$K?(k8~ z!2SgkqmFL&+o19y97816^eYrIQ~#<*#=WWD?XY7|QIv?b(*A3=XmK2<2LL}1PIf#1 zs>F8#xki7^s$ zzH*h495WjLN!@R`Uc4l=Jf#jK=W~wsw?x>=z3!%giP+-vP1;AYQ%*~D)0ESH5*vyE zpZ3efA26e(qhk|9{tfI`T4P|@Ji0dI#VUf2*3Yx+2SN=++AE~Y?3)0wt_ES{(jk|K z8MCH3I;P`)4!k*<{Bwz#=b~Lr!|t?)qJ_K!mwZWTLFn-zGEy>Y5zcYox`V zEmYJ-A@Zn4rZ?NJZM80~Uo~K)&(6p-;y*NA4m|mqexRn%TCK{C;yK!@s~Ta#Twkxr zS}u&Ux=27b&`R&Ikg0ytlt!9L<@pK}Zbe1!<$nM7c5P#AR!rov_hfVKX+pfnBujP3 zuKtG>NlyT2widFQ;z;^Gr_y#Tj8eO@6|;FC|JLxTYcgy{C`O8|a^y=I`?G$MynriX)6iw&TU*ob1_h1|o7hni9KHj>Yw+ErPY&xGUrzy`|3|2IQn;(xt!|BFjYFt$5Hs zGGJbx>~C!ZZ_#f~ZrF)JW7saU*1e`qXo~xFWjLPw+ilMAGt}CVXFDT5qu!peeA<_g zS0F`vp>oBS_MdzJJwwcLJqygY#UtpDdFoRQt^J-F|vm>yM@HUKR!K?6xz7=lBID$9e4dpv@A=hDP^uj|B%S=2vDRux{ODQD&ro1 zl$9C-W*z6q6CFa@2`FYD@|N~a7YgquTa8BamHZiNOhS#^;HnMr!`)`SRHN3E!GQ;{a_h4b2e`bdjw z491n}rp+0Qqb}czmA6nwAyr6GaV8E%@Uhlb%oCgI-%wILZA;AA$)t3g5Mzto2s%(8 zH6}f(pdnyeGx*Rt)zM6HsiLeNiX%@!bN?0Y?@J8a#s`UX^fe${heQgdoP&?fDg>9( zZdYmf7HH8O=S!Hwl`_T`Xfqz}eyAsd^`w|g8bcP6M?f)TLN5W@4f|5vG6i58HmjNW z)g2wUZXv@>JqY!CYM=C{tb4z+?}PcNY0wZ}l}XJGRhf)W&KVS3jdXuVmx*x%C4>fB zO;)rqvVPIeW_eZhuR+(`egzny$`JqY&N6wuq8yZX=e?|}Pg~~SQknN--m=VpIqpd4 z?aRJ#=B3pX?EC8j#LVWyx=XvUWBcUsWUXvw9KZPlCQx>3?TXo*I^hwZxrx8IP7AbI zgtQf#=0`?1^g;5f+hDvS9r#Fmy_HK{-pqo`=Hu@xo>v@(d4Ho|ThLvtzMW`y zd@_D)eo&>DR%Uw-eogX>-;2`^Ri zcspfxM=b}{OR*evg!^@f(Uyj6)8=(j9bLy0{mfDu<+j`U47W1+)?<-AfkOr$^j_$} z7?D&1;*wc(XP75)((E~4Ejl!RO@~1pvqk36Q7w$}A)qiF79ajLH}0mBcQofFu@6Ay z+FOS=_zCu#F@`3``8~HzsIvLupVH$43gS1ZE1McLRg&%75;sg;p?`CN z@{laUPvb^Qdc}S(Ku~vCv}n3Ned-Z|TYk3VXzr+scl=fc+Dd8kVv&WzmMkfsEwZ)?jP5i~{#;v792R$_)Gw#{kuW zm^5hXw40z`T=O?FuSW0OYDPo~p3=~|)YiKB&aI}^Md~LR#`AUY652&z4KWlvpvC1q znJV@?2YJztNlC)quJCk*G9B=)%|tbMw| z59VBpNSx*oD2PzU3ZyH`WW+H9eHz58V2~xjGbG=@n}DzBNGSPGEF4(vUU1gO!FgI- zH5pIzl4@3gMuBeJMNFUo5E~C?$H`0hA|DNj9Xb7dwQj#w{xOy*CX}@M`)Y1#Hy`_| znP+5ByWkIQ;Io66@9R*3jZD*p8m5!?XjVD2*%=;IoG1#RmUH;cj;Zk!A&b!7A<4vz zjz2bfznWrj4{nvAcJcjl_2S60-Z1i{$fN#;xfjKYqb-?@oSSiZT%_M_ul$}4*ShZZ zvUca@B4RuoA4l&8XP%nxAC~&1Y#dj-=|`7y+JEIX-bL{M*kD{uT#uBhoo*a_rbWhd zXPe0Hx2r2urZ`9z$x>K1*l{anr&9l{wZ~=d<#f?`REGwumwUq-he?jc6_SCdGD}_6 zq{~ojIC~2LUGml?Dh&n#i-dKiluY7r3y;B;<2h;h!sipcnvwgU7nD-?GCDc-bb8hn_tKgPL?q|t@6uS0O5c@I94+UVjy^iO6b}y8dZ*&{{K!i?k>u%2X7BOGMi- zEWzK<3=|RbjJL6bM@I{4nO zm+z(R=nz|{uzB%asBf>R{fTF~V4w=vu;2w8VJ!MGR^;ElJ|#>333nM!{)s6`Hhyg` zJAR`bX13|@SZ_oW71dh`W_RPC1-nyHM_EwXG}J_*bWBbvcQsN!{@_?*Dh>6kty!5t zh~qP`5<;CAD<=2g^93_n5_%zao5iuhLUs0z6TJ5F9koA*-!#IvxS;yT*mq&`P57*vxnFiD*Y88A5XB#{NSu zn*N~|zTiLLgYU=burFlT$+{}k$>c6L(T$z3+-u8l=v*k2wiR#6tm(t?CueN?L|4@c zDl%0>I`BExj`%lx<$IkwR>am-d?KyazzdQua~i4MIS%L<(suj#npYogttsDW+!Zw(uCU`J!2o^C$mCmri3Gv>S zu~hVLb6DJ~)ZlI2tA^oHg!Ht1f*|1UewB)8@u2mW^gOrM20Dp~YmgkJEjq*0@-`S~ zyrUUN@`!IBvGU44WFRn3YU-#4M>&S^-%WtLAn=!tLkVn^!sR{^j5AzA=O~QhLD48K z#}K#bwZPc@KYeBMly={MG>x0t(Q{u!tgsyxIMML~Aj!t{ISbzL1KRlcc^xyJGR``B z&wSu%;2$-X=Rz4iJd9Tux%?;Vf&8v-76WNG*<`Aa*klwPG~4~eK5SnbJSZz#K2`TU zFrBUBZ_7>)ck?#LuOJt`wOL)To^QvSOM)@~AV^JRn+{F|HPUjuU11RmB_MigXmDFy z2&56`%DH<5Vk+6}X^np;M9;lU6W|%JWVBpAx&DM_(>s|}pOqDJbp+n^=~#8Gier6Q zA8=<4`;do95cj9NHZr80B~k~4h;@?Oxi3{folBmE^nJ)AO0;kW=bAN!ChL9PCks|r z&>FCidQOZmsK_cC|NHY^gg?K?orjs?z=+E6wQU)7me|f@1%`kJ|J-6f{u`rfsRMgWpivY_#IsCP$U|BYr_9V<6L=+yw!9Sz+ZXc$x(%e^ z())ls<+*xttIYRzBg($d%6*41*fU(_8$6Gs)76tB4s|DSiq=LP&49 z>sw4~x7f)}Ie4OX9`4AaPK4Da+~WA$wuJglVW%}%_24SzHlyNzB9Y6k#OPW9@C@Y` z=P~?qJOhiy3|<@7bx$0s?yD5Q?sRhQ6hKyjCF1Nttv#hZUm-7z12SokK225MOgYRY zIZw9+_yadHpDzzD&ca&w9rHA`KYZdA!a%H0EMwvCF zFNLbFqxr91L+BoU)_=lKChF^C8gJG{<-V*a#(S z+@{l+$H=_B0RIbz<<@kUHBA%<@75rDR3H=@RVW(P*mvh^8w)ZTPn0!ie%7qQ;~*%b zep_dsB62Ca#tS?iy?4;;stdRbT~W=?()e^=M)a5xYCROWSvI@`8GiYiEJ+SkbV>N` zUKFR>nbQRb=Z_ShL$@Y}K5zq7rf+fos!S?-Y`}+td9$xAOg6k| zSQN_Oa)XcqHZX^CGS@>PFcecjTVU|qmQGV_;OzmMM^yxTX}&+@PB1@1Y%ES1pF9&l z+%rK;pWA8r#&weVDt3^i4N* z?MscTi^f~yCEJiCRaxu!E}#o_#|}grL>ZTxI-#YmtVAYJR94wjNyD0!JWT}Em=`VF zv9tKcfH&Qk=)l`OfB`>%fvD~qj&rv+w18enU+_JjIxl-C!i2I4R2|Tl;E5Jl`l~&|d3s_M)t{k;ME=uWwhH3t7a| zMN~gVS`jjm)l>c9==z3<3o5Femh3$D^r+)5(8*K;wXdQm;K58vfyWR+p}!)*><1KD z;Kt(^;GCfZI~1FB<|$&IBoH4TCb_9M@$VTELRiaPe_>h+ct7n@y>x?(umsg9jRVJr zD@Ygv9G|92EgNeOW4Go6CnJ?|mIA39*AOG=`>rvROoiqTO@tu1jmQofD&bErTqx{~~r3z?!BvZuNO4K*QG~per$b2*k zTz-Yw=TT!u#O$Prq{UNAdHH2wnxU2sY~IoZY-wSIi?tJ49`9LY$164AL7J#8$E5Du zq(QL>g*-D!u^l4X1j)OQm~;Sy$wr?bjQrbS$BwrN6A0~q8p(l$?S4ffmxc)fOvNBvT;56~sDv=%r?#5{3SvNd^#a(R zAXgi(zi2{1Xl*2nwd z*I<5*Yq!;ZyOYehQ)07ng)h#X@BhdstfBWql;5d1 zrsr04)>D`5hm-YgH)3skVhE^JHNL?OhHDTfWehWiWuTW3MgC2CvnwBN|%J$0-{gwk{&NhP$>Fcd#81UI4)HvK^X^*F>%*KK$glU zkt+I0;)&napr`^_QKIKEPJCC>)A0c+d1oNr z_Sk#{dD!s^&ar9x)A9p0Hr_!3=rb*sL_y&U2{yJAhpnjnds#OXbGv^)@8pS7CLzQ@ zNy(6e10UpU%^jERLn|se77EyN+=w7U%1KmQJ<_`_^XS1BN7pgevkT3vPhWE%wU=+^ zYKDA<61{U!hknkOPyjF^b(tIhGnN;N>Yi7~;i@zaGqf=GYvZ_L_RN1f58TpZ$dc<} zfXC%|z;-)m00l@D1$sXeZOGWpJJm91)=)Z_s)OaVg!5pgcg|f!rLgS>>2Er)7l!Xb{h{@_8x-`-VOq#ESzmSD#BjrID z1nS$2M18hG_X0}^0@``W9<&$nGFI-m_8?*)bQh;GYFRK6lg%^!&+Z`q*`07A#3Vq` z?m}wOV=vF0Wkmw-c}gJ-jk4ChQ%YfMNN>K)InCF9c1Iui=MF{dJe|$EFx}t#HxJra zeGI+)C^zP0eJQhyh8q)&ghiEzgccCC(D@~nlg)1K@CyL_F1Zv_cDT(2g#n9Jj)yH%`7xXc* z;X{JB;$Z%ne|G9bo^U!0P$Nn5{c%&$6|m zOS@vv+Cnk3v3XREDTY1C?Q)v8c_}5JqJ(fC?TB4BON~~+R*7g8X9N5|&fsJZ3FmPA z&?r!TS;CaZ5*1JZ7*-k9qoaJ^HPKZro|ret>CR~cZ<|-JicrI|%O6=wlTWoVl8)eONC{_-_ z-oo{)r#Kl!aa=g#m6M=HI}v-wOW;(LOtU1|itv?6$)wuW%fT1d^-Yc2XVZ6VHWzz% zO1jh~Ozy4kENzJVl$BheLAy@P7(GtBjmbVOo@6D>d4DWY&^!GPu2xzoY10AtCOxxN zf_ECd1jEe-dF}vif*St9S?NzeI}2hyvV?y+ynz*ABKdnMK=brK^!o&3{S9VW}M5t-FK{o zCMu=jL2JOpm(acXIxzN?Ba{oH*y=)@DzhzuG)4tm18)duCpdvu2WwJD#g^(Cf-+03 zRgy}{U4Sdl-(955eCgDXU=&JP^?}leDA!ydUCR|s2mxGX>BuH1<-{wA4`qgNd-f>!2jak1d6hJ5GN7Z$OFN6Wez8} z4I4@e0UWf3_BJt5Um0|QBFx``QdHY9S!Pa*nk;Sn9hiUs zq=~Zt1R&n?!0%e11;rp&Ir($MM(Nu!lm#F_Qy~^#AyWxbc?-ICj3#<#{1?+U_u29nHEr%dB-F#-9+CSvL;scqRRDzIj4A*^72VFd z#(F>~qiNLq0)#Rpf-(-Yx(d=C6iO2vQ5EMLH17Evz!@mzR4Rkk#|+!J zm1SyKl%c3${gao8jx3d$Iu+J9JCl_=hu4bsk?hYOu>1*WSs=^c;9`d5YsjvB7qC-- zxD8f;H0>A|fNPR2ou(}ITP$`r$FN9qH>npKau~$KeVv8G-PHNS*8B7yOZHX9#%x6X zQx2+&_Ge^imr(3nDyTMLR|2V@TqMjQFRGi9HEf;*m_uY_2M`z-fWW{21P1z+gx&2Z zL_RS&=d4Cn8-oR)n+$J`LglwlYPkAY;*?jstCjx#n;XpR3U>&+m(u|ljS3zon6RrB zJ|T;J#|f(j5UO8|tbLSV}fRu@JpI-}H`(hrR))VC-{!2yI| zh**?GrW#f%POXvaMR=TwjV@d5);~BeJU?Hw&7^*>vSS=9a4?ygK2uQe{kwb<*v`Iy z3y?x4ou)DNTL*Txngm!aiNmg*EkfED$b&LPXHumVX)|AyzG|#ghI~#_DiKgrLO2n> zsDGqY&k*eta!Lg{Y_(M0vG2R4o_35*uu%kHqZQ4M0K(`l3#$im5MFQTckC%S#ba#> zNq?k{^5H@Cz@>!J{g5*#_7#b*ac&&^%-Z&nUNDJW>2n~f(iwc#Ty}+I!!GYv_lfR; zIl#7f<8d0mwg$ltPgvbA(v~LW!m)n!(jgIzsaR|c+G`a6(bL&}B<`CXomA~A5%Mz? z1=6GCsLMQ+q_XX#z;}wt@L6lw6+*CGO@H@K?x|N9JE_eY3Gm<6K-LD9$nPf|VA0uG z21Y?xnI`oa%2AR5VL}m$)_?^h< zrF%gO#SyF9>AvAS_4hKd3a(UR8#CY zwCHTIxe1j&b9BpL<#QbTXoDjEfgJeeeEw?lxPaiR^sy#XyZQILd`F6ncq}cTlWiWk6d*>6)(BOFjV>iZ`U9YZ;i42-ntxa^M@C+VEVptWRmO?dw3O?k zOo}ZZa3uS?8%I}~1K++dej)$3ApY?7=UKgZn}2v5d?8nc>hj1Pd#X)+)ovVDkUUcw zY-3w9mV)L_16$K5;ng*^Ei~Rz1}3`*atk6zGNtXs!Utq^Hq1DQem(Oy3Ku2J1jJJ? z62_8H8$gr!-u5zlPu1!|#EY-|YS^~0oeFI(_kM|$P~$c0nVrf6c+e1_`e1kNmqD>x;KrPVc;N7`d;@MaRN3=zbDyi} zSe0V=sU(!3tLwlH1OU&MX(X%$cs?MYXEM&&Mbl(4`{U(tpe{(UZTWW2St6H8~ho5)S)cS?Z$*2e0?Z;riTgM2t``{j#~n=!m4rPoK%+ zlenL6h@+myL#7i&Ee18DE_&c;^6!CCRb|jJ;L;n65Nbr_LYt2;OdP2pgcJhur6CpG zRFEdYMH2m$+@B=6(P9tjp#*Z7#n@X7UHY06t7{(i75|>`9>n|+p&<{D)`Z0*f zd4kG`#IRH7`?dl2db@&6Ej)*qpNh|ivnG0>+pOxNx^5CtGgCo85oG>m0XzJsI zvH>)wv?HS-4A{rz2{Xld?0z|7tg$kt= zi#$-Cgqx`$y77h`)a5A3$EtU|mF1#lf`r8Y^rWYv#lfgh9$l%$maCG8;avSjPbc6X zb;~K)6o9&cL_Ql?f1&P%fdNsQ=w(he$peRhJ4hLbcCT|{wAt2Oos&Fz^@x(HCHn_Y z!2*Oz2+>hE&i!&w$q(4G@eX&usSt9RmPWee*n`Lm^CA?e$p`vx5=(x&%}pkO3&ZvS zZyM<-J;$E(wzRL-TiavrxRkjNWe)IFQ9CA|WU0&vPkfur9NW3KUmzTTnI-c?5hcf3 zM{agZfw2_8PfM$)u`>!Xhf1s6?bHER25B4(z%hW119P=GeUxjhTw#aP>T$OIc&LBy z#hDXA6hM)J(x8Fs*p8U;Qa)mu%3pm|MIKCoX_tJMhiToQNDE#}Mh0}N2?1ovSV6SH z!Q50*bO52D1P~fZ0HNV!t5mGDy6NIM<-N5_bFsvz01#uVv1WTz{@YGf@zhW6wpuT2 zu2yLSh~_?4+UL;QOg4i${P)WCcB>hz=BXW|p3ULxSH-O0mZ6KKz8hnbf>@`zrTimg1 zp}DDMfLiNv7@0dl-uSR{3P5?6A9^w+Qt|1R1-(sOL7Z;NJY&jD?yz)tBB7JrU?ej4 zToP(^SUf;1&_|k{J=G6(O~?@$qa$yQ@dMu%oDhOh?Me?=RL7TB&uJ}5#k7x-`{&N4 z^MPu}l(alRO_xgnHY+b5-KYR=VaC$KAp*`;`XZ1~n==M-!tj%TA|k3CUzau#0GSE& zwi${0uIDvr%dh&4S9e_)0JyROeHy@g^6l+tdswEmsvKwm|5IjU@DC=dz-WlGoD+>E z0Qp&S58ccJRiNwv%oQLOMUkmYe^OJn8|I?#LnO2cZ6}^MKw9Q#lsihGaFnWIf6^<2 z(!;`rmBSr?lblZdmIN%tS0dk!bnsHk_t_1TtHtOqd~@1aB_M|DZ(joV#_yT+xEddh zHnE8~IP2T&%U|@MPh^ysPynm^TAV=o91~jmJ>j31ea`>}yzB&>CM5bT1N$e(FQ^$Y zYWg*DMi{dHQmyIc1XO-}ABojy7}Eui|L+H|CsgpD;i|F#P0sKM>*zbRl7H16RUqpH zsy%=+`&aELF(A*dymC=aXclIFa)%(KtpQz05~auhVD5=D*2EtnyO1Sy7MrIVuW}cE zI?oRRs-JV%&Y5M>FU7PTc&A<$0_nIaR|*^Hdz48O4y~vvdFE=eG<%#Y4V=mDAYwF^ zZ@g%==)7oD4{uoLaCVV(zZ@YZ6|EWaSI{UcnV`=f@BU<76#Iz>W5}!#bxTupa6dXw zNcEvXY%QXlkN^x6-0Al%0kE(Hz`{W6I66`9M~jV2+?^G5NQEO{nOZ?G6bo#i+_h_x zj!e}|^p5wK%WlJeH=t^n-7yoW3oJg-*byR08JaW%`T0@s4?GIsct<(e!M+>0|#LwuS zpCBS0I$OT72 zt>rqjd5%kx>!U*E-0kGPXH%v6q484c%kmMn&)tcl@!f4de|>^f)9m7Y%vCI`rA1@p zBlbBcV{@<20-$IgnuZ^+)yWP& zz~UvjmP%nOeu&=E?{|PfoY?)91XlB<8}n1PzG8O<=6k#-pMEkaV;qw7b*@h~-=Xrq zHqJx-w5L339FGo;VX&p-^5``I2M2# zSv?8-t<8v|67}8-h5(umb|!+p0hx@a8#iY`EGgxlQ0iW9jz^nWz)A2N@aD!tg>O{< zfB3bXW*ofOn))&&vyz8BU*I?qKu(oa=-CVWz;r1M@$x}Qmx*keM%NI)$)sSMClb#o zDVxMF=+%63(LS#XoCt~smdSTJWGaZIOqr5Cb=L9EaU|27$fhY*>gV0}GBq^U76!g2 z3goKEsTEqXm5So5c2kjS;IF`gi2o}mvI6DAVxXMZA}D{)c@?7RDDAarTGh=ex%@ib z+E@w}Fr@FXW_A=Gd>v)il0cLCF)x8V!M9pGaqzvg*V*;Oo{N@tnbZ4LWj%N^=Py<>ZHfRUpOy(Hb2 z?U~6U-s2*KNW_}RXt06!&2n10mHV&oZ0AFzT8%?Kd!7S1GI0^&3Q%|uN951k70DEp zBkMMzUwx2@5?B`L+u(||U%tOI5w-WzJz(Wn*{R&ra%DZBmZ%5R67^&dGK63BVDR#N zB62U9sO$g&2L_`^K6puynJu0ca}Kf=2x(W2lw~52ZHSMs(6_zmXqnEP;C$!$y8CW# z?Ni%Al@!nGtQ($X&f`5P84i%(UikOr;d`CtyThCjk24$kq^p_T;oV`L`n{{C%$&9? zzpDG2xsv-Wv@p->2O3(SE&tnji0mR(|2WW{riHQufG0GYOoGD7H;OVz*m3C2+0hL4 zWglWR*rUp#wM3M^pMP;LVs9bJEsB`@EN$O9US9RQSluDM#CW@31M@ZLb|-|4W#ZWj zV7pbm?f6w-{Rqp8tE|k5zu@U01f)%a@tyMF956emDd_YW&?!AhZIp_X4{&L{#W&Q^ zeB1tlQ!6bX+6n*@t1#+Q1XAbG>tqoWA@b#Z=gw46TN4NTK2WK{Y zYv;YT_l7C_V(U(@g@XEuM%B_GAz8c_evSeHGIgcw4^uXNteUDDk9$*68vb^<%Mo?A zX{~jPMN%(jsqP>-r3~gNWd6j7O3}c4GaI#m3@|CcNMDYmpp6q94As&VuX-xtO-%7) zEH>NO985JLu!{Z|Rmwzv_p$A4YvJJb6T|I%PLr{Z>(QX4;YW`>vWtla31wl-pgOb^ z(J8*)i#$mNuIr)~R{o|RX9jO)LLV2@KXYQ^2RRhQ%K>jTMet&HL#sBi*78gw5P&9puLtV~Wxl?n+=#%|IOdVTWVrCsqe)HLs0;J!v1O%jM<@k$MK)^&vG zBKk{1osz9xyar?=c9&aod-l%%#E7&l%d^G!RLu5X@_bAZ3N2pjc{5$5$?u z_~DeED64Duj9cb@Xojh8hTbwq=aFVQu6~rK$X-daG-_-yhTDqXjUKF*h$`DSu5MDC zey19yaC@~&CW`zdpBLAWZTmPPfckeu<}S{TI{040@w6h%ZPTXRXE9~@t~aOYal>>} zf6evj_V2?5&sV*&p95n4Gfy0jFf+Ecnxe{5;BlN1YBv6z7#p?$CHtQPOtcvgUp#-p z&0%`?sdQcQJ`b-<;AJ3nPyf?e)-;Nzrg_FzgQch8m+21(FMcEOFOBK&uU)IXUa6Zc zHD~8R6gF!ae$R!Oze8(|Nq3lU#nFP%dUdWnzHPAQJ=u%=;-a4(Y;{?WdY@PM(dX3P z8+iO-143JAx~(?B%K?e`2J}TG{hDikeusfAZgxO7{en-xJKJ&KDSBCVNzYyG*VsNP z@znjwnZ4N4)j`0ZR8yYMF*N-pG;uo_p;Y)#gfEZ9P=c?00!$(SGwLxK$9@KDI-|Mc zze_m>Vd_)in&MMn$oW9N>C^31Og%}BSJ~NSBE6T;=8Q~aH#;dVvKMUFpw_9)hcJJ~ z<*GxI$24S$n`~IIO;t7SWs21i(#Xe8n5nE z9l~Q@wc4Pqj;uub&w0pU{Q@$itw?oCO;E<6VHI-#;u<9L4fS0gHC|VNb(O z!%u&hUqzE?u*B=zarvRn7|_?pvdTZ9Bs#riWpLoVETP{;6N|ZXSv^v}7KmTo_Ec}M zoQL=e8wA_bDJF|tQX-E-Lp0yZ20V1$`MsbN{5ld-zI*lfNq_PP;xQ4Yvri)6T0EF9 z|3W7B=HTPWSJ7ARjH6hJ)7O?ItELApBrX^aNK1UZngIADx+U3fc8H=9J6k`?W#KdA z9sQH6@wAnDLaK`e`JLp=V_jPVfwWUE_}RD)0s|E3`^&`Fc&II)3V1cFN=i$r-?5d{ z2QzjZnjP+(+iRg6I`Hv#EUy6q6c*$*82JYDgCaGEZQ4?Z0U{CUR=1bb%=KZdR4ZxI zdr;6P9h>+>?DP^#$JZ#8J(_-{iQ4Z@)D zoPwnOaOJIO6}IkfR`rV!m$KJvZS@BSzH^WAj^r1?CFv-@2Z|zSH+Vs5!SWav77Z>x zpI(3b9&?Am(ZjAh?h_$!E8UiP^K0gL4b-c7_7GtjB`~OnpgUL;itN#hko-^pOcoC1 zQ{zVdHLx+nV=1cWMAb4nK*S+iT7*^{5tk|XnEo5g@>!+&(|hQ+?r(HHCwe6fE0Jdwk%m5DKiAY4eHHuVGjR4s=g|!t|izO z_rQkWu7L!1*WeDp-7UDg6WlGhyL)iA;O-Ed;O_DkIrrW%-q+%Tv8%hfWL9xnoPBz$8*{V-Ad(;kzo5*k>{%>k%xVnp}y_IHE?E?w}VE+0rj8pgO*Ln=p8r- z-+@zy8@{!drk`KuR$DbTDw3}zShlF_M0h?jhJNT}sX~tVfHA7DE{Tz65M`Nyx&qx@ zasCq$1w`f6+d?U({P*R12Tjw4hYBy;2Kn%eUfe!#y@C&3K!~)&Pzekm zb?cFUY3haqxvA?hxOBBpr_lT~lI8WS4uP1mVU{8-T=Q^%6;`tUEbJ)%9UAB}4Gkib zlP(r+OrCCyJa94w-4E;#h_~?fZcH1A39Vj^*3b3`H^hp8U&5EN^~8b%Q;Y8He(g4cjNV9Rskh7ADc zTk*#H0bE$%?OAM1f2&z%fkkv|jWaxJd(QLd#5DgSOBw9X=^bz%dS8PzGu7`i!hQBt zxh{}r<{GMiGi!tHFt6eq2Z=b|KAPq12PX;X-xK$%2CwAlos4$w!q4oASbtUY0)7n* zvxWe~Ih>Gnz?BLhps}v1Qcla3v7_x~g|EC#2a-wUq38TuG?|02qI#wBB}2?a@AE@) z91#}WL|;cl{MDN%iZh?AKEGSr6U)7pL(f&4wI^|Vw;1A7(v}2DtC1b9nP^GhAgvtX ziZKB@68OYB??*X1+SW9fjWKR*ll0UMi;8Pc@mR3DdX2<4BKxEng0O{lm$E(7kpnmb(&9!D)wu z3I7iUGK{MvGPL`%wVl<$h4~MG=!tyzc0rFn<_FsEMkLx2;`*7MvuPUQ~`wKK8Y>z-Lb zf|!r|ENAzTo6Bw6Gf0~RSrYLs0gbIQZ64fjTt%;801%Da4=ppBWG@0XLDzApaDfg1 zK{al@tJvJDnQQW%er9X~zkO*g>=<_~#V|Lb2qduSF`m&8JMt)c>VD>VleQA$;%76# z%^KXp?XBCyc6QJ5)pgKxdS@+r?U3axswuqLg|+Gh5!Zvv3DfOx`RYqmN50-fR~>K< z;np`TJBU}Z-mE$~UqtIop;&C`Bg@TD(&ri#ztf-s!jOiXOm0}RWP*rQE16)@VrLnP z3{w#hHBO6US^U==!cKF|GlK7EAF3PQ<M>rS@3m5H*r5aaUxUc3?BoPNV8gKYQ}UKY2{0uP+^f&b8lFe~!^(b4v$ASP@R z?QU6bYF7{?Q=F*oC^^Nf-cj1&7MSbo7_66_$HaZIZ>U_MSY!G&{C*(n3e>lJKAGVj zJ8~#;>T2VqvLlhJj4y1ge&8_}edo-hLjJW-Na=FWFg3A(S?NTt{`WMqX+3*_t1PADyB<)p%?g^`T1p-wB+gJe= zhk4w6v}jKr8&;CwfGJ9jInd7Ylgz+}8OD~B)BZzEr|3InZ@I_(v_X2^y{*o-FEGBH zAw{1v&EJY`^66$zeqX(CJtK9Dx?SoUK*?uzzPIbk{Al_ z=|-Sf9m~k3TGdATF9ARa%H9H5SW6Q{`gmLd&;W8kzCrZa214o}eZn`^L-*#BVCKJe zu&1_{b;D4OkmQ)|q6#ro0z?Kv*02RSsGg7|8%L~O3_NDjIT<$=qhekPQkjI~S|A76 zcBxKM;Afe@ZQe_#2I47=|1mFKxJ#v{iLxHA{F&@d=7jfmOk2F_5SZyb&OJ6zEfO6l zqTpTB>Cp9~yoTOC(6RH1o$VUUMUiJ3ZGnr71*!@XtA_=wHipbZuynd zp$#I(lsj&tKwahm;|~+ES-meXIrLdDZ>da+Ttw?$z5G897PlU@A;SX7R>QG}#X6MTS`3sK8e3ex~ zGUnEe>)E9FHIM6??dxvYLC1t>txH3CmB}pa%bFl7#AXY6A(b!qljR(6{1gH26yf=(>BpCN@krQ)fO5ju%! zH~go$O0g3o-s`nfS0;$$Qr?29H!$iLJrJJpSe|W*AOB@P{Y5Sp(<(e(YuMM*#b3z^ z`ecibRsEtB__&r(x54mu4+*_XRD`B)nte4bDlTfenER-l0zd=AlEwDxWb#OLY&458 znfgQ?9Hm0S4Z(?Oj51fT)lADjk!%oW2z65#Xo^FU;+u}iK0Es&=;qc@1LW~L$YPeO zBgNII_uv|qv%hn?MfJjdR>#V5rblksF>MdTwx}R>wNa635CeQ#mMkFg{}WY`KwhI~ zsDW`?9#yQmC>};SJ0i9Q&@H&|;612)U~Bm(hMUC&^39MT>Gk-!nxNEk`@M|&K$%h*E8{NFD3 z`m9BC_7_jSMr6wEd0`4m#lQvj(YJa1- zUyNrfk=ij0e8q7#|D(b~WoZ4y16jV$Mi2S6nyVz|X%)uSi&R$Sc6|fw5eRsG4%z>+ zTC!pAcnWjzIhN?r@%r21+GWt$Sz(=6?U*xKii>8%1%UPFlM$K!7VS}zcxiLr_}S!x z5EL2cqc~V>`Ce1H4A!A8>ivv7^-K`DRX`{j7eo))n6%5M-1{42xtNsEjf24kp(z+1 zslmyz2*-l)kuA67bMMl9#(%=}(qRR~5j_4)iwp7priGu(5>m$LguCOd_@Y2L7ucc* zTVnezu4%9r725zi>QpI7NJSl?NLFYk*zM;|2N?%44GB9>9)y@4vst$S;4k=on+6bK zN}Iy#uFdYl12 zW0;|aewbnI&Gu=97x7uRj9B}I`M84LZLFRCcLlrd+8o8tro;hu?1-c6+ZYWrau>sd$n6HB@P9sAD7>U;p)Bv@A`QwU0T0DgEbswz~N=+{hA&n5vz$%?!%0W|oxL?udOYLrvRJvJIvIX$5?vAAGXe zHEI3jldYJZi+(O^etRK7|N3yTwdfK1Xs5Y8$9pZzqO%&-c{^u9D@vu?F}b~QHRY~! z#BC~gTI9G?2r%ULZ0aC}ZOX%qqA>P->{Khf3V!Gu=7P6rMe?BZ?C&No2}5CjTUvN( z$rgrJ)CW|FU=tKX;_5rWx|s7AVgEr$pDJ(CP7s0d6?sNz|5xze=Z!5&>1VwYfIqRo zMZ;UOe!%)c;(2!N&9zp2w!u02+0tx@YvdY%*l$RF%)B2s?1K9_Bm2OR@$s=kJ7zaj z;W*|g|AM3ZkHnRmZtFy=$79>d?bkLNMlYQ{Gp`B)beOHTgDX-1tC9yJ(pBp+#0YzB zb!d&Zhu@U0uJcXDjXb2E5tgrnej zn-|eO$p*_~6r3UwI;(^q>IF6LO$S|$3hq%qE}2-J7EZ8c$)i9Pd?M;6OV6Mgd9b*> zIsF*f9NQx6vZD&{?M|5M0k<$6dbKg`$C!R@lWmN-pj_?dUR%GW(+}Svy*Fk8x>-`u z6 zE^OO%*{|kKAa9)CtdjL@w)Jr3zDRJ2*Dg*ZY@@Vhx4-!IJ+K*#5FVu9QJ#Y%`)4vg zkl%j9agX}0oWGT|0p*;1IZJ1W8}Vz>Y%j?f~XQOKYi9@m`f5nDnpZGZh7`}Fwd&}qY#@QvX-4yON@r12l-p7yxXe)}t5h98S87@HyAI8U& zW+}!q+~!e9NPrZT70f^u?-Ws+g2jgE2mX^8-e^OQ5`Pv+in;ABdjlpj!XOmQ{pF=Z zx`}sY<~I=lnO&0(L3#r&PW43&44rwKL*+xF z@3pKr#DDXEKbVvUZ-zmYXH$Y$$Q7Im^?APYKefb&k&O4%Xhir#ob`hMk*=WT&qzZ& zAr%Y@y4ax{)5F1T>|Pv%$ax3{748!?u_94ee&4h}jk20jC}ts9Uqj`Rg*%@ zWe0k`uQPD5M-(rR;HPbdo{5&5VW;k(!+TW5E`JlLvzTVaL^8*YnvKp3#k!M=F*NW; zBK!dR)o==0_^>zTTH69UEI0wn4Mfe|2{~;*@}9E8PJ@GUzHUJ8;6i;}a)HN3M0BEj zy`UUAUB!x#{P;uT6!8a1Rw2rdt+Pd|#nTvZ2Zmfu4n?du{RM6+^kj5o|DqndNi{EE z7Wm{Je*Or^Awn&XZUGS>y)VGZCgXv;FR%dm@|b!MgZ6@R!Cx!BRp?>_oC;$CKOfL5 zoTP(vX-}2d)!7FDj-(ZWZ)3i9?AIGD!SfBYe+7 zE}8J+1+e@v!dTwKAE5bDT{$J%Y97O$Q>$DwBYxG(@i;yqT}(DD%JG0oWZGh?MHKnv zC=(Gsekn(Uf6241td@QEM1&EpYp~#IQZE@5!u1;YaDz-Pwc zbm1c7o=%rMOBrSC>eqJrz#;oIj*iGi&W|~YAn)hA>>5~iXfB&K2xHebk>}dx)D7As zsnW3d6*_Me4|N8K_#TwH!|2+1JhV7iFD?ExCJISLzo$PX`|_|j^EqyZ!(8GAj$%IO z_x`MVTtiYiDRlP5>gb2fGlBwNWDc9B1h1!y6Rz5#G4}d+H@xZ2+E#)e4t1nM-j2CT zeadBLY-Nxf<7miYfsS&FseC$=SM;cObTrRX9r~Nasdhy_vBzslA%S`ZIU=R9$Y!p1 z?x^Z)bPSy=8d^P>W?X%pJpUvlzA(4Tp%_&eQOER;Fz_%bl^4*Klh+;V9?P>srYZoS-DjlV zKeOqR{D_E3SaHeoQ8;kPm7+4Ih}YtJvVyMt2>%d2H^=h{sXxMLC+8J=e}^5&>s}o; zlON9gGm&u(u4ukB5qS+heV}4rdVY6lX>nH7YN73_ZfNhV`s@sI{Az}zvM>xdr$1ZamD+o zZ1rH&C(*c&TYr`Y0d+0qU6H73KZzh`hWd`2duBP%QEdPC+UDz!M?Z?+0(;uGIOsfr zx-`9fAWq$r`4!kR`xkYd1@0DiJ8^6xfB7kL$yV)&!;lyd=OK0?pu#X8%-^u?$N~5J zvJY^^yJU_!azf9Pth-rW+8?>Xd-z>`!ve<4&klUH9fj|;rrN6(_tmtezSt&DX@~=R zA-RGjXxCQE^7Zt}Xt#-9KIZ}yIyZ6ht%{-VuYO@W;?-ZA;_0KKU@emv)yvHasze*A9q0a)5S^Y%8fC|L&g10;~!Gw^^9 zjwDy(uO~HveK$t-%fE->Kr_b~<`y=jd$grm?xImjP`|3;GBXh25w0o^*6TeZs<>Wr zvIzXRu^{xS1xIVH{0j>047uo@pwBUGftMf4&7Q~r2LMX$L?n1_@(%_9zWVT1%A2jq zI|Ux*v!OELgB#>)(L;`m6}(-2oylbzAh%@sLHoD#_j=Z8ojDiW0nFD)8|Js_`>rdy z@|(&1ZV7wdqyR4<8MSB3`G18+??es=!v2GQ7EPdV<#%=^uSGQ=7EW0=n=6ikzSeArONl1lfTPv)-+yVU7M)qfgP5TE>2;eNfhQ z`m3U@BA8jWPxe{7+s2@ng^cHLD$!hDQ?Ux$;TzQ~8MRx?zxTSDdcIBMyfT)5y_$`` zi5_yQfSIy0d-l_%IgeoSi1dK1K;Qc1U&sm8d(6JM1GD&cQ{j#w6Ky z4Rm@3|vy#T^h$-d|X zn0dO5-K%X+1fx3bzl40VIy!9>f*+NUe6iz9(-)IpN^ngVp2XXpBjT(Th%k!Bk=K2V#^4 z$Fe|hy$*qkJ3vFtw=4Cu-R`a7nq$5q?JOeK@-in1{=*r|A-v%LkZ9#2BX4_elF?7+ z;u4jr*p}0JzP}IPp>G$G`3HoLeE1hExb_^imF`0RW|hc0mcyCS6G+w^j%1#`ER}YP z>>T)Ia>GMM+N`0sSm^87gTgbDYVhE(8Z6|%t1&-9iHsB^6A?mLWupIe!l-$W2)IZB z9yxt;jsyEno9wG| z^~l5CZH}P9q?^5j+N3-X!vUt}*)ym!)hVw4LaYxWhE7nznO^ENogSUz>}mF5B!8@u z^-w~+fl9Q9b`}9mf})S|OYr;b@HS%)dUy2_ugBM2>{RtM!dKFpK2N4|kB zdVLrJBj=|A5ZXVqE9-jCIV<+#<~yNxEgu?pBUq`o=FcNC!|sU;KES7YCL;MDrt9VC z*NZl0T!DfBPwqLW>FY0c#kbf$DwAd8K=kl{!GwR5#5wiTApPl)&!K2XFWc|QiX2a> zG%s#24NKDe&twDl*WcvUp4il5$<)_%cT+2tmg|>nx%1&Zlc%XF2~EixQ9#aVPw?4H zTT?a>2a|u4Vk)V4y~gtq#5mog6jB^uu#~ZJkvIhjJ;#ua+f5wct2Y)T+tE8lDWObW zb}Mc0-d%Ev36ut{j%?$Dn-58KM_}nsX}8UNLX;GlFtd0hff$5yfPeJD`a>l~=Sy}( zX@0PqHdxkPdx8QXHvg%o$8K}<+ch~8J~OVQ%83Wq;H12w@hy~N<^9gIW_}(gf4FM@Ag5hWOhAy~&b|>5q;_vk4BxVtnzsHrtNQPQO z)!^vT-NG`3f9Q$&47a?{er32$28ImLh@KO%HBvLj3F8fM(k!&k8*u zR>9JvKtJRUeUF8|w<+}Va4h2aAg&D8Gp7~Hie$dQ8X3(C<~WZC3h4}e-h|QGK+<2V zN9od0XWv`R%-b4_2Fb*{T+A_{gX9TQ2u0d_UBWDQ@%ZPA`w6pW6}bi_9yIo4&CS6- z4;qi(#x9uawRq6-Dn1e0gQL0Sg>GlXpn8c+mr9 zGw>l=zM|{)TPw?DI-F;z+oUfMqj(Y=Z2u|8#87l(xW$UTb}BIGWBdw%d>Uy7#zj^M zriXf=dZ8uD0}Und921*AxzrNewBAP@gik)4ob<|drzf=&m?i5Lt&zA#Eli#hTl!{U z64m}RpQez14w8rT{bXswDBu`*D}dkf6nNh0YryE>Z9KovQg1#aDWGGStAn z6(-f{C{OpZwdk;?EP9Lu3B?tMf7zpp(LhgtS&%5lj4H+lC(^jJl{$xs@DCs=B>cFLaM+*QTQYC@Ur+^)_Xc9 zbEP`F2`TrD6Z#n52HQnyqv4lrP=)eQC^?NW54DVRcXdL>a4k#sn*S?yg@HMrOE~-* z?WZ!v9Hk(p0_|`3Dup@(iZ=Z?j>alI)1IeTfKH^answ*vlw|Qnrmfv584@RIna$SB zY`m=~t1NoG;c$PzX^=@X6PuuFbVq4S+pjagq{1YQt>w_Pv0GITTq+DPRQ}}q@h34$ zLclXDQ)J+~=o`{d1431f&w$Yl|Fx#8vK>55;HlubWG!0T-qnJy65>V6kZv7emHo0> zTgzwd&VittQE&63l+Slqn>#I2>qyudwZBIIH(~8bgEYY0#5gV%aW(ejBKXp7*TJIQ zWa6(n;K>}I>Ro7Xo~kz^cvOv0^5WmM)FcO0|-%*aJ?vx8CYPc>k0#-&IvX1x4QcnFQ@gt3Pz_>iVoC` zd`;?~eYMKKa5cQ8t*b;^9Tuo~I^}%#>Y)6T5W!o9(CP`Z?KL1KMV!bDQCp@&k@#uG zh6Pqg{3qdNK#%QMpw#uOfzjKdnhs}?&4vr~obaa^nhYR5iHMqsZh(OG$jPx8GP-l- zs9JC|jM2wB%GF9qBxcE~g3H$knH1^By@5-dK?@vzqTX-*n^usyzbD#yhKE0A*&XQ| zV$0kEJZ0AlZC%I}j&wxx<+$Tka%Jywyq<}rT(`Iw$Lx|Br;frEgp-PsAwsY3VgvZxGZW*ldKO4Oy$d7BU1f|bh0NZOKYb>H)!sQFje@60xy03XhH z(2@px*qP3rvBI<{oo$n)<=A_pIjut@&9&0Hp1;>&|9ND}U+c0P?NTe!nbmIy8hFx( zm6JUQ|C5ks>*8#^L0zj z$k#gjwj66f+B?A{Q2l~4uKcq1x6EzFs@}!DQdx3gxu)q{KZKaRCjiQTe5b&9zDCQG zplZa+s={u-eq)Aqfqw9NVF*6|w^-)=_ffh@wTVIOUM@vinz7fW&=QEU`@qvay*lu$ zH~8qup^P=>lXT|^v6_ajC~vu>``gOgVmx2IUfx=HFtxNAbxLPuLrp|24DM+S_agoL z@ky@toAmg_R{ujCPO(YJa^eWbRRu|gC`EA9Rl^Ywk{a2?f z^fEa#cxw5ME*J}^9~_I`j5-tx=irxYRw-7L`pDaUfr^&t79*?8UJ$rOU^7ggxB%o2 zdMK80*}U`()y86knPCUGNsf4Fysv%(wzAHgwOFV839(^lkK2jw!)bk^JOsMva|BO7~E&1Dc6l>uziY`wj+cG$0yyQ2x*MLI?VOtD+8gNFm%AFys!HFz-dgNBq zroo9bHxb^Wm z6<8>vk09(Y9jI%fLlhBT$KC8A9#Bw%{z4;>h96Mu-%so{x;i**crQP`{o#k7&cYEE_9HaKBq;qNyX z!`aj~PU3m1)tIu)fu+G^X|m?ITThQw%KNIxL5bLmm3{}T<*qNIA?of9{3-PYro?Do59K(jka7025z2na_SMX3 zc(l;Cu1Kh6W*1!%32teKj ziU>d^h2Q9c8kfNX)Ku_J?vHjDgeNid3BVZ9T6V;rp>y`iAv?eo7N|t=8cQX|I3akX z=)FIE{^XmrB-8Qj6Lo`Ecqux_hEQpcapR&G8g15)LT#8DTKCJ}0ddjiH`mTW>)jPvAsF@93vWR>V+imtFSAMrUmJSW}I zv^HI;8YR2`Yr2QPlK{ao>|r^R-HFUxe#DMebIS&$tRP3S1rZp$@VId`iZ4E+%Xp-7 z*L~QAh3a{G*b|9=C0rgLVG{Zn=YD)x4LYLic|9>tTYKgk?l#zgKUMpEiuBQkb8@Ek z={5*ro=BY>)$DN^kZNPSalUG{^c$3bBFKGsd6&ZCLyXXlDohjD5To*Up11qIllWRh zxzLjlQI)N&=y$N@)U2oOqf#z!Yo;TUIw3cJugZBI_)=!uxjX(&3IC2*cZM4O48` zl_7~1)T`A^gWe(MUwSye49Il~aA7SfiGrGLI=X*-^E_Hl{mwKsAg_19%&A9l4>Nh0 z^KlXK5$14`U49?Kqlum`L0tv+zB5>_qys!gfLsk`18nF$3o3pPT`He_egZ)~2#KMDJZ+#!% zxMtrLQlQrwEGF9Rc*>lk&o&A!BJzoOq!!)+&`GD54&DT#_N#o{uCIrOPsfV(uy0om zym2MdKJbG_S4TScoL`P$Rqmh|_ksk~0_%zT#NocSI6HDHQG+Y7ON{}^&X1i*C|}m9^UN3ji6GWWYslo z?C*zaDe7|_D-t5>XQnt}wMHG(Hr1X|XXvOco4<6nkiYgC`v8*$n+Mg4XwoP98tx&+p1*jIE zyQJK#&2uU*o?+{hAo#=x1ggRW@ejpTekn_ZPUkJPYS4s9oikP#ZxcQWhC3i#1tS)P zAaK+Sp`XIvhOQ2xyFGal)O67Slj0bpdTu5D%{h9{cbWxGgr=F2!z*1`n5LJ8NgP4LcH4wCmLGh z1tjtJLPO!#HrDtIb?ibZFjpiTGjnG!P$o?MB=Voj!`8%^Mq4^evtbc)2?U6GC2qj_ zA!q{#z;;5KoviC2VffTHR$CV*zyVWG4eS9-;UJC-Yn2NpvQxQXrFD-@B{8$?W*d9g z8|&+4|HRIp#Ow>Pk>Ec!zPLVE7SGzJisvWuk*|f#;BAVmuf%?ERY^gK$=F*x)a z9r|n}F*HBR1Ma-TABZTQW z?ZMmce}K8$EPIdtX5$ZO9KHAe{!=dbSsGIZe#^Vw6HaHO@5SyMVeXaA!Rx+}p*B+K zN%gNaMVx;ZwekrHTFCkD>|0pQSMKkYHVug#7}J%Bn*_3Jpd7tGL$E$^^aQfx*+plq zI={++#%FA4p&pzB)LJ=A2vB-H1v8Z zZPZ|abcRXkhI3eBn7VbkEbPlz`t&ld#v1&>V3?a|K)USO5x*CSXN1pYON*L%yIT8u zpF-1#mJVTd0qP{I2KPm*fTSx!_AFMz_)u@O{YgU5H)$CRSOLGJZVoVeBPv@Ji67$? zjZ$j;5z5v`UjrRb8^J+jcF5Oo0_oe&5ZPTR+gf1dIq_NM%_AoMx?r?~TdRa)kUeSv@2~j;B6L0 zciu z!LwQkJ=N#wG{jl~yL=Y`*rhjkj3I}&%N%n>K6NRa@|fh94p-AMCS>#P(qbBv2Ja97+8#P!y^9N$ zpm|pKx|E(;YIi4fNXRAy}4q@ySO{M1HPW_E}_)5~+K3f30CQjHFg4 z>V8Lcn`G~(PSFc0^8yvS=&+sD>SN%kvjjgP!>un}$aHwt@T>r&9O(@8m^fI^%mD^2 zyr=a|lbx)H1-o=htZzQ?wInN=FBEAz6E?g+6t=rnJ!D5C<7d{l79VWV>#)hU0PIkm z5&}q`s@DaNZ;e?VOHtsNs&5V(EN(aaWIT{4q`lNKFDN}Te=thlyiA5&JWNAQIGW(w z6zAUl+0mg-4A~&Yx5M4~IcNCOSWnb?{g4>C9ui4Tw_&xe}OaN^# z!2Q!kmn;OIBhvlo&341>r^fj_oZZ*Ys-plRX}*?)APy35LCOS=+5Y=xWl)8p+Ip*y zx-q%ExqZ5k$>(;Jye5~7MdWPS`Eq-6aJw>gaz9qL7R|HdvuYWRgf;d%Iq9u~6A86Z zjO)TJ#SotT!E5 zJ+P=a$@A7=fmK2p2RP>`B7a1zEXz&1@<&+25&Y|~ogs;XLh6w!!4tOU;@7szMqCy$ zE}pkzF1D%08FD!c^Trr{|3*-~h=lq<0#OAg2B0=%69Gw|ms3}#Mc&S4KJSiS``!Ji z5Rwf|A2PyKtk`%xUs(pEJyMwWWV}tfe?m;ghpb9|Ck5;IHf~Y~Ck=k`HuQ*9rO*)u zokEZyrOYxU9tJ-&upikGkP8JdAb)@sk%QlRatUncIagWRtgo@b)@6;$x^(KUw{HX~ zbB!aec%+x|2G@@@_Aj2bO*fdx$o5V`nVaEol9V3-F-jqi%Ge*jB&|^Yjes^*u6Cz6NR^eE_2pHAu#X?}Uqh|5Q}d zvbvJn?fy5FXolU`FoJ{;UFTSO+3FtXTq9MH-|!>I1tcSH-hi0Sm@surv0O^dQ}c<> zC6(Utph(-M=iaCW5pFuIR4h*Yo0l5lC|=ua>WD~%HLG657}2KUX5S3&ac|zR1LoeC znWY~0hU=10l3M4 zY-+(5ghr7yzzrL8UZM@i9VtrR2BBtNQ?1TEsani=H>Gz>6B!o1u$Evrn3#-pQ?G-A zC8Km7ZQ_F!77MxVCOTrtvbM5cGN_#C;GOB7TDJ{Bl2LUY|HImb6WJv({u`sId&?R_n%Zp7Z#Lh3~!>Tv1wp{i=bF*RI_ z-EVJeOj*OGkoTU)cco4L3> z9CGF*a*&oaRymQ`jWjO%8OivgPd=oEnfkFCjW-;rhPaI60-2N|$b)+1T8tlS6T!@}|Ii`KL$3dxfaJ zffS(h-Q-Q4o5!7J0t%I=isYj_>`=q(UI_293FRmHFasOUx)hnEq&N!lZHxOR#ss5u z`3;X#3bi(QB03_{rC#MH_8=6AB=z#OXXsr$SaTF>~fQYz)qg#cj&^~|s(eX}# z(bS++RW-|cY8Z=mJdOStz|)iSQuhiGQ1$t_uZH(frY$ex>Pj7r<5Xfdl@TZ4koBHg%#J=a+Vo$e>x9Mrabbkg zVP;PG4s^Itb<7^X+JL0lCREe$n`Z8muRu(fn%!5mRE>xnw3#Saj$)s$+O^0j;Z_4= zhh2=e+D;B%Gv~;{j48mcF613IR6~YPJX*0D+3-o2fh&Vd@#$Y)-_Iaa=}}8Itb9T|EL$|4@RrJ2;g3U z5#nQ5PA2?S1WFdzb<0lAJay#>HdyN)Kq+JSuav1*AIdhA2ID=@y2?6%R*qfx9u|8$ z;Tx4<{wrS7A07aB5NnXBU`l2X@+n6xs#YjrL-A>Hs`fGHP>v;^z+wcTv|&Di4WVAS zTjdcjgpJ_VniFcjycZj*@5KhhC&Xv>$cmGyqjsyxEfM1sh&sbjrSR@{oo!S5qI#%q zehogTDp>UAGWqkW+Arid&-@iAzeKAi8L}@CdJ)eo^2S`GtCf0z!V8TiKp$-9XZh5_NH4#f zwKe|*91wUiM6UEPV@*kJbM54C@Tynm*hgm;bSs|R;62vcEhf&kRjpH1+!L(2XY?2n^j zI=^qHRIMyTk}mw~yT)`;4p8KC_yvrW{axlzQ+0=R8=}ZGh^fA7H!6sy?GZ~$HNXL= zYlcY;N+7C;$R?G!=jw=laKa^d%x!b;_Q>N+RWnA=VDB$>u=!G9K}I56V~!nlHBjQ|%P23&ktXvBBC4E&59 zbL#Aoomjop7|@_ZQa2Nz!4_MDHAeOotj!AhMs5>k;TX)#4}b!vr`y0&uV8!;i}ujp zj)USeh9POY@q95+z)!&2!MUzs4$5(DPqY=>=Cr7{d@<3FquZ@zfsk9^4k-YEYKGGW zPAo<|ZPv>0;?Co3b}DF2#oF_rWITo4~%ZH&&^NF@e{Ww6(dABB-r^3mO=X4G!=hVu8NSWdsbjUDu^l>fk3p z#>B{Zfn`MN+!=ySmJxl~@Eu}1Kio(GetFF7u@xJE9@vGbg1Y(7ZI#}RNxeKKFawrSM--i3{y$hCZ2+xG~n>`S6`9%%N1A4Pg>J(4j;W zXt(WX!Q_Dr#Xh^~<(+`;QzcczfnXUWf(+c`f})~w{?4PoAr+1 z6{-NFp45#5W-qN;QgN|pZwYK<+5O_GH(K$+_s+CyHt7Ia*0aJmV*LK;Pu~HwEJ{Td zA%O|9g4}*}v_3p{JWvA<9QNL5p32>XGY;;wny%ogQEPtDW#xxkR9oX;!2OwJJ`5aS zpd3G_Z>p7&04Dl5sT%}TR&8u6 zX0S+Sx8KV$wzy4ize1^^@_~WKHW3`nx`G)7p!BqM? z0t%=!3W6Zgjg*uiEg)S(cS+}fw16Tl9SRCVNOuU*4U$8bgml9I?-~C0{@(l156_K21nJ|Y6471<^tO+k0H*stbEh&VEJUy)<+kaRv23mNZJjn1aoj&Rne%rK_14=$~W=5CK-`btAb5b1;# zK>op)_TYMSdzB_^_C~Nl)OTvzE22~xqP4R%UFA@elM%52qcqLS^(TL`)~C4hJ7ED+ zyf;8uzc&pMnMHzk``(o|vus`X~gNdhD?==fHK?aCPkT?d+P)b+zGZaoMXlwAY@Lg&+!|jQE zy$e0Bq(NAr)W%M<0%3(R{1uczL1t6TH=!_|eNt12fqvm{v-|;%V8;7SBCk+V!aaiE z@B6Ir7fH#zjqrl0hG7u}4JbIUmSroR-F)}I5q(IM_($m6aAECnf^bYC>uj<-pQ_GS zz1#ZK7(f=|KOb~#Mg5roENZ3ueFX}9a+P*yv#{YK_d&(WhvJ^%yg7$caLUeDq%RTF-YTZcAul*kk<=R|HpcA`NR9u6=wPXT+w0Bo! zU@w8}@=0qk?)l5`n8^g)jph~Rt7_T;1ykExy;O!qb7w51mv{^Z_%v4 zW&#qVxkY!?;rRNxsczW{m@I!Judx?|VilOqB>rO+WF$gVHMm9nhFhOjc9#=_@*s zp8S_2pbtWV6|t^A5k1;n@8@P&?^drRXcl7Oi-Q;+)2+!rvffh3^5AY@SEy`2*GN3c z3hb`yhD*g2fZ~fvT8TF}px!bcIuD|j+%L1fIE0m^h_#vQmlg4MF%5Fg=~fW}Y|%x! z2mz^aDxlv)Zoe$H6mrzwE3ZM8o|(4vk@)1Wy%!vtw^rh{cz9Tg*y;IXJ6z)>Bm&|N#e>|I`yNRuZ+kRQ6k{KED5QX9i;2myP!}0-LBtugmx^$#LbiExZP?93;>C`xnE$5e+u8t(%TLwmCJL< zwXFX_D1~WAYzUasU-%W!mc1oiw1?xne%bL8=}|$xxJ8qAH;G>9{5+$aNAi1kS;taG z-Ytd@4XejL4hnwPGm?&-Dwe1p{wHL4K~}n)=KrY00kqRw-N9IpVqZ2zK>SDg3!ZpX za2@YkiS{pe7a7k&XxgiSU7|DscD-5$Rs@rbm;u4~;xr&HkeQc6Jy~O^(pJH`!uxfNAkwd!Hy^9gq>6_#mo7omT?CQreO+ZG{?D zmAi5m4@4Y8;uX`Ul9QuiF+{=@fAUsCaNp2tuao}Zwrx*8a3jfInG80{clb{c1A<_w zOm}u_Zi-l}eFcY%LqgR`v>A{hbc4eH?=Gugi>6X~FR)++F|t+1^7z&Jj%oB4sX}6L zSh|7lQKiQ;1|@F6khscfLNwXjSi=51*O1y>OhD6B5MZN!HZ7C+%RzV}Qd@gf;e%Z9 z@}d4;i^W+=p?kqfu)H%<=aorvi#q;3d_>R)5;^F1! z9NY8m7t!KWujGIbCzrUuD6SALTV>PMvw+u+p`poDbCNq+_o-Roq~|8yF$u69`uS_% z2{E;>4^gF0hd(HN;@hfp^$gv)2#5`(Cs8nj1;7x#ST0QR@7r?;d7PEY@@X1Tea(^C zg-e#)V|)OL6w32p2JBV5)w06oxt8JRB*nV+5KP)nUn{pAwEoSz8bj6(ZxTJ zj0L(nIxU5m>4A`~S8U_&sFQOn6>LQe14*A)>65SD*~DsC+s=M7d+i>X=~=L4)!c-6 zt|ewUiQeG6b4mMTGV9=dBm@WngO7&@RYG6^%&|@-L%e(3=t~g@oBWg^xmpz0#hI768nBrU^yU#r9L=PC=u?#Tjh0*?;Tie(?9Qrq<>%t=9OI6Kl65Tt1)!7Lf8ls;FPP?N9_7@6DSE{ zKh9Vs4<~+sO-B|#&7XD#ow9*?@lBL=JH=k}hh{}(%E6~ITA#(JgpL!&Pa9T4&7DJZ z{o`~t4E`|I{i#y+umm)m{>BxWI9`lC#h+^?0H*3YwUTy=5zw27;wGBrChoX~Bt84k zVI{+wo>B(h&?l`$xKlt$t4WxlYx&8BB2{zq^=$ZVh#X2oZWK%kd5l>KksZ2X-^V3KUAS1ll^_KQLE{+!!$4N|2kh1m`5>sFTXBKKA&4ORoa!k9+s z6RBVm;s_WKy{h6T{ezCap9L_3-J*QkQH^&`OZo`ln-hI3<=}=F(1=7tmGWwc;X3xf6BmFb zxCnHg{T46|9X;}JY*n8xPqWr@c#-?^k`c&)2P_h!(WHd?TWEY&jDL<&`=+;xU%x?e z{kt}p_KW>SE3Pnh1Qr?Mwz`n`L}C(Erjvi3x+;U9`!~2Um1-{b%9HfT2B=jAN1k4V z#vFYeR|+NGJS<9`OdfbQ(Ss=`rYrKh94G!LRb|A{d8;OsM(E&5J9&rk8A@MaxVqI> zVqu@@$IWZU_;KNeeO>4EPg+ZG1;GnAOPD5a+0(tQq7BuY^Kk6I{pI;w%!5vk=|T*+ zw;!-7^#BC{m(=D`X-#ssj>+E6G=SS67>rH|%(c0cK#wt^sJNnieQbA%oS1NQf3_P9 z`2E2Wk7yL7eZA%RuKIHI#A$!gvlqkes{!W>Wda+rPoWeR4q=s?2VfweJ0{XF;vK^c zRq<|Wxf<{kQy_TAE1LyQ~6@G$-@RJ zTx6#~xk?a1@~q1-h^cTgnGXk!x$#n03=@tMzmuv`=g6&Pvl~I?KX@cRwhi7)BlkKA z(NuQ!SYZ8~kFc*WXbl|q-OhlaFbx8QX(S$mAT^_kHaI5g`0a9G#p8Upl-SSzC^5WC zC8mD@$&nQvB`#kDJ;rDJ?h6XY0nZBaKY%<2%!y8dsBPyC1X%b6%TZ8k}cF};{fzuv)tZwxTyVbd-Vh0)!hy{8#dD$S0Eq_$cKMfSwj z>IEa_t~^RM zce|Y4)|>sJmX4kHr?IM#8p>l?mYm$@1KVSzYa7Bt4}HI<(S;Xs$q(1myPQr?uC+4D z#bX1)O5qZlh&*!JJrhX1G+(<{Mb5p z1?AjUM-rdDKN}o)miqN--rOpUy5?kbwLR>$K=Tzp7NWKwg)gm9#i7!;LsGP^g2ac8 zDin8#?i-SJZRKk5WOHq2r{;3Q)5i@N6qcU0yt-d=dF>H?LHt5W*K_z35(l_s%aG7v;Sx}qjGtqSOJ&d>bu|JiRVCR6DU=r;i zz}5gFar;yCfQRt&$nBMUJ+BxSLIq^Zw8EE$YS`?DiNo0^(xg)0hf zX8RrMtH;{fRm#aI$rz`viaCN<>p;v1QuHuL z(Oxyp_LC?32M%iwJGCKE9_@x+jw$AgFCBGdCgPmTRJL2y=mdZoi$8YhqCjc~K z^$@xd51B^^i-z~1md5Xeeq?^BCvm$#N)Uv74C_DOj1CcGERyxqw?D3b3BzJac;~Bh zgK{-V9)c@qh}M78`Tx1M8JY>ey?t0}{&}ejKam-TKdLT_Z#I&@;6S;_rLZ+q)@g!E zmfkX5R3|gckB<$!PU*ObN+fVyT8L-905A20Inh-R^#ef))wpzjzjH^x>WewpSFnWg zXc&<8?=tz!01df`E((y#tz^8qT}g5s*hcsU|LipYvyWu)mze>F$QP7jz6_I)q0J}Y zs}*-!Lir)7Iuo;eoKe2E79*D}F`#PB=LZmEMF*P-&^(Jp$uSoOs5&w)(Y!yfn1(JZ z5||mt@3>m?LwXZWlP(Q(t8Bz3c4IT;^sX{mMH!sg`>{cGd_gu1v9oBb9-T|>sdzRK~gaHvWd1(&}GBPhU5{l02$Zsj@rCZ9HA0KHQ2cLqfk2SH&7d4iRj|emB zeP}k}y}319f5V`ARgfMm6^&MEujRy`>(LA`OTPFf9 z3i|)C+@utB4AO!0|AbXyH9GOZ6IST#wa~-k2``3OX;qBGdE9jmbR;l69>QU_=@2K?JK;ZWfJI z&p#H^hk#Fs?O@4Ca3(VEg5w@#4xWvgm}9Sc8Vy?ip{A#=a>gEI!FYHH7#gzm&;Y1^ zY0A~e?#F7FRh`11e&NH+Exy*lZMSZb0t*rSWjcS^Ly7Rl)tfz zPflVzK{pjV-$sH&8KE=sZ`_)qliPfAv;Y5?qwluQ@%yg{tzMU3_EvXFIP9yH{WCmAMIOBcnCI2a%Gs)?+u??3rV$#pz_h%nAC2C_Pup*}35W?~WPx@REFtJD zw~?6w-z%w@t4@-GlIERD=%?^$)imGDp*2%L`mDWW^dzMSwr02n+y$AsO5 zt4(=(eE3YbX>MXuvZu&WO1XWed#%86+zKEEcpl2}~ z35+*5i`GYYt2f6|@ov$DXXSSq)mFhZlr14R0A`LLth5ofbyR|LYimJ*w*`c{ zYd~zdIDEIs&p+3^Tt%e6O|aMznkFC~lKz6S6xCInK=>?4){DRPdpVqqh>LepK+d+9 zgx|&`e|JJrTjh8GdryaIhnN@2Y<^cdQnCHklz@+JjmJKGJ5;L<2UY+3d%^7JkGhE8 zJ({(_i5j!OU#5;M2H@oX*riIoetLK3%UWPl^_;q!`HQ3g(+a?#zn|z+lvzf5{3@7C z_a%e_P&*|<3=1d?3>NY7fM54}5>e1aAK(}nAG1EblYmekD!5h#ia0K+XSK==L;8Z)~ zUHEq2O3ywiYe0t&ie5yQiQRIrmlnxS8X(&x*rClCFAnbzuy_@_M&1m8qJIP~vXZ`` zy!#SKYpjq(>n!|qEcWW+hJ?q`l;37{I+w*po9^Cfngi&!gqkH9pe|z9fb@Qa{d24d z*Ui#5EC3cx#MbHvj(bk78?I9WLOlLkZMy}AyM=0;@YZv0lsD4?gsy5u3xUj_*&a5V_wy#1Bh|Azrg+D{u24^?~PR= zJbNax`9{Rw0bx~6Fpp_>i2qz?5oj|^WX8`RT+t=FbMyK)r9LkHHKNz>DfMlP%E1G& z4BrKTvx5t#N*}*72Q__V@BS*}m>wN70a5JQ3NLFtecZ8!J0I$`@tj;2bd5uS^WFw}il zhM0US*GoxnDRmF5s*htUXnmLlYb$j}FMfd|HX3V-+KFVSwL3Zpt?u~SnC#_W8iovo zY49snN^nuTP>>GZBXArl0~upo0Ok3l_*9oR>_{MmX+RAA8+|s*nDTJdGSfKEM83`hamzpI=~_7Ncbvk2JL87Z7f$q|a~wX~Qpg zFt!Xe6ch8h_B?GHooE*EI}h!ovZebGvF1EA_q($C+tJtMbhH@{bazIDYD_{jUGZ1d zI7dV^LsAReWS^@C&gsfXzrDGkl~*IG%k{#@q8<0f_+Q@^om@Lyd-(Wc4KOOlhnH4K54u>a$GfCdceb2qsx*PG^*Fo}pYhQ$sb!n<0PRrlRm;>5rMj7Y?Vo*m4W_hXqI=2_}tJGI_*XB@1>#7Dc0 zr4>YHLy`+Tw(a$#<}pwnKkqo9*gycoB>#h9PXG+NdZT9_l=Wy)S;GWz;s`Gt^0ItMk7{gY$8;k>KMkaiLgg!<&LGaDQzZGzsmQrvAoB``6*W`AC`t#jqCx}C~W#@84c)$s4M z5G`v#*%+y~W-jJQnrv!~4NL_cr9+Sfo}}=JDr4DiU#%Z}%5|p#R?Sc5pKm}N^&L3- zTX3J}>i^n;0>PsMR|CaUFuZ1e5mL&Aj#n;F#g5m1F(8U~l4bPD4A=!cQG&<86Hig2 zFbIwOg`dSn)v;SPU26KJtDKme#6kk|20%ET=AVy(sDEnwbaX@Va2yCs<6#siZuiC( zr2{H6Li)!UaA0%M`a?&UC(G4f@RM=Azi;1G26Ca7wX4Bkd8>0F46^6LcyynOrc1c1 zC0CmU;fS3kp{bha_&Qm3E`_&54!O*yfQQhdh`*%m#AAtN|E5+3sG=5@Vhe?Cekn{7 zVsF3{Nf2Bxtdzt=rO-@uiGCfxiGD(7Rt~H2y?@uUg`xgH!P8_jy}R5-w5Sst3SfkY!WP5skyjRP$S_}&FfW#kruTdU47NqJYK9Bw; z7EYgu89O~prB!CbI|xGJj3TWAVE?j|lfULl+Y-=vZV>NwNVrHbPY`gDx@z2&ex>|tG$rStz9_5LZ((Qv%{ zmjT^9#Z#8% z_h$c|@UWAdl`b_^P7Ip!I)*s$>FVo6c(_LB@16n#yN12G`2%Gm>oWY5Kq3~^+UWb? zzvZ=dzEa1`eeJLM)xrR`ZTE=|eG*uBeBk$x{t1g}lNjTdO}3f2=SAL!-xym=c+U+8 zut>$?>ZLm1r;7(qj6~DCn`=43Fni%s>?yg0^jl{FXL8$*U%w>^WGFZV=0Bs2O}}{4 z#!a{KN1Sta;5n=o#gVf_?1b|LofIDxe1aRzIx}euzfmKKXJEci zMJG1jh=9e@uic#j)j|z5>D@U`o)OMh>y?HL;MjPhbzdwqDu(vUGH=KNgvsOuaso7b_k{N*Hi2`1^Zy^#gcc zto;O1C8qdYx`Ptv7g$$IKmzDfM<5UQ?4|gsv3um{GIQ(6*on8ihSe>vp?t?v{;fXR zb?ds{Eb_G_QAyri)=qLM6Q+jAl##^B2piFguY1`b3==VQNuPbAf=3Lc2nK=OEWtfG#qP$xL%WtOxgE!bzJ_<{(H;7` zOi&YeuB^tL!&TNw$~NmO9hHCg&r6jCQ?bW94^I6?8yq**8Hr2AafFlIi(9QICOWPq z;^lm@iToy^<5EyF{itLfR#)55bSctS?oxEA$Hc*du&E|Evtbcpsu~}>Rk^WmRqk*Y z+7!8Pz&q*EY8k>XL2qL7SJxnVPzjWuRLl_i-Y2$G_y<9s)U>yxu*<%Hnio&bHBx0;SjFZIeNGB>`wM2s-3oQ?azG#19;V6l7dUX4#+@;^KhvC?H`IqGC68y@M~o z=U)4?!9-!-1&V87;p{Ppi38Dn>3ZrbjuU|Q2*TX_O)t5oZsM-r0Q-*G8w(&z8s**NRHC%ZXi9`&q6m6^wqg%lpF^{kGhJ z0~=IdBQ&V$OZ@`gK)KtbY-M(bpwS07NP5bFWL&PE3#ju0)}RsKAZaVN$X)Y7{j}}x zgMnNC-B=|rzzfXij`?gE^^Yb#`jM&A`DAi(%Cb)2KNR6V#XaRuJt#>N;2j{eWB$!0 zU-1;}Gm7bZ`5)6q15oC#Y#luF8vz8n@%ML4LHc5^UXU$502}`|w&yx}(Kh9CG#9=i zIuFkW;?0LU&tqJy8PP!Uu0=UL$2}bHvKNQ5VpiPwtEPl%pQ$Ba1Qo7KOX={vvo%v^ z@A0LTJjy?o>mR&arBgA*R|1o)qU5qLV%TQ)f?6Y0uLnW1QTH#FU-SWq!1RtLiq3q5 z`(s9W7V&sLCTW1XvEvpsZ4v`a=4rl%8$kWTD~&z%I9WKrzJjEK?mB@d(ed#FAwW%l z3Fr$XbsFSZ@#I?jLVD?FkhpO6 z-q?&2(N@J!nUYd>1C_VA#WWl#8Hsa-)f)H7Oo$hAy}@~}n8fXoU#22^2&(rwmlD(s zz>Y`&?1*;8Q$L&rzDlTaqy6YPEPJ;a|a-Qp#TI4y9BYtsvqKn`2&9~Ew?MrLrM`20%lA@*g z%~KR9sRqm_ss!uHN%{ESZr2OZ@ukBJuUB{lUwt!I0eVGTQK_(gbNbGwS$HO8p}`}u`O1uxjq2V|*H|Za_+6fY?w*kWUJPIs z-k>W4EH_;`_4$F5Kf-Bed3CnWEzTaxsK?Jm)+J#Fll=FcEI~j2UnE~vE!;PrZ{AOX zSRDtrSkJ-?KhzD~$>LFHax*A6djp}$VjsH$Dx$331x$z_-9vIMKnS`M6-6FVRe9) zUYM=S3qRtrmn>1A1-BNoMDGAkW_BD&v^6l;wESL~6tDp-n?W!Qut)q*IK;3TC#3b@ z9xm+3JQUdH(HUSkLmOIpG9a2oBOV5Wq-!h`r8{0rj>IJJ7O1XJ4hr7ZafG*Z+yV|n z(9o6EhijJbuUL9|#_6*ckD*lCf!PG1CkfBbrp2y^erW~wfh=?uOP>jAXt*#vZCgA! z@$8%}HH^A*P4Kgh-)DY?+CVEN5x19@ety@4sRcBjvoP+_a<_~GU(@=Mlt>yh!*De` zR>xfWlgB^-2=j%w&q2NQB|-NT%CqUWoPrU@rs(2RoJ#X8r_ch0AVbK6<80;cJ$@Cc zmEuhk{OlK;U=_KF(NzWS%45)|yB7pXcDQ1~VG!p12H;8Zd{0d=7pf5}VhZ2BuiXYu z?)Wl06z^)}r9JYV{Jkqc19w?0HLeef_nk|7GBf4ID!x0tkxP?`#Cd^(5;h8uy@g<+ zOkzpo$RB?VA#B&RH+l4rq=iy~ve-4&LD}-7m-Yxpuw%T*ap&HIV_V#GEOs+!_9)$R zbFo=OnB9}YG$VEfH}XAj0gNnGn;{@ICXQP@h^jCq(TW7ScmAEett*z}EA%bTy&qCo zSO@wOHANU?H#PUMY_j7akZSaUR*a2m6mk+R2?Z#w+{t_h#g&uwfhNzrTvdSwc;ot@ zZB19Y>jKn}EQ0r;oC?JO%^V2s33H5us-C3^uemp-pPxuP)cmK|pWbjk_{!>vs4(%) z<+8G2_DFLde4SlgN2AoHRB1h-;0UbXZLV?=ME&dTA*wm7`EfK&af+XNP2Kd>?#;13 z;my03S8@ZF47S&tH;0q{Evv-U!~7J277hEKUh50IA|iW&1ohg|N|#o&ztU};H2z0gIV z^{DU#0K!`NfxuJvO#@p(tP8CdItdz@e^w4_l25MKerKJZuBM@zj3C+y`XbFoGV0Pm z?xIL!u{}p##L{-c_?$u-^pW2I!*XiKkawp2i14G0;O@nWKUE5V!O&X3a;AWN`Hs7P zx_1z;`d}&~Y~JP!*<*=MU&xSD+X0KIruJ^zI%8X$uUbf+jN)*Oc;Rb5*~5n^=j}2# zd*tpHFn@FoU56?t`^{skYM1gTKlyyHvS+4~Q<4`9+*Z1}Wu)PF`%-t-NByCL1 zuF{}YUKr_f1>7BMl0{&zDt_I=%}LBLiNE-P`=)(;_nb}y1ld9crsLtI_bwE`y^s_# za>eW->aORhCvC{Qb(BMTE37jcy0S--?FJ2*e~WY3`&)LPKcQAW3zSl)Ywqn#lWU79 z6cSlK1wJp1EN`e2uW96g77VJ@KRZ%s^D|;ykELqvTqf zLyhtS!A?EZ#+G>5Rhm~VJ8RQs@y3{HJ2LBicnX{0Fahy5X{H0PKn1TftexpV)iEZ5 zrDl+{#K`hMTtQ_8AQN#PacLL{^8vij#%|lqxU)^j$XsH~LrklU2;W=1K>B4D z*I12mRnK{9Bw~5r+rtOx?1l6@Exn-_9IM8+oCQPyqU>W;Zx%Vc0nW$LMjnd$m+m*v zD3|ohJe!w#4(oH~1U!CX%NuyXE}jIi)a|ZsT_u5*7(NQ`hcRx}OIIOOLZ95SQ<{5N z7BvTwg|7Gb1DIF$K;xx$Qo$OCy(8u-he6cvdyb-iEbcjiM_dfn)Y47zwd_STyh~1l z1MwqwY_a48TeCB4{&5-JTc?ChX60;f!m~ha6_qszIM^Vb#3LJja8IE30#&hQ}%hXvp+6b4gCUiuqLGg$F^2x;^-9(3Vm~ zv*L+dSv^-NwX9L!fi*YyG+(ZI?k^@f(w2?gJJa?3eqP?8zyV@+39b@|-3x$TE$DsA zm2+J@@adgfxrlw+v32Tq(36!T|amSz@~7Fx|>UQ@AA%A|5#Y+yqN!&T0`J#ZyfcpZQ#HkMP>yo z_Z)zYaGL3>TbfH^V7eJb&p9@izceL9|vg;}UqlfA4>R)?*)Riw*XYH7+oofkInzvuc_(vKAI@#NNsY zWPrXWmB{_xcc;~D+uIDMYRiD%+V-AG937JJXeawHJ?``}ASLms513-J!HAO~WifNV zGoYo$xAIEKiik5gVX=rYKS~{O;aWr~C-FH^7ja7!|9TAMLrzIAxz;N1yeX^+4KZ0X zbo!B;_krWt_UCZm8OfiY?C7;Ou{u_FJ-Y{42}b+Kwx1K*S{p#bJ*S7+TuHtZIv*^~ zEnZWO!Mejd`f7F*P;rgb-O$xF@{}Y1#5Fy}2}2Jhwq}F3jh;%gR`r-3s=dw*Sm?2aB+OXrIS`5uK7*&MAOymbJ%11T0bfP}$=g<66!8;5pZ?TKBDmUfeFdHqzd zf{2341M&`~fD|5z4*C`W%Oy*jPnLHa&_PF|CE+?FXLf3f*?6pgzqqei>2{gyHKzPq zfU4yGO79LYU18F?QVb_rS9YFSz4>1PXvTWNp-FCHpf`tui&v`RBY(%lU`j|ju{-b` zS`jm10JHU7t3xte;TK5~mse%Xy*5@)#IriQaLybvkcu+jA~RkEPv1{^zc*kvHjqF; znu4dODd$zL(c2?LbIi6d2#L5L6@N<<+HLYznjo?obyx^6-Z)*XuN-Zm*-?Pmd>GK= zl@zHqg5v2XfpAh?$lUYmdD`Hup z5tk$;w*VVVL6uGR^^Bp}YOUc3NSmiY)?%BGST z&R13>x1FIyYQh-gRXpN)O~V?;iY$U{QWV(}Cs=8IY4 zHt|qQUya1gn@ZQRDm<^W$&AqfH?%cUhppX#F_c8$-0v?m zj$uS$E(YZe&+HCl|AhgXGvDu^)niW%Jv8EhH`MEDy`y2PMl&dQ4z@%h>DNQh?fK(9 zb^sVliHo0J$_yHEAZ(IXAlqc+=HIZvuaj)EbTqF9(LXx!x1g~}Tmi>2==L1D;a9&w z6guw|m*;$7rT;U;R4MvMNg{v|{*esAW_Ssx3N)nwV#He`xIK~Uu&XcH4ocjV90NZL z1KI|AW>lfS)lVI&E%*t}6LMg~pt1vVVUP+75@vyHF~|6rKH@sfcg?T(UAE8UeJq>}uFu(u2O=(BPmDs{ zH@zy7_v4o*R{UCyU1g29yf~7e>$4S83}qK<#rY>~Bo!3UUx?}G@T8-iVw@@>mlD$o z54}}A2)waC&L9cUQF2CJ2S{klvIOpdvhOvR@en2soF~&AbPv@*81B;4%gX7 zCeqi5`Lw(|XXWmp4Tu*6_oMS`Up_njcVJFTWgOy zh`zwKJ|2t+00;T=BJ}t zg*7RjUW5Mh5pVAUJEWPHb4{JD`_i=4vnYBj{uKo?=+6{0Kxtf80XxM0TG+*X7-_5<|hY!_H{U}yHF5osVDZV$s<`6ic zW@{(M18|)9(!2?}SFHFwV(nh_>+QC^pXkj)_B_CX=w({X;j9`HQhUoYLwdX~;(P zQ#nT`VlZiU&gFSV*2B2JCcm)Mcu$+_QzKL1uN_}L;$Zi$Z&sBb{;~M$=Xgt)&0;muHb5Q~!i*Ro6e(bKDX0t4pcZ3VhX8a`>iM zBm))+M#J`&6Fv34-t3S5J4;oT=o_{bxttl7!SalcV9ti+u7|>wQqdGC1k4dJ488y- zYEr7`X)%Xhu?O{`#^3#0FYd$F4thO>0?~QjNyx@dlR1usg0ieAx95 zLpeNY@TPe-I;p=IcDh?1mwLHXk3b8#Y4UOL@`(TWr9?se5heO&L+frU(5*Ai z>P}bZn?nl2p;|5_(U}eoyD1d?CMSM-7F$ksmE|3qAGbHc$y`7JjU`S*CptX4*tzO= zJA8d{?c{^hDj%H2vB_NJ5D|PYv2w6*L9&xDdQ(+>R^9I9!~wH3=A=zUENZu7~ysK8VPfOfBudJMw?4&!&|xFUk8n0qV1B74d(?}POX_+J*U z>S1@htPcN8P^|6JQR9MQ&7ck=dyN`5+#{_h;O}fJm>sTaHdkbL#PhH`!XvvIOyA@> zb#oy#c=|Zz{M#RtZEd0fTR$~=k9`dG^99;UdKy!pNAIh7Q{x%K_Xq3k$B~E6zSpD1 zCp{CGaNOmnSrK!n3c~*6wUw}h?|UkR`Hq+oi-`V-GBBr~pa1l6ajQx7+UR`o(9XDj zPQ83v%(laQ2sqPGO(&1;V22!U`Bgaw^|<0I;kwN&9TsqEsG7a#zY-W?8_NLee@g}H zJM^kAF6-XAs9WxyTF(Dbd^vP@v48mNZ@g@x`I zT+gWdU!-o09@099rZ4R8`2Iv`W#i}k1|v>?D>(5LLifrOQZ*S3*Y$x-`TIn!8zats zLFJ=^@iqG23dg*x%8(Dwo<-2kF*BU+46~aV`hOGF8rxXD;qiBzwW9K~znZ!>V(K&Yp$`2f1FlsDC+f#F-TBPRAzn54mZ7|@{~!#$&i$p**t!!SF2$D zI|LRcRMOMPROA4APC;Zjk+L$eMjx)=CJ9z02CItCFi)MANu~eEvwB#(#7la|$h= zqq^q#2cR6;Vhe=Jwvwqup!`*2D+Ray#>oJSqg{4db|&)+xHOfNYS+M@mCE_&`sBnR zaDVy%%^eHk5O!CSng*<6e2vRB4_bV@!;DMWrssGDHh)9f?-1chT>EE&ibm7Ls_@J z5TI3*`5jFAVp`>2k&!+N0E2?1A@&I>ey3+kOK0aUMx|SZl1_bx{pY8BL)VX=(@(1S?Hippzq>_!4cy8=I$Pu|$tEo{ zYBw)fvIxKx>xMKI%WURTFJ-pzQkU1)xaUpeUP{)fYqc+7es--jAfYw>!%}a-XUS2j zXJ1gNDQ@i7&Yw;Zin~uoKmsJ74C)Wzo#%}DQ$!^r+qK14Vd^hD(jMj9MV()pwZ=!l zYVJwg@xcvsg00e=l0$YX3wpg(dBl@d>iXdHdFQzMY9Aj&J`i786&L?u7rr-ed1_7<#lhUK(m%|spDU2+pwV-^F&~1U%caqM{&D~ zk0v&16`h2gX^OWR>_MNkwZ8JQKiHFfiQb^T{2K&C&)Sa|&wtajpkw(su5>pWvtoQ3p`&n5W1a}AX0U>j~%p+4YA zmiMqSenl;F#yq}lMG=-=(rT{RUhS~kY5~60C;%;6a*B;!;2hH`eS!Ad*a3S1){=~O57;~^DOz( zxo4!N%!+aF1Jl{WL@#n7E`7sc-y3fsLc(&`R@ON#;oEd_uz8Qy+)V<4r=)$r)-ANj zbn6X*Va~0%&#=Q|cG~2W2|6p2)|o7p*~#SphnL?@$qYxc zTN~1T1ZdfcbB>RBX`UDsJTQHSF557pOz>HSZf>6DX2cIcBKFR%BCK_noOJw>3srcJ!;J=> z%CVPH(jxXe{(ouDaZlCmQh*KHS>-ni2)@IBWf4$4oJZMgsy=YYfOQ+W#J~#wMXsty z-Kj>nJ>SufJTjdDrD1H%GWV|^xU{wwX$GKnh?6EAlbOX3SAF9XlCy|{UXHxLs{pdaK?oQ4>_ecP z!b^nrK+R%ALG3^A4S=10ug&^0%1tXI9){2<7- z^ll>{ciuKFpL~2`SyMecN6B8bZE3hYDeNfrs)lTF29(;TE3&^u2eKB`OFcSB=Tghq zt;A#p&)KJG@m{(!HezPxbbkItwm76+?P0zba_?@Y#_JNlVPw1R8YB}TdL4gQj@|vb zC24aA9QQzuYAKATQC__htZSjc)Ap1z0pJLA0r-)Mr~48QGaiR82_M3i&yNxFpk2V7(GzxEB?zZ9O^ z{j(o{+@a@VYjyMZs&ss;j6g2TQUV6fFj(*QB{|!ko##};)xSpWSHa| zFFBp+5oP&*Jbh(UmEY4gaNyA0-KBJQ$3Z$2kZuG?0qKzL?(XiE?(POD0YOT-vYXcFx+{p&diM!2GCC!#Pv@zR`ZI_Mm8nP;nN{YRwNQui!wIeat9roeb# z$f>;D8^RUA=1{RV&4DV39XwUhyd<4kSRQn<^UQ^f3i!G{4eTMn*9EmIl291+dVLQH zAhs#%DK$zg7k>O>M?ggb{BK`^zjw)|zt1v4`+kC5Ck)U&H*%-Q@xPnm=UgQ~67r_I zP2}zAtM%@f`gE#|=<1B=%D4I&dujLOE>S;#B>!SWoP&$oH72?R$t&XDWFM z-I9p#-Claxc$RI+y#HE;fE1IIv!SlB={|n+d+SLs9hW5f*bK_R_#BE1nJxOi?>>T_ zPs>j)zt(lh`AZ_@UY@Y3jaD}9)YfLXMT?#}-yow%1!xr|7S9Wg&B3cZwqP*Fo!3BU z9FKd*`_wsphE>gU;oVbsk1&trMKp#jR$_MZB`3h)bBA*MV8aB@!d>hlpY=*L9#CW4 zaL)#Z#kM5R%9=!Ec@{aF8|di#odvE#pvm@YOTK(*Pv+$OLVTuvg~M^S*v1YVo6uDN zR$qU+oujkrTS$Bt^t&m>s6W)*@=hj9%20mEE0KO!aY5qwByeO0JgY)|r4u-#R(M|l zOI~wdf(wi722&-I9uQmxeoS1`(L@ad7d6kb55^FT@_N&8ZvY3nZ`$yzbqpW%d@tE) zwm8Dug*x%WYI6Q6k!gBP`8{YIfDFFIMgfyP9vPqk z>~=AoRVAXo1LtypK=}Th4!(!xLte=$)%kA6F9K5t1}&N3+$=ig0lVq%%I^jhzZy8s z%VJzpJ&3u640bqi5Sc%2tO9ULsh{^~>;`zn@l)gkwyOE=lYz&T=(=>9^4fqf7SDJ29c# zE(t9q?LtX`nvk|B-Ev0m!8yXOuC7ZzF77usk6$idE`a?l36CeP9_^icr&;R;ox-Ot zGcS2|Ro~Zd1)`jYZSutxmNE==2Nt7&y<2}5+Za_Mqy+dc2F@?{$HMzgS5D3^J+d6X zwuR3&o57~NPBj+uhVeIr!l|Qs+tLNMy2?uTr)B4+oJT*89MPYUKl*G|{?;dTWGyG^ z+^lg=-Q9isO?D>B^m`+Y#Mh%+uQtuYv6JBR!*pmA!W_vE6`F(UE;%{PF6mG&Ww01(}YS?*hV)0CS0_%H(l_6Yp_gz7$5)| zrn2d}+zX_$wywVSnNiZ|_~A6`IN?Zl%t?k0s%V7a6a!XFKRikBl+l{)Skdv@czHE% zcPzFan|)A3$L>YvTi*q96!Zf889RSCnK(JUaXoj@TsFV95T&+jg!8XAp3t=a8(h>6 zYdwsG-H*@@8yk`mb~HOfPMvrtKZkAjuId(yJf505KMVBZ!~S`Id(<|?Z3Dc8G; z|D^80YZIT`&)Ec%Jb4$&6Lv6q!875q*7IrYGCRA|?IAJV=heyio9pAgx=H+ z2}4Wt;FgRIv!R}i1-q8cj~)bU#J3$jpTAR})O84cM&TLDI|#-faM>{=1iBUoQVdD8 zyO!T@93*)ZGFo==kGJR{+f@hL87+;X8wX;;Xp#BEsWM5=em1cOO!)od`u+9GclRgP zczf7imf>)|m*1MVT|#PDdm%8!G&j)Hh{ojmG=En#?^k~|0V_htEzq~`ho*M#k_~CJ zfs_y+^eRCeI$C!3kGFU#hvQdd@miYPlxAydcnM_wmtCi zsZlaO)M6CS1KST_g3T1hK<1~Gdu1Moh_mjMm?Z11kI5dXW$S^|dG}1IjK9MRlEF$` z!kM<4d=0e&`yrcRA_HP#f+dSvU`n_QWy)y7ko{(#Uy0XUm4?0AAQ|9~`GO71;a7JQK> zlCmZDf6RcAL=GE0#k1tG0Gn<9ff_dy*G>RIvDL%D?e0LiKHL?kV;M6}@DeBu1X>@o z%z#laEa#a>BdMGsYRZAj&Zrz}guI;$?SaHjj)_g8hRc5h^#M^&3QKNd2Ow6s3hL?!1Cf9y`-tQu-PTQQ? zaq}Ux#V_T1ecUfzns7Ux3D?|zecdF>d>X&B$!F%mi3gg6+|)0Ck(PMdoWMCZeW#?V zDhv72L(5M#c$7aKoxkyCU+7>-uW(`H~3V4_b5)t|J2BOPF=gZQII6;?T zu`qJ`XXX~xUTl;g-o{>e>%e1I;`l4EVK@c5*Rsr-BLeDA&g>6l>T(0o^Vv5014CdL zE~vGe*^~N6aExSzQD)hQw6p!zoN;qGx|*vQ>51XG zmVYTfIPst_zeihlp=oxn#hA!JJY7>jUt!ZDtG z+WYny<64sCrIIZ13f*g|<#hg@pb9jaK^YN`0?<8Fbv~Ve`e|RutvIw^zQ3oTa*QXL zvFxjkcjUkom4Oa0Chq%Mx#)Ol0S7Ysm^G;Zxp7i+@+5@;RBaz4yhLZWF?`&=i}k|R z(pG08?@PY&DtGJ-gX-jL{I->Q2_KIStfIQkRUaa_E7Ighi%G4Uoa4nipt0bwO!CR7 z9F{j%Rfo4Rbd}}{7o^w6N61Vq4hXQ_43!TsEO*}>4-;=WP_TEzEZy)~PAlGMj7Ahh z1d46wos(d>dHhA$g*)TRaHJSUK6aqE|0>_)KDY5`{L=Dy9RL2EzzWXZcNY5Z^_%m; z83Pxm$3^Mx)R7f`8cA`rhdzH@FjcYh?eyzk*3@8q>Sawodxq0yADQL)6ZeW7S zIzjY@#~_%tc-d@ug|~ZK%-FrQ`ow;^<|FYaX4DK}EGe{i`*2B*kl_uLcy$<=cv*B*Z zuPYX;RlgABkmNjUWft$(1sw;*GU?0CE)X}8liXGo9+U4KV+HxtctCHXA0z&r>YF|A z8LF;L(Z93SA>z71a~Bo>EnDU9u=*BmCxChk4CO&1ys$oY!P_1Ito9-6; zLpw!t``vMPUD-qozOQa zL?dnYhw@%G)uL*5HI{d=#L6Mk$?}WYoXADY8VnVBXe|YLXn#y{H!eTd1xHc>E`J0k z1iNJt>?_nlA0V{LQ89ev)AuIrVe4=rxdS3Zsf#P+yRYf67~KCE3zHRKEEa6}2OfI; zDST}91xAaX%MN0A%IN(4Kn18YgM(sSY9xrdVUpFx1py3bWp3F$VlBPkez6+*VKH>G z{8!XBHnG=Kex=Dp24?4~-P4;ILYckExVw8499PW>@({g<;%;B{^(S`&@Wu-?|Mppt zt_Na7T_4H%==i9e8?2T(aK8xfNfGq#|MyA2!fa`Bzc16L{%m|Xmj6M?s&0;-VFtssxyj`aK(FWv=>^ad^2*&VUI zH(*L^O7)IJ?P^DYD^MniF-e0X+$|1FjC1T*&77TYhhP6yp26A%1SVN(m}6vTIon%E zfcek%fkgr50e<%eKy{k6ro(Udn~-hU5kgWeSUHjvlfEFo-E_e;#>O`n(AZ(~=zdLm z?CzN@hhFZr(Tli4^2=I0Hr7!JY+J)Af@#Ot_qBaCzWD&DA3AF@5Hyv2--qmi3QL@; z+C_*(H?wa(V1j-+hO(fMrPefu&z{=j;mx#x2NCwp_zQ{+IF!MZe6tjfE;JmJnZ>lk zkE`B;r&uUGJy~F^P^EtY;a_5&Q3bkqGD)N4f;_Oc2vm3XoAd2_vjKt<25VCgG}Z0y z%_#zMFX$(fViJT0m`6g02!_{v`#gt0jYSp#`kZZn!-5D@XMG;uy20Nk!Zvoc6Yv-T zgyuur#$KXwqmR1VLc8sY&G~O!{|DNv3VDm}U&LQbxn&h*0xqNG zWX9EVe#3XFn~XuPAEldYULC=t)+9_Xh|~jgg+fz=f3xZ? zgXKyuJQV_&6Q#U?IUod}_!w@HGsY8Cb9;FBGsdow)?A6aPp2@}@z4?Sp}V|Hn19xs&=>ID7uLP$L8gHDqWE z_7ShV@LY$8Bqm-GG+sISbTmhcytXKBp`Lz(Jgcdt#I; zUI-5+Q+Vpu^gR@W{GM;?ax!K02FsrYICn zfC>#0XdQ@Mpi<|z3LJ|K#13jBd#w-675_QE8jk!?%C~$hMy2}hhqs%Y=e*bL|VD|C|JydKAweS|U40M;l$4%8K%|gh? zvyzXVI(cDbi9T&Yh6Jyg%0_&*pn5=|wc^vtXNEOfxfH|Lu^cd2^W%nnpgamoS6`ef zHlc^jb8Ds|{HxUYdd-HixCZ41e;werZ{+oVUUaLm5*^P;()%MX-96{z1&kIs zpnF?zO(HR#E?bFHEi4~cd%I$Tw2tP>0-VV#6WRQIKpE(O@ra7<`}DL(n~FhlqWXeRuz7HZ|77 z)v4*``0-h7D)T!vYAN2l)c29~=N$zA z%n--hddlFjLNCy&`g7fqRaMU?m(RzyV2Cl!#Fjv?S;0p$uTgK|uJ4kIu+~8tqLq`m z&tT#@RMi`^UH$aXX~_S$|H5rc-naZLRGA6koz=41R&Ws=JpHz1actgQKwRMh@ci%3 zL%R^7Z`0$Gtxw=(Y;b1q>db4<+lR%LJ_%}VP26aYL&l$*S>q2l3!Ae1!ars!b%cw+x|4+*Iv8P8*Wo zJvfErIjAPl^NY?e2efGrA*A-@>kE~-c>g^p)kGt}q5Mm|%<6TL$D?0MHYV}_T zs^4rXau;eMX=p&GO+UYodkl9#*9P}%)dWlZmXJkS_>CcyWv}*NJv}Rp^l^Eb9elr) z#kf^NiEm76@c$$H0|>~j4nM#FZ)-a#$g72WmT(vOfA)v}W`F!l>sfeXfe*1=i`TqY z{2%Lgz7J{obhWjl12feuxaAnl6IQd_hlotM4+<1$0*k#r#`knX(*a)CBqw_$R)Q`# z#*_-1jzKwKc{B6U8oU0L2{~ivc=a2A=b64B1vCK9q1S%P5V=Zv$t)OXZ@ zKLZwp!WMu51OlyJVizZK%A%)}SD@31jdaJ(>CF$DwS*J%%*URcq}C+dG}IAA>?o~u zBfh|m%A4t;VR9Z%H8XCRo$(c7S7qIsRH56jTe$h!s1Bw?fIK)XllHgGuDUjtgyG9G z9c)mkQQHmlg+soPJ#s3+3RjIPSg^791_3H;q-%%@xaQZEvL$1wy)Pd%mX*qhtiN*G z%g=L?d4B%5U}|sY8xBMQ#g_Qq+sTT2PNs=zziCrVwPIdD0mZ! z6cqXwuB$03HmEXHtS;gVLm3(^5n}K0>B$xNQu)>U5rZI}{1x4@{xC9>( zVPhQZ>8X5A_jBYQ{+QX&JleZfaSm?7QWe*^@}{7#NfORn5O7ELw`2Z+sy?M==u_W;p-tZ+hf^3JC=mH2!fCM2ZFg??5XqI%naTH# zrUk#%mg9g|tR3*MSC`nVYLIpypL3Ii)>AI|G=A$E&4DY z;>60|D}UWz@_Zn3D|hvo9u!mc@NOv8Ka%&_v$T#0OlIQM8JyO)s#G)dFb=?4c_KzA-(c zKLI;gZK863(cinIvwnv*H`%pv5IyeeaFNw z@dWymRcR;!Xl!CN$}1AG{XIQ@5%?+641UyTa1dIIFO#SIFb*DRf4`rlek^h9BxP&B zDiEYDIom`O2i}-ej^}d_MtL=eh`JH}+i?(b2W#up&lJ1ibX@;;0~8%Ex|r_aY{Nz; zOJrBgWSY=pJ^nG?Zv^@Q;l@FSEi^@tkB-t$%3q;QN|D<6*`O~$UYr@WzrbXQ(S_1Q zfvUM0pRO;I_KOaa9LVlj(`UWZNr)W$B&<2*uuXtS&k6Nq^XCR~Oo;Oq7&6ZC_vfdS zC?(=c?fu=E?bbCTEdE)xM;>)kEZvgQ^tTf#)J&~P$QHyQE6JAVLij^X+dWFbWiT*1 zGjD*2B}f+gxP%0k_t3sZiW%@DcHOMYv53{ zpFSAhR-@BCMmh`9t`#Anzr&=F>aR7lomy>^eQvAl)uK~VOgkC6GZi3 zkEIy?Xg;+Q%-nt_yqIErb8F8?+hVECOISfdQDsP86__|oA7=Bs?c3TbH%L!YBp2K` z4oxmSPyofaoi&Iz%;-YuqDEC~a52E~+ENj;`d1<{bztaXc&tl?{s{m2y;lBZ_4QxM z>({{)qDil9o7+HmXS~DnlP2$%eZw*@QE%2Fs&|3J>X`h4;ib<~sk{opsvWrU$usvH zn>c%`cMI-qk&D?^Odpe>m`9T{*D5=k@Pd3;!=`2iFmpH6G@x(c?o6_xc}&-S!5R21 zDuUzSEqRugYbXc_F&N?~XTXvi1ykLSAP))14Teq4GKi8tqpWYO3=O?P9bv>R?q#@_ zs>iH8lT*FR*-T!KYhkz#vLr_Xl)RPIG5L4 zpQ#PfQ`b!>5B5PLQ~1P9s6}dcZkSySSAH{`%^Plv|LpR_BEX-ukzuge8N7|;Dr82f z%5pf7HP6<_pR=#Awu9R8LpWF6J*K?24>wd8L$|L~ti2NEy!)MOTA@{gfLlx-!ojW- znzBvz0t@5SkN3tYEj_rgitSsgO=!aItIz_x#kfiN3 zM(WXL6aMXIh8fF-^+3uTc^bB_fAqOeo!GO{1Eb?EjE~9IQ+k(%we!YNWOU?x zwqC`bF?_F|t1~M;ORwcjWSox@KT8B=W30`KY4Aubf;APvAK~xhmMyGv%Y@aI$R0Cf zhtSIhc0T9A{&}ZGN>_wkDpJLVt({>y*u;RA6zm6k6_qu}PpW=we5@-C{G7mrKk}>>RB-wQ3TQn^sEs# z9FkXkLbUaOA9~LdEp6-JN&Y2PbnfeMD-5Jw{oHa#Z5 z;zu2yNzq*Yb{=2%{RczkMEtFi;5mR~NdERQ{YF!^s|s^r2BW>K+&r!ejmWaoyn>BA zR|a8Vf#WWNv5cDo&OLMwEp7At0VMy}d3HqbQ}Q7lr~tG}e{8EQ7RDfnMgb>(e9)Yu zksvR>b%>?K51$d!E1bLUj{b-kE{p-`b5qk^iywtae@|s3N8-}_?yo_DgX^JJjQKXn zJDNmdNGy#$g|s8@t@f0ZiNIX3PZIT=-uaM=wvv2Xae)bH{gN3q)?8Gj3Q)9?igsKu4g|CC{!YAcUCPd z&o1?n5&fU<4h1p)4xPIl7n6$WfH$2L;o9t2PS~Zte>F*(2&rXujE_``zsIUWGxH)cxxmd7fq{1le{@HH56^EsOm|d@kG_oRQqs4gvx~{(6 zDY9$0CHO$GR3SdpkWtx8W+9m$8m@vCmj)^WKq2NlptSGsp!Y<#+xD>Cz$|2zI}sl+ zvs}p&%Xv9_GdNkp2WUDUD!mZ!8ywulwh>2APY4yuz3#pbobI)*_-)>siq5K73wL6> zPIOvvYzc@t_KK(@>tZ$zZI6&)WX$IaWScr*)k`h?#ThhK2fNC@L*Se0%r8EtGYr!Y z!>!&Nus`ITJ>jw;R?=1(k*Y4XQfEFERP(Np_TX$3pR*6bjvI|Fg6GPJ`DM2e8+Sok zIu`br}+7}8Iq@F6fn>hEAPAtO>Ut=e;^OLT*Kq>S^N z@zXd9ea3HKHw{YC7+w9WjyKO-ljV^KWHj6!+a{+Y+d$qw;i=4K$1lAQI|bgZiNkMo=nTVdS8kA6KY8A?^oQ ztCVxtYp;x?VI)yC0K9Si&3jG!rT*Ooolh@f?#ewI#m_|BI%&kuBi@MJXFc#WF ztP64E`Gx+u_uu7B?X;}DlaiV&k;+7y+BI9Y?{q~viX|EwKyngB(ezH}Px{{HiKl#n z@QJ!RBuVVq3{xy+j#**Fz+GBW6AA2NIp4DW;l}0Mdp$1t-L{(_<~rX-VTc*_2+&2| zKSxcY6!QZ#bKS%y5J$XjHV@VC%QGkI%0{zTL`r=ayQX*^wvUY;@aZd}xOP{M720ak zh_py4gpIN*;mU`hzV*J-C`Igh$H3{Q1?TZY>v}p1aIHq%88-=yjm1nQv1-u{FQN$L z+YR(IiPWFaON1#~?ZWfh?u!^cg)c}t={zlkf6!cnX~b|Um|5th0gW*(DT2k}@06B@ zEGZc{k}?pG2$gZg=L)d0B0l60G6?y>1}-p!)YdTAStLmdBNX*r| z+UrqT;Z!Gv{hx{={!c~QSt9F8MEYi813m7Kz$7QHpS8d895 z0B0z(;2D`JG71G#0aZZ{r)7AGbQ=H_t{Z_{qjhWqwPts=2EBHZFQt_(ZHgGGj&=1n zdoZ#e=jrdJf(;Z;1~~w+u*cBP3^dJD`+amiVctt&ony5gCXtoy9vVyt`}Ws=%0{3L zpwy8bF_@tmWjl4o$rlU?>rcLQ-oxv*OF`9Xl#$)iQ;noxnE9z;XZykw{_s61wx5FK z<3wu35ftePXA1PxtgckgW0nui5s_zB57sNlyE2^YOkLgj!l#WSw>LZo8dZbXTK0a< zu6sQ)#@E{;4>!AQny&?a_5g_r309_|w4h-W*C@}!X!aBKHWwm6GRrESHP$l}@LAb! zZje<%ekl2YJ&+J56ouy*nQp}FQ8kG^G$=A+el{?Y>+So*s;Zn)*^wts{xUHSmhVed zgS?YXBAZT-aFi_4cs>(-+}ouSm|9TwDaLHeUs1`qmv>UaYgj@3+xlRFQq-Iv^&-Hxi3#U$1nvgu zgQx$Pb^qRG|M{*HXUq+!R-c$@NX@V>{MxY5@AB(I@u_5OoQeN}Yt`Yr}}@|ST7I=(lWP?-_10YOKD9=n}#avyviM*SZD&rn{g9sLmGJwn@qn&;FKj& zuU=EW)*PDDcs67E<|`2B<%(xcMU7xWXQ;?nQi#pXh~vO?-J}6Z^+jIrQ>dX2Q9!pw z0zxH@^@>t)R%J7t{J32CCyZWG^dX9m~qr zwqi34O$EARjU`i{#j4!ZiQQ4Arjaxccy_ef5kE8!+_-hD;?=i>r>B=b$j7iY^oWMX zlbg6`3LT}x8#`7Q%?WwR_Y%1B`K&iY%k4(_rbrnxrASdt0VTTX8RdI(_2V2>rxlvz zP2&%ALePg2ay6^*ttMBatw72Q`<|+nShMaFs8dMzI9Au%i!L@s(h>d?i6(0h9_91V zTwLLX=UrU+rlq}4Mc-OGne`W=g80jFgCCf+1jr+fz{4MaZVBfb2>haWl^X96#WjL? z=3DlU=(0%3i)OM8Z9~1%6luD3$RGM3=Nj#%2bU0kJqL6>yboKV@1vH;|9-^!oVrAv z+auBzxHTw}Oj0dMIxdEvTXMu}Z~_ z!$#{t&bVF+u8)e~2XKiLBm&jzX8220*7ao4m@#gqoqkiBCz>d(d<~BJAl(nsFTJB` z3Sh8!CIhGm$N362s#TU{C`x>njw-qt(n1bi%ZowzYI_zi+A`!Y+GTfDeLm`1UT9#o zz&g<+>mcxzh>xw+Z^*t5BX0DBn=-EdBCV#?k|60>n3AJSmD-ivKxn_*5vJ99WgNMp zX;#amYQ-!yB*NFj4~VtXKwl}3{Ts!wYfaC%tr1%!N>z^Ir6z*M@{<+xVZbqA(4$k| zuV9h_t01SK#!~pul9MTd^)9x+M8WEZFri8eS}T?ycW}5U19#tw zaGlNVaQ6+Ix=#ZGvZ5lU-k=drW7ApdXTJLsp3{W>3g8qb#b$Oe-XWTY1=255r_x16rJ;?SNF6m3!CjLX0^ql7m z`%nN9cQ+LxqJ2#@P%eAR=%@ZF;5I z(6k@ev8m+(F<#i5TMXze7BH2EuC4-F73c!%rWr=n0&6Z&C>0;hB8Jppy%$pZPh=0f zs|6-@0hdWA@a8hnc$|)zq)|dWu4Bs^tYX^7%YVwc>-sF?&8S{&7YMm$O$s1?kKmpL z7K~`8b(`@W(fMb9GDwc+8e-h1lOr`qGijzT<)-8(yRWsMfnC}Ns%6leEkI|Qq+)$JH}vUi+x2HV)6Xp7Sjl!X zrLly2<&Ouu4K(!iG2aR(Z&9NoX!Ul1mMeaE0{-QW`nLm0C_zRsKhH+Z@lD{MV_zOC zBDV6JjbbcgOBDwv`VTzhT-qN-hUgqdz9gSjU)4+2I5|U-s+gE;PF10jj7u}L!e|MH z)tHzyh?OR7@x}^|E*>oXD;psRv6I*NU+viUERNB{aHK_Nl*01*ko5HJIK;+|%qpo2 z)zz^5B^&ZBj3t0NBC*uW@;1f^f6mD`jg2|jg}udH#s2*VC-q;fj?VCZ+{q1N?fyj1 zOmG;GGCEy*N_?L(ot`%M?J$-*CA`K$MwW|HtQ8h@2-pcuJO7vO1lObJ7s!lOh=D@li+%#e7fqj;`e^)-iM} zeSCzynh&8EY$B=c@y9O5Q~m*#ezg8v+z>8NO&*3T2`u|*g*-wNzoL8O)HjyX~E{aeZy%2<|OxQLHbB}^HWWES9VzR zA?Hfjs}31QskmmO@`5D3a&T-YMAU*_7Qb0knpgAt!@tWzkpMstAy4s8}(aF+GY#o2HrbK#q>4SsX&pah}9 zGdB_7hO6=A22}usNmueXeaN$3_n#B@q;Wk{XRjsbIXyv{kKSRNR^0%+DppR%T`B!m zjQ@OWdCAcJ&H3C%dLJ40;!IPxF5k0FZwlY)Y5k~q+pXY*r=)BA2-j5!e3R(`&0z!L zsFCS`+p$fjvEw<~zi#42pQ9br(dk;R3E5{eBv5GTQQKxzs>KqT%XOS{~r`RS&R z=QEa_^-5j#x;9e!V0SfSdZVPsro340c8=l|emOHJcS)r}<1kx$pvyxjbX>h=$j(DX zWis3;*p9flMml*AK+h;QYQj?JC!vxmH$nQFRCuCeSN)jdm_f>xtclFA#h8!kk4-lm zi&Pv9d%Thvi9vV~Uwy^;diN)`BRKiJ0A`P{Kc5Xhw+@hHW|N(4(&lCTm{+hWVsUQN z`=ng<>MHag{YurvNy1}+h!GmYUdb!+B3e3Kge@RoTX zS{W^g@?SAWr61OgY@wJ_+p)W^=(FNruH6VuE5G7o^e7$_{%r*flzaDOo zH&H!J{EF?Y>9>0RiK6v*4WM@RJ_QM&_B&ZPFw?-c7PZ~{AMgFsH>Zn~YO=6Oe%T!= zGs0juo>_}m8$rZS!Gh?zk*(BcB`r6e`R8t`bvG~(g;1(}s$9=DDt*lo^!fPPO$V9a z6q>oOVX4QtLX#VwyP$VkUH>)e=VAD9!z6IhXsE>vj!RbSfQ#awem2Kun}}Hy7Yvb8 zse#~%s^QPC93|#mEK1Yv#R5 zWL8F?^uwOI>ly&)zTv&U;C9+VRUUScspE$E+sg)oaW`Fb?| zh&;2!>l#$5(eVZODvm3r7$}&+UtuM!hJ^Og59qoKn3AV;29TLHGEIE9yLY%U`!gKl zl7eB0NI>myxF%U^n+tP72S@-%hk}UE&`6Mr1!I~{#Uz$;C=Tnfc37ce>d7 zAx9Kxwj3emUAUj}P1!-tNl8UGhjP+ToLa z;?JzUKq3BQ)kU@X5SQWwpBGpU6QiLdC0PlDJoC$V6ALx7IF!$fZ9#?zs`@}}iaLit zg_lsHeiQBe0{9UcIMxD`YEHir-I&SWc~S73@A@mL!hgIRnr!gL-R@SqHU6waNa6RM zk|u#J%Hmz1*=Ig8D7n3UE_5@fP+<63MV5*m?ewAEnt~s*yy*}KD1&bicNF008LBIS zmxJ0skP_6de!rk$T0v>T64NQ&Z2}0Uu-&HrU4{=SHTAWEAcy*<)@>k~18+yY&a`-@ z7c_bJ?O)I|iP$Sbzo3VfmuOYEbp(GbqVdHyn4B0EOg%NS@YA0;^f<@&)NZ3eV_EHJ zQ3U&TqlpV`J0uNIsT%z8;95puQ`Y+qc=W2F$=W`CSbzwLwID3bfruk_k#w5eJ*m0n zHVF(sWJrhvW@y=4Ir9hok8Ty>FHl^&qgqM51EXbhAgexU7@B!-qZk#mpA<}LVLTJv zgDEA3RSa2D@Nvr6GT#i86ruQ87o5>Ef!Co=rFsDsWOZP)%xeH zJtR8OTB`znDQ3Q-W$^~VayoNQuEGL#S1^M?s?QA;@{YdB%@r1M?5!BE^ypYO&bz6U zQV|6m?cKu9e?L~iFNIdL3Zc%CNv6w%>i4B})Z-L4DWtWIR6lc3aD zV%B&iAOP(_fe%#dl}j8^97$awNR_A$cw0^gtgT_W&axb1KRgIGZO+;gLC1|EnvfAe zW3~C1$B5v0miJtHbl&B4exT&NfE}fAlSlSARCdRGp)o(K>_vqatxZLyd}}3E!OHBsMcbK ze)p+?z4Dbg90=#Wnb;X0AWk`w*J`o_O=N6oMOQ`v?@J9@~{C z2-Dq<1GI^U7SCvxjrLJcfbi|eqI^xhu3?Hb=Q0kCH26DEqxynP%Tl|`(}Ae4WxE#& z%PPGA4hzh{fKp(bClcK+WFGPZEM`@qug`y*VVrEdzp||h4G18sQ4gBPrJOI6aiae_ z+x!{TfJ@| zz;wFZTtSfI7a6o8?}nAgwDFm{_PgZ{QUD32?IY@<@@7c7Htz@GnwVn())|$IG3$2)zskz@ zuE0Rv;fGN&R^WV#SXZB`-B*fbhY|h$rc|E_Q`6$R3ErpQum}A@UsFIuY@9|3b;?So z^?k1rdMGz)Iw<`iVqglE4a!h;{jGzD?EONG7J3Cq%=!&DIf_2Gq}B}y>~8x3R)KMKEjXl|d(0YGoxFjnQoswwKKQEuS|v;@e*{O8(@c8P+z_ z&yXk5)-b*t6)vBS&Nw+ZKA-;HJ?If%}$W$pDr|Zbt6bgnaJtqEa%VZ+-gVmwN9?mA2Gkf~%M*(yV4USrcvae*L_BfgH)}zgwD1X`uUdw#- zY*5umzBiTF#?n;=?s)N5tI5r`4UeEgg}jHqw-QBPPKE!D9(W>WLl@u45wZ_igm;FD zF3*vL%H-Pxe2IQUVz6W+h`?`~#=n4>kVc$0OpOj;ECXmrcjA6#9Ehms$qi`pLb3(HU1B`(R9z%kZ zMEd((1;CaW#>febn0{E8v(2boUOq_@3q({yB+J(HE35{nH`X;X7W^wF^LU_djAOHs*T5*NRSR(;I7?Ew zv{(zgC1L1zz1k|=rp4^C7u~duw`OzyHNE=uI(zlrvBPTxXF*Ozlmy5F;r^^b{PVoy z_7E{~HvR$qF}n4e=meJj6RK%^#hOvK$B=yK5E zjY8*H6$bMGzpb6}WQ@1ZphzaQA*+)TSWa^SxU~wYPOB)l&FKfhT^+k)1I5w~#VW{x~7 zkzI!IoN29cme4l~5z&%V*1AnKetV!n1hq|oSPk}$F16kdW zz;a!4rwiOwGX8Xr{PU6MFE&oN=*G(|`2g2XPi^k%y$r|_@Zd@iU)w0H`Xcxu7mF@a zKI(`S3D{;W%P_#0)aw$6U3%N6wKPsgI%RP)H?^NTm_%szrxX(@ZtYx)I-2? zrEd?B&fsUfbNPQfU3FAdU$CaTLFv9U(nxn*q)R}$Lt3Qs0@B@`(k%iaC5<56D2;Ro z(&5|u-dpdlvlfeW&OK-Enfd0MZ)T@3m<`*OEHlx+!>7UH5#Fv(##fxoj)8VQ>}-o^ zF8v{4+RuBQ8%puklAmN$koNS}WwuETx-}OR3Tg+TvUGJ(bhlzA&zI}CC`q@p6JpeO zUQNZxfPnaFmjp5H=~r0ktw;3vbT_OrxAZpDXxDd>?`suSMP2tMvJm)Vqbktn!YdHR zBZL$y;UL9b5&8L4E_F@ z0h}fJvYRurj+^j+`0Fm>{%JZBM~Pl?Ym!|HE^)=oEq&IC+rbP@9`#SAcm$Lnv0-bZ z$9K&YO&}Q?GZIv- zIJId+H9c`ZtV4Ut7>x%Avc4&l05%c}Rge-C53T0Zp_8UH!3S@u274!F*8eh6hPi#g$Xc*9vk;9h19;yNb@ZWH9$X_GV zn4EpLzV^!}LfQi<~co#p^f{z!^Ku7?rQN0x+vWkfm7z9M3&!LyhF>@S*Prz5q$2hf7FqSKvXTY1{?dhd+-k#T)k?mDUzKsl5Jgi@rwZ zujc0VFq7N)&9oP_g{ol`fjmn6W%o7EnKOS<5H7$v71QL`%60h@#q(|)!_+lJit#(e zlZR+1cJTTWEpRe#IuWKNKGl4di1I6=j&YPl1@caaxf4;HM>xRS7H-=O*8Vonf8rxl zA6aBK!4`EwC@>Jq9a_{O^4zFhq(kbFcT*8(H6vbG+#529_rmCz< zyYQdz2_DdxFb^oir_BUom%JijPxfIQl)x*d^*EvMEX6V0dZ<@K-9GScl&|N^8jPzC z1PYF--;z_l#u|nf}ce31Va{lv$uBKgwi-~(Rxt@QYW2vHynr3lH`ya3v zLGNza0EHrfswo1fF~FmGk%O{rPy}1Z*p+7YJd~Glq*C%Cxr%#L2_CZ;i-#2LDwJe* z{Vh!c)!S0&?++MEEoE64fw4aL4KG|uf<4!GFIq;9M168BY7Jif6c03Xp%S6gq*bx)WFbvN?JwMk8mc-ApN>Su_Xh)!ass& zv%WeD21EHsXw=4D(}{H*yo8KAN4b`VRQ@-@Fp4q&m5?uCG~o0tIl0~1!-bC_=AftF zKZH}vH9PRoQ<<$`@lzQ{5J5m<9*(g?3uph!TZ;zY>JRJGJ`&(ywL}z!Y=_gd4IoC# zdnhv7U9@nR0J}vBSDPJgH+TaHO{|^?O$@gmA@U+PFWa0O%g1qt4!cdq7iZxFGad(rXn_gkK7o2~AjoO8;hTrRP)3Rt(qs>ib`(I=vpp_~5H-8>Y z1=6?;@F_pB%U3~gcL_&Bh`+J^vQn{n{3Hwuvi^~-64%ksjJ>mV(A>pZ>mlMYApUQ6cPUh`>Jl$$N z(N+(@f%pA>g}TZ_ci)@6JEO#(PmVOV#?J)$j|qJ3_xqD`(0ewYZL2R@F7oFzsmgZt zyz{y-LzlDe9sfs`=64VEKXG6z!c(SI8Z79k1fmlKPCU%Ql2wxC6nb9xG=o;j7Wrj< zNtGr^aY;~?HPsYuMz!@kJT)Efg|mf&l;jC_GfXv#bwNLZTh1d z>IXGn95!+M$s$~Fqm<|~(wo)dLBIE1a||0Za*k9{v-ed+J8q>gMe}>yRCL}H69#QR8V-0K->=lc!Ulorrm)~1+P-y$)C0J zW*@JKQxZ@3$;X+Z7K+WGhOQIEHPt*>#lc{X^~@fZEoO~RHbreF)-f`ka012aV>3Dh z++(2|3LnSo%ZFcll>xXm#9gZ^6*fC=I}ej1=ZA+ZCd@x8zRtydO+-H1nis5TAKRDDgq% z-x4E~thG7BM^GcssK=D6o0Z#b?NyW@{7qSr=&o$OV56Q`H%Ze@y*Xa8l#l5|-mBG+ z42?0t%>GaDl{cNOx^SUPfx4i5p~8f*r%W`S-`Y6dO*J$K_a%^!5#ZFz)F+zK7K$~t z`Y!&?E_Xayd6s?laPY^k79D;QpB=wv0iwv0$3P+6$ccOqz*T@%`oz$@_YkG3mPSkZ zf{X2KK)fD&AXq~8yJ9-g{~re5R>a>wtqVUD1bk8pin%C~x<5!mns6}^weLKYu|N5J z(o>k;u&aqEA2%Hqu(w^&eS~(l1+u4IO|Ci>-`sXa97n75`&|j^hT;~Gy`}IMITVjv zKjPP!7N<=#Kq4TBY``Ok9u>GLZktq7>$m=D5b{2UGaJ%PdQDe#fM9bcxn){|yNh-o zmj{QJ7~Oz?A9(?1-o@>VYQD^}ZiXq`*8s`6Mfl^>iTO9BJ$)F?9Igy$*v!gYunbA@ zeW!Yt_vD|B+Zm#@XR9L})Aq2lR_4F!F3~!F%|3qE>DrMp-v^3n%fg zf+xQLrLPEJfU+=-Urce(B^$4h#Rm>lp%xzSeE@X zZ(;r@23znJSS8vI@0$NKy!}8O?Q3fZTriC6^iPK6Y2;H=ULX8EIt6BGIgIS3hNe?=0$OG6`Ju!>QXu4jTu<6a>}UeKDgZqT&X zWSthggin2eP%tPfV z^v_8^Az_tL$9IYSt0<7pY@g)3lGfRIkraJd`acn6iVY z^&EAG1t9b2h42j?DWt;`?E#0LP)mJpgxE;AZXp&6W%eF1T6UiWmIeRQ?hW`OqLpSX zuLWrw*UA>f8y0WA1!Hph9C94pl&FSU~JwZt-oAK^x>B8`EI8wP*kD3dAJ(*pJrHv1=@wr^nf#!*C1k zBQoePB$$+ZjoZ%?&oNhJE)p1wkBWA8r#sBDyQYqbQuP_;4^Q$0<^UojePv(N~Af`_e^ zN71 zl{vE3pn7Q2S+zIjDBs0i7|~ar&1DmAF^%W9-}j%ht6oFvsdM646X+I{GIu!rq_AO7 zF9gX$1H$S>{lg>~;mDwU>My_}6Pqine(OsPkXerFZ1(C2@j*h@pniTKTJ-yw-ij|) ztTM_i-e&h+q-U!aEc8-3UrguArZ5A#+G5Q0aVyo^Q9d0up#$a@0Q0VqgV6@uA$bOz zI7t_c!)+}$TuK*Chsr|`h9397f@=i;TCzSRpCg}&&rF*!lD-hLF1umivXdpmsPB6g z@#~y7aw(9IWnyW!5s`nhj_lngf;17c9#!mbl8WcZ{)5zOec83>bG^EV^Ge}f5hL@sV zJ=c4|9NuvKiHrMPg%XSlf7r}|j$kP~5?bl}ewV{3t3vV7wGgvzytM7j_kCJ(35Ab? z)ohU7S7SG}y&q#=o+f^AS}LP*BbVH#<$k_To5(RULW7H3XpFMRKy$H{hj)>n)SwAU zjRjQTt6VHmy?Wj(87A%%H?&X_r^QtDMx^8ytI!u~o^s-D87Vit3gR&tDNP_*R-4PV z@#pEiIGNy;{i7+y{7Q8e)+lzp5@*p|GZ8EV#?r2scj&x&Si#+>SE1cIg$V_{&VtuCdYzEB zA`JTK=mlqTgk8n@gAlX-A_#-oQv}gjeD`8U&pG_Yh4{hX@$WtLq}5|io#bL`7IP1j z!fvanm3UeeGB6{#0q2ht*+9!3B%Ty}3l$fluvFo+&m0u`YCYg6~J=g93`rT zb3EOfs;zs|9{0152oe^aDw-*=jF^ba?s^meF@jh-QI?Ln5KManbrvKQv1syX({K)w zOe_i%7de2WC_cQCtIsbIEzkF$n(1Q0-7nksc<+==^|pjBoUuePt>**{@JL>WIrw0f zReNw^y2{og3r1w^pUhJ9FxE870yqMhY4KL3J|SEk5W&_B1$7{AtLXH1c?e+|zgyNB z(0})lW@3#Yt3N$$EKEx-LHmgASl~(ORr8lB{VLn<@ykMc?T338H&2hp+5j;g{=$1tqC~zao;|!cWiT3KEB9z9Xdx>;6qK^NA=y zg~Df-9=J-JUw;$LFc}>4A(#g!+M7$xRDz7uh(tWVFm6c3n4~m2oRS{@Z2es=-u&2^ z)t|mw;q|7smE2CRDHEmZ0+2aBvDM|l=RHnvW8i2Fp}@oPOjv;5#9`G#*c_9A2WIc$ z*$rdRUq&B>Ic=6TR)5^oZDEPzFi8t`X-OaMHiBb%T0SE|Ca^oOHf`THwA_T`VeBic zgo*nJ|7#6c+&kj=dg0d*6E~Z>a!?fu{VT)IaDTJaW{A7!p$y(v<|3_IxoZ(71`;gO zO}J-Zr#9fb(&W6Bg(H@I=pSOV`^k>SghBz|3)0_p0B3MW+$nUpC~$wnXfiw2n3vol z(At+x`leba{0K&0yyQ9R)j&#+NuYQsNLT2;7E!V!VOF0-J|>+8n)K}&ynF|+DS&5@xQ)m!aZ zXQIq3O8jftIgk=>!eIjJ@@kce|MNx*hlXv zu2bUL7DhCO(II?A3N4Yo<`55GdS`3N<3idk4fd-m>6o;X=7TX&e!5BVbiYg?RTlq| zu`~AQ*TfHUpEMF0NCJ33L;VW2x-!_XCkV`p2(OjEPO;ND*(#Ea%xhx&&v zT=g-$J*pl9-&Z6}`<)AA)r!2-j_0@R#E<{3N&-|89}w>eAOk2ezFV{A*$SQ`e(Aj= zp+5-tPm~}G+HP%uE(>)kF__4dlqoD8&pa@wM%kr!u3*N??D$fta7HdMeHAB-isdyk z@{EW+@S_A^C4ASxWp>eC*C9{9r)({I8p(MsJGZTmdW^&Ak>Ej(YQW`{aKa$w~UsK{R4V5`wYtCT&Ry_e{ zjtQ)Um2Cn)ZAkEVEvsP9%c?-jCkuIwvu#S9J| zvV*`;Qd);tIGf|I0J5dq46c6z3-gYXqWL`m{u22R32gvopT!1OkSc7eeuFDV6;^Uv zx-3UbeO%-yv=m_Qllbj*&}_p8xscBge00C^*PzA78T@nKLc~s8GMXL}Z8G2340Xs9 z6Sv95H}S{@{9BB}#b5#4eBkoG8MG$R71hK?)a%exx*oO^h%l}o07s0&w$igl4-n9u z$s?%_6EjhEO`iAt>*Js>IDx5dTP^lI6hm`3ryxS`7`Po1D%qfIDX#8d9SO;9DOEHq zL0l$qb9lqnTbjn2prQKg%T4W4yWgI+YY{=o@I-i!aBLT-Ep<0-#hde%KzZkux_jQJ z#bb@tij6&shP{=3o;h{9)-=tj1{VYVBYNB~$TVjOB$#IjP~t7c`j-*nH1eg2Np6f0 zk)r5n_d%)=!9G1hGPV6tqL4X6Z>V*h9M)o*sO4$LEjMvMww|85u^$$lHwc_4C<&q< zl%ae`7ERC&f>$oS3%l(mrZ&mC@*dGdn=7;YhTCiro9cWfPuFc>2Kp3Wi0wGQN~8ko zWITK*?LG%0FZ9smcHp$y*h71t$QCTojQL>8rA%=hfD#9>Ke zxH?3DHH-!85EYTBd``!AH}-@;iFfm;dBJJqU*+0Wz@L&p0}+hgSboztsFW_JVaC6n z#-%g@maLVyz$GFyC-w{riJ%HICYk+Z9BN8J1bklb#3Z306&`5(yT&PXpvm+Nu5+{< zDlqtS;CiUbWT||L%*6*@@-&Q>FG1U;%D011Ut+JBFV^`A)%qvYq8Pam%iRMIILz->2Rj1TF$Iqc8JZ z29T>LUM9x|C262!Iw1M-tjQ7|npcC&zkSlVd|6{5O~7)^@mili>A1y=0lV2^amccO zE2te1Tt!?t?ZL*1ol6`hY}RRT)vN&y)bn3$8rE|6Woj^YkA$I$e>Nt+mp)*arjVx*ny3l zXZP|BqN*h&I?fCYsksKZ4IJHfl*&Uo^yr;;K9DLFy)d7-&70_Zy@ z%@1z~?z_d~%4wio9{7OOewTNiq15$)!vcX*QVy6?s`q*fHe~jIG+ z(k%o%Wtx9slX@hJN1{LLbH*3MZa(QBvJB!50y7EgVca=igG+=Z#OBLZ1EXr^IHMii z&ql&`?KMQ*MK9y{80~{9BC!Zh8M^>xT8484Bwxc1lb;C%t%>;jJH-vq@0{oS)XYwn z-JRCJ@^XIj^w;)}HHSo!L#?|8SDJ@udz}`TDrQD>^Xf4_Bbi(Bn1(wXdH(T8q#?30KKDG!)SPto;{Iv%6F1HR|SPJ220_O=>^U$Ryo!^SDAt{_^;(l#mHXjp2*0s zhlhR8v&AJd2PB1hG8O?--yKoN|C(6Oi4dRU@MjK!edghtcq2bC!%Jd&3%=gYPB6-<^!(!!{3{?? z570jfuVlUUz?UDZPT0!rKrYNS$HVV@M3V;usq-e6-R2H`GVG|~{A-MZ;;W%PWY*d# z43k$?UVPkl6Fj)=NBijOj;%+*E2y~bUlyrks6JRJFSlbF1O-F33Db#Byxi|8N~;qS zhu0_@Pgd=21@!)POZ)yA%d7MwQDuI{otwC*Fuu16wI~e$Q$!ipiYNg?-TR1wCQQH% zKpjr*BfKgaldJ?*mA7bQB(x$}q5Chhg|g`XaxjCNg*kZafP;DJa9Ft-mn(XVdw@RJ zUOUoLUzDsbE2CgPQ6%(Hfg;Pv{Ko4SYIIq0r=#ny4+iL#z7&MlM6D;nDmv$gcmc9FZK5g&Y zMHv|qhR@zaOyGM|lE$s`MJaeY=t1%=`6E4^M!Y*K_%gAa3>w|j%}v*jDiQE2&o_<&K; z5AarF6ak0jPwqN$tO&NWm#RpMGNk zCQ3I&pb>BAGKBRDjy`fAY_&SLN%9Wy(aP&2ly+f~f?S$3oQ-i;?38A6orsY1{3R=* z2qNhZ!E?E7t4@r+KCYa}!LRx_TzonN7kIu&`xZ{+Rf^K*GqP+hvR@h-QQ3|1iIjcm zq4G0#pS7fE=(2&uA&o#Lsf7Ms(5>a4W_(vnDwm+0O$WP!RfButK<=r8v47|#ni2@J zI+p9LR_QHhgG)tU*FW^UhM6ynuuk-WXG+Ng{zDou`)J1X4@v3b=whSV*k+|uRBVr) z*u3^wqwr+1#Oph8fsMctbH$E7iy8y!d=`j!fe#-E*ufY;Syt~i<#%^ah1;(i-Ve82%HdSBLm!HFJ9~c+640V)@2%r-Cd;9uVx0&|^+;*Qt>6yYO|^ z6%XmD34#s`G)>X<&+C zN_@+wjHq@{*<)KTwVGN837|zd&`r*-HEY&psSPZ<_@@-_4B6>-p&(YZOBn7w)F%gX1ZJX_Xxo{8k>4WV7Oo zw_4MMl!XRDwBD|XGWb;eW?aa~N>*#9*AeCa$fK&jcVh=De zA*7D=QuOBshyVki+hsFCTxKKONbXeO6hf%}aB{)6>!onfj}XNmspw*%-v8c`|LX7) z_0iIQaOaH-U~OLR_gHRl;hD3wPsSCGEwx_?r*lh}WTxYO&P$4WlBL&k|nC^)L4S z{e64+@aOB*r|havn_oZeULIZ(F|I=qOJhY&vCV#2Cb$G;0f-F+om_OZTZILX(7yy3 zp0$B!GTPV3mt}CG&7`JRXyH90^1v4KRk{9upgmDf;P!@>0n@2+_7q{^SJ3! zEZ-|2c8lKyQ!AIS6I4N9KRQfQZ9>c;%<%|PoRSg&r3?|=9RS=5bF<%V$bM}$m+nbR zDIaLa4;5uRx{ppW6{>E++{vJ+@Us(`Vz#4w5rS&~U;?)JtL03Qz-T+TfP^gY$`xe@l$~?F+7iBNB%Ti~y52YzC57e~`RB`p%ri zm>f8Fu5Mwfe6{`R)p>2uG-~qtd~o;Jxl8VAo0Ugt3(DAr@~`1BM7sep*&nLidVLh3 z;5&7@1POre1UlaO1kef8pV9t-D9x-!up^IAIhbF1KEf}XcIRcnU82!}S#;~)-0>lw zR_{8SIiwMsALgTdMu}q!(;@&LPL>!2QMIM0jixE=n6OpTQA4UaCms`szPrC*uC0*H zzm4DSV9gVMo_);wWq^$R$jW$u5U5g+a86~x7eD}<-nmpgGkPNeRvH<+ZqT^eZaDCefD^&PGK~ba2RtmBNScZTFfr_;#ZzLX zvnyMEmh-Y@c>R}~tBFH#@ow*rJ%L~UN1fRh1k;|vwCSrQWFC{fqS?_Dk+#3wTwd# zqpUHtiWxT*~Vw#45cRt0m2{V=G|8bYSi<#d?IY{6BRD5QiIobz0H2Q6W4wZrROq1EC z^~DG4OXZI$Z~QXRnsh9NkBx@$TCxL?xp(iWKP#Bh50y|VVbotxVVMpMyZybyY+Bo@ z+et)DF}y4Q$g%H0zBy(lAvgSGH2j@KYzm4s`wvUh9WVrVjMfuwi-N#n{pZBc2;_U(Nl91VKch#{9`}gTs8(D#Wu(*`c_dnGy)8; zg|Yx-C)jR}mnf9x&gwS4h{u^E2c1uykWC^P9l@5DK6xJ;lZBF-T7hJ$=f;54Jt9>qw+5?~2`Y%o2EaLOPIfAH zjEkcRxDjIKs^(EfC}zQvQX~|!%nlU0o&}bd-Ev0n!(TRE*AaI(6smPNAD#MoVtsNh zp`AjZFchk_=UEWwo&>U@!*fr*T|9*lVG%MHwFG~vI23||UU2~h3zEB~DHLqO5!#RF zV1n3&Q71cMNB{DOWj$w56G#9WIdhtVOMHH{`c>C%8k;D|7U7OxeIZNA3S!E>@F36a zs{Vazu;ml-snh+z4fi+DAeI_e{~#&D@>{CO#-hTh7X;>oi|_l*>LLv$C#m;RqlGas z6d}5WsQM5-Mdf7QE+ zw_(YG3EDed<3-V)JM%5m<@fos?k8LBm+KJWD2`HrvdNCDMn9IBUG_vTBC!|87u4}} ziLhe2Qt`fzOUpdb<{E62llnV*;}+P}WH5AM7QX>I(3#;Hv;cDU>s>Yvb?D&`QvOg3 z0ZK1^Ge3=Bk617d&CvUWbuTW!1{@0LI`~rZ?Y@3kdj0*8uSvEY=kK8nB=}kCdI=8u ztp3cIaAk6S{P*PiE~B;iU5|zb!?YPuBX(lketTnC3B#YiRR2xsIrmt1#PY|zu{Xfz zgo24nf;j(;A*R6JMhvHi_-W5&M_5&-hlNQgKsVuP1nQZT6>!(VUMSpz55rx0E^fO9 z!(|x{{rl^$C>13l8a3EfG`;B5U|Z>gt3}_K8#ssS*IbYWoo|o$<9A4OEbV7*-c48B zc2(_OUblSOJ-$}{*D}H@_o^eSeVJXnGv$P?Zl%EZfa*ZP;01MqAW2cabp zd?HbSLMNVjK}q^=@-QnDyLbvc!#HVvIVhPLL7LmAL&mVE(A{H3(x*Bl=BMO8ri@SY zGTQP68g>;Tp6VyQnUNuU$%qL0>&*+7w@Bzma^H-<9@(5+NZo$jb$YP7Qs`u%d#E{c z)R@!A>X7&nR}1ua6=f&IG39&2-v0F;*w|wEVPuyYX$+Kl?AciCIC!tXwtb!mE&Kk8 z$VG{$I!Te0_kyovRrK&g_VzRS5)(y}D)v>V-Y#uADEF{qF{MKszd+EduoBpu+4WPK|r)+0=omD*NzEViQ(qsf8)>nuU)@O<-hR- zUiuCm2K)j)#jBhfugmE?Oja*LZUm;#Dm@vK1R1ban)LWd@5u{FfNOfBW&JS1){Eq# zsj0XNp@+SrMK-g3wt>W@0!{)511A9p8e)DS5y8OyT>|PLE2NB$ObqCibmfUJ&{7Wv z`$A%YCNZFfGUvK}a>%kCf6=YZtGu=OTEVq0qw&bkF`}elgF7b;W;Civ%}r@kK5loO z(p8%_T6-4Hbnt_B6d+p##1>fq&C2IKV`P!!u`^#x=Q}PJK~B)ORmAG zsPyx!u_Nmb7MiX6U7BQHQ?*xc$KDyN3()g5*B3$j$MCWGolw4oR%c zupuy`Z43KU3+$A$`-c>yGc7co@%HVs!m|-LDo8G%puNCac~SWQyocD1xX+?!pr+XK z8l1ILXdid1*nPfXL4yErJ{pOn8mKy;lc=gmY34e8ulbN4c)$RjE2`T`Vjs%pyWW)r8^Mty51WM<36di#>Nr-`mik;&V0wP_yK0Or zmD8BReQdekyOH=yHz_RqLj2h~f4U!~Sr1Ynpj9PNYy6M-EB(P&3Lq5FZkBYqKfz0f z$jlS~@FQ^LSip=GJNB!7Sad6wa&5|!QM^d7D$vvwAdMk6jRhNU;D#7O5ze{9nxbyZ z6pGac&jUr>0B6i>h&JIv=1^UomLdo@meQaE%}a=iT8cyYHgUw=1mKh66OR!{X&(J* zdQ-I@0(^_Nwo$A<04ah2{m}7UfK%inuCI)mO__0y@QI3`K;K z)A5;nUzWgAS-quwY8=va zZ}-(Uj0w1oeLzN8gNBqX991g%!Ex8F~jTFuJULH2;$RC4d z>gQa;9>`arq`S1Czy)DpF@-`LX(8xsx%uC!1R9ac2Px3 z+K<&Rq>|SfdoH10=0%SkEB~l6%S)@r|H+95O`!WP01BZp_b6pG{_6Pn-})dU1ci^( zX0VKN(ejrOa4oIfV!>yMV9*w+C)Xs1h@a7VmVTpRw%g^`r|@=J5S8>Omy2=wW?mK! z9%c`#Rdu|1{hOA>VN^!?jtf`u^U1eg4pGHN@3?hm*gRi2V?{$ns|Tb*C=&Y zS{>$z>Z;m7TILExMZ8gcv0F8~&iFN2A$JH<2vEYYCW;^z0VP}kL8Pd$7}1Dmn_gYi z(LFK}Lx@9yUJ`n7(f|ZsnnZ4nR4-H(VZ4`844xd6^2wPJ^>9@$$*(-vn;r2yf;#RS zOjO>Jj-qh$km_NXh5$Teh-DK(Q{gm|QKOnNDLuq!;+VdDUQhe|+hBhT|Er}psD^eG zAgvVmPoQ0mY3f(+v`N32^&amiCk)Ka!AdcF8p8NB1jJ$ME`2kDYtzD(zg591{+`nD z;azZYP=H?U!#;^6XaiZy8$ItKPy5RGYX5RY=Z4&e*VV_ffj`rO4{i^*uocMoUTnQ5 zVh1)(hI1+j)*c)G;alW~AXLrCgek$&TiQ%AKBTQU95P^AWInbuKq6MK4v(2u-%Q*C zJH9OA`9Y%8!8(;FI1??!n=I7}XZ*zS_qu?~{*UNygtL`NF9LHaGfhEj9~GsX#KXfa z->rWKOMbG1RQgBCRPvE^McZ#u#=Fbts$lxgzFo8}d4l(6Plc3O- z>QY3%7E?l}!oNJJCbkK3E5MB&z={T4bt$T!eBFR55gThgr4uu zM~ec12y1W~cpz;EPmNm#muF3`Ty4&EOegy)b0*&_=&`;f4!k-?Q9o!r9oPef-8Hy$ zP>PqDSYX-~ zB7EE_v!&o{@r8voPXci_1@H)o#A6gvn%>80itE34EU@$D(lT&RKp6oMb%-8N`N5B8 zXdzpP_ASa-IXT~H$dP_BBVLC7*;$VTCU%Xv6ITlyWzc0W!dVUJz zV1e-M;C-G2u7k^LHbMXXpO*J;P3vR%*!R=@QU>)Ay8Z!)Lp?T^JXq2NJl&o>bYfP1 zI(^aM)}aju;yxF5c|ZgX_uhYFKcaG-P_^WN+s18m3=c)-!1%WJPwm$-M@uX_`cjJ~ zA$fzZut(p3?z14?E=&KW?dOh^TE}sV5?B$T3^6R4h)I_kgI~(8$X3{vS>a0HUKbI_ zGT^^;KFMsZ;#m%Q6^|h+mZ?glPnqay)ENJ-Ntx^zjRKT`@jcyfK=rlKL8Po)*J5S) zAvjZDVyRrbEn4*E-`YUVcEUhA)iF5yz?@1dI|0stkgmnXa47tt=sNZHFtTYjo{JLd z7*>HN)$>PG4{G)T&z_gGQbuU#(DA>%4b=T+wzGb<*RKteq@3+Ssea77-WeV z41TTAFS#x!iXkPMCPPN$n?VbWL646hg*E44!f}Qw7z+}dY3PdgNZ(0GUNTF&^TBwH z&|;szK_hq@GT`(ED#14=mKdamk`OI?89>EH;6(?;p(ooD1*>OpU>-KeVo=5z38TBa z|I_Y8n^X3$`Jox%FZvVh9E zG7P%Q%`U4s8#fR$&N+6SDg5k{V*0RKT3$sPhU2`a*aF7l=SMVH{YPzkA@?D%t?yFD zwA?7iw28Lwk#H_iG_2tK2d`j7v84lIIL-HH!Q)7UnW8i3LIWIqLt>CQm@m{?@wxbrVigC#55$t$%pK zIO`iva~2kaoahD(F~OBWisb$_PO-Rc#EJTlz(wY|;# zo5_k4VBr~U`K2l&>%~-2D!oY6*g!WPg>8d&N%9@d;Dr<#Sa2j?ucrlvAsM4NUrFDq zi=6g|kkf)^BXSPuWZZc2(1T|WcD3R6MB<)ToyhAHF)qG-cO&nwZzL|s?LQul3LKB1zSN6i`@na7F#*nqA-wmI4_J_+qEX{V zLq|}1#MFMCAcLWR#g7(j16%u)AO_a=^nJ3JuxstHhs)CWZQM`gcTQIs2Mr_c@;yQ? zk_UwPjwF3c=+R>miU~y$w5g+h{0#4<{&0AH6YI0@Z<$`T_}aBSG~YfIC)ugsv*x<8 z%a_^UyU-LFvOS+x(8L$%{(ETIA-8^*Zn4R46xE(GP9n;`Yu9Iw>Ur~xKk+-4H;d?S zOW%0;;Vol~!ZJOWriBwm6((zI-@7a&-?$+wh&KCXazl<1c<+bj-Os;^mvL6Le;#B= z>O~V3u0d4%cpQ8X)r|?O7+e`%_ZCi%uRoC|(Ws(*4rTKYAu2arx`Ld>ro!`yDmwD$$w%y838K?q!ap0|cDUS*&F8 zszd7pm9q&b->EzRj6?V+M6gT+tC78T>DwNwmoCDQt(S|y%?Yr}tT=)UE?8v*d-3pY zwemZom>VIj_klK}G(ibmJoG2pDKXNW4unigBnsP`nI*=^%eYt4RWVUNpJxPh7~w-2 zr$WbO5%^G1lMnh7x-Ey2voOJ4g_g zR9+QXO)*1FKhOxp5S8%CBxv_*-eo-MDLpz)=gmlB*IE-Akx@G|TRzWoS~dw2=2%xzMYmg9cM-%-eo+A~tYZ&3(Jhj9@OS&PUh-y2dwZ;9LZu2IL0jDBP{B0(VD>GUOE+ia195^>Y;M`_f z4*2wKa2M&43)Iri-JYp#1=^Q3syTNmrwALq7}}tp)W6icPcJh$<`_Sz0Q0;Ykv13tu1SqsGK>Ls2tr_2L@!CBvaH1WXtd% z)CvP@1Ovq_&6q=3^A`(|md(OY=6$M2!7v)r9Rgf*ErfXB@IqN~6@V(|?53qE{>qJ4 zpYYY#g0tOY4!g-Lbzo+WVrXr&mG^6o*>qv(Hnnlt-aT!m|FZ8O7c=S`_4hSM;$d1i zb_IuKIW*ji>PzHIMd7Y=!sJXZcxlz&kT5~3v62|Y~WE*}(zKuWZ`<$kT z$Pnxbq8}`2Oc3aWb5t1fnGWME6Mrb3R{VD7+CzDR?<^+g*Yf!$DG)7qwVo|Zao&LK z+woiC8ri0|3}=DsJ|RV)45!}zCi(iDcVCq;ohI{0T{m3`=`&Bk^X4POOP6x`1SQ~H zXC{XkpsY3R`^z=K-U1Vi>Lqud@ZtXFbJS)_QD|I~71qG`HHavU;aycki$9TtJ1JO#^>T~R_v>Wx<48Lggw z+`^_spW;qDKI$8L5p|RRlAf~9Beb!FViZ8s-KX9+vD>HKt(}+>tzd@NT6F)hBl&qy zkS5X|UYLzE-e+~4dU7-PNvFzJ5)pI1o=NS~YUk~Zf3kzvDn5aPlrbalnZ9esZ-+E! zo~sKi@_reXsmW{$!lEAL2;NsbX9fTza8MImZ`}ys?kY*hw7lIiETG}P*`Z{iMKlV%T(wT zR*kT)L*VU46rF%-x)=ceo+eUsjoo8Jxj-DzjnWz=ZxkxUL*3uqmPi+|tX6)zKRMnj zi9ipMaZ8%qL|BQv_8#hOO3FnU{wa2o_DYm8=Jk6;{*vIjaDP}|#!KG_f7m9DgI3YL z+B>EVgz5>J?%(w44|{2ucqi;X2_bVIJeeG{==OP{3LLrc!{U4jozW#LZ>QfdVh16C zUgBOfNnuiC#rH1Lr6wH5;(_M*(<+@wSjuO*id~=n-0XbvxW{f%XB`mg!KeBeSwb;& zI^QcNW!`plH!8GJwkT@hS#?C`xK1;Z1o_)PvOoLk(^;;&DdN}nL z99~ql(h`c6>K_YLY%H+mOxcDkv9D?FGUo9G$Ux;6AtuZKenUhD+YNTj3Q3(!)i$Gn z(@6Y%t?msko6_ezMaIXg*N*7hC8GYyXWqhti-HsOmGE4l`H^5x#fn)zgOrk!{}6I{ zDJ}L2<7L~n8QHEV_KY`@HN7CAWpP+O?3V)O%c&a{vtMfHk>ska8W8q)?K{hW#X|LB>c@Q5hbArFC=kZU72uGStoondC0)&XpF3f zkTRw8ky4JHIKPN$w~<6t(RD%u?M#Pkzpbo8COV1l&_|NUh`u*?_``lg_y0!ZGURdVhfuOeFMhVD)oSvER^vV6$t>yD&UTLR zABU?%BmSFL><{o-E(P0Kg=6OrG;q|pRkX1%u@rzzWu<&SLXc7j)`efOxaO*N6Cuea z(#e<6@DY|4glWS1mefx}Un%P8zLGW%?#2Wf)uDk^9Sa)ohyZ>u*>I#+Pb(%T{1K?C zy}aFAy~R6xR2#$mn9~HxFA}}VKWm6xxiPs(PYBe0;QI|aCV(lPk0xF(C*koZ(an>F z1v4$Nwth(9DuTIhN%8jTWeW||_QkX(S1kwH8=S;YAD~7*%@H3dNw6d{Rl!mP-sAOihV6jK0VHZ0(UsD9v>Lyxm_@2K+ zsxF)on0`U{HNKJI7rZmsB4!eF&J9)lE**Lb%fNDyT$fYjf)p&b7uG$wqlCa?iy_VT zCnhu#hLH=Y9xnPH6DQ2Ro8_?^qQ_GJF=1;m639c}!1s>)LH4c9`s{mrqf~o5-o)zg zLLm5}_Sl8xpm0w4qDUt6Yy_(d9XME$%L$OR5@P*G%+K3?JmJW+iAMg}1qr=PZ!IMG zQY*YoA^k&Crko`*2O|hCXZSNcpT(i@D46!h4zp}VH2Xz`Zbz;u7;xC8YKkshsbKaZ z8AV!_YWFYm&s8cZ>3D=fA)Un&j#GV%2+V(Y(l@~HYBroJ*LkEV$h zcXxLW9)d$~9wbQ6;O_1c++Bl&puq|5?iSpFCunej6D-`}{p#Mjf2g8r>)GAup6=79 zPwz0jvRuh7qeu>iV|m$0l7gSWPVyyxOjS;HTD90?la_m*!$udr$+ZN?OldLalWKml-W#rNcqZ#-fo~)-!%EuU31N_Y^R$OfT%;@UK~V;peadm>ca%a zQ;k0`Z-ti235oP!~U9OTW(K6G&td#A+-^n}zfRLtwtIwDk92{M6>*?Cv!6 zSt2SzP{aUHV8r@QcE`6gHQNv>^*Iv_4D64+q(N~~Fk%t5naCX*((FT#!pAaKvJ}b7 z7~bxrbTlH9f23;(Tk_X266!ArNj$a33aJx%5J2gaB>O^^RcQ(M>f5`f;SJXRoBXjn zHt}|eW|`em*`^}h@rNBVA*2!i(M46=yt5_LnSZ*V?C0O_Go?izB?JmLYa(EQLpw$C zQ|-@mBiXRvpom5b^LcDdr*yj!NOVf5Cr(OuF{p53wc@-+RW1$$=tf&xON?gL^j}v6 ziIi*m1($E|hi;S~+}5mgDq>*a31*q8Amw#_4`1{}O72YCzI5{b^3(g4Mk*)Q#cY9;qlog7w>#QkaguVjZg)fC9(|V<(8!X#;Q;pS9}yNr1UiThjz7BY zzYB6Zz2`i042U!|LcnP7@|cLBrRaMHDW{GL5&;V8p#d=|=z~5nF&ONswQ~5R$k6IT z%L7Yenw}G;U^k@T*WySz+EgG=!5y$BmO2DU4KUu*^2PeKCnJ6FgQQ7e36B(tC+6*e z+aiezq5{umZET+N40= zai!}&T^8Amx?SF_S8EY!P!oIPid6hr$Meq?o$=z8>`kF+O@uCRBPPg3 znpB={Ux@0yPqLl#D+Vxr%hd3)NZ;7#<;f6TA}^z`nNY`^G~RHcT*Cp|7R|SX9->$s zGQ-C>dT*S5y@4$pE!#!ezH4o(EXlZ^A=RV$rRw$Y(n98pH#g|5e8giux{#AvOQ4DW z!e1xkFfmH8w_bqKI2s``{qk|ghZkys$H z*0$F19plXj=?9)3{+^~XbXJ8eGfXTw)%m}buuC(=L_|SF6oH>q!G(KaCV`TC$0YG1 zEH$#lTw0GTyN0HaN~rX!`7DwgRUt@9p@q2b6V(?3lrVGoiXUDJsCjf5ydq;kVYpnN z(VyC==%ldgoX6Pean}Jj5u*QgXdh`+?c-qF)QTr06wx%_i&zKFRmc3Z5zM zN3BReKzz%SU0kLse_+IR=0ItTG!hU{bi1$|1|tNlk@I(#S*4^JW0DTmSK20Lr+ zU}nB)n6i9D{>oI`c$roT1{9pRvJc3~Ut$0BIMBoY3H?JbXnl3TgS`|A2S*`{3zHL; z9K0@vx-rxED(VP9UXhg~)PacKW2!e;zxXxH2DzCaoIxxRlkx{qOHaA3(H=fzLTwn_ zlf-FLtB69u4pYJyx+zW8&cAN#-Sm9*j0{WmbsyK{tLn!V5_U~KjW6^28B~^3wRE&u z`K^%KT&pKEPeVx9Q{7cP; zAQUfFg1woEaYjMhibVS_Q5*G`=^)D)1SrFrkZ=K4|~bplGx0FxMA7a3tclh(HjFDjpc zUTHt}G4P>7SnKNvf@#flB$Vjo(F;kCLma^fN}X}p%^LQ?frfZ-Z{hJtSpu^?98e5l zAcul3D0YM!@D7_V-!u+-vxII=e{b(D>^+J19i+F9T|T_h?jyBvp2tM$%K|svHo%02 zkK%HkG7yWRhK3gsB9b&f_VU2WIe@M9PqO8bJT*gj@wAZz^wbPZ8m7fsedr(5)Url- z;H?tBzE(+8fBr+>MPakKz>MrjHb#w}CvuE`9AgAk+S!RCd4qzYG9niQA`2X}jd3+7 zr495GZoK70d#XbJ&j1@ws_85Sj1ubt`O;tt`QO&p-v1g}$cH;78 zwfvQ?){budbEa_jBjQ7YcXHPE!zm*uj0UHhhzi==5Gargpl)iE6El=Jl#g9MF75IQ z2TjPXU3awb2Ub${#^*QDu|O=Tg>g$AL-b-Z!x(`?Z(LKhX1gsDN39*+CC>Lp!gNS) zQja2df=!5Jv5^*yXF!%&QeA?zAfndgwUI*pPy>>`mL7(6%TazN6<6^SMUVwf|L3S+ zGR%$<)GsQ({`6iT4Yb5de1ECwfyzGq2SYcZ!QH%?`GqYSthEZA7lKzDb)w$?I z?&4hg6!tCIBH`S_t=92V$>{pT(;Zv;zpKo54($Gxgnt|zINloinFXMJ9Cnu?d+3hM zSxitPii52zAb;+F^!OM62C6nf1;qDhtN4Kg;-N%&oU#JLwOg{ymYL0A7?7PYq7cdJ zgDfTN8l2<+0n0nvO6R;z9~HH#(Na$PRewfHTyqcjMSfxrJ$OP@$X+s4S?ZKVc228S zwSHQ{@vYt5#fJ?s1rx&|K@`)L!T^Cn=gJ6naLbnP44mwyk4C5|RAlEP>)jYLO9&ne z$W%?euYUrlRfn6FwHo{RsT96z;>a@c)w$kB9V=*~?~nC1pC^;-RG zTYNv_OkoS`EfdUMz_UBgbS=oCH3>$kZw6q8-G^{4wbQ}K|LcD(PNl;{4{|NmXe!R4 zvyGD6xzMa-nzj?g3Ql5qOK{pjVBo`8vw&tC1D6q2oJeqp6}vm-m+81*ri}2kb&&{N z{&pPX9Lkmr(iEG0DF6NS!2O8o2+ha*{3j)?KXViW>PR5Nu^=Os-nU^2vZm&x)IQ8} z`Ghg>7W6)CMiz_4$2)|?Gg?_-3uwBbjgpzNr6|ch5HMNcye1!Qz!hFxNL`4ZIsR3! zwkOw=x}VFtQlPlJLm5!>?#&MgfH0IhQ(-=a7L&~)dw2K+BM>87FQb{~LUSjCOuOgF zqdrir2|Hw$2QWn%puzO39WYqgWLa8fuGvl}EpcOgKdKedBT7ad)nUkvzrjHHJfJAc zjS4@}$Wd|ad42!4dv+O|_pSEUn|4YSb0I+C_eIP-s=`h#Bgg3bzV}tjV+#J7?`*|) z#9mohQj8%R#H8w>9YhKnsEdchMmA__+z4RA>$Lxi9M-T$=oIc3jkZ;VqVFw>_g^CE zqzFwexzL!N9~Pf+6ib>XJELjk)c@r%#;;V`6pNVY#NN=r?>GE!9t(zwgXd z_2lmqwW_SV;|wns>K_w2I({#2&xLmyvi-KMnp|D;Yvu3GY}?H2_+)86Y!|L8yFf6L zv=h7G%DbBwKeUaH$5T3nZO1eEz>{T(le8+m(i8`0hDUL4vh(M&ocPpypvikU=)lmD zLwvhwTX86F7E1Vceq>Z32vkuIIxR`BavfQr<*p~C#|mL*f69rcWI)SV6y>$92r4|C zVE!T0G_c<8A1=sPw9q&bcBgg>>cH_xVkH=Kq?7zJ2e%@kkJ;RCO&}>@A-8u5ZL4fLtW&C zJv1Bj&UG)|9G}ey(E0Y53=E&~-J189FI`S1molHwzASG+(btwL> zZ6|0agP;6x0zGLo@iD$K3EJ_tVIB^&$EywRUsH7med-J@ZhA~q<$;2%UP@HnP}Nk} zi!ec*pcC*!5eJ%Kpng7@;(2QF(s2JbcO9NxyK-Vpy(wn9jqYhY2K~ha!nk?PjY2Y? z6nbOwT@+bNVnM!U?GYODd!qYnaNo;K;HjB}KNWzRNEt7QQM>n}U`to&zxk4Q{4G9B zPBy=@7`)HdL`8LRS8`E-U##_UZ5>J?nPViFC0<<=R?w%IH<3LNn8E3if{qD%deeFF z9gRvC#<@~&k7&u1M=E(ATj|#D;0Nr7%S^9)u-07Psx@^RC~|Ohl3M zg<|@Hm-`#PXfRDh`?n^CwRLUWGHR`;r1f6D*!D(r0`xF*{w?%L_Jm+pImsp+*<4fI z%(e28Q&ID1{9~5t`^SLhuWSc_?Dw^x6AsZkB&mLpsedTtq7j+`Bnf1nhFnuH2}{m| zjvB`o4>?J1!F#CA$Yk49mdHnvE$-f0>Tk*rfIt*3ot#&RRJd1((@Kc=`ZaMV9x5~N z4_^Zj@i)t;P7;r}<}i?(^2w7|PPe6-soPryx`Oq}YBw~C`U>=Q@s8db>oAZ9;MJif z55&HeScV^UUy{CJ&$b+8n6fxNy)0?GmrE*pZ=}X2*xu!1$zQ}j|GA7@I(9ReZ#Qvr zP&6JDXZ{3NoDSJveg@v0&|QAUmDauDQ6++wsU|Q2Z?g=8?jLn}aL>70)tGYynX$2? zy|dgP90x(wm|wdoANB`pZMKw236w^7ITH)&{FUIHHl4`@Qi4Y0wQirP^#X!Z^afFu z7U`UA-?M{b7s#Fgr87J-_bDQ_*4McQOhQgAFFH!I)(#mBPR(lKcFZjutUzHW7Q`e= z+A1TyegyCJfloOPz2T!e`lp6Rt<5 zR3Ru^-dViZ1?~eosrXr~KREI-r&);&RI`2N;wA}_g#wEaCvA7-UQId#Pi2}M8vW(M z`XzFrzAT4!W7V}RuWzWVTOTe7_%RxiZ$24^Z9pRpyFemLDJ{X$^kKVd&L5?^Q9B+> zpNH5q+HKM&3q) z@i#&palVkBZ3VjkHn~q%JUL?&vR_Hnih;_SQ+w}m!L2aAmCCPY272_GCAhojdZXyO zEXoy!Hf(NWR>Yr>c7$UkFmm|6g}VvfIO``;(UN1+?r<&BUHqQxGCxSL`*GpF43Cz+ z6;^xpF~Qg0xkgu(cB8VP!@?o+P|T`9RWH%#6%R$@J~j_;EJ6B`4$>OG8>|A4zn&lC ziV%g_>`dgBL5|z_Wy6c*x^l&J30c%K_$ZP1_;t9z!=F$3*$X+A3u)(LbyiN*<&Mwa zMU@zGC%@CgDY^Y_nXA~Nv-K^cutGmM924|Eb~^KO6DV}8O}GPgY_-BTQPCZTH&5rJ z2+POJZgYnAl;*G1e05Baqf?0BWc9Vx=$8&Jzp%|GT7EliHuf@g6%Ey6RHZ3oINKHb_;g;g84m`RMh-Bfde94?ZUhJ%9tnXXO>Y;UB z{NMR;5y5b}=ZVvj&ZHF43TyUX`E4w24+R*6!ax-8hHU0j$&Ewku2d5B9?GM;HJ?44 zN7<|X{CS>qu&8*~b)Uv|8M@BeUEx>ru}*jQSz(sja3ZJaqV=wPO{OmKqziTD>+KlL zyC2L77B;0}X|QZH_d(Jv{!#*kb9D)=;H|B#F-~L@#EcJ|(y+1ARwlXo)OuxYNF(5p zn@oNmth9~npqCBOJ4~p4b8fdh7N?e{ZUj$+MW3pZs5hK{5lfu*eC>o~ zzcyhV{OG3D`VaHmZEgPGDikzXFBT+O(n|1y!KQqbMU-Tn;d@)yV`#O11pBI_P74>HC}Ko!*SrBYg)GgKrdmPTq_IDYL2f^LzzcMuKEzHcD{q zm(4zUs_)cs2_xBocad+=o;xsNpWIjS$Il)`f87&b0gyLaL|$m(4-}h5k?yW?j0D^ zEPW3jM&9_gJKC#|ShqEvqPBB^eTc>FlakMlg21SPm?AuP0o@k>@k>*>vf`v zzqm`I#{Q|g<*{SH-)^eGp?^2BXEE;vYxC2#P7{>}!YKRq0-~w2zxfH10&mg`M&P2D zry9cl$rQQcA?&t*>`PvyGDnCH*Msjs58JmOQ!gG|xgozqIb^H-hN29OIyYy>LwxDO zoAb%ICQ+g?^Vv;#;{{+#Cwg#@o!$fbZ=R%IaR)xd6b-wsx1a4%#|bDVxZmyBQ_5g8 zYO)LnxZs^atDzrU9nnrwiObw)O195no>_$A-qT{I9;ZC-U%{GX&>-be3Twdb5_OV= z`j=ccA zb>dU09H`rkHem0&_Q#B9wxe{i|=A%z;fDU_^9U=4vIrUr4ONguAgSLz%x zkWV?VhDi<;Vic1O5!&!t6~zCj-K1&`LL6F79ck>MlcliDA8|J4)sj7Eu1L3#gFtaq zTZAYPjF8`Yw|`4H`wRkqo_>4`;j<7+tO(s8+LUr zR^3mxK~WHu`6Dr16mdjo7h1A{E!JNTU!60com=uWiITu@gdd|O5Aahbq#KERJ8-(M z?mZr|+W43D^j?Xz`*xRO9rJ3#pKaq6UW*~>4k8U9PdP9XZ?Ag#m5COi!q zSr!6&PXAuEHb!LGay=Wyz)y-fHRIS`&95s;J<6UUFQu ztNMPT2(%STW)Du9RZAvn!ea)}-ThaBYSK(UgQHnQ4vGisC~UGjJ0a(^EwQE`l{X}i z0Mi*qzwtkSQ|pP_R6UOG8`&&4;l$Wz#}kKA=q?3dM{^bTyM2KHEgL=l=K;q`BF#xl1P^%0iV5u!Noy7{DIypIvU}J6ZxrYO%A1I zrxNoo2irGb>Tgn2!{hSD7TPs9a(-kaq!zKttB17lCJuL*+cj2&oTgw;@!)*sf>b3O zB)nm)|C`P?2Qh2WPkI-4-o4#1O{)Zd1-NTVPMxE{FM@B?9(jX)y!Et%AZGNAf z{cFAEa#_)DtXT}x1{PPSm+5^YtH>RaAJYA=TX96?X^exH4w2_2&qpZId6dNHt}N1KppBpj6n(GQSUhmavUDdTk(# z=9DD>-y|m&c*bJh#3O&fPLLu}$M1Gm3MMy(InfxiUsYEYTH%-BKmxn_8v)qeA#Rec z=W+}194NbsoM>#GG23*ED{KHm^vdP8g3z}?H?Nnd7cl|HG0BiJl~T6%C2s01sShGX zqZG?hs{R>ow}8ueJxr_vMRpx1Wt$Y#ZtWDP*BA??e_r@YBW zbg18smw3BF6aFghE-;!#57Q-Uvn>9`dW)zNCDga1UK7M!=W6P*zXR)n9X+1Mf~06; zBGJVh5S-VyNFw;he`damT+xq;#S}{D%q&5%AE;m)G#r_hff%r&+TeEHo5r53Ky&qF zIt=yqU!yDna*O8mlKAr@F4sS9pHY(U`A^?`!^{1_?<6^VY4S>-IuBp2{*_3|q=?iz zNLO*zV)=xctq|C$nZBVWD9H-zh!O2MXLs|N1naudZL4Re|5s%9n~jysYV+83>8~mj zp%+tx8^MjLM$NU6NxlFNkl9^CoK3i-i2mN~%qhIPRcwss?2?2&{#4)<_h(p%%;zv& zNw%~%2351;K+rwbfLdaBZuu4DaC?6#QRAZxVsHA}Ci`Fc^LV&po=kwB5TvP-Z`RKb zs}3HZkd<|1A9FFGFi;wAW?|%=f4?Tc;czUoQIT!~0U3`R0h#+EO)TOZn!GrW($nPH zgT)2&?fbuel=H|{H5jlCBKB@XbW12zq3b4(;ZIw*q!>YzqlIa@$~3qtQ-%Hb)-^6# zU*g!ExtF^-SassW=u$FkLQ&9?E53!RiJC69Au{ZqT0T);IIwB`(lu;FYtXq_uPLCi zu_o0uG^A>i*}yN{!}h^jR8VI}`V|rY$RQQ% z&mp?gkXi}*G@US?FTHMkPOVxL76lST6t5C0NE8EVf^6db*2s~%9;NgYIt$~(c*)RV zbHLptaH2#|k|9-}DgUzTc78Kl7F7Lf`mCRA{N*R(azbGd*M)+RL2Cv8?CWgS6)|j(|itose6G;Wzb4C_64H)$sB3os-@r$!Q z!@QkJaS_|B20NRG?n*0BuW`2i*<_*s`#G7<`m*p;^ZqgMH$uL7>2;lC4wCR+b)`3j zb2SOmFEAJ+Z5c@wi>QJmBpQn5)JbHqO#0yH?@fyENmjJ=RK1#zV}|-GDU*H&$ za?)Zhx%Dj*6mAa8Q$#ESJ{8f3`gOFm{dMyv@Hs3Ro_F1yuzx$lKi{|F-swV%9b80H zPMw|YhX*p~h!P#oXbR(vsJFk;<+Vj)==7O!?(W9Bm_G@jqzKX3{-yo6$E#bC=ALaz zFGN(&rCa!z^DiW%SELdOVz#eR9RiH5305l=#xxyk8x;j#F^3WWw@43_Kutc9xTa?^ z5H2~Szq#Z7&{0+2IPiO&CbI~$;*jlnBKw}UbvkCUOn*`oqcQSOgUV>Ph-|iXN!A+# zB)x_vbJ61zF>~q;m49bYhGK|`JuvBER+%UZrczain_CAUVK?p;*HL%F4OH@n9$oY( z`8zL1oCNO(=#CYJBun^%`chnusXMRr#$Ffia%tkiyxo{GCSFq!=e*8_MgQ;YwpkJ+ zmccTG@NO8V`glsiprd0lExI6U!LHG0@1l4-CVt)lRRU4R0H2X|>Ri|6I8{0$)|71V>AI?jXZf6c}*Po zER3pOEY+W({y5|ruv2TlgULCxEx#t}#DR+}xwMYgJwd`E6@4dGE&HChQNs$L!BMw_l*QNii9iEcZt&5m^G~UVC`Aa z;I|&3_pPNwP+=SDL}9!aAW(!!NO&_?jl6~~t5w05s}p&F%mZ0OaWax zD0%_7pvs>Z$#B)pxMFO^-+hGQ_l6GdmS>)hptyB6e1y)_iIRD7&^(0fspOb?;n0y8 z@)k(ez^6=&_YB+3{sD<-1l@n=i8wj*-%Ge!x!jd-z(U3S+b+2Dw^TILEG2V|m3@IR zns5}g{oSsoU)4?YXa%DTn8_p4?2x#j8-Mn+ zKDKKoCml|IO_O7!-4b^zR}2Ct6m|?U(oy%U7li#7|mHWan(ilS{)RnY@&6*y$0oXCLo~;p_Nt@hPVe&(3^AY%7j}_~>wRk_#Z9yv3Cd#`I;}CpIP?1SqQ^eR3R$b` z0-vfw`=UXcPYJ&~M-@JgEo8F24bUOvy~}<~FKf$Jn|hrSOlISL5-;duyc5&}v{hVq zt+t$!NmRI!wbKqIR02lxNQ;;(iz8xa z26{~RoDTNj=bICQ2{d`dfr0}uMbt1*t;A=@UXL$fUv6FAF$W1uZ6G;6W%P zX9oKwDl6z%LIuu5aaG-nZ~GEe@4H5 z%<%zu#iSxjSzm6(NANY6uUm(wH# zDIOv@K|D+NJ*{-j%s($Wg#4)56NVdBdvB)-9wxt-lLe)RmVY7arzY)U2=FHw;7|M{ zyi!C;Ya|2broS4CHo>&P)whp{awXK#&!9p9o1Gmk*)|~F@}8z1@0~_Hz3v~SGsWS( z=ewwP?4o{MCjS$o>rnAeN0;SA8DGL4M9bUfCD};zS-rpl}0rf-Q?HHO$Cd6TSN-Wc11{c!;kRU zwKLn?j!umd`^VH9iP7o^T_*Rg-cHl+)Z~7CtS^P5D7eX$c$|sKmH4`$&NQM@*o@_N z8%W3dv~K!d{qCC$>jKgEC(GoTWO#mfpe!7S6_r?oAJynm`gbjPKK+o-^RFBei80Hp zUccV?b2*{Jg6TQGw|?!|m95}v&E?(l!-C!0&Dd6S2S6aDbUX&2wiqN;aP#Msz}+-=_K?MYt;_oy%yva)ReAE0H-_m#Ct83&Qc&c9 zA7rbfoZr*RQ*x81$=*%c4M+=Q>LxIbJ4nNE@N3^bh2)@GsfVcPPFsH+czJs|brUbi zsLetP$q!=k+5saF^<2fV!mlX>mVm#CRg$1b7}dCrWj+eb^`3lwe%4oqr*~=6ljHVR zu9Lo~3H-5f?ewZhQ<)W^Ic^~lqe~P64aW?Qa?8uj7aEG3rUBy1bt{1fKo% z4{rSO`A9ufn69}|c8E=T`c#2&H`4pJy)g?VVqGUQ1M(gWRGZ=qaiPHlT;To?3A!65 z9Gcdu=Pz|;qEjBZ92WKX?X4{qtt>nYw?PTI-k;j#apvkq^Y)ls+pfJPK@BXC$09Y- ztHrU9C?mU**5f7>tmq~sQJwR;RW%@e$Ggp1Aet%9fGg=JwvRL3gyOENy89!63Lz1G z;WqXck|7m*nH`gHF8~V9UO=I#q&s#YuS8>y{jUMENZIIcE>QYVAlnntrT1+w>});W z==mk{o99;02z_^G)p4xbD~P%FyZI(csIXYxWN+{2onB4hs_{<~=GygML?OV9ZeI-b zTfAILs=YuVZbQN;fQ-n|ZW#w+Dy7|u;?pD7{dGhwUHy0}ix~u=5^B0wHvf4kl8AW- z@l2v2Tx~xUACj@zqU#v#t8t(=!j`A*22O%RpK6$>7xvhvZ+K>Os6ECZ$@b+iM0)cg zu;0-R?1DJI9YQ;ijA<{DJL$lS7?lfD%+|#r1r=-T#HU&JL!wTp(DageLs0H**1nje zU%cvqDmpk9DIxMHcx)bm@R}5Pfsjs1_YS!QdC^?w0cYi19zo!1T55tgFFZWu-3?a(sy@Jg(1C6eo&6VLQ1v9s`XN#! z+A(nlFS#-aHmtG)tJ9AIHi(WH?*&Apghqox=SES)SKjj1eA1czDpBhvb;SC0!@{Qo4u> zd9b@4b2J9d7yhKfq3oJTCrmC1uv%h}|F`y50JveGMlm*MgKr3a}K|Q7yRZKgYFOcp=Bmkvx0v zZ+qR>dfdO3nd%dLEDckGp1v(;s>211xFJz?^d<^LJD!Le|JShYsZp&gXcXQHS;XY& zD(M*+lJ31PNJA@f|%*f>#v6K~TjD`VM%1$+`sY7wQu< z6PkkHz7flPa~hER6(`(+nGdB7SYav}VSKuRxHo_^!miDFGv^AsJZ%N%9D>E+M7GB$ zK^G&*fMB^%XI{b{yGVJ+gnd9>UV|r5>GJy1plX<|xl7bEp*Z znAB9b+vsHfN5CY4sH5W;84LUO(>u`Cs88?&Pjc|m)=;jQi7l`kFdatSt%j5^E(s$P zGYaDumc;ph=a{)nJ$$#M;wZ85gUZG4p|9<9o6e8AU=M_`9O@rPg=5=%Ad)GANajP+ z8r`M0hAur`l61X&tAbhrlQ$;4-<$9Yj0Vf>IP};J{0Iq(gIN6<{)6@2*+f~?f2^`) z3f_yIJM{7MQV2!&e~WK5M2}+^q5y!Un_UJUbtMt@U=k_vAFZk2_FqwqzT0nzTX`ySOQ(U0_F=zcw$|g9wtoR9P*ptN*B0L^Z*9B1*&Lz z@(2$`Uy{FdD-3}2#`>)M)6;iECOP8+WPggP)dq8U&Sq4<%3^h|fajE&NOsEBO6{Y_ zTC_K<{&8T5FSv8C-vIIdkN{!{Cmb2E9Frs6P1vMfr=BuWB!@I!pqLj+q!_6z0&x=P8*SnLP%69c93Y*4bdEW<|k8B#! zTeh9yF8blIDpD*phN)A@iUghlZBpPEDeQ>0aY$1d7hUS zl6#V>DwGgd2qF8}mxag2QbvGKv{W1Y0P6T_4@f3ZD;{yky;WQ&f#tQKeTGmS z9?Gi?j& zPBk4hu3#A$T-4th>J6XoPPho))ah7e9s7Q_xcIzlnEkYUpW|m(ALg@V&{1d3LW#2A zRcBCgG#g5# zTsqxr{t>EmA`xELrq{i#^KN7DVSL=Pd2r-B3)i9k^bMyC$Ihr|#RdXP;j+tl22>+w zi7Kt6zb5NL-)Rz$w9EclR3Cm{ zf$0fKQ_Oa$8PUQ3rZKH}F%3;H0*aWJdM`B65~DrTF+X5&QDA!JqF4Zn3$=u$L9^md zzH8HTBnz}n*s4XaP;9LDAXq?o)Tt|yb`h+hH;5f7hP>JWjL+%47c&S7o{_OZTNsCH z!Qju(Z18`AsUoTtq3qP)LQxD)bVPcZPblRJcD|_=Vr$eG@`!66keEPrZF#-t)4xvK zK6!C1WALeiDf6+Oh5q5o)2GSh+=`D}&(zpUH>E<;CS{jwR00f+g@FHZo zhkAySrKI}QkYD{$X)+_-EA0W9dxE5)BwtkIgEd~o^3C{o;J&0=3dVlD)4Rl_?dgaN znDW;P-1^n@_g&xAH0F<(bsaUmi?%Ys7swcrVocT{#z0B+Q99GuOYjyBG=|Vf%Yh7E;j8vU zlVccSD0RVSx4`@`OF(@i_Osh-&5Js9KPya)h*w z(fL@Ry)yrFUs*i{yR$aN0nxE(7O)r^O*DM8c+Z<&E~LM-_C)`)Sa9!L83V8w=Mtv^ z&6Yp$piNVS1wRu4c6}i%0$T$Puo#-h3>eVJIKK<=5lq zm9T1;!)ocW*kblJXSTp?QPY8D_c^m9izgs0YB|^XK5qSsz_It6sV<8PIURHR&0Voq z-!PCMs`&g%YW2@YjOaHwp;wt2r$RHUyJu*44) zip2Ct&)J}Kf>~r7Uowt~R-aCG3+X{SK&^UvoBz>5m785`iZ}@Rp-S%Olv@rYc_x&j zV7=dCtG-fUk%&i@mmVRt&Nq2cuD!=%$x-4Ge@`hp7;b`t%{QS^vD~Pkh)`J2XcBD3 zsg|SyWWw2h-oDbSkNL$hRdwp1eZP9W*DPX&dV-)s>0TIQSqS)b55HI(z^@BQ6^dCS zBGWUSP$?9Kd60vS3%zOa`aviTzzhwxNc7mwDKRE*RvQ~BQ#~S8W`jHkcwgS(WW4pJ z@!Qlcg`>gorJl!7Rn?@3N2Z8H))sl)3UZfo(mM;~w>yo`3vn^9m4zgaEpy+cPxtkX zx8s3D*=fGReV2xii?<@(QL*X$&!T;Ub7i!U!>=tweDg^e+Gt4YoPVR@e+>LML`v=* zkp`HEou(DzkB&Z{f4ZH8GOJnh=!J8ZaPhIrwP~w1y(_O$uGUf6o}qz$!)*eI4f09p z@H(fBck6pJYcVMYbTlct5jZJ2K#3}luqVHZktYnXi6R6YtuqP4-^OV7G!*lKC^;w> zFOyK1Nk*g;6wOQ66uk4v8B4g4FpJHnVHeaNPTh>h3|{&=6gn0305D-9FW}H=xi9|w zoX<3`VQKq&`64L}cR}4TbNu~Xb@i)OS-stZ23E)YJIcwoY0b4mGln{6fZ8Z0A{rGj zR`7gqfef2cUII&R&5%WJVdE*cyvFGw9q8)chIxVm%aUHx>{{4;iz97Oo91MJoz>>bw z`XnWgsOGWd8J)plY1Sezi-6Lpe;RNSo2Q=LdL>FlJeNUk!he{3~7+`H;-cA*{py_%}Oci4fR!sq5`sVgQhU03b{ zBb9^OaJBp@!cFDoTpOSxChUN(YV|WjhlM!Eo&)*`G5kn8e&_!Qcc9+CFtgQ&)Vl{} z1Yk21+KsSs*(1hk`}c;Lc6P6^k3w2`Qj!ZCUshdSA{TzNh(u0*Etk-DBr75PxOvR? zM)H((VJ|k}&gP+S$R(!C-&4gQ`^nL@^IC)gQAYtEwx8*Ywq{N8P2qNJ!Y>d|&aKwp z(TBH{NeL54V-r%GEup`WRlS5}4Oa8Ris5wu$vJFL?M5|&#w2K&e!| z7u0P6ax=0(&-j}z|19`PicD` zT~b=v&jg8^$$nDU5Nk}$<Druqm94>!hP}?R$waxBmazhoBQFS3!vK0d zJp(>L#}cZP*^`)vX0Ah$unMKwtal_5+q#$4W&>62@cHzYiXWMGV}q$r-m1q>1{YV( znWdu46C?sJD!mk*t6espj|2SE7iAQwt+?dRZ4T-q`evCAGu=?BV)#3jfdckxpKT za>LZpsQCYhS7t#A3_YyZan9s!;oIJ&^k+vr?21oiZRN4gbM9orDUj6WnZSXdG!=I@ z*X@*pMc zBkl$v1^46!(H`oy_PXol$z53D=inIH^}b~mX-c6Bh+tudm3g?kAdJyBt_!6PE940jJN+I|vxAs}1V zGAX1ZSt~X4%pCocB4W2t{_JTXK26byhTThIZvtk6G1?>cGkuSX|RuzrY$Z6T-@ z3u%TF)BPCI2FBF|tq~^N!NKDXSz{FkS6D^gI;JoE_Bu_(DaTDN#-8dRd%oPjplmU2RF=^Hb+L!Gj99hOvK=-lWGksBqc=I@9AY`1*IMp}hE_d5N< zV%6f4O%t0>()YK_Prdp{(Ff9XW|Uf4&6JM^{@=plVJnMCVBnXA%1LGqmip^^gJa#K zgtIW*;8?Sw;|Cd2flRgnx%9QY7byC?8fxrnj9v+Q)Z6(uFg_u0$bE`532T33Tv5WY z;?u@?&2i8`%Cor8FgaE>GZu~1cO^!qU`-6pGbG-bDq+e32<-fiX1r{$9dtQk`G z26Kd)$4#Pr4Hc~r_Hr?-5cEQ^iKRLoFU;igaj;-MZVpPpoJ3=9aOL#!yT*g4$-E$? z6$?uC+rA83`!|)CaMqb_Za6J3cNRQYBW2Z!dZ+33y*&MbxqE%NoaE}&eZ z`9NWr@AvOJ`pnVcKl+AYhvS7hQ{5U4rl>-IFj?@<6RSeOI28i;BU|K=lohm?U738; zt-vg3X(ESA5?0VQoJ5_PEaN=63_SGyf4~4WcrvAxPy28iGD=!lc!Idqmak~7HAG{y zcmRvdjLCgaNay5OLuc`R7F<;|rr>;IzV+Q#vkUfpb+>1?21?*D;R?Mc-H% zfA;kU5vah6EZ$0^UDlAzdM`<~08P4I51~3Y`-z^m;=;#F5=)2A(80fP5!I8Hr0!n;B$aeQo+0#HuahU+dtE+pv~wg2 zn{O`&>(_9kxGqH0KyA#U?sUqdS9c-mFfH`gM}BOU7G-^ro^aX%o1jkQ>*rKJSBA^_ zb4G7b#pIsywR>#ImM&f&86LU6q-x+l8V0SrMzt7W`RRp1!{meTU zT0Uk@dYb~iQnDrRp$Q5X%h8L-i?+4eqx`+KAP00-F%payU>lV_fAt(5A4`dPv7Q(4 z8!x$4=7DRkk+5~S%Roh`dG3P_DZH2++cxh{37U>E!s-dDw|fxV)wDpz%9n|6--q*r zY$E@_teyR8>fL=t`mIm$?_c$qf@g2l?5y%>=e=c!!@IUGnPNAmNb)_n^U{{Q0jDhy z8qav?R0E`=Tn^JongvdsoNkiOd-=3M5x}lDHcT4vBKIZ>9#R96UyX)5mA77Z>U>;Vq7TF zU;oziwsqJcwAZ?Fevdb!@h9)?NcF}QuXje}1>qf>Jq{M4?pvWT75pC#*jO>tagihM zf}(&#IWjWTgQftr?Ts**Gj%{bDyZk?F@@XmIAMt+?bU)<@RzPLk|N<&sj%hjZ*vCi z|Gs8-4!~+1k|f-3{P)a4%l!C4uP2561N6Exe+P@7u7`%oi3Pz0<``*{59IR3q$Q*> zgYPN|iPc;a{XqTr>j=n|EHu%Ij4Tq#isI6zP}dZmmqO=Q09#KFCA=i-rHO=t(f)AG zZJcHt)rwWr01ArtNH1g$CUO`totFKSSC$-7RhQV$)*FAp}UqnQ_7Ne(hk`RwtFn0{!anyg(BJX* zlLE>rq_;3hgJC|ysq_>TuzYR9TN3Y#b(Rp7fqQP(f*!%~(eGL}Q$tBzXX}TLBhNk? z;Y|rc>i86(dHulD06wyNx2Ydpa(EgVMSUD}??Zp}NEhQHk&f;=_{zY92C84>Xyzy^DyzegQ<@ z@WiTuU?~3o0q~&hgYg$(Ws0k$yR)_K{~_xwqvB|~s8QVA-Q6v?>)=j+;1VDqxVyVU zAh8`F*$M)W*0!GN~RVZxTqo8M#^1@M42b2^g zS7D#M%MSE6+oWlHbU$&bU*PSta-ZSB>$3?#jSUZ!!Nv_Hpbd+PB4b&svEHM+)}o8R zP?Co_PDJZ)ifhZ_U#n?hKu7|b0ZC#@U{|3i^XqqbQ*hH3g&j!P{B_@?*Qk$h0YBgz zucjyA^ubGYeBC7H-vjS>^r^<>YPDvGC~bqm*>JiI;^x@IO!n@Ug0y6X3#_VC5j0 z%?=q#d@P5h>u6&Zd5A_$AEedB>C`QAx^R2N-q0UjbR2#AYf-YiCMJX%1=l9sI zm!@k_h8cqdMS-9i+D=Ka6fAz}f(1~b(SnTnzg&TS!my(m8i$CX!-(Ac{ySc8Uz;8X zj1YiMTrMPt*c0@hm~$#+c!+CQFj#<3R!ULyNu6r(Y)|bNl_@}CvYYKZ#~#d2RUG`a zj0g+w9u;#Zz(p;YA+-x~Nw8yin2YtjqXAGP@?f?V&WX+j)1)yt$O_{ndfh?&^0}h$ zrJen{xz?{CFfvA??inQ zXEJRkH|oUdeL6n-d%s=88!zta zBARKzDt*tNZkqkA*J6sQnC4W9iLYwhl~>idO+8oZ7|eCal4)$Z7AI_^<~ z6oT)(86W!BlmF|taSFnT1lmT+1cQ(G-8R06=zd13m7fvaN4;LnX=}W*L~BZbtBq@4 zxhL}%r{e(m+j{CRYtDBq4sgpj;X}azc$LS}pDx?wLxe2Ved}qeV1As` zNF>mBM*}(lXx{)q#4=KN>AY2EnCLDhGRE~`i+TAp%9tFIFPyxYEKR;>@ScVo-M*1? z=Fi;u)Emn67tkDSM{5;tf-&2&P+NN9W=BPx((9zBI{L$bifAYOwCzob?Xr{h?RLd% z@ngnhQt^sA9Xorpk}qAm1|+&=7hWS;po#;MVx~?2i>9Is@mNlFV8d{S~bQP#C~gkf0EdR73S=DDcBEZe5Vjf%?;g7l$lfr`JL1aR7H& zJC+3J2M+N60E&`iDEz1^X#6u@|2T_!wDTRyLvjV5X_NeSK8HcN2JIXj?S)Sq0${F{ zIK|#<6QF&@rEw$(ge*ctS5lfK zN;5WOxjbT@m)r1dSg<&91yrF=MV!xH%`qpC)o1cyVB5InNLFIg)ijCP z{>rT(?xzZ%?XhohV9kG#m4O7qOp*~~@P0-I@O|aJY91r0y(??)SbisbjK}6bK4mZ< zK#>YUN`wa#sWkZ`!Fx!4=G{N1>>B=b93INIo37%U`=92g4qxmm?g?GW#Q?gaPEjIs zKzBqII&e$YxcaIKb?iQ*-?&@HX_1_wn|S-6>L(t@6um zN8y>(nfcRnYz)X)f5Q;H$?ppVjuA6;XelRF8zTobKqpC_OLh)V67KU7%**e$=Xx7w>t#v9vpm~Y$%rEo~#NtfFp$iIyJ{x{8a*zy& z$cuy?+ho`a^Wy4NV0^CW1&9SG4YUEn*PRyUe<*AosYegLHm4%DeS?1|8J01a z4M+FvbN~dV3DHG>W(z|%TYez$sk7c)KBqJ@RcA?*Vdbw6j??tM5rhA6K`irzY4G2Wwf8?{0vTT&}Qv3Vby!+FREIgGoBRnO{Q+72v{QwvO9`7DeZmU0{yOw`kZg^;fL2$=9&{Ri2oCH`d+lH0o*#2n@cuu2z z`@1?CxrWt#Eclg0jU7vxssySJC`}>v3@C*d7jN2V$0=upbHD->GNkMqT>I#vEs`4{ zu+IFb_3#DP*o~Z?^U*-HrKl(%2PPB{u{*#FfTGD4+T~j#%x(9LWdBpOj_4?HuK|$5 zZxZ^lft)H4bTmcL7PPr1OS?IO%rtdR;`bEM(oXp0XXmeCxAoN7eITFg5)Jx~z$Oz+ zOm62;Xk;R1w##l)@jB&&Ge4quTVC{yCM3cN(`0SsrA7=oW*@WixNYU08ZWz zc|HXY+(Jk3Yno>F>|07<-JyTRwz#1fZS}V@hqz4S3tq`Xp8@>?bOP8H$X3U0aBw{V z6o@Oc`1Hg0VuvW-e)-VKt`jl|yguItsHjxv&Hu9FC?G!!p_aKJ>i*>!i|;HzBI6a$ z-tB#p0X&EJ8xFn;t$yuQ%H-FVu$!GZ1ynZlg5`R9sgWsTr=)f);0(t`ye9Z4^VMj} zgxWqX_sJq3zDuNI4-8JMLa@u58LoITL|L@tmfHm9P@6?NmAgxk7Z6$O19!!dOPTN~ zyF>dS*jfSDz~Rii-{iCxM$Xw<@OO1`C&mo<&9#y0?29+A;_pY>5|f!A#h!RfyREnv zlZVeTHJ=WkXQNMEptt`6;6f4DR1b#%0It9s3^s+*&+f%dd>Vh@aY11K=hr3o-zNg2-MAkJ#jG&`NiZ&vgkY`hTK9&!iu4G@@Is>O&_0s`)72Q3i2Cx`x z#*maeZIGjg`eOcqu^{|mL0ARTY{@?6$ZeOcMGt08j1|efsNxqov!lnN#I0y;gqd5S4G~YU` zfGGu>_?Ns_5f_MP2DR>=?}P$es#f9b1^|?gi$j&6rMO3)r;7h(T!jLXla@Y`l|xqi zPt$*3082`$+Uh90e-8{7*zTkR@3KA_aTd+h#s3KU36D)Wng8n;0g0J_)D#)E$ow6X zMZy%!QPF+JWQW6Qu`m=7#?)Wa@8fU)mI5#==bfcc-0i00>XLK4a3j@h@$lRE>7jyw zwZnKc7r}T=m~}&peq8R6wG(tRnen=NGU3?Af#$2+|}^Z>j;3<3vk z&ww_##BQS=<^@S5YC^vf-F$oazgHdjzg1shVPqnINpxP_6@;F}R3~Ylnd$QYXfuU{ z0%@J-fospOCs!-D_a1;|VxEAYKNOfzKpO9xg>NhI;}VcT#ma$$dM^0A2lMC|}r3K6zGDLI9xefMF)gx^HW)Y7QYXop*gs~LZ0j^9C`t@_&-}{#zB{yRb zK5118&PEkulH%x|OZ}|hy%OylI)IL*@L6FS5FyAkczhA_O4u!5FF4Sk(RhI$Dr^pq z7w^__M{z5ZJs(um?5#aXoQh0;hdWQ?PC6ddD7BNIsmlh!qDBLXUWbUilX>u#Ph$C| z#pZAF>*nvct=Y(Y_CXkS^1`4VXSf4V1<93+nY<5p-bwt-}EpGtx-fRPrpnWoSZ zeHUz?S*VRrpzd{)?i_4*t)CM(ZAQCiJ=XtK9U1@EI+mL(bN^A$Dt95b&O*Rybp7@9_uXFV&cu$|*BU<# z^~PL196^<5k9So=DNL-shj(G>J$H1ccOjm~7Z}_b2{!orV-7Zy(4BjGql{2=# z*N7BQ8HMD7;uV?#K#VH^8K>IuG$j}Tgc|EFQ?AZewfE-N>S5SfpZq!udz=SOxLdfRS^caT@IF!h z4bf4Oc^{%v>{Y*acGBTh#g>_~G4|nV_)DE{>L-~6=BB&fUU@S0l~@NIjxhFcfSMx2 z7v{YMC>hnvLc*n6z)ut!B;NE)}Eq{YdO$lFN#=TN;ccyd&X zB{V)2)NMC7XfWsN@4Eddf|sF|fqz$)#)gOj`01BlNwyRJ5Fs&sQ=>J4?i+7NS}Sw` zh_5!j9RSlMKr_{$QUwZ#eH{1Z+SZuM)ROn|$O!N5Whpq|(xm_iko||CI)`GPB7BLJ z6PqDR>@xr?SOR2SP0`k9vR3O1?e-H9c^zwwg zH{Q8qij1l zuORta;|YW>dJ~MNZ>pnTK*7{bd?x&6r@atzG>tV&EaLvOI%k3SijWG76m0)L zHt%2NpbbTg)L~b%dd+CS65??F{V&+~1D3!iXjnnbU%7wkeE;#W^mhj9rorLOxO1~g zjxiqNEjcj#>uP?Ap?!-v6_B`FkON_Z3m~#vVxBWa8$2nvzzJ?fUoa^y0Y2UfgDgkI z64(eka$>vaJo}+-ujcq^Eng&ndr!d#m}VqlLWmu*8|NRlTs$ts;ZYV<&4m$#?2#ET zbaIqqn^C=%iKTbb2TLb<$q{U#BKhWNmdbNZ$@)^p>8D6?~6N-Ugys z%9Y_zpz)4T>|iSWwFQ4VS?n{^tH;5g=RCG-)U9$+1a)FuI3Qub5V35)pK&mUDL>3x zDG2Y{=N!@%&FaLExTQ!&Qy+-+9J?0iP~3y&Z=Guw=l+4Hz%T?16H*OXdd^qTG3FBk z;JMYEtOu_rw%-#uKc?{jDiO24U#(0=mF8Xk{@zJkldpxqyha7tuk~ej83@tuz}zji zX9jM-bEE;St^eH*L&KUEVv)WaEk_jxO&^ASi!c(PE&;*tUjPdVxOSikhZtBaZr^Y8Zr053euaz1YP20Z5oo?$r%zVNLtC zZ1lSjz&%BRITET2~z(lQ-!9Ye<+4G)K zl@>y(d{21E@)v-Fmne60O=Y~R%u3Ac8?r3xd6a?)>B-k{W-ix zm_D}8f1H(FS7*XE+LsUo@a_VW+LWIZN{?0${4ui=>CSW9y zrUs99x35a-v-8IF3jO}G&8Yl>_zJ{W;Nr}Mw!&2%)k|tI!K}ppn6i1&E`?}$FuwR= zWTA1p9XS_L$Z956y~Ac6Odg+yhg<<9i^5Z3NruM&U!scBVKcrz7a=L)baq?dx1~03m!skr|Q6hi{hP1+&0B?sNrU;nV|0}oq zuXB10Kh3Naw%afI@AB1|2g`A5l$@+WFWQJ#F5t5wM9vqO(!P+!L=#{mBy%)^Fi{a@ z6Qa<%h)2l(C7R2RIBE!EB6~{$ydXq*%3dIoNT5kENibL-yB-IwQ@4Bg?RWj&WFC)=9C zho!Q2d7Ty~BklnxSOI#HA%0&$EHNN(Fs;iZo{J1Jl?p|SjD=e$pRE3>*jxRvz;_3b zI0RA3ECCK9F$gHZaHO3Ua*D=b>2r%(WE@wN*&c#zL`mtdg+$Wg*OpETx|S!;Exhis zERfqirnuMp*6`0WRq%$aspFFO{sQKpIbybb;J^pEPWXvnwD?)dvYyr{hTFbtYPrYw zut5x*PXo#YnThPRH$pNHtgV`t1F3F2!Vq@);R z?42<(0eUZ$gNSVlgMI-4rq)uz09BkNFM|Q6>5Qc#en@f{eR8rm#5PVUbk?!}p&Aaf zkKx9@d%Nb=Pk(q%#qcU8eHLL3Cd}?WzZO@ec;Ssd<#PQo$*x<}#7?BXMbrl?^tF%D zl*FsRv0@W*o|km>3I?f7?QyEo$ul_*rf&pfey@e044;vmKbUPg#figEyM0XI?r{~f zZVut1DvQfE+A~vQ*=+^G1i|xJqhX9etonf)pHE;X$&Fs_3&jNF^tI$XQud4*Y`8{` zspBNR4$7)@l=BH7wxQ6`=La5Bm6|Uxl2B3{-i%rXocitAmYYkP$V;`2?B}82?j~Vd zldp{kh*Ln@J||+M95f?mO(qHr*f|&N-=fBFeKwp(;p9#~E=-WX{tA#v=QGnooZz^V z6Z%~^=jz^Hm*eJtulu<U1{9SM8 zyu5w?l>`@2v)03BrBS*1=8u~hSlj)Ll~#Xx67R;@>TLm9Pyfi+(XjP&qMn1&nRL^#f;_R zwi!zNPb2o=td%VUX?hh;W|-ohM5>%Us$@@B8M}j@7%5dHJXBjCw@JodlmzGjyElvu zz%Dr0GCD|`e2`%qe}Q@vbwJ7QfmAtjKq>2i?ApMqe0IYB`%uai9e-c&5WH~izUp~9 zJ$R8nus7&+(-s^|&6+{IyzgS+xo+VEmJ5Q8sUks9w~|e8{mg{sMjwh}aYc|3Z1FK8 zSW1iEnk&o!tQ@*K)SG%F3xlVaqL}eY?8p&v1jk?J%#n8l_xI`U>VmjG8r~Ot z3b6yKJdE&)ipd0)M)3st7LbS=L0K`5pz%!;QoTZnZl4@Gq9`T|j_UV!xE+i^)QlKP zaTm?CR>(TqTFk(G%>AUPFhpBfShEN-uAWHJ2*?k-Js&kgy;|ZjAVzPV@9LLR5lIzM z)gS$r2I)mMjB^e$p9g(#*M00xJ{iBd5wDB-@>k-YEDVmHARXq;{8^}^$NEnFv(jF8 zf=j>4kT1RLHgO$-nwd#zJ{Pm-zC^lMiRQFSmlY&}8mmyx96LriOUy$krFKmB%TdZw z(S{l-4Tmw!<)3|{J4${d@R`d{${HcNjPP#G3v?E(XMZtwu{00*%J;nK8MUO4*Dh;Q z9$L-ZJ=+LHUg#z79Db_#=HmBI%W#w%mbS}UMNM(wlC#!6YEc|d0#Bf)M_8Z}OYwC< zt4hhTqQZ7}09mdc3Kdnco*8wVGKhqSSjvP@ErI$|5DB5K0_B*n)|=?F0-vU_fzG&pn9XbJqV+?mH?t_#;Lgw z(XUI&a5%kHU^N(7UWNkuUc{)RlwE}U=@phy?!=)|q`M{fLQOgi#(<-08th(=GbQO{ z&VWe3pU^cA@Nw1Z1}P4OEu7BMbj%QEa3~31S#V)$74?p?1i%YnKr`6~)XeD#!C7Pz z3CC7Hl=rePy&14B-FTyp4Bxq>)@DXOtRoH9rK(|PB_Ej=7bNd4D%0Wm-tzX0D9Cg$ zj$yKuNAWOOVUKF+9rk>9h)81M)+E9db~zIarG^yt5j9lq9z^q4o?RH}!9rlee)ayh z86HmQ@&T}uNJ!TYJs$k5Aw5}JfxT+gFFhN%lbAjf zI*H1gy?!fUnRae4N-H`Ub^*`)=ZnBskB#rHQ?R*_o2z!2QoU^?tO8B0s8FP5;|fMZ zTnKP-Gcy;b48?wZfr#6JGH{FF^eT(E#vBd{>y38e}#!Sgse(}pZ>AJUx z!+@#botLOctS5o{EEGoMQ;YSOjvYwl5e%59g93qL7AV!o(c^&uz23;-_sDFaNJ1@z z509x=u#?-04BR#Jquh7SOctUr{f=u8L-H$vf`VRF9pY2n(KWf-E zN2{Wzv?w0MlGwnLpXb==3=TdYpa1T7Oe<)L_7r=&EswnTJ#ojL5+7~JdD@ji_Vtbj zXRl64(`!?gFFoK^{TJ}26oJPo_5+2+hnbT>PlNX-TU#M5t* zMvyx$4QV)o(Ux=yLg)G<-#k=T;QedFQc}|h*bIgY`B=7d@IKz0D9gTO(CyQ96#XzC zh05~j?u3Ogf@5?tc8D;A(=mx9{KMJB2HRm}E>Xw!<{^u$xbOT$L9pTXIQK$G9V z_|@X{Ke%+oDWL%t?c`Bma!zE9dMXQ>Lp_XT!n8>7NzMsOARLu(}3pWQD=|^nzHP=>734F=2ojsU9Gz6W9 zD_07%5g6WRL+y*a6>l=K3MYbB2S?AF`(d=|*hcC5CWvA!M&D&1XjDH&XaYgwYft0K z_;EM8;I)^cLR!JKM^ZzD7Ly*EwuV`9T$-=TN9y{|Na0XrVF!@vta*Q>n+NE*%6upy zZ@A({mGfWzxe+ZyAO3y0oqL}2X?oR_weexQKx5x&u~NF5`pfYbTM2I^c%x=xv2Qc# zbBk)O7<6OACi+XBoxCl=QtsrG}!d8^oqbGO0@Rk1< zv5-eCd|8*#kOU_Uv*e`gYj5Mt7}0*4P8iUt-NQJzSxiRx1Y@L>%T2KMb+ zf85a?yCTN4WV+(w7@QlAfwp&Y7Y>RwvPp41Te1A{b;mkOR;phy-+NBL^|+>DP8j$* zsR(Z>!I{#M_NS|@7LfnmwfcLP>6VO8aVsYyYLGVpI~+7`=ha}~qc>4#y!6(&S|#R2 z+Q3*Bt#BisQ*3a}rNv1Xsz$g%e%OCaRuRDhJua*uEKOR)VhEcOtgn8&? zSP_yI0*8U)Hn9OX3@GO%b{s|XED8t7Jc(6|h2m?CYFOWAqXP2ZGa~eW{Pn-F8^+Tu zt9R>WZ_VChB5bLHZY@TxhGOtIb!Dj$GO!C2THT9tEN)(?p10I%mzK^+-NjzTBYR!E zN*7O`XIC2_BkXEd``*jgAKM#K)e}8a_4Es{1+^?L%)t!bv|LW4rvE%M*AAz}EIh|Vw^BgL3 z;9l8|Q*-u)$_2Ah`aExTfkmuUD7 zXe&O9f|&FgF(qW%zbYg;MjXK^Q`4A>TSk9j{G??P7&O5(<+XXc3_(}$@kYCb=x0}) zGS`aK!E*v8U>npJgD8}R>#or;HB*~w8(kj#Q@5!siFo31jkEW^+i!%YLFq1Y7ErTt zNI<$0(3sf{nN&rXTp{mi`cvz1NBxIA8Ll28-G|2Mr3=GS2jPGO6EaFl=!#ETit7bX zUvY0wu>DCTq1r(I#|HX-P=+*iT+mo#=pqQrDy*8T?LCdiVAp@)LOd>v0#+vptPVlG z%?MmQc&+jdKaTn^ALBR2Kg8XJKudf&KKH zTkY5gUwm$(A6eP zQtuw`NHRXn`aUmN0t~HiIdoM(2G~OPQyYIsDC#5;u$0!yGoF?oYEx&TS;PKK?{6P*E-)H zpCIMO?5{njDp*=cJ3ty5Qt-(_z!k*#5aL0MApt0*P1{#>izP2DwTe27Im7u7zauuL zc3dK;>bf5^l`cwc`04WL(UqujMGk^!Xs?ZvoY+-ew)d=~?a-yxv%od9rzM&y1(3;E z(z19eRGI^$zg`*X8|0^wg?~o15!KK<$d+DGOO9s)-%zb8D?}54Kl1F^F{z24PzSTO zUg<6Df)qalG?YZyEAjd(GYf^bJ20n{|Cp`&YL{kl>rCMI?`Nk**A_9oL#powYi?EcU(OCdVt(X;EcBRjq5MrsRq>s(L=`WaQVbUfO9&EE$x z+q0`o>}Ij~uk)lg-X`o*P&2cJk2~Fqs<=jvN=IEOD(+Fs+R7~GA-H4wXKy}ALWM$T5l@L(!@^y7`40al7`xbfl5gvzw`);1Xq4s) z7WK1I;lOjMU>0IX%orX-mC9R86mpfY%ijoWg6?(DH0%$nHTlVU#!V$jEH>lQ^rF)w z_AxD6Wv6a7Y=S6e=AAL`mw{88p2kJw412msy)6zoIUgpgO)1mzr`?zBfc+2=YUlQZb9DR^{YO+ z=z+%h>HSM+N$=cR6`%1AIY#R?D=&96=-31 zvy>BT_)o}2J{}cV(nhELGvwFZIe3}v1uB(!Qn$sGCEM1_C5$`YE9#T@WZFtbi?YJ& z;ryt1#~>NUPBiPXTaKg@Un9;Yi;09Xo-!=;;BlL3 zdsUNOI_(g1$X?1hB{orQti^A|kk2~$8JIj3My0d(a95CwjqRPc9D#jbi;jFBP}GC# z?Zy`?&EZwYa^aSF_r($4@TX{1?(OG$w|{lZzOg4r;rn=3;UC$n?KWRMG$s!eR}i}s z7bhvk{Xn!(NbMJ-KiVi^E0Nez{L_!9c{p6`K=0dy7a-a~ zj$(BisyThB+YH9nn&|nipm(7Yl>c}v^iyL**Z!qVkP8!G=T7x6xL2H>{uyfCkfOuI zbx-3Cyzsqb+wRwIx$tQ}tL!{to9|~fc=VA+Bf+0Or03lvboS`g2Ts{}U2$x(EOi)S z{$k@D5Ar&`JlWcVaZ~zpV}a|Z`A>$#dbFN1rigU?yD%6H{HrH21b)S#9iOZcZzG5a zb1XCyw2!m+Dzb$tz1p!oIU0$)kwwzBJvpgOY_A^KVy%y}pkv>zD{?-<_k(@-(+Btx zOZlZHhXsqBDXDHKtI05-j&kY?5N7mH_7+#AA{Bwa@V#s)0(E?o%f}=)XlWJ)GRpHc zX%_rHY>H4XtS6yjiyBR}Jy5~A7Ih#4rjfNNaxwPkqk^?PUfR9NvnZuw@~bDhoryXN zCG?MQQ0XEV|0JD1a~tz65qU?ru6>0tULK~so#E8V2_lfo2Qu4nL zcXq4&7)R8;lCV>M2cj_ZpZUIsKXjc`KDJk9q7Vdm=9xxxAt0j!mX8yQ%HoAb?$fA8 zX%h}jU?F%HPH=FkFVB1j-}KJtsz=0hPvDO~!v87|tLB@zLO$%4!C(6LCU@(UuPl0w z-h=n~{?jQ$BC7;4G84;|!X>{>WTWl8oX;=6Af_IDP9;TG?rQt3agFBQ@M2IyZsQS=xxv` z#3td>CB&9Z;<-IL>deQsnU)!3=wev4XuLS{brDmNd(lkjfYKAqK0`_CX+#&i_gf7y z^#?H%BPp^pEv?G2IPLm(>3s}R#kbM!Kv`(@-x>|Ic{@Q|JdzaySL^0?H+n7tiK8HNy%fX|KWMAOt*q$oN{^N~^p z264c0hK6gMZSDNe=VpsOBijv|xT|JeZQc=6f0h(|M_9z#{etwCuqRq)H)S5RT@u`i zn!F+wyuNWaClv{>iWg{<=FEM#tFI`q22>$WILqUQ55sZU15srS~gRi z37-%-s@dgZfdelQO5V?Cijwv|H-Ra5t>M~K!7x}I#h*+Vo@nb8w?la+@uuk58(iFw!%O`l6T`&N(OgA zw}}ga-6u#J&uKY+7eHiIqp z|0Ga+cO|aB!Pll5G0jnjSP{c-I(N|@r<_NH5He|`A6)h{-*VF-c3WH6a(aGoc0_%5 z3S93*&Zq+uumK{eqydkN^U<^gUNheXU0|3A@(D_#e_$>(8zQIhi^ zi}-rNv-8CdF(dMSg&;7jtX{)aLjO)fkP2C=nzOo%T&VTfuSF1@IEZscwOP{%S9 z0rwSLJ1*KOE)LE`v>pM4TAaSxT72nix0pov_M=0}YDWm`q_D`i83^y5UOo?Y!D{*k@UPSm$ODyhDy=xyB-}|NP z1FIh}P0S=~2wxsd=@}AQV5qEXG-w*GHLWHspU+lHCo|A9zLWDj|5~=a^Jf|SL#xD% z=U(7aWZA|pfHzFky!W}$j!XT7T1j#<3$@ry)8}xCQ9VgvP?{!EL*CQbg6?5IWwwlm zO6}x7YgQAi9Z>0ZMO9l#qQ0sPRna9G=Xb0i*bWqUeA&(cUWTEGnPN>1co{jygl-r~ zn;I%wmCTtq@MB%-mS~BlrNPY8-}cdgl6VlJuOhE)P?Wp}yaGbXwQeoqp(KY4{>pa9 z35YmRNUfduI|ED%tckNpezxCN0+R+>D4@P%6zu@B*~K-&WTs_TrOYOWKa`B_mBb$* z01LH4!zFc8a2YV;oq?X5qg!^hQ;;@E>or8*U|AI1ExqayQ#JDnTf~tR~}nitAEM8cHWxEt0wdYBH5< zpN?X{Ef)QB42>am@<%aTw2w5ndg&(8e|S~xM~%pedtyp5&+0HM=F&xx3rOQhY3aXQZ!(an@V|X4=Gu|4Br~w&+OPZ6 zdDy>mW1dZMWcRCWGj)llCMWe*S%l#aaKl&hEbLiGu?xiGgu-M_H}R=s8#@3uc+|M| zKk|Q_KH6%V2rYuI?3i%Z`uQEeFOumt6V=-OUD0V$E-2Hj_{@u2FWOo|kB=}Ola$_y zbB)t`vds$bN@kTTdHZsVp-@BF$GtaXAnc*<#Cy8PH}t(I$XaC;Q%hLfI*^Qy*x!mb zcv(bQQlr11mD`ndM<&!Xb1ab;%?AdJ5QkxG-= zSYFhnJC__0CAucdYmvKRJYCpIqpFKUXf6a>=m`p|2MtY?Tcyp zkE8wRq_~}}ER7ouui#_APrySvAjGiJe&Aq&jtWXjWne&L>fd6TOi|D*m6V!{|MjoD zllcOuFN)V%MJCf|cjAJ)vY1fsE-k@ab*HdiU@UK^JX(iY0WG4eqeQf=&R<^7Zba){ z-p{OWmuK!G#u*Wdt+{o0Y7LkZxQbj{QS~-l5eT0H=%}8sSfpV}(4>_ZC{?reu)puc z;>~tO$TPUAC>^k#94TO8q711>TL_0l^tg*rHA{=iZ*j5j2jM+-<71wizWGKVh_qo~ zmJxViVG3(xM%bZ{*o^u>8;%|G#RGYWI5{L*h8r>Tc?lZ|4G#Z@DP4iSEY8niN%SFA zCDDOEk{>9A!#@H*D9{zoNvVSLh%B)q9yx<{rU%(;J2v+69_Yq&(7+97z68K?I50q1 zUR)R+mG?nbD}zq|Ts!joq>bZRK=)kdJgF{q>p%sV6YmG792@JEH!|(huqbvUW`DpO z+l_Xnjzm;am!kNqOh9xWlM$(7FgQ*8uC|2p{CumAKNRgR4sKSYdBh%Ycc=nR9xI4l$=2!z8RT;CR(i% zz1}yZ08f6)A(UYA;O^jB$42eO#J?dbB09xq{LnNlX15qWb9c-8^!BgjO-Rs~?X>B6 zwRu_1doPWet>X1Oazc2XnHJ2@#edcks^62Hl?p2zt_9MI) zy^sPWJ=Z}@+TEBlw=gFqEn5(hs>``xs1y_q?9eZUFVI%v3re#ZlQa^v$OiI>$ipvR zS)r5;I|_uGa|T~L%#VBu+#D_Hv0(Ov>SlZ4EsBHD%>zh(oP9Js#0YV&mh&)%{ZMaD ze%F6KIN5O=uP)%-@ZKS z;mkzOxKnk7Gl-GYta;`aGfqA2qtXTORj|I)yfiDyh6$h(eF`l3CZt&DVZf6U1xT9+ zBSb>Vu*)mnCc)@%mubCCi!iOx=skbffuPBVQ=$nn@ujB`{2Ksrx!jJDrWn$l;)`~5 zx#NG+dh)7kH@5$?nAoki&J&qZY}|Gv zFnvG2%$lF8{3wq;P|Ibeh=NJ*uS2m}4aA!UWMiD&pT*2VbcUrvzQJ*?hM(wD-NuGp zt;cygplIuO(Guz5Y{hj8jTyO#pe|fu-18E4GW_wHndzI!l4aNRW(+et<)0d?q^GEk zxZUPa&sdTL8hV(z?|s5TNL?S<4~pG`cEe^X8VyCJ(NP2C|9rFC_npu3(oeEwh8Ge8 z2j?aDgKCdRECE0ZU87VKN-R|i_W-s-zghpZ0kbfzgC2~>rmC>NFC(0g6L z!Z5PdmF^#w`zwRP=ST!>siaeB+tU?La}V1i`uA(09Sg3&)R-A6sg`{`AS&7T}TCG8WF zrrl`Y_Osh>cE56Zy*=w)U9aD=ESB=|GM73HnTxcn7o^qcEU4=i=7stLF;S6x2Kgz2 zr9;l-#9=>4qacl|!8Yf!XOh+aWRho@3L_(OV*LHeF939dbGRndW`ETY+p@m8X{QKyHx;Pu$#t(5y|+5uZwE8zH5;9R zl_kjyd-m#&_WJ|>bO-sXbD4^#uUvT!y+k`|3WouXjL=~Svjh?pkom-l&Jx@%EH7L0 zxtdbv$BY&wVGrJI>goTJsZ9iTXz9QZA6L^5hl9)$t|)lh<;`C-PKsE6DiP^kCXDh- zt(&y@t*qf{FKXuc#OQp*j)qL(4E8lJBj1!==#{j3J~}ZHlPUKrkDqk)s=HCmEO3|{ z;9p$%n`*}i=w1QbX=hpvCAb6}Ce~5@X`?n}wtqgI0QW0_HBH znA&onFa*kf!urAEFo~u|H{_fwm)6JQ`@{Q6=8eIw@NQVDpqm?yoLMJJZFx9dUN-OB z4}TUnZwZi9nEqB#;>SM+9i=}P7HIu)rh45V<}U2ojn2tZjSFoYYb4s{(H|_;UmAjT zl~nEePFTJ@p7FRpRB5r|Jzz%P!Qf|ypC;<)Qs?2ZL_1$Q0Ig}5yTtyynh{yGj^pU( zVW(ujuHPcUt|@a0@{}=3bdn`D)S;X;pEWc#sIa4Q|8rykxo*3Br-nS6c1vDOe{Ka= ze-?V)w(6dQb{VO6*VyL``xV*R7|qsN3KC4;x$ol*S_cxJ8p>D3b0?>W|K5^S=twpy zf|;I6OL23rQaXLE|6A+H1RJy2Rw&!o!v^AVK4cOPg_x>rmQcu?&)8ikHwr7neiO|9KO+M(_WK7jd9u)IgmFya~m zh*m7+vFP`{4g%0xe*74$FElR(;CsbEWd=^E#mV(u6;;&+6W4Hz`33;chc;_Cs=SSn zh|F=nZ6a=?xRTUdB=G@BK8sd?#!k|jx&2A@fdjqdi*ki7UlSmkciAU92Xgd`;V@5)*%0w1;K zsT^A*PjqnFh-o^IocQ>qcc4BR`Xj;NG#9a&DiUcWCk!YI&DK?Xhc)OFt_WR0C7Mz~ zf2!}#qPwG30xz!3JHwLlLLl`swx_kd&z{o^8@(*;_9uVs(iwB;Z1jL zN<_LtU`tDPcT0DPfOL0Dhjce0-Q6i&lG5Fc!1v(q{mxnM`H!`LnP=wCx#zmCX@}Ua zzKg0$PsR5S8#NVIuCjy_BkuSYl0N`_hCoKDI$GS!7#R^Zc=!QAcQR6J#ZZtKCiZ$# zBK(NwSA~H0$YkT&m*h%?LjPf+Bik*t@LZ8G+~Ftofoaa4(Oz;zsz$@flYD%w z+?AE>hzK(YS7@Qy4@B0-Y)b;MNOB+tb08H%y^1Z)9%^8nus!G&tbUKeJUzrg*VPEo z$2Bvl!a+3`Lu^PS4^J&LD8(&k*O`9-~ z-`~D7->%PZKXxiIV0NKKI6gl<4OdVYf!spj3VA?{Swo*p4>`tQSdcQp92w~Uw8As* z&{-Be-CYvMJ?wMl+;r3ZQ7aM*nQON6|DmEpe>cc=)I7A66^#lABGv?;_EdFwQ zeSdW@c6@k=PT=pr^m4uP^iyMZ@|4+@xq`<)(n@*5ksNMZOd_^4awesBX4_suQkSu7gL55o~Ddqg&~%&7dhi2stfhw(VwFjFXyi`H&9TbJ~!9l z69OMUDi!W|Z8s=M43OwssSC7+h1$;v(qs!cSQE>ZuM zTg&Y5adFC-bhUpzyuXfkIq;>R)1do9I~|B5jz>HwiG~bxb^~%G21#VE*!vm_l1a~D z=b9Lfm`Og>QIeCOOEh(yA;L)XWFSd+z?MA;^V?7SIR9~t@pr{rO6vHksXCm#4ssS(e-~| zF@*I=+av!0--Gz_0{)?HWCWu`N=EzX{Y37f`j!Kx*?X(@zs@(&*m_sI!}?NwJFrxZ?39?7(>eg~5Bs&pCXMkgmJMHFrHBHqBzK(O^W($cS*p%j zgoi<8dMVy8)3|<}1Run!*lVT6+=<=SlPKIoh&sElzM!1c+*E>z-=W?a<+wwG^@gsJ zO{&B9=!lHx29a-LpPNJuA5$x{K7xJU$6+Q^^$!g_8p%Jc>j-~c!u)t=?&9iXf4Ot8 zanum8$JpHZS3=aYvzFFbt-rGGz*57;+}_NGifhW@H*g;Bn{RTTS8e1j~Jr zTrHxf^0d>T0wAuzISlfBAByCEg*DE4;!s%he^#wY!)s7jx~Jw@-CMy+V~%L)*89qx zXO$;e03f)jR4nfYMBk~M1u`4mg$s(Wn^2ql=HI8^+4+^FjzGX<)S8WU(piF$J=D>1@>az-9dR8rh-K=kF*+ zw=0dixp#J3|Ff8+Wn)&EH}QMQ#^rERl}vx=r7Vwtn%Rx#%v(S&7HZPmjiaZ&7BkW@ zvzG?41g29Iu@TZ!xOjwNTn8h51SE3}jr{Qz8!!{)Nl%{6M3?9b!{3%pD?{IQ|`kRuxUq+cvmgO@B^Hq`~kB=DXhmo#SMM^_8aJ7;M;8|Fmy)A zVtLiqo_>gjPLXs(`$du>Fnkl4lBuEpX@)ylAR#dP0UW*+C>r-# zGqsp2AgwJHZxHIUbid=qRP$@$ND*eN@tgZN#mpdGPB3;;VJ81?4Jv`qF=DD2S|uri zafxE6e&k9{&0;9ts~$a>;#h?DGua(v{T+|V9{-Jh^l$uu2e#V9x0ZfvHY0J25&JG4 zPVr%UBsuV@_HS=8C5mI?h0(P1wvpQ=%bv+sk7K3LR17@4re;$-L=p%)7lJ&X5(#q) zW-tw9SbIyPRWrSIm%(JfZ=^_0a(4H}`PQpePqs@|MaDK#5*QVE;GP{Wcm*`s?zc0jt7x4gn=Ldfix zHD1-7> zHy7SS`c;Pg)s`FyUv0^QI3t+UiI9GFVdUnGgxpaq51MJhawGr#L1Y^l51PS|f1584 z+T@gFC@{8Gs@(vgm=F1l@E)6Qyxsyz#WaXG`jidx^;6N7E;RGwR*(M~>i-^meqpmj z?>b*mBt{qwc!adJnaB7`s3HtOive@CqDXBZA-Nrq_dN>z^NGvFA>>c$z}#OHBWCG+8CHOHA3A9{U$Dg^QJ+@a0_qCfv*Gh zxnLU8FYgR4dB`QpQ#x?M67T_)_&P;Uyy^>^Vf~?kSd4%ay}VY^`*aIj%BaB}{17y@ zO^zeJXjzdMHFno~TV?=w1uj`VN?oRqF^#!)1zctmr)VKmq;4a=Vj-C}1PzM=Icq;! zA^udikW3gbf_S}Ul=rWj)08~Quh|5c(&9XFoHVj~i^i){jdtbeD z+Lz;-B0oHZxVA{_v0ZQ#RaYXCWWWgE9)@8o-vebsj^D5k1 z|3fz4f$B<~bi4P){1H&MfE3u5A;b(hgM`8Wx_}QD0#N$fOo<{g#Ejt8b+dR%dE*o{ zXm)>(K;^t@^2Xh~8BhS+^4szmV5jVVzG^+pxmKJ*U&rIT$3LZKK7rE!Y<6JT_8#vR!&?{9`zr50R7udX(^Ejd{soJ=Z(El%+B)zE zvbHp^OPE=vj96=44|G_IrX@qd(+68P)|nUQcpMwQ&Z?@a000j7xwbyduWDP*Y%zkhD1In4zN7 z|1Ah?X*9XYi|tGc|6ADuEMc_IBBq2u>@8fy%z~42C z2*R{_jfwa=fLA33%qbg$?xn4L#(zV<}M8K?*Yq+D(5fHyjKtr>uN^%NfU1u3g@lM7|3 z|I4pQA+c*FSss;m1)G9B5)?&V^l~b9DQ5neGUKa)zPij9!_Bjl&=kG&wU0N#i0uEo z(0kyQ3`eG>ex<1GOMv4)TBM$qjS>DF zPX}!5)q%d+7{;rOp%Mi%W4{?WeWvCNl>hI`0aL5$(u*^v>jjd9e8W#}=_8UE;?pKZ z;}S)FX3N2CyOWlZ(nUG9{iYxknGY#@0@OFODexmhE1A)c4>*xn{FaK$f#b4(B`~FW z0f$LSc(g1JvlJY_0jKvs%hjm~g^j?#}AAwinN z34wq?aKpd}0oarzleDGXa_KtOWHf+zE^vLlq$DZDRC(DY| zRN*(9bE~31fMZF~+a}hccRtBAja;ux=RGqop({hL2wrA$Fem@g8~x*qIdyVEa=Bf- zpmsC4sgs4mIhkx!!{nuIiXx>NRcmKOd;nvVk{2&*`ie`Hxc1vwakhYu*fXq|=y%T@ zahp?V)pI(FrXM78;~2X7MH@>uj$4>%na2j{TAZA91#<@lR0V+F zAi$b;1YvY8P65>r2vo&I`qz}FgvNl&Q-!|z^hDrhm+sdFWi#W+&374h7Vtf*JyQ3w z#~E_ZkF~! zfS!|UoGSjqj5Z$^ya>koDws?Pri$Pgh(Zu)feX+}qCkR%%)+C8OgzW%wE3594d-Pl z;wOn#)+XGW1fCQ--Z2Z6~3BD9cH4uD$xjA!3QSVYVFWmTN|Ag`SYWN zSma0%a`tRdu{uh6`eJCI8i7sOey^Kc8rspk{l8`7960x^vB*Yy9%Q(Z#6+5I+pl_taZQVwzxh*H?bgO7=3UT*0(Kp{8)oH_6{RY;K{Mjx{K#p>AJ(-#K{ zoq~ri44Pi#RaH*v?|40FtR7gakc`ee48a!EL{mRk+SE$BsItNM-{cn8n}Zc z^W8G&LIv^+FQ%?YWZg#LpQiIh$3E1L!jfiyi#-yFd!uo)_;h8M#c%a8=QK=gIZ31x z#c#?fM-B24W!w8$33cWs$`)SX3=NXR|40V42UId75J6m;JTSahFa|O_dEN9BrFBQz z^-trl28idtl2Cjlc{h;-*LUk9e5UW`9opAdzvOQ_^m2*?D*)G=51xT+06=2TgP80a zIZ7reP$H4HxZ(ydO<2%ZXi4Khu$-8W8!zrW2-Un;W+Gd7GE^)-J+?ayLZ+t3I6D&(z{6{PhyuFwdXi+mQD`&wt~i;`v8 zes~dD=?rn^z_tDd5jKqtEQ&XejiCw$+=gYW3%7?;pcN)HCM}@>kv9ufhLfY* zN=cLNi#KQb6OOFoBzz%jDu22o@0xHz;l<}>wvfjAwS)rN&CCVb6+W}m&%90e%DiFv zwx-{ZO}9MLxzD*U1;5C>Vz}fWdr8vTi20K`qs%_EEO6h&Ng{{LQav?h>wa166W^Y( z#+)?bhOjW0N+B#Cs4DGa`~WfwSHjWyDjH*u*Fu=`smP8IWMhC%w$M!{>li{2mH2|^ zI7V%MU#my-wx0RJkpg!;$pL8;8I5{W7mY8G2(dg&wmClYTE|*TdS6LqZcB)~@3(pa z;B^A!iZm(TS-B#RNDmEEa3mv0q;NNDr=>{`;^M;??(_cSSxngGbPE_b&4ln=HU@L) zZN^*#g?yUhye9TJr5!IvXqOu-=3$dFRIetAkza&xukv{>9os#uu-26ozsUz+UogMY zT|$w;8(kh_!YHhRs=Vo=z@er;hwV1UG*J4*wb36nj7_Pnc{IFNOpHcFviu^6G#zof zhspxtr#H`&3HSa|!n-aW5 z4~wqFZm1`9kX;3H{VLr)PIiL1Fvm{*9GkU$TKka<5Fy;yRz2nMsB;XAyo6Tp&~i*+ zbLF#2s)gv}+Cu1d$dU!c=f((FR&e#hC11RRLatAa$422H%n=Lwp9wU?rSjSmMXUm% zDk3MuvH>(;PMF{VGL5t3Mt;zbO0olbJmE&udd|vemAAo1ayE-1neVFLa%YbhpcU4A znOZ`2#-6|6%Yhp8V$+!2jWItb7o3#Ae4=3TYfE5IFqSXHNu>sVBBqBkG3iTMxmx+F zA0er-&j;maoqBO$fV) z$qMd$L#IhPCI4yXh2Lo>szI zQ|@o2g+ro=A?lzvT1s%TB;kqAKU_b)uythl&^6a<oYT)d6WUq_z4Z zR4cF#oeV7@?#Z}`=irC*JIlPM{hj-YyV}MGy*1hKT$v}4fl{0NZGm(2@84=^Z_>&x z`q9cDhZJDo?)XHCr@!!NmGRDvYAV<)iLXuN(fzuo%;vRVg| zNKmb3dapC8F&V^PIV)7c2RUV$B5bjuW817VQlW%HAtC_Z){{B*hGllUo zbQ@TBlHY_&LyKg!zZjl^a*k*!m1=cVTdc^oHqcqYOZ>4tIOyV5rw*iF9rUx46`=d( z%W5#T^3lHPO*Z_p!63NB?*M(q&gMYkb~Z3CIg)LtO8&v?FXg!!XUg3L;tDWsIf`%HVKCo*BWK?kszXRnjFhQlK}sUwLz<(5VxHdv}$`!6z4;yandeEu&Z zGlEnFhF>li1oMF@?%3IsN!&nPhSCa?@S-8#YKfzSJ9$b+0hd3>n|l=-i)%t!y@F<< zn(vJZF0AI-ch?XPT5|~ujMW{xsCiw;K(N@stxmghRF!%@KMGO0uBBhb!C*ai?}j1K zhhwy;D$Ll2&ae#QJtUR^Uj#f4x^9V2a0As}nng8NOeRnw(+crfswYvr#^jNQ+miLd z&)Q-G$XoNQ<%5F#pcc=AsImW`EMR!dj%y1>J0K>mVx|7mY^I@NRfbKahIFo0Iw9 z_<=iXx`ZA(13YH>G}k=h!zHGfqK1ki3Wq4aD>(AARAZxl=MmFoflv$lqJbz8o`)qU zr+_FnkBli4`heZSHV_fMm^2aeZ3^1*fG)?)8~2B|u)gXqQ6xUSX7>&LJc#N6HXt*) z@&kh^yI3DO18yU#s*;3YmRpA^3N7|phxN6w zo8dpRYjS&V)bb2lt>A2NV39|CYYE4e9nP&nr-fb#bYt&;YcV3rJs`j>y${}lz}Pj> z+Rx-m0iI4V*puBV`n6*ksnysd^Dj<>NHT3pr+d;TL&2gad2WGQ4iU?@%kg!>_gd>Q zC$$e$n^iP2!Mf_HH`K$zffq0|AkzSmdq0H75$~iuI&H?5wX5hlf}7j8@a@Q`QvkSH zdf$5sL%}dB$lJQ)9T|RVt|Jf0fv6L+6;M`+iybGc!_MthYz5m$`U<2S*B4C>kkX2QA3K)lcHeb&tz==rc%UEyl+BR|~H! z>g*XHyhu@S6=12Z9<@dO8gcwC-DVt{6)Tr+J{{}J=wSI@q^6H~E!a{9lbWD@c=6lY zPt9H~=0Enl@z~PSMr60uP-73q>dLQw>0R%p?ssl!hk|_8VeLNK`3jsF*i6U^xwIM{ zk}hdl8|k;a#}6YN0#5xVmtp4!;vfZ$3BLf(uvp6nWA@m{%Zdq2@txJ^Fdk=JU8zpA zup@+i0y|sl1+d)@MISu2{xq4y!Y~C6G3sEt4{{#ywq(Ljeqh0duAJx29wnWAfLCPC zsO@(}S@(IL*VV$&@9z^}wXx~v4qokBd*If>>}O#Ei}2JUE0D7~^OJ)NOji0A<#bsj zXhD$JvasRnrjJA4M?)vj$jb%5S5KftcA7Z-ye`lvnkoqN==a@P3R-hd6DTMd{kmjI zGyG!oK9CZ`1@-+cBNB+%JrJPRZsYtirc4c%qERnTlXbth00EQ)dYv;&jsY_u${|Yd z<5ybF4}V!8l>#|N=KB?9pEu};Fi95#(Lg{CX?YU7FI@Efj@!;xCQ|rdD}o#9N?~9K zFsQtX5VY=xG`_GHtKOyLYa`K~1pvmA6}AAOZJ+>2T2+nXow1|lSW!M z6qF|#>J!3E4~Ic(0o?jH7TgKg{pK(4CRr^A@D}EPw;1;g$wL)vnBG%#wrkh1DrC(u zFMf>rTApY}bfr)>d`KN&X>i0g?Hl{ea<9zUnDBNI#?FNgw328-NDz}@X+e%P?fWEH zSa${Dwb0?xAeWDu$;*v1n<^{X&UP`UxuKpG-h=W5ch+{fgVwt;FL?HS7bRt~-QcJb z6X>3tfhIY_9SSrM5W;dSTw^X$!KJ>k;f`@NnpEAqY7XS19S~AXac8QUWIsbtAet&H z=+V2^3JK)8FnG!(N3hEuE{oNsxF%*gHJtMfOLjW#?}Cpdd93hAE0qLX=Ub55P#9dRhh$SVs8^aNBnJ4`f!^*A=Wy1 zOX?fKB0Cn44h+n*pO=7L9rUx?y4{zYz(KxhM#!5C0WU((`<_);jZj}e(|xV&It9)u zTiX8eH9zSrGx5Ja*=gx>-wv&aRTru$m^y|~jHm$zj%H8)XTMlnUD{voj_ZN{^rBS< z#}4M-i`X=U(moG|lj5%=N_(O8Ll3gEtdlHY@Uqvx&P(tmlNxd(vY5U6RM-|)jS2PA zi39+8fSJ2K1#-_p7IqKkdk-XWKD`D;q-z8qFa{xB@0t|*j8c<>-Q7#mq~gs@?!0B& z;qq#pRq*32c%3uRBCk#xtf1PpW1j)pxnPf|nvHIX@kfWKRj?h)c?Ka~BFKZ<;Y03W zFxH}CI6JaBzIik4jI4+_o+~atox8PZ9=Eqa8NVZVYst+fA)Yeujx#|nK8!Vs7TDW9 z0?Ccj+@39yY#(|WH|k;KeM@(GF0X%>bAKa84SM!B1nAidoq|3FYtcqO8oh}*fO{(3SkLxe?|MFHr>Hk7r>aa2+kHrexP1rciyZDn&jJ6~ zq&UOFBa1!xm=ZoM^~Nzy&4andii<}0f`P(cTUEod@GJ}HnYKcUTt&EfDxO82+cgAN z50n@{&KvD!X5L&qtk!at;F4>Sa6!!w5|v}{HcC`QUALXCjT9-PjIK-G#6SORP#_`3U;2C> z{8IlO>z18odRN8^Hr0L=F_tHrb4r_A86W8)6M%K+?1GztpfpjF*1W8OZU6Y~jMh~6 zK#n%HISX8MM;Nu$6nCKgKoiPIX+t7MPMP^>p`GSj+x{=F9c;s(Sg9v^s;4F$)$}T* zUMQFMIxOZFJ0gLz3F8rtsoT}oo_T?e^vR#MK)luCk9`CVq|62f^`?2yw<)1CDbmJC zUm?Hzk^9Z_?cz?Pk!iZ@KppV?$1sn2jndkN4^j*3M_lr%M_|%I`>&roiED*`Y|bt* z5OEqo{-{w{!Pg#+_wUnF-P<4i55Ln?DC2o^EN9u?)I!4)Si(ix)Cw2w>1qm#ZYEpm z)3~KpR)kgtB3Av3lvQ?eEclgVKm8@Hhw$k33e_*5?8x5%Wr@rf4&imljg~+vxO{fgZ+VxJ3@}l5Fo3$Oje^$F>sfV zx`-HURKP3AZz)uzy$Fbwd}A`?bkgs|Kw#ft7a%wazTo`OGibXwr~}69DX#vJDOZrW+NG-L>ct6I-_? zR*=Sw)yPflWjk_#R3Y-dcM~v$e)#@P8WUdcR0UC@ zqOdr|#L-@YH^y0U1LD=z!bUcdT>R+>fvgR7o}5;7xu@}+hVxolCBrnH?C+8gNB>#D z1MxpA@WSAAl~{|eL%kX5n9|&Glv)9r9g-EU_*kmr7(}nUgvHlrOhtnf(b`8*`U6or zIH%?HTU;_Wpce1hS^l=KRm1(Y3Rh8fY~|U z+2~;)aE7yp+^gU(Zm3ard~MkoV1D1(a1-1%RD!*F78{AN#p7 z1k8f&;l6FTnn+Y`1?k!WCtyS_ORJ!}TmXI033fx2vC@vF3krj^_i>&I;?C@1lCLTE zANc;g+fM@^iys6}ls4tg_r=n8y?eVoTPuZaNVS+ieu@P8y-wh@-u2?kJq59_=z~j+ zgx3PVe4_wiD}k1a1!?aJn!f0u_b*KjsUU;$_li&|id2xF7;(v!f zJDdFLN{ps?h0&piVW4~Ky8;`K?mM9F5fO7l9NV($i{ba}jCd9_G)?~OGh^3Z!PiyH z6S=$$OOP}1PX8|E4Cdj=^1M|**o{|xi=7^AhO5kEVCVfC`IiEWgr!W%S8BfELil!u z4@YRF1!Vr0e&CO@6JUcRoBc8i?O6wXHQnj=n>X6Hw6P7w z+xEm62D%?OZRnFh1E&q&pIuN7ojrYygvWD}_iXNMjgJ6j*WD!X1<#8LL&u zN@c(3N8=Nl-2{ii1?4%Hm^$XeK?mB0W4X|v&?O+0_rebx!(hk(FJ)s~e#WBuSHHK^ zk2!X)S`jm!JT}r0y`1#|2ogUfxVgQ*_E`gNGwL9xYwz)I#T>PkpOmUjtzFDAtJD?2 zOIh@ZQgNO@4=#UJrH_H*KYD?WeDOac#;WgrcL}zDLx}k3=%7M_R_9DjPuS4}ZQCVe zhC0130an+40Ch~eYdcTz@84lEb7udM`|$THeM?oox1P2d(r`IZkr-qC4NHV6=XGc@lH<_Iea} z-t5>t_jx|Et-vtY7RfsF$`&u?ztsP^d)r6d{M1UfbGw8f_lv}Q((&9<1()?6LkdzFo-6z2`NYSij7xE?{SF&oJ176lZHI%l}&>mzgbqgHYx=$w7h2O2!4s z>q)sB`M3-wMiR#m{b#^8QX}sQA7#$T*R#(0rPukL8}}M+O)7E zkNctoMw+!70EV&R35yIwaZUr^!ewp=;R$6YI^-g*F5pW7zn}dWN!zfPx*8|hO>n}2 zuf24(pbI<3lnNIqsL>A^4hVvFOnkzG93VbC|GuzKcx2(SED%GHh%iSX*LQ~Z(bRv5c{Ua}$TxPh?JYS;8t&JKP} z(_maEu2)Pc0f;Lkt1$eFPXx=+axHQu!k;8pGPDc}eskrfFnmcHQx6;N4syq@##0!G zNW^$)7uSns4WxOH_t^*^A7f&=Q@ord#zwlejokTO?5b8hEA+7|1jHLSzchrn9e`FP zM>Z90Nace_{eZ9Qyu@M$xW>+o3eh|BtT9dEc_V6C51RwtGYVcr9i*brD^L=ktm~eJ zz0w+V%_+0zcfl++MXpSFD~fJZH#ByQeM92NX0ZdMtpvQYku>~+%26Z@+o3D^<+{t! zOTUeLSzVxUa#}shc-O_nT?PMhICI2CR_t@--YH}C@^MtH4*Etg+pcbNNc9kGM)V03 z!JjEd4Jgl6o;#Ln46Qi&wiC;}rb80oKJ1Sj=*ry(iF2ZuWK%mggv~CdMXz?4m1kSQ z3^-tNvHUve`o%@rX=j$cqV!4~v4R&Jac^~NY&MKTSv8f^0CYID%I+^MUUyAfe%F`uxUR$7HB>$f5TG!2Pi20Va%h%#58|HWs_~c1JG9u7!PRuBawKr zo5SWeF%((TO3$yd1M@2qNo#(23P^hkHWv(B_x;d<@bOm+V$U0MXNeyTR=Xo&ZcdeV zQ{F%8vr5oYzX7nel5gK*klMHbTyyHZ1qE;@YH%H@UREjA0uU zCEFS_A<4zv^gqmx@07kqVN4MlA{-u7=rKmLteCZFFDFJxyC>QAsrfD^U#v+F)U3S( zIQ0cZ*6H0SGY{27zHip!Ov%5*k^}T_zteNm_fI6fmtrpM_*5%8K&V}4s>%mrs@~jk zawMH=8)^hCM~>_cbMr(xuPkdKw7GI!#L%a9qq2kCv^3tgvXS>3Tb65g-EIm{8fK>Q ze-1}xG-nlvIvq>T+5NK+n9V1#^;UnZAJVylt{~=ORCr5Kwn4c596zz zm-~|eEw@^}mbTWE#FpQo$&Uj3k8w^LcKL~Q(O28_cw4OXmJs{BynNs|PXs{3^`7SM zuhp&&{*JjJpdww15;L$)Qn1Zdz99=5)RI+>IgsA!Oz&m|AvYIO+u%5=$TcceQpF7l zBa|~FZtd#_`9p1i(fJv19O-V>rG#3nC57PWxTc1Agx|emTxLtbxr!AAwg&FF@VkEk zdTwF1q-vqU9a3xrUEVC3YC6keT|lr%Af^R685#^SS#=U7IZB$JfVwPXpMd5F{ztxx zAH4nmH5$I&R}eO0=agW$`bJy= zC?5g9w->)Kl7WdS363-`9E7P4n;K>a8I3z} zBJ3npsm`MFI|xR%7MlYeen#4a>4zvD*K?ari(B!~tK*d92u<+d|UWw;3nB5{k{BE3BMqY_Plk_kdPPLei5O$SNAo1%~#<5UN<_ z8>)iuO?cob%EZpe_8H5x5ogDI^ltEU?A(@LiuB8Vr{$u_#*D-ZRAf0991oI4y7F)| zVG*xf=>=aeKnV9si4cp8s%47pUG87O4@j1Tim-8YqNG~uTrcS*lrE?l&Ov%>aRdO> zVd`&+xfP3WFHMUB!L9FxRTfYos84|=AMgN@^fiEJ${q@qxD7pOHkLUg2yHxw}typ~*5j^6UC zgK{4#B)^X!WoeLT`baj>CBX^pca8}QJ&yzJCe``nQ;$4qR9#_|riA&=FR7@g{#DZi z0H-7>v`T1K`b=s9f$UU1!}wSE0|`mgDP1YlTvOvd(p2FG{g(rsryx#C-k| z!{u;n*UX&jlTZ4&mWzK!mAb}P)HzYbt9GCa?zcyw1@JDC{+46Kr0YZ8yceBj`SG(1 ziBvfp7r0ai1u8m`Z&BeulLhG^XrZ=sSybtX|shU zub+j>XJ}T4Z=+9!1r$I?efZt|ilL`@2sSsm8je8A&w{g0kdndAqP_r9;_p&?myynR zDg+aIA`NXHS^+0V25Tg!E3-OPx8*mBuw9U2oeD=|%c?$?x5vD5X=ek?>RZv*6#^GJ zUSthbk#)Qyrf?NmHG+@7qP$l%x7Dy@wdi)K%#lKHt<($n4{^WL-t!$QnjluzEX0&T z;VPXMR_5xj%GcN`_=^<)d6=YgIy%na)u%^L5tE-Rv1We^H8}<$`q0$g*u%)z^%*;x z4K`oFeqhF;ahe#Y3Tw}HPnXM`r+a4R;oInj>C3~zhwQO)+)>R#t1RtAx*UsGgMaua zVwlKs$=bAMo;61Gh`oB4z(5Xal{mR-O^S~9S2Dgan5{tPB;rtozcecvJhUK};#+{V z(XX=L+YpR3;g!GIxjuX#R4psuB1t{@Kcm`xhRf;Ez0y29czbNJ9P8a|1rgfIO9Z3_ z^w2>eB6-QebhnO{l4)7#iS7pOiM@?|D_qSm)|Y+3c-=zP8O`J<&MC%lBV z`eTBDeUh{?(==NO!Ijbou)FZbg`j|ZVevC5^>)tDeGd!eYvFzu7e}f!2s+ka_I>~k zDs9ZrC+HO3a<&}33ft@87c^P|LDJ3j9^tNC@E~a385ttk6`M4Rb)d=#hbtsR(g(m2 z^iy?&JbZDR8J!R_flr)0M(QpKJyhk9PZNC$|NfQ7)I04%6 z?oLu>N@&@Kz>5hv6uA9&iN+iGcvnpuPYgtL( zI4B3kDW=p8RlK7m%GD71il{`O_>)}Q9T!XeQ+5X)H6_M(%_{P_d2`8f3my(dTIfAB zB2ULWOacrcGCSS8vxnWq&-S;qbY=yoUWyxiPIA2mbNL@@HZ)}pKW*iVR##+;u9&Q2 z%0hh;F)-;NV+rEI$+w}xk7wKDm4dylSBz1{5!z4Qui#cAg^TP(7hwxP3r04kt^xPpEg}^S#7dY;M5~NtB~d5AJtzz~!vu6;=fx zdu#+`4Olvzp=qf?%|ck_m+!Kav$SmBp$ax|2%^RWjxaSmPDN;vomgNZUL_Zp73EFQ z*rs{25bL`%SyWOT`!hqsjY}jA-@~Q-*++f-*69TgFK4gklVtq<tuNg-_d|&zl@7XVJu-)y*Fz~CU=T1nAAQFBnLJ8{qt+^OHx8>dt5AN};1GrDh}f5up~dVKEhiA?mVF zB)N^k(5G;FP*c_Xv!sHs|18N8T4(JavE5>O_5P8aMf<|x_ru$ujCmSkrt&8wuIQR5 z#6zGNH8*+&b}SVw9EPC^u@oCcrWy%f+R4-j(}XN3a2X5)0X%f9v~0RSMpRl3ET*b3 zL`LKZ8TI0$pWWRcBk+G(z5v_EkIOo56N#>tCCA~=*&mDdn-jESDd8VdI%JX;{Qyg# zwFo#}n|$P2RhtA}nW=-Z94%WtMN9xtjk{bs-@@hr09Gr-Nocoka! zC_4(mure%_j3HfG!sEJjwhN)+)q{akDstMeu851ABrN)5K{j_FB5JV=7L#r`A_Hmh zJYZ2m1|Z#6i-OKlNQTylN946ZXu$$n=6E)A0N-I}UJDwJyjPPC8PgikR?d z2RwEsi!VloB`KrvI&9v5!%D<5@r9!@62{PL&|%PyS;y07vyD62kSfAY$;e;6snSvCxroZq$=7h`rtulveuS(JYe;cfkWrl|+R@p+j z_9!%gNX3GVQ!c4o*&P@5To6m$z04=w>=+(9bkNBC_W7Y`ip5tGkXTUgIE^|~g|5Y345~-@wo_nhep)b+kO;~BE0E02AO%+{NsG>M za3fFy?u3qVs!yfZ8n>C@TQ6BPE?Wp@7?dePHPxqB!vc8w+=f$#Nsz~?^rv?>f?gX7 zqDG*_*9Bo`Dbxe5FQ}-(YJMoC7pdA}% zMWq7CqSSGu_D>ANDS(i(0M^9HC0gfC4Qs@bZ6#K($^fZsBsEM?-uUU?1uA{@K&bp# zR)7a$9V7!nsx-nJm7A;v2>{ndeb`e4(*FQSf~`oQW?t#AE>SZ}i40n)WC=2EU|eo4 z(JFs4SO=DDBe8lMVB8qrfpGh06~d^1ACL=x5}Pne4jo>x9Izm}vwIwdPWF_Cv%a*E zH0P6^T5ve<21l?bA)@8LYNahCXOBV=5C<(fPO+qNHu;oPD)C9`*m6jmYDNrJh~s=Z zy)s5Wv?iBgHZ(vaT}h=FYiO-CW3B#IO_M+{8wh{h-Mipo(7bODYPDUylM`%fBzg~E zpm-0Vz#0;RoK;4JrPGwFSPU&wBdUo%bO}q_Pj$VfBi&>hIBX#?K~Q~k)l~Aah78)h z_L+s26Gt5M%}o3PB8$BL0{F(Ow*dk;7vODZ?>07)fd>YD(T{|f7ay=K*(!@`+lJhU z^lhN?eVsKSpOPp6Boa!b{80@1AVHSuoHAlWIKYvePl{F^=pl(V(Wt3>!ij=ex6kH+ zTe$5pmPscUDMPw)AG_0si-zi@15zwkPkwu3JGsqsOfO9vddvd_0ngDn@xEB~MXU!+ ziTHi!4Z$8?3(<(g4#E_k;Z20Bl^mro!7WZ0(7C%b_Ao8}@$YdB|1RF7rxS^8d6s(1 z*!@(ezNi7l1UGl(9;N4Yi_xB zP$mi~h|$W?Q^aSQXmk~Okr6~^WOm+-x#N$$J`fYF1n=0#s6)sr#I|EeM%qyf{ zc!PWu?cLbi==Rmg{${B!x@M`Y;Y-m|D9<$S?4`}-zGQ@L7Ay_JspbA(F11&3R`yqv z?Tqb%@a2Z})um?*o%2kphtrvz!(h~O*oG6f*hQ)~7C-?Jo=vxsIGl$l4r5`(d6Q!) zm=a+%q@$|%4q78zCew_JBcJic18s324@m)E7b&o41 zBBJ!7QZ=bkzhWgSK4vVj>#kDUoOOtCLb@r*U==OUCpwVmv|PS==1Gl5#}ZSLR13DB0iNyjb2SKICdo;p3|QoFK}IBmF*l z(?slVICW-WG$m#Y&1&fa&9Z+1>&0q$+a%Di_Wnv?Z!K$Qr03Z2>d~moC0bzl`RSI# zgJea^xv*%dewN7c_+8exR5pN@Q1q$=5Yf%EwP`#?2~$Izc^|2~_qm!?bj5zrg`-an zfs9GQo9WDXqfeOVz9E_>k zF>2TK)MUhO`8f_+h*dWfQA*jV-dwR*F@c_w2nr}%f!Ay)p)jC>iy8&qv>s*&9)8Q6LG{d-BwB z(i8Y`;vwRg&+Z~C-OMGoVj?^vaSNPCKPk7Apzt7VV~Eq_>`aRHCr$!05N3!33Un?Y zWY{W`jz3w*yv-MmVAo9VyI4yucyB~Bs0@s+{5rmJi$Yw1c~RNHQRNG-=#s*GS)Xki z9o@r7y!ZF1^9BYF>MNU1==T&qT17sK{KAHK*IGit4k*CT;_A5o(@UtdRS+AITE%!{ zVp1H}pJ`~)i}uVTX|PkMIwHX%CVRHKWZjGieQ`wq!_%keKE5es=gp`xz*#~l1?8ft z1$DQ0FteR$K-upVCh)U6&Fyao%--pCWQp&-q<;xlt6EVv%unvybobHksOz9P_T7>! zD|1^ZiBndUY)1lOEI{`k{7UyPShIce|B-Z+aZx`_obK*!5D<`Vq~Yl9PU&vxmM&?K zj-xrcq`MnYQo5x<;Q9G~c)`B8&&|$G-0aMEXBg7dG3AI=8Wl_Av@nvl=;)D|K8*cA*r$>B|h*7E@mVk8`0e|;q5OOkQ#iqL9HeSX=-7Z;MjY#$KqZ!HiBx#xk zKW!?}Hpz$#txO<1D|cTJ#ua{yZqc z`}DY-UTG02WLK(+Ca;36k$!L#qzS2>k3GGGGi}B2w-RC% zjiflOIS%3mC#bP#V&c*0tR2grzWnm6q$4qLddzZ<2bpm~w1vdBmT*-uEU*bb8-|I- zqP=K}HV02T%@Vom3AOLkq)x%DNuqa|vP~)RLgb&JHDxk!;XW@j(;A#+k+ap-ZX|x# zKzDw}r-gL5Wd2;Tylg`77*w==>!&wERBS@v{k?7pj?-GJsGj%rmOJej9%x@-fHsYG zLX#JSfkHDmIx1=cKQ}GuZk-9@1Zl9rD=ku<{VB?ub0x!0(r73JLs>`aT423CS`GD` ziX4PAK@Zm3C31fi#^AubQG=|vErbw>34{xX2iw$;HNqFInZBkVGF}iM_fnMh1t03!Xf?jkekJ!jpsHfi%JIGDN_y1ixC1bb-{>a;Kf9XkF!T}-MRh4Xi{(kjuI6<-M>&U-26Z}}#>a`JrZ zhC%P#)*GO^g{6Lv_l0bpdsj}oBxp7?z)OZ;jZz=XDJGx5gV0A^lp^7}YD-3Yvy1)& zPoQKOPS;pPgERQ`*(@erC@&CNN+=UIJaD;)+~CP`oY>80O~%7xeOM0vT-Q)Vb7G{5 zE3>6{WFvAZ!G9rfxPnga>-g>&13YzYZfIxIq*9&@N*D)SKB2)#w$->B+d4q*@OL2wVPpVc?9n2>-B z@WtK^_+NkS5r}T}otyQiW=%V>?L9s4&h2ln2L$ehK|(w^3KB4}nw%cs*yEILm#Wc# z(DWE6JTyZDtutDxyX|UF=>GQWhnY@)7(=(-M0altX|FE|r}^*!8@kM&^E9h&UwOn3 z3K?x5t}nM4ZkWJ5n!A|)lE1q_3cETmP1hAEMxo#{ ztpQkqu*i&6+~qI>f&jUQ9B2v|=t%tf!eNzniEBYHD^#K&#YG(`t=%pue4q;9incUV#Ws~w9QdbB z4ZsU+e=6lkmZm2-Bi(5JMcs<*W;M|ryI0rlEYTW1JJ9~WZZUuN@GP}WJS5E!?s&4j z3S#MtFG<>%=ZT^{kSE0kM+e0Q7ehnf_n)*7*~m_!;B z#FjK|?Te$TFMOp6NexWHHu&N_NVz@Nd7EL19n>L29zwlH8I21UQn*AJJ+S*r41!dP z^i(D7;%YsQc+XpcLGxnylLU^@A}@@M8EbHKRNNUK3HlmnQ>dDove0Bmc;YS&!w@Cc zy!)%F1&r*06W4?QU09A*vYsR(wyGMC)C>KWSPpbbdAZ|h+X{HqaB9te^ui0Z0D1%V z*u$+$EQz=rIj_3|4jn#S53;BSek2@1a-^x;kr%7AF&@+HppRIzvTM^>RGZFwkMtBb`(FQ*-~L z=wHb5k0KtNmO4yC7vbi+W=8(Eln*8el0{*)4$u}Vw00T&5%NsE_E^U>WS-v5gc-+mX6B@h|L&Oj?}RA52+J-Ww`9o2@|d!zCUF zPjF*>Ur2{gUL5reRWxpRT;VMhd3KX)49=Cl%V`hBD z9Fb)>qS6>Gw!#s!K}LTk7gDQaQ;EVkFUuWDv>S)UNJ5Q1hlI=wr5e@>`nqvD{B{wV zOf5wV&`U0qri~s@_EoLN>hBqz`*?;th4VnO1pdcO5*!DoGIju0(W&quu^OF9qi%rE z&4YTh$(;?fd#H)<-&4-aT~@` zgcs#PFGjxOjZx;r7PveT^;}D12#R;yi*^Jk$#iHv9#zcq97jb`;&E{cAV?)Tr8u#C zHX05?xFS;543eFKI=Y`ujTSXA$~;kcVm>F{U=JxJDJLF|CcCNwRH@v4&{Zgm{;Xc{ zzVd+u5;4jS+_r@cuv|Lacp)gL70ns4W*m6WdAu6D-rVjTIA++Lx8(&?*x2NA-*MM_ zaY;_kr@u!6Vy#Fvc|0K2l7t*-<;%Y1ez-oabOKDTZJzr;BCG zu4p#d2F2q;B8p+2zqw?{Ouiufn*GtJku z&IJ*ud@DY>9w{G6&90cVF}xsoz5Nh0`DXm8pjWx}+t0v(YvcD2eck%nMge@PNPJ5M zxl~qfhK`Q3AcK(Q9CICCmR{esdpvZ{{Xu>oz1CLym< ziE6$XpN4LQiVl{n7^!`u*!?Cpjx|m&h%7Na3oK?x>iI8MZ5w!w62xl@{6cWlWRtr1 zM{yo=oq!?4-CVo0-_Ir|7aYP{(;4DhmLwj+a|{#PzVmCau$0`D7#PO`H=Iyjyu4%Q z3?GJf4Q1zS0u~}m-ge_!9mts7qo-HSW`Hs4>q~BN+o|m+Ij36FuKHn{huSdk{cShO zu@Zevj6`gGhVR(fw!u_v0lzt-IT9v<{}BC18ksHVi10go+Qhkfx5XJQjNlr&#n}Wb zL@*gEIe%SyDjN^Y(oStl$cwN(76Rdydi~-+N2Oiljb9WU#TRe7}~s{1cKT zmPKv~G(2Y$byA@jm!+l!-{_d)W*QoGl6Wpv8X9YoIN6iB+n>xj>x&F;U-7XIz8rmq z!mO8$d_T0Sbmhejwk%{@g=95^I)98B0HsV3rEwy*>e9Vm#2A=e`eXZs^yOE#x(z z;m4$B-u5Z#7e=i-TcnF4ThQ4>4t`tYT|V?jbl{K0p&%StP9peSP_Tq zkwni#AK{`3ym-T`@W!6S7iQHe{5+bp{EzOi2WcPqCw=)?pa_dJeG_VYTs0eisEzs{(C=1%}EpGj;9ghcW~qFZ)yA^VGn={85s({ zPqu{xf@PX0WgNv_qjPANSc_e~Cl+nY9$b9$B;ir{e~A1o*RPX!esi!?Xcv+++Xk~! zV5diA3&lsV{L>Nh{lcYphy9X+h2)qs(~;N_zKn6gr}mcQVu@jdOUu$En91iMzR^Tk zKGB)_mq{UlnJH1~SaQ@2RItsgROkj^`QS*9!6f(K6ILiK?^>lk zBP}uiV^yrjYCDoK5M7)~AQ=-e`pDs3_;iyXIL(_CMAJiuAZmY|RT2b!#@g~dHp2S+ z-BElQtGB-1m#Y0J~xbcq1z38YsaC`J9i3Tdg2Y>9wh zCL5$tlbnB^Mj}A$=92I(mt+rb0c=@}y$M)+en!n5{k0989n1*Z!E9m`5;qz6=m{B`jiiE<(l{OiT=-!Ef4%r6Q`3G)sc&C}sBWBm#c2BJxwd zI)xF5n@BeH!<--@Wyl5NyQFGuT#Nq7OX$H$!3Q*@XBJqt&B}UqP@;`O)BiZF726CD zT;6i~*mbC7S+OQ_XeDEOB)md4x6Fm|t5PPa5Zrc1D${KGZE04J5-y3@@1jNI^RWoG z8dGg+?Ta$myC8IY6x19MS|$2-gKsEEGK)b`3Tx$^3&=zg5rAg~4ii|ak%;h-k?uZG zf1de=8=kQIDbbUUpw!*Ny6?%+byE}L@uwY09yr*?uCH`x>Okv3a!YB!kNU60#h58k zcrs8=y-k9ofR+eTo4sRFau4G`E%q6htajCyU z`J;S~1L3!ik{ilu&a94()Ra5+J&$Rkd-ro5FJ0{uRW&`Bc28~IHE#uLh;tohD+{V% zCc>&Ul!(?BFb#PyTL%!kBZ(=ZCkKrcf5V3&oQ=J7yVzo+wN1yEkGp_@^85>}k11z< zc?b*Ee?YuEphZ2}xWZkmAiXA;$0Xo(`&LGrEM+O`n(KQJ)jD_dbpB}eZTCJ3vM`qz zqx>_}-P%6Sai7XfsD+y2rJNQLtFb7pP^=#u8I;R66TA0<-G=gY-CyhP3gL!)T|RT{CEg^W7U9ti(0UGVGJe!wY?jymUbzFKk6yg9ob?~z4+ZdIep7A7T~{NSAi&%~ z#mm^jT~0I}6FH*y*G(IVipO_cRTXZVhCoy+yi22N(ksv48uc==Ydiz9!g|ggA_lkC zFDFimNWTjXHO!!F>YS)RVwZL*b*}^UWhaI*y5LPk;$w`WkQq4$fvi^au3 zN#dbasXV$-7**>$-krC@n-)NYS%;OVW@-v-hbZx@YC&&wIU9J!@r@|fPX~w|3F=S5 z?V>NiW0H{q)eoq@owP)Jh;|0pXjf*E?1R$pLaBS4{xl|zBd;(dI*rFe9BA0&%j>Ss z4yI^Gobq+{TxW6o%nZ+sp!K8~ORM=UXA`yC1JtqC!4^$w)=i#o2n-c!d`&!bc)~Vx z!m&#Qv~)^K~~QK}$@ zEj&TQjIgB7?NF#pjV zHsHldlV3}r`x54dj4*v-Y6}nIqwJQtud@s#@hmow#O;GcY);)l6MA8~Dm2)UZiOq! z5or98-~`I;ME?aaKZpLtUko^wa^WAp-vXywRUlVI`F$@DQ`yo%+s^{O4$C4uMbOj8 zXB)Z4w$>$pIKz|e7;$j4%~CoIhTz$SY*qx6VjV_@Pq!}x7WJb-LR>^E#fRdV09$kk zSXX$SKO@^MqT8W2!(!&KhA_khM8#^k-!zdgCaHRnR%97@gpr(A@e43Y>3`s-WgR@W z#XId^SafD_l;hAOI2v?IW(7>bJWEMvYIv)f_)6@w-zP+gmmfEhLB7qd3Ov#gKPN-| z^Y|~iqH3|zPdghtpTocK!b%U`K7pnf0WG@(IMGf6tdLlzpPbL3Gnm%cG4=Tfg9#cD z5{2}I(tz8Vlnx3e^3*p)aPw^U_Kf2e#8NLysigNpU`L-efHu-b(@`p@;4aZZS`ZAP z|K|r5NOoW;1OvN>`j75MxZN2c#8nltlE@~d`nGRys1{GT)TnAC3YH(=XBEi&Dp*b;ye#0@j+@m? znLHLO4J;%OlL>yP56uQtq#`Sz5SQmie^Wk!6g-#W}?IyN_i_3@O~oknS_n>Db3;^1U6)XV!aemZ-k{` z318XR?%AM5>C@;n%R(&$e?zf~lm6}n7r3C<#}m7;HNpb?|CW;UqUx7PtJKa`CFOy^p;15#39OR-l2WKz)Wh?N(oK^{H~BQ1vAN5H?yv1% zMz0UtCcpL^%^$B{5oFO>*@#O`f65q@T%p;DOmYp5dZ5H)8k_tT?COYSi@JzpAA~FT zkQAN@jVr7?A;KeKEeQnGC8LLR3natfM_I?*Hk&IeJJ45-GDX-B=ss34$06 zk42*Uz%Et|8H5VST-$uKt|1E;|FrUbvUa!>?#7GD#4%`sPmM>pZ{io=1c`V`!?Qh* zRV7skkD%P=umEca&Qfv>hL(VqlM)6+EBYGN@<4||&%Kr6i?P=;N0pg@46s7mk>Ih4 zo#5<|;H7|9KQva!WJk~Rx=?+=5ty)jf(r0hp;<3it?w2V#!gN6AP~{~KS~WfEbDC} zt5J_`t|lf-O}hAxcrDWP`lw5OBrHN6$kXQRjm2#9mHRa0z)yoFSI&+m> zgcUGJcH+e4XF5A5>`f-2@8toGonS{~VzUg{n4tzMNZU!6p|E*hb1L|duy>y6b)b0u zvD_|r0)^#9oqUcNTR!t>O^UBD-v9VB)JO#V3yCTaF(F*IRmXaGwS!>l6F3_t9AY4- zv(Stv^swn5HpmVecTq8F^!bN)D33m^!W@U>GO9y2Y#1t;U$aYCFwyn*)1O#q(?-8V z(|6WpTrVM)&h7a(cUq^f0<#LW54520p>_uLCvjXG?A1|=1S6Eb{S4$En{gg~7ygMQ z|LaTR1w`*-Hd>YY1cBEr55w`v^teLrR?aLCt{AhKLjmE+2guQqxlm%60#AbeDm>iZ zDlKlxQAN6jI5}n{_6wN)2Zi@g#_2$!Qv=J#w~XeHHwHU_C-hBvOV#-{%Br7X*Z9g_ z3tliU>EW`+A?L53j0L$Rw8R@Wr8d>Tz-<+8b3wI6y$7t7rS?zJ&$IT3EU_^kV?l

{h|gwp?nL253zIVmbDIzvgZ`1jtn+wKb!uGr=GI4;g4 zVSCX^IGQH~+F<8@TMEPK@hu}hxBkXLrc^7$oW(x6bt@r`vyQZ$r zgg;{WbvTJyfF|az%Q15bV`qf=A{e1H15Shau;HAa@#wYOmiPHCqWRa@ua$~5lPeHh zgjSwba)JzmBHb;OiJp*Yqy7ynn_P1kSC?jPhbYZf5oiq9MC%{8m8X?zm871 zWZ$n_r8K&Q{?-)t&-}3_Ar2Xs^T7MXM)7BF<bY%PTh5Q)1DkHRbDk z(ce>hq@{^Px>Px|>1!a5>dzJmGicN1_ta%vY4YRXk>Rb5L{mC7W?5`KpRl5H!oO3i zF7xo<_L?^cijRTqUOAz00#zW%ZhC~1VR45b^BI~ZWFBRU+7SPDVPZZMY0AmL(!#zy zw|;Hw<7N?O-`V+h12qs}*vE&D(EbV{69%iU`Sb=O4vnaA4KHL?DT757UbglItfXZq<;z-k zf7mi)nWiO-d`|(Z7*ovdk}M@ESq$O#4<6ohJZ_y%`Cj)uc5V+jUe7(OwB9_3-&&ng zD1IncNzCMrHt#=~dW1p?NtwED{D%kP|SF%Do({#oSAuq`~S{ zn8d97D%oH`oR{9e;2Ln?z#)+%#vckPgl{vSv9QaKvO#hw+YjJJ40~UWS2^c#(UT$2 z@qNK{&Yx1!W}SlxSnF%HvnRLG5gww;r_%k_0td!q%dIYg@GBPBL3dePnA;y{LiuwgdUZ1_kKT2nxxp&=PF*q^^ZOze?ScY2M>oaBhG86A z60_im&|ve1~D0Lj2B%|Bp#vbo9Bt>Dmg``(#i`=ASf)ool0HWd*_-+&iUg zn=fb;x7Yi&UxVVO(@h9iQK68>^N1+v!s(G|x0ov6=oQgo{sdR4gU-U65X9-t|629v zPK&Z#bK1@vNuYll8aXfry|MnN!5DWB^Yg5Kc0Lt@er%|Tg&v?I`^Ck~B#o;ku=fG8 zb~ABR0X<*)qu$FsVJ*4n)(Ga{RoLlX-)+vZn%iZ?mHSdyfJHVY{~rn4!y!vmWUMK5 zVhsev_?U^w7)uXGZ0GHQ^~Ni__EvM)l~-!Q&65oBfLt~<+zjCx+K_A(mVRxOIl@`i#nCXP8R zG5YOQR|J)(khjm?>por)OiLEXD(!>5LX7g7y4_m zWhdxxr4^SvZrq#qSTwQ;_-r#s$4gdKH^_+$^OA>q{7Hw%TejDE*J=_|OfW(;3O|al zPBR}{?7W1@Es5Qdq^HsC9KTffB@NM~GpWodfAGT8Rcz$ferfrfgtFv{$P=EVZhdpS za`h@+Cdf>lpHM~l?Bo`}CD2XLO=?WIJu#Y7L+z0!uH}e=ryiic#TMfC{^7;Oi?=)f zjQV3hpiicA&vXnr&A^X>s^-@~&WRe9O%-0{`uo(iktl!9y7a9N-v+6uBn;1-vopbb z34Z96_j6AZJ0CZ@{0HZKZ$j|Y?tTjAUD#$WUgRn!vA{d?R>$6~B*#8rb8z+~OqSvD zuoa&?zL>W=sA0)5qN-;%hNLz1xb8ey$D7<~OF&?ZLH~YcEs_Xv=D!>=sEN^+I51LM z=`I=cgC>#YN~tfVi&A$9m&V5A+O@oLM1|Rwe!G!QEvY}9L7w1Q^xL!umR>nZm{GP= z-xcUp+&Xo~Ot-9?Tcb>e%2pummfMGz=_Y=v7>VVZTYD+`S(Py-x{~vJ77z%R552Gu*tHlR;ZO2sD1c1_rpc;Q9GXNqN)$^-X$KW=He-m#kTJRE`cd5{N`5I`Xg>C%e`FiSD3RDB~Z!8C*&p|)YD$vl@(ob@X7f{9qqAw_@Z5Brt4bDeJ%66+yTv? zWL#W{WRJ}6A|7P9%N;u6k_P>WEA=>xaQ=|-4mg}*KCr&zv~0r43u$J7OkQR>w}+10 z7M*C^FcUP5l78=^m^@*TcqGXT4rF*B^iwqA=llp)k4QnmW2PnV;;QYbp_1&uJShM~ zJ0BFVneC@eG56x${TT2ZBwf4*c{19NDw@PR? zeqCuYa$bgqi`|V|@E3SPSshusoO2PeGJ$mndX}i(M`0!8!jl#xHqz9KPEL-CuB0d4 z7S?p2+Wn)CaGMzD?E_O@2-62L>^-ENJAM^W?0Ds+GIcAqx9PJHVbjU#hyTycO#^r+HU>Yh7})!cBi_c=PXIrdSV}4#qGbos5mGp+M6w zP#vEAo`EjClmPUOCbu6Y#@Si3nV~3=vEuoj{piU)7^|TWTE3r|bG~|V&QWQQxvj28 zrg&iv!KRXHjs?5kjHYO|!WoKqLxi=5B}PGMJToETd zUVn-WLEhBAHce;zf(8LUq%CHOfC^;Pke304kFX=~_*Apk`Np>))TiA z``@YIA9cB_{Q<7U8(B)MMTR(_$y5*ri0QqP01Vd%UA@@52;C7w-Gk!eqgQf8Rod@i zi6zvyaxm{inQM!R?iyG&$pZI@JV+n1M11-&u}S}ls0hYHGx*~2Jms*^4GeW(cept- zblswR)FU(M^sTN<19Q;OsKjDgni|M=b3{cmYggHnFx*pK({q=w-DBMR`W`ooJQba$ zp17ybTcUHhPw8Elo2Xgxtiui@YQ<{`G37!d?^h(3U%BsdB&Q6nLVPa6v)9`37qOaU z(VJbH#uR+Mauj{qg_wCj0yFCft`869JW;3pNJyh5?F8l+V?A=)L85?&rm?JG6Sx?y zv?I9WiQhxM9`lFIn>KGvN}q-_kHdZEeIyf55CuJSHi!Pt3wacm`H!QFcc7?-;s*So~m`12uHR*Hm7yn;2&c}X~DWyIu zah!VM;XaJdc@1u-57*iHK-)+1PvD*j0e-6&qJp_L z6*C#eW}eJv;TEjA@@@BE9+Yxt00FbpUcm~meN{iG$9UD-q(^_nuSErdhi33_`N5Lp z!zPbft!2H_&d3VnJ_hZP-lr6(T`wi=ZO(lOYYm3E+L9B7xWC`YG9s&Y@DU-?g0x=& z_ST`Luz=$0c}PyJ^3B`OVcS3@Y!Ax3I-qYn7``fY5O_cP2VJ2i;tzU~&Z2)+?W@+? zp+D?zd`ExxWF6BQ&g&^@;}9axT?0v_WVnQ{I+E!_o7kIO&3M2W_W);nHFdfZ49uV< zg|FY1>|ts=|M@#MDsd*q(YH*HHcP;`q+IQf#E0}I3YH2QatF2;6yUzkE9D;?hOTI@ z8LSl22|_aX9S(po?3hg(+ijTZt+U4Viz>z91d~}EZJ6h`t}YF`U3*9yOEh8l7?g{juju5%Xc=u2yD6d3!j*uKBM zhyKfL`J&THlkm@W6E)(EiamUyo-t4WlvyfY2}}a#3zEnt{C)P(&Nl^2P}3Q4bn4a< zW8*OU<(3D8vGp~C@8goR;ELfQ7U0zEqb;EhNEpKz+tY_=rYlA>r+HM7pxvjWkpM-W z z4?%|287C@MMImQh56lIWfg76-zpPNHhHAc=KDcU?(5^^3g#^ek{LWUA{l;gYSUI>)o=^DX-KH}5$n?O3zh;@b#2px}bDtH8om$c~QvEn? z2gQKl6#lVO+ItDeoL}t|YhXQwl`}okP9OZZnMi&iMQr}0&bpnFiN}_PZ|9pua>BjS z75@h|gwL57Df}shJwcyzC+@km@6)v0&2`@Z2MFag7i4M@job^GF@Pmf4=K?^quWgx zSXhj56d93=OJaiezcR>nK<|wk|%=RM3O{< z{RJ+}3%DEPu@&I}cY_ApvByyR19kQbBqlcmHySWGtmzLF23)gQ{JF~5YB*cMex<>- z_k6G@%JY$1bm%!MMI_UABNCg$eBFCY0DUI}6;P;;@czD1V5{09OZmaTlywi-W5fV2 zO(ecrk|cCx62QPP8vSNoT`_|xU0Xy*Q*}#0Nu$|MA@IW&DH4ikOl?wRH-dW)>cmow zoKl{5bf7J80O`&5W>GJ?l)1Lu2Fw)P5cE({7>W@Kw<7J#!HxI7L_8JoVLk>F1~Wa; z_^~)uvi{8^#X=!)^jCOqpKZHcZ2Rctqor83vZ9#c%8RQL zL9cpX_ft(t)D!c<%e5vam_n$Nj;EejjQ#2oxk?XWP}R?$wb&~AOY z^+anfmM3U#+&oR@Q*`NiPVA}9*!JFi355ZTfI;QOvAPHxjSBt;7eEaC`{6Vi9cM{J zkNL|}F&B=aI!&L(XTl@2dCu_UXjdH>1iYmZbTuUse*B21S{$>W)G2S?=9}~_fJ-9c zWxxa)lJPuzg6hN`|C&aP`F@PQ_<_-TfXwjWq=^GndbD3j>=Q>)AD>U3Hhu^x&Gx6N`^k8my0 z`phrf;aU^Eb!EvcbSmX%2#Cj~aMs!qhOrBM_u=cxR=cME5fI=1OKHt^I3-=7X@VvX z!iGb2TE*qM?4VCxNZ9eH*7FF=3pJUXk!EXH3V7WlI1J6EVnej;_hHx?EM#It-cil| zx+skk&W#(wX8seu1A0h8Pm(1Kp5Sv@@pH42m-WUx&0rX;1?*>GNfANzyD5KzSI@f{ z;Wv>E{x6?Ie^&TGAWPQWhOdY68$HAO)W+Kr9aS{(T_BbI-$OmBu)f$Dh<~gLIFYHH z5tviO{#dh()0Jdd|1lpXA6q}mfTwnrgrr3%Ppic_eTIJWmN9mYz}@MK==#rk$wv)f zGiKM?f}H}@U0TW8{Dt3s$gk%Q?^3Iqt$oreSy+~)hzR(?@FQEv$OiSel>JAjA5&%v zn;%n27Lp_OZfz5KMaj5LSWC!P#+2l^weqySEhMt9Kb`iyzsnZSNE0c)Q?f1iR?79m z;6sFuiQblhI@7-Q62BF|3 zbHy=hx`c3>Do>j($`z8j=iiewJnz7C$ZBT?A$ro8Eek~o-bb9O7?05o#$qg5q0y(O zwx7?3NP3L7%BYq`-0GkKtkK9N5cPS7cuQgOILtd^CPdz6QPjqbapu7=RLijURal8< zNvs9>O6CT$KNgULf4}qJ*TO%t@tjkqmhrN=y>)HBpTn+EB`F|i>ZkxGMN-?KSAivd zdP>?$YJG)Qep1Icb?Gy#gQ?ljX92!aKg_-XE0Ibc01xHu*NMarNv8D68UaWUJ;E1! zb4x@$6UvOwl;qT?^t5&%)v*YuwnQ*%^&~6+^P{}nx_Vo}T>qG#x@D$1srd;oFUH&E zhI+M%q37}X|NZ46moU%I9n)+`#GTF_pX|C_6w~S#R?D*5cqThhqf5?`Xm>=kokT82 zdb~%?-6HHCPSS7yf@HyS1t^OmBUR`RqC;S!;_<%rJz zclU^5Wn{Nq75fD2u79Qe_ye%J9^OG?J=HAqDRUZJrl6gWhmQBzUo*y}56TBX@j+nK z5lOS9zqB6NeyII`OXEgoLy{Dxh?)c|3o!{fKHd1gdA>pPb$=`*RngWE6&ePAuJKHs zRwuLq$P$O|{Ywk{W<-iz5bw98kZ$D=hr?+iBuA7Co^sym6VUE@9IJeN#dJzAV5+MyH2^AkPy`}mY8aC(|lRNR-8 z3RgaP^Yae16mCXh%|Gh#hur8YW3fyB8KBNC z!#rD_?L`0HiysEB5?ZAVpdg8f=j zXT7ji@ltj>v2vD)etLOdXcLi2;pbh~?f~uUqJ;w`SCfTXhPS5dx^v*BciT!``+~Wg zby79kFWkn?*Cc^@ZL<(EVP!lOfcWpD5Ep@n(==%ip>;yX5O0002Hfxpp5 zDRHBskF}C0AYaX!;|K^rMa|G0sfu8E=+vxZ3(az(; z*OCG6^3C12=Oa#`**p(;j6X5A07svOUbEUSoUjcg0;SHbMS!M`m_+~(C=s{P2MACp zkx-%MZddTzf%c{$j!=F0ba;95)yj;*aEn+!J;ImlgSKe=L6Fo) zK;#yre9p_o?`zAjVz4bLEJLpuKPV$Q-ePS59ZEgqgy zZ~Bi-r-Sv)DuErPo&dwT zme|DDy&c;^hJ@XAKOmjEzVd<^!m+yI1J-+I!%PGZpk{4}r2OE9smv|=smuj6CEW!Q z*_Q1D1Mkr^lEgyGSW01+r20!hKDmc@bV&u3_47=t>RJ;mg2Oo$mL~T--vD^Z>c8Sn z@1yTdCMr`<(Pn7CO-_Ac=;?JjF*U{M>Zd!ifgY#!!f9pMThI4%WyiI!Kjzljv#Z6X zL@u1kmP{u&$G5uX0Fw|VG{QEww9H?-aqFI<6s>BVI{rT4ztAtt-k`yPh%6UA>2oD} zI0?%oG&DO|R|;-HqbQyd&s=H0cxM#F)-U|S)L2ysf!44_6Lj}<@OdMYaxjeidh(+~ z=BGOs?#(I*m)EPVwr7!!z}GfI2T_Ab=wg0S<4sk89E=gj(NJe{|JUf$7GyIO*xDY+ zFJqaOWI#!ld4Btl21X(-&P7V`o7*kK-bUY5Q6^ZL<7=ZK9xOy$42tf{ zZ!F?IFkUYD(`aCa_uqf$uHneGD7YmB_LK@f*QlK1?*^QH6K+_TUY6X?_0+{{l31L9 zh0@x~3nKWw1S71Pr?&M=hp9ux#BGXzJ~4Mhy8~Gbd~A)}m|*sDxZDz3*2%&jO724M z-?Qigj~L>`>sQ+k{(&i2cr}4mFpI30PTs% zGQR6g(GNwWx1P?Tt@UX01D3X&SPd0#P>f-}*(0!nIsX-OSdqpB|6@3^F>)~?dH)t1c@AQ7d7BKO*CGdLR|WsjBsz zSs3SUjV(qCR>l+C@WrkanliMX-T-tttsNu`Ffl$^M!*OQxg1n1WZ8A~yu#?^WJgy) z`)TE5XDUqxD}WhW(Jn9Dqg!t53WUWP^Pb8^?K;l~K ztAS$@l8z@1yBMqacS?u<@=m}h5wO56Y#?zYaVM9s7QrcghP7jLs7jb?p<+Dw`5#Jj zoJ0@>M=%4F3l8dLNb`M92WSB!M4g>T4LBFB@ghuC@&17L!~p*2Exa^w;37L}XbEIM zuq~}MP?P!|tww_x!k6h_8LV7FiO-_1$9n(-7n(%lw8%e@XL5C+GnM$j8gb!}`J0x~ zc-InEG@?+7Sqw_9`y*#YEp`d4Z@>h1qs;7w_XBknzuM2T=gKp8|Hz4SS2h zLFv-mR9&Tmv((uqAwEuxrg?}?mo`mXqOBE6=m5wuG-PtJaTMT>iYwZQl7;9Jjh>o>kwn>Jr# z{5g(C92^9bb0hL7$606vOPUx>Ry_Wbl3>%qruk$<9jnMEe zVgth^85S+6A8$Lw^INl_uS}zaoq1q)pv5*Ez|k$hghDr0%*eHG_k4;N5AY^)CWJ>e z?#XOG%D4%@6&9kWv8UPK4q57ylQ7B!S0ZS|i{HY`(}dfx9Y;7x;uq>mc8d)lq>db) z6&Z7iS}AK*eZrel0sMB`hA@8r(`3AjW35NF?+G3tY3}P~CMt>qTi%YIJZ#s;F1wY@ zdme7DwjI5cVDB*CIyPqLfe<}+^XLkB5KIir+no6>6-H3<`0p0OZ?2b3AeRry(@;4e zW~5V;5b zR~N~g2%S8)jci!J7WcY%5Tm1xE*)BIy=EHqqhu)AUZu@RASVQ?x7<#5<@w>QOv)29 zf*e?zwRc1CTxLT7r*``VUZ+d~u`D(_!LVM0+Zt#V0vc zwC$$mKR%RU)77?K4LmTFJv@h8zYc2z^!M)Ss$zuzr7$tVC1`U?se-j8To~w=knFaG z5IW+z*1elcER+fq`S-ygrb}=?)2^|pJl-(=0eca6;gGmpe0=p8>x_o(7Z%n{%fU50 z9vi+2Sb#XXuG6UiaV*zKzfIQS?=F^S2V{OAytjHc1zrkd0%hVWtY_l&Sy7$)kqF*4 zv6ZrfXqW&dd2X17449<1^@6Lbk%9-;=Icl2cC&DpaX4akP7sK!b%R|3x?9{9UTpdw z1{)1VfY26(H&95tmRhNx4|Ya6+bZE5=Cja;pdaK{?UX`IPxI6Vtjc1-tK!oJxxqed zAG`TAxY}{dxQS=JlXwBoJn=q{LF2pTkQ6e`U+opi006s({uIAehjH=HaP$75c}*ml zSSn-FY=lZQ{W4oqtt@f4Yiv4?i@$)$#+#yx!=U?jfB&sGShA~rYu@am&(8+pG00Qh zNcpD;g${IxAL4C8G|O$y*Z9AGu=pi&@*KLgF!J|&?|8EaQuJ2McW;;1vDPp8r|Ubk zx`|%?AI%rVXlu`8WiCPy7<0=KVw?eI*D?BtMo~*T;!7#KmA?dUhb&=@qQLWl36`pa ztL03+{UXpIZzOg)4<0i2<dFjH~?gId*@^CJUE;E&(*Bry=> z<#=c9SC4&Pdt5+LlaM)v3WSfMEnCwLZ~p-^WhNf28}j#x$6R=Q$-t!t`%E;_)ued= zjGH%9%YG#9Zxva}G+W3Df&A67;o?7e*+(Dw-})Bz{NcL>O4}P56GKK5BKvsSOmwj0 zF+Xc@CP|dd_Mp=$`u?F}abfrflVJdTc0x~vK_?BS7;$BW|D5M?o&NrRJbhzSr``8= zwp~+`ZBBMgwwo~7uF2M9+qNg$wr$sB*F0DE@4ue4dhuPoIQu&LobA0o2QW6wFp4ZwwElYCXC z+6gPYI{LK4YXU;-vxAqprQ?w6bi!W%1W?5TyOl0c68V*?HIPvFhJ66sl>PJ-jH549 z>NyVGI6L-#Bp{!lEU>89ep!~nWrmPg3q2j?X$nTPURUO7>idDu8D`l{>QQdBFTewK ztaGIVTgH=hEjit$Y2f`7aK;&YJe3HKuNCR#Wtq;*BhEt;O<*aR#z#pAOc-_{fkFvu z|GfKAq+f541`_AmQS8ipAwmM_@l6@+>u38v%)*ZZ_|VT5)C71sI|%oR&IlDJUQ#jY z`Rn!h(QG+(+dp8tJy8}M7Le!*;}5SOn-0|6-mGnSow%|#RX=CFaw`kY%-7HDk`z-L z3MAGOC=$q0ku;&h0R2pw8fELRTtbADfWi?>Z%rTZ2 zuuNG%k8hUWD!3e!iqr^<=TA=XdkB3Mh98)NsnK^i9$oT4eT~yn0$F4G>AHFO1*6&# z^ORl)&@emW;{N)*xCY3wV=g>a>b3}`d0vqTe2oR;`qt(^Of?~9?u&!_+k|7_Hxw+Q z#3(eIs!qH~PELZ*u3s+8p4dC9vc#%N)q#k{qIs7gNx&N>RFAB5dtWv0;Q$Ogb|169kzJ{uRF;4!4 zAj%PmC~#YdtB6JQ{r+}D8w;B+1*&er?zTgIUYPzB7%Z7k*0plgVtefi5gwpIO3hwx zCPNkAc%>@FJ^2IUQ!SW=mcE06l}IZjNE!4jKvX^D=Obc#={Bpc;1*vC%$X2N2D;Zp zv_+D;dp83Khf>`M3aTAFCbW}*EsCTUGl151rB+`qA&384ENk%Dc;jqq$&8XODvlo% zokW>loC{sCk1(+Zqx1u2Jo{Tp(19K90{5d81B2XX#MdDfW;Cok%BfCB3jC?gzQ&>g zUiPz3x2`1=4Y(vmmZ4}G+bIshqI9jgPIs9Z5$@q=fIc+3#ULkon24V_x%hoHVkW<5 z0?k}iWNs&@ty%z79K(S#d=5@omER#!6qZ>Q9OR8HB|51Md`RwyosIyR{?DZr7Ca)6 z0_uc*QQt&idF=vQ+_$C^Iz|_$AF;@ZzE%i^JP8VgEMxQ7{;yF2(z>#Iu2Xz8N)J}? zU$+@;I9mfTeaH;ZU^X3`s+AuJo(BQH2&Y9 zO(Xj!DJQN-)_eYs-yz0dkjFWY>L#=k0A?Dd7gK@O+72Hwem%^_n3kK|Bw&ZQ z3UKd-WhkoawxDAf#gzREcgrEYI3NM`6Uq_3%m2zn}9S3wQ<) zUpY%MVhyBkRc%`AZJGa58d(Mq{heu*k&GsN<@T&{P0qh6tBI9v!_Xp0Qe}tw%FEGg>u;)}cS*kW zebtuVD=bPO(gdS41R~1r78q23_V#$up)Utg2?~bOuwZ|g-<5F!z5-SP2gqD^8SF3{ zA*%2r|7S#$vWP-_)t!65n@>$%9dEu#0s&~MIbJcC(Dx_VKfCLXW6uVuQ)R^E_}SIp zrvF~L`G6aLr=u2w3aJOgZ2SisaAK$?fS6e!qL5Na7=w?R^=j2=+YA28iRi|p`hgjz zPHZhad`JQ~Hm$Lh#Nykzf14;XhSlA%PX9Zy*#C}9{hR!yA_uJk2M;F^`}iCn%sk$O z{xeB#z%WYwgqW+Zb26;8hP*Z)zQjgWL_soTnqO*AAQK^RT`>TFrK4Yl4FDL%4^bFE zz))$Xb1jJm|*~6c4zg-?_8OypF6G&bMT4Y>?;4KD|cwp_QCDH z<#KJFxFwP*1$3B*wBa*W410nJ17oDQM17Yi9w(1G0*Ffy)nZ-FY`DUB>^% zNe2_wuyJPLMLAI;Hw?=hR9AklxJXObV1OOP6{sHYV%GxZ6e6ow!%xH@X!k~oN3c400?>FkQDx9Pim-D0Gj`C$%d9qTrduTA;Pn z$g*uvR}XAb591`}v%&Rw5<{us9H7iByL1U0etoMD{QA6ynuT)HwNUU#M5tIQe?k$0 zYYy{ek3S%RJ`OnzbVO@^7<_vMZIE*YZ@ohRN*X&?P>=}FMqzr$@O^u29a!Bg<_qGLLwfGfj;y#x4h`#L3_2w+Nr z7{_sBMfRg%0^EOzG)3V5c9&gwPJIWRd4~sD(l%U|6a+)NcP<8eG2fhTfQd06ldzXr z3T?FIfnT zebaIgjrCQpjxo*A{aHT0VII*KaVG!KZ;w#Wv#wn#UnaP8r z6`{%?Q$ECKa5Gd+Z=kEr?J&;~U<@z77&jB@(gO|U?<*M4xG zOE>Fxlotdn-VI+EgrZ;&oI(bkBo*6Oat)baoy!E~3T;8mA_4E$0K1bJjs?biI@lJB zB@7W|rw*Qk`poTiR2c;5=j%yjc)!)9cl-FQgYcnZv(DCNJd)~_l~eDI4s8K%_V}t| zzgvISnMRfW94-k`K$D#aOOiqmMV3e;lhdJ7x1T{B6Rb)=t3|T=Ed#E+FgLdOXM>0n zqIn<;{$f?pGOkBq!EKT_pgbjxs3Qf>qiOqOeiM%Z z$Xg5sFaT5vm#BlkG7^RmMgqEKUMI9GDe${H;Xm)kUtv-VV#fM7jhgZc2@Ec$MF&pF z$yq_h9hMLv;#7cxKpnCikU$%)p2@kibj9VXxmZV_j%A)9(h7cvZ(y{GZxH4v=Wh_= z?-*xvucQi{2|Nuj*`OXN|8oVk5g(T1T{q$@-B!1HZ8n7bV?)w&*Tp(6NN{!A)y$-jdcARAnYB|7_ZrLX*u4>=sB&b;TAC({j zFTj%!1V{j$gzw@s$8b&037Hxr_5=4{&A81~D1hnHynhfw`BEtFci$UQDgI>I@*yU} z8RRLHNx@!MGR!_7<{1O>;K`bv7C$ec&=oW7hl2Zi4niuHM(Ek!n{Zv#QdL4Knhjhi zE!-0@biob5oMwd(N%AtjQLgW}rqt9myrb$)m4^asBTg$yHxa=QhX|`V>C6%B=cOm5u)v+fg z@h?I86Jq6nhu)_pQcl!2m|c#VUQ~S-jB-+`3MiAG6Uybj%gD*$yQYkt7;Z}8ZNj?T zW|R}H+ST6LR$rxLE#ME`@z^|)i~|FBEP)IY7xoNbS4Yai6`~j(qnwVfNz5^SmcD?~ z$qVU#A@J4EfIqHzk|At#MSu3Uxg){`Abg3b8nnflds3wUz*W#b8F|M`ju7g#WXZ^A z;vv%rQd10iC(I=!`UT{~9^+iQK|~AWxXMgWW`-9DZF~8zRu((vD0QIedK-iD01`QJyL7VVH{2_Sm1e-X)lMkS_^uG{ z@2y^>L#Kt?09*r`unN0uCC{-UP6Y3vmfgd_%A&}@ zB3>|9tvdfN$B*y$IgP%-xfnxF_LFo<(q2=CMDO5Pc$Z!qAZ0(U+~~VZ$S71R$hj!h zoCPHp$(+Z}25K7slqh;zB(MNGwliMDxg$6roPz>Ldm^NgbDU@TNDw4&S*6b zC{sX!W`yhKu9b*^ETPbm{RE$d#Y~_aIfKY((g%bKnp3_9%mn!$Xj4&c<^tZD9GKWH z985}^sm0)@29QAVS|mR66Egsr8KMEO-*dZ@x|-sF1@7*t5OKsP?3&wnn{9@D<|t-(G2uhKNXZ~3J-X66Gdp-PQ(%_nhF5+@IAl4b z*a1VJoY>cZ5Rqj76S?>WdPFP)p%G*B4#?q}eCNz#q{JMb~ry?!oVn!~oDlg7D-9 z5=5xr#0~GF7--}eP#_E4Wz5YBhxvNPo6rA?&0d1Y?5Ma&VRxz%EH+<0KYxMu9zOK_ zd18O#;_70>%9T5#<4b4iyFysKcZMq3yg~Yec*(+2%}Rib-6o4Ukd_#1p~3-}wg&|5 z1&DDpCAoYGcT-fkF~@9v^U#6*(6IWdOiN(1Xn{5i!jOQ_Zr}+6L^E3Ois-yEziCix z0{;yl*x(IY{95@y8NRV*=(5B$_ThKRVrXq+w?=%WW`?Su5!NyLD0V>+Z3 z={`@lC!iX1$NS1&j)Pt6D`HztLSV=+3kLLMGuKl`F-vF)n(@Xkn@+Q!E5S9$^lz6b zJh&BL!u0$Qg$z}s^e;qI6vE@=&M>8p)+?6bzsJG^Y&{I%&cgIj!1KS@c@fXupUp0`8Lt@EEwjzEv?&V&un_F>e4rN5heiy?Cfo$amc#8= zw3e{PK+N3GQUV8@#42!oSBaQ~gs2rqHh08K;iw_BmZ8)ju`_|u_QsY_SU}pXEJI;u zyJvPu!uOWAjc>8g0ro5(Qd0o7pWs-L%*O4(jmkZG!1by8=hvk7l$HoRi;^`j{P(Vm* zmIW4ofrf*Eij1ZPU*ZejudJX?l!Ff5Of$|(=qL2({TY0_E~4NR`1K7IM!>pdK36K) z`T+!@OtZki$3KWbem#JF10QzBBjVA5U4*LxbX9726$mqn|G2VxjDIT_F?0kxby>zu zHw%Ue{P8p5|7j{RM^r38Q%NkMU;%6Qp%0$WE;JNx_I_4qMtFlDLpy@78h)gDm#XC+ zOo%%1{mp$dXj5;1HSzws88tEjXJfhl^2FFl~dUo})9Il>``rZx>8_Rz2W> zf>4l9({*@GRW6f6094eR%;0Ic-J1Q__ism^xHv7_f?lt=U-q^5PF!!*fJ=6Mby!LR z_~O?tF5KKLxZa%M!D9ga!*y+$VIU*<^6 zxnV@uaXqime zy~%sm^MWlf&J7NZ&k*Jr01_9v5L^z`2 z5s6ckFudsiAT;>349atyagFsz3TO%9AZOiWU}yyTmCW^%VouZ6IHVPpp-8hiiU&aH zc_(VFnS+;WVqa#`Y0+&A5eOwJZWF!`J=j!?{c9e}5X0kn$<@;(RwG-d zHpu`+Du|;WI*gV~T_qPGY{7*|IT0c{1+n@lJG z_DkJoR#Nes5&Jxh=CXtXyHQIT@xOlj7drYx8icx<7Qf^L_}`^*3oZVnMu zB}f#2fHB5bbC|+)NWuZ6^Xw~#Ie4c;1Ptb7F0P%zM| zAW&+B3fuIHIIP`2*q{LB`?9k^X)eQDI}|wFbbya*%YMpjN^u$>w_wXVY!Mnt6~(pJ z{xq`=-kO*v7>wpJ8BHAK!rn zp26B+Um|z{6x~4HwJr4Lsr$pnfzvtf@8$7KWfK}lNlh{!*EwEsSPsrnHT)uxazpuM z!1If4qu*vuOg`3>3)G^4n*Ls&fp$rz7RtihQYZX_sgiM#Qee28eOZ1`8* zs_d+r<7ChJ@vcTeI5n^uKmCSIW<(9TUMUc}xwD!w)#8YmB;p2#83-crHog6s3G?gl zx2C-@jKFSBl5wU;{**#~_{{#s!14a>g!!G%cfy;64w99tONK3*{H{sDum8Tvay-I0 zT6n!ysFe^(tm9!XF6l1|(f#JiNND~HCDG=iad3-GC2-z~E%vrAAH_bh2R3}POQ4GI zw(VP_u!q2lJ%>(7;q1Vvbf=e=C(W;S z%)_d0XRk-X4K12m2ai+fo^9aU$aCRmXV=m7bLl(J)^~ju6LxoFE9Pu3ZcmpND|bUH z&>W<14xJVq?j=n#4eFe+7;=zW*aU_%J71n~*;({aSvyj`I6;mE};F^sE?3vdP1Vm@qtGHi-Q6UfC?#R9@88>mR}F> zT@UfaC(E(D5;*Kh^3BYz01lS#%4Bcn?%|w*#o+Hm9*jk_&27lg!HFD8I)42Bd}-KSw?YjSi~d<5ur zoOcU_!|x3I^j(1*R%=e|F5B3ALk4(qj@;LBz1EfMeWQY51(+nDguayiJm-GPo(2GW z!~Y?p#nKH|^^3_9!G5%WeYmz%yte6ZqcaX=B`JC~v@e8kRhXGWUYM~UMPmvMilEDs z8Ra1o@Cp`@W+J?Q$B%yA*lilvkRBVlRXTzF`47SQCGw>;sD%%4E3+bj!ru>D8)&<6 zBnU)0Ru|YB&%eFDfz@Kw%Q;Mbrg3l6-Ll1c%)Y_81hasSjWvpyCc)OIy@4`G@eRyn z1FL~ohh#wL0p8SE6uOwU_av<`MqGx9GQ+kfLEBDY2*&4u~Xq9~^1;0{^2b1afJv=Eeu3J0b>;RnLI-A=z+e~jMWWdwFHf{mGoH*QHZ?rXZY{xbZs~bO@v{p;V6|?|62eaRyFzaS3 z)cl)yU$h06=Ui81>5Zju>COO;8-;tAn<+nvh>fQ{HNc-6c@&zOyaFx;O2e#lv$?LC zTl`Bv&9u<*j6D%49R?y66w)E%5QAM8$zYWy8}8Tl#n@%&U@RnOyj2NC1-wsMp`obj zX3Ny0n?;1$cFS`y+(utL*927y_NIjh{c)Z9b5~Lkk%W3+f<+V{!1hooq(C}g7I7d# zklbUVNO5~|t+ttJ>~fX`(Q5nV?VP(dH!BId)V^a*Y;~m|WDB%Rp|v$HqMFAefQc1E zq9eqH;`AcMW>&raUCgJiIXCYnu#$FgMb*JPsc}*$(-$ZBY3^bIE-lgQf2k+jo0#-2 zt*{s8TXPpv&gqFAUuB5rXFTg`te+}8s1)bIMYo!LCT@#$7V>=fODtkfPoN2%7-L4>d8f4$|p#8cXScZPkS{!f5L)>8?ode$#W!lNk> zF+vp7xu<%mM%>iI#xg%4V$dq^0x0>uy5ofWHJEjlAT5yjQh-q5N;O69mu^Sz>f!_~ zq+&wKqqU_dZ^HeCkeS8tn?}JMVCnJiVea+g6>4}t!=*;MhT>XRSCq{{&cgiu1C>_mum8>FFobIvU9@T-b<%GJt0eL&>y zoW4$Z2&d4N0gTx07M}5NOEAiPU#umdUewHnXBm;|yy4+9>pV?TVL9w5vAvEsV42EY zUzH}=KTgdt+Z#X0o$iTCb!L^JUm;RJY*TSY=FH@x4}S(UB0#f#d#cK8l`zc=mw{$J zZLAFC>??AGP`H>^=IvCzI5u4Xem9I?Zh3Orx~Dl!W+>v``tzJNZH0_ufvubG9*UKT$zQB?{;;l?16Pib=rrsA71k@@HN2 zjdvu3RC?S5(imjaFe5DY7J209$X`{gZ1|@w*z{}*JjwBSOY}E91*5k@_n$ytCV5v& z%~x7i_?kPoRR4w+c*bDt;N_Ro;<2u}=IHhpT>CDuqovyQhV1FNwXD^9D0Kd1dAQN% z{;F<`s?@Q;k`__@z5QCSgZ1}m%V0p6d^&QJC5pqFAU^7)kEG#9?~K4D!8?QFrG5@eU7;jpG4Hx7!$+^YMuwh$mm1QP+|0fm!A8Y zmmX0c(fjW~xi7T&)NSqpWgbD~6)`kwthB2s9t-Sv$jjFOcdo7C+s|t~-~d=!bf(%C z6VpLBYn)wcb``-mDD0K**H6?b(LK;gf#sb5j1+SYLZe9NwQhst4>_|h)hwzp3ibV`0k!$i2UKou3Ov@l+mX=iWw8ULDjV(p^uv52 zO7-5?vTe(zVrx_sgUKzrRrU-Yb6zruBBAdqG-ZF)`;#oS;kC6qFW}w*9}%NdbZZfZ zz?T!5X}*y3bqGYyjM*expNAti9Ad@hn=@uu>=rn{c5zb>N0<0!QAk>ZL$8 zYaV&tbY_tj!d0-1&R)EDX#&~;cGlDG!^YJfUcjKJaQ2|V{I1R=jI}CB-l|K*f}hG0 zh5ccU4L7^9lHZ%AK5&d}6M2e_*u1Eus zt3FJBoFXu>c9RS98^# zRz`T$@WN-vSiTk~6-$e5?4!V}+w+4DXQ%wM!d`s$uGy%VMS`qOk|ZHRe!a2x zV}oY(eA$D+z5RQIT2`cUvDQJ>k1QP-+fzHKmw!#a9ww|wC9^(gn%@occ??AN-i=Ld zNsN^02C!uR7K)$M2MEwI?Pq%F>I=s+9zb~LUg4#A_M2~okGh#KDeN!ESDVjhfXM$XL8_fXa58#c zen;h7zNGK{)qN5h#TRzoE!kVA@1NT0QUixWyY1(0yfnP9m3Atr@d{nf5> zN+R&`Ec=c0;y@KEA{`#GW&hl@YzGq8+xFY6WykK}-p>=^y!e7?Mr6ZfG1A{=aqp{3 z>dqw9HD*?eq5Yr}8|e)VTY1;2i=hm4*!S{{X7fKtb$`sCg)Zr`Ey_V_v(YfZzLODk z(LYz&$yT8zCI_CwO;fh`C*w0dtxEUqL1uqwMb$g;xDPB8Gusj@>bUz!7nsQ2QJ&qN zaOS+9Ze}eqj3Dp&it9NK#i%Nm(?=UNDu$&8BDGZdtIp+${L3xc_g}XDD{U;qe#yCI z$`h{U6u$I*)O$HG=64d0l3Y#Vv}MD(P{ybp|74nJPBS$&2NLm58Ge@Tv?IGvo!eu! z<(|txvk6iTuXLNPX&tqjzp`20dll}!!Q5oZ65^6}IP8cjcOW_rQl$Db;GJv`wC*o# z^NL*$j`I@c$PH5;a8Rq=@U65dRj_RZsMg!5dVtNhANLQc=ig!Yeuw=f zR{pZ}f}L8>19|MM4EF90ij20tkJCx2c)2lI@56xm4Bh1Z`UV_%Iai5>^YtC;%Znv^ zOJV=^8JJLNrqrTd=C+{6_i446u1OX_1Jlrzdvh!>#YgB`J7d9LW_g#$1}y}5{^D(K z_)ep=JeE*(Bt+Tt0{mTXjK493%HJ~#8xGXzWl^d3O;5PJHV;ajHR&WNxaFEs*=f~Q zR$opWcwblY>WO~+8t9Wg^r)XyXXA0M5%Y&#I&bX}t>>bqTyEWAPn#f?^UzV8R5Hl% z<-y|hBTv33cA?IlGem0R$}1H8`{95zt%tNE3@W?lszr5N=+fJem!3-*Ku6~EGDa+J zp;e;h!!=|k&zM|sDolwn(bc?qm~Q-`P&I{oYdW&qzT=;0TVcNu)kBk7tGyj9=k9Lo zXOKx&i6J>A2 z#hF(wJQOmN$)oUv(*nX*;ii!FP6h?#)G0zFVs&j;Zi~e+)s!J;QmPcBy`!401O^+! z*P~0stw~U{NQabOIlV$9?7UpS{^w~J_|*=~3teF8A}03HL;1jh&py$8V2`3(FOjQC zH^XgP`O8*i`|WGRp%wj1?#*Db#b6RXDxD3Rdhu~%t95JeD|uY?Q#U&7sbug?0z-DC zQ+?gwz#*+>l=TA{^2p_axq5e*SX17ByzI4`kbHyG~9Z1<1m+Y>VyVp3j1(9uv9KxsPCi(47EhRa&5BM zowihLMkaah4bVUd9JsJ93 zZVEUo~UXXDolubR$#iaJ`@C z=tj9R%S8KgijG#+sW!>MzxIZ`RfAOS^@joyEp%98GRM0v%;T>zq}q!46YEHvQs=Ah z89%jc7^Y8K&j$!8<d^2ScLun0{p=8?sMZECHNXh z7>+}v{5?^X_rzF9+&X2bq+%Kmm)aL#Uga~IISkVgX{_-7J2MpB)4NJFc+0@#%FczV z6`Q^TlyDFfDpiHOsI~3CY1BA%6|6InTAv}((y@3XC#D_?(g;*oaDEH9-xPs4+7sP~ zle;{rc$X2IavPn?O4HqkUthI1Ux`i$GarvFQhwndy2o6Ki41qBk^j!1xq5C2 zmlVFpvy|)M~QUmU%&0P+=_9CAMO}08LOkbqvWu6J7O>b95#v?Q1SyBcD zS^{j=o6Uh8)3W$IA8P)-G+5-^Pvvw2RACbz$p~ zCME>1ke}m>zO5X)h}xX2OazGrKeyVB6ctdkvPg0DD9tV%kA`x2Wm-;*{Dg+vNET&} zveHG8Mylnikc0nz4j1mAQClj51kYwy;h^CVmy0e+hI+L^hGjN3EN$@lHBRAH`C{kR|iM~xf zraIe;mG>pDoZ6>fq>#*^pB0B+zx53~?aw`#ma~{W#FUerUU6Oxz{|1{j>Kl$ggP>b ze7%fZ;aw5M7N(}u$a=%mfk7=EtiD+|Kaw-AxCoOrgburC{aARAJcW6XEJ3avsh67* z?w8PXTxg5Ug=b?yKwBe-<;|swB>xAFW|719(;Sj)J`PYV*xxf0&YW0OUNMNwY@At~ zA|F!AJ#2)Xf6x)9Bjp_oRlS$S7ghu!W2I2EVgQWuea6#)LoLpO9|T<&M0Hqq$AtLd z6$+UlM=5;18lHs|Dr>9{#YQUHR@W*RA|$7-_Nh?fg*1xhB2bu>3{saYN)B+XHC3cu zhBrVo9-a=2z6)f?#C_A9dvQG5otuconGtf%hr(w`xRq%bigWN+K)TNT&edP~VjQ^g zO+}P|T4>Lg7A+Dy*lXC?cO?X;^dt+#RO7t_`o6DBG_O-S#Dju?7VSQVLcK=fKgA-` zPo>g@>bO89uCRQ{vx|EHAq2K$pO139`5;{NHaGEf2mV}u$@6mEF?l(6(Uf`rkN>E= z;^`mELqUXQf9mm9k^=~lbxS8?p^Pv_Txe5pu>n8LT6taYy$as`U72D57?*pw=Ie{yz zg21c<{Cy5Lcm_ZJM+pa^BRPb@AsvKl17xg&zt9!?sy~rjZTMi%wqULOIJewc^bJb5 zQ05}x@;&y?8ohjEWScubeU!^hPy>a|8E6Lz7$|2vFCy_i!o$^ za_a}d#UK0m5+R|Ne~%rX_`Hzh3446B{x+Rdxvp1K)OQujO2d&WJotcP6;j}ZNO1Ki zyx>KOpcKC|(n2?ai)}M2?ko~75MwoRSBli|koi|GV+7GJlS2g1FTa2X)4wU9G4Tj6Kqyr90dB z^Zh*hy6gMYkK^5}ZRzXlL(6t@X+88z(Si*9JFiGNlF+%O=4pIUWQ?XEe5j+_g%AzV zvpdwD%T$<|cYufjAu7gy0UUqsB%G}Ea zkq*Z+N=nLlx-~-9o&Mhy&knZiubXnvEm{m3fnn^;@lM&h5SXv7$<}rBFfFhaYkcHL z)B|#5G?JFP|MaxvoZBW`6045q`ofwwG$+#c)4$*RLV|z}i%4_YPg>=t!Y@OvMVUwK zA{9?Q+2iHMHMJ|0ZT;?=XHYckIZVWTH(z{kp9f} zpI2+p`B4d9uxOwy{Xvnb#)k=|-`{3itFK$9da>OnPGU+WUY)dDb+qxAacm#-q@Jyl zNozx%^2iy>%+`Azf=LsFS)fC7@B>O!A~veVf$;{<8l9veze7o?KM=)qDN3+gl#iH{ z&s!Zcu}uj#TORVpu`0*j#yB?k;Z>4Ef;8z1@AAkHx+flAP~fEr63GqNMzU^fOP$@@ zM*fDqa~z@6H^rOp6+})@)qZb0TeAmgLcESLPEb1XTw%7@q(&n0B{8J{p+Y;9H}90| zswh8_iqC*h`8bH>kD_eRy_VolWY_&?v{Ru9=K)bkzY}e$g1^J{GcKl@2Dc$eQfon@ z4o!A$%&Ap!X{ycBbSA&es*A@y4jfcOvcZDKWG3vySjoTEt8;$_Bi>A<3k^EYz_2BL zUl8NDLv4V2jb55_$}GMxVsyElTS~rSWC1ZG8+>3kcbV74bItE;dQ5~)AokVGnVWx4 z5Tn-9=lx_a=-$QKi`$R)N6uINeeF7fKScwVQQzeS_0YL2q_J2XPF ze5Z>%DSfjf65x)h^TqQ2I4T5v;QvtjnW|+5*y?q8xJy^z{q+P5YX((RfP}>igCvhSSN*)p zxc>aN-1k_A-XSW3P3Zj4vrCrD>D!>-589g6q&T@XKQT7@C=Kak{D7yp^%ldLFoO>9E`tmg1?>qc#x`icr^ z3y0Z(__4KJT$%?YL?3*fsO`L*Qxtf4f}f}cWK9EeTO$qjvwmg?ZQm>GTvt81n>UMXQ&krp6rD+y3)AfL$ZnHqPyo)Js1@KaIQyY@sfuw@J$P?UkS)afGG$? zI{70=Ln$5yZZ0jcpT6J|;~U-AoeX;N6JnD6nSavT@>tRPLH@^g%&f3W4gItjG)XR@ zuoYCoyxaX6)H#ZU^na>-qifdgK6<0SZ(gn5tul`+Uz+NRJre<>x-!}J`*LkvStK!N zxH723+B5r?=EM+3+dWhj+;AHP{9)|J;~b<}CAB**1!ORMpd9o~6-p-DScZT%7l;){K?K%5lIUG}yA z`1Ee?e&A_$-rd9H{rVh@rmK}{$7q%FB&l(Yl-s2zDxb^=eVf@VCqPEwYR@-XDE4|D z%qWcBgIHM(oh)QLDQoCkM+7uj^lmoh^s;DZ<*2rK@((aWP|cxnSB`) zqs0Sph-Ai`eSQ0!P_CM2vQXlR@6|}P8uK&HMB;H8=NAA`&>Eb6Cljb;%5*Q1g z43xaQ#s}!yb1^Y4%@}-4Z5pDj65jj>`>EuzvHjX{_9ThAEDaixfLXE zu;Elem3A4zZ(}^=e|8)-*R}p-Z3?_;YD78l|JZLg3XTGg0;xi-b(%+g00=w%kMJ=L zw63ZPEM2{GARj;3x#SNf(|N21qNI*vGlk*3ra<0K&1*5-JqO{hU*~w&FbFi|=?G%4 zInkUjJW%Eot;)r}@5>NzbDW+2t1&s*D#@us=wHconBdmgJiztRa52a{THELhTYU!S zDowm!GHBC%PpYo_H_&q=nCsjx;o2$c6*^En2?A(ZwCs*dnJ<(e{OD-c{F?S5zFF%_ zu@6t%2n5J!JboEzq1gswx^HYHFW1^-gj*FPeNpjD55nHak=UoIYhPruGwYtJ>Hd7A zSy#?!$6X{S*)0iFW$*u5WZF(Cq$T+oLo?p*Iv+kx3Rg)guOQ--xC8dF!1lzubmBS%o6s?_6dwH?JH zdvw-Uha+~%tLWgPAgC0>zDg6&jf_#Qdl|G5Qse5a9TO#1yG5?+4E1n*+4UFUXZE$v zXXlq7Oayh(JP+2BtsT7mS12t+OvtFD?eiVk0p@!-eS$-{K`t0U zKQ&86C^A4fOG2#6>|whaJi)R2H5zV-OT4d-N@DSzwJb8bua2=+vDu*1Bnc;nNusRt zU4C5rI!0^+U)sP!(wO|c07^Jq{A$&dkNBmB{1)flE@mWy;qh5nPW|HGD~zUOaxYzh z8Jay(77etUf&7vw{Fwv>5*G#b>&@NX$+)|~S8Y{G;ka_|;W|t%WUapsTx-0uMSTqo zPA!DSk7q&XKkaWXfK8U)CDv>HP~?Pk{c8m^~x z!l3hqooQfW`bqKHuT3f@XFAciw4EoZVt3aEw~oXenhiQLhhOVx2();1KJijxVxVngoLlFpDV=4g zQnB?(hGC^QDhQo8B&?uSRXb+67P_~VzrR=U`)&YEEvH3UpauuRX8Me|H#hQ=%HcPm5 z-sT)GyrBI|Cjtm+rauPA0DoG&hv)Y8|7+_iprY!!HV6^|!w?cOGzuymGIS3hHG~4v zLw5}@AfSYlfHW!%64EUpJ#}TgW`<#8wJy%WD z3vR?!pzKi3=PZRS+|BMoG3b~M&L>%~H+lQ=C>kie_zFLUpz(5z=+CW9zwYW&Mk0HEMcuy|rly;{adzM6wAKbvFkF)T5r|1G=VUYy28k|#4wu?R z;r3KFDyZbG5CwZD_`n~#6HV9Su|BAzo97&K$BnNtDQWwA%VH)U>yq&Key6vdz)yog z%TTw2r3);BIMsYIa%;(A^kLG?ri<_lv18Ffa(eHw=M}+ zh4;vz5#Q-aj~F4YdjA{ot7TEQ@4hSL7I`NBRDfhWCG!CJ;GspqgLNj^*@lB&q4NW^hC+)kqs5| zpW}uGo5I%*(_U~~dHVRazZ2)vLXAEgK)*?*vLjHZM=<7QJ(dbzVVIcctUSP!9AJg3 zA#js(!5bkOqY)OUQGB*sZ@o33;jTVwjcqRVW{4ys?fgoxioU(c8%OqhFf+NFZi!G} z%P{Rgcy3KDzHP4W>RGV{{y2qNAQdE;h#dDQj4x-|bipMK7?$wSQsX0#u?{05+df_| z((FAA;9TLTcaIF~<}6awcW$aLctJjFvMB0gzRjZIM!Jg_Pa+vQD4 zPE1LBysW5Kp5ZHat$*q>M0oQz6rn`eg^usTbc05o+EgBq#Np@IF2y=ACb9HRF-P%s z%5Zw#Ck$PVQpKHbe?@I(9&OiX{q&8bteieWAFCyY$kh2sXYYlt&O~kph+qR%U8L}P zeDsF!g?pmj1QPF&V`oL;b#ICVZGA9(+!4{E6>bka!naQYU$Ptfbvrek+KtxxUxS2f zKFHRTX2;?YsTG7Qa|g0)YUnJDSz2kRu0%2#gbdU(vt3eSl<^kneb4zvkq7Ux7fOz_8*RcUPljI_QU24d_($hF@)4tKlccJF76fZ441{(P#^+P- z7jDnMr{c5|{2T64hTsa_V$y`Nu;po`8ZHmiogiHo5bH~0H0=-y5V=w?qOt2WbJQy! z1-=qqBKS{q%$2iU`YzH%p;(2f+VLMT0c@9us!V-4GQf_~oDs9GCkW^Ox0PU*J0 zr-o+d83j5A9%bD>Yb`wKO?&-|K3xJD;yzMt8xp4m&BWQvP*&JI8RvfU`ZmYT46UHn zJjce^65KvLJ+F!?V_6upFscYtrZp06%>dJo^A)>ppSzr_Wi;W^BB0FgLv-KF)GYI1 zcq(HdEgxldUJ^LvFb}~AOtCFFLSa^wd#Se)?71@BewN?h#ZVj;<{eCE*L5Vp0otV{ zFB2iTrHu?{rSl^=9P)OxLy=JR7EmOEj*yr#z|wxKHZpj$yf68YYp3T_S55Pc*Zwmy zeQhR-jqT>uw|hmA516sFsIhH~BXf#+;7#4-5oWgVK`X1y{Ji509oyZgjCuPwWAzQt4K>`n?uK~12&7m|(5V@a2(5zm8ty3$PuqPi z-<%OFHWk0H$VqViCI| z-7*;zQ;IGbNnW>;B*?~=chs?4U!aBrRLxHvJtckiAn=K1?S5cDgBukPW1yZ5Zdr&{ zzOEp;#m|2O&mAAClqrsOfy+nuQ7O6(zD%-ShQ$XIgK(v!aQdX|rGm~l-WA{owzecN zF!Sn38@+NmF?A{Zgoky&&?!Yt5)=~fxP2=K3WbAd+dzAAa9V^=URIlA_y-}Y=Kf0O ztR5+~;DB^ethMxNQkjc{z9#`Ri^fW!B=3qomPqSVWsiEaw#;t1oV!0fa`WoOE&${HQb~B!X=Ts<0!m_JNOOfMfe-; zkctWP;C30!(t@NEl28Pm0t__(;RgOGTnZxv2XkP+^ev(zJzi}hhrj@iS1_~c>c(3p zcKSa(dRpf5|A1*x17Pw00W0lw`7N8|U$S-R%cjGwWrO`!wk#6r;(}bpohgZXxX-tF z!Ne|*xFPcpXkJdw|0{}_7J%6+Me7U<2KuG29C9LPo`AOcIzl8puU+8zUl)in^F9kT z3NHO|?Sk+>E}#w$39z{Z;)6igLLyCY1+#$pIArwtx$?sh{soKa8g;;g#mxR|Zcfm= zqHTE7UDvS%7<6*jO*Ux#ejH=r1I=?)=%n5i(1S0hhhNH|r35yEsX-ue+0N2{_BtRR z1qcg+(F*SaaAuWh1oHuKf7ykXptk|j8sI-xYG7mvLC!+Jgdj+kBVAi zSi)LmKwLe5KptF+wzaq=Lx>yw`i3i*CuTMMI*=ona7}5&faj%t#}EpU6HN=)`easo zXBH1v&nsp!kNl-7DdA@g{MCo9+%!gMSTe7?-EO#umF;X7F-nPcm6hZMVV9KzDI0#) z`>aQ4G<>wARM-0y`Td#kxkD+m;j`|nsPB~ddD|D#PS+cqtCEiCA=Yb3b*Thl@>??O zhe$MY$WY~^IkCrhC-TP|fyvgj%%<1Y%b7(fuQO4y8>vw*Ju(b^$|5aTfc3DIlyrxF zoj?Me+$?HfU#`x2wT@-w?AHh~R^(@RS+0~E+a;ku_C4Ghz64am7!%OemX5SuGaLtR z3pA$2P0__(^s9F8ZJQ>{(+5>?Y?;^-u)fXy5*GkDBO;d(SkmYE<^$)|phs-xG6VSY z*+yYSM@nZW@x6_Ppqz*R)n%;dT%pok?t^an>I135EK+M~ffc1@b~U}bnZA^3`BE3T zoVUT`)n?3PLt!sSJJd;GJR;kTlnwf^Y)DMx&0^k?9ZxC8|^MNE?t2B zw7%DI|9E^%c#gdz_H+!%KVcY5)@Jv)nWcX&*FpAr7LTU5gG&{OaoezYKbf!}s|(tRPYL>SGa zCQs&1rN~&4d+nEi&uG>zg5Bna^}H2bBhmiom*gM3Sus4X<4}Z0JHi6nljFXEU1eCB zY%$IAM#Igt4E&WEJ_^qUIR?NVD@Wvh49BEJrOD9^DAc5$d854Q`c1b?Ul|$K7EPdOr1wei4YHjv6_th`4F$L??Vjl>1pC4 zJ%Ft>wl~MFydA1odLt@6Y<_-kAFpvfpBU(aPQ3EP!OuZ;ICWQU1Wnv5+Z0am&*%|D z*~~MN;SQ-2YMwSes)7Y}&mXfjeSVmp{5MmrlIG(O~jj&g6S zZn?N+zZ-Ps^DYZ!1F^LhL}Z!&bRfN(x{D6`A@JaER#|-DY+zJUv|#qK$+<#fc+UX1ZT^Q8hX2T%cm}B>o)c0$rxA zpxQ2aCn?I^gpX_1Gqz%xr=Dmy#}pG&icA`P|3rX!yznEnkk8~T8yHSlcvfo^hFu9T zAbyv_oCsu!2WwuxGyiIf6!$HriKE^vV+N@ab;UfI{y{$SAr*NpM(Rbc+boJolF@IA zd_MWGM)uMzxx8xQE@QEM<=H{F7c)PMhYn!b19NfjfwTU9p8)E>nYUtIlL)O@T{ZA} z_hJdCGMXdB2i=ph#~VvIfArfVis_||m>*Q0AAf$UpO*SUA9@hH6iVEff%q^md1FRJ z6#A|J#IvB;RJ^aAHC`1^J27%yEmB$s7h3e4oL})|`4qdmTD) zw%yF66|tmN*sReH8=k(Bx?2ldrLKtE=I{r6q@h}?|BFySBXbs&w6B0jd=|UD^vIDX zQohD-DXZn}dX2FSU>f{f<{-&%GrWl}*9;jUbIeDk6Ciumy~v7R**qF7$>l?YVp1fF zNLiAQ=sSzE6pMXdBpFn*1(i$`6!#u}3)gKuq7Y-CGsDl-r|=EB6B<`UDH!v3JR@^K zu6WC9cHo|a_TZ`NdQXFVgjsyyz3a477&G?z{;{ z0&1FUq$={|=??rdUo>R-X%GCLX)(*%hEkILaK%qnX!M+ul-<5Q#J7u7r8exGP=Hsa z(l2v?N^jPInG?R8;k!DY1sj&-<4a*$RLKPcSkeE%vj2l+O-A~I3y2dIJ`-3I= zPb{Iz6|fRNZ3HHQMTMWw^&aVbGCt!F@&nEmP#ttO|P4`5jz9ESSV~;Qz+* z{DajKfOfjNWGhYiRzE|%QN;gW6=U)iQGeF>>U|mwDcy*IX$DlSH9tkQ0nwC+qq`CG z$g)wzEyO%Iasz`W=Ht@Fy2&(ZBZ?zjK6<%kR#+_#K#A%U=8>)tY3&ih(jz$CVmkZi+ z`zgQY-?rEHESs|YG^3$d4`uK?cz1lB-drIw&5IW}FUhDG%i*%j5SXD&i^u>xu#q5;~u%cJ^N;$`@qfGkaxW)>)*?bIMgkScQ;sjby@^*Ru>u3t zYWMwC_teIp)G@Cq-1Eh+NpWlkLg6fz+;de%@$^H{0>kx|!R(qH~rH z>%}zS=T0HqI?GZ%>=;C}{)qE-6W{+%+wi_Z?LU6J>kXlZ3>ebcNWBkM};p^pqNeaHiNQYW3A89-7skT6M zkhQ%hx5kH*Aa6_&m3)_ZvxlJXrAo5WU+$E=rX_Y-t0auxt;Vpd2}=ojRQcgl9D|iJ z9flc9UiBK2)sme6TK0*#xqmpB#VH9{(H9s(!v>0kQnWp%0G7<1@7Un{3hHGV2u!nH z#+8QH8&gZ(Dhh~ZTH-$>oU{%j2{vFNbY4RfMekODEo%xJ2zNK0%O%%j-jRc7ta8GV zlgrqb(DOFv+h!)E>_6Sjqy*vokP$*od|)SVy3F3f*yc&NjEL+)jAL4tzs<89=<^EH zw=M*TR7mTsQZhp+nc#-%(q(p;#!7Nf52lD3&w8nCpz}cTir-2b#{e~_yT=aH8B>bs zGo^`2dC6&x_k*g3dgg-k9$v`AU61lX%^w}4aDBfBQtK!hyj|;bRRidZCx9jabe0MM zbPimLBaNo5l(edWiMuQf#!nwa$tG?`*{$lDcgoE0yq0$s5)6|sjBf(JA$4U$9)$cd z%#@8b{*H_pDAcW1(_S%vHbdC*Z64q#+SPxPX$F?7l~)FCk;==u1+YdoK$K~4=Q1fB zWrMHKkLHMQNMS_XazK=(yi5Td=!R~F`1ElLzt=R7b)U@4TJ(C}=|1N|#q+rHM>*u> zsiYDU+^*jRv^n|48Fc?MrK_r4pAZ>nGRi10_NRJ!i>VC`!OKK*hmE!;?0}EWx{AnN z64q~)Z~oSqxD*U(>k0}MgM^cp@*HSt&Sv6Rv|IKg zfgr%yTQq>PL%CqdlR8AsU0h7j^#^c4I0J;V;_a*|l^ejqt&4*^9i+avAf(5IJJKN~ zXqiPM(1tGV(bTE2R^a9jx7auhT?|r_YFV&QjV76LCU6LPxZhji_%SAKAlU1&<^^hY zJEO?F*Iz~dFv6c``ynzyq0% zLOdt5N4R3!BTR2sGB)AFl;MK~;n)y!bCS;w)oBqV!Lt&WOJEXEYUz;+w>_j3pT?)_ z>A>oi&8rvI;pFdfcup`yBzQ(j-`wut5BN@yd$-AnFtH=iXj<5IsK8!o{f=$1oX9xg z1mwe0y2U#P&b2!Tz(sHECb?P_r?FMP1i$uM-XTno*9xY}H}QC*CUDrObk70yOPNMu zflM&XtR8gQ#yv0;t$dw`M#yd_gizixDL2M89|AB${hBuNLkYBy!#97 zEwd)0@U1^xxz$=nb##Y+#bPPw)Er7p zOIz2!I3ro+6j$y%{Q($MH!^ytH4Dmk;WPW@M9{M(6&#f`Qv_sXC0>uoa_{HR@`_0N zyW`v@Q&r+wq$-YnlRT;RG9mmc!S0#$J+Nz_JHpg$nz4y6W(q$~5U$KG;6T!C1zmMK z1S^Tz&tW6(N00q+!m6Y5PS8=7P=c$l7rt8-wU;kqAk^L*Y6<6AtRyFkoVtUWQB6j_ zp07Ekp}{iXBNm#otd!^qC406$l_;}WZ2QKJ+>KXUXEL<6*!pXGyj#4(PtT6!l*zVw zyIA{{c_`Uv^>Y}cBQ)igaG68ck?9j@Wr~8p`9P0xcD>bJ4M&TH=Y87mj`lY%+S2e( z!~7qa>6KJG!2CQJrH~iXk|Mwu+Ea(BDS=eNbX>WGv=qkp2(1agD0Us7it-_{_y!MY zm9&&HkleX*W8J4FhdQ{j@sVt2C? z@p+BPo7ncL*tFTnrKq?lHsgzQ7Vp6lQ4nKvtMghRG@QKtT@KCkw=cq3qcapq-ikFp zv#&Q;CLP*Vzqsf49d4&If59(SUsHQIRp;52a60im<8^L10ytMy(pl4F;0G3KS&K5T zYDx+>mA&a@B#Vu%#8^=ZVh{SH=M)XJnM&OH4s|Hg$I@7qNBzXQzc8hPhw+-zfP1A* zYK>1~&#mI77Sh<0gK(aZsw&-Gq~eJ2h-D+(kfF<^K_~B}KKW9UWOuc>7+Bmr?eBSm zE11!kUX2~+T(ziKvLsi^c7FN=j$TZ6&73x z7tc_|(W+A#3#0uO69!xf^9DHvIR+jc9tKVBkbX2f+h-9>3=CRq3=A@i|9$DnI65HB z9gs#^o=)bj2An8+yZ;4n;Kfr~1?V2%z`!8*i{2Z6HF7bxbLHZ^{`_CUMQ@MEXn^1o zaDo3Kd=EgGIhw*<9GzUbOq`tljjhE@tRpVKpbWT3{-UK_k*lSO|P^>aPWwWuu>vh@8ByFHWqrWnPw!;4N|Gam4uO3HSAsEp9@vi7~57+N<)hY5+dKQ(K{0aml=pMK6lN9l>Y8ghp~$0 zGn>=Wz3@y0Ih6(6M%)k43E?)rkV2eD`Pk;|VM&l1TKq%v*Fm`bw5t@h#UZGO-qb)g zP~UyUx09~4#N4M9x8KFu1!?D~FJBi0@}mfqqeXZBv=Zx9qAyuT7-=-mqO zvLD1h>)5k=kvRZymxlP?tb+>rhN**zqO*ge3!{;v<3G2Qi|>O6xuxi(zt~9k22er8rDUj@bA^b$;R{AURLB ziU>R!2G2wh0d=dhQM^T7G06lHk*Y(HW$3=N2)c4pWle#a$=69Ar| zrE6YrH7t;DU^gUG5{=uoFy9{G{gGcF|Iyj;^;k{fSqUb1_jlB;o@BgT!!t>g`|D$wo4Vp0fugpC=^{8e%v_rAB9wFW$5W}dybc}VmRJ+Qg@cqp*2!C z!De9kt`%+5q=hC=*15ai^z{(ZV>mZSF;mkEm>fqTBcw7{ha{(@X|PNEJO=0!Ashw6 zxIIT23H+A><(~s!4^6)%^cYk)5i~lnyEqjSxnf(mxo6MVM8 z;LY?W^}%o#;SM~sHmrm`6?*UXVBd))1@FjVeLf;ObPz^91V-#^7TuHm%9}r4BeQ&f zS~*Q74iKczhU`=Pn*SOy6j;Z;g*xOFtsb5l)#+7^Zg;M!o~k>-up4E)epP)BU5tdt z^$uDo>=(!0WlB%bx}yHq{YU!0D|hv>HT%z!yH({Ja+q*?E;Te4Yrm7*6xTv>SEA1$ zuasu7S*`Zwk6hQ_pVLj5)vEzKeOM`M-(LXxA-S zh7wyll!}T{{uIsU-`gjdyqC)UB1fqqrfzd@djT0AN7|@xob;vOP6a}+G>jvXZVU!S zno}rW5?f&dqpvmm)m)Ao$HbP=j||a{o2q@5@>nA6iFf37^*4w8&yy7|sJcxmqzHN@{kN>1U*fDb6dyto}L;r7{j`ClB@o;dqF?MjU`RC+uN#pVZOsHayzF~M~ zGCwgxNu-s(sik!Y6=1h4u;sC-zen0WUO#hvFFcP=^JDjzT5pIMRibO5Ix1zSFfGQ! z&02-G;-K*TZh^wcRCy5{;n1Oq&UtcVo6dDZ@+-r-iKc1()4c26kxs_Ehh`Orc+ zMKYwQ$7K(IzY?IB#k(n63Ts4;c^ltEz05Ywnwey;LLFY{S|NB1P4x)uaa1SyVAO(T z>JN0Uu?8pY)WJZ<0?NNoBLbOr?|)4q`2RKSe@pNGH1L1RaFU$O0289%XY^k` zr`bN-VtYoD85;rr!1^>UwuZRU=JDRT&VfZiSe`rb*ef5DCf$Iz5N@SIei%qOwU8pi z;!_ce?fOqoZ|I@mz8zFZyv#_WZf$!jK^lYQ$0#);D2{Eh*_=gNzPJ%JSGhM)he*N`F}>bn-|@g7Dt5U+T~0_9e24LaU_KN3?#VLv8qm7xDn*}`CTkDro5k-0 zG$Vwad3{1#30mueBWyE!bUl>;C;0*QN0|v{QTy8Z;mLT^qU_oe}jbT{K;$KLOuul{fQ+y-|3 zPtWD!3vLZG0yAq^#Gls#%&$A6(*kM%*Gp>GYdyC9x?PeQJji2-fY zi$gbxkpjf-tzuU1qAUV69XIAjdf3FbYxg_n53NT-K;WFvTWZo1bJ$S$Z^KBiC3q9ZQZBVXZZujxaC8TQ zNdx9ljhuUH6%2rfD!ucv3z&MvI&AD(qLr@Q4;uscn*p1*_*X5gHN7k?kpDxtyIlkw5z8l2Rr-eJ*Dn4FGmnfSuNhAEV;V|dA=Q~T>blzh@`DnhW zy=V;x?@WyI_VEt(?rV&@NwTd=oTs~rh|gY?KR9qA-W)q&3A&VdJR8>-V&45NW%bFx z{o1*XV< zn^1vkn>pg{mo2G&ktxk9{}=8nKli)wIUETIhZw+`oB#4fkGJuzLEVGdHo}N$BaBoWK2i?h8F`WQ4*DsQfW9qQ-8Bz)+gl>d2?k&n0NP> zdY4{u1?@J$H{jZ)M_+Fd#zA2^om z+Cp(-H2p_4PTvMPt_GKAE=?(d4exhaVt*3rxO>mtyQ4s8p1))m`!#oTWBdCvrssFH z4o#j%+*>~vdvuI*j_*obYJKZrx9f@CI*TrPLz#Bq)OePEi)a+-!T$7CBjCsCbn9tf z_X+qJV4~kzq8@w0yfk`#N!#thI~&Xvw)1#L$BBO zz>Oj~rhXop^q02bYM)S)jq2+K`}q=$wO!CfN3XDuzS~z*#dym3eBWe+scea9t<1$+-*y0R~_!xko(4wgy`*L{l>+I?hM zh(X(6tjX^mUzn z8abaZ^~Vo=lae&$y;SBdVbT9}!OTDV)2*(h_aMKu7l}##Tzt~A`TLY-b9eN$wG8~; zbk_mleqqh51=)~th%?b3DTCnHk{sU{fEY^Dt9gj&pm|SD?)giJFEurBsZr*$)QER# zg5X#L`hi;!Tp6$Nvu3JBz*(!Tm-GBTgN+S8rX~>9_3o1F#C9bs)TrMiyCvK-*U^8`(Pa`q>n zE)@o6`RKM3$fZ_Id=St2UwgWOm!iI9o<|;-H0ZrIY_Y73DsgJ)pf2aFH}X0CU~SiA zsHcyqw6$38q_&q`VbFP8&TG@^18h{R)V2(PE{z5~yUO8*sn^9)=W_EBOKZcaHj7N#Bln!iy7)Q>K8OcQ1u{#4~enCfx_(`)*d(K`n+N(=pokFhuu@Nw3*V z%7A@s3rQe@A|gBYI`LOFt{GB;h0L zP%+{=ZgA)jq6T038Gyip4h-K9;Gs1F#Brm~jD`J@A>1C^IGfPt;kk_hFaM<%v)}s| zofz2y@mk0)EX{b&!=GEVQ2;-Y>29c`N|6`qM%stofT`{P`%k}-q01JD-u=&yuCV0L z)dkf%D=I|;$lh~`CQj!fcUPy^ovopp0@rKRbK#@ELU3Z|_vdpddncXcR52-z*N5{w zuLq_*ZP?6B+KU)nA0knKYraUPInJI1gDlEViz{R!Z(MtDshZhk`o>BE7}O0U13a0U z>tR58$R6<$DYmFR>X>&fS*=eUQ5fGC>hCY3&?hCN?Ih{=upU)Vq>j2jgNY|7fz!|F zjc`BaL6n6#jQk~__dD|wgDx&UTk{mMBlgG(NqWBEL0^}oDWejX{eX5l<;sY~>iijt z_N&iyHelz4zzerP8Ub&$&vlnc*&>dSx{y37ALgL$1Fh%}i~^0O1lA8|R=0H3M3k5G zMtHu%!$>%aI@g8LiRX1$$PbHAx(OqFrPrc;tY)h2uA&E{T#b4AR|9qZ9<%^nZXO<& z6mxO-19=9i-%CVtDgu)g`AC`OiAhBAtQQa-i%$@E9yO3788_@is?U4xlIC-+oc%j;f&QkfK)hwV~A8ZF5g+r zfeh`wy|d=tBa>(t(#|IpIa=Gk*5>rjjpR6@*;3LB)&{BjMGqwzy7T<8DKV>dmvpgD zsTmeHn?sczw7mKo*!szxqnu>WZd8?nCx$&ybN)R_0u)SJBqsd14(nl8)z{DmIb70Y z#}u+AMM(~c{#7?f#z2Ox3W4LCDbD@G95TvO-#H~!)^g!xZ|e^){UH)`W#yiK=KLyp z3P^JR;oc$@ZTauBu`1JhI7@LfS*UZ|&mrn9#39`~W;@}uv%*Amp0cHc-*CO)_2-4|?P#PJyfL=2dfjM!3YVOru2D7}Mhd1o zD`@_}Fqt_c!=&sYdEya3UH+fFBF~Di$o;VZwWPxOGS`(QG~ZN04%#azmdG3+x zQQ?X9f8e&8m4IE4CmJ4?IIql4e|J^m;piD?AJS`^!X>e;%EEfw^yy-ZffU{OJNc)=pK3+?`J!bSMg6u2;b05bm1!B zPeurvBJ+b}EEC)q3-7fqxt*CbVlflrUN#hp*dSfR=H{odT+Mimi$<{Go30TthhI;~ z5sSGFtacw&b`fBr_x!Y2qwbWlsOa~vm*biuFCDnqXT+{R5y0+hdNtAPnDvY|*Osh1 zbUP@BS$A5Mk53@Ak0u~#U5_2G$IATO3v6~lpze+s`K&OKyL9ssNw~$pj8sA}Io@2t39;+UN;UT< z|Fo;SFCgCuJ^Rh0?RlZ8kjpF}OA0vqEqwX(FgDtgd{$-fSN=N`U+)HSkG=Ed?x{J# z`MUy|Pf7aERn6kepP+RtoT0)!jGp|?2)UsYD?PO^8Cu%VSIk9P&)4L<2Q2)(2QClb z*J@bc*svm7&5w8IEh|7y6?|>xB3FuNiAe0Bu~}G=nU9EB@awH|^)>~?DEtmjmFtD- z*jJ_ob9i5#{@dR^S)E#+@^JN1a{J%-G* z1i0$9)KM-G(w68*pNMImR-;S&Q~Sc=v&;BDPPm=V;E?yWS&I|_>EXGvQ9))k4*(k>0U)Zma$sQ+OsECtz>0<)fu^f17-6SaY08f2@yqnr%z z$DgUiuJ#X#eG-}tbi23KH~=j8+ZvF#v~X=+#=Q5?QWzYeF!97! zTCBpZWd*8)$?PkB-+r=;Byn1lu-$5>*SoPB^@YCyp)lbTy7e$9zmr5P{mbuB@!C0^ z8f|4s7aozFjZbvf^OLEFnKAz2jupM)zG&nKkyPJDgKHCRegx4#&|JPNf<3Z)cGUR& zP@;*&3L|7@_id`M0#ZSCOyPfx-!a`*w3v)=TNHBXh?Kz-(y)kgQ%ysga9fOI0Ka~d zD~IZ+$7e1q35~DM76>L-_zYJG7O7<0jY&o)kSulcLo9@@PMQkbJiHop5g2vTrtfqmLuU8cvP97oRMNu^>iAEE?3}U3syUY^=ZN=h2KRHqx%A9pGZjfTmGE53 zi>3mvxlrHhgSb$T;^D2lfg-v!Q*)thaldhy)rAOBC~bsw&tU>Rn|tdhpNC|Si+oEo zZKgk&@}3|iLaNI6$4(%O2StONVUsxb0=?U~_c1ao%mFS!4NU=%BN00xLWeg-FCo5h znZ9$><$z#Nq(Tj*C8{ycGX2c$|x60 z+E?XnNm~bQIY}>s0*SAOGI|m1`eQLIk*eRhFqI&jK@EaSZtb0zEGB_R$=yNX?2h$^pKRESn>&TZ|Rw?1VA0${JAqx`4)C3lNi5#4WLpa$lFUKE; zG6i%~V%(L&eD7NSxSP$-1+0RSm5`r=%U7;+zHoYk;@|l9H1Df~(XISILK+7&fiFP2 zwAM&Sd|*%GH@u(!_ee>VVEus2sav2O2eu;-oNk);eny6U(xe|?7I7Z?Mjwc zD+j`hytGt-EU)T&$?Ma+rSF0mgIO|A?z%^-Q;$8loL(MLMKeJf1Q5=kDx_3f+fBNN zuVoX{u<$JDvhaICQttWP&D~c=MnSyW@48?MCNI9gOk@sMul~$Pe@raF>VUvFDM@~J zm7)U?Y|Lk{0s)>~N@_z6vkY)WvgGr@HOWu6l4HmKZZ1;X!HJH4W@>0YuGH!UVQTfP zRcL^)TTUYph2~TS?@BalX~VauGft2I<1w^3GMC*a?v1)z=`F7vwmy4st6H8M>ecK3 zw}yB#e$V<}R=~O3e|VT|9vDfDV5-f3PRJ+vnZRszVG1hPVGQjVtcPUP9`XJ&U})+% zukdJhs;lMBL?e>Jv&n-GcLCEwh{;rR7L-8v%9Tca6MIV@jWx_%?w~*$t?+q&cYIv( zlz3THT7av@tTT8Suek`J*L}z7I6sYOEwy@UtY_=&(85sb5Urpu7h&p z=atjA$)c#Cq3al&yyMrhHq({yz0dCvP!nimL&l9d#O4P=a*kxZ_Q0br9lDEBkw1B^ zSrEVuY*SyZ$>VcWp5AlDAq2T}v?N#hb-7})vbS`@J^eFb1jXmnY9pl_{NIk13O16u zVdC#2olpnqf1A}|*(5Obrg~(b(Z!wtoU9xK&vfICH>JYT-&)VMfrT#4m=7tzdGw znbhVE$+C}Ss!|WP$4|)Qp1Lm3*(Fyn5xJ|@6`C{{p{GhzUUhr8%Auc!a@w9DQKfg_-2X_IQe>RaPCwZ2GM%#r^jcS?NrciV78 zx&Ky@`(5s(V%S(I$a`WQ57@90Qn-IE*fSz<(>>x zw;p4(vU}#|hIv$x=TzSQlo_KS=A`M1*EVTe9eHlw@f&AoNzN~Ej=gTV06AoxpTpu? zfk)hXteo=oKttxZgOP~f1uZ>#*8ZWh252RtNtID4xeRKhlNc1EJjx49jslFnam9(4 zt2c@2BcoFu`TN!znM9)t{M6(cKC@))s}aznQs|x58hpC*tTirMrH|wGoo}w4bX|Mn z=N-$8<5l${YiA~5mwcTe^mzRpmOvA|cTvG=GBVy+w^zZR?EEh{sxT?^QJ&dC3;kbH zKA_Wnp~EBaU@f7kc<4${(oVVE1WsEuijUsMGqJl?qf}Fdhcn&3?sRDLmJPdEi0Ps! zc=2c8f9mLoZc2hh93@L$tDRZ!CRbaO6XlO9Nr(&herejBZy7b88zI2f7Lw?y$g7{5!e+6u^;TdO}L?vlClAoK&FZx>)4 z9x|lyEj))#gIUD`QG$|U%CQ5O${~`9cv&GYGTclH_%1n2W$>XH4uCfBMwDR7g$gI@ z7yBMgb|dH#p3>xmHIQWtFvC408?yCqAfP`4iC_@DV&egBM3>j&+%Q8gHTH=1-cbZBV& z+Kxcl@s{ww@>nxQLoViOdeE!7hhoahqC;sgh3JS_hBKN={70QHjdl22l5yv_n`djc zJ&-KFmURfi5cj!7i5I~r%_{1RO$q|0LRLi44F21eu32yZ(!^(M0b^B80ZNxOyow5-q z?Vw;@pA)NCUPjs5)DFe(Bb`TobQ+P~NhZFl3r;Y^q7C$M!J;(>B0sj!s=jzmgEaqz z7wls^yWc|BOhwiE`!*54K5B0>3kK`DB;s{=wtzHV4*NO0f|#a+hZhBAj9X34Z+_0K zYPk)ic$34^0!=lwS==uBMC>9Z&33+)(u@}_Pn$aG}gHPUJSF&#*INwdQf8EFp& zP|gCxOu0)WN*thO0emM(`sV||chukx*zr92Myvx8oV0y_>31tvE><(EK5Q%~?3n1j_rM0b|v71)@BZP}gkOu10 zB+G3y&@gf*jvoGU#~32na7XPGcu{?oc8n0K23wyLs|H0-+gh~d37G(B%Hwz$sY%xA z_Whk2)2Y^PNmhq<6lJ`KPt_Mi=Mg+kt$I*nmxEme&7|uXeOFM;6^_}@|Lh>H`Ed<+ zHL7FJnE`N?rk~>2-P#pU*dh$EB&2c7p7o&cBx|G9-qIR|ozizYi^g#KWBg(op zI#$kxdv~pR?^=SszXzq+WerC}jYer7+FXr|XkBgE1#?a6aW@_Jy-I#p-9_ zFEgMdI^&u}ZCnJ_(M^OxjC*ocvI``<91iJtmjj{w$Z#YblgJx zH-b-{4c$P7Moe^1;vGSLPO^74Az}Ssq_$} zy|ijZ0^S6_?5t@^6{^pz+^J0i9}tC7wKS%Qt}-K|gDBg(6weG>wVpXLqJOLcond&pWXXpHrMd4^itqm$+*TYu3iP797P!p0Cn$ z_%n{34P4Z3nUO)Fx9ZWLhhSolWrNMGLy2{PS^8^}{ZbjkU^OIc!o{vBqfI6_i~ow3 zADVkRkJB4dG7l!HO@~3lo++aZ%Dk0*>a)_s7yqVSNQ6>0``QmwFQ`Clky0le`U{>q zHuh7;Wq(ltc1;9bG?di&ZNcs6d-JaO0-8v6X(V22gEr^?KwtFYllT2@c&e(*$3LFc z7~FqS7G0vm@ujmLjPxV&J^}WR(?c}ZTQNm>VX8`4m!K1)={m6|x`ef3W3#$t(AhTE z-(BZ}W|F#S9!>QPHq8acA$2~U%EEuI{S7h~H|9JR_X2Ed+(F6n36wl{1s1xaJPR$&$M`y^p!4S@{-m2A{P>BFOBfurN<}1XaL&W3aF#M=Hq5S$5HFm(>9sjF(tAsmN z1iby2-+F@Iiz{oey{(kK{w+tVsCg)nuq)w&vIg*V=M=3`hHn$m&~~~KdD3XJ-}lw{ z)04CHJ1ADbI?0gZHmu)(KaAhgoplWX zW=7h--PQXsuS;NUK@<$hek~TJwLmvYL=Q7$Ml3ByHT@~Gkw?QIG}nPWriYm?r)~s) zrkSvHd8RQ3Ca<(atGq1#+xkYH=(**FvxKy*U#^UXZ{nFXi%}iVO15 zI@%MQ{7hbXFq3J{vZE6!MR@|TVCp0jiu-AOZY>1;ImIDfZB`ly3*SgMBHgfwnrT;t z&}?9vfSKwcX|9EfG}B=VoXcha8~Wpxxwr^1gNqut*z}M>AE)&UP_PjMgP&W~1q0R4 zlI9wyRQ~OMy5KY(ip~9d0KzO+v)|{4vP(mGcq4z!0t9W19-2jmJV@r$Ms>(T*DmB$ zPun)CR!$Poaa}$L712YZyt2#rSS(q!2Vz$k(QZdU@`{|KXe8w0D>F~w?KC4{ZLO~yA zmuEDnM@i<@LKm3D1W>ZtE~BGrP$Gh9b*r8-7Nn^J<0MHA?XzP@9+cG!UQ?%(B0dA< zCoqrMBq>UHEXxHCMKrK2tTqgrEb`r;-*$s3*sTql$1Y#5_vI<0=-Y?kXQzHr`5KPu zvEPrx@lr;vgAzdU8n>ne97&38t;mTA5BPr4HVoV>9ab~5O2qshN*HOo7r}oNnt5(U z1{=2Nk>Ba>^F!6={XL1LEG6t#wDMQ2yOXD!zd8x^wLtojgZ#K+R_$* zFO)e(S@8pO^W$1JLx7YrTO)Zn;+P(MC=rzMG|^3!)XLjY>=Y5;)+K`96KO3I%EJcB zppor5u+f(K&fCU}a?7;DySm|b=+Eyi#%w$*)p@m)ut`IgL_>0)4o zwdi%x~(N+QejsBx_l=wzxaRA-lnOiq@pcAeS88 zW02GJpT`rhIO*orcV$EbSgg0CRm-8FVA}I2ihyW1>YR`6&J%~9B^CV|IIz8Hq5eBB z!J&r}g>=UBtAVA$djuxNEPW(CghYNk`f*nIYjqmjw>4eVsH_grmKu^|{(lI;XYnK~ zPPBq_y-DU$6W_NaZf38K@`RNg@ZmMGRY3=PYqP;;>3Ra>(GO z1+9GM<|VlFD5EkhN660y+|vccxaY_-uOdrlvy!2zrnNroqIM1;q$cJm2JE1d@036_ z2{YUSDmh98OPh~JStn?J1hJKIIjXIIX+2079aIcVfn zV)#A^UuIzs(gnPziMAZ@2qs3||H(d=e4hwE?=G_Ro1mhd zNWkoSq*vIUqXTKZTUQE7j@p6DRt;my0`$f~U)+evm}&owF!E9t{SB4aTNA9wL37wC zuMRd0=0e9FvPoG297I{jq&vU44P5q66&z^yNaDXoUEQ%5PC`3fka$#!Uu~wyhM1s_ za*}fHf^Qzl z;F2HkcSyV4=Mr@(aP~I?Rd1DDTl`o#K0=lMgni{G5~uM?Z8{*QDxEd?+n?+&KiLw4 zbwuS<7)3~?(Z*0UJrT{nyprUX8lFtjibR(8`=*O`d(1N`*WXblk|bVKqC=Sj>4gmE z;N?*7uJb_00-*jXrI*Dw`yOT^P6xQeM z?8+*fe~0M)m4eEXq=`@vJCcD)#~06rApEcxFd+K%kpa687hKublwI!UIjyYNr(GIO z9yeRk_0pA(F9=PSia&t`YH>Q}4FLwF|7omBU^bcU)NAzwlKxvUwsZ)1Fmv{ zErI2b9pcys;XAH|j4^UTTDED(EEkPno>{rUzci@{GslfVD)!{JI;ITqXv z&)eU{)brzPO##+AEJvMNFw`s5wE%S3133}20LbRgDbBC}_#T6co2}4Bd5*TvmaDZ8 zcf?1sFt>;kL|&{_wtJ^Ke_E1@q&}iQ-EJdO_&8t}A_9i9VJ4FXOM=}UHq!HCWfzJG zvZw_2`wbw2W6pcHHdUGo8ULUnHBnk@P4Iq2FNs8e2NFiwgGd(>CGCzmAZ5PP2(`cT z1{fJWg&UR>T+R|zmx6{b7~pzkF=73Vr1f>$*}?c5v}pCzH{;gQ?=cg~ip2;NkS=iy zpz|zv%e1a1dwd|>I9gCVBS&aMJnohB<~5B``e3a;2u*>f$sFbLM5=5>{O2MlwxR5@=f6SqqiFh7o_QWA>o)nF?dB* zssf9g>^}ed*lM<7-YZcdB_8YPXKT;jE3Lv0J&x(5BN%h2xvHuMAwC%)KgWBRK$pV| zZAdGfFY~Y>aDBSOu~{85Us`~M|CugG3m;d6sFbseJL{M9JoBM!`3u);z>+ag!}SGm zY3VlhA?0%5h0sNUd8@iI*37Gz{e3BC)@1-dK#5NS*$|F3` z?qMq8X~ZV@QqEGi&iTR5JA};zd%dfJj?!q?V`0w?`+!vItgwV;E_a$4$L+4d8(*Kk zW^7wQ2{dfKF(_oLz;Uoo^D#PJ?YEEXXCxc8pg*@Y!YXKxzuwI4UmG zZzkOhQ*f)KrjvE>D3~Kr;|@qGARvDxKpSPv-_@+*#ytu>I@hq zho#)oMkOCp@r>!sSUBpg5QQ`-K^+ugl3VI%mWz-%&|)W_L&Wr9421Dbge0$t1#0o@ z8e-5>xv!1jyoLISQMJ{~C^#>HEJ~Nh&a}%ujqnLLLVVwyA@Odbtz-tlvj?ZfU9XU7 zN55%FK-F7d7WX*Ha<%X+q~C8)4?!W|8VbTuE6cSn@o5*kH84jt8WsJ?|{ zkabTbj^)hwlMV3`3d}%rgYDi0QZF+W`j4Z1Jr1RXNdNvwf|v3oqg1<)Mpo>dLe|$m z%9JLo@Y6`HW-P|SqexvTUkPN`FtDMFjI+OTODw!Ei%}|apSc*++|N}!hItkkZUr6V zo=#phLVQb*jD@xKmm4zB{eIi5)m_(6)c75EKqUm0AyJp}vRsA`Src-$zB)h;88!$y zea9NLS`euDrWUn&2w^-iZ{!7TE4{s5CKCy&ajiV)yY!9%th>jr`z_jSwcH4hwv=bW7j8NSa8K1mL>_O}3t15QmU^J?mIL2hK2XF^y%e?UIch{Kv8 zPwN8{Xb$y8gbBmOfls30p#bL$(n=#qKY~MYdGA0<2I3}Okjq7Xc7ED;k4zwdexwHB z0yMZI@hEs7@)m(=*ZRBh`jrSVW1DQqqP&)&`oJ#xBTcO&f_cC9F zW{)^^t#P(n+evX)-9{aB{D`VTjdz_Kn+<5a*;|ooGD{S9$CA!<6N^q zdyWTI4k=CSD>m>7q!DvE1kir{(gJCwX1lP){}eh*Ymd;zERzGn+_LpI$}nWpq1C51 z_jAVu5Uk3YK4wf?f#F&ZHTEeI+M2aPZL5@c^mym5qu|ji4yld#BX+&N(V53*u4^(n ztct7IS8xgMZPju8FZTxerUgxEnUcpG87&|g{nw7pz7*wO*ICd>W@M^}F>~}$vsCNM zkmk)S;kDj0mR_A&tmwtgV2*cF8giOn{5JA;B`A5F1m-Xk zDe9nl+<6$il}pC=cKqPeFnvviic~K`!w%6b~}LcI;*d5BwAA zoLI`BYX>q$<6q;BZt})^a3($@r&k$cZt5|pEc@CqQM;ck8|qnBsE{rb;e)Q5W*sK) zIZu>1P9_KbIDJ`9a~c`483fX@t&H$7&m_znLBbg4C}}6w9wD%ZfY+|B6pi7IS4JR4 zL~+>pJA(|D<9@w;GLyoRoiT@YW@{bz+Djrc@e};S0ImF&+d~%l`9+#TyRcjsW~O0V z$xM`vOcY(l7+(RGZ-;MWOm*s7Cq_g{5lT#T?xj&)B?77wfQ`bV5j`dUl8SB#F9IY& zFPa>3(7|&IS+C|e?1LIe&&3xoYGO($%s;zE_YSTOcCI9K7lrsYku@qKWOL$>H~XlW zCLH7=5qcv$*t1b5{iHaYHE(E%t&F$P&m=;dLCYXMSU1)lPuiQQz<=FH2L^Fhc(+w@ zg*=Wgh=giu-QMa8SOr63o~YS34Tic6qj#!MHy3bf>r>3r7IeiB+zjAU#Wzmix$Q? zEHkEcXyKe&z}CaShzU?LUgaEo%@n^-=8*tSNp}+>;P?C@ae3n7@N#j!VSN1baAno0 z^RB;;TCu2Tk+V=J%RlEa%p@cMUtH!ZI%0$SGFzgWt$r$__5;@XpWqc7bYJl*4}Zx`EW%W_u*iiN<(Y6` zmi($!O!h9NJ`W$! zG1>CNWfje7Th%>0_^uFPd|SAzht>IwoGcz#6PfW$*-Jb25p1}4b6q=9i1&%vxaea_ z(&olzz>$YzywK^{N+&J$to=64W6Pem)A+Z)dB_zX%8_QOtWv>o|3@H{ge@kN2WEET zqEi0eD7k#rr3Q7z12!(nTD2{CJlTe-GeH9u9USAMDz2q# z7sWNW2A9S?8%c22K!Bi)H||d32^K842KNv&NaK=(hG4*l6z)AB}b_u9MEDG=+67daot8t``1l@#T4R*TVdhJ$8n{q+Y zdNH=tJ%8P!Ehh=z^46cN9D;K030^hLiRqM#gVbylhudX4=2Kn8hmioX!$Dm_}ei3A+*NA)V$Fy(bR!%RK`Jzw;_5$ ze=je5E#l1!2@GUY12U}*xo@uMMfP^j3|LPU$s2UmN5lQpvNY|UK_|Tj9l1m$a2{A8 z@8~{EVxZ?czzuM)3!6VoAE38aMDqxahQMV zHN})S0};(izX_ieW~_y!#)|K|uT5wYHJ2Bgt69nf<;n$~hv!&-)vcxHR+Q9f9Yd;} zLq)QH@$HBruW$XVF4N}qpMq8>+C^l9x&HW`$(F&4*?@+`50^(Z@I$0PMzN`(JyW9U z;jF4IidVUAHP<$Pqyc5MngABWLc*AFwL5%xTK=6R--3{He+zU#Wii@{L>_|2qI z0>J2Ql^6Cvcn~1`hS!DtVCA3E4EnkLm7kJT?P@r#Qqom`__zV$vr!iF3r~>u!+U7a z*WD2TL`z52Bot$0eM(3nQgwSpj8ts{MVoEn2TZa~(4lm#V0tTQtspQyv{KILKeH!3 zJgw@DY1PKjCIXF+G>aiYn;l_|Y`=ql7{OC;p#)@hhYUSMAvi%9_2#IW=%1f^f6ceu zO(OLnrn4oWM76E#a+zvDP^7#GOnwi2;iBk`mPopjmsp=($uR~YB4FVP7})}hWWA9X z1+emUaZP77E9WQ)$2`t6 zl})lkVz@BUcOMcmM&T_|i25#%VJO(M@@lz6DY!l;5r-Q6{#Ndg-q+TE-(a>H_^vzzEvd5G{+tg`{~+cw?xbwHn2eivf0ox?>hpLfQjpr{ zxxfe_M`p&dR@+A_MFY+_;txib!Sh|JNuid=eU!q)6nb9jt#Qa}jZt3{hJ)jEQ6)j_ z$Vg3y>;@PsU*EH6%z`)MY1aTtT;Qg=(Sv+7PH!%#rDmw1?*`J)=Q15Fe8JG3udaWf zoYZf}GN+}}x??g`uI(Jhgz-rMtK07$m-xgc1N5Ri7xT51!%O~N2kPRwDRfCIQl^W_ z_R~M|d8$^Pc#{_L!8x*47Tk96pG4tLdhd7DGvJDkM_@eY9gBsRx&*KohPvomA7C*r z7;nXF+xIbs80E~vzvW9{Y>lL?IOG+}D99oY;r9P_mDHa8_R2zIBV@ozQdT3UG1m__rP(gVUBp3``M z8}Gal5~I}VXK@oMlc;p|Foy8OgWCJA0s0@i{5pBs7>^!2YB)MjqD?s3x!@NGNXRAtLP~~0@tbBc72YW}v=wzzeKNMjq(w=b80(y8a+k^*i?)inX{gT;Jg@_3 ztjfJJBTg5=i3+s4uUvadZ)@}J)8xc7;$|c-Dnko(XJ^c9oez;__Oq- zuy>#bAI*E#n55c!oA<^M|1wGpsb|>uo8&J9hw=MkOue+PmMQdK@H~ev@;}t=#6l)ZdBX1G`orIz1!~jo?u2 zWqcv|w%1(Z_n~^~)Bv8G&$Vw$rFdR)YnG}>r*I|>W=3v%C+jL+oqtiDqn81>N+Lgk z5M-A*auY3B+TkS$XCvOA{$5chVi)r#T2y`f8veu~eRp-ubi`>2dLymE1w+kqmC`=Ca=p~i9eSiCQl-uMYEoQ6Gct{*Jo!{?uRe#nL9yiEDa`!@pYqxIm5?gz z+H<(!p-WYQ;k9*;KZezUX`2m!9j%7`t1^3M2?dS%q1fAJC<}(p8K4qMMba8qZQez3 zY3s@)nsFk*NTS1V+d()_Zl=y{4q#%rCdCdV1LtvKn#nj$hi%rYGFSL;+r%u>(VZ`zygp1Nx zk+X9v3*ZOECoTwPb*1r`j0-X!1q*P|tfuVH#+^x4MvZm7S_=(!ho{gC5wMiJR9HZI zY3*<#KiD+s=9#3ca{h4X)yUaq-B>;VN#8XOb0%9nhA{xC=DWQi2w!4>>!nHR(CrFO z=|W$GUT(88#sDo%>N;4Suppmn*?73GS{93488js|$RNew6<6&x!R1KvW0O|egNl~! zUK#(FL$&nCrm-SnO^T7^-I=&AOENsm5gnhn+w#TEYl1InW~8w8w)UQ=Klb_`>JPi| z5%}l4Xg=0PNO>O0=ak?*<{cv|UcSEEXUmL@&Xf(C5A|3xF~dP}}{3itc; zERv@scdya7;<6c9GlciGAESmj!4Ob{8-T!pSRxl26zYA^6+{sCtO4nS^hDUc($CZU-hxnJO<_GS z{#vsJ-ou>eU{POwS0XP0u@CXGNVLn#2GrzQmPTPa$1@zNG+6XseCI9G7@8xQz!Q!= z1=-dO6X{m)LvgbX^fRNJp)DZ|Tb_-w_x?|Kqaj+Ofjrg>+L&#R%r#`DL}{%t$cva# z8MX5u#BEA=$4nHH8FL_*KQ?hBt&9%Elu6!<(R@Mruc+BM(*>}!@_)qchqtaY#Y>$f zroarQgx?9>Lahg8tqWBHk^a4D;oQ9aGNIXLD;eR$ku*$N_H&)se?ozXBXO}7+ zG%asPU1fq{0f-9lu-%039|f-(uL)IWf=^1^$Om^47;0yEl*;UHzf~rqG<`pMb-CV^ zB{&r<9NDYCSMsh&G#xIAT{shtn}+_L97uIia->J=c0gCc>6!&UD$yGyLKNW5}vApXuI%h*gpdehzTvu2SGk#E+?f})TuYadi@wM_I`<(SD zP7ndT$PTjql0|Fr`U*}jxjcdcXA&ZWAC!wRa4X_BR$oRmjfB3Oiu12CnHFK*oYZ%Y z9%$2?i(U@UKNwifit0WWTZxl<$HS3=*BRbE90y+)qcDcV0k@$=v2_kBn#W~I!A(KF zL^T>x3msGz2zEj$5kEQ4AJi*q%`w;Vyof@Z!n}y;0z@MWI7D_do}w`LN9-cVKj)g> z%YC}6aed#BaAkKF*7T)vT|T%8tX=Gh%CHt9>v|`h7=f)C#rTk}NxB+%zI#!<`Hm>s z#q0chhtFPT&8#<=ci@8#aG$#o(((QdIPIXgA~!Qb3f;*H0^m=cZXt{73(PfEB?j`X z_YQTn39e4`^Kb`RysfDMHDA#|K1#x&)`FpLH7~0&L|R}hkBV94+Sj<29ffaA@TSSOX7;CLTJ+Hc1Ig=I?}Pvv=%Jw2Ka`31Z2J-g{<`b zgz|Wrn?TX`=QV2p)zRXO1uqg}McMFoB4QwM-NIn&O6=zw8iejonX-u};`F8Cq3W^c z>XB}Pm!s;jzf7q%&v~Cnoeb5^$~TuX{6>_sOT&gjPDNSj@3ElB+E{7*6gg3^@+uB< zgJG*Cn?LX_0flz5Pp=i9sWrc)`A$sB1~SlcuVIfdjnY*m?8f2Gh=_?=YX}myH#%p_ zQTy>8o%40K#F$hvzLqT(6PZVCi;dQSq9zDTQl5KmQA;N#9!U4Y&PPW4h_AyYn+JAm5v#p z49Ze|0!or!MzZ@Ap5u(ZK0otw!;aBZFv|FeB#VLfz&IZ6DJ4uJl>%Akl21#{g9>Ds zt+`{ER{IfVn8!S5uux6*L2m{;x@He%mT9=~w>bIi2rDohmrN zj<3nXIE}vc{n}JWUu6ti5Bc-$MNXL#r0MqN+cVwyZHJV3g}sW4(WEo@3Fy?PyeVzT zPf$L=0#s+XC?_yLF#ps1)r$}TJvH12fY1;h-TLRkQ{R|4P4E3on;m1ifdfFOTakAO zZa?sCjVdpQM;;Z#_csft%7@E7AWH;20MQ4qzoJ6%mJEVr0?m$jLtwH14J&@OxI~3x zeKWnps>e6U;FIofzU`!pq&PQzyb9j>4R09stos%c2De)34Ox2Kv1?eY?z}}CN&Uu>AAw` zg7JQ26W!{6evQDJ=OSm(26!ikhQe{v<4DqgPas^>Dh0O$tpV!ipmv5sTt@PQtu*WP zkJA|Ihd5a`$rJtAUQnaDKcpc}!Ogy#MGWgH;<#bdZN05$OjZ&|zPlucOE>fD73pk@ zteXMm60y4!Lv#BIk!!w^TLrC`wO*|7T0kr{;bslB&L>4XkO>b8uMCH2-qr6Ew%U!r3%o zQIQpzcPZ;1ujf>KDQjp`yYOj_s6(71)`#L*WfyR!K@SLWHvWFC>zQl3cV3#}=KFGXOB`Iy2LL@pK`iIenI+!NYKY%UeSi#PzHz z@d*1EC6_UisCM!bH_{IZ6R0vfU-tdY381505ysCD;T*Y|;ZNLs%cQ!EYm~PQ{!5Lt zRl0Wpo=n~rE=U^FDY71Z*(_^o9oD>Eo<-RguY0F?e|SoCo>`cFET_(P>~PQ>_+jA5 zu9%#(XRE(#rr}U^3$oVmJ3gLt^*iKMD&VA?BcSCVr#(j%g#yPGIw5s02EnM5CQlnc zR@&WxsC}e4sa)WV+uI(YqJ2(B3x5Mv5k3Qwj#l^w0>{dwqPTNFHPL542@dq=)7)wl zN84SgezRMnVLKV=5*AD{u(!)K&Y}0%P*0X*jJD*)y`XTf@0@kI^n6t$qo26tP$yA= z+Zb-eeBe}F#(*zUga5eKeK#B3nPSPmcW}I{6aL0>eX}gf#*a@XwOjf1%H!?8yVK4) zvm3JLJ-qI!q0hywtpWkg-`<_SwAVS|-B!Tbv3e_tqn{CsJ_sC$&e00q0D%(UJ%n7~ z^o@PNn-!s@W9+J)qmrzMrzj2(_nb8G&EQn*`Bbgit@-DbDZ^#$Dp|2xX?Ry+YwYLoe&52`-VdiAr$MmNyN(J?|nBS9i=1W-}sk4BC zbj(=bz5AU6HB`()>;sP@J=@9;NaY0C>0 z1CURao3O^u)(YcL1-wSpSpUcE{gms+?`z(jJePO7ipu&NvmzpAWzDtyVrE!>`4z1= zd>bqn3@^S`O@cch?*I+}q(QZG2z<80Moja%;AM>cLAyt*8A_j^3gz=@(x+H9?)22y z>s!{R{j6#o8|GIiL~ z+PZ!fj(_gdI$}TaYGRb=t(Br5*82{K&~bTxnbMECAZ|b}tj-GZTUSOeMF}gh5U7L{ ziC=J0-^PAp&%ku?p&yeGDCF8me_2?`ly;u~6i|_eGNmQF4WJwz(<`!G9DmQNhiv6C zUQxvnIeOVGKtM)b=m}4?liv#z@3+yaXCs|l%N4qrcC!?9i2|AaJjxaGzamd18J$^a z{h1(rEM@X7%zY7*Fe?d(oGI;fFp>QWDJ(@i6NT@rjuVT}WN8n_X|%WCDVp!bp~!;-o0MtNz*6l4VK<( z;tle|EnlV%ibDSIrYm552kcqeAmD>pA%6k^p|iU7*Dr#x%%eX36w3=A7~3Q>#C!Ltnu3*xJ5NdDm9Gz7^(W74 zB^Mq0B#-JV`GtvyfKSe+A#>BM`=Jwy&v#NXYqFH8_Vd}td!m{K8qMi8(Lc*}CKjeJ zF-@(;tJYe&wLJ1#+eA}mx({#$NkqSS#T*#-t!`&e5-W}PDI!TLpb19|Z0Pw67AL*1 z1H&wO!1s!@mw=ms_-=tjqDO7hYLl2?S@Ds0CGKF)1jxo*Q83&IqIF$+cHg^&|Lus{ z#A&)aP(O!)4KM!LA>8zfX~oOVtpLIEvptQ#E4tMhIW%NM30^ zQ^~M;(88DLe(_!Fy@&cIEM5cX7lh1ZZ}vRAJ3vts2Uq#N@Z!|t_^epK@oR_vPPK!` z{o#LKhCnw6a^jYVTlaPw7+LzhpC=W0m{qsS8pe;IGE9uCklC@=wAj!bM6W5|Gi@U_ z{?zP8Q5WCy?d1W1&Rf~_Tq9|E3LvW~Yxs-ja3zoZ*3~i>{O2LrBpiHyOV+V6dUN1=O#MTTV6p8>%z&@VGyg~fA*Bf+e1Axs zhE#x%wz#?CS>KuiA@jlHW@3xP2mV}6RO1bXY^@Lz#vdMiPL;<+aR7U-7nKAC1%j2ye)l>|ynp56 z0EC}0e;d);>^HrJP}Pm#d6+G!t?y>UVZD4a~sX^M-)7 zw^<1eUS9yMA-+@N%_pdK;9E3auF$=)(w`u!T{w(B)!Gc7^lEQs$2!&sdEpB5J?Dch8e@LRMvk$S^>4i6~lAS1ma$T9|_7!XRur#$38W7atD!myKv{ z7FHZY`f_FM&{0JRXo~~{3z#Mh%=ca;>$Uy%*Ib51-hCxh=an_gy zyb3m-bgU#Pj(g(&n$~iXn8hjSimiyMoX2@cV@Pmz1Rh~4khV?JdXcqVOIf+NL%Pfu zW|cM?LY5HCjJb?Pq3Iw=eC?&4{TG^S5o-q`!45(PmuyjbrHsD;hw{$4IG~NL580K? zf4X&?V)-7-*L86D&)cgIkb!&|6J^DG_g;+_H(GsBYkWq_CT^f^ZHuxjwZyOVOej7R z(p6yE)V{#~VWT8azn|-ue@=4ehAM%g)2>YMLOgC6ffJ9=q+Ap1G8woL8vGD?Ty@Fs z#g0)C>k_6e;P%2TW=K%;UJ0X-XAp4E>8S_=cIgd=Be{PNxRw+A@R>Vw!K31%ViP|a zCcs_b2EK_QgkJ$xm}_p2*58vBw|Pm-NNTe%L8a}g;IpYqMmZF+vg(UZ5r;oJ=w zz*X>syy1?9!FXQ?3n~(&>jY(ZH*)yhZttqcozu|+tlgvS_G($uIF954PO?w36`OaB z<2aDfbjm7eY`)Ih<_MuquAAzXQD$)!B)DP4ATs`wsGcopH#(*$Eifj-RK{ljE$y*l zjBb#>2Ieap$0%^_fi2=mcY8~;j6CRa>m8hM84BK8A z-Mjg_y7_$Jqw`1U5_S}@}jRCwqu0e4)Jj`D5OUjF6I|U)BBb2K8*2Y`Qk5`sG7inEZce`2YTh&p2+5^wT73s8KQG_= zsw9-fFPLD#c&5K7C6N16$-}Bp27LN?2=Fv*TN!|-D_NYF1*|Xzu5~m&3SfF;b6CSA z>DV9Z?d+Ls`67$BZ3&dtjkGb3Vvf^INS6HP=Ict?2YH4B%R{cQzM8guSwtT9EP8L> z2x`*14?;iBV2-RpyOrA~VBfZ*d|x*u=X{e{tCWmkJf+QT*%n;eO-DQJ~sRMF^A=SJQiCPFNfIeB_U z2dUiEWtdWiLyCDk38L94G~m8h-Z&}V)NCu@5AuQAU6j~BTv-9 z%_?Yv4STILxu#d-+52ZTFA@pt>1B!}hNshGa3MG-VG%f(HAYfqYkIJ5^W5&1%vL&b zADcY6(Q^>}R8R!|Nxrre`bmBf=jBODvfO<|RrH1K(YjqbcYDpFftWUppf6#131hd8 zLH@@Y@{WUg+e90?JPaVgg5NU_<29We-C3a$v48<=EiF`2kx-AKj};b=0>MLLiwjBL zQ=gRF3ZIEDotwO2iuKe|A`cHbG(%4hOE4YLWzk9zRnme@U(y4`bjs(zk#8$Din!G# z1D`=nd5mdNuEwb&5nodD94daFHkSE`oQq>91Qt-55x_s87i8a`i@qlOYGsk7)=!yL zP$3-4EJarF95b6zUbyrF_l-tJkAsJzJ>5?k2gRa;{u9E+iyJ-SP|mu!piQ6x@VeCl zyHBEGIcd*!rOBf0F}|+yA&~Rq*{njqstx@}qdeU`^!9^k^i)DY<*GF~Gr_%ExozTz z9bFZWW?%!0?a<#V{5eIJ8LHnqzMF{sh1dcqVwaurQzdDE@P4x?HrT$HDuDONme&~- z8?I?3Xc-+6x)|k$rQc^h+;*HR_;4H>0oP@%9Hrb$$HF56^x}#u+O0o~M7xbxX~knop%rp}xp6V!>o3d_{9%a0M%M!b=C{jNH+DX__Z%!pF z`g3~pp*tc$^i1cMqqp3GcNBG-e0?&TXC;%OcvA`%9k(TUHPTi2r8aMny_pP!E)b(d zDe%8W#Kg+Z0@X1p<7jOE0`A=sLK4gBm2&IZ@&d{oKx2R%Pb9_m*+}MsR3RGOmOe?b zM{97y#21&+Plzp(uY1C)z=j3rMzX0z$VLWaZ}`YwdJx?0tZ6ihXij*pX5hFBB{kX8 z>B>0NH`!C?JRPH3-@7@!Zzb&);N0aq1P_dE7YYMLd|}h*u!Zyy&WWK(bV%`K1RswO zI!Qqwc4$Wo>T0szTVwl;v{f~?gw_&N-4SP95xXY$#letRaU7G5FXzhkFEu|&gglFWQl>(OMX4$|AZ`Vt}(sspTaTQ&O94&+L+phuF zo4l=rT<_`z6C0Eg?|EbV>5FTIQ6`JKNSs}11LQjL1OYqtX zR=3kyhy87G?ObhUxwMDP>kfd5V6Q&ZR{IW{&tMjb6 z4?yVAVc>^@(R=LhWXTz^=!nSg5Ea*cL+Yid;)pYG-1U=h#P#rtY!h7^^0Wa7df5;; zs&Bs(!i&eOabsD)?#^>~Lv*zCAS~#u#T!1n5Ijug+Wflifh(5Q$ZIpa?#}jc|8~v+=!Qvo zK-5lO4b-o0>33RpF%T`W9#0CpUN&hWAK?!hmizwt^suviU$x&JV-h4}0)0Rodb$M2Y`bplSSdF}4_&@Jw)K`;x# zeh4Q{9joHKtjpO>s<1lo5ZZWS5$;S?Z=R>zm@dwXy?nK?}%O-w+oJSP}RPuovEX1p77# zjo>f{dNmzkVZLqj93SIXdAm$=HRvqxUd@H4HOZw~2j6y$W>jrw#kdPK*iSY{uB$!2 z4(*ENCT-Hv^R3#6&v$=5wC#RzZWTS5A|S(jK8j(%n$I8A5QxbvNrr6GZU0S~+Y|+q zo%K~ms?uJQM8xT7MkB4HrM6yLdEY24jkt5PF*$fo?70z_`EFB7My{pn?)&qg@v!!N zHHLO@Op%hWY;uW=FAf>T4uJq!%=w2Q((0(a1GhSG6s-6;@eN>9UqYa+?fen}&IcAgj! zqpjTAg493gh}ifsvac+$aqq>#!BEG3RW9KRn2s_J6P=oeW^gRFr?RBzh-UDYy6()i zuV*<&r+CeJ7xw#Gb)YCScpOPS&QBQ={t#~n%)7Ad+~ zvkjTC+-ICZtPUVJux|`Bbpi^aq!S+SadRNzK11KZF+E5%?NiPi|3II8LQtJ*Y0I!= z-1lW2NlKK#zL0)tWVT?b_fh-)>zy>-Y2bF6uP4SSW4BHC24Y)mbtb5nGD3tJKL0nb zpxp4rcF{q;oDT_xuoL}=ZybR_8c5?mD@t6@In$xaIqcI7x5h&`Cdx16wb_}B*cF_F zPMDyC8)9*LvAOQ6RipbF23VbT zE>7~Z>I~2XrJ^#m?Bf6MX*8`>3ItP948)EKJxSm$({MH($CnY4b1n<_MSfs|n1|n1 z(FtHLsO52<`#5w)4>!M^7&rt?l&4r`lV*E`dC>d< zxh$KYC9qtyH(l_OmYiRXbKBJ(UTgKho0f<;G<*roP_LKbE`udbiTKWRd7k)=f3FmO zEd=fKR76i*5}RR3S~7YTOt;khK9%Nab+{)+h>pMYl6xQGnWD-mJwNSVZWQmUNw;Am za;?c?pG+Zv;m8ChB}m}vW;Qd}eR6gCtk+vkA(MCK>_*zHM#BPXdTtUByyfPM|Cz{x zkpM7}Ts^hCi9f&gueYK3CBSm?m%*yQatoHVRPUG{H7nYaj5;JL`cXS@H}!w4s1WsF zjdAy* zK2O}`qMi4lUKPBKPsJ@oKLUxnw`a_?#q?<(fN3kl4-G}jKB zm|KxoBT_2ZI9yith`w7CU|)RTZeC;rDp3E)pxZ3N^11toj-WfXZ(lZwFBt_G9!a`g zDNrAQ&aka2P~TZK5O#lIcktkT=jTH^7iuLazO$~ht#H7Dd7k$|Fep|Z%xVrO{}B=0p0WREkM}uu)Rqo6=$}m@10?#I z3i=m?ux>A3=>^fa7a;m_ktvUu(q1me0LUCP^>-`_i^(yx@{3`AC7)Rxf<94bP?^YH`Y)XM-Tf@M7q%dCEPFm&kjm}{kX1jpWK@o?y|l= zdIfs?sW`oAWZe)!FN-asT9GPawp)C(sP+u!)O}ppnsg$r+W9C5AD(P&W)x&#z|rk! z(=O>qCl|JwBTL{Na$;lVt8mQPAB@U`EJyOiUftBGc4d_a~W6d z3RN{MY^BFgFLrS+E=FP1Y29}IDxkYeW`QiU47}Dj@YvxH z9>Z!78EI`$^R;HGvmuPEX10yD;5*vuG_HTj5$IYpJdT*@l)LOy6=-mPdr{?AQsePv zomf=nFK||a!m`hAysUg6ovdx#vU*#Oc=Z%%lJXEEtC@I@{Q02`2UTB-VO2ev}&X|B@%tf9k$~2Fo=A><4fT&la1+A4+BxjOE ztzV`t^tpp={frE&QlaHnuRkINU)9P|>yi4`OFE`*b6RksL9KxN?xS56&xTjTt*XYc z;EqeUyU70O=68`kyqj=;6YqB<0CLU>)qB}c2K1Ns?G0))zu$kfOyafWuO6dL`Huy8 z_08}c*qsf8=>pwB#w=u-H|PBiMVZJ{dzb@x#|Og`E{7grfUo8D9(k1Gw=4(xOq4Mn z9-PXQ-8X>yR!{t^Cjh;(=?8Kc|!&Wv#O zXb_vU)o=+gqV*!`EdX^!oXR}_>Wn&-c|3UD9YN|Iv-~n!?Seb^1vfX7DeUigBhbht zH0v9%Z&;Nyj~!IUL43v!O`KELih8VsLC9&-_&jD~6;VkYUL6fL< z)5l4v*W3iiK+Vz)f+CYZ_SD>VV+ZbxAh77X)8+hPt+>69E35eL%*(33$Zr|ttm=H< z=%u3`2lclo1&bTqMa`CaA2R4zS7t7aiJ!CRPfTEL)W~`$o`UCkWrfn(3L4l8Xq|XE z%i<5gXLh`ofYHR-sVMicjO`B9C*7ed6YV zK~t&*zeMpKKYx>c*_=5Y{sz+U=-xwi!{^6SWDslSP z5$rluWxYM+9UEdPlilaNgQ^)$-DYUpA3bh0vwKFn)`EM%&dXgA-+?8uEHwN|i-#n( zY|-wl3B0e5D}swG=vyfJKNqNVXmwRietn-0HDUZ-_85W80>ZK>;sWT|d`(h~N@ zeIupZHvu!&o}w_DMSHHYk1Uyg7-Z<4-oWySgY2r4DCO#}llS2|xDj<&`#u&b#;dM~3(+v{!%vM0sGj18StQE+akMzYX-8iK-Ua z)ZH;Usc9=X?JUO&I6ZqK6s*E?wm4~5cO@QyF>Cy|j{Yt&0`Z|~5i8{MO@T>n)cxrp z-rm}J{;h$8cdJ`h)6IjK-}nqx=bOO!LvdZB>zhaPCpf_usVCn1P6!BxQz!s}9wHJk z!apF&|AzQ|0#W{dxBm;I@_!HTZxq}oB;bFVKY(8NFI?dN?)Y!K*(Z?Pe_95B>}T;` zkh%Ze``O^ZZ!pLI?)-1~!zTpDf7&_5e>(sF;6eWPIR9pf jC$PkS8Ufb-nZ*AGI#FE(747LiF@YZmfJ`zzPk;SC^b4!p literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-57-17 site Document Inventory Report - Site Level All Sites by Country.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-57-17 site Document Inventory Report - Site Level All Sites by Country.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..ce9df6fb466cae491b1809b86bc4cc5ad223af0e GIT binary patch literal 112618 zcmaI619V+Y)IS`vvCW2!okopqH)w3zwwt8Ejcuc`ZJUjKW9Pelo|kKV|2Hf5&Y5#( z&e{97HG9t}%0NP4g2BPTfl(LF=z#r?KMc_IcM&^VXA@gzeN_*86DM6pcN^q$IsQdR}Z?d+)2t22oBdqre>xZ_r^^QP1+*D z7~Xw@-u-k}bmo8BLVdpIop`Am{L+&l;A6K&95$UBF(d$|FS}c=5jcD#g(@S?5G5ve z7ha9e7f?KJ?s`91w{#mkN z6Y(0#b^C`M`6g6z6)&SqB2)(&W zR04Wm)T&epyYmRzBrr(F3Ha&JO!oJr7Y)g=Db!y}H%!QV?@TY?qAXwjh#<3gUmkNQ z%D}=Ue4%Oo3JwNF1O*1B`2WNn5rn6XW0S%AY;bkSwU7`k%);05;HQ7OPQk z9TD@exQQzpH2_&j@r}-oo~S14Z#{pQ*|t7dMqCBMq&id>v+@I6<^uD~SDuy$+<645 zE`+dpj_h|OVdPbRbgc=@1uJWeZmTFIqeTULquj94Jre?#>5DKtcg}#6W^k&;SVi-i z1vGUmJW)eVrk!km+6(#~#A|pV^=UlueVeb7HBN3|agcV#PPpZ?y%4s^E+FrVvA(Ro zp6iNt8+VgJ+9_4h?G`ILqL_qjvL%EG@NQQl+7>(di`g?^_D*6Z0E!5~SBWY3c7A^tCPP(dS%?Ti#1?d+YH4D9Xys-;|P4+2OnMK68DhC4P+zKPBz z1;S;WeG?=tSmT_w7Os;P+{&2$GtL}W+&WRc8$;VBRJpzsgDJ@w9ebcIK(cf~`L#nu z1OW}>>v$d^O|zpxteL+x&MnoFNl~3FnMdE}BD`L9o~V=``os}C)9e!6F$v;?<&V(P zmCv{uW=J@&8xktRvyfsJ%@xHoMmM!(*-ca)5j);|V@6D(WcG)_ zfHdHt5VVG>?(2eds*4YsW}4@Yefpi=(tt)W<<^XHbFF1p)Fsm`=c4R%{7qDm2Hu^o zRdvMex}mjo)6PLj5TPtqA?+>NkYzpA){&PV#h z{RW~G7S6tFnaUkRSH%A*f29AQ+}Xq0-t35q16;F^WMM3Y+9Zgcw<;JCsn#hlL1cD^(e2%VMk^#hNwL0a5OpGegsb%c@ zWh1}`IS+@R%Sg90m;4_n3`WS{LMw#LlP=9thULGc44GVpFke-yC?bL?EzsBS#7pi- zX@8oeSD{P&?iDNY)RHz+D)icSY+r9y)ag{NscY?}ncc7&b$q>f6Z1^=eHEkCu3j<^ zCb6_D6cwe)6wMa+vqw5{CzTE-N2MXAZgppU0T~-ZUaxSJ0GD&C0wGiw!Wm9K3Iij} z^(|WxTVVsEr#bY+RE`qI$ePKA;*$+8b;~T(kwo$%-|)?9H>Yjp@rnmj_2v(>@jGC2 z2vj(ao#w0aZ&W6MOgl_1i3}t0fWO66mrWjThWBIH!2qM`_F3ZCGsi||J&oro0N zf5uH8mBir6@|(nNF>5HVH=j|we2UA(DV_;;&cu~Dj|m>e#G}kt`biu1jyr3!ylrZM zfAYt1jBW3I=N;)%fNRaNFB|N{=%nk_pluHN+BC%c@jFxVc+yTUH*;}|v*a4f`RPY# zrYuj;$x|NV`#b-_ne+y!BI24Qz5;%^uV~ZDqj$zHp*ABE{fSIAw=+Y>`N;DT4+}Z?6&h&q zq9);VIr!|cl?^u8GQjSS4Og4*&kbbGJcpgOQu!n+v9cBHix!`hT9FiM=6r?uWc%s%~xzO&TtINR^;Fg5NhVozI7{O0HdoKYq&WG_Pa< z#5()`8Fq31Tko9AO-!7fK+YD_u>4iPvyL^#Kio}KUR~LNZM=r!Zlc;!V0=|88}u0h zg)1A&7GnZw*=$@#^Kd@5m@bxAl;44!(jNHMAZ1yn683|^r|NEyNs#<30wzMh z3JQVwMhkvSeRyhWD>yXC&o1cul4HD3)9W$Jt{J;Lq-1w`3v43#K4<&A`MtkdrTge_ z4FLyt{kpV2_KRO84uF2`eqDO&Lnt$zKLrNqeGk5;^NSMrrfziT3z|AOf5-IH>@03N z@9+!%xuD?pc4KpmT78YEt@V1&BzT^fz4>uBH9)dS39Po-*;4o2sJ3|K7fjuJ->3HV z0vw&Xv`6CrQc3LUY%)@Ox9EIz)<;cDHwL%z&K;eS-=A6JFD|%VRa#$-u7#tVTNvM$ zJSDGDJ`(Rx-!y<9T~y70m#){nWe=Y(O{a3tSIyTNchK1~Gi8`QjADH4nB~&7dW9Kf zNps~%-;*7^lCR5@^{SP9)kZJX=t`uaJETL@N^3M|4VU6pE;KH9`1E#zcoFtbz{rGy ze}h_7vNyxv`ESC{V(_JX!M9Nu%CHE>IJ5=GSb3QAmt!f7?u{tp+dW~VDKHfO>8QqL6La6W10jKWu z%{~n$O9hD85{{*HRHSERN%e63>j~sH2RBbZJ;}4~hqt9%iY$*eYr#=LtYF(cCCv3O z|4JgUdgUHk%h+S-Ieb(byWuti)9I1A^`riJ#xoUUl ze95G4d-OwfNYN;8{)D!)W@uCE#q8UJkgxr52O*sE-qNeA{wN`_x*6OA3g6B)g%>Sb z{$0S!Bro-yScltU%%853x0pp7mwreb%ga5Iik?TeUss5x7(YLHAH2i34-Y>^{Lnh< z`Gg_jo^E%ayKCXQz^7_$1fAb@nXU=^-Vm8Sp#9Wzs^@DgZg5)6g&>Ctzda!`p0v$B z@a0#ep5yWPXH=lqv?!j)Az zLb(fSs5D_tyy@B=Pm^T<+WIZ?JRiNNX6nVeuaCXY{ePk)CNtdIS8uelNeC~#uML^t zZ(Q5Kjf|!f6HY$)eZ+Suwx{{0UnlG~n%78~v&Eq!H0Jw_q!MT#vp(WlgZF&3pRy2y}efT)xl;89`7UNlylV!rs2UO!qkhY zi$lvRE-9(uVgF@zp_k%v6wv(p`V>(TTGyzM*u=!$K*?=+50N8QrD)bB%V}W)uP4eJ%}l zLRcJ^n5UniK`V>Y@0+fiQdG$Vaz812OuMZ8{!GBzp?3~xwO^Pg?V%&Y{0#JOQ2Lp2 zxj-{gcqLBzJQ-w~teJf|7j`6(fr6n`{z#^K#RLRqth^cw6O=LAr@`K_DTqhz=5g#I zq1lZP9?6*bl+7rP&?8$0#TRd`z#L1Qje~2G4c$?9_N_BJr`d6Jx$p|n?}eS)WnKdk z8-*oDdMZ(`9dYek;!k}ly3&9LqC&WWk9%E&e9aQ`q4@Yu9QY01Pr_>N!sZ@~)el~N z3l93LSW8C)c%k5zP*3Mvbq-Em5=$vw9?)`AqXxb7lY_vI`8;= z2WM_Q>H`_J`Em}0afi%nn?!>OuTgLFtNLHAcg#xE5~92(xxErh#j5Plt9QR>3!g`{ z|Bz@Ds*KP%Itu8TTMYYbr+SY+71#`$%~%Axm;!mqI>9+}?WfsZon6?xCRW#4&-qY$ z$D`*xr5qdBW}G-RxrfTFy`gqzz|WX3C-9+vm8ZJ);&}BDiGpHjERJwo_t^pN&)e6U zgi?79d^`^y;h5-lQ8x-B@?bN@>G5F7RH&*xfPVG|RE+5$bb4BRaHXlZuUDO^xL#fQ zr#j?c$GlbAzn-`Dt(APiIM{}XOx!%&EU-H2@0*{R?@f9?p2+kzKd-^Q$9;Kb(7NXI z@0x0U?eFmc7EcTwa*t8-Z)#CH+@n_dUin@5YP?6qeJ6gz`xtO`0U#iBwl0gsB9 zd-p%*LjChAFmI}vLLlVYKLR$^eLDiS(_Tn4Kx0-^m7>a>v@AixGQb@b0rsx%nN*q@CTC~lX? z8}o8oxcwBdc05G$AWv-&3&k5qii#XgBPVJ>E{&lS6K;72$%uRct3w<GQ#b1hpcM zLXs0J0)^V;C;E4Ddnf!ocCpFl3)dG&?CCBQ22mCm?d__e5hlnwX#02)P{Fi;R{~m>X#9k9sjFCGO#%) zQQNHazuvRG;3B+};~Pyfa4{-T+ont$?xrX>c=A%^{*PqZ>Hb8*X1Q-i!Tu{y-4xjW zq^A0!)%RAV)+Qs;=8vj1L9yW)H`dzV^?y^p{X`L7X$q3U;X({LkXIBW8+@#Vl1H=> z8r^)SXRV5$DMKP}Y{7doppoA{O`e7!O&CA&_O;6-7VP%I0wj6n(QT?@t-ak)me1{1>10GIx;4~vQ?ybWQjOuEW)PJ zN5%#I^b*B7Tc4W_g&{Q-N(Z}>UyVRlFp&H6Ig8^~aTXqw4b;RRd-5%Y)htE(jYAEQ z=o2gqPr9Rn4SS!%;w;GAZoP2l(hIc+wfx3mgRSJ~-|mauUI+BW1s6SfqEfRNLfaM> zNy-Bl-?^ShSwGsw8VKRW!qS@E(7L+SM(rq>9{KdJw+1I1>Zg>ht$g2P-W7j(e`dw0 z5ZE~-Ydrkp9pm+>qc!E)awSTRC{c z;$;%-QpmR$#X5B(z3EZXfKlXlm^B#p%s`S-dGNgXgK7-Pa z(qFC~U^-jcb-T54*coeF)_8yA`qs*qvkQ)aLI})holLR%wjH&+@J8i*X! z&Oh9Xoo)D{c{T3`xD%1Orr*K!S^xw;++&p%S!Zi0mwCX?M zma&g$gup5yrEaW3UC@`^5EitKQa1)PAF$6OFP&O|M;-(vT9Jks;ZFwI$FvT~@DVh&_!qH!%U?!h|uJ zb@*I6+fp`hM39PI&XieE9?5dzwaS8ZXsmL09!U%IRE-R(#H~VW&_u^ac05OkHVam^ zIpcrS5kR#jm)JpgRy5)YDu+OB$|ar`jp!kRI-o&2|F(50K^yF89RR9&w>e{DF1e9Jy5Hl%rze@lOBL zk`E#z&4Sf~<8XQ7f0GJ+`400$-tja z57C`7_U#52+lcp!v8YpYNSF0ZsRI!^vNLBqOayxGI7mq4JVO_@>DF9w_l`CH&;yU+ z{tu*HJj?$O7yR|#_8%eK|4V(s2K&lClU#oTsQz={ux)yUSGw#!iW9xebYuLwRdmQ8 zytUmFHSY_EsB5w{%Bv{DWn(i5PaRdoBPUCv7m>bC{lZq{%&NZJF&^<$Krf-?TgIXr z>aA$rId0sZk&X#aGd!oQk9V{U5zDJP$k0-Q$z~V1Q024=#Uv823Eh~p-5eip$5Wo- z33bCTYm2A{=|=yG?XIkQH>d-;1OdKl&E-I~{%`x2OYVBm(0kk6=rgKG*MBDU{r5m| z(47qovte$N>@+s=@eH&%61<}#C(LVue#B^r`sSGXDg4z4EHbz*jIS&sjk(ojz+kTx8s!h*OBq_npZ@ej3ffug0VEN zA+vrLT6S8EOiTIE5qjv1BsL7E;!tPP)F{H39b%B@XHlG$;J^tWP?WggH84U*f7QF8AabJN*1*b5-v+N4i`fh0iCmkrU3k z_g~hWz!R&Cje$(LKplxfDMdv^Tl76`5df4ZM@OA|eLUPmuS!Pc6N9$j6}4j5k#U86 zC60FdG&OQNOg{HQf5$6i&~J&X-M{rFuqRt8RI_Axqf)VL*^JkhxWhIwm+ycV-f3-+ ztA%!_gfRA(i0lO4-q%nCYu5pTY;Sia>28DA)~zR^+(L%n%$f2-H3RH@Z|tNi9-d*< zyL#|V{_<$l@?DGoqvJhS!$NqIWBxMblu#T17u2q^b95!dXdetmqlP=|3fX%4wD0Uo z$bj?8X1&`*!T**3(Q+~Q6}i4=-)*6k>UsYTJa0=jDHDG-O^tUVtCI~#C@x(5Xu%1^ zxI71o53xsVf&{Lt+DIm}9oNr>?6;>YvCYJ^0sEc><~McKY!p{VdW7P)34_z9&(UA~ zlJAvt@~x}d6XQP1d*_6;RgM^ab8h1uo1v>OBSogf`2Y(u>FbRngM~{#iNsyr?p@3; z>_XPSILsK1A{)U^5UJY(rBprpBp8(3*YmAkFIQQ($|><1sH}Sd)Y-oTZ84UJgRS(6 zLad(Nq#R-}leh878gw)RrX9hfr$M5HJ4Xz@N9w{5a5x9wxN+KK`=fv8A!4yXd1`D# zR6J(#3^LsMRKKwC`>J9tjhjDgHrl5;rBb%~#Fot{BcsoCv23S&opQDwb_BuAI%3e9 ztq2m~5ZY#>P5bGjxe}3s__{HYuhaG#&#i-NH4W0W9$Z?g^#JJl2(=52h)5C`mKWz z{3to2nZWz$l@#pZp+cU6Z1V*}u2y0W$pNF5qg)jq^`SRHp&ST|ZxSDdgxhVGMcf@` z7$uFx^!XY-##903&;kbI;BhQ~iUJ)TW?KA9=Y+fJqX-qH@@>c(GrYNKKKM6ZV+CFR zJ{=wEk{Y)#X6QGaDtKY<0`m$}HX>|gg!}$-6}j+-cTttI8E27oQR@l1EAL=+)q^Lx7n$jcrIxOBh~~0cllp%jl3?CD5#CZjG*n8fFe^cD|%U$bsc`_ zSRgj-jfeCt>!$h}X}M4euV7kMovOTEd)*KUQ3KpQFFQXsR(1AY zIi~G5lc|U-?Ys-d?jJ~RH4<|Z_8`gTcUSq?3Z21UM!bwuJSimZfcjzy*nMG_t6^9^ zUqdO@pm#qFHJ2x{tfxjKAy6rg$|^8<@I50jXJ{Cw+l(vNxSnu6MRU($K7G+p+NrPV zMa!F35+P0AmnKb?h^#*3kzNXE)~b}}C|&=nP_VOdCKzZSg<73U87~}%*F9L9FxgN; z^S(!K6TwTy>TPi9QZ1-~(AtN<)!Hw7iC4QaRPHw7p{ye9?PhaZG_)qc?Nb>6D!^(5+xJrZR(ot>nAv6D(7sH2D>2KyLpGh8)%>yGt+cd4Ydf~m$X8k}p`R;9sTq{F6tG?!6QVBBD+guwv>dg^N;2qyFcCh@Cw~lX_ z)Y|)|@L7O!9DZte30}xq$bh$wTXK3oIEH zVeou~S=8RKOCY#$honXb#*2W*IQ)#g!J2AZwa)?|NlZs%hAtu{;f^P&>rmhz_M8tj zc^$5!wQ+P@b7^g8$OOVPmq*mOY%21(eZhE}4zf1tNRFvG?l1**j@nK5z-&filh8VU z9|PbwnP)uE)0w4m$v1jE1jg!FAXzCiZvNw|ecW%p1!HGFH!@|>UULi}cYb_Ze7yax zBKD)N!0PnLoA80KFt|7h7Y@0Y{zT~lZ9T#g*8$j2u!FBv8Z5~E9vM<$OSRh6-_@bU z`MU5f-#Uo8zMshXQiPI;`Hrd0KQSyR9W?)xMe(KZgzhRXziS$X)R@1|XdMDB$^VGM zOlMN1BIf&{lVu6f)|H4#OAg)?0hXaOETstsXf{rI^iPNv78gcc?u!YQR6_c3iVt0D zDdBH3P9q7OPs(94fdFBOq6rp2x-df^a8bSq#kq^D4ArC~MzrimWb%W4={*TnhG!MB1Em}ZxW0L>1Hbxu=c<3OHxye6X=Z%pg%YlPs6 zP8a;j&FD3TJD6s?-B+bQoOyZUHlh;AYnH4h>w~wW0YBwx%PpSpxGY+AuHEcgG7`6$ z^_*=IxYVQ7y^F@-d9AnhOJQ0QP>^#8XlG+=DH6Dia%85Fsj~irvF8ZgLzs%}!Fa9@ z6O9hXU=qpO%Hn?JQa^WeqyX9I_nLQ>dQUJYmQYr9W^@)!1mol!Am`5MX5e5w< z>Si5@v~_7#{^6J-ti4zif%ESqPlxSsDb4DeA6aWvpH?YC4sY(~a!-2+7?X?Br!Ov{ zMI$A1Y{=ovK3zks&S!JSW`8xg&ZcT0WBQ?20DZorCj^3{!KK4jvyoz&^We@%)xSx} zP3=zolcxT|ODLz|l~V9uVXT6LVGa_8KWE+p#Q9W9jFnO5K>00gqiHbdHZiTJ7_S>8 z3cWl>&&C!QNC5t8qNJ0!KfwCCk#NBb>`}PD$i+CiE3K~j%80<5S%OF~KKVv>^n7RO zE_i!^;o2oph606lqIJ+)?Ei|KD^EjS@|V%)yWu9nWr~m@$^9xq=BHAsn*D4XsHXOC zsAVb$d-c*=2u>B~rdQ;`?q4_yV4UR9kOZZ!P|KjO?a%NClV+fwav1W;DGLdxY0ikZ zF6Rn}(Tv9o03iw6q$7d13_{YMVQFkgRDgdV%_Xf6;GDpCc*ydR!*%THFtuU>gjM_W z%l%c!Sx!C{tK!bmdg(JbACFd+C3$-nJQ^+ex8D)*87$NGN1hldfC?L^)5OIo zcA*$)-_OQPxYKGXTCs{2Ou$CL+7mr23m6a%b00jUim=PH-Lkf=tK1aj-W61l>xeok z5z(p2|K#vFjTlwpHd625@X;Yn;MMQrYkh1z_dCPnLGab;Wx>59@Tpzj;wV&aNWBOI zNaG6tFM%B05)jdg2U!`F%kSXbHHkF0$7!znX$|lhv_RkI+!Y|4w9)-eLGJIcmRgwr z-z09j?0T>Y{&8ZJzIH1&!DVwt)r_{3WVl2yC0rtI(-OWz->KvGVSI3ZBfy>XwYD$T>f_iIa;_9&w_Dv%&CEr1gDW&yo|G z;(^ResK}f}Y!RXTjpp>n-u|?e3S|4;Hsc&4P)n3-8OMyy5S9cadk5w|eFOd=Dt^cO zrb5GVu?INFm4URN`KQ&j3Cs4Yr>BR9z{l&crSH>CPX_w?C*Bo)<)lS|&HemNqSE$A z6*<=jH(3w`XPmpK#yd*Dx^HzmYO;9WSnTl~#KuZa7{hKL3ayo1)Cim$mE5l9H{?$b0=U(ELlVt39qR z%p7PW@3R8;Ai1N35*|Mdzk_yht%|Ywrkf~<2H!9NwG$oCIntfRoc;W{@%vm-jvXsl z>w2G0BFObwpFUHefqz;X^iGt$l4I>_YUoDtVI}R^y(Cz3JWb?nLgJxDBQmijaFsXo z{M_{6>SD8DlepG<;rrd93e7VPvyds=)q=VMB=wFL05wSJo`47td*_MJ9UaUKKEpwf zt<+?mC~gWMK94F-vqYhoJqer?cmus=Su)2b?{&8>6fPCwcrY9-#ZcnLe!F9OoesGt zfHvw0tN2pctUT?lePW+H-ZQ^$1uD>oL`BeZ(p=&?Xpz&w61w7bouglKD1RHJkZyd@ zDRKxlzpWC3dl}}q-kmrl)H|E9dlx!rQmLYc$`w?%Um~bGFf&*)@hAiL*)tNE9?CMO zzKsb!7zejW>Er@JY?X4F+OTec`=osH%7JbX!@H@qOmHOf+ET1Ca-l!uRc=LDg0?F( zT5msq5%Jv5=6oOogI)U~gT1zY-_t6^sZ`N1{#~m{%A9iIN8RtZ>xXS#&)3V3v8~{b zcR|wJMhvPl8l52k9~bs2yhOux83ar8z7S$cSL+MG#-b4RyV2HOwSD2GASL`wd*#x*|Kp zPa$TOaPuT01rz#m9Ex}sM4kQGDDH<_(QL>MK+)Ch3mTF8r-rY*@f&EOxAtum>hq|1 zE*){zln-UUN0=%XjCMHa#-M*_tUkW>25(MxhoWD0km{WS>lIJzfF_+QMP-s^z zK+c4xMZ4vD%%IO?A1=Wvi^gI4L4;|!F{L+p&b)QREK{6{H$z>^$4q^p=-LB}&PXhj~AkcW;>0k+sk57Hg~m=!Fd zo~k2Uj=&jjDY_e&+XSX3#4btVrx!t8{()0DM;r&Z2CwG+TKQ%fB3zUXd5m#K*x8A{ zsr%3I=bASLkjzS>H5V~UDspnxLw;G&suRLlwOsS0k*v2XXOc*ag}4YXVdFdQw}nek zeYj;5j@>dw9Kv>u<8%$&ydIymB-Qwzp?S$?%rTigT^>v$f~uD#8c8S-6MWOvdYP7- zU~l|!ngil15AGORU7}H5?mQc%zL-;l-A_j_om{!T9WZSiZ*bfsQRJ1TKYrh!(U+~# zX6rc?G5s+o%0CaP`V7+CRam26k`gtdyr%qS`_^y%rIIGLUY>t8`>N-xN%qvK7nHF3 zNsFgNX=rG;&>R^usUU!b8{!<*&7Ul9;Sw^OX{D#dG{8vI7VpkH0#_1|8) z(*vo*V~hurZjaY7eq%APx_=x=$EoAR7WwAFt+DV_a@$V72HaP}HcuH3MVJyZwK^|n z)LV26>Lx)ZWA4d-cR(UkIV6|t@^(z@VR~Bg@*DrVNJqRs=fsI>zMRkryd_3W*+5w6 zEu`lGgsB|YRS@WO1)NQKs7`m0)~idsl+cCjBIOS;FAn%{+)YYS2+2hMq>DL9xF)%! z8W+Y(;-{ca#H2K^$A{WBwT2NE$B_}UoU!V%H7LGaE|v2Y3SPP-F7pl123||V;3v{T zZ&KK!p37`~&3<0q)vf&N%~#DGI_DLO=@mfnx5V|g%&gGev-$YRap=lyvBOO(HbQn^ zhz-xP3*%2*#;?}a9eDyU!R!7I4~=}elE(t;#Sjk@tJjj-Yp)o$hwoEs=4sZxSI=J3 zyZV4M!f?H;@T}blY%qrg+Ga4vOiR4zc6h~vVYZWs#5ONUP*xegfGO#>7y2{I{VCt` zt|Gs9k8`qlk`Culb8*Uf^6ciVy#3TH^hZpf39F%3Llh+i}epjY%iQ8n^}5g(5L4fj-?`#*4#M9~~>3>eNEMr=H?y z;L%%yeEC(|crIx>wAIs}cffr02coP2){z_cj43l^xI8l}mO9^RMlAXlipDKkV$qA$ zDEBgc(X(5@8rSROot@1Sm_`IX$;WB{Lq8H#y5h69;=R9^bOEL)LJSs;k;Bbkx5)t~ zs)P*Wv{fGeyA+@HhKCDid#Ux*~sjH)?G? zZSY=Db*uMpb?Zy2ux=j@9Fbwzy?>0_H501>nqLsgY*^SiofhU>(_I$P(f+B@k_|bY zLoF?Z)*5akO-6q?HzZCnA=&4zCooXgsD)2=PJvltUpf>zsi2c@m|DaX4u5?-@n6bS zA10~k9=8yk>Fc@Vc^3Srd>$J&Aa0lZ8zx-*U}>?5HcB`#vens)g;hUjU66|DodZd)U<>BXAXpl=V6JR7 zsJ79Z(pCrS!y^$k_Yqjz$7Jq%+H{UVXJl+|u6_19K3+3r)T7wPb_YzK`bOQWzxqh} z{t@!qTiVWc61I`TZ>klpn`|@<%R-3@PbyBwy}V={$jc%4LltO$5ctG~m&qL<5fuB* znJSdn*qkb6t0e7!1UR;jJZ+V)H49W+Pd%N-(kZUm84qca=(YDhE=_Ezav}8dfsAZ+ z24G6GJB@BQ+jP<9k^cGJZcGwOPsgC=GRGui{(Ye@r%8_C6m%l?cKq#&56x>bqOUz* z?^dCn$0aUKz&X#i;CH3F?bm*!ZR3&sQmT`e@0ztj$KoAnl9?@vlX7b)RC?ww?3BbG z7Cpq$trjAPYN2hKwRv`sUb(&_T>v#H z1cQ^RY!GC;bTujT!#|jqR$%YLpKLv0K6QiQGV?n*a;_bT-A)n)wb8)7(=16B;sJ<+ z@s~BFTA`!RmNdzX7De<)auQT8dE}Wuo}>^AX}I9^0?Y$^z4;yHrN(?iJ17VzBUe?8 zn*7$#7@w+B9_wx}uP4IUg=R`GnpDHg0Y1L^j??3bh1YFaue4o%M0Q}T`=5E&*l((; z+n~B%K^~YYmgLjs@aFw38B!plvm-ZJ04xWuInaBk*u41|1`Els>0$bcrj1*RF z*A~Fb;BWtw2AbKxTYDy2byXLw9kJHhygOc9N~KM~AU-_$y_5dC zg1KA$EX%;wu3C)pDO*JVTxlBODz7dRY$Hz63j?R_2jkJH^V;{eAI&rrcZ&MOoTV=O zIpJX9mPW*i3RnJ~p(>bl(|>wCunUmy4me?Ta=uxjIK-7E;43MSHa7JpLtt(ca&w8qpuHowxuUI-n=CNKj$eiX@~ z%kwRnfYaVvTOfzJgZi@{}!@ZWteHkmO%Cj{p@tl~3`%fc)V6;HO{2Sduo&ErTzN zoexw6zNfyfFA#Fd6h$mz%2w37pxUFdlHz9%~2 z=xl+v&4V^zO1%8?Xw|bfayZeH>!tVa2=htYF{bWx)bGmxB1>v`&1ywrmV4MH1>%vQ z{Bs{iowQL0jG_^=MWl@ADl=t|+;2!fm0RGuvUKz;5X)t%?!TQUM^3=1P0mXv%b6OW zB6aGb7GNw+XaZ#IEI-QHY;;S^#L%e2SkUaDvF0)f@`6(@PXBaiSKM#e0oVyWOCnDF z$+qPgxzKT5lsOBj;s`;YXz)N2^m`;JqZ<3hrFB0+hHm@&m~2GSMUY*O>~Y#u+|gG^ zYwiK3#|$y4+NOuQB1KLPAqSIls__`(6H!%F#i|^|**c7E1O$7A073~_i=`!vr76c7 z8Bn&FT#EtqAZhUU6D`oyzm0DJ%FPe*v-;Y`Hs{Zxxl`G>V|R}YFuVZ11@_EgBI#Ow z>2&!ooDRxXcvPTzq9g+@6@UF;{VtY4KXa)_hx6!L1EAp7_Y_sBN*jQxl8|I&&UDax zc>WnjY5AT2X@Nv!Hx7Ct*ydp)-$Jmn-zkOq%tkyXniU%gy8w24k=V(k>%Bb6Ex&L) z@r4&?B_G&OH3M47liG|Q9l?uBOjYE5@e}JM8zD3%{d{&#y0K_0j4zc^0%u{SL}`PVIf{j`P)4 znYp#QSJvmODlV}P0`V6~hnL>Vs$f2l?^}H#Agdjki*dz37t_yoG~dS;eUUVvzXAjxc9g5gH9S1X8!8kNoQq%EduDoYi=eL> z)N-jMo|SoUCwxu%xe@P%PS*BMo;Yj^$`j$mrKW1EDv#biEoX^JZ%ua#V}L}yvR_55 zR%f+Fp@xZCM^AH0+NL9ya#mNHnjow$)Qofq)XlO~?&z99_hQ{pJ%sZbv|-qJ*sMG@TA))F*?o$(=vSZjrvOL#*Xbc7xw^xO6msBt@B^ z49JU>yL5h4N?83F^x)h!pYQcy#ZGfcu}RnXW`veZZe`riFxr5~VUT;CgN#;qdcM>( z6cwZT2X3zW6lqr=&y$UxyGb6Isrq05z}EEynYK1*(0-)d49ZXzvxv5U+l^rhr7#l- zafma7XtzIT+5!(?! zGf`_sTFe6~FHAru7TPTX2ldggksF3ToTdqZ`n0ozwE=fIJcd^)c|5kQgu+fOmdH0< zp8+pxU!FO%1t>DfB}r)Y^nag+6(AnJs$v|!5v6PHyHRY2QcikL=cZ9)a=SKWv`aZp z=fI=+{QibPZy9>jYASn%Mk>l>I(S2a+?Muj{Ac`D7NJ_S?Ep-WS*=T`_lP+ zzfJMRO^~b0Dz5OMLpX6iJXt1TKRmwzc5GkT@{0t!UTwRURm!WH7Er&0P0zP61DO1{ z8+Oe-E=l$}%Z37fe$sHGA~!rH$O`ANm*y<8De6B-hXr;$@6v1e^@?ggjc$LxnWoVD zGW|8U!-~5;0beYYfoUUbCD3b*%Q7`T7blb*E|lek-;S}%r#`acaI1_ReDUs{C7XQg za9o--sf$?p{C&yX@%u$@tCo24h{#VZlBO=Pu}kKLMw?7fAa0V!s^o*M^&AMO`K7-f zI9|Qm*3NdvhvP}e@YAI3$p9;68B`_ugCzdzI*3~)-riiXuN)1eq7Xp~zO5=ps*ee%`$@Sj^^47O{=1tk(mo4sf` z;8*Vzv7q;5DEj9~9`d6MP2xEF#0k@%K4 z&TqxxV2g~nH`&jDAM;#i?@s)231od=k2$~hFB&vN+&;J^SaR?%xkYctK7dZtxFlg5 zv&bygy12C1`AFuX@(A^-hF60&vuWE^k%#RHZg(&*eB&_1?*zWgANnY|NBsir2sXdT z6=;e%yLBPK%#Xu%6g2Szb%ePk@T{5`%mj`;H%bxw?&~PfR1)c4xcdppZS7+`qDscc9f&L|mFg0?z~{A;jjCtj`xl5YYMCw#1R@*CeomdMLb>q zbk{(|H++|1csoF}*PTXDrXpAM&>Uo#yt(ngX$X7w^*pEZw8k)~|3LnGXBiPDs0==c zwDPSuMLnzMtFq>No)wZ96mtPVedu!_$2`}0eSN6}to4yHiRTSey{MsB8I24ySBgqlmO#;4LW-B>WfO%h7vr+rAS^g?cZ@;j+?az|q zs*W+9zct7&W^+hY=$*bNYD*LB4U5SVYWDg)gF(AmY*lG>0IClo6RvuiJS}8aU$Q~v5+XDy3!)5XU(Np#0D`;mPM zN4uiLh57@nFkkH#W6FS}lz?fS?sptu^{GjMxS{;npL`S#F%ev1`uCHw0Y)S~f_{6C zvH*iUClOpuOzyu&i@=Rn8u&RK2)Xt?z!rmGKa&!5C8KWrD>ED~6aww8;EE;k9h;lV&nk`tIiSokzg`Sp5>E|oEz`G_}j8n(#6yC+gdUtXJ){4I=EU#g!SBT4dM|b37aSKD| zm#Y+?M8?_u^;N$dC;Tk&@<}EH3g~<=CzAWOl;ZS^%S()bEMKm}iQug-V3~P5hq`N( zzUhD#s2nv+h&TIk8ueQnp=v84F{n=gpuCVBm9Pk$Z7b{==65o0fb1sREyD)Y(f$Fm z%k-Fwst}V#e1M)_9m>(Zw9WKQ^So!c`kJ`~|G-MWA%=bFqvp=T|HsuohgIT6ecy0y zvN74Vjmb^6YcghM+qRpG$+m6VuAR-v@BUraeIM`hJb!c?wg2es)H>JtuFqQa+wHr# z?t$_V>p)_BasIo`jyYSZUGo&=#gOBgU>rULr;?zC@^FYX;4=*+zsdt(G&Yz~!L`kw zw0?qlKI|e8g_9+-weE!Tg{tG`i=}=-(BRB;g)190{d&;!N%@UiZ4$fi)?4yehm-1z z6;5K=?L$ml$|LSSC6z8n-3~V8lBXbOv@Ii?a(VM7ygN=`;qpxLNv6X(L_r~NkdwX> z4Vlq5&~sQ6uuFO8wOP-(2_2!IPC5MfmRt-O1Cy zWNF|Fd|LA{=wG=kS03HSAVOztCt>iuan1JD`px7g^ZIhHqf{e9LwU`76Ve%ul23IM z&gXen!>MGR@NBewmvkB-L? zhem~RK~bF-sS4zOwVXFT$(awSy5mB3wzqWk<`e(+Sf|_hpVkf3u|m#y>;~IQ8F5Z3 z$xsiabrymYaTbEQf(BkdHB67$+7`fB`5Z{N!*}UAEx>eQ+~UBw70AF&KR=fkqf~c9 z*^%9ugBwY?K+012*8N3_kKzN{ER~4B-VEzdt}8I#EFD#csnuW0j%?7MD(4Ho40PjU zxj>lgfc)JH@pez6eS2LXA@$18rK{^F5S^PS0a{^Qb~_hhAk_w%#h-QCuJG}P`c?G` zXKdh`C1VoqW(Ce%+xE@XF5$z_BgpD$i;=9Obr63Isn$mv5x<13AJn*+Pu1YevE>kp zPaN8`%^h?qG;vdd`$6b?p+#e5J`S@)LnC+o>ju#pK7KQFPv1JU?a0tAz)!TB#s-@p z`y;Ep7a+0xbJUF*a6u`cTJDs7%U#H8l~hyz%ENFhMsJ?r}|L$<1lkM zmm{S3^=d$&%W*81$|x#NlPWPBn^X~>D^5=e+?*AQO9 zv4h`@?Y0j$o|y1@-|HYA{?cEEWp{b|miKuV@sS*v%+w{lNcKBm2ga@!q}h2j%Dka+ zEI>3$*(ykSfx?V+lZ1`Tr`7utQ7>`XsHeasP7WLH$rcaCQGe)^+$hlz%Z90a&nV3E z(89fDk^!#(^kva30M!dNdoDJ9jQ;Nj=GEW$(G)5YYKt2%AgI*}|B%v4L$3|U?;bZY zno=&sc^#kS*B#do_CPuv_Ej^FNp=VVf<8K*<#Au_O_X!2xv)Pj8&`uaZ5g7AG?7Tz z0d+AMQp{1Vx#g1mnNZ`1&w2~_6w2n!#7JpS{%=I@}AlNU{%DQd{-r#A0f+w zrDX}Bol(HL?H$6CoZ7Kv`Fe%BL;L@b$8OxeSxlQ9pD#z&zTVAJdfAwMo|@Lp#NqNv z07VXQiC@NAx*+XZ8QWk(!02+5 zJPkgd*X47)fd>JUi-$h>E4*KP zp|MCgzSB%-pcj{^xgkEf`>(I9h|_J#YopYU%_o?o_SLJBEhx_YS5>Gc5O=u<4?mA3 z5bj@;DDq=sN#sWyrZrY5ue%-!m9xkHB`=deT5ElKbtG=0jCP)}fSWoxk#C)&F-z$nIGU+5{ zi(a%jKcUsJjT-4A&S=_KEWP*`YVm5e$+k`NEV}Xtpeh40u@9MDgCyp%6!g4tzNuFK z%3=|t2};8%-=5K=5-yw`Vsni1P`?Y8cful26t8n!VV-{uMY1)aD&PLx(q@d3pLs>q zZ;u_Q{Zr7Qe;^kt`{L-wR|D##&RNrQsMM7b{PQ-}3mh$*(X7r=z3h;vP5PSk@SimP+@x%2^8#bu>QWc{j zv(_;zdTXI<3`dC&Y_X-C@m|S(Erlf|``S>u_@%_BtJQ|CG$68vU0jgVraDQRF4hD~ zqizTYlWs-`y{jeT8{&eO?jX_R;S=bUG(j!Ql?@4)3IN}Fe0Ss%j_SE@?~K5nIDxZ5 zkc0=OF;sG#=zu5XS~o*~Al3eFDv9AjZg#wf8u%jp&rb&sU>&M)L1hN$qsh@?D029$ z@HG1Mi9a!m2hX%J>-_YS|J&BK*iF{t`@KB@Lxo4{M+XB_`rkNjmpv*V+I=<~u!+4M zly-jpbV#F9(e2+HXHntnco2 z$9z|FyS;O7P1E~7OU2_rKhlA7!#$aAyE@rJ*dL(_-j2fEXDksmQ+9S_0rLLy@F!;Q z;3b!58q%J5TRun|D}` zNe4f!Ce_unwFF&2_VyrR;Ip zn;D`%tiIFq-Kry9O|W9LN(N4Fvmp{yhuaBsA<)*fjx>BDaKw*c&7~LtI|yFP0;Y5} z?IplJwp#|RAPV@R+D6fd7LlqD%-$!0T+VnF-cb(I_`#A@J889$sFMYh*71MvpW%?m zRirMS8eFYRwW?pAXhB7g&Y3JsnJQ#jfO7S6K=e#PH!d{W`R#$|YL<1H4guj(>CRk^ zk#JUwp#uZ{t1GFDuI{PR7*N`9-m#scqbBtmP_DM3&|1#y5G;dOa2^l_!5=bjV*jJJ5VO zavI`pAG64POL0qO*cWeaB6G*&r~UX2fy-=2-Ch)iJ6FxzF=b!dfDfOJH=#|~$W$M( zf^$AmR_NrD;m*84bF#UNu@-7>W%kb z5dq?9QT^h?v{boUZ$xl?jq;%J=DhrhXmbk8HZ@vf{^yx~*@|9`CGvG}T@xy0;|{XlQ^gsR-1&uK*tvQ|6~+;x zK6hFSB3@kr;%;mWHJ%8a;ZAaZFL60Z4@e2Q(%04#JWL6~)^#Iv^1y|O^8*j>8>^ky ztmjCs&bKbvTooHh>F!hzURfpmol(iKS^Ti`Y@Kn=P65JqP>6T(JYPeZ9h|qqY@MHq zPv}uV=OTTTh&jNq;D;`iu^a6%=l*9fmn4J6Un6=oB{S&M3OpHpEn9{P+B(4mU}%-g z5ItM(_XmCp-u+V*Gv56iHH$Vq>1?1ZpO04TH*ALg!+Q<9##h=NAO`)DMx#q?A9&Z! zvKH;^dBdP54{D8&&RSv>bic`kDaZvPEQ_RYXfW;F_i{K~b zT^Lw{caeyXf#naHtcFs)C1Vf2Oezh@VMp>Y8JmnFJWQ|sy58#MJ?jR7dUNzR2nOP- zDRFX{AYl8IT;mgKD*n9%IzOhi?J}~IW&E)<_mtz0s)K*$x^$<+G( zeIllau*wXNp(QBd_#Y`WH&e|7hmt}*@6;ZZ0%$45T>x2@Koc5ni$jWngrs!NDPR}j z=i?;Lc*Zt*QumpBG6s2@IO}(pWbz;5G@1*i0gmD~>MifuT-V7p$HBK@vod#e`wxH5 z=>Ns6%;>kR9;plc4*E%(PW%w ztZrONIu`RC-pT3Xdp0j&6StW;5NG=AjOg(F{|J@487uD>AJb$61=$nx7+v8iA* zaS+W1UtHObT`;>ErjOHzj~CSI_o~nl_Y=r!a~3C`L*VybruWql1|hxwtgREFIQB*q!$ zx;vy;u71U*; zCoQmRKlN;DRxf{M46onl=9%BRv>6vnU3qQ^xWCDOUoJahLcFlu{{UFp{9~)DFV3q1 z?1Cm~naOUCKG!QF_qLCFzFn9qoF4ha~9abp*b;}R}#c`XXQ zOz2lKa?+&B1+C`>ld|5j1(7To&^b z1u{vvO}#*TC=Vihqt>3ueQP|0Rjb1F2ywT}a^H1ENAghiA$LO3M_FAHth54IMjP(0C?7wZxFho}EP{Ub7MffY-bHcBWSG9oJ}W@Qi)Ddn9x8 zl~QNZjl!56wXZ>^a1Qt1RWKU5GlgC?LR;03%Vm*))`%3&T&M3HMY8Pq$0y>E&(>7p zQq-(j)3Xf&vqUTc)zR0z?b5lDmQ*?`R-722caFwCWC0<4lUeEM8oB}Lr?y8@IMmlK z>|WV+ZFq$lNxShEHySzM?AE}K^`6L=S`{90x-^<$e+gLaSAgUBK#9;`UH4MF^V7ar_fmF$$x%Rg1O zAS0!Nc-wi2_Cv$%D~&m-urW&Nynq^*@^;2W@=#u&9awlg`n5Wu`*>$sl*=M+^rNVX zJ-1)(&Lf}>1-vdc_UZW~i*HE_?GDSR61V#8WzuC=5DxVEcB9l58Y^~sEsiQ}PFv@j z=L*kg9*6xpl?KG%DUZhg!Lc6DABc}kQ77cI{;fT0f(q9LnF1p^vlxkay+oo^C(4rb z%DTH#dnZFj@^kAoV>-j9+b=~pq^mQ? zZ>|l$PYX@AB)2%=I3NiI+_QEAxs8XZnZ6U>MwoT=Gh9%GXPN%mXWx}^oLQkMoUsNueN`GuHXJ}jV$q~j zI52$?aUJ4ov_a}J;2M@KO6Uqx`8jx{I{v%J6`tj%=f>SWolz=%o>3~!HMIHMx~zN$ z{C!poq@K#lN=`|5&n)cez<_HCL*(?9=ggDKOJ(^+f8%#hlvBv@k1UNRLel}JJubGk zfUpUYT!+b}@wvC>e!Ajg>3C(XCH;AoTRXYZof^ORM!N1fT8H_f$lkYHVh=o4%49Cc3Wt>e?urI8aw+j4;C&1_Ig??$J)WiABcqj z3%4>QeprcZ9UI1jF+8W>&3&!ka)PXFc+UoCx6v}JtG5$(15h(OSsOWX9|!*}z)1Zg z4^XnBl!rWncWW~cQMhwsBsS=jX2=iZ*0MZU-sV2Jb0=4F zFfR;uggRln{-ZQ|2AccQG7zOq>2F>7`P7Bb23^=8BT(RPK+w@|h2_z& z<4XaRAX!dXXRIKg4zT3@bp{xSdYnZ+ zWZc%rrlNT;Au*V(!z+_VQ4*n(uS(*i4eH7{twiU7$Vg6NJPVN2)RYTo)*csQ9N*u$ zE97ZE*OIp-+ca;Ib4m`8%kqCkrgyEi+9Q}$#1k<&!BbGLyujbr+o%QEULI}>t-l4o zQt%WIPWh6%;ifaH(w=R5p>=qqCT+`kR$2VEO^xc^@_Ew}{wj#sz%3FYp zSQZLPjIj&dX=LWNDv&oK(qiJ|EPOm=Ny$=R^g{(!$G2b)b7;Jqw4+J?Z#cxbty8rM zRl97)FI7S~pE$&H$V0^d1a zf9mf0&2A9Hjn{X4S^Oz*S)Z~c&*!W#!xK`-RDf792afkGpKwF^WO2oNA$Q1pZwDR1 zFx$g%_!CJ?7H9GyuYBDHZ?*wn-Wk_$L1(D8D2XXIaO?KcH;tJ%DV;OEf!D$uCGP-r3)-!5ufZ z!es=>;;%ent-f|gh&#KL4BB_fUV7=|*^A-!Kqx&`mMyg7jmO8O$A;~9p4UI(?~DQ= zqCzSZ-9@$JwZsj4OAs$$!c-bt=<%5{vg3S7iS_>fpmehPlbsUDo@v7V@$kyjfvN8{ z=Wt@sZbxkta3--H*!>)ZIiyIbUut@4akCq|Om&UgaJ)`oYe7T!1K)y0!D34<{jk@p zXWRbev7h(XI##g6_q>_*@$``Cf?suqHM`N|l2+VuUXTAZ z-5$Uzta8}hoAo@|!84=S#KT;JpMF1jkYK+po;+>+-TxkZD#DHNZnA)G=o(~^zTxX zpe}HF=WA)J%B^q(f{en#)OXPgODMDAhM#xOl(6mdV;(C89LU*H1LWKnQIfDV} z$P`WqFMtV6f&ct=7He|Eu#)+*hh{f3Bs$|qtQGU~Z`uWe9inowfH?!v0+dUjqqU&> zi~pqbEvTlMJX_#dI_elQD}Pli{$^900kml0$JJtxXRE$8%H%=b`7G1_I}1=k@xNJ2 z|DRceez?B~V119j)d|(xKLL)Pmu&U(CXT3J9lt&)V!n2kB+!V9g+x#;a~JRlrQw4 zqU09@EJpqnE;30DUny-6m8EZE6Z`|eguqy3WuwL~4hO$%6pb!$g)rK+?PBU-ca@K~ zv-1y5&FuRTim5Gs*lmHA)qym)uCBPxNRX4BW{HkJ@h;KOnE`}5MjsF8`n!_vWZD~T za9wJxe$$o6=RC*LP_C?mx~W-aBlBKq4l!1QIOyQjrNIE?PuB9s^)N9ISR#B-@A2=W zsRH?pHO>dz24hNx-8QNC!ml0I2(JBpay_?bKiD*ShYAdl2&*i1$8UzM)PP2gC*GwU zBJzj2qat(Em;j5Xj-C3i`O8)WEaP9215Sp&TH0dKE6s7nC=e!{ylr#Y;Ox^E* zTc0NooaBbeoHo#1{Xp`r#rhWQz+7ZtK z9ZRscMVIo!0>G76vs(HaUi0GT;|rY6H6~591-(S%a{&()t?lBZ=AlA~7~2T2$bCk4 z&TglYj1bsj%?vpAeABA=L&K~5=}9y4W>_fU*rqH;TJ;KEoX=)bPL|&p;UB5h*xs~A zk22iy&W2;^i?stJtUBh58<``cbxg{+X(s>aL7u>H^nc2Y2u{41C>cn+26He5u|SNznYTrMsr-d8-m)Dlk$n}m z*?RPfeU-5pl6)Uonz9x4gIu)%}r3e7`z)f4hk4$ z;#UwiDMly$pWM~GuQf@kMU!L$z}{m+1R{=?L$P$xngDl|2MoUj)J(*VAilmB4;Ex6 z@nG8^)_F#wo~;SQODarOB~I32#a8`?Nw>_SR{5g25h#0+AT=* zRfZ7&lCZ4->(~!9HVN6AsQwiIdCbkI*t9FyI~l3| zw@BEIio&7^wKiYNa-*8~AD4~WnJ71XV=k_1riyLcfw=@zVLw2S`#(3nMS{D+WF5s4 z7Mzf6`9AJ|Yd>D~xVhUm$r z3(BTbI%E<^2qXIdt0~Vv;rpMUcHQTZ<%TdVK;LDy1KxFsv$H}=Tm3?jxk_Nfwy1tq za$^MKU&;IP5?7GFY7yQ)^%>2&UVRbB`+rvig$j#c{~aN)@YPxvFbCA_&I>4ko}A^w zFb`ps_-Ih?F5fWqv&_d9uA;_uE4)wElYg~t*Sg$dm)!lWxMV>%e$kK8DWt& zHZwd7W-OULCcRAatPRyqTC&1mgSJ7L&Pev!8qZ)XfF@$}D!7Nt2z*Io;d`Uv9^v;1 zRmMT&n|R|Hl|U_a4;jKyG3$=L;E3{%lCF-x(aOF(oPbuqZlwmImO!i3)LX@DXMxRGka3-_{k zv_=wtE45j4krF$a7uBsG9+~4S)4<|>QZ!vYb>-{~+LCG;a%$T;H|dPlOyJZVMu~I4 zc2h7RW0RHEl+|cw@S0#50m5f5K@}1@`TMq~6I~DzO!p9I)m&GNs{*ieIr~qDX(=iw zcWh5QNKd|M6q;s*d%r~rc3*9`C7^<`5HT*h$#UK+e~~9(MRYpc+x$@)X%=9*Ls2m4 zZ7i+e9WzKfHJcOZZVaY0`J$iI4!d3|6W(E95FK%Db~1dC7{wnO#)(n3uo%@w?RV42|Z5$b+mgCwX? zusGT$XG;0-2%hXEwqA}>0Ictc=$NuT@UV1LemoOZjB6q2e;Ggk?LFO|ivt)pvkyb5 z^;A?nrFy=H@_h-ije+<;`9yS&d#vE@`CyOueccZyEfM)pzF^QGz0rib=dN9c>nSl)u7$viN-8s4pJ97B^bHO%xv@ zx4i3a35r?IApFQ}N6ci~?3C_!SlYx)1l-QMJ^V&t-(btrrS z@}RwYRdkcBAPompqEghMKmTt@)%)9VRg+BBsHb%5t>-`oo;`lvWxWI@)Kzaf_i??8 zL|T>2VwJSmKJ4H*pw97`si74Q)v6|H1?Vn(iQR@KmP^<6=+i`pE=mY;d(f0qtt$@>2uI?{A-a(bk`v0UZ+bqXwqQM=v`fy+juP zp`gSB;8yORQ-j7kYf9I^KdxtfD+*sc=K$<>;4mi;&B=$kA`)u8W*Ez~2^vGM`o((p zoovUomDkocUA}UGhxwUs_(Qr+$L?eLM_SuW^$jS=aRu9IPzOue*A-#^pAG24n8{cj ze7^Jt3Nvm(7O&LHAw1(1uY4}Oz|pgtp6D)Jo<*wW5@KpLbR*-xVt3V6|GF5P|36j|XImxgeqC9(A?&{Vd08d#xkZ-4(6gZBplfG<+Rk;lx{}AUMD`B0 z!1$y`8N3oPrmf#uCmFhmG2&{)OSetMf6@dUHpJQ4thL6yngG*QBrBF@z4U1Gl-Y3R zS)jhc{yXrnMsC$F%x(KhkU75M4m<*T{m@pua&sZ{W440B;kwLp@?uy}#~b5Us}w~n zGD__nj<{%9xd_OZtvPF(Y0bo~i|1WgLmT`G zcUjpI^Yf-%TE*wy60UXBNTkbFY7Bf2FnwKdjtD1oZ7h@`D{edG(lpOIXm!(n0zG1J z9pX^pj)@B-9%41`o-Z{|j}lBIeuW(Re}RWQ>(MASSqk>LM+x%6Rk;+{YT($-{&~UR zzA4XLR_cJIGyv5f|El`cIy5e8#OOL+vw!j=b<6#pp>1)x&p&N<`B1eg*7py<^{!x978@OTZmpk2R+h*fy426`tNWZj^UmySooO zx`fOxdBgGW8Q=in2sV%^Ir7NU6Cj0U&f6ar+shgK5B_MwSpbaIk(}Nc>PnN?x?Z1? zMw%5FA+7?5WQu**gV912LlpFXIRpKlqe2J7qkIQ(6o%VW zLVxzt&K=iexCqui9(7kG5skH;bq(J6Ua{?bL6OZr!TwQ=d8NE2J=ik(^p)_#43`g} z=ht{7_KxOh&BVXv-x)`)?nECncSY-c60eJb!E7p7sgL5+(m)_^guW0f( z)j)@At*oUXLyRn_zTlS}oZuH!cmP@!IMmEUBOFr?FK-{v%#c^|ml8Pye4gYPHe^$$ zJF`-hhT_a`-?4pY`z${hC2|EO#KrIyMYu&-JovoSb3_PE75){&>dFu7qMsc6PEhmY zL!~0d?i2N(sB9jxGH10gSwx2#*#h)(&4c^djY~vUad;9XzhV|QhK^y-R)|<#78Pp& zjgz_378fy)GII8k6Gc(ir~TDw;km|68{}1NIK+=-867iOO+ns55czAUoVam1DF#|d znShGia?o=A`MNz@5h!6k4vCntdY_=Q7EQVUnUvM;yw5)FeFn{B)#fF@GD6F|5ZVw* zib4P8`g1gazCuZVDSl1V#VJ%yk;Bx}d_f9bvg`oq#EZW6Nspz+=AqxEda;-h>{_@GEBioI7XR?;I491<;L#~Em_Mc7us1U8EeQ^2J~CLmR(WP>KkZz690 z1bO=P7sb_oYO4KEw)?v(>?G`RjF%GCLZ>wT10IYLNKFki*Z>20`+3|JV2|REr53BI zBVGc*-BamuO)glEE^_Z6{4!u$&J!du!9BF2OQjEr%%Y6i@@dE|^Z!CSYuhbP2JPqr zq<0Qzi66G7Ot~LLa;Zr%6dwG86+Rc%DJLLfa-deR(K>$8E+^F6g}YpumWD$_x;Tv~ z3C@9?WpK`;oxR!4@`u2J={n%hCyB9Sw={uyaWG#hkYUFd3a(ZXdq0wio zEH)c~9-!Y-+AKbEfv1@+wYN3$%_9_RDsMmL{>@64*kUvb?Z2o5Gm;fT=z`unxdN2m zXtb!Ho{ZXp!=lo-fnED&Y8cHQ!V8%63r_zAq#HpB`q2&S0a&r9&^QvJ^ILpKq6ogx zFK*g{8d+4gdmP%TUPE#417=X1=_g@PWVf6oNw9*v1wQ>J%31xN;Z@QI8ME`i+rHLY z9G?Dm_ZcI0h5OQtnrL{mXE}*DhyeP>Cc^n20mSpa1kekx?_n%E{zdyCg&TjvlJ_f1 zVk~mOPeJe#t7yTIU87c`(!Bec|AwviP7UDz5;0l&yG-tyw9>S7226b!_pSR+AkMkG zPPH2`n+iG&A*y4Nqba$oBn?n;uTfN=JG~xa`Y}2YWWjk#$fl7p=kJh61@3uPHphxU zbkZ>$9DWCmBS?=n(qk%$b)d`^!j*zTh#rB>eX5#y+1-a(D>khx^=nrfmi%O8aa8X%rf#xHVI46h3p5 zr|b)Mp^9Vvbw@kAHE73}!!{nbM4hP!W%oKVB`7stes|jdUR&~wbssG8f5rU$4CENc zC-i@cEX&0sumO*sZ^Z>_!Gk(X8my5Lk9Iv%p8g-0=R>ah;(?+#zIt|cDiLnOgfV92|^^zqI|O&hS_-QXIeOxkY-4hK^juC8e#aN9oOlT@9lH_42lgsyCfS^ zjBx!(c~#i+Va=(raE$?ZNR8CvlO=#6c&_#VH5ci?<`6~n!P30TqohfiT+=39wc-8R zwU}UkE?^QxOFD#RNhnt>FQ3T9nn;8Wq3A|#0NXh}4f~9F)7czL&GJo27}t#qsb$5$ z|8o!{q|5UtMaCN9Zj@MJl$MT<*Ek)FTdx9&OHohL*)4*^e}KJGC{{Y(4vK?Lgpz;R z!@s0cn!Nk%8+qtxY zcQ5^T{kJ^N+Q*Fwy7r$k?~5CbP8c_DOOX9f;$v$jPIxiKUMDOsa39uq8_TIOB@|h1 zdzj7l@!aYz6u(ssWbihS4P;Qy0|6Gy6xPnc06&A#%IlCx@3-lGhB1cJXP?%Zc%@%9 z9&SCf=Wh-V_J-BvQ~xBGgw!}2nH096dXo45sSq57WU3F3e5dS$Bu>6!!!#O2huVrl zu;bZbb%A>5C4c$%(lfp!O6wRZ9<7^5)$>ZB{(d7~avg`0+ieoXV!JC`Ph(bqX{VV} zv~MXLyS5>Q{?1sLa?(tuh|It zG`~eGQi$6lxV)3OXs6{-M|T*Y*z=5Z0>uwe8zl-yhXjth(B< zEUrGE&Yqkd?rMh4;vAK)ceCxWffwN+2&vs4O>|@N47gjga>;j$F9@Q8(R!rYM2URR z2%41ETfonjyIRE0CcUlsfzuYEJCAKE#P(2zTr=fG&s`Ibe4f3k%AmvUzCPUuW5awZ zDxSXzC41(hPA{an&#NBCO`3trN`S+%#8<1K0{65$n@5hY&@G66OQtRUwwM1p0#$XUJM2AJ zP1M2-m}N8mv0uPCUb1EE?k9hMMG{`ZN)JMEA`KRX!i2-_Nrqp02|3kpwR^^^tupYn zkY3qzlB8!T{pegD{rgx9#?i=g-QZ7!dOzUt$jkJy@9f4p#Xq1HH*g;%+Be#Twjri+ zY_vxwF;#Ipy_>UkuMp&JA?@)e#u+QPCE3>uOtbWg?st^)ynaYSE+$QHb$@Oy$MHvX ze~(ifCH91E^;5@yZPSJTjtojQ6pA3?tBVWeO^1iHXe;);&+;0SG5Mu>&1X%4!=g?y$BzEodR z*{|P*2C7Xb!$y3tdI8A2TZqLZo8NYQf~<&MeEjb?#^yH(c8MpJJ{^2YLAAhu)Q!Sg zdwP^2QW{eH)iKoirM=5%h2GzUF(^CZ9|N!Fj9n?%@wm+hF_u0t)cl^S1`f0oX0u`2Wv0ox%c6JQ|?9OzZ(!2P%f(&m`& zso(`hRoy(Cm7+-mM0UQK2^xgeVmh<+;f-hZ3 zQ{Vn1L9-t?V~=Q+KwSm)T!R zA9+46E^R$!qx!bb9aH9qCE1Fpu3Ot7R@m6i4mn5hP&NoF)a?iGS{-ddPUDYb?rc%+ zL=LIS#UELYJ{qiSm4te^G*2l;mlxk8xS{&ibICcb`F}X=6n7Lzr-w9IVwNkaM_d*c zKe|wYeuW6=R8=ma%W74K#TZrHip6S%J+|nO(_9Zi;{J9E8`oTXUrPJ9Vsd|;01874 zOBBY{FlW%Z+E3_ap;N)@!_s?@oew)RLUe*z9l)yZ{=imJ1BKkSq5z&&o7O%aZB>6=x ze2d}RyJ61v`7k@|9Ppda%E-DOlBnXlaH*id2s=U%ZuX@!KAkO4RvM zH^ce&>xz#n*AI^^#36cimB-et@UM5*7GVJfcW00Hx^_~8oW?KlAm4)I%d@h&z>tS` zStn_Tt`JpBU^v8s@4WLi98y%(-v*9Y-njGfC$@XI21`N;_MJY4NMpl@muX3rJg|)G z8EMc$6}27fglJ-%j0M7NdUW8Ir?-}v)I8~p5q6;p~h=%lS=L$gz<*oj+h)=rS znp*AT!^?3Dk3BeTQFd}!!k`H?v8_JfDVU2zA+;wN>f*gav`dRl>Zs z?;qUH)yeNeC2>(nZqqiMj0!A+-g_n3)bVoxoehH-sZeuz6qf*Jn$@!vCcmjfLjSv4&Yrc;R1LvVxI%_yFm(j1 z$%SoIqg&{puU}}`%w6Qr+^z$p_k*!$yOsb>(#9>fcJ2Ova-){G#XoLr%+FL~k;d2- z5|~s=#8&z4_({^NZ0&s#baP0?hG<)7?B{v9RbX>f$lO2NcCxhpJq`S&J-|Mi#KY=w zj_pnZ`nVHy(hBp(wl+0U8g*oFfXqWFC&izSPf0h{xr993aC6R5QP1yL$#1T0?%yxE zp+=UTn=*l}>dm@Y3_U1E9P`w&qthW7Lsqi3Y8ym}@wUHa#j9#W+A~EP@{s;`rw&UP zP?(P81#(%cu+t#J$YWMSIoA5X@x&mvY!PITY=&?6NSW`g;c0fI4q;Q}3bVFsWo3}) zMQz}rhl9STHet-9-!`j5&oSF7rphcG6_XQZ+^5k!Ie$4xleL8CVl?#xZra*T1v=Yk z94hccX$yvsDdxqy%A;=~yUJspBWz87$~hyTwtu{^M|BG~+?+?4c+livOvEM60Q;GO zS3j!_Oq+d5pSa7PJ%BPdPYwrMzl?p6;edSIyn5S6qv^?RkSd2jLs|PBvlIi2_OYo0C1Z53I#r*VQjPENscVFVIJ{J8-7a z|E>zXsnP3z{7kDaGmm>u<~{Gvj`vU=u_VIE%R)&4^pYAeD`6C)y6Hl5NJ=8xicQnT zjXKm(1Et~R*4gL>O;Ij^QEKel+wWHW?iLNy?P%e*pOZNfI~UsSuG7F@sS>F+gI{8} zCa{z==CEP3LyqJTZPmRzWLyoTcA(EpYP^Sl zKQ5J2lf@7VPPij8N=0T z;_Hh2>!st4P>d1`0PVeIYrnLw0kKr(ZDQ5QT!zbyp*RoH>X@uLI~1h!IGspi zq0WfH$>;d_dj%7%TE-lSeW761p9{`6^gAxB1A&0LK`-YJy6pii;arnBD|?&(Oc9)b z{+RY}%hzO`n!J^hNPeeG{auaJ^Rs7U0;x}n==XCHrHbV3;YanvD`CLnVw=)!?04*^ zECyh1xtqC!_%u{gSkYDAW>usy2fUZ(=($G;>jibBHW8I}f@+9hNBS>eQsx{fkdsO+ z;Gv-`yl1T>0biSYW3GgysMM2tqvyaHb-+@u?a=16Su?)t?4d;z(xzL*)08^s)8uop zFob3ygP8?D0e<@S_|gQ$X^!;8@zW_Q#Q)Ji*}V`7L7zbqzb6RJHHb!>rIsyr6~;+` zrKO%gZ3?4+$jnsurAq^ILWE(nU53<*6yC3mCdEL@HXWu5-*avZvjHQ1C#ip;v-IuB zR8ZoZ>thBPbhwe7kSdX+50sQ|?w>|B_tnXxhuYIlxHOfYKUnM&%5a(r?HP~SWwS)# z2KB0LDxz?v7bF^HbJl^k-u0cH<>^`CzfBLSUgO109+``+5OrikP0|Q5-S!+=fjo4H z=D!M~cf$LbmF2(dXW{jbEaUhtmCW@qw?cmF0r{lw!#?k?O-CUfITTz;r&Gs07RPe- zZ5Usj8=B0!1^Po3?lsu)TfM7inCO)OBl0t6ai)!Vmlq@w=&gO0srVhVGt@r^s_m7U zrZ8Vb8w4rl);CGv?cxKMg%W>nk0DOb-D?vxa7^&l$s6OaGgL76%>?6=6>-(t|A}8) zLW;!v|IziAL2-3m)HWJHf(Lg9!9BQ3f(IwK2KUC@f+Pgj;O_3wxI4jV+}#_uM$XRt zyyvZRs=n`McXhF=>Am)vbBt@u^&z>f>9a@D)zI;rC;l$mNK?RHT5?6NdAZCgj|O^; z;5PRQjn8&C8YhuH9a-RpN7+1~C&C`B)in!>6@^DJ{P_PeEp>w}^5aX%523(o*- zSsaa}&i3*s&7||g2xp2_X}$=1bB^MKpl2Jfc9|t6(L8@l*I?bHxYpt%pG>u4r>(u#>6I{Qs?7%-ep5F3^83<*@8TkI_3l?f_M6R%#yXCSo z;J?jPva>jq)!S^s=b(?p)X?-{vH8^pLF^uFrow0Vn0>Qn^+``Q7{pCwvB~<8zWYcZ1QR35Z152ZGSv}N9 zb<3T#VM@VF(~B-MUrYOsJ57n88(ZTrN3*nx`K!kapLI7=daLa%!?ut(Rg9O#F%`7O zqXoH>v&`#r=u%fAt`^?Q`{&NTXD_lIZU(1`!BT9EAoJG&iX-yZr}RpfJt21k<0n{+ zR^XTg%)PE)NOtNCy7}KKsWba8#c^kw(h}?l>2UV!p_xqjWc$9KNv-DHPcrmPLMWX} zFqxY%?i-hsvjj7lMwi+t!lphJ+#cDY%dGrrQidotw_Q_m0Of~|wEi^(X4q7-*{_-4 zE4@eT9q>_LHGBmt_P z>q>RJuL9x!ZS$u1t_yudS(vsFUfN9xWMl&gC zz&eARJ1XvmGr0P&@zggoIdrf&7q`AsUoY@ZggL-wR(y)IPrPY?#Z)eo6J-brcS2E| z`{}l&8&>4raTXH>RE1UTF|}F=CLX$#uJ?BR=O~_;yruf0DUK)3W(t-=u4YvD1*T=?8{Aynj5Ydu-7E<0pcgywpvCZHn}0 zC7@Fqd*}DO_5_R%$1q~LIa_*pAci^K!MQ&Ifg!-6l`ddb+^sj;~Rj&Vs-Bh2FfMf@1!NE|GebZ3evHIKmt| zh0301o^-&;;5j--x2{!o2*!47dDq1IAo$@$mBGp|&|q*AoF-2zn^?s7} zcdAP7&%5GS#872@ts2=^iN(iQN@bNSuXpM^5?|p&G{a@>%u-*K*Z;Ls`}>Je{6>?B zfE1AjCGfVzu5yxka9AZV%a~{85NqZOg5H}?T_w$MCLNrISU-a8;hu5t$<2F}ZQ}#d$G)M8X_T%tn-s;EC4_AK&9n0C+ zxZqg6Mfe!ZY6SUULrckS>f5S_=I1#27Y#FStD#HFbQzV)MuA?}U$Z~CdJ%t8OFYAn zi+Z@zKp|W=V9sm9l2IJ^PK||CrtwjaER(8hVd(zjcIe3jjqDiN#y#(26RID|9`kSI zt~EuhF#!s~=O%*Vs5?Xg%jO8AIs8UBu1A03S>F{*m4?o?2B`YmTTdEYf#qAhCZ>yL zacb^sx##UhjnoTN`$|0a&Ngjn@>^|wnnuI`u2a_21OrB=1v3x7`4!52#rPbd8rrQ1 zMU(wfKQ=TUmvH0)_lJ+h^hTHmwM-6+`f1 z$lBdyA-tl*Qq)_&oU7v!KYS0I7}!x=Fx9$_d(h`_6*I~M#9anewO;uF~Jloz}MXV?EYkQ@jS3&b?MiAy`Ih|=ig zjQW^%z!_IP`S`o9ws=}>kQOT^FT`K8Soe9koq!oH#~^zT%_8^^pcsR0L6r(H+X{OurA zZtYItXgcS;_3ekxkfJuw-QY?cR!Eq|ygA0zpHv@tXwcq;ZQw6H!*Vag~+s zo{YeWRoZO*>4LW+3cu$=wb2?!VP-N#rQo6bq_`=#lbX*5T~C#$ZZBAGTQc)Eiu&?I ze}}o*kz<>1Yg@bQR6Ir(x;fuC<_`MAHb$9PObq5g^MXT1^-00z6O}BKvQGd8gt~q^ z6OD&^R^?kz7Gk_e(ifU0A$qg+$fMT@<3RUj<>Lmn(oXX}rX8lpqftKUb*GvDCd&4v zoG{hb1Eg4&K=*p+v&VR=YZy1+5JO=1E1I!zNRJOxz#K#De&IZH zqA#T`^+hNF5xD@kXr$zgIMSR0pIle~%fTW^Y_#o$r38DZvn93$=jnam*?UG|?MBd>8u!vD;~lGO6qr(XV1+K;9y}^Y$KY zCA-dOjH+Z-_|QdocjCNptiK8QPqlDMAhVdX03?KF#Vm(0Y{#C>o9G}jlmU9HZ}2HT zd9$r?9wBDuHJ=#SjhOjq(+aNrn8g;lECF50f#gK@9G6bi0#*eavsnGx1c|qZT+pRn=8qn#b+I{H{nIq z0VVYouBBWCa^-FQ?-0J*b_dGxY~Jv%nb4p^)jJg?9^?J04x zZet?*!O`J#PNflv7iu*;@vg}FJDnMyxLXKYQ*H{vfFq45N%NH zst=6rR=0-(lhA;GRhcO=Qls?ZS;rwl$&U0AloBfR_+b>KsF zB!+dzyj-xa&)5k~D85wqzOI0L&%{zg#}Z42Lg`VGR+suqoJ~94{p)t1<_g7g-=7~3 z1-in2NR{OVdGX8Pk%iPJ(*rtk>RX{qI~k-tGDPOPySba!VY3SMM#bPWr8+zd3l{?6 zu-P|k5|i5HgE2Yv-%JmtB|BxtEY>Um?WpA^6lVnweo1JibSLk=PJ2GXv~O@2Um-=Y z*yUs$8RDE-q|eM7g+Ar7Qa~v^$B|@3(FUd6@s;%q^;b$cUnV(#>{8rsM ziTnpJ^;oNfs9rC3EB>nv*2kK7pq$(19Xm;3Wc$s&dKeY$gK4@!_3&jPwth-G2HMhtE z3k_99(`aR0*F#uKq2anIE8z-7x|gVlf(Su~q&QcGpZH==n>s+GfU zNKkHUQX)VgseH_+va;|A8RrA!8Z}p26$%q;GG`=H>@{s2``&hW_9+n(4l<7|LQk`8 zR&~3L0;Eq0B-s*T9iWvQ83Ot6Z5<@(6bb*6dC5XgqXG_v9shNbi5az8X;L9~G26ng z(yoHpyU9ZW3nO0v7*0J6qV%tyq)) zsh~a3#-u)FOgzHMXX&iScLwI9RQ^PI`N%W;gaZ11(Z#Jh@#sFx2iQ~2-?SyiKrf<{ zyPDu_K1)yxs09}sV!1=O%iN+$T?ilR41CF0bzW0lji|q(IH|$)E5*2u7|KnW(6PB=f&ueO(le(W-LCoh>>cq@4eG&FmcgBl|b(Lo@TT-x8t*-KoAd+9+G%|j(Q zRL!KV86RfhSH|=evR+M|jE@jrx1}jxAx8zDum1A$bS`Dq)ZSN@CCJiY&Wi#ulVUr+ z?JD?EbSLurIK;7L+|==Fo)8s<&Xbs>NvW~wpzCOx2d&}nV`<`rLq=6f9nzx!o2)W_ zoBB864gAaR7JO38wio8rMacU5)}F5h)rs@!qEAY@Y2QytH9(OwrK^h1JX)65m^C^O z4Q5lZdc1(cGq6({^Z*gfU1y#Js25i&w0NOZs2k;ad)T_!M5~qRd)V~WolBzzNZk?Z zE4LbwtBf?E13lfwFSNnnMdW;VyZWHltw3dZ2H5}pJnzdkd}_2#=UUc}w@Ko>a%PUV zl5e&-gQ*;Kk{CXRhb~vp|NHwx@+k~5jsn12WhhPQw(+8`W0x``*bkTJC_56k@b)Ay zJ!pBN0(o}KVGsh2pNEN;QB0x7}wOC?g1&s6y_T(562Y^E7W_b(J4`agkBbf4(G=3Ls@th^9~$LrGH~~j{?hof2cSCM zpHgB148f}nLt)vivh@fq{V%+xRVHblGy!Fnl4PEQ^!=$#mUu+e`_pkz!fUkn81q`~ zry%zi-TRJ6`}MdfiAL@IR~uFoK0($8NgqhwwI{utM)ms%YkevZzZVZ#+;S05Ft^5# zp#$5i0bh66hibbuj!lg3poB{KbiD+wnuX5IRUY_ubhmpc;SUurd*DS}nB7n~^D4850Sh>4WOOs}$*~PL zYNscla8o_}(mTh-C*#Y8v)0Z{bgvVN2=#B}^JOV@K#cWprIyJFIJffE-Q_bZEHgIA z5SXV2e)IA4lh~qj%<-oM>aBJ?_8S|MkshXOLpX#XZW-1Q~xDJR4aH0geUhN)N8V8UbE-nJVFyz-5FDk0FT9i?WmLbYm0y3(Gcoa| z{#VdV|C*>=?YV_-X+G;e@I!W?bf5*+M)0m3P2AwTycyJ$-#65OS1K|r;bI(#HI|b` zT5aDo1@36Cdisl1PND4fn9$%{jWrMrE&g4sHO_ z@;*k5Hw~GDI?ffsCYxGMEpjaEEusN!sL#(gBJ1(|q(4(Pu!D$QaC~~qNj!Xl%SVhB zY(5KgXYm}Js66^`5m)-8U}mL`6&2CZZ>xJTpcG z^3rY}4xMyc`Fv_ETEd}$;G-u`2Z~k3ApW9TZZ)IZ&}NA`>pDIv7qr7Qc{jB6T?T!u zWfiAYr1#gW7daM%rg^I$KAM>hI%2I~%(T7!O?rZ6F;NO}7OhnOk);t#?B8yO9nnT~ z-m64kR=`O6%BNSigxiZR8_u(ySPn|s)izTY86KC{eiRJ2>6!L&8(ELqUlE z!{6M@xs`x_hLHK6{`s)2#dgu4L>}7=hr-HWrIHSY-?Pa86jSg|lm0NOKey`PNFr8G znIl4hf#kS-L^r5oWU5)Oyb%1zW*VWNBYZRz{~Grv%a2zH9ILlPxZ}f`^~e}vb&(!P ze>NRS8)#^3wk`@3uw}Wiju%sAV|dihOUq6&fnz=S;_)ljM>TyNm?~fe`iqyOC}U%h ze(Nvqx^?;5GwG}|5zoW*N!G|>zk>`FC2qCZ+TBKGJZL{eLE}CtU}uDgG>JPjuhVk1 zyPXx}Xs#?|bTyO24UwB;Fe?4nzTGp7fRWA4J1z93;l_-fzWqM{N#;xGsG}DS9%yjx zeY|F+YqDjPKJ$bx4t&+zJ%*TZHVE>gbk15^0kidK!EL+Q6 zMWKst<4qAZ_?cXta#Mtet?+JFimJ_P4eCpM$esaFR!*xGvu5)^XkleV2sBsf$$4+z z>j56l*G?rHOJa)!a2s|VZ3M;dd1Gff%ntgXktav7I89RisSljd{$4lRJ+QF2TmwaM zTJUm5T6UBE$w-a%6j>TmOU)OQG4a%>a;r2t%$EExroZ=tCH(-VV2CnD|NAqYk9B(B zC5vNK23v$VQdB7KXl%eprZUX;TY08?NX40R$Kw~%J3yKxF#wAlHj7FKgr7b)?cTZX zAls{xMz(0F06572EMaE8cA7QJBPE}VFQXM}fLbqPE3229%&sEAp(CK3C$MDeg`{?0F>q67=u+={i!8zkyENVcS|l*smx`uc-S%bG3sHR_P52N;H^ z$QmUQY3!BLdenfp9zx(eEr1AsBsMy{@}wNQ<)xji*aRTbXtjKSmNtSNLk~lLyY(@W z0k9anBBHmzlJX>mCG1OmC$It6cZ*1y!gGs2>C~ZR;qNxlpCJ-<%%k8xq)a ziNK>Jcq4TFZ5(@W|NF|n9yq{)B^D|gwtcG_GN+(Rs})Ogi~Vu(foYVpeuP{Ua1k1}u?H>LyMY915tjBS0vb2f%gZ!+J3b6QjYw zRL(kga>}U;z{ku}l=6kO@WyJG6u#)&{_M$%ar^S;p)A0}RRH+NF=NfrLNL%2v^?D_ zVXvBl*Bryj7TZ}y4g6Oe|9FibCn$cXCZ1n(UN`{>yCm>V$4;1mtHUn5YkH4dH$pFd z?_441T~mat;EgE(IE3r}aERqB#&n63-Mt_ry6mt2;Gt$xrffjQnLIg0g-3qB@|>0} zvqqRAE}Z${pSp0-P221T8aiwQhXHtk^IMD*mSzaM_P*<%f7g=)Yli`qaLC-r2G$;> z7h?nP?TG)wJ^l}Uap~Ak#dx6=^Yf%gN77CFZ<6Z&JDPBme8=28c=2hcx=+8E_4cUc zy%DU%v#t9k`{6;Yg&F=^`fgQ}oN z8&$A+>H{+eCswHX&_5RTu=@o8>fUd{~oW2kH|e+P>)ETn=W{d?iO( z3Hv`*yG#5Whz1;xcG4?OtFx8SYM|`BTXnOc@olq%Y+>QzwWkB7{M)w)ENlMQe}kZ% zM}-4!Ht6-60(1!sXV3qS-u$4-1b_ov;6=(izr~5ZjfuHb`1M2ZpEo~9PdE&g;aKeg zhZqU5tuCa7fZ&W;MeNL`Zp~;ij(BzfV;)a{_Zg9GRk2+8gK@7r&}teBzOObFq$_41 z@ca1e*v3xrD9#6KJ@Uv12mNM22YmT6yZ?N7#nH*2GCpn0_QBZdWZ;xpIvICFM%vJ8 zad-29e*nPQGfAe*+Ig}&_hQJoQku^3pc?kJr;^%+m4WYy`bY-+yEI0l`LxeDEt&jz zqW!;5JF$zT+-#KpFz5@`FaL2jYfwW%^*N-ZJV;gWxo&wr9u*IH6!aut_zC_`@n;J? z4FeSa!+4rJySi>+#m#C`eC!$}`XQg-FZsJC_pgQBh;ZC4y?_QV^!6zuL_>#^bt-55 z=Z-E6BM1NKg8J^>p{dw?(mTEM5PZTQ(mR*%|8?ZCh9Kz7YaN_ zPL!^QqxyO1l!o!hM=BwrrOK;5NUKa5N23pCE&XOktqV5kreU`OoO`riuWyd5^{LY0 z)boIf)dK~Q{`cg9$fQu_UV6X%ORqa#2r*Vall-(?fROSqu>1|7O2asPhrSsSx!&e$ zbV@&-0!7v=rfwr>^q;)cLIT3sMj%Ho6i2ZIS0N-l(Za z1;)s@e1}pS!~StO3WI~(pIyZr?wXG@w6_2=y7t}h8$6q~PoNXaxIl#An$llKyvT}X zs^OejHpjJfB|O}|heP5t`C`%6H)zjt#g=RFDGxUYyMp63>H|=++fsI3J+cI;aJ~n{ zKiXomg;wM9g<+Iqv2?skWW!HSzE4UBkP=#?Z$Q<0GAiJn)))Gdqc zqMOAI?6Tw}K*f0<2y9M)u+yoT${|*{QqZiC_v&9>9+=@=k8smO5o1cZ0tMz$R1eOe zMYgus=Ka7_k-F?ULM{?$gDaf@O-J0^5DSl92D%$9ZiiAy-~1Wb6Ly|b5I@Ih64U9L zkWY`%C;Lm>cGyb0Z*a!7DkVUZl3l<{%Kr^jtq9a&7-n)~y@A3(<7pW->7b_DzRbgg zs{INsvlrz-el&<&p;yEgM60Vf{A8$ZYY8)Sv0tx)AyHesjY{5~`}V=fK~2$!bH1#A znfoaA*%djcqEE2^MKLW~si)t%Kx?qnJ5T{~;vt;Vbhp#6ymoRre3*JNuoC%Y<=#YV zbyA4sA}x*A5-`ERpGtCCN?&zE38uTTzdgIO!NWJ~GICTi`AVo(N zaAmb33_O)!&O6qh$<}Ydzb=+*PUL~rJO*B^XDBA@KY^$Sp@vw+!OA>uS9*RBm+c#R z=N$sg-;v?R69ABiIV3~qRhaDg(c7?Z*r~^HXgH${5|Uf{mFnrrb)gx4ESGpzd$#Xh z&j7_3IVmYq4{9w!Ki~2NH{&vu()fBVJrcPx%Enyii;g+Jhv9C`ITLCOxQy5KzY zp6-aS)54sdv#ox486MD}nM_83N1H+G@xPZ9?_#}B5qVfbAt!98Ul0Ai9bUalnO!ak z#fKo>)$SJfSc481wh0Q0rBR)BGi`_exF3U$)Fxo-nzlwPlA~N!k>q5yYad{yf(k;#~%IPRTm7vC=-( zw7C$Htw-_u2RJ9T4AL!c7iqxp;KB!F**zh%`POf7e3^MNs)<-3d3`YYg9&Oj==y|2 z_39_+@g%TCUp@;qTdw7%de(Dad>pP7Y)I<%pj<7PJqbO*|IKG40j6#3n|mc@iZo-T zm_GZ}CoB7>Ia>vgn!r&$s*4T0M8=U6XdqouQb+Ss;7Q6-;HXb7wyJr2Jz^DiWyBy4D5I z%^gU7Sz>DVQ3YX-E$~Z9HU>K30j5lU|N38k)j7`TNadBxWbTtx%WvZ>VqV;<5iQ+9=w9`S^g{$I@{EOOVON$au3paQ%(>8*Ko<=8~dJSe2r;5xk{gVT2fG9Lww zH0~Ow^}sN~X}yj81DGYeKgY~0@g!ufWjq?`Us_mzH!=oW5%G(+g?>{f%FSLf+n>VI z8)xM9BMJh!2SKQg700*>$K@wk_G#uxI0unsjqoDghSnB*A@-(Zqxv1g`XVpNWrAn-3z5%r+j~Nt- zyei;Xd4AP+F8A=ZKHkhP3-5e}yhxG#7-JC^B=l_X=&5J>v-tCKh~qOM)Zy#c3sCQ0 zlC>9ABam%I*5RK%TtYXU=?AlrZx6!hG_ zz;&tD9oHvgp*^}?8R#n_srkV;$d~-u!v8nz)mt5=dxoqiSjfd=@_~#TXl9ly*51xA zQsP$K-%Dh7KAc5Ohq=?nnxJN5OdQ($fpl3Q$yj;m)v^FgR~dzJ8FtxZ=96i?3*i|= zA^W-Mx7*mUn8@6|J<6mvx0+-r`wkILU=+eFDrsIH5gFv^Blyp~mbWnewgzD(>8)cYgPxc4ZQbPUtG_RK@URi9d}o|K4;90i>xnn10@l? zc78sEMcnLaB_e-t=-o5o(my*%AEGiXmldgTl|(e|owrUCI3s!RhV@wKF(`%_uH9CI z$>b3<$=ZLa1#$!P1qf*>g_ZV~^#S&|?Kx2EQNhIH@U3Wx1B^|~iz$s(Ee%}hBbkuv z9;;ffq6VF^kslq)VoYglBI&<|kn&f>Yz?s|5wpp3|8o%!_?MZh_^}@Jg0=tFAsqPLn8IgCOptQ|_@eO@@ctL76c{==e84ulO*Q6t zyWub|7lJ~LDE%GM?(HBIxAp8+=81_zOz#9RypgXb-1q67u<4b)dFwuHXnlbHTxbYc z;OPp*ww4^UY=R`#6A2}d#Y#PW4jBU;#L?Vo%Z@FjsbVHx>Gh=+-ER%7Zm$sc{$4u$ zqf>5dog2k7Hy=przY|YhT*`Cb#s--8?#7># z_$yj{g>T3g_@E|5Phphj4DmA~Y}7xn6LdXajDQyIhgZ!u`mqkprTEyau5;r1t0yg| z%XTiFTU}L7`Or`G^Sd?8m}?13V)Y%{D_afB5l>2gXsTI5Eb;_`d_k7Ug8nf?X^2>m z<{Lo$Q6UYA_^UNZL2;~es{F)ME|TOsJtV8rX^^?(*+_f1N2v` z>zx|k)uBuvuA(B0FOJjW9tu6lrda#j673C^F9grVT(YRJL=oVZEye0TJf_B}*%m+i zUhj^Vma1mRTbg5jZ4T+=RT3otp2-AI0Y|5CSBVT$4}xUH+o(-$hg8Vi+@DVsuKgQB zULUd~oa%#OcMp{)Q*y~KTo?&_8djj(sh+gIMlL|N7#T$cD}}=?u8pG}Sa{CVF+hE7 zg_2rk+~4Ygo8SVn|;iKXs1cl^hgiig!2Tw!r6O~6s{fUacvv+5h=Z4wF|qg zQFbr8Uoy;hbI(?5Y|aDp(Pn&k{d7<5W=Bq@4{aQN<(4}7%_$@bRFvO3NFv?)+BAsv zo7f6PPwD7jhyy3ZEH(IO_~O36L%Lxt1+NV2`II2@N5R2|2BkC_mHmi`Tt>akch}8r z1%;)PnyDfXr>RRF>MM=a-RPMW%_Mte5S>2iW0L))GByZLBF%IrAWL^C2!%!EDK^Wn z+h@`xTyZ@sSS$C)-f0_Hsuj7=!BI+Rlz1=GjXEsMnY7cZaLMHrc9zUscEZ##|IEi1 zYrWuynvx3Rc`2oqdy9qU0#AhuSTG&Q34bp|@sSc3e#Pa-vXV2Y@P+s4(0e^8ED886 zalLqM@xnbNgWTr5SIov!PCv}Ga`#?EM0ldRG%Alz@?7m^L_{(TQ*J%%;|?69Rs*3j zw+{z)=6)Ar_dS(;NO``m2~fG(^hG7DS%%d9Cq@x%^n+&p1xa9%#57u8q2;qAu}U@@ zRT8!(qSgOpIs%)XKbFa+ofV}VM(yxX4jbyg4}EgApU;_}TT&)W(+XYzo$3Ofz-hYx z&#g^@2_cHD>pF?l(Kwp69&*wo&qA2mcv#_+J}>=atxW{ z2K$2?ZndhVC|RCD-Da(r@lamdkwHnUX8J@BE@kdgSAN*P_{bQG{(lB$U+S%1Yt!DB z^i5lK7A9nkY;0iyxQcCZP!Pp4SByRXmzbUw6fOD>SaPeG;1p zudkJyI9AkCNaXwEuHXbm!9gA>;c|Vd!Fj^H-OFL1%p8pKm~lWHNeV^Mdg|gGM=8dj zu%3x^Vnc7xkN7*A5$4cvlrt-t9w5>JS_L2NX2|;D$;43MJ(oS0Isat;wPWOA|9A(f z#-Er?sDftW0FODMZfj}INXVq=EkBks$7B`)jba0@NE5Q}y}S4M^X8L>{rU6s!Zj=Y z-oQT>k=M)Z>hx}4i=0(~mB>$xE7AAnS@%NCbf6<+uDt}%4yI^_*Icz|j6H}3wnImE zql27LVC7!@ZP!_BP)_}JQXHmqY6^3S&!E_}Z(KH|1j)zfTtIbPNYt>-$v@-fv;(Le zhX7aDwC9-($=Fn10~w&Qq()4(p+0blQ;)rMN;^FxYrK;Cb=zrC%F{XkS}`=9tkXDB z?YW?7?tq+cI2bUWn0Q zyu@fMM4Q?Soi_yvsZ(+pFwLs|SX>|qBO>-+%;e&R>KFruTJ>0+zXGS#-cSEnjH1UI zB=9HFq`MZ4AZ_r>Qa`#9^>J)jUABnz$Pqj)S0!Zqf;A)|-5FIdWMk`n9qSMLS|6Mk z^u-V5*>{q$r*6N-E_B_N#Dq1QxZYIe^h=uD>=`gWJVUyjs>cpPelv*#0S%Du9X%C_ ziQFJ+-qm2ZxbqOI^B_eXSw`X4{#BwY`#g*9J{G^t&qibfbJfWQY7;rr+}Lq4;yw)> zMwtF`XBix>#>oJ3P3L96vFh%UQAGV5RyIG(--Cko+F9$*^d&iVswF0)6YVX8!$WvB z<5n7cC)#{=I7Nct>_i~n{lhU^eN+P_J~p0MB$S$psC^OJ1U<7B(zswFD*HY+|1I$?1OAb;y_!3P$~;r8ge3cq@NHc!+h_t9v>T*1y4u` zbVXJ*uD44h?4Ev(G?4I!1dBV?yUAMjQA|u|ITTT5x9wC$YSydjcAQ&ymnvRnFsF?8 z>XMhp`^^Qfr7n`6{>&}-da3V1=P6bL$aC%}cK_tLjTNE9y>tXMUWSpWcy<_mP)B?P zF+7XXsE6XS3TLMqcN|cCaNTjl;rVb_Za}8-t9j+)y3Kxc{NJ!jH79So+xa77J=IKU zn|>xsB(H4Fx((y6dcZdoBlK?NNB3P;4si^asmp?%;z<09t5E)nt4uI<6@D$KSX9B> zr4aI8C5e4yWBC3$nar-O1ds#_Lke0io}?s<$^PukB3%M`PN#(~!B8U~hlK@tK( z^yoFOe&wNV*GpH4$tsOuE-s(X>(2YR46`C#C{6VB=3-`W?Y`p??2NOwEAq%1AK*CP!L32C!EVA_KU}Gs-ubeXZAu;l4QD@ z>l^FW=CfVR6*6%t_b|er#D;BlQ%r($;U+-*D1RT*rt-!V))YlRED*3Pr}Ks9Q|3X= zQX5T4WUosTy~b7#NcEjdUABc8u?{W}ooS@~B(;g=8nghR2wA|pk##o4`Fj(i3$(tC zed=toxdD5vM%;1H@@ll@MkXc#^8f;cOGYY)N3`uW!= z4~>V`d8Y<2H+bK^B(tQgSSS9MEZsl#eOG6}sTl9Bs6%2VNc7psNBT?c&ljxv;y0th zD%Pt*N-gAg5?c|8=0fjYsM}x^&C=8 zv2IVYU!P7!71(3g?b4mDU^xJJX>K~jP_5X@yqd+r9wAUmv^X-M3fZbJ{ElH6%g*(P zOzt1`Xr|r3qL2(El3Aj`ddlkDEWG6gI7yfV@`6$A>Tf6C}?fO;+&j`$~8@57(^>C~nMp&c6tX>Oy zs963TbDN*Cf}Q`Jd?J?;YSGAiqqrYDb&LR(?*b*p1NkzXmdu+cGKFxr&-_=w+?bTr z4>!06<-)b-ZC!ewuYkcZlLDvHOLoe=yOTq0QvzOGp0dMOZT?QklS>P~im9^|?dp># z+8{;%|Ktk0*xlfHebz*@j%{ifH6=&_&x=9*BXx;(BmLW}W$L3{Jzn^;q70rG)HuE0 z=iBhpB7iU1r@a{*zWLd3)|sOrIyGN zAkOlj$qG$P7&ZM05*~pV4b$X$pu;C#_b@jH5C0?=-&oqZRm+_g&!l71vDy1`AVeJk zJR*OCP6vW+6+b)g!KJwoiIrVyr4?RBemb`|zH-z18+}wGi>Q~Ka&+@cw%1l8idyBz z^385_cz4~n?OOf2T22|J#wUfxto8IpYM05%)$-z(i!P7DUR?ttutNHmzV{@W9}^9R zd!Q#ORt^!I;CfEZXtZU&!-kw}G^#cDxek4DKh%WMwT2d8j#z4emv&I!&c&@~RNN=O z4j6ZX8^pw8k)OGi&I~E!9KbUjoUmzH(~-klwl`Z*$O)J)z43M|Q}A)Sg2TF6k~R|5 zE<(ke9jpT0I&Ggic+J189!pCHE<*H>mhk)+Q(M@PYlVy2_!kxtJB@s|MPAKxO8pc? zJ9g2|nw^?>Rj)mOJd@>8;rB#9A{z~wAYpx#M>{-87Q*3p1HgTs7ng03?DF4Cv3T%8 zyXmF(TG@IqMlPJ$_@f(mv~o1jq+2|x4VOMjdtH7F#qSo*ds0V74J#Vt*h(MlP=$eZP-Ky=4lCroMtq4Uk<69c^JB; zL{%&(1nXoz2l;Z2e%HCp(-|HG#;PFbJa(8B1foTp>V=QtG_+Y`^;dF@vLWB2$YC8#M)zSV5SUYPTb}T@bR+^_FcO)Vw(XhbM_SAA zuT58)kgHCC0$EQt*@D`CXfjn>wJeZ9O|#+oEYlso<9z)S=+1$uTGY)VTW{U}mpoWP ztFce8PuR0;+sF!c>Gsz`9MW{N{|;zVz0I}203iTQcKXh~I?%kg803)B*LwEj+EqXl z+Hbds1phaW^QOEruN z5H<;l#aXL^`ypr0bsdLxCv~b@0wA@}%2TEvY~)0qICG1M^FA4c^532KMsK1J1Pk zG+Y@X`-gV z{6*2AH|4TRepYcaFmgqa`W=rb4;@}{#Q%Y8|C87+wtF1TWUphrG^gvH%ARTu`09aiDt$yX+EtiYUS(J@lREV}rW$fxJ_CRBbL~nKFR?LxB=0Q*b#FO|mk zzD(KI<$riFSkS<}APAVBwh+TNav7a=0${ik4QKx_+`1LPKj9auzbv&!9nF=8OGL10 z=@m_JDLIz9z9AXuC7swbh(|;wos8QIJ($Vv&K>l->x+l4XndR%g*XD7cH=OsRu`|Npv6I`_%2>RlLKH=hto%s05)~_DVa@cEqq9j zcu@MCzcL-G5^B-SbW>nHZB$a$fxfPL&tqgIdxWS@A9QeH__fQZ$+LK@8dN zI|?D*A=xPrU*960;l{gbPhiRyeq$lHJB49fpkR+FM21$$%i_1!*^$h0u9rZh7pn(9 z5KL+uH`^?iY{i0v4N)&UO|8ppkm=@Q-4@x-G)iH7=ohjw{NV+(;jng@I2d=Y1Vt2+ za16l6;TZ^-%N(^j)SIRNroydpFOVasAR`Sqa-=*H;--CzgM%i4z1Z!~r`GLax*wJ_ z?Zgc9J1uzVazIhPe7)7Vo%fbQ&Rl{ib77n)=|42q`)wGlPMWtTMN1O2VaE#QW#8t0DSYS9v7%;t0wLeY zS^Xfm!8E*piBf9H(xHw^9t*Dr_ASA&lVRQ0I14z2OA%9{{l0N3Uf#6)qE433)saxD z<9YWuEA|W+sGl{WcWRkr2fV+eRXG8KhsOH%Jzx-xQa>4BIYilC{s44L;T-7eotQmD zy1!Z`Y~&&Vnde`vnDF1PxkH)c6zHyrtl|>&E3;=O4!Jm~uDsCdlPnphR)QZ$61^Ro zTdIyl=9diCiXWmvraF$OzGUod>-qq!uE>nM*e!V$pUVTrp4>n3^qDd_M5CO^j>aMH znernHW3!gI@r%pLYa=NbMzgh2>47tv70^@{^+YuPY6r)Axt{OHsLYqebJElwZOUNK z#y2DIATqq0JH+)?zlHHuZ-H+j_GLQhWf?xri%hsl~>v=geslp=E#yC^tc^LS$m` zs?k>5f>*4-n0DU{z$0QmgBZKmFy7BW{%D@;3Ip@L%5Jpkv42O@VMmyJaPfiAUO?Dj z8^_0YzlV=5hc2Lmt((l>!-qEBtBYi>edSnKv^k7-x@6JqchIGBXp#95ZaiiCb#uPU zHq^+4)*9i6R(=?lV-(D)R9=*!-G}rGTHfZ z#0pUWR^3W#;fL0z1f-(!-17~cCO=KTw*1?#a9BOA*%alK%FNqqiHPS>YCG9p*^PJH z?27ElB|=S-m!By1{!JMyXGYEcASq$ZBSufo5ntdi*we4V(51bkh|HpZW<5c5Jxm90 znJ%AOWQu9|lq~77#yKnmoONBp8^zqPP}1CLCwsn~aeR7823Gs?>3m!G3NLg1jRwF2 zvy|z0)S^B&3BMckX1O&OdDtc!Vcw4s-i$Bl zLcsRW{tqA3`K+;(>4`l>?2xdu@_bgc-b$Y=SILpdK;HuS>5y<1^D`LW3WxA~mE+-& zX<#zF9<-dgo`Yt}M0^(dP&l96Nx)kr4PXYiFfmvHK{B8m3>V^4`L zoGJQF9$&m})&6&MiRwx?YxAxD4_j{;RY%lqZ6-Lu65QPq+}$05yGxMZ?iM7tySoH; zcXxLV?(VK%CGWl8?c3cy7>6-nP^Wekr`Dcxu4hp;6T!^Ch2^$d+!dDupp zFK6NU3r9O7X{Az8OiQ+?%2jWvZI z^TASoLpVJ5L#>n>P!Stc`-S>wGjY*;Oer0bka1#vUzO{wfjh9hBAT8vd&oBBpwH@=&AS#J5SWh1H3X$*VbA46g>dMyo)P;V6SY zt3YiT1rh$NEi~WL6v@_Vgfhe&9P5DwIx9F7iXev4@jbHDy>xi}Kash4%VDignZ5Si zOF)In?QG)&RH!>mHP=9en(=J!CE7Y+KOutTssgktR6}gd*Yy_wB1^{e*LqmPT9-2& z3q>)()P3|hR^ZI6z)}lcQD^Kyz-_gU?)81PAf&1>b2#OTx;oRSv1tr_LX`c=7j-qJ zyvfsz-v45Ek^f_N4Te1hj8a}bLR|U=-&7WbaLdeRg47WQ#+0aK2(xi8n;fRf5~c(j zN&rHcKWp=x26Hn7aKM>3b_`R2^FjrJm`Tf*R9d~ifn1V0pyZcAF;v;9AwD0(lZ2}Q zWeIWei17HBP`^_Vetu zZ_pkdt0gmNc_aj2T170R*mRqJaz({_t%$JaI}cp`vb2QiwzFM2eOD7V8Z~;IYP8}* zGo6rHtVhoMIHYfar>pR62h`JczHndy(N*DwN**A(`gwKi5>q}x4ES_Lm9C2*14jWw3+BIWgOj}=;5L}ur$duLWzi?&3fI5PcLRr5@ar=1>E2Q(7NvW-%Q9X?O-6Q@xdTFQP#x>k_3igH#=c0 z5>pEm@}I_!$+Fas5|*y`Ri7%rm;)b!P#YVD@h^DEY7~{1 zeX18FT-Ba+YLO@G`~l$IMl&Aad?lI4sN??bY5{w?F9?PqXyL7jb6$@W&(ORy_th4p zKY50W-0OHmxYdos-=B8@9yLw%@=MqTH07c?;#F+Mla{IDsWlrJCF&ShgnUH}S5l zog}{NSY;4SeA%HGUN(s_fo#H1b{F?;{Y`?h`T=t1HSRP_+{75t6+Q4v+q=0iCzC`! z7dw-DDMddQ7sFIIf7tzgZ`hN}=%BY}4|Vk-{4QV6rPr_n5Q^!4rkn{Dw!n&nv(E_X z(5ms21(C{{wa56|kGB^4os4625FNV!G2JWC*T`rIKUcF3eZ!AhS1l7VyAedXE(pw|xH z?`%>VV~rp;qyGG!0EQ;OxQhp$OF2Iyre=ek9?><1_o+La6Kd@o^Cjg55Yj?cjJvka zY&*XB&FtzQwt6OLNP+SEiFC2;RY!(2(Pa43wq8Lnys^D}&VA7rzewsjHR$VqG@{gMI?JNFjaW>u zwONw3f9cpYHoq=2?UmBv^b_XItxbRAQ6DULYI}%H4At9<#$=}=sNPgZ4#wjg^k#Iv zc-m6?06_$tGVM0;^B5QzmYljjDVt~4ZWgkjqN_(&-CojscOSsIhx_BrvI_U>x#$2= zi_vcF_lPDrxk%h6(rA+NpkCf8BjQGOmOFt`QwD<2R}}d-GY8m>vn*NxJgZr*A9L_BrZbKNnWtHn`OqIDh+l>bcJ_zk_3yb+xqQqlyD*Vs&ea zN&t$40CK&I+VwDmP6PxMJGdE2AWj_fEM5(GBZO|~fVcg(STEiVvHkW*Ic^({frMR{u zZ-vQCet74$YIl~rAg9iA41>3ZhWi?F%L4bqfCz0GJ8Pjn&Wj)|qrmLw_)$uhH$&y% znV0?u>M3Amv7|3@-<4QYG-OqKnaWE4brweKmRt^i6ZIQO=WJIzR|jl;q4J%vQ|?Nk zYWYYotiYD#6xK%7&_Pp@6JG-Q^48KK?MV9J-RIn@)br${SdONvDjrft*v=@;u{i5v z8I{(L!Tp>kiF4Cr4AXC|9+Z9^!RznN&Fet9)trCT8cJaC6mM8Vyd{BZqV*CT`0Ve^ zGNe#EU~^HCqgG3=FeQP+lKBwAFW_i=ak{fl>3p!XMVf}L!aC-pe3jy5YnnYH&TA2f-nAoL^JQtOWJ*Ji9f z(9e|q{%0^Tv4Ik0S8p{d)w;engXc02_RMHj=m6!_Ts&_)h~9Yr zWpfV_X9maAd)g0GlYTl}o*5%5g089D$iXQ-NYg^GTa$n{&Lw6IMV>!{$dtnQG!XY% z58TTX(9bj>bDp_Pjh~9A^`*jZo<+y+L)>&yh?*mQ;yNCJ#W-1)-_tKf#wZ}=baU0(p zI$&Bbgn`Z_A>_){pAk5q?|*Ryh1hOd+&VX46Mz+O0e4Id#BdG&#c)Xy7o>XKJ<|%m zzeN9$RuRcBKF$tRQUGOtD+bkH{7e7V%|ytpW~Q?qf=p2+XnT{Y;&ABhW(`h_dNlBx z;();NOw>_urbZFJXy6f0U5j@|9P!8HJpmw?^4;JqwbuQZ5swrhq2j;DTGStEE)!B~ zKGa<0XUrc|cbTg4$6M33u1eO2|sIQNJ`Z^n6!GPcLf6N9Ng0tJto20pMkX_S6 zgD>AqG(NmF;i-tx!ac15=es6rs!W*s+wFe3n7y5pvHK3*<*nMq+$MtJd8ec8a!%#IPgD7sv>1?YCm1+K1zBwgIGJ4AEQhbxy4)(H1d z&QifE^V0z624w)5wnkYkFFZ%o}dv6gHK0EJ??JL{8y zQrth`Su`VGrY6qhMx`BAeKn2(q5u!Rm@r{QB}<0`Of{O&2*LmONm=ak*+fOk&1-S+ zI#`T8dZ;RKsKn0?>I1i{0I{HZuAL!0ewDxb!#dEi?*X*zZ{WbpKhVnZ;zIKUXS!)x zS)uFOk!rmCbdX&us=js|bHdI4G16qdF#BsA9Uo|O-D)sLALoKK;BZDquUiVT4_;LY zRxL;0Wh6`7c>S6c?}tkWxNe*$Q0+pVP9?u@ zmdf&fbXyTVjGpNhPY6JNKMS_2i8Qer6L$x&xgz0;fCAiL4g~vQnd}rDWlZh39)$l< z8KhEyJiC>5zI1GR1LLKY;)t5zX4y+@ENE30mK1&vP_`)=0A;($M~}&r_zel!Jtytt zN3u=}Fj6AOQa>F~v<+G`DPrZ1^L!VV$0clh%nZPBa>1+85n}j1B7-so7!PqsQPz!X zj}9wsKrchVWp|vWUvNOsEWv;Oc0KU7t9cq(#7YLK?AUmpoyQ3$omd|91*|Ypt>L zB&>(Aq`{{fu>eJ(*Xd3GSQ!g%-oe^)zwd4Cx8Mvbv}E$*e4g zJYlY^C1IYlB@Z6B8A%t$kF&npzPY*G|FS?bsWBC47?QuqKOc)9RA&Pj{{AjH3I;?2 zRLuLBsB4-2pTQE6&xFBbaE< zn)q$x!$yv}m)z%ND1SjGXjT^243Df)yoyekbY+`4qR{0;a z_Z{(pMi&*kM+x}69k)^Kz~g)pEr^JH!XROn8a>PYG1xD`jm7EdKtQy81TmdKnssBAFi0 za*QJW^A<}ZUefUy9uTKVrqcm&`k1ZII-@xhFsa9Kij>>b{eQdljVd**mTbgEr=rvc z=8boCBZQolZy|K8BBVq#3n=2xJ%@~Ng%&Pb$=UcE(RS5qe3f=Lfd&fp+WY+v($9#K zv({bx#G%Dx5Ga!w`K!i0C{sGT*~0F13sUE3U2XKh9+3A8U^CbtNhbbfGjtyr`Q!t= z0TpiQNtDkmY+xDaupEj2`rrv1F7m6Hbb2D>zVKgZJn^?j!mjObXx#EGeSUF_3WMFm z#s;fMRRE745XPhI%;?JOVLs*hKBG$MpQPsTr)~Khv1QJRL}#$wDlssGR29q{Kj68! z8F_zIJD*<=?wYs60jw&zKF75D>+J=pBVC?GPN?dI6Qwsb?L&diWRDj+7Z-2N(Iyc4 z%4?H%=WcEbW&exDvJ0^)HQ+zD;*cIFaon>7M#)7gNpsHKrTJ1R*@G18#=8V@V>t*+ ztiQ?qD!t#AmVREFovpd2GZ8Ul+P|*SIt5_RPgNbu)D2=`O=uo7pW_b7ouYy-X9U8m z{Epur&nHMMRN-oM1wO7gGV^*+-TUS=+}zdk8!R$1kA$x{8_>Hp_;ylYx^9*7RCiYucFm0B4dbm>z`q8gehHKLPscu1=JEGn z-)hwaDd;n&G5nxCK9Y2)XNJk>6i;Vp(Aa8SNqF83=&#~*$P@Va4LtN@DDWPGLaZYr z=ss!pZMS#y)=W16WOh0>R893-v+=$55i^)Vve&AM7^SpeOadrEdeQL}Kl`~n&2vKU zYwzfx{lK1xIdU~E5Ftgr$1Bj_yF}LBJOq%r!x#6IavXzJ19P{md#7s6&-*Fc+s~K22>BXz%{68EIfX4SKnprt&<@Y2_W=gPfVH3A8FjowEip|wY8E>k zb*%n#+|ed`TMOE!qSw(z1))5b0KU=c&Z4Mk%{k9F!_$i!j^lplHcwZvn`8k%L>y;* zCfjRv=aDAN-f0HLYaAa0daQoZ%CrP#j1**$H&LHEy>AQw-6ysdvT@GZMug;pBIQ;V zND_$711`pNpk);eQ2WUK>;QxR{R?y_=VnpdXbkNSH@3Dw8Xl+cKl*PIp#T0k)3H+&1Go&> z=jbeKfCB7v#c3oGH_5dFbY6OBvI_x#1kqKmBXeVaCZ%63N%{J;PepDO7^ZGqBx%`> zQOs@O)l=0J-POxhI+VE1CO#tfwpxVBxg^HI7A$zR zldy2asxAz@MVoBAmb7-MY(8g+M}Et3hS;`O>{}PmYv}Y}=z{+uB{_Pi*E%uuDykKa!|> zGgb$gh-ZVk5C9|{5Wz2y`xn7SO}UlMPFCHht&U}PW*7*el!eTShmSg$_hTN9k=V*ycp}I(`9n{o>W`F1hDF;gwExkynYJ!z?mi z?+7#yj?*?aLG%$9vznPr8G?~K^&8mNHfgkIU|d4VQ75(9X|9Wx8yV-s(HFNWPh!jI z%y0Uccj93){>+C!%4bJ2iBTRz6?IMm-16{Mo(6+GmC2-u9kvQ{d_$)wUCPDD*2e?5 z9%D-G&XY5Lx}4cE$zj;G+}8_}AL}}mBc+toW^LY(wz%l^53leVyS_glQhU333(5nvSZJ!FM#LG@S<8Bwd|BGix z{@-|pIae9$UO>r%vEJMi9;+a1jr90iXl;g;Y9A4!WZ2nF`#am%<*3Q}JF|M^;P}9t zPh2G5B4j3;WTs;x^)>ZbQLzY=L+7KG-|a3~)*Y$;>TH4!7{elM25(5DUG+H~^*`%G z2KWpoa`D4j|IKGug#-8u1pk}QK=*)o2h19~qk+#o_+M#n5zSY@Enem1xV?5EBZcd` zmk*g-2q7&?JOYideb?=)O!r5{+aemMt(97vSAGW~9Uib=URqY)beMJbi+wFyh7m98 zc7?AO{wBT$qIQ~=v-0aqh$kl>6^en#cX9#{`6dhT+KzsJDs-Lr{~{XPv({Lmua|v$ zbNZft#9S)oyFTx-&>@cxovH)lWBUCPh_E89mf5#g75_@I&Qf6}(Tzy@qtnds^8$Oq zP1BsBTU?ETWb5*!XBg`AmC%J#2gtv`j*$5qtLp~HmfymSBdTV7c!u;wTxdPF86&A+`eX3xGlNwPR~H~W zKfO1)->>#ZQ-@zG!!TDSeVqQbMwir)Rz0&Dcj~aDZe>A(4yI_ld=y7UM`q+a$8{n! z3O=fM!@CG&ZK`35sk<^-bSC_xpjvI81P%U;7&GiVt(#-W`7t^*Wp@+J+%^pZXYy=3 z(u3|(+RSY^W#-6ky^U3QWcoc$aqjo%6x2&;GMVgNDe$Qms7;D}a48lN#{vTN$+lT3 zDC9iVKz6WDZwzU@Np#`*-O`69eMNoOjE!sLAvj*jKe!QT%z6#5{bs_J2=dBfp- z`aVT(!X?J9$HYcB(StMKYa0v77xgEv@u%Uq;!&Sbw`g!NQX26qd_ zOv#}n1@yUZ0Ry!@B4~ZfDOx2D^2xOj)A_GO=V`IAYNO5^HAgpldA=)LVz3XM_hx2I zg1P&B8o|)K3$JxWs`KLyX)PYgV@!)>ucpIqmr^ZL1{!fK67e5jXAJgTOcM^JN5^Cb z5s(a^mk)=2D^BDb2ngVMcxhKCu+?mvX}i@?AEd|dA0)iWHP^0u{iJMBZH$-RI*fFn zbgFF!#k|j!Iu?8VSVfu1Dhrv8v}sY>zDhAri!J#S;YHMb2v&*2}`q1bK-PY zIbWdBP7~qaD0ZOGxQsOjbLm?@pcMRc`4Xssr}Im(s!8`cdo!P{nw?-c=OMRvYo~^b zrIE(Fly;rwE>Qg_MgnbFXhkh|vq7XmgMNPT5>#MVrNmb>A2Ut=L#Wt2>EtvAE~Jsr ztCE3!C1;TV3I~m?d_|AsbUYr@VyCp(%};v0B~_!`2uqctEIzR`CwChdIJmZZEFy0S z>8*@*=Gmmq4Gdvx@{wqFUA4Cn`t--SNsD`LZre4L@BP|)5&UW5y&w?vB>wk^8Zz<~ zm*+1b;*mo3isDlIyd=jS7; z{>xX-s`hn04rN;mGfJ!?A?M_ySoTXM&R|c^ARI~Nu(ktHxBz6FbjSH2TzE1o&R}2a zv79)`p@bMR4Rv_F7)(re`O*{d961x5GzH_lD91;IntWZk#%Z-l=f?u4v1qF;6&ASJ z0pG+X!(({PvV;~X)*@|oW$hfd7;|pygN)xeNWXY4^|dYR_kkfqJ;}S?KibSL$iSNz zoH=m6^dc8hC^mk9Nsb`H4#$U~hMB0C0BvSJ?eRJL#m*dFaP^6|Jr0Bl9n28$0vCfn zOaB&zHTC7Nb+KKkIRahbb!RcYEpC!XDhY-%%|WE5SUhtF477g&-)_%K7?pN&ZK3Sapx z{tSut=ED6*l!sPz>ELx9-Xfwq=6F@?s_n483mwQ=8Bbl6q6)Yt>A%kv=!~4x)ulW$ zGQ2#$nq2yxzqc)vodAnM|6x|TbFdWqkclg8Td{^11Sq?L01 z!(Bfj(2uEaJ<*l==(z}@-A{%RC`hZN;XLXX>Uan$#-5ufF>1^4XkA4IS&oJ4-pzGi z8Mlom8g0G|9G(u{JS4tzPp6z~ax<{01+6-+CyHgHKE(5xym{4JAKG@W90Tu@PbR1@ z1wC5~GFd#3bu(g4szu~+Qc7?cY#w*3vs}Mhq`}A~xxZC+j5EBa&&?aTUjR9esELb( zWVFHYv#c%nHBCsoPEHZu*{39{lXl2YQHOUc4eINjsgUy>R#or0<2Ohn-_8xvUF@2) zOIbl?Ac^#sMd>kgQ>8eLZ=rb3=OuL77|+&^_k9~C>V!m)MzFB1l%ai4nxT8OY9}u{ zJwqeN&s_UI*klX4cobAU9#c}>Zl2uigTNae2BtTl8e~3L&6KkplLkeWZqnC-FGZGa zfb}gxRe@RDca*H5a^yPQu2(+qX<4AJU+idk7-L0+q7e@EZAucJr@AnWoDH$t@#u0~ zYB=Z7~}wSp?3U7eq@$BR5|psSg5Pjt8s~N(KP1foxfrXQAE&~f*GgyD`J4A;wy3XHn1>ABD;q~dFdRA^=m?Xn zHugoTpa8u89dKonEhpAeZ%^Bjm8rZDTR5@$x z34d+WPGEu(CPwYYLN0_ko#wpg_@#YOs`9|ecicH2OSy!j#wV)0=Az!OF_U@C)v~u1 zwY*F7#IQZRx%TJ{f$YWRF4j}8U*uLr2~r&yp^YScEsz7w^yUM?nAf3%6(k+v1xqy< z*Uj`+8!xEkeyKI6y09L%{A4Og5X_Vgi6ISLgE;PBuDs=momMtB*{Vc@cdJ$#5YZ)? z2TF}-fAaZwnrxHY+aXqKK};h7epPZ)L|e6m%BGxWlFsIEUe;qnM7ztzv%F%gwY{wU zKQfJ4$Cw#MP_(M3&jCtov@C#iHFp}HGWO&&H)^*u9yDgfjiYp4Ex(+Rf^=lp3nj{~ zZjcI62nP<<%TG0xrgEp55k5cC%;6OCNUQzU!qIE1(IXUc7V>L`)os2smLth4u#5E1 za1N>0ZQwSuI&OlbWiYM6plL87SDN?-;gQPuQN&N(@oJz3KjQ>*qX3=Hec7Dm6|Bck zLR;HcO>0H>Pb4|V$zN2J)3?jh4J!CWd3)eLn|YV_nn->HKruf*gLhpYgOIL|433d!VQ7~`=cGu;=Lmz_ zFNpC(-TK?1Un08WKcC%xu>wI3WJIa`c)riX-Rz7c3$>{V1M3!8RW$XNI{X9Bkmq6O z3NjnN4c!HHL-?%9pV6W60GSH&V{behcr-Z$& z!1)am+LsRVUCYyId5kXPcJCRWjR)k`Cc8L9t+H_b`uUqCkhGb?I+OeJo0pwb$PIM*tvRbwO(pWBSL=&<2Fp; zn52g-cS{nE*}nj9XQokZ)FajQ6oX%B($8JTXYY# zPH*KLu&t^(GH7a_NbjI^ZZUYxrzC(fe;^`)j0yd{BSD*=D`-c!SQ;VA*J@uLN%!hJ z?)1KE-Dj{*eRY+=6VNeEoAw-Wq0@UdG8s5A)ok_b$OH?{Co_bU2|Urxj>@G`Nqk$< zX*rMm5qUiemi%A8)4>zdg+G{b?yi&?xU?Q~0h?^tHR<$J@sC@pDfUbbxx8zq%{#?o zA0>)6>!CkHq$Bkuvh{Ekj&I^&)*2QbW~CKzuk;CC*(6TO`*3}>sIPwU@UVB~e&yS5 z*k4#kyq?Ik+FO{>-OCs_>!u$SJNm;{Urf)9aB5J5XiKl!V4s8eWz^DPP@O{P#9(NP z(kzTG5Tw>j*cuM0ou9PZschP5r`SPm;n{0v?lm?U{!HC)9B%Fet7g*lULZvate73n z?YBa4QJ-DlQY8SFsuHkTs7)^8SB%=Jiq|>s6*k>Q#IAi_dJ1Cctg+xnXY{el-utb_9~3CaSH*Y&PXr(rZ%3k{evb zxWJ0!tpaK82ivMB?%sR{B|=09oS^%M)zP5|US01D-FL<^iv9M1v;K=-k32+>9Tyx) zz*po$VEGS^=7HrGY>xkwpFa9=`iD2Ns26S%Q8ZpjXmBGY{^1kwV{=~zMRRfs4}S;q z`O!(~XYmG$6sc8GNoLkM54Uo9`D{Q;(LuX?WnbpS2rX{KB1suHyU`Oq8E}D>jzrulA#t>1(B*q1~P$H?< zv~GI5VmzvUG7cN^COo^+^24Dt@B++TFT)ZNVmppqvoq@Zc3o4b5C2;0ZpfZ=He%Pb zSaByizG|0B{4`|Dq`SZKcxpX-`w&j((d9h zykHI$>O6k?;`B{YfLBB8WEYE|{5H+5E@SFE-?jAkv3BOwI2}GdfcqMU&;&PP2rN?= z+s+}{05?)$1LaNu)(QuUU%v5ELtFdD*_xAz(AUKUi3~=F#nS6#&@L;5`=F)l$$ShY zjt{9}5)BE_m<3@$r$tt85)akAH+9EcZ^qm))vqG+}S(@1q{Ri_a6UbRhX$vAaYOFouHT81#1MmdjO7M`BY z|8aUbqh{v%xwif!=|`lbp{?nTcjUamdpv4c_=u6D#Ndnub%CJyM#PU=+C}@$8}w7| z=NvWfp4gM&9i%eR4_YRS&@%}z6?CJL&`PS=>vd}?HTyPeRD^!LcK2lP|ROCpo7*@{?QFcX#(99pBDOf`D_>iyVn&3pyFxjw;h{6LyyVWr4$EJwGHj zc(-+iG+;69dWdX=XA^H=e7rEKWKds)0OY8RK{fhro;U?2bE_(Ie8DyRB$~sH>b06{ zZt)Pyl5hpeF0-{9Zkk_Xf(`QyXozezO99cLy6=;3Ku%Mc4xW82;(czh40hiRRP^0v z=${B&WX%j<{F+4(OG6is&c4*};C#|6gqsiF8@~?ua$OMr_L#4T2#&HiDS-I&dFXB> zPG?>EP`$4BQGKgG!(Fg^X}d#>mkB$qq5}i8dPQU+zCqEcvqJWDs;}nEm0c;cOrEjs zFggIW5Lk7SB?E?`{@hChGjq4=!&R!KN3!RR=dx>Cub0TN<>cz1U1Hs_!j3TvZ`A9f zaa@shjJ&nz{qeSk?F!Yoj#T#>ae4(lYun7GH-5|KyU%RMKh+rJWA}C&3=+9Ic0eBk7Ij8D3oU^nj;(_4VzwdH~dJ>y^@C%ZFaX6BfSho^+K(T#TZh@A)e z^R<4{_)*(7|6ibi;IuUP z$}Ho_DevZa5cQnJB7WwF`SG6Sc1)eZA&HVFZdW7u5-()K}Y;cGWv(CHsu zBf3<)p%(A8({m6w>3lR}Kc^hO8Xy&@or9!3L47zigR;zfXKZ~rD|F7chG%Z^3x^}& zb_|j*b`Ma-?5-X_0d_%?`|*M%f!%@#dxD&i11B2e?d=;ORv0>TyXVybY_LRqp6 z40%}|b%0oY^FKik{8pt&?P%x4(4ieCBA>n7M9UUALU+=zx*%)t`g66W zhTCd*)#*&E^fqvRj>K`8R^3t=-HI^M(lbb?xsm8+o}UgOfAinHia(-?;Fg7gCy`Ch za9gisnDq~0+JM032gW`*=qhUn$4hmiEW`{L2uGmQo_$_ZT(3T-yIM3a60MuuGq#x5 zP25!+L)*{MTdn18=ILljmZghW={%7t?1yC^1)oUE%Y_{j7g$r;Qj!Er(UiO4z0sN} zP93hzi0Mg!!QMGQcq!9o7qR^Ip&`7S<=9Z?oNcH&Yq-Bp^bfV6H@gLj*9>RCK)ug8 zYTvL|d+YK^nn%kjb%HC4?xJPdimOKXBF=^}&o8SVa6nk#px#8__8DDi-N~oVOj(}9 zvXfq&4yW2pe*b16HOV~fmrw&9)3>N-!G@yVqBwu%W|q=FKO9@jJxorFhxm;qo<0X! zAy9n_YFeZNc&bgHM4bI?Ub;}e;tsS&@HXd3NoQcAA2`SRDv>6VfkBp?dcj^8>WREd zIw|tWw%l5lrLU>V6PPQP2CAue@_a6~UYg%0qjgWL3%=IHUQQ`Mn`HkOXulB<+t<`& zGN%Tti6Hj=@Y=}V6-neJgjaMUU&G(BDc__379=Scbf8fqvv>QQduUn$T~xkqf=A*3 zDK;*)He_?ka)VT)$~wsEhtSu5=S_M09H6jXO;sV8foe|bXIfAFvZ&zktcJ?P1xKM4 zCseywMOMRyD=xmdR3NP+dEzKE6$Pc!XrRo^oTqE))-Q*>M&j6}Gk?`}g)&EkxP~1d zH#-jIlIqk9ltxDVx7u{#O9ZrIIkM? z;hF8XPk~hgX5;m`!-5%1RaZrC4|QuQnq%074qQguK4FqrvV>%+{V2g3 z^|@F`D}Ktm<2AA7ckPNif)$^f6p*@?e&XGUDUZ`f9MG%-75@!3t@P|2*d*xd;vo|H ziG%0DEqKK;&CrxivmQmGB*UpALJIUR40pH58OknarfqT(J7A9;buY*^=sP^$!;o?1FdfEr;gF*y6~=aF3D}#M))Ng_H=e0JmKbTN zq&|DllimpZ(49qOLoS55-7bV=11_XF!1tOAZ)CS2q?-drHGK5=`J10NON0Xbp*xaE zxy|16yEP9ZYXAV5M}qJebq0wCKZq5!+bwm7v4&GAU z4Ywn!<2Uuf^RD9rz6K@qEJSe=!;-Eo<+QdFpOm$2{_7timRHW3451 zJ!9fMr9x%oben5mL9O4aROiV+TJlij>hAM^6T-+>GoZWF@}?V5Nao7L6(;sO{DGmV z%XJX6a_~2oaEUn?-#$7sWqyTG^>tr2!EW_gnpjZ(;&X62(-6Sr4TX5-6cP{kv5g>y zY+?qU#vaCe__L1P`_!YdxAg1Oq%#u78T{^Chp038;VJE&*bohEerGO62|oc{vz@~7 z)JOULiWKo@g)Wg0SUxWvg;{Mf7;9rG$iM&3AO-LiT0XXjY0??-fklfmbNs6(A<%BX z>vchCf?{e8i&(~HcL?AK_k$;<84_a>lJvR21}73o#cEUg;Dm{`R0ETaYpoV(tXrZ} z5#o}|k!&Fr=u>lWNC_LmW&WzgFlUglgi_VTrOeL+Vm8C(fHMrib^(kZ$p4M@?>S;v zZ$gRi6foUc%`zdoO&Yb-`*1x+Wuap^FJ_U~>Z!%MK+vLtVP{_=z4fgK9bt|GAH)z1 zhUN5oE+7gjXbwGUt{QXk7cKf8|JH`iDHP<(l;y!@VCMdUcT= z{J0%+f@>mpP#2~Uutv0PoUaV`#r#r!x+n@h%{ojzp^r}HrDDky_Q--Z&32^7B?a%1 zOQ@oBjV+=s zRS@fY3GNQ7QSUy9_{kAUJ6onrq9Npp2qaWBbZl~WRzIG;RP5qLJG_aF!7plDPD5fl zLTkb>XrD#D_?>jbXYui7X72IkryJwD<56pSJ!^dK%+3Sx60b_8#XYpBI&R^PQY(+c zpwq>+M1Afv+o%(jrwvf?SzzC^Ng&TX4;}LbS|Gs={KV_6!qdu+I;EVShL*EQS@2IJ z=9SwCrc3Gtr(xQkU7tn{z;()A4;(W@*lWkbKJcChCJB8{74DpRuY{JI#U-FJGJU z8*+!e%=tSq*TDTfVq2(3>G(2jo1xWbQNy!ez)lMFXOj5T7%Ds@IiBtOZ-UZ(;VDu? z#=F`FtEk48&-@99;X#KyM<2S0KJ>PC`Es)7!@n7|70yzf&{1l^UU(5)BuMcVsBg6l zugyFh^i(s3Ekr!-I#n%Ol%Q5g&!Y>KmQdQ$L$}jI*xQE!pY+_LeFlCsA|zVWPH&q# zJul4<^>44~_B1cJoGKVEUB-NNhn73Q10RGPA?E;sSY$o4tD#LBaM}s{`22oLfCw^d zl1BzXS;?VNbvk9vvWa-TyT7hirv7ui=-a{(at_J~-9Su10iJ$8G1a^ra@d{X5przX z>NQt=@5u3}(;r01a_8naLP8PL6o3R8(QiAzhl>mC^OqLg#{IN++ml|g#^H5!`Cw*K z=UFPVB*+yWOPbZtz#Pb)5$gSQ%--f4f}8Ekqef=?!;wB~a5d!~8*Tl&Ywznm_jn%$ zML$Q7NKp$!BRbW{hDPZJTN*^wZpZa1tYwx_S5su@XuIjvhXdbN!hPS>7&CL>_xag( zJ9F+`m4*E%1bD5VTL@Ynj|&F(?k!*awMoLwzaqdYggWwTPL)EH**_nL+qXW{uf2FG zudtC!uZ)$muB(RzidikcpjaN^mPFPQ2*(mS@Wia05=E?G7sxnJLEf+)2G-ENY~Yxt z$oR5Ly|QP882QJ=*Mw{yTI%gWR8>d{%tW!Wn&#AtMAe&2!#|UcP1@ax-hB|}q#}L? zi-JO@gD};*i}kII3xLQIaFxOn2Oomlzgqxp<52ALdnUi@?8|=4!Y|5v%d(B?GaQct zG#N95cZ%k8FuBy5K6MNkAI>0O<7f7cW$6TDG6~C#2Z$=0Ma`IghvtTf2dgG+l_o{ilCkv?jK^}j{m0d@m!993l0ies>~5fXZn_(jqs33OyM6P=qW<99?>`MY+q3*_Rq22>HVdk;5AftN`PuaIN1RIX z`#S1vwEat|0b#WZIpVF;Xga^>r`rPLLUBQqTkN&*swcydYkKLnAXMpTY24>dPg9h$BNhdGsE|)lN{b!FtqDzX}k(EV7#Tgnd_*m95;8 zp82ScD{L)vtE({&MLriiI^HXfhq-Q86mje(Sez;eNDR`&R3Nem(c{>3j6rE_H|+wR zUU}^vFkmw8uOrr{MZhAggmpb5h4rQU^fD8YW!W0FD%Y{>`UosO!lIVKh`V{sS^aXX-qE^BV#XX0=oz@c$u&rFqStB zza-JIw%&8y$gm0DAkHPb@T3-lf9j5LFpCyiQ|~S2cUjZK z^xtbs*`>0i1zcOY<9Vi-(fgl^tby!{W|-tt+Fv^7MJG~#t0;xnMS8KqO7|&|i<>yq zDnNKj+96tSUeZDBqj@+@6#vKS`3y+LtLM_XW4@AVaFOJI0lb}r5Hu!LtYZ6>_{;pw zQDwmXv`70KGpbpf33fiYWPAbSsSesJAdiq9nRV4Sb4*f! zFqj!u&aKi|qG{E9(?J{QInfBpOw#1GPg;4HGo59BGTT0Vl_Fdjg@y$@# zONA=8+p>mGr?Xl7@umW^KgZz@t{O+(-N*O|1_N%0L`zZ(a+AMO^x^i04)1R0`v22w z>iE8&K_UDoj#u}8n0m{&s-7=iSXxvB0RicfF6od)I;0zfA@dy^J0H|p`O_jduGl0#!6GUn`EZrT?1hS750-o?#3$4o4$WolY{Rmak_~5 zuj{zzBFVXIxI`q({w`H&<9g1ifDHlluN&DHZ~6fTf$k`coUC6NVVq6^J;KTOgO$tz zNAWIx|KO`wVlBTFfH(yL#EA)jgRlMppTmT#(49{D;qu>yTEJ(yJoB(LXj zYsAsWU~5z8nMrB2RO-LaXG>iS%C+>OCn?3E+dAogfz!-`sf<90`!V^Z^57jsUW*=c zl~!=2J1g^E+|iTMm$a1kf_1Q!0BUPX9FvD(M=SO7^6=hj(k(vsZmjrSTH6 z^KBf+`ZD6ymOp^!m$>!tXHfVyA;#zo*MnJM_*U}ziM!X&>P3teez|}>fW3MF>?Qsh zUbkS8zdGwyt@M!K$qfd=tFYzSi;!$2JgZ$Ij9ZhK1Z6{go z9TzAG&cQ%QG>flR1|8()jsaF4fxSO$lEdkyF-lJf?{N99`MGNR5MJnM;+Okcf!1n3 zYn8xPtjxW(+O~5)#@(3l;PQ+4^e$SrB?=UD=>s$$X{f=LhRkJ~gT*S!fL(nh*09Ep z1-&zs2|9BVj7#tVntAqNmxqX~pP`y*a8K1+7&hK9KJ^3Bcb;rdTATfB9&`ZDH?GxBUL(7hI)vtLAtGm36a&tI zRtE+^^8xHjYmzarVj|^(-W5XBrQY*s`;n422IiOiNE`SEGOpJ9ZlJWVtM%|1&INB& z%m%uDQJTo^_tDinx#72DG?5!}!zH;bL}Jh_eaL--7Sp_SiM__wIO@>WSAyYLL4KAq zzBx{^ZZ94qX1{@Wl3#|{i@vS?`_FFtrmg?sz?7I=pGf=YB~THv*{Q;Sr&;gh$^9YY z;yj96XxA|@lLGe9J;(kJG1*P1@H}z0UXDnuGSl;!qTF{e%B*q!z&+NNAMU9HR7RzX z5U5hW_TxG^gX} zO8U|uzu$*2XF-{96cHFoa9%fVlYW}{1i5v3>stjM>jx{u{9IMYeu@5_<^|+N9bLro zd{Xe#zWFcy(NrA3xsbGB579lyN^jg?V2o^<$(Mxm{)Iqzl@-3*`2q;UDzOw^KNi?e z;9avd-<%&N?BCn_=yG$Mm8_aot1)7KO5oM6razi)tv0dJR8qXXIj_B0jndcIx{vf^ z6mKRQ&hR+t)-56B8BH&D=29uNnH_db9-U+Wqga`(w!wI&o>4q~uVH@+uKZ`4_AzCc(}z%YVz zszVqg?Io7~CjMW@Xdep~8>$bvEa_#exG7IGY5$k?rr*Wq!j9V;Z1b)M`P(mz<4isG z#P824e+F?rn%4=)$01)^Y{EuRWB=GHjN_E7V!bTp$M>PeHhtT1Hr<90s{bi&!&`9O zS$6)xA>v>Kvv#?Zd4}B~7+@8aR|L6`jni+Fig}8SD{{eBEUHw`liF+4go3T?exTR< zMm2-*+952rqz_!`o*pniv5OzY+^)RL?XZkq+(#3$LE)z|=YnY-ywCoiPE(!hvTqFc z&eEVtfkMItj-M*ji_9I*(PIDKK=^eW-0OQc zQibJKZSzcTY}(xzsV9(>W_I3=Hkg>W&Br(XX??oOc5(o>xEq!Za>?z~Kj3P)fjcEL z@e-b@cKnS=#z>Cac$yM&w?C((P}0+kxI2gXD^w@ABMLA~Kkz*GMlt-d!6B1!&YKmo zP#j>rS(PLg@k-PGSVp>)rEix|h!-Z3i3tvAg_#NooiyJ6^V|6T`{=bU>zihEI_k_B zxb0Go#=g0w`;v-{&EEQJPYGDh(%08ynkww+-XF=vqWrVuVDZ^znc5<_7fN69-|yqd zedQclHK!r8%Ob!i#x;K1p@*lHjs~T=w5miIqVcnG6n<6%a;`OZEhC-QUcwx`Unlw} zAPe*1kNRe+Zy)aujrp3H7MBX`U|+90@0x>zRd(9+WPA*9Y8XYMsNNuiTc_5hLh?t# znC9)SFn&2(Q_2q+gt{6jAq$;S7}jMxIicn%PrOl+y&<@=Ew{)9;aZ}NLYD1_6(PDxf11GvucK⋘*nT~b2aKy#KJ#M0ds z(?X<6CQ6h^5V`>9q<^u+?W5-FgMZDU!CZW9)* zIq8zeQJw7I_Ja9d=xg1<@6y^&(%h<>Kj@D*v&%~ABAQ$Zz4yE1)Y!2GD9f?1@qjI% zn@;ok;0CRw!E1g)g)qux(r=sq1PgXJNinizQ1Ru&4x(LYItr66)fm4YC}Sot#jyx9 zyOWaA><9<~UAKLGuU*B-;UfKC*VnXW`TuntBT{K;7uLSHk+*XNgf}5`N=z8F|GF+X z)WMqBDW7Kj@m0MH6|!DrslTf;UNRXt*s7p2n1Bk>c#uLG*Fwz<*;6WEewQC}NF%9g zx?E{4=dM<*0|y0 z{puz+Sr>b0seD+b3{ z&-23jIbuJz^wI=w)%n?=clFuhbI$%YGt9QytbkvU967wB#pu7RnE(~1&cZgNcKjSD zRQM(v2dAKYj0=YDp)(d+eU?LI-mhP;GGlRS(ZKfnh!1_HVE>&o8ffTnkMw67i@7^z zd)YiTiU@O5Kar58?vXjo5G4?`bLMh{a0GFdTU>vThrX<{&SL>ML@rgpUSqlLq}=Is z2)EfleyEUd2_~G*Qu2+t)Qjat$Qz6W(`MHc^aNb%98IEpBmLB2eK`C^PxkenN$$nHF2DO~a&tyhytWINK6cOD#70|` z^&1X2_f!cOj{T9+brwL$n?=5Y@-d5Q3VkJlH*;H*xE*@tO5qh{qTh_Jk6(a$5orE( zo)9y*i6Jb=X+uMgn2F)A$N@1D-1OU8)8~*nKGVPRgsq^Yc6=3k!Gq`6PxNZPGz zvn!JL_u$uiTkI))5LnZi1#EOmV?MNB)+h(!CB;$`>NR}=7b@^7H4t}>5 zgKsybcE+tWhr186 zNCE|Bvp|XbWK4i{MDV)zrtOs%fL1n;k6HL}e!Nin2d#Vp&`NTS=Du3B>_Me?v@ZPs zrH;z`x|P$+!ua=-D9BPYbt)ge(yJ@H`5N(1C;&q`lljDYa3?q3cBmLvFOO+4Fqx*j zom2)L`VVd>@GaGzH5}nINdj=gm%k{!89?!4G=yL+zagR5{WkRtQ#Nyrnn2ODx9>tm zIod=+ve{U2d~Fl`Y>}ONwlr>K-1%D$Hpk9Tz4nn+xX2s>NRF6?86<%ENaQ_qD!ztT zL9{XTHt%H)RJhLPi4BJXxKoa-({~DhEIGp0*gupc#(1e7k5H=XWyrZ(5EkI+9uFn zxcwTK-aqPwT0s`3-edX9s&)-?>^Zg2z1-rLwUGmk6!%*(Xmw=i$sJWQGZ$WN>-8bJ z&Duk=(D%wfm&ux+Oh-b}>PU}ep%Fk)EuGI&>G@HC(TcJ`0;`*v7s(oY^Ha8-UvZR- z7n>aZYE9^ZEk*Y{?3RsK^LuksVB{rWwQ_OBY6h~h8z?x3Eh<^8kVm8%1(&#Z(MBhd zssn2*J+`P&;JhkK&8OYFb(sB`p8MGQoK6J#l?>i)-_O|N%xc| zxw6wHH{e(H`--Ey2gigiQfz?ujWLt?kj;7n&tndf?-G*hJ`~K0LxFR&N ziB7s&JmVoNtZ*xLz{P|8mvxe22GI32>oYIjvl=~Je_t3=*+5CbziBx$gNzfsrb~~; zBiZMa_6u(phe;3Fr>s^*a<@ebqG8ub+xW)d3M0#wJxRooo;Db$F~o^i=2A<`DY4FM z7#qejNMhYHa-62IV?=b&GXT_xyt^qpA;ltRgOaGNFW-;i2(?|jMkPUH6DeBxl*fR$ zyNYWN@zX$Azci-0VmE@#i{HY05^vi?5c9hH562|xrxxuRk42qU1XsT^yVfZet|BUj zyr3C_|7j;Dw+YJ4kPP#u!pT8VIpu0xIaDJ3Z@-Omk)9hWJ~%q@@uvPyJt;%6qjh*x z6dnsSA3e@@dhuNn;wC|WWWDAesQGq*_xEaR1R>BCyuKvAT_g_?uFzIn4T5hk*FZXX zDTU|^5L^q@@K9al$g8nOW#q;F6!i<&C70R)XBj``GKfgw%mQF49fdkIXZk?gX1Jg1 z6g+hqLZ9}(J5Q`Nhcb72yo<~J!izk^xv_-qJ1BpiNc@_>k^uLtjc~>TRjsKBX&~(4 z!MJheqoOJZYOwDiO!3B!&12x0bVbpnY0!ghOLMFTseU@_PdP-LIzS@AZ6x;nY7l2e zUcPh=3GTOuPFFh(lCzmq3H;2)eVN9W;oHFJ0qZvsj1jyX5kc4yfyXbC&OO{bf>eVo zi-=(P;;0!ylKg$cKW_U)p9jHl5qv{M60dx;9eI*H&e2-r$J80HZd;!I3b{3{ZCPtH zlQbbWeN7NcbZ;7aPb@0nP3r}O5%{H-`77k7d$&@PPj#NL>PzV~^>hB^F1Ejr;Bh^f z1p0RO#rPGzJqYxNKX_qS7&nrBuc-Z?6AxK%$bhcSRt5+CWbgKRr@O@eR5*}f1~G_& zUPAew(kNQ%9h603Ed!HcKKHytT^}l#9+EjW4`h@^;#YCmcYgNC5r8bqIGxQhxC ztFQym9rtS4?Jvbgg>iJdEw7O9w|be2_*Uo=F-xXjL6Xr-jgetqTc(7)z)&k0VPg4q z3gsqvqnSJKqj4q-cxM}X1rzd#?k+9N$)RK`j>lqUqM9|DZ}TzEQ*KQRiLuZGr~BmJ%KxiUMI;MhKqdezK=u_ykX&n~WMU z3^am}owcbI2-d8lqS6pSZK0)&l{cVYTVuAlaw+fqf~{HUc-u06S9ZL3TL92-X0bEu zfwmhD5}ZKW^8>|tF(^<$wD+m|i`<1EK5l8D+;8Esa866T(X;be$DO=7*DAQPH3>U%Og)`+UyofGWeLLaZ^(c4VT>WEZCdmIZc(fiA8^csqd=d z?L5)x&@V#Ph0HPwUZHz>a1?Hr0#G`v84MtX89p3JISR z58qXrZO_5mq3MCD;Ss4ga>eqqq+&XWMhXXqY8Ja}q;lR_iH3TXsec$9gE#G+$X~o_ zA^u|@Y*zXF1pexF*@_pC3kulad0B$pp*+7Xj_E>Z*u}pS<=Tri|7!BPN-IiJ1=S^r z$=;t0O+O*jkE~k<2{wbbh|>ebjg{^Jt8~E=5C*LrcKG^K_8{vo196`?7-C+Gg6?l_ z>mzJT+8FI^0ruJUXnarInpUbh$I06J>P{-&&=LVqJBT;E3<9ME%EK`CyI^VV2 zW#bwH%i1x+ktUnRV&F)I;A@Rp9$;M&W!>*Yx_8m3gtc%&Th;P=wRRMl(=m+TOKjMZ zIJjCXbjc%NSiD1+?6S$HuDyP+YxTaqtC~lNKmLeU)_s{+-?8%cINGG8;SO^V1?J4^ zycZB`%6v`afBCjQb_-|GSxVCR0X$Avx1N_j2j}9wZT?J$ix0A=?}p75d4yIgs!K^r zvvGx0c9SBLqI&YBG{rWMMB1WC+g7nS8AKJ;{}o|sz>4LvwutS?vB7K#%y@jNoC)`C{9-zO=su^B4uO#jj0 zE8Sa{{WCJn`!dKYr9BCKMvS=;UtgEb&Yk(&ne!LpI5Xzd%c^#S@$~zV)GVths7$?@ zip-YQK(k1+iPz6Z=n1c5T)dVrxG8L_a(Dr;+O5@jKRAwpA05%}%JCq&5;Lz_ z-d^x#F-^&`i_SQ`w`DXt#&2(C^EX+i@S4{w7gy(HNHO>RgsAUqk;wt|REF6oP_yg< zq7OYqzIPZpg31033AaV!qUH>YiJY`kpHeDJQ~ilPjC^Em>(ZFsn#A~7;v;%7=jp-R zy09;Gsqh&^D;P@V)QQbmxJX>97`0W?;D)j222)$6Bz#~FRJ5Qxo0|!yeh<@Pq(LWN?98?By2Cj2;pw6E>7M9MywBqmPj^4xqr37iUKF6@ zF=`AXybHk|UCaVEI!h;@6yyLf>fH*s<`eAUEf!gx;d_V2fj>0tbR)X_;QaDipmFZwewh+c z!`rE+-jNn^827B7-F+S$nrh3kc@n?gzn2l_?|V)A;P~MUb_dH`TWW~@_ay1g4bLyw z3B)z|UJk)C_K`Bw`gdOXQ2Npy!ld2%#E^xd@QbNt<#;ZAxTgd<2;c*BBC_+pf%rWr zM9j3!imFmAdi%M-Bqf`mDWhuN%@$HCOLGv<*$G$Y3P;8excIjY(5JH$H07o;$jfW|qWV`UjX zyVlPi0`cJT7$ev;0T_l|l^g_|{6zMt|}lcDZ=tIef!W-(hHb}8aK z0oyMF7;m)ji^Xlf$l;M*|0P*wzTn>Ln>EciK^T3b9R&_a&@ZWf{c>)KC*1j7x}8B$ zx;4E)!08&NBZ^ox8}IsDWE=5rn(Ce`P+>{7#3X=Rz`YTA#NW7aWq zxA$p^o5Zg_s#KwMBZ^1_!)0YYUtRtDDH!f5b@ARKzkDXk5Y_r)$ZM}P{yZX?YE7t` z+4nu5qWpEku~C)}Bp78Pkf{-?{huPWusP7o@v$QwdawS1U+(1wlUZv)+AUPj?ac(# z(E~We1o8&I@Q)3C(a#r%l~5K0UJbWOI7dxl-^K0u?L#hdgq{6$WvcKNAbQT4J08`t zqE?Fsiq2qmmTA5ni$ZFaBiv~NIU2B^EdmbHqL;&W8|a)0FB7f=JVJ0pddc7whaXsf zzoC)!=si?znoC;9LT^{-t;+FlO?wId1Z_l0dxA@Q;eMVwan2X7;JmuPC3N85(RFZ5 z?=@$GOeKrQKpl#Q!vMxC6c3L9j2ULFN!>Xh_0#h#2n~mMWlUmd6`nSgDVil;cdkq0 zZyYFrqG!zS`E7)1&U1 z=pKJOs;r|b1>KkyE)9b8iy>tTkDk~V(@6;9m2tzpd1TbTG{EKUtvQC88A8T;oZK6$Lr3<>T`@$FJV(MELM3w> zb88rOMkO&LAQ0Qa)fuC6!;#T(N0wX;-8KMsFyCE>s!@DI9g*AU!_}Lsr85yEY$|f@ zU@zg^uwgo3M+hu=1E*HVwimR(rhZCKnd{@kkGZ_h27GKkYRp_IBDbCUtU+cnH!W!a z9z9iL`bR65O4fctX<;ofi1u?W>NtQg2-#S0>+yYaN0;4onvEl|tuleOR z={Kb(UD{UUzm6mIKlYERvEp%Ncpu;O)8HN8q8Vo%# zy^R+ee;FsSPYJ<(KRJ-*&$%%QY#M^`Tv-K6kvk)_Q$UHt&Vzd9hZfrL+I`=WEVKyJ z1pNW`6HTFX)h%M{?hLU15i?-L2Gzw!zUcJ(f@1gN1~FR$@&8ggsZTEaF$uy;lc z6y#IjI2h%2LK4hu!0%xTPbC(Gx91U+$znDqjaKB7!Cgn>lR>k9wKp)KF!zMF_ZX6H zJsLQthpx=`^pi&XRC)F*@Yg2D*+xU{Okv+4L<6;?Ah4@|wI^2dZ)&DJ(+3_ce5zTQ z&f#mhxaS5JW7fK^Xz-7|D=mC~`BOjt@uv*t&Lzf;+c^o}+pWhI$YilvQDAnXNT(4` z1+4vHmzlT@Uc0nR6O<)ySZKpsF+?q zK)g47Yz5Q+od?(KaAUQ|#Ikej62W*g?EfYzBK6-yy<>xG1-23eb+^c)KPoRNgX%I~ zqzH(@tO6ooFjx};U`>3zKDfzn@V?8bWnwVA5$FAdy6?A|azPTgfqN-~My6k%v6=#- z{t=@xy);9jYQC))5X;o8ExQ1*OwD>Y^xb(`vfweIT(Ib32|riA-=1XR1_)IW!TYO& z`DnKX@4tb4b7p-Oj>e~ebYRDw-D<@i#2FCg^C804F8uk*Kend4uq$zdE$}XR1H4NF zfp>`j@Gc3k1%k@^Zd8@M#%=QEoT! zjNTPnYlB+&c7HumtVB-osPeS=z?Z*Y&|^w?wmKn&nQVN^^e)=EJeeS(~ZR9*KObi;|PJ<`}&*e|4-@=EP&cO z!IHQYK%JdPf2Zzj`83x%4PEx%<#M-Vcu+UObO7Um%9JElbrsGY44q-_z@R3-X^hTPfyJ3U0QavS zxbgb8OtVy4=Kk|4Y0AvXr1e$`@6XCq{p7_TSu@;~OC!*R(^U2XHC>LMGwY@EM-!xn zfmiqJLp>;n&L49G3K;S`7@FQ;az8^2f6?}NhMVDkP9=J$D^Gqf4 ztzcBC2@wRK&&Kf51m$0njX_!b5xrPUzswpZx#w(|TM9jKkTesFQ$@>@@>b&a#puxK zgKE*#ccJHZjL-(w0l= zPMDm{$4kdR30D!}Q97s_?!LnOj$C2QepRRwt5gL1$E=<~&V}E}?wqu>*@mVfh9mtc zP?%^l{a9&2gK}3eHsaj;Y50OAV*Oc`bJQ!`aW8cS?7PXw-g?c$)774rC^?L@9^#iH zkr9|ZJ>>NXF?ICL%IJ1YrEs0wo1`Zw@dYkt<0aKMR+G%iFPqbxmNb(zcU^!*7DgjM zMA146&#}kg*k6J$&x2#Yfc62{Uf@rKhf(OQQh0B6?W1xCqVDu%y+Jj!O%Ni^ zQ`+43-{Lz@SVVNWjQ>jMZ*q5j>Nq@?hjO`wVAxcA`WAk^z`{#m zo}DQoS50%C-8ni})345ISP=Kt%UbhtgRRT%38l`en+516>gY*GhOHpUFKYczD>Cd< zFF+NhM!cSbm|H!fAvk1BzznKoyU*DkLI(eV2sifebEnl9v7|k;jW|@_$__e1A8L)T zTEkmwI^z-+_#3Y&%Umtu(QzJeh)LZVB+~xh?{`Vk*B*r)eNwN8#}~Gbn!vboCF~hf zAX@FAfBel_|GOC@8Y=n()DfZUuk(B9TO>c!3zpK``+L&}THDg1)dTYQ`eB-gaQ|iF zt=s5K`*k5%ErBLgbPQ>2K)}cPE`6GHMCZoD`Thlt`h?j3-v6EYzxTJy{_p(}aTVA< z_gM8INjgB=kp6pr%>UkB(R7C6TVSHL^Tk=NJl3IHw-pcjXP~aL0&Gd^ur8%K6lo`v z+6s=6RqqU`Dv$h@nJ0Lz=+N(coe<5AlaRwq-vwv*^Z#OM)+XbK5sF6e)F>kLPx z-Ep{d+Rfam%V^>H#NOJRo5QO>xj$TtWG*=o#A#}A%`<9+Apn*AJ``>5B4ny~2^J9I zr7Wh!%eg-~a^ME{6Ko(IU<3Ji5FIAWKQV*vt&MeHyruJSQO?(#Gp;C;*1>W7T|${E zi}W3}r>N{DS|~P1H`rzzja_|BmJXjJTzyui*DJyy`pgtB!vZXB zZk7j$b@!qqS0(C=XlG+|kIKYfgHjc&4s z!+VhMsp~XlblLNvdFC(?l}i}5zWR2}+vuyw!kO(4ES?{SDmM?OX6oEWS3c_{HgM^Q zOfe*~{nsP;h5yHEg+8(6d~>`}wd$;T(7llw`vQNyKH2BmQ`rh%>t24Kq|sjK4ckTJ zN0-BIz$@g3*DWFMi|~nV%?T4hd?Q2lG9Yt%VG3$t51jDgsZVo}X`D3aFtm)u9YkSq zpMdlh4yu9;y6CGDOX=XIa6HuKQN{!vQAmh{GMKbHy8Nximb!0mYTDqwK_D1ZZGP>U z5SD#B9^tzS4B_ELfs_CIP42_~^Ea72KkX>+WY!U_wH317MoTMWP~Xx}K|SJsy6bPN zBhh0QUJDG@m2sa(3oBwL;q`sSzZDdRS`irTV)Zr2;nM#1ki3!BM=yTUC883KryiHX z!qLxe^}A>sqNa6h!1AYwI@t*TY69efS2NX#Dmz&9>-9N~dY^6GRzJXWzK%p@J&f>5 z6M$J=%(P+Iy<;aUvF2hov7d!z{;8EWy1lhI`(h?rPdg7P- zcGcfO>-H>eu>Lq>_P=}cC~C@HCQzSAoX4PRQ!NGvK9tDn!z z(en^K3*;d@SH-2j)fw&a*6tpezQ(;HOIbQN{p-ropv6M2;ffSJxiQ1&?6y+GhZYUn zDw9QphG$BhdK9YwB~loc4ozPtst#+ZVEN<@;#5MSn=cLgDnSQ>JL52lW?sSm^?^m0 z3!5uDEqat0POuY>{L&veUMn)LK4Z}Sim8=}vz$1ej}(IcRwbbAZI8gxfGKb=%s#rx zv6)`p`Xis%fD2tL!8_qKiF*9&7GlEEgsTH3TXK;N{q~sV+r)t6C6l&{DcU!pLnm)k zM|1Xe(AjQVz<6&D3u)J?Ofg?&Y&etNQVz$+}1#|ysKZNEmgK?jv(S_Z@1j5)K zdhGVl6vq$Dg=J?)cz_iAd)zU&LsnYU$vQQTiyic+W4j4BGA0M8ZySf`J^;Eju8cZb zlp|aob?94?=I__>&F;?YhmZA#-WR&2;dpnlez2W&yh~;iR~e#y3q{dcb(w{bF_vIx z@SBQ>tj7L5dmQY$E)g7Tu^On(v+gcjp~x`d1kTrU%h78?n-)^1sY{VW+JsB5S7V*uU77(EPb18SSH@yc=S-f*e(Dop{wK#ZiTL+}krJ0dc}@Z&4KG&B=v$aR zlyyNUL=gMXMS!IgDX^3Zp1+C{P4x2gj?LG(j=PJy!V+<&Tuei&AKM6~bN(t(T9E7^ z;TI6yzxw$-LmrU=b}6TJQrcv(4t70VCi@eD=|_duz34r$OsP9DkXDFbyUz>c-OMX$ zE5+b6bYMmv=aiWLS?oEOQ-4I1aQi)JTS%_&o^~>);`6fRU}1#z_iZFHcc?>xD5#-e zINRGznA0}ivog-JWO>+W(L=0RGR(rCcU-H`lU&$$ z39q&VBpKki(cYK{*g!9HUB5gbOtx<*vS3%3b1O$Q&rc;p6jNYtNh2jGZ%Et7KCbOc}oNETvMp%-fzc-dcwq z7()h17}**l;&|lxl_3jOQ*hPZ1{SoRefMijtRilwrh1CUnT|>MpBqG!Hg=dcTaNS< z%y$nX_U{0^YsRX39Yh>6Ry1}r?@0!&QNs4r2r4pYg9LG1&vRuQf(>c|yWajP0w*b5 z`5QgEh-TtUc=e#e4$GI=+MhcSPWIW4>vCr}3~M1sSX2Ve(6csCFH}pzS)%RtIeUTZ zvky{XDjoCif18T%42s=n=V*re8v=xtXENn?an5m56%GwIoOp$cSs%2@uN zDTDI*a$O8JKQnW`?RMaKE9w_McH0o~B2Qezo7byPKPhak$FQn0GAxFWq144m)az#? z-x$WR0c2i=j9b&gAsA1DHN9l}5*hIgkCSNLZ|=Nu?EDKNhC)GdZ4*qbeAibo$5#Ce z`FLrn@)mi5zcby~4%1W(px+6>9)20{=#awlwUkK5!y-~^>86v(nEi#g1(7~~jiNUQ zWTn@P$Z=mjWxtmY{c24eJ1KBz>3%Q||In95p4h$XpAkV7vSvxlVd%Au*1xP8t0s!V z8*W7V&!lKG@D(KlFW|Vusl@M_L1U00dqUOOMOpnIjCSx0e{lNTtt< zqEt}1MCh(_^Cy=+w1^X|q+ogyKk(!TS$-*OY;L|G;b?uRabsv{z7sd_$oIaEHCu2% z+7tE&(&Y9QZH@m^Q?oWMnFS(D5%f!{h%xf8hYpU=Fa}XlB%V6)4>jG?ETOlB@HK<` znIOLk^=dT1Z~9Fq=JMO~Sy|?lGlrE;S_ixBw_bfsIru`TKL}BH2zYkbm#;bl(MWd}S{j6x7_`jO~Lw2Zqf5x2wy#=bLYT@-N|M z>1OC=aBZo&6xL=94@dI*G^AvCH8eapvhadGdAxhubSA~P2Qs#ap4?ToWSh7P-1rrc ztZQRDbT-P!U6R3GzG$H)H5!3_yjWK~#2qmW)naDM6tTu)TcWCGjQ=2?2z0x8HlGv0 zqfrWvBpylw6-2iGtT+;n%`tEECz9yqMA1tgHu&}^G(}tK>_hRP3KL2dV)HrGa z`R)q^Z#n>nW^oB+C&plnp+%o?$A5`;4HQVlC=9Sy+Jc+V0Q;pyE{|Wb)o{hTtA|vG z5mc-Bnc2X3a3?xQ>)~it~*GA0RfO^u;*)l5-?K^Pc zh&s2CXm&J&;A#Me!@nQQ50W%{>#-hoTWiol4||OnXaU$D6}-E$N`)xbYTeas7l_?B zkm9-iG>oyb9sd4ykOVkA1of07xx+>ACZ`sN;@cnsK6R`;V zIwpK&X4sH?t-ehEH#~#?4G#y)p$CgW|Ip7{yHTolx0HxA1Xu5)V_<6n;K38{qO!|= zA@gw6L!P~{0jcF<P> z|DL@pjgwg7PHFmPMPJ!(x#Y#OM_%F8v)>u%gx=G`q$vsu9wEP3f$}uNuo{P`NtnCO zgfm0hMBM9a*CFH;^0cUDbCM=t-Agvf0-ij`2{wsB5?xVb$$ncnQa-ByNx_P{mfp@5 zGkSZcs)(@UR7dsi`;E4)R*}=ro^b-Aq0^f!67P`T>cFASADpi`w@~%fw8(w%8JNDB zgj3~@Y-HB8DM5%MO7J;6yAYPQzSP{(tFB+lyuaR4zfesXPBysM;#=D(T?UDwCtM0? zTHfP-?uB{mSmHd)@=@rK2y2|oK*I0`mPHJhMB%=?e^mPdMOKx`ptHe$HD6nOc|13- z_N6-p*)abPtb;hbzAJB`&yEL`6g`zV1JYHNmk}7f6P|R`cbBO?OPn zNTl?K8Z$A9Z&q+(0LA-eWgte;fbkr9iJu~|6q5q)Oq4Y7lDF)uU`6aIflcizY?auz zlEL=bh;q&g#T4mD>=$mI zb$&w{Hl*GV^5c{acK{Dw>{=KZyOBrOQ0R6vkSX-g;viZpJ*{|N0OqxhAjklQu9e>u z52QVtSk8%i#%5{>Zw^wAKkgU?I_Xtur-M(!5089!&MFRiCj)+FofT8`+iH&09b;|&?WtmxA6fqXwFDjH(eht8j#qns z<7rX~LPzPa`xlj&_<8DEZsZkVCMgI@I-JvGak{q8mB6A|!8MiyMq>fc4~i7=DPvNr z5(Ald)2K~M7uQ{=eKHa(^KCLA`Up}pG@cynir|yKwjP#FIUkG7OmWWQ@TV1K1_7w6pl>HHoaHx;s-oQw-q(^Dp+2E%+;H zY|23|IP5}q5AUzT8Sq_$bSVIxTlJDM)}KV#GO=7;-BS_0`_K3bs6mvgo9pI8JR5z= zoiSB4r*09jow&-qUq`O%=OrlVt7nt^()}#7S~Ej%khP-Hsz?nf?)>h#HhPVfwb_@( z@t+2xf71TSgBR1$%^29JYGuwIuT@|>WvWLR--$0YmZhd6*zL#dv4h?J0M}R!&B1dR z@yTiEQ2F2W9_5gb7o+uFV8w3${yL zDRa)vkSw$vy7K*2{EYu&RJ#Q6VEeyrqS|1-E^|;$wcx>Snh{F5>{D#s-#Px>Xq+Sx_m>nYy$BGs}eZpd3 zU3(41UO<4_fCLLY5_9!)3E8)6C1$d&pem|IDoOWBoFe}#G5ERPfL@CD@?^LW>7}g! zg8#RFM&Fo7VFK=zXu98BE1y9OUSVa6Nxi~aX3qgNF3VZf&b5n*j5xkTBMAP0crH~Q zy*H8Q&fb+Gv6z-oPfKJtQ}9vN-NT&seOBsvCD;G!Y%lT6epOw?G8YqZGWN@am}gvH zeBrH`QXl&ehpI;#^!g9lNO7i-(-=tn~_C8JP@&DCi`C8Y7;b4k=H{HS* z^^xPG#K!XMDlJ3KVWElYM|i-!DhxzzoRqc8h?KycY*4NFTr9JkE}LTv$f#2-T-8Rc z-be$Z`pMGqW$YVm{%~|gU~Q0qJHMOruA*$r*4$8{rl_GT`?%U1`KCV@ks6eqw1{!>S%(s-9T^+?(V_eB?Q+5cb5>{U4pv=cL@@l zg}b{Gg1gJYVc~Kn-`?jx|GAh8xR{#m>FHJd)>BpRXYFCGpo#3vmn(G3l(!g2SC1s| z^&40Y)!Fl%fdIT7@>MS?z{G7!8tc@(Lx{OFV zj)Kbd#v%`4_WN4k>c7qI#-ZZVolD%W>8dmA51(#PhyyxS!KLy)?uGC#zZcCDI-QWu1}Z9d zVZ7Vf5=)$^z_TX#@?7Sz%#`M_r4V)6)a%*R#roR#F!?(0{J6SQYh5+9d%`oR+B5m$ zTW2VQyN7G+UudveD}22gzRtExx?NMf)hOw%7vL-S;s(?KHWH1b`?~w6_|e#pJAx@= z)WqY2Xwmj7lUyA+c?XCAk6sK2Q|%S|s@i>Tk}y}lAxBASdh&SF&4sDRNh4zDFXnGi zhTgx`CqR7oB+f+pNKKB#ePj)7ZT3 z6i&%&vmw}SPEA!L*a^-ifrB3>AQUCZ9LN#+ZbL}P{srHL3Ug8}bw>}o?R%=ZaMatu zn-9=YYiY=^8m?|VdX8e{1|F2_L6J?6&+j5*57eIX`UOW++~oNmA35^j*-T~6$uurD zcc6!&gR?hAcgW!ePLsZnH?pDr3R;N@%04e(6SX&abIpCn!c8&uB%2$VN||K+U}1v! zn`i{F(LAbx3ia=D=MQ)*ySwCec0I`n@j2S>*^Lut6v6^MU#JflhfqbbI?42;3CfjU zwU{mw$w{=Nfj$(^^K9!tCC<$z$Bj%^!e>k*Z----D+#HGXs$ICdHPMHf#-SNHA*ug zZ|fh>5{<(4w)=MpwhO+8#dD`qe-qYL41JqcS;|*K%jfpbaeOlnS7uKCxBAy{3sC(l z={;-iZi)vvm8A1O-Umqc*l(`&zWLXj$9Fz@_3tk{1t45q%S{YAd_{=2{S^lYTz%)+ zGt_Q7OwNh%FL7hZ@d>V9KAX(I=ofuhNg)PlW@abaH)RfRY~b9@!KePKDja!gS6AGj z2;{qKrE>S88Lj1D@PLVo>$;Drb|0(=L+yhgV{cvU?i(>w((}HCG$10rMfh*(bR+FK zOO{aIwNv(LZ5sAwp!ajdTa!}C^vf`hx6^M|D&QBD*;yOYc^UMh&0tuQ%PrliwFBCY z?m40eAXHH!aWma1MJ%{}vD=k2G zCzBQyJeYfg=_^85@iYvwqH{L-j#MYxTedbwyiBq&*e@3?=ekSVpeAh+C*%5(%%HZw zn5VW7M)bAgTx&vD7j}m!NmMRQ)^)Otb0k*L6(WZ;_j0d^L4Y|2bdqI9lrPg=)EpWe z!Cm{BB88{`DVEJ|4e`bC79lKq0+sFOsdJZo6yc`peIM3)kf+KWn4(3TRi<@-$ zBZ>W`?1{5+-`CXoY>s2tnWYO>S|{+K(wy0u0ejnxCgeCAF;33a{jRL8pP$xP*41?E zVBj17Qs;7XpMu2ZSzqHnV=@0@?7y*HY$t{!aw+ZG=8l+ zF6iS8W8PA8W(s5O3fD$WN+f#gmnFvQ&JK<{J-FJ(AC`V-c!Hi?26MWXq`1lr9eYNs z4Lh`=s;(hze#dE)95=Jh82Pt5m^_aOE}M2iK+O~bgN^naeNpVpA(Pjkll`m5$M3gC zeM3tSdrQv2T~++`2VRu|H-&viAvRvS3~W7JKKcZFlB$=#j1xUxMU)xCE&7CW5IJYq z1*4Wf2pNQe_jCzb7ksN;ePo>vQ%j-|t|FmM{;wnL=egs;g0olj@|bV*ajQJf>1B-c z(pf5MNnmr7FR^OyG{3S6O#_`IYNQ?}_D)Y029B$ox()5;+aNw2S^7C0DQ}I5*KhjT zu43xd^;)QjzJ=|lJa*EKX+sw|XRWdnZ6UufBW4oTr2Uix(}Pe05vwB^K=n?07k$c) zRmhRa27au5$@b^;!7~ND?W2kzf@R zWdHswE%@=ik4ZQ_8l7-ZKK@Mv^t|2T@}Lqu{@l`zd_U_`o*N&RQs}D{G*G@m8?v)cE6*e~2mqQDo6 zFi+eiARNW+6ql6ZD}=td1EvjG-8TU4EN#a+Ck@=$Dab%Re)Sgk*L=uom4O^^XD9D# z725p6L|x)7#-GnC2}B@;uOpSI?Bq=b;YxNtV-Z_0dfebTMNmc5b?w}H+MF6*8_|lR zjhV<8zCLwNhH2+8GA;N!rR_c9lZ^RN@75=>o3)VF>G`L6rGQQKwPNY9v|?{W2AzDH zF~)w0j0v~R)w0EKM%DF*3aR`2#@7%MVIF(*%(BTH^;DN2Z~oXghvAxPSshfyb6Fc7 zBjkR)df!~o>(l>5(p+TwD+!<|#-Y-E-x<)APk`uoQywaYL( zFUYHl+Y?r1$V|DDh!9eA()Q_k3Uy^<&5sp>3|ez+HeR!WICV~>dzl$v=d3xUQKXff zKl2*d?weI@&FjOQnWi^7AC`E6qv$9v$2>KTzFF5xmc_r5J#YG8%1t0=+ZgP>C@e#q zb;_GL;M27#3fB~+|5XF)_zrB3##b`>aa@WiH0t5=S6?c-$P)io`-klN1OJ|Jw_Ew2 z)W6|Bn3y=Y_ZUeLTQ${LIW{pJVB(0vYu07n>64J94N?^u+iweh8LPBX`DSBRC_$DL zIwaWt{-&?)Mn#Wd$ zDD^8*k_L=Sisa?V9NC{R*~?z+Sl_AUd1OyxcK^JNEo7{e*nf41ONwB1vDhMSHcy1M zbGD>;JmK2BP4J&pg40tdeSOEb*@lnQd>WJdt%B8|O@NIZ7JGG_I88R~w&%1(&bZ+g zU)x5NfYOH8C%)^cBS<$vy*ow=w{+9(*6=6w;pTi)dH~Vo$l9cVudaP0+=_qZTGmmi zunOVr{@)8LHQPjSTjwa+$4#!kw+TLg%{;d(OCb#H6cR7LR(zy}Q|1i7?)Nq?esd#*{u>#^z4hSeKV!%N{bAwY@m{DM;c-ShWzU3$un8G zlj`TEwUftB=%)#_HN3g8aCdq1Zr8kvVIldp)_-pjy#bpU-w%Ag#lSGRAd0W7|Be`Z z3~Vg7#!?l_Kb>eu5B4NmUSG5K{N`NyHy3T$ixG!lc~X*57SrV$ct9a9CT-2m@|>n7 zGyRqy39xYyGLCUlWuJ-tEz_HA=AigTW87+{8^_1`ou1itU?%HNnbUv~eQSGU2WE2l z^*OELe8_A)+b$yf`BP??wDzKgIePxYO(Vm{dJF=jdIn6hZ&W65(^5%gK;+?M-v978dC_fD2hLrM>RiYwGek% ztAg&EDMRFEqOaX~F~LNi+Ri)7UTtk1_wCU~{K@JeqzoMO*-=`+8=D5+m>7{GXl+s? zWg~U&aai;Xe6WcMAmd@W;&1>Ff)#A=! ztYN}I9e_n$U$n~(t0>)b$iu3|uhZK=gHbl(jFcli$HU;$$oAC)U8>KL6_yd$_P-+< zbBxUDb#ptkrfEfdeK^_7?>DI&Lopr2rf&13PjH~3z7tMTxPJ*P6jw6(Y1qvF6R-SX zTlUYU6QpwW4EHWX0=i~-JZSdCH|&eu56cxW{qK3feEPX4iHO6yIG2>%6!dL01(PIJ!M`1|Vc;n4N@tRjB8m=yga1`YZde*8p>0%hX6C zLU_n3OMrTVboea~otF^xkwsyDu0X@r^$#0JOOxQ;1bCn<{;h+9h^6s*&#Nufd3XUl zv4bcd*z}YD$#(Ii%=PhCS1t)pBlD zAc7x@K+t$An#TU^vGdWM^HA4~eYt7NvtH&JW%czB55xP25MwOxn#py;Do)QvDUk*jL`_s2fO&E*Qyzgzu14G{xqXml4cTPNER*wYEUxlxG_ z{jBjiUzQ#1tQrg{B+}N?z)Ocu=7nPIR(Iu2x-evSQRhAN_xh7^q0f)uAFP@$j$S1C zpHc80tx+O7Pzaq;nzUTUo}HpSydV9h`$RRCo5~-xsei(VY_?megu);%(BBSocQHRx zpVeat+`D2(CQ?VYjoKY&V16S`{&eiIX+%6=f;#lx(x1K{AQt}hIltl@-8@I%Gur8W?>ao#Ke%-TML|rpq(8TE1?AjWYTteQgJ}b|(DO-PKVdw|HkLOQS zA~#X62L~l|#6gcTEl&z(!9|;aUsnpn)_T823R|K6ec1)qW2xlln71J8Jd%YR<&|KY zwFZ@7M-{OUkYufy*9Pv|@JeD&J9g);B|%P$$DJ7lnUXo*A-5gbKbf>FzEC_}tQ0&y zZRJN)=(dB1P*4VvF`(FoW~5;{zC5|%5Ma_1l659$o^HQFRlG*X9(o~@qQ>j$2&IgP zF0&dtyxKZyR_&WV9rNA$`#nlurf%|zU~SDE4IMKK)BUNqMw#|6j0Re;%6X=Ab4M-H zhP>iVs!>Zx`-`^lp9Z6$?T>EDX1OJ2{9q8)5>>x6(NsRGN*y?+9$y=cz=Xl^q2l2e z=!A%K`KWSz@B!1Hc_T>i=>HO+y*F)1^iO)O#S&J1|~UmJ!|2&=pbpBF1U7zr1Y z$^NJh!J1Pg?SRm5od*9+ZI`9>7>AAG7|0kMo>x2JX&9E$YvWGkp0%|cV<-r4TFTu^ zf-skiS1-j$3XR(;xtIFg`7rJ_J=wh6Hv?ZPvwVi=YSWVl)MQk7~SHqweO2vc(}WcIH!Yq(2ZR4DCcBA7)(TJvwYf=hBRTsVG5R z%Qo@nOJSJHLHzrM$ghX7tHmj2S|^T&v3kj3?kD9xrb!Ta3%obtM_&k`(ua3~b+ahh zB#cQ(EJ>@5Ke|W@Iq%M4N`y`ROE{kzAN3@A$U){R{)&5mD@dLh1_DGo8&YdEm~%OP&ZVqXy>-8= z><(uZF-u1%^A8uM){|&0KVY88~!Nj)= zs)xvCalsbG?}$ko2=RfV6k1OZUsKJ zLO7^h+T^klsfQ2et$Pkh87`M2xT83FKDjh0BDKbd&eANG5V}0cR01w(z?o3;VXTfD z<1X%p7V~g9yIs-`Pe4*Z7^8=wO@wUBK zkhHJiWnOth?9Cm~&&4l)+5yK>qZf$_S?Vh;>&azx%Wb1i%1}1qJ!dLo&brpW1*fuY z3&WvDo&9-K)|(QXs{I6V>eP05;Q7&ZZkuqMVuu2?^~ARLw)ZBmn6X3M4oDt-D(L*zyhmID6C3R=F0+KNsWHVCx7$mC0jQov^QuIp0Rf7%>d9?wDdi6&`A3jax$evB37IW4;f( z5Apu0uQ0NE;hOv&*lCF`nTxjHjnC?657E!r!F_M8E_%AVPwL|#%FHrsp*Z-uA)WafSB?J5fha&?2}S_fH%^9i^19UiNHPm z<6e|eU|dqr)H(AGSMaH@VxqVMGCJ-23}N6?DcWeyabBPzC2d&K^29IVrD5RDO-4od z_q4d+BVyNG4s5fw7IwhLF}qt!TP-JwJ@C|LnP;ulW}-_~9{SW+R!OdV-b6{#8U76@ z#}wZUTx?t1D*ZnvKAQPIdU!p&UcE>IEz=pN~%# zj@1UP@9;)TBQGZ&T!Fm1Csq7gDsy{zm%&=DAJ!z?ibyBS?OBVef4bNCRRPB!4$R^d zC=%hBQ9oo^s_NR^tPNlK+nvqM1l0NE+~z_8`^(=aPLHe3o<#4eeXWUT8=KDp#Mk|m zs|o3ifnK6>lE6HjB4XkL7j3=tstYeKnSBnVb*J7Bt;)zQE-8|g^OD-)bE3;qp~Fh= zQv{?bbj1%T%BiO28@DX_wM*V220U_9V4@5B8yzkt18$O9qK9Vk zHV`S9MN?`&;J{BqBV#!VpK7>~BGq)#_uB!&+R31aFo;NAC2K7ldeDw~HGIuiu;k(- zW~?`OC}jmjxlwt~=hB=#73OCg7{udV-I$!;#&0Nuwtkjshr-(x+UwL`s9u3P$9p_m zT*1~r>~$J3oHZi2j6K$9rzib&*x~^xv31G+wIl1ip7P)~!n!-#8l<-A-?2DKbAikf zqWSIrJ>eP%ze_u(qOoa%XP5m&9g5CwlY!l-o5m07T)0@1=J=mNhepYJ_y718y&Tb|S2QnPhFUE3k8AG8@F>qA@8&P|lyZmqu3AMK&yGsG4T~;dO_QucsqycbO zA{@D z6Lx3r;$(avL-}3Zr6>8K;rj~j3$ZAa@JsJFcs~TqrHFLPJYKX2blu&ME>IFAc=sd} zd&M=l`)Fw=!yXYg(?5L=`;4{+uYk*ygqKNHes&3Y|c5u;#PiHv+iw|{ve z*9=AMUI&EUzTlt^oG1vl0-vA`2CPfk#lbfmU+MCTQ`(Bj+ZvE`FvrvtRFleV;fKZEj7Ug`h3%lJiK1XbA8OKwM87P6#%4LY`lFtFfsF^xZ=+azkioA^2{bZP7ssH$^aaH9uZYo|j~C#v z&8jTcD7PhZ)pfkgw$}NOXY@I*=f;_?&wj*u(J3BN@SW5)n+`X{vONtUE!bdh)GA+f zI2>ca2tTCTO>8lUhbS*LMKkdD;Hz$jN#uDRUt4CY<DBH`c>pI#flg*R zRqX?N#eva2)nw<&I*1L>qQ=hZS<}E&MMuub2Wdr{aCg9Ob!*52HrN$);U!HO_M3>} zJ+&M^9_0j9(O*a#OZb-yf);tAvqSJ=1jw zI)1OSiG80&MshidgN8x&;8;Y-f!(i4JsdvNU-2O>T&}-M+g@WX0XmnhJ1)796&rnP z;?#DQVlyEQ37QmqZQSiG+iOMl{+)>2HCq+Bs^)FCM4luLw2)J(PPZvY`khcpCEq3n zEXsvUGsfnV+uU&VQ*{n;#IJWbMX~T`T6&+L+Sk>j;M%=~RU%x;Cmm}t+v zk4HaC<$M^LIz>9uZdp<+Ba|fDZ;Kt+3MTlo-Uo|w|8xnW^a zG);}~8A(5SdgqR5#?~Jb(%m@V1-GspFt3}1i8;Q8MRX1&-+-#8pVqJq$z8gJphtd% ze9r#PG=TUkEE63U5vZR3D6%Ny@#e>l`)VlQMJ~m6e3+lgjxT&8zC81p?AY~Y+AxyC zt9?Cb&%Ne(cHkT0IuVV^h2ChREP>b!85yaV5B0LHCqjr$ z|5!b{xX(u?Hh&iTnZ@Quo=Zw3db1_9BfVix^uSFQs*P>=)vmMo@8-oG_8^-491q4) zH8{q5hOS(m-ZVJ3wmclg$}@ueN7nZUnN1QnbOc;jts%KSyE~;U8j5?)d|MTI`>lil z(s+xPVP()9!qsr-SDpxo6pOFE??7^HKs#&LQe+u4Qf=yavvV|BNwK<2S75~A&Km+m z4=g4GLri~9*7%?9%Z4U)(=%Q3Cj}!YWP?WGoxNB~tZ`D5v=&L^$?GL<^D6?h&c&Zr zUfcRDFN&XEs2zt8`p5&&0x2xKbsUumY3?_Ep-uj(V`k_T&jVo-D5MzQ z(3WtcMB$}AOKfluc~-?Ra1Ip6FpBbLPmPu6gMKb*`6K#yU_5{=g#8!oN6RpC`_9N# ztm*sUOum=$4Yy?ERo3z0cn=&Np2LOyVwc7MJcKg=6t(doJz{ykj0a7ly0V6N>c0SDUxPcQ4k~ z3cMr+YP(1sJ{~k}?5fr3SlC;h@sxAnULkE^Oc6_YxC>VN3oPcJQ{x|n6I>p1G*&4rZEy;qS9%Dd z`a2EJ15MiWr|<@pUT;?Z=iIkfVbVdU#piz8ZIT_cwU`UfbL?$IHKoxXOvlc7+kKUo z>i+#SLE~Ufr%y`7m?doVN&V⋘@SLHxBG%xFT8*CvGR>7d|k}q+xcxjnsHxQdJ;^ zExn$|*u=U`0!J$-}EVr%We!(rP`7GvY zwYw;>6(+uOx0(qPP>xNVRxjqJQo{sV_gbzk&+&={)s$cVv2}0EMx@*cOD5Ie${Hmr zcxO_m1ep;*+QtFDcWnZMjrfR!w2e%BNRPkiRSEZ}PR{8i?uBPji6;?a=B6&UwF2>b zovs|WCk^B2i%v=vmXfZCDYH_!u-!@=$SH=~U`gjY?S=9|#@(Zg-szLmJO_mPPLdOl zRz+WHOC2&U*d==LRj~CerF?p5K$x(teBOl=d_4HFP^V>cFa~K{#@1g@bCPU~ zsO`0pOOQvcTRSbsMii)nm;?#Ke%57mdw84!FIDdygIjgbt@O+N5$nN}rZlEQ+f4FQ z7u~mwvOV=7{y5$NgbHoc8}-Pd{VpQ1f7}Egw&2Fx^~WiSf7H1rWX_r{uQx6G!#;qR z&R&1N#rjzEv_YO3V;wD@KHh#|i+-xB9&C?u?1Jlh%)}x}wR)U2$=bf0H6ms;iZsb0 z|1{KWF#cgDe5|qe-nE6{oY(1ApNtBZi)%xjZ=u>bE;(8Fo8@~Vg=5-~1KdW{6WQ+` zXFo$`S%|ki)vBG|7p0i|4*xjr97g#s9PfE%Lq9-@H0bOPbPl(tj|q9RS3>%m@rJj@ zzrEe-QH4%-30OR6F&K|O@B(EVXb$N4?d&dqPsjR+DIR1V?gPQms7#&>O_mM6uJhX)N(lq!4y?EKGE`H&Wghi^Kdj94}BMD)F33`C9ebw2(d3#bSFVP!3 zuE+6o>Nm_bWp zVUVccL5BY!+U5Z-^qT=U16R|9r%9aBXXgVTphEcZ52I+@a9!EE#z2?p9Yo5to}GvR zfrA_Gy zFIiqZzjtd-gLdg34pE$eY~9T2exO)8V!juS7epCsF?gE|i>uo@>B480Um@8D9CLF3 zwcDzY+Zpfm=cK@Gvpn#e_M-Cyaq`nx3Ym$&?hhv|6R~fuSD32#2{!X4ERyjcW!R$( z{Y6A65#WKxKdX+mTD>zH^y{!?is|F4^Qd0p3|(buj4C^RacX(><__}FJagOI-=&UT zYZuT+{o--DKP=HJ>ue7=t_skn^!T$yWo*91^r_jJ|UEn}8MX_lM+}$%c z^c8XF5#1qXDHzKG+S_~(Mo+FY=b0d{>4qe&B=y@lK2`68`FofJNrF^HhMo5oA%)q^ zA;a;5i0+1Tl*ar@_?cv^Qez`ktyY*c+Au8rz)9#2GfMX2_00H|@9rXiQ)oqPJy7Eq zV;(?$=py~;i7X+`7!$k~03;oiwWW8F^m%G`mhWPo;HDR=ldCeYM?lZ?YMLdULj{kU z$=GF7Xxty?*2YTy!#7gYcpJqHqEixC>l`Vr@*`SpRDRnTpZDj)g&vDI*#IX_PS>8g zvJ}@rN=PNc?sc%`F`9@n(`~qxd!rwKQp~?-i|%wnIB%^%ra}|WZh94TKb6tI=Pa5k zHL-jPzqQKSRuI{L0h|VimlKNb}4#xxlcD)}&(rvFd$A*b#Na&KWkY zD-_(7zs9GJ^CZu?z*h%4J3$Bh!HTErFj`;#Z`%uDL%mEBm^9Yx)EzkxYCmvTT+}XemcGmt}x0aDD>N1s{DvL1#38%sk#h zs4z&UJxE*~**>gK-*OY&F zldQeXFyOY*t+e7eW>~U+)G@R!D`9xjVI> z`(P@<_qEvw6y1;lO?StyZIeg3Tx(jHzNSp$od8QN!+CuXdveXay#V}l;Qw21YMd(`8P6_OQtYV)mvO#dw$ zs(Hc{SYYAQTAF%ipxN|TXJF6kXptx2&o+69)Y>isjp!f}IS3CU`PT}V)3}ILZvxnL zh18(XuE{eg38=klQFqfn?!2@)^6#&hBAlaKL+-%pzDdJ<+ogfSTP+l^<;cayNKp(l z@1r&WdF;CnYZ%fz6#zELegMFxZE3}se_+$r|AI|xC!%i#lkPp$QFHn&OOw4?Zf|+M zz7;5^w=&2%VGft0#j?gtAqyB0GZTrvX4}Aiv?`LVSilse<;+siYgH3U69=Uv=s^N( z*6Rb=m3QT9`*Hgf3^%I`3hCVrysT81cKsKfsqB{qxNMUx10n*!wXyJB8D)$p?u-V2 z99*NzDq+bhI~2SYZq#=+wi3JI&%bs~x?A|-&CHKncT28yqOb`111WNf-R1F#G+HZs zx7NEK-hUWyrZK=lP+>w4`c>mR)#5l3z9pK*$=&NG742vEpMooRAcG;9v#HLso71R> zJER{@z*kOqMMu}7iz-jO8nEj{Auu8SW$Jj(wLys! zF(kK0T4O3QeAO4&VPBIIplx?*>moM}{C3MT{9K?PMI8cxEW=wB$?bh*9p0n+eHM=YR4iZXe-UK8}ZX>O^uG#p_lZOe1AGd zgSyqyUi#%EqBWz!LjwIzJ*`Q=N3F@OwOHzr`MiK@7>9N|jB40lE3b+_A%(H5B3cfh>D^T-atEQW6)*K7>OJ$_+1 zhc-~IF9p+??j0eQBzk<1jWJnAYYY7sm%drlL5Jo8rk$AuJ+r{ zKnSxo!n@TTr||yPcdJV(;Sd2h2mh4bdV2{|cit15 zj@<)V4G2N%y&W0Hf=ykB?-G)Lcul|oVs5{ah{3Fo#w5hr)PzQApyibo!nZKgx=H+% zc9ZzX2j$?=fhy}xKdRJHRJ+4{tRN$nv^ko@**(9kYLgiB>8oRGsweff9;?Ij@3>w$9XIBJqdqx7$7YUg4T|pmw{Fitb5SrM8DA@&qpJe*2=uGQd*g{a^ zHuuGMX(0&GOi^eE?mVAOvg3exC*U~Eq)?sWX`r`YujAW&|D(d8+{CJ^iabk2Dn7u$ zaE}p#LZBB|%m~sjnFJ3@drcm_7Uz*ungici5B73-225zWQdS6*T`~uTM&~Cd5-ljm z_&TfYR6OjA%Op%(gzgfO|C<7#bn1lR-Fl&fx8Gv$<$6xtJ+Z4rq=#_oET})uPMZ6@ z$lkY#4w)~z>lNp8I5?&uo~>O{C3yGK;Hv9G2^5KtLmhe%yw3xN9E#B$rM)A;cs8!| zadY);^JD`3jj{?&U9VE z4CTw&NW1JT`zQW^_9c;I?FP@iz9uKm#J5MT4LDI7(p<;NBIkuKre*~T&-^vh9GDg5Qh${MB z_^Cp#E0uja0kps>S~OI+VU6oBSYnbLV<#sV9=8AP;|@CO&GF08$t@iZ@-GX#@ou1B zW~6&qQ?cXd<|DsiA_s!jq8MnXi~z=`@DSLJ@nQa${WLp05qa;{7cj??4=n%$C#0do zi!@M=vYB(W&`k^PEFTn}Ql|bk1u2=8DpG8t3-UW6Pu^xum~A~D zFqN~dOzcJktHyQ|$N)Xy%DAA6Ypd{r+7RJ5Ow!u2v#ZZiqfYxy%F^&wuE0}0D@zl5 zCr%BEBR>!=E@fmFZ3V|`=}BvLfg?{8vrX3G&TP%%#9(?a&!o@Ke(}ixPgjKeRz0*8 zz8{}!;@f697gep~Q06Cdluj^=YHkmX#vgMg$DJoc2PqSDw1Nrs^yCsI2Yo^J8dYWA zu~W3=Bx51WnV~1#X0x(|t`!^E3inJTy*tS#NB!miHK&z9y=Gq2t+&@keBEIwQ=1`$iOt8xG?exIquj_k)S zNlLjr=gqL-sZEaLZXIMNXPsVCkU%dwbI0(1FvqumIA4CpO;dCjC=pCMnCDJ9uIuB5 zotDkgaOMF24hG$NNUWS~+)r0#b&KLkqcvp$If+mX!xCUVuTv7MI8o57_C?L?a=Mi)6|%^w6ZmQxZKT>+6?1Hm*Q zkQQonf-GNwf^lu;2mn%>aGY~4Id6$Pz>b83j9lyZy&Xi+MFhP@qiKPM0mP{YIoG!O zSB=j3a;rYBd(_YX?Y-+;hn647y9RF@*+>{qV^|C-H_~zYLN%Jq?6p^NLGL;S5dhZ$ zFQq?^f&EXKoODF~1E4C6zu!vu>>o3>P;Jm;IxyAa+Opyjb-g$OWm*IodtebF6X4JL zt}+Pwau7NMySw$>kEEG;zaCjr87=&p+6+>z;!6EtlS7yb^Uz*N6q6hjLO5zeXwSIYWnvh|Z>pgs;7lbs!22-*i!%&9HLcHuJEP%Zz;yWo9(ax? zWmp`ste#JG6UD^;>_;7)^t#6SBfjLbDCRM(Ia|#|mC2gyL&9d($gI-Ng|xWPmNu@W zr`Ftwni9qEJ7jB;!dO%^Tn(mq2OEdRN=l@|#m%Y442W%cx*?U3tBir2YTvb2-FoE# zxagV2t?Q#3j(io(JK^zbfYv!;C>EP=S?_S8lMF=j>{t{N1?n;s+Ep3Sp4Nd?Z^s@U zjz+py<`e#$?-8@|IB+S<7S=5FhD8eVOh~NJ>=oLUbIKgXM7IyAnI!)NK@)RB}%qflQ?`vJ(?5EVJojPexTSjh?Qoe+>)P;ZuJ z-?M6tYKCH{GwbM=Z28E$>2~JK<54WC6SfSW66FSD7rz$8h5B>X1}M zz?(1qCWucM;Ii>ko8~8H)RQfziD7kyZnx_YAP&}j_9V_ZRm`6-WM$_laz?JD+T`4P z*osuMHtJ2eMQsG8sqdZ-BZSgrRVV4VYPZz$JFxJ+Ub2w*rNdO(t}_rHv-JIqkqc2-0DCPJXu&O9EgTkj zi88o0wV5<+z-^2w?yZsOpa3$@ORMP+7>WNPV%Ieh+7_9N?sk`Z+U?rWA}@|piH>q4 zElX?6|8Ilk^dP}|X>$tRlCZ|0m|3Xh$ttCjA4b!+2gl=2RgTp}UJaJUG^IX1lr7k!;-mOY8RY<&Aus#1O{E83Kz2fy?3XZeR8``i#Mw|rd*m{Y z4|Lc)t4A0zi3@VrErSU*RfhS*hiMml(W%UNr;C+PWJSpl_1QM;%b4fEuN%R04Og7t zwmC4MFCi?*f5WIk=N9MtgPwYB0lC{(iWIKk%>%!g)C+-?iX&^8;4fEs7(5zlEKTCH zf-IYsGx^oL6N_vx%^j1ZKr)|`C%+s`e3UAx3u45I62{EVCdpiU-*b2}1xmjb$$r5V zGMn?rq9#2$@epU$*UYceWl*BdlCT8Wu}Od(6QJ7fzH-zj$*!#wnJ#W;<#A8G^D{^k z_{MA1*GIr}TZPYZ0l>B0jSea%%KGnZnsk6iu&ygRioZxJDiE+uVdxH(vki15 zkI$TaztSUk^v=fei5gfTMo)Fh`@T`tCnov9@A-w^W=ybq>%!h3h z`HQgVRZ50!abSrz7yBWd_(yxUlW2Q@u*Nn-qtv-(|MN=Wrp_D4SdVH-FUUI8EYoeP z8`^DI!&vohr-3~f7LcQFnt^2*Y)x&6*epeg5NZwNJ5)VM4X@hc^p%Z%H@lt(dE$fT zQYGCF*V>$#7AOfh!MbYyUs7 zi>mf=zrQ#=J0{w8?qHyzf3|RBICP|~Kj}dG`PXq_JVq2}45TRSTQ>D-oiYKtzQ*Q& zK-+#h$$`c;?-}jwEb32#jiAJHllp!znvdcik32a*Z82Ku%?^i@!mWs?STBzd=O8lD z%1-tc%M|O-aKd*0)pKiSddkBGNE6m3NhKwq%$r2xOxEw{_j6)Qufo13k%X*)RuDIV zVK2t;HT^!3QqaS8`yV>)gvaep|6f3SjQol<;KVKy+fA1b7bG%Qv+|D-BQPqWR(4LX zWExEywOedOU{2=K!uuaM3=;ki4mXx;v&sQ4y@_F&btaZNm07K_+KiJuze6 z?Tv!kl{NIE|A@4@l|}M@L|Q{4IH@kU2PX#b=htwHrT;H7j#;(x{|I0gw5&%wfRk^a zW-&vJSYFo&eq#t7CT0p{2vW-t#HR!v<7#yY8(`Fg?kpq6pNfZ9>(nbBRcLT6g}*v@ zuexGGppm99y6}<@&fH`zBbr- zrf@p;b2-M}b#}w-|Cw@7_#ac&|CyTLP7f7cFoUp?c6|~$pcr$C>K*7adpS+7P=d@b zu{Z>rRaFzu#Eg8HK4tlb{1p(*22KkD6C9>1T`D0Me%5&OZVeYmTs)oqLqSv~ppi9x1Xp4zVmykg|lN3WBK$J-hb@u_qx?^=u-9f`nXUdzP zq6?aOI)RPmHCZJDZQ2RXwO?wlI%2)<{oFwS%?d|4SWSPJ?4 zcd{V9WKQ&$nD|CBaIx`DvjEgtbNc-G7bPYDjcwB$u+5L9()M~9F%iC%l_D_?n+c->0wB2zTi!Izkn znl&q0tEB#m%WB0$Xtx*m(4N?v4!9GMpN_!CPYP7B_!&P|9s9eHfRrWP{ZrVA3VAp9 zTm{{O8n^uOMw99H`&b_$L?7uKm_c`7SKRm|vhhN=RaPyJsl)R7IqHJs((LO)Y+9ef zeJuXlH=iMrbPb<{e^pba2F|wZRG&MvL_X)3#*+a-QJI{OO-B%rL+R=KMEm%TEB-Da z0RRjFgrdX~7COB{E(1cG11@iImAK}ycJxm(4uiV!&nK$VLmhK3bM&3H(~7q@GB1-_ z{b2^FXgRP3saQS{?l?XbjxETf0CVdnE~GO>Fz1%+qM7Cx*? zivU&JbpBKC& zpQ@13r!zObRM)G^X49z=+E1+5I|9Ys7G*Dx~E0mh7s0$|K~uKzJ+nmD#vBX34x zzAt+pkDHFKMGwn)sc5doPK3$W2m$o+c0#e>@c)mPwYJl+)rBb(u-%<17T~@-K)tME z(4U!|_xHxo=iD-!&6y7|&O%KwPeNDATt*Q~cKIOst>BHN>b&E9Dk*_jXm+$(^UXY4 z>i#camgd^VbcP!jrFa2;^#(l)1UOoT(a8qt;N?(j%pn%LlSbRWn6K9@4PA9+eB&Mk zv-W^ZI<;8b{Qo9CKtyj>mXyCY#E&^V!P{)Rd-jywkth)?N(=+ zGL#im&img>^cEG3=rx3AtKi@k0c0?lLVp?`O3UktCdSHGS!Z<{ zIIv*)?MIsTUi{{^`n>Fo=e_k(T*?mf&2_x|_>Y}WvxU*{`*vzf`(=wh%m9AhWb*n> zd1b>(W*2xKKDK_WoS8R<~Z;&)Vc&NURi2FRmIz-u|?3J5!6SLl))3A|I!fB@NM5M~+}<;A_j% zLR5LMK4+3N^}Sq}lZq69j_!K3DXg%kGS5LK)u5`VNl(8^8%Yy=Ez=2mHup+gINd|E z1R+dnwmDtbYuk)%?m(-5dXsaf8Y1scU%|?28=V;Tzl=cSIqf5&%RJ9wJG%IGZydH$>b)K+`H!7 zjB5{+CTY~=2&vLh#g*ffHs;O?m(c_%pjz@^WA$IHk}y&V01wq3r1|M~ z1)XI*V=JHPudJF(GL-3h1=iVK2F_vp?~M z?Bx2qRZ!MRYY$f5YTtT&)M||0G%vp!%ouFXZ9I z^2E-?hgnfFS7FIz(_N$tO%tG$JX3fVi$@cvcnaiMCZ+U0Cq zFtpPyjtX{|$^$~VH@^>rmRU;vZcUp|8=@#Jl6?@r#LI&x(ODuOf{MNovs}Z z{wC>g4{A&DywGTUD(^@w*|u)Vy6jr(kWg;DFJ;V~Zx6*3iH@BmxGZ_`>5`jMoR`<< zFODwCY0=C3LA#$1U1vfTA^<+OGcYWAQd8q^B2RA4ofxaBU;FyPYE_BZzx!P&8DLuj)UadYN<1?Noi^=hAqg<=`2OG_4OGr5R7& zf*MLvQXi}EgtWIeIz3Vh78lBu(}Kd=SMQqc_)@a?b7&jQOi_HGp^$q%MSdaQxh+Fj zsbX#-ev+u>2*pwsp?5b{kZ$KSge;ce;u_DXI~hAU<(pPb2CW>vcJb3CyKDP6xt%QJ z?%e0+6in8zS51<6j^-BG(K6GmLr)52p3;e8iw}8{cI2Dk5e<+gN=iA(@KG>jvL%Aq zC*w$Oc>57Yk7-qPNkc7EHCt5#M6Z=M|S&*SgWyUg(1Q1d_ zUAbDD>z^x`Ga3no?3Zz%6E)9~pO%*d+95_H*@vb*Y4(Ck`uUn_`zA2xZ6ZjEZ-1|*ZLH9Ey&`?3; z<>MTi>iRD($(-a5{R;3H+!zaYT^0hPV!c@~F0h!zf84MoN001MVjQL9BP^1K&T>lN zWYyg9&}Ux8!#Xx|yZfaoX&7w9b;{UB9L*)O`4il5RVo#c51qp~b4*t3r3RXmnneWD z8f$^}*p13!C(t=9Ph``xbk{-Sos8dFHnS{99jw{HwAZ_paL-2G5r?kS!m8o9Br2im za<^K~9kv1N(~~8EJ3HH9xRtR&9PYC-5mcs-DjIy_RvoZre$3n$p-6x}i@Ay)|6<{r zDgPnx>a}u0Fcc?&{dALm_ADWMLS?hJ-#=SE;ib9y-Q>|d)7vx+EJTki`Xn4m+{BKD zG)JNKd`t`h!p;z4t(xZ0#ew%<6m-BX#jEarw)5^BqPhH&CALFn+L{mG26# zG%DYloR{QRT~B>JQq%I-Ye82gCI88YUw>JJ|s6cb@B*-ugMbIHM}zq6&BNV>N@ z?1R1_kDWK(7~3G@z5uS?1@cQB-zflje9(KfdQqiQmZAHM{E!fLBA{Srhh990+!x^2 zuF1rWcCg-T?%%2?+?NR;>fD<-pIWx{CX2>J^c>oOVMhD= z6s(Fy)1G-G;t)WdM@PjW<~gN%5)#NY!;PWeIZPKPHWT+M;0{XNN|1V6yFg60&x3o- z$Z$g0YW3wvn90%^p6dz{Cpm2B2ZbMA$?CFOKtQ6pgu0d-c;(!PG07+nWel1R{qCb& zf+y7Xj!mWW+ftNu{VR$fgV~Tz*9wZ~!KXsh=@;6{*e53t+E3z#fY^SP5IUiPnd?vM znmogH{rKcw+QkKOQWFw&A_rx%=P0Vs=Ff*24!*sBrf{Fx^_2SS$&>X`+RkR8R}7BG ze}Ltcs=-sVDF}IU#eYyts{`<_0<_COSmLVCrP`nZ5wY+s+Cq3$Nj%WxcWh!tOLta~ zvN+hH2jJv$pI-7GoUP%m2l6!-oJF}L2VvZEZle@!^T)8_23>x&RMsAuM~RHJ##@Kl za-Z$g59t#9+97usxIWvSieg$G2I=_ka{iUO;s~0L#ELc!LjjuZ7PtqRiDdCS6sX5i zyS?4RhWs=Q^UL(8zcdCm+Rsa$@n)XLg)co8gbnz64es7`W-(?vjJ95pyvm(x*<9f4o%#Q!9kerWpARA(NsnCD^Y$<^f_vZe-V`-=_HkJ3L}NA?&j z3GTU!Oo`o#{qpGatqblVs^xQeE-lZ7I=QFcoF_=3Zh{nQuKZow(f<)uS-kXk zu=6K<+RB$b5W%f<6@OSGl1HC(=Z=07pi>t)t{`Mh-6qfCV?q9O`4}DCl4O4O{;3WG zHT$!{Tvk{JXr%iJ%yWbDlsl#&KxTt;U&OP~GuoU;mQ3?9=qSx#=-866nTHm zjrOm*=c58LL(8*PGR2;m8{pvUs-&m>N+^N?gnAiZLvy<61j-vgZ^8qog7b8l-}r28 zYE9a3@voosAv0V3h6V_M6KhD}7mnnQWSM8yQ?fOgLR=SG1}lq1X*x7RM^>xN2NvV9 zp^q{P72U|&x-kg0KTNu`7>h+rh9i73aWQ#a zr0qE-bY4AFLy7=fJ_ac!L=*Y!M};=%y$M4uPiGGrKayv5$0u zMIoZ^3g2k-IhqW0`xr_48};b(m=7uEF%7>lD*q~C6qnW52i+RmA54qRg*Wk#tMg0W z5WZ~;J{#L#JW7=r>PRi=c6~jJ8yo5`t0&pY<;uw*BlS!YP5PN+$K9*Q)!)YxKM9r# zmCxj#4=iQ+-@ka3fCj~31fs%Jn@HXtf6+5Kysrr_<=1#;cHf+l(J)=o!nVn_z3_IRjSk&vVoRTipbQM00mF|*S!Pyc9W)89 zoVR|N&b>i}#(vV18N|DQPLv7B#cRTCpWd{Lp1leoCuES!p$h`V1P$6%UnG@N_nA-Q z_34;@1|H2>QZ$(7$?tO+L7nOJTo}*tmUp4 zzuU>eE!jko$YZ{%a~v}c(L$FkscN{Lk3tozo6bgZlkuWa8EJY!r81@V*?qu;$aNiH*Ns_=;2LB z;7|IRa1r=}k!EivXz@KZaV~vFHn`)JA@Iun-Z|{~pWzSg69U|)xQdiJaRE?8uUHWc zEtt~!#9c!KxVkMpFZ-%@Giq?{DSgyN`wVXYAzO!l*9n`~hp}AXd+4!Glb^KsIugqA zZ9&F-*)Ep!R^W#ea@qBJmx7w`6dZ7?)WNL+#Y76)Lft&z`f4cJ{=D|}JiN4i@W+Fg z>v)ao-ZQtpf>%#iH|w2NOi9>GO?IJTx1WVQ3xlt7JaUpRfSQZbh4R6=@9__Y*A7D)&~@KB zvFDQU-b?L_&VDsfu+L@O5a)UN2n6E_(|D7J6DtvOfxPJ3EeGZAF5h(KW*NkkbwMQS z7zDUa$(Z#^x1ZE__BY#*`yWheg`Rl-{!nyNsN=}k=A(yE9OGHJ1P*5u`-?sxlf&2p z8S{B?QdS>-ARb{FztK${1+PakX4U7uVT+mZUBz8L@uB}e2Jg(EULkJqRQJITWKGocvYg8e5Ae{YSRTC)u(#7ijWE$6>Fsb7ZHT;&b-qWd|5qs1;fc$r z9L--ewxu;YW#a_p>o1kD4>*(>bVh6g_Xk5C;3dJ78P2bYMH}=1P(K9*CJogqXQhTd z3%jEIvCwGiM)g+5j<=#sG$j?e{MiBdZ7UEff5;%M0;^dDF&*67Qoy zlb{{N+TI=;rdzClmlIoLbm+vk1-+EuVLqAh!(XoKla&*%ze#(ZQ#DPhDIR}*K>Lhq z*#sa#{r1Q%R^za|1Op}taLLKa4R*ZWgyYnwHxTL&rxYfnT4iq3y1uxwLDA|4swt0F zjHdybAzwyYW!tWCDS0<{?8>{o)%L+MVOLW;xv#z)V;|w$W_5TUXtVNwBlQb*e*ua+ zSw{|?-xL@leIzaJO4>oY2BITl+7*Hu3IGDYs1HqG9vm>FEV z*ndUe<+-MExQbY>pO3Ac*;n!Up+UE_`+OibScq+(mb_%SLQl96_IUp>3IXopy=e;& zdjp7mK`#^@k6*VybNi&TM=5Zr1{6OKltd@{X1;T7Eq4bZe4BB?Zj0z=BGP?t?(Ke9 z#7iM@ig+wXgG;^Bufy)n?bW(;uiK+3n+q|y$~pTtP3ez31;rgD>OtXi1euC)dYxPlF@4ylY(qVjBWA;<8Y8%7=iJPW<+nvo%!U2k# z>rgk}S}m>oy2xPyPwT#~c;8w{2ccI=2v;1fL!Kwqoril&F$N1TEpoNdGSBsv_~#`I zshrzSwp{pXhTiqXjVi}UtWPxrm)9EyGv4zW5pQl46%qD*g4|BK#4b17tE3?d*3M9L zs?{OQ=+ zk^9S-0{h$zDQ4sPqXFX6~NA^p9&Cg8S&$9Wb>`&%*pJQ(m8Zo%1 zm#5HIE!`sAEA_7AWK4Ww6B9V{N+_*yX%V9Wtj7Y^;65FVfjH_P;(|}L-+L$KRvu^f zf{;Vb8oXQKM0lUUn_q9cXq`LCTY2wY_=M4V8GqaEd|SCxf6!yt@?La9o#96x^>(k` zwZN3t=-X7B;!O|10}ZA)o3DoLUgz_(eLg&|JKT-&tK+)4tAX&~9ND@)fPvtYxb}?0 zvnJCgmFB+TQE@t8L@7CIIs7;9~Jm;Ys7n=V!)+|(>Aa^*!!lCW#ulj?^)#h9Aa z@)Yk>bEQn+k?Cb z8ewxY%v-E!snm1(+($T}^+T|M@1v0zob&sitxz-r3PhoXY~&{I3E1;*;~X4HB?>X` zF8q~Bc#L1a<-0vR$}+r4BcRaQZmr;jw^#nv75wf)`jOC43sS8L!=&qy@j`7CM)2hH z&4{f4Ndcle0})Z1#Ap}j{54R@zr{7W8MUV+oI@7vTr!X?)iF>Kx26D(8|XD*45Y>; zeZIoutn@6h(WrD>Vd|z0K}Y_{KuY);bug`-#Q)w}Cojt6Xg=?5SA4US1F58V@L97g zhvYM4?1J*FET_sUBkO*W`*$}*ae=w_@4uD~HyJ3dG()yo7^HtRH=Pj2S1w$dnp{z{ zu{0HXlSSh$eVyfJ{ash-Z#p6$;`nTOgrdg((22oxY)?zuYA^RBL7Gd0ru3HcL%y9= zmJ=xzE5f}F7)A+zVf1UaD_XZB<_y+#amD(MT5v*~$@53=MO2?!pK|=@$SC2xi59L% z>d2icqViSVRejtY?a~bVc>C)#&M^$W7(1^1TgnFc>scnEDUrL11hi}ss?51(n&_-U zJ$o9xcI?ysVKnN@+?48VsWG7scpCSwl$!Mph}vW7(|SW&SUd2B0K8&zrxyvhD4RQb zR|N`cf~|C~xijRSH*e5z(i21ow1RC?21j!aK$Oga52m#(jrcLR#BVUfn4t_;o)OO? zgBJ_PhHvbbRR7GNEjf2KPdBcVydaC&EpAh`Ob^@`xtM4g?LU`GWN0`L2P{VQjT(6} zNFipj_-R6BvQl$Tw!c*!9-n71kGQ5D1Guse&d4oXxh2*w(}TBd`y2P_Fq3{UF%Yg- z-Aua0D~~f?DI5UHp}y#UiS8$Ug{Z0d}v+j zk%g{->-)5G7t37oo;J7tT9oy;p*QS1$^0Tn<$*Ay-EPZw#PWF~P@4>Z60`x0`Oxrd z@k5ZfMsXC=O=RIwU3<1AW26T6Vel;OZFLUtZ!@)PE7#_~(_}aZj+~CxKjuG^59%o@ zw`Zp|M-S;UpE+o2sO|R({?!+!wtvg;u@e~;bf=kUJp6ckITi)aO7UrxA;&kIA6I_;PxpL+hzlhr9l|64OCYJ%}#b;pnlR8uRy^ znz1R<>Dl!BF7WZ@{yk0nB?(Z{s%h*#0xqtes?|IY!{eRHvFHCeFGmcAH3<#4nhgf< zUTTb|^)U}%#}Yyes~&sGIvM!skkrV(2f}3g0igf)Z8YCrfIn)V>cFw$QLAPu{T~J{S6N zl<$;97o_yX`QA~IQ`gAz*I15K1fBi`=DWUr%Snl!{=@}{eeYAvA{BapCd6C-gJJ94 zwXITWH~--6W&CfdM|+on-Ls`3nqpas0W^MrKje?yn4zjxKk5+-tGd~;BxfTTXK&XI zp_*HottX*t?c0a0VGE%>Zu0K;HvK<`Gw`B6&^wkoe#^l`lkk=!(zvDSqY?hG*||k^ zLsJEIQn?^saz94<3Ricxb>sJ3k@D%63{KJB^95>)9g|UAn?-wtqSk0h7#1c1icF#5 zMfk5UEJV?Z_LhIjm>LMw(+vcUmsmSD5m5GhQ+^1R#^RUwf)BxBL>zS(*CF4XzEvDWD14@`#tZg*L?Kq%oNYSYdOm8Q838Z2ZvMss$B9ip%Ln!TXA4i zf>)*cJi)IsYP-A{Cq#FyQ*dsW4Dy&6D@Tzq}1ce1#UXoL{zyl%b7YrX8f@p<3Z_*md9dP?AT^V05g?9I&$ zCQI>97}s_!Zqc>!(u}n3g4oUAm&-3DH`6zm0@28by^*F9%?E7m0q01cqgq(l&F^Pw zFEB7KiR`JwOHffbxQS5IUZA3pppc+oVq&7O6prb~vp;GUK}A8Kxr>5AjPl=KdeV*# zZWa!1MlZdcEL;sZz3lD&y8;JZ%ol6G?l~F?3eG?5{Xn%wE*5sKAg%y@{SmAo48n*Yr47EI9R#j`iBZ&fPpXcc}w&Z2T7*x`ZJz)cr&y7YIiF$p*g}EAvi%y+sjB(E_8po>^Gi zSnFR|Hn=tz%1Gk}^n45GWjkTB-TWF6$YH$auV_*}DX)$R{8!{(Z1zvUI;-H1Vw za!o#Mj_Ru$#k$q!XNX?wrY>}=I3c>@%;l=!&X{8i&ZA6Pq-6+%M?+@&=W03E%zJVb_IpcAL(5V!K^882yUZj6GPd6hm>1=#o=+Bw7GL`teyw%TX0Sy%t)I<)JRuOnOI7&n~IE{ac{c{-hCT>=a?%Z5Y@8wBd$_TtT5hjcy zZJAC;xOR&%sBPfyC?v@XD^;1Qit;P%ZCx=9j#6ElJTKNBc?Z2DB9+>-xpE*Op3|ZE zwhPzu=J|RNR;lDTWn?w+E8&Dm`HHLys&3 zWlr}>{6$>QQoVrw)3_+ws z57OigyI7!}4}A87jx!&s$`-74WJM^f!`n`3;G_4JI+lih_26dD9xf-7oYYtQ&-nzq@9rVth-mdBQF zj1nbY3gkY4=nzdnj0}5Xs$ti^2ax~Aheaz@C9X8Y7=Yyuxy`)=^#xbHT*K+}jn<1u0e|%^!gD$_&`U8I;DUnfmru$r zksz2Dg7>gYQBZ*$^GrUlyukl)`!WAt<{rL|R)3}3rlaPP$wSh9tZy(|!O7qNsX!1e z!JEcfC`bp`Ep~Mwmt7+)6oMXZ+8UIUOD#*>46uG*l1osxin@6TD27m_R~wa5aC2$L ze*6O1`Z9R>OU>66bR6xS?g=r)=Cr_qmt3G|9P?~cGA~V2GUxW}C%Dsgpa+A>?eLaJ z<%=(ASd*+WD)5w=y5$P}UMt&Z7Wi+uwJtYm7`1Cv)wFc8OszN!x!s-L%lV}S-N~^U zR?gXmQQNx|$jUNh%jSx2{-7DXRLVeAW73z?bGURoLWqx}t9|t|5%trB_A|+XaQ-Ov zA!KA_0jXR?qE{>UU5yd9)@lsI7LMG3^cYUU%*|6wKNV7ciw>MGcJe!C?=JWvR<4@j zj$EF`h9gD^xftAeG~sZIXS)!*R>-oDPpy*DZX*>TX_~UnN83@)D(t;`Fdq<<2}25N zT+~3_Q}+w;E~mpU^Md1PwY%T**y)F4PvfBvDM1KvbKD|7qJJv?h=VP@DzQhrEF%`9 zxhM1aijgE^ND*Hk=iL}lvrS!Tt?i`7@%8&W;-bkYk8Bc^!?>^k0#XKuW)f@U1Id)r z{JOOr+1{qx@QWW08xNSr;sQ(dJ-Kju7JD6cW?!d~&aA_2f4|{w97);e7UU^v_E22n zJ=}jR$yOBt?Oo?{J^Xe0p$svIUc$P38RZZ29e_<7W)uw87@)DLIM;c`nu0zacvO_F*DoVk_&mg)uJ3QiQL1%Akl>c9(zI zJ6_{=8jEco_4Gx$LkjX(*z$d(S*H9fp#D-l8Os0?0IQ6i}lc@PG5yC;p*(b{Th6e zv^A)}r~W)Byuw+BVmQ*Nl=|sObh;~VrGz01{f}n|*}ste*WmpV-+v9^L^X#V9t_FH z=*d9WsV)+TGq=TrgG5kpRjMGMIu}xSIlCu?f70e|B)YFNh)OeNJe_v`H!|1OIK;D zkb4T&0m`pAT~cfBUoZC#046rs+e_Z<=Dxe!`S|_-{KL>#{`_YWb=OPz@rt&Vzm6%J z{rut?Sm}WOICM$=Zaa5dD=QCo*jWqv;C<@9wrnStCBfN<4vCJ?foCy9ALr>V+mo#~ zsyF%7vp%a8f)=<#%%{OQLrMBc(}Q<61q@4?EPDyDNZ82bZ+FG{OCZAxp3b{J*4}Z_ zU#L!Vs6t;UG}%zll8q<%l1Kyz-`qO~98lihUOcJ?G3~<2n4+k@-#nO})Xu4Vm^rqo zWp2T!F|NtyU8+%>vP!6J+_jK+Qvmq*A>ZmdbHv8Q2PqQj?3|Gv#<&=4S=P4!!er}^ zhh3%S&0h%*BleY=r_I<(XAmEE@kfu|c4I2h<*BGKx1rUY-3+3=AQ^G4jv=+^Z4cZs z$laT>^XHhJ&A8%Ng?pi9|zs!~1YOotrFx0581NkY>w zOZ?!n%%@M?F(q{eUu3si5Z%Hrvj_u@R(rb$V%cC#Gcc)J^_lrT3yG8e!lo$oPQW1O zR}EfCMAe?xeL_q)y@6nCD93Z+4UPfQX2hEpN)C4XDm}U}K4pu#`&$TVNbur4@M8}{ zc4R2HErEk>EspzV+`yD!n&HWmdqECqVTF!1RJyDl+;;sAfbBpK`B?)AejG{P^R##Q z-;6rVkV|zlL~FT7nTB;`-4}^=v`**i28yE3mP7~U(rG#gDb|_PtO3J|SiAK<0tV*X zk4P>Sz;}Ma$#c``DT#`ttn3yX>K%8!?pKFrcYDwtiN~+%XC^VOQs0n~$FJQc{R=OI ze7J%F{c9~3Od{{!jU+Dwl5i)rgWn#I%^z&GYbw2ynpvw*;Rvn1zCBq4V7LVY1mKPZ zQ833KW$-OlC8A~2RH*mR2!CVpzYmR)qPW;d$21Yw;}y@jATDAaFS_j$-j$g1)u~@| z+|zCTLt z_Q}?s^roU_F=<~@>+kPv2<)%PYK(jwEo@Xcf3b{7C)gbwT}H>C98Y}i|>b6v|Ci~)OyE9 z*`W+&VK#BZ;1EAg*K>k?L~guVy7ur8YbDIXBx-p^tH4-~y#&>x z9)3AH*YU^X6;{BDb{?b&z5ob(<4urqN^ZAWC=c_lEQx!S0fPH1`*xXg^2`g&IU2T) zxAOEvQJD4%^M1|o0?CC3^CuIQl=~QS-|1a}wJo9K6hB|Y*|AaB#F?6@^vGg>5KaU6 z1JD-?pl8m}(P;Y?%X~zX)GR{$O>O~8)nc@RU(_fD*ZE^`kl7b;k@wpfPB(|i?sr(D zsO5gv$o@P7j(Y@Nu|v&!_5{Ut^NwE*1&NBQm ztLwIXABA22_jinH{1>9aVJ+2E$<3U;Uw4e`cmF04m*xcecfy}?m(#m%!%)0&Rern*NVW;R+Hoc%Y zU3^myrl(z&qr+3i(qu<7TNzzHTDm?72#x@8gNAD*xQj#p-Sni}fWum0@52hKw*?>HdE(Xtp2#bK)n zblK7bg1Fv$J^K2zrF*O)Ens_)*6>m_7?{+D97yigDuj)E5dvAPc4K3QTP=88V@H*2cd2E%g0{obw51;YAlJqLB7vSX8*hI&v z(<=qfenS%~)FqD}bD5wSPX-inU@9P7#EBDAO}jaborE~xL=I(Aj){(YyiwG5gen!e zSS2WO$pG?r$%D{hR>yv6y{eiRl2jabqnKuYbckKvqe3bmGHy?l)HYPIkhiPCVO&d< zMZsMEQu{eIFk6TUIC>WRwZh0du%BONe(tD=udHQLIXqCf+UKgIiGbk*BqRC23Dz0z zWCZtF9P_i>#nl()#q96SHilz3Se)X89!o0KUIKjLqiMiEj>kUm zWHz>M+UXs37z3iBfRb1n(Mp~2z(Q|ctB^J?K3CEApG@e`B%p{(dx9g1@<+~g$M%g%FaP;Qj=BE$%_h+W$G{piC)@_pWn_WEY)3p1aF}DZ zFD&vMEV7P(+8oe{u%=#E1$-2m<;Rd?&-M)oZDt)OxLzgy`-ztlT^x$Zu{Y7fVg16v zD$PXnQpl9~o2_lU_w&$aO>X$(+<^!nS-Q%s58Q; z_k<$X6e_~>UQD0bUwQ{*D~&EtNa=6?Ez;Yx@`Vawg)bejzkXj1>+7xA_z{MGoTBKJ z&K(BcK^HB}!C)-O-aLpNty+L=xfLlJGvr88Nh>q#2D+GNkB==J7zryAVdbgJ3<~85 zA!{qm%j+T2gWY6x+W=GQX&TDq46mt@YpPYLmN5$4CTno#TjB0dVkSYPWWr|WNfcHcEyZ%2WzAf;g$1T_;VAVuP1p7Sh8XU zB{E`yT0#_Aa}l8ZSfYw|UZ@`c*{PgHt0Ol8T?Z)Szw^%pA$G=k!9hjm4Cs%>+#nR$ zPb$=rLj_J|l($p{0lSdJUIfiGJ=(;9;HLL}(qTF1(+ABD4L{;LTHK|o#Bsu}&})4U zWu`K`Xq55J?er}J~Hwq!k_-?T5$&IVoHc-#YIr7c;K=kn!Usp zSK9JPK&jc0>cpK_=z*6{g5w;;O?vg98}ue}vNga+8Hcz!e$xBO{e;~J>{hHg&$&aI z#{KPeJ-B~CgbD#(GpQ2 z9L+UxglZNXdnG9T;J-a@qgRcZxLo%Yo9hijJvNlSP{Y1SD&Z(Mgf9%Fs9?mS44x6i z{=9kS3AG?+9~F*t)YD$MD$9DnfYSI4cB{^GqJQyC=|Y;>t5vbfGS48Xx?a8tv3EgM zmu?-*;iYvfOaLyXK5WWR-Z_zG?asH)CmT9J%@|AasR{1elxwQCz6F~wz>mp)u;np{ zFt=?p5uueP25nr5&N0QyWE8l`uJwN6PFG&kNeS=ge6_YXJVB$m|Ebj4mWFb!hvDY2Td2+!o2RXM$psz;?6e-z+crHhTAiHu~k55u~4%27gh88|WMB&UCKh*DsWRt%o;;WH8v(LdXU&IPN%}e^E&gL4TP!EnISewTbsWw@+05O{55_9c-A`rP z_B52lWglK2u;m|+XCrA|Tm?wz*^n^oY#>}Ff*~yM43959mV|?AUpw>9Ii86F+fetCbjny&t$!f z|5PVg)Idr+Hw>ZE$NwpWGXjpwjWNPsAy8fH+Y$Q0>&9ATdl& z;wkt=as%?81puQ-zv=zjmW$LyE)^*bRhwd8r+b|VF4iT7>Dbmpc_kIoEmFe5DLOPq zDmH^5*`MXy7L}d_*DcA2@P<<%M0pjq_eh%XrPiT+%0AHO^hqw(J(=asCDSsZ7ZyXC z_2t8YWEHX$#B^KVR6^-*ikM5+6V*W%ysTUn@{!^uS614s{ zJA^;H|G&KTPxn8ik|!zWZ>xX_rT>?(^UoFjB+s8DmA}mvMyEfm@ZSQ zzwIN+U#@?0!T)srlRbSRkpH$b)W4kn4W0bYb^dIMC$9Bx!$$w_B>orks-c2}{B$Q8 O>?Hx)reMmaU;hQVer3D> literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-57-34 study Document Inventory Report - Study Level.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-57-34 study Document Inventory Report - Study Level.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..adf631caa6b8e93ac3c6e6569b0139a9b6f4bf00 GIT binary patch literal 246320 zcmaI7Wl&wwvMr3eJHg#u!^Yh`KoZ;`xVyVsg1ZJt(BSUw1b270jeRTUyszH<^Db2z zsaiFAcK7Jfwop}ohQWbAKtO|6{qJsr%P^;kV@ZT@JC z+V!wwynG*8VC213{e&ARK{kl@^A=jyJ6Y$ErYisPK@XlkMLiP9@!G`P!d&~_w863A zi-b6~Pw#+FALAvXZ4u6FU_^hUaM>PM`6PRztlK2m}~CA zvi0l8*D!9IhW3=}7=fQAiPV?=NYHaShV?ocebiVZLZu}{eUHLh{!2e4_KWzt1AX}i z7ZPkt4c_X>kEslu@-jg|L(bxA3EZ81&+K@(SXpK|5%?cTU86Yy=N6$&Ek53J2Kr4# z>d#(a5Ha~-{7$2?KZ|5Yfq-@zN1PhT=6*|g)|MTe#Q3pr!-m%T#`X*;$-%rMfyUu; zam1&p0FRK!Oy35Agn%G{fq+o`f7%`yu)TqknT<0W>%Z^6lDg%gIWWQuXvW$zZDBF3 zmZK5cBj?}=l9$%1GZkf}*E-s}qZ@3*x_8*QHr_dg-9*CW+BH~n3Ikndg9ToIlPQP&>X)KL45867A_z4lG-R1{L7H`4gbB@0@f#kmT5 z8Pj_vv!Q+di4J-q{df~)H~4F?fbqE;%2@K-reFtWyi)()0fuRN@#d4ZV)zF8zyfAd z1H}M+w%`roXB0X$)9Z=&jC@8Ha4EgVyW z+BGDQFtI^n1;q4?PDXJS0XF!zvwTcv;y)-3+J=`CoQw30X5q^a#4wUBk?Zr`CNI#W)o+9j%U-vSNlX zumT=Q#e`2r(ENMvBsxjo1;IweC06pK##`IcgdbNogjh%Ef^*(kA^7G$kB2~$iWblt zZkd|UYz#X)`p%v^B+s@fTBe(3@|K<&_ePx-Q+DoKY%MG`?K9%dKrf4|POO4;6GeFV za{n2TwKkv3f<;Pd}BA`W0g4;waTOCu*UQwEbkae4ydx4JYZG*GeaO^J@hkc-$tBXZeFFlzWcpMF?^|7 zunZxywl9{Hq|KJh72eq;AHS2!Kv1I9meTrmXLAl67fV^Ea+rvacdG#jK0B<*bsvmp9`feu)s+kj7}^)B$1Vqhh1s)MNF#EExR^Ok;b};DztS+!h1W%n@mD2;qScNi zitcF$GDc*v`EvXx@R}{^E9xw#RWF|6^YKfkBV4ix6wYEphHwa}3)PYs!rusHY!^4p ztv(#@IE`}czHPmsUI_E8Soh{a9Ge_>z8JO6!d{z)T0VYdYaC12>fvWEZFZ4e;W#^a z|Cz1$G5GkYfc5P^><2$WEqDi@d=>V8Lpu6@@#1dp^v&4b{@Xv0$0m*{_p)P1J@|wY znki&o+NBhUmovIT%i=W5bLVhty++tPTs`r#1iB55bYy@m&KLW4^Ke%ZZ)P&EYSoZp z6m3JfPq2jX>oP6UG`0KJTgFG0QKQ{<6f7kUohE$OlB7jyNz!$!DrX4_T)v%yWaxbq zaO$@kt-wP(^3ZhR=Wo5$N>tx6mc1&5L$Lc2doX&zT5hD}8>Sa=h$tzsv(H!`G;;#9 zr3{{u>L2_E^f@boSEr%0X^Pt8a|z?q!;=Z;G<#(HzX+n8f@(IDE*+cP4?24} zUOzATN5ZxiRY!KR`(GW9|6=ir9lsSBVB6jQl|?@M*S7ynz5mm~|4qY*O5b|fQAFRP zrhOe}x(N#H*i5FriTDLnf9L0}i7oy!+F8}w`&SembW0s`>5X2m>mM5|ptdgz2d(re zxWKURM8aaT`rX3|wm+zQ3j>-kEyAe%i=CAygTdlME--c6~Q%)d55u|uB}aYjmF zJtY|?SC2yOBS?;<^g0iHMgu--*k%Q`Iii*c?Z@>&c#rM6B`JK+hSk;5D0sItS-JnQ zUieDPFhtUt(=E0U|9Q1>spF^rQLg{pL0bH26^nOvTh#f$=~fQ{~;=i zlY+8&Ky~i_HSH4oU*I`gnwhyc18fWY;P{8Y-S$^!;>P)d=jT_ZmfBB^Nnf1jJmAlh zO`~aPqB&(uWtTkL8trPNO%*ac_s$yUa#2vACJ~5s9wY0uNK}N zq2Dj8u&o>5S8Tf(EWWSXlSR*fLrvbw!Jk+gm-McTu9}t&Z2i3Tm__`SR~m8dd45fw zng6MH%U)v}O?{Ve>wL7hd+%hqxX*pNhR;bob9`=Eu|I#;7qRx=)Mi@NnXb~3+}5hB zF;>%RtJzl5DyYFy)2gjWQqwB0QCHJyshLsJDyiXA)1tN)*?*}Z*@JX5=-puuE*I@N zU523Gp7@Q5iG@#9go=fQPg8`7jfF$UcFd-7_X(tTivI(1W!!$L;RU?dx$(ol&fwHW z+c)<#)vj5eWugDh?;B)w{g3C)96LKQ7KHnym44r=1AOn3dS(yD=Y{1L@6M-IHuQw~ z$c!XP2(=qsR5<^*HgR3(QxR2D)G$Yt2f^oSmKvW_si?t zXX94=%GwjQR$oW|vSEYg_AEBHXB#_EIQr-|>+>7(=GNH7)eKYa{^OQW>yu69uBr2THRF9hg~&l*?l|O)XWrADUyc7NB-%QdMAwe5vER=9 zkg8p@1O0ihb=~5!$1gFrW8(JcM3G6Q{<^-x$LI0n#DLX6KRdVm^(y}T;oWQX^u3T6 z|MawL^XBcX_taUQr|E+)Ly5GNbWp$l-fsB`pelpZNrGuR9dil1s^3A{C zT99tc$KS8#I*XKqM6XiB?lgef`@yQYeUue{bXM(YeC`>> zzRI6mk=LjGe}KC&7<_)diJsJBoj>bBb3Ce;HG}lcqRZdU-azd6z7hL?OW{S)`N{G5 z#4TCRK-avYI5fa)Yv1j&Z>ay*bCFLw^{4rZKcKtrmzMTM2}4>UdkzoWZ?t9lcI6p< z=gRce6&#SAqrbTYq#ZSu1tKTT*t>VEveZ@>H-8C?sEqYA(~bKn^8P(qcP4$iZxMgz zKKFp_-o%!IIQqr2{ie&y`Mt_u_D@r=2i{sAzF+h@{!8oW6ZD(jz)!3sqQ9Pb&73I{ zDk^8t_jpTPHPo{=OTm3 z_e*#)!)u-motjK1~;;hSw4pa9hZKX zBwgfHQ(QsI_z8BeVJn0Aq>kn4^Op43nm&4hdGMq>6=#weSR4V3#@YMhz<>jZYt3G1=<+PP-pp6L0~xn_k;g!Ml2?3~_$ zBRM$nx3?bggI~Y$X_5W6(%g#%h35;m4+w5AT=k2V@udL!5gvU28IUCG> zTeI(68XA=EKjo%o&Y-3Y|TDnz&}}`tgBm(2Ux((=lR6zW~IF8Sx2+(&}j+(n1U{9&dogW+c2Tv zQCXCiP*EppJ}DMrWUx@t#`$3X+idEXAHhZR-C5}#cmZ`z&B@`M!d#uBJCgbRRzM!j zHDLLSzT0b+pQQMm#fOB(_{p^xmdS!>Adrs zN&TC5bA4}U?z8e34VEFbk+~`S-Ir& z-d4uyG`PG*>OIiw@7cmdk&OxRz)i&{*)bn@`D}9XIUCGzn|GW4b0((Ft6mI@K4P~a zOPdxObjHv@TUCti@OUM4)A94c%rsft!G(jzFqlRmQTpp`%_^uUhh(VfUl2o(K z)sR44$U}R=uHxwVJ$)x>oeGmz^N3X~+JB`+;YK4zD6i{q{|UMjPKEc)iY%-1MGrmV z6ld?O71=oC=R(}rY;fI)MjT4|?ree_?O8FmS=4S{Hj~CmOvW+-eJ6yQ;!WdVzjgC_ zk{)jE=v!r($(f#`X%VHos=8q z+8fj?JiN|w5j~%JI`8!9++z%RFcl=!~HFp~M1ebWvXAnNSj zni#OhpIM^Mt5XY_RAe2Qrot_Ga1&w7!)9OsXa65{vr(~(gF!@{1_l;fpEtyl+M8q#mtQuX7|vMV4xAaAnj)Yb2N%?Q1@) z&*(V?Ag8sv7Am0@5a7MDxED0zR;o_EdXRwMi-(J2>!c4?UL<8{`u?uCbw)5(UQ5{m z!xIt2amou`IEbcGPqwrupAaLzPIobow&LxUFO`S;4@KY6_b#tyH!qrZg-0(M>KV8P zdB4tC#Xye<#OaXswwL~+kSx2X+g5_MjSMH{InOR8GKyENU7Vq#MxX2i&*Kn9`4sli z%GxDqcX3TKROsZfNL}}K<)N7K5OF~d5JhM3qVmuM>Pbj#Va%sG%CehudgEi#FfOr= zfwwreYE?H^o&0l8k1TNu&nlUBsi$Da8kV2D z;K6&{abAnnuce2T@w3uFTeW+s4~HvZkB6?7q{^7+o8JP1EczxN`1-;7 z<12gyMCT=67MadR03Lu6Qd87y|DHg5kOJ|lqcL+bkl@}fkeREWr5l`N-MP0lj05I4 zi;iCrKplB|yrv2lKI4ncJP=AVccJ|`RJ^s9`<7B(gBhpPiR`V#QRbaXRke3A!LGsW zx&QgXjXfFeiNlt=Q}7QN=8+4P#e(zlg|=+y_yM}&h1l@T0lMrvouUs&|toxyFT}r?B_}^Tg zztfz)g9JKSnf|)RKgj4Mk&%#*kzs%4JLYS3x#ufuZ9xaI!(cv&q#4wio5?&OeFy5&Rg)59q7dq}P5x4p8eYhh|g zXL(LxB3Qt*!zuk+Hd{cHhN|J-Y!+hCiOn@m-zg2W(z z@{YRMb)l|sr4gghRfuj(ek%4G?JZ9$SL4HX!>EZep3N7?E?C%767$&fET?=3Up`sM zgY_g|rpY7ZR_`IUPs<;h>d7Yc+**9wIvb&(tCJxnP>uG!L>es*9kZ9bHB-RwWAtS- zeQup(ghT5OC!-8XGp4fXymM{>9fobPdfG*7-yZp(PF!E_rX*L)?pLFHjo%Av_xAlH ze2G=-Yy&Ij^+EJC+fZ~spsUGk)U58U+D0m74`OPfwnDA6fBtFPSM3ZE&X{Z6EVtM% z(2HL|O@tqm$i+pujtf)1;Y*-Ohm=ES!%4qT%5VhD^G1!>M~zkHXJI4?JCRxzI6`C8 zHm2bEw<0i@$}sQRBM(i)hLSr2-L{VMUbsj=;#7`cWqK{S=*t24n|Sx`n=l58#qw#) zvE@R)Q+s1!lb-YL7jmuMwp+Pl{H?HLoV(y;9M>&xA&eZqc%#cKdd3_KxjhPxdxmT1 z>mYJL%#ZHGg0B-jn}`uRL>^A%$2cRxf{@c76ctSL$t`hD=GB4)rk6KAfA%waCpq;< zGp_xFK=yVUzmAXr3tzvT{FILw-#_RZTVgDW)LyJ8z`mBT2PsLVNMi zP9-_AlB<@lfTAUUqU^A@O{j{l6ZGLF_W@IQVGOE?PRBWQF@K`a^COa$a(BaZ-roY2 z)P5w@bBYbqXe@_7)CuiAfVZ7evjy!M=jS2fSB{CdlGOH&pzTQ)gvC^la(yG>wA105 zFH1D3NT(KH#Eu`9kef48=|onuD)CnKXqn<2zOdTWo%Dwrzwea@Ml`>mo~pDyE%~8Z zpu3Za9xLN~aeafL_@eVy^e3v4T5jtVmS!JyQfnH!YrDQ5eZ$hp_*qpy_;m-b0}=+S z)akc{K&s?H0eDu1jT*#aOMDBbm1TmuBf(a15-X<{5$TXxt8eNy7f<~wB9;Kz?rhS` z@{*S=%D33Fn(8UTyizDP6b6g4ONuNaLLL(oKw9&juY>V6;h(ks z#OsjTAJg1brL0$bWvdr1uO{rHfR9j^dp%Wif!rR?C!E=8h8kq1gn*P@}wXhB&id!Jz;;*o4vt_;2sg3*hJOrE&%#eV`;Adnn z$u`O$N!}-Ghle{Ae-9bR8muu;8Kv1d1=8ZTM~?%(eh>UY!Kht5nJ7u@XfYccY_0@% zpIeu|uG0r=iwYjE_rmK>EWsY(O$4K$^Xv&g9TioLm(9xwygN_6O*nl?O6);UAK?T@ zmPhj{&VfqmWA?o7s+ci324F=ZO4f5}-O1>mr!P&&KVbWJep5N+%bB6NVxX`7B6qsA z0mKYui!_rCW^b&AgF4MH&N1*!9O+)`mLe&Od%4+_N?49}SoNWT(W?IB>z(}Do2@{dmI!3cWf#7aI3to=KtuX0f_pqZWt+ZO?6c#F((iVh$sSO zlr%H2YYvcz#!-Q+I;>deEpfHMCGCP0NCvz%OL5oJD>%QSg%1h|MK}i`XS#u@F+v6V{w3@eDAfLswHUqdKIb zNqDpnh6ajzw{g73s;dhjx9znLZl8+|R+QQNqSb!^#~JuP0e97OqijMKl|ok{2fhA% z4d>1gpRG<*k|A-L$sE(>y##O3xa z7tG(xR_Cvrd-SXX9MhUufYi4>*m_lfG}f=P&hReiRv>#MezwUQ%00m=)m8?@5xKjj zqXsKPUq19P|D(ozuJE}y53Zq<{Mw3ZP2=U3T}la54QXg=TuBh^cnTe*c2Fql1?yij zzVFJnOvW98R%-E1>-t{!EmA}$Rp>p5*3pK~Y<~SL+k?+P$f>BD=f8d8t2l2Sb9Qug zbGmBK6gVdvt%xP%U3op<-*)TtG|=p|^ni9R$Sc1}{Yr{}`1_Ja%9nFslno`?OzJF3@d|5XPW#c;qGLi8Bk5BLFB%av(?pH*RSgH2swo0>7lFJs z?l6c(shBRv+Qef@7!Hb^B(o0dqzYb=S3M5XCLRLw3L90jZ{x=8#RBfK>QoLb-@g3P z>d`!AY-?_}q%2%`caP$hg4Xd+A`3PzUQ8XOU@=C4rI<6sa7^OPX+;r)bAg9uS!7_}oo;gh1@f0HlFo|Hr@d!k1G1F!+v;MDQJPQNhLIB@#-5{uVpiJ)a2!uDrLKN*=DqlRq zJ83Y?tqEgl8A6h z57Jrod1dsHQk6!Dsx0C%S}-6Bq~am#z9)cs_1nfINajbUs@8>(B;Z%WaTOix651*$ zo9yzK2gDAG_I)ORrr49|7ah-p>F$_{6{|%{2vqG~ZIAJaYmbZ%oF?m$(ma*stfm4R zT4_909FAj;`7=z$k%`cn=IvBXb|pF`7<$J90?tH<87>JYjQI7cgd=XiU@;hB=;fj@ z2XEN+0fr+IhJ2eDB_M&a2r6%;@A6oMEFfVD8irhxBlW!b(_-c$1i>qXt|Y7-H3Wzg z;|F(hF8gQFXd;&kNGRrXf`GVAVF(!{$)Gb12=HqkG&^JaTNl*k@u(PB2}k5kfDC_m zcj~Z;;i!&H{{uj*wUZajrmz?@VY@S9FlG%kBRpMih*~J>J}I216(dqwSH~2UchmJRbe3 z8gq08ZTrw1kBIlEpcx5t%39JyjT(a8x=bykA z!IDE!(mKNQWx--5NF2v|g-Zy?%s9)AL)M^I$_5bqt#-exX6txjD=_9w@+Db7lg%D# z{~*^qU4VubAy7_Oq1pW7POrsx4)P1CLlUw!jNMHCa$k7MzsER{TuId6RlF0$m!uR( zUEDS!Y zSt_`xcQz9QpoxzmagE+kQyu&K5%ARN(LC408Rc%!q;0 z-?2vdG5jfBnA{!FckBxwj?K%7N4A-w!H?0YP5=`7^CF~qi-mS4(!D56?-s}yy^P;zQp1pJ*DlqSh zzJzYs>k$uZNJ7pT5&IN4Ys?KAv?Tz(?lVB5fES_PP3S}OP~iCb{#%cfaTkJVzpwol zv^O@{+jc0inh{ZCXIw%sol_tfS*Ca7->VfUiu${(Csa~5YAf_mLS>8e!KDdaod3R5_i#rOyks&p?Ma8s8UNO4Wi#B>?^j z$cvBtqdWkAJ{Bi@y9{TFc_jlHQgRRdUY9VIx%I4Lp zNYqOE!XU#o)$VsO0qOlw&;dA`SkJ&f&qCykne-s~j>_XQFdX_472o zf&(Xlz-}TDp&HY)y`?8eWE{h}tt4Pdl!Y)GZ6vQf}owR1t|OQpyQ{e`BCU zN;4*XkU~$u!HNx_24*in+Llq@J;9fmv8SWMB>5OA>y0c)I3qpc@0o<;FYXN^hp8e) zE#-qk!?4Y}se5$7WpnxQlaDVfRpF**xvLy{x-7Klkfh>vLL@)3Xi0!3EzMt3yE3Cq z5-O;f1ko{+U;Kj~`g;{mqw)I376amp%w@tTv7(W<@$XCDPq=1t3CVgDJ4@Nk!M-Tw z`$N%kcB}^Ps3aE3xP~g0I8PLoQElks9`i^*q8y(t$A#3BQWr~hSkhfwBC|v~jKajo z2*f?mDSXU}^qJkxdpd(*DWI~%v|>x4HxalTDcRuTem%P7n7ReJ|B{VCL(91KuD-X; zrzKanc19bM99H+|!L#RnaKq4Vd%hL$`Cc&eROI$K69-MGTR1@T3OiEl0L?4N7?@Ia zMJvkxPzNbjsW_b#;Cd72&=vWu3|WH z#}k*6rBD7QjIEAjE-D`c#y=}j2?JVs+wDT?>-ng{-Nxjph`11G>QAB=-A!8pvSK7* zT!h{%BchGI@?fq<6Z)eE9BH}E`0kXLM245T36S+*TIo{7-g1X`asbSXQ^8dEO_VIF z6Vz|(1}R_tf#`1lX7$0@p_f?de=(HIbq_Rq+d}MxDOlP5m9e~6S6EL;{a4p3R(6sy z&Qvpu^uQ=BA#caz-7Wp~%HGYe_NAKnymr*Mb*1t>B^zg@-Ph@>?=Unb;rUM$Dam-J z&yJ;G+jl#?y~m=IwC4xqI=In#iF(VAY;K?wGhn(Fpbdw3^Z>qJtH|sm*~rq(UB&Qp zA-{1dkNBxmS}#QsSn?Mb+XP)@5CPpyke`Ki|6pxujqlR^)tg^k7ze^nyVD^rbB}dW z_US=#>XPZPcG0)b{dxE4CTBa)1sgb2hSfOXyCFhUdA?oGvMz*Az<&DQZ0<T;De- zYj3aiY54n{ny_jE=_soA1GwC0v)@`~gKDOntA56e6Ka_EeV9;Dp$Pdm!;7+<{t` zPlZ|jF2zT?UY!^tW8qERA@u(tvE(!%a0y6T?U8xQ&Tx}JtOg%^^ z9_jrZGFdlGAF)D(3(R01(x1o`d^tkP(6+!iT(iBEt{8wj;vZ(nuzm zPj}64C|cRhPcdA8aqr~lcH`K@{keSxk1phlUBS@L!~upx@xc0TQQ-RM)N9~&^*12U zJHzv2ok@aIfR79TC@y6r&eEwo#c3chfU%U*kse>iF^(rR-buEPA|+bw`jKG)^E{%c z97#GPPq#o$l>dhg2qRgJ{-EhZ11)hOL=~;sjwZ`#$d}16qnw~Z7YIq=_$Bk0#C)9cI)qidzlQf@vER#t=d3K+HlU}-F6 zb49guXUgJJ18#B%H6^p{Jk&~AT{FsSO8t6@*zi0SX}cYnuQGa6Nh8EI=n__})5u!l zI=ALE%8?B@t-{L~sEP>72}D{w(_y+bSmC^#T$3qx<5w%WBkz?T&Mu2w3m&Zotiw3v zY4~F*qQMc-_#=k-4g`)7^t1?$0nF0C{MZBjY0!2vMBlhQ0&nT;txC;%)NoHep@%Ksb?_kI{#z74MDW~bU9wvvI95LKhFCzMfaRErO+N!DzBwl^ zP&VQc0yw2~rpEaT#pw^11rZOG7_s3!45bY7(Y|4kT_)J$LbValM3H%rY(*-1qf6t~ z!3inwhNxCWJse4U0irK4JY^9s6Dl-&0>f8}vET(e>snrQx0il0^LAy@I|xYbgc}W# zEcSns0SIgHDI2y6Eg_D(T4Qf%sq1P9OEsjc8X3rI8GZ1eU82w~R%xc~a6Oq1l*#*7 zT;gTJuJVh;pIe+)?~K9`_{9wm+%X|RorV7n@+|pNrSIpDTkXd834+HPqj?%ea0i%2 zNwDc71@-rI{{i)}+rS|sh?xGKS5#HY%{U{rqJk8XG23QGtE7(^ZQANVue`z-=%*KY zi8(<4nJ!nb*sxJCs3fS-tw`u=j2n8NgJUFi@hM^?SY;3`h@C+4#5?SI!y10W193W9 z23>;5=4;8p37Pak)=8KqWiS_E)&LDeFW3WtMg{7u>-D6?O0Y#pPfp+68~gJz__+#t zj^J-sR5L1S$y@1XfXAy4(_N~F3PH9ek`MPc5z<{SHYa>0}DS@+~BujIz0%<#onVzB_ zI->a>nX&k!5z)koR+_LcBuWp}yMMBjizGj!(4o+^J~x*SZ3d!qe?Wl>10OR@fgx5j z3zl{A>7JSvDG$y{`Wu7c^1PJqaz7I_0Fq?@B&Tws@`zGPiVk8pOjYa-_tfN&l2+TI zZ2#22BD_8lDauM3yj_gf=)S;|dRooZvWF1sc- zsAp-4YK4;Q1d_85#f)eD0pJ}sS~`&*6*2ycGf?1v;*2@KGa#)8DrOvKE6nmx78g;Lnh`tPQ&kGo`~o9Ime-oWLFj+_Ot|QTRhS!Be4T`5@QnRmN+-@VkLjRW=c6_-svTuD;kcE%drx$%tkzC1*c#XNA~^)B@8}UL^SCDO86HN70Zg!FJfe=2>iM+(P(Fb7?kj8 zc79JbUnL>-Nx>Yb%hO_5SzQN*s%HdAG?$dAGGbdLMay~T_oq zX$yFVc~oo!KEcUBD!{3i21^G>$_liJsw9yi@|lNrDVoxGe6O22+e=qFgDxomOEU23 zQwBCg6}@(= zPyV@z^1rT%qOQhAUiAyWKcJ1uHiwNP1UUuAll+bb=S8Q=8UAwhaI`C<7KcnikSk-g zC`($x)b;#mOJ*G~lV9tYhX+&~FJS$$*d$5vzZ|M3vXq+3Tj2izR1hLY*#MC5el0L#WY1y{@hB#N@2egohT`bZ}PB(!NUp1!@+dND`mE|wa9R*=k7BK0ji2V5M+H7E&x^z_9 z|7zU6NHV2DFDsHylS#-zLj}j5q$gI3fSQE_p^XE<5q?5fT}2~4W(r1Jn^rk2`gl3V z4pPNObhC0@*84K37oXIS&+q!>1k1|q!Jfm64>KEy=Pyr%qi$_kjj`Ocrfl*oNgkkiqfs^*w{%hPFoK!)n%HxYal;z zUt!ZU>T}#&#diCsw0y=OIWApP4J){dX%u*419xYh5aX(H<7O-Ylxdz?a=R?AAeKjbm(#*6E#CHsh1;eKieljT5K$+}Se~gniNEq8`t$ci zAB;e3Sj|*thYyHDt6*ZLSf!}7v2wbL|3aS#%yDSn^!Bx^53Z$#zmhye;KM?@P z^X(}+|0Q^yME|Y305!n>U#lGa_{b-}29VcfRpI&6&*ad8dC&!~hsy*jVBqJ5S7RK9|rv^-q2bi8YC<99bPplXr zMCx)K70uAGsR-uzoI*#DmSLJiE>hXYJE*`jhx|DssR(|i^&G52%*G(5D{074Tm<8Y zm+G7SS~Gqb;{Jm!su<3(xgaFyX#rTQ`(0sS1JvawVMh0%B~pTeN8`S?5NDUvr88{X zPMKFX@nc5o$GsfwxB>STC!r-Qd6%tS= z1Tz#f0EL3p-5QgC-~*--uBeIyw+7ru6tL|EZ+~Y1tOkCW2%3PLOOP!VwE3K&F0ZF2 zH>cA4H{l*eV3_cC*&5YJjrmoeeTpn>O&p|wOi=-LG;BR*Oxz?x5%*Cd$8Vqy7>L#c zDy&Tf26eG4&n}sv@hcUP7nj%bybt!}i&kAfoC}TeX^6!zu zOEJ^eF50MBuw@ii5sqxc0`N@MJ2^?Az&jP5g_^Vxt}xe%GG@kDbZ;vS^N6NH8dQ@p z+UY<^k_eO}5~SOwT`3PwF$*(nR8MLQ4It~r=t%xr7I4$bf=Z5Um>|#nxR~C$rsD#q zS|V{rUL(Wt7M2w+LTZE@F{_$|QJo3&`a@!LdZI2zN#5uxibrgCg{m+-llV}d{y?ze zsrQi#EkFokao2rCpJ3^wWm&PvlWE$=#$6X=_C59x0rRFae5YHCc6F1;NG8g;h*~vW z=EF)#T zH=g#tk_bn5J$5Dqpoz8uAQO4=>1zZvMQrNHD-M{~2Pda9?ZMa5yT-U|=;D7f2vc#3n=$G-CZD%hqWHY3R^*EVL-x5$S3D~MwzD|i+V^j4pTioGx z0{^0t6B(#UEe)|6%+%7@V>G_KvrgZPXiU=E9=F;@tqd;xXu&P^J5S#0xfsan?N?6! z4U!Qh3=5WrFPEy5OQg|Az=&7de}GrCsIOiopd#RZiltz2f$*rZ z5I4OPp(6$5vBN$7v1RgO1fM)=kj@}RRUsUQ6~7>i?-VaB+~TVmQWT(|-qQcP#s|w_eeOxLwLz zx#x^Z5&!pTQT)i1d6E%WV7fQHS-47n25(Fv(HwW*ORc<6TGVz<0lSwpVM5~WI}*F# z2V^YzRP|>dW3BGx@in(FXp2_Z#%0n5t}Y$WBioh#D(VH1VE2Cob-+p_R?&<3)>o%3CQaFr_3jxF`|FUP^HOS$FUZ@#1{pQ7MnY@;r;H>Y%zh+a~C@P zbH)zmofhwKZj`g#74CVHbaAE-;*%_;>fQ8xTE17CZC*;~*2o^c2E8sam~5XV!tYly z>04S3LoY*qabIEX_3ARhV98|XW`=XUl^~2{r>P%|@xB@gwH_Sp_>4u!UIRWJ1HmHk zW|HYauj>K3L)#qm4Q6jwiZS|FW_aNJ1zpvN`HiSU0fzNCK}puiyBLN|6fwd8lhBj{ zzXv3TIU$0e=#E;BJG;h@Yq-@NTiXzm9VoWyePVAykxS_#LG~N^&1u%lq>>FT@zFw% zc#*Blp!>TAGavrwg_T=#)2r)M4gZK-Q6JS@EOZlw(ST1)!@7J%R{-*rV{LP%!TAI1 zZB33bYhG$_`u>A+GjqcV<+GpJ`-U5;_8{H;2A#-?zbAAl&9WrNjA69w2trfT0?tRt z=mkqdUf}|YT(24yx9HOg*tw@Rt6$!ut^;E@lf@-dk#N6a9c*+{0@YEDNDZRka`4Uk zRvI&X8y3%a8%O&)nwTEO@s?hlKAqlY-a$6e%vvO5xo-X7?ah%*KFJHdLRXEHCcP#; z9tivzkpmU{H3A*RPIld!ef7ofH!m5>{C=aw$tyl`bCt(RrTe{ey~)Vw<4!}_Iya67 zFdLNM$xoZ;_O#L1g#ac}flH48;gV2Lf}%kbkz*Fp&a|KZ@SQ-Qt7>WTvR;y-h80bj zx;7y|*O5T9nf9P0-LPJ&mo8|me2ym=j~vqcp~{DLDIS7Da4GIX-X(#x5gZt9+U?J% z<^H$-w-IMYC1-XID-g>Pb@Y+Y9~w0 zFP!2G8|8n|*xh8;{}bq^nKr|a@TeVfwJ<~lsEm!w# zh8~+iBY|y6TXEYvA$xNivl!UO{?=X>(vz4x?Bz8+SN8h)i=ZC>p&G|g82mK&PPlqv zb~pI;`uO|!?oc3$NRB_B?GmAW((l;3XVk1x(UB(j2wj4-j>9#Qr1l9+w!#aQErc(i zqra*%hGry2JFg|d;8`lPs%N%2!*e2n@F}gceRqyqDPV@p8?X|`Ind@ye{17WQPN(B zBiG-TMkTPFx4Y;N)6Vzk5bwg7(j=NtO-OfBdGk9Dxcd~A`()z1^KkC4k0A$=H4U%dCn)yvt2Fn z^sjLq3fR=uaP(vtXUxsUzBSK&;*u=_G}R%pWOL%(w%>*d(mVp!K-J2n`_%2f8#ruO zCHVEMIiy`PO%)QlD3ZSZLUY*=szy^cGN}fr)nSgtV_8xpa%{0-beskESUNqzZp+rs z=T1)`3)aOJak%Ca)$V~M<3|v{^wQYa(%OF3MOLg#rA8okq=4@b*V zE+#E-U}A=gNCOx?Lmo!e70$HQ_bR?95S|l{4Iy*%SxXah^y{E_oY5jI#-c4OE>!Zc zfvDg^o4tP5?U~$2cGq}f&Rei#lmb0%K@c@gvUjo{ZEz|r7#0&#>H@Ki1$I%h-R}_e zi`j_r$pMLrTj>dBSaxnPIKDXJ1%fybIa{c}!|S>6CqqHnoeUW-#Q!lPvJKgicK7JY z+T{`6r*hMVzE_fv-Vho=ORzB+0nU;dYxFyo zypd+%%j8q}`(#0nThHWID$}@QI4WNzh(q z6)lnrTrySUS1gyJWUBrA8@lNdR*TM8H$A;1>>jB;tic?8&Lit9A5fa!V~|iRtbz8U zR3hV*wu^GQ5{ys=qVo;*HZHPcus=0anf?X*0wwDlZOki+F2OwB_IsB_8xaIIKpput zE~sdL8XiAnpU}GfP+03eF6l%C%&mZ#ZGf%k_6@O|D7a#fIjMZ-sV?eQYwLK zYA?w5gx=1(h72hfWq?{r0vnkTH^d}x$!l%5_1uOs%N%foW=^UXM*CyD=O`X9)cmOh zBo4o7cwvJ#)H!!qCKbN_KF(A5MH*JUD|Le@YJr$9D7_i9f(bQhs1iXwsT5Y&od8nH z-y@t3d2oG5^vlVRd{Gw20ZPXV8g3?mm@=Gy)Ius?OMaL^cn5p@gfss;E_%}cJ1%-s z_+)DZo_Qa?aZ(p#BwIduX9;ENNnuicqrQ?QYii6QSNIx--Cd^!JV;4=XfH~ts zEg<>p^5Jw`M05)}%#~|;U;Bw{O&_7l53i#v#73e~JScvlgn@p~1hJ4o z=ObJ&7MswICRuw)&eW>GXD#)?KPPkHQ#Y@lg-IW$?$_h)^&d;bZe2V7aa6^)JpNzn&S~9u#NxHx z#<)_vFax5D?Tm8ZV$FkKaR(5~Dz+rzOXFROOIhetPzT+-WDpiYpt1;d!Lk$u~3q zvIR?n49tVTp(J9?banH67r z@|(KAa03P67Xshf4fpv4L0NH*5h+48ky_(V}y1cX=s56>~}my`}p3<)QUopqr~_fU8Hwk1oIJG&6^orq4@R*-N?`SEt9C zI6CUd#FJy{q%bQj`G2)VA`* z<`d=gpbO`6MnS#yd^zKOIK2r03hRWtedae=AIZFe)0_S113oW$=qu7`r^*_o>I#)P z)r=TZppF*-FJA>rFlv7aV-SkGsfxwMtj)^i0(cm+`nBR&y-uEw#I$Z`pTFPq;^76z zz_l1i{Ot7kdygbq^P^(TQP)sx#1#GmzV;;e6E`EicZku)eQIxL9pW=KmXlgR-ukXY z*4A5_PM@eIzS`1CLRmJ8bTPJ%4{t+=K9~b8&Tc1D?H=cz)M%Zy1;r&x)kUT=nk@5^ zLa*GExwW1K@vOJskN_lBX}CT_sT-LZH6^lz4m~AZ%u0wgL9iJswe_NEsm7So3k&Vp zUHhOaZ>{&-xA7LksldyZU-yMyM%xjMzX@iIP*{P2dcRkqY($;CG)79k8QSq4Ti#MW z#Y<7^OZE?T)Cx~zw@(ODy_w__H?mv(!@2_kG*(5SlB4hI4ZmYUsxGlJl@plc8Y3lH z9r8aTO$ORX<7eWGDiUXMo6b7(J&QlwAdPALGL&a!oOdtQ)FFb4cePErR6@GdpLADY4=$El*ADvMoHu(kxj*eCC`n;d z9|NI=D`vc?DOGtycAzqVm4n#*%g#CwN9`ld#6zT*kf$L@;)8yB1w*#Eu-Hg{tjpTt zx$@@VMti2H@m0i^7%gZhBIR}r>YvJK4cGTWx)JH3vm#pA3j>L&b9tt!6Y%jl#E|!3s%e>0 z>FuMwD^-{Nq(f7o^`md>Jib{YLu4WhUh@j}om!IeG1%k}zyE}sJsyvsQb>w_Q1iRB zLYor4KA?*;iEtirs&#q?0(A7my@7o|i@LNs!yfH=o%@Rh5#MMX=hhoou~TA(eALGz zz@$*kjtCTMzTfi%*4hVqLv7KX4aAEK_8l{!cObQDt<3_NuTvxk?XIc^#rf#t;-4O0 zzz|UOSX5X^T6+>oOMD(a|I`I)i?!aJiny0D%1oKQH*PIf+cyemDV{w|4J_zs5?(*j z$|NBF+j2M2rPp}CjxK3BbC<~N7lho|Jqoo!>8Tim?WhtUaxXT)! zv89q2=8c%X`uk(fYFvPyG1Z=HJx4?#Rg6Qk$<@s!Vs}I-9)b~4#+9MX|4cgj`N#Vi z{J+-9uIm;@gTAJcX3Qd+O&m{l-+e7zl(yZHY_=~Xj+`OHWpwVkfHG#6&Rf*iaKw~o z4Jw$GVfxI`Fu%%Iyw&VUsOpLs0z9CXMJC}0$%)CJYWv>O!w8K`R1{We)!6oLi-rJM zbl!vq#Ehtw{K8KI5-JO0;O{9ryfT`8F?v+F=yQ55um**QOXf2UyE+O_+fl#}D=P!< z=bhC>#rh`SRMsxVvDepsIaexWNzw)geYaUB#n{s@V*g?HZz@Tn1J^kyCD@%BlLqe{ zwJBSq#rSfV*E>ewYnh#*$ulwIKhOvWL4cQq51~X88A20;ukumH9bwizG#RxKqA>5S z!Mc>9QQxFN=rBA%`{!kz>-gG4_$R#>^yZFA59(t%FA^8a8J3uao`{8nYOt2^_PT0S{4*41g>w=Nu7MF& z!)u$z^&{YvWtvx{kz_$FG@Qj#u98g%S4v?DD<7+giE!ek_aGO=hA{a8bfy1fMdj8R z*NWYGrA)?%igJmpRzEC#XeODyIObau#|K~>lK*F3fzIfu0X}jVJB%yx_0Zs! z(vhGem*07aTZJ-KXm)@L)}#wMo(WKZ>W%x;=M=TKwK!xpWeg#ovVH* zYr05@!r)rd`=_LI1atsnfw!bUsb)q+&Qll~3Ng6JAWUu~|2Y#X<;%bkWEYLK5V|Dv zo;eHHV!2A0y_ul}p7J}!gmA@@q{2kY;W(;p1XhY+OxAgpENtzd@)yf7#(~?xhh?H8 z&aEF4fem!y^D#+zhn!o$Y`Z&E3&PhM&%bI+yeZw_00mo**~LBIc4NX#yppl+?JzmgLlzN}m6^@@PQzwg-`soEGTnLbNoJ#ej#UiA= zn~oQhccN&UWAv`%yGut3u3%R2%J|?&wZ3(_zR2m$%%DC?+0wOp=E!WYbQ1(IY#AV@yFMpJ;3|Ox3 z-*AUz1=Pl?I|GV(jb2tJfb_b2VLkj4>EP+(pw1EB7gVdtB{@t}{`d6W`wZRWvwC0)LRiMrw#L{`5> zoi8Ehn#(R!Sz={uez_MOqhUy1z@(VQT7>uPsXPATg5L-ko^4Zj zaBHf{*p0e`nUh}qtEKeq)XBZP>1<`kT4WL*FuFxsD!gId65iGew~Zw}Zl3syKO0NR zqTBAF%%(1|F=}VD5ruH(A6JIY3d*;5w$GU{D@#H%4<<0V&-OJVit-UrMf6E)SfIC0 z08LkSo@V@;q(Y%zTFTc=PbsXGDQ|)RrRM*K5__1pC)QEzsG!%jKzxZ*B;tr1Ze`S`Y@)g#{E+dOoqste_|s zvU<8oyXW+rs&3H~;7zF3F^){(Br*dM5}j8p^w!25oUha#v-^A=OT#X@CHBb+yK(>g zT-b9ZLlqaGV}2xaMhjb9TRHhJ$ZoW(pUjsS<8s&0gNL4 zk}Tz?Z%MK)3b=CV>544$Nz&Krs~o%Wb5YJFX%sc1&}XIk<6Bo(9?1Wl*Xp9|b<-|E z#@dMaAp&G{bjnf)GB%p~IU?zVPd%~Q7!|4=Q>(w}woj}afjlm-}VjXznVCD_y0a(}g>10fGh)E1QSs`xgB zdVR_{z!NbC@?{!8L;@ly?Be+S3dD-ihAy?~AL?;3(u~B#fa6z8NB;qMYvW6k#I9@h zqnHR2HFp46fiqQaLfcT`PXv?1XmV-d=dzB_3Rb+`3x&=aaK%U}SzNh9z;&T3+r)Qk zNM`t5brpT(*j<~Vu794%yCP8bnf+Vw24-;z831X$pN~rQ)@~Y@N0m8$ZzY7oB5d1% z#9OvszW1MA&*J`1ubV=>bDe&tQl$F|>1rXP*YdnM*QXq+hEwmgeUwI#&2f(=ifPCx zL5NiDio3sSeq9&A$tp2;p7#SMwwd{4U{X6`x$N>#5bf;l&}xlO(Bj=evJ$Z?o}4UQ z9v|P)mB$?<0j?c1Mm;cuB;0)vcL3t-=4d2ion$Asu z41O8@eHdMnl+LZ`xf0VOj$v<{!n>bpY)8TvqLmf4?4k;lZI0ddmqeYkqCYn{CADb} z=?WXsL{*|jv7)_JnX<3YV5O0XwhLc=fIDbfR?vcbWc-0?Xlnu&y3UL#egNOufXw1+8E zKiA1iDd&d|JP+SZehzM^!2A7d?-C2D7f?4}INzO9{l(`kr2cW=!~t4^_`Dyp;i``h zG+31-enUYW|hfpS(*`l2fA7(`Guk&_K~z* zCBzQ4!Rg$hOGU<9iFkg_#!6OOly2^nG@1E}|IDlm%(uwVO-G4g^uyq6A(dOEc_i-1 z%f4~GZX5LZLRpYtSWc?t9s0TOq6Dx0Svc{UeMGneo}40G{S^Nsfsj3rQ}~IY)=e!? z-!Cwrk9|Z9iKTaCWGK;UXz>f}gobjIe2o!qV~nqf{1HRs7FmkiZy=Hrb9`zbtA`Ri z+s;L=V2gnrop?Xfh$ADo92Fw`Wz!G)@P(r*{WfdJgoE{qWQe%c`$fWm*#l3v2XFlx zT>l%J`Zt|(M+r0y)hOz72tGgmTKcTU;kNh@Bq8JnsE>e+6*j^n(w7d|D?U~(%fGaO zBTnk0k`0nqyg*5liwlvC+qa)FL|&2T$o+;QHqpmQA7%9jf&{WN{Et;q0)J3@q5mdl z!u%cIX(R1?WVOg0cynGt2v1VUyl3t*grV? zcXgWcUvhwDU(X4{$3aNrV$a3+{uPI;;Xc#}stI2og+R5-j_kiJE-F8HldU-?3JzfE z8FyQ6Zo36aX@3m6wq<0sh#%*oq-3?xX%kD2d8HY~zmlR#Y?cy?<7~TS3vJ&Xg&+k@ zU-qF%0DADaOHUr5eG$t27vrF1b?j4!l%RU{0w3POr;*-%t1Mb1cerBm$gfO;@b%~+ zr1?AX^hCU)ZsP(K2rfx+2-K7D1LEpCFW^aXy<#$&-JVSBB0Uj{@MBh9*p6L=>PaF%9mWhoq_g>n6S*0yTeew8p^v6LwvRSwB#gV*Apv=va za|T?}N>p&^>X$l;=n&iH(h;e3m<$B7+tQVb)Yh2uyF(YRt6|FJ-Wn#*W* z6%hr?0$1^mV^hm4Axt&#-i3Uwib#veLlwfqn*$$2x-ZryCG^id4+63+1daof*c+Y? zfL2pMJLZQ|SU2LqpEa4%#gpFJ1~v}CpU%a)3hUSExqp)1|HZ4NTZs@N?URt5#u=74 zf3RC&Lg}PwT2B^FhX|_AH2KvMI+Ggo02k~YBVLhO!1P?kfBQUy9*D_#A#Dp|gOv2a z%x9e|A$HO$WHf1Ddn6Oi99C&}EgV`0%r3qbq)`j(d!@no2#WwBjh0o*;nvo*-Ki;< zO8V_=0mYtBs<1xJUqvB3`J&pX|12aMz3%(m|NkKYgqZ=-#joZ2o6hy*zkyV5{}Q zGH#RNr-C`-TBu`}dQU%Tfw^U_MI_urp5F?#H`9K7*$mXFA@bDI@z<%2Swxj^RR#+- zAt?uOY_L)1`)MnYrR9PlX2{NsFiTuUzTZBYQXg_xCmRxkt7M594|1Z3RNXy{ zD3Q3&qK+vIK;Yla8Z&36qz_ZR6CN1La2SKkCsPxYMOR`z2?>SUM?Y!Gl7fn9&F~cE z2K12$7|O@W%XQd^rQcgCs@a0naVk+h;@A;W5#Z>@Mgw-8ptBG?<6bF-Cs22LfW$Pt z<#STRO$?KU`t04Y8u#%p{OssJL2k`~zyfbpGsVZ};e)rsBePCjPDeHzClT4M(PoF< z29OmOIumLs)9$LzEe-K6TBL9|cXAy+xjt;1+t42DM7Ly1XuE+FI)*D08Y^$&_+4HNEjVS$_yVJe_upOqoGBG zah!|6Oe2ScE|<@kvVikAH5+~{?UH>D#~l}Jru|GaZ+WeKP3Aey8(vqd4Y*SI$G-0Q z#~*~T!V9+`==k-<%#_iQ!<6_Cgu%5CyVx&d3T{78vLQlR{vOoUn3$vv3H`$$R-6IG z)VRo4=Fqr!o#I`(ape+ZdcuTwc=$s)wRz0$AU4}-(=LB?g7! zr9?gLyqJLNB-f@c<_{STAMl=w0-Pe9YPpB&n+6tC&rYdFA`UJbGGJl$aOVn;d##j| zD$c6pbHr^>MwON5($a$XkF4jteS}|Nlb*=Dh)YiRSb+gV2~o8P+XAt=GX+6RSoHV`!fA$c0OJkm5d=kbCef@jKAIpUr@%Z=z z%jK7#uNB@Uj&6C5gmLq1+kk8jRzBa3=|hq9Na)`Noe~WU6$MJMeep4{`qwCi182$X z?tyajSLHx>lK9Prj)Y=9R}xa-dHoTVS1@}K5VR^gTVLgo5akq6S6^{kr})q< zLh(xSXzC6WR%dV$`iqO`?nA=oTndrTspI?U7CJ@>_F#6<&Gw3lws3)ZcuK{If^gM` zJkM?96Jrx0#HH-doI4Sp-QA2$1k|0+qfO2A3}py1`Hn3QzW4||-Tvv{2I}8IbcJb( zNbiAtgzd@Vtk7%+o%k8<_qaeC5bLjdXPu&YaJmAEgXwA$1MrzJ$$ORM!2h46l`PH8 zNMuMd|3yqxy+-{tbp|-@!Aa;T4*8GcK7eC?+WaZ3zF9(HXL9OdDSLnCKl-%Jq5C}i zF(w5xvZj&@G2EMlR`8hLpJEnY4&NvJ{i!IO~j+VF*^&vTn^ z*L0xKZ=yjQ8uonY=~0s1MlA7z=}xR*qj)UIKiEXaS;0`5?6*J8+Qv6cz;I(rrr7Wg;KED9<;+6OZgx>HK@1AfSqgU4#f#>UkzkfNYSMjNR z5@hQ#Xp80a^XyTv8x&|k4ZZvb&R8fnghma6tq%y6cycW@Q*uC6vF`~_FPx=B9d*_T zEU;WABk%<`fOr*vX_(94bM%iKdi_dt__-1|x@j-*T^+z$i?jcX#U>TIu48c>5dg0Q zuRM+%whoLS9&59etf=sqg-+0L=fP^SqB)3EXMZt|alAyEV2rjmoQ+nh<}^`q zq4Yc_Ql$|Iyor8xA32;3#i9eiDWUd}ZRW(QFRJe%H?-e8kxT{Ddzz9a*123vj9Xb< zO$5O405Oxp)<4sd1oWaivD2}*vOUB6%nF`;8AWxXlA3r5U!{!trW=kAfA-iH>MSj0 zmJjGbdH5E42HUq##$R;LOxgZJ7og9EqJPfVvcVo_L`}!6qxZ-6Fx;=RhkC=;U)N7K zMb)7vMlP^@oQPyq95f}N#|hF!Tn^O{kfz1mS|>_};E#87V5bPBb)!xOb=Gy`rT%T4 z>enFz02w5O$RtBN-SgC`5PU8}liuC9juF#Um}?}nJ%AoAu-0|CZmCwYr~LD7DwTc_ zc6u*AP5Rdv?}7gl2|{B{oeaazn;@Ghn;8UW(6;Fo3^0@w$?~o1k}Eyz5o{99EEe92 zt}ZCndrm#h7@bC_BYU;p!&Vhdo{G^%`~PRZ3u(Yik-O06`=*C3qR}O&f$cxA6Po0B z;o387W0aY$wr&CL)~OoDVWlaXU$X({QtLr$SCY6I#bdU~2kN1AnO1nxXlg3t4O)JD zBx91H?5$3#wC!E=(oNZfyCx!P(^Gyq%sWJ8Mr<;wyO-1z0g(4cg=PqKY>?Bf*7hCM zwt$q$r0_jq;30=C1#pt!F~E@7_@f_Y}n`!;C!qUvN25#n;GUN{&b! zcBhBcLzxyfi|Ro~<4Rf@t6IjG%Bg`rYK2Z(``AuURM`4!9H&@R=^)lf*QrVtrskO? z5M{XoOoWd!#Cl9b8Ug2j;<@TzMNSby`hgCi@Z7xZ#=OEkrT}W*JuwTSvanc0!m=<< zh2^Ij7!s4U9IjA7@G5lW5h^IZnh&;+K@j_N)Ykrtk#7Lnr!c_V-9R>#@wfZW40WBM zl4%;RZ&GMfV~eF zq+Kpu5Xeoe9!NF$%~m}(BD3E9R;{|x&_`>}5*Vkx9QSPIb<6uVj*aMc&luB4TSCj< zpFr0og=)??MGmtAu^b=RX@`6TK3};8w!LM6oNR!3L*rSc)OFCiDiKLFJP`(b9}LMZ z>6%rc`i*z~b_`~egY`9LQcMtVtEA{O3dIO_4uxc3Y)2ls*N!t=5GBnBQeVBAcyQcj zh1`JuXD-@-_|IXcRdr8)uRp$ScEcY0Yu_5!mRs5@mqf-mE_5c`peI$M(j|w4ty@|a zJ+EPa&;JYNJM6uBD%^tH{R8aJY_Hh6tfi;F@e@N2D%b0nxjhg>j8SaB`LtDoe5bDb zip^%i9jVTq<0<9Uj3#2kDl%Td*dCqzO;xEGek>HY42#k!C=!)4Bo9K19cu5YvI#wN zZQeWH)!!gl)&RPi5pJr&%icR`2_VxPp#Gp|6`ZcGb%FDG4_Az%DtL6raJ8Vhc%FhL zmutku&}#wdekcN6c&ocB;zkPZaq;R2+cKjd8_ySWjV=c4cfi%SB4qt^wS%G9H+;QR zu-29PtxqV6S)SC=rU)4>r346q8$qau)z@NpYWwr=)esek&5foQ7?$yWmPo^Og#H?m zA}Kb3stZW>LYpbV8{EwhHwXYaqbDBeLzI;3&XH=Onr#$eJj-Dr4e%O(&LNLUm!L`{ z(+EF`CyV36s;w#XHcmys?xTEahvmEje4B3=YMdtQM?1tfvvlNe`)K@0Z6=-^zq!z7 z=tkDT{oHkynEO|>PTN+*bB@IQb5X?Z+5`FXrJ33^O0zO(t0!MK(>B1L%dHk z3plGf5D#4StQfM4ga^DSbShtpc)3gClM9k5)OQ=E4_LZS{umut8aq|hHNP_vE=NFk zoeQE%nGw8p^WF-WM7W22*yfC#3YGxKNa>XO_e5~fBmE4iyASWTQY3?<%HNxIw%00q z#$XM;DYvjoaK>!?T%zOJVnod*HB-@GC2pHs#TWJ`%V!1Kcl{-@DyrUUTAF?U@ul!W zT-iM^H<*iP2EjIaJRJYC)qC-g1H@^nmie7L05dcO2Sc*P9Jlc0D^-RrM3{TH3W$JB zi$zO8e!! zcL)t@qhQQkxx3!7T%I{&5Fy~e=9x#vP$$wz9KK4eTIwgAcTgr70#lD$ND*iRw7i?} zloi{=>N0c*?r6fBK*-z!LvY*!xFm5T#{wbQXBlH8dyC?qFbC1y-%Hu-sj&fYGCwrV z!MYY1=J53Q>ecU1xfGLrRul{zuY6|IhfmQ~aCko{Y)FJTh#LtD>>OX28WrqMt|uVc z61eOYbLWu2zT`FS$$MR}s<|_#!qiTv6rv9ZUZxpD3aX|M*OYRZ&>FSHL%ih0w()C@f?{l>Q?;+?Ag&CCQ&2!J&$r&LE>YuZsO=oT%&3Vxob>LK33q z{UBXfLvTD6ym>(f4ChE;V#P(5YqR$X!RqyfB;{pl>z(%H2~&=L!>qP_V_u9y$$8WF zwAbr{lb5HFKym#S3y&;m^lawjpTSdH2%8==_`>Mq)P!Jr|0^;Ee6D!4eDg#cS|(Yr z4>_XBKcpz6Ma`OGlm9{hZyIS3*7Y0;f{He?$sFZpV&<4;_P`#swoa3bWxrsIK0-pGzTt}^QL*RfEP0#`i3XIuaNb(l0K0lljx0)~G zxQ|x=Qn?#6Jc#GnffqJ8*ohm4@L$66)kjuYxa|T>5e(>wEsV-8-09bx%V8t9e<@r| z1ax2XllS@yG+_yVvk28FV1?lcq-E%0+tKwVa(OF%|- ze{;IlH#k1=PjP6+++k?7IET*_rAT!s*+qJNhd0lnZM0!GN{UI&F}vT=(mMmH}`aS)$Oj*yUY zJ{t0k%XPa!#M2{+t4nmdvoXe@u4d`oSGhf4bWgz1o$XZ4|E1nb2mWDvj|1;DMs#9v z-7}(QhC2)qOZWKw0kDaFa09TB5Vrf5%}xBXyPFUSn(j>ivQoVz>Db+~4d=wR?OU2* zU9;-ei?ks_jm{^I;KW8f^LB*H05XdS=FCa#aZiC~yym`bIT*_dUE#VK{cTEOPyGmF zY9DdSQ2-^{?q7tb*_P?j1dm52#q6EK{Ark8OoN48m+hU+m8nV&brS;kaE4oejr{5) z65Z64a{=II?tQNj@Y8~(ae5~g`rOF2#xWEHJr_=6{PNZH> zf4#dcXkH5~y*Oi=O^{Vk1B1K=XA_b@Ap~{H5h7R4Cq}*raz@ui4|SfnJa{&9v778R zc0A{7Fsk;{P2z6Sy(CJtIU3)1JG4UlY+txy-C+H7KRNh01F#15AXZTIEDmwbSC6Yw zj~V6W6o1Qz!bOmEPrDRiJP1J3PxNG>>*kTMUvcm;F}g` zeZoM+pXkmx{D)X5Z__Gw_Wy{JWupjxG?>$STlfI61DYb{hjpC+uboyR+q4CF3NSX= z2^>>%rNL_nJZZ8Kzwz7XN%JYdfU1zyQX=05ZKG>rg>Fw=mh`Uvm#MY1le)hSl(ZxM zWSRT=UjEO^W2HS?x)om7u(q{LQi$LN5Hd{frog5{)_F*uSazL5;NhdAbUiS=UgO{d z)d*n>;$6#2JE7sgI4nmRSXiv}L=Lp!PJ0@1_5QF)9{PVrmnXRI@^PB!(QB4 zVeqK>)EaM)4%c2^fN;4CZeiLpEQ295=FH3@Lh(v5x-2~+-yGlMaQs%D~l0fu-@iM(GMP!=4xzXiVc(q&ALGVthbQ)K=3t^P&8 zKW%aATmNZI%EttOc5>;S=D!p9wazyC4SzP-ZH;loYS<1^klev+=mJnwE+pe-fO$ojMuf|@C$)|l&MTz}ngIN({0;ISm5 zCbv-17f%7DB&Nded*cP{iMW)~YcNE}4&2SM_zpOW1E%?#F9D71jV?Ea_fL`y25YIJ zv9nRIWu_KW&3s()fUPaMoa~?5xe~-;WPylLv<`p#lYUQK0`QN54NmF4v1TV2`;- z+B3X2ZD;-6a3CToDjZfXsNSP#PdDWGM>u4OW(_cCZ^_3*DNQ<#ay2B{b#N`Q&DcvB&Ty_lo>(Ul!&FRb$E^_6D zGw%fNHhX#OfBk0O7%)=9`IZ~-&-Fl zF>@_}bA~Y!i^6uci^!U<6-vl4-eWHv1kgg@Q%F>Y`_5UbXt&qTTV6)($;>OlrJDOS z(cI)vO6;RyuH3hdG&a1@w-mpt^QS)R4^-L~Ipb9?dHt^XPI;&CX_pQ{JP!qW@q#f9 zzrikz-=(I1iy0i}jJ(w$gtesq*!yeJfe`kSQ|aQ%b^pKJ<^G!*KKaglx=S>SZ0l3L zN_2=kN*S(WCflDdGyyKM<j1BmPG+Q}V3tPr?{CQ_|YEQOwq&q81a21VY& z3=i|S%~554ZXZNwV9CYS%k%H)<>;VB*80E1eCF8F(|nsvIn(u*H!%n=>r1em<5VK= zEBUzo4_lkUyRkBSDqjYT8qc3qqF=NL;Wt2swKbJ%3%{(~4i_6|WGHf+9I>#znUx%+ zW91EpwnxHW)qWc7$9iAo+tqTQx;I09^yBsJV6D;XsLaYlDP^=&&CR`RmAdD`Va=Ro z_Vv$)4{6!-oF{RhpRA7Egb$3$jTxZDV~*Z2%HGd&<%N?cxzbxHzlh!)%XV~OSy>J*mLDe5NZqVVYJh3d(qvPONvNzAJXhhI zCReS+)-_W%q-0JiaXN8&{;QmTS8NB-YOsNcIhxy26_wNr)cF}wYd4W7e_8dl()^k` zCt-j3QZhH0Xju#Mvm)VQZN%W9t08-2%X27w)#SzUK0okH4YLLtEtzj<3Cf^SUh7P@ zHw^4dY5|V7cJ}%WZV){~umT;+D1A^!4GJ}Wg}wcY&wcjixSgRbAw|WNCeOXvcPun6 zcd&^T|9#@>n`CNN=SIZ3m3K$|RfMM7Rj+Y88u}O0si*6R5k(OeJ?gyCyy+wDFBMJh zTuY3Z9FxD;t!#3G9w;D5Va=c$+yO@C>1ZFn6^^^Q?k&o(4^@+hW`k!-!|IH)VmTSs z6zWF`E#63q@4YcY#rwrCLi&ZD*i<*avKj_uAYIqIL!)u&zqc6TIn~xhM@&Kf(S7Is z`Fe`t-S5FpY9ivxzU;eO4ratamyes2EeErewXnv1jJijA%7bfORL`#Qssd5A3nv?P znQm97MK%r0Lg441l~4_A9LxX~PvcZ$2u>T(L7FStFb|%>8;yp@N4}K8sb{m=XKM8b zg^Sp+0P!F&p}l=JxvV_wp2^IMr(4~-73ze&-*?DX20l~=6mYR`?(fe6G9xqOv=2V^fH&6^BHOb1I6H0Yt(zeb^$M^v1yGuxDL*syk!`&76r3|6Jz2P;t+y*m#y{ z;`D9X5_u%aHC@>frGJgFb{zM)w)nfXsIV2t@{{l#u^rU05H@btW~i#ke^~gh9vM~j zf0{A9JM>Fv72b?8w7JGUSQazs1Ht5rw7Lo9K>-7y_=b*-+j|E;Q}z*r@Md7!I&RN@ z6P)&0d~NZ5xuFm%()X|CHJp9`iE2NN&!bx$}iL|Ci%CwGp7b^5HM+U zJ-GX6`p3`CVYj|&^mjGadx@z^?bH>Ng1q*3a_r=|aoycBJ)8A*FY0`;pts zQ(`pM_yv#l+p;q?N4D&r$KN4Q#H9z;ffkaft>e?5aZ_B+|RW@9oN#R*%Kt&6UN8}XvOiCffeVsi~ zm-05+CsMoNCr2zFbipHAR8%FuuUt5jI}C-?Pp>zSiujnhB)GrD8l2Enq^6B3zHdfT$WR!9|_@s38(i>vd;56QrW4e#V~$-gg`>f7q?>`}ZN zV7{o7vfju3q9jaYG-}wT`(D>?pBUeWcjAs){>1wNdABc2J?~NizbNwZbL`Z(nb%5c zr_x`P&yDh@^Tro>;XLBMet?8OLIzvlOYx)cHHWJ+zgLn&Wh14=q2{2yTviF5t3(VTv z5O|K6+d>Duw35PFL97G=LpbLlI%d0~sFCXM33CaV;jpMlV*`vCz{7Ws@0j@4T7Bvh zne$h?v0gzpGEulk;mH?W~hu zIxzw8a}CjvAXN>KWs^qkSeTnxb9t6EW^-AHZ|$&epMNDIng?7lb0p+gY3kxa<3rU} z64BZLdp2dJG%bF`ql!8GWaNyoz&~n>sQUW9NDuH0GM__s_w(Wq2Yb7{N%4Oz=FhaT zhS>hbb-HlDYA8qlzDlw`vAg9h{vR`M05dn!^ZK0sjB=)@ZQr<0N4ujA)sS4Bb2Cau zceh|lP|fhhBwGcOzo^Z8h=f;=HvXN6dt+lx3jDoJ%09rERR;ayXe zQGp9TN+~hB)nDUAn78J<0X;dD4*eN6_<%^N7~j3SccvWiU?(iArO$ovC`a&E%v=jONXI9iY|-^)45m6Ef)|(c}7jQ|wDaRTQyCObAfndD@to;>ilMdl9js zmgFZwz)Oo&Gi`csG+LP~wS{L_NJ?%@brTV_RA}aV1OOqf_?;;+DMI{}Jm|Ni2dWP$ z-~twpT!s|eFjVpUt>;Sy#!Ll=U29YLp?sxU#|EIx(-gcCT60(@!nUSSyA)Gp(T>3T zwcAmg+z_(=cOscnbtf|uf3DD3RI86+ecroOSV+1#c%_g$woI?Ua1r%u727r|1Z6a! z;Y2dv?N?Tx?T2PwBb8u$xkuzbO%Y;( znWUj07c1NLbG;G zs_tWU>x?dD$8Iqoa$f$Pl($-vX3VSTeQO~{`%$4ZVNFhqV<&fl<4AOva%hsno*LV8 zaNcvKrX^$uqnL=kOjq>>Paj)Ve6`uLxbWIK`|?9Le-2x*(TRzezfKov?b4O=?DV^V z`^P8~jj$7*%m4=Nwa(J3;Yyb;1A~mh=!>6Mx=*sL$C_}QGRBaz&nq1pUXp#8Bidxozh*1B51Eo2|xK=*lM{AaEj@+k5Sf?3QiM=oNB2R|{J?Y1bL z#^qa-F>=&b)>(-DL9@c`l}oIsfRWbDP9c$3`gfw=*i0CsHRDd>H+iF9jf!*ZCBCRm z85?|(a&n$n)8s9{urEsN#kb4+#u6^Zs{o{}>s4gf>N{Z(3D>c0OZhgn^uEu0iyG`< zB~=p_*vfS~=guDJL&TyXG^3QQuDJ=4#~511ksTwCdE(fI0c!q`AHHS=Qn1&VxPvu#hCV2GB12 zz>pkID}xeGox8kTgF!{?P4+K82;!#!81=(dw{PMRWEOk2R@8@5%xBTKI{RF1yy_Ww z%sa+m4cEBvfHpGA*uScU3)!f73bd-c_O73Iy=OL}t3?Hwwt?;@49^cqbDJM9u?Yd+_**->`Zo}5aQJ6~ z>Em^_eztF*IVk0~|9QrT>2Z-gz4hL-uuB9ub>*P#SY|1W-)SsOAN#vlat}s1R;G3d zG(3AcsRe%{bB=s{tjk3yCBp6hp~rA^uxHt=@Bf0AJrq#cx{?2WPSaIqRaa0~lN9@R z+)7*deoHoy7Vg9A!^Y)-q?hqdwE}vzYC!`D6A5I8?>Bn2FeoMU;sj;j;j>$RROz<* zmxxvP>vFP%X<8yug)oy7s*v{zFU^v1YVRqyBnlILEwG({ol`Uo!Q-Ic4qE-W_H5NKl#koDL@aM z_=&=zn94SDD_e)Rr-G0J95s7>V@`1e3aqC3UfwvjnLOvTGd6y?TMuOhhkWCCW1YnK z#>y++mTD9f{5LgmjCmr*<0dn^0yU8KoHGlo?X`2Kx9jSVC&w&|Rh^Tm^&5EuMmsM~ zNcRi;-eV0aO8W2GsGf>f!8kWcsHi$@j!;%@4CKl|nKubq&Mtu`Oq}h;Ro>i5Nkxod z7)+e@lnOjcGkA>p5R6zn_3o-|3Tr(0QfD>c=&zL~ToTX33GRdEh+?Q-yRb}j{_9xk za-5z->eV@Zz)4!7AI$pGQ_H)`#B$YcMjv zmWaQ=*FSQhqWJ#iM#UuldhEn+b{@veEG`4cD?pU$1LO@cHt}=F1an&jWknfMCSneE>yKg89TD$A|-UB_GCF_riu|IhMvfXh$dv$buMW6Or<( zUA;M^sDnq0q`Gh6i+oowBATa-Os7=VEUE3ql-~0(2SeQbu2)XPgU@^_?|n%|Z^PxP zgd(+eqr@+d2ZqA&SMl^^VBrX z?6{kyVu65+CW~CF9m!Q;!y80qaATYe$Sl0sp>I}aW$bf$)8lUIe{@B0>z|`GR%4=* zwMs({#<^abKB1?*lVYgMn49(pvJUtOT4eD+EeSV`K8epy>$sBfic5$x36<)o&btO1cysFo% z8peBfU0!3fW~LBXb8#*x{rAH9vbcB^OqR zA%C_=G%36C8)cMRJoCLoBSfD>%G!1&ht(u zw<(-(YjIg;_U_sJzHZOY)@JV1?9&y)3Ll7c!n*~g>g^lLqp-WXB$Snt5e8sC{DCMl z60fbZM~ALY{9GiAprnIK{F{vyDQ)hpq^;VtdhyUJ=reE*c z*FF4P5vt(7U)jDK{j|Vua6_+^Z6DQ8-pf0orTXwvHoUz9BMc*E$J`AtL<+DSXe#5wqvs{je%*7w+kp>~Msxb)EuS|P97d0^>)kGlti+*Wkh9z(Eb2XjuPRMXIrMy*$9$mC4V*MaA z_~7H6_Dtoo-A#Dw!;-NG{^;EH)kX8)Jx6g!x!i%~^>+en#zYnr2edN!XeUrT0uTf* zPn?~-P-^c zi2N8Sd;Z7|x0SwodNsF^j3&IYaNjwLH{0D0Cg|aaOlS$zPMmw`ihmJr9bTGavP`61 z7-OKmpVoXb8;Yb8x~DFVKm!KNVg>JdzCWQo@UL4V6nMt~! zJ^z@Dq|>_>2PD9M1tc5-5+o0zdyQXC?$QMjCnAfKA`lE|FMrS^;ALHgA30bDYyojP}R6>zD z>`(1xq@~Y&@T;sGK-L9%RF#RQsPVyj)~L2NtJD&^RDa{tmzBUBCl8088+1)sw~{_h zigHCrP2Xzq#(p4vH>?`q_WoqTua`mrrV)3PU^=N)JtA4KkUkN0QfD2EEf?4tfD@B{l$Bu+YCv3>k;25 z*|7s#h2gJe&Q8y)vDigiM$Qh*U!Ky_(R#i{zaE2uoA?X|f@D(`Jz6vB9oB}yNHhtTJKI2@vo{j zC11O!$6(p(NydC^lfjE!xs0DkLIH-&Tan(#p$yx<^!;;8*lnMGpLUQGk_?TOTFc`h zq_9*XH^(?a<9s58xP}z_=o8W*O(y9M%A)~)TXX?Rze0LHVPCrNNNK+h9)k8{bv7?Z zXT>E$$l0BlDp1-%h`*0o*x$Fp%sgq~{Lh0tZggjL-pxU$qZ z0K}bHo)djhG;F>K^8*clYy!ItkDQq5U9QwNEhVTAVlB4iPGK$&AJRQVMV()#V7tf-iiLtwr*HQBx^ z&o<_0uPc+Rvu8Aap`pBKTqYf!j)b#Oj^4Zw9Ht0wBs(*AS9yL3w9v)4Eu#db{q)`9 z&)`h5Afq+(cxG45NQLI1r#R#`Y=`XzB-o3gdAQv7t?Qs5XCxJvR%INR)>tx_pSsTI z%~5lefsmCwi@fgpW5YU^wjccS6c43JGpg~r!lv zHH4E4^R|pP)fJ-rkf*%iRTgpK$C6j(^Pn(%ilqOf2pE#` z9qw6$VL~(C(chrHq8Ivrft11u3^;bNWs?80K4Cro#DR3fw2TO;J~~2?S_G?Zhi9#P zL|@&GH1yWl?J0;N{1qFS!s;(cmQgog<n z?#m&$2xnfM&`0}&3h5xR(f$x)I0h;(soif@+i~~0f`;uo0WiW5^*4YgdH}0jwKxqX zaHuihO8u;44U@%KvnhT4o$a@0_Y`UT&@12?@35r5>wy&ZNU_-xAg~pIEV6nbX|Gz* zlr>kDzv^_E!3sPsQoCq3op`g`U$w8sF?Z6tt9+>?y1p>RZ+qaywS;ebn0oXLwNi40 zSI?9zcU{cU&{Wd6VZsPr_qU|0#_xiW0++Luje5S-+M22Vz+n`blk*CfZ8XE=rcp3r zJegA!JdQ-Tv9zml(wSJ2UL)b~>g7rxoyVhV5_+O>vwXN5+qwzeSS}qf?{80}h3Qu< zFbiYkEd3eO5^3zGAqn3oF z!K`s(ovbGMT_c85jC-Ht&pa5Zk-j_r%$Fy=^!SN`-FLqOtM<%gdJtQ;{j8JYDfY%XXv zyK^*0>hr+<)oPA}^FBmaG1DY(3s513>k3ML0;ahq5MNU~>WZIf=SzIl{6!raM7NUO2V%xmFHwlo*`!AAa7Z zU#c4>#-0$TJ1HZSnoaP877JXSL!J zsW<(8!D^B!Ek?B^M+P`q-nPD&A5ZL8%A4pu#G(smjU&!2z>($-jdr7SOy-F z7x{~U(^Vw&M7j>NGY(BL$WJkXd)hxRV6`WQavR82XA~BBWxw^wSK4SW0xKGt(_(}) zTM^(doH&xUe$*H~F)!Jkt!)^3tDP4l;F{zRBLU0B_tDx%Taan~({RLK8}re=Ug@{* zY=k!{xz?W-kF17zCG!q8$dOpUZ>EI+se`NGzq z81==@Nwhl~k#D3G?Kh^p9o{{|6O{V~M(L9%DGu5etxj~Sy;w>?ha7+jKc=G7xLda3 zD}8Q;)5~ZQBCC$7b7Ui=Q9!H;ICbR$nMZ9-I-R~teE-;q=-%h3#W8xjrr_d6WLG&j zf=&?A5?LhS@sD0h1w}Wc$*z`@U#u_);21wSD*_`9VaxD!`7}l>%_Ew==ib32eY?AX z-xf_^a08t!X`%wsbG@WdXq?aBq`xa&cR4Z1uQ-HU^nZ17fW^Q8sxq9K*PCm!FTK`L&8~L*h_Nwmda-_ zDNK;$p`QL&gQFhBc=R+e#=qgl1`&BIExI=dEX z$Pc^PEiB^3!*lCWSn|A0b1RpqFqHl6R`k)MbA`nG1xWa0e1eDzYQT2=)#dJf%}=Nle+-rG zp2^fBSx1SHsI~d^u*tyUfKA4hT(6rzAYF!Z#2U)@cj1L#U_?+sk zlKb&>1GBQjENWQ<65MuvMMf5kKSlX|(wp7QC9fu|bBq_H#{r%m%mVaK9G%Nc5}oTO zlg>9)<25@7n<&R(IE_A9Gtr-Si@RJ^+P#%qX9CU~ z5G-jUNcgA7ZN;q1N-T4?bM0!0`NiCT4?uj-c(Z7sAm=Kk&Yc``qotFO5Yx4|XbVC> z608=G%;}45w80|>?jxa%QFm|*sgufeHp)}my9~?F%>Bc_tjA^ZVWCLHMgbXYXe323l zgNIy9HM)yz+gbUgwkXi(o5j)|jt(IA%ivb5mU7H2?h((xESo59y zMQ^=ecuNF{iDi=XQe5V}hf(G@Fl>XEm8Hk8SA`?wAIwqK0TgaqS4Rg-YtwzulFQ2Z z?mknHFi!w(yLY&TYZ|VPn4sN8OKMpZbLD)mDcOX-{4s}RywtiIueJpL0$Sl*Ys)8Q z2b`{Lc)Jr7R9qbtO2(uie)fZ*kRnL%Ki~f)%VMI4TTBSat)iSeA<<(!It7m)qj@J& zFuVl4U4YNf7H|jT9%O9-+M`Hiw~KpQIPZpjW}NOd#Y~^!tB7dw>-`}GlK{u}hm->= zAxKC}Lnb3DxJ)Va`5Oio_^^|^mKyOs49q7%8MGJ|tSjUbbUFgEoXv2B9%O=fs|CJ2 zmtcsB0+tIRoqz<~S8Os`EU}oeze~V~UUvTB(K?gl7a>-cPWn#Dv`<#mY^6iTJ|emEgH|J;iQ?~r|SHx#vcd*bgeDJ zUp|EX_V@7P%s6SeA+IDAQ^FblD=d*ZF4>tJ(c7vO^84+B2(LgJi%$Qi>xH`eh2h^9 zM`kT6nfBUYbKlE1r>`}X6N-Kc@#i&f)&N|(nR5^XrUnHc2fXe-i4=(}plp+Z!;GA+ z=WE!qrR>nhMw=C2stT9#whM7!_@@m3A#y?&7qoDOO3Ze7ZL*KPy~zj&W#L$9Bz&YP zK?aoWF!loucwn3vF@UIubBi8|s7ynXGm8K78K8Z8Fx2n>V;V+gvL+@mhk^fwr&QBm zt!uqgLK-dQ>(1kJ8<4~%Vc5=5wggm7!cfN&yn~pDmru-)M+4%cNgAtdz$Oy64Ep0r z;~X;t!zIIkhhK%(aGKsE{3#!=pAoJ<@+uD|NXnpuk(=W+2llq- zS>5AnJ_OZyrj=`kRxRgJTBwR6V8q0J5w2zkb;mQq+U}t=e-GyeT>4WlD`aMSdCFGar^H^Mv~b~6iEX& za;u_TS}l=h1C8d|lr4l92itr}Um!YH8gMgid@|8N#5=ImbH+Dk)@`ikTTyu$9WQ(r zl0`AMVf9+dg#Cy^=-6aL{W7EI__}|8a~$MZ~(}U<7;WN1&oab-QS>ZWtYi z2=PxwfUm*naTa&f;8C(_6gO05y`+yH4dwx4G4aV*2NCN;l@+Jhw~d+km4AYcaUKN} z%}UO6qGlbA@e9t-6@&$GIVmUiSHZ%8`sh8s9o_Bs@``zMeJ_erSDJo@+Sf|27L=6B zU7H8kf{##IUL?pFaY_FSc}eBIm~<@P0*l-=RKmh*?;>UsxOWZ6P*7h4p1lR|f0t8T ztcYtd?2rnNox5t6e3WUJIFBCp>Sezf%Nmy;av*B5+VGAHfuln;lzWR;S~@t`?ZlKT zQsU@%*DajqbcFmB4nUXzm!7C)&ynW(~6$-QXw|6QU(eBct@#ZEDS2UO;t z9tt%COhj1ki$+ohvMDP9e<|}4K?4|h@_x9YUi=5Gm*4=VG(Rq#jj^OmJm*N5xuDb- zHjCq=M^n53H70S4_kYe?$&YUdZd(vyXS5U&l|5o?NiVJlo|%Od@Qu!!>%#+o>m9D= zszvBq?5|JP8ptn$*|@b%&!%w3TIofNbI7vCt&gx5v~sN}D;f@2f(ZtshAi0zhrpeX zBzUG-XJ7rox2>7pWv*5bN5!|jJQExQd}OT+-fPUNHc!A8YY#Alsd5&T1*W7+DED@zy4^0tg2A#Dajk%*m(k zmFH62*b;9ns94ytk~jmt-L6)QPs{+=y4Zf>jb3{2G+gpRqO~t69(CN? zXBYjff;qxqb4TI-A_9-or9wa;cHEwkoj9dns_@)68Uzq) z9DrEks0R-3rqu$o+SeV=M|Y)LfL7Y9UP9l#SG?Mmp2Ean8sjwM8N*}AD3(plhna20 zv1(zI7TSP5t$EJ#w(=xoU{GkZ8x=v#O6b*heaIF9!mkVTOY*+DN^5X@R-?#RZA@*~ z4mb4pC6KI<9f*H(q$kmVuPsDYKq40Np_@S`b+gX!#OOdT&x9j8z^P1rvZAxujIe#M zB8xQ*V-gL3k7=>#2xB~lFSqlF*;$OY*@Lj+*sdqBY``^NwULkAR0cb))! zHxV>I@V(o{It9II%y~thH5yC|m#MTJgI!;XHhhIEz`f|7{y!Byrc7Q2JjfKR=AOi6bOmdJg4mw?@ab- zOfi72iiM5JZf>YMCyOlLdL4rj06j8uthWV6NP$|md8E1J)q%_|@D!aGrqm|PC0=KMHa*L$?0 z##1L_M4-kyMxpfxV~4E)ru}%ghP9U~4$(#wdh~opSCTEwx$~XsIG=%r>nt7q%LfC&QHSn1l;PM@1uT7| z;u{X%wU(K{kv0;guE>4)HVo~M1J|;I)?u1Wm?OA5^C_?O@=JE(Cib|ykrrd-eZ#%J z*(7Sh`>tga!9KvhN8F9jN}&Tj=yyLJ*RBzcBqe{iaBA2A3Cb=d86}&|ivDUe*c{O2 zDSnwgz|l6y%NwCNbQ-7?4VLN{znkN=U3}vMmH)E|)C^VgiH!gj1M@jy;Y^Z8ZB%S8 zrkvGEkmpE(6&j3+fLfxsl>@K#i#C3{XsOPQ1aP;!C-x*)CDf-eg?dHPT~IEloHA(v z?0s$859vB&eZ;O| z8V(gPQ9+q5|2}5KlA!56KZsp?1?Kyc|9@sm<8%pNOb)PS@S^_+pcEzMG4A*@2Me(3w&HND3f1a!W z@MMPO2)_VNW=mw@W-)`Zr&K*zK8BNe=V$;_O!cE?U@;8HKnOT3k~eo`A6DOMd_68} zEm3OR11|hbyao5?Q~p~~jsJYf{%Ld(Jq3<8D}XG)XgUn0eC!FaKU^k#1qc(YdGb;M zdr}xxPH&0n1UY5+hW_WgLQh-zP%;j{2{r6P`7*^C-I^m>roV?!Wj2rye*pM$XdoI7 z*keL0HiPLvQCGKysSH6#;|kGZZ)I6i)7LlW(GlBun3^-6-?J>-k8XS#-MH;xTl&oO z_Ds9~XFCt;YchFLpbcxxz@pE9O()v@NL1miS z$JB)%PZMsWBs+C6N#x^*)61@-1J3NjPRvZePd>ECRdY8{5tZw`W~ zbAxqqJPVx<#o+DmcXB^RK4)~L*R`q$9$hjGwu0Kk5(N4X8VX#li42+B1CnmdO~evvB@)>u&F< zad_tgt4@SdOSAXw-Hp12GM28%UEJ`#qz5ds;3$DEQJ!6G2_ZWh(A{$`GdO~wk0qKM z7wwtm-mj5p^Ds(7kxO0T#5x@;++x&=N;m2RF0sV(oB~ zRJ-wv>j)WF%J>uw-4lXFbcn6Ne~7)az+tjx$lx-eGOfgsboC+^hgjzBIBD|}ZK$Di zJ<#B*0waAF?uGIU*Fpj;OiTEpfVKl<@2K}<>A}e3S>C^T;4MYCcIN={9}Bj8GtqA~ zzF@`7z6pu}pbY2!ibtGC44MVdau!3K6UsSHK%TI;bopjN{xBpqe&{EV$sv~PnNa>% zyB6q!W)1GC_zF)(`&KN*1gNu3`U|LMdfV>VBO1`++_A#<9=lkx=iu2Z83Evj;7*<1 zf%h8Qp9hatcE?6XM?ZIYhm=!7^v1&!d~U6#P}r?Z85Ryt>_(?+id|=pmOSAB6aUW3 z3!ctB&M*0&Zdmw+2*+2N!&ibpCUy!S2r4COXB4LOD3UrR(G5~_xdUqNU&5F&qjF|# zw34N(VVU8862j^!W;nPKWM&$aOe-I+X%{B~6fnkN9`Pz({vt9CEP$iTFQwoMS!lo? zKz%2AtdfdNLLB`xkXJELu{eMjZ}-^a?W?DBxNI$=M|)S( zM9@R~VBYpN+cR2AqDNgu{69N{@gF;sK-z^-<9s0+nbl^zn|=I=0GTT>oANhO&Z$8o zVPC?eRV)lfZeh4y)^e-Of`B0i;HFs7q7sekp_oNxD=MUFB(!7bs~0;{#m|HGKL)V&Kc5T>G?{V*3KZIk0q4?tJQ=m5J(mX?}qA zE)&lB2t>nD4V52*`eKP0N@;v&aOK_#(v<$Na`?a&0{n5SaGCfF#+d}Q~ z!97-llmF9P%>B;Jl+8UAXQLFp96$xmWI{%&zH{jzN_@6(r0D=Y(piwbi z1Ry&5LV+;?RVzy0fZXMPgP>6U(fJ-?Tz+R`IGLKQ5ZFHaJY6+YuUgK9>|rk-6UTF< zhrIHWPuDv94EzW3Eo;t=^mcU^t6uC_S1p=mxYXqf3C*goP85~rvVe5`)=CfE~tRX$k#4?%@A zXH#gJuk^?v!Ye(JKy+3o1wsJPe0BRyZKQ+QAb>amlgp{!%z!TwEffWiqx8i8k)tfc zU^f8jcC>Bfg}|oK7ss!dkpmzrP8$0aWRa865{t#eFWA~J@bfS513fT@F4O8y0aKi|NnmiIErK6eL zif8g*jG&ZB_pw)PBV^dmQD(#D+xnVOVAKE;OTodeNl0p4{^6}Io9POrMI24u1Z-0= zgoWq~FnVX$J57(#QdOdq%GyKyf8C3ToZ|Z*?%I}oN$pbBQ=CV?2AZ`YDBjwh`GNW8 z3~keF9=>w@as6TUE}Wbj9lVQ82AE;LB}x{4R0SkmpcRXOnIB=}Y_%C5A6`u7+fN`C zs}sl!4+sqB!2s}QeWhoR3?_%_cl@ZQyo~T!=B{HR3(RafvRBRjJj-GHFNLkvL=!evB8%<4~&bmjp=Z`Nf-Mp0ACBK$Ym3fES& zn3@E(v}A6ss>p7%H?N#gU;hl%WaV>^Osr^e5^569x!+_%9{$#uxSpJ=YgvCbNc54lZ_6QBfI)Ox7|92)~3LYkT=WVYa9&b^ZP?*W04P8|shX3QR z+yM@2vT`3-&%0s?%M`RKj02bc2NkT{JGK5=?-Lj1P-e6QMd=)uNL!xs;Hq;GuQprj~Dna?>8#aAIIiTO-}~b+4uXMz6XhR zh_dP+RE$IIHOK1BJ{Whqp$P3DZq)3dE*klXL?(MC?aL0&=Bc4T{?Km}f zWGSv+lpQ<_Pbu`JLxcrgoq~m;$ikghU^!zL>~oDifMUrOb4FA4GIid1t6C@48}0n1 ze8l+Z*v%P2-ZLsIioP~)VS0G9gne0$iNZ5;bGvWR@?`!oh!c$gsysIKW5h!lbfMnl zT&pV}MjyP`tP4R#ne={-%0!d$%bH%#MT>5rY~`Wo?RHvXtVFd<5e$A@f)p5-Qbw$b zBHpHeO!^i#XP-n-3;L8gAidT4hA=j!=Nq{JV@z(|#nn{2MAI!Xeyea3QZ!1l*gx1l z1f{-6daY1l>YFkoOpnqmRvOF%9RM@Y#HH(~mC%HmdlucCM;$-&Yoz^2mGC0Ow}8Rx z&Ve`IMh*Z3w^AmC|M7*%#i)A(QWyeX|uv!Bg?vG`NKvEu^#Vj z%w>X4lg(TIvaO;NtH_Ujc8w%mU(LfrOVj7=Ez+35>p=j?xPasY&WiEAzb@zdD7*e{ zHEef}y^TG4(c5>Uk~PK&O7RsWx)~XG$}ObPrQzl(UC4b!!!-La2q@-wz6@t~cSWnt zoeXDPz1Uyy=`^kB8PLw64}-&~HQj@NLR$#%!XzE!3?_U)Bd)sAJxp2)O-=YsY6=&~ zhxd5D|Ndan(I76KWMnn*%ozRlYHC!i&lg@2XTr-+@8ok{x^TRSQsN0=vh_$#08^vy z$g%N8_r(~%@9D6Vje4+ma}xqVCR?I7j9ug+{4{O=hU^X|T(USE!PAOaQHJI15uGq1 zeW)e_Ht7HTV`^|ez2eQJn)o|NCX}P&;+p<26Hnb9JJ^PTkMB}1Y;UP zRp$?+&`!^43p5DMhznp3kn#b0fDIDnz?Bv9#zS)6zqGoXaB4xcNaLW-a&+3(NMb>x zUjT|zR4@}JfGiY?f>ex#Bbw~&)5-iZBQ0|xPwKu8-it*Ip87EIBi#RzQ3MR{*BU{K zB&ssKt=y!9TH9Ufv`PeY=6|qK*WQ}+T~Mvm^p7KRlL8mw)Sr(8V|xkpW7>mBmi5zYeiymz_5UgEHg+r7in&c*JEVmrTMl3Tq1Z+BDtIp06 zdty+pOC`xCvPmKBO@xz2W(Vu#x!}3WmR-a zH<{hNlE3uA(vbEIe35MWZlXyS8pf;Dvmm5MKvXoDBP}II0nA+E!|BfXXul|U$LUNn zFh2#x423MtO;ryiMert*T$d%^9RDjCe)mV^^UcT6M-E>lpt|KVWz?Me3(&q*alfL> zz_29`jo1&3y%c6uX)U;)hzqu z8)USicDPZKAD@t(BHP#ke7t8j%*oVUsKI)y+o+%1;#$0YiHR-5nc;-_Tt+|hVSW6s zM_db0tbp||m+gtN`t$jYy8+%0=DJdojh!;y&OW9#M$ucBECwj;*m}kR&|7~Dv_}H9 zwzuf7wYE)71~QTzZ(DihxAK8POX<)5HAJII&AUd7#?D&WlSuFU^9c~ zXJHA|(4|0@wDRqlvWorv7GpJ+^lzBf63MACbe;UX>_Q8^p_R*(6fCeC`u(D#ya0t^V0y*AzE|if(P726b0grS@NjVna zaOJFqd+qVDR^Ex@LYc3s^r&bMC?z0=1&QL2!;it(TyjL%kr3VvAD=nZK7f1;6@D5% z*P{gjIUFQgOYAH)n%0iLI5_IVu9cCxXq9;*{piy_T_1b?)>bjp%aG?Kb^j;CoBkxq zrndP3v7ejyp9GZ!9#^!EF@oEkq*ULREC}S%lqP5VMT&?+G&=#IXTbLb-R4_{{Q$3c zlsZQoe8x!S&3gM{MsP^Rtfm(Oca_GSZqpP=iHCeJSO!Rzc-k7e z_BmQ~bDdsqhg;|{CQGOC9@>q&cXa<{xeng>*}kFu?darcrS_kVdjs=)(W)EmAD$!H z45GKf6nX;E%M^+_d08b7$y*DjAiMLT^3?dIj93OJCKzbC0MNm@>4R|B`8} zX>H1@0;Cz-g8l&wtcIc%7VXOw(Ys~399vPyB;Y`tzTMjIg6UFM+4>EJ++s88ON$q; z>$XfP z=S@}^ppCa?)r!#`znlM@Ts>Da-;r_Z{zb2Ip0}9eJz}~F@kaLR(YY?yuvNaoedMEh zkuoh)<~3mU)QZG`*G2j1R9nI)Rsl4-vfr()ud`Am#Xl?zYU%Zur=sJQtL0l~nrprw zPWIJ(K$2Huq|*k9g~`#(3$~>wXcoKGh*Y6TUf-GYG~Wd0v?t+qqF#Jfn{6pr=bHVC z{9(1k!w(Yv?!IZN#Nd~SaZhuW?LfT}o&=LE&H|raGg+=M&^6$8aCi4$+JlggPLJkUu-S8&Ps7WtZH)QatJ_qnm#n{39n@+(+wU>g@NBe?!X@Hc-?drOJDH4h- zBahc#fe6}c9yttiCC7cB0<%DJ$C8q!qdS90^-YqO7LDF2azH^7^{OKOJ(5+<`y_IU zocOTbF`=di+g~1^v*JI8cyy?|H6Se+W(|!$U#5@#1iB#yB%H6VU+lb>8||jcw43}M zRVYP4R1!GzO47>2mM>})Xo5r`_O_wu@h9%Zu^pMQ)qTV$%`CM-7zYBcnFkbAQ zZa`1+l4G`J)zWjGgs(US*M!&9xFOxwYdXK0j%G=PG1KPg;`yOg`&ibGZ_u8~^}VgE zosh*t=P+P*}koPilQw@-+xjWV6UC?m!`$oW`yWWy^UrpFP(#E zKs9b(7N`jn{w*R7almuw;3*yLkz~-n1xXR4#*Xn-Ga&2|4fQrJg`-msGCBBd@;yXywKsVTZ#(g?#T%Kuozxw#)3J2Vzg;+@^=pt9r%gA#OPGDidxa+HwLU z%{F$&7aemAObB}!bDz3sUg2E&n4p*vBNR91uw%Fyimn##cj)VLW*5yLZn+us zF2)9MvUS@SM`b+50b%2^g28U%gGfDsCV#&m9fX)K5{b66m3>nyh+`KyQ9ZI3&!FtM z+S1Tlz&u>KQsE7T2C(sXg>1I1{g+YHLo~;0-ShIhUcQomq9;ye=BB9qDGQYhL9?)+ z#W@{@u|otJ&FEU4kic9yx}l%?NrjyMbmXK;;k-kQ6k3PPI~$QO4>Jb?2Tk{2&nuKb zjKBNyk85(fKVw??Za**|1h3~7qE%YSflg?Ks={ltJR@A@E}(1z)CIc+SpwJMd+tgW z5dw8bxL_Y%X};DrY>okbm=y6vHx%Fw@N+UgY9ZXJtdnMOwCooi4-Gcq8EXLi`3%#4)0WaLu#h5bRdt2 zM@kMk04UM^3EP9&H{eANfe8HLL}C)epJ5Rd=e7 zXTCjL3p`R5dpEag2V+xafSVEEmE8XmRsooU;kgvy-CGqbo+(>o_x;mz7_<=K*N8&D z_${J0G4g$wser`6>nv_Fp*^H?W>N1|-DloZ3Dk*-8_sTB=xR#*2UFzcTGPXVxh~Vg z9Z+yy)n+d!T%7Cr>5>Cwu*ZZR`c63pZLZA_C8BdynGg+WNbD7nV1JO`Tn)AN+>QBF zXbjqC-SZuFFvBWqH*<76?G}b@LAnF0oVGXtgIsc8!agB@g`5)+57}4Yvo|{B7KE(dj7f&hg{EdfR zcN2LfQnBN|kEKeyvkSi5pC5ACA6*Mx8aY0FRz#lbT{GCWC|g>{#*Uhul|#b90vcPg zLGW*Ywo7K*%kUZeit{|5^aGkP2&YL}Pgtncdq+9ryBj(&N@Ad!Sb)NKv*5YC~4GJ}Q9n*F!514vd4?aTHWe~8mxIeEbp&>GS zjh84GS*>s9a{J1$JUzZiOD|#Y>SL!O-?!wabncdA=ew+xF=jo(^lwdjzoScAf3l@H zJb_q~G?W)^jkMktRuW}vN_H5|A!L?+eK@^zd+7ul7DGeEM6#i{_NGsTMMuPyL)am% z(vEOjQ9hDe%w2HQ++T4t4C)@fX$i>(X^FzSvViV)yVME%u!#(~42TSHtV|Xo`Y;wM zwWa&mu5)i(B;gK@sD!if5;>kfv>(Mhp(EKbV zMsVcot1tDn0JO792PAfqFK2o3%X4tt`mq$ao?7!=x#NFs*9+@s$K-wob}D$pk$<^o znUN-wd~tR2bY#fE>e3Xk&sndVW$xuWX#55Js9}6zEq!cfdwXt0LjdPaGr3IfJ+8dq z7yd&asr3ss3P7W7E@8Skr0A<}()U^!n@l?v7Jv+kG%z5F9-(;JUvCO%W$z;L%4bO; z3fcE}kF+j`{9MLN`q^+jHEY)eg}PX0p(8j=W2`7GKrj!#;$|I4 z@Q~+L0UzYkoU@CKNz_@{>YGl2jZsQ9iDlB^IVHIq8y~ND3pZT#Uw|V`em#O}0l`S1 zx6x84HTJN~QOfXdSRsi8v#vL?hEvS*^FCr`X8I{CDrBxU;)1yOb^jLg1 z`r8XT(co65D8jo2(XKHC$=TiKKhSJC9exfxe@RS@kNGW&Qe>q{-^rDnf%mn5PTsv& zO^F`zyHU~&Fkwi~x)ny(lUwTjp23vJEpawV0TA~D@VeE-VTAd#n!*`p#9fF-eu46F zB7%c2;5Fpm%t2C?1hP5N*|K_NSBHvPD+OORk$u5^5oF!Z5?~Yfh@;^BtlKMwgE!-ouc?TuD|Twbcx$gufyVx-o2|DRW0iN#Li~GzTMpM{!y(5ovDoH#sB<-> z)UftpypNEifWIN|jQ-N?0-mkckmPLXHNoYfu~k z8H${vCM>UwUb5Ayah3!rO-AnjG4+;FaWze}Fz)Uy!!WpeaCZm}!Ciy9ySrPkpn;&l zEx}zAB)GdvaPE2Dd%v~5-?P@Ksp{(PlHI#ZRFjKne#-z_hYrn?$JCz74QK^wYUmF| zC((gEh<{EZ5D!2ZHh}})Z{q$oHs4j8p)!oPZ#JOg+pC=`GX7Iq16GS0@B95hBw%La zxaAP*?v}0uC9V<=ax67p8>YOhs%eYs5xj{6oEOKszfywXWO>vq3lufxh7{HzRQT9v zn)MY>nkP$P{2?DCoWh}b3O40D;bl2%|I(iIYT!AZQ&Tr1feRUhpQ(Y zgXTVb^N_Tx61`b*+WWWLv3k_nrQfyguXn+1@~(Py`OsSWy5ir|&ZW2n&@v_)%*1(K zp?qnjaC@FEA5sCmH&!C8hR=uXez6PW^|s7+Mph8cD>uIe?VzR-HXwu9w$Hj=ZY`Tw zQjO!z&Tys*z~Ta_V^*OGCaDZ3oehncm4TMePzl;Vvu>3lG!NfY0 zpd59^1Z?te^2E=O@q3#FzEBF}t1T-hcVV3SdF~L^Gi7bRFb^(O3X*?>@Sjoz5U@_IsFtR#lqqWiR&te!%QwFKJg>qr!z60>38Z z^*;d*L7L4EB9Elzj}SRDkY$tsCs9JQNdcTBJ8=;tFBhlzD}7Yy4|chBa8)>1hF$qr z0Sdq1pv;i``~faa#H0@&Q>PiADxVpIFDX@j*SLQS$qW#bmoYmix1@S=;uOQ6+u7Fk zGQ84?3flP6%?Ar7E60-_ZvUjjllB2skw4BFC?>cD!yp5BQ7I4rLa4RWBji)$=iCOt z)D772^7VAlqu7mL;0l3+S;(6celgrijb{?zm^Yr;%(V$3N|wQ5r50JGN?lZfEuqCCELwE|hoi(pjfI%(ppz*`yiuJvIW`q8|`PG5`hL6WQRv)W{kUDzAl4 z<3=VD9pG$W;!AQq4W1IP30x5vvWHTes$EhWs(TKX3#DV$-m{XqLWh7Agjl;L;BH^( zUh9c&O`7|3zI1gduRBp>wT{>xNa0rY%OMX%0;M7m#F1P;kbg(F&lWB-iN)opo`S~U zZB_s!+yV^DBeD*9=!1a7a`=@8G!DGJU&HJdPVtI zDZUV!cmuYatnN>^S(k8TTcn?NPw70s?pgcVIQ4z@Xj~sZ_8{YQq-@CZ6xC9;SbJkJRS7N&$fMS zf5*1g#J<=lcvK;eZ=XO=D`DZ}09XGAkR1f0$R{5^Qj3(!TmhtvBY;SX5K z)HeCShFP)m8gM!~b=8-k4d+s%>;F8iY<5q6N!4v)ZgBaov-QF;RpW{6fXTX!> z@lg+Lt__8U)2yFUjC&gV474u|V6Y;2_@Z7i0~<;AnWPbA%LJfYtIqL zXK#bz&PZOC43v2L1I5y3*WJ`T$<7{_c!4VdDCG5k*8Ly8QR%6Xa~HO1EwlV&lw*d2 zAvi~dCLkpyG~rmm4wg2MMR3sZE(O`kAdTb4xTA02ktHH6nI{pL&>$sYQ9AyVA*7(D zxDo=R3R^wz?znb}9$GIx(9XRms=_B#m1~44jcVogsoi*_NzX&$0KSo4zC$aAl1>%# zTl2%100%IDE}#o0LK>!W82R5WFt1%MnSF(WJwfM4&I4YCu@(eg9Jd3Rt&VDxyuS#S zi%?wJ6my3D1WsNVOZO1$?W;XR!Ope2{o)r|pJq1gkC3>y(Q>7)iiA@0I0goQ>ti5B zM`MwanbZw+dardn zAJM6KjSR@x@YRzwEB8yNCbI^m<=$c4u#b`5T*B3Xh3p@sDof6bGbB%rt=?nD%`NAc z^LevxBN9ja&mlQFFp#d65C?YkGuoj+n^L&@i2GpZi$MSb91J@k8lCV}8{6y%UPSIt zBSh7T<%#)H{FkoFZUCW^ z47)1~q$BbrD|xaleDIkpsqUF5IXri)EFMWP)!5=Z^8x?kw~)Ab{4H#nwt+rb+aW9c z$ErS^{g)O6V(uiqyp#=v-;W|<@iicfl;rB@K)muU&f==x?dal5YtX*_{m6Y%lLrtP z{r;YmcNS=xYCeX^chk$}Xk>KP2IbAe4>C?&+AXrskEjaKcTHF|$na9T3~= z#nR1iG87AXSmo!)A*B$u-R37%Q!);1bHj zzQ`RYc}(6^4E_$5fK8+-FFSt5Zb$IPUsUk6t|t7U!s7giA1_Q=%r}YZOp=f7+%z?* zrFjzY<5Ir78p94F{Url#y~NpOfoR#f)6-&$eBivfL@X2se3Tf`#to>v5U*v5ScF^f z^AOADVi)(;F#beQU;1eQ=ND>0Ry_F2VK|w?h??q;*5ArXlo&gb1LjD(D`UwaB!&Ni z()ig7-ss`Hz1I&M%|Sgj);zFD*h{KEW6Gy6Cpb_t(*Z_g7!0gMlm0!bBEWjV$%*Bl zA|+&1uCHGkF!88;(Bj2_`|T&T1PO4z!R%z5k9KnA2-QZ5BZ2PnVnf6V04RmIj0-G9 z5_Yz1@+g49L6UMnq{6x)@#T9~kTFHs~ll_jm=myZ=zm2SiEJh11r>+2Pas`w;I= zn$ec1)wEjH zD<*~{9`?Pz5CdE70bMxPH-e2rW@V)Lud;*N+XyPA9DnfaTILv)X<;ROfC6_StR{PO zg8dc0(Mu}qHem`U2W}Nus_dis4O#LJfFv1Zt3aD!?LU+&9tL6W|LbEJXvKydFI+k_ zFK0{^l1InW#g2BCWD7OsQd=r;_O7+U+Gz?$Fv*COo=r-CK{8je;Bq_SV7UQHdJy(n zQp5pUe)j+fI*cvp|La<+umVDHA4vL%7qshF3}ydZ;N)={`fRKPdfQLqrb^ z-4y!&aJHewrAG@57N%!USwb;jXNiikD9K78m_hXRc8fup+Ew1!Dw;aCV`Nm)(vYGWVz)oh*Mt=?G9_8>n_Pn|K{F5zzlmB z*>+o;w-T|AeBrt0>te7m^wG)GpRHhuu(OQpIDvao<@T`PmXb?_J0rK6Aa##Btmy=( zGGQRvm;qZDV=a>sAe2ieupG_%+`gJo?TV^_J@YeKGe)mGX9M@-3v6HJ*id;%D;$Ck z2_Jr;Doj`#Mv0jYOqy&a^T(2Z9|CE~{$f6QJc>r`wfx-^#xM9L5>LlK+~tAcVwZx8 zUGk8ItMLPkif$VxAdslMZLu()xd+?IbAEqOHTQ_xP&3CZEiQ|ljV{+>k|afq8adml z#J15}K#VYKsm)uUXI&Ws#k_5uUy+$fSrg(Uj; zUoqv{lOGg_H3YoNfpQ2DSy3>McTnRT(&*VW+*71z50B=o*bcl}3o_sYJ>dp%nn`3rTSysT zfX$PAf5u;L(^YitlBzx&MHxSvlhNf`qoWd!a-x_wIySNkh+zQwYR5S$VuB^?h<-gN z$*F*GKS~sk&9xytA3p*h1YDPJ5(H9__~mueNUtAKnuhQ5J zz*QXz3+4c*X+j+pH@IZP2x!y?t#k19=Zgr3eoIgnc>v_|czwdqT4>kYj(8yR=wkNV zYg$FYF~XayCBAT}r_mDO$~(zgLhOjlc^bSHb54?o%CF9NC9H_WSU0|>F8`XwcWIz6 z^dWf$qUYHH`C&D-AIzxlm#|Pd@&XBf;TCsp_KwD)6`EIgU4f3DFHa5%3aZe>PdN;* zq!6dk#V3T2LQ7G9RbIo&%>6!8GZ+7ehVch*FL5ljtOrS~v?{b0t=)@rY0ABk5k4yN2n3VBbOxo!YGZa%LdaTXpyJTN z_-v|LIoGe-l5EW%LWx(732l}ZJ2*F8s zU9Uj;OsjFR<1`fntTf05A7v$-j~JYh2P~6GsPw>#7f$=KsKe6N2{s=Wu0B3lmTngK zHX<*QQRXVJ33y|!aq9)65&kscH6>)vZf!E_R9FvM77{xD+4|Vw;fyz@e57=Y$gAac zx+?e`z16|Nz!&Hd_HPf+mN4`=6DzN$mes_KSEjO?D6sieeex|j|9({W;#CeDBTrxl5TD~VtPm!FC)&Or9ZC8It4Pkw?RhdCkhQ zgMwF@4AG{-VYyTJj{Gx`=$pAiCv#L+&`$Zs%{8wGBq{$>c04#xoE-hvu3NM*d);uh zdr;KwZk~cl>J)$fYQD{W^KgQU6FNaD;AW1IOlItPA02^2)){whL@w3V@f-7jQu%~P z3|t1=Kq6d}ABteY^nV~;K3Q7}80(h2yvFg#5ebA>edB9gm!zk!|IR%r3-e@ESR7^M zMv4+6oo@uVIVp^iveHKR+P%H*jp`T(UxDb%(IYbf24cQuk-}jB4qFaSbt#oA_kgOQ z$Jg5Be}2qs>7BO2`8^E9;59?-qVAF|g207YQgW=$QR^t4ed^L~d}fOoY^i$GL8CtF zYNy7LDuUp_9UePfob;9b+jyO+NhP2i^rxaM4&lSU!;D!P2?61(30|pq9wA;-Gjn8lj3p9T%gu@Su z0~Hp`YkS0lRd}EUz5e2U=>9t>~xSe+;*Kqg3rs_&mrOJO-0(nUEttc zgr4(A-(y-PEV)FXgtV+BB2bsqM40#TpS9!>OVJ72j_Yc=oekmzE6&Vw z1UK&Rtm%?Y@h%F))Xv_1Rss2*y?uzRVVD0bQ+tlx{%c#!>~m9(AK98kh->gJfPpfw z1+8DQ2tc1qYX0L_HX2dVBiw{zrhz>h-6~*kP6&MFTaz0gpfXEA^&70X)X`AN>$XD?@aQQByM&?!DY&WQN6YrutCRc?)c} zU<5><@VKvwjseZX57|*2N)NQ?<`7kJoBa<}fKdKlua8;9ByoN-T-lb7y_19tM~{no z5?QS#1EO3g9tLdGU}D9vFaZ*n3G3NSZ|`PqeiMa}(R~f3A8G<&s02WuhK^|C3^cuD zRz5#I)vvHEj#{?s5$Yq6*6Cx)qL7JOD{u^*43>B>%8QvMK;1_5{O`rzGM`FlST~hV`!-0=1=68m-go>7c&G}u_4h_@syx#lOhw3Q zYG=3smj9w=;L6vDjz&Y-(2%6HIYy!?afOwyUXrli!G?#s-^KexotV51UFvF5yJ)XQj^O3>#F#Lg)RLXo7AJ8--JLpxe0 z3@MJzK2_;VuWQNYEals6#`{!YQ~qMl{0VppT;w#UUc9S>Lo_aFIn=67)Zm_t7ziko zAIviuzKQvG0?-BL;C#SG3^@}s=CR~d()L`-by@Mm zvP`{-F@n8-6KS6s_D6ibK!AN4WuU>xUElXRAvLmcw^2%BRK9PJ%fOm$7q;*Jx`C zx`+9#o#xUWz{+~K7+=B56ecBkZH%2c`nE@|MrC_+!}13ErM?JOG(S^L|iaSKK*}04YsRFq!j_;6Jgm4e|nOaLg5@SDgv~9oHARDRe1|V>24ZV z^GGgkN}iHyRn#eRBk2aR2D!Z|yC~;ZMRE&KKA{wtw{#~V^iQ0f?k(4$QoGgi$><6D z1{vpnk3Dlu)7?0z*q-lbdW-sR1dDE|L6XgTq*n>@pAlWxR5j=!a$sw`BhVWFIShK; z%8I2P!?%SO5NVmyeTSq3^3)4>9z@}G6emC~Gt_nXRW0cIb}0y99)U z@K!G3vTm{}f)v$DhHJg#`TuCzE(Aa_iE7{Gxb?b7fflm^nf~^BQb((O>P|~z^SgrK z7k;`vX4>F^#T=$sJj-TX2qwb{hYop}RnD z|1tzIMiPA>@UPK^Lr~B1_c!eFwVM-m+uEQ&vOui2AE7_(vr<3@#0-s}eS_6NFKL=m zQ6U-mi%#@#6th%6VLjh9HwP_Ug9&vM;EW6`mOzEI&pq#s%|1^`o`$VYcKThuer~Uh ze0X2UMSS81DHkY3MPB%(e??f${Aip1>t($V5C!S`6$*!omDYJ4S4~^@+{T?|bnM|> z(Qgd3%7-;dn{@k|Of0voTLi5ewNKmRHBX?=GOXzrwZ_seqfyy!1{eUI$5yvOXVDF|FT ztE+3t3PKGdT}Ugz-02qVtunF+RHoGUup&T^X^tCWDb9)#9rKHmBB!xxA4k=ht_vFQ5h=Z)_@L1^~F{Z_sK3`#^p zrg&`qm%AOire|lq%gc|a)y9PfTN3k@7~M_7af#*YA*P!?OWc3pDrs+$ zmH7q8*gU6v`wcPamo;(jy;Dv`cj`e$aDxk*^@b9$`E;ctE&rT|wgl%-`pBE@>%T%s z;G$e;{5UZHx%`0KZT9g3(bK}hh}T<`iwd3o;lt?_>wgwYqM`!5Ax1VIlsk9Vbti)| zM0l|c2rLSMvzHJ)0Lu^pEJGrxO;wj?KAW2B5%>im_skYfaxiuP7f)Yu@c-GL^nes? zUUyuS8-GXp!GaO6c_rW+rDmDGM5AKaS|vY!o1Y(qrJ!*)u=zBJHR4n|43QWPjoXg_RZ+HuPH{LEj{uM`?0LlETCffxwWiT!_;NIUNZ)z+ z^|2u_Q8R3Y<2*sN+}r>Xl}NQloshU$73h8Ad-rc`y4u>S)fBe1v-|J&g3nHl+NzWr zh8qztc7KFqzRyVa93xYrV znBvGZpSK>(0&x^$hZxATR?!MkWU11iWsA}gWU2bTu&Hm(Z_XPa> zC|Q?wRw0Vz0%i)PMzfC&=oBlKgOxto@pk#m>=RD!!|OV&qp{GO0^SZO_^?ti6u5`p z^s>(my@LDdltek9BN62@@nJ2ZadIoTQUu_h;A{h_P(@vJ>`|)$GA!FpuEHApyn{Ya z>e(o$5k!M9xIootC=;J+Jy6+Viymdiz*{vy6vn4>@l;L%m-3m@ELaHxq;D|*g{`T3 zP@VttU00rOzyDInz-DSM-q4qrBB5yio#xPd zUbhWL(Aw7%?THb`2vFzgFKt()PhXr}fLuwBlf4z0~jN7J+}tXIQ-y(bAw@KTrNPhK6Hen z?iFy~zO?}pwN8#%-P1RMTg-GkZB>cm*)kdqtmUcFRJg#u-$KgcuI4?Ry&Zu|>#G5) zPC#+y`66oV?fyh5r+4ElsQcZr)lWCz-%CYB^&;QOGv-RhOoLgA;^Y9s^Pu2&xI!Y} zI!I@ci-+cD`0gomZT7t7+xm3l`F=iuO_PUD^VHn1U|*c?Rxp!3=~28#XnZZ4v9+3j zug76?iN&#E*;DDWA7_`}?wnoGe%Jo)J>ZZ=4r}2Wos&gD^LSi}~J~F@ro8i38QuMocL_`$|quiB)G`PU)h#@k@!PGwXW65Y5pqPOHx1el09I}%r@bOd6DuRtR|sU=q9{VxZ&yY z*!x4%x-BE&t)=bINrd61Jde0ug#yZ*^5I;vE8Be*gM^%0O_TmDQ&^bc%@6PK(O*I{pFS#UL zLHHIK%9ktS$*kN@vQy|fb#_?ulT#FniOuMVas3=;<_AZKk^*>z{2%lmmM7O< z6RpiV({lq0)aUsoqdtB)3&*zQqX(x=a9e*B7?yF4ki#KOu5x zZRR(L(^_Nq?^NMfvOFYGRQ1m@;|cW~6nbMaka5ThPtn3R(V%vTY49{zC_UMKQg;To zkWyFK$yR9RZ*MGedp?_mUwnSB|MVktXGi%YVrMZHE|IDXgq$c(g6s?@z)R~KuSoFo z>I%~6Y+z$Yj$G+LS7x@w&x_4Zu)A86MG7Df8}SkiC=xY9e$LWwJ#P`3(qtKO4SeK< z+^-f@#5G}Cw3_m^jJF&eEb|8J2*t7^CNw83W&3q|w17;_S7!@{hQJAMyrJNH9NrLw?eZ>NZ(K>9{H^+jYGU_W@AcsgbW(0EE8Fim4#Cg_G&Ii z!vTV@UVa>vJepgBA%=?R^sl3peKl|E_@nv!v}`l;yNgKsAzbM`Y3DLI974c`ZAj{F z3T;GL69;BQQzN-9#Z^4#xq^FB26}*AtOTWpfL>c>LXGKh29b#u1D_b?6)oFxlZCUq z{{MQFCjF;Z|IvXDf57}HB5io<6qtf{U9{%>t-<&C`0n+1c_&cRVoW$_6;t#?^sKIx z4|aU$lhBd-#3I-~{`ns!rzFY7{i|az>GUvOf=;35^Yh8SUT2)?6gYo%ibR)LC$E+2 z&K0^1qm2mB#k2eUH_nlpRehVkWLxDC3o1>E^zq8!e(>^KRFI)=ZwmzyvuW^D_EaY| zx>{22;jk5iavw{IVc2qNso=R(Jw+f)=JK-P@h5-2H_{JahM(%!BT_mxn}d9OdBTy> zpGSZGNG?Qh!so(yySxXGT&i#V3IY@IEu{4Ji9ysv6WUol|*`!`WdQ8HzLXA?0b1_)2l) zsEF+~&#h;l0oP;ItZ-leoWKvf%OS>{Eo6EbIKSw@t6Oq_g=;I^B#fKPbE&F;C3@K2 zFrR0@`IXiv2giX84joC?Dza+SkDu}U{DauFqW#u(vb2WG3<+oY7JRu{BpU<5MmNF0 z3DKSceVpbpbf2FHHQkP7ovlyUDlLc4vqKarkq;(p9jbt4lZJ)D+-*sR#)M250I8FR zPfw8l`|jiU{Q3U*&Sku6LAU?&?(*7M|J(V#)xYymsexxY(bb-nt7eC+TwUDzA4lYQ zB*MJdAcE4G;A|r7ofLT~i#ctWrpRldMy@pzo>D0bS2YZd^k{$#bHTKc^2 zG^wBN`=5V{A-;m=Keo)&AAH@Ie;9Objki-Y-i>%50ScoMI7%S_82AdEgAt60Zek)rTZO}YRYtPX~Q+AX7O8yu{X+XOtUavLbD zl7Vy(){u12!=;PY!`EN)zskxdZ~yd%FK|&xVJL@(!|VN*`(DP$zO{+^&u`SO3%#8@ z-M{JdShZTEDk&YjcKn+5nTs%{Tiw4Myr` ztt#_i^wDk*;x@Ljgiv~VibNM4x|mS9qq>xk^TotY|4tz3)~ZC>9@j+8(NY}p5Tvg? z6b%OpcgH}8bIS~7(lRbw`2CaLfpDRDO*>vPb)*FAeALDl)S6w-UiXW;bBGI` zfz7qQ%op6m=GO$}@KE?F5EVq`*YSxScN&4~X8LTmt4x!CTkhyRf7q}8^rLq{3x%HO zGwH;`7FNZc{T%S}*SGl7_q)<;B-%W+Bs-krVxd^P<1!nl<6^WF(6Lsmk;wBAo9HE! zfel51Jmp_|pZ&mZ=D5%%;vz`VG0<4?H|M5plrHoco=x44KApb4ZeD&t!)eKiFlycU zr1OG{is!imlVx7?cISSh_ovF!*FxlkXO_c(=HSo`O_>Uz%_1%d*TXFMdHzxG`8IrWm_aU$NosCzE1nX6B6$&e{V(f>E^R5BJCA;m6$YO!RBHRBkAipd=w2s=q;$kkh-f zJFSQL?#H7uh--e^%n#x(^AZ9VOTH22xZ>vG6v)vr#n=Y#H{)BK@(+qn%Z~51e$Vxt z#;-o~q(0A%|JW#!Pd%6eTJNZkxdKv5z)@ znIU6;>LC%R)LMMwPO-yz;Td6+pM!dM7H(9)k(M>zI$j=ct!5MHo1Qx6k}|M?Oge=6 z!!I_(U^P%p!VL^WBVBu`lZ7kgjvi8hcgi&6Qdg*xaRUdS!E}D<-uZi|;?_AbR-!Ec@h3&{&A23jU zfDX;Lt`OoLA)p-SH$K-P!!Ia4tY}@y+c>XlUpk=YJrK|%fq9)TL9u@Kn-8+M+je|6 zy^}9|yl?y+PP!QJ1&N9FzNe?*2rt=$UstST)P*9M>U#TVzq7TvH7M{Ya(t&JyH9m< z>A4x-XjYXqa+=CCGtz&$pkcA7iX0aFQXI?0;j}-L!>`K5kkt%#Zaay$2l0 z>>{rvzY44HnRF%1p_j4$o_L3jE?#zwp8mzf^Xs%B%W*^Rf2n`p$5PyBEXF zhgO^IqBd|3yM5+&9)D#-<7rlULkv|T)drk$8WL#M{>^ekbJ@YEE^zs6jKb1Di6lKu z`*=$qTPOS%`!bDe3yum94*fi$*t1w8r=t>zOS@6Rndhbz%bkksHBC*8PhxmBp4trZ zzTcLwsOZzFq7ihg~6LeNfQ39GyLAps6y58ml3Uw_y zn4MnpMd;>tzP*0E9X+ol0isF+bQQ2HrB~ZOJ`E3a0=e&l&(a;^tw}E#WggPS&&rp2 zpSNS;e`+t&^tVT6{cK*XTf_G*og1%A6U|%gk+M&sLMY-C(>1#$50dB_k*b|sN>ee~ zQ?>o?DW4c;1;xDvl^92;w1ZxwJ9mvy_+fsyZcN2b5Sp{+Fa#hC- zGm9$cqJ+@2X;UL6{&X)y7;cl}Bx|x{9nM(4zh6@@>Ir0I4f6FA(4^BBUi~goRnPk} zTp!(aszfx)#Z#4)E1~h{`;;I>B2Z)mcnDB@t5XI|ggEyUV@zGu+&Aa{jvQ^{sON96 z6GNhi#zb1^{6M-XaiIw8aRF!N>>M}0ap&(#V)_SoqrzD*{NKw?U() z$&p#Bv>k_!ukvt-277m~RCOJXz3r>kHZws8OwiCI;0XNqlSn9hjt?`#5=6;PM z)j+A0COe|b(}&Kgz{`wegVH6tU0w_S?fVEUA83~f)BAWnnUGLk#;8RJ{+b|{pR3kq zoyyw*G{Pju4SYHDzb{`e>C0e@+$?xR`E4R!Ej>%>ZZ`<)ZEJzEi=Zb!MxBbX6G8z4 zKX_g#A+?IGaBuoCi01+$)D)M471(U7sY+cAIdq8I0n2}D_x)D>=&b7BZ0g&*`4{VZ zzaIP~%td-Y0bWBfB?Plkg_^_(Ej)lWjuiTxeX7iz~4bN(;t5nWCPbUvUsk5 z&7}&@@m=`UbiaI$=v{vlvFll27dG-A_w}H3>Sz`V7u|+wMyrDE9t*dnmDI^J#opsQ zTfxRxwM|oqU7NH5fD;`~ONbP<`)ZENDwAST@b-BJ?Vgg^q$uCDR9`+yJ zh@2cgL{Jc65cnQ?6hu)(D={V6<@`oJLpasji+XBkp-~hXx3B~v#(Q-jhw7JVh>B!K z^b=!3^}DgaSoxh9l;2?sU;O@kDK2lgsUFec)OJY{nKWi;JX0X9`=&pR zISat}>sRK%angf#QN28+j^FpenN$YjBp6>f!DD2xaHNCT`1#$?*V|p@sczNyqd+ zAsRR;RxF*Ms-*B*M%SS@KdU`F3H*x!4(<5dovA{)VmfdMPl>PD7VC_)jy@datECs7F9!+Np_7l_A&1TSX!U$qLtF z0!qEJXs)3iY(Qfq2>y}e@Q=&`Vk#NV!*H2B)tievkgKLUBq&JjQzL~s)O-!&5 zcr$5yP3&O@htvDzN?71UtJJaRYP`?5^EbMn>RNq5ov*Xufknd?)v-TuYtw%oXc*yw z&eZvUPrv;wb%Y`g?JbV{1+XX`x7MK$lT~adFH-NNu_x2KO1a;)&Tx|udp(FuY!JCR zfF79ScEy}{Lq(HclY>RyO0YyXr(-2MSQ%E$9^)jkS2(6`Pl;c&c3u9jd?5_M>7Dun zHYfgxm1|&Vz~v%q6098UcAYW>Vsh2+#`55XM3YS-|9Q!6Rm@BsRUT~j64I*}f)vc_ zQl2Q(>(Ysk?h~NVlh&>)@Wm42P6ObJd-VwkkHGjZ>fVNkTMf6BSe7zMHR@aYta0d4 zoTEiZ7VL;KPYq;J5~gm~UPr!1w#i>H4RQl$}m-774Yn5NEqe#@@AH zKDIsE@58sRFFTFAkwjy?|AnnWE^j;&7f_${Uh)pSmRhU=m^2r&7B5kEeLJ6ZyPs$n z!-LMQ1^>4=yI#BFP}4WVvxrN^3iy$?N`1rXZZ;Fg^&KZ@sC^AF!Sz&Iumcv_7qE6Q z6ymJtQue*){l?_$=&f!a!LFm^l4#PPjkMK<_7F*2X|sNAtfGuCDLz$Lm(Sl{qK<0D z_y$m^XPXsaq1A2W;6PP!6InjjAgZe!LhyPJhg2P_=$)k20TOCft`OIzPfPI4lKYqh zI|VbUxDr5m`H2LTJd4!TqL@=1BhXfTchH5Hk{NaS)%h+Qm+MG)U>wQTI zD>Dc<9fI%~Xn;H9VUg8xU{XWIU?+|Qeuk5yy{=Op zLrUIq;BxZRc^*EA+Df_yEA3UUbq>Ee;s@4?t~*eAG7ZV@q~BVL_8 zwlo2EKKa?A}L}}MAm8=V$ zERPVSilhT7Nm353)RPNP9;o?Tb)@nsoH(ojM{1eP62_X^DbO_W@Fzj`a?M_H3oD?T>Wf6C6Jv^txCzHy zeDg$Na9s%R@7tX`pT9dVj4JHk363oM_g^Duk1*ci8;*91q8y-FjnWu6Mwokgs_m4p z+eySef@e3X&S_C-m7R}tZk*8Rk#s*Z*RE+r=JYX6j=6aeZ?`O%$p6a-<{ePtgY%+^ zxqrQac)*PBlFC06tR{dr)wb&$vSVR>xSAXtRMGc*=KW=gFrI(fB?@K^=+wlg%0N)0 zQb$pwB8@70iA^rV5Vb@DW#yW1VO&ew50z_3g>sl+Bb%vX>9M$Q$U8^>kg>TB{V=`v zr9K+y>qWyQ;Yfp@jz+}6Gh-6FLXv~;7+GrBR?*BolVFVupqYe#nyesYp^l&^0!p)t zQGBk(>m66!cNL7H#~hC+|9k3++fTp`)Nq+mId#O8#ss!8S)^DY*!w7WbQ3P`$`~{O z*ZA~R!hDCO+dmz$hhTsTo`9tVc zz{!t?x`NY7QuKPszhTU981&d&IbxjCHNSYYXjtr=wg14UNR0u$s<)l&ki7|fl}bR> z`Dzju7Z}?7oe_x7tiIvMwI~JyE0V0F5Ih=Xp(ZiGr+NY41Kgif1MUjj$=>NxT;ocA zgD@8(_V>Cnx7*`?703K+rZNQvrfadXq4hBB#%k); zVvMDPF2=RlbX{pZNi4tmri*xkcWdh-#o(cp!5OOk8Q>7LE#uXIcmw6J>d^zc#?u$S z=~0{?@4m<#sjrV_LW+|uZ1`T`rfe3(c}Og%bM|6NHF=U81(MR^zf^1w z_2{w``?YuE&)P%Gam%dxYe;n58tTsw9#6T8>0i4&Tx z9qSS7Y2z(hIXO#iX}sU3IGRk2FlNTg_J!DnTPLg7zj&6|@AIX0TsBrKY4uHb`Ur|K zrsT*Y^F2;XbfH56=tNsv3v1QN-kye-3z|?T$448g!Ve!-8WWYno8a3;s34Yf#sQz> zt?Lq8d_R8|B1>|mD?PPjr;c>ZIFr9v{QL8N_HA=!8X+8fF{(`(AO z)s0(eY!w3YX;qCO6trVYkv@_>q8KhiQ#XpHd8h{Fo2g7Aj{JMhviALi(STp2 zcv!)N+Ayh})rWC_Y8LfA>-vU4OIE}29ZS%nj_?o6sHU*^DK{fJR$OT+R-6#UTb#v*3b{difXDQ)4$sJsw z1{y1I>Z%)T6eLvjAuTOLwKO9_m1Ed?#UQQUy=78F|8?bZnfW`iJni<4m%RO0vhXHX zO1^bl`;1gx|7_twIo;}ns+|N!`>I3o8h4EIYI^sv`-8_*dr++WmX+BwI$16~--;z4 z^>=2+F#*06t3o0^1HRLqBiy!jKQCuDr*p?T%Jcih)(f3FrYc%*)uQ%m?EBmq)z1Q{@>z7&=$CWCWdQz_$#}z-M|S|)6);_6IQV+_D?#! zWJ7VX8xn4ow_JBqq$j%7^9?aYY@!;-gZXTw;h?Sk7ocPu>mno9+tQbqSw63Np%D+^ zNOy6VPQ;^KFQSX#Vx<*e2yM1{laGpVTJ4k%x4$M4>}TRgi3o4Vpq{d+stA~Ha#Y{^>g*W5xa+azqQqW{5|YTtTR zUVU#?>{4F}|I8nV))=jKAGkEnkP$V}^*}Q?T3E3(R-2Uaw@P2^SwY=KjSD1{1&S2DT63 zz?oiwgAZ1sSPWtZX-lwR+j-@&U{&jVt{s}5uAYt;>FVCDlBThq5AOQes;$}9-`tmD z*rlTC$ns8Bh7mJ=vk~MG?kvU|Ve0JGQ+@!tiT023ALt>3_F_Qi;KM{&;eAqPq0{*} zKRr-OqAL_G{p43xb{>UCF8y=J$cx5y+uL;--9M9lNnPC?WZz_^C(tqPR?pMZJ8(M& z4m>icj_vwU;f)UzWCg^ z#eI2=TE`XyU~B@{&U{K)xM_ygz8-7UJ(A@D71B?E80h}CZQnk14-A4`)U_sao6pMY zFe`li{~qLWvU3iO zy*c*Ye$Vmw{$AhT@6Z0|Jl^l;x$pbBuj{&>xA_P`1&-!HqH81%TtV|04V*^o6LaTq z8OrZsFKzR?v-fMky^ANT`YW=5qJUm}y8)WTozAqmkXM90#=kk3= z*AO&UMLX_yU#V@lGI%fWqLuH(xA3qf8fdW+SZd7;a)z--36~Tcj2HagQ6{A$LmBkA z-F>&TL~L)bRx=|MIZ4mv1+Vw{`FJD}Ur}$IJ>!G0%ajVaIXfN)iMcDqh1UGS*6p3e z@$lcFZ<}8ebx5!1L)Njd`+MpK3%Bb!Da$S*yy^eKMLgHP-iK3ON}L5M3Ew+4BhJB} z^Bt5TbTP}pf8MJ#O@h29rubKjR(bBZQ2nH>MlEqd0&PyZneyycGmZ_74tzXZk>H?y zuHb923T4(YDI9O}^y~=zdb7TmkGgW#+1W_lVf400Gy}dVGllj4b!JH1Fb#fA%XmLu zP0vlW^@IoC`eLb~_zTdSvf7pjEUv>9yl=o4Q?BI{nj4ZVNJ9praMPctAL}#3v+qSo zhte+7GeiuMF>WU;6S&>@PYUzuLtM_L1b8=I2A3Z;puNz}a^FKTF6R(>4t6ot#(ZZ( zl{F7zK_C*C1W?mHB*cp+i5C8qd=N_=AgG*-YRuLa);XhYt^L)zH_xMEKK5iToCn!k zAhamwKY;Xggl>MlcQ(eO+vlYVTzs@7N+Q!mopd1Vc*A7&cnCow43N=C8wbDc^7e8} zJ*%nCKt0;upUhaib|y(+OQU?f{c!%}IKRw}4gU3qd~ivf8k~sgmeZkk4O4l=~%Z6c0K;FM;Q; zxcODwq`ne7!Y(rU*{prk!vSdQy7a|NtR)$ot zq-wIuGgn@2d*eL?b`=roRArGY5!UyP8!bw6ZE0b1pYNW=o1iO*O1MeRH9)YOPiYB`=*wAryFaXsIQIN7aj|#~RB+2LF+1DEOdEhWo(tUS@fGjjVE6+nz`YmK2`;Riix{ zjwKw&jhrM$`y}5bSYjy3?e{QxqH~OX6o3;0Xf#+g2-*BNP84yuyE>{Kcx(=&+5}ha z0|#IC%BXLprgo$;Dy6+V=w0y>kSX%!sTfNCYC4^~~FITTJ}A3wwzR|Xr={x$*|CTtV31l#*&u+(USYb^$SfLo{PKBRC zZ9iQ{#B}E->iLVH?f!1nY-!{NdGYIE^o(1IbRTyj* z?TQL#-=L1!>@tV6gi~4EuCDMq3N)xQKOi0ro%(Eica|lMdDjX(yO8m!<5Y>Wor47; zwul$R)5*lR8x%&}^1C}a8m~`|AbU7r7@cN3qSw@b2=pGm^!xeA-M@kK9@Deo#{Jn$1H3!lhh~!I5K{-CV7x}VN@v$YZ(a2V}nnAov?<*nYzgZOnKQa zy(wS-_(3>vb_6o;M_C1cy$dRG|zL_+0Q#$&{%J8td60Td4>@^oVCe|n&&)x`u z27x!xXm2)4#3V?@cu!2M{`8R@O%~uTqK9?6xHNVCDuP43D-gJ+(a@I2if2c0VR37Zgu+2t8yD z90@OhF$>-dF6oeTM=V9nfVq?(p&y?_azc7Ls9M~0EbW};bR7lJ)$Rs=W`{?P&dbLW z6uDlKl%fds?@5)jW1jV%)QLSA9xvD5&S>EJ5b!*2HqWsj^mncOu4B&C(?pP@27*r zYrNa|mS-p7?5e`Rn_ot1EgunzZ@;vr>u%j-hrxKhJSh5VcK+`6lVkDtr_{m2Ql~)* zU(G1e&lN1kxe*f+GUHaply(1P7^&)7)Jx_z?=Ynicaol+vvVg|?myn5x8FjYkA)ns zg>1G8Swv_TJDWb}sCXcoQt2;xU*q%e!!r;TzZWS3hmix0CtG*vL&HV_RKo;Jqpp+S zRv3iKQ%3|B2eq=<(9LVz6T|D+N0vaSq)sm0s3T3R1!@0qzl@1SNkKOE@a)C&q1yEm=?4wyGhTccAF-Sk`aTKu?aixVa?K+v1lkwb%=M+yno`kc+JSI1^mR2pY9gFp2-Snj?)$$wp^1kTQ z+4QqV)K-jB3A_)&2)X~1N%hGS_gRdL&z6qqnADi3l}a1`DH~|ju4Dy4OAdh@fsE41 zq<0q7;f;2D(S^!;+ZF*WL46VO7ZJanL(h1qsCI9_ZV2ZdcVq&_DSWl`zQT)g)C4%) z&b6zhetn-f4MHP9)aJk*Y(wfIO<^8(hSnZJJ#5J~Fzx_$>N^H_wDSFoO?rqE#tZ5v z&X}$nv_2+DsnndX*U6)avWLL7&`(-?3W|=+KGMHk|1fsP-V!FcXf??Bp!YM#KA`64 zXKCvlg6w0^kaK3Y@lV&$zARkK1r<5#_}0VmK8NB59n3!>T#YO-msPx2LIu!qs?q;$ zbAgDNrmyuYf6xIrNu*8zB5}aqJHl2SYR`PIoKGgLu6UT9ZX6hqtzhZP#LYlLp+;xp z(GftMiB}ciw6=+^uMd}YOQ*L|7=jeUZDKyCaJ>vdqL@G!k=w9~lGrF%7DaD2Z4&8@ z1{_YI(czbsOko%|r{wdcZM}6n;lBaN2+C#Qch*gm0%Gba$+k-&=Cannytvd{Tb7O| zl9G;RM`CR+Yk!gSc4G9=t;!jO?cRgp0@M37E!(oTzp^M;k{Op21ZG)4p&K7RpOQET zkRG))PPQn#YDLn)2Bt$iF2M#aG1XoMb-2!Wrp%=p+Yzdrc5glEE(KwrREB#f@AHi0 zv2f8Hu!BSA`9`NDLlx5AqQupboR`#(%G(d$q*nk2eWa-J?BkYzLyzF4zZRrs)vvTl z$Rsm%pSIhX^)?N@AuKVFow{8IuUo#~MxVg4uux<%;#BTc^a8-<-a4NNa4a}h=GgCB z?YA>tv`$tSdbJMSiWdH2{I+l8=tV(_WhKZQfA4JZxW)|Mya1V_V=?R!Q9gn8L?)IZ ziZ3owp z$yL|jM6Opd=eABz>EE2Q31;LN|>s%THjq$fQ9Nv)h^k&vy&a5 zE$u&CG}UyXU=*0anUE&0w$K6h4gb#LKS!BLBL9lEjz8)>g?h?e25jtZGNW81W}L5U zEVuOUPwH_f{?sjT^M?PtzhMJjTorC9$bbf>zPU1fj-}QxYDo{N^DE_5B15#Eo{2=KvCy5>^Lf zZLjq}n!s!)N#7cS4~8}@WII^45~Pc4(ngRjRCvss)Y<7Qha{A|%sqyIpYh=2N2co( zTQE=dNTxtGpWlfM&h_lEqePZZcye-g_1XKB1L$3pwt z&+1F8h5VV*h@qr0$Kb~y-f#XK%gp_vnqEO=^c!?#LewT6^qx>ZdO2a5xzg2A)bcT| zgX&jN29ar>>`}d|)&3;UD1BOEQ6*Po8*lMDC=nZRn;C&pf*FA*sTu4adGeP!yss=| z5YU|HOh@YL1ttF-64?7g`?6Bhx>O?LmJ_Kw(p?tLaNfzgC^{Nn$OT#ycbPasZWUqb zXkx;aN@8&@6sCI8Zc}>U-L{*(K#ZxoOdy9Mu@0sL9N}P)4)J0W#fS6qJC+}>J1kKc za=AKi*zlK4C|z{gFhsrK{Cxk^ zlvVEI`g+fP!vo5wyu~(wC%-e)+1%Qks5(9@=?&$a+R*$E7^uxTeWdew7kR)Jlgw>> zkP7+H_m(CPIOl>Q??Zcosah(N#cQT9`Je3XNTED(Tq57DK8TFKH#dM1fbdB{HV0FQ zBF32m4v<@S!H^l`d~UyWYu$DKXxn(XC)Y8%P$Vj_YZw(o#!N%m#rPbt z@`nA(;D+~irzc)tV}|7LMeddTyYdmo48PyGdZtY9Ou>#{-HNK_5h>&}Vg+viiDU`O z^t(#3>T>-*)mKgIlwwlQ8N=`;`w$S!jifTi%Ncnr`zYpZG3z#}1RuvL2IQ@Ah7gN% zIKrB@vYjyCMayv)Qny zw`K-Dq-fx(VNVfO(liZ_@=IM3uI`UvWH5lQ;hVk-#6oqK*<6k2;$N#|YxX702#Fve zi<4J{%N#L~v`vbo#;4$n_R)0eX3&E)K4b6Hj&gi4nz5|xOvbO7T$uWf0s(qygdOxq zfjz2}P{%I|jPp*b+5Pw`iZ!x`;r6 zZ<*zrp;DyN_)jX0DB7I`Wl*^XepK%mx!3BkU*huJMps>4C-FNw4Za4<1iZb+uknQB z`fbY8jck-+NXC?W3r1dd0`LcEP6fHVZxds`XkYR+VB|(=cwW42!0$jVg*mW@2%QaB z1n{dM*EYVsBTK39EfnywpDExmb&jv6+K(lsQq#g5 zHn~h`*GArviVEWh^ed=w_xF=O#Yvr6JJn%Jw1IDDK3BM(&KnqUTS0m#0et2tnXz9% z0GBEC_d|s=^x+GwxN4d|hMT0(8h-g2$3)MtfXRO93NV#z;>A{3(8+Y&NF~Xgdd_Pu zRq@ME3w&shvT#QjB$ zfj&{Ql2%RM|F|?<`r2jlND*uWL{2r+$X<|&;^e&M12YTF5z(6nn_kci7BzpRvaqNv zDhYC~WjazCgMH?6_$s}@XVgkx&0s|E2yvGTLV797B##gAyzqT+IF**qZND<_LZoW` zr6%L=u2@tMmeoHb!g46fFK$IW+NDQ;J^+H7CL7T; zai?Qg6Q@IR6Sn#1;Y*HLnAeay&YZ7Xrx87%O3AJvd%c_&5xzs!#Pt$IyLl!g(#E%66O@(SA#S$w z2P=@45h8qlXuKi{1WhJur?gdj3R)Uy!)62*K6{BY0!72X|IpTTeoF<~!;ru*b3=D< zazG#psGbMoEsz!)z#-I(-CXY(w{d1VE%I1;q3hQxW^(hjQ`KE8C8FYcMTz9f_WzW4 zB_MWNMZ$kXn6&jR2_SPV2vmIcdNp};oU0^?2TU*?BXV|yr!%#guVP?*_D=ilhg=UQ zu?aJ3_~trDF71mdzC-_X1Y=p8&iGCIwF}6uW8*&eKQeHD)#htDQV1}eT4ov42b^QmeG%48Vpu=5V&ovC z*Bb1|ve@Bh8mJ1kt*Ikl1MOK}?1=420WF|te-xZBIMdNukP2QO3V;%>MB0)hhc0A! zWOFg778Y*iI?mk^>4K()b>h{!gQE(fEf0F_x){yYe^a}t9m3% zWczhJ=6ZSEYHni^2#xEj-LoN~be|&>Nkh05No~%y4kes*TZ1v@+tZkx)1|cTCH1C; zcjj-xg3ME3|3oE&3x_f=-f<}4U=!Ht7pMgMgA&=#^93MIPU)0lX9XOt{f>S%jj>A9 zv~cuWg36ppg(feM?>-_A8cE3{Z|g5>V<)tb*L^$YF8{Ff)lnDK(RZB=A1Ib^$p)iZ z9U>AEQ|M}f!B|(gkf8W_zIv2cGH5rFA!1YDrOz`ZZ^n15LFVP-tSxn0b-SqIOTPf@ z?ArRXn5yBfr_g%`jtG7ifIPmsWKwa_{H05T#7{}XJTt@=UD)$~@BDSk+XTFYI2ia? zBJ%z!Il4N2$S!05Ufc`2>Hz#k^`ZZrnm-eC%E2xWq(5kd$L*#OL`;ph9QNf0XwUN& zo0n6{;L9=%-+`~Dmh|k9ox9>YemrmE?CMm*WHEI4U-=@RafGY(I+!1VU@2xUSEJ$M zO>lHe7B76!NdNWr&vu5(OMXd%;jp=kw~dsP~jaZ(vKA^JF01|8RJSrfqtCfIKu8}y|ExCdfkt{ zb_Xan*LBvLYhv)Gh#gz=H4K)%Q8sgAS@`XTGm`Ql?s_rl%rpayN@2J+$a#s<4~-1C zb&=}vk}lAr7_pN0l={`M)E0P_*Ay&A3YKT9-e>oL{rKFahK*}#O>VNhvlvL!I75!r z@O7E*ieNOSm~U(9WAb>O4xE0{)( zHp_T#V^4V#;OQz>QFnJG zh1K?}(LwD$mgI@$<&h!iRmrjj2?b@iFX!8RyhfEIo9e_f&C?>(BHSz2XL9iSKr~7^ ztyFmIqu%c_PZeKji7|9_dv9!cM{SG60Ah0TF&A;GUF?AZ`=2sG6;MV#gP$iqa+vv& zVbRxk)u#`EGIdAKNYLtfhjznehLQA2I?PTlbl`zdNyIrdP=H3<@rbxp%cR)ki2H6Q zr=4yY8{!>gzm2-5=D(-49u5crRn2&~)_Q*ll0=H6urN{WbQ zaFEN~j}`{Cg#4DtDF?O z_x7I8ZMAH{mhiyRzpkL=G=lX4ew{!U&suiysVdTB7st?sFGhuU;9>SrTj$kwv;uvE z65j9o5|k+vVt3*d%EZS!%yfRF+jV#~oc#|J8 z>a;P%V5gnLT#%rr(ZR+dKL0xGZIc|RhL!|jKzE$eliBG!-#>3{u8@ektVh5vzfDO= zl`Q(}S(cm%XTzk81{4wEQYBx(t9u4|=%+g7^-nA#o+5kSZ7$~fq9*knU$>JM555ES zz02+ew!T*o=7Wtft#c_P*=|>#dVVlBH==x`Z3ZI}NwGG!A^cI?(`&Gv$NU#EF35Us z)VA;No!X7-0N3}grXPSKW#e7|w>P{d>#*T5MgR8t@s$)ZbavH07l4BW`sX3m|LLD) zeo0gxCPH5VjxCEmc@uDK{XieS#-vMYde~}Q?Zgw&H{9lBly`bN3>Q21M2V%QKKX$S zsjB0gf{DLL+p2lKP3m|pYglRrgq;lq3rH!AC*}ENGnx-9c4oQ}UQsp6Y^lTpqyi^^ z(Y4vX;ooVnC(WE_!{UxB6sJWr+aiiv` zDVmDy(h_zHWq&y`<*(<@czNno!#^NEfH0k!AH8`}pHs|`zipW69N zHaAN=4-Y?{d7Yk51nkE(q@@Y7vC8iV7~1HlHM^PE$lYBTQP$I$UIwJ*lQ;W$`?suD zs3Z-Uojao&Z<-QX{{!_12`CUGp8%kZET9>AQ+@1l(nv$uOFZutq9ERuqhJjv7vAV`7RtIFUQG%7PgK?n9Rq#3$?9KLx zn4T%jDOUF@GxlNNB=U8#zFz^RV&@k=`I!7$L(Zq0x8EZ6BHuI|p2v#N3NwAy`fmN7_Xi=FAo`_#pf?oj3CV+&LrDIrw>zlW=x00Org$Pfo~JK_SbB<7qP?AIv$JuS0eZOsTydBQwZ@FtK)AfViM^Eb~#1vD~;M-M@@>{~qW zpQ_#S*@R=%RxBKfrHv~yWa8OnATaEk?qeDOZ@Oy~rS!l|poKG3%zAYfpyVdfVr(HW zb%jN*hhvPhP!|)l%I4iuV(MhN(Pu3t5Ww_9M?NHD;Q~7W zaHy^`H|e&IirZ`njN}}%sGN1r(B(hg+bmxRv9Y0(%=r~B-SAyG{zx=XQxbZ)ik#$` z!>b|U+$8yx&u(YGkYD%&k{GwNe5WM7vExIk z7C3`=eyutlznc3ye7lnrDFX#gB~#TfUgth-S~6f&Iu7uoOQ^XBE@k;1@q$K8OeFj7 zXU)gPrCQ`A+=;-zi^WxZ(Q>4H9Ledl#f6He-sb)@{&n5d#e+F<_&NBHnq|(|)!@?T z7ZH&L@O2hb|D_S-4~d&2Pk^k1_kf+iCMMRDc>rp>xwl2ndB&k&`S%!Lb7*_HXATGE(uNh4zLXf4q!m7C208Uhn$vD1*c}*a6m1fYfYr#)c(D3y6z#^u@zH zD(0GA0}*0uhvJ-vySg&wN&cF^!%aku&pMp+@}1GdDt2Z*N(6DYrcyv+v-O%Xqy5`S z31j(Ay}5c!IGJOVS7K=is~yS;OZt6V^ydP~3j95rt=i)Gc>9P_rI}2Nm%;O2Z+!uc zsdqdHUQh!g~U`Xo`Q&Oi1*Z!sj9^%)ZUh`pOvMkrvgN5kQ@^>$LW--da z&7^cs<$ox57TL=_qR}uK_TAUYG(+^CY!5GL{$`l+mnJ7whlJ)gCu{uprsd~!2qrGS zZT5h3&kTsgeAaRZ#kUe)4&9FeFh7V7kv~M=;`!2N5-_QdoxgI6) z6&MT+5TG?iXfqwfD|~g{Ck*(ZVf@aaoJ1rbqRK?SJ1|#9{Cdp7>9NM&A>ieG_Mewm zI@4l!;oxp0Z4@t@l38tu-plrgF83LEC=jI$e|$SV(hvyIlV)p5K0SJjo?Y$mG@qr{ znI^&aX)K(u$$Xlwr1tOR2xzPpKx4H~$enyt{V#+uZs*&fx%HpS9k#TWw+RV9gfjYA zlh})}Z_mjUM-!#|-yT3-nARx%e6r4C6IL1Uvpmos-5P7LbXikVe=9=B%Kb-#I$9El zDZtOR8(nSUB;;4{oWJ?c)@IXi=EirdAXtA4FoY$=_}Np=sh*~P2+Kdw+pD`LGWOj@`2)HR_bDJ6bN80jN`$#AJG1z8k63OzL87$Nqesj``{nyog$4??0i%{D6Ux zx?2}c>r$sgiw4j_0NLx1&Hw&`>`eW!L};Z1E1A1w_BYz6+N80!EsUH2O59;sJn+}p z8K^nwRTJ4v0u!zkljoUpOsIq7=IQhO@_(fnLseJeQ678UD|>h*5UN z7oeSm5#9^T(wM$$2xRAn-&8XSjlqbC9=#;^>5WehO0d4QX=kaX8!eHyb9v5kq+j;d z039%RTXv=WE7ocZaX$k6esIsNi=6Uo>9dU4*XEgDioA}1j!<@GBB8l5k<9C|8#)lG zAES$O6lbBWk0JN@5afzUB0H(M+ z(<-rdhC)6Q49H5IU7wOX96)B_Kwx{ITsAZ5odk6pZGUOHj1aumFhZWZ+E~A#b`6ZQ z;1o9x0&sGT(B%D}Z26^K3AhpSOvhWc9qb%yE3-SId%CzZnVdlZ~#inr5_(hc*nG9N=+KZl zQcJJP;0X|&e*sGL7pcv>sa74>nY9vQAZ)&O02BT6-WE4>*ty-|1pjDoxF7O2-BMj@ znB1HFZ1jvT?pbfP^U8jmP~ZNWL_-@hK!=n^m;vd{%w4F-VRc?E`Gc~p)dd2fNfi(9 z!~PC92EUlRkApe}L=N6~xVrKXpYlEpz4SmTdZwz$jpItZ@45ipbimE9-R+B4@tW@P zlYl}~FfF#2xqFcwEg*Uw=f)4*56QpnD3tS?Ke?Z?8NYG*eYhC)=4o$tU;Xcq%-#Y1 z_X7!S`npRez|mBk)^K5Ec(+DNX|F!n!!k6Q2?_Ena=88iBp(k7qf3R{uJ@zB(JDnp zt9krMUP$_i89W6sbs|`DaG%`OY;<)c;PlAUOJ-2AvuQmn+DH0MxM+Uw;65{EZZkQ3 z2SCOX6cF~+AnsUSM}E((%ZkEC-{hteAvm+s_55Ke>{_-IEMTpR+(k{=*$1$6>P8K4 zyX6O+=~aMDvA|{q@56lYg*k1#c*fo*_?lbP!*)9NA3&NWsv?B|znOx)^?s5&q{+d4 z?_eg@MvJ_vyyY=PKhWd)?Vun%fODx6m^JV=zPdl1QGGD|^W^TzVkdV?74ELQk0Xi4 z{VQ8a!W*?AXzPIn34bl$%`dy#fDU})pxzTy+_DWcjo)JrFBZnPh0rJPxPvpha!&-W&}Jyl$gsJUTm)Z+A%}r$m`TVpvg~6-(|)`Zv$TNUQD8pphKtW51_(+ zp!Yr;@P7QMsR(}hWqZROT);Q>vfENar2fQ0;25xig4K87Z~Xo<`0fJgWF|2+?ND0_ zQ%y=1c(=Y~NJ#cuF3-}9c*%vttG1G{M!|-r=7Y+41_$t+$G_q}BPP3e84q}iM!;Ka z;fh@M&aTNQTh@$moqCsHY*_H^Grm!j>nz&|txLvAmq2Z^rSh*(LaGmBFGg5gdSp+F z9QQrY;gLn8T3jCIvK-36A0Ws|z*|h)O^*^Wan{+GzT<0_ld@I)MxI%SCaVs1+MqpG?GreYrE z{4>Re#xwg)J||InnR_p|hzIO4jsXo>McC^H_KCN;KZLO~r|OTl9Fd;`hXQ}u!pGzh zP4Xk;K)VY=LJNvtWF{;w&fr~V6#cu09gG;DVVeLBeM=)}tEh51_gNZVX&nKu;~Dun z8@U>bz_AxHG{k{6ajOW1bu~0H=>bGN9i0^86UMWvU8*j*GTg{S#;2 znQ?@{ti>0}hd8vJj>=1|OdhqrV_C-edlfe8zLWqqhRAGMe|Ea4atve`mmcUrQ8{!h z+!20H4#yD32&MxBN5Bz7WczI_V5W92)oL{#3EE}83FlU-z=g>AIP!8qYR33`?Ka!X z@GG7E2LE_2+^Y!C!546q#TRYwb0UG#~0I&tQ{LoyIMn6PO0?W7= z{Rq}FE+YF14QS6zowQE$VVpG!ZB*qb|0c48ZPUyW{KLJEO7SaJ$^hGd57`~Pf;RpK zMbK`a+G|S3EeZFu0*Q#PiVjx2{B@;X!cD>shHQ>@Z+NkXh zIZ_j}5=+AYdVUtxi4I8SRrpcV?kv@B5{Tx5fEX?XOZ(YM1>gY+0@{v21_RrRd6q0- zeJCotJlWbeOi>a-q}aV5##sk#DurY*6)MgDVqhs=XQP8C+xF>m?_h9`EP4nwnkQ`T zFrVFqM}(a>sr~*BPQicO69QB~KxB9Gx%3Q3Ovp7Q#nB8_xJLreMt;7iJ1*dfV)(%Ki2eK&=H3m3uax>5$m?`82 zB-DZa0JE6M)kve^lLO3F)|`J`0X3%1;`kA9klvLR z#M7oAU=SX(B@odgc;b&KS~lq#r26u9e|0tch6U)FEnqjW1dkqGG+>hGhMJg5-0GXA zCQ339e#i3#69=s!_gM`=;B3?WSZ&;VuRa3!I7o9s+@vOHbrJvkp+l(O1Qg0vQAwpk z8Z20?gm_B|aIY_SB{7%`G4zlFbbctbjtY3wC?-5#lI1=x7fWTgtBwOp8^YwUE*%{_ zHn~AbODq4A0I$F*nb4W8a~~;*^ug!R1DzD zG<%t)o_+tUWQP)5S3h3q1%*^C>H#^IRc?qwgWvbgRFX+JK9$#bG&$RkAM|!3_B3-I z3+vcVfZ`YaC8o>^G1cK* z&wTE8=b}2uX=_!C`jd8X#C)PWs zvpM5RsATF-yE+9NaJy9B?Q0>O0+_t5#S;Ontf#=rsxM)2LdsTxzd`;fPcRQIynP5#02CJ6TmSPmV+FE z(pTacF3;-(SAuwh95NFMatKZFRRz=!=7l4xG3m=8oHZ2xjsFRE9DdETAeVVgXUTrU z987kYJ8bNsVjU;{7(&PdE2}RKI5`xB|Lc)ru6m>su@OyL3mMF+aVf!NHn=TDSZDf_ zNF-j2(Fe`DXK{Yf+FqBv;!Ulxb~Dvu+nr$vIFrBywyluf%{XpH%ErZjz=@G{!5{Gp zTScDTG$gpC22EhkTOdJGV9LTMy#csPWy<`IqLXE-z-~ZE&ww#^x03tSbIISR#)&B? zw8DVzmm`Om^Xw8%$Kjh*<1E)m+~VF1P)u;dYfdrM8%~>kjCB{x`nbY1J|{;322x!d zAHXyXoM-N}{ITM{r){kLArt@b^_VP+wpLwcb>g+sAc8?y?+ z1&F@;coc{mYpa2?&r3rWoAqA({qyV9FC-J7EL`Zp5R%%)AOx|BSS;E=_ZIta8VSLu zE~%fSEZVJv=LzD8RNwWYy2F&h)3*Be9H_Du?(R)am^II$!$JCb3x*&)XdO7iw~@`` zaiSgVsD-Xs%p-?wSU+8|f|wuLS}Pu05?hArj(wu&(i569Fy{!y!|;qLi4HcZevZXy z{pF4Qt$5b$F8k0)d*oD6U|y#|>C9(i5##DO5?n;SZ75wpM&i%tK+~`!%y4rL zm8j}VI3T5SZ{`fOcpqp1Ww}h-43J56&r53!{uDASE!4CgKJwE0Sy5n;t~gaO#d4gf z<{=__PvgU|K9)vmUR3d)K-vlx@A~WN&9}TjgzsS7z?hvLR0FJW4cYt?a0`C!SVhWf zmTAZ%v*{k-CcSmc;6x(j&YzmgK9zP4$LvoMqf28m20z=xiu6dXVlktGdT&(}>mAZk zsZH6`s)t*tzMCF%G?@BIRk~E2iFr?+%f+W$z?TijI@C%DCw;R-S}+x1CS*Mkt_34E z?@(ai;IP3-8-WMMOH9YP73DDCKTrxKPjmAB&7Jeq(td@E(iZFPc$4!KvOAMonEtV< zj>@zKW^5=}bx$y@mUz(4AM4$$B9sHjxA{*!=upb6!dJ^=1}I;I*bsn1nee>I#~HEM zc&xGvb3J$2jG~pTV|eEN$@h^^mf!mlY&+@<5~YIuQjdhYGs4!cUB|f8XNbXP*BD;- z?P)r0&p#hvz4@QHjojtkc};gSQFZbqv$G<=CRj0gzfCj;9-;#Lc#|lPob?* zL;OCFk{P4@M}fh7hyts#!)e}}pGuZQuLxQyUx{IDiJtZ=t;Edeq@1FYRc8*xSK62+ zaE4!tZB60D2DhF8t!t?P0o`#J1RJiPZB`2=m|tn5P!h#cCiv-3Szi}_%xt)j25gn= zW0uz*Ccc2JDylu?Wrv8dxa_p5||XDOj13pGx|F%O7P9V0?$X}hO|U*AX~tkLR{u)0t}U7 zY1JzBm{zu2p|jOxj8Heox@Q0Vz8?7f{%MKOq*hhT;y5tT-W1L>-p>&869mfuKFkiw zhk@y)YmC z5_=rb_2TH**MpbzK}>i8FZRUp1WYT`u7c|*$W2|r#|ON1rkg=n$UwZNnR|n#PI0Ox z`8X+?i2EfC0iFp0X{&+_J1eha-3*8ng*4`^7juKFEjHPtaVzI-%9kt=?;(Q!sK+ZyoO^ z%;b7mA|-(ZXsGd6XC{;^O0!$@FsW4HIW>t=iGc)w^Ut+K8xVh;%b( zfq^>6exps|g+EGlZ<55=la;$+cqs0)=nlg-_UR&zS)6i(X5;FG7UAxrFkdtV$>JHmIjo-8-=?P}p) z{7cNvqA4J*gmHr?dBjNkLW!}TQT~b3Mhlg#!pQD=tLG6LipuNswp|1Tv^l!&?8I^QHUU6*Gq_RD3 zXWd%k&Wv!hYoXlzw_jpel6%?eLZ(-wRjcjP23of9DEr3A&CEt(NMzb@<@tUqxHvoM z@~{>iII8@|X?IV)^@tr9>qNL!_c_iOcX0si_<_E57pMeg+fRvwJHpt^=25DLFLw$K z5=Bseo^A$YS~H)+5%`=+^VsOt`goXgT51{9?mvbbmj;Ap&6*jwWp12u#4qsljB;_z zAa^a3BpTwpz(rr>BQhz9-4%KIfDNp~t(1$1+!kOZdEZgH^Ca`wde9VpeM@0>MmjvdxJ zl%-Nca#vMQddpF(6}I{YHH!EPt0!-?y9G)VsDG4TydZN%o~$WQFZ_Q=_FaRutNE9X z(!9kM{JYnyHO?L@gC~RH?#lWY^A;TKfAZ~qxPdo>dL*Kg3+z{~Pb$(=zyJ=`AC3bl zo488N)xOd-6X8J&GX}o^pQDhcoE>4*L~9p?Bs!HFOCKFcvH2;H+X~ zI0#=J`{`C9rhQK&NZQL8pIf!1i)n#(hYn0|d`wmgXG{e%W^-r9$Rn7@xyvIiuV+6N zjKCTMOj8Mkj9?y>v`Q*a?rJRIbk`AGzx+~Kkd!tWH`Z=bHy4|>vDOWcwz1X?r+Y%` zvF4qeXAcbjfJC9E-Dy9^6$l@@ntc5X$`FZ;>CGv(Z`)8tCxf(-6Eox+Blzj<2#%Qb zXF^u!=J-gC;@*4!ZK=g;R?yYljs+)W!$N0zygFE2GXxx&km0dC&}f)bIGjAS6!1CX zTKYdceRW(E&KK>1fPhFN9U>u1wjb< zjf{>F2WV7O0Q+w&u>YRREh&X;jGNlrT_~^>F%PtGpaW+7LR{Okbx!6V(^`u9O2n)+ zGO~y-KWz5!v^x4fV1iEhoeax74V-sB^qeyf{=@7kUSrifwK)0O293=g^$5jPmb)tj znRn`e-ktX_qmgF|be@xyjZx^OVFr+=7fN7Bxh;qh(TWRlNV&yr?1$_#xhXrJW!dw7$`IN5gc3HyDDqkB z=$RMHg6u;_7D#aX*Yke0usVr0%+46nCatL$34P_?yjhr1v#rivcbMCr4TH~+=PN%% zezc{neG6UH#e zYT9M4BNo;8J@i<4CU0FBSe1n_wQ+VVcS4%_#NFmQ3bCCK7k5CypiH%Ojf^ z7UH5RegU);^QR{vi5e+!VW$suS&$!X1Rn>OPahOuX13tzqSMpOrE(t2gus4HvYN`L zkErh?=UUHcjJ&_}SN)#Sr5Oy%n*>r;2u!L%WjRN(JdUNcT!{iYj#Bour1baR{Mkm6 z7^vRL(ZkblQ{tbf7h3xF_}1^m8>OJH@q{lu7fIO(w@FHv+BR`c`!tFjHaE+@#t4mx z*5I}&U|!1jGqgdmPeW+R(1YDsx+_*&17Hu5uG4UQIbN2jG*nW21HalAZ)k%clkj^K zaK?4;oQVD9)yV$pR3MqH(i%;ZpFJe3{Pw^;* z&Jx_`-i#gEVHflV6**%`Xg3+}Y##DIt?(lG1q*ru7Jue#P}$F2af6-YRF^9H#>L}i zfs3Dn)FT^90~9XLgK+j<6h!;j{^JyRD&-L;e+IZhNXW zedoqNJBl-avoH!xisC?Wm6bcJDy`+#6D99G* z)OS;&3Tj!LiYSx1`aZoZ{z# z*asi7&WjN3Xrq&N*DlblDre`JP#yckzf0uw`Ti?M4}L?gpa~}=Z2lPe3|p*Dy|NpN zBNDR>67h0ZX8lG2|4xlg$G-eiZ-XCMOE{WC17I6!%V;NDU;c5&M zEsJ|{$%`iA%65>-!cje|+|vA~hXW8p^g10}NSzur1T-^iafKkzj@FmE++z*fV#}%0 zTNQCxzPIltoRz4iy+s7j{LMSBL8kkY^;~nZp!NzTEzM_6>)Z4bACVlOc)uCDsr;$s z6ycKckL$VyaqO?Wa#Lwf>ykBNl+hP!wtv_H|AtOjps@?uD8vQ+)2W>Y$1~^2M=0`G zbQeUGINj1wBL#;~Gu#%vzq|jKgg1@ENBZc-aq4KJV`j(U5;H&Z)$(O1TiHgzK=UVk z-M3jCj7e8!co?L!BzmS~IjG!&42Y&mgG2VFw_a84bN<@6=bjQZ=)bVZTzY-@jF2h; z?T?{+9r;p-z4oo;)DATF!FssMto{Z2r|T8Fe?FouM3sZ}ZuP8V)tOkK#c4PU94}i{ zS_23lMgF$8Eem#pS4&r|sNt=h|H{jMwS0C)TkEDmYK+e$LVK4P$-GvOOKLFA0XvQS;e&xKf~#nsbIcKwN2&|l^AC1H7V{;GR36d=7I}Dh zzZlt?%Cp{C65WwmMRjWKlfm#`FR&YxfbkaC`Mz|F-5_^oc2{F=XUMBAuaT$l7cca0 zCbp-!4tq3_Bq@#$zf35^EK`?g)M4`ra!cMuQxVfx1fYvS${d++_+=XROf2fjXzW>t zRBzCG`%|9w;x1nf&#Us}v(8nipEn}(4H_z>S7GC8eaS5egGU!2n99`7L0t?k#Xa<9 zeBDlVa5hbf#)j;z_Qpr)nI>i&IUYZXN#2y|;#w-y_(vT@KMB=Jwg9}s2XfVww zPTj`=y$wqd33JE?Y7k$tyz5*HDc`vK>s*>yZxJ_68ahkZn3x=3i-;| z|5yj8G8{iWRE8LA5W}G?0fnX_w~3}$+!Lpo7vG=XB$3xsm~~De|2^_>!ZSQ~@^ON& zxoO56ZNZclG!1^uKu1=a6k~hNrEnod#cI#c4JS-}paS@YvHGGF`v0u?=T*NH;k^ue z)QHm$HAq)!`@KuqG7;<~X7+4&&8AOzYVu}_`IlCKxJ2z*JWVV^gX!@(nuq4l+E!)q zV1DVdDTRq{rGvzm|61tVjxTI*C5xoJ#p4*{ik!el#-jVJwR%gcYwoC}z64mT(Lv`+ z4JGKPg7YOPY^sTl{0aOvU#6PTCU^vIc(J}c-03RGDE68WCsT|@B-tBPIVn`u;@YDa z1Bxf!c~&AhrZoIXeQg74y`ccOtbmXE95O-@4?It=*#4HpvG~vN)(YaZIKYpTea$x1 ze4s4l-^ zm}8!0MfUs^SLxGx57i+4WRDiWC^)dfyHS1wAq4Iq7cLjK-Y zO2WD-x;?~?ttG>+Qsr|m?sg@Sp((U`PkliigJ0c$gtO77{!kp{Ac;F2I7*$ELF%gD{?Jly#2S+eXekbcnaD zK(2zAdc@l7Yn3wxOW3im#W*3#J#s^()+HLEgfs4 zC58J3A-w_upcCN)K3d2v zqfa_zcTXZe_-Zev%^&v7^o<}auM@QSa%2N!RUq{62Zh@rgGcL<@knlc!RSL?xuv!TU^( z%5i4}l^02z1lt|c#5o#}{Um|9 zes5EgB1nffaZV;Qa{fUR4BzXQUWsLCO(bmdzGs6BD+FEu+&c`#J_(^|BM&SRdVEEv z=2{wacIsq_PTE7bNx~a4rD%=S3VBGfS4TT9TXRb{TtsMT8R#8i%WdXq-{pscj!>#s z31CIDgU-Hp&YXgszBuZ2BA>~r|7VoxM+&jbTm)E@(2}h6QYO+Q?sQ=aim0izn)Ve` zX&hlZlDWJ--QV~S;Zkko=6ZYZ;n;B$A)s|NfP`HuQ?G0JrQsBFyOdQS1^MPsBa_X|gj(kt~ ztyv7q+XMiy1SU12vTPjAHml)F{kI~HC2Y>#sV$)W>sS!Wp9;L65=116x+PhuCP_Y1 z71U<&T#K}3Ou>HoEgp;d?ES~;ORqm5QnFH&1+NS8Vw0)UbYt|aOKc3c;p{7u9GLUE zxmjQ%mvu3fB>+KK;@}A_5`0|G0#mGcn>8nl=3;Jn8Im}B&B}Yv^fWbi(WsVlLRPQM z`#>8aAkz*H_md3Uu3^5xNVxOK30exUFnang zz$$rmI3Xlj%5ScB|CalAnGj+12eF+UwD6RRBb(l!9+cn6aD-F}ZXF%vQu~e}{?5`H zm2&A7E+7_O?O%fTMz7q!&%yh5^h8vc5{$3osf`gLJkNP*DzFkv@RUDx6a5QUi}X+? zYMxjm%{B|I5s7gSa3yq_dM`33g`_iET~)%cD-o+2&cGOuZB?^;(yR`%^V-Ck*BqIh z?jGey;p}`W6bELapJ@*PGtnoThREO_YU8nvDa06Sgy8I+s#N=Kk7IPkJwCr9HScAF zE&{^MCgDR}5xdX$KiYL|l^`*$A2;@=ptorG?WP7ZA84we{$qX;X4R@dK*F`_-_F0%WO?+?Oz@ZLcl?%_yTSK2c2r3$nm(LQNMAeow8&u z(9@_fl7u($ioxmcl?0uV%AN38zxCH=f)kcH0R5+zAGuGB+#PQvR~lq~bERh(qxtZwGl z!q0Wx!iu2R<~i;3y9{@*=QoxR2x0#?tE>O$iQr9r>F+6B;Uzx7o6_kz3~;)}Szmz% zv;8&u&qzeNnM-Vxv5~3El@-+;)52(<%q_1#uCHjh8r$*z z?Wc?{==imRjq!u2Ed9%-f*a}#+Fd5k@65UJ_PdGnKf@|livXrk>~dTxIOFS)pQ{S$ zOHoEY_28Vp5Dw^;J#Q~T99yy%p8n%4fx}xJ1jqbq9-ivkpgh7u&N+NTuT@LQg0BI; zv^{CP@q(VNIV(2QA*F3}vS`fWGIevuL7`&O!z=-XihCqwXVr#6wNF$tED4@KxRRPp>Y==`-k%wPFS5jafdaU z6$(&ZEoe=S?0pGTwS)e@WUNx9KI*{A8EYr+qpn+p4#Af!IkK)3 zDGX{_wO1{2Fn|KFpkU+2e*1+*vIK8Mf+(i;E0Zn7afn3T<(hr1HA|bLGmd^#S~EP- zEonamkBwb1Lh;*s^JX}sXyAKO=oY#2gL?k<=O+Bz5iu*Pir-BC@~c9(08(%RNZ}y7 za{(2lGP7r7uv?gX#Cfmm5`D(wc$c_v#@78V92&j<&i8GDoleCvR6l zH^(j#w^(823S?F>wDUZK#s{sE1A+ahM%#ujeAh9HvaI^U)i}nVxW`+pra3Ev`GXkQ zX8x2798(k~0$Ny^oHs9+rZPKt;qisVw*c=%oG7N+h^h3|kNF2m^>b`x z9~^~C%@o)kLW0;1Uj&j;>aB;M6-d^B2!Z5h&ycI{H0H4P??!wwuy?o7+0DXWgZxpb zxD(?3KrK-rG&qb};Pg@c^7`nvB{Q(m-km)j-i$1976I=5h7l&A*BM2F1A3=US~;#{ ziTLzns`Fx)PG_$kDiT_lhkApRvQTep%*pFrZ7(k^oA`3xHmmRr{ZD~L37AH6fxl^L zCz{FWspIv@?*7K=e#g%4(d%tXxaXn$fh8QV!CT8#7s>g@&Jx|Rhj169nVx)J24GT&W(`!|e7nMsiF~0ya4KY!_28%i9BEd9G zty*(&E&PRhNk^;D2M(^w6lfs9g!u~meNsDly?)lqsn!$<-m4Ev*PJe2r|K03hi>OF zC{}{n?y5e18^>htlYLk__czVZ)#vV{n*YIM99Y&6YjX^?(8xwuE!57g7Pi&9I0|o4 z*@fE1-$^yu|C4Ioq;?-1X0LAib1N|SuLb?^<3tCTbl)~mZBm>gK9#($kc)O$C^7?T>inWoF z=4E=JoZdm<5KEa8k_r)dp3n0QouNRZ0?d=Kz~4HxQ+4Qml z1n(NmtM>VW_ZiSg9HoXi-jWi;DRRCWFJ{^GZ8W^HzpSm50uw;u_*Px910P|sJy++g z686X8w)_>vHpU2cvORE7N&AU(MzQSj)1tAm(SUv2QkY_u>B}~Apqg3$)s!b=Rwp2{ z^jRBNI$2(OA%z3j`i+F~hfx!A)Fp)^Z#}Cl@1m+d=@V17P@)BS(q!mGU2VmLb9Uks z{yTMB$4}&{+eK`UHU+Y4kZf(xrxzhKE5cy_thRslu6kFt-Z&_X7HXbz5t7)-OeuKJ z)Hf(@OA8@B`)u&g%$W`%P(TO{WWS)3SoB;6<%ddymgbCbYsPGd9rSQ-Q=uO5fqj_^ zt^?CuLH`YrWG6cZ1z$3s;gHpdi8k@))uGe*A6rBSZ+wO0lzfQwt@mB;0RUngnna?g zV?UiQT~~HJ!Z6DUN8?eG#cOdaM!c;M($;Y`0%BS1@4X$R39}_^NC>N+fRAxT?z1aa3$Y>1W`&rW$rpMUoY|}uT5s>to2Su5%dP91k4M{^yEhA`RZI5#?N#NYOcXN<*T@#krLz(oNsgD3Di1Y` znIA=lqdiJr(n9ReCMZ;PJcz-VCrkh9${V~yyq7Bls3DVyVcZ7Lu$T;$ov#dLsJ1KT zW{!Gs#qy><;HW_i<2KL0%nUXA4@gAz!(6$g;}0q36Q}7o4onG&F(7Ap5M0oil+tAMQWH}-Q8j=Oxq(u|b;k&)w0p!^{w#}k*zVUi3jKR1A+HZ)c0=akzn4Q3d(@&LKv+d2Wm z7W=yu(}{NzI{K{iphEhe`MeTsn%bIqm=oI>N1g0r>F9wFAfh8OfA})f1c+7aFAIR; z$OUHkS3lbOW2L8O1+t;-hA1_Xa+RTs8ga6OSb)4smQIfQ&alYX@CQi}k}s|+WjK&UR*?Uo`CPg<|`|5l=lHKLS1su8J#M~4Q> z>$|HKiAw*4@_IK;iQ3adm-84H1>R>+GA+Fn$7bND1Uk`o!scLYYXbQI*2lKc{)D)b zaV09dGL=8GdlCtZ;A8+5^Vk0>rX;AC>Ufo-!~2Dd9gT06Mhd>L{Hest1qHLa(y=mF zC5Bji^TnBMIG;Ygf_HI#Y!1Z8#InVcv4S(l4<{X=lm{X!%?>(}5SL$4N83pF{kfLG zt{C7JlM0!4I>sba4(J#n`QSA5?T9t~8Na>>PB(vZ%ftUV5o1dUiEoW?D@)SJz2tjE z*?7;r>F=REn)s*~sYqySE`5g>jMdW`3-a5=brqcYVrr*t0M7S~!#x4n=c@_S5E1l~ zv%RDkBSS9Tu+gOZB)8vW$$-dd%<(c#r4=KxC0K4!mx&kcWQm|FfM>Tx7w;pLG1o2w%6+y-_TpHiC2`ZxbzOu}J^7kNwRO+23 z;e3ZE+KrT2U5U;WL(Qnnz7Z|i5?&DCxeU&R?Yv)|tWL4y_So2XPHB7g!Omh$}M=)2!*cL90Og(c#59WJAWB=^$jpVndCeW=pQOg@`miP z6rIS@r z2Ltxk&R{3P?|;3%dP%~d8|0tr@t)`=<3IjC0aJIT?)yzuDB(}~vh}QkLXNkb)k6Ws zFa^*}=t#^?Pp+-eXq;8m=xN}GTWa-!@&4Hv7=7>J33Jw@L)=4&hV?yl4|zc4-qn#dR4B$Mla2Jp~)#uSvK=A~N5+wX<-sHM20(xA1jpX6>udTGH6T zGMq+;#)(~-ScR`Ewq1~-5l52iWh2-k>BxPxZ(#y~xu}Or$uRAV@dI*68kR0$yn)6= zG1XSGU{r`U@rRSvOKa$?mS*Nu^R=5x-F0uR=~pl4gdTCcqb76~s2fCDQuQj!*p^1g z?l*N|J6#e9!bvuLctzE3<126t>d)`gKUJXqjaw2&5#hZ&z6?FV^k~%{LGLsn`+tC& ztaN~hj;Xhp4uT8enI?E4=Ev9%V1 zE;ViX&hBgvzM(tjYm|f1?v(Fu2^ir5%FqVOi(S#g(e|9h7lHQ^)OC+#O?@RJleXi_ zMG{!9)avBpwF~VKuiS4hkmMeWZEm2h6Bj6fmM1HbEp$f9Ic_q30*3qjH4nex_)p{^ zDD6!OnRlty1eHVO(#*lYQ`784zC)G>N**5{4JGYitK~avQhsrVO}Z;CaECUND`zaZ z+Ak#`O+08m^!IRrPKK#!^rERiL!n12^^g+12J)wq*Gv@vtV zqgs-`R^CTBlxHW{AZw=$gx8Ett6a6#uMnnT~d5Kvr2<_m&P*zP8X4&lU5NJLqEv$$PtqD{9H++kr6Zgm76o6 zGRBi90f%3AL35)-%@1Teu!o?7j888=S!-!o=~(TUnekzom}%>pa_ym~*GeM4`DN&o zDFV#{BCI(jaFVcm3Zjn;KRXK!Ir>gYT~%uOpvsF~$qA4d|1_}|typgWJv267^aAwI zSp7p|US7v)(8pXSLDQ^h0e~t&S|0r`E!Rjy7@ATf;5eBieRIio#U`mZjwR6bHPob9 z=3pfm(#QwgJW89Vr5e>mgbR%t@ebv-ac{+j=Fub=I{+R1ohG)x+RG`zA@w^B2NkkU z`g*m7ri)C z{uoO1FG4Lm7>A=dST0GMN_EpSKZ;nF-sbJUkW8X;F?+#g&*o4wy-g|q*7TsS437Yk zEy#Uqq%~@sUuY(JDS3OmQ0qo?I!5ZNoe9ozsc+h30lXDkQ9C^v!#!Six~7Q(HeT|_AM>c3u%iCdifey)5ndQmQhkyc^K z?r7r#S4N7cu(<~=5E1e<{6XY5=lf#-P-7@(i@;eBB)vADMK^E-EU*Y~MeO7+BmQ9s zX^}(G?(U_)9^H+z^G6h`Pkd1c-^EWMYGH*RI#ZkYT+PLcXS6IWM(ZK51FUo`y(N5< zcjcud7tcs*#NcD*474jL09|Ot>FiY##nwy+X~s zPkqc?{lTnU`=todd=74`WF*%WcJoKSWdl%LSW{Z*VyeH%SupdW3)o3tmgU-WiK;72d%e!55bPL-$2ksSDnk zOlrsamKoW8eD00cN^z-kQ_;oAVIezahBIry2ANfe zyVJF%p-+LXMX7KD&ZYZtQ*XI6)(@0@O(+$7fD~l1V4Gd1qIJ2NJ+t$r=ve~~C48)c zdL}ZCecp#;Xw~(t%7;fY9~JQxz8RVWdLtTQs7{6~1muU7-!1{+XW(b}Kh|UTAM3$g z1A0?%l(xZp4xgx9(1(qGyqP_#(_5oc6K!Osa8qbTjruy(XBWBAA&~VCu%5R46pA+7 z*ee+h`4SHWA2H3tt=c?0yYgr|ivwJK-D<_BKw*Ch%UcG;nGGh@rLv;E&lspbZ=;OH zjYFbV4KK;jwY5Z_?*30;3M&Rchl;a|dt3JVsN6`}lw7$>BV>i`?|#Z4ddc=(Pqw*R z<_hdcGq6D!XcqKUkm)*4Fy4?6!u~Tr5y9>ZP&vhfdREfm!=1HfpEzUJ1VbZ;kx_vIa@e;F1IlE?|!9-?X|o(HJUXAJZn6?wq!HspM`> z_YEC_&=>*%kB;!qO6^?0EOz@a7Iu^^!M%AlmV|A%I{9JBTB8G;XPtbXzZ%!baoEPh9 z1HdQd6j2c@NlkfsHZ8*O6PWL-o1mMh#}Lr@ipVj|RmDMz2+s7C{jX2CA*@L@?SF#l zVz;`{$mtpcdM%cj(SZDdE+rE%cLg^OzkYpIN^OO}Ip{+n!gWdm>R2Sp@Zc#$w@1*N1?l?Crb%it>LnD8(oi+9>TSmgd{Y`RM)42sE^Cv!}I_1!B_>bmR2 z+U6|_YX(lG3ucYjWo?hdQ~v=@jpAajXXwV~&wUsL@QoK}C~J#BMoG-@wL4xN63k(I zi+el+P<o4&offUDt%FxzBdUCaB~ZCZTEbjw3HjIX zSuv}6%KGz_qx&e<1&E#%EF2T+*0GN(+IZIh_@NS^4>1lXdV+2oj63(Z-FC8&wkiyl z5RYiAj-l1Oyr1NWwjW+9m1L;#$-6TPXp3;%t8x4LMU%Z@lH1xI>6XYda10n{f?9be zXuLakfGU<$2!_6Y9tM-r%@w-aPhCtq@u;PZ zlikzJeo^>Esrzx>jKp+beGJ@F6kqRVt5Ms|TJ%tnJ2v-J8Dd8X1*bQe-GVJ|zMxXk zoO-vDnO83FuX3J5JR>SRJ4+Q(J4}Bd5z6R^H8p<6Jyl-e+o~l)bd!FWIMg)*QKXk^ zd^f5dW|Mf-lc)GLZ{Q-AYlkCqHp+n|v58N9wiVrgo=rDj0LXjG82RZBlJIDmt?e!Q zCw3jqHUXEIzXC@m#)8wy_HY#0>~rtqyv$ch2Z1AH104{KBb$)c%_=463T3`v0FOxK z%7C%Jw{wPo8QP+zm_-MW>ng`Z32%{x3$MUBYp3;|1o;7LVl1mm;E=^9z9|tXNGR zfFbN++-NW8>mX$(1l#<-of=E$F!~JwWnW`TQ?E_Vw$7&t{{h!puQVYA%Mll)6C|Yi zZB2t@UfrUYh*OX70f&iW9L^DdB90Te;IcNE2|L&H_)18V%!|;sWm<+jZ8Z9o8i^oS z{lc&#(8;5oyi_b1#oMRi-ZC@|qjNjY5~&Jim92Tz%2Ze%Y#U45Ysz>Pc@Pn;fS=D* z>`zQS^8ROH*0URmH#hrsaGB|=&-zF#)seQmyLR;6&YX-G{LsKeH zWtpO2hWsUMM@!$x^+Kh}x&7_AqvzM6TF?MD)cY4}^J)V?tp>h#C>f>s@UURf^Kzt1 zjz@{-S?QeEd~x$96rv*eZ*4@$&X_LMA6(6$s!lqhoe2dz7-p@f_0?1Dk)fHX+}&B& zs17}nV}#PEW0@GR~@UoxY~B)PB?tJ1BAm&*fYJ> z#|dqpP#q3orsGd*jU;=lc}2u7?1=VoFdykT83UgW$t)n*7|FPMcA68;4vs(;rx+K$ zdY9_dbeC$)p8us<07?e`*6v_p$LH2+(e=~kL+A61Mct3{2R$Yo2bc*C=y*NfW&v-- z)Or?ulVeG=(jYLopzwiTUmqiu@X^2!y%__dKc)D2+uad?=#E8!!w!+v?WtD%aOaTd|gKfNa5AU5+zEqp0^lk_ujET;#1A;a+ufTtq(&P4%`MC5wS!bX(B;%h1z z`|6n0iVvS~{m0zILF@zO=9SXfM4?{qKKLVrPE6WJABsX^k)XbWgj{ZBeP}tuu23;F znwzVvJR13ZTV?Eun#1oX7VHWe$@(Y9-&X5__NjvfQj6CmMnr;c@QlwQFvx1xZp=P> zK+QTs53T65I5BqCl$;bOVA8*hS~CJvwODGw8oU)Io0+POwlQ;KRmwUJ173sz7Ir1H zw_4CzkS(fOQlC^-I{OO%YrQHVj~V?$EJj3~1S#ax0J*WrQdUpg*!B*kd)oMTh}LGy z7_Vjc7)VYOlVvZ%Uk-O-P{Ok6z#tStBVdqp8x{=Lms*|0UT73@XcVx#IxqqyOv+Vd z*>|cJna94%Rmr-Sa#OA!=!`g@7c|oU9#|LZMFP!|LqH zzxB!mbIGW{@%-1DJx!g8(O1L-eMoEb*!GlPsLtNmO)2E$``#Jq{Cwitz56AA&0?J@ zRhZg9!yi(c(@*h9RV1{CS=Ubb%*^}oi=KYm!A7fgE^7#nOVnPt5TPoY;ashqSL*6a z3$oCD_eKU4WfuJ%%P2Ww(BQpZ#5AEud+*+CP%4z%!{sfhte8@;nFdD_FE9X_*>;!I z;%>uuhLW~P$_A%`jRCQget74aD{%rJEgw0gJ|idbDE6pK)wKQSJb?LAe}l^Fkh#q_ zU*N8l?+ z;MBwQC?HIKXi56nAF{M&2^jY^%dh5;IL_8=>1=|}Ls0R?^TBE~%WB6bg9O-r^WqFI zEv+(vjt&*|}Vrjwt9`QUGrpKpydou*iKU7DKPqWC>Wk*JIZJIpRUejdk?$Qt?rQ(BI znXF2gMfuGKzG?xHlTlqn?PIz=F4bP^Iu*tBjKiG-NZK&|FVUhI(N`-6j`o2h^%D}) zbmDW~4Oeazb;#>UAlJ~@qjr(v-X7I8wO-RwZ*CI9xH~=)g^jDyl8t_Ft_CQ(UG+8Nh@7Y+o7~J`@YzDR@`!EaodE9SxHC`t$x4i0?Slv5!T=_|%~T0{`=`Kugn_}{=w?upxkMz@RI ztG@Hg)r~rmFQ}OjW#kV}U{*g_UB=6vQQ$X~Ng71R7DXH@`?_pEfuD6JnK_QrdMSkM zGSfNidD?~h-%F$5a`Q(J3Lv*gJ62V^gOe@QJxugX;q##e;AKUQezc z-V3A-4g{z#JuS{hH%B*zo2dMr4YaAAFZl$Q;){jnrB>sEY7Uv-7jQaejz@9=yM)os zGV9QD5_2+yq$S~=4RbRBx6h_$;W9SI;W!q_<30n~5qblsTJU@Hs}xL9gv$m%fIerE znr+iYL$A-bz~n(B4HnqHa-J%A6a0*RHT;$6Opv??* z2@-z`a-@ALaUU#+GGj}PFJkUHuqgEn+M#JEk@jKhh$-{;(i>M#Q2d<{!kcS0&AS!H zYUU_ii}(7*&}({yhL)&#bUzWMVgl2dx2s-3uPGNtf5lNVPw^e?Pq^cKnI;aF`)K^l zPYLgpIfe#g>QrHXjzzoM!Mm{!e%4mrB)&Se$El$q{yJ9wd1hI3#_Rw9NvqRx_@jas zTz*S|;U0u)9i|3K12leFN07wVsxS7vCfU5d{3sQz*5La$PsDw?dsittA#SqTkaV|4 zF`wrt)0V$3=satiLQN&~{X>eoAJ||19#QKIGrC0fFJwh2p6OaKy1CnSTq;tku59;X z?8n(-{xX%OCsGL8`ATUqs54*}UMbzuz?8n|I@9F(7xcf1|B9awn&`K!U*D_F%R&hw zelF(aH746|a(t~1bHb;ds2A~K6QTS}2`R*`fRh%QIuTYg2Hf&i<7Ufg`*8YT7+6{0 zeOs(w8vW(m-rEiyL)hlkj-iRuq#*XEg!u0x8W{G2lUb8u3IB6M`*!| z?+fYO6oHHnqy5>$ZM4gu{u=-E-fD77UyPPRGKwHo!U#@lIV_HQX7;Z=J-Roly&3v0 zp$Mf)EG|XG<=qbF)3$ z3rFXPFx^w5LM{|Z68&v)n32vAD$9H-2F^t`rfo-cp27DxZeV>xzR~K9xT)>iLn7V~ zdYKU0-vri5JY|klHBnhMWLL!9JTE2Z=plrAILcUhPIA(a-=@gz!a`T1!CvwlK~+c3 zjzf`;=lX5eRllg1=LtNCT#IY@EB&;`O5?=L4DEC}%I7w%Mna%&btsOy?y}_}*BtZB zGLy?2gZl+}t3T=N9w&b z7R?;2A2+D2a=#S}idayByFaA?Z)}oE%P8pFHyCGIFQhZro4tkOe)NH|QEmbO(pNLo zL!uJ2L)D(<@-AB0sp0Q`po+tnl$;sjyk4)%1IY#lEFWacOX)pR$C!*3m_sXX5NWEZ z9OOv+VELIADMoPsPkaahw}!vM_;E5JGF!xhybFAJ8l=sjml7A$BbhVuy?zOA*R zv2)y33)9!bA)iH`-C zmkVHC#VuYB?`^x;d}TRvALsxd(UhH(<%3q#M2%Ii+3(`xzTTsS4z-c5-6$+MVy5FWFZ}ry|MNljt*K_~h zW;5EH0?B)hwyYPCa}m4A5L$j30-(gu=Bm!YZ>sBRCWR$-xg>m~|2e93FdaR&vmQ#F zo-j)jsy=87#{pfKq<1Hptg9Qg$Vja>|`%(%1FG+k2f?E87&9$Z@@+0{~2px%Y zGiTI}(8kGT0|--n0}P(2Vr@sutf*kEbk7j{q4XD<@z<-%yH2hR zt<7;ParX_UT%;FaW5CYM(?T!R`n#0p$4<7HN%c(2-m`nW$pPTYCSv*CrgiX4y_};S zv}aI+5*EZ;k3uUC02jwX+E zOvk%W#dYzrnW`bu4gG#^Xg44k)C+Bp4FmT4jY?ZSe_=RV+KJzV7L`pFkF30q5j)SU}pVv>mJ_kLZ$Bm2B%CUVVK3UKO@u6_wJvwZe}rtT=LQp7Gtl*>IY43S#kaeiMGyLa zJDb4t(ZNtm49-utJ%c~ucS--KYB%-VQQY^QW9IkeFx$Mpa$)x1^ne%#DSrkRd5xb@ zmt?k0Q!So7Y}xelr12#D7Eaf;0I^vyW<$e2@6dOrfMax4g3iM z#d?z-le&hzm~oNiMLl?`@yw!c{WAlqKSew0xwWnTw4x9BnuZcFD(lSyLoG9IXPb(t z@O{(Wje~K-8Y%Z0UFZGk*VDvOAGw9lx*9;t>;{rx)wm99E(kdId9nkeiEvk7Q^Wg4 z97pb!45?O(`u7^|XqE^SgRBuVa^?{dwV%UZic*HkyDjifs^doH><4G#@N>CO|I1Be zYFFlbRG(LF$TN$JBF`^k(JcG^F2pR z@~kNZ{*DB1(>&*7j&jD~evI{alWqo6=}%7>m)3*ac(7{aClX>hcDomX@0+37C+gk% zqUU$S=skWnV6`$QS$!#A<4(aPn?9PoML~hih8zC!JxBHm4H;I31=tjLHBW!Cgi6>n zY|dmX>Di50zKucNBS8VQN^@-}D6zCQ4;3*xILH)oBX*}f;^_Cd1M)?B*#_=Q&4UZ) zX|#euQuF3+;D0jBD~plUJ6*$tQM#HhEo`AZ;Zov|dNq|-pU{cjD#XZSq)j`lr~hyk zZNQQwGHk1DC_C~q@sxc%DR*&!Q12-?O-9r3#=k7$lJ!^osQWrCk@i4+U`p_8BuIl( zzG*TUCF0YpU0g#Q?4t1PPnZp~TScF%3%`gZ5*QZ^8xZ~UZ8fxW#f)+^`Prc>Y}!-* zU&`UwaW;Md&QMoM{JT+HhjU&Z;5(~Pl<-;{{FRBUWx`X_W4N=afK=nVA_ZgYW%=M5 zYCUp5yiL#Fml{3T03NOeZ_eKPZd#k!!EYoF3oBFo<(`dAiLp>~)fvuC77DmtnUf#{ z^Ime2HR3REx2Q=0YvxX{r^K|nummvUh#T*%f5J;O!0H*7eUPP_K{SWaF-_==y$r1J zdL3kEEQ1}Fq93e-YJ^Ud_iGPPOVi=(cBr{Xo6N?LbquC4>r0m4fRBY@*W+Vh*0VcB zsJc4uqoI+R>xI#=Z$5k(boljgEF%HdxCToA@zvw0U;?sD_kkB1Q?yrv7gF?MG#H(k z$nYyKZ!2&|x3W9F`Au-79s=-ninV{W6A1{5hDE??G8x*f zVMIAvt#wQP9j{=Cyv2Kb!CusV=>~42>jtTU`ZZIdmO)qX@l{b3p~aI+>8I(p1b=8f z-Ut4PZFN&oQq`JIkb{$eWW(KU9p-+#i97F{@A27;Z2BBiM{v6Dulb=78F~F?Xi|nq*KrKL1e2c(rqRB_6>oyO$4HLH0+XmNb!UHwPiyF}`*}g!GDq(=ZQojt zH8`ME`fHt^p5Zz|0Dfg1`H}NkV?U57Q2!eTWj)S@;nEVQ7j_~Y+qg*rJCir23lYaM z{qJ!5FXr#!@ifaGS5=ebU#49qp`dv0VeK28{~})be-SSXBK`(#>3U(|)allZsKek0 znc4_H6-M1AYsJ*2j!PVp=l5j~(Aj8CrBeX++-FL<2LR!G7W5)VKQNF>3uyU8>|dd+ zL+V${Myf_&oyMB3k`}}g+=MsxYElW`%yF}hFmC0jcIT5`8r`t4t>)A&vAL>D?jGZF zw2-FB#s`cGi=_@Zq{YSmhpx8{t2*ksMHNs1iA_mJZbAfU0VSnDK%|kB4(UdvYttpM zNkO`mZlsZoba$t82nd|D;eEe*&bjyg;{y*qE9V?@%(2#7zZo6##Zc9^ncrO{4Cl~X z;}_}xD7&e*y3q6&JoB3@x8fc3MyVHL%Z0%Hpa5Mt&l2#K1J+h&kv6)0Yl}LFs_~)q zj@?FFuBz+l>RuMpuF2V*-Pcyc0~pe?Bb7Q3j5OU{>k^#atBtduCeh7pFP)hagNlho z)h7)hzrHd&oI|6I*Z)CnfZ{`Fq0!w_b}6`c04%wi%4 zH^e;NwA1~xw8(}yaqox!o8BWc!Bnh*0y}xHW|0l-q@}PD?jud2jBwcNV+{k?hez7#s0t_uGB6J|DW`z3xMg_+17kU`xOfVTWegLK$rgmReYv5~ zo=2CjK~A~DDFASfX~#lanTEZ}|E>Ku7Ov5+r*;n!;xzBEy+DffUcQ<>kO9_!RR_l7 z*N`_Os-oIa7X~X=-Te5Y_@&$5Z;O>g%c$eb6>sk;9~-xuC`*-l74HK{>ENB=$?7)(7mfoWLhY3+y#J*z10}-GAQ6>mQ6NS z1A50NPIov>vUl3>VTc>Am?%Pf*#xp{MRTH!hJogCMfL&}x(# zKcJwXlvRbprs#~z+FiBhrS1baGn7!oo+X4MFSKxB0PQU|FPpVGZ5Ki}@k9ot+(444&I%ADPQkUwZYH=Sf;b-8pQz`^Kk4L| z)AHT*7lbPEoxuEtN*>c5Q8w96>m=8^kKsOk-B6Jo!FGQ#&0MDb&3gay9LoJ=#$#AQ z^BRsta(5pE#bWPUIp@b&S=X))gj9_BF#0gpNa~rvz<>mO+Ee*d6vRt`Uwf=kLj_=< zF8S6$ZxaAZ9EJn1Sk|#Jy$`^`?X-K(`*f#-%5}!z@8-v|{EiBSK@EtCONxlXKR{0P z0wh4ED|#=q{yw$|)a0t3kp5ZmJ!5R$yM%&bv%1-uBLp04bb=3HW7$YfPGkGpZ1%2i zT5QamPwX-2@gG(HDMS;B#Puo}P6EB6=~>x;Ud_{UW?(G7)>%PIeXEw9L#Q54{`8~0 ziq~%eAR(gO>NlXz5L#@-8~t>r=cn(a62)rKIy)}wq;j(jjh4NoPjip0K7>Q2IjNSt zHs9dmsp;uy*y!H;=C6^XS4f&cEO|pSbV$TSRboH8>|dQttzf2q=zVlIgM#RqT9pwfNKco&b0cy3L|dB@M39o z1)jpXY%y&;pdS!=Dr2wR_mLARIKsc&Ks? z*c_^i9n0BP^jecCP&Eu<-wm14RF;pMYVY%SaJM0|U;Rs|40>})K;*EfTw!k!oDa|@JL+6Nhe zttuHNM=qeQl>;C$7_L0Xj)ImVW($``Gm6pY(7fUof`R#YtG5yj=oh1(4(S^@MX(3N zo^P|4_?o~xv34g6^k^`(@is~pffFyJB-cWXW(v>?2PP|tM&0U*KBW4et=7k66~jO( zvEv<4`3>K327XA0V^^GjLg zG&Ztd3ST8E%NvX-9C3JAm?;=W&M@y&i{xkFo`Jkiydv+h=qOPIbB~q!x4#6YwEmmh zy81$|DwKG|L1JW4F#{2A@mD1`^}VK=t1RZW`!}mXX8g!{l{E3r80R!ZTyBvmocuUJ zHMwmX65SJKE@4Xlkp|u-fCJD2serzGE;4IeO#}G*to#h*M?Ora-1@q|f@m5Nt}t7q zx<-q3Lwo~niSJ`ToJxcF1>MU2;TaUUEsa@J#y2gJ)udz0v$pyZ(+_W^`eZoS5*(Tvvb3(f zYNOM)+H{DFUD<3%>ri7aA^n+k0Y#c~FoP%Dne7^G1vba#2q6 zE&OEe9sh6>KpQcM0$l}OD97%sa zfHGh>DzAawbi6hTNXp2*Zf&YTz0dBfzfQpg2+}{|ECj)5#n+$p$BZuI_Uy=~wH6%8 zAj6+Srs`hER9$_k79&W9cc8+;kV?4X_ZFgw(s%Wq421Rr^7SenksV_VTCj6F@XaByX9zF;6ytP_=j^uK4o3GzQoW3Vu^5Z-e!dJW8h(YhnI*p4dn+Wh0vv9o+qG;wVaT z;YM?`f0m*W=2-UG%Q1@;03+RoMIANF&-U>A|0t#GEb)A|X{9jB!gj2dD4%Ly=#U_$ zunEpp-v{u5%!96<6l2>F#L7S`X7j(WC-$Sl2CB7ilCT~FaRS# zd4o-mUwq)6TdTbE_swY0B--I!lsGa5;9O{hRtePj_-RJQxfVm3ho+i|7*22gGBnp? zt)YRUl6tb=82&Gxd>&yarr5>y9dG>yF&oGRn#1y~=8z21L6Cp_#!ywg>sctNUrVN? zty%-a05GM#nT&*~l1c}VBmA`(@MD4(a=SFfGH>t^y4|P%fH^orW%-U0VU5v2 zk(1=@4D-H)qPrf=Oz^Lu<|FwMnBhR&LMkxBejX=<++R@Fk(13WCbNQzERI2iL^(t6^zfCaBxR%t{;*Og^`_h^W z>D(prvNuye&`M&eUjO4OoH9WreY0rzDlT-OSZlpV)fpRbA25M1#VsUmWo{#Sob4sjFJ#iK>B`&EKl#Kb+8 zTIL6#5($>3bWFV9&ZZUVBhXD-<)AE-&{?K!-#PL3Up?E20Nu+wTalpTb32kV>Beyv z{B9iANi?@s;wpAiIBK8I@^L10tPro)XD_R)H%P0Svf!tI`IUVK$C^j~dfWS|>XPcV zW-dn-R(BS6s@)r0tFAv+H@Gx^s-Dn$=IO0r{`#yB%e}kSpA7;^G;{-mkqSq1K-s0E zQyF-nk0 zvlIF{Z(?lt+AE<~%}Py3SM#d4#20TN?CyR6dvT$bD5t9ig)99f!f(VVWowm2YThNo z(&=w$?}17NM&rT_;Rcke^b_;|ifK^IyFFjrEFE=4_B$_u@MqKM_2H_=)jE@Z zVDI`wNqOD9v(e5_GDwZJb(GcY^!H#l{*>!0k&X z@|T+&RQlW|X^?1}OuL@4Z;FUJq$wTRc+_5D0U17cjZFZ8%<>4290bGEaNe#+HxfsiXmtx6)1qP7Brx6Nt}Opkz){D&C9L4Uc2d96gyui z>3wGioVMoGP6FyP&CIO~fTc!#N=}4M{FtfLVz;H_gmrrUkMLz>lTKV-A$QEbfH>yW zb=ZzmAj6#|tTdo5U^dzE82k*JmHAoc@sromKFW&q;}DwEP9_ZGgMr9=&{N_zA1vv2 z;yx&Xh^nKcHHl?R`q;!F(?LC8D8ycgA4bXetB>R?Q0<#`37 zV-5Vxl{!-gWc(UhXC@kvxOa+%Rgs-(TB(E1P+3&wHkSX`yXRD7N6uwpRvB*f(eCd6sPtF*gUfdQ>ljDt5e8`@E#WXWU;)8VWHtO+_ML=9+}~!a~4Nq zyLzW79OYJ7lg?VY*pm`!s;|0vb3hA|X_)kQ2&MT`Wt%h+cwyu5kT)9F<Jb7e%L;}AbJ- zW~%e5i_PwH?FqLil9UIfhk%$H0X^EeQrsvRg3F;=ZCdu&{3ZWv!MKI1cAzUgVe2nf z1Hmk>_L-{TAwRtMg?zxzAg0;Hn965ycXzHBf=9%)D`r?|+PJcck=U{bumuLvoTm|1 z>%X=u7=AA`jAvBf$InwFt=iJ2lKMXeuRO%jN(tU~ysNJ? zB|+>TC0PLsZFNWLc0hvLx85vgkKHBfFVfN&W4vDedt|E<@8a2ul-tX1vyLGkw_ghk zBwyK|^cf#_Ybtk84Um5L!n3|H(~l+{zwjMMemyUs(L#A#>#BscPZG6&AhqK~pDbdN z&`&Z5t_!;E$9;@uALOh@3aW$Ix|qu9SS5VfQ^h!g_4x&ptWI&b)J4Ox$oQmb#da@> z{f)*yr*~@gqjU#rHicW7zQkf6p<3o72V&f&J!>+{=jW#Eyb@#I!|WkLo9k4lQV#bI zr5*Q_g38uG$)TK2e~+zlX73dH5fE>c)$f=1e+eDQz5ib7oiz7)@4?;m*xILnp7a;| z$)?8dSl^nSr|>zbtzd}GNpiYodZ~H(oA>UX@!zMg1eLwmzfZANb0V$TCY>q;XZi25 zQF0~7ie_Alb%CCweWrW%lr!aL*iXT+g|aFpo90jdNN%Qkmr^!cvtlpj#I@pW*s12V@@#-7bXQF_ zVn7!TbJ*AfmadlcUEEg=1h0QI)!5umkvZHxD^bu~;z=ORaPqAVt&LrcUW40zQV;OR z0Jj&NNPhzY;ABqx+qrU%_j>&09S@zqFTCBJ6jnT5qEvU(o^%U4A2SR^u0peD$RfFA@Rq?%mWOW@%fmx^iz@cmk;6-JUZU+s z*Y|bfCRuI;#wxJ-hl8iJGjr}j)6+Hny_e}P8(vzaQVO}--*q8;tDa~{0KPo)=f(58 zUrjW)!FGHND2sX}(fe5Ht5D*=JO_RL=QIljL)q1BI%&YB81}qLbQGllgNuxF9WR@E;p*0uW-l?64$%xu?VCl%dxp^EEd_FO8DMN zk_}w;8R_N)0oAm-ev$zPy5Q6Djvbu2B_q$=5@d>xeYC){D9JsgHlX?B0{sp4aY0h+ zwMx4JYVg3v2LVLRKJ zvlB{EU_QYvAVZqP!)PU*Zv1pUbRbXqL7r+?&OzfjW)a(F(&{j6DtQ(qsL=e0A9aK? zn!#&a`g@?)zT{uhP;bVmUbAdXU))C&9OPa0K^FHe}ye3GUnpPC_2)eNon ztvVpBR4H8pEiu}<;_|V0OWu`n#>a`&e_UP_v8%mHm(xYf%pDgDUKLmb5AXRdKB?xqhN*yx~* z3GLcMtOz)d5nQng6`4-A?>*zhohMnSscx{x08Dj;>f-7#efW#|!3)!_zFQ>Mo`Vt}V_vEJ$2@EBAu*i{Og|^>y68TBJ1Q(4^xQ zhN%s7=X7UgsBn94E6mn#0ySTB_Xv4UMPD`6P3YEv$SRbmshmf94vKeKkm4spZ0)SRPdago`bh>YOeQe>vlN~O6xoZ z50(er%s1{Vp@&EiE*aQELTRzcyaU@5iGTBY=(}!3pV)sHYHj_~d$nbUF+4D2ylxxlv}S2!;h~y?`uDMU=Xe7i4t?60W_$Gl;S4OfC0&qI2?y@_g?)h&iwuOA zh3xy-TBm#{?M`EP)k%+ir3alb9t_@X!P^ODYyks8mvZHb#)zl0vPs>s7S{g5nxrSB zN99bFc)LH%=TD+uH1Q^yz^z%;Bzwl)vGL7M`Cauw8mLaDvsE=T3y{dy|g+U zS~%#t?6twI(z9E~Gj~oaKIv7kp8vi##PRvQ!0Jh93g_nfuRBEFo|#kt{MZBa6?vcr zh^_TY6puq|a}wV(OVt5>bvcKL_7P89{LSy$pD5w)%)3p_Fi_Nefmi?Hdd2;)ZfaQH zb2((hWO(Vm22*9Ji2%>t*Cq+f0DET>T<>yxGDPSuG*=8z>eVO7Y@)(B{&aS&cI_v)AgRmhli_| z3Qu<5cnEy*Sjg(^vp&60=)EYoXrN6?dbD(ptW$X7??jc`VCl}$a&Jbwa}j){r%SeK zpUBn!EFI%3TdOBXK&^vYC!j{36HZ0V8#$)Q(yjD#DVre?^jKos{64v`lq#mZoj4~ zFGI>B%H~I%vdo`Pq}kV7{{q)_}D8Yt}(|CY4Y;TY;Dbt3xpl}NcGA)$zQRN0Z_ z^g#YGDcb__I$h0}e2w}$hh2t3BReAHt50?%)8(L#d0m~M`>_%8vwasm5fK413W01p z3huQ{4Nd2ln+JcZ%yh}Eg%!oM&3)WkQ!V%T0|FRcwK*z3Ac}e2X3G-|%kBR5Bx7pQ z{+m|%U5MS<{rlpDPjK2kM@V(>zfee?(5L?O6tWd^NY558P=ecLA0efUg939Bq*Q5i zrM|MSYO+e5-FX1XHnht!=h3IKA^zT_<<;(pi%t|1+zw^#A_>=5lrHkS+nG|*nLxs7 zAZW+BswKjy+v2u}hU=gxU!$R(J*W5A)Z!W8wUS|0atJlWyg>~S9qWUi?X_wUrnI&B z!!mX3m_I`s;eQQuRot8}nhjEXN3y>NLsT?hhwur1CV2n8_7H4^@%tBAeycWe9Q;oS z4GjICC+iz8-`v}K@I94mw&^=~B&zGDQW%e<*%m`)EL|FSBW@Dh`fk_H=8I)=sn+^Ci@}e z3VJxnQ>h3oUv#x^?5yrsdvfU!@mzm6-8h^x6*hV-)ta7urm9`5za42(yEnhZ#hK=s5!)#$T`V}q?M~D;^sv-%vZ7ukQ#DBvC z!jx^PZ?ulk3M*pC$3Ix(H>%1xP_B`;Ld!<^^>QQ+p!xj z8%kHi{hF!PBtp$EZQzkBvKT$>?p^nMZ?sn zIBMS!Q3=T{{5ehO4p}xpJ|pv7pEdhJG&kW3Jv8ZDRAWV!X!1>EEpz8r%USZq;Z|yC z-cIU*`G-Nj@H(iYprpRyjfDiQdhICZqlvPO+U`9S^SLa)d3y(>unywY7G-=2WvLDwn6k~VyRv^n)Xp~j zm;8#TnYAfAh>~d(U!wn2bq;`>;h%J3U}>AbmKO<3B{*kjZpP|E$0IO!|6SNmf6NUF zYg-e1Y7}x8t8Hh!nG|*=W_$n9U$MbXaBJYH;ruXri-i_SsG0FSi7-kEN+%MqocGn( zL&aC9Ni-(dMVDn?(h7Jwob-jLov4bjdi-In7P?%~fa?4D+Ge>O|5;aX$sL{Ky$dnX zkcTBe&_itQkSZhO=`Cn0RA)Ftv<7ZQt3M=4ng_ zIQD-3D)UdpjOv2m;;rfjr2E01E-eh}w`{(?zNoR#a7!;dcGLK&4?3IIHx9&zvI(z$ zau~Giky8?1F{9(*nBGd?q_88j%l64r#=&`yGDf{`hn4I>d*GHaWAXC=%I+sGJa$WL zP~IZ;5+EFH!5qSW9kBwm9SsL-)yLx%{2%xyD4;!{og}zth@5m+AHfqxC`ryE0yS{O zPwnxe)9=ey-=-Mr?e(kD0z7ruN*cFq5-)r&df6`OE((O5PXnjwx}D+&cp^ zR()C4WYo|Uxv_Yb6i?j5Dq}jDsDCAj_lyG|GUhfAI(v-*WyBuAG}?JN%F;o)LeQFCPq`NHmy z3Hef84-Nn7_bvy zAE`}PeVy6qY$H7%lp$_V?^D30CVSNXLHT@aHK+>mhiV*aZLkToC*?l;g8S=z>#84auW>c606DevTe@F3bhOsgIN4 z0?!5&^ckX-z7NE`}-1X*1*W*+C=D5wGZUyWF8Ew_*7P*!f zyiU0mTje%6sLL}h^+cuF=R>ib`~W9-yEH?uA9sylHTn&DDA+2JDKnHR?I1Vjr%z z+;EpKlz{gEO@%jX4V^XycKN2O&;=Vi?W3RT3cpzRRPHaTUilwUoXC|IjDSQj;lt+! zXvJ5;CBR$M7PXhUS7za$RYLLqwmNWOlAH4K;{w(%IdB(*qpX=oyd5~hsKdSeJZ6}B zvQ%c6G*LHVcO4UI-`7Ln7Lckl^AG3^o7rxlFy6tXddAai zmU5@R=?YXECk19lX15FHUNAHdVSR!e>!J!^OAQK0*c2|<8~XRl*%u1nNr7KT-V8kc zfK~Z{ZSR5N_c@H5<9{NbH*ptLd&zYZv?+4ttvJ@R;IUIPrco0YX!XWrPR18asW0m3=7cXy#jcAknvf=@ zOK`5jvmpG)`ugIkk_sGPUS3i%TY{UiK|KA@E^21e$va7_)bx~;_nsb0#*4fbkESL{ zFqejpvItR-M-(XBQSyH2O*rijKDDOOwf|(FTqF{>`GZXJ7y+!oJX2{EZdY5Y@6|)j5WH^<`;O!-rW)>s?P_Z9R%On?JfA z?A=5$pN2|g?SXL3)ha07MmIYtZ}iPO_(gCgkHxq05=pG4pAQjFmd8Wx5N+jszi>=6VnxAJIZp>A0G{wZnehLh;c!0TJhoM~2`bJ@Q#O2}YZNcnS=&jn^*? zW*|r$`EH&);|8i;hPDms(=`TCWbOpIbTlSuQ)b`qDqLfSDoH>O`T0U~r@wb0nIZT7 zI_D7YT_ckhp}8)^uT0WgrHx*MikG*Vr9S}%5Qukc0Qz*YXE`t4pDSF8Sw?>(fDH0ahRjP40B3&EQu(5?EO1<(%R z8PX2>s~nT?vVtTi-vgotDLnX{>|RCYz|Q^NL=e1U!xRl1+5kATG18$mrLEmeS?7NX zv>G5=<$A~>iSnH!ir=A)x4e|AlU#B~3ft%Z9_z@#!kUYY`f3v~{Fq!)JYU+#Ln;t2 zmj4kFJD(B{q<{zja2XHSz86B2IO>(QI2|XRO+N}J2Qgka0)_ZLGnb&tW`!z_9dICa zi&;6(PQ@6cv4KZOh-U_iuevzmDb^T9)eL?~w8xu)19cXGMU32=u4j&T7;O^bP=fFG zS*QuP@qUJQR}DM(MV;Aj;DPPN=geV%Dvs=Pkc6yU_svW=RfQRDoR{oPCl58eDO@DJ zlX3BDCE^POv)z=;@kY&nl4Zx}muGHt6Wn=vp09$Hr1c5dq6%#NaU0dfz+N%Q8l5oWc~5gwUi_Kp{Tt(Ql36P#-|ziVqgw%Y19h!3 z{<%-3ZE(MoIklNo4r7J|4!u4*zJ|{bCf8nH4%RKSRnAS2%ZD943RaN)+`0*WL=fLL2Nyo;e z<)%(wj*9%$;m?one!ga?d4H6DelkcS`7eKo;Byp8KkT~TKdaJ~d z{84<0QWHiy5VJ9K=y>wprFigdO7U|PY_oi8Hggp#aLHL=?A1uPrlOp=gbZO=HC9TATwt)a^npYCGT0(#5Zw2`zffy zS605Lq%#Eot%fGA`<}Z{mam_;`eDhJ)A{ZL+n-a)nUu#~fUT^3R}qI*&QZ zEb-di8L7hcygM%6iECPf!FQg4?TLm9YKk*fv2Z=uR5Di0b(XE~uWIw1%7jl$LQ$d; z;4IHF#wVfq<}x&8z7l>0pG33yLl{}L#O-h;j1!h9_HBaYTpr;`8wVjMS)gC09>Gza z@;He<^yp(YkTX=vlfjEvppc-biHtXjmMnN9<(ZKaB2dxqf;2-Z;)L;FrtXTQ9prt8 zIYRgj9T*QjT<|q=JecU z^I6C)#Y@?-7%d*fKewpdgY|cser2#V+sRRw{kzlZC~37_JMFKYPU`S7+5`XM9SgL9 zL{Y9=i&)D<0aE*YSM zZUm(S&6lY-q=gN3IBB9Xv6>?+)9oQBA4!STrMV^d?2P>$|Z%aGrocdcgk^PI3>i_rmtk3K@q<**t5fIQfmj@5;x`MV^` z3vVjaM}Z_+=yun`@98E4C1pdw5qHXNm91K%^5~rB%NkwORGi@j z=Oo@N!p6)~r`7o9sg)4eE4kK|Eyl+N&sGS(`$Y^Z$UwhskJr34d}fTvaXJ32ATbWZ z&PbpZo7Qly?J08G413<-Ik0(&2N_~3@2GvARyYKvZaDK&0+_ntC&%Eo)>FLSfIS>A z@w-h**~xqZ75eDz&H;+%QaP}Zml7TKTtDQ&ET0}Nt#zzRA`qVm^3XqzNg|%fN)$$L za!zw|ed1SnBU{8Vl%fJmfwN31514{6(iA@1lfR5%Lz;sMak zH(|fEg`075_Poa1N)N?yxWIgVkHCktvKKY=rUZ_M$v9_7 zku&G~^c>7w%Lr#U>({53TOlQ@!P^zNg#4C*XYmp5M4in%=UCgZM8;`2h|@+H({Wwo`LeOI8us=w zxz&y^Iol*U&H+>P2yo*ps(Wf&e0q`rL_>=Y0wDTwf#{1s1N+22oViSI;9Ch3Eev4p-f#*l=xhta;wTT^3?~##&h{n* z%HM`SE9j2OCF7$PGsV}8#X4^;Cdf*VQSdjzZ4{LMZxqxeDG{vI&;bs6(hhdodpiuzS#C6X0ums;-KSg9NheG99%hb z`7_b3EnG)3&CrV&orJ*J5OftZZE}P6p>UZB!r=w!`5R-hxizLwV$*rEii{oBrzQdV zHlwwvnugi@Ht3l@j7%bCA-}A8kYN8#K4PorSi{idp&_u)`zFqXOl=s(=x=&4@E9Wo zqGT$LP%SKGMM!UBBWGLBFNlkUE#c)au zLa-JYZ3{5Hr9d1@p{fm#zyvj`m)`K=1Om%s_|}}&{qwrs zN1~APZLF?sMznqKW7Q*{uDHf|G){hWksJO%;N$uZebHL>r{x%b3hm*6@$48Qh&y0a zL~mEcpZY({=77)bQjtQN%D58ZbIayvV9G20^Z0zK+%R3yCt8~he>rOLxVYxp&;fp7 za7j#{<69qxS$?8G;&*DANWwpW&Q?~+^ijgFGHoq!STXu#0rp33Tx=5gvFlXKYn z&E@!Nt?#<}#Z}Yn+KTMECz(d1hjk28AqE5L&>h%LhZYo?(Y^)Tb zL;?@+^K;YW4h?13^qOMc-y7%*nK0R;5SHIHrBlCWj4h!r5Io^bo}b!BqjoO~1>D3$ z0I=O`rz6SmWN@@g0_3fsRY|$n^d6#CxRRQW1I-5d)i5Bh*h>O;+bb=zx zyn}+lb1qSXKcNuYr02m}Nz&B#;WiQv2|(GGw2CYPL2xUD939~lLEsErI>Qo*Q6*tU z_z7i1J|#7>uv(4W5TTtGS$O0B;)Mk z=$63e78!7{p0b+%vrMN?#~o}|a9CckPZ1K%|6Tt1Jn{G1FhRrgN^ZC@y{x1tg9mvx z-3tN9>sHnPa}GYSjkvbggw@1cVsmYB7NbqQSS(30EqRg|=dO$iTRJD-6SW0Txwi$R zi#Uc;;K-O!F2#khQc2+q(Ae2h<&Z6{5L;b)uymqD4vFwd6uopJa2e8JS8}uVM(i~;Ja6qUHviZ4WzVy-!_)4}=*pzuHo78f}+#)B#f00w+e%_o3mBrNd zPpd(Mr4@s>Gy?I+B$~RHF8fSU-KdAm$eBIn#y3nEf_}j1rY-0u5?&oERdpH7?)QiZ zcikX|DZ>qN49NW#Il|~kgAjm?fVS{&{KJd^BcEr$Iib6nite2q6dSJ6PV@1LOobes zKLW=DKll#@dgf}Qo1F4y%tj|>$T4>z(O%tsQ{feZu304{ z>c&$#C&hi(qvjc7_Cn0yATV{dMbXR)A-X;j5MY3i-1RI;x+RZC$#UHx0+E_uxrIzr zxuU>AfJUMJZIst1`rGY@8U8b3C`OC8&nNMFs&=qx+SgT?+w!)wCMJzR!N@pb5~oTx z5XigeYV!Mnxja2;cOhDVmPo%ZW=C49ZSI}68)x2 zyoM#}CCD91LdKd9SQYW`c^(;~jJ{$@I5j?$i{=@vAHvTz&D~=_vr8Br>5lJV=-@Y0}}<6$?{N-t9_E9Wn`FR+v&0MSpHET z4Uk1*PA6bdozAM(CgkfW4tF}&$SP96&Vz)1d6@d);SN(_=Nrjn_?0q!(6kU6<)|m3 zRhbjVvlw0IeapfuDuXNZz(K%8;XJ7h3p@{cdlTj2S4?W7kMHX%rdP4ye{cb4$^vluPcL6Vp+pe+!NkzY96nOu|1qa1Z zT4jqa%XD-=e7z9i!EXmMG!zYV3SrhV&@x||TNyx%@#$kQF1`mY0#2U59k`G~0?vvY z(hUN{dv9W=zvc34wi@iRv_c2G1o0@~t$`K#0E-L&EWca8LZ>$tW84r~n-5oq%>oes zi{@tc$VC4~1Q>lRnr?#bJ(U?XF$qD5B7w7DrMFE&GPI(*w%?d;j5Wc^&x!wcXHu?Y_sguH5wFUO#Mo(tAyZLKkctA5L__x} zceiEbn)?4^Vl^bgv|RnboFKOx9-C$&!zi+xl~lZnE^0yqa!cW;>3V!3w|}leu6^S? zGxO+pu)uj4T=c?XHMb_%nyLg}mv zHS%0xy@3b}(Hn>$^!p!(=swqx{9f6EenY75BMEip5!G`3b7{rgyy&IOn)G z0p^J6-KeJ#ZgGI^=gFvN#7|wq5WYxyw;_C!`V4#iH}$c3wxz%yTs{AY%#D-dTwKSw%_y!=Z$!0YstMnMg}>|JUAtCa@@^!x>$^9S+LiBrBsI#{qc(`p ziZFn;0C`3|0rHqUyp+;>EvW7&o8}J)f5~{w-B!k z#m}Io2Wh&%RLHBy$lsP}&8M=p3Rik>KG_jsj4o5-@P|swx}G<%Nm_K{lGJ!g<4|Kb zyi>$CF%ObSIMsCOpP1Qps~vYWJ!Ny5nqFGD>=C%IYSMPUu2pGHPS*P@(3toypK`S= zVtA;RatD^NZcAa?^Q&21*+H^6mpC4W9g_;9UGd-3F(1N!#x$1fO~stK><~wxG{xsL zYcHD36GDe0qxM_H_Jp=k6CT-i4c2Dg9eR&x(=M(|K24d!?!uLNpD2}&n|C<3dCh~c zX4QOpEkRkf_z*lvf#xuAP+mcR=4$aips`jVO94EH#r z%He&FETmS^9!#ImhWLndhV(Akr+XCZWfvUbj#T~7`n9uK!cBco&@e_w_ziK{@P*sQ z)4$K@A7o!VQ~e^zNlwr45cR3M)zW65J7mZQJvmyQz&!@vL&zk#k{HJRCdFKoNnPV- zo^k=LQP8|y%nuUhHp4oldiQx1+2W;PI13o(VtEA{nk}YNME>y=LN9Y$i0F7rxjwhc=wYy5@2k>}LhfgZ^-f~;$^ z6X$NV=Z2c7ilR>p6e}fv`@TqZ~VZXxgV_{6>Q&^u%Qp5kX%mI?Nt?Jz~&d(^GTV zaDJPp?|AS*D43@E25_i7Yxt*qe?5MWGWikJZQ1Jk6?mel^+d`FR&WNe~7+vA@i^-O<|3%bS zhDF(R;nLmGIdq61Dc#*ApmcW+-5t^(-Q5z>DUEb@=g>$=pU3w**E#>^diJc?EAD&k zy|vA#hVql8HN=(c85Jk*Ca^KiC6q0!6Mhdc-GHrwLh7P%xZ0fsGdCS92Pqf-;k zd8}C}-8;3VPaHOsyFbZ@A3En2$W2ZuOX>CtU7HR6e3YZOQ#}RAt+s+cuWIOo67QCp zlvsGbA7DGXO*9thEdxzXQ$x*$;rUJXMYn_y%i&(+& zhICL5Z*2pM3^kwSt~K&umEt&Zr0G4ykHv~$Wddtculzy1RmrC__3V8T`xE^njJaF4 z69p$MSv6HA7RZ#{Im7nkA}2Tex~-6J>*U|IDxC&;W?K9aQySBLlN5<#Oi``hLQ%eo zOC1$f8NRSVHD`*nq-&8i6CpI; zS5_2Y80?CiJm`;yjP~{R_t{Wu^^1Q%eE#@-FZp&jw9Is?q>*UL#-sz$O6|zJ(P@(- zc+!Gdj_W&T-B%>IXMz|fyb528o?Wp>_?mHi#-vp)q{GRlxXfiwS9tkWwS6P<(iXt> z4jR=`$$=G;WzQnDJz=u*llR8DHN%s>VzJ8FfC|eV_uGyojrjH`&nouTyF9uqdVDs! zRp9Q@N@Rn-|fQf9mQU9Vdo}n8PZ1a=c;`fppK>f z$OxAGm;*iA)*bwWJOGpkB$1gIK5r%dn9Ed*&1 zHW-Z{mSRmwHj=B;zsy06$;@~Id+!n37)Ms_jPWqe`@dSeCjX{=U*&qzf`mOP(YE1- z=X|mIr;&BRdc<{sPrVFqyoEa|)ouP4A8+Axg>I$Aa`(Nnx0+*ll(bCgTa(wJyVdMU z2LaD&gFE7~MLR~KurXyqPZldDSwu^hMic}tzueX8n;9Wdyb1v{Y1#gFvC51mI-wE$+QK8h6vTRU4<4JK*4_A;+^f-QUn zXV`3r4MdR6YmU*y%P%PO;N!+u4xb^1Jt~X!hXMJdmV1i6+W;xb=apK*K|u`=~vfVDGWOi!kjU|KU1s*UO4?LT9a zOXnk1mkia6987^=T2F_~C!mMJUSVe2H)p)L#Mg!KObC|xZ1XVNmz;<`{^EJ~`lF?& zZ_H=YJgsptSi}-GO*K)4RGPYOQa055sOI#w>@H(0~o-Bi- zokRcer<(bZiyET?l|AUzQ$qwW3CGyjFORgQY>$a%5SoTHNN1Fnios2sJ2EO~wvUM=_G?6!w#kUi! zGOZ|WX%=A#9a7cueedI1C9U8BrIM`%K$)0l>RqY^e*6bY87$~u(b*+p?sX&$L3Swh zD9D6HK^VTO{A^@p!ni8CiBHI_j3q5a*Avf{V;wdZivd#z9n_MUr!hKBS^{sY)4V~rB!*pl^&Ci1=V)TWPl0nlHvP2!kT2zYeR`g zuz##EG=wHde_8tHJusFhszK1LnfcYm9dP!I!8Fl*5l;?*+~Jxi!)D>!E*Jsa?OVn) z1mxMiyePNWB&ZFH*60fek89szD6&GS3hqN}Ss~gS!Y~{QD?0R`pU?{oFA@^d5wh67 z11$V+vfZHflTB6O7MU|+w-uplZp(55*2Y^jrY&QZIbK zhG%2EP-kPmo{*WivQUr1T#}+)5~_HI-O6HXgNfo2)7B`}bZ2-Gb0QO5&b}jKtpvCv z^ZlYFp^dzGH`vh2*0;?wDR2mtA(9QTUGj{3$1vsa3K z#6gxf#bVmSF8vXbJQOd9Jyn>2B3j)Y^aMS1qUvdRCk~aTrAjW=+`eU2G`K&V8GS{{ zgb7&ori}p;)Pi@Tq-FIek?-LAP%qOUx3XMRH#zYD$>kQFpdqZy4*$d<%<0dQK1$`aW|cnpx!0i!06G7n~`WZ z$8^+6pc8A(+$+ZQ163BhQslkEIvn(_L&KsF0q zGo;}W`7Oiz_K!CD1Hv(#PRD>KgNF>hBMS>;&qlon4vuKV0;7@SNcA-YtzV`;EXb46 zOmaA&Vn=s2Icwhyn?c2q{)QKqp*Kndn{Qo$0zT06`2M#}-ekTAwDWTQk8dJIM79!} z;7+B*lMb;Xy#?Fr>;MDwBZOmIos7DG0ab+wOCZ}Htt1mci%LzUi=T-|FX67GjzmbR zVmYP6T!AOBqu?-ooTcQsZfQqaS-9a*&ii@8xh1vh7{yB4j|)LcK8!ETTUp|nFnjg8 zx&)cM>`TL~KY(09t~r`I(CO~;xU8N#f9;d<`Jr}bUBtK0@aw6xs#p%P3ZV7Hk{(1P z_MHh*Ypz0C8dUNS=j1Yba;$+QF|mv-Q3;lXL`BHJ3X31GssvxSpQQHHd$CfIOz0(%ofm6@kkl6mL1&k;JicJ=2^G|@2X%t?RwoK>m;#J=N0l`Fo)tzYz zzl8<{*#v6$iG=S+YGbpCHS3%=#7HvNXDq+&n(@7{ygb5OsOy)>CJgW5&(>=ul4^0atQea?n2?*12bx|9EI3O5J2f zG5y)#emGr zM!Yr5drxK;U-8sWVl%_>dvNKN#F1&HrUag_aJzx|;-b_QNW=-Nz7GOA6%DH$7A1u5 z2b}`#pmW0@oD5PTzk5`EPC(@&v2%q}$#^t*WD7EPHe5jNu)n`Pz0A8Vu+57w=uj*R z4XG|fAndBFTe)lKAIUR9)NlUC6BGVQ%KL>Blo5no)bN!ia`+L?nlF3U_>vHZo?6=U zGs>TJ%6ZPMphS=9UA6*jIC0LPzvh-z!=wqjYVgPIuB2bi&Nv#Py>}t^bdBT0C9~5= za2TkZE9O0xoEFxBQig3+Dc|dU*_&CwhXL0HM?fk@yoHwnB(YG>Uo(330q*AKwd60JKPp)Wns+zbQ>jxQV@ z#*V`fE`y^{1azryU(<2@8DF0m`QY85-q(x!+>ZOvecwUp3oowDRR--EL4%5+48eI~ z0gSm;IasmBVq+)SArlfZI5;ly_k1c6RC3rOLs7`ey}HPEk#$tGesj@yktI%8>hwDK zLna8cDs~_SGB1$o0Bq#i`K>a0Bjc%1jHXNLXsV=C(-b_zEtroX@W}{TZWWC%`9R@= zh?NqLzI{sNzRz)ITz%i`u>t4nI_geuS|x9cU)ifh7MPZb(d4nV`;0a_#%>K8Yc4Hj z-8V7fk8DV8bP-n9SSZfRSa*c8goaC0w8X4-hz2^wjpLXpoF)cMp|}}M1p{@04gu)x zgM)ibE|J;Or=T@tqDC+uQ6QbMsMIQ2S~Tz{hAow}eSZ!AX^tx1Hi5vKIPOUk@id<) zrCjfiRv;w6x>mgqvR(Q)?D|OB}WfL?8-TJJgh<#-1CT{oX!Zn4)Asb1BPAXq5@g zF_TpePd$#T2rG4Q_tgWMUv2WD%x#!Qg?@!qfI})b^Q-QR=hC1gv}layQIB$DnKi}o zBRl4}KKeZvU-UPe_V zVgFua&v*I!<7bYcJ^S7io?itiN<&of8qBqpnb0QFfW-KL!pEXz+b&k`DhySN*tZJfM)Uw?ty)svH6OR#d22up)7X{AxWJj7(kC>;RB60u5**s&<_U=*xtDFtkA#_Tg7Hqq)|R!|um(KzIESO)nc zFHs@G7^XX|l6wpTbV*orGSs_}Ib`f3NZQDfY5??A%rK!AT-s7+-PVxip;x*p{)L1& zy$&cOkq%4u^4JLb@;`h@(!*r|N&-dla4(B$LADkVyp+uBI$FWNU5q@Q0<+}d@D}I@p zAy|BUvGJgw=W(eCxpr<$hgOYjGH&D^)rfsAK^`is;GhZ$`9#0*;C#F1`}&$?PA$&V;NGF#F*grGSb>Sh?61{(CL84L>Jg&94?zlgOr5-D$k(+Be_lS zX=C~1RET7#tm>h~33Xs({O^&eZt!5><9N-DdXGtW36qAOth5QqJiK5vcHDatq1bhZ*W>ez%(lws(~^;WrN}^ z^E)`jsWkMJgfXvVozershCBXrRuiWQhySXB}r-2e%Q=s{k%Zg46r6-Q2eb|GcASJ*rZh#oH+|qjKiUr+mHRvS2=U1miEvjD zqah5U#Oej|VyuJOK!4p1WeEqL*p@e)5BpAwG;OK6INp7)=hvT`OUs{(b1>6@p7W>0 z0<6LY&G8J8ILXl{V+={lgufrr4-0Mpt!}hk6#Ku9~AX|<6OXWJphQn zLs5UMZ3~#r|AV8IoVrw91!_3cKt92c+9vB3Xn_SX3u2+7EIyJH;6u^)UGf|sVLs*m zd}jY*Pd+=pcYW1Qa2z+kFEO5D>P%cI1Waa+sB3P(2 zC5cs+rge>;H!pvSnn)g7GKlF9j=H%#zBuULKe;F8z!4oUVvzweboS#xXx(&+#c%D% zS1G8k96}`Ws+K6H>5#<=La%1fB0<~s;{z>DhqIWP=vNpvoqkKwUsPxQiH(&`v-Kwv;Tw4c>dXue8v~aJ(7nI5cAjvCE<+N%x^bM|IUZ7x3@{@V((vPmQP8o= z*^C5%p;mys(`5_?LOO>LiEkr$BfyUQ}`s+E*;A7TCnxyZ|$k zt44iGf)l3&NZAG@K=m$tH?tr@%IZB)IP?$yfi}c_qc&z1CMX(>Go0H9WK@TXh8r2J9skjH zl$&}knGfOXf7l_~>7+4qc_v$}aoxuuV;FU1O`auR>UE{>K=^~z(`MF`#e&t-VP@El z4cr)!S1sTAYtP~Ra;0b;!J{&{JRaGg_nXTB>sp=Xjn!9@%tCT@*lO9G;>^# zaIpvp3ra}QQE8w4JQwXJtKd~==2K+@V8OcDf*&7;Zn?E_L!ItjlX~2LiwR~=h!H$S zea7h*TYN;3^H3+pSa5X6)2|OE`KGPi*ZG_{(aCL%f@J-ifmN)|Jhq8f!O2BaWL;0= z#Qu9?Hbu27q$(-CVkGfss8@ga6WMMiTT-pC9(<9#RBu#GFX<@!7mCAm=}-p|F@iQ= z840n)HWZn^uX{;aPc^j&(Xg%=I4^`>URqm$Kv zVgtsw(o2h6$}NUb`$TO#pk@?X4TDc35bclBj>E=6&3vjL@gZADf*|GJ0uqZUfE>Up zL@w(S8G&BEV_lt&q`3&kSRsVAySV{*gM^%=4Xb9uGOVGY)FVZPx`P0rAu+>iw3jJ9 zT4M6-GbVAWtPE%iyRM-0<4{iEW6asN^TSOI>;>Owz~ds1#FPP#i#YnK3{*IZ+_`c0 zCjG>u7;}nu7cj8+Q+yjhrs(75L-Ar)bUG4KFe*w*+*awAWri@7M9(Q&5(7T4J7iK~ zH5aEALu+wI zeZQJg!4geQDk3T-55B|=FAk&a^{{yb zLO*!*5|T8(?T}#ZIO_ZqIi#omjF*_(1Z2o7!UyD__REIlIH)a)0qgCWmyoJVcVY2U z^uLf^Ye1oYAuHCR{^bU7GuN3{2^3*#xgEa~F33D{3d%}fwZ;c+E_qbC898bPZAMrj z9=5xUfGIryQ}$CcHiHBbdr@Mf|C!HY%;R*@4lv(#-ADD#eVbI;Sln{S z^Sd?SDD3rK7m|Lvyg9zVET7w&waX`nKi_j|%P6(ENQJo9&+Y9C!TwU3_*UN9g_@PL zuVd-<&(0Pm<`({RXn>uw@!o~;HDq>#7qLH{+6q5Jy==Ez5q^G!A4EkK(O zqCFqWLJQl9`s!lHVS|YKrn4qcVqFK(l$XxqFr>Xr2Ad#+!lWFePaNhV$L5YzgdA&) zsK0!-5&flj+CG|BC4zX`xXnd+eR4gi%O8uLizp-cUm3NXCcB)g3JdIVvw^bh zntdd4)ApdZkRq_roHng!5!h}nFJ%5jl#7|PEb}ywUQD$)Ia_b$%hF&zv?yIUamZKM z`7BOz+_c1x!;kKo@8Ure<$Y6o|AFGL!;87R|GsQ6khNXoi$pFplIvta<8Cwoe0k5s zZXzHAebKBZ>`(sVY))|GLDnrp=8Uo*BSQD2kCz}pMJhsVHY3!L&Tx$3#G-`3+@lOTa! zO2~or_Kke)MYDA=_OLQz69JBhemU;|m4#&-xh@QGhGJmtK3yh+0-5Yv$cH3EZ0(-_ zeeemkb}3gIR&6NXP#|S`QtMcHHg3Zcan9rLYUw`I)L7s(^$}*WE6;DeEbok9kN;w~ z^dwWcbV%!MyE5D!p|Y%ux3^9do7O0eXNf1+>^ZW*tpER?or?1AA~yyH{9 z^?fSlyl0dXEvC4tiH8HL6%Tx~(k?C>S9W|b_|qHT>ya-{d)p(yxRz+tCrS!h6cpKU ze30l0C*^15(SKe^NNphMNYE8D7Za9UK(&E11S7fei|jO(G$)p&p9I)ku{8sk=E(Q3 z6ME_C#2+!{9Dd&vHbdF5LJV!GH-Ok-$XOa}Nb^0DH2N3d>{2s@`M)dyb5cYDMF-=j z|B8-el5Opnh~Ri$D3c?8ctG8Vg{b?0x?u`!_7P}1czJVmyUJR52&pmV)ZIEv{IF)j z3xEZH-fbFKfB^_jUr+Fhq~6g{Ptai22bqSy*QB@;4UaFxi2P~CH>f-`*7wRu3{+E? z?}=j^nI+2fC&+BWePGGkrYwQIMc%exDI(VACUddqxTh7{INX9<%c~O3RF^Povko{X z_bMSb5F@yMNgIbMs@09uj=++`Kd2@?;!}!7ad3Y6mp6CWTpEOj02dk@k20aoYQs?l zN%W@ApA2Q**tfQ1j$5n}=SoU0oHv8H9(c1Wekj+JUXKhwfLc1iOxf1?@%sDYjx`6eH59MPB;$e&E_^5m z8W`q>ULLH67A+|z#qwg)^EiZnugm;w>{GsFxG=+Q&s~bZQM2r<|7znyLsq53q%s5y zfOdh{gC!s>BM`n5T^7O7TYg=8*6h}M+l_b?Fm5O*kkuz5;Nr-!!}Yt7dSiLyNp`r3 z_mhhM19U?_ee*5QFHJN$nTo_GxE!d+Phd+a{NmldwpFE_vKd1Xb1C1=`bRZV^zdGi zQXZ08vlbL|B9#jDHEq&qa_snHPNcifuR38Iesr85U5j>!aX#a5fAVy$*R`#G%Yv)p zxuC=N8K%=IXGlp4N(Ay%O2uT9$TVf zTf9H@BnI5DmCi!!hQ9k#Z9%{5NAchZhxRzwGVifTwn6N8Yf1lmx7!xjCXZ~+)+(V3 z5O9l9<^X*#kuLs$SGwiB&IE0{5t$Q12q-$4Z{i;VO#+hzi;3erk)Kb+6c*)pOteR) z^;c7;?oE)#Vq@2Sh&QXRhZj)P1fZzhwfV^;m9H-LdFN_DM3sl6)I5t)^8fGi!wm3; zVg_(jNjDK!r1@!cP80w28(X9v@$oJg-`}aKDutM6iMZ-QbjaRrFMjb}m$>pzY?C5P zqz7j@)u`5x9S%mh1aciB9JA1-T|Iifr$4B+o5R5}-OBCs6rq4PN+oa{u zQ)&N;#~%@MsQa_}R+wcap=7hpw>R%rwZXrs}0INL#3UW|+CF#7|VV^zhC$y9^+O(|c`HdzXDcYWS#u+xuM@4{EELW4VB zx@D8hzja=*%O<3P!Va(PVIHuq*&i0_iF8Smb{w5#>GetSVd1#eW5Z|454qd#Yi0&G z_3W&{J0bOaEf;adbiL0-Vq)}4443r1$Z*IvzG>OAos@PoW;y`PKTLo8%VbmMxu{(ms&;ZPkY*!`^=XfB~Cc zo2I|Wzyc|<-Sr0ISP>kgN=Ej9oM=R%AC?G#l2^ZoCYD(3UxHd?OPV2#mR*)Pc2xcy zg_zi~-t@!EALp^@DSa~}nZ*Yah{MSTq$x$5^dn(u{1WD}?BwTAymds97<2r7Q1R1d z>QVB*nNJxqAdZoU^1bI)QBQ08m393mzQML947~(P7+$G zzvT<{$0ILWKazoS{Z1Ic+-+rC zywoFn(-^=dXJAH9yS)!^QBtTWXJ-It2+4mtoF3{Mw_7;!H;l8`B4c+N`}bczj(pkD zA=|8gX1c-C(aaw7_d>~bV)>m56a&%0EMe%owNrI%lPyip2j5G^n=VLf96zb#E_aGV zzoQ&hH3G;6J>VQOKsMk7fi(-oD$wL;f)e7_QWIH%6IB`&sk}l5fX%rXOXSZz6OQa3 zQ-pb6*c(Nk*i!BNtG*%JWFs~$!9BAq>WAmgRc{F~kWFJxdRn>J_^7oTPG$HW@*xty9in6lhTMuq!e}gwobsAR6(VYHQ z1`O?<=d|!d5y~&4G<5Vs|Ef>(F$Pyn{IQWg z5QrID`|1KE-=AQz_R}GsrgSh;kTXqO!+d9|T}Ng@qoxA8Z)}5Ev!z;;PF6%E__NI69s6*!F{FpMjqMyN7>a4dzme2?K<2raQ>3ht1*Qiha z);|eCu^-eNz5hjyIDmS}p@pp*F3_|T`_5}bNr620{IS4YmtNxxM~b{sjypzD!Kn6| zHcU`EX*j&vr(Kf)UfC=;I7&=O=CfFAPL=8YziYy;v1O?g|1Mc} zcOBc#&f7xH+@id-tXEDSLcP_Rr_BL4LuC@v6er1LcP9~}pSu?si5&x4^aF5v0`sk3 zdd+z`@8G^rms}T5{4x+9r-PO&vi&W3kpakF3g`uO>LXQk8BXy2~+%S7gSsb@d`h0P<6Z}tbRIfGrF7M9Ot z41UaFk4W=7i3l>6S(YL}pm!kEw=_S!@wvi#r9;-n22)vCrmpxxp5GS3do|*+<@8_T zF=Q(kP1LaB;hIgtXaIOi7AVMQ-otzYTT_-@$tWKn_Op8dRzP(`qj$s%iX=*u zF|mS?b*YJiT-aQAwQi95@^!Te;`m?J{}`K9Y|1=1^-JkqwEzYOE;g=Cz}&fh*`;rl z&sa8TJSvzgL97_TG-0s9J1V;DPacl$HxH*0!8eagl{@5T=-q$Z4STCwMh|GnM~2r5M#zQ5m&c>J-b}}ZC6%>O@=f*EY8E3q2P@}pje)tY0vO`v1_`z$ew$m; z5F;K-wBH&t!j)py0SNW? z85KD|6~!Bzo-{0H)jJ~fbnl*tsXVv#U_%+Bw|_GBzh0l4;IWHXX66Y406kGx0S6l% z7IR@(b7x?@qS2)8l&FYfL>}q0rZG$Ezqy?HSH7Y^8N*%`G2W08Gu9gy$qaoJWssPg zmLbCR>XE6->HQlf@fb}&qT(B<)ex$e`zt)r( zq*hjwzwqi=6fq085nBTttD8L2OdOnN4&W!H<|OKXpGZgNvBchfldRyA>)Ok5+(uMQ zq)|Jh{rsoMyfKtrGo;JG8_favvR>E(Kw#OOHLhcD&>P;IJHrU2^|W-N*1IvJViD6Z ztXkS%lsF}16*wj86fGm1A)L>L&RmmO`vX$z`>YUfm*q~6NP-Ay)ycEA2?oxe zo3Nc3O04N?P+&w5nutVxlgQe>)z9Y+)OskYWsPE*Q(UmT6sTYeLqwuH6Pm3IYPwD* z{@(iG5V`=CAD)&Cb~-yd$QdH?T(73saf&$K-l3teaon7s=H(>F5-<1vzgavW4 z=LFOb0NE7%;TabfxHFkV*etb_k_h>*C^kAdM@@VX!wUr%U6OM5lG_T$W9MtcZd&*} z=jvYY-a&b^C}~=h3op4}LCQT0<+quzhQRNf)ju|Ee_;Ht|4zJDLgqmA33e?`EGC#k z^$EN~z!A(P76~E-(TPx*4CBWqj|9PW=_QBuXf1LUAuWrViT=t)f+(3GKbMKglxm6% ze-;~QBYVR-lZcuyk^YdRB$HR)(`b?WD_Yu}9QF6-DlQ5K?%DRCv+4TT+sFI;3LdCa z=Qiyhv!QN|+F&1F6GASGIq#?jLp*j~-x=|L+aI+Q9-b)Q5<^mcru}cQiIEx4j%e@h znGp{kDx)YZDittrpcr9dG+hmae|J!yH#e?LsHJ_>^bC)gB;g7X#zYMqHU8CmM}-N5!Q2@V< z*K#~sP`EVHH|U_oKz&$%#=vBU@W8pMFe7|B+sDUUjSfA~r4Y_l79yZc>&(3A);F&t zz5H^12=r+5p5f2VB!B(ZnLYDr)KpmBJ5E|bJiTQR4N)TjeM2KzFK%5sxG`cZ4ecf< zXs}{l3-bX7GD6?ost=ba$Qch&wUP7)xj53_ap7ogcz$PvV++VH>zOLg$n$EsdADGf zO}mmR1;OYGR^UTxCuU{{CJH-8!%u!6Y~)Ab-f+mgKT!U=?Q8J^HkPmmA;NZl9E(Aa z&(7%!?cd7#)WhertZpyq4X?XekU!}}_=yZZIUR7b5GNB5-k5ZFSQv&Qy>-B6jA+kRWOwfL(VJpS6=atX^^X{Uk&{&%YF9T>pF* z6Jt7ZFJegY>>z?rNDW3FUt%lKmN>rUbgM0IOR2?nudSu#q^iq5y*6<7m?V;duHYm# zC+J)DL`|R;R9n$wDU;c}ooP5F zvWSmHkupIw4s73C21%n80oUFGZ%+r%m^<^`Sc=p%ltOG@CstV;lw&WN@K&2E`R_MI z#!KUJ?K@xU;~rCia|Pe6FZtyCCnrDh8%!LIZpL*9C@UGLv62jViB{z}-UUc=`H+=) z+ffqB(ZNdn4hKT&4?A2EtU2({sK>YgC;WĆTGU1?6nHRMJsVeCGX{2LL)DwVE z0FPmvDYpW}rRdLsH8^|0NYJp{7qIU(e@4`;=*fehVwax{m*-x@y5LI^S%yf8ZIY%D&ud@?w7{i8A z<>LH^dn>PBhnuqAvXn07RBmn#PHj(L>es4rQWXp?@Nf~1b?=X8ZDZ|(jclM{_6G-3?zT@3>UoF>)+qTMn=3hRXtSUAQ-YmX|-0XlirCunWfP+&f zwt}l=tbQGW5BsM#qw~w<_eq~d7V}>Zva>sc+xYn3PRabAecW8GAcIf)wmw(a^QB3c z!t44z&(0?=J}y3wKazGcXTR+db7IcfeH-!R#xvWSCI+bUaXVZ}VA5|q&*W>238P>H z2d^9qW$_j=DiTjps2w5i1%0N}oS(-Hc+3&umoK^rS%tW$BpJ#YKF`R8Ph{EZ!}mG> zig4wO791`LCMl!R+&VYJ2wXDX;yz^R(L1=?>=@mRYi_on;A-{>zq+5jm5T8cX3=W6 zF*=TsE-i#P82W@V1N}65bu21KG!Vcv^lg-A$Q`#^7Vqp6zt^VOcaMYXo7Z7)h1`QRb?*s~THkS?mo-GPibk(^CvoDKy9Nizddzx?pjun;`@zWOG#yoJA1FDTRZHkJ zxN2isO|kX7KkjOlt$`Tse!x0hUtQ%Y1E#cIZWsq&etO&{%H2Va46Pp6o>d6?N$XVF zh>gho+`(LBs|~sv-ixF2<_~tfxgY2kEB70Yo$jAoKR@1%J~(EV^T360+y;x1ivU2c)5@R^jA)G0%6b?I5=oR~besgv!fdiy zRy`=F1gtI>EsZ&(F#BrD5WjNva3-oUT?o^xDStP}o3hT`IXJP<|5JfaJ@D0->-7vI z11ML9>u@DijGy=E@5900-%mbn0yVf2*K~`e8v|!&sSUOk3yX6)`=|y{Z4IIBUQQf$ zIZdG->HKsJ2<>WFKG*n3+4}-Gkf|NDTz-!6S0o!EuU1S!-8W4@(5@ z)cfO+z$~nMd}Zwl)Rq`!~)_3lEET4)Pkb6)Luclj}TX_*&p5G z+#8B*y6f*9&5LLK1lWnA#BWo3YvO_><}^@N^k?#r$YIbWu}p)gkQ#-4ve2N>)3p-P zG9L&`+K z_&n@4{=Tqoj2y-hY@A)SW>9Z_moM^EhRoI@1i`wd1%Y*uQsOI@fS?s*S40iuI6RV~ zhA#sc<#Hm-vC_xX3cXbrSaq#JMHNq`qHuVS5*oaAOBsfi(h-*i3Ivg{s4(2N@A7}N zAWqGNn~1b@@w6FLeF3^aGR935sS$V9&)R?TYg!wVfjlS(Hmw-#ijW-)!N~6={lEpX z72E2P3~(I57LKBQd_`WSReH5Cbt%qtd@LO&>S%zVjWK43}2$}`)0uu-?NZ>7U;N;Q`FE|d!{sY#$xrfpnn~J%e%RBbpl@=j14J*wg z6XF-(eZ5WrR(c(zg>DJbvRPaQ6yF3{$ew&ZFq$1~H%2i>pa7WSD>@G2i1ec^O#_aV zDk(eBu{<+n@wrUy%853h{c2cyM8iuvW{OL@Ov-xWhY1bg)Da zj3_=U0Y8rrsEG(P-pa20qSsX7+^j3;E!;ikub$L@c=&Mt3{?#7{NgYa71was7I^vK z*jYSfMMWnmk#hs=ishxjpTKM={XA&hI!B4%OaAV-iQ>r5_&>HDG}5we_J&z6ln60J z0^&IvUuKj4*iMb7SuGpHfB^Ij`#p=|QOo5wuNnp54na&g2?7>$8RM`5@l=Gp8G`H| zTEJ;*d*1ul`SJC`-I0$5K@V)l8-hK=VnB0sH!xkmKo@rd@E0Mr)RO_A-6QM>_67MV z(=(7kEDU)+`=9g-(1`+#4Pt`pY*~q`!m06Sz?PDNt?4Kfou+QuRCx>5Z-&^Nywzh= zcQ>ex6j=-7Lp4!QFi`{sFs@Mv-tg8mbnjg6{o8h{%NB^aI3W+aqHDZUQt{TQc0}WerW`{2DR{scZce-1K|t~;oMgOu@~>)s3JARt&V%B{6^i(% zDCG^?MPEm>c1#;ZVSmIUxXO zv3X>$=+9QI^x8=EghR|*)nF&r3hwM@mS-1J=lQxX{uEYG?uxt|NlQADPd9q~hv_94 z0mx?bfr>YKqB$CaCV65TsvxA~H&SGL7TBH5M8uJvkME~JLDUNlZxfNn9=&R_@8&Y* zj=Kf;*}lkRuh$P+HX0097juN<{F1jTJlpzsH1k$0^`)Kq*m{E#V_xvi6g4ET@*KFr zcMA4iK^zkH@_X9)@$9DALm{DV2Zj&(pd=+hL*Av+WoX{9DVL-60NsJQq+M{$pr1AS zsqdH4<($ZNPrsaH$S4y9iW0&7Xz4P=>dVGMV8ZI`coa1)tT2-AE&a{wAET@KFRTP} z-c8rrd<*AG8>gkYq%=SauHRH=ETS@-noxGK)Da!cpe&_WBz=4jr;aqv{e<;gbV{H^ zZY%Zawp^9kOTgSOXe)>NDZpVhx*9K%&iPcrl;7t|b00%X!-ws!blKGhop&)!A;G%l zgM7(WA~ivEz}gBEO3EGA`^Q#-S2YyfKN=cV1m|~TUy2Ufd=>qXGqsp4VHw z++xloy3R=Wv1Reg4y7lR128FKNAiFG$7Nm}%p`(swYj%CT27FP%{UuRG72d%6$Rhu zj>W?ZC+mqEPgO@U*(>g8e2?%c_wx?@m5W$(K=zcPevP4q9$_b?;!@K@pN>8+8O7UT z>O^(az|fQmhHI*`0-#hF7FvTf_O*GC56!<^~nz8%|tIUA7ZT4 zXs-j^erH7pC(4Dta&FF>k`~{npZ{r&=|9X_N;t(7PVcs=r6{Q`#t=3r+7vD*=JuO> zZ+&1T7q-#FT-Ab#V!GknSMC;CC~2Vm=i$S(Du|MK$NQPOAfVF7bIPvKJnrWNq970? zd0-L-F=EMdfkn|`w=SGs9#*`^{Un&UTC{7LD}L!q0+ zV6odbckeq9aAW=msotrkqrRqwvH(TR|KaJaqpJFz_i^cNq~ijY5b18XfWRd$4bt5x z9nxLWFG5-xln?~zF6jnALOK*BCH-#RpWpiZ;W}%{TIZfKXZGxw=Xqv!7b*7>LkjsY z<7fc*Z#Y>E1A_Miy)82{w&IkJ15+``d(CTil(1J--jK&H8UID=Gf~}NjAI}`B0Sl~ z!}+QC74cAf%4O~SBtmN)<**jKD4Ix0_KR0-bLKP`3!|w za-gine_`p+SW{sZ#`vD8G;6K@h~_k#HZq=&-D*Et#NdN3cZyLY!yhJw7s4kmtmBIl z>wJ^pKoE6;2IaMyF1kW?2a9#xbayTCrjYO4=4>m+xm?4)U_5Q;Bv_Q4_Ru%ymS^qS zQ%HYHVg7Y%S=Y(+>p=TvL)O^htaNO!t5dGn^8oGFU!syeJA`~XX`iTe?s=L>MrTZ{ zsGv<7$Rk(}%C<-Qxh!!pfAs?>PgRG=ig9sX5*0^`fZjy+?KIy(t|!AF_(1Anq*gLq zfu%cl=LTcmAoY1ZpF?^=D7!_2F3mQNEOEb37e&{n~e%f2TVOZ8s8^LI>$LmD0drj+_1XN94!xe;=nt!G4q4a=79V0`&qY!IBL_TZ}u8` z^?-cI&rFl#hA*=3HYKZ-xGSdZqYh=;#^W8ED3b|6y+Y_xJPq1q42UDXam@Ee@b(2x zD8h4j$RfA@Nb*|r07*CZGYbWUmmhn1+o`)pAJ|8Mt~<*h#nQ68rngCM=zB>PEZcq! z`l_!VpB*>GWl-LuhD-JTL(gynrHnDyEx4g}ivUE4aj^!1a;W816(8^BXHxle_c!_3 zwY8>05e-_=^2)C&VV2|_XsAB2@8vp}YxX(owS5@2m(kx=tnjIQS_xh9v;1f?lY)6p zh6D9}Z3J)t=*t#PX&a1Hn|~U<{{wH^Ulq)@{Vdw(0*vLsdWUseLA}B?b=9P^<{m4f zIBx2DbHE3fQ?CO);2B`d-b0Go>Xf3GUR<}Y72YUDLrUv_Z=xQQ>HML1E&L?xewhp6 zwPi(%#PVE9^|(n3bJ7}h+2ubLx27}A(Gn}-zdU4F$B;g-(PueZqp1cxES77Zcwf7m z-Fp7#ZjzMQl0p>v_O_%-QoO+@%`=*?)&FLMg?^W_bYZ>PBQlM~MUy|=n@ zHw1f_{{Opxs5uiuOhP`Th zN%@|A#To+vg_B~Fogs*4{i}@e0v*x5r?YsFYh&D}`!F=fX|vX3iPdj?gQmjG;-m?( zO|rxQ0Xl-OMw{#;y?%hZ=3{f(*&uhK@pefZQG4e`6~*mnTCkhxdD-+Q6d@g2ZelDl z?A9__RFKtUts%Z^5 z#$N^S^K0?UaU{yIMz4w|p~iM*iBiGA>KzR;Ee@;)RfxXX5#LJmewB+fF;iE~V-u6S zyYFXdE*H6v()){iOO4dw#A%2IA;=lcor|A@LPWZ{_Va&$xkO_4PnR7!c=uw*);}B$ zl@Fw^Fb(quRhHFH#UCYX{(Qo931*$ojejwi4zX;;j*iLZPII-hfldgyf~}FObt*)L zn4gN)Q3j&_$93cGJRp^pM4+J3uHkNXoGiz)RH4W)^w&peI)$_&oRh;B_rqMDa)K)X zJ8Du6DWI>LVpWU>&K2i!OiwuHTjr{MWg)1&6)b4f<#%n>R6#G6ik?iL^o1KGW$sv+ z@iSe)w-t3En=mnST1k3-##{anutUUrppdEGN@anu^%Wiww^y6MU$W4qaN$Cd`xBI+ z(Fuo3sb&1=S6hA@1$YO39-CN~>B6f~ErJX~SOf03!pzCI~PU&Q|vz z1jn^A9kH@}pl4|~T}_Q7Ny1(WuK`13a2L)gr)eu}^!h#)u$gD<`SCJZsl%XCO0R4txx z8e~9`L_8t?{ScqYCO?^qcSa4xu|Fn1kthM6&lE7nq1*oq1|BRDpBJL?S<;#*;>W3* zvkDkyW3-H+dhH{H8oznv-iFx+aY?Vs4PM?sgjh zy0Ypk+m#bJWP8#f_w^0ZV~CE?cK@!WJ?V5gN?V31&NOrCHxO%lJ;h2K=K5wffIM~OnaYrXa7u}=D%Y;h`Sz{vV7 z8{!~?735ig7HW*fSzCr3t#P2dbGl$ipd;K=C7SM1QBxmoM%v$q0wk?1OM?%frfXUH zj%k@r1Vt9?yR`B;y6*kl$=1g<$r=wzI>EOjj?x7FVzwfe<)~nhJTV{&$~ybX4C`*I z{PD)Qg@Q+q|KN$I<`dux{8L3|DDFh@eB2t?QEMV5wexrx1^Rfz7>69vi3e|O)UtE# z9y<@42r&6LyFw60JLGysyMwR8xEr`VUA z6BKRWEbkd6!(->Ixr+|v1-Q-viu(a(JG>yH_7FXDy?wm+@a^bzz?*=bm*Y$qlx1W;Kgzn0GcTyRQflJ4YTzdh|(w3SC14tGe@IObhFt0%! zrSg;}hOq=~W}roSYnxRy4l>9M@t!DQ;z+Yao_*{ycpk>Tpy_am)5LBXjV|$b0`%51 zp$D?9Nbs?4PqyzN#zv}o{5BZcu2;XTU-T?s7ZJ?P2ci$W*I7D#Hh$_`eqb#5HFi(s zLg^@JnW9SksS0<{v7(gU-AjPaTT>f>#1RSWCTf0Ep-M;ng8?fgID}OhmxxLEYe1}n z43H1@tssRQYor1?1L+gv2v767z9vN|$ke$hhomcF$E#2nxUCJ3AN*^*&1XeUVJy&Trs$7Su5Cvxb`NN1biq!Y}?nF}NLb%U~BYPN%5lWwCuIuq;q^_@gj~_pDy}`J)1S zDDG)rE<2t@>TjM{G2H;nyTH%4i2-x`2LY&h325})T?y=KkgvRM3tlj9z9Z`c^6 zG3SX{6E{s4Ku4o>`#-(?Q7y53JtW%Yg|h(qRDZZwLgdynx8nx^P@CbhO#$W;WXNRI z8`hN>Q}(2$Y%pAHfoVvdrdsH#WG{ZFx+-@D95X)RE$yCcqrc-g`tsfpq;RJ}tn>7o zNOvY?Yq<_%4zdMI-N`@UDp|_2#JEJLCaaiz`~&n6!8tAqrBw~i|Ay_^@#oFFF@9m9 zsr!%nzkwGs`eF(^g(W*E;K_c>G!wBHd|lAcj>zIB-c*z=hOl~OzS|medZ%^U4q(t{ znEyWvdev)^$uZ*ZRUR1Mr$wmKQD1D1v55u%VhCG6vF7g|2ZrOjpUxH6)c>?BgxndRhpUp?4*oA8BN?ZeNNDs=-sed2In2k}4)(>pPIOnW&QY zTSoi{rquXZQ+zldX35wf3Dd(hmnL*#a#hl zZn4V>AAzjfGK^1bp&#mWV13IhM>k~52K3eM`Bnd5dX+tM0>>mZU)~+Me9V! z1+*}XXN`O-NSHkyLQnq8xb>UvE^fjJhLSoTnShd-wRwmbL~4og$zkryCll!~SamrP zCF?kCeByZRu(07?Sfg|5CK5aPBQd#oFIi_5IYPt#Y7+v{i@!6bwRJ zCD#7_@O3j6T2h#Sr}&!eJw)uA0Wby9f$ThpQz4!ehagUIsJ9=@yEn8OO>~5_R-VAS z0s#m#je%Ptyk217)O{m1S`DjmHYn3VVOBE(M6sXBw5(_Glr@? z&%C1DM6nH^XOzCAMD5V(g=E%>X*Dank5&P~wx*YRzd+sOYv|_lWs8`ZZzJ|tXP5yq z_va8$a=biWoR zhpVLdyZE1f&+V+Xn=xEo{t5iF&~yJX#5i)LSgj}Nahyw^vDd)R{OPlcAdRlhiJA3| z%=Vza&|3QZJX8bKUJoM)@j~IFPQjd|=tHfYs?A2+&W@74hPS7W9dNU`6SgGcta$|= z3Vrv7_^$d$ER*5yB&=a>tqwByd~Hh7z+FUWm8IJm?_Up9DX^G&iNoYJC#LJu{8?yo z^GfNHdvMjGX9$Mpe=Lm@wJIDqkGyj<2i-bPRtzLSRq>?FNFuk<_tc6tyx(q_J}kH- zTP|M=F7%c}*2K*2z z;D=;=I!jOgo{dYlU$HJq)0*W4h)FFKnFd7(Fh?KC49LG64slCO9bkT&x=}fmjtVP_ zq#|^bEFjbA08ItZ0*z|kdivPDbu9WzO^o=3gl`Gz!fyp%1%R<&Ge^hPG)0O-#jQ!G9?6Wr6cQFz1TgR@x)ro)ZxA35l5^GI^eq^i|-v8QcTfg?d zRG*o$3+axw87x+8!x+&`A}r@KeZU=+Cpj&7aBny$S>^Kk6D zgdFupR4wuR{)_v?;fagFP<~=|*3hg^^4#~Bxaw|30vKMEI%uMHRZ!uS>B&) z@H;?(I+5->Ep*Y9<(`K#gL`|$S*^^mYdiBNI^-f>^E(^XNO@*J(aYVlpS&GR-+G5b z{U^Pb#njU%jH@cS4-$@<_93u5%2*|FvNRX`|2p9!)L1NblZ`GqScW24i`_o6-$>a* z!X;_>nUYwKA(d^spBRo`PadM$opS$ZQYCRE*Uz zp&eD)f#-X{J28Jer8qmu4);w(H>1=A)`Q=3PSI3|&yzUoQVSqABh6=e+F$azB}2AW zS7;oiuh75e2(U~3Ho#*d33L+0h@`rg+){JW-p^Iu&LC8xo9uvT`Gi~db!?hO#wL%_ zhbkE}_~mPK;6eeF3MIN4w1gZ$)*$uYF&!pK$x27vwzH`el}&#sycOQ=`|#8GbCJKI zq*Wp@1M+Jt-$1yXDSaL~)}aJKerD5%UKFwjysBqy;4nshA74-vumRtRG{YcR(RGsCY!VB_%}NG_El{L z>Bf9YYmg>nPazf|tMDXze2NM{jUWt9Q*x!gzTz1t2sP-4Xus*;^2S}i+j-q#mlXc{ z&?^wGXic92UOz#}L+rV{EQ=bv4I0CSU`UX&RmGv}DdV9tfl@)2u#)JQsn(M1zv!dA z7yHZpT0Gw!A#syzpA5B?^-s4?Hh%Sr#wbz6=qG(;89RH`N9kLQ`baRGsi*^GhOy4s z5}4VVJ{}#5uhZt-dhB&~7Hm>|D+GPkJp^s85ifyj5SREERUv5*_Z4X4tzLt?5&Tb@ zQ<(bA73{o@)FT-v#x2K|LZ@NxV3uv6)43{Uahhh?`WL-ibap!xDI@SpANLz}&1}iB zvwus$F`ULU6&Nm?Lk_YqSXpO@M|~0`9F?*qW|(Ke7&U=nI=eYNGS&r`>4 zjsK(htHd&Sy``#~VzR4DHI|unv%dZB7{AQ^`>F^cxDt_x3Rfn1?P*{(^K5A-6&992 zDj)P$kD3yRISS2z=Z8)nIbFGcx)(BXz6vEOA)#}X)1uY6Hz6{eMlA4fM)Pk7ORX+1 zi*`R;I4DkN?BK!h|DH$(}a=}F3x`jf_1a^2gy`fjZN24VL`w&>v6 z1_yQZVM)BbF?$CZfkV^ZQt&Lz^8X=vW?(9T|yr?R}V|gLOPg^gt^bh&#+!y`CMU;jWx8-A@_yeD0T>n|KPxreZA=I1&_9% zpGU(wY~4*LY0D@$%B-z&|8^Fht01Rw`VI8ZJ;5+t%t;j+4;;ra2Xk7*5Ny=lR z%@!}ysc#KVYAZE5b&blQt~%Rf2SM%?4}J`c9{hKI0xSt!a6}B>%l>F{*3G}XAI({H zUnnd=-hY^NW&r229eh-mO>fdUVdp;RKi+DAzy>#qStps%B*+^hWU+^zb3UI!%nHf0 z`f@4Nkw7H)F`%j6?nM~7NWmnPe zjZVHmxwY?&=C2F!wNI3Ai4{m*_q22Zp+nM57^)YYh*&lEvx-iHnAVP&_DenZ6cF!o z=9xFG`$adGc9m|CD!rM%h%Q z#1aYL*}1PjF0i-;wZH0No0gJ1$*x|x6Cz*ih*t@nUsdvuSE;6txc=nf;UIUF+-zZe zCpzy=@7H-{hP!FF?_8@oKjKy8<`Bs@OWcJ_Pp->pi{!!yW6zrBX<=SA#JtM#U+0I# z@I`p~QR4?fF#hXNvw*e&Z>=LCmSpF3kc)-i>!A_3%MxN~D4qYdJcXns%FD;r%e)UK z2=DinWBfs@Q)6zL@3;~rcS=>4BK8Nne^W-XG^nM*RJoTmWHHl|=91S8Y+r8_w_}6H zp?7-Qi^mvCJ~cj+@AgRqX#NOPGudZlX#L{rzv_kT_BKfiF#rrg&I1il_E=sMb8p(X}X8gV@PT~L+bRoLn4 zcKHzed4C#6UQBplUUh;2>{fn2MNB^c{9b}izBOz->V%X7xo;)~F`yCg?L^IsBP`OS zTQ>Z)Ha0${Njmv4({9*{q^~O95T;sPky2Hrzb+@-5FCs-=i(OAJpmxrT1;0_jgiIw zTOBJ~S2Fa`?T|}n>YvGfNZm^!$ZkI^&67-o_AhpAckx9;;Tu}(+k z(|J)&PuWD6T`>^GVrn%XoF|`?O0f?^;0a6emf{v9Bf8Rc(pKGflq|d4Y<$s&Dicg_-WCxxqDaZ(SUvCY&eb+~-cYY4q?M*7B! z`;84>(4~mUUEEfTv4_i3UdyN0N-l#ae;h;93WuawO)5n=?4U;`f|ixI$&lY;bTe z4n>VNN}s(FHGSV&(omPg54Iu0{a<64Q`wt6Y=o*YPfUG?3NiZ%y)rY(5Pwj%T?t9) zYGoeR0yed2!tX;#9old8a~p+ho?L|C);z^i#iZfehY_;uHSs&z>T5ek&b*vLD)tcp zqQ-m6a;CUc5f{vPQGq3t&|xLHtCu{;Q&!4UUkl=o{}$b#Y!D`!etV56jOMogV+hit zE^@v<6ca_ybf=7`o8+A*Ob{d2pH$yn6ix%&zK?;?%CpxZ;CXQ8_K$im9T7zBayV_k zs(K)N&z$}#*vj1r{ceP4P&uBR3J1TLN=O7?qODaECs!?aN zcDpG1?Q@YiX*97wS+#eJl=L|Xo05n9n5hl|Qy^VCM}%ke;_t^!&CC6{p90@thWpOd5Xv!*bNgyYi&#AmTzWg+P+@{^ znduus1TnO{N6S&Glj%u%nWCQzVZu(K55dFkiQ{C(?n5BT9`-+fKsES;rogaDDqj@e z8HOreG*#TmNOcqU+vs)i;q(DLMx@dR84jtK(sQs?lQKriwifbicTJY9+n(NXWl+wo za7Q1BylGeIc{hE*OdA;}0IU=vyNzKUE?cLh65A^ugDN!-3;9pqoVZsFM%+sA90XA; zNvh}XEk0nbzYw;LCaW3z8UmG%Ycxon>d^)fBxNeMngq+r|FePh_DRl8(%paU+`Aed zF9t4f*=)>^{dQv&#qAg77B9WQozTo2w%YAt^EJuz3 zzW9$KX$)rEOIp$kvrchO(tj2#BP%N>lX4v4u>eper?YHn{lgBBXPeqN>4kTVZf>ZS@_?thSs+?g+gZ zrdwt+sIBTO0aSxg80eeXJI-*{mO+tOZr*ZN`0(~gv!>o$LxxJ-3ar9MpaoUs`&)mD zaQ}z<5Rt!q$N9@^oj4aaqs#`*!iO!R%x@su2O`0_oEv%k;a=|o7e2FlSJo_95EP?@ zca##JZ?2fv>9VJENR%R}k$mKs7aEQWTTsXH7RE$N+D$jFY}4d%L`-$j5@G~rz2#q7 z@hLJ7E=P_3sQ~jS-?pA)$NHBtPFFOm%@uvb|E2`TXk5$>9&JugjEci2JGIQVTowW` z;3N(wF?T91`S=VIh5`QK9abn^48{F{j(QJzsP6kHn8AHR&4Y`>!LM*MPU2R>A)fo+|dTp&@Izum>#52NV%>JCgUqm z4D5jy0Y`~=7zoKy2&N%yrD8Tf=f}LKWHzWtgpi&;I9+~@3`OzE4xIWt86#(|u-eDm z1BRJ-dc&KZLC_Uq`(M%wb-#f*{RbX+SO()i@W7UZ(*Hqm4Z=eoB15tsLiOZ~b%{B` zvqK+rh&l9!DBZFiKC&(Nt(*?a>yTlm?f1FRzFPDWj&J@st&# z04bEX>FNZ7*P^As`%~_JNCNMVYYh`5o|{x{osD9MRU*dE!eVE+M+O7HcP+6MnBsa=s?0SE0(4%2>L zbCG$qDDfYNswG*RoYC(-uCLhP3x}BA;+W`3Wr@HaED!=b`@tu{H0Z%JxUE%8z_#f3 zl}y04ayOvw7T5a}P$(8eGx^QgBinb0!oLtfPm2>{Uuf*Q`iu8hS3})FIl?Y~;mK2>dvzyHg@E^~tZMYM^4!q1FXB9|kekcwI;^d*JIGgLY zl6~rdVgZiowOATr1Z5hJJV)xzE?mmd-T%!C^>S^r2r|Ynb~r>q!bXBkV|B)79DyJx zLIPtH9a5u6W#7lcL8xVzE{4levtV63M;kV!otnCEj&y4}kLU+w3o%hzKYlDe9~SWn zUhJ;181XCH_*WKwNzeI=Qj$K!ua23X-D52F0upDO%(v1UtKC@Zad4C(Gk6vbc^zUW zvM{MwON-$jS(R~rZboIXl^J<(Ld&oSKBsI`bTCIm4xPaPNMx||8(v{23@L&CkdXKw z9Ybe30{ZI77^PxqacI+tp-t2{<1L6K7Yo)og|!UQk6(3Tft!)KN-y5ro*0~_mm-tNO%%GJ`%1s zv1$;D`yo*@tXKWj1H-M@i!Vz&>J|Edko2y1+XBNbZlY^7ks=;IZsIY$ECPzImi=iF znEUsC7pZrjKOp@J;(s&dB$iRwK0#Kk+nGfpv4mChXJjTDZaH;jf*$_tn8x`I}R}>~XS&fwY^<17Xqm&e2ikEayK; zT=CcKe}hg}Mz;gf(uP#MeZ$1s}MHw{CX zPq~*F3nq)?_-lMb@uTu2sQ$2lvDdxv3nA~d(2-~&bHbhra0%fMANOk}3E{Xbam-b} zLtMCT+BV>R)$F&e->L|o3hVdYst{e2QXKJSGc59u{l$0TdRmaQdGylLy!HbpzcwV2LXq5T+UOIpgS(z6@@vSA1MR{%g8(=K5({6m`TK+Lrt z!@TnC;)cZ?8x|wIJ!h2m)D}Dvp7a;`QC|jg% z4#%$#3uggr`Py-!lsk#OTl3E;VUbhsns@g42-(2d@%r`FLxW4to(!#1@U8Wz>-*Ex z#7U`6JYs8OLB#;-BV7+fYmc{H7$aVL4yOILC>8QObS&@QQpG(MXA$8dGe24Nr>T$_ zTE&8km(9`Bz#w>;43>r!^u!7((CCy5C1=)`j4f+B*||Q8)MKx9UWHbl5hs)H*=@f+ z&UUm3JblTG%y@ znfw|UG|Ynade^SkY9f^l|Cj4}HSG)OG=XHLLQVHSzxdd@AjB7#z2`sf;@-bW?2W1= z@fYNlrDL&xtX^6UZqIuDbeNn5o>(yPpII`lZIFMuSF-ViR&rBq#oC+nfa-(MZ+8*kh^6kfwS|0}#B@L)9ZXHMfU{h{9YJ$Z7KVDfDMyes#|A>g) zTm4SMl)-QcW%<2&nbPplN4%p{bn)WfSiaeV`^TR>ce)cjUAt$B?q&go!I=f#?xq1| zWAVrJ`AHbl`@b_!@ZX|bNZ9Kgb)En_ar zPv`Az`I#`=gWmYp=TKr25{yHx+YOXvBY^X;T=E70oJZBOmXSm@Rb!yP@u9f(TSRip zY_ELXvoU${5ezJE%lAX0jE0?e9Yjy;sVlA zb@9$D{^GFIAgya$oy(5zr)7$M&f-%rk<`VcfwH1_j{1!}qsX1(r_Peux}+XZ$1ge) z!UrtJ(NDdghlJQi7yyvO{c*^Kcz#Vdz}h;aYDoMupAj#n&crsm z>;kD*fRraK6bvGv^Lk`%d?qKY+dB3v8#qkeuM=v>YOft7-+Wyd&|>5zT{+u*PZp(S4-AD)$)n$cyTLi+l=-h94u96`nSILNTgU^^+PK+suA|!CC|ANm= z-V#}lRj}pxHvtFj$f}G+Z9~)=WhzuG6579KN@u{5(46$k1Kq&dlZtrM|MO5z~Z3ggO%*~#93oKOKET0$NZ=&R%FIbL7oSAma^dl7(bdZ)CBaw;^4a)vu& z@a6iRy^m#?G%MZ3gP@2UmJ-4xwx$te+>O7eAeu6p zayKK|Xl#5-#c&@vFhxfPh)f8bMlhgxP%PzwW7}_Vy=uLUeCbGIVje6pYq)wD^2UoIs`qE^(07dKKI%bGjF1zdG2W(T?m;?94?{A_$+*PWcmNp0 z#VG6%ENoagJD7RhW&L$Te0hU6I2Uz9o6dc$J}=m=AP z0lQ@580RXNZ0nM(WRLSxz0Xy&zwuRbfeEU|R-*uYNqY3|@mp+$o6BlC7y| zs&FXp)>JW7_;#4Q>}MXiweg1emy%U#O&`=B)`C4bMQAG4o$+9FP~_DDK<>FM4MoGk z#JKyiW|x_WIaJfoOC^TwuN7IL2F@&z*w4DvE{KJ!?y$14{3KXG2KY7^Z;Sb~iaR}r z$NpHXr*qAhX&arPgkTE|Zpl)jxP>-SNM#wa@A8F)#OJff)`s zyj9}Wis#EFey{_oUb;Qf4i(chj!E*}UOhg)pFAk9h$||2!R7YPv4E37=`_56lgU}i zS;yXGJ}FAH6U2{`r~mxO@<9DP4U>&ImF`}+IDW|bqQ$!0wT&bAmW6e@d0?foscTY? z|GGIDWyDAH+NHE=w6L3|!s(|rQ92sf=6P;?xs{TMvhu4&jM%BkGR$_A^z4x#m~n(3ZU;QRFj78u}PTirI&dSST+tN$gKlRj7Vo=g)bAJoU@Q zG5zPKN4v23l~$Actf0VK$LsFF)AenWv}Wv2Z}|iDwr>~1h6(!I^E;AH8ZH)FDVcYg zEB{qTf>RAzKeACo5jWS#8JNx(#7QV;l`192mMZNZxYyw8-Wb&z2fNfeSk@u%c9^c2 zEWEsa8uZ!YE)*0^xg~)p`1d;nZyaiyIVniZi}7+;E|27BV`F#>Q~;!* zf*=PSZaG+?n1epzRY8=WTy6I`ihK5-As(}C&*I8>Uw{y^7mRy(y}DJ|hn(EXJyRpT zw5Z||VN!`~?q~VLSf{PCq@h0PB}f~VV|>}joFhu8sN#rrh%%+e5f9UgpRIc(+tdu6g3>A&#B-W`(}eW@b4i{aw9Pakx52)~t#} z$y+VjjaTqT%BfFb6J5=FFn8d=7`sSd>Qe;0wkwqR6AabDuh9TjoK)ea*cNh@&^+@_RV!e=;ShXW8pA*bld+iZPJ*xiFX{lHz>EA5Xb|E9X_*td_v>r1~RRX?&M|%##aiZmCl|FG;K`(s7%* zc%u&cx^JmB%lv60c^@Lix+U@nACtYYC_<7qWYmldcG9j+0C?gsl|%x*kFQEEi<{by ztC|EZN6v;EaZg(e)EfMnCg?}@Y=n#`$l&OQR2LLH>RU41{97QI=#iShx$Ki2^3|tv zH$HKv`M`YU*>CTq=c62I!KkzM0u5>I|14Ov_NSd3SnyD=J#)!Jl0dXhqh*Cu^un9w zV+OpO?nlSQ&@?0E*zg%!2c+eYpMra0E$ucl;Ko*dJ@~)yUaXc;GrQ*(>+jJ*Q7+Pc z7B%QZIE?x=f^sP|P=Xv!$wBB$T6AF`NExke`xE5!_Cu#n?GiQ{o3;1Of`Ox~1((r!(6$oek z(M5XX{`^PgvP40;uz>Cmf6efGi>evfL~4tXj3|PBIYZONAuG&k;3gISt5g{dNUZ*g z$>JjWTxwNOsPgVK1(T7g{?O$8#0!K8yeN$kjMbf9fqn6n7)67BcZpf5Gq&tv7Woq6 zFh-(yc>PVY*k-0OS_DUr^#}qV+c>jtF&7Tc{XlY}z7YGS-~+#oPn8+2NB$PH81|B#!xclB9atRX~9<%{kmN>=ZnI|e#?EIQ&WYM;Na3UjJi6>)|p z{fV~P-Tf0m0X$hqC?c!Bc0y+UT4!SR%57JX42U?L&l&o`mvcU6>xZ6NXdgBKunD?ydnLviB zww!`E!js0b?jQE+W_z0OIgE(U(*6l&V7MAeN7)6yR8bR#_$@(V*uBI9jM6DL97%KU z(R^d{>{`I&jeo7*qax{3ahJ+HCp0rViEe-bsxPU#J~4T+zUKK$J#YA*VBV{*k-rbL zytVz#+GLG6ooOn_UDgf1Ci&ymT+L;A3SHLQg5uRmiGW27IZFUbWhn+@g&7j)VU4`c zYeU$rT;cFONqFcl82)nV%kmhTpHs7_{m@Ouj8t-2Y9&6m|(7VlQ^HNsxxJD@mcmGaT6`D3ule0Kr)-D2mljG9O5g12Kp(Mwk zi1^%Ldp~J_5nEgI_1yO(R8Q*-B9OqVLv&jA1pxiXE_o;bmn(+{EMjejiREjuw9jXP z?$(O)qFL}T73USRke0$5zNAC*PhESa8ev@3DA^oPC2qa=XTUbJ%h@o-D6pGb%lcn9J zK~0RbiD-T+1F+g~DeO`3n>6S9OOO^%{QRe9exD7EH-AeQ+3jS+8C|RC{QTG!(7HOd za5#8XV1q-4aj5jlE{WN}X<5$?9OX!lf`P^NV_I7`81K080>$+cL z?kbpcNvz+2`8Vr}=Ac1dSS*Zm?!u)C$0yBh{aY{=+N23(ywsjCg(PqR)uP(k{r#+H z3wP&-uF(UCD0e6K?u$zUy49tyu23=M4hB{tP10~L43Nz|-1rItC;{Hk=9DH=qelEG zW!tnJAa~BrQYY_=-;gz#xq?U#JSR_kQ=Wy>#^^3DKR=yyL?)|^Y<6(sVyU20`Wv8jbJs(GfzxeE>+b0 zm$oaO32WHMJzEa^-&>n0!#)&^^VG73i@gz5wOnkDx|kNFgMfzXaLAb^1Y{8r5aJcA zFr}L2K8i%OQ!d4@Ia7TIk%Db^F$xp()MhP?(fRZKt2`Zd{JV&i9I z3UDxLU<@)6TlX>&J4zbahM;IqWIQXbj|qc{l7>hfhdJAhB4#5r?KRO_nEB~a%*iDf zAHUCL3r|;X7@@n;vL{i?suH!Yey+>f7EqthM`jO?i;T~!uaC91v6z~${T)Xo<)8YY@jpX{DBlbWm8>O8xJ$ z;=%f>GFOS$E302zRNORmes@z^7cb&;lr=Q<NzOiHp39l8Vb-+nwdZn_>t zV?DJiHd)yqT@q!%(3ug4-M^QA8)dB{Lr#aD_KzKO6i1i_@^w{1KibXwIVjcwx!9Om zQXJ0Z)tCDK71N!HqMf@>lf#i5L6wJqCMp z+{kt(m8AONzl?v}xjK7F#$$G%W5w`UYsGBu*$Ii|UwLEv#g?YFrmd_Vm06H-r-FR# z!(F-jS<#e#K`<$miXex^W|z`Ml0)@PREusZMsu_nHyDjnJ^CI7idq#V zjdnGAHyEt`hx@cWO3qR)5$aK}9qa7^BCFJ7H$(TQ21QYE{S|B>$^WOUBsukMeNd-2icLmE8pmVrQz7#Vbid{8-|7f&uqJDN6QY$U$@2+mY*W;FkemHAw6D~l8zCibQ$Vx#1 zWfsu9+RoCsP%PA0Wa)ooz(y^X@SZ7SMh@)A0yz)Q3ulT|9C^Mh%|lI~c@4Y^5M9TT~3VfbHB@W#J=h-71IV#^{IUyrh*9i_dN&;{YZwgbJM(Cu!F)R|u#LwVb^Gx* z!#07&mzGeA{p#O^`S4-}#YT*3Vq+y@CPJV)mXUX_+#@Uzut`uu)*|0HG;wySNNnH~ zWlQBj$4I$g#(O(F8!{bpfq_DmGSxZIB%(vf@^q6e4prMI6Y@Mtu1cjUlk-dcD=~$W zsRR}15?ZFxp}N(JwK~f$`XfbRBFbMnJa7YP1Cs+`nOXPTbJghUfcu3O1k9uRE4E|F@VWeAg){KA zu0C4CsqFi$lCoQlpZD|TcGhKz{F%h%ZzgG`g^TIuv;-yN-yFMTlhvXaQYTKac<5Qk zj-3^VD~|x;^M5!mPK#(DPlTkT%W8isvntbauhqC*gzy)xLQwZdzR=vdKBkcBTW0hV zUCjR?t-QCVAGcX>IRJvW2vZ7O&~}Pr#al3M{UI&8!)AXY&zBM#@og{<_riq0jkhrz z73kV@Qt_HeLL>TdEWo>X&S6?KY3Jn~jaRDgLVH>N6?f{E_zx8AlW?tk5`5T|%HkD! zhIBTi3$ZMC@SxAcU!A0M^rDr4c#s#t<$w7`uQ_0_-zoMbO+hv?_pOedMeS{9Xy$O~ z3Zh`al*dmLz;=_Mqh9M*gq()+7+>%=)9)g3>xsnVmyg;Mttl=_9UUlhqPTW%@m2ky!7=R`yV z=WMs$%hIyd5L87OL8bka_zrP2ogH}Q91GB6h){A;#cJaq$W>I>asGcq1$!OUg!5Q( zD8Ex+OIrnLT%Is6NkpdQ0h0toJ0x$IOu|^Z@Qs5=D`Y;A)V1v1p|tp|MzL2&A*p1; zsk+hR?Yv9{fDF&4LiD<+>ZLnb(6H10JnvkD`ljJ~|Hs+&zZ+XGeKDG>4~Oe@|6;B&~c|1}YQ@7Jcq8mWV7XC$$hUw=8R;_Y8K~qL=Se6@izW5azADQJdxPw!Pl( zsN(sg@9jhSercPp&!+58%cygP+JD&JG%X3%Q+>>BYtmk5u^7-ZoQz+TSphFZL$GV1 zH2|NK-LiM-A&z0+vk_MeOYjCRgN{)n3&BUwa)VrX_XSUMl-ON0B16@5jg*euAEj3A zSKLc;+n}DYIS4O6SHb{bdHt3_$A`pi0EeyL^(;U3&jf=;W9Ulf1C}#-4zdP#^#6QSvZAaiIM)zJc<9yrbF+$^+a_Z!Lj6%{!d4MJDaHs7^c>u6(xN zm1$DQ+Bk;f)sBopfp&96XaQdjeY(naP$0&1v;!{>2-b&%N71p(3u)I5bf&PeKW;cB z#PfS{zU$`YUDCZXAxN?ogJJ>qR!!)OTYCw9K$KgKOt$Hs0^)HpMj!W`hEQP$i#o-o zT^vMOkNQWJb>zmRO>@N{rOB<*Xu;qiM@FTUI$tg8@Z6Fgb#ZJ>Sc22=v3|O;v@H5e z)|Ko)XX4Pl0x=}s3QhtWnL`X4xjx(+1@A{EWtzB@{d?I3fRs0yheNOrVC29FS(e)^ zYr57dz7N{WQGlJsNq`-U1H^BKAABMZp*?=t$`+5=+jobpkUg}+*g^Tru3i5l{2R1s zMGwSXY3i_RZGdsyTuyw5%f(Q*-52{s@N@COry&sIu35Zx&K^%*jFDbR+J-bm^XCRd zU{J0tY<8>NOV^Fw)v>P22Nou(y$)ZgQ$?_p>RN-gwF&~iJ|Ez1p@j7KWLbv|cf^?W zD0x*x=8quCp2Q9I9Bgd6mFQXiwMy)6DbS9_~XRYe^OMzh$>9* z2pD#l9GOQthaH|$Cp&R>>qh>!A;Dw1?STC6+*SqTKVOJbu78a(k4_&rxc%EVn+0(H zN%P`cM*CTYlW!&r42c03^&7Z<>_pExz0qWa34Vd!q|TA~1%C5wsWGBBJ63Ou-Qa}Q z=MP2-AgF3Xf+=*46eDtjy>_g?Fl39V@n2HaBdbyEZPBFdbZ3)hdoqr1eNs(CKTm}; zyymYu?<(1+`}U_;d!_)Y0m~Ju{i+RZJ}GAN>tx2!p;{aB7Ebp&&tW1_3HP6Oxj7ne zV)C7wfuJhO-w*KU1aRcx?n-mtyQmG+$$4>^$`Ot;d<}4m5D2>vHMSUW6`7AzPn5AaR`?hT{ofStBH#9g)2%GK&6@0vU>JPxIo>hC1)Xp%-%ja zeN3ELEEI^XW2J5-Y6FV%{VKiSX#BvKxe*w25kW^ynx4@B8tTu1C&>!t{Sz>FfB4S99 z*H{}Z7g-$%5S4MoXEZyRZS}9s5O5;yDc!$^qdx{!Kg}kOVVn6CHvF6;h`(&ST>thwl}*`zr>EZ=A4_YM)5&RBE8EU6P#ty?*};M zVllF$jJ*av{2Kn?yd~8m9jQW0j|LwFj*ow$P+%y5MBUi71&ITo2XI0t95xbha*z0o zrGo6UXt8aXk}m^jL!yeR(p<2!j@@kYqnsD=MYG7E?~j3iEyxgS&jd>{-6+ za+P0MKM*G2Ugj5q$z`*rz|VG{3fz0z&6xYFT03yBS2SEq2pgvp6gv~RbM=w971d<7 z`?6z*vidpgz%D;N&u*tyg%G;8iKS>@tbzVXiNX>M98KQEf`9e{(-6nvGapk&qau7y zj}I&uX=Zv_e3zeQpVNfeA2ySgaK~Rq46n9~lc3>bHw1C;38tS4-5KbKMq1MtibY;v zy;gxyQyl!6R8xIuFoetWVG0HSORpFV3tv2aN#x&%C*o{FSBU8{rB(NsXKt7n%Pl5F z8GU8nf*y|n^mw_FE?=V7R6Xh~8b)*c-;Ev#`#rclYmwXQeT7q>musNgls@yiWpWYn z2}0)6SeZ}$qtwM^Q`!P(N~B0Z%+xqA65^&=-QjUCOo53I)1;vw^VFVqO5K+sGjJMz zq@{L0+1sE{VfzS5O9Hv)CrLFQVI4)TLXy>)BBV4uicia0o@*74Td1mFQdA33KF^?F z01#a@b`mY&wZ`QwgW{y*yHHp7A9?&rVS}O&!B3rUEJ5pSO@W5Ej}cx^3aLBRi-GdZ zgrI}y^8&7ajJyN{fo3!zxl~2}Ti_zG#p_^!qrD;Fk2xvR4UI0JR4%0<^CR=Cv;ckQ z_jSPhTVIp_<{y1b==rU_p#R9W%WvHmHB15R|EXc(HSGAscx}u11vGNz$qh!Wp|tye zxAy%(!4`l&Ba)9=VxZizAo!*|-IFt_&pY|~P>@Ux6iS*UTz+UYAAU;?^0C?7KZjTx z+`eS1Gu?5Cfs$nU+Y!;D0wDl7Ai^^4cRV}HJpkgcf1e(N97R?VwE6OEi5UGyYq#YH zhh_fwBQ2;bTeRj0u5uwLe=lL%RXHd)d;zpf|94_NBJYzifcv0H#|&RI9T=i64gD`9 zLmV-Osxc_=*s}#49LjEpTVhTOY9QD@e(xd)8!!5RC*Q=`^5RQ~BkCf8qmYo~TTkW6 zBjLnr_~x`Ks9|t>Cvt$acuoEHYB#12@2J`;mN8T_} zmA{1hG^e}%JGp_~t-;|!ofj>r%-5HeF6zII-~YFnUo?C(^XJR_xX07>=ly5l=j(vS zfHF!`ufIgJ*Hcxu>y}33sXi@wo8_8(nGd^9Q@c5`dFeu%8v&svd>u<;=fEgj_ZtWP zUZf769b?+;T8T2EQ3Fs*?ALEx0Ezo^iPY9Fp%4m}6x?zQ?fI4^B2hvyQ9~5ZE?!@p z*H;i8^c!Eg(con~@m^2=ZG?PU_CP=zGLh{3v0fb#2B^UGYCdg0!oF?aJBL!+i7ka4 ze<1G1Sq%Ar!#8fr$JzL^FtIY$9-If|tk54R`>)R_Ub(0TE|OP%L`Fv+{t|)}tD9aE z8dAK8BAUTi0M#cJuJ~%*0F?yjDnF2;kxa1LhZ+-6D^5btmr>Xu8yo>AJxxGQupWoa zg?~&%_LCUw1^>SPOwTwFLuWVMc&;4Wb!|)HEB_L6hLGY=dlb|n`)gJo@~)#E7gWi! zyBiJwIqEhd8cU0|p%&XRrXvhB#HhcoMwDX*N+GHx4FL-4Xc00_q}c73i3+M-9Y$)e zk(eK*X@pM`6Z>?-fluicX8~lflywOf-a*c}tTi&N_!LDgz;6(X5d!CqkcUViEh_vD zzKb21rimdh5R!tA34AM>WfY?V z(oTa&^2~G4NjiIuxrJyd-dY6MSpCx#1L8G8QNO)zfe9^SGUPm%_D#rS&Ux@(RF^W{ zI)NGHBfBotKUsTt_A}7bCy)WK?gz=~Q19L=#tD7~SAY9dZ_99Ser`CocW`b-)ZKYo1_8dub#|Q6cc%TnpEywQ7r&%^@(m)(*@sVu zy)5?Q2$m58tJM0c+I-y6G`NVbj)zN30U?CWx~*gUf7^M`)&ztI*cYs&(X74e$%mHl zxIQGBV>|V4gSa(o?>O^nh^6&iqItE!U36v%+sOH)-e^meR=J{*>EO_@`A4^>fCG_k ze0lWgpuboDdSI9*RDflAULvD2I68?dVqvTuI-+PPyIZ}loF7duE!-il_lmUICPDh& z!=hLoFl1EkDCb26Hw8&m*@hm>#FzE%ev&e#&jfK^%+x4f$nfv=xqz*PIo)+vXQ^PV zcl|r*fJ$K0V#HimZ;Kny^Ol|W2GKoeGaQx!u26Pom0Onz)3IIcZ7 zbP?fLOm0`Kt}`K3byvBr)8$a<*YI|2@qD+vu>Lcz?$)_|mPi{JUEA-$I-N|x?bz36 zPg}_et?CJ}+0q-r0i)SlHJlD&MD*ji;@q!aoydNwJ@268oF@yg&c8ldMp%fLkD?vIs4!u$=aTydeb z>6)Z;7eM{uwP+1Q4|)4~a|pxl=_*COAq=}0A>_dijtOTas67kUwe8c4Z+t>vwdd4P zo_8#ZE`85(&oZpQ59iawt)sHNTFRF-a{_vwZbp)cq+Tvm>dKtJ1~mR931rgXi9fiQ z&f^hgeXA32q+kh?7NL>eHN4i5hix>J3|Sl3?C9i3{jj6l(dojtFz7W-j*C_-k^X~M zC3fD-7$qB3*Ld>BTz7wGFu&Q${p3;AF*H9IV20$GVWvFhen9^Ko#v07-1YaJN;((C z>jQl9uu*>vUuB0o+WieNo%s1{<%rfYfC>>9sH9(0Sp__gZQNa~KR)*M53UBaG-~6x zv}MNao8BfRe!S(^e-}04qS%*sJ}4>l75Vls8-WT>Qm>od*7 z+S{#kVwgRN!-L11d~cu6Ju>c#NnGknUb7{*x<_YGCaNJlb2i_eKAhF3KIw$CM}du^ zUI0y21-(tBf^FCO$OOqmENkMx5y`=ow3;u8^MEVH)`oO0&b$Jt{w@6KK`v5WXTNvx zo+?E?n%^gHcOi3rRzml4hL24ae>+ANIu!kOBtQe%3>wG{X_uKE!JMy%_@$;vB6Q`u z9Am>S{I~6Ynir0d6J1Ii)hLp&Ak0{~*c!%@vXM&y@8lr^br&&@za2_sp~*ghpagjx zNRqG;#w!EgIe1z1|2HKer8T*Y_5QFBrOH4oGBF?s|U>(eL0@;VIiC z2xkn5<*oX!b%Uk?DzbEmiff2!$GyqfbsvM`dSKX{bvz8UG7(hZf0+ejfG2kK2W@=E zoU?z4whS;?c3q-v2fmjqTLEzuowxrNSAn?RyQWIU=Ji7d|J=*#r@8y5Zwr}`!1C&N zE-j$cN&C{abP3yHV4K5Ht?BEAU^;vKri9zbHYf4}QY{E!bv53Zd;DpS$qq-*M;xLAvkkbXwu#dNPrz|PY>W-YYUaq_v zD-yARjFaq=H z1L%Wjke2tC>|IF%+0AL_B6@7pvRO)B@!{6kYv78C10%(SKPEQ0@&Le~XiOvq@{Ha_ zd2?1RW{4d*WHcws(dR|*^XOo6q6!i7$yT<}jj9-$2dMMdQ-j~%yL|JZnj(F~-)Wn4 zwv}}G%16DU%x3-=sGt%)iC?&4IRljG&MV2@TB0V;Uo(8K$CrmJ-lsf27n}pOC29b` zw7acZBjz%%rAqi+`5;9e>Z1qn{x4ll=!5=^a*Xt|mg*ecj+T@OiG`{Zw0(LZ4C!h! zFAHcj)&==l>Q?Ji+BL;s@DY=mHC6vD&hC>FevFf|%8ZbI173Mu(3VA(H3P?+`VjKD z(P|E+Cy0Ois0q3A-yu8j;(qeeAb<=YNlM!NFgge<8&0CX2tB0VP%CLd^~Hvt*670L z&qD-2c2vLX3-?t$=d531tS%O+ftTafw}#=Q^I+0Pz1A>iG9l*lpRYf&ocwOt9Am|D zf5upLpuB)=(UV7ItR(g^#%oAo+yoq7e(tZo_?Z7T-!tK!X{ym;pE4k)23j@8g(e^@ z2yc_zgV}JzoF*I7enA8cyS4NDKR&sRs$(_ZGWoVr@2`@r03OL*_Lfj!nh)v4aXhVy z{Ca)ryw&GLAh%htaO_KW{`FozS*rQKhu;wYEMQ}ucJr{2!CjF2V7l)i53?<&B*x8vI z#RaTYST%`+XPhPm0}=ged#?sp37XRKOeDyVg;J2^q`I0H`Q`Qw74wqi%&d1L$ixx| zi9Yvum@*{1niKQ8w()fja0y_Y8r#0rX!e;;UvlzGc%(;4bSpVhS5AV(M@Ij{_?^uL zB9)E&P7Q<(6iJF#Y>!iESV#{988hkNM!2B(=|o(0v+lf?;td>SgUu*{S&$A{N+8OR zt$xKFKb?h;Y$EX*`SA`)EFA%aDIxXl+pk(&*8##IAEN>epzrxI6>x*!Bu>u{__Qmu zAo_v{_dxu3QO*=I&UMT>;dyoJ2k@O zBvm@$Euwc_k1&}LyYm_oSQPVq@eCYNvI}N^2rj%5+IHk+%+o%m+&HTucGfnyV|w`* zKSUy-aBm+_^8K#6u>J;=CbP+l1@2d|(_R9yR%%yEa(<$tSL2z3i$Q#DE|;?_RZ4@s zi*H&k16{>YDRO~IQSXtPGXdu&d2fD(HmlMP6=>Y{qm;h0>0%Mo80qxLyi*}ATVcjc zt(0H_Xwj!vZ@;$hP_DJ;u<4w{$MlJ{IW*?kbbmq?Do3MA@tao+{fjl(eg9I1?fh`R zgEC>Vulhn$so&Oa+Ow#S4nEG@pYF=ld%NA;2mOpU(cey)mL?}2ompwJerQ%Z zzd0;$pxOtdclLLg%n3p*O8^(@-ZOB%Xma*SqZN^CIhhFuJH4=rqlZNJ<;3v9ZD1!e z8j6rLE-{;FLks(BU+63A`D#n?F?qPCO~Sqr3S5^@>sHF&fCTUxh8-YtioVI%Aq>JF zl#&knB=FqWWsl4n50>(if6UXG=?^1SJrrrjhoDb;{T(8fK0!FY1Iez!!obcTNv+n~ zM;w_eAEF_MD)tp&Ng4UAB5y=P8cky;<*6sri#Q3Jgh_EnGehMvefl0&8{!Sn>lfea zR|M^{cvMSr?+XwSHA_*25!)t2bsV)Or{po(#u~Mq={rUtKj^LgM=iBvs&`Pitb0uB zY;h}g9~%NisoSD^2>J031{Uz?#w?D7H9krL?@h`lKa)$xDX}3? z2cf4j?T$Tv*j$NQM(wJxgef1{III0?MIF3Nc%aD;5@#C$z0vDMGI6Z04*y0ZfI#At z9~>#9gcB?N@B2#+Y$oo+&u%?xT7Md1(D(oO&%u)&VFq8l2Vgz$xV)2u+~_#b3k~s` zNc=(m#YCh^$%~h#Z^*jpP!RtzEv{6=fK>cSt_b`s{bMPKW5f0hC4V`dTsifV+o3d$ zQoL9Z6D=Y%=911^Uf2rl1}n8{9hH-~h5y)!JHS?C8nx~VP~{$12M($lr`Fsxagap^ zCenm-gt=7Pz_2E@?g)VW=YfA$KqRq`z&d)odi6Zis2=rpR!%p);Bkesyxq_?qtndCrv zE8|-7xF{q04@*_&NU{o}8ER`PE}7;+?o3gC3bV{Pa0v%yaGeO4&y;9-N>;Zev+X<} z@1Axtx29C94H2EmsP@vh=%j@oNFkB&k-&jSN8Jo1vV9Q!bGT?FJGsV5IAQ91Y$otS z5w~u3=)}=!rz~mNv3>02s$kGqV+EUytRy*7v?OF8R1z{x9EqiI9@e)iD`}wNM0ojj z4~c0bKiG}>f7A&bHTHqHBtV_1xi>NgTz{a?l$#YVCw5~`L}UWNKh8u!X2`~5q|VnL z{t#`e6p=*jE*a?3Hqq{V`@C#@FX2q0C|LJgp{vdeY5+6i-!t$60en<8ZYI+At6&o> z=5-je|9Zmz_F(7#?ZM8}?cW5ZZM1^)(L|AJ@8EOyH+07e%_bs3z!S|T3PM6QV7U32 z`~-X!7_d$i+BBp`6}@;Do(k;pRz)AT4ohkw!N#va^Fn+D+7n6|G@-A)k+}(MbBxwl z8pH5^>tWw266zp9gAx$lpZM}n>p2yB>ajK0O|iX(cvXMQeFB}zR*wsC$JogIE(^XE zFdgE0th`&=7W85L=&|BUUNyiGFtm3bJU#L6e@81_FZ+$_`McN1VZOO% zHp!hUQJamLLgUP?zFG>O?amq>@+w)UU?ziF41PsM6eEA>Sf2q~wd{Qpx2($Sj6Ec4 zBwZ1%lpEQsAdvRQziL~YpeNLjA*MR684s8*FIrEgKec2{d#c5e#QcgInm$NU9gMG7 zK1#IV4%b6gywAl)?b>f3p9U^1|9&a+@Nz4n4wh&bJ%P3?Cf%5_Ycm+hZWEs$ov{Cx z)u7UlsLFnuDI_G9Y4l+C>vz$9q_-`!$bqZ?EBds>UM+0_}k@q_Em%ugNjvrbma@!SV*f`AkG1bP~( z=_@by&%|7>B9=g0A?AN8ks$Qb0Hvu3Dtn4|1X5TM95|y9+p+P(|z~1MXv_l zJl}TyIy~sZ$(^2aRf|3*WNvgxW}<&jda@COi27MAp|?kDnsgA6tgL{R$El5vmr{Iq zP9&)4)4F?U&ZLOJA@s)p9O}4?e-BpYzqs+L+lN)e=D{|$^IqILdt;zl|7nA}%b-|5 zsb+RAA@b18I#ATXHOB?j_>rbDgdN=rf2U-uU zKvJ)EEnC^c@5-CKuM5K!nEJoI*smUJIxm+>8_E)ey?z74wccreMS7PZ@VP8Doklcw~O37y}Z&I&#?vz`;6z^gnULCt%o)FrmLb%jRYU9 zgJ|R?rY87_UJYq=sjR z*LPIkzo8-g5TgR;lVq|MjtcAX2jhS({$E&hIVMNGok{%^<%bf->{Fp{*3w;21G z5bKP|R&Bs`>_&j)7+V0!*jQ4T_J6mwONAyOL-l zHm9^8_9N|qJO&bf9l&*=T#(Yw#-0(eH+Gq>L>Vj^7_xeo&}X@E+i5Qy{4T@4zS4naKGIC&#k)BNo)y^cFVv$Rle(4i8r!BRIOAv4VeO^MzQ(S6PDMe(C3A-Y zyVl%3P=@2t=6hk5lBc`Z26~tdPeweA+aRAf()&9OF=0fT#O1`{D|otAOr3wg#2w;#X0gy|#nCXwZE_TLg%vf)EVpuT`IjGkR)ghO?kk7*cfYKoQYDOR z76+RsD=yGBDX*W_u4tvM$j;mCCK&%YQUkWMIa$Avx9z(h6Jm*MrZ% zX_0)B&a;Q+CaDqRAB+g&V_}=Wt!h6@-11J@`gaLcT)?YjXBp1V3C&W13Ind~1DXY_ zu6M2{0IaN;DN7w4!omInKR9p>LPY-b=3As#H@1CIsiQ*g_22(CuH*U5dhQV^*5Ahc zbGl|2E3OpBWj;eb;bk#{TI$Yq;&AJ!Tt_#1+Rwg%+_fFQ5!G82t8W#(@<~HgBHyRE zA9`DC2@vRO2IcOFC?(wc55*`nObP4$f`-BJURF*v?sTM_Z<@FwFtEoOHwL0L{G|k# zQY!*AH4vb!>tDEWB(c|Owq=NVLQHZWB;-E-lBc0km{xFU9VzvpcurRwE}AiPD8hgz zvJ$y#L)}T%MP$y8bAw_AWA`4bdEkhzj=drA{EbavR!Lo=O0@E`W9mA_^m#*uCXs@= zXNk=w_B@w%{N*vlWwt1is)`hA(8kxuqoqK6FdZb>q6I82Xf zyCf1s+0WN(GlfsnyF*9`Z1PE!$)VO2Rs3LLGhs6jux{?Ar2M+FspX|(_tckEa!ji# zl}vuH`wV0Ynnk6d#B7yc$%d zNo|E(5jRTJ&Z6NrshJc^pcvqj7-Z3Y**KtNX-6z!2dl~WphO;rPlgNO-BFWAPKxu9&UWOfr_n?VZm87_ok%Za3sIH@{EB#LE@stX;WIV z`bW)F7Z<;~)2F93voCXln_&y#^0H*71U0SMNl0`_89xM6Rx0L+Cq+a5F)9I6sMYT$ z3uwX(T}$42&uB(`H zGE8;(gEx;iUTtpX&Aek9>AvHgSXce-SFRnKjeB?{pZnr(Ve6oEQNII+J92gBiMF=F z?jNycVQ@sN;8Lgbd01{uJ~`!(ieZeO=Ww{C4QWEtT$m~|R3N{QgMUFo)|Z}x4lRS} z)HWwHvtRs4?OIlPkOeWaOx^TLbR^G5l;P=!XjvsNO{H(`E*&U|q%+Ie3I z;g<78Pq6(vignnDcS>G!O^-OT?oh$r5)@etGP8(ST>XpK_6t^xEIZ1)V-|UkeRrb# z1AYdwCn2KEHs7<;YvjORjUN`3Et|v1*;BrKiz#&<_vXw4BO+?&B%Vet`N~${mfDB& z?o(f<`I$UDba^>>y^34zsP-}8W@ISB&$POhLiM^>s4%#+K43kK@V(R|qi-3_8$y_E zy$MMvG~rj<#;nahy0T@}rB0Y@OIE)C*9v(tHe4TPL1U@pEnUr|9Df+sD&R zar=JtAqO;FTJhsm^Rx3yyhiYf^jI-Ekmp9VEVu07yM)Tcl{p@=g6rTDTrW%pWg%}x zxo$i82dzfA%?R4)10~7&aHFQMY4`k?+-yP4#i*TA?_tCGWw>|z47D^02$kM6y?as9Ox1w zd4Fnss`1rJ-ymbbpM3U*`J-+6@BQ@4TA+a|iosWJbo|m$XYz(NyL>;CsyNv~{(B_7 zfzs-Js$N7XPa;?duZphd)G<=?S=C)R+Ltd2Ss#qj11Vo4?tNIKDQwnD4c7sbl&fTU<-+s zvQy7yc%{VWX=0PPTMBieyL+O;?qRlf;k##XMalW$;xwmjPhHmN{4UzCJyo&acz-Q? zpHQXw!_uO;oND8;cjnO$Cn9l0?taH9*RjrwTzOT^9c-x)e$mvx^Spy0cbzJNzry{B z`gzlfd*vauUKE=tt!K)-XOdT5qrOF=V6U5%VImkxS{&F{XRyfDKbl(>F4GUB$CGE# z{Be#+wW=H`#`bP92dRtDnqZrzd&bC;Atvh z$DVT^%EP|fm2fWn2DQPy_O&>!l*`FAQ^1T}gmbu!CPj#17?aVai84J_SRMzvh?IN+t2UsW`hOG zA=|xf1y7C+OZ<(BZq6AjNLHbw5Jc@ds}3s>N# zg4R7XZ?~xGMoc*xTCPviz-@7%H(?_DLLG=eU9rSwTZlPYFja0-bgsd5Zrx zYtKDKZjSh@#yt4Mu{5@EumytF75L_L1s(c7(V2QrTkA*^m>4~VsldI76)*4pb37&z zJM2KeeM{gaVt&!y&$CfM*VRDjp!*P50)tH7sYFn>T)wmJvlIQ+>33s>LWb+lF@oj| zw^!;|KXUhl8pj(F{Y8}qZkJP+{`&FLH#Sm3}08*b;*HWu^U*W)HOe~q0G6p(d+W*43 zoB9~_p3O3{~G~O{G6^yGQfq|J6*NQFAnAD}EMGalT2N zktlQdk(bKKm5+^OU~@P0VZG9V(WV4lPy5+K5J_TuxsuJMPKq4&oj#=GwZjiqlS`Pu zkoq7Ev44SxVmgyr#wOeEdnr`*!ZV7-NuUmH32mZ;(4rfbTZF|I!|A&p9S`t3LV{%7GE!$x+z+t+{Wj)QC8pUKZW(bWGawUFC)X*#MiR8Tg>3S<)pdnU;} zFR&V0ai>q|vix$Dt(BX!?tvlKrq|tDS3xi31o`+cR`Vyf-{z9R4%(TcpGQo8aUCg$ zw`uZx;zlJs($12_?#rK(UueszaCKqqe_M-qO9@GMYEfNt`k`Z9`;GLS#cRGcs+{xf zlxEVCOv%n<-}pn%nM;x#YpEWhOSFm3GO3t*13r!ll2m&&ot2NT3|QKvc2ml67N&1> zVj^dI>r$QewUZ0hw|Jg*{XKjxXGKbJ-sFo4+g=vxs|czTf5&K#4$XWDW&p-ihNJa! zAn{eTR|3p*(ukih&AKUTz-HAVLRs7xO~A)5ruY$Wv<31mgpNrQ+z7)mWvXqE?w00Y zIi}`*SYu)b1g7L5uTw|DMU}HbB8>luBx>|f=b2EpVTp^>HweQDQWl;qadl6J2a_0#8H#SN?7D*^LnY;)G zI(G^9+|re;nJBat#l$2oKOeGleF}rZKq+GbruX%S_sWaa8nL1NI?1e>(ns9S*(_Qs z3rI-1B4U)%ABJ=`x%TWXN!7f797Ob`q=#d|PYXfo2JVc~N!KQTvADeo<($T5E zb&3(^wmD8PdRqDxCRO9M)vDO7p4tLCWb%&;9%qwf-;$ zck^@lwwVjG8yapEdiPHPW-udy?HNBqT&rMAdz^pmQ9N_ zb5Hb06Ns(q^ zjJ+hyFx)l=;qyU5W-}V8`KP_piY0`}iaxEshgXjxo#AUh2-VvNJgyBZ-12SJunNN# zDIdw0iEq_^J|C{}qyzC9XDiQ_0Ry|fM()P$M@~`odjhU9&){%EZV3%zciRsJ!U9{SL`u-ToOEcw&$dw7K?QU+!g7i*rm zE;(0l3ym^`$g;AM$jYO;OEGr5;aa4(bO04}1=Cs|iwbE;`?MXW?Y1hEV+*iy%O236 znutK*V2|WA95YY}$SU>9V3~<&&SH7WATx@*(ZM8el<#zqWc9$rKe&jQEZ_rggn7O1 z@F{MJE2g6OFH~#Sp-R=%#v)xjx>%2Bb#Sf}I&LsNpFNeelBOeTz*i!TFJIHr9gQFM zrHY0%S0h|##(@l~P0ctl>(Ptby)}=GXk>3dvL5ky#&c$FxgBu1Ta=@=w+ ztYWdk(I1l$@r*i!2&B?oikB4$W*3&fNqd3~dFLuV(vaHo3YJ>!<{ylE6nj31bcppt z|5yV9loSF6h;L3#gL0Ac#IYvgIj7~LL(F>Lr2DhHROTl#POOT(9x~qhM7^5je9Z=F zH6P0W)1*?{D6{nG)!wOW#dk6$z4=Zc6h$cv7(cI_%H9ibA` zeq8e+ukqR7Rl-4}hxJ4XF87>sCLk3l`*iAHNAWZ6)MN8fIj1Aldm)pfm7R_rYtuwp z3}wSaN%hs5iFAwsd6D{~MdPoXMZ2XV>Zj?58J-p2Mt)sh4RzZwwb-HY!TgVZZZEr5 zF)fVc(om7o%dZ06s)U`Ks@5P6Rf{5XdLgy_sPwk6Saz?!knT05AyccP*2bC!4q$9* zVNUeQ!JZQBTZ$feiIUEY-1L3L=tC+k*TS4RZIwIB;FOaLN>$B=2})Jp3Jy$-ry=;X ztI@5!gW=S+_){=|xxxQ}(&?I_=r|%^CP%9~!e%BwE6v-&Xb0Ncmn{ZItnGYZ6|>h| zZWpzMrj*e%agt~(X_Qo0VV@W8N~=dC>GM0G-{AWc&~Wt&=s<>M5;ogK9T1BBTrf$r z(nOvgP~u?p>M{U^iJKv3a1go_ygEzG=5SzDSw*>6l6y)kZXm4qyqDEYX)caG*1N`>2z>V*S$-O*DG27qn=2t%7Ub zPRZnHi7Y+*eSas5gC!e|AjQnbhY4|YF&D=!H06HeA3wDa>{h-f7d+d)_|S4Wsunv! zxhlK<)nq%mo2pCHnamR*IJem!T{fk&x8q2ZW@bTv{;NypkmxGmoPz~Kd$k|K;(j4N zDlwD>r7~#!rwn<=2aS2`>;mdM>3{e|sur&lC0FNiYiQ{aL(N);@Z)TgJC+IRkP?}# zb@xua^hW!y?}SP7yzsK_ za+m5MCu+VvMQgzE{op!KrMDV!M)M%XmIem32ao$Q!u$@A}lo>0dq8%Erfh}SUN)D5J-Ddw^? zNcj7qh$Kb4SM)uri?tM;(}?rV9SQmiEzot$43dbI8z*`QRwFMY-w<1 z`*S?;9L~E>>1hnY*e3rn%yonoWn%ULpYp2> z4gE?C?iOJid||UM$OA(EkEyqgit7F1g-K~a8bm@tN?KB+4NyW_y1S%n0BH~ek&*@p zVd%~Qr5ovx?rvsa7`PAL-@D#>|8(J+C->f;*yo(EkVYRJ)6v`3d<^ZhastD#5ze^X z-h%?fUOcE~|`O=1QZ?}?e_nI&O{$rjkjO$C@g!B6RZ9e-b$G=@g$sujQCzHCxEBCMH= z;U{6lW1|83#@|$|*srPe&|k;<&{KEfM%fc!r8(=fa{NZDc0#_$KbDvKt!-!+mw*{q z@ezWjAXtScE#v(rX3*7}_otIS%lIWPwJEuwv9pLA-$xbWz(5Pr%G#Z^WaB7#vVqwb z>w^Y-%z?{%J+X|TaeFFCHK9{a6?-?KVm~hTFctb9u*^*oPcKD}2x@rlRA}eM0m_+Y z2APo8y#Kb>LW7lUf}KTpuBi#(0C%cuYHihp)HN-fHz}gdHxByOA=eCLCfDnowTFi! zx6x1rclfQF3v$=S2gRPDmS(Xa*^#+tXaKoh9&G*E+WwxzEj!G)=Cw0t`*Ar*5y+`puqybm~zHd7?kll z`|Iar&XOOSUlc3B_Ms^ZE(}}UN&Gw)zr<&t3l$};pt3=*6F84%3#OCq56*PmB(J(Y z^l7*sxr=h6^KayQNg&~F)m`l(Wr@)S_hsQ^gNq;icz~FlWTexKvEhI}E}MNOIVwl) zd(Oi7QIrvpl2DwbUcfV1RtKMBE%2;7`PF#Vw<bo7IEKG7w-$&kMELbp}fiT{zGcEh_K{xajpaXh6q z=ftzy>WPaf|1r4>kSLrl2+5g7+bU&Nk4ZXBr9}yv@d_gz|5~hX@vm?BXis12?^VBs zeP9~NN03LdE9JvTkCXcS_a5^%@C`hI5DJ!OY>0`$_H&edit9eUhU@0*Tw7fiqqJQ+ zi-LCYl;D?Ff-_`)ytdi4M=`{i^~J=$xMr!CNNih(qBaecKMCTsOdOu*O?z^Yk#&S* z{K}@N{WR%jH&wPw!eS&%LC`G9juAMUeS6y8-3s$+xY|x7E?any77I1{pi@>d)-6dM ztf!&C&=COYk~q$vNDN9(7JjMe()X`C{ILGiCg2`dP;k41wU9UD+TqKjd=2C+>5?VM zZ?BTV?PJ{ta!TBne7XK2i9Z?^l9Bxe_NuMI9tJWd1bgDyk$dh4PSHpHk#3EuGjbPh zwr%}_6+_~9h+ae=7Lq^AVQB{K;`6(2zhUlzoQ(ueE^4^m9(6rr1@D7pF21(Y^)V3Z zgH_`b&m`R+Heq1%NgjrMbicjyDD%^U{98aZdi!{J`1}21VS$l6IZK&$0>g9IxUZbP5kF&-#On-Es+M@b_%+zLdQ#J2Z4yxIS7&CXuPX-|R)Y z|DmWAc`!NTI*MZ+EIg1F%c=G0-vPUt><|6?kxMl0z^fucZlPks2S2YU{#H|G-~M8O zSWtx_5k3%)R`{Gjmtno+0XO`Gi9svLiFSykOSZ@pDyAH?i6`Cv^wNJrX_kFh*AGsT zhW{!0rDtxP(Rs1u*zqhrn*0e*cs9qx5Yw2K@eOl0N-e$4j&IQ^JnMcMXN;KZXHpjl zlB=8B=4<0~l(6IC4FkPhVB!0U2Nt^`ivleVd-gIs2>F@Aow+==?q$fQ*dBexW)POT z7B7m9RF<2Y{S31+u%rzbWA^?x!|hWf{DdlxmJKDP-cJ;!-v2&czUGge&twboXntqx zB11Ru*1f^fB33WAlH=&6f0-mtPrd~YS0QIdQ6Dj5is&UDx~w@|sZMa5^CqNSh3;a# z5i70l_*B!o^&V||#5C;fRC$106#iQ|wF1eTbB-6bClU_VW3l(+9T`X0LuE(JpY}29 z8`si}a-9v(IpsrI{W?pRiNe^n6?UXXu-^@Cj%GXF)?UR3|NC+lY=1}-d0%dyU9ir!#lFdUb;xl4 zLv7yh6)JUbm%$K{ETtz_yV$#vG}mrpJy7KhX_t85sKX-W^WOD@!?vl$T{WUm>tnu| zDMQB+j|Jnoi*#u*0m1);a(7B3KXGJD*qnITnx&!WN7BvO+9!jqBgA zOyd6|g8vxj;&H>}{w5+u;*rlF;jWv!unj-WLU*z#+uSBM<-FupIjt%!vlK zQc)QlNqn-$NTj`yI>e{uenkGY}w#yrqf)SL#qGxZ>@&|o!_)h&*! z`JLt7?ny8S#PQa6Jsm zN3fHcQ3S__=nG%RFKXH6Zkq{5$A>2a_7k@_6*ztLC*?_Me%~VQhB5*}-FA%8umr+4 z=P!rl_qfgi2o0YWe;<{<_}K{r4+Hs6*ti@fQ>mNsJ{QRsYh$HV437(WW7n=tOFO_kBkiyHp-W^H-%_MiU0G6Tad!*f`4+ds`b z#*6@!z>-Jq$K2u<;(id9;}H+16zvVn273Qmxx}fX~e{uNJ60_{xGeawDsgSvw zhqcF!_h-tIZ+yMnE*FuqoBqh7mDF9sQtm^EGQXWEwpB-m#TJDv$JWb!*N_8M<$H-f#KL@Y9VuCBwNw#suac0hKgRuvIyIaP zFJ-UT`nvxCRQ4%OUGBHwK6C@6gJ$rRL)=VP_x31$vxJI!sJ~iVA|^@7YC0FGsx^p+>&W=k#QV0lGWf96fCL&%iw zZE?dLmS9W?%b5#N#IwA0nc=@`%qPeOkjr!uFyNF(Gpj6RxzAC7g&E*8Pt7R0dK2z$i?vaQ|lqwp|y;};GW$)$pYF`)B_Hxcf zr*C$_79NR)aIeC|2hIGlF)U8$nNB^;{IT`&IClA7BNjC){?5Mt{eCglZ;fI*?Xt&j z&N(Xgg-F8+#LIe@R*JDG=&H2w?5^KyT3E=JJ10&^{#M|7)x(|Ea?K>&6Oxf$Ky60w z9YE(;mKqMQDNJBfaC_|)0`YqHh54m>{`c#_zFj5q8>q)H2Q3>FRyTy5MgoCKlzvKI6T1J!(zG0ANU!{D16iGP16#gds{ovhom(#VU~ zcs%%ls%1vKnL!D;dE6fEv`;v|&Cl5-@`&ps;bm*k{#}IDi2p^*!NI$0bJ#B2Ia2v} zaKB)Fe`;ichd3$oBIx$Q_4CpDy|>5$}_ zGRbS%B=>v-2LgH7*m{DU3=-*ZhvzTNJUl)%&Fu?kUEPMBd2FUfOgS~4@2Ul>8;)Q;Y>$|I_P0-9hKU{thc2dU0-@cSvs=+g#L(gHWx5( zq7Z5T)y58uPTJ|6h|sgHZ$C}wW~wJ;s3~q=Cso1jM`u$mb{ZaXd;fCNaLV;!qm!;_ zdnOXN^7XyQhI#Mj)ikkC|Fl*w3f34$iDuEWcKU(grqjU-8)Ww*q|f!fbIg!24%^=! zrB!JSUgB~y+N$}OffmD00GV3U*GE-&yZN{r+vZ~7q*Qg&Ju$Lb?$mj~IiC%`FZ(`U z)smr;L;zG}!;I&AV0tD(&(^;El%b!gRcaSAj@Iz6rRbnr=tNGu)0G|gE*_tpHDW}` zCvE)pDc@=38i~t7DaT8`VaWxDvcu8~+Z>N}O$+Td)KzsFV@Tzb0N?u}CJNfB$WNYinI)6i4CD%KCz4wz^rBc>QWm5erYbi0yPMb9M zHH&nSJ=2@pEzZ}it8QgegV)Q&4?Z;To=7IbI@9wclKc$a97QEK$!(vVH*3M{) z9XT=Q$$=dF%2Vdw;B)doeC~N)pUg*m ze2+?6`p?WRwDj4TVHxXKZ=^Gb4~GxkwE&}S^0zBH91gp2*i4_XyWJ|A`l58}bc(Dt zs2*SC-}`NzE_D4m7-XKFI58&I2~zI|xLo#5xydq2b8fIhS9Y<(z?UVgs2jd5R~MOX zKK?sg%VcCGCi1i7K@Tr6P6?U(;2^T&I5=3(Oipc%dQbh|c)xn2skC>c&qL9)|tx-Mp#5DB#5A-K+(2@hK*IcPjfuARdFl!5f1e?xvfn%#M1YU>mq zbwqHSgGW=GvuFCnmYh{-18D35SbLbAt~7hL+6F&guL~A^is-ocI0XH4&0x;(E4#w+r8Lsa+)MaT}nr za5sI}FZSXN^%J6B71dRt(`;lrs$>78P2xWrt{nU~wd_v{;S#Dwm$%3!wzvBJ1?EbR z==w5KH*$JH?qrh!iL5NkJ;Mfjgv_w?c-T47Ds@ruic9=IZcc-7p>b%9$vMQR=Re}weyQjeX35ig>^fbsu=@E{~37Gk0pJv-s8<5 zjC2URjEuinbE7l{j)!$nf1hcCbHAnC{rS!R>5H5$URzGj(W^t~1DBD-F8WS;3j_dM zSI5~<05Hb$=P>TjZ#Zwz^^qH5eF4PRi3#{D9vWx#;Mgj3l}RRS)m)QcrXDR#bD7 z;*xFQrjb#6QlFT+gb>|h1cv3%DgjpBQAnxlJ=k+KPLmg0k6~i-G=2}c2FU~Vg4kN> zv!7!1ju50NrWkB-Jof&K@H(TV2-wPxgpt1XVy$ePAh}AjhdV~r#v8C6#~WC0zW8pi z%^YB`#M+ak1-MMhN`lu`-Q&HoA*^OfZ^F=M^qL2s7JmP>6_H!kP%T6cj61@h62mcg z|1mV0weFyL(!DH#_sGPCt5_ws2fp7iqU5aK&^CkS`5B74JW)O=6Jx{WYRX{X^Q1|} zbI=y!%L;q*XrSBE=23aH<~HS6^fK2_21D4b6Re>j0>|&t*Z=0AT^RZ$b$55Z6XnIa za=y(oeASOcFV?Od9B+)vD=i?2c@OJ3hfg-e$B`nLq{tw_e| zv!boPrXXpo7(IypBxLI`w$7fUR*uG=q=dnS;}=NSmnZOE@h^Sp&D$0|?lVFuXOop!Vk1* znV7aC%58PrN4jaebUA38>`G|Ty)!iRJ)%n{_z#MYj2|hFdRCOF=Ytrud|Hs5!5z6G=JeeMfWtoXHrZ zmo*T;s@2R7cXIR3##!!t)?bl7;}m`Z&4r=qm!;upn@3i4lMi4O6L2744+Vnw@>Ps% zFuEqlgTIp5{+>aL`fNiKUJ*)x?XCVHYmQ@O)@IkPS6Bh4Sx4_~ZS(thU$3xtIpd=- zc7e0+0%!l3&&bLjdA!QkZsX#GavFBfyx4b!qefb|lNlc&6;C|FRiU}h(Xb#>aDf}A zRwVMm+r!OG^mECTzVLG`V#cVCFRT+5Z;dD6qP?xeCgq*?^ZKnGdJ3WGW{qN)K#c_h z=ru66YP~&17PezGuoTMG>P}v*u-7`TLBdO1Ndvf!$jpogrYBz3`aLW^*Co{@n1^?t zdymZ&=3U>AbZSOS5(jQvh+=G4;&xf1P%;o)gMD33UJAt&mvdH4_?>*)DNja7{$46j zF#hWN?aq`v%Rb31{@26%Ay}yz9T6++zn$rP-uLorkDC^?0efBP!xx zKY8BT^6c;ZFt)!6W)PBiy&DV;pUH0dp#gZ#7c$<}w7)M~*D3>qh{0Z1$sTIuXR9GZm|zf;AH)O8s+>Mhr9 zpe3>xXjmiv4Fb3Ln7X>h*Udij&-<3LWiewwt@0CxA45lMG(%rpN!KjS?_@io5{N+M zg`%mhkD;Av&exZcb?*sm8JOi=2vAtbx{U3)>YrNP6>syL6N(pdRN4(^Et42ii`Zru zGqMS?%W8?PCXAMM!FEFU4xj4bx8o!28XgF{V(2ZIjV{ShJ@`z}F^oC&c3L=E(SFfO z3#U{jDX>G$sfOf2niQ?n#+bnjQGVGNm#IgpyHiUX7wk64W-ua2ms8B~;Oy^&d_|GL zh;VV%;hxw~#d}LQ^63cG+jiP3zQ}9}$@pg%j!WBUIvTWBjDGYbuR~$h9Oj3+3Xk`{ zSk=rdX#U+{&KNBU$tI2i|L5TqSjnZE&#@@z6g?*qFJvSg>wFbxtQGNtI52JxBS|z& zKPp+0oT{@oR|~}u$=y|($;NFG*40ecXw%{AO2O1f>mY9QdbY(Hsz*R2mxe)=_3n|6 z0(s7t4mH=BkppScfKr=%dNYKRSF7&)fnV!C)YQ({`g~`*@nQlMw8?YHp%t@hi@_37 zpttitbf~#_+;9 zwZTm&Rv`2xd9GE2wq1$VAbyU#6#1ri6`cdvYUMVo3in+nqZJWF99S8T z7rSbQoLhG|pW5Fqh#-1FWVzC9JvnRhWKB9bi)8i8yH_@fp--l`s{`jZwF!};uK+*T zuh+Yip+kw!tu)?zhoya7_3SIAd@Au4BU!_KC5TWUxn=|+=^j_x1>T?SBO>=h14x}& z;uaIT@X-CDL*zkdzJP;C;TQXa!-j*&Lhv<8vSTmE!(;Rf}x;s=gIUEgL%wtf9{4b6Y#P#~Ou;K?pCf zf9Lu3Z_fNCG~^A#%V?*-1@x_n-31r0%%*|fEV*LjZbg3LQLX-g5H-5{AA%El&KcPn zMl=@j7M;?MLR@TlLJKtuwj}67cY_z-@YSz`RaTYI7SQXz4u^hJLJcHvzlhtjxBaa{ z!_`k7$>88umg1M*LFP9@8TayS+y>PZ9&f8uC?1m2fM#6WvT$?BHjHj{h8@(8Bf>P% zVFA|${*=w}d{7^yQ#U;y_EM%r`Lj(ugZ`_UcLA71+u@iXO)15ek=mK4V>l&r=9{x) zYU30?0%3}XdumiviANn#Ky91-FNhhg7TBLNkT7|R6Y&nTL=hE1XX$tOg z-xr2H(c&dnv<8lI9}>wJy(g%J+WiQJ7Y`5R@fyzlN^|Me0<@&Zb>? zNQy&3Krjbt=pq=~`{DjGX{}8y4Xq9J4PyQ+KA(KN;GC@#hjsn)$R}lXz8Whb5r98c zlD5$6=QOarD?nQNpt{}9uiSl5)(_En&q;gV!e3)o2q|<3Tli%P_9veq8ADC?R5DBj zM_=N0(b=-i&wX=s)Sa7p+(GsE@z)7?ICF+`afmCJ!&i-Wa7I~}RK+-iVcdJ-Bdgag zh<5(sjz%2mDjH44dEJG^B-?^Cu`^S1+%8?X8M3?XyKF-j+15%fo~HFYxT;tWKf-GZ zAzUr-rSEkoppG7rTE&6iJQd0*CttqBz}2*$4exIN@X+ceW4Egq@AI*LnT2X>$l%j`?sK2>e$ug`2g zZL|o@&+1StKc2onnmD!%c1UMWMe+Izk@!QY5`|Oxj^Uq^JwddsAK`afkz zl?x~SG~>vl)f5f-#4@$wfQN5U)2}9Qmp!A;ox)9^9nD~qHucX*Vdg$d1T6=}HAC;_ zMJ@0$?d^D`y{IJP(>*5MA{eR3inD_q-;l!WInCz$Ua;w!RHXEIQAHGB*)lB$F$Wk; zkV^FMnr_=>BP9k(%~+XlH$>=ius9zaORFq&aHc;Y&`tAQ9L^3r6m|6R{9yO#b&Jqm z9 zR%Zv#Yjm~$*k=~7ytV|Zt1X%Q+;VTl#gi1j#hZ87=2u+yKg@XzS}ddS9jvftxR^?Dd$HyDGlP>Og}QGUKTU~NYm5J} z-e*K(&ST-qWBpa7tz*Y|1pM8D)*U-vQsv8uKV9G$T8r#`W0yZ(RdSz)ix0tqe^`k? zMC3kbne6`L{2`+csq*a>?w_(PE3WK1&Ru=D1b=H1YgeYF@(4w+IPqfeCX zs}~H{4<^sPPq2J6PNa4Ew_cdAM75@{%B+x zk220Ku2O@XJX&2=9_+5qPG6pVA5?{|2UWiSrMomb9{l{g<{$hrNJORM6V;nvE3@+A z>pBGHVE%eg%?s&Jn$wDq17ra6le9g$cTk|wK}pRSuvn}U?hop+nO_PWzKtyUE>c=-5uT!@sM6&Z`Hv? zGU6?1)szF6z%#lt*or#aFdsl{pFGZ(MYj9yZ?~EU+7rAa3-UC648!1Q2iL4NVfvcU zs#N3NsQKWKNa`YP#eLO1=%1MqmPeag@DGHCz?46lkUuR|-2|bYZ}}vBvF5z7<@uaLnk&^KC{fq1Fq(jLxM+b+M07Hqz%vR*l;Lgg%mAA(y z|Ahw6^sD~ro0Ih$1~OmWt!$A*=8sI6wu1ncFDjV%1GUnTQNP(CDO1zYV`^@G|E0%^ zVS1OeM9v>I8eO)J#0sqYA>A|A5R&$~JMmx48m19>%a}2+SxoR68%liJmUe>)FGwI3 zqh@MC5SvZm1$2BU39#LZf(w60IMa3Q79KKT&gf8MuKh)UCXYr6wZ)bSrEx3r*sz#-b&Y7l?v8-m}U8ADsX z1PxcAv|%C%S0rDKQAwe5mUH_)5haZd-@>g#_#M8sjX)o|H&Rq7ht{FR-4JbaPtWIx z9(hB}O}&|>2>O#d%w}^>3c!w?6!h3-uYW)|`BsLJa$oHgCW=X+F)jz)l|?NV%0uhq z`&a5PAFrfD0DN7~{_+*(Kb6&OZZyE&0$dYbVKVwnHV?!^-t$%S($kqJBTRf-cZ0Cd zMsR)ZAS=J51ph&v)^3Zn%?Oj`Wbs*2<6--o&qE!CT7I{6|9>VK`6v7?mOIQS1NvlS zv^ahA=EyCcbikz(9YVq~-J#-88p^E{XT(TNO4u>{Wcrs~TiyPWL-4jMTcHfRyE0Fv zDe-Q{*dBsY`CZh151a~??iP#~-@f1~+W2GB#U0Mgr9{IrpQ&MdLs?sY|3=lrmZvF; zj>7h(#ZQi5x~W zX7rvSZd^2)%7=+uZgXJ~2~#r1O)LPcS19bDOO1f{P(rK&HWe_V1a=wIgxkF(Sg7Y( z7AwAU`?1yC;x>v|2WlkV17l!4Ot^=rUGbRGszt;dpklB%42VJT!?OKAi*^ShlI{f% zUiM$U1Gg(nPv?+MH$apw2bc4~jkJo*H-cb`<;Vv&iX%4rVl9X8cDL)}s7}DFtvc_o zZ|VyEk!*~N)vOA>{n3Bvr;fffC*)X{BVdr|8%>yy8WZaoSw=~L#)#LZ<%W&c6Dx_X zyH(2|O!Y~Dz1H&9DSQ-~i-v}^-ol^nl4kGU^snTmu?2P3jn!VyjpFF3q3Sy$T3GQ< zW~Z9+G5k9@;m8{1tn*BS3az4#AB{xPu}`q_2D0k6zmTjHA=&S2ajy3C%+N9zHkcECP}UiT;k0UDT4k7Q)K98JED+OVN2uw!sMkhm3Vs7SSZ4w++b znN)Dg{yrqCY~5K82XI33TE!iv@pJnp6xVv9T(Xrx6b>u#nRiqvvx_*Pus(ItIRENN zs%$;+rvcQmlA?5<*yVcR^_}yBPGtK+e8E`RMBTCCwhe|c!AnBf=x=*sQx)FT7Xh3aX5D~9aA5Q?t)Gl5gzb2@Xd%f5T!7gG)aC=#Ht|1XG;Rm``cf{_MJAYH9Ni$Uuik!xk;6OQRv{F zGs>svfV47>L35I{4bn=?y`<9&$2J!cIc@BrcuNZ06l5sw==!rU9Hn2vL#2>r6QsSI zQvZ0XKcN^!ZN2J#M7Ca`P@{-^;Af+^ynsp=J;|1+rht~js{RTL;rTn!`{4QAZBqH~ zHW8dNwi5<&xh}@w%N;saU_HFMMqmjrA3|>AfyiyZj$-mn(mxh5vU`5ppN>vCeH@goHva^JDeJ zjV)F>f1G3_vcl47IYbmG((W^A=cxmb^uUgJA}rt8&G5VJ3#}0ZFX^u$%G559IAeFD zNu|nd3W5GnjzV%*?(WJLFX-EsY2BU}pB@-$@qFE9HAwS@Z{~cVDr@h*HDE;>})Q#4msep-^rI3#`{ zW)xOEl-0$VJ2%wvmEJcE9xs2V%eSVq!oH^S3(klapjYEf%x?yT-_Z)i(p{|)ZM#SJ zKiDOJKU!U!Xb1USe-=27zObDmXeOHr!x}0TuI{~=>&@1?)pT_m#e$L_12h#FEq6Vl z*>hj|5>e+w^gGh<`Co~I?2z#PB?h3h`0cN%!XZu?tHH7_YQ3#QfI|Hk2nXX+Z%I?tQPFiCymEjL0QbDJGyH)3qxAK>3s0VV7Q=qCBdik(W?XCQ$3V|D!gFm z&{7(B-RNh{6|Iu->Kunu$G^t9Sn znIg+bK97T(?`T}EknpL(*7svgirg0} z;NW0-a)IZ9 zLpKN2Ke0RisuPYzs*FAe!I55)6;=3(?NFPRLduG7uu4uJo>gI|QP6!Kni zqX>%rl|6YF{h(rz^ODXfst-ZeMjYKLOgGI@guY}RY-FoNWF#htp{x6M4ywed#xL;w z&2SF29nkLVh>FlvNYQF%ZP4P4y9Vq4TRkKDB2YI}?&AlBD8&I4AeUC>e#mKElGBWcG@5{&9x|?&l&|FTw!L{QcGrr#- zx_{IDx?#g()GpbH;WtaQ_yR!9WaTchQK6Rb^bVc1oxhQ;!UJQxx*LPPxMiomccz6U zMmiLW4{J4ypW?^SoiI^w^%DRmfhU1AnlR*i$UB&IpTa~Y0Dpois1G2A=}a(~C;wvi zzdY)1pGUcVyfjh%{d4}XBNwsAkR#4Xa=YC5$9#Q)eTZId1S7yGdLQ8~(Ve9R&78Tm zvSE8-lU0RI2<1eRIzFYgctdEr1LtZ#8M|PZ_)|)AmH!Pz2;>$i?_*O%Aqk!crBKVEkEVrrcsvs1Tnl_G|H^k;NbDs<=9Akiwi*Ox%1|_@t za9y=a?HAmd&t2~-O{Gvxuv8{Zgr2KM)QGZh(qp;e+ZyjSqO~rUjZPZybK0^)o8H04R=Ivw9`PYNz-l+xcCoY9 zSlaX!H{Y16wHy`!I7S3z2*&@zF(6TZn@8w)PhC11^S1qtzAom|E83T=d8f8#4Oj?J_b_a zG_BWlPQ~!ND1&dr_iQc8xfB)%sdB}{pH)z6YKva_#WK~I-KufGD^Nu!jqHT3^p6}ev`{(x{$}0#A0wHGsj6k>Pjn*9_i208Z^sG`T5;;(0 znz8QUYEJ8XyCa21i2txn41-xuncSU>Q))8>+L3f&l-hB%{K-^}&-6!)lF&^owKB$ybQ0A*4q!^`gCwJ_zD_#`doeCLT>0i;&00lfuC?RXR*H7V8BrU-M7M36gl5)jvnZ1PZ7E2Zo>BZyz# zBy5gH_QHV1)U;ft)nriH{TDN*^FvQDG_3>~5N9ErqNG>mx)pOCzZLXPFswNwZR0!x zIcH?HaO6kpK_5pKMNh1w=`***7zUn%_|Jv{FTmHoF)aI5@v#Q=1u(arpX$ZAAnheR z;1oIaq@1^+_tUU!;L$r)RKbg5jiZ_=kJo8Q2w<(^~t9cY>V7$J(%PX?q$8RRg zc7clt4VePV@z(GGjI^rx)t$--uKo2xHq)P(T|=ct6lDWkoqoJue9(>8cZF zx+taLw0+yPoaq_87Dnq}a8C&*wnP;UXhe_DD9T)SS6A0w|HGWNPq7HcI0|$m07o30 zi5YYfbte>70-;bv(K^sIg9#9IZ9s zt>t@~Z$U#3lr#@uM8%4omwvro*J5%uA*QUh@`arZm$Oyleg9S0UmAsXS!bNq`nvMd z6L-^9^;Ww`L6ri}NTA^qPRQJ4oth#+kaY}K4M9pk6{Sy!l`~L-4r*N%T1i}mp^67sULNxCk~T#YQB6gMLms=*G$uptWX~&UTEJ45ICPCMFwem9Pu&3pLI=zjct=6jIg# zlQW+Zn4C3Ip}sa;AgmWD@^?I=UZ>-E0R(f+ z8cSmSy)U$<3zSKX$L$!+PWmG$`l-NOT;izMlvdfXe-ON(F32&NaoFhQs~j)E=3eL6 zNqhWg>TTGgS!{mW>&`#jj!p3(SeJ@88#G;?Nt68u=vY0)pEZn_!KmGKzUGmXEDi23?Yh3q+N zF*puAX!Y)Y7Q>$RgnCt?re~Rkd_}EfA4y1A3@|ZDLiE7^r5bZU;y{H>NtQ_X&gkpi zpiWGD7`EM#E`=IKOnINVc3LM1*eUOThl#Z!>_NAUUoh6T->kuHg?dOXK0hsHJkZ{ttR6=v_%G5~v}jDyG*NJv^wFb!+=ztZ29##jFO z9$a?4@pgs1Oa~}$cuN{JpNaX`&IaMfVkmU)4W4s#aX zR>C!OqvyH^4$RrfZ1?y`m48hCSpcgfgYH9OnVL>~3g;wZ6=y{hS2**WAAlDG~262dfP)y9N)?PIG*?01Ii*Y3VAXj$ZWKo|HivkZ&x$YWNDz zsEze|AsRn7PNbjq{5OZ7-+!8$tzk_~T??54mD|7LH^jxsM!>x{;wlCWQY6K*v!I(~ zQ=b4xL8|FBs+FgupyNh6q8j8l%;JSbt+dv|czw9-Z993?kDyOFu%AAPuyne<^D3$T zKw%I7g^!czX|5Y9dhJ)<1@rs}3h5JmL#m9MuSpU{ltYCG!WhJ6L{q=vHRwKXi-j7i+BfFys9b_d?b+dFZ3zLqk{Klxvw> zfxtyH;>lFi3(c^$3b-$_Wjc_So;IzW%6{}BOe1X5$=d?5ov}Uh)ovGU-J$PwnN0D- z-YxL!CUwFANodol*#acNCtVa^^HK({wPNx;Jv(5XYCJv!LQRp)+-~N}4H5GM{TD1x zAJ*9{ENmJ)y3F1?c`5P;4XWS+_9tkfXJN{|#@=#;IOkm?Tl=T}*%hsB04kxB7eJ^n z(y%`SF8>!pAjf6%Xj3)2`1Y6o=RE2%0CaQ>8t$Izra>9-s=f|aUKqS1OP->CO-ZFF6tL`Lwr(X>l@ZT=A9UUqc^W|M*Z?qna z+9Vc8R+%T$M<5$3TIZ*(uPT!|iJN#d5MmJp2pgsY09*_wR)9GEtmGHKs~O{drwkkb zv$(QEN;bx^k50g+r_z>Nc?h(+9pebMMeO}eD57>N7_hXyVGZ4jEgd}qDSE^FNxNa4 zTLWaOGcy;>t`fTYN^zBaT8A2(1)6TnGKlXa6>hi1u&Hi8N9%5(3hFz!Dgs>6i&S%n z0A!H;dNR1CO2{?LVqBeYEG-!%NL-6BzWUM3CWR!cp$HcnZ*i16ylyiQ9{{=G8;7$T$kPX=m zmoFTLeabO!>k3Dxxd=E|ZPp7RL7JN8NQVG^Yxl&`u+F}Y`>Hih-f5l{SD z${}##ZJPUgL4;*1!;pu=EA6NYm}9ro-`m5mxkZm8Ev>oTFY`O7_H%`_&A|mqZ~l8W z^4nrC3?RCH)-*W>cWy+=N=dX~L+tp=P)P}an5!@N$LuaaBiRAaX!o=RXhRtE32>`J z@muNHuNw>dAKlVZN++CY{=+PkX~;Szx8foPmM~h0&N2x7FR_V0LjC@Jt4XrFUW_iM zp5qfjT7^{W90s%Sg>c%X$>aUCHbzR0PfbMyGyK#(PGIPZEE9xDG)9qVRr#WR7@`ln zT@qG&b%3CoQ%YnrB{=G@CP7HYJ#QUR4!FeTAFx`i8jqHQv2fUX2KkG~q1{tTz@f%f zKqm~|sIC->s%N+)y{bXMN_1M!zp);^Qfo06$z& zjYn5!J&LoUD_7(s-{}(&r3`9#;nJjSP#YIOK5M%Y8~0^DeDIyaYj)wgYd-i3+CVg0 z9`t+@IOLB?a;zS;wQRYtG3h30-?{(~;OYXbHcyatzfCjm$6Xe%HQPw7{pwx-DR}2j z7%^Sw+-Y^ENC^C=NC=$*H0T%yyuzO(lMj>0N~do~)-@wii36Rzt6wA3tg`yji zultqQVA;vWKAS!c5w<35FV>45oJ;dsXvuz9jFN+ljZZK5+o*QkxKu(zegRbAuJHx5 zHmqGReM)g^y@Gf&-QL1M%QvEUq4a-mV=6H~)qm8tD=XEU+f_bp;lKCl1ckcTsGC4- z&MRCYhZ~e;RF%iHJ`E^33a%uVyly*BWqe$}RR|yQo?7HBz5UHzm2IeF#>q+aKGWCo6 zI_oz-6AadEJ}Y|uUW5KFz9Aa$%nT^WE_+ut-5WZhM=J3`fmfYnL zjHo*zu8|pd$x1jfd1bG(5A}V%waL+7cp!guBLBS{a#&8hZ!sfVP3lpH3?oNfF_F*~A&RvkV!fa@uW{f(+ol+Yd}+l-_56jH^!9 z6I@xjnswXY%4$&3-)kdl*OC2ByFd$c9rh`6fF3>mVAjuc^(zspXS;y^I_AJM&0rSUQ&E6h$tvN9BqDnt!X?*xvGgyCI4Pe`W+kSVSJXulN9GSPT7|&bvld&E_QbG2Q)L@UI_kTs! zVuB6eo(f?sR5x7%6z*tfna4mZaYimhD>Wfoudl**bGj(twu8_SYu>nfzsqUkj~(k zu4?5a$Q40{Ek8`ohA#wASaW36L$Nf(IRt%+zLS?3q@swu7@LA`KzFa#+6A5eC`R*> z#mf=5RriKb^0E2LCev0Rmd*0a=22)s=pv~wHnXp z-M9}99v4;IN%%UFu58)e9E>T}sMQcLlNm@N)`#h~k=oqUf6rkq!!mTWFovAbN<-yc z%wVq>LuUSpglX}#`~6t<`)#md@Ytr;dV9KA@vsQ>(VrH6+f~MVl z=o(C`w&MPnG0%A9HV^`dz3%GEDh`t`74huV37>H>&EY>k0tIyW#|AK=9U4B+3H2BS zc3nCkN~3{3+=D4V zO@RV)D z*H@)67a-MdJTEA}7Y5fusqQtXSOPWb;xRaWr8`1d?=KYDI8hFQz@}EqaC!<-e4rT5 zaMIy2il{pzvtph1pGv(rgm0c2MK4(4;<<)$HQ%?u*TWHizp1ZEaJZEuYs*Df6>{KI zQAPkmbm|uW_YfK22I3*o12<5!3PBOtzBcII*C{Iws<134z?CACGc&I5J06xDy>*yx zdz)If&vmnO4SK9Gzg_54TihOVq zQ%Zm$HnO@sXd4P+uZ3Le%(+lutZ-daS&R+J=}ag}RgAnUXM9;F&EJ`7w+0lSHugX; zX@+8+KF$^JomeQsXy$@7sT2p4=^gMOvA{=^Rj2{^(X4M@q`MhGLY?@c@L(SsEN<SEHFX`GAiwJFXNS$G!n7i_W>coP(eBprZl6{Xc_&fD)+C!y(p&wwBG{ z^F3R-W)Ivy85PCkKMgL2K!3thYU7v#8QrG*STOSgA-YOnO2l8#5};#m@%KB$)Oe>T zyQjt<%qg3sRvp9(loy9n%3ZLflBrUoq;T3|I=^Ghy=EJKcx4glY5i@pWkPh-4x->w0K-UOcKB26|detZjIjY0e;LM8{V8F)f-17QCSZ&kK~0 zUhYTbHgW=#Mw#C;97_b7fvryK>m-oK>f%6VcS-Xn$=nsxnpUR2(GtTG|LIpsw)!CU z2Zd(V63Ap>^a>Qg^&I5zZL+yuw~j}XQG=U;_@LCZ5`@gky0KjlGV5)#q5gx{0DTc6 zmw7RLC9!1)C5qZ#bDu~FqZb|+#)1?s$_UwrhaF@Z#|rE zg?ksN!R}amnwpsqR3q~V-9SS8EvAs2=#~_Bn^UQUUYUgzifpaIre@tg*5m&;fx33y zSY&7d4(Cr;?E-?o2B_(6G`{``$<6vIl|X41yro0B(o~nyD}QjaqtlhMTms(6EmuZF zNCszS%awfkAl-Wv+no0!)y2R-Nytd*`fe*+(o*_tKTU`I*ZMpROzd*`^(PsEe+2VhrS!h}<0K zerjrZNV^|DX}~cWB8qK_xBatg1^=^a75~u6Fa}T1_m!f8c0ck~EZLYQ4B&WeG=*X{ zzp)94SE5GB{-Av2`RyF*%x^Y#Y(}6B+yTA3tL8AJ3>HwaG6{F}nV*`1p4-CJS9h$| zFlMW0sM#plkof>y>|>CH5$Gi)4lb#1%kRC~tn-R|fFG#9en$pp(aJePe3SF$Z%F)c z%<1s$SWH6Z2j?6=vL0h#F)}Tc9FW2w?$#EgS&2{fT~QxCA~Ujj)B)7M061@TB`LlM zc>#9%7H!-tu7Bd+SF0k{Gl8CgKQz`iLUK30F_LCnMD>5Z?!2q}JA?WYzXz{q7GWXi z5lDMqYH_`Ws(7@3eMyMp)K6_#H)G_y=eXrJRNcoQt_aO=JCqYDQfei#(p7w_*;U-tAAt_(or4p@FK< z>R(m3F@IOzR<}P(6iu|5KKL7lI>!|9(F)`r_8LByfIeFTLZ^qSPH`dP^c{h5GUzRS z07UOYCVmj_(H|Fn`w^Hw^OoVRBofay6;`{aBJ-BYYgg@I>KLZI0YIlqRrkBWtu(vx z)M>Q(;=0Kn3;;4l-G3P)1R%ySKrsZ|6B`f}xNOBM!yIzW{JqGezaI!mU# z6DR@{{PPwCnT*{it$U6gKp=glX*vhe8{Necd*6V|^!4r)WJl)EG)acM*4(gGtJ<4u zjQJbDKJP0dDk6-POjIJA)>z|7iuzeEH7^m{xzU{{O4ZVzD9Z5XX;@QCftaleV)i7m zId6H7nLd;)kXKEVwLgwn!|cT4RePmHPWO=!GouEVY%b@bv*J#RcL>)2LDL6giQ~Ro zIZl05e&U;`7G@#{*HqK}2^bCvyVo7w7IK#{btw|F)Hz8dA1T0GscI1a1$Lb8byI!; zOl7ITX`~g; zV#ApKP`q*;a(w>ZSuDA14&dF$_Cv%;eqLFC zq*9m>>lm6;>bJ&_5fHBME{m~v)>$ptINU;$F?bQC4G?Ccp$fkQ$P`fcwcITAw_(I` z9gOH2s6SZ8uMkCJxnnC~&HQWwd*^4#A=KAn=>v_*2?N(WkUv~Az-m>A{qPEIli($} zgyyij@q^EFnGcP9NsX&+xkAt@h&}&q@4Y2#Ph9IWluqyWR$d-rfphK)r z1v0Q>CJ)e-=T4#ee`{icYyg4BLOBCtDk`B`t{RM$1qh-h?35Oh?Oatw0NkPtPh#&Y{$v zb}aw>*i@fpc0*pNMV?-^Lj~ho`2=VN_Ua$5d$<;YdNWxDMHZ-!TULpEKtP7ba{9Wu zsg{<^0^#Dy;z+ku)tlb8on2ARduEt-j{WGwHg5&steVre0{xXvJ1Km1x;wpOpEo43#7`R+$N+qIdMtvO-1MLMUZl$6t%>?v zg$=t?XpBriAnE4IcgfqDv91`w>cU;k}o2^&)tOsV{$=y*Id!1Tt%o5;grx zi3*@AJm(Bn*q5W0VubBlGV~vPI|Hm?CFA8I&X?(bHkOrd+;+0~)otF$66{YgYT9mw zSF75^`a_3U*uARvDOtICs@ODYzO&qvc!wnLt|6{Sw}&~IdVu*FN7ykBb##2xA1Ie( zCcXU`kJiTM*T*DGun;OX&ZDW3hdmSd3yp8*Q9R}vLO@?@GmeG%8Zoc(yiYPNXolh) zT)0B-4ik{kL>TtGZ>SKnS;J5WRfWDRYs1z;s6h)cutV z2^T8LBfhAcyo-Kk+-s9_6rp_)t()iWxV{)(dXyBw*LbQYS21tPIGAAUO>7$@}KIDwVWanjj$p;%AB z;)ItIs@^m(kRfTVj^*c~hPS=#0c1FPU1^My-({ti**!+V%k7@y5W2eSykBirKx0<7 z2j2G%Vx6UUSv^bLrAT*pWrVKSrlN@)n8WYW!g*j0>umA7fjsgrh<1KEcOUrF@hN^2)?aSFk8ptqXGw|Z z)RehKEfuhgxsGXpl`qLl=-bg+x1NbVwcQWrFb>zdTv>ciPBMic{Qkz8C@M(hzU%jL!Pf+t=;t z7U&Ze_S(M361LHEV8bmY8CI=>xSegS5phljoR!(qPR(pUNt(CdNt4Y;Uv}BY^8J4c zJMxKqV6LpA6c}U+fu@+9Bh}7|+~Za!P$8-CHz^S>Mz8@6z}8w~##zBg`S7R=BVN@r zaO#H{0yXuWmYnRUu=Q$+#T&-(dym&=|KM?6s1QY~M^-?@R;r}Y^*jf9LTJK22mAlw zOJnhCQGBpicdnm0JDDR~KpJin22z8O4!l+87r|SK{mM5tfhd=6eFjn-yV*;tqVq zn=G0dPAiH76p899K_nIKvb}>w(k*Bt9k+u{NPv(Bt?Cq5OtQSG7okp=B~h&Eh#o}V~-Bgjx2b?HEc z3ZqpQ42Zc!CG(q7x#g=MMZfu16|3L?H_C$l&*{?y)VhCakju|nFZ@a4wO881a{TwN zAOCgF211ka6RdwcZ_0l`j>d?St43qnFH0iLuej7MR}6{)(fx-3C4oe^;tNQ=$TBxP z2Z(R}aeq`~a0PAJ!DCq#Z#w6$?$CLEqr=C`59Avsd$&1^Oes6gqh_JyY83cktPeDA z?vNp(op4Q@O6V~!>Y7-n)QAQg(5kfD2LOTgv}hj)8EqwQK$UMwdN|x%v~PX-_VD!; zneIUlfuIosmaEk~YbH1ab~HJHh#3Mv^i}*996~F>CyF|$a;qf6j}eJEe#}-WFC|g53tyJMo>wk z*7^;QG)_U7iGfwZxw>$sK@!!_!_SXK&6u7ye&tk+-<@uG)HF~d7$5GahUMBl1D zN~m4vNd$N6sZNYfSNOLyR)~UnPC^@H6V!8v5KSmea9A|SXbY=%)WqPQHCsB0r2cjnbjSXL4Td$-kpJWxHzVyKY@+}ajEFTx))a60XX(T1J$Rv ze{j{~XDM~_rHY+I-+a4pBvpL@V=uKInMcw&)+2+B z3MUo}x6Vt3l%@4J;dE04_ZYy?h3k z`K1@}PM9>&PkGhIf!%8Mb;Yn?n(9j+Fv4L6hpqU{$MGcr3Em~hxkBPq8mjOxz^~Ra zvFl<;x~YyAc*X(OzzUbUZ^6-yY7Dr z#5DLj{MoNUQtTDN)rwgHC-8j_1`Wg%+BZlm#SI3aP34jc?e?}_S3an+^C@N17{o!i zn#_rwQIMAlK#}`iqwFCBb+j67Q#HQ-kKv~YI(MrEXww!M3K&58S5EWnrNx{%eSEX8 zNN3?^q%!iWiy$$;lxz?vwa}xSW*`0W1X!Fu1`& zBxj}Yv0)*3<*ZUoZT3sw4ZQGaTO~S(x~G4_%0p#JqO;)Asw{B>0-nVTXq8cyd|Efb zQ11)+-+5_#-3RxGoDtfT-$4Byh9l|d+x|!gSDM8Dq4x_w7g4^7_^-m426R8DFx-r| zxf%=HRl~85<=pz>!z_HL#-WWI_CP6ss9AOdN&!+fz+rX0kghknUn|t_6T>y3*#Z!` zt>6n6^HzEngCG)o`?10QqaU284beQ8)md9JyStH~ZJphJ70CzN5S~ z3fNSf{}tV<=2-V05I-Gdw&CD}Tl?iTK^@%5@2}Im>0UKoF%G1ufSP7Xmc$=~6T_K~ zwKTQthcfS_huFW&?KJ_wQ6!knxx#?wkNLEO+)hG&UtKnI*mTX~E%T;^CSgu=4a^WW z1P|zIdiUl53K78#sE7ky;9ym)=w1VL*mtewhK_l&IGjD3n))`@%LR`IlQx+5w*CMI ziYFa3tLR+^t!8}CnEkn`uQl{C7u`gPkG_1+Ez;G7>Vr%`3V;gqL4@_7i-z!YL({SL zX8^?!fJ1Es4)qW?)Mt>ub#Z?)bET>-sb^B#j!`vdXw9uiLdhQqngnGcf{YQ_!C5n< zN;KlaYtq1fJO1OuN(ZKj*1*I9sT+jaZrzA`K(%Ps^@A7~eGl%A&KZnWr5=w{aD!tq zV%-1@;hWcp!x^shlB*5b&UTADd>n5TC3mvq*fk%4(jGXy7sb(mOhBWc0{}v6w$vw( zdP|ripdQg;hJ#w|OLSMEn3*XQGxJKh93=7|bc14x>p(9wuU78b z#2@So+rE3gV3*hI7;K!C3?-%hgfqk$b3F=rpOAMF-QL-597DE<8ZHe)kS4TXQ*Q45 z*(BTlp%8a~@_MAQOxo8}f-S3;U zwS9T#3Oe$Pm8hoLB>=L>GS*Q8-H(;ZrY@02_ za?w-Fl};xfKV|19ZgzUZY!+A zdb2m=w=ZmKiBz2#TCE^aF8{1`gwR$qo|RqY>GboEMDvP;!5K})`FZRCLlQlCT%{4P z^qacUKxvz+UuO%8=H&Uzeih_lSh}1Ztfqv{Mx;1_yXFS z8~qwvjz>M~S|4k@+neK`YK}Fb{f*jx`?cM;Ji2>$czp1~4`^*@m_2an0sW4o`-Z(O zve>H}xWdHX@>eHL3E)LOup>|SwYRPqJUF*{`+Rsn8C4$U{yXbZfC@4LON$Y$0W7DVW#DF2TApL zN-{m@8Zz{reA%fX?NsE>^RDvlW^XI(`M|tc(x*|v&hl0+@Pd^HeUae8eLJV8fXm4PDG-IdXr0+`}hN`k_msPT=mOsC{n^I%wv7~KskZViI`uqzL0F#uY zu!e~MgH`YIW!U|Y8g{fw_$L`m_f5{E&-WB>>!_kwpDKrwcA~jBaV(JH$L`%Rvw`U z%kMkN(oT5fd$Z6d8K4wyaM($e#PY;SG>dU|IO}z}Ws^_LLma#8H2ttwC0N7jwP3G> z;XUM|Ay7VZyYl6cYO*qml~ivvu~&mw=GQmsm=KX(g-^r%1P*YfxWD?>I3lr=WZvs2 z;(h}5Z4gcql^1`eI8Kyhn-y48#E!qF|@Dt9~KlafFOu}ya^>*YCo zX<#%ij{^6JsXAUn;s>EDVR;o%Q)G)c(;-#l1+|5mP+V+e!RU`HDem;4^b2HgPMthY z*j&h6dQu`Puj9TIS$tM&SKhd|zw|hB+11x8zsL|fZi{otAQdVPaqsYVw9lfjeSwih zv35IMtvh<`0~7Y0??CY)kdaPWz(?rGw^~=olJ*LvCd+3{(5HRQz9wt$&eBm2V?mOL zxh!3Sp5X)ho_^+QVh8pnlc0%yH9XitKh8` ziLTY;mR!l0|5zMlmlM4r;E5ByHT>LqvAj)l772o_M z`W?2PRTWk?>ed^^a<$;n(k;rP8?9!w**}u#V`pi8KHX&4FGhi>#=%y~Rbkka`S9t6 zTwz`z9`0UDg%E_^1ocbB7?TWirHq{^w#BD2|I zaQU9knmBwyD<{B%H{F2K3eJG1`IbJm|0_~m{k))Uod6Lt~Cl=m}6 zUnND(O-Toy%MpJcp=LdATcdp?$9kz+J($01@uO;|XGvs|*88bo{u7r8P4k=KS8)_= zStMfi4}4*~ZO>Yc4Q+n21jFOaw5rCSk>}6gYdw4N z%}}YuU`cCU>S5nK8FEnDv|QGS%=+8wZFOXt=%3Y1IKG?nd&=ckmzAT3dk1Yz%X_W6 z>odF@oLs@ve=ZJZdw9-R|9D>R228axk#9;8vA#=2>M;pEXY z_S$9I-}XdMV&?z3nB=(I+%+jbzWh6+=KgTrd?ST{u6ENjclUN~KgvZl1Kv@mXrcB8 zq76AUUE0nMT>S^ML^<+aUVNNE8f__-&I!pTl&{<7EUGRl2i2SfTVFTlwoG9uK89l; z;QK{MiMxy+-ag!)9ojy4nqTw!O$Lu=4J1rEO)2yzN=}t)fBzcQS(l#qIx~TN0jZmg zlZD^|KAeoSD8&cC@pi&yA#Q34gHY-O?Uya;fmN@y8d)yZBDf3M<+IrEUJdn}lS!dd- z_e#@Y<{PV19tA5S+0YZIXMnb#_o*VVNJxdkFIW#nHZhsuO=I#o@=Al<%<-5UcAtqv ziDF)=ea22>=QS$Me{ctl5Rl+d`3K!3?Io~1@ED>J~97Q-GbNOO$b^?LF(!4NDEFuuX6n1 zwWBuhv!^TcE$Ym;No8%~#qf#7lZIymF4xIA#ZgzM*q3$UM1FBw)AN(cW|xDab?L4> z_**)XwI$AZ^%yLBa!Hd4ihm1O%`TI&@$JUU3_Ho1?rwSgu1(HF9$n=FSiILb$nUhJ z<~k>O4>Gec%?gbAW66fi-&<~K_i?{orr7aM@Al(m+f_TD!u}+(c2Sd>T(f`E^~aBE z5gv}T?zTavIg3B%^EL~sii=QAlWmi^53$~X}TZ{65kGx(}CEjXN4Y=bI-U2!y27JEh|sj{{@ z$eX}NbK@FkY?2iASW0OrJS0a@LY#6pGVE$H?YwmDbKS`=CeInW(ahbr?7Mf1T_cGv zmQjRdJ&_hT=MQ4WOUNZV4_uqO=8D(84s!%0_Zy zYRNZSv(Z2<`Bs?xTZx18-L#xVrF_5QP*soOQC!uPX;FB*zdL2G*j!{|TX|}xEr-#R z-Z{n>?}nYPPSJuh9kyLTysS~M`g-*WFUb;#Va~9c?c(s$B5cOuvYt~CC{kx5)<}bw zU%tfW%e7}0xrD*@VfknqZno^=g4LW&fRA;@#^Nr{#$T2$f?=ex!AXISbR(i)OS-5p z9*SnD4_2XZCx0q(gYv8T&gS|NT~Yd&%y?IK;)`jN6ZXayl}YnA?2;5A%k20#SPC+j zIM2SvSf*wu4@9?oKeltKRP$AOhpyY!a2F3Y9b}mRDZCs3w3Z{sSXk_!bGnYu)PeAu&um{G-b~#4)YM_ z;&;A5)acKe4BciAMZl+ybh9^O4=V2M3V$9gq^KU!_^8f&thos@NWbpJEzGu&IAI6}aWh zHh3dccG%I@(FF?E65zsB1jp^<$2WGi-J`_Ok?dmdI@Bv;B3tFYtT*%yPX!T?fEoBs ziiWNPNm&&Y!rjthox||sT-hxhswE;>tQwwzBO<{dLoa;fMMGaF`fBYiJYJe-U2kCV zQsPZgng5V()Fp#kFOgq!i4wd9oaP?*4H9O_ZzELLB-rb4B~_%eyP|wmqbzICk7g+b zV%cHIkqu=#uhPV(_#)WR$3yo>eyePs)S5RWupWV^vpPF=piW#LTTg z{+c=d+(2j#qnpG|_y}Gol)X{gX43ovmn2Fk0sM#QL-cJ1>Sw0%3cNV-*xGy}6b2Z7 z$hA7<2pc=eD4&VOIG4XphB=Lci=dq`O*fHOdr|e2r>{W%>@V1Rd-0!OD9ZC2oAgqS z+I}AWvU$R@duP-U$H`%&tbQ&trtk@Ejvxio6c=?ah=BsVBox({kNz{$FS2G#a)de| zZtj&kqqjXyv6+?6EksS)(GgAFaZu!FSE*QS$u`{`s~buGxN9I;3{@b<0mG3W#D7Af zC^sr(_a;l;cPPcWpv==77wc^rcx@K*0+Ag#DUbHdt?J4xp)~>@M=|=VVKBB04z}vG z^s{o2PB}j67eAXeUvCJrW15nQOOInckF3o=6Zz1}ockn!NRJ&6#P55KgU$X*RJz-Z zl|lfgHI}Q~Jy`l70M`Fvo>M1F{1)Q_HaqgVIfoIxj}a#A1saSk9&+VIELz*uW18YA z3m;)5L4J(*K^MV1){DqmBJ@Nx73|d1M2GdfDJ$tzv&=-KP!X_qV(y)Pl6POM3AXxL zm8h^@Xx=^U+*f=ViGR~7^5tP0ud?l4e3(0HH*>KaiOg>95LW1ivFK0sJhxA=V+6Zk zI-8KBmhv*+KhszohYTUjK2fc9Q9aWbTf=1#8~;F$OBl6Gz{8J#9Pv}~E$nDqp!ByH zpLCTh&Zyn^P%GGHi6Fn=56B8cbS8Z^dNeVK@^71FC7+0ZJCTZ0(jM#!s;NVCDLU%6 zwwMfhScPTs_z6k<1kX@EvceO-6?Y9K_=BoI_ZFLUJW(2gZt^XcpEWjPF6}GN^gYG9 z>2~kvyI2{K+E3ABgw^x`(=tS|3P z_oHexIr@VZRe!Cmh)cifQls!mp@Co=({uwHjiOM{Z2&G8ujGv-Vk@rwQw@d%968M1 zKn-|Q=^6@MiUV%JG^2aDuzcpc_tLJRVw7dtVw+#bj5?oCTOJDp?&=#MsSPQ7qSHgf zt;jn5>_2n<^j#c1x;xTNmMrX5JZImVIwL;6tP1yunA@=Nx^ufc z8|eGB6B;*?Hh-b@Kx&oNr#1Vz|2NqRiBip(4aN&8B4LM@vBBH$2p$8V0_h~E!!X5d z=@y$Z6EqHm6B4bCWI!=YE=1+&kZ4Rm|CSfZ`qAhO`uH7rFPY||ecOELx!;_o$7>kR z908^y$gq3e0lj*(Cu)e9)HCV{Tee?wsT6#{M#Ln3)I4+~%Zix1x4t3DyiI;NN>)W@ z$Aq8#vMgt(EzN>GO;z|N-g|e7&BV*T$mNin2qA#a$Hw}2lZ&l-F;&cjJ7gmwYa^wI z41Ps~?1?HtikP}Ugfl7w&YrKh)Hc~kl1Pjh+h^rLs<*1I5;gh8Q5`S0d%nfHzv%e}hLC{{A=5DGE+J#pcZX+j zDYT6d|CETf7!l7|Yxol@CdNL~-my2r1>~HLl(MX3j-pLjVVU~4BrL;Jz&cIEV4(P@5F$(Qi(CK6Dj!>Q_&gW81y^ztGYHL;BxEo&iFiD5 zDWVoO(%T;A@3urid@ua}J4Z@8*_%BQGt?o`uv^k0do*}=v#HqHdcDPt;D;Mi>N1fT zi+X3iNS93(=<$Hl_CxDA-E_Da5%0*X zWu<-9#6E4drg%|*D+$U&GC~%`Y35V3rtHNU6Xy>Tsi7K3j2tSNGP@gXrbrVcBEZdX zq($WPYZIa4Ok|z<*0N-N$U|HY!iBg1RaNMl$_52)X0s`7Fi*@_d8ru86rBoUa+K6u zKjxn4igIMU(go{W3;dj5ovlABhfuvEBKfTOLM7heb{nlaS@0`KMjM>yr zxsA`3mcC{5U6nI2MpwB8d$B{l_#~0^W4ye+#YbrY>F27DcPFpiJyC`ph}XwoSR#J} z-~Vh2L;0Fq5aW$Wi=Ni>-_w0lgTsfBxCXspCABolW+VIhHQGq2Kr=gyq{{ZprzRQtAf#2Mh@D73D z_)$)4A4(N?u;XpMj?JJiGa&kW#-lxqNMLc$*EbpG;p#Zi_1xJipZ()k1n1z~alLUf zx61Hn$8dc7ZA*Bsc7rlVz)0HS0cLU^k5+&Kc1F7a)Am(O)=uV*@Vd0v_u*?bx}SLZ zW(_vgi3C&!A~9Lgu9cWR|Ii~dFGTR zcX2K9s8_eySLms9_H{;xH=^dgQ}m+kr_Y_G__-eQ+s8VYr95x0n1^iSI%S|2v=Z|^ z9V7kyW0gZSJ3;;=_`N<=b9NDi`1;4h|R zlAUp|QiUn<=>vLWaJWqF^uH#Q$6Tz`*gjr@eWyI8=krHSq(RJ;)U(=XuaqVsRY!AH7v?tH8`a1#D02o>w46TASv6AlgN{!FKHuSl6s5qBE zwAjhS1Ou(0M01F-vvCk{w;*aXX*(@9^j6PhKQmo&yYKtJBkbtQaEl&=l=M`HV=g*v7T9@k{(@FCXc1e*C0=~{2 z?u+MC)M+*y{THx<=9QIV9eCe@cArs!)7?wqLU_Ra)mWY`PKDGtMwZc%txHoVRfvi} zt=|-r7LlOUg1yby^<8(T=cA)HKWY?JY&rgh+Iy^u!htZ;81)zIE~4WOdk7NJ_-bM* zSE_h?X5mBYMwgO?%5bb7^LWMaLzX3RqmVS%O7eqMA|;Tksap`yHeS&6R{tqtO;lMD zJhG=N9BU_6#H91yH}cKfaR*DJ+0puT`df?9l13(z)otPQ)xm6hQ6G=h=dc~qA7yQ& z`wDIt2vS7KXa|E?h_anLkq)1RI|-&y+!+l>z~*trOlp+wq2*YaE>XG66o*IBiot^s z1;}RhJE{i};fN(E+)yMu=8}AC6`LM}tdw9pB+YQj!#%KZL)bp1!UINQOmAo%MYN&o z)7_1C)!>NYZ-ICAj_N6VFMX-d(*00lRoQkHUK6{r+v0W8sh0&eo`sN6Yti$4M$FiE zGd4)3Rc^5tG!7?2go`JAh>~S` z(_g@(wyJ`TS#jN1bDA#tBbZm@WT#C3w8uqLCZB!|C;L zw`E-$WTq_Pwx`_Z@_R$?nsyf?r9}F*_%nz$05c2O8D4hx|F9KzCEGuo^iEOul4_K5 ztImY1T7}EN6WyD2UaXDFq!46^=f|48-s)_I^COy$8^=~tU8?5m1Tva-r>AEVX@Y6d zbXlHuB4QN6zlAD=E>z)6sqxCz`INd?_Mstp{RjKIc2jPHvZLzw{gmH~Lgupp51fln zb8c>s8|#s;AHE+$ev}Ewli0Y{t>%Yb(BEae&WvQ|c-f5zzsUDkx;@mx|4v8f0TLda zkn|CmTO}E@b)Wg1EHgTRzlY$NJ{;>N_WC*|4T@>Z2X^U!U{>0vBpD3`N$cN_F64BF z5k~6XRifWTKmA!aprYQrTy(d}=lpmL7BQEz4tz8&`mbm;EMD0DXdG5Nr-{~kP-FR0 z@5WN|XIQd=MIoRj0HVke|75@_x=)tl&|ZJcb`d;DG2;L3H=@r>3!7);Joh|rY+@I= zdvs>%wwthP-mt`R z(itxkQ{NFM(kHWnno3VTFX^o=Uc`_BfxjdRN*2P=jLrB4Fye%!ow9I;x+Cl+P( zcUUpJl;DZu%y18%5Kn2LU2k@*b|%OV0XO5jBe=H&@O#E^pHG5iBp}OH+aEn7a(t!bSdS^Wjhsyun>J8gRRB$)5 zvDJYOPrpa{X5Z3`8mm9v+ZPA32ksZOOXc`@=Nc<>flFPva z@MP1C%MaCt_Vr;wT1rp4Og!yZt*)V*to&&>GRe8aWW+%UabVRD&s$uhR>*i@5o8T9 z?=az_?h7`0?iqKDS&FBKKjRK{?C-H}a-4K5Q^0!gm}0`R(<;K<`h~#2nWAGTnJQ{x z#Ao<=%=_xJ+uH}@H#C2_I3-{qc(Z_Mi|-k=mDEucr7%f>QFRCN7xNAB2F2Ehl|bX! zctM^alA@aa3BV3;o+Q1&rh^HPDWf^M8B9^M_y(L#B+zb%Lz;9 zpciI4WZDx+_Uo`w^(hj(xu7DWwpt5Sf?G)(E$MH1W15O3EO;_OBAplEhCs2x#wWK* zAlWbVZbOcdm#r^^Q>2OQXVNRd#UuN_Gzm4vikN?CQfqQoUhw&r!!vG8{qQ2SK3Y8< z#kT$#ca9*{iZGfVTl%o;q7&5?Vl`?0oLzJAmd4 zK9Slhz{>JCN}{VZ7+(rqlk09sAV6#`P~4{A*8(I=lme1MS0I_7q^|zF&TZb4}2*}fdxWA zBp$XtVj(t(c6|H-8UG1<{G*@0|`F+%h=D zPGA*fa3D@>;SM{a2W(~%H;$I%@9x~x%C1nx=jC$hy%_g!UvA}W#jx=bSl6CjP<|mi z6tP`4r{WUz4|(7OJcMDm;atHw_U`EN_N8a zmN@YY{pBPBHQXlAR344KNSwiMM>W&aj_lYTxLaZ{DLvibW6gwf>@jP*Vft;e(dX6E zvPYZD`P$pEk&pCYEZ`%}TR8g!H0?J=`twW4ed)C|G5676+f1-OcTmIxD!F&0X;0;9 z{VtJy?@2W&YtH1seT^+`4yOMaTh1Iz|HoaiM+L2aY~<030P_)pS-p)0$5SGfP0~Ft z9q)wa0@8Cnic+aJ+C1~PF_;6!l8VSp3axaAw&uK_rDf>t29=)g3n|~i7Mz{70Y(s^ zbCoRx)siesWV+LM-S(AyYA6jN8WC9tk~&8^4qQm221k0A*yFN#LwkkR-Jx?dKfW^gq=xPWN7CdSa;({_2UGYGmPi9HQh$l*LA#Lg%y&;B0I z?&BXnoey&~?guSvcUektcG85qu_=6lfA{T}?Vyr)E0EN5?-4hI7N4^pW|qO@OSG{F~{E~JlKCo!42LVxA*Z|3X`-7U5;^3(KD{>icc1Y^~>`u za(Uh&S>!EpW!@qrx&`qofbQ5*O1@C8mCBBwQch z>5X~^xkLw|C_)ODddRV6r7KyI7-a`t&DB_fDgK4^EDgXH@JIJl#p(%tO{d(J&Y!P` z4w8g&OjaWIQvJ+i6mTu%0=f~5`vIv>EH%{`$nm1TvKB?R^u`PKr+bmaGV)eMFu0X3 z0v1EbYx4EUEpK5J#zr86>1ICxXQhAX+$V4!?yd5%=Ohh5u;Hp2jyEVW7Z=ml z)Xqa_)g+%uGCu&1XKJ7GR*aNV*>dE04wGpwI#N*DWjat00B^j-VCWZZ#HVm6l|?2O zRMKN+Yas-z2QKQ?g&@4?W~l)g-lcQYU@_<0`%62Tr*VIblW!Z+frk>qf@M#5CF$01 zgBJ2Y4FVclS`Ohe0}IM*PW3y)IqWw}#35lI>Gl^ZpaKNo<54n*;4M!5jJa`m345n= z>!x$20AmOFm%31Z`}TL&onp;@ATEk^#fD5F_sdMnb@jFWKA-fO66JsEZ zpsB}52yE#FcM-vK;uNi8@F2JnsytC81ja-W1rZk}t zXclbN_I*DHwbJ}V1}by_0PQi2cgVr9@nBmuAqr8^m=JIUEo{msSMwbSao~o*VnJlU z4gXA0MiAu{#fak!GdLt=3g2w~ChIy9$-dv8#Fq}H3nBw<9$Xqsw%BCZ{Os*Lv-~55d02#eHz4qF{{_|(~Eb+RV zLQ|g-*cVf~{?8yk|BXUr7W$jBW_)gCY~Z1@)Z`B(bq{39;2-gLU@6r7wHXQf$ECF3MxR`XG(Y@#@A(% z5Id5P4eYs9wRYotQKkK-(-+lGfKHj*`kqB0y%y^1Iv#6&6R=GP=L;m}0s*TF3l>H{ zt^4V|>;7*cX{s0q2`jw) z`aBYsB>ii32}7RzBj6)21PVm{J z)|g%pxI3V>7c)%_gHF*kMHM>%?^A!h1SY9(?Y|`DR}iE=dWj8uSo#QqeD|7;E=>^tlCy+R1+} zkbS6=OH}YKdCM@;xMK{M$A3PQcK^ITzEp5+ZT0qC+%=wfJ3YDCS-%C-^V9A(HV*Hh z(cOd6S3=(|ZE=fB!m|`_H$KzK`nX;nmUwz`2vCShv$6>tz8;O9e4RpWiiI1DGE6h5 zfVXvtM{U9jh6jp7T>Yzkp1JVzV^5_|Ke}{8#G4oS4)YZDcE!sm_5+j$PWc~jrX8iB zs096(8rTXHFW;JnKfVYvib=7EHb%_{Qlm}d${(y}W`lnZHjpazo9Bn6tk^qAMLhS6 zo%SKy+Twn*@9P>*FCKVZ?Fksm*d9+VYW&SL-DOSq-SFg5LI#agA8<6wMmvN6FU%?I zfcS+O?tsg^YC%W7RzD0f4aEkUs^JJAa%7{%+6ApY%gxe87!i-bDd@V97w2u<(DcHq zM4;#6!PD(UUESrUtc2nY{AKK=4e`y4ufE<*2EdcIbG3%0c|OIlsyB@#?Y>-Coc#bc zZO?h2^d5$(Lnf){O3s?`xG?Zu3O|0j@OZxAH5uL!&)9}gj4k25CZ0w#xb#xnWCX9d zafa22^P_=N+zQj@o=GL2+0*6b1G`H~`*6&`hp#6&6U?su2clM_?zyAD+Vz07AM|!b zc|meMOL}2&PNys$f{@aZbJQzrY7swzGKC`oxRStpT_5mEGGm-6@IN8I>L>dfAv_Z= z0$Ab~MAMnRr!6?0i@s*@$X>sBOu5N=hci(}x*#nI(~YM4J}VD)6f1ZV>l*T1l=kkB z=Li0EbpdH7LTEjmM!ln+v=svbmf`=15Q$^Qxx8I=XmDnfc2=p$xC;U$gqHR7xg-*F zJh1Dz4GNq`M(UUV+I$ov<;XA4HeTf`*!i?5#v@JDgUk~<9i)jHL8K}5^grk8d{Ibt z7y_p3%^m;2&2V`(n5x`pvH;@2?YXXgWxD3^{!0GXfIsQX?{bq2j2p~YrB{#OP4drdfIT; z1z)2}gByB@IZlH)`a>tiaU6afW6HDkKQOyD@wV`fyOPw|RYYqU3p{(LN)}P#<;`<` zX%~G$y+&ejyhLIVc;q!$*GfOxf4oNuQ)*xI;^rPsaLj9-=4Rs2aP`xHM8u#h(Eun( zSjV7D2Q{R&pW1#pi(m=AxhZ-a%k2@KWc9?gO#-dCZL1Cr*rw|8-^6Y|@;N*sZ7f=h zQ(tp-?>1o>n!@)5Zw*InI)AHg8{d`QXTEDs{74p-K^X5*tpjRdWq1sb02?oHWfopN z#!477-lD@=96F|~%|5Q!{tzfi573!xNl1PLwu5o5H)Zk2YNK;wig~9RZQ*nnhZ$0IW7m*MtjP=WvRnHvhNoeHf9o3`E5PJ zHlUHO-|MA`l_{URH9vAFBl#_cUY3JkY2)DCaD#8+1Ukf(@pZ_iEUm9UiF6BX^@SVQ z;?j2g-2>2_d4&8I9?t3fb@+4aCAF0z%UYg~*bC7>W&O|Tc(Spwwr}Z>c-n%JONiV? zMy;RGZR7_C)(cfevKUmvV<|g$xY{7hHwl{FE@^@xy@OOLrW}G(i14Ir7ooFS^zu`u zpl%Hpp><8SN@|%?i~;Y*kDD`t`cNExq0w*2uV9wtVG=Y+_ev#Jp`&l9u_rfU&m?3~ z>_G%aEFuV6WEd;dgkTmO2mmUBc1h1#uTFCE)=CcVe5Jv-n)vydn#%a}ZU&9(lOOln zGC~f?4>}y%5NFujETzKG_~#D~UiLqiLshD=UkxZxuNc7?0g3vl-VUOeEow$Z`B|qk zMfy;wen2t#7QkAXQ`FYU-8%6PNU#=#n`N?0Q5g^pMkG}2d zSmS}SoJ%GVu~>kwW2N8_Y43GFmX;NUNoD>r6mWB5OYRTxE1DU29#-GCiY^E6*D{>Bokiz;OpCaKTcZD#cFQRb$VcYydB4s9?u?z%7NIHG2(Wo&9$OPLtJ8W^4 z?>!+7rm}I@sXL{%-g9PkMvnurl+%DQL8^oTUJS}jU1cl`V zEaAh@QJN8QJ;-l-IZuQIAW`_VJt2mLV$aBG2(@=1f1wBJNd+qxL~`%vRY~t)?_QSb ztX0l4UF*&I6V^|XR=Ooz{d~M|HJM?QFokELk)}uQhyUA0vPHfXbR0clK;7o!>7G*E zWxihfrW_LsH$(>#wlabq``}JI2k)O~ww-6!+6{yuOlk*YWC7lf-Sb zt>F>ohc*BhayyJ`?>u4}wio(3{=V}VWWFmArGa74zA*epU3?c^!{v&U_H>5~!% zgbWmoso-XjQ6N2ll6m`$12;Vhudm}*Tqj0}xOnhYfT8Kw75+K7$Zz`W{9u0mR7VM2 z9vxi!;O=Njc9|Rj)_u3jU27Mb$|wjWO~^!-RZzW#q>+s~PPg37W7ZLQT_2m!l6V!7 z3HGp4wLn(=+Wz1-FSIiNpCogw)<#;>MMNDh@Zc9S4sZIZrY$2c>gDo!>|tE{ysBx9fEeEnDe>hyy86^(&QQ3nZ?{vt^4EiO z{hj(}k<{dYYxsq8TMOW=^`w<{m3fQ#Z8%-)q< zr*q2pG;4{Klo3db)m6(1%w21v_DTwmEdruF_$OPp^K$ye5I<#QENrK> z8wSE~>=V!tl&n4(&OM&&uAn~;R>q%d~YB>aUqer z&nOTW?|JvZlQ)juH%souH5^yAag|H!phrrbJniiGE3Ir5&Nrj3&lrU!y6-2iN<4x* zBlvvufBL__Ri&5wvVPac5MayFdv|noddtnq8MEnnuy-inb1T5L?icV+B!*Q@)eP=U z`0S2$y4i~UhvT$nm5+*h&l*hg9qLnT8O;Msh`YU_A=qXTCgg#a&x4DvCA%88{LhcV zv3mvAgsELU*Q@%aDv~l6f!NCZ(YE5yFXK1f$4re}^C_0QG68jY5C&Qe3iHk(f05mJ z0q%D?XFpD6tE_ZW0X{bi8Al#f*@@N#6{RGrEFt?8=x=HME!78jGQO+6Ju)QxXa<_mn3HBj+o@q7?*c!1=45%!Ch zzwY_Hy$3=Z=YyY#FjP;;DEWOpk%NAtg&mNjUTrU^Ps-JF@E9m}0R7)Ti9EjaRMRAn zDd5B*eQ95`IwmYDo(ss#@cGP3D*ygg#S*J~XsN!}>QwnNYbi17Da#u{fC2Z)BPlU1 zF=E>2o$Tf|>@ac72Y-w0RFSDzO6~Pe^pVW{qk&nU7u(#5)a6^n+w>68U(C70pRk&( z*+^mcx7j?1E5yd=nSnM+cSI35tCuN(v7(IQJc~AjobaH$u6-VN&sP<%*_Gj4HJ9Yq z*1vy!D$lacZr6*igMVU_iS?7-BxD>0U%j*$vyxa|)WeGxjfkP`%h;x!40B6nhT`$i z7&p-g;)^Y}*W$R$Nkx94LwDkPspSGdYG(YvWK~)UqC+HBd=UKrdAtMI>ioCDU}^EP zkcrvrwNgRfo`OlX43#3AQUWKc`Q> zbIGI~o)4M4ez9)cQ@*@X@$Fc)Q7A5UF^z-MxYcZA{AOKHD^x9CvUGpanr7E+Jl3?0 zTA+u@pZE##%y5O;YdS(Dj6!l;X2vE=DJ_O10r#=LUF{R{82sz+EDrL-;$Ki^3Kyz1 zXe86PCiCKwdof?wq(43NxmM&`E8n_A?64j*Sd5$=vatU|OE*hLchB>`KNYH47+0<*W@dfeSk)$emx?5je^vrbC?GBn+! zj;xaWRcl${w5FHZS$GyWKdFCeZ00E4Yf?HcOs(_n7`JsEwd+dtzPk20a9dbNp4e2nZPa~tU4TvT zD$p^GOy_jh5<1W54tp&c&dN8&c?Pn$z*EkFePiWc6E{CH)Rrjmo90lcX#31J3Q+W| zk_)o)^hBsl0Us#CBmDo59bdGy%*+jx%nPlE|QK3C{Vj&7=|36{rb z^ur1C{-5c;v0XSp9p*ZDEW`^Ww+);KI<>3>dNI1KgpBP2 zZ7qI_W>;PQ@#rDq#oF1ZaCbr+uK~q^wDzrSb(4)Z#w5V9Tb^|vFqt8t zlUb>9KPxR}Isl*A7QwbxR!sQSINSZ>`F)h(mQ(=p>+`-=mmXSrKcCExkpdnaD@r-~ zcm8v%pNg&<{8&hM!yB1qNK^ZDLtCXmW^DkQ>`tWTa9(vkH;55YRz53g_+M{n_ zX?uKAnS8o4Et6aoY1r7#zE8`Z{$bVtD02~;J5H{6+9Y+I=}lwRlxxncP21-%b#T?^ z?@TkWe+b;3J@YFUvb9DZ8`Clme7yB1n#yl?c6@UAc)bj4ZVLoK(|=aI+3uzDO|;mP z!fIiR`+?oF7bT+*jK>pQ^Q(2mpzL|z{QAVm#jWe<_ujq7gbC{0sAim^e5JLfGV}cp z#1B21uA-0k-pNQ8lwQ(~^e4DhL%PK38iXnCm8A&6c9ARb=v>L-EOYXSCy#;AU0LoK zOs8i3p19B=1M1zx0kt8P9-p?D({R-B97QG>4$sK3RufS+|;s zuAkF*lGFGo%F#m_~MmQSb|_U|VAbims+{Bxx2J@l(_ z@wshOm0)KZ?+Bes^|BC=Z*x2ETU(abO)x2=kiK4)5C7Z4@kHcy^m(-1n!dh*5J@(X zuLUQTR!g4l4)C&x<3hj279O82ui)FuB6~aNG+(60w}<`o_f_ZjnM=fcs!h8n0WQ>C)wKFWFKNjVoQUdPh0KKw9zfkkt8n@>*lw;?+@Os65cwz3*Nxc3;cl;8B z(melQ%#O7FbxJa}35nQ`db*gEIH-xt^rL|;2lNTklo>xl1SK=$$Sls+fHhk-ZUxm9 z69uy&Vm}(T{*p7%yPAh-1Q(j7Cny0ik%c2?b(90iC`3txTWtd8Z z(pldkwP&^2m4*I()>#u+=<+R)yUawMEG;r$?D4+p?2~)kuO~NEd}2c$fe`p z%Mlx`heFk?_@ye24JS`}sIn}9iXZEcgUKsb(Zb9fpJ!`ijL~bmZq} zm`zg#h=w{=X0ka^8`zu*u*g!(3(6+?CeWxV_C@MwJWe)=jz)q`d^584dY8-T*rnOS_@r``|tqK``i7tSrEt9zghJa#*sywn62unzli?CuCXs6 zL|}Gk$x|ELz3oq$^g+%#mjK?jG zM*4=sDE6DZw>wHarSO9f5{09T0R!~vktit~#lT=F3y^FE`G5OxB$SZ>V_!2=T`mO= zkfc;jWkO>jx?zu2sM7;kRE_$FhDDkVEpH!>tpq04#ul17h=LOOBCch|kr~r<)4O#r zrlG$>g9AT@1d56GZz^rFI_rXnPG~v5Y{_o(U_XtzJJkecVE{9jIPd@FF_NCO2Fnr~XpfU|5b(J34F(!Y}thp%n>V#dJbg#na?(>QkV1maQ3o1(A;i) zgtu2G>U37(uZzAUNkBI7U_^u@v&6Av60Y(L;6Js1v|+fP-YEGuoSn)+d%;7HwIWzq zB(=kMwWw3CK|r`t~Kz;>fsCrv_TI0FQcawBe!=SGbnDSJM8Z*ak4XPKKMVlPC$yFH0u>p5e zzwqb+t-u!B#E-B_gu({VD}LBZq~V-rQLA^tgj+qNHkL%0xluaxdU}cz)pf@+^5dC= z>Yg5sYD{Y=TZXlf9HLp51L0X}^R2@agpN{%wd9hFwd6%vCfkMrM`_j+#T78agFO^8 zWJ|osPjRS+Y3bIR6aO|T=&O`|4>qpN+;);0SyMNuSYwYPV!s%~QXDt07%_)Qo1n{? zBw`Eqo3Imw_q?@nWDM>D6ctt*b-FbR7GnR93};g*(-N7txB_QdavuAadzTb21%uYB5s#(2JH0S)jMb z{j6mEDKw3{G5UIJkF@+&FLSI8UK=FvK%B^)L>ua_!L`&Krow9I_8a!|$)IMm!TzX3 zVn^z_&*_+SA0!9#r$|PBjI7ZtH*+FoHfHi}7ww2N$U{QW3Oo*IBOJ+!s5F0?C?O^Z zMjQ`@eu4^pVSX5lPyg(4>bKjz)B@Y}yOP<`%(fn}2>-fC^c?TAyS&+CZ3Vm~C^CZc zB#E{c(VYMYC#Azxr~wNt04#LDForw#^PD(FVx6vvt2W(3atA=Zg2)@Nz>cXR7Z0BT zKKM=i*aF*qS=w>@=C6ps*tlcON61SI;d;ubab+pHv;EQay6s)ZhRScQj<=2fEjLLv zL8c4_p`vIQPBS71g2fSP)aD5Jv$TY=BkMQaJ=AJHDm+RGW=V(|BXJn%1q{OhFakzC zv!RPP48Mai_e2Z5!Pw=lAtvM&IfQnpI1D&H8Gn=asGRF~?sTEpB{6f=G{|g4<2AW= zN2>KzfN$!VoY`w>d!DIQ79@;!A841*6k}Q`Wx0PEI=|cJG zk*iBKvC^>I+)N|fk_~F@iDvY)i>rb8Y?0YQ%IZ1&m93m zm%amH>)>UqLT8*&P?zZRY^ma-r>0v$N@k{Fb@X`Ecr6IUpi!aI{+%Y_`kqYDrNrj0X>GF|SGkvRXq1UzT>`$dZ z`4ZZewO8Gv&A`6-8et7QUR%ZZAvkVILfXWXly`%9N2N9b_)rsQs+4~4?;+rwWPl;X z0{0^#j!nGeCryN7J6P$-01spl$rGrf8B*^$H)S zV)!7jQCS=@QCV&&)BJXzP^W?{a4j2$)Py}D@hmAMnfz|XBI_^U9e|+=fp^L!BoTe z`DWTgH+J+iGn?vbQxRJySDO^C+dTx>(ayjD0tRS;!3v5A*NX{$X;GGk<+f4IDPkl6 zRY+RZFaqLXKpF{H<3)HZ4zO7+@`)b`Q3-JSXN|lWTKM`6W&T;QPbnoVIR8+WNqT;1 z*jo*so=?bwkIizN18yJnRq=+vHZDDI)~-7mr)0AtZ zjDvxc!D>#x)~pwyfN^Jlm%-xJewFQ)#sZY-7amIqDAVs)8cTe6$eAt3^wLVxI*(lH8fCii4-GXoHJ*Sw>uyv(g6*GrOixvzN~jAjHcgz$ zsLdaz>zf+gXwKi>-Ujui#)RHl-)j?Ey0f3q!(f)d7&HR~-Fc$~KrHrmnFM4gRmPz> zd0D!ZIv74~ap4hIV;DmQ$re9n)E=D(M@SZ=J{_qRvgyI1PlMM19RwAqnv8&-sY#M; z@#8)+s7?K_6240JJ=x|*mo?~Q>#);piF2BJNkrZr$~+0^6zd$Yz{3EouUcZE2Kuq1 z#C^bKEP!i;xGjd7X2t_SxUdkw0VmXv5jzTSLLKoEz{PU%cHs9`Q`Ksr%rgU$l#^xq z{J2H+yMm!?3#KmPj5cybS4^N8CENV)9-$b2x{3%d2gBLR-tEHU#yID~+p|o=0$1EH zDnJIVxWPLO8_O=-K^7z@X@I%`Cx;6>a6dUJJz*l^g)iZ?P949OO^%No8rJS=z8Ao+ ze~hJp{RW%TTVhkY^dVnfIATp}W#H5(%UkE~`oy`=MBVoDoFnvZC7;s4vC(zjolhL>K|egGxQ2{b;h>>>T^4cjPajN%BgyhHi)H zED{k&}E?L^`~P#7J)Zd_!T+JxSe%>wlyGj0F|u zp?-%0DkjIRF3smnFk!_vK%#iYN(=5*z*d_%@eao$z4`C`rRTZiJ+JRKdTS=?0H^eM z02v_A-1*HWaDFrNENC1K(T{Kk0u5qTvLc^~z#AlfT2?SEo30kKB`qU{1I$;qUe>qG#_V6uH9 z)h~Y&NU2;{pnzd0KY5!S0vR0YU*g1fFRG_}asSx@#0M&nSStwi07Yiu8pfM4U7J|4 zF-a}}jv^JH@EMa7SXrddm@-=BCcQQ)iq?jZ91IK*#AK0AhR1RQMOwpn5`PJlCv0Za zW^{ZC%i+>q^mE5U5NL8@Iv^L|=NYydGVKyH^CWlcI`X37nigIZ2~&gBssoq^J_EFX zxzlw0E%JGRl0YuVupb!Fp9_G|K!zE4pf*-VmY%@y87TP(oL@dJ>d34%;;s0N>}1<3 z==%$Xt593t$h!WHcRYN+xj{WuGO(667pEw%j|~|mF@-Ix0A2v}FDdc+7xazW97*vg zcjkCd9aMGK67PQ!d4xh~0d~YR3ydSnRd7vggm4weAjWcgCYTnH;dT3mFZT`{G9Csx zH2J>k8Ei`q#zl7~o#|P!0|+%M>3eG>?PesfB&Afhj|Og0lzaZFrau=9c3 zuBI9Ck{QFpc3*!883`6$T)#@O{44yGBmqCe!XFV3lkg6Q0_T;{4I1EzJZ#mNc0`ci zp_#_Dho#92>p9A>RJm_3m?Ss-Zjj0KBYMfLwL$&Iv_vM$c&;7$sg?MkQUG#oUY1d%B| zWr59s$k&KQ$V2>qMm!s_#RrMW`6V7Os`x9S{?q& zH_sSg!PByf&4&2Uf-n>)*wmiaywkCJj+>yiZY4E-abbj@G@cDiPed<3-rm?Zp| zBfJa!iCUhXG1z;uOn44D#jU`pl?n^`kBUi7| zdVKYE^#k(N+R-nJbQ<>T_W#+=_5ZV-+6eS^DXQVa$E^97@NH0fvz zAo(Ef4Pg+ikD3>u8tcImYo9-&yOSOpDr!$P=WLKs@R1Kp#s2J)+ri%@%fUU$qYmmO4k zo1oSmkKwuFDf`l%tAF-cg__Jo#t4^{n56bP`Z(9q9vd=&W}Ww$>POKe02ha2as!#u z9x5(3t@H*NZL0K0*j>eJ)K9gT?jCK($$x()7R$i}*&`4xA>8mn!6$M`>M4oWCREcX z6cK#32fTOCn!P{tR_}MOG-C@w%b5D%(c61<*oVDJppD}r$ONDuSU9CWb$A3OpzIx} zAyV;_zAst;KM3p>vdI2(5z9siDBremfyr9KIn$D*ay^KJ)xfuKpYQ?oOmXTC1L|2W zMnbUxp~fW{Q0~VClmiq-$*&O!fOhf#?KD^cm-AHMC8xyAQ`uTE2@FEXgF%-w4nmRc z!l)fU!0!!V0!W83B88C>$)4VH`YK`E9NI&G-HcG`J;vf%kd)x7-#1^|fUHWZ)}j-+yXh&$S)v^ItQg2d0Gb+#8bY^~xpF19?~Yvwm$Pr?l(CR&b1ca8J=; zjP;@d#Bd0Ht~)R3*_P4yR*b!M9(h$$MNqm>D0t-yF{#W5msJ*|)4kEwSzZmYVV+F2D_Z3qS6&4>jc(0GuTrjSI4}VPNw4Waw`7VG-ydMs z8smpgDV`F42FoX8XfOBntU;2g&CL2NH zj=1A20xcDusKb@%)@%)8N~~Y38HIQe;d%t^dRnr+JVPZoqpp$w1DCJnST(%t8y|pNFIa0xQc$F_UqF%}1JKbX z1Vos5rXV{^EO56-#6_gbLlS4FUTlW+r4^c?+bUsi6Dh5KcZS!cjUNn@ubR~A4x#16 z$ptn3?uBimCBVWVkLr%d_|)371tJ z<_O?l6VYG3aFzJ8G*zx5b<)ZO;~}I>?9X#Ax(4CWe)byt z9Rvl%cBM0oswsM+O9Z7TZ&Ibz+4A{@R1Wc19WM-#azG96a5vy+$tki1O%G@#A!vC0 zj#YwlexCFOk{ zIwoIJ_J`T~Ms^8@Ov#MvQ%J&?m6Ql=4T_9S(*K+++ABf@jGbvj@P;wlfmt#1?g#Y0 zC@na(;xL%_vla5LEJm;w57IDvQVKAj?vJ_A2t*wSi|X*!me7ASR2=CIrecqkz5fYV zggXW?<3bxu>>>a`gaBVvsV*I}hYZkh!X!%KkIxg!rA_k7$-$2wG+f*Zku0d|0-$}9)+jE7`-^aW|KJFb8+I%7B3FuzixS$Z1 zMq+rQL3hT)AGHOZc@YDIyNIDiT7xP5ft)TK+}=d8Ievg)E&TT9tgzEi>}eP7>%%|O z1a6!+4*omnIwPeq)E9n!)P9(dht1h-~(uG$`(Xga` z1T}C3Q`j|A2MDJjd`ZBTz4Nu+5dppx2Brr{V*B49ivXXYu+{|)i7fSmj(Y438BjlN2-(p@GM8w-8L+t}iGYyssXvoCe1(E5FYEm>K&#{oygZ(nQR^} zT;nFpb4Bol`-f|f^IE~ju_ttpdD4%!bS-b94=fo{!EBL3nfK&wnU_p09S+~#ogF!N zId^8HYZQKw&KhsJejYGOSGl`8iPSH>V^P-TFdz^CF-RT)M|ms|1`cPn zTu=EE&}7KF>+i++KPI{UtD5F~1UU%vh6poAZu#K_i&TOf$Yk5MRY|Ikn&X z+`)c2_RJ6XRy!eS86@wkJ@v7Yzvb-x%?p5zHUMP+7Hg6QH2GWlfxrE(H(T+*n|T>s z8w$7lm**NI%=|CUodNRPI8Ncr(pt(9gGLvi1${~3_QGOKjHB!If7QTE$*=6yNl+Uf zwGAGY(;~!mKXy|IbgO7^`T;Dt#x)yyV8c(CsUyFQ$&&>_aw6bsC zF?ceoy~?ViIR6kp?d1*0!7@Go?c-4_ya*>t%^L@t9VtRU0dW8E>C6iqkNi@sClM~+ z=STgUaUkZjAdr+tuq?wDs3G8CZrfcC0P_yL6JHy3%!@q*^_c{PY;ZqWg!|(2j$oR& zs$){x7`EY$CVUW@>K`g7jg=8GL7P`5BQc6e{qI(p!>rTJ^pgrp0ZZ@`h>1e4i6I((EV#oJ9DgifH#4>`^e~{epmdGVH_+Pmtef@cyH^i%D z(TgW0>BEoSgvHIdqEFi3Jipr97`#l_X^x;Oumi0gHa)Ynl)uQdXC012b?#Drqhc=ehI>AHb=dgU9WXJP_F(#q}8+2K6O(n;sCZMh3N zFtEhHOH>tZ;TwQnxDS?a)r4;8{A^XYOr)h;We%4mPdJ#f#gJ~Bs>6w#vL)*fHT;Pe z+RK_-7U--_OlhO*Bao8%&NBKbaMutOVT&9t$xhBsm!i>;Rr6QhW1o?0xp25O6ENH#8G531IDp2{&CuNleHc=yA19b57=|X844dwdks)9}5eZQ- zB6duX0K_fAyK6>cMl__@uZPFSr;3xNDWBu(LW@{3aXGTcqum_f4*q7Y6K!51WdZ5g zmBM6KeqyO+nvGiyzz_qK`hm84trG8(XX#2KM91U5LRO-p1CW-k_v&nGr||Rjda`1X zGi}v~GGpuuF@EH6ohi^=>Mp{c;HXyN7_ONUmeubIS; zE0jtp<8#ygWx~$4dfsI+`sc{KSb?djlYLDZ>}Aa}lE4sh)QON-q~d(}t`%F`bOQU= zgGVFFS@v{lWlO!^jAPPS`2Mo<66& zW|d@voJMvmQ3lm*Ow_DuPGBzml<6gn0`NEzM*iHnlr~kZe`PgIFrRsJ!%Z3V?B#nv zQ0+x72bz3TBL;!yG)F{C;|F_0j8yyHxdIIJj{=vAI2ft3k`T#8;?%&jMBOmVQ~*WP zJp#*HEPEpAD$}>T{G|Q(%TM*Q8KlP7B@2SjJK5r^r_mc2jt4Xj52{7z1CqB8V>KQ&5EH_sc`!|vk{n$9u+1aE4 zLiPKoAj>-3UG@=}vQmjBfnXFg$~%tz0Q7Vpbhd7J2x5lq+9;4h7%F=s8^c0;mLv?g zL4nkc;Dlj8g4UKI6rF)PUD(#D75Zox_<;lr4`bLvAILTlf z6->oF;VZMLJ*6*qD$(9ayUF=pAoU)g1f_2egx;-2Hw55V($65!EfhEARp-&vRlbhP1s{DmW49@uAp53Gfb(WJ%) z)II4=0#o*V4|>!hULX(g0*X^uu>trqiAA zUh^j_lx9P$LV1r4WIwcM`NqW!+iZzXgU^pR z@7D1uyDm*PrF&}e+~M*#k9HH%V;(M)JP#3dG{#cE>npLayaE`Ik~Boy1fMHeMK*RR zbp-B!ZL#?_BEoTXB?SLK(5*4C(>7hv5KvPLD$c`hHz+_Y`j}RbQIqWsljV+*#SJbt zvd0nJ>WQT3#~Z{pnk9lT<0z~uTbX-eL{Q2X*iRCHrMo856=+cSnAK~yJW&#htOPDa z&q5-z?-U#}4r5FD#ND9^DL#Im0r`<7_FDUQhC7lk(!WR~i}&(UV%g6$7hzlUP29a- zG5WXlEg-PR{|vAgr5=%aARKw@GuHS7s_tSWIc_I*`4R9<9b0@Zu<%#bd6YmLLNlx8 ziit5DH3c!t)t`ab?opug1+u_V5HkX?XX9cV3anfm2_ZQkUINk+!~3B26~K;-aZZ`( zZPaTifdR082!91pu*lIuG3CO+=YmKuBnMz}L6Xl4yA0)KZsCtlUX4qbqljg{NF3!r zucMm1bC`f$)mdWqf$GBR4(DwlwmP0j?2q1CdX-xfB>J3Q1fGQ_Rs@LU=%^csSgw$$@J_ak&bRHoDQR>YIS^$n;}OBEfGSxB#8W}U zVnaCCrcrpov8C9i`UR-0nt5a%!cgbwPldz7R+f(E#2w{Hb2{%{$*o;7d>>#K4BR*; z;C>f@fYH-`lCPN(A6W&o`?gjLZmL5aY|&?qs>ZYIHN3y7zYqOMrho7B1ZMRp)vt$! z78lx{#nyEZ+cnoGUflHU3MBqbr%rceVL1d(T>>qX*{lD*g|cgLpDsi9B$KG3KZtoC znr@$+DJYVUmU?v&qWKz_V&e82wIxN`8K|;4W=h{sSaLgxq%3j0(2;X-`w(Al!1H{D zBMBwKlJMr8>$14sHB(uS_}8fRt+E}TA)0id<99GHGN^G&_DdYrpe|r>jMP5FERJVv zu^YBR&5#bq88~|yKR#J777~vuLjXS}C>JpR<86cQaL!{0?O3LcfW5uOJ9Q*6ZLt@C zQKU_hhf{&xS$0|-Ep>bD`&xegwP8G}tD>B~xm(>&h|oST|1T!Gk6$0f?h2Zqz}?1} z&AZRrqicgtMu#sO-}8Q>4ioCz?S0y+dU_?~zRhj(oWa%Q6pr(|Fa0;*+OCx9ezqIBJ9~el&!aq=&g6+O?+Y@!$U_o0n1dtU%~M( zx(5Ct2>~wv3@%!AbYiBiB4I(=Hl(TQlqR&RM9Re*>nNA@a2#y|0}4qG3=F&k6hhPw z^~8ckvH5s^eQU(w<@I9+R%jU+m|CtN$F1lT7x=vs2=EN#Qv`uHpi8}z@vajsiYXxt zhn;DefeFJKZg-bU6XKO05c%pj!$fUO%7T<#A!Q>Y`h2JqR+NnDACesf=Tj@jh2>MPG7r?wd&C!dg7qx%4mWAJy*-Rm8$ z`|G)_OGWI}A7)8$(lzJ!$R@lwpx?2d5G#!|h)dfm=TdV>FV!gBw&o6^fY7;gM>Fb$ zZjFI!)d&Y3u=-Wrus~Lu2u}gCmKU|o)KBoAK475xIQPw>;jR9?3$eO=I!zyrS?oT= za=dkI|8)tagYq|`QGs*9=mw~z#+ysW_+m_ueGnUC6DUi?5lB~&9-M?`SH2_@&Oyaw z3K9wes8c8w#FwI}g1sGNCliSEJ$dl`fuxhnn=o+flnZayW;dq}lV;8Z{#OyqYfQl# zemGEv?&zyqGbf;;Z_dz(7zBb6`t|nEcX>Hjz0~u-4D^^)87|FQL!0aZW2yZE7{OS&8BZlp`31f)Ycq#LALy1TnuTDm(9NJ)2h!~Nj* z{_a0tAgG6#+1Z)dXJ=-2X+FTw1LXxT+e;=E!GzFqtoJ)6EvP+)z&yWA7#EJdy+Mv^ z#ULIX(2;dWG--&nqQPsbH4G<~{iP^cnzf?tD{+fR5(50RRmey3C%iY)ay;Cl7zU0r z^X5^vu4Kho`(LAnzzMY=&q|Tr*p%KMTbOT%!}h^Paemj#WPOfaAB+K#SUTYXKs!D{ zg6s}ZnLT7tsZ3|-lE9RKEI%Se4`7A-vkM&AJ55aUWOWDb<`4HIY8Ox8`jZjnhek~2 zX{DYZefN{Uu7q3tgD+rNe}xO64ZNG`1YZw}E)9=QZ_IVTPa{m;k5+bC#vKgS-rU|3 zg{lqUcLHpjaQ5xKsVU;xDnt!gLc0sc>zmSImU?{3Lw`$Cfy*Nd!y|$84igOeOx5Ms zJkVIa&E=u&c|2CCCF&RYB?ew-6#r@D#lYE?)gSaum#$Mkj!ZQ4tknyT?-x4AIRL|W zqxT91t2SCGr+dDLTNzPZNu;|y^ZOMtwiGGx(~p9^dw#=b`;+fwL&7#gyVS20Ku!yhwu@wA=Xt*)Xs|A>iG1-bK(^qnl9N?(uR3`7 zr8!?x;R21Y`1=M=YtO(RsH4Cgrgff)wsrQ3hNFaDH&y;-7#m(wdi}DWVCC#};e5lG z^`2c*do-y&{rMNmo8PIolxFyrMjZLWa{0JF9wxao&=5P)gz_YrLdXhn zE`uc!o(1$)J%iEvL7`Ce(!A@1pn{mHPv#Wi5G{d=!;-jRAMAauhLP*eq<~6EHhQvC zFA9Sd694A#ds+`G76JxCVS&4DhQd1t1EA~Evq;T1Yd6i}Cg)+`1S@S5yr>@4CV@^7 z{yrO_!K(HH7KIj2(})-Ce!LdcTsA%}+iuhJkGcVnhW@7dPF$@@DX$>NIT~r2G@dG6 zFtRV6uhV^pS~c7jf|c)%>P5Cc@HhX@q%pXoGpO^V&vfkt)Ex69lL9pFmiaW{61n_V z+TiCDW;`C@&xbq)7EHhQSXKXoIA23-OfH2FQS#ugZ7dqV`{rj7ps>3tcNhHIv`Ed= zbmr)Xo5!o8+KRFFZ^8E?fb>3N!Q`91yEEWG4pI7pQITh^Z@xJhnl+1Hw(~zpP+B5jm9z zcV2XF4w@0Uv5agN^1ja)ZN3)m5%=pUD$_Of3R;cW9mU(SE+r^xNCcr%~7x1A073yE);obM_e5(H9qkc)q|iu z0(e-B^#KOxGN7lNT(wj~*vI}PPg6juO&51L|22h8I$UwlAmA1*$sN-&#El#Q7v zRj@yo6RV9pFumo?Zt0aD)`0}a<+ctNV9?e?4aEKURIQ{aeVmNzcabea{olf)fg;z& zq*W=-_+fDK3k$!_M2CtXPXIL1Xgmd&K($-EB&n1Og-jI^Y9z*)>AHU%?St5zGLUdy zeYeE-1vZgGIOEf^cXMo2gq6PpLI|ARFBmxYtQ<*_d3xnLG605cS||@x3WC8+AGxIR z8&|JuPhNhvaIU3#Vz!4h$Mknq5@)}cQ0Te^8VuCJ6#;3cfi0j0U9<=WOw2BI1uxF1 z3IfA-FW(k_LWI4ynq(E3LEzc0EzrRR9L)c!FOxTZXeWE2*2qP`AO<+v1wD`YBNC@O zcYCH_-9e8<>sXnHxxQybZ)5saPJyp4Bi0qB9jlF=%{INAr-1{!yH_@2EQgYL zbhMSBs+Ge}b zUFTYC4-_=BeVHmyW)ar};cknC{4N(dz5t)@>9&*dd;AIvb2goE#B5)(CUHItp3}0F ztbypGsPr0mHzZ5Bufl=wu6VzfaYnWdfgZL3f(6$nkW3S*L-5G3CmVbZ+@4&}xOiRltYcCnKY|B`Dkws4?8sf~_)>l}>g@nMHU zafmY@_t>Dvq%-u3h~jCIVTr-pC*8H6IN9HMls;=SC)@3wU* z#tKF*FpZbDW+oURB{VfCz;zIsgms;hIj|RnlKz52gC+xkC5$W6Zok;hWQOV@I7nG z+k*CYH=uJ#NMYXPWv!Gf63)g&MdQ=xpaWmC*-cLtFHxjPXZx(`2Zc!W~9asyA zixI}i+rX=l=k&*?;AT@Cqg>WkZ;j!Ff`d|I6!!=EN!`4{$#Y+5G@hI#Hj`T@Ux)~> z<8Emqr+3HMB;~tmi z-xHK6wbTmdt>9y|yIm5^!SUS-5Y*4&{gIiq*z zIg0vh0*`kKwr_X-*t&Sg8&Y1t#`FqgYU^z#uW3SsqL*?`USRnl{@ioDQA>RlCn7MZ z>)7BSt3nQ2D94p`K5Kt?2w4~ln8UZGZj{z())cdoJ47B+Bc1)O9|21^k3X!S$;I$@ z1#2ezH<*qX`YWQ;7t1D|4$+1n7qxAG++XiWf`gAA8HN{x%z^tUk#nbf4yq>8V+*6m zKg#2q%>-NUxb=-SxfUb z`g=6+2ge5-u?ARO%WS!#KBO|(pN9Qms9$;HqO+Sq^4fg+7jX8s;xf6`OrWf|sx_gQ zg#MWOmvcrJDubhE@y#wBChZvqQ!cP~^I8`m|LZZJl3>Nr7_tf6$ z=TAjT4Oxoq*Ut%CBG0tO z@yIxfz&S)~@9+br$Il_(;HZ1nCk^>2|C_Up9svRNh@mo6C1Vj-ePicAQ_FVK1j?LC zF^RJ!S_6Xjll5P0wS)t?qx_PViw4*)mZW29@g(xp0mI3qmVP5@?~xDc;*sHL!iz}~ zH`Vh0`dA{T$~5mPLiZmGnAm$M+cdd)XxKD8vHWgf=Z={#T+my^!g>5toy>F~8Fmi3PM6oLCrVN`^3uct@h)`5T;0Tc-dLJ#bYY1#aA57(yBrPCKVmb58|IO zd+Di7u&SdUJiR=%oW9j{tB183iaC(nEV6ie25Np8S{Ms96pNK6?=4flE~)*ba&Wu% zhZIjq=#Xxw3^wz)tqe7h)`*s&HvtvwLo0VD1NE~xzxDyFj65voM_*(?%KF9mK&tYu z;&Uu5wb8C%=AELNw&H`kFGfGlEz^ZsTtlbhA2N^R&(RAV~D`IYm&-oX?hd zPkNgd6Iju6^$_{M;RmjF@@nL3X@4o9SMuue_=HVAcSk$3t}fT-kKr~OKM1+w%Gh%u zW99luekLtPRE?|&v^FbOHMJ&d>!~to^nCYY;cspIq9^0b)kQh9WXn*=Jj`r0 zG-9dzbm{)|a?(-j3waA~F>Uep@?1Ze4J$kG5qid3$J6cQc7GpgyKHRWIBd~v?j}P6 zd27E9yz$F5h;Z}b2gzf*UuN6kEuyx(3)Cr26OZo+4yb#*`Vq#tNQc>CM9|-tylRxg zxJGf1jXDQg=RwdP?Hf0T(66+%P6nQ3W|pBAs-IHiCdDd{`w6s7GV>W4c-FW)za3#C zVVl08fd-owpFV?4VFd`l*Oan^28L5?+^QX9pswk!o(tUrHU?}V4K&}3{ay!hU^=h{7vt4)@Tv@e=8WKQ+2j(!gP z_2_Cv8bqVgzcLWjxbSXOtI3KAb`@uD$tPRYo3+z7lPHB4>$#&2+18aUU+}tw3o>_s zw1VIN2tLA$OS+MU10llhMUeKTWP_dS7;iRG*t4;?t?ebPCo=o%dibr@0-bDH=buEI zl794d4-KLG1%;QtP2^*24?khde?@;qUc1RoQ}(P{v)AWqQnR&#JjU`t(D~*8lWnB= zr{Vho57K+xz7tY0sGP!X^8qH$O|&mO$SfBsFMl$ct*AZ+&KgKc2|PM6L^4h`Viby6 z)G&Fr0k9@@f*&>r>N}O_a1n&0NR;eVhS=u9fcXK*RN`58+l!UX$uB08G{mW$7G*v3 zn`&1?9h3z6B=TV4$A#Hx?A~)zInO&>uO~hF?*oq&)?dx4kZERCj(!CnKYvwAA?DAm zd4O>pbc!h^BcZWVItsz}Zhg2afAv|gwC8>C0qnr5^XMa_cV`=2q?^uUqF#+}?y>lI zR0Qy9s_ZKkVo3oUZUlGmz_H}m_=rW)iQ$wI;ea^??ac5?U!xRH`=LE2q>P_sfw=rr>bh>ZVV|0}~2MJr~A2 zeW5=@#&Yf%$f-UeDL_{)>3)j9Q`WJ#zMtq{<}QZ#I%jcxeyXHZvDtEQg_vxPZ)j2$ zHvPuXbN1B19+XU`zNJH@FEXd37>P;r$hcveXkRDj;1Bt*rpdtKKBs;Z^bD(Pe7w3m7^zFq z^9ftvayaMGIUYU3D7_U%SEWnt&UX{IAKXDQtdmai@BR_d{xePuzD&JB-m=) z+;uY;sgiW4cl~_e$Kr$CE$G~b+u{Q_p5te_U92ydmVvW5x%c%*bQV?7Kd3{)*H;E6 z^<}9D5gHn_unypRr}?ScLJsVq;?xg!u`ca{(!FU7!Y^rPEElcwARY&@ni5Si$10KJ zQmoWd&L$voqrj5dNjHdgWWz~o(<9KjGtLBogN2i+>711Wov#hk`%zz?FKh+uj!m3i zHO}{t24WscCBR}-vuhUB1R1fO@sAGnYztoZwI2z;DC=kWfBd{@NtU-Vb$p}T5{8{; z=Iq_T`(vqKO2d&qv-nl;zRqj>tJj6CVcfiEhc9{Yk1KI1(`8qDkA;F6=KM(#eIv|j zVUd{9)il+sq*=%G%X&7OL}OLiaR!^@-p|kb+5C)4yBz(8K~r|;LxKA@bS#CJD+ew! zYFkid_uo81zCJ$RcvW~^lhj@f97%1{Uxsz`z<#8BlcPBAV?cUZSeNd z&X24lU)ROI-d_=CSI9(V8N%Z4xB^h#>r>J27Kq}L9LMYMiHZg2D02Ln3v!;>cXh4_ z!9E>mz})pio4Ono}q;TJU!$ei0sNSW=E=dqbp86A}OT#>=c+ zCRn_~040ZuhEo1&(25uLV@pPcoQdROv-%#W?hux6JPJ-=>+~-qi%m`sjM*&it9?zA zYA1jBoWkRt_4WDCm9jhUa(UuJ942`U?{VAFwA*{~DTr|F6c)#)edA}NQIeK}1AR?i zGfGk_qh9!*ya}|AuY5`3?~>XgOx8eF0SHR_cQDL81*xB;uFBH%LlnDH*b{ZLK9)Ll zGRW2CHhGYIS|Hq;tfe_?6&^Xsc>+z{y;Q%HCVtxg*m3NX_Hmn=V!ZK|d7-e;>YIs+ zHK7IK(bE>UO==@Y;=r-Q&HiP3ANg1*o~dPr-fo>S!}!PV9i>Ff)QsAMwB-nQeXL*8 z_zi!$EfhGgibq1>W)zW-H2(a4`nA<#bMX$rk@YW;uJe-FO|6n6M|1L5ri1Uj;*qhG zBR$+@CxJ*Jd5u%RW5d`SK_T`}qARyMI&uXR?qE56$?DW!B#8+(@4axoE($st6|6L) z(zn+m$fBw++2C{}xEP*HgOfIQ&B%6yyHpKWJydWBFpYYG%cpg46 zh&L@QZ-e_of#9K`lw*Kep{&pkF?-3K+C}lbDDyRaR3tBQwrt4Ur~@)Upj6`}JIbYi z`1G@&b#|s8-rqoXXH=pRQv5{0ILD`#o}{T$%O)CX7L(a-mu5HCde< zSu33|AV8CApr<4VeD> z&G~Jvih#M|Z?8S~&@W0Q2tU3eq@9cmiI*n5^iRo^Eiw%uhheeLHI>4d8I~~I4jq&} ztK~|~;YmeOD!L;WTSM2}+ZUv9SY5j782@GQ298i=( zRsEAODx!jOidTKMLpCk_eKOIXuF*!iFeai5vX=LqgYX&u*?^+~FJNzKb0v7>3g^It z_}3}2Z>i{ZWZxE;$c2$V3hG1{2ZLB2^1jSuUY>}`wFXDd*7M)y6sp;Kqt5o$WTZk# zXoO1k*ZF&f&oZ<)S_FmYf+%P#{?kyg%(*l|0P-Xfdh46?H5%D?_N7^RqmQC>g|;!z znG8LY+wo7;ll7)Ot-_emevbZyfO$0! z0QQ^mpX?@Vi9^tJreZq-Vq|_e-g$TeqKLd=D6AKVKlJS9pjm45O2nOQGe3L%k#je7 zLt4wB;5{Dq9NecV+n1M*|1-s_7@zP%rCl5!hSxYLavV(rMSm+`JQ6S=M8Pazw+sKN z_<_BgPfVQm<)3dj|MSDuqzul4$RjoRt{BRIO_GF+3{^g#;K-vRxdJFxi`vT-COPhj zs6!omqG62ik;B#nujb^GziakQ)gMBW6yGCS2Yj0<=wT5LgaVFdRp*77Z|5pKbD89+ z_e!Hh&Ss5wqhUpMOd%2H1O}4P5q2oTPO4$940<`C6B?p#lH3frnoc1DLwRt=Tmfa) ze`-iEcs**|-5$7JSe?1LoM|k6hHz!``o)L__p^xNE+Aa%L<(Dn4^zyM%O?gCv-R+M zzKp3DIzGIg;q_9?GalDG86Ux$?!*z_1E28{u?{x)5(lOf%<>RLlS8`~$w_vcn*{*{ zOLW^42#Lb%( zVB<&7sSHQiKSyB{^s{i2mo-HC(h8t2We_3^$6_yP@Xt4(Lc=4YH^@alPpa>UBcbp8 z=NuupC?5KC6#gtV!j zj?jH$d+$EC98HJflD9&Hr-%H}agIwi;#S%C>>O9Dhk}j?g)U~q{bm6H*yKTj)=%Vw zqy}=vaaZ(SYw#kpFW(x+GE}($3lKk&Glp_KsFwWP&z!~ZMm>^d^iwD+7e>wA8})+! zsDFw}&gWQwsG&{V&SEN%5zXiLAKKF9|Iy}+yDBqBd*=}Dr84F`t-%ZBx+mTHH=f<6 zh#Fn!GxbN6t+1;F(LP`DQt_CvWnAf;%tMkEQgcx^~U@E`y0>dQxvI^fBEPi_!CM( zCG_JE?yduLBQNc0waz`8_;f8^o7JHS0EcY+Z3{OWYQeZN|CpW=2H{8efc!!5QMGRG=!O0;l#bpT$r)6sMe7P%NixR=iHw47t>!<;?ef~qO%%&-`; zhDxtN?`F9>HyiVos5mX4MxI25UIg?Ukfc{{skwZt7Z~IQJ#vH{@s2X_9aSO=T3KB` z^qDQ?+_rn&;xZ0gtltp=ZyF2>Tb<>Tc~YSj;=suI&I^`Odh#$QVXLEiAgu@}?_9ZM zwG4c1O)!=J!l7BDhnf4|KON(6>5P2Nv^z^7LkatI8akwTMudTYt41{d0pn5V;t| zIA*VU`o6zYHt;dP%hujm2_q^w-Sx49>QhT8_V4QvV<=TxR=+)tYYmOlp>+BWe67Wi z!pY7NK;H&LUAubHZ=eSrPKmNZIoO zhb5VB7ii#7hfq$;$FlizI@> z8D|~zXCH94cZA?e6{v7Nw7N=aM%VV2yQR-qEJb{;BWEkp!|sR3W)G!CqFb1NL!?c3 zY5!cH_KQ!`Er!0+3^uYhLmNVw9WLT&FwkP_fVW4`#1G>NwmsB;Fi_GCx0y{WLtEz> zJsJ+x{(55%($P^qi92Zuym4@3;&%S+{$|DgqH!C%am1SO4IJwbT)F=2CqV4F%FQw?62+eP`+6m1zG`sKV+EUBR%2@-LqwP8S_p%0lbgSW^F9Y+G@`I%CCA~3v8J2(ba*(eSa_Os zAR!)7rXzR%uR^9OSk~ ziSCm=Kkx^VYd(KJcq9MUCHNbsmetp+3#9t(B}eZNYiD{O^D(n${oJOPyVY}Jc}OwY zMZS}KJ%JezZoCJeUk?aB&>-->%j5#EJ}J=0WcwyT#Fya?;qC+ahaavXuRtd` z$D)F|dAc3<>!QU98#O=Jt4HjfP3mV$=2g)FNu&i^9cT{ji9D2)#oGmhiWQo}&)wW@ zx|W5>zEmR_f=LLR6aYZc41$L++6rhMr_mtP;a~~grtPX#LDwg8fFSq#kJ%2SICN$W zlD_;b%e)PFb9kV1(_@U#Dv^VZF?4irWO5z9OLzJz9v1Z|nPz(Fh$aiSVn{rLp){#Q z8;zRtelp@DzObZx^5Ktz-YE$v2gr#0PPP$4_WW9+2mw}{Y*vtzS(mm?e23V-X=HOH9n_$h)aXJ6|F>}k&$S|(D4Ce4CD=}1zoL9XnuV|9?>cj3 z;q-l|A=vC8^>^c_Bbo3)p9g6r;bWH7nJ>+@;5$KbkUXM@ASe#_OeGW$O9@2vYPq9~ z3Jb#RZt*ISkB%xlFbYsTzYAoxT52N=D5e_9Hhb;E2b$VPXKJOnnm6+K|B*MOiex$f zjm}=!b!&X)m2dhW#Uwn2rqAIYY(}Qm!%lL|Du!MuJ=k5HNcW~{ z_6#D|pM)qXLjuzWZYkJ8B-e%O9>&b^#mlW`@xy2YSpVkn>AvE#SvOiF7^c@Q+{;{7 z>G*8i#NUi;LwHJM2bKN+{zG_4pG1;;FWNn{KF7)l@z=Dy;{%ei6_e*?m{1+h&-5e_ z^#-C+Y)n38Mh2ZC7!bg!hQjz630(;!`4|0JcJ}To2)Bo%0gZ^&w8PoX}h!Pdk*T7b5{$7VqO^lMjXUg%~I79LjO!Y9=J@^>qm4kWyG@`QEfSR_-5Ac=}D>Kk)BlB10|(ujEOa6Muj=PAguzZu4*Z^)*DL zhuH#x4V;f(yesf55K=dcvs?kKL&O%jy_+h@m%?WWr~{PJR`-WlIB#ca!Sw#P?Oq2l zEhu$P8I(ew3XD8W^a=;SJ866*^R|xP4C3C4PnRc#R#J$OT_FC4l+#7GaJ+mGJ4>iL zgrBKr9OBW)m)Wl@lHoNtQszEqP~rH%`F#GHvV)TyBVTw39(erB%tgRVec4*vB=iTe z)VHuHKuHu+R1W+jN{6pV^a{gg%GJen!76WIWM@W}zKHK_zl@JilN^B&ikU*9RFS3R zS%0ym5~2@@n;W4_<_F)w0?VU{`8nIGZk?B!F8XyS{eU4BBmhcB;Gu(HOFjCPcKlIu zWwq$h(~xJQ9sq|t1fi`O#DZ;wSUZ9$1mgB7QWM3|9eIX$)o zESsEpTTDHXPaA(+89WyXF6qTxLAboI0VJ7p5|WdzX|=!W9Li-EIHuje8pePCuG<-ko)Gw) zr&{FAb zjYG-&$;4^bY&f9c%nj8-6g!zKkB_=Jb3iBDGijLle!Q)#>+Q=wrCuy6MkS$eP8d)? z0)M(-aMOS<&MsAJJe-N8v5&GXizg^mhZPjPEchKiEQ0?ivg={f{KT{7A8gv2#@+EI zTlJSrY6VN`C%&5M zJ3?X(tBP>yUq|i+1e2O*lKXhv{8w!^5ZMJbdeeZ103z$ghn{@kK&E7&k3LFEziY-> zlRP)|mA%BVXu?y=s<3qU`a~}-ASjY_4Bx_Vpxt~(m_5;h4)b@uNgrA3Kb#xU+CR*+ zu{8s?HXbF|gz2^OR44il;N{G`s9l8dze-~#lEEXo$O8#OQ1OL4_%|qGuXXQ0HgQyO zhl9aeOI+jAvls8Gc;aq|*w_jB$5`rR?WNYe>E`#b^C-COBR5WAVh@iNaUTU6D#}_O zlD~e$pFk@iv`eAfVLy-L%0w)UzH-(N;1Ul^mjX#txcnB!OT*{vf><<;~<{dr@%luvIkfPxg$fZhRFM_z=!F_P;IhSrn&Kegd0pe~xIQ zYjM;KH2MW4DSudel5+efdSM(rkwQi~CN2=^usC|u`MX(JS?H6^^82#WiQ4;7J39}|3a+$c zvML|!OS7ko54Drl*@GVr1E^|LWHAikYk&lsjx@QTJ_peR6ZX``^W9A$jGN9;QG%yf z2yOD>rwdAX=&#-_oxr7d6Z7HntEF9oc!Z1C%Yj>?P?BCvW!s~hUU9|XQ#6rq=nd;c zV&}t0&ns%a#3cktoiutPhm4s+2vqB2|1VeHM(>H<`xtRNA1_MQ`9kK2Cx(}>(ELcy z;Tsc;J%q^X+iV0UfiJBa^aRCEi5njWu#2zPOf;L#s~Po%OAv!X;>SdzJHAS0nqgAc zm$7Rl{vFI>=(h9PC)x9QkH#uGv64T=mIod$#lbor}NJHrj^e5QOUiMCQ z_!~N%)HCJ<^t+NZ7;zN(1B2`k#kho^F!lOxOw0CS-^C5Dz0ENY@eeJ?31idr*!eu^ zp*sE8FP@8xQ1IO#!e`koWUAa2C?(^`Uf3CDrFWkI2AG{75)=@WKr#f^>`_vDxAvDy zv9VfNsN~n;zy6Yypu?WAdixm=E)@k+2ZsO*2?Rv?ISF~K<9E2rtx&VZ1jJ>T!^!X! zokI~X-@(X0=zF=DD(j(eKT_ovcZS}lU)IX*s!4Br)ZZGdB3}MX&yDN_-{Ai~){YK6 z0oE&U>-5dmhB~X($~|B4-UNOsH9iIeZVr2gEi@zcd78J2>7X1E^p85m8}+_7>I$S( zOZQaBPY6R7fbrdf-;A%nmsx|bzYFOJp~PN~9r6w<{qj_Z!eMeSO0OZ^d)jh`D>QIX z#(0+sOz-wcp;C|TLW3#8$=571otKQs%wn8_u@A++k_;_Hyjs*_-lLM8aqx{C38p<3ngw}Eb^`ORH;Pac# zvrqm_TH(J*^J2RWB~$KLOA5#9noWn06#WAHU9|&QzpLcoMfr^+=&LN4rk(m*98U~+ z;hrg^`mV~GgLLv09Y7ItU}1zZG5?i3R&@_T2*=P5Rm>Vs*8-X^zatKf15z){DL8** zO&E^iC1F+hiX9fpL`y@qf8QIOnbnctYt^-X4=}k!*7mV#xcV_|>F12zeN?2G?j%0} z2wqd+;Qn!~E6WNBrXRjDtDR6!jhr2`3zy@{4k%42VIvtBjw0J*giaZGftr-Agc zjhL40#+wm)Zq7w=Y054aJr`Q%A@xibWljhYSk*gh0QBIkd{E))A&AQnM)r1gtV8b> zzBlk&2CpdQd_jvK3!-B0t~{F7htq~+KLX|Lk8Em=tyVn_Bp?*qFeZ$&@TYv0$Iq7C z3h714ql}~7=l)|R?I*-ZdAEC-?~j6T;yn4UUEwFhBpBn#yyL@PiL2o(c*hLPCm?=i zAEvLNdLle%sp!USySb}ZWK9Q~Wt9!&9iL7eTj}0>o~qKIFNSf43LJx9XgVJfT__M^ z7RLjioM=^DocVSyv|uD_QVN6cYV$Oj28eSI5-9yJAf9DK@|tZ)32Fly`_OgiV|Ldk z_5!EL@mdftQP+GUkRVjXvp1^}RqDkw5y+@LnqJ2uM+AjyHx_yR%lK`Zz~iBhV;Il^ z$6Y8PIP+#)SgYyPG1i0#-t1L}QwDU*{h=-7Zt1#ezBqQ*@rCA&W&Y6l==_Dr@hXw&sTim>z2dsj!_Y;9 z;wXKb6QMysd;z~vHd~(;uG15t%LzSaD0nl}5K0h>{f?SYEXac4T7gZ*EoS0dn;|wi zd^WX=Fyj9Y(WLbAtb-}xH~HRtiVDIf7~2b(0|;5kA@Hn)`Tv4AC4^55d&ffzv|=13 z=-jn8I$B~b$cvH?IR<+6zmTObGNh`XQaHBj9Txu!STisGJ76i00v9mq zIKM@!W zSDQ1=kNU8BE;KX4GMg+^bW&_N^#W+hdBp6h+Y{keo8CHleEyqF8BQ+_EI{m2R~tDs zZKt-tVIA3cg)cu$zeNR1UuUpI-Ut;*0K)mVra)Hy=cYVC!&;W^ zCJgN0V;i#cO<7ahE6sN}u_LIs_vk3|@8&JJxOYUY7?RH@m&pa6Zhj;J9qz57$Y=Qu z2On3+W8VDqNgacE^(_aQw7D6&GmyO4ZQhT&UoNR%O(Pt*1eMn)BWw^Bczys{x>jY63Nm7DPtIz130gChzf|MMfZ4` zqeXY6d}d|5ezg7I#6Yvzj147fc2sG+TG#3c2oR^RIsmlEK&nSfe0Mj|yUZO8u?VJw zET5;eEBA7kr2*p5G2aL@;CJ;7G4OxPOdGw^Do+~I>KYG^y`IhM+!vW?4yX9rX-LFH75JOGRY*a*!lJk0d`h6476ui{%^sxH8tDkI`vB=ILiP1C~z@p((%cq z`(=q=>^$ZymtlrUh6I!k+;Lp}*(g8WBP54~^{1$JVb;z|JvUyD^=;ZVY)56$%Zy;B zv`Q`w5wgYZYTu0HhOFtTRP2}1{Vg}K?M$=8(|na zV9P8NurrAVf!_K#zzG@>KtIRh*M6seO#!&UgVMD}#h=XM6>8A#eg9Q*VeH66p*vXM z(9|%=t96y9!f^XfZnt1XwM}av*1E9l{_-vZnIiTL#rj2odOs8m5pKokw&`%vP4rCT zB$O7kc1Zm#=$3zlY0SNM^b<^zA~@vAKiIBCHTUdp39abCUbrrKNeodMl&q_Eur(8OV|{HS*6e z7L2TS=WJnb(n^ko)aS}dX@>Ygu-GqV{a4M8mOPj4$M_~@EgfRk1r)qc#wF{}?)~({ zp*YHhaMY{dkCKOY5@&UOv!IRf$-W1nR&rd9KLHzc{G{#G+%%ns4-|hI&Dz~`+P5cA zYdO<3Ycg~SNiO-VM}+c}+S-;XPK2c52EaSY_|Lp6$MZ|SwwHvvzCcC{Ko9h9`~@;6 zEoco;`dhvKG!aI97>m9efVpT-&m_L}mNk(wgVGII?qc3M?%d>ThC1c8(&@9kaXf^B zB0go%0SWLxqMjMR66@zfOw=ne+Pc*0FxrfNBSz}Tfh-~?G-gC>&z1GhdhPQ<#c%Gc zDgz4hqQP0xxSNo8RHXu2Do}4WC5rg;v}<(o2m@MEn-MzmQeF(hbylFld*_wWfaC+G zcIRdqq~{~~`|MD%%{O=Zy=8xVbFD0mZU_jH#hzUEt!5WUa}GSr`&Kujs7GfOM_tFc z2A$hRxIPy))=`puelpvqY^ytfI9vN9aLRFxI7#c{y5}mHKu&x^@mF~2i-Fv`Sbc|D znW+LyW^p74Twe65e?0^u0$p{;*4=K z=@a^kUsZSaA9WRgdhrr$Bh(WtLi$hJc(zN}#=YrvoZM(2&$>201yo6LdK9uhQ^XK; zlnbSAlOe$W(*ePgXg!9P9th;cSpm@9%qU|SoedYled4nu11A0Ka-0w-a7M~>PpP+` zi{0#?YZBWBt>7R%S{VNkzSR5F938Emtg0)KG+vF?2TW+J{`9|&0Yx_@)=%Q2Ko#*} z1`j*e<39suVGxG^YKyGpg+6P7IA9!soL*bfH2LhlJMtE})5f&N>lwZz!;Ehwi6pBR zGh-19h>p4J6^CT+Flk6g)I8#X&Ivi@q`-dMLUsZ6t;^tLNrk?lys50JmmmYeIH2sj zGFy70*&1f=o2=3J zvvc4D;2B7v%@0WAQw#o{sEK;g86UT1bC*Oa&Xrwm8L`{m!PQ`a{ym(1Il zh8OjmUco!RyHHtbsI!659N>f?nh!?L+ZKMcxa`SW^kn?nQ508tnqhsN=536f~-e)5*jLXyE&?;WmZl(grJ@0F;_ifF*usY_9{By>BGShL_? z()hPMfQwC{slvV&<_cPr8%Uc-alfJF^VarM5&}O?l<6RT9+MK?lCrlG;rZh2?o5J; zZfv`mf)JV*5oXe%m4PrXJPE2(4664%qM2o?MH!` zsr(t4oiQNmD@WeLu9!?`wZB*Otqw&+>ZMt^msh{@P5YIg1Xb$-GokvH>B&oY)vAxC z_wmTDeIN%V6M7OKw-GH#TL>oP-ETVXfQm>`3Xf%hDb7 z?#%M?O0pg&$Z_$o?FpVvtFM)v0c#3U6(Mkfh!0}1s*{qR0LV6!u z#K-Rx;(5uLW2dM~QRXl2gSOvcnUeg{n_*VfipZnobKXhvzVB+%Y9(aC&}$xYrT?Ou z6gi7l0{{LiS3V>Lrb|A4)Zk!rsfiZGHzw8zu`TLlTS-`14CPQaeODG`UwTBg1}QLn zRf)Xo!~k`19|S9w;bn04!@%@hI3-gnj;1dK)82_h;A}88- zdpy}|A%@2pC46$D^`IF(bsoPmmMBq6W`LH&OQ{cnD+b$TH#5!ifZi=YkW8O;5f#58DK=XT_+y<_KgKh?YS_Vb?^G)!W?BP9@o;EmuHM9xjU7%$dOCZ$7; zN)Qhzmc)(3UT5Vz-te93I)i3ncsD`ZzzI3Owos;-+tfGFA{0MRJ0E<}!cUZWW8@{} z%14C10jtnTZ{xbS(%i#7L_BOdvG=oJ_q=v){ewy!%$tD@#kq)UkqlFm_OOfRK*2;K zXZo-W5M{!8%GcN_P)Z!QKyoUhc~yi9tef-H22fZG+d@jh^sW?&J8`6zZ6duHNGjP^k%(F1u!~kF!8ojF0~NGGjUVbW`M!EgXG1*i$lxO zV+NLH-PHY``zEZ;o^z=BHI}V-tWIemW8(%bo4m%do@YbHcAftJ7^OU_8~()@qPUyE+U zt((6oievYe?>u4u!}gqKc!;x6=?Y#Rt5%M6caLlA|Mk=Dsxh?YK_XX z$dm_aeFDV%C|YN*gSD3D7iA~q=VxQHH~saZ6<2|pOn`wTg`)Wj2Us&C$dQe}8vMwK pLITAcK`yu>iZfDEONxPk0i+Beu3=>ZDdq%1d!P$$?+1o90|58|%)0;p literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-57-44 country Document Inventory Report - Country Level - Selected Country.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-57-44 country Document Inventory Report - Country Level - Selected Country.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..7009a515f390765a5e87b1f3c4409bd3b2d2ecef GIT binary patch literal 35977 zcmaI6WmFr`(lv~`Ly@Az-6`%+Tw0)%7I%sS3GUM3?(R_BTHM{WXb5h>JveWA?_srQdbI#FJK|~^gLqkJ@6DXb0hx;Etgs{KA$pRdJ77jooZBIuF7XwZY zd%HhcV-CICcu&d0i>&XjHFe$u%2E#zmt7<3dnbOmW2nhLhZ>*?C4CCVaJn?Jw6fH_ zHE(ok{3=TCt>XsXSDKo_;(4>+)DVC zH_&e?+;Hv;kDSd9uR4tma1zdv1c&H6fj&K&&Hs}0sH-?Og_p8;#f8)N!u1F*$HTrY zi^Jn{1`*U$K}CyaXKojThl8U;f`ilizjBWWG!p?<@^WSq-LXR>c58h8BhVhO} zdt`i@l}NOX@V}^}iOb;HOjX4X;LeVo$VNNqo^5Wv^;ez|H_1??4lT}{!a&!#paSdV z`z3M@VTtNfsW&|bj$4W->e|L#Ac?tW6AY8FF&Tdf@VOK`@-`K%}y~7+}rs)iDbm1~_bo`f=YB4<+u(Xsr^OGO$ z03S-r%_aq*<9F_gR8^ z@sM7$LrWF|pHOtXfP%Tn*(Am)z>egaanYirUiF=4A43UQFTZePs<9DO_~tafLU(lh z2a1Y2WaX*{Qe7)-5>&8)R-9?`I?)pp!w=^H@gJN`ANQqrn6pi=$NxRp`2Q1*8Nk`% zA0GQS1C>5*qMxtI!@ikCbLujnccW686ha@{F-Ph+-c!@hIJ~a?p2RpbNPr6CG6DVw zAHe$t;C2WISPBoIMg1-pw2!8Sf{qai@qT-4&t&b%j|iK!(OdA|vb-kOG+2@BRD#NTaQ>CL+> zwEo{6B;fzCNL==(6cx5)>R^xmJBvgx7Cr2^T&zu;EzGrm&NdEKF8_!WkCMjerNM(c z>kK*ub9!+PCfyouVP3 z(M>DuWB!z^5?v8!$dBV)_?Y_`JP=SLu#Pw28S(jNQh1wZDS`dTm(NN1!<<{;-&fBo zZ;%VIv4oyso}!{Tb}cb_!2AmTU*nJc|9B4cw6pk+%N^QkfJ|=E&NJOF3)LL-wuRM* zB4q?~ILpQ9{5C5+Jt&p;h|49xFAp7!O3D@HWzJu4?rz8>soTYz-2@c_snYB8D=4@) zwW89>`FG1lE}&|jPQhmp?&+?D#<(12IPg--6it(^O-iN}DN3eXu0upmTDElI!BsW{ zAhHj?ZfIB%EHbJIl$v|xOT6@ytv(ie?>e`yHfid2eyXi+?PZtv<{*E4k(tBW6YMzmDt{)nYdBPKvQGXmH%veV|R)e6HVKoaS)G|cddmWRs7?9 z7~3ccin5?|t|GApn6Rhm=cA<>J&BnemoFWby$DmwEaQPf@}1c5)k^n!hiu5QCsNIt zG5+|?Mbr_c*`v{nb1C~5QT_X6~N^{kTqrx(*J(;x4Azxblu)h1o)ij>8*(=0d+5%Jr z@thpJmSw972Or)SaK8LU{!mBh#cp6(zKZ<6WjgME^Ti$DY-OI^k?yA#>Lf5wFKcd7ZgQ?R$r+2d+TN$GL%td+YX1|p3$Uz!c z-D5QGQkbm=hHM`C1(Xp|C8YVmf?6c+dghA zsn>`ZU#Hm~(n1F=vuRsNzku3gA^y7P;y+_uHEn$hQmCTW^ik*DxWD!Nqk~00?n$5^ zs_6t57#AMNT5Z(6dUzoZ1odp|91ke|(5uoI6S)=?!I zEs6G&W0_iogxrQvLgWp)4t&M}gthFm0^6Oie~ItK^uu|N@3sJr2l{3xma6R09{~W3wz=Dmw>Aswl1qe_0^BhPZ)#8VZN3FRLST8 za3dX-mZ9uMUpd#UTf7%C!U*43gg4s$(cd-Dapsz;k!)8cij$*75A$^b0zueadhEOx za0nN)uMhq&k7KUaRjbtR+fLSB`iU=c3!J@M+E(l&pHDO-JN?}fo*}PK&#(7KTy4)& zp;H!~QRQ7-;!h_Uxv@hvua7f@eY^XYV-K}Uz8pGTa*7cNIz;*QM07JKTcy|x*SKfN?(_f>AY2$jee${;qY+_w2yQ_*| z(Pt1zrYTEMPma^B*HTJQc4d|SRGiJqP*$&=9Ix$JI;zA<42=~ofjG=xcfiRA-b#xl*5ALrt-Y+w zO#f8SNTGkq0B|*tin~jNb{;I=J@+b+@_6zf(t777lwveUwb&v)I(D;3+EI>DADdYh zdfQ92S?Z=8Rf+4T6!!78WYpkbto?VW@biOf*W+h!LIXIpW^uQUBJyhVVp*SJaVQfJ zZ{v@6H|Y7aUW{TeXM~(SKUPq8z2eNVLHsm7^PV^!(0!&aiF?v+eaRB@dpX@H@*iZX3p1>O z;>Wf`y*x#8ZTZ{kyxuMRqG%sj@w2I-I$yN^tQAchN%oIf+PoSzEa7-cbt|!#{k|Fy~d_+D=PJ z;<E8H5hcY#ej=JQ|+>91LU!9x`Zc1`9*L|z}fE6!SDxNwr%P%Qe8b1v3r6&gg zPD23v-&4Cm44$LZJhWX`2Llt0Ox%T+AWhpR;)TcCf($YL_3Db2IXBekGb^{2>@_zI zbwJzN2SD59@$q5UtB&K;$RgaSluDS1HW01byZ(utDOW!{bE2QuL|^LEG~s zfCbLkirqjlUdQOY*}SAk3$oPd*MdY4Lx-_5-DoIn)3ccst)OrwMq7~7=}ye5(l8a1 zX$rm4BsKcm7CnlNHQ%FUwy>S|^KV-SC7nULZqA@TLM&s^SRdPLXMfpu;p6>@&r~mXPjEEXm|_2VwC{Qy3-+g6oIi78id}rYxx%6KK)@55 znw3vrP!;I!%m{V|$o~Vvw?N?=K;>td7IUew0 zJn)>)a1N;;c!$L;xTYg}xF$AA__bGogHEwr7FQI<$%c;(`{{%BkI>NO=v7;SruZ*J z4r3o3#`Hy>4qq!IO<|N6Yu7w@W?ZT2!uQ zG=zi21RF;qjY^13&!43>J~)V?uXf%yslo#*GBs zZT|qbjofR)0J~YaA5Zpnem2!hVPr`M-=M^wY3+kxklptL*Bi%9b{cJ+oIyA5ok7Vl z0LHUv>N1Aq#XvTM`TVVOJdY%P-smsc zNrEDGA^xr`&&o?3A5TV>><@J zOP&%+3y9v%yL7ESGS7Zh{jOl`fLZ=6rtg_zY1~g4rY0@Jo`b<6+yRFj7pova@d^w% znI7nL=TNVDdWfk^{E46#S2i6Vf3~Y9hTS?(lL#&QmsMP?au=Qq;XQy(~q>diF8bAiklNCN1Y^Jc@V;(w>uC zQIZ~59@7wD^xOw*1gZhj&Fg>$o1L;o^CS{J%M{<`vifb1`48<@1(GJ++Dg%_+G76@ z;EUFRZ{|>;NJ!#ar?z6tso9hdlQwIB%Z0Rcxb=s?sr}K`m?QS>tRA=QMkNIaux+?v z*f4Z#lmT%fh1Y<&%sF{9O9k;hZ~0S38)_ZbciGNRu(P5k-cc9227|cMKll&bpGV{l za6Z?}-kXSHhPu)v#klrUHCA~|L2kbr`CH)~xrqn4!dN(}&W$kvQf+G#u2g zQh)o~M|e+2bj-I4=IC(ADW)^7$pqGd&d|`@*pn5Fp<`nfrHef|90_vaLKAuOr0_xF zd_6Jxnb^l+e=(15ms|p~vxJao^8q%TLo{ zT!-`ZRIn;FnygJfaaF!DMx|Z%v*4j4A0cuvVjljo^`}w)LA`M0c=aF58o7)G3bm(4 ze}OMRtfN~Y5{(@BIbD5A<=UQlWdy=@`&o2#s2wcPpH6g{N zZ4evh9Cl{f-^h(F^lyy+A@ zSiIH6Cdd;6mL5)qpT*f%e4{2MYMOFKWq&V!7@D&1wO9lLeQ!>e??;v&3C%8ccb;yP z#+MGS9hq?_0`pEZ;p+WLw2w8|c7&}qXjK=B8gfoAqv0PR>Kdwt$dBtGxrsT#Fy_1cj3MSG9Uc=?eL?p! zENnnD$a3YM zezHhVSt|};7=m8?N43cd#=FNWBUbi*d0#`+V8XN=SJ6tQpS>Ah#^2g|7XFOn-f7EB zxt8OnAs5>XTD+~NM_m=(Wk?$ zvD4P4T{s6}|IPG#6_jP!HyVe8wmLV6=uTwrtPk+*XKPi^#uUjMULA?xmcRDMeakG>8%r|!+YWOthMEsPB7wKd7sFbQP+K0 z=MBw_)o2@hqsf&2Vi95X={tG){+71V$Rz3avna>m5ycxyS#L49;-ZO=9)Z*>j5i36 zfL;z|jVy$CyzWUT)e5BQ6KM-}<)Q?Wig<3$-rasW4groIM$hAuh4$G2!Q zHzt5GJowl)N@@xB^u?!|;uureoOOb9R&Wk>AYFHA6Yi$cBR=`pf+MT|C>DQ*~V_ z!LHhi5!B0AHmV1@Vl_G4O9>PD%Zt2OI#P)QtL$?E5RY8VTf&Bd&&$7IL)0rWXQy|` zc7p7h)|&=-0{4L}f^B5B(DBkggK(`1WmBm9xwLir2oE6+ZJ`h>XFK->~pN~ivL-}8CP>o-ee1qyi%B$8ZB zyM7^iOG80Th&wIfvvbsi4bZa!H=q05BQB%Yj>9*pkC_v7V9=LS!M2LNSBKaO>(`a? z=jV-@^bJ&aNv-#{Ljh%CYTdLh28lQxkI@M5u?!?OFAlgruMDNe1e7`zwON~kVp1XW z4;Q>rCRRInZKj79HZ}`jt#pYJrN(mDG11J-=8Pk6vnD{=Gn| z{T>4~vJhzDbQqOYD>(6L;L+rbgX+tGwS{O8sUgS0|}L6YO+3a(Y>^M@0ld zCn$UMYb4d6G+S*`pm~ZXC>S|BX_yDO0}Qi`j&^7L|(bUB+7yZfvIoH4r$ik`#y z8H^(`+Een*@NWY5;^hAkmkX?U>wI%DR4y~Mo}yw@uMu8B}&UZTF!@%$oc zGQV7}+FZTdT)W~lF({A}CYOH3!N^X%|!L&Y(wQxq={#8Bc~af14C?bP^J-8dT^^YQ|()f7g7Ms?@m2AFJ>Yd|Y!0Y~I=yd=4h z&)RY_n^)Ztqro8LMD6C&u#mD0RmTF653~2jHgfXUXt^h*WW z{^pXR?WQLjO**n7`DB@aie%GI9Hij$I-2Wf~U8pvvwb5^P}EG^so6okgDR>VUMN>%;S&V zawjRd%$312PbKMtgMN;d3sc|8G}zAOt2RX!kjVzs8$ECc?@%R&>zgZEu>V*sq;QU1 zAV3_Q0~cQZzeZX9W0d>HW%muGR{F*2O_V%ovDT!WQ&f>G*~KrgNW*L0W6gH!1Ne03 z;-SlLEimA=E|k`kJdek$j4qFIG=j>yw7>;#j<5Keq;&OqRp1$28zbc$kc&A*mR~hg zWtahVEYi{^-+7?bNTj~!vOxIU*}0V~$uDx9CZQ!xt;w5~0HJ=M`;?{k>xs4iGt=lF z5qzwb${ON*@!0pYHp9ejE^k_!0}oEpKJ*i-(kbhz(wQhmPWj;1eEAGMsTL`+6N4>=fngw zhB~1DeckQ_9dA6VcMfqGNh+1G?#3@mluCKQp0HL(`xa=3G3}{$wi=T@nqg+=TG#=X zo!UKVe;m1zr`lNsz#GxmEFovbM@Js@f!nQ3X&kIO_97CVJ^}T1yK+qG9-Z-XYZX8o zZ-491dLd1AHY(G1ANayc+s77Dr_Pc%51w2>JFY5(s&W*crKD1(k`moN-yd4N@Q`%W zQJf<>$4aGyR^CCfME|7zW;~ar6%so%xiU318)^M1(Dx&G-AL07Hf?(3(hepU z9{P_ZM3o{mTe-1Ana1%8@xmW<34TFu7&6rD`W+hAsQ1p3xf&^t#5%}d6)Lq7j0^`?ag-u|<{0d%LM&BycEa3BhdWWXR+ffdq~-qj?-$!G#Kre?7Ej*Me& zc~;m`;KnT+e-NFY+P)t2Ik@bLzIf0_pQ)q}-?I0EM5t4g#~DDMIgaSCkTAgdwLV6z zr4>6#cv#|L>6>3fad44tgL~?d$89TjYMl-LLj6?YO^lEJV;ym-0PToDMQ615C_HGp ze>chyK8QeVzX|NH(+i-6($czZ2rm0tZ#Ic9X#0J`CC*|)e+L=9e#u0hOzc{!y6m2o3Zpgx5ZFV`WuXnjF2%$zf9t|~q(1mPl3 z;FFjXSO&SB)$5sGB)pq)>2>KOQ*EdTbv|&ZhYY^epcBA@bYts_)h2!TSzR|NXiT)cb2Tr!0|DS44#|EiDbY)W;}O$RzY*p4m_*h` z>$IQcQElR+O}K#6SS@f6PM46DVh%iHoIPw(p<8Q3O~|9}tk})LN{3Id;@%b~xFk%G zd36`@6y;BdPHt8N`{$Uo3qSGS5{Rv$lQA14O}||CyjJk=JA5rj@weIf6yYMT$!L8) z89GoW}>8IJ*?G5N=+Z7JzgYKVsH-Yka-GQSGxpxW{zqAy!Jb zDq3bM)xB4y@iyV$p%DWchAG+0!~cIfk2Y_p{sh6(j39avFv139POoE z-g%1m#JM-nt2!T851Nn_T0Zd#IfiN1GHie<14Z^BiyuQS=RaTKt1rT%SEhjBLUgM(|NjzN9Gle4ith$)* z=8o9+F+T$_gAQN4#i#G;`1n(!xJ+UVLS}o)v!aiY+Ie+#wzD5K1mDA!f&MyZDJ@{| zLkbtsnO*cC`4AHSd)_N^=HrT$yMOOUaH@pzUBmYeLDZlev;-I(sGS4!l@_Wx;GiP| zxSsFRx4~`ZydY&t={0s?a5Z|4#N?D(aaR*Lfk-IIeS&}3ua~*TJv!-H5b%>4ezdye z4aACb4dl|pw$uAgLv<+;ft9wU0hKVFHP)f3GxPxn!R2cRiozgWqgoEp12@}S{e>v- zZXN?W!3{eozWq{)0iEIr^6`?`T&=W;3~^to12>nrXuPW3)eP2?7G zt0cGe)Av>1kkPD|hV6I}pmpRQwM*GdOyB(ikx*8B8}qDaHMp!Hs1CFCh&nhzUujeY zp)U)*--Gt~we62YKZlXUcl&wM3*ORMHbIV?PzRS@-Q0!NChwkyCAB``Uf>XC!%D&B zoLX8~fArH!db=tOp{2r0>oL+;k>8d(LOQqfxrU&L>8#_1f)_82U+WP;yk@tgqXDBy zw1Yjhi9h{0$oG@OhC+K3(m9B(C6JnDSPivHoE!d0Y{kB&OJnavRaiVkwArfOcD6-B z5I{>Hc>2f$Bhe?51Ijn^%=_7!W}6Z11v03n`WEL&QDd-2!~Hu9&mF4z1bt;q^$9(W zLh+MdH=yY|?AuxJmEa^z-vSXNw`MYN{Jf24zsE8?SdAXOTbEw^v{+P_drB-%?{EOs z*tI}NR}j5cnIZl;J%XFAAbqJJ7z@L(qtME$?$`Q_C?0Q^3)SHxS@Q>zIR%QCH?QD0 zqZP1;`i_Dr-f*m(Gp!_nnaF*7_bHbS zRc=cf={q(zD!CUbzqT0rec3rUR)>munqytflOC@_jbQtAP}Ey(vIXT|rUP?dHox(f zHju67K}f#scY?ET=WZUpUs*K7Qmt$I;;hw#hvXSk*C~mZP&+ZG4|T#47~J;)@iPLf z0323!gc}=K|0TOQ+#Ek|Hm**Btgc66#bpf~{8mZKEJ^-U6+Qpp)R@ z5V2-f4Ve1HP~@|{!*$@`QIrG+M=JHjQ$gBGMiqs66ae;oO4f`Rq`rH_l^u7kAdUKsug#+6Ei{(qe(8 zS@%FDPTG8K|Be3SK()xq!%7<}x0##)+$L+l;6nP@S)drqg*58!@W}piV~I~6=Hu@Z zQ_ifExBa3eq6d~z#!Hk!CBWX1;tX%EpA$V;-Vr)9_~k}tpK`vV<81bm1c$*$m+CI^l$iCiI)I>nO`?V)mS(ej9;Nsfe( z8ys^Uy|%N~l(#MAT47B=^`5qdQg0f*^29yyF}Os!e~!lBMPb`?RTH^~+!^XIyzF4Yc7mU~z1a{! zL=~YmGTs0(|K{g3OFK#^e0!537RD)}2Oyr5syTP3BbutF3FN#!e#|y}l=zst6yXHg z@hd?(wL14qQNp`0NR07log(%gEM&4oQJgPEn)u`SH9i}vayzI><-Ev<9&ige{R$I| zlg`tx4}`Fu9Qg#%y$b7C&Yahh9lhNvQDWmT8vmO@TUXr$R=BjZH=H{MK_B9YqRk>` zK64pIJCm(Vw0S=&l1M_c${wan&}CEH*v4PmxgZsEGKWMVL&Y+JCqjV3QUWGGZ6Zo@%A2%1h{5jHl=rD@CkPO}uUZEUu&&$AL^($T_za z>CTTaw@SPsc-m?YQc~_<)7Y5zcz0H}pJZ-94m8{vOG$B8#1x1nq5vM7W}favPZj?c zWZHL8@ZUGubpq`pbR_W;UIPc=cF(+Ed4o3yN1rf98ql96fkG3QJrv+LR5g(dcK?+s z?6dk6R1}Rcj2-*|{&+L~Lm*sBhjtu!6D4v2Js@`V?@t8ebf^4$xX1dGe7Hmua*W!} zXdL8gdS*Oy3ue+ZCmmx+vw6J)_Gdb5WH;L^kS5-Ebfla!IR@2ebR<#^FVWqz7`LwT z`liJ0Ic8v^5;gjPrNQy?%m;+mzlN+!Ro`NfPV%vAG9YyD#|y|Gf*=kCs&5_W&s~pZ z6Z53#li~w#KLpkK4YfA>y2BM9SgLYypp)iq<0Kfdr}tony)Jpuqj|o(=->M)JVo_= zlLRsPa_2pI)(t6;V?8x^m(j=q1WB*=oezWI%@2@KgCRc+VFtL*1+M>VpvTzwK!?`H zO6f(DP0r0K8)O_Hgn%9#D4qZ^HjdroAzeb$AjcB(=T2kkK<(Bolq5B8MLk5_i3v1= zzr40K3-ov9Y9rliL+=i&>XQhVA__) zHuw9XrdIg9(H%cpu4X(smnWF4h=UI!#hF(qBm?GkqrdvPq%hiG`#rP!?S8)*=&Zzk zbkXyz^NTXeb-0nICpyNh>}0JKtv_T}Mv<7^UmWQ4ubShdM?rpsuY@7QJq95bE(tO{ z7Ctqp-&!d{M2DF$#MVn;bC8DMlc`43p#N)#A?x(xw;r+R$8FyzJ}{B_3o>c|WX}i| zH@I_w*V%@Di2-kH{GwyhkvJdg+d{NVhwlux!CpRFFX^s^L!K4accIgtckM5JRJ5_!;A~ z>`oPAJ>PFjSK5p>!V`m$--Zt{d;MDHNfLhschtbqNG^Rj3PY|>QvmQs}kiB1m${OfpKS+A09-?&lL204|n~pZkA%< z_kjK#09*$Y4d+a@D$&UXAq|4_%9m;-YJ>w$qvN`npKxbIhOEOonT$7j&+V_pxbSgv zO(~?Z-M~^VMr=W(I}u-quqF*bFJ2r@R;SGuE_0A>z2r1r+=_uKrz{*n5H}J{eAZ7m z`oZgWaOlUpNY|pmxqf9{hjI^7$uo%kZ0Av-)k=ku&Z#sHW*Sj){;xiUC2=iH#r`)& zDWh3O$fR1stC%y?kJZEvX0yiELl1n){$4mlVIeZFfh~gANB)%$5!$Sd@PkIFFYx0X zu;TE7nC1;D4tG#K=!XTT?$!fbTtvQNw<#~;QWlS4*~KDUM4&C#?T&Sy6r3#pL(kjx zS4DG8vjfFlqRg71BTd@r39JO8AQ%C-#4%xkB}2P2ra{vm`+dq$_C$w`1m6y`GAf1F z4I87*NztC#JD?~C9%|OT*4$ctxN*3;7H1jPGXbz~p`y0uN8312dj|lBzBR8uj1x|M zFq|T~ybTKO0RsN9e9wy}&jqptp|*msFk~_}3m8&+8+NJCQz% zDIF2ChhJ=MTa@;!Bbcqv|MZr7ivv}}9dy!|41^VZN6Ff=lE9;^1z(13fBMxn9g#nq z5^0_!;X6McLwV0=1F1WIF6x(w8MnP1>g27}fS#F7Mf~(#mxBch?Hx6j z;xj}7rlK(qof3v#82_U492g6Wj-Q=jV)!(hL>KGLiG)ZgNmq|uyCS{dv1C#-3HtHn z7F4Y;LcOMXaP5J0r|L`dWsZsr_gL6-})!^ z$la3QVOT#FxV|{7GW9Ps-ICmwCHcN_%B(M;2>t;PFsa12M-=jerS=ZA;($CF8-Ci` zz+!!fPwVr#{ldrPgX+n0C2IJCQ^Vu@nGXSQ$v#?3Yv0bc!xP(u8`Rtdx>Qa4xwuhO zp-@==VHQx+m70SL6Ot%+M1R2BRWz1lw2qEfT}niRq)T~I&A|XT6eIedL!=wJqtG={ z?k^YV+(_d|e}kVh?0n25`F_H+wvl*S{(eUzg}n|OU#loDojpC_xxHyy@vh^tC5PXu zhngC^h52)9C?`V-Umw^Zi0SY%iB;)EicX3+FOG{Km>U764Iln#13nzO>Rb5JuCroX z1ee{Lfa{UrqqPzxa-_I#$k+%=g|GikO=vbyhc_(V?;YsOCm9KR=Il^3LlN?-$i*8s z6RGq04M&}bf+(>N{BdKB+5^_UcT)>_HFP&B3>+4#>uv~6Is5t&jIk(E>mE(J@o{~9 zZ%&K9mYnNQy$HKZDXM7G*1YTUYA+?%=0PqE;gfslv-y4ccZMr-d;h?>sbl4@fvIa} z)yuc%vj%8s#g`myL5TS=)}NMyU-HaTb7Es;a*NeUrEFl)NU+l^5lHkoh3p_}*XLd0 zUgh{9b;%Vm|D>}Ec`@t`#`!{@(BtKkWPw$t@+AbP(`vCzwych{zosTOB?liCk&RT` zbMghNv`EWu9B;bVV+>dAO1BoZkM3MuFjvkazsQ~3{fVSJKiXoX=&3Of={_sZ(4mew zvhQ2fZL63Vn%HeUWy2TC&t`FI)vHjIm#D7=zlRJLlWW(tsmfLZMmhL~b294e@-OL0 zoEm&TDsY->R5749!wyn;Ai?hz7ps(~!e9v)C+b*XNoziZ&y&cmk!=KAlhKj`lvC%I z(k^Nq4gV4C(vP!^4WL=%bd#zU4|vn!Rz~Q&sduUxKIbg3X+vw~D5$hpM7Q|TA-%K0 zkRpJze*M)A|8!eGBjLwR`8uEVxelDqM4*6K=`q&*5 zSE+if(5`A+>2G~`*anfnyLqI}jPKbsYs4D#2)(*(OMx|utV{~jHALRgavpaR9@$jt{*6bU!CsgDvEM``u{I+U4*}YM#((9;t_yF{icrx-8 z!yDpb_&T+!dV$103e&h42#%7RX-}Pz2q#}RhF-4opW$XzxtuzBz7zmFlQ|uau^1RV zT!|WMuyauHq2b?fGKgqqPQ0L+QmU7HRLx|h^L)3xS8i9Lo4E}=xSs2@Tbs@8XZNaG zBf!l3)C+08ZIYyY$N7GU*Xz$(HApK*%1%_SnYm_cj1H^4R54)Y5z#q|*cLn#;YM9( z|Kmi~C4W~(`^-Bs=a^(>U~jD2bR2ZEcxg0$fIo0N06D7rRP3^A(S(%6md<^5*W0LM zB?#UL69+rFJ%Y&jhS$<8AhaWC(krf7orw zT?wy_m)(7g=~a}2^h;+&6UQOB#UjLvQ`P>QQ=z zKa{i7jxZ$%pjyIds70x2q-*Yse#C}f=~8AU=tZ8!!9Nc8kflj4HD@Xe_fYEG1#NDJPj(u5sAIHgrZC}%pW zr5+GDVZoU})HNnvkeYWxTIA>@E{UiOd*2HQyRA714{?tfL}p?KJ)tvPMAbj z^`cOYUFZB5=p(zGM-B^HDArF(O8dkZtJW%9@5XJ9TdwJJX&ecxskk4w{Z~LtYR2ps zE2A;0XLwk)2JHJ7FOT(o&0LAu@ZzrcQL6MsjC_+{Z2!eoFdh%b!!6u+fR7*`#LAQ% zRcujXBNXg?N_ulf~YmV z5NEIX&_2j1UI4#<)CARQKa{J9bg#gCSqL+*xkd^6-H7V#=Hg4~OCi_#m3mQ4w>9^5 zCbvTDUNgKVW6;dIULLwpaA;KjqKk3AoHLc2=EVM(adR-$06TtQ#~t@-LCb)qj~97Y)tyS@Qgo)I z{&9aNBI*4Z+z80LOttRlXayruh=WeL{$dVa^RfF#%7iw7XSRVN_yoa@u%{6SkoNdH zGZfdnP5h;8&T67(PVyP|Pnd4q!Bl3oM2S}bQ=QMBH9Np-|Jv!82I%JY^6~IKvFS`I zZYpW|*^~4W3w%(!?X0vz7bVT`2|)%xR0;t$g|3*8u^ason{*yj+gE{II_xzTxiqj> zRVc!-B6NMMh;In5r3&uL&HB$o;lDvY-uJfGG{u<{tlP+9ZuvbZ8w8~T-nFF<9-rfW z_8@!Hs`c@%9D((Ww1J^5YdM)k)*xx^AhiF1yHS!JxC&GqNLn8cUn^ zl*gntN_B#}+JmB0lc;H|j}K%((j`?`+lE);uT0sOxMJhhVG^Dw18 zll8?-MgI+0AvE^ia2)ST*;CO=DYbbB)98Dta83U6_?F}5x{c1UV|s!~X6>z}LM!;s z&d+OOd4_mJ2StTy%O{6GI0c`aXZ%90<-@I~0x}|pkKlUYEnj=G6G&Aj0~;sjXicHY zK3}m7rcKHK`}PJ(Qnk{)Aeb6Mm1celZx>Ex94j?K zA5@h@=mmvX&N6_%=AskBLeN}a`wjNuGV6bM`8oivR3z_NLRXV${+70}@YpE+dVFAm zc*3RvjK8Qaqhgh@RS(k9e7j$H21kwcp6|Mt&Ybd*{^p;a)yc_drcvc_)4K`Cm4FJ> zq=bzI>b>X-nR8hLz8MbbRTKH>8^QLnvmEMRH}R4lL7XnbZY-C;_(9LgW_YJzC%so! z#H~5X)HHtjeqZslYb@9<4)PWvt|iq1+=Ne8WzC%=6z6@KddZ9B`O-edy1jX3yRl`d>PVaGiQnmxIZ6d8MG%Q$=qSx{Ad zo3Ptyspj<-HXHO_2I}$Q+D2;e#?QwVy!))DZNxzHmo*Y!)2gM*gb-cY#53S)^wK<@ zoW@Lkh46(o`|XYX@agxeU1I4dH9Q^#TB&Mt6@k@j8v>iST+ti&XJD&~lMN=bo) zjV6RW)F0h+9YupwM2_ z{V!MuQ+1l^QVKPpAAszuAp*om2Mr7da3GAVYL+qHjvC&WL!ftCPMbjI^+$DxUA57iaM#S(| zCIV1az!*Dv>!GI7igpTOAr5v!VmWe+puQU^qYg>$MpN+T0es7;Bu{X?(pxJ%1S%Ym z0NHp+rUVam^76}l^Kr2C7;AY>gf5s-$@69`;JrCYl>p=K(l+Uj_L|m@B63VcvVk^= z(|fYkp?@}62Cvdua-sGnb_dDMe0lKpO$6R(zwt}oBCmv5{l#8UpA>bs2K7a&4cn`* zS8}>K6h5l5c(pNeI^UTuSC8b0f>|SMegUBxs}|J#`urL~u}7aW>K}%>MRzEFe4dyA z*bTHPge&r{`DT|8Ugmf6)3-;yTa%yeOk_(|PDcGAR%89Nwbu%LLHZ&li1^l{>09e+ z$~Qc=w?9sAHDiDZ)uGDn-a^r*RyvP+^_-MIR~?5Mht5^bQbEcKGvA1AK|Pn(OCv9n z+&76_em=`-v7IcWk9@@r?if-fm-Jd2@bLDDfxeF&L3Mz|4V`I2q~R?KYFSY_nm3V$ zD7(rFnZ$g-*9bJeRXj?7E*Vh>zP;uwo$pZK^$rm%M&Z{Zao5rl?rQEIox&E2x=!E0bI8OhnNur-p@6&?&PbpPUq@M$d9s>uIY~bNhnUN;BY;Lz2O(Jh)(B)7 z50cMDKd6sC`t7MP&cWSfv*Q>GQ<~NbZlBppT)P0&C!9Mk5PrmG@g4U}Y@0W@WsRRq zzqCzp#!AdEkXktQLvIn1a*y6_gI55^-+xalNj*b zKsli3;w)*)jXITZAXx81on{OX?)SF?y~0!z0^yr{yAZg)-*=L&=ghgYPN{CDn*P;( zUo^Bm)jc|ZT+dc6&3tLw2iO`be|-4BWG)qG!>ny3yU&bi5L|c4@h+>d3t>JT+`B8| zN{{s8P?1@%+-y;{NQA&4>JYcB*r}R`O4HX)#cZw!k-Ei(=Db7e;)j2j1vLV~%Lxno zpjb|zfc(2HI$di9i4trjpGv~b{?byI5ygJ$x5|27zU7)K89o<1DBclDQhp7WgWDp9 z$KDF%PNJ1o9LF_b9;gl-_3;+!YM6_c?XXl?n2bo`EBSPu1+E@3eni4$EqK?Ogiv%| zk6S>En#h?{sjybG_SP(jiZ`DzP6hpO@bmPPwamc(A?hoG>S~%Wu^ad!v=cXx-N zL4v!xy9T?s1PHFd-QC^YFYXRO0|c@s-@9A;i=v>W=S=ssKHcLT3wunHs*H|;bmxos zJcHVuRL-Jfax+7%Mwtu!j7F_Sg@|-VE?=^8uPo{SI&w+pi+oB`X|!nFmW8qRK2JxU zP-6K>K|psXp85sfR7%0PNyda6^2#<;YS1Y|K!JHnVy-4nh;_SZuI4R-l^PcEl!u=j zk?TiO`JHT3yhHDRqU}>R{6Gi(Oi#xK{9%I;e1vFzhhP%rLBd&{$|lJrIUU*LkNgdE zgVOI9Lq5x<+Z+B$h8+-2wGJPe%euHc>PhDSIDA#fw zrQ4!l*GE^C4GA#T!EdTKOIsR`nbzlTS$%?mf3YG&gM1MG(z*+(wY>aRD$esOf+N1p zDEw(@QTpux30_S?T+#=MnJ&1a1Z9oB$>WTj8bZ!aH{lLqrz=7kb9Z2;6C{2wFK+xY z6Ft_)_o`OrNiCiL0QFA3mW-+e?D*4oSv>S*fucx3Ed|!sp=mEO zhgOR}l_p{gtA)MJhK)zK_eZ2i1>)m+(TU0LzKhbYXoh}NN{2>iLZ~UHV3n~28EO2J#D|DQ1v|$S z`drU?+fVXnV8Me`I_8EOpI{E&>&%WyKaYe{*hM8vMeF`p2&$x_|tF^mhtJ`98h< z?G4PKRY1VP-6rr|HihyJvcaBJhQ2a*ZHR-0)-RDT&wn<9BDrbk3w*q8FkZ_Ie0*q_ ztN&-SdO(7e3>6wRC%je<{O>vf@YNXLk*>+*D*-`=7OurA8(s(Gp>xlJq9@qAjT-g> zbD|kk^e9KfedS+fpM(z(!OY53u1}E8tjarAK*xn%_#WFH7}Tb-T*UwB>@o3PPE4NK85WW z?`GWXp)rEs9??j?o_m)#g7%Hx#nQCA^Of{T{q;|mIuF(nF*Gc5;z#Eg8Uef*dO5tR z1LaZbGpW(t$`?%TT*B{>!`d*i;a?dU4mOD5U)dQJTKsb?qL0Lfz;5rj1ZhxqY@a#t zt`7g!vk7JTVIv)k{H}RWr&_Ju8EZq&O%1B}pz#lvtst`4o~okT9j+Cn zH+hqIM8g8$(hY^9Nok*ZlNd&mdD-=&ps>4vv;VqXSUYlCESn;uU?Mk%hw*X1v8+3f zIMO?J$rxu-Q~Xd#AD4~aYFbMD84TW9Vw|=68QdK4<1PGyyf^`I7_~OZLW-szm)!2a zy>vLu0r~cw z45gerG^JX!p4V?_wxC;E7rm}c;_>72oLRHwFID3X2X1#qq5rQd_~nYl?c(&vjB{MqpueF}&cOk8LUTV#*zf+3dG^2d276o%C5JNn zb^qIHw++g4Cg)$LrXgkQ2TD;73dc;lxZxllxdVhFQ713M=3pmOx9*w<#Y;%j`FDzxLr}) z3MiSZP%m)dn`UjpN^&eD!*0RpK9FB38L3v`)L9#QkrYRG1%3eg<~EKDRDwZRv(MX0 zkbBvH2SCs6xF0|7i(a_q3;C!HVLH4zUCY*W#&%NI#z`;wOjTW8qPH#gA)G(43HYkHLn z6}Zw7Tn{O_-~>L^H&?fHH3ll!6zz6u*iuZ}ctE1v?wPMfdvCJuPi?ew$e8LF*gaOh z9SHUgYJf1Q^6z^qnhz4*jsbb@t-#YJkyPeSGt`Zs!Zw|_8L+unOgc-&hCYu5%4+cN zR7ogp;R~pG61rPGiKh==ALnm&%QrI}b&T1yAK&qnGj|K>Zsp?_Ox>=Im8(|fFQrKx6OwTw!Qe7n7WA)QkCnUk%b znblu{V!;G7K#*q}liOdxN9%rHEbZ>TXglBVd;8aN8<~CKVUVBdmeH9{+B`hzHc)SI z03Ncf<0Y~mD-UOf*w?f=S3+)*m$;lzFX3%6kfD@Va486O2Ugg9Qv9Io=r!qZ=%$|Y zt*8^oZHyS%BF>E%2O7AJM#pdemK49sxS;U`!?=Tpe*;~qGG{jKLbv2O{cDY7LaL;{ ze$(IZO4!L!Ax6wTC@V%cfkp7_aJ!Al+xef}G|X%{aW^Z3)%dILmGWRL;QYWj5um> z)u|<*s-;09-X0SKT!WgBXXbEsjxSe(>>VDfn!mSfpnN?{r*zcD=2R2r=r zGCa69&$|3`25>+db`-XYokd%pmSNyPy}M{;Bnf0xIPE;kXgCmYGKQuodK_U|=IZ5_ z2f_7AlZMvL-WO+`x4N#X(LZu z6?u3Vna%MQJ=bz40|`1)G_=yHv;O7$c77EqE*9@;3pyAu@j(n3cK`MJnbk4Vf+1Vb zZ~eR`@Pg3AOr<%G2N2v|e5Ym88uuUt)LCVVfj2H*=(T+~gK&n+>3wbuI+2Xbz~5&^ ziTw?|zt8N_e_H&LpFhOuhZ5Tau5Q)n-G@co0WL%sK?4Q_b-5n`F38c|)&`G%MAG7A z)8<`jjvG5#=q#HWdIm)S>$9F;Rba-~R}Hcp@v1IXFXXc9R|M0Z?^FQGe>%UY|4H+2 zc`TCWbBS$dCxzlC&gH1rS63NCjL?g`%ulwUZ^|o7?z)Uj%{j<8^dW=ng^Oq{xsyL_ z*fa%t{lS(c3=hp)NF)Bsb(;H5nIhQoaHieCTIWXH!1|i!b^xLbSpO4)VwiacRRuTQ z)OXFps_Y{KLnq_raUMo=O4d&-Qev$=ct}QIR*LK{iHe4gyA1{uvGwi|n%|g!6>PmF> z%^$uh^w9n8Me?Ug`O&J$f!H~KBin>&>k&Q#uk-iW56Q4j)oBb@D|5{JblfGeF>tgB zJ+0!NWfiy_757}LfLH)$S#cn~1kWkfC>Zh@Nsk^8@G3|J7t#2J!%qd*r>zvVfwe!C zqzqg2xrRz**_6y9s2+88CH~AnnHgHZmDu_Ad4jiw!5t>`SStR^C?7b*_%plwpThUR z1&`v~JcFfiR}gAYKbb58n_0A1prA0P z=r~GFKxpMR@3;yMlo{7DUwV{>qF+Ze6RdDd<-#-TtaQ9X&(y>`f2b*GFbtncT&j8~4G7%EFvFy&IAnKtD5d=Avu0?k(L);aM9vJHy? z?P=^|aa0!vjh=CoW_-^ayb?c%O5Fq=M3r;LsO_|Ky(|7_N^8MfZB!*srMxp42jmfx zrtg+)jFIB3zM&Wc7d&e$}P*^|Qq0%@jMMd$sYc$rJPk)OhAfON?SaqNFIDvxj6=()#h-r^g*cp&8d z4t9AY2NHd;t-aLWiAt}z#hjS~r;}R6Klft;B|q40%*=ol$|k6FehnbyOVIn?Y7{{W>m*^i(!=QooJxwC>>~mQx^dxeTu{f znpBEh=HK#p zEV`(IfozU`960rAW^pZ;{RUS}G)E3Uqoy;eIo<4k&7Y%{r+h|Ge`q1>EG2idmus&d zzWAd=CFADDiLYaCux;|8|k?c;C9Yy&c%B z`Y!Gk2`r#5zns2E#c@N*ox39?E$HBA1vR`M+CQt%!g*HcE*Gd0w1UVAVGCBG&_sXu zq1ipkPT|OMQhfwMm@Ub-x_>zrC_=!+szJZ#)T8#(>V{v{)9QBeHA!&tozL+CbjWWK z0(i5PQ){hs*&u8<*i`!Fc|ztX<`6JJ8DB%PvV* zHwo_S@~gQILp3mN%H&qq$Z|R&4=hv^+N9n-I%p@LZot-i-;#IsFBy*~jX9ratGyRx1SvUC z7KmPVLcoX-=QIBF#KtIFNw>1dYN{ z5l3361Y>|Re2Tdq6CU>d9?cE*qZ&60_AfD~-b9|tzpOZ4sML6BaMIKsuLXcTl=-w1 zohbd=Lm5afRt4@gjZ@L3*DIH|H5|yQygp0gl@XGoltJ_qV%3@v$dxxpMzT&7ojw7- zoR|7{@)BJg?mO@|G)K|SaQh4C2t9!5Yb8EAq7>S&joAI&Wof-282{`MXsZhxMJQ$h zV*y5~aotb@v=uaCCZgr3UAF{(!G$)d3}pf_nS%ceAjqQLmJvxtXPsuP#%VHrB78`~ z_grEG@u**d(U8Of8vuS30Q?}c19>`}zBXkUNh@(p26@=Ennt)q3aTo)-&$r<)B1|& zFPjE>2eo6&Di^PiTcdq0fj3I8lT3F`ZsbIqq~%fz2F?KBgZ_VfVEpe4yg`*e*h=y$ z{k;tIWK(Imx*sE15j!X2;XB3E7$t(xj_pAEiVnp*SO806BA^suY`c*yzYy z1I-HXbu>Km=rMNo#QA7>aJESoTo^y@x{>){xjuX1A~{F6^HDBIgZO+h=uSXwz?t)b z6q4B-8Cwot<7^7);R>~`TO0A`a@o!KT=Usg7-zDk9z-r(-6O^G*i|^DZwvS3WqEyX z5woX&j7dTEc8LVX!f0baI@1eTL(2E~LJWV}6QfcfsJeUL(wrmp2Za2Ngn$7Ma%Vb4 zw&b>|=nh_grpH;~hm5`2b*Urukk^!lj+Ubg2Q$}o$&IfE{jw83=c|44**EFCdfnPt zPgn2l4eXh@&yMe&_w0REdUZiZ%@Sg*b~jQ%4cyAzPLQ3f;2nEVhHTnVc^CEXjCl`S znv>IW1;6KeRlFm1Gb@c}{yhPc?XwZUQar(dK0f?mz;yU4|4$s=Z)?>l^P13&v;Q!K zZ_5h;Hx5ZOgTWZ{+EYLK++9pIroU}qG9-tG4P53Gs)RAhYTQQ(9913u-okCa$o?el z4tCL`$Rk>f!4l0J12!jr$TqvWLF8;q^IN{vJId+{XB=7wF!olcS0X}C@nd<@&BG8|Td9 z$4`@oWx5yR4%YXoF4yQGk7;bJ{6%!7rSEn-ZP>1bdJQ53O+IYC*1N4Dw8nW1)=Q=@ zx!gXJ&R4-M8mQslZO-)@L|FO#zO-vD5IzZ7F{$v?5N|Jhe`--4S30eFROs|RK=Q6A zf3aU-CgwNamO3IOHAYCE2UQZ`RsxyoQ*4Oe{~H1D^}qVF*B52};~ZhHm#WQV6+wXw zqwZ(wue!QP2GUBOGU*ff!!1||wE}?&CS8<|aQpoEap=Sc$qVVfaM=TO%a&QwuhIk3LX6X88k;`AarCj5nR z42k(_pXd$b?Vn`^MY)eD%}9&INPnSi8pJ&fKkKAvE}I;V&Bd;X)lq@tGVOr!kdmXF z@w9_)9|;*|iXYmA?`p%YoiD300;&?@oL z!`D~5jAB*~0n*UEue<_NkY6=e)xY7}FWk!xy2kP+-HAKfpO(#i@OW?DBZ(PvtF+C; zY{=k`mYz#>9r`zK5ZiOd3wO4)+Wzcb)7#KZDUaH-|NGi+-`TD0NB;ug*|z z!NFyaL!0m-i95>P;;ICc0Q`aiFntDaIv~l@XA+$}KS-A$H_zU%{lu=;W1e5GkasU8 z)&u!17m@Xdcz_J=K_!m z?Es>y1}$GEToo!OYU~ym%3Lj9R9l(hu4?SN@Fj#h84EWk!Ka;nS+VClh-#?YlDaU& znOaYYw;+%wO3^_`knA|-H~jHMEaNbCs^cJMf^uwuG@Ys9N5RpJrH-!(8tULpyQX1t zr9bUAa(j@tsngOwU4MqY3fCq)mbw&PUl7P=_R)|7=J1RrRlF8#lh*xG41~P-m6i2C z&7U`AQg{rCe;+oP;$6?>4(woqkl`a&&|HqI=sBHx4Jam;&e2RfS+>;lccB}O@cCRD z{uWgG#`yu_gX2dYU^9lz2x-Xfz?~l~UEmg2`f%RY)gz=@^^iKX>se5w12IMO4bs5! ziNpzdIoborDonE1j+jt;Y5!$ws-UmgH!oyGy4=AA=)yg6MFDgH>4hUrmsH>W42~YQ z`UB-o`Ou@YH2E98SA0bV2)l#8pGG3!(&QZr$c~bTS%GphCWiD^6LX*$VcEL~OBcJu zhV8dduMtqlC}$-nDthmn8Y!UliAnPN&2vhx?}(AMjr^exk367kZaW!^?urcnAN3ZD zql&%KG2Ak8BTRiOt|<=?It16GQixKslh&pxW;RYIl{X(xc?n6~w~gjL!~LXvz+$X_ zK$B8^N1#AYaO6a>cH2Dh&TYo>J;r*!Wu%oK;-wu&q3{VHQHVku>18#Coee^A;;l=U z1!!Dx`d3|oWW4}md&Th-{`XNV=>RQEqNjB1BDai__M^T1Y+7j@0gXgA9E#1ffp=o?-&HofE!3EAfPQM`K(5!g2(| zjuFvSqavNJUwcZLZAwZWryu}6V(YaJ7b$9Z3gwvN`4Sg3kOZia&QNNT&QNA8Lf`HG z_jzFVIS$9XAN8HneL6N*!J-aH`gWz$ujm2c=^&c#egbfz35MF;{2@n&@S!G zXD7|pm-X#kPb_?1pd%c~|8k_ZkM9q;F|N)9y!|_0l=YUIox8*9B#CPGCs%8`b^;>w zFPW~iSMt4)7yI!T$@nz%-67iF1vHQ}MH+0_poDrUBQ0%hF3BT9i{hm@Qhtf4E0Kp1 zOVRG5Pv)uW$ICU$dzVRL!8bHBCcQZV*=3l!8JzU6#x*l5lH%60h^Xf9767{ICuoaG z!+Q4Ug;_S$8p5hfl#lueBLqlheWD?u*(d)yT zLESl%2#U|O10BHG6(kiCHe85i*DPKHHKW%Uz?Ry#^CUQhF8r1#!QR_|OfH__b`fNf zGX0M1bT_7nG5-sP=Lh(`5M0$}*i4`B?RClXisz-!R*-OM*j<#fRnsDElj9 zeAF4?kXyUAa&aT5Gg%@?94B!H+9{26ADVRk0f4P!bV;ZL7yzWVGbq&+vSLv+6Br1*d2 z7nV8jU9-0<0P=h<#g~AQb2yE{RY6QRj6C{`=Nb0ieTe{bn#5f0e_za{_P;OwxVi_cF(IM92|_vUUm(f^WRmt&f}ahELXXl&SL8K&!tZH6l!B{yOLdp`NxDgdqY zLw*gV&_Q%NtCMx*vxv{B!@+kQ>Z*yEN`2_n|76^Wf5a!q4WyfQpJ(jSLfy(6Uu9lV zTS$8NBL>KvHb}-I&K}TWb)~EJY_U-$rtsE7L$+#XoKFB5} z!U(iSzU0M%?8A?8qSOKevdEyUFfGeRjeO@gMh|RZgs6TYyrn)oJoj7IR~Nr0FRZ>D z-!Pd^G>G79d)xtq<#p0f#sMCcQwA_)oc&;|z>W&lye z#%}P*T_hxkE1AJ@MM417c*vHJP21kK>a4AhqB^6!0>BQk4HEDCfWdg=T6`9R(T|v;`*(|` z=%Dg`dGkvAA;Zdz5Bm?FnKSFr09CbyHYG+ivI4iZj_>!J^E_qAG|vz+*;U9ti5f&1#9>p^^vDGFnvN)?iqPnqY%PzO3Ja4{dl=rp36tlO zvw9uVO!TFY%rN!xU|7ob5xSMs+M9Te2TXJ9Kf>jJ)8hO3@=5(!A zDm4p&SX+|hmrYr`f>O|CmD7lN9b*Stg%mOj5!3t_PnFF0YWblK(eeFih<3!Mjt?$QdS%IR6-V3YG^s0Z$Rx zJ<`a61w*Wxm&^l+wd*S@1+`sI7JVUKnYq;j)t}gEySZ;szB*_vZ%DTkBGG_f0$VkP zyVxzM4`Q~mJr|uKcQIsS3y;#xPi_gv;g29q;5STu(*^8S-|5V53c`b`y6{%vm>ceT z`_261{c}tCR`{mx?>gQENQt86dOMGdt=k7Ps3rRvFDDls|E;Qwk1Cc~_sAa{J@i;K z^eX)9xT>p-D%$+tw!3<4CCkX{QHL!bS@~W%HvQ>9v*v`v!YTKS>Q)cA)qEPR{v>%>2T!(0Ygz3%Y}tp~MF&-*fp>8Ir1`Z( zqgQEF<3fQ=2Nd==v;?0rK03P0tl+}l8t$K-t39whpd5{`)OSw${D(WJe~Mof)l&-^ zWRPQ9Hj6}`F&DH<=B|%XhOgf^9b9diA}43DZeMvgUvPi*OpIf6K}PnzM|!JE~e zqTbzA_^)c%3*)yR)LAHzE9&U zYKbbqhWg=xV{RtZu*o2ocp`iWH1V*_WJvwLP^(9v;q^dtLu1ib()==X&?xR;l+ z8P^4pb%v$!9#!y730nRWx2Kxi_uqhH4qtcGKR&~;#1fE@HHr0zd* z&|a26bCGwUvz7v<$}$~<63Z-+tEn}VE%5xS_GBA?^!rA>I#^*LU3Yf$Q>F=lqI+bo z0`knI$uwo05YD={`9D$H-f&b%6g@^75|l8ZY;dp!z`ASBwG+6qi%zFIa!!8yqvQHi zC<&vMphS|Qdy|Id(73k};C>t5&Ge;!?-gl>>KQx?>RYOe?cx^o{@xszLlj2SBmM9C zch`gQGf@rKf%zv4OEM)#2Tkh$tbmEQRg$HKRduoFXY+>S-xVTZgNx;EwXG^^zJ>Pf zrHjqhuAD{43F`gfd_WwYu-}XQ-Fj53N}VtrZ*@5G_cj|g8NuEuuw}Tr(BFRs;_iE; zRp^y~(vEnN%g7W^QSc$9*Cl-FIv=}&bD`*+StF; zJNvEpu5g&w{Hv$1tW? z7{sRDWb;WnwwSS;ql1^nQ)cUni*b+QrVX;Y|4tu|p1jN-pHG$#A64fFMKsW~s95QX zihjJvDSSBM*c~05Z{Dj)POEE^^zBQkU_#9gST>yr2vV34MlgU2uRS+exA31z3^nD& zWKb$IfWIZrFsx)vyE4LbJtf)8#&)15do9ID4eN0u0aXOvlLk!%?5bT4xUKH*+IVR( z$1ZuitZbiOm*`iw>#+!Cs+AOyvUAf`4c)v={jMR3GBWtmyYM^mJq~oY5?aq}iR~gX zREFEd{99pqximMpZZql8sJ?yEugus$8tf)0!7)s=2%bOD{5$kjS9_{FgVEt-)axBR z{8H6vI)}5#BO(QNQQjm3b|3IF^E8BIap{ufP4AgsTiW!0;tI1KT^v6)vJlPZgM;&- zm7|qB2Y?%5l!?Mhvb0)gocwDAe~+8=tvp>$N{Q?2^)ZnrttLAtlx5qt8Mad&cz_|} z*jVEp>-wG&C$J_YD75X>y2<4{c(#;wmTkCHB6MwYKW)%V31r ziD^@2`++UdZ9-vU(WnT^hC;Yi3F5=}oEfReQMLB|qWG8Z#a3lk-!D1&0?r&}ZW-7Sb4(vj+VK=>j2o_J^{m{_)N!KYltv2gwth6phU#v|zC`A5 z;?Y=3R*44BK>b~B`{C+umhHqN(6ixD5kZzf)>DEX9$%Vcl#DaT(%-qOv(0L0LE3Qg z`x2TE%vsu;qm1b_Vj*DW8ege>;KrOV#Y_?KP80Gfj#`8IRUhrc0iw+?*i=nonBRmi5ThjN8tsK81h(pC(8m(Qo34IWnBFgsoW7p(h14 z+nAg7QbQxdNO8LUkM9AWbj1}yS(FC@VfF&xUx+LD{K>S7ohO|mp)2#1 z@g+;(l`g3fq_{4!2YUY6dGcCV+!zzq>BN0>8ua$dyNvP4W&507?*R22Qb9xJ;vEQW zcCRz{R$8Mo15U_*%Yf+7kV`Y!AxiL0tR~Y7!4C6NS=^tv`+GMpTd}3~$5TIwp36>6 zHIN0-0sDdF^clz0%7}``ylHOcW!wOVTGGqWzYup%Kwk|cU-UT;^4K#LmONDO z+aQUFcKxB1Af#&kuzqMYBpna5bjTDF(z2pppS($p35ChJCLqziQ!8&;Zb9>FOTbu! zr)sONbrxg#7gyf-%G}l90Ojygm68`&Bba%mM2bQ7@Jom60ps}a*p`9y@JpP522#RUg!?kh^szkH!1ufMv&SLNYVKFDJhA(xw?hRGV%FSqR)SsqcR;YoISdo-@ z>z^+11`>8<8XhfvEdD?u%c184H^8S%0t00BM=qd5V=Z+>E^~?jAUDcB^0jmy8GuiC z?<`Mrxz!PxfWwx zRq^)U#~2XGKLV-LTpCR#bQC9IqKF6U*R9#a`+IbOG~3nk#{71MYDR&JJe8qZl};%F zg2ZJKe>r)=_~p$9Id2@SflZU6`x*by0oc3LKOO@%?W$wnmcx6a`fLDwq~HF|X`6FY zys52aJ>|f?{?+xy+Rs*z-wEbH{)D@LP1Cj6hAq&p8;Panf`G2(VwS})>WksHKvf(I z>om&=2UCw!S1I;NI2Tz>0?8?qtusLH(gc_?5Ht$Izr~Xx`$PEipTJk^*Un@ z4b<R<*#9vk^ z4B)@AV1q$j4Ry1%f1e61X(368xvl4o^=Ys*d(t=ScE(fizXF=hmTw3;@l+(h5s3yJ zGz5vn31gbs*8+zfKj*(LZ(HJbN4>K_V4&GJa%!_fSfs^UNJrm&;cHq+Q99WSplXgW zCsKg$_wFRE{e19Iv`Vu>xmB5RNDdyK*(L_b8MODY2nEsEfs|Sh>AmrCU9j(Qzp2rr zgI79I!WX|(0>8xLyF<*zl^~N(u>0=KN&OVEJO`X)IzTJS>CUs zdi1ev_Ct;O3iNCvYm7|sR0e=GJ!$)}I$2q|x*hGmZ}(DYa4oLh>_(1LyLo*K{^riJ zc;91cdN?;RoNG=b@==P&0|&U z^DyS&_nVsYz5_E;YAIJ+1v%8}YML75M_SUeJv)8(E4I>)UT$96(V(UnR_p>!Wm5Ow3C}F7OQeF{^g+(mL6x9%z7uzPhL`un+~(n}MXy z^jgZKgwvZO$7n=-Ar&6F*!1LlLpQ{Q&prJrl7FZ1e| znQ9(4rWF(Ww!ABOyc!gvq7FdMjj~Tr3b5tUiwr>7g@oCYFjMV$0k6Tx?bTqyFJ@G5 zQnv}pC*MI{;OARJJc9&*|0SCMKgf_YX&W%5MrK8A_Z(0B#N~#Np>a{1pdEJEH?lLp z!5B%{1+!4Ng|T2*P=qk+XDxhmR4hYaQQT_%Uaj*4jK_J`WdlqeeWqxJFJK0epv(NC z|6)kVjKU8eZ#pW~%(IC`@>CKUM|zka{Oo=gZf$X=4ncR{DKP>qh~46H+nH)2Aq{zdVLAm_6?ZQ3|scgfl>L#Ab(a4 zOd9ml6@7?o!rSvlv(hgElqC9UMz?v#AzpE2&&T8nzYdUks!3$~9a<95k-qILS8(kv zGc*n}pZfYTfEIZxmf4J*x+Cq)C$T*6EihLH6E}b641KOP|3EU1Xm)+sQ6>vp0j5Ep zZGquhFP6zuiI=4-lKnByF_rpfHkui$>|Ln@pCN2?0Zq>wmm!$b z?|^pH>qp3h1JeCUrV+j@EQ9%R9aIG`9K2@z8lq+@C&0wy(@n4y*V;o zBjrc!`qiMBkUp1H)x6bUcH(*UTKF(WEJRYMC}wOquy(?4syrndo_!R?wi- zjf~%9*p79qQ3(CRO_L+%aBHTX#4z=ew+|@MrNFdIX_yRy7+>jCbn(;s$zzGz;F&aW=2E{L}F)?W#KS^ZesnZJkWM~^x(nT<;3XJl zsp<1iSk9icu=@{9bZF-qE`M1ZSYj}BApV?uC92`*6q?!am6dazC8cE~vL^J0wBHlM z>L)MsJI(MaWHtm$%K&C1SpQg~#CH1i$MvaH@JnZ!q`}u06R%?Hc6Sh?kb)M?=#4s5 zzk5NZP55WkCj=H-;7FQCE;%Gjg6uR=r+_25*WjD17ogF~Mz2c5Vfm>}kktTf&hZ$l zn~P-iO#`HZpYPOX1Nkb2aDOsVZDl3JmfO++i#6YST_!nq9qHxBfTK4_&e8)gr3YY2 zpk&#V7jql6T)N^uLN1QpyNT6=@6}p}G8oxCnSz{FnfELaC^EdN3K92){AMs25TcMVjGLQ$4*>9bkwBr~!653K>Hy$Sm9CKkW z?eS=MR66_et zcI(y%>P~IR#gzBb(-ah=F9C0wF(K{70nsA{mK-m<&$k=%-me(MV=t4ZIQqN9^mb>o z%*g>zknYnWrsf18nAR9ew)2unmc&VxxM61Ux z-P~p}RI5jg&R!11czd1Bm7e?FGTUZBnw!7qbLPWf;sP+e2{@!Kh{GDmCA5Lp5URkc zVMB&b$Jx7J!mc0BHDOVKpjc4XG<;~_WV-{Pw$6i++!V}9yp88_HU7>USKD!|pB1fLH0FP8C2>mDMN$;lML1+Jsu!0AhyIShnFe}2^B zL_SHFYf>Nv9t>d})b||k`gW;FF*Qmpi6W20UJEIuz?UP1 z=w?DT%^!-A6vE8fua@w<@X6m*DYDw3;d#&DMPhlS_qh-suEzic4cFZ1Y`X%Zm&RwP zy;A+P0h(@&lcoc$LUIO8Adnk1!YFim2JJ`_k*L?)4=?D14F~sV>)t+skpASfe_RqH zDpdrrDuV;gr{xGOhCT?vae=i&Gjrrgjji!%77-ac3Uh{+f8_<3O*{0(g3Phz=hQ1~ z7a-Jd_WY+SJ&nx^lkpJYS;CAS^Sx-|Z|GM^DBr}zGfl`HVJM%q?hwR13p#8PaF`~w zxUJA092dz6G!PMvPCFu?MN^jtKbE-vVG91--HV0l2r+tulG-uc%X*>l{b%pixi)K! zKA0Bj4p7wJaW0cooxQsI6nE$?56Y>-N5>yqznnLHG9s0ubZL1)Mf#>GhSoTW5hUZo z_im_;SB*QY?6E^H7NgC?Xg8WxQ^@oYKK)1jAG^jwYY$bwavY>2H%|2}JpSRuYcfzE8`CdSK274{@^mwQ( zlCfDT3tIzL00CYQ&wA0YNJe(9YOmzy^7?@LQ5MU2%$`}y6$mHHN`Dd9(iZC6XkMIy z3F^=;gM_qcU7dO^bM=zpGSvLkKB6gZ@f{1Ox;ZRF1S+~j0ZOWX2}(*#&px~PAVpoR zYpuLIIpQ`=?3cAmbskUU#VjLMxj32Zmab=oysrymjY*sJX+GWw8QNg@5c*(m8lQuh ztMbH3lEq|P6LXNb+j5eWIO~JE!YB7DVDdz*NbO7crXc|hR`aB%?@FJhY_^jW%oq96 zmnM!EO@hda_Xe-Zw*K@>oh+zjU123LEL?I~hS90#(JWuj`iSwyK_x5Qda2>63H!2J z9RT}bM$|Ic{sO|_c{e+QQ?w-s=IrpXEVi?(|NGP$Ae>LIOv;?C1`XLNOd zUKSrzfp+3nA$A+Vbr(%)?V6>2L4dd>#C_U{>)b<_cUeZYXEMNzM1jIlyuZ8o<@9&W z*2OzAy^VVUrO73n583Iky0Yh)q^LLVKcj_jnLsyi!>BHz^CeqST!}38$Rh{Lc5bZx>cHCT-796+r2L_1uWZz;%mnyhxYUemzT-N$HcwoL$#^r4nub z{hGkgFWug?+fZ?tj_TR|W3el?0W;AZ-VZw>)k6R48S5O7=GfnT=6{>w+r$oM z6WO%A-7d4#b;SRC>0a`?`%2HpZK-|yuj5wbX=I#w)D?TE{pb!k|HD5R%B)n{M33n@ zDM+~Uxb{hG-!V_`@M+(b`&3+7q$BNuUTtl-yIm;8G*joh!8u?FGmSrC&f^7zej8&_ zl)5Lsa&NZGn8TbXmoR6uPYCmw*fqs<2H!VaQ=HY9c+c$q$Hv-#Lbsx%*Y*E26hFkA z&_A>J?c>Ln-9%qZbg>9g|0N>rF5XdV!238Y`s~kQ!M__~?Q7rFo)FJF?(8Hn|I5s! zws)DDZ_B*;_Ws}t`mbUc;pr^F?nh=`2TuT=q-su9&Y^DbGue|XN>WZfM8Q#UIYzklQG z_j1bet*S2Txeqy}$8qH}AHKI*@MFifNI&te^RGj{PWbsdD9!!nPtVkuONx8{uM)bq zd&RDgv;Mn#JyBe5b!5kb#2?Nk%>CTC-U{+JW{EzJi4ec}+I6QyQOt#=%*RbPUo`h~ zKU8y6X(^03@am6c5BIZxqL>9qPM50$COon4(6D^oyU&_oL*}eg)i1W(ca~;w2v*o}Tls)U zN9O+pj0cW-zc6R0sNfYmdw|*DcJGPy(&ndG)74JuvNx=Ln^sgQTU(`3ewBIav!C&? z4N-6JRu{^!#W-g*H_rXeeUmSPPieisEKB(CWglyLVw%qxasME*+}>!MV`puhZR|*FU*lQNFLb@YCX#@|td^ zE>~G^JF!VduQ}E{Q@OQ08`wSV6L~n(I=^X;te(*_KcS_SZuW>l$s(R^oH^XD4 zMRWgF{G9({(UkrB>SYyHu`a4=Fwha(c|$tYXQG+mAo~_VIoE(aRxq zMdi2Gima$VdAcG(bo>7Q$$NKMht+=#-J<_qe%Al#pZ7*-Kd$@xy6nGqDd+uv`~lwV z92WOhox5Alz|cC8l_9{Jkx7I>gn@&DgTZw9#h8gY8hfl685m?)7#M^Z&_T3weqKpx zUP*jNWkG6jtX@TK4!Qxr{SV$xf%?3d7#O%w^w$85jV}U@b?NJYNOX-4Yszm-1Zvn0 z!~!T9X90~$$xjX_$}cF^Pb?_FX06!Dt;^Yg7HkA!K@{DY%t*SE^NUikX)oA+L#+a+ ztrLhvP_(ZH21G@UesM-(QEEzXNl|8AdNDQ=*iWh0d<9y5hn0bW7sZ53pa{r>lFFP^ ztXkJHeOn?2)cP2R`BAjaWCv?4&o9bO%FoZnW^elIMJuiXHJJbdNeV^t7Y?vyNRT5N sfi?J%6NLndIf7hpM-*qIrj`@~0|Q7ILR`bj22#ukg!Vuem~?@70R6qQr~m)} literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-57-54 site Document Inventory Report - Site Level All Sites by Country.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-57-54 site Document Inventory Report - Site Level All Sites by Country.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..cd31cd58ac4f886ce37c6ffc7b2a1bc010d192a6 GIT binary patch literal 123019 zcmaI7WmFtN*DZ{@yX)XCK|*jFAh-v2_u%gC7J?GuU{>KkC(AE)mu>Wdi|J6Xv)6vXDkJZD@ z_Lu6YeGfavbL!9nBhNo2b=*L4@KzS^bYv+FK?qw)}2PRRQ6^>cQF3X2*1wi|Z~Hsd{t(86!anxkFBFTd-4d#$eFAB7DQR4Q|- zGS}Wdf*aP6uVCCZ4IQY~F#^>mh*g$;iPLjBh4nfa@vE*8qtX(hzD40J&(lweR+6MT z(w7l^CB?>6<*AwAPiN?ql@1CTauHKb;O^{uV#mY9$}-c6z~?7(jphiPU4%BZ;J@Vz z^qYv(pSi#wX7a<{lZyy@9ittqU9L`>`^qTNauFBg}y2PkW{v zET+|RG(vmiEIdK-(ppXCXRy>-M|*d4qpfK74m;Pz8^^GlaJWpnDr-)DpzBOfp5@ZR zBC!X*P}R8zZug<%HW*Gp&9HMtXeLBOb7WIhITbTHP!zOgqjxF-Dc2imeD*a9T9(D7 z8haVjdpfhReeQt{dOYKJ6JY2e9;%`Jv;WC2y%PC*kz&qx9ng5Jxm=;l$;$LUD%8q9p7OoAJ>fpz*6GEPjaYz z?O0S|Iwc4p=TuafqF{w*(pIcaR(K<8cIOX!d~wTI^>!>nt4QVQLM#rLCnj!RLx_Cg z7$nfHDvpGSE$}CggucnyD9$3l7XKgZf>}}BXG+grnj*p;ZvN$2!{~KG-Y?LDNZ=5n_?_L!dva#(frrNzv2oPeyq3 zGKLVSv~WGnQhtjF`r-cY`=*rfKMhKpNUohexL8q3btmA^g}XZiqj-hT=c=Kcj2^^~v5tI0cLvJ-S%Xll(@v4CvytDrxY zV$Gl}6=rZ-Eq8arRXjj16$QUOwl~VimYbG3YoXoW5DSyHeR6i=1qYI4)asU#u(7Jf zd@JMLD;xfMC-3PLd=cfI;hJxV&SHWFDY8V;H166YV_cplW6b6{i1Vy!Lme4hX@#{y zC{=Pp!H{J3y$VaFxks|dOIy}LxzKyhxox#cNw-6#rmm%jetOMj#QFL9MbazP?^%-J zOZ9?f2)VUGp@al&wnVPb&Mw8+jm&ohd0I_L4VxR=bLhBOs(Qu4M1&vzRG~x)LwO>Y zM&RINc|~)%m}t_6!!%h)g~%W{z|CH>4kx-!RaH)`gGpSH%UR zm5;>>ZfOX+65i4}Jvn=>|agD(wG;boBq?#ofW##@NBZ<{jj*iK7a=>==@F zKB0tWa@i1)G_op`>ZvWFKkypoxO2EQULtJo{yy-rK(?5e8H{Cfxt|()O-GRqd0NRM zF44nE6*Y=|w?iZ^e^`Slnv-{Guy3k$8_Zj~$6Cf{$#OAhDwvA5m8R7oI^hnZUrT!$ z$3)t|f~~yw{VwDbJKYtU(E7%1J2Uj%ym8%za|_C;fW5D#BQ-nxm~JW41Pa=0;>ZLM zl~J*)Jg?eE_T!_02^-~o z;~_ugm8el87Z%+sJCsk7IlUTkU9vt@$Z-N;Hr}|0)KpV5_A=G!4ro z?G1Z#62>FHhU@8-@};AnXc)Xx5jKSvl?+Jj&i^VRME_0ge=G0*Oz?lJaH70TFFT6J zThx@V({wjMzCD}Cq>Zp&KuszicWrFpuhGux*4}v$c!7VQm`iW;23`Ny;E&4tLU7RX z>cM%2`6uEQn>BA9UaB3dRnpf5sUp ziuIIWm{>guxs4z_lGN)w^cfA{SGCIuY;!^_5!{dKgYf>d>y{)(qzS95p_=z*X|i&g zwx0h&!Z1YIn$s=15wE@4H^e=;!_-mgf0XNgbMP(xG;;TgzSQ+$5_$IrsfnugmjCFK z#YtYt958h5|F!B8{QtOfu{1OL>H>%@aN>9e;A#7c^D18>%cEaMQ29q=Y4;EsY*6>; z@hF;hk{!RVvJ7kWXmpUmlpAX?=PxeRDmURX@DzRY%OZ)O z%`Aw(0v3Fdb`9LBKyR4PjzUObmH~2>V$9dS$pOh`Rauq4f;WujujHh5b4{lT6ToW6(^eebgLPu6Me@LgseS zg===Vw*LM}>|N9cQ*v`(wlmnQExk2Hug&OO%U$}n(7CG9!M2bYlC|}!G=oKIe*N{; z@o4#}^n=vx*59kUnXSJ--8OvP57zuF^CundS8xo6V{12>x5VdonW?8nIn-NRM-H#r zTY0TU@q}M(Awi2!U?nr8vd<@sgW;W@-kPpwqSGy^={n!o-p=fQKbS0CYu8szq>qh- z_p(X;rFm1iWkV|-%^Y;EAM9+^SEx3RMjsu7jNPWlKQg&mtQIHtyb;c)h)rTf(9g~a z=^!T~d3!qQPWF#o6pp-j+THZ{eb3%%eqoh1VUbzAJ~gPWoN{s2h2Dn$(1ZL;apm_G z>bmf%WbxdaOXhz+n%nW*Z@w=q_}Y_i@?zW5(KFQf$K~RRC)dwBlu;ba*WuH&Uhb3V zUtuo|mxhFR9QTu?QDN(TosK$qBCxb-e8HeN*Zjf!0~6X+=AHYs4+l%z&DOD_r^g=r zDQwEb+wuMGP-|;8+qDgxKz*pYn~!t<>xFv-b~Y_#qR|yN_38Yqycj-^{80wWytS~& z#k$EYr*}dQ?tEyp>I)oU0kOtWL0o*!k*g!7^tdxn}*!fXt*dX6u?+U^Pd ze$o+oW40sML_tD@&f3(jrPp}Sou}#w6pWXcC+mugTk@?Jxa5)a+hIw|e9HNq-f6I2 zJH9w^(Pp()%k-8{{z=eRMaYqGJYFpf^_z4`Q3uJvi7M21?}TXB_0Z@=zvoU}W(ZaR zI$?f1y-gQ5rS1(8OfH+y5rdIP*1?N#ln916%2fE}{>h*!8t#6@zuJ3kFR%hv#Co9_ zH{crG9(J=qLnqL31xdn9SXed)M1A`O5-W2G`ld~c34<^Rnos{HY5+Eb9Rx|q6kJ!N zzDte2`b$pk1%W`b1LFGFeEk@1Bry_2@N1%V_1U1Ra1@j$e&s?`*+n`vh*vP&GqV_s-~BknrZm+Z)br(su|V>1VS@Xu293a6`@q~U zulG<%W|2adn$>q!iPaVt7O9Pw*Lt2LS`LTrTg&pQ|KZSMWnzrXp8S3jo+USB1S zE=MNH-gIz)cPP%R=tfk<1R&qcwFQi{MA%Sv=+u_=3&Ig^UR3C!#ee?(F}+W9#*Kd& zD>@b`D|1&W04CTU$#6W1$q_9SW1)zrT4tZzJ9NC?%tatFjkuqxkZ3mY#inJxlMvGjW19H_m0g;L}*Kt6V*!P?}!%V^DRJjoaDpK~xS8_;t60z#Oi3F8pbaF%MVHGAk$|5ktlr{erPfsw(0~HyK2ch_U72d0V}%su36+zX$>CgLz#9H!j>< z8aVUC&N|6XHCao;O=iUJho7p;IL7{&^+3Wd?um_kS~*tFqMV_jn+PYDrwm)uWCO^t zUw`8d-a6Zfu{!0JYe!-ut0PwEyd)(gn0C`+6LR=F8eay=p)_NiTMPwK&tf_{xmq#I zkA+u33&%d0j&HawVaDkdR{FaH(<>!4GE}4*2x#@}QPe$PilQadqE`lNvjVCaIiEgc zDK1t37`EQ5*V}`gJo#1s2-F!l^kDj4v6kPKmfJ)dwW#BT!{xW}-YuL^FLvrsplU?_E&v7X4 z_bEyMa&fA};8Z(tK^%~;qI6kR@<8_;=z=@;Ae*@(N^jMs{JPL$Xc3QgafyQVyT3KS zfRRFrAci3tV8I1aCIO}@nM^n$E};Wu-5O(*A+%Q-KZIx+poX9mTG|tMH&)QTX|5H> zP&UAT_)+RZ5@w4}<0mn=DI2h<8exXcMCBpzTGAUKewTQf1n3$%+63(WS^=Dxnz65t zlq`IS#0Zy{R`|N%al%w+A6zg&6c`MZx-UivO;244BH;5ykk=b0|M*20zx;;!mTPqC zkO>QdD|~=)?(F#oJ+-fD_##8?T!4Rd!(4#)KdB)3QKxB8!e<(!{G8ts@(4m12v3Dd z0(mMszF3%8wm$^}*x1_y1Fo0t(4ndXYi#HK}Fr?ByV#5Kj&yW>nEXI1=FBjW;2Y(rJ$*9e=0a=`MA%w4CpcvWOjBbE9O-C^Km0jRx{ujbw zo2KB2rKCu^dO9QbGQlJIQv)G-P8*`x>nPOV(lY{?AJgnzgg+9^`BW?l2*(R}rcb3O z!Pj8ip-RC-srFHog2afsM?aI(vAdo2(wT2Vl>>XzINBuAlr&ZrS=#nIX)#>r?!+cP zp9n41n-mFucU=}4N)&T$RgCo2MJBtpS^f|_qgNw;MU5Eds|P?h(6ibYQ=nwUni4aL z5w8Sh|5`w((9SCTeJTAdR8;3Ydn`SA6?tg*$mv4l8vLup3`&`ToUTMMGB&JZhrs*( zB{uAL=eHr00kia6&L9kIM(j{iG!q6n0(%Y(#zTGD8ixyZ=fJH?;XLnej<-g}E6apo zqGc>M;qVTcC@>*gGQAANBQla&;qn2pHTJdyQk){p5OFDj*bHvewDN){q8OcgUTdSU zQf1v|SOqf7269ZTZ&E?<=uTd*9Gxs;&5M@Q%ZG@Fm>*ys z$ahAU@E99>&d2T?y(wh6(c=)KJKMu*R_13i76t`y<>%(}K%g16#V^T}Te1%?0rot2 zKaw?V=?!~xM;sxN#0pabxI`*pNJ?j9DbnPlsi918sXG}6&xkR>{i(dU)QV!uJQOsO z8$1N*8=!>8@NU6Ts8W9|PPBkkvPD*kpHEi!w`T%Utn6)i1XJ!LFuJXVOPMlDytw9% zXF-ow7_;8(&zxWV-qkt{y78h^1?8GFA+||G1I+Fih4KB-?RKLo2fsWs%lEdpeCdEm zY)LhJ0-dN_B#6amTWTjUvZ~zlnKk> zG)zhq?g)((jG=3-v47X^I5b>gPa0vUTY{j+aY;hbI$7PwWlA=%0#+aiP{~gA@&1z4 za+RTyQERJR>Qh3;+&Myxb(?@PafYNBf8kZu|C#U#X!}S5_4}6XqqrD1e0=49l(I@u z8hwXdj`L{K37e`)alsYV#2w-1N34%NJ6?Q$Awt5j&nZ5^9Xm26ckcwaz{20!rCAjS zuH=e|w@E=md1XjG^SHuNBdYyanZ=C(O%i<~`+jnKxOw%kbTaeQZJfuWl?BcWN@PqU z#yrm;`I3v33FT|TejE2xNTF)tIBA1|29`3(E#St0G?>GWStUWZf4YJ-fwf)l*SvvM z?TA))#^(87z>*<+!F?CGDp$GB+6_cl_x~gi1`?22$HCeWp_t}pSFuA zmq*cxW;{Td_Kl#)Brxp6wWdOGqas_EI9<_;(KYnI=E!U1+g$ArG_$by&FPbL%!@f< z(jvq`_=%?_VKIV2=XKjSr50YB2AWxl0Yvc8KBkbBm%|Ws(EqhsdVRF@ZuIT>DOGVK za3`mbW}s~LObRyTU!}BK4i+(%FFGey-ckaA#ttaKE3sS}Gu7UK13K|Xz~3vhG$fL3s8 zGOVAz$RbwK!S=+FJ@}DB?_n#uH3Un25 zfblGOxj(%*`t3gBk#O^AFp$j-U5Zi1zJf2g3I2wmR&er;#DuNIpI~X$h2)=i+zz)f zs#((4XPB}glihuh*^Trgf^y?)zmBpazWt{Mjt$Tdp8DIn0OpcA7wt^m^3;X++AizY zHTx4<=JQJdX7rXaWX#v&DFCEoNuGex)eHeh9xLDmiSa2Wo4d4doAt!MKMIzks~5vG zOOpkloY(ShAm0^z;6*I#*mm|jD$oaUWBG54Dp@n7F|)<4lEB<)9qLO#Bt(Dbg&l&0 zBo6A$cuqcJE{)`WdgBSzww8&1Qn-w)ysJyAJ< z=S58x%xrO=hUkVyOsa@~xuHE1+KpZR&$3E_--0!I_jrxQ6%k`AuziVX>^BMv}0cNfS_@Y^%{Ry@m|CqbY&BUK~p2xc^I*@KxM? zzrnS0@e`9U99;MyqlP^U-^o%|#YdV(;>QkSkc0z!cLN2TQEoe*(HmF>uU6PtF3*~6 zz>i@z>Dyv-q9HO%P+7ZHlO(~EK8f?~HhaTUVr|*qaQ4s_2S?$5M8*OTI&i53Fj-=S zG)hB1TDsc-pNV>&SWfTY$VQk)v3vNO*Mvz}+R-GiBpuj>33$s`glDaSSOk*1r3eDe z>jIgnwOyfG@g%r9b;j=)KFQvvO=4pRSk@NF-tXR$_#Ucvg_y5;?KZ4lEIci?&Vwx=W1}>bBl2iU3B1pUnNXFs9 z9XmDU_fc)F(gqoN7v6AD4+0t|t>g&s>IH4eQs(G4v{&>dUX!1}gN2EG&=mS};}rqN z=4j>^ef+)7mP^z`sX8V$!5(!@H_ZPyqao~DG5{#Uw&HSjEygx;x|&m?j=A0(rzg)* zJ`p&KkTOnOuWSpyZ8#TlkKM399hoDTs9(C>VxGL-$$vI3?rRj?*aNEkD+l6CY=U@3 z?(gs4)Hrjv=?BXM#FG9@FlS}}K64QY<&KM*rK>}5bO@I3$F{%=;>M>T4cCWvqd7C- znI^vCr<_FlH{dqUoieJg;+N6{QzLGTxYEx`b~k1~M7u3*;>YbB7G5OATLq;MCBOV*M>130S`)6}%QaeQL2DlpzXARDGDpZ^c&z5fgPjuWTF&J(AL2GE>deBui93M}ZW z@L5j>=?E}p@b*e*iUYoi6@Y(n{#}xhpJprcG@|=*ja1}O8+}9B6@XvB#}H>5M~{&o z2E&!82T;3yf#pj^J?H^k^%8ba#lmkTYmL^}zz!!u@9US?K%+5vv4``an>b5#aS;h` zXZj6N?QLBGd&L2E8?*PIA>yH9Sm^pYZzl%OV-biz>f6JMfvtM^~D(NTUK=y7-39_v{b8UM#*Hl zUe?W3*7n1{v$3KN|9ZH)K`BdFC)%YlN#=mNFTP1w$|{7Kam=h&F}p(}I9(Ze*Ka2F zyj1?}ia&s~Tm7~d`9Y846yJB{j4#fG%txNFoRJ8F#8;gJ+2;ugoQJrc)YTlU__nT} zMcO{AdlCd@=+pWz%3_ImgT_#=DrOS!iALMR@QWqeXY9{Z8Hg=JUuY}%BWCJ2Fv8QQ zGmyXVG{mfu&Jr2^3=U7L{la6YD(jews>lUtWqi^5G_f>+GD{*Nu#U5VY-q_!5WI6Su)oSM){xK;ByoM0{3f2 zTCGTo=eZR2pvQosvNri1g%=+8wQ-Jw3LV!Nn$@3mnL|}sNn|mQE2k==9KpHifY_PV zWJ0;t50tXBgP39z!j`X$NeirIo6Hl+mYF5tenstR)^IW+QgGbue~f3Ko}h61X!rtU zd-D7@o>OFzd2T4U6#sdVP-ZVmvxx0xf%7@eWxD3A<@2# zNppcIZS?+0-Z^Godc2Ff0;@X6l_XNAPS7U9g;hGk*pUU{LZ5zk?k}okB^J~eG zK2S35t(8-ptsJ~lOO-uuf`8j*JkiX?Dy3#6`a@>W)zrUu=mI!hQLcJ~+aeuizz=t= ze~mT+1+F9XcIj#=vc`?;lk0Xo?Cq@_6yr-DytxU-eo)sTlxgJYs;{+fvV#GCyYVC{ zQ#F42;SfEr?$)_!+VbKI+VEQvE-)gP)?(xxZZf!SjqP?+<;MHyQ)09+V6h8DBIblD z>FKzkgs~(PDopKp#)Fgfm%q+dpmJ7k?Wg6f_C%gL8rp=O!>sAg^tPACn{nX2Q2)#rAVoA#rfZKFQ{d3h@`;9< za%dv`10^_O9UN@ss!-w+e)y05CpRVH7!+d#^-a=S)m{a}<`p;dPDX#p&cwR5D=eLL(>veR z@J*d-S>JAvQ#)==v)u`M(JJ}Cv8efFO*~w;U#vdga%A4#O==bV9Zt92WNGFLt6MSy zYiq49$kYIt+sYg-lVGMYFA;_jHRecT3Jg_=dH(Zvm40?kRyMg+)i`LOet=QSUXy(K zcICjp@le*nywY)CIV6qKW-%7D;NV}9QWVmSlzF=t!XnJh0q~N9fAiuo?QSJ z1T+D-U;qLxX&CsUR{v1E-Y8w$yU>K^hTuFTVjW8R?ObJYGkgvEm5Je_Mf_V3<0)~n zJ;uyX(srG-3!eZuc%C&PXVriI!c(6X9MugmZ|I`stp%V@pc zkvc*%h<=xZ7Ku!Ku3W>3u`DXe%J{zASO<5SthtJn5^j5Qh9B`-(^!Zc85>%<27qr` z>zh4$Ws>1x4NqDN$-JL7bJf9()-BV(<294mkHpi&s8r&rq8I9=?JsTF}t`%5>1vps8OJP}7t;d=s8{dNq2Uw;^N8CNi6(b3% zF1!IiXr;_je?Igl>rdEC-LbYY62Ba(3 z9aqFw)>6juhZu7|3{%8zj_1Q|?a+E@{KB_Z10O`+i$gbcV`lZ9i!D#d(=ho^y7Ja| zx_FJm-FZPW?#gEay>IYdNg=9 zm++jK=d@{FHKr}!;2O8}?@fy>2T$((0%ho1Vp+q$Jv#{Tq<3Vqlb@!iv!jv_(bH-0 z(m&Z7xDljAtKC+kl7r1y&qpWY^-X2|59}VEASou;+(`jzSnJX;nhVRC;vdCb!=sjh zsn%|M8(sOcLp}e~!P>LQc*nGg{&zNqb024sthnodr}FVC(#dO}y@qrY^kM*XXJ z+{sLKU0h}&?CZxTYd56Abn@9eGwd;sD@aEJhf&*vwi6X@4!Sf9p#3A{@VQEZpnwASp$ zfGcG&hjBl`l&-qJ89-3s(M$zLUED<~p4fi-jWYp-0I3o<&DU8}2m7 zx$oRwlb(QnUE~takbCG@=Z18|Ti6NNooQF_gzgxZh|9e0pT^rG-OG&$ z*tZwpr09$B7d}PUlGV#|#H<`0>Xl*#ZF$3mf6Ii{=TAs$@Z*0HIl0=cLw31wHTiIx zcfFwUpH5AeX@h-DpJ+SwGJ~3YR4cB>580kwoMNRxkj}_kPE4oefW>IDf$Y7z>~n%}#D6Cb`n(Ep%VcPr@HH=Rg8b6GtJ4ch z={2A;IH42m?O3MIAjQ8p3H&An2ydF)!z-%11{OS%n))2u9-z28K)!iE zzy5`Lro+CB=iMZC=n`J1*nA^;8-{syLB2<)j%bD_S9;A$>Es>RAb!Ju?x+e@Ycv8j z#}+hxeETum&9WeVR+W&H7WA!}LR0uRUl}M8?)axC?H857%eK5($m-;ujILeUDFt!e za<>$TA64M9WF(LIa<~SX|HZK>5=4()%ne&y?>+ely^VBYlrD0pWb;HxVQ@aOW?wC4 zVfCZEr1~Ua7^X$Xj$|n<84Jmfq%un5jleURML&Qz&dNx7@vlY2P}R_ObI4Lg0#neO z7zb~=N=X#ac0>|Qv5A}>!oP6#x)(9iM*rZaNtkuZJ_j%W3X?v5CDt?txVmEPeOMLTKK?=|Anw80GJ)#^BF?V2DPr`xr1K@D#W+?JnH(;{*r z{#BF&+4{9e>QJwCO2nruD5@*R0<^?%E(Xkprv87|)<^AsHvDt!+AQ4bPk;wu&fRnP z4gH&Zsa4K}RDSZLK@k;+(i(jEDMaJ!{xYVWfDzETLO&+Myb?`AWAv*?j8V@(IL)p< zDe0VObci%)m2?SY#^)}5ekAJTUhp+y=X?cvaLpf~sk@2pYTWKp>7gTUr7Q96BJ)|8 zAUNnS)pX= zhtPLV#5IZ~Fvb1-MF3QB*rx1)((JIl6*ORR^njv+na}@-B%A@)PMZA$9dZ;{)<29X z?*9EyLn&~JP~~WZSLkgIXr9t&@*H)K-9?t_=bum!LK*!A{a&LZSOd5D7(^Axw ztfjw`u;%Sq@kCbJj3XKK{gGvm`Z&im-&k5D}1v)7# zk~~U)_ycB7K}^8cJ(PPmQGRH&4+&fe-d;-1a4P(L!-Ol)bQXO4!QS)sDq%A`Wzerr zPR?P;T#fJpw&I`2k&rQO3z?aFYxurV4Q8e?PKew=1+gGV%NU#HbBrg(VIh*vuA7ctZOHsdxe-*+nHT6tJp093oCEYlGaNpm*r{33mnO ztcWhVF2Wej=V{`-xr<8Y;5e~7Osue8f_8r~_}*9~-+^pJKZzoT#fZZQCFQ#k<2xr@pN3vvJ!I9G64GBWFY+EsGDwoTKx9zDM# zP8N^O$#*b>#xHHRX#HiAEHjKzE06u$&G$(jyEI5S7Yi5Vo>B%Eg%3uF-B#@YxJ^w@ zVD-yZDhmMS11Vzg2q;Fa&KAxm{6`36I1!lOU4jtbB?uIA7MRSwnv}lUuKnd|8WC5a zWK(tt5qCZ$>Owp7FrB)C3)Z+Gl_MOCTxMhbYRK8$kpkJwRFaR37HNlQo#kDcPN9ngib7ja76e4wOG<8lPswOnb+`rP-L3fY>}l5qV_XvL|qjU z#0F&v6p(*Li1+-%ipYlZ;Tn2xszLB3271pcU^ymr-FC@9Z8U){4fk0;5%_MdOeihx z6ohQ-e+uzML~&$Ol{N(P1ya_2-c16HMF<84CcGe^thMEJC1_z10D(h6XF*{R0D%WW zju(K~NjiPU$mUj}bK5Nj58~tX$vXM3a&S&!-8)8#GnX0`JsDJ{j0(QkrH019D1-1x z%T)6YA%sDthY;ZqdBL&AS=`z%Q-Sl*dgk1yOSxb*Qml+)5t?Ydo+gAcG{=&_BVfn1 zC^L*D?d`?4gVp*0QmfUdAa4)P65PA~i+EZog?zJ^CY5{>L&UE}xhR=7dVCqR^mrNd z5;bTWn#7ty=v`s@;0v51u*rewd>pr-0fkvcRfzl#=ov5-A_1vUj&vOT(7Z>~f!uAJ zvPZOOUl!+;=yWV;o{CUJ$P@>v|7fv&==Lj}A6racxqYaj1Rvn-4Zzz{e1NxJ@3ohW zHHxj?HDhCixqURhxEP=8?>NDWuKtF4w8~Yr1fzD0T4^jRW(ap=gjyZ2$CCv698r)2 zO9BPP=lI*q1A9e~ptXcA@wvJ;a2)6HVqQ ztSSBv{9Jk1{knGB;y>HOZ$`a1L6o}I7IZlEi9mb`dN_~Di-G}S3OaHYLong9tSXNm z@IYd zknul|hfM&6fD1rgy=#fT+2ZV!M1k!cMh8tiirerQ=&Q347oxt7s?>hAMkfE3FaR4W zeTBd`OkFcUrW!5amSm}zBu!UM?+K#;LI+ChE>L2DhKlqRP-4Mk!W(|3J`}V?3Hp=_|DuaD~&hV%Pp@pnouX4QSvnetB@MGWhD%_-_J-2WPdvF zU2s0WXa5Mueqk@6NV9jnDTEW&z#WAVU*@1VE@Rf%j&zMDinH4%@JJ_{G5X!^*9hM} z%%>qC?I@P2YYdnt%Gn=@WfVFMFB!!XBen)xOMa8yvR=M8x->ntXCZI1~@B zB`I*Rq#k*Qeg&+BDi+#^@)S!@Li#bNP(q?XhQJUT^aAy_0ycxD@Q4zz7qDwFQL<2} zEN~fxdNhz7l1efG;;1Pw@5`8^fLSyr*`C`j21Es!&GWJM6EG_@-3*9*42bE_sW45u zJFnbu&GE(g9DP{>7&`mPgs4`w$|m5u0uI1C5Q*DLngrC-TcJ22flYw>Ox$pM$x#E2 zet-ApmiD^$WMp#o`x`*q&$JlN#EDq1iAcZ9Zk!0hGqNrq5a(N1s!!aoP5vMNfz97 z{k=DvJ9ZxXoL=MxZ#o64(C_|!ZT9PNdg)^gjVd7z#asAjs`lK!X3Tbt7}7?ypjhGP z3t(mez>F?=-0aq)BW+)j_|xYDHW9&12Oi)y0SM!F)Dm9)DrB*GPXll}2He zQXXXd0jmei0vjS=W3Lfin3`b)h`iAupYJ_#58;YMzwfpFCjL~3S9En-FG^w$TRJcd z!X(xr4~c-yOd&5N-KKxL?Nat@Dxm}lS6*1Bpjp7gzG)CV6SmKjD~dn&*k)5b?UsWJ zVUO=HrsJEcbR3wUpX%4h-|5+SEMwI;FoBN2nP?o~k@q5Iqevhvl#{48aS})%rH_X& z0r2zZyNmQ_Xl=sYWol*U%F+` z(AAw6`LD%K&=LJFp(8M#UENY6DUCz&Ub_rt&+;$xZSXey$YFDZ@A0gqhN3YW-L(>A zi5(p@q?d>Itf=eT{^$|Sa5vD~om#1e+UqMX4^@DPfl6!ztpF)Q3{>I4YdH1WE2%>0ipl3smDY-=gBrPioQ zbO-(b*V5djlAT4vyUux#DjTI_oY6E)a^Wwsc`E&dY^VXL&*<5GL77oh(z=#p9LWKmwB zeOd)~@-dq~!Ov*z()O5nci=-uulO}=>5Dn57w}iIa@;HN$%hSYGe3w9m;-zdgntVU zuq61jamWT}r1o$7HYm-%-@Hxc!NRiP+Sqa0*sav@l-_lT{gtTCi@v9xmF>Fz47p>`++8?sW)%)pC?0@2R} zCfhd*i6467B}Tpj`ubs|q#w{%0_^zY-V_*ZtSR=t{h{#RF^oQcIzML$SfvDi-%^5} zj#-@%C&C_-4fj#SIt%Oe|D^EdJMB?vbm<^`#Zvfc@3Z3Mb;ZKpp8t2B`&EFT-_2yM zD2C`$$iUsz5aJ;=Y>2KNLUz#lD;()J4O+$$Lv42|p z_IRGfLD9UCFyrS<^hC|2DXk$t%(yBzMOjWMts(w|LQyB9kt~=vr=Xu$5vDQ32$YJ7 z9tMg!Bb-rXIZ9%Muz9=VE$t;ZVOGG_T;GY5<_BsPrTHK zGLYo_<&xp|B9Fa|IVZIh65R8g zL&w>OosvW|xP$_2b0>?hNoSGyZdXwxAL@FPx0q!~a1|h()c91w^LsKJ@{jHsNbQptsq$E6hZP(sN4QceXt ze3y!hZtZMWb)yWnwl&DCR3^Q!#~qQe3Z3y?ndkoR z#m6-3%)*{EY|=DY{xn%Tu7H??u5H;F@9(!OV@!2w)}e(x+9_I$Sy0BM!2XO}DA!TV ztmZ@xxtg3pdi-m^OXs3@N7h8ub@ds_=8{k2!$>Cug9~Y?J-^rYzV<&KA|>~cgxMKf zLd7BWt@Bj?MP%8RRnK7Z38w(wL;c1Ctni|KQx%GnxU7-!?H_+*a#tSICH+4aYB8oP{`NO*Zh8QIc^`q*Y9_%;9LM^`1gRuHzr_)e*-hT56m#TCSNj~ zi?2W{!^q{Y!Ipm&=|U?tIdA4mto1&eI=C~j?q8-7p)Y*&cTa*ig4uxY3;J&xd`}sR zQyWD!lb;EZxRT62R;9`eCC^J419F`COS%0$$L0)yc(GAtwrOyBJjffAL*@Xtc%lKL zWnBON(R5W&aRtj3Cj<@dF2NzVyNAJp6C}91yE_8}cXyZI?ivX0?(V_f$-VFXu$nV0 zPIdLJUDdl~q>s>sOq$_iCbabHEnr-d>(3QIQj$Y7`CcvDZ%2;@ul_sPoR7t^hYm;tqasB)KYos^pEJd}k6RyEP#r3rUP3~XC6$DgV=s?Al1SB2D zqbrLhgX9#?WYZ}f@wsyURA*~;{duUb}?MyhNx zge?R?{#96(27pXv5J_etsF!T&X728kEq^;*^nMxGIl2l!TPJ*xS;jamo*^P{@?Id^ ziOO(>>L(D41?VUoq(A=!qcXyK5;_S{sZ+uATX&^+J0p&i-dbJ%1N=r$UB3;LVKaKI zcKD+w?qV>X8t)6=-lMBUa>oza=k+gy`G}eo0%cZ`uIR8}dOX@UIj&lvJdB3$T+y$~20_D&qEToF zM3WzCJw2qO(8`InakpOmje=r62{K3?x@GTpZ}43>s@jsyCDig2@GKa(1{t~bdnEIa zaXx6uJoKOQx=Xl7Rn+hS&~6J<5k5tU`D5T}M;-0oJ6rE~@n9;{#m9F&$uvd66?=s` z0kJuzp1i)I)~PWys=f6+KJh$SwM`q8T%??D;wW3-c`24KBft%l=u*H zA{KnDZZkk|2qm2j1W1th9|<0j0VFuvCS><@idA6f_J7Tei>RZXi58SuM4loXtqay6 zk!uQ;j_HrHfk5dX0F(~5fQnTFZ#sjwsI3Dej#HBIJukhtT@Opt-p?50r;=qVF`b1< z%=K~<;H4f^>Cw|oG{2>#lJS2jZ7H~H90f>eOFg-8<0$`9+9@z)j9FSE;Wjx)$ux5L zUvtfM@N{!uCv-`Ius-tiK804MzJDKA?~rKiJaEbRI%1ruuJ;ts)y7dkkgR+_MqBDh z{gbNOR#WUs%CvlK&~gn3vLDiI2w{3&J>$_k!K2Lv&Puqjs;$~aj$1Ic~%M-rKW1s0WrE+&mZyttqf9$0p*r5xsb< z%R%7{$Ud^l%W$C(4HJ^?Ks5tp9T^bOWDFdm^$BfO!m~9ZBU*<8h-n2-5!OTg5tH@5 z^ssV{N@(lYK5@nQzos?AI$ZNCZ#(0@o3>R4ea0hp^Ww8hJ7ZJt3SeM6G6?dD6ELv3 zCzai8g}HgbeThVX&*$&(^EOpzr}{fQdiyZW-U;^y^py5!)mlQaNRPo);4q1MAj!|f zb^v+q^-B2w^03__)kX+_gzFAqZJ6L6*4qDJ%^kqn?gW^NPlcAq-SJ;bYMp(UU=?%{ z*BnG)8@^U$mu8%}csuZE(7N;7;2xkB>GjRC!;Q>ZO!iw4PP(CUTUsUJ#rDgvXI-Kr zH+L#}C=k|!Kv-|tHGL5vC_lwd`#H^Ww`Zva%;n(V-W6$~>ou5}t*F!4M_?S1oTvRAZoD_qnIV3I&vlpt*c`ztZfbfGnEF@J!897FVJ9S5Rk<_OVh?+V}n*-Bmvw zFSk9WF&F%Si}{wvY4a|WW93P0J%B8_i)Et+J~<+o45 z&C*7&d2Pk)zN5O7v#19c$^SxkP$yN7XDjHycdsE}s-3vX_4hi=jk-F;wI@_~>U57V z!rnlxf2@p0zyBuOAX+jvU2~&P$-#_Z}26kZib@S^M6#J}$VQzBlTrhFJmq z0KS_w;kvl^c5=*mc_9T7kStqC`yS+jrbL$+IG=H>i27(SQVLIavmN8C%+=!BnI>oQZcl#9oXQ0D->_8B>0#&32DPbArNnlkYU>5Q`#faOB zFg);-(98jiX!+9(ycqWf-^`6;3tO)M{e$W=JEC5a5~aNR9=UH}JN1oSPN9->@Gs8G z*}yiDC>+`t)&XD#32wp^$*CPzR;VVm1FbKqu`_c^vaz|!cR~LveCM~x?{Y1H_jz}a zTd0p#e7E)9D-b(geFB+(b0!9Tsc>G@uaU!#Ch>NDv-^x&JyaJ0|ByR$7n26T#Zv{ELKZI44QMY5!;COTGCCwiTa` z=QlsFw|8DfJ=*$w_ygC8pm&Wz?A+d96Z{S?A${Tb&8c5j*0CTTU0cgPTvmfGnIkWm z5w$Ghrc9Vf0rM@=)4 zAW_^`F)+y}d;tntJ>4PPtmb^9ZcjV<6I?rd4kGAD$YWf)lB5{OV&&hgxI5`Mv)AbB z*MY9_Y~S?GU?-|ZefTK+X6M$dR1ol15#tf@D6niQzro0)um&X};7ydq#6b!%w!}dW z3D?V5W1bYqQ+&qt(W1i@Ng51#J^GBB`?cqiEj$2ngR(-uyO#PRoP#>5T#qna7&q+B zTQ@B(sK@SOhzd)X3QH6GhG>r)cOGo^#J|VC2vvF>*ToTAK#;D&jZP6^3$)~IPRwCu z_}WgjA)OE8-xn8XTiyA1VcQ4V>p+mjO0%?^ggGF{P>Ul>J38Y`@^?3N7RiTPjoS2k zJ?wP(+U<={og~~+5WyK)QG=FXiD?`d8s|WP& zyt`%n(#Ffus0K@;a$I05kh3bnR&{+74(5d99R`Vs|5~6#S?UP^lpj=lZdF=@dnI(V)8{I zGDvYE#rd$=nUf@pb^|41mFhlV9v6fS8{nn@B|>8>MH+VY0S3U5Kg1;DM;HK0!VtyE zpFT{gk4-qVW_U`SHtQvKEztk;XRbfj2A{xCs9Dm(iI--ZIArGV&izK%l%iZf*u<5l zsZq*J;EXQ8P%Vo1Jo-Y3-fZZxG#JL~Kd$-@Js1Fbcp?9xhvpx8GB@A4k6=JFcD(+x z2w}4bz^dPW+dfE{5a);%M=%K07?dst(a)NR#@ICIaRN^S|Ii|0C`IEpTXFx9V?WUCF5~SVb$s76bGb9k`aU#?Dv-X*sZd};I|HM%LgFYnyeQE&u=IC~G zSn}J>S0^5NjCGrtdQ)`rG(+Hx`2m(m@Z=3rnmtL@2K#uW>Y-b?U3YC8{&wiUA0yUNB3KEo0E!fQ? zdhm3 zFoCc&9(uL@5124)N(SY$`?%d1y|&rRwG-fA+|2g8-D!S2l@Umpd`cct9?}s=ggG!_ zoGM*B^n>f@kZ&^Eq(&#yo3r#@NbP9Dog(GwNwI^cgtKfSL7XYYPl7mHVVfG|Gyue; zTm?SH)gPoq>q)WqLZ~I<2$W}l&(mS{;3(&XZMx5oMMjV{086<5OIvzIkU=(f4$$@v zfTjO!2PP2kIzZ3V|A{B~z|4jA+&B2AXf^KCJVXqLI2%%zT{wUzRv```_TT`Xu<=tt zPT8`{svd15+i1U~u8)2gJL91E_L2^!N2O3>;7TVudiX|3WD9$pvO5Y*2u+L1S>`lT z^gHcvy8rW6Ct(}(Z^WA#7<-T{<)MZAq*&q^*LJ>}iSWhz+anF#;%8C}NoW)R$VP>382`-@93+^_c%D)ylE zX|!cyOMCnxb3-LF>5hdlW=}MHUUxoGF*7MMz&r$Gz&ta+ydXI4pOcuO4w8LW8A^?) z6IdOnV{@-jp(}<;ZxaE=o+DkKTUJ?=A-U2-yKN}Jw#G`?$HT~%DhXrAfU#VQpO*n+ z;|Qdct;6u9m90O256$5U`qJTFfZhSwDW_ozgvu@4zff8COGLBx077M!z~dHB2h)@e!7$EY4H@_#9KXDkzAxfsVA4mvpcwK|8 zE!Kj=e5o85^$V0M5rkwk<#t2AFy`>g{f62+pjdzcs28zDDJy|6@HG#%+ZDkQ(yk&L+i!KQZw4w3oxDqcQ8@Z7cH)s}x=Bh91JLr0=Dg%3@n17_$Qy+ANDso*)6pvc0MDb*Y z61Urzt3^oyDipo;)vP70_HwG+*?j2A(0Ma(m4%qRmnzfDnvr_75<0H&eiRv55+sDK z^(JuUHJ>%B^DY~|-)aj2o>}(Zg8`ISk*T1Tv z=Y0yYpocBou=ADAe*lQ&JZtJ$m&JkOFIzI$P z^@tod0&}a>_IB$iT?(g{o`C&bfc-DTD0ABnc65c-=ojC{RssYb>Ve|DBh`DHYYfXs z6xK+I5mofPh#jluA>o;Rft?rg=l!%LXAjWZ1cYY6x%bH9fZ{un>VgN zK9l!^kK{xZU64ssbg!C9J!t5%XeLMCapGR{Y3Pmqs<>)v)B?*h|YZhJI24YiIdJ5 zAhH!?{-4g)g>C+QTnMh#TN(*fj2TY^F4kZRJ6-LCM(2M&UO%-qvHUT2wr11q$diU|DfmL$oUS8dHNnkDtZhom*xpA-40tu~EMnGq)5)sEg37*9K z4TU+{Uv7~EZfENeXirF9|9v-MMRsx6+oM(u@#K);^{_u%XfMQ>f&H z(KpW3AXI(50D1lFSBQwiuwV-1gs7~tET6za)JY57>%RJ;ZdQHgW?nU7B!895j9#O~ z#Yhy^$my%D=1RrM)Ai~1j$$_KYw#W4)EH4v#7k$sXUm9sUG)*N%g7pWWjjWMSFAQf zJTxC+74)h96r|_o#g^m8JO9^_wY1lQyEO2DgU8C6)lH)hjY4ucfsypW1XF-J#Kk5` zAP;&4)V}mb=>}oZ9va}_9%U|O!%*25;?zQXF-KV#>sO#t^ZgU@=K@nWTmv5^tOBpo z8hSj!)?m!ZI31GF3@LIW!Wbn?C>x=^7;Vr5j7$H*{(?cAIzrruR~9>NilacBok{H3 zSe7^y-J?Nf0Pnly&G6|ZIB;cU1ZQF0;U?U>>MVMsUyPZ}B#lAqZllSr6kQ-WHk z8B!9M$R0}{Z-W6l$k@{}81_ZaK*a1lJ^W>>=H>LUy*K2kLRpeNU1#L7(x71wme&ut zdN2lplduAL(c(xILYq-#!!aSBD?=q_okEQq_4kaxV7dy??fjd(DK*wjFQwZIoMoOX zH$=x)8_aJ4lrx)hb$)`viEdD04?jwpT@%J3wb4z-czKro*HnYw-kK5-brWj z8@9F0-SGQ<$W_y3X7S2Mg&p^P=iuD;HYU;es8MkSEs)e1crr}a%u+=mXIHk_D*Dk` zCp4i4RSsom*>XjYpz_wOBI$f`HsiSa(eKU!j5`rd1t-B}9>@XCKoNETd`&4uoJ<#Q zbQoQMS>d<-NZv~7v7-HpaTCV|@wCcc%~!Nk(4%YAG*Z5{Wbt)uZ>aI%IbnOuO6#Qu z_m}e*R~7=za-=~k?vy(s*_Oh2X{HMs+XFUQ_ALEyCcNG+o5?%ugv-xXyJ(di#7p(R zk0XZ+j^d924~U~`7$KK`%*?vKgh~g-{*e&1+Z3?JOLAUPWze*LBtSmMO4zTd z`C78Oy8Y9l?x5eGQujHQ>t`2zrepGtOTUW}bs~tM9u`e3bajfwGfVeD(;YdSYaQaO@i{aaZp^) z3)x;W<5(hhB`orp3OYYlh5rN3Q0d>1?em`d6FEAeIL zO?O#fvMwJjqBzOicV-;;3JQ-Wa~JL2Nv0cSzTpX|R*Q4T*;At1kV>WM>$w9%mAl5b zq-0JN9+y5D_SP-Cy!|0MGa6a)m2%CcfrER86@Gd#W^hx%cAlVQ%7*OW-=u7T} z>0iAfW!)HS&+<~3a8&M>kCiy+?+JItoNLzmy~1HE_4(7JAvd-NJrqDFkI-LJjOJ*o zn{Gi0KZip1HG%tw-XW z_fX-Wq;x+Pr8T&EHET^2x!$x9To9eCramA4oQ*IePW#0S*2ij;pbEa$r-}di7FW<6 z{UaXgL4#^A-|=Ex+(j0~<{#G%m_ap*)XFdG3v8mmyRm}Xg8T?Pb&}wCz+<0t*zcFf zK1T;x=CWUmAw6tnA%+XeW>=e3c)E`9=JFxhXoQ|^EgWtB3XjA<_||J5jCsr*^XuwQ zRvO_Vyc_ROnJjTff{(reZ?|CgEYLHkw(t=)Lc?n$_!R!yx&Xhm?p+=`VsZx=tT?WE zH}WklQj$y3F4XrmKVzl8Nje;`&UfuZXk4`(;i1^Mle;1qHnfa6c8^vJtEuTP zk6(ueS@y8oJ|T&UJD)x(1(&^#3~s{CPXwbyu4dMHBquzaY_RC-sbf#hauzMyu6*hiafbaC z1fS2-3+jCHKm)ro+o3`ANl0T}MRqgOL6c@`#FtZiqC?JFQ}UjnQ^9Xf?Wuk<0YzSL zALEa&&tH8pXOUBOG35h!RZrTIgL>pkl<8lt6 zjuyyRgbxyF6+kr|_T&a`>u9-l#MiI$)m~l2F86Y5HvILi4YtGesXg&wG1Aj({O#_w z4Ey_7a0*KFr}bV~KEGHiW)x^a!U{nJLKzs%Yp~*k)Hmj&x%#4y4zxVCv8v_#oe%i; zKu2#;FI~u4Tc?HEp=hjYsBdYYb4WVn(EfI%ZeX<3$s+3SKZy4>YC)`D;4QD!a^wej z6P2EqnC3JoY3+9WN=J3}M(L1*KQQQ;r!-v)bMWbct(J%VbvWdG{FWBzOXQ{WowzqOy8^AVW9z(UK=Q#JjAE-j(%5_sN#>_S*6u^&(cU ze_f+m&Zz>bdL@JfVV3gFctX;#Y}N|NE*#jPRKHZCGM&Kr+Xf?E^2z|S7!LvWH@fyj zvNh6KztfNo@@c-tsUSCSAQuXH;X2B& zM`{8E0@AiqV)$3YGs9Iq%=scM26=)rh?cg#m!N|Ir+O_W6P0@#K_)u+-V`FFj)<`P zPp4QaVxE*E2qy^!X0Zj_0z8A%lH_=a#3`7&&KNikNBEZydPI6p`pv!-%hu2LO0wuj zFi-o5AN~$g#03bV=P#W#D;6hkhA-|ZpkUy`i)18~ffv!lI}6C9jgcYm19L+lA{*J2 zfb)BVFJL6xM~W@2%_(gaiZ<%*W9Yo)F}^PvCS7Kn9ohK~xAto61Q@B?9Uj{#{e2)- zi7+m%+_D12^J$8azr@Leo2<>obAdwN_ei+v@8-$_sJxon(|zc2J5nu}GxguC8tQht z`I10AfIw^K?Z<`X8U32+ju^~so-oY9Pil`T%bM}oh+Fw1X$Y!ou3?R}73Y8+KHSRv zc#%?fUz3`VzI1Q*!;UyfQ}!hGgND*X`t|y%HNOp&#=Tu~IWoln((X5^#lb*DuSaLz zoS4NUOaXamd@2ntdHaY$MK22nD-wNmqH;P*vm!`&Z}PKfu43L2f$pk^4l0O7Yv3w0 z`TD>WRtJ=ZOhrKRXGr`uo#3GB|N;Z4~Y0)d8Cd%MuiOrf!S)$zn%`ulr z!mr_POU7b-Su3f%rsh@diAV8>?tVD+F*SnrQC@o2S?&zfD8c9uK*e~W-Z$crol5An z^}|#_AxlsG`bhpM>{^Q0(?a6uPnCu393dV(QMqUfq!OL(V8 zahy00wJs9V8}V&>!`6ELvi*j*65Ua^XxU%0mZi?Q-2uGt-QacLup0GA*MRR-X13c! z`&^wL4Aqp+b6ZOUS_(Wg^L$t@(1-yh^~9n%PBxX~ zEL~CL6r7|A!#C%7_Y0^qhhLocX@<7wftH?nvtbWuk}eM+<7O>M11!I)^hDTxF*0?f zc-%97&pD6|b{AU67_4pBS<5)id4f=&y?=vX2NWQg^n5-(7 zz*Sphc`m7<9VuIXqN` zP5&wT^nhE$*MD0$Hfz;^#5pvBiLjoeG<(`>R9pcieOdtZ&;UJ-5|M3boj}#_W2GUl zbj%uM(5}Ym8#bC)RfXT}VsRL$0D4vMZM#C^GUqOpQVaQsVBA~9;P=_{){&pQ(y`pD zs^IliIg5;KOgUDxBX}!)-f!|vx|i%DGg-9ZbEPOVs4U@z7sXw!Hid)K*7&)Bpd*9C zM?CO~cqBLeT)Iahp^*8PUX`^Ltx$`DGNkL+<$$m%i9R_|Id%F#>vmY}jz(*Yx_4RNG4$7h#b-$1 zPs0;OzZRT&az_O)oP%dd$0f7|os`zPB_amSKg~rGl`L8gD6VBe|GY*~#n(E+`OQ6E zN9F*$^G(Od`Y`>}*}|m|rHrDJTTNAp!Gf*?D0Tn!b8f4^L6xMGdZls22)$T z{;JpX$>|5^oYv@nGr<0V)gyzrM@s45na_Vj?i6R#Q3Is|j)&y~N@DtfcLR)?!+Wj8 zstV`_ikV!=%H?qU^UNQ`gotaZgyGqi3)QV2#yxLb&r2cTH{(7Fdo+C(3h0{t1ZtMIyz{v(gYf;3Kxg@HeiDbmFQgiE(j-eX; zb5#lrpG^x$f79t(nk)k~Sa%Yawem^QueiUdf{UGcOeke@*qpBA!7N5WlqO=S9xZ%1 zmSg?ll*-xKVU!j=OoB8LjIpP+BT5<+Yjal_0*(JUY1qcJC`Mlu^R_pl)<{n$lS8|0 zgmwDLe@U7@^U4hH)GG1jmbfA5YSZ3Ufj99aH$oa2XomH#qA>=ILpF;8#ks6m7TFhO zLb*za6O%!CN*%;`_Z{j+n^2?gGWt04fp)$%>l17K&f1b7N-$hSU-%ybUD{aQ3d@2v zUOh&fvBqXv+6$AjH6stSfD}RHMu%>q`={$M6{4>s`s=`pzcw4M7kKYaaFd-K)9HRy z=d>k%KrrInE@SU;GU}tgKW6#bY`R#`ZjhkGH58nt=_@y*!8T!+NEdPc2bk?Sdq8)yn8JZaaW4cfNJMN&WhHs;@~tR zC}o-O2ro?Nu=0Doi=gO zN}!vQ@?}U9E&aSMp=gtAEmt?KCh6k+tA24-Z0KCyPRlv)k@YZEtyCMwCoaev&fBF7 z`T$xd8(_nOCKvodWoWa;fNy_X=Gp|DOQBUG4&YD}Dd#^-MO$YrmiJw*W=$kqb1GQ4 zh7KOnkMxp!oHEExg3H?Bl$PKR#VFlrQ6_fgUyxR}<-aXla{C~54Yo)OwQTY25}Xsc zhKy05gcEh(yW=*;7>Uc^WK#=3iIdaG77(`C{3~u4?YFvkAKt-(G<>!sXtaKhr`@!u zMl#~ZQP=sMG}eG1i8qcS{Et7OOaaoag?pmE4$YdHU^Z7@9&S{uS}x(Y;+fZ-G!^nF z3L))}JJLuHJ4t2#GET1>;h<_!b-(ghG14G-1;&6doWtLqfdge{F6Tl~7J#tbd;>ZLvA($euVb5MOME+i z@NO&Lc(pjMk|5XZmVfD;qjXbLNfk0?fhqAffj7dt0&m=m!QDH~%s8P6N+xkpO?G`K zLo~L{bIq)*{n*Ii63_nAbpenU*-18^0D!V{F^|fmi)T1y5zWL6(puJf*^5q%aY|-5 zWXZ&>c3*}6OhAYy(B`de4k2q1kTV_E=G~dzhgZG`B}UHPb=WY)m}g;MRReK(!cQ2S z{3K5Uw4Z50P(jT8e}tcy1G`?PEQQFWGf4<1x8`59$9F!?{fWa5nLq&pLF5DDARKDM z?iyLISf0QstyDi#azq@N)_ zVO8)|dk;v=f+>T+j?Tp1^f4vz?+0$WMa;G`?~@C?lYPQa-^N+L zzmy;z!euE{?+JX1IUNs-z5PnH?(4^tVAgxhe0ElU-gFTMO^0DCT1+dtD-ql;LEC-iZXH*kiz%=bi7!TqKyLfnUgQ=*)Q z8IOL=U6kwVUd<9>-+#@m)m_L`P!IRzwF|+; z+z-S`$~-z%C_BjTSjs-mxwui9Fjws>PB$`Pu5<;09|3`AZE^_YF99*LaRO1J6%#($ zy5Y{I_%k)_qaPO#+^5^h^WUsAMZx07XjO?)@V($5tRS{WlbqKEw+-g}DAk{5FZM#C zUPoxAK>fQ6&5#4szssCuwlhVaXp*Et+4Xg80Qu^u!jE7KIVT>=4xAoj@977r`l&hk zHG9#r&u%5_oo(wiJ6zW_^Ma=0>fUMV82xGMv|fB0Nz^ zn=uy7!U%!>kKlV^was;TJq_^{s`rJaJzJ*r^~33f9yqZhR1ev>LfQIx$p>5M>Cwbn z7RGURL9T}|9I|^=6u=6lC=NemD1v+d%hx(?OfWy#O}IP`C7#0d133>m@Z}I1CWIrk zt|6p6Kry%54$EHK6>OM+oKkgda#O0|KIB?HXXU}w)poUBJJrULWmS^V6u8zDl`T#F zQ=Uro-_o1IEHUh3NWut73Ssl7h1It5*@2-atJkCBBf9t4hk6cA@!0mJE;lu89=(mq z`GHsdej$&|)xO$@J0F!P_9EqEMZlMP(EQnpW3V-=Ne664D_03Kls2kYC^_^OkKwD- zNQX%-Fa6VNi|^qb5=d)jPeKWPQm*Aqt^0v^HOAAfq31Pna?ooN&F88zxiRNaT&U|1rFV zLVi@p7icqbHosAWwQdMt0u$hD#P%7Oz-Tm^!pXa_nW1aF>!bVnyIRRzS!uy(&b5z0b<^ZI-0V$(d8(mv{?ua9dDigqKr z{+d^y!cWZO8WfsYf9HNsbMW2R(s!<(Xl$tm<==vN^qABaPLHgU=#8C7N;P;sC_M9> znK#c0cEd+>=s>KUB_0A3dy$95;)!gOR=JKGWhbu70K?iQz^}Lw|M4rH7{)qong+*m zEoz830#VLDM!jgpq|FkJUR855u>CYCyTkhziBBfV+sd*zrc6Q5JJ9hf5>U}2%pNk7 z;gIKnw+5qa`&hm8n4Rj$ZNadmMsiCnq)dr5wbOv6V5Y|qdmSGl2?rpNZPuZBzUyQ76 zTt6LT?L*X-l(NGECZ|Jlrz$!6xsi=vS$=YvnXmMJ80GtaG3l!7yZrmN#GAD~=wnl# zZIYlXtPwpT-NcKdh~e~5FkQPj^b4hlAB{Efu}bE?fgcr?XUYU+n(tI`_U`3dujmtK znXpY>9Q`TOAnEU19;=9{ZGrf<9MBv2Ab)18$TcYp11pUILF0<>8dD8}HQCFtS5 z>h`?Cn8za7#T68NZ+y>FrvjjZvAeahlBA1u9N*~{{o>y>ji_|-(xrQffXeC6J>o=C z*p47_+71Xj5tw=4cosNT934Bc;H(ELsRZjRvRxw)rQ8mFh& zMaJ*R%|!fyuY083t#1@qj0;_{p75xPr6_r*cFTa=tm~^yP(zLWZasUaV5WH9C7Z|8 zD~I$;Ak!BbnhCp{4hJELiRf;4u_V%aQKMXcswDkda_vvqGuT`IQ`;P5;N*Yrjwn}0 zp~LQqpeIGEFA`yESrja2YO;_(pCi^S@K+qY+D8mrT^drT!z|YLcxW!O0@vZiXNj)< z{7A%zeOm3dP9ose2;9EfDDkowD?JsJcbvG0OFAX8j7!Rz7VTdso7oWFKS;_~z=|yP zWQbHc-m5+6v6Qch~5v zrqgz5a*inV5r2LD3{jGuEw8DV4L8xrS?2naJe~Mo{;rs7|G2N$=!h2ySUYV+y*vlJ zb7(U*l`i|*PSu*MU71)umC(TUB|{duL)nds<(9mb`qJifOX5q;rOi}dIvjud${K!x zxaKKMQ`;rvRg4XClJxA?b$?fFA3aJietY?@@Fo!`7xhBx3An*oD0$DqQ7r~F5rPEm z9^XS%wD2wnRnd_=QrbPSGO%}5*DVde+hVK66nI3eT+|BsN z3t1hxmGnB@edq>mylTC@_-($8d0;mQMIwIZPd}zhbYbVv%K^hZ>!F30Td16ka(p%N zJ{(5&&$YS?%wR?>FE$y~5lAX`Zdf9wEJ*JvldrdZf3Z zA6yvJ`lvs2C>wwH@`#qTTvjD&J#?LnV^)CBc!#cKaUxa;IIXpU)_YOX^9qBJbI$hn z-9Yv4xdCgZR7n!eh6)$P?sD&j^0%8`%W4mi9T}Dh;;XOr5ekWkjAfAwa_El@TSYRt zzXF}-I5KTAC=PUY{kC~9Fhl37$wDo%#9r?0N(^ghwws$}uufp3HnzT&xo;Gt!8cyk zrr2qkkbUmzkiASjp?h&*aCP^WOuN)(&fRMk{1dU^QJVZx#o2b|p<5k9*tLOZ;#z?H z;GXdZqwu@>u-JInEEKu(NqE0atgye$L}!#%4(RDE>Kn9 z6IZ-;5d(5%MLNP64(`-Wa;Dvua-vV`C?X>)lx_11LSb>LU3u%r8ZlKl3Gt}K%H-)f zZ4!$Cn|>ymtOecMCSJm_we9)Aa!+fxb6vEVFvlVKFBQS46zt_y!^W5zS{7CtgyNDNl=9t>$gxxmwj(jQ{pB<iVn&sM(Jy?8mD6@_r?CHOX^ui~Fe+Iy9Co3zizcDfgz!`cQQo+AQ z8jm`&%v9#zJ`FyKmo82gvGsm|Q)o!1hTTE&kzb%}wU5bg1v57X^i!r%xeuC+Uh}JO z(2EWz8b^)VpfXcqdy>0&J~IP2StOeD)x3R8me@Q_kRf(42%`S|d^U@)Sb2!Dq{}^D z(=JSbycjKgxELL@Ttfi%7&$lgW!t!yyLE5Fay7#ds1$d+T{*twXnm=Sddq)V>7;Te z_s~z=RiQG8wA90l>NZwNFCrTOdqT&rauog-8~P)ZQzn{UWtM+ghfp$i8G55+ zG*Av1Du_AkmcdaD{e>dqLAQ~(?i{Q8aQqzuPeEgpP$x;=^wwb7>s7F=?eW&${_0y^ zv%u4+HDYrgEM^l0O6~K|9QEHZz3CHO=PvYFMK>&1Fe_9?b$=lk#;#3&TRR=8np&>i zWsE~+2t~s-9aEVPm!{UUjLbRgPnzqOz>YP18v|(*g zXm0xkah^lh29x?-Ge2we=lr3$)@72W^iNKne4lG=2BwK7MKq@cTcH<{zka;ho9z+d z0nML;RCJpD;L#Bl;WGTlCeiGxt7;oAM}c7Eq`dIaGzG5s7l-xv;T3(e#;hT7N5+m@D_}kKbJK z*bJu_l&E3(C?_=0-**nSTwTAHAEUu7{3;1B>nI#qwF&%yC$cQu`^YawQJdV1DA}lY z;M`b6thH`SvWpiou@ro!6oSaAVJHz>Bs;dg6*M4iKHDk-+4hFgtuJ-n33qCM?y!y^ zA`!ct!O?};z=n3#{V8~O=ubXTcq5(9gCVW)YJQ;3EX=WVvZ3NasJ2MQMJ7W)+FU=E z)|EGB%)4-)@ax_&95S@CnySCYXH+WkA24@u9H8j_uQ^ouxpyXa&PCD?HL#K#=}?yg?NnP(dk3OjQsf2Uc;ZJ*sp zU`d~Wsy2rC>C1Mzzqm@TX~sDm`ejD|S#@%o;QNjH##H^Imd*Lzj=E4rsBX*B7<9Q$ zCq)M{7wVji=c*Ly%Gs-r;GJ@Wrt%Kh^;FEycch54Z(Q)6ADXku3aY4*B-#6dyJ#xpd5v;LoB;y2? z0`6s%P3?GQieyAu1B)?Eppj?#D0kX10dU|S4CB0Y{0F=PQ&2jRN!L5iSYU=FfXv0!>RGm z-t!)5>=E>~ z9->@v!SXkhEfL#W%>2{hfYcXRqan34U-Z8xX9gj+QeSO2Z>3gkOm2q+YCyLOV;}#H zT~BSlhYRvX&X$P1Z)ZM!gEaEa^YS)vmF<>DZ<6WxKeE0uE~+nTS6WKCq@=qMff+!$ zyQRCkJ0(X#Lb^j5L~`iv5a|X98M;&M@$Y-z`{8~%^P4a0?7i3Cd#&er);g_WFns9U z>&l0{tv0-n+KK)y$u7lY6)u&uBMM{_=Ubvrf)s zC}_9eQ=u>PC@mRhSrzA9quDpk<+8N#nji@??_5?3KMdt_)i#E^7bgo?n49G7&xPJt ziE$T7h&_I(sMmdqr~JcB1{iT(hcpMLaRbQRpnLuTZ)uQ9ycg>V+DTFTO|4~@PELLn zsCv+BznHbPqT``zblFI}8@i@p8RgaY+A7SekH#v(YbEI*+^fB^&u`F^(4f8J>E(rg z0hvQSoAUskvzz~N(do)s?Q7~-N3p0eP$JxtE_fTv5I(H_I+EvxJ%WXcd1*Df!rK1L z_lH)E=|~iDKh7`Zd0Lc5CNPG%c*R3&kDl658FzI@C6JqTO@5vMpp=yWnP%6Eg0}K` z#6icp9%4{KPfoWzoDNnV-5%jyaCCQ5wL?;mkDnKd@6Fo_&u8;2FX|U7x)g)ww+4bM z^y~d;U8}3hF$2h<(3*IHqxTrc-TsxlmI2N6r;}(x)9CX-*v+tUs|aUlR(C#U={9#u zXK4xj&FU|j8;*^vJgOtt#7cLJYmpzR1N#H5iBE=}<~LSF$oH~e2H!}416Raf(uk|h=!>s6BE`_q6SXu6>7e!s56%>5u zGGeGNx|ipo59%1re2|cid~edJmT<7LF_&<7vPqU)a$!76kvEF)J~V%N;P387Wq&mt zj8dvf2cFtr4}WfwzOW~|>=mNxG!(jIv@)7oYvRP8yd!=;(-^cnhs+7VkFIUl0A5#v`zP`o;HV$3od5G<2i@r*$}A>nn~~p zvtFJ83K>q@*s<*IsTv6XE!40?sMJ z_wHC!aJZG&`#l2N9$i3V348^G1^@zV@v*&XL1f(x5yXkAy=+}la$oK!SX zq%vuf3#v|)f7ZGaq*sD-3BP1UUfDhq2zKX%3At9Enxn3Os@{+bY3uMZtu(!>Eojf* z3`|4J_7a;qEO7Yu~7oqfPI)yj+-J=jgh-lQk*7T+F9^dMxyOjZXcEj$IXXpS>IG zh0P6;@ct&@FU*vt>TG7dT%@wHRui+vj@jQ!yU~XCdd_}}$A=#rEjuAwtwP3}A!i!3 zb)2KgJNE~}ByFXmMDsflmunH0^4j}6V)Phpw2NWgXQeTJEr zPu6Y-uGboB8Lx7E)*0{c@Kp3eV=Pymz&Td~?>pIU7a5vqg#HAn2=fcdm(B zh6MH1*~A6);mj-m4U~DQkv!X8%a?JFyd9H!LV()zTH88EA61`LU09LbYT#KO z!s7do(cc`pAUQrr&=+4ys(qO+3jFfo=dN}SGFp}H)U1fCK{=Z(N=Ar%%)npO-a^*4 zda!7zzMeK{V5OmkdDj*(T2r|BXQl5C?_<*6-SQ_@Y(v7j2}e=J`SIwR_Oh{gC-9F_ z{dXK*z@ZO?_Cg|u31hQO)6P6MOobqrJey?AMJHW!tdG6PPtW&Pl1_#7#Fm$0guNJB z=sz)e?x*s4A%D~gdm)$KsyfIh%lGFGoOPlZR480i>5+uP6_T$ew-G}ot*tYYsU(7= zH>ePQ+l^!6(mMf`Im3%+l}$6EjYdQ<9TJ9#3!by?xe%kXO)*4&tQcd6wi1(yUv6rd z$*k|nhYHfcN~3F^jRq6mBRO$V#d0CK&>sw72Ut%5zl`G`RFo(jGOfiNcb3q*0^Fy& zaUXX#s(bLnOW|6DOU6qntXqX$Al%U*Q|Q%!w?C@r#1X|5KeBD$*da)~?zUzfS5wR|5L(n|v^ z1Vei1m4lf=+sC^XBD=B4Cdd@-ca3qEI@0TCJ#-n$8A>M!jG(dw=HbmX%d4BL?2iy@ zr7tR{kXwoqO6|;j4nMARf9=)L=-roDPvd>`xc6wSX^4Tn#^!n;M<504bv)0q0+Z@K z)@0)IftsW0Uj3*QkoY_fBAFFt&Bg!BnJ_kRY;q`WI}BOyWh3iJONL8-BI}W9CP;sH zWrEu%W-Vlp|0-!)x#HTWWU=TbNP6BSqv zz(Wipg=;H>!aVg3YEuWsKl^>;xoS_kM0;yX$1(h*GtdMCyvHfnPT!yw=hlAukwq7c5bMyR{}=vewP$3&gq%qcSsyf zQ(2g_i49*?NxRN&>%TrbYqmMcdZy%l`r}lVDp3u_k&*c-#s$_CnOpokH*Cf?ht{uhrKc$nK>f$K{c(UL0RIuRE(= zZ7tq@TNZAlD>9c*cQ#k0v{9CnhMfDCKLWMj9HtrSr>rB5HbZW|2t&YL8`(>>SkvJM*p=D#M)*4w{pPSQUeE5Ulu$@qh+Df?4qwvHew)LWmCK z5PQ){*U$LQLZ>CNBnV`O4b?5~+hhVK)F>&^YTWX!sU<#C$~r12aJ3qhFV#@suteAh z{R%|8mc?Q{28K~WoGJ9>9>U&lsO4luqb7?VEpq9^>OMRiB|YfLxfxhsJ72N@=p}tv zu%Q^}<-T|oGF)Zl(YD#0IEBo!5439ZgV1n4nGf01j;WDI&MM8>g^P7P<-oH<%K~=} z5fTGe)N_e!cV`%E_HFDx1n9*x649;lxo@)Fe zVL{Hshxch0#_OtwiUiy@dtYd!W?a{1-y6t=2yGehte8a&5udGTZ{a4rKOw~kv>W|3 zYc8-Ds)sESFG^~?T*SHBjU00oZ~2XadJw>fPeB0Gu*-S_+J%8$yV~)8@mup7^26+~w?d@gZzhz2#9$ zYJU0-1{t~!byc*Q>W<|ndg2v^JmNLN$%=78Nr6}*HyCULBi(dRiCM{$`)cv(Xfum!4aUa?(qTHtS`&vm?YFFV38^OzR2}UV{0&GnMK9u!giJUCCzMU9PwF>DNqR=^W{yu7NE0{-Roc zRx=6N?p&lQZ_I|cc19~I{wK~`>Wn5j^h;K`p9MrszHR3?bUyrSq@ z?u`+$Al~ow(XmG#&%z1Q3(-}npkpIuurYah zODzC0Vy`%fbgi%ab$HfK-OB+zI)}MvXX6mAlD(^bcs8ivBBRpzTF@SqFwAK}Z30$! zV~XsBMMijN9;AC%(J)o{$E!tvwK^!e+^@$l`Z?xVJLdV3i(0{b>Z^l&xxZsP?>3S$ zlRjI8&FeUnq16|IVed)2@Z_x5P%+~~3e8j1elyTa!Chf+63%mtcn4cR9Kl_t%BMLb zEk)f6!9oL*7zl&Nv@5pu`>at0$gY6Gm@z&Pi^=k@h4NvBH%-aorHKZlxSI*1p zcXV|5BSwWzV}{{4G3h@g>pgxrLcA{=U4&0RQBH;)6$#TRbYWzjyi-KGB=_%;fxNo^ zBOq`h5s~EQbEx;42+2wpTp4%Xi2i!w7;cpFoaE{!md0x$n)W7XVwf1@ax<%|@&wV6 z^>GGQ4-|qF)~`&P^WdS!|NGHId)E6r653MRp7Z z=P9~PYMhsgx(tG(jhkU+tVA~mv_}9&7o2;lqX0_EVs5hP8y}+c;8v*sn1S=|Z)dY*4 za`1O;WZCDspaKN%1gqtu7c1SwkiG@@6%f^4cEqd+76vz3Sfr4#NKNW`2&9L2tlgk{ z0WY{4oW+uMWzfy~)!}orECvg|NAR88CBWh29|)A|%ia7=!PkL3xoMwk&aUR)t2vfm z`6AW7F0=Ze?8l`;Ln-d|=QZyAg=Lq<9Ey>n=knEuzyoXDz<9099VK=%c3&@$Z+mQp zjex>l^tTESsmSPscag2pYSGkUcXDjs{+yD3y~CO;#;Y-gJIJ0(BECy%-v}QG@`4kL zn4pj1T90;a8~j#bF}S^ieHrIE!fo+e$7m{2wT?_5mZeemM)R*VN3 z@~$(X_FPl*w=N_$5(coR?k2I2XO|bjvXm}d)0&edoMTXYMRfR`TBG6E@h!Z<;ZAQ% z5$TH_T_fG~`w>8*kA9{@*K(z6GrSnv?nqe?x&7hKv2@pbI=i+Ca=40xF%DHB997W` z0gm_yIha!?YDE1)JJJ`aB=cf4RNKig_uT+}56_aLxetNCvDP}ZdtVx3Jv4Mh;St^Y z#&@O&Li{RFn|8pn@1>@Bs%XhPSk|gwMlGY8Lx^go0-`F7fi=TI2s`^Rv%D80)U^b4(aX0*lW$vZVT-U)s7MevcKgxZ zzuU5445np4Y|=jzst8c5%iTdSefxy=;BSs=l33a{3lIwdr%AAuk+~Rwl|{mcIaVf6 z0CG?5<}QS?+t38Vhsi-Df3;ra$l_{&SNo{ z+^N$uYCDB6(YWL-vl77S+S+;L<>$E-?{8{7fIJAXwdn{CrV8+L_PMg_*Xf9! z8x}Tlc#+!KyJ>V13BL#NXWXyk(57%$vY4ix6bt`Zo2nvD{%h@~geThURgV2KAJcm; z=a0bH;C!RVG69miDPI>X&n;$#obp}fjr>;()%;@<)P7UtmmW@|jB^#lKYMkhk~%DS zQ4jjeTmS?f#P+jgz1k(0g-J!4)xJdK=3TO{yuK-JoJy0YnxSH9(vb#u&jmTR;|Cv; zikEXFU@GK)Of`H7pY-nDP85?w-9V@^(SRiL&E7E08UAEp(vY^dEYY~}`uNYDMw2J#uRXR_CJTJwvswqWug4o3 zefQGhSN}N*vKg@4yh)VJb zZ<-iF$Zi)Rf2s*3EYE}-ti>r;>T#7vy7`}XY$rutt@eYhk_9z#YK@P~Ph@9VFv})z zK$%ptI3#%Get+lEQA1inv|KqQ=_nkm_%gnGMr)~rYW66o#O{00Kp6$?-(=4iiN2&> z0!(KEMulZu>3E9$lW6mf#t&z!yNtSG&1@1T*4* z%GG{t7(-4W!CuQ8%yDp2Jdz{ziU2-^i+NV45~$clEjxCg>~AF~^yPnGEDb0}dArX= z-H~g-+lK~ePG4T7dhEDVHTbv?l{ucg@TXc8kUc1v{$lUWYHU;hCe~sV*-ebcySU9k zjsM6Pq2E`s_cwO>TVS{QO%6kn=8($??RSH5zQ?Hw9GM`#m0fVD5XN=r`5;oyfa}=5 z)UlXUU%M`Snlu< z__wxazHhQni7vl~<=48MKuV4Qm}T zhxf#Gy?4|;>qNr{epBcC9G|iME(GZ#){KP8D{A>5dpL<)rd6H5qt>)4Y{sRW6~-qw z1L>BQ1wwo~@~k+W8f)Nveh=j{r@`UGRaV@iVKJLAg=sAK-jXYFYa!@4O;URX zU^H%mW7|%2f0;a)xQs~>MbObgte1t|3RILP5yt25oYq|4lp{U4< zjY|6xAR4|zNytHDT!OI9OWYf^adots+0XG8%3IEDXVDguPj#r7sHW`HKHoFsq(0uU z7Dy}m+>rgit!waNjdzZhX~>gvi;7Fo{DEPo4Ua@2MwTln#UW{zk=6qV{&Ew?8mXr@ zGO{nU*ytb>&id>H5OnVb3WI1@B6e-otpME7i6Q<{k$i$i(i_$iHm?;RbAex%SCwis zYHJ|nwR7`)-?`qX{CpMkK8J>T7c3nP@o_9M>voekHHF@NTN0W(o4$_qHcg#9crZDu z#uYg$J#x9zbPg2VemA?PTBMv($JVqBW<$HhI4H4+a{ombEF*2oD}(hp{X)s|^cBZm zJvCEvrI2haAOS*KI(6;R|Ku;n_OmY8HBztyB2Er_2k3{I34T8CL3y2Vz-LiYw?h`a|xIk=g6TB9|nXF zkYij;Z2Gqf{*N)dJsa1~OH_5j8`qvcOr9b_Kv_xb#R1MJ*MNxP^UmhHmRe`PVB-N= zGY(A#Q}gsvWXZ-HdV1Kh%pmegRNjl50z-|m1Id(qxB97XGLk3|v%iuC-SKVKkILPE z3qe4)rwPR51LD87+LA~*Y*;O2mH1hRH4?Z!`g;Q~VRIxFR`gYVbCWa{j1RK43HG&F zFZ}YY_9U7(*5_bjT3i5jrSwC~AisI7!K_g%E=q?}pTm5@nTDJ+0){lMr9pgG3x*Ib zWHTFq%G7;pe&?m4KkbnC3fqL^X3-&h%KW*(I!bQwbc8*g6D%I zgeDXH&o=}L?7Q5GW;ku#l4&Wmo?Fj-spWN-S<8FH(CBNzd6DJ163SBMK6;>?>AE^% zj84MiY>yIV#bVI2Q2j|zLc=Fs&(vzz7rO6D&A+;f-gU8+NH$J89jnQwn>_c2~fKeGdv8Cc820kzHGJ(BLeSksb zM4tMTBuw(e4YPiVEntm|=mvtL|mA$$a=&ZmFG?$RoT_2CN*vW#KxdUT=zt>-1^i$*>OxOM5hrzaDRP z1xy=wwtX097^uxBE~ZM96;4a_o_*^N$a1f+0@mdUd2<={9)^(j_JG8~4F!P_*R4aq zf7KDOG;XK*9y+9ahcKMGvu@n;V0F-jS4RUjMkS|ei=@MkzM^VtqQh5xk4ia#n{maK zPlEoK%{LiK`{*kO`h6Z-P>pTqw83o{I6bPvX$Txi-oTMGKoe>>%7IsG+cfa`4+X>I~DZ8`Clf5isrH`RKza%}8zj>S8KRMPkYs zE&}+{1Etm9T}tpS_JY_@4G`~^fEL67Kc4xwOF6SqOVob|ND!2WzoiF6&hA)YjQ?#@ zzNmlORFoG+DpB8+0=I+L6Pnw01?3^<+DhjZN|po!pjN)tv5fRO%2Q6AsiCk@$|L5n zP};5Qcpm=(i~!`fB#T?XCdKfo4F~)=B66q?xMjGqc60}9V_2|J?6gC%Z)!gR8wmTR z5lFQnM8R2Xys%}l`Yr;L`cPHez!W+mral4>q%9Ns{3r-gAHt#-;5u*OUd~~Qte;do zb!Z)O=GbxxtHya&(xaBr&_w|O(Do}S6~(#h9}L8UbX7Y}~t%%7d)WD72E6;o=S5E_kXtY?a_SG!*V zz)KWG&&!MuDV3*1JrZlgj}vQR!UZ{d3_PKxBgo(zo>1ydE%3=->xR&K@99&h9@uVT zxts-zWr8Rv!Rk#h^wPG(tk}TJ`2d~?rS}iC>@n(BbYn5(W=4s;hK_fNsz_VVN>s; zVn?;1;|*L%Q+J*#Y$kydb0B*}%`SGyq8oq4PYdIlMm&9@0eto%X;Fd;aM_1Ni9~18 zw7q~#Yl;QG!I$~Gw@c`tGDQtd${w&Z*hk9EL!uA(4o(8s$hbSJO5DqX-Gj-7_dKhH z{bfHIRugozi!jMAVP?8$R7aBPKx+MDAIpopCH zNh0K%2f%NDB_U(pI6UmiztueR_wsC#;TT$tMd}HUWDeC^K77fY*SxfV;u&2@q*e-3 z?ufsUSsxT0@Nq(6x~?_N!rFT?Zj*ZvBII+$ll+YCYOsxD{ETZ!l*(Tz!OZk zx2IvwT*(QQJbPRnoi(@AF#P>Uh^;#N@vFfH%ISw~My|LMsd-v#A@pN{9>Z zn*kqQxq62f0s7JOx;b)q%7=kB7^G|oF7fI0w4hWV?M)#jIKGcBiv;14q8-anlXj8+ zmc%%|cV=n65i0Ugk`4w zc2s;+iH|6bRayD)m)fg}bT~|{v8?FEAGCgezpB<`qYKzak(hACDu;S%YKcPEt}H@4 z`vNROJrPjdzQg+Mr{ef8A}+4Kr8mdwX%FkopFf#GS65?2C>o&@JGzy{j}o%W;sBLy z3Y^Fzpk{eMNuwgHP(A^oa)zfIOco_wbn7w{6!XFIVmrQJvLjYm4-AhV(ML_ z-PVLf0F#8AZu)=qS&z&>xw@K8?hD_0Rf@V2BcWg25i9-Zd!ccJ1*kw*5S+w?7_N`! zRR>tN>>m=n#d^q4*U?Yjid!A`@m)7|cEIMa06*jQx_i=Zmc_#OII$eQL& zMe)iTfbuFV4{(RFP{z$}ZPjcAeTfzQ!V&cc)Fpwsj)CBkGqM^!^>Ui;FFBq_5M8$# zwVk~HC=GUkyU_&Abg3!CYjLGt`RG|d1dYAD_3CtH;I{9zP6G{69?&SkZHhGu;>1 zn+i2P>z5fQZ*hL`D%oi9x3!UP{vhS5!U^K|^Wk#awSAS+OY_na>IaS$GJ+vD=W%E4 zXWLo!qMGLLkSJl$jz!|N|E0_4inJ6CgYAtWyD8`~jpsyFafn)!QLFDU{)sKe1HO)i91H8r{M!QZLmw3>p zcQxy*8C+YM?k#!&Fo!=s=P=TlJC_OQ4V`nk{T_kxrsr1^db9)A6_RO{fRMDemC8Kz zN3(G+<&(qBN#tAcyzx8=Lw(jcSF+RVbyF;QzE|NF>x2Q%4mdxj7QhThE+i<8kw>m9 zyFnF^iarTL%>-HK!G7wiRI}*q;uBd1Q37F1PtJm<|qgj6V3{2$_p4mX_SsZ zDb0JfO~BgOl?)$y<5Upx-jKrt%cp&9wm;H3&*$!YYmK>LSLzAl8pFsBs|W^v^Gxg2 zqK(z=zSzEnEurMPrWc>uaZgqiL@56}IzivywfXV;CF)SN`DOb2ceRhTNv@CS)po5X z&hP`pY&G$-u3q}&2TnIluy18VTlEEIZ@wDqpOn>iH5(3LY}3DfIdFyB3qmZ^tC{w{ zdNO3wHqsjXTEmDH{h&kM=d`15aKIsq6LO{jHRVy|^F(3q!<|3X#Q;h^U7l8hx#EDd zv^_86+y%JDw5>ktzAo*LDy{fLQa$m)Pc$*UjDgS9&6d?JRqJw-UPns!MT7+)+)sVr zTcLI~84Det_0VzpVyCZM?48BY7#}}4ZmX+&er?6|X-y+{Rk@XSUh_?r*Py{L%GR+; z0Mol!-}cb6L#OV3VabLv&z;vL--O+NO>{Z)@x5kutRcFh_JtO7G=l>F=rw>@mpspc z{BaDPf6rX`xVIPzRSMVm&YVg96zbz4UdFSq^OJEAm6h7$u2xJ6bwFWZ_jG!@a6JxO zKV1CKG^=_Iib(~XoV^2AL7koygxTi=tgnFcqt2V%9~}+94bm{4h`jhk7@+Kk)96i) zQ-%YzA0*px+4L%?YpL$>kxu$6sSEW2$`DV0GQ>7mF*{{{Jt2AHwBe&f?D+MYy$um% zwlxkf%?4cuieH`01bAPgBwW8JdUSq$mgt{p!J~PvF^jcx4ZTf2Ch`;T;Bc2F1wf*s zyZ-Ybh1-RXjj|@~VN~;P=l@3$b|%TX_seGtz~6E;gOLm+Au--qDC|I?VxJ$WD^RG2 zO*xUEcZt~|X&hum#l60>fP@*-j-~)qjYfI7%l?(8Ma|1w1ukp?))p!blX^Hhk<4qClDkMZlP46;nPR6=h8&<20|y%oK61bi2Yb6#f;F zs&K^g@#GZi67E4TD=0dSOp&h&Uh*p5oGt*|jA?Vz4j~L3vbo9HB)RUY7tU5J+lPXK zrN|$F=bEuYtf_6nzcmgzZiI5*7q0{m@_*DlcKRww`<-<@@}p;Pn=Wd3!Hq|dgjJyX+O#0I)D1;t@Vj}UK2>pCwTFkgO-`8 z^FKBU|3q5?>S^&#=XdfS^^Ys8+YJI?gqp7aQDMXp)Fb8LPwU8}MVjRYr6^Aaivoos zLY0HJ_}&gcuuObnEafp?_n#0_KwmGPC&b<76x01$5pF>VVET_J8r4~^C9H26OHBhp z@`ZpFX8X(Pv0Wc|bmj04obe|ZLv1btAMgVmBxg0Jj&%Yr;6L$-LJh@YJp;ZHEM2K_ zOb52Nh_J&NE=p5wV*?~CA5(6XnV*v+p$B!712gCC&GLI!W{WdlAEZA7N;9|QMwX1snRoB`oiC=ADBL4yxD&|6+3VN-X zTG&m&|6db*RPn>M*;WbHMC0%}$dK=G>%cJkQs_ig3 zwBMuw<>UC$V}`F|{D?gJX}{wGKBT&`fg(VpeqL%RKlvDc^1?$z&F+W z#ydjCSm{>CWi1JCj%=K76k$luU7yj{hHEmj7)R&*fw&SCuZH3XELtMv70`joavZtXwi(>fpU+58x4zuVEL zTUKnE58t%qCJ+|tVM->6**#5S%`9;_{Ilv@VZtYG-NRH9Z$-%-;3ax%D1I3B+vQUq zK&;)VMIl|1d zuC``8NiV%n5?#$A#+$Hduk+W5Ed=_kD{926_X+1xTz5u3<3Y<&58EGeb(#qdeJHO@ zR^44PcB4meVhU9(r(w1vfsWM&%(Y%uK?RBQ30~Jhfc=D~^B}EGNw4{)rjr7O5Y!gY z;?{UHm!usbN6UlchM;f~VO8eFnKMW&B-H60fGBTX4=C;ZPt|zXcqDClG&FIT=*8BT z9>=K#*`K{ywUfnGHzy{Cebu%-jvQtTgpU2k-zSgr*ahjOu6W1En5%4w{eap$PE~Dp z0#E2`(6kJmCx{eOr^4d7OblALpNAbeo$FkCc<^gLzdlkwKOCz|G&j$lD{*+vE}Cdp z+e&x(3yTap#JGMj)i}PH4K&Jp51MEa<=kVCTPED~_(bVky~f9s)dYNmlwsxHK6e)0 zO}PlZs|V=96URS*=k)m)UHtW&y|8o<-K;AC$^{<=wn=t|4O?&j3?vds z?M?6&v~O~&hZYiia`>lDtSUJEr^!bx^LupeE?u1d}a3bu&6Z&Q5e#sdB zsZr4X)3NZH)R)eb>7e8w*zU2u8Epouz%r^JN1q1a$^*c(>omQK5-gqlHw|ryuU~Og0kF|?!;W9nwqXQ$C#m&KsgfDpx=AYMV zQdleT1xa$Dvdx7FNOCcKY4J1V_KGACQ62E)P~ee5_3ttTZpO7W))>o}h_f7B!4v$5 z6SWx&Nc_ zO7~6Luax_*RF$!pOS%OysZDx(57n)8;(@LL6p6T%C;5REeZG7h4pQ>>Ww?#m-*~uQ z6`j_-P@GA)9IAqsjo%sO|J|PC4rt9vuE4p)0(6o%R>P+XnLz2PwkiHk8cLN|UqFWQ zRl3?X*tZgd^AnKad_5tRmsJtZZRS(%4}vcc78+0W)YKLg+B)JDZSU;Gf4~>~8R?cr zt;V71B;gyAL}3`8%WMK|Kc;Sa`S_#3Mor~p7-iotQ;q9|@f4Po9Nl-Ur@Vnq-z1k2gq&@e`k5@$!UN{1dC(w6 zsw*}U%`P-kJyC^a7gkJ`rmSyugI5f@7`UNDxKRhL{&RBwa-9ro%bOggzcUTvHwXCl zy)yke${e}JMs)54{CNNOLi<5Pz09tfcvBA~T7VQ~>ISnS{9}M?6!B8n#Bn{IL#2j0 z!4yqu!q5Xr8`!Iu}}%tUS!>xZY;j zYLN6-7jxl-mk~mDyhQ(T_kJ0EW`!&BzvHsVm)B{8TkCXbv5z2z$9kF8nUCYT`x0N; zR9V91NmG$A&K+6G1&EIOAB44Vf8xoY4{SmBe~wuT7IqSCJG2kqA0FS&4EFag^YlC_ z!MQaD_jvSadObHUNdzs93T@6l$x#TSi?6M(9k99B(88^-r(Mqtj8_cf)(9a*SP57l zg5Q(?YjR{P)qh-uJWHi!2WS+OVyXHeJLmf$yFqA8aPqd~MXt-epJVzDnxC%kgCv~# zyjsV5S$ul3F4gS&iLifXWf)lK`dA}4vekXZ15P2y)( zTIl*)>rX;hG|s?FI`(N=jW`C)mp1{8B*M9%RhXIDNpyywFL9EtMb1bNfaPxrLnVNg zzV?iisRATDX>L~i5In-BQq-@9$ZTaKeU4c2fRl)M`Yo%~1@;3SH&W&98#Qp})}>uP z_eJ-{Nt0Fiykiq4fTo}`9s=ztOAfESssJU*Ygyv@<)v_+x4K&m!Afporryy-Hfjq; z#;lU2YZTfK`~F`1$BoppBL-Jqcctb2!RNo|6D_YP^po%`xH$u~dlClXA(f@v zG62_bg&!+KHQ9btx^NM82F`j)zC0?Wtxe(hgkI|KiO~_}>n5T!|!e0AaXzo0F+XhCRptY5rn4j{>DK}?n;#cf;^W&6kh zMX0<4H>Zg}pe)hU^aUTLg|WKXR#bFCM;CJBtNQ`_*!i4YN$dDVYGxB2trcfIld1Ko zs^p)k{l;sJzou403?!*{4^DLrfke#_C701t`R)Fz#18<6Qw!<2Wwl@$mzu)VBCrTf zeEE>@!QIbWN@)7%2*3jWw#8Uy{QV#$t3s3mZW4?|k5u<|`L-LVH%`u;mq&V5mtL^E zuJoUenLr%vDu5!3=$i`-cM1mMs)9yY(WbB`JYX^1|65Fi>>R_WMaq21@~l$%uGaji z&EJ5~r(hZAZx-$7M9DZ;McmqZ_ugh5MXq=0ps#siW^5CYD7i9OVsBmf?p&?C3wss+ zteB*LG?7cR=|2x*YQs;wGw_Ig01Ru zyVrqvox~YU2bPd6@Bc0#AOGKZ%|`7ULTWb-3S0%s@w>lAug;v6c_;kW{-n%%#41ZA zV}vF|KywOn>8-jk0n&d{yYLp6T8G7d9Y;p#iv!#vt7eCiLak({%5HNbU^BAD?(v3y zo19PsO-?$KX7sjx$n+4e&PnzE-MpJ_W5knYr`9R|&FvlT|IY0N?kcM#&zXA>TidM7 zI}L6PL}fa2?)BJ*Ibj}^cFP~si=E~g+ZJz-`7eMgpn zz9Um{_`>9QPsf9nx_s6_+Q$?l1|GFr4-$(@Vf-X}54BspH4Cf3cX9l$-$m9ee@gS@ zvRMgASL`?5&bnH_N3*CJ3v&6~jLoXh2l(N1T@cuXg{6Pqk8-H|d_U3|K+r z;L`uY)mui@5iH@_BxoQ&kRU;WySux)6D+v9Zrq(90fH0UA-F?uf)iXe?rs~~$eo;X z?z-#yezI6lJ>50a-BtCx^6?U@T~zVC;|c^cOD+Yo-X!0m z{^Te{kH-<%l{~UJATef%D_EFQV@reIZ!fR9FgRbY+i35;oRN6D-5wN*x}JFSgL(gE z+WeDWVN7>*mmo3s9c0#@X`1{6!me0c#qgj^t~#a&n2F zS6{m|u)iOpd8h&9-`P|OIY7id5@J0fU3{rxtcG_>Or;KF3{E%EO#IFBZ;?Qq ztNe8drQK@+n$W(ZJb_5WU%F9IOvgliqb@{XP5z*48xru@NQ5ci*2h~{&vPbI1t=L& zN}ouOs75wD&Vj`9TatIc1s^sjgcpdD6CriDdI5#Vx4L_W3{kGSP8sHX+S88hc-8%- zrhyT904K$X;H9Tti}-;6wpUkOcRgbym=A6xN@JtwaozL%S8uHJhfop>Hhd%niiDuw z61^s*B0C%JUTb!@ZMtjrp$qLEZ9uDZ4c+D3nRw>y{t-4b7hI7MQzF)`SS%WHAjHej zsLVFV*4n8Cf*<{PRk*QA{E+pf+O#&P<(vLs;IR%jnLd!PYgub9t^29ea~t)p<8;q+ zuWilPqQ^bJwmb@M&>i+2K{dHMi*(CNLv`6p*|I%%g(Je(TpC5_4TAE4JwPS$<9(^k znF?X5|S7Eh~h@fK7N-}eBIqOTz5l5VFy(MSh}mx z(kx`JN(HYEt*bG%cHGmZtv?7{g^D2JzV~fl?P-6=FN~_(``6%zps2rXjWW~07ub~w z%Ura5fg!wHB3t0l59yv{uvnT&6KYCV3fUXtFFFsCbBVwENMZ(Tq=Io%Y0XG4ZhKAQ zKXH8sz3#2+!cDE6Qhr}lyN#0-kQ5|xZop26^Z_wvTqIEEatz_EM87-f)M#{&NcDWo zEA`_6gHnM5woV6@5zy=as7#r}Q+}r-Rc5b-RP!2T3=~AnDk3F1)a)oAcZ`&zpwVs&@>+XNjw{MLzBXa4SY-LFRK z;~^>!fy(!NOypqIgp$nGiUpOaYR?M%e4@+MrJqEs>*;w!o`ZaO2F(0vt=Ge5VHWwJ ze&L|E-O+&SPVl#Ug)RKw)hQjbn+z>^Ku0oo0_ zrhP=ChPhyO2GGJuQwvxVJyY$cM4iab1s~I*(~sCA$BMS$$dvW(DD38a?)Q9Wk%mET$QjxEF%E=vqzbv=MCN=i>@ho5q7ys)}tU%y-8ur}i zGth(57d^i6+3z_}$Q=Rhj=ck@lYl!XFx1tlC!M@b`?!NX7Pb-af&AbH^K|aF-N%R7 z^7ie!^A)hD!?Xj<^b;h&$3*ErT05682s#pdRsldt{PNEgmC5d&5L-8hr33NKZI z*YN(aNp3dE=iYT`G$isrAgps)*`4|fmB0z@To;;7`(3i3kaAar#Wk*z6D-ef|NU(M z;&%p2Q|lziEaily(Om7W#F2v_Hq2qaBF3tYG^y$AGxamc#>ld#P=Nd}B6;G#R{j0xFX?gQz=fCaYFL zx6bY~!ra?oPj5Hbtoqx?J&NTX&+bFXcClA$m$*<7QFnxbLJ%-bd9CiL9{{#At5U_R zzJVq>Q9J=_IEdafSriruat}ekA+VYfVKQa0`Z`I;W<|QG6(Y4BlnK|w#isOk%-L~L z_|H#_k;E7z{5V1&WlkOuq!XFgH&zcV;-`OIaM5-^+oJL)A@7c^9+_;{Y-Gaq1jKHh zw|!X1&o!3T+T1}s55xE)ir?A3@Zf=9cefR3@_;nHfLi*P+K83?vF7BatcWQy{I@Y_ zp<@4rw86y~{Xw&a3-()JNekdl<8h2fLvR=hC_I)9x&_ZtHE+HY?%*5eNblG-Vn0T( z9FdVp?cCLH#>fh+EcP0905v{P^bmX=XhdRVEfravG?dem*8% za^l6p!aj=^wOsK&GMU-VL0z%zo0^yX;GURO6jU!*s`(Ce^>kD?j z#EY_|M-U|i<%P8+usAq8I;OS6e`DeE%7>`FLKeL>LoJ;@eb-;5Hphdh7z!RGBYx3g zn0Lc#>H3Imq+QhWBG1r{8V)C1&j6%bDQ?E=WDl0J7-9@2#H>6Bgh+<)I#;6C9X(y5 zv{n~R&zz*xx>aPXJTLNBTeN z9rHODhOw2v=MK4_=;@aZqBSWo*&hJc_=U%S#r_bC`_8LZ^zA~hIZThB-7lHSIWzFe zaWn)=YR}1Vq43;Y@vR;rZ4_3{Vp4i;HuI0UJMmVG_3dUOL#^C<^JW8o!85wn`%7bx zlVtrdCpK5aMH}EqW?Ts@xs~KfVowu22~uXwB)HtWdo3+5lw^MxaB@8vIVxTm?^a`4 zK~!xfzEVP}drdy;_=E`BuBp?c^C6ZB?_txf2H=k};Fv1^xLg*^F26UA++MZhI`c+_f5?;TB@>fc z{8tYlWJ2#YAVfz0t2=M|z5yQ;WQCPH!$Ws`}0&wu~5 zHfQd)u!i#@90QvCjINUDW$Cnp!d}W7m`XGhrV$@JU~5u;53}Z=Qz>2hhBS+S>#*JU z`_xAs>x`lK0oaG7fk`^-s+c_&14i_^r+&4Y@xEe#P`rOY^82@+^=l(#I$7ZeU~Vvf z)G$vil%;VlY=rl$He*-&kIWgt<~P^F2R}!#HPbUBnStJ#0*L#s^RHn*f}Fc4;-a7G zD|nG2)7%7))cRQ-AK`af?YoA0a35C8K)5&ev3-Fgw#rRJ{WO&yfj#ED5)BEdLwCJ_ zi0+d_<8G1evtYoYCTGo)wIfp{3^8r24T4v|P$dA9z9(V5jay~HJNK^grrduzIjgvb z4z$Y+`z;gyFsc9>3eb((K%S>gL6sgXU~0Ju;$G>sS}sLoFi}Ufj-?G1_R{+BPoz-rr27>b_WsBI<8-5V&ECe1vrK)6kGFc$6|m;@tr8}5fzJR zf02beckuZGr{UtQVe|K2zX`rU8UtdKX?Kdn0;Q+l5-G-YHh&>sTQolKzE;FX#RvgS zhpSU~VkWv50NI(TGhZV3n@HnvC(rj}rv2VV05{ZoQQdRU%%uc`FH%t3crn|v`}#h!}YBTSej zOGc*lxpQe@N4Wtur=2J^A5brd6;Mb84)X_+w3BQ(!=~gPz5CGAtiGIWk`9<~&Ro5; zPseM5UJG8h^Q8-#S9ZC5i_h%o28i`zpEebWIvnYC8BSbNB5T^BAZP9`f0?dpy?Ls4 z&;4(3TCGpG-?r$B;=j9TVv9+HsclY=h5NS&1{uEZ^t_1t`q>*$q}C@Y)Bt3Rhhd|; zPnzPVGZ*&9SxrJM8~hU=>AZcOI>4{0Zr?pR(r9YhCEeA`E|8U03S)5}ePH8pAMsW$ z$rP9-`SUjU1k#I4lI{J=>irOy`e3=JPa@{O;mTA(*#z?K*oaBvnYoA$`l<#)x_VL~ z7{AkY{T^_(F(8qfdgS6WVrm{5pPYd+5*f3HWBIF*Ml#YLjTEI!jlN=&D!z01;KeHQM~t04jt+;Inu#i+D#@ia_v(fv%0;R1?oO^#@E8 zW5Ni(ZP5o>6b-FZMMKC2@0=Vo*E}n(ewnlH!iuZ?+;|qoScjakqjZtGD~>;WL&m=# zn)|iiZs-zv&e{J1a`bZR_1j5E)kBCqv+(CRaIbJW`)UFdl=7f|2Z$G>-yl&Lv|Q=F zHw4E>6M}Y?z>O`-M^C@ju-}PzVrvA7qfI4&DTi;XdcMp68&}svn28!y&!}G2J5v6w3w#tR%h86|HM4}IWwbH2A1o5kK717^2KJH(W&Whj%&Z3+4Brw z5{rBD^wFLZD1jD{Qz>LoMhFwuR=Do08;$;4WgkOsxn)cC!j_l7110e>+>V{x{Ezyw zKz;|r4nB*-6_K<)|0ja=^A2^dqw(|~?D*80nOMwg#RY6a-}rT86Y*B!zJ0!OSo>2- zK&1WvLrF;I+w+F~a9BzjogDzm`J4l~1toUQH-0~&@K*N|I=u0_krOX1iBz8Wa18Oa-uESFG1Fz+za{V= z;vI4MlZ;JDS!8Rj<)Pp4cZ0Bh}eBP*xoRblcU!qo3SgsE{>F|7tDSyiY2e|y~7 z5KzAlql;(DfYG>f$^at3g>B99ACI+Sk2dwoX;0M!OA%GZV*Uygp=BCiTezLQOtD}8 zhc9KF0Ql0Ef3n*D<4ZlvfqlXpjLly}0jmti{9r5b^C;FDPCM~QSOA%k%@h9gB3-2z z{dpLQ5jhZYn%ptz$64ZHwePV+>*c``nZM^J@uEZZdYT;HE9x!|k;c_?I0v3WPxmUh z&WXRZ$9X%=-| zcHhOsw0sa`ZL>Bnm$1*vDo&28Oyy8Su7P;M>@^BW4cWdH0;06AUxp4Dwyl#2FTT7B z`AP&!4MR$zif&7h?dF4)D7cl@@a9jVVV_JjdNaU>{!K@?8!kfQl!r7F$$GxcUzuG} z()$dei2)!HQCEO&8jo`uvv&C0%<~#=goA7Ayx%mvJ202ucJD;&_fa^Yv1^_A)<}E3 zJLbHeWBMVeSPndK)7LKyqwHs$iQUA%$PaK8E8WgdXlbEdd%9*dUz7eO{zneY+ zT@W6=-81>!pV=Swd!udp@W@*(H@g-0D7spI;W?3iK-}~B&p>)Sfq|?819@=xyl~;y z47R(Q7OgfTR>%`l?YbS#4hmxev`mlCsFW$B5Fsj5lh|A!xl-z_C9(}Q9=og1pJ&Eb z5+qbY?pI%9#x@CY7`52#@?_*)GMYJV; z^csC!<@UDnjR{0Q|K^ zXq@Jz7cd6u)Eo`I^8So60+^$91k8a5S~GSb^s^<^GGG#NvnCx9(XJm;IUR}dFXZC zf3)B>JDb#9l|LE;ayct82ZKk*Gvdjg{&5`DxNQ5aiDoH zn5aa}q^;G} z?aqk2a(YX;I26TK$+;2x1u+YH{C@r`A^uG$M9-EpACX7jZq7E$i>$PjI9Vnsgn1m~ ztAH;pH1CRZ1$^Om?y~cAb#M(6Rn*MT_H)TqZYw=3E2>G2&Nu2rx(tWkJ^+Z{4uJTP zl3-vD8|kliM)~X7pA95GYq~)jv9BL@<8K`eB?DTak^=Fg2AcMTWrzF1cEojhmyuFC zni4DF@W%FF@=CKcjj}bOrQz%3z->|B{Dp`Xu1+DvO<F2!tbeh{7>giKiHhA=XDD z6^rk$vPMYV1uibK01#+9sJR4KPdfpmecExW00AU@Z8eI(dk8b|$K`?1NV>6z-k+~8 zf6EM62#CB7k~-$|T*y^vQ%-In>fHr(ki)AUQ-z(OacNRWN#CgqD6{{%r!A=GP-1&X z%D56M;@5fBfGcymV<|UD-xc+A#G;>f#RK=H>(qBeahe)yi_l`MM}j?7zg_$o{8#Lu z;if(JvF$j{(t`dLpyiezVtZx)zx$b=Oo#bwwX?v|MJxaaDf_uUqsZb=JcC}16O@w+ zPSpeouI_Q2Qo5|wM5UfAT4*o6ww{1(9vUm>&E2&9 zUu#~W_Rt%nSHxm38d!QVGbLvLaEm4n<{W_U!R5ed?lABwv4;AjZD5&OwYL%PTeG^X z0*W~wR(pzoLlqJ+8P*QGy8Bpox{68C-fLP%;OLz#|S#$HrCt6 zt5M%2&WUn#U!hHAeR7cl=@a#B|HkyK9c%;ACm|_Nt`OJFP8@S|AJEYX@}MySM37vZ zenf>jHXFjA*ulO23s2h9rfcmN5eu^TO7?~19tokMIv3c zyNhC=yTuTP2@nM?GXX~erJKr}$54&>pIqIyQO-KX4-w)%G@ihqLjNBT(gO9iTKBJ+ zU$<#_tz+U|=W8;uYi{>(hDBe=X5FM7Ss)(VoaqH_XcuTr8We+d{RThBfH&;}q+Vi; z+v+32ugY&C>wR@VN-Mal+3%x|3+q8deT{`5)W+lOozW*Jq4S5PSztE&X=VV!aL);I z@))cH2jmvrmItqOHi@qb+v@}IZB}>VktM2yisO$oVn#_y$)%ls@ejif#_r$6d=N9~ z=4&$^d}%UmxE$20Vl>4eG#!1}=26-$RA zkn_j22j`3a0ni{bbaM?rM|BwBf|NV}E@%m3Wu1K~K=5p&d(NtxF?XJM_{9}R*>swG zTOY{W_^7+1&Hn|?8`b=anzasdPJ+n>oUkY5r?G-H%7&9sZFlg$D!z>^3Z9e$SAl9D zJ#FAB&_X=XmI0}%&|Tz9q%{U5@sBM!N|G^YuMey$5)0M|R}%01@catI0m<4^#9g|- ziTQWljs4t$!WSFE`2mE^!STR*M`8hFQYQJjmirsE+u~Kig65d(`u3VF5@x0sIzY1y z&+Q`k!a_i1c|zi*1}P9$#9@_9`{)5;Yr9e;%jj`v@uEO!Ttc)p?8ljkui^s) ztWp0T?!<5FkM5Wfo5iBO6OY%9H*V(iMvzt7dtxfg!4O0;3m@DbRk+qc{x+}9&hYR= zBz&oyVKR%hM6>b}$B39LXR+TQGOw4?9>kh#wd{++f}eAxMmWwfmi;V`e7;2*8JT`Ea4z(VFp^>$cQjY?t2p zQGVD69$EY_VhV(cQ9l5;WY|zchB26+`{?x!|M~>--im|M%WIEyAO1=|BNk16&lu_C zVvg{Ilq0IJ7qnDeioq)%iT~^zA&pcS6E1QtNkNVgu2Yiod9}a$Bx44?e1l(`&^_7g z9}ISySjxH`3jU2C@lc74HnFq{gNI;YGU2s>NAs|Xo3d$Aqulu`pT@ISC5-E!P9AijI{~CFp9@T zx$RLO7$^ngO&|>ogd8)$33n_rz*|i(6+-lagCa9b&4Q2jq|hwWGWUCm8w@aT*8^Bd z=4jzn!bGExqYLrXz7kEy%EcHg8BLc52@%6U%4adh)OtL!8?iWb6asPu4j}=}_UEHb zdi{EW#3?YNm)EbqKF+0Levg+A7UVBct0WQ<%CYG102w?AWr)*7K!*o{wb%!aumacz zrgjm*EK$JW3PD^{ZOls!q-2tGop*O{kK3O@>dqkIZ*!{iGoFYz;HjRJ#~+)m*zUJi z=i3o4ppa}ETD&Syx?Ah-guM6b!wvfQy^5we#%K1yOe@mZ1^GpG!x~Tb%g>*z427!B zD#q*B2B8wVk7E}U@XCz%h ztHXy=*cyS33y4p&HbZcZd1CiAE1N;<-T;loF+bE5UDBVkM^dqS*1|Vi19n*0-HXNc zuhB#O*Ga8z<^SJFt!e%LbyCxB{(qg+hDpfPtc;43lH-JxKPe3e`0RWzS^B5eW(2@K zOus^}R`&w;n|RZB6x(H6#hib;qU6fQK2Lp#Ca2Xd_;O7=yCNUs2lIYzvjYIdrFVT0gUtK-7N3@7fUkk5Dmc(sP#fP`zou4EUDX`2aCt-W+!uQddfeIHm1{FM)@T z?*J}4GW==g2J8p_>8OULRJe1zyZ-eq3j}(X!2`X^kXHfLV#B}s$W6y@ zy}1(S&dXO!Q1z%$M9C{j)kzG@MGM4v>)NQs|69bH1(Qqlw>+by@TKV2r@C?+{C*qs zihrf0T0ZTX0REywG*R{C23#(=k^iG|<2{}J`Pl53qw$Kq=kQT)t=k?v&chd9%K;sr zRhQ1cR$ZTVwHy{K)nU&(ty@{D`$yPak{I^p6>rw`Gy~cY5_%|gh@H!qTF#K`}lSPs| zz%kic0e^_YqZ>m3D7Z~KBan{yJ=pd-1a4<)wKsd{stJy~Hm4fQPmF>dD!Y_vsKXnK z(0M}8loeQLa44L|$QpGEy;mITNj3xqIu>PDDUi~K0}OFCbF{p??fPtk;4r%tsIGp{ z%MZAU@)TM)Up(C;`pYoxr?8yrOkcf~`t-g`6q&IYlBbn6U-IZL(^>ICtZ($> z~VIQN#=xMRzuuxlqSi|pEC(SE+1KWq!A*7y@w$9ll zAVKx(V+#>4t@E|~EJAB^*$$5n+y(>_ajs@d(%-10x4aVjO%$?SQ&MzGE64bx_8KEn zqD&_HZ5^?&z$pE;d|35(8EKLd{J&+{QmLbnFDCTIpWukDJ1}d4w2C%4BRMu3g~C!7 z0CvmpSlw^(IHu3PIRKfddL4|A39jYiKzYuY&n=IbY04oj`w`#a|FV^h7g&>-Pe}5^ z{qr|#Zp-SXB@`ae1g3jg(QN{p>+`N^-)gPq|K{f+n<9p1pK+v5VY#6hMXr!EeeV&y zxP&)S5NjM_$(hI7f*-jDWCSzNvqys$En;{_@pcKL?~p}iIxxqHVl)kZ%V1@|#;HoX z0&_Hu+BJL)alS4xNafYPL1~ z1VE&^_+(E#T%(G}q%V=o6i)OhvU3i{8?J{vs3wze4vyKFU=%n9zU(@@qhxqz%|BUD zmfxN5CLTak-Mbx_Es%-te~Qm$M3~tDo#Ou;Z8~{&hG|OZYfpk_rY5BD|S=*%9(7CM~wV~YxEKwx@1a}uq+Yh!$L`0ryK0ss^>V}nd9A8&_eaAp2sW0OFUyuKv%avvAzR03HLcSEQbHX-YK&vdSF<_B|GQR zODCm#bQEOm^mEiD+FME++E0T}u9-SzR_|tA+axM4DTL#3F?o0?7CXbse356gd;xa!Xwey5Wp-c1(kH`a@5~}lPH7BKE=Qro z@0EOzVWXos-7q3F-jeLrGOVKt@Q0E$6wFepx+(4nWA^A3m_T?Oey)I(TTj$(!%Y6YJ!bi+Hmb zAkqXV=*DI4RM-Dh#A4Ch7~;jL*LQ5B5Z)m}wWiAzLE*vgl>&@q@qc4!6Yr40lLwVD z>}!=$jPglIHAk2MZWZa^IE@L`3Uy$cWy0{M>jY!7XPR=MJ1=Fl_+f@dG665Z#F(nl&eGdSzsqfCoGUETUN8pqcirA>1~sdp>S zLmnXu=IjLcC(1*V$^($x>(0*GsflxhhI?w%M}gBfZDId5`Tbv|Uzgzg)DqC#%o;w8DtY6&zR!>4cA zR(bl-XES4$c=?>OV!T{KeTf%Fu%CLMq!ENg$(G+P8r_t<%Q1thR$7zt>GU^lXA2P@ z1VTS)T(q|f-XA~XcJA>QBlo)G-uQ z_IZ2E@6HoldJVJ$r-x>@iTc$xi5g5`J3`tcFMvRDua7`Kf2TTb7+Q1!T93d{GhyLS zdzM}=zbdC<@-Wgl0_}%2RJFwoqPf3M{xYxUC4EQTU1*!yqbtf4ecLvSIiuZh0yefc zG`K~R^D5o=IiIy{p}>oNa(hMHf%~ZrD`oNos|?{x_LEWqcotrgL|xef9d|bTqzm|c zOyr5#l_epScpcWL*EsBU+m3lg7noqYKEW?pkBncH5*Pw-AEN!R1Pmd8sI-i{Zv9+X zd&R?JujJI`ZpCJa5qpihy>1qZhjVLyFgFEw{*( z3A^Ws!~cOhdh?ko)DxIuhL4+mDXLyr7@L2Rr+E}2La8A)UY{(C6M0WY^NXB558wGH zZbs%@s5wMkcyAv2w|g%NIH2_?mk4XEtW#~AF(!U05^)0l5v-?Q+k&0$wI2_3%}TbX zVgvX%DQ|Tf8a}mk__{U{g1af1`x(p5BQq}88y6kG3Z2pX8r9(^XtJTr-14eGLb$^- zh7n3wz{v$_ikxAn!o@11+Wxp^jYW>N4(1Q5)#$(bsJOWu9;r-~F=)(1A>_W)=N*du ztd5ae%0Vq>7U~y*jRZxYwfluGFm##b580iHJus^D$h28OKU~j3Q%=DfJ607|S0{>H z?DKMAAsNIxI)zvF;^qhe<=bTWkF4c`9t*wv=Hs zAmeiPtl*2?w8Em4;8z^Z_uI3d>JKq1;1zsy|GZ*`W28>Gkjy8e@GtS(=Kx1BcTe1p zgKDZ^ZGkY)531P;0&#sNGVWV#(F~@bGal*dld_s_f5s#t;);mnTx+gSZ`v22SKO0_ zq$hub1gKNmqJfiK&gHYvq;ca%FL31R=~DS}(=NQ+-05h(qRYGQ8}ua>T|%djfzgeJ zKJi8$9zmu7@E3pMQN2qfgp+lz3zBnfV#? z8+OiP|M;|E$}*R1MNgR{*po)B=x|T*#KM#BvBzeGF&xIN4Q1Z1x$*L5h0!^`4eY~e zGjcZC2d;mTU(D%j7KHP?<%>%}<I(p}G`Pwg7&Kcf?tJ8(k&72&XThZy?=QVOg+Z!Wp+8g3nNg*H_)0QWr zb}Oq9s+`1O+96ZGx|c2&qG>|xE5W#@%7D5zZ5qWIPfQUA`rr`ukasm=h1$1Q8%1d8 z{1WjMD5u0XA*S)gQfK2!qk2|Q^ayl?;BbOJN8O;QF^CrY z&s5>$QPrRZ)~$kOfrg?tIw#HmX5yM&xa1@znPB$&(ffp(e#y^$923`10)_jk-KsV1 z*tP*^Q8(U_;|Vt+4fUS|SzA|2>|WFFa=@f!AhsSTCCvQYSdQXLJIT<0Y@b zpWmILAux#2|JUfC-b;84#UK2bBSwl{(T=(->%v6{jIV^?GPp>apuvZ~=3rCQs>IcB zX$oYH@oc(HC;9nAYAoPg=QA%w!!d+IyaD#l1Om{02(w>(WM^iF}w*23o3 z`d8wJY3%)NmL#5<*AbfuD0dk_G=+JtM9%{adSCt;El&y$3BK#UvfwPlT8S*g$)Y#= zJ>NrlYS5dvo>ctJ3zdwaix=#jSb!x$L=dU%n36U!T!m2fAW~ zCEtygRKm>*Z2%(_V~IDOg7SvVD9jG%b3+CO5~UVFB96@=g+m%~yZ96%SQ^rjvXwOG zPyFm7rh>NwyF&|A7S~Eo|B6_z#cKbr zBaKZKRLZ2(m}vS}W;_u4S3bM@q2%(x21EZ;lLD<#?_k4T;1@O$rH0sGUye_9~-tH&RD3Nvt6H?LdDyrc*ve_lsHTocpG3R_* zdz|So9`&3X@=lnuSPMWhte&@r?+PN(t7##G)*3A)eRRAvk~rso15IBB?e|!y;!%$D z`T|aIix$lgS*v08yyCvJk4IZ)T`LnUfUV77>C7Z*R5l!qhyO?%%@9rb#R*->^sn+g zZ5`=qc`hDZUF#dBykqis@eM=pzu)U@(}GWlcFt!XaTkfwHC z<4e!iDcMlTcKi%)%k9=rpl)3;y1`z#)+T-mcT6-F#>m=JiVlK*18~QL*DJKfkdiE1 zCWtH3U*VHFqY%*7! z+cUj;^j;r#iXK`ofG9b?Q}=CWvI+m!^f5r&)@G@#vpi!{yS}k{B6xg@L3?5T3{BR} zW(JPgyDwjssPX^QIyVjLe4}dBRernL>Oh!o_ zkNmS{u5FCmZ}#D3>#;SXgPpV3|Mg8yt%~9r;J=25j2{h9P(kkqw3aLh&fnxRZZV9D z;p~D8WstOR4aPqr-Lj~wGJFi~oYQcl#|S>0)ezE9=e5t1znr}YZB?ksT@!{njP}IL zZ2r>CZ7LbsFnkKGenRo%$uf?$t>zvY^UQk_r66OU)ax|?M=8FbBhN z{E{m8A*LrA%x^}QQLSg82$OUE-TB!i1N~a2<9V!*9!?cC5}-OQ{6phXoifK6++Rsz zMF-qT%{3b$a`(3f^2dB{ux*#$>8~S)J65Fh*x=7LIY$H%^G=GtErI&$1S{^SF?@+^JQKoHPRXpVTg|C4RvZ{# zR>A{n)#7aJEYfhp#b`Y&)R>6aDgOAf{B{Vfp0-;fKDR<#??_kROesriKcQ4X)A=I> z=63L7m~p#)t-oXoSmS6enkTVGM?crp&3aZRoMc-zc1seyR^a3=zQ;MCj$Z|L(f>CNo_C5HIMzY#3Jf&F+X_H+t$5Y#j9 zcU6tqHT=#9N1gn&2DgXdYmKtm8=tRDjTD;fh9owihc-Vy&D<+WzPYxl_1S$( ztUJteWop%(a;}?D5)8vVSP|OcL*mQM--=WoUObxwEEA!32Us#f0@k%YW}ZolsB<4k z|0a@pjucugC&3>n&uW7y#$#rQ;H00|+0WUd>v>n?A6i}vtn73=jHA**{DHVE6yw6( z)95zSy|JSTO&RL#zyE9~P%)%Dx9R+vW4 zhV>aH-@;4=|CodF`n*33Rf`wZq{pGCJ75hgDLH1n$tx5@xWJfeO+8*lTl3}d!xrXW zn-%86oW9=*jmU@n(_fWwCSqZ89kTv$WHy>Mz#vleF*;b|b%>2{ch`J*2B1ye#{weSySlxyQ{kG>|?C4C_;g*y?NKU3RK zMs-N}J)<^m_ihYFS-^)uNG~ObSl-}Si!*-Lcn28BBbuWgF4$z&b84y0*Xr0sEw@fr z7n3dGG%bL)a=tsR3I4(`&L&Oc2)5K_Ggv|@Mpblo$%a~{T+N(Wwe)DKbh>&{9al`? zwzUZwKkELB4G*2cU>40TyY$m*r|?fxV6?@Iph)H)?f_;)MM?8Cl|FRMgGfD#pY0FyDgz~kFVWTf3Pk1jO{O!BVNFn0ljp3M z<2GT!PIJQ&b(t1~=&inO3*0A286R9tMTEB#{~OzY)&&Z98htdi4U}T3mPP^}PCfP$ z#2HBngxMo!4_BGs`jGP&hXjNP?6}I4nONziB{F1CPW^3IZKy@jAwd}hGx`i}|MFr7 zP0E{$XFJ0W4k3G1R@YJuVf>kIS@dZO7ait9U3Bzz@YqU(N(KXuQ zvPvITuUgg|TbZuFmS5KVzeHg`9`9h#g7$4xL!2Fo8E(NupVV=D11Qa>1v85oR7dHd z5_Bjr=DKMM^mapOao9{%-f-`QigD^`QiprrmavMjw8g;mkgg*4hzD@xFW~g`8rMO` zkczL2MajtFpwM5W@FKs2yx#VV4+Y<3m$9PmlzA-&#Ze;S__}lYWfSS-OKAfxcrzX? zU=AUP>Ka62xKHzboY?*yJd-xHFc}2Dsdcj}{+JXUDIkkAjU7!gFeygxSUj0ivoN>6 zZPQ$RgxcG^!na$}=l^`@R+3sBf*wUPO^3s@D5rK-| zaLE{V#G%SqI1S8(HqT4fSlC8^4Lh8xI;lqNy;sCB+lZ2N+(4&X#g|qfa}t5&+#i-G zm%p(A;YJ0zFq`XBBypsIA#N6%bomHN$${A$dT{6w%Og;MNxo^^7@5bTw9Rpst`6)zK9)Z{p*X8}9-ESz3f3}E8J9kYTdJ~1mj)>iJ$tawWO+rf)>qp{{Cmypfb0Kxu8|=Th?H}w?CqgGJ(h+{h#aY=3UfMKK-NyB`de1=4 z5<;yIcmEb7uHM7_@cTuXkA*04EL?;$O+2xC7b&F!#Q8)KBF*{g**;~YU^u4??WO-& zt@U+xUioF*ZfzkoK*Y<{eenm+-udmjMQ_S?Fa(Q9O~1M1E#KPJE2u9hDmvPdU)VII z@<=pXK}U^^kXYVwZg{L+!Ykm~vnfkbjx0 zcn=gVSOW!gPPlWp+)fTh}Ao4)Gd7;H{r_vd9S==o8(%v?CJ z*h<{rkr6{ME%M3jiwVapCiya3{AoQlR>G@d)rftFX9alZD2n)ornBF@GX$>XtcE(H zkY&G3DE-BxjMahh!eD&<2BDHESq*r=-j6LA3?C&@Rbtzd(L z>V}IGkNQB-l0`~9gf(AtXjz)3w&d=3&cd_OW4s2c4UJds>F%()O}p22bXqY>O{@Cx z9i|@Av$ql*DA8swDRQvWs7k&ps+d*bhss;I`nHgt;xq80L{+av;py7%5nxs)!(elP zSsk@3&o2~VMcik7(@-|V^TvuVo|V`;mepQ!h(fWCrYY45PO5upw5s*er5k+qYKV?& zq&Z~j?&WcJ{oKAg3Iv*0&-u^lj(@JF55mL;^_tUUg>X>yIi6$xpn>mjkSh%-lq;Q_ zqw;atH~yqtiE4)ym*?=BUA_67?%^!6tg}>tKOmHU_A) zezz9gK2!+#p1EAPwkN)?qupy$+Yg5Y$2p&GmnglD=SmkU`W)wK@ok@LmzAtjNTVKD z2q})b7;^YoM+>^FY(hgq7n*@qxXri=!m9@BYh5p!M>i^Suj4c53$MpuFq=ZZLE5T} zZ*};ZTs;>-3T2~A~lf;i2hMa=sO!Jb3Xt1bz)8_!jWg#mh>6d z3)w5jZ{58*?>f#Al%!Zy-&Mej2d$X1Etn+q-fL3J6nDwkI32T>^$4nC5&Q+Y807O% z1pWII7U1bQwR1NCjtu9y1LFWVaxj5DQ@(Z<;L6De@kIFzLaWh##p&6FBKUu-s6XER z!su(C954PEa>_Mad+JXdwJn53jl{LpB8u$#4HkFuq`a)>?5o?v99_iCw~`)W`LCWV ze4??8i+|XQzJD8KLL%UCym#6?V{DzBbh6} zwN0AD%Iyx6^{-drK<2OCPeS>F9h|ctGFXa+)NL!H6yx-tmEv&1oVB+_2}Z7bc-f?T z12)ZNO>cQUE9^T1NX;7JxAEI~a%w}i-w73^PQQFB5l1C((!x@JzRLyn*ctIn_Tu>y zoh%EqbHNg)5w-3{`aKY(!tp@mLcVkj$#B3r$qV$gI$$N>;rz7%forNyA+Sn05B{Ir z;NqhObGiF-4RJ8U|IT=3uHTxtw>|g#2g670%psfd$yqobH)+W%CA*@(gh{1mU%m6& zt3d^_(+4JjoNMX~!`dOzWA!gi*g+k%^l=FMe74)l~hvX0%Ky;^LqMg^&J2}$L81q(mDcqoG8Kf;tI<7kQ z?H@x0IjB=Vyp1`zdFd{PsAle9QuSynpt>RkxK^j~P~6@q(S|jsM?ZVE-CEOg3-$cl z1so7fv4CbQ?cliaa|;=mwoX6An*>s~nTL!&Qws{E;FiZA=S4KhguNxuLV62uQ$LkB z*FLO84OWy|rJ{}1PWx$g;7yx{nnaf;s7*k4ro+?99L>WK-UL{YVofD?iucgI?eV}? z7W0V?Q7$XsY16mV(R-_89q4ug^QJJwiM|lsd^~hE=$M!~LQu`Wj96GZV(!wd^wDIi z=h;S2`8&EcO%{17o~)xv`Dvf zN?(+;ba!`2bJ6i1-kg1|pq^VyXuJ&jcE zyb^q%w*GIo@{UlZ%0Gn@I~j$gDA&Rb%VE5fS<7wHaBQ_Z?)Fc6MyT)B7hkZ1voi`D z^6n@2c&nsQSMojm9g0c5pn84b*l~`5VVv50(@rkij^;gj=i>i4=c|w@lU(#bO#-!4 z@z$*@ljEzCUeoop=uUUU7)(9=Pc640siE>4sUGCXydJ45Vpb=@esppUGMHs4uTztf z_g!9?vt#kb?YvcpbN#;YujCi!LDeV5>2R$tn$=l>_jPE)v)|R!YE1-QehzU z_x%0fNFoD^I%pl|vcbghB7<-~MPM)8HlEqs2T#1vA>C7v#?0k@&fy`5o(NaGF=d}%h~vPb zjwmHgv)N)##@dc!JyMaxgd>#GR!JCz>!t0p@K-4?e6M0nET1TwEW8#C=Y>dvSwol- zYMa5H99kB!g>^$*WZ{omDDilw#@PnqYgDvUj8P z+o4g}NdDg|0$0go-EPvMQRPWH-h*_}0z1jT z9-_igWk~YIFYHzHoL?-tK+V`ExZ*gZoGNS1;?hb(^7PD*W`(W5{Ar#Z=!;_p&S8U| zPXwkH`XI9osd%`tvIBdpdFBx$uLx3mbGx$BT*+>m zT6rroGz?Bz)(qdX-dvuH zi{)K{F3reJA??qzh&oxqt|Q#w(^({XrDqKSD+36}i1=uCqV?E!!53x_gm=tt9z2i) z3LzXzs>IvGM6wwZ>MqKl6WP~NW=gq;Cd$rUdDPs2XXl?3sGHBLALXZMyA$Sx$4raj znDgroR&;@-H@Rb+k<1kTSjv*w(re0#B+FOGUZahfkIWhE%UI3IazVU@-We`@tcGio z#LLHG5@pXI5F)Ed-sh<4BX6P!FAo*Nm?k#)gl63DN;=E#8qK7FIEzt3PdvT-lL^cq z-Vu!s*ipMtP5U|dJH|K2bkg(1qvZ5MS0UlAS&8s;sozfLk02$GP2{b;l=?+|E^BKQ zvT9iqD{b}bzfG)`3L;3LF^f1)&hI2r{UBzAUWzKD@)Z%BlrjO^I7-^2b`rZ;o=NF# zQJ;tg`p*t9>{4{HYoelnZ&=tyzxan?7u#<1(;-@3?l5U?7HxQ(ggQ=87P$0xAj>@^ zY-F}aW|oIyM12*l?ST2CReasj9vf4LDP+Qh-i%+BZQR+z3B|f=xK+A-pO4b%wg8+j zW^oSDeKv6p@tuy~H}%2OB<(e{neqKUN!2I|4+46()jtR`R=~C)Ru@o-B%F)0c-WoS zMY6gR%0X6_QHIoB`d4UzYus7N2_?LFxcOuKJU*q>?W+{B8H*;{=yvaKgp|&6?}$M5 z&MS|b7w+u5$ez0NruM%Hbh|q+w#!4=GTZxX2j(xRKDc3*zwY3`HhUWpJ#A=SHh2lR z1}3wk=5ygQoK;Gic#k7vJO9t&YTy1~j+fvfX2t6S2B;MFzE{y9hFpyo_cl}~KXn=e zTc@`nDTM*`N&F!xV5#&z=3`I8nRD+xyStM^vzvVW_I@y4J)0q$(lp4`@OHuC(vBL< z+ln5S2IW_b-Y~hLK8x|<8}YE1Yezpwa+w>d6W;ejx*+-J0oNRdc(+G8PYqj%k9 zea&vX{;s-5@U)2;L5$Uk1);H@S4DNtPL?{_NB$Hym}YYq8Qy086%B4_a)(69HkI> zx7k(Mg$I3i*JaG6AkM5hSs&e$(Fn!(ew0~()W6@hMwsNHaZr09C92UZtj(+X2$H~d zz|p*HD(Mxy0Ynx*R3p+c8|dzE=w`o_#Fa(zTSR=3qab5(^NI5mbn}s;} z1xg(m^dl zmR%$*yMynj-7dpu2b_aNZ$6#qSf1&-~8@iXXbC8=u6y#DNFWS>j?I5@N`PNcm{tDpAb)tvnt>K*4n-$ z1=4;@1dLj;oBygsyCgspc`Ep9=cs71<7m+Dot@dSRqF$CoW7qK=2$>Jc8osQS8uX> zlSi$-!iKfkXmco=kD9{e%mA+ZW58jp%RrP%+AtF0!~SU^;CD9H-cjf0-#1Ji_t?Db?WMh^X+|f;W++?V*Uv=~4UMUL;ZF93 z*o$g`PW*;kgs+S7OBppO9TO!V1#_I5RiC_AX_7LCuMgJCsDx4!H$~fuM*0T1*WBtG zaY*bGrkRHWp=O)!d(NW$(`-#$eDy^11usP>{#@*eIMtHTTtFUba4UDnq>u z`OB>=vZIv4rdcCEUk_2V=|d`m8vTsHs&I1{j#x!$slYirR4-y#Xf9Pf_ok>H*D9PH zkr@mzZP`kq@Ug$iZ`ZT;$8TT!Z+=kR!Ti+k$8kA4?vql?yS@J-p#4o)C5LECFde~% z@#|6>D?D3m=B0fiFcr$V%)TlT1a%*)D;@oO>68wlj=rXVfVOGs-(2PO8S)IAv z*1vbphx7Mu64l7Q1Zx#M`$Ia&dpQs7$7wl{sA`q+J(|IeD{hX(j_aOpH`E`G7aN;d z#RX8Y204i=6UXu%t^D-I(;4!r>;FBRrA-`XYT4I88%JBtDo=ycAN{mw1jBoK^4#n*HAASci*X73f+I3&D%$@`61vj zW;oxyTS7r;f=~95077?%1kt8M3CZL3Yp$Bm7zn~KTaD1mkeX$+x0IaEgrNq{uE2f% zN(_mMCgBbvAy=>t@xlEzzNuI^y|y@yj6Lo9o)ZGn8CX^?&K|6aq+hRB3QHlBrzKzF zNbm2-r5LBtd#DjdWxu>~n0b%DVjyS_@&7`FZ_h)1MSca#np0~<+Sxb%x@9$Yud1M$ zyQe)37$i3+55RNoTty~Q`-Mk6sA=^m`B2XauHThT_Wm%kE}J(IZ~q!{_I@bL@;90Ll$XaZTW>{TGpaPH`bhqHchF#2Rv~d|-G4c1T2)Wcn7CR&*DoMsEmTKvs z=C2l9YAuDU<(!p!Sd0X}uPqqD54`8ChxsSs*WdqAiNo4jK}atUs)r%%gIXZj{o;Gl zlSw~>9IvVLg9f}ZKg&7mtJJ2mtXYA{o_mB6Z>g*6>I4 z?FGXZcQC6e0rkebgpT6-p8OR9eN_YQ{XK(>pdbTJnTUV8wG zkhz><6o#Vw6LRfsHdPt-I$J%j)czJ!7T>Ka_j}t()dZ7c9o&^?QHxMb>-ZUA!uk91-@eB#alo-<-yXkzPswah!tMv75^Y_d9qUMc%S7#St|7Dw(!gaidC{Ktrom}<$R>~D7 z$vyNyh%P~caPlBu1X5V>FZ6l1{t;Vc4^2|vQqh!1Ik{R!0JAwDUSlniBLAWLFXLP; zU>MG6?uZ@~di9P)RJAd$=w~WP8C{r=0lcb%8D`0CLmt=)_Qj?-X(n&7StCy=-=j_$ z)Kws3IzG0fV(-V9$5x=E@~V{F&KEr4c&|T}=vXHKMoMp4q@MCTcc0^v-#`Pb!VaSl z_OWcAP{Xi=O`903Q_3(ITBi6<>VkpFSYDFJUT=QwxKSjJBmKHoq#cyr6w=?2#=}LK zZ`Wkyev_UdJoLeNR~BRN>#doLv)}fFKo^zFs+6?+*A~LAL@k=ar_^7b_c*HA&>|B{;&&>GVq_AP=0G??B+QN>n?FrN`z`#Kzk1D^ zGv2T(&z_xhS1#`%&OFHTR35P+ki%EKly?kOu2&+aR8#gTq9y3(=ynP-k3EZ~dYw!TMt1VK()j!<0(Iv=&dV*-HW%cs5p~YMnYcKmp^3p?t$y zS*ePEwyNqrA~1SCs+g7yiVKoQ2R_BWD$180_hPdw(Jv4j;+M>W2KN9SxRk5?FvvoR zyYdfLt%wz2&byV+c1Be@E2s7N>UdwLN@w#|%sf5xzW#sabhXxbGUxRqVPB_%?+3af zRL~Zy$p34LV3vvA14r_}V9a{#!=^v|CdD~jjV6tgC~?K%K|uCxScUv{0FD@Gb%+IN zR)G|rz$b9}?I&(W^*cmOun3O-X=#OPCy+fFA z4$j`;Pyx$CbDA;;I45>f$BcI3ajIV!;C)QOTS61j(;c{9m1VK0ZX$!tt|G2hx$ z__PZct9VdN2WD!FKICgxdanPy1pM>3})ojk7Hut;Mw zscy>r*dGHn^`Fb^l7Ev)HV0Sh`+^pL3I~eMm_ke&Q?Y~k%eLYabM>W#lQjI9zAqq+ z;k8W}9Kz9+eBRFlFhU={eHHB~h1${2Ns`#7KV>&&e`WeUrbYW>h@#9eWy45n;Em^l zwxtVB7*o|q@Wk(_%r@|PI(SRy?A_FuR#MkUA7cn|J!4eo->>mC)%%S!XEG(f*qB8L z-c8*Q{v->+wk8(rZ_w6iRTL=Uu~RNz1@!h3*JH*}z0rz)W{86)cVpV$5C*J%z0wnxEFi z{5d5{V3*{guNkKJHKUztexnqWeCE@@8G7PGxmJ+;G?8t5YTkSJ!s)OdupnKd)pmxd%`x_p2QtAhR(qQ;Y^39b=zExgKEzmY3g1 zmHV{=5Q+^;%fk_eqclHltx*|rn%IiphVk}$5b?`WG|e6*_b~%FGlgJ&S;G}6Y1s*G z{vU=r3=)Ay@u*I$(bih-2C^cURFg^=>#;9rl`c&UC-FK2_rmkKS*1LDye^%t>k@X~ z+q$7nu3F+(ri{B475%XptTM!^QP~4$q~$%2x|lX;PC&IE2e`-Nz}|QQ=5*jM z7)fcCAW@|1KCYAJ{fnCri1@zoj~arMHI@Rjw*xj`>>b9@T0ro16&ZY$=b9w`MqzEl zaFqF(4M|hMlzB&8yk0wx;_$%ncWZotHJyyVM9Y$%Hpj>q+*gP7_hJrSy1FGOsQs+C z8h!*T99$!ZKDq>5@GA18;F|npzTb^j64BxDo92bIWLyuqPOf20o})^&5_NrFO>uyU ze`BK??Nsne3o~((b;ybdvmOSunE!YJ^i2n&oJ#N@>oemwt*)50vsC^s2L~cnDrBTaXKf! z9r=0MK+dOjmsc)E9igU%7<};x)9-!;`NHsRt3HW*tU><%MP4-*or)b1szgGV`SQ7y zA1ehUuW*4^C*Yt`FOX4v8p{GzTD(rCtV_ zac4+oC@Hv%WDABIGVHfCehZPO-lqaZ5&VUc*p)YOQX6E^cLA8h^>!(+e6<=qc=zJr z$NNV)oFxfM#>6rOlOdNJL2g+@q!i19)}{OEx6Vwp=2kxzKlQQFUv&aC!013*uLjhv zoeH_p8?YiR?5O&29XmCb;;m&jvg+Fpt^G|L8s~jzrw|ufwn&@oUoDty8DMOQImGd6 zHHEOB#PiP3J}XWChnv&V;XIAH&=o?9tXcreoBaJqg>$8CYxjB4j-MEl8uI6%0$+sN)SgJ5ou80eebKV zh8MB2PGPcpaJLBJPZ1;+w4CSsqK!`p0}=Drw@Sz^$M`iOACdcrcW5~f_@UO%c0dfe zBgPSnE?~|0COpE|DfRj~26%Gj%gPZ4C!*X+5vXts-`Mxl88TwZf74`BpU~ciBUJMX z-c`&BrJ)orLbZP@E(G6j7ifXv$O9i3t&C^3`YbpH`-#tG&~l9VB;puvIgNh^X;W&Y zhX#j*zaJ}>&l_Xd2i2-15UP-;+IUFlAz?OO8l?9sdaGJlH*r#j8*778;ofbaYLI!9 zC^0;bb2`5=vjOyE5cFh(h|ST@gRf_09XQC|U}gw8^Uw5Qh- z{iPns$OSLoBK#?|8P{)-s*<|=wEPq3L&smB;`ucmq#*%hPAv;SgP6c(rK#@b88O=h4CE zgk7(t@Zq7_wy%+Ke}DKx0<%_$&H%ec_&s!lwg0s#ECHMWF830O9D1bA2E^)X=Ic*s z@%B?>2|}h@%Js>RS&GPaL*WoEBkD>aWoF5EcO?l@rC~SlTKl}H*~{8}4v|_Qt1~0a zDU4sK__K-@&NQBVVnG%%N9Hnd7gWsf( zGeILOmI5J4^aas#I5wyfpTsSQzH*d22SCPrpQ(MnZwI5{M_ztNOz(jq#9x!t$txv& zrW|!Ym`jd zC(ccqZloN{^S{~~gD*pqemC)sQH!5<<`{M7g>sdJBg8Tp;M8H-66i zFOKw-{Q$+8uBA^Ax7l-G-LopK3_y|@zAsTgv+Fv`g7p^ML*pw0y|aTp`byx~RDBZ6 zuM`#~c$1B(m0{*-6M{l1@GkpIaUpV-E-^{lrrf975a*-SyJ|j4bnrwwJR5)ZI9`@b z-zzz-DTb`m8yw?zSl%*16T@bK*#iiQmmD9!-DDzIk~XJwY+7pEQ3l0zxQ`F4wSt$J z!&rN&^0ZPWD6UpCSX6g=fiE0}C+HDde2YqmXNhC~9ISlx$0M$%(>9pRS1Pl zzLd39AK(_gUS1hHdE~z1o*CXdK2CG&{s*;L=P!>oQs)=?W_#|ou$E|~jE3x^|0XV* zc`{yo$B-fXfjB6?soPk2pv&Y^;l-3PgHXxGNzHpTCgUG~hunswZ8S?$IX{z7EUU2D zUAw|zg^pq*gciwe9GKIHfQHguiYCk{#8)XyL-2fkBc<|~)1&$3-o}{*jA>P*m_v;B z$2M^Lcd2t{;z+@-Q1xw4CU5X`rxaFW^Vd*h<$n!KN;O``#?u%UoWnr6sf(CM0WBw| z{=Xb*PO_b43)(XliZb26zdv9cDqVuFuRdFl@rCJI;Y&iZTmINtc5zxhJ7%_vc>`UjF!QS;_qCM@3m(#oLeTf8aP)p@1+|wjVd^pqEj& zb(2!O**FcZ7+ZWUzU-Wk>|Zs`aPw21xIGJ^G$Axnhi2ix+0akSk1 zeO(HfdAj-H|D+^rCe^i8F!w@{jS54MwF{nCwjqmmP6g|rd+j(nX&XcaF=EK2N6w_b z$amBZoq^o;*^r^Yv0{EE%w zHWb<8*J<86?oP@EWrX*3zlEN|{Fs=4GD(9_y?;G`p>L4hUF?u`kz6ygV60fg3h z!6|2YSo~{(z~PCv!S8Hgx-wo;YxM!Op>}CzX!5I;PCxRI5LW5sRD@n#j&OpOemAGd zxx7UGy_+g0?841g`Epv2!KG@|kK{KUqg-_7t62oPftXSSvjCfwCfC2d3xb>jEjNfXsQgk73Z|gS_`;I{fn*quIdYAyXQD+x}K+= z6~3^8k%!KsbW=h72<&d_{`^+RUUQ3=WK(#}tRbpDfgq(16vM9-v8|?!}O_(CFgAzBBbvpc>Xqb*tHo7xp8<^9x zOu?+fIkUdz<;m?NR1(7BcWPGYT>~M#qaeY$xA4wG;7g@fnz{scP9k>))={~Mh;BL} zSz#@2X9!ML{W7UkxPw69F@BvmI?@xdvrj-xw>of{0e=+I{s&H4b_Enk z;VqFR!8eKK`EGf&mX^yMs|bBPU0)<*s@b**?FfyvwA#j~Y12?wChXKK6Ck&U1Ne%S zJ{3DNG_<7xWs^4H)n>u2QGAX$MkZ09PL}tMsbp@S4i6Ik17>DwdnfQf#U~Hk1Rh9> z7^V|^I<6vjsvJ%9**j02*93MxcciO*i`)WM-5eLpD+QpR{RDjcGD_D5VAtz0ae z&%4a60>xAr+$jLsj^&QVHu^m!{R6oL1av-fMrK!8+6HwOqe~fmUI!}fj)tBh4~_UX zW{Q=zYUnr<=kU7J(cn1;HC1iAIz_F15<4aLNUdxL;4`GofMIk_ncqMm$1V${{u<$j zLU|`6h>R8-A5YX0?tb%TXI?6ONnuuc5e;3?U|E6?wzg@18X_R-vUl2MM(H z-^7lo81{&fCX1D~tYXt#@M$E95_ZA4Fiz|(3s@^IFGx9*uM(wWB;Jf7c55Y1Hx9@M zo8=y}ft>d)i7<88FC%DORA{<pxoCHHW?845HwAa7PCPBPr!8OMjkqHnF*A^P}5`0kLht{J_*QP<5 zcvM$QNk!TjRSitq=z`9q_%Ia+i;M7))doXUW2`esxv{2~F6q7tp$%P!c&f7yc*?0!S*lV@-Q%4}Ol$SK7b(HBt4z zxI2*hzH0Gnco`FMSDBx{z*+ome2oVd{ga3F@2hnT)2332K6)Mh{DKSh>D;zTyEj{v z_&eFJ1sD-a!~^m!JX|avEa$+i5*$$JYmCb#TcN=WPO+dx$2t1djtEbpVGO%X>W-lml@^#!uQiai~CzZqeSYV_p z-X4JWu1`76or!6rceyT$v&>3T7=MP9^5hq$w|IVsgExj4oz<+Dr@WFDYcfqsa7 zIGvggiO2R((+n}T%TDnq{3@tP-2#5Wy;fHg(s@u#+SlUu#fNX3xU|kgvWLFN$9=!9 z;K=00ii^iaQ7f=VyJFPb;8a=MIM zZK6eu^Y(vznT01``ng?eL>36CSQBL?74tj;f<+T<$EJW+UW4@dXSY>QZJt|phH82XFWPF_DHj9_)wDUI53jsmfCpt~Yrv)aT&$5h(t@;#S7V)%AAf6~qQ zPEWUkC1vkunPVUStVF{$N%upGelUkvi*OGMEEmC~MLM$1pr~VfYn?_7B&a{QXHC>k zZ#P0c2qT>I|GATL2lr5$o{4?F_O26{eCcj`u-7nW*>lY(C+51?1nL9fcUS_UZ$^4% z+@3F$Rs$Ro`X!L*cZA~-L|Yjbtq}S}T!|ai$G{dhGwPt%m)zIzg7fI{!2_~`QZS0b zPME2e@jP3P)Gp{E%a$;%==#{ah&|9hiTT_Ma@o~6Qg-4xqgLzfV!Uyl|R!M0H z!FyklJ#+z;E-61v;(3Ef_hAG5mN!$y2i#Y;d(wB`SMJ<&gcwu2diHKL7{!?F#y5-} z8?@~WmiZ$SA(ejaQZHHpQr;NZd{tQ4>VD0marYVh&#=VD9t^5uY&$#5cQ2Pa1|=$? zT0~Jpe{?1#bVbshrxg*Rsx2mJet&yL>#o(8^VO{`AZh;Zl3@7+{*E5BcrFW+i<7Dg ze69EnWjS_t1^Q4h_#4II7Lkm-3&?EQqW#Yq#*~lNeD%ovjpMhEMN>Vdm&0q1v74~r z%jw~O{)4Uct$VZMH=heV9{}`KLA>GFEZXd}3sg1MS_AsS=X$IEZ7xdn3wKG)f4`!j z^B8S1As$v~-ZRFalay=@t_e394usf;;x5VuLij^@NMxGWN~vcfQtLbBXQV0f%?U0) zc~VX6a|u*AwzjstQMS-3N3Agua$o?ucbY-w8I(=9$fMBSXlg$Nv4M<_z?pxRj=KE0D$A7=$gdOF(=)lMVWr# zU?W}9@L*adqmz&6DH?pudtaM_$3g$Zz3jVig|0#_T*B-HRlSXs-?JN$uUl?Zn08S9 zs9G_r5qNpbtl}xQQMcWdXBRihjaF8#dCA;vtMIV+hbD3Eq81H0F`NcBbusDlX_hyfqZ&mn#`q-U_BPT^`YYDJXFR&3stFYRm z`o&1gkHw70Y)jR))4~UTBdOMH7}W7lJctPqJOT@fJk`LuHEPLs-7hN(#>J?WfZN# z_6oHaA`iJ5+B-H28Rac9ZMiYt_v4+-@$RzMaJ(VZ@rZn~w5ZBEw5T6!!B4%%gGD_u z677=(A(U^&j92Zrf;0cpBPaK=(&y0EJ53W6?2`mFod0bvVJ39%?WSCe;2o{-)1IIh zF`gVQGd^9y%33rj86!I=*4Ks;4?|_5N{uO@IY-4g0%1a^i)~uSJCP(VBJQBj>M~0* zC7R$HY(0K!!BF)6J=r2st|pkMLoiWLFi|@wveN)X^n=WKFQ}om!S?4@>IP4whcA){ z)-}GIajMwWOcBS<9A-8GZc#1fPFbjodnsQUwd2HLE#2TSCH=hGpd0EuI3hz2med&` z1L*U+B{PAjv+{f7lCHy~J@H3|;T(elz>jNRiXFMkgd^_ePp&q5WKNh|x*Gwd!&#to zXo6^9;!{wxXm-g~@Gx9CCp1YgQRMY4_>H~49Yh#UcDNY-y-LnMZW%i>`}lDV5PzMZ zI59%MjrUu56B^B$DlR~te(}XbulS!UcB-V7K76EMO7kZ>t@Gi#^%u9OuEe*cTHQrdL zcE_s~esAqET5qX7!%V!++`akgH>^U2C$I#Rt5~BZ;#fhZXYIy1^IN@ew_E1nA|;rh z9XTs>=HKz=B^EZc_y;k2az(FVN1qsG2V@tr7SkD%a0e@^A{I|^x6e)sb+xIGR=c=N zyA~c!I^uzoKGK26EC*iUtwu6DUG--m<@c5N>PJfcARDi0&))71H+x1Qy4yx%mmfL< z47;)ANT~QQg#MUqU&^K%OJ;ta)E5Gt` zFX=IVrevjrdf>833*_t0g1N0fFd+Vpt`xl9{wyrIs}gJH2;Z==)i!gR)9mdVN z#8Jegy=wkNX;SeoU%lCM^B5-1!ElSz8KRje!X1t{*V>W*L>-z7#%I!Tgk~%aA`T-=t_fUxb zX-wF0#tEj|*8by&ki2uOf7Obe9s8$zM3)9<+{2;_NdB!{PU(&=im&94>&9hmB}exM zz{*G-u~ukCbVX6#oi|#Skxjh5*H12X>Ll$2&zLU6?xH`+GQs96gje^};sNw{f|AS- zQb~M*X;IdjyG3AT89(ipd$5gZ+>h;Jz;yM9)sLMz33un4!0@W>#p8&RoQ2N^YT;L? zk9?AMBGnuoJo`uW{#e@o#`(&~Ceg0?CgWJ3*hnBn&AI#rxEde55DsxBQ5-NYpIlSm&l3>;8)_O95Aa-c-am5aEjn68E)QQZGq z?v8Ny0_8SwjsTUShA0ZAM*tSTM}Q)sM-B@`X@>OA<%BN3GL)2iF{bynmyJ<_S_uaD z<(=2MrN1-Gd*Ny)3E$KOck?3t6bp4mGv*V%v`+){UqLp^@DtAkTS}G#g=l(Yb@X?l zBt8bj8%qB?$xw%^o_U@pKKlzwtNx-QPsOVfm`EpnOhx}7%!j!FPN0pi^1(gZWC7@F zi}z}1RzV&sa@^K5@5@ovAPDvb@Y9XK<50Tmb6=S1zvHcga31RHBCEMV;=YQ@kTjkv^_f zOa~PD)X{8~6iwp=hwo)XfLtngQlkIuQicCpNkR8Ibw?2q%*foU6=R)%~v*wCThJ#wE8%p;dNqUQ4H`5zb`lA-mJZ4bT`&T7LFDp0z z3gHIn>oQC6$F;s+FIL`@UBi}=W?hgKmt|+l6|ziQg(t%9Z&aDfHIwebxNz$>E_>Ze zoVh0LS(LjT<(iGLA8ADO{k~5`Pxs6Wt$Ogx0){B0hakV9Dcs?5nXt(~Vp;8z51{7l z0czd{pJ&g+eLw*`Ecnn`riA#ElL1KX1$uguT&fK*C@m}LH+_krE^&9)2cz4E6*7}{ zRjD88DB9yRdHX#2G#uKx3aSUMNPBmE=~**UI5cO~ApB=$%-ipTLr-HhCx$UZJOLDd zoY#r8E@EH6zQWf5SNhY-j4(8nN^6~vQv`dV2@cFbW~Iyq_X$bs4{yWYV0DQbKX zKKC8r>c16RKyCRUoy(8%kxnhFypN9n^#mMTNOwzX4A7KUcP?wz{8$DmkTh00+O`bv zcV&H~JGeE5zlMRn?kCuR+F2R;-kW1Y$O^9gE8A9u0X2tvKg+>FIzd?j>oqN#9L-={ z`s7C?e*R1}Lmna*JZ3FZgmFq? zREQ@&E7sbK-_fwBF}QG8)wutk^eC)_lP5n-;GS5X%=M*6qnF3RKYtKF1+TcmDhe4i ziyL3~VNMBj{Ze|}wW)lGG}W>_X@gu2??UOzoFC)#p+$hQa=y(_Vp^5sz1V-^qn9&7 zTD4L+oYL*d^QW46StZ4F!*PP&LvOApN>a8cnb{jI=3;F$0FBZ{{#C427l4*Gk} zs%SaDQ%m78Zdp95s52M>-^Mw77VR>z7{>);SlMv!XM=K(jpJt% z=CX;_{a1RMw}a3Szms0P>gqj|T_N>D;158Gcb-h9@V>3+PEcL@)L`TP8vMB? zg&Vpvzb0sE({z1YENrG5CRT|>{GVY<0L8&8CFeiGCgseI5DikS)#$S+j5%kf^gJ=% z@y%s7Fr{`7Zj$MsU**jF?SK#!Xmzx7_?P6REOL2OfOs&GWZ%IA*rB1NpmwzB|4pa9 zN+O7{x&)PT1eD9@RI>=Z!BmR=!yheuUxfs11MUN`kSwnPKeLTJJ))|AL_6|#f{I{- zI|vvlbkO?)#s7_P)b`-x(+FF_(v*tyNoI&+M-EoJv#pCnc_hZ^0o?wa(~`O|j`mHL zL2PYCA+lmuxD4PE{<~lm5t==){R;SmGjir%&BWet=G5$HHWOOa}2E@G|=n)h*0gK%~c<%SygsoVejbV;vLGgk>GA4!8RHK~0S zP{LficvAs?f9K+Y_rGOv##@!ulN2-OC@AfbIMz~d*YM7Ig5`N==%|qA3#7$AlpNrx zqlMkHwK3WtHfSk!_mfy~|28Yed)+si1abfQ3=`)6^OO+HmJaoB?ggYul?09@PYVx8EDe|^InVRmf$aeCdXjyl?C_=!e zyl$xIA!@+F<89+Yc2F}eI_e9aHaQZsSI|*ID!IRdvG%qr>b>4fSG?M1Td)cR`Xr1Fk*6Se1I#G3vN3>K4T$Gj( z=ngw^`F&9I|4rxf4_gszQUeiSWh)yX0*rRw+hZry`dDuRcLy?~xc#gcxIRvVKN_?R zTOq6po`RJX6?~MAGi{yX8oC{Z{(V_V${mb*@T+oa6emCLAS#81I7RTQBm~r9T*M{) zhfN5}OE0LwQMByx!i*b>mBR>?*-VRs@1L2lgm!th_%~@P@BQy|9NxD&3Dk50C$_Nz zaLYG>FTL&ITb5P*?75qf(<6&fN%u0k*RUo7zBJUstI%c?O1On1#XYLAy#3~+s zHuJ~pC$7Bv5AS3W90-$0HbsikOpUU3YWgoT(cKta1ZLjf-Ci0~$l%qHORSl2Jg2j= zhI~Z0CUXlM`jT|5SetZ@$1qY+7|=xY;E^_raL+M8@IdsG%sKm?n(qDW=ft7J`kT0p z^M+*O_c$!SX;svT_fWpiqO`Qc9_)-MppM^zyW2J%>UfTXc1Q*VSGV!5t3??-nRbs9 z5n_g7zay3xN@RdDfdkQ^+#g3UaVJ@oNtn|XZ*wSQbf-yW{%*qccR4DDu4iiJq4(U^ zJmD@xJknBM)7lu1ZqO5gjA%=BBx@6W+wJtb(f=2j8+{e1<06P+HK1Sn$`MGwVs z^*LBC?Y=z~xsk*Lg>x#5HxVa);$Up}aA4za65&;lMti}CcbULHdLWLMAIE=|HIekO zT0x$GN_t1}6(p>_T%&c|*gIaey?&{kUL!kcf{?cr=kZVcnz5L|Kog{WYNAHN`z7PH;ZMDC5OZH*U$cI#=%Okb@KW!91?I>=vEu`e;z zf$XV4qGULQw6QwNr?)wp6s_&}w*DrkUc5QLY#W!g5~Df6e-+Hbx5RWfX?|RI=&{ki z)%%fSfKogtzmReyJ=LOv*#@#a37}qao>^bn`sfKRq3sbaHuXZll9YXDV+wBl>NV_0jUA43Sui3i4eIQgik;*O*KTcoSu z36EQ4F^L%JzPjHaTzx<(qlZc-7n1lpWi`mC4)Ph~Dkatw72P4IQx#3IvF`|pt6_bD zhuAYkELvkYevy+K>4jWw9$So|Vlbz_KycFz(F?0{24%ik$9Q)8Dt$|f z-hw30F}_0gj%rj_4Y4{h#_}*LK3kJM*{d;sN9hA+zO%wvmRIt)wjXRgZnLbIf+nPY z+*dd#eap!%bPJ9ely-`P($0`A&;g4w1)e-lA%&{P->-eOPpi{HlE`jknNA67b9DL8 z$BAP@4p*|W8Org)F+Bi7E^8n0f5&cif?CK^8pA^F3xbiJSIFgx;r`!`J9rpprAtWWG) z99g`wtkDSMwR@?!L|id5wkzgd$J=#2UJ&^xs}S?r=U+aml}61`{$xdJak6UJAJ;c% zdYk@UP!(KK*OeDaH*ss5u%kZzdH9a_c;XAA9I9M~k1EcGgl!4ik{Gc$`4su98zLV* zsX0FbYR-p07+5r8>2Q|-qDAsY)PTyug9l5xPq=r7$tIOqnJt9$R=51-Q84Dgx#9n# z>#G8yjJkG732Bg$mhKKIk?!sikQ5vm=@J1!y1ToPZV-@e2I=mZp*zm2-}j&Y+?>0) znRo5I_TFnhd&RRDPB?YcD~cFyfIsb{wv%gLl;lPQjH|PKi?Wk2nuxW`;2C_C@XYfz z=shSk)eVU%Tv--Q1NgxhZXpXd{XHtjZ-@CQyIIza4*VZJXS)C4b1qw*ZxZIE7r7Zw z=*9n8@*n15=^I*kpa~Z*sYRz6TBX8haCAw($oIk?5ieG*-Kk(CPVC-FPH`>0mj<3S zp7u0@hqBL-oYevo7+ly7La#>=W5+Sh7aZMs+r=tL&y6Bao4QbDfS3CamSYy<5k25U zo)*5TLi%y|jYj?tgLEABzZn9c<&_4G_?B{F4PmJU4z zKKSP0K)-Hljm=rvUNxDbtUYQj%QpTEO~-D*BDenl1Ki4uBJyG9Kz+$L_9HlGfvJM>wO>(k{WDbt_}=DQ28vE5=3bzQ z^?+x^;9Dn?Y@N;aKOe{b5oK4c3N(w-#;!^P)7fbK+ehI+7qwr$Pt!zM96&zh{xnT2 zxUMn%r&(X!f116m>Ywyrvx(5+k5=v_m-h$PZ@aafY+kAPE>|Kc*b(}ai$J)vEj(X@ zpS?Tf%@>*6w`aumc?%FbWBz}Mor|oVlzw=?UD>DIZuRCrM|GB^-99NF|7V@K#9{7j zvDQvno#g4QvAtCI-^(F+p?kkOZK0@Tj1j}~zi{7Pg0A7*FxPS}-T3D_v=TJWYfiTaaA zX-4;>5?ja82-VnTyINWmU|z4WiU4oGMd5>?``?5zml%QwTDC7u~8qXm5oucZD`n)g#8+B_^SqNUU=#P62)_bl9i2A>_sG&tghVkSH*p; z=q43WEYB;TpDnbi0A{?`!LHSab=-UQnt>Z+g<| zJCfoP+{**h*696`@{Ku-Xh)PF_WE;4pF17Px!pK5jPJ%K;^oTM>&_k(SlQU=#mrwk z?nQ2FtL+$x7}Ig%feNi&g0LZ~hyF_!K2K{qB~x$(ktbJS(L4}ddRtPuZ(#FVaiL~d zZ0QS^w+?t?3*YeDD?4F6U8;pX73o?n)T?>TsY)qS`Wej`$DHE%=XbZWH8Ikx9;Znv zux#HZkK_IW$At>jr5OuH4nIlViQe9NoA^Ew8GtQtep}PBW&>l`49+&6pa`Fylcd$2 zIV`_`=z3&CU__uiG;}VMGN_9!X_GbL$nQf3#!F?s;y-Ejvgdh>+*SNqOOkIU^I=s8 zq7r?r)W6lQga+nr7ihLthTXFw!6H`@TW3CJ?I?F)Z>Rh8G^b71(A7ZYuS^IL4Y>-$ ze3~z2WjAzYttAif%l+kX3sXnt&0~gGF-){RMQ=3skrpl6HAH_>wFN~_4jaoh}eI50y z-^8+xSx{ZC%A=JzVPIWEk8kOr)C;^;-iiJ%s{os8{eFGJ6i9Q&vuM?(PL%d^b=6dw ztFfH{NB^God+Mc@tE&jU|G+1+J7SS~tgafu8!2fchXB~8hTcJR`0Pw@8d zK3Mimy1E;D;F`>CT}b=_=CU?m${^5A=15VLCEp$GF9NtrL)&w_Nvw$how+L8iO{d0MkO#P>$Un`$r_an;C@^38G zj-+G%M@cx}worUN9=>Vn-o!R}AV%A|lwNpJ_GurwhB_h^PQIc|TABuhk}?4*UGYuS z093j%lrYUZ8tTfB__Vmz_P~nICxQ()WR9eM_`C>*K4}}OW4&nxwn?ZkuuVMHANlb4 z%x9k@MeY5;%2Oww&jZ3!Q&SBNn+}p$(=$>5+N)nnN2Mo=pKxHNJq;7NDXC~YQ_+0> z1KzS%67-rpP_Mtsx#_F@cR4qQwB~qOzlAY0y!2#4En1e)ek}BQU`^XOb;Su-is;E` zcDpWz?B<%yL=$a-);!uY=U!zIUB0NFP^DbCPNWsgorTBI@{*R9O0V?rwDm}>xOV&V znR$mko^dMkrZ?}kx~3^WK7P<@w_K)rilG3*v{c@;nSY^uIcyRygR#h^Euo(Kf6YIj~!R+He(Oh8+#~Ecx*>Kseq; z9iftsntzv7ch6#J%B71>Suw?$P>9qfxz&kagkWh3Z_Wxn!slHEU`~qiaGEGF!4l^M z*Nb}j{g+2~K*p2gb6}bfRD5y^;|?1jQS!&IG?rl&cgNO!dL!=t9D8Nu@TeFtG3hVI zkZ^|`lvmFfF8vITAz}QS3s7u}2cQW}`SXg4&UW-GVR|jlDJ>cUoa}~z3+?+lD$jLP zHgQ1PjLQ+4A%4G&)+o|H(mVm!+;S=t_n?ft@Bx$ZU`da~Ms zKkM>P7o);>i9wLZA!k0t1DB`<<^ibJy)_1?JvNbx_Z8R)# zeD{wt&Z`RB@%+>_?Axyz*SSq7W3AX~&hzc}aP$RL_miPt3G5q^cj28HY73M^f0%hD;8P*)t08XvqFdM{-~I zHlDRFe`57)IncrajEv~LS`!gn?Y?AyQR$H+z)SCo8Y8!1c)HDy^sVC0v;Lgh=xjR* z2e5-#a&eV^&Q7v48W5AeqJnFnU*6w<|a?AlFK7MV&{{dw`WZ2KJ;djj= z>2OY~asB2;gKll|g(X|3+b7RelM|$E%wlh7F!XovT>M)2#<9l*qU!K2h+=IcYi4Fsb@q>T zYWU(yqP3glgOi7nk$s!$KqHcMz~*j zvL-C@MsjKjNHBv%M`!6_VNBT_%G3MiIN5!v1^R2WV+gu3%7<6(`W3U0N~-r%ynT)C zU-dMl#K0?0`^Hh=0|NB6K!EnbspE&A@NeAR^ut_=#V8E$W9BqH-Wn)rpxFdLoRjo$ z{_{rq&~(jft&t5uW3dj=f||u1_#dQlJgZo-9|7fYZW6xFYhg9O|M}jkPO3Vm=tNXx zl4?Hh1#JR1Reg37$ydYJ7MO!oE=%z+b(kFM(CC7+1NU>?GR4kB`rzQ6!=t1@-MSjs z(v@TAQ(-wLv6ea?skk@Mjx^rlX}y^1_SEFhIYpp6q8e+-t}QCdJ#_1Q#^vItsqE4Y z5n49K$lM-sdZE7=k5EPCPDFEib=JV(3_jgQ-D-hXP7>U$q6M6bJzl^;7@S!R7Xtc7 zvxrLzjSSN!b&1POz#YgWaWVfCUH;9eBcQy=#k1+~PNw?KqjRME7OUh*+%fH8qhhEX zq`YgUSUP+yL{tk&F_N^&$_RZZgT_3Fyel-#F?;VvmHS2Aoxr+STFd z;(5Az*57ttLh^RLde`=yscO}7bt`U%$b}jN`(@UH^QGU<*D1`xhVv0h1Wd-4r>-^& zm;r7N39O6P2ooPJ(E7xRpvdbYx}c)sVYAb(>8b4+_5z% z*#0I7p+>&OYWx6XBOG3)rM>#IJ7ZMf$_ruh&to$T!EIqA`~ zu{?c}!L!RS>rp%A)k`vkiJYblZQP944`lwDbi+dH41 z_my1@-9mP}RLMRFoooS4WR6_&)g#FU)o)gfCNWl5Qu_0VJPbsvjiCfqhHEoyqv3;t zR%06$4TIh8s@0xE_9*rn0F|q>U0@|P9}+*NRmV@Xl%AvT?h5QC1eZ1Tk-j@r)oLXx z?A;{~@#meZJLb2K7>1wQ_3f!j)^%YFh&RY$;4A0Dq1~0!dLP5Km-)ImuZJ^rid{8$ zQ^yi`NjYL)U~YwTm#Z2%@0fYZ1=a>j&b^T|xkZ|21IS+Kv2Nx}3kbU?l4jlG3P?zn zex!6Lm%M`y63ReJyjCs|sZgx;^gUZ3AJuIeEM75NseoejTXhr#S$F(+xlW=d=WuFI zZyjXKQ@EO+hvwjr)}G4R??p_wZIE;o^WFyKO^Iw=`x#o6N00kg6>`+dE;+Vb(a{`n zJW};POJ`^VREd51VxDVfLwyFDD%BV+#ek#OIQZLGYwD{+HfMXkRTRme{XmxF(TY|8 zxO>=k3oX1Y}lLqtivf+Q>k-*Xy$uo zw>#$ce9n{tPOpR8eI(DI$J?c(x-?HxjsDiruytxxXAemH}Q?~jD%8rE{b-d&xE_VeMG!)r_AKVB?^@7zoB8s5n@c@UzK`||VVR%XTs#P8@*_I<>S{KO>^fUt3*S(`^LYD_qldUS?lLSNGP zHhFWNAi+@6F^?a=RUuOsr9Ta5LIfpd!wy}sTd{9*UzQ%(cj_p`8eB;lcq>>BKd;_~ zPyr-ERb2a~(%5T{TInSSRY>1j0&VQ4&dr}6N^AY?(@l>qyDy9z79Di!4pew*C6Zjc zvsK_lIN9w`_Nf+p0-{1rzM@aocsuhRR1o=VM^kL&F( z8%cX2I>l!kk+9h{1cGE$k0MX5`9C2bqdq$(DfQf+hzH}cyXc*rDb|l}9eQ?|R%Z!J zL_05kF}iEx{9*Yj<(`;BqGpO%wBQskYzjMkw=o#(Tt;xz=jp@tQg^;?0Wc@uYj+x> z!5V^J*g}HAct!>( z=gf;M*GW_Qlo)gaevBY3zreemD>C>oV^E#rsm5D(>C9WlpwJvOA|D$On|ihz19X}2 zZVkcAPt`_?H3F`AR68!kGgc01{h9(bYi%T<^7r;S5mg$(U)K}pBd=X- zfz-u;YvZ&{48qn?Gt>Af-(RAspR39_mj^3>uM<}#PeLpa-a9lhBWdvFG7Oh?`da%C z;pZNkoBOLaG4A#|w^i}u2?43&HsQDsi&+9J8Rd-+vq(gx(m%V@XUw`J{xbaDx9|fA znT7XN%D4+G$>;+iZa|CO%~|3$$e^1c_Hig5jqX#qI+;q2BjDRn+LI4}jC@`1!~@IV z{o2Y?hklsOU_Lc4iBOu3ps>%zVq)~*w9T_FOQl1LH2_rF4QtMLB|o4)eD3olzq&0& zD_osHUc}A@$jSBdy|}W?vy$G&+M6Np%`OrQK4)`T$S#xUzkhUIIi`E;tM-FQG-fs; z*i$~!q4M|s3`An=v7(U>r%ap0!Wt<(s}QfFSgTYhDMunFO9HBm41NuM1gZ^_dV4;i zv1bNA8n7CYI9J*Zme@!scP;j@ zQ&YRz^4Zn3>rp&QwNKEVaSeGZxqad~U@G04w4XS|5q?7;Wl}Iy8V^C;!u>Ypei9>4 zYA~Hi(C%h?Hly))j@r_oC9s+UOD_Ox%n(TIWx`ueo{_A%^MP`7YxPU+m#x2cqJJT( z%Xc)nx5tNxY&048JP!89&Y!oe2arA~7&eWUAf?sxwHbY`DClx&dp+LYR8&m+e&^KF z)a}z$9`=Z`XcNP0D2MJD$RAYBIWNpK)(%g({#A07!AmnS>zZm|`6uF6*D5a@yW8I? zZN@*2zaywf$N85TLAHFCU8<{Se|8lc5?ILlMPp=m^yqA>ntPuGN6f}jidLR0rvnW= zT;cXRkjUXsn-1abqQ+?3@uPMcu~N<;l7BEuG}&d8Yj^8A*pCE9!xB2RBCG|($ff)E5qMwrGH^#WhFj5Yo6rA6>uz! z1b8j#Qg*!rd8~Txjj&+}7A+919}h5|d36^xT|KD97{H><3Rc{orwCHJe{1*dKX?V@ zeE(ylNCD?kPjt9*ulZ}%=!-Pq{_b|?v;;M&BQ`O0De)r@u9wH?R(^Ng|#4 z^HE=A^NN5i{RYIbqGn~WjQ-Q)U9wdWdZw>^GSx!khv?i4i5?0`I>7ajBN6P8H+mSI zAS;j`7fNvQmY7YHdpl9}1hD3>`Gs$od!+3`$NZ!3lGh99Kk&QiLyQv&5gU z3+gPsW$`A%)OnuP)9k5_&c{PC+!E4zRFtICddB-b`8A6Xz((UTKa$S=Vx#=R|HVe` zHQIn~@x01_4@=Q&@w;k7sS9Pq10QCJKhZ|fPi@t_6}jYCQOP-3EPeu7qwKoX+$Dcg z(7EIYq{oDX11QLb9}85}z0_lH5X<%7)74IXXbOC`_a3JHjF&NswEeAfm@6jqT$|q4 z)DmwMHh{ilY`o*IYVgec`<7tz{^sv}^U?kHUGh6tsYgXebkZw)%TNBjA6JmmsA zf`##SevF~WQ+~3_tF?;CTkA;!Y)8b?!I5c@W?I17WRcK|CrAFV0?>?7Z~B&=SsM#A z@@Bv#hw=8Siu)8Ei5lE_$@wlMb1Y!kG|H#p0Ju4vszlkL4%x)&1j=9A2qp(hQf(sB z@~J#H?SP>N`J@3F;iW&}ceRV^5zf%$IS}RpR4t@~>is3V^r^70F36tJ8X(AbJZuJc zA?3OQUnW-G4?io9-f+&CEClpSME?)ML?iP|>2b=Q9)IWota|^s)Fnrcr_zo6ejC}A zi{P5&;mRFYTZy2xAqvHRCC!YZUj6)Zt&UL!mb;Q;F z`i#Pce}J3VKKm3oK*HI6bqME@qh7=+ujKioWLojSCC8NZAt8L;!g&i*55OJ}wfO1- z`By`;4p@=W#JU*^*?gXo{xkQl1A^}RFRT(Zw{YYyH_%??;O0Eh2_pWu3qSiQAfq}+ z^s`_%i16OKRhlaapOu0{5EfJ^b5i>6(*KMU4IKFmm_rK^I?mGuYcdn8?-|3Yxz}uH zMCj0T@i#N)HJ3inzkm`~?zMKmr&5Bp$h61+G!))aWg!w(r|%-KjJz*s?UgSmm4|=j{CGagds6zT_{H~fvkvL6kre& z&zzB>1y59(sRdsP9aqQ!l6xlYQHOv)EbVn>;(^cus4?+1slAHY)AW%DdYP{e&|Cm@ zl6u4xfh+qg`CZyB@Xq=}sTw`+852tIS-6>7A`$}J6-B9U7kD*M(*ME*HSfE#=EaJtZ@Ps< z&IrCHsRkg-Z}$@`0K!PPhs~yWaQBe{rJO9=it1-Sw-3*Hjr!g3^UYry6%YcjGzE)A zshusgL?5@cPoI0HlMZM{!BOS95PV|K7ggEt>cf2s7hoWYFlpcYu)s%)ART-cMSm&f zIiD>?vKGs!?f&0;RrngR)ulxKkX#!43?N>2b4$`^I>8@krH>EEKp1=0_u10xg}>23 z&8Oi%pU8x>C8?XD8Ss&oW(8kpSn);0hFScupi->&$x}K;^!AZW(E5Yh|CIIF*LmkZ zW*%sgAb<}Hc?G(v1Po&T$KNIiJosOiVuX)`dFoHJU+5pyK!#F*Z)cgwK}L&r0lY;5 zN|z(9ekWnB!WRXYhvQP`8tmQEM^z2WXZ-&h+AUCYdpZCIa3;u@jRDIhK_*(sQy~gp z%uDsw%O7qEz?D`;|oktbh^4bxmIVSm@i`DpX}QZ7p0XUM!=H z=crAX2iNsRi{8?B@C4`_?sReJ>1{GyzNaQvE#T%G6KsZdum!z68HA2J-vmJ2OJ?3Y{Icb^wvl7Zr~|9Pk?9W`5BLE>S46S=Sxa$zj@1@g`w#{r-AlSF>*_VM{o>!k}mLoZY7yB%%K`ddkhgdJWci zlxUx>x@1M)+g9!<8ZoWEzhd@H{N)7=N75kOG0?>C1idl@30(#|5=zS&QVw!n^ZMSJ zFL;S~s;A1Se$^iS7B9hf4+tBdYg@ zTJ+=Tr@OuA^8hD}WW~LqI^cBhM}muA{k@f!TLr%3@6fEC^(%W;WcFJStrpV-Y;0RW zmXVx4kG@G`yA|EYz6KHC`rE;x*O`q1a^jwqGCXL4ODRmor`zQi1B#iu)1N!g9X|-n zAuO+yeNTZn$Vy{=OCcYRO1p%V=r0WaaIT6vw|8eduZ_H1Uz!l3L#;;^U;na-~K zIjLT<+ngH9b19qdbSW9Ft2L#hLh_=J^+<|Hz)T@|IOgS9P2nsHSMO#Hz^zxL(0P&) zoi%;0BOgCvr`I;u3iH-eSFbQ$d5JmQF;-lHj62kh2V4328qkJd# zJpFl}%iOk!C?Mi!Rz*LsZdKsQtlmdYyy|*tV#4|6eDJs6^4cdmn%p%HT*gSTH>Be) zl3n)M85W^l_^hnHF1J;F>%1)t3Ip!a%JuRX4lZxWHGV@r$N@>4_=l@#f1SLaKG)eN zq4x|IJmq5z$%mFjs@p<0)TC>3ceUCfCHt7~II*o|$L`#L`5Ve6zuk4TiS;} z^^AWlTL%+$j@a2x%oNKAG5bnf+xvoh39YK)3jB~ed}f%h%${8E5uY=zNdQi+48Gt$5(j29=`pPa%|)q6Fgy>(W9FIY#U|uX`!= zctKItBKNWSqY^;Q?c)~2dVp1Pe zz-=&#$*Z&*t4tdy4u!9s8kBxRCa7-O`K9IN9%n3f#8wbFoPem7!cyAS!mgY zCCs9q6wgBloVP`+D`mjdo`0O3cCKPkBV|}nU$^dgFPo|{p8EZaUQSx5*^F&?WhMR5 z@(--6aNFy#E4GrPW3}=rpni0Hl)gm34HT6lmf_8_=Q|r(>G{R0xXzz+_9#=!s^nV0 zE=?{a--N>|+^a(``0o0CZz6rC)9Ij{&+1Xi^ADnz1R<&&Hd6)QvjD1^=e_rK+h=n0 zvfcg2kS`NJ@jzuh2p{OwaJhP=e9=lX8(I(A^}V-Z@9osc`=C-H4*3oC;%%I&o*1zz z?S)!gIP2?vtS+Wy-^_EFYGWgC5(%G%-zV3wB8TI&O?8C>EIWCC$>{dbly9Jk$48Ik zes8pn6$`hDtBCiF1N&ZarPED)V%B(euF;cZ8eT|`kQvb+v4KX}6P0-&46%>vT{)c=baf2)zkUxO??${>!ohAisIs8tKa5!T%c2l0uns;hwWrbcBy@*TA zCNX?U?Y`w@+x^1oDJ}X=$BL7#TwmB3^-DhlE{|bE>?PEl?6OC*ro=90tn!^A15Wz% zk3J{j>RA4Jo(6G>D1bxwken=qYJl)^l|&fEi#q#~fTn_H3;+?k;p5yPpJd&(QT9ArF3qGv&WTKhdbHOqz&sBnZed_6Do(fg=G>eo; z&nb$O2|k5;g7WFTm~eOdNche>)p@Y(1Itb0m(8e~aRWU?;CJWZ8B@T*6{DOmP&XiQ zupJP2-i;*?bldh>%KvOC>-Z_V{Lw-o7a@0EEb~5|M$n@Md(gK3?^&bjfks34_cHqeb)IQ?rW`M_$;W(OPPIB- z-Ypz|bu2R^^<9QhB2Vk8}+lF3g6Ic!-ckGzE$Q>Y( zk>vqd=Gdt5ljkZn%`kI*#dBIQwrE{pgkgGv!4mSoP-TMtR@gE^g7RBrach7Q`;g#n zd{U&wr5cBooxDQ6$z$qec-Z6l&}%0~)hKQ~i)P*G`sDG0&4LF}nEa`$5XL6>o{ z-T4I}_dC&fVi8JGs8?#I%ws)u>)la*#L@jVY`bq92z4vtd*_XQ0uNYQ4(uyC16r&l z7s;oRX|i8^bF^!G@uAYN6ixMt!JDO}jPKLr@S+()4g2Yu5jDuP zBU&f#1&=cplGMt5qbcV@-HaE%)c<*`w3<1Pz3YF3gnC3IS9dU2162G-zVPinZl1OK zO_B}KhnS|6+p0!!m+uC?UasPS47Z;l_CjeB3KzPKs zvEwWN^5JSmCEf~h4}Q6j}4oj7E1pT=z#XuDNzf%2D?f3_mv5U|sSzB8Y2XN?&T zvmM`u)vG;@g*P~n7>jw@%dfl8ha7gNSu42tn^rXa;)`=EXqD`l244A@TJm^F+|JY= zfe1`%@Ybt_=x>MAf1mjn^d?gLBRoCL+?Xaf^Ygp@RR}A6i$D=6sw?Odi=8^sh2#8u z&~+e1YuQ)9rYQc^ry!&W;E zS_f?OAO^t|#gN605_3{=d!ap^WR`$AP9Hbo?snFnpbVdVo?fP~H8cXK#0ALe*>z?s z!VWi#Dx}x?4Z?CjYGg#I>wBp_2YTtU*K;%a45l&@1#09e`%0x)?I57zLE>MTTHuIj zt!zeyB?W?v9eow{kAR0wtEscta6yc;EcAD+Cj(E3CiNHP%b&kTymXC24uevBN-ea? z0AHpC`7b~&K*+B~&dZY53i$XBeZh9Pjl1R<^mK~k?qodHY^opceN%%D4^s)s5W6y% z<{sH9{;p?l?BRUWSo)B2owUcmm+>K{OCZkVhC;*)Om*%*Q&sC2wUVB8m@bc+W16ug z&(~P#a|QGYG&~4qw$lNaCST0ufz;S~Ngt+_5(*+gjt4az5Xrb0m1(+Wf{(?EB$??ptYxgvs;CV zrxJ3p)dvxgBA|Lu>-s7maJ*|_@5!>=`OVUlxT)6Aa!iZ-3e~vf^tiXUnaIm;MXwDk z9ZOhv8qfrVf1>3&OR!NfOlJbokJLf$twsg&lhXhUn&HkF7L)>>00@Ly#KmA9Q{^*@ zQn#veXZVTq)x95=fJOGfs(kr2SwC%nj$uPNMJk=@)hY$OdORzIsTx+EGTgB>I#ARO z2Tgw;k<%&Eb7)-S63W&&@Q&nxXSbvZ;ll@d9^{&?N8q(iDz68>usHOEM?cAJ?F}-~ z#b9l09|sx-@-7U&!{3Ov?>RTDkM6lZ9yop=!QdXqTK`6Za`MI%$_Ny-B&oBjYS z`aS#^f9m$r*&=F^ngrR0MKHNSrzE&8!2RmR$c^3fR_KQ7i`;>g)xdeF394*B1EQj= zM`HNHraMe%OII-nhA0+vcCRq)B|pvslk<}x;8EX}@7;0a({vZ$Kn=CT&##;BGqa7W zA)WUUrklFO{nRH!7tyI%hiZt=r4kZWPeb-8*#G?XoVMOeBZH!fO944AMWZ)pEb|6! zh<~+9SYoSB5NQQDi0L&z8GHlC`t)B}U`6Y2A3-h_joaiqvuJ0*`M+}`i~7&pB5?oB zEu!|gjd-Mn4rePPna(8uvb563742^#&UgP3GjhxJI(5{6y+_9vbrp~JA?aScY>WG@ zY3FKU$I4!qiORgQ2NlN-MEH7U%ymCh#+ew^1ky+eUgKwYU|dVqZt#1{zN&Q=C4QWx z3*4J#J+~2de0Eyd%%+C?dnBqB(=TTzNX=i1AmA-g$pk~-JpVrI>T%mM=q!7YSmHn0 zZ2PSA7bryb+B=3DSmpcVHImq7>`x{}C2&os=fh_KG0d#%#|TTkYCU67T`MogtUco) z@+Rt^m94!lA0RwiLX3{K<1QUBLK8n+?Z03tnaPMm|0&IyK%HP127fk@B#>9o`SJ;y zNyOuXAK>+!cszGr4aZ;*Inz%{5)q$s(Zo2S({8QD(g=iZfTYlN;9Wt_G z1FYHtOHu-z$0-NGwpUeSjkaz8R)w$CI}}USvA`-KfaN_l3Ue}$auju+H96YF)up@i ztidp;2Yvi^q8qRi_pw%GaPkpb{Y}P&V{^5QM>TF$`iuKX&?lIz-{f1>^w1r8Vx0{I z@2!qY&)S6TZDd4PuC?fW?>>(Te@NY3H=4yyK6SyG)OHKm^9qfnp17nT6al|XJztg^ z{I>V*+>&DgO}t6Uo3YYTk_+m{uIe(G;KSGk4qHNH!Kz{I9cv# zMm2X8xth|qdO0%T?d`<$(}G_m3Gk#2el8k+xUqDzus z`vCbenCpi?1=Y76{yX39TI&H9wY2GsJuhmPtk(w%CuFGn0LQ4n!{*hY<<-p6At+SY z!selrB>6~4Og-xgW$n$2i`^K2RIi*SY|3d_oN_NSY^6Dan|XT689SdQ>~f>I3HPti zFM@B({|L||nX#F3P1Lueb_Vr(z#M=Cm#ywW>j5V<@9B&!Kxh;o)RC;Ye^jT&<|tD+ zv6}6tG%mv%7Cn_vf-GS@Qi;f@y{CUWT4Z8@)r^iv8O^)!o3H$<<_Zg~EblKw>SCTJ z%S+%eQp{74jOyCsd(x5asQO(*jV}Om&FGkm?}-+W+>27VycBAs5MtZqppuaGh@G-c0PxI6GzF93{o0>|WCxwA{DLmg?|d!ja_|zQ zmZ-pP?J$ljnZjx9YoQ(KRII}=BIX>EVkes~dvH$Js@ea)!S|`qODBEc4GoI@URwdY zp*4p~utX<0xgaTW#JYTl<`?yOB$$!*l!Raq(Y0yP{ak6;iT&xh^QEkBqH1=sGiRp( zWmLoxNsAz zd*^`(dPGx}c%r>OPuu~;8R8WfC?4(<%`A0@%^nl|C{VdRIH(L>k)y2nuA{61+p>QW zXy&u``+F8Vh*I#?kVgF=EFr_t78`RiiUJ|ToxmdW3Qqnl@Lu?7Egj3(&l+kq!H!x_ zzFPAQ!pV=ZWX3Jo*w>^r;ZE?m-+kWN`vZfqF>0x+o}L(j*_yFtq~)u|qaXTK_Sfuk zwzOvB?j0$ZOM#%OR3A@c2TFc%X^;B;$J5)5Pp%D15XyPO+sUi7{c-$1SX-{yj6!W} z+ES^B7c@yT)FIF-epLbsMGqKnrUz*-EJymSV!afO5rb$pa=)9$1Vbcdzndu{qmLvm zIGE(!dCGMQ#iAO6ch0g|<|c7~W|xBrkf%{~glS-9bX}$RcPwteSiph)P~K7#mySgN z$tw>YyU}sYKj;=S2l0hg!q)5xvAY+pcLxCI@vdgDpO`whfcxw9`L^UpR4>A|lxe0N z8Ly*SHJ>J{TQc}1hb9SitFu#eApmu&$0ys9^^TZG!hg+*HL;I4)RN8P{?fg{&){?3 z5+wQ1(a66n)ah4&{HpJqYkA<79|iJ-mn1lJ?9A-3c~w?i{JCZML88i4f>b6)AchkK zcvYTkOl^Y|yUZfWvBih^`@H|4Nr4D2p?<0({d1-}rr-#P*Bp9&cg<;&9X(PctAyiB zM-ZeT@>ffe3ZNW+PFGM)bS?RoxAj^3%#BlI_ODYV0_0CkdRktn5*Qap#0{Z;-`v#i zDr~WxycyuTN|Qp-uLfF3e3jkWZu!y(5l@nmm%-K(%-E2ES!+iENDqJbkF^kXcMko{a=% zHz9N@rb-E0#*bmmFRxCaBxCkxzuO9mV!wKF)-0KDbMYc@wB^GBciS>w!>{x6G)+l(!I}Kqo&wV83ntD0u=fo&AEZ9=*<1KffbX?hb5=ct?*%bNru4nP- z7B;&2N1oVBe#035Z^EM<5~X+r?ljOUV`AaO@X5#EYE7cfh7y0&-Py6Nyftwo{`Ujz z>=0pz=kD+IJ~lN%xzplsuM5?m*C9|oU^h`-n48_9sM%{Ti3fnNrLQ4@GaY?W2W$78 zF*C1)GO(CBf;+H@#Z=-|u~$<8r$(46wm$PTjc$3RJ2gEe#qy6H&iOj)lgsDc>sOZ; zJr7-;Mpxe7x(P?THk@{ALWB8Ad_DADI=(NoKDowtgPEU2onuWL9&$i(vDfT-yScLu z{&t!PrdNc(vI+FwC(#4XuGuCJ?0n)SGjC)CV?bfF$UsqZYPd_W{OhNAmo*wLVb{bKxA*q3i_mUu|9D`g2GA zIpI(T;uq*K`x_X2k=NlAvx$E?xv>y${B813II$5idGgY2;PQ^>j>D_KZ^EAXs%|a| zqNo=chG)dO4h~X)Ya4+OA@XKK?e)4CJ~GO(Mx^prm5C-NxN7nR4V`Qr|%i z%seY7@{+sS{l(GPUkAS` zcvs2@;H_}#09{+=R>njoxAe(^)t`!{BJ6g=41gIlV=c$XAiDVrbHq#r{Uw2PS0lOx zV>cyFU0OZbKHj$qyfbyJKHGe{z4oux8HCYBpZBjgtTa(1uMvV-H?{bOZ)$w=j3D!y z$(F-I%KnRz=sV>0ZH$t<3D@HjfEU+@yU$Ahk5WfWJ;zV|WYRqE6gTzbR8ANKEDZ_g zq#Umvx$`q7Y)mNjaXZA;hv&+^Wvk)^YjaX|N52GWA*z!n%}prnLOdPcWM3QJ#!0J= z%o(iy2Kqrg8Ak8@QT1(>9a$Amj1ZiG?DA{7`x)LcdJ|9k&rxV}Lq7~iM{6Kn!3`M7 z5QARJ?Rm!0OUumC9h)n4L(SR&Qb>fhrfb3m1_WKabh&x1HEtY>kum&x_TT73CT`ErKFaZx1c4Ui+zYg zlJt-8ee!YEkvl7W!sZGFMZJT%ALERcBRpeeEUoArf%=m+dQgxrGM<4SkZEv(`FZns~*y)0-pLZ#nZRio**#^V^No&_Y~Vzcl^6@f3jS!-R=- zft(6mbyz_LaA(DOl1!Y{F({!8rU28w33Q$@OTq|lzfE~(3r5xbR4 zw)Q+w8#tlFIfN%Ge%FV32-HN(0yPn8DBrq5L*42>I$d+M`nq`79QYx$ee}e9>_6Ku zGbP8GlY9hGT-8&a`dxn}gW>Pk2yDf1CQU_{0g7rDPEl63vN@sX)*D8(upIzggnw*F z@*fm;gw5C-g0wol^%Mau-9Q~Aq%ptWP>cr+-xF$4%)%JVZ#QY>yDg*Q`b-RU(~hui z#}W0^0>7cH1%8c!QO$mXy*mV#%kB2g09{=9*~=h)O@DaZXXehB3_!Z~i#K4$%znIG zqO&Q}$W5QJ1pDMhf{IZ=Ap;OLrV~~c@;}B%wyl4GBTlyXU-cqG!>p=`JM}03!k+}a z`S)|U6#ZGDC+ih2zRGe4Q;DE9(fF*n4I_dPEsi9r2YCN6G(bJU0sU*o`!!a zmcfvCE(Sx?MNj;b{oNmH6~!?R0rSl|BDfgq29UmfR2WIr{0!&q7AUM}nIFmSn9Z!) zRc&r9)Dj7tB(>F^WOQ@;&^vga(u^|KC04Hqh1d)QEv9;)|Aw0)dz6$wg=Lp)sUh~2 zce)Pl3!MADR2|Q?pTpAo>hbL%G1(u^d1_6kv=^$I;!|rW1s4JO$mGd7pqRAZuS2T? zw0*vzHUVBU?QHiWTKOD3XR_j-@_yg7_x=w!7*4vXtGl}DS?gXUa4XXci5Gto zrJZ-mNM_Ab#=b2SK{>k|`6dn#_=|VDTnuc2Cdd5x2^SLxqw0jIJAEBGwKs!j*~krm zDR?s&OiFG5q?tcJvVMRrk^ag){WuNiWy%}aQ7{*RH`?zxg*|4w>{r#z}h5P#haAd_Mh-YD<#oDj}w9!b?B=M6bnD?;I5^I8SW`g{e zgo8t4?%L=m~~IBijhx-#zvvoK~<3_6l^NR@+pgCGY>BD+b!0 z^16GttV;SlCk{!INfNf?&qjH@oV&* z<*#_Q`Hjz)RQ`7YVF_6_ae#R5K+bLN_6cY@j)Oy2(7S~!gjc#X>7NvIPy}Se7%f*0 z{j*gQ)>VDyc_fbr`D|){fLY&QupFKd>?PWoO-+k^!d4)i&$eUVmt+5StqZs7tv9~G zxuq9q?KxIwQ!^_cBP+hld=5G9gQdOYHDt~rwe&;20E>sEx82Jpf*B5hlPkm__nGLl zj{(8ec)udIdjjk$UOudwf(rXk$WaVuI1i4fdd{z;{b0Ju56{r`as>0w!jLR5UWg8P z8?<~Y@FdT_|pS-xI8 z%N`bI^nZ26wP{Q`Ji?BUzx!#BvvjPubk!$RG%6cv*MyLxK8pAxdJCDRGKlT5YHMh2 ziawj`ommJ!D_>%O&}*rW6ZQes>q$3<@m%rgHzSYEHb9}!Et=_Iiu-b)<3JFl6q(Kz zDCN#~N(0g7T~_vV3|5L=`wr^b%i!^|Dvs_u-egI*W8J^qDVpWGpUS4w7GxolcZ8OK zA$XH(QNM*g4JK=E-~DpSeRJ#^Gt|>IxxJsPjhM&KPlWc!U+cC^i)mn08}iXpT>Z_O zDuTwHN;zl<56I4bT;|Z3Ob>fpv#HOuuYDWHA59e-`TagqN<6FkYw14v98*Bslpzm^ zRSWRt6{*CY;yP!DC?H4S@!wFAK_FxGek&c{I=ZZ&Tkz8!H*y&c+YC#LyK zQEITo`dA3#7l2X;Fm^Y`^*TTlv`;JUHb0HQuVH0$@dyhui*LW1e!H!37lMt-_jJ5AK*wnzkgAh`I+4^J0xVfrtF{0(*T z9$0=RJrm{mww?|d79i5R%UM|pK>boaTA9qVW0-XePc1!f_i>P24#x|>?%!*2vYu-? z7In#w$OvGil3%fA8Ae&0&37L-77*?$veEHJnrwEKi<`WoS+TX5QGHS{Iih zCJfrd89~a_v%7Z-IS}_@U{_&0hh{ECYdqIMYt6XuE+I~!!GPgT_%LO(Qm_>H?iB*& z9S|C^3vIR+GlUwy|7gUZIhQi6`>6@#4o)=z;l22-`}GQt^Lhb%ZDMLk_q&cuOid<}5SKEM>M7Hq#z*DW4$H~vB zr<7IM^{ZolZhmJ4m^Uqs&5HnGg&j(0C3aGiPERLNk}mH!2C#X;-IDqVV=@(%6RA2Y<%n`VT;aX7hjaiThjMwo;@+ zGF;aPE*nQ?`DxCNHGe}5qCbIfXm(%Mzhuj%83M9fG-cG7t?fC01D-aGzG6$f5()kH8e z0hX5O-m}2clECrU)=aDtXg) zyl?)W?t0oC?Y?w(-t&ZuDTEB46+k{Sc^g#6*ro={LL|!pIrZlCd!WV_IpOv>FUW4Z z_>+k$5K*cI^la?tNL_3wVw8BeJoRF!M9N|z>%r4IGlwfuU%f5MnWiG$FzguqX8X+; znyKvQ(Z9Y$*kz05dY5z^2pIK`xry5`0fJKQ0^np_VRa z8{EQ6sO?e_Al!;$|2?ed&;>+lkEI|H64blkuilbI;NWmvejw9UB>zR>d((`{Av0h% zS^lOOr^d=!xJ*PC;HSVKvq_w#<$9&bGNh$7n>=J_9&Zs`Y+X66UaHX*$qi4}-b5SrD0rxZA7k4gHi*axOHN_!ke*Q92uTgXI z>$lej3JU=9!}NUYtVYbV&f0#5LtjFs4Q*uAWy0Ia1WU}AArS+=T;h*6_GqqGs z3wylDw~#(?)mKg1SBbn^Dii~AJQVH@*_=LHD7M)}HYAStyT~LLW7p_}DM#pj&pW;P z9^~=}mmP;r0(rf+T+9WOdHtS@lkoYBK4#PL;ZOF+$PWepD}-~RuGBMKJxo7;-Q!~T zCxncNkj?DRSbe~BND1ZTNytv((WmxQ=NZX*lS62V#f7IPNzy)m%pN6aM`k4Ngu{Xp zpXZgaLD{xc5qnUUHD36qL2|2%qQMKuLmyG z>xW|7n+z$ul*+9rQQe0Lt?3#N(VPCCA~OqX^}78Pd)!To;`_7L*cT?bT9wJ(op_uY z?q{ix-mG?OsmG-!@3j`rA)Af~C&$Z~?#qR=?rday*bT~wf8FD6i@TLbc19{qM$!7!y~u;oCRaRrracnFTzETk+kIaP zWiRi)zy}u5;UqHmA8vOLd+>uY#HONWKj*2y{rhgX ze!qW|JSwu@L z0n#NJz;*$II0wfkD1B(a1gYxI@Im-+W#D=7`~czWbv~>g+cN`$m`1iU9Z)epr?ai{1kk)5NL(aJd<&BXjR z0oY%z;7Puz;Fj(o`~AFpMH~oj#BH@I`haB4D0jC#PFdEY0AT@Q5~Z@9DT#%{?uv!F zN>IT&eN#@XEt_|&@Ug` zkUYmdLFDaAJXVoGxDV-Q+kqcm@(}~~Lp)pQqdggWZqh2pxb{9u&yftPc!~4?!q5e} z-4u+}<)@I|7MvW(terCY4L&6fcp1rsPf}hO3!fs;M7``IKY1l%?saOZPC&#yqaET# z)#lTLf4Ly185G-jb~j+O_m3gpQ)yirjJgo&`gS4IA9W$w6?Y+2Pwflx#9C@;@RrE+ zEg`bKWpLzBRx0La7v*h`!9IFbv#W*_2WZ4X&0*%2fWHu%@!2TsD$${ig9T;2gUV_w z#<(+^xHaP4(eBnO3t;(a0p-=4Xczx;S7&s{XMtbF_9??2vocdexOw^e*DyE3(pq8O zlbMtp;(M)(QS?t0Ph4RNAA$hY(M zC?Fuw#?N)VMPGfbWz2L)m3E<%n@K`yL`OVr{Y7a)mf8;-pe;f48`)0jhbn{rhCy&cJtm`iH+2p5#Tp?qzyO zHDB--&(_+Z?`Q2<<|3YklWci>n74svojdBao^;Ql2#=SArF$zSl@M{gk3y}uoC#F+ z7>Bo9=gvQF?{t2pK(mZ1zl06)Vny7B_6|hd;V%6B$!y>s?zOEWIAgG?V=m-yl1UZ> zK!ixk?%f4O#9@{xy`=VY1|g^&&lKLHv7~thS;=Xscpsg&9?vHx?ELu{+AC-s?`EFQ z#JE@%pNLSp13!$JasxuLmOKD;9;ST8(y=3@I0s2|>iDOEZB8rhR55Dg`KHkYn#db6VJ27^J5axA^*E5d(@>tgf$nS#PB>0o2M`t&=1}xp@`3Q(wq+CDkgrk1#O$!$8Wc+P+(ZOSjqc-_`uRQLo zgMGiBeLr=DHQ`|gq&MCn363xT=E@IunG5VL;RCu{_F@lN`LQr|;tA1i0pFBJjmV6a zCEkUF?tZu^Y;3&)?{4qgod)xQ&kr-}w{B^hbgB-A&JH|4%t~LtX-B5?w9-!a-+(rd zb9p!@om=>kd3-zo`!);y$qSk`hXMZ#TTYF=eZq-}`pW;&@~=PHZb78x>Dit6lFOJV!ISMm zCis@oJjtTGSF}~HP*TngGkl^oF?5# zKwCCMOs4n3OFi{y?@D#If`c#gQIDvR><8S?Jgy2;R?#ZLK$PQ$NMjN5*#*kTRBUpt zbSaLbG}DRpOBON4d(&jsyjHUY8GG)x18dx7c0K@H#< zkL}OtQ-7Yd2!ktK1ASc>_#f~19PI7Um&{`STsMi$Aqshy1#*QS?JL{b9{Ta;XTXZ& z9z975(}b4^n(=Svo7%T87e^2)R&kQ$G(676Ml!60Yu*36z#9>7F$n*|W_Pt0dY- z{WE7#3yJ1HwNm11m0qX!eHGd4ny|BvI?49tK1deo!M2YY@J-6VkiuvYpNypt0uxs6 z+X1Qs3C0dEO>GzMCXZDFbk`_}HwP7;UGqXwSvWozkiK_ASQY-R_bROV5aq$yZP^l2 zPuOi277)K>of5D? z+&H@5Kb0ylQ}Ngsl6Ml~SORSoFxFB3FHJu4q^EYjQKrE-T5gX72!y4hY1@NMD28gS z)&;`~GB*c(XG2Z78Ygf$-kxnWZ8^<|zC~LJymH408n-}Tov1YsWue~F%6I*V$FJfl zwz;Q-149>bdwX?vbT3v}yh~!5n-6V59*&Q%D0kw?zaT^3)&nw4gFOlXeg54Q*&O{& z3t#!E65g$8VmLTPi5C+ChbiLokx+%($il|c0fu@dsdPE}vyeN@GP=PhFDYxKs0EyCSt^$^@^=OTFw{@LNE?yCVE&jel)G&MF{t9^Wlyf~j(c_6K{h ztLX6?i0WOp{FuGRedw5X)LpcL-&z?Ie^_*uMXP^2zVU((4Y^H&a4$@iNh)r{6?|RU zyX%7T%N~Y9qSJU+=&yxUzYwgd{VVL7z!!Ajhxmi2X@VE4#aZ$=I<eT;4e=C%ODX$g&XxH*B< zZvWW*=Q0_Kq1_D6g8nHxOvVISa`$aOlMZk{*~$HA%8js*m3A&~%4Ixa-e|~YVkti* zF-QZlBhClJ)*PVVC+uerX7p0Ry6tRqt%c}tqT1NWdg>W=WIn7Ex-Jaqd6C{6&t%mP zEmm>f>y6}&u9St)X1D3*>vLl4RVFw1IfhQ3z#-%zii@l$H{4OX@4v|%m|o zjydP?&jiJJg6_VLV{zR$2}jvVtY#GetG`{O8cM0Ovt8XiM9EslISda#8nhvkf$2Ae zyGl!Sm6#aI1N_^Xh-w!Ch4{w( zcZe<-$5n#`gI4;?EI_YsbEr|bkQ{}DiTX6;QG8u_I zcr>XiM6B9^ z^eftYD;jwBQPcv%ykY3>+X6ihk+kDT-al*frO>mMlv0FJ(dzlp9lmz5kS{5t2KE|L z%`PwuYY~m|xYVnQU)se`gUDNweVn)(&mC0RCcu=}Nk2c5yJXX$JO^`mZlK%R5S5w5 z(Yz&ciCGRFJDQ3NeRzKUqotc@DSqykyT~t`u@x1b&hAwQ!d>RQ@dnO?g^DD04iz~y zSoVKS!TeZQX?58T{PL9bjlZnA%hkkK_HOnbql@$)9bQViTx!+QbT%bP{?!td-NH2d z*IP_$%{R;m3_Ru6;%@p3&_JrOnClqhyw1BUQ~au|DPo~OUYMk=mTcaD@c70&J_S~J zzdyDZw8R0y6Zl=TZZPB}n_m;BIORf#PJm3a13~HV@~E@BapC~b41Twl3(Rto{snp- zI$8QJPNsXod!$%TD!bZO>^$kRmYzBl-~qBa1k9C{Y7 zH@olx-@z%9q|XJM?aCn}0?YD5sJH8RdwqAJIf47nYEtuRXku%0&6itD1V>;%x6vpE zSt{{syZBDY!+7ff5p^wXO6?ma6eij;XZ`+P%Ha$9N-PNQZgT&IMM3?@+g7e!SI+f1ZF5 z2q46>cz3!a^d}wa#UcZNE43fGc0U*yqIs&UweP%HPAF6oR8n{2V-n^08g7M7TjcK0 z3KTLY5gl5$Rmm4AW>|kHhKIh!A%{xjT(!h80V`Mx%3(xckSI@3Q z??bU0eYr>mvMi* z@`5P<*h223S7=}S{Hs^@qy^M{UY`s{q!8^S|FVFzeL5+KsuNSkKDlC^2Hq|Y?|XBl zG;$Bn`N+2Kvkl2)0*z*7)vVvad%x4KjllZP)@015_1-1yX-kX>5p$|dzl+{W>+x9o zs0#p4Ig0SD*lqJ>m{+>qAnkFmz~$t{hJ9mq!1Y@xusQVt+t4eQUahEMjEUs=Sm<|b z?0lM6Kg&Xwxt&-op09MrxO{$S@GCR@@@RJL6SaJO)muiY%5P}Oq(y{|!n+@8}4PR2G>a_b|T!e1NCCj00y{ z%87Xsf*~vQ;Yz&l7;Ov@pRcq6GloX#j7IryQf!19)UHQ4=eC72A}$B8@f$m>9vs7J za~BW2I`Sq>?7L(MM;FyVH4vjsj{NEkUkY)+0jWI!&pPg=x zFE1ara%Wz%4}R<)fp&eh!QDRl4(p8gk-)>Gd9caL)(F<0o%w5k?hQat?JtIG<3{}u0qj<6*E-<+{`uI%a-uvkU|^V+Ig)!$t4iGT&( z>+OthD93!mk;?g#c8J_+!AY;dAXMPeaA5F9;L@<}TnaYJ*InC22j4iDA{~Ajk@l44 z@27~bmDIr6DN0NtEqbA$I>04opfC0kS|Zr3;uF!zpFz@ewH_9n{C#xoz+?AT-WJpg zm2Rgs5UL_8nSt+t;fMaiTHaDrwfmQY)I*I0F(fg`@z@}nH<_|qbM^^$WwYj9% z&7h^XKx3N0w{L;QcypawFLSnS3qJ-84a9dFb!29s9Y)l^Ucvmb3H*jI8|W>M=(g$k z8yMX`U+FU^Ul`2f3x59*Hbsn4L$}YP2K)yNj$y@ zWB**)r{OC~;%*3EzTry8ZA7YW@FUEnjq{()`Iw!J#GcUa{kpy|W$j|3p`!0-Y^j^wMY%t3Yk1$8DCJr8l4Qr&2zwYRICF{( zuhZxB$$J<|^d7GT0{!bfKJozi*Gn>ds(m6bC*qBIo;#?UB=5&Wb8Y0SNt&13JoNP% z?1g;Y_s-eT|9)+0eaqTjByl7K_YBTF(+Ew7%%p~L`33c9-w}6*n_eD$fvVU({Yd{s z*#RJh9mEe6MZWCt7;!IzoQ3_+S4XdTy`P%cDx+7^iG~fJ*01g?sqqCH)1H`&xS9ACIO0f3uZ zbz#eCdLe-Ta!x<7;7*hqII~I&%bco_SnGwiy5wKV{lDNRC(5w~l`TQF0R`1REhq`@ zKogmDcjn4A3+I>iV@z!&OG1jW5od}J_`~==>|UC4yyEx3!P*51;@Qvz^~m-u4o^l+ zFZI#dNoUvmo)p|sxY7*T-ACf`e~cN{#q{6dm)o(VtGua|GI1{t>^-vGnM-r8#@?*_ zN15RU4wc|Qz2i-dR_L;jvhw6BO_+${xZ8W2@%$<<9D&n}ej>=eRm?Y_Ns`f>Bv6$w8fo>v; z`(2gQ@Jh`+k(b*zow>3k#-K|*#O-98{m3^9`$v^mq)QZ%IN8 zCB%;M2-^N5_-3gEwrX>WP(8kz>7w?>0idhuwL?B&6i{AT$cspQtHhr!QMc=@8d*if zb`X2`$5Qb9;Jks(^tRttj?XXv4RRgH79SftPQ5&6T*^!HGoEZ(@_uwns`y^Nik3-~ zi;h>-fa~RWg%PE_1i;Am(c@U^;}IkPn4*f9j*8WYp-Y^031UqtkK)oo`+t`VtlK5j zjBGDxrwr#tWl>MYa0Uy0dk*0#Da9nz+?5SKG8q4N!6-he)QM>h02iz&yT?m?8x-q9 zZTmvfRb>LM56>jbIS#1lw=Ag%t$vRr)YPT?4?k2;jroX*sin%aN_LOf#C9Ye(014u z?gS<%%6JtZc$YId4i9KgX3nY_YfM!&DQ7cnT_rETXVrRTodF;=0RWp4%5AXU=7E{B zu8= zRKhyYx3ao_xpCanXz{kd>u>{T9N1X3>~{T$=(jrY(}O`jeZ}#MH!7vDW6$wL2~Y4d zNKf!XbWXwc4fLI-UvbA4vRM8G zc6bl2RnocY1f&PA`^r2&=K1ZFY7NNC6Nc6$YQ;Z{gBXxiFUd2F`q}N@`g8G;h zn4eLj$701|D(O~*3f#SaTU|j3eo|)8)P^#p_1AxwV`BG^mz6 z$ydgN_74P(p00L$?O*|5`DpX5JRc_$Z6B&b-kbRG%FmV1bxq$#EthFzB~N`NSYpb0 z8hM@;(qS@z5F!I8A3nY%+e8j2p`0U`hqwE)(`oGk_`Xv?fi*Dc9+Wk`(0LA7elqPa zURqXG`DHa=O6`#pC&K{j`zkK4A<$lWpUpb0a}%;~P`z=bS*!Ug`6WE zHo3^0>jc}2d2!(vz-6)UrON<#Brd>ZF{^KDZLccBCtfbXO{?n}ag}IWcAY40aRz?p z?gZe%cj!d=Kmg|D)9G)6)#E%L1NEu9y#^1JKHjI7-EtD#B?8X8(XHt1e01vs`^H65 zB~ZQ|Ats6<6Yp_;ZUK^GI)y!1652F@(5N#eSG>@(Pr&|Sguf+%CX3JG_()7N`kM#I zaHQr{Yna(8Yl!2p@v&l$u!1h*!zbE>5;{Ia4*m&(B*nLEK!e7B28E%+H!Ix+^_<1U zs(9y?*^Ci=q>|Z9eFI#!j(9PQOkCm!bB+^g`g(DAKr1Qn)RH@_MnYAp3Ck?1-xh=O zg@>yLFJOKqTzBIF8_l^BCK+Yunf2G!IMCR?>D_O%Ed?M;TUDiT3nG#dc4|!4!g^pN z>H@t7EQp5L=H6|bf5O?a27|1XyQHM;q4Pw_!1-yS@GLyJ_d8oHI0QDwshhRBoAfg9 zb-b!lx0t9-`rVzNuz$FtfXF}G(dV1lin-=%*MK@GsB^x}-yt*aOM*Bbh8hbF(*Ht^ zRRp0cb~8P9cn4!QBL_#puR1^Wj|mj@{a8364_!lN6vK3G)rOJ>mt$+U2m~*FJ zbcbL0Wpk$mr+R~DO^Il&2_%8lb?30O(1wIdHq&{FKLGKsesf4qXNn!Ry29sq46a#F z*IVPMdQKUx4EdCT95UDkaCjnatNd()#mR-rJRh8yaLjDLNG*nD95n(h+%IlRRAgh9 z50{uJ+`!y?&^brXFz|C{i1h8gs?;ElWM~tJ0Q*-W;$&-de9;o-WH13$WP^EP*)#br zoig+;`eZG}pl#bcD3EyR9|m`^sw#Xj4v8*k{Zv zdJ!GvWU18cO&1w&3m8Y20o*R7L9VV&({QNSoJieGHP z72#^mrTXm+XsE!P3k7V0~g%-2Z&HZk8xbdBmn#Q}B5|Q_^4P;oTK>&J){L*Cy z!vr>>Bx^is`J~Dv0ZIfJ>C|1|ff_rqO`{Q)aQXKfTX}}6;!;RS=kjRdv(Z;($MlW; zFUJb`CJ)rdcRJo=hz;KJVOS?eiUFrB*6-XhxmKV3{{TeKk#xd=Pw>}ZX9_ep-om&p zU)Qp0q0g&e{U|?m_J%;`l^E_pIdj&85RezrQ{;`8Iv&l-x`f z7Jz4OwEo&5_gyo=In3Tmt`O14Exkz@opZ56dWn-(PZ5zj*!7R*hIBW~KIBQ^#*3l| z@!TH|IMqQ9-rs-I>;Xqe4?4;k%)=a>A_SBUi1xi$2#XGWXcrkUJU`xe-ZlX42wR!U z@R~E;CWH@d!GPhV1VnlEw0q5tl@W&Yr9yi4bF9Hl?rPE>ke!PTx^1%2 ziCka6OM7|ma(0o+7shV^D#WzaS((L;b`j26!-;2Z?DBIs1lGlS;$uWLLX*24Ai=}# zRv$k1wt}1A;p8^o3mMta;&Cd3*D^ zroHjPYp$M9pC!rXql#zw(;V34TUV^UAv;57L4u3scHfkkK&7kEBA)LlJzV-5glo9a z%wyDPLERZVnSE&b&DC~XE6H50*vNIs2%oLYI&WG$0Ka&v)*DSa#MHpxqYX#MrXggQ zV)#xHeLuUDPLRrMy~=qy!{<@s;G&=OU51ccFj;`;GQawSQL~`W+UB%?A|KBPm;I;S~^mTL-RlPrn zkhD`F@nmH`k09<<#W%_!LyBCAtL3z90eas;{au%91 zY?gby=8X|QdOQVadyTWr8f)ja$)gXhjd!w4*`9C7>UJ_-Pvs>_>2B*jDQT#sCQXPY z7eSSD2Q0@kLMvV0LjDxhB7N0kSkGP2g0DxICINLB(ZO1~-TOh%0P&@EbYXN5^2$SF z@&z%Z2cR$>)YZM00^#05yTaJk-~}60)N{#8yEc9cxiQZk$j*nf0{i9Jr`(g_my98Y z<_H@+XGTqBc7NK3k4F_jscuf-=0BP;PxsooYdYaKq=W0)U1nL&!f3%q-s@FoXLfD8 z$Lh_|4^vl`&3w}>4GG^-13XpqLbtu1QwWAy51iji{hZKc;yA0auz)M>)Qg=QZaj(dH?3&^J984@^^h7-RZom}mMI;*pWetTrfX z+isI|D;Va3Y_;6?aYR5}yL?4fFXFADUfk_@4Y&hAl^d5y*{olA6@_eoVyX=^%~(q@ z!RUNAY}|BNi0eou?z_(`o9?c#Vr@DU(eiu;kx@wfOlbaw> z{(ig~2zdS^ujPjUshpgDWLLXDFA8~#-=>;u8nnAyubB-KPBM%)-~r4A#9^*-seEt4 z`Ns~j(W7^Lb?9~vx~$L4Fz_j=$GAkv8FFe{76bhkkDUjyYUHVCOBdh2 z-)}Ie0AKEpbmuIK2WCL3VzPa6`D|zAdcs>Uy^x>wz6ZG>7M59mYjuiAcaIAeyJ9KD z-%YP47(hi>&d28{SUp+`6{~KdCBUfi)-h4iA*%w_{;h$0P743d6lF+nMBz?j$d9r* zUJ0MjSOM$SYCmKH#5Fimht0@XU{zw&ec@|}D|Md%=GK*EQT(wyAJ@Ft`y~?>_uFIN zE~_(6{~r8Sko<&quIZsPZFgwzp7s>*>1(}I2rK{#{B<)t&PW6b<(eL}nOjE{?Om{s z9AAMS)U)Wv8Ut>a-qiI6BUXRhPTa`q0Ud32*}b=>%1;!Jts|u~B9-Me+qOnbpRR_H zH%u)3=>J6q3CGPC2rlZ2&!k-zUP2F+^9LyQm$$loc^%q(vFdDbdK~K;nxh#xr`CRF zI(7UkP@OPsoVWd`l?1pf@O^mlvsXHJQH^cJNZWY_kf1hrJ2pvdN?o3DJzs9e`+@pkt}E>-EF2znJyx8F{SIz5oAZ^ll%IYIi@mY|enR z<49L}F%fkv|ixsQ^%#Y1Ob-3`2{}cO$I? z;9X!I0QSyOi(QARD2rfgsHtL| zK?)Vm0qrws3sC`3Xs4J)4je>a66NMbeE9VPf!ss*S$($`MI~pR%x|E~0eFxXatq7I zA^(U3(r_mKH$!LnQDRa*eD{rkglsAZsP@G@f3v);4Y=oT)&}d!>?_QKheCqPqRc~s z8{HBI=TgD|yLZ+?Szr*>$tAY-DgcrNU=Y=VBX_&~#yXE+T*aa3FQjzr#`R`y#bnd0yMEbHlHL7Rx#33 zjbH4*R`uD$<)MX79JFMjrh(7xSCK1np2V+?vDBEm1&Jtm_Rxlwf`Ek3$f%KBg~TF; zzqK{Jdjx>F<%l%MvH@}uFjal{{jy;`S~gU#N_++)t}tg zV&5@#Ld|@c=uvg~5(dVU-a9l>U6*|X5`cyD?IqY!hfcwNa!W^905Y-L!_cQy?}6D> zCHBxedNg|5TjbVsjmKV43F7uEZ$EGIPX=(}lNVwZy)+Kmfv>a6vecVtg90CQO0mD5 zwQ&Vsy!x?qdWwL9WxIfiPTcas>&R4`IDvGuq-)zMKATWE>PkU5;w!$Vo)7#OhJFa| zsf!S?c_xDu2`Axb&p-1Bj%Kpy6}J~FpWinTdeWN6IBn*TPj;}8=K%6o^5#w9Zp(yX z@}?;_UBU#Znc_&FQ`KZDkxM5JP%u5uCP|-yx!f&BECOcdB51R*r{RJT`HC@?12^@~ z*w%R=Tekj~nj&c~A3Y|EF+X$Wz9ul$81vVB^eessv>gv1%CEU}fhLP3bp>Zj=fI3X zCh5n;_Ge&bX(P6&D2nSr+j@A7``t-YbL_?zB^se z0P>83JapN6%ZD-nLzq6eT$2$#c8|CxRRrZX@td;U6sv4viaMa?;}FckG7$08tVUzN z#EcGBzESJo-P;8cJ9S*^rjFT#B^GTG^yVoq0Lir)SYq|kwJ+&(1QQE`!FfOl5wIRh z&_Q{%8I1Tgiw^H+ zAj!AIO`!S7@8fRqF;FpBLO)iyko~-i{_kvx6EwEC-C>!yuJn14ZwaB=I4DabUsZ6u z#a+A!<&|nFTtIB;XOOi-M7QHUgDgJxpNoG@86KuT@}vt1yZ`)DA@mn%3G&ZHzUx-B z#-q0GTG~B9!LV!g4H)kxV){Jbj*k)-e4{J0$)g`KZ($e)m|%fd={3>oytj0geb z7VvYs{^#dDpn>X0cxs~Rrzd+7@M=o1XbtR6IeE*w(0x=KMdPz6*uCOR1frq{rQYQ& z%zp$*mg{vQ2SGm^r7GX^5i5@#tv-s5s0JTn7JmlH00&Z{+%g0s^3F?N^c21j2py39 zSR#3?2z1WPJ55NbnZgak7I+3hP6Sobq?n=)AQGy#lqG@e9s%6l6|H{Btyvdp9lf-I{3<>nF*SgNbIOY-NwfN_Ez>93u^Km~D>1JCZWC{7y}vy>Qm9)v ze}1aWqM$ymgo;~d%m1ieLCx6az74G9&lg(hxY^5+s)V%|`eouzO7 z%|%Iqo8j`>eufZLPkk zMci0zoww|sD}{Y<_sgOb{S>%u!SrZdxhQRLs&oLw^MI~ZJ}EgEvf`DY{Lu!^)7b(a{9OF=_URAV1#*>%z@Qfl5W$tGp! zMK_6NvQQ<5Wuc=fVPwLDdrcy3bY8-waJ{54cP02F4M=oO)I3@Dx(ch4{$N3w0bII` zF~;Q$0x?bw@8J^j@Zf2HS&{~t#wfO{9eZYmC8n8J+d_x8&+^f(tUQ}9dT?N4zrr4~n&=q-FOIEg{omK0@MLk2MIGUg z2_p`+#A*HN9wE zlfxxM*<9Y1oeV@Fh8h;-GifLos!!ktYJDGl_RSY{ub-}rhykP zuwA1Z%Pv~nT5y+&<0vOSrg#4+nn31YJi(UOJGb+z*Vp}STlO!cQ!Tc*(;TVZj}vut z9n$D#hrDTJ|AV?0%Rd>t_p`Dg*^DI1>&<6v`=L=hf`w9}(7XRP<1w!xI96~Cl%+DY&X(cZ zVDHi_1q%-J#R(_4JxR#Mn_xtSIcE;vc)c?|==7R^$LOcdJDzIIPd{~D~6eOK0+ynAQ~jmh)z= zPwx1kfoEswI}#2l8_pAV3Ko+&JA+iqWYfh^p4A&7!{*QpoXB6s&2_Cfgc|P__6{@3 z?4hPzjJ!-|>$BNLiW9m{*FTx8k&wj0C+hm_t%KL(Pr5znAmz#YmRahl234^upf0aE zEt!PNur1k^OjaG#QIr#YB|L4+E3~ANgZ=_(rx@yvSRz?}*ZIg=@bKP|EwBN$$6L2y zfOtiUWHkuh4*Nq)d8=cM4{U1mek2de&Au@fZqqwHRKM1#zNEfkDnrHj;Rb>jmA00dsXe?4|P2jGY}q(V3yBCu5_(+c!*VNQVi;NO9P{3lsT-@f0wB&ez0x*Eqd<`EQqu{b<8X`_<;n>@>62a&g*9n zL!tOjjlxhCXr%SSC8zn%3!EP|7(1_SR_m5165}PrjJ!@=#BCVowI5n_la2EPmAAs!gJ)1^Qsi8jt6dhCG#~1|FTQP z&MyD`PIB6|7e~Tb_&!cQ;~zY*-Qs3W7Ay&i8?#%J=r#@?wL22(evR?XjR)})lvk147TW!F*5ez_ zGRqnHrNOC?e@eVhn^f?vb!4FJI;hywKug_#b-DB;f~Z)gUumx_T? zXguC=Jh^*u-1`T4qJTfeo8oR`b*7VSJFb*qZBJPm4VqkA6?_6v41xwflV&N3)8S2OXc(&U$Gr`ij$>UF?Tj5($ z;;)~O;k{~Xazu^%xDWU&4T#yC?pl3+6zZXSuDOwf(pzXVN*zeov%E(In?N;aUrExB z9eSH`@{|O=k(K>Cxt6Dz2jKF*r$t%(zHlEnYtKs{FI#>MYu&+m2xNYKLYz))8W4ceQIFjlT-H>CF{bJ3rOpFwn9vDY*H@^$l z$HWO+8-4FKE*7%3{oXxH@>-iGm>x=K%3YjL<@nQET#nDn;kSOHc!~@xL+ILDsayn| z`^*AOlsEO-Yotv27h-A^2Fz-%mw4HyLT|unly3-cRO5bD&vf8^Q$r_E$FQEbIikGY z__4p@F8m(#ogq}S&pfxj@Lg89Z>i>~iBG|K`5DCi2hKgr!8AujpKkACvIhP_r7Lvs zz6^V3-^L)Rbjz=Gg^RQF)4)Oa=n-q{w@HrK;4Y{9*nIhWDoPMue_d1R{<46uZ{>dH z>pT(`m}UCm%4G(DauRr_r^5&Ddd%jOOZW5N>?s3X+yt7bHYMx6c92c)s_@GysXuLj z;cvqUBK;47@f}1(A&WG}7 z1`1Ah%*eUOQ*ev+O=ECj zBrqIEq#nHW$h$;K+SP6`$l_ZW-c^HiyM6v{?buYIp4QSo(0zG3xA$kK z@tWH*zU!e$_1y9psGC(|gpZHW61Et@6 zVPP@c^@^J#NiKwwi0cS`HcSS>Q8lkL#vESHN8+Mm)Ut7x#LC9Gi+X-bMcl{uYRKxDpp+?*qi zj5}2{5`cHO2I%k{hWsUrO= zE9*z2RV=J8qrEjXI?{_B0*YcCE&pGC`F#J}`du+GqQ>|6Cxy?O-JvfNJiXKH=;oFq zav9cn=AN&T60EnaKWFLKx8*eB3!cv`&t~nPbgn_S%yI5U1KH$_!7qBYwo6KXpKm%8 zAu1euE|f2<4A1T9>sk@NFv@kp4b2dim1Vr5j&7#QlwN%Z)VlQDg#F6fu)PjFJj|k* zJAT}GyWw$g?o`p^TQ#(^=QN^^^`r{H+v0_b=78-E;c(kli4a8q%C?j3NP95( zeQ7qCu;<%dHimg|?(HxS65spHElK6*?iy{q9SYnxEyc9tB_uX3{=4nHn)dSL+$nPI z%+I!_O>T)`<~J0gK@hVTOzo%KmK_9ld=0^ z;>x-D5}el)U!HuYcz*RQ(Oc*e1;^ktUfA5R7a;(@dtp8Z?eBS(hk3z!!r%3wHrqBTy+8Th z^=I^Fp}7D20p9E!72kjFesGzQ;o*Hzh5&CyCJ_b^1`ZAm2Fv9aVhoe^VBkj4UjsBYz9==PSYHoB zqHBCuQ+{J2P{Vd07C_NB3ushIesVxjenGK*VnG2mYc(XkYq9|?*a*aeD7rJ5k#r~L z7o}p;Ua9Hj;*7+i)Rf?oqRhPXVr(X`pHi{;3bgzVD+2>B ziU}D&5s(Qbl{u+cwX#kz=amC$eGJ6>C|YN*gSD3D7iA~q=VxQHH~saZ6<2|pOn`wT zg`)X02Us&C$dQe}8vMwKLITAc0WP>BiZfDEONxPk0i+Beu3=>ZDdq%1d!P%DcV<*tTtUY}@JBwvCS6vF+sUKIa?XegE8dkFhq!UZdum z&wOg4s+N*0I0QNf3=9m2aOs>j$p3f&fZu z4-9(`(q7Y=?{|dy(CeOhX&9vF%Hr{}Tf>iZ%4X?5}-bVr?T24M$PIFI^bZyqq>QQNQr~^6^Xg_hk91zH-54`bp@_70RUB% zvv!6jm8M5VGB9w|NmMzGy=U-^85097%S0<2i-*u9iX~ui1>D$-=aDtQcP2u2;R*$h z&KIRRjm+*Mf+h(B+;Iwac08N?GwDrJYGMW@W%-T?Y2cIT4OEG!M)E(EJ+j_;@{C!&ku>6{CL$__*rUN~og%P=_A0M<~w<};hS zmR_j9r_)b&5dH@J4B|Dslt!3L{M_O1W{s5}`ZG*3XD8Zr)>#bQY!^^KZ>%Thuj{(% z-ND_gn0`iCa=*>W4lf~Tn`{YYa`UjK`O6mb7rohQ=KO=?TmS?CoUbxd@ck;$iVxU7 zbZl8+WDkJ0%YglF=%4`aFt#&Na6@xk&rm&azAPM#q1{uY87-`TdHm zX@-aey(y_0XV|)p{{95#i}VWq&zxOvx0QIHvMs>t|Lttl|7nhqoukP=du-z7WCobg zfiC~sEnpGm65K476p+Vlzjw_@KGM8GNfP1e<+Z>|SLP=DdF7q;esIWr{}(*_>Q}XS z3agBgY$5Na+Py`O{GX&};zqQtIjuQ>XM4GOdat0e}jk)1kv4^$;sTn(ZpEQ+0nw*%;_JF0>4C%`iW6MuDS!yHyJ&dhm#)l z_u%hAgR4V|=#wD#?+*StuqNUh*=;O_MFtN-DFi`DoX?}Vb6k50#%QLM4p6Hk%SKlQ z=&~bu6~5)Z1r7PvaBQOtc|>Z2CPj33l%m;OXlW#Ak23B>SZ-WbJwO&BB5;2IHHC(; z?^&UA2kI5^zq%js|I^&r!`kFODtD>L+hsCicVB60{i$Xkw<@d#=PgHDKw2$MXSZ1E z>w~I#0beZ%`h4wbmX@hBE_c*IdVatYBI@LKbmfu?AWW~*uEb|zRQ;7!!G2INcJn0f z;Sh8c>6Y$NsE^EGgaj(Qir+Hr(jskGnIdh-kL6p!O!^6pi^go{Hs!|BGMpk%m2a-}d8 zHvxSup>L-0}?HoR1A^OVPu$8R z3aD}gVeYi}ICVZ6Da>9#gBzDF#6Zn)3`>K{`<;e@EVw0finSpo5T$%7R`f`LoiQ#2 z;L7ov#%wcdtZXo!Q@VPI&BrR83wO@Omc57$9!19?FH}yT3H!vJw^`XSwZJ{ycbs7R z`?>pxcqPcSZaI((a%yzi^KQ_w0C{T~V*dP-sbw;0x1XE2w9Q#+o#o=}t2|qdC+PI0 zfbsJ`(GPl@oc{sH@(sxUjp@k$<%^r0qm`kZoz*{*N5@Yn3^1ceJb8!Un8;=)g%QiB zkfnFR|yaYkY)TKi#}=GX%JfjCW`7nO&|7{Vl^-PrRGYK&w}V`z2=+!k&pH znA*@`mZruv)YpEow#E?Ux-V-kcI-IqvzhQssGcBQ%c5!lyTBRml24M_TNb@>Z=c;~ z54Sjgjl}KCV5KCUL*Axq!MGo1Ps$+Nz=w_xdC9IGc?1G#Tz5VU4OcD4UsFQwCBgaH zZ&;VLDrjQ?ZJDB|D^?F%F+D61XHl)cpl77Tp$(m)wXGG}wPL1lQXx2BUWp7bqGiSH zx35xVA**L&hBU^gJj)KQkw%Giv?UAiewhZG$cXy0~egr>0}zk1#afJ^8O|FXTpTzvv)dF|(c8 zFLzJKp}@Xf6mXohaD%QNwid!PdMi&6>IM*;I}-Dmf2;+fN7d!f$4jC;#A#+WPJ$o9 z2~H$*dXBv({CQMuvI06C5X%G(V+KLICjYu7$l_{3YHO$#e3=`qKc;LIe&ExL5_IJB ziEPJy-xwTapWUbHF84dh^?NuaOFob& z+Qt6A#B(w?F>!VRMqA(q%RdI5cYQc*wAMYny?xMW@u(kBs?Vi?gk$A&@>9gp*BD0^ zYw2D&<@{_>YZRXV#F{#re%s>q`+(dgk2Eg;MLV>898Mlz19z5%U?BoA_Urh1@A-6S ziR?aH-*jyFoVXgL|I|sUso~<9c(~B>ecFH92Y=}JdRYECn-Q{W)^p9h^Cmj^Jlh2R z=h4&iRfEOkx}1C0Va>I^ab&f5Ythg(@%Wm%zK+%LW|Om-^v$gji#=v2s>8bNb5rlj zyP;n|d>=BJ-?3q9kf z+nmm0>}`(_lig$P*KG$mDvO$BI;-4m zhPtZ6Z74dcjBO~os?=nR(Dt}wrP$=d7x+DteLTi%)|8uP*vXnRa|>;59_IXd7(YvTR_3bT1y7hZ9lL&1 z-%WgIfa{ktJoyQ%X$zU7oENsN>UluIY$jxON@metIwrB6zFnbFl*xC8L**E0slzrvu({hjhB6v<@%lotw z@<}S>lYO$VoSu?neqy2d`h34k^!c{8)X|XGV(0sn`*l~l`c=Myb$&m*bM|?;aBh|3 zH`R?I#(Zb?a=KZld!zB3e zFr)W{JA9O@=WTOWj*I+fq_khUarDosjqZkixH==@^u%WRR;%!2J)dw5YJb{h@$imo zTg2_li@`1@tuMr2L&V{D*i+O#c!Fd4wHANR!AwTZcH8o!RdBC)i`KEoix+0LWlj~B zUg|Om_5~r*18Il0WKC-25^ET>{f||uVxPLGKZzLt1+&Ov(c7fkB!QlBu4G6q`n{u% zY5X^aI67*NjBR0vhMy@2k%yI2j9*4-A7TUc@Kcpe9i`LD@3HYo?D@g9L`O%j5Te$3 zMv8exB2-L@Jo)qk1p-2ZhDgA)r;7>hYOqLMR0_R2t^!WewqV%)T}{R)S+CYTWtUO{-P-US|SXn z+c+LWk(|wWXb)FK@nKwRdLIwYWj%MGBgOoMz6GLCq!rmQoe`2o7?ooU5AF3lKo`9Q z%o0iUaWL(VhjGTsQIMOcyb%{mga3(|aC$rs%4qcab!fMpdv?IJM089Tf!H+$@J!6p zBaWx-dZjw-&gYJm+Q?wz*Z!fq1vwUJ>2g{9^c9CD%XGuS!+yW zp8vdO?D<)3cWZNR(GY!@n|elHP);b)rAj-D(tjo1P-;kz`pY3h^!axt?{gC}La<)P z(D&};;*X#$LnK^22DyL0M2a5K8 zMM_(K@tE*`Ut!r8`1=5F98H#D{}tlF$N&>Z&W62}K8_Flun>d=MnHr&F8_Y&srSA`Dl_f7ij z+}IMwdZh*x`j)Xi#Q@WY=Se(!dA#)gp#Bk8_iW<2?K&qSzMK(sU_~9>A>rGyYI>F# z)=`;uR(HCNpujGj0p2pZt%%~}q6+QwsO-;d)>5W>E*#vjo_*kPui88hj+oO2>Ca8M zD(4rWDiZbOf=UJAjDe{$81T{R0nzgH$~m~o5JonA`Sijj<%7aWD03?gmmc@m{$@MF z!{RAe7k~7@pQZ0$cl9fOlZ?+I<{UPS*LGysg=BMhxLI&+XPWA&v z37ospem7czA;mkUp*)9x%O5o!TluEUpMTUk@<%c(-4=hSVx?lOZT=vNBfMYT8*xGH zb-AmZ_tP_;co5VxJ3HfVUy!vHzu$ZPZRe0}-n+x#Bo3W z5>=J-^$Ne=>N4AWU0xcZ7~+FpVAzF-*L1B+*tO}6Sa+SC!wa8_+j6}+#Q>kXIcv1r zz-NisWyr%9KF!%OvFYp46*YbJz@+g?FLGb|JFsWGu!OJ@>!9-bkZ0W_=VB+XE5cNv zXyR}+)tX`IFRxT zQns$H&mXssrt}s(5(gQ+tKlc<(2zyigECmnn8sg#(%2Bj-R79sw3bfSYv{f2xFFWG z&|8NWkBo=9dwOnox+MAO=pM~=cz@OEV2w-=F%>?wA1sva5v4v!bZR_&yQ3v-#NkmQ z=A0`k*Wefq`FxZz@2kw@g(qYs&-*iJ>)5*Gw^j9U^G33M__df=-kP;1^9eFOeLfxM zQrqm?jY3OmR-x}9>LJq+KimY%CD%?zvZ9mYr$`3_vR59x=$Xghg{s&Jy)nv;bbXz`$vi=aD#SwMKfdn+Q z$4H74{%J8<&H}3N*Wy9iH9Dz6IdZjddeeU98ngEBhwq!HjryN~bjJ(O=PwDb^*>Nv zYOXLU2n$|I%h=WB#v8tL@2duA)dSJSW_+vsta0h8OGg(zN43gTr&WEv7Vm2er0GbY zU^ADA)%oQU9Tclf3bF8gj5+yTmMzIWAlo(8FKn!uHs{TLH+xzBUUCVnef*(A7|$U{ zXzQgo3YdzugjF#7#&Mmu)Mk5HJ^dNMgaViWuqJdte6P#r$Ht{#qu5icLGquB6MkWU z0~ifK@zJV=1VxA03^ixQXw_ZB_(d4q_8|9t2|^Tx?P#uOWLm1?SmFe*-lm=tGn$ppAH$(IV3 zI(ik@6;IXG$USl7dm)=GPZ?`J%jJQZL1M}#8S3c=AW(_=MVMvGCl9MTtDd0}yGUCY z($^}*B&y-mjl)~>Tf?6}jXMT%e}=>i_Ikd4O_1F%b@k#NZR>qFEStsK7H^V>07{as z)zv;K>E|DV37<&?xQ~zwPa34w1-@gQm|0L2)I7@w%o%(9h=BwrQd^eaOkNY}LNeTI zQz3(mi%Z5GZB_lfSO8NYA6d+M!nh>NNZ?)`nsDha`*2;w7k(06ymtA#E&I@udb)kC zvMGZg(NFmyt&%SZ`=i2y#RjJ`_hH>xkiC8K>Wyt7_GVG1;v&LAfw92aNA*DLPh)q_ z)fl^=xxRD(ief4i7FN`;k1wzlU?-cYf4C5H&D1QvUYjobpyX}qn5llEkk8L` z;a@5$XPd7it%i-fvdn0gZT736w!VMeW>`nWqOwyc7~1vfvh<%|OJa}#IF!uw0a9oa z$}Ue4iUVlnel6jgN~x$$MrjASxP0p36rzmCj~`AfU!8^A^Pt~Ddm@*ONT}mvSUd$C z&BRH&aj?Ey!+|^E8u|BUrP~f7`WENXgP^X!P3*!XC0fHv1u^7@kz*>XsB-Q1^Sv!BlCHQJ4?gu8>PhQG`X*va_)3!mPW21P*g2+~No^BeHpF!u6w8?}_B9>1hCt&0$JMIV)>=D_ zbHYw8Iw{kf&ncNMO&;%70q*6};Xg4Uv!`uLX|aYCZEAM1hF!y~%n%i}r(YGF{?s0B^H$5<;;_d95t&IPcya;y)>q+(DVbbXRnIs63g@Gve4Kk0;j&EP@HgBP-$|VBSFBv_}*J`Hz@32Q&F13;DHLimsvo z&eYi<=$qpcWxl%LJ$rZ;)$lUpi7^9Xy<;H{#{TZt0yxB%wTU9mC@g2I`W5A>lESPC ziRdXTYVtZNuV(Wia`?@6RQozvD%24Q;|KH_w-jhE`=!@jW)DIEi(u7mPmhh4JQySL-^elBggKp( z$dJFCIoQp?&^}}badmD(*fqLdO9-3~SNq0Zt&~?DIoItXSMH}CjtZ=Yu6ksgit+Xe zI@(DrI4e9mT$l|Ss(Yb<4n{oPg}DLI#b|9O@zvGsYLEEacQe;_vc53V$H&djFF1mC$yv`VcB%NTa`Dvm3jo>;2@I<6_zCYv#tzPcJrK)n`Ky+*nJqJRXJToe zH$&q7hrKi*^M3}(bB4q@)kWKx{HWt%LZb$M8F>7ev)I%lPBqavLs_Uk(Arl8}_alQEP5tTY^6EUs`BaXjCbltu1FZ zr1dD!{uA*kGh78=WNbf!NZ9Bz$`+ol;;sU?B43_C?3HR!?U)o$r}yqv_L%LgG0#n! zV}g)C1|SK^tGd|;CroMmfwJDnM)5-%o}z)AFAmqL#UZ09?OY6Z!Ga@(mjUKd^hv*b z>>O@LHpC{S6~9S{BZ8Q_mB?)kQAAvJWiS(qafssH0UAA5Fyx}p*5f^__)o7LEa~B0 zf4vT9w|7!sxc5(?u`e%scc(-w^__stc0!4m-q$kkL~kreA|}1;n^RvJzcu&Ep)fQicSM#9b><=ZY8@?j*nMyST$a0Hx_(2${ZP zF2T*DkY|UgW8G=Zkt_IiU5m3f5?(iYIR;RXhP#DQ?Uj1lXYtpw74)Vg!AMhdQe>M4 zF4oFL5u;wW32!bQP#2uE*rO{OzB!Y^MhC}26!&a@bU&a zxBehtLxfa$i+ve-DrdOiL9E0*3`zRNOl&`snkYQDg@UECNLsIjyx49&by3#jWiQFF zH}Z1r_u!lP+pRJI#s}G$DuYpdR2rWy1*W!Ib#oE2#)sN^N22JD@6OO=6`4B;BJWbz zM=)!?r|yo(nj@S5aopz)0i)!IoLIo}r&0GEQZq$ju|aV(4HiwjuJR|ABc9qP%iPI(ZPCepr{wMZ~hl9ZyP3Mt{!h z1V%*)s?wcRm0dm}Fo9lKYU4*5Hop2NK0$TZkerwUy7I^;Z4;+0nrf_@F@psaV#VwN zG^LMul5lr}9{dbyTRQZNPEwX@&bmPB9sZ4~ZQ>AUoo$jtosK#q-a!PV9HPTea*{r0 zNqhN(+nfH%vu#UbC;PxsLrXdb@8YN!BW5(q^ObxV(5`M_)2qM$S+2V(_Y4iFq!Ha^6B~trmc-xh+@o?ZnSQdoQzxhs@!%>mptgFz~ z*AA`YXujeRzvjX&N2UgWcip{a*gZ|?(0r{Ylli_}-(0=8#2cM@zSVAEA->8IG1S}1 z|2X=j8Un?4^Y|5B&F>EEY2IC3Ny$!GN~54qqq%+GKEpJlf?kx<2|7NPWADtnryig# ztq7;M&d%O_d)|!1lL%)G`9(w(+2<EaVVDqd z{`6r5wLmDxG0L~VPh^j#h}#Yp!5z}dP>kG->EC$->wv-wMpcCm#>+R7*2NzPZ=L&a zU@BxV3|(SAAwwWhDz^bxNAYi`R_s~lV$IUjt7|15Av?|$?~JOPhj&rzLK?1ip~u;T zryRfj@KZA$?Xk*YSVs2hdU}tmvEy79l89d{Tma^MQ&9q6VjM-l@y0g0OZ=gpGXYB- zG2)z<@51_$31-*UVN2!(SDdAPU^F0k@*Xo$L;H-fSwGJIH#18alq*C%r@`IOHxA?D zb6)GgwT+8>u)QPLQvluOk5_t3jSw*@9M0RoVeYNzr`$Um=Yor7x21;sWlull0^s;_z_yN5jX@#pjO?+osMjH@|SCf;56-5n7dI z*f?P07|siznUhq84fS1;*CBpeR{bVNFWijx+3Gb~IB?o1Q%dJI~0fs2>T~zg$#(ZHBveNJ6 z=infiMn^u8R$qS$4PCDcPGX2{pF1TSW;dh^cOL;sEs~~>L1DQ6lKkYuI+&HL*l?gs zaD^R4gHXanaRD~6#()G?RroDDw@uz{^ljJZznVi-Fa}fIU~P8k}@+| zp6w~xpPnByhK3|no3pXC{>)XB)(LP5#YvmBKcJ5L^?L&ec&_ygT5%EZ#35>JNo%$- z^?#1DV5-5X`IYBcQgIW&5+G_VNMO~5Z^1)WZEitnbrb{iFBt86(JZ0Q#hvmcloKAo zQi^nXUzZ6bk%P&yfRcrTCh5A?;oshOarvzFq&8Ro1oF(_h_q53^E&oe@bg{Anl5t51OeU^12<~ix@*S0H zi1I1D^2O{!XS79AZ(=HbY_+^Z99)$~Ykpw0zI@>OUq_N@Qp%4k2?RyLZpP*B&hb}I zvb7M}VC8jEDoOryjyYIwD+=n%T(IOLv~um%A$(|e(x9AE^wtt`+qRF&&FePRsjmpG zs^YY!bDNIISC5$-txXc|ADkBJ3HB5Q$sE#?3+zorxi&`g(iRwr$M*)&6X;;vmuNg` z!SFYK(JP~#u^D$o@rfAhQr`;Hwg!AN&6aa(bi2A<^CZt?x`=P01YHKy7AnS`bY|f- zxPaBU;TwE2N@C*Is_C3bO3)%Nj*)kUe*#0fDNRH~nar#Ucn_LVWbtGevc04Q#5H5> zikXb@Ae5)HM<3EQ{Dw;QsX0=y=4TCb&4F%8ekx8b%rejux6m zf>_k8e?kaE33UacFS0&vOh+$5$(Ja98z=yE5&@dB;2fuC@`&@I$Ow*DSYi;{8(L z3$ciT_-#+EJ{`(r9Am++eYXZS?{M!|T02-R8HVXI9VdoOBLdZ%sQC%ygX5poA0BH7 zS`-Fnv^U}&^gQehx(iJca3mR z#Y12*5CdGLJSTiyn6rHzFl~Cp?3&i7L=2Y{HcSR~{whiNsFwBVkjuORw1&yLCBeqEi}&VG+2NkUn=ni>{6cQBKAfrPsV z7<|`xoH;D`enHWt0#O>EE)d6wQU1%y zMI`i%>TJ`u&2Qz1X{(A$sON1`Ngo0j!^a(ak@?Y&THZpL+K%gc;BsajkIK)%DX zl7?LmXLJ)-q3ZZep}YEZ&Z`wA1%+KI#* z-G&XBnG|js*q_4G@uc$7qh`5_EOX8vBRZZ?l?p(>3aJXHaTFBA)zq`kn6R!2xjf=$ zYvk(ME1L^F!L~c!n`hiGSdCm>P79#Z08ghZ;0 z9e!JLX?|_~d0EgiMTDbj>xm>apEa4S*X8wmdYwd8k=!4<C1m-6f_y_NPH?1eZ9`VISC(yD49}+v)xr&f8Wr6j2BL$O~CM?PVp~8 zF)}jUn34tl8HG1_mv~|1-~AJl=hJz3<=vH&5OZwndq*~x!qm-WMYV?otAaN@O+axH zH57q+W(i~0I|a{iuV(;!CV}lvU?ZI(K>$Me=+sNrvn*4XEN z;V64|89ts{8HjF2q-`n8`?>8>_}6v z=rw+y*{R!9kRpJ%fzOjqC>(%x$L{Fr!M~(dCJQ@)>xfp(s?Fhob6E3J zMDA6On>dsxMdBph1T(uPMeptc%G-CCWJv~hA$=?LvD0NI4!f9{#r$B!AwWAkSz~mE zr13VPK+9qYE#tb@5+olEG`=_`mVmwgX)Gl%k@5HW%`symuJ#;s-F;rNrjieGLqX8( z#Yvxp`djJrL__yfVH(lrGwz>QIS!+YBi-OZu*pePE|>hn8X^%nelF9rhD@8!20^v0 z&7)Zao`blm;KaQpTFoRWVU2#0CK%`6<`wL!HehTVXn zZ$ra;sWSW@o$!>OI}A6_$oS1QDjx)>VjiX5Mj}~R&K_p5*lxRE#k-WqZ3r`b5W;W-vb7v12%;i!R{-nRD>2P8dFhy!vSR zQari^e%YrmJJzUsSb02f>zW-DKw65A=6O7k2}?7iX;JLB^CGC_5jsT(0IDW+z262yxjM?-zI`9e zMZW%l3ronUoy|sx?JzGj8CABZQkf)~sW@lU8c4QR^+%^{6})IOKlIh2S@ad(9eB>m zd}j!Cul|Ttq=Y1gGi+||akm-fbMvC%!Nu1_YW1D^u)H;LC{fq=6Ek>I{H|zvO$A~f zjyqp=X)z?brwWvXXWM728CP+6;^A@v4I*o^&!M}!Ybs@K70s6pt{gA&TnpAH7?v?{ zr5BI<2elkRXA>W9^e|W(Hr=tdW$*pfeqaQayKHCg093N(!qUmdagtU8G;@a$;=_I{ zhaAan498&N@Y)b<$Fz_wDcZ=~<^_g{1F5v5gjSu0k*0ufrg>;%ImK%LWxMcQDgiMi zl5hiGuRjzlGD==RJ2;GaxzKDV9SVvng1K%z7~ZV7EE#eCa5zvD&A6**9&8az2;Ho` z(3Y^6wkHVU-69yS4Jd;t%xp;piH&6d#_K7N+;J13{-J3*!eaQu!hkrfULVK!eVl$c_e=Xg{{V*#8+x>9NSe|sB8dWh~+ao2<(foLbJ8BF4#?I;seZ7Ik)8HEFQ6t0xJa$zZ+1)y;MMNNN-#*$nwH^J_47K4Yc~BU}0$}jW z7!51X3~4kF;>*J;*Q^T%&dzLn8>%2P9B>)xRr1pD-5aKtj8gp`xlee(M{jf6LiKe^ zkibsNo*c7um^3FoxS$UWdSWgdMea#Jk8R$L>9?`eIcMr)@1`ERM+=-?%4@hgwyp0f zUv?$#Pl=u;YzPT3CMn*9V=qKrpgc3TO)??HYWV-@Gt4|IVF2WrdW2sqiyn%y5%P zs{@}nSR^5)5Hm2c2b@z+n(JE=TQ}lUcnDWTvlGiF#8x<$*6%eG2cQ^`twn*+irTT^ z50*IjNWXUURNUn+=A+t*s%F|?MfAy-66aLtfh7$Z^?*Bb5PzZwrCuTVzKSmOy&p5K zTRajtOU7Imh%#t7yH`XgMeUhX{Oq&e24c@_e65Hnd2}a>Vj`6v^&r@@sX-U|s3Hf7 zZ7#Br1t+{m91ayrPHv+A91fBMUmOA2H0a01t$ptAOTa3S8f7f?TK&x|^Nfl3AkczP zT=tGQFtnPj0D_|K=e-niT9&IH<~rkIpn97y|7u?7JJPh0*n5&vB4-)Ra7ZwhDL_8B zUAw&~Sd|%8YI89Jm-QL5Y?UE9A9HZ39K;zRu*`T^bqp>?m5lu`8sr|fI9i0`Qn6__ z0qXv3N4!aY9BNL5GrTtc)H9@n)zvEyI^pDY-P7snhInR3I@PIfT%9<_I!nwK`phJt zR}9~BhvSg)ELbibEHPA$Lx9lDB5O#WS{s-x2pqxbtHcany88W4&87!~#E~MS(nI;# zR0v_En)5*B{xrnIRN+-S3-lgw{B@tBl0$b9QyFqkG5HU5S<$1E0$u zx3-ScdgO>D#){Duj4DP##=DQcfvy27c=7sKr*z`4&i>KDprEpuH^$dS?E|hM*@(m! z)X{;6L#5xB2`r^>zZxqu+xf-SXhZI8b+!OLt9SBsYZx?#4L*-`YB#5qp{~wC#J&P8 zVXkJ9o=BLmkXNb8%M(j*XyVy$QX+i-4mv_B+KfTglfz^{Twnn+i~9+%v_OoEP8c{7 zQ`@fJ;==7C$0(pEM+pEwd|)KrwY~D=a&w#b5M&BDBD%9-_gk?|T}G}9>o^{8%sqf+ z@$)t~i<|`&?4XwzCri>2(LdeWyU~P1jT|G3n}GNp89ZH+GW0;-^Nq@F^}^8yFZ>S02=k3(uV zuBW10R?E);inGM`x{;4>%8jq99;0~7HCMz@R0VPP;8!BILPdYuum)h>5}gx@cQ?jV z5ZzkJ`uM&Z^e8+68r?)Tg(L`SlTAPtkieU4+Y9<_4@$qZ!?g?wu=ZqP5TP=h*ZlDs2s>&^4lC*HK@|v?Ul*`}w^HyQT-cZ&r2SG_WZ>2wI z#-qIkk69`oUJ#-<(FzSND<9b>4N-#PDd(tpUH7v}dK7;y-Z#LDx|hrzsiF%Q6C9*R6mDpuF-h8m3Ssw6{h3cx0c(`AFsBlJ};os5PUJlRW*9U26$Wye2_&ZEZ*dTyV1#}m}TPg${la|%QB>jmymyA-7-m0A1cxA_9`ulj>PjkZQ?0Y`zWrSRvl-2$AY^}q+{%KZmMwW0B zsou^BS(vVX%57GE>r8V-jt=%Q@fq3Bit-80FI>P%+KbK3`Sdj+zM4^BynD)g(aVAf zp&D->Crl)+z-B{Jc^Jiz{o z%up=n>G_{IqgFJ`#w#dqjyV-diU+=^e^-Ngvg3~S`eXRT64y_GOD7o?y~GTDKeUc|ELqN;R+oL<-fwS2YR2l zhGHwliUaIoSMgNmh;3uo;@1dppFK^O-s(e^%}E4{$R`NshJg18l!W1s&p0j#+Qht)nJ zz_FmcnENvsZI*E4LR=U~0Wd=oicl1k2=5k%Jok9J0@$Ttye!l<%hQCJ9#cq8d*8ne zd;??9Crq@rbK>^2#pfF1DREU`5V=MpkesBP*B-H7JcfJV-6{2=P%*AYDnt3Ymgbz0 z(77iK@ZC4#a8y{X*FMlDkb4VA-QXWB9SQEhLRB#r9#$#8P|J8#;p^EN%ce4h7>+8# zkmD*r%MnV({j7u$?gJ8IMd>x)z9>&LFc6N^RD~#LpY=!aPd$x5R#>pk?GQd(i7CvL z@D-)wno?moexo^Tk=;UWnY>CiAX=BznwgseoHbF@3EWSBrk}>3+HCCIE~g?YhF^bbd~6 zJODADh(JC1b>0eeNjR*LjvhR-DpWgUKx6+}!a7;YUQqBiUQX<1Ox!y+D&8U|FHY+jXcFHA}t zmKi-hbwV*$<3%3HO1dP&lL4jv)5bUzt0rCq6er?WArTp>5A3*pm&_nPpzxZ*OdL z$P_+u5XgBK1}Mrn{9=pKy*a&@Kp;GXlHG?77<4$+D2SRBKH9InQQ(zGg}C-e(Ez_HVFcq}A4Zd+9#h?_`a^m8yu zRlW-odUr6&MHP6;1r664{{w|bMKn0u{Ch`zhOhX z8J*oii$IJ=QQ~%8^#Abml~HwdJ-4{)!QBq-?i9D;PD}9?d2n}kcXzkKL5jOmO0nYZ z?hXa+?)Q#yfAEvNc9NOwWF}c>*8@HlfGu@Tc@To57)oNA&#LA`7e12q2b$DAd4F_t zz68G*(#k>wDs<%``F_w(&DWlD?^E2Q;eZ4x_o$->2*Qscy_{FccyxwK}`%vcc(UDebIm|MyewxlNjFgLXMNAcvaR4$~S(HWmV zi06Gcy`Z>9(4-vU}Qj}IZA3K+@0=YF@B2$LYjDI8@< z)GCoYrm=j`wnt%<14c+qjO9#pZl(SFnFkU$r3mqrY?GS*&{-|E`e!0B=|2Zym}J<% zMqrp`Y!!_|u6|+z>I!RPl4C);L4kZ=z>s|Ua=RnKq=wJBVC39o(mHXUZQJzoZgQDi zy56Vb>649yM1V4nvbEyT%Sdmr8PMX+=n(;^JQ1Pg+^+V|wcRr8jb}RXyz+eV^+-c=6M1!9L6=&B#Q&S z2dg5xed=1*mXa>*3qjEo1eZbu+EMn3==j(0Xl@86 z^Oj57WUmF*LBtQtoKHfrJeI$Fc)24j6z;6Hcnn>)cKb2tb>~9SRop1Z1dfVL@z*RC zjBZ_JFdv@tr`X*@=3FeN8Q^Jg0Y}t&1EBz&ekN%)6Ii^0lnRN|8R@jtlo*1P02mlL zJa8(M0r?PTjtgnq!qwQ7lxNGeaogi6{wH)`CU zc|7VT+@Bks^UalcD6GjjOYLzx%d4{5E3VVIDe3UFsAk|vs-WhAD7Aj2Y&Lii+IKR- zH6fKoN-)VcK_ywYT0)a>hiLWPqJr&^38VZ&3}x@^xe~N}9=!+rD9Chpbwv<#?8IuC z`V9oOP@J!0bivDWo$YcSyh|k>%i;>iVqSIGLcRTLB-HrdX5(3Y%?#HJ<1ZQwB`H8q zU#6MY!eWgA^$-fQON{_TREKBof7%lg2LPvlK*IW-^r8V1sH^31{>^z!q|yn zIkhRm*X%Y3A0<@#(uG9wPMcerA^Xf5@)HeSW8RP0*bGWazI-2q>3>!?h2DA=9fW~> zsnjw|!p&>;phb_}wtNtrUw7i$Lv#iTq71MTEKo|k}5VSUovNp_Q_C1ut5m%nbG$;)WY z=!BLHq#ky`3Hh_bs)$}pnO8h2rsM=g)UaOS3_ez7l9TlZFdgK=x2Mevw?Uy($pThV z>^8S9iXglfMNW!9+M=DmJFR3{M*{)tj{;u&6iBxQG)Ld3Zld&R``Z^;;`a0JM1qs` zRQPC^JnBQ}6xAaBb4~8!eGl;ZHQcZx)MrDmbpQF*`p3_O>8pE_mdRQwt2e8ieb37@ zr6DDCNo|cX%M-B)`5!K{%(oM7g_y9tXTCPAD$8aCxkZn)6?YBqpQf@9~P zdRX~>+3NiZKlC$X)EgAdw;F_?O)#kfI&};j zHr8li`D?54T{?N|%1XcA+pIT=4)*IC)qO_nnFO(hecv-BI#L-sMO0<$Z?|u|!vEPA zke38r-6Fe`k&>&$$C1j`7*pMW(`-%Q<16L?NN0!wkdvGH2RS^-T5{(Zsu53&=9q8>-PWm}m_5;Y=7@ZW!$IZsN_A$yd{}|D4W;FAc3@^j;@p`o;_r{at zrs$YWa&j0nIuJE)P&x2s7`1Hll@@{3k&(P&%j*+}k~L6Q_Zi7qdT~hwWBZcXipJO3 z?PE}B{w2V}VCOIOfQMn~88?X{u`sNXBg|iV{PP3j(CAkBvk32NvY={T=4)O^A(xO( zD;XlotQ>(JSbVT68B-X7MPSz}nWNVfLs?&zg~nQ0bV{Q${f8Fcsg1H8iv+bE>mzf$ zynTu2mSUNVGR{0LzGGZdxR=xKm^{=|;+nyJSqv(C({q^`w-Qn09QiM_QDE3vNeFe! zf4p&eWthQw(9~zSK9qwf*jDiZR$tS)$L&yU@QBK`bfcc!bfxJN^Z27RCz6HwDCwC( zgD+3$V86izUDi+EcsE9P3~aD~7>>ji20@ZeKO@NNYYjT;x58o-1R)k^r{fTldJQ`R z7ct=UHa8bBBEZ{OtlB@>!v>Ek9||Pf1gZ;N}qa*l|JeQ6^B-*F&S#4?-irU7~_U zz6Snkt)jAlLW}sxZmSd^A<9bt9S|F_F@gXMtJnJII}^7-UkKa8XoBpYhz3Kbyj(|< zYy!odO9+LE)pxNA3r$GgcLBq(fc3T?nSI3noNy~@o^9#I!}%PehyeeUM;T!RA>_gg zcHeW6l%!j=H|Hs50#4iNr|IvuF+L6gF@C45{JT3it-VEv-Vz_14+ZCg>1Sb|{E&&r z-?#*h+m8vhuU4L#J{Q31&^xP8=h{B)M-0<@w{LWl(EPl^7ERWIjsl-5*2qiQ^n4rF zzIRNO%ja7u%G&hn`1`2l1OG;-Z4~LZ9E$o%e>UY0;@SQD4tj24CmT}i3h}D>K@#8= z#vbe@pV5eVMruIWG!O!1*fgLGull*o{mHhui?PK+E?m92JCf~##n+;@oPTmYGAG$sw8rpFGWGp$oVS z(Q*VI3<`8j;VDgpVFI>x;YwKPDJ5t|D`QHP4Cb@-0!`HGw4trsWAmv=Nq-Bp3UH2jMT7gd)fd_Gv9FlmuOGO>pOMwjIh4h;+KT<1+ zCsYxdpKlE;{f%|AJ8$YF4%-Xq*L;I-PJZs+i$jk}WxJCubNjDCrz4LX$<3}fJeCzA z${LASg)InI0+t$hWb5`6AE8EQDv?`HOp})fI=?`Uw)?}B2iFO*BRcH<7}mZTi9Yps zy%xk@gifCyO9@5ORAI2MA3?*J2rlthuP0fGIULG3%>F5*UfMtIyUNS z$ySm!c-YZ@H^e_#A3XcatffLrloa&Ic%ppwna8}@luK$faEv#oiy-<1)dg zrh2K?c6r#f)Q(LTLpUb;dX;m1cA{&4a3B}%oDqaGQLwM=k|;{JsyMHV0DngC?%_Bj zh4jqRO;Bpw=J8QmDZt6$?t}3+gw#mNb(QJ`5qol-@wE>(`R+!WtNpkd(SwoeB%tA$ z1`Z#ah+PISOyoogoW*ZZg2PR{%%ks1f+IGa;!E=pQw8yC-^ z#tiIl3;%@2@p;2W-e85V>_T6}Wa}>AIKU?ze9(pV`5K*OfSrWbCW^tqH${?o$ zixatlqMnkJVX;^dj~h|WzlNhtY_*ZlN#E+qSvBqEV9LK`h_b8&n^e#shEYXfeF$61 z#Y0xYrG0;*cprUp5%8~@e82LS0heh-!M;+YmBcG6OqU2_Nkpvw#r3cJ%x;+Xt~TK=1c zsoF(q8v{t1&_oy)H$H$c+Q0@zHA&@kq`1 zF?Oo(aU&8?7pkA_6*4+A6P98rr~5K&8ar;>wd(j?gYjUkkBLj`Z=DUd@h?Q=&EwGt znS=af8^$9DZ1uZO#C9F8AQlDwk(z8Hq;JJ*^Jgd~YRjVU(uc{#GToC=HohF^bXfw* z_f?Wf&}DXY*=Va&{1@8}7+-6jpnL57ehuua)v9((W9lcm0mVS~+chSkcY;nR4)0FR zkR*s9nIg1_DKs`xbR-Ye#i3@=xl+c&lZI3!L2@Msmsm$zP03s`$I$aHDi+rGs69O; zDBGU4V9gB;`YaC>hWv}TwrV_mHWMqP5B|#uU9jiq*|7z=TlwFN@CjnMeTnOoB+p2O z<`E71Ewp`!BAg7*xc{O0Kx3xAzte#jcX_^G3Se!zTt*ZHySf}?l0ERR2@*WR%z{1j zJUVkdGrsi=izpRxR}&h1PlcAI!J=%@sl7B6sT0XN=hC9Lm5)YX> z_9z4eP6v*99{6jf!HV!;!>YjSoAzy9lLKcNb;CaK&(&B_(u1h`J~aXzC;w6HphKyP zbb{xpww*9B1XQ_gqJt*(A<^JH%HI9S9|wR;Bu`U?kYr5G2Wq3wSpEI7XS&V;yZaaE zU<&*aJ9>&TGDza2L=0DgkK5$rsNBmK|8$MjmhxS)YUVCU!JYU;I>i&DZAV^A{zN^I zJ@UkofaWkh5QKpO#}+JVavO`~U0@biz@D=h{9}lm#iqh9smyCPr$I6upuAJxO5@U& z&iFc*XA0*z6iJgMJ03X#zQrTBPq#j`i91!d3;bt9t;C~BudaJ~pL)NmoogM$)9@n$ z3xi(0A`9&&I>UD0q8`YODlPov-!L5A@|tgVkUl~rN0Q#J6g8GWoK4sd>on)t#)m##gR+No6QyPnu$-h8XE&^+FjtvFMi2FBty z&hy!9#8=$@t=@V^69)^OtEa#XU(aP|I6mnc_P4`l1q`e8v%=BAvjgct!(g#P$qNtt zl42n*Pd7Yg(a|o!>+&pp*HgpkoPN#;fK%v&Ud9+49v1H?tqw{LRK%$LMx7QkkaA1R>B}|c%ol8ry z6A&W5=G-MuF(1DkkKD9sy^X>g^@@ z(uFOFZiB_~Gj!Gl()=wr^!sB$#crgFztQv%4%LM0#0e4E`EWswDB5bIlOY?&&nLl? za#CspqMnTx#>pOOEgAZ74k-F8wK>B$6qyS7LR-T%b0~)ZFWCAk--7T8euEZ2W2!`+ zIj!BSx6q)0)#t!H2@T4V?*As?g#>gM;+Vlf8Q#EJ^`5bW)OGY%0eorn@a;yB?LeVr zD`&xBL0WIY;T}wIQGTNz12vw)u+-J%A;G_-L^vXbb=qlT!+Y_FNSMLk3XE@P- z5}pGV{VJbD7n}n7Gl7z?8Mc0HCNnCayO`yCICNN7K(GJgytEWD&~z2zX?;xP*9J2F6;q&hx4=bs3M<oY*2F|Q-rk^3s}O&N4Cw3H{ubiuB$OmUQakM)F!Qh$9t)9o887=|w$^3OgD zAXgHC&kLe{d1NtZ<8$!01SXgVmx(iJwU*!8!Ptki!q&?K5~!^9EpKDsw;IAl6UEPR z_6ql`dyg+T@FQH3?&1($0?_RRpo=L|2YFyN|ExzAf*kuBxT&l5Q!xsxLs6U7`0|WE z93$a@20sy0Q#?9aZ^1RjVD=3HRt-zhpi<)c_5m6TK~aJG!2jZ{r$8+vVnd|m2Euw_ zEKz(*#HdjdxiyJ$$H_O?VKN)rH*i%d{nx-)1dx7Gszhw;(To#sp1&VwqWn39gq~4B zzyqo_3yltgfi-Ax5u?}bqs1HaHU{>%3mu3yL@~NVXMY?d-k?sL3FUIy)>}J*Ax_{J z4j-^JNT%?4H4%>OLR|Z&^s$D1WxT<6Nk=x?RMIsU=!_V4l9cZjc{8NE8+s{z@~_?M5WmqJU0J+c|sry0yad zQPFJten0o^>zBY@dfyfLRFz}gVv*m9Eo577|FKNAV(LxGQcjlWg1$x{MDVQ*U+l2k z1<6AS>zwJ}w^+W)Br3tWC!hom_hzF(EVkAL*O0mpOry8iatvv#PI!|bTaP(df;>(3 z9Z%kVYlHidhiCgI45v$LM2{qO+n3IPTa%OeFV-e#Uhrc^b8jf_>O^xjSMI<#e)xv; zY=xgQ_J|1W=F<;5u1$XNxxmHE%K^JBugtn4%<&c88fFn&5f?*C4ndkIx|(0A#&$Q9 zV+db+VMYFhAH~yE68iJY>=w84A46mcQ&>J#6;mG*JEU7MwZP zqN??XKSk>j9xEabg}prS|6Oo1$7Zsv%oCV}BsO;Ij)QT|oQ<}PKIH&pIpGG|qo>m>Vd5ND@d@E8Kvaah8`qI{9C5 z7`l@};itJ2*WY|igG^dccVLo)hI;T{WAw0ciW3%Y);St(oNmx#Td&$-C7gu%As+bs zm(d>yD$-@HIq9mKra=vg1@R%dHS+?8fNdba$rP?-)1Xjwh5tD)m4TySBwWf7XTm_n zJ3Tx?E_4W42i#emP~{@A>5d%O$w1Sn&}zp!`Oz31kMY>p!L24>_zs9ERapK8D^sXz z?t`=GerMw@|Mc|N*FIxIi@S3DMg6BaiWsOS8x0?0$^}p~%V4L;m=UNVD4a4YnDIb+ z!s+ITQY*a}!YPQPb15GvqO%yPCn%t@wZ$KQMry+>k_1tIt~5+EW6QnKy9@ewTxLH( z{#&p#wL>^Kcn6QdkBtMvi%CokgF00>ir@f~;v%hs%)t5Fqajnn{xpdv(tGA!TN&X1 z;ZP8Z#OU`@m*DvmrDHhgNU0%26Qj&sfpSdN#H<11)T*1+5U38nt_e6Inw}4}H@DIt z8@L2A6M2KJ&qFmA=>yAzgI#xq$bl2*J)=a`<~`vDKF9Zn+6U5S$=`Le?L~1yy#A-! zhX1eHz6LUIE+eh!Z%fd}n@3dq9ZD>et-Pr#_mJBE>2@Kp$(2lD@fa0ZJIVPWo%)%% zWx+_WYc4|N{G9uBPk8n0dad@a-}~F)_UPfe+c)Qfhw+8;)?$hHF_jDVw7cEO(4~!dziGPTxxTk-4#rV)g zNsVlkjT!Gig(8{;%Z)CcO{Ps-B~A(&ZS<3dM7a-EW*}3g7(+Js0~MWcW$BQ}yxAZp zkl-or)k#hgis!55ieN;{)rD-^husObh$1UtxxgD}kBk$x*GG>l#O;1rU^z%E#V^C& zmhi63CC_?U`AZWO0b&t)y~K3bB8AxL{kSVIDf@}F52|=}c)+>6J_DCs zP$Lthw%bQ_gb)p#h`5-{B;FPFB`VhLP0BxR$z%Ha_tQ-i*jvHKR6`R(tn-MLo(Y;R z_s10z*Mgt({J@Q1<-X~(v&%;nt;}1F zr6JtU)UG?G5)qbff}c0`Cmw1l+SPmVS@Y&f<3wC;fGV)_dZ16{1LB&E@B%#S6tm8{ z?UZr1GLOkI4{HdBvG2ggH94>a+8T3k7?`IorCFz}l>3>S8L<-rTDbSWI>{P^U-S^gw<6?(f zu@&DX-j1=C39pvFt$#X1d@*Lzfs0Vzv3)5+Hy_55dU10s@#p&ay80qZT6}gO7m9=5r?Mks8qFgYg|(HCkKaVRSEvjx+u>_ z!sJ~G3ddAf-OS>8mk>g!t}#>HwJA$sFfb4n4^EK|SZ-|}3)qE{Kr%I3p;=}n*mIt9 z_wvrOHNg*R$5i>IbPcYh&O^r!vc|v=g$?nRWFakl>6OJaGZ9!rv_BE^SVTd4)){1U zR`H$-uQQkbqzTB2I`ZE?c^d(FQ$yYCpZ=~n-l6P{ypZ^kGWP4$_Ux`4QnoLi-cOHt z<=dyb=jLupC=87}P;gw+Whuntu`nj%N&*QkrG3CTY<)e|q}@>~A{?`)gJ5!`(oZlF z7vBt}14JD0(PipipO9Gi(IA8z|1uQE>#}(&7!iGAVK#LLOw@%;s&%rklnLE^Mg0#d zn*dbc^L0}?$JHMnch9!;8z)aZ@qt}N>(OD;2^m7KugTC|(9{4OgV2Q)go%M9R^`Zs;yo%9{cOOL+W5x3PyGv9g$1;p}>LUo{pb?-7$T8FaXXPVbX1#J| zr+mb!FW^q&m=2c|A68$^V1V;>VgNaWY{HU=qJ?h3QFO9CZkh~Shk}L*2Y7ee;tj1_ z9vxOX2VBve+}yquICNJ0b5E2tn=k5zhv`yhg{5_`l^@dYk-# zo^UfX7f?k#d`B$07!y0b+f%;3WV{F@D>>c_Ir254iqRReS_mKm&oS62EeZmRWU*;z z?#F2i)YJYWVd>8sRQ(9YA5+1Ol5*!S@~fk4ol-^yIj$!3!~Y2YcJKc^J&)}c(PHw_ z4HGm31ybBTuf;Uq29}=Z@41*X1V|xv$6VM%v&xj2Tn5615M&1NgNrr{TBPb(QL#;e@3bBD3V&x7ya>pK?}|CNeG_-= z#2*AC#|0!WJgkGg@M$ooL+e+#IgdT-<0*p(L;ASsCS%^Z#wa+b^ zp%lH!!NcoBjZ|?dXJQTmI!Ep#9u6BqktgtsfKS-kr7B{@#5O5@rH$9G$(bFv<&5RU z6O}wAMz=tq9Ep|&q=lVP2X7^l}MX~S~tS86$s zzgGSGjkPup37ICxCYY9Ra4jL-#{`aq|7*J(YRC@u4?8G= zrgf4c3W%Y6r3A3Y79m7QJnH_?>m?b#(fHyPk_B21EsBft1`}fqu^(*t$Zgi{{Nb-8r@**G2hD)LFMqrYn zarx*FfUopaVZEtC4rI{YZH03YKP>{H{yvwvZ-gGa6H1H0_RLABr5EHu@+hA;<@K>* z^5^U4esXygo}o_`J5BG4Iawq7(ET95lu0y0bTFW7t&wkicm$EhX+*xWi>*0XTX|R% zauLc{pHt$u2I-1e`LF|NVU+4!{xYY_m4tfinF??}3K-e|vgF504ADijaH!%6N-Ge? z;Y`#C4RR#L^m8|wdE7Sl&nP}Q;EdOAF1{o+anq2fv0I4)kV6-hLm38D*M`v zuUUqP+J+NZ)DaKo-P(qfUBeNGGs6Ycc!MjW7LlU2*_I&Q2pr_dKGH9)$r3%#Lbw38 z>_^3vgj7MT5Xd8=t(Yl`PlbR`C`7}70B8w84oM5^Gj8w}98(di8ny&HVhmQQA{TM+ zMgh=#b4`{ELv4q!dP{%c37t|Ydw~{v zFV@Ev^jtVNdSY%x%^G(pdT2ZaD>Lz$a(XDvUDFz@fiSEGt}dUPaR<&}%tqTsPe=iR@_uLq z2X!F|O?`}oqLYc(aI*0j7V=%D>Tg2~95z+J=!OY=_cck)DuotNmyDmV&Xzg$B1 zojDo+!Hxu4q5y*P{|g)KzWEOmn7=lO@5Ipvn4Shwq<&}=0KH-TiPqT26*4?EqcOCO zIa-QB#iu!NJd~x0W0I}(gZYbGOqUvyrqTo zslgz@0j@xNWH_qNkqNtJ$#%r}Gc7f&Zk(~?(}=r{cf3iV$2S zjb%^8#l|oxx+SeyBSEFh6{8opB`23E_;Cou@}(euV;>*7E|SqX7N2^xO*7g-V{?r0)f zt^)pa2=qXDf$06k7mS~z-s+_}XAb2Q;0Ht%_+9ze2)O7}4#8sTISVVMSj9VgViLQ> z3?Cpl@gXgwkg!n~3!9A}ZT16ncEL_pr}(t!eEY|Tw2tDRw~Q1#V-K#hI=f&3e3}&c zo_S6bE`ssWKQ>MF-{XxVW@tg6cwA|mBD7G(w~RU+N@b)NiB|fMKI~)cLHr?O!0(O2;$lLTeu--j}N4Q?t|y6w_bbWi-|;)iiCHiG|h9K zi1ShY9iU)I;k+e(oFp*UJ3HiPz;Qlo8-He`hDCg$5789VQBhKG@$14Y!R5>)A|Z+fg&I*N9kyB2wR!#H%ag3`O1CW+{F*dk=vUCgTO@0HWW7SN$SuZwEGYzrzQbP z&ZMLHhzEUzbS!CVnT>R}i?U1?rnxfj^Kdc-5THG~$rTuuCoH-lq)?846 z;u1lNk1$RpRnn3&>LH5XVo?9h*IFa&iI=JXnRdK`s?DnqBX@eR6gb&dk0nS2oO!6Y_&W_bw*8JXhb7OmEoFI@>33;VQFx82GB%1t zY}luWMGs(5IqX_J5MJXaDH=c+aAX$3ROgAqm_z7Q17~^pnE1q~n+Yji%er#oZM&jS z3_628*4mHhiG{_?0~!V3qx(Pjcmct-HJueAX%<6`-A(Bfw6A1CaD5mtoo@tRdax1;3o-=j?& zI^%%Y2YA}C9+o|H5WbcDlqn`Hkffud2!1pZXzH-$Vh|J`1yrWtRMILVQK|-3uwbF` z`iMS{udU{r+&{cavx>95gJg?p8hy=~(=7Aj2P;zzTcL-1UQFDWiDR!>)6uWZ9S_@R zAe@UK%r#T4!;lv1UsPKORCrf0-rqLRhB_NAC?ilH${PVLEoRCM<%?NNx%TmiTo#*J z>xpid5)A&vXrm-4De8#=_8uA@QXF+`An1v-r#Jt6Uj(!811ls})lz_$YGm9H`0C+s zRh+_K@!j+O;3ucgGP)yAyws8xSTLD0-*gPv2Xr+=s@@tVA7-_pOon6R(iMTaHoU^L?=GoqMlNp+Bjo37@XfdqcpPS zB*^>-Wnrq>rkws96!NH@(F1h&Dcngqg7u`!F{>q*@c$%3w_JhnfwCrBOm2GY<|N4K zn>(-3*OfiGp9crw)9STH?QwA}o^O*PpLX3zV(Sl8)mc>hMVJv#_m`w`O3m>VGC|KP zD4R7_Tn>EVSpcxkHxoWz3a->%f4P;qXT9hnDbb{oVR{FDT{Eq)&pKZ{v;$$B0~t$T zTtun^8wd||t6xD&>vK_2zakPSEeSk_!%q|^P?ZO-Oix3I*vdu8Z$7tIq?61#ZTVj;2(6`ZUp|;afl%+U)r#woPuv1{hZ%HrJ@XZ%I+hj^(PL2; z*spYozoST{q=yXNIbkaCD!A3BU`1N#o1#eyx%*_H%?t!`Bdt%AwDj=AsR^|!KhJ0V zoptJB$;Yu3lezi+cH-I`rE)81>@F@3R7xj5Qg56s3hX-P2Z3x?PbNpd79XKNm-21S zIevP{sio(6+1ohR5@RlBN0H(qUPN!znD{0XEwX8_bv*XVz}*DjyZ*)D`MCsQd2I0S zw7AC1Bx$-iGr?fb1aOE$K>+~>*^dY8n?~c zILzgFM7nEooL!nJJyK#g?9B?QipNDdI61QV!>wPiV+u=R8XY)c&$QAvuj5-{LUWJv z>Rl4kQxM#nW?AI(-+K0pi7~eip)pC_6;R7!@(s?T+Zgs;=tlo7Tg{vc@OFC)E##Z7 zsdzA!9L(vT+^C|1wT5*ejfmZIg)xn^|D_>cm#F3o@rn7tUByzGfK=SX`3V02*PmFA zT7Nw*Q){xNE6^spoc3RdiP;gY_OBl{Wn<(=WM&7O1DgvTj$uHM@}p|D`+JR|aQ)a!2b=Hoq#|yp$-nan|*uO@8k>~#5brXN>^YK$bjMv1>=Us zD)6_`!yocV+5|2ZxuDWF%deP5^H_pKqEnNSS|eG}xawOyYt9Tlj`f90v|P=g0KViR zWwUm;kEgdT$B&;+-d$Q6fmgI5&0SpUQ8E+4h&&BUrvX5v30z!svjjRYNw5BYx@?_S z`O+Y-x_YTq9d0L)LW9Cjr}Q!nq$}2+{}as1efdZ*TXaU=(*9$O)k37_4dIbmJywb| zAVeUJK2-rGj|Ln43(Tl9bO5f&em-}laKw#uqxZ>o35-?@?SxpaN#=va*H-m?GZ_Ij z{K=@%4jpOo7HiQ-BJ9B%JR7DavNm{KS_)naza_$3va8dOBPqb6mHC2Fdf}J z9iQuZ({(J!BY(Gydk=JVr>+R54Ybn}8q3c;dFAG$yRQuRU0s!vizwe(@uMj^CvrX3 zG`ElS&qB#TpQQGV5je5QT}|%p)jq<#W_hh4P|THKbD6PB!fS3;$_Sd1?ZQp9c-6w) zOY}VtB3ErrZj#~SNSD{9B#f{U9kdxvd*=;at-3fZFd|MNEAL9sON(3<<7nKjmEy1< zDcxD|PeQn8!lhiSvsr}DvEU$v$R#+`NUcY3OVB(M7Ex8-lFNSO$x6t)(~XuTAEY`r zsphz#yrHd|a7wrw3qgDCUfWgCzbwT|(7Ts9Lgh|Lle$<;5``Zb%RfoVHhR|IX;Ar$*$kCVVwtu8=Q z?AG1fmr+iZDTgk7(yN1;8Oud4#L-Hd44H8*H*DkzXF6AoL8k{yYMCyuh5Hw~bHFrc z^AGFjB+bQ9-GPVXQ?A6zs)JMd141vLENJ?Y^L0!W`R^_SDxw#E>7JWb2)rvbKI4aSW{9UaXq3|>l5|7v_fu5^-}*7+t1z|x3M!2?wvWc`9JO(MoOdw8e&X-t zuo_3wI=2=7lyRx+?!Ox^bG15&d479Ccj4|Asz%)vA^9$eTx*TKP7mh6)!!-ca(1WQ zzS_=Wqt(X+8Al9-^kI#=>8FitM7g%TW2A95ZOM@**pgcNkUVTVMcs! zFm@(oKBeL~g%vGRMF_d1`oAP z=Tg##1)tWeNzz9&ro%kuv)u$9jm_Vb#BZEqmKKep0__4D^fDia*6RDrrDumSxHMp8 zvjqDDrZ>G3;%<*?5o5HI;fF6j`LWR9#+=(Q5Ec^q70qO(DE*=RI&x=j8v`-5;Rw=I z^oEXgi^7R1wtlP!WNBa{EY`8sHA^oy93uIEODMN+_fm3*SS-v(7-QMapeakirNYxL z^avYIYLm^v73K}4r^Gurm zxoRe8^#r>pSc~iSF*v~h|4ugFFQD|YFi%*D@-7IahrsrF==&0;`-_!2OZwhg;UdfU zP)7^9;o&}xL_-eb7%c=|IcY>?j^g!$35yC3BnyS0@-_xjgrLl-0YYfUYs^`wC*Aya zq#h{~y*>Gx;(ibco0Z>RhfQS?a1CX4^kwQ4?BLcn*kx2gf?@>>p42aF!>r!A`|c^k z!X&>W-EWb`zB)SI9wF+XP_VUg!#QzQ?E07_=-FbwS(xzc8~H4s;~!L;KKME|cXfTP zV-oLXzqrM$crmC~zpm z2_z^6bpYPgL!z~i>pgr2&rpwCzR_LiX2n7V1UE$<)_moNOnBAXw-`0 zA&XQ<5?dnh!KFJhz^9YTF9vkhR|4paE;wp~qC9@2CWm07CHiE~?LmAj3z+NG|C-i- zyPD+Q5IBcR9i_ztou8%6udjzjAPmV+W1+Ud*whQz#i*PiT4=PD`86=O!!`7Omc#F3 zrfsSsXLB#e4KU%%I*^#Hi5_ZAeb?|Omi9P84U^W77=4Zw zsE1b7<)0y%bv8jk@JC@{WOrNUx&(7VA~-C4Z2gjJNxSpZb6sG1(fV8H{!$iPbxSr~ zbj+3xGCq#taN+@P6LOr}=&$R{UpM=-(O)uP6=>*&>1cdP&vuK}w!u3UJH#+@9oaFS z=`oILu$ee%TtZ1Pn6zQoqn3LOqXN$b2rQwPL~BGaV}~kb^iwasZT0ICE%BtuYxjQ6 z$q9d6PZPnp-MM!k+;c1gc+vi#ib8h>*=4hcgpIQTZbhCbh3+6C85CV$0}P*8?X@zX z#wYxs4&X-iu5D7z5L{+e5s4F8f=0#cqdBT#1J}k-1TJ8U~8o*PXGHfu(DIu=H zJ4lS8F-C;Q?_!k|2Oa4`fFuv5!%C3nBTazQFl;U1?z5b?J8@Eyhsk828>I&OltTS< zf%rLMgHGT>668Iws5*Y5M%vKs>dQuwD#$O1?L4p=p^bgTcIvzcD!HWkhY+f@vDL3a z((^C119*{|=;>~VT{)$U2Gw8q^_xg2>nS-4o1}y&ggbsHJ2ZvjC2}VwD{*0bPeTTm zt9>@@KJ5VMv6`)IhpY+2!Xsk_ebF_eN>mP3dS|~|PA{ZTOKBdW*fFsLT49iE$JvY$VK4!WO^#MK-2qD)*o4;Vu zQ*(ZmEJYQHNsoAyD~Vr$TUtc!yPe|hqj9`;aPhz*NM2uLLI+ckxTuIoIuPc^=Xy0U zq@47pNb1Td8GQ;4eq$kZ6%@U`x&L&1ow%-llVx`$VCU;N^Rn%}myDkWwixQYue+bN zB#M3}s~ilR=2%|xvZp(j;T~*y9{_K202Tc2ZRm^aH>=G?P1H-4ueGk8*->*7GK)_2 zH@|MA-q+(>wg^lM{x(5=adaqdJb@&%vIXt3;H{3IJ8#!IBWzo`knc5239kRsK>>H! zz;<%Y&-=nvilkSkmUdyVOoud|Dyp*Ci=~<>h1LC3BnJ#VvGjzdICY4k1RS3-J`5rf ztGp5e%m@lA9O#pP1vgviR1dd@?CC*pLYb+l4P1~e*WuG9QX%{a99rO22>uM-CwcRW zfQ;+1#8Un&o#_yK;q=hnD@oL(e#Ah|P<*id21&}08S=yZ?6xD-Ym<=UkEc$7y7A`s zVox09H|`@BZnUw;FnuXW-~WR8zpl6@!;e9Gp@MKw#_GLLq3`e&EV%HxZltI5p^b_H zbWvVbF@SiUKx)xKxh0Wsy37i0aOo|fd|IS!j<9H1Y-5p+Yx$gjE0z#r)j~NIaGX7? z=7?)YpBop#DKIT=t(T7alj~7$1;|!6p}YZg4{hpshX&j$vV9A}{{0K%?>*gL+XP6E z4MxB2a(Q*(>-O%ZfG@3$O^4v(oUXjVIAxuR8pU`Yi(uD^jMpE)?*#-5jR0jkaFlfi zfl=%8Re#skZ5XltTrvG&h@)T)6&KwL+{RFY9ZM~5n* zrYI!~`B_cFOae(#u1Ues=`p~|uS%}2~L4rusR zaTX1AoCNm$>d6jkiop=}+KrxPj)fX(rVCG3k?BqA zyQGwIO5znd)L7VGIAA*5*mE1*l{34>cGjemFZ%12Dnay{op!UN-yyBTqKscpsk zb&x6926SN%pNn#L;C2Px!8U({p%psbkYia8&56GLah5;}w2jC*NIxJ%AkEV#m3NTS+c;2(pcO0jyF?9l6|>%|p+Z1h zTEeup=K^z&RY}~vgdZB%o+NluQq8L@h`Ef>g9-^rTJ^i~UUH{}>%~4so{uDi+Nq>( zs?M8Q1O%KxVAHCPZ(6|Wa7e@X8V3m|EMZol?BODxzAvuTbRTzrNSQi#K%o%L)^1Y~JKkWR zeKdV_&E8^Mni0wWTDGsQ(db%zR}n9X5P{q`{w!)=tf1m-)fs zdF67g{SJ|G#X}WNVGB&M?*f;=S`oLN^XRh3)^f7@j@#n?o@#lSId;&Z{bbQF_3m{4 z_65FI8rA_J*sjQAb|&T<@Bh5nSNplnoR~9bz9;5MN@x5ua2;lSIRBi%j3z7B|L4!%~$G8DhNj20rxX7s$Uaij>7L86q2sq+D9>d^cHmv*)0-nV@c?sk9Ga>QjjK-P2hO_M zImO(zs5rTWede)lmmuU?X4M-S=aLe*g4E;|dTxcS3B}UdtG5;`Gzi(OT=*6eqyKI$ zy~2TOKgUK%=|K}ScsUCJrMhOnH*Me_xqs(KOZFg z8ix_Ec-vFzm(uWc>Y93=s3HL!F}V@H`y{3laz$R?X!1I0niJL`)q0N{Z;(8h zp09D&R_1>`Dbu`6cvM6)7HL?w6v*PKfD%Pc-01o)YBF}Yz?+>TVL=3qy&dB#$^(d^J4-!@TMwqh$38sLvBmi$Hi5EQra+rCF2;qr>b|PwtsHAX7gnE zwl6kKeM_3Bs=Pitdy<;02-t|r$Gf$orTc^=Uex60&h+-oyQt~sY_(kk()Q%%g1^ru zJJfq!4!(`6p9F`OfLL?Uzs94hrem=2Z)0FuYr8{Jd;2=yV`zckbgk`BiM5zF&eb6U zh7ZCO7T{}rpg$g-OdAx9s(&77C;pPBc9kJ;%)oyNq~oU_y@BB3^UPo_&i4Nu5%ytK zJ*KW(kC|_|H8;$gbLyCpvArH_C-snEwEk4{%-B2?8gO~H@8bvi+PHDG`TE9E`fR8r z1|{}AY%+c1s#E|wkq&27Q-lr(Q%N;kPJ*>+Dn7Hm4eVZobk zh{vu0D?Xc6P)QB1hr>q3-}b7ClnpRo$5~#jfUbQVpD=mvB|j*MKwJEc%{r@WA|&-^ zTtcuJ()Xkj-~^eb_S}vjazRx3R#xUTCztxXZx?^Gp#=eoFi$Xv8WLc5nkijv0z3z` z@(m2(nEPq3J~)pUPCZE_j`5?jcw#e_trVb^t#sF9EcZG*xHl}l8dkix(01{;Onk_( z`e?^;m9ZOO{1oDMedMjN`rF9Zro+HxG21wKmqxqgMfq=cevXaT93KJjZZtDuOUW?& zDrg)&+BtaQ_1)=@MS7k7c%w!lu5D1KG(K$7h1#+mDX-x#Awp3!%Yb|?0H+;`uSChH zLP&#!Brdm(pM+-#Z||D2pN9iYm=IeXkYn{-C!nQM&{$b@gT))(GhYcF*GjL{S=z(9^_nLn>GQ>cBQUlbi1J;JY%W=lY4BWkFn^%%mue1 zK8t!_9&ZhkRI!@ZHfdigWyOQr`MzN%WIn$*QuDJ`>ta}Lhhxx%6Ih+9BU+ip^xr*J zeFchpZEclCo7L`t=q|^GgiitUZAm@FifXfMy{>>{wWOJJUPJslc9J4}X!gX_;80ro zyYM+Q*XD77GbMPH9eF4b^qAyF|0SpHLZ?Y`qS92Th#Ep(xft*A067s9opBjZ+j37) z%pkmorh1AW-vg1oVCDEeW2I*1M*^%+g`iz#UCjkPJ$v%}x4>=4p8V@OF6h^?r3`1e zN(q5YuqiwPg%>@v3C|7*Uo^t$yb9xI1BdR8{vE_z80&MpWr65!vl)9&{9l$NLe-vT z8N8nG&#}(pYLpl3MjcAn50^Nl!;Kvp&E?|v1EAEn-}EF*k$_<5k!|pSh<|=%X|HmZ zSWH3Hi0H_%5=LCOfkxsp&7|3{=)YKv#DAuX;alJh#2;5NrePw%eF?$(kjfDEujoXL z$VN`gO=lXzW0UJ8K5xJ&3vx*eN2m=+d)0$CUOxm@vLvPP@=Y0e*~Vu-8)g|Ck6ak< za@_ryeHQ#e;6D^Uo?mM3joraylg;Lbh5I^*WTBV0$od>!5IGuqZti+74OPrmdqn<~ z1*f`AX9|oJuHjWH0b|8Vow@oewO|uNq!77kol?5V=*RGgd?oi-7hBwlDs>EPU^0@= zNU@@3C$nD}(NS=QXgYyDpl|&lcKZdDI)nPBG=on$PlvVl?-=%XPu|rC{pqO6Xkc{K zqr~3Dwpx-c%>O!5ti|JHodVp=mOvliqMhq7nUDXPknS)Qk>>5PSj*yJ!M0Cy*1k&( z(l<@Djb8reA~Q|59fZcVeq&Tsa@GzFqC$%^@l7wQ+bZ9MkGBE~vpQ|r17|jC3Y$hO zqB&$z3-l~i-VEzrEZYSx9>V?fz*Vk}7Qe769wO96T;pzcs2}2&6q7VF*dhB$$_3@! zNVn=LI@aToJ_Vt4BN?NylPKsSFD4G7I`tD^cLV^$kPR5=s?TJb)aYGyw9n7x{H?pO+AJ`qmw1dtpSID`X^@m!neL0Q~g^N--}A1jNtI+;47EnWt@kd#EY}i=gH{l9ahJy zxU5*^TLJyhM;&nr{HYEzm^+h{{REZeMJd5!)Lvg;z5@IR*APK-dBW zh<%)4Iumsd&b+5f5O_LQ-0c=hxWrbf&N&3((MO9ZBCSNOD>;{s^G%?`8h51fC zLh&>!!*kMs6{lnnnjF_Y_UX@5`cM5-*2}G*sc+ixkmDrORb~TJjflzIvp+uUTpeCv zM*NaRDA2RkD9(}MuduDp7w94Z7Nzd0(9zV+j_(Q?D6#HArW^wEkMX%3qF4_qsI}RK zhP|@r9Rn=LgUTUOEQdSD0y{)+0cGPYYj=5?^vgtnR1F-{iTE?R50*)!K9|f$w!f*s z3L3DrGMhv5prD4jj;6&^hwIlL-8i2#*XR2k9yrA`f#aclInYs#S<~-k@Gn_lYip4% z$7pLP>@Iz;v!nWla3B^f036MT>+`Cm`oLPWRfsN-qYxHx&$Hv(duH+<5$NE%UAZ-x z$C0M}CS5QBgGkl;7jG}yToP6z$O9+$aKTxjXAADAUOS)f!o5HLF|>ZqtK5Kjxi(lR zG1rsVDt_mGcNbuo8F|8W9WjakWs(-N*L>Vkr-HZI`*0mVLA+mzh8M$7bA?g>r|W2T zcNReyu_Q|s(8~F~#09SNu_}ix6N?L_w%T=UJqh0T@fAD@j)loeE`+w(JJ`fgtFQZ# zBtM&Xopt}&un@pSI*}LQ zfaAv)de?^1*(F01mboij_X>m!%L3;Q6Z^Hmf4`w90DdnDS=r%th|~V~;@4g2b+m4TtYqpqcybwIEy}h9;4JBzB2vY-Lq=d3wUBw z=9_{CFDbA4y3TzY=db-iC35^coNnZoSGc-EN5L_d`5Gr>^yGpSv);?{rS1LA-#*ljc#ex746-}b3goS>SU>a_mr$1ptU zh3$1H+o2-zLH;=+DILZfm_XVRy?Q-}5R_@L1WJjYLQc}fN$LNF;I)9g;ryn*@~uih z+iy}0NJ0|k^7Wb=&lm|MyR=KnNPGw97a$Db*uZO`+2t!{{Ji{b zUWPV=11h-LQBo^2UEK*G!;h80Qp81Us1^YTMd^fQKRbQn3nq-GRhL2k`dPhqB^Xo& z91{5@jt+sw&tI%REW2O4(3kF)a&0h>VZ4qR4(L)OcN!{P#1T41z(k-B$b`V5cq8&} zq$L3l{i(RvU|Gi{bn)IUlx{&R#9PVJ_T$Yp$X^x3kY%u<(Ehk5T zeqg4hA81tm7S5&y%ofWC7gdc2s3v5=+-GR!;!YRvOtfsh0-rtWFnK|3dV8vf-!Q!i zxTg2lkly|2nfb-|LVsU={f+IA`QOJaNa;}L*ha%)*?3Qb(xh6CIEBiXl1r$jpc6tw z%kwJGbOXHX3i`PZ6sKI&S3E7A2R_M0a3mxSL_C5^m5*bo27Aeg5A|6GDf6MXT*0fA zeaL33#kxkEO60_}cZR^hdBeY2yhwvPO%0-eBe6rEfUAnlRqqu+1OhV|NjEGwyiVy{ zrh6Hwk7=)iWLpb}EKr*ABbwmAb3RmeYFE*oO#KgV10RF1+~KDZSujnUb3xPlh)#u( z+#{Nn66b$C;QK&~z%z7=eYL7mV4_J>TtiyPz8dTWsxcg-y0-!#{F4aXB&>}Pk}Y^Q zB*t|VD+2%1*G9}|U8#Vam(*E7PhCCgM1$zK{_jAOSzmZ~6-t*0cpOB##16=Ac zk6wiVGdV!h?(niZC)@FnkRdcL@r?KjI6x4iA$}m@QC#vaE7Gx=Xz`;2-H8pAQ2^X9 zmN|Nv#$k>#c0PPT(t0r#-OuIHNKe(f4WR%{2@@kwfU0tGZ+k?Lx^*B3k{(zf(nfd# z99yxnNC;i)udHto4k#HZujQy{l@oYCNj8i^WZ z#c?0c9`=*mOCgzJzUB)cNmZW@4Cl_^9j*|mH;+>+JEZE%q)@+3bWg=Fhq4*TM9`ta z>op!4i^~)XYD!QH$!kB+PCFzaX+O0}MQAAsHDik_8e!RaDF3*{>Av5vAfi3T`lW*ZhWNpZCLm zl}QKE{laR=!Rt5sj^E=2(!_!(+_j{aoXIAuJ*`D_)6{*?F0x-jM`*+y_OB<5)qg2D9n z&)M;zipIRfqXw~!(A-%0fHaDEQR7w|m80=3{uAK?8nHH_BuXmd=DjRvT3iVMR-))g zurZw85k_tb54eS}*nRk+Y7Fr9LKrXi&ivjbzC#)gV2xx@$xkn7Kb~2wqS27rd`V@?kH^OisPUUt|vmx2Q8^I_{aJquR1$znCLHZD8NsnR> zX{S&wRth|f*sib-^iLjO?k=nb5P#Rp(l6P(z(|9tz>0z6@?Yx0pr@&xd?E$xB!8D6 zuyoO@+2e+?MvAi?CF8RABn03nDeIp_u+YItI>+eEqR?nMZ&N2PMg>nhlp!(013yss zQ^7m}|Gn4x-K8i1@H7-L0y;o>g@0AT52BO8ooLYyiZiC*(&Aix zBoCrPh08irLST9RaqcqZos$}*9G`*$?7pF-MfD`=-y#J3e_LED5`l1R?H8XZ`R_%P zpBVgC-_S$IL>wOTOMKL@O!&3|t<9HShzm$!;i3W#L<%dqzW~^DA^JLC^>d6NOO`<0 zvUq$nzZcf8Uk^4rBQD9JX?tXd54=jzf=dM&%e`kRnDoHajC!$Fzb;Cf( z{;#Ap~KU+VY#YH?bHw3dXS(N zm83)?S6BZu3Skk>9DeJFY>CS-TbtAc=%7}jd4|}Lb_b5`CxYYo4%~b?iq_ngvwTw# z%jDC!)#+nc)XtUa3q^?*46)!V=dT_zqrKd*Se5hUHg>@&d5E(hg8Cnu{dkTgL>@0({Dy^k434>|LDt{0tucOA4(D^Kh&p7OAVO?9e%a;-6t zq4W15juJ9%JbtyUKifM+$h3z}zx;hFXbWfFOL%P3r~J{Xo!s`mrX#(T{p$UJd(IA8 z?^W)*ah`z-ed5|fyH{WgEnuPnfD4-oZp#zTgjdSwInrFYhMX{k6`_ad>JX{FjqM*F z(oRE?QBDZSeEm@hlkpPbnZhR`<9cLI{ zP3FLUe03Z#bkRA+MpOKeho3zs)}*iFkBR_*_%j-8jBH5jaX@&#vGRm~fQ<*D2$G?R zHB8R^l-JlQvxFchNj7!MO~5DCkls@zdD4g&#IKIDn`56?W zFJ*-D{#C8f~yQ<46nnOo!o!%>AAW7#ZeaQ zLwB0OithW3oQcT4>Q&;H1dme6D#>_Yn)5%D&0gjn9QN_t4Ss$eO>55Q!e=}gsg14d zK(?7-)Z_=;G|}?eg>~9TO6FYq%X75*rM(2$C&5bc%hv`cKVFzVMf!m0|BSx08=qA8 zhOCyAi$4uo(vSM;yOCZF zYU1x9>T2N%dw<>rH-C++HD~6Wv6sd}R9iXa*RYWm?#&bi5O3Zz`yyCTZ6OOS?kBYUa`4QV|Cns>XXIip7S{IB9B+hq3i^Jcei%+A8_fs-|O`<`(nG^D&Nm1_hw#kv%zzbY9(Wv z&0Nid;IDoxSunX*;d3FYqZw8C&3#}nr$Y3!(hi#CtZ)dnTn^Op=cn3#elB729YU!f z%E~QIn|Jpc6nrj;7j|Li*(i3NOvk;GCm{k7j2&J9azC$G>zi^eU8Rt8){r=Ic1P0O zt8U)-Z~txOX$IgKwK656b)9qzwjke*X0}7`xkU51OQ^FUr7Dm&y*#;C+hNA8WanF) ztg~ouM3G|kWEwSy8WTEM#iY5gY z2Q5|`oQWU9(pw-kglIH5AVXpl$dI$MYu9dct@UC##f%ent|wotEOo~gitWusEr2Tq zq~Zj(5NYrqzUqFBmH25{EP06Mz4-OHNl=1cg0ZIh*ZlD0Jrz2Zs%!l7SS8Z@)J}DrjO@Ib*h@_sLNUek=isNc>d0~&@zqTtZZW$V zZZn^vGe!n8f45WYh$4kHG>3|2j#0y6)0%0C*B@#n=V^WI|U5~_l40+eLh+J zSofwnhCE)fZ0pjUJn%co#H})S_JuP3(;yAliv}3hGzDz^U#zO|GN#At*FV@IL9})H{{SlRi6;ky16ysoIeNe!_M4e5iX!taV zRszoTA=+Xk9q%9Y4C9Ib!?s&~Vf$219WGTyGM{l#0_k)@e80~cf_g%)H*$fzfu@4z z58}qk>%Th-W{s>kQ>BkU7M9O*XG!^RO-b`Cst*&=DlHj=RI?+ACjeA@bhVhTJK!kR ztvi0I>^W{JhcbZc=S23Tl=C^qNKfOfX%F~=hYU+6GmPR> z4KInb`<(-Ya#0^lB?Mm13Gp%Fg+L;oIDtO}lQF9WE5A956dZYsf$5c;;YMCBIy1j@ zNeT$Cn)muK%pr`Vx2h!$^|&IEhCnq8-r86OMH486!|S+?&{(;QT#wzG+_?e;VhcHKBJVZPBw`29{Mn9kiwY~ zZXzuOF`Wm9a$Aqnd%Rjv0h zq(K4QHp-cKY%X?{jZtICTl`k$Dc8N`8T83Xm2rrTu7jc(GY9*l)~Pxt<40pL(x-4m zr5SQEB>Gl`Y6$NJeEH5fr3*|8%L`3=XBL}wD&i-h0jQ9%7*HW|?@AU9l^Vy|q?(2t zZ}XJqsFibvjZRo>V!zA7$CvAeEz^%3Tw-so)=gqm`A*4PldK@4-Ak6U7H{2xL__<+ zH0C~I1=eTDSVuv#CkY8!ddKp{wwT<)qAa@N2s$*Z8-+!Bilod?ocLhxQ$1I+Ar-e> z8dCI{Mlg4-Q?pLGdi?hk?!<==&U1_k5(=x+=0Y*II45zJK-JO{TQlE-*{XwQF=<2R z1m(MZE_R@}dYnO&##%PWb)sbW%P#0EaeI-iEb4I71-iySdvL?if-SB=6i%%9o| zF;Fj;un4Hp|KYB2g?@RPb?viP|3}Fr6di!e(%c5I^DQ8;41e_bybV01XV^x|J|!Pu ze5(rAJ0460l%H~{5g?%iD8IA_P(D2ZuMUz7RZPxBwQh~hJh_8d@XF(d4=iDnzWDNc zvgTFZA5wWzSkH>m0d!{%B!L2)FbpYJHRhAlGLf@x8KrU7m>Ptx(ALc<`E@ZJea^tW zgLt8=-wCg~#=KZm*R-847Og+j@|})4rifG2;(yBWFpJG{Q0Pj`0@w%sN7<_^`_1M< zs47f67P9OhP+4zenPd9!{Cr05?H#C_E;^2!nMn{|d((!H#WHnao5N;?UF!#A3tN_7 zN2@Vy_P#$*W@%5$fY1(d-mQPd*s-~6D{Z2ZbtjYH=_ z`)>dFLxFWh*yjTdvEMm5s(f?5%rmYb=p`1w9&ib21MGn*`j(y26*@GBCp%t57_%pP zC_%(X{UX13)q32VBIzzgtNa?U3C8U#5$}b$VcNXgf(t%NZj3Sh2_xdkw8xpnDj!A8f-osHX(Ud5c@A3!cCA+u3GtiNWOwJl*>NtV?m}x_fx?uiv>Z>d8y^aY zT7;CN&jxF-ncI&13RC>a;VqWGM4E@;XGjH9>eb|>me0bfYv zc6uRI@#NkiII9x>it*LK$#H1~Y6ZqaN_dvVq3ZEx3st_RY_nl4Xit}-)vQIZb5Jqh z8^qgW>%EmBaGnb5Y+05XxVG3jV&aq!D&($hC@8XT&PE7XiYN+B!F32Wq$;bXwhF7< zFZiyK7z5g{em_oCulMuYt^HFQeG1?0AFMFhpIok{@nb1f->_Zw&Rvv$GdFsGv>o30 z-qG6@omX=_pFJCJF5X3-Zo%4F7|DJ3xiqs`7+j-@Rc7(t)NzF9#`K5P5svPa$28i) z;I&^)vn=`4e6b(xLi^q(Jz=;1QEHt*J$a4twrE~UZy=S=> z)h`J;evd9!1lP@kc^hMDroZS9wqxB13kc#HP*kn%-`s%b`1DY*7JPs*_pp|4-n4`% zzL?t=kcC-gu}I>=%jYpe_kw4dIO`?g7-v**be2$ow6Ntj~U70OkmH3 zXz1j!=e{~@FSd7;lFb9eRM;%Wwri+9kj{npR<^_lh5i0Q8A8kiu+22s`j2g?I|B!R zZE@}|RG-#kR9p(lpWkK1vqwuN2~UGRG&AXDbgQufelcsa1c!(qM%hzaw(^#rd|OS9*rTycyo}J6I$D9(#}* zKDSFWP6$vE|MZI>*W0<{zD?xd&vj$HE>#De_43KYaiiDbDUnXNaGf&Fmf&8bueDY7 zq3qv}e^@_94;c76Bnp4!LP)#l23*8%< zmp-jivGAGJs`4R{`;=%55h8zBwFu@ncmkBteK-+uO1Q!x^lK(+SZ~0RfwZ&>CjW72 zT2*fB-PA*MSf=ooBw%z|_Xgs) z8F#-s$P*vGs~+k3&9Hjg(0g+)P1)h>73{I`)iwd`bh@Mt2&UZCTQqDgPx}?n>X!!Q zXJ^e*6P}R4n<4uF-V{N`Gkue=$*sEiJQ&cMBw0>T^qiYS5%GGERe_Tv`2f#EmWN7g^!pJT@qTAJ?|Z9&n)%_&i_3RvJSt0g z#f&Y+YWF_^a_sx~IY;zLB9R`k+Z{yq=x2DroXMG8&GbNd+?zVy4(<6nuoT+PJy(yF z9?KYkp(MYfdEZ-1^|CeB;%h>;1drI*e5k#URC1UU;z@-#U3EZmF$+E4-g~!^yx)9O zqIGgps1=Di2>~JEIftPZ37*+%R0@n_p7C}Z(Cjy7elb8l(E;cLhz52KhGzYKAu8av zC|T=eym6ht*BmVU(!i}?*ZlR|;KqRYn4NFh!P$lH#~FdZ=_(*O;NR{r#A+QMRc_r#G585E0FZ=Z&Eb zcmD=rPaqCE3Uz-ACR$yB)S`agE%Xx6RQkcu94>bdM2UnZd6w=`Fhc>@JdrtuB(w+2 z=79vpUziyR+i}JbE@WwDdhx<$(~o9nlgABebGb4}7F~(FFDCu!IrkmrfDgTX z+xM&b00_tOJqV777$N3wq)bCsu_mhtWw-9h4Agn^w|g$HpYBQR1W)>iAhb{^BjNka zJ9`avn>{=7gwc9k39+4-~9xrnD{OU^aXM{3u<$1?A@b=3cd{jh4>i=D`22FG{YR{(Uw=T)}pyA zhVNuSJn0yr7rz5PWEYhkHTpGZ)Jq@tx1AJS^_RC;2W6sdPok!zQWzINC^c$58zRjs zDB8yVolpCOiG`6&?=@uzrw33Yn~tzU1$;UkDuAOUeXka-l!dOHPO@~VH1s?8Et)Y} zflJs^XdkwuCFCK}?Su+nXLcjTiN(x;b8O}&6E;)^xazVvlNT?*RquXVk|@X`j$X>z z9=B^Wes?-K+b*oDPxUz4C^)E9SY=vBC~Gmr;P^2$d>oDk7oQ+TWd~evvieCoYwih0 zlVB!D*|H?R`56vwGzQ!l2|bvm_bb-!5mxZ+M;l)x!cE~q%{Ih{>eJ?G+MqM%UVq@a zP`>=>T%FtAjNIP$O9!^$X z9u>(Ch(7f;8~Z=Il-akwba4Kx?DcfrI5KTClz5ywRnx#{dF;C-BT`(|@Ah_PQcv1q zerCFvk`x*=3q2(&DSyCt{Hs@QZ<}i`LI3a|;h^)-UUD^D&F0XN^KzEx;ticxGo~Y! zhf|seY!8bTnO^*0Kn2S(OpwF^+*_20B!aXV1sN{>opS@k{yH+J?S0Pc;vZtMZt93z z_9YqU|P4o!o9T^^(l;Y7qMW)j;q%4Q__t!fw zP`?%{Fi?)9|CVg9s3?kSTS_UBu)RpuY%mr7VQ+0R)eif?wzZYL!uwd^^K;4b;NRU< z4^LeK!_R2A37S}qC0lLz~BtB#xTz4D{4V`9^xYy(Pkkf?OS?nrrYW4XykU}1^opuzed zRx=CN(dYbZ?^<5LalYGPzSsM0ju~%8e=+V|dqFo{8y3q|O6C}k#5|*gijAHE^eK(P znc?7XXDXT{`@DW`SUe!T|1@uUt-bAxbcv_oO#-y~r)t$!WDaf7(j8=ycP^MHGYZlAj(G=8+q5$6kkk6%}r$8r?5Rx2~nA8|5K{=l&)_Y$I z4c)6?hID}FbhWcIfiNRls1@XEq(=iK*}`|++|jf$Wi=M7l(DCD7J|6Hie z|LuX;mLFYu5LuGQ$cLUSg)OVGTEp;r9(W*4{N3_`WPYwqW&?`kp4Ebf6NjFlUOol* z3RpqDo3$@!m!6N!sBu#bkC`Wa$iPx1y5%}4MLHt^t)BF^_b$cBD@NMYIwsofCDHF6 z{!BH6$f+WZG6%w}wrUvTodElWWt}P~#Y8fe2Fsgh+;>3xO&hAiVJum=qLE8ZNXDCur`l z&B;j0DFnw3{!22js_N4)5Xg^uO<sz|Lu3#4&ikrYV=;0FXunodWMmP2~kH&{<+3jlxXL1+STM+2)>597mGE-vRo^F z4N46MMA0Vy(EZg&@;K-pQu3`=~;g?c$Cp&1JLk{Qx+jeKi0Bn1tjPZ~m_S z+%7>O#^@bQ-L_t|zbj=GBDe57^uu11E$kAumEZE4Bz4F?G*i|rfYn2=vSwJ@88nF$ z7~cPok;4leEC`t_tGXEu+DpMqu~&}kR{*LO7f*!lqTG>s6ac4`X!ts^f1b8zNK+B^ zA({QxY-gTx@<)HH*u-u3e?0p6IlM->gZIfE@{0y~m@Dc^rSfgiRVjcxd=$bQIo&{A zzC6veB28#6ImfrGtr4HTA#ixa^74y;k1=5KT`HZ<^;r0nvYplTy<6Eh^Qhx6#g%8N z13{x7=g?`j&i#y!Nt{l~o!2+KaUIdfKWW!VkUqQyQbGO*X=HQ*;o_cj3F1S!G*I79tNGK2mrsC6Q6$`uX`L&2;4Fi~5kgg~oh$>U#rU1y(nDYniaakEg1DzujS zk4V?PfOQfl?wJzV(zbO)!GiscO!<(;ng5$v3vQPn6#zgX`E5HPWGu_um6uGX&0C;_ z+!k#WgsW-jC^Pdf)ko_9P0+LkS`?uk^Q1%z2I{sfSB_WKAr?O!QXb-FWsg4SCQ;N( zcoiK)?zmR+E(-47^&pAIdQ@!w9K$UJr${d=0y~QYC5i_)J1~gp$i)l7c1XJ~vcPny zahl1?1WH3u+}r}Jo2<-TBY3Bn__6goFwx$YQ_NUDK1HPqw#!Pi_2WO+lPmRCyKB?e zM7=B8m)2z1qTeb%A`uXCOw?+5#kjKd_l|cpq2q&8*D?YH8r@sgKRvYHRpZCk?`&3% zr8F+@^h^AC*GguaJ+O-j6ufR1EP(`f4Q_IefbMuMa_~1W_kO>X_KBtM*Q`!vr|jlg z!_NU;FNeqTwk{s`%fEMHJ9}kA*@(xVvXq(4D|{5p@UUETl;c$R{&|J=rs#;i0M>U$ zTR5vVR!p#?>p_QqeL4aE>(f!-6m%Qf&r2oqUx$_gP%#p#?jZ`$jOO*Kw@>yPw5>(_ODPat&n63Z20XXv#k5`r+t$dO+dwAN1c9qd@AMKE{ zXn=tMUx4)eck5hPS+n-&CXux2LErNgf}iecx(1|@*{>zO1y0IN8ah)V%2IVAz|belp9T| zogIoIxz{Cd65%%4;B6doL@^+4No$qiZQ zawD@ zm)IKe8UFO1g-=HpI`*yDX^|c znIEVHN-ft?#=jg4p#*zeN&YKy_$8=%aK{A3KIqq!^wNRbbpCMRJz_EOGBPE@a)x(s zcT4JU(9A0v3VRs!dyMYx%CY$lQD?V?_j#BW(CZ>MaRQ7M;QBImM~X~=r9KOs;*>09 z#1*-NNnn0C@sGeiCTu7GCT4}abhbB=M{m&H-s|)mXL_DyJI8s7KS$(lClWSgvq_$%)p9{6*VW4W7Ri<07>?i-*Eucz)r#@nwwjou8zUJz z)_kT`R@mAB;JVL{4_*WIaJI4pVf0Q~lS2K>ooyLcL^u0Q48tp_0cg41=+=P`K=~=C zx^YJV-2xdwK8AWWU{N+k7(+RVZ&^Dl-9IIpcU_)~t#tLeB|^Jou-k7HyZ(ubFWlFF zr5{aqR!8uk!2JFROlGIRtdS$7a5o7wA zQ+B1rr$3!AaF_U7kKxbwGwkS_jn^sEM1PVvFV9OccUH9uizCSR|9spOQ^+YXU!!hB zy1)k7=wGLd$9lrob6I3hUj0E?ay5z!T0ti;-<rHIL?5!AIbN)&ggQgulILKpO4m`TqEdGe2kEXBC03 z3zig?q6Z6kV8Q5$EURub-TN1@qX>?z)LAb-jGONF=|McD-B!`??sCJ@_8~ZKj8~I$ z@1I)j4Jog*c4S|!8cL60h?Bpjw1`&x>`^QVEovxma$fhwU1~GHR=~<4MH^2ik?Tfd zsq2#!kUXGGV05d0yyC)k>C3D+*E|Cm$B7Y(7LH%pK+(tgG66|gmk8!E-QoNJX3a9@ zAbI6k7Ui*?Jd4bj&mapJtp{-_DYWMML`804<5pO%=*`JZ65+#>M{|YppI!mxl;wGS zoZ}N@0Sf@bn>s=#q;U{#D|c1a-gvJQt2JIu%$@Ie4--P#NT!0s9-5dNsXOPe)i93ePKv;dDwlV>~TU7$Up zv{D#aJ>CHzul84r@IV$Gmqe`;*YLA+AA8cLv|TzJHcsTGYcWdr&Q`nwT1gXBOpzUU z`TQEW&0xtQ;^XYvEEQwq6VLIdHTQeUWK7 zPvx71DNMvL#6aywUt5R%lU5ZUpqs=6%cE`yh=?+DuCW<`5C2Z^VF7Olk{D)9gAsp&gK)ZMM19Th*;CF_+*b~3F?)(J1^ZI7SsBD zG3-n0x%LaSOfoNrgH0wDM$ft^G<09MHjflrnsiTYB0bovbb3fH%)Gwf&2>DzVzK5z z0P4Jh5sI*?a1eBQpaO}4bosT(rQhPRPVUMz1}(+^7dt}#T>;mk38GK`wO*AvM^z6{ z)8yrWc{BD4lb{;y$NCCVG)W`UUlP57sizrHLS&77dl90cCt@*uM=s6tv0Eq%9zJ+h zTe31`ddEEJ<$OpB-N4+iJ~#)IpV7g}Kt7TS4-!Oc&YOPt^7}dvyNwSyalW?Fl%pL0 znnYRn))BI#^mG?v=eEQEI)2Wkc`WU&T|tKC*}roO|wSkL_=e6 z8EDGY8DIugak4Ws$rddbDmWpKT)SI7_sR09N?EiF*#(tBh^z?04)xDqQ;2MR`;^4Z z`nU(X=;|F9o1QL!$<=^9RqxxM`hFR-JBk>zoJcVp_&$%Q-mH zkR6-i~7Dj+>)-QyU+;1j%>S}Ola$om+zt%lE@3iX4M6=1c zoTC)W<)QrNR52$9BdNhih_r|l9UQn8$XOd;CaP4hV{8_^Up#PbGkhDfS#*5E!O205 z6;@@-@Tmi4Oj*(-s$oTj-jg1gg2P0AU78;EK(G-5FFI*jV*GHBiMvWy93e^gmf!*l zegwtlO>!58QUGHQQD&>no5=pYBNF$;F82m~#^U={hd;|C%4wMu-UZsnr6xHC>*`+P zw4N=E6E8jR#dsLa-!twRBfHoQm(8HAfz!cm?o`UMAK&68>!4pbo7aN-5eDK9Qh@$n zCKirY&;b6K1@}GDpR-HC`59d^J+XX>#SRAtf8yUViTa6T_P_6S*;`dHPAzOx_fdohH$381A|yeM1crl^VqXt zqIo_;Gd;I_ioOm9SASw|nNuS`2=03{&Q>#YRU0<$R)DvU+p(Z>3Q>P-W8lw#$r{WN zVw4k?<4?|u#u4m(@qWV~lKj%F05Ra%^V=dy2G(hFryBveJRh;52m0GuzOG~>i1}$k||Jxg7 zI%VF}cT0Fbn5THP<;aW%0ge>9_*xS>vz{Mvp=LzHQLo24T_+lxDDseQ&*0eoH{2{> zsA|H7k;JyFL_zeAAu6G4IcXDQDlV$RxbC*2=%&q^_e99Wq+JFV+`SG7#63=8WCFT|K(g0s+e&myh}IzrCQV6*AcVm5vtBi@nCBcr9VnUT$z3B7 z0b;#rA+Wu1BOT6v#nvYWI-+`2h}=)@aREQs0c(MdyRlBS9`EUhJ!zzhDd~(hECIw9 zcK-?rMRvzSjfAOX+`@;tXa5h8s;<-I#oaJ5og21D zlSQmIl7z&g`3NyVN9-%KNtR<#`*%-`4azk0Gy}?Jf4Mh#FV!!7+v?Rj$TU*s{nu!F z=wTST)k>ugZ#qT3k!civtv8K5_QA`Cz4gCTeSRlQ1bm#PDL2L&iI)1|K$(-)lU)u| zfTqxgU8}bNqt{{|LQ#_0TtCxA7``SQQY`gu=7mN_o1-8pD}q{3%Tj{Ij|x&+ZI+Cx zJZ$`S)&g%(*YfN?+QthWE3T$0388|_Xn!`l3$%z1cbI(Y66Xva4c>H=;%poZHuKdp zPy2=IRJUCAeZc?9D`hut?uqD$Ai3e$A!6I@GR1n!?&3-%`NE`y{aQZrK-B-?*z_gX zr=VjtG0Dmv`*y-?*-XMEa4)#K{s+m9ClTU4`={a1T#@9@=dqA#*>U5fcCh*BH!49{ z2)ouHv14zw{^vP&wWK&i372mlO4bHa=6X&y3?8|4)?$sCsDzf*V(pu#NOB&ohTo4- zQ9fYGtV?(OhEk-EW}fo&1I+^KFlUGdjqR3+$F{ev!f%|7wKB&(XU62(*%Q#!rxSw` z*S;aZZK4n$#gN1Id$Ppt|KVh*s-@Bzy%BR~-o<|K55l$fBP)1LW{j5v&>3i^jvY;~ot zVOZcldOvheRK*6Hk;FzO!ouU>wBpjNqi6!NmFo5cE6%!^SM`IX_+ks28=pO}xnkA^ z0SgCWMabAV1G}=)4;??@W7Xq+vp=mBDBbhuvhPbT7= z*LtXdI8As&#FY@BRNxbGP$lb_S<+U74Y90O&XWVIDS{W$02Im875LfJgYLAU1b&?hSc##05$!xa0PxK%X?=tk7);*lqpzECK}oiJ3yWG`ufe#(B@;$eAXtN z@#f`CTFcd@dfd-9VRUKSBON8?i?4-$p|8cSxOZ%=_)TsND*mjkHxjt#&XL2G3i1-) z?oza4L(M>VraZ3!Y=Fd5Ml|nx$WKfYGtHraf=t}|I!qO>ZB1C$Z`tf=!2L7ds(TG+ z1$e%O{#H|A_cpK8irnSU{1*C&_U!)o7`&tTkRe;ZxQdA`!y9pcY0TZI?*ACoo}OjJ zIn5)QZ#{&#OUkcAxQ%4R1B6Mov3LI5${PDy`mMf{KDxZr1j-|O@^Wi9|9a^~85=ev z+=F@lE4osCu4S?`VcUvQC_|w0w>J6Urfth|+S`{u0YP^}W8i^CcO^p2n0_9G^qp<7 zObqYd>ZbCWt+rRfiFSu#r_Q_p3T?J$YQh+?7l2OtvCD;QnR-~*BeRZ@T{*cZ1J_^Y z?ZGO>qRIet%+7ggpmoJxng5lW${X{3XaAI5$d@_AFJE)&!6tC!yMW!La}$@Pea_(s z({r1Uh|ohDoszo9%P&cfwmm=MD!jP*%%6GzA47u^fu5m$Ol%;#quSqCt^Yl%{DX51 z`*%Zc7&I?I?NLjbq0j6kcSGC+JaXk+68y%mr<>*V&3#9lox}5)7dj$uaK&BOOV2Qw z`zod2L%SYv^%+@C*}<-v6ZsqVs9fq>p?8`Cr6XNfx2^l&Ro-RA6Jqryeg20Fe!3h) zgYNh!_-3p472Pn@L)!i9^y2h)7dRYQD^3>KqAGW>kT=%d?4LG@j5k+_3n*}0e-oCDkOLFEH*G*2f?>{&}~?} zIhBJ)>6-W9#02`kNo{m#UZMb`f+%6)$ZZres`VFPTbR$jEF+&<1@Q-J=AYqyL8Ya( zp-`G6{C7z}JDinZdnpjjw2mZJ{-3r0RiZX~JmIkXP1o;5Y%1#ZzhVf{se^jEA)Ek> z^Xf>fs$B(yi!-)(!AyUKA?85V@f){@xU33_HKCiNRdKaZq#XM*r!<~dJN5_;ij){D z)cQ+HyNds6nnifJaO*9&mwC89O6C)qq%t?Ah5`__qeV{V2k=NMyC^_nwu;Sc*)S68RHXMM!OIMqF%5KkJi5Kqk86>%h*0SclX&8DL`3#!BiDeLDw)oZ_` zm;odOOYU^ZVx2mrK6L4Kux3=VPR8icRnUuWvU6KHOP-QX^j1&n+v!0XHYUb;QBj=*NWhG|_!-s;V-%FIWpxc4hD_M~K1VaL=rDrb9!nSh^KA@*;a18OLle!2W@QDM0X=Hy)ukxTPU;3Q3 znx+>;TKp8!K925s0xPa8Qw~4m-1KZ$$7JDQfZ56N{b&{$VzS`bKy(bLS%5nwtFl$x zQ~J)uT)otMQd^JOz++^rGWLzo_>}|2T4<@t>zo_O>me8*I}3M@%Mu2YbYyUU&~8QN ztGKgYnX?=AzP);4NKGC^AVkK=>&XkTqDjc0%Pe$p;XLPrH7g0Yyi{?{+Fd^WwImcM zFd=94yH}c>;PdhFYZQ5{|A#(4Qu9Q-BBl^`=+EldkJZR@|1iujGdQ~al|AQO%x#W- zzn4AfMs414F-x45NIZDQ?WLCzWXY_StE1^r?LQS_2j+gF3RS ze6Tl&(M$7?*aW4{bW*SXx!u4{F~IcRuMsY5{WkF698kA>I8xX2STzr>%gbl<*wGri zp#<-YG)!yBw(p`(z9DP_*ZRbrZ{AE{-D4itHg$Dg?grra7d+hlWcfSy((Ld|(t99n zT4DUVK!MAX+(1CvliX;EiYtEPZDRk$jDCYW_!16};JbfEuG$ z&z^SrHTQ^YA4>BSZp@vFpW;!JE({+05fH&6`Fl=x7js-u?UO9OkbIFEcd&sZvUzny zWIxlhR(IKVSS{&K*QPkE?{MEXHJK4qm@zL*) zax;rZ0?XF;+iTLaKf}rKGN#3Dv5|qCbqIVm5rF8BW80J2QioESJG+M+=enn9DM?kI z{Jr69oAlZ37!gYZbHXsY+7F^^~T&qlh-yJt zxt*PcY!Qebc@YBS6eu4X)IYbGQeG$3FMNBr#uzV9Db2MB-nH^1Vg?AY+b+?!o)JxZt7RkCwyg= zQ{Y+EIlkTjsEyigO7(00eFUEjZiQ_6B>!;_13j+O)0H3&XeFb4w?d&yO5J_xTI#MA zl`n8YMVnN|C=QQm7`)P>>;?)5q0WJq04?wOWX@5I0nCb@{7Mp4 z???5E^F^H6b376dUMG7e6dQ zS1X?@D5ML!HQDT1O8TEJ8E3Z%4zUSTf|E|4xVHvlf8wBSt^m1C%hCEe@h2fVtu?Dv z0X3)eC(Kal+}F>W_6&qi!JkzLpM>OFR~Zqrmm6{AbGlky1X6E;r#UxM1+qMJc|%k2 z(*ZH8F((}Bn}d4_cw-rgPE*~ji8Vj`CgL|PS0Y=(9pmErm#o7ZOIQ9QDtsJUUMMl# zbJmnJxM(f~qj>bOe5bt(NH!bS&jU8)&u)JnJrD|?n7@-K2Xx-e&k=pjf?*GRhW|h5r(GQc5dr= z+PAPYq;;<6V5)9zZo5uC^Oud&VYS}SYPkU$%1oQ{Fdte0f~ASO#|7&4jx=q>ywCTd z=s*w$u%C)`%@D95as2V(6YV+R?@_nirpbv)=wDv*$@vlP2o3#h?yYRV3ElOcCT=TnG- zE(1s&yEy$R0(DC&3F0LOtAnYfsYDwN{&YuLb~Z+$(BUs{Wr9}~)&Z@uYQ zgBbI{iC9S+TC%&&S><39&T-*?^H`}>ZofZrHa56yd}#BIDkrR6Zt_j06$+e_bSCxSnf=SO`e;d973 z8lW=EZ;!FsRq(_SS<>t|Rq(cmzxr}3_G`R|{& z+$&XO_Cc{=*Oov%!kZ=fV^Pb;yDiU~ze`7&d2Qm%qm}qA9w-+hIkpCmrcEEeXbfK2 z1dK1coUPBbUMMqyXpi{Oz4_3TPk|a%Cn&=kpxr(=8*CPDSB|F=tuOK^yA$xap-qEPZq(IRzP_B(}x zEuf@8ln9Y7^% z3XdA``A!UblxA^YgGkHn7;BB?$)pN8nXkEmRl9_wThA5TQ{NsAp%#Qtz5j^>DlAcy zXE?+am%9t>Kr%oLwyP%#cBe$DwQ@#LxnPITP=4tU8p@bcF2f|Ah%~Bp);4m{%zOwM z$?3x2_pqgcEDacBxBN30;xC@mH7w5UT26P_L!I%1)b*{IN&TiLO$u)JL7!D3JnRg^ zW@B(gJQ)4IFS)E#J0oJf&);JkvaX(J)4xEbFov@&9Cx9wR4I^s-xJlQ_6~)RB3Nv4 zMnZ1Wg{2<1{T20 zKOIxXBw<+eKscaKi-+EBy*%GSK})kCEJrj+-wU$Im^7^m-mx2{cd-$!J59Ye&o8&d8#PX;Ig zQEnMXg~=OHt$5M^ez#Sa0k|ks#Ju;QH=_MDzdMT0n+e_Do=U(WqKg9Uw7#^T(dY;f z4TWcdT{X~f>v(f5nLnc5eSoetu{}e8bF%wQ%W@H~-)|Ux+|YBFTop_-*JG9=o+qg` z*4fg4ZvsbN(wqlN*6h(+f8L!Ei6~QHvd?-2vhd1U0$ZYf5|Ev*qhm#U(ZU{ zh#`w~#*0ghD2(UsQLpa>+f*?Lh!+5qjc8iZ>Gf~jfjU0Z__L5CBnWQuPcw#w&&|lz zfe30n5V;W7C^A81OrYFzGCU6||Vi~_Ag0&<}h(@vucU{+}ITARps-3miq@&mTw0D*9 zIwd_AR0xp>eoCpg5nT`!M}6G~&i;F&Cu@lIKzEsApg~Y~{V)Iie2U#^EJvoylDu$z z{b=WAB^S^p&rJwjv@oKAS|Z5l;&@*95`}Ece#H$D4Yxs6lvX?QQ{J)`=a)O%*7cOG zb#iBz5RQ{2Ye~K%Bu@f>-rF0f zfAtRhq9&DK?lt-;|3zyU-Ykk@TS5nMxEV(Wk??)E*I6psqz1d(CaJg05>@%el%0V{ zZU?__%h#O>0FP(a7P;@0P%f4-gfn)OoolAh78YlIjcXg&wPrlr+d4A3px!Y|kUCzx}IWp6)~KqKr0i z=rmB)V2a($9l|Ln+1YN=XT+KNL!vPlDN0Yjd>GzJ)ONoZhu?eOa;JiG7kqWy`vaH^ zQqsAf7&?+h1)%P_#bxM6XK&qOMZb&-zdmWxUpbpNxt5%mKwnz~d@MR$FW-xc?D~b6 zc$*bri(W?IeBe<&3YEs?@C(%w4P$#RY`{{XRx`W{1#fe($&y4jd?i`n^);<^M0_A8?YZKr!>=G$oSKOhlVQd zHLM!ignIav{*5mR)!YK{1Fy7sNsHSrYYl}SCL}Fq`=Z~eWC-3)%%0qr>(<-i9J$Om z-r~A1`%fxk{H2D|Bj@WfBWHe=!Y}I$1OC! z<>ZdRG=+biUk}Fdc)NeOC~ZkDz$i5EOz-PZjx=+DHT~ zf>>8jS|510TgOi6lLVYX`6u~Y*J}N8`rQ5?j~gTsa2WqsHCk8gAFu%fXY zs<8e6&1itY&!0YEbO`ZDLt5U=TOHJ^i+0R&{9Na6E>jC>a3KAXNzveQv*qtow||Uv>*&E0{ABNO)2E^3o~Ng` z_ah$}9xg}Z8X3iR)<4+`E+M(>%1Ud0_9;Xke~GoUwyd7nmhIeP zoAyQg_I(KYy7)`JF_AmW%up1)&$|Y4YbVnwqq-p$6(=u*3qcVk6S9ph9yZ!Y!%|@= z9p&Jw!Gy8>R;^G?^z~9HG>)Vf`w}VxAx;=Jr`6jlt3M5@M@qLQdkYs+8U{D#~b&gl*K3pppgAQ=!HKBd(!jQwupt zYX+KiI+;N0$EWu-BaDri$$eZLR;Aa{p(GNN_6YH3{d$7Vbxxs5*E%+P4?{kvAR!+) zBB}Xw$g8xYGHU~!wq=$?IHpaJze`{0W^JI!f1c&O6VTXpLzdG3hF~fVBYy z#n45>?d~Tv*rIolXbZCQ0s`W9)`FocRp_q*&f@-G0X-5TaNOUTd&s8DW^YJ4iYBv1 zc5+qzw|MQZ;%Uyjuu2)|NZ|+cgO%pSNHw@N_Rp(_eI+u z3K75&w1B9NM}UG%g}I61voU&nCORrbZdG?XlX%ixxl-ezL1FIEH(@E%3Pb zvmzUNVHq>Q^``Xv*OHylw!(vQ5EM3Kd0WN7q;{D#i2-BU##=LXP?w_&@S4J_CK(dd z9W`k%UggTg{~x*3BAxu-ew&IrQD;kTT+VbTOhi0#Q27q#}qesJrG0##a zHN^$$u&S_?raa~aNtiK!=sg-D1Mso6>&91nV@b3vD`YW%@kz;}!YL4CCZ z+H10r;{D*-Foqn^jGm+5)C|6%qXf^=(6zK*Z}%L;o`rS4X-`e@k>9 zr5-1Kd~BULr8M*vjT9W1vPN88j%7P;Nv7p7WnXPMjqgb{KCVNWzS!9RX&aGSBPNge0)9gcoUgG)V)tZDV zHAJwsw}0>%kzVQ6Tq7=S#<15nsx7v}C{BJTslE4pmN=0+BCaxx3r*>-zY`?$3;*Fz zdTUe#R~KoB=n@L3Erw6Vc{aVh%U*ps^NEN{_v7fvWREI8!}ZdS;+X2nX%cwcVUrCA z2`%d)QD?ckw$d6TrEI^E>zVskFb~69z=99nn~D$G@++5th%$Aa)>Q@m5F7@Xu1Z7F zp|OCs2#s6qA)(c_RNQDHnu)Vs82zLqFjEE%TcJ7qKfb95n57XRS>G(N_FUWAzbm^1 zy8%?DMcc1)S%QOdYg!$oDc@;fL3Az35vVQ;i59f1hvWV&j3m@=!LYT)iigWjsL#|60%g(GD7BGnC0Rq5i0*U zm*@N+SEQXCQv`mMhNuq=NYl8MHS42aIxVeI`R8kI`2?RSqNbuwJOcZyM^9ktyk52z z58(0c^{Z{a?GOn2;XzHpS&{teaoGKdG-EgQxMtn?2E%`@Eg)IvItVPQY1HjYlfN1xg-;H%{kXZ%wzsDW{ z#vgm!Hq>4X2mD`#a}o{9yi?7EZfUms>Q;#&X0=PT`TxHIHId4Is=qgKP412oNb%1^ zH=Pxs6*vMXEQti72-6Z)B)W9OzW)-)^`qDPtqw}c`XXr3-E+&pM)vTw#-`s+Cz_|}f8(wOz}>6M>G{2|f;hp#nhe&!5bG>m3;^fm zJfE%~C8&^!>A_olI{Ewo73FSy|E{hH%Mg5XlXgBVl?w#5ul6}nArA_91?a1ySXg!1 z_b=_`)RuCdFI_Q~#WxQh*;Q6sFsv?0?Zga(7YH*+S|(+LHrRZOfc^QOdA*LfBD&pK z{~RSeWW|=F99({l1p=huHu*_*i zC{mFB47R0*Z z!viBbs}2sG2@h#U%f~O_UJw!08@87eOXl=9P0Ra~iwDb3n#XIKwkTpIC04V>J2wC9 zo5yoom7wUX`q<{yCSw?6-?(=Eq*pBskkWh90N2RT}H*s zrZfPn6|Kmw&4w5rta)NsXYeppr(!-;e?df9N7)$Kc5KhyReK+ht!L<#;Ct2gqKCmL zk|+93&&mShrir-3i`rvVnmEJQ8J5e11eJ}aiBm1lFrXzvoX+PcX6`Fv3s>~p)xVG- zJz zFN;}2l#P+6Vynl;9*a$A_J7aNpQQK~Pw`&tG6{h9rTPF&SJ-bFH;iY4;tBOx=gF_e zrHwL-oh0z6;Xbax$_LV0TH;8Sw;bP${belM6lT#!H>Y1s@iGj_r5jYhe(1a2_kJn$ z6f2g+t*(Hjh;hc1(;2%i=&L2tpUHAepW(K9KO#Op?C+P79GZx~d$^N`522crdxOqC zl*IdtB~QzYH5T@3J~B~3rBmG+ZVVj_{r-^l6oDZL!PD72?aN>dPsCS^j4Ta4OA}x- z5C%4bwG?S6stIdnbuNcYf*)7oA1?|1R_jz1Z@=pK=MzpQhhuxORf8oYxufU$cX9@K z$Io7FE;TQC#U7f_zAKxDpE#vEO{?2WLR#s$Fhs;O?=U>l&x!D25y3%OM^|$XrKtaU zO?QMDRfe^H1z!lLXx?a2+INn=XkeouFLeHed$?TEy_3^h@+>wb3ua3g>oOntO8T6*torIlO{C$(2ZMJjP;TO94Y#TZ?@>< zRRmF+aRO7?C9t>5gln@?s?m{l+Lj&(8}*LaHA}jAjjf8k8pa<%KbTssmeBI@qfWWI zWJ9(ULetLr%?!AEGsJn@+^cRzvQr>0f+7{I;bAq0~6`z zKlQA(F&3!iw4SRnTB8!VyS~GV?Rb^#sZCGS|5tl?wcM)d6mQ`9+6&oLg;j- z@nnmf;^o!V$6ER{wlpm0m-}Pn^~P(MWn+-UyYJYE|HjI*8A@B2DYGu#A|AY&&ehc? zg!rssQ5#vcEPfq^w41Utaim(AEsPkn_;2wF4{8+a2sNyhnynzA96ldPb7LX8e;IQ) z5f!!0YH zHz4~a?*=s8YkdfhzF#)>TasD)=|;DyYYiqlsoyqQG z`8LB9yBFc#A{+m{9avB}5M`Dps1o2IieM^*){%(PVe`1i$5a{j{5Ecp&ska-2%%2V zo+O>k>fSq22i#VnG*ovY3&D9L_ym$=#_}NDIB>W~IqiGv{^u}dXlQw4D=k45iT0a> zPGY=KO|Bv8PlaxqWTi+yo!tC0-xtrPYwKdY=lW%kNZ)PqUTaH}Z{nVcc(uf|o>f8I z`0g+rUk>&3FehD5dc!muKXZnBO7aHyhJWDsXH;%%H-(6FYT6pIB_YRwP~tEo$c#l- zO4{S+x6Lgx|4msBmTh*qJGRjHD`7b*4I1*4GO>+_&3s~&i|hHRl&PDs-1zGw6@!3% zWqqm9Q!Kx#yik>R@N7yfwgm=`wrMEPhfa{asq~YLKG0bb-Fh)V=<}oH7 z;|FI^JgY6cW{A^Rir`l1>+W=i9#1)j({wEVOIdJ%mt`FMa7xP)6LU5E!NQiE+s#1+ z_3PsoudB2jn)+>1OrjtXnz)#L@znkv&rBwwm)fRzzt%?2Q#}fzC3H_$WxmIUt0Ieu zHSqMTfNxZS6kZ1{aXRo?I)^O<#m4;PS-*a*OS|a_4R<&g)WGWMDGD6)+o4hCTs^X> zgMHq=Xn6PuG8)qgnf~g`JYLCd@x!#8O2jTT)Eg%OD|Sw;3; zX-TiYSLR2lVhj7n2KQg_B?O<@?%{9R&&;cjA9R_=zHQLxbM)9c#eO}47UG2&MGG+z z1Yc!KS{&kYyFHOU@KEJ2xmlj_HTlcx5W-0~s`rzjz@bTzA|!#BaDwHnla+D3-mvp( z%M=IW5yS%U3MSd6xV-yd@U?J4+5hi|w%4`8Zzaa|)vkE(tzZb|i%!fd#ZpY4YuER*d;;INn>kh3ui@^Mns50DnHHvdEL*p}qw^z_WO z4a+D&dXc!wkmOZui<<7Wqdzkk;8wKC{t)o|M$$3=?ozJt6kZfjVqUdGDSQ>luNwy? zcrgwep~1)b8k-jij}H2@rK2Emd=1JC)>Fw1M*ITe^{!^p8uKviZ3U^%U5vMEsux5C z8`?+LHPE5uQ`K`=U?K()QN;!K>!!$ccxLW4B}O!+oYYc^>7S%)QV*i+cwN5bjiN9_ z7C73>S|67lNA9I}N70%QgRd&0gmY%k>~$lUDYJVraFILf_cCpyitc;esfE>qzckY! zZ)S$bzOS8z4El#X4J$VyuD9VO)aLRb{Z#0pl}nD6O=Q^9=r`c#(!ABS0mrKKX|9X# zlB;8j_=g5lxiTP1)SA7~8NK3GRrR36fBV^3h!qX30|+4szT-jx7=wfW$t@%tZM`eM zDIw%w4@b8NBOGLCivN*D8RaQglmxmJLyTU;R+o-Mmuwx_TdTfG&7iLZ}JKApH6ka5(?MrYDN5uc0B_IKB-$Gh>ksc1mGEE#A~8h zX2SzJKbg^=p>(bI@13uzEu!<#ot!7btFcW)aaR@quX<~oEnG2mGfc6NKm<0Y~rMY)kNT3b_m3B&Ws<=|)b{>it3wxP8EBvy{r#|BKne}WLq zyX@Z$Y0Hv2%<>CYuMh=N)y-;+Vgr%3_A?Pg_lyY)nixJf&Flen>`M==)fXZ(Zj^^1dzd4>Km?yr*E)X z?yaHr-E5+08a<1r1Q0^^GsF%dkH)NM_ctl?Pg|&(V~?<(=yAdEceHOu1VT;G#!ex+ zR=;8)7IzEW5e&gCu}y~J!+M87wy2PeB?_Oznl24+_mQy>7P5*+E2C@+TpjX#Q2K`! zZ+oow?mmz~xMzFzQii$n>$m03Zyk8i@(o1lkmbI~wY;-W_{Y1NyLuL?YxO0TlV1&a zdt4eN&G-O@%LNsfH+KAm=OHSiZ-8zLRp>@6NEmvXO9p+zMqzb6Mx!SZ6G5&kY^xvl zY|LI4;MF-(?HTwvDzwz}OzvZfWPO-L53#AQ$gC6|wO+UjeD^RtS^sx&!O`(b#_Ux8 z&T(U*EF={{V7~QmQplN))hL={>f45(0!73034ebdo{R^WHqHrJBSA!xFBWE zxL80cdAhz3&akeM{^cpn5w$*oXn)t^h;(LEzJR2W1;FW+ogrt(Sh1MOz19Le6^~pM5^a&;vs0g zyVR-{rePa^Vj`}5PQ6_QQ- zcYzr^%z0brC2{_OaJ~un(rKLe~n|9c8-=-rW0wmvmgM z`6Xfz4peh&t#N+%;3|Comrk}t#o7BAi-(%eT#D7$tuq&Dz(V+zZWO{;TODm#cfaL* z+e?=9JwY`B!SfS^lg3{hCSAC7E%nglyp9F~2}$fe9dfn^!P;Udwx&_Ecy$2b`hEt@ z5(FR0!n%0V2HrBHaJo{&0k-h<{d5}fOrc0!E1g(#$Ei;^-WWKqpIl4HTuBe^$Iq_x z4~HRJeYdFDODnjc|K{iRz)(~!+vuA|bgM@TXjyJvN8A%SxXM-k?n}&Jqi4ZiHH1_P zYQfSSOPCT|r!ReDFq52?jtPT;+q~dX^fAp~9h=$M!8Ww#qW%1+aZGgSO}Fy=~nI-)#}G_03&jZ2Zx35#f7G^NarmVLXa^MhspyN1s> z#Jd}@iRF_|MDcav2uBz}8iy1Mb z@VjEe1~hiRuSF%EIqc0y4tJ;H`B5pCYv)$85-{WTM>MYSK2iyzq9G14hX_Hcapn&B zJu(O9HI)A(=@^yUquo&wzY@asxue{Ogr2Zy`h407UJmtf(-(P<0N8K)JNHNyYrvl| z_MXt(zGuf&La-&V08+&_d><-FI-M*cpNi@y1p}B?rD6NL$RMRojNaTt20vt@;J^hS zxXnz&`btozAJ%fy-4HxD7X8c+7*Q6UY4q9Edn_dcM-l_zlSGa^1}J@A z)R=)&>Jc7?aRh8DfG=2iQ-*D|J=Uo!!Ws(FrC##DZaJ`he^6&MSR*;khTw2j_Ns!F zeJyGLH08!bnS`dXN=fC8~4wwramrrb}g}w2fh{-^eAPPc>s8D(#`TB zMR*gswclJ`j0|iTx}5vgG`8J4RyXNAP3T{SfUmS|a^sGVjSa1Vyk*8&{#r)HQ3*`a zt`23NE_0>`S<$~%U0B?A=SZmAI+V4HK7X-1;|0lCb(pu6HkrtuAPP{{q3s$JT6Rk| zm_o841MJaZZ$(+dF&o%VMH4u514X7f3u$#v1uj?DGXon}VmvRkJ26T%5|is?UlGdP z=LN{&abuCt1J@39&RpkDK|EXYRocz~R6fI>kK7r)qW{MXkDFP~)vKQo8;Pe=L z3Pg3%jjv(2m^s<_{X9o6Di=yyi*x5cdahjF z^4I*=(9&@4>*L{eVSKgi?Q`+dy31z6e)eO+redh7)6tEwQtkYTt=M5BBEeWmDp~mp zWO>=p?>6V-8Gcc^r)aKv_4MJ6L#;p|04TR_7`NuM@fr->^$(%_#iKVbx)>=&Ts1hV0+(3b-x z5abhQ>oyQ^38&2B@iq5raT#3TwI0GR+XhmkqtX>bM83tw9Q4TT6sH!$9R@mo{ACx5 zw4W}n?cL7*QwpQvFC=n^>pA|GSL1&9*H_Z_&@LcrI&Q9~3Tv_*%%1xe)-{`2iq~eD zH^p9WY@V%CG7(n)^%(b^Y4;O43C{S;h0$##a@X9ho=)wkF?T?{k!43gzN%@fW_s*V+j3(I==TKuWwitonVFkF=*%#JM0 z4|`kHFFJP0D=(M9E;TtAsPVkat@<7xYqn1#@YT<26(|NzNA?~s@5eYtzfiYmf#z$$ z6U#&r#5>;;|4rV%ZhM_?driEw|9!?7Mn^JXBJb4R5Upp#L7lxX}hOv^Y1vxl2E^DH7t%xTYZP- z1In1u6vo{P60!U~{#Wb$-wy{jMGxjz0AwqsAxH0oM3V`MNIge{9|D}KGNSg{*?Epxb9a?!N6u3@hrl?I$HL6q+!>E#RVFD%)ns{JqFeyT(Ea`RUdQ9rSyucILwAGaVWIBHSIdK@5sKWNwSm@M1b?7etc~ug29|G z+h9+{pzy#zZ7s@3vbS^F5MeDRHsOuR=QQ=<<_m;YNE?5*MO!oeGJ^U8#1*cse^z^@ zgPP&BL~r4<>+}Y$x;|VG*5V97Egcr>hdaD3M4@4_+UjhEPm1ODJZHmeE4)saN%tg? zX3gf{L7IuOzRmimrfBQ-<H8;+5FX{ft6{3ym5u%?0!gP51%e-E zuPy{j8Mfx)$TrHriHm%8rTW(kWiR=YTY^*Sf-y01c#ecB*gYhwM~qP0?^^edQ1rvg zWiR54hlk}6uR;x0#T&{A{+&3K)f1#x-_ zso!_%{H*NqON?N*6M!Gvi8bne7nW4L+LFts1mM%f0M7kR! zh7?4QF6r*>yZQd!yYBn0b^kic4!i(Z6=zdEzSlIDdD_0UH!g~j0% zUTM5~lsh4!9*$saHxlPH_>O5f()#JZy7dFiSZNH4cglR@|=;rBsX{(vFJy+z^kSxz34liZ;^%TO|yovKpr-cHEJF zI~`+iZTlEJiBpo8o7KAkdlzRnmwUg~9dS1<1_#bgbhpc3A083<>kyOtrVmqAb19{s zA?iI`jG<5;Vl#?pCo!s*1R=SP7uwMvx6Z%_dAvU(&LV31P(Wyx9A}`Bzkw0RfEHBhUo(02cnRl&V zW)GdoI$E0L+b<3wg0IvIk?Kv;62tR^rxmZ~!v_2ORK84e@KaqqvCAp8pVDY*{q)bZ z)d7O|rT^mF<@@(FO$N8qnt0|))&D`WKkcf{?D&|aFgTLwX!&Atbti?)<;l*`)Z4uyNeXNdO_Jeyb1`aJX3*?a zdv&i^S<$PnkLDaRaHVL-%x+b<6_lLH_PXy4syHnV@_2+l*^lqzfFW&X|cw5Q@*nEU%nFq!4onj(W4+usDpeBctj*rEmktn$m3sKRgfC`f-N9dHI#F?~4Yi#(b$ zsVQPmrRX;J_A_BUWlKT%fJ&HCEreu>=*_WDRWnU$L{j6FCkLbe+>j@%rxN<()T_rq}l*KA$ z!86Wk7sS?=-}#5{^6W7K%o_T_bD_j2Kel%z+_KtA|C4gM6nez2&X7r3QT7tPKPld# z+5Aqd%XH*J&HmH`TO|rTOY>aExg%gqfFR8Lf?V>~uTzTtkl;2BOS8$DO0%D?RT5@& zX3IO6#cVd;n5x8OUK29tzBn7(T^~EUyE|KARo)sHTb~(oB?)V5y7%_tYj5-%4{^1% zv)cYK-h}z&j>6A)97(~IaQkQu7s?;y^6yc|_MLB1xy7}&my=h^b4;o~1NMB4*6{Tn zKg8C`@%k=e{~DVV84~Qv95{pmKtkSc)Ly-U`~(n-dTM~MKuAStbcQY+Ax3U>O6Q@r zZ*+%-f1kUL9~A3{D~gKx6`k=HkP)0+Qfk@`E^AV*{GEUIVc~AJ2MdZ z;B;;*wDjowvS~1#1Y)%ONNNxjLYBs5+V8Zl8On(K6UPlTEEQWamIKK@!yFkY_E_ow zvf||oVRuyapTvQTAHS(K#go&8i~FSv`>oD#;s-DxaWA|?k{*SS|30LBvp2Ubq)_dJ zZ~J=KKD&?SC1t@&fIaQjINWa@1WezER1??;>82f0xQf^ZR8q~zZ(T}|E&s2D2C`Xh81_WS3~ z2@$FrBM*p@j|l z8;QBeiMqn86N69Zf=E;QSLC1=s7ng?zl5~Fox$jSA8B}O;M;J~daaUKc0Z8&aJy^8EXkw1vP{s9|sKNA>cmYh`=8OJhQC%XWVSCP z21!n%^Z5*!sxC3!esikQGmK)|A&uA7#Z~K}M(QgVL__hrSzFXRXmUYN>c?x$q0m1F z{4SLfv;MFCJz=zuyJ&m5n?F&bPfu1n+v-1x`lFh*GunFRUWj3}kPnq)Yq3M74?`{q z&_`KGDYa^DTiy2NmweGgn)bLQOWAst_*~G`igu^p@tuE4*cgtiw5^jXj``d)W*q{L5i(q!rEKDo)fZ@ijZmew;InZWNvq@ACmOIL z5z01bwtFHuXMAb)Jl~rtIxck|H72ONT0QZue^!7?M>|2}^()Upx-Fk@2y6byj1YmD z`2{NwFlql>a`y6RnVBp0oe#dhYi(L?Kr}EnqJ93Xn$j}3KxBJ3Aw8^%!Q`o!Kgr~t zBwX9i84FpgDi=6Y4(q3MU(ia`mDWf~W_`wjQM)v){UkJ9&#`2jWdRSJ+P^FA-!(?8`r4ig^Ap6GlhaEoN17RJl!@=T7WvK2>+jjS zhdaT-xX*0X-x@mh#fQHScrW}xirDmF!j}3*j?x**4f}lw?H)o`gU{N#n98NMT(OqI zz|Dw62#m3;E=z_p_p*}HNJi(V={ynpv&gY|K-SWB`@y9mbZYau&}T)O$c&lF(ro5P zXc4UQe%@I;sKr{lM232~aQVMkynIcY8O1TyzRYl^%ttaxcdaX4)}4B~VciV0?fgd?asrEUUj;Pt;M(=!JNgrKWs>=+UG|zJJfE%=sns z1e{lEkWjzuu43lahGBN=WN+)(!29f+tEs6BkKM*2oP(e3s^#0~q3WF}-vwD{(jqf} z+mnrYuMYozYJw%}0PBprpY9d429$Q1M0dk-=wZN2+lGAz`1s9QDxowKQ&cQ_hTSZx>0py44Xe8AsCm`~_)dU_F@U!T|04)|8 zUW!%e7i+p@zPeqid(nM8cSh%9TKG+UBG{tW@$s5V(M3@uz^KeAu6*%{Oex6yF1q7d z44>ITI_Gt%A9v~m@ScsJx_b4Uuhb@^Df;qzT6t-|uH))y^wEaL&yBq%;jPkg_&1#F zoZ$26n{v|DnN$FIzoZpmzhv|Q*TSurn~J^q##^$vdFPdVZ}6sr=Se=P7E|gPxf6A1 z-JYEbm5x@=Ehxwdlgy!v9bglpe@byX0@#(>p;6WLQAYNy$vbnHaSe?LyM@G6oHBTX zffSVD5I%fyYzx!D)?&7i@u43FMM7j2J|ta)DNpjC+-zezfnd(l9Nr0}_HbZIPD8!D z>L+Kq6ukymRS`~}IOTT_c~dBruPBSiZ7a@!`!_E7GsuB%wL!f6wJKX0w249uQNm{lz) z@za&m1$$DI+-+s4{Y-6CvR(Q>rCZbMJa$nZ57CPoP_9EyOy2#qx+_|vMi%HTn zs!lYYN*CXyy;dJ0B;AmFnyxO_#KTu+-xD%&4Q*=9D%D1gLlpZkPn)1vJhcV%9hJBl zQfgs|3J<3Wi(&w$GSS6eAm=!O<_|EG(W8CT(tDl(sqmJPz)%S!f1_{tM}_PUv?XURufyUs3HO|Z)7oR&TUJ4}P03@VpkPO@?h?Gei1Ptx<=iAT2= z6aBI@E?t!!8lR-Trv;`b zJ1fW+Ntrr@aOoy3y^dyC@pp0-QJf=0sz{t{*e8=+7-mAr-lXQalP!_xtO0@D2%=yq@R@>jx#M!+wZEmeA5=6-`0R6+r$`8Y0P>%iA1i-wfcN z1*R1IHfV7_w>@2+nJ6<5^BM>&<^~A$Vwjm?X{W0O>T?%eRrOwZXStguXgF^zQ$!{5 zCyB6N<|3xUWYbS=#q9siqU>eYij?#@8R%Fr`V|@Opi;!$oq!#4i}Dksm@{8XDcfdY5+CmSdS33d!P4W;C0g8j_#)%al;|dgYND)F zF1}qWtClYy-UL;M320!FioGH>HXrfD7e_a?X5WP`$kct=RM$Z^{_%DikFX2>k#s!% zBWE+3bllGFCEG#;UU4c@p$wlKx zVmU6&mrd5{$rZF{uTGPOQN>Gq2X^^qe;aYXb+x?(gqL%BeCN}9wyzF2DvLLgjDCpx zU1kc$Mkt&#k@vH=GQEFIn8vMUk@)EnEJceb#LbUV&zZWYg9dn)%g;-lq2e;|pW&BM z0nAmbVV6?TFJwm4b zp19!Gz6o>3WM(wW-@p)t@N!;U35=}Z@`@0{v9Wh-Wz*f}bj9`D5(-lIupf&cuV55? zT|^gA<>c(BlMcwO;+`X^%v9H77vKvSx$bZJq&tYG5@bVx1&V`i2!f6%`j~`ii7ZOj zt0Xus>ak&hNd|wGNUmSsIWexrF^NhxGooMi270r>1Q3>jviUaqma|2w%6D(6ZA>-W zei(%6>!xyaFxN7ECPuYc4Ze~JXP#u;xRQ!4mcG53s}j;cH^o+o4Yj^05!(4t;z0Xh zAoescrJ<;HN&43M$D6h@Slw=G7cG*3bGC170W9*AFiMHo-8}eeeQ-;7p&(32t!qtN{LNf)lZ2}w z9O!Asn%eFguP#qR)+eQjvJJ!g%8BD|Sa*kIg_E8g%gc~x=OMXxcOXd=96L}o3098X z?k1kpN5=0fd1_xMwOZ2Ew^)1}_PhJq_L8USl>qF#X#d&l5Tj;=703{|teWSbEU9X~ zIS-^xEn`t3uh~paz*hNunEnd({*Mqrh`AM57Lmq?Xp*UtKlMK2Vk4q&VYAY>eipafQDM($=Fa|v zTc|f_XLrA^Cj94e8bf4bH!Kt{|uek9Zn zcS^hE3^R$`?K3HsoWnDD)@@OEeQ#?1CAnW<>tuJ-q3!eOkVXtHQe)}3Zm{7n2MM!<7d+$_d7lQHkzc%F zxTx_;f*ED}u4u&N?C7se{s9+m;vy=9hsO#DNz9k$s|cH<(ZI9^!=S+{r3M7%4Y>Op zwFM^qy@1(tF8YN9>9BONu|*rM!ESIvNAfebN1XPuI6ML~N&{;OlH_AO?>`y0N7hSG zYwA_Tv9T;RGoLE&t{IU_ab82hQZE@HLp0wxN4@p$Ep|1FI=Ty+a)X!!_zkDBawsO^ z3$#D7LAt(?A-!MY{x&s9@^#y~t@ExG^FB#0?GzrFV9OArj-Qs;h%6bvJiuCyEE)a6 zbW}b5Ynj`hl+x#9x>(D@pe;9sNTLW3nH<_qPUdRA_UE;sb73pCO(a4!E*>`I87sfc zj600aG5$nb{EHA=&NJH`$gm6AJnN2HbH8u0wyiBK3r2_H_7#YzAkE?XKx%o@5Az%d z`^MbG0=9M>Zb3INAGSr#tLsUDwNT6mNX{FdpQ!7c85ReOS6nd)dZxxNu!o& zpbnV^iSk8Poo5oVSS|5Jqvzp4dcD*0(JFiNb@f)PGUQnm@w7XO)T-Fu{;<8@&Sul!Y{_dB zbpNVrnCsC~pp29a8bl} z{V+|`fvIhg_30<mV9{mj;WJO?F+>j7Gxk{G;^cxFS_(H zVGc!@96x}KtpvyK(i@!}R+UFneo?9Hym6{9qw+`y7%qN$jYlZ^4kmRCDu*EV6t_VZ z(}F6efas%~{8Np``7%Twbwem1U9vE9tDQfLBaSftTDF|*j28(abQ5Njs{a<8HTf?x zlhiV^*TYPT|4S#vwzg>8E{Fx=u_E($mQ0t#g@P0}%##iB3Ll|`MhEHreD3L7 zs4$#mBf^IKdy=jU$QU(4P$0N}f8}XymOw)IAg{QPI~oU~rj9B@G)~=kh>g8p=Qp!c zCNX#P+oJ)H2VZdfKD}|oVIlnG+S8y0=U}w|x|#d`bu;(qBGEk?Y7}QDdjp{bO%gB% z`+aeTzU=|c<&K{!27jynvTwSO{&;smg&e}zQU5S_d)zvCkui3xj-3jWg>ytmP%Xuj zJ;(Hq!!ty+&KQy?R-^b1+E6+wl-~rQI;nI<^JdX9b~_l{E&{X0aQhGO+BBVs@NWz( z7=QcsQ6Vhfw2J;=LPW~tMqSR6US}i%8YrZwPqZb$h|CJ$&1DZ0)aB{cx6!Y*@UpV9 zJ0M>;3jQb=7oYxrO*yZ3!IV?Y8SlDFS!da7mqN!|yXV*0+dY{XXU!{kpa2HcqH77u zHQJDoJ| zHLzAo7VFagn^!l*!=&zVzdfX~Fca01&QaVYI5N-KQ%Gqokn;s=ee|X2>Il{nyKSY| zK3CD-tR0ue$hsUKap@V!!v~`(6!v2QJOuoruM6lRym-BUx))2zbsak122c4JEX0=v zJY|$h_1o6Plj}++8yh=5HS_WE)mtj{`Fn;14fmIa;s5olm*W5RtlkTM$1Jw@nn!B< zjDr&U&p}7r!P^NZH0|G2-iZ~y9A}@JN z`^aZF+0g2WC%wTS3wK|iE?o>UxNgf?bZ<@h#n~5okkN6F*6Y^@YS?>6!OtZ|z zPvogmbTk)CSv(7DR$mjdhtNSCM$lEvjyWEAoBr}$u9vu}l-;uy9&6$GCD2AB)?2Mo-c{^*<;^#~p5EADYnoxNf3^uXRLr*;JGH~=C|36oe}!)jL-P^u{S0+;F%HUq z5~nm6YVen}q%OQocyCy?H}TnDc~imncoe^r%0pMWuKW9HM)NCPR(icsjVrT4+D_IG z>q{Sa5ReS^cU?oh9}n(mH9OcOo7LI5w)nyg%Cd5W^HVuU_5)FQ(moE;r+uWZS}o;- zmH8F+@er>HjX$?%65)T6gNyShLJ*%wJ0Uw;-WonIzI|@8nG?oe^4$- zvM^NJUIbpZeuA*elmc{NphW#$>uT<$!Bx$nbl=NRF7=yX=YVU@kjn7=K0T>uM#Th8 z^AT@+@d!=RcdaFCjj;Th#f8s3tZmOPkFsqi0MZ9bR6GWeQpEb|SSmU`Jwg@Rw@w%L zzDQTy`|7V|h0YUwCkp+KAV{xNvIW7L=jViZ`3d~Ztq!G>ag2db&03r*V7rP3}-%<>967fpv7-PL75T%^X6#%jNIfPop@FoW8n$2hZfGfjHJ^C1XzO zCrJ*O7!VLPO}% z)TSmbooQv`ZQ6@)>>v$A4S!-af6dtCKkG~5_?5EYM_pXY+?_rzzt z=m2UqvAX*?)5%dZvTu(^*8fPS%F?v>ER#)f@NC5x_H_ik;`>WP21}%oAZ&A{@yAa2 zq`%;*sss=Ew$|J`&TTP9}|LCGPu=uGN+Zl&q}80P^?Z%W$B}^ zNtp2@Pq;gkEpZbhg$$4sGCopc=F=@qWUuwr{Po@timoLXKVH8A4qoSv>y~}N-L~^v zIA)#b=FuFLWsQNAFoii+!4lInky__glgIr)Hq9^7`G55!N!v}0igrwLGyERssO%kqXe^Rjaf~--}vsrl=K_ZL1 z4xb*(b34=V(hB3~N*rX7H{u%$Rjk4S2fEjx6@TeB5TsG>rOQ=wTR%bBWqM;CSu=JlO%dXEzq>B6 zo`AiYf`89v<5jI#KvN5;5Ze?5`oCl_FjxO?V4n7cYmd)8FVmZUrww_tsrio|%~-3j z7GPDp#R0W6E5fbP=M}w(-ue?QD_eep7qg^kPg*M5cv?Sur-J?%v~?RaU0->}E+aM!T_2VWOUz!9M-g~00wfmY)XPD) z#^^13{SgA=+ApW}g*iW|CNLMlE3p`euJGgHGbRM%OZgF1Y@v?(4eT} zz<=!gud&-f7kSEs>ESk?OeQK}kS(B7)A8Y+z>bL2tm3*OIqhj@-apozq6>H`=&|Z> z1_4SP#w|%tYAmd}P*$Q%#dNy(HA`f3-RwHeAo1Gy2a|>c&I^SMGjn7=klW2nKeiPW zt<>uK)Gi?=&*>??f64qBi^lSRyB~s%^5r|16It|{o&Uqv{rPg&ChjAFs0?Q8{TeCo zg({wGa4#KWfH(IJYOyDctHQ#Z=8}Q(v)X#M`rOq}?3{c_0#B;vhxVE}eJvASJu)^V zOzy{&$LRCN^%ZD8$4GqAVXmzUFMie_>Ow||Q62M6FF@LwXC;S7MlYLBRm5z13sBNN zwF2s>#d$#*Pi4K$S_fLm0Y@bNl*uKW#8vbjvy53o&nCfcN+8^6#i$o1@FSCHN1U(B z>yY-|{`r@ks4dpeMm2D&ug_4YIYf~K@Ajl{M7VS-uvK}t1JGY)0w<4uUEg{pUdW-~ zd(E(|J3q5P$iyjtIBNh>4X%q9XON~D#}sjASLLeM@DgiGs}T$QE5q&6ZeM4y!`to`7*P5W$BS>3UgII z@eN2LRoz&=h7AXe?~2Pkf{AH9#+P}3j=xHg1k~RIZ4&Sq^a4DpjT*7x?W@`usizx= z^thxnA|J$U`H~e{Qz)?9weY^Zfik`Ow_X?^DZ;_ec zJXUPb&P$f1n5AXq8mw{<}Ygy6Q_?OP2!320UqRt=0h(TTeC<9n!Sm2N& zk>lrjRTui+GxIgJ&(1C58-bF9ovj}ZwBG%(8-Xe0S^i;9;I5|`PYr85cW+u9(cCgu zMLzqG$zUSR%rG^fJ@U(;7@Du6_j{bZ4YeKZA~9{|+qkn8S3zw~ctf&s0qyBS$X&o* zm3tm8Yp8!-pV^k~AU)h!89O0$%1-5p?RP;Cd4vHZp^G>7VuPsu{|n8nZ~gyOn89Yr z>~}jSFEHaOTu#t5>I3%s;)*4s05;cWQF!?OU~`AV%O_*k6D1Sk-ZFww;hhfb|IS@% zX1;_fU7n$<;Yg@GmS}J1Dy3ER;KNjxJ%mej;5pMbr|!fGAvFhEbas}|a^6%|{RCz4 zpE>iT)UR0$pM>2b`}6g!g593iqI=7tRD{%D;xQ{~S%I8>ha@p`bRA5cetNH;`T@oh zKf*wHD7D?{nGo#gx>4P3cV>KTpwrXTtxtN78O>O`Fb-tixZ;4g2U>}zVVHhH#5^5_ z{nQxvOUiLt0Nt31!B+BTUj(;}-`Xz0I(LDLh7Myn=<3iqCCvm!TWIX#&@|7OJ^S1jP4?_lg zh>Z0@qCq3}c%onN%uBVLOQ+?m|Ex|c&O|IzV-fqzENZ{6zO&u5>m3YM={L_FJ!)G# zaqhA@)$hrmd=^k#wy7gs1(;2XJWmi*pjd$e-FvB8a5h}$hZd0TIkcj^ZfJB_V zpjeTbWjMFF%w<-JvW)1p@ciC9)b&iC87R!8?!Zd8{!el3ybzOkedqPp=(o2IOaG|} zVCc2pWrJE6UXIlWzP{{@-^>dfs+js<#=d$=3BzY+!?O6v&ovBF^nRGA0pZ2#TQ)9A&i0a>Ma}7PvP? z2ZK?8r#hLicLGM|8+IddtSm&i>#y?u)5-HTJHFL&lkcnW|FOTpguV%Y{dLBa=>Ob6 z??o;6)D~MM?yxb!CFC6Ve~!m)nJqjOLTDG`Y+rF(DhPJ{W0;ct9m3f+9N6Uq%iWV- zta4=R7B13_(f63(Z*Wyq^IdtZj-NsD<613%d8i-!eNRr~J$LpMrP+f>#lJRh>6 zMea4yHo4+1JR}sgVw(gw%SrE4iSSRxI5@XsJ#+S_AgK(@;lAc6<@9s2bqLysxr$-a z!{NF3?)QV~RI_6}OuhKkT1!tRIY1@35@)(aX$*LRW_)P1JVgPibBI(v!t z^G@a-A>=A1%+-^b)kCL`#9mVC$o1c+#tS^=5D0TQglMvK$d{}gM)mj}&fJ{w{cn{6Ei~N$BFS?+ufN0+%zBDLVbw0X986|! zShzlk&yBhm@X7o2Q^(5?2r)Ks1z&*+wWB9aeWR!Saz?eFhAJbR$xu82DLNPG&jvfs zAy)gDSahux-MQy{YIeGJxpi7FH@LNL=;~$&cX0CqYFNE5^S(QoHcQ|AvKxlWnyZgs z#}Sn>M8;Fzb`sPjsq7J!*8s5*4V^7Da4t#!0Et!h_;k%^$!6J#80SYGpnsQ@N&=g0 z$TMJ7(!P_x%0lDid!((eS$C)d_LkkDg|a1_<)ErXCMtoS@r&=i$9NgDZkT?P$AWSj zS9iYAfi@_e>sFqp!j9=p4^wlOna$~d#S_6VNag|a;O!k&gwjskXJ$@GT*slEp@NxX zW_QLfBb{LIpSxysEdwu(lUIcz!DwI^%r6w`$!3GoNj1FL;txA+mP|xQtB4bx~R~_4rbKcy&E)2&$e=HvzQ`vJ_IlbK0dH;eTE zGtNB*YlD2P2d9W_5!SD@&bwgv2;$SgsbL%oR2RX|!Nq}f_XS*>Zt$~Cca?YCq-m5b z!_o?D0_)76QJGo;k6GFF8K9r6xrLqls7O0%-$gn%b0@{`xbY+aBr)3fa>-ZNGtBt3 z>vmUbc43_4edz0NcIh`RlWvw;x~zMkLBRnH3J!|MQ|#13xnFni*Ci~wlj@_!j&Q|Y z;(}e8wCDx^#jcW4p1Gg$68l~W6mOKCDV5{ZxfyEv)?`$+xmfRdYn6w0qB-Jyv8wtk|N;*`7KH=MbWUiX%6Ff(w;oZ^{S*h??oeDsV;szI*aolbGZlZf^! z{+Xp{YIr0jV;JIx27};7%sUUIc32?^)go8BjLi>)a3#MJOqMyVhzqQKP>$!pApZ@L z;6S&`>f9jWA*y-oSF!0NnPS`IOi>(=^FYCJqxh%vz9g1i5<=!!e^lNd^5r|vkmwNZ zursBf(wG?+lP8ul&FCYsSJYcS!RW;U{S@1}t#_Jbzq%lvUR((CSL zefHk!WZCaG{(UiUgo^}3!sZGwj>UPmtE1+xu2$yORPH7E`lbzPd2ncAYJwS+z_eEF zn$*Jj)qz%Pz!4jWJ0k>Rag{`LhGf468C;KB72vvUjXRG+5MLVefFYgfQzhrq>#eh6 zYcHU{a3aZHT-`d}wQj;{LvcONa&TbWfd7UKN86#D~iZ`_a-?|rE!HCRP$`Z z#b9J+DPkWIWi+V#{Pl1iAW3X%?V`wT##Vqxy#{9+0_yqO2+PiW8QmcfXtgdC!FUbP zo8=vdK29*@OuT_=-N#PCV4XiI$jsiP9o^j@YfH6eT^U|}VV2eELw@{s(rUSJ6*Xve z<`Ix1c35nd{x)?9>|o@_89%YM%T7IXj2`EpXN;a~WbCNHp+XA#WGB7+88iLO*>nF| zecidsT`I2VFN6|!JS+w8Y=4K$1d+Nw8a{XyGIoqpZTeeMw}H?b4u#g0hp=-MOFghL zo{s><*2(JrNHW?qMC`g}(-+Tkl)?AhZO`;|8 zqy5K!9FJ0Tt&UC{Uir8So>6|x{$#}2sRS`udU^7{{g3}xtAy34si%e*mN+pYwd;BF z{;A5Vdjz;Q9*FLrSOv88`i0Xw7sZ&!slE0>Kk zmSVe8b7z`ktHem{8p|%bCxQI{26!`2p^t!eV#xp5%`4QU^qNGwZ4}q$&q3xHa$h5| z*-gDhMrNr_$eofBQ!&>D7ljA9Edpwt8!l99=y}~Ttq-WyssQQE&L%(vD6b?dp@Zp0uN zVNttV_+ajff-i1a$k^?R zq6Rne{a%sb@iV{QCyO4zQ!87z0EjDN>>x&C?3G^j{zG9~_CHBL<77Q^a~%LSxcvj< zFtR`n^X=oSn^sB3Gn6-Bx{jI1wfI5{qr8Hy2T-*PU^fs3ypf||En!&W(%~LwB;$GQ zb4_~&C=13=e+ep7j@XK%7!`^R$33dsy|q7eb!*wayDlk{RJq1VN~7%5XEq+Q(BhH* zPgcnW=;*L#^2qflKCdJltuDyu}B%eat$N9(nP%pFS6)Sl0+M635_8ydhZiRQL zP}Sm#kD~s7Gi70MNinftAQZ(=!M!ymd4UR*&%6Ngp5c8GA5$uX10B$&z$sLb0A}1} z38f;kcXKMBCSy8fg7~{JvotryuT2ijT=$80Nc$bRvG?=5TT;DyieECT`t;_Pv00 z;|6dDV~j$^q8MrpmlT=KR*xvl{Ljtxp zMfd++d_1ngrgtZPblq8UvjvHz4X?v`3KIRcJ+aTxzyf0l1i-lHEp745h{A{5T8<2I zYm+j6p-~NP`!&kSH2MB2l2edl@m7|`V5OKx2gwDBB>M}NqIEocQ$PRj?1#0qwgP|g zXk#4d`ht4tXVtKz>+7$CKRI4LMgk6odWx%ewI5=AuXa92dsO_j-4IIFc@AFVKnd2J zcE~@Pu3y0v{f}a9MbIUC7>X#ztj4$Lh4m$V^Nu4KQ4l@%jAb5Br-l$DjlGA2RiH@z zO>|E$<&Cs+hTHheb;pfOt6_Cis-pv5kwF^`9ny>R`WB_X1Hd(>+=FWkQ5@DkdO>JEkU4 zK_Ir)2>lqd;~ctTwEz|#MJY#^H8KSAn{bg4GDPI1@b&5(%E|n+SId`m8ixu3@~kxtQ*(s}-&PKsnl1wG7Pqk?lvQ>jbg2`ZME- zG_JGiBb@@Omt2MZJFBv=vu%ubkpH>Rb0vWb(Xm8NF(_$* z6GiGn`9JAHdwvVm`L*8u)?C+IdXm;z_j~4SY}=5@CrwEuBKvzP&H&a>!2?Z%gM$*m zi+_AFRYbO*S>o$`eKl5O>7bpEXdz6+OMRKF++^Q*R77x1+1f)NpAl&YUPrd#g@vF_ z`^fYu4yTJY?&EsT@2)1&`g%YGO zPD+n1wyVzfSu_N2QTV#c zbF!Bf>xR2FFfG%%%SHcWfBMPQ$pbNY69vW3EXPgEkpDVnu^Y4#VT*qlvXXGm(E?dr zefv7v2kj{mKK2y+Hyuz!B5A`J_bBc1hP)TwJzAB!!vvaqN!S(v2r6jNKLUsdp@DlE zw{-lzXfm*4%qw3WAfDy|7RQjH6p7#L*Z|$%_QJ(~B@(rJvc}F_bn!)Uh8QS@zyZse zZ-x)(@n8Lsr~s(?)%_A#8&0#AR?ctBXNaD1Buxp_z1oGJL2c+L4)_d24F-u$=aNt6 zuFX2mnUt*91;j$GN6iZg%ojnJIu4ZM0rv+3mh2KCW!!sQa<&N|+pDv%$x;}?GP3%T z1sKIt867p1Z8EC0?KC7-sGlDTa{VM;)ehnPh{deHRvgLVC`fO=NGNy zuRI3ceRB{YOQXnvr)IVo)jQDQ3^-zbeGO@$gVe?a!83LSA=mJXFI!r!eqkfZ&dz>! zPnc|Q-b9Yz4CVmKVCf^s;==Wl_DLn^wslX5Gpv8d4HbKsi_=8)Q0^nK+MT8&XecJh zYAokb4*|Us7_YJU$!iDfOW2IVgcO$QRT)zG%rIdk1J%ngp}dh#j;EEmZwf`rka#A( z$MEB4NEfZ)-wcXKn6oL}$6|IO2c0};CCt<#(XX!_avB}de>sf~3Ai+H?SM-|Z}Kmt zm`n2L16|O`=Knw!D7GNS9b<)!mqnd-4BVP;p&DnPNWM9~1PePuvE(NksCQVUnQ+PI z7Uas(m$O)=ntQ9NcsDE_qd@!tE&j^}ZWsZqoeknl9rI@~a@Tvwf{Eyn%~jsIG+#~~ zhVb%qQsOKy+}lv>A>k8=zKM`$Y$p4sj51wgGgGYrcTya}1Y5m?{BH+gzT#he+zxv$ zDe}8Bku)`_In&33D+Y=a&LCgo$TEPyg(80`e3i`MVbjvFYfjw@lH1MEpnwfxhVTmD znykQC5$0qe&a^o$&-3=V@;w5Iv*Sg7CI%EK2DXWf^yogc%yb5_uurkrvaNUZE!b@b zoTBD5*qjJ$)Mn@H{2GJ05fS;HdBTfr@Lz{hvac=fF*50}IPw4QDPa5mOaYP$bAGKY zi)w-nTit4cg1FxsSr5xC>uAZ$UGa5RxO%|yuT&p>SpHgQqmW)H;%dBsii;4Ngusa;Ir`>x25=~Gn0YE15<{mGw`SUv_`k>$xu zTn$^47xEcS=7Iqpd?KpV6-<(voTO#Ju0JlNEC_cGM+j4usvR`&za@G;h~fUQx&tws z$7*fz)j{aC(px$--Lql`+VB0tw}B~>ip5$-Wx{=JM;5#3*;bDlD72iU?>Ix8!*}1k z+MUMrj$JBu8aT^epYO@B?~E!}9T*iJh_yk9|A@6giC&(Z$PnR-$V2CdynIAGth@T> zFT#%$Q{@ewke_Ae9z6PxKqHXalJdtF+vI&p7>ZF(| z`Q&#ekSsaEe%u1uNx10iExO1NvFU?Qp^zbWEJ@<01V4eEdGF01$-!Bj?kWab4(&f} zHsdfWfzy#V%_GsZEymV@)yF5;;HQCoC+5u|*6jb_H4HQ2H%h#C{d$*D;Op^Wod3{S zfKmqf4_&0(e?etIzxA)JdwqCemFO|@9e{JSL;OL9WKNMLagfA_V7-`ewJR2w*Rs~T z@CZ|Qb5JFgXq;;bd@9^*8VA2qfjQh1t?lY*@O+gqz&arcQbw>J|G)(>7kve1;GF=n z>Hswbzq#`53V>>9g#-X8j&evM>&4iIn)^{ar~#}Borj;^rHb(1 zyPbQ@m32E|{r>2#fNbAA$O+kZ6Qv_JQ5Dmbq`U8^i9DPe*b2&#kt8U^gUUUTeZ@!* zwj0OhO6+tOELuxG1ZFp(8iV{nkgpVR2e{}Uz(ofEE_xc9?4=cBE@-;^+(mM1TPJl#(I|4gYW2gtnV24=40O;;5z9u?|R#vZNE%-v`r{(}h z2at_b;#7!-UB2^j^EfR#xZdW|{k()0-owDbUof$7-Tr0bIzSwEO2t|===W7SXgkii zve7?{u*sE5_&^0MhiE;cR<9aMO+P9mSMCT;`4imPVqb|7^;!%YGEVhl?6 zvTgR};ZJrZ%Du7GVOhtd2V}h0>n$;`fode7#bFAy^QwOTT?HnbiekwTK)xv!XXYBl zFx)nl1~sv9j!plfN+C7Y)>F=?CLAC;1+7!sV64os11lX{1t3OD#dw&y-WFDXT@e!> zzWTjeA`m4AC8lYdq}OUw+2rnRcN3;LN&B2>GR!;(dUF9!0Z2rJwx>#0F2Dto(rR3o z(Zb8t`WoP@{A`IQ;1ZHFV^4sxr;HU)d!3q2t?^0~58|(nS|BDs#DyV%)g{VF=WaaR z<)V)?Un5#=Gi8nbietTE#Y_Fm&ZEal!02HDj2_s=raWz>MWeNL%Xz)x>s+MA0Nymt zGx=Zqfdd_^Gr)jgeTni8IO`pLR9Bwv3^`lTnhgve1g7-PDB@!ZC1wNwE7W6CUd<}` z<3{f_!njYFzZmGPkmV>~`TqdnOfCom@wQ|)@!?dCcN>0vRI~^xaJf1f$YADLXlN3> zpPkaBmywJoXR$2x6! z%S0`Jk<9r#9;BJTV&xtQ2jm_p!STcG#(p~{mu0(r`(I_5`@U>NX+S&_i(u%&gbu(D z!SjhV*1XzVE+-V-hnq~)(F|R0C+@iduuObkN#=2nIgOV{w}it!tORdaNL$^huy3Sl zfOQ$i59Q$}amcKJpQHr}wNaGD$xL@yOF5CR(_r68Cu?#xVG2Hqt(MviXP>CHua z%2b}iK7p!5=Y7ATE4V#|cy{-yZ-4S1{7z~*Hjb?uC1=IhTk*{R%G9ZeHy#hsN7v@89whoB^mus!wg{C};& z6$qBgV7Luk%~=$Nmy+|Bu(cDwwjoGo;`_~nHnf)}Sv8IV4@4$;O&Qt>+2_Wi>^_`r zY8_$%jyjTqh>W0sy-hNlydJn1>m?t%&YfP!qF*BZ5A#ppxV9kX#pfhm`xliWm-MCJ zO$jY98V&w*Eaykz;WISqU_sL)4kd*mR34OZQwyGiPA+zvw7C^y=iy*;|joJaC(zt^MD~A}w!ZkOaJVhaP=o@1P0}I=@$c#jy&XTXzL5!95A$nde$nK zd#lVcgP)BrT&%dPSE1tvz;WGN8o+>41babTwFGmUMJAa9qiD&pL!e*q~+LCfyvxoQiWQj*ZKTu+bSf?FG`xpEq40%+EJa7 zKgGVk!t<-wGXceX0sLWInHa0l5r)KU0iObgzgVVw)oe%A^i$(};J?O>r$?_2y6L8H zOX)y&3!O~H!Mt2xNZOWYCJ>l|`U=cJ5e><`C>8H4RStb__(zRu2K)T<-*8I{2XoS6 zF_jc*6~hg`Sw&9;^IxrYtUnfKEDG*~{}FZO08PiP4w<9a$-GX!bL7simI=7rwh{fd zV|UCMh}(2t@Y(7R)d$tA%e_+rcpykD<87#8#0(vb_2F`qLm>QE3K4K{wXUrO?|cNd9GY0o#~q-j#ob=u3c8TeUCamy<@_J0)aryP5)! z+gcdFDS$?tFI`++fJuRT$8|bgu8ha)NFh(9V!FUTfmXnXnaVR@T=E(H?{4|iV?V#+*y6s5>ba)o&TEgYaN?_v@42#h}I%gte|skx*C zSj;UE)x_Jw6(8{X9r%B8>$}^j*DN@Y4UMeVRGxJl$_`NP5b^aC$?_-H(%Z}~rCeZQ zodFmh4VvP=Ft9M+sJ1i?+ymIw2z0qS;jWsdPLP;ZO zYOjC?4U?Hz;%2XHYzsef&aDuvYRa>W0Mui1qW1xqFo{j_;OU5SnlQnpTP?x54(dN{ zWg~wUJy%jRBJ3`upokyqnPXy2$~T7X6Z z)G;l9z+k>0ky;RFX4US?*f#r67|p>V8U032>jygighK~cpJ!`p9J}88VTCzYKBXJJ ze{d-(vt*Nz=*O1U$r1r5xe^OH`Hn}(4gJ00MkRa%CWB1K|FKB(|HmTD$8fpUi#Gc7 zl=8tpxPijZa}~_Lc1Cy;X7!K4_iUZCCBEceH=dR~WbH*O{ynYObLDf%hzqr}z4x)e zVq1$t#d~bCJDJnlpR`{(>s~{Y)QX-+w>B~|vsSC*Cu!lQlA|L;pnLxcS{>4>^Y@$9KQH{KoCE^W>j|M<6PltrGw)Dn#Q_^j{wmODYs5 zqP8x{>qlzj`6hxz4%^u9$!HhfV%dn5U35%@`TP)xxs?V}8NpPd$fWZo>3( z_9u{M@~p+TaPy_#z`3!#i#1|CS-aY0^_Fjbj!^2Mx>kM#YmFBwLVEuunvkG>CE3lI zGyLGvqGU;uQ`57B1}e(L#`oH?B|0x^D%J~=f56Y}0X=GWcDJg5&1jbuU{fV6jp#(( zz`3hYdL%)Mu{1%8CifyWpjP@(Bls)PRUHFE+qR_#ziesaUc}Y+U)ud~K-yuH`NWOA zH5N9k0pXA>0{as3A=F`%xOdgy?p~&w4Pjn2<2Yh`hKU)Q3!F`H4ic1WP0O^VbPFPH zr4l;TLw9NpxFFq1v3$9WFkSdykz_L)TklKtCusZdg2{yWxmuUf3eFYUB1KIleXd4F zXyaJS4IIu|JR;8Xomy5y5)kU`dS2~e}+0Sb1-*HQ7<*QM9B+_m(7k!Hu)KuSO0?+U~NO@s`hqC?Bw8L1<-zkx` zp__%O3&EKnyaR#Ncps#o8Nggtm(iq{CIq)-wjFIh{`D-`XOq-p+vdB2FNNn<2%jZ$ zD~M~_*ZH9ur4g?yE>LK5gmMrTITl5}KqR8|#NI=SWw zsVBg0nv;y*YFh3#r=)Rg%(FZg~GOW zfmsDRWf4h?12}xH-%w|PtZ9mQtC`uf_;8=5aV?QFa0)|>luNOU=^+}HEd;C35SGRT zHvj6!m1iCO)WhFw;ujN#pz0Wlf05AIWSobLiP$HKWHGED!$ zjdj{67OcZVMHLDwgzg(xAUKQ15sR2o$%G+@+p+Ay%YWM@0HG-+562B zG{=-_og`R7zvhozxXJCgc8ktOuE)MxitXnO;P#q_<-nubEQ62o2r9D_0PgZ5J-qTU zaSJ@x3~qlUR^M*nOw!I1&e%y6@J=gTW&nqJ@%}kE>TI{u&6v^nO)^a6l~%dTfDQas zyhV8@%9mYmo|bT9fE99n`Q89$Ln}-mpSZk!)|Z;Z-=~gqu-ia^jrPnDK3F@{N-+{} zC}D-ds$q1Dx6wM-CJ(qzKGh5J-WH1?2lCPTblQzDq~Ae^3Yy0_NV$mP1q%!=iYsnB zs*N|5glL55Em@_*#-O_RRl2RUbAOzm&tW$CQO+l1?;zbBN#R30Px$vJB~2TtGx#Tti!SIvZ?t#5Qk3FMtw;q+QG&5-@z(~JnbrpG8DUgZqV5-dtp%5UdZ4Vl-4 zTf8Me{?Wr#+>$CBEcJe10CzyG=@GEN0WPbXXwu~6(JXrLe+~_5D_`$zhij3}nIzJb z2U@*$6RsEDn>PA&{L<6Gb)`D`^BLAD-1=mhFp9a8p?ObUWmmmlc9SWe$tY3t;k~Q0 zTcNyegQFB`?fw0}ywoQ0cTlUm<}M&@>sY}UgNqyFd+coL8HV6Z#@6iN>1kq(f9Lpo zU81~D$O=dNwr%N0PDHH}qi|&_AXfqzVFCVqD7w!3J$F+f@lbytpP~Wjo-Zuei z;>X_|*JtEuzwsoGPOg~g9CwV z$bqzhII`Few~r#p;L#tbz;}iVX#*b~M~wy!w>{UDdqQ%pnLhk+)I?@g7UqFUlHNa$ z&ZN-l$hkSYZJGBEMY|=!3+!xLV9#qip}+ z%QlMOT*RytO~GgKZ6B!Hx<^@B{@fO;BzKGn{<2U@yO)9{XpK@~cft}(sH;1nScJv# z7;%hEH^Mk$c;KD)BeXei3eK3P$VPvV{vbNWZnH8!d8XvNa{SAFg9tC+a*%E3&r{m` z)5$3cGDqmx`Lcre*v#nzsz6@{tQ>8kk_x(gIO|;B8NGkeQMa}IkE5)foQwygjr*~07!a+ah#^b(|a63Mzqpj z+B!rionOLL*~Q0|2U6z7%XazASbIj9xA7ZOW~7)#4zIcJDdEI)D${|GEu{m`Dw+&~ zXhMOOrtI1AGK2R+M1MYh2>tJhBDaNCqV6)>`he2L6Mb(RVxK6Mo>7(!EyX`We*Gy8Lo*FS z9Mx@bLm~*)QpgMoT#V1rq}M`I?X2V6!L?bI{VLv(N9`$Is(Jo6V%lN3`B6v)MXHPC zsl1`l&lcm2?QC?NyOYL^{?RU|N71e<;v32XYGpQ5KQgu!bT%Bh##`Z1<79g<<+`bn zzJo{=@a_SV#vP|TXK;}^<@f?1O%}3x3O`|wf5D#P749;al5TNP&zSK?e|)I=Lu9!4 zP<1!R0;*LB7TH71-;b7isA$_7(9HgtkB9+==!`jD{?W>4tSxzwCW)`QUfl`x< zqaGoFQtSade|Dj8p@Z4~Oh-QOKhr4zHtmqjLUZ^}TY2PBoEp9nkc&(Le-3!UNiN10 zz!S#S0iLi2%q4*oyc){G0~IFC_*4;$ETv=f;vX9QLX;ZY%u}?5t!_c6*!LD*HieUk z>*neOu+mF!fanE`#y;kB9y)Z0&wHeiMsg$vgd@s9VW#T^{!b%HM3c8K1pZaFu%fl7 zh^(r5ceQtQ5u@RvH)WL$I=M!1g%oCV+$e!;u!;hyhnkArWK)LkGuwM=nL6@$Yz|Lo zD;MkPTT-p2u|EgXl|NPV6`!XmuR0DL2Bhjv8raro5_!h`!}HxrxDZDUVlOgmpXLnc z?9NBLfzb)#A{HJZ7_M7aRJAQ#Jl~ORd>VRJm0}M)7xU{DhqF+DlZnJTF46kwZuq`> zFRd~&nY12N{dimUK}R{)0%<9LI{m}gblC~NnLV(L`+Oc0R5Xc~((PjS-$5*{DDlGS zrWa!Y)N_gEr=(>)xwtQrl;)gyZ6c3lF+viir{{%8LCg|>-L$5E4!i&65lNyr)WbeR z!^=&)&SAO*q;P7;85d?GL$E}mya97D%sFvJX*5KEPZZvoA~hqjgKA8=81QPODmGqg zR`RMyq+g39{28Tpy;3fGSL_DDwk?YnEr%#CXHvGO#<~wcrgL(}m^7kLEd}|=Wp(_- zT%_{7*I+^b*Z`mr_T+X~0tIYR z2Qpduz{w^EIcJSv2A204qo_x}YVpenE0zEXbLf4mpEAAq-7qCD9~nchr-2iES@~1b zK4bR1TJXh4{`Z^Zc_2Stfi_LV;bscQF+GS0V2T`$&LS(S;9XYyVIqK!Be9tg3xtl( zo7w(M^v45nd7>K5`BeQT&iOWlC-RzHv#&755!P1?G~AtKFNBzxgH`txI$I+wR>NZ3GO3MZ?pASU{uln`)am7@@< zI~++L)a+y;inqO_i7lyo%EW09STQMK%e#q9VG0`+j4SEORDQ&e-~X|J)<6`GT#A#k zRL79avxYZ=>Cu?wArC7FT7^Y*UYX8Gjm2PIc{fTwYLW*jqEUEAEN->G3l%K? z8nW~}N|?NRelG`gpH{w8hAr@rR=ZQ?BE{Bc35@LoXRw?!V~V02WrLc)?oT^naBO`m ziytr}DjvM;@#VD@=j{hM;V~nuuYqih1E~FSDeCshOh1NMs9#m7C1Ry(_SgsJ%%w#^ z(uFT&OKB88QL!{=iKg{N*SoQbrfp}Wp2f~?r=E8G`rV;?0^Ab4A{=r&!q%5?j7ioc z8MbX#iu9XP!O8lNnDyHNKU8iw%3}rL{6mJ&3~dLqM4roL#BOaXZIWJ~ozVEnR5;mMOS91K_ICwo?Kl!LA+{eeA($tI3*BbV;WTlMn? zo{6>b>#BQ^?;wF35&odpL1rXc$G zi)cE`;TViTJUrr;dBs_iR%~@h=g<+ihfm5Xt4IX%d6!5W>=1> z(~g$OWk9e#8$Sf+cRp6)=8%?};J@C3!=XP5h$_2~AlpLTD(Z%k8FoGBcc5mqcn}bu zo4E*~qDYl9eS9IzR(0sAS~2aWjW43WYXypnShfhL!wZVDX02a766%`5H3Ckg0WlVY zwGGY`y1d?gyj8eZwP~?El-2?mHH>3#Bn#>gVoo{V(eTk^b6rUG^rW9n2wFVq<(>Gf9yhaPHOooES z9@Ec`ZTK~;KO)9C6c5+o#iKTb8!U7}-UShh*bt>p*os3}4H zSB7Rn1BVMC#&G8SYV+KTF#omKuNH}ukhARtX-L}0;4N(x4nq+0xuN2<6jJ&I5~b| zW;&dyU+*iliLd!S?UyVe0;joeQICZwm^WuCYRE>>cX#XI&)xJl_u%SGd`S9p44#Gl zJS-u>CNZU{{y4X(o3Mtd&g8#JCW7p&_NR~|?&_345}1RCTNciCIvu$3i{kzCn!TRN zA?RnOI{1#79)c4uwF9tL5_G{BE9UKcn%ImDoWg*5Dr|=X=)PZI@vc(xax+6hpSP+Q}{_YXW(YN1rL8T<&LBkJF|w+{q00I2AE zloukyKzSiex;X&r4FDtE>AJO(Cv_&|XbsxS(-j@Vp|~K^|Een-)Bjah?}>rxN<4E~ zflpPo*cQ4x=GQR*9X4arH2!W!iHNyR(_NTs=3J>2gOeg;nv86|1e%r5YqYZHu{b8y z)B)5V5KYXmM8~U^@K0!YxK6bcdHK)>S7VUWKw%{@_tCJQ!YnW^a0Jok^%D_Hwa-3b zBJ65DxFrky2i!QZ3RW=-I-5OoBlWUM%qb6ewZ2p5&cz@?j~ar23DuE;)8~vcZF=H^ zr6hg9D3fmpRCIdj8Ai^iLs9(A3rk&4#~&FaJZq5l!Hoq_V*k|e2N2(nKT#h8sAcO3 zi<`IIMZI*O><@V@w*S+i(a*}G@brW9OOXi;l!L13dh&kBPQe9 z+v^*ieoNq{%5odCIoSSNr67~HQY4~t{EkJi{~>8J$^68=*W))BZ>z&xM=5Zs9*y4c zg#t!5WGO$2PCQ-tWO~RZFkN@1M!uAp41r7d>uDkaksOp*dgU!p(TS&vp8zo4hnswB z>}$Ied)_7NL9Kb%dc4A;GI*x*Inf(vP(;j2iGJn`o4Ud^G)@H5JsoH^+;f^vkmXZY ziStsH?znWru)Kv3&*LV@4X60kVimUZlszS_=zpO0R?Y z+JhvM0m)+2VtA%F6Dht&j=198JLVrrKIMK;wDqK{l}1$93(rblwJ&4$chDxIYnh}jcrCC@-Oo#2vth$iie zpp9*w47+!)t>DzpTb9S*s7F%**gskUk=36?NI{_;0B z*UvA}h(qOnow!((IspKg(~f2Bueat>_A(2aq*{GS%PGZy9Le3WKTsxr?lt4@$!54eK;P#1*n3E0_~1 z0B!tKU-4!j;TGrn<6Nui!WaYOuUUo2bkz+0#MdS!vxYSN0-%qwAfI*!EVTdt+dvb= z2wr6V?>dFMri4wn1MreaP&s0n2-da)E@%7C#x%1OKl;Id@IfhNJGffv1f(~pn(1em zSQzeHs(@-5{V0IZsPLxmTuqqTsYBwV|6p?;+{yv5nMpGRXk!#Hh0^AaIJdWVum@Nl z|I4-G&nfMnTipBcl6vz5c}W#+?4cNS|0+5=;q}u+L3cA}pcWWSk|+hdFl9Q+^xw=6 zJvX+@gJpBZq&TbGI^K`aXV#JE!8#!y@`*)}O&@k1{D5zHyDuzV7Jqe~(K4hr`iP_s ziYghq0`xG-BIz%VU}+s}VCChbyQa2bdu=%otFQHt#+g_-XLo+V%HdPZ0=r3DjQgme zshwbbUGfLGJhJiVwiD%)l=Hx!1omUZozx*Uw(=IeZnm7L9el?}KKz5L&PKb*Rs-T; z$a+?!xr2W_!sr&=qf|M?Xvp>CNh;4jD~G$M;pw9%cHc@}FS4HOhx$J@f^xYbR)BPDiF>FYyGmHeX2+6uErYf z9Md#DbYL3^fN>*_E7jlHeFPl*t~j7@jO>864H{8ZUMyHA|cnwq>FLs zP9N!cw-GK=DV20APV{uuZRIY{YEJuryEWCc&L@QW>LJ>@{aD$~FVXdJK9~gK<(o7* zKzFLaj%BKjTU)#C#4+Rj)VaO*SDz3Jbx?Xq`U2pwb<@SOm3Qhx6*`!WW>I+oaDiYFn!c(K;|X7Q3}$foqZGP%?i+=*_A6vB^8)JJw`l-gPlml~dn`f*Y^q_V`hzPHWNu@tENzGCnCq!i1 zk4oMlZ103%#oN@>4}LNk@H0fzBLzc)(Oo=?KnMP32+&A9npm>aY+?VlMW{uW;T`@C z)URgo1UQ<0u94el(!xf6!^Mki!+}X2!3g3ydD~#^n$v91GBp6Q$JugcGp^LBZgw}4 z{9Z~J>;A*c$fs58;un4*`8yB0SSQ3OpIA7?^dao&MyJ*23%)gp>hkn%^g+uF!d<+y$zn;&cTa`#_ zjGG{_}lY$5zYg?e_Jzudb6p zn_sJ|1#%ee8yumlV=!-kcCHp(?4zyX+%$8;uhLq<<(_`ndhqv0d(<#IrbGUye^EZz z4AnDIFF?Sk9x8f$|HJLG9F;py^&>UzyLtfbF-~JT1k~0fO?>VxS3<}EawQUpzD!f- zRc4^B*2a4Dw<&<0euI0a`hLYcxi=-HnN-&d>49ehHOevK-_B5w8jx-%6B%jE?e*lzJVVBp!WYxriu=y| z6T%;sk8_cdEC!sxMqihCp)92tZz`ye&GC~b%~r!l@0M{`)U}&bWO0*-eV zT|bJ%r0R)Wz8nxo0rE8sUB0}p)9KKXnDhSUklfDI)wzbjb6z5&$^{>9$dg->q^k2r31F{g0bV&z_t25d^{n@Q# z1DP~+9ornxA8MXwK*^5w6FQ$;mlg*fm2BIFp&~xsE0qwG&Xsn&lB~FDn1TKJ>oXFq zrjb9p)5+ae{4TyvQwFmSVFx5@7uYYQcupKGyh3gR{8w?8*N@r3MrWtm9vxX-(<_})?5uAXt*$yqlyyb7OTt> z^BR9LgdYj-8#;JW*pDxI4jw2`#ct=2Ebnfbsp1`Vm}+(|IV21PChp!^zT~WmHIcjF z#=1^6pDx7NPAYUN%B;IZNt>3du&DKuG%wLKCYR%8N{dyw6sD!OjNshhUx0qtT)!agr3&DXJfoOt)65BnpM z@xdP+^?F)TMDlvKFHs?MCd^*$Yw1withjY8cO55ZN0Sba*ZK0Tp?~h$el5#}fnEzu zOlw6N&HmT?Rt5!C9UXh84qJ{FF3r(@`s%eBYXv+~_<5i{$>?B45e{D_M}5zVTEH+L zosf{%c`~B34DtVhDEaeC__1#^f>VFerBM>cH8*+g8_4I(mUJfa0>$7g*i0YQ34NWN zw(>f5*SEX7_u>)wcWB!;h+X;fSaC|YkF?|!luBtfekYC}Rr8b-_21B~UN?qgqYgfX zjN!o}1J}93kFWkW7qczC79U%V7JFh|nhDWp&K+&Fm_o9^wZ z-l^|+%yg}EW!=%SZgysU>~uWI6B#jM+c`s53j#dkE%geTlp^Ep%3{Du&B;t-OZgVO zX7Ccpm=9Grqjyc_3-pSlFp5qI-+G>ci+=73$}1^bMJDBGJS!TtXWPRJdd7T*euz4k zMhC_70oy$L!I^Q%3I2a7>p~EZ;g_UEVq= zJK1ySSgv}^-tzK%F?nfgFz$5tlTZH%`b)Ofi*x?h>aY7Gsoh8g9AI|wf!0sZ(HLJp zAW5xYH?r)4xe|ZKH-!&w9$^i@HDH9y^*>_|8I!EQ_DJ0)83F&;97ztXlwow|40r*9 z>YERwc(w2DH2s%fkWa-e(itr6%}O+Nx$OQf1zn)OcgptB(cWq8y>(0bYu6%PU`-ZeC$=I_ zZc+ds8I7R4622Y9PJ9hMb=}z7dG@<)O~wSVx$O(@ym0afU}tQ=|9@x1sqapChs=h6 zJ4|P%WtBQ^t8o89G=+jqWUJR6@GG2(_(Y;Sm zNZRDmk0(cQx73lvraWN+hnCs$FHbR*cFJeJwTS?@&masd3^3Ittb7<&y}lKylDXL1 zaNe`i#Sj#siECBx3_XFmaDz4x(rwcD^kzy7QeQr)uY~zt(Myq<1v&(I{P`AtPiP=t zvFjWVJY1AoRp2!$%nUL%8@p^WaNgh9wm0ci9O`f;C#^frOV*g+W&YJ&N|Ev?%8tCw zp3Vmj_Ad$~#ufJPENQk56Z{j;O2*~b5Xg#)^PyiY@nFm1%C=jH zWdcDb!-p!&6FS8`Y)v%RUA*Zo_IK%RrR;`Eb*i;cOzP888@>9!G4LGtb)?vlyPY1? zi?|Grg@Y^xhLt#Vr}Ib)tK5-ra-ir)xkWh!eioM^frZ)!_BbIHC#WyK-(rK*1IEd2 zCMiqvMt`x#27VQJ)?0~~g92n+`LQ23;@%Z{G-{J`_d8dmZ1Hf0xblWEFG(DbK^R^r zX)(tyti}CGR_rTN4b8S+iVc+=Hqfo}w3ZE4p_B)|^5__=TWBc;Kei)s1OJm$djpZA zCH~BON%FH%s#}F6DqvCvE;*c0VcY7$PT61XS{|QQt44oxw$cA8zSUuh7vgNE7wbY~ z0RC8B*z|hz$A@SlPQCC3t)ecunl3{G35+Z4f=2UB2IMYS2ATW6PJqUUJ01@td6!&= zK(a0L*5KCg@Ut<**dfuI--5yn9T?z~F(n+&T7{YPTOucUoga~hH7$Nhp)>*fAP+2Z zRBC!$kAd>p`hFHd#Z2kZ_7?nGir)7VIt__X)&0KIb@mk|&W&u~5b*)n1_!&oq^zb( z#kBTIfL3j;es(_Lk?xsKy+w-4<&!6N1p2sC zjLDm`mS%)c{aK}2>A2tYjYiG;pBz%!^EOvU&zi}5xse_#gsbMZXl zFt;{^u`u9ySw3w^dvQc%Qf|cy6LQrV8)nYTS->w7arb}z^P!nL69bbS5(>ymYv_Oh zpIqOgeQ|hxV*hXJ_S&a|nBr8pyN{P$xhLnkc#^l_v8IMcCYyNm21q-@u|5IY{WW~x z1nZhae1)C%!zI)OrIc;Z_k9Fgc`*!ox;F*piF{0k`D0Jy+Z#Un~6|NZc(5g8j-{hBv4&T}|iqeGNMq%0IT#4i6%ABTfS= zLW}U;+Lcf6Gk+4&UofZkW8CQP!1#CVPs4epbrb=%LxI7=ku#LVED z=FNX>htXg9Mq%^&BnO>H4i#=pjG8_vSc)$@82N__BkOVqtlm~+2r{=7&>Rf*QVu6Y zR_ouAFuoslA`*yQMI`+!sIjJi!=!2Zq`=4kZD9#J_71jGPp}gw330-HmlB&iZWjV| zTPtH0Y35ieIM<-GP(qcVv-`Uc$(SA7Cq5v+grkzovsItN&s0Hh0@wFKP+#@#*f5?C zkqiAqmuCFK*2k5&SSQ;sC3XJoAqTWHU9a_ac)EWPyT&X1Pn!^yad2zh71U5kJ1?+i z-1x~KN^FrfUc`(c{ZxxqYc=`427iDDWQ@N#Lpe-uhn8_Xqf)LQnTA3a$zHIjo_Ql- ztgT)ojD^cK%HRym2L2A1CX|ESjEXn!ZDnPZ-WRW|3)t^|2wp~iVS*HRt%0Zkm9hL? zoR)U&_!HUj#pMY4fm_Y*wo5nLBCi$J_gXuJ+%LH^D1JjvhQ!nZ?&CPu}SdwYnjgJTFS~^oOig3O;J?cAW zBq6`~yWJvkhp8aXFN^~T4T-_IlD^1x+BwE6h!mIOy%mRhD+{fKjg?1P8v4X(g(+6! zB~u@B?0*9u$cYWo3RvWhzQZ#)BF zHs7)XZT|sxQXX_p8d>{=BEFJ2MP|Fj$TprO!YIj~WfC@Os{LC7CSm!ZQAps;h3Ude zi56m#&zOT5xt>)px_F43?O(wyOMl}3JZ2gHz9R~o#M&&nOYnqXIC|n zU5CXa+&lsV!^%87Qpv279QD8(VK%{KI#AF2ELn&u<@-m@Lc~Tt7d7tOJxs}rA7;24 zJxw=YJufZ2jqslCsP>+c!q~X74v2uGy(``5)F#ih3+NSQ>K|t34n4aS{}4Alqbq?T zv8K?0kP%rig&r;_WTU{R`)9%}tr~>J*&`D_gLx9oWCYy3y!l_oFV)}hLvj~ymxN8{ zoz5p>OMR>W=UPPdZ)9soa>RQc9+*fM1Yo#Z`R|1BGzq;~d$Udr*;snp(0^-@C^^78 zfa{{>fb0}GU*iISuyiI?zyFj3jn- zmTNug%G@7Kdg0_{VIz$QM9t7p#6%ws!1#983=w~n2i<|ma)uNPhw^dU7QviX{EUXGh4W)~LQ2=62_2^%IRBbODaKo^?#Jp)% z0~#TBUkQnE6zTqVieW1m~$fZIn+ zJ`mr5xGc92=f3S=NAlad&Y_+nh~-TG$z2m>zES~u5En`JkfmAE}Q1{Y=(tyJ%VuRoo{azL(G-B+49M1(gsYV*E2II-}`lc@w zvGw6%i|k|st3xK+8s16$#k+{jo^Kl4gsVON&^py#E;NE5kYR%iY@Z8T%eyc+frj#@ zW-n(SuCDSN>#b`#g)B>n0&M~SNVUZ}#h|8lQ_b+{iX2*@m~iSSXJ%GCO=Amk&nzpB z4}MF~@J{}hpuPN;pdG*d%7Q$WtbRKGK(dghlx1iU#ar&lwM=l+rQDGu=T$p&* z+qQ9I3CGt$aar^_|IoF+%3Ept1H_}3Sr7-j6@BTFIFBVla-}}v)Yns{Wf%qEiUV?c z%rNRDb;?6gz>BEF)rVqoimQ+=i@Rw}im*4~ri~Q7`iAK=$DaZT%Akf&6p*0Aw4G2& zN%WX%!oCv7xI27kvp%)@RFn7jg%0FqUW;z*e|@Iw^ClDW?nGm zU(BZ=5qKB$lTplKgbPZCDQQAsaA{?Zt66d66!Qc@r32lquE0D&#aQ$G|F-iQuyJ5J ze*-Dt(tg5;{W^ZJc>f~b?9PGbPYDj)?Ur;;r67B(TEKa^nPeOu{>rQhore_hRj1qp zm>~Fd6LZ@F8JL%qGOia=bHe`$BB(r~<@bt)2VIuA7H!>k2VYp1!Kak#ROgD7HGrFh z`v8n9#ckt(!9@Zr>0IEd2JBxus1K0>HQQH_l~ z66O{?=vh`O!|)!^QFn84F9blhPZ9Osf3+}uLKhi*-D@}5eD=WyMZea`$L4LoE1Oof zym{q;l{Iwg&F^8m&#Qww%L#4tpX$`H6s;0IUPaLNwj*u>@q6sO>D*`w89cXxh6n2x zMc+kErg`p6GMKiCZGf7jbrb_M+K#B>NTd`okA{ZOQngha1KBm=c3Wq+la<`_goMRJ zdfPR&-*P?ows;`d>rJ_%pqTfU^^hy;0>}t8Ye~P;cdJza_7toY;U)x#H`bYl5RP)~ zVl@;hw^3c+XcGO0Li9M~wmyP0U25JlKsjePz*T^9{&qTsaOgJOOq8eOydQ?6OuQaz zA$fgIQD9Q34T$%#f5i}uy09+Kkx(qxpIhmB;ZLCHR@k1=ja1M6mg9sqvO`);IJP6S zZX}j0xT}`r8{q3Pewh8_O!Bu%8j7z!II>({Xf?S!Jd>`lO&x9htxY-7 zd?Y-Au#jQ10;owNdy6xmCTlmZGdw-(0p0`aRycm%m$TRSUZuKoXRga6!f`S!y#Nu( zC@dC80N{)&WBZNS(1*sut))l2ESN)exd~+rg8_!jz$8Fi?jtbSqBITZ<>zzGoLG9g zwea~?Ja<4--pKlhehGD6k}UwFc^l*QTa?(3Uws3X?nDy)3wP>uW>_m6p}vCc^g+Fd z>J9oSd`ILcdl24Pt=c4O_{{CuvN z)!BZAoRCkd>}&ou9#yx079b~43W|6DS3i`^?P>z%UdD^v!#2mMZK-;VA9z|4J_V0#w_?paEW1DP98C`{ z4nv;sZOd|UPF8PjXEU~jZ~UDb9-G>_n6+|pwoYzpt@%7Dn(sWN`8$3)KDaa!@y-!3 zmdxGnHQ7S<#yVN5^b@vv)A?~vuC6}%X!`Zoo{DT>4&)N0ai9okd5p6)mGgY3+-m`9 zb-3Soq(aRKPL^ST=x>o5Zg>hc^??s=RetD29#f!UFr(RY%>3Gudd&B>0MYOf)TFeArkj+Ywc;#*cssua&0K^$yWboAFaCV7qXj?k=x9Bb zf6{TXc2S?7>?tOn;gA0hrNYgvrpB%iRD(NrC4`CMA&?olpo92CabxmPH&tKXH@gsa zT3|@#lmy@`3w~ddQr?M>chMo8i@pEPRUT>r4?^QF=cp~Miwc$#Fli$xAe77MuymIH z1rCec_}aj(}IXBxCUL7ZOy7Ezl_ofj1;qld(VHPK|ooca;sVf4-merR`ehM<#4_h!-0 z)eG(ook#lv5Gy9f%AxpR81}Dk@wAjS*NlTj{^HfQ2xSJC$ zuj4uu*_!F)Hs*G}Of|#Qke9aHK;&Dx-k_SWn0Z$k@e)?^j12Ya+Q7L=vy~BQT-+l& zkQfihNpg~pC(1id!FP0YW22sXoXx-*KmX`dO2oTI>Jk6&3#jfKD1g0UTguG{rYAv!6Pv@ii%C^Z)VmjnR2_P1~_;+qP{tP2;3- zW45tvH@3~jwi-2RY&N#9yuv^D&N+ z(Wp4}Iea*~#5Cxn{XoVjSekR##9UHL&{!JA=k8Qn$t~@1pR6uz(O6=CJaA}k@@18q z0m+wt^_D;!wHlj`3!EhMMY$|Zm4xO=In*&atm=3$EX?;O`EXcR*(TJ!apxx0&W8+> zaMz9j(P$Vn^!oOP;>JJScxZpS%yi#(yor}XpOB<5#36ZWUFXIeA80dQ4EOLP2qV~v z$0NZC1H#)V5w=(;j1%Fr+jTWqx?$$wSH0vbm_y{;bRS;efAmKgkx61`@ypAu!)IWd zh#f$Z!Kx*KLg6I*9PW*W0{d+{>fq+No!>n|DTiQ+J69%2@&p!et^Lt`u>cRyA0P^t z6Yp;le@{O>j8;~waDWk>VQ>h&P@D>n|G^2|(N?CMLl0^NzVZ!wF$jNx&VU~d%$%nX z?THPn+hEyYmcbInI7al zW#UdIZ2j7R`(^BC%T&(s0+z&4EH`4L@ok7q36?FbPkSdhsMpBc6h7gi{B`0BXd(B^ z#6d61?$pe^b;Aax<8{d4WOCB;=56YGT@%^vYo?U|@_C!uKlo*%MW{zyW5)bpws^mD zTW9(V1kM!oc6~al5$lU8$o6yum#E(7S=y!#hs`O2q)%_$_ z0?EaYSu;NKzyde;y>zQgc-p_n7xlfNXM2s;>U1$8b5!(XeK})KD=wkk0VPr(XpvQnn`T$mFZ`SQ#B#8YDShkP$w6Cs=5DYF zsMlwEwolFOJ}-`1S#P`D%T1e>Wj_}XweH>Mwv#fgSX}5B6?Lp)?A3v4&NetySZ@D- zFz1MeU?g}HgD>-EE>131ST;R*DyU6Py&Ql3<5Vl(6Rzy_NZ zCF?xF&Vj#ut8;SSCwoj?9v0slSacf|j2t6)0+NyFOV&ym99-ZB(vMta;)rHIh8Ffl zwRAYgqj<~f+jsaX8*J+ZvGlNetfkBdsLKE4P=eXwVyX$4YSRpoel_L!4XCAS#qj1c zrF)RAliz5=REBDy@ZN-D^-WM-E1z0vJybUT{&#S``~23;YN7f%K~u-Oh;?k(PLSW! zzc~Upe@m3ZU_&J6yGwsCfJiakK{uLy%Z{mis_RmRR;UNV3Z58WCoQBvGBv-8elQ~G z^~cL|G<|>`uS#*)htMyb?X3$L43PHK1^u>~j z5oq!3bbttsV$)aM#c8gi{N?2LYbn9R(9E z;Q8GRry!>2(A0*MySMN6n=q6fpp-z)j~lfC`>3)u><5nWcE6h%Ha(@Doj-K!+_^5Y z90DE5EvT7SE^-c{cD!z@>tFkpR_7Lf{@!h)Spe(!YZGaBH^U8%0{9z%kU=Rixa(tk zkp6ZYqV5{D>IaTiFoghVf7zOL3~vvuleoJBWgH9(U<+bmz=3sl*z7?S77QctMOc;F4`#hCyk`-JQ?0vX7YwB|ZVVG(6FH5GjVGg?CC& zXz$o~p{0c$=s0E_i|Jtj9=r0JC$%Td&AFYpfLIrj{l`Xk z93AxG-k{=?7v%E|l~vLW_J3>bQ(P7#tjE~Jd#zTkfIE$2oCUbkEj8!1Bzjt}{m9*Q z9o{7;U1ZQkC_RplZ9PP15o>GBRAECAZE&*C=$OH6^@V}oaQaubP4LfI50gPHtjjoV zY{b3#FtQ<9C=fr=iLs?byqz8tZ%#ZLR#M@Y&UH&qv1?B+n+pGz*|hD8 z6vg%hjlD)%KQKMe*gUemIf}23fm&CQsff@#0kALEFLV5Z6u+lPxt0$vXf^kznQGSQo(}Um2 zyw+U%&vf%YjvcKD8WBCo|E2Pxv4B)w;#9U>+b_TG4Gb(93+8iJhm0?T7A96<{LDL`py;8-8Aa-UhLhv>U@G1~rjrHiq_wyBV-ppYK8^fiG#rfdVw9N00X2_f;r z?~|6^c>3(cL1IwsY`MrmF?M)NH!iR*ZB;$n@<@#xbBcgJQt$ zFlq+TY=FBq#Nk-t!3jfbfLm(=ffQY52*f^-sD62{q1_p>)w3yFB^DNM<6BqwC+-5} z7E1zbeZK#HBj%tuJA9!V;*X8g@acYVpiv2$k+~uEOXA5DU7M06PyvawW;vKCZinH# zfi65?*a>7rsSLi{AQVUZZyC<`!bQ_l{4y7t>AH6?xbL^VNJxR*fKn}NC6fb51&hUx zVng-S{|GuvURTtSA1K0wx)5y?ZRfFlsPCA2ez`j||FYK7955Y|O>v?1u)4nfSqIs| zyNMNJ_Y0(0d(*DCzjNs|6qWJWrT2HD)blkjpPR6fHlUI?V>3zt=VbD@TV`WpFHicjkWdSc6)e6O+qRi7+ULeUafNp4l$PP`a9MIBtLiR}*^|@Ln zs|&R)*|TpU#Hs7gi(#&B@5OvpE{`2K)qel>kOq3b{F$^M+BV&Vo36UTT|sHvgfHU7 zf7&{@6N!udgq){H_bQopqOuSFwO=O@YMo5^ZQ;9*4W>P>@|EY^w|Cz2$hG&*o`s-? zq&XZOH3-2F$8K`gGt&h&~U*xdf^U%<-rN z4BNJsg$%}D+Y4TmU)+ChPG8*p(mZtQ z^b5#cSD_zZA5*%x3qR@BL`=* ztIhlF_!b#uVG!w1GBk)%V~Saw(HuAbw{PDMu!+ZhzJi*pqliu|3X&mZ4T}5pvW#i7 zfe{+QoK?2I#)IW)aGBcp?_ci7xbql{Q{nO%oWMg#HQ;eoFf`WNHo4puJ4%)fFWvyu z1x+@y;)hZ?mw4PcOMfkEJ)!FeD;8mzSLfQ7e|it%i2e4paYjyqn-F8t`%n$mZ>s;Uws` z;jbj=wlC!+=!{pFs_do?O56n`&nl9dpj&!g+rOUKcQaQw-15#{l$vJ%Q<H9`00d!9@S;9WLU1RfLVCexJ7qZkd;9y#Rb7U77(<|wLnHtg9QFb z2<+S^pB9tY`)>+#Uc^k^*=^JCX7+I7NALb*{o+B8!>L@|ji5@c5YgR0ngJ$6DI_a3 z@qPVu18Zaw1#~-AcF9}$Zt&jC5c}>GQ>{B4c3FEh=Ft_eF{xhO27=&GjKvRgkGaA; z8>`2CfXAU^xKDq?HjSM0P3HU4SGPI0w_a+fCQZykeb;L*7I`=ka{$7h0% zZpfb<`K@sxZ8WYyqL)n=<`NZ9Cd-3fe|xvOi%140zW~^D&zN3PkBd=uIT)8Hs%T>B zDgUwa6MKBYv~5g)QAGS$();g|(kCefQEv?S#7p@-k&caxi{_qM-g^u0Wqm(wyT5Lv zQD+WAPHt9`Zsr0S-QQ~>{<4bO3`7r)YXL?n6Ez9RH+po;qhN|(UAlHPJwU;#AJ@@{ zo5-M_vX(>ZYD_-^p3K3&yF|A1%=q?B`Qn+hSep zmH~mblpLEWWY(_Wn#aMHIv>m}zhJ|tXUEdbu+N1m{0P>!o;eCkjVx_7O6$JhD}^oR z>Ud{YIpOX8o@lgZ?^uO6S6_oPXH5$=vzIw2)7Me=eW*1TrrprM)ga3bIIRJw8QrG$OZ*caCbR0xx{AUeieEg>$W>rBzv2gRinZlBP69MQ;^`W?r# zEr`Hw2a$C~`3I#wMd!eWG666;N}rC`h(p$KG1rUE-j04rCIv0#S%^sDB>euFGi^Cq z@D>Pr+i6YvxZlyjC2f&m`l$?yyBi8HX{0Huw4{)v{{ss_e%a~yP}4hDWI-rHQi1!Y z=mPk^jKK1A8PlE`an)Kb2BJzY{ei%s6o{zy&puC8#}H`*s$98uk#hU;GZu{o=xwM` z&{^Hj-8)0emASEx3%(3-h(`~Zpz`0-Ka@LW#_I@rCV-w&qnJA5&$+dx4i~Yn#!bsr zB1?uwq@pW+1AUPOs)Np6iK`5ZD-uj#RYy&dNM+irC7uvatU$AU(A_5|!w_XpUhR?d zN`VH&lI-o@wQsq+povG#=BnaafZKn)&lv%3Yv<1RNbe2z>fRfDt>Hbn=Sh4yySu+X zwh$SbOE+JI%fNid1afnw=s8TsrY@KB#Qz4qOhjp<-t{kORH%BLfeSGY5oz+N&g4)R z>;iHed0uoV3Y%wnU5wbP{&?a(&6QO%(K@=o;#n)3ZK&4Np}Eb-rP)Id6S3 zJE)jbxp8Kyn}L=Wqyeu@usu*9@)=ffJwb#?`r_+KgL)t5mslWQC$w-3K; z!DWly=J$MFPC%yeJN-b7)%jaSIsxTA(A|W;{ii^L3zq(;gMYB689!$ok@>heR+%Z=UK0m*S{7R?SYI#TJ-YMfY3d z)eU?D=fhsHo?ZdciuwZL?NNTuw`+wPXse2vi<><6nac=DnVft>Nd9?t;QQ_Uc-O)B zeL$r&tV;v2R!Mkq{vBxIY;W1*>M>La0lim?q;eh5>@}TT?fEzIFaR z?m`fD#pSK;SEbwF$T#XcK9zp8`e{k+oemguS6g2Uj~F^#jrNKg`y*x;FTIM}(q%!CeZM;_AEpEHX<6@SeVcgy5)P2WHMxyEC(F+~l{lK!J*UT{yD z$4sG6+TKkCGfGf3#EnpSv!__oAzh@}#OVC6SkjI#dK*1AgG$mHeF`nGb-uH$2S&Ob z{cw_QMiuK-Itf=k$AhAG8bKac?tX;ae#ERrqY!%AbhnpNQ*MctXtgMh-N^!*JD-Y0 zhVDQnrD>`%rt6FkX0KK7Zp1SZanxtGz3CGhz{b}aa$61ax;=gJmb=0h{#N`u#AKzW zbwV;SOX=8FN*WC>f^{d6Og|p{3MJHFchd)9-9e2Yl z=`<)(78x8M;n@lGDyf!RAIv+}RPl!HOS+hpm8nV06@h|(nws!Y8WQ^R+etvp1 zr#+S9BqPtuS#95v70xA!^ApVS711mz9~q=SnsR?TepNm9xHs|WuW^k51>6121nt}$ zzxR1wRpM5@EG(QX++DcpzZqslaVq~J@y&oYwN8ox1~-}n3rB>*3m-dM2!dL>L2BMD zD`y!m5$gg6+KIpHrv)C0U(*7@2W{nmz$4WLrU&~cpcf+{csEKH?%)SWME#AN8BZ|V zOG2=I(ZhHR2z}Gv$EXAOv?bk5wixfPvoS&O=pI=1)0(Ul!*q;G3IL zv8X-hhNYe7gfVdX8;@w<5f(+? zFk&cI#+zq2$HBO*ihM4z+Jsud-=?83@#a~Nz@G|3x@4fEj5#&Tg+%S_b#Rwx%=yoO zV5T6?m=>iPej`sc0hnd48E;s|O{I9zHGI)BdyRB^zm}OU8$Ppi~Kr`GHfbW~6OQ=K%3*ZW!;sSS=(_>4^B=wvTavK5rA-#zp@o9CQ;y51UB)*f2? zoJDc(pA1(n1Uii>mVil>W4uZ~l)JViEKHAQ^8zPp;Pbfp?W6{wx&uo^5>PAG?S5#z z);)7bYurXs58M(7-SX2x2RwWC$y*lZ8YTs7rYeZ8Pn=iBPA5+%TM{r z8mY^uN|d#wQA#L)OQ$VWbX{cKSU;+)(SH$uTjOQdBhC2ey{x;n**uii?dxKgys7T} zybsd9anNr-nd?VY2CGJ&qNE5_Z_NGQSRn(Q5uElE@10?Ri1ngDhCzR>8O#BzK=6o2 zk{4mmWk#p3>%jc5dujogm2~ri zy2Hh4R}4`UU>4LLnY7sOv_ITTR{=9N+7n^w5uW*#?KrLfzL*>o@W5~^0uUp@q5ZLI zCr9<;#v^8L$%cw^Gwch3DK6w2gSRMC1v?H1`w4hAKW@Gb0n{OYHDPN|-a zTk97_1&eXISAv8BN;HvL!6D15TE)dMA1F?(5Lh`#H7rgt6Z{uiN+O z@$f$(%?>)uK9tzRkz&f)sBM{)p00pD{~XYr@i?rG;0F(6QH*5LQp52O z($0^f?hX#@?~1hz{Cd{cc?}(HO?-?L@(q5g!lJ>cX7v{(I;kU0&7otw62$UOYh zGKRC>>*^qlPYL|r9%YVDrvOi2n56$W93$o(y^0nLIfajk_{_;qhHh02t9Hhp+p$Dl zgz$_=KtNp(TDgwnb3J|5gvGZ+Q^ubY#|+!pHmphuB3a%(9l8#YQ40s4fny(2zu>dA zB_I0c9_+XUhIVm}xwT~nSBrN)Lj<3uwx{PI$4b4G)bm@jqXr+--bHU5I*NtNgP&gm zl~fmqGwiq=?`3>$-raq!?%x|lkuo!z<>pQrb_(iyE?u=)U88nPK=qG3$btg=HNStU z^JQ6NED#4kGZxRLP54`5nrv{4G9Z^VbJ~9&RrWZdatR?>)lwKvCy|d=oi%erB{FeXf zcEtIG_c&9q+^h5D7lE5{Wu4ugmr?WCpLwG9FS{aUq>k8P{OVaup#I80Ph#MPI z`u&_*gN)pLUxCEED@}l6o_oJysOKom8kfp+N-x#cVz`WVrk^`x~u+Vt+uNI`t|7_hR6gmL1jPT*oaX4|`j^xaxwzdHYV8gAPuef~t@_X^y8r{r?z0rOzj!&Nb8q*d5}g4BLY`(Vl*v0#U~ z!F#lERfWd>kC%;;bGd%oQX&hp_?Tk8Ux?EkFF1cvq6!`URJf>Ybl0C1 z&J2z5%}tzKY1x!>`{MlJ2Ir9BYbirr6_@F+w(z6GuGQi_SzX1Rk{&FgX4GU>qE~n0 zB>hDt-Kq6L1}8I}qj)U7W)$sam93uzvbg$gC%FNHXua$fVPEuIM;2wa^(PNE)Jz{z ze%qFpo7p{J88EJ_-?w*Jv=SGN8(y5vmQ=&6$ctxY-s?Ve+#h2apy0+mw|^_dgsf-> zM*3ttptdl#vL!#lW3N}6hH;ate0GEBIUFQcFgyPW>yUA>KJe`8S2+LHu`YCaiI{(w zA=8za_sd2xXc7G=1B{9?OGhdiF>$O#hJGSlgP|?HsjO{Aqnc4ne!^bE1UKy&m}U8C zr-;hflgKbLj1&0OltRpz7DEGL$zJ=xK5u`N$HVH$Sv7R*CFOFf;MNzBD6E7?m8(Dn zb|J(m%ATddRMyzoRl#foUuQnuMEQK0SZs^uPFROBrjX&UszAf;&zFCjS4ogWYpeM1b>NK&v<4^ z_K|ijKXke|dx};DHtmjyQD(St;n%m)xpn~lTrl>oWbfYRL`N_0e3W_g$nw64a$#Dl zc|#PW^Wjz| zk*H9Nw#otW7Ds&P_ug7G=;c9aJk7}E6D^D3%@6^(IydlYIV0A)=l)htOaf92tR?97 z__TAcCW3iiL5+G}-wm?7we2=|-HetslVuP?a1YZ?eqOL^GTKE;!2?s0`q5SBakt?d zZb=Z8x_-;l+)Ip+JB$&C!Iw?@st#{}Olucb zG?zvgY@Gbp`#<(3#zrcW5d$}NHuZ{_^4^VHhfcoBt)pLfsv-giJ&Rt0K>P321hyUf zz5Ds`->QjwrkJf7^L5hjX7&^}CP|xlYcJ~}5K*~?3yVSYIR9g`2Ylv(616LGL_%J( z$*cqfOBcrN*@F@(^dTEO)<(U$Gu^}Iffj5%L1zQ-&N`cjS-ISdPRh_H^=08Bl=#$X z8S$cP36gC~M~Z3IX334uF7xMVmF$nFIZdl=7>}l|KRB;cTxxV?Qhllv%dJndkAXgC zS-!9Ok5R6&XbEpc140;`iHP)}x=0wOrrhQ}TT9IRfKxFK+4lLtyJZgzFspg*)s8wN z@9%wQR`hN%f4Cg}m4eNm%KnY$l62S?A^>pK0t6 z1wiD0H6pKWMiYR@M1)>g&IXh1@g=holkc9ftF!lbuurJPY?+L zaAu~T0;jx7WtIsRUKyYc)@=`NsDS0gQnutTqwnTg*eR_8PF4?|_q@!lG!@nR1i8So zhF;La|7>Z&rrW|3bT|}q%cRfJeLcU>4~XJECBU9{+g}Bmuj4bFrVka#)L_}|PZj@o zG#&qHe1S7~gO48n_|=1*r7v|0U+=Uw;LXlw9psp8E9&dLbo(B{X;<>e6D-wkA+5&F z5<)4eH8?n&eEryB?8DE5-Q(Do&|DLtt2`6I^ha#K0=i!GEkDI{!OO9cs@BtQ{k9PK zV|o)X#VCGJ^5c%ypE38zUv3||2I?ljq6$&}Q^>K&h9B4nnk%vOIz(NSMmBhq)na+@PgyP4iSV zVj~2%uD(74wiq4bW8evJ0_6X23^FWD?S#Ij?%&r>?utg&z}!J~gJ?xIBKKjDniUma zcWDH>)m2hz-XJ^HpB(`Jor2@IOZL->&iTCM^E^ec7tO&>htskm!W@ zfjYk=oCJ845BY;Pt@01vB9Ig=X#a*qfXjSl@$jm;qz!ja7Rdz%M6NTu2;}sVYm`7e z_Z{}y)ZMZhRi#2Tzkvc!auXlrhKZIxZs#SS!=%OQhJ0_nAFZ$z$33C0dh^}5{4a5D za$a;oUlxQN(qP8_vdLA#xuyPc#KBGVrM-I#i5I2KmmMG>*1y*t2*997A$aUBUL22$R;X2%{`-G5yb6+Y>wI6_ut@vctYE0 z3pxP10d}@@Y#s~y>qT#ze{G(SpaF4OM~#OdWC~kxHmMeGmv3I)cF>n*G-tyLxoCgI z0tvjk79|$Qpf)7WRu{K^B2DFYr|>J|%>SLZSvYqLIPqX}{aEiFc2>)ej8wls`^h~{ zeBjM3r5JHsMuVQ`nepv7m4j$~7l?c&|L}r04!xj+tH#+`(Yyroox&1t7jdk|u=qQs zm4eZJRKEdv^?u>p7hqkf*7}!Tv%h&4rT4jHj+{?xu)ulysasKnOogGyH{3I=P@?fe zBiDh#w-$F&2=rs!wr{_P@Fu?h`JvokuZO?{3&V-AW%M5~N0FNk8;Afo+so5Tlr|yZ zZ2Vi{4c}h3=zKP^Q0$@t%Hh_Mt;}hS#QPv|i z&lL7aSDLQIuH>q2px|T5KxaShRZTq;L;h`~kj;^1SvbsxS`i z61E08!nSdL+{iavtv;j}WEMabm8n2=$$f>uuR^!^ zSQ3@K^aIr}0rC(AMO$7WE^vf)Sn!ct!Ql{5x4q2`kh?w+Yn&aJnEflzRP^Z$WzU{avJzR{;nF_Lv??CiegN%6|nXH)3yg(T?Zy_Y?0QruX9 zXV}O9yDK}SSk0hTWNpo4X!YRBc(ni`jJSZmIO!@>h&a&a0kclu&yH85+VlMH@z}kg zezOR#droV!;JsUmx}k6xg+>LK(xd*~FZDMvx$Fh_B$B#w9K6cV(hG6fsFnq7DsJfz zYU+iG?_gWF4ja^B)IGv^`4E|T6;RiObCrY8XVM8B1Vp(^cwj^6pYWnQ79Q4#?gf}$ zX$K18&I0>^dVGkebF6J`q}djW{vD++))OMH*gt@gqemo|L{arBC=7|i6bD;*b>Yh# zj!Zkk>`cRid_Yu)$^6D4?H7qDd!>D@R{MO_b$jE&BzunA9MUW}({maR9n2He zdh8IH)$79ls_qrv{#4mth+=&tIa&-OQ*8(zy7@qz-Bvt{F`)C@=8l)j#8q~?l9pM{ z$tvTXDzk5Yo`-?ReW917qrkAPc-d%F3B9k*I**%S-Sm|=oamb3c!-JaHAqvpw~Nc< zbO}~m;NuBRZ)@p0SCOP9z@SepbV?DjRzzNUtUcZe;Y zHDh{`c{n7sLAj2d1Q;QQOjha@?D!o+BvR~qdjqIdZ*}OXVjI`tuK9 z)f8F!dorqmlh_nji~z#l;zltsL>Ayv3h~=oc0l`wzq7>+IF-3oedc5cP(u@eyPZIF z@CCRjnK0l|IypfkI>u9jab)HXC3zx^cBTY_CQ|S><|k0(ND&dB> za`tN;59>eg%;njDDBV^1VHw;@uyA#&>>s;bgTpZF@+c=Yn`wKx6N?h;Qmv%*h#!yE z5eG?||Dk56>@hIT>!2{qIa||aqvg{U^Ndy)BToE=iVNZxLn!hAt_A}%r9%46tI75D z(gQNRJ2O~V>Kf{JX7oMEz*a-d4e77!Hwi+e5W*VDS@Td~@~o zZ5A4K3OBg^94W2Qbg{#)7H1QFmH*%FWcCCYCG}7Q2b^u{rau*v7xH`0cCwRwi}TkX zXNR5`b}Oyp&*MXr<2Xa|@`2J~ly13V2rXu7ehn?hGffN8?W> zWdcDaMZr3?(Ix2Ta?kDsdOJOA=n0}T^IulmJNM7jkJMlAL(v%pYx+jGSI^dbh}Dro zhM2Gfg+r0lRU1-3aseL5QDhzkr34*x=(zI>^$!66&fu*wlE% z_xiInrHnwy%P*O*?G|RN*|HK4>(mUe5)vls&|_}b=f{)Fw?n0KRlk_VRQ~dA9`tA~ z2MNAhDmG0SoJRRqvZjL)Hd!mq{Mw3-{J1y&Otu^!q{1WpPLR=-lpIr_6niPQx)$T_ z^%XbS*qr>k9JYMsU7yz1subC?G(;*Sj_aw0vwvTw_1?MoHTv4bTQg7?WVijr*&SNP zg9{dBY%MC;4mLCa0nx>m2ofYnp|rqc6ScZEIYM>Hwq#%_>}URE|2YM{jw^`osy&s zfW=IP6sN3*4cfaQO|NykAk4(Z!Skj>&Nwh4qD)I9d(5Cg^@ha4rJ{lAb~Kx( zVp?}v4n66_+Hrh-nPZXhU>A9z@KUK)gm1X8OhHU+!+lvvK`d;-T4Q6mc7}EIzDL() z`OJ@YkFLie*Nt*-M{==#IxVcM)xjG@jup!ls@plY6`ENxCbDJ|xlf2f95>35+OliYzpk*y6=^t`Ag3}0Wz z;EcR{UOm7yIr*yk+wsHPW<0Ty3FPRB1R3?rsJ!b%E{{Uc>37B$ zp)U=Jy;}c_%+03hUB!*fNhWQ@IUY>RS8a_OH3OR^JI$zA@#(9rM6*YfAQ}Mh_A8k* z0N@oMzBLk_Og#O%BhoUH z0uCl~F_w#l2&!*02rt7H_Q0FM8JDcP{hbn4H7^3+r^`SF zPwAyHvx-5rJrj)ya0R0|22-U1=CWU|xal!Uj(Xc59V z+Pl{!z)a+VwEniouu;nrC<$U6c$D{^{Z;-cI|iNuj}fG)E%Ir~v3}f9Zs@yOQu_&! zHi|pdDjsQ!=y-BPR)k0 zor8vgNrgql10Cj!f#9G>m({Kw3R+-++n_+uCGz|yM1&zn2S@`V3`IJ*Zb{y!+uQ4Q z8(vpoiIyhFnshkqBSIS`?#G6>^|fB;=VO|Cl3#PnAkgc<@GScC zt>NkSM_aBChUI&o0ylfeu*zyN+h_ohHPjQsg*x;g7>~3VJI0VNxC3>&+8C#VMA68$&*fTY{1mO@5830z=zy)+;A75R#K1lT&01GZkR4b3b^3X}*cSqw1(?`eM!~9S4 z=CFasnI{997ro9d*>UGLjw_Rm{N;+HGX#b)1c-^_ zemXitSpw1N-Z^4f_XTAVMA#)7Ii>IrIWs0i@=ddG2`i|&Nf-<{BZLnruZ2;vHKPu^ z2~vc}W^0P@aoxRs%g;r?R8?lI{ZhfAJTg_~g73lf;YCNv;#8YAw<)Cj1_`n1JdBcMZ3#an41 z4d6_6X`sZZc)$YzwxZd3(FL~Vg%A#0$H4(s5Fm#k#7$74#~zUSQgc;N`jLpNUK_?CDl*yOIUET<+KIWIdD5B z*!F0+P>Mr^lJR1~A3%xM78bvDnS#pANi_5gT;`pvvjSJ?AHn{sO!5K)M+Z>JCt^Vv zN_*XGT*NH^rox`0H-nnUQ5g_o&lvicz(ezKu8FYhpb1n*wH#*aGZ{TPqI3l4Lv}>z zsvPgl_bia>BTK+**Bej^mPr%m1KEf{MKjn999Tq-rf&(Bo`UVAH;3#6!wiFpC&b5@ zBf@f=DsTz>Pa>i8<*AM92@aPaRF^Z!3!GUZAnabkza{!U1t#yLdl+AAM@^jtn8p;D zqvkbsa&3KaoZFjm^j8K@Wf{(g_x|YYkqC0;5PteMC)=vo>2Hf+HBZG`p$@J6Pem*? zoJ*|wF*c`HzH%uU%EO&26AG}B!t64o{+z$EMo)!Mq#?#mNkU`-vaes#Bok`f?b^hR zX)^5YxMana3G?EdB=siKZp!A-J@oyztK+HIu3V6{#oTg&sh#38PhHd1Qi-|yL2hEi+77QkUTn(imBx{ z4A$&08HjXX??4%obf_`6qnK9V;D7<`5dtPbN-4fDycFqXWs+-{Q3^Sw=^(2=wk{T4MQI1C`wKtmI`d+@HKUd)3tu%QGvNSna zg00TCQ&qQ-KVYykaAL^+$c#UhCKtybQKkTdI)$+w1^S?XKfR)$4=ok>WP3#F6eW3p z6kr*Vlh;cH?h$%l2bNQtLJxc|VsFypOOV*#D*QgT*Z1AuBydowtp5;-pT(6QMN>O1 z-BOc)vbiKe)HwJR5CNtfAI5hY8%>;f#x3E6u~M@#rnoJFZ5Y@7j~neYDz*>YrBU%H z*E!JdpoMmE;^kaWB8?`u_aliJhG>Fio8pVQEf?cSiS)$?*pZ| zy?O_KD*(!CszGL%Q*TzJeio>kCy8#v)4lP2Y6Lv=*J^}yRKJ3YFmQL~J~U1jyEp-f zvM7M-0%JYVgvOFySIe8*$&lT-crj5xg8qru78SpSM)Y^Bb1VX%gCK#l;p6^LF=f

`Z~`7oK6$-U;QneC+Jp+};vKp^EidYgVLm0n8{=;O#^CuvLV}E1We%~o zx+Gv4efN(A-j6z%^5lo<)v8)RD|50wWkVXBr_V$MY8}MMbt25Od-$97AN5`4QdqRJYWgk;-J^_ zQaHkS(&-VU{2E=)M;1XA?~oF!MeEBUL&g*WOs|koXOc)jizWWWcPw0D3k*A$v69=$ z2Y6yBcbaeXlmQA_6rIu{%ryUbrXd~L#ycDC5t?atzLR5j-OAg`0hs%1h_Y|)Z!9k( zUPq53QD2Y9FMrEV@w4iK1crpS#B<<;K>r#4 zl7P~hG0RDeQYRk|Ki?i{QSJ&&9A5LhI2_|)5#U7|F0zE@-xU~jvOKZ5e7Yc5Q@fEZqK>-v0e9F z#4GLFdzzNp&GIiBA1Ux>xrFiW1>c90Qrg^32S0V-?GL$Mo*coSrpmC;!HELqfiG~= zOPdqQ$ky{<;t7Q^QL$8(!^@f}3M^Y*7iq1&W9*@mOdprt#LMP| z0}P9otqM1KdfnAw-Sj&WN=lCUlV4?uTzo%PN&IPGl_o9<@)RA==F(EFy^A7PMX_XI zzZm4;z)`P&(LKmT!l zw1@?CrrdY1wXDC>Azj9(*{gsh#nVw}qMn{gBqD9Ty4UC6FA_L7sB$)SC3TXyK;zY= z`zE5N-ecjQ^{{ZkhCyC9xZ_CC#zjo6jI|fhiboppA=9Bl65P280hx{%VOJ=Xa14I8 zr1>xTbXb<+KYWP)KeoOytjgz$R=WELh%|>%y1TneKHQg}OKVtv>s`{7r81c3LzB58wxq`H6& z*1^IQdnY>~+PItF!Ym~kiHzPilB@pf8D7+b14zp2Xdyt}PWTEFWM#xN*hOenex394 zDL-uzjv`RuCH^St6=s?9w7#{%>_zpjO+=>_f>_w4iBvfWKlDb51(p8cRwQNbZ`s?u z|F!=xCr_BOGkv`;e$%vKV>Q=GhSgD;N%P_kJU>Wk9-%bWjU%{QzuPPiLB*C`&w)*U z^8$q`=^4`MN&pn5uV^ZP%IT(~9fAm=i`bJycwfkPk~Z&g+WEG27^a3>hd!|td6Ory z9ji^IfJWH41a`{Kw1-CGUfc41pz0`ps`0BvXmIk&!rg?(0=5wXK!}oUktAon!j)YdBUX_`;IlAq@=ZUjwbXw49c4gp7J-;>! zo30`GT-0OCg(ulYY7+Kw>M z7pxZ43zi<)qTpUylD;4n&KhYXWsRN@Qu8QEvss*y#6MOnCh?CID-0lpK`h#adL5yx zzZ67zduUHfMuT@>u_LrQ3hoe2hV|p9X@2I3)J@|f;JYKMqQFB4GkM`FIzbKsnT;=@ zIo#Y>D6cP)&wC(8@!;~mmk~;LrNW5VV2jfHdZZn)$>mw~ zcDo30KuCCYMxyQ+9)?@qxZE+j)kDx2J{P*`6Ah8fJ))3lrw<5+{jqfc+!h?85|Rla zAcq)znrT)>HO?~R4?yACik|oq)FTAA6y`*LOEDMkLq0b|glp>%Xo1J22vIokSG2E7 ze>E3BLOzFD21XhB0$afW%f|R(ZHAN2#V^B`P-J+sRx_r6=3T*&y5HDxtTGoFZ)ZIf zsN&@SG*_TXm8x6_b%tEpE~s+ z3uKxCYZ%(oY^tV`1!G5tS7j3&D*`+ELS03SN1+B?r7a$%TNPOb_}3HS&1)YCr-l*` zHP8Ys({q{w0j-fPOT6Vn%&bMn_vZC)W9VRq- z>6J+5+buNSagjo=mu0rIUh=%mX%_jteqPtqtHS}`d*MkTvr;XxzmH$eKP{PU?rgA{ zU=$&G-wrdw`@GWH*u!xQ@CWokc=+!(WBUvbR;nA1n3W?4(2V7`Y^tltQYn4Umomts zR7^v(|5)vt7go#uAFE}jx2#lYrC{Lb4H`NEgQpdMB?f~R73zH2k@jIu-&$=8z{R?U z54$D}cfouIc&0H~Nfr5N@O)yXuNr=hc@mrcLJ2Icl;MjZR=9){vNbc0`_B+tNDTS} z&+^R@c6d^Iw(7W9*85oCH%{4$p#6#1Rm25@HN&K_U6rxHJ@&o&jJ$ZGsgpL;dyV z`|gdraEwab#$_OQs^5<0~i1477&=i6N7%%v+oad`O!?;VW)7WxZLF6pH` ze*Utfp2U=vD2pLhXLUu+(}M~`CiZ|&;#$*Fd1uDPh87xOU_2}(PhPUFB_p9m1T>%n zlVF$qA76_nhl?{0`1N+&2(cL>KFICv*$sP4m=X>JJsy}6Tm%L-m~2EO&QEzxj4+rg zCf{PQT-V)bn#+@rc-tQkZ0N=Z$dRHlw`Hu_t9i+L-+o68#P`CO{O`9B;|{!jy`3^b zZ`O+oYMu^hhGQk@RNC+U#8`1NF6iBvvo%4+#jGvl@)1m#0uhECrUK4EH_!0y1+398 zinf|fbFHn#g@d)vj#*EwHRjw~Zo0068HS57913ogB$7rJLKk8q&7&q8ul~YCwDEY~ z{d`#uR7f92{gC+^Im$I#SEh-M9NN&`+vu3=Oy)lKAIO59yz`|0Rt& zhU3`47vwmu@vD(kU4=x0^96O@jEY>VlfWwCA(N`|_KAqA{emS*9fLi)y8LO^{Jh!G z1&716*kj3KmORHN60)EOK^CvUl_12$ORu3wVBMRIzbS~$Jjza66R*Y8`s}wlNC$k~ zonXE3)#e688ZKDtZ`Ly~uw+g1WPw%7e*0Fv*`~bewWIoU!kGMiLX^mE__x6L_e#6r zR0QAgeIDZ{Qd``vguO==Z$PIdzP}AzxwFKTyZu_~)%#iAHJz!}4vMH2d_ofCD2SPb?RQSS>!3bPpSQ%~aW%Tdv0Zy0wT;%lsR< z%kf|-%s*DUvOi&?x+2{}$=_yh-r7%v9X9B_F6I`dqgl=9`uX;BQ&+TuXHZQ~$nV+0 z^%`5@3Rk|t-IJxs%T}g)^2e@*z7O9-39Y|>Ud|*wcU%;ap>XYDw@ufFg?`TW`pXZ$ z3!N)Bw0F(q8O^_N6$jzJc2gvsMhqud9{Jszs{>`kPwBKcfqcg38WSj$b*`6pz6hE~ z#$yB@-WmkTI5ERJ3^Jjm9Nuf3VOEaJ{w7S-i>+g5!A^X^MD1y~k zYpZWL%Xm%6-KNPPH~yr(a^FAU!&)os$FI^c;(1%~XWb%6)`unzvZJ@otoISgh6qyn zTL5k=xog0fzXlD_sP^e-X#o;<-WdF7uVql{{QToo+P(kBAA6Q(K!8m|z=g5q1}m2; zCPBJkQW0?RGN(eRgsU`9_8;w1^=c}A+^*SdI5Gty+C))m4MOXLTmRrJd3a@(m>usOWKvN2;Vmo^mDD+9QFjbkq7wl#jDJVxRlmuzL&_AOa z*rET5LlAow+N$3^S-bV@f!rDjmtA*Pd7a%+A0{`!T(i+n^t)`8!_)FDxhi0qPmPK< zJnd^I3eIhHN;Nl zPum8ICE58O7QZ_skL6?dlB5zD?W#``=el#YtXkEt?$U@^jyD5webR_%1ah8pbFFJPA_DB*T#+XKI(VlxgV0`Uy-`;UeX;e_+Q&*9qMoF!2P)y!TOXho73n zA)ZaT8x=+>{_J+}uS}XaH#jIVxP7)@DIAycY&_NFmdrjc9Ptr?xhyJZv`n3j zE5m@w&qpHG;)<-;p0^Qez<(IK3bzzNr-;bUoP^YVfp|i<42)s~EH6U4zRqB6=|y7| zW}zLl;A*_F;Z#EJ_syQ zxoN`r255U#q%8!Gns4&0?yA}i7Sw18Vp-qK-)9KShjOb*7ho#S#C&zIVV>Vv>(zns z|8?=i$d9cj{~<;6Zc1Q`)8nW5++KlQz-9p8A?fkxfPRo48}U~rDejDj*Y1|;DWLzz z&kbdL^#d1*1jd&n$yv!?GY_U=`e+#05M9X_3-`_yXK`w;fT^RC57pHp(r!M~#Jd1< zi*8elB%p09=@@dIw&Jg=G*!Eq?c4EqeRE%ILe@pYKa0G|*zxs)Yb zY4B1?IxtQ0gjK%&C{iWC0-9l}dUGEVP>^r2|7Emk3Pp!n@fzr1=s3ap?IjAp^I)WQpH&zVP^B2rjUZX8wrb)XY6}Mi=_tXvGIl z;)EqKO~EQy>Lt^hUapUFjC-R|Yx>R7?ytwgx!g$5t3xk`DdG!iAY6h-aHD!_whS@* zYpRu!q3t`8HBk-IR&{v%mqMO3hh|rX1e<*%2>b$)+^2o@orX)+>|Vof1!zv6#7f*u zFw)JROJZ2i1^S>?SK-_uc_PNJYiIEz%PYDlbRbEldFY7zrfPLP{6M&EG*&AhVF2P5 z&|eWq9#GUs|E*b3b@peh`*{v$6yI1Up8RJ>@!m>y+9;f^N1hvK`vSBPARZDa6mU|i z`M67k%yZMXSx2xj*Oq`dHkVyJZZ^Z3l?+C1PPwGlRjy=M5|S`raw_8hIdw!#J0hW+xbuMT6xC2Sx>qu2u(Aj_pY#oFYzRfC*9Qer11| zkb}!4eBzIIhcqqnZ3*~oDIymBNcxAf08SdfPji4vMgfZ4FT-r-^Wn8=;0?CB# z>4@!9>Hfb>lV=D2!PsWmUJaA*3{gCHG;`&vmoS(4ogvUu{1z97{ws{Mg$#K)Cd{3A zm#6l}65pw36R&3rY&TIY<0_*$TuOzO_eLEU10!bvtkOT^$X5zCCtTZcXF-wH)twjv zW?$aV%;0%BDLPQcYlFO9Y9vQR~j2eU7B zGL>$vSwglQVN)jeEotYEuU!+G2B*V6jm&EgxgH$N&U-5dcOTuZ(<<-HueHt68r!|y zrSzEGIlKRmvru;rmIaOJth45 z@+Ww0erv_Y3a_>@3o>|jYIG~#)bR}2VczsHzIO{Wxn1GfGFW>>m_~)sk{MB`@<|?L zr@`vVfw!j>fco!j*=LW}pD%q=ee0;s4%`V-@8k>X)w*f-N>8Gza)xE zrUYIbypE1VSiJo!e%ZA|4!Jd_f5%&f>6I(nrxv`tY1p1Ix`}L|oRDBAdU-@amGevi zOU!tV`1G!6i3Y*1swthh%=pe1!yffxb;^q7Fxr{xEcENga6+5~vv}xGn&l)oX$a7? z0HwJ?ITlysv*`blgCX9IWgusk{Ee!-%`aQnCQ9E|dpvcL#X8pd97c*^km3Pdv^uhk zcn5DQ0R$mHOvD_$^s4`3(;e5Zu~I8wa(ZU+?$m{a)_d;Q}tBVel$Ymz0 zs6F{ZQuTzmj{YY1%bT)%1Pd=?4XaZsA&u!i5wmx?(NpYY7BzvA*n3`m0#Ws>umVMm ztO{#GECX*(o!$4`_5$+_^sGV`R{geLH1y|2tIzsv>QU}QgHe`WZblDOG3O}VMvb~c zi>$laAU(qycksf0x}yIIVKU<)k~ZW#U+v!P?;i3$q}vMzF0Blpu_4myzL@qkizWl z!RjW*>?Y6a#+KY{eq$W&{>S^bSW_-!$*< z{xHE>*7rrVU#@RER{Y29HL*?>n6LM}ZVzeE$Hx8m4x(sr`=jPfFv@ezfv;F@e|zhi zB>f%c3fb+wcOp-=EnoM2vv1e4)y>tBR0R?8#@K}R*6Cx^2ScU<|DeFZC)FaNzo z5DV})Z4ZwUE$`FstN1F~X@cJ{IUkke5C5QrLQXoFk(0M8zlD9(nLz_ zYH6!}^4pP~KsCTS;C1lEQ0^(FMU)A*hK|H*A4xIkOlXA(!;q*=}`_! z13&TG-k&_GCBf~5huJOFvxKY0xO~hZM!p&MkDjij_BjH6XX+pxuDD^@aT640Hex;J z22zgvq${@Pb9+7fXsK}{ZQ)G;ftt!SoA%IO3!i;~?EeIV_WR_e zZ=kf#xl5a;@7}FPXf?ud@jm)}7^YLb-Bl}(NQtQNA1BsqMz00r3eiGnu8iIYEWQo8 zhW5bVZ%cS@wp#oRP$#b_2W5Q@C#U}iWu0v4R(i9aiKQSacNg00HYj|b!cY8A+=8S1 z%lz;*W+S?=B9nZ=hr1$`0d%BSkwWNOdP z;dTvsBEK_Yc_kVf0~&-Hj_=(#hCO@nLML0v$$Sl!F$upz^%L39b33RO>5oEs)8hf*BVZ)LmZ}V#90)hp@FuRr-)gJzq)E_Mb`==Y zDShE_iyL!sKdw9!@N&(;yw772Mo6_xe8o7kOxh~pOtRkk_v!raS^%4KeusgUL0aSf z#NDY~Q}&v)E5G_A>4Ez~+RbUrH!dZ4ku^-?Ud{cQvcCdeffdD3VAJTM?eogi#Yv z`(OeMlz8?2A769O$w&<3MrLsd?ei`RW@O1uI_ZVaKJzj>KZBr;|%7 zk%{|zWgWoIzBWu zuCZ0T9Y|q^lnAgW+N5En1q#zbF6tngb7>IMrjIsE^~2(7MnTq^2YmN~yFiyKB`K-t zl_%lm09hkuFb&EzcB9>&3zqCk{m7ZbH_p|#X~saGeLLfdRC0+)%Wd=Mu#x`)A{iD1 zahN!Saaf>OaJ{yA!z-G3`j$tb#p&4pI5#`nzwDi^oZrC$-FO8NlnNf z*x^U`&;tf$-3hO}#QfU6r&Vndz2aN< zoBXsO72NxQVwFS%+xj-ZM!`ixTbs$g9dgu=qYM+{pzinVOCDfI6G}d%h839}BK_x$j1saD1Rx3!&GEUS=CtgXqIc+r#Y1+`_d1`Z}m3>I= z^+F?Bi}T#k{VBBU{{=VO__Y}{a1Qj%xWVuOf1qU4!pPqq0XP8oVd6-&g(5Ujnl_Zs zN>ZA@VEf!4%x@<2e_b|y*QozO#o;3zGZ$6AE2LVR`$$;rSx2&Gwi@lAz{e(`8eT}1 z2$qosHxrN~=-TpqGv$lrbohiE;=T>kv`G@$Vdik&V!`lH7Kk5@kY^wiQ3a#FPLHhz z=J7i0I2^uo8b@{`F4mh3t*H8)ah_%LlVYyS@FsPI3H!Z^gi9z7AI%7ZjEyi~m~)#} zU^JTg)zzocImefI=+lLaVEiTqLf3`3u-0&wLSoqA$dFGg#R|2bk)#Ff{q`zqFes%@ zq{6`FzcUqQ(MVqYFylC7ZnPIF4dt-ncgU5WfX-c#Cn-xy=!X}X1Wg1D+!mSeXekc& z!K&#U9=i|&HI$U%1lU}DE=3^{$Oyx-2l5OnF<*MD!wM0%`ySuM-}PN7!# z^reR#TH;qSlDl<$sY*IfsEft7(%A&d! z0^+1yS_}hE@J8y_(b8S)7KFE06nvz^wnp)5lugb$>qcv9{yuzSeUbC=Yq)Fw0n%<8 zqs$LKmvv_yLff{Op!Z2p^KDcMUBt}5Oa{yxguylxM58!iR0XR+dwkxWnR?Y0*Twu~ zhbA|*!}nh|BO2G(8t&X($Q_|G4QozG@AchIhgP`mWr!)i7zUGvNJ!j?#O3obA%>Pni!LKp zfG~RFc6;yA)HTIKc79Hv^u6(Vqzq+OrU<%|V^p|@E@8B>SL6^r5CmV)*meC2M4(KM zIT=DXCaanrWd9dt^IedT{Bcgk@8(Kt7?Rp>Jw-zQ;p>m_^G_GR^<5S<<^mz4cR2n| zEn_rq{Pk(b{6Ru!iQsV|u{?xPglzIuJ>RTa`@AVEXKDAX+QX;=?E2CtB@(qU?ch>Z zHA40rNI2`Rx?}i!5Ih2HxP%%S92EZ-HY;NKI}%8^s9p+PuT})T8X9hPh=f>q=$R~I zbTgCmN4A_pD>TML8?>UdQE6i@Rss%L!iW$xw8YBIKFh;5?`W5|1s8i(&eXreg&}4G z{bfR!kP#*zG zc529p)lUh)JSedtw`g0920Y~hPXL>5w%8v^js z_4;M`zz0piynN@~ur1q%5?2RDC{E*AzV?A`fIVRrO8bn#_B!~fe)oT~-rBed}7ctp5KMaCl?;M4d<^3dA)ne0E9d4du6e~zdruXo$9l~KrjQI@iWAw;K@-v8{-|>6KCmo z+qKzzWn_K`*{*3&=MYa12;o9Y9P=}6cwdUwnh8gy+5O?B8{?-rBwktIm`b37FVwe7?)1vBxyG+$cT_L2 zJyY0y8mAKWORgDnW$o=uk##pEutcgO5ePYneXZ)0k58+_vs${KS5kGAuv-)*=}a;X zxP&OS_+1u_4xi{n4;k7>zkI=ZeJ5cE4;v;pv_Yb~vJ_$1nU)WP79`M0VeX}A{rehR>kC>h>Z9tIkom#oGR=4{K&_*rxH zBjVt+Iqb-MqBK?Q-Xizc*gQ19D~f{)7O-@>e~27f;>mbQ%~v4?>pukiMj0ELf4#C--al#E{RiWDSR*Q$-?eQ zN^)ju=7Jyo0A>2U4<8YZKo$``Vz3q$?(G#tp86Vk(8k3f0nU&L<7Prd?L?5pm7*-z z4BCUuE%G1HpXe44miZfRi^XZ6Iq{JXb!CWWaeL)#i>o8xeFul4&^rilHdL@vBub)Q zDH2#^V^u43a-8kr&TI7qX*p=2D3T}0i#d1-%pu5bU`2SBMCHH6U-xaIdSIqRiKw1{ zP+~*?k`!!QIJz`Ecxu%2yb03}KaB8H`Os6hr2qHybS`SHGH&H~;oi(mXM@3fLarz6 z-s?Kvc6~&5W9@u{acth8y@ezj-;xZW(pEgl_@Q3EU%fzUH>Sp1i;6okg|~GFaGElB zB_N_fLE{oWarV~yF%|f3O0Il5!Wz~Wtz%K80!TWC&-k+oM7l;*@5FkIwunLHJHHU*0gveL}Da_fi62Sn=;YS>8+W0}2 zfn5x)D;*}{nedaM06|XP0DDLU`OOMsepWVOJ{R`50Qfh0krDHfqZ}Ozsv@&dVFoHv zZZFg{{@TM2{U0@bBowXUw`nOUnIzq+_M`Sf@r-{Vr)0tZ$Y~rvPNT{W+L%0)>J}WU z0vjt$3?s#Q(NpGN0!2HN?- z)IOcjld`;P7P9yC)!vj6eMz^os6f4bp-{E8OQ6cNn71*%CW#&J5&YE zWmhFx>&rMaeYLt`2!R6rLOJn%G!Ss%F z|J&WFH=@=;bUV#QC5og`dJ#c;w4Yx@L8KfDz;#Gan%)3h$8ESVj!d~mNRb3p?p4r}fq_rdljVc&0C(0vaZPrfsH=8s>}z!0YHEzV#rFWbK6JCd;LI zN~>DIjIyjVr~GMdeBT;MJD4RJlr$}KG&CZ}Ej8>u6%DfW6*t^+&0Kde-Lf@PvM4OZ7Q~zC|Hc?QR>6E(>l#UBG293) z8SSTZ(lTVA6y0$TJ&d>{P`*S`m{0v!A=Hc`(55OTguXOA$Fcr8gwl!8h>o(CUgeZ~ z9f$7cF>B(YgM-QH=9(}ji2fHLSe7s{#0x#~!~x;p(Wv>iQr}?0&@}ra7)klPb*2v! zX1!@Vd3F^2%K)zkTxW=H&g}0}HSyjUr+nHHlFQYv;OJ}i~3jnT+bSA>U2dH-;vop zC~t*%&(mrETuX(vHX?P2)~y`IW-oc+BVwe=Ktu+hpY0550y+ruiYWt zxEo+!Jm4<|d$~`PvXY1i)(_qa(3&>g@#Y_P392{CD}uErVFf@a4(D_v){HHH1Hp-l~R$nFOwe) z8vjo%1D=Nq*aaBzfzs-ASc74)X?fD%P>|AQ-7Y{aWOllMqw?|xz)`{AUl+}IpVRN zWB{)2H}u#1nk?`pZYzT8l-Ts@l5kUy?4BWqyqmoK>4I=_;Zvd?)BC4i+MWF6RjzZZ z+;zbTR57{c)=Es#ICU`U-1pJM#y#YsqEcbvyLn|4fT`o{4zJwnyo1^KD+76j0oR;z zIVDhi2y_WB4P(lJ-;{R)1hUo)mh^JHb0IxJ3dq0M?iHYA=l~e9C#d*{IxUFh<45m< z)PWvRC3fa<=TS6l2w>dwQ&gYoWJZYchDFk@G&(WLOEnXwayEYHJBQe-I6x*J zQB!&d79cOyQ*l-DRwV04`*-*ZKq+o{fE*f8!k%lgz@ylpF4f`j+ zLp!63#s{Q`TZj}OEp5L*^K#e$S!wk?`zzvaQ?3s@#a4-g8dV?I$9-FA)`Y9YSL(&-SPGNKMu;cb#StF+CN^1BM^TB zn!uK#DwqUZiS@>(dav{?0VYlEtqm@Thrd`W6E>dejQBUScenLUP+cuI{8OcJ-;Qnr zpDDY;tef4=lj%UGnqLB=|z%pS86>heeG}u*`@8>9Eq^1HLT8&vo^HtR- z*MUcd4IQ^o)JhAC1*V>@!?xD)0_=^dqZqf$1*qi2Q>ei-+#bOTGT1AvwFEZHX+p|#Df zH9{P&H9r`m7S8fkxvPQ$sbW&4tS8&*|6&nMxh75ZP<(ok4Td}%xq$)0g{>@Wa86KF zJ1xprqCHBgscG2oy)|Ou*a|owl}%N@2n8AcOkhwnee*hKhw%bOo>3-@ z1qOu?AH1|9i*0X_r>u2%ayr-fMDaCdHEu0tHS6^1X=(*!%zUhvq?TLfm%*+Bu@&eH znGQ78%Lu3!tYHdGG~5tUqy&)vC5TyYXr--Sm2?CnXSAA}wKzE1P%Ax}9ushJB&5V3 zl4raOk&9vuCZCeaqo%16aU8WNN7BjbfL$J0wwC{UQ`&SEuXxCPl2W`~odetM|G=W7 z8P%y3g`+`i1us|>cX+X51hB0^3Q}N9byn)<@AR9c#u?(SI-otM%Qp5Y>Mo0<0g!GT zWXfvG1broO2-c^~D6YRet$1l^2fTs+yp~vP-WHH%5x`%Nw<&Gvb@FDJ=P5O=-JFhz z-+DHe>*m?if4!$}HyBUVVcDD@SU50hs;bess|^mJ!pJQFN13xNO+Pv;?Ik&c_W^rP zmWx-}L^txmh&s!X5&DzoQB?Ff0u5FL*==EZhG*Fjwdlg50u|twsCOE#C3Rf-W6THD z42WaH#ZW)Ih!To|3gFDcqDm79Om&!`GGXg+1C0551G(sLD9g(XNwB+Y?YddSclm!iA+XDU=;Hs#npXej5D_=ofg% zu(MkHe5ZrmmX>_QSt8=HJG;%OysCjiC9)fpECE1 z{&8S2IUr0gW$22@+iuB92p0Oqo1Q5uxy^(HmDb*J8E{O^O|{g*#Z$%Pm{Tc!ywdG; zl|P{&ix&s({?Q@JP;wT(ng>xwJ6H@>)Fe(KXsAjOo^OY>+q5hZQ~y-dwwWMs~3{myJLEBzR5@G25X zA2TK}l8g8w9x&2Z2g`XPIhZ!un>XP$NW5Eu^yCHb`Vuhh_^{b`#jUi<S0> zZL|pGoORXNnlz+AmJM197L?yeOt0u6t+bBG^3%ZGcfVw`!ytUsTXWx!lN%U1!jp?P zYTxqo_kJAXy8(Xu<+ZN9a=&wT$*A;q>=SqtR7zH2BH=r@0lbbYeVAo1NfbR09q>H& z@;J%>fSa2V0s@#4GMti6u5tE1^=2om^_+WeDBuCvcJZ} z7n_Wz!y1cTBhwoW>xadaebv<&bN-TDM0YN;ll+Q^MR)%DXXJ>~lgsIBFdJw@c0_5& zLP3)#fGaO1b_hS}+V$A9DlpzXNvdhh&#NoEEdQ|P!w$G1!jtxAhS`jEqy%e=V-G(L ztUk1z4DQHKl?LWwhxHDs1Iqys4*`~AL|kIp;|sTc#!Ek2-KyVZ^7mJvZRyED5n@&s z>ou@WGP>9SVy*982Hv}I8i7caxq%oH-^sO8!(M~8L#tNcZy1U{>%3*Vr-M!_0uctn z{XrvBb9lHLw~(_Y+c^0QROo3R+A91;wG&pz4xS2EC$Z0HZy*2qbc}PYVfj4>xv4lp zMdw#-Cax!amj&+1c_d^3%+f%I3<E&4)v5F=bzJ^InXL$bVHe6-mIjsGN3w@ch2dsa*OZqUnQ-+n9Dn zjsKCTh<_w1&ZN+CM1nq&ktB4Ti5Jc#YSA};Dgf=}wJzA-_n8MUxbj#UKYka71(-%8sf|L^#ycurVk?sKB|4>AbzR zm`MKpjZv1l+uUDpqHFvhYS=Z!_hWU7_008ftV#C}5u5FJAoUFp*#Y9oum1@LOL!Ox z12cJ%hekHtHh&*jF-$om7*Rb08pFsMpl*Q^uc9^M{WY?L(TSq?yBxGj+eVXDoj~hR zK?sIbXV1Eme%~AE8CT-+0W(Zkj0C8>35KvGjpTeU-7%9RD#p#3vF8Zy~M%xsG4GN|xIb+i^uixdp z1asdm3O%4c8P@UCII4BFE3{b>TqX;i$ZSeW;c> z?g@#%7XpeFJxsg^vwkK%T8#jfrLf8tWH3G#ZwyOj4Ci)cs2>>k*a2>2q#SmpuPn-m^o=dOpq^`mVIO8jZIrQS@@R5SS_Zvz2=?!ZPWyL zN5e(qHU64evjH>5SQBumt-XGjNTxk8f0kua)zEM4MFk|hr~pDtU;Zhkia({(y^>`j zsA<51N@l9bBoF8modXCk+9B;?iKI^S$oT&qCL_lwiJ1YrKwpRYDdPxj8yDoDa)7yz zMTJM;*6U{H7XY+4JscU{HLzpMJIk=C%dg$n!sF@S(S9kbI-JeGuQS({tMPn^d&_*R zc7b#3tkb!rCOC*HCd-`Y=v_a`w5DCA4=SdkT73T4idU+y?ncd_0a@i1za^m(PQ4qt z4E;Ac&e066j*wyyMh1;kAP;1GjH} zBBIOK2*8&_$Q(^`M^IaqgPbUn`FEooowYG`N`da4YOdV$JFYIkmF{C3LhJqX(G zUV0ENc~a$27UfrFRj(U1qmJfq7=mEu{$Ei@}~2BZES}!+>XrRIq)*O)qT) zTY95H`IT*-RI0VcFlR+)Wk<(Q(uR_YD;dtuTj(j0fW3zXKY`+1=x0&fgw2i|2 zXJuurvFRSxWNDac>hx|B_Xb}BZX}-sUj&t2kUQYHQ|Sqx?@g4Ro-OUpmCmZDLPH9kQq7S#5_mHc+9&v4f4;?a$+aDZpGYRuOrqE2h$ z8qYE~4zngq%>L?R2t4@z&GVmnwsvpfyIqOqR3RFoucn5pgaY-3=P+b?ASnEIRDApu zQOaqDE@TVj%%Kl(3V+CRfFM|hYyW(-ZEbTA(&jF34G*;UczYkn$}-^7saLSswo`0% zX38Dp0^*I-n0!DGk2akasD%Csb#8m;(WYoih94#ZI*8nm^xl6&UX}qoC`?RNHNb=V zZph`up1hejM*DLW)AfOR*oPclQziQCDGspR(_$t94YIcJ)oc z-xGeM6r_y~Q-wl-px;eUQ4@6%6vnf!gkCu52%I;*&%SeWy&lV3y{m+a0Is}kw2Kre zqLAtWxC`{cyx=YvH${q`fo!dd`_yLOq+jIN#?t zBb1J+K)+qP(&ZS+6&8xp4jC}vzqcWH;wKoO3T(bhmlM@{g3U_Odb=P~v6E>Wk> z9A6>5>hq1Z1vhkI4ep=L$CJ%|pJaF+n)n_o`3wOGvVx-=RT!eoQ}q(us*3UX(;e6- zF+t?elo2t7FZ_#(yzc8ua_D=Jt>giLfWs0<{|N;*dq702df?QGI!u#-?wi^Xg2L(RbOfJWMx9#H%9z~Lre0|oFrZc5tS^Xs zWb7Vaa;HF!Y- z3d(ZyiUr$=Du`Ed$^IobYe2u;<77y=hX4YQ<>Ml~Q6nihk#!SvnFh$hBSEMDe~Fe9 zLqHf^SXDa8jnMk&`sW$kXyR4x&G+o$&)-t3 z@+DLqay4NjI2fXiZNueO+5%VtjUm?-pvngjF|PgTJI z&5n1=WHBns)s^Nid?M=AGg}ry_eKOz^!ie769w2An3zHAV27G~%MO2FiWNIk{kNtW z`fbgBta7~c$Zy#Z2MH~z1l354(EJr{Hk0jd5>GjhTU1d$nEib5;y`J9P(0Q{gb)tM zynLR3sY3Up(P_tzv4kv~CGl`z0*atdath&EQX=ew(I)^@LWxH{`&fTA)#rOtWYav^8DKT;WHF)Lf?iIG0u)Y4|>)$7^*84Vv{3R!4M)pl8+~ZLK%>A z%fOCGZ3rmacf7`DH0^EkhE=tr5lyJqgN+oT=c6$WKYz#4tHzCqarq#J=Om$HnwCLA zLc$U8+ra@vhctSN-+|A|?646a9X=pI;Avjc^k}2DcF^ z0B^HH8((&Y$*dG=xkhg_7BY`AWblu)w9oByPWNDJo-}2$`lJXtN_poWO8#reA}nAUyx5jkr-ETUjV#qhZEDq%OUlez$>kp zu^-#xg!{&mjwv~S9vlkFhV9PNJMHMeTsoh(0XLTpLEK(*lf(d?uJ<7_h7hHMr-(vz zqQQKp3sq2eF1{XmQQ{Ok)A}N8_dn*CVVibfRHR+Wr7g}`bzgt1ULz&+ddNyE8*uLw zXyN%rKr73e)T`1Tz5B8ugmcflTdoy2SYsSW^1)8%%*_Mp7HO0CSt6oT)c=EI$ z!Qayayyqv0e%?vz1MZhpU7M3NaP}WJm&WAt<3Zd4+RUYZEupV(qLyk}Z}|RxuA$CY z8hJKqi{#zxTgdizZadxP-QU>H4%R53jp|D*^cVeZy|kc4K;7BzX8?8rgg#D1`}W5C z5?tKpT4sIBO@5*}5H|HmWq#Uz#J|vX%*!8r&cpT6QcvDUwYxN62XGHzsU3avpl-_H2zy;dwdX$yk(D3BR0*=ZRa%XP}}0UG6e@yWy#zU zZ^9KNGG#O9$T`eFRerAa?e6_P1649Y83`*B>Y#rP@yi^P&x(W}8z#HaAI@+uAu)5H z`kBFH7eZ9Jn1YTA@^w_y2vJCU8unL}fTu~npz*t*TpS5F5>jEIuL?*jI*h7+ivjua znIB)9^6LUp>(xVL{Dj~i2vj`v_Gf4UVsYZVlA(SeeH`S8iU2cH+pg|4K*4N{sJM_OR^()uvbrY?4ApR zxQJFxh_o+f3R*n>bUwYoAl&%-v)-GMTk@Wk^zT5Zl~K->vDE~P1VXCeLhZLt?EwL< zkqOBs=A?4@xbsRx>4ENV!yJk8umk*RNran-{1gHW@H#qk3GKj2-!N|MmDD@Pf#|cO z3hCy>qk=_-gXT)gDxU&#ZNf~p71m93AmeHeIT=SD86juYC|*M#1!O7=!IjiiB*@W| zz`)|el?u-kzA>(rqmd}`nIRp@#XfvD?SnH#DG5A-Hg}Ge)=3bXhIC`^Y4>;^$+9_> zpgMWQ02s?Yl95XhbrHDLKe##j@XW$MlkJO;t>E4dvRQxda--4y^MCwVNT!sYQKJ0h z)=_}~8{N-2s7_1phl>4L6Qt4LXNxr#lj>76dk-WFN?B055hal^lmnnSG@VzNq%y2R z1Of6{O%PE^0#flCB35}wIAF7wppDQRCLb}Uvhnje-#8ZpqF=UYB23UPh#^osf&eJq zV=QT8Pp*Z`sK)O1GzxdUES6OmLab)!T)6x5?NXcZ9g0!`>M5alN4;I5Y$4y=nIbHnNZ zrTk0W?r^3U2g$Ste1E7|zcJq_j?Bf%-KIBT$5KBjj&y^oR`Hm41VOZF#+F$I8keKl z2;s3=y?FWf!R7hb*;AHaB&eQym$f7HD(#|h2@mBm_P68o0uA67)xJ6zG| z(&%K!@^~T89IQZJs^2-YiJ}6+zENsUc}`OjRQfAGQUUa2$Uk~=T_ecm>y*Z((y99U zztF&;Wb7yZyf-SRp1|$WL`8T_M|;;6MXGwgAO{6z^Qk zxA1Vkk@dYpt_3j;V*@)SFNfCudjN$(4+MiIIvVXY2AIF-HT?z2{uE$h{_Z72A^TY1 zC1cFo8#0lrX84wqvby(1z)hDyX2iKblF3&K=yZ|oGjd`~edr1oRVyJm8>eP)Q5ERN z?2$9NWBUE^h0j#m+PtXKgh9E}o*Yf{y$vJLAXfiJBke=@Q-;|y)b_YhcA}Nwj;$KF zO#wKz4m+slq?3-sUNM_t&m=A*Q4q*ZuTHqagV;Us+5C_AbT`f$30QE9dz#h63hyMJOKWqo*Mk$@&%m_FB8Be{kFr)PSV?me1BUALlcd zW8Ye(fDDv6_#4OyU1C*?0I^FMdJbK%>s{J5zB)n8f6KdkQq*5iXI6m7_#OzrEi@s3 z84sc)YWivaY>*xF#QEce(W=?tIZ%xwqLmg#px2N<;djQ?OudEl@LOQB_tvMv-7V^G z!dV#;Z%}70L@7QY~abe z&W}F`1M~(=j@Z5a*j~ZAG_YwIwpl77@l!vPH-=1VkQc1Px4*h{dMEs9c?#CHz_|0TTJq4MzQId>>S^Dcq{04^zd3&ldp!QC)g2fq z)m;5J65Ek8EnmxBE19YqQRBbaCI3_l*0d|!R@6#UF1_98bL;TO>SK0nsmc3XF~r~| zbcB{@DRwlP-P1ZEuwes^tl2VVl$lca^zzEvA{E9?qJPQ-Fj&EBVggLI#aM#VUoG>{ zp1tC2_I0{-x?TS<&GSk-g3ZAG&e{C$peBlIYRwI|&&`*?>*NeZs%OZYf)jr8)hdZ< z9Z!dv`g=DaOMv1w!MiDb`)btw#KhQ|6BuF-rfU!qVppIpf~rqOgQph%oN}Sbv#_In zqnrASkih&7Lr4LiQ-1f$iD+B!oCKRqZk{`auELdGoEX{$M>)sw;EYfxF{VI3vSd#TJ{v z1)Nl|`TOukiOG_p38wXdASi@a!Xa0|M)4y-t-b3r$a3Tmc1Zm(pQ)7H+ve^qdeObb z+a2vT>?9QJ+-#f_v~V>{YS&YQ2Kl~ZP6CsWk1}N&y7PWb-qkLAL@+A2aQt5>Tj&j+ z;fe*71yPjI={cyyAc+d%1J1`oP>ZPlu_D=U`=I%@v+*`w^ld4(a2}Nwf2nl++pl-} z<@{F>wJ`fZ1I0QG9|TTYHg=ne$om}Q`DJ261=niJ zU#K?rlGP%rm+XC!R2&JiuKqtM90ZJyW#h=j3uvobQljCdZu?h`BVS%$_wF0UoV#f* zEFVERs4NUydG7cRL=`#fdmnQMe<);?LaQJFO_A&4nje^wks&{{qs?KAA-j9Uj96w!MgNa6~OVK_(#`rU>{KVoT@nu%S2Nz-Q?T=JT zet&3QvZXU_N?Cz9E%TuwdsJSb|SrhYGrUKG!= zNEl)kz8{Fl=pU|DSTpfYPv0X-=ws01hefHa8l zxMDd&srF@Iv+Uj9x|qua-izrELn9E&xxas||C&(|P1|iy{%mW?3^;iH`PdSL7F?k* zJOV9F>}wC;0ks=_G-)_M7B&MWthm^t+$g6=J2R@k*>Vq=Ma;1&xUt=*k>{<0^zj1v zHs+oI02#Vi>x)?KZ(R7>-KexnJGZ>^4ZdL%z$>_6MUQd#l6>)+_B=VlgJ5fNyEoL0 z&)A+fn?w2Oe^sTh;jDDIo;c*ijVu1D^VK6b=_dh(fo2*9>?;JEQ+D#(jhp5}s^jNw zoY-eh8vP7kpYW> zNLe@(>BmFfS@(*3RCt9>!Xe6dRnqyt(5Z0k9y-13#GT?sVo^%1uU1R27J%0%5#rWVfO92D4~s~r|B%El*{cqcNo9}W`&bq5PJ%Lfkhkg)ow2liy_ zjAc_DMQXFppWTTChXfu*913-#sHFJz*4hL0V)l#W0;-<%C)NROH#FVjD?vO(bij@s z=2qE*k^F@_&nH*$BQKVv9I-G3++pOHmTJgOKPbLXaBrBehl`_uz18-JW(!s{jEe*^ zCu%#7JabT)dGy4*-TzmfyYLT#*5lSq1P#5Yh^TWjZ+X>1mqH4Mx}p8-hD)l(rI**( z>>!XEe5?!?d@%SaDWhFI_;o=`1{G z=!Q10ioevg6-TO+X<&LXqgr#aqf?VF64L31bAkPY8$FhS>(diSJx#ukWtbw`e=b0*b|3{&BUAt+7j@p49GD>po(-K`g(c*jjy6Zu zK~bxL@8|2iFNgj9x9WEzZexyl#w&0Bj(@pp!=v_X65p!lj_7K>xxz zajfxy73xgDDGs5}!nCG@1CO&3Dpt%+Jbca^N9p707XI>Xq@{Dmg$&O;53mMG)5nm| z7Xg*Xw4@zObOiFT`Y0YhgzgUJB1AY+xN7=F{*1!TV=OspV=NgfN0$xEKeGRL|JD01 zmyZjdXruSvtKSE0mLJ}X8fKY)&}Q5@9$9G_d2Lqt*FD~TpOAKN?Dz3$liPu?qtHad z!Vge8@z;pA5=ikvQoSF)>6r#n2;pOWWgt)A zV#TS%QoDL>iimdq?Oh_fl&dj?rM{;}M2H|gbX}$r%n_@UPpimfpj#<6#Gz0u)gjKSnJ*l$M4VTv31_s0F9 zeI=2bXq4Q2m_GI60Y^Mu%9>JKZBW{urx~JoRkmG;i2-C77;@aqVml*W4hY)t_z`h- za;b|usb^1B!|U|?H8kWXzf>jnyX(J7wL>j9QH`Z@xTU{Pjn%*0P7B~|fh3+#@tRG8r+Ciux)4^#V?!u#eQh=U6Z6uC5FDITTXRzr6-QLn4E)Q#MJWyoAv3 z=c^1ULUc!lseIm;JVav*4v2O+0b(S$dthU2k$}#Pgi_c+Ax?`+ML)StF{l@DaHmC) zk5avXSq_h%62A$EuS*-`c&r~m*8byhqlUuEgl}6elV-s4ogNT{LQH|PQ9uxz4)qc= zMw&dAeMIz;oqA2m+3{@mKc(EAjex)B6mnloggS}ih_Z0dzU<*se8rG1!oHLsd!6h# zy5$m-6VMehKAw5tbhAkA*OJ9nsm*`BQmKBlTt-PA&7(F?O2hjmMx4A}i4Pm5!vaPV z21c{{sm_5kXRZCX<3NTLs>pLhmIl9Gz6)2RLKxRRIvzRFx1fE6aaHZ`F1-L{CM(tl zuhs+}KDg$ddl1Qf6=3E#$&vE~7=A_n>^r}&9XU0r&pOy!atYH``YW}MQk zox}Bapb*#)hsQ;J+veS3r;`g5>k zQh$@J?W$e6<>u}!`bI%-vum-Y6z5XOC;l8phKk@^Ha?jZ$V3;1xR^D|r|T!>fQBhY z*T)+sCDFndNA74Sl{FZ)-e^nk4~C+6?xt@0m2+hx8~kLK3>~uJtLt%R`oP+x1P{IK;K*8`f71 zKBreRi4}J@TixY<&`U2j8jVWL`Pv!{rrIbdZLqVxzPmBIJ&R}ZEu=Uhw@$P#jP<^h z_i^W+QQ{MU6>)X_8RSi}rhf*tugk zX1ow)8ijO7p(d!V;`t!W%5%I@7+}GlfHiC-joiN~V=e(cEIxBAMO(LiO(!!oI6gT=obYYynfcRILGFBXNb|kd8_Bow>mi)EXAz{X4zZ_bB3ZS(8nLI_Fz{bO< z;uBvmn{*B(4P2TA^1DV?Az~Jnrt|L(2s62}5tIJ+Ql0$obiDEC)bvw3_2G z_taabP+@F4Pn5T+$;M240j^&@7G^7Qvq%2U-+u~Gv=C};TIWmdjO-P{| zO&S-acCWdH7IZlhg@rbcl#VYlDfHw-ry_f6!_nedi(y-OxwhySxwY7j*tpIe(3FIa z2iC_syMz^7Ae@QALo;3A&%l9{a2r#TgLd;&bnF7axZ^0YG?+SoamHhZMSLRVoT@V% zJ0>})3Ve0kb7P7*^VIT-i;6|_)Qv;F)LyUA(+tmcTQ&hsMQKqf#(S$X$2aFlZZdDQ z(SEtV%~^m2QzY9UNb?R=gPivk(B_Sj_~2&eTK*#vaV+P-nC;GT*?a04OE|J);ND3v zPQP|$Nl@w~D8P#EQtAx?AGX?3ksKL9pxEe$iddoZ!Lr_K{yEow50UQeOyMI3#zkcp zDAQnS^@Klyv*6|^L5EPz;bPlAPtCvA@r1w5XR&sAZ71m(nQmGWy`O7b5}&~VaeS#B7=+zp`Z3h>WHu3kxQjZ-OHCpA zpA=gF2SuJjrZ*baIaz`qUK~Hx;JbyR7%@{84tn9Xz(pQI2XNsEo5 zEuLa=c1QevQd2IC1ONci2Rj@}%Q>hjM zMjA9YGLX(m0z|9;hWJvJ4c3z8W}B92$C`D<7$WSI78g!3a9zp5L`lF0!M8QilV;Vp zjl`T}an!_QaVl>xWW@-r6d3kh#t;ivjn^J=+bSTpR~52c{KRdfx86> z5&Nw_HCh}tlM5#(DP0r2dubz6BnZL=?^5G_lo-zkZVr6%CxY;Wc|~Kfh4u!qB;8I3 z`_!@OboEm%cnk#%t}KDM?`DP3N!aG2c-vL{e&7Fl+0ahh;#~^$>=EX|86spe%@v@_U<+mTI3P zd9p`OH+R7~Sqs*@L{KX194rarp~Ig7P&a!#(Y~8Ekf(7_hId1eD$ZarT0qS;$J_*7 zh~E#;WAo>{*DOZ9!OQvJOyF<_tG$3h{|-5);QbG>mH&*4a^L;P&~Ap-y_Qy$quB@| zA8x9rlME>Q;FD@+15Fd_YqynS=NG~E76jQt@5|crxwGHD4}Hzwl@9SUX!5;!ZF%X` z`byayfFe12^ZVv2}knr+~^%meJUZ@T{lfX$)k+l3yPKJgeeK zQYqv28jFQND*O}MoY5q1qB+Ut^w0l-+54wN!=J(~{|Tire0k+5ltSH;7a%(dd~aU4 zinM6`_eBkgrv=`5{^z0JYIa0E7W5ZvK>Puvz%E27lZ_iIHaQVj8lU!@kAjA!02U2S zgk3_Yt4M}eU>^1-(>YwLfjWjDBehMZN5e&~tm>#da(IjsakJDy&_+t6w2f&LC7(=} zo6WgWi$w#=W37Y3bsGcC?O(M^J}8s$(tYXdKbU=#LNiK4|2lD@IgjI_U20h=$mKAT z@J~aKXiGTXvr;CF%;U>rmg*cIYG zmN|$K!FxE{(vYhPyd=H0FpIbO5oE!HPKLViTf5vp0uj zzWG}36UBeMhAiSi^t{69DwI{pwb?_htG&G!@*88K+$#4MFUyh;?n;%AZ5o>#dU2PnK{D#CJ5RRElB~F2x z#^XDC%*aQjmmk~SUHwQ%Antt`{ZWY{D}%jKJH2%J$Igd?>7*=~ikaJk<^9SV_tumZ z-y{D`xsAf5pj^5Bc9%i$?sTB#6WC($M`M%e>AHO76+45vI9N2L!FarJNJ-{YSTvg5 zh!1%H0+8lF%2``0ORma^9;-6_oM=rSpsqwhG|gJ$^uQ@>cbV&0vI{i_ zDGZC&WNi6;XlNy94mjziDcaUHj(Aw?Bs$|cCr%!?1+FJ6Sb=;-LUW!Nr3jzIIn%Sb zbyB0s$^AQj5vZR;dFyrmoUvm^y%)1%GP~c$^#=-p`O8ARd~`>9+F6~VV5J@0{^r1<5 zFkwsfnOGY)h`t%0(NXAA+RMp-<0&>&ES$pXAS}0_5Q?aLMO)gbPC;+e^-vzyW54Sh zX2)s8@s}2hV};xjIViQ=$X%6f*}SskdagE~67yR7l6YvSNJu_j-5=Xdh?=Um(S2fx{;0E4m&KTN2}^RWTFY$xmO|=1 zZQOB+ygT0uHI~5*LWlCtZxQLXqsDtvaijrp*8WxPT&2tNL1p_16+Elgt zU%uBimk9n|^SV427G*767%>R)7np(A#5~wAXGd+YZ?>=T3tc2836+b*2$d_ko{>Vk zVUgG_KvaC?H(w#fM#CsA_s9?TNKfHGWFLKFJBUkuxbhUpJ<+XD{6W;OtU8+&_VFcM zC7J!mrr~&;AoP;p@3VlUI+xn)Vx|l94XckX$-`Sto8_AmAUCN72sXI0bILm|dkWeh z$XabRGxmT&TveI?^8Z1Hwnep-sX(R=KdQXGwxK_Llu>~@tPq$I&?CiGA9nx zfro(r?3kIyw>JlsFAHDRW9;^h|J>~UZE!XH`&ZMzpS!~g%j@%3PYq|}m57w{Y z|9GVy!<*qwG*a`|ytdAekM>J3EcGaRGW}-VJx@@haB%4T6WN@<4`K z>dvYUF`6I?18O$i>~w{IfHVhk&gR-ha#hR&iT>zi=%gO{=dlu#o!H``=Kx~MUypc> zcDn^FgN5Ng0aAXamO!~xfzXxt7AH|oa_gzXh7oiT_`n+rblHPNfG_7!^w;}wysiqC zojnyc0|QzP@=LfT2}&ZLyNz&lp|#25v@0ZBp8CdisQ zIdjGWHcJeiTPvrlec*W~E(+S6{zM?bx!qk5epto6; z`s9&kPzE7=&PL~30G;4fF#@1-5k*KZcq9Dpvqn6YB1b_K2bv9Iy`)A!; zK|jMf#2g7t;^pW&qL1r`G}0de^asM2F{@2d3Pjj$hG{=W4UtsA0GExmEVp^f`E2%Ga(wXdnP{OE&=re&?#E#+8m zIB}8=J6hbw{)T&mP8i;E6iyZma{>Lvj2#aJSh<}Vv7RC?BGBigI3fY``Zgku91#brzd3@J zbc|HhuM&nJ^ah1T95S(UJ3YjPCPAHE5?i~wHY?Y>t>>O|lp-L0E+C`B4iEu3Zp-?n zfN)c5RywAeXvN&uXRl8+FKh2^9+OYM>?NZf?hw!p9{XrwHN40-cR~iOrWPM51b3dT z)oLM^R&Tyl+g3!&KdX5#Ghh@(NP!5!IYM`64;$BsU1eIQpVBdtHH{04u-WyOmtLF; z%f-VP*ZCDnY+M7-VVBE}_uIy|P5PBY5#F}Loh)1K8}2iUbzTOWRkJO@qGI57YP({_ zq9>%7T}}PS>yQ`_Kj>pt8w15)k2| zvz5@+73J|g8gyYMh!EaeTT3AMoi;aMW~`bI(F5_16~sRsDQAk8g>y}}Je94ZCF!Zi zD@#v&e4Vj39Lk)=Tb~q2sa1UY(x;RVEWBxAyhtO?zDSc}SvdOfxsUhlle_)yJ&(fY z!K$DPU7AZMuEvg^m^;E1eL|U_AqV+T4_$6alD$_+$Szwt78}H+rs$kc@!`m<#QD&; zW{hHHXhx_j*o+hTOjTerCa~w^1Z;X|Jb2dJSX{AV(d02Dg1%VcUHkVJ%KP}tA%5-J zOSh}7w{Fch83scR4#ef-9;X*dSHr&?5?XYgaUpnK6J0}G@=m8ss`C=t@w@8#8MYyD zV7&02stOVzrLaI5I}{;4qaCV#(VqgdMdw5fa_mEa(`HH}qY-SKT#H_PRclRz-ObdaKRYQadb+)#dseRW)AH=rWTMdm~#Pt82v8e_|2{hQmd; z?`#d;%!7nNI3z+rUrSO=OXg_acy4mvKE5|b3!H<@;MZa4(P&tpcjgAc*`TGNx$Nl2 zHqY~4Kc~pW@4nRbNBriRoMh?J zXWF7Hz78^Pz!rRzJS3*;>wgK3q_=oy1|*D^f|1)??2O;=<>kzcPtwQ^^>l=xz}HRl zO(f$ItTzOUUT;z9O4R|2Gy^+ttnRKU<{h-{Y z9=i_G_^2?!J|U`;rXKj>^aWgD*jdUFO%X$3UWT30%3vL^M+~uj*!oAqfVrQ1eLweB z98b!pRk-zbjVa}OH40^PQtgDGw}Dg?v~|RQo`^ouzhwSwt_#U$AM_Lg`X}W`7}E@`gs}M3 z@3z$uKXCU_B;v&58}?FE;y~RJdwsJsmiu0V&!~5iz=Yr2rIaLC-R-d7xcOSiGSp7Oh>RA!ZY0Dg<1xFIePbvOc@ayP?hps@LAz_k*Cmm!xh8Hq|+1iD;Vj5VPq(}2%vYG2tr8Yz^<-~PV~5Wd z!du``ZrJsN7+R#eA2*=U8@N@~i~GpRF@0mW08VW9?r47toY*83y0B>Z&nQnC%(!cc z#N)~ovXlA?Xlo+cCZ5;Knf$qXOj}tRg%I1BM9RvC87sao=3X~9^ei2rFFE~|r{-|a z+btn;===1v0SL-mhAVBnmR6dBktB`*Y<2RJ2;*@*-|J1Xp>>rhMoVUru6|m9NR2Eq z&m$tA`-HA=Q0OQVFc;aRSc^t2%KRWkL`=QUw=g<}0(E)(sgQzFrD3V^Ehr`EJrR8r zqBwaks+U`3XBN=V+l}NGzbRUd8#V4<@=c%f$#dM8Uqm{Cx(9~^Tyteq9n=CiKom<6 z?+vt-@rsq;T&VLA_D-3jW)F?^^$f}*>G#8mSq2Li-rp+ad0;+vC++bnm%S5Cdm@wP zVIsHYxEM=9R4?KmFxpYQuHeJ=%ZV#)+bX5?s$B#^nzPD@ezkSYsld07;29V(D5sWS zRtHg&Ejnoj8*gasge253b)?6d|3zSwbIU3afe9#t3X;e#IG&1QP)f^Y9eTp2RJJSR zBzME{J#qwAZmzKQQ?E_IoGtpWWt?a8eb$Ac8qU}UTwufZKJ>;EqSp5W8@`9uY%noj zFel*2Jo$Uu4O}&&3r3WV{}9-eI2MCO#hoWQ?k6c)-kbsW#!j}jt&^l zM&QGiI0kKbCX&Z-o_Ho4U7@`nFa?uNer$o!aN*8m&~EZ*JdR-7fX_Z==<^;bGiSbU z_D19T|8NEOPuXP>c2(3z$YYI~g@={n8aTgv*;~F3h;&7A&C+6)K z)LYj8r+zXRv507tYI87RE9T$p73Brk2JvS15VXQnSD(rKV?Bi^hmzaD5vl67o61PhA&Xe@=|i+l+vb$^?$U0~hLJ5Y28dHtRf>|b zb6K_)pstt*VRHN*1sRRvVpTOI?n*}i3(3=@LHz!_Qe>oVyWjm*CzVwwo&X#0`|`4M ze4){^-TGgfM10;|nfV}m;i%wnxqN%sKc(#(Ke%`3;@cJ?;Zk-w6(6@H7#M^9CY{v^ z%8wSp;BHAV20CgNbbsB^z1IBt|4SwD+BrS#D`L}ZG10g9$v zYQ$Ry*GAWNid99g)%W*oK+2KH(Ahm4T}+`?qs_Fj{xggeA(sN%&xIWZEIvOqvEyB#zv6 z)eb}FLtfAe7NDWi!K|KwBu#vRLdeqzE1buxrGY45-^<+Lc^q9fIf7=>)qT*T*;xaw zJvbzw#F8(SL>(Ajj#wcF;aesU9=>yA12?@zmJ~-#YhZ?(ZAq!UiQCZ@lf<%fF$L4p zusP?}MlSWCf@g;@wQqL5PupCFTv5B^jZZyu9Xii&{wda1&@ZzMX+%bIhCWr|O|#Du zm5J{l_hoPvg%N3m9oi33UWd9te|i~elf-ecW8skp_XV+ovE-pE$1{%R)#5qIkCM}} zZyzwDooK;Y!H>fQUm^>U>v9wDx_TmP*wQvd)nkLO^df?=!4RPX< zzy$w7Ly!dK9x4}I^~^Uf_V8IewUt}N|~%7BKo`L%lxX<#-=gxm(54d%F3*3#`&e* zw>zX^_=c{W8jF5!$MF3ab9qucQ)-U$M{GrU^ccN+D4p9oY4zVTj%Ru zQ<`Eo#C|zS4~AU1dUasHFy#pDh0_TfIlX{RScy1ML+xPq`sEV`V4J&eJ(CXhcYctu z(qW(K03jv~k+R2>#%TJ(VulV&#G)0eU$2CbAd)_=&wtr@N(`U@L{r2B)6L*YRlGm% zst8s8F$I!VSH-nz!1%fIo_Q>Rq< z{$y9^%kN(3Zh9~NlngLEfq{`Wl$Fo1z6^+Wlo*(uGcM870gLlJS|R}*Ed3o?66oe7 z`TWTRTTVAV*4K|q+Ud=9>M^1S-ARAGFqSUZq%IBpIkL%Y5$U%WJQzC6@iH`DskG6# zf`A5mb>;8!wdWr#vrY2M1(8FGjRHHlG^Hd)OSgJ;ubjCi`M=@D61ykYDdB;9FMNVLY{a_9GB?C$euhW@0Ns^0{+VsX7q1h zp1KsRitqEqL}q#O0Hs+VN?(1h=?Q{T(*md#C#eXok!T?CN_oUdaHfsOq4 zJ^|lZ4G|Vi0J=2;xCSB@_+xNYT2;eJZPIV6k>H8i8cPBp4$!|{U5_2E^_66qo`3*M zfs3(fJe@J@+EG|(XsP*kVW%2drdg#xYC_G=cK4nmM*7DQ?|*R(d5hn@D^-G`Ir`37 zjwV9N-||hML2!`!0`>R6sw2k^G_VBSDAs})v=D=`Y!jWDiwDg(w8|9u4%7%70IJvh zpdujd{3AI|nG+v0hqGJBf?!kaRoU0*3Usl-)3jh1^P+_KbRONMV%7L*iaodb7&WsC zY7AT_f+MdCJNRxgmF3F`J9vZIa}jgEj}p^&}<8wkhT~ zXubJXv21Rr{pGgpcsu=Yuxz>Or?(r*yB$E#h`hq){ylvC)u$reP72>R~&`Vo;4GtFH^Aq#332`|!}WA_8DoHPkx8+4^I^282B1*pG3W`6Os ziFu8G$|o%hp!IhKxueIIvdO48%iwF&Jhok}yVQ|;og68_X_szCg6*UU-^?781sWJg z(@CFFRJt!D(ooNPduXll2v&0?;aCRVMOpbZNcY#OX)DLN==q137@f`riaZrnOOfQ) zdrT#Qfu8cJl>Qy@HE^cE{E#2wY5b79-+{*=_tEY~j z52g@i3`Ku%fg54okl>nA{9uu%>v7EW+gd!DM!+k1y6$+3EN>5=mHX$;<#}HGy8K=^ zc{uF!6xHKc7l%mpG3To*!pDz9YkQjdd)6V1U|E;|R>?O2E7&eMe&-U6Pf5_qsEsd} zJSjfV$K_iECyJ>npjE>I(cFmU$91jrSi}{2!c^J>$)zrkDzPGP`QS>3xCi@hV;+}y z?dhf8-i_mvoxoXhFz5Z}Xo+F+?=2wI^hO_lVQ~E&oTbsr5$)|LFwro_{jx9Kk0To# zW-v*>-0oU=T^oP?m0_?rIx~HIz-7+fuRk2)0}1O_JJ5AkYx({n_8ESf1ow;n8>wAk z1~YY>`4C#OB5<-r8)=h7b8%x3y)BB0K$9k(!8OpCM<)x%W6;oN(+F%H?f-T&ho+qT z$plQUyfOfK8K8ZLFWV4y>L9nbFSwG#`c$V+f9vG7$-1U5Y!NFZ0{{y}I?&_mz!o{l zV!SJZAg|BM0DXG-Y?!)HdV7rYU;f+FABNZqt^$IaE>Jr0$T0JnbSayis*|qqzLo>k zc5=MMaQTf_6dfFBpaS7mP*m&h_fO0cj^3h`&x;Qkw_j`WzbV~zon1=*9tf{)ZT3n> z&k7_&1-T<7tbqgQWHCo7$8LOq1SH}SVZ{XoYBYk?wvtc#Y;g(FCE|)A zd&-%!-652Q@xq3s>Z^)(OJXPt%_1U&XjsjP9ViSq_%`fv>@HNOxJYc_gTJ`F>)|(i zdAPW!#^X)t&%@_{hZqDUM^BRBVDYqwc$*IN5&^CSuLnXBN8#}*gOI)c!x_ zD!>9$Mph-#fA4>$z%Z_RQ(zZK^3)q6?=5;ATw#y5PHrDUqX8EuQ~)srwoV}i0#jh? zOptNer=dl2KLcH&^$@vV6VU%00E`r2>Ing1Z;0v2&7Z8bko3T;Mz`ok1R~;dB87Hm3p; zeRIayi1{h^;FcK~cqsw6McKfeFjEnc*nfdT`Okv`6oD7W_lf|0=fnUuJr_&ftZ#HN zHeD_EoTn6e!_St`uqrdabcr;%h_;5_z~!eP3!pdsPk!=vqm2WReauph&g4?jMmUCN zmu5$ejcXc9%?Me_`BV9t8b1U>_l?u$aI;mqU+hvxJHE9~lLUP>xbXnhQveq{UFKUf zYUji)CVl?bsob=DDD?{&F=V{4mf+m`L$Tq*n4>X8XE1$5PmY2fIv($N!rb`pJG!Sp-WhHoFbBm$4oCDn`e5!lbj~so ze{oZ_Qc_xftBb@>+#APPuLM~&e;2sV!yn^4jCrNw+ZkKr^v>>BJn33@0hF%V(IV&Q zKjc<8?A!p5TN;Ny*;$lR`(MA;sXSVF-&ZtsU1E4mW}8vhm0PDF`ne34C_*HE5gkT18tr0> zwxn`Avosu;IoPj=@yQ;P=*nZwXT57cxn)KaG8l(*tRz7`u+l+rmaV@YAJ+`8oAKW? z*DYz7Bs8y)7|~*g@R3G00HJ=95|6A)l!-?>?oXx<1(`T0?oB$bpqXGaXeJ29h6ed^tQ1ueThfbb z;m&va{Ox*P9Dq(Rd(m>d77or&YW&AQO8nhP7{ix7w{v*uUBAdPGcXByUI?dFviPpF zPM!B${(hxi)1YV3<%e&Vqm(w7xv+#V71yID?5m-u@bhPNeLwO(q#Z6eOjGQ0)v|uu zXAf5j`gDcR^Qdh4Q#P$DT>mN+%k~l|q(7|n6RX{*Bd}(1L>(wLagvoSI^1>7L`;LH zwMRcr-o3B}jB5&7Cg@_kQMxs`<^5SF1!I7{Vn*{b4{YyiV@uW^&D>($%_rX9ly8i2 zP(eEbwjXDU0*lnB=?r8+l2dT4S;C{}`e6H!vo5;YRAsu0ZprWP*DE4jhZMXosK+Y{ zSu_sN8=;8dFm-SPma)oV5v#Nst-nIrQ~HgWxm=0y7K}fau$x;UAHm58yA$6vuC#Wg zt{{N657y7m2C|Qvo@rVpv`lK~w|wMi8$EiaG52fRT~(Ak*Hro7nc%zp8_$cgByi^= zR;IfkTj&##hTni{@`4M}$GL&9(DM5vCnEUI;sLH^dHeOPC63qCkR>x?e2OJK($~6> zM1qI&EJoicse5KwW`Bo1G?DPh-<@TVp5G@|Kv$6Gfuw)v9mk;rJPJg8mIZ`seEfMZ zi#@M%ZetWwX3PN{e$+mqtEz_PFzS$IM~+>s4IoIzn(<-MqZ;izZikP8!U*gq+F}af z8vj2(pwB;1xJ50GZK$1IRU{_g^p2ap-4$>`O0w6j9;3XjK`n4G9`_W1sP^)0QYtNB zEyw%Yb-MJnh9VXTDz?h+rHz8#r*~T>yv-v8)5A8omJu&swz&=gBq4}};37&-K)zV^ zf0+8}psK$wT0|OY1f;v9K{_vuv>@G$GzdsbNH++0=@gKVl$P%9?nb)v9lpOeZ{A!}(@S(NmOlQ%XxM=-ZJ( zK6ukywqplvaFyII{n>Tr{qnyb*r=NO8v73u3dPz&vkCx@_5TMR>jQZ+^VSyORz}4$ zFV@`5``*T5^i{`r#^SI&R61(QH+@<<;sRKXVpRfTX=ivvLJ(btiR0oOECs2KrXBv8 zvpFB;xU<%?6+TzS!qz6(j#tGE#8Tf8`5TTe^TBB4ca_j{;f&yag)>5C$!<#qY>gdq z)jfM!?C`=Oh)#+PQ$GDakmH%KXN~%AaI}yjy?ZTtLlbGB8qMWU6OHu_?u|@$%`-!) z6gaQRdF}wT^rAlb~5v0;-b6!GH1 zi?|AxIO_xidx8(RpTUE-CM$md@%7@L{&ft{8PhXgWOsJ!@!yu6kDL8BYL%<{@;7Qpm3j(qZ3iFAZzXd&Rs63WILz&KyKFyz?fIb7;D&>+ zt|@M%^GlL_5gryGnP0K$MA!%bW0W9P`RHFbG0Otwz@_8|&%gdu!Eb+yIvnhxFlWT} zJGO%Z^(#0~Uqz9iek*u~!^^p8W0LW3cwYGWxq+WF|i<_Mh1{OHB{t@8`QJJDF`~~|#g4no*T zsj}y~GWePW-KsEF{rqriE2b9men$ayAyKD0LSgi+Scp4sCymW7DhW`o7A(nDj;U@vc~@QL0CjKmIQBrtyv;hyHM@rV*h4yhrTOBz&BX#(%*9 zL3oexrnQvqjR~-M;0=pFHp5?v)pOUj$RZtQx;$A6F?BhLzoIq?JOBg4vRjTnZSLP) zbTgt6NE1p3oaY=59p?8UtYd<97HzErIL{2MufG$%DDhdM*S!_e1y+~35u>`Ga>znE zq3bT~ylQ0@1W|b?>1h6Lr!=Ja_j$YEfA}x3#eWWLOS`98l(zR3D$P9OoBou1Z>jby z_88$A<1M_AN-+J!lx+46TrsWbb@~GVmi_N{56Uw02y_g=d zE;d&#OpjoHu2}s`dcY3qpE^i zG_v-e;u?T5Hvp7j6Lj^$OaJ(OL|kzA%Y>LQlhSANsI=ZL6O@eq<%^(kqq+toJxZPh zSi2zvASvxPqIn&JS_9Sr$@5UpbtX1p)L^gg{>fqR$KQx$R2h)ee*JxpRe0edf}guX z8W|p3GYJ+#|2nC}q)L*!zYD3H`I7TYMEY+S1e53fkgv;i9IvJ>Kqo=RaYeMCz7!Y( ze!z{z59VbCCrvnz*_d&y)Px9X#H)sJ(8pO4O zHHs%aollp8FZS~Lnv0iwK4E?_$dK^Vy1I$Ifg9ktg^qj}*h=jpvk>5^4^E?stgtOC z_K(MAft}%+Js@6d0M`(m4EZjL`Tx>J)bGvCpLs1?+4xo^QYsKV9Bndsd&H`P#0sJ= zT&jzZ6i+d1P)l!7gjDlxemFfOU4zRcG7Zn4X5IgrKdF zr>HRHuAt%!Rt#LulYC&${>x7n21GHiV>-O1HFTI13In>dA(*1z07^E3DFg>JUJ{wKky_jxv}vA6CQ|3y3Nt~A{}&kJ z{GzN9+<`&jApGsA9+HAYA1a(=9u(ggzsPvkw-6zPWfS{JM0qsLa5vPO0$bHvQ%A1im>*5}BlJ!*w=EDV)~ z!HmTOe~7sqTaax5paz&&y2lm1G6*~Nc|d$jBkLVaTw&NN&|j zzvaPd-&$Ffe`ZM_3gm~&==$b74wBN`vR8PM5evNq&>}IQ{(~b&$_O$J-VI> ziVesCuG`+nR+tL$Xx$XqAT3PAHg;P!kwf}uB~}nT* z*M>Pb{J$ZWyr!P+?SyJ1ofS_mdH_j*?l6l^%MFLdutvrJ+_5YR^l2?1Z5xP7?)v^P zg^*&b%x?f{-v*`#JP|Dmq+UFje;5{1Es$?J>9s1o9KFk74a_eb61dRe|IsT(1XF=C z4Z6SiES6edZk!lr57m`HH1Z%eL)$960>J2hfMba(R#$A~esmW~hC#cn8DNbVjm>p8 zM;o5nljh$W8u=QL58zlEOfNpe(^w$y& z{}CmohBT~54@Y%L(MsCZe{Zf2FQ1KwDKI0zX7HE zpP>Eb<&m~`QAd)9w_{wBPDy3X=7q<*mLbKD|Dz$gnxMyK;$%PVEeX!oB?^@jTM<_) z(eoAP`oBN>PpSqFbnA;N0l8;0D6=F7^CdJ*#u>`H0L9aEXyjC2||_3h!YbKswmT*oAgDIeV}zE z9w4XtEkGd+N3+)L?#BU%0(DH$-J#Ey_Xkc-L+`c|y@ho2eShNJarW64SM$Z&yq6~_ z(AYNcO&bJRn8Kyq#_*RnXpVmSOem zAiI>t`SDJMWrH}q(*hq=nvk|(o>~kKK#r)v$?s%h&KPJY)7=jU8O0(IX2rDp?Oy!} zz&`vTz8!6(vA(sm%JrihE7GAXXEede7D-DElC3d2uJt3J1!S*Rs<;s#g{ezY&H*jR z;7tgI`zz#?v5Y|ex)O!e7YOt22Pnd=Vn#lTNw7)t_2rQZ-u>Yndc zU4yebzNw3o%(jv#3fwvxv-KVtCDU6n#|`QjtkQ&XXt;bhMVTu$6#y&X>*xZfPNPe3 z^X$SWj?!%?C|tSa6JMNq2iNg^{&1=tvYkVb#+joN*uB=vr>vPL#O5cAwG%S!+|Q3+S4EEq zB+TZ*s3URk1r}|i1?4lJIfh@;vkw8=VemW<0qgk|SBF5Ie#KT6%i}$8n;D&XhP(}g zK9GCkvPbR8XJ<{O_zI$ms9B}<3Qt1QjIsF((wvATzK7o7b8MUijgoPAMH2f=W9$*(a1_GU!fZQZ z{fR+>=5&r(*U;kqljeeYdtR0Eo8?4!q|X-{j{1Kv&h9+?vakAMo32e=PaB_L%ml^uygk(eKFo-wQ8MX)bHKEKK z)^;gK9Y_(}>n-fQmT`cV=runfhF)jZ{34g>D z?$vVtcOYhE%Uk~$Muc~bZ=iO%9U_0)T2_e|DV8lhbr)1Id&=*5Z#>(Zw4Jo9^5tgl z{Qi7rt*W4+UGt^g-Pq3_8n37?fcN1Xat!Q^0>;x0=Wiw#t%WkoSn-@6P(M#fE6Ln4 zd=Xx)7@#SBnmG@YC&hsqc~nyRu+% zzC1}LU~KN(MF7_4yu+DyC)7$LVE2uwNZ{z%t{0z9^3$H!woFcmo(t3*p7eYQT;9ZM zFce}#7k>mM@Z`>`Zt()kxG z)XbZ@~VIDen+}558ZY!#BugQ zFyWNH-tFG%O)6t)p_&+AoWJ1RU)_`m_!VTV@1W|xe^S%CwTX#=gp9J4Cy;g|fio5W z*LxumpD2%)@YYZWolk@oi98<&WPE%VIwYvyCL|-1kk2~$nQAAt-|rO+oT*WgRh_hB zj>~<*8E3}3#=;q1C8sq7C05f(X+eWH*!v&H*#L}13k1}x>=b4) zm>gJquP^$DF?(q?UZjxwC4+kF^@Af0PV8@GW7>0n({9u_*$Z^3kb(CpG0Bu(ME99h z-0X`LU&+|PBpVxdjTjn#d%fj|bGBQ#Exm*5oXb9S=t;LVkGPx&vOl(9dI@kh)a8NK z8s*1M?W8XMCn0F8g^-KXmKT;V2Hih`;<-fRkI75PgB@f7VU}^NB2Ssw?76`1uI0$V z=3pe=ODqj;NFTgyy{1_^$P8qiLy#OChr(2ZxmNojlCVNS;Sw~&wI2)QQ}?{ z0Qi-5`^id7p+wJmp$!#qMHf4bMuuJa?;OX3mEMrbc97T1m3GA?O8J-&6G2ZY^!EFW zvOMWlUR2`LH!9VWF4QP@bVOqI8*?_|0Al#3Bz{kU;9D7BO7{tWnkE*^WFMHxO-xQi zWE6e3hVh#*9BkJ;yLdQN_*QIvFM`Y8 z(|q|`=sVO{2PLzDr zF-7Fg-Egxq7ytM>?W1rCW!Sa#Qo-m5B(yD%vq zu}o)GdaDfDDJ6ov+0hp)t|`AySH;`@PVhx*fLu64fsTod8=>gNKa5=HFOeA+imXu; zBUCo@+VtxGd+u>*IHyt0ETmk1${4u=v*QX($@)R5bGH630woH=aFj99=!ilXG_Yt2 z5hE4b%p;mFf9d5EXKx%IUI1Kl6Y~VjZN3@yiS*Ys46Jw#9{ZtzPtN8UwOOKR!G3?9 zmHzfIL`kt*7}#Xr`lD`g;_3<1o{C~`pW;^IHW9U2=B;dXY1w=Qop>F-(4Wy!pCoO+ zX_VusjoM&3(#g9Lyd(bfr~18PC+dF}jEy_GiZ76dxEr^3nIxkB5lww7%z)Z(5DnXr zUe5_54~p~m`G3B?*@dAvG5UMJE6P}sq_QCwE#7jo>2>CK^(ri9Fn`WwPn?5(5-lSD z-3(RMydA6Xc>OaAR0De>6OCH>N&PYt%aJ}`x=de$^miTiEFcgO{res4Nfr5n&`u&& z*AcmiWSM(*fynrbT&%_U=}rnLZ19RV5AFt~W&VEoX8uKMvBYAww$iL7nRywSlU|yI z@h~f%&2sLPMLU@8a)zJG4DpBpD;;o<;AA#_U|!!O3r2n5j=5&L{wzmqtE@ zHO%3YzYRLube|C@q?*};RR zlzXwlO8fBUfS@iyM&>E%9J3e9@nCZ?5tVgIs7b9a>cT^VI!%^WdW1qnxkG< zvKiBL);?A?TXj79o*ct;$X$XRbte|-0;BgklS$*v#|7(=fy}j*6u7wrKog&fhGia; zSvkHvoFOFSo#=hBcHS_aap}Os-90NF_0Yucq`LRH-ZT$;;8)^3Fx#S(o&y^-z3(+$*FL(TKm&(1q;CU#-DCKT(Z8PNQ<>Wix&f5{!%2I>qe)y}P+dymhXioa=f5c0> z@pL*bSvhYyEALluG5{p~7%oBqw|aaE_^rLX9TC93iO%!TWm`Sbn`c~PYj~tA;~DrR z51mC}85pgH71Y-d+jK(u^P2duuhqhnJ^dAS#7mAWx*Y!W2)TW>jj-6%I}*y9TjL+^ zxW&BlTMBU>+{Z3Xg7@~;jhpNGea^4B9=pY(B;TKz*+kU4ZHstndZN)feYm1bW7(iYs~ITl8|g1R}qh&VP4BT7e;#* zs5gso@LNKcUV0+fGrB%^wYN2q(OiV{+Pp<-buiIdpP)8j=&_D5nJX#90*fj6J^z9a zh(6@KWNdZ3jL8ykV@67mu~Q^{TUc%K2qd?5pv6;AJvIV~-`7PVo{!!V#M2A!(n8u# z^{~3{%W~((s#V^No{;+ z!Z<>+8gtzTmzSL;c!OLpm6}6eui!hFFRO}mkwlys8ETzKE`2c@GeQRb}7dI}s<<4eN>R-|*yuPQWTiRM}cjreY0+Y9R zWL+P}j6Q*`pU!!_BJ?_ieM9E`ncnfe&2fVtugsq?Yba9?e!q_Oh^v@742;mUTgK;^94=XV*4>eKnRJ4_8JtVM&1*2p3fogCl3 z#((~sGLgfE@#HMFi_e6`tJU1FVqW;ys-U`ccj=l8R*`y~+<|g$(7^%W20f{)#ryPp z@;tPV=)1w?koBsDL6VxyGUDEwr=Z`;rM?SyKdh@_Z?9Rxl2%?$fspMOW*rgLsWHC| z@{o+WBQ*Glu`T?cISjPUukmF|K5WBj1>Dd;M=7FFsen6@^LUB~6D$9K!oCC2!|K~F z={6O8J(qf_eKaC5Q|6`fJV-_?aaNelSdx~!&WoV}@sp2v_c8%R)ugB&>WT3vK}9?I zWd}JEz59u-jL?dEz(Ov=iID|9w|l7-@R8n z`MyE=pD?)N=Oi`x$!z>xWAlIH<|RnHzQtf0hD)O$fIbH{gN`QSB!Y0z-9W0Q>|I07 z5_994T(&hg@{=LyhRq><0sX~=1=d;t9HK8W9gTV@{Wk66|D*%|;($Gy9#XvFM&@xH z>eW)F|FV$Sen*o1P!1@`Y|Dp1tP)%)&lJ#qMPRuVj zJ8%C64p^2+szzES0^jh2p-;wNW?z_V-{lU}-6%FIBY!Qdh~KlmTT#t}%TJs|$e&L_ zdO-{3mJREK0VTQTY94W*0x_8?veMO@fqGlbKYj?5l(t~{kx`w5`+z1*s1L6AX~au) zqO$)sI#Rkk7vui2=Q;BrhKqLmh=WJ=O?tM~#8`!zHASs`JKjD@-(s+2qVY?;_Of7a z?Ar->`vuapG@BVg&PX)0fVE5rOc0Uw6?jUee~0GIY{XS`=aC@e!cAe?vx=q(y;w zPCPt>kl5B2a{j(JK%m|IBTZen-|7^L`T#w6qWeqTJ3z@aj%i5AXW|!{yR;k+0#>hC zafRgXCXw}cp^%-F*MHi94Bs+z0VesoOicK9nVoRxETB|0fNrBBvZ)pr$d^-Vb$s@V z^st6BOSYJ`{x+%*Jx`fX-Ee5aj8KQn8*V2oRabe+xQPWr53TluQvth09Lvp1_<Y?C(eFFA*QHVFW!{@ z9S$>4LJ<&6`Rq~DX8bW<{L0`*TFHBUP(CD9D)_AOlknpTDx}y6JVc<6?|t89jGL9& z!Oa>k3(?FMYdlX1^#8J}*aY1?Rj>YO4&75-7MpBAbN=O6qwb&3!>0>d@+|i0z=QZh zmV>Bv?_-eXA*PgaZCYp7V^Xv>Fk(uqfS+^Hur8IaBuR$Pfm0-wn}ZOW+a}pm65xUN z^Ozdi!%{S#)y)V`QxlsakI}|~2FY(B#f^}6+Y>h3LN|@#8gh-2j%%6^c8QN1pfCo0 zwcvmJ(f`EZl)dNviNoh$>&J;-qBnXX9TdHJb;2QaF6Qs3PdniuBfSr#B(F-PPyJ|a zpplPEN56LTHJ}2{nGzo|{cSQh&?(Fft)VHs=cG*IF|Z z!ME1}hI_I1u3R?vC6o%S)|TQl+cd!+^*q0~YYTG~WC&ffsuGCZv>SH`zmgq3;tk$q z5UkJ*83poI}Mr=(gJBV0^FSO&b&9k#mw3)tt9xJuz%3k_H>u)pXv6k~<|5tI4;nKoo@*BNjIOS^bqx;6AR~ohteZ>2Qd*(5%QSh6U9s}< zOj3|KURu=FrN|?KxH-%xSDCZjFMY^v@CHTQ1Y$FhqPr<0NZBM*A+)8BkbcOfJ~W0U zO7R_8>BoLhoYc?QI}UWQPP-EwdmGvb*_%SxI~$Gh*cIkm8v2{LTP`&SzbDukA^xKCu60BG}|rc9*ed-5NpqfXb@4WfOi`+ z51WI5j3P-EcerU?tv_UMKHFJeR4OtswGzKo87!y=i;_o6LpPr-b{S5Jaw9<7CuOLl zvGbe8H9QsR{Jzn2ySO-7q_?~x>8m&yg>mf;^xZkf9cnU8upPeoLxy>Sxn8A{P)l!(m*CB5BO>Sxo=Jk@ zbbOr!=yn^JL10lLP@le>t~IGk_3p{P($F{~MT>)c_9f(Hq=n}>auzn>*_kaLBUvMA*BI455voHhg_`j^jg}_m6R(gHo)PbjiMPH8+QQW#{bky zxpCkiOIx%+nwfQQ!4V`+92+1SSbvHQXB<(re&cw8U?xqX^WR^wN+r6~Ko)33q%scC@~Z))P2{_K%l`s}Qc$ zNek~5e^yzvXe8dhF>c1s#lG|EC3SlH3z-g@V|ddT)fk~(SB<`CRI{R?sC4MvWaG!( z7b`L^^MuBv<%;OtQzhq3Upj;^2Rx7y7d((>J-#;*jltrh!=VU*7ZP}s~>WZxJW{%y=a_yEnd!(g%Q*4(iBnu>loS!lRt@}!D)(K)ewQ@VIV#Skg>0f~r8SSV)d zPKx7jxN*6c0^0?6{TR{=IQvL)UJYo zM?#_12bQI;PW-{b&5)T;k9<|`_g9)0VfF62l;eQmPwfr#f64et4C>6eR=xSYJEA!045w9g1 zis0kF0J_Sdvcr%2H%y!sTp#zM_^n3G+hg7+5%&0ZA`3U$6(QXV4gJyYP^UcR#%G*#%rADF zWLN~dk$>cDYa8uQ)LptYsdbm7>o;o+`MMgI9l4ARnt2bOzIR59Uhw6G75-RZHs+^=J^+(mVrRECEM z(TySU(>yMi^XZ$od=cxbx;8;yx+f81rj zr>f4^lXKZ-V7&eFyYaWFwH{&*qg7&Wy9(CP(l43d`+{JHe*)`LAeM**Os0No>SuWW zOD?W8rMvU1+Q&~VqUJGJfHhfK8#{U6{OPaU~ z&H>%(53PD}Z$9K1TK|pBT--pOhQfdUf?g>D@gPh*NE>(HDUv1p$Bj6$g4_5>QQjA0 zAZ7XXe`q1$r7J7A_^L%WDc~(MyKy8xTnPxJ7Z2(Wc2zz+3+dE}3dPVw22pR<7NjvX zY%esTU&u^&)ZH4B71{yH{9+~nWp#+Z#RTqHmGl+T3^qM#)~fF4LhH4 z<{Y0nn0>=Hg=vF-l$+b=SKPs+z|9@(&I;;G^`s0B0Xew8u-iKW6IILoog}}$7Sg;4 z64z-1S`10!a-DT4E7REIa>vNbs+{KXD$;;~LDrIcLwZ{`K~mg2PlI+TD_BQ_-c>0E zV{K|k;a#yMhZ9pjU`}ax>S|_DzgW()huX-akD3A`Tb?q}$3Y&l7lFB%JCa~}ks3dj z9Oy!T180bRh+@pqmD(!B9o8FI^lJYn2a|0idZApN?n)_;zs$7WQ znn}gDQp&esZ31fXy*)*2U`#rJHuU%VCP)vqBjU^hg){07=z4V%Pzv+ni`7Y+ zguhl*I$NO(c*W&vGnMwtPMG#LWLG^DTMH=HblFI!EJxBU-6n^6-nVbj;oQp_gdnW(<4vlnq1vN4uXf>C< zU>MUTyxn5h{BkeJHm2$0ZZr41p#8%*WYBrIv0l<(aW5K3mJNmVd%K!@8hG|3`S33# zFF@iM)h~~$>?*$SOAtf+1>M8$7ogH9WEH3nFOzM}_tT|Q;5RT-VwF(x4;(I5T0y+pbzje_CJCA?L2D`m z$Dbfk_ANO6qDf<23V6;sw-5SfJ@gjE$aX4&U)|BDpM{ccNKE)1IFnJ#QgLH#ajHio;3yzR^i%z4tcXs5d6&cCwZf8#&-35cg>B-MhyHM zkJd)9gzjnq5eq>wCY!pYGGMl5_~flo(n|I;E1ur;MZb_Xb+c-;!&a#g1~-i#=`Y2? z>$$stMG7AD;CVq_bQ}~xN$C}au{oSUmGB=ByYe&;2P)}+pi2V%w_SO|>o6HNeqRX)L@_`{74t_W_RPcw(eDZv zl&huWlqP}1OuQ(u$YyETRQtH0Zv%02GY5_$BX52|l~xZFeMc(8G1Na_QPW`*z}^V! zoxe8;z?wa`AIrwT6mrttvEP223Xc??t;e4WknEr>!kfI?`m@-%_pmAXu0>yMKf~0X zHt9BswCQFqw9a10l-TM|Rl(j5YfiWY_9gCFQ)0>~L${?9RYK$kb9S9!z{w1bu7u8$ zK8oQ*j?s_rn|+*0eC;RwHHI+9@KH?947oJfgo%)e_nw}DjEz>!J}k=PL+)oPlrDz1 z53Uf1L=J~Qg8@R5>&bt=bL$9RDw_C(;d$>Cd>8r4tT*0DHJj!YBzEa#OBNYLpS`W6 zn#9meH)W`PrZIASbb2vuV*A79Bl_=8pjx1nE3lYUd7&e&{P2`?_C{^%5q#eEl&StO zu)6lRWnQzCzLwskQ)X9jwkvs=@wB4E;r!F=L8x)oGWW9FrONTbVSo>RWxyG@v$%v< z1w2^law>J$YA?5l6bhS3vu2n{YiJaEIs~Q(ZOjTd{7e8Ka-g%jhUp9SazGst6aum5 zd&o*C99@6~Ik4(6BJf*N)P)D#=tGsvz+VhR3VtN_%J1L*C zrpHD(OL=hop&CN;=e%}&55^lHz<5f&`YfA#ZsE z!<9hI#rQ}z7dt++eCc5oexq&2^JOe(^dcM@F=}4E@{=wWIq^q!&IGQNHzLcReabSy zErrf4=%g3>GA~0K-QX5p3t{%=;NPURH`I1`Y2wMVI(@O^Jolt+<)mm%&}*|_$tBKU z>sMiv=6Q@$?#aZOGVZUHm7M=o?|l*OUewV>9FA1VtvgoN>kpSLi+=#sw^w?i97A+r zVT}icQ6EG}jX@qD1yz~o>EZueiCp0A+-ieoUM-xj=w|*NvTi#@%w;O+9 zcH`S|Vq}Ucw=I-v+>SMT?+aRPgIlgImY+m?u9qK=%bvztZWhTNAIKhVm7Z=ee2-h6 zZbj~U4W3p-?k>n4m0GTNd~cKn9_}U$?sZPvGamdOj-#I>FTtnX%X`C7pG!O2JI+># z9u|4Ri{-{$A7xp+Kcaf0a<^zGL0F?ROj1ccX&(Mn^Rp|Cw=l15LcB<1tsBibO?IXWoi_#`QW=v_JTVN@ZqZwSBf{`N|{HwXLX4w0rikzAzjjf*R!Xbm3j+@f)`6j;2W=Hhl6D_-@;_+I4AJg-WSCTU~htmJ2?fBZ*EXguj0YM(6GXN2`!un-jytWer{XB(0%f3;REx|X6q zvLrA6lXqDm-t9iyp*<8i;#O)@Zf@0Ui;9d@22*ap<*0_0*|w-sbWP(^0z-M2O{ z0kkkeT$kjadySGxRk$}gA|@dq4vWLqqvt=?3kIa?r5vBpIthh|bl<8~e-f7o|DO7F zvZ*}z*7b&HFPPb+2(j<}zsZh1Y7|Sl=9V4L>6%HoE=>wH88G>j>3_Jwbj%&C3~$QL z2nkZ?pol`hTzA02Dva2WmXH}23q`8q5t8`NO%IV`%|QW?&KN=z>}ErpK9l#e+hsz$ zn>{r7Z_i2ZSL{)$U{iURyU5!Ntdq<&gH#h1(>G2+vf0>HMEd6KP<0`yx?lII=g<(uu9RF>5yI zxDTE5BhTMXIG;!*^n`Es#$5H(41gRS%HZ1UPh1zhT$6A&{cYlYn&*iPgy#HWt%ye4w%fIRb35DaB zR;v7Mr6SUgZ2W+g6F(NTI02;S?Desbjxk6UwI=xz)H;yX$?8A?k5m#isf!Nrn{)dY{U(br*$W9& z)IfFicYhav?k(bpv^-ytTq!GSF9%xNwpSNorTT zbBFILo(9ky zlLR*&4m~S)VNCfS^kdXW?;Lj?eNun9>LN|LRT?Ccej={kd0V%_ckl-!Yp;WOS!OW0 zBs(p;CH z4Cv|p;tf@uVXKOtJbhhA)CT3)9`fMds4wh7jN~{nEZ}F0=Ev*CsCl{_1&cg{lRe(B zKJJM;++aN2`c6KHwOkkbUX}S?C_Sz}ideMV7Wke_`#zTWUTOF~c8lB(KV44yKH;}m zq|L62APV_JwYlc9*NIQ0cYYZ+ZFddf2zZFm8&`JwiD5=zfKb3>+Ip^xcYyMNTPnHL zKZhQwoQy?cB$ca9IuPqtZWgXB0&J{`-M}~0lfq_CWlzTjkDD3yd&5t=7{0e; zPqzk-Ytv6VBKOBikBb;jJFJi3lhv}P$(HON1xYRUIR^Kq(T|g?;6J`M(oZW%zURJA zrx;HPm;EhQzK_R8Pv^nD$HOcN1+t|LX8(|_4}wMR;Il;T*L_bko=%2+t~*5re5T`@ zlPp*>o=D}EW4rdKjNdyD-GT%62vZ30Zna@&AN?YWbz^JdoEb$*PTa7eFWWB=N_y?D zXLQ~5hfmW1*9)hfFME9p^nwT?9g)=UB6eYC^uqbW2d4Wv-`P1vP3)M4&5LXXx+@$M z-=uebDWpHLB3UOe#^xPZOdUhtY+F$$An_#T??uYqVFvCum{pC7b^KEgk7HEVpcA4T z7^7B|YlWXMp;55ZV|&CNx@Uq#)*U~u6*6INHbhULiZ39lbs20ibSpRrab`(VoZtFe zKupk&;d_7exVQY!YVZ{ObgBCMfw|^Axc|ewai0ba9=(rck7|RK&%VV?%uphZ*W@*_?+v-`$0)>qC1}H z=y!hFbuycQcq6WUz~`ZpVhQUK$59AbW|aiFJPd<@&L3a0R8HdsQT2!xlE;Sr^M|4hvlXtk(@63IpV;ABwskUd~tpf2t@z4+H0X|CaRhvJ0c zHv9@hz)s}OxlJJH1EWa5PU> zk?OmX4dEOgGNtZ+8+(o@*1J?x`C+vIJwSJ}2XFO{ZXbL!ogyGb?OiWLJ!AqL87ipMUx zn>=nh{U3z%FCrK)>6~W06=aob(EPoN0%PpOb_oi;Hwk$O#4)K}eb_SURT^8ZF8F)% zJifX<1O}gog?0`+jI?|#QDn7@nZ9NQCM6`k(Ol8co?4zBm(%sRf2GwvP&6v|qLdNf4M*e8 z@w7t#y?axknB(>OkA^V2g{rBa!onU&r6*)RAi7CN>g4qB)02=ynjl7pq8~Ig45w=E zPRHQ2r?1uM|Ab9N2q&i9sC}Q+?@h9m0E zM@^}+j@762WusdjVQAu8|G7TuPncm@-8#y6@S3&HImL+Cd>eUVVi<1rJv?TUrWp@O z&ge^ZjhU=1>hDyw-y{9=yT+nqG?eVf!`r|;8vU8r<*8eDreF2HSH#v*cX#Og?!-R7k&@KP0Z)ouH{e5%m>U(ttOTdsL$5{E!_DUy{?_f#3F+NkUP&ka- zWGzo%fzOd6U8NAV?yQIRLlIMD@mTa}jrFwOyWXBmHSk_dH$D`J7R5w7e3izqATbkn z%3F1ofQTREb8rR4FsY;|(``YpzbFyJC0ucdR@kcTrzv;fU45@e!6Q#`2a8jYIL-n$ zL-bHkW~hU%zc_KGrdm;5k*vGoM*D<81{V@1<|Wtrf})pB_^Vn0#$3yn+ka#}PhMBc z_s0jd&}p6{)>7`_db0b$!>#s5>oe%|uxra=g^@-Chdh7oK)}ocE}{j zA(U5Y_$T}3g9A*&5Erc{I%?itWYPLqvcCj{)Elnn1(@SSh$E9&auj^|=nF1wr6vHG5UC$A^#9)H5cZ|{S^tbZ)Squ{Pp+rH=TOma7knsh2oi(Xh7aqooF_K0y z(K*g~l`kS9epQ@2eH?F@g4y*h)LLk*-YonC`?Jc+4p-)#K>V)3W75-u!DH>yuE^8y zlSasR3mEa_>2dg}`{_30@y_>(^=Z51?&-1H_bKBk*!K?O$=W$^%76S2eSF?mQ*>Xh z{Wv7!2P0bY4@lMbWVId7$gFpyKSDl^WkD=yn&=5jLX!?x9$>1{RkC2~Do6IrQ4&q? z^w3ST9~AL&)VaHBelkgaN~RYrHaRX(bt13I-;j}bEA#o5Wo37=JN#;KdtX(*QN-_9 z>5hzN`RK@}uC96B{u|ljpuPU%?p;G?{m)Y{ZqNFwfA0m-)rstnO~!A zo6CJGj;^Zbn|+7NXIo9{m+_a&>k0kIwcGYhj-TzTn(BD@imnW<5PieCJg&Pi=K}3d zrgMrclG#~dk<@$mr%5`AXoYh3X(h}y$d-@m9FOX7d>D2@Y*UToXf$hE?H}D;CaTD- zpT`m88O|ap+R_O&^D5*aD_@+fw$!Yt#;3V2)RiI)VkKp1I7{$(Dd+lhg4Qbym-_S7 zORcM7*Q@=*WdWC&S+iHurpyAQqE5%j8qZ8GclX~Mk6h>vU%WnkEPX6~(fYl^v1Dck z5)+zXT7Mj%ssc$6{undyE+>**DMqk%Jl6h6LenG*<4@l1Jhtim(ydF~CBvL$Udd>- zB~-@^5Xvl8E=hxVAe2vd%JN8xTy+}ERMRg_=4n0OM@OLUMfT_2&i&cZ-)HgaGL25K zUfCinIOpAvZ3;F0OQ<(KQ+T4B(y9V930p2I;%kt3<&f&Cnly7CZ}&&GjCe^cNs)3< zJCL{@>PLN@dTVE0zu-HVcSc}5@{XQM)^&d3H_uyq;V2`9A2Swx1tC5C;2$2dRG{ouXq4@jT z9q<;s606KqTQtGX7Lg_NdboRai?b z$ZvPxHHE@&94deHN+;l*pbEybH@0+B%_04(IjDSvToCv ziS;yAs?%|uKZ=O3wmK#AhyqE%vg3z@qo~>4rJt0`Zzrwl8@-~_a7&H1Cd_BHT<6J` zCDOv8Fn`NPVv9?@GP|3xaM4muUMe>xY9cr|BabbsL9=KxV!3`vJZm#*-oQRj$y zUt3uo?gNp}ASfIJtW4A9Af_u9thY>m+CJ?^yysq&9-S8*dduFfYI?_C*pzMUC8)TZ ze{G+J8IRa}-ZUt4otDR?KjBa%?Im{k^qNKIOygjp-^lEaAHrzgl0V_otD{C_=COC8Eg^V;gjnoLy!>Hgc zhgz;@EaqIZ8cx;qwYADARQkipER{cr=%rm3&|ZK^dE6^MH!8SwtorVxB}bP3Uf z_I^`HzjI-LeOB&n#iS3+od)Enh?XpHbn-64VYhea%YscrX7RI)e`HzUQ9t#8bY-O)=g&G3-8S{I0HeR7xsTZ?#-_Zp;^h>hJV=VYx@N)$AZe_aS1RT_kNJZ zmz5WbSXYWp2(`RV)W^3we><^T-|f9+FBkoOU%sX77bub{ceH6ikz`CRMpbxxkN22; zC_IWnraM}61QnaZ`Ah!5~aWy7Lv~4gN7tgZ(k8t2_BlhU)Dv{F|*)5X7k2Up=z0Ji$As z!+o1tTP}@%GevaAlY55xRVmk7LQI*Qt3m2aD|vki{5D_m(@-dFX0m1?^tj`T?>8!G zQiVh+miGbQG>gJrz-kPCGoFo-NC{jtm0a$PXA$SX^y8Zlv&Zm`S63B_1Jf%j{jI-P z&+24lAq|e7tiHDOBC0Aa-PvjByC(^gsR3mI0lrjA#*2oD()2)MP1ee9i;wMmoB>3{j{I0=#1_BH zvyU)-POY?EiZOHE=@RC=T}Bfeyi28Gik3_p8|>)2Z~N~2z=rE<934-JRk2IfEZc(= zbr@?fbfmN*BZgE{fP(nh$EWc_j=x68=IW2u;HVy^1gqEbKGTIr< z&n^ecd$fPwJsa&LqIK-UqD-{(f3w+R^oRzYJ)5XUPU~(Q+1}+4!6@U=AK3#U+duHQ ziYV?yAyifL_unx!Ax}%A`$Ecde^XLSAGQx?x`pjIo%Y#l=qAEOTOQy@i2vgK5z|og zgxQS0gcF;WR^~fc@7~`7($R8uyuEIS=)LjaAxXUM^QusuE@8ae4K%@C;Fwg%V|sP| ztZt~6T$q#8)pv5Ii`x4TxlQ1k73PVqgM;|0jt!Qx48wy*;i>&8ul&hbVCF|_*gdwM zj)5H!TlwSc4WDfqNzmO`%P`s1b(c52+?`Hg{@X4kR2zJ_wsD9)2Ac?P6111nkh_Z# zrQ8^=WSQ@l@%h@!MLGnDP?X@P4qde} zj^BRs4i>m+;Sn|fm<2CodZ>TO-EsIRhMyANKO-L;ml{4E!`e8gIZ`Mt)nC1VNAqA1 z0}%&>f`wCY!NO1jo_iR<8on|YHMiQMeMa8p>wYs?w|VTF^)LwiHunAQBr%|TK4V4B zkQnKvdDZkO?eLcw)R_|pLTF66Qfg26qP8t(f53=vm{X~fJ%=xT#tlY{f7ub{);5Oy zG6{%FFkGT~0J}%>1*!_x97G;g)xhzdyeet!Ue`*F>=VD5p<>8tV1fNiL?BdGQM~sy z?p+s_l3YDLsP=P-d)ybygku;yGBhIG3Lmg)KDB?(jNyKEd-{PJ<(l7Z?mZY+o)tSc zTQXdyz$ibtv@W?pDY+(qxK)pw#2q92P6u#kZs5=lIv9h=?sqiO!Z~GtX4`>gxpfia zcm&vKPveE51Z!+`bZ|Bz*;qHJ?iBeMvw{yp_D%SH>10`CPtkCzsaPtO@}#|mPnFNyC_PisBNDJawpX+Nt8Z}ZB~~6_VR3$IXy(xJyqbFRD7-N31rQ^nu6O z=2?oTTUg*h=7@Ghu~wQoS_`^58qt0=w~ZcJ(bybBw@!?LlX;I%Cz`@0g3)_~k%-!1K2q=}`_*T9cBI+-OvR@wT^2vY| z2Rl>Sz=}poqdJ1M-!kJG8E~Z76_c6gtTMGZSmlWR6i`1Y>&SW-N_~lWs;T3E=7Hgq zLg4jWH@@9WgXf6>H%}f3Yx2URy(_s zCXXq_UgK-GO7&pAQ@b0iX}QFqFIa2KZ4Mc<*T?C|m3lH!J(LqKv%ooR!(9{oYXZNt z@6oe?hFhGalkAS^#Kl$y z{TLrMQ_Z~0f(;z9NL`N{XhLW~*0-KuCzBu`cHATiGhgfDG+W><*=>}4GFJ_P!_ap~ z>QC3|MhU%_uD`TrV=N(wNgt6=9J^+mnbwj-y>Z5C!XiKE9s*|SuSAwlZUrKKz8z|o zX#}9$$xS+s*E3`p#6pM2Zb*?YJ{G4_;?)3x^+_aSrQ_LE{jydZ9&r0IFUeg zz9Plmfh1m-E{2htFL_g`F!;L8FS(1=){ghRw!!!2kjFT0~B zaf;PSFNS7I3!FT-aN2#<-GGF>olM0~6x;9)RhKYj5j*P8@_YAC)B5dUbnZgvw|1De z?$@-c9Kr-)?idI5HMoBZ?iX^xkSK~p;_*Jh*d7S_asx;&BRHRQ@F1-gnnONHX&k!%iV`_+`f&l*rruM)* z{h(v??XeyjbtmDZx%3s@hcB(kVZl*HI^SPzjZ4KEcZZ>Hp-yy~cV>icp>h7iBx-ri zUVgz$|7sVb2tRT6Es1P|x9JkAo?rwc=N^QOOk?bamB*rUGV=h^8GmAHP)>ULFAm@j zmHY@7nw1I)sdyDc=0rGLZeU`@mA}RHf_JpLsRn0A=pl;Oo&ph{+cr=lcj+0cV=Hm9 z)k-Ud=BE~keEmaagX#X6>Om+DazV?b9c{26_ueThnMTYj2dja*Z6oOqjMQOr!DS+g zwXznS$TibSe)s}#iWv;nOmQMybiR5!{Zb@h)Wcf+rZ9vIX*VNH_J`HclQ%?^XIPsm zzi)uE@$6!mj~IeQ3+cmyQ2Sz|Ml7Y^Iw!q_df2M$xBCYlJ4?1&6=-wFV4pq0hv0?i zD&7(spoNkQ9^<)FVzgOCdEw|n(klzizV2-7(59qQy^R%lCoXoXAniXgXRu)Vnm=5& zqkb1_jXP3@s;K2-qP^<HSQS`DEI(G6uTw#pRx z)T9^}_M632hsHzkU84_wX|w1IDzGq`rb1Q_fy<=yNn%BTT=wKGSDR-Uo@BRUmon#3 z9`H_aSgDr=vN@uX&RNrRi_bg~s^5&J>GF}vT17a51Pz|7iAQ)#Y0BTp=!t)e{iv%% z;K|3Dp)g2Q%#N^$?DoqSQ14>KaJ>P0yae$vNw$cWvhBY_3eveQ!e@VcsE%OM0_qG} z${YzFThqKn_=`HOJ{7B(J5rCT=;xf;sFd2_$0?0svn@iZ2Q8iCUBEFvE=7ZFGqN6O zIJzy4WIwP}hbaf6AzbF_Xr=MM&tqeB;7Q$aW_iIqrpgvks+Wkk*uV}9Vg3^yb-K{` z)uKzvOqr+A^Z52$r+L>Bmc^}(IBLo`oVzc6SCUALI~kgJcL{S_E3<*@LE^|n6voV_ zYrw6uqA_k3es?|k&d-zbDZ5bn_(b9mY4S@+KEj7l7i3RmV~bb4GL{JSr^g($y%AN3 zWE+lD)Qt!7X!u=HkN>Wew1=a#P|NAr>Miw#hu6RKv{0i(Z>{a^d{IcW7<&>F-WrY~ zQJT{Er_;?gj=h~_IA~YOv>oKC+GK*tnF!6p34DsO9}yr3Oxu-By2QI9)@fbSipFCq zuO1n*MObSQWC0y&51wGpV5U&k(L{1JqC7Q>4_Z1T^5H)rTsv90pe>Xp@zf)K$^#_| zqY4bEkH-|ZFQxu9qT-*xUC7}UVsA_}o()QkC$%spMt9Q756`G5>7{5Y{nInbpL~7< zJaFin=mp*?MIAXR+lrNyL8rK8T+4Gq<+1#ZWSJzf^+-MPCp?%);equ&nBuWD{<^bq z7xh*fBk1ad(86|)_N=Qo+U#ImfV=P{?x4BX%u0PBLl4Vfpo}jFFCe}=c^Hv#MbX(s z`6>5k#4ZF(W2k<;kE_?lCgV}mrz#sBfNT=dhVq4uf&4CRorAOxmE(J0p+AG4g_l6u zV6_HmV~pdd=T7{Tn~v#yB9%1o{cGwYBaQrS@r^Y?i^&3x!th{|IstN$-2IPy>$pR) z5My33OO{(9h`hHmJ9jJ-bJ-%sjg2bC(}>&H&_lS!?YXM#1+*?p*H8EJ&fL#!9c`Sy zWb@(LeJ&Xl!0w^qGst{^Lc~&Y<#IK=njaYQSc_ob3q?0(>&k*LiobZ6N@EK;oq-CP zEa&X>j8moEEGTG7k5#IDn`Gl#C@^VtDj^OCJ=f_(EqqhpGX+H>i>wEam?JxY^{ z7T1$5oZ!C(4>ydP9PO+oFDmP5H0P)sL*5RX*1cjkfDOj;5z|b4TsZum8B9KIXk1S; z@{B9FNMPD!off}pr09aHhLZ1Ro83xRd40A^PP+sX-jm!&p%_lHUdbnxCBaW7DVaTX z@R>dE|Ej+|ed|lKmdrA1|ERU@(xUo&cW7q1SuNQv$tS`rnuIv1u@q&u*2w*-i9hdp6(u!H)jOZ+>>n&%o{Ahd zC39NuAMItESQ9oWTjT@G`e;9=&9L9|96_qno zYhdDCY^QCOk%@?m;rmGqW-N^f+!%{3^kjPYiofH&46!Ab4Q_nMEjNyro$goX!Z_vV z`gga9b5=t`T>zKjY@#Vho&2`@9k%5x(e<*RoxX(Di0`rjiduV0>;5v^R_-2Tlf&Cd z^(Px$Fs1vGgt`O-d}9!XVZ0)?pPUC9+o|+Rn&(MPt~F;HePvY-P8bB@(Y=oHPXwm1 zn?BZt7XRJwA(1TFdi0g~PLEkr^<;U3OOIGmqfYKHh62lU3;cGo2<6{>U+yi!=t#S) z#PVKRBXK6%NW0#3wzPM4n;%6BAKD92306yC`BqE4jq>9S+qB{8nLK8%bBWV+cb=|} z)Peo18fuP{SsJc|tz((_WQ95JV*8a9O);UQ5+NvMbxK@Jh?jlS&%QGetL`~GmfF;h z1XJUgM<1U-#{8Uvge7<%Nvdi-`$+g5_J=ss$60Vz5CN7$faN-0g_+^n7d(F8?P3xf zO_@b+oyW!LT^%@ULt?*dnCCWtIVC^V=~XvBMgR1E2h*}A;|}vKn03)N^FpI=w+Y{b z+tCD+*P~zj&f99uVlra{Up~}CxauuvgfT2V9bkL7tCo$z-!D!Itr$LO1TO6^`QX&S6l8-DS@JA0IOc1moWEMQIp z%rPAl-RzC%C}&>0e74#9*GMIBKQsJ70t;5O=i*T7c=mU(BXE)>A@C1Qf+5Q+VkSVI z#UbK;Z4?#xJU0nW7*)rvU^1;;!7&_b~~CV2MaC3_uI?z6Y9_tQ1v=nXL?tR9D8=8j~AEpe={^R zQ5KQp~CCsRgSLw2>K9_w}KHQ zh}8bbQ2wx8LO4Z8L&crWlcYk}DNCG_Hy0Fr0<}s~7w6Cc4Ng{$4-Zgak7AuREjr_{ zI-zw6&!(FdzL%$NVF!DD)ZEZsa@XTg@m;nhZ3`M0-HIo*DvWscl^wz=QRX(_060!b zw-IgZq`I=V5d}~|no6QF+r3WEVlH~!E67jUs>xSQ2#@-bnz31ISYL8?$9p0@=mB*u z(~)5;jc$?X@U0g53EdIs$lGDL-iqS_Gt-310F+sEgWTQ@#&%>3#d?_N!7nN; z(g($AQ-{q48^`7>T|O?k>*WVUWcm^L|9gqMh{LnbM!qwf1ssB;69$mI>6r=SDcb(C zNL0WJouW_1^W?F63zBj>AWF59E`xJ$wPy47~jE= zX(3HdOf|6fStuysl7wfIo=Fxia9^QPb$us2;X|JYG~`R#Or;LKcAoL^%)uMy;rWGn z=zs~|9ne9@Gy5nMwk8>!RbcIr$Ko-*b3jb~iIj>gQPS0So5M%E_)KKHqE9!Y3Qtco zKTl8Iv?4*E{GVB|C(7FW2wp7}LIp*^Lwlk(x)w(FOO&j`?r!W79xbG{O{6DcX0}z1 zN1ds5Y$ZR0M;WFsB;K;0#z{{$}0x$Nv=sJYoNL4r8C8X;aw*kpi~&h2Q9=g<;l}hEl~!i$>R{ zP=y#90OzD|Dsa{%y@dJr;fh^)N=eY9Y&`xOjx~IFf^^pT#_YZ41pd= zLa{81Zox<6?{tQF^Yafwp*D{jD^;Pegoo#c#o0VitT3v(@U{IVT^v2Wq^%n6qcI5C zqe=BiX$vF7)A-v6ceTtC-_Lv={0~(F_@#{@qQ@qX#kvNX#4Xs+Fl)eE67w#!xv#wj zL~AvORx67Yn9&N`xjFXW#an*6Eh~qco%17iE|2>57>K8w`rXbT@q`gvFFBUv!x~w9 zvGuiMcpxKNJHhPOcGCHMi24ZfUpdZMw*J{DTaP~${T{wWv{y`PIHAkjy6qC?WsS6F z(j7pC`0Zp-^+=Meqt}wY4ybOaqUz}+u(n6it^vkybR!+{FX?9$Q|6!R=U_%d!^I=2 zTi4D4wuf|aQGc$Jz@y11D<5WUBBUW5 z{$I5+FF$Dux158>2FNMj!TT)f_9W5Q-dusS!rcw~}Krrp#q_-nP2 zTZ1t;Gcv^w5A^DvRIa-u#dn18W6NF#Xk9i68!5}OM<2$uCF^m&5BxK?+mp(Q0AcKt zm9y*9pQ@O@v$I3jVcf=la(`uZP2}%F1ugF%5%Od4?*msMYK;DVA{P2zqPL4oZ{6g? zsE6GH=slpb+khu~9WkrBP$26h3*PxP#GA?ho{>G@NgWLSIK|McSpoJ1lKG7?T60_u zq#*yWAfHPodIIh@4#AKKgLUfQRQey9{@L!I`FtAo9U$=s(1%CjvYzeW|Nh|)TsK>M zFD!5xEXv`VeG_}YQw+}-((lJai*}-MttVzOC<6oor%t=Gu?K>L(%490WXG&2OWWh@ za^=;Wmt)dP4)IuS$lNQG{k*4GVdSBX>|!G9v2$v=U!4#kJ}Z_`(7{+K;f0Vbx;s|R z7O1yuL?bgF2h);AIw0Jg3|7dh8D>u^CK4Iqv(5DpmS~0L$els+6ib%AruN6+t>gQ} zN}EP*m?{(O>|(8~K=%0QQHks!rf)h*#L`C`=OibDdr*gL^~>v$`GYgvTh*b&-spbu zUGwO6(v4k=BS9njBg|!^HPIvXh7hMARpKNvJ@GfKin7&NufYP44pM;lNde+-h)dJ{ z!m#tzQux(pgcTh!{Ej9bBg3!qE~(`>GP+;V7=I=L(o2-mj8aHLwYT{Kd{XhTrVnT_ zh^FZ%FV2!}K^@^ze<IE#Uh)G3@eiH2@n;ijAJ!S5 z*fU@Sg~LSc1f~xZ+6V9#3SajL@;_~zb{xSJ$t9{a!;vC#nfOet{+%N#A+;;r^R0gZ ziaEhf;qN{m-+{}99n)gH!OUxCV{kvDwGTwNL&uf@i17MH59-xmAK%IiPus9)6o4yk z^$b>QaOFELkWJ(V;)?5h*suJy{%R~MJs=APPXT~uKQ-q%AH^+qpto^J#&&Q!NvmDc` z%XbQo=|+Ccwfro7!kIkyWOt+78px<3J=YnvP#@^KjNejk02BeegeNl0BoD!~VuE3i z4GC)PNts&ZRDJ9ki)3T^=6PbTMQ?WgmuNlh{-5QTJ!+pU>iV_gJIvEnu$h3yTS!m& z{!XA0g&M*?+9NS7fXpm=NVM=jh&E=3tyidrwUQsf_Sl?VpPs1|`mQa2X^`!|@NAa8 zGT42-s^PN>tGSqe>>l;VlmX4DQ^Uj!)AUc{2mR>GVnB}mc>o1fAJ}R4<8`OWXMx0H zv}%$)Ybp{Si(dC!r(X zk=vUh6M+7W$Ef-MMN`I`XCvosT8HRfak%$@k3b1GF}!d(0--zPL`hFe8bo=apa@oc$*n^v&SZ zE;pEG(NMX&pEZqT$|Puw^iu^6*R$fNByF^cEN!U+%xmQH86Y2!6qB^$@^=~t3LFn6 z76;ftMn{zVAtGDcwZ*~T0?=Eu^3a$3x%Iw#39|BJ-T1l@BxVR2#OAwCKAE+#DPaU=V(Wdx&Tw$ebq1Q69j0h$V6c)DVU{88iBSW(Ze+qJOWTqS#p?F^{|Y8m|M!M z*pObTbuA`M(?1i%{IOioZ-7tta=6N%j25_!CSEZsgX5c4%E(G_IKhM!W|fk(-keQ- zh|IUYg9v<>KLX6NaRXjQ0C?2~(!RKOHjKgE^uS_Dp+V$IP)WucoEdYY?M!XQz#R?U z+Wy_OWGf!V8!!d_=D_z$1f3D!?QpYNSZ2DCHJH@Gsbg*+k1kBPdx&+#(!s}CYPmZq zb8t8OJ95j{01#}sw0PAZ#%Gb~yS;GL)}Tf4DmPN_ztJnAIGZ^2-SMZ?Uo+Pr@DUSJ zcCa+cQFFo2ga|)r3n>OuTM{J`mi>g1EjO>{gwjZOj88fvmXZ$44IZqEgGT!i=NeQE zS=PTfk>Q@j`hx^jQa2h0Y9t}R&7rz-5MV66MGTSKJV7KCF{qpFia-f{#7GBr~x94iiT{44O;>? z+5Irj3u}l9bzY_KNQEJpj_x=Z(J$U6kgKX1yA?OF5_NPSxpmE8hi{TC6iW;Ssa&^D zVl$qQex=_1DI-&e6qlzCN(ASKxuJoX^Z!!0nXcN|njxGd<|ds;fpn6z>F9=RAart0 za?cLLfU>Dm^ke8oG$WRn3goExiBP(969b2Q%L1KLYXls(8c*sbj{|*zI$;3go}qBc ze(!2@hC~zp$DVLZAQz=RUd!FraH3IwEph6-3o>8nz;5!@wdok%HD$fvhU^_E&sl7x z%T&|mbT?clmFvhnCgi~48itYpjSr8lcQnQHT&rd3S}nR;?(7suFf?VmsQO!mI9_-Q z1Rh{#Q@o*B^K{a!0WR{3&3r>LHc?sH=rvjLX~0X+C-TRjpeiE(sqawp-VU<-$p=1# z`cHM^!ar2u$sAupl|*@uf6;|&$$$f+HjZkenRRu8v0Zz{MRTvPG1@0kU=D&yQ*?Lt3*L+-g5vET%_*2I)Ttlx0-5 zcII?<$WeL@u1+XesfOGeiTnQz?Lq16=fmn(_pwMU`*1G9_EFaQqpZTj{x!z;DHeJCFwRiA|OI~t?@{F7uhYvvQ1XfI!{zQM!!9TbaNy+M`rmS7&5Tr_QCwsq(Z2dRCN;-g! zXm96=su?D5s&^k|WDDsQ{jc97)nGO~8(ArNmbCKEeXF;4j6tuxy*wgGbC~eI$nm^{ ztjKW!uK1*#BENN|m@(uaLexL&2A5wGdJvv`$ik`B%m=v2b(7=hrpY0J+JJ1H1erz- zeO4U?!**m{ylI|f%}YqP=9uMcu)jTmEG(0*!v;(sNMfwgd_#;E0WsbI#CW>c{6e>A z>c$1zt{Vk>E;V-#kf@n|N_{d+75JYuI4MY3i!+XVShAlXsK>Ut^&6L7X+E@Xu;P)d z@mj1rK+KCXZ%1}|Kb>gW3cL-~=s6@w1E~;*1%Kmv1yxA7H!Df0m!>v3;iK6Lx;;D5 zUm!U>x^ujtx$_c=>35UEg;@|K2nog3u)rGXEP%wpb``JX_5!)yCz=k!e5Zd&eRHqN z!t@9z3#;(8LjZi1lFVd`%G??nk=P{nrr>;mBtbcXww~B@@E`lV#~K=0QwBir$H;ZG zn;E-d@=Of(mE;ay5pUBnm1mFbh_9Kx!WGI0sUU?6U>t zy~yNmNiwPGt`+4hth@LaxlF%?1`qk6>7M6~L=_)K1pzx8|5@Cj=D(d_9#Zh^FHO&| zw31G!^r#!M1$-~BUAgUcHk=_Clx9)Yn&t)(#m_z-p- z-ot%?&bt;MIXk1@aAlTxy6FEZQqLUP?yFIGLsZ4mASCv>@3sCC#?lhK7KonK+oC2-4@T1WhZ)>1VGv3lFD0F9Aa+mFI z?obQf_73|luqQH-l~9QGETIrZKo;c$&o+2hh^sNF?)R;@xs_;DhbAyum|_^<_=rRi z1RA=M@bCOApSS$SjPhmLmMpeBWr|mc@59k+@6>{plBx!(erIb^oOWmxWcC4Nxx)cY zEoSWmtE%H)Le0*aA06gcsuawo*D%=H@NaizlOn4>#OaL!AbVrGf&W814Q( zV8p=f%r!11SHy&FF^3!|ZB~;Iy2af;{11w&hL8xz%Zw@*SkSNGwhHPIXjL1ABP}>F ztTrkg+6EfzAZ?fWnE2%_|3#+lFb+A;3p>%nnm!>qaxmF#Fs_gfbyDKE75md)j1BSEW0WwY(t%P`fYLo0Dg|EmT+ZO`cR?wSPFQ^ zwfg}NDJ`ZoDD{~uXgmJR^NVi}ODsE~u$5Fi;y)#`*w9;1c}&>^tnepkz$?Av|CytB zL~tZ-h4zm2aZf)erlnJAg)Kl+|7PY+p#E1|D4!ezQG=P&F)k_Z5x4pcCNBh-Jcz$I zs&4ES(XW++F^A8sgV)6&?S}d8Cds=&pzlH3w|G1t z>#=3!wQ&v97`iBJz-1{oNUql{R9$0??vb^ZCX*X&7ui{4&Umj!8NeIzcFo|Nn;Dj| zUtA73DD(~ME(roh(dsSN5Mn|X2_Y7J)r%vpwL(+tt8&^o_1{>_V-H$i>^z@j5-&2Z zS&bW*!iUAu8H?=R{#O}#_)Y)BY#1uZcjO!c47)^{ob3+gZ^w9i!6lacD9AoOO*M>x ziGTVUfnK+j0Rqh?r;}~%IhxD9H)=eOfdE({c0}QS8rEMNAs!W&O~j+3FJVZ7{$IzM zJ6}oE0zgpmM^jEL)B`tc0+&NB7Re^$MdZ?aED{>M+U~EPVci2<90*TZxaq7~-Za{) zL1z`sgve!5Jhj2~AhhNhOWYJtL=7z@)yvXSUiUiXMo*_R1~>dSnn0>%t7_Wj=vIT} z89iXNnvrDuj0CQcEx5$EFj6FX$mt)xMO?T~F9zf#IjS>?GnXYS&sID28 z>)y5(3IMuZZ%v20O-?tj=Wd`*Yam-hd{{z`5Y0NXaebGZkGMZ{n5m5&q+vB_uSdZ6 zq*;jx)IP^K01-VZu$!KZwV#Sj)Z;t1bp6E zB+VJY%P55{e?y>i0D(S(86jhp=vS6n0ebH8^@Qd%a{hz(DmD_9ku!gqsm_~3^2^5r z5&`AtEb}smrLie$N6Mbkg>o$Q0@>aG)*YE0|5+)q32hw#jlb#+b7QxlR@?p@bL_)H ze~VWYfb7m0e1pMQK#RLZN#|d13YGQ zYp`i*@!?Gt3j|qgH~!9qjYR>9^$$*ImSt=tEBfcA-HXKnkb^crQILbSw3`M<4tZS9 zPKBwLGsuYlBP--%0qEKEaSieOFUS`k8s5p9wULENenAp_@GqwS;#k+?6LCNe3siH@ zk%amGMjoN#U_=6NIOXJ9-Dui=T=3HKA5$uFFqcZehAVtZPr~P*qBnLxP8mKsHaku|Wd#L7NU$WK>;91}UgD%pZ z%0pz(U}nF>&HwFTiGUuK+WK#?rh9=)*TIfJ20N$^rK8=-$}OcxpD+kEA}9us1++W= z)!3I7!Hf5S>0Ox@y;#()K|98fO%J5d+5*G3IRljAJV3|D1L2#!!$yw%QgUgt3?fuk z+xwy5UGC-ZN`BAQ>R*4$gz2_e>0{JiSrj-w?v|SfO`kNL5xjhd)qJ|Ka5Ks(J50)yQn01#BwSHhH^t)+C{brKphkcx3!y<5k(#dc1a>|b-1vx-v-|2#7=+P__ev5 z?d%(`O=I&3yx;k|+H>ry6(#HSoA2UW5r;kcUTZ)T#S%5$#&(wNv_1T<%f0ZFiH6p} z*t#BSHjgIanJwG4^U5b=kgJ|cswJOY7N?RKITD(nH2B-Cl(&7d0hIS{(`%) z>#t+e)kr^iQ^Vhir8s_SB@FO`qsfQo*!Vs_R*%aWTc(*U@kajizuceRw`khB-0t~f z&gkSao88FEXMWM>ssH5faNXoZ(cbj4x)3M(k%|ZP>M&C*IaA1XB2|6`=vv28$J{@) zrYPbRTH6nO#==>5;R}2WokZbfz{uv<@!hA;2tKZiOw*`We$C{LxfIV1Oi1wY)elqp zjk3$xc{7*!X@qmz9mdaPveNhJwhCEhwJzDtI|b^hFLqw9_2u`EKbqCM!w?zaU5xhW zK&2RMMg;s4N2ym;onVhc?RM?SR$1@F8DeF_`07>6aogu~L#M@Gc8{op%qj&qyjdCL zmE=}CK4RF0L_JB4%A)Z44Jmq3rD{emory!?Ag=NIL~v;mIPCsIG%*KmracnBFCJo| zftg=b7@3MP$iA6Qa&F4?>8EuWl+|(bu_W~7>M4{y3{9DN^&qr4RQ!joYK$JA2Qgwu z-85;op=pB@e^%=#`Hz8(Rhi?_d0pS}SzZ4#3(lfCm8I3d-)0F$M%z2ug)FalNhiHwHtG!DT#$3tl-g2KOX8GXRa5Y+eNfA&KFmmue6S|mW!S! z34mu#QLLIltj77?CYfupv=~xNYTq4r&~VYHS63v|JD;c3l~~U?Lwnoj&s@7c)$`X!vnhqH@KIYVU+HPDsQ(Fb4yr=l~$N&Io^(D zy!_ji*Snukne6v*p@b*n)3VyL4C7B?tIlW@kdLA19i#pCyyno_u2kmGN<}HShf906 zY~ABjRKM3{&tA?S_uI?5I8-|RZJq4wWz)-X^^A6Qpvc=jr*jYa+)=OF{G| z(T--J{9DqS;}`LjJ#qVxeKfPe11y^EM-+H|w^jVmbi^nqhD$TZ*rc=_*vR&#aV(PS z8~!?-xy-uCZLot2rOiRT;M4zXKS%HvieLAFhm#C5ySB4acF+kei^gAC8k-hR=p>$| z=y*;3Za+%ceNOAAO0jW{FEWlN9~-c9>+jR8L~d%JDQcpIuXZb&<=<3&pufvM(0=%I zxz{rq+t(A?;B4I=T5{eY8zjXt*V{#a_lWKe>I;@D$1Cl9Us8D~Hk{7=g@p^b1oktx z2c2lfU3*w8ZtO|hhi#$#=H{-y&NoN<`h5GISrpbfJxElCbp}z#3{_4agnerS??+@} zzVPML=?;sMRb_nJk@L-`8#Xs%I3H>(WBODbkoLfBO{(j066F0|^lUaO6we??XgrKB zKxuxhYVr@M(a=F#m2A_t)~C(7D;u(&Y24z7**7%$_lmQ*vDLwYCp6Im$M1C+D!zO5 z7njrd7Fzsqr&hnC5gLog#B;^Jn_*QK$l^Rch^cN;AM`0KYg8uU4|rPEEI5D)MU}65 zLx>?PWhVNDUO=YSEI(-Q)NX4M&q&KOslkTkJFF1*#Us!KY!Q;r&jpk8Pp~>ocu%kh)g3IV#~g?P zA(Rc@NG|LQy zo7UkV1Gpz}ZZH$P5d9R}ljqQBu!-iJ8(Rz9J)HB!){^kn;_FwkaJ{7{aBsb8$c;xh zk%FrfH26-VN!mP41w@LYJ$_3}<_`Ux4>?^&9L{7gl3#Gk=mG_; z`O4@@WIpTkB;fmfh8{|NQUKL#kDjiCeM_&J0zoW8f@=wKP)af6(j)nSe)6fUcX?tT?r?kH`HRt;!*3H_>Y*c+Xv>0vi~DV_~kUqZdUq(GjWidRqPp z9<>7Pjr)oHX&7xkY?~5l{gcP-goYHOw1>nu9uAEFjbWpl<;m)!5baHHJrcv;PbI!k zmYFI#D(Zd}Vxs~m-chQJio&la{gJJWeHKYqf{!miwiqChH=lRQ1MRPm{&XIVo`kph zZ4?42&T%mXh3~7}{)oJZ>wC*>bhQldx?71b@_@f5!7hw-N4uzDi(Uj^1nsuw74z$1B=ZE7eLXa*ici<9S!>#Xti!*t}IzQBu672KRF|$6@JG&U(Zkjx|tZLe1-`f7nd8Nzpn<@ExPp6@UZKzM` z*XPns3)A~8N;-~IpU!WeETp>DJ6)}3&6*wejV>3RO(viZiiCHR8P!!>q@wY!l;iM- zCH+k6`n-a4MxR@&f?^cuSU(KqW%}P?_o>Hke;uGO%N~EjcJGB5d3=3icsN5!Vn}QN ztvvRUcq)l_xCBp_*+XY8*{%KHZ)dHWZD&okYYC@8S<|YX2Cw6d>XJWw9{-X`pYpUC z9&bms*4JU4bu``P+mp{=EaDkkaZhuamirfnXmtVCPszno8`STIn9>qNNm0&SQqm&3 z*jOoa+XKp?^{Bg!^$EX-Hhj_GA$EE*cY4O40Nx*2RY&yd4;*e|+q_ir4p|rf2di8Kn|Noddc91OZO;F;?eZ zMl1HaQBU7rx&2_uI+Wt*pc5VNdU^sstq@%16uO5~_8zH5GE(q^Jq{R2S?>b94OKQ2 zXmf+}2TuGKu`%`ictvSN`V%qx)O1`4Ys{#(GQQZg7IkQRVfgWMhcLqONq@Lk9X=D; zQ~Q)4(mC^uGW4kes8NXKz#w}a=tyb!$D(-PSt>=(jXK}HZC`n~AQ$kKzemBk?e=z# zl$lgxUH&fXfU-}$ZaM2g@ArZF_lFk)W}kjnD)s~^3`^`B_LpiGhS~43Z9`|;Y^Zjb z+t9>UpVEExtq*+FRR}dAO&J>?{XK!dSNOUOoTolt5`3}(rGpFIAur9{9T|cXbC+I=8?N664@C4d z{XM{Gzg(ZzW7rzMtm3E1IO(NVFD3td>D4N)|o(bRC6m^Hf`UCAjUaHt&0A&ey{=V%{*(}CNo{gOfVA4b)U^GU{*3JZPh zOwIgVsWb6D?*F6et)rsszOdn87+^qR=!T)Y8xe*sN$Hl7ZlrMt>5`U^?huqNX%GRC zZX`rXq&vRb=l8yAeeXYvEN9(^v-8^5KKDL>Hj31re_-GTGH7hsRmjFptn^=}^K&xD z55Of8T?O)FJV}R}+k})8>rnFe)v$mrZ`AwZ7pET!)7OZ$2VcI5FO_7UoPRB@6G;U!l9=2ZdTuOqixKrRsREpt7 z#0IM6`_wQ-SUnXR{-C*}P;mUNC*SVJmk(fmzIOYj$38rrh1 zLg}X2d|zLMgNKolp`ltf5cv)|g*BY@@)*BF)i+QuwQE8OQ-z^a3S||$gmEG&3bMeZ0qlx`IfNV95t5xUN$&@3YoA%670_mk^aIW(%-mjEepgh_Cet~=YgOUv>l zPfA_=O%Hfpj{=vWv$}pVIlC%Rjc#6L83Mc~)a2V%tf(d%jkWTo{SV$Tb>&l;I;}%# zT3KZLG?881j2#x7EG%B@1+RcwPu*;G^UCKpQ^n5wib!ChKjA>6g{l}jIF#!H1c?(E z3aJaZIlfNW9&$&&bkFG#D%>ynHS?`;u=mQ%{_R9UwI*e@Ol4XN2AuU`8B_M-!|sXY z=|$d0o`5-V#QI$E;z#TxBOK7b2yg=YVRA%4boqz>xG`yy{pHe$6Tcmt>Uh z)i&EAxi0AlidFrdDqw<-{*dXOeK~p^*QNtid6e@Z{B0CN3)`e9qP4IM zMy{`Vn?rY#Upq0hqj3h9B0v?QMf||WbC}<3yS6RD_Vq>c*(J-LS zmI+Nuy$Z{B3JvjMgD_|qPx$Y55^Nq%u3yMSaBj_olwJGpYM+#o1G729OQ!FJV1ovy zuC_vt5zQU}2A&!6P|9WyM_>~6hHQ9APCN*oL<0;%my`zgYO7q+vUAgj+n`u;1l=my z5QmzSQ)SB}rA_|{%ilS*b{^;|V875Bcv~=Xv>WqePx}wf^;>*VmiM8 zMs3OHnSXRm-#af#Ox-=d0Y(y(8mo0mLI=I9s^>&L`v>(IwQ%VISBR>K;qB;LR&qw+ z?G9>v#7hRX>CWwkVY~X^xltYzp#|5R)zHG30v(_BYu#mK$pojR?gNqv1|)Sy&wh0q z`M2h@SNYY~Pgs@gUlQq#6p^+9d{!w}|la>L^Yg&9lUt1O))?SZ}k=mBehhkmyB?HhSP5unNK6MtE#+Q&>p>k3z1z8xdM*hI^1%( z@-@4>^{BKy*VgY+da@zA>^^-F#t8D6X}pK`9T(Yp9eV&Sl&`~3{er7iADD&&t}c$C zh1j50KUAZrrX8tnHq8p#2F_!X@^I>o$BZ!%*VkJO&LLhLIEg5)YJ67opC`LGVJYit&*6oBQYO{N@OAl6l0e}$?i#ee zHQDNyE-saiM{l5L>R_}tMzNPCy3fw>0Pu4Aw#1L=jc4t*WGjDT3TybzbU5@RjGsp1 z84hV31J*OEtA7`UT^?~!kU}!iG-*esk5;Tbt4Y5-O;lJT2SMbf#|kHL+Yl(WqNsgu z3?^xAkbPgm{y<3qP@bt&NEa5|CKWMI|L+iIW(kE153uT5O<``?dEnY(awlk`Vg zY$l;12tZ8^VjydTMZiumT3wAG1-k!vdpUazTOE)9=T){q)Ap?vRT-$9Oc;Wd3;vt& z=}otrGPPR7k3p~=p%d*BgpZeqd#&yW3XpRh1;n~fNTN9wMrKp1nKMT)jbXGN@v^ue zWzbyZFHjO)_12CEnBOj|X_72++tPW7Vh_{H0n1*G9t)Z8lr<9zPA5R4c-2(uocgZo zk)@bi_wEa?Y7q}kx|YwC%Z6ap83af%W40fVHZ?@F%?<2q2fVFAdHGjKwp1TLN?<#^ zKbT1D=-V7}x9P7&VH>^z0-p}7oUo4d3h{siIsjMmWhe$4ymn-Jf#hyy;?Z4aV|yAX z;@+XFf(Dnwa}}uQ{!oB4NqrWc@C#!gr7`6S=1QfFq69wD<03|4U(tE(6{FPxQc75t zcl8t&d~3q-15>l?mq(2mOC6JVh}sidC~&3Dls27!ECV5Qls#D`PKB`UacuB6W0l$*pV?HZVQXR6%P%@({p$b18W{vI zX1zvf5dYo2RL5$dx8LQ%>B`ElF>lL-K@|pzK!I(!HyxPQlTLP66}t3<$b8nu3H`u; z#y6kZTRN9rKRg7se=*B));dHw_0N{O_&eaTpcA@&W#!6Gr2i>z%Fbz+q-O=ouMI!4 z6of91!riI|)>nSM=>3))Kkjr`@t#!@nX$7EOALgNxLt{d)!TU4jyI_85Oz)cK|pqbvanv=rd$uGfo7OvGX0$l%b7 zlf?#XZ=iAjl(c?U@FVndAn-y+VjlL_40C|btRavBLF6ll@dohX6L?X6$`&zH-jdQ# zd{rfl(q#bWONRGb5}_MKfC+7ZEuTfCEja2!dd#x5Bi=0T0KU@^imwxj$x*DPn?ZnpgTt(z=?3 zFioelbngLQ61~w@nUi})_{yXNlqAxCvS|xOZgO2qa;khKF!e+mbcX`VS(r3}K>Un) z7Ko-ALDqzHhWitO1G&+DCG91q-kQ`zR-6eVW2(v{y2U*4c+}{E8pZnu zhCq-3j2-l!vEu;7zFXphmyJ!03I3aKh8xKmOAx6P$pEK{SAXQy~}9Qnc>`fFS^8Dg6yEfnHNq0Q$1cB*YLap zFY7pJ8JGeqI&CI_ffbt^*nkyHS$%g>(V}Y3{?OK-3x12l5QOxrR6a^;dKKhf9D(#b ze37bB638~4+XzNIwOpxxt~DtBMx^T0rz35p);?E|>AbGXV<;ak$w;D@E2RXE(lz~! z$IqCT-8wrbc{p00uto~F;+y5KiN$UKUM`w+B zj6WZ##8obdMC63O%b0{#u^nUdkiCp!dT`O(`0M+m1EaIHxNB77;rTj8JzP?bOfeeR z6->``1CKvn{~j;50oja;RkBcHRfnEGU`3kaeqTAhluM)jWCGE0EP1PlRX1Toq{A> zzc!yJP#O#4RQU&x3`W8>j{rXb)jQyUtbLINCn)NUI7oZKxI>H|+Jv7f*cc6!$E5aH z&Y)MHBnPT)iCBcJWSlxr+Q`#+WdpSaZuuoHF3%@Ra7r8s+oLzDK8*wRweG0*`>!8I zd#7&UJ2dYH8K)1y4;7ZUfR9{ll%HZKgSsmB@1!HPu;LoKE_S<1^aNuhggu?G3Usw6 z04!5xe(Yth@lHqni|5#^SB}>B#NVEB{`>#GwDiuxt|UUo*l(UW9$y$-8k`Wd{=Zgy z#&%Nhf&|et+5E<2v8|)bQg*ZpxTZi_vwDv>e4|odV|up__(`+c>eFV3 z{MCmHtBe3ozlf_2J`Fbi;`4xqKa1^U_w*gQ z&g7JXk-nR(dw@VzD`Rh@(KR(*Pb)t$F}4?^>T~ov4VLfN;i))R%uWB+cr$hz^mY4Q zGUzn;L|a;8$wB4*KL@Dzl9zT9up0XJrDsO6$i0U@GkZ=G+A-anDDVX!*Y9b+NuqOK zyqM5`;%jWLN#(l#S;G0WzoDid43b{(McvgtQm_YMbQrQ&xAaw)jogq9E10nl3yo5s zf*@9(_$WZZwjkftELRRME1jO;c*mspJ`j-F7AkQ7SY`EP5UsREkV?VL(5i%i6l1V7 z$({)duz6b}3Dd<5&@PCq-do{DLBz~qBmcRE3Mj&44H%~ULyrLkX%QzZiPXBmy%HLinbQ*HxZSmHr>3Sb_fwceE>dbIaEWYirO$?~duvxemFP<1_% zt^)@sv4;qu3_5a9LrHz<{If>T_poC2-bp*#0|=r=SURXgL})bS{X^YF)uE_IaWgVh z7arIjjLXVj#G!E%eI(^!iqy*kl zfq{Ql$isB4yH4Ew661Q{H!#a(>}tT+;xIh5rUC8Fp$vx(tI8wnD#;w%3`GTerMpj@ zkA2op-``+_PZuKb?nY zk1*R*5nwT1fZAPa)@4O!CF_gR;Ny+|&=c1@+_B62)ogd|D>yS=zW5$9>l4J5<(O`i zj0iOq(p{~`hagAK>JGeMK&c2X~;0p`&p+W!Z6JBLvEZRY;ED2T>NwQ>hH}S)OC}e z&lEoY!D*F*r%BNL$>9vTJCEnDyu zPWtgdN)x_W%F|`w1l2lLDrCNhuUGd2D=$+%bWT)=%0zK=rknwd1omG~4jW;T8w4y3 zd-W=6vqnU}^R)CEjl{lL4iE*_$PR#g9@WfBBFK-ldw%dED9zCgfY()dCW?=e{V4zy zW)Vk00TtR475Ay4rbbMB+47n7Wh)k$Bn&V51@^Fq|1-Y#qU(DS;iDlq(BHPf+shMmD6O_wqIG_$>k>P;0s+5z-4vK=aT-lWG)1Ks}jGacv=)yXc{Qp8jiCt}4T&z@YpJu}pXr-q*nb zN+cuFX{HTj_~_uz(%95~Y!#1B#=TK_%WXsJ{qxSQ;QCb&DVJc5G=T(3QyV)hI=zj5 z^=;I^REcz)L}qtO&9Q<|{2m*LOq_&sx2C)!z^H5FmHTYKssy1xf!lA39`dt>>9P>N zaK|f+7(VzC2A~_u8FXO9>f7b!71NG;ujAcM0XKeYkB@n-Z&oe`(C>?0HRw6l)boC- z@*bIN-vVrQR;2?B%-?SGZF{^pl`=OmH+Nb!TQM=en_4j^QIUX@kQl5v#iyBxS5Q#a zzQGzH-3f!%0hrOEO6v)N7oD=m2yW{T@{^0>uZYJ{sdWiLzm^DcOgAq&4Nig}YmB%+ z@C=&;byfPF)AmO~HCTHT&3Rw?-<}$YFqOQzPh37PwkO$eCZXMk@52X@{%R#P zO49n4W{3N2{MZn_myA!)w9gOlj2^|4O)+0RkrfRl`Nn#-VxwpVP^cvZ3wGyC*|*rS zr8iw&S0c0*%}<~V;UI><&og@J#`$ld43&3y(vaR^Rr~N6C`vgGyqD}Ph>s8qai#Wk ztlkekCZ%%{9E&wS&HE=h7*JdRqN4*@U+taD-TztnRmPM3`|+yvF){e{#mUY6%Z-?X*fe?rQrFxq9=?w2@azkWH8BJm!P z{BfyVmD1yjtJ_o1+cbKVsP8fbInj_4Dxpmqjt{``4qdz|mSYqwrbs1Fa=%uTB#Hvv zaME3!_&M>|r$+RFV?wq809#uCU5+dppv&=+80c~sq%qNlJSPQ+oHXpFwB`S&0FeXx zC5#*=ce?0zQ~rAk%O}rXG6BZJrf{s5XOzl zAbuFDF=AfD{MJCnF~?+{61aE+U#}1!h$i8Dc97&rsL7IRxvfr>ydpp8tiO^9?oJUD zDElG^Td5B}i1xBS11PA-y7!83L&qWGmpA5IOn=w)5M+^xz~3IO8vp_78SP%JGR`EY z64y5-bQ22E5fWVh{i3XAiHppirxbw2Tq0A$;TCPLc4`P;OK`Ju)}_hKJkmwMNtmFV zuqp)@A_y8izzQ9H4~M^39iaT^_2Q&$^!fL&w;UM%;5x1}h!Lf~k_3W?C|i5{<8r!j zGWBxgeC79&c^iJCpWprN1-gVntsvH5veA#`so%?h1Y1?YQKk)BJ?ntebQgIpJi>1} zT2@U=O&%K_z2BUN+}H28uL_-(glLw1R?Q(n0`-5+GwrRAy8n4B9v? z7oI|AbUkm`^^r{egmid)!uMn?8OW0}q75iXKqfPy1d%^9tUcN=Sbx#;1Na%m2H@JF z$4}SWW89mN&_;#+7R=_1-YL(|^=ynL(HcNx!_@yvs5HW&srI>XQ5}OYoFgas6GW%Q z>DqsNau$PXd3`CmuSS~{2tIDvm}tqZb<0nR*X5UMu5W0Z4-tClzGh#1pwz7 zuqf#@`L79vqqv`O)`JR6+;1Wn19=;9&+iGLD%+#G*{675kfaM&sG{Ao8WoWvEk=bD z#t`FzsD24CC&`zOul>Kjkgx|hg zol!N1Z5?e3pAten(Y7h?6$H4O4qXTI|ESL~#EFa4n=AR1)aOgf+g10sG4=p`yAdxd z@L$LgLQSH>cf|{8L^h|P5AgLZ^RJo!p=|BHQ1KEo@EFZEfxkxcY64spb~ZfH@6c25Q?bLGek~IK zAHIo7pe8};suu-7u z%~oc00zEGKJtmi@n*Wk_9-ANY`HN^7zDE9Y|P;rb-5Mc_gx!$$)XJ&0&ek#(kHH=9a!s|`#|3PNm zEKGnoau5(Gu&I%yrIt38Yy6SH9ykR!z0M{tA%XzW=pcY%EgFOs1Tc~b{}@Tf{H>5d z;7m?E!4nk70Jat^>u5FZ2q&LzkpQYHhu>vl+$-z?8*N*yCqQ7~ z`QOfw?UyhA#n+Yp;_EC9BBG(Kv8c-kw4f5U(IV=+AgmcXkj5Vg;x=6L>*e-&x_u z3Z{!{IBXp=I}kY8X1o@Qra&&@m?Ys=k8Ob@NA&!NLB9zK8^rK^K_!l&L@-1NbVXg^ zvR|hDIFG0|I|lu+YOQ{4CcMQ40ft}mx)lj_1F@nT(N>)6Ld=9My5Lmfnx%LDxZJt# zK`GYs_nMu&o?-kff%QkUD!o9N)Ys&LWX>3uudn}zv#9eL=q%cj%I_tmR;}c1Q*Yz^ zRz@F=?PnyZLq6vbaccM%MAWJC9zC_lPk-q(n!gTRJXv8s7TM!>5(}$va;WfxlilPZKYp2ocYB*MivcMcNZ78+ zk*`0u&o)`s2$a?&T-MP`(J#c>O*`)GxP!HVW}#vA+em{8WchcfF`Wd75r0{`HbA{$ z&6Kc8^u?RUyn1Qh4o7U|@fm@zO9}Eq`nDn}bgI8k?eoGg%?u#ukZG{Rs9FO;l z*Ud!}(|@9M4~13vSW9h4v*-!1qFdse{rPK!DS=j%?Pcj5{Yx>fy8lzQIP6K(;!reN z_(paV+G{ktgZfrW7QOG~LH(TN*=kre;F2w6)I86&|L>#<6893`5$ zL6s2d29R8lS|G?Y6G%v^mjhEKg{#% zSV7lCmbPE77>13KcM5JD_mA7CcOu;fhs)gbJxBKv&@sIHvjH9X4N^TPbSx5<0^3-KPA@V~%LLeFv6fSquB z26lpU&R@`^UU}u0?2a;94@j!c8*_gMeT>xUUiMCmXoL3DH?@lXh}@(nA?)QXRoq9n z1M$JU!STiq_zzK?v~x!I4|mY|W#x<)L93oa6$^l#@z)bYrCVm7_R=2zq*(u6pZgo} z*^(#DoUE!~m^s(g6ga@j;M#Sbc=Q|iXKO&X)O?yYm-{B!8;YlE{t8zN7r}v!@>iz} z5YH)Y76)ZdlNI;hz=H$-_u#AlJ(z6$kzWtJ14oeULjAi(5mH%r*LR;_J(0|Bv*t~> zl!(Gr8F>L{VL9x!rxv?w<$!QGk!;iY3E6U9L+EV^gZ10Q_Wt)wWA6=y(z0zozT?8g zUrrRQPr zqAy6_NhfExK#Y&;dqftB_l*HQ3uc&OxxSkCw>G(Z28C5l+2z(c>`Jt5U&#?av$FJO z*bM=fPHA>}pwXYT6OAYrqOUX0iBRDe!Mu*qD9QQjYu+&JNTWUi1^v&ui7>%2vq(cI zA7}#-V(1Edtn)(t*l1$IDR-9E5(Q8bf9x?+TbqVH;xiaSDJ)|m^O+EtQWT--p!(Yg zm|&eFHer=Urj&35YdtvPnx%&KkELyL zegRs3oL)1KG7#Qn+$VSdRKfEV=EJSZk03&tK^YOnU+e=gy_x(+hyJJP7%(hAs;f~B zMR}g+?@4DL;p#6LxHAbJHQKMN&hchgA*dg-w|N!#2=ioJ)HDw;^`8j z8K260*YK^vkR(?!Xty3?=D@r6ZPF9CI;{6R{Ry0=u4)YMJ&S+7_xmd>#~Q2xo)+9S z*e|5-23*ha-Vwx@6orKHjeIsJ4&Rn}$io#@qR6iX)rq~P-b}Q@FxDVOvHXkClpX`e zq!2Nqfu6Q}o8*eE{gD1F-6g9Nw+Y4$?#Bc-tpXo?>)zep^2reYWsPk-n!*`1@!_^| zbQr_FH*#fqT^uxl@pBFZG4W+r95jhx&0Bx7gIdQY7fq~5o78XyXh+HILuJZW?l}~{ z?DIPzU=;1 z_er@-pHvNGXN?_4o30MI_g$|57~By)|#tH&9#8A z63*@SFE;@L?B65UPQ*!+Jud0uuKi%TGd*IU{iD7&zNJ>JRIkw z*487V|H04GVT#(-Ie^-guJ;a~1-j}VdCfqxe5{w4hT@8<784W^a{aK+Obx_Iz&l+# z&J*uQHMgWd0UgPXu*#;hku74 z-+mH*PM#1jcLrSdW?$Bros9GCE(3B9Mj9%dp37CgqDzNL))tJFEmE6yALADCGJIR%>P*=Qa~(H*lEg==e}Kkol{ z1Y_^Az#F=2`Mk;_o+VHlJu7;|50J8JEPRxo=XLuKC09(1^}s)Q5H2pG`gyK^nEnR9 z1Bfc0GpP-fXwD@{M$~@vEF7T<0+koZVK4wXMS0_+S%hu3lK`O>i8Bd-sVjt9)3d$Z z?tV>(b*8TXn(MB`HigJ`C?;2ItF7;+#F>ZfdvW^v=&dss>{^(ldlTu&2JTv4dWbwlB zYEV<4SX?UQ&7?yS8g&ienEP!}sC6M{Hn}U*G)c^GX9UeFhIclGy*3yHkrP;~Kh4Qe zio@D$E&SA+><)_eD{v48_eyh<=uve)ex3v<6SAA(vrLbDsU`8e*7r4YA~o0haqa(5 zOy)^2wVhhs0dd>>5Gg<%dI9@&y5JHaFmbrKaW{InLFN52Pyv;=bECGbY|dv&W5AZ9 zN0jN;C(zca=4nZ*sFDG;;>xU=_*L6528_Y=h>q^mTtuT?UU1=o&zPbcLk|vLi2B92 z$)`3YIMsuZP7H@%0h%I;j>U74e_G zXY3cBCnwG3r-F8;KSzqSYkfcLi}uf~>rV7Ht6$>U`zoEK%_rH}xLl4a=(rbd?@^W8 z?fn$MUBRY;7*X%eb8tC4+`h0qLx7qD|liKC~^U zlwp!(=>NqLqZ*S18tkLFU}e|F!9^oeYRzn4s&3w}FcVzPf zTv6RU`wkbSE`Bi&*4T0oG+b=2bELq;N(uw&yLoR6^n|%=aw4>2+ZM5gNHO$Zc}`hg z;Me#F3#)BaMEg@xu#8bu46>rq6_?qWFsZu-ff%Z_3UoSvoIMCLm%k%LnMw!I<52FK zjjxV!b#Hx_?m zna}s5hq?bob`wpi>Oe;;Q{o(#y%aeZ|6Ld= z*!0;?sMqBd@Or1hDoTh??DxEkfgqrfx{59G?!toQ=N*%7%6JcV?-Qq=fns((zk8*X z{IooH6RSeU;!voM z9vW1a{_AQLN^z}KSF)yrs(4Vfpt@q+_=X>geh~`;tIfZgZRhaoyHKU1E>yI&>MzJ+ zO4o>N+1t!8;uhT$^=|G;Jg3n>%&62*H#nT}rW~sDVthmH=@Z{er!BevSKG8G#wv+| zPE=pAI(xNV-?A{k3wzz*fF5#?fF3ZTAb(LI5-GG!w%;PcXNuDwZ^!&m-}ZKryRdgo za0}S^RxwkDn=;bPPh5vi9FC)fCo#)~sJwkLNu+-CUPcBF6-wQna9m#>HgUU@nXeEG zcfypO><+nSqdUpng7l6#J+u>KnW=mm>wB*JSsi)|+=0BUfI&;&<_5}J>07eYb?Qbu zdft_x;@Kc_RA-{>UfkuCS+;Xj1vvlyY=d8u_j+ld^X~iiA4BbS%?axIo=n4w2-YBh zWr+%T8V}bYGR6}iyNr1Mcmre?s9pcr#`;T=_}JTlk$iVmx(bZ%IxfV_ETUz~<6a-6 zZ*XiNN7#p0GhcePlX73JZb|}nH*MlVp16pYPMLZ*=p>HgHTtH5J zy<4Ci-oIJ*;RK4t>Zz>f}- zUuWdoL&)eTmcDi2)_$O-it_qw%_vG*>f1@AZL?(&EmK#eRB+%k{22~9rFp<~*utnw zcVNJwaQ$wXH5l6ZOOG$9tk(V@C#HKW9=C3l9j8Bx+QMJ~>lKpj$EmJ%=>B;I>$b!V zT;FD@edyeQL*Ld%!{bNYwIowC6~~L~?1F8@Tw7#`#8~(8fOks5XKsJ&{^2&*=WKB# zcCy(Pefm>X6$0-ekSRaHAIk=U#6D2Tcla^CRUcLzdj{q^K{ZtMe}|5no$=T7!^OPe z_G)Y4^70ORpQ{leF)tl4Q|pHQe&xsQ*iGI*AWMeX$(KK~r|0}Pb-t`RB2zL>`IyI_ z7L(s3mA*CbFbMz4b<>aTL05w3v?cR=F43G+{>-I*VO%ZJ(&8T4qtneBU!{H7eGW1q z4wXItw`;S$1f2*%+uNd;VGKO4ZMc5OkqECoW8=teH%*e6C=hHje6v5sy%IlITivV# zKDMwSy_m{fcq{7v75m)dpoI6rMj#+c{Trj!JCg!6wzN$f^+1tn&We)9@TzykQhpp3kKG!Y z3{p9b5SZco&vV9D z>7~=T!gj)Y|xN6hgiQ3`y+;Mn?97#1J%`FBN49QM7I}- zfXw?q^3MrzR*d32+hZZ5`y-+&@#CV5&G)MB(4K4@NFGG>Vd;x9;6@9)sU-|L{szn5h+3?as{(naRV5 z%HciHIt-iDb=c@6g44;spWbdfYO|}+NabrqL-ZN7<}aVS1{$dcvv z0Zf9S?W@>^yoqi(eI{AD`ua<^l5aaHe0je$2}{gYzp9ZixyiIwDr1^&S$Rp>D#lk{%yc~?rvaw)l${Bm@!jKW{`AdoGVdN$%`+9Cb|?AG3f~Dj?Fn`MZ{K`7x)*8e8!fetIBs~U^wyen zwT^Rql7g=fTT?6R+?K|w)@Slae*4nPZ(6r(Tho-M z+i{nnrloT|XZYE|Gcj;~$KZG2Gm}NOzWT7lHQS$9k5odh1GG_TJ7s#x%3OJXH>CEr zPH6MEHOl^eFZH2iPTAje33!lx&=7NFXnS~GwrMHSp7CWshnnyC%*3Fe@QOdS;OU;5 zxymmvK4*xQ$S&khp$~8@64SxQr#kY!sUJNsZHZhV$hY;nsU3JdE%yf!|YJw%ZEg5UJbhsj+LBfb|d+m^BqR|VUKDU4>k3J6;O zkP5VyvjBx`YvIb-y?>`6*B1M!dT{I|L7IYGFFTgF3S`}nEfFn&l)40euC&&I#Bb{z zOzwg+b6q44U#R|S$Lxlqkt8e~tRmE5a4Teb}pi=TBbflrDud4c- zMH#(N+f}$_L4S(yq~qL?=&3Q*Top$PD(6t-i%m#4k|akbS-hRgv`N7oQc~nnc|L zvN-x~$}f!?Gkc-F?!EN<=${{F>hoSlF9(?|moc)V99f(sUB}ScglHW;bk^~G$1cmT zNr_OimauT5SLm9TTNbkth!o@{7G_f6Puo^8civ8_l_%ew7xa2t7agBOoE^m%qxMBC z!QyjC#8=cRnn}jrm_D&YK82Jo)pk8D=Z_N-yqy+N&sOT9Z|f|k!Acs+08z1e4&4T;29@LAfrUe6(663(kSSss+tnXb&^yp_A>547iyol z>chZz*e9d(+-)i>$!r9Yne_e1H&Pjjb75Jv2J~=08O+q|D*H+D1$oynveuA8{-nIB zS5h$E7wP)%kALa)VjrWTLzk@l*9piJW;+zUiyJyodcX?9ZP4 zFP{G0p9UX&N>a#_7R|SI5jf!FH7n3Eq{9jc6`9 z13?Dmd-ONEO1eBN{a#IhqSwFo@}_uVQwFA9!a4s|d1t zL6JI~Z1X2}Iqrz@UcN-N0>is1yq?V@$}6WgGh`m9AH`;S$Pv_AKl{Mrn-yWOxg+!k z*T>TfsWPA6DZAHK2d^g=``@sO952iaQ3@5J+u;f>Q1pm?gBXBH>?aEr?nNpqJ@lcGM~jxku^H^8hBH1JLC-I?n&W#wyjHo;dAw4y z4^QSg*Pt;-D`2j*ctfm$uK5VW8qE{mJ=*@pr%cfpOc+^C0j!J`C~0lVW!9vaFn}*( zEX;5(VJrs`l*~$~l~+EI_kP}s1!ol}JjAm4ln91WDifuk5F`9lQBosyZHHSkzWK~? z&=90}n;FXs&=93yBzQkZ*93`O)mfbQV!```;=X=fviEK??8r#v9A_@$(h1%y9i@_0 z`m)xf1)1U+zo-v1$P&-@?vD! z2I!3b4Dy*NM*SQM0o03Lx{^!CONXL~_WVPJ*w=!sPO55o91{Gky zFYACwwx&3mCf4t80aWigAa|!b zJa5jjwb3UtShO3?J10sWjX{o)WgT!;gdVTCP@Ga9rT`WAl>EbGPfkGzU*{cPVsuDc z(s1MuGIVm9n9&OF8B9EimAr2^WHPgHm`pFNz{C19vr|PTxxSXW0F(}4+6=MEjk`Zb za7%JpOJvbNJ#kWw4^eXrM76v|zw?Z9dQsUG&ZK=l)%kM|5*Jnzr+zy8hL_=QZu1H? zMg6L%XbX75k}mm zyAOEI-H%_QZ2u^h%yeY2kaTS@MT$+xIr5X(&@2BmJ_S&sEk-n+?H11H2ZFpo6woLm zvGOR|SR=>j;7(HL&kDw6Vu&ps@QpZBft-Gp_!JV}zDjP7>#8J9+?LDI<6!o9WPs~R zJ?`iO0WB#li3N??Mp$cYN@s4DWcG5G{+#$N@~*>REd5vQ5@;xdSyvvB7C>)n;oZ=t z9BGBYhG%QN;<%(njeth`jx1A(DZhvB<>AUGWuca?@_LPdY8Wm!q0rk3U)}&ISPTiY z4~t_u$Hs7&LQ;w-{9acA5F}h8D+a?8CoD-c)Gc4RQKNknyZ1T9ON>TbTWhp}m1&gl zB=s^d-53<@u$*pPEgcmlHKLXm5@6>waV$$mre2gXX#XTMWPp&fj87G8JCZNwv3-lr zZ?lu&4ZWD#X}PLH9NAG&kDjkzT%S032n3BwLV(L;#rQYE2~a68vK+pnJWK6Xo(72P zcxo^4%y-1`ucs2+pIOY%FpErZatm04LXzWu^mIPy2tjY>=dCV_RKcLuCwjlGBW|D5 zm_%+MS+MQS{J=hZ@Np8*mh|=y9q~*@eQO$svN+N+AM;X1F)K5a5hyOkas8=B%Te#S z6W7o77TCh4+v4!N_HpbzQ}K~HEgVtPH2gH9WQq==)vw!CuH+&!v!< zzi6KW-Xby_CrD;uocfBX?2a9)RmbssoTif6%S6iqUFT0yx^b1r>88nj+ zh9@9~zbUyTXA+P+6`&?Q-4PH{Oy^^~QhZEEPMet*^)5ay%3dUxK&kk}i2zeYfu+3F z)~6Ey*IY$Q5Xqe+EDz7zDJoPD734`w>o?2#kT|^#| z{HNGYa>PSBFKF-f|6}SagX#*FZgC0j?(P!Y@9CN8neJX|jXP9~OFD*_e7hao?3W}*c#aVp0+lw&Po2P9)l{d= zuC$9SAU1*SAh9G>u8ZsY&88N$5?g0pP;fwo#hlU>WEzAE0>x<-3=T9UdGLh#Y-&n= z*1P+sP*^`P7POT`u}P6nq(k_X7QkONHa=jTm{Q6IfPJ5$h_z+4;T{ z>IQP*By@}AmpWEv5Uc;XMwCPcbZwAneEwk2-jGJ^`|I+>X3RvzuNt2I#SogF9DmL; zugF}NySbDY1ygK&O)W(Mx~^j{bgJK)G`rI*ZN7Vl>^BxXyEeFVccLUkMLbc~Oe1y= z4Q8(?=MWbRdslfE2x5Aiq?qmAvANUfe>EWp0U2drZ=Bg1_eNhXgrFgXAh8~~Q00t( zO$Mg;3@afSaO5r$mwV)LBo96e&*DA$)NnU)3=xYhGy&5!@OobQ1|0PR;WXZpGoPbi zSZfFNod$N3UlmGfD-SpxtNH&;k-z_)BGp0Y%j}|CPz=%DZnA}hHR)(PqqfYc3eM0R zwX_A<218=N0CK#12uGksmow$T)R@s&yyE{M_i(v-OfG1F`~{PFADYbk9s`kLgpUb2 zHXJNZ4MbPG6Fxs$zJFkXjt(dG*U|A2N#ZqjPPO@&U_#^{k#GFKjCZP}Cdq-fM$t|9lZ#ke6Q(`~ovMPlI9Lk&me3#E`^oci~ zojK*ya+^VYNU|#3gT?7Ykqw^=+c=)N5QzLv{aFgpK4-q5oGR^dVAn!Ja|4&@d0NShvET?6LXgmhOm7LhoO^0>6pF7s6XkUdQ1 zbs0MGP6Ijd3)rX01hj*%G9js_MoOro*3U3GS427Xs^h#sZ0B4CSq4n)AI_lomp%*^ zhxSmE^2&HoJ zFAPW^$q+se1WJ*Nde9AF4K9N5OL7F7@J6juPAq>Sa|#L|5dhf7$P-k;I9@HIkuUXc;UQs3>(c z^bax=+8N9ubC&vEb)}rap1`odW{l2Xk~awR>@5U*6qzw!Uw5&JgmL;$(25BRoTqV2 zwtz#oIHGdLm8INm7TGV|9=~t=8w${O0|i})vr*y*tLpuGyagB%->`+a>Ix|jTt-5F z9k9EW4VPW&(3wNPCINGgBB^p)T%Qc{+Py=i7k5jk!LgyjiA|YRRDyp!H(iq2GBRCK zQnB6gZ#GRegnBKICZOp;@CLj?xy2Tg5O(_I&=viZjvQugMRnnqgiu#vb}@wW-2G3U zCI3=B&i5LZk5jHN`78&hD7B@@XR!(b0W_^8543#&^p$OkJfkBOCAS<2SO}WzgCngu)_1>53BQ@P@hv40`nxx&(jMJE$-mq_|CqC!ETHOL)+Pt={KfJ&ABOEYWT{P%Oxgj zB<`z%9RzYcUqV8iv*gkIXJXdOpi{P>6j#u~C>=*kgC)~DN=u6%NdoH}4t7E|{XndA z))qvd7&Kl_IIOBc0*^piQd^4X>8FCfKRwS9%*C3YzGdUBXMKLHU$Mut<1ce!0?(Pn+K#-;BtzZX`@yuIi%?&kju6R^EQgX?Wjj z`mQ+=aVb4WF9#2Y(5{NS7#Elx#QNl4U<8zyG+>6B5-xu*6vdDZ3 z>D7&q1Xz?&P6@TNC>~>OgH@8iB@)6zx3{uA#wBfW2d=7OTYnc@;=)#PH9`~Bo=Ahk z?C`5JWGQC)4Ltr%0thCi<0jQ1v8a`okOmrC6B8VG*QE+WSPVsTxstA3j*VPpx5}_- zDbdhS)LLd!*n&x?ZCC-2zO%51a2)IV**)uXI}48=npIbd&&Q2?pAlVLA~{!0MS+vf zDh(jRc#<6ANkLL3yHkxn%SGdZN(W_?JOfIk1qoC!$rg**0jNTt{4Xp1pYnfM)6B5Q zz7{pASSQ!{rIuS|+O*VLNGfXW2UD7VFP0McUc=$l5;bapQBa>XY1*rfN5Yo3c0I9Y zfsO)0Y|YvOXsjY*e_l`&fb5D^MyGPuTc3P8T_s&vqUBGzNuLN3fTn;&?5>aKI&CK| zO$udis$3az;-Nyek5SawetdUL+AW@ZxnZA?S`Ohv$3R;lIKC$G=9sx`>UigFVSAQN z@LLZ#oO*-9RdNST1>I*QMB?#vOd=rLoiDr49#kv8a5cjE{Pe17Lp%e*saEJqT9N39 zO;~miko2P^d&+G#K70D;tl3<;uXR{+sjQhmzH6;@yuul_-pof59~+nKp5IUHl(02A zaZ1C%p>pNj<9a$fMs~_t8RKapn1(k#J+BxEuS;qZFw4SDev!=B?y{n)Q|b?EUWutWL8>5rKaUCN6#cLJLxZ~0d&t`&!0 zaDw{!SwF9cAfeC`TgzP-Y>tdvG}_Opu1E=n;_GIGd8+4!s^DbCh6*WXi}MW>tuewO zhZ>k5-(w^in?;+l7ioomZKY(kPY?PU@#GZKkIskzzOqNL5e9EK~4E zM2Vm0vS+BzPy{e}wVT8xwB5Y~jwP%`0Jz(+gq;X_R8-fmmUS2R0G>qJqytW;o*L3e z*|*V3ya*Y0BgTw->4o6I5L&IN?)a*9c=RaEw8TMH0kom9*ug>pG`J-&#uM1lcfO_& zd-)84y-7MYcz?iIJ0OHl`ZH{ZiE??=R;#q}ikfdzpZKF|<-qkD9%(qd0U#&ijvuMw z3xMG8Bei_VQPE5u16zL8AMo%BWT1H)vBHcO{@I(Fch&tJ_z*cS2J8ikzkG~rd*6iX zN^fyV2%!;Qjz6;ct^FIwQ8OTrVX6+{ljL_$y11nlRqNvmy}mc@-ga}3z5sPFXyYQ@wE z5iyaMglLl5$&mqE|9v1K+OIk9KTVJ?h?A*Yzk`GoQjfc{qe_bpl}ahlim$}-S8R@N zi5_RrUA%p7c8=n%#z$L@ulF|Ney*GL{@Ne{5I4E(+*4KhSOY}cowCp**9+{&=v3=) z_(T>_H)5y^Le{uR*ZI^Oc-ubYQRYO*%n|UO<czrHol%mjDTuI|}u1|u45A@dsDtHM>fRsSn@t9p@3Yfao~dpUzQ zL)1`H?dhq4U5&M~T>}$tGec^@g-h>{#W6D0vebGp6p8j&MXfy z+skwLwe8elAO!7Vl>=6UoFIr`=L>qcJE_hFS=11b^9I=lcVxrIrpjil#>(k`{WFw5 z>W79u7`=`L-p^O|s>EUopN0ltlx(d)!{@WXLW=vY6{t~OI_!VNm$slD z*VnRI@%SaVw&!@)DCwH6D*t62{Pwj_mM*U2S$H97Q~L9Ap0zTXtJaBlV6640j2$lh zH&pJk(@zvWsl$laALhA$@QV@_aI|%xeXO{slITEPr%NPBVSZFwpl9W-;|gE&FSGB2 zo`@H`RO(k|zxn|QYi3Wi`}9x%b6I9DEAGA0{$|TNFN%eXl!s&FRhh;ajt%1yn#|b> zG*wbyZL26eM!W$_;m;12cxP-xPkV2kF8BAM2efo#?doAOb?`lrZi-$x1w~-mUuH`CJ`TW9ER` zhWC71@&YkOQ0~Rjs#m4lauLFs8tms%R-|M@@&DEtvVNb0eQpT;Wsp@B)@49}cQ`j? zX|iT68Hy=>qnaBdG!=sm)kjW^sVWTtSKPoTOA*{J;*0sd^BDlVoZH2Ky;q!r3OQJ} zWEw$e_ZBY^AyQ=bHiho@t9!GXD@O;=7G#t(SEgjUNEV;p!YGlR;Bw{e3i&i)Jt(fZ z6$PF;>1BY3Vwjw^NQ@tWK{ho#fm2B;vufo;LAkPzA^;5anPuY&>r zM?n8}OC{u7_8ok^p{V$9bt~!KTPVsPpb=yp)Ws+IqC6V#W%Cn!q453&iZ}T2{V8X2 znE!O(j|$wxQ?=wmqn94Dyg}2wTZLC!7TE~L6yN0B$+}0YzW>KzOjItDQxw*prXwac z;Kj1NhBz)@Zz@EktoVPhK*&NTePKbqmE$@4Av4xp&O$golJHhiPa1}FZgd~q zaQk1-qE`jOo?mEKSinGTM3VWPD}3JLs>odaT=h`NT++Wi8O3Esif1T`Y_;TSSH35P zhWij7Lth2oNpdPT*W}tsuVG%iTT_wnS8{*IRV4oEpU9jNZ+UWlgvk|f6JO~U;Y#0j zW2gyn&SP@4%UlVm&=jlYy{VvWx?XjHem!~U)bNCptT)$@q0eYe_kUb@yH^AFcBU=| z(41DN9KOGOD|EPQyDMI&_`NXlMr}#Q#Z7Ksl%uN6m!yt6$ONQsWpwbq!UNGd#qfs1 zch*4dn6GWh4-qGyctfbkL!&WpG#$gvn?OfhR;4@*oW+}h`b3?CV@onnyYB)2M(E2| zcQV&kQb|X=7xL`&38KJS7)x?usg}m% z+33yf3mRzQ_1kYF+Df)XV)bw7`m;xL4_5NWqNDy;?27~>gPGbyPLbb#|AWA#)YFWE2jE7vZyuDr&n=S{JOML_ z|NmxMm9_uWio*5r{!d2ULm7V)-34VH@aS>i(Ue4G6;)%IM>aUfC21(BVEi#S4@FaY zYE(aB!PWoTN9J2*I3*&{g5k8$72QUfFHRtY}GV2xmU zvFh{Ozj&kw0{jDW$qoJ#lvJT~b9ozSA6*XOcBY7QWVlvwgEV}`@(|%95{F+#WB-tj zdh#d9FsyDWO2*eml6nwQ(7S_(4!|H=1A~m=Fw|;IWNmqVgH#v#U$f}_&n#7D^s^&s z;+Qc!#)2PWu#nB6&rH#sXP0C~xBoYZkby~bWBc}oh_(iGjDt?5WDb~|>YvHYCzTZl z7mF=NNP7{gRR8HChexy^gCQ6g48iC?Bveou`&$vj6woa75V^z8j5VJ) z$z&G~N8wPuNk6>(*+zr|8IBl@hWCYnwRhaT-euqkQK`}I{&nJa;p;g6{t z>Bw9r?rFZMYwTVP0GdBXAqka+%5hCYayV^)Lr0zw3f@&MA!|njyA(a2Mu&B|TI=uk+_a8J6p^Z+t}NHoC8d zv(y7p2iqPP%)sOOkjQn=i;Rn5NbQp0>yF6@LLt44wVNP#fz`L|q00QI=m_J@G8~FP zlv-$&9{u>!iZX|P|4 zLMu4crVPjcAtpN!>JJJrRLctA1Qwx=v4QW@81(pXnu3hqLX=fLK!`Sb@oeKkh9SZN z4=RZt`dMloyreQ;G`&dcn(A^~R&O&`y(pCpP!$?ylGPAfrkDlTddEDzR9lA!nC;D*p7wBt+(0zUcc;s|2(_nD$H6CqCX{hTB>ATc(MfP*WygYKGWgMw)ixrVmKRt<*L zpp4GM6o*l2REAY8K?G|Q5f*pd{9fT#L z8R+$fO#l--+dPQD1S;P4{-z%m#EP{QlhD^pV}c$6y*Rn==NRitYiR-w<>JGJ*H_2RyUjIa(7mvr0;>OsG;*v8OQWaWc>f`a`^>(A4I_BYi&t z%6IdHfKv@*@{E7DG)l_UW3W`CnA?qn%d@=dE9oq=Ku~}~@Sd1kjV^&@NAymsD^Rl; zW&MH(?3IaNe)vi$D(ZZ&S&U3(jo+uo8eBC=0HczWXfXPCymA#C4;wogOc>i*UJMQ! z8E)Y-3$Jjruv1A_UDL3^>HkypvhXJxZbpyqk$n$?<1$)isCE!l;CVf7*!G)-e)!uV z5aZ>YHl@eY=}z=TXVl0-Q*k1&<6}@|HKk3G8#Wa7v_{jLPRkHj`4GEBfD)n^$P4Kc z+$lRfNlMYo=_pO(F)@Is#8lojB@(6j=R6-qF>bu8BA!1{{mViOzF6T7fTsX~vS(AG z4OK5zLRDG26OcxV4>e##VMB$W7p;J@$S^A>%Fvise{{PWEH(AQm>MEDSA9Z0;tMLc zDHHSo3iC8~e}*0}KLjP}P}HR2$6Y920qFPc(2Y_cucK(NcXuGOA;JM6xLd?f>90*Vo zQ%LNY@lP}Ol1==cjC-Ichpv~J$Yq}|qP)n)WQb93*+n&BO%{1FSZ1j;hHjQf+aV?mv3)Ua^|U@C}6XKnfd zNFFXv{CkbOf6P| z;5JE4&|62lw{VRL_g$@fo*er=Z@xM-Gx8W4Ji09`0WrEs1T#e0%1B}@$*H_0HfT~a`cbr!0zmAhfYbOSZ-?F&UW|E7U=E$X|Ynl)sK;oAv;fJWj;qqm>NHj;vwXC0^mL+igeZQ zj3XaQe()6ffjfEP(VWI4D%Cf+Xj-{cW_7mc$g`#B6gOC=JNcul<(?O<)dD( zXW^512s5#=%yrUwM#Sf7c~Q1kip_q8Xw0qL0S;dJ#C!aoQ9D!$6poNGKJgQN@rh`b-S z8^|A@qh(&B0)PXENo_g4?4b0+4Hq8uu!p<)vSj%QT}*+E2cL|$!B#)4jd);aqM)CB z=ib%lIIQzW!1`y8XbdpB{;za0%)X@J&^Q2cjQe@tm40eRaH~eP(iD#a(R4rH)ym5Y z_>Nf3Tes$CQ!yH9Y6=1(3~AZSQ^GE6=IY{>-)k#4a_JEXu_S4%l$h(|Mq(JUOPDF< zCUH#EAm^;uHd3Lqt#vLXr=_jLKDn_r>G2<=jhE80baV(b7-S;pApH*Y)XXgEJA{FB zV%u15-EZC#CKj@rWvZA2$l0mUDQq+tUi35{t32T~1p%B^$JyFOI#=f$&$;FI&uoYySH+2lLJou=l|lBC{` zatp8htSaYaxVUVHz3}AtEG63b`P(q`<6D=n=iC5|HiMO`*6E+VybR=-Bxks?90gihz_@0T^(*r zZM_9%Z1C0N{a-!W{!)=KObU>zKrihgyllP|$IsC{qdYWloh?rOW+5+Gm0FFDtDCP3 zW94;NK9)#e(ESD#jw_yrZvbR~N-lfh_`}d$<6fuCUnTD#-fF*Ak!?1z1t*j{aio$c zvY93LTtrykrYy8Tk?(eb8Dy=BmzUGTzYJLplyS9M``vOYkr|g#XSvMsdqlhHjo8vg zOBnBHUD&cxZg$^n)C)^Qsz0tG%ciU^7rc3Xu|p)*zF}2rTI}A8y5L7)qXvC;zvp3W zh+DNRPfQMC$h_8LDQQ!7)fN3KU9nZOIarasCF7z+=BMzpSB`D_ZZL1>P$OU@rCCVX z_0J+VHhs4{Pj5gg*OJ+g(!jTu_xu zUf?sDB;SIHdR5HR4=KXIPgejK&lC>@Kxd+Wx&%k>1gW7?C&yF9zyq!ovCohi;bp=T zABre9aO5gN5|RpH$I{O+NP^oPR~Yb?&y7j^CvH91WAw;~a}~I-wAgGPM7N{JsH4ab zoWK5kg%o@ZZfkz;93Wp7m21tCJcEYwFADst;D~Tg2trl639T0Kemc0$uHHJllx)FC z)*B61{d8e!eFp8jQu^Gi%iJNMev(bao-=*h8&17;nf#>{k# zUOjK5FbhWID1S&{x;R-z{{n^jec@<@UXkD8Aju_S^n}Ls-|T~NSMWUyK?`vy3%~oP zohGtO77Pp6$k?;Is((*rklq{jon=uv^=DeMBk9Y7-(0@n3rX3bWcWK2{F-d*cWh=c zVqCxGd$>Gl3&OoA82ash)4G!3nw2fhd*<}*rqwv{jkvXO(vHG6u~ zk{=T;DOHw~&8r%A)phEahvoSRI-j#xlFzBz@R&%c9(6Nrft+f$Y|S>5E71_|DfR zucDY`YaiDXYGVzn&9auZxGD@H(3ZN8IaFZQ8vvrXkY3yjO>fcuDS{fhjU_Ts4X&w8 zP=Mzw(~ZYM9|JTfkQj4Qj$h~^)$mO41cAJ<$_ zIG=%#aF;b!`F!#Z;GGMg9V zADzYGXQq^`7bBP-9R@T^e9Q|VkcX+A`xy}f+wvqTSkstGwZe5zPo8GNdm0TFg-^Nz-! zl_;TGKRuB$hK=>@+gjM-7PA*^}_>v#3SEb#XMDt4^h_nQ-NBh4zymL#;uE)8tv&^pZV@+R`u|b^{T~?$hTfvqa_w-MMC0a!v0< zf2)zTa>Z+=zqin%Tm#esFvU|OcU4lGROK)WGjTqm#X)uZeG?$JD;ah-BI=Sr{L*A& z5yfswj5+Wtb*>3%FY}lStrlNl-933neGiNW~?#2t@6_u%3GEa_l7=-_@k!1?sNPjUSjC$P3~4Ob;{R#<#NFrQo3J^39zldd$Hs zj8pXL%lZiw5bt)<)_Z#)6vx9!SE`2TGY^(zG04x(c?ZDx}Z!N z>{TFgxu`%Lf*p3@C#w#3qmILRLerU)Nae+qB*5rz&=7qh*_)qD+}K%g8A}onaMg3| z5NfhzNZ?nV502BT;T&E2pdaB@N5xyDk9u_wyRkQZ&}7s^ld4{5q~t$|5PfI);M1dD zS6crHt%JROY8^7-n#?lV1+Dn~*^njUf&;d3qlUI%%mC!JqOulEEJmIc2GzkwV38vi zTG*#;Uv!!v*5B`}EiAu{|GCkV7L6`hGH_uwX9IKWAmmQLMF|sw(*UMiM$HyLxYNR8 zj{!Ew@fQjq-hDQG4ZNNlc5oNg+pNv|_Rzxi6&$8ktL0Ngpw;Lp%gp(q0tLv+o_nhP zFfj^uDud>n&sRa#V#Hph$8u4lFO`9Auo(s z6RP7lt1iK;1rdJwQu!Oz1}KwS-`KtrSbb`Yp^tU#&{rEW(oqCaLpMnovj;2$2Be?n z)3GqZPNd!iclnFr{~7pbZ~T~jnXoXAeP?;{F3Xb(2JR^2aDy}iwyqS=LgDk8oi*7z zLb5WycP8&_$T3O_4HF2!`!NMyr{v$4gN6v;t zH7CgnEA7E$((v<13&$XLa*sVpy07{&bha2M^`%5i@ESy&5>?Vsqmi}?e8e@)WFGDs zX}C3mjGrgIr{A)<{+LBp!qo+PeUqD*xPj3IBn+-(PT+I`ElT5Nz4r)6`c<7Hk}9bBj9Z&eH&8^qLd%?rc6Lx*MQ+c&y5Q$nC=tWq1RxT{=tGHbLd*@i z-2o_%s1rH}+0VsHKXyn{MHcv|qk^i+0J0x$6tsK;AJ#P+6?N2bGhZG550V-`IfAov~QY@Sgd_z-AQ&>3o+N!Z;)XX+#($A zTjc_tep4wn#I0nRj?7SP)?l9wHJm&c#ZL|HaK>E#d9e(jbsb1+ zI&@{v$6r4>>%IeM{cX|&NZ{@r14I=y>;hR&bTr!eLBQ*Y=YJI=)?y!4%LG>6pY)Iv zYf8}%K@&xSOX9>z6~G9;!K@`dq%Y68EG2&Q%w?_Sk^p{f0^B``zj4xHu*SZc=Kz zN~Q~r7;-q8^4k6oX<-gu=eG>Wo^Y_%5bv3Fd{cWB zh{4(tXvzT8Zl-_~+ZY-%Klxt6CQE)URb4YK*4l~f+cTH_iIQFQRHz1;#w)u`PxELi@#88?wONbkIzOnz9Up z@nm*jP)75c(xjYQmiB!nS{>6c!3oo@Fv5>m|2Vq!j9VYw=D}E|Y;y@Cr9pz(qrOs&;{Yict`69s|!FUPmD zXOx@$5s6Y=p#!jSo@k!TYYrsM$BaH-jGGOG3qf3IRF=Bjs9d6_Oj$y7*YA){X26jk z&LCYmI^_b4!Qr7tAu&N0^H+5mR=zz|kj|a^>}%>&6L0(zuR#7Ti5sMOh7c_z3xmT_3ET? z0b&`5M%)?r2PGvHrbj1ca4Al zYqecTiVvWfMAEi%tB6!S?A8q@6IhorM^e0z%9GO9iIrQ~kvF|nkpDybWNYv%>Ot@| z?NAm|`h}sd#Omei_2s=l%~>W(F6Rl{Jt|jAE>W@2^fr4bfQ@y+lfp9HpZe9yNC#Du zZ_PP@X?F5ur_nnK?Z0z}g#S zS1=5zsT|Fwjl14+Yu>#1^fYY2rHfW7lO_B+C|57b=~6GIGqCT@ z?b#sv*rcxfH1ezUbrww`+5sBZu6NP6)>hasr83rIY@O|#%Z3zoL_jSMF~Gjm8cn8- zy>?HxJWOwfnd6^@>BfNWas}tb3L%B=I;YaJVZ&$2Q0zNY7lU;&VpZG(rbAP+Vx>h- z2`y&^zbgF-j-?08?gN-T6|Xv-#=zklr42X2rEuXz-99 zYy>9wab$B)k=k>^T9uh$Q;@x2f5yIym9g)cQSdjJe-L+-r;vieOW38Hju2r-71~37YnEVH!?c}k%FSmkC76VeHN~C$4jM>pxp}DD zJrpgpl)sZPu!69m*WlczR>~7=h8c2p@*?zRpxkB*5iG2?H2M&B{q|#ayiDIV@ae-7 zpG?3?Ar>6V?w|8Z=6`ZRnOmj2aTWxzT4N_dTT7y*a&N^W4$mi|2*`8A6)IoTEkNua zXagK_xsoZNA;PdZzJy?N^rYq?btFXx8j3o^MG@TA8~m&1a4Bja6CRYLG8`ZEVXIk{ z8!u@u12vtHbNb;5qn=!r!I{%V`|p?;irh^vGrgNf(oZ$u}n9@fx>UMZMkJe4iiz`CNZ@AO4DZ zkv*fWZ=&s8opydt2S@6LLCH7FJLk{K&yee6V@KnlLf5Cz?;V1*er42?J_2!4aaDG%ZB^o*be6qbMYs|J5rLsI^i;e+a;`cfeg0L2?VORb zLAnnh%Li-4JB+r(K;EAg^z=lZP)$q*EBSX3uIf~dXnXMxV2+7=xVAlG=#xD6JBP95 zBo6FD69uF4qTzGuKAFHR)?KQ2>I+ zz7g8803OC{#?NYQz~e6vUd{dH#Bh0Y&1u)kpj$W{suZf{_laqLVNiRB6qRx@w1{8_ zt3>Ad;z+BP$69VP06H#M-{N}FUJ@O`rC?nChsB-m|3H4ZM_E~_aA|DTujwKS(Hv~9 z{3!&U38>1M;NP=*4pENCbV`5%&sFj2?+6zkhPukB%1opT;%7kYl>xniE;jClKa!x` zroN)y1Pe$29_U9>H5DlTyV3OFu#?>rp6Zz9SAE0UGqA_9o(61qP%MJ*cfJ;M|Dq=? zws1`~u7N&o*Tpid?zm|57gGnA-%R*r!N$o)&6vovK9+pK5M04RbSlrJ?RLl!!Q@Gy ze_lq%U{lBhA-;3yw_!(e)uAe|27BjQ`F5U&C|JB8nF}}js4NRKKrkfE+* z4V*$f8>}!(f;Ch=iK~)FHf%3ikZDp_`ZG(ADQbGR;&{qOg9lFsz;f-cHz-{LmZO5K zv-)RasPrHZuo1juOMr%+o_6D||J17lNkr5@YfKov(W<_E_H!LNet!viGtzu1@n#MR zdB`(eAL;?MECxvay?B323YvNge9-w3nDza79e^wcQoSp*iB>=Koit`X^og~63lXLx z(3fa&oZEsnScqS_ZR&wXha`I=g(!<(^b0;<0AkEWNU=g|Uz9$B{$(*T8Y)Zwy5+vv z^mrLRl-8jnt~ydh*1A;caU%@UYvI1UKCxossjyxI_pRqV@}f74tAl4+zKS;tmxk$y ztufxd-8LzLy{f<;SySg%XQqzE_bTe=J`vL&Kae&6e4W-VYtm+?IXDM%2>{sKrFkXX zsRO8WG@(?H!kS>NhnFv2lj!t7tBuSd^zp1@NYu#e+o0RO<1bQOn-STIe$+X7oP=+{ zh^8sG&TZvq74?3h*QpyLCcocz2jv^J@_?01`O zJDu7608bRjlbugNc`ys^l)d^}w4*>fZG>05dt=&GKYc=#+TG#pfNV}+ZM#T!C0hu{ z?+*UrI{BT#DyMiZ*xDllh`mSM2CJkUF%XqEZ!@Q$`DXw8v)MA+KkEnAE7jM)kUj$A zgS*diZ5Ez8mh=}Zf3B^yfU7P$F_9ta7wQdC8R-I)DqAfz$=osta9;tI=qYQB;yKaR5JFYP-Ab-t z^R&rIqL}Q;jtLJIn5JLw;o0RlVzyOG&Ltm5$VQY-FLS31%S3YXZ*)ev>dGN3Ob+}& ztVS?qjXGlP^Q{bj>K-Q~O7y(yi}NU;c*xwTdWmNfyicMW&t2A^b2wK5dcE^CgTSXj znH-6yO>d6(9V-EB?{;5d*z6SF{~?WoV(A-e6o{1eqH;61f7q~k4R42bJI?VXA!GgU zIX`Q2Cgm9B{|O<^@DoNgH!r^OkBtyCsALY|Lmr2F!~kitRkJDSM-j}!6tWkpRssA& zy=!S)ts$*9@f7Og9mJ_T?1p|e3y)=i!<0E!!)%#wlf>*czmpiBE;r`$=Bew~)4ha< z18Bt_VPh=5$R67{-Ct6oF#)4InN%f``3K2?oCoIVbm9ByD)ca^;x%K~%!?MsAHH-a z1!H~`!JP~$x|~DVWXYjHs{O+B9>|wmef*uR^TL!v)SYU8TgDwYB7%6Y+aEvt9V9z* z)qV2^IqH;B>62L-Ua}4K$9@Go!5!@ma6o)AU!oBOB&Yt|!|j_MMROC2o36v8Q!&N5 z1ILySi)W4aFy~Sw)#)@wT;j=rPL!{hBE#+^&S~`a^vNs=xUEYIQ6bmV(yHZvQ%#v| zi`?sGYS)GLuQ#5-hJxr7LyQr|{Y2d|neBk44z2`^8k89^pg+4}uu!)0u&b*9@1jjt z-NQsmx*zn>nRq6f)>T(z!aJXRVlRF4IY$6GycDr~E#nZ-2Ah@p6AxhC+=TK+uq_@^ zJj#DnIaW*S>fn&6-eq8h6r{dj+%YVJh;}C3KW@Q1Gzg}klr%UjjuC<28)F36L~s?6Q_= zW*f~~_Vj9N31SQUELHh#C{}x4YxOdizH6S|Bs8rEzo()on<>FP1E|?U>u$;@#}Y)D z-=%Pu{i<`61wK!TOr56r<861iB!9W-9JZ-*47|I0@y#+Tz8hFR!n>)WT*7{HPK`pT zNFmTYS2+P`Go(U{q?HboYUwQWPyDVWt_q9e3#sC5J@z=cs#Rf3$~J?tR0ZX;yPSlC zq6Lh~+&`)@Zg}b#zG+M~x*tk_aQ_mf)|VzsZtikearLZMaMLP{3afF8UsKqW;~4@^ z7Z$!fD0`e|hSY_lt|`f_Y}vtaYz@-D~D~u*E-FI>krh z{`pJ$*W~Av(5Jo~^hZ>tZ-3zPU>@(uE|_G3>nauO+G2oJR5TpnQlu{zb|tiBHmD5! zf_5FeFad871h?PrQ*j3|{}I6@I)140ysQJ2^UJs8PC8nLM&z2Cr{&4rE$(O-b&(gk`{6hngIRsXVJ$7Jgy%yD$3Oj*uH@;AIn4wI9K2MkocDI_r@?; znnet4u_Gx|-4lr19CDEb=Tcu;^;12`QqV7!M}fg@@(-F; zjApVK%041+FEp*NWaTbyEZ_c~`37mWKeF^vfh)IVh3B#@*$qEGQuV}xH_Br_yg;q} zgigHvK-mv+*xA((O(%Rxf@Kq0rnrZO_HI8TtvjzI`fw z!bi{$Kx;m<{f7Lp^9+w!fSer4Bc9`JZLEk0A*uIw;vwI#^zXfK-@seM4K`K|+!g1o`jIdnQIv zTSc`+!^6+tPX$y+E4H4WN;Z6w1sARFf|Hxu?2BxFFDfK!O9VbjFMfMrtP^?%m6 zL!#V-#7Ga?*V->ve77;%LWYa|&FBv$o_>3rN%OS&Yz=%O+iVDXM)qwW`5Dyr!A{54 z3c~%cCdmq~7aE|2{qYa8X+9T3h^@p64N8>Wpc++94K6-Tr?>9jBzH&FeX6ji zbx^@uM{OP$$Gh{4QkxxgY z&xY}-4>UV;)8(90XY zPo^RsypIud?^h9h?N*0QcKbc;CD1(y*!|EyG0$Wem-8Sl^hX3}!w)NJgd%>Cdvc;n z&d#+UZ%L>;uWD_DG0UXBd$3SKERUWt;Pi7&UD1E*=<;NJ$-Llt$!3mNi~jXrN0Ix1 z<_-r70k*j6BiBUa@*Rg&5OIS?2>&d8Xe};3&z&FG-$~ zLL2aT)ED3rx*ef3&&DXf>CjRW*bLJU^Jy#~!Hm z7?;H2zvK{z#%G~gmEoHX#{5&~fIfV(7BjtEoO!f1@H^K<*T!l12P_i4_UBUfs5N(4 zFylVIp>?{M+E2C~^1kM6liORrJjjdr{nne2f)e**A5ze)@F>2DH&X7TrgvwFfb@bd zLS#h+81}ngGBpfSH0wS;Z1KmTef9NclF9NwsGv;uypLe^NW$G!TRPgL17Z^O_{JeN zx1X;Ho~MkD{|;`K&iIzD6ARu-9f|W=mlxMoO`Cs%XX`;QxHiZG?!##_E1VmXDki{T zSCfQ#zfcszbv;eNE9u+r3HGC8JU2rx?L|U2eSqm~7O=%nte#t2EJmwH-hHHxEuWxw zX`yAQd9=L%pQxL5hCRU6%FNJrD84TR#Vr0Kn&i!hwpbTWO_u+AA#B@HaEfj0_gQf5 z2EUQW6y1BN5zKc1FVPx+dTXG^!x0igVi3Y@#&x63_Hli?SGO??4W9ULA@ngpYPYCh z%#DK+iYloYdV#*SUP{!+`MSYnV?gMxgDmsdr?S0L;~*L9o4cu-yySS7K(M%6)02Ju zRVIwSGO)%sbvMktv`$|6ozO5Lia*-$U)sUBULQW2`<)oqg>{kaJ7g;y_cLeS^4;h~ z_FQgR9_38P$$TZV?{TtE|E2mSd{xFLKK{$26j1wuS;pHwizzNi4&>2?b*21D{H&Y# znG+Mskoe4pA;zR2HOv>yE#ZeSr0N^){CSAsWurgx?aoyR#eu=`l=-7}si<5pp^x;) zrncS6Banx_G>E%gE3uO|_kLiO)He0(ENpuB($d~|X~+`KQPHGiMc$$9^5H0X zILOu_+DKvjNIk^Z4pZjoUgZP{| z;*`Yrgyk7A-(&G5E@eA`($=0+#N}hivt=obp9Uk`cmzl%GnP_-HM#EB=EKgr-fTV)amq++&*V2fm<|aBO z_jBJFyi3l}t-ThxxI@bZZUPC+6B}jmJXb%{`LgU58i-D;&diYVyr{TXSBkc$pYdkb z5FFwBP>|ydE`FsR#C;SX?XT^Ut`pcLzb~Eg{FweN8T%j6DvnY@c_^hThLQ5_GU?Ir z2mYeSZJVBpU)zU=OFC%9(DO}JBT4olHbz6Ih8l%V4YEEIW0UsynM1v5MqSz6k%~dW z<}VPqe?Yd!LvqEy^g&-wRAy`#6+|l=xA?q^0Bld_Zk?>{XxM>ri<}XzBhBSnbG#_( z1cuf#nL6QOKYJI2QGylSDfNx7v(Bbt{Q6V6X>;4Lh~ zXg$y`WRAV)Ob-W|bF{!=qHoU~#EeZ$DU1Q!ELVBQ*kCOU;o@{C$C^Ck{+&HA{u(Mf z0ls8oT87(m9wzq%-zd7K}%d)SGOu$lSk|9tT<$YtUOpi7A^-fdW|!=^R_S_8Cq zY?yn(vsm5~;GAP(Vai^$YQ+^5_XljPx8T+Z zzFZ=LMb`EkV>4e=l`C{MH7Y*cuDqz2agL)ozZZZ?!1?7z1$9%E)%sk8yjO|&Uf``= zVy%Z1g|gqn#hx^L!{PK;-Tc$uJjwvRb0MPDJ9sztp$ZM2DaPJM=LM~_39lO)qeVe8 zF0XRqi`b?kT)WiV=_}}uZj+ZxJ=5n9ys{DOG2v9Y{lVokk@(tb8{ByFvT*hKCkanU zhJ6Eq@App)yq~8)1iX6(UPWG0EO2P`^77@VW8rWpr3&9*cK*SKWr|-n-aE5a&m*Z6 z#yv>%6WGb8K0sF^GavG)*#*hPnU5VRvh%eUESi%R+;86*o3as?LY z+%a$Z7V>OZ-lfV@LVgxnhS$!_x-pF@Id{EfP!cq7K3=(NV6}&LSmS-obNPi<)cs>`HohKk_2)ZXMs|E=X@0Fp;C*egi06;6t=L@PkKlM>t0Z7H zVUYU7;F&TOc_aM#(rol+_ceP&43nImqq2Bc^trUv{F7Ria~<--zQ!4^i_N84aavId z(u0lR(>X8qo4eELlS<{^(=GmHrW-)nq`5|6LZ^}{cK!)>uFgk0qr64V&zF)>401b0&ue-tn;G*(o8tYG;y>l*%iGMqS${b9s-#@MA#ASx zq~u-7+ys8y)Tu(h>NuV!SM*IOx$pAcSd^Xll;qLP-khHu?M9_tJ6zkTjMwmr`MZ7= zd~>aFa^;W5CVzMN)e}2^Z;F{=W4qowjz6?l7Op=?7k@>GTQvwx6j&$Nj0tU{dz$>= zzPD7Iy+L=q*u?*CU`uUUS8e(Nq3FP5Q-<3TDUN>Bb?l8$H?)J}j1)8(3i>!QD&7d1 z;=ZmlKj*j7sZUXnGUd4{sph%5;M*3wZsez<6Fuwf!Dm_}1{RTC4 zzbUWgT*LY58dK#G?(kHexX9VY*_medYn#c*iEVY>o@AAGHR(^zJ~_~aDQG>w@=5oy zK5#$U5dU>>FKzr$RrRB)ldzG1*nLfw-`I%1_R_8>Z|+G7u8z>MLsg2~pk1t!JS%^@ zp`}*B?RjqaIl?vKX?7KpbP$SHacF|%acC6Jx<%c+E|!DWt|~czLU%IN?{Ts!Ug0iz z{5V;d&3;*D#FV*(`V{iM*EfA6(SiORTED7SGkVn^_D0;G*mWfM4W*BNXN0zxv9I!y z;QFghv5yUFVN-?G6FS^cr#4x4`30TwU0_^$Y6#c=90S>Smn4wda2rR@b{$TaLQpiUdZR%Zjd z;=|I}tCGbg_bT%Y6qEVpCn^4DmEWv)DXedms8AJ~y%jM5^R7hS9xO%?G;hEo+;7wI+hr@>A)D-)VU+&*|B z6*=~{6A7c(UKg$7QC@Bb=dBmxHgokUb9{{#dr>+pZ-=asa^2(m?dGFL`W?eWKE6jf zg)z5J`m(d_#$d_ZoyJo6fsW+$*~{~-Dg54-kNtmMn+PokNg7<5u*4eSJ>cy8I@!7c z>5V_db=AP-tVEDm4r@A&RvVfGc^@UV>Xz?v<3Xh&S^t%J|0X6S)0lZ;GW+e+&5B|SJFD_d~h>88Tc^t1GqVaX6 z7~im>zscx9BwZis6yR1^xz}LJp|{%{>DjOK4W~6&jGk9~X3f%epQL{OumjtQU;rbQ{w6STjD5)?YxaDUyLs zRdI--TNR0r&cFkq(Z2GP4tMU%AOeEWXZ{w{#y`TZOxawO;>@eRe<7KWL2k_`hK2=e z!4EL5ddco@cf1@vs+U)U*LECXM-i7-* zxp89UO*{{ez=-z6tTKOtV$ucqN`=C7uI2p@QmHn>wtJ^zJX1Bggk&{?+?Ejvo`cFx z)7`*0pnC47X+Hmz%zCNi&2tuP?U(&y9YDQ?JV*V?`kf2`Be%6S<(R1OT-U^<3Tw2z zh!xPXVgqi}uR(=NFAZJ0?5d7lomO)E+4SPQY#NIlMVO%0B8N}4qhXT}gB?1rW=$Ob8; z{vCZ&Rg&ZB9l`xl9Z$#(erMz(W@#?ZI>H-eZJH9AuJakM*h;?UC}rEk?Bi}4dX2d| zh&SKjNqqpmqSj6B+Ug}17sXmfUB!Dix3O!1^Cgu*4e(1}7Kh3%{RcO?RcIq-VeQyRYyhinw&Dz$f84W?^AW zsK&;cHq1yXQ_zQgkPbopXx?Urc|kJ5U_7vAmc7BP<0Yv-@yLaioB3tCK0zXSsn!FL zL8 zX^G{~Nz5R(V%!AYzO(ctpCGcPp&8%d$K>f*e$^`t$B`raNI6R0QKx0x5Xyu5H^bt9 za%30vVvbk%&h+dX4h@Y}KY@~nea{_ge^z)*Cjq4$f?r`qFU-E<^9Y-}9@uhD6OTyi zb#DE+2_1HVe_BCtn22_LZXha7(Eft;H?@SyC$kL|_F?AnW~jGavs3?&K0NCol&X>C z%2&KR7#H;g>pl$vhlJB=MYyWMbIYqvMLMCu@>K1!rj;mITCRo;0ljo@S>lbGu>Rc9 z#_x}5jmc5GH!GC}23KPGs8=`MUI(G)C1=)+HLt-Ji%}o{dgGOtkz~i%0G6x@0z8MB zQB;5>DEN2!VMn`8BsWC|y`Nogfv7HFx^C!Uv{sFe9qUGOxs^Ua?v~~E!@WG!Vr@_0 zQ*niwbP_@PPiqe#FzP1=gu>0zfer1|_Sx{k#}ezKJ`Qoqw5LC`j@W`j19b~|jO)!W%* zeLJlQ53y;ObOlVt127p6G>V^&22&84OI#$K~qZYcK0Xtf=RQJ8u8j~ zS-(?Bs1RF6{Dmt2!5{k=JGw-HzGU?5!<&%2uYp`4K2-MRAb{pIGx?V_*nOs8HhWgJ zBlTD?$DFm!D;C?r1S;Uu)9@8&^up@s#RrnR!(P<1qru|82IvgxuLt<)Y~+(>?krU< z{UUt`96YAyjG?y5Ez2G;@#E*#!hI+g!5BF}i=O0p|A! zG7BpUteeDe(J{kq_#l10=NvH>+@e!n42Iv+EMoP+dw;{HV&yZ1#FQA;DnI_i=K+9G zYKNAAO!NX|qR(<>xJp&SF0vov+ngd0gnTX?w~Q+_o*9>(IqDs&X*0jIsB;IEhMR0_ zTFXy!4FJ*m-?TL#6odokTCF!m{4T&MY%~^`!;&#HbYM4s5{sgs@2AP@ELT^rR%7xP zDfPepe%a>3K!Q$_B7fbwstyk(W5b3Nw`l^R<)iZlr@^YR+IbAh8i`(I{v3>tQaq^& zp{N?jI%t2Yqnss7(u46%YC@t18$@Ldu^{jjXKVarbmd>zt&zveGI{9b7Fm}5Ts}UO zNGC;2*L?73S%b}I682)xYO2Rm1$OTvwl~fQJP;jFnsW2|C?-_|;JP-($O>*syx`S!jbZIC@0)4{#-WR!RvQQ}%$4zIC;I+F!a@qpP5T@YgS|hH#rmDL+Q92Q=``pBI(b zqQmWjtTE&ggmi8Z;Xx7<_)ibN>J{gPX2_f2Pz^G0SaPcSQ@HYX^Fw-Z^bqHg_By0=TXIQzf(%p(D zY9mB-xOZ1N3PH}7E(mPuC+p>UJDlProrpO-kpry9)4rF@Ht-JI88%67D1%8I=Ep!UR;D3OWkDtr&AkEbP~JgHS~ zchAmBkSeD|LE5269%%>rTRYJFsNPPQz48x9Z60`o=Jv!Scr5}kt$Uy{cvn*ymPDT~ z4=3a~$}i}6spw*;=;OvXCZn%_wpsKobg+s+3@~_M;v;wwHem4e<`$?X5_%oVUKdqn zihng2$igugD;k=TgN$3^U)`l=9(Bi*I#XdN!hYA$Lwjf^WZTQ58f-h#H-vkkQUy1Y)Ku~5prbY!o&R+nXVK(Wkab@a@-az3-@f@kK2b6As!r=W8@gHwXBlw? z66#+v-$MPjPzmk3{i$_`+4T+TM}F4XxC_i2;kP8wf%W$z1dMFZDn~J(qw}z*pP(^{ z;dhaCG8o#SaO{x;^l#wR2i6(r2*8y<-N|b9=$&isd(uU12@pwz{2Xa8?-Kj9fv*4{b4bdhkZa(7T%6XqWS%aC16aS{v#Z zcUGu<*To_g;xN-NrUgKr2}1%otu|NCn1iXhn|!IdeHVhboBUVA8s{cUw>24XtG*FD z9^`8iaY!?Jzx{Anh46$?Dj5msCy=~e7sL=^kq32}u}emhXnsP?y(;_RJdPK|JMuV8 zf$ylgQ^m&_F4B1fhca$w5Oau@jdVISbrWxOXR|2nvr5m>Y3mg`6z%o!8N(T#dq0aM z{3Ikpuc&aYzGNT_?AqSj>z_tYX>drgm2n{n4a5qgU;6C~YS}N6$;snlOpEv!OgGMY z4+!u3LT6f)J9j1@+k7~^+|hKT5}7KHV;_f3F3btnYyoU?)tu)~r@x*pikP$gWlv!H z1}y}C>@$6^cP2FYd0c2FRtxe8iaxd&erPz|3}3a0imkHF_iCeC4fy3B=oZcUaPMJh zu?nQ)QMXu8yEo`W=yI-RPuDzkqzuE>qJNs6z8qN;(Fn$-Ghg7*SNWN-X5hEuA6CWd zXkqSe#E& zxSIF{%lQ}pzaSmoG9SNBwjdeN%CpEDnT#ZYlYONx7n`9INxgD1a@3gIxL5m=T-qIN@S9mQ|n6zVuvQhv_J5gv7ww;oH#NP34MhKjQ& z9$B$Z#O}I-!hRa7p|7kZ(3U8m>-XZG3?woYwln?MA;8a|g95sO(q9Z2uNd`Uo=tDd zn2jIX!~(0u~$s)*BGZLnfCow z*n_F!U+pH1vNCU29GGECXV1}i#pPR_0()ol8SC+2%7Y%2@M=^86bwc#z(tKB?MVEn z>9kTl4=9DH2R@Gu^~37@=REcpaH+TWXuW47t6wTI2+GYJIfKpd3N%PmptP&z8W?dX zqQwm!2UELK9Ar+9Ke3kk5qY7#zc0kGPN91V9SqaMxYzA1lcO7$UK7g&GZVdZFA1%u zVx$k3L?7uY;2C+W8|XK10~FqLQcV?$Nv~p|1yg~cKaGh5=}_~dV$|+tUu|41qk8AN zJC}!RZL?N+L$6)W22s! zfn`6>kimuNr<#P8!Pbl2t%s$F7nR@fe4*=@UlJSpjY_y6Q2f}LBC0P3fa2E*v1fIb zsCZHjLNUm&d3H3x{G<72iup2b*|(fDl{Mf?j4gnSA-?s= z;wOrr5Br^1*W};#3VqCc*T~-tSp^~S7?3J}$Dc@LhJzeNS!@DC2Ektwqz9SdXJbVB zx0cm?qJ*)!edGa=wa#kVym}R#m$ZegO+)y zk$)vh*#~B*c4$8!loA%{PqAR{$X%EI9yj0jv%B~I*yK7;-~gLU0Y=x*O2O_ZK+`LB z1c>P}Ch-m;C?L{PYv+5E{av}# z;a@;7FlWR8)w5JlUp#K2$O(A$a{mkGU*Y0yC)NR9Ic14dkVgLk8G(sF3F9!!<2%9d z`L%{Z-uaJW%%i~Yl0}nmAQWM#YTJFWWN3(rSCzmr5(h1(5{)WA?-`4qz^4zfTH^m@ zZ{KH6;L)8n?PB^WiAMv~BcKV4KmTw1QpvIjCHSRnb#Zc7uV<+-CkrU?<$}>N% z#(f-+$+0lUl@fj_jZ&U&}MfaXf#4N#EmkFEDZ70&Jq zg~cA#+|?XX&inL<{2`0WZ?%njorv9k3MFULbhmS~V)EFUU%dQga_ndWc)&jqd)b&h zo2yc7)WhiWdcNMYDRYNz=qAMPbfECbExYVZrd;o!TXc;lrsPYKSK?JK;e2)1P(Sn{ zT5Hh9mGwljLNs^o{hz>{XNo|TLh3HPg-$?sIpnu{{O8pVtq3;q*y5)&u6teF_wE+A zc|s(AMd%8}5%6|>Z>CqZ~)RvrVrUvNPaXUoKrvKdD`SJKgy z#crkYV6y0{R51PrJs2MWV+*NsgLdh>Cj4O*T+5?5K_BU$ocOJR9(WM~{sb%f{#7Y_ z?KmbvZRHpqgWF!FLS@his+@Tk8x~>QbO-Mb`iG96{XZd=h3~fqwLdPPq6D(ne*qu; zmd1XfHyKts&d`s)yYnm&-ffPJYBJANr0oZU;K~oM?8*e;{YSkJPs8 zBH}O=W_CC&CzSM=3xhD-Hbo2-^!{){iQ=;IKE)Ms(IUie?5(lUx{Jaw|CCwjQF6p% z2cN@=Ctbka#uf6>NBxuQkXCYsKZ?p(??%WNF7JS zR8psNNBhBSiYggT_)GK=BpG=GDJM=wK{u6DEV6`-mZ|AYD!ILhI>i49ub=>lb_68a z5eX=I`SoaLpZyZBO`xuqhs`r-z%h%q5viN`L4-gp9|3APk|~$RH>FSV<>+L@Z$*xv=fN>R2Llx1zM!|@SwtUHG>mKlji7 z8zsxP)zjcw)aDFY+x)KbpQaQWG1+X&{8m474g^)N#Y16cm{Zc{ zcjf!$m!UE8*mzW340&JP%TKg2qAbT(-Elp_i>|bzQJ*S4DsUli{2T#yqPcY$Jpep+ zT~lai-`?$-Dlp%%Rs7V+{zRG!0n-I#vAjORxa7;?)^L$`b?X8A-`nBL-bQGy%j(iJ z{Fn*o(OQ{8%cD;vW?_yhR#Ow8d>vU}fNKK?cIhhA1P4^6D-4fZ3}=_n51ru2!X|1{ z7b3EM4`7G?DsD2Vm+WnLqI6|B9L5@P^Q9=FcJPSV-^aEJ5I0748GTu_^&+4MR1|tX z*59-~Y-B%#>-{T@$v|oBS+-61Z`k2O_m8g3LHeQiD1N7d7TI#lsu4-)WM5MUzI>z# zBw-O59AU^4+U#R{bvIoP{8sd$F0$bO1n(R zMi%q3$##BgU>JZ;7#Uk$<0W_w1ziR!4^zbX?{ z_RC&o;~6QS;bb59`Ki%I`z4j$YGO$s6*${PSYpfmA!dm4Td({6Mg4*#N5WDfs*Dj8 zyPi_#!A&C2caT!SlZ;8HmVtKne2#6n6)5R}2%!Tk5|}DKI8|WX5Z&igM#4t`bQmt? zTOGy$M|R`h)5C22ekCS-4VB0?=uuYz&7V)IS!&BSeErpoDY>co8~18H6ke*=%Wt*} zj|yRQHD%IvHK)^dMSG@Wrz1rpOe^E86Bo*`d`vNdFK+Z9iuI3Nt&3fmHw#Sj8&lo&j{1W)M_~+}MR|o0xVQeXg!B)|ExMDE>t`=*@@lI6`DAyFKxyX2 z*pGp=s8$kVpTV+boH<+7sWJQ+h3k+x#uyFwhl1$5A0x_oya1Ui34VH|9lOKQ&e?aD zql^l-(SBeOAb8m$_pj*Pe_R@OY7iIw5cUoCR+`$9QX6YW7k%>;58UbdKANQ)hQAr3 z#+ak$!;7*R|DMd15kJ3j2n>4cx)ktz=h;Z%7(0mWBX~J(^!*D2rwmZh-byAPrey5; z>IE4i|Ajt8xn6EEFt-fX>gboV9=TJMoXet)Xm`%w_vibqW9qVIWQNEvoRqx{!!q2N zDo-!w*@fM72FVibT43!#0ygqc9Un{&V|LjkH8v=dI~6G==oZiddu-V>9erf!HB7~&P~xcr;I`{V`Lz1BMsdY zAA(fsXv(k=uY66JbM-@=K!A@}Wb3_$)h6XL39SX)JcllxC8)9h;Y*1(&JhJEsTu3t zN^0FTgAu};0FzXIrWRKq?QsY%0`?$tLy<&ooitx{{b+2PW=UHcMABoOcZi#(!1To+ zmDfjAtFof#9~g?FZjaAUD?56+ZmhoAKL^vKK0`@p58{r2_Ml4*1&k|c?339|O70X9_cmKPCc^U6CCj-r<#dd=X z0tJT>opO;|_-YVv+Cel5!~m@N?2;X&zJBxV{p7JBr^AasuFQT&5qBMkxQDkQZZ&4T zp|Yf_spq?nv=Fx-2NqPvcs9||my;N;)V{c#HAdK5BW1xd++pA-@L2}E+V@EJ``^tJ z*Mg|r224eS7738O>xs7kFcpkHtL4mg;(Ez(T6FOfzd&_xkRi`)GZnWKskm-ExK&)o zz{EwxNp@pWZ4}ELZv{*%z5gp+1-9|8Un&%!`aa$=wvVfn2 zK5l>q2Iou>bKMT<)a;HXe|MJ?iOkxNUYH3ED0qIxzc8ZYZ^yI|W{E=oY5p0|rsi+j zxe$tZqO`P|@2+iY`n*2~dme)m9XKQ0_gcTndJiPw%1Zv{rq+uS=4oKE;63mxk& zF5#_nAX`Mm=*SjPcRZ(+`>fvhYuEfKGR1OMUk}eo4}!=fQ2-2x40X_XRHZd;b^Aqw{VnCd<#daj4!4VP5>`p z4Eb!X0cH&%JRU+}7v)L(ABh;F9=ksM&3b%3@vWo{56DmtrEoJByABZOol&`Ng&uYl z91dGVJdU~P5m?hi3ff@8I%vfX5s`u1bmZ9!6MOAf z3gW-}kvhCO_AS_Hw5Y%XxON@}66nca7zGW{h2NhOk5L`O|)l4=C#-wXbgkqV+~d8x)kk^`!4==h>;@JuCC z$a9!9$A8ncg3**y8%WpL(BQptmH3s>*R$-CNz`p z-G&G-Ni=S~4|3zC8L2$ihehs5m$YTyq9->Co2hE=pqktOQ*~zvH`|K5rApLSc)>~K zEirm5d)qWn$C;{7^eUcZID2zz2#~Thku%n!K)p?;ANgw3Y-qy@v@*4TfsZJwNfR8N zJlZtdsM*kc&LoJ&=DO$vI;Bl`n$zcUU%g)ZxiWWzSg#` z4_;R_Ir+&&uETe&7+rzYa$YKf1x0DDMOZd2VcaKn3Fb8OYzL!0mJlUZqOPnRHZ#>% znFyb$SOV@)cw%^$Z$kAWxj!ojUw$D&?_A2FY#`q8MtQrjO-T9 zG!hSF zgZAMI&OfhbFc8UANVz%m8F-+r#j?_??vzrgw7SEO9Hh=8uVEqN{#aE=B~<}p&A20@ zzk*s-G>tt~g*p3~ek5a7K)v=Z*jDS&9rP|AK1;L_>&_l5h1_j*&_T%F*Q2MCy6p+4 zqTiNYltwJPEigw!x1a^1Bce3NA($&j0@`=t7H%daCY5-9*gnVQzcg0J21V%*vM6oyb{y>TD~-c2DyJ!d;x;oQ z-a9@oz~}R#*+cV2cCsN_#*$$8rXn`1sfy$oOwmge*oo!M$(q*g?Dci$X`1)V>B3Bw zjac2ah?J3+@#7#GCM&!Kb78PqKo5!paX|oA6+7F{LkZBCYuQ$pdAb_M(}98bdIZie z8HN%A>m}DXtdH9S8%$)qOAEI1IM^z&;rEfJAnXqsZmKyWiWeAdQ`PkU$PsdiJe<;l z(!@$ckAU;xi&PTR>rTlz%_*?zZt&ZlTx(dg3CoRPITvex1YuqU!n_KNq9bbO&NkLa zy~oha>1DFKxBK$R-J zlIx?5gA$urOUnzm{j{$A^c3Q?CwI!Yj*gf-%bkQevKZm=&K?C~&YMKrweeBdpME*RZD!tn=7V>Vae{Uh_c6Ls4cl|!%LZQzKVEwmD-i<_JzXPovE-`>pCX_W zR@B;mnHxbhd8;-{=!fFOXjMa8SxH*Tt<2K4$`5DS4X|8C{Q$O0>zC7m(HkbDL5&)) zV;3PZZ$=Roqh%}$`ez8rP{K&!`)`*&_azv~|H7y0`d2O?U?L%P-56auu7t%_A1~BP z+AD*v0;9F8K=V^%S!0TbzSVQN{_?Zj>{2ol2Q3qTHKLjO$qzM3K~U+3G6A<3v{+UU z=#EXw;8)>bW)S&4khL6)zy2?z+!#}3^tVyhi$t);D=@wCwWdA~4GZ5$4Hi~_MkU~y z+raQQa!bF&XB*rP#0?_c8<;pMHY(M4Jte;$&5&LNWh8kq%3)x^h6vU%zwuMVDRRXO z4Dh$Bo;(tQ#Z1uC*_%ft#y&C#RcvN96g$)83$&P`-xU`2cuO#^C|CXl7^F*U`xP*E zrTfkC@$fDkbpC38-RA0`e+zDmB%KHg4I zXpOaDI<6e^uIKc?;<`rgSm2iTwu z|FaptRodIdtm=n;Ze}(RJJEa_WHIF^ey=FDxa`9jM_awQ0h-DDhmy&0a8hpfs=@PS zD_FTi{PI}-SA|U;?EFXN)5B3wAfq%Ad!wN0V+c>s<0 zr{boUwEgKSH1uhR|G7X}IpwSmo1&rf9PNMtKQbu)j>0`HKi7C8!#yBEo1W;_^IeTd zZ}5>Y$9g68EiHWq#xEFOU&WDkrD`?6&f7ogFoqL>ulezHkjtt>Ax}SpB9Vw65yr15 z+DOdrv88{JVK}odeCknNg~DB$k7>u5kIBtRpw9IxWmccj0n;+XU1_)WNDpH=!Xwk_rAvAM?Y-UWvM+&_mU4?wSz@rdw zMf_;r@v?AaT+J+e$rU~YO(<8!R45kgK}k&Bf`alJsZ^dX4PH~RI~a;0NJ$%uuta9K zi&a;mESL@(OPL;P51HSbS$W(f)7j+ zrLYJ&%@z@_>O@PU*}{+pLnVh~bm|~u)C3nQdgkgai)Aa9p{b;Fesl9-aZs^P_y+;^ z07##%wP>|G%I-7UJ+&91vm?ttVzKdZ*ZcmuhC9_Q0hxt%?H#rc45xI8UnA5N2i+0d zo|{*f3$3*}3r)fi_1)_&d@D0!!VzZ79r~fwAc7|>Osrjorftuc{V1+0)6<+3Xj)$~ zeYed+W<__#RVY?>>umS*UWEI0yGp4f9i98=DsYrmZ~z4mzY~rg_N(byH97_Lp=oaUc;vE9NmRm3Bb@JRhC~2DmBKEdH)&;jn zk#$vU{A_J?u;3%Q?KjcO{}AmAHWE>X3SHJIplbLqclD~|{M6Hk98>-Jofxl zxh!MyH?VD6p%ae;^m@ac<6=$xW~x%W{&Ms9tmi{(;<=_x$(I_Hew^=)51K)xSSm9K z3OWeiCqC3CRsjW3re~oP&kD&OqJ0MDc-YiLY~la1+XGtsEn={0!Ry<&;dSDrc(cTr zcYyCF6T|Xy0O{nftgL+Sei!flsyvZ!sTEm%^tn<+&Xd4bZ5~Pn1zqrm2=KzD8VDhb_d)Z>~Rmu2QTh zO^#W>nCFqEtMjE;y-JZ8h@DLh3rc#lpUML{Y1Yn$2VnGY2`4`X3Y9<3)Bhcuy1&TaWV!%alv9kT}gvXYeAxm`w3-i?-57_!0Y3| zC?%(lf`%vx2p_CTp8XSS+x9-66sZZF!2?0M{F6dGRE7+jXSk0nu_=aCUeprb2f=6t zPCfjNjN_^kWg$w?ub&Xd%{JmfC#pgQxgBH&W)fZp$EeczMV{fvRDW=eLM=`RHwEJb z*P2tHnHcgjq0NJs(SqYsHAS3M46ESP5z~NSea9s_v9cq%APN=*t7^Ge^D$u<_{c24 zjtMDg>*y-ffz-uE5NY!d3EQ;o@8aQ%@`2b!(=U$z=aXt<(F9D)OCFp{@&2(w1^eWy zW&8$^t3ApIa^EtpNAs_(q}RVb@{t!J<=OjpiUmBCp~PCPiK=6FoqX8aT(?k??%Fbb zt5X$EB*_;=Bnb_b;O#s=leo8=*S>~ZUZnw-XGZc|6@>?F4W`)X2bFn$$*Fn&jBvG_ zVnO3Q3I?I426wy&JjUtq#I8qZIharyJ`G&=!VSbu+i*OJgx5XEmeC*vIq@h@_nNfK zOq=lPlAjXp0QwPVRka)-R??JI3)-=XS{CZm{S%Xc6Ue>ER zq=nrey9oU7=^q$%v8=PaJE@5+G;>n5UTnN|g?yZbckb*W@bE7CE7a!d&!W&ToF3=l z&c_i(?(`=I8y~OqkaIHsYIv0RR`+0f$$&7A^OD_ia7j5_eCP+cAJ*kRX6St;C1*{7 zc3D7jP02qTb+p;Lzpuq&(u5~+sewbmDXnS1{QyA!A%>0W(9B~%IvPBlfJy%XZV?;B z!!3shWzW9|xw)nUN;xtwqU9&ryjdpYNKe&&S@MD4>Q&(aib}~)hYwQmF5@zU>KkyU z&nS^NV46`ebqq*zZ6luGk;i50#o|6KcEy_f)sJD*z9(&Y_^i=S4msjDdURrmap~j4 zD3PC1`b%PNERN2nR3A#{p5r6n8hAyvG@iH~pBJ~0*j;XMd>S+ktaWU6P0qI;^N7`g72?}JjhoagM5At3MVmYlS zK2l6XF#oXuCW!WS9;H;Z--n_~)ICMX2G}=~BTg-~f!2;T3?-?=q$z#5qU4t>#kdIi zK?0vCv0JvKq%;y1o}&)-oN(J&kVy;_rH@w?=tq9){e5v<4CZ_YuLpBRs~6$$_e%cQ zFn*hvn?R8OuMf9~yr@!Ry6b@jf7(IFVXyGV80&$pyfP!5T~B>D zaJ8>GU zJ&C-Agg1o^q{!9?)@ekEe*mJD;5*U7l>czDyYz+)4KX@hW~gED4fiRXr=M^4p}91( z!jC|@m6eG0mz0S1y)sQx5Ift^kRj`*Agf6A$jiX;oqv-~gypBIBSzTmh9JqVAnH}v zuztnx;kui5RjduKxi+HU-folmP+iZ>`am@@mHgn7SxRs(@IO92tt-4GeY2tn@ zt=%GC@w0>eVa#n%;%~#g;S&N^M6-~N9_x@1wy(zL-+4=v9VU5z#N{oJ(7*E`x=Ht} zO|3%4td6C>2VpkVnp=PbvR^zo386@;d*0YRQy9=7(dSG>P&KU5TT844(9RV^%YI}9 zkKC+P<2YfNo8%%m{Z`+BfkgW6Jm6~LytS!W$XNYRE^e^6{_gqrk@;fZ927fS+r)Qf zoDX?RN2dzDvU^bRPDd2Y^4!ZRkr@T4`!Gk^bv=t0-=6YX-*zl&+_#6^v&>sE^Iu|G zXMM?wcubydlVct-7I7?x$LQ>Fs8I+q5`pI^9Du1B?=2n)znF51=fZEVV*P+5NzSAE zZ*}ces;Dj;zG8ox*!aDJ5h{F(%k#xD!-ncl=$u&gV7)Z`7 z&p!~|IKc}zqMy38Y5@9q9si1o9xLtsQJrLDvc>;U_1=M4|K0!iW$&3Sn<8W;7FHeVc)KElM)cEf0$ytwI;d3Pz@o$Kd$N>o8$@dn}*y=t@1WO=; zR9g#+U|{BISS8`77zA4&jpc9_&jhlVQd;b%&KCJWuEKDVt7w2e>?R7Tvv|rSbcQ&z zhkW26$wJZ<_y!h+r-7u%ij$<;G?h;U-h}X6P?)PPGnEe>hxuv(|<;h`J#MP&Ycfubr@& zI@duz_3D~i$mKPZdtSQWZ2VPLiXRYSYiW_Z(A~d}@!qY6?>&E)uVw}tnI>)6JL7u9 zyNhYk)SkqabzQos%5ptC{f~4MLuD0cl7*QKZ&T~yw~!h7LuTktBrfl}v2_#wl;6>8 zu4#$?ZouwV7}c6%2%grp6(dcu!DNHst}3A|g9iC^mCiOmt#bheJBs?(-i9tUiX4>x zFtUfGM(->lRm676099s6?f|huf*eU>dSjwSmJ^Kfl_<|D~sSe3mYo;80NkNir` ziqRFuM&`59B|Z=)YiJ$d&)FEL9gc}F7MnQE3^jTd^K#dlp{9oL6@R!g)E*%2bQ*Kt zpD_|u{-rw{6D7Br;C6-M-zBA+!T?a^w~a1=)VA!o{43t*&VQ2>3{J0^f*3iPpbbf0 zLt~mjRiEB?qllih+S{GHEn@KQbEexK z6^1mz*U4HFqh6LnYp0Ud=mg;O#l+`L2FnOI6&3dA-<#Fdt!2s}om}(D+6LSZB0H-$x{kanl&yW^l^pE)Oc^yb!^tez}s?49<-hsO^u5 z{~&g%gL(SMqf%T&zO`HHM%Yr*Z6hjwkG^s^jR#%)5p1fR zOSuvPPPOuVj|XE@W1@6h9~;`ilZ=BWsm#cXjBrn{sH_UN7}nJ-9h_i8qA#9@@$I`a z3BnU&t!?mPi&1@9-YAPnqt^gNquu-N!r=owDM!;Q71IB<`aZa}sA=w=%NCrdl-m9= z0u^S9h=p!RD7EZN%qERUQsg_)A%(fW9_Fm+{O9!Lz^wqAVgr3^5PLSqG+$b+&@`(2l zBc!R#$hIf-kV?_~YxB7M0|FznxmZhkUw0C0p^~=q6hPC6DiP4nKYwGxZhPhW6~^kD zGDlzSwy`jp9L_$0(YnpfpXCH>ih5Y*GlZUsfu6}oWm%tSn)QjMHOEA~UeKd{qxiSZ z@Uv+%c*6O7z|^6E61&&`En4CF$|dwLR+Dg)bV5;aUeHAX9IP+JD7j8K^QnV)I>!eR zPz$Oih*Erzmv&3C@U(w5trSl|V9&gvpp=@_YHn#g$286;OKx5tAnFjsn4kc~7_NV2 z)$QB*e#4r-(6g?Suh$wH`|P$1f)&>TI_JRxw;^vlpv$$<_7ulEuud#Dnfj7VCt$9< z*f<)M+e;sZQLx*YeY|ILgJf%{bW`H`bf{PUd&z^n<@_B9$OaDcj>%)v*HMaHe7k<$ zeZ7~zc4dPcT7IQ@i9DpTR>$A=R5(`NPbb{5);W=hy@glM69 zFD70*H9+tx{0X1kr@4MLDLqv-dWz_FK;K(Xm{U^f+B{C#wB^n}6Q7N52_pm^bwuuH z+4yMrYyAdulJ6gE9VuwAFg@}5@&g!&i2H6nao=%L*QXT^KcW9@ucxtiH#oO0uJ)}PWKka*;&f-2ym5}FqQE@%*&WZNjgv`i& zZDBiT1!`I8Ne^$_Ljn2&ny>>li(B8@?udlVgo#yJ+# zwS4%UdN3yJIA`m6L`Qji--UcZ*u?yJSdWzSt32K+$(U08;IWux&K9~28 zy?WG92UIL7fysm@#d|7U;zQK9#dWMscp*CBoa*)O@2UMeDc(mjrM%mKv_tM)tDv5j zW&)22BShf&(g&0~3^G$JkL}dQ9?;=zIA79bRHIXo_d543E8q`mDq)Y=GlVSsM5hlh zviZ>kS-JK~@R&3O!yQmNq$+*DiN^H+(S+F7Yd%v{@Ixa;(VgLIQON`DVc&F|lV@%9NAZ=VPt zUmjpQr&Ed4ar#dmyN%1!(NOu2OKvC|Jn`U+*O1pMXX4q2Gzn+K(|_(qK!Q|q&Yz{I z#1i65Q67TyYSNCcsWizCyQc99OuvKf)#l$2Qzo3lXB9{_9e2^@fpa_8H)(Mx(IXvf3!fo8cKV5Xr6u5=bIrCX9ql| z%?snoNUuHD49SpL7G(Pd*H>HR&wa6JXtmX&q=_+33I&I+3KF+_^^ES{YFA@bC%nknh(Fv2#i;1DGTKQ3U%kH;UeLywR9HaL?_ z7V`j0exmwIN}L4`Z|rZJ^>cCHuK?a&BBI$+ICBZ%OrGz^5=&{tE|0Jus&b>>yw|g#K4nwwGtOPunN?Hoglve}V^`h~iViNjfe1YtKw`Z<8 zeka^Sj2=-xiWBu?3AGzlQ96=o!@H=~dffqp4W)4wI9&znhihtf}kvCR^}6iO>rdF|{{<<9hOip!TL=`&BnLNN$r zHO5agp0b=tIFA``trv}YJzreBt6{_1r@vfs%D ze$(7(p8T4ah(x$J@jYje(DY35f{N!4HFfm7Z9~O{|li5)cw@s=#^ zy;Q|{4R{`@SB1f8%l|dH1OPVm@vmc7zm2WuHoqwM4oNqivXc&QzfRaP!d8-fHzH^lSYHgo^E9RrJp4(Pd6THsKydG_kGAMK@i${-U?{n(3jtie*0W?NJ4`vwHA^o zJnG3mXCCnyq*CcHbC;?6Crl7lIlp0&Gnpa_AYU+JTD+`)MQEG_>OY(FZ~0dyBw4bQ z_OTWO%2$UtU@<0mKq)-y=Esf4_V-M$IKo&;4%uvA-xI%2a#WD8Zou7X{V7&kMKd!j zmt7xJ8cpM!-v|t%6CoceY{Qm}_Mn6x$#S>8kpJuVpu12$38>T!>iT}=-NOkB?;gT#%iQLV1vO}KlRymlC zkELJ$RBZDkh1|q)^Jj5qKAe1kG<|Gi*Bko*AaWyJg5V0fN;OE%QF^x0MnSo1)F zLLPIQ5~ZU=i+UL^?7 z@u?OhgJO zAL?G3jmfo+^}p8djNh_GzkXt7EVOXTWAQXD7QogPsCQs`MLGNg72w|QcE>zIS~ez) zKiGg#?inqCQ5Kl#KRH_?e`&%IG6d0|tY2N$cI9EgT0i8pwJJv#bvAIziFE~9adAPrts zcC2rNL9V}GY|!c*b8z(y<)erq@l+9%xyd57sl614tw6to(E)B-*iWH6uG?7{Rk2ic z+K;hGDdhVNGNhUYtPeQTC)S}`zYHKlo0P(l%o|REs5|_c=!i6sNV5a4t;w}c;)9v6 z5J$i7TBeL@)B*p~kIobQNCW-o@$Mt}gMxGhLEI49;q=4rp?Yda6(H`XfEK%0Il@+s z6$dNyiaOs>n3+h^*7B&GziPww(lA57=WfJ85O5~OQ}C##^P!+vz0_(R$6}vblhfeC zzT0rmK;X0cvp3hSUMpz{8v(dVHkACwtdljAdp;mKAe5b0R|QBl<99Az`@s~D{bw%d z1CKcwtp}oWS6DpuQ;%gz9dXugn1(uxUR_IY?LW=o(Ps+hLTly)j=1y4AJp0-s73V# z{+W5{3HvB2Xayl|c@8wUI%g(`iME7H(x7jO9W}J^7?CBNuxVhBDj^m&*mw#G)=N3& za@b!9n^qbsw-*E>5i1yO1&v-43HIJ!i6%kfE!jYD(X}p%IVjj}o^-v?Jc9LCZ)j4l zS|?xVu@r2u6MS|}xRDe0e`Fmv9tq`e{AvzX8a01MjLeXBnrGh)xV!@9TvR1Cag;p1 z4xX<0M8=*A28x^fVpf_d=6>O4&00$am9aezL?7;+=tG;cp4p<&fLnhOQQ?n#2E;#a z=6whMyfhBOzGheu8RBrp_Fy;?s}Bi?J^;9>ZqA5|;j+`_#c_ZUG>RlQ5Fgk7UfL_j1NwC*2q6MW z%}$&A^gP1X=&);|oJ<}(Q z8gH#~)?@u`bT*i7a&Prj{v#1=#2N!k=`9s1r*td>5zF2-An7{S#e>(C*pTIe4Oz}o zp&1QN(?(mKP8#!NyTx6AsNP(N!|(+qx_p{?i!V(?=weS0 zhQINB$ZFbN7R&xT35eNpDr;-tOWpbA0IzO-jP;!4-{Q9Q?Y<$)(OcLffxpF{`hO8w z4kH$kT@$(0^Kt(Z=G`_`8rfIVDp0+){2TB$%#E1(`W<@*B1r*b;nygeVW@4PBRp^d z2Z_kBV^XK^ItMKcg+6c)Gi^m*6TGl@lEy#{oXPV}@?5ILO{Qu)yknEftfgoFVwUoS z5wNNRU{xt5;P4zCwQ~V?`R#T$HqY>RaXK1m$Q^N14B&TgRd4ElP5CUU$tmNMNo-lU zA?N40Bv2Z728mh&&(EO$hCOZI`%D1TXnZ|{0} z(|17}&|$Tmf6J8&r&47^&XxWJFA(Ink;eyr!a$1j`uVT*;7&gpY;`*=uR|%`osSj**d{XW z%qD;#zsT~a#yruMk&G#&=$!2+QUFD&=D3>ZKHSj{_~gHeywPsgD%Mey4C{TkpyBoA z#s1Ld?I0&8gL4_O1gru%JIG-cWHf=8>3@xLAIl@1=(CgFrl0;~UbW2OiIdKXE6a}+ z*;G1w=!l#=L-woeA=*^%c*DtiyKfUH(r~a3Xv_F;-uYw63PTd}#JS*Wt}k1W@PcH$ zI-^qMwDr$%Lszbt$_Zas_1ez7u7Y;{Zv|?P5!*o66!Dqv_q2QSX=<-Ie+NEM% zt1QPUaw3Xb&%0w^Vt~=Tsk;pPU3E0i;kV~I-~D;5WT&&fWaJDmWE!eSARy8K7t$FK z*!Cgn^v+_h@y%8@h1oRG`gOApNGd&Nv;?X2uEqyiyG3l0zHfO}n}b7&3WkKbM4+bQ z74@-ZJu}eqdyDDWC<-qa*U<8!pP|5F1Z2HT;0gVapkCTB_2u~2v}aUR*n|{F^GHIv zW-s?=>Sz}x-p;)h93nj9=<^CtLML_-gw~7VG`YSk(~Z>2XTS9`r>AV66BkbC{VSl za_Zn$|7i$$k3O__y&pstD6i7`+%Y8M%Jrc{UGoQIFYwBY-$Gg-GBFNGNtE||(_6Qu zn%`~4NG=oYjaBXI9qL}Mkz6|9^`JoqSh_bK3n-oA7U1>K*#7U~a`|oR8zwT#Ew{&G z&lCKV^E%g3!Lq{ruU_f*i~C9Lmha4i8`-whJ`s8!5sespfEf*;aj4{s2avaYAqc*V z>r}u3`~rb_k*&FOVvh;Kv;d&P)xv^<34-o&rhwn^4_URy@VhgCy8@7XHq-OvzoFEJ zKcG3t2PYqI+V9<$_xHZ1R_qEI=V2@iA82E+PVo5%{lW8>znD5EQ_E68*X`DKH9>y~QqBRCoA zIdJm5E}`Si+u%Xo{={Fqkb|88q`~S3MZ;6&CyaP8_hPy`RyD}wyR*^)5YIFVIYu}m z_6=!8RHr|BN{wA{^O-PuiVT=|^i6@aC|*LL5a?m>Q>UWqsXW#9TEVMuCaniW?^ESG zMn`$BUWbvJ2e~h{1x~xE&Nm{3&qa;@mEFBymCsLyv*kq2@ya=f4~5L758}XXziN`? z2@^uoTVNpwABchOe2d_wr#{Ad(P;nqHu9V;=X_SEJg#S^K5$L`NB!!3ilxZrGN!xy zs@yT3e^!7Fw*LbKA+7?%RVP09p!YZybi%ys?((|Lf2d#BD|<#^uRQ+dGLwEU>5R;J zK(BzjTM7z`{9}x7qp{JvwGuW)%@yxzD*BtB#1$amLR?vXDss;&6&SbX&3D5Dwnt9p zH$5S2bvih2XmEZYThq_#d6~-Ok*PbGdy3#fR$OiVr}J1xG=@9z;r-LjGE2W4qkMMd zhq~CIAc$A+YRgMMZ?Skl*36g}K~V<<1mLllLq@UAV!{|ubY62JLR4Yz`LF5NbN`1M zQ+`tZb)#V^ZCgrfQ1dV}L(Y<)FhXX7w*H#F^vf9oZ+!X7cz1y?R<`|E*#_LB(H{C1 z_MH50x9{ocXOjG(oVe~#t#+6CeDY|f{uK%LXjt4^Srv|MvZGe>?!apSk7o!fL1x8s zubooQ_=6CHuR|SNGqx7`XA=qY44nKVm4xLQoNiAs`WMLM4sAA2P3PW8zTE(eS~If)tE2Vs>z718xW3r54UGKmzt57znb$+ zvoLK_+jR+3#HV%V=MRvhYxT8rf!#Nrlaf1ZA}?jewZ{486`R5p*uA0k2ky1*H}raL z`OAL-hKS>S`mHF%N@tgS6Z;rrkz245Xr`F@JoP4!Z^#BRrIHl4e34oW=dCnI-WJ!& z%4SR^+aH;`i&t-%MwcE?m+{~~5eTnkTQKb`%XbzgRXm9&E%d7_r7f)4Mjj}+O49+{ zJJ8?lFIHwQQ@sCjZtMy|N9%qtO}`=!T{Y!mW$3E)xtB< z@~E(3JN`510Ed9UxCQ`_9QGu?ZU@FuoOgXFh~9p?L;D@ezZrl@Mb2B+|K;D59<5`z zX7C2*`bZi1@uIzozY(<7%AaX{2RuCz^V+#&8dm*cpea=1PT~?kbx9M1@wG$#@n`eG z8-hHQT#vkhHN`Y&+K^UV5^9Sy@@ZQ)L7Rl&oRs6s($?H*4th6`a-y*lBIUV&YPbFt zfr+P;Z_dqslUj2fREA~=Pl0k72xF$0<~-~H;t@#>jVfef|JNi~p0Qi}GUxC#j|Cdp zC#i?>BxodfKPogcM8C-*{ez0Y;rk@(_45eNXEBN_9(X<%8VTM4`*)k*eq+~Nkh5Vy zEpqf?@zUXFAK+Ve3+VD^||f`w*X|Vn1gv5 z`Mo98cj<^qTR&7?imLwwyEnWD`Uyz?Q{c2j4_=vnP9ht*B0sHvS>aoD;#=ZH1irv# zF@i;nyBoNR`}BXn%bD5y+;G|hjh5=oHx_|SQGc9I9lm+PzF~X#zm1y}sqL^advkeY zgd^3@P0)=cP_C~x#I-)vdRnj=Dsh;Ar|`7Ym%}!>wD*|sGTK@WW?NIQ&{%BHy!cKB zoER)vpcbMQzgXNBhA~kobP+keUif#9`aQk40UYXHW$mbNcrwhN(-M78<-cdfNWz(+X(l=>Z(YKwC`?1@EqovC zo1Eh$7BA!^ejp0}UBB|;+8FFvaguNPa}-8_o=|SyI7zae;55%WFpxN$?`6#NjiRVzoF}W6qTA&f)rS`@`RzlGWPwf zQ%WUMj*WB<;%htSswiE5Z6eRy&;!^Eo|$Pn?l=3Nctx3kSDiZ2M-6fcDy=L}4%(x! zYtwoKW2LZVXFi8;Xy>(i365^$Vta#7bN&Izv~j-yQqERm{7f(_5+sT8K zX`MVF6jJizk5ow|R6Cm5c=*UQ6viIFW9#^P@>Of17jWl3_)v6}_4&Ow-bX$1>Z=Bn z1NGVhK&m1;H>3;3qnj&^S693rRKYG&ZTI=R(kU*mq~3?G9dJotLF^YUZ5u0Gi$&&_ zbYds0Og&&_wx6&vli}pa@uAL$`c$UJU{cKkwL`F(XU1Xbp8roQ(dG53?1B9nHtYBT zk*CdJ<{okP5b*M6eTG(!->e{eFaK8wzH?FuZVj~^bp~2~A=QMDX7Ohnq*wak9srRa zjy(+{xq;Ofy}_t8sOtllxfO0nTM+x1OZ$!$Zwjd&A=)Q+lkZ6gmYRs} zlCUN0Hf*85L^a3$+fTjuuFYmbcZNFZ^=gw>U(>*VdT}$zgbB9%1B9|M&PIH}7}rQ6 z4bV=Y>-Z4cb!;A`&io3C3(0ik*Wx@LAR}7Wu`qr-yM$RA$lHqBVg!0~}ICaJE$U^s-R!n0v4?Vfs z>fV1l9cDo{zsk>ixJNNm)PiQQi}XSf#kBsP#{JurS-BglM=oQ3vGW!(X#GKfPj!`0 zc_1{CUY@$eNl}d5N0NgR=rQ3n&JT-_It~uBWpEA1Yt(emG=3yV^F#ST-jk2$C1{nQ zE&&lpmJoFdh(LBt$JZ*G9#?SXzk@%Fs1~6EHRDdKiwqGWG%S($t?d<6SbPZtde9$f z->CN#Iwq`STbHv}@D-+1UOJ1FU|XD0uwucM^`yml!MZ2Q+pdVX-lDQ83|(9TS_xyw z2zAL&@1W^drRT8+?=L$%Z#ko`Zx>|PuW3~GKsvmPjCb%yC{Q1CM5jJ}d^mr!P}8#c z_3Igvtt%wnpQkH0E}7ZKt&3&>(CfXv(6aW&K0XTjqYJAD-urMsd2Hj|lJZD0@_MJe0SRA|qMura97v&cOeT+mxP++c?1&K5;xTzDUE4!pW}!X~Art6IAusTDgBtCP!XJey zQzDty;7%ugGBR`%4zK_9mjkc8wrVd^8r>Duu!RdPlN?iGFFQp-`8R#fDcRdR)Ib%}w*^Ie9yjd!p!{pL_c1xqOpy*F&9)R({d ztRTAu(PL!h9EQI;VqH!;DB@xxQ|;+K`p((Zd0IrJ&SC!oyZ63hGuHj&!@WgMs!Ctb}r^qfoUHI!(xSG_dm-u5cWnl zWrghKOfI$;{T`bt@jCFU_KOZbv8=brw#wEvQ==hmr2BtUYQV)o<|u%RQ}SlVs_tNQ zuSqx`YtyhX1;{vw?hYQX8w4uW!<88|BanV9g1^DOV`%7G@~8+eQ!=^ZhTkg!x)p=| zCxu$ruVH&Kq}6F~zhWudD}f4=Z+!oR(ZY(<*DDp244h6OWxY3J$(#j!unur0ff(^Y zm70N}Z}Fp;J;z1Ns+c_ET|fP=Xy4FrQnXKn6*T=LpWKdcPK)Is#3_VA0E`pNI4_;% z#Qn9Cl%sKOG|C){gw+wU-HcSZvD(#Vp(TrS<&H)8Ee=w2d}!Fg2>t#zRdiGa5~&^v z0xN0OHm7mrPb1kO_4vdMgnk3n>Su(_F@MC>NVkJ4428{6zk?R%8NWh%xEf1392#hD zH;8|e{y}btQ$$JZkbm|zIrktCA3l;0UBX=!{3HRt15xO7#|G$5e@eb=;uJ0C+RK4H ze<~Pm2MIqS^mzp%hQii{Z+k-hf}j%K3I7J$ZCEDP7-AlFJ8RW6^5QgwLTlOoEh#@Z zDJjp8_mvflKjI3W{`De1Zx+M>JOUX!>+lOc`l(&Lmy~8!uS1_JH?8G)HmsrXXO@5-1Q}@H;coyk80gF_ zm|W4(Etng5XoZTS43(xs0nxjR8&yjSzVsOm%D6n#anwPn-|?cK#M6)c2>lv`1qcf{ zD$q|nI>tlExiyx3Pq0+lT z5ySOkywy?-77=sUkCW4=&;U{EZFS*lv+~vQMMBb`*PHva{-jVdyT|u=-04gstx`bl#e~5mMQdxS?f{*so#8Q_2%FZFVNxP zF&H4hYBA{9=82xoP>hwWjmu=WZRr2%>DxTXd@3RHnTgtGXnAdMtqoWXA2DR*85Z}T zU9_b;N&&kPK6Po&bY?cwd~0EHn0x9Pv7>mcow&Dn5<#N0C`?3CtZ|baDk-4}Xb2N> zN=G=)9zV^@-MI)W@K7q0geaBJN(s~Dy+>B3g1n8oL)>ndT#_zpQ==iQvr)04#(!7h z#~H7usMdNK?^WfCm;H0$KB1D5+M6d9xQVquWB|40be7B6zXkM2KZ{;iHBz-Gn=6lU+5>u%C!aVGc0jq!Qu~#addjCS)n}~i24VsU|JTrOm_70R zKj6}nux45AvCoWA#c8Z}K2OwKD<4l<)enp}SU~2aU4hLbUSjhI?O&pq)ndv5#9Wz0 z({CnWmYDDV%@TtyBiw`5anTQ~YiehE@dkfml>&DC?0~f8b2&Lrh*)2*+^-r)#BOYd z(cWV=i|6vNEZYG$>B=*$j-~yb^}Rt{H5q0rY8Aww&y!FWs{exZsmiqp)j)z7KWvwE z@$s#{zJyE>`1c*a+0}}tshy$Bi)qit%;P1(x?O+1127ZELl$P%Q1J_wv-QVW`FJ<_ z*xz9yaZcKCr=cBZ1_O1_jw=DSk^R~SHg?HpR43e7oRe^E!w}r0ulSFL07_W4=}A{L z&#`!bI4Wr^KpX)B%>$zG1(v~zEt3Pqr>jrzt}(ZM6AdhP4Ej$lPjlfUm%o?TsJCNS zr|9prn-_vW$SQkFctYQbfqfh=k~y$%_u8xlD{Z(pcD#H_X%0qO$@%WLp?b};n@;IO zG~H@#7@XixNbqU<5PMLJj98r(^xHB%U;G95;O%J&{U#!a0ox;w`wwPP+*wq_!H{w@0ew9D^d$c@HLmsd5p=7UbgbCzccYpJl`_Pp#+yb+YP?qE_`B<+ z54aAt&n@@o$Nqi($9x1o2r$q*W*dk2dCrN#Wzpq_$HzR()is2lh_&^B+by-K`B!8* z8JWQvPN=YCbss(Cl=D71WqPl;0z^OzWglW<@kov_HWcl)_kQNTjeY6pzdJ_@``?X? z<=fG(JEKE?PiT!;kLH)1-;?NfIz1#$rD2WFL8Yfj9Y0JNXmEjC_}xQtVtIg*Hy^TrZlNuhnRU`b(aMy!+js!FYn@` z#KJi_6%xES2`}N|3w@Gf3TZn#(Yjg~#kv(%^DOh?-$N?1`|jX*ac_*U!44ausmI=j z3%gW!dw)H)OaJa0&*0o(v)v!bPg^x`oNnmGl3Nx4QK0TwdzrLuC*oY}ayp10(cWie z#pgAm(x)xd{L}o8Ao(E~Gqv+Oufaz11FO2$>D0N~`9@UOw5Jb}#ItFEknp6fVjQQ5 zYdn#4E<120K5}OFHWSIbT)`YipnqnK%Bh$e3fj2+Iqds2{tq3w@Nhp~ry41{q-0A! ziZ_UNBcB~>ym>^;G5X56wPbNsq>F)HLFgVT;uPQUg}M~~O1rPsj9z%Qa#&58@7VXX z$H+>GBnIE$P^5I3_r~kkkw@J&JI8A8N)ptw*#ykuB%bHWQWd3I)eI77>oA092px&b zU3s*YLK#pj6my9Kui@Z4r=}*ZW}I()+Hz2#%FXyY=(PxI6po4tQ2?dGmle}=D^=q8 zjALgq>tKK36)k3&`xY|dF6PXnC_0IZN^?73Gov-46f;;51m|G_}g6pWd!1?wJ#_$Ba<5} zh}M4SlL!U5afTDg;Sw$>Q&YV#Lg$Dv78X#;2A{6{(Yd>W;?Nn$%FOo%O5(}tkgg3mrwVh?A6OP``!*^pB-4?32F`r01zpt%2dV7Fep+7FTu=(bp zI7VZCQ^Q5bgchU{$Uaq%>lIEkA~C8v{iCM(wyl1Nyv_Oxr=Cm|s;^|C+tfU#wy6yr z=EV&5xn4EA(!P||&4KssH0PRZx$1Ly>x*~Czy3P>5!{vvV8hDE_3LI#m;9; z9}(Q#y)KWcA;|ol(zlqg@#?_&2>YUkFS3(dC-#XIsCky|IMOL)RB`zG-BIy8GhyY; zoHOfBV>?u=+7!&$skJl7&_axB_L+)7?vjP3h@OQaZqOYLP!N2=ABxmej%Ulnwi*hu zwPh2>u3jAZYS%3@pRubP8F{Kk+lz{DQDHHH!*WEacA2WzyLKLVM=RCN-x<5kPcitu z!c|01-=uVOOa8;@WPHD?EI*hoVzL(CaZ&TvV{}kky>9I`y}Ddc>~+`PD*GhY#eG|O zY95|H+;;LzIU8x}SDkjX!q{_0(mL(fOUwmbwTZWVc-b94JykB?+rU6h_6l=E(i3xA3KgNmt5IB?)DEx}(>Fe~48EG}e=$HC+m{*9X z1MA>~Ah%Dyr|#~2SFTD4v<)ly+^o^mTi^%=$+HE5>3y2Hj7j^<(?R(C$}r*mHF1N2 z*dQ`=nPAx%4fl%kW0cjvghtLl+@r!W&waPrZVrsMw8?OQM_~rKun2Dhe(UP1WCjS_ zYs&2EqspcH*RI?9{D@o*xFckl_!kZ4t>Ry5m@lBua^&>-x7ff#h6TrTX!TAq)DrKT zzNKW4=CEjVP}%>%=vIiiirm_#?k#0Q(4FGnn+-~DNOFo&b;jyu9vArzh*BxfgMQMnq3!vYrQN?5a zkE!=NV@O3`dn04&EJRnd@~08G^*$s0qRj zk2%b~e~}{gyi`{=efQUwB5Q)j`=6!Q-%o&B4WQnz#8GVs(xSHsY{Ne!&0(8W7m#fi zb4rp#ahKu~a^AMa<-BcAp-kB-^Wets()iPgec?f}QK$2)F(V*&Yr-@*zoJnLxAsM5 zP}9#wn@vOO{U48enu7S)z=%+Umt?`q#yz78LhGv(@v&wQv^=2p(tA#+z@bBQ+gf-b ze9ES1_n~_2Tc&ts`jO{te`Gj`+*rCvmD3P!dn!d}E7FpYDCo+cvGfPAgv> z6?8z(&Jjp5^$}81(KmTzZB8dEpm#UK?)xb+i!M z#=oFDsSuroXiMCQw!{Sm=~8}|{}zl{Cz(4PZ&TZL;=vPtXUsU0nFo6c^ASbAb`_Z} z=6{UZXQ8?Qsp|w*Rox7$RZ>+E_4-M_ ze@!0|pYm>UB35EeBI)CqChTU-h%xbsz*$?u-#b!zvM67Cw(wX56i=?)#hg|C9-LF2 zTbt2%TgnC%SM71fE**ZPm*ow949=`nRC8}24%Xu{A3V5%o|*me+oG@yykS!f)?JBr z5IpxpTx?qc-z?imr5h55Ux7Go9cjjSIvdPgy^E*$quuJs#hfvIu2*6Ak@$|Q!0{@~ zY?-^$p+(+f=HAi!=57wl*U~0)Al@J}_V}+qpEi3OK1o*?G^v|3HPU$6BL# zHHe7l+2V9=t*eIP-eu?S@qcyVphP>gx+WRQ@6JWMc&nyczN9~@uhwhh8YpHSDiQ_Y9007Q1filMKzo zIA-T4Y2*kjs6p=-eYj1&gG6{Rg-<}>H=9CIB4>RiISaEnhaWu4_SCiHGV96Y>C|ch zOZ@E{>v|fu*CpPk7JsGJh1ejOD+)D#6N}M0x4K-)zMsdfdhtxHp}me#@)(CQ4SvG| zuFJL^=mz#!VLleGJI5R|U`VXs@_~2#5PscVDg{3oHBwJ-ON{Y?sC!t zHqW#Rc$z6#q!uX8!5n5b!`Cxv}gy}3m34(7)GIKaDVKQ=U+)zN{JR^ zGYtoQXnwHw2i=n?(V_JJ(d;GGz1)Isyb z(J3Yz%!#nc&iVPPd1w?yBB8hzEA!76wjA4~zb5~6DZS;pFoDre-^Q0yo%DH;rSm&2 zIuUN)e#{*qgU>%_FwawzDInBU3M5w+tBauB@N&cAXzgI`hUyF$v`1x5}t9!KEBPl%YGpRjz&?_xgR&d7%d* zh$q1hQpBYywY_lL;L*j}v;(uz3BLE#BIw?d3gN#@4f2B+>a74P>aB@Sv-_sSlmEVQ^W#(L?X$hn??-R4Sy5=am8=3N z6sPT+2J^&Y=EC%IV`kKSnF}|K_kNtk0UcwQO{3tj`Y`Qm@FIHTEl9Ew$^WnNLU6MMf_Dx=0%HCe><@KImHJo&HQ5 z++I94HrdwmE7*)-(NkObG~%wt-=b%>eO3FoT18U5(rKyNg4q73@^K~-$>ln|xb1Z8 zMf#R)cr!AbGS_J=)38GgFOZozmr-ly(^iI|ekL!y=LcUrhN`qgyezEQpHfwz8Vj>p z=k66W?R}d3UVl@FN2&If$o1U-Pr#Ttt03>M^FNmvsuV)H*`4nUwjyczPB%TSfT z6-APeuwYE58ub*@Ph!HGWI?f8yLOtSn|PUZ!KA99RF9a*>4P!sqdgenI)(?;M{`Bv}6!u?M|Fph#c=d*xF z>X=euCYi^ntvU|v7K%7(8i<5(L!T&%QoTpJt>O?ZGJ=eRTzy=&GPPj<$ipzif?PP-83h6QbE zRG#5_*GHxeikz8ba#LxUgGJC>l@-EV7s+3SVHEEJ-L2n~hc3NVQH=kef5b`ZM%|?*aQoC?zj~Xg zZmiIQ+e*UfH>*7o)>ljLscAMa8tM&U1T-{M?3b)9gDov4i+IrOn{*#p1|{u8)g6h+ z)f$>vLa!c0?)W{!@NeRr3Qph?dOdQJJ}H4x4e<(RB*@278waJbXqZaWd2Y@`K4z{G z^4{;M7c!BAj5f%!&=&H1Pln{eVZ~L!cuHF>x&9Wn=ai}(8<6Kyebb(bC8vwlzT&cv zVkWpWw-)*S;>l|}cWTK^F|-pCnGM6WztxbUZ&dnF5;|x>PH~#N{~6>IOInwxSr)Z+ z8PxRSpXV2!N3|kJ_*g|rrII0P8#^8K+shuA6=InDyb)n<15J%9&7i7Nvs%B zP3Bx1UybUYEciJ@q$-$2BtnaE^=@@VmJx`kR=v2(`!spA0QbT_oE*mY%qsGOS4B)D zKpOI#rvToIxr&zlm{1kNg3cC@0)WmIZ9-j5x@~b)xxCEP$oGl=14Cj{4CTaIrcXcy zNlL;pf@r_M%M98!(_! zp2BSt_JvzSqv?j$SmyI~EzUqDW*tVIQ*i-F)K|$(uBL|Z{^OEeP)-l?FLGfsSLqJ1 zRUKXX$0YTD$NbW%IF0t14hi%N5hZ3>vi@KI1lo-6NmKw3{54CiH20I@Ro(^I_&Gv; z$t&MjdZBYGHVEoi^BULutz&RAFMq)?4zZG><7DPtGSEc*FFf%ppM)ozIE^cV9RxO0 zvt*N>G4PWa2#_X)>WbUOOVw)~D9D?0xL9?bid&^ET8(6?b!hzol$6e>^Cwm%FIxP0 z=ks0uY1|vW)-myFH*tDTstP&3GY*`|(7|59eOe4MI!cV(!jJtm?iVg15xWXo3HiK7 zCfkRA|IQnMPMalqvVVNy*&!44ifv$H=3TYTc}aiMW`{jFwRsrN~g;pV>fVUlmQbpGIV|0BVr6^K;lPgNdE2O_%Rj!kr5}kx6_F3O7B6F^p zQ%dXAEZ+H-<$6DDCg?dbJ3%HmCms{`AY5h?cj&TmH|@ii=Aqq4QkBirmWR|a@?dLf2bAZBVAPH4bZV0+Rj^225RL$z|`@QqU1Kw5JL8mxo6#EbMJ{-RIQo z->Tt9Lar85=7Rs6-iG0erE&_~2(fq?f0ZBqK@H^;rM8-)gWdOInq_w7>5G~z6bXae zSi#!J370NVQz;Uqy}mhUcyY!5tch0Wj}jf5^ypwbF%NdVKU9R+H`Lmdv@5q<$y=Y6N7 zcNjEBKqgZwG3o>)FMjuNT0pQox) zROcfc?vT7F9KNv7yhQ^t(wxzty-%%Obd@JMB3UZ?a50YpS4T`1YvfJAknt2l#sfy4 zM?ovIiza-Z>{#P7hduF88`+KfNcCh_BN1Rdn}5_dkplp0o{F0k4b9D!+M5)(Ez&G= zG{-_zAaq$1#BVeO7Pf1ZPBMHZUNS9*BWKYB_J8pT&zqD&9%5x)=m>`J=38Xv$81hn zWfr0i@n07fim;EVIjqrrpW2`_-L`3Kj9fpAoxjmP{lpb1cOXYr5O4qINbB#>X(OC< z<)9r%`T;^XRQ<_VzcG?}=BDQ(MakNNY|JptGn>F58>aiOUHA6qrJ*!+#JwO*ob#)> z#XmNS`^yp0U_DBMxtlZ%TQNSRs>E>|szE){Q}FH=XRP6x#+k>=$EXFNx&!1Z$AN#~ zE4#k8T9l?|3bLJt)t+_Zw%Y+h`@7FC1Bd_P7LXy%nThe3a`o0GD$2mglfWFEBu{%= zG!M!&!~$zx#005B@)S%zMKt)0f&nQvtTPHhxuNV0x}|MqNg(c#$0>mh*}Hy_11oY! zL9)tg!HYwLLvUKgNMv7pzlPLTc3;^@lakHE4k_#)6}4KZsNLP{df^|Wd8L{${`vB( z@kB-)F2HR1eQFMd88!LS!rmg|W6GC)MY1wh_=a?*IK1VbxJ{tk@t65Z4$$DtEyh7_Z9#BFCH zy_nx??BHGA2;^f1lNl$tBo3i`=>OyDEra6d+GtVSHMj+LADrOs8eBtgcXyWw4#6c5 zJh;0DcL`2#3GRNH_q(U+)cryAG&R%P*0c7byS?$xypi&0OHxQ!F9BqG2>n0-ko`%b z$9UkAN_@WO?~xw~c}^rAc_UDR*?_r98cX0I6pYeTBI&sJ!E|b9>DsNL(-(&Y71tD4 zOh-JXA%H1KKZZh70q`y)Y`0k9JnX(oFa^YLll&5vaWlvnOz63CvJ5_6^2VOi?(PS+ zjlbK#d0*18e{q`;E_9ty2>HGn!j&5fcL#H8$G#iyhSkJ?&=j{&KSaUgKLO?je7V4{LwqVh;axeshw)A% zdM$2AvBIRk;7m+~k-=1}d3lZn=H&a5m7i_82U!3~*ZH5~RXz1C=`#q(dabC0Jky;+ zUKuVMI-BE5b~rJC*`2PZur{2)!mT1NSdx9L=c;NIEshybThCtd0}&Z^$rZ(ADv!=T zZ;Zb@R_puaw9|&TCjK0@Y?Z-=h9|-JM;}W#^Ye4BQlLw>T@sooX%EnyENF_NT+O&l zFOcCI7E0Olx+sz7XOgPalTd4jbFv3mMR^2IN3D`m5C|8>6PT1HZK=RTHS4M7hZ|}f zDnF}kWKA<*?E~>DMnnYeq2lB=6ZHLG9m4sHlvV2m`9SLP{F~y`z>InbF#t0f*(Sq) zid4$!tcxb6n@WGi%b6v%9Mc|HhShCQDmC=(Oa)w9;d&C8HQ$>|3B7iRpFR)T9=7eh z*i?Uqe@Ct6AHWY~jDE2h)1hy|%Isin)LOczg<&^M^W9YdR{g$Fk?6hAiQ()IRr(NijK@q_hFjk44b zAG6_tJ}Wxz`>^uxn1ErSe9!Gt(7L*DX4e_-WYWqU{+i03Xm0z%vB+Gui6A9rq&CD> zP;%roi>#+MmV@(%CfioX8IUBIMj2-?aq?FT5S?Vko;64sCXidjOf)YT+HnyqZi$R( z+AJK%ZoL!Um`X+&m#vtK2g5)A>LaCBeGheE9MNce0lNh$PBh$amnz$jLt=SMuXgKP z8=ShS=C)E;FfQ!@C}h*-+zrx1B^~isRkawBa+aws9m#TNNA#Prng98h#JEWhVNG_V z8dI++;xc(AqZl@~^;9-lDfFtxfJUSnjniSbdOUvWmXIJ`9zEj?cd;D2$1rPCvgFx< zr))A@4;~^}0fxUGE4rNufx%}|-1UvE&MJ~rJ*e7umeJ_xo+bNRNnei|gMt{869>`9 zoP&AL0E6$fy6UAgn#ExRIe232eYbDhpyaQ_vVT18dofMw4Pf~IHij9%@)RWA7h^GSZ> zK{SLdlkxlhD*$sX_$L;?x~;JCv>52WUE5l7KG!`xtX+R`7JTB*eQ~*bdhp^1$u#C@ z&I#Vb_;L;chIhDEkOfe@D@Ug86l$UZrz@73R>~ytjHv4r>d`X02XcZ!^TvIR%_fDb zjV#S&Gv6slC5H2g`Ro;MnpyiJKy3wj)dKG;+~j@Ao#4{6M4HXflq0qWVVvbw`;8;p zPN)_EAbak*QrHzTM2T_k1Q3NWq6FF@A^#sZIkL@ky-1kem%%uLKHM*Q@=yuViU!4{ z@gF;4a-St_kyAy08T*6F6a>szg}jkLyI{v>M|l_6res$$@HI9UYM*lpLjghauU5O6 zi#~11j7Rw$a*j=dL+E%k-NV;yFka>=B<}|SB779{3R7Nt<~aDeeuwe3-~9t zeztw4YyU$eF@V^uu_D|^=s8r>EoY7OZ&4rqXhXmNagYC^AfgES1$Ka?!tpmcwJ|?3 zGnHjWdN{4T@vnKK*WGR*ToBBx$;+2UIVIsrb1sa9)8x9#;)F_s1zxg`6*3X`f6&h_ zkjMD?{p*C<1he&XUO~i0Mv5%nQ+4Dd9U6MfbNB1#|!d}x`$21FTG3C$$s?nGP8n6~@x%uI+{;bBPT8i-a zrd95ZwleISaueq&S+6VB4qx_#Ds-l17ar4lHzqRu*khwFSpa}N^I%DcL5Zz}_m@S= z2TvL_|AUxKbtkl3oC{)8R1MY)1_J$GhWHA~kR`_ELkZ#P4}3^N`FWN8aSaEt1-D<1 z*$}MSYk{8C&^g~)dtd~b07vL%HoDPSo(FH;lN`V7qWT}=EtHDB7P}eQeM%=_tCqn# zFsb+WE5k3-Iwi_q!f2+_%L*b4broWOZ#tKhSybc0cEXy=jAu5YISigh1H@)#sf0wK z&}Ek2cCorkfu%TLm08PZxlkPmK7}h0*C2Slb8A1|#<=6BT~e$7X%I9JIT_4Q{G|e% z!L2eU8XSf;7i1t>$^asSaT8jGYr2Jj@nZfZj>%)!fvE8aO2@14dS{tQsVifX zoXoBKFNPY*XW`4&EH*_RoX6NFcR0ck0wKqvK#b|g*AzW60n;t*Uk{X9{CU2pL23-z zp*3VF0lx~o8+D!`DFJFQKk45Py=RIN8${CRX1;%lC7n}ii^h;J03_VFp%Ac+R(H@* zkL>Ng%#~UhWM~w>u_+t_HW+jsj`5Fkz}(A@Lx5rj)uLgEYFDErigH#^3Vd33dv$X# z9^k7k&r#LSrxfMgrwn>G>s^=;B`|q%J5+w^`SE#>=qLC8lc5E6D`5Jhxrr`9qHLA; zcA{E8b)n8rjjK=8VXqpmaUX78s`3JJ=12}G99P1{F^ZsP&W*9RtY5<8 zpAKLVNp@ZcOj{`G)k;2+x?CKuA6dR?0LngptM$z;0}!R_^-V^zSB)mC_~}Zwg?l(D zpIFzcF)$xr%yNnq_9Z*VH4?U*7}!uS>QwpC$o7hyEbS+41>c%wGK^DBkNM?pK%Aq> zq{2mI?(j0rIZ#D|+B8T~QGuX94@LgJz7lAF55h6Om>+wp6fK=fdAO7=Oodh(Ium6| z2UQ0$s+qqv*b-TluX*F4#^xV|rA;YubTjOO%iv7%Lx?Nk6$dU|%KJA+!YQu1EAlV<_M-x;Y8Oc#%YASV4z3B(cieN9tu(je zU&`CY2cc;^hP8p%XjvrIHvPAMSLWN$=q;)7Bs*a(xKvsvwQ4@T91m&2F%km0kg2$D zo~ighk|9kXyaBd6W;AJhPTZlyUZ!2+va%FEg#&Z<4~24%VN2>EA`*iV06#<>6LX5I zRzR_)SXr2Y2vkIDT@oJNE1dFE5VYefDAUmMiXNA zz&DmsTFO|N>nUT_LE~#(@u%6jB~5UXssb`+s#h37C?_*bwzvlErWC@!Oz{RB>G)xW zeu$nql((6&UN9PrD4G>l*uxx-+225gYPP!S%9l_S+?nNJZ&nR{m%wHb0%(%}aC5Bw-m|#&WcNhWCxj`u@A7rBNBi#X>V%VAEb+k3zZ-Ys|?)T!xFs{YRHnW zFhTFJtd`XHd~jw!<$BcKLrj5wb?Ce7w1^-=n>c*RSFey?AAL&3@TXY(MH}rLf;M)8 zEvT0|T;;8lFSpl5L*gQI1Pdt9eErzJi3<%%EL>n&>-NyQ`D7B}4>ed=KeYwdwP0KX zKV_4)g|qdxq%eokC+&(WZ}BRcy)3ou$4 z2Ds03yS^{z-GVAP@uHu8IWA&4*4!?_E;yJTw z_r3SQFfSakM!3`HXkhi)K1pC~F?0B-aN6SAM?AQ)8*E0!V26Y~XDg)C1i;(%`3jR6 zAda$h#gjX7h+VOC5Ify&vi(ymnx`bZWy2O72xM2ZeLW7uvM@{9B`1tOgDbyt&<`Dhk{3KV>_S@KE4Oi<`I&=JhqHl|hmd zY8LdgVMaR5){Q#jXLF*U#X8o}lz^Ui7HPs6?dmcBqG6o<@X?(8ubxetdwVnwMzfPf zuaqr9euCuB*B4*!kQ+ODzkYvAC_e*b;i&Og@ruKtZ=Qqhdw**%;lv_BY`i8>NhYU^j5Hm zvaIlj>#*Vqlgqeiw!c;82OL}s;eFnY0_P97j#lcBFeH`W$p3OFdihBep-pxMTT_dI z1{4)o)s*BfOp5G#qTdm7426Rl+2M7>-MNBqyrAxA8%3?Hv&S|Dq$QXOl>xGdz)@E! zI7W5>m46r*W#@E>9Y{bW1NfH5-ct_aG149^@m9BRf^_8Dx+#it%f;6~U0Sw07EK9A zZEoH(PPi4iz^?I^Nu?q1j}5PS)4pqs_J|Kho3b_E%C*y#RZGTOTZ>);*^Qq%x$NsE zYZRoXAncSI^(>KxrDSHGPdTj00tjpk3orI@()Y7hk;rZ)R)N9vqq3b35d3L?S*q>Q)q&AHlpQG;i~G!#QD4`;--sVW}27xLq!OPus8$wxw`+8<~#qE_Su0@&ed`>ytFD*VL%3QAzV8PXD9f`ajhLF8X77?i|m7o*4;X12GeFh6FYc zQ2!jR*%Unj*NB{2vU3#u+W~w#n+)_+59og`v-htxRZD6wBqCQgOP=iV=Z?@`cGNLx ze+0Put4^K(M2)cd(k?6N#5$!*O%9ZaG<`x1wt$|)N+I-^G&aCLkl|^|P$>MzfgmBe zx^TnGxCzz+2xz1((s%QVQtW=W0MQXygQLq+9;=&@)(`6e66Psg_wx8|_efcz*Rd(C z#JRhKxv3S*Wq7f<8qgndD{E{*ZfLAPF4e?1d;~bWo;eMCvjpw<41bxE;>`}MHSL(( zBS~o(P5NgtlH(x7Ub-W{V_n~LF>ct19;kKqj;KlJta!U=9ouS*iCm(sz5 zyycmv?-o0HoSaZfay-h*=TAz`*$KYvzCsKF=2nF+!JB~dLL2<=_+>Jd?G zSc_ZAkG5ZSvmpIq2{qIocJ-*mz5M)XEi67L4r6xntIW?PZCpiufF!M+;XEw49A1(AoRDb$>@_S&BCb6%PMi( z;l#)*PkLcI%Div7?*eQYzc%(WmG8D9U06PCXLeak+RoPXywIB zufvK|21mD>ZsrdVE3`)RNcwi;B$l4Nvb~R|SvUPr!1;%plG@1dT_Zor#BXVVKf$AX zRu9Bn{Dvef!c=;x-?~bY4P-$Y_@*3P^7ci!T>?Wa(Y9w+TD{grm^Eg&IA(*!37)fs z+hephAK5{b1PKCeL|{>!JFY=((cMHsCbhx*&yQ$eRZ?)+4&a#%efM$IXub-@=_7Ow zrO{pH%0djvAPgcz)@(BQ^oKAHW?_AwR4rhxtK7(;S**LUZEbx@)@Qk697?BJbmfqr z(40jl8nx0Rd z!q4}TM`O;z)w|C88sBj?5C8P&N@$Qcb9CL>CSq%ZIc+LA^*KccX7;>Ek$=*62I#_e z^o*_dtJmu}^MhHd?l`xK`IzNd{x^21KY{yZBk3xz*f*w#Xg}xc^sy|AKDspwYRj;6 zK8fQ4M2v5*bYGRG!vVgwCaVOM12`RcR5U1{HY- z!Jcs`^cc;?T3RlbM7AyRjC=g3Z5ycqeDByou0`(mqzxt7zRbU&rnFWIsv8Ye5vvNt zR81wun+i57g-OG-zW`Vy4%Rkw4u zM0#X5_kGtyP(Gtd@v0MCI-R%dLCm079jE zg_mGay(cc0KhYDDbX;q9Z}gx2>lgoG+@Y(-p>1o1Gb8~YA?a+P-``H}QD@ZW>^c1D zcljdbQ52J2iTb6-1M#z2xN}pHALc$5moIgh!IY7gPK)5cvZ#2>Uy6==8vg@=ES76s{*{TfJ&yNQ*7?c*DGuArn4Uwo8X9phrZ>OBn z=p&M`kC?pp>8hPU&`&q!j+p~l+#y>P337` z23sYGZeHtMn7?#eeQ^bmv)Vj(QUIm3`1y@!%el~5c`p`{~+vjc~8ssj;2%g?Dw9MWM^j$;b&^(jX+0oiSYrlF%C54`rN;FD7l}Klf#kWQw6! zukG42@4vAZEJ$Z>;qD_?>m6ZZKHLY6-OL{)EO*hPb-q1z(H>C=UARBYzu=TbSdip$ z?+fMK*E0jGK}M|HoVE7h+d zge{=;2n(-}!+QGtxNY~l!_DK_xNnD!fBHzXx3>TD!avr=J^CaC+sQ1CujU7F(~!}! zpDQ4&w_%{^eq5eImn2#Dyq&sF)feZjQq+xE83x{L13akcx5FEmz@a#PYHNu^?`o-v z0zA1#he>l9do7J0N@tCrvHPn;OK>NXPh?tQcdOiHLgm&MNmK^ad=!-(pMKOWLjV8P)nY6`2{?galPC< ze^Cz2O}rad_-(Vu2z12w8#zLqb8rxjD(geg{9#E9&<#kS8&_7_j5ygoCWlTn`HKgr zM-YrZDxG1=m$Ff{^SAYn1ldPsvyj}_QqVLHz^Sp{*sB@Ck}dvpu!qd=^Wrt(OLs3P znnw*$;1P7RI1ZDt`H@EC?#x`7zPV)y;A#ExkByzj2Qe|y0w;@#hllZg^YHmpvaGKE zF)yiymL14t)9~xp0syQ50JsF{u!^v3f#~b`I(|uMa4C{|SScYzmouQVEMiEPEGHU8 zHGAXZbR@U6!ymlzD`g1e{=o=aI~oI%x7RucvtRLrYDKD_wJik=nIE>_Ms}rRvY%ar;g*j2vN0gD850a^71P@^hq`c3nR6S+_r{HJ((k@9qQtC^A z-J+=d!&A$@-acY}=|H{&l||j;=+0468RM;4c9xOBb86Px@u+h{x<1ohS^w;-0xl)p zHm~sD?kNr6gqVmT_@0K&s&AqMeMXNkzTRv9R9S}++*^KQH_OghlL;k;)sbXB)xSz! z`ugdLn;p3q&P=DImx}43KPb6)0s))`;UGohb+y*wtz>GpHvWAi+c@7*j;g#{vd3-aatCA0L%AbMmP(uxc_FGb47w%|t4m zd5Nzl@&TomddzB5@TA*J`HRPp#J!>!puW$DXNRuKYUziUCAojBaI*TP^uI@f<U6PUl`US?L zZ>#)kfpSl9Y`jXO#bMx2Ntz>Z@0;08cg-+!Sdp3cG6T4v!Uz=vjuCB!C7A)%?<-<2 z@OT+wFMMAl(~%iiO|9hg@ajKaicRyQ1==g3v6#+C{CpaH!{a$)xm=ETM#i#AM`LBZ zO8(#$l)^N5IotZ!<=Lu23Qtxz`$IvN2BD46a5lM6*#ZUS_obL$p~!LYp>{Bj!ws?> zse?mfpKx;?iJi#NEXJ}0iRo{=Wx>lw|9>p{+1&OVFCV5^RbLV>sn6)JV3T;PpQ7G- z((d-<{X_INve~iNI`LwBF`sPAC2)#S6ZFvh7c(>e^RMWv*uRiXkFU?691Q-fw=BTs zvm~bv;a5%mC<$O zCuncq)brca)j1*Y1^#RDXk>9k6x6QxA%|6tp;3qZY1$4m<0v@WFvp@B*4Z(?b@dhd zFpwk1@U>t$!`4Eu@0eq`)zQrb$$%^ZZ}7L^pbEOTFS&513RHv}vHqV|Y$g0+zK%yp zp)wk=SXLbP??=c>7qH8%B5^*p!pwM=EI(V?X;&s|JI=5FO2{HJKx#x3xdTVLTGEWi z?UwRSN8;{xwObo`-rQbq;dV;ovKZ)pE}SoZ{C&K4dd9K}wqG{1XPNZClb8T9b_??S zL?4Ds|G7+*)n(7BRk!b0^>LZ?nl{T3o;YxR-{2syTYAlL9GuZN-Q8{LK>U9F0bW>h z{ZF#9yGvUenQ$lubyem1DGNdm{a0n0ON+!r=ct_*Sk)nA#sDqbvxrR)@P@Rn{)^%) zHXzM^!V&RC9;#EttU>MZyDfC+EJHm`qPIdjzZE!^6rDT$zDydCJCKfE6;F>KJ6DPf z9O^V2t0tS#54{#=p()S&;LT45ul!wEaiR%eH(a&tins~O;`yuG6o40I*;(>18`c=s zKIN;5?ycWJ)ab*hbhQS_t5vLZw$3SN&&WsY?&W`Ttu@H1ys`Rv24{Pw905CAclmwx zm%LXH9>Ze>ZFoh-$U+%?rGWanJ%ijAZLT$6;P{2g;_IvNx927Lm?i+eAb$BCf7^JUOU_(tv+Gkw<{2tMY?{_^r&*|0R`{%js z>w_706aV>_{heled;WNZi9Ec|@gmwc@C$}2T2MGv-QmF%9Rl_JX{tUaDGdvTQzlHG zIx!mciE=va{6~70V{8`<(PG$dY_1NV6yr244lkUUM+0wGdSD;EqNj=|yF69y61L-) zFXI0~9&>VQG(dwW=NO@523`T+K6J%g8@u?qRR7~REOqkp=MUyy zb$N>{Q`^W77hzlXyu!;XAaHHsNa;pqxlzXM#cA)nl}l8Urn!MUm#>+5N2Ir|>w!Gc zzT1dBJ)1zAvr!l^6JP8i`lE?R?o*r6&4tzDUl`pN51p(TCcg}YxJo4w+Szef`!s{I z{fYTz{!)ZVrK76#lf&Ixnq2+0kz7X~A>buoM)}KQ1nG2j3le;lt2sZN2MvoRIaG6e zndjI;T(9o~9mb^I_#Rz(#Yhl7(f)D0CpZ$xQz}?nk0o$ac4}EmG9x&YL$S@cCa9Js zK)AO0%CR|Bi~b2+x+PGO+xTamb%}^zcD8Ch0i=s@NqIj5Cp;S6)27oMkPu*n_FSR9 zZrh4NDTa@AMGP%GBI(GQ6Bv=(%6bQ@aSC^Kh(|&&H+4X`q zURU2#56^10wy*LyI#r;ReS4J=>k)h}v47~W^a^7~0B7~0kl6(=iPEtik(XM(Ueb@| zdC<|8Jwbeme}k@ls)u|BTX!WnUrLwi+3~F8fv6vUgO~Eq;dhOFPP!rszb&kMwU}%y z+pQ~<6kWDra-RCHWwYw_By-4P{72@CijSXv7jPq+?_{Op>Smhl_mn1YP7E;!qyEbX zu6l#AuJaW5R%4?=S%J;0Imn!;%IFE&)M&s0PL_LhauGv|MOQWI17`{OgT)mX-}reb zKikx}1Up?3lrke%`QRA5V z^AP4O&PRh&eyz49e1HBa4GO~b(#lNEX9^FbK~|HUXrq3T@C_6O2=&~XGEh_o68z(Y z8(fMTB)U(-`!+u~WOQf2?vCmf+Vu;GO=o9|_@)=x^Y^OnKyIws>&heTw~!Twb;n1? zyL*)Y@uXdNubUN6ON(BmxwQNUIAhLA@L43giM?!4o3F?7iCE(+Msbb3J^WXn=-Iv| z2$GqGR#}S*WlRDUk%wM%^I;)Swe9WT)a4u?Ksz{qz4aw#-YDI@w+^3 zKFZTq4pJ>(!us41!~`*NlHoe?fNd`dRwA9}s~NV@`0lg7C5ht7zT9TX>Q$GFDknGc zL+9$KebmnrUc*7QhazaGS)u)kek~Zkh5VOBD|L*XNXSoWRv-h4P}bhuDDebYK)BF~ z#kG+9MqOxJ>+TZo+!`8w2jj*VE@NrogQYobU&Ntxr@}-;RnqZn3`a|MJeo)Be#~!F z-fFFvf!g%%%&zm4Y zsE9Y*D3px4rvGwSB3@sCTT*v(j=FZi<^zgt2nklAom6r!W;}~65q@K^s9^Z1r9@7b z`^>*lk%T^~F++^NuX@KdE+h1iXGo*8v#%X^R%>*F=d_}Jv`fJ~+C%smfPJQrm}UQg zK1**Wbr+}i9-4Ky7ygMLakkE69VDxqnA|yWQFa0)C%HjAFapl;K9K0FH1-MZ9s<2y zZ7WlyZz)wWmWlMpc<~a$gCEz1t$ECjSVol)&!_mReIpC&gn+C2-*4$_b_=weYs_kP zv|*wXZs8d>ylr*MnRi}oO-=@!k~`Mpzd_!7;vJlQ!XIz999KyM24df`11gPrKDRZo z${NgZJ_N|X~*;#)pDL)R>;ZaPAl_Yf|HsSPc&vg)@?%VyXjIMql5QIE8ka=jr z{zA3Lo+~{1b_795l`zTy!U$907n8H93`uwh#KayQ&V>n_7GS}`Pnde*&lXmA^GuuX z%A4E+rR@a>l>K@2sZ~t*GejT`FT9;ypiq|zMH^EVl}DiJb6JWiT=lWYxxZzMPMxp3Grp-} zqUduMHp_0I4czW!#}R9F6A?$DzcR$>5@7nb`1K1#PFp@smZB8xT*vveh#Zi4yvJ(> zrcV_!(6tk=Aakv{IGm|?@^0wWA(gDgw?PRj(gz`cT(nSM4{sqc;}1(1IulVDO@1sa z7?65BdV79Q^}9MAIg56QW#u{%Je-nn<-tYvuY?T5-OS$|AwyS>m6OqO;O->+ zaN^XM_;ockImfiL-6ec=Am@kqlXDW5W+Cl1umu zT*-9IaxZJz5p7T^vO$DL{%sB?-3J%@&McZ2Unijo3)4~WllIK-Ze$-WEF`E*jzeYo z7axW#TCC+X>)zD#mZCCHSyG8ol-JvF{xBtlWkuQ_AztHoDV7qQ?Fd{5CxVB4mJM9G zsywaJN@^jI@7t&BlEUS8Cc2v?z*6d7r1Jx&yavOY_b|Jk4EmiomfNhpsw1$g(6*L5 zc4Z-d%cQ#5qzQ86f?8z}8#LdfF(K$x>~A3A(VHRqpf!_sWSeUCu~)G-ae6yMekQJi zHam0A)~6VUcWZP^q3#zEM*=%D>D(ce9{t!nZuI5sTDex)o%LYL!-98{cO}_MP4>Fh zvn@w}GmDy|k>z5c%Z&7g5d0+tMsWl1ElX@-a7oq)y%&wTo;U<42dR))bQ)NUnj_vR z{XTNQ41$z0+8n{^g8j6m*(+h@N1?EV@IF4NgVt=D@Ue?uZf7(tm7)@g7MBV)BXvIg^0x<$({4{L+=6zUf+~|e(MuL0bXhLd3iqbMwb8XH7{#J ziz0zgu%D1L4W(4U?$I_ApI>~JUn@<-e+kqlO%YZj@GUY;#Z;tSLicVCZu+}o;(vbn z0pVwGlsmUYaArKNDxSD*EB*(aU)^(6>oevf@O6=lf|W5ygEQY^>+v)2`lHg#{=iq8 zr>oxvTt4|;9r|;<6cgtx*C!YWa_y==fzK8=+z!p_^vCB2+!8$uqLTc=#@)3FnPO0c z_B>Y#wPjQ z#aJ{YbNJ0qo&XNmC4i+m6_*wJgka^O2I8JUGv^;hP8@&yck6oje+!LwjuwX%-Mqc{ zR6ohf7Ujtv)moBN|Dzvi)MK#9Q1|rkS}E+Ck!B3RPsa|5wBqV|;`B+Qt|~@1+9!Ds zff1PIWrTA+Wkg`+c#xJZjFSo%AtY!Hrougelh7qOSj)cJ#+^i<&~qmEphcmYnw*k8 z|EY&|pxO|9kBZsdr>~I}j%4kS7wnYEzGcd&dpI;!^9XYe@rf?7M1ZAy_KWjHSCzxu zoTD3C^9%X`1W@T(_ml9afTB8vC*aT*Ak{&2Z?av74j;8fpei5M;Ufc^iOnU6llThN zW~5HP3X(zh>@$~(GC7?~CeO#GR)qKC@NtUTrs!OC1hEc6hD2h)_;TlVBl-@N2A553 ziE^>c@YNmDOQBi8;UPL?xK2GFd;vDrssA=s-rxyoBylo&1^9#ZpKRJg`FSxV(d5h; zC{av$Dx$W<(duvVb{q`f34e>=Ze}`olN0eut9kl8?jp4?T8rzKmw zZ#RET`8NawDm8NIp1n_D$8RPLgkQ$W6%%_z{xPPamBJ$*XV9QV4xt7GMdB|(u+I%x zp7o+e&PkJtk%u9mNHBG`21RQB5Rv$|7WgMIXljU7uY{~f^Rnd(HIiLPSu~4Gr2YX$ zNkjs4TL4{Ctj%BeQU6Pg)lARVp>uDHymVm@3O-f@1O;gdovvpwg^!&G zpi{Kd^luf-|4Tq05+wa1Gm7vxr-==wroRPG6<kHzl@SQCuKHXgf z8rR`g4uGDmkC#@yE$wn(nO~$t<|C;c5TyMq`KMCR$ZN}3BF4qA!i>hdCRoeW%U5gD6nu`1wexJzz zC}Q+!kj+WMiUD`blrWL&3>f_%;7ufO5bR1t4meEjXYn46Si_NEoPr_P8-WWxX{6x5 z4EarWk|+=y!|SwPwtJYg8s_DbFmHOMbXQB=5fzm`9W! z@_{>~XbB`4iU{y1OovDUg2@?NN2*Myka%SP?iZc0?FlF@5B_VDNC{wtu1#VjFe2bB zV#<28kLECmfJ$w)2+LzRAJz8)@P2Zj+c&)f}Dy`kJlX08j$F=SYJ5y%nf# zIDJ46132k43|Xusjx6*ML5z+G0kUPE83B;FQ%UU59cEFPS7O;`P1=4U(Uj?u)!8+x z)zPoOuV~Frb^M_4PRY@1WF0wvXk>Z}-#gXiY)mG4@UT5TMrVk3y5V(sD-n)-50 zF2#L-{2va)jZP_FhC~nHBd)uLno$n=f-%HNP0qqQQ?Drl!d?A77@nN5iWs3B!f(Nd z8rcFDHW)ua$#L?H?vOZO2_JnWfMR%@$6m>gEpbDXcbHx~c|*`rxlKdR$YR)jn35m) ztn$zJE^qp@+Ne&gwLFRoSi^^)or3dN8-YtRvukTSOOZ$B!(uvr`+ZCq`0W}x!+TIh zF|E_&fNi>}?W0)PqPU2?1Uy0?7is=`)kiGZ^|Wt2_?8TN>JpFOJ7Q>1273QGYAEx# z^eZvq^WPhYHz3-;HlO2qSa3HxprguccTr{}eOoOYMp7xkx)kpep^k314Fe$wZnw+Q{+VrFzQt$w| zTvw!8d^kMbK>wB1g?c~8T!LWN**)0IJxsqkx3oWTcr|&d zyg@7Wub#N+ren3*S%y&+6j*5I=sb85#+Q+7pp-$IDe)a8mDicRS453sR(D0Nm{d=8tkyfocIc<0CL$vWPHjV;`2}OrI)Cjy=TmZujz6To&t^$OD2~@E(*sR- z&|1wIs`Vb&j;JJEkXL+M2gNa#kOUXStw&dx+-Zo#anyLF@awoVZxFuD7iN9l1o2)( zY#X6oM2`X_l6*v)iAhs1A>Wr@mWMRa%>?I)DA2Sfeiqt{V@rQ+^`LTd2;l$J!8 z^^a6U)Znq-@Bi0N>;L-MBKoa950^*2BlZhi^3KD0p7}&tV^GFY2*+Gj(#3m{TEyh+ zC)&IlY!vvp5z(ciMp^ibI8(?rd2SKp?@ZY7rjW3}ea~8nn6xES#uWzvkX)I(UmbKHB-*0x6NyQMGxRmKA{!boWOm zuJR^(ByukW(PP4 zl)8M=H%ha=>%iZ~=iLhg+^0T+41SptA)ps@L~!3}XP|1cNUtCY$=KypT%*KmYT2xM z$z!kP4*cP VD~MU-5lJ_0w)ZWWsB;{}7%SX^$pcFGphT*Xu%cco`0=Fq0}f%&G<0Dc$Yj-W`K8NLi*e0e`qA1{2v;3 z8u}3=fkf%7q-2bzUtu{378BNuqB$wc-FRN+`z%8oK7@*03V6ekDL@?FzR{4jZ`V61 zYy5Pt49*As*gHCjc}kl_t1TWPV6m`nLfR(~U#Ese-$zAcIRso6w8^(?M!w(e{X_3> zf#84m%Fy0_{tsWrx-%gZ_SW8mExv3F;iWjox}K$&k|+4^1V^^WxMXA>rQU2FfzvX< zR7|*}dw1Ef6DraqL(U_|N)vme`$S$m>tjXenaacSH@sF7%xxczNbry8VF)#A6fm@f zx@>0H_X?CmzyODqI~*DGEfQS!vxt#^Z_$c&nHQ?%0EEEMhmNnZ50QPIzJfGcS zRV9Dg{49qs43_KZaiy$9YFsx2JE4C@<;R`thw*E@{V~R|J|J6C@>iCbYrHuu9)WD! z?2Z503a{AcQi<4ai{R9_xo&22Ov{EsILXzqOPauwpKy~Xzl=p8w|bCug?>QwBZO*_ zgeqsk8tCNRedjDjP z2_~zcW}@3NPbf#2P|G_XGYY9Tet_8O`EqzbNh|^uaWr7sQUB*la97qv>yJPqgVta( zlfGL(Bm%Zg!`b^%e+R)Xk4><988-#|m+*ZBAv4n6KLI7Ibt9?PdEiW%oZ_${xjg$< zquvUTHc_DGdAd6}%NK8QsfgO*jo-3TWwQY#KjhdN9=-QgJTBA0JikzRJAwQKRliAjqD=Q%P=O=p@X1`)kDd%L)MvnNCnDo<1@8?7nXYXM1qUs?}Wwf`MEIn+puP{5gZ&N07c-YA9^7uv+4S7V7~ggOtw^0Q&=bW^w6KtzbnTwumq_@ks8r=(VH4NK+uQLLx%*{>w=8PX)bdFZ#=g#v zcWCkgv|eaf<@PgCyGeiI@O3c%*G!uBu82x+wEjemoZ8XYWcGpOf!2hJ*AWyzm^MIHoZRs(zUR@69222pT*j!k!5S4 z3$D@NIs9`eJ0=aTsK$A(b#($W3mGRP7@8l&^0 zB>>du{y;83Qrw7i&`o~OLylBQmZ=T;(VpVgc_8xYcPS2=?&R`~SC$sMXIa$F#Eqp0 zIzo(AhwpTJG}z#r|8C$5dS4kR2brS&UChF&r|fQKF!n4KKaDVRVsGi0S=(wd{~j=A zvI4;aY}T}Vt|+=3)@`vFJXtR^$Vr8RPAbx&Xhnlew5=wNXUro^3Nzx}V56o%V^*y0 zX^pl__lAr4)YI+1V|(;H(bcFV^!2Ku-~2UKi3$dM_>;DM9-)jZv|!fK?d*8CuG;Ar z9^-HqhYql5AUYfI5;;{pU(8|!y<8{XpGwHCIc|Qb#pfGYCVRa1{@w46wEE7245|3s zN{ZNCL)h@2`hyoV`2SobV#+jRI4Srl-p!R=rSdhEqCIwiO&@`_7lF3=4sA6+tJ{oa zdeIpbmI3d6sY04#H1xgF8 zIqhG^3e}r)7S|s21|=^zcmhQ(%IcCh-%@UI5T2Ai{DnN6X8S=PwrQb3=rd7t75&B7 zJZ-yPo3SD?v^`Co_G^pA8~l+VzSAN;aMFf%;zz;DM3NHiqd=iYeB_ym;7y%r>I&i( z?$_GagJ3&>Q0cm5gd49-xUPEqP0;hwt>dq+elD&i>&85&!~QQ|ux!X197ShZm30c;n3#lC!7_b;FuwY`ZW0xg2wA=<+gw@;i<}tb z5b7!^Dtax&j=$~?#!IWeCKxaGO>Sk4T5-PZd`tl0$yxEeb2=sx{l}4s)U5{n$DFRk z9@%4;E&U(NI>3h*JlFyK%ZkhTVAbw_)V-yT@ox?V7X0T88Q^&wo62C(q9r;fFCZh$~kZ$5coRq>Ka^U zj<0!qRN5f?14jefdwfdZZ{eYGy<)6GlFr@SvbQ#AX!X3^&^TR|u0;O{!UxHaRQMMF!3+(ml;<86sv+PLpgTgKg({w4YM?>|){%$ix){DGjp*s#^I@fAru z*WvD`k3Wf6T#?ef%s_Fh>Fmsu_aQbg{Ui|5x=A$siyRwrf2=xeL$@lv*=>{-F*Ywt z?dD^G|1|&MD(NO2_zpOOaqDo`{0|R^n1lxF4iEHaOSh}vaRfNM9v*#U$t_GrcK{1& zVviekQG_Zc7qmQ{R+|oI6B3#fN;dtpm0tZJGr&+qa%2yjL23Eh)wS}9^~s$2{CwM{ znX!6eHQGHc&Boa)5L;xaUrSh6bv5%MB2K0WK0$Vzj}AQJbY^Pn$z2HXG6{4HvqjMH zxrQ2ZMC9}gEw0sC$zRV|C7`YEGtu5Rqv#nE+1zmEI-glS0w-pM+KL~{PM=*QYpIf{ z)lXk_t*-MBxHY-Xt6pxRz=pwzJc53Uru5fo3**zZ_Qwq?UCT>qSE@t!dnqO3+fMNP z9cG69nN{7#G@PP@(=YrV-)C0gj_SDlW1JkPME4eAVHMhUOKSm&=W21oV001*{=~1B z68uPa(n|nO-F;a>#2=PJJ_Y$wDtuZZ=1K>kQ`&f zf}Gcw@T9(5cc#P(fHQJKQ%hWSkoXLuVf}#Nbua#^<&K|_?ofhy!c^Y+$`O|U!KT*x zYQq&H&|&q82qPp1S=Tz@x`(q1kmdtmqZ)YwWjCc>M zgmvy~4)CQzAEB}+L67RmKBBY`%qprP z!haNj#X&{YAj+o2*ji_Dp`6wz*xpA6P68bgdfHa!wE|WUI3H%SYxP&%-xFu97$$2M zJ%nEPUPipz%#0_31*Bih`G($`hHxSxTO`yewIOh7M^WPrH4=CNsF6xPvcp^+^=)BZ zJ9(0NBaS}8(0J*<(Z|A(-icQdf<}R7g8G3|Bj4+DPAFZHpl?=;FqV9=6J+D0qgq;6 zX#d5tS3uOlt zD}yMfrEb|F9ihjt()IWAeqR78&YflG@<+u1Mykso1dUdRBI{9h>gs7y|3D}j4yd5F zQZF1gtfAQJR>`Wnqt;{`;Pgm=x5F1E3(ednsQDGORv>bhheU!WaMnL^;^+PSM!WU= z1UHB4x$Qi3dwfCy6FK85-&;bdcX-MVx(74<0Ro?2#L%v2O4%-O-t4xg9;4A05B8-giI&{ zHl{2CPn#{%rE&l0vfn4`LTPo&!+k3nd&$&4}Fl%2)l-;I8&4=97P zIep;7WvKo$2m1WA)B$a@2iAnId3bTisX=uk)AAk{_c+m46YoknNwQ=21Ru8~nSKJ9 z?%$;mD8WEoQpljPjTLUy9ST=zdo>=74 z+Fg}}hKTn(4{grWtb=1~IL{Qm7*#9)%KDsFuYjKZZ3z3Jv@|7$s2V3ZNP)rFikC-0 z3lP8t>WZcu6QYs)+fIRBGigu0fIj3gb|eM{wgQ4U(Y6=;L;g%e4b2x?x}-M(Sv;Wj zkk!A&dCt9WSkY2VXqZ0ELy+j2ZMAh}ec;IttOO3NGk z>Hd7JRK-o3UU|WQP{IQJ&M~-yr-pq6rAgvPk&R88B0K{je_kfU3W03C@WYUn#`ij$ zO{r&D9v!ae-CZXr+n=7nr<=L?-NpS9V2$cpKOJ?C-#+^7;}=V_A}g_QWYgHHTKre0 z+%CBy>bVEA)VpI+%$cO6*mWZ*KWt!XtR?c%x;M0tP4jP#FBi?{`)|*7#uU6-&Zi_L z{_`cXneP+F>YI3nyV<9Z^mqp(;A8cl)zdTT4pPVw+L(Sjoi-=uG?EfS?Ht^m#kPse zU95k~y?R3+IkbEI4(C@^1AhK7DW0K&%fo17iLYNlF~zk44KPg;NsdU?##rwu$4Ecu zeQKNDFDW|aFNb{>K_Q-iEXE8N(TIfPzeX)?UoaR{svsQ@DhbrMapZ%_6G8~Q5mO=S zw%{ry0lE&L+48lwXHymP&y>h#-#&B?V?{gx>y}@~jKk=J>`T&hl1?|GR%BhpuWkt5a-8%ECwMJ|o;{O0g#AtB0emdrVbUO-UNDxoAUGqgD z68hE}Wq!e&fIzea`M-!5Ua~h5-C`nl#~dtI{{M$+0D&qj?th?qiu!-~q^<+XhvuKz z;)5lc{JUji;vq$kJ3C1Po`CZr<`M#;Em+irbW=_n-6nEhBrAg z8bA@8`uuLJ{BN4=l&y5WxdOQyjwfPCj`7cMUz9B^hzUEL@_odT!69UY+EV%2#*aJj zTA08KJ|jYo!nyKKUayCB@RG1C6l*M*Xsq%+pbU2HlDG%`SY}5V+!%j#Vj6!)BIys# z@x6Ykx7&j>GxD?Jb6fUairfQBT+XYn_CFa`^KjZ@hb2c=1I}-c<&K{2Gfn}Iy!e?= z@dI9(sFncFJ2g{|*p?bst9KE+5bC@r4cbn~VBcGf!k*8K<6CY9DPnc%sg7gcUE4gY z3Q!(u;RpFhK~`Oak!%D&IYrBIwQnWAE}^u#rY{#(2A!^~oAgEqm5z^s8tC)oKe+rm z4ggm|{9r1edsO{F>6VxGKX!a_c)m-Z#~@lL=6Ws;c0h))D*3D&St>XstF5Mt zd>-5}^%Tb`l!5=_Bfu=oglB^3w1G3<0y)KHFQLap6a6#O+a_GfH6e*Br++W)*$RDq z+YO2PsZfjdUxDk*7*-QY;;Hnd9}4TfUSGo0e22@Nt%8}~=rikQq9YZz>& zu2~JfrS^lK315ne{(PqW)w+VKMFjR1^82jJS}Js@ADg!m94g=yl?*wc&1c0ZA?hGI zDv*^@_KlmQ{9;^2<4qJ*DO{k^=sXI2GhVGWzr?Vf7j;K|8>`{<0J*wiaUU|PVXmxYW^dOq(4J);+ zbDFp2m#nPd7Hh1XcoVnVZ*|8T+&=2g2HbnQ9t4=3-Ib|%x$XC9XHujX78|GOL zTHXJ%HMJ*r>=e?_LpCrCcSwCNnO?F}v?Q~331_W1@o;H60F)eJuq3~;B%4})RzvSEDJ4rfuT4F9f{NAyjE|<=&e|6SM3Pr{?4I8n-{4X}Ea6N;z zM$A!!iv(Bn&ya@ZE68s+Qv!R=cLSef1aLhS&pb#_OkJO($>@pG;d?yf?t?7csA?f@ z6%se98;_S;m0>wJm2S-86KW(2?T zOs&{43^$C?4uEP`*Y^b@-8P@06MD57lns0(f^z8#Y5u*Bf+zN>hL&Gnaig&}gi~+* zz1bh;%9k{GV{J5Hm2rPeZc)Zw==U1z96L;fZ-V0OXMc`+E8~0`U`$k{dJ!v?W;97i zR&!^rRQ`Gn6fI>m3*R56T1NhLYO@Q4_C-M8cvzihYpDplYt#j`a}6QqXW`oJLJPBO z^d4NsVbC%gKS75_Cv9dsLgW_@{;kcW$6Hk{Q%}sr!-u}iOv5skpE{LxihQT?HhCd# zl@#~0J04X(;g$_%>Y`8KfgG3&G)>kE0mzz@j0#G1Ogn*@Y)GlRuJaO%ZAj-{D=D-1+5;+0iPF z!W>F-z^jYImi+?9>qZvy$=X}3CyJmRdU`5kuwV*HDFF|D$*+=uO9)4ep>qCs{Rzv} zinb8kM-cD8+&Ch;X)p|`kSicldoOrVxve=Xy~ub`aj4z);5vYQ`}pId{`DO`daCWd zh$ceev&{4E8z!X^9xSJ|3^CJjuC55Y;E;&Bhp2m+Rp%w-WPi+rf&Pc_ztju z#ewSa6TeqCa^3J0<^){N?k+i;Om8*gHJ$D)gO#^hq6<~5G8-D(=6%ex@*lt}B5(DS zH;RIc) z`Fu_z&h;@RNS`XOCD|}4C-?EeIf8>ilAHcJITn8kh55eg2|VBtdz0isdM|>AF690g zMmkB7BH?-8TG)k3Vfk@vZiTg4rTGPHx!UQy@AvFCDEaZKoeX2TpB{~^@2CUHMgcIR zI^5aqp*y>*y5uZ}M;zM-J^4DRJKy&Nr$>LfAN{9O;Rg|VF7jAeLuJ}lu0x61cKsm#cdlRfbA>)Oo%aXEHV0IiDu`_My_r zS4f38bWG;-;QJ@oRAJ1A^nStRV`2Jx*0-tNPlJ#-x}6y{zg36 zn-ryh%zYLOlQ7=FtZ_sk8oi0A!rE-#{9@yD{DSm}c4I?CuvH~fHUQSn^t2>2-PB)f z;;PU^YmXC@#iIR!QKyLs4tPoI_iZChflkzejZIE;9(XMEq0_1o;Tu2Dy6?)9kd*P9- z1O5&AgAE-uW;b0MRc~B$ACh>?FQEaucncOu?K_6J4d-k!X3Rd6{W#UVj+k2(Y-}2U z&&Bq>Or2gU4Ku|!Q7F#v{T0NlB^uK3<_}_+O;IR~j{APq=i04-*(9$wculiz3FE&^ z5c|bC(!Yxw#rR#B_ zt=8w_w*D-OP=RP#;WA^U@?9cqo8t=EjR!IR1JUD0YE^u~R+glV!3m1>e6vLi9%U~< zd3|cY9F>Y_kq4|R4;V&fI>9iy1A2@+*%IZxO?(N>3eqSeMu*&>~7>l!8aN`X=67Z~`+DLtk!fydSJi_k1-kdG%T{ zGvBz~Y>9b2|52*42y_vQD8)OV+~n+gZRqp5HPqE|{Mit{#-(bz{j_gi_kH;$sgV5) zXazEaqj;Gj^Aw6H#=wXU0?Rd6PyBvAU?y$B7)ICB8&@!*a(Ek6JvoNq8nc_ z$NKH7vAfxbP;YJjSZ6l2ET2Zy&-U-RnT*EHQq7-DQ0Zy)o1JsQf7fMRM6ntCd_!3u zZ1QL*Ij!0Hw}*sj#ahg&#f`8>?#nuIeLQ?@C>jc|9@4;iU?k!e-S@wE=6q`QrP2X{Xw8V;RP=5rfe&Waz@OqbO*soXlG9P92ulb-btmq&H zdL-H4axR_OxqogsF~94gi7x99lwk1LpS+3x8XpC-gxSTvF$ZoG?P2;V7A)#zJFYaVG=my>|<0M07j z0vNKy@YzcI>dEWtc**J;^&P#g>tj31{@Kum9NN?Y zXvcDw>zwpp;;V|?wPj6b^c-jl9e)(K2ql3Y$HJE-O%O{h^2?cAL|zisC9d9cl{lTz z0}iBa=8XHhH3>^^_T&ar`T<2hQlq01{C!8&*2!ifFiw>#7>kQt_jRWeE=vVFX zGLO)A#X#V;UC>CQlz?{8dK-N>4)s)&FTIwXU);ft{>ec9vA~}tD8TAt7a}$wR+yU9 z6z#4oJJbC8ocZ9_%bbP{z+uZD>CdiXecAY%CZWwT9(yvU1Da zy*utUheO`REgfpxmc7aulB1K~utlT!MjRwjJ-R4?^Ti&GX~Q0i#$xJ|KUG9tIDX0N zR~zsNG2k}tK+#4EY7X9`K%LwQMMvtA$X9L3tRz?!=O?nP=j=8Z#8$x)rZuusHW7ql z%sR?_%ZCI(646r(^i`lIkN~Ty+n!)6j7}0i>8|{G&Oaggg?2Ma5+z_sT{;Icx?bjY z8&M#DgKj|P5gs zdj(5Sq`CU@gb$CD=Tnc^LUJ0&L#!%8@4#-f^7$k}2uRMEQH`Mi;|cu|(byrV`jsQM z$!bknFVx5QtJQPim<*iH!srZcyGZexpY>zhFZ zbmtNDn+HoUhdw@Ev9ABCu%IWe1uy$o?t!{HW<)@>AuEAS8K6WMC-DvS7i$OBxy9qe zs@PhKLGSD<5KhaQqUzJHa-?r`VYg5R0KIM2;SFg^K_kYS>8y|;!oH%A%4t9YeUQBc zyxcxD@vz4g3W9f9`}es#jk+ih^#wa4Cb3nAgeehoh#X;Fm+~OVn0326DFJhcSi<3Z z$Vs9&;iZUeV>2QrEGzg0*du}~st-1C1?OcJnp)Sa!n(K`xgtmxtaIV~i& zLd+;@>o7PXN+NoaDA)ueR-$_Hzekb}&Df|Sw=-AYdexQO2K+?yb|4{uAWfi$AN)*~ z=ThNe0m>pV1M}>110DaOBHt5WaQ>Zrpds?tQ4}M3%0c9k?rb&(J~xnFFvZ$D=z7|M z5lC9oRTd87g~2#m*fM!>@fD8InQsOSV8}lo1Zbg^ypK>mz6F?U%zq3{CgdS}+yK%V z1f&eGs`>8`$^RrjSl#?{@yXvkKeAgSfVl`<_FwR%7nJ1P2Zi?8<9!i^di&Ot*n7(5 zP6y}3TOc4(LA=8qR}pfuQ54u8!_^*_2&iE?6nt{q>st`->w*~1ivBP5bg{-Ys2dO~bl;aA$;LbQQM9a+Hj*Jm`YuwnlcXPQ)k zzyETArLK$U6HqXZP7o}*0~4<@+BbwWsb~l(?C|I`O$gGD3NUGbkGS$jBf!F<)nI2+ zret%m%Rw@!D8!^CCKmgliwsjF7n^+v;y82Ez*e+x!G7?jNbAd^27!e65DXB}1|mS7 z-_@yaOTb_W&O(T<_$c)ke|)Q7d|Mm4GX&|Q1)mXq=*WK@AL|PZ(J~25?^dMR z-?KI(&J-(%R)6Q#ta^gGOMc^vI6n#0u2Wywct8IN@d952K(ckN`Z%ZL;TBu_Im0ti z`APKmU{w9lVcq3~gzv#Wl=)$F&^bQ@K-!z{ssdRxO%0yT_${KgJ4B|kGHnP% z6$}if1t@-2rne(%Q@(QY@bOA}*$Eg0SD&o^?$`svSGkS=vAq-&6|+r3nrJj#cqhLB zvQzeIfUHB@R9{x68vTcObSVRaenF_8mHsWVL;1$ZB!Dd7B&46+Mm@)Gz8cUKcLy{l zFh{s+paC=-V7zBTIo~C*nDsstx5|%avMNYuQtz32z?7W$01*D-);&{OiOw1gHIXoPGB1c~|`w1sSDXS&qa_>l*?v$9M;NYy!pu zq&(nD#TY?MtPfY7q8m=D4t*7qUJ`5Y0gXv~;@FXGjp{3_1ia zCisxsQ_k|j9sk7ZA2>3rf4k84$)LMsGXUX-1y7dfD*v^Jd~5Z+68m?WF)+Co7~m2B zZ ziGYE+5Cr=XR@B`A+?plT_3P#X=o(#uhrLG3vEo;63Enl}fxv7z?-r~tZp9omd>f*C zw%$TZ7^kK3c*mVoo<^rHun(1?2U|L1Tk2LO!bs+&*o4)*TGlbRmAr+Y8L%~FfxD1W z(vh8AXRIrJX;1i_>oGHJeTgKwQN+?;=o>=65(Xu74njr|PN_(%N{q#Ut)m97^$HWx ztH$;fx zRzlf92VI21Y;Mxtm%xkSC86f1{bmujK*|K~1nyk;p*XMijaj9T5kb0GAtp0GOMpSB zWT8Z_p`u$NZE{7%O7H+#nPcPMdkAe38Zp3H_Tx`>1XnOKZR4qAltus4qm!5W30Duq ztmp~8q7ehy@4$}R^2%9E4DIz>Em?4(8t>YDe<$#g%YuJQN~5X=R~0(b#?EKLIXu<) z*Jp^)t@e-NJ$lvC&O-05*=_1r2C_n2QR!*J3!bmt_RSH#r1srq-b9;qrHS5C;jgJ4 z^^hKC!-n8qsj_8PqHgJ7a6vf`HQWKGtFf`^flJGHc7C0?-%oO$X7|MvNCMCDmpvbo zIBYKocALhF3>bZmS~74cuN4z-fUAcWZyHCUM6t;m>MlCFqPUzF%Swb5_)mo?U11;Ic&Z;vxg;8ZSvKN|a~M z22*YGyK&ZG$TR!>>f*ry>Uxfl&ztbF3*?c9IsIbLD_~@L#i*|eyhGy&Xu92!B~5OY z&uu*62_qCac+XnNBV*7k} ztK!-_uWlxsn@`$echs$xhGuqw-CrE~zPr&yeJDqugM4ozN$-oeyhcJ{7~gPvXhhqZu;|rG)kp} zp0`2^Od=M29cD@DTAkM8KDgV%6ff?_Qo8a2qtdS6$$J|_8KF9GVKC9wJ4!@1{hsyE zJ*UGIgieAfJ`6$X$$SC_r*$V4)7G{J1d~_m%N8$8GxzrD(M~Tipfx4dCp*i&SJo$W zK{;t+VxT}#(7e*>i)7UY-#d!%A{a<~Nw<)(nx|Jy;jl@E8hv-;Ws>| z=8noP(d4Fzi@h7=&=)$hY}%2U)021Wt`XjpGrmvtSyqCO(gUQ_qKK3lDM++~QNt)l zR{fqp&&Sb(XC0)!#UjYOg*I=yZjI`}l`2CpgK1hS*Tw5P=e~-OKRlC;$XJHIr*Ft+ zW$EvQx4h8vD(Cs%a)#(pt>^Q%d+;dJE0PXnSMUMoobT$)TK=PkS0TDK|nro zG=Z?gq7S3%VMByDDMM$O5>fa8c~`ij$pVGLp*!UomjnncDQ%b}j`#+5GGpP^XM;{H zQ)oTwzn|44MlVz9@4Jm%B`80No(=-x_#k5X!A$*8^zbOQjIF{1)$N+5ZkP>MmNdak zvw=w1y%szvYVA}c|f7AL}{5m>he&`Ma=omlsPA-9!Q_*t)inIV>>Mz`J>1Ydw z3k2!H1-9rQ#TmXGKjp#&Q)p%Ms4uNr+5_%sPWs9_PgLU^wU;evPd7W!AELOdIf9G9 zx1HDQNa+uXg#Er5T*CPXOv;5$1Ei?G@W*{YYp~yrP|4L`MrQ6qwlx9k?Z~>h8o0=K z_fUC9`_O|Cb3|k@kTPq+4fBg0rm`+Mi98I*JU$XgC~ULwk%$+rAh6A|f$50PBz8>W z--8X6jf^7Ol}f@@3N?%nNbL|vLtYg2B>%km-Rzz}DE?NUhix=L{dp$|{k>_n+jPu| zD8J4hS=_nCTfc4-OB{9o1PeF?IrtG)!oO^md*5plilXa;J5Ex9Mp0wUwIwGv|6 z=Pd1M3L01fpNZR5m`YF)Q$gfhowX@Xb1`<&)ZIUKv2_bT-vfU33aGz_LwIqeT5h_?44gnN|dQB^`gF0ufq5E_{54^+x>PDU~$p^wvQnN|5rDThx&YnVk_Z0_Sh!vJ=&k)oVe#B-*@d|LG-KuOw8_dc( zd1$(tv9zFa&&8|!nB~!EiZ>1l2uW%gM4s0&92D8MOmTX~_#_@4bAMaV@e>;Q5&sey z#i>;0%Y*Mei~_Y?yXJk6`-dmy?F`c7LGVFdNB+#xKQfP%WwP9{kg?q&C`TUM#;*u~1>;oIOuU4}wpi0%iumf1@UNyX~ZuIn@j~ z@($^&X5d8MRQk=L3winA2So7na-?*r$*RP}UB_J|V2MPF2B9uedWmeGdoZOXyBSsSNQ=fnaqtlp#*FbCFP&^%2p! zBN0$Q!gV_$`h)e7Ipe_B=T&IqkNw+>{Y}s!c38T+&l|Vr2Q5pJzSxm}5hmJy@dmtI zG+H|-(D&b~VV<$f^=0vq&$fdj=)$Ah7+d7QZ6ti&1h1Fg%?}ry*BI&h2N` zX@XSr?JU(>fkw!iD7>(C9%~qOoWs4w*XIxJt)Mri*d^f3>Y8Yk;7=oPLho=wgSwwU zxc_3zDzUi9RmpiE@77*yk)2DsL+~&DFIGr9(i0WdTs252-lZn~4o4K3E5Q`|8WQme zdVPuyz-nHe-`M!!^((K1)+@xOf+;Zou8($StWR!!h`S1H&H1*Opf{XNp1(^yv#A=0 zp~whemng-rf2;L4;)*#2=Q;jDI0!==3cRtDMu!@9xWDZM-4nd|M+?K+VD3A_^_6jOHz`=t*{~k>;rGT)GTYt#ny`)9PRRBS6h+s6ucstEeidJ14|xfwB5p zphdZ&z9v`fhxPYkkh3~ZxTT9~HVIs{eqb{$YgNAg>Tw&0CsWe~Oydlc4V zs2viptB=*~kYa9}PY%xyW8dUGjP&%SF26KuK3`CH7$uu*m{dtQuk9*n6%xC|nfoX_ zM}0K|>@TqG;#4^*^sZohH%>=lLkeXGZhZry&9ua?Xs7AmDmfH62;j1$JZw_9K!YC4*<{03K#rxnI1i1!Ooyz>+$C~oJ9=1uDR_w`KK zZyfuI$u!wiu9&SaiNzygzL&+6kCOR6t?bGuB*7gp^Jk;)s^p|^tjs<4*|>1@PJDr4Xhy7G{-ZfWHTLW&rXIRstcVx%n^frLz>nwhRcTjDUjt3D34L>RLXL~* z1K6P~sBPmV+x@W;6@T2+sI$Uolhk|gSNmTE zYadbIuypDM^-d_Av}t?DEUedXpSqFa>*o!n8~1(qI7uaL{l44oc3?0%+5P~>ITqK- z_T2GVPX@(E=$Uc-c_#E3vWd-%aU0fk)zsXaQ}x2L_1cvzc5huenR~M~En-sBLYg1_ zF^mqtPNUnYrVfMl5Thv}l}~obSY|mt7fmcM-*PX=zGJ$~4CNm4`hy`E@+SzbsYAUM zCgh&ejQyrdL7AyzMAx{Tf2wn&Y3l;*o_p1xV2nqCY2kWDhp_P_$2Yt{uIn4)wpP68 z*XVoI@dN(4M)SilIUTM?Hf{ZI?J81#J!mum_e#J^o_HOWh&aMe`j~XcHFW$Pij`EO z>L=VYoH3^K-)t5{gVzymP8i9URE?OZ>UnRw0U=@d8r zTCsm>J8PSj>8)ptte<&O|5mpbg$Zgp-ak={UW)8+26oJuDGe-0`sO%>lx%xe8QIV{ z+>U|TQ5|Q=%+Go;7E~DG+Ty5L+rgw%zJF(udFoj2jXTf}f;E+K%rUDN+pd$(1B~Ve z)ax$|8_z!A08Psm5%L3?X2LBvW4!;Yo-5bGji&X#R#+Nf76CVvMph+05*%+zFY8eZ znaHGiSZSl#iSPUFJ5%yk$tM7Xx(U40b=gTn6B;;vcoA^%F~;~xzx;5H6-UCV#7uvl z>7PMq5*$BVdLjgKoHO@y-{!IrhH#HH zOe+e6dQMN%9E-)857$^8Y;^J_k^{M=r^rN3kGTlCK1NTmN4{36R>zL8*xbNh;9f9!)^nd7 zy*=rOp{F;KcG~~R<&8JvSgxhXP5WBV`wSZcbk$V!GvZjQaP>J!Ij+-Gn5Hno04;bYd~ab4fEJZ!1}fC`U1H>n=7ZOy zKdV)5EPWc*cYLo|yuTTw+&H%zsJAK$nyy0z%$Dy@t^B(V|55brLTJ3>Nkb^fe1$~H z5c-*;^Rd|Hlg9?H&q*DMd$Vd@ubia@9ps+j|47Ypp(=zM`}~yo9o(LX{dvuZv6E0t z>YCSzF(H@TOj>*<#4JyD>)58QktZc$6`Ijf`cM0}v{au)g0k>f-r9JaQ~N<+1iK=t zOp?r*W_V%H*Oti=7&sD9bB%qCd8Ls4_IKUj#X+w@F*0?%hB2$b8x`^7B5Kd{m50{3 zs)7sRDFiDL6m`!TmpQdMj$E{_8p$Y=zn?fAiJ{|DxmI_~S-fy&oY{t{9pOaaEu`kkZms;hu-D(~#~hw>4kcG z``Btcw-ex9N$?ixtCK?)bnt5aZBY3K_BEWB>kql;ss7w@jC~GfVoRv3=4%{%T$Roq9i83`(t2&B##m2JwDn7p zZCl<{y-s}j`er0zX}yKMXT9eYwZGAx=hnpy9Jf@#4Ff#*7j<*;}6=K_E1!5C{q6fBrF)g*v%gJGq-``8Zp<8FPC(I{Z%rPW+h9 zRzbU`$Pft5f3)`pXiZ(M9o%@h5&!I@I&+;t?f|$pVpR8SL^?+x%0OvR&UTO3jC1%NAq&P2yX`-H(PU8 zYpWOTu69l@-TpTW7(bZBj={@k(I61K|G;1iK0#n`_i?cPUz--wHZ9YErYqow;6IwC zVca(Lg1XvUK%w^k+k0Pb<$oRrjRXLb?)^vOBh1^zcP#&ZQT(s$|9_Q&@;~qpVgEM~ gZnoCe?rwk?0Px*WgNBayG8XtN2`C_Z2iOJqKaVsLnE(I) literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-58-14 country Document Inventory Report - Country Level - Selected Country.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-58-14 country Document Inventory Report - Country Level - Selected Country.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..32f8e63f9b15bc7ad415cf38d07822d42486d0f3 GIT binary patch literal 31265 zcmaI6WmFqnur>dIKRNTTD`={vtrLQf#y#I_Okg6Gj>UM2uV{4=L z$EwAx#ZX!bFJNFOVDQ7`2fIB`WFU*liNCISx`{HW2#+J$h|T<{1u5*upLZ*DVn=_e z;D1u&$WYMuNUbI2On9o~Mr*QKBkg+gbl`pXi!Qd@ZdZ4_k7C%~(C)VZCOnQDC92lo z(qgIq^Qh3YiFOU|y=~?~vxyz5Gfk?w+APh)MW-h1&CdFVN#(4Wiu(rfBBUw$B z=F0Sw#FHEkM~km+S}=pTM@c>`Y{WxKBax?P@QH)qJ#LP*el(#Vg;y+R=)ww|m95|( zuF#@Gvmy|5xnMpxB$bTRVENv;BLnPVQ5J7~!U}PPWna!;Qj)EFg;L6DhCTBHdgGs=t0r zi&(5oRYFX>R|7x-Eoxb(3}v@lTs&y9^3G`v@2s!xcJ;nH6MSc}eFVema6f6s8F|*xd@US z=>nff%FLyPA?KY*ic^)W^UXL)H7JR1OxEtkF@q$kH^znZ;HqQUK9ZMH? z>wo)kO8l%mz=0q6rZf@=EEy1zTBjb9P$v^`^C3*OG;$PEC<4EB+2_7r0MT7|P<+~S z@K}I*grW5N;xOU<4Ts2H$7PK~{JeFQq!|0FhD9BsLqJ#vzbZX>#?ru)5t7&+Z1wBR z-qK1p!s5LM_|;GXYPAT(oyt4ILC-r@H>vIz0tHEXMIM<#8GI{T8)welM$J*#c}c?)J{M9{+F@{Vs{wPlXM0 z(H(XMX7l41O8sNDi*^eeQS-HgB^6=s=3w8AD~0&TWn&@gTf`vZr*K5svpHNJ-b+8R zc)iT>0Vd5f<+#dF6COtH?N7!~_95ybi z?huMG&;?$gnj#^)_N*}YK=q3GU(Jv4|7z~(>uCL-%3a#3ELaI0nEua8|Vib|DM74G_&fA2`eDLX~nz4;YFDYEK~E6Lc| zw7zHl~`dUdbr>lS|T4UpwkY=*^Zi3uyQO4d5%)v9PwnXYKT?lp}6to4O9CcN4n zcb!=7#~l@OvUPS1u3}riY?+^dlC4Im|ABkwMytAUw`N^KM?cdX_{*64^UaH_Us}+! zEVE(lvRwqFgG;H53`4F=zS!PA)#ROGHnJ*%o~-VdJ4Xmyd>l=q+V3Rff?KV35~W}H zqCbuyA}aAq<|`1Wf${oUBcE(k=?EZnE$5Jk>PExCjSeU47&Y=k9=u=MF;Pb1+h=6ni zLPYDDI`YXUzfeFm4PKQu3`eK^%ZcaFaB=QDF6x+K@q3&+_oz(Ng6d3cEU``T6T%H? z(O8WW>5@P6MA>5sc>H<6Qv~g{O_hyyv+5TQ35A5^v(cWpM9SxJ5hM7-bj2FU%u%mI zb51MUHufYZd+y`h`>#8%7#Cvv>kb3?FejELJ{IfT(OKskZqgu zQi!lTQ-Csl)9xNm;66!dC^t3W&3vUSiC5LBYu>7#cvrzZ+C1>1FxH|=17H{)am-{c z3YSDXFGNq)^dZ^vGI+>@t15hB9(S3(q$|OcNG&TWg?K@`zo=)p)vX<$zOB6t$@}MY z@x-TyLREEIjF{FHKy{FMWigjuQ?}y!5mnA@5=-4O$2bR0s=Xh&sFGJ|Ve2^BM=-6U zUy=_-<+(oPqXzZW)M)37M|oAc{0qgPAj~uhD71V3D~XW&548W2dH+v<|0fG4seT#Y zK$m#?HXG%WhR`(>>HZM-TY3b?BkW2uIcLd zkEd);i+(IZx6bpwW?iEH-|sx^tgSsgpkxbOIR81|MiG9MA8gim8&zU#>Rh9Hnh^ZDa|D=< zzovYBGJQ=De`#5L?Re5oe;Ry#x`RxM2drI)zqJl005bB&fCtVk55_gB<581;Y})yQ zH-Z8>pE_AH^pIvJ?=17m9gF6htsi!9hDNYYN)8b@}loW3VYEi*|$A3OM zEk6Wmc0ryd50_7{%JqU@`;0e(9$q^;+1T$(A8vyDjdV|j)1Oy&G&dbnDz68w|Mj=0oa~i%`DToDs?v6B7++w%0XM3C^1n&DH$LAFyuGz_tOY;bU~yGH?p=GgZf!h! zyy%^yZC3ac?*cxQxuw}@hm|D9DJ5(F)L>3l;{TwkX&v{0w&GeYEk#?l_=CcS^p=5~ zIZwc`TRx?+-|sbe^IUWdiVi+mB35~QAl>(L`YKgCxpBND2Gn9})Gu0JeGkU=9&JQ7 z*3{CUO3mlIZ;TqMo%L>>#!movz{ef^Qw`8T`@%UMKO_ z?(OT0wG&9IQHwJLU9R$fOJB8Ba^S=n2Y&=vx)b_wvxCj!#e+AUyEEAYS2qH>+3pY2 zbM*2oJ-SUHE&z#;WeAK*3vk@Mm6Rlfo38M_RnK(NzwPrytGaEsdTyf>>^71J3nlToV~4bKhF znv?7{89?B0Yvu5pYjb<2ezmwGg$I4=E`t9AMS1hBhUQyvy4xr*o_KyvmM@O5-}UWL zadE4S=8d)e(9rj*$@7kOUx2&{gWA}5M7c5D+wHH3nOAkBhk<+wsHf$3KhtxpKwlnn z)j?o6;nUT|&%N4}gA9XM3(o}I#jrCioJCjOFleB=1`-xhV@$bPFoP)v5i@MXi^zvNgq9(%$Q|qSr8={ z$0h*%awY&Z3&bX&0qRz&Z!PPuZLeeuwBa(|w`V<+VaEc?C}P36u=PaaL}NJubWex4 z+l`;*v$y~eTo>B6VgM5*nCY~F1l#dfvGbCg8FvJk9u7%*xyOG^pzCO;m1!-)H6g-$R(uTkGs;Rd6U~KL@K0>P zsP8|qAyW|8T-mPHCYH=8p7%2>swNvX!!_P3Clm#ZiHn%6E0eaZ1V`NNJD6giG?Pm5 ze##j13BY*Z{tpovbO;q%UcsJQq8HaF@o+ zk3N4CS&62hlJova&ikJY`%GP2s-dWvC&de?Rd% zkdP|njzu|(pepgO9P8j+L_flf{exIwzJDeD2&uXX!9BLzTGHkQM?~?Z+fdqG4o6tBU5gM(D zavkqHf0!vs_j#%#PLX!WxN%CHQ(5lPM z6GfAeD)d^W9p2rt-lWJFwVMpHJJ+Rc@{Sd?i!%nrE;(1QSLbpcS6m-q{xZn!SDyCL z%AbR-N`cuq zZAS}u2O3|H_KmR|n<{~iO=U(1IHPs)^epR#=zNHWjVzY-8W-T1K)!*g-VK`@pD$Dl zaf3GZl`8!<9d6i3>MI-dm|RyF5aw$Fkjtb^>nxIWqfva_D(fG!M&Xc@NoVG-lSJ8! zO2z)KHq31dV4l0#GYB&Fq;m}1q~s`{%RUbenkmoI{v1p;jy)X@$kZB_C&j}$RDsD3 zB7kCGjHf^4-luteC}cv%o*s4X=765f>P0yzX(A;PmngWP8vPj*JK^>mv82hkO?dLR(_`lI(kv=WSUOIU19^MY5qw3^$Dh?DLwB$ zovJnWR7+KyWa${OuGyIvJSh|FIA)XPaZ>n=Ioc-}9uS#)l{Hl|!r~*%FmPgObV+f+ zHCU2lv%a-utDu&HKvP)IVaaRd=45fluYYY~54Rrj7260b@0GcVokUxO*-T0Un^P5U zF5vj~KKdx8p&T><3rTU#e)K5=q2t6@zR*r+jZkS(x4go(qxRh;T(wB4ki?8^ZRsma zr$K)myM2$<$}P~GSc@2MEM+8i{ou~wZPD{8hj zsq~G;mg|C2Zj4IYqO`tOY%?)hVK`s@8+=~GfhQ>qO<`T9r3_Sat0<7dqjTjexL#zW zA^Jy`J_N6S(j5TLHJ;?^qL%y>JJ4Py&sJ#4WYqrky!&SzSpDjhm-2>= zhSM@LSihS2b=z{P1xBUrCrhA!kEYl9LX;2~Hb#L=>$*TDhkNA8N1!i8c~u+vH!YdF zh!mp$b;hBLPsmYyEFf`rYwJWoEfIl+T0I9a5ie4s$U5$u$F;?K0ed^Pf99^16aN%> zk`Z;qQAl1}+p_2%$r1k>Oe8-jFw|vA-Y0-N{QUaIJs8AV`;$v`d_Y9RKF?6hnZg9q zNv$G&RGAWMak##}ky`~*?-!6Ni za>JbdqUjKbj?*4_BWXpeH#d(DN?@V>!=$5oe(OICG{*t}-dNb}3h^%DLs>;eg^#WP zqpUh+AsYD=3J2hAkk|KfhyeDwTT^~FqP>_#hnLOfHr`B2g_=i48t!RlpQ5k+$)w;u zP()?SKo>u2>iwzO81!uf!@)?YU_1FXP^SIm1)O{f|BuyLeWTXhK09Zlcwm@s*nIHS z?M~ogZk4`kCqFEf*+*`b4ouywjdvrxLWtk>ZU$r1-OHdXJF1VOrJ>ZVsLU@g-bbT; z*HGq&G+-69YQ~r4n-@{`aQk~aPv&l@iyM0gD@z2Ilg>2R)6)o zLWe*EEGfbn%4^x<0U&ohr)))%lycZ-+Qdt|gYB1Bcly2*L|~cN&T-i%nO%J!l(AvK zD6*WW>LaBRvvy9*2Z6%4qmeX01B&fE8H3lCuI$@qeJI@H!X~N|%jN(dvNXi0g&Q1y zyg=zY1ISK+$JBy!Ku+`u++lZZeBTE7(c+=QU16WMyAFh{wQ@RY3q%cUHXY;bqb#!7~kq;F-Mgi9L&uqYX2`T zuj8{)hMV{7=^LaXoz(U%e{TPcJZU8Rh!b5eGI$gdEvgTBIw2azLE5{dd6eaH&16xd zEO+pc9+xp#*8QlZa^Sl7r=udlvjYWRl@51qpuv5L+V;o7u}Un>!Rk)=#o|#Schj7{ zI^_lWuM$c1x7Q$bzcm(Y6oeCUai#=gXp8yg#5|TYOg6lO{3n(d)_pGC33VwGPCe2> zpecEHhcIS$Y92Z{KBPWfOyeCNHevF6snCF0;A23!k>qR+&6OyNbeMoW|(^gN9eCmJkwBtWaJ4Wk&XQjLU)i1~Q`ekj<@M1C% zys=S3s(%*00)~xT+Ydfe_SrHE9P7tWQ-z!$Ll#IGHRj{U3oJ017G0zcn&FOOOe4*qyIi&vGc$DS`b`3D5%8dDV2 zjDdgMoKE`R_<9qfK67L;83ARpwed+ddFOfV#L<6GY4SWMP$E)fojr5Fbe8JOMrYZ` znnT(gFv^3`(UCSvk>c*mIW|9kQy2y*C-tTT;LdtEcRLRjRMYvO zsW#HH&c+`6xmui|T+Z>)bIa%3Z~0t*xs#pG@P=wQU8EP$E1>`xlskk$Z#ot3@g7rT zrOnJU#FkNQNAYArQ=$k+#dRfk)9!Eww~Ana=WZqrI#6)tv1j^?Inmn=b6)Bz_K{~^ zskC<%_MKfJv?QIc^@El<>X1x1+5NESMOu~%Emz6Z2F__!QQEu0 zGY!ZL$^rH?6OFedu?NskYL$G5aO}?Fap#QV#>I?FE!8SFst~m%&Y1shRHgM>QI<4~ zhd#*^ft1JV~mi} z-J+gZZfRVYm-J{ggdSM=!sT1fDUIUHBfpQF3AP~20{2}M?h04W)^6SSAl|$fG`f?pV9!e|s1>BW~tTu~N2F@laQcKc-NT+3j_6g-jy+9?*7YfUk^1;J82@iDpJ!kB%|UOBvZW z5s{`#!OnuzLaR+0z;hZ+%?_)r$UQqOtVimw-=?kn2_Es)`$ufSL9>|X&oV<*S$Q(v zQPg-3m-|>US2FfXBJ12YHibKZzFu0CzdTLpX{gyg!!zz0hb)a%Wmc$+HywIVP8YOt z!R0;2-RsWz|ACr3%(lZCH%a|+qh94(+hMaxT`HlZ+AF&D@sYN#+{xamlfIuDXg&Bd zd&*7iDMpjQIs7cGqj&6Q$Dyk9JV);+*p+~=YSR$lahX!RjdhWN7wVFe9q`ev?1>f! z1!vM+QGhT}T=QU6<)Cw0FvEUHJXT5K&xn$Rn{TIR@_(+5%QpWx0m|?P@uwPtyt$(+ zdIm!e7XOTJLar)>KsHdE+zPB#G+7^)rs-U$^#sdtj5UDh0)rTu;Cekw%g3tz z=sPp;v`N-Do$O^g+se?z%f=Rn0MSO;N8I_wea5~?laqguLnkIAu8SjX=VA0675!&% zYIbl!v;x!q`ClAat0+AN&zdkkCJ)hF5vFN{!0X6|)=$`?VVkp`WMq!xOxQ__mQ4h{ zo_z%}jb`(ruw@-yK2$-G?)N06&K4{YbSsEcm!SW^Ys-DJl}es>ekGPwNRpN|NOR*u zNZn;LjXg?dRrUmjgYtEPJh&kGbWAhLf(3)7QDGfnTb*ki8eo`}qA?>l90`1gG)gWU zpaJz>^ywJJu_|u>@WVIbe$p*W)j+cOm!Rl~=)F4kly?nJDA0ZdH>Giv&^GPGJW<1w z4sPtw-g(fii73>SW-^`krRm^F#^aOJ5r z+JQsSE0UHn$I6y;=+{{;H+$Zd+rSjtEhyXiwF>G!vVQ(ca# zUXEw=r7*>Q1PT8UBj+i*KOv^c3LCnuG=WwLal)8l#LLDy`yZx>(26)o-CQG~K^q5N z0;U{zTfRDHb$(>8RlZcDz=egqw!@+L@fhLF!vCJfrYCPdUV{9$W^sSwf-Y|c}{D2HcFl=weJzgQC&lz@B#p8-MX?yhg zr3a*t`;=U+)ORSDxAg7(C2cpfVzBQ>z)BL}AlDtzkjfKHFI_C-|8-k9m+{MPq)E@7 zMJ|E=d=_*Gjii3N4tuO5bs{k5xgyRzX<1gh9mIgCS5hadb2Ff@nnA1RjySF@^=A~z z&FS^E%XW&GOdQo3>mP|GVHk{Ai2iG|n8=?~DMK-vW3$ze3imqjQ#v)cjO>Cp%PDcdbmU;5c4VW*5d&ookBT3e&1RGpoYWdDFN?|7}7LB@6Cj z%-7?qLkT~uJnCdc4pn|68eG&e;X?`H<^EEx8tt)gPSIU6b)_b;GSQPM!6iv4k+A5M z@Hwl5{O~!5eySJtS-?!iH3Wh^qoVBkBtO4!#03_LRvd@l!K%cvvkxD1sLx; zz=nf%9k#hvVSaCOX>!Fkh=D~37oO3$VZy)66jbbgixjozuoTlCNf(b=GyYD5Zluz> zT|`UK9m@G1IOs6)etdser`<>gM^Y)O4Fy^RmySA1AeAO%yWlH%xN`ad`X2VQF)!e< znCO979)();k{^Ab;mim2k5-6Q!;?<&VxxX4RH=kZz78;BN465Lq9Yg`UdK8n_y0%B zg5aQN1!Ous@~6UY#z%1n#3wMd?)Zh6(#)#o6nZ#-th`=J;s0Z?v!q`0^GH zTAej4E4hvy-0v1)B!1_8Kw1wAJ9OuE6)mwpDI`69j|{ex(wHGn&GkUgBU#X4zD%`U zRNLaM*;Wc)>*w>f#&nz){#OHqIz8&JL+k!^^8BK2XH@f9Sr_o^pA)V=Xcpbolk2-- z&(dxWi9|8AjlPE?-!2m*1aIq(T;FN8FQ-DLxTnlaedia3dBI)L47e!Ep$N$Df7>qn zQXxeghihOp3-^|DqQs8-3`AS;6sCnn>wilj3=j}PzN~E14dhBfG_ppwpslfApMC5d z`q0yUv`XzPCvz5h8tp7cN8qLkYGstE8|dJJ(^D){8nC&_W@hE`nf3xN*z$wtqM>Bj z9G>h}LnU9FYEeeV?y&3|EFT?)9+x&)bn7Ec+XeS852cool0fs&9JzEct{Xt*;INsy zH~I3>-aR#h5%7Ft<1g@Ycl7YO#Sj)8YFu{uMCVN!TQ}(&{oE`$I}e`fd`68p#*=aB zLct!f5?0U^3eMya+%6I%)SyZL8IB@ct}cS*UVXcY4ZI(jZ7w5 zJF?_qJOF3zzhCY*?udo5M&`O3&d-%0*6QnLz~}}?ITg)t*6Gp{XU3VmU!;QBA;UmT z@9QUY>~_3T?Z#hW9yN%cf@*+|Bc=YZI5BYT<|Yyd{;)R&Wet8kIdR4#ILI`BPTIuH z@PCB3KSv%K9TBz>Ppkf`*}|UHcMRs^(!D&J?mUJ+!_m^-gxBdyrZOKBG&x_SU(}9U z-B7o0RNY_V6Y7s4ND6Dv@K!cSHM}!cgBDN)rT&lDF>p=h6?}S$6>2tqW!mWk4GP?= z;(Z3NWn#Gmf0nGy){IL^fsasw{+pzPYKq%4&^qf&|YX_h*w_c5<(;N0A2KWH;CPwNh!%wW3PdGD8&_XB!1AQ*Abq4OkVZvw);Sm32S zj8rb93tF@NIE}ymG<+wT^;DE7_N(mGxu6ETNsRS_76(~fp2k;_Jcg6vL}9yCEuSpE z)BkaQm-20AD*+~oQO5sf+dU(hm`>Ib-csbE}dIn5ovM6?{ zeT!2|J#A8YOiM8?iL}dU&ogKVVEyLv=<|>IuE_KA;!o4&q<*6t%0zH(tPsb~h1uNn zEV5p?>14u)-lMdnh!z;_g z+`tzkbZm3OJiCat8=WY#TinJIC5QHGnBsx^s4(qmgHknWVi;6}NpjiqGzPJ7={Yda z1|_WHFk1QEWBN&j;wMB$$;yGKil-1SBg25hChF#U?0O{AKu2Y`059dP!=`Om2QB(f zw!34!TIA3o)BHG+zbeB%0zch~I_?@k=dl%PgMR!tsU zTQ)Enbk`H-K0BVqdz#ImA_v{m+u1>4Yk_R+l|~|hqP{jA=g`|QtkA0j5P?*Ybw`(z zgD_sVL()gwKtB+e(`4SV#DRP#iOgd5+K(>E7^Cz_;t;e4bhXKe*G$g|tbr)wjT(Eu z`0U>v-9%gwiuX|D=&PlICR2FRPFSK&g%?!=&*oJD(6i9XwsG#4k?+GYoOtavWK~Zk z)Z8ZY^>yN#-=h>oDF%5J0J|1bFvHGB6B67GDa+BlLDtqbD z=lewem;>s$-&SYr$3)_~Mcug2z^V!jJ1 zD(PA$AJ#z>#c%{ZhLi(euu*U>`xJ$i&CGjHFNvo;bVp9g)qLt2C}sX$F-WM8BwUUJ zhT`QpKTFf$_XEBM3)Pq^e-oMHPAIChyaWc`WOcsa2KIwQB~2pal@4)`69ncvkrRwn zId+mXqarVLM)=pS_x#$spVz*2dQa{$j;*KfuO*ThQn&yg6U(2_p(pO^K3}2b#Fs=) zK0J}i7D-#KbIQjzP3c!@#OlrO_mmcMK8f`h5dNvi78?6BU4wR%|ayC>GIpj>YX6FrR z7uE6e-p=V87J=R>aHh?D=SE7pD(Q?=ek2ku5{2Y!D>A8HhFbHuJw-K54ez{vZM;2H zg3}iV#$#$briDtvcLf+n85k29c-ij%+Bzx`_5dYpRMJIf_B#$T{Ql**?+`s9N0tFs zNf+qD$lLjJ^aVUXDhC~B_zfS0DYt!40x!t(gAb!IE;%~ja6R)RZHB(}>Y%uPo^E-v z0iwHehb>TC*bJ6%R**Z`mtg&YP7{7i3NOT;s-(~yvEXqowOD`0V4eyIbO2$fh+#1% zVdHz#zCY|-i8IDX0z>Quzd9WYEL;A}=``vhFhC9Oa6SpohNR2THASWD_zF!^f#@vV zb}^0XlA+7tX|yYh?I@#?l$$ zIyKi;Y1AwLZ93aK5IE`i{}b4K1BtcD{GHPtEv6B_DW0%!+^eV>RVFqI2E*Z!6YuR* zv>N?xbfD=y5BFo3c>C~g{5>E;q8NN%(6V#hEyUP~W3S>v%a4TVavkz7t8J3sTNAW9 z7&ou#CTvo_2JW1<82YOA;6xF@?kJoKvq#YCNz1ee8zyYruXmHDxbinJj!jINxL`a5 zK*zTY$A3P_NaaKz*`A8Pos#LU_udtz-tXv9?kD!(ts%yD84!-ZJ?CmCMi~kn+t)!2 znh0RYHLx9;9P|Y*3=4u=VickUuv(pL3Y=1oxapgxu;i_b5Nx?-T2aWZqoCrZiXZsga-xLz z|3_R7AO~n*g_nbyUD2bJ1B%lU1F08faV04P@i1m{;ben~@9bV3+6@yJ{>m_~T6Bz9 zVP1$-03YGYpSbF0$xNhCR7ZUgjX3U9kh5%&61sF|sKQw@duhge&=?rvP)^nH7y<{O z?a_Cq@hIG}jyA#@#GHBNK~b{!t*~QAOS8{u3UuQ7crR(lRXF?yy<9%n&5UD{Y}tij z@lIO#Yo5jQd{qMrn3I#fh<+dFfuk%(C+hP__k|dSA7B$O-Mv29$v0~6&S3KD%pnCp zJ!J-x`Jr(H!dog^7C24*oI6=34gSKY0FT;4EAX+tl3L0?r;)24^{))^8ilQOjVfl2 zre)N9e*bIuG3ld+g}=}jdT;sdl`^A`IR6fKU#tmM zTg%+d%jh}ls*?%Fd9UCN412{|z^{z8UJ$!YCAwtF)?&YpNp`7%Ep6Ll-+!sUWLLO1 z2+kOBIR}N>20~}p>hoQx(GhJeRx=v?}!>67^5yp_R^@KNaL?|xuJcIgrJm2>M` z+#`N+?dZcz!bZ*mpr`v&_Z}=B&tT!Vze3Pk4I^TIOkY?iQ51kOsv_uA-VxpO!Z7>irm}GC`ljdyd7S&PO%-2h1{)@iSQ8De%F^Nk$X|9VzSTI2?f3U-Z zm$sZo=9IPTF`|i*wVO2V(eEduOz%y(T~}uG0cyu3a%F3_-7R9j+ltLC!X@YR6s#(o zMgrI+h(b`ETumhM7XS}#6_zbxN2sWVp*LnGiNIyE^9kHKn3$?A35Oif+s<$bh&+=O z8o6?J)-nBMXZ*|kqM&b_g5@hv(6Vk?X(`M3qGQ`yO__W`=4vt`nl(|u( zNqSZ%Ulfm#A#ElKQ>|lE8lS4rB-wn@UtIB^=%lyj7*(IDpfp%U=IX+K#_ zT}(G}awVszLXxsrD5v;n_V3KQNM3A3u^gRln>8om>Fh+#0dNR&aT)u_&2^d!tNnS4 z;Y2a4*tAjY*%d^O8`l4V?5%v}5cY`oZ1q>9>WSsc^?^C5NrE zhMSwnonZ<5mRcDzikq;C=A!te;@(h)TdHKGnVV>_! z9PRfelp&v4kZaqsq$8&v8zq)`)2bVF-A67^f(X9f`#&DE?ln>^3@TEtL9d_$5O}KO z_!<}IJVfYiJT-2wjs+#0R5U) zhO0l|Rj_Eiu0fOdLF4jxT-hi;I-j4C0&uzLMy1>$k#f`vHqtfC#M&w_&F>M?q!MLR z%0*22iZ2rWT?k4=d7cUMG;URm@ct|wBbHf50Sw=?kE?!`(LNSLh(P`N-GLAE3+EYS z#^>Wv)*rBfVNgg;ew1KcKvO32nw$2a+lzzHc7PlpZ55KQzTsDyqB% zvIPNeo#$lk61uo(KljKJqj_L{76!>bCjLuXKgoM6DVB}WvnbOv3OZ^EGOza)eFeiR z;7-Ie!((NjQcIvxOQ2Fqpi-&sisZHNei~ZqFHO6S-RU$uBsz|dpPxIJvYLlD<}!sk zgt+I$h=hM5Zc+_wnVW>(zu^?bV7twf7L%Fu;1+y;+`Er|P3^E9ExLb_Lw3hC6~ANm z<1|sM6MDATwwrY$CvXFQUUVwpeh}WX!!fSIiP=7c4k2CfHG~Aeb=hB3F#iPy{p@VF zwd#|QR-9iLV7xx04xmXk4?whC?hHW>;T7W^y4J4fwmh_kC5C~1q<7TMNJE~W#=`MU z?eUTgy5)RwkSWfxUYZB>#62dLn9g-ofVhR5rv!M|_J`#Od`!spJgfK4e6{Bup6~qY zm*N6ym!E_7R28L4eTIfm3+H=EQ_#3wa<3%nNkoc#j?N-5$fM}~bzh#3U^P-nM<6~- zdW~%lBQAXoxZQ!eJ*v2GRDM#|r>_<&@3n)tk}_FHgi zAH!1JU8Kx_a9Pk565yIPXtD1@Nk)TVX7%GVPOJfnskzngoo@7BfW+Y!jlAzk&Ty#x z3av!uB}Qi!B}T_KB}V>c`;|8-NXo#`v@E3RnnDbN>2jrHOte^Y6#@bVunXZ}iP3Ja zmBfchQqG9cKTH&8DgA^g5Ht^qIaZ8bI$WY*I$tX&JBN+NuU18$p3HJBYW~d&@kJ6E zXw@69wdAy~e9At&@e(_(Pac^g5pK{r{_%nXjz4rde!NY5M zE_j`;&jOMhm7Hgt1>QMWl^q7p(x2Jy`Luj*xT>5CYDd$&cP^? zG$o-xe3D#*wFQlCg;h7j_ep5MDBJ}V?96J*p!IY2K!Zo_diLXa_O?7S+)y(ODVm*s zx8ER-@AmVJ{D;^epzE8Vk_yFpK=rTRo?Sl~fCY;R%Zxl>{-Wh$Wi3A3>~r{HGG)#u z(kafoQgmwRr#ik)hp$J<^G$<%{)pvAoiJaY8$r^aaRWc>7Cg z=21fo(S`?6=8)S}L5t?kl@w64u#vPR%T5T6g(=NSWvm+eb(EiT= zI!Z_fZCm^4lGH|*3F{W{c`F!W=t4$u(VV4iu^T!d&4B1g(P=*;l4hdTDQv*@R0*z* z8{)#m4odzdcQNZPslOz3ur0Ffg(7mfUeEnLY1~Bz@a;K%e$#9n7dJG_6e{8wD&p#N ziR4*~nY}h+-S5TohS~spch+K@p(@*2UYif1%5k4B4#&=8Y8EOX|8b_ve@CryFHDX5 zAtD?@4M87r4r88IUj%JvvJ+{C&~H&8C-94y&*@`hHjB@4|2ryRLss&?wL#Jba*Mk6 z$OKk?N5~XNtdNf)^+S-IkwMK^hrJnx-fL{)=@cGYsp22Euq*&YRws2j7}J4iy!WL> zh1e+XL4B`3-d)QtuA~)>6ynvQj!+_406N7{Q-=DTe;9qsgN24*FPpNkcf|>o+r@ip zu8?5<%a#k<4Q_T7)dDtxF*uMuG9!TV3M|;PWpf8;=yZ_$=!uxev&eTx^xX>!-dshx z#8v(0l#v%@pF{eU_I1v9(?wt4s>36?Ew0`_1p>vg^R6p^Q;+}g9~XA654LuL1g_&zd(byV#7)5_yw|MYu7K!dw7Dd2un&r z(lAQ^GW@V}eHQj|#^oyA(~0|C`v*La9!)pj1j~Gb25M$Ghn4{;a8MINcEfuptc%}8+bya=b0 za@7}|Xaf^UUI=_J`IgM76?`yTpbNGL=ok2F?5KdKM!%Ptv4rhviz-3+@uskf^r2_n zQw;{Jn;~JtYdr_XrS1Xjtq;2j0|qy06DG zsw8?cmoj3_AsbGwAQg?bU2yN=np&zf};x=Xb^i;F&$j zD=vTeY0<0yrr7r2srY2UoM;TMRL{d9%YGc+Gg@ZdN-_&FGQiVx!jFUNy*c!o9FTr( zkTg~#G&u1*N03Hsln0}`TH%3a+Y@d1b zms&l~yJF6X{Y51yxKa@HRifa#;jP7F)`RSalNUF*(; zH3^v9^{;VkQ{@ZNIoT$O(&(b;aH;&tQsA%mhp7x5?XWY(!F@uLN_%1_rr z`SOPYOQn$U|EcRMprZb^f9X)VReEUYlx{&nK)SnAkQo~3l%XUA1QC=NnjxjTOF&?x zo1q)@eYtnN|NXuD-aD+tFl%wX=X>_qXP;eXe^lW0iQ)aJ7-JZ2S)4DYJ_Ke&4sI`F z|3&2tP9#1OcJt|DnluCRl*TC>0x=-Hdl0K&{@%8D`$*19GIy-tP2AeADk0jnU zIPS_n-QgjcjJCUK7{(b8bGMd2seb)6Yr`a_YgE+Ylp4J(2s=s9W}PHQp|`dwI)16* zMbb{!4|;@=8zXQrmJ>#)8l&cPV9d0Ab^wKHRq%|G}L z>qI4T$$_h1cv8%yK#cF@x}fTmJ@PT`><1f_)`AXQa28L zo3l3!QNKC23w*bIeSZKB6seFfnC8F|@prD19&kkE`i9;3h`6q?EOuQeXv|$Y_=i~t zcCB;=n$Y2KM|Kz=k{o;YdB!%jXADYH4g zV~-)rvRJlyO3xuNkRq^_Wrm%J{=|Y{nsY{g-Nuh?<&)ua8a!TXT0!Bj=))n=7afa@ z=IdR7CX!Eoh4p~$-bY7vufpgOWBN5_gvMH(2ZUa{_*;8p^7b?KSSstLKYx`ciBMsW zHT*aBT9vW-a+P?ZG_-ZKy%m#mp5{pQecb7oU1!Ff4dN6?INSYqa7XQWB5rMVW?$E= zJs_8jVWE}UPFPeEQR7y9wU0!}7<0q-4x&jcIMrLqHl*xP^U8DvUsYvrea`eo9VttK z?Aizyd^p1(_I*MZl%j1B;;4LwyumTFX-eE(gCSCxe}@f7k%@zbaTQ5rPqHRA?xk>q^0T1v@+Quvbknr2SNor z;ND9%#KGa##1on^bf20|gul^`qdHp6RyRrs^^CSLE=SlI6ny3AciT;nN{u9` z8(>$52F@1uuio^frp7=24f@E&O98S&${usgfxHi4A`6~@jYceevvk6HOISsL5`;`7 zgDDr$NpCq1l9J!`ZL#F@AY9Y;mb_`;)>>`-wn?#Z-FOUmmoabZO-aYR@M*JWg$+IE zEPcDNrm7Z6a??(Qm4mT(>>D-9#xpq@>g2O!FM3t1!z9`f(T?&mwEGT)&@;5DL>Yv) zV08ml%?<2G=+oc8kVRL$6AWJoI50fvy0Td=8|hazZZB;ZLO_kW_FMUp3;r1 z-MF)!`nyh^AkpD-`bv$|PE$X5+JX83v|Ah~lW+q;WmNG_3%(q>xJ@(}yP!NFuY%Pt zqDpLk`W;X!J%Yon5+a$%={eJ&w%K?Y>GsG+*V8PB1!;&I>mIV?>T`nOFX7J&yu!Y6 zM`x7T%g+olfs*G58hie9A#j;j2377`NdTds)+ z6;&2{%yhXp`HybdYZkU$cv+vZ4cPcxar(ksQ_k|ufIZsRT>pxq@n~_S{)*x`*YCVF zH|JE=zBN()B+XoEC6|xZqDX?<)$_P7;P$L}-^+^RDSK(_l#`gr`Y;##S=F*^&MYXe zr4{<_XI~$u(FJ;itT1L0F9$tZi^lF+20_Al!^tQ=fNcd2e{mX`{LY@-OurmpBKu`G z;;C#D@GQ&tm@BJUQYVP;)!LI6z?i&B9Bc^@jpF-Djk;dG$Mr1_@!=>g;Z32z-5m24 zJ|4Y$#lYuMZKkG6nMb$Jh1!5nuRvZ`7gUo~<>;p+&tnFx;matNxLZ(sPITlAj?jy$ zE!X(m>)g1^*Gcv`NR}-RRhg}A427wG4*11cyPC^PbhR{f^F0}!(@ZHx z?(s1jNZNrEK9gy&?h=zIhbDdoxX;}vFWa$|BEqr!byKxOJ~ijx40P7-^t0PGVnz5C zVqoJ{wPM2aP@nXMOhjGCNk8*70X*XFck)iOz$A3%SVe^~Um_Dpz@N3FOx|TzwX}E< z+cYPo+X=SB*B|(v&6xl_O0bgOS@!XH1JIwo?-^mTt?a7BOh0wy1t@*H_sZuBTkNrg zI9p&LFwyY0h#sHCr$H*wg6G_?Ubb_pHX9GGRgBIZbHz8STbPv!DC3dz5HIA@^(@K0 z)Lx{yC>~MI+`q^k@vb&T1pI)hkbGGzc$$d~G6-W~zba@YOg)`ON0s9I)^nKOU>5?idF zxY9%fMz{@vei03VASKuv1L&=Q&O8V?_$C2M*I>8&bBli=UA@2H<^o?cPF4Ekn3uM& z=b3(2d-sTz*dr9{Grd$KB{?qt)8qby7Be^f>~)Wuq3ltHtti{`b$B0ZHiR{n6Ph%XJh*mTWXLc%vrPDn2_y$gn2pEtfr^18}*TCzb6 z3Kt-MrrmcZ87c5F?4!u3OPcN$$C2FWpPIGw@*+5uxlG(K>Zp#|v(8fsdk%nYy2ZOk zPGJHcmAC_a8lHDsU%UEpxABcJcb`&?>M-HNZ1H{iuADd_0g1}-x}+GeSM^%i${X~Q zu9ZJ|+`OFmq_Tr1S$o5qa_8vFEMUdl<1}*!uM+&~t1R`b3@Wy$k#j27F*^E@vu9hn zGhrq(B!mjq1z6$MqWNKTfE8|GrXQ8Se`8Dr7cc40Cj=APOsxCh4p0N$r7bx|Cz4I; zE1e|zFMNjt{%y=bXb6qed9LZY$tUmPZ5C{fgTgDwpZQ@QqE|x@CASe-^J@0rId;{B zFIs2?Yx&#JB1}GIpZy*kk6o&vEu^z_P!wdEgy5G;c>2B^DgAQ(7tRzI{^$#^FAlA* z41r;Mfnmmgd?JKV)sqWphT1%~=0o+@>?Q)=9jhIrJ1=7$zQvsr$3i_TuN*dlRUQk( zjO74h;M?}yjAQalk@A$mJr zT7Tz8S^GyGiRYm$mSqTItaZ5Q-6-?$;$yBA?AejO#Sc-;_cANYt+^Ii7zy%fY<&G% zcrWl=y%jy)X-#!a@y(x8h*h^#NyLJAWZ4M4)1xndn)_8Pi3pa9Hlg<6((bxS&FoJy znSjsinoj0yD!r{qF^QkkFX40F_!jfTzUbbLwZ!3U_-+(Ew}G&BwWgSDqt(vWm z73&ZnZ=W@q?|?p9_QDE6HEMSAjT^9oTTN%bM?0@h*;#cM?utf$lao)u&W&ezf}|j$ zeZ|FO9RD>#l_X8GeebBxHM0T;TT*v#x;;b*^{UQ+G?tW?<&8iN=-f( z8-j;##G0^q1isuGD1NS0Gg~x+tLgHwxhmGO(dgKcX{E3o09Ldk1V`*^UtjY#+tm3fWs&Iz`!9HjTDoMi1wpf&z$aTKKu6Uo0xCiVy{Ve zCCDfmEMCp40OIC;ND8WHK;g8bNvu89yC+)6To?Enx9gGJBGwO>5hx9& zF)nT(_n84#1=V$7Pl%sKw!}0*npN=Z8vCl)nx|fd>iLq&YGIkO@vJSU+X69{Tk{89 zD)?F^aCDn3f}=irEeOzdA4J8`Va*C;Opr2L<6F70q;BTP#6MVH&`L+fryO5^NH?N{ zj^Ai&UhVjky{`9x+`fUAK0KN0Bth%2`s%y@T?$-toxm@Q^=mu z`hM!~I=gBanI}DzZ<9{eMBGdH8XSHGYUkLhnc;D2Xr#sv!Z1y8VcDEA&`Lw#6+ef0 zJs8I2?>)jCds5jHyj$`W9s7L^9bHtgU+`2l@BF(!!)AqarvU+2e-hgVSUm$|({n`= zN+WLp8@W3gi}?fdlP*t*Qb2=zJcK05H2|{t*BQ|=1*8-hO|9YlPK-`>fM)6;@zlb?xkohDe`Lrapnr$A2s^NCNZq`jeD7|$6=!ouw#Y&;Up@;TV_!Tup6X(#nz9Fu6<9k4sc$l$E*a~s$bQxZDqXum#zMIX8ZKpWzlMy-pQmB z`?^J*ls0Z2Y1bcknlEyRiEuX*Eg?7>kF00kZk?*8?LAM~&>y;)JAm7Ich+Bz)Qntg z($4g4`c)A8@d$#t_9hH3Q{(4Ois`BdYp<9%jjRa8Hw~#48;;dt^0#`8yMl%gpYFU4?0ai1q)I_%#!p?p{} z!1>H4O5pG>2EiRS-TNGG@)v5KMQ*dVOk>#S6bO>tqXJVs9(PNDQhr_&#RPWh`-^uM zji?6%{B|E3#V9m%M^j{}HBv(k3KV-E;nNjsi5R}1wWLrG)Npqz5n4W1Z|pIo&iV$t z#^F2s%u%wTSd*IFJ~=*v#5ZU{_=%6-eW7ZM;3dPpMc)Z)2Gl9CQ|{QctjfYwpd!v; zw@?50gqN*&e8egaGgA^36GhZ5Y7$W{Cm1^>b~%Q>Vx??Yk$@u2F`E+uTKSjZDM={k z3YB>s+eU6QoWjWVBMooeR#zfJCCNMy0WXHtB>~oo1vY)44n*ab_Q6af2xoj^uNO=e*G0S-07$*4uB8BF91Vg#uhZl8r482j z9#UI#?1rbXaAOfePTG}ac|jctC6A+5{T=!>1{{Vw)W&R))B(J)=+psoG~xL#<~o$< zmH`K3e#72!%3F196#?ezyF&|={fi~~J`;K;lJKrpe_#Zh<}fN8IN=eJk_oKdzP?`Z z3fc|9`SIe%N}a4tI~Bh!7J^*xl{Thir*k$ZHMH`8;pybfTbTmD&)(LJo9Ea=U?$mK z&dLBc`&z|Lz5KJwjUm3X!%gz0;Xw`PG==BJyCiTt8f{^3X)rabxG*OiO4x9Rlzk_} zQ}OjTlC;Fnq?)j*Spctzs9#heT8&`obVIw77J|3kFT|;LPLD~+R@o^!XS8^~zB&f< z8p6^Gl!DYe=|F*oW1kW{m)THTj*ccK*A&GS;)|9e2|r?n-j)v&#xxZ3Y82yRgoZIP3sf_C1o**xyZkVE^+XD!M_a~GBfRzbAKE1Fp zSlcI;zh-1)<1|8RXw+tcI z8^!trEK4G5RT7ZFgy{YSsV=HYRl7$jICJVLnES-SQVMG?NTem0w_Nd1rZz{}OA43= zOSqUBhG^q=P=;s=@H^gBW<#Y$0eRd}yW4cFW3rWM6}pjmxEbfxxG6F_7{?oJL~(klg(4Qk>C3xbR1;*Re;mP zB?YZtTsKWfwO3b5+=u3i<8BJ&4oYH6bmWx>j|2!X6{7?<8S`w_PUNWZ`~sgo@6Q9S zZ#}g>oK>_|i2JD9a{}b@2EGSmLHHs}T0_xW375r(;jy`PKag{IaPHa02S3d|*j%e$ zJSfRsaJigWYb^4MmMR!eCmBb3t7$2%5E$&p8xTnC$HIOIKM)V4^OrbpO9-Ou5bPbC zEFVd2pxarUcWP~kToKp$F%zz9Qp$)4(Gygs2vBM`Ci-Cg>sj(!K$k+P%Hk8%7Nx|h znBjR`_5Kj~xr+GNaLMdKJe#|^Sk+BjpV7R?s%<}i+Ogug_sjq zdAYu;XBeDpR-M8{=?Y2o;c>leqp16N>yvUj0d|Enn)l9QYI%_Ckb8)VLM!vhZsPnjgqi9k`}1V`4gXb=N_RHkg!zpp+~-}&C(%43 z<#Q1jNH&I)x!jGji@a^jS#gWn92{dEDlfWuqeVt7W%|Rh+G8(hiq~!F>29Z-%*BYY zcZH9cZko|XwI-wLEutg+!O#4xya+1L%IDS^~eH3|EwLNiud=Ofyq_ZQ9;k?faiV? zGs9RuD1L$EaW|;!ok5i7W~=PX5t&7XGsTn1qS4ycew3>XEQ%*+cb*x-cugH{VmI`F z@`c-EDv}esXFq7bfq7}Z(JEXutp77*WCW=Ab{*6#u5un7*!8D_^Qh^7kIE-7-eV43 z7!tp=0VKD+o#mq0CeLU=YQh(wGbf!N8hyEcejWIF0){li5s<5nNF$I0BGWtB>s??k zYrnhgyPfQ=w>^|gRz-kkH+uu@eSdybAsuX#6{+e)Do1%9P>tbw@y%9Zh`A-O+^srV zveP5V!K9l&dB(RCdBCja$&xueZ}|)Zo`Ciyu>wXi-%oHf!|?0<2OX->I=}cKUboKcjj}&sKMdUi6ME9%atu-nn7a}u zqRZ-gP&fMFI>Ybs8~d4ueft~rV_ZhDUtIE*A5OPy{IC{zSvdfeLO$3hL9^?{t43vo z!|IGSxhy1fQk0+s4O;Tq)gX*6I+8GqAPAerQFB-~dfTnHT*nxX!HU?uS4p88^eR;` z*YWCXOg;tk5AhFKmphte=rV;)qH*GJ8Dnr7VcCF;n=IDMkvwc1KS<#j@m&W}_NL*1 z8SYFkKgXK9Q)lbt|80FDi83+|M{T2-MQd9i3FlhqevSzgPEhzEt}L&0VI=iqDO9U7ZPJyM>fZgmFh_XA zVD&3{j_`tcGV0;5nLE58(KR8>$oyTnc`A(%8X|_Yd zPtc`Fn4VrG%|1bE^CeYk?mB>={8*9d4!B?4nhhJyW#;IT1(6MX`6;NrVuz6iufWHvE(%9RLKuEiAEChD{ zMv41%F#)C^V-V{2?@ieXn%Ns_9G=h7;q-xc^c2!P`l3ZT# z8yO*w1(v;23!t*uP{_(5N=KuFyZo6mV2Lj$f4$D9Z`6g$bSYAxUJ`poxLtsLMeh@W zBPRO-0b1{GnO^jHZ*3SB6&@khwGYbu^td6Vm!(}vFXI+G_3;P&8h`2Seu1^ zW&AP{ME26383@N*dznj5U3&yH=8S1KcdZv=|Lqt!^JJd$AYPch(+M z@?OY6kx_RWWy{j*KV+kA>}%!Q6l+Un0@A(B);@d)5JsmD6z9v6Lt=l4wcsB?ZTC*d zGD=keE&))z%S$|#I|aj~4j+Qt&ohFC;SdP9nh!iuzH+!YJfi{n||teucbfxjv>jR=qh|0w@Xr zD0+<~_80t3mnnJ|d>@?6^Y@zW@7`bT;J|4MGf_TiEhmT}fp5hxmdB?cHF$Jn?DcZ( z14%QY;v0B3(c>G;AVa*HVIy^C|1v)|n>USUW}|!>C^Ih2p1BkKE>F`2FUCXNETuvx zD1aII0yEqMX4u;zeo?cqw^y?KHvMeq90~Vq7HA)Jwjgx*l*#r=T<51J(VUS{JFR7! zqM(k267M)rLCqN5n1WGv2CDATFZ-BOyj^zh<5gET0l4Si&W&zlla;s4+O`Iv=qnG%Hq{Vb?~gZzk}NRA9Zl91TnaQ%6%s9fYUUV)_GVlbffLwV z&nc@r0)br)7Lf|PrlnHCnF$+|z+X~A!l5lOsvauLg*b}{@4-2}pR8H;sgyK~4N9H*_2+B+B!sEGCD zo2NmuuGWxL7fB(`UQ=cP9hNLXY4Jx%zdEG1j~}k&A$o_ZqqIrJR??`K9MLNV-Hm7T7}c0n>RdsA~qiuox0uR$yUfnQ%J_T_*CSlseP zGZ#8GdAeZ9IkM1}BdHk9SUySiDL z-vTIK3qmhaSs+L|4Y9TYYC~9o0x?LQ?af+RVHfYV;G3va<*7vT1A;Q`yKMC1XG4eBJ!vwb`>5iBwFQKvq`hFP`Wn zbKbh83A2+p;bm!_ii)9ohGg{F@9#zvfg2)e14bF5jPZN&DG|;P_x1*`bF{cvr@({L zPvFx?;q@-JmurwSO$@@}1_wJqsRL0#x)S|!%_kMTTQWLfv5r=Ob*mHLzi5Pzp50p- zhs_^JcJKaj$I$BV1D;}o1d4+*%SLk|^E43VtHaTzSiJL?zsA(JQ^vaI)wZ>3jS~A9 zuR3=zCuq1xYw52bI6dHlv0#lgPm4KZ7dwkho@M?sC<*UG@{xxubNeN5{xeF>fnI4u z0=6bY>t53E>eB%Nk%R=^XMYKlq03=_l95RJ1>?Itk$E8~;$@7o2EsI`vr z$w(QuenA8*z4oM!wCKJnp7@_caM+?qC~9m4MzB3 z`HpMwb|#5{TNh!%uY5hhpFWwp4SAX}-`h3+W+rqGS^xGYF3w!-FRSD6&3^id&`C^n zRmeLdQyd-i0@vy*$xcv=!?!zvp;_N&%M6{3Y<8J%&IcP!iP*wSQm8p_!dnelJG-8T z-Y`ncnZ43@NCIPMajqC<^q)<&*^HaFCVua6Y*AW|BileTDA%w+CGhwoihx?NCX z#1q2%=a04A2*=w$)&U$T+) z3)d%^&}5*=NIDe`HEr%Ou53uwn}VzqswDb_9t(Cv-boZYK2;7#&1#ekUoX+w}u zkKw4-N~7Be%ml$yG3eQ56ud~oHFpAAlPqChO&) z!-|3lBcS|7A$QQ3T}SNLBUp_bnP`e{UWKR)cwJ>Kpa(YAqhF>^FfKtRjh-K~K~123 zqxs;V&N3~vrk&wn$+%utYu(Gy#Uvd%c&MJ3lAaAE(~*;VoamM^0o^#~_w~KqI~m&8 z918xUk&%cbDt0G`cYdEe1Zn95nP4vQea$aV5p9_i|eLtFVFpj91opcuYWGSTL@`s*ddTzW_j8lmW`w` zTV#r8xY|iicTYYwuSf?9kOfq)@4QdK7f6{OrhahDa@$1~EdXZ)U&$@0QPFCJfI-qJkhZ7=GunS0oYpG>G@5mNR0+30`^;+sa1_xb$q^dcJKkI~dvO zR^&)fqol)k!_MGn{nhvCQ}H9Ik3jBJrC29_l!F9#=0`M6)_JkYiEGo9%dM3$xeQP~)pmf|>B90NM3;z|P z3!kPdMZN$ks^-h}4-}uA%&uqRVxD>xNbJhIkynH-u*Bto%ABKng}6RgXb&-D{|d=^ zvr(s|ZZI8g;>0V2ZsK(IL!wJiYMOdQL|%}|34CwoYonx*^hoO}Z3fG*&&SF^@r=pm zW%ak63x6N2DH^mdMaBn(MaH`t>fMUa6CZvLh<=MA#)J8>9)&#OxyOt|LFfEgCOAZ*x8v%(=S$h{i5x!!_5 z;YIDhH)POJBS=}$rg~{xs+HD@<@P=#9`W&kA`PH2i|9yC5qP5c1aImp5ge}i zcp_1G!P{};Z6Kc!PI-j8u6PEtsoa%J&FFcu;;*AYZ)KeLTDQ8CT7wC3^U0>Qcvh}9 zi(kWzZDPveS|>s;)CDp_x9R|O(NQU*n&?AZ?MlR+XMZTOuT+X*lD)}R?7V74BIdt_ zt+e=`VKW~+3@fC)ku<`k2;--yJ#)J90XIUc&YYC0m7keG32;M_ewKriDW2PIsTx5( zB^3%K3I!heObcltg!Za@lPK`S5{g`_>BT#BfVn2(^T?#j6L5^4sjc%%rsfUp)BH&c zE18^2#P`tr_oy=9aLPv$n)Jr+S~V4QMB*%FhUxLcTqa-@yPEw*NjHgHi*~pbQ|*aV zW(YQ>$hf-gA^&QMxSA&RiZ&KH4iGfP4*AVBVk(@g1c@msrt7ri3ZHcHICYwt-eNmR zkWFBGimlY8?TYC2X&{gLx}!GOk|-7iwjzJ8yZgCHCe|dMw9uf9UXNV?*`ae|@!(_s zZd$5C++31IwE3nb)984!Z=n>r@rP~Xrh9*h0 zuBq~1?OD&~v&}bUut8|6bobq2?uu@@Dy`UvgjbH8lx~wy%9~6((J&1GAftLTfme^= zX~55GMmCIG++IqxpkZOwKVpu{ung6|C@qO-3Uc?3_- zo(jeV00#ZJ{0d&oyr^=^P8HUC-!@GV#l*>j|P8tOU@6L!JG zFoy`F<*mqxq5lN_^bbBoLGUgJDNZp+D8gwq^u%M~(p z`spdh#Xjt>4M)8rm(L2v`2%tXI2DuyZ}Wu(iGg^elv5Aq5Vi&l+wxP#_EE!iw538C z%Og2KsegYkO@i^w6iuuX8u3`P$8u`q-`SKc(JZ%p8In#@{N<5CNrDDC@JXR$WKQ}? zQ$qKpU~l91U|ej0630g|QYDF2i~ap|)0uh73Mfxj>zl@DlPyZT$ODDz%Vnc>E>rIm z%mw0JUIlrHPN5glz}rNj=w;@9mm@@@I*A1$C+(O=oN!&Eg{~8+`>;{1Qq9Rjc+G?*~G#l1~p2 zK5nyVg#mG6Wb$jFA+%YFUNZYLsIBGf0e**Y6sBPhQC&)d8+%LxQWL@_MHr?>)A}MP z@XSMt;bQ@Z{^KcdL9M?B^YQ@pf#QXOcqenDgNgRSd$LdP-JndMqOorp|CI|2jXxTo zX$2}4pC8WyOtC0P}t8ma=YOK;( zDo%D}fJa}ZY}uK$T}cQj83x8f4=?AbR+=LQXt2iUB1181ETk}3+uyUo#N&_kc)rV` z8*8p>d&wu#F@Q+ClQz-;CtB#>GP?W^k;p_NXTaFUC*6#3(FV`;2&-HP@y^Sjigw`^8@Y9yhxqDeGr_#rnH)yh`^+1N?_DWuM&R{F@bBZNe&p zV43J1!P+e=Vty~c=IYWPwka|+BPTwjtGlh9Ih%JrRFnB#5!MR2xx|}V-lsV(dC)X? z_Nql-6-sZpraEiXEakCohqs;HsK5-AW9*J+52!OMe$tf=^tiR&klR%lL#t-{sPwju zi9(l%v6`_Wd94t>5I=(O-2<%`DpPSl)z7|W(?)Sl(H29u%YmKmnN-q}*X+Kx`)8dt zxc(Bg(k|8AE>}b0i6mn5`L5ODY9gO3vsUKaEkZ|)0}tO}lL zV+Xo9#v9Qj#F#p;1p-nQ2t^N*DCip#wxWHt;Cn$)6`82H`9Io?t);GyNYdHrQTBvm zBw8B{vxxLd&)XM&as|8co=qp(ndU4!0#O{}3o#o)c`i$NO7BY+Xhqm!oFoi32}qx`M;M1NqY%>q<=Prw|c&N&gC$C6E!X z-&BD&)o}GRIqy^tk-buMUDnUfT&mr9>vj9@Kug6Mmo2F27&xPsKO#XO1cqBnEVr5B zqC!Q0sN;nJ_Ofo&vaY<3VgRqhu`6dNw&fCPC(d5NfxH1E{L$CkuZ^rj#gPe_qfAk( zMSzfaeQ6xg@gzftyPU4C7Pq1Bhu_MX~8 zLwH@m77%hvVk+70)+8Q#cwR?&A`4x_+K@u}*V<8M6e>#;L;>vW<(DYm#owPxSy&~H z@Bq8dJQqAXELL8)lav?7M>| z8nAr9bwYWza&erbYMb}+wnpl~b>vxb36~)sw)+Is*21)!2=S&8c}tq8KJ0Z3Xs12S zl-#^mllHxbd3um-qV>?AY78C(om+Z4vY5;Wq_Tc(e7`VsL)0~WcU&DP*TYp7*;m86 zC+ycCLT=%7xLQjaGQL`C5WnIU%B~g*_NL>Sh}ePXx$|1=Or#XEhS>*bq(uwqm$ues zVgUZPEY9^we9Mf;o8{;9vRmah4B>Tp0)~JYJs4R>V*APk3kna--p$|OMp~aa@aP%TXdyuAPgI7TO3>*ahcVWUJOvfuT?9O2=@YEOw;sjWv%DYhFP)B~alQR+2B8=CZHaDo_NI4zLiDzFCq?|rNkYEDLG~tL zm(>w{HAjaRO%_*>Qrs&gbl+tVUo z1uNTUzRD-e{y?k~%sC9I}U{@5Bj${nrJ1QC(%74&&|A{sGfad#uHsk*r+xNd8;PwwV)(1%1|Fi%A zNADj1wg27mpTMUNXs!QgSpde|e`B})ckh29em;Ps{--&j|D*T+hD!bK?*D|{e1HZ0 zPlExVyZhbR0GSm%Ft{U^}i15)FES_byNy8aVZ@V`6% z6Nv8ti|{|~6z5-^|3Aot|NWeQGQ|UI-+vm>qyKq{{|m%VQxy~I;XiSKA8BBjh9M8% F{udJ=CXxUE literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-58-23 site Document Inventory Report - Site Level All Sites by Country.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-17_22-58-23 site Document Inventory Report - Site Level All Sites by Country.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..dd6140ddc2611a45f425350e21aa522fa3463ab2 GIT binary patch literal 136817 zcmafaWmsIzvMvt6J-7vT2=4ASI0SbH?iMV#Yj6qf?(S|ugL`lY?r<01-sjx&Q16R-+^f355v;2L}fxQ}jy*?0@`V0DpfGwX=0LwRP54^{_W}(q(kF zv2IWqv+ZR@eNGx)q~*9)Qp55WB_6^qxrWs7O3=KgsQUT$P8XIdQ8^6W;nLX5+)U%v zq|u>KTT}$YyKm6DpY|`U#ZFuBH+sDzFLlEodb0R@Y}N?FX0szk_~3M|Oxr}IIrO!;JY8b*@{2I)BQVR|%^?KSa9Luzaa^~d5B6LQ}x(-XKD3;m8L zGK=^5A*YfoEL9vMg$)L?yz@s4yG zXf(^^2)K^0Iar*8rM2pGIVp*?&W@glMr+}o9p=v)Z!9COf+5l!DvViq{w}itxfV+g zzwzC<1uD;kuzC*cx20edR1LaT1ZD%3HAXj8KuKs3{=(#IUv*D}z-9Zwj82_1AY~Yw zsxX$(yk^oHJLVs#ASY9gHW7EffBDX1bS8~Bp76TK*U1_qKd>-J^UF@8<+!~7w$aW% zm)=BQ&QH&E$-9lKQ8D$HvhaF?l?_2$(l*Ho!t~;1TO-mIJCfe~F@5Gn@|QmpA-oTW zDe!uU`1d!6ck9@)!pZIdYnOrePu4*N?l7@4R&unncVaTMw||GFd~^>y086oRAMxRi zwIgA%nZy9NtP^2DlKd5pX={;M8NrQ=xt($5n4;E+s_iJ6Hld2u#VAZEj>zag>H@@z zN94R6Dx&ac7`)@T1k_EAhSBDJ)*r7a7flOmRFz^utzC5JwKCWlSf?t9%#>bZB-O%thdTB=@X0 z?_J18=wSt8;!#~SkDF%kW>>gCt*V3`8^E_igO`z2!fD?1?<1ExH6k}Jz>JvbY%|1` z0_VyRA>`ZDLKd_ZDthjMbgGS&++dpHie73?YiR}{hdi|nc|6oF&Tc@*7xI*)+7CmH zlEZ6qEoqLpUADJ&F4;+|Oy|m3rv6EO3aE`>r#p~^?)pQuwYb#$hZcLru-2cNR&Z5~DFHm92Ei8{lK+hJC#f6H&6 z^Njta5|XC` zeHMACAeGH>xu*xF`~h;Q@cZjyN29b%nMsMGCi49az94ZspQ9_Mls{2wjZPT>6QfFG zN-5i3>Bz;Myoba0^KiFRmplU$24iG!p(TQ*NtY&Rqp}~;Mocb4n9nL-KZSj-utZ?iDZe)RHj=6?pAAwy!oR>2xYr*S7Xj&#ZkNb$q^h5%)~;c^0S9 zu3EGRB(}0E5EG-!6w4Oa*(I5{kxqk?r_>Nv|9WG61{obiR;PFn2bXiL0wGio#1Tq2 z3Iijs&xaj z@tcdtAgEAoJI!b3W>hADOgl_1$qZwOq-tT64qRTG<{7Kp5Bmxkh5gU3M#Eg9fzW|X z%Sv!Z3ZDLM6=WFYu3*gVmM=%n`$Kt|v*_@n(s@{DS&kto@HrJJs3-#Kf=3@$MfoE@ zN22++6gX+4QW%_BzLVH3=JjQD7Qd9vA7XxfEczAdoQWfQ8WlKlNu-fOEyFFB|O0_^9jIux%Fl(k#g0{tHvnc;Z$s7jsdIv(yU9 z>G4}hrX2V8qla9^*MFiP>?k?k4S@1h=>LRtlz-vH&Ccpr7-^Qm@iXn&_3YBW0O8@t=&YE8tF7M&~kegQj$ zNggIn>N32gD}{IYN0ce%va|36m#2ybFYMF7K4^q~3L*`@sW{-Z>RGQPg*80EvWac1UT7U<#ZIzQtPU@Hp%}o6s=5evHzFIq zH{!*b8HwQ2SNU4Zm5g$%uK(_eSTS$6M1W~`{$miq`vWo7Hdbp3nmUJzJ=dxGABA9on{*LNxln@50m!p*S|hXVMp}`J;x_&`^rPMSP<>QWKKRo9&d|WG_H0}PB?PdEYQeK?r8F{p{rZH{29p2gL3G$5k zymh@j`@UQx&p+<`5d~R)dbmqY7kqi`bM?BKLLstd6vSMtn=o-vq2J4LE4#U|rsG^Z zC$_d-7&s|~Z`I?=amWy8&YDQ>db=X7`m;Dt%V$u}xc+i@H?(_)^7=e<#PrI?$R7M=gQK`l@UnC7NMm>cLUq>8j|4|7fyD}VEpBzXDY$fA$EztTXS(Gt1(`ml9$sg6Fy z;VIC@_=_C&Ap z{>FZ?&(ab|zdE({YGVQ83jx=w)JPsMt2<9^7lOIIy*;XH4_?`GwP{Udiu>Dgk@jZf zFuhg{8_#nF7r2fFR}pIwRA0ip{_;@N)yenm=KAE}n)q$eceS$dP1#HUKlRajS+6VI zn>JjrPSMndrA0?qusKukKBR1ZZ@~M(_Qnrhp_W{cC>GX%@KIFttqPUxXJ9oa6_bgc zShT{ctLJr7#^@V`1A)0@k*Q~$9>ad}uZJVoZ(96kS}%Y1>k3u{)~$Dqi;4F1Z6oBl z>wnZew1&Q3Tt9D(TFDCgIh`~U&^P0E6m{1^T04y zn{6_q?Nxt?KT}oN{5-j;0tjhTZN}#2i)XVhA37N^Jo?a7Mr@BC9I;>6zUZf09EIJv zr!Bxq2PvsjWWQ$otsfVXqV=W72y1pqQapxR4~uPCJ=^et$^J62H;@$O9XG64_h5AE z3KFZG3@4i0<4Wo3U>G_;`86_I=NmyZVLJRooSSA&F;pcl82IroNWq7JQBbTZJbk4p z;-Nsyb(y1v$GcsO6?7@;>^+W;M=|;gdpNqE{=#5(xslc7 zBkY(prdz(=a7B!6F=^oD1cUG}Ms7JCNZ^TLahJT58wK$pATYG>vec7YXYN2_~B))e-ytCgF=X3dY;fABwr@DW)EEhIsa zCdT)(S=P7lB*1uM$R)rKY;jn+Bac}cQFEgIP*6_$%q=~`XPU|Vi6s%=RLpHss1iNp zbL=p)6AY_s=04PJ{`?5omM@Oe-&-Nn!yoA^uXsKJJK;-gutste(WL~w zNMo{xkZkqirJ?xkH`iZQWo0)>?M^H6cw~?MFnfgQDiXJ79jo)Cp7#EbW)%cRkYh{lduBVz=1NwglX#M|BL4ccvzU4im*7g`i8B&%Fw2{(DEd|yN>AR0 z_RSS1chP`XEZY;EA5h>LP(Tb&0D~V;;8Akm(h+p|++ss3IBn6Mcabvqgrj$M#LVXn zD~E_8+04?upOR7dgp*|-Ulg!kuhPmV&wxwRBICCeH_VI}gQ#O3EUB>Uzhy{H9Q@G@ zk*U{Qp8VwxuAVz9u-Klzz+8yHT%Uo(8r>7yHPy*q_y1Uj#S0H7sLNgtlQ{pomwrGP zZJ*~h1%X`g8e@F<-vJT909UZA{?)g5;Ixvgp)Y$<)!dtq`rCrwg zXGPDD9fpH7i0&WjhSXl3Ar5lauUFQjisj>*F>8rw{xAi-e;$0K1hOA{Kci;VJMUqHKU;^!1_H zBA#Qv~0IUZ#oL9+&8V9Qs% z9d;ypqm!TKiw~_}fVci1PaYPPKSOulqNjhp{xQ4R_krpTc(y^cULx-6wN3fO3~h`j z*b_G^bmMr7EA}ReG{;1)csYJ=>RVUV_crW;|4qw2bOmvfm#qlN&k{MOUFOnqJrgnw z#~Zzy5i13{dYX9_jKex}AN-`AkP-rF^ed&3{7>=&l*k0OLi%5VLBSqrL6_=>*#{`@ zn`iC9-d*_u!X(ya$Our!sgQ%qZ$CTLavo$~eh!*XTwaFs)&8cwU~6l|0P{8-`~ZgR zkO9^{^t;~wcP4~IFICH?LmJf{u?;*)FilS6uR^e0qn|WjACTCfyCn}9cP))MBzFx!u$r^&s-*)yt}lzd@&^jw z%M1l5Q!Nn>#(Vl2sAM=|=o3>!Z$(sdBxtJzM)rMm}nwsqYvMRd$Ov%On(Daxz~}^0sZH7upxa zP&fV7mcThiwT4BRyO+i+8r#FII-Z|zC4Nu@eb^@raAIUqQ(ze!0grZWH%A&spS(bG z%;#77I9pT|L!C{8mfEJ@{;E`7rLh>)UiIthhCKJ0S~1dTSm=AZ))OgKJln*W$Xr{i z6P!0wq!S#$Hdlx{@~S1|v=%wp6s09Cdi)-)bnO{=FJh1=ZmvApaFR#@9J&>67#rQi z+*K$~QN66xNwz^O=uDu8Bzc#$r&~!6BXWD4!f-8K$Am>TLlE|~=Z@Uwp>ql$gar0P zfw?nFAFA6YK)AiD8wye~IKu!{v;e|oDboO*yN8^dU4a4;X&HtxQIZQ{=(-L;bb zwU>xME(MCtSA8Q^u)07+42kiut5?3)ZGUw{0WZq`Mq{+Lc6wb zvtKvfAnV4m0*^_!Q>a0Ob<;_%jE^bQW(MfL-A6v-A?!o{>80PAHTG}GfjyfftsXfa zv36p3Q@J*AwaK5yAYYg0g+HK?sP_Aa#^L{KY{|22-=<&aQ@zK&oGCJ4y1wLMTkEV} z8z+tz{XAKo#ONJ9NX5t*qR5C0Jq}?9-l^XLTH(eeAl3m3L73W??{eev!T9)+`@nIgFoMV-WX!=9&#diqjNPxU&xn6XY>UHhkM>#*ML3n}f6KeT4qc%{XC-M%RD0>)%jaiM1(<20kCDCr2D8`D0 zfWC$wl##B4%_K??j;#g0Y>jzX2!raPpsi5@OAUV zLm^f#C;rpDwxC}0Orly3RgPJpXNE+T9LX} zZF+%fXP^7k*jh$jVvB2vipAyxV!1YJZWkjOX~WZK5xxNmzn?0Spg?kp31`|AMkuG< z3~Yc(uJ4ig*krVN4qKvsUCW30gfXVijGt{xa@$5~6#{(n(gyXU&Ks&?{8Ac>#=JPL ziHR}ga|>)hMkT=Ne@wE{_ET(GDqR-?;w$W!BActZW)yA5b(^|1e57>iWWk#firmhT5XU8k1vmIVemmL8q3fd1(7;%=KBv55b{>p#keU{v*EFL5k<8Uk`h&)T60;J!MOmRxbQ+4X<)sA@^cRad11Fk2jTPV$*p@_EKZ^u@^iAg@fH}SP7BLl;%QuuZNScg$vzm z?3fTl9sX#Fc6Ll3T@{Y+F3q|1Cw)Sr?e=mKXd<5%i6aJ{9!?vclW$HIA4KA-o}u+e z2&srmyOuM#h$>`}wn7dZYC5wR1m93!oZGwwzl`~Ef6+_wGry!FYswn8HFJbXuUr_Q ze;hgu*+!74_q+=sCI``*WpkQ#*KMC)jm@K6E;ht=6%yxa(0$N3!RN{)#OFb!4$`<9DjU4xA$e%^Lr_NSZiDVJ z&YIMG6y={GmA#xB7&T6GmrrV(u3)uhJ4uakboe%q6P|z|uvU1!OCqfGmrs~Wxz7); z^2wK>QPV|yku{6S)7=*Mzd9`^p5IG=fqUkWe%cmK>uU$8;~zPMdJ^Okh13uIa!SqQ z7g-ygi~6G{s7h?y(K8>Vx~62jTvy2%+S)URgjMk^vS@#lu!1wCHLe&?>Nhy*kwl^G z?x=)U?oF`g^zH2e{sb(J|5u7Xy{T{4ZWL$#Yf04i%T{|NCa@Ro=f6SQ@bGKQh@bYEchmjyyLKPB2W_ zw7wPVIY%%moUTUA@7wZ^m2{RY?7TaE64iHfROwOwOPl>FcGzzf0zr#MD(?S&$#XP% zUu)%msgu{y%t?FI0ZKiO8ubRO#v{gW;U!v%R4Sr^l~xL-3Z26XcBG|pQ=SUntqNAC z$DsnA0v}tv|D#wVt#~>NKJ(ufouEIocpBi%@Uf+CRBDP;YIfdM&*}uy(7Xji)ZEk& zvr5?Qu{$g%)ZF>7@dRwEmAhb7YX)@O-PG#wkci;Y$oBaWyI`M|q>ziM^a#6ruF9Rw zlN;tHS@Nzf)heGiQiem61u$+NaBf2UgDc2bP5uJn{oE@6>K9e-cs_#aE`b%3gion;5|ot#v$=8NUS5e2?6;w zuiW2W!*XFc{~}IoK(PEhu&z8xGbMV2B1XBKeVR;t60^XW~fKkmEt)JGfWydTk_gQpEoLS`fV$PdiFIlXfrs># zlwl;q3I-V#b9ABy{fsGQK7z}O&KbO3K$AE$NJLJ=e`An^wL*JMKY;Ud&Vjf;hNDfZ zD7NP!+=`t6=ahj}_^SPV#=ka@9jRT2c>-EmTIkS^P>N^TzHJ7)R;Z%D87xmz8kQM~ zoUl8N5fC9Z1UW0M9nS7~HfXA5UG0paTy3kk%md|gnNfiNdY(1&w3N+4*^kv8qXg5| zwfQ8Z)#O?rw0Eh)vFH`eH4n2>Bqb^}=3~TrwrK}ABz-Nt)9S1IID;O0Q}p!p!!Y-n zC@;o)Wlpa(%^fL1vKzT z%ci-EqpW?k^+d=)eZ#PLwi*I{>FB>lVVT2|yun0;F2M;7$%sj85l4c=a4gzsWxywH!{OMD!{N@pfnrf5(MbD?GnGY)Fjd8v>t$FX;9kBI zko+VfgK$*1Qxfw#my)i@3uO+6n;)bmizE{f2#0gS|3@$yMJyf&5(AK9BMw!h?v)do zcfQ*S zk5R5}=A*rY1wP>Fe}!|K8Ym`3WYfV<5E;B=05}2&T zykx`Sxfnt1SmAJOi4F9-9zJFwCE0gIp@6!NPK4r>fy)b2vhnUi?`>A|h#8VisgFny61BfbvNE!=JHqw4dmL`{&T>FUn+bbzy=Zx{0f;uNY_Ss+a$kY}6VqB(XB*V3PtA_p%_^Re6@ zA8p{_eYjB~jCFdHQ40|*M*5pcUE-{YFVXOG`963)7-WD04Z~j8)Xi)KKbh8BjPe}( z*sbvr=5M;y)wQrevkm)34W^K(1AnPQGko>;CK~RLeiN2Af97G7(_{ABiwHJK zx`%R~IB8plc%Hsg)D6u%5+yB&s?JK)?kLM+6r@pZ$zsOAmKR<@s?FlrHlHnR{L2VnvUc*oxcN_%&m1{1qT4M5$ z2x|e@{tvG7OAa*UCCZw!e<@^${<5=& zp{QscH?Q@k!O)Zg+ue%?Z1-1SyQ_oato2pK$UN!39$#%cHng*L6su>2*JKe{RMUz( zwZ4hFly(#cpU2l^1&b0KAEJu7F6T7Q&(1YwNmPC;E!t9w@xTmJ4m$OdOV*vk0b`ALcAgWICs1u%PqF;>7d zt2W+VR*)I+t;I+>Abj_G9>zWJc^Ds(2I0QbQY606WkBT;Bxb054nSoqK;=A+493N> zf!y}tgJ(xwOj#{RaXZ^elf66v#JmOOX&f~uXrl9ZJonXkyv=muIlN6&$qLebDZtta z+K^52c(G$a^)Os>qF;poU|J#lC8W`EnZuK)__>VJ5DfY{ELj2Msds^J%LOo?6_OkN zM%DsYQ2?X1XsHE~C7|JMtFIV=)K?(gYK!8DeFY+EJq!>@@qkEL0S-h`JS(j&T2Eiz zE?R`@gEcFLs^=@(Wt~xUy4DN^M!SzU`^a@R9c($z9rLnKGsKQB^46>I*j?C?w>?>(C;ZN4@hYv zgTNQ9Fy{x0L6Lak0#=wnN_!UoDUCfGl=n`C*x=vE5OrWKD74yzAgWHMe~S&?ljJTa zdS#wk3^fWuqGpEL08T2;?~^VYJkH3KS7@;h&S@(Orh^e8o6#2!(gMrL@lnx+vNFEz zrqN=)Zqn#c(NG6o8>QCK@6<`K9(|e*l3yf2I0Yec$waZoLHV$Nl|A3BEQ11AS=u#` zNa7H%azO~lb6D~au=2a$-OAU@GAQp>zJ9mzjA)@0iq@t`w8|u8C5QAZq%;b^3p|Gd zq)-4>a1F468AyN?@OMk8m&uRTxIIh1b}X%kU$h;JTv18x=|^OBa7Djfq|*N~8L4mi zQIOQ0x##gr`sm@KR!$lBSRAPg^mm%)@pp+wCzQn+%IL(qn=0v2DAvqC&Q*IxQYHj733)qCZpso&<+YED<*C0E|i`76zau5y-#FWB_U? zAS5nd;m9-u1C)rOKpr?2{j`@5D^+~V@*aM6NgxjZ0ZAdKJ3t)cqCsh?xby=Mzy}~; z6!IMb9`6XK$-88xMF9}N7da{_KnvLO9|3@Xq!5tDI|35l>97(}{Jnxl>>E*iw6QdO z0Hb7T;xQb7K^PoTQyw21=b(y*kdk#GEEI$iQLGf~9=PzO8qugCXRy+6$gc2o&iFk7QB_aE#ZEeLMCwe?S5t41_SkjJNg;XnV64n$PthT_k#o6ivZwW4qyQHf;Awwb0Det z2n&N(RSF?=7XevMhuqCMN{tL`?6y!S2*7DZKe!PcGD$K*7^Ho12$x^REI%gfCa*H< z2{m%$won60IAk7IY|M7|+Tgpu&v8f6!2lEXj02e*x%(k4f=dX?!7rGh(LF7nezP}< zJmQ^Fksw<%>pJ+s02*M@Ie-QG^@9Ut1OZS+^!rQJ8flAFnPAnmX1y&71U-+bFw=rV zB25;q7Ljd@mqP*NgAACrMx+cF!FDlJAWklj{PUpl%eC`Z3|aQuzbaaY@W=?I9ms&a z!w(FAANVl$w*r}NQcN&_t+4UXg5^Od*+jy37lZ9?ltEN?9S|RT@ALSUFZuSRy?9a2 z-f8^d9k}1T;mlxYncI*n>C)Ov&cvN6hHLgD#1$mb{2Y!0v~=>+oqqVbJ%tKDMNsKQ`{d1&_TKj(awYrfQOeG ziwmgl&JSwF#b9~7cBt>}@IG8*wmU8ue|zibOnAH1>+7RQi$IK}W)(tj?35W}a+emu zCE*_b>Q2~12T3k$0tP?;27mxA0D(Ag19E&^A?$}T3n!Ygj04BU=5}3G$%xl|!M9_Z znk5O&vY!9$rWE2+LBBW7U z!pW5Kz7MkTeAv<%z{j@5eYl_Jwg9@}!UfQckaxPVuodDhi~^L`#zUUoVR!y6(1LeiV9OZ8mAO`}*BH z#syA^>q}vMBSq4$aM)jb@k1s-&SwIA1(4)20ZoEO2t@Eh1fWUK2{Z`~5ELVp)M|X% z(kiNQAODoa2l!D0`NJG$+IELI#J!qnXej%gM}w4sKu8gUD(V6RLTUJtihLjtlG6Zz zF#ezF4!B23x-2iBSq2`c?r0+8MFeEvfk5~!00JRJ5J(vagxVC)Tw6|Yn1N(8q1E%+ zl<09aIob4l=@lrKBO-dv-EGJN*(SuW@#lj)H8gbn>=Hq`fSU6`sChuVcAkUIN;(Q?H}+`B z7t+v0rF8MfSAUQMSkgy;CAs{=k{AJ&1O!A~ocSPtC4H1|0a#KHz>)v~G{BOMdYdX3 zy_*6cGIm32!P#D zKfB*@@%X$x52Wu?6-_B*cd0MZs%pbm{s10zn4;Ne)GE=L5u38Rv}o(w_-MR>veN)= zX2IMP4^hA;J#O`$?Ewz=3m|f&(N?0Nr2Ig(w}LF`G?k)AFb#B@4<0Y(Q2KwdzWj~< zAL|nbSl>=dF;Yt|$F3nlz0Ti^-K{wo$DFB;&a0Knv9KU~AfPq?eVI8JAfVa+0d)>W z3v0wT0V|3=BKOLOUw_Rucc)Boz*9x6D0_F{oDVZEg?U=j1{1QU&LoB8_Z z69Zs?ETsLR00Sgs5uQGpg^sJ0d;Qg^J1lP%V9=W8r^A#_31GxX(i7; z{3KfHc`q&{FzBa*RUQ#D<=aS9uSiGPCwh{mVRCvBQrlh;pdk$~lwJ{?4+!-OSZszr z!w%sPY8dGa77^eOfD~)^o?@x!ffP%=2-3s}0uc4ydLbol2m}x%i_-uFAWFNJvxwsP zwu~N;fu7_;c0{!hrlEh}>9^!P?)^#Ru$Kv}4+*$0Pk-g{T~;frg#zFZ0OnN(W#;1$XfOJpghfs7*t0iRIw zJC6aW`H4;n+BFU|fP~>#n1N_i8PF}Q*JvC$%SZF(3=L(3ipmw`0uC-9sw4yiS173W z;0nHl+6xW@*Gs-;duA)>K1=BJ4Z{0dt!E-_y0cKQA1-gN%5N*>XDFJ}=T%!Mni<6T zL~pj*L_UjH_1Y23uG}XeHsARuq`TzuLCPSh@Ih2)j|wQ~e0rrg_V&B52ZlnYrLfcMfTIj(x{UCtAf^q;y0O#e zS#Mq@j<`q7NVNl@yapQfgbebMi#6A}vM)isO(U8?y`<6SjiQlDKo%*HGuBfp#0`@k zv}|H6C>&)|xEaN4(J5vP66L2=0Xmu>Q}~Urc#WY^=W@Aoj=}err0=i6rbkLli9=~F zg`f%K^X^&_XnG)@ zclV+yfg?z^VpcQ9%Yr{uGZ#hZ0butVFU?GF+ zr3d50yyx(YLM^R~_(U19g#LvJh13!r`J4HJI2EWe6`-Q$5eF!}S`kpuOFNY-bj2Jw z)AOPzyZXQ;{o%YqzNVuibt@gDG%H6U{Msk5x2XVap>=(l==x(m!v@?OIH!?1U%)Dx zI7KD=!@iDvupUu++4;!->>70eddCqo)SSE1#C_;#rn5wpoZi@=Xcdb-&HpUR1dr2ET8-vaMD!PGg$kTz76xB<^*r7($Sc{t+SzatZ*j4 zTsm1Mf-VUgC2i1*O)=CfnWFnxa;1}puRKJl?^IozPpSYqPg6~s8A{c%Cyp@*JJRF@ zInt~RYw>(;-=Mq}1~1EnMtoL>+`+80HcfYp7NL`AkQM=MQ@DCmR8?!T zToQl#Q9|G80i$sk_c*Ppweq4;FDGC?Gp}1EQZ_1{mR$yq<3psAg3vRA zYUOTOaWy`;76%;S@aAH#gvKw*=SK@nfB8QzFxkT?bp^h&KGP;2Y3Q<}WbzT?xLDhV zc)ZbMRdUY$NfwaE^zN1rfLkH}ZrRx_)uCU*7Qtp)YW2tC;;urj zCOkc}$e3OS2Cv@6g=}}qU2#kK^az{r?;0yMBcNh4(5QR|b+d_sTC)FfLYFqI%L9*Bj+p$yufzDf~sYlq! zu$uaMeW%!rTCu&*5;e3s25`mp{-1Q=KjM_QZ8?fvG68<}6A|z;R`Re}da6PAg7x_d zrOg$ia-~hw9FY$!L_iCrNJQFw{vt~{zHm*PB#VPI6P|*FejOID+E2i0Sn%&w6M47V z&q%D%e=crXKO?il2xnfm_uc)AD3VJlHA>U?tk1B=MJ_LDz9TvJkV&T}UoyC8c9 z8)QO;c+PPH1#%t_Y$paVzyfzjxl`xy9@Nq6drv}!=zQX!o02Pt^MNEws`6DDoTi%f zj2w;!*12xS^De4?!k7dT?Sc9kc1}nV;2HsX> zS39)|0&l5G$@b|=vIpZ2+o)3qHAFMR&2^{@=uJfuS$WwS&06M*6U2R!BPtV7`_1Kylr3*0K9G+GT1L11@O9izc>Q@B|h!7$|mBo^`&80 zQjEq+P;tzFradB?c6uq9g2y<9aS!PH2%F%q4J$SQfMfeWoa}cT+gI0n8z%It4hw2E zZIToQeE-m~={JQ+&$X!(69D<%*tG9+7=N=5$0gJYo^gO>USPhGwLVmNBgNiCxe4}Z4uAmMq5-JU+ncz9e3_tTa@$Q zlR2C^u6?m&l0Q&wm$Gj1vZ&)4C;ivu4j986E}8Z_jT#I>TJIjYabS?nB3IJY**;|Z z0?=PmgIQIbYa9i7C8dZs5Wx4Pl4&6&YD-v;X2{|T23$bH8D}qolE>S#?f2r88o%bP zdH*T+=sa7fN14hO2A*2R>leFJvJ+|`a4qgROeK0fffDvhp=8oNrF;mg}9MaCu`9QnE9S{99JGp>k= zSyl>QpcEOvz>!~EfGXk9Cl+iR$f&u(a04-u{*zVUaRmb6JvJ@^B9P0NMItBOa~ZRk zIu=eqAuiP#R%cr5Bpq_x@eTCMBvC07u;-5u?|ZHf?0GrU;NyQ?I)6NFD^ZA7Q(l(L zhzTIA6!0c{XvfF-Wy|h`c*Fq;$%d22@1kLr#pk+Vc#zK&#+TG z&wE3ITNddLWA{`^#w19=+BI10>QaVyhkYdlr(_Cc$&#I>J#Oxxt&YoWE^?{bG|bGN zGG+ArOP=p{5AwOZVI2JNCh@_hS%X(zYSzJ4qjI{=p;jY$3ZHZhtjPkgYQ6K4nPYyW zW#;sOMD(~|oy=r0CdMXM%OAgcPJf^adv<)HRxc1c*E^TWm!;X-IDT<=;BWJ`zpbj8 z%;O=og&Dk3BM-~8{V!*RQn;7)CCyZMb=09ks%Ss+OBDU15Z3mDt z`DRXUNfAFQGO511xw*f(KhR9s;~eWAR_6Zl?|b&S?IQL#ZYv>e)BtIBPi!;z{2MLY z7*9_d8?!p3F}MLOSg3BApuL$O<<*AO*B;UQ6Jh8#1tZ(>f$!{$ib;cemeWMj^k#|V z4nkVlgw!7w9okylV+Z%(!qphp+Z?#j591@AI2ku=G+#Y^bQ7u5H%b(HQ>;nYu;G~?bK{=_;3+?nRrE%PBTL+4ZC6W5@Hw%R zl3VBIqSE0zWC>kclxTg5ZC8JDYZY$)!F-lII!$r-=$oxyNpNXH(sgTB(~+QjejT#% zFd0;eKNzE@u=VV@pO>8Z{OG6OUN$WjL`loGB%R^L5!f2Hv^Q#ES2=!LIAn#01iKPI;lSQgkU;pxwMN&f+Mwj1`;mG?Uv=}e!^%y-iK z4i`!T-vKasE%Y&Y25n~GY)+<@*0|-Q@qQxGfv)(nC7-<_JyKJ8E%YIIWR7NmbqDW< zPjQSi>AqB3A!P>-rF;wT|ND|hyk9nO)WP?Mj3+xOo7OsaiQ{oG_uien_F(_gI4Cd0 z$3tQe(>CYl%5Waveny(03gF%PCp7|vu_F4Ed z4X^S+aY`}HHrBMOX0CejL6XwfB=HBu0nxO@j{JG>czV!C3ufxnHfG|}W|{N~;*3=5 ze%Ws`efe`dwp0b!!pq}i)EqSI5a9W9K<1Q*B3a6xGhbW`k|QJM{ zST|D+za^mcBvd9UW}=YGb(COr^+MSda1>crfW;jwCa?~p(k(OjJ-`Qn{2YQl^8$Zo)7~WcCKk8DBcS%R{ z6%H6{KNA)W^qKbdq|52n^P7B#W7hNbl5NZ{2kLyhSo0@UBm@Tb&}H z55}$C?Sn<Vt*DaA`27s2gVUo%9MOc-!E-t>F{lL_hKTe0`*9& z0!6)ZcL{^i^LL*Wq-fuq+s@!rb`NzZPRwIp=*EjMwmg>$5?5IOs zx77ATzuEQ;wu6@#{QRx;j#FzRx&&XeqBye@znR1KVUIwh+;AR(t0ViI%n?>sgl;3 zx<~zTU?$+a4?eH2P0`@?(co)9L@EA{?7Z{m2BnQc{BX8h+Y|4G$+@VPh72XnM@-iv zhe)-oEtQ9tuRlM#7#Feb9t|phw_I)UgZ}HFQ;04;iyG&nYR(a^w~dXd+tE@cy1Fhh zi~0-9X;SCEPAS=`{_)CV&DKN3xXEcN>nyY2mF=F*#A#S4{O6!jiRXf~xv&S8jX9Q7 zAp|oP2}qF*RK*7RiGjtlq-CHSq@Ze1DRM=)7y@7Y6&z%zR+^@6O>2Wr?fU>@%~FIBY=w zder>yoB>7@4A*CyQDUu92(N_g`jruRS7R<9RoOs(-HznDx8#HSgvg8zT};4PLP5qj z7CDU~B3Tr3?Mj**Wo0bQoPU8+KJ39H@*P1XC7cZSCa6D5Q;#RqRfHb611YWi5BbERlHMJ*R=e*n_?2aDZc1QHFCkiTHw6hgXiSmc~vK9%a~0>)#JumnH+bWX_-h*JPi;7<&w%37a_4ai4YBeXe4 z2`&AVbhUve&+*tmPu23hr%KK6-cy|eX*X-k^jZYt6a+oO7-g>cG^P~%v_fo)5Cq$*;DHj z8P<;6-m*NQpwac^-Pq&Bv#Gbc!e=4IF3xXFKGr$qc6#sUFLzWb1wQW`i+IxXwYdDMEV|lZXDnJiI@oPJlVjO!wGA>{ zBZll)0_gyuM6GnG}OWG>m_xsERB6vxB_;8;45#Ng0_THj{e(E zTaUOqzt%?{<7|#pI&5-Yh^vj0NOh`qWCs(fE69#8Gon{E{i5{y9*0zvuE}rY%=Jf+b zyxmyl7!wVPn4il!t5*bVWPMiz(2PfS`8%{;bDZ{6_r@>H+o`jnxHk7J%L1V`TFVDntLua?9PK%E4A+c#j4~4+|p-+i=ar*CpFi}vy75k z-HNmX(tZJ5*x#GERQ;%nX?(KKnQKU`!xGxQOB;tGc~^AJLQQbj|G2~LD;z3So^q@C1EJj+4y9r zi_p3@YixRJa=nnVI6n5FZ%#QWWwxIp(PN4En>S*63hI?Of-_ zyiSM1YUpapI8LVX|NSZyZj~ABnT)0=T$LaT?KR_ZZmdUa%f@2S)d8y10%Byl>2!X{ zZ8p{`k+RrhHu<;A9%j*mnjeTAtdDqLLH#1#XI%EUY5iC*{{7Kr_#m|=dlTVQvMKNw zG~-H9T6ajZ3EJ(PxILKKsQGvZ{=T4tE}8PUNHvcXB5rT(2XjD$1Y;W;wsO1@e{rrT zTDqh6t*(qy$)UDbX7t39qtdjBvlyMFATK#eCsmDaA-3D?S)Z}3510JFXlSmfd~po8?7IeY)*Z+tjT#~GpeOU zK5g_-6U!mZi?C4yDqw)^_nPnCAXn-e6Tlc6b1nUhkDm>xt_ba*_TPy!#wZ}BRXQAJ zEubWA{@?;7&}|tE2{b?=2Gt39LkYAFXE&BHP!BiGd+)2aKJJz4@$ zz7pChmrLLtoZ{z^1gKhf5{hX!ZYj9f<)g5>99eDFq?z)q&)h`QluNqDKb9}C9V2$Z zO4GCfb<(Wvm8VuVPRejg^1LWS`+gVjQdL*(0K2&s{ zO6gQdBm`E?WEkKQx7~JhK$xP3rA*wYu%^bA_5#N~IC^-aG zvX9E5)b$c(8iBLusCF_LBvbLMXhqo~PTKW}@rb0Rg%W;tBNOW#p;8>_51Sbcu@Gr2 zyhXuI_B$KVh|ELu_^=NQ(HZx6*hmjCg`j=XBJYr9L;dq0G6AIu?iWR?Wh`QmyDh-J zE@L2WE)VzNkA1cxfhfuW4Qd3H`mssdzCGqKSZl_H|Gp;@$9u*wA%@@@uf8z43LhM% zHY<3sj!x~h zU3(7*lKiOW;!91EQ}DuSN%-pcvlt0PN{%&_xmi9`120szN7gZT!DxgdulG58QQhoU z4MC;XR!LZM?gv%$UFs2BP6ND!3YAvjN_F>cu@pp)+4(~l9n}C*5moH!`ql{q*s%yZ zm_0R5yuIz$BAZ`6MQ!7(#pA#>6PtNaDwpdrhg%Uh*;rFhHq<;N9J2nZ=y^G0J?eP) z_^Ve`m0C}X40T%hB}0fux`=9BV}8%*l;}(LCnole)@f_}ei}WY%e>rjbGqMf)*-># zt>gKYWa!vP$N}fWXe1w{Ppn!e#Kl;bdlK6G74s7BM{^hnT296@!KV&J!4V^YANTj0 zKnK(DR&&tHyx^1P4dVr4hOS&T_~AoS5jE16?bxiVOrYRdj2v87T<}6G{fG}?2qpc( zh(!CEoxF@lbaFf-%}v?I8G2mCP~ZHBT^YE4^E0FWPlgF~D8=YKm`XZfJ8dwnwK?gV z$puXUGtunrEe#~g$KF{llH$!T%w#)fq}{J0?;|0gITY0wZ33qkzEk29Qu_r6{5ZN) zMemWmpFS@yxjMfoBD|A}GtIb*sR`Fg57Ug4+JYcwBWPJCJs7spIxiU3{f9h`-*`jD zF7>b>Kl1=~KF5;d?$4ENDBCE?g36oAH+V!Qx4uJbZx`Cyb|kH{Mp#-gNt()?O?Wxns`3JOjoT z%HU8W3uBP}y>VcQk3Y_;CueK<7BK^+#?bL2%!0sAS(vpsSzw9CFqO^MX)yZAR&QvO zUZn<~;|u=`9%p+n;QJ3t*0_8oFcX^h7`Mj)I_sB!f+6qw1})CY{%wx;u0Yet_X}$i z4Gw8YMg<>bK)Ho|tW9;;CfmS@8@|2 zV-{+D<)&0L7Lj5|A@qsHPt+QEDO~MjOi89FpUDaxeR{51!M*M=u=>I=lVrmaNtL#p zJotD0pm7zuAt_Jz^F2SDLpaMLMZLvQz;crVXmdY4)=)a2sW{c8? zC+meoc*9n3zlm^8ro@#r2hB|;QdcqIE*k72;WgJLqdJ70kZf!`@(TM}n;_A874D$= zEIhl7VKN<@pnjc25jI7{ODxB|83l$fZt56w>DZIZua}+GT%2uh%OT?v*3M_=HM=GX zmORqXFI7p2UQMAL+a^lIYem@2vS#-CHWp6FBp#$?NH84S@D2^TA>Hg4ho81ZK+WTv zQXenec7eM$43`?UaJ=(kj=n#%YdXW6$ir2Lq9r4=SQm33%}v8>UN1XDhOJ=t-qf3ZY7h*(IS5a`+v zF6b^oCox<{_M&PgVw={kEAxLtV7TbB#DcVC^-n{aAX8`+2W!@2ZHZAm3=XcA%MDZ4 zG&jY1H*4V|FP@%V5Kd07=ugQZ@5Qny?2Jz&H4)1;sRT(pJj*qy7u4b^aU+7JGzIbiyA_T;-Z82*pNIxN>Hn#oFBlu^t8McxU;Jp0xz0_*qp*;vkAtPIYQ z`qC@&3BZZ7k&Gmy($=l;6)02^Uh{*`%cBDf@>9{!DA83ci6rc7i2^>PnKh8b$#?In zrNE&{{j?lim*i+}VmtbtCN2U)bVKSrz49ln)I4b_sp4N3OgJZj@hIEMI!)**R#JfH zb2$=>M0e*?`30s6pZ0fnvfCc$^=f%c(6akhXAglt`+F^zEbTCZhA2Bdy7cgHyg_mo?#?+=RTsL2;AIZ>m`E z!lzjRyw6zhPQ*sUsCIv?wLahrExL$|RO}6hBw-2W@iXTL;q{;zHefjj(xoSb4_)YY ze>2dl%uMfmPtwrqVb1)%?z6KWSW^Bzz6WjscBm-1V$Vs5nxokx0{b<(}tvla> zzA_glYi+Tai@D>`$zczKoacu0$24A-SU+Lnbav<5df&o?ofqpzH!Vz_8z&P85)CQh zrAbUuq2ox`>zk=l@ec1+c~wVLQLYK*cSgefOaa8Cx7|~hM$?eINJQcUmm}JSbK(P& zM2QjLHjH4x2%n%u7jk(mBsgZ)jNDpg2}%pmLepeJ3WZ| zYcRKMtmtP~I=Ah?$dE;owI^Q}nm&gQj+{o}DbLMT5CXh)IW1vtGI>KJ_tWU)IC^>0 zOXK*<+$L0mV2SViq(858CrX3lGt}}A}@aR30B%U z>PI@g?8nK7;k+S@nC(g_NO})iK<{UXkLNED;>ED2w$|Rto9n&V%X%?PoH?6$Y*wX7s3!;^0c#wbD&t{RdEOad)cl*v7#u!Y9In>P263+c0AVisTQ^^kR(GDx-Y?EE zNP`beAX@rd&#WCfsnOI1>K%(n7=g` z-(pH~a~YWl@0riK254RdRu+?PY-%|7``d}I zgHOTuy4ZcbBS_TW+>BaDpcZjUR5i`fR&6iUMa?~~(TW|%08LHtPhjThzvU#)uFTrT z)kCBR@Wysy!k`Fdji2bQ(;s2|;;<$ve{Wvb5`zJK{#g!c(H&1nh2|Dyc+fBiGHiFp zUYD-F+iJzgk$Y1?h@1)k=Poaqp9N(>zlFghFYFOFw60lc7a3OKWrAGK5i}=m&7uaH z7k5C+IdIl(X-a=3k~4i}m@b>m*KnlU3m&Cw`Za5@<=(aiGIO1O${Z+`3bOO;FiGTK zZ%8GoB#=rxC#w0ki5Axk*`7rC$rQ9!v`x(@0gS6#c1Y#8F@$;9O0^0^pO~~#maXB) zuZNpjx@i0Q2Cl}ygR!0x@1*Chap=zH*%&+und^4Z{bBmy^!1_c$4}Kz8uKfox+BJf zWdjTClW8;DQ0F^_-t}!WzsW{H69h?;hReW6c%ah&Hm-FQjLuD(Eb8iT(w%NaM z8ThkY;xAt_gomw`hO48B^$Cy)E${1Cx43lw&xSQbrJ{kgI?gJIQA^Qbk~i{$nXxav`|}FJHy|^h-Cxk`;@zym!9n7dm_ZH z`=vMC0p(Z(?+q*6yzC_BrR{6V6~^`9%K!FJa>?Lqxsi{SG3Zd@TmQBMBmA<=6y~(f z;Z1gkk=u4U)^Mv0-_Q)}n;U5Ku?p`61(ZhTXjZWMdRMYzpY+TXX~g(jJE}jMJzO0= zg)A)PfB1-Z+%X5c5{*ZoY86gEd0WknxZw87$3=1wqM%jlme@DPe-tH!+A}AB#=dL@ zr{$0meZulbVY%I=dj`ZHMRy}4dwiTBhN+l`zLx=3Ha@8EM3Pa0A9i0@3NJ~iC5yeX z3^NQYWUf`%lcihoDTG^~qGu{eBC`8(!g8ICDzX_;I9g5{NaQNlZ3r^uW4;wBb1|1) z?fw+p1N`Ud)2i?_;{)X$mU4M$+HbZ~hNtJ6e;XW|15rx@;8w@hWdL{`x@j4>s4=GE zmtYE8sC34anP+35MysaIl7WR4T669MXOvV6oE~6IJi-mt&)MHO%tn_*Hl310QpCg` z)5PXX&En`J@MF)-_o`goI5@UM(b+Vm0$MuLnsJCOg4Kbt$}Lgi;4GavmWO2P4lQKe zHNEbHkSwb>|!&N)_zQq%HPZ}v%kCj`w>7^ z`_%oxWxfu?4S0!KXzVmvZ5REGq2a#F1|XMoFR}$&OoI*h?I@(x({9b6`V^{o^`36s z=AU@-B<7@8+ZOGqKZG1E+AC~Hp?3OId?iQe>SHcJA`XZqNOX@mp?hn8;v=CKtKM(d zH}XZgS|;ZR6d?;n$hI1f=CsD*;dUOOHkW`eK1xh^jY)b+G!Bzr2EE7tY*BN3+zPP8 z68c^%xac;q)yruS-XG6Y&l;VjCU-wNE7wec#A+aF8r!=g*Ns#VaEa- zT8l)-t~4G>PJ7j2F0(U+7ZvtaQOwLl+@#oxRTv|)+{qA&gsClt3l$#m zm&F@rH3}pe<3I;B>{%V@uBCA{kBYg=;Gniy14+=w)M@S~RSN%O5_u43A7Rja<%04iS5O716<;w+VHUUjF(ww|)Od z2!#5`N5W`$2t0ntADXV*%+_^ckSzuw@46uhpXSijYY7?FLw#Rzc^EgV>ldN!dR*DGtU3n90XOm{E)EUcGMRa zhLJ)nU-)p`?6f-w)2BS_b7VxA@y`w{us`B6ogQy}z<&m)b9DIg-V_kZYMjc0qce!_U)E48pGG zV)~*RIMF~>=d!V4Gs%M){kQdlJTuajd~z}fp|x9GnP9RylM-9)(^GWY*#}A?d%=k$ z>wWF1bbXVz1#7v?o*1t**jslzb2f4E%Xjic3V*?j?LM+^#|tz5rfTOJ1H-|fvTt-8 z6DS(nOdKAkrj+7c>36!d(ckbc>bsFfAzf|@Qg$o?g7^2cy*c@7&wd^ezbgeHj@3ux z{vGOaZ`v^P3B<;wVG!6a?}ZF6WczLe5f3fB8 zmA_8qt)8^62f2h&2PT6g308)6I08qNXYY1Trd;DnXWw>QToU zqIJQU5nB%6@Hs5TH2TsQI=;KDNQP8q(X1@1g^>Tk1&yhFQPKN^ zc6c;AOeQu3`0!*E;y*u6D=*_?o+W647Q1kO|NuaKW_niy^8PTwJA=l2c}+l@p6oO9968;x;S@eA_hSZ7+)fyR zp8>^fbIy?uDDIzutoh$&)4p_T!isloiCw8XP6n&T$J=1YZlqJ1<3`*aT74opXIN5f zVC?yXFd5sGUYZ7Y2eHT4y5MNTzLqAnTA7?P(9J(c-2aEf)*JNC7aLfPwVQgj+A}Af z(b*cVV59uUtcVsjinGcCeDAzk#kszl%*K#)Wl!K$Ck`Zo_1RnXLFryEqO#U$A4&Iu=M58%SuX& z_ku&kC1SrwoL2F$a=aZy%cOyPM6Tq)bLUc(jIioFKzh@6Ak~0VT#T-SH<$U5hW2n7 zuDWUdTZ@3?lsc(h>tYoTgr>&8N$)>e7V|#R{-Y)FS1LoG4>&OgpyjN)s{}yHivOpj zTj-yiTl!fd*b6dx4O8kCB|yddL< z`qxY^3MLm`A?m;#GG;?8_mYoEKa-y_yS5Md<*|*fgb<-lw3Y!p^XcZvbp6m&`WCr5r1H%JFvg2Bb!?>@|zVZ)=#%gP;~YoqAXtd z>9i!^L4ibxA%5A61tnN1?y$kwWZ4Yl_p$!WUv{o2U(IOEm}3X4QKvK(ySL3*A+S}~ z92S6lEC#Szu*?<=cHNk7rx|HP^`a4fLv8at*3}NT>P}(;wpMk`X+VJ~Z?xR)#yvx0 ziB}FuGc7#Ni3Z%(I{uPG0BwLH>^de{(>uYFA_j1o^F)GVw=|Vd6b)^VkHErZwFDI~ z^KQ!@0jJfnd+}qkMW&HKsRj3rbWEUYp&ki?r&>f4Mk(?vQXEnprye(Q= z1Cic*soiJ^3_jqO?RseW79Gzo^5&cMKD*G(rgI?&@)oU_zE!~-@g}aHZI&kdkW{T` zc-2k!b{vYyP5Ml8lk(vYIn#ZmMTJ^ni8;VflwAr_&Gr#0#D;;B^X93kc?}4EN7Fke zU@k6&Ej$~AifKjB`+7&yW1ooC6;UxETeU+dkgK<^Nk0YXlo~RYNz@q}{XhzPzxc5H zjEVHI>e%3d*dmTSEafsSiCC1QneE?Cx-;Gh)fveC2%g+d%#RhTSv9T^fDfMBN+ias z?32gd)(rjc6rC{sJ4GkPtk3fSwbDBpDM57P^9Xt(08U@6ffW?MnSWTm0C38V4f+6_ zT1x{d2Kf;pkye?lC6EcU!%i~zG}ism_@hL zBTV=>tM23@>{+A4ii%HxCDX3@RcOssz5mz{>ok&nv5QI7=9L}k9<(3YY=5sSq(op2kCiZ zgd({dMIYuJLr?PW1aIk)4_Uvwjqk_Uh%u99zQV?Jw_~qD+p-kZFBzCypAQh?inhk! zTvp5}nKecpMCO#K140EW_lCua{5Mh71e{tB`)VpEpMgdS*4L@hx)CwpJD!i>; zo?3oB6M#edK-v~>lcOzDb%^F~&XNoi-u_u)0#)~HGt1xzNQ;e`QKRZnfT=?@2(y(+ z1A9kITHYuh9+QY-Di)#bk;o|TsbkMgQ_9q&^~0tccH-MEgcbwSqI(2y48?0-#+c!| zf-T&+`U8lJ(K7S+B5vu_^iHP=>H-~5-9N+32G~VVQSYgze8fp$9ow|HXVa-*=k6aO zPq*SvGvuJeBiFLoBk=W(vF6%S&*tfm={TN&myT@+)PMA-<>PVxWV3PO+!_WdW3Z9g zOo|V%I4!qYtze(}=?VT{Vc$YGdka1^A)j4KSG;`wa*=|ky|qzeBs4tP&fwQBkqg6^ zY_lp?p1X0LF2Tu1sME#A#)xf3hvp`2dWJF-Xl|xzeIi-Nbza-4zXWGuUhxmUg)^)6 z_MOTRMY69aBh2zkN{LC7>m)1^4W``EZ$-#IU~?;ITWtc`Bb4t|Y<=OKlM zpVCUcCoW&_r4)Mwjn&tyWq#PasmuC+L}M3NokdlIMvuJ8Om8f`(j5>GRXoqx{C$DQ zt~(DmtYO0paWlZ@D0ul@e@24=S9n9tzgd}@Pt(7TKl6Awp9{Z)WAtu*=1FMOjQPsy zg~9e^dDk;+yV34b4Un5%=eM$w8u?#)HyvWHmCn=WeiNwhPVH0Y$X^i9?w}(gAu;;@b|6Pgr9&nk(0qC7rpVX`+AxLqjtfafnjMRva3O@qaSf@oyUOF(Ft@I zvzz7a7j=;`gbulT1i*eRI+g4LdU%?4E5Z@7EWt||Wmx2vO?BOsd6w{Hof@s73B|^a zHy4{5R=ipzYwd}s0-g_=ESpzSNPXco{4)zy?flf*V;^?MV~TZjmL$qnrIw{og_Z@j zY=Of_y~&MblNP`9(N3&wY&6g8y!S~X9$1np!LT%(;IgDdBCw>~kS{6KJabidP|lz- z|KjH8_z8H)^fse#?qH~eh35SDI zt<2T|$eACEuxSxF31t1Q5sHIGCQQoKvCEKX0m50XS(G*fkAR=b457LUI6c7=P z)q~>{xJm_=SUu|d<<{C+B=T)BPRXzj#W&Xagy3Ow&usgI%81~&Q683~E?GW!wq}$mZDB+dGv*bxHkx=r zVR{H$FQ}0FdYQS6QSrpcIA45w2&pzN`Gv1cLfT#uB*>2QD%4$P;xa}kgH3tP+03?i zYH$wZi}=?JU4g?`wZStk`ZVoUb-RV{S6Ll0Ik?)r5ZpsFdj~vi(Q19y^5DXn>7FV8 zIBnzI$pVcQ58FP(jlq2R*@4|418pq+&ubvM*!c-|fm@az6qD#4pn*H{z^$%5B>mn! z!CD*D&{+I_7MGOLz2g0=*~9&KStM3r28i9&{*@%TJDFKY-6uC$mTHCe#oTCD3`8LH zk<#kkDAHK@svo1!Amy3?l&Lnw44n<(x_ZD1t_%OXWb@{FallJ97f2J2E5`c@n)66B z{v;g(H`OvP88Np{H0r)67Hx)@f?}`7O8wk3`-j9!`Kq{W?|rDdb=Bi8xIh6gwtJ&=Z&e=y>ebb8P~^W$022vTvjJt zg5Ib*$l~5d(3N-nKl=?jRLulK%0f1G_g9-}e$e+O9_WQQ)uemUeHPah2pY{(pF4!* zqph<{Rx1@8<-`XAgXD{`y%=mk?N^8&!JK6at4C8bZGoP+!FHpYtq5l|;iorP_&CCE z%{8a@f7>v{s|xe{bx-=2If1s+cLGOc>TQcKt<0X3XCUWs9hv{ScdGXnHL6R3*%3i# z^Vk#ye!vZ(qT4PB7PF(*!ufWGmj|tdFBDYvaqsf_U~6xG(Cyne;_)`j=vz@V)A+M+ z>p@_~x)G*PuCEa$*e(s_Dd3_e+$9y|Tdc|~7rs6|%II5lt6z;U++n@i-sJiYu-GST z_yu*dY$ehaaiZ0~Umr-ak%w)f;(w)~<}hH?0DJDHE?`6MnA*SW+%n{4PV1ZL5p^?d}&Jf-)j+Ewh< zA#(VOwC?t@7cdhy8F{%Azx|N1<>0@CNL1h=Ha1#(1vtwQrv@J45N+-?!zg*6Leu|| zuGHPYf^7XaHEl`qCVxqVx)n{xZCx)AOZ5g;_vRJRa~KPIaW_htXCS^-#YB-GPN?Tt z;$ke%Fogu>kkWt*5 zAkmWJbXPT6gWeCbuJC}`Wlp@R5k+li++AoI4H;P`J z7>JaKfk@eUb}a?r8k41~Ag$-IoU|@d&HPY>r|0&Jr>SqL0^_(J!W^2h_9M-+N!#<` z^wlu$L=mJ0KakNR>aNY)ag%e0BC>P5_E`9+NLh8Ck)9W zT8Ei_x+={gog|yxXm_1Fqife8}s44<7h|TWm zDu5jLhSaOP7ZxfMNK;`~DJ?QzsEgo}{+5EEXL`h$@5WgC8T(l1+NY$*nTtW$#y}-p zw{E?q{&mW1cPH^QK26?eD&p)3xOjr(|qc?ag!Ul`fttc*$oE zPDB0JR@-&0t4s5?C6#ec3z|L}`i+A7MfSu(Hzq-A=W{I0Dh8X`DOWo3rP>)#7d>%z z)c}y2ZZE3xs2MHAZ>8xzzcQRMSiaVvRc*LqFwz2+<+Qc61h6c(8!aV;2gY*UZt%n7 z17aW#@xk@9)7F*}sT#O-#EYt>jfS(<@Wku$TQUJL0BfIw}^ z0qLvq;3~H)a?_cv;OI;<@|`}T%dC;{A>DQ$0E{`b{3IV(z%ZhH6R-fFY2kI+(ofL~ zYdXiY-)ptqqEpeZ_8y*kgWI4l;$O~o$6Z}BnqWV^SWR+f#z=Q`6KDrzldp;!5G2Y; zZ7BwF;`^XA74Y1ib#c88aN5#*X*wze&MH`Q>xqN3n0Btn8TDidWd1$uR}8@@cE$zFW}(WBM-Y~T6 zg>8OiUt1H$af6+IJqQUX@si*d1;SqYxBlJ0a+=5c_2e6rga5G{w(8$yS78~(EKv4X zPasNo1O+I85r&ppM{>K274)%E&gFC>Of>NN0&(5gmOqjqXB&`q+6Eq-!Qm!>!)ojY`bZ{qDDZKp zryV-ODBN(SckH^e^#&R{`Oy0x&bWN7fCp>e3~d25;>cn=C9FER+$Vz|ZFrly+tkYj zHAEFa68qsAW&TOxN}rC~3-IjQBH#k69ioo6Arhs!jL0f&rH%ubOZ+2wQmA4}y2sys z7V21tFHzv7C6MhL{BN0>v=r8NO1cvz}qTLGo42U&6TW!;R*i&XDFztc$_ z+40eID6JWRzdIIM^6|(6G|umE7}ejaat-%aG>Hm(zDCC>4DM?#=xkz^zVeWm?Vbh8 zoW)!_7Yx%+*l>3BiJ{6#+5j2lU90=b>TnmQIRY%1d0gBZq@vZyPHs3N01M<2$Qto( zmg{qu=J{0BJk)i=e=0!-BiivrYq4 zEj+l^3lu$bC`#TkhT}y4?o@JoFt#g&oAf}`$$>Ji(*WDO^zq06w#$YAcOcW5rZY25_f$>kZHq{FPz73Q=O;EYuMGql`VhOx*w`OM?3y-?;~-rIv+%_`k0lyk{j)T;Q~0L zUoLb{6bZ;uW2tpE1Nm&VGbl%A!bUad0(G)vl=(ikJ|oWEu^ z*X!65_g}Qw{KUek9G6$l4RNI+y!=F)J|;ixY|N{3V)_s&qB>RAXZ}f&vCLVobFELi zLxOL-ag}0AYw&vjYj1{cb~Q z1Y$pyuw%H6hmCHa@Q)&YYbkl8QTUeWT+o3isPR4db~J&)Kp^aS6M8`>gQARdkiyBgzst_=emAJYSF+fw7^}6zeP5JcHwkdWu73ez{N+ z6@$+AwKNd5C6XzGg1OBVgC%k|3L2MxA9fjrE1q&bV-_1Hy7raSaFf4-H>9_(%e^8R z_p8u3Xk04ACHyycr~vaf#vOQ9FFQVsOLL{wj^@>upBt;7V;`61DBiVnM~|}zq&Woe z^ZUo0td-G&YM1ND=8XJy+4$1+y#rtGG@Ag_vE@^^5vY3@;~pG~)0za_wCiUYQ(Ke+ z>H%X=WQz*ze)NL+uX??{w^z<@aj$M{87ExQ^Pt+CnQ`JnMi1-gSHkj2;3c@L=(N1= zJOaP!QFt;MLm@x1wV%f>L^?2Z4nM$MQl{lgg)#2>trT!?OO!I{Z8vQdz6`tGq=-5z z6I{YNE7Nh{?fSJA2E7TncU_xlIg}gSB6uM}zq`JQwNj*T=^=m1VszKbP zget8%dN7^-k$e7;VR)_6yyiiF8+hISMY+|k_0!8q1JC}ePP|LMPNRY@J!k(;t8R%6 z`XOn@s~GnRlK_?2Xp_*>yePtpWRhAmf!-4$p{B#Y#8B{>gJ`u$g3TtGea!(m&MRz$ zDzK~_FR)(GU2vdk-FO=0OhNg-W) z9X$YbeW4Y>@4pHefW~`LT;xiiMw#S$6r(wug3qf4AR`FC!up`W9)N}690GUq-5lgD zM6=sQtBq<`R#i&nIUl#aH){NKdhm32CK$z>Q;4gI6k`0AfnK4DL0Cd&U=6@)kQrHz zez3IceaOZnoJ5>TI=qakejniJUHv{Z{OzN@DQ&iQmq11}`zeps<-jT!Mb-B6kL-<)44!nXhPLZl!WIR{&ikUbqT<5i$}(dU)K{;A9oI>u@PGM z+rHGR4Ub+J7BaufSry)_<4YqY)4uzT?{|uW>fD2P_kFTtqJVLE^WqxvLp%Q9u~}Bv zn)7gcxVP-7X)VzuH165{-1!V#S$I*kC>Z-`x7+f3G)njiOF;Dqj#NMzHJIkIT z-x4&>tnOtXVUi0QEgZpC>ImED=g&KE3=trg4D&w4t1oBom{qf= zSK<7d?3VbMcMkD7$0+)X(>fxLvO;`_j*uV9-_fYf6RcezW^myE#l>B6w7JZLjhKF# zE>^Zx3n#I!WI-l53T@S(?a#NXgbW^boHOCmVxM%MXCFf7H&fmmGL8r3UIDG3D9!Px zJ6zbOU3U1$rV*475Q$_Qi2KJQ)IEQ1Lv8rB*$H~u2V4kKiDG5@zLoHxngn`DJ`5_Aj$A? z9&_5xjqAq*Ua5xa6^7kz`=0Uns;5=wcK#C#qCL(XgS~-^;D1mR#7?Y66(0V??}N{c zp^A{PWmkm+(E#P79oT?>qC4z|28iy^g=@f!ud@bd{!q;eD#4ZTVoO)g+hdzR8U9H} z{e*mD%)U7ZV;JjF*DH%J*{0ZL^_vZ)6WoIs_hK%GtD-xr5sat*D{k=lTQ^1Le-OV! z@stVnVe$S!O!(0k1ig88<%&0xZ7EEzzQPZ8KpQoTwXBUWAXBy7d;a6;17c*W;C{v~Xaj`?*h#+A$RBZgbZkLT-0_;jO#7Yr-I)MSX z#qJ0ROYH81aNELRO*UU%vSWh=D4`CW27@&gusk%UDbk?}I^bE(fN(BW{h-EPbH(oi zL^P7x7AG{4nwm|&R)o7qcbu8Y;waIZUHFv@|KtMwdDjauwBuWNA42nsBy#T^eN)*4MHyUV{z3my zQnlW9XJfOL)Gj9U}hpJN@Wtm4z79qEikU-m3(J-`YjLRr5q3G0+&OT^vmRX<262=rKn` zzJ=E7jGV7^-btL`X=t|;b0&Dn=+c)Ze12blP@B+v{Cu<3q^O@7WR>cQ||L zxDVYI8(bC2*kL34Xv&m~;JUf1ugTq)HW=QjC80F@p)Ymv`}YJ?&>SL3pu4m)Zb zmjN60U+AV9jdYVt@y;wdXpfb?Nno0ysxeYp^K9m|14hkN&{O2V%eUk1kU*SbA~>Xn zS0yM(URjK;Kx83TP4AlJW%Sz6T2XIN?gDb_S_d;a=G981JCI59Gqp83F7LNDzua}y zS6GQVrAmdlDp`L5j#d1N4@wro`?4&(b_vCTKRZ1JVv7uAcM)B`RW7KHVBGwsct>-Y z1N}C8=dyd~74-Dez?=ti`UvwaqnuOb`gFEkHFNcgCttr#GT-`1TN)N#9j!puTX&UT zt%-)kFnFhmZ_~iq#W2*n?uc3T-a1IV_ir+41 z1zN!3ZQWXuGa2kzKTTH&ReMmIMTgW()cNUZm>K$GO*5kGyVu6OWpl2e6T0f3v3)Rn zhxA-&%lHt>@VvEzz-=h|Y?9&o66wjAm)&kB?DyjAlF}`LMZKX6Ly@A#T*>torqSB* z+{&FFlDkiSzFx|snj2C63@ii#zq!z)KMOl-` zM~-j{7(yebFb%XmVxvj*aSO}?zh2x43(Qf(;x>|13(R?k0ztc!NVC@G^=u;l8k^qi z^moEydvw%z`Irmk=g*U!e?NDL-LFG3r3ZhJp&mzl#d_keHzQL2EF$GK&(WlZ+CwKZ z`+7E{GYmjAS~^7mP|cSAL0M$~4@yi%X|5E3?q%GR!@{`W`%_-qIT`1$pUFV@8$JKG zdcXy|BH%iyiv2-^`=h7fc$I|h8 z`Tl&*`TYePILy6s=T1EH%-tRjFv5t3S2OXxN9tv~u8BEEs`c!fDY#ffWqJDrZazES z?#(RR#yJ7mW+w>CUcZObNcv^PuD9GIh3kFq_n#^xe^G(%T4OOC8qDeK$<9|?(%&~X ztH$gdzj5VO{<(Ju-%_U?Gjv*#YdDpF~vjIk-;_6VW>4!|m8WO{4RI}r@nA7nCrvlwjwvqf4Dw}9FV}Ccz@)9S9W6bme+zH1IJgh$zz{p|~1pWBr0Z+-7{s|gIhGUf?K=Pr3g z0#CF(oZ0WKY`^`?jNn5YW7v@be!AagklDgd1g+7g-GoCjqb#vIPyYBA`hGk;>^%17 zh^qf`0HW|((~~NN`-jzY+%4V&^SS!6ne??%+!ax&&l$MN^RI_8@;g$M&UtN~ zExd}?l~VP}qGsNXxVD+N{Cjr8-7`` zuGXUHi!y}ua-eg17f4l#f8?M?_P)~LG-X>|kB#bIBq3*@+pnA=NRv<4_mr+0(UYE| zNZj*BZo=UBAp!}E>JOa~nstd{%HxXNYc2c%DfCbmEx1qEseSdyI%8CAdi53Wck<$w zU1a(lX(wXr;5}D#zYOq!zV~~r+`|YDY)7PZ0yFc`?-OXq54YTsC>>APwc63x>+znT zMhPEpVos`y0+HrvJpt6V8jWb#({qS6Gfyxi-&I=yzR-2?a1P^Hb6D(x%;oyy~ ztlo`byjq4VsmI9^At-(yQskZsp`8K&&iv1cY_F1?R8J-(EoT&?IeSHo&cdt2UQQcD zWZ63OepUJeZpemqpywFGmDO}k-^7_R@(z+IL;3dokj>7VPD@N5iv3%)ftDCXqgCmi z_U5&Q-w8w6%sLZDZyi*ZG94QPt8nKa$jM%roISlf#e8UQym73GfE}MNeL~!<(=YHd zF`@@sG4r~;zr=;wz25lH-`^2t;c^;wldX^(aJ+|~g3b;~ZF|G9A=E<>+2?*Dh(0O8}e8;m8^)rg(8XyELiw zh?Db5qQrh)(&O$b`4Du{Qp|&&s61dSOXRr2*OC`2o=#0q*g#sx zzciMklOe0=PjKit1lRHu+C}-fwj1FhPY5{Oc3EeYG1}o~qm2U8puH*Nvl2WH2iF9e z8V2f?r!p4WrVn|vO<`W~ZHJSz@z{18`%q#{y@aq^&NUb81k`)Zcz1?`6}k%GZ#?5y zSzt1bYuWeAI;S^-st)&OOf4Tq!*+VBm|v>Q_rZ>x?OKM=9Y5PfRG4!4@rlw?;#R7$ zj~V{5)!B>ZgOelh;T0eA8v@FQryD#@hH3+Gtxu}Lu!dsKEQ}+J1HAKy6a5Xwvc@lx z60m$}WyM&{amE)A+tRd;A{Z&G$AOG*WU$UWp^7`Pj~l$p#Ka*-t!mJC2_3>@4y_Wu z6SJbnKb7(T2Pa=#e_F3p-lGPv#vF_lJ|Y}PmR=0(`w?8 z*JBTu+icSeBje`DA)`VB8|K~SLt^)6H0Iix?P$@tfcip6hRr#~&2lgRlN2;NyB`vt_{auYFh{+<)hwmz!f7-DvMbQG4x8*kpzM}w z#w=%w#N!QMWAq`DeaGhuymRw0o}Y)0&o?)H^(BV9L(z4*0h2>$(l5)2Wt~>AL)w`m zN@5TM^RD#XOF9J*oq8^JtkUhSlh1=MSXA70F7H9g*SU>@58xf2^dnqdVGt`t3V1ia z?Ik7asj;JTLDH>IZvL2;`~F$i@d1McjbPVR-bV=&opoYXQd*p3b6LvR8kveQci+al zlXggFUKD&|_ON~}AAlq$?*Ew}0=wG>^qD|K%z-*)y33WOKOc#N@ZMLCU2C<+Y#y`Gox_ptCSh+23n_$e8 zRcdC&;0|IyY094{6d2fX^%o?F68=Ldve**An5PiCze=mWPam<0ta^I?#wl{-l@~hy z_#Uy^f{|yQAwh(jajSmMh_hD-@yxL*_Y8U|Z|7gG@8^{k(77Av7nV-i(HqZ|(Nvgk zC&XI;Qr(36U^nbrnrfa9)?0DcHJx?gVk=W-?O zzlia;_9~_AfWaY7ow%%GuF-p8K7&T~o^bZKlO#$+nL%UaAm^Pj9GTCAY`~;XA#bTtTd&rdgZfjwAn$^Jy#F-ZmAq_3qNib7Pf7LwPsGEM1DB@5bfE zby(kr_mJDI{r#`7_0$LmYU$urO2%=K-m5C`5Vn|Kfw#?&l8z=Cf$R>_$f=&16YrS}~f+1MAyIv@QkK$46l;53Fxuu&!{r>SJ>4kl|a+p)@d+ z?EJ1n-$7fxl|96kqL<$;)@`c|us#pK`u2}ivG?mjFL85IFfKp9`d1jh7a-j#UQap$ zzqfYPcD4pSW&@k7Y?BOfV?@j9BZRg*>bRsrP3y1I_GRR>-N}=pffY?&dJoWzhWn>l zkPJC(5IXJ5EqVOx%L(7VE^j?st@6KEB|quEtm03Wc6lgmNmD<-J5Pg8XwvuJI>}*o z!Oo$1=G%7~$D?8Z#k!SJ=NlMN&@{N~Kc}?mbu8GOH@7JR$*T^vxv9A0nlYM)fkRn^ z^~9IoO!@rHr|qO1Mj|~yk%a-sdk!295Dei$&+cg*>FKt{UvfdvI8p%UQ^#fdWn9Bh z;0YoHP}EZL$!IySx%!)hvq9MrCkYzWb~NG0KN<^pt!s3ycSmN9zBgvrOAag`BZdT^ zr~%eP+aw=fAfU%yS_HKi9)~5)rFp*I+k1Sim;$?T)F+!Pzj>w*Nsho+rnNL~xkEd7 z?#y5o{1BWN7#GMn^m7@9)S2Sj=YG{*i5oGR_aR>XMVu)Z8h2Odh);8csWx%F-=c>` z>(rjy915tlT=G5B2wtP#6nHK~$Zfa6!&-`Th|aM-XXJ!Ji>kz7T}pW}Z3K&hUMlfl zSV1d=(1z3^i%XpX$F0qdS+Z;}*u*vV^Qp*R*QsM!MBW9qF$TGjQwFHHW8Sb6w`rGm z@Tb@EsF-7jUID5@zrT`IjB4kbuT7OA5OS3EFype70*W&B0LcQ1(jlMxEeEF8c(XKA z>{l8YUPULT)aNLT?Z7(VPSa6lw7I-K#xiBU#sS@)_@QEp^fFn)A!DmFh?%#AsT=X^=|V(G%FnAC^8A^RSMr;ke#<>51* zO3iEyNR-cEzfwB(C3@0boYN=GhbpGdo5@rXxbZKD*1%9z#4UxjByi)O2kY`{tFV*% zd7jM@X40G<)?;3nL7R*KTE9b%nP0Gz8V~OGztliGIYrS2<`h zZJ7Zt&k?IB?rJbK%d_MhuU!i&CI5=WnnVsOzJ`6FI32=9I44ih|1Yq#q2Fee@PldZ zl_}1!xC$lwKO1DfKGQz>0T-(`2Y(ihfZ|TOig~85_CCt`Vw;K86c6u=LBOJGmK)CQ zCX8S43=f-OD3-SfxK(jY^8L9RtO;+Q^q2kQaz5hjQd1pl?-v$5%=cmx$sG{gM>`-q zXdY7iB9A_+G>+gBTEkV|_9*{Tjv|!p-~+;0&5HzfAh!!(by?tnWG#7 zM+SRoATC#;I8^%I)BZ^Ke8t6N`BE#8_5010bByIH;2G$xHC!y|;0hRJPSERkOB}2s zg*A;-#Gto_GrX{eJR$Xdal2gg^#_fXb%su#_b{Ero0Ztn9nfP%>ciaMhvW4ONo?|1 z%+S$pDgHIK&LIz+Ca6_tv?E&&B(iUDL_DuOIY3`)#yO?1z$m?jE-ZjdORWS8Nn1C5 z@zpHqiWVL+A?*C9yu!-RjQOH^Pr~PevC`vR1pRa9KMbK8>vOv>-?3-)#ya1`J&g=CP;_)c7|r=Bb@@v>u@(q|+A0Kw zOg;TmUq=b!%>=bq03CuWcLU9NSZ(dl_ye9gVP;0M6h zIHwMjsn0$MC#+~GgNw;2PEwW;UBHiD$UEqu6e+{cYC7b;3bxOWMF#ozyNc5X9Zkvi z!k@z03AkAsgLN&nRpZJ1E`&ra84R*`c(=93b;P8%p;hqSeL?%)wAj=;QqSkUTC}rK zkH3CTT%~itGFNTq!;Y2K9_lU)tLq~OMdHlMvaFS|Wg{q&n^%AyvbIRiZX{hm$gabM zJrJ=%JPn4@C0g%YkWWfXZBDQsH*ypx>})&AfJXn_7T=Twc}VWtiuZhpkM?-GK~_ z%hR7~pbzzaQ}VC{-r-H*E0JpY(e(k0(b6$TdzN)9(npHTgno{}o)@uH<{-V==%PAm z;)G#K_`xm_(*(ftTq7#f0{Q__SSJAbIU3{~uC0ZtCDD^^!gAMqi8 zUWXQf{;;iBD^o&zjYp7wUv`r4aAD8r7Ihf451r3tZwbeU6L5oMq*8L)??dqO-2XXM>~@rqQ|PBNkCC| zIPPjYSZ~6P&Eamkd9^<<8^I4F}tmseK`|`|WS1tOPe7*Yiw?+q1Hmh8W{nuBJYgFXgN0foy#^e$QS>E3u}%?Q{l-ymm_<8p|T`lbF8nGsD& z`^zi)M!}Y>jp*h-dYjRUsM(v*fBCveTR!~S7<1rLPD&#~=#6Cu{Kf>09?%E-7U1;V zazYoKU_!{u_Kjg)-7QudI}UF}=hp-L=IJcJ`6K8P;Y?$% zC&I@kNhiX85@f}LIWQ&&bNT<<3N9-@rqQrRuouAtAG1A|xlPLMu@FA|>wXDZEhhdfyJUSM!e2vrZr4&v>afFKNBYOX znA1^fpq4cAKV`vL^jc3S@WirxHKqs)8P6}}x1*!vaY`U=IWab6;YTzWh37+c|5)=7 z*v-Gl1ysuRKP@tL^nsVet-fqa?bMT83W1gxbaF$~b=eFwz1$`z2J%T0IlH2{jD)J@ zBSQzD_NlCBsW)nC1hluNWf7V`vL%z%KYObe?wworR3ARwPvv~qcqs?)j$_ZJr^k;T z4IPHIM6{K-ze9MJ6qDm^K3Jp^OX}y8Qw5FCFel1H@6&_3^s<`}l--sJ)6-;inlfhm zNV7s869tBLoc;aqqZ*Fed_A6C=qDH6@0hr)bB|pb_0ksjUkK%VOK`(Z6sp~fmS;hp zqVW;(mwjWNex<_0Nbx;GYAc(P;=RKG?IxB7cs_M`zpDLbkiFgY7dPb!9~cYOkL}t3 zDp8dTo|QtKuTxn;f~5c*=7PpM9-zbQAhsvGyO5hMNHYszoVI*j`VzHm_Ler9GVvVV zTo&kgZwIZ#13~lF{X_=h^7*2KhpWif>VW(&9;u(#`N{a!mf0;r)C)4!7L8IBnDtQc z;t+snsz<;LBE9G+e$6%<|8&*$v%{Fc!?mmH!)`B|?^jMsSH@speT%9K%rJOjFgv)9UF6}^0$xu&9X;#<(TGN);t zSFj5nxR}U!P^Qx3!%U{hs5QN5#vcS}-tU^~?DVaOW0Bg{6-=(65IhwzezM6P##SO} zycT)tUFgk0+PH5JiI0W}7xvLD&lUoJBlQ*S4*ifC2$|`|PgTON%95@ZQ&LWL$BvE) zbUo~ z{3xIO8-w+GRJk1l=4SV}ZMKWZt3xgB7oG&?8Q z@6|UooLbiQSt)Iqr{BM9sC)rfAP0D^pN?|A@{!Rr>{Tk9R-6ds?g}ydz_tvU`LeG- zX5uK&RTJKyW6OlpQj6KzJN6T(Lt1|juQ>>tl`1&Fwl4_(PAn%!s^zaV`v=(eP3}h8 z_AT!Qo_zT~y}o_SyhV$J{r-TFC=w8qO)-0i=UY}YtapSV!Ji8C52QDI#n z`PP^A7w3!-~u#>C~Gd`_HVSZNWs*ClUD7{AS6ok>fX@GQd%;JP7Omx|t0;At~jyGxIE`u|ye9 z-x1IaL6WC7OBT!P0|oNj3UNz|E|X@#P`4J0lY-`d#D@5Y&;GgibpO39HQ9&4zY8XEgM}W z4r69)k(fF!B@uuDo&B-#qhk6GjKF}4a1_YVS9Ly4pmr4Pj3!9P4xHh_w&LO6LO?0T z`;hvfxHl&GKO>#Ux^{hKpqS!5F4-R#pT8di`)4jy|0MmNxm3rP=1iF8pi5k_d$)A| z0L7T%Sho)t{7#;Uw~nJBstn2o{6XZ2`-IFN7wO366iy}%StLQ^R&S5KbL3AwHv{`?Sk1+vS#d!wsZm&m9j};XxF5m>u;4>g{>VKQF`}1`q{fnrm zOpZjDF6Pi$iHU+UYV%v5MXz>btumt40nN)Et+a z{ksqNPNbyL~Dp&5Z^ia-LLyRrhpTEv&GGKv9jDgn3QKWXA_|D>(Pa41_W zlhC5Lnn<2VqgVYz`nNHH0>QV3hNy{w}w)qunQ9n)^){#q)!>m4g7Bb{A~{zb?s09fP}o4 zi=X5hM=lp6yTW4?H!+1jdhCUiW1nkV|JESf;lL3Bu+bbKWfD4lLu2;n>e-)`a!Bd< zD+@Cu>WvWY=}ou{AJrN_?m1vFW|3(+6#8&F8aqDb^WdN|N}fU?(zTkycq0&IK^#;G zASB(#co3N*Y23+ypgLQKoY=ml#T*k2G?x8!>O|$cc&+dI&a@^wZc62ypK-ROs}2y3 z+2m>QPmpbvLtL+Ty!dHM?nR&D^T;5m`0@6EjQ|OtUcXN-&t|~`3_ywZJDS9%%1IvU zEm`{;2y&dJlwQFM_~3CO(=cB5q#$f^59v&D30TM(ja~|n3~U4?I70?* z+`<#nO_R!5i9h~!sE7!DmntxTUvZulG){0-?RXID6rU7?{O*%K1n|rtvBP(v{hTX^;PZBG>xQO7m60DLHX-4}Mij@${W(#ngov!k*vYXC@TZv)R3g%Uv{wNa&U;WV8>;bMO z&`F#BUnk9Kq)Jz9fO~w7fD(`NXeZc+w;mgWdR+_TU0o-X0Re#VqaL}oxOzU@g4fA! zP}}Q$)yQ2(2Vtqmbg-Sa=kVgPfDU@`SX#ctYI<8^9~$+n~&!7D06p)uUcWE5d_0)B;i5G#J6I6|%GH-|bq?5<>?;Q;=`)M}RYC=JUN{LN}tgnIU)#>01^? z`=393!lncO3~+*IU7&5vyo%~20Tkai=R)~93j`Vcu=UbvTw=!~*DF!l6Hc(#VgG$z zk(|?_f_K0ta2(_l0#$odFzNwb3vcS=1S`ZqL^liVPHp#yX5kZk9%}LN7mB-~WBB;k zK6h$ST8n*~dRedZ-MMcpP*xK|FBBbV@l_MMxlk`4Gdlq?vkh{UF8kPEugwlC(($cE zuGzXmZ{`!fvWoY^xv`@U_gWo|(x^p8r_|81t6mf0EAy<*a*CU)iQzDOxhvdY9A0W7+!n?WeWLGPyC9u~ z5U`NJvjDtt%>y)^Du8Tv5N@G2{=LarssUHCu1e_bLEt?D6Pc^%o9j`k)jv>xzRCTr z&sZJ%!HnEb7jD<2*_`&5)qs@j%hQb%dvojWu;>i-9?qz~+xcjJ+T5l;<}E{LOscR@ z7=OBSI~;R8B8<9ABC3C&jJUf>M+&}@_*}0}XMsDjrrD4z=RzV{i18x#x51*1t&%AB z5x&x=Uh$sx?|k9?jKBg)zN&N{ZQp~u4Hv@q<)#h?KaIec%!8~{3Cz57v9IiKzhizE zG$q7%APd9{5gusz5^R3cmi$)>Q$#IS<2}jl4|5_+6e7%xQqF7F%6^217!Bs5R0k#^ zSLAx_#oqSFPYaQm{Vx1v)yg?Pg-4EZe`_xaJ1O;3uVxrsBY>9O11*9h$G>hv| zjCmR~Ii0+R_g;0)I3v_r>p{`cC2v-?Z8hj8Q^Iz2-V<_mBEJ)~o8u@G%kv|SaC;BG ziLJ^WaoU80(%Sn$+eNwPrM2Tj({Pnu@?luev!f5c{Dh%FXRG(q^*x!hYcKU{XwXzH zV)S{$1?YG}YbQ&hT7G-gBZV;hj-H-LR1%vHLoY$?RnV>mN7KY&kvN7HV=vRuJ-Ijx#x#A9xm2(Xo3+zaG|5Dt zVhI@6j_WoQYZsAb%E~%vG&SFwh-`!$HCt+;+4Fb(1gs-N5p~4@4>@V{{HR%H;b&%l zlaQQ%IriSowqxEJQG^?{gFCCb0s>8qu-^F3o3P#d)<>P%>i&~fD?!Yj&`KROx+S-l z*Twd~W<7^CU}%OP@wZ10#j0&kJZwH#X~yp%=TEhf)-DH5FdtQZy%UO=BLcRb+gs5H zY&{pOxx!pku0mL`LHHdvmIHSCeB^oAuu3sck%|h_(SPR#hC$u^9uwMhDN@XCzxB~n z8G(eRT%-B~YXIW1kHb5>UR%;J&%XX!TL-W9X79B+NL40cWaeeWw+ZE>it!!68GW%X zlMk8yI;hOeKrr1${Mbxt+HJ;>TbN}(LQC}odrY;7{@V|yuT^tniTuPxq{r+*CPrc2 z4G?R^)*Cj=9X`eY1a1M#eXPiDU!9df{K$XDKak{oe&RiCrddo_dka6={{%PuR7L_QrdDr$D(m1}>)V9h*GoefWvq_&ux14K{_IsEO<_fv zjrTOyu;d`-=rj`(ULaIv4H(lX4g!7`M5@xY7#-|Y({h+TzI~6v*)u~uX3OM}-lkN;XdeW4=U zqCiINHW)yB{jbml-{Wt$gyW}#{L8(xS!Q$wqRKAA?nm=@OtpZx(|~wX2E-jp)D;cD zY?sfE%J`2}1*@E@?@tI{9%maf+wCpGGF5>pM+M!@a$92fS>+S_BeMsFeegQLt`X`q zp$KsYImfMVk1#OBbs@+|v2P>PWhY*nu!F{3?UH9K!}PcAi!LVH)+$qPl1=t}^-sRZ z{F1o6=PvjIW@5{2rzK)dd8_|0Verw-Gu@Nj@9tXRY5OtS9^v7kc%)Wo+X^9va21O* zxN#jWZR(n2g+t~$3VyL~GcMX`X_+J>`0)Qeg45$Ahr ztqEi!69b$d_VnwF$>(S_eUN8g9weRSZ7ChMn5QFWvg=CX5G{`1C}qJCv{${qo^&v4 zt&>|c!fKikot7f-kMMp|n{8N10-R0PU`)J-8g?G8JHXJow1=mQ#zO+My8`+A7vV6e zU3Fjep$K9E_FZ$H72>g=lQzg5^g8_>;dg-AlGe)j*V75lrZ&TM4ePrDiKpX-y~Wlj zN4K=>LLqAk{b0;DXN}*g-qrhDlT@gsOXiz# z!w$s>{P%m%7b0j-aE*wHY7>qlQxt+gVo+^3AF0`>PUz^USmm@p^(Mmk!q zNwjw<0!sgmW1S&wkVSS7zZylnvb_g-(A@3>dsjR^+qXTKmt%HMNCP1k^E@lYV__-n zGf#G@XVvpMl1qU3$D%=D`e=LcUo4AjirV^Oo^GuR$bCEC%Q3H~N?hR23$PbLI7jv^ zbOtus=hf((AFkpe0=rp8JcmlqY4nl+uO8Iz&z0Tur+qL|V$AeUy&%E}()R*&cJp*J zHWeUmB>#Yt$%uzsPuRz)vZqgAMn0FSdFr)mqWR5rbZ#H=!=?M7g6tFa?-d^fr9&>) zh&O*12VQ{(G+I=&JHq0B>O z8UiNOr;QtM3Py#r9L-T@aSP8e}>YAY#+j8IQbxQ`eS{-8`PfF25Bzn`=q zEsQpsyZ$i)LuesziHq2VbE77DYgO>>NCq%r>p>@4BK^Of$fbutyAL!u1fM`vTDFu7sVZ!Byo4472^gSVY^i z(&=KSA=I}bFF~aHew3$g`hfV?B7v9UdC5aAK*>#zgy$r<3Di%U{_02V%TrPP(h{tW zq^MWa7$lwmJN3#HJM5F*iq_K_)3g0wY_3;8)AcVl?<;D2G|%Ji*Pay1A1SLL9{BDB z%ur*ZoU?gJlz`7^sK96<0%`^-=8%v!LGzbHZ+kx(_;l272&ieOK>mY-!-ETy&H>x$ zsF=%i_UhZ34c3Ey!?~kaB%e}g?*E_!9M6-bx)@6Jp!aP0ib){^fP|Y33Ytq=+i7Fv zqV^B5n~8k5bxwff@8fj7jXMz7Ptay4u1T?3xsdi3f%ZzHz&<|>(=akO8>ai?2A$y! z@-n+%%pfih+Rb}~e1Xtz4kqsm?0+iT(Gl+tCn#2q*6FL;@fIVa-a%Rc080ggfJ))! zP@CA=s0CeE8IJCg3lp(a+bs;XLH@Utqm0UWfOe7;Z5;>*)lW~oXP-nkF}=4b2}F_)R2l!uaWrWlHg?NcGb63AZU-6xjcp^Ku^k9L>7=$r6^O6nqUoXNzDMe+ z9v!D@`H%F=W%G1x!Sut8HF^bpzskyJrqx*XjEy(YPn0Z1Ys$?{GT&83HNE_yd5GjUwjgCC%g|^6 zwjR51x}-uJq{0he27rwF<6i}?V}kq;oRXk|pX}!p8{B=yHn$X=DsNiKQVEfm%TsFislpUW{R!3etS#RicGl zBhRlMH+SLd(q?xZ&fHn*2VOoI;rxxJkd*%MApIWG7exmc7BUK^!XHJK$3wFo(iX!e z<(?|EULGOInFM%B@~_cAk^o{{hS1F;C$&kdL74-q{ri&66y~V`4^~%0Zf?zP#ZX^7O$p?L{i5Qp=v0>%KONn< zwb!!g=@8U>*|WVn_I)~^5r6W&E%TFCe<^G&&WxqI*8Ns6Yhx)s5vktQ37Ekzg=jWy zV_6d>0`UU@yKOHs>eRZ5AzD0AWzKEA1O!KIC`p|h5+5@F>uE$7snHeKC%ng-4A*gv zN&BR?o-srxYc@7V?@+Lg5n81}hoGwrTs@5*mT#5#*I%mNe@nG23nqE4v`;x2c@ct| zQR_3Lluwqa(uOIUsoI_Z^<-}^@7kRY7~DJ3Bh|9}EcJ@x*T%14^C3n|8le>J6zvfS zBdrkxM|F<)ardGQKA~UGSRG<-a<&|Nf*$ zkb5s&W&jOG>_G9z$u>_Op5=xHuc3r4MA(BFslQbc0ICxJR0oxsui(h;^nEBE)v}0< zl3i;(f8y^=9K;3Q2GuzIvdjS7h2NM@e(04ipEX0Ip2$8?d{IssR{X(;HpzL0lxjXy z@`mQ9L>ot^O!~_;0EZgPF-Gc8eK%kecZ5&Nr=%#u;V75(#|8K!DsyO!h5xkp=1)Zh z^Rc!LOjPQr%1r8a@FyRMr!9BC1cq7RHG{eDr(=s{0sVsN*a|(W+@LS9WdX7c$|ZBh zNWS{@zwP|Kc~=v|ma-Q6)#CB&^Givg$p}Xfu|i6= z8Uv((Nq`589I)RXZSi=nTuoUo-h&1uMmpME!a#WAl@RE!|C$voEl^&(%L>l*b@dyu zR&L6wx3$j+F`ze(@K$1JxWrLzW$>=(R@lJJn1cf+nPA`A_}nJx*`>Jc`jNX}yQ`g0 z%)Xu@b}0^ZJ2Zn4Y)X`t6Fa^5+_J8$?LQUQzAM2aD70&O)rBfDFDV^!#(P;1!FlUM z#b&l|(`Mn~p9QveAvsHGVp(x?G79|CYO~I)ak@2DCTKTHcFZ z76jbZFi>c|cAJ_DNM5@gA#$Z2nvT(e!aV6Im*ETb##O zp$QqDt`YZCBHd;?KBNk|ekL;J!eg$-J;Vd%QgANE7o%tHTk7s-{C-cNpwkTfesV`- zf8#~H9CjbU9->_zYc6QcbU2;UpREu9^wRNSuQ3K#e`em+^SWR!ujq&J9Rm{&^-c2H zKkRT}1?~EgjxIFZ`&LK1%4vs#L*oI$hmL+Jt681K!_PC1D1p>VKWL?5-@>SI;Of*i4y;kf)zawMm7kxs@2!1NN66@!=fe!l5VAV&C7t*r z*;2Ohc<}PbdRYPC@O*gGY9>@js^C8LkaI-wO3bACMR@C#_=l?|DUi+15tz;c=}cfG zSa>|Kbul6v-7NH6(VJ9H7-0C~+HtsQq^iC;QFLWO{&O_MJlH2n@xsbLX+rMzw z=I)gr-OwzzoOl`;X_VW0T62v`1Ng~N#GdBwVJ`BW6q;yNA8`vdOMH!!}94Wtd03*n=#f*gbahACM3qyLUs_%Yp2h%vO}6UZDZ) z$Kwl0kK6gH%OI_;+;49*mp^lony6wQmw(K&-12i;%YMkE3tMxnd#Qz-!e$MgCTo_k z@3$`Qug7&9J%cO-yDCzcT;vC&XJ%*Q{HXg(EB`s}quQV^pD> zCfi6cJ1)XJ2L{XgLduj+?w%ZcnqCfU6vI}azqg_8dFDR`Y;q_bETzT8R)ca~Emc(^ z<)kD1j>Wll661!fUr3Q9`>$Z@bE7`GCt>o4#vdwUqinq#aIXvco&7TxSJ|7@7w0q! z%Umd+GgZku*`9vj?Xs^|9@qD6{M%neF~1P6C71U;H39TXJ==s`s-%y8D3IUh&4DIQT>1e^0f0V z3yS@4JGip|)RC%Sjdi9odHW#rH~m{cCW>ox_*2y6s|a0y^I9jZBg1r-T6f!I*0#ld zxyGHnwyoytS5>@*+!rD&xKLimB={IQqn7rav#J4~5A26=hE50*q^L3c_4Uc*`XZ6#4&b-HE zJvB#H_Emt=Ffw{*Rxv(N@ppnV@t&mepOxJoDE{`IcBr(>ATe47le> z2?3H3W%<7GVkhL@E+@;j3+36m>-pB-F{i*5}GnO{SdJM~@-8B~}=I|j6?>9%wk zZ*%o^vuvM9BC7l~!e%CxY1V21-mj6}X)J9qntlO=`;|F<10H(VrCt>|0x(&YSBQIy zj^9#!zOr0>$f;6SNIHuROD`(@jkuo$BxCB)AR-fr0*g{KnKO^KYpkyw>75|z7~84H z0c`^U1I(}C4NL&&yA+LwmTgzNdu$OSYKdhJ%U!!9^TG_7ONSA^H z??I|~Cv>hrf%H1u%gMSFH2S`ewe!PijOrhC^ra*?YL}QVb6(=%EC@`iEWWj-RXWOM zISx3U6B$&$u%gf2nNY-8kfO;zfR(I-W)yMCGLFxv^Zw!T;}BypB{Q85fFtH0I{b=S zWrzO+vbnpR+PVglv43;WvZxb!O)9LSxIrbTIB3vY zg6^70p-FJ`M~S-|K+NeE`=u9mt-Dp*8@WJ5 zTq-%dD;l!&NI|h&m0{7A>^+mwKCU@))RfixHqMiqW1KLPK(!I%*{C{ffWe`|g1|fh z@NqsB8Yy!Y_@{)so10B@e@JZJn^aJ&Q}r#_$BkC_LLF^ILPtH-7u_fL8Xb5#fjVGO zVvq>!c5_ zgv&qWp=OAYfA8K^7)l~eADf%R{G|u{OlAUnW+pBd(c5x8q|6)u?$GOV;!Lc{Oz-0k zkBp9=?R0u0>LoOFdu&_ze0n#iud~TL`(__!&x#eU@3f)RJ=ay` z;*{;plsvR>>;NlW{ULgpkFTqKy*Ghs>encw;>v>?hg@taf+?a4kWOl2L98Ye2WJLz zAn$)elMKVmx#yO`m7c*yU*1_)j`=4t$7xv<-?~3=G!hb8t4I@mu^+r7PprC0ld@$k zUn%*yWWhD0#a(PQ5o+$xZG-W4qfr;G=2NcyX-!nHU?bjkA#vmJ*VB}j8^5RR&gnUFt~J=jYv0lDsAUDV??Ij zi}9`XXNBy+$UU=3h05eKvDs?r{fcK~5Ve-Cu49)Yfa0@AJJ@lh<8{ zPiF-+SCt{Qoy<4bPgb`Kei^JX&(OzpSQrALPeE{Hi6RE|<-1jQU~oo^VpCv1#CQ~# z-w@xg>{81p1~_^uZUti@4kNDuyaxpaf<63CNusd*JwT@<|2>iPMWHp+7=O;D)PNo@ z+KU43cih8Xi-_39W=Dn4Z#$rzt8$yu^78{8DKfI)$JsYnMwvS95Vo$hjrDC5Vphoj zcm&K8IA=Y#bVPP7f^6e>)%&)vA5R)L$hwfq_394=hMN0w>REQU30`VdBe0;YduG|C zr6@zgT$M#W4{n{v`9xbPCpq-yp=m7ATk>yc(#F=eI5LACZ=ZtK5=@sAOg(bUJy5bp z#o^xCzc#5A>_Um|7hp}&BL9XtEGdX;g26bvedqsU0afAGS8CFHX!30?!uVv)@lOia zFCL$v!CLsP%i|MyVK+$3U~`y#?&hp*kynFer`PC%nIqWycJM`$AlL7a7|ls)@4iUj zu-0I|Sy)79wOZWpjuVy2dkOguNvkg9%xBAwwsTr19eP~3arZCk%KfQ=Pb$m?2Z@0^ z6p2C4%jDO?-`el>s(WU0A4ZSucAvkroWT+yTDz)~cZcktR|?6S*vCw}r0`8=ypm56 z{;QuruPE75Bwo=K{|ms>zdcRN-){tp!T+**ZA^%?!~GQ#!PVjj_uq5LV>B2fdw_!< zb9(}Fm1Wo50=y3zwJ3Mt0{9Oi$9h`WsM&YU=Iiw1O!BBy?2|(6`o%3ThCqV-N|9J=-lR4zNB&l zXrik$LX9%fF{|vg&X5tf9U?B1-s>DRpVV(IgB=f;YC5CA1sIR znx5vnt{Mjy|B}(D>{nt**-eVjmWS}SD`?-s1btbOtTPVMBmNtDDa$G$jqA){Tchy=1KkTmEk9wv){y(DLGAhod zi53kZL4pNHaCZyt8rXb#=+! zKF?3ruPogIA7>p_|Ll+$Zv6?QLfj<9T0>?q-vZD?s9wCo=t%URAH5t7$5qBwY~%|v za6;nOk+CHRwpm1tcyole;koSDyl}NXu`8=4v9s6&&Bm{)jHE{+GiDhzB&-XMn(7!3 zn6U$?GlNaGthw@O9=?(>c>IR&Yo8v^^>@0yh+_;R!q-+^nuM*LmTvRBWFAKRuiP+4 zs9S3rX}1&)uKMSR>cDvIJh2RX+wWL`WL1(ww>9HqPfwD1lIi}gjn>mXEX5ko8t@1w zKn0=Jq*!BOw%r_0N4FJpT0LdvNRxbra?~%w(+_=;IDo+ktIY$X5vH%IbDFKsiW{b! zEs6KSP0?O%x2pf9^)=nJYfZ!5x;;|izC&hp2O>awF_z~dgE01AWpuk%Zg0$gW40}i zEndIa^=$d6a!8R+DUpwB*)!Mi=0+i?CmpJIu4VdBC4F3}?Z#$y;QP4;6m`h`gpSGk z!tNKTNx{5I=Y(4pq`2|`Z$mw@S)H=6o0GQzJ@D6V#eUJhh<|Kv-|ZHA!zos0HRQ=~ zT7hgm>Pgp}D(1XSd8-WdwLpOC4w?tJG3D0dj*&$Nc{}VetvlZAyx#~e`) zE^|rk;#`RkhZK{xmcI#(5w4W}OZE08IWD9;yD`aMgNC%O-&|izJ36|SFa1k5Pc+Wu zlgp6SS@aZ;>1TijwL5VvF(3+k4%=E=5+9aqYLeQ-n}S^sVgdspMyZHpY9RbWJY*yv z{$dbET^L{_kUNs>##hQ}CoV6i63Y0BemmS7D1H6B%7u!}S5!PPbW6#J~;`R?6#b=j1;U#zvQ- zlgXok*Dezvk4Cuv9AGtS@Cb(qfYwg9bm2_9l#kHu+Nh02Bjas}7GN}S4+FhNZC|2d zZn4-_v;gF)cX8(5Om(fPqd>MzqoQKN&FL>mnVhd&5{QFVX z{BA_|+xS*S!8Y^W782Bz5*@#bjT-@<3zvB$Mp?$$WuL=Wozh#(oH4 z7dq`-OmcDwjMZ5TSvE9N1QdR`c>+8-%tLaM9JkVp+@NYtqYsn4xnF8|$z6^Pz$XrX z;ieT}ktp>@OJ@Z2%BXSqv#l#9t=Z|&#He5i6WE1e>clnp6R>dWg0#w+M~^G+l35ZC zA5HFc(oux5_x^t1C?sW=o(4;NQ{nT(Km82c3VI{X;f=Mz$qns&oVOjLo;VT9n%3_l zIr`Yykn})jI#_jQvjp8@A$T4!)|^*s^z)1DTYfq|BW!7@$G0L8%YT`tJ}3*^5$ga& z*0pE$IKwS`!=d1S;w&I37lNGoyI7^A{Lf>Ypf$`l7YB=iU$1MY&0D*aEjyFlugI)YL2!O;2>@nUqeu*^wTmOy+&Y0c z-$|6YbjdPNfmSERT#`}D)y}wqh}}$J_y(+eGqM%+I8joWmokg*_17ekHzo_D3|;^X z2K+9G5@?Xpg7xMH5^+mcym{5&2NTDxZwHM;E|bT!pEbWKWciX@9W0fW3R-vlKqz9H zQ=iXS0`j;uj!2YRAXBXvoTZ$U&xu;4OX&N$EdFwyV&on&o-8K)Ucpu95e);}M282q zf0Z@Nqkn&p#@@FqePvd!EeOrUUSNa+z(cget&WZ*!3OA5g#mNix$w!ZviWqq9kJ%5 zu}!Lb<@|wW(B^LjUocv~t*dVkdE{e%iEv;2enhg}{o^xg(JSu&jUc&eMc|hyTcpPI82~#cz?w6A*P*Imkl$-F_PiJh+ z8Ptd>vI#z%f$#LZB3jN9o_YXGrHx8smezYWLfZm1o^=3dof}-rXM5& zo2vb?(9hAnq2T zGnUV7WbItiDJ(4#eNupymOdy^>HS0rbXktM4T&;{2iWcd;ph`m-h!1w;{vZ}ysS3n zmwBywI$AhXuOK82h_F*XuGSC$T5uT(cvW)Ng7mwAmy9d`(_)Cjny810G(pP8vcNo; z?K+%#{@h|G=3o@PvG1HaF3zIu!qy^)+y4_9?5$1nPiW@6$QLfuKdl)6T+KaP78T?{ z<1+#2$U)7daxg;XRC^~MwDua80cMSnOfc+wjg*?g!$tjr7w%ru5w$b-Zyq`ZQDl0f(Y$9UA z-TD1nUSmOz|4ouq>!c-RO~lG3%hKqPviZ9;?Pydp30?%>_FCl2IK2vhFQfwC3n})1 zN%tMkd^#yfdCms2;X=yncVDCcndPx7dpZ>ao4)_~g;-G&i zWok*c!ml^#aq^TwateqYiGsJBzGA4@l$Bw3*rH@&O1>gtvw-$w#G6N&2L?Ld{^x=+ z&;YAhPEhuXDvUe2GeIxX z+!$A6f{KSMEA+~LUx3L}IBHE4@EylHl=#+LasDZ6ba7{!{Eby(w$049#$>ZUno&Tl z*e&X&^65>30-spyKh#U-TM`Dd#HQg65u{3CH)VWdCBA;U$f4Z$lL0ps5vUR`ULKl@ zHAPRI-}(s?B<7SQ+~kHmbVC1$ngc|23tQIz+q%S)&D^P~F{egbrhy2od@nu|1>azl zuTMU7Dsc(MH)^Hgx5?!l+=oIZMJ}>{B$fXp#r{tcKih5; z>>dpe@2~8DlO9@Z6>&O;S{0NF{{K6%)$4x~n>J5o{zlgRejX89h0u^_h@TK)(RdFi zFF4NG)(Fq=d(JSu)WN?_IKfIff#L^XA%ay<*i!+$T-?Q$_FUE&-|f6^%#Pz3nGI@b z*2UzyWf!}Vf>}hZ%c5QU#S;f3tz(2nT5*0>3ADLT;<~Vma|NO70f^d_aSoA2d2t~p zOinhN3Qj zT=+X9_hnp~oySXNnuWc?W|nKZj&Fn%hHZ}IK^uw=?UB7w?!UrYX;x0qwQj(DJ zor$S~Vnl)Fp>xzt1wd2kd15(KzHcfdeD!)OB#Ty7!~)a3zYaaYLf?kk1VBbHeg*;m z;CbNz=sjpPjL_7 zvhguUbdAu<53jivVVHkEY4|-7`0smAp2Es84q`0RO2oml--W+#&U_K^2;czR?T||Y zdtfn1cyl>aTzU$C@{ks-ndE)X55ZMg9UJ&NSr4$TNW7$}Z0fuq)9gz;8sHotu9IVp zyHR6}qnm1i$A3p6o`ZohIR(f+!%}AS!zp?aXj1h3#h)jcJ73xs0%Zy_RYmP^@Ciav zqu?f?fna?$OJChWn_t}$=H1W=Uip%+;YjwI8oDzp&eX`o{~*71V2#sG253`i*#PGX>9hGypUwT0`@u z)5BW>fUI#q3!NtJZ*l5Qeks(|rqmLdo{;eBn6pg01vcPsNh3x%8`#%LBP2W;+=5x0 zD(S4x;<6oTR z280W|Wm~UKV+yV9zckdCB*v#l!Oc!Z2X(^O>}p^F#%d*08xs|tVI`K4PA)@!rREk^%GUb0&sw5zm#Cd4)gN02^u7bWjV&)j{*f1y zsLj^bB1@)1{EUy0jyeAS&E@|2^S`+~J%9c;7l%7pKuAa&Z8=7LR~-(s0ng8kFkrb> zh8^$VS2jk>0!=KZD+OSz4c!SHdeMNbuXg>n^+EVvK#%O22QuHR>ruq0T{#`C1TBi|4oM1{eP4Bo%4>*oiz_$@v@po z>5a(%A@iKd;gS_XQ&aCcs)1k=6yppyD zff!A%8sAVii)KR0AIDTDFbWQ6K3zjyVmnoCsArFLmHoNIR;p2TA$L1cPbj_81yfC8 zP&fBUJ1n}TpM51Ulq$bI##}O~839xdAxu4>mR^Nh>D{!OuIxPz+qFyL1uz3}@TAXp zXF)K5o!SqUxHBz0l6uuBd1+&K{8D@GqtqCzJ36E{&zB~i_8|9{4t?}@jE-kQQ{Fz; z2L`9y$KUThiPhP6`s%y*dx%_qGd0$&}@If<`iRu`r;F=!sMG+ky zfOlgtF#x?D7}|i0ZB~#a20d|Y3CbtI^dXONKWt&_f&=Pp{cYWV-v-skNbnc{;X5NB zd>3+7TPG{#hPRJBHIGX9@cg5}*1f}ErB&S907SnRYfFjmZUfqvvAIy6@IF%0l}(L| zGhc5i#0qd>Gx_cn{D2hEAjnO0c3|s5IOj6#r1^z<#a%%tmjmBeh`awLbPz_6d*yQ& zRepS|d3chpaCWqnY9R?G*@QUO4i4wKpO%0H&0mE~t15?nX90az=mobhL>Mbz?&ZMT z^WEltTwp|7iCjJ&Kpu9yn)r{}+Vu&?MQMKL>c9GwUU12rMqD=zJJER3leOajQSLzk z!vbNWX^t>?&=g0?`w86#_mqf7q~p8mI>sSrC#Ov@ff7!1Ckkfb6ZW8rj$owr<4Pj* zT_`(lI`+9$J|J!wPhi$1{Ie&1vt?tfJd}!UcH5I!46iTryL#xEA_S;tu;bV$bTgZar1`{uI8)#7&W<%Tq5|0J) z;U)SCjni_1yS=za$vgwpQ6fH4?zM&OpU?DnJ$hqp4)F5>*2$fh zFz@v7-b5!XWsmu{r{gCNLJrETINTGM?z3S6#7&3=iU%lUefz9<7uvq-4{5jkT1k?6 ziC3L|+sI;>Q=5DvtEa}<+eqKD?SuWvFRv@G^#rdkfH}vW5KkhDaBs2aHA?gVCr*U6 z%Oj66y7(_uxik`$LB#c2Q%z#cf1UwEWcVS&1%(k7sOdd89-tQzffDuQ#Vk1OgfrFg zPa8EM)_C^xO66tP%0s*j?F3+h>fnTX_|~9r-H6>6c#iM$H|Z^E69q(j$`#@mMr4w! zrZS^OMRH62ILYvt82ANaqDEW|`Fziv1|4lWAs({an&Bd}OL~r`0-e6&uq$Z5OCT8q z!T@+&`@0XArptX)yWA5Z^jNez4E1lD$!)lqjN_mpJ}P@mr?T#(Sd@L#0jnP`+w)F$ zrX7!|)!-C}*Za5x-@<1f9a#n^sH7eO=28Bi58;FNiF`x=R8e!s41EdS`uuxOqHR~m zI}|bu+^Ew5Gf5FBa&O)ylO;B3Ge=t+t|`gXxUDVbe!axjQ@$bYu8K`cZ?iUeViWPg zjj>obuA~jwk)YG`dT3iSj1oKg-;>ieFdJ_UVT&QBt9(sf~oHlQu`Xj|{-3pzd`rhn%(b^1sK z0Nvp%HrrjLkiZh87*A-k66Hd}wa&Ebi$+*J`$V;Twymdgktx=+Vtb;(JbLs*D6CEL zSc$8H!W>I7OP~{Hg6BGawcT0g`WK;{IKW?i@dHX-MUDleP*_hXpyeP`{5rYw_?~fnNcpksK%(a30LC=s_?X$|lw`tBT58}f zK0)2rf|C4!FRHxq@ zom~*05Q}f*5xm1@`hAd`yo(x#L#&ISP96WZ|C{xD?S6TTdkgF!n9zuX>u~04ZTNy- z-Tn$b`~B(oBo)kq3?x^pt1G@y?F$8B%$be8dxS%vMl;Ux85!;Mq`mpOE|O@*BF9Cz zQk@Q^Hb*lY>=BUiB?2iU6joajh#!Kks*5$3r80+F4jeb;_;LLYYGSGvjbM4cw&j)M zuD5n|=@F=dnLXXss~C`cCOJv|2%bvVDFM_sMx=pX8?H}=gdS^iQ#t43MWxD1RX{vA#NQ;hJ^jjVXpCZ}Rombh#^Nn&vig+9FB|0z2 zj=+L@r)SHe_7?4lNvcwu67zaq_j623dn8{ctt&-At9g%Nw-8*7BHHk zQGwI<#(9L!vB;XD2o4pz{WOt-p_8*g8^DuE>e}OcrW%YqWpsz1EGkySkP-%I|EtO& zL9mAmu<=L`jNt=pJi<*KBuf5gja>ThOVb;&F#}C!NafnGDOmAQ7y|(vTt|lZ0mis(*Hhr8_Kqdas=}DM zgd}BFRyeY{uNt{5^GDW+uic^GraakN4k$dHrESB7w><`qd#c~FM?IwU+vGO(y$U=? zrU_g5#^&?Elmg+wXw5sr*g*}mKg1DS_C?+-4g==Z79bU@IBw_B*9v3AMAEt`DJL@a zfW35PIVTY)QZBS}(d*h5mblaMqKYrn5pvi4!y~;XFk?Zdd4TB|BV82$OpgS>Ed`se zPlm~J%cgw6@<8m_vRSQNe}M_VZ+^&OA8Nj8^)a$v82@V-odFrK=1mW*x!A0PcDkjqf!Uegnv@MjJ-A+4S0s@1B4+w z5TRHgdw%y!m}h5ua-K0 zi($+D@lBnzenY$goPbHd31GS?-VO2;sqadB6pTIEmf(!9QE@1@OB?pTSQ^!vkd z9h9DMf+&``hN759;|?m)mKcZc<^nFndiy?FMhHNAu!1rQa1U(!@+(C-E&NF9d^Z{a0@yqVVDnZk9z}2333#b*<^J4HaP)CNf}RV34S57>Ub;0E8sM`7qE!mnU|m1_O`>^v$>?Q|BJZT4co3;`*0fN?MFMv!6-k2&F5 zX7X<%B5gYV_E7ewFuM}6t>@roWy%fES}_glEd?C^n=9TD&t>II@!Ja~k`OQAS&s4g zW?gfx5cn|_4o<>7YC!Kf3CENHz5nHjDSuqoCO}E}7a3yGq3x^Xue!y<*5I%Af_sbf z)=qo(WTMV*;~w^LYV9NbN(rm#8oL_V(64$=!!NDE z?vl4$5}-aDxRKENXNPjTJS6KFa%ugl7%u5Fzqz}gT-;4zjP8Zqn)$CEL*uZG)tGz9 zrqtVV@bt*zlL5DL{PP>-#YXC`SR?C(`VY;lmMM*|q}%75TDppYQj#IaGD;Pzx*UcI zp9>W}i8<`_TkWHtM!mo|FQz#&$t$v4v}`yM3El@X2%zSq6piJM(^$NOzr*O=-@e>R z3)%V-!Gzz%)50{B&t9sSJdGyRWqLN(2|=_nrU^9Z=JAkk(9kz_Hz%bj3~1cULuCWw zDzen631Ea)ltUQ$AHmnJB^c7=Vrl{8Heo9i$@I4R5)!6Ls4nFT;KIo}h@LEDg~#sB@Pffs5RC>9UZ82vz|02j zkZi!z48C~EHT52{-hiN(O)Z6--=N**Y9##=pt_3b1=q)%BSmn(uLD_d`H>Gh)4B8a z4eBuB9dmuGs>7|nu6g0%p%npOI|VyKZc!r@DtG1_v-o4yY4q8=X4@#i{S4PpS74f{ zJneD`8kng(U2=eu?Z4`jX>Pe@dY(U|Gbf@)y+HF5+$-Zx#&zkoaM#AU4;-E-Bu`IC zw3w26Rc#nuj3fDr(Jv33;C6pSMAI(=JsBylrv@f6cCeAvPW&3X(u3WyV!G!ZSQm@- z$xAyVOkE}nd}!O1Z9(Hn{9ylpsoR<(k!Co~@PbuFIX+zb!)1`F`>27B%yI3fdE{XF zbT#Mxeqj{hUn0{CrvtoG!Es{~4<3zw`=U%c%@4#r$vXrHtv2rp4*axv#K>gksGcLd zNVv#fLWLJF$4pm=$DCWVPoGb99lV^?1y{0-2e`486J~}vNz4KqMJfh7x~4+}YzDgT zm25stZeg}@3^}Rut2|wsNsb-Y*$*!2_trtYul!v6^=m8Z7As%T2DY^w;ph(pVC@gm z2EHP^>YYO8+T4M!6*fOSGj#LSg0m?7rgg5tSTp%+uQMr8E#*7LJgS zqCPm84v_pHAGX6Ts6ds)4Mf37f2_7{k`NReK z_zOl9i%<>k*n^%uFTK>S#ckbbKm8iHJ!|T8=*G{{%A+C9gSjF5cxb#PjP~;zUiC_j z3eh?>5~l8ReU2{oghi$~JgPsLgK+2~q7yT5o*dG-C1RCEt5pDKsy;Fp_eU0F;B5KB z3NPg;$~(IjXGBWJxGm}J~6K0S&NJ3`L41|V^d<#IU!GH^P1Thzy zdZJj!e(;woyhjPJYk5KtZ{yZO*Z_nb0mAaNYsjWX>D>0W)Z*sBna~#zjg1^pK*7!m zLE=$OFAQVPB2y^(sog`z(GGDTWwI%1jI(7G5Uvh88g*Ai!;iQXbs>vk3$IoC9#M~Rrx{_plv6UGV#(@adjWHq)`ct0bn4*e<|`PL)3G*`g~KA zywG$w7nzQCo%wUp{W8<2p*Q{Flnt<^2TwPd2flTd=WXgHH`(z5?`{_L7_%S39TmbJ zfEiD!M`bV)HXOT7>R*mjo4vZawrzZ8P+{;GzifC#Kd$n9lRYt1SHV?8Pri_%9N*%f z95^!pHu>gK3{x*!5I9*D46Qn|KHz#X63yB=Uocxk8(qw0+}Kke`cZ2`P+B>21yg&nz!aR(Qj>w-0Ims?m5!_wr+y5o1RBy zO_-%J;`qK-$@ZTeX3R9YQ~lvdh~0T)viG{^$O6ysnm~lYDYyN)I2xuROwc4u7--bD zRa+?}bAsP0IN-liGw}lDX5u^e!PVj1j8*h!jKd~J=7FEL=n@J{!^$z(J=(eDn+)z@ z?|Nx?JQ`psjkBxvs~zOhE}{t8rhktwasp40HG-z?p_nsb_(Kdc<6!#vLsdOWs(tx*bgJZv6dr~T=~3U>I_kA=|)Bj ze=;;-3?)?3q?G}o$RV0i`Oj|xh1EeO9LrQ_b^#{*v7SPW_Y8V@@!<_*4ITrYV}x(2 zuD>lE8a)5BG<1IBMBA&d5(+l17cPH5Y=7~DDL=1WU%^+rxCj)r{;VY}MkMF(WecA&{|LcqDBO8mt1@+L5D@Il~kVn9|8ZLVEn zpoKoE#6$X#N@kw(ebjen3xyB$VCb(C5l zHZi*{_6y)%wW@mu?8^_*gVkIwE$D^@vnzwN9#5W6U0#o$Z62;ojS7SPt3PU{MyJ3# zO3XLqXVmU?Z24kRH{qF}JD=IyIH)@3k1ZHC2n^ zA>a^weS;?25ro%x2VE&+e*z#)iElBEWL0laBegv{78${%`U&3}yg#HIv$Fa1X(WZc zP>`_hlf1jaS#l;_-jnv&ce#r5copPH-&&1mOD>0-Ubm~6N>7{vMS^QE`Qm%s3))BB zlokWD3);*XoRaH+L@9ew*TP@ib?kBvVJEL%nd=?%@m3qW`k-n(S1daH_$jS?LaD zq~2{0O0!rBD`qa}{o;_JFp{1MU-kj8g1_)-cQtVoF_>vOe@K`HLYWE;j+(xIs2yki zF&LW)-;Pth=u-JZ3#ta@#G%OQ^KI1+{W`KhlxwuS63LZH^9yx@0wT-{t-hINWG0=PH9fs4)i=Q)u$!KbPpUa_a&=h}GFG0UR(F95NsncmyQF;8`H8S#x41C0sw8<9=_be>GO(E!HH?D+qmD~o8h`;~ z&#vPq{unaQcEvO)Y1MG~)_BJEMMu3YYlp~z1VVMkC|_JfYq&WT9yMhBW3vbq6CJlh zf$=wL1$bir20KsuO8FJr{^a)cO(;kJmg82)R*b(EIdFO6I~NqIVkQ67b-j&ASjc1i z2Rr9DdJJQ3sJ-OID0+hQcZG(aMw9y%U;(&UzC-+US(lch-mCWkgL2x;(oe(O;y>)+ zCbUeX&`d0O<&;mdTRBU+X{;UeY$-uLRMdrN zK@xgI3Os>SLHs`yW#GG=&AcUcx;rE>qnP%)mB;Bj?*%~@yjfQalZCuymQ?b8h53v` zqoX~&N9b|D2sgF-0GHWNHwU5p7c<{UZ@a#+FzyW5Un}~tL!I2uf0i!`Xx{i)LHw=z zt;RhC?H_zv4v}GdxqDr;hzFNv@9!1PA&X}m5<7TF3c6%iknqjL?yIAvxTQ`Xs^zJ^ zNS-FEt*yj({ilY_`Xq95=?k)`dxuXSyqzW9cXjAuMk!8pbCzrauBb~`%#LR6fh8H% zv=aP|f%6I+P8A5`(y&rXXcKeDU-{5S7|S7`vhH>ZHUfeLJrAx$j2F(JD&NEeRucG| zDO()(Qmrl|EW{ylJJMX?Dcy>L^mu}PSAcn~ihL5Pb_rb>0{+u+k~n-J|0b*BjJ1Mp zYT6YcB-BV3+%{o}EZNV_acjgxWAHTACrZh>Vn{4$&h(ZjDOKKGVTy?^&BWYsX4|7t zjnJWM+mrrY%Fe%4Z?5eYtu9ymD*AF8{>3;U>;5>KYb3aNw5Fthf`i0R#!du<#GP@= zu2*fNbm+EUXX?7*`Y-AV7x_$K`uR-!{wUi!&DcRIjdN;J%$)ei>tawoajMxQyun0> zW~{Hw*NFrT*i_?j&I#0y(fbnZs1r|eIy=khqyG8KXj(3bO1tdNP0HAj(sb_Ny~rUj zv5q*jV7t~&yzTIctF)^92VqxbJ2lg;TRDG{{R~YS<&2V2so6~t_%X3V1qlkn^`AUZ zgXN6pOTSy9(qa@lj#A*_1|#eQ)LAK$|B9_wA^&xQ3;|9{&&z`m{MkIHE{+lNX??YO zhxJ|cMM66n{Vb>^hZdtw+#Vk(c+(2r*^AVxvcof&M*Ft*M1{OxkUQBx*3Y5w^U`J}}0S>ZfhoM*! z-EWD(w*(te+xTH8;nNA4h?-d2dfv_ma*Wy_)0X#9=kR6oTsFCSH>1xJup}*UX7>iv-)SWnx^p22_DLJxaaDFh#JY zbi4RUY8IBQ?K1oODr?ULmr(z4QZ-Qz! zqGDa3n_BUNV0gWVDADN;#4b@P}W0w?+%KN$JQpy~0Cz@nqXvc# z9_Hx4DBo}9MI`-|%^s{{p&v8i@08?y&wqSS!UwH4m-4QzRoSq}$sK``q+qa%djaku zok<~jgeRGS!M$m|3ww9>TI#R0kk}sjzTU)sI)&kvpiw(y$msxx z7;pwMx_Pfmn^^n7Q9O(StuDl|B^Yh@M1eHAs$@;k>n8(cjQo2hl0JSu%(yLl!p6F# zCaYgJCmMGNl_P)fub^G0`!eV_KpiPmV{>2D8hUuh1UG*s9;d3>9x#R|zWX&fp0SO+B!w+yoyk?iOnS zPLr<>diaomR}iGVx8l$US=-S-AMm$!6l(oHQ2N&`Svww;?u~W648-|u2W{Lrn5I*; zbusyg++gX&t>7in1cj8LM<`CMaC&jWA03m8(V1RHDa=faz18Y`!t2hKs75%?>B$CO z8s7eTa&vc1Xni$|O~Fc;TBl>R{Z1h8+Rb-hM;+=Q2HWlKcCC?;RDyNLZ0~!tD)C3l zo}I3LbT?b=dl6JWp68WW-nlyZuWZ70e|9)c|ybFsLstzc)@`m_jn6@OZDQLk<7%Cd6q`a-@vGU_!{(b$A< z7v`ADy08fLsTd)T3GSfhTwY8mKexCQ*=Z@SO;u3Bw{*7>a&1vz z(V?u?llJ?myyK@E`GV};vv|}sl5%th-m!$dTo>jRboK@$@GDwDmNJxQ2p0$v)k+Cf)wbSkvEA=j4RL@;n5YO6|cYNh8HZm&nm9&YWdas;xb);rTZ zQN#L@p$J>kcG5k*c5Ng}qs7>J^QiW=2DyyS@rI6EOcBFFFw7L_l!wht*PUEuhfu`M z9l4_{vy;My$dbY?;;~f*N7LOIg8*X@>}g&ER8|>n<|!saVhWQVd~NPgy2x(Y+j9o- zM!=Z;-Nm$qdS_6-fX1pnE{t`l3PyVPR>7VvDm*@M5Bp!DKwptb&}J_{+VFkOz9ziH+k=nlyhhIxY+^PqS#NC{3Ls3>Au=0Lc5#n(GT#~v1;UAe(Ryx6tJ1mHQBj%cNVkIpTKRbN&@s@bs8N%>Y z8u8;yjuLPhP!22-Z7@tdCD3phS(6)(HI+rwD^scm z=T(EMRbGydK88$lS@!3J7PhAPPi~`x`Arr~)VZCm9`Ud6Y&%^s3)jLAcYk!RM16*g z8;}XcH|WC6O(dCTE8lOL{9`KP*g~6Hl=yT$v51#wVP_~jH1}Q5Ss64WBB&;{reRs-AS{0-bLXymI}@ zkIYphrn(WgRsySsu8ztZs$G8;uiA`We1q@KH&sQ1#=QN3j}s?#TeU?#!UBC8g7KGv z&Tq)iS5FLSm~Sa>N^7d1U4D-iS}wc6^+z}Na`v|8Ey&%o&tjUDE`FubEyrUyZ^0H8m+@=Fd2q3)`cdExQ=&J{V7IJ{lP(FtEDtSTUy}ZLD}jS-jbC3L{<%)8GK+mhUT~*)wEFhXQK0&4dSfL`SurH zz`EqurCtjd_aV{`H8sCsWM6qTAWGbO^u40ZsId79s7kr-dJk*l_6xr~#;bgy%Wl*l zp_cmLjKjbkGjJ*J$s83aiL)*ZEV20RdMpyF1Bdh81n@a3VW#>2A?U)q`ZPvEs(u_& zBy){v>^Q&jyMxm!>u6P>2P?{YKA@w{(ZEAOHOUsr$yOv5r5PXW1M9lZbid!!N}ufZ z4Sdg|qV0Mu!;T_#V3PaKFyUfILw}rkG1)0Z$DtcQbZ*ep{E5czf>M$zkJvaAiIs7J z+^Rtb2`N9fi30AN%BQBG#@=tKOuwNElRxh`8uB6Nn*orYQYz{^3zw4kuH6`ufV-Mr zB^+Z=o9eYxd13ULssD&hL1AwO6*Gi!W7q|I#e(@2Vd(kwh!Lm-I33=}ew-ae^!1e} z?0ih@R}sG!6m%_<(E(y3#9sW;#@i<)j&i#qgi3d2Z{y7ZljCLmoOIs-=00@E5XJo+ND;?7V^} z>m^0*$?CE~f9^cA@z&o|F=ECU?(X`wqzSx@`{^+!eT^B8vc}Nr@tw^bF-9&Oy1B@H zfPMlej^JavZ}CcDlIQRRS#%>d;n&9C1t6RYO~1@7Hry68@ipRwC{_RL4y3Bux6EY| zMABZhwEz0fz2Pw&{v>{Nsvk%kBy`vtnELUk4L>^%W=x$Y_yLhui;GihV9(c{Zdw|9>ry;h;FyI% zP^WjMj$Mf%>HB?Qtvvi*UxIqGD)lH{?7Y3v4mLV5x|rGv+6P@*exLdd5ym^|epnuQ z5qMp`JNqT@3O&rTleSBGpxaREw~PHC+3mZ&{?kDmF@DOO52)#^WG_3+azl%(A-`daN}|F&@4KmuiYURt-b0>NyP0@E^_^zbI6IIA zBG?)mcO}eyslDNsS28vYZ}u!d7B80Po3#Owp&}Lv$}6m6pshd^FJR>5ZniD$97DxC z!ucEgpT_>n#hJ(b(W;4E{&{jJ_`(hBg57q=7Wa$Jh-xexjcG}F0Hm_HQm&frLeSNxhEiZNbh1(VpB|Iys%*Z zXQ3}>9Bau7WIah~vtOs${oWp|xcryI(P)qj!hgroPM6Hz!BN!6uq$n$ZL z+qD%6(yZ-k4*iTZcdQ*l1rXDRVPK#}|Hi(S657Ffj4ybg0K?WX%wH0@p;2AN#O{QH zqyRKnl_xlmD%@@4C#Zw*5FX;@0lFarL4W(M+HcLAKR#FudX*wrxkr^Z4R)jkvzN!b z#QZnaZG%iR$xrOv)+mzst(P`N%PLS-g#XDjwh=RX-nMAdNVCa8H2_r`o5=C3us5uv z;Tn^gFA26~xuU~!2yvVhftn=gCzWutG&md^hjVC0rhi#FzK7ok?~}pYI9HSVZMC4FN(GaG?^`MSd00|+IeP*BuuHPQ)yB= zf^NolKA?4?3TM!FZgjj+BJRxq$|OqB>-1oF&czLa#2MS|+QHh2_Z$35 z*0W>0;_j&pns}7KiwxxC!loavX@Kag9jq`p##7*to0}fsx_7>CF%4oqzINqX@*VJYKhVl+lwX3sXQ7BqKsq=j%dhF{x(^b;NlsT6%896Jabt}1>@P?ph{G=T$%0H2(Zf^ew(z;%_n2LJQ zS+1?UrFR*p(nUEe@M@Z~W-fcaIQ;#9)`gmsPT#e`mo<%csD-w6$_}CE&7ix|`W^-^ zE#xp<47h5bpY{>D${)LYi&d#l}IMi`~X()m1}(t z%KsKM^ZzX>qMGAjhlgxNe5r0(u-zyXwULPn4;DF)h>dE`i2>-6#x4ED#>(xJqn}&( zWh5o;%{}4eC@xEHe4fvKehW%#|~mY&SPiU@gmDI!JbVX_+C`a#0fL z#fpE?TXz1sx^`JYlDaT9uwcbRtwzjrTt;^_Y;Cv&yfGJ0kR=SsG{Syzqb)yY;a#vn z;1|%m{UW|&kaC+}z~IWOW}PT}1@GSu9VQtnhnl9x+COuvin-y+EB-VZJ>JB}d5_oe znW#Sj>(`m&XEqn_M6ADZr6#FEWJXM5g95_YBl+&kA9=Y}(p0zcqHcqo_gHZ_0p6W# z(rq!$3vWu}J`8rD`D6j;)L-Yso;|0Mfl*SN>RCB1cmAR#&Hc5+1t@O#O!)OxuG8bL zp4u+jBats35E^={-#2*|{`Fq}#TIGF-Plvb`A-Q1BXke12HMgFwOyF6A+@MuyYb9u zrin~R+vS`5(N;O?Mz|d@#;p_I*HG8j)Gcg6HB|-e&o~%}P8+xJir&}cgsic!n z?LfUval{-FA8*6f;{cvp{4*5)pc#&pRoK3{7M7e7C|sx5DVT~ZB$5?$=w}q4c4VED zSf9LV_>ZMCC_?Pjmgu`gF1sSYuaPk*0>8$~u?xi+6jM`E-(Tf5^7JO`%l!cAijZ)` z3yq=7e6}IH7jngPKMO>^y3|=0mCye)7EV`Yjs-wtQ3x~^+3qX$_#RHJ>?5e;J~Tze zL`vYmAxh%GzyrTS2Ea%M1|tb!PDHJUUC*O(QDuk_BKF^5P${boPARuF!)Gws zxP5W&W^B-Rf662Wi5iR#tFXh@V8y{L%Tn|v?8&)-r#zgD+Q4a$$6L<{ZdJym)*RgG z#FGa5Mym?z^+B>l29Z|k(@FfEM2Jwr-tpgmSJ?wskx?6DCwKaLd30~V>eae%Ji}-4 zzTy2>Kd0H3Tt;E#Uc3ah`AQ8tjJ#c}m z>w~MmB48fX(bLm`15=N_YA$~7*y^!o+7eRoUh7MukxNLF$9c5;5@rZ0!1|yAOrQb` z<2434Gar78=xke@3q4{DI(K6hvyc+JbKh?y_ z5uBm4%Y}nPg7~9*&#{LajepyDNEkUXY)g}*vbfL!MG?8Gr8U%(1>AS2D>MEW4z9-+P?cMq+^j*;-K$MVO_i>=jZM&kasxVpYb zS8}MCh_Lh4B?@0kbfhe7Ho&Z#sJkkFS0rUEWhY#2-EEE}aA=+B&qNx9WSo@oo70?W zX8SqY(;T3A8VIgJ0Rxr?g9Ql8g&vH%%IBg5_&rGsxEWvMKXXh@SJqAWp>^P#%B4F1 zdfo7=#I71L3Ntabuvbd)Mb*Sz{zcVRbuO3yJI1h!ioy*k$ifIn*H2YE!ng4PXk;)Tyb1>^;X!;GLKKE!tI#`Z4c? z{Ac#bX|_^g0&|4Y@hqUG<6-OeOhCOdbM2|8v*{t9r?F{+Ee}^w;_m$xoNXARE+Zdg zNQkEL?=gHp!XKvnQooNX34UYg>bI;Y=2E;ex7J;XU}N%>vrIL`460RcW2?~$>sP$Z zMk{I>oH6QpPQqUA(i^i>1rLIG77MH|Bdf#oy2yOIe>1%p$$u`Sx6^d$TGA>e&(h-r zKV=f-%Isc%n+igL`SDe>3RzSK?hJV9zUo}g;Hg8cr<{h%2{Dj7-iR#`L+`$g6BN^} z_vXTL1INWx*IYlC&2!b28Oymx;D$NkEI9_nFAv%8yRHZ8t6@h2OMt93iIAJ5j5cY~ zID$)^&<)|jEood)d0?q; z<=E{3b2#bq`gQ`trU(WaO$8F2EW6#tqfMr8)C@QWNP~anw84Po z-vZRu<1Xt|8AQ>vI`6mp^nLf9UXBx{?eiZpPhE2D(6f`HdN z@rnP)R2B^!VQqz>M%pK`mU+aG_~oTfV7mzDMTHuCM=pa7H8{ICe+-yqS(7~rda1yb zzGZadzy?0ScAuRU2ysWN_CKL3Gih5JqnbSHRftWG-%MQ7gOdg)^Kk?$?nPz*=LKMw zdid+#X?$l@Y!pD*>3X|7{hOO25e6xo!5I_VxPvzRpL!IMQx!2b-`n#ND}JRgqk>K` z0|Vy(mfAx3#PY8w)@bAENLuRUa6{P6_ICrBs+ebk1OH!&xM4FzNI+QV^cuaY7%B9i zvKYyy^!VHGuqIY8>zICy8m_mO(o9epM7hOf(MfTat{vN>2r>H|A9lDoX7kh4((Ooa z*m&!eKcz-@JZ5zmdq~c`{@QbobzU|u!z8~hz2Po&A-Vab1g?i|p`{@^zp>b+jj6$$UgBCmWMceuFipcaUGw7g_c3njU zu`0g#1`?liaraam1qxns-{Nj= zy4O17$=Bvt;dcl6EiEX)I&A?=7BMJof79vSWO8Upv)Go000!I=X@$Z04|f0c1TP2C z0TDr;n-I$>wjknlR4&3ROSsH`@8;}ZejSn5Ftq}i)>04c*9R&x6A8u?S1^`R|5*Bv z9u9En3L>p;@UrAMCvu5XUP?wH!90j#qaI;~%@6v1_8#l|`B4#v<4YbJN<94H>xPdM zpB6fq!@KdyI_w7f0p<8rNOVKv{di18#7iv4t|aM5NoXv>@#+tt{zYG$V+AJ_^v%u> z*@uj|ggYPS&BZD1YKO}ILy&NQK2{<|nb8IF11`~xP!f|NO!aw-2+Zq4gpK^UWE zO7C4BhkXyWuvLD9mgCv0toUZ#FI_JZ3-78w@r0`S@Udsds_TWSW{Sa$nZsa>?c0)z z+#D4as=4T1q_X{asAB1Um`+*z zQs#}k&h(%&p=#ATo<~1!tDIR|5Cdy9^-i-|RG>Ge_Cmfx$Bw3llQ0gK>R6<3y31Tn zEG!i>tR6>Io{e_z6V<7&8`RY}*-gAtE_|NGtuxpdT|$2BR*aQZR;3o6+6skjnOore zwqV4t^0nTff%L-GoCfJ~mI)X4Jul)rn&tD;xDavG3Xv|8Ur?=slaBu~wznU+IK z@Z$g|1{T70Xhz1_Uhm`p%5p&G>iAlL2qC8dlgv+# z3GcD@Z!c$ju7T;F%>XwPv9h+}^h zXx_7VT{*xfEq?lM1^|0|NfWQP{sDI&O3$iM7Q%Ht|CHvOPnF zlOGXm_Uy4?y*=9iIMPq$Ro&cFSz?SB+P`j|wJut1u-b}bWsAIQ{|I;qcB`&ILtiQX zxvrL#6uGD*lDW+yEr_*%_J7w@zF}lomjmdKw+RzW=&g=qM?2}CI7HqK^ye!H;fG&A z8v{r{K@5wD2Gqt1#|v*+PpB#qSWNhX#`=ox4!fB&{eKf{k&^xDF>wL^_*H1I)>}i> zJ!(H@zT6PMR5G@8MWoZXWGq8d8L(Z)G2uJ2Jm5c+F&UMj1nSybj{SMXh+y{qj2KD5 zXBV06tzUdFO`-c?C8uc5emnD8O63gJ`v?X1)YX0j(bF|M6BxC%p4r8^yu2240L5Jrfa{P z-ciQ34ved}M~MyA(4+G` zCOLt*@Cn+&@Sh%I+o#gT@>KngRTf;B3(7j#)$?3A%!D__A4CG@8Na3KTsp2I!5Y0o zZ?13lZfRb$LR*+}Ch}ZVshi4EH`+K3`+Z?%n~wRFtcjPxZn0A@6ny9QZHISWQ9DGo_N=}%D9yOcDQhM1qm(j}CPWZWeXr}vw9N(;Q(#~3<9eu5A<|dUq zy{@k$Hq=TJ6l$GkymZr9RCbwSaCLetRrevzYHg}f5QoD5vVmA64b!E!q2x9DK4Z4+ zY5v~5hj4gf2SwuidIoKyB9lf(D|;eA0jjOt5>>LI&X&wjO^%tvMXp~opIP7IuL*jt z$SnPYvaTD-+*<%`JHruV-_<;Z_Uzhf&M0wpn)zgOmYmQIc|LS@r+RFZ=Emb{nHc6l zV)4%c*8=QZ1hS)`{f)bmjcbRxWstQ^?7e7C22VOP&J>m)0yZzI*4HcHtHN$|I#xw0 z_|5ZHwX?gP*&tf@gWt6qXcyaSPgxCJG+$fR@c~}UnAmM0d(V&G+*ZnyAFR#3SJAK^k0#30u6G~F2ygF%GD|y56U2^@w*5P74eHjR(P7*^ zs>oe`PmHM6C_zJU`;Q5FVEt>s$PGRz?by_I7{-AwtU1o84Fny=)UzSViUi?TY+n9p zVsF+$p@MBG7U9>tT#SyVvU-WX2X=>@?VoJI=*gv+ODBuT=rkrfyNK;e6u|9<`tJ=& zilA;^h#<^-;-aLjS8{TZSg#7A#Asqh>IM{K() zfD$9ThFFDsfJb85=~EQRTqY7rz8A%VmHtdK8Vg4nwYQ#vdB5bU==@}s16imqj{Oo* z91lh#BaKtFqn-kPDuLpNpG;!x(@e~$D(Mnw*c?t0Kt@kda*fIucwSd=CU8$Gqo?6@ zw3cG5P2fRdCw5P@XY{!{9eiL1n{6tF=8&4tD>v_uTC=Ko{JK4BIHe9yD6_MIyigFn z3H!T4`AYa3o@=vRawXo&aRn93Sxr@X4i0)lG^FK?`C5??*7!x#(*zlRdd)={4-zM z#u1~L*PHRW!-KzM9@4~nSN?K-(xZ2)$KUn?M)A~itlxJAMe6SWcCHVioQ<^!1(#*O zcDcxs9{k2l51Q0>$mWfGPX2~+*oxK7ch)%n;VxhjJENCLnH^>$T;`>?&klcYnLuRB zI;P8MYf;)^q=Eo;Q^PJ?Q=XYTVjL^^Y6b)CN7RG*^53i^3G2 zqPQ#$4FgKyUq?i$ENm2)(y)e+RrL6wl2;mk>JP8O(wi-15+3Di{4gp$0wo3=0ZxX( zVeq>ol#nlaj$?vz5?>dOFX(4b`Y{k^P~fC#a1M&CxwOEX>uT%Us=#e8>95B#S-ANI z5}4tQV}}jOB@1=l@*i-7F+8=2Ec5*%0&@|wuDuMfJD1)R0nCK-Ex}U1lmDQkL}J$SY`4g3|w{b>0EbNKV;xBTxtzMvEI@p>=GxUGXi+&x8j5z>d|l%x=0(K@x>EAbP&T+ zv(V9n=G8l-|)TMe|Lq;@W$Qdr27U!Vd*;EaL zY5ZQwEC%WkDTfh`kDd0*n62oiOKOtjF0nu1vqh!rh(O8O1tPlf3 z)BHh~HU_!!mqnSeM@o`P`>|mW+S_WC@MMN}b3H-Cad=j1SUtzd>mN&aFbG_P-;dD@ znAml9)<2UU>1Kfcg-?^TI}HU#nx(UI8~|ccpSUG2TI1Pn4*P$Z$^0JmTzqPTybsX} z@Ip?<8BeB_wiMG8GOwIlk|`nw)mtf(d!#;xg=gB+2GkE(A9R%8nkLy_JT);eO)8cO zxG5CpJKqD_u$(_H^=9_OE7j3Jx88BSEH^UwpnzIMTZG5}E3EJKhF0iXuL>3Y8$Y~vE`pZCvbQsGR_5OF`d}(N9x_lkERibkl$z*z z?a}1fynK9|mR~QMK>1wsq&G{*iBk@vOD|rqOvp*a;a;e}Thzm#o7tkPs|W4Va#wkO zZB#YSf2w!F%g=LPN$XmxoS1B{SjrF7-kIBlU1zk1Z%L{fq9>VuE%Wp;HoEE~^8THl zPU$j>V}Q-wB5z8XWqwYn3LM#lUX)IXA`3OgLxV8 z)#G840n8dSm$tmt``6zhIc@HiI*FJsvus_iGt4D-yL9MH;9Y9e;cjjo_u;#YPP6K1 zeVPh8q8z-ks}DPP-)X3*6UWtCAG3>|nN7=KZc^-KsW546o z52s{6PW=Gnl%e~iX``u4hI%2kCWPfNoki#9p!3JE<)^8*QPW1vp_skUvufje!zKo2 zF+kE#daT0gxjBbWoEynFDMadCgues!TmU>aZ=~` zo-d}R#;1X?*nQ{foZKEGA!Qbcv{@Ky1oCy(7Pw{$)-ZgHDh*D$6_D(d%+iT#<$4yDo8@f{pdO z$VrJ|;IYZf;kxk$Z;V>6PzeSDqFRdqRnNnT!pi5*&ayHZA)9i}vXI5lO^wXW))spM zta%7oTfO_$M9&>xvdzhH-Q(GHrwzSq*u41#Hp_c8IG42spQPt`Hc5d(G6~jTh*nv)j zTu_BeSa#(zU0|_1mXhFyK!Hq}y$6x7lh!Chh%u|i1jf$r<(UL@44rN2yh#%KP?{HYd^5=rrXw&!JGTKA$-9X9i$$|Z@bkD|m~$|yTvfxPSK>TK!! ze%(Q#Ja?^5$nQQZu9l$J)J#Hr`vADD_UQ?WBqG*|HR{;@i2~KC&LF>N!}jys;+n#I zy{9COe}sUY`+W3NL{)AAs>oL>!)fN%Y=wUE5A8PxP%;?aAyz|$T#@BFndM34E8HhY z8}?KPFQIjE4yJe_V#SDDH}X9ckYeA;@QY!Pm~8dfxgLw3dL7g4fMiMs8dqT#;(s-H zut#TiRf12SGdyFdCv}W4JJfwfcIM|lr;_&>hWTR#^{GVI2%LtlD^XI(D?60mSfcnG zg2Th+@5LwA>KBlc+5(3n=Yjt_e=3jJGr25khgfE4oK5M&Oy9$UlS-7#ctOy-O;~y9 z*o0phj*MB2wp(9jJIR+vx`|y8%f#oBkt@jx3pq!ApEn??3fihr_A~PsDpU(M#cQ3X zD}$fKMlx`_atMup>3=w;s!FSbWZV6HiQW54(s)7gUPOH5I=MPAf-`F8r2$~1{)`kGc9oM@y>gNPM*s3l8m=LCE3EW_xLFwh`Mi#7(_G8(dYXE^2w{RS31h9 zML=Z9A!?Z5L%>JAx*vVJ-yifUE20ClBg{deZtwfCqYd-3Ft$)bfG~J3gX~R1z{>#v`GaFJ_M|9~2jc)~UxLa)P^Z*aNQcN8 z`l?kl(cM~ELx2~jT-3)!!G$dkuw)81bL`mYtbRP}OYuLS_ikITcvWG;*A)(nA~~kP zh>B-lK0@N+5R7Sh&jPT`rir`?unr5p=@T6mAQ~=pgna9{?`*6>1A2+d#UNiuci{X2mZwDp*|~tr#6xPln-Qwjy}&y^Ea8FSF9kCV#zQQj4sAa!R2-3 zByB$zmevBh34H{h{eEE24p&n)lJ{~BeCG>nbvyu2KLu1nRKrp-Gi5d@rIoLM8hrGn{uqpO)fRl@#cUG)Y z{UO6W^fzkUQd%}}pTs@LDelj>;Z{cEh4pAANr)vCv*NkNFCXQv5oG32)*3FrRE#M{y8Z`e!j8v!p{*L>A zO>D-ns@ zB}O?JM8<=h5~}C^(HSrl$4i6qGQTpHEPu?eHI*KeAb$J@3!i`N94A7I@vGD?`TY}T zrt(%_cwaK_TC~m<92OHh4vvnGbG?z1(`?mYljn`{Sfv9ccCp?NAsiX{hW^kMsi4#U z9?39Li<{Dh^1dPyPHD^IhJZv4Z}z;9mkol`-}5RQ#<{O=1%u1KtDVZ1@N#JG`CXd*rHTa||<6WsZ0hX1v__h^2hLyp_?Q>6H0gT%-9}>sB@lOxgWq#9C z&1Lo`4=}Q!e6bfQMCRf#0dZVHs}s!Op?9><`wrU8{2oNwx_I)avWe46Ji`i`c+G*V zmhbytZ_q=kt@o~`nZ1EUGC!bGgYNq8NEh4si$n#SP8G6$OMnGVID24A6*mqTv3N2< zIC#IU-s>rVZI>LxQDH;yM(4j^kXLqp3b+0C8XGYhr~a}NF73P0J6cHW{?el7u+P#L zBL6(|eULw$I9L9}-zUq*WOHL*aPIRyQg+Ubh}(VOR}5h!&qiU4mZ|U1d37Lqz4^A-2BExoh9FEYl-ENakSy!Z zd=(`pe#YMPVRlmSY`@jD9aPGk`}P%FB3J+P&80LRU6+y4bj(*S&|#FrSrDN>Pn(CW z1^K-$EhpuP(N2VWE>F9z$!7DjAGbW_7upG9sYs63Ut%^I+y67)}0~L>vbPq%YZ?onFE&4T0LWTZK`d7xeyA~E(^T+1ZS=GTbPED4}RKK=nu^d)F=_bX zuP9fAyWW=b;cVs4DQDk$%`7m2|JEZi@Ad|6`K0^^Jvrv2wv$HP@W9mah=(t-Z83*NuE!IQk?;Srw-Wym2jg9V%;OS=KvB-xPSIm z8Y4-ZUOUK0yl|8b0{~Fq99L5i6G&*SFO*I)rtRv6J@LZmF@2jXnjjm z^|ZuADh&b%)%E-;{=$75z1vuU37H1#$H-NbCeeT{zeD zNLyUPj*a>^X$m2@bWfQN*@|smB@_f7Y^9B^)po>;zE$cVCmDhP1-ZjRbwH zy)36z7Jy}d!3q8hiN(ro=Z?fp@BK+AvIZerg6$rE?n3|a0h`&L-L@hTcz~5r(vCm{ zq>1u4Cr>_K4%_PG?)KN-P!WY+rwuJ72UQpMim~7i37{~#q%c$y^MxR79{fZ$#o==Z+;p+MtPFs93E(I68 z>_dP4la1QUr>DWJCwv8;a}#4aMM(V*y67eqc8c{dSjPH7G)c<#PMdGtcntM+gEOMI zj5cCP6%i(dv(d?tN&@JI{4m=$m5jwD2>Y{WhR3%5Mb?$z0>0;;0n>95>ZIrt9dojy zCG|Db5jt_h>H*8ZxX%%u|C}@(EF+O=pHlAu;3}u3F8rUlC3+Gt z-T_&xr8nlAi87W8EZVOw%aFe1lHgCG;wXZmwjli}8|->>AMde(6Wqwh`O|DBL$;c) zb)0|4^xj1^UN2VtXKaJXM>4-TF8bdke{x(){dY;2eFKaT(&h(u5C&Bf^nwWtN(%oO zlvpjB`aY$LX(aS1jO4=G`vJ%B1S$iNisR;|(}R?1VBSd@EwDj|+xJi4}&HMx5vnvaQ6O3^;x&0f*Bh8TTWqZzrv)Vgu zitZ*(1yPD>nv*KOqNrq7ha#V&RkEM_!*IWw|4;uc@V)2$RQ53XeKUiqN{buvJbQqM zp+~O*ggEe9j|jp`JyD};BI0dar6BBw zq=C=Ovbd^1xs%&DJPEwWiQifa+0Pe;SrDt3exLF_VLsI=@Qze_Yt=vKfOg>^C^$LV zJ&PZO5p%eYUo~W1S_!kewawK);YKHgu7~&D)J`VL_#7y&nbf%qz*=;!ri_CiId!6J zjkq0(p>gfQ0Fp%be$o&An;2`WF#v{0gg2FjfT8X1K1s9nHerz;Zz`}x0 z51*gmsXD(4pU36!U zOY*6C@DT2lH@&!+qs@S z3%As@pL3?JLk~PEc}~SFqHU=4W4iyn88@I6hpFiU_I2~FnzXTqAbkAiJhz#rt2Mg6 zc9E!biw@k)vwVJ6C26%eAM;It`#hW(ne zvM*Y((}ui10Z08Hc9{1PZh&9VxDUnzwM@IwPTn-~Qe@3{{sL%V_WandchSxgvJOd; z<@UMsG)70Tg+QN%F<<+sh%_rb5|kBEUwwL~>TR?mf2^2N%l241;RNz~bGy}U{CTWj zP$}NHcg6MG7U&p^kKsbCqW?=WrfntNWmXmiB0hoxpL3ANf^}Gcw07)n2RPc!AG=s? z4~CWEXZU+{?`x3A7ljgw0D`ekL{Qlq^QI1eG(X)#TIl0udl10m+W&{g`TY-%Ymaj-3LM%`{<^K~fU;mW@0_LC=fqd&lm;GMv$Z+7r8Y4T+ zgua$b=iC9D(xI28BQrDaEICz=_$*`XfgxvFyQ05$_LrjxLR}${Vj^g>_8Thk~TVmk}GD}pD76`;@?eQ=oV^$M{%Y=|`J{QBiW_gcx#MejHzU1#}% z_!8xv@OhRJ5BB%tDG0<#OfZS5#9yU?GSW<@^W%+Hp$G0BnRP~vzP za6~i}h;u6Tt;xLkj`p{sL$Ii~d1B`&;+7w#$Yi74My}M+}=}Od) zk%Q$s5EZWXle;$O!`Q+Y$v@mvi$2RdA~GwMc?xQ`Tj89?h%>(gkpI!fx zDFb59f2B8=o!MfW0Bg|YJoeN6l+zyX5|h$`mzc;-Gg3x{GlXJP>sE4U{O~_6kND?D zc~ja#-n4-x5)d~Fq?sUlCIBnk>qqZQzlM`UxfRV5Yus6zzNXmhNs~0@_Lby-dP3f| z4Rcle#8gqU09L9B?RBtMt=RgMb<@4`Vj}hC7)U)#c(vdlu_b8rAhfIkP^}(-YI$@Z zlI7X`S^b=q)Z&VbB|mU=IJkgjBi~3+zu7lpWAX`OandVX(q6SpBnYJT9>QaG85?AO zv7VKmpdq8JHUnTT9nyX=)OVOoSp29LqBwxO2r#0XC6BCgjVM*p3RAVTTmBQ5GNAW! zswBZvsJdMG*x`qwE1s!C%FtkL{kO@TrPA+zs_teXF(81z*tpS~Oe$R+F9-z%O5quz zn5_21>ZR*LC*>y|P>N2zXD*?rPgMZld1?rY9a@|R zj1m{;EKqVCJT)l9w<58hSsX~O^Zj8p;dv?hv&MH@;Z<>j{nY~%q%+0i^}4$d7exi~ zAD~-g(jQFyo;_{z^Te{IN4^76Aq{Hy_^ctYi!Nti_g?z-?>KtoN5rmx%484lfm~17Ap@aRR z5Bi)QTc!$dd@ZAJ5vT)6mDDY31(nwui}g9QNS#@V;tUKDgik$pC@~tpl47$@?o$ z>h9VLfF3k~^cBOTg>35T`jx3)xe_p$nJf7#sDg7l=S0BgCbu&)jAJkLE9OW> z7Y*s-ON&gQKB?($^mlsfbMBnaYhMyYvuhB8MmTChlbx~z2|M1keNc8#@cBF)3~Itdg-h-U9lOhZ0p{J zd1#_~)gh=(hiD!`sEV~{Rn3EOFZ!C9FiM-c9;2W}*UBa2>R+tPR>-+^)B11Y)3%p3 z`nQwP zcR?J(MMbVvG!;T|tflS{i|5%>Bs|T~xNFcC|1}BYol-Bifal9|SvbBkpI-?)YO6Lx z^^^PI$LcC>G&VHaO9}g|Qr%lx56HL$H2LXnUtrwhE2U8KZCpG<^nKG!`p#OF1 zs%*C-e}6~K5?`MhUP(AYKqEb**7V4<-SiOTL{Y}At+w$~JT1;h4UXy~nX_}_Vet9U z^LHQAjNnTL{%pn`-&V`si%-l8Bl>~z35iF+DCopd)V3EV+cAN*NN~&;M&E2hhO`~W z0$NuRhSp;!B76>L;$V+xH;HkWSvrXxyVOhGbf(jH0bR7MPtsb#HTv;X&>snmi3m*y zQi@&+&h->9$JPeg)mWf))$?ewIfycskuozLqn(P} zbK{iP^Dy;J+3ygS2TV-e3}2rdoNw12ad>z=o^$G&_zzaiL~_@=K655zntn=7YZiE_ z!?dH;FOg3u96sg6X(Gtczlj4*F(;%pCX8R|yL)ko;LyYG#Kh>UN`BFgUGUBK6$Qhs zSXzi6o$4jmo9dM+!1=rwLA!1iEcC6CCu)pkvR{UR3l30VLkWaXwwuBL)SShn}u737{8GZTP zMlHklqa}n~?W6XOikh{Kc?R8hySpIEe^u4T3vY2B54&Cm({4->d6!76iYBTD8j&lc zlO!;ty@dPx^%T4~L->6SHAd+hlNu;Q697H{5%uC^d9EVgYsE|P*H!b_`7kCmfv=Ml zNl}=J*@xOK^K((Q!^Y3US|1aP^rJ#b%Y1rU`H@X5@=G1a7PYaRY3(RZ%>3l9I}Ck@kyRws@t^Y@k+zO(CzTPGMp=Hw|j$>>Oh{Qu7-Cr z$9k&zL{;`l^9Bg$DSmD1d+XptBOzpvZU<862vdNG>{J67DN}jnBM0kwjm6F##Tzy~ z_q>*zLTuH`jOGnWi6^*Ih`(mwgMat-&AAX$&sr{&Nv*fVY#x;pcf*9(@hP&@+Mt+8 zbrNdc%n-%dTCS0UVpxxc=byUL^;wg7=*KKc>%w>Sj32>6Ib;&S)d4?%zOwp|fIAX( zcxfmH6j;L#CgYREO;PA^xsO%qquPf&%Tb&M3vWI7-urHgm;JJSxRA&ZZ#GMjO?rz@ zKiedgW`vQVhGNoIDFDbrjXBg@$pjN}lk|+2o)s%=_c(G%FQ%HUwEVbduVPQPfk3#|_f|@}t45G^ zzpcQHnN(#I+3M6I(VS6dX(xgoQ@xQYY7ke!RGv1L-9&FW$vA0^OQ{ zgXa|uy3J#~hep}bcms3zqMU|gATx)~Pviju4Fwwfha&@RF4gbd|{Cjkp zQakV63J4Ow+3>n&KxY>2E$-pz^_k^o;~;!C%A>m?5m5YGtD6#u_YE=c~!$gr{ zR;V{w|39YQGAzpOdjl1bMp04}7)p@t?vjvhkPZRq&H)6J6c|9dYv}Io?(UEt7?2n` z&g1(#|LdGj^KG8BSM3$|UJJVR+nLb-?F@L&8ZF&3LLL?38r{xc)>e+P%|dp~GaGQP zF1tv}*T7}(ZHex=oe~%=ZGug45}){QO2iqlB{YaU3amr04NPA&=*#TG5wWDQ(&o+5XJ(}ZM}tCSskKr{9b&9KMpN*(IcHJ}&#Zm%60?i|%c?N)e|04KnP z4L7#@-`=8v52%mO7U83CBUy3Z@=xy^m42_;R?o5yQ#p_-0&)FI!eeFXPnCjGOjf`- zGVvHNEF4pJNL2nr2?iryn(T-h&6d0K2}JqS7)d|$)vrl!5bLDx89ocS;#O^J!HlBZg%m<}6w}lp zmSDe+%(-m7{amQ?Xf(VgFX2``1o0C$hDu{&?Wmf;tQr-;)ARtH!g9B%}@#0*h5K2GPO&NLwuMc`kO(cnIxc0 zffN~_*EjztpR2PjnS6tQ=lQ&jVGqB`d#%f-vTR(nO45{`A7owIdB_CfbPhc$dp+IF zS_QGoxE%mq^G5%&wxsyN)Xk+CMG0)O!CBOyjuv9CWmmc6(%Y4dnS4=01XS3~zBGIS zd`uxhzm1*?W}w?FMal;&8QJPM{dE2Bf;p5jUmF80fV_?(Uf>Hr4Y0>y*-Cq?f3m4oA3+-jxvm^meBC_yGRq@MVFL zA01_WiyrHQO6Nm8tZmJtr69x3padpMV8xyK=G4u_r9fDvNw^gz@9aS|&j@sP?LV3Cxj4N>l7rWpUuyy2NrLSN_aXp%g7>(!auud7vAq|Wu1dXze*?g12jnAH&hc+thL-$$y^3EB zgmQiZ)`!jhTOY=K@hiX4{WIt@Rrv2;q}FRAEGdNM8kIV;?%NZbn->~yuoeG4IbYR{ z+HNgm9~&CamhsoRk7`Ridm%RSxb2o|Qy=3(b3E3_VW=K9qR3gv1d<(-zg=GeIfVtmyr}na_elI^a z@ag6QZ0B$v&)c-jECM}*WzXX)OH7}+s|bJZhxq5M_J3J7Y^~dpOO-BvuvpTeHy~G8 zv&)bfWtxoli=W|xZ5E-#^S!Ubt3EE7k~3!zaTu_zgCOM+7#zqNMnqcYfrp$UX#!-yjfE*jTxfAEv~Y@C}cFE@{oLw|`^* zq>4{v=q3%LGr^8ha16~uH*2U@zxh@ty!c(0(38#ar|7a7tDq=;Z+g^^O}g8KDy8$( zO&FYs9?S?HLx5s8qgixCKO9zQS()?Vri5)y64J#WnS1butG{AWOf6JwwMD(cF3Y80ZWo44X`GCk_2WDz~aSG|HoP{AC>8S`~>YV(IW4|5$W1hXFeFU+OCLscrOEzy za5BVMw=jus+_Ro#DwDq;RUD1Wgk?$&Avt9AY&NG>jT%`F;j&an@(s#f`as)w`$7YW zw#}oWZphcCCG7{S?>BZ4w9p_d*D>462cb$WMLvrRiyxb%{o=xr<^M^Hs@9slfXpcO zpZXv;T|a-w&DU(vcIaZj1WkXW;L_+%RF6_t1CFICq^l&wo~f<`g$`w<(@)>}=0$4^ zKELGgs?fYF5xSvoa{Leo3t`)nLwI;|{Zm%TXxLiYZt>!+S-71lx(cfU)MVaFS*Szo zpX6ZwujF8Y7FasUnlZakVy-d*I}@j@3*j}YLV5xSUCAgnWeE1iu4%pkr~S;Kn*0p% zyzT8=yz>*Zt@L-ByT7r6sBTjky0*eIK0zCLR9{f8EYJ9GeaSfDWum9q1c^7(Aa5dF z(gCbQ{~s&gbbW3s2oc78SrSe`fd-rnJ<373azPzEiu=DW#S#~o3$rRCo@8zv-~32E zOC{W_dU8G6M&~Kx6!-AEqI?sX=P2so1MG^Cdfio-`?|~GFm|`?Ki zy3)6mNp8dK*e=tpZ^aeBe|5P@r3N^)B{r5@o+16i!TGfa_J1i_n42MI4 zC&16u_2*I<|Hn^`rPVGMDJ-_ix~YB#s=i#W2JEoD^k`V+r;qVSd0y;PH6sVnFsnn6 zqVezVZi-`-AI4X)lNkiT(|4P4ifGxyD>)U_qqxN@@xQBI@rVOQeA%RtlROxR z5_StH=i{f3xBryWBcyFJ}pZtKijdidiMSZ>5bLDB~q z+6_cqi?25s;W+ZtwBq@RiNz_6%b@9S@mSB7f>f%>4C!#I)W0PE?2gSb!RX_%TBmY) zVFF?{^Rtd)#W%fqGttF6A^j|+-sd~`Le_wP!$^x^o_R`1{l@WZh`%q0{fx3y*=@gq zaBe9_U)y@zziN)`xOd59U@2FQWLQTQMQLzpMtt1NAh1>zU!L(7o^=j^JmU`{>xbUq zMK2xu-M`sGoxl9`V>@;IPI1BXgmW}+SnfDYt%8|&_iAiPNRexek`#@P--;RL5Y)bU zmfY-=F|- zMP+el-pVWyioY=zSvDwI+71d8Ccyd@dkq06Po4w>Fw3PAiH~Y3h*U*weu@}eauAs+ z?AFzOf5>Y>tUO2KOfuX;QpH`WMB_O)Tb~eAq5yA`-{sOy=`rk?;;rOfGVD?HsGM8Z zO)X6jl4bPN`2HFFzXMsn`R_oLgm;|z>#7xn&jrEQ$Mu;kQ$xDJudI!2OFTo&MRig} z1R0&#%xrasi}5v7Ch&zl$9rZz4gJTm67m07Rx17<%k;YdmX*iH=~ZCXDJIhd);=;* z+^RE{DEz^_wCbA+H7NT~L+#bRyzu(Ov~LcBv;3tyMjC&~kJ?IM@^~b3TXs;zNHK-= zbdy#9>!4F|WbNQAWUvL*I<~=A`yK7vr)FPmOqRLZ_rBGLsx_p|Y{rhArLsYz()P_@ zfM3?JZ+*eZm1Hq2LoKh(dqYp(ZyXALEeRHFp6Gfh0{!nm4Z;5oB)`Jo%x7k6A}bfC zs*W-LI!1sD5X&45Sf3d(XNVkJ0Y2lM=e-v!r_^5K*rR3%(eAd_&=KZ_9KN*u22O=X2O`rBM= zCg)tbv<$Ko$0{Ive3Fr%JS$+F6L0h2^nTzMLtIF2F;TuXb={Ab zM+LF3-tCRxmdT?N-C60ohUFtWjn8$$WV3L)BKogeRbi|!3)s#oKZ@F@1I8+#-e7;3 z;GWcVkjTk#dm(e}+I)LqTj_eVFUu3kmPlET2}p$h$}kRV%!;|gdH?pUT~FdhR0XVJ zLGlsBi8$d6rDB#uSL-KqeiDi)!V0xm{~~&1?jjvJvPPB#mU=evh0z31y)` zNBsj$$8}x*wc-dB{{cXhZ3aV60FjhN=jU~O;1ZF~r8=1jbMdyppMuQ1lBu^4h1lU- ziQg)ZQ&}<09Vms5sIko5J45X1U0HJhBBJe-wj*5tB4p~JDU!F2K^G;)USc0cE|RgH#cA zmq!`h_n*P+m^vu;Wj6x5^{daiu5F_(H|m8T0_|yM4d=`0b}{S0qqlWqWltB}#o8(k za*}M{kCXWK@iI`1)%NEUP@9ll#Hjmz9*2xI9OWpu6rT{UZf0$@MwH)?6S+xS2FTdp zH|LOwQzH)@yS$7d+PP3aFjP)RNSF zpZ@4e8I_$drP=VXslYR$ycVcTabWpu{R>ZQG(t)vf-ZUCx?WT&)O<8jvhxCJ_VvLozWJS$O; zqP$ZY!k?$BxxD*U$Gi+zD3noTXkh)kY}O&z;UsC|qt#EC#q&#X~`eu~L@2TZKAX0#wE9`X;&D3#2IF4vmua$DLH z<*_aSlDD*1+E(-iBwtex<$xZF94c+G-AQ}`p2W?KBbY7*eYw7jA4N6bMeIHoekikI z&m_xKqhzZi_L5}LyPVvTIB6*JO>tKFKD-qzRcI>jE3F+TV>5#-q+1D4Fro<6j>$5S zRUNjMZ;k93-l|N_Gqej_blb!?b2rs5{hRZ4A5v|G?vEg;4DUiy(6-IlWT72Vp!-CPc4=ndK1Lb-GwSNbrK%mPrRz#RO~*_GMe_o z$5WF%#(f(VBBa&tQxvQ5`#GmyQ$AZ2gy$9I`_M{qfqXpXJIiV(&CZ|!hWw`ph=Oq= z9&hyvPg_khs!FzjKGm&(PwYkmpSoJ3g*Zj5OlX<+zI`lvlthMrA3X0eiH&cQ0_i_; z;xCOYzO-2`rN>?_Tv4Ki2-KyWb+}`p^2AgiUClmR7OedVo2mwlufsqr;j>@s*XQ5s zXE0m9h?PD3uJzJt%3H-5=sI80>BoLQdFF^0TDd8pI+YuptApFNVd6BVKq0Hv52#@@ zXXS$A@allMo)H;w`hFRszLUdY?+A4yM^b@$33)eEQlVZ@ zm{l5=o3-8d{+b8H?g3I%Gh%ckAU@64|ZPVeIa8*Kef!VCGO>o8h3H&z%qsNQaO39R4s!YD$7G zH<&wNh*{9!NVwtm8YQ2QU?i7wcwJ9Ha4t``*?y33{@Cpc=e|Kn#6|w#hL1l_SkJYS z@X&|6=+8xvQS;8>RP~J^q3xKi)F=m8ATvpgx|9QQpuK6&JeU37Q#BgM2x(~CW(t{K zd1{o?XNV=v7_HOi)w62{GTDWam8<2cYUf!A-r-Y%o21)acel@|b{Z$i*d=HKxiS$f zb2%^6FbV2sf|#2%-ieB2D?5HpguMx%BTNZ{O;!PEa-J9eV%#fpwd4ljtjExNL6liF zl9J=p)l9EAhcHQRWg&6`y*85GFuMA1p?GjEnD zEXpNi;-dn}OIDTPVxn*Q$S{}QJ%BVPQB?SfT?do}>=Q5429+iQY@CCtDI6$s0SLu2oXso?jN1MVz7` zCY!bFuUCDqtPDY~^uOm45Ioe72~&M7d$mmZqMI1+_lxlms}$@xw70;UHCr|FxbJdE z$hFih+HtU7JGQ-4$cO&lfz(|)id7k+?VxmzaBLNEqqct}rSYus4>J>$O;;4nlR)}S zgSdN}#TV;&Yp7)&qt=#M{hm51Mj2p#3~h`u!2W0w*#gKsnS z{9Q9*cNqo?K05mf`TY&{aQuh09sT!#emQa)QJ zMBo`NNoeJ3!F&!wp5z;P0fcNKrmllt?m0PgnhaDzCRusub zN4A+oS;>YUrKtoMK<{)RG~yLqy5=%o<4kjsqUb3;?IFJf&quPnbim;7m2%SogUj;J z`>nhtp1N%@pKy}zx0702?j~Z6ImC-ZFkLq2@8NF}26(U`;%OzogYApzj}e-85+mjB zMjI48wP7I8Tk*pcE|6)Rh>5!T5AtLhh&F@0=uEAk!YC9Pko3P7x#uoa&0-$SXFuMo zk-^10yeZwg1OPi1jG5s56aFZ1z9LMQQD||=aUxELdl3$la`rB-u+LY>OjF{dFFJr@ zrUM-xc9t+bZfk}8|f3a0`_LP0B+P0gc={uul;79vxANdRLk6Ot5KMzl_Q}|5XdYRBPdv$KQAYL5YRL@`;F#3Tn)xU= zM9!k#pI8(1R~&G_HBp!1fd0X!J+o}~e^k{Zld@n?9oYI&R)glRXmeU2tC_8M!5Qt!d_hGu*2#KW)FkKJ+56kHuIr+dfai67S7*%Ygtq#V2?L=}rhBj0MH*kblB((<_|XrG?v#Q&FK0S->ikS_nzX{O7rd zKjN^;K;FI|%E4AeC1T2JdQO&6z%#m$oi|}4C{8YAVk$$%6b;-JF;G02@GMc?T!Qmt z`|<->#YMV#laV9S7$UbDEd6k?KdU;C)J|U;zmVa?Q(@S{cvzIeGb{orgCv`Z@!kK-%7I00?NuahdkO}(PH|o3ISg@ z7_9rP6LW zzv4?wRJ6>Isa_xKtpfg7Mi~0}Q+#f804TFJr2K7=PEVM@h2z1rm zUu!knvV}*O`x!k=pz)XOPkSQcX=fBVU*@sOXyD^%uqV?XA0h?N<8Fl`K3diK=gx{p zql{z8(qoWfYl@Ej@7N_kY*InSQ~~H)2^3E|JgY;Oy6m;iRKU(bg8t*8b`-q@;C+pR zAgzG+MLT4^gq@?fPBInjSzrk)S->)d+6!+BzV~0aDWEPPlW0=+5y4eH$YaSEF-cZ# zFw&ZA;^yRv;v26!FGLPWBMk^%MRx< zATFSD1aNb^XdWeihMngK&OJZV#!_MCEu=47tGYF1o))Dne#M>zqNoCh$OJJ}0YvOW z@pQto1^^<62I)%AE>g_R{LDsVGwscIGC>*}_@S5nzLdZI5pw|vdU;XKY(R#;Hrwx6 z-zvgfHR|P;^CZE-QRuh21|qw<-C)zdJ086;WE{vSTzAuh$`>nv4oI3bio zTk|rG$KL_P+s9KiH`gZ(q_6c)bD4j^t&6MnGtS>aVp~_>Cl`}PDzj(VEEW+MZfx-2 zTeq}U-}|b^rbX~W`xA>GYwncpspPA`0HNUZhd^nJ3(WZr0-CATy!uz@(x=m6Px$nOq#cCCliHdkLaWyPR-3232P&B1;@Kl-fJ?>{l2kx@3#T- z9&r~H&+**KPrJI+x0d2adyw2?G*=C?zTRsGOt-sZ!jDOnD0e0!-GANUX(t$|d3Ki* zJ9o+qprzYiNIJ~;ndfgMS;HA=MB~pjSn*=hiF+5(i+hxMYxWJ0Q8y4SUH7|nnP)r? zc)ADz6%}H3i-?Eznkb<^S(*d&!7hcs_Xo=r{Qzh;jPEz^+ty?HL*{zs2x=j zvv3LXdYN#^6=MD3px$r9SG(1^{!3BRHVpjW>itY)1L$4-TK}Gwu%T3^Kb^QU@E%Pk zQmET1UizvNpwoyCV*UlR%osh2)JX7??+mk)wcn&w(>|YP*c41a%M*h{#RFXC$5|^w zv6z8y3n|o+`KRLn+xd~yfnVyAE)?|=nC?!?u{Y80A-)|Ic_Dej`KJgEMO7H z{7U5=+q;<9XKls~X!EMSjsu2;QJ&f9*3^BolkeioELL<75ZCH8QF9c~)dH@_6-8*V z6aTiG?wyjK;iyDp@YAZ}GV^af$M=xe`VH{tuC(P#GvSp_aqVCG9=f-{V9N&Z!3aEw zf6JXWR!`CK3m5UqD`k~RY0FJF8zQ|+I&!;&+zkRXzYz=`@?1rK0dX1NW8Vdq6oHRz zC|W?zveJfhrhcJP?!_p_zgiJg{Oqb|?Z15dD{C*5;#6_QO=eTk)|(ylZJ9&gXP|8T zYl40CY;64CAE{Bj%u!ekU2pA39_d+5gfxGNx?6f5b!aRBn_dcdUd&D6~I_D?U7| zR+1DdhgPkSo%A>b;~z8D)1DjiQ63A84kz5%2XAeakB;2mU)Dz^<9S6R;#ioZfuDwO!lG6FvER`6Kwc*@<)RE^=z+D4p7ZQ+!zO^W_)$oOx6qnhn=CU9C3PP_vjL|9nHIbuQq_i>mGlv` zoe-O=ptCE4eZ6bo+4)@x7(Q^8bi4I>;V*<0=scV~(*h1_?rG+!_G&Tv?J&g`{I8xt zOu#oxJZqSMOjIX*jBrQdOB|GmTxUvECf#l@HRfMh$TvJ%gE|b?B^+~-yl^&d1necA z$}S&m7@ov!c&Fwu8?3-m-?Dtt#`#{mYRBLKYJYX8F{hS>i+Gz~AgnfiG?9i!v!TEU z)WQ+}f^fbk7emn8;$1)7e$nZn-t;^V71c}q3J?L+Lxwt*jvVR{X>d_0tlh3kujEmUT9Wrxk7EYbRH4M)u{+AYW;xQ?vPxYLe4SJ?($&-wEkD=ya0w zzl$!!(Q{J=h1|iv79XGW8de|XfBo5HjBtDcudZkw*_HY7-IwAC59iqe=!Oj^Kn&;S z1!PS}TMxddKVWHH=jZ5+c;O1Y7nZSjgZ}J7X@fei6vo(Xvj(d0<1~+yI7z3QF{R$M zaZ*f6TlLGcPz|S1o-)h3%WjUiP$!{HL*&B_#`pFf9?y=>6h}v{;B`*D=ZC}Yu~6sH zS%y0`qT#S^a}JCnCp}&qg-8T%BDLX01B{4xPk>dvJH z?f>UU;7J`^=R3E5CyteUs@LofPl|WBGskB*f;hxzBi(#JgOxh^n%%AkxJg?f(}72E-5cHWx)>xYwqBB4eL^ryhkb2JxURf&xEg z!s`8!6TZQJo=WUb>Qcr#2&KNM1n%z+hienOxb|;#_tE5v8U!lTh&8=Saw?B_B zrQx=2AAV}To&>sV+R`gEDa~;3<*-=gUj=Y=s}6{EpRD|6Q*J|<{oyF*6r7lm2XnWn z9uI)8yqbTVBom`HmgVFOjzv0rHjd}b8jo^{p9XZaJ;(N1N(dv=R4P&rMNl&-YSqw^ z{3Dft9b;ITZ&L6EkGi&bQ}8gZOwJ~D8DnA2tAm+H!!#!|dw$hmW!?#Mlvn+5XswC( z?Kw_&xoO1`vw0&)NJy^39~ZeDJlS236C*X`Qx*}P4K2pr3V1$e6n z=YpF4Ma4t3mn2NuQSe~k0(GIMWLk0_UIS#&bQbCe{^VH1>jhBI7@4tp9QZfbOS|w@Ds%3zV}Sc}bT&bC7K$(0|s} zIrxx0^_HBRgMf^jazvexd-mBI+k8sm2_(w2B;8k|Gwh{E+662Td@pso++Voo7QOQ& zHTAFXHcwzNuo%T;6cp|WFJ`9u*SD-HIPFaLIR$fiGqxczL%V|n3wQ-CfF!tNu77$6J+^1z(y~6$J+N^s<#_Fu0CCxF8y6M|B$O2baGOU;GIm|koTz{pK&L=CcBYdTD5rLi28MXUI* zF@fY+8AzT{e`H}YOx^xO*$UD`x}9n7%{0bwcia@)x_A!*c@zZo9MjsD4Qez$e00|zY-WSF> zXZaA#Z-5FUMk^K)xbV{C))ILZwlT)~{AAmdWRMaj;_M5Oc}W!N{*FNPTZ2p$XHLMw zJ1rK&mXS66A0?pC+3Mv|DbG$x12MyA0RH71$$%MmtI-#K-Y@~&(&*dcK{xYd&M;}j z{zY^eRvF0HeopR5S%4_tuO=wmO!Oc_v5Pq!JZOwLt2gvTEzr`ry(o{LQ3A zE%Ea+&-oVM{tie5-+(aOp8vbQqnBe9Rz4)o%M=~D7r!aasLEJ3e-e8d7*I-~GA|DF zMGLerx44miaH-fB&x&;dh}yYqeqOyowl(bJ&7Hbq1FQGf!!#JmW<3;fWn=ybgn|VB zLcxsZ(Eto@4S?ab05H5$i4R)2T;vD}IX%?TzqHyTceU|75jTlMk`VuXb9{GRhbq0w;0HtNm0CjM&J{$xgoG*4gnO?09B0v^`*&`hu?~y^&6p{ z+S{wGtx=x$%{jFO|23s`%in%$rL@(Mr=x>X8fE0889Z3P(g$CTm z3;hsjhTp6ia)zHs7#Kz+80cCmk*W!5t=lZ>ZU4^Z=cNOhGd5`Z%`y=$mm#w{DC%h% zRN4v!&Z?>#`y5CF7C#C}vyOo>_)H|X3t-W;)5J|CmiuAb2o{8Aeqo`)&ksVXYRfWq z$^uo~47ewsY!gV(YvFYFg}=6)ySS|?g(~CO)%Hl_3x@||$JJxM!=Kd?hE^I2RJ|@v zr0>y%h&!RCY15@1R#38xMcVe*{_1e6;R57RnKqV8AYrXZJ&QqHNdKFCBU(;CXV~|K z|7e3`d>gfH8h@mv1Gn*X`2$*)y*H+xulLR&k&>pD^GGSG`xin*e)#Sb#zr%@7|ke^j}|re z&)vx|2B071$=|DiO`rvt!J7f$a?N5~gU{U+oF$>o&_*H1`%!%-a?X0_UudINTlhF) z_p^Y|iH9BZTAuU*V>Uv@VX@ho{UaH96_7WFK@Y-)h2MytR*jeo(DKxmJiCOw=%qT+ z0KWBSvWp)0mIuFa?K{k34PE`H1l2HhBgMzIwIfh{|JSF0TYe9aK6($uX5yTNS*Ql} z8pf0&-%<1@)d+iR^siAQhj;I1&!b?51Uo4aePrDnUlyYpy^QMVQt{Hey_J9{G9U5< z$>d$=>54b*JWB%j-ZF}UfiUl5lT|(6Nf~({5I^?xt(E**kg*BhIpFvRaX@1P8ZL}L z!$q5nK1bsZ?r(MrY8+l8c@XNYYpL)KuuQAD{|=s?G)y|?6q6?68CcrmjFd2s7Sq6;KE<6b16^nYrsrHH1 z33C~HCHW$#YS^$UJY(I0XTW3_z?K>g8y4Zv7IuWX0ewe4(UG3?R+P~Yx=S%Ve-0w%$c{m<9#QvNuVUoK9ef?LWNKY)gxd zC|~<3?5g=8d9@4_*&KY-R%TCw=`%9RCtx!yH_j`TU9W&T33o@O;h$n+l#GH!4+}r? zO{18HvuhcO(Ik#N%RhV@dvK{`VZo2sbY|yP59xC(qEcuw1oV*k~U5^%hXAGjT27kx^)v zRMLvO)tCa%3rN~nWy#M-^WU1r#ZHtcIkJ$|hlWItcXr!c(WF+Il&6Xl0C&Uz?x6hR z&N~Abi1H>WS>s8lS-5=$)ZT0ZK*#iLPBhxRY+yBC(H^?L_PhHGdgr$-D%6Ho;riIMb?45(sRt=7nJC;R4C z^`iILNJRTOX??pJ(SB0dP5YV!LWHdD?)H;b>wT3FSylJm>K0t#vU2QIf0`Zd49?-h zt@gU_@YrKpYwN56Pc5vZ*}e#|ReyB*QjmINrv5I;N9+UIxad)G1Oe7p;YP9;=J*I;xHS62<=zN;t40GwrP9Com7WHvq{;+)Lj?8t5$yAWJ0!}8K zXk(Cey!jie-wmZ{m{>$QA)fNK1rGcsusOc3oWJv_$I|xLyuo7pfwu^!D>0LngWN{1 zro&XnceKix*9zUMZ|>pOC;>x&@##WOCQ^x7o{y&24H~)nXM_rwU=^F*%>%VkC$BS; z&JV>-Dq_iCl&~be8ZklfkscEz$pcF(AX8Q4Ppi>+nKw#r>nP3iMTU^vR&grs(i>%( zxhc`}rJOW@YfHzUwAZ#u#!@vxGgyToBlESMWiVY5g{aAoecVDX^?V@c#j6sP|1 zWcc8u%qVqyhOXUOSh9a$gTKOS(<#k`)`DWlnY zEL^y_6ZMZ@+cE_>gAnz-yU{(k7P#W*_UoPFa^mIa3%wmO8yO!%dlCVBKOGq_Ip0c`!TcSmk$*Z;uV8IS%&O6F?_Lo1Q15ifzR{xX5-R_GDl>~0>i*ob zVLLR)>-&n-8K+ykMU#ZjQ*ZTCr5c!f*-!w{=d^lXIp%hkqFaBU&xR?(pejEfmRQ{G zCSs&YLv68PpJE$}bn~nm?~smgK>A%eF1sKWGhwQetP5m%NE?(8y$QI^5$U(-+DD*jD=U8B*j}2<^@^1;G?g5598H;J5RD@{dt}_A48Z9+ju5vwzQsU5k#bJv zeno5;O;BjF{B{qPy=ov;H0#k|sl03!EhNg)dmHrQ$f{`vC`v8$4V+2oXyj&Zpb}$* z=JWSS`UF{q^`@hrPG$qh9w{IGN%dD!YDt>A44#G7&G{07AD}wFc+TI2MBys{;eJ(c zc)m;l(W1Vjnp`r$MfK4=eEiAzrcY4ll=1F-%k5kWEaO{xrSN_HU(4yz)C)0OyQWyZ zyl!(M(wPXLDlZw}*+rNQ0|048!X13Q{2?gkkg>v`)ah)-nHTBtL5FIDzwkysY^TEB z#vZ>JqXX=(Nm>Aayu=+Jq^j|`D4LtFL}A3o20=Y1p`}cr2f!7xZ#Um2yi#Ug=e`UE z3Iz6tUmU(%qQrNH{@v`O!-YwCco(_f!5_ZfW$x~1T^SyBJKkA=)j{n~KJExZnD>-# zv$vp`$dUDr_pM*6mqCc6rn}p}nPu~KHH&k>N0mBV2a5J2az#&RDz|{8#-i-*!g@$I zWXFa{gvIi0*%v_M2`2jeU61>b%}34=*W+PQS#5XwC|)|rSiI4ex}slbAX=7tBEX&f zDE;|=551_>`Qnt#bqC8C&&0!m!q1;1AD3%cc^>=kpg>^r1Z)MDDZ02fG(WkpIQYxw zT`4?Q9I>r5jz#+ND{M;WjFuA)kwPDRBxnVt0O+MA<00X$4^#x`4f1sIL>A-=5pbP^;n4Vk=RBwog zR`-bQ?A^b=2=5j6h1TiDLtW%lZsdd$oyRA|d9!D0 zhQ(5MAt-+xb!`FI%e(YyDLVSOGjNMD^xxwcjBAHd!e2sfHcV@E8Idus&2&rOWe59P zSZPV~X{@`cDPHe{KC|EEdS;)n>d*l+exBJY8KblSVZ`4{_3P09`n;HBn#W~a4GQuN)3uIU`P4*2j@^;-HX{#=#{ z&UyF}B7AjsQgiYaca)<^nl%H`Ts52XGx?!dtPrd--@j@A{$Ld)dRYF~slNRS*f5cn zwHoO3DiMfdQg#wt0#AYJ+WEtUpAV-B)d?`);eS1i4)~oayN^CBjLJe5&?+jB1zDbw zZ!eEJ6uPLrq`h$7?b!PGk`U|ak0alhmL(S2|j1%t@LLJ`) zcvSr|i5 z$R#AF3c{sP#eKN_(|tGFdw5M;|Ac}Kqas`#UA+{(+fhEL=0S{Vo?HYjf^3`npbai^ znIWM z&W^Ls+G~9RxzVS~syEi&(7872UDmH@sz9ceHu6!GAC9e7p{a?jziigp!0n)+Lp5w& z0ioqzRHItmjFG?(fgdEy2r!m{ZAg2`oEx>n`oE{@4czCeLSxJfdC13(5PwI1aCId{ zQ2X9{m6nw2x?K$cflW^zxoBCD5``tTrJ%`CVAEgQ@CCG2q86$fb1n43);{B=++Yh% zxtn!4gjLi5UNXHFCIYeQ)SMRMfJSiU05@+NQ9!if3cuG$05AA*2J&m)Xg}6vifs;4U&1Y z=Ua!s^%+xH$^-Qgp0WMy>$svjhvIe?KI6+9hSd-Tw#YV7yu#|m8QMT16(>G`c@PAc zhrrXEd9mqbYbEJnzceO%l0hRlXMVSOjbRHo5Hu$1=+eo zArn0uelDkN)1bibbjnAl8cK6al~ z*RGE?^I$snkx;0s-Oc!&|C>(nWrn7o@?B|1ycEq{b_Iy4{r%ecm}{uohGfloYvN>( zVW$pOvRG^XT&;z_>@61ml6>S`=CJNZ~i{F-uCGW+4ys;THQRt%YLdC4dwt&ZJa6Mqa3c08St80koo~Z0Z zS{zeRHNZ#x7m zh4g*@hkQU z56JJDaL`VK!4f(Z+LI1VMv|FwGgAek>`*OAsqsPqfrolm2>-Q^x}D)umvBaoz5)e! zV<-0!KY+?{S;Io@4%74tTx|w;5s24hPBOH||IO&sDXKheqlY}fm>5ew*CA2-8tO19 zmb-wHh(-)Z$JY*ML>X&|#Fo`VpoYTJmA$F`7Cry9EO<`mIu1A>jM;IYXjB8v-^rNK zFI&-SwYy||CZtFiJ&($h2s6KyCLnwt_0CrO<}X&4NBy4b`7#@<%^a4G>du!n>*23{ z6SI$QG8u~G!7Q;?FAOYAQL=u8uOc-$h5V>R%*IL~P?Q#SLvN_Zz_l|~#3dF$T*>22 z;LwJAayc{Jhy|gMi5=!LaM$cHJIvgq)QIIfauxepwG3_BDPqKR!~H~}T7@``8-@CL z!^L~Hu;Q-ecz1m|QzGT2`F#IT^5mPFc42Y6JOjSw%4sU18H{SoqGkPPi~hqZs9V%5 z6lh||SCwRI%3t1!@cCNkNs5Ymh*2%$&3|ChEJThKs5lTfW+Oy{yCu1q3?>t+WA==C zH}vtI((Se0i~>rUKyUp=De2xQX96wxM)Vc(ZwS>VuG+H=*M(MELJTdO9EZ_McqvOv z*KKEjz3|$|38)!x@`d(V)dntAw^=O};$&=!-1+?wSI(b&PBCBgL0WqAZ8B<-xOy?3 zk8}Bj{52`PCp?{lCpMFWhry0rgXTNwm0G}^H;J1g*v1vJHr_M{ZB!A2oxhVr9l>anSOKy@Qg&!ZEAQx zVCl;Ur7CZKQ*{n>0U#~G-R0~HugU4sY<0Ezm+idR-qS2kMuz0P}5n| z*LICK5P1O=@9p+|cxB6@Iw51~T+_z};QbtEa%vtzHafNLHp$QJy2f?NHwL{s+1|OBb}Z zt3VN6)7v5utcEYYGO|x&Ui&u-!V?yeW~M@1JFAphcqlj25_x{NV&7&_tpOQS3;~fQ z2qzj{W+v8Ek_0;q{vetrJ(i$h!JN)hk^l$Yl|uADhG8m2})5QwJvY z-*cNE8R--O3A7lHKy&XWNAioW*|eu(4lg_OOGJ{&!C;HPVDnxETS6*Cg;%1Jazx9$ z=w4y0Ts1Mv8hi!akOe41^(!;i@i*tY$rgN0 zQ?XjAgFK+)^~>EZQtJi69`geGs1b1-2Y@v(r$NNPA%d?#0I)VlQ0@!P)tbT?z;u8t z2<7JbF4G0eO<^9^E)(24ePzIEhiA~Bp~-6%ec1CO;BgayW;yf-iHg30GynHyGxyrV z2=*Q}uTHya8*!-$_F4P0cC(wt#tF;qO5}Z!AureZtoMrN+_S#p`NG`J3fN&+WGc1O zyyYdvkpAA^+gCz!BUAzdzFz?}$kVG}0RDpV{;~l$ZWGlqqU|3_&v&yI9(8v6by#c( zbE3cl+YpvVfd^hKR1i6k#V;@&!6}KBW&t5TTrXZ_c-IQqYPkKeJ}Mb%#Ml zzZq#IUqgkAUfH_OyVoS>F#M#{ZQ<4^E3=40*It53ssh=xehMFr!{m79r7HWWBK?oq zBr`6lu+J5E+$fxCEe~*1M&ht5Y#@hh8%md)H*r)xydWP*g#%zfgZUjp?wkr4B!^zU zg3gkxr=jVifEJ1JSo%|j2%=H)T#OP4*|K4kjo2oaY9pBhy(&?%tGY<4`D{w*%B>*e zM+rDW@p+a=k+<7kzIo7STkK}N4wrzyLqPvWAZDn?7k7L15J$hWbG_KIvr`ZKEzY3f zduT*5NETh9O>M~j$zns(IU%azn0#0qdZ%c2A%E2N~_Hi6|Qlv z6xc=%Ij_HsWse>DJNA=-^tZ=X4xr z9G=C`WUDZ$IGw9uF;2`zEYku64;-W_T>#i|b?iQEIR3#6^O>~I58H4kgl3j-OH~Y7 ztU7`Z{R9>W@JoH3ib~Q0jqc(Zv1*GCeT+#rdHECBdC%(k_2H&}zN`Qg=`OgGnZQSk z-PnA#<$1p_uzRtzlq2QDq8Pm8d0p{mYm+&nkEQnmeHEY^bVeNpj_`N| zn22LTQDvWeUfbB~-(Wq6XqEYx5xc19P_NS;I1Y$c8Gv}@KrmcRQ_iOfK$Zj-5=UDD zKT01euQwYXYk5kH9nTv#tXZQQqMet360BBMEOp!xgbKYV0aY{jo{>3=Znm36k@Z;N zO1kx8|BcboF-*3eYnZ?P>Z#*B#8bxFa8y}prPof92zANixM1b(A)S)V-e?cxl;{b6 zwt(+VO7xW$?sf}SzPc#CL?$+QV!@ExpfhcDs`z4BU5yvP2If%*Qd#t+R;SM~nKYQv6LpMf+io zx!bIU@fFkcJSDm~7CBoUsGZHi>{kMsz#-|i3QIu;JYD{7>-_*x+mFYvHkFSDd(}GC z>qmU|Y!8?q?|Gc`GCY9lDS@@kfBGy+Xxa^io)3mD?M9}CbAXyvMfvzJFqW(#Gd(e@ z5zLmwfv3%in~yvRTqty=MGmVh#DnW%*O!9&07Uufa^8(?$aG|4F_rK+_x1xr)zw?3dZ=;9*2!C zYX&|%eBJ;Z#ZRavkjVd<2HI`VKaihrvkRP^e1s=m;Ov|%ywqKq^fxR?Mr-8ll zE@d4!cKcCz)DCa#@m6V|40>`ayoiJ^9QN(y3)FlF5o4bTF5JU`W`!2bSI4QPap zKHXt!??s04xZ!=g>)f z>#3BaydIxk&A3k{hLfi_wWrZrZwCUVpHyJ;tVChUgDYk()#}i3(*Ey+edV>C<7}N@ zw}r7PAS3h4TIb_YP_bAVeY3ElMPvcK*Y%KG^2g(9RrqsI08Vgu=b)q*9(UACF-Bo` zxga};GsjQygET@8d`*AkMZUB{jve|<7?_2_doigb=)zm!KP17=C>dEh>yQrTa~R<> zwS>^bg!Q)2a{}q6)b4LfQK6X(?h(gk*GD&Ao@uDXr;okEgPIxDLQG2de4@YK-&UAP zT5j|B%=VwIG1qNzfIgPD^hpg3mRXb(+XVT}E~6-fX&T31Hp|6D*=)Zax*T3p1Y}(- zB2FFHx@O3AVEz7j-t|E4TIp|F7gs3pZ)h*AKLFzXOli#^FX6$c`IW$0p3Yn`NKxZ8w_Nu&t!|2GcjhJ@}w0b&s2W{!5{K~E35SJeF^{_+#+~Hok1nzl2hZZC&#|TW z=qc~eXYExFtlTIhzE&>$YKI0FVX@&f(&U0U z5P4-a<)>eN3d%tV$vHvZYm#rv!cgue({d2iPZoIs)m&Q%*dM#E?x%X;pCz>(9-u|$ zK7YUA+1>gj^6cN{?V>1ZR?+Xc2r}eZ4|yHZ<&)3-YLS8VIm&=E8XV}_t5k--iHKnP ziyH0pGYw+j97#32D6FAtCxx@Oc(Oe*LO)dG*RG26uR549%Y~=@ul4elpMd&2ML}H_m8(uT;voE*RVG_Cr@<*H7gATNQgg+$_YlgavBEY28%W<*OT4H5 zb-r@RgR0M;lKSdSf>Z|@J`922EX+(Vm7jiSF1jhj&d6R|J{{x^QvIDM+1>qDHH3M& z$)3ztD*{3-k7@mEuR<$-%OIfs`iR9jAcHU^54s%qq|;*6eX?P+({4eUo=dx~J|E|5 z&fMo(GWp%k!kWQlOHK-Xt86h_0%z;huidp(%d;OkNMX9xhj?!%LNW7PIOoZsffOKg>*Y3f!9rf$ubY?gId^Cg>= zGOoZ9w67B_MX1lhxi4gdZZ^blkN{F56x3*EZ`NGUF~xlO76?}PRDR5(H!?Y95i8}~ zzd*NFU#(!c%VYf{5&zC<9D~bsg@&-tCWk`wowRJGOt;c! zT${JD9MzQizUCG{hl+}*5p6zc>qx0%0Ac@ib&o)>?=5u3+e zjhMAzwn9YIw_f-?XR%g{{gvz^oC}%-z-_U1X7y$kK($eE%z$#(y{TjvRJ^N_a?|># z(Xr32E~*q<2*YA&?XQIg(1+-2tYRMb_|n~`%E3&?F41B_@y%d##UsJ^|K-5n9B1zn z-n5ME4S0GAi;g}8Oq%1=);$RC-_xR<1*ipMjPE&-4!yT}C#mPYTuNBOziU)|JJ7(J zc^z$&SlnUbs_>UVA)wfrQCxc#PyBiEaqsx=ZqSt_`+_k_4JPqSq36Wh7-tNEI<KGsLOWOouysW(L6{s-~5%QAv09`{hH&XCHzIv&3(H~-8H)Rd#V*sDq;Mx z$b={hjf{F@Q%S7%LExgcUiET`YOv!P1+|zHq*H=lhNsg-Ykm^HuI9*kiz<^wpZOO3 z`H1(a`su7!uupQ$la0V*Ulx@}L=Sn=z9=Mtl$}h3MG%S<)B2eq2wpTQAUF(` z9StPaieE-zMWG#vL@7lsa^4TkG#ez|3ycP`P07j`f|5lJlH~s9h#V4e-!Hit&|wLV z+_45-kWhMVPch||8|10Jy0M9CM111hd_`04Le$p|6f&Q(N|~JF5XdzZe;@2v#xtP2 z35i{Vym$|r+bfC`8k?IRUNeaq`zCqzZ~rUTSkNehCTSI=nRmo#bSwPerBRt>kaD#3 zZgu7v-AOE&xN9yp9S3ciJXcWClh zuY}^Dkl{jpAN*eX`WwpkMh6Aw&eT4??BSyGIR&*C2BALp?#hW)dphz3 z7FRL9WR&c%cP&GoFWnpD1Ohe}B%xiObqw@ZW&DI?=;{esqbS1^lEd z)QnFU_cyhR4G=;P_fNa$boP8tlK3v2j*EPNy}k`(RTk0fiFkAEfshjH9ob%l0Oh{j zBnMP1;nxhk>OwxRT3>MV$7YT5(FQ}CeXE~0Xjvk8b%%Y3ZwX}fPeVE{WgeP+wXcFm zqI>lllVf*eK-IFfCEuo>GtS~r+E-G^g zj}X%Q!cl7fdy#eSL0htZ`!$LRYjEw=MUWL!XZMNr9&lNMVLyiGUN3ulrdkGd2HRJS z{7TxE3{n^Xs=|K>uGL9uM8}156^^#FWR#;}@sl)>};X2k8fzJ0|~QTdwMdg1o@_E`hKKnEV(>@9A*Ze%A22(6rt((Wl% z){TMElCt$}c*I~XclsN>zd(P2_c~^u@Z%;VD#%~YA-ZYN{AKS3irPUAHBd;5g%F#p zw8Yjh%EzI|0{|YP(I{5ci?I13ob~@8kMCFFkYY2H!)QWy>J}eNaD>*^9xFAjq5c-R z)Np&@NoS8diJtR)cQ;_kwrV)n=C!JKy!mzh8;VEq;I+ihUdLdJg~Nv(qj$R@vuuw3 zx~UK33RyK{C#TuSg5JX|hcT7wcTbINI%~Y7&kdMV8|lwNyqGxqOxKG+%U|MZO4w@G z*I9A-kSAThU0%#xvr_8@E)$&x+e6N7{$!;PdXu;i=)ng>+qi*;?iNYw0Ih`I2csKy zCQnH;2YTdG?6hpG;e&bay`C9c7S{kYHFEj6{fRev#k0r12RHF?38vt1Z8qy%yXo!l zN+5^Dp;fe3HBW_HFK2$ED)0Nv#4`z+bvtL>-j$h*GuEsI9rHwE&mWJCmh|4Pg*+~5 zkk5~6%`Kzf*LmKn5Mtpb8tKR>p(=u8kaFrPMzt}Y2r5XAKQJcvkL1^rDSYA= zMf=UY30Us&Pxvw_L~72zO`|8Mt{iFxTAvr*MECap`Py)-IW8h7-?;F(8=alzY0+MC zjmm`vZlumF?|w`fRi|ww+FN165~;LRHkzLoDrJl5dID+wzEBJfi{UU8F$!j}RWu@U ztD4(xsn7-KQgb&v_e1_YnVec`DVI;{3SbdO$2eE7=xvCHerZAB7#{-VB3Nz*yOI2N z`VVkFA$Y5w=-@1q*VAD$O5mw72Yn}R-g^Zgjnp+Oqvx);&2i%c(vARts&?o%#{3ij z(oiTId_MsGKOpKP77)$&Oe${0Se{d6EcwbZ_#6UM!`HCiOie|B9U?+70Hlg zmAsQ9>NRwwBZL#AoQ3m3-{V+LY!2*KX;S1JI15*<*CK2$*|yxtm#*X{e~5-@yWW}1 zh*{-%SZL{32-d$D0g@NDqaDQy_t*>dZ=oM0+dSyE=r;BDf#kszL_bgqhxD}Q(7vI{ z9%4gRA}+euKi2;QA>#P@3N?z_Ne5+8r1VAq>FQv1#;zzc$+WF)msIwRh0$LvzjZ4w zc3%JrhP*N%ftg&f|KrO;lZ<&qp9cgd{Bc>KX!8It!of%N{|-E4Do#1ll$kE%q8Zul zt3!Zx*cx`g)YSJ6KnvS}L!tJ4YObOBRK*?apbu&2%eYI`!MG#D{(s{}_&2u@A%)&f z+np0p5ELJP=DCAKGN8U^L&b+B2fphnvE4~n@QgvoBlVCyZYPR}Qsx8&yu6v>480;y zT1L~#>DR-mD)KCD;5&1^U6FEH3-dW?XK%B$SYg}P3l{WbW5ycFBCJzvZ|TsnzID9G zN?!OxH~#!r$Cw{c#$}UXD^P3uzL}e}DSPR`d9RevNd#ViU}&=jYK=Vbhk5{+`5COJ zW8q+gPj+T$vQq`JeuQGx;Sx(Ee`G5w%B*O_Ud8#J_Id!{o6SzA%fEm3Y5Dq;p%u!+ zeYaDtWAUM`3ol&CK^EH%7iJi6E`|Z;B7v|Zi=SMq z+(37B7d033VZwH&=0P6@P-2c0CW*)5IUEkn&B+5`7snp$+@Hx}S)+*`4$f2BBi2pMb7#{_1QAf5_43^?TA6m{(8{MHz3?kx-5fP3Of138gI9T zyWhDPf9@lwbh)hMt0zd>!DB0(==C2_V7@X1c{Oolue#B4k3I4Rt6t?3=OMpQrE}V+ zqL^sSC8*z^tosv`b$tj+5=bmJhy1pM#`8O3DjDM1JZz;KvyBt3FptBCAPL2cbXV#4 z|Mjxb-=}Pz8!CVXF4JnJg^Rha1?l;xaVC6D9+mN*O_@|pX~bCO||sq zRYKR6x}!6_xz*m`w-v#Si<>eDCMKrT#88{w#;;SaG_Bua_yo|1&V9 zVh9KCwIb*UeiiyVFnHQ>yd`3sfv)v4N=iupQ0@?RfZfM!2FgvAlym z|168!@7jx1od*-Ls?A|pB zi!+og{ScSiC_gJisuN;#A>#DyIf&_jTMB7cBV>^gvvST--iXz*jXVw&O8VxeGh#R= zMy>3((gT#|mmpHf(ewqK3??*ga5ME=M!$8}zZ?Hj@x(wT0fG4%Pz>uy$$(qXm&K?g zCU9WZ&kTLj`(PZFe~MQwE>;9vgaA)czpv6TGgdQ}4qcyj=mn&-2BmfNIks&CSV;7o z*wuBBcNYUxcNdwiTdYXRcOMjew81C#6=!GDioUpC6NaW5Idvmtav941eVs| zXrzMQOCJlr8JmJ1vT4>*+vir8IKnD~nvg)M)M$``ZiBP{OTe-gRWd@whZ-LyRNU^H z5D-p6i2Ofda%&U{127Rd=TQF%+Vic_ls3wOzCXlE`WXaO+#kNoJ6Sr+ps)VyIAZh;qTr#IfhRCPdK=J0Ei z`nWEm>;PE&e!tls0d7Qq4WER|5>Aj-ahvPsU_$9F@85&Ni(K{+g9R&jPEr!IRcZFO znxy0i)seoU9?!W~z3$F`HP3!rB3Ym_SvNRnU2oB0j#@NG`nN#EFK6zaOnkbI)HzUe zzFq?kB7a&v2d}hy605mmLQLn3D>Co4FB2GHMsggbpnD)OUY3b8`Y>^XXMNVqWsZZ} zXI_Edk(s|7#?{fuBzR%!xN!4rgKdzAc`Dc)n+MEeW<{pTG>?=*U+DiXS;!E+epL3o z?Kv&tw!C(UiVij~L2gdq_h``yMBgAdlk#YApzC!W3E24JLR4jZ2JOex@X;Z2GI9@x zL1BUr@eKwI+SF%U{eVZTF8u)Reiq>`*IS@)8;L4kbgNRt+mF+gJ^=er`Xd@u)S{W8 z+lx4vp*s^)GLJX4^?N6;%7EhE7-c~O4ym?QD;|MF5%DCA78xEc7oBbdj9mR16xJCx zL1TeEF7hg))Eb8iMiuaG!T&$rEw7FZ^ehWa8B+*#!vQ69S0ptD(MMNg??pV9sl!9ndF2*-^jdjk6NJ^pl)fuk3r3~a&u?% zp$gq~xVQ0X;;iNwqBc6WSu28vnbZrw58B zQf65imZ_#!Knl)>kTMvERdf;#=P3QU4^%NN@SCbX7ycn%6B>4q{DlR@eV8>y2n3)?*`@lTmyb=T4Kc=mt zm{lyZYcc_g#3g_?tgo45Rp(Bm;#lCCEf@pt1!qEBj;7%efx)$1s|hpTexNFGPkT_9 zIwqq7Oe^&Io8;GW!ia^hL96zk#fe7Bi^U0TbLi;DuFmrKe_As?Fx+{tN(%S&LFxEX zjJ+~|PNz%s2Zl}x0#l4miN9o-$e#iLVXP)NNdX_pvO;^w(j0yDg7V6gQs0hj2s|oo zU5);epy;MJU&k-0_I=HQn}Uc(096QlD^zctJ_8sdrMpxy+H0=FYHP+Sf}dHyZ()9{7k*d>9FfBho-OQ^R9ubO4zl-z3Jy!nbKY~qT(V9 zN;QYGuM!t*RG)Xnq32N>#xakO>d+X<{$*5e^wuDxT!=t$hq z1+&Bvw}seE?)s>ocm%`o>j zKf5;zWKA&7$6r+&W*ISSP+H^&bLA`)`@Eh+!%%}GssYw9!j3dI4vJtg`5ZwV#1Yg% z4h6p{eFsVkVHk%9XJWto_%l!##TNDDyA7Iw;Zsk>4u~Z1vWJ;J&wiNG%%P2 zz*WG-r$3CF5TScU5iK!htfaARP)w}o-QE>06Lb%8MqPeqz2mVG;5p{}5FQ`Rdjth> zu!vrz@9)dw3NoO?ip>u*F^*_Bz5g;J%twC21@bNIDrGA(Y+t!qUhHa6j&Abl=K+Fy z?W%>wgrBbr*neU*M!Pp7jYPoV zNC-F_A#4gh0*9lUfP1=OL2*o1-_Io^!lN&CHPrv?Y7+mCU5!Tb|LkhmhS(eN+RPbI z2#DfdcIp2-hKSQgppt8H$xBPb-@yiZ$m8piaCK9HCI&IrG7)HEz{(iM4CnAu&xE-Y z-1n6Fpubt|62ENMUM)to(jMYt%l*+r!lnH&Qu@V4=}TjS=sz1J+tkDeCU}xo%a?G$ z|2Ld#)bCsp1ZlUd5FFUxblHEw;Qk8+_b=F9z;F&a^-Pi_jToKuU-ZJ)=Ei2@KL4$q ztw1cZG;Fl9KrDtYEV7Nj-eG)3uTCiN@37njT3)|jQNFzH0fn{#u3| zRcS|CvT}0x28>(+@E{Ze*YYb63Q@+`XE+CfdS=XrSEYkG$@DU9zN@WqUB8)| zDM1fo^Bnw;#B4$|?`eX=GeTZmh}P_#PtO&3O4ao)uSr|H7-wjXCOxHe zQ#WVoy}Ed46*tIwtQ11)Uqa2zEM?l6xDV$W;U`MA#r(}zM;UpzyC^OOi&vwZ_(2uD1|H@WJWEPpbZ{RLezT5OfdAlg5(;+z+{|JoS`GKdVQfD;Dt7d{KPagS zFWy4nO&bIRO}JtL+81%263Te)QV$~c!{^uwbVZb*SsO33lINxs8Tp(4S^Wqro}Fov z%~dlaDMrh@Y>-@zB#hj9@Oj{8jr}67#&7)VMvAlqrWLr9+)2uFOTE0`{|tX}j1J{@ zC)vaPSsEzoJzTxTfZBEsqS3sG%>G zKa|xhz!}FSs-C491Kk-esHUToUE|Zy1P57w?BX0CsDF59N!?ed=3@^n1!g~l{;IU9 zaytc+^%P9mh|Q^q2Y0}|2Hx;L_Zq*@e`YUTWp*3}mhx+nJBd69%za`(+~^8f8f@Pd zbS=@^&?L5cmrcOWW}muuv0c6PJie*?d6@kli*7(nDDO~wapEzL7fl3CJf@UFbsum} z%mbplZI1mLQ4P9TG)o)~tFadQ!(st3p?;`$klI*qv8I*~lH|g#;17Pazuv{n8_LUf zRYD%LDvQfAY+Wob$4NIr{f#2Mh4G;wzFaYn>6_IxkoZ(xdjW$eh3ZZgp?{t)l+a1d zW`d*~c6sUhM?5ATdb)6(Sgwi6iyT*~2o@((bX9f6d|%CxZ~ZJ80xadVB6bSy#RbsD zE#kAzS-&m#SfX*GN^HGZF#$iDP#WG;w)NUK4yuF`?E5dEPK(EaFIUB?x@lj;k7rW$ z{xB3nljaumn$aZP^8exY+Apo`p3fOj*TwsYr-v)MND=?GG#&YCn(8r{QcimxS%BqX z-Yo?fnG^|{o@u%+9xa+4Rjck%CGz^6OVSZ z*<#Y6&eiO^E^R(CAbZwr-e)TW*Hy91!}l^~mq{5xDZ2u19(72G5c#k$N<+(KrV9|J zOiJ(XSJQM=Jj=gdsajPZo|B!QB&@a;bG$H>htHBJbXF*60nIlO7T71})SgTsqQ67)xhe;!HU_IXN6TiUiwKPUB8fk8ug z2V1b$N33~a)V)+@{P{2klIe)=i4UWrbB!_Vh5nL@NUVG5)bp=bWFOv+_;jis<(;LRfr!fw!}>HX$xW-U&n~n zL15U@3S3#PxLrDZmG}i~Ecy<65&Ffw?N29`7*w}Y8FlHc&PV~u`&G1DtHbX3XC|$j z4RKzJJjMB1v6-b*+GKPJ1>sVvmD~~a*QQ2@)1y_aruyX)T{l0lLY;JJ;~?~Df$rXN zJ-0APR#!h$muRnA!2U`p7?>*F0D<6(S=K6nATY~v^5JGtPMphAiNmh(Va?-Z!7anr zjsCh37FcI{%x&JW(*>Ygr*BcxVM19%Fa%Q(~ zwi_IX=g)<%jU*$M?V8Hf z+K}7JadV8Tvd9s_jAJ4AlHIrJn#(}-IOS8D*W)Vis=(Wzc*!nP>|=vozX;>v>j}7E-lTUvi$r`o#*&udZsI;G|m}XpYnY&5`-~9R@U&BROkg zY`?o7H)}?oPLAbtn@?3*l%H6_{dfB{t+5=EE{yCP7w2KUn%?d%OT`h6%yGHe|6%b~ zwIFyp;{Ce5tWb2zqO(CkSU++{-Ne4SQJJ)Z^u2;x?vX#sQvjz;+BF*idJDVSljUe) zDXWckZtt;?ou)l$WsPR%Fnn?YQt~MF@G8W>^B7->|FO)9(S)0i zS5VKQ7O8y5G(I;kbI75)IHrkA09Jnr2V#r~u1ueAJv(Do^mCmvQp@7|`G=ER(kAb$ z)nnv_4NDy4`RN$M5B*!FrupRsu|?e|686PjuaIyUHRSLbdm?qLAh(>vcCPK7Ei)xI zwZ43+GC>A@22JRzRMDJWu?{K=te@gR#qvhUbGCBlkmXLRW})SQU+_XDPs!lN+S?(V zU{+%`7TivP>?&dg7F`&{joQ%Ds#Hw$*d2Cb)9=qXRnW6_)Pn(zKFvYB&|Msh=7Nmb zRZ)9&vGohWx$i^)lgTFF}V>b}~g!RZnRbT&F*8A%xp zm|QR+jzHRKEvJsnQr_W~Uq3!#_o8txpT2&VI7SJaNnS9jj^If;{1Z9BlbpE>yJCyNF#?mpjxdlv`sWdmm@mILZVkEAGF%mnaiE_F>{7F|KeTK_rj z7XcubLju!Mcd`n_#Jzw}kIqaCmZ~7D*W1Y}KJ{x`UD?1^$_FHGoVCDKN)Xse1>9s1 zSo1OiF=a_HfnowDm5tYkzhg^km&ik=NMLSji_#E%kY%4^QZBEbj*K3)F#9|-o=VIV zyonywo^XTQ_!6bl_QzlI$V)P+S&JYZi%Jq9$ijS+MXq`kyGT?7^U)8qfDX?w_?MO6 zm@2x47nIy?did1qL4G1HOnYRpcg~SM=|*|&NVbfBC`w{n)Usn6#1V&-@<=!Guzgui z={>uH!vq86|<)w66hpiEW+%47x&QiAUmAQU#ZN$*~ju7oM!)_+*})ZlB;;(Ya8 zv$SQ$?X!+YpmBSw3$h7#IRsb0%TbF;ZrP?ZLd=tZ-jb`VqjcJz@e(Tm%Ji57Md-Jm zO^^=4IQsKleJVnFp{KYO4M72sIeL##e)+qr=7{9?Z}<1%UCbSK&8-W+>9Iq5e>MT< zn0==vIJ^Mhf#m|+&&KTwxqi?2g+`H;DI>0XXIP)@hM$=&wtZY^IAlrJdQ8z=mqv^I zOV`xiD1HI=jhu#?v%|}KUgk2Ex?Y%NE0CzF#NL9@gr_qc==(4u7mb>tKc?@vb^*|Q z?3CssgOS3Ae8EE^^j!!JGBkwlzec z_V{BUPH1^qmBHun1COR*L;+_6yy8F^+0M90fq*axIHz20A4-%M4QA0J$s|N8m0f!g zn;E1kplmtD``SJj`Y>2UpQnF7rkXWHUt3ZN7!;#;L+etfmC5e}9iugnVj#j(oOmpH z+~d(SP3`-%l-#OXvaIUGv2Ul8ZLL69%^aI-+ttbq8RiNkp?6o3C?d@|l$@ioduYcx zltx!}s1Yx#$)tdh)o#YcAKmp#lpYUdxu>kB^U6zaIi2~VOJ}U+sn5Mq(ba~f7fI))O>(T8&k8M=7YfF2&%ccD80iu^TP znR{X@nUs<4HR+;rm5t9qG{|<`z_}+$#Eu(SlvKSJQ?35n{LQ2?M>}#_t}0qF>usA_ zKYOE1wH0G058o}QrFRkJ`^fL3d{GWLtfpGvEQ3`b&YdI<;TZhl?(;gVuV28u3JJhm zrU+zU3M}yx`nd<_Cd87?_a|gAJ@m_@oX4%Q*XZoOnnWA=lZ38LohA&xoQQUlE;qzq zw!lePwO6v?e7NPcSYVE@!nC-JPnD&ht6&L1L_b7)S# zd9e>cO$4<(d5*s2!d+u^Pu`~yeJhl^2Htf$ie_L0l1mCV*5!Kf%hbAe=_>MF_~n6G zCKC(kXw-c*eEnvVq!?1A5f_W2T(l-U%C%?&<)L7ht+!u^UWg?8aWg-BBxN#$4*%0^W!3GOP5>Ab6_=3 zl3W;>opBp@qk(f(>C$CZ>e%ps&h^j7lO{vYdsV}wbmJl1iOxVe$9Vp$e@-tFS3YrI zk=GPH4SlK7WK=`Z#_@NC&T@lG-;MH=|2P@DsLF?|{9*_;xkXhFQSVEjGC2}TLl({Z z<4FUOTa*gefA|oHQ33l8NC)@sOm3`ezO|_9*svc)&auOAIAnw%wyu89aDnz&;`==G}{jPS_7Yuy&G!g}19TEojuRQj=J?>)DA2bx94 zk#(elfbWN|W6M?G*ENC@Uq|5kQ3iZJx|+F(Z#om^CdA=*IiGg`!-W*{h;$@Ww5uon zhywERX5^LrI>A=>osU2U%aqnAHo9Y?OWk??-QU`%13dy&cz-a&T`k?-4h@( zwbIi@zfmutrl}#b!OkAai%%N25IhIRurXw%%QHv^MoUjPLrF8v71-rU;%_~bj!g4#BpaT4=)3u z1$S}MoLm&6z z7@==fi=zykvK>>X!UEi8d)+2amB*-w`@`=Dv>Ey-gJ&yO>zukfF&@&AHo1j zAZQMwaAn(|RUSc+$mF)FpDZc+>kd z#3bb3A^=NP?HZ#nOjMX4!8nvJs*sb#VFP&tze>5Ey`kDt8~HXrbZ}3Z)n+- z&^LE|mC++~6?(Oie$DUq&mm6K?|%+)S;D&jb>|#*ewevVv+zLusMp>$_iUwdhL!zf z+q8~fe|epoE>|IZ{%l43EPB22Q>!gD^Q{}mRqtT-zk^k|^T$wxrYcJP^{X*m>v`Y{ z?{;?gKJtrAxavMKmOOa(?ziBI%V_g!7Juo`89=9ZJUK@_5fQ)mw0M&dzgVN(;|I*D zIfg%a=vb9<9sclQr?DO}DtlJ(@Zgm%=2;RWN%Z^`CtARN2N4AXr6ul&L=wBAN>X62 zUBe}R3tWdm?|c=*OznV+Q3OE~kdqWa(48%@l2+Q{i^lOR-LhP4o(T)*sGP z6aHjMWXl;BARQcT**VYVN~+5JyRzf9R2DLu_osBkpjxRR<9>Bu3_n)sOh3`=$AnwO zEn0AcZe?n7f(YGfQCG75_zPk~@a^W*cP(*-mPjjL>Q~JabOR=EAEG@K@ph^gMH57{ z`+YA&p(8GU7tqd%8+G&{L`_0Xxx3z4Km`t!OWqIN$hAvk};}d)tTl@m=>2fSaN3djC#7WrpIOeZeqE zrZK-(v=i22-?-#u|VI4i-*ja?a;x={?FB({B;U1-9kgy#sDT$QqxVf_@%7~L?+hnKYteu z=-qu1UkIfW{$+|tYQ=L#kV4uT#l0zkn=wi7rz}36iXR6DrsP4wl;f6?1YQTZw(e`-uYjtm z>)ItH1(6adX;B2FyCoz=y1NfuhgL)+8oKJ$6nP?yWYUO{QnlIct6gb6DY!4w@_)cIKlNjT`Tl5)8=%$>gTE_vA3_2_ggW3r6XLq%_uK3#Npyt_~VuqyT4$uu3>rQ0*9eMaY!edDq8Ir z1JCN{tnb^KR>%T)Z-YG;*15oN=p-1wAngwHz}zoapZ%i-HOKr~oZf|nza3zhy52tA z9lkxU;PTsFbz-PsD8ko>op&?%0{)DIiGy#tw(MI7G_RS%%8kr}XuH#eM`f0(p`Vs4 zDdhG-rK&;M0GA}C}cKt3vnKSNyL{u3jWeJ3!)@h9^07B&`pmLJs5b02+`dV+6 z`BI5fWhXA*r816Ra%Bv#i&%Y$>bfH}pG8fZ$c0XwI{*8$+8q(Jt=WmsqC^q~?A( z?uDOjSwA1vbT^%&l#qt*Q_o<;tmrBl@)YX>0_Ud=hNqg z9NuHXsRIb@?vzyqggNEZoQV%ODjuTN0K3_Hn6{D3yN@zx(K7Ey>XjrLtk{G!;9N==j>4QzGss&$4`A(pqT@6)qJMeO`uBX zss`c(IitK|i(vt3*DV^y5AJU;+G%DJj>ZA~5mjIs`NsemhAJo$CU6IGM>!1iM&uh} zkctbne%i6WzKPy+2^VPIZdoO^rOwgjhN^p8bv4~{=O`4UmzO z;V{hIYosuTgTw+7b%m8|vwi1gc}Kfhuvn;17yy(fki05fWXGcOHgueC&&n>n_5Spp z&N_^3*H7A3FZ(T*V$kM-@J<^4!YFd~#dtS|P;f)#^7es8!|wZPkuSu3)M_)|@?C~i zoP6%}27h?vpn??y&HP|TAob?A2}WSG4QJEVT~w8$18wC|`(0F3S>|E8^s%n=?tr!% z;YaV$Hgiz#W3{BDdmhoIdlo@A37^F51~9~E07H~>pv=;lA*L^j_-Wn+-yGjKF=E># zy?^v@5$S*aTIgBRmJAWE4d<0RzWQ{^OW&q1*dN&=fJ&6;Tm_43ozu&j?Obv~gno~E zHOFz+<*yo?_|4Aup1Nzf-{7I&qVg)?FHCgcC&GKeycE8)PvU^5Ps}QzAqZIzB4)LD z)oo6f-;b_lIglwXn+%YpC#Vg;=e1*I(!OJOSc9>oT0+jb!+k$9_CkBGs6MWSnV(dN zT?|E?4~@SXa`bE>X=;eQgdSu=f3p$(Y!nG5zNS{I8vP4r`+U=dpf3xDsqCfJKi}mI zKX&;sdu7{jBU*bFb1}GFaJW67o!5{#i>}t0x9#mV$Qk71=v>omAfudLP}WZ~V;<_|;GweBn(neNg3!LdTN8e*l%pD8lB}iSo*xrT^I-#&}r& z!Kw0nvc}~>d+*Xko+EqcgI@g+x!7xNlQu>#ZzH7n5f1ths3WaZ!5-7&Qgu`c4>gv& z)kX>62=so=A4`%}XUl#tor`$^78`$KBfFuvh0*8^%MH%xB6Z~tKND6uOieh`UlbA3OFw&?GqzrO#<1% z{m$c9x_`6_fzYf!edhVcclBCjvqlXs1<|{{AYNHoJ(%k-ErF*<6r%w}0HGi+T>C$o z#${EdKWZ3`R@`r;go4t745F;F{h$2g4rdG>C7du?w7FO_r*4s3zLoQqIag)#Uw4qANv-qJOBDRo)Gc_-Dx+mQo)@lX8=e#>EB5@xijhv2BYnN z$*QS_yZ>~eDND`ggX(QZT*0`{{ao}QBwbyD;q{isY$g5s5gPe0VgY)yImzpqTs+89 zY2c8Isqm^-i>=30o0O|?UUvFx0xCZGCrM<_gA&;GZO-qEU5Tl=1u%Cz-!b1 z84ar%N$*-8vTAt=OO=_FVmUK7e4I>pWCOSt20Fo)xnZ)bTD3D=#6>h~szuGHolSsX z(1%}4?bjbY2B+wK{N&!EB>Vxw2ljvzVE_xa0_~xFwIT~t@mZ8GXeh)*451rTun1p9lPywSVY?fX?Qvi$r2?)ON~v`y{y^YZ(WxT2zv zM11q_@_l2MewBt@IqY`LkR0FMy1zr)CS}S^s%mw=| z*{`RB#>jG;w^2X5cxblhk*4_kNdoWUdFEG6a_@Epnfne>?7t#kRa4K60Oxmx;Exq> zek&K(%hG=hhUJ9OF$iP}go?~+GR%8-CYW>{LYeuhzIb^V{aJQ^*NL$ODE&MX+g+V* z$cmJs=L@V|5=U`RnJ08A^6ek%E)Wd9{CvPiiXd&{C_0|I#7e9exjmgFKJUnzyqFM? zFlU|%ssjG+0G4$LNUW?n=YbHyMsoLy19{~!j@U)AmKAAS;}%T`<_UB~ZAM;y#3 zzKiK2e6CTxtVMJ_@y0J^2vu+4N-2nXcx|Q`gvalBfPt6*1JS$_yK7o@Q#Ug!k}|4G zJWH|3pkW`5#5}7ibKoo%6}JLDtTyaj(kL@gpnD?X@$*+X1k{zd??jqRUzOIle&r$Dp9yn(nkClx9GbWbp0b z)9<*dFSG2Ua|e^x7hCZbeeF?ke?IHL@CY;xYop1XX}o59xFfmzGUE=d=raA3)cLpI z+ck^d=pL>CMuqCS?lDI8J39oM%ju89w+GaslW7}1Hcj#rHCxwK1V5FKD<6%P^a;~i zu9+Fodij0(hX^_53YQ1Qs=txLvB3W0_Oi|Gr7MS)=)X+8wU-(;lo^eWf1PaLY(<2T zh~AbvaC!-gueUXL_T~tr&Hhw!v$9MY3hhdG5Ik0kM!6JhuS{(g&DXTjW(vtiMgKJ1 zd{@|k=^?!NuKbq@(fMb2k`Mv?Hs8GZmoMKyyQO82CKy!U5Y7Yon2 zS)}hbaRkV-i`J<)MCF3KDB^F_ka}@M>!kxi$-s+&mi8mx3G$S%Rm#?3N?I(W;;UPW zEBi*PV(riX-KARRqoKQu)Rgv?P1=`Ob^-{fZHEB=b_znl1$$ma${Hm=%bkQo*Bb7V zko{BfIy$o1FpAR&m-~UOQXYw#mu&qAjjTFv>GQq4$((Xn85M}7m|z-Hl8JxWGyxJ;29jwd2~r)FGHr}jD{C|(JjZ`|YCoVD5QpAx z_A4#~5+BaAD&u|AHI@Slk%gByCyFDbk*?iE+-l1v~iDm(~iDK}6smh6Ul?IY2h&QadE3RNt)%ljwlPFalKiI%jStj&N111nQ=@W8$}eC77KAC`xPzk@6KO!G zp(e=q9S9(MVC^do*FnNooMBO8mG@P`Z^@AFkqa%gL3=^qe*f&C2qcYV3l(Q?xM9^0 zB%UXB=0e@YIC@ef&rE9d1LS+oJ&x-a&MoVW3JE(K>(2{nKU{<>e0k;oT$yIkmgE@t zwtl42y;ZEw>Dsy4{Iu$sqs%mOzHy}IM8_+21a5t-_!lS=cd`s?LCb)L2=~J4z2>n#9_BI?-;$$GJoFN0Tjx4V~PJ-kbT#@gV4!FVNNB0mHXO$a@!Oy;!8kgHEgV zFY10k7;r81jW$Xgnb|Ubx^a>vl{a}EAPl~asje^FY(;*!x@IwDZ|l2b;4W5%s1cr_ z4mkFvi27gLM{x-#Kr0+K z`T0QscL%D<=Uxrd7x{Xry?*2>R$!g2-|PvHnrfOJKuoZpJDBN$pv5DxCsswj%;J zbG*HmBkA8?cIPAFhtT@agd@sPK5chRmoZ%NMVUuwxl4F`X9VnJbjcM&G&+pxjUG6m z0s^hA1V20m?Vbp$MuUQo2cr70*OK)QcG5c&&0Gu~sMt9?Ce}nI$&zY{MIic9d(6w~ zU$`gDa+;K}Th$1yO&@v|c>gj{)&Z%CC#%5Y11qdZI}5C^rwwFZ&w9#yqlXoDtwDB} z^Cck;P&jDw4Me$9I5=!}0p-)}zQO_(*1aW|;n3+~Zc>3zK`f)>t_)6~&LaC!#0rKh zztraAgZq3J=xo)|M&}*m%s#CGz_9N{(IGBE@})QlQ7s-3>)P%*3ToU;5kZ%a#(>kg zJ&x8PpoUGB+?m^M6O*&3QsNdJ!#2oOsHOIJbjMxQ5+lJ_b~c+7Ko3Hj90D}Rivc6P zF<``hU;m36{nn>5{TEL%-3z859vSMN zSsu>jl-h#TE)H+c>p;70DpSSlN+5mxDvGuHu-te9CSZjwUxt=khV#`Dpt4_yX(xi9 zM<0x(pA2GC@tKW$MLp*))Hxv_On{QBsQF6VhAh<6^v21C4CmNX)Z>kXUHE){c>Kml zYRQsEp|~;^k|^_7#%l1Vn>wwt_9@(6L{sC>C`Yon4(?zd$ZjPPsv1T;8XW!J0-W?V zPfI&vJA75~%vS#nhG=S4F4e^$Dm%|i)j&p`a+t5}nN`$ijQAYr)?UYGweR4}T#E3kbJ zld)l=(Gg8l+!yG{W1Jc9gMb5?DEv&fynUR$kn5@TfZ9W6DXuq3F?kH=K!yTkb|=YC zzuz(5vlnu(I6r>Ap+~sXx~#<*OnR`tq{WCh_NX>w+g;6HJ>k?1(r*cC}+^vdcor5L8GP9sECg|Jn;1O%sGvJIPI+R7I#~pQ%>jYecakHw%_rc{vm79N z`P+KB==Bm8rw%)2sCDDbrz`N(z#^OwRvH0|a8f%_ggbP&3!{W1M86rnJ#=pv_lfgU zS()a{b?Cd6`4Qlsq+d57FwhHA&$!=;^JA~h7im7{7q}Rv5rVnxQeZkK3Q@A#e+|JH-PoDzD!9Lu{9 zO#UfA{|_erl!35Tk8Szi|3N1Wrgn>>*YPIbll0HD^<%7FqJq~7@KSuGO{+F_H+}D$ zwxTPZ_}t30#fuIHvALX3J$LUw-~FrnIm+POUa}k{0``(O=U(u9d!ItigZ0GHuce;_ z0tcfHFNy7q%vQG54Da1_kGBjw_#WWFf0I@7tMU@F+g5jVjjfwdHXP6jFIzfzUH^4O z5jk|(Z(1fe(Dj$50>D(bj_)6_Wm4s{ZT4G@89jOEd!ftc?i{I4{9sjE;%HI0fCLzB zE2BjHFOwFoO`j!PaVQD|JJJLWb_%#VO;w~^mo%uY0Y$Vmpoj*pNpVk?tlf$t_G9N; zDCTsGy^Q4wk2Q^TF zilxF#(%0`2DHT|lGHXF7`4n)OfvVV9tj$7D_jtPRrX@dJ2g@hSlX$qyxw1IEAf4gK zP}F=Wjs#LQ3)fCaQk>(3`tY4M;kHi=A)@E@T&4Z1(nt-V>%UrJ%<+|y!~W0!El(U6 zmmorip4CUke}i%mrk>NEX7Es^326O^L7_J9Z61e{MG zcA|l9sF|dc7(N%XoMNb&VU(ZoX5H`ebBVm4S1U<9bw=zSh^M!zFY;!Pn>v^Io94GT z7sH)&0BltKJu$Y>k5?_$UrO#+6jew<_0r!-g5KZ3@-7C`{WQd< z7)Ct#W7wwT4>Uy={y5_IS7?(hnu#Dk|?JbTj(Bt2jVQU7^an(Bz2w zi}wDc0ApL{{^f_GWV+`P!DQxsfs$Z5{(Rhw3oz*xe!{_;6{NZpT5tL=OfYFV(U0a= zAT9-~OUqY9%j|EBj4q7~H&Cs7Sd!jv(OwD47(K|Dpx@UT@9a#O&Z1xKpTF_{jZr^B zZk>K?c#Iu>eegq_R99Zf;y?ni>0LJEdrojl@;PwRgJ>R(4y_FE4Tw<}W8Y}MKnN9i zrl$* za^q2%0`^yjs0mMR#I8f74qN_jOxuZ9|7Ilr7Wi1xZjFL-(NyQ5jm30!Y?OwyJcbI^ zR`95H{AwlPvgZ8SfrQw>VhPoPPs{SDP-?5io4;KB(0JHYAJz+1GBxlrB z)q9yWa&52rie*2u#1_TM)f}JTYu_T#pD#w4E*$iWNby}6&(AH0MeS1Vi*EXx)WnNy z`sUl{UL(YAu5MNikce8X?m>(M&3wG|V4e_jiXYxVl1{P=Viycd}ryYa% zv~D?|)#`LcQ;qm@J9OHWz+pg22_rQt-1R7QEYur6$n(x6?>Fx601cEMNc06wL3hFv zDp4f*fkR6T79-T_w0M@W_Tt6BW@U~Q?4&F{3GpWOY+jU(s|xlg_fJw}+EaiPHx}Zh z@M}YXkcaMXFi3{^PJQ&e#C}D`_Ulhb9?$@grh{o=C8S6Pc80fiY%qRkH(*4cl5ZpS zw9uQ0eXAkoKK?S+r72=qsZ4FpuX@7X(bLLiSaI^R$u$~$XbpF3Y6iA!3$GLKO%h|{ zCA>XOb@B|%3D~#~SCde$CTLMDtSr^ST-PU3d*9uR=JW;twEyIUt+Y!%)T*jVt4dy$Y7b zA?gPQC--^+l~*9IBUPRBLrZ8I4FA%Zgbeln#(u&b*Ag|P{a8yf z14@Pc#W0rc<4>-ZvG`$6uWoCN$rh)$lZS$vU)NZ+62(6f6cvuov;I`V{XC@TvNyKJ ze2<0uYJ_Zo>~nO@iAUlZRQCmSdO)<&y0&gb z+FH8Fm5JL_U6A;3_oB4*Qr^+Snvels8Lr-8H30j^Yqq&P6WESSE!jjJ6(}z?49Wh^ z%Zeg+sGpgPP3ICc5cpzRYIVMXO&2IUNd4AgLw~bsJ(aI$lQi%aBI(DmMr>g^B(OIl z7V`04%JxbEaSD;oKfv*!KZ(;Q6oi-l*LU*nOqy5tmuS%{ZVDQU*C+Lt&k9vzAAa`dXeSU;%GP+V>p?Ir3hCKyX~Ds6<@b6q`ag}{6`mOg=mo=4Z4cQxivgF4eQ>| z6m>E_;IyC(3!6*D4~yx!(;M2;$YXk;)mbD1jE z5stqZp3wFpJeDiLe>$51&E)K#@`Bkey#nF5{xG`duP>hXy6*2^Z!Pre^dwzVV--^E z2cV*#eE#F%Q>o9=xYYwWsHij8_(Ei|f`#{U{vS~ruD^OozC60~h<6OE86umF0RA|2 z^X#d&l8?p^f7V^fm|5|_H#*l&DtDH&VDpyyRRWQji+9z-u#Os+DLs-F!%0k}gzi(a zonVJy8Bg<+$nc1;?+k}Y`3yQZIENBgbwDIY+5m_I?M3DP+hxY|H1wY?OPLicP*Z<` zFwxq{DgUq?5blW>N#wPG6PDzDBks31yk6hgMBJsQLwDvkm>*NxeWrfqW=f%|EK4kC zkyt4}J?_?v*nI&n{hsWv2Md%hQ{&*x_AzRj<2DVcb`d-q8{4~6#Yz^~{>9Mn_}AV> zH%!<}B>xhjxsBCCU%o#TPVx@9-CU?w$`+KkR6f~Yi-Y_9FiET zeec`oaNnB*GKjM5?|$vXY&FswR{j@gOpkBx6m+n43zG>%=edRd5wubEdH%jg=6M}M z1azSK!JHR})ADZ@38asYwX8q-XE=XKK22TXR$yhg_@+iY7KqfwOh}_~;7c!INyft= zr2((DHUkI784K~~)aV`I9+VSp3zHpwhJJk4-NctQ{lYB*(U$+|&co+2;I6yJL)lP}E+l>bypTs5=r?qZA)0J*v`T2}!ax04(K&PkCOD`_*8t{qj< zhj)rua9sJRXN;lGQ*w=r=?4#pi<7=Cy{_h`tL-OWD@}Tm9?wu4#m&A&pzOTo1#_pREq8#|&K?@^%CAtT=i6!Xwzs$ds}dmwpeJKQOPx#Nj#B-ql1^o?6vN7Uc#bU%j!L%3Noom0y-NNTd=?`xV+9@rW4Nl~kTi8Ty5% zqXK}Cvw=^m418LCBpH*uKHduzowyXs$4R`DVabuBDR&c9TMtasN|vC1S>f$39D1KKCp@gx6B`DJ5 zMU}s2%g3xD5Q{%%2?DX%;A#^*znugl_vO;KUM9>DcWXN+e-Q69+GvD46l`*DGc_X; z)V2pjG#?{bc%v&OD1WK&&n=*jX_n~>y41iyfBz!>G z`K-?Sjqddn3v1PbS_e*S5pnyr!rb5?=QbI%&@bsOBd&<|>-AE7zlw0od2!|5bk1gx zjz#r#pq3$;OBsL<>?u4MRc;~s@LXGrIV^c-wD@xS>XKDuU9 z*ZtBUh%5-9Zg^EN*i1(bta$7E~j0#LjuR_tR0s>cVD=F}AJSTa%!0pdq zR(_?n7y4&bmQl-3doT_Yj`ZRQy2Wq*gH{Nb*f3M-aiO)!5EagCUYj$cDIrnz^^kMU z5FMPKohQM_HXr05QMB=alP~98sb%;dTEw}yXI&0BQT;lCD|4@j1u>%!q)CWASKMuG zFmoDKN+M~Zz*78t5rG~vQ)tC!x;v!2BUiXM`atiR%Y_r|Ad$U~po}WYiPmzoVp)!% z*Rpyk;nBs!aFbmG_3OP%1Iu@{aYx?Ox4bGpolgDVzpkB|VhZLeOoL&n@8QGz>-=CeWlg-hbIBjEyW+CD;e5zN+REit7p+-1#p&eJF zvOxr3AzluHfd?}*JMD)RTXKtnR(Ur}lyzDsi)lL)8Amqg$LnA0&*o+XDkV;vV(38R zs|IkX>T;Ya;EhtNHN|7g)QTVx=OKsYZ=dC8S)s%O{O1PO4qr(7cz>&K!ocpBLGBxw z#$^N>(}kRzhsV_}O$SUp`-`>|X7-#S(A;?GA4nP6cE%~XXDx>t8m&kY!`+YPPPx8} zythdAHX6s+o$o~FR|Ku>H)+F;;C+*Hkd|*ht9UAJc4>PtOOZE!1>u}!7oU$HJf$~K zGmZcN!B#IH!Jz$dEqN>9UCgtnuyQ45Cms`|If{RvI_L^bG)FF5sg8EeWbh%HZ=h9Z zdk30tu@y*TqS6kQWkLp{WkfrRYCJ#fXdhJKc-1lmql@b2yUD*todqgfbKC1_5?8(3 zE*i=w{047nmRFhZX1k@^kl@g~85B_hswBxVhl%p?{&*B)Uu2pKr-Z z7%#jl3evyk=SnF?VpS!AT_O^z_KufpabI6)%7e#7-(ttB5nn{2D&)5LYG_KGiPkx#3;_uTf!>P)ZL;L~^H283R8A7JWH5XI9i z3qS*pLHooRzy&i7(!v0&b|@#AI{-gXN|HtR8Q}v#P>8@ySaF98=wF;nDu+0ZyPAJ#L`|3WJ36WL`dWr?vEiw4E=S2pQ-~V!mIuFPI)#mAlc0NLbGq$%s@Wj$+F~|pk-jUb)kW+!bEo(EbSdl2_qzW< z6DDdN9-mIOr;Y`%Tcs5FoQPYhZ&W9JGkZ zydqmEY}Ei${t(AX@y|)4vp#chWbc@Sr4douR{#{g2s5?=Dbf?t{eriDDr9ujV_=%f zuV||-u6Hwvj3tyoWyy$ARi@JpvwrmJHRiAJ(17!WtA*C(@C4U@C@P_dfQ!z?f!g1} zo{!B)ugwOZgqIhM4k;m((W`Zhv){LQc|4|jEec8RzmXhTc&fZC&Yb}8d>mLTxgKTNT-|mW$-g#K;&qDwgX&QW;SG`Q$+ji^qfAv zPI9$?JtAkf-B+w=KwLB|AH8zy_X=khL<=EmxE|E1?NU7(KYh9FqQ$&hG#Eq6r}{(R zcry73jlVui+`>9qvz*MGBvk7Rb?*1a$j~esg25GF+I9%`^uT*T^=vau;++(9y<|;U zs=laqo~dhU;&k(83F5VD6Rjrg9nR8v)Y}XP5&U)+;lbG7B3d2kv+`;q`aN{$d%SO; zuH4s6_uYO~6l2{NXiRR0cToHsbL{*L7a}%&RG_e7I?k8K%f|Ma*q^8QhszTsq71k!s6Kzh&Ad)nQC#R(g0 z`1fJcU%l?M&EKVmB(K%B58!Yc45D&ct_}Rgq zPr8d0K-%~-*O{}2D^IO2pB+ahRG*vUSd)ip_h=W9{EzVn zJ;A~k4$;wkem!g7@NqY9=R2aQ8Y$wMNK06$54_lP*0fFZG9Phz^LNK3Z$NzPRg2Fl z`8%LDge6xnVNu%W6B0L5E|1#hvl(;z)XSa-JsAOq?xI-TA>!AKtw5|=O%PtzGd1um zJP%z{FXuoaoW%tGX$NclJ0h*z;7Kc4{YSmLW>)rLlAS=AEA`%c^=2C5qwIABT^GD- z7Rab2l?mA(3E?x8p|5#~yu(c$>mMw11{wL%Vp}M)GY~FD4xY;p+Tczig}a&@r|;T# zH91u;;!3N~Qq67XO6fv$0_zyL_uBY@xKc2>g&N~*XzM%{)Rc8bAcEzM2TX?~dhnqc zmaHU#XE$k#CKr2ibfHx7AptF;r#+{!NE3Z~VFKnKiFQ7)`Lc8oiLzQ7nqTCoSPngo zmIdW`n5DU_C8VnPOotDn9MAFdo8NavFk8_?P-BVSIx zEm@GuI_4ILvh)jS1}Xa{bT(DS4w<>3(j;EiKq%gb)gD*V`Bp*&wv%W{{)b{7psdQ7 z29S#`r4>Eh3mcHq2bkpOmJCyTyP%>WmsZ*@x#$R5g8NKNKPTX-T%?e@>S^U=w@xC< zY6wSbNEeaeP+En-kCv5}Tf;O>GHr^-@`yExm2x0kl!#ChJz_U9UY%5G<0NAx~=cZoIznItzAw@F}Ykn@kYEtzkqeYfF$HF`e$y2j#}m z1lo!V_nj`V_e|^*=*h@2956^1fXr zF|N6XY!~}0zP4=OM;~_#h(?U8JJK2`+H%c3asSp!ItS3+aj<~3qOc9?MYd2WT2jkEfQ{B|m`S=RY1^$-0P$&nKX)l{HMD**kXDk^pFQRW6NW3qL| zRUNqI5zjDQZY-dEbPUu5o|U9yu`ckehACBkEkS-qmz@zNouMq&-&eUUapId2FETK7 zfqH~yI;A^WhbgdON*ej>Is5v)wVf7(_I+e4rOEf#RbjNaZGB_YXT^|8VaahIq9arD z!<`qRCLUgJ8QUq?HSf%HK(Jl#+SIJ%53r{NfbdGkj?mL&n^4H_K@oiAvN9lr_Js0y z_}Jk03$f>G(YNpFI|y%2icU8SwLHh;m%ZbCr?yU$YHu$I^WJIvU0m&#!Cbq|n(Y{O z@xMG1(_CKlJFdK;n`CeFh1@_JtBcGuW@&FqC;jthTNVhf(+#bUuTLf^z>qu3!!R=k5w_PDA$^-ohzM;AL&M@PH=*00rOdJY0K;s%5C_&*vSV*k_l-y#3sm-w&4|Gy{2 rqyMQVfA0qK-rXv>mNms?)&e%~K>D(Ng)qH(2fX?|{rP0J(;DJUuXF6Fs-LVQO~A`)g*0R`Gi*QrNmp{aSjBhnKmt=j zlqo_)<|ecpmpSGnlNF})*%*G?g|!9q(*rW!LbF-b(JrE9b4|0y>KgDUWEi(xky)9( z`tC`hZXM|g#${8_mTVp1|8Ky0%v)iW=gR9<99on z5_~5@Omt=Ts!6UC+D<9)fPf)KA;mb>&c0_x9BhnCWA!i~7m;%$lmF}@w2>*-9kajB zWVp`E1%QCg2T+kpZhIC^n*;&vFpfAilEwO#^sFW^ItfT#xMo1@ePeir6k(#@5k_V5 zx;WxckcLNyr>AM-frNk{gn@ui_`hP01jb(1!Pv@?0rdB^JfT|(nh6l1OF7n_VGWCJ zz8s0r9zF|?o4B-Al_4V`w${_T;ZDuQc@e)R95_s9_cSgv1X}#DgY_n8*XsslnE{M*|8FH z8Qt@DMnn7DBQ^9y+VLjxZs4~-Zi914q2`mepYRQ~{`vGq zx-xz`E=yjmoDK46Csc(u8_cXoqT)8+Euf4qZ@1N=Y;dCJO`kG;--=KB!w`P(QDg|Z zSt4HahWd++4KsrD9$0rNsQ(Ea0QeV1wuTB0wswvT`gV4IX(=1i{Q*o%kqaNuq4u?7 zL6P4{0SMWrg8U>uR@kSkgleStH!^2;#u#IZTE;84qiI_O%2yYnu_V}|V)j+}h!>72 zc-obPKcHjsjOBl%X>`z!G4-&M`R8(0<+}kB48K|NN#w7+wVP*Q&$d!rI1#KxA20Bb(N*0#~kSH#zO)jZz|rHO$L?Q z69*UvxlIRd^F;^6Y?azagt|EsR%^9gqDsh_OJc!*+&7JIs9e~#Yn39tns2N%A^ad= z41gl!9sV8lQU#fL^^QtEEJgHMr8L9(Q@PsCz95QsV~vk~lsYi`9R$HKr!gJ`O(c*{ zqqk*bNVzerZ122wZl5^QCS#Unw33WNzfl!AE-mUaKG{=QYd>yG{{!BssWYwlwwcV= z!iEp>FN(9={`c@;m#GFn|L-Vbfl+j`VsJFmcQ7_mc5*PcF?IY4Z>2YnLk&h_4|J#!-7f$i#SXhcvSoLnHB=;?0^H?}_>d@*XN zMZGji-=(8V{dHJTJqw<5o&)>+D%myw{q7N}AxYt_?nM~ZXX>g+T0@}iaEsMHWw)>e zD9D_zU`gQ->^c{z+`w{$|Bv=Z`QMT|xmy|k6S-YQ);5C?x8p)heZJx|g=IknH1{uz z8PuhpX{_eU-Q93ykI+knfp1Uk4U$r&M!y`?Q6Fvz_=($i9b7mh{E5=4wMsuSfRv+B zOIY_xhA;1B-R%P}B3#p)3-r)F8=^uAEPZU8aBh?|C{30$U~nG9dQr9{4-YIi$5_D= zE50S6O)yTcz>sX}5iRu4kTO;L>AC07w%Vwm)uB{X)6zrpd(Cph;pO^O)Z@F)izuyT z<$_rdv4!nV5fQ2^ksQ9AU6S!z$#eu+Dm776%Ui2+=$L4-TKU6xgxnitD1o2B>|t~x zaBxx_f;kd6@@tsgjUmq_vJ^l=D+X_JWNU8f=HFC@;@=;5hpv~q*ln_omfT?~*Y(iH zZZD&PVZyj<)nA;N01SLtwpbeCnTBHDs|1zX@py2Xep}=t9>`@D_Px9r3~>qv!3H%h zDIX~V0;*nEWk$3b_h-VkXxP#K;v8IKL)M}e~DB) z7XEQZiJLwmfyt5WJAu<|T31?YHmz{+7@G$ynhtZy!j(RY4jRJ3qbN{JpbdS){cXLt zX=09lyyGy+vir96hH}Bjv0~Ai195D4-1(y4Is$cqoYAE$7Ch)=SDdQYWs14jah=;-wgwGS+!>WW^Sg`z&&- z4$2Rjm(Q%;+xS2ISx8;q^%o1{*<`KTXN-FAwk7n#^u6hL(B^Dw&<0`PMh1=y5m7$L zca`Q>dP#CW@EbDV%?qBJho4~lULRzLDjMq@Mz;8*KfSTD(xerEv8u%j!83QDXhPjH zMO7Rh()aDORh7SZP7&{m=J<~fyM?%R(M)v84Py1UarP>7!MP9A-De0Tj(#h%v{}0>$a_|3%@PBzYUe>ag5n13p zV%ppOcQgb>Kqn(wlz4HR_JU0|ke>~CZw0xrjxfS>M;Gku{ z2IlJ(oCuq4R=vA~6u0SdG=bA=arKx{hDIM>)Q?2dS~A;k%kTV%LWW#NBLSlNIeP{{ofi zNq+GhSasI_G4JC3zr=GiGd6Z|1V>x&8`EC~p0=MktTfFZJbPCJ%(Wh;otGpF1u&49 zcFNG!WGz-3*z#m$e<>@a8`Y}4#NdJ64)-J{Z`w0sOvP4;>_LBl)L=AYj! zjrP8)X2*Zm)qE6F6*R}j)wui}L7)-*^Q)N=_IK6z`0s|q9VXAyG4A*-vAsLyUc1oY zH9W|G(6lAOkT64bvCLi)`!TU_M_j6yc~1AQFK$;k%ZhE0u;ex4YIKSG#FzKMFBuQ| z-&S7kDSVucJklx>Pqe8Z;y#S7ZN#ugwnKDJco0`6bha%c7S(LdZQBMvTCTqIHhK1RPNn!;pp2Zg3T?g`#;sG=4HQ930!3PCXl^`I>RpE z+4c#~O&ol4tcgTYWH?HnjccUSUotIyI8gRkWUo)O+g5BL;VVvnCT^*jA>DWLO$#>1e7;{^jSV zw`CH)&%af9bPm!j(zutT0{Vq6$T7qY0*>ME#fbUGfJCHL&w1Ad=D#L@Qb@><3>i3*EssMx-8%@YnC>$rSjRBmzt}Fe_VlRHpB~&! zu$_$miPfEAYxZ|DS?vcliJrl~)!x3qUYL#=uA;RKmA3&rcnz#voG5hcd>f!98{BuV zmrjYdg9SQBo)mDg84!vxSz@_jc-j-FCT5U2Wf*pma7EUr!&=&7d^oOz&hH=;2Vib$ z-bhNGN(E=n;1snTq4Jvu48yk1Cn&i%a>_f2H5M}VbSktPUP+vD1;5&{L}q1l%M7B$}6^5im!!0}z4pMDJB{c?vsCy^7Kg zb9S{|8wTf)b4gf2r3xjCnckkou)N{4Y4=C#20J~&27#d2ZJ zeEqZ=bMm0L+0-#YxZmUgKva3N2%p%MOL|AEE$>1VI{&t6qS#e7Ws>h(UhCGrMs?yr zu&1>fYsH7b@_PsaK^Lh+NO?`V^P4r<&7U-S>3;HKdY!?>a4(sleIY`$L;5hDhtx7# zc8xt2^^{TERmkqw%)uOXjkXn|jj|I8PlJ#O`_K#p)0aBJKFReRsAWfkLe(vKocJMtTU)Vq(MGM zXn9_xaQ^zG31!pj)qK7c$lI5=l@TlPI>@xMFrCD2_zp(KQ+l0U(I_~#ZrO{xqCZc615{ z)m<@UsESqeC5ixB4iUlC{Ir0kwaZW1KD9c78p)@*3{PY5I4|+0vAtnSToBkWPY}yL zL<#-%zAPvL!Z;v=Nv4fCq3jKzVc_HukUg@~zHn@!wqRv4HmfV>^-@>`#E*+LRJKo9 zZk57St-~|3*n^K@vv&d#3V!>+)ql>V3==p}Wh16&^ z0JPzVt{rEt)-k>Gu!qk&&4k^=m>`0$&{}e!dYgT~_LJuPuB-56MJ?Hbr41IhGmNkI zF_?hhPbB|kr1@it@HMup#V}LRWwedO ztWKM;HlufLXt#{}`hGj9efXkt!T-vlaavYt6n{38MUPv(X%~bgu~=+(GUFI+NXo~C zM4h&&AXp#_1Memm%){-)Io6MUE>t-T*tF|Z8)gr$?ay*<(V@TRFo@?!jEo=Ow#lKq z-nqBkN9$g#nX*uAsb{ym1mL9bBR^jHH2C1@#+JMJCQ?~8yG1QLp3M8uAUsP?}yeE4`+S4Lmbjr*=if{STbhCa}=_Q+7QFu!|zyiE+8U&3}eb;A+j zy<20dG~^6oJbnHU((TbDh~BD)0&qc14@usz=>`SG4K^VoM}tkhLtNFo53qJGjjQ=$;RoiyT9=D(0n=e zX^p4umBwJ2PBm25`ZT=x5%6l~ZQop9_)I@)NOiA4q(@5qJKj>Q$hdIq{`H}3{6_JB z8V4LvFpk+Lofaa3Uq8le85C)^N^mJZ1`<5!xEGitNDk7h4P1Y>d( zKA3z>_gYwURPt?WQ@i2cSmm>u)^0!($pqCZ)$5c?%#b^>WM+3p-Rj8pI&hbB>Gz<3 zeQ|xI9Pw_Cm?zFa4yX+AaGO!;!6S!S*`YLy`yc#g?cS9W`loo6IRS)TlY7~~%y%+F zwJYEY2?ALm`s?N*ws+u~=jzu(&tpSx?*Qi`ToW|3gOgrElpn^XbuouC4b(zU2>b&~ z-a-7sQ%>z0m3?;d3r9j0^iK#!1Qu3bV9)IzXn)d|_$MD?D|`#ckeTPuxSI1Iyy&7m zOJbxBc$TsxX_<6=;nmWl|7cnF+4}H-uQ(ql8sGD+1PQR2?)m_$pU)_uJ?uF-eVv#-A>E;fJ3*%gs@ z+dp#*a}RfI+@b3)O_9aTHx=z1Wjs3JnH~+atQxg?S?5%^4s+`;V4RHK-Uh29`eKXd zQqI$BSks3_@>woR;#<^xG??hKo%V0Mjm+mRxa@$yi_TzW2u19@rl|IbP8q%slisdS zQT#f5+E#W+KcV3cPP#tT<@jW*>1;Bl27*{E*`AM24jy~Ets1cmdkmcNtsFB2()UY9 zwZ3iox4;p6!M=8qI#KFmz9x0A@QvF<<;%}Q^@}?|^ect2NYc(XMmk-9C2tPXlIUJ* zkRnzD{K(a?SR26IV7S+c$!G*$5tlLaSsqQ;B2-Xu6`JGrQ`FI5_SB}h*^r_Sb&qFPY{A$o zHvc>>>?5)6T%pQ4cW@j-rqV-{QED%p*o=Qqad6xQJ%aeG#-(UFe?lMLiG}>xLkbe|tMwXw8>%+?|S+UGSoIzD)JAZhWn|pUHd9x`xj!0cO($KQ> zBnouG`);o#SLM4gIO=pi-XcY``!hCFJ;+NbA#b00xM&~c&&2t0qKm6wLo(6}0Q26j z9+25*?>ckx>y}iTa@2NSvL&ggpw=kmXQcHboa4oX!$`L83nq>DM~lrQ&$aCgB>eo9 z$o!`|YtSf_404h6>XJsyS_EwBtxN3&6`ew)-M)Z@bq4&-kfYUxahJ0^D#b!F)yQnQ zhP{~c2X<%7oyyl)+2ZDYr`_fF=dJQo2nykx&OcsC)|tlco2}X2&Khzo__e3Cz7#OXTETbgthQm<+*QQ48hAMy+FDS^XKB>@u*)$uMN2HBo#T$) z)(Vcg)clTYeERuJx>+u+_WORvUOBPk;`ANbpm${`7lE}ePE=)J6OerJv9^k9ySSF?ZoY$9&mTw-cl(%3QDv~a`>KT3>K7x0c zFV$Mwy!q4zB<{gE+^%e5KKZV@T+BWpR&)|-)GBSeXALEvUrkKh#644Qub8uj(B9rr z9Q#Malaq|suN=yhqi6Eu@iMw!oLan~_TDr$iz8iTLQD?Jy~2=?GE!un)`rby1eH}P z!c6(sPfUJ98bCdLiM*W~npW0C45)BnlXu~69qwv$g|bn@o~_xonitSRTF2^_zlkWwjj{r)T7G`&*=xeU5SR=A3vTSmpC!ZA|Yn~=IM>63fd z0V8o5eIzg+rP}-6(sic?>Ft+79jM z8fHs;0`m{+mi>U1=bQYYP)K5)*nmD1g4?D58h>d1)2d%1eg;9Y&w|j4Ils-s$HQ$T z9=pK`%*V0G*z;pdSf}e?Rz<20HhhY8ov?w-XO{U>t&BUcIj&ymgET&LKxfWZ9d*E? z;O-xY#Y|>n>MGK?0a3!v_O*6Fx8L0i=YqtYLB!!3ij3*2s}v_0uNJ!yqqklA4bYWS z@c1PCe2JsNlO~XLuwQZJXl1lm0~Au5%DYc-L!Llv8pv86TcI5ss2W(3)tSojv{w_5 z74<{1SU92k^ftcOaK_8P$jin@Zz3-}q;pl?%GEBgz4L&|oo)SqFo&o1KbZ<61b?&+ z3Sl!3n&7>&F?}c|-*fbKUn;48KnvUlcA*>)*SNK7?{AuG8l$o5Nri>_3^k)%wbPVb z6J8)kU05^dl5~p8CPS++KIj8tvWBj$_dg`@jNn1rH3n2cPT-O`rZ#rQ`ZJ#)?LVx% zyaDIS9K4}Vz8YLCLjq^e<778op$x>djB?QodJ^Hn5Yd)N3SY3E@x_P9I-68-T`v36 z*ZWUajJ{D{Iqe3?@X9+PbPJ<=zoJRu;k(|nw2jF3_|1L2f{TDzThF!?)v}NXnZg3o zuoE3PbmvYp>2WfA>PG-{K%&gZvX;>=F|8VN2{M<*qFOIx32u*xD%UFR^7uX!iAKT~ z)W$Gk6JX`eOLtMbv__fc+yY8S7_INhxFOXTZ6z=DS{i9et#x~K6Hi@}*zoaMsFpDs zM5&SqyLSc=P!U{{m3E&3M80?aQEIL5QOcm{NWtdeJoTVxd!ru7yM!U&BR~0 zz25@Ve7h?<0bknxJTy$|{!!Rh3wkUw?PfztJAqorpEVQ|Bd0Y@1i~Erw!@ocTr1-* z+D6pc$4pcV+@{kBqgAblr*70pz*-RGnP2h=57OvZe4Z_W5}K_<_x-iEeYq3J0`W7< zX4=V)yKCdX$>Z|Pi5sJ~=f#XYOFowBdTCoWxyyYk1m7W4LHZX$pfVY@sPlH?(5L8( zF$4d?ojs+ocIqXc)<__2*gIcaCKJty6NRHts4ST;oW*^f(~Ls@6ugN)Dq_($qs#$W z#*oC(oe19a+Y&cpbk}}p%o%Cguakerx{ne1KTT9w3e8F^fs%n6CY zAZ(0)l(`fuW*^~JZJa!@>T^-)gDPBsF6CvkTOe`l0!Kzp*^#)V5uvf+35`xs_+hA% z=RIX`Pmz2GzWUyPT_5hwW{9YU3VeQZQaU47Us5EkfhT-^RmLkG^v#R|kJm@H4qNfD z*kkIP3)~+O$y6U;*ytw0#Bu?w=T}HQKQLkFdX(o&eX2f|#y#z$L3f{HsC));!qATE z5FlXiAt4ZLy87uu!&I_wTf5FTySc$4a!wVO7@&?}YvIfxnpH?q%9ug9)bbnpeW<6< zQ`pZa-S|DUY19P)`QJV;|9c-ux+mfJ(y%hzQc{Zc_g+9%D~94Itek*U_gsiykUTk* z&PM-9AGZ`yGD>8Zf5_KhN77XDTKW?5DXk2N)G35h6W;-nuLk}C=LePo{3Yao-}nIt zvt^v*`2J*5O`{A5iE;>KVbkiJ%moHzExtxDE|WB6dr;yed1;ox0zE~jP)KjG7d1|; zE32a{zZ#$2ype?La{a$jYR@8f7o!SZd-Vn(qIBEbnIZ!!z5|e<2Lcq<7qp8=D72ty zi@}+!4(eyFeU2`GDvL%vUbET=^vYeSTtLbt+~5D&P(WRAy6KfFJqdcj^;rkda)%V4;H(2r z8sDY@9|T4lpyW=%;~zIQSxoZ6Cb_U}-DMb`7cz_a$7|ls)>=o!G_P4KgmKzfpIB!? zOMpYUN`W4J^w|;{2g(CCHCREE_M4jeq7J9w`a3X4k{U;KmeQs(@6BM5+XdpswX*%K z%odeT&oHQyfqR`Y0ht_!*CZL&9BOLSFw0{Nn>;A;O4#2(um{VQFpN`MHq4oqCtKaN zX8dj4p$y#qs?mPZ*sqo<8#lEiBWdjzcI1vkwUXN4ot5~MsLUzX#Yuxt8+nYt3XBF& zjWY}O#9`RA>fsCx;W?f!W@Co&JHs|2nfON~!LD&>#g{^%=cCY^At);~t`);l@VW*V zh>CCD;h*cG8ka)|ebCpxP*C|YpSP$jEYu{B7nafBN45nBBC|y4_ZL(8?xnZrq@fa; z-)tAeD3}{Yke~nqLym<7Nr-?fT4jL1i`oc`QYa+MeQ;>OXw0Xx_f&;|aUb9#r1>;e zLwI>_OEo!w4?12Xryy2oQ0yTZW|va85R93k${a6JE)~eS9lbf|)h!ZtNIJU<_;KXX zDc#_>g5Eysl=7-TzHO(S4iq6Ri=c}*wqscc0#K=4+8(7WroSZj1f3Xo?+19qk;Dly zUg67J>T08H2QbG9j7!0(?tXL|u&#tBl?i914|1js`}%{_W|HZ}VCX4Zl{ZR?#H6LW zXe%F;NvK{>2)S{PB;=cgV3Y#zP&g`F$0BG^fP6b%W%ah(DbiSx&|tp=wI?V*9eBb5 zRB@6BvtOvr;!SQQ8aoY;LJ2d_6P1^Zl&ORKiEAUJc)B-BXd}9|b@wrd*lpW#x&=c_ zG|p1?yw(OwS!kAlvg+JaS+9~OC|V%G=Npsr<|TESZ~$oUi* z(Q8jwOHsA$yG#j+x-U2u!RRF_H?lvSzy#Ezgdw6(xA#OY3#t-;FB1`XpMHEKMwkn1tll+l zdq|+toq?sm=cUxrlH=3Ll9Q*NKiMfo8$3{m$zTDFF)5cB2VUW-3xZM&;WS4Bu$w=j zMqZDct zgcSHHs(Yh^IT?bFE-y}s8hG0wsu*o5LM^~cE)(|JFE?*W^y6&k9tb^n>liU-sKKjV zop;XAgH34c&qbc@Cm6*@Ng}518lWz^w{=UHFxk^Jm(cnP=0gj^Bo@#)4BY_xqn4=q?Z>&6b-(SXzuVG}{25q9 z(wZR6tAMv;p5;~6>yLZ>)VFNOjG+9%fPs4Q&!;Qo%8Oi&a}k@-#P!_g{jBZ3F6Z~3 z%N71y=^_njEw)-WZk=Yh?*i%goo}PC;bb=)Yr%!Ad>3{0N<*SYNZi-v?U^zIP6p25 zH~=Rjp>phX&@y}ux-F2LG0`dze(aFo2RTF?iUb&b#>V#DmF2A@yZz&VGBwFzvD%Qw z+V=cO(Owaro^+oCGIGVxZ|=9>rXQuyVeCYCgjd1pWX8bgUZ(Q1voK0vku28${{4xF zVpjP+H%dt@>)iEg$hC+l-pvmmdbKi;&fzvJ=ol%gB4{-@_heL( zr7eQB*VA9%C3jC!WKlakuc=tLtbjGJYLH}JJ6*7e(QOt5-FyHX(ae?Q#!h9Qo%4$) zSRBpa^o7nAoD)pkqJJZA*!OK{T^6A-X`92T$A@+m*m#1!ml8bP`+=t;n!eR8K+>_n zEJt|^8duPoC7oAH7hE(1oPfqjv~UIJg?``(M~6kc<&z#LDE{?b))Bq2FW{xMrj>1RDVP0}$`Zlyor_e1B|qT;=<-T%#;a~e`=a%8OR*q$Mj5RA z#0x^&byq?}7=AwbcD=JFP_TW3_Zt(ZymYft*=4&I+Ks6P)sgaF7hccYZ}&tEyd*J1qxt{ z;^wuB1)HXHQ@Pml*$FH}R49x|+rFt{&DooPW=Uj{ zs@`wjSV8n08eqvVNg_iV)~-c{T$vy6$3sq?gv0Gy#puVKj4y2efP(!8R7C)Z7M3BC zyiWC^5y$V9{n}g7$eH?==lZd_Dvg8t!_)JGV~lg=l~t3=5$<=!S}NTgnL2~k`t93j z=cF=rk|Q{L_V45Gg>{YYidjzkBZxgBhI7u#YyD~PCapu0urJWpNui32k+5|R(BK1- zHMJ&mIiyF{4@__dI{b?DL8mkALqr&4x#y{hLG{Emc}XPq4fiK31W#meMerdAiQA)3 z-|c2dz%UPkY}*gL%~&zZXg>m`2PT}T8)ZCS973>%)T8fG>sNXC#_}#CGc>0MOc^eO zIP}>qf(kXpN6TO059H#p57>D@8;xt4A2Kru3A8wvTS~}!$VXuA?ceB zB04=rH660a)y^&GqbL1DWQ=Nt*0+P2LoAvbkxyT;Go~dfm0R=R}=$t1M37-0Cu8}`Y;k!!wTg27y`fJ`dVp9l*hDW1XC5T{#F{$_z}zveFtq4 zo7x)_*O1mQGE7zZCHNWW)&jKik|KiYuKDVsrJMI3e}H1w)JFr=*I!9g?G=mE#mk}e zV-?FBIh`GVE+LD zF4KQY4CQn8jn#h$LWHfB(}e9*EG5Cww@H)Cmt)edhSG}v6+s8C3;Vglu@U~_6NU}O zXC`unwQ^61{@ACcq^VfBtU%qrYLI4LyG)>Iic=$cDse7vKxpq_*1Anw8Efv*7^F-h zlP<4{C|r>Em3WFSiMrIEa6iTJ69M?N2+6AvOy@w!bsA*`7^#+XfbDsD=G7=aqBJwbrVB_ z!{~B{;wRF`V=R^wDF78#Ker_1i`cKA$u#0HW5?Ia*Q`pq?+|oQ)ub%>h%|lRZ@~xx zO2MmV8?Nt7tIwWq%j~=G(SQACpilpW>F<9HG}ezQ4G&J`Kd#bkF)x!=M8f1CNJBCd z0DmbKxE%UYmBb@w_S{j)yBH7whhShQ%9hAB4TEKn^#kp{LKe;E9r!2G|Nc2xUHk}I zKUT1;^~T>05}|2bd#vn)w;VUD)W73dDkRusI=LXMA#6XO={VcV-!6}Q`6?rk0VXDg zUvT+Dvr{5N7dELwJ&*?+pqq6-k3tI5STOCn^%o+al~q_O9g{+j^TjH14XY=H! zk9!y{fNDvg>-wX*09=}Y8XJU~)0_g^Klp#a{e!<4E@0iT@64~!D`aSLo$*S}f4zGS;-7b0_}S?@kW-RZ{P<|0uHw>T z#d+L7Q&KRd#VwF}xN0@K)~^8(fv`)JcEX&q_X%q65kmzXBE!h8U!Z*=8eal;mire1 zSPO;HVuS!6!-3u@7w9k8-GAG5^E{US+ICLp7r)0ncxnh|+L^uOo%_(!p&p;9&$mdl z^peQ)XST%rt9rj^n`Eq+RBLFq_Kw?J~17`m;I6Y++IpTtwG|>ccu%bLeIuUJ{uYwO^^||II?^+b>VQ(fjqmuQm>@qO1)K zt2y1$)I!MkZ9@Nnrh{5&K`$5B3eAw?c)kVEUEVt~oum3vH-S%rLAm+T2p%2GIiiZ2 zE<5?AEw6jJU&|I~XsnpF#?XpJ3VtezrFBp81)t zX)O(Xo@`M+^&rjN{v{_M)R-&WHUIlBc79DoM<%aaJ_lu;(hlriJfD0b zGZk#!8+D`Bu|Ne4oH<4F3YXj`b@=aD+L^F%=cHEw)feuf5f&5Q6EP$v0g%V#ArW2f zww_ziTq@souJ%~b1w}E@Z$3gYT+ecAig(M#8M^3B&Xp8#gAjv*P(j}!DG;PFwYIZA zmG&D}E3JA>OsbU?+^{d5?~mblC$WOi;qi&~xEaH&_IuEVMHRC=_o2Y0RitMVl1Dhg zF@=^cJvuRQ!uN3zh4;-*YK1wy*mzZGi#jxdxB8xk?U^BD#bz`C**k}6XE1rm>GkMe z+rLmIF3&^6-erH7LNw5TeL>Bz{1fhAX$`Ay-ow|vc-#B+;I?#X!$^`W%I3o5@#*5y ztWaGfy8|Z)Ylr-`j$uAM!;7((uFrp9c5A@#yb0aw6xL9$6XX($k=C|m zwJ-+qP^;AHVg;# z+Put^Ob!*5J7VyaAR`7w;hCfa=ebBv#ChO7{@w+5j42ECp@dNH$>q(LImtyuSfNEj zT#7yzINZK3!=qQA$O6NYalUq1kVAUrM8)SyPQB(7m9erxifHN#E92KCgNnn}LV}wR ze6~=_E34`oXkak7UJcw|2K0!CS4lT9wn)c9JH&TQ1Y#60VxSFe%M(WWeW2h_tU^%T zJ>HX7$j1mk4`;&#m?mvT3rK4rK@DZ@Xx3|@lQm?2}SVh z@r0VDm&-wwA?L?&lq#RNM`a0t#0j_UEkDj>`|Z7V%L5tT`~ijZeB=-H^$GsBVaPn5sRx?jV~^~!KsDwh zQRl<-Qd0y>n3krker9h8!;`c96S5Vr5aMOX;i%2RFLy#b4&MWKi2~)GnBjYFi`qFo>UJsmLN9)2=wau@FtaF|mAZz_ zsR<&wClS=b*oMzFCZV$DxavAgqr*cZSFI!&hQmjZH~q5x&PoU!{;o`&);tx$C@2v^ zkRFd5w~Q6aud}=ICmQQx+*DT)zh1ur3QJ7NH`wXpd+gMYl}=n z>o`8&jX7=gBcZiTLR`6ow_9g^)V67G<}jwy?3XwW7v)eZ*ZA0Eq>nX0Mnb@vrVOef zP4dWQv-6g`0kPmxq9!-`$m1b4;38`L$Pj;Y*qzD%(lMJ{#Q&kJIo75ri?6~ z2RkpT@fg#}*vhiujMAN*rORhD$Kjh_#SC#BAGI$Qj()dvNV~X_^uyyvhLRVNTy61i zkK}XrkMD_tjcPZ5GX8*q5C;|dxI?nJCu=jZghfI(B8%lCjBQQ42xV5u&wO!@)U(^F zj<1F#*QUlMMZ~iMH}r)hYwH*d#(vNH7(jhBekhlu3!f31+lGl zvEwmNgh*{xFMvVA_Yjv=`5hlTzfLFde=L{X<>&0{JseKGpI7uPcR1D`oG7VdZxmTNOP|~rJWP*BHw;@ zM<{L-C=SFXEyn!ZlWVhn3Es{X@-`xl{!{~lqG0(FV)X*{I0!)&{uta=DOUE#>d2LA zi`^gbs_7U`C})dixx_P2DB+oPE0dtr`(>k{Lfzaf5)G#1dI96-pdfRu;od3xK;Be-(3uyo#{;e5#whD>ft=m<36I0^y9G~?hOm>E}e z3+J%y%_{h2kGJuol(lyKtkLxZD~cJN~oivrOiM}LpRf|D9m4xC#kpaklyeC8* zamveMm$lpC!Bv${SgfXri6SKVACRtsR}oa8({I-l$pY$9w-=$iK~S=xyI{={c8H$H zx!(9b-)q!$@l8FHP4QT)3&b819EuG3>DiVJlOvCJp_X1dRJB$CxP!1gAQtl?NETP< zZpNNp0~jAcT{`Fw!R^P55yUa?0R)F~oXCrF_rC($J;^}e_S@pGBvEhwEH~n{cARbQ z$UHbhV-8BIA5Gv}h*d2aiBu9SFc)Z0B@jkW=y~1YK70%e@nZ!Pa;i+j)vSZ%r~QBA zzl^|VI#q*LeX-NA8(a-9D=^BVQ$D@+KE}GpW|skXWbHo{DCuGiZWQfZWd=P77}iSJ za0*m|Ik%=&0NzL8La_i>2)`fW*u`GF#R2()IhJ5?pn(|M$^`fz|G|032i(%@Kq^*) zNzk86;KW-(qRhNNYG6(Yny|Ke?UW}xUZYIb{L2K%{HFkJFkpFdFj;79tT|+(?Fj4Q z3=zjN9BP&rR0uPkDwZK}nzabrrljzq!lXaCg90YHBO2hX8tZ_T>G#jD`d8YF?fHYq zp7X22{c$JlBr{7}P=IISw2C(QtfMvTEbu;s%4ua!2H<_HfyemqAZV1yk$}}&f`#L3 z?SqzPiX=wCru70`)}X%Jes*pK$EINC3SoSCyK+>Oq=lqnEn5aSw*MS=(?b*;zr*hX znsiFgpF0Ze!4uK!v_nLWD=HUv4#|afN6Z7~0M`W{i{>swo8nh1D~2%ZRri8QuKHyn zGrOdKTZI*Um}O?qB_cUy04Za~aB8q> z3eDh|_2-niN12m5OiVi$;6VmwrE+s?sxsJ0#==ZR;K{Xvag})u1~k^LPmuxqX<=EBfNXEig6W`SWDw?i?L9(R^B#JxR*z|v1?wyHWU&U=*8R$(JSk}Tg5g~>mO zkB^LYB?A>}i;2WAjy^DSN5tubngPU&um2;!C$*py#djeN4vR*fXun!dv&Qgi?(ePA z^z~YsD(p$>>56!+>oUe!oM(Ar>R*j#n)JZs0BeRcEg~k&_!lYK0ux$FB;3i$(vkuV zH7P{ZpzXSFxI8oV6eSF*4cK%#rIABe=JrQ#TVu`_*y%Fv%7W%rGo?}37!%>?A9(5Z z2SciG=mi|J;IsNR+l67VI{Shsm{iH0v!Y_-?l50C#<0(C9Xln|fQYJf{!z0cfeQ2) zCuE3;7f_?v+D5ab=TVRTC+_-xBBs^(x>!cjytM?)DF8yrGe?%rvN_0%Ptrpqu$G(BkxXc}Kls_uHO#;%$Q*NFw4<;i2L?PlyPLkd^hK#nJY^pTQK^KgjDWx$ zSUU-I_BwpzD7*6i3qNRmdbA;MxYiPP}CVB;{**6(+F?1;Egfh zCR7v@#9X|jI)pUx!Cwo(t{+6Qd1FH%v-u*7lp&ewGBUK0I#KVr@pm8epHlP2Qe#^RtNF>rg*z@z5jq1Y`%+O zS0H$PY)&gi+}V*u*E4BHwCbb$)!aVnr0qnpWf{48EIb6x?2h1|#o4Xfu3kUn^Q-iA zegrGSvF`KklV-|yC6PAuQ<;hpMkh6RE7!cN8lJ)5cC3qp@u@wrx8(`}@ziI5+R@JG0iBnP>2faDTzKv>yDL z8Z-&lrVQELGJu_#b$n7wnew+`fgyeaJ49-mg@pkTtb?xnvBk#>Zl|nWn~%=}M`Z~B z&O?piE@wjNCR&(+p_fT$emk#DyX^K~UH1Ca1ijz&sc3V)MIp9g$k9<=RXbhHpjOfk zXCs1z{z;n)+ogt#UW4^ex~=XACrqiVNd?~jjShCz#9j7mDf$8h4O3mEMC@UFEH8$gFoT3fpt}^!QQn&Imlj(#vx+?ME@SaD5sbP|I#ja{P zbAs2`S8X83Rzl*%?RJ=C%iGR*)?XeSDi}HbTW#0gHP~hpLzLBdF)v&Y)6Y3MgRxs< zEOTSy4w-aW2NLhvnmsOjDL*ui>Z=gHs?aMGPS?-!cBoYjb2UC@2-T*GLRjkQSY|s| zky3=-uAlrlduJjJY2>UKD%Vn#0jA>RlLK3^*jf0DnB?D*7--F+oC0pqxT>0AhDa~P zs+r@d=5~Ku-H&&^kK1)OqI5~6O-dF-<3pCh5TK>%5NGGzh)Po_)tWP&7uYbLKTu!r zazo}E`fg#zruv`q6~h+3-gP*Q_wwk@p`_w2;VsY-28kP}6us?5cWR@ht4FRii%Pxs zbhr&*rOfl*ayjLrr7IcF4h$0I4GhXZL`1*kMUF$TtGU*KEB9K7d7TtUlT^2wMc4O6 ztQA_FZ6lE~n&;b&JNrYo)Y{2z2!~p)5^B3PY1k#|$$&q_GwoS{>oy~->ko2QPwFj2 zClFZWSkUBf&PgO8rab00wR3lGEM!EOUu5o9>prpk8I;E8VbG-&9^xR=7`^bryW(8o z`ZdIxQEe>DC4%=P{1?p(G&gqsu_EnO7;tmv8$927}$}*wP}}p(X^wQg~U07pzY0nO}G>;tdC6t?~B>5c=uyQ?Ai!@1Z7*K;ocdQigPfvhH2M*a(5WDQwKo-3e< zU=^`RdM%t=ZzwlSrfb1JCCVtpZ*`pHslheC=F{}Ydtd= zvJ~Vi%MDMX~)o!*4~w5lq02EA;h`%J%-k9s#q+>)rh3le4KjOTt170Sajt8 zpYOSu6bJ3uJn8*X*X`@GJ6aym4$9j<3=ie=sjJ2E-2g80`UjWRH^2WqFvuxxOe@=y zPsoZcI{T(xeZ<+!hWao*k)nK9ef$!v%Ja`yn*~uLKKDr^J=*@B*FJN33{Dt|oz@m_ zuT^i=t|j2m=yEJYCF)tW_zZPU{u|V*$Bgl8e!*v&V`8=;IrudRqNCU`|JH;EVxWeD zj6Y|$o*Ky!F_NWVCg&p4R}nf~j{9iWCBCEW_FhEc$!g`a?joxEuKVnUOH~%e%f1D_ zIF#IHD+(h?yt9KcL&m>8zg>SyRtl==m3Jb-Gmd@x6tU;*jdlhtVKW(o8@FC6otg6T8 zvMtWCBeRPtbUS1@hLZadjDp+FO59<60St=R0#hA=RnyspP_=MxBGfJgS@IfCYzJ#@ z=%Q;nK9TX=YBD%hp%O-OPMOIv4?h$#>-+a*z_z~+gDzr#lzPBZd8l!|$7*Ap4$&Cu zud`LaH<2M*#w2QS=y1K&|8e{D0A5CK;WLQwyPg`u2%C|Attr>$LWE`Qy)%;LPW}?) zfICbdWv)%WKYtLc{q}b;l;1Ff`~${;@#_%9<5Clw28l~!A#n@8&p}ipjq!5euV+VR ze8U!g4>I+c&n1+}61)JDm8KVD5>GChg&2N0UJHuw<>M*uzePi_jMb1ujLnnl**{|| zS^5v(>5*)h?ynilOkz?i)ZRZc0fb90$7o|jkb>W;@1Lc)PkN;K8ukk(IJ%`Td*j_$ zmzjBi3DLxC)I1>E=0c7S_b>5vD&s_2(`sfGJj5QtWs2LSkQzzgQ0hBc805%`4+{L& zb_P-a8OJ^|w@TATZ=wg)c}QHzPxYt6ds=7XMCfio}$O zkhBnO>G-q|-9L~Fj?<;xy0RLD#`8G?eR~gj5P`j64WSNk zwJ*bdzwMeG{Y;)_j zddvKtsxlt)^Ggsz1e6NVp=pfP$fO@!+_cv#%a^kB2fx$Tld+7Fxd#*MP1aR-+Is2! zERVyo`-ayq*CG?)ci$pY7RT$Lst776JAMjJ9b%O(j^1W=JeHiG`<5yHfS5Zl!t9}E zh{8;3N*GW!ps9zW=o&t7qHAvRk8N=M2c{?tdlYW`d&G7a`A#SbWeR-WwokH^_`D;( zq;Qj5vI*)Z6-Xk!SV^v_sdBW*6Ln&>7^~0D+GMneU$w~z^e1)6XkRXdr8)JbV+sa8 zOF3Fs=#wu*I|2+{^1wBWe!`hqQ%7UQG@%tKZ!rcbi$39grTIlxjoQxbZZM;p(W~qnqwAD*_KBB?~60i*bZwk1pxva4c z#iL51?Q?r_4zn~&gr*Fr#prUwE*(=W&nBl;AW}U0JE0tEsicfIP?{|MYBfWHzM|)fbWho zE4f|K4#klQqQrCH*4_%&tdLC$??L8msG?#7PSuteX@%A=!|~f2o8e zIXwUd*fi%hBzFZ}>LJ-7PVvT6d55&QJD!*@aqoq-7&8{|1V9z|YWVtw;Ed?{i^Ocn zLIQJhb-9Cky5KtBo3FlFMK{*7kHZ~`Z1PfhH4S1AQ7-+{BoO#?j;qS-v5cr#{-)i0 zQpQ%D$s;sisA;ZL`-GV%5`@N;4jl32*^Grj{O%DqAZ(Ej!%w8fl5Hv|bm2s)-a*vQXd^u)uczBg-QA#9O2~Mb`wA7;q^hL#Y zA4g}ei?NHN_IRbV{I$vZQUOx%R7Bk08`)){sENPn#)Dj zF4yH;&EM-!hX7qSgHA+3nLS!Qh25Y0P1Ar=X?-dVlx*pe80h*TfQ?ng1ez#?<{YHB z)I76@GS9E$2oEYUwI32vm0L(MO~ZOyXLq%F0p~waV$_BaXx}i1K!>XQVq8GhcNflA zmo&lYe)e_c|JAKSr!T9-sCx5bF%ox>Ymm*;Q`=O}uIYA>>g8PU>$r!S$YO>_A;L$8 zzo$Q3$}=(OA2vSuDS@QYcOj)8uB5I@|{*k53TcOZGLoWt`<*N{@!%g)#H#DGf zlYrA-A@FY%2nm|gUI__ofRGv=au!M?T4@hjS*{xvaAK$t1?Dox-_DlpmE~1 zl})HNkFqu?aGja9FZW*uiSsHS$3XHS@wgKy^8cf|4;tY5CtaLwHi@@_nW8Tat8#y; z=-pqwO0ZY~(dVjp9Pahc9*#foaj>6K0n=+I|4IA4PcQGjPhS3bVMsMpAE{(Xn5>|K z@mK3ELFiQwQxv9Gmg(P0@qA6II!N*?GR zQoR*IRfrWa`>{lp~4{XX7OWoS4XYD!47ro$;_oUFw0um9} zJ>?K+i_YJZW_AKMW4RTDCiv&Ro5^EG)3?e*=e~|S0^CnV?~|$oX!GWhe2Tg$RD9ZP zN6>hR*RuwqU4CD7o%F=M3Ts9i4WW;PE^z(+aJSAL&aI^7JKFX9SW|KOlxn?Bm7#f2 zTr_TMEIBGowpw_(=>`pqtY|B6x27%_+M%#tj}6ZQT?*0ELQ^CVxOB=y%eo|_WqhXH zwP?e1I?_Jq=ZGRVeKSq1Z(PZ{d+(v{b{qr`s|he^CNZm6Asf~mKm;PYNxTJS!r$WV zDkJlAz7`}6w0DM`LmTZ)L7F$lrYrefYi(@Fll|A|Q}6nLN(yq|cq$SXQ0+y|U&h96_m zF!1>LFrOi*!DA7 zTYO(`j$HxKXSpas^U<$IpX0}Rjc5Db+%%Vzv+DF1m_)?wnyIz0cmb{AyO6e0|P znEFtlyGgnP!l(8zDI5Wke@ijUr|?gxKp~|ouwBLfavQifp@KK+_mfeg)t#Dhe+O@5 zH>U9Fx9~w?z@MsEq4ik!&oWfgIH7eDw$Heyl|w+6nnRh0S}381rL0!bbxo)-NaSab z$k(U|atZH{A!x|&bCo=W_(69ynWjO^S3}+9VSN`|#+!AmM{U0RA8m22b;}2Mm)^U? z+sZq+KiV)e{96bxK9z|_viw_y=S~LSUT$8^lCivW@$|{M4&Q!eY#}^zY;0(?w-2;& z=K!>xwA%EGp2kh-Dmr<(-y05~$f#(^XgXWZA^_<`C??K%bs7NpwJwZSAm=zKbSA?* zeh6}y{Aop6u%!Ney<)nfS?9{tKXGPEK^iyk9ZADG3qlDM;UuVu1e1M9S}~HH zumI|w8I(TcaweKEe0VM>vBI7Qy&Xtk))y) z^6f;|Hj-JGYD}wdET<}ZicpegEiDReg&&M#X^r9lk z^mIz+$Z#Vdk&B$_j(JJ!mnG?=FoC<-j%}Nx*H|x|5n+m4PW372Vgv2ZssJG4Dl&9< zH$}H!NJdHl^|Xkue=Z}GVEWAM$N6?))8>7)Bl#=SNDZ9YQl^p$re$Hh%72%PI5qZo zq8df4!6x~ZoY0~UAGy{53<#ZgxG!tfs`|IVIGT!-n+1YR55lO_$oUfrVQ%CYn%0&IU(6S11Wze>lUFr?QjT+%)17D2)>~ih>*$@vIAU~mdXlXp zGI0|YSo|u8K!1bgE1-G$3^bG}GkFcB_>`O(yR~cR3^wAKDf1>JwQrGYq*gIp5oH!z zHmn_BXf%Q!H-n-V18|3mD;ZJHhXrcFAMq-OEVGsKaMQ)|eFoK^41BLCPrZ4?=6&YB z{%dz(HO$O8quTN+==#IUL%188uF+?^l3e$G`1@`w*pDe}`+BI3&m+@XNB0P_TiaZ& z5ZnU^SM6_A(3UdGz`x}5u9hc(tOUP}=H11%Ac^}0l=%At$EkZV@=^K2FeXJTE&uOP zYX4~D(4TID+k&^9JSIJG@0hN4sWZ6LSR8i2p>o=~rq*&HBfC(|2LhIAq(q2_p`hW_ zkrz~cd3a@nzL4Ds8WY5e#b)=1Rv8_0=!$``*MN2YAJ7BZ-AP*=fK25`L;bez(4h2{i@<6^qrz%?13+F5 z5_RSuRMYTqOdYe+Pih|309Z3TJ5-lo)351+ zrtHGcY&TMzK&%@5Y%)Kj5yU#&seAOAn7a{Sj-OHbYXaE$-^v+Y(*-`g!RC|K#kTLe z1UD!`-x($qf3Pe{+>BBN`@K;G$Npi(F(3FfzCCaSvYtL{W86L%G7>w_G@IrV(x!m{ zh#bajBEorAd}l%I>DEM09==xXWOXi5pN7^(r`!zkIq)bVdxD@>9`j2BtJR~^3M1-f zWsUc0tDm2rSwG&BR}k(H-74K}qL7@O`cA>W^>Y+oOKN2~qd2;qJJC`yG=8n5sw;5l z2ebntE|)4OJGM@I4yo;323c0le^E=c(91D7a(j^cL|BGbsQ-c5dVH*Qj#VS^f z2D}K5VdKBtcRQoyU`mN`Sa2~_`6z58_|jG84h42q|Ix#(?%sp;5%cGo3O0r1Jsh`wgh5R#u+J2u4-}N}7Wh_Q^w#B}LX% zf`bwgit>P{=lrXRdMH7sXbD08=_2NU&@__>(uG=cAr&Jxrj)tYGPoRTB@_5oSaq>ur^d0Bsv;MbRb$%I3^sw?!P=nD3Mv%2;s>L zwsI0~2%QlzxJ(7O`-)q%?jz=p8RyO}1sP3hr8|c1uUamsa=|mWd+!8ai-Dm50;^*+lXt^VDP=V&qFGHe*AV0&-aZvB%pq7zz|ZI03x~QAEdSGmk+RM-@t33g;IzP046|N5N^9O zq%YXv759@Wz#M*C3&P`AT~{nNM=U0nz=;6GlQ9bOuyMu%l+N6}&U!rO4F&U=0L1ly zY27oS@PgDE+W~O6m7@ZNsZxJo!}Spp!w-*bU^~l4`mcCY4CEve&FW`fr~fz95IP_t z@r#zYRI*7&zkfZ)k8%nN=@Ixgb1Pyvqx3ktZ2Bv_<%ufRUZg)-RqmQ|zKnO>Ydh*l ziyONQT1isuD#>7(+d|ZaS%6R=%`LR-pqG(jf_yE&=`oJ5RtJ+!srJ&A?XJ~NW_pUsCFIO zcWBQ$qyvo*jo^$5!~f3tt!ELf3!C1H4X0VCsgVkneFGnbTR`eZ1De35M!YmTh^)Af znW$6jK4ot9x%qCnu2p@Tp1ZKy=Z=5LT@|hEjqhs*%mYCuyopyXVtQuyca}$0p>(m) zA@#tVC?gJJVWi>Vx=i_N3@;9{ypAcTk%C1LvEy+@x3_ez&8R9) z0exH>|9eFL+9(7_CfaAK%3*KbCe?SK^63Pl@irJA+uu6DlDxS?;9`0gk425NQLRux ziq5$#03`Yiv(PR1ow5V~+PdphXD^NXpyKOM189jD#Tt(@Wx7UvvtcDNJLlNBydN4b zA(AdlG-hSvj5Fxc7ae3T9`N%{;j(%FeER!R`cQqy306>XUeF7ks`A7EIJ4@7?5G^ANQuB3AwT}g5ib(Bw9R4soPFXx+=N7#sihsycN39d>b$~mCzeMP1NyndOA%g30q&+1T@*-nG@bu+ ze;vKvflP|-X)3HEZskO6y;w{y26bnySVpcxnRsZ+S73*hlN{@fI9pMvTz! zH6v;90>mw;h!w^&OT#IwXAkb>m@(w0Z}$PTIgm>$7X?&=o(9(T_ADq`Ara3Aj(CF& z#d&}=5Ri(1Nd(sh0ziZWd_vx<^E}@?-o&6K#4%t{ITGnHPnw=wo}DQ!=B;!=Eo=sj z;3+$zR{{^nm03!*%oO776iGImjUKGSZyETcbVBahl+8M{RO?kT;>I)-l*O?XbONW~ z2%yYEiW#RMxZNe#Q98vE>^ninE$R9lT=Ca`S){j8j&i5;bqpwXYA7EgIp$H=Fxwqx z;Xn5=Rh}2DZe9uRYXGPrfh;cPq#Rc%2VEhDPF-<{Yt*+sjmDqe)APu!uJy}prb_<; zv=#2Ax54s*bKZgG&!GdCOV63?7%8*|gDG+dG7SHE(vK>byu84dy`DJSW-*O-Wog(` zJltBRU~68q6W(LIvdcp0QYzaS2p#oNw0i>Q%MdxUzxJ@4hksG`EFSX%s$lhkK;g)y ztqls(rtLP^6X4{HQ@YYAykyqd7)QK&ASiVImosudO`$>vKbW#ZKFJNJaYZVkiu2!V)5RA&yyG^DcpV&;?lB>ur{( zaL!~c>ct=tPrwN^6P&dYI)dHGPWDoZHv zVjq`sRamT8H{CPt%;9-=8#L3Pjd%cV6pW7C%&*v7=h_+Lj*MEMgbxpBHOXxUHvuO{ zL(W@ABOJq8Q^J5VBGV4UkOz@*&?YUmcf~7C5rewyUvcP+v5y7a7YzprI7zIFFhVT^ zERaBmL%fg!hF5&wi*d>bf1dynQ!_dQ^dQ$FkEx6=D~Nu78%D9BIQb#x94I2Fgf9qTsK> zLdK&J>uM)&*dTHbPW)0^s_%J~28%OkL;O<_0bx?uB2uA){EUJ~^c z_H~Clc97MEAQt`u@IZ?r)8RLk>KeD@poNm#-WF9RQIZD;XPxDN+9>~zJFs{pPgzs4 z^7Ev$^BwQq21_W~4C++o+usNcbs&`Q*8KDZ^=Y6-i96urO(jAqMEwj+u^(E5|9iZl zct_gQ;fwmwTdFHTbYd;~mvsH4lXE8J51S2&r<>~cCAX|tuD#a1$m&!9zVz+&EherT zc_))%>oXTG@@>z1D$0=oG0kM&`4K*Pm=7RQ4}mzyMdUKDqs$8nUq|YEPJh@N!)e}MF=d8_9qBVGiXX>r^dS2%+M|QxB9!>UY;7+uj;Nr?C zOXVM2o-6bBhux|1xCTkGGcSMtZn@<1(VNBBEJos1xCVzjaA)oY2T>GrWV&cf>~FN_ zJgSv<0zvQZ9mjfS)SH93ySBz3)TP;bv;5p_`E89uwBbQn>~(nzbyXx^OI6uRk-9kk>X2 z5Su^DUu38EnVh=Y*Gy0B2hGwL;gGWyEJxsZ`iik?>?@70YW88|BvxlrHTB1Gweehy ziEOdG;d5IYM`fPpt-0ak``Dy=^21~Uc@EoA+HcPPXwx9_Sj ze?5vJ$*J6ZndNRut5E8k_1bf@0j!SsEyp2HJ94Y(RhE}T!$ENQFWEgJXoDP{PAS1` zF(UQXiVZ%rQzFKr(X#4QfOxVutD+>gJ!p9>wZmAv;kY0WwQH(kSH zT{+nLU+%4i6@2a2|4Jl952ah(KjEY7n&N|9sPd`SJh+$RG4s|W-~3WN#fg3<^!8g$ zK0L3Ah>pKlbRF8HsoiB3OqsN$>s^?c-%+O%yYHD?a3S_t|DX}(?R~!^YfNf!pE?I# z_-dDc8{*ltHc+kH-S!d|+#^o~o2Hh$Yhrv969L0t7N4}@yVW~6>gcK$0o9tRZ-W+7 z*E^yl0Ei8LK11OBUt!~`P`7v(96f>=;*x!)iid0%WsIMw748;lBUd*>N95WJ^05*Rz3vNQLm*hoi04!fx zOdfcFvhXeC=SB#rSumElmO6FcTPk=+;MK~+oc`DXdofw~Z?pMDP)h_kUVVu)BM~vm z!fXoPl`JHecfOj6>MnjNmmxgz(<^L#1Z95Q~31J!xTH3DgR_?z_0Q^*goi=)dW7J(GE%MIC zA-)4dZe;Ijj``5py#Jc)9-xtu|zlHRYvIeCLa%o zT+vow@EODZ@&erP-odmnX-ut2P(Verdh|auDxL*?SoYlm$hyH!DkFb+x{g4|K0Z4t zFJ0_6Wse%)e|VJ7q1ts^#)wnjv05D(*m0x=8Q3pc(tS_@Hp(SmU3en7gAYKe9^@dy z!Caci;&4WOa(<~ku5G?~rHo(n?Dz#Xv@Be>=V0lL<}eI{N)$y3ZNeb_UrnB6%;_az zXi;jmQHB%U;BnUu(t3mYS6ttr$>hWzlU%N+XZP~m8}spB1hdH;26<%I(m<)w`{m6Y>B)k!3lok2@g zV5QvNpfjwWAlMh=i7ZF}zp5bF*>Ip{kg_=-Vy_EriYTIe(=?Hzn_8`-?QGT!2&~Qt zf!NT5i_2*eu3hN9;J2~0BF~bV3ZK8Lljxg@h8+BfuP(Rmu}FS(^)(JpAd1BwywIJN zfp#ijR@amA*_XrXGDL!C~9F~_x)n~|P#K?yqf-mK4{xE?H|gv-}Ae6(TQ zI=CaeUc=ck+~c+8&6ponu4>~3N}?Y-U0pa7>Z1s*I0uPe53MPgl<{+27xwIIV_1W# zI5iS5htJ{Skk2id1oevCFR`;(7EU>g{*s z+(KtZr*ZuT<(loM_vg*=t;=n)kC|-)ip`O>2r0m+DpY)ZFw>L);Gf0}#<8han9Yn7 z8#G!qOCQ<1o7fV;mSdKAvFOz~Y8uyos@1U>MchCi7~#OWOif2ZjXT2aV{V{abUn+B z`^E4x_y)b19OE-2;hp3@i{>){}Avr>6@T_B*ztk5+MwyBd$9QWgN7_)@VDALG zK^<1^vvT9`+9gdl4WAI;jO_Na2h+-n+0CF=_eycDZ0O<0W z*~IFqRd!q>7jn;3!nN6}8& zy&wSS2X{UKXy4GAbBX;uz|Swsp1Vipi_&$tYrPKq+dl2lAKl|Pf5b5w6M zZp^srT>w*H2zhdzpMp=u9rA>&Ni%rz|h%v4r;nVU?H_vcxk*6=OeJwzDo zJu|32Ouzlg>Y7sIA{@Rs)tWOTMPZ*AQ`L=+rT|jIfv_KG6Pgmpn9&_&Ga?dvNOwQE z6KE`>NBAYy@I}kvEQ?5$|8JL5oah58XyEf6!$@5S{gD98o(%xS=zV|(yt#>+V7*Y3 zc-j6vlW<)aP}?5VHv#SXON37~171vdPWcBft?^Aqm}W;l%*al`Uah4y2zV$hin4%! z2Q^s=j0?R!oE2pY+aWqCQAx;NXdXh4nABef`QwPDVEv#|zSHdjp-yql1=)~~5(c=| zGb#OhTITKL2j6-RU2&VA{4&4irM^)!li;1m7-_jLgoH&ON@VBQR_QT!#OzL^{w7L3 z8Qj0|Xr34nNEhI6*PV5(KQe4VX17AITAV?Jd|uC|R@q(@l>&+5Kt{hu-_@`=RFV2? z$PL1gc?*af+8

S@vS&_>_deBaKfIt2WZhkw2&niw?bjfw}*Rp&X))4svq3{5Sx} zuha_gR`xCa_`5ZC`+pA?BXQ;J7S$-5>^{_nXNO4& zwHQvWV_PM0xzQ$@Oh1L~zI7`#e^!XvP;dIV&B?F@dPU(`0&y5G4*N37MQGKbDM7U_ zU#;Fthn!9odT%u@>g8@f%SlV7!@UG8T^#n&Z6$8G-(CiGrEMcw&^9@2K<%9j;}#KD&0woWCbQj2<(*TE-uOjPHvaSpW$p_;vOQ)oEA z+=Q3q;wv=P^fx>CF(N6k)3hk8TowJ2xX8#CDksAE{EH%%@XdwpTn`}@v(rVaPTK`i z=J8}PYpd0Ut&0%ds}q(!c7a1%?ZEK|Ik-&S;XlE_9x)&dj4^Ihpfqw6RuMhAX)^a@ zH1PgUK^*iS;RxJN<2HuUYX$D8{3BRu&dRM@%;cYueK(R%V>*$I2y$7BoD28n&33e& z8;o638tsQY>#xWazlhbTI0cEuE4-I$E%ig)s=v!`i$CuhC5S!ce0ja@jAiP7-1^+H zlW+KB{53E3Qk#qqZ_(EntU?jG`SeoGe&jLuWJP=@yIDIbb0;3t{P^qZd2}R^XtwX& zd6*QW21x=r;2;gXKma(*Jn(9!>)aZftS>sX=(un?7i+}FACkc~m8tXRy|dSw5TuRF z&$k<=X~O}O2j{+eW3ojQ)w?QlZ?fkeYGFfpk#7hR=@@jIFHuqul_n%?bqWN8Fek#m z2a4DEE3$9*{CGb2$H&lJ?Y_1$+&v>(V&c2D!Oe&>*BAuYT}a0S;8A}&{)2=uAl!8F zF0`3B`Hu0ST@B2Rr2kcyB93}IMj z@s2yP?>;;aqdVFQEZdM2nHRiYBwoRgxJ|A!p=3^a%Z-a1;e(sR{h}!ylNS#T0rayX zj9lcINOtTfn{T0xS@W5jqRw0$xc9r`YvD>7kxkp%28a=MpvtHNk50vkZ}w_1l6T^D9{LU^~HORQ9h-gjXkzgD$;G zyz_;dWiM|x;Z`_rJ{p?>s$-~~PrFnO0Wcio>7x8^lV8BWl@s{f9n7D{okAI2KK0FC z=AQ>=UmY7la6`#lGhP1fZj_&I)RXU|Q)ls?OFlPM>x9`;T)CYmuW`FiFBThrLUnLW zeSa2Y$|5`=VS=OeJI2R%=-M1@P9{|+JU2ye3JtMV-UrObL!M$b2Q5Dv442K%+3-lX z_o_}Sp#M)`I*8CUu{%hXO>B&xvZp`A&IXZ2iXvY($H zo8H?pYwX6c?Kl6v*FS!)?%Jn8D{sSgPrO(1{EPhoJ9H|)fy5~t9iRrgDvNNBG!K$U zWIB{rDd9BWmtRRDE&Sx%OHV91O>IYc2&cCf~>5s4&6Hc=>DrYo1CgR z4|K?l#lp0_jh#G5qzFl8;fXUpuywb^%7R5sA=FJL}<_^=dOpvIQzA`nFY z8Nr3RgxG~T304oM(_cY{ljhV}J*m895pdl0>%(MqzS(n?q4b!Md#2ZXI9Q?L?lg!o zLFCAT%Kc~kp!S>T+YaVFYu5RYn-wFp%VH>=5(3f84IWI8-Av9Yj{S``@nnfN;I27{1)V zS9G~M$|++rBc-yj8cY%chHE-O8)8l%sCEGJXq^+7KOtP&K3qWt_dy?h0po2%Uemsc z{5Y?R09j?tmWRoUw9kfQ3e2svmoVwMcf*#vC}*7PO5|04157hTQB#h)G^S%dB5Qn8 zLK+rC`*RmnBU}FzHLXZ#nILH?fUw?-*7i$0QW;&kSGC6gKU6frF(K)3Ona*lzEn>E983`~ByTFoMnXydOd-o%% z_DFgWQ3?sfg_J_rl@=pWGdOu@1buo-`$*&BLnE9^I70mB$);{rUbHg8Wvbc6_}-?g z*VPPskdsP-D7|4DLw~!!dkF16TA?OBJR`=cJj4udRLi zbEh7?F)&Rc75L3;QF=#(HVhFU$xyC2Jx(h(53~!1#f|vjG@w87kDyY{b!Xxc@xN1GWcsXeXKcGV z{j}G=o0~!9HMf#HE@eF?yeeT5zmmHbZq{7H0v{_^n^3A{sY4ifzSvOjy=y-d2d-j? z!7t;{5x=?+u-Cv`$OSp`6w0$}^>Q0}j#+n^1 zkVltnNOu-s(EKA+@FI+UO%iS2iGz;Xv4AB+tObZHs$VC|`~cA_n(5je-^kccC9=#w z5CIb4;B!9u>e#sUR{~2r#`SALLkD-c*R$j&>s;1l3TiZWOt6|Y!6sXJkj=3U591Fb z{BBR3U`ro}G)oYqT+P!vk{W)>tiKs3S6$;gTdVK5`_w%Lbd*ZO2@TwD?>^qyN4HnG zKfI0Jgu1u3FlgwoIBPRqjjRqG6+R?fQs|yac}~Bzz9#iG?=XU-eKy-uahdhD-z~7} zuR>g{d6tUZ9Z4Hd-aqE_7`dtAOmIHb3h`qUo4Uw1h=#HthWK!xDN#VZhd=+{F86 z{O5CvO*?oo~=r?f;oHk7U!mIt#=G!Zb^^pZO4r`IPuE4(l)>aW-*Ocj#u&DO+@3 zo^x9m>f*d+sLA`HwLshrk7nFWet=1EQ>?etW;^Q9?$_7HnO^5z(I$mcTNw&h%@SE! zXEfSTp=*fSHrA1)C?e_wMW}gyC@dzM%Vf$lr{22Y#CY*jyi?t~D1hs(Nw$tl6GL@K zw1+xU)X5xfhijgNcCRc=D}T{33^nX0A+dEow|kN}Q1)Bk9K)q@0!4l7U74VO2fsonb(0{`WE&o(?MmHB zQ6|6czktqXLi)~UC1ECq62Asohnt^%2I@gP=t6pDObgWsW}7Q#xp9wG&CZ~mp289Q zG##BqU=zYJU@U|^&m+wTZtX4E-u9dakAadnMifPU_=*G4-($FfPve6a`#8!>)Lar7 zFdhcbUC8*`gf$w3)A@`@5<)|J9vq(*48+f#9pHs}m1Lr$)n^8;oQLSZf#Bl|f|w50 zGcdL+r725Xii2S1O{}PH@tLXab>9pw_H3Ok^tkX!^Ep-gk4?+zW0E2sD^Fz+=8<$E zK{z2c9_s1?vVKuSTkhX!S>WL{cc_Iac(9r$yxX4*r>M&yDtuyVF?RP)5#Sqa;9T~B zasrM_4uzL^#bX*E`s?b=t*+|F-X+%^Q`btHO)-8KORl@1_L9X>s@5(JiXU4c1S(20S9r& z*WvWR+xDk3p9UKD`Sgz_*;)f*lH7eQSO0}}e^-?68j5-Pxt2{?1q3@RC3}d>{jBa? z!oW9(z`2W^hp+-Q_kz}p8oP?z`?p>;Cvfvq=OnJ$>CF?{2 zeuE2mO7)vM#V=;RY#w*^W?vreN2d1%a(yv`5XbV5iKj|5(uawsEWqOCt8%ys4+JfV z{-$Gs;cLPk>zIL!NLhg;+#;9jneX<7xGH-Ze+1OSjbvN7j3=O#^u%6+u|FX*R=4e0 zeNuiJF$!xnqHoy?90wynJnxH~r(lKjoR~SY*xw);)TG@B9aglvy0Y7bCwDKkV`4WR zc-$&&`c?bnk$sIuFX{O(D^x0BjUa0Gi)RxOkMTT+xknW|T&9Gb_Dsa;d@rt{l|5f< zK0Ekip68Wu5m2P1yF*&KSsFn~1O!1qx|dFAmhOiC?elxz&n$D! z%$YjZ%$ysHr02xgHvy%)q>)?<11m==zZp)|apMsWx|#LZ%Mn`nIAbZU=@3Nx;BXkV zqWX5_rB^&LK62&03~Jm9^iZ$FZlfb?!5fNeIo5?gQDoncLu7HPL`7~p2b2~9^-B3W zbRN%!ZwL2JyWB2o>}Q-e4LRxQx0*J$pH7gUAmV?P5tl{o-#!u3kp*cGXe_8;)8h$X zpC4072G4^IsGTp;?F5n(*e5KLdYn@fozqE`xpKK}9jDbuF~sb`YjG_Q*X+D!(sU zU_z8pI?cSm!|c%+lb0ikj91i2tik0xBr*Ow(t5`b%h?&Pug`sTz@vor=-w-88yQ*0 z89N^KJ^@WxY1|0aENV*A^GEb<1Z8kOtuZ+^fByhEyM_M_p#80@iT%CQpvjzLqJiH^ zJDyhoCONKKr(bLmynD@sBBV=_Jn1tEQ1s+qDDm*iG@$XzY$-CIaQjPK_)BHvWGg2h z+t=>ITwhX{_k7zfc$hIh%A0c5=-<~lf^u11G<@1&+nQ6@N-i1zuoT8l5(XkH%ebQ~ zS8_)wo&hO}rYB|#ESH_@4hFld&>JvbUA1s^9TFRuIVn9oev(VhvW-T906zotNtjB8rHG3UI&|*m8-i~q*3q2Y~ijl ze$Xm|zMhJlns1TdntGXCx})f6e_D$Uhws5{;3=Qe#vBCEq~e&Q+@Qn9n(rm;EyFT9 zzKj=^sK@!+pN_wRZ@iR(4%HKsPPSQWU)*07n0T`ePh2BD8v9>Kj>wve5BuB1!H4H} zJ&6CbYqSr2;9(yUAheUl?Nybm^Xb?dE`hObGi*+fdhxOc4~+(^4vpy9XulQqm10bX zHVf!|`jSD;jTb5SrbH}^C50?=td=zqO@Y{6&t;O?koUX{eZ3o-@kZ^@I}+YM9uJY6 zM^6lSNIo0CRo1uu+4s^rthEj1G}2Ly#7DDz-50a@{d`%XTG?Lt@!zGmO$K+Va5;&V zVRzD6-dVZjZN;h+5MUyJY~Y!Q$7?kpL=chg=PIj0cIt{hb5an(CF^EE?}L^c;d8#U0TFDT-O(y3*5bu zFY2KPrFPF(;1^g(rEyw@&?cCHT>&D{0Od8JU(6=ic5Vxcmcj?qPinA1{pa|*#k++i z29|MUOSIgdX!#f#IW!N)8$}MQSn!m#&&k1=%UPSZ@rdr}k?D_*hrJ75uVZiQg?wDy zPXBsd8aEq88@e|(*LigQ^=olCy}30K~VAkVP;!@Cn%Y5 zV!@qYwd9{i9}o#uz_(gxijB2N-s7xebW=OQbNWaI7&Ueb(jbN6E@HKD_zj4!EU&-q zN^gu0jK>d$M2UmW2KA0gzhoRbeYvo|@%zMhc>nQ`wx;{t@Gswoq7UB-e=WWic~5s% zC`lN#%qQ@g;zLB1Gx0TFTYp_M3RGfjSRXMM9R$xGUkv2d2$V_vV6r zkByX&+mSTzZu#ym{afZd#UW?xt11!LQ14SOv&6dGxDK>xY%=I;5nvs;81?SbTPqqr zDO6tZeDm^s_;Yu0JA3yalo`(CUXJhOm5F}7mA{oFD~BS5(d{IFY7{g5Guz1xb!h^c zeL=TQNxY^;TST1rfr{vnv4tWvvYL!G!HJOQEfcHTd(~^N?B2x5#(lS)@&>?%Gm7%M z0N#n@2nlW}@Vyi%W}3W9FntA{gbzkFPgfWWN5&jh~*J z-*tC4ahD(c30$t&@D^zZyMiX#QJ^=HWcB;nL%%Vp#-f;m<+1>CxC1Wolnv>oBIrW-}cEp zMFG5OZ*=O{`vyhW-<W7O z{YujYLmelFp=OvLrp2y!QarV^pLF-?Mc7KL@Yg5T&9V9MOFP<6wxsKwWqSf`AbE?+}@0+8KA3EhB$C^~x+jNf-}!n1di^ER!<|H~YnfEZ-r z4NbYLyOL$M9o+?ujhVT2hb?FmU_91$W6m@Q6IjJ4yf-PrKRaCEg8r>2 zotDDezWSlvR4^qMjE3<2Ger-*cZ_qLQHujaLD$91?WIpj9XlPJfCUiz2@w$novqGY ziSg|{9_FMjY_9F;dtXYt*7uP%N5UCI;8?ud2^BVxmyUEyq_Bb%k-Hni z3r2i?27!nKnU|re$SX&N{PgAY-`Bf&PuEjYhJmQUi$_XN*oBlF-z^7`J%L8E<-q)N zF%(Q5wDiLtiS@i>Gg7`eAG?BK4RC$U*PaWe`dP)@$Q)oyJA^fln2 zpWi@+6zf15J%5Dp3(@1Ssrxy^z|?}q>f?ULw(xSap8WBgd6Is6jSYhz5Pqr2N_IXP zF9h%_%=jxy7V1B>NciM_9L?OlR8?&Xv7w|w zmnfqt$M`O;%EXsD0MUJwMygBACIt$YW2TSVUVH!QNXY~5*wQy7khoOWNFUPSL?KnYB16aH zS+2cH*&i+? zz8}8!-YYkiH8&wACUL&bb-8Z0?X&K>QIb|Nj(fKFqJ2%2LC+nn9d1dhymY=Aj2%K9 zCIuconJNjsPK>?zQm$m#8I>Y22 z1WpF`cYA1ZxxIMXW%YZy+=}!K0!U@=-ULPE(mmVy_HhVB=ewt6Z=pi=re$9M=#7n> zhgHje%Khs9E4NVs883z%QD(;w8gIx@ypLKRuxwM*1c9t~uhp#criLlAdpZOCthzM-HRjwz7UQxdr$2#CI1crqBJ=cZZK^ z2KFzY7@^4_j(i#KH=FznwFIEwJw0@plKM-mt(q18DX5R#ebu|bpmkzl^ z%$PORA!pWE;tMZkk(>h!Hpk}On5)a?OVT&<3!>Bjr(U+k7`}m2y!9i~QNh9JTabru zIi47HEa*lX**}|M&n7#j0Ty|=9CFgDcGvHc1!B(_`Im0ij z=+C-S9CByN6^OPJsKFW2R0YeRf8!5&xm_a^T6=^aC}8)@oID6wlFKUDXH^=K6X~ z)^cH-)kOljfmV8tg-rFErZm!2D$iG-a4RZ$FZcVuw`&_~vtlBTy(gPH#$6%*=q-J=_}rQ* z^4;0pOzW*YS(5)K!J+4E+A|Puz}=61rBz5y@umsgJE$zvHy|e+lP(3$5LqVTZpDNC zkpc7iWPfWTc#D2>a>Gs(8pC#(weB@_LQ~wYE5q^Z-)?h`pP|-{Jlh%h8TIyz<sesFEgnIK%wq@dvyqXJxcF!2A=gW{#!~1?2>zw;9`WOt zz~w;$b8TMR`~koyLwsS&kc6?fNsNOmc1C%tMA1^%m{>$5aauBvCfMamBes`p(^QyC z&4RW2)7^17;f(BN@4P9~+}gcw`wM$mx* zsWItM1q}h)n!$(Gsg7onOBH4HP#k#*n)|PCe_vwYHaTIA6jXu9PvpK%4P!_d`7ytS7}}(ipOkJOYX#6M6~IZrGRVmMH++uvyK_ zukPr;bqg78>OrXAQ~RVpW!?LoeILwEO@oH;s!VEjsLEt~a?YUOYNY!^x=f5CC?Pc1 zYOCVBcRKAZ9in)?M0-9or|5Cu?OhA*+g>#bbs@@7_~i9b`jF&}?l@x08S7g58C>@&NqDK6 z$J;5pJ8C(oUW(MeL>gYP2=x3JND7W3#XSkKow;qf12^=y2q4z=$ z#)zaE5SPrNJHtGYlV;BWYtf{G6=i@LUE~I*EIt>}-AHTZTw%VSO+}OrFheCH)ph z=|S$seM?tXP}n1`+*Wq{1?-=w)UcGLDT_8N4rCb_qFrKfAm(VT(YlxxX0WB`? z$$VjS3z&FJc=w)3sI@yw@NomIzpvp89CHGI>-lTBDiSVEuAwKwP(z<`)uCm2U5m;0G61;>}13X zb|Q`fx-=i5_gZ6$1|;sW(XU#V1#Rn(UyPB++q#yj0VyhwmsGO~GzxU%E@A=&fY^9AJ5FB07x`#N?8xcwt9ARe@{h4hF`=a0-&b=}yZP8x z%{(K6+68}b1D_qld|!tOY-E}))G(dAN3+VI&Cc+!;zUshwVcCmc1(?@2w8;o4oN0% zbo{Z=`_&YKdvL1^wTthcs~1O}^@forMIQA(%)KaH9Bs*LB@h*x7zy{-L;(DZ1?R4YdGc7Wv zJKIElzg=CSGQ~l%NS4C7!H!!oJC*uptvxPtFQ<#nqdGKLz1$n#I81Uhu8<5wm09Yl zCS8VN!`WL1=#sZCQE4y`SR|}7rDPJ1TX+n%9M4J17e1fp)r{N+y`YrBm(j_wrwhyn zVW?;lzL(ZaAR;+8f0xF3RQj%z;%GU?bo9~LrFd|#);krq=SN=Ji6l>FGJ_Xzxi%|2 zLOS7R4#nvnO!>xUYnH?XH4DCb;}vDe<%y-eaH5_1QoGmZNTFuLudQA!K;8^NdM5pI z!}a*5Jaw;=*(p`Tsmn2&Yt-6PVGB1+ZLAOGW4$FVu9#jj&Dh)@wx{LCF}I)WP?L zy?ifiM~B!th0TlaLVbHh?N2<@1p`&Uh6OL+2xHNgu_FKW^(k5MPq@o?@=r`jvhizk z+3_3gFtbgE$9f~8sHomjFuNQ7EZCirI?965rlBShrDJkZxvP=-@dw8eQ)#GQZOzII zLL8rgl@RL0STVT=pD&ovlF$pWBmaW>l`J8|ve=r3P>FUNsDtBBZD769fT&_p4M)iwCX0r02Q4Hqc2_T!Z8&ZP6K~mbbw` z;~mXFl1F?4iIrFWAp?PNQd37YILa}M|84^01%bbG97VukInz=@6@07*8k&sp$}AJE3n&+C}+lyTP4 zd*%aA1OKS8JQvFF;bFYO$mKs-59D`!vlvLj$tF{U#3rNYpxN#x_F?Rj?Pr0+u}QKE%2IM=K(G+FQSK3TB3 zg4TeA)N^8lK}A;C_}`!RBK-M9?mWyC2S!wmuWieyv&41=gEbF?JZ=jr91at>?8=PN z#n`6ND=-8+_~#b;@!uF-OC8v20*#_bBA#WULLSnJIAvz;n!qbrwB@Z(*uI!2&}|?M zm)-~DDbLlDTV=k#8&URsR_;5D!JgqV-{5&9o#uYObuFt{V9H+t@z?hl!DT457#ph$ z2$OvzsvK#z;}?^Ox7o3SkHgT~IuR`Kmzl6XjD)x0An2V!zJHQ^jI^~%CXAesFuIXp z7fB&sl{}~pCH;AOa@Q-%ZLr=;4zN22IfzCaniC@pVp5q%XRxz<7;uCACp0Uast+HK z{}UR2C?K>+|F>oIrSk)Xa}zwo$fe{10M*W2q%Q@kufyw5DCydhT}8~$O7T+|5<+^* zUEg9_yTwj+%E1%8^KeHVbt0@b;TFf|wk6be3OlXAss~pww;2@&6p37RB}Uf@fM+Pj zIFI3<;~7{qX7Jjuu6yE8bzh|bcBhkbrvS1NED>iHYV9fQ`3iYy9FR$S^l7U4X3AkM z$$7dpz#q7o`FweJaTeCX@0d>-M2R1js;o6#Nm?uehj-zVf$d)?SgTM+kt-8LH_EIb zeJNCZ9nF9B8bbH*v;Gr?GErYA(|EHsDu1s2TC<1gvVL2Awe8kak>U|m>>6U`!bT`r z<2IenJVxg21^8b$EVrh+tZAY^c((@GqXMDOs6x@O#=bjW+gOm%c%rO9^Rs3Z9tS}g z_1il86p>5WHD2KH=)HqxS6#qm=!$B7md2<1GNQ+nQ0t+{&9dPo$neY8WJz+UqD#Ve z_o6u6&YUhlICrEQrOog7HbX@F$i9=38M-w&^nn|wGJT8tS7lP!V*@@E%$t2}VY1;x z!=g|Imm7o}uz@+8ler!WfuWcJ+5&^;wse|e18)!5JgOq#OY{9HcY^sDVq0+fiTHBHl+84N-4L6xDW%X1AOUU5LX`B~>ytiOss5=?S z)WixJb<9u=ple-1s|rm*#$L>OfLi--7M*CR#fizG9b1Cd76QW1(AcIX?!(+Qq;I;h zYhP+yT{PYrFWH7HsmfZ%cL80fJ9Z%2Aj-Jh)CnzhWhF9+qO!`KN*dO*w4RUE$}XaWu;i!PRVV-oAL=Oe znB7hr4FWMP6P&Ue;3>wW>;@zG#7S8$+1ghd;`v4?gZ5g7vlnHpjU?u0dVRanT*xAx zE~5G|(u$Cgte)x*N7pw@Tu@Q%v}EVGr$-%kflj6(sC^Yh0S{(U3Ot4o3jGxcWZKcOge9m>X&g8{ zTtUJZ;P^CEYS~zO7`rtmI2oywvlK|>xP}->-*=6nWGXa&Am5Bbi@)7$PnJ*)a}5V{ zCR~&^MjAi2U}TsvA<@cKi|^bMv6QlKaJE&v9p(3?E>%F=Bbg%BR-(QcrU~z0MdqVX z;PNZXK93qRB4#H|BrTp|%F8bc(+stAVDpwPU`q=tT&$hY@_5fGJ6@>?57I<+IVN@I zCJl;BDCC(*itP~5CP?0e#H0ftOg8!iVdUQqJ9fNHm_TR;)JP62Z1*b?xim}=AlKm~ z{hlrDYr$gewU+zdZ|K2_K2j;ld(4g1&fP_7WGV*X;__A^K_!G4KegQyP!I#ss~5oj z1i9LP{Y4WBLTe*oEMGxd@CL$v;uIucBj2nu0K_Sc_;>*0KCaZ93^D+=2Y2Hp2ey}~ zuaW%8)g=zzV=eyYVI!8zh1ymT6wXvyY?G3lNyNyyOO?0*`wWiGCeH=TonaeEqR8Yj z*5!%?@^=f;qR&u@G74<2e|PaEGSz{ZM`kt6XZZHUX2GLJE+WxwHDjDj@O%825USSv zdwS;=O7oXQOG)zOVSWIwn%>fPWeEpGzuU;Qe~2U>3The&e~Slq_ z&INTdDpLaDP7a1{Jhq_(2mWdps?AN~W57!WMXK z78JZKzdkuDCA)&%T^bdjYkQ~Urb3)Y{s>5`a~tWQNcJ)wyO$r5aBYXMJYhR;J3A#v zy9V=fT)VCQ+nr?2of4asD|~V8eE&yAVGX^<@`d+n+B>Z)#Br%Y3CcKdjETD@0Nc*2g+!v2`Nk$>{JnUQtUcmDd>{G0uZ}h60#JHPzY2-mXy6e70k}%1{j;% z0184r45-Iq9E=NU*V`IBZ4j-^;qGnA`mWdM8huG6^9L zN=k+#9QYt-YwoygA6ik-u~5LC<3XF`cnMV)4IJ%Cxo?U2WefpaFsJ(nM zS2N@@l<1v4p*gdn4yKaUmM32vuFO>dEk~NLzY|* z13WIz1Gd{i11LbMDA4<%XhX(!-l;w^_D1U7U`cKHT>aN9;D`tXd84FpF|<^Y%Xs;s zupN>kKSH(Pzrlc;B$ddA>h`f{Ib#m5Z__4<0zbshEgVr}Od!%e-(*o|a*Bg@S&L2_ zi2&6$VLW+8pvF6?4dzglFO)R~7aAw6HV{SurYuarMod-*(WQ|_VA6ao{Dmw`8z~RM zAW+|CBvpf38KX)iv=jm+Th3Wp@zj@Hc z>SO5TN4YU4>r0tsG~AeIBrK{#B(#9Ah0ZUrq)g|ZeGOfc1rt~KG(En45NA2uY0lFs zC~bp;x*VUoaS?aM4ll#(dvZ*uMNid*&NRf1uG@`X7d}n^J(>mR0nWr&iV3-zK2U~r zCk@OVC+iKS(RR+%l{WM3EVbsM+tCH?P8Q!#zB;~-ph>|DVH2%yQ!pP!?X;P z@8x>BL}U}`2Xx)`KkByb5mUH$Qwp!tmfPr-*&bmQ(1??nipla8HCUb5-2Uy^8k#)4 ztoQIgIlP|OqccT3ynp<94&Y@>?#y07EL{0OIZ+gUCQuVsNl6T^EQY>Lt3IalxuB1c z4IdK36$kUr{IgRh@`URt4wTbph2dEi>y^(YmXT#eJf&N{2fk6nO85+(i|J!JIgY!1 zH^p?pL>1Iv1ys{_giWqx03AOF&Exi`q;(I=%S{E-4u{bL4D@zkNm))aPM#3DgyZzw zyYJZY+~?DX)0*N)@vgt5ZHp2pcmqOGA@ ztk1*nmWTwV3udYiH-~c|`1k!yC5ZluY4`5N?W7A6+AJo(02n*NFxS6r_H`LbCgu%< zy6qe5w#`HN@_9e0Lj;RtAwGi`o2yv6^QS>n?`20g2DfcQ_Yha!z}>BxsA-cLe)a~%oJc0cyi$#^juxc89wI~&dQdS-=(1Ly+;z$0n zMNAOeD6{z&oZB~Qttm|&o@Xri$@g#Ys616I#B#%$eDdzP&g zUD_3U))tDPjm@KSOfl?9ZkN-%%}Xf(6(xlGXh-b2S!%Qjwn{{+I2+&xat0@RNH~Y< zhem<&%MzwMmZ*RVz_7}&9v$WTu8FR4@x;7APIpctc-y>!UCfL{dD}pU%Q2_>*VFvi zOin-jL%LLtWjBwbz#^s#VXV}L7wder{E{XIz)>q5z;l74R$@1g*kYSY+9+$DL$PuY z_7<*ZJ;li=isQl=ubc!u+KJdZUIM40WSS+xR)nuqN+#8|UJkyvu5W7GKAXN{v$@#A zQ_`g_VRCPMXK6#^r>x`(4cc{T#^`b4ZA|uQ@gys0&iiALg5K$WaJAAxNt+J9H|d$J z61>ysB^Yi#$a4o+G%6JC|6qX2SZWHLMwNnjFh%sf*6%M zLbUjpP_{@5P;@&D>Uf}w?=yK6ocYZoq%gh|}c6$bhV#-n>l2$m-Q`Y;W<=qFu6Nu&a_} zt!deQz&UM})kcW|(qV98N@TEER9OH6`&eq^PAVA61^yTRCQy{+gE)!MMji;pD|0x( zZP-v+2;iVKw6}?g`pTda6k+}jl%m>>$ue_d)MRO-;ncH0s%2GH>_B=xuZSzx=)eR7 zAWfVFAOP{62Y%NAEhq-L%E_N2HcH=?p)3FanhLS_3Ykif%3ILAV>Hn_^QTq0$AhVf z_O;zABar^*rE+VJ?J@G*!#^bg8nq%jeM=WpgO>XZnGGjGHc zoG|YD%CXf+K>Js+enjwNSdnx=c~CWQ2g@`z}+#bY!X2)Tyw>*_o`|IlNZ1k7R%TfaOm}%K}*j2NyFeUqg27yMUbv z#BHz&q-n>%09=!F=`>}r-(s=5Ifg}=yGgy^ki#G*?&~Zh?xxNsw%(`zShBA&HfAI8 zpK?%Lv_B(DyM$urQbDx|yAnwK?p%kb&4-BpNrn?{u2$i$(TLK_d6#`p^u(~i((HW)glzwPbp}s{q3JxFy zL&TyiGS#qBacYfRFT&$gY;@UbxBkI-;raQZZ6@`5l^x??frH7^^qGQ!@89K{z;^Zp zT!0iZ=`@Y8-#W0n)g-`bNgQ_dY!TANKpvDSI+H4`NSpbp^i^Y}GURibQi*_~62gi2 zMg1eKdWLAHkW(tqVXLL`j(y)X^|WJjf{h{o8?9)51Q14dSy(-ggYbGwzhh6yDIRN6 zNctmnln)Q82QDR)?uVQ~v9CycjdSDRXV$it^nyw3N}mH+mCoR^=CUg!8+LiWx=(Z$ z%mKE=8;{cfwlxTLc*5#_k+w7`7moF-mkx<&OvPer&|a$mh@Q^&BXQsC=%i{_iIAVE zD3Bg4M_uNrB$aI^1-?^EhR<5dt`LIlYWll>a!zxe2os7}v<55?S}}WGf=gT8)W4_P_Nwd$j2GTv4rr7d*F*8QrbXf| zO^1M}k5GR2Z*zbcu0;MX(t$_qon;n)SSjBxY`OpKPxIgY%KFDBUbV4HDIx6m!9FW- zEZqxQD2`a&PWKJxslS(rRdA&m+n52@pn>Cv)iZy57Pzd<=A-f#Ni}JT%y()`1UIWqD>WVx05s4`BprlnjT zWm0VUfFs%8-8j0^9QgKy@eBFK1@VWsKhNsT+x)}h;0w7jRF_BY*i&ult9IkKg5;Uf zU>n<-u@p3a8rYgf39qiPZK3g&GBDXikXsNzk|}L37Cs=Wvthqkcnk#)rURR#P36ZoS^m$ zF9A6v(P`R5TW7F~h8nL~&+Jqtz=MVW)d#zCzYL1q0ypL?!~=(iTFuiJtr|9W&+otI5Hzl5p7n%2FRiIC#BJ4%g>~BVvSl>6gtlMn@z~e)>!n zpTzxqLmc%q9x|OMYB8uGbI>#$PJeB>q)zoeLJYj^lyK_kg_H6 zA4vNzbv9;|$^ppfZdXruufreUbVRf%Pg=2W&Rl5o{;c%olLv2g931Jb=Y(-7KvN$t zlntOcr5za!VZe6Qn{@q;=G5;QEe=M7^5{w}wp^7&4Cm@MdO89B zs9R3SrU29pB=XtF`U`b83=D|cL@#r)Ngg;1+(F7fw0oTsqs_MN>YU`!t4EYnE!jVK z3Kk$#LWqvSaqgFcN`Anejd!>MPKA)mv^3H!#~wspm=~cyO+L_nlUVZGZEi9NTo|?w zc+*Hv={feKx21ix-r62}$ED1LD06_XirO*xBuiyZc;ee^=Ge}?{Q}_#%q*EFiYPhO zI&!mP3XG)yep*^Zjh#`DIaFHhZl?~oGDzcS0FD849GI)k>7!h0C9wr_}n zD5aZm2Cth;?1gi5;oBk8X~8IhB$RfvMaSEfD<7Tuxc|y7Onr%yUL%)#?IjC&4n{ zon~LC`uA(ldsNFGCuPO&Nt3II43OjP!Xl~Tlem%-q`!uJ_;=Cvk)C5qeOokJdk$cO z6qBbjGG9^VfHY2P&jd*0%%3+7&0iZx=#+4ner^YP!DghDfYWy3a)+hE6A7K{1|yNV z=aNvX!{PyAfj-jo?5TdRYeJ657#(?Yj34;E;Div2YFB!|qB_33dQNLeDyDsu+&_0V zoexw)rljQoYPwtsuvvNe=tc!_3p17;4iRv+(iee@+MF?v6NaAz6cJJF_`0-_0LVTaA-wU$un1zrPL;_j@dLn<5r%hU>jp;%x8<*r?m zbY!Y#qIbN-2D@WiTfL4 zz$@zKEW8F4Ep!4tr4leVFVkQ2jd#pj%lYq=i>7DmWmiD*4mIzlo<0hWPgem_wc`?a z0o=akQS4twRT(m45SsF{Dt1&ROb6MZxg5jXs||x^nUzU%seeO;ajqh&z`Rfy;nr0XGW3FOhEiD=& zAF04t&{Hj9c_EZ`(Hk@bXIn{#K+f`7o~J3yyAQGbwK>J5&%W}&@}vjtxk6M z0TwUGwNwgQ@k8{Me!l|@;>7N+B(Rz<-I$-U^%c7_FyG@v`Sg=X8RL+ouXBB}`3{x; zwQ(Nur#+pr)(bmW9Qeo)F-K)&u6=9^;smbJ@u|PHWpPyQOIVEz3SUW#|0WJo!m$9{ z$m&VpZ*4{#m8kb#Fa*$iurm?#4aj6X-MBdmVo53Ygi`l76awP7D4%Y&Z`hjM`^E3)2eP($>rDa z*2Yq>fFXU4HM67m;Oi*6mIRvAk9i5~3BJ|hiG%N@z0R&L_FS~I%f!YZZY}M8Rcyw; zXu-}=uII}fSSl$s;hW<}to7fG{ka?~nQ4z64i465Zfn>NTkcRV>K)so1B@JP=q2gC zY|l&<@g5f;L?YHiMuQE+Z2t=xZwXFDG%)oL8_+4CI8k%@~CSAfEUI3j=Mu1Kb+ z99g#!{py2Ml)$n`-v(E#{qp^#iKxAw?g1;u%1-5`mMiN4wM0FjmZ&F#kRkk{2ZNXI z6Ont-L}dpMI4~GR^1(}r%xv+rm~)V|KuEiCq%0GGY(sp6g}&`gN6U2X1m`=~*WGt} zYoFQ{s-$>cXWj5Da~|(W$#8%K_rkv~58vxF-yPiV zFZ&Rq!5&o>ttF!T{rro25qk?!Zc)VKXKDM^@$#zY#p(|6CC1zR8kny^w>u$ZEECUO z0NbtdZO5+y>ql5#TxDfe`~^=3As}rUjPH~W=YZKkO+ly6fKKU2YNJ%7e1J>qExw_S z=G*ocoLXrC(N+MMScOraB9KB?V5EH3HhiU=6HRN8Xl=N3=VERuRLOLYgyDP=HEA@e6rREh@Xo7t!hWPnKlM*4Cj1#O(@V5pX^c-2!8Z(@oc zW3k!J=3uH3fmQU!s8S~SyN_*WTMGxbpBQfEbDE5OT#p7V4L^G9kzGtYNGJv#ujd z7tvoD>Xd9<>#{QrY_UbUKEX}83Tf;dPQ#Vo&!UddEwOE_Jro^r_YyPbHh&zVkLv#* zR;hMgP?7;fdd_Qp-ic0P7l^l&f0%?m{{{_sGb9(J^#X)p3v}Dt_9bPm_&>VV7W?}? z1_g^$oFoR?hnj?xD+<4q(EZ=zL-n}gt=`_=btcL2j}qAQ^4x~$&>U}Ehkz-Py2`xn zyWY2r2OF)|y>CTUQh5S6A`(Jj@!QcWG)Sse$LSTrh!OOg~X0o1=MGIw!y)WP=}j;9rAZksmkK8q>KcfC1Hj~k|= z`fILFw|^flc)seD{TvYUpLybNgqg9m)f82h0*~XAP_yyx#MrP6DB1rUV4}@{_~Q8! zZVuDCPo?Xc_j!0_0xtupd-|W&vZhfyHO(`&8Z12xzf6BXc<~#Fe`!pIf9+cB^-A4r zsX03jqOe)Z@Ov)I{2f|zOuEB-D~=Y7)~j>v@oj@W@5x@|7Z?5XV5`e|)cd^3k3OgV z-oWDz8xYz`(`~g0UJgjiH=r*n>DOHQ^E(V|akB%u=@)zg-r0@=PtnV|OM32dzsB}a ziKp&Y&g{jWt_}hQrJC}5j-lxIQBDG(;3Yj z|6R&C2veU5*A$-uL(T{CO`mSBV(Lk1yvoit6Y0H#HfLlayV*%`k-cEU2DMIYK7{!@ zE>|6zJfIIWlLlT z8`tdJ=h81{o9e}TeyUxPeEq~||AaOSKpqB7<}A?QAMXMz{r+K@;wY9s3Rtwu4|^JR z8h-l2{3@DEgC$`{q#(=&)mR0@+oW8a!Sv5U)A#uTYKw9GK)davN(Jje-vqKb>*xCA7E(@O_ z@93Xoji;^L6H;9)$nPX?9_!i~2&A2Q!OzBZ5E!6H-(M!a#zSoZRluuZRZ?0~{f@1q zKA5rV(Cl#M++GXq(1DM?V|fh_ps*mf!N@nD9~7xUY}1xP3=oM(x4ONgX08uwrCLdw z-h+ZZ>Da_4VyBl_I^I?a>9PztFG|sv`59;-<#M7RLnl~_?Zjuej8S%Rb2{au&K6Km z5=9|HlVA>a%Rl{$zuUJa#ADrNHlMD3%);OCiyJl{%tv*K&w))z)A zFY*RYt3@P>mUXzUDaU+i%8ez4J#>(M=axIUL;n^9=>c7#K&xQs=GLJ1wwmK;D#50` zg1?euD;VMS12YN60CS=7RNP@acQg1mAc#u-@&Q-7b~0w~84e|2izBx|=wqFEj*H%z%M$&^_Zlw%m)D8;H+B-!d@$W*W;~C~&pw zjsRq#in58??bN-&)To$};zn$J0*+eabc~DAd|mN!K(stq_ss-X)E9dv9&z4I68R3d zcd6EOhDjpa=ZPgUlsi+0sj+lz7qqhDu`d%VO~<%Uk%rIM8exW?nl}lb4H5l??PGMDtJ8d8AYQT0_(buGcR zxCb@_cMT-Cy9Rd%?ry=|o#1Z4-Q9z`1$T$w1b3IW$hr59@xB%xj9uN;C9|r#XS-Zm z4wc8bd@oDODhVmxi=n!sUa2J&SVYnb>OmGt; zCV-a#ukUspSB8UcX=ymEsKngkm;6m9S&BR5$b(7Et?)Owhhwa=9>M3^yAf}=sM(t3 z1t&M`0^R`$V4E=8&kitqxXajNlJ+P0z#xEhDu-n zsauZ(Oj9=`$W2|3!KJH(I)&z^ku0xobqK_i4YL$!;hKj7tgw>(XJJSA@6bS>X=o6c zoOH2pWAb!sPX z=a+9D1(WtUZa_yTuTvlC~sJT8->*%|uK325IF8 zSBweRk-#V3c|UTEa&9-Z^1V8mN=QgzmLtvD}q-3QjvL zO!$8=kYQXUk)hq6t?jH1F3f)jL{H?yw+njwF+b3LKO#B(3$G+uTsm)o4u}D#ND0WG z-c96UB#mEW8By*L`=%0V+p_BUV-nv2aCfF?zisUjwBRJU1Uqp3xG~Lishx@CUiZuj z62yGuXF0o%++1$ko@DTcWbMIeDqkMWF-*pWxkQ};8^o3xb}7eAW` zZr0!)Zg1TtwzGSdudaip(>rU~YlkdnQBC2^F055Ah`1hPPMB_o%U55jI`Z`uUUC2Yn#w%I zXo{80UU#zPtxS}~g&3Fj_u`H4=JXp*8Dzt+@Upml7I@&S5B!HdgjtdQkB+u41u^^VdGx4>Ly$6&qeJSOgweM996#TwJM;r9bkSD?P-^T`bN z*pWk#Q&$@=l^uy(Wqe^{^#hN==sRZ~B?l@VsHZ_Ex1l1Op09lIpHTdorwA}kURup-go#N6yx( zuEq*iZ-}G5V8reBlgnLZ6I_-sYnOrn*T0zF$%fb9CpbXwBx$cAbWd2#D-ft6*v1N| zILzbjqeXl2*sziW2TW0N%z<{EpJWC;%rLg3oc14TIz`_pd&@oMrw!8U?rn9xeSz`q z3@Q4YY5rDhlTSB$^84zABTq^bxZO>R`))63ZxAAo@iAyD_WWr(`snraFX$k}Wf6=# z{}>uUMbMKPz!F6aRl`Q?NNKZE+Xfh>p)QnQjM*?ARG$#=QXxe!@X}zN09GKdlEhGW zPd5U^>R3iL)v7kye+d9eQ1%wc!djXr(#PWxfCi8Q@(rTTHV{$==@Y)O9=bQ51T+7& zgFUsqtQ&@Mge1pw7gdO%5+E`VvW6|tLG^?z**IeLV&E~G&dIp37!~tUkjf++*8(}n zwo7%A0zb}=O)E{Z(UXbW6qEKpUDSUoIYwMncIsbr}#DALcs3Up9u zAVwFC)4Z*HXC7OiVAQD2dD(i|wwIPThmQcU7J@@O27+ngA`(h4qN;RZL4v*+0B6{b7Ku zo=k4Rycp=n9xM1DVyWk@1ulJ&NA;xfAhNIoej;412!F`hQ->N`GCN-u$X{?w=Bum{ zk}o0~ATL-G;>G zz|ABLe{okNWkC%Bb3W9oZIG*_(J1Z5<|$|zu)k0-6Av!H@%_&QITGf8 zF=Yg0yHnyF(jJCs7Rx!5X}LbQe0`yB0-m-`Gu5ENPgm$BUL5CtQ#$QvDq_1~lBW)a z0r#8g-k_1;=i3b)^K7u9ZdBH`yIahV-z7L%+1T0$F{LBiSKx;dJJg{43w5+bOhN+C zSP`53@yMo6_9G@zU+1xghADF}J7XWSsY|oJva-{3A8cxx6Lez1{R}DWDHTtJjL=C; zyWv00Rf?S$@m{Z;x-vl|m+}@=y@653=z;Kz$MS4j{P-{X=`V7*m{#HOTEo7cF8)eZ z&?j4btm+r7z{j-HDo70uy7WW)ir26$$eR;eTb3Q~Mju z{bD>@iPVm1;46-^`5zS?Dnsip9?0^2HhRdn)m$YxPpdGtUZk=rx9b~dk3hilbIAUm z)shW^$5WV#&#^?0j@RE7*Diz3&I;?qYR8<>Qd~46E&!}YpNz=-w`h-mp|#?K}n zgrLYkAH~69%lDenWv~u)QSWEusb_-FtpY;PxFCAS#-v?7<=)>I%f+OOZX66Y2u;E8 zNDWSwMK~6Wk8HUupL>_?GyW5%mkui^j^OccT3m?#H!b{RmXI<|C)^!x#TNz2xxf}h z*b>`!aZQ80sMrSBQKw2tLMrMAMY2LW!EQfyI> zQxY_oGlO72OA0|;UqxCe9xBgTJ*#8P`=>va_wZOdUsaCl2TWnkWv z_eh=mXB&QSflCMDcAt#~3v9p8g-ne1kUFv2diu0FjQ*#_%l}p5VfglNjjPKXSoh(}i-hKbUTUC``=6!|~{_fUYWxcP1#*3rRa)#D8K z8N&=U^ur8uZ?;b>yok@jWyIPy%*Pe{Ze#8Azbn{v*XAgGHYE8ss&W zelGNx2`+T_3C{zxW0Z$y2~5)tBE=v{fXdk~-90eJ88~Wy8fC%IsQQ`*3a-&l5H>zNGsqQ{os?$ zu1V`JpKQhST=a8U^V+wft0{M- zBW_c{(;~;ELVzK^XHy3;Y*QX?6os+xW2ai-Rq#XSFc-W{E0PDLXMZ<&Nf-+I+tR{Q zOSUk)qCTKX1e>5B5?9{|*2SF12>TC0`c!$7c7h0uugEh(`@e$!K5uMMNoAx7A1 zt3zwNJ^ZG0b)9cICSNiON{|sXZ`0b%%?G>yary3U7E-@KQ+Bfg*el~#^9>)@N?MFI zqT|9q?jbElrVV=~JhWACOo?=9t3dE03Pnw0aYStB8XTlHg4EngGbBvCn47_CBOC?K z+q{VONj6v>qu>;g&{-w?P%o%?Z#w95RB(^_ammE$v~YqoOCANX;1f|lS$YP|$b-f0 z&FRO;=GYclmmO7rZ+F6654eTt(5sDcKgRTPn`~pu1?6ft_uBe3oqqTZ>Af)%(9M#H zuHb@gkgpdtDRYR8;qaa;R9r{>U^&ca4n`G1U(`%8x0lg#?%m^r_OHK2sdG^h<+=vB zX^6;N|Adu>=H0uHVEM^jo*Bw`_1ds5|MKKn-*F|}$Z=e9KC7je&8{Wnr%MaTJK4F1 zcVXME%YHR?0(s;7W|gdOv#p0K_eFwJymoOSVH>42yZyzt?}5!|gzz8*kMbNG**}x{ zf&BI(j(gO1<@~K=h1>?Y9|1|@9{lK40&->cp@i4I{@Jj+e4#McFelCIe(S*>f4Gu4 zrJsiM7Q-1nO1}YZkhV<=_-7rQt(;3L++LpA4hi1T@Jn*!X@FFgr`7_VbNsyneAh#U z!qY7{26hyJcL$hf414*HP@GG5%0{vqJe=>> zq`=`=l66~sDDMiSi+gd}tym{%i>-dQ*jZ-HL{}q{k8!T=`qXjV@}uMkaUGXNW#mf= z-T%cUaw9pgz?EVWt=2zzDMO`0lBv><#=8ZsD-iAKiS}XZ!!pr^{^`qtg-kA2`OQVN zRX`i%xU$EH#cJq2dl_LtRv`3;w%C@)>y~lK@Km77{O3cHz@MhyU=y{)63Kd7m%eekur<=6eP_%I7ijPK%Z;W6?QUXQseCGr0uPl z;4|-G)>_fA{@{Mq?Dww#nfH-W8F>d+Kp_;0J50rU zz78s)cJ&W9I2=cSH=-uDZCU6%Y1Uu`hpC%zoHf6Ie{%d#FIi+Zg^@piuB|m4oadY+SVs?{7du73E5~lzVr-dmh#NGxx%(P%rY*QIr!*XBD)w-2}L88 zE73z9Iq18-KVja=z`>NCu$hDX*Viw@A0qh-QJ{r?uh-loDiH(_8pGsA#)T@F$dgy3 z6fIJL|NUvyNA>N!-3W>n2xdb7#^zTWiN?VOB}_l=P%(q7i{Y1@-3x;9U%PgP6CMct z1o6Ov4zZC?X5aM7O6u6^Nd3;K`GiD&;=m@K?>eHD>ZD9kLt9ZCju25y$Z!ct_%J@E zG)pm_;Wm#-LIR|ytY8MRc&CWk6f8DOKk%Q-@J1VYl=!nqQp|04*&8sK5eA`X?k_JT z(oMWGBTrnu*Rww7xvd?>xS2NS#;a>0FOKM9cte`vaxEzfoDL&#Wxz*>3_=H$L<>zz znk!Jf=7?i_rXW`S7#H~NXU?u@TnUN-m4f661qod>YVvoR*TIxI+=9^g)8six+5Qqk zMLFVXc4xpd+eHh3ykHUL06nmq(eIn_usko~Hou7g$n2VQ2+|vHajGwJVCc--94a3Y zeXnK3A^w{O{K2F=cry&DJev~4LayLksL%7A|EVQLjAXp8MkB%};;bJ8h;#)te?}VO z38`RM(8Uhrm>v#xWB1}9M9xDvsBoXCi4}>$^82O*YLwNKLMe#n(Bs112mizM3s-^~ zFnFZ|ilnZF2zev#%k7DnHF#R$#7`Ivftb=Fd>=$arp`)@x7_D`4(Q6-91@mo^Dxup zNKFD=!e>9z?#&4`6Y$u_d$PzR1Rry5(pCP#izYhJVDEPU-mZ_F=o)~4>-eCgu9_5L zE<4ckeVu`eJ)(Gl1V3#v^h~te3_EoP9p0ldcKMq~oy9aWCXzXJ)NFKSDAt`^jG=)) z65$8fuZC05!iT*v*V-1?VZjMlZXjyzPRMBklJ}Gyb{ZU<^K}Dy2N&w=k_$XOBBB%J z>jmY|=_*!?3soKHW?4(eSrngm&eqD7_=9h3;tU1twI+g;8YkB`1ycd z;UpcTOLHou*Y7nRzg9-y((gut5o>4H%+^G=G}j$Uzj{ds61k$`KSs>Gn-Sl%T*(wx zk=<8*Cn0GKO7iD-0+SCH=MD!&zFJ@ZVEy)%JaC=xc~LPPa;u=PNgPUykU`?-8sU2u za>;}jFM#Eb5ytW+{s7IN>dGn6R`VG4oLc3g8S$%Lj>qu{>0+{JQH}>xBGVRAEuzRT zN12HD@k==({7as7Wwq?PCnAh+U4sQzBk$n$ajB!jXPn(&y|BM-s_)C9gO{+V?~9^? zn?GU(j#S(&pa8t(SUa89G(Oi|Hu>XZA1hsM*q5qiZejRPki7?T;X-DEiAcg&&co{} znKFa~dR`AmvftkiAj5`a3YK2Kx{ZLB<<+vZ}tCR}m zxE<=tqM>Qv4iay*H@qQq(~u&X+|W`4nOTQqpCt-rlYJ%64~tWZk@VbKF1bIK_W!J#ELvz`@K^VKfi9FXfr*6QgQ|V=IH?7)L`E3v`rYOy$#|yrM_NqoaAA>d@aTPPHrgi9KFZ3JKIR$Pp=(MK*KA zb4OKYqhsh~(a`G2G~?>)<}s0Fa^&v` z9dKYS1g1f1QgsY0HoDJ{zvsbh2$Lcb9v|~CA(?^G9mdB|D%YO-7b;;eaz?ZuFTo#q zXFj1K&AXM2?E$_gJ1CGF1Tp?LH&@ z{+UgmMxjCLsNc|B`J2|h|`#bDFUia#- znf!3>pNWiXa7FX2iO6g4=>rw}((}7ZON+CrRts%cbwhh^-Pc@pQv4E|;ogqduWt@c zauI?hAFrL5<#)&~LSh*Bmr?a`jn%#MvW0|u_78CWOCP{7)5&M-`6V~f-+N*Qjw{|z zWvd6HK8ePK-1@UL2&ii*?}|iS`$+^jGt_tF+%wC8j$-@A*EU~=Jo-`m7TD9i#X;v0 z)TQa=199q}%&)+n*}tgsEO58D+lgZn`O8m{OSWoH9EQYzI1jNC0TqV%VE%@6M-I5( zmwkXU-X(L?krR5RWZlj3(*DR5-ox+m8x}BTesil+qU0-^7fhWkK=+v+rbuJrJn8-6R6|vkTxLV{LN#w(ZWt=Fkh1zsXe0YgEN1 z3cd%jSU`C3I}pVJH+N@4=vX9G>#eMWO1(js$1NM=fuu!#=9>?dLO8k)7N{FnLl)$P zx1#f0FPTh4%nlau&`CnCXflYcM>@YRR6Qr>J; z-YM`fpAD4}AKV~ciym@htl;hH>r5`&0J$a058A(_zt^))>&&^}4q(1c+AzOW-*;Wv zmETP6cT3pwCIxr_$*4VJ&i^YsdM9!~5cVJZvuFZ^E5EZVc`d5>;C=8u4Fm!C%-cE; z)XviTN7d^5iZ3bc#GpO*GlwEdoV@Df*=?#60`!Mjlv)0IDzl7jt7JoL=;1Iza_Ila z3eg=8{Cu?nsHi-MV~@~~70`trP~-$%2!R+ZA;=DVnDuTo4Quqb8hwhc)H3!%?Srze z(_a;J6~WB1eX`Hu-8KfrEMz=~Q;FvKnu=A}4&SI|$*A38{=L`L)bnj3=asSi>(y-h zP4tjc16o~r=s%#I`L*9rEqJellA18~=r__e##HgX>;(|6O7=xB zz|7Na>|SkqA|S;M)h1RE&5!c_apyb=Y_J9h^C=>R8l^iIa8bIn*@cO{%q0F1c%N9i{1!UJ|>$Z0+b0N+BafzKXD_?Un!YPQPgaQ8)E6oVKS zo9Lj-#MjKmQ@DLV3?Om*_8_jnM{2eE^*wnb$_WSm9;_Z8M`KJ%j9zpS45kW;KMvafR+yNSDzFn!O?RIYs*BtW|X=f3+mX|qE@E^`t4&e<4fJ7@F8F|}#lZ<{k z7ni71#kQQ*^Zk7Q4}H6k%s(J}*V6u^i5no@*Vq&Iy!cXgAkA)v0Lnf1X9-xFTue!d@2q#LVO&w ztw$dAZgT_;Cf)2M)F$PD7!EK!&z?b@sZMzX5Mq50F?50w&h%2J>GbFvXHT;iBl%;M ztcMcn4OF5dxFnq z+M2S7IGFsS6jMpX>ouN_Ajat?rI6wPgQbj(i^M5N=sAXT+-~9kU%jy)*^b^ZN(p81 zvRi3`_wJHYOrSJqbz~bK+%7-@R@NXRZcv>1}Ehejc=hGEAP+VDD?Th!izV6 zqTG-uh-FqIU7H~M@vI7~!}nI=zA>uy-lH?hhq`X2XSS%o;j^pRwVNc*2rjHFvodBP)KL!^Cpbe29o|_ zJxZ63I{V&gX5Q9dG)N}qk?+ci^o4_+)tQ2tH?Dd@u0CUYi^Wuf>CwSMiD19vsarFLZ;uDy*~><72N~|B9Hn+-7pPX=W~LZ0ye|vs&w> z5pkr*Ps*p5AY+B3skKD5uLgX1@45+fi}*x521%*_oXM^q^vA17@iFA6n7l)x#fu&= zn}H9}@)cdT-&$EN)8RZz-6nmB7{!y|VEa!wCWfLT!!1_ywNrsfALCaDg6th6F9HD|Frvafy1*?^MmFD8ACelc5Io ztuU!pM|rxRtwo1DWzl0SNGPs26a-Q~eCAvkb|`znthFud`_3-RfU~J6s438ukKYUy z-zL_7=B1#v{eA73ILxwFQ;tLSzq#xgiN^nK;fG+N{2CuNY(q|UXdx0_c#F7yw4FS% zeb(B0v!dOZJx0_=WMj?Gr^t3J-j-`T^SeAS??IY|cupvaj;Tf*Wz0cY7I@qKcz>TV z`qjIK%^~$EWjxVJrAc>nNvPImlcZ(Jp2hHF{6*Zg0xD-6u}T*Bek zXg`%P<|qX*6=;9MS1HsXP_*gCaWq!xnf5%z0(2sU)vP;TrzDFvGHvZf$&ffv%WSr0 zX5(!|S!L1d4Tt*!PJ>LEnb-tXqdQ7t+J2n@CKV=eY%PbTjoqq(;8J0Tq4Fo+k3Wf7 z5(1uKnIZ$aak?(<$e>R|n;%gb3a;gjP?OZLa|_DdI$Kh}tqGio{Pd zHY~70;y(#D1A1)70;R5J4UFCv)pR(EY&Kk==Y&7a&}0DdNkr64bOQveM^28-kkOqp zN7aI(VT?Z3QLa`>A~8!=6OaXzN0*aHJ!eFUK9Xk}G?ca33=!gmFJ?c+ zN#j>;rYu(^-=c#}`1VnOK$04sE_Rgjxk%gRbf*lnAI&MR0tcTx-2RqaBO$OD^#^%9 z9#n22ZXD8g@xu@cnI#`iQek6lQ5uDZ6nuq`&*EkeDyXbkM8iM4$$@K4 zLM^Ty5(P?)g`p)3LJ_9Xa&r$mV-Hp>P=2uA7`&qCN>9Njg^ExQ=%?~&f9$87OYf0M$(pKtNWh+M9sg#erLAv1o&{q zgO)Vl!_IW}j1{Iu>1>-UEyvy)&1oGPX|9#l_58gK`_Cg&{#uvaXqQ@%&a8ez(7=;M zteosg_@9J4TNh{R9rr%FgK)}lWMlvZmH#OGl(rx7m_7+{x*!;e@1}9{T57Bm4Ct53d%{I)Uci#i~}^_VLKY?bUAUomLnnRsZPK zMZVVIx8+y^(%uOsf$A5Wapjl2zh!PaR`o9KmCBL}%Qa2s`XR*hJpoV#D7T} zy}?IM4rQ!4pQJlah}ATFMS065-QQN`7UTKy_43xrgQ=y}s8c#K8)_nIVQ^1txEJZ? zk56*F-=xPcw)!8^;^VbZ>ee>oUcH{HDCL&NoLt`AT-@Efd|aMAb&5?&mJ_$&8>c$3 zq4t#_zw~Q*J(37j!|&|3H$Yo27rITH1y znGBEn8zWI&x8cyUhUMwzL&NBV!{wvIlj+k&kq_*M0OAKewz|+B&TlKmtlZeR?Y}x@ zp_j>_!Bfk3bir6S{oq*iX4IirI0wIEvr4g|)JNX-3skgBw-{M%_JY7Q0-Is_#04OK z&_l6|%jTtTs5TZO%nUogO>)Fb<9+oT7%!)WF@tvoPFca3jo`D`2_Vw4vXyn_to>@( z#clRs7l@y`MfCkd3G#!9U<~(d{7q~7dU-w(pSB{`Iw+TUrnBCLN5$4#9og8UDxWA@ z_dzq5qz9NhVn{4D%rVIsvPDfx~IRVHHW`fy6Ns2&RE9CP*gd zPl&ZpWr!MrP_>??n0PIkmMWTpC114No5~Hb{Gwz#)#K0uHEV~wz?*iUNSl1cj8U6> z&-M;&J>2R%UN6oorC1A(QFM7K*_Oc}<0Zejy#^dI2-{-l(||LgRqhO74Nhdy(<8T< zHVsakxv4NVqOGh(-c`OXOZ-3|Y=}_LN6f7@F#Uq80^f*M?+vFil1^?{R5__(Q1|6g zs=z`SeFR~L=|Ei*9ioW%I__o{@qmI7^cNb5H2i>K|9)bx(bd6e!+ZI;&105F{0e`; zrS)~p`^m;-;*@@a(B5FobP$~V&vj*Z)T9M z8v@C?J`rZVq_&>9YWk7HzZ=d0E+m!#j_Y@qKZt$+J>CGhV>PX%GW>K@6vZlHJ1;y3 z-^diV*Os9h&mR+HXPZJm9u<(o-?yi7psG_gbO!0(#zpt`4F3&;{5$S~@+Cv)_4soU zNCM82FkJjsrQ4`cS$b#lFJ8hbm!_Ad@#vQcSDh2SD4Qk6wOdSbCJZrr@=-=wugWSibr3oLQZtmQya%DW;7iR&%P;w!sM_3xB`C z7|y1?aT3p4t;UpX4lE5WOOrLv-FkYgQr=fh4obvktn@ozEq8qx4N-S@@V7M^*cNPy zztgD<2EjH)-u4KTYLx5&*XzrPNI~J}^1j&c23_-Y`MD9sR_Mw#?9$NIBQ2y~3N2{( z<3-f`eIRHFxJqg3q=iY!k$KUbR9@WQhQ0N%%zp3}1@B;4$D@A>oU6^mB|{>Q0l^4i zks$4;UG08jmtuX|btv;fJ!HMFf_a%lH`OChOZUSDHzh{%dML+Hg^aVGjZpSWwy$PR z!=r`9bwxroGrItr6mZ3z6f*ppq0FI!DY+mi<|D|_`b&y8UPcj=JuJBgEfD`PL;&(O zP(%PSDf~tk)VK^Dpr(R%a(}eLAUuhoPXNY<*0Ll144t!A4%q>&us|h>*H|h!#tFeA zMeqIT^G|mGpcgI}oPo(z89V!NxCg!Zah1WeEwvgeW9)GkV#z-lx(~w(yOX4Kp}B+G z-Nh&Of*(&^5oI2G^AhrFu|6H!IyrR^zeJ~51y{9QD)(zb047xnCj}M~EB{HX!~J>W zXrFR|=nU9hcuX#$-#BM6)CM2pohr>Ck#M;A#A4Y0y1E;eH9Sqzjp>^NnzBrxC5|%5 zk;@)0gQfqXd%&cq(h5JO=mkOSCtiod2OdL~t?rQV+%(MhFmnF;xQy~}B|=}}t(Mxc z&cAL0ym6Thayp{o%iua^Fo{qr+!HVkvt$#ZVw@-6i}8~RC#yssQ*?!u`H0Wi;W_Ds zrnTu()hOBhU(-DVo&*S%VGqlh>`r9n@*{S%np-v~Wd%8sEr`J2g~yGnQGD?kUB)Aw zyY9m_EL6|i!=6a|E8+4036s#rIQQejYS0m7&+CbK+S)VUaJRt@{HfaSQ>2eRoRc%P zPq#r3^F-?8sAiATfK(gnjq_ErrQe_g6hZF8%exd7A7X@dRAHLHh8UH<^Ss^voy6B7 z(j}^Vz4v@@gIab|2-5{)TgJ>Am0r-8pqgwU@vn#503^r!xV{{uA6(l&ZfZ*QwAxC& zLPFO$YrhSuZK3-92=D6vQGLnmU1(_Z>kp?6R`0j6L(*s{9Ou$#wM6Io}`72da7mkxLIKp5V3YnWog zt_(@EpkA$R8uSi1|I)(&WUXB80eQU(W==hddzi_~ zoR5o;k1&Um?DG2<9!>Oo3F<1i_npCdB^}@~0_18i8(>54Sy1tV=u-LY^Aiy2Mb4+g zZ6x`SP;*6G!2}|NStfI!+EKPszh0m9ewice{HfE-x^Us=Lo_gM5s^>KBen1rfKEEabnqq^wO{4qc6~iOd^%RNhkd(p z;EgMp_JJQfx;oOi=lpU6t8xd$xECa-7FbWzCl2?u#n~~`sNtnyiCa0bp3ZtK?B=_H zq&p{je0&VW(BtNIz>{Ie0FqPjRuwaK(|5y)Fi($8_zEMd3sQ~#qkF*vCXEV3u`Icb zU>Ti*EOtk3qQ7hcCvC;4%IW+mR`tfB&dQ0-$HSJ`q-x=yrvPmD?*f!Q9zISU_f>lW zK2ECwpd*;tM^b8zfR$j_V8vOZUmM3B&)7z zV}CzXOHrTeSdkD}C+|mhqf@>?K@;zS%nA2}wHNlRUbTQl!V)h_`;J*fa}-<%1t~X* zhSUcK1sQv9m9mZgDxz?lCZ)GDLMwjveem!WQB-+gjAfnq)c%~9v~BXzZ-oL*EdpAW#)1h<_-y@=IANbUJUTRf8r>>YTB{c$@H1Fx&y@Dj2aS z1c9Sw2>lfPHgt6m-R;Sfpr(rsm=wn#)pINHZ_atdE_;Av&sPP-?i9QojP4rZSKHRv zx<8f|y-ejNVMWk*fjhVWM63f&8yN8*?st~#n3+3+fihw0Cz1bL9=0aVG}_W(nhlGXOCUhhD{%wX z4?!D10Jam->||XJ3B#wpvD&&g0S=ggYG4mw3I}mySgTw(k)6s7E3JEMDv6n8H`~~| z-dJBZ`zLn(BxYZTjRgO>@x}GQvUt`$RXjhLk9;j`25(bjeI@pTt3tx{i7|wznzN{@ zX#DC+J(4;KgsNJ&ZvK#1@uV;JE|xaFQARo_yEuRQp#dRE#rfcgA|ekPf_gq(t819Vz~L%laNYZyM}`5E@Jj17$Hp0 zX%F6h{{zh3X4!lEHyeLQ*%u*AtJw7b)!d5L=oaN+7^Qf&0D0Aka5{k%Bk45e+I_DG)DZqiAKT%Fm&!O)!Rt`WpK_~N)O=FN!p`q7P zX`==Uq%%xPH=M&7!_=+QWno{&(x;bsHP+x42E*J$1JY&Jj`+PuJR^KITUylA+tu3N z`xKf^v~&ow3s5IvHMlQg1teV=vS+ax#)o>N?N1VdzDdhqzzX;!b#s8(8&TP+NcW1xS5;oS>Ev2V${4tbhvVt}aStrCn*O0dKP~ zy7NAo7J&#~I$&!8+jW3muWj06C0$Va$SHN+_Q^bgk^Dzjc$PYYwc~$Y3-0Q7&f*&6 z4W89X=&3$Wry98Y5|k0ApXC} zrG)o?Ke4oIIFaEs?&1 z1kJO;*QNB-QoB2;8-E^g03WS)t+vnV$# zoumGTIEegEyrB5X!nB?gmr5h99a67v_sO9*wMwG_gW^o?76Y^I!=D6P`fCldVI;LW zQTIEl+a!BOb&6h4nHQ+oMThOIRv!aTohA4Y8E$>)LZ-vBhGzvJLEKC89%eWwfJC@UWZM-1z?Bj zln_AjRJ|^Ed~3||Sc(GARDE;UU~#+QC*y%cA?>A>c|qx!`GZmV=4CSM;$a$c!qEiZ zra1TZ&yEg#V#o$Dz8&t?&pE@N#(JXG>xab9^^gE7I$hv|c3#d2rp2hf#P89+V*+S{ z0q&nRx?~~v9FguvZ?+q5KQ+$h;q1PCRviTpN%OTV1aXjf3sNR{%=X_mD}yQ&)z({u z)Q!pQ&F#~TOg^`(CtpH<6nB&@OD$w_Y=oJgpR zB0pgTMz>c+w&&*T?si-~Mn2Mge(lHRZw|q9KC?8}T4Mtqy2TGRO@l)Z)S`b#VZG_d z>VZYYNuIX`3#<~-IKVki5&0uxWm#_8l|RBFj^JN^?F>mA6jF~=37)V$7r(Y$HsZ37 zaq+wzbFob|&XCJtm^a4o`!|B>MI_V@5{N1|F#xq8n+Qnyyqvl^E%J6Y^Lcmt+VAd9 zg^+A$`j8Q>V#UVm`N}dN?UBN~C*y6>{S#s`K4ew$J1JPtw{ep~IBD>cx1mR@Dus?P z=oEqsDP@)+@i6$If&IvifLthu0r>;8h#dUhlS^Pj&$-IlW_^tfwk~U2)}>Q-y?rA{ znQI(z#Us6xH@JSRv48QbZMwlkMz(hn%G?ZxBR}V-TYk<^7Rmya&#}(hvv-@ZCST;m zjO>B)S;JKajr5fvL_MR)@_IU9-+fABHZ0>cKHB7;!{KBZ^h_8Q3<%n~=hhRK3Nk5+ zMMrkZ_uy!TE&wl_U4REIA9bS(#kK-&n5So0ukVqG@--pZmZ*5(v;n5KJ9Jk_BrpC&$QYDjR4coL!ShJ9rcz+qTLYA2*6DS zWK#>iAT)}s0dCl!^Ac@9?nqJkHV8HInre0SN!4P`yD7b6n#i#5g|!63!Ng>&n|d7_ zEE%QyXcHf-uvo}-H_;JGmbI1rl0oH62Oo{vG9DdDClnbh0YFVHkYKxN-ww*HlPqL| zYnD2&qqHj9eQFiofX0+n`z%qvxVTi@WAx_7cJ(>n1*00%E+rc70c^DQ*2=7Kja?Yw zR~U`BS)!mK@UcLF5t{2p$vM91>DkGH*Dp6LZ0~D9btCq^7E&(?QHM*X4^>qgj;Y~d z?0$P&W6GMAPs11f)aTFJCM$XzE}Yuf9SD;Q!uJgT2Z;f>H#mR)Q}4;#*xH)i-OR=9 z;gB;gk%P3XvC4_eZlrP9&q&4}eexkS%+!zFXuRP_HRS#L2)g|=cudrFZLQNCm$A3x zO&-sm709F%K_(Ok&k7K+>VF}85)6L{^6|Q{Wi~H!@r_u=;hh8uZfoG4A!2Iwg1YD3 zbNItzs}r>je54s;yDZw9MD*_m9NsM>LE~B4{)k5;n)DmB#9?%gszMoZ$qks|374XB z4SWMy;tQ3Zc!i@e|L>Z;!-Ld<)J`tzditLEjygI!Ufu+ruSZ?XG%7vOq?>bgDn0xw zH!cy~Xs;fp`8couvz3UTO*R7EF3hjLZLdDP4eYF9;E8O6-U_ArJ)@ z+ONW`_k5ss-*bL^7+iP^Avao!*avqE5qr;2h+WfRg{=3~Vs`YY(Wd_zT_-H|j|(G| z4l{Ggcc8^EY6@r~Oq^gkR?N%RjS9X=`-AE~-QuX@?^ ziGNPPqbC1kcdE0eRay!BGH0^j0*Zb4BjF^?91oB(vGfh4RS39|P_sqg00<0K&!XRH z5cra9x`!R$VKP2O?jHH=8k=cyI`D;<=Yv^JwXSiZlMCL$(?Niy{YSkxe=u6*MF95- zj1V8gax&qsB2coxu3L6`=BX=Bu)$jY07@Clf2B;l`cSr^G#KxJ)>YOCv~uji_psR8 z3E!v;^I!3r{_p_6gII%11yeGEkWV>kQMEz|8;VbpQ?-vlhjJ|W1QsIzr492DYzXzr z-71fOA#4P<)|^oL<-OQgeJ?g3J|RB4M^>Cv9kp9kZiyJDK-3wIDus8q>uj6a7u7>` z^K0-yRl%Y^m&u=3)qZIYE<}%QU|{o8E&cPK!p~6vRLXEf;k2x>LSd=YLv8s)BGdwB z2;?DgSUlRHV3vW8U2hat z|BA0vsDH(mGz9UWt+-}| ztgZP^2>IRCr;pmst>~LmzAcJs>I*BMIQIMO04T1Xlm`%%iw#=nJfcR?_58*2>g{$x zPiT~`kX`M(F}XIYJr!Y|*qAkt{WmN2XB-6w^duT-T*Y!V(=Q=I-`{0WX9ToU zXM=2Ds-=to=;}`F#s;%5f2jQ%vV{V&!w?`gts;a?9NBu+)jmtP2rG`{v?4SPz!_ANa ziWW7%)wmfc<9FuAx3-CP(TaS+GW0K*R5@vHbiR+0C?05m`pNY6-*$CL(jFSvri9W= zj+DUuT*#d^8kx2nU;7-s1fxi*tP{L16xy`F0cpM;e#z??P=QY3I20yo@v~6ixOyfT z5sMPzg!I|`X8Dd|mS&<7#N2MGC&@I13;we(#eo?|5XKc0YXrFXFyP|DLL3SLdIjT)ShR=! zb{rI+F$_uDjpvJr0)7JC4$gHAb5M?Jd!nu2Hm60s<%@}a9Nlg$3xwPPcSr#UR5P45 zaAGmyX|q;_7k3_Svr|E<#Ja0BmbX*S1=@u%{^+$0@HTd@vJXu2!`8AitUf1znJoQN zAZZ%@!{G&eRaO>{PutVx-y_}34$t20NGou843DzaMV$CQk+jFUjIWN~pP)BCuS$}x zPp1PdyAL)w-vsuRy|GGFj0wE1q^-?`6hUnTT+qO9Y;b`85DWBmE+b&L?Yb_dQU^Z) zGA2gO3oIjA=gtsxvW)1z&yoa|oZ znPd3GXa!NFbi*%B+(RAkNVGFVlAZX-V%4Axla8aQ9Cd~?iGn&Uq6U;*!Y%dVV5y7< z*k`Nj8meD9iW^OK-n5Z+@wwmYE`|S!N?d41GxW)n#Er53&WG<@VGgC@YzUL+fet02 zK)Y>63nmY2DE8S+FYg3&pDL*$4g||65o~aQh(1P6`|i-l1_;Nbq8z_ZC)p)#e*A`R zsVT!l>|FsvfdQ+{G1TfLhN!=izvT9>n zF@r@qyZv64vBhnA`xQzRl@AO=wu#_q))mY!0Hvq3dspeWe5cC_U-ti)`pUQ{zi8{B z5l}#-Q4j=?Zlt6HX#wdPx=T6-qy-dd=}=G@Lb^kcZjc^_xIk9esB)Y zdCu8;?X}k454pKNnUqfZ;8U`}w@0+x@DULRt;jYJX$rcl#eOwULd21&`-&Wkhs;|d z&+era>9C)kdJtTLP!7RP__M)GSjc#%YIHWuc7(G&Wri`8eQ;@2Gja8D-r2#C$3!;unE!K_1mXf*ZYG5%XL^LiTOvl__^t1w=@h0I1epjpR=0nJ+5 zn$Djn!}TAtRE&ReEs^gkzWGvs{!1B@My~r8ah=6$mSo;jf?!3No8wz6pi#?30>G4D<_so8=F91T)@u5_yG^67CTM zf8S?~zeq~%ZG;z0H4KX=Xh6Y%wJcll?B=`wjp#$7#6Lpkh6`(t6NFfP3-#sIPy|M{R}E9%b#U{NdG?<-K?ldH5tn}rP@xeq!PM`v>Ectvnsz?R|8(1dBh z>vq5HA1C$X@?0>+ue-0`(5cydX!5_Nywj>B!4iL%G%MOJxVD-$8Aeq0k!WwtHPpvTF~PdO=w2adW$3hZb8lkDc2jMjT2+Nx zu`ZvI3Yq6Q9e}L!T_8R3Kq?RH4_|Pnp+%K*UG7;wRqIA_e(nEYDA(pn0-e~EqT(6^t|b%rqrJN- z1A7T%mrq)YanE0d$4n;ZZZxkjUsclZLL?nmc15y}V0#bi5gu&W10Zc#CEQ zHWQE_%`LjC4#(HmO?Aswz-0L&d5ygw6sy2=Ch;GuAR`f?s=+m?P)r4A1)}X+S|R5u zmSp>K?VouipWoN}=p336Z}9aR(vs!)D88>tn0e-YIFUes$6;8qPV%f9PNeT}Ghi0B zPQgz%aLb-Zd?J_yo~CIFhe~K`;yXL(DC6)fcFAtACx3o9;2ki;J=hO&aAtVcZ&}~n z-?t*3M7sn;0rArS^Xp!fG3Z*+_S~t@N92pFScJt03W62DZXuY4SXXI|XR?}_PhZiA z^yI%J0euh>tcZ2}iRjVpdOtVIdbfHlL9-AGUmV2vm~Kt}k@c2JmIrqOyFz6Hx<=wj zR$zBsH(V;N02E(T(n`F+0ri&o(0LHGV2du& zMF>cZQvv-Za{FbmrI4fcUU?0&^vtxSkHja3?Y-dGyv<_Jh794+HHaGV1aKc=#wWKg z7)T`5R4F1B*v1|}?uUE!F5H0#I{P9YN?j>T ztG#~HeSxN(%XXV7T>i@xLO2COf-2^T;U3VYr3hZ;^y}@oZ(p2?<=yT9wD1?8g#myT zj{U2q@BNxk7G_zp3eBU&h#qtXdI2@i3*Jh$SK+L`48DiM?`;B~%(JG+&6#KF%0^&c?U+~1E zg6nwSO0<8$yU2JJLepLq>=LCBud6{Qm9`4j9nS3Q z(Gwt{l#0OCw>bw&8mC}}sX)DyI zs@#>kcp%~!60ev(m7E+Eiy;!O_>;F9g8PPEd!6(Lw{3g+fg4Hw%4D!nzQcct7!U+Y zWxBIdb5q1(?JGEB91^NlqRoI5p&J|qcz0O^TQrr@dw~Trh>@*2mdCH&cTA(dNEH%` z!_p0Wk19Q;F(`2hhQw7?6QarH#uE1DxrWs4Vgj13f&d%+vuT;kUk<_>k=oj;3LoT( zmk;&-S}e{|3f&7<8aJkox=+mtCp|auj!A&^(9d53 zPl&07eTXW3I{ZQD6W>;)t7quWML=vQJ&A%LEC7b^#d2Yif8U-<$m6VBmQT}&>T8b7 zE?lzY9^(U0q)?s*Ghnact(Fz;4{kEA>IC*)p@Q?>%)?yT@n%RxW!Xg9tJhm$vL^vxq;>qY zmRIG>RrRr~yK3~9VNG$yO~eMo0wR(#-K{9>rIqB zO1$gW@g{ge^a?Ra>QmUypZe+JFt6mg{+YL%TaBTs6~acC0H<87K4RCOn?Okr z`*Fr9c{uS4Y&x>|Y5ue`=#&lAi*KT|+bQ;%KQt>UQw~0z(fTY#C3KuHe%i1aYVI7O z>mR4HVep5s?oXAnhb5rl^f#{1#PMSEDgInD0WekHsg<-_jDX%u6gSZ{H*v=`BwYU$?T97rD1OX|NjT6~;75 zpGXCp5J$j>=v5Uz=^u3T{VaeP>=xzQj%vJnTGB@V-<;@UDF-*afJP)Ds+3nl3>PY0 zr1Bfg+N`b@c+6k6@{jS4Jjp(IOO@Q=AY1a?pDfcUm=ZA7+m3WBsjpayOa>>@n79Be z!9}3^?6-h%=;)D$W2^dnd78DJ!;9RPmyAFbJYbO+jV2}B-$LWNV*GQI+Bdyj{Q3=& z>)*A(v|sEuT5*N3Be2L2x7CHjClZsWGM)VM)KwV--M_(=sZ?{ZSDvI#HbAX1IP&x= zH0J2*xKb$b=3!ClWb(kfi5^TjFX^IoQGov?k~^hVjgsQOc!Fn zz5ReysRt+sxTH3hN^6q4bxihlrUBdr!C-V!V6M%j1bU1SMa32E>tnl9 z!0!*1ctoQp?dvVich#4xCrbTBS8rSv|z& zedQX(K-sCA8*vW)6itfXNC1}}Sc5uG(`$?^cJiyH*eh9*Yy{Z5`~V$vn#vceO&&H- z;UYT?%2k38l4o6xK}>~{$$U6)%#D}2VwiB8_?=XhI!A6To81U9|G^{qv2E~X8oAd| zh^Df$#{%o`e1v_4L2KZ+?{)?Zg=r8dOe66i1gRNSw81e^$8VPlD<0>&rNn;zM~UHG zDlz>NNRF)VC~^5J=rKOycVAFI4tQ3W{{iGNU`})rL~T2FAi%;mSdKDNFgLH^pB_mC zTM}RR5z+6nDm6P!PG2psiRr~;`t=SDd}Dwq51V$0D2(m~?LEzyQfYQPB(>E_D6%KE zRxcPaCx6-=Z^>Wj4q)&;K`{FgMHlh;Cp)+SXF*#7H&WpmxX?NF{;)OyMUsQ4cI8pB zx!dLRw%+U)wRG&nKaEv|)KDJFvgG7GAJ`r%UE2^Idg%K-jV`>9OMbYf-sNnfddv^NKoeYnSM!n3Q&?2{)lOkLK$F@sEJV70&!C-U;2XW*|XGq26rHfOde@(@!Z43xvCTo5O`2QIf<+!=6&!2 z*Udkl1yOV1R07kHlUGHZCf}vB3pw4xNTS0a@{KHP)`w?V9X;no2w{yEMbkZ`M{3;> zM{FMXz^=EWmQ4HiKOcfKjH>6{-f*_cdBBrKhur;vXKoKT*2IPsE8tj%5~gSX>r_=P z07n7kbvE^SW#2$0vq5Ke4JsLfl)icAgv*4(%YxcGpNXcM?_s>fkNv5n1Um=J1e0hF z0k#GZiQAv52RwwIM{cj=>v_ev5Go*JrWL+4RKv#jMkJRcvEI!4+MgXE+SJrkD_l`< zGu!W2ANMReb2kGjut7-Xkp%rzKhgO{pxUF~UOm>5@S_fiAkfMh{ ziuS5$wx2xNKX6!k*r^SP@@O~oa!fH_eCenwGdbU`Qdi1j+Yx`~u~Z)7K7Na@JprH@ ztB25yc*s0TSTwv3wKRS&^ds|2J&D@|Qi34tV_5$IXLN`lW09<L$v;z&i~K7&CpB$?(M@;^Uq6N_=(Iw{84pbe6x}K1qaGaE`_a`vQ86R zvhPYsK%xH`<*)iR$t7)zJeu` zN5g=$f0xN;2587lbWwm@ZYAT@?MjmCz&64+_-C&Hn0+LRzsw9cM82RL^JSQX3~fFE zU#+;?63P!r)tQ*(~RzfaX~&N{+cOK-H0XiRS%*#WZwT zk-*GAe#h0CAJUt6nsjNPTV*3Qu^XEyr+1anD$3x@-j5Bk;|sEBh@C}a_2^u3SG7f| z6Z;r8*t4`=BMgY3$xC}+kdb+*kx+DAM}A9LFWpks{P;-gIQSG)eXNOHzNoQmd_QhB=?`gizwCJgtUsGL@1)beV%;i zZLQfnaNQYYV`UBK6*ua1PN&FDj4)yW%1{_;ljj%5vL3j3PG8P zH7+&QG_5dx@Q_(~3?wmMPoM40$XB9)HLAHMA>yBg?FCDI@awXck($u-#Kt<6c(I=3F=oDBsM>CEFqk5jOM{L-8vC? zQPBU7xtI>%Mp0Gk^uZ12SPk1rRN~;R3(&HO_IjWL-iY1|4@B>f@ z#EBArnt40-j1Pcsey2JW5nT_BzCrqWc_0bR=S2MYE_0pXvz!f^YRZEBr%K@Tb<$yi z%fCddh~l{5Az3&z7sz|fGbhXz3X zOH-~!c0X3btm+g7^$QnUHhlr-;LLO+F1tETyG4y~C2(r4{0qbDgvurk#Xt;0NK_0_xC0K%eHdP`ML;$nePdi{%tB4qN39EMxS7B>~0B1x&cg&t)Pxp-k zS#8SO_p1U-w{ zNMO9dS+qXFTfI4!ig$}HJS)G`sJ05Op==4k0Wfm}A?M{a%B!c@jq`6P^t=RKsgOOn z0oZ4AWaY-~6Xlm`MVQ}+A7Bj*n2uuJH)(DX7jt!k&5lNrUZO+YdrSh+o4)@IH>yH-wS3(f7C_% z?$N9bPSltM{xWrBF#sq3$1YX!_0zjMU)BPfs^`?*%wHr0m{tG={ryCrqRcYd<5$6C zx-TIdfZ8b;Vpu?FV6cdn2mHF!>jhPObTze#M3EqHCfg_;5y%K*30H@j+ z@4~nHR(keHSpzzJQ1l|YOzf6}y|hSv(g4{m!47TCcyV}#fW@oWHS%T%6#XM`k(Klf z<=vM^T4RMQT4&*>W3g8kHzYikru;Uu)441*+I06;(;Ps*CDbg@0Cf?&2Bh~Z?4M&z zxNerdVF9pkBDPjXaNKip-Ef^65aRLQYTGR^+$~h>wl1qr90G7`NU`yM;35-<2G; zj`k}`e?ERXjE_TrUKCyLFvw>~P*>NZb^UTJ#@E_j8S|<>9YBn`{RQqH_m{|Te{ZZ3 z;n_2h%{LgyAs1VYZD3p-Z<=VW>Z|LVE7$tBKW*VHyhvRK{b)`)uTFB03AJl} zk!7=2JgDg_d-qq-{wqg*w^Am6u663dfEWs74@!ruXuG+`)d|~Iax_&sjqqH2grV-c zGQ{Ltxn4?oOR0NcRec;=LF>abSX-$(dhrV!vC&vt)J`Nrt=-WGn)S(NlhK1LK_f%(Ed(0km7q*!4lpkkSHoZ<~gW2IIvN%Aq=oqJ~Nc9MC`0pPB6; z!=8au(MhP)|58}rApOl~=4s>@^7-}O(g%!#`uqaZv=}YZc%-2vzkqO4C4GhiNE?2^ zgRy0(p_rK0wdZNu=tQ%K-+5>!l`Y+mh&AV_x!;x5-;Ta6r=!hypu00FRAUmN>59Lq z#yKLY8IoGyCi`4Ha86f7`t8jPt-KmhU9LAS5Stw+L@;Sz_YK>9eYCeNl_%i4UjYkW zU}+@*2gx_Lipa?hAI;#OErMirVbkG76&K_(CN4d{#>YI61HwiVIDv72?z@h^mu%Zf zmNyj~(*()9jsXN`Yw!09baC`MhQRmG0DKRg_LUf+r-srxLcJb@>tT6&!1&M#j1PP0 zG316BTaQ)#95=DsnEH)fga7IxiZ)G-UXq;rtzihXg#91i12kYzpS#IrxfbP!ZUPt# zIHI8dgGofJF)Vff5#H6Rth(>k5+?>8U_>G=^z2~1ydTT#FwasC+o|=gJL6z2CO+D2 zEUh3q8HIISv_<6?(#RdWxCix!>djeqC)f+wgpsYu;iW1oXwX(EwgI@&> zPwbcZ?;5c#l-)ECd7rk_|JHs&v-@5LXo(|&TjFu_mUy(H+|$umm=^F48aF@U10=r; zssvBL2HS2#p@;#tozDf3bKxB}aNDL=z!9`SvWNi~Y+x$rC>??<@Fay#R2j>D`)d8*Q?5G|uxfrX|9k`LsPDkp z--7!*SO3=*6bK$AxEd&)g5fp$i;z+_bi8tbDt5g7ivdx@lPsfGX234si4r^xo_LBH zg+XZKFZ?Vvs*c^V=~B}#UFF2&Bo-2wHvq!%H2-`QMEz6ar=uH^hvPtC8V{pDal1FR zC>>Cl5z;@-fCHP0)*m{;JXx*=gP)A^{eAnkGLQ?stX&NT%UhibVURr^#-saOG+n}7 zExFn>2uJKR2~E{R$JfcSb1A$fa>!*q1w4cvMf@dgCmu^I`!}^RKozyH6k8~C^Gjix z5PJirNP^&kVWlJ{DurgMOZ4k-<~e2e;7XGWD}cvqD7tHPyi!D6t>V7bk3Xf zhx*D3e2cRvghz+t5U4<9X${DPjE-`Z=3Sl%*Imrd?=~Z_W%8N1Qv&x`HJX8mMx-}u z9!HSTv3(rQ%0GSY{d#4_MBBJJA=Q&LfFe58+L0L~haTSAmJxyytngt=tWu=n$il`$ z(GO8&yg=xEBazI8&gXwAcEB7QUjnajZ@n9)7GlENj%mJpDD#zofk-7(GAWB-RoiXC zF41PExE9#wR*iGnyjHh3d5tM`aXwiyS!7r<-B0W9*voe)MA7A;Hs(6Y@A*3v$BZfn zXJ-_>CtgKALA%SILBRVzUPg~@4=B?Et@GyW;k{a})nZVX2PFR3dyVqYu^?4H@p<$& zv2glK%-HE+Dy=db-a!x&XB2520Q;AvocuLc+LnOUbAx!dL&8Ohd4hnG)Md+Y1~#cs zRFaO31xCGn#W0axmPLnSDf!NX{d4TE@fazEE##R3?=6SrVGrw~ES>+?sP|8Kj)vpq zzYOT^<88y)IpoCtlEZ25_To}o3>D5}bb`8>DW0-4 zzc>5$gomBvtaPcVa$?Y&*D=J2Pgh?r!oxK}fA|BVo%8}q~AIdIFs9c{Q50XAVa|^F#j2CZ2HBU zHg39=KjNIb1J7Z#D2|*ZdOzVk_7WJ%ur8h&d2*#(tsPjNfL-Xf7{(Yt1U|@G0E?huHmVT^K z*gNSRY$iX9cilR^Vv?bIbo8c+qoW4>>MD{;i~m&2@=wL@cJlHS;02Cb)^DhzVF$MS zw){(bW2pi2L{}>FE#`yIc_SKSC>)zpN5cScZ1K)(K@%wOh2qOB+U6^Xj_T%9(VgjX z{CmxHziFjQnxjM8z<-K*j9IjS;w$(^C9M0=*jci=@B7EnGTO1AQL2Pa^U-~lYFIt5 z(8$B4yQTNtP_D&7R|B!07$z!&ov`oNzxuTbPWr!&pkf;DJy(qiF8+OhG!1-SgKQF{ zv);bE5DC^-Ah~kk5p-^6xmdh-;w+k$Gf&F?N=I{}>ZJIn;1k?v)|p9T_>CG-JOlHE zDmtoO{1?&swaOpjx^m z0ryjsuUziq;<}ufH^auMswZWmuWU&l*!fX)k;d3&6+qM*ez@?97yqVJ2LpcD>=ZMCUP%w#e=cy;q8uriyN9K2TEACTjJ5)iN-0}-8X5>IKrJIqT z_8-tp=|+3MaX~9Bw%OKbBjx6wvh~XLm!+d~{jtd8Wa{;yyjbxtQo?|H!QbDrs~^Do zV(ll8Dlx_H(jAmQzrea$0un%CRYp{qdLP4t;;|##4b^(Dk;OOs&xFRhv<5%E0u8x zuOKr6ri>(3M%ai}eBH|iVVH=aOZw~^6+B`nMKB2LW(n@mDRwt*F7>u2o3s7x{bM`Z z`@O5#H<(WEe5S5m)pN8PZabvD2ctBi+c=iKVm5qq?^l_q<1-((OD;1Ghj2))0lsPh z%^rDNzdUAqid?%mJ73Cp_W0|8z(9dtuFpsR!yw-WDp8)m8QQgM$?Z5c^fkOokM7Xl zWrCW(b7eK|9ImofQnp!N>8Sj>e_pCIn2J5-d2s4C+Tggc&PZG`jw77xUfgO$G0|}? z5ijSHP2@KT9hZWd=|?5=u)5lYrc05wa+jh@JthtwgiSTUnGK5&Q`Pw3t;&skt8$0K z(5A?R1KvrOR?85E33?Nozq$s|gG!+Mq+*89_dcm7Uv zKKI(E4JHcvE>K(x3uli(OdN>rOV?9hahw3WM-b-bZ+gi!brW~}2H1Dh-dF%((kTBP z%9E*$jRU0D9L!J$O`B`ns^Kc!6(j>(0C2yZfgg z9}MII=*B8}0bXE6cg$zYsDCu^(T_}>&L@+TQOo1G0Pg^y9rJH4 z`HH7#pHWQT%m0`@8h|o?W$WOX-v}VsjlaKZ3ep#Q^@42i0oeGzu|3z(i?%7Bqq*=E z(Rp}25N|%*c^>0p&4>n)cP+~4Iqu^bUo|CE`%EnXBdBm?T1toSovoQV zdyg-zs$ZDxHccz7m*Z6(yI25yLjS7t|W5dOZl5jkwT7g=z4bIpd!!(|m*?iC_x>3-c>-9qNK z8=s6jG-3U6El`C#{frA*u!%tn_S@;^ps5)@XTZ7~MT|B)$)ZVFA}GX&qa^EvDf}$w-_ttk$?sWkZC(#UyTz{4y2ULr}ffxs;%8 z0Cq$IU`Mnwo+_%67;^WONggI7hDq0e-oxJ|>RJJ7`e=Ty4@w=d&tvlii^L{kd>t6S z_CZkMS3e1$R&hz|&|TNKcM|M(k@H-?)FRJ;9Px|W6J7kCZ@!&gY+qU{KMG6AmlQ3{ zZ=Rw^Ni|?bQ6*SkPSR)K(;I=-Hx^aCP3bb`)B6VHaVCH<;+JBki|LADmih|$KiWjP zX#$PR;4CAVp*Mnzlf`hAP%?>2VW4!Aa>_$J1#MF1lCFVez=J;XdLI@#{vJoWB8TQx ztL;}_Ger=aR>N5U~77h-%fTh<~)sIUbPAISr#jcj#4u}vo zG|@+Y{_2~#3eYR!ib{p`o6~nb&B8M&3k@EL%~ximY*hD#y2d)W!|(DGboY!5@L~Y7 z@CIEWV7ckism~9b{1Hw&%d4|}ZgKWlMm>HmvMvcbnB>3jWC{BD|04OaYT>@|eDi)9 z#OgS}#d;QI_@Qp-P8N?slbb=o*&7H|7W>#8P!VPIE?`0g=^l~;D+#fRn?Zcxt}{8^ zzX(9NlYcO1v3?ItEG@ekrz*C$E-3C|ZL})0f!RFp7vzb{)e799DWVbjA)2)V4XXpZ z^ulaqUicB0y<~~{EV#9xC3**VGPC1IqOF0!rsem_q<{@z*$jedfIZ@e!Xbv$I3cYE z_i$lP=ApnokIn$Y8QRd&lL65z8u2g~Bwb^nDBbZ|awH~!w?K7;a!~NLjw8IS;}&or zf`+cNK3ubef5p<%Gftnqcnqc54$LM9JxO?eHZ68V^h+za4`iXUSo%y@L&JsXY1`t- ziD&0*sbSQeYl5G3{66zD)CO8HiMYMI^z*wWOf8`KoP}|Zmb+yn_?p(2q(su78HTIj zu|oEq*QQMdx7wc?)XS9>C+GX=viaEy(l!%?pJLiKme86>Bp6ULEz zSD+w5(+SL@DWY8ZgJE;w_G4p0CuC-NLLSadsoyP40UUD0>Pldz0$GCcXja0#9#w&^ zJ7u+|pF9Q%K$tJYeGclaFA2J*P@YY{tk1p?Fs#FYS@{@5Tn zWfDswNB;P02w}Ufy~(40BrTK@l*O*G4$77vy|hO-f*s>cjyv}z9NXfiW3ih-vq$Nk zn~TjN!t9&1LK~#k?iB=@oz4Pz%ZC$Y(U!iY#?){L$ z!aC5Os42oAyQ#U4Ws@BbfmEX(v|?;jqmYwmNhm;ZWo1<*Euiz#G>G zZEL#HT^FE+WD&d%^jcrw6%pAJB&gSxR=TvJ{k^V`E9c9z zgm0iX2S=+^8O~7`^JfLwX~hZf=L_Vb{sNikpVGV0*(J`SH3`vn&=PLUe;_%^@oUqI z=&;QB8*M=~1xeDK0>vj z^lR3Zty+=3RD7c2o_9z+cz@;U){LVv2Ms;A<}R;6XjZZ#p}j9MupDc9WHUgd&gkx0 zW>9AQEcsLy`@LA#{$}^#cW6m6l!`?sKV?wU$A~umxI?{Rvyz5xFM{X{Xv&7-q|sC? z2~n-hBvE`wwb}a8H5}qk2~iFJGeJx(N2blc@2S2DU{gICyo?h+V>S#41WQXI>V+-> ztw)6~01(#74+NgVZyMMVVqIvx&`HqH{IhaclYDZ;_B-qRbTtj#WCYPx&=+Ywl2Mli zau-D+i|sk`B9^uj#^)5$ppX0x7?x8*hP*TFM}!}31a~i1{Ham^42ISMmNNzH%Xi%U z)4hX$)dy1{Ve>X;$R104`a*`J+74JuHMMu!)*0L4eAPnoWE6*M#0y{h$sRsTId7M_ z*&}zqfcc|y=sHwE*>4_ORlAf&A@2ao^FD>9wGhCq?ofgdU`cIv*I^=q`&Vw<=Z*~= zV$rApm*J>~b_Pcf+glWLYc=g|8t!o9Ov(rwv&L&%>y=i4=}9WAlJx++L;&N(E0RKQ zXnte<$5S3lcFnYsFEY!>zQ7rdH^X1M$Q9!DfuIu=!hOx{B6_lRV@>0Si-4HsbAvtm zt&L3~)8BwNH^`Ql~CVSQLV zjY0p_Zj}I@MIM@W2B^LzK=qxW$KcORX%&hIRKvQqGpkTf0rL6lY%6cte7>7Cmy1ut3fbAtfWbS6EBxz%6 zc9jOL^1?`;E8y;6lPm&zRq^W{Zcbv3N&LkR+&As(yXSNwAjlRnFdYvsy?3Di?uDd~ zkt=2wQFlF0J!wPct)m>$TVb8q(3L%sY&U4g{9ByM-ruqV{Ry@5S)i0UU2|_|np|5< zp^(V>De!r5WO+lKcugY@v|v!J{@IaAo1YQudMs6QFHd10C@LkQj&mp*@gDx`a^D1i z|4X3eq$a|DZAhjF^Ocj{0!m*e-`fvBVomJEmtDkqVU}=v&NO(MK*|jr2u^0w>-#7l zx#0a~0ysGrsK`&b6u_;jvWKEarppZjVEhW`;o&5}I-sc3t- z8)}pv2zKhJHnzmeuF||}*;$)5i#Ntp+mTuC!&BG{hY5(kNi!XQ1uA%@VeL!@s*W)c zEH#6qB}SG9;tDD&0GWvUh)csrm=EBEHg?-?)&)Y8R^P+KM&=S@9%5Q;MEKt71=26O zxW;Oft9s5;BN5B{-X1{$db7yk4RAh|Hu6y1zjVKW zM!BS4=GnZ|b6B4naJf#PCsgKa6p+Ub+gQ68hwpozmRH zvZy(bEOfocAHcl22O2N6lM2>A>>V*zISitP-*XiGV{y+BJmO-orj~A!uVpW);azeX z9EcyeV~Zs(*qWVT^N-8$-Z~|8GAn0;6P{Jd!{*_sFmwPOH>?_`uniirbj@5|fe?gi zd=s6?MYMtBTcQ3ABwsMQq6Q@2p@ds9+dQNcE4mn1q*)|q!0)@}MqIKe&+JAz&$B8_ z3HZ=!_C&n>R}K1X3#;Z`<~bfzTv?qHH9S^9KtralnM-o&Rm`UfFFXiJ)a}7k+y8?-kGlN_w(`&1r89qOK_Dy>|Ox$YC-Q? zuAJ-Qflu$;%0=wkj;&L_gPyE>vNQ~G9v5t*I|Z zK?QtRMyQIcY{_#NUhZii1{x}UYNTwut}i9qjT<#+-hv4}e#!s0taxVffBV1rGe$js z+gH4nxs!b2j{Oc4@A|b|pEFsmM+pD$Rq#G_h-h-w!Q0mh2xZPo8bSY|b2 z*}ALI+GKCe9Wg-DWRKap>eKOTEX+c^n(Sq5vN~+VwSsNw!{`s{qZdbsiBGYN(^=md z{;u4a$n^n`Sk+raJBlcEK zAOrM0sYLGgzB{dM+umk4Ra*x9*0%Rl;^>f!M?2Yv>2ar*0V#=3eZUl(4Mv;{DT|r= zodGR1zLi%>Rz#f135!LH`BCbK3)dn_If>7Sx`X>)AcXN-)|-w*8#g*4h9f?m0co=1TIV(D`6- zZtpdzua)Tp+anLqMG=>F^}1}DV0F!&4UR{pRb!RtxqOndB7AnX|l$o z{#N7g(tH{6H7bkftE^5K7gB3p8=db2F~T)}4FjYeee6S^Smsa#5LA2wjq&Qm1qn-h zwO6RgcBcT~i^tJJX|CPQ7k~O7OBC3V?c^^PlPi5}BXbHjEv$JLDfE^zS)_Xh!DNaB zQD7Xu=g`}L6S+sCdslI-bvJ<{UbXa02n_FP2dz23k_v4N14=x6t z6+{$V9*}n^1*Gs$bkMg5ST0%Ge6qabfDSquEeY2dIkQt+%*JB{{Kb9EO1H~ouQBD{ z0#qgcS9*7N=?at9m0~#2y0Y`s>dpTWKr_}84oz|s1HCyMT)a{hANe~b22(=PiQR$k z(2AH51DLJvS{;(%3cpB_xV$Q3?zORcBA(UZg>&YZfmD?F7MbxXc=~?Q`@I3Xv4I2% z(iA*JO*yY}jouz1nq#(wK}f^}srXx>&~B5z(gcy!sKY{l@y6+5edTBi&5i=h=EHy{ zucSz|5fo29354V7p@qjdVa1=}JGCd{*?dRrD9Sv4tA(|FX8Qsz-f!)2p3GWuUlGd+ zjkqK+8IN?I`H1LCpW9-Q%`W~2%VMjK*h&(f3DXonaJ5eOB>{1M_2LDvvdl;DQZ|*$ zaK5r4x$O)sQWM4?ui_EcYZ}%#R%8)u8^8QpATZGPR9zU@UCWt^c!1hg$2mPjW5lBs z;#loq-30a2(TR#$#JVrLhn^j|faR>XP+3>FtciHiLbB^d8JhPLv{=M~7K^7CF<;CQ zw~2>h`f4O@-h47hEJ6-u+gUIMaqm5)>lwO0iw9F(;zJJnQ>*cO_0T)&Yx2+#S*(@T zzzUJW8gxdpB0JHu(;>{rkvMD9>m3bSHJU-ebFd{6NxvR~ZqFa@ zu>-(ZN?iQ(QfAPQ17VZA0@)@jH~)qWew}2SrK5Q@i2l)$zXgp=;tDvHLAU4F4Zr#g zqR@G#xIE_rEB&7#rb^LAN)iE#@Q-8=Hp5FmRiG&i5F_3i!R?7$hh2Tqc2MG`tr@o=N#5^-?)zq^VH?WRuJ^Wq+bbZcNJP>j5dSVpn zzUftwydS?jvEtWq>?&)-<;9T%U7xL(Vko;I-IzU2WmL+fxlzp!;MhUz4x56$MN!4EJ0MXmEx7Ob-a=6Yu zGLgPc%%|n$DK}bAFv1bv3R^!8aEDM$quFWBR-aUk^t^^is-TRo)<=NqZdBWb+**6w zA)o0(4MEW$VX%g;M`FjdV;nxjB6$vW*c+`LE065^l}DxZfT2usj?KRGLi_Uz#BKZP zgd9W!4CLV52Fe_m0CrWa!!Vc2?52va@?@Bo07#_d51813@)7j-fBx!S<#WBYB~TxC z+8IgMpHS8qHaCaVa%rEra`ve?Yaw+xdsl9-cdVr2B4moPEum=#4}pXYiK8boprOe1 zcWGuh?RfrLx;!yv$7A$47^ycS5P%sYrYroa#Fx&WDgtRgSGT{d_o=6I%w`5#Gd~^G zDy&KI^cwW1k9d0@*dfiloNMZI-Iu1Vo<(s~Mx7!**pkz=M0~yg^`5r#3Y`&`?#;EI zmg<*+f4|9tb@gu`*KUA|$khz|L&HX!qxmww`EKqtKYXZu>PNBqaRIk^N%6f2Hiy6o zHCsD59)RP-m*!2-y<)}h5o`CVUvIbV{X}m@`iorbA8&lkVP&bm>@*~~T%ukq63^MHQGZ0fl0&4dlwcZXt*T?dEeGMR+M?jO2=%wLS<;gnVvNkcZO zpUOEp5rav)b1u&_vL43$HTi|5#(UaapBkA8f9?445eK_}eZwS{Ts=puJ(&8Ridft2 z=-uj#T$`A2__d~3dpR;IPX5!rQY$p+K%T<%Y+4k^E_Oyr+CSfuFCww%lG2)Ol#ifi zHuKa?6}$DBZ)!DNZ`hi-SBKiYfDX69O;w`F`Bk|XeIrxzdVclnEEGdtGfQNp5u;~UtLPQR^Y3)lEXL6 zA{nqqFdDYEoam|V^=5zc-&v}%MBlKj$mPtq43=kn1amelcRdugl!~TEAz+S(Vekbw zQIk?dPm4M9BF{OhI|&7#_q6(N_ScsUAU4ptI(Gf3Yg)^?lxj3ik2kP9hTU=H;lr+f z7|P*EgE!5y(MkQyu+!c8xYWz7dIVa?O_Ps{mq+~1FC_}%k0{YM8(Mc;nMRS1DlsE1 zCw3jC+d9Fg6a0OJ8AO>~;TQUccU|mX2DYoiTb3~WvqrPhWPMdK!g~Kqnl{(JPLIsG zQg^yK-yBjH4%KogiOzIz*iE76H#za!v)FR7t1R!>{J6alPUZp_T#m-f~ z+u`erYbPJ1R{7vGj!ot&hlt>NiIsz;t3}VsOT_-cCcV$5KUdxt{XoCk5(R^YDQurL zd9VZ7LnU3n!2cRfI$o_CnY5yrVeWfU!V>9Puje$?hmLassUgspJon^Y2DYhx{k4Qi z6y}_ROWkv)`9gA#MnIr)`ER7D9?y1v`{jJ<%+2(p%&Rl+)2;sPu)*Ev&icbv0enHi zUms6K#f9KS<91v*#^K_etx3S}^fiaNc0IID@Ige*WNMjLOEKNk=R*cAups_WbVt-D z2$;C{G&wFPB6P4ChWu3iCPbZ5xeiyJ)ngbIa2UTs#}yG&#oSv77THsVc^|BA!2hy% zRS&!4Wp(&(f?{o#jv5yfYX)@~*=y9e;T~y40e@#(!R&BVv$-O}Bc6xl5gysyVEQK4 zshbO_!PCbv=imOIY-($km%J$hfwn;Op;zCT!RKaMqRS@WVzwRbL%^AiYC3sz2Rr0=%dg5gsK*sw3D<3I>9BxPL)Gj>|CPWH+gJuz|63|p z-=SB1aas4?Mcs1u)N=lh;>)4Ki~YlAfBS6){C6g;-rk+(o%XKx?OaA_eytNADJ*oy z;Ce>o{~~p3^pMs;G<{)z$M+{nD;q!OHyCmHTfvF15V}{MkgCaOxULUu%HJn)-57E9 z3o0KSjIYuERygKmRfc?c_AG*Sj+xnB%w=eD%S!kQc}Lp*eLvl1)>HJ=RO z{~%PYIp?jx%B*r{L4DV725K4nsQa~1(liU|2nmBD^iR`zf^0)IrCkJ1H~yphm{Vx^ z9Mv_?KLF*(7F!@(wv|jR0_CqFTPe8pH%^-N8jXXciC4$LtRo&itc_C9XXbI+x7mn`4b$IVERWF>2-C0nV7uVUOSCMq|SSW zC7aHW_iw=GQYC$$0s_9$n`c5Dro-(-S!|%;;ITC3^o6vT6c;>zRF_lVaMo9q9Ll=& zg#fLh%Lij4GG02mZ34Y5y9@jE?RS~@#-F)H0M9IuS5vQ66GfY0{DIKcaP zDf@iQc{w_0#48@hh{oPJWpZ{O&=`Q0t*Yv5J}(%B+!Nj7Pr zQM-A;l0^WnSU04xSY|VydMUGwm%6;Z#yxK$_foP>U8{Ww^RsKM0ST?~AC`IxK1+^L zJ^O-EO>twtcK&pVP~3ew0umqrWl(uMJpCT$5*{&_V3R8dKk@hI(F6#W+tTjFY zR&!6{jt_3A6Ks{{lpL~CSJc`>@ zd^E99tLP-`OjEqoU=RANt@V|c{lT8>OY{cy<=-GEde(k?Kx^C=7Gc5VxJy{=-{)UA zX=8b8HQL0=+@82d9g2HQC-RWiVzm?Rvwe3bUgsIJ;w+?hd@jN7ook>}2itJF3iSa` zvb=|t@hfVXGv@JaD~hn}l2&ug_G*XSRtxa0MgeHql2dH-0_T`k=?k>q#tu*{S@NJZ z3oeOA?~B|uRamnY#B7hGFvEyp_(bKTVOhzY_o>T@=<0;f3$z%tDi9T>RN_t{m}kkK z&OIYFWmb%XADGT2CVG(zap@Zl``&m95fYZewzAG~3E!rZgUx%q=57)YJSFV|wr-(K zrdw|i40CS9eTE$#v(qN0Owd`GwBFfGcQt8OpFvD1b&<+%1$Q#KfL^QN@h5k z-P(}$BS6bmoO684OY_9A;DPBoblHX(WrEKtbaV4GHzR%s60vu76=AKriLDwR<7xcf$=cG1XTvq}dTnQrY%Y88Q&i)}lku*qGCTHikrOaG zxe=EKEcP?WtivgdqD{kM*HvTd8fWpbWx16p(P|Jn?fH&=+-l0jqLAIL`f|XOCscr5nHv`cOTVM>+7WK&{gJg8+fj2b}RBhR5N=;W%_? z`yzjPe<+n!yKShu*q7wJp3Lk3?iAd;vt*LPZBmgC+=koqGuYFD??>?x9&hMl;A!ft zZ*MZvgE4du`U2QEplx@h}8fGONIGdu1H_&UDrxQI(uhz;`DPD`bp$ z&|aVlp#EGgZw+??Okp9=!Uwh>xexahLbuSmbYIB+H+kSeSB}& z>HoW}^BuRh)sKqS_~9N{2WJkflclRVm19QI2Z{~DU`LGKvMmY+_MRQp#=hC9y~XZL zylIYYJPuKSzK%}a5HVH9c=H5W9U|m~H*vkMPP~rPS<5+HEzkNSy&ds1%+|dTKeyT!g`k-P zDbYVU$I?OcF*A1Xz?LP~%3O64MLaVFS=#+3zfjG0w;TpO%h;NZX7X(m8Y|pZ?#Ep? zM+MbrS|_l^^z=Q%-x=>6_(l`-X83JaOC+adA)=gnPtqmSKj0dh|Fsus()sx9{-yBT z?w|bt^zUc!gb;P0-Hk$7f+ngw)Y%+Up>@?)J}*1JKfrAvi1#NZ(axB zy5A92$EISNL6c~o>0i%DFv1m8I}wHXiI?VN(?RE$%RF0E>pvpBmbzzg%i)_*HU-A} zLQduF-Vm+`HiwF}X%19L?BJ=2<|XOW!t$V-oo6m=RKVBuXi;D7rP{Jl#y{e6}Z+V>OeI$?nJxsf|Xj{n^hKj$g|l8`su zZ6a?^U#)k?)TdKzL|11_SH9KP*h{-FA0I!r3Uw2o7N_c;#d>0IMZU*GZQnzLI#bD8 z=$1r;@AlHm#9{1($7WCl#^+FE$ZXO7efJUc zd|G~b`L(V~&R-HK_ws~QZM3p+r?xiBEn4)<`34z9DnP3!v3Oo^Yz|)Su?2%U?z{#< z<9OUd-lxv-GpuT+3-6x7dxUu`FQPGQu@bYJFF64YpF5Q62OB1M7Vcsf`K(u}@qilR zhI=+REVdgdom~I7veMZD;$oq#Wr@}*o3YE zu=@Jj?Hrv|-$LTMpx;d~M*X4gmUl8?Qik$NUWxR>iVG6YCxIh7;8_*wE1kd@wZi)f zSn`_t5?okpH<&7!^nlOsskWU#}DgUI}GV-iGnj-MhYuvN`>pA0;%MAxO;l-CA?v3O3r zSAC%DZNDBw#;HHeXButV%0Es4Hg;7Wc3ivLZz!P>nv6H3ASISCWw{~Y%b0GvOAd|# zhCCg>G`_Yhme_gUCNOl=UVS|3)JA)cfQ*ew2#5;LoX0dLz@SSN#nnG~HS%WM{+o?6 zo@e2-QHZZ?#~RE4Bv=rm^;m7p^?ik!x4~K`g3$Aoz}uA3+QF$^md5jqun@DiaI?l- zvcfE>=e^$h#&MnVzpiVU6SBc56%&Ob#-0(adE%7dHizuasljbNq9VQ^=R+pJIz`*=oCJE znR&^xtNOlvD-h*GY?Cjpu#{n_JFplH?A`ji*v6<5Atk_nF>rplKNjA1x^i-U>5=95 zwJm(M*$g)Ab*izLH;lh26iyx8+mhA92Z?ZF4rr#TJB)%TqdbMdDj-3RjCl3=FPe|VFt$Q!OURzd*kW?)0KfHU! z$lY=e2b7Kh*sPaBv0rzIG&BOcA$~v>RePv_#T%3y8y=Xo8x{<7sIeka zrk~b5o3+c`S2Q>OA;)&h)gr{oJ3>jpkPli(jo#x?UfAb`=cNqog!dIoq7R&QO^7+< zd)*{@PH>(nz0K`*=nw@BKvZB~P++Aeb7sVAnI=@C!Zxz`H{qhCz3GAnT!Ur$!vF!$ zFqKW$pQrx>te`r%1}r;OHY$BK^M#>=aD zyJNBa*zAKMI(9EQ-})|?qo5by&)E6H$;8R&jqACK=Cb*(T-oMM49r(I%9etj!~s zNElk82e)K&m<{!8EZDVle)J$eSkkPV>f4oHx*{(X^&S+^A-8c{%MvKfRPL)Y|_OppSV8ZVo*YB@izPmrU z#@oaGvJ8jwz5Ld^?GjSM+6#d(rn!NpMl>ehr}?|0dB6Iz30M(AZh^jiKQy&_muyI* z4Wxtsp;rm&(9yEHf4s$0IUK(-e7fQ4LVN&SdVxkCv3eP~=X>dJeL6hv(+lQZwe5kA zPmPiRq86io9@u^e6Ktk11~Naj+$-}yM4WZ6#3Wg7eN6U9En5$y&bwzyW&9mpkPKGh z63(>U9Z-E5=$UrQtJ48z=q)eoJpMKW?~mk> z`1+@2(ohpPM}By!m3DV`;d1=wu+57fA!xOM^vime_FZg&UD_2I5S9m|+;f|o#PAkg}t zWd@9bVL8u48cF38QBw|Fc1Gn;BjoL5Xb&WIa!hOzHC+B9s1JyGQizH|)K9!d_6{=s zG{fFdR8m0)ePUgCXruIJV`6TNG`vK7HM#cl^L`gub=v0C zj++mmEq*EA>*Id$(uCXjOt|L$>+2?2=F|A4O+GUhPCU>ol+9-`aT6SwbJs}<$u!4_@2U> zK~Lx_iuQTAAB-5Hx{@U{mxy?56aPchA6De+gURnP-W8EwT<3q%V<)$CpsM>B;d`6A z^%3LHF=EDoH{R`(yJR?#G_x&kl@?n_v0?TNF>5G-SHQzmkch~yHxOMeI$xGv#0k0# zi-nQfKQp(m_F|(1@iz9#TL&Jy631VO4Z|tey_RLx91&1|a%O)ZQ$H42_aMB$5@2J6OQrh z)84nw7}t_4FO_78SLj|#EvNJM1XZBX49bXj6oBrbs`Kd#)KB|LZpESX^8Gyxm18`~ zjAdVSydwv$s0?&~F>&A5%0YllP4(*plbUV;Uzk|jp5_|U91ZDsye)lp{q1sxFEegK0;<{aX^6WW~h9CVY&P6c$j$0fr7mwX6c5{a$505V>F^5 zB2a8Y@0L}XvZe;>Q!i`!*)yCr`^YTUpSZuQ{$4ey z&PE42=7joeg(O zeqFI(t@?#1ha~4=E37%Rx9#shjA{TT80RNw4@ z&ro%3ivFFo4iVQCn!B(7XxS=%ht;=mI|0;VU?>k7;f3|FBllu`W%hA@iIy*R+k!|| zDz-%tQJKX<_d?eJ1VFjj72-zPlKyPDH1a)W`dU4{d zPSx%15F-tmmpL&k_`RIe$t^=DZ9r9ed%Ekuap=oc76w}`djVx^?Vg2;vqRX^ZK{pnD$zIiU8ucy?XAp9I8K~nM8VGUXN8(H z1s?B-VudDBdX!L?IO<2B5JHVkYd$@!FgkYrt8mw#vAcM+jq!9&`ronJDTTX#CT{YK z{{m4tGl9KBbZ^3N_ftfnF&OHVIjqT(H$K`qhV+#+x?qM+nnh|6EE8{80)&q5aj$ah z#nC$|C~1;8CR6xl{L7uhqU!iS65N5@C)++elTf%`>(Pl}*_|G!TH7G_J6`+b={^=ISDvHTA*2D2j0W&G}S z`%%9d)|xiIUC@eV<#&cFX-4lqSw#lw-B?AN5Kx7TZUuStcBJRWc=0Z1q&H~E&hCiy zy#Z5VQ>u3)YF9fFT!AuCj7b_C;cjtYVw_{gYUb>GJN){u@(k8CATY^N!yF?!%h}#S z0?dE54=f5e5AeG;0IJihH64Dt--K+-ju4V+!OD@WnDhnt?WPN+F*d%rfW{7+NB3*m zV|UMNIrMU`jb6kZl3&*1v9XR)VA~o_5llPAzOU`G@y!QF{m@yPfuO1E`#xkBR9NC% z)h5H4{xRoJczJ&#$Qluz@ZGLB$0Pg)03M2>%lEj4IH@lSvvS7vzDpMWDL7-<)sfn+*_@Fj$*{ps8+m zZ%z@AdqF>;6q6u4z&sK{L@>PW+vhn1YAmt{(C2Im92P{NI_vZJ)(!qX5w@|joq)#( zAT%G^CPxXGl(5S**^T4fCkr{ZvM8>FzDE2Hv7|eiB4c4UWTxas<$ia0NdwRC?(GcN zX9?$#4Nds=#7gj&2gNS5H}(>h8-3K>7TRrJY|ek<`ajTSRmfX(|04ck$}Ouf6L1+d zCo@Lp?*W2+QxV~=Gy=pDi~hd>_8Y!a-DC`U{V3gJ^XdpDwI*SDL8Km_D-@a{{F_yG z87xzD40dUko}YsQy0#Pa27EV0*fY!SV& zGCK9z{Dlg=&fm)EK!N|6K#+u}Gd1)A>IZtpCHM-*SS+I)3>*%It%F`+M0+e~M?x1I zG!@>M6my{^&|S4EIZs{FSP#svwl&7b0ht*Tuko=C->*BI`}5My|g?ks92D3?y5201o0j+!Lc* z@j`eonZi@Irtg_hnmBy(k-D=aU_4R)BlNfT?egotn|NN8fJfG45|3W&_tDwBGex0r z0#s<2K=Kh1HM zAUqOb;P#Y}P~ZxWN4@X@j`cj>Sm)X>_xo>)0JE1z=%Hd`sD-z%WuUtZK5nW`X%<38 zo|Sy`)X57gOY~_IG9-A_R5s$f1=RxztreeEJ~OP@%B2{_j^%*Knjbgp1LaXzy87Z= zu?anFo?9~&;a{x=!6O^U_?h_(1_Q0&!T&i3RCJo`bvxoGHlf)RE0fAgG5k)0@?(qR zqV9fTCU1&ZhV$-O654aE)oV7C#Wg5D`0D__eIu{`^P*dgmFRd*lHMPA>FzlvFJQFD z0o~hzYZ8g^blFOrYGL`n+S?Tyq;)i37T`=~naJkv1Ij=Lj7L;--`{Uic0_c9UtWzW zLU9@ePk`b@T-fNvt%Us9?(R*#J~r2YeDe&JCN4IyIYnM!O5VQy0{2NY#*^no92^2V zmLXDR&U410DoaCIMpY4sAs{|}NkXQA_dWrM{1>Kkq02 zV1_u})>8(L6?%bI)t~E@tg3oGxqLpp1w)K+Cbk5E%?du6d5wAtcYT*!gtZRJ5Urfd zeFhWPp{m}P?dqq8PDB33{TFUq^1kI~p~_4M@2r;9wt|c3;OVz5i(~Wd0^$l6faiaI z9@>QveVZPiY<&VRV}mn;S7%;>-aah0^hr=_YvM+G95Vjg%o=~dVGy|1`L%#k3}5U7 za00$8HLHHRYh97tyJ7K1J0&geE+#(wvzpYrwY%Zul@2!Fw?Ohr9{P9X6*$8?dtf!s z%}5y0`Ex{U6Dko*-l(q>szf?BM&Y zEXJ)GN_=Blga04lA3#8Mb@%}ecw5^^L0&D~vxK|I|Fb{*H~ZsfTF=583w(&}TD<1H z;{RB`^Lm_c9hj+R!7ayVp0JwbK15{7eNdo46Iks1F}|l8nhx;7COO$7u@ZE_ zF{V`5bPUP?%bS^(*4Xv0Ovo8S$E)7}JkRt6DWCy(4!!nUhR9XYOJ>19d;4`hJ<#hA z_!+P$6t(~iAP{K%61zB=Qx-j)yaJt8Y@|DOPH%qLtR0pCOjoNOYFC6lX?2%ImR=8?Z!Gev&HwaK+BV9vOz%{?Nlr0%c?S1*Ev8+^1Wc`)f zUVfgF%=7cd1yg%F-*6xjD7M7+-cDBJb23d#`%Rm=E7O{bGtZubUH*o47PHivM!}m< zq@d8ha9vGNu|buoVs#N`7y?0-s6ZR2b8{_f!DbUycm z%j^5cWP+c9ZOGx-B&dpSxRBdBj>sef-%s6?!S!8Rv`v=~1Y|)4L z5GPjtUis_(k{8+%7#niD<8yzPJ>Y4f=om)(_uDla&B^@{|8{Wv3YTWrVfw)}@yn(t zez|dT%B$#g^M*|JBJnk_EUGhA^pMr*%(9{ZQI%A5`|_j zP*ZET&5$=Q#GGW1pM5b=v@GuPi8US8gC_ExCO+VzjG|RsZF+%itQJU1U=Lj>@Qvvi z9UnhPUzoOT;Q3T~jkM`?`kfAOCzazHtu@IKxmt@9#`Q;8t?3}lca;sTRrY>>DlooB z30iGVzBOj}4Q^q_!4_poMwYB!dT|3~R>uf+8oalkTxc%s(&=FTyuQj;h*h)$={qKd zi6_vftV%->Kw}fDQC^Xd?eFRNi@;BjX7Hm%gM-jwe3?AuhjH*o`}_SY^<#-+Cn;M4 zR)HXO$=N2NIPk`#ay*}dFv_bzMAVJ&-;RTjJ6Kz%ex}$Br{ns+8=&ZT(ZzHRXB##; zSt7e?Cewr->+z5Aek0Hi2saKoY@sQFd~}q4QvM2cQi{~h&jx)7^5V>}{RJjdj4qTe z3RKP2_;h`tv|n_Xn?E;@V?vy_z>sm4zdt{v zL@5zpYVYsPY`3l%Ve!whJ@TlVV(FHYroWv~p=N4TLbf0dSxL4;7s4NE+U`*bE`x#D znRx?DEJ3o^$0g+G?PKhXCS_McX|d;z#Z}1jukT!UL-J-o(U5n%LR50@zcELGgg@UF z<~yVDFIqnGs2+RIn|J5)I97{&FeZ27rHzGT#F5~rU6F81lvJQ8b2E&HPr>FDSObTm z{q({3wi=!GG16I(cC82r{T(KaRDZ3Z?bK?U>~mXXFORbGbKO9)G49FYp{O@wQ`>-K zr;c5dY^{ER{`KlCr%>HMOiF&gZQN0T!R>$NY3@?3_O664$R_(x*PoBBw z*u>dey<2c^i(JgUV)~d2#XOpvxmMZPgcsz)8a6dEfSJ3grU88mcW06n&11Uu3(mlA zQ4t&mZ^^T~Tth)fh`|s?IRlpDD46Po1bIk6ZZK?WmO+&K8D)KIWoYOX>IfrlaWBKY zRIQB*8E`Te`c|M37x^6gxRX+n*oYP(eaNYq)cEAavx1b<`ROwzGwxtXM{9#X#JRlY z`b=$*p1N*Ad9V)}nZhS-LM>9mbHnUvxbmCfY~FBV{AZUZ76JaOjSPd$&fsk%S0OV> zRhGkvta-LZ{+xY{wH?%!AHuon?lI-HeYl~*7`lC>V(pbM=iTpQ(+aH`1l(f!5Ds>w z(3EYu7g!jte!MqMY3ad@Rczl{Ehh*HvX*$)^70tmwnG_0`sHk4PMr=b&M(h&-IT(` zS2ncpOn9vB^WVSG%sp3=KCterQGBBLYk zv-K+ejNyCzT%B3*S$ZvJBIA6N_*o(_8)I!=OoK;i5v-{Q{s@03w`^gZTPCcwMD~~= zJA__7u=6<=_Rl*lQo17SQjsb?Z0!uw!6pW@q+mbTtEj9&ep2;g<6~WE;3qBEXJOlU zC<#>vQK_+f`Qsu|$obTu!?$#1($i{Hz|%rBX(yq^?}&Sz-riz0_1v{|RD4kE`EqZR zKgfPH<{+|aU)Bw|wjCw#T&_+>F-NnHt(ltWRq)ugd5Mloebo{JoaUX5t~pm~fm~T@ zl36O7CE~p_Vc_CxZk7=Aq=_U;pOQSyjaUQ9KGS(qeZT)Gja){V=uz*9!q^K0SrnOD zjkp2Df`hV@HtR#M$NqoWp-JvSY=y6-Lh zE3$MQuXWI~k92qmQAiD$jIxUYb3+d5b(7TZH!mm3mb(ey5@^ZFzvLPc{wy)T7y^;CkEFA43Ht@Z|~A=B&E9=u1L}DGTjx_|D#*jE=7$9QqPLfh$4_qpl6M^ z;gG!Q6QZpL{Lp)zXlYvyPx3D@+_L?JVRWR$Ly3xD8F&K4<>D_r3{)`uhBz8&u<0=Y z7C-9vOp50ExAXYA?>`tSC*p6F1kV8^L-Mze={K6PT~(M1GZ^h<<>ql+XhfEs<`r!0 zxiSa?3mkVDjAh&$aPFadXla}84zB-^vF4&GRe++ET&z62 zT$oqZI*l|HDJ0D=C_#Z<4M74m$UNqp2C=3C=a>=Jewp3{lPAcyHrS|S=g!60axHIE zBH1`rmqzH|MlG&{{@;XnQ*v46eC{i{(zKD(C)us{S&Xd8!gTY&~^3g zPLW;1Ex`whr3&$(hK$N)G7HK4&~O#BxHM21017eZ0i}J12fZh{-L{AA24*3%+==*r zndM5JSkBAYo59H%K0wp?Q0aw$-{9abwv9M~dP1mJ?sfNl;B>Eb#c%W8RCHFwTDTM2 zb)wUXV@p8Hu~$SLSr@Z$XnTYVBV#^aAluXdt6pm9FV3K`I@neI9RlA}XMXWHone@M z7;g3Efc+uw>vC7-s^GE@3!6iFxUAu3Pa4WM}RK! z{yAzIrI;U}nd>GtfjHuIvw5h7U!FNxS2mi(B2wzZ*fquTuzhU&fKOi$#kIS7tk71Q zMx;ebA#9Xg30FQ0^{w}vMk!+7I|fcaEjW)KTG!KAfNM44&bUcvY%FFfiB*esco9V? z-)^9%Nu>USULs7{Y8Rg0c3;HsDSScFN#|)P{DbBqOe2O+;8=T}*mX6YZ#+Fkvwe;hY zN5NXS+OQv0h7zAid*8?uMJ=KbDbeW&G#pYZp5W)MaF_+VWu2LKt4Ik5heh+nN(Haq zrr-54ssJ%w1C?C+bl7fChUcehsgLj}H@in#Ce>aQp$8)8QpcCLt>hF2wdk$s)sO;g z12{vO1<%M-kx?j^3aAQtI4#3dq}u?faNP*p8m(g^s5QH@HR!dQd?~GTX;Z{db*!tu z*@Kb&I8T2!6>Ok*GROglg*}FTW}s=N+V7+D3G-eG>l~}~Fo~>m_t0QM*tfs_Q#Jy1 z0Hu!fh`|iiDBGzsPQGAJSby@Z^B!KeT?(pBqm1m9o@yio!^}?&JKGng@Q3e7vHcV* zA16{Pj-W_aI8&gfW_6`{93*0T3= zcHQfdF}~g&dAQka(|j%Xvj<32NU$;ur3DS6xJG#%Mzf!=x494rl37;qtg)VyuIdUGX*7x^~XaSi@GC*{0u0i53dSUYAOXql(Exz0Q?Z6?#zh+}FJ1nA?zGPkz zYza^Bak9%+wZZ-i1Ker?8%yEuirPMd?!;WE6Y^8UAB%mZ0P4W5+9&2p>EvSh zja?NSzG6QO(a>1Bc^s)@;WWrtff}}P01roPiC&^Y*;+2CPIZ#s$(3Fx11Nc0^rHUpUZ7zOz9IS$*Mr9}U2wJwKID+;8AL z(iW794xF{_fpIpB0JL{#*}PY$`ie@<< z^feegz?AxNYbp+TVdK=2=(IBk_FoajvJRIqp>9mOLraGTmPa1-xXQh|U|pu0xZh*W zyOmD0A?PT+3neB38}x9f6X&27YXhJp?jbgTG=l2KlX^lbMB2fcm6d!y>8P}zC0XSa zh19N^W5v-TAXeWiqJym2VJ(jcsVj@t3f;NTSm^hCSD_@X66kJDn1f)bX&iX?J+|Tj z)m2bqEiMs3=cc$qOs;QIAKS5pQv=X1jXt?gfT&BzRO%!gUmHd=ZwI`b>RJa*g6@(0`wzCf>~p?Hmt11s#NYL-=_s6oqD2$O?M&W5xmYi{*#0e6?|2=p0Vk zT;@-P%J#u!!Fqu}ke0c9{BEYHTuN&~+B8&Q=T+_i#X=J}-i(`A8`8*g*kt-G0;epI zdi9#}wdT;I#n06QsxR__pF$0NhyuDb z5)dkJtXGtZvnreE{wQ| zwiTOcXe!VhYb==pEmq~OPV9~{HI1Zsz_X*(j`*Q@;Kr?E6|cT6JUzYiK|Y4Hp+_`4 zp4`MmQ|Kri-q^9iXimsezL&t2&u6_MT5dPWH$}>rDMgBE3MkQ4&nVxUs~_j6I<3$w zZyJA~6M{aJkgHjZZ#B6ZZ3R+h*!NVm#F}-dK%GLu$FaKBUUacBl8*4FNHkf4@F<^; z=Hd!BJn!PlH!babD*D#i$*jK^6~teb8~nhmB|si=1RnkXbW1qjK;Rd}tJHXpD6SFA zGvBg*M3+TMUNn<+XdCL4rbyGRL;lbQIoD`6J-CGU>p7t7;eFT=eIK<%{`Vu+=hP+Y z+#Zp(z^y@%WRhx8(s42T+>#>>BRqj6U4hIjsipK_&&E61Z_5|&ZSc#J^`M16W=Hdc z9X47Ia>n&qaD7w+KY&Z5AQ7luH^X15vaTnS#*A?@?ev@4JkdmPhn?8@~+s7il%EmIO)9!jv3ss?@IR215Jgjxep>E91x& zO|x1iRV!wxArZbFen7092Kq{Q?B6JcU2A&AZH?F>QL1trFEtT7mY=Mk4+D+~gC3pw zeg%uEmG-@p|3Ch1rUamzkj>D091j0)Qm} zczJObr<)r;h|qf_e0K>a9UuC^EL(5wZsH|cT?IJ>HI~AMmYhrxtaq^mCJI(Rgb7t*&|0wsxr4(+8Myma zgzIc>hr4g!)O{KlkQEg%_5PHtjpWvJ>#~CF^@X^zpsy1?LoHJa7ka%Ht`?2q~|w{wOKnioAs%yUr6=Uf!(gknRvbA30HVOJy}|M zb~8MB%`tmm#hHuQ<=(5)KT1K6+~$BA-WiM0Fb61DsK65lF7I2X+EMwVtQ=5NYSSyt zhNk_%j!i8Wi1EVa++sj)v4E*ObafTbsz4W5H_b4r7FctMLaF$07BQp->%EZLe zT`e%N3%E=|fj5_l#^ZF%B#jd4aUEOUU=`CoUj9?oUDszBZ$|ZMyFkc2Yf=FDdj$71 zuwX>2v#KkijueZ-29`#kS9qdNsOX@i z7RIS1-XDf5!Kj&A}79sBZF z5wVr$Y!qV|TdFuX(SP6}=hFT#GDPPv@+JAK`l?>C#>p9yRK>((bE*oJWL%n|6-G-q ztj5HwL98@si#Jwybn#&6U)cyrh@HI7|7yp+XK{=sh9fOHqZF3choq-($00U$WL8OK zsIG?XFWHc9VJrdE5s9T{mbWoZ_;XIiX>82FF6=GtD)#R`IH~_)b##XR<4$fEYxgI5 zW`e_jl+o$hQ{wxS>GZV0Z-=qmDd9C1GO}EpVy&>KBmW)?W#_hKZrHDCT>*cXTaZv5ui* z>Ek2p)qDuWU=vAgk3V)fp7IZ{^rQ9X;)WQ4f3}J!p%mDF!BxQ1;+@br_OFMUR<&VO z7Ylvi5)o;$Lc)9L)v{6z#STgcPKu@&Y+A7tOba&W?Hf)LFekZZ3(`l*o1bdRyRyTg z4>?!LUUkSgO2suJl@}!Om4jnLA)*%aviQxS(!84AAO2k)ifsNWC;V$$-&sx8nO}Z! z*0}Om|94{H{IQ-8^RNhC?_tNXuhN`qzm|fH1-Rl)ekP@08sz!bAS+;xRY8{!6KX2= zQGR$id8PkY8D0^wE}z~$hYhF{E8TSNy|oJw(b*7zo0vzp|ME~jy>OwJpBk1{a5V&z zr3BsBZHVw4Fk>|u-{*C8nCA(i$P(Gu{PvRoifi39U2FaW%Z8TGPQH{SHxz8JfutBg zhRPU0eG6I8&2Q~gaFUBbMwX!xG#uajw~Ji0_R8;<4%Xe9?=)WZ6T6ymhaZHgZb!`x zF=tpVln0b{WTpOg0rlDF3yH4nG4^1ZSb3G2PFs< zp1FwtH(ZS`H>d(AOuCZC=|i6Ny8oQGCyncwI(sca&*=%ueDn_EwCV=nRk3n9?n>#m zV*KZ0%S(p#Z_ejF()-A`7iXHnb@`rcdQUKJjUCU?{&f>K`W)?`j!xHlO~^i*A%Q|ukJ>h)QZ3FPTrYxCS=!|`%}+Ol zJfE@btXJx?*R_$-2fM2w(;Fp4Hs!@~w{sM)@XMJ&xl1Y)8i(2116>|Mq2uZ`Lv|iA zDwE+(!FI&WHPXq00D4BbQ4^LzKM9poxe3zWq{0&&yXwar#|%=oWKCp_EyjFQe{8zp zSft`;*yEMVNDRV@`06Xx*SkNl9l^=(1u%Pr{rPP8xpjanGn?#WlQu8w$Gn175sP!9 z-Y4a1Sev%2<&nBE>I7Sz<=PKLJ-|)`i=QKR0(2FG!#-xq!!XVchthjAx-h z=NZbKLX7veZlsdr3D*do_WDCWd;{K!15hhJIkkrz)mdJAGkiI2)SY+A!6;Z$~-)j-IAV4I7 z=#S=#>Did~-Y0KVT!k9QcW>x4#Avv541GB|j4miQsR1$MhA83UiVxyKM%u?8zzC1Mnf%ba9pxl2V4{f^|LuP+eFNwxL}B! zN(}^8R1JTA@jBk~cq>|PBZ`5$Fm!a+Z-mm|7Xayh7Su^id zBD2Z@Mr;?>N0paZznOjLk;Z^78Dk7^KlXQHkh7P5_*w=3-!gs z>j|~lG|t%uktO{mHfS9Mc{WA`_y@5lz*I>bjth+_Es1L5(LjVj!uZ3us5$w@My=SO z0e1>ixpm|(HXnb$Zv4qAO@CKMuFYCd>kTo%m_1%A@t~X-@Dhs&YC-=5EQDF4$=9Rt zN936;Ue};fjgBwKS8-f1#X!Ln{t7E;H6*l`en8h{z?3|#Gl0yrk!j+)-Mzz=*`MJU zmlO<3L;`Au!!^lT+gz9vIzR$AIut~NhDL&1EEv;tDkia%LvdJ-wZjS(V}A$}HyUaZ z(rdVvqH}x{aeRDC;H#a4#3)!~LhZGyXoHD01mkJ8J=XPSqwJWmV%qb!-Y&&?zpR{(`9^!h4t=7p(mv% z&EN|fhW`}RIv_J4Ayy!U_je%nV2o$gZed(hA_=K3qWlYPM0>2v5O38v4ik|YFX6D{ z69(}G_z@1EdqFWFcDSVfWmK-$iPZSpA$SE82TFI)^H8cquA@c|y%yK!BlT-=hQ)Hy zY$cmN-2UxB!K#&t&XkCK!3OFM5^7#vDqRb1GjVkCb|+c4yHFO4vD9WV%!|C*?lP9w z3^}4mv*ide@523*hsuK-1NojO?&3#Blzgqv)!F5>w?t=|t==u*_jXq%?vh7Z(GH*V z6Mts)1q$&et1hb5hqx3k_`JY+m>3NuDalGGrs#i4v=Yzs0(P}K)&Q`9*G zD!ham^_yt#7r>9uz_AvfRCD^3=*CR`&WnQQeAiz|75?Mp&}4%@?sm7@t?_3aLJGh4 zlr#x+Q5Nq4%|7#)LCNj)bD^6-g#yFRDza4kXr~YL))f4hT=;k(eYB@6?z6Fjy(t;sd z1drwh@aD3K!LH6?HU-cs@$b!qB6}2@fegEGn+!OB|7VJ5UokR29M9gk6!mXkps+wr z-{URbP_S^>&4n)zN^U*aqM;IFI>%#p!G01T>*jv}+Z9=u? zjBGIVF`S1GTcfl)%Ku~dE0$)v3X}q6nIMu9%n(Vc%vc%9Xt8+uM2FdJOqF3YsMbGk z?IF>L)>;+tOEL2uEsHk@meZMgaupV^yMh@EQhjc)kazS|ZmzJ9V{gTPrANoQao$a( zl!_?mXzvz&{`;{Cekrt~RS0#COfrS8O3jw_x~YndSPv}CU=SxO>2_V{W_2Pnodl)M z60^oD0Rd{U~LV{b(ZBA`{6;jX>-<|2s&;Q(S(c$ z8mrC6JVpf1v%Kfpqw_AW`y-iE`S+bkTU%xGz4^)tWJ#l-$g6YSoZo7uXX6!C90WW$ zVbDNFOo}j;1;G{u1KEfiooOXT3JR#-mt)X0RObqOL>qCDWOJ3+C250IsEpd>8Z zG$Qr=kEKc|mnsM(CI(BK#XenvFgF$0Vv`g3xF?2$(7Kt-mTTNg!4LbVn< z^t(?D?3J&~@pv6t8nnlYQEh!bJ%tO^l1cH(_AwNo8flFuP(-f&EfJiPokRX+e1d=l zNpYeJcC$C-t*9z;euWb|3vgkwj^c(P^2L;Z6Jjh+Luo?QgpE;I`^6MPB?c`m<`Aqr zzdzHs9|80DGDZ+@^*;|;>cS@p=tj7ejifJlgMvk_hz@?!&uSax&3qPwPyq8ONzKm{ zGAS^T{#G&dg8Nwwt0wHjy6M^17T|5usw*A@Eyobok1M^vL0vh}0c2@U2yKX6`9GA& zAyq;bQ@e%vtb?B8#~XAcK9MmxA1vIR6f_3{U`Fh68U%2u_zRjCc1<7uqQzz&9%yWR zK@mJ1Bo7TKp-y6f*=zlJalE6bq%|HN(EqcjJ(SmQ--poj_r#mGr4Zae+ee@%_1LaF zL747-9H31+w0K6lY_yMp0)%fz7UgU5bq!OjIhS#8q`}{T8r2tUT9(>fo(@EXE!(|N zSXSu`a9Cgl29yHhJdx;rA@h(QU@@x-eSQAh4C7?u{grK9Xg~m2je5{TF6Dfoj1&Fe z+2+6SX})0?C%PtpVXHxlZZA6#AxwWrZsvv_?%tc0%2qS&Y&nXrn@)diVe}37IkgPq z2EsW5yJpOUQg9S9&Mkzac0==s5t_hE{x53SLfc0L&H-I@f;wHZHhAs8SgX(p+Uj)! z0jAUK<_dxwzsR5+c{i*?rj5_swcjmwkOD|BZ68q=m2Z1Q2XeSsgRZx!Ve^&xt-}wc zD&|mBq0YpKnADi>3+gt3Rz*2R%$$tW4bC(Uu7`Vww0S=e*TftXu+FGtj9I@c_*GWE zcLfIW4nK^Nu>$8?#Jc)i?Y>ehJB;Y}H>LVin3@*fP4GVbhCS#P`kDeNV&gPQs8d!t zt?zr4&_lUV(?RJE5d%}OY*2=(>u()IWbYShw9v~aOFdL8PmpMgzK3CR!y6_KffLTL%B-z3tPNRK8_8>Wf?s1Gj$Em4X|*k~YY_)+-HLv#CN7H}mU z#(x-j(cbIgVK2orQTtE&WP%H5#b^N6R4XgdXpC;7u)SpVZ~45b5#RorQSv7j&9Jta zeug}ewubTLsBrmobjHcS@%i-k?m^$k#`bz457fT{f}{NE)WYzPZsZ*2c)xn+RVXZz zos?pp7_n8TZL12$UQ4ybW3H%G2nDgPz2#?cA{mA`005LOzNC}HZ_2H;MhxjarPR#l zldt~=U1PuTrh0~C8&G(Hu!f>pnWW^gmXEsQ*E-xO7SxdenwG%4@VS{oI)96sN0`fT zGLxOuWMBK0{&b}R3_gp;7jx)5`!fpK?Hu=H2ww5gf!y3Y3gz%hV7dPr(d-b*jxvCqZc;)kCHPx z$2-+Unw`Kf!1!FiOkjV8f|nb6`J^1PGl7goVhl4*Z8?G58ihL{oD-T=7+?%k@E8)L zB+}pSDgd_3Fh)*b#Pq|$oNY$!^72WNSRkSrB8kpbQSlskFr&*Cmv>aWIO&K%@tAQ< z5rC(y4_HZ5kCz38TOyfvHquj$pN*V(K0jvZbrI16$zq9i~b2=`|d;-BXo zw}*&{v+)n;kI}8)L?^KHpMa&AwK0a*Mm*g1$y1S;?@#`aMZn}A03tQ1V~Zu ziR@CWr4(EqL};aq{LQ{VRjntgC@cY1h_&68gD*sbgKzQn)vZI%=_&LPZo)7(Px#{a z>YYHR&u206K{MwazIvS;g8hiu`hqpx4NCW=kw&`fB3%N~9nvD57m)7mlx`6aDQN`hMrou& zkPhGG_uhJcowZo3bM85N&&)U9d^0E4fktq|a!Ws%S0_!! z!>LUps_BXQVIA6A#%Mf1ko8TW1hA18no8;6$3E{zeEf;*0aDb*qa z7tQ+g_Q;F+5hR*a>{w+U_03D)5S(|%2^1rz?U-MCP1aA#@aBG#CeBB+C{)4;4FfN) zzreOS>~mqKae~jTn`$#ymAY^4RGf$*w)8CQRB$T7o+<`?hw{6@tmWEdfRe+qZG!p^ zVM)){6DX;Zu_2VsV0LVM&?z;^&UkolYkRxd%A zOuRC&4U$YL`0SbB$%%_>CcLgq$&H&w8&JfGSQ))ifY~&0I8A~>+mdh)cDe6dSWy3LBoKSj2yQ7^-vWkfd7V*L;f0> z#^mg~^|fC<5z=PpOij#1NGlfR!o4o~o3u4DQR+K-Yh(kU1Uq>^+Y5wlARU#UHu{bF3Cb)K}_l%ZSq@QWm(pL_zdtca%K*jW70hI^Hk z2P0|g$M&~Y8SMyNa&MpetAkyL$(TtcVqMYdeD?VAU{O%LpZHQjxmx57&qpjnL!d9M zT&yE6T{2xqiWI#oR{zHm?=%N^@<&n>ay^WYKEgBzd+~O<)XVx#WO&s`*CUY0_p3G+ zrgE8Pg`KPDEen`Q%_6YMrMb4WgoEPUdE-K=aNiFeP63>iXX70~AIi8ges3h05(=eL z49VgUnynauZ)L2|4@;IRf1g?863Ja z^t_xA1@SOhd%&GeQJVMqrx(fslT}Qlz#t$JeGa{3j_Dc)$E(Uts=_L8pd!;qXtZbCF17x3|-QpuImmVzGps zy>>iW*94`D#z0oGETIh~oVw;a>G|}q(5nsIWqdO!&%auFF^hnd{YZ>GJdEmRGo2;@=fFT1aS&Yby^f^Y%WshB3eR<6sRD4uuY7^bc%QjFgz zo;*ZDv4hv2Xn~V?(}^%G@u}vsM3i3{b&R7dDv)^J3A~j0)DTsg4H%SxsUw1fo<`T9vpeV-jC7$VZH&ta_ z+J*mwPw;@ogn2+AK5Zr#yW|xKd$JGfpafnqt;Y$4XDN>1)h^(mqkKJQ)?i$H zAW(2r{g#}^ixnE*yOZT^lk=Z1bT#cdTuj`n$@TpE97`2t)HI7r+W&yX z2zqzR1}GE>R80{;jR79jiyV|~gCf{M#;!EG=b^leBbAaD$yMB|O7NJ)SUjX?SD_@k z>u+fqsNR-Be}BMWYAMUY2#oc?Z+PKS670Fgd(kp-Br1HNJhEbFOsDyk8qXDOH$;s{39xi+gF$X>U z{vn)VuGxWyp2}z2N){Y}77%HT+(Wo0dhR8f|Ve+y5dX0j*5YzxnfM zDv-u)fKT~}UA_u}yGuA4Li~;Omz9du<0oNQkoAvrmAH-;KYh`4It$mE_`;Nr>Sj2U z7H9t@YR^SZa2Q|FWIlM!zhs)~?kC|PWBQXH?g{UQ4hc{7yqqv@|5SFncQSA9Tx@AyBmG{1YO|A_-*5uP%w(qKVPB@mq`aN=PWmaLLAr_l4lrx~aB{shR4IF8=eAWK{_k>0Ep5Bk0Dnq%0Qk#nSqn!T?o+HoVbL#h1ds(T( zd7_}otGYfP3TUS;_)BC0i)`uJWnvcXJ(*X+iiF=4->A}JZ%BoSyT>SsK6yXQ!#UkOYS^Xo*c z)EJ~9dK~yzc5v7tY`MPY%yzmvMFjav5t}PgcB%UADhuB z;2sOzQ201rUq1Zes|>)kA?{jTsj%5`+j*EAIX^sPF=75$@pUftYa)vBLqv87U!lvd zk;>ujUvM3ub!mM}_XJAYK~LyFXF)co^Ghkj$Mgjr`~s!RIMx!~rkN*AgZRulLWvJ5 z|CSh`WUb91K7ty7Mm?rn-K^YhYpdowot6G z)pzlCcDdux%CqdVhl4+UwdnAh`0V&S3lK$~JO&EkMo#2|0ImY8(kF)Iy@x1OwKQ7N z7hG&_1LF1I1Hlry-xbq|{{Jxewj%!iX) zlb*u#hFwiW`MBw@fW7UC?jy9bEs#C!YI4=7_~y1V;y7BZ-|tFTHx##k>@9`A$f0=T z`Vqg*v^Z^|0TKa0WCI>S^r*m1aoePtTEF#IgOK+*oY|0W(rdb^0|c8p$t}|w++DQ$ zxI8$##OMYD{KyM9^Db^@RP$w)bu&!iz6MCnEy5q4PRze4?dijC=5S?5!)8|If@MgG z?>p7IyeI#3+|CfKJzE{=n6`(VwKD%*cZt^dYxeQOW=DYe$}@xhVS!a`HOjiVTR4e_ z6+HP3D1Ai$1C)hDaiRRUtTJ5#03T@4jXyzBEv!|(fN4x#j@8bUhPP8utn*@`Bc^b%Un8 zChN4|C48#%0MCVg>siEC88DFNAOKNFg1jXb(8_gj(u*Bg96^bqldrD6{v7(X#t2uq^nWc5lER5v??9 zc`ZoexK_3(-mrM{Ef|y2Cx27CE4|h-y2I?xtv&mHS0E#!;z> zsJw4(W4%QPmJu*<4JxIuEi&E88hif{KxLzZTdO7Lg{qaYnCfXN{)*9Xn}tT`6Fh9S zJc`a`cyDKK8Ij|TFe3URiV`_M^d@ZLDOw*#X{qI2y;LMo(o-&^JEUk-HYNMdP1%&K zfAb@PyyGNm_9vox!!yB9^(e}RwN?y*Cm+^MF-^say4v{l4E?!Zhj-o&>UaEFlOr!q z)XKQ-K`V_2uB9(Q-1*-nb=%m^;=(ZfXs4SXR}vNhz}CF2KDm`(W2ka^j3Va zVwF*D@ix2nB0XEZV4;`N`C>X>Hia3`)fQu}k6WqUj`HcS2^}!M0GM};9E>*L4#_j% z#7Vkn9Bym5;ZnMAI#eElF!Z?p6bc$v=J1B=Ph8yZDwJSc_`_xvbOcM`k_(^46g8@c2@E%)<%+C+|-5gJ_NLSvLg2AYetJiLnpr3Ot< zYAm1vU*%$n>ecgR$uM!BxS@rbI4!2CHzFm!ScSe=^OO^J%SgHDRS=KKNNEDevf5m> zjXzKC#mOYMhQ*1Qj@V1$e;r!IbzaBaKcSn&?;lMu=2xn-utu@#l|T#nZv;UG{T3}c zeQD&TWZ`!nuY`RN%BE=M&3Ar&%OL>Uee82?5_>&9o>G#}oJ$e-8?gQ_aH{A@z2CpM zfXlvR$8FPss19erTz)0xq(Jt?Lv))|SwDvfd&^|_&Yhnw2Z~8ul-;1usUG6*Y!L-g zFIJUbmO;)z(!dP5!+&}(od#n>qU4v@GnRJ6yhG>J!wT+3y$bE#DNHEnbr!tF(d&e~ z6=BdLeFivzU9J z6n0xpt;Ex+kbxP=4LE+x zv3vRP^NW8>J}+_955VpF%>;Fjz7hm$_}#M3 zfd0FWG!ttKS^ep0V_{ly3ED?=#{y4MubRJ9=~vl)k6#wrYd_q(xOsX!)&_{_iCyPC zT)k^pe9Z4t>kukO_?ZN7l6$9iLEXVKJRgY8v{pc2n8ONXTk#fCJw6}!seI^JTQ9~ z&u$ol{xbS7%xSZ%vHIhtZVO8!he=wnOH2B2w-FrE)AAV!GJ)NJwQ2jtq2(qd4`W|p zB~08;_+M+l;@%O@*9*Unn7G;0m4m8S=wBIrhWneXHbdM+4`uMaG8bvx%3X^vF_2)H zZo)kSJGBAdl_ux4EF7`yL;nz?-A{HrCKL+zUXcE-12}_2;!dH%MS=SpMw8jG#=PVf zf!4lk(l^yY;YTp~;w8^fuLe?rOajGALApZ!wTO}>3A6ev@-gw8(eD~xer@NA%Z>DV z=pL5}i3nBTyq;)rI&1R3uDYyB2a2v~>jxsE`=gd<3%q2D*i!iyV>9d+wddOWM-~KM zlxP?eNiZ1`hmr?l+t#D~p5+peKL}MxXm=51>vXnpKEm^81wB*Y5yxjwlV*dV@F44z zB2``=KUJR7pJgtHk;aV%bisQ_H_H*=H)F|d%iM^+2%p-CQAVLfjDP^hL)#k(fmXub z<{W=v@!%xaqo#Vh*5oMUve@dxV=CCq1-1iMlR}%Q8m1)IH(6nLTl#t^>J^_-m}-Mk z!}*CR3>~=4e@n1Pv_nit(z|gLKE=OI4-6BV=f;d7f$&HmcBTfdgNx3OuH@;ng*{xR z$^M&g$D6JbkGB`2evQU+OwOq~2^V@Zu>#p)E6`8NTVFTU4_f-ui2>NtmXN1_4)^XFon`@6%m!ajOW zah(#^wlJbOj1J)|QfP_vHHUck(mPvA9v9MXX|P{iNynt6G#`wK^3zR%HeMzyMi9SznE73LDG4wa^q>82=jRe;L2KW9VAzn1kI@CXW z;i`|}?NRj@_`V`(+V5N_t5)Qtc09jjCw}~QRT7|*_<(p%02x4$@!gs=&sOjp@k{R| z3H?F9f1(6o&~|GJbXllViNQpsq)cJ)c;8m(tR4lKV zk!M8ofgdFRE8)8iF0+gFx(;~)K4oj!(@4&9*|}|f)MFe@j|2~TR0A$={3_&s>pV7Q zN%VmEMl((JlaVAVuZ>=k{v@YK0?FkuEkf8d1dmA3JyV#)qO;5DY`(NhCbBIq5AQ}4 zLU2gsl`yVCNBZ*LTLT8VdbR|+{$boO&=cp429u^w4(@?_4Z>Mej|;f$Yk%}9S5B(B zkSTGN4>vjM{Hv7F=K4#mmp(SrXFMiBy6<$|K<8<6TL1w4i0h_ZvXTLjLkppU=-ZL% zCR36$ma$;cUa*TAS}+y(mxGXQmw-syI|jNY;%?jT{*lD?|C$nqX{gNcT5|^Dx9SNv zb4*|*tZWnbX+we+b&>*e8Fn7(gQCgx8oKW^nx*SeSR56wU7m@R!JkNN58v`z$uNf>dE!^&4C{s<4vV z(q%bf>f<6up``$WpTuvkgJv5($c21{;G_GMzXmNv&fuT>79w`)lF{^-Xp{NIW~f7^ zn7Bqtm;OR1t^ z3F0z=o5LHn-qJMI1P#?^Uv6rb+Wq#lU5f}xh9|;3Gtj31Lu|(ZRw5Nx zC*$EmY4t60{)Z)8i-)@#`2rKL8Wv#4Kx1r zG%lqPuw<>o1uhYxIk9J0NCZ`wG0E&N<4{u)BH;6aCngC6sqjGK-!)FD15KuHaGj&= zP=Udp1J^@cCQId0WG+7NlBZ$3dYuls;NB zcOIrM|Ek7VY5zyt7Z*wpq~F~+pttqg`tQn_&BCO&ZI(V`fAn>Ee8wa z(x)i9fP2OEf_KM8-y_=}@0NXd0nJeUhH4D$o8V?VSqf{Q!p;!OK+<8k=amfU8E)8aC!3f+B39P_zXF2+H z-j8u#2yzyVA5*orhr+BVplJvdb>WHk4Y`EM&ZnBn;jvu6IF%F;NXZGR&kN0!5kTKL zX?}P^aNjK+S55=%^1uhI_Pf0E45h9Y92N+il5)VDQoYw>upzStqydu>#f1LQ{Lb17 z`vwE&zkmFvizeiw?A!IL7FS=7W4z-o?oZSGR<9=~%U#+W+dA-q87Jw`#2$Mr-6 zmTn>FDbxH5o75v&JQDp`pEJH7cJoR9kYx~e5SU3=597}H8eAeQAvRyO8W>eO#~JPD zel`-mYp)^dE_xZq$7ml^5s5{3%Gd=k(=wbZAo&`8nEXsAXidcD-zjc@e&;;rr)GAt z?C!J%mY4IJr@yv;tT`l-9BSP)xY9gK+v~KzR53H6n^%wd8Ohv|$28pG$n%d!BE{>4 zFkYbq?OUq880*k7-i?E!IDYH>RBT4%c&XvyCm14m)-4Z11_jRGmDSnWn;S@P(hmqeRc;>!S;wtRHR* zEP0j>i3$}(Nljq1{nx~LPK5X*hd*-=>@yGF#2fjE8D0|GTk!REc7jn>rRN`?;9mjB zdVu~>cqQw#2fqARb;4F|2XbMyIUauJBbq!QNS!yi>^67klVL{<=U-zS6kiSXA+y#_ zVVJzC^5WyZo8ZA^KiWrMcWgZhUO~le|FTFWL-oN*dAS|aASf8JO_)x6;^lr%QCgjt zIJ`#Lc(Q7DE1>tUTiW-}SYD+ci7N9m?%c#hh4H;rs6}Z2m?Fx!RzwLH>fT2bG+_dE z0P1jZAK_Kem}Dies=P%bBcT<+3f+I1EtEz7mxCGHEX=`U2OP{(hr`O%xLna=+ynH% z_S%u2`l4igSs4ZUAs3H5JoUpj@P9f+1RcVN>(*MLI~UHSwLUjmoiC1BcJ0OfRpWWz zYRXb~?fYI8l}4GP=Ix0t4cU#cJ%c=}e+I&?@}YB#DfdgpTXK4pxCa%OU(!HKA6V^2yGxF=v(8&SKPbOJ-i|eyGDkuzhU+MK?Vv{1A8hn`3yxkj&pDo{DjzY`#!v~C# zCU3WP9vG4t2app1{7CHW$7i2IP5jn}Pg>?k_u)Ch_w@5XGP>JndOaLAf{;jhy~^n1 zcl-|`%VX!xml0WC%2&VF1ZdZy{*K>{X!qs#eJdrbDW&rT2tXx-O=|xIMG8*o`ScqT zFj2ZG0*!b>mm#cQaP*M_VXM`_O_Fzrk5*nMp|lH=6y(yR;cSe%Vy85l>qLa4=Py|i zMG#4U2%gJrTXkam^>O7)4t~|g;o{RFxWMyG+P82juTqpgpOIyAk^R!xh{|r1Po(Ti z50#&}`>Z8RLzfLK4rv53NhS36f^IGUG~>HsQn>`}Y&zH-tQy=C2Xap(jQv9|(Ud@# z)v;V}wMuV68(b>-y8fZ(HOzcrgmt11JX1<0@E_8M*+(<3e@IFfM;9B_#x^URqGEgW z#OAff8igm5C0^f&3v2|Im@9VtS=1O%=d(b>3w-!Uzz)U$%CdUDDZjgWD%^g>nUUI- zL>gukrDs=+RR4F##_*pwy*k7NaE+OCqQa>SXTmeDi2-a4P#(Tz;J$E)DMpqW2vsk zbd{tB8Qo2EHO*m5efHrXdfP1M`EF)hUe8bWSfd!qxNtX39~@5+Osnj$;J5OSB%2jy zyw#d6q%1TLqV;x7l)Ug=?GM7Bq${TFCEsh>9y|7Py6a9+zbRkE<`n-Qs))tG{=I+G4BR__2s5qp4% z2_bc?m!dyEKm-^7-7cFE;xZfIMslYLrw~H*hm#AoT`z@;euO9nNktb6_5Syk{8xvc zsE?NZgFA0z0BiGdzsGWe3(uUbeKM|iY^nWHIGtO%Br_fNb7s0k4s}R@i+MO5{0joK zC}0UuLm%}DfzU>>VYQ$|rr{_%pHG8vP%O2gZR-cwT# zjHJbbTw1$j7D%<7I<`X>ax(Ycu1U_*F0~L8K~}u*F`YluXJGl8X&4o`e3tN9u79!r z@9*2ohd*DhK4n*Z+Wh)y_ww+Xh;bc?SQ;yGif#7GGQlM%3qWir=;WfK-6|}Ag#IPS z2n9ouL#gO62o7X=T<9?DqM0G(s_O9;64>4V`{8N)hy4gO60}LKO9unH;*M2ooySd= zV)L-uR4xpYrj zO8G!TeyAwp(S3B1sZezj=1vApg`b_k6tf-eix6A`029F7o*1qF?iR8iSI`tv8QI;0 z=nHE)pHN89qh1P|R)88%(+0QPADmBo{99t=Z(ndF9FaI&U<8=FVKb1t`h(>4(Rb!7 z#^k`cb9D<-<*V&iug+_OrcsmE=YzY)&Rud}+pIiFTTsR}lz$D6A=(X)$^KC7*6X7P z1>dRLB}f2#C(!ZMCxA|%{*3kyL}_LX&4MAB3&fQexzEuIo9 zon6`Tvz(VL!|T7?TumH`i+6i}?19e0xc<0AlvgT3{X)oactIe6?S?NxBiP)+x!VEG z`>=rvpU@~)a=up68kFT|b(nbk`}lA0Ls3EaaaQc1zQsAU{_ z7-fyACC|c+Nd(xeRwjaKNQzbzU94H>pWAGF>0@Jl^M$6kq1V0#^|?coR%&Pr`C!`f!mILvJ6KQ27L& zc0>nDE#n1_6Vo&dyz?ohO_-@f|Bt)uUCjJG%0c?}r{XjF%+Ws3q0w&}bf^rhXPV4D ztuH=UUn+l8dE=Lf)}&)Gd~7s~*ODEG%)NV0{aL}3eyD^}38Vgk3d?k8*zNBnX4BeM z-A*EMis5AeK#qL}^35?b3Ay1fqv7u?VpCA8*?(A~?tme{W3--dTNDHq>pv%kMi{5I za<1&fA%PD#G}P0RA6` z?XhQ(99k*Bd2ZSh%ZIl_qVyF#oh+2x)Cwe1JvRoV?h&a{xiwg=Oi)2wHUQ3PbFx#p zV_Y0nz>N?)S2d3^LNN=Tlp>*+Wp<$0^(?Tw?3OcnAO5oWx{kQRp-`>E`RLTw6YG<6 z3GEaLg`rTbJI+#?RuEJ6g$H?V zSM~2(gDszsPo3@$Zn(dJ2C>w*`UgoFmfuoMHWn35y&y0zTzubeRu^e7IZ3^j8ZC^8 zp$O3}MAe7zDJm!Xb~%v}K!Fz58=^=7{cZgBtr7*_>EoRqWag74 zybVhhOwiux8ZV0W+?j8gF2B#8bwAm1zg&k1M{$%2ludSIHTtp4?6N0%5sAGxzMzh; zON15Em5TR$Tw3OdHrHUIoYddh8@Ir&CWE09v-l0zfzAxqpaqb#U+=Pcs6!8jkn)FO z2vBX4*Gq8N zXZ2^!ge#NtHQ1b8*`> z7%t0r=-*#|MX4we(Wt?;qUlAa2HQ#}TrK*>+`u_pzvhB8=zM#`AHPGQV`)Eg^KQE0 zwySFQ^19{I?(wzqzm^eRxmO)o?aS=qohc`Dbu(SvA72iVY5(YLfLfFCOoAQYK!WyVk#~9Drx5I0!9) z;1h`o6gu(L3rf;|lZRQM*u_)m8OBNT%R$N12-4g>9WsVRh3+0Rl0MZbF+U~$F=c$B zm(i9t(6Flz@l-$Y&5R7;OGZS{UvFNxyhTDklKW=-^~mPrLhAPGuG53vl|m;A-9ycp zqsE*@R)@rwxLTmUt0+4ujw#%5~LAi$=izyxA_yvMqg_Xc=t$F>* zy|{r3ohF?|$U#t6`fd%cBk8sz)UK25dsXFJNj#r?(Rsfnb&1u5s)HcKTfEuPO~ouo zfrFvI(I(y(Auv6K1QRFx$zS?nZMpX_e1!Z~#zPE7FUiHjxqkmdYYsir!v|=J25xR(8U0;VX3Id`n6WARHy>?8{N(?t2{~Leqf9?8RD*ufy z@X~kiFyI&XDPHB=cwJ8CVX}G|aw9N>R_V!@B*=iZ(xk^vdQVt(j7&r+)&=B(ri3kSn?-Ec4Ss`U~WMV+Cq$^K+ftGqW z*cTEDG>HKga%8SYe;6224#C;Y;12x5- z*Wj$3Li@O5#qRSB3mOD~^U+8o)j-t&okUelN;B8#d(DUZz-t$U4ZV`U%wLAGJ7qgu z2l8Zu7Zj?MJI3g`c)&d8uz?dNAwRfhi-4FSC&uhv`94uCgdV0w38Rt=Itpq|rmj&& z(Ucyj$!b7xSpRmJSyA0i68lg#-}SC6*a(gsdDtw>NRS*^QOB{ew$$gM0@L%W-&JF5 zshq|f?qkdS-i^dxx=CT-7vj&}`P2O<&3cdu0j(;DTH}ArU+E9NQUF<@YmgI&?FkXP zj2uv;P(nEYakHe;{Shuzf^K>sW1)kINzwU`FfDNXr76mG-9YMYHcbkxLDs;rxZTM- zLT07_fFFS?#{y=o*s)*r!=hWclxtI-jN(OtRe`3i0BH=lX)M@)12@DNig3;)))aMP zrckUtcpfO~1~_A8L$nDWGKcEwv=l+Ov6KcSXkJ28)KVPEw}~U}CIFulpLmQwO7rMf z)0>j7?M**!SCp^gPT~Xf$4!>wvRVSKI1W1LV;jiAV=$%G(}Teg8{grl&2* zvgihep567kW%gzu@!_jx(2>SRvR8d~4M`5VFElR*wCRm4?!s=ivb63{6wV<;k= zoQ}`r`?3U<6bdSaxF$*GV5v(3l)P;z$cChNAs=E8SlROLmx7I2zr1h1$?7fbQ{#}X zd%Lf;VNAev>;p2&8Z@MA@sPdgHR?$SM>ZB5&IEA7(77IR81cSCnJ-H@9MEs1_v-BGkv)wMgK83f-f~cfNxm=9XH}kS^ z@GyH=t*YbA>)*624x=*CcU-uNpHII1a)>HEddICh!{+(IDX)1FP%qT})WrKczecIM z(&{izR9Dpw(lS>lD&mdmi`}Z>b;hsJ3b{j=LVyyEHBkh)2q@tS2qHy|#fU~k+w|(9 zj_#3>7(yHp^penvlLjF8(j;iQ{H+RB@%NOD z5ATALg97w&ANENsK^w?o-spJ`dD>UbSNoSMIydA#yskc;4g8rNd~kcfg{?rw_hRck z5j(JPGMrOMu=d#a58om`1fgn9CQJ#I-qL20@gZ%+;gA8_BJ;7O0TQu-b$HCQ`ex!D z*zsi<&kqu%4%Vqe!I@|&-ejp>IO8Xlzt;s^_J2fwBb=>FdJ&jYnQ01I`=}`8Bpx1a z`ELC?Sn`u49Ou*~K}Oq^qY^KklY%=kdjju8xl@c?G=Gj5Mg~u*fC+Ruafm5TngoTu zRF@+9wU`n*6($yjl&9l99Ez=j&@~4#+>v~;PanKSubL67wA)T+?5@G3 zgHpWI#43YXffC(?w?4ZSjPSyW3y(+^;$rw(L9IJmhNFM1JEQ^v0OZiyY#$Ia*@b(U)2@ z3CSCLg+2NPbe{$Bc3Jv2Z9jLU)H;q^l)#DzWr$(XL`=HW82nOxMYh7W%nDZm_qvEc zmI42*^GRlN70+_et9T4qu}oDWeab{vqsI7uP0D1)XcV9fjPL1=1FEl;4kBgcx)v+T z55buN6HDddZPB7P|JDX_wi5>0sgA+n2j)~#*$HqCgmf)7hC|^GMc1jnhmlRQ@m!Qp z$FK@Ksh&TgdQh_$c=o)cl`=v@hmQaCZJ_Qqvz_&;y?$+&B;{-uN)?O;+v1XrS4ET3 zoXr|nS+u-6&8dmrvf~54xu4eyzgz!5~Y_ zVDM{=e#vz?Q4A^3G#N4~-wax440?P7DXcjU6OJ=f!B~*sOhZ?^NBT}m@{(EFoe#!q zgcke!4I07QkO8MRPzk;{vBV%fl!R#E%K$1q0xvo!4n5hPC|Es%1M{#!7K1X*NEqGS z{hxL(+MKd~9Y4<8#jTLxjC5DNH2IeaPE=O>QSGkT{!WV>CPoCx@uAZ1EK!MIkI>*A z7hQ;s1ub(}5Id3$jJ@fJNg;opr%t{8-al09$`8#5f6q2an7;pOyOsr6w`;@(()?WFdXMS#TGCYKR=?u>OX4R3%L)8ZGD$I zrsYOCrcJbckA!oHqG1K+KX?TziY*-w!)d-p3m!)*%oLqL7aHK`8xn)e!F-|CBFD22 zc&a{UCILt0_$Y}CSK_sugsvwv$pc~t5+G1*QRPwt@=c6twbuHqsGD$_Iw>6~ZT-U= z##!HZnzOJV4B@?xe87Sn6^$A{ z8ajg7Bc}HA1Q`qkEPk|L8`#>X1TnC_r|*-+gk5WoJzSQ~Z{vO{zjM0EIA|Dgm+ujJ zkvt&OcO>asLXRGkP)sP2piLe1<7ap;^@qdrn^>QHf6Mf$#n-Owq51ZyILS^0pEcK& zUB1i)--V{gknQ=jf+oI5_uoUy4!QNibc;=Xqp0?jaS~DfUAsPeRL`4l{E6SWyjett zTl&V!4{sS`6qf11G%cJksxVnw``%?K`Nj=dLA2R7lN)lBzt8eElia$;*d4js=h09{FYUx7P8^l1+SF?BRU- z7xhB*sip;aLOi(+^NM3mY1x0dIZw_ZKe}u_rR0uVW1w+?q>v`bq0{B3^f|J!3C?$N zZ~&ypIE6*J&A|FFA1>rvL$LZSRnE0&Ac^as=HbOcxTPZ9rF|wJ1zi?u=gq;17fqo; z!)f^dMiT78L-A_3m+qH#{?RiLiOXN_<>Po?*zc%WSBcgH(A7ssGLne`A+2lU>w3nA%bNpSdHwxOW*cby>t9I7QEM`zm(t%aY^|lftO)l@a;!<+`~(F9p63ScQHm$q+U#fl3?B8 z>yCY0rjqYE*SQVIAr~TBt;U^tiWGVSQma2T!VyoJDTV(@f?W=Z{1D&EQI;FYc-C{f!epAMcR;p z76_$HT*C!_Te|;ULm5C_LH-!O7H4zU-P>UX>D15>7M$%KbJ$I0sRJ`}6hmvHt-N1z%%%%Nx2cWG_U>sj{g-_QxtLMksK2j45)aeD zu`4(<%c0?BR9_-zDhhX{6DDVR!AqB-`*S@@@QK-{&+% zM228j5dC0DV}d|0oTI{+&vY1XnfOELwBolr*B;6nd}lE^zn0H8Nr7m=tMzPQit`3+ z-;UoB*T^=#WjG65_X#QbWH|NyH_6xMy!)z*=`@)~>bmJlNS}EMo;M#MUb>XiCny2u zIx{)U0A;Od-(Ri?_7<3EESJH)hc=K+dCm7iq|BAuWelTK+Yxh@g z;}$k8`V@EK@loH{i>RXnko1&&9-)mb6r%v5?mqRtiQPW+ZtcXBXazI8)}s559m&sw zf;5r#@WO1Q@jk2T)RUXRPdZh;l8Bi5^-OA?Ry%KR{F5ETR`CfWq>LGX&-7h8emkT= z^ITnEk@w56OigB65Ek_?M>rqZrHd|b(%8OFP8#Oqrk%Pyg@*=Zs?Ww6N5Z!)ETd_7 ziB>YLC2ORHUm_h$eAlnW&bD!5X{GmBnd}c*TLQ4gzG7bOCve{H6y18u8i>O_zsPu( z*EsUm`yzvhQ*BZCGrQ`7qpPax{_OxywMDc-gTg{nPrTK^U#3E* zuxf;T9RhDZqUZ!v)5QSz_cW2BYwR8)$_3(xZj{z2d81G%9_s$?wnVy!Wwr9#{mJoO zNd$V3j9b#=Cc;YWwf9hOQ&KL<@K3Ruv{#~(F|Xe%@|OhHh5N($GG6*d_`^1F9JGq| z)!s2}AXHD#bpNJTf7naQ#5-aCNeG$y;K}5mMYqorRp7{l9~S3R=!`B|c{}}v5jzM8 z^b+@?NeYu9E53J`E;Zpe77sMfpH}Hi!csodRqXoo=Vs@V$31qFI_rQ?4?fk;$P$XF z)A?RGDf70YyHTN)vPDq~&#EIj$90;SB*@?XAy32ccx^`x|5eoYWE$MUsNXWF)WfO2 z;P9fVm6lMnRR370Vq<|dXUaBYiG59TmobkoKn5zm2r*#>@EamJ*lw_ER!Hh>s>+3E)n%tKJykHTojzJuY~6c&5s0oDpt($8Kjh){D+Xs zOKGuJ7%$tl&B%5|v1h!Itmy>_EsMkQVZRhGUrybynEg^ik0e)Z)qt?aYu{N0G^Xt( z#L@=mgH6?dk1qBh7FxNVc|FqKWcdE1)=)vGKGT8vkuBHJqw9)DfU{P7B~ZM}D!*=w zb8&WXL@ha5&GX;z*1v$xq`>RJAG7&1B;jvfi6{w0cp-`N>dJ(h$~xhr$wLNCM`L6? zgp?_zkCbxs#Q8;3yNx8GimnqPXlFWP`)y?%GSNwVhdz=-M)bYG!yon|!aqn-gdQNZ zo-v7fZsdQ6KuQ8%2`Vc*43zb6r`!iRl_8H?KZKG+dhxSGtyYsSv>NXjPi9HKcD8ej z|2SMF8u8z}Vt;_waw*u>DjYk1pn;>#t)h*EiKPH!Dl6st5rULLurBR8ZtM+EST$%Z4ndRj3#;g3L7 z?d9#}>Mh>kquLne$DAfmev#-^{#irp%8kiQdP1P~1K)4ZF#$~Rd^GWTISG$PiEf@W zESPDDwe>>+R}sv8ONzHwFI#A!wlAhVxq<=U(XH9pq=W@pb*rtd#>?`AokZI4kOYN- zG+>fL#ac@B+PZJ}|M6ZP`?+}sXr-`gs~pTco>1=>OJCp@?V|JtzaA&Qfu-pVZ6~1g zQ=woGSip*e8WD+TA4-DE*<0Sq-H;t^e#1+8Wy&bcYsUCy_sJ&{e%)ir#nWq1k=}Uu zEMUt`DRF_RsESum^fkf-7JsY5Ivp(hzVPhkw6~$2EKRX53+A<)@R@28>QOg@g`P> z7XrZ-wZ|?j2ZeLW7ez9mXCqi$=)l2}Tuy+jl@RMkVt(HC;|WKmO*Hb)E=cHYdTSxc zms;U%3h5uBGUY6hIT%5BIm4gn`792FN5Qm5c9>-|qS-GhbUSiQ!GOayRa127N(HkQ z$tcpYRJ(tff38wVNyj4;3h6AKaGY9%t5F^(tOw7HK6>ju)~vJgfmQ9HB13N`z@p(( zxb!Fb@RJ}C`G%PS9lt-pfIxZxinY=36sz7_i{_2K0De`jx9t_dltenyZP$r}FH<4DjTzqfo7dWBUpX)~sXG%jAIMi=|CgbEn>XR3f@X9 z^=PGPc{CA^j`JnmqReK}L&{e^^mYTa`liXJ?wV_cWjo!R07M-E_u?Q*1WiejQy(TU zo`UT8dqk-vWbI|h;T#M(>ippi3^{jaZ~sf%O4B{R9M;8pVP9+e9|H4zrKP_I6h4-@lBGyq z#_)D0rK1s<{3BgU*pk1Fkx+k0NaCqIR!E)Dg8)jWB-t0TtV&D3SKr<>4R5gi-{g}2_cR6k1nd}=AA8}&ivB_Wk3IZpD8W+C?Qa|SrY*Z9NH<8 zpK5=m8_9+R2Sqemn9pNtI;GoUe=+Aat>V zj-=AlIH>^-D8i(pC2v|B-&OdTl1Ri%o9WXf)a~+ay;_SkVw-XxT2x_FZdRWl6^U45=Q~FIBIHmliT-ytzSd=AJ&;X?{ON~!4{H}W6Y&06D@xGizf#>=!)FreVfm3=@?{tEl2$AKRHPv{?lLF=mv9_*!1I5-MnT$r4& zgN z%5R0-=2|_Wf!b5DMN;mK8$@zvD3C|W1kG2J?t)jB(XI}{>!k6S$WCc1?CbQct& z1fh7b670=Pj57-2RwUYgiQ1@-XBcVhuk6uWE9O4K@Q0k1!Zq~3D4m8Azdkc?G$`Y9E;ecWY z1346QL9rv;fOpt@`KEEun?DFB2b|0yY^E@U}UlzFWwgDzI zd=!`Slz~_jH8i}C5Rs$-vX=)|&H-$-f08YiHk&pr>YN(l9O7>O=parj|9z z18#EsR_07@`-O8O8`CdgGe1HQQ~OIBMOlwe&EoTaNNGskn-tD1t0-`aeen zlVNs@png&L^{4j&X`m%u;`>WY4^;k{AnOrnEh?J4H}8pgn)Yn5To_h6-oZK&&Cy|q zbB1G61bJ_0#u|K>pc#F`?axno-&=-lsLn+v zau?^?r?79y776DbZnch|N=DZwp6=M%|6OIib71$kB>dy(!1315&ny7-d3Tg49~5Dz8FBtp!J!n=ZC@u> z>u(QY6q`nW9Fu3+T~^_8Zshti+{$KxVaVi}qdXQ_eMpJPX zoo$rl&V^+ zwLQ6})csuEl>)`(9m;^3cW-`30ED63nF{kUw3uub*}KCp7=aksdKt|;7n(aEWZFGX z9`%80P1qs3Jb)?E01c*J?SR3`Cd<+?bIo=-X^9)_`%$fs9#Jy#s18GR{0#=m=K)1o zZdCY*MvjVW&+GfY-LuQ!yl=I)-n3Jym=6n$@5y#EqO zCq-y-$%V%B{IK|pqgc{B*%?hMr~WUGF@B}erdY&GH>MS#S6~tFM!(_nXsLeM{C#Jx zswaP^s8wa<9cOsCQ2&_F(eZnEdoH}wknOj1)#U1$Un_riX4__F$0tksVY_f$*#&}` zq@CCeSKi&k_@QllJf6}qY&)LO2c9fToTOFhm8Lj2GdzlWlbt`G<;17v15Mt;K?jDG z9OBze+loVZvrxjn^CP1QL7<9y&}m6}mFvg~Eq6UBJyr-i`%_LlB?DT{qA0I*MNr}C z1oID}rh)Z#|8POZqJ_qhusgM5PzR1j5-Y)=Bc0@*Ik*)Oeaz;D8^^Dv6b+3gnv#OA z6Ph)rskS|4e`+o>&KPQSS8#0x4NLuS4;7 zZ973b8T{mj6X;2!iI4G>NzjhB4fAlIJzi~i|C*{p=u>BKanoa>Di0K7^-`kphN`B* zUW5ti1f75P<1*ZFEoLG3YNY5XQ}OZWNOF zq|h6a@1n?J5)1M*Ymd;F-xJ+ugZo}?0#D5({HXxkM9O$cjM}{)1zWmG|IL@g<8Se4 za(-YwJ)F$s8lWEb;21u!26tyov0Izzj~86m(4B)0@tV z?`TxIFwT{Fdqhj7JW|Q~*h;sC2R~pxTxNRZgSD3P-A7!FQg*RaTx+G6sP-Oz*`Hm2 zO8;bnkS8j$%Ip;N-)&2Kx9P8tq&b%xRcxoj@QXC!n;clSbn-L)TmHZP#U!&IygKkh z5QyK}9uwaiQ~LCXOpy)-QQjxn*av8<_)-ouQU&^MsAu>-g%R;AMf;lRtD9A|^op$T z64yQw@4|0sIrMgx`rm}FIw_A8x=wW^f!#GO!i`(JJ-DwcvA~V8gxnP9n0NhtW+IB5 zFBH=syxiaTMT2Q7+P^h9tgUO~mQia(C9U`J#kM!16QGBg^KYR~vL^()%1Jiq$mW{r zX0DZ&oQj%9;~%qB-#-R4e`PxeWWTQkop6ZWAxZU%O#MSC7md&qAW0zmG~}9sNmz0w zbksP$c*se53*JL@Mkd>?vP3?TY;pJ2Qh!s100g3N>Eyghq{6*QoK`}_*RP2~@lct8 zfA|`Rh`(7zb&`0*HHU%Rluw?#a=I19ddyYlv$c&98 z?VaTY;W!AY#{Ak%`LI7&YqOq?DTk_h{pz(bOK&dnP$T_b^Mi52V_!j2+#6M@41x`gk+ zaKy&e_PrmM7zIL$KKiihIN*1?X-inh7v5@i*=M2j&&rteI)tOMBGVHzQ`fc(oNzrd zr3yjW^3LMLE^r^%NyX1<{lSr!In7FJpqlM77dJ_eEEHIbIBB~p_iEB1cq-H6(C9B0 z)-RD0^<_D<8>_Bmd3{4=-TH7zz>m?8eDldTYy%o;*aZ?{N@)p}rVraybN(pRjoR^8 z`aHy@(QcD=$$Su1)}Jgovi*?Kh!2@p85(7zNeLd>db`qyZvY`N^k?+ynWmnOTrd7b ziN6u*i1UT~Y%ACWu*rS8;>j7Kko`)kRt!|uoZ5Sj3vPw^tyF$JGti^gEWzDH*BeFO zWl^p;v|)22vm*Y4v?ClVfsw=iE!<7;##uj+ik2Lkc86=3?&9}km-#`0-H!|ZWq7po zt+3j&j|sm1&NaHSv>TNT9TpCmhhkO@s(Oh=uXrdL_py0+V+qoibdc8g-Cz}X{Pp}8 zSA;0cW@jS5407DYFB@Jg*Oe=-OUR;@!AFV2$FIW$9{zmN&tAx}Tu3_~tFv;dE_ZzX zE~>k& zMOZ#&cAGP_r!;@9=Bs0Z9GyZ0C#$cmM!$4;`Gsvh(em4Av$2<{t7xb;)$1S(Qkygy zNw>_PSzzI?utBO)7B(pykQXZK``szOQ)h?!b>PvBKqL!qzD%5P(Fdnmvl6b7PzH)J!PN^TrNccqf3_fQ_)t@-TX zJj!16=g;$`gGI%=uKP5$%g}Y!?h3z}k9E4c&kD2Lh7&nW7p-^YYch3-CtavJUvI}~ z-u+-!u&^l&OM_*rxetxZ=% z?8e)tCeBNGof{E{hl7?pfF>=0j4;|5aPPpN zX6bwQF!IK?-O*l!%xXrxx&Rhin&K}n$T#^*!@=Ugu_`yiSVUNLdT(1*V z{KZ`wHTF-{Esq@o{&rIh4*k24J&SoaSeu`=b(*L=5JuU*7Z6RI{moC96nK+nFaj6F zJk=2XPo~Hn4`H_jWMA?sl{rFuxE_25df2`NnR@Zy$_@D?${}0rHxy-P)VVo39^y+M z-keXyHHi|Hna^&@8!rG`I?;oJ?DQVcfAb{$iaYQrrfAr8z5Q&DI!-__!ToN}o>B&* zQIlmrzyWFrdN?hhXQ?h*q^UNX?_nsCz^*H5u{|eSDg9a&&Qdk3am#C90 z)W77?B5{6rrh0S2YoIBFuoQENtvPMM*de%bSDYc+A8*1C1mSyZl-H0dov3VPA;W-I z<*}VrO#C-ipBJ2M}CKH3dt2` zN7&psxFV)&+}%q?&mE$5xW^ta-dWKoi5pdtv&nRGq7g;+m&X}3DrU%64B26Ekl3Ai z%*0n7{&T@|r^!CO`&8>0&55yF*S%IP5N-{y;A3p zfqcq=HB54-5TlrMh|q@Dsv!PH?Iu-o5aQ5s>PTZ3oh*fI{)n?Vua@jVb49v^90ZD^ z+9E`WV1)eEBj?<2GI7d#^WIb+jj)t0!VT@l*%ZW61Z=)yTm*3;gnp|1&K{!Bl3=0+ zRkQ#7Brf<#3t^khm!EvS1#2?Bk}1xe!3EhLr)t&V@~YK$)SS9#hDYgcu6F`$FhqkG zVl}h_)??ElU{eB|3@!@0Au86;Yof%kGxfwUULQ0ZyTLvOA4O#X-jBoy+Lli9*s!Z} zvFd)h4T^%O%pZyAqKG3xyU>yqY_a}&`0AVi?c9>5Nt6VJBm5XOd4QifA>Byi+kw-4 zb?@zG#?{%jks@LCK}cMxd^L!r*xs!)?xa01a62WcHfHsNW| z$g&XFbNVNn6Y$XWt`r5KnDq$3{Q^V5brl}*4}$N0EK4?x@K#Ir)|$8jQAGvk^OEDL zUDfv!MWC%%GJ9~+tXeWr6CN{&?(V-5RFh`<863?ba!@>2M`4rQ*$FwPZHYAnsk|Y9 z1ene^`i=hqoLW!Zrs{Eg-^gac2`9!zJDxa{LT}l9musv6X5Z{w85hJxDD58o%@E@P zX@|Bbt9OzHS2P2(J#UH+LtGI!AfAXWDyax^tja3wLQdiL*su1i%Q~JV|t369H?ZS(u= z>|g6Om&=NNW6ffiHn6xty-e>LSw-%U{E+T{-HIbBPh&*nA-=N@%85e>fzuUFPzgIH zWr9_$E2Iz%v%}CLZ|-f&eq-D6uQ>DBsKSsI=qa%zKHjMJAJ!P#G}=ze=6SVt-)I%mA;b36O(i* z|7qnEYk(%vKlg!sn9UZ>AAM|)u@U>D)<0<}D-EeF^bbw(xnNZ&!*)T$?@yR^>HSCH zdFy%Hz6Qs$yEjp;6L8os5hdY0wlXG*)~LslK9!yj2fenFM>Z?IBx?Y24QXFaKIKh5 zqC@?5yu{lbn($X~cY)C~dYCR*n`QAg)>}lKD51V3^_n2=I#*Md{T)~r?C9}479>R* z6NxV7fZ)8oMH0b3{xkDk6+`;3x&&wu*n8(!`YekaM{OOsau)p_`G^{+%yCPk#) zLAr{w7Rx8pY=yv1&GZd5K}l9vM~rCCIlG(BBv{vtZd*M&{l6l+-)yX8R-4DROMg|N z2)&ph+z4(|HEOPnO!5VIfXwb9;%vetMfCS>XHMbWtzu(5XO|@O@uvc>xIe>6WIl)K zO0uQBF{qjy2ZHXg2GkP6bIY$Fhuiy0i5eem5PQ?#HrfBmpU1-;^JD`2gdk0we6xOj zSat9Kg{-VA`WTim>>x}_cRR2v^4-6gC(Lcpjj(wnSn}WCr+Q+Ve+ii%Lk~g76wJEZ-CB%M;H}Wy z{ZC^(dvM&{-HK#!H3{ zn*;7HffFTyk_@T(O!=2xxAU9fvY_f;(`Wr`<1arMmlFz$xHeQ!ix4_Wi=33W3Tv@i zeKNuzi9j1{#YljVSpU9`Gk8TFF);+jw8oqzRD4H%oJcCzo-?wrX~3x85ZNlrjbEJg z8RqR&ii_B0HQ3oibXQu5dX2O7&n6QE*w4v))|Z8+n)i>1zY+4yORwuBbC87psw=%I zoU2Kgeu2RtY0F5eSVR>hA<_ z!j;>%ty9~lXLnD3S)AcMfJhw^bi@)R_kx*^Mo>dLE$(cen_atK(vGSX|9f3-+)z&2 zl#>>7$*pghpm1|wo+4ry@TrJK)UTth?XR0ZfzM&l@Vx8pg#FtY{`tNY_f8jD?BF7r za_a1CKRl2@N0jJzMpGDXM7{l$F0U;bL#NM-b9Xo1#r#PKB}ItN_Al+nJzm|CH1}*% zdLg2EF5SY%oPQx9y&{!R5VL)i>JVUbO|V+2FsA8P+o&k`iaC@3xJ7!X1Zwh;#5FyW zfpEzo{mmWshmNZH#)04KG?_)16^Crs6WRB)t$vK8dOHRMP#$BOS0Y| zAn7$UnTsB$h?!G&sQf#FG898h?14!Sv&uwSFqNu8+}t_<3A=H(xQ@CTZlIDs^ys2T z$=`W7;v{%SKzFP#Bw4~A)R*FNOx<~{H}<-CmrD~D=IzFmG4Yy;IOlaXEc$aDtkgkWjVDWPh3C}TqW9;2^ts>buba1$ zI#_1B{OEIAhWB#Ob2Tv$)$C??g@h#e47Gz3o680zdWzi%YKQ6yZMzDtze#;jq*2W!uY z2EX+Py>Bfgf(qMECko@e0D&S*Lc*KDYUDL^S*;4bT&>V1KNAY`4ghkQ;h`63$w!Id zhCgM_76xzBk2A^PsGWg|6an?%H^(v0~RXo-*&;Jzonv~W+|C#tn3Sn z(S)O@?eBIy{i<%FM=Ka**c8dEc8^(YcS-t-JVC`BYf>*pf|8VJ>7yLYro9cpa;t{z@nH^z;`aC=D8qq4y?p>jOn2>UW{1QL-T1So z^|4($Iq7ivYnmJ*?UuM(xndAFDK|+aQQW2MVMFS$ojJ$nc)hQRdr$?{(sN)2Q)+3J zABbvtmxg0{e}o{%{+{mo#0;bT>0I`rocseDQ=?WNKhWj&}oe!#+lcr7d`elR>)di z7x+{i+7}Jld`kG`IjZn^Y$22FZGa9T?_Ks|dRbe(+SKcuU@{x`lXyWN!2ajV`m;8EEee%0?7N@$GG)N z;%AP;oje6UAjsJ>j-7?G_FL-)@F$TD1?hKND_fIFJqnE!UM5JSff#ou%QQyS`ZN0d zV|M45X3T;quj!>8jg#sz+*rL(fQ2;jYJ~8+t}=$udX0ax!NWmmO4lR|Kzbf(yPPH| zNbwNK3F2A8?`frLX8w86A>>EZo-o|7+Iu@y@G$wsoGd6kwEPQUKQ(C=Lx4Zg0Ds~q z;gup%S|b@aH~rOEv2?1oohc6Q zJ>NyWV;A-7GWnkvU5AQ)I=U<;lza*`6pAt#)O5jq4Im>SiMv|yAxU(aeNl-G&KP@` ztCJ2T87QR+4BD87`bg8{YzQh+1RU^*@y#x$tu(5^=qA5jZYo&p+agj}wktxq8-9e( zuASNDc64f#*gvM;NQ_oT=rXx?^>&(mrzZFFV|^(cMZrz3#N$jUZC4SQm)KKUpT%B*XK=17+brtf<5y{HR8k(!XoT^XZ3to`2<-NQ_x# z_4@VBpUVj)7EI6iz4dFyu51NYYcB7W9~SK1ZpLOCuKoIWKXU3Y^|mR`B`-{4+Zc(U zsWRM6{f5gB)Z8q{D_u^dC#cc#r6&rgEWKr%EcUU4c10_B$7tdayh!l=e|Eb~!duJ`2g^RvD>JiSYko*cKo za-H-=P2i7>Yo}L5n#!yQ&2bBf7+s8z9MWZ6i&0N1)#d%vA@J<4 ze{kcM&qwN^!gS4zvO{dz)29lIyOG|%?TuL|5$igc8Ibp2pxP8?hzkua-~#uDNYLFd z;n1{JJ%6b)6P@zN<*=y7Z*Og}Xl3DHxD86s_5Rc@k26;{nzzU7+IHbwgv>rF9U`016iRzr!t*Qa(JKk;90?|x)23$!;v3;EJCKPvF)!iQnR0xUi z3%9YqkPNBd%j}qpdjU{*_5un`CEc+Lc_kWq?0*fQMao8pbAi%_0@GiVQ1^{ zM$a#q-#oX1M(DdktBzycUO~*Y-_18sLWRZhCVP8F@APU4SB-y~FxRg4A_@U+bo*kc z-{R$3Qtbr_aT^j&0c1pucFQ;rQz`9M6rUcs?ynFUQ*Shdv7G1|^UyTF35w<*aH*gXp`c%V2y|BkVeZw=OL+vpRNwzPCA<~-{ zf&GqlU>C&s?GW0DWK4UJ+(`#s#Hd`LVzw?0DX3UuCqB)(9};y+g{GI(8-j9gv-ZU# z{o+*@RMEk?NC}Zo!DI6fgx93V3xsr9x_8Je$cyGWAAkK=bv&^+_Dp4ixmH278J6LQ z-1x^0fXamEci;j83^*(A@(2Q7(^3<}dEwzH?{2sXQ1t-@gbs9*=? z(T<5bc*&JXuwj)YSewOi-LuQN*=6A$zfQ~)veE_Hp{03942W z3IEo=*Am=yIyv=bwMMscH?$vEC%myvVW&#*1MyFx{H_wg$ zPcsi&3?F%>jupuZmctHyz~Q^1G8HcwiFk!fs>0e$tB)Afdww3^OjyX|By@`ukXp#?XU;=(~tG=( z!(&^2{Q-7zU zf7|Q6*5m%Q%v7J~V`-Qg^z>~(Qyng7#0`nEqc>3~+VMo(_`imAPmOA2L8I_q$RZ|B zS4q#vkaX{TK^j_-8y9Xq=pZu)@?L>g66VjLlkn5C|91eJ;Q1udj&twd2U{>XH4s^$?bxFZJl;()B$7G)H+xnM0+J z$E2ph-9{(-KLREZL>(Q+$XM9FpWcDCMty=Oc#?ycwuW-eOl*PWfax&mZZ)KYaY-1V zm{AzNuq4h0Jjcvs>fyU36-SAcA5<=W4}EQ?+jM@^1$!WjkA$lCU5Cs4%-Rv^>s4I!E2a`yV|7cAG$N#IE3o`j^DJlD+ zB{^bv4fZVwaw93-qOo-hbNl3c@j1Jpy=MJ_M0Jejsi^Ms%N*_(Vr7hebX?$Jaei(u z9wswDeNbo{k*A6aBuyxu@cr&s!4l}&6);~&!V~M_^e|!i=8)eESGvH3q6aY0El@?% zlSg^^XHfe8HWA{RW8thXfEyIN`{M<(M4lZo($@I`x#1A~~e-0>!*oBE?8$5s;fC zjQC`W_rAJHenyrfk8lZ-eT$8YZCy-?%ho{*pa8>XS7x?{xR|-A+Z3)>-HRoB0sc87 z5&NSu4k1%b90*hx4SF{7Aqhf2hk^CL#09`m5Oy4jmtUR6-B=z1w2v_* zzz|JNHxL2`;8DjuysB+#%Ad?CzLRk1q@lOTP z$nikn2*Us#44b49A?~^mWOchCJYBxruZ+>`=TjQ)#(pzn0zd>IHd`?)AvLoMHoM!- z6Eo!(Xm*Km1yn-t$b|Oa0HG8eQ_^747mkmM!-uw6RU>k7lHy+QgZn_Qu*L*DH9L+D z;B`Mk{DvH~UVEG0T3?J$y561SRJN->QP?yd%lkgyd}Pz;2E|~+f5h&Hq!fv_B5#!5 z+j_?j_q1703&B#Q-LW>jY?vxf^JJtt3Z++KlcL zwXc&CWpGMTDmwf%2zl7Z^hBUH$LOWmDaHQ4_~oQ2_CU~Ak2mJ@qjx4_mimlKnG$u; z*s|>mkMRn8E-YImIW6o|)aFnqC=aJZ!2wie10@1@j-Rn4o-FhXV`(U445)HB$@9Ft zkld40RiT8yLI~N%zAQv`sEpzgr-{TN1C@)&@Z?m8{6OS^6Wy>x1Za?Nn=z9A2J=fw zqZg!Eek%?;Q^D4~{d{CiP)>R9mofr`qNUpC2T;dfdq6UQTJeZO?ycfN2`sM-?K6bx z@PKX~>Uj()34W|Uf5E8#u)zhSZ3>Vhx{=*)C^*l;k6)+t!E(dl9I}IG_+y^1oM~HF zcdF^AaRtl3;G+K4P;dBrcfv*ZrcTE)>)7|Z#l`1c!|bQ+`y4;R`Y@j@gN{0L7D|)_ zuR4R0Blq(pGgLOfPdGxZ;IvUd*0Emxk34Arox?o(jrP=r*qw0IzZcH~f^5)HMR93> zP)pe{V3YT5ZGoTtd zOH^qk{WV!1`c9L0yd4QkGjtn)*4y;4&NKGks0o}llXT)_`%4{Il;It*j)?k`x-4N^ zUs5{?vJhhPW;LgmIMMS*9}3{Tgd~gs>h`B$GG2uGrFeS&T^UUSy{^K%ONVvdp!)Fp z3QSK>nqsy~&4?BTFpX)&i)m3BpZ;~? z_Q{KD8G}z9Oqq}MEc6dwo<2=3=T>~=dZxx+x+xW!HYvMgvywH;`&yk41R&r{gcl*x zJ=8OtEG5;ahWzT6N|PDsUTF`=+!G`XCHbNvAFS~zmT$(#1NSA}QZV-Go!%ubZBIvJ zz?8pU;MT9Ezwi2{rZIoStm~-hU95y#oa}$Jd?;;TUi(MkcZGDDX0`Z|g4{^c@Xw$$ z+DCxj@E{6l1auF$PMikJ6dOUV^u9pfQ9-S`K9R3SYG+ znjFIrL#Ycsy9MTlSpw=Cv7g;uYhKi;`&q&Aj&~K0@^ZaeGsY3<22*2p9(|M9k|U&b zjLydj?Unhb`^xGu*qya84v3CTvw+3WXrkex#e3fLav}YtwI}+Y#e#e1${2vfIF~pT zXtw-`2W^@vEclrau=Sv&!0QOmj3_i^iA1dhGmOm$gY$my8dZ|;h{ z`i3FhVyz)icv+Va2Q1+og+#=}L5&T+OK+Cma8~y}OK>PNf!=6U-vx_>yr4?fcd1y=D%!3?sT@=+ye{}Tu{L}3$lv&N1M=zYSgo}?|u1#CD>0No1a-b% zhu1l6yj$O+S&K#w`%YE_Z z=X|Dl4NKeK%NI#;xC`oznd9&8s;ghM%IfVNG_X4E-%(D!O>3?lnlaQl1Jp)25z(lK zv4ZD=3uM@o@)B5jYlbX(3mZ?l+=&Wixar12gQ1$zl10jlnZAG?s z7^xiGhO6aQ5pF6s=h^@rF<}RMRjZ#NIxNIN_8ibph~Y=#@jL%dxC8b6g_*5Jq~1L+ zBLJJB&~Aj4%N{XS+rKx|w6lASeH7BllagHE__FHq61niBMI>_iYq^BJBUuUQ$IWBD zHDMDv^8szZwj|-6Mlh!a&EQ$ zjy}AtOiGwY8k>;fYzh61tm-8+Yp|LhRt&ETNX}t{YB#D;q)iHnYsCHAU1#2#Wwh*tG4dzaS9D<@$wYgw0N6%^JV8LWxZ0jErv5W6 zYuED*Dtq+Lw8kVuz3{tqn@g{xjvC$8e7Va5t?L}0L--4Z$sFOC;DI25>3ClUtTrRn zB^!vW31u$mz0=GzS<9pGzH|P|6#r#9N!RA=t85K+H0*VjO(x34w2T#y9C<;Q8V1nw z=^5||I+jqS%$~$VG;V^5GPt;M z&MXyWo*)r;QR$`dTr7Pz9^$eZN-Jhctq33IN&+nZU^f@0^C?w5_SkRLC+FT zCW$aCo|57;B;XgKGaFJ5HUB~oNiq##$i|u5(961z@y4cSEU6_1U=P=?Q}}k5ye!DVe+xpka&pa+*M61}L5tiE=`29VN8)Fd#)6XeD#sL`k?{m8k_Rbi zA8|JbDYz#;i1tvowbxxYPwv7JKL=ky!t+f3)poT&h-^%g);}P{dPBru(u(n`uoQi( zxARL*z~kEmlP`A3A6=XLjHh;EGOU*ey}7$AkED5(7uBY+^wt{-Tx!BJ&Zl?FL%1Tp zyX<3qS~`JIjjBrbP%kh%w7W?yva5rkZjBKQEZj@z=!puW4IU9;Ww?8I(e{(j3jx`> zmPsKU$y%wQXXfaq6cM|H@@G#A@oCy_fq37y+ky_TWrhABde=#Ne?2;pg7rg0YzslP zSV%LZnC{1rHZZO(XpJ!84h|lF$Qr9SxWX#>)-iqQx7TSRPC0IJG4@mk;XC+v)!}ak zeIPbg=JVrb-kahK0!A4_8Y0+3;EBa;Fa|06J&8YaeljF!-Nvihi;ASA$N)2$FOuz| zGxZHWUJouL1!aqIqq2nluZumjWyGqLmhG@fAzMj38NJCF=Mc;Byw<9JT@UIPzt`y> z7ONJYY?|17lD@xXe(KdviawC8Go#eXYNmWV@c$MT4_jGG0t3G^R8BH`u+(4Q8yxE< zC7gxf2FIEe9Y4sJ3S_bs$fd9Cy+G0D)lg$sWAsYcqu$QPf$<4}L+(?gNm%+#Z@^@NO%2J}sX#V9k)a zH<%;bJZ=*0Yp7_2u$PNrg`gLTO)S;%cwr`=kAnsCadS`#<|G<>gDa<(-!&dYP38qD ztyoa9-}YtT+P|s9gtN|cbHizQxwGKG8Y!z*)H_YL@8#(i%-!qDB_}cq=K`jba{=WN z%?Aq0e7}F+(Pxeh|Is%LI~*_6nd;VXFhvytgvo+;o>&zM#;Fj%AK4<0q^zLD?8@Y$ zZUtsROA|R{lCXld;UwzRWEtnlW#FOr{{sf7!ILSieAWi>j%E_j* zQ;PCydI;6I*-!Me6&F5cl2|%?h7SIXi>RKoBz6A+AgQDa@(iKpdYwGk-s|#-qn#sJ z*nE3ISigoN#dRT~25Ms-b*EDvy}AoghiRd|KJsI;v?%L~^n}wE*aUSVUq7b;x-wkW zpEG)kDpp_haaI*+i5rj^5?}TG= z(DE^J(%Tg9m69!i4^2?GSdLyqUbL;%9_8q38+*sL1~7 zy$Q}C3J5Fj9l8!JFg)m7){ZTBW%;N7YFTyv+`QqO7gkSLz1@S@uBHV#R=!Mp`#zi} zWE1%ZX6@`(Q}6CG(rsX(!sT5c;favlnF;K}*e zbfe?MKP|t^HI?$KaKiz7?#FpavKjajf5W1^hXBShVLZ$)wy7l9&&i#rf^Z~xs}1kq zmo4*Gje0eYY3J?N!X378bg^?NU50O7OR*rTjuqBUNw~XLVb>9k&so?)`z{ZN9j*A?5 z7Ze2~%8`+w9yA50ZEu9hoT&riQ9(U7k15=i#|cXuX|EQZ~krWBHN`)$g}SEjyc9ae0@!+bDB&epFHIyIjP{3f zZsRoLs8+0^22fDEM|vT9Fp9p*pyt3qws=74)d|9;1EIv$;ZZ!V#@jfNn_rkjE zsMt9VUVW8V&?)4{f8ZJLd;mOm5l*lphRPb2@=+Ua9L9!@rxVBk-L=dLgd0+WPpiy4 z+JY`OM6W>{O-~{47Mm7Z4k17?&WsZ_c^Y)o$*)z`CHjNXzz zBlRs^i6^up{Q_G@Lkv^oPT|#7eavB~Bw!dNNzZ}Gx^I(tkg%D$tEIsscpKi~c%>_l z0xJS<3-kmPr6kVbM;i$Zi_@2Vn%E2*MgnGkRlTkMQ0b~w`AFMjNM?22@ripIhBZVN z{UG#sy9q3u1OOS>I5uowwHddVFhUOvOS@e>^8LBkz`$8>V8e_qfaGF0hind#j?UI6 zp)S(TQk2Z^_u2kiylVitbPtA)+7%YmEx4YOCe+f{mLqoPKNOsiT9wTs5%#%{f&Pxa zpA=A5A-#o38VvIpPNk=)faPl&-jaA{th0ou4BT_O7W4>?kABy>nHoy!I$J+{9C`NH z2yaRlQpcwN&FcrI1^{9*{X$nzk}C|@mHj;aM)0{TO_2MRDAE5u?kcTde10@(T*IrY zx4}~@We1!g+HDlE-P3XT8Rx0?hxE{aDux-aDs)~Jnwg9t^0H4Pj_{lI=1&d6)-|>uR>w#9tAy{loyVYI-sN| zxeEL2U3Q?q*(Ocnqx*?d{Q_^FmHP}2UY|_}YHWC*3^r~s0c}`R6dB86jrAVowH93j zhLSwgaUxoWQ(RjX|5{B8140te3`i1N0=o)DnP0!dn}VCRDC|JO=CAuEy+(b63-|%& zcr`r{;$t~1T}K3_wq9@(c|WZPlsH zq2pq6x2qQkJA{?%g?J=rjp9r{1vEbV+`3)|dZGQIXz#11q}q@L5Ofi9DoR=5J-^3x zy)<2eGRznxC<+AC&~{3SrC{+(7c77hjTU6o|K$qw6NVkl&^Sa49Y*Bl_uuh)``YwC zV1xj4;&LHD#Gau4#GF$p!$Vxdg24iOvQmnoPwG^QXM1YLs7wJ8lih6RIrdn!Na%<2pIsJ_XR{$@-qRv2`^NZrv_YyT4-iDD$ z_K;E-caPGIQitI!U`bs@O=iiy4wr{rC-Vp`1jqvi(eLf4ac*0x)S1ihExum@7}oYHnsf=qSzFY zD&on+UVlSP1}G#=B9@WDOXsaR!$fy6kuk0hTg=O+QO4wueBtEHWNGq6gZDJ#==P1A zGk@mJr`}MmzkudwJ6fxF6O7rGh1${+H#;iolwK!2)zKdgR75-Jr)_UiY?qz1Z?`LE ziyt#4lZsc|>Dbw$m3-;iH6YO~yYL#(8gK7^)fKAs6te*S@Tcz@Aa04!8Q?o^UWM5w zo+fwXi^#^)TZN7#s`cdMZ-TAiy+(E8w!K_Y?mCWK3X9#vd_Y3<9Dwd_qp`(skvCN{=OKv#jA{(9oJ>qSI&} zgStBWlbSXsXuDD)$s~IOP}6-Tw}MCHlElW;&T+bPR`}=84syOLP8D0I=v23j{~^N z+OZ@!KX8Em2T+tGL*YkVLF1qK`o~$+qn+6Dx{}f? zQ4%WNYEM)9Tcrs+J2(9m{MBK)l(sZj_(YY7OFOUS9UyGjqVAYSt0kgyqvpYS7XXm$ zqI_}4fbOM?vo-zpDzstFGO^<(_Rn0apdb~Lrrf|%SvBsDdrlY(IaB+`t!v(*4t#rL z@w%f4#$roNr<)%bXc_m&fDo1x;)I@5sjmLOyZ%!1K@m88>R3mXOFj~!->ekx97_$5 zuk~Kke`##GdK*^H&*c&OyxfLw!-B<;E1(K}D&l~wh@hO7= z0g6-*QX)K{NTtai3Eo5UGw=R6W!LbhdPg=3dJmTXa%WZ9o z(BEDBV;Lrur#h1b95HDMK`sxQY?WVj zI||RN&di^tV`D(Z`WuGmO@3b}aEzF#LrXca+88;g0b(C@BG@kGw)cVumKxeK*x+(9 z8r>}mlJGYdt{IJ!$Y)tIzW$&@&=*Bn-g&ZI-F`JedjeffjfCEL7cmsg-{?)_v(2R`Gar$$cAzg=ugeeWu20LD&|a`B)It3 zn!tE?{InJM^l$wFdt_3f?}qKS@K3Ti+Gi2wzv-pdiq!%7+5BmB|!fouOS)?S8s$-cy|MwGL-41zn>fu=eF;v~Rw**2^s$M#QSz;hby z+uzmE$Th6?W5KU1YV26jR3%V-KxqoOXFw^$xOme>J5D((oC6l9kRfH?;MzwQZIRpv zfpz9bt%onT#%|>FoR0>oEk#8EIWVDsh}{8Z02EEW&@SH^VQ#x`B>SJLbwo#rdkugb zev{Cb4dhgbpra{@wxG>DS=!AJWTvTm62GU2mUhA~KRbUFyRE0r?gRN`muS#`1U8vq zVsbl&LL(D7yFD3>e_PcbwoWtNX{L7+e}%Fs-VMkj=hw#5y_Xsf@KIm~74?mrgb1;%P2@x>M|Z-rPevCKa4 zmsf%obiUF+t#_mPW4nfbX19EKk#Z5e>0tbV-AH}qU+_vE`V8nFpcBBpK(;z|gM;e{ zpg>%i#it*}7du4x_REJ>cAbz(;Pv@FKt-iOZ~m7ZM*;a^2(`=&QTH#;SbS#z5*e>} z_HOT+4B$D$-*E60DfYx;+HJ+X zm^^%zsrhsOJsW-U0=@ko02hkDrg}IG0B{B7V6Z8aes(Wz;?wvGj|&O|AfJg$j00e6 z7ilL_J=b9^3#&41&8ztE>OcK5Zoqi?*pZ(BGeFS{28w3pdTa=+7>7`9tU%(n{8Ne7 zZ%{q9j6p6KKv{`lwqy=NiDe7jx0}ij)faYyh4B?-5Rt3n;~19ls$7zsHES}OB+?7mMv67}#PPQyb+-&M z&=#V)uQLJiPE7AGzvXbUETNb|kSO19enczr@rfeD6AR}pTk$CX`{E+NtCn_Al%MD1 z28SVIC-5O6k_=bJOM=`o-h~c{eW8FY_X5)%DB2Y8!@j$^R?Mw*j}Ju42x{tm0>97u zYKpoNztxr!e0uuJ0(ezloL}Za_Zyr!rx6A2DB`^rljd9H?fLvcKqVx);FVLJ$ULBhoeSil8(0n6M7X1N{B#8MSf%fO6? z$cO~+@gM-O#7Ik00szZJ@c(9~bNgC7npu{GHV7HBO7g{Q7cTv0!9hp>AI$;aqxsfh z1xzX6#J}Xdinu^TGpKd{d?ys(QndD|xK-U16^%@NR|5E!1 z(AIeq@HCJC0GDdAZOl2k>-6tM3im1M9&iSCvZsUd_OIGWX4RL6J>KcB83nLTxOQQ4Yt|0U*raDRc%uJsLK$|Hn z6iDkt4_teOJ-J%Jz4rh#6Y~TF{h`2&0@8TjEPPvuAD4g(Dpn30)O(3g!OB4<^gq(z zl?&cGom`l=C@o;#kRh5&&TX)dsvc!`d=kqy zEjE9XUr&Ez6&lRfQAYLW)D?g~$S87i^drE&(alA4Jz%Y2!dn*)JOQ-XuWK zAYdcmF+hTQsssA*8w{`feDF=U1VI2tHHbG1*^SSZVtLZx7_K)A+!u)o+f-7RdzAP? z(i(6DlmHS((H0lDHR*hf(9O|KW;fZ{tHRIv^IsHYcJO~DJR*Tq85*pk*eh`%UA-&2 zHphuj!NdUv@UY;%RpFg|UN))CT$n`-MvV;3&C?6}>OMwCB@_Wnrr-q4Xag>Fh$4R= zXirc$!ovgQYBSnB>#_c?>d5%N*0J1Vnfs4|R=Eqgbru3vqwBA)zwh=^cP4h!zSj70 zs5j>7;Rvccd%UX}N?~I4J-iE3@42Hpy$kU?zQEwlNU*`@A0HQ`?RKeRWbhW@tDLd@ zy+)*f$|xis6tB<}0AgGT$T-!Grzyb*Akv0iGSk*>*B!v}61ue~?FRu99@`sCMP*yB8K!rj6h&FW{(fcJ^| zZ-|bP%=-|XVz2tWvy%?5Dz?m=jj<0`!(ZxrQ$NWpFgM-(_R5o~uf#g&aD=gk1Jo2D zzA*1CK*^|P77{Mq0)C>yM@D#eFH6Azmo5cJfb2g6)j1UV6yZy( zoY)LmVxIwE!4e?rYKpc-BR?P`3-t#wGQqt9w|_E%Z%<`RfMCKOrveFH`+JaoqL(M^ zz43OQKh({C94rxpHILBk4a{>uGR=lhS3rN1*+Hw_MN#+{p0 za*Xj9Z^?n_Usv-}4DDOYser`Yf*c4NTmX^X67!rX+TcmS1x|1?`hrPu3Gne=7-Tsr zmcT~XkrUfR=h+W!do{;TYxyDp+GN64v(^^YA%c@WRJ{% z84v9$+D=Os+&Hb!8NKD5M<=Z!r_(#}uaoxr|2j39B5SLgLHc$Wqqp>Itl)cG@-`67 zQmzb#0*!Z!Vh2;{uPyk~$zq?OUOf)}Jm;}xqi&UpBB&GN!T|{bhKOYY{)~e;O!;Bn zN77(sRCwjxnDY z0MD)NWIcF2vHhON`7wGoR{c2@0sxJ2j*_E zJu`3vo+AxtZT;_l7#h~R5R3HXXgR7lX!wwY8a z=0IN%bteUI`w^Rliw|I9GoW{2R@5|I8*$VRRl^{3dU$;S@5LtG4?x0%a<6V!3v1f9 zWuxDP0QS4ePW*$cEjyCTGIxc*^#2Wz_wPglVcs)*i4!i5I)gpo`X`53_vJ@Ll|VU> z zsR$prxBv!3EQ?a$#o z!t}X?z~xkP4l;xP`Nh$9zlhOxMM{7`$Yx3->&WmYHlR`t0rUxx`tlB$ANO-!>^3mH zi1RWfEZUlYEl5`z0f}=HD@wY?7#P-p!-(?kAEH9SkW){i79u?E_ILhqcNk1AG65rr zG&OjK!)oVDk7pJmd->SrncMOENqL_!3o|4x91)xd=%Sr?cAvza?FO z%!itWs@>p)SESW>F4&dlr%{`M(sH~DWp^`h7Cvt(h!O!rFr*dE1b90HF-5?<{$IJ> zf1T57_-SUXu-$&qf0wV$JXnrfqvT{2deKI_asi(eA#%RJl=g)*CYk^nA(^8Qgo%nM zn-GQ8MLa_OFVS3n#8E>S6WLo5-~}PdQ}zOxL;_8UNrJ%w+4VSZox0t_Z@=sJHuI@V z*3YGr5tU2gj>nsukaA7IOZ3pw?L{R-(Tf}YIB|hmqS^Fixj5iRDgngdiXv(VKH1hB zJ}i~J%j>i_8F3Fl!3xlm4DtI4Vu=BPgK1qR@myq(sZ=OpWGvi5`DFE1#op?V1-?6g z#36`MW(jZ@i9tXKh9m8?kW(}cOP^cRBICHC%=Qp$BT7ntEhLf_zqWK*(6u~yZsB#8 zWr5uGF~z;!w}yY7se(6TO&yoK_ZKh+%@MQh0|!3Pb;3^sqs7lsmi4qwG2HfDQ_DTZ zhYe!jd@?v{r4n8U6m^lV9*P-!8-Ksk&C%SuyJc3p28~c6t3KKI zXqInRt#$dgD@2(mO2+B?`J3&v{9YuPFkyE0`L(zz#S3rzDVOVyNp{_$CUzqAEuubHp|5?E zrX*ekjuo4j^Sq?1S1?FzYL8QuPM*nmFnuE+^Ls4}W%!Kj{K0I~DNY=Q+U;WscaN)> zb#n+8RasoV(Vm$a%Wf+eCJ3I-8VzF%V$~1a_`aFk+NshV8bBNqnu9wu?>ZeK0ol7s?>amk%W@s@MhF9;M8x=w%lCWL|&?GWIqoDcQ*;! zntW|UK%4^F_Bjz7<)9fkYcf%2z|Og7{}wfd>$BlR3MY5^abbc4_E&&ZI-i*y;snQ? zoY3#WIal}ox*RwEd)?2?Dcn@G|0KBbXH9#P3c0wY(+Rf*rX~W$2)CjmxkX5=7F_0A zR>gi*XasgwgoY|FHmt7uJT$)FpjuvkYO$SB@l_<9Ji5cs#n1o#^yvb;%_7+C;qQ7w z=jHADuOzsLnzbG-O(R$eO!G5SDd{P~HX!kP5#-4zf~0!#unm`dgMs~&HsMFhjTmG} zdQCmdHJXmuH4>_F$f4j?LNyI){UjnxU7kcmwt4W!%)sl{A2~{PVGInwwzd(fX+!(0 zUo4(l-nw;p>-sb4ERaq=H>^&d8p1e5zFqD-k*|_h;)vHA`_zTpVr~^uV52VVO14>yBWY-2><+Bt1--lAJ==l4Bhv0>C_f^l^ z>A{QqfxSVmo3`L!YSs+u<$V_m&vgqYuv`#yOce==x|M8#>t`l3H~LTdUBRKv#XO6rhxW7+#Cl7^6Ru{zm(eS?D zQ-~c<RwCw}3?42+E3a1dVT+km?mmbo=Dk5k)a!a8$p)!|h-UqGrTU zio0m8wL;d>)?xeUjL0Wo^>d{@7mib$%6 zs{ZJ|G)OP9VVrZ2`8?=@yY6Fm^2zwsjd)$um%kGKWMOdp1nDq$=FdVUJ=S;XpOyB) z6I}XThJ5K|w~6Zz)XYp$^SPKs_a)NBN;Icsx~w1()L4aj=GZaHSz;bSDYav|Uyf3i ziZ;|xX*i5&F8}Ns-BI!zfzMoqQq~CBWrTNgUZAsRJ^PEfi=}zcSH9;>&!{DZymnce z^3ZDL?%75t@e^-Ls1DeS`pk_`_2+ks# zNI16op}d!U>CJ$3>Bbv%Wcbc4wKg;QVI66(E>#UXEBVO0xFC6VQJD_c_m;P3L_wy5 zaSW5KJc@_O3VT#j@37~?Lqrl2wRTj_iY-34(`7C(HD*fA@{3>QN!Pti z90p7c@4Q4sVm%4mXQ416pIWTPbnHMXk6^$=9TW&0vp}gvjvfyT==DYpzei>ZMG|T$ ze0WT~f}Pw}WZc4;UCT}HrNg;bBSV3UJraqrzf5gUK%!<{S3}d1e*K? z#;+Eq|G}jzP6-XLXeW;flXD_-)N|Q8uoB8M>0MhC_>&{haSd`?O2(&_CV&e&lEB0T z781z_`S@zpRG*x13AH@)#6%`F^ZgW_q-tI;S-3gKNIznuuer8zO5jVD?d-t>q9N!+ zT)9%9jll3m8){$Vt$34>RX7p6IyidX+z+Ew$2LmeH$fC@G5Rh8L8JOHLK6rYUwax? z#*e$%1+Tpn719c>J(3zKw3zhRv^C6<RXU+R7-8?|gRpvtx zdBYVqs+|Aw&y8py`ta||?cDREPt&Wetc?%b1seNKi zpIcOO#n?Ok#0Jv8cJ5y}=KG6p;I2+TJw_e*IzH4gMc1h%;-rDCrXP0DGpI^+~ z8~m&I#-ESOUK{mrGJpSh>lGvroDH%SPp=gISkzNv!$o*fXay;&6Sktv9zD71g|Ga_ zh=n|A;mf*=h9o#?m?bA=U%P`VP*Jj2gAkL(6*zp*P&BaEi1I{gO;n#MfDdb!FtBgm z`s0rF*cCCRCDRob$Kc#}479zIyKqpfkxh#8*^1?luRGRRvQqtu`QCE^uE#YMbHc#i zNkw>53C@(3v_D;KwSfHhuGQbWOt)l&id#7uQG>h**x{ggJFf-hvhf88;(f3vp>Mr&w9@*>S zRl0ckJiFQeDG!U()GCGLc^yb|dCZT_LqBuV<*nK}JD_B37S}Y@b&h!_@ayYyStg2E z(ADe!;Iz%4H0jNlBu|nWu6^m)jkP#l(>#$rhWHh8aRnZ)xFUs{!_#HRHhRO{zg{lS zHk9?4g|uSj-LH#~`FZ#Y`TK)YWZ0K7<$mQ9uI@Da`B#@_jvaSj`v}bS%IVxfnCDQL z1NX{yoSL&YR4$m6(&u@z3oK%-8t+HYD4IQ`mVV(HJt}ku%!g}5d3^*FW#qv-DqUrv zL0j=*6vU+0h$$i4{#7B-G2#eTnVQC2+%ozL<0mbXz@Q1PDX-1jWeB>0k2l&iL_fRY zl(|-<4xSS*0o$O)7(}5gTz8F*shQeb+vxJ>pSn$DNyHP6Yn;9R-F_oH4N7;Jvw)hF zLjuy3fX2*r$fPR59 z`igsdg6&T#3DpMrKQ_?!gEFMC(ezYP*pyhl?YzOEIFzpCF$m&GhBo48>VtVUAptJQU9FJy#V+cmO-M?h(c(`~ zq;hdhMi^l*Mcd0TMIvim=oEqU?BY;{6By$6vxHhkZ=6f$-He*6qO$OxKMQNy4D6@p z95;L^q0jvz<_6(X^j%kzYn=N#&ED#0$tX-&{1-R^JxHW^1r>c=8-%n?ksmYA+=?k29*Tj^JNfzNK5=T~z<=%&fUkaI>xC z(Y+&86yAHaP+g*vKHq-!r9cw)l)z#5MnYczUFdd5%d1F#*M#aP4}6iY&53nN{DthD zr*zl}qFBTx7O+L@w@z1Wy5IM`krce%PE7o-gSd2(g{Mvx^gl~F$V7g|AryNzKsl&o zel=t0v*)_H;u`h9LF}YqPWN%vZ6uDVu&i$HcHZCC_>i}z)R%jMvJ_K&L^%8;4nkZ%$l4 zWZ^xpcZxb>hl7*d4(YRmJF8Ok`dG4nM}L4n;TgYW3l;{lBszLu9D$yZF?o|G4u4&i zpWgBcG5xcxD~gN$6C|IbG?r6jVQ5G@RJL^?XyBt91AN6m%>(>QRe$ph8f?x|hpskZ zl6v=eN0RYr*7teI5@2X;tU;gaK;JS)6Yq=Kbkr#3yUY?(7V&vGCQPD@8%Vim%w9~nSfH# zDv{Gkaa`Sc6;QP9Nu0#4gI>JKbs83$K>f4X7tbK^*j0k8<&-WN*h&%;3tHfVy4Lyr z_yj3GW`FHLRl(9q+5ytgkb+MZ0&RoDHXsdQ0l!%vq_kFG?OD{>G-LwjwU=ZHF$ko&~O!a_=aj#Ss|JT{E=tRj!8}YggThL z^-6DH7o_+hprItnUWwOVnOP{b-GMos{KstFSGzQeTW12te?L1ly0(bv9a4R_$n%`D zD43Os434QPgDE)z|8jTmI%4}ey~oHry>@UnxpA~dlbu-go=TcSR*}&4OWeQej((~_ zVTp?vUk=`oIEeTx>>0<9XZMGWSqjl9kDgtp9ogwcH&R=`Tjzp0(9fuGx zrflYd(3U`%HY=3{EG(-rvjF`56{+Xs*^2)qmN5}wbtp*MNijCptpCpv!x^0u081=k z1;JHQQE`u2)>dXg55XPdKYR005-Jozi+D=R8W!%t%Xj!c!Pv#-lYCnzyle#UgEZMeZE@9mHUQwUKC(~9kT9g%D z59deCI|j)(cA{CACHL`EyY83w$rgzoQuvKL5i(|4+HxeN_!@CGSxh99@swey2anrS z+pC)N(rJg7L-tb6DY1!aV=aCwhJ4o1&%orVFe;tJhr5DgY;5nmIb5QLTbMt{n17VTZzP$;-7v*&BNhh2YTNwya3S_ zauloEP|fK}-DWVp)!K05n8VUaNAwBOVp|eM?K5)v;>xyHOWvRmu z^A{WMc#zle<;m6_jGNM*8w*@N&3`f^)}!^DF-4^7--W?w;9otFA@C~>?f7JscpE`X zm}8-tpnaUhSCK7L>D7+y$;raDszNeR<|P_@;M8S3M%8djfy_5&lw-|dGuMQ?*n zAvOu0E+MvT63^|~QD;83&9uxQLl?uUMdQVpuZx(H+>2&H2b7*@_8CfAPb0eEz29nx zsXvIB7)g<(X=zoC#c9{SOYdWlD!z?&2g*XL|JG=z&D#m$;*qQvxLP;AyWz_|{oWWk zHU2zpsOj-onrsIDh28QZQjvX=j_X|g`Zey5!tCu>$}oh81bl8}Cz__lB1O?rnvaw+ zFo*+|Gc;W5Y-{I#J~vzR8QE^w#9cM(YV(em`m?0yJHjH??iZxDggwzZyD9Ui?ULYD z)Z`VhApe5`Hdr}XUZ0#2g~RKrRo5@pFUOvDFiz0j2=yK~BikX(j-r@P?g~>}*Rq-F zO!$PzQOzzN3mkZfQ1X68Q^?!-cuvdl!>}uJh5r70HM%jln3}cs;AhzosPEVd#Wi_UgFGMQDb=<^hr%u6 z?W#6nzeL64NIX%g`vXetZ>-T;uo-Nz z|0jXsyDM@14Zb$jh-r>G#EKYx)47ZOIORMlgpf%i{ot~v`IegwvD@0hmecc#vm@%e zE0^Lo=OEGheUH;R^$`oscum1!yLAh$c{$2^6BO_M|Uq zMlG`}(+R&0Sj(Vz?(Z$TA`L?k2&xIs*-Jo&H4kvJI3!}0`2UGMT=6>aO+F9%i;|oV zS;W^9o}Dj#h#8UpD+C#H#mf!DxoDxKJ6e^8Z-grn*f%9|N;Hlj_w$e7(Ef|$lwBIL zB-->d8v61&`4Md4_3vxGXoq1qY6Z~Q+R2eB!?VYZpdH04Y! z={MRgLdI2iq+ps*VM|AjRL<|n8kLhES2S&ss=}|5c6{Loo?sS9YdEco+El0TP*y3d zG{&o<~fFDTdLzjaqwAjNm=|^*lAq9_ma#j=xbfC zMNS<{F`_Z&8+J^qJMigSwkem4$&wb5yWXgky%Y3`7c(3($>& z02%^=!FA9sdAwztU*I6V*#zruG0}QvU9PcSH;Ap(V?uoK2}4xtaOp+Ob0c>PfI60; z2)M7{+HuiNadB`iqV)(U)Z+Bj*5XTFyTv5Rw;vr+Ry#rG_aef7T4HgJ>RtQ5_}(vN zA6Wf>X<{Z>L-_JwO3#qc0z+k8qe0Vft!XuB`FyroI+=l<@tvIK`PZ`Toj=RqA6g}D zJof^ZBFi>*0lZ4<$Kd@K?4& zPC&$oLTc^I-x*+HU`?D&^0WQE5|}j5D(^__lgYEB!^LGrHHgh>Z7N^^K4qZ9uzo8{ zxdUB@H}D@72Cp|FcUGT>=c&1s(s4Q)eS2^T_0I`kMntx|(d;6db&J_~xrmT1VPfU; z60}S;$$*q$#@xL+1psuJyjjS|Bc&jNnM5<}&c9fSOF_N?jIp z;5vOL&BJFT|N`E8-qBp9#h5vY~-Eb?}!eNj?lDpZ)Q3*l;W;GetQ(Tv7(oj0lYLV0xP?M=- z`*aioZn5a6V`vPilRt{#qJ5;n)k`;#{==(kKWao?#nm6RRr2m3QML}m^VPd$P+EUu z5nc6Y#A_*#i6!eMM`N}E?qYNjLXvu`e`-=aM0QKlr}cLtj!PA7YqlP!K22t z|B?Ue^wCz^L}(FwWygfO*3a(%evwSKnW)zG?}|>7azUAH#b;jJdePPzdVGZOn56Vp zoNJuklWkUbS2C+)$=jD>422rXKJL9C17Qz+C*IRVzM=0$LDnj(m|DW()`4Vv#Qs*i z!OJ4bk{Z3fbo57+R%Nkr!KY4O548F=pY7P@FLZ>`olkC3fLVq$h92@P0Z-l{qvuvd z9D&A`HM}0E_$kC9@FzanS3|N+(nE*T=P=e-;&AjVn8I0Ac(ch*X-? z#`2;r-MQq5DA6@pUW?on49WmsE%j-JTECRk7nR-szUtX*@F5;IL@oT5E zKN5hUIbJC+!#M_S@#0uBL?-Ykz0N+0ZJvJ5{{}lmpu1Bdo_XwN?Rn)64uaAC#`^L5 z{Eg>MT|DOPu=^^j51J$t_#9R05||GFzXkCZ@V>z1K~(G0>r!S!7oPT;KX zvy8wC3sYDlGr|sq#Aeh7+HmZcFCNH4#K|GiGTexv&r8@)XmI#HOz8^rWpREEOQH{{ zDv1sRlKem^9R3jiLV>PuPD&M|M`Vc|@yHppGd;*&+p)2i_dqwMg9dIu^CbYD!+`<9 z^5VkqsJsudS{Zcu=h~6yCv6G5Z7N z*lx5lbtIyax)jAwr&T(guNKLy;ZMAf z%*Pho-JaW8KlvD}$)pX|mu-^EE}g1s@2{f~#5KBP_~vL?sv9~X|F2KoooC+*C)IIW zX@>h+Z?tKT_mJDJ3pz5cK-v-5&EB8FlAN1Wck3)<#vMk5gVsfe$^Lqt`gNm8O|{z+ zo#OZG1dRkNvH{~1){wtK3N`Jf{n%b{rD~}wS;Nu7T#NZnr{dxcq2vq-@y*B#G|_6E z==HuK1$gpX4xt2_2X_b8IyP!ICjJdk5z#3=@$z6l}9fZcCXTGwIAWd z=!Fz0>A4PK((cBbxrI3?Y1x91R9(&mL#3c_V26G&e1WzSUr?IWn52=QMK+L6L>_+m z$_k})*ij(doHO|1VSeOO;O1yij|H8i2 zZ62#hdFC42p}qBp21bDTlMO!Ff-acp z4QD2L#+|AwoI#AFX3aCdm~rZ9AC)eMuY&cZ=A~ItHcSAW=u=?HHzCDJ4+EZ@C_vgo z7$Fi;hFxCqHVHRh-d#yjl`AcgdlXWd(F%}X*%Xq0c!o_#%4Qgk8By);@f+IxVF%fqKzWFds;0FYS zls2t5Lw*AB^PL@NCor%+_`r|?KKSlI=2W6yG^V)5i2I{muV;|e2!Nb1Jt63UTg(az z*5^Z`QlexyIWfzV%Ez!Uu_dBXc#3(b%0TY4<^0lvK{4>^oF<4_MYPuPP^TDLWaG9Y zf$97CW!C&$NYm) zYCX=|0YzKKi1a;vOP^C(P$_#jgA^9|L2?CzVCdNmwu8hGrW)( zI5;oCA5?p^18q7p7*35BSeZPzvtZvszdF$3^;X|~I%IWNr!!6INT4bdMY*U9hu-S~ z7KV|vu5|yf++P_SK1U*8OC_C3+n%m~l7q$deQc!2OztDK_bv|Fkctf8GNS;O$<&O) zYGdLlNtikGS9LZs>YS%xHaDt-Iynk$2NNWN4~bMz5RCqj=|1W?-cPSuZ2si%DQTaW zH0?(Fwx8X8v-_3P>+MU#Z_WwDfxm$}qw$Xujly&$blXF*-JFfY^}h>42iGssUF zEFE$tCl32b8U<-w4YoO-J(H~VCzCwOR2UhN6XWk!egU8xoWnJtHv6lN*p`LjT@oBF zj|1(EF8dT@hul=*O{prRTRiY?$!Jj6Bl7r(NIONqyQx5JPp*5l=)KkHemj^!ui5An ztSm`x*t1uEwBH~2r#r}Boy$}_edWq?=q1`wQ#cH8WP}bwm?e;)fXpXWbe7f2a7Dq}E^q##aZ<$kQ;A6TGGUZw zYTcyGZ)FWvdr>pjCr0Nhb~I!PXRxn<8TqE{La(IN^U;Zsm`u4}dHkfSSKW6V?wNheM|uIkkN#k({?ZV% ztE6hzcf#`R@r=j)p-PJt?*TLV4hBCv{4`NVmpTuRCEEGg0ccIb+$Hws)r`ohbsR@O z4?89Mb^R6*c1@X6kf)4MqLVDKp$_G&`K+O_L4_Ta`=28V$aUN0J2m9lv|I9O`g1F| z`m@mUwpI5ew981nyT(3m*ssXe#%Q+IQjlQ!&V3(m&^nO#)KI=Mo;x{3{P&iuLPxSu z5zO>lT8f){mD1^R{oh(oCfJ|_;q&d^F$Qm^W-S}w>1U@-nR$#F7Qe}3X>8YIL@DxL z$WM5-8~~`-lK}46W0|6(nwB2ImZi&AM#NOKl<7%0A!24~C60mX0o$EH_XjYgH5NO` z_b+akcqUcOpO2vYz576e(!FAez=LYX(I|8bD|IRCYijNO(GGQ2@Bz$+g5^Deh7s2o zK(t~hk43-tbr68o^5e%~eW7_V0N*PPDl>3OEl#fQs;H_qn7D>x%r^jlKD1fGQRQun zL}ZTpZ4+@D#g(MyB8d-3@>#SBG_-bhUCTf!76v72DxeCBP1c=e^=IG5%{P* zPvzJmd7^{UMoiOzy#w{p&>sm7r@4sLRFOz4IblFyXtu86JFG#ca7E|}D$$e@ z5)@)EG3>dDmpX>9sxi{a`T{$Wad!9BD(ZiWJtkjjEKD(8w+I5u%?EWs5+eXP6a|em zt7n!Kc6#b_uhQF~G8&e`_pykry#Ey_dF#vJ!H~r)Hi~0OaN3kdmRTIHFj4}`3P~a< z!C~CV!QzcuLlVF~lf3V9u$wz)^c0nH-}uf{JM-Dr76{oIy@Ljit5`tyLpsTAVqKnn z&yWO#x#Jdvb~5eMo-|E4=;Rii4!&HHxfruoqMkWD3=aj)0od67-hh?wRmFy*eHG}s z8P0eeHXm7z#=Pj)FLo!kOyC-+RY+h|o*XblR8`TS+)F0xogcve7gui`Rpk@53vaq} zQzFtG0$WF!SHl9cXl1ilAj}U!NU&_x|5M&D~5u^FtOK@ z65&TYzbXX0MbzNTd z<*ux3M?{!OxIzoneju_wW?K@7MUn$Km;Q!uU_D}=sgzZ7MVD)|7z0kaD=!twd>X}E&I2;>$DSI7fu%o_S+ddM*b!-A9%=Ey+*rxl)g zht9I->F$z1?qQ!Z=cb$Pk6Mvn$Xv6f{|^-<`ny4{qvoNltY}m?0^O(0oiR7ZXYrTg z>-(#NvE#!_bOL_|rkCrTr=J?Tlc&tK%oRKal2*zaj^uFTViK{Xkuxd1Gu!qO8V45y zsPL7TqoOIgp2oPDSD*TPy_hnj@HAx7Vt_>7QnmeT(Wu31s-vx`(%2!N%DGoqEcvu7O;+|{P;H{Ybcy=6 z+*)RbkBd{zq^te&;r(^Q%YiQiod(?>+UYKT?{IUo zB|fo)wh23on|k=7B)dM~>n9~5{M(t|5+4^vxl(S?YP|=pEKS~siR>thB8Ewsimv|y ziy^E}+8+52_#VWU7w`{tBO@3kQZm|4?)wdil&E8wJ|83T_Df477H7sez;^6a4 zF@U8HXgiJiUGQsXax59rHdhpa{#0F-H_hr?iRJpy$K&SW;>eLcMe5?4QoeBs@|&3vUBGzeQRjh5&V`cj%#M3Cqz>>Rx7$T9xljff?D%gz%mC66dIcRx^w!)nz`1sGr);mlv>1tD| z$SOCF!`8dv9oCof+kvHOWT(WuoYnz=f7q`*HffB1v26GXD@7D=CAs7Lo*y6n&Qf*O zB0LN#(@XJ&na1_&B={g+#a=5l=1%OsoU zcqp9k&(7YoP`vsp68IXN)1T%8Z*YhfQ=o8goQTx87Io zJgYp(0sz5HrDAzMAo@=2EKpu;;oyKxPK8Sy#HUzS*Gosns zuG&0J5;lV)#}ZPtOMxl$!L}!J zW#+Ai$$30i7UdgrEvHfTuXH9RLSRUdY+2cdo8UbO-ztV>E@o5r|PU9fHE;gU3luF|-P8Rvpmq)%2s&T~odQdRM@GV2SzG`FW0A=D!C9mu^4ff-< z2V;D~$Z>R;7AHdq1yWM{V2{97k+(`tv7dA^syIc#(2=^8_=+%b4Q!-t6PnK#aZxfm zcn7yMMi|9R%ayyi4|ct;Qynex5gSMQHFy~Ri0RS&F=!&Oe_J}Vl^OjTMy~0bhqKC; z6Q$DV3l2^x2c_Lu>Uxiagn;(Z&rVJ|tC&v+EY5%Q1fL{Ur+l`A0xsjf*T@c?K7U6s zx?O49&AqeR`k%!lEgQ4SyoujaHZF&os$}{@FJ*ZI)XZ)?XWjyOu~3udZX7-JwV08P znY}cSB`}?$h>eh*!o?#D<2o4eBOsY;XylI~K{Rc} z2$=%`?#|HzE`)EgS0zzQqU#ye=raEPw1t%HQVa`zu+0O6pXQz*D`M)9TO>;*_lG;) zBjHZiRCPfb5dLj2Ee9~gEi^p`P}QQqAPUlFIy`-P&xxT#0;pHtt9mWhc+4!z7?WK! zDUE5OcXCc4a~Hn#DpTT2S-+%%_b*(A=LZ@E?hu=TVeSyo#PRPSBxh(?wjg8tGq?oX zEv9{OVlMcs5jN*h_$L~FW>F^0^?dxh&P!L{@sle4or_jj5}uu?TEQE;csD{9qOWDt z@gDqj0uzx-jpm%!JH#ckgH1bn#Jg%Kh9BS@ z7R#%?_VhzMbc&=?iuuTI_q;Q6W%GQA551Ce3fgiZ3Ayk^!U)(Kz%Y7&z4;%*K*Eeo z6k;SFcS}c%cXw37px2TChQAITWczRT*)Nh5f#I9TluQl%Pcz)f0ttcP58&{vK+(9@ znyJNH0cmZqc!N-%rTZN>rkY<1M~X0Gjo;kIDP{)ga)Pm&3N!hCYfuS+g6>_V{o7qkrQMJh0U+zP0pYvl)qFjM#Va zaEcG(BguhJwSRk)DN!67FN~(8w~gF3S@ul6dK@c_refgXH8q>!A(BAYxe(+5l}MOd zFoS6*!`fRSt(xhzy9_1+ej`P4lC!%%&bMB*da_-zDl)c_lIUUlYHSX%U$v7zalToG z5h-X2F_>*b|VC*~_ zQDa&j{`(xZfI>C{l6N;`Zd8PEhlS|bqpZL7 zy1DQs(yub?ueRh!_-acY#2LY)PK5Nc3nMpgB;<}_dC*J~mK*u^4LsS)Z<=s#g;LE+G_n>P(IhFf@B4tyQ3 z&jr(%etBnb$wMw#p3;F6mVgha#Mdc;;#FVR4C@aS#9{=b=;gJN-ltpOQbrB-;D?~G zZE_s(MazoBsIj}=+cE>dD{#r`QR*^$@C z`X93S4pdj_q}#nW=8u571*E{f3?XL786*@2&;@+J5P;I(W=a&1A!Y=xuA9YE${VMs zL9_dN1S;oMlQ-_>&42>nmfx1o06S&>^Hu9%&b8tk`Z^xxJ^m>@^9h^=V6y|u#{Uyp z0u`kYZcAVNjr8j-o$y5~i(pEBOK0Vl8s55)-dB15p-O_5ot^^v^)Fb|ecQUE(bj=S zkhP_OUBb*VWyD(ZdZ5D+E`dtF>ejO>fIoAMGawj8`+_tvxOAy%8=3 zhVLSF&wK`qEgH^hDypptZ!q&S_egW42K$=@z*MUMQ}qW-HG)qHk$u>D88UB?LLb>W z6BDQ?VjS(>MB^1mXi)Ba1Z9kH1cmWbIgf2MSZRO9$S|Ggb1IDX-xRF~4lqqjsHJ;pm8;1POuFUyU7BVXCVf;Wp}&F zK@g_ZYfQw~0lX?PU~Y+kx#bIeDr}(lFVC7|OPRUEdKHAysaqgn9H!M?6TOJ0L&ZxD z?{?|}MId1!mf!#5h5nPnPZtbU^R*{3&Ok*NAmwUX2fWd_Ys~=EtEcd&FGyLPn_MVM z{a=1f3W;4a$?~YgE7%n5k)SB@qL)*-OEL4$lo?+Y^wnj?7;c`Wgr?}FuYJ4`Mr8lz zh28_dWH>T4^(#efUjiKe(IWMe=?!lB;(q6(S^5LIFl6ay07wx_>Wp=Si=I}#SW zemY=duMYIp#xP!O43#LD8T-x1=`%HFp!|Pd4wzb1mtLGXT`!O<YGg}UB+nuzOlrGA-?KcIX$b3lI6QI7KO@SX7TFH!-g^9#9_);kg0af3ld%%gr;}4jh*SEP*N2 z3ph+t!lPw*n5EzV4miCBTCPq_C~O18YVAwQxqxHs9HNK;sY3?l)QLh(^p)o#I@hfin9fL#GYZzM8A9P zh})b>tDe(YH2ol%8^_SqFWOkTaU6T;!UKB%R{TN)6cl4X*S_b;_eR_=*+rY1?qJ=6 zrbR}6-o(SZFO!*}?jlu-PjWA7(_WX%?_5!fp_Q0$Ly-x$#?`by+%6wQUBKUVq0TLM zKAaT`wz`w>LhDDlI$mvrORS$b^0%yvdwXenO?{kSoGhQZBeFI;epB+@8;3AUE#6Oo zg@%oP^46$}hQ;guVwNh5H;aqIi6KMO5C!at@qzHPMNAyE$viel*W%=?E0{Ydpeg|T z1_9Q*BM75&aSEu0K%gov(!ZuWB{T+Ho+|X!rzZk8yL7)cD4Q8iZobR7vw-he?UA~d zJ^oM#@KRf$H}3O+E=R%?gm+S=%}$e$lA z#3DzEkh5otiq%ol(-%Vv)d+0L_Iusr($J3P?f)$s=fJsVjYT%v^B}{OBqoYI*y)2S zY0G^y*I;;>6Z>Z7F#JlZt=E(S&xg#?+fnTOD(sz@Ck_OxX1%H!DrHpIc1wi07 z50aX`N?&Y#uQVCPmvWGsK$OBZ9(+tR^KwhS0SdtZ;LL%qsX~erG5V0*FILC)p1wFx z=oCDBVbJsR(D$GJd5@chTKy3Ax{=2!;}GySH@N?N<;+%TqYDA{R}y zqoYO3ChuiQMDtT=+45wgPt+W-4%KdIcaDfJntK@C=J%7%|I-7lU;7oWjPsD$y?d%gbM9s4 z+URTkb@ljO*1^kULB;_!IF5hn4ck*ae%d%ihLXuQu-@Efjg&q2C8;^CKdPur*1#Ps zneUcC7b=ivcrkTFBI`B^|1_O9I`*M{6qYmtTiqd z$Wby$ff9+l#T7SzX~KfOLQ5J4g5|_~+<0;4L8#`%G85UtqtP>gTtsfaTDmB61O`=w zgTx-02iWDkd-A>~`-^JA&l?^)bC+tLO!Q7a8ZKfbgx^QR8(XsD-CFD@+lg1ReT%c> z$&*^DO?p0&Q|P(hYLQcmPr2eDIq|JPO=8lM4Fa@UvYoNNbi9o3*j7d9{S+AO_|-GMpUc zR!W+DU%WZfpKxRyC*ccOQ~A>!dDny!3NJo4vxPL?uO$@FZe}jfuJDABSY`W!{&V9~>DfmV16~iS5*-MhvM$Dho8D;jNWr6!HP7*m}mg=c7TldRipZNBS zHRhxdH-v@3R0?7FKviiU;|GvgxDt-mSJ4=QycWWgPepc&AR7a8vW0FsS;r8HsKggM z$1!UA`&vDsxAn{)jug1-Ne)P($Y|7~x@dffM2O{Kvd!_C*E-f(()&s>b6Y~>eZSQc z0Iw4$SENb#&dL>mM0#kTf+HD0B89tIJ1tFm5EmcDaG&=l&tk$hr(3|lX(oi{vN4!T zZ!_j1DCE-|=QXjmdzH_7>DcaJg|)7%_)R_l`-1tE z?h=X&-stie6GmYjROL+{1r9a+Ic&E%rh(Egu8sbvVQflm&7gX}7p>sRUaak3N4g*kTe=h&?6)7p<@fC%Bnw(2R5N1bC}<`V^zUt0o$g0XxlPAWC{6EQuUiAi75%GJtW z{Rn}b$@>nxgr~BAr;=2LtbE}?N`{&l@Jucnyf9WBH&3%P`EO`6I7Jj$vV3)}Z$j8b zOjdC38#+zWDfv%3FZ@nBQ9a_d-^YO@nOcBH>Ca%%XQ0WJrhWcmXSBAS3eHNdJw6Y! znsR?DEgTX}3{eNY(NcnwB?(V_{^9!Zg{>pYhpxF^D<2|Q5HHI)+rqdBarlz(MjZC% zU_~4+5xOFL=a6qJauJH;MtNUZHreWfhK<(fG+p!_(iaoQXSWXq$)*cwtqw?=A+6OP zp<01`=wxUKaZkogJO@9d-&y88?eE-I+|@Ql=&i|)=gK^Z43ygBZws8GfB#lXdy`gn z(Z~Mg?{Bsgmdnsb332uBi*okjMQtJR85(Ynw8K2yYG^v~CZfyUrlK*CN2#&QCkTOe zJyL;`Us29(k;^1ET7&94>oD`N-RV4XK5J?Q8GgwfqY@;^9Xo-|M&tE^`R(2(kkvYv zEXUHfb-BCZ<0AMuf4g$rJ$-*SXHy@*Cs+|5MS^NQ(|es!jmaSX(s2#d)6IC{s?$ahO`O@pzZxU0+FaC{63fQf;LM<&C6pCAw>7GdcZ z(D*e;rh#YxK0Y;BdsX&h6=w<_X#xp1lm2z;LHZn|xC{TFtcW^!Jx4oGFZ# zq1(X1ll&%J8d@Z){l)MUlygK=sZ^_@+G0hvwSmqGUgD4K!9f?dI&~oZ>Y$&UtN`6N zUsi*$m5=sSZ?fT+4Fj*>J>B- z)qHPUaA7sqzPpBa(3(qNV65)gMa}C%27<*7Zgtw7qpH;N`B8|{buIle4hHMFdp8V; zJ{+S(Rbj?HbcSUZ?;)`a_#)tW&~;0Ef*Yv*(k!aEVlsgenO2C;Qay>{H71Wd+?K2t ze%2NnK;D{XEgux@2eo(}M2-CiWdXxuc3fNNk

  • SqE9!xM(zrhIhkj`hnCV-ki+; z#t+Rh1+J!&Km!H2uaL=#Mk!w}0pyl>5xK{OSh5)nTr2C|E8gZ~rNm z5J$DOyqID3`N9wfi&e+k101Qf*l|rK*%D;T^u5n8pP(~NN9v>RQSU0OR%o%;I;^ja z-3~L-sIxX}{pc{J!T#FG|?g0UA>3#4X1jeq3 z)_x{m3h;D_!Jh0^(XSoTNUg>unSXI2M3QM+I^B~#844CX$#V94zSmlh zIjMc1+N`3H3D#9ly`df!4!nS&0htDf-1{Lsj(8{S(P=ZbtX)Od5!~Fyg>OejodUqs z()-?97z&12LEhFS@5t~|a~*j|4n&=pt$?ypTT7Vk_82(pMl=GPKSY>bV?u zeH?ng;cJ1zFCU{P7ZXbcvY>&aQAY!RM$t$CJ7_@;u6`0%u6tb0L!Ut+YcV#~zgl=@ zQD@Hp;YEsqs{l)N^{6fK*NEeH={DootXR2p^XXV$MhDCPA~k)?Yr&Q>nA8OI!;9bE zeron|G5@jWjmMUrHX^&Nh8lY?R#$%gOYeF&b-!~&R5{fz-B^T$fecr zkaS7Y+DO0UJ$@MJ5OC@@xePl;5CPmH@ zg&iUE6WG~WFM#cSDEi>B^{2@s7KSNsh*1aAeUS5rwxXJ{mfKMqVxezIp;JveU%r=XHTb(Nsa8N5AjZQqY=vnm|Fx=+`Av zn&B6t_kolkE~xKs8IeH5?tuWkb{prHF=cA76pea$nymZ11qh%d(CeIGatxROQ4Udp zAHULae)!7*sT9aDGT*N-`@BI%gh{#}hz0_BNXwJpec__-cieWqGLgauTM^t)R|*3| zfI;P5grIdlr16EtSoJO?UmJ<`EC4W`tgrSP3*gqrvEWX??l*sVH_2*2fVVIQyv4Y0NFJ(S!}Ok_vt7H6RUvDR zdGTY^*YZR=qAP{6;X~>GOM@e}Y2VmymV0H+#)P+%Fm^6{pp`@uLV}nKOAB(WY2PQo z!n!LEuZ0em2DyCPOkQrB*;HB4cD9Q-%??FL7k zm_YaB3^d6Z?ognCfDo2r;Tm(13NH1P4R?&I(WL6;RdXO8?SPPCiaS%)B>NeH0?|}q zL66?OR!AV%g~3xUIf7mOa9ON2EuS}{pdg7}LruF4!v6MLKZIpS}V(udph39;76 zTTY$(9*6qIJ1P=05GeX{E2zU{K-uJA+YJ~a%n(k|D*C}vT z+0yoxulY%5nTh}X$xch3`*vtWth!K5!PGH?Vnhu%a5Q`RKl{bv>eBvtcU%wrrx&d{ zICe1qUc{y;l=gWzoD_d0QQ8ZwA9|3TWu0UJgO|PjbzXumnbeRQk;Uxgr^2?dYD}n? zP9y-(1I*m@DUf>(vaowN-+Lg5^XWA(B3&Z@fiVd2de@}bXOx;8?CxHgCKYdPa_24E z4wqN+tb!kJ!Rwrf7I}5rUD;YN^SHeY%J?0@TT5;>3GtMHcbo}w@nNi4w7}l> z5lC*F=JsrvWc$$5xKR%)?_0Xlb9w#4ockL&YS6R4AwbVw=oIuZSc^9L(dbRg5&TIi zF}#-|5yQOaSA1ccR28PsQzugP!g{v%de`$oJ4L-wIaOtH*zQ9z#O*skU*vEvdJg!< zCdC;Z9$DbmW8ZKOz<76N4h6o`gt;7JHx zQ^1T|O>W%apC(bDQVtN%;GnB=19TsF`M*u_}oFSeFy-`j8>-cDSWprKgCjR+ng8~UL{?h0B z;FtRMShwsv)4MWWu&MT|h_O7`oKxD|%J@hZnE~q43+*)L+V+2W?O+=Q#Y#QVQ$025sHRsb z^+LJ4*I_Zg*bxbwO&E`GOx>=w_RI@(q)-051>&t9f9xZ0AZ0cfZk7fB2oILK)ASV>!$ArWP8ez!EOfrdGIcPghe|bTipf zpT;e8|)8k+!1nYh5%X3WwIK5ih;X? z)J4Q-qXJ$@eoLV$Ek6PJ`h2INr@@r@kKat8S^(py;$9^rL;#0Q39KhMVBFp&Cp-KrZWx>w=!^U3$-V@zAu)(>)qS!*;*-VL#o9D@>3+x?{xyN^{y9R?kR|cMIT&p zB)k>?<{JeFTM4vWEJ%A-(DX$Iy?<$PNCg>`zgLtZVhI!cI~=}_zsOGQVj*I5Gbt+U zeXU*ZtN#P@iPEnBig8vZ+2hRGpwM%AbxR`@6G&3etnEVi&p;d|&@*{N)~rWsL8d9* zcn|DavnI-;|NIgieD~Z6t$5+M!e$sh3iWn`DBT#3Em8`$0963Pp6H`00Y72%J0qB$ zv&SF0pepqlFKn&{?SA@ey4xHwHpYY1N=`C7@&iEfm~V-kFnH5#yX6TA&5P5s7ymo_ z+1cb@S7J2HD~t|B3q}*0Sk_K2TYP zDFGn$5gJ)QuqEs)D&Eqj!x|~6pF&n%V4s$>TXsDAw&h?&QT7A@; zki)5&Kdvawjff%Mb)m%z@VT0y-vO~=+SrZqpBeaYCiS|9pAa{%efw4i@cJ2d7i^f| zo&osRR0UKZwSz{3ZEyM96Ds(e&dNT-Huc>=XWL9UGa>ZX&q&15N!_8(3o(M;Y|$}R zP%8UHKN_Fd>?SxAE-25r#MCh#4m!|29Lt3Ug)RZ1ycd4p7zRTQcqtp>@-r6IzxutU ze$26Z)ry$;zK#=$;!OiXcwa*%Gn^6ZjU3-szE9R)R{G?QMYVBf{S*5NB zUdp0Rl#25NdT{x(Dt!zb|IrJ4DfEbP4A4_$nJNoXWJKQXLpOiOM~JKmV4Z`N7k zOJw9RK5&gr;`%eWk{l-O(R*R~)bciF>SVKTJ7}ek%5jpr7v1?r1*7%j%afR+x7VY< z^Jd5HxzF>NZ3TwGwn)~YSGIUD|E2!V-P=Cu=BHM=o!cb@xnCsalaA+>D!8oo7|%U@ zEy*GeW-25XMxt z->!}+xhefu^6f%i?me&J#QJ4kbpbnbdxpUtq&Qn!S^nQ5xy)<<9E390Ne&8BRx&P7 zUQf#9$j4X zc-$8yFw(5u05FUdPgrCiigOwO7cO&42u~i_K+3FSzhosvAI^GSI^CFgz0@+A?Jj+;T1g5>e==^n&-=aYBxsvo zH+3{EDkkKB0ss|aF0mN0gA4-FSFU!HNQ75^o#Kydx5C)v^O6lw#|?y)R=cLJa(3`* zng-)SalK+n2|!#SS%u+Wd?HwmmTQqS5&k5(lA&c-@S7_)h2cxun0nZ7caS@NHJ-vi zL?XsZySQF7Yaq>oyw67X_!tw@o#N#zF*eezZRF1PVpp~5S)q?zAt2ts`K2Mm?EthY zIkKr}LnIZyX=Oq?9z%_PuREXZ0XN_qR&l^$Gde|KBo>A~3>L3+`UV)MTWnK3) z?3LD_YfhOxzYAuuDRO1XTTyhQx}mXa>>CnCHj5o7Z6)BHjilipRE{EP*bZIMFV|g; zUixk1%jyD+lhf*1#=9;q?kf17!-iCL#l^hGonwR z2>whtYCw6m^4zgpV`#?ivBd1s5PRO3J4^g%u-Y9Fb91V^ zoAUlypH+gM`VD}!m3;digVe?i;F?qKEhvCfx|y@eUp*#@5&Te-+>OW*of!OrH(Ck4 zqX_a&V>l@oM3HbY<+r^6MTX(&Y;_VjIm%mDl1qp}@h7(yYS#v271t(Byve2QWenS> zDB0Ga2}v&QrvG7ne5dp^3S)}c5aIBsLXR<`WyP#bdpR*m+C9m>PtA8Z`C?6apl0nQ zz^N}NvQFme`<q0N=+B8EP-8vmIs(l9fX z|8qDpqdBWU)ah7y&hDRuz-&I*B|5u>u7MD4H$HEqZ!6-zp+s5^T~fUc2l_fne;8l& zyxgA*Xt~w$wY0USB)0qxO@0*Me~fe5u**-Zi@w^X$J=79w}ja5<>dp%c_IKJuJ<&5 zf30?P@OR7&0Tt<5l$e2al7elv@(o$gpq8w1%z^Y)XL>g)2)VhK+6Ko_MXph)k}7Uc z7@?dYacf^c$RBD8jLy%9<4AY2E+y1rEhz*~$2B#~BmC|i<1$+c&Q+{1ur+YUh2Q-X z&~pp3B~=R*?vP?5=<;UKRMS}&>jHvB0x>Pn$f2 zK=}v&zPx!G#0&0r*fJg^$k@#pba1PR2iz5K2 z4pVKX7o62mwfYgh^Hq zfs@dLZTP8~u7qpL*m`qv{HyG$qV`en~||^{<*H z05~O4p;bb=(q~c=2xO=78OFcLA4o`|PU%Xa=9(J!k){d<3ITCCfN55WxN%*0)U7daKAkYEr55C^tT)C=Y;noZp}NsUPGNSiG* zdHpP0K0~uYd>ef-ET8~F>cj8uR}4MPL$JBg)o=t_eiod4f|Lw?7WD;?5`UNCyNqr^-zTUPbCyglZfOFJ8AR^N)gt`NA; z@gi%eimc-uF@>whsu6tr73ICExvhpJt3|g`@!P{e#$D0>!SnvXUnPwN9XIM&mS#CIpHO= z)gKcK?31LGnWouN2(FYyfZc^ZE(8VS3yYsgskd{E?t54$UkmrUxHwX+LC~=Vv-bmV zP-$a^K0&AOmb2yPRoGq!zo5|)2$F8D_Xv0Gf(JqK&d3nSuGpkmtOHd}I9wqil0E>I zpr5KEvQqc{ovsuf`eZZ6c(mJBJGr&MX$WRM(V#@qM6xPd zd`_t}%~uYb2f``YSH3!$|Y;1VDaw$1d3YGc%JRRjg1z;b9NtyuY!3ofg zcXyI9Q$ou=1YS(Yq4?ErvWQi~bLJ#5KP4d4O~!-E78DZ*J zAXu~ke0}%sbO~tQ)_l_zJF2!k%1$DA3#eIQ11(fQsu2jYP0vlGQ6l-hpH)GVUdu}Q z#z8qSPBEo+sNx+hQLcv2S41TO#h>Kb?zmX$pRzmfs3|eNYgUoZ&6`V>Tkvow(n9a4 z5qUc1VG>{nk=g0yojvR>ezw1@r86ry^-|pEbCT;ln9KiIv!N+-_-QL=w7Mc&bj4&H zQx@u*h=EBD8A}isPQDElemvVIuN3Tcy<&_qj?jMceg(H0DO_YPx(HhUVlco6f(kGS zW9evQYuG$%05$m8a6l1IvlQx}bvRkleL}q(pYJ8!Vsi^_NTM8tdT_s!11@JJudpfr z*<&LhYrxX!3{6WFY8JvWzkHXaoTX(04^^;%Ll8A4aD=JhaVkQS?8E{S@hZ8%tSE1a z#x~8Hg;?LE$)b|#*q<31Zd@X1_#Q6p&pztww@xp3csYALpCseI7h*GJDty`weeNvJ zn^T=Nxd3pI{$|7d0tN@^)=G;0iJF5_-HC$^iG?L^G-+vZr5S0v0LTjcJ_i99^hdA@ z8MtfdPBIV+#6_5~p0DaYzs2YV`Qrjgfytj`0N2PNr1=?oP2n>UktNf+F8P?S2B6D1 zfL|EQro@2`t>S_nryL&_AoWg75)KbpnV&pzRChi@R|*|nDK#6(j|jDx4U4HD3{jVb zBFSwOhCYScgPN-5pCuK9{bxy*&^l}Xi0u~JtM`xWEZP?izaQQPWz5qUGnGFfaYffe zAszzFsJYQIuw$uc;V=wUh^5#lGSx`<(oUvMm?mUNfy-bZ2;iY(rDf9vGNRIQU@=vN zAu=LQ$fy?|{p{`r8G--P@&(vNeq7dhn@DuEEIAH`&i+`u-<+TwO9}sw(jk+)=m%H= ztwq4;+TJln4cBNZwupnzxjQSz|N4+JLeEz}B%*B~jBCBWCyi?jWem+rR4fK{^8~QT=Z0qI z`k5UU`rs17PvmmlRi2&Q*V1;@4T*g4`1XmgvPyjc3!2KyzamYR2k3YMtShQ>CL^kr zM{Jrk3~0jmEE#%C{)3y0ITe8E{mBLqBMhqmbg;bjTXf`hixFI4H|&>$kRD@q&#f_- zjY+_rv-_iaeU6x)n661OWa16@_13T={EyLiD!`&p8;+z#;e!@ zK-p0chLvHdWDM!j5+2vJvt0-kuO1AXQjyb!bwym{Bw^7f3$nQb5mAd}u$Xki5gAB} z=K+fnG63nmS`>7aLNc^YJR+|RLJJnqGRL!_BTs(`;9mUr-En}Ms&zrWaMFDB|4`X~F-Hn1(k36aup&&Kszh^g zZzN81b{~E0t%a0^LQbwd@ah2bWN3M-=!Y=Z#V__Sdi9hHkn&vL#O*Ir*?$)It2Vey zRCE6(Z=Ym-3?qxpdX2PYgsBj*d7oY5v@9)78VQGWrLj$ z{#H%Fvd<4iQ!KukfW(4=$7$4|Ds(OOVo*KGx19o8^V5QnghWX0Ux8$H1}V5wNm_K4 zgByVwa3^$>Q++DM*0{|K-+IZaaoIvJ!=OwVs;NH38WzCY=Qf-|OoBXCr9Zv95%k(v z5H$iVzAgwmOQ9ZceL+PPX1nvpA1+T@!9EmB1v|9q5NZ{k9Fdh*GJ-nj$nras0`1s9 zD=HO87Nw3OwSQtDP633R1+XSoF3~!FYFHzdY%8&PRR&09BdKAE^2Sg9E>P*K2SVk~ zvI0C1>mV5rQl$~*sN7^VNC3Dt>cgHYkp2fq5^O~ZHS6J11p*6V_v!MYZ=}IcaSVL>A8Ef^wYMKOs*+BT~?%o9#gXVpMP^<0oot$7>Bhh;R z1I2p?1=f%l?_emiX6uR7 zU(rK~JAFqejqT}uu)A?1P9yG(9ZNV#BDQZLs{neRQl6PiOVvbrM+rn>PU;JtTGAM| z_wvK$huN8B_udxo0uOOV1U!7~`8-}87e`#CYcx&i=eZ7d7Bvs^3i0qQ-*cy&)&ZIO zPM#nj%513F{-Ot$?G+NBz7)~o4*%i4Qm5zlQ64~}>=kHsC{ zE$#foXg75DScpa>b`YlU3~wT2t>h?$32t%1fX>~ev4?5#kAIJA_;>LpJ)KB&%d^y5 z#^(2SEF0){Trff~LRWz|QO3OPQ}7QV=Ne7~?OyJlI!EnJ5974*zpiw$62Hn_ek~8u z_yEC5;b)Fpv`wXk$ugL-@Pwv#%kQ_}*W+2Eb9!}q*}T9Q@so`omrQ!dgq}vYT64?2 zgECP_L5x<8o+3WeM5C+Ni;N&TBeU~v%pHI1^??9k=7mR#hNzv%O(QKEmqT2qsAfOn zTec=w7cJo7XC;BcdPfHO;!0lzx@*0B2_$|7sA%-o6F)95-c(s9tZ>1?-x;97W?muv z!W-nPXz#}6Mz^m{_BTs?(KSnD4PT0$LV2cnXD@9w_a!52vtVf$PA&KUa;d$Nv$DUU zY-emAgfBO&uP!}n=$vO#J)F+$90sGN!#13-#V%5{u>cB)@NBx3#Nj+daTp6L&YK)d z!ITKAAsto4chDN)GMQ#%9Qlkl9%zdLc}NQQx=4XVD@eXYBjBr`q80O}9aj3wpxLP0 z6%nNum8waV`V}it@iAkGU3Zn*=Bz`E6Vgpd2CHa+KGA_hrxla9Nr^@OLd-AtKZUv6 zoa`L@rSJ~Kb1qbV_KXjV%XXqNp8ST9z~+a`gAwf9#Fduv%cBR$8CSC2+zF3|$Z&ri1` z9waMT&V@xw^|M5l$M3SnrLqCMgrZk1fQW9Mtxe-GN|+kz%=<{?z0cLGqAT``E*yPw z2xLqW-b`oC8-2n=_YJw!XPsU_tKz~(zr5K(gH-)k9;B|Dna!;3=ie1I{le<=_ixtZ zh*7()rzRtQ%g=GpLae%>h*HW<_2!DjiV5_bL{LEC3cO}Z355Y2T+}G=rbTFeDS=4F z4xO5ur6?%r;5XC)88nf>5sW6MR1}TDC&G8QtqTYvFz-&q&NkcrOv08&(85E{oxpc@rvrlm{GXC~nCLGSa(%i5TLclx{4G;#NqmRJ1knxghE8@Iwtc9Em( zeMuQx61@b|j93Y^cqtWCraHnE2&EAM&ivmfo-jk=6 zlb*nj6Aux`e0CRE>1Hmu6%*kZiCf@A`boK^1ce7_8$+BXXJ=BpKXDS6fiOcPP@r=G zA;VUgbo|Le=54-k1iNN>-^E&T!Fwa3L1kck<=63*TNL67%!|qnjw)YxMVA!j%ld5F z=;$6s;=R95oi{LeP+!@6Lcgc@(JJy;NZzVD?V8BTIbuCH+gdTGfiWVSaMorn`@RM_mWavG0~- zS()2PNu08(WIGZNV*$GV;8(hT!J6%x|Bs}rjEnkd;&gX+gMff^BMnD)cS?6lw{%H^ zbR5mmCEeYKlF}^=0?*I?!wdG!eQtJk;$~;QJHwEsjwwg1(x_M>r-hNcMMsa!9FL@& zVk9>vKs58Fva$YeT-|dgFs@F6=UpWUNBqip?W2@N3avCZPtoaG)&~~--Ee!iJ3ZoyM2u4Pumr5j2>81l^)xA8J2>UPQ6YDB7+AI(VCCrQ&Z z_-Rv#wn;{0Xk`N7S-Ja)Fs|@pB-ha31%3BL=v?b>2~`hzzEWDA!)4iiJ&Hnl4*6bp z+^5Iw^h%3JA-hslGPdjlC=bS{0+8cI~}8AqfoM|hDzm*WH zXe7mH&2bPnI6;j?6BCa{XYE-2^yQalB^`;0(_@xaGcg!MfJR|x7=yR@Id2El(NR$o__=9Gck4_LCrE=0UTKl?>`zhNoGTf2l14)*7|J?Q*8=PH(Q2sg zROBF}33{;JE|L4IFa`(ajT&UVZ6Sn6Odwo9JlLj&tP#Fw%`Cq2WaiqDg2QOQNz6ng ztZbijjL3G)x;n<=MgSDfPD}eVS;l)9rYZgfgh-q!hf^L$PATxx$S1f@j5WQXj;~&1 z5idS_knw^5xtF4}FZfW;Myv6S_A9yP0aX=)w@N~hJE^ze6HG-2`#Yqk>Lsz3L&$>I zsS{_%!@<0(mlD4f5ml~#$ytoTY8ao$Tgf6F)7m6PXN zHw=2`w%!2UEiCnWyf0+)+`DqxB|)>H0bVi$Yn1w6PBHle9)v#Xq7(_&Ra-LJn_cuL zcmgHMaJt4S8l1te&t@_4LV1DEQbL)y;epFV%(&R=emX}niC^c zT$wGsBO8%R3I0PVSQrbHF&>P9Hm>ZnyNk09b^{XZ_{zB$DVaFNWzz^=@O?MDs+r0P zT8H}R)f`BuFPz&RWJ^e>(qR$e^q4~hQ<;b0M(8d2{zg^zatM2H4}yDW{j9!;#e@W8 zfG_rT!2kMlk3e**@7%0EHEY_5ZSU!UcW!@sJs@y53=-nWQILR%)#UU5#~!D2yHt$^ zgr>(p;h`BKXr0kg-ECKcLie{{Kg@Lc!x*~tCc1lLNPB%zIL(I-*wAJEoTpiJ`^qDR zP{?TeaDBPWaKi-d(cH!Sm;Bw`k%aAYQ7xZ8e_Tj|ynk9w^JguWL_Tq6fMuY~EAJdz{YFQwhn$+y9il??N zXJtN(v!wly?~R~OMPYdGT%4S94t~w6)5S+_uiVak)D@Cn9>pweQ`pskX}YdRF$x8r zX$`;FtHgSary*Kq=e~#X zvw>3WglzBQNhs0J;S)AKEUL<#&WPZof6f-l`wab?2GFC=%Wl{P=bj4M3zOS|LI%I; zTD?z3>L8epWl{ylt;Ez|+Hd1>1-7p%3l)BIq*akka>+-opi6@$dwrY3YUDmeN3S6%MPsOI!Sd;=n(3 zY5-nn`%@`TvNS!x8R-*6*uA=TXNlJE*@5=|b&L7Chi9p6;vs2xrNNQjjw!s(gLCWp9&f5%A?4S-I@(}7p%4l4;kisR(=z-l|Vi2TS zq^Bxr7gy_f#CzTn44N0qpCoXM7I|T8%vgh?qvFo^NYK|nn?lvxl!Yck!V`CK7=|dh z=G|XaEns91oVX?g=)!WelJz7Ru~pT8q+aO1#B!ih%F7*3+g8AiyTO=7s z<*zxUkQ+*-^04qv$QH-^4?I<*=z-pA1?7g zc!C@2`$9T|^5Up(sG@Ph;|g!7$g`VVV{lIGFUcZdLLmbkps0e_V^|JO2`sgMRVic~ zvHK7i;Q!1d&c{f?sAOSInl+Tj40Q|D88hQE z=7=oA5tYVhu@#P(4Kn&WxsX~Vn@SYUd0FmIqTM(&MiOfDIV5CeDAll5(ASOI;kS#> zWNIl|fL?N;G;Q>Nvaf1AR)5d%+{ZKIDVztICGbCPlHfQvm9Yc3icWCt$)V@u*^+=Qt{o5|4{p06{9zDaDE9 zv(a!E!WEIaW{~U@)Y1KPYP6_{QRa!l6Z1Lo275>;NjdRwG}%=hpi1TTgRVkh^k?;o z_mvMUkcd%s;I=JnfaTKR#tT6~t!U1WHRHg0&g0eK_2zc(z%j$_ye%)F!p0__`;NQb zi%W8PKK(rs5Nk!U$>RaBmL%jzD_{04_rvv>4r9pj-o~qsBnK&7QHQO&>kV#VfRHz||*OHOD$%RUZEBk50ly7T~GOVV3K^G)Bs*3f_nm|7wl#NA- zOoB!DM{a`!P=(LAzfi85Rt{<^vNVxAhl*&VCwA8>QNuan%S?$*{*n^SBrk`;tYyQS zRMb&P(ovlq`Ue+94W|}G9mh5%D@B*kJWcBKg_pusvO@y)1Wg_1UDlh(3wJ`~%(qY_ zYEN%LUP+J+);lC#Nd+COsJ)oSoeuu=o{5WZd@(`bfSDo8wa0G+x-2v~1*$36uQD@i zkDmzM!D&`5N((|8X)^16&qA`{ZAMiuNm2#Mx?)L+%L~#kFo-CXDk$%R!%Ua(eitOF z!k>WB!k{CVo2WGl#jOyRyfCj5jo}5!>+Of2$v5Ly1-;6(-+l%TTpPcK=KBx*kyUm4jtyvAGzoc? zN>uaB_%w7YRCKUp#YpWN#qKw;ajbEIL1c;XSzs|kQqO<6YTLkblptPP;1`0UCY#j7 zKZ^61>jVrT?&jL1{eCt%x!@4qn$8g4vLx{ko@1EU_MKmYg{9=K#K1TnxZ#BI;^iGX zXZSF@YbZNs6R;3j^0ph->OjWq9zDHsHUo@VUte;I+fHpq$vM@UcGVBtJk*AP?{B+N zj+N+ZVkBbgGknL+whg9Y3;4|u&5{De7<)4r& zu`F^^py4^2sFMoKxGXg-_(sPRH`CCllf-kW($H9w#L1r2-Tq|OSzly$`-+c!@a5<; z6lT429M6~eNsY7JNeEa*I-5Gl;Amv}MhpoGvmLvBC?|1dx{Fp)`o|cOL85Z2-a(co z>Vm=$_fM9&3s5j5@&ox6_U9h@kyx`-%2@i51hZ5a@AU}?6XSu_JokNAb3?zLY$2}! z4L>G5^R`b>zc6a$*&H?((5Oq62>{4h7-JauUH;Q~~}->=f+_eMAzHVf^B~ zMEbxYobaV9JE+URnWA`Z>4xg?lT78YAS}XX5;2|=A|?JP4nP5j{u7W4n%{d1#)>#> zk0g2~`Un?Q;Kdteg*WyrzA&p+;pfq$<$rXCJxF_z?nvf|Ncb~k8q&vL$i^<~t3FNT zC3IuW6AdDVcFzJ!;jv__Q2VAzR1}~4_uuO~DdQ;a8l6MC#9Hj?J+WwG_Tb{1CkcKDDxu@Tni z?~dZjSiSZ2zI=_E-L0^e>@T=TL=sSd5Rr)Vp~8Uji%+&_wIhW0p2y3pL?I&FISPo% zkvc~8019wZW$9SqB`mfCm?d^rEL^p(hgfj8Ok1Ajrb`4!PawVeKq=}6R!B>IWJ?76 zGT9)Fn&kZRG!g+~Hjd3t-D)>`lPp^D}Dh=&x|jRN4rUXpkhsafCvTM8 zN@B{~;yUJefkPTS@i>+pD`64Ca}hGuU}9nr4Sv&BEEQ3Oq*)SFM=7(1ClTIIV--aj$Q)hkQQeJZDOl`@gk@0UP)N}aseSe@EQ#Fc<0haZ^sIE_g93b=w( zfiZc_YyE;1rnZmS{$qUCdz>AgHyjAOXC@A!Y*Gm`c%-DXxN`6BxP82$Iye&bCVZXs zN@!=L=|hQ#u@6}>%?gC+#t z${*!>90Ll;>Y)eM~v? z%R^YO{sZFW0WIp$#ue^j1?e@(JSG9R+qW{}WGPEg*IeI=sMfior}Ia%Z@c$VkcGL# z80DX#?$-8sj{8(@LM_xBFXgn5SdB$#g<}2S$e>)lnb^G->^79I>;77QR|q%c>+%t# zyA?|nFYzW3wFr-HfYx(>lkubeVza#d_sSg@ee~j;<*feze<*+#^P6fr?z$Su1Oes_ zDqhAG?sB5>n8*>mzi!${R6M@ps;Y3?Gz6kr;awVClU{iS*Ql3~UE>*;71ne15HYy5 zemQYkMEYHDs9^?WQ|Ckl61%ihse2u$FFP@m(FJcR5+7p}jcf+j!&uKY54~UXT`VpR zN)ivXO6Adw!l+v3@$S4G-n0NJ%sQ+@HB(byJ4A_JRSSBf%h|v)j&DScg_Lv*+xD{sW8R?%hG}ehBvs;$vo9;{p}q;I|VU{6cBP5w1(R=k5UCO zZ0Ugz%->Wi)Bj^*%=zXR9M7>#PozgE;`F{)MN&VrN3F@9tlj#v(I`5fdg^a$(tLlm zd&*`g-}t_Nj;U3d@rHEhee4j>=~}N*Qt~;mwK*kXh@RYfmZ_p4cV-($8mz$GfccN^ zumLYtn*3S{-Ip*wWQ6GxQ(JftA7!`HeVt_}iD$8aByJxpVsq*an$Qc=RiVL-bSqp* zjzHs&1Se2#C;Bgd`8o7A{$jwflnej({T4Xgssgzx%I|xLn97z8+I|-JbyybRDT1Cx zKHJDWwzVz+#2KD!$B2WYZI;q$Fa*yoWV0fm6zecLe7b!pu&5su65=9SDLxd>1lXcW zz`DZo{2AG95#0{G85T2-HH0B9ASzbN{icb0F-g^nv?9yMBaGy{ieG?HO8)~tE$iU1 zE#7JW!lE;aqa24O!O@^wGAm#b=2=QYQ^Q-;#8+ac{XQW|y!^P44DxMuRp611_&FKs zpT~dE6;+F!e%jgK`5gX*7gl=k_6an_2x!?Qz=?JmV1>jw{p5TOox!xmj;YT_7);QJ zkSL@tlm^_^q;ya)k*B^Xf}3Z%w`Ux;AeMSrN+rD)0z3M&0kn}envPOI1$T)S(t=<&6es_P9J~jc6uQ^~xCs1yZo)?>^Tl{u^hYSn&sU;_S(D*k#d=K2;FB<^K2~QE zsD3ovo)A{E57SqnHJ4>m4z~%>*DH~nk`@9^CRCqFC*!k@tSYT#LE!F}f-g_7ii=`} zP$9KqjWvQY1`%RY(i*_$!t^CIdIvT(>LTl(c&i(k?@*hevS9|J@E2k1P*^@HpIkBI zebvd5EzTjv-+e4g8lT?ClU^Sx*9xTkD!+6KhW8VR&m?T5PiYqaAh0156zipkdLt|i zOZdvhcFzViN}oorSr%$3_#283hvb}P=8=iDJc&O4vhk0NMM!pmy|-)q8^@Clx~_ty2+>6jLlspbboFC zGJ1XBHu<&ZX#RNpiXe;5%0^sj`cuZJDNS7y}5Ta7TWF75!asN;E&Cx?bkVu)8>Bib1PY}dt zcq|g#2X?V)$RJcm=Gx|?bq!g-_@|ZcleNR8a5r9DCXPW9d}=((eG|U`CrHFo8lLTe ztSYHWcm(A>hXq(eaF&v5Fth};oRlyqTG7|AmIpc%dhV?hUyQw;IjYPIWPlagjs%ZY z>;z|z1TO`=`k}E(COdkj*M;f}j=+TN6I6i53e9@CYJIn`Fm`If2Z4y@|50k_VOeh* zS&e#hb2TwxYSP7j#A}hR*GFCQBViHpK%O>dZ!Bh;uiU302YwnfxpHAi>;yX^6Psno#tb!BLE28j428}6np44tguU}juLH&N zkL7m36DTY<>g03G*z%c2Yf^lL@&3o3p++L;Ur1Dehza4stvc4js~rSWpTOBL;Sd8s zorPvZp@&Teu|am&xQmKWqt8FYLwWRR73Mf3mr)(MVZ%_#{F+_Df{CubpZ>%`n>P9_ zn!d9(<9Z3XbZ*bTxzjp*6_{11eV_$}54AI}KZ)boV6To^Bp9Le?PnnW*o^b=yYNpe z`CnfeFCcm!v(c*DCkVW5c^HmQrpFa}w{m8IaK)I-90~|mK0uC^%!Lxm6nGN!SK;CQ zR%vlljw;eM#K|!uv0uRSKPbG1GEN5)of=p^zGXCryfN4bJfUyWTdK~tQC9s7yT(`c zTJVB-Ne`Dj4mp4QWGu)np(Wn1DYdBv25zf(n+vKn>OEksEVX}%ex9{QWQmRW7z;9# zHESxUDK~5EyjHyAr@r*Gu}W6vC6xXr3{rE!%}G&N(HTmL#lQEq-F9D?aK$da$8m8c z3EPWS!qGe_&;~pI+fo=-k8c_AA#W3Q503{Fjl-%p8DVF`&AZ6!GgF9fYsC*R-!*l0 zCj1f0ufs{y0yHsyU5=Sk7&{}>7r_Xv8E_iRhYjcaj7P8Kw!F`G5zW8GeyvojnOuS3 zBDC_fk`sgo8-NWBlH=YZZx(J=iE_;qy3 zCHsEeDy7ja^tYzCf98)h33154oCn@7Hi|!cD~J9KEY}))Dmg>HT3)fao)U{TttnsU zi~gS4BP~rV(xu9wO`Gggn6aJlA zb(x0;x7WNuP<#w*_sR*46Q}}7cGDxA42wGina|KPA@e9()Q0%K3lsC9NK;M@mKOHy zx%F#XA2*9Q`_9h4D`=(%*@^>g;>0F;y+z2uh&Pvg;e&Ke!u-5hHVntmLV>-Bl+nA0 zjmgMKK*v^6OrKj*#6CWJg!WeunJ`#&&8IgQacD$^Yj`2EN*OGw@UpcxU?nX>DPPvQ z`@@zY%QP)vlns(g*?s^&V%Ym~yvjL`i=GUD zj_(VubN-Z)HtQTrz*=9kojtjgj_?p&K9%mb7C0~_TW)m`gkQ114!Xp{qM5~6W8c7*RZV>lARLy z{6M#>eGjiwXYIS0>pLbp70RD0(W{$bdGxLm%?(z`cj}VanBNz%XcrXFIl3t}HVos~ zBIj}-IqQ%rroZZ`rU|&Wp(#Lj^j_7s!wDheGB#)vd($QEkaTZQ*km0~HEn}8p?O_5 zR6^hhb_)-jJZA+)1Wpz*b>p|_ba~gCb1wQSF}-DW1CM7r3OzCT z%g5Up{?APh+(G)zE$_nl_7D8-rs{h<$+Cy=X?glK@Z_c^9y@In0>htv{IW6o;}+xB z;23}^I5myWRebFa;5!V{6ykSA{C`XWqodFDP1jbi-Y0`nGXJDW>|7fqD=QGz;NB@^ z+k8Q*xV_%D{TdWMoo+(FiVB51o<~GU7fz2%yTw!iN3Vz$^C!4U9ds7ngdk3D{@1EU zcUqL~n$vdXNCN%a(8z%~=#BM94aT^8n4f3;v-7DK^kYL!Ec5^!*)J|;CTUzXfxQoy zwVR2n3h4RTAN5}D32Vtkw?;4rufk6E`fhWM)!Z&CuH2Wx0xYsI`Tt1R9u8TmB4bUd z6KfzS#>Y%d##nklVmogatY4nZo3ms^4SPC;*8+HgVq?DJzuj6iRT&*-6I7XZ+z)tg zw-dh+;d5;fm)ec52v)w9iOL79XG(wYGEmZ1PO4!TlzkD>{)X|ri6AQ@ClBFlJAFk> z1=b^DBOl+pG}!$f3<@G`w^_t0ZbY6NIA_c1%LCW9!G146U0f^8mhUpEyWop`R$&zv z#2L3wwLYRMKHei6cBro9^eIAo;jU>w2U?aG`k4#cRSYn;4 zUZqnC_JATR{#M*te4_XAR!kWKU9il)#2!=2cimY&WYqI=wU^P@wrWvamNyivF>%ak ziP3Mbx+17NB~PZ1`-8vFCB~-Vr;DA}@k%M{-&5Pcv!cd@w0OxI>X0W0T=E@V`WY?AJEIo{uOc2xfDNG9*F;&n2?x_!rh{i^&6R}8c(N| zDzc^Ac}&uUEsn)`w()b>Z@)V{y%uG2qvnr><9;MheBU82q0TdSICCL0g}5@{z0hBi zEjvMnE3LTXapT^+$D)xxB$OprM4s>@b?cks zm8)0rGC^kY{DdmXXD7D+E`e@}Zc<~y?TOKx8fuR;aVtJ_B{}v1n}f3_VX_RD zhpqVJ@x{E|K@Cfe5mi0AF(j?2$93nyI^N_?TLJ=O4EpyoYmr2VGymm~K~0Rl#DS68 zN_WYiA2f+HS4w>`U6i^@xHL8<*RJK2BPz_c^xKVeYDxX+4DtleqTi-Pu=L7N!i=(| z`mR8);?}7&*R8BwA3yL}xM{zJsTrPxEs|LVF zZ4JhC;w&l8RKlbDfNr9`OcO8lv-2Tr#5J8-+**$ncK`nRUSd?+&b%$r3o2u^*4P6t zTg#G{QED)+hO#muED!(7r;0fnflZcWwL-1LK<&f7xgRcykJ|BE7ggP47G``gUTX92 z`96BZDKI5(?KOEOCx{Xe0(FJPBl!EL7I0E}vfr_A zei1nTEXSxgv5hACgSPPzz{4!INAqFR(jF%{wMvq+EJ~?S&Mc!x!y3GhNqG?rWLn&1^q)in$l}?#F=VAnD>g$dl2ARM8|>Gb^t|mHp}YN7=K*6MM9?#`Q0n<7g$u zS|w_jM_ieHK()^=v+@_c19B!?Onu1c4vk0I>eRw^M(|@1l84OC3OiKM5=ZL?&o>$d zBUxdX?~&~9k#ng)_2DT*0>5oO5xM!8@h)zEN;g^UojEOp{Ts?JC`tarH)$SjCgxkbGZy%WQLYO{~VecXB-0`c3V#g~lm8k<#T*|CKq*P)5gRyml^j=d!<&BxGsSw)bTEbi>11qd4F#Hh zf$H$=_Y8FDr39dNG`amKG0x7K%?w3}j1|xK>_<=b!B`E2(DMDvob%O_bB;=b%x!f& zGQ|sX2sV{mb1c~PW;8{!70yt^8zQVdEHMg7BT}W8%BN%*G2UEN)So5blf4@Nv z_xe+82=b=>wP`xz7c>a?A#E{J1XLiShP(_Ye1si=$ETXT&NsddpK+syAH9+*s?vTB zODv(rm4kUF%3NDibl1SLNfx+IF2u|O5|~*>aD8|%=ZQM)M?xAkX(uqp80(SS4iW`KG>v5io500r zr5(W~Py8P8^_V|w-n4mZQu;Kcc{~m>ZPEv%9wQ-=BtE1!QLt3dkUOx&paA!MUMc_JFmy$G z&0wXFP7sp8?{EN&VaIIR*lxpIZ=E%^UsNd;Cz#CYXu~|eb#-aj?b<`ySh@j584ROb z!#d!#lr$tuajf{bT)wmMMKI4DUsT8cXOQqgPTige<3;(@yj1y>9gu>hxLA8iSBK*AW#*q%N_GhH#7InASr1noX0jRYw2 zBo86*5_vJ+zNxRd_X|trq?CCb)__yx`$i9zYv$+0iEEl^@hSQI3~8*D6%pYM#>t)` z%;m~s)^D9;&N`o* z_kW!7|DY3H`n2D>dpyUKz{3deN2UiR{58weCGNm*o%^g%?9`H`k?O~B zJ17PWr|^%R(%wrz=KN}(SOe=ZteokQcKYDQ%|!AGDPr>{b=K{aOgy$Ud^_JPk`wNo zuJ}K&A$-ovNa0U0>dPs>T8r^Qn zz}lLIDx3s$pFuI0Con*YD$`Zx?~gIb)5~?$u#ymnID0m@S)Tpx`FS5^qQ0?;!nypJKMyJE^`o84&cwmjkUSCeCXyr? z>@RR(UclWTkF5v?xEnO!jy;CjAE>imAThZixY2;gVNHLaFyNZa;?GsaR>Rp6_A3px zz2}2PQJ#<7qC?M7DI%G^8L0_Zy-sDMI!g!lKA0$bGL zX(I8}k|d!klK=*W(dakx>WUdm>DnSfnyOn0N*c|63V|QKNRd!PV``HkyAj-bP$!mZ z53ZA;Ja^cK>)YFXGYCg$LWYKMi%wu*Lgg?8)H zttVP@u{=R@g|pU{FpOR3yANMiw%RrQkAV38UrKAX!zt+sO%pVE z5H=jD(<(04We0uoLc)$mwVp>{UZ~0Bj5J%rQo!pb!C`1N6&s>$zYoLKU?CGD@{Vfu z*F|ZZaBkcXHuInO9neD(dXg+@@C2XJil3XEysS6oX$He!Enq(jONt1x-%a@&yn5cv z2)~JR@PGLv`m@3h0$H-|Hhevl-{=|Mr#9Z6=%}KJ?*ggx{~qd5h4sbOK>TA}z==%l zjKG{K_Q#rSoUSCx`j7cA`Plkd20XR1BqS|Dd0H*b=`-|`w~VoK1ny2>MAv`TOFn7< zn=!lA7VH$L?$S!$<}dvALw-Gfc$Zq;Z0(a)$-=TUMMS_Ch9B8VMmDI&rR+aK{g^Ua z*!-AEvXC6HcWax_D@w*~!dgPUGNvTQt(B+sZ6T3;{pqyt{avhHK8ynJiFfP55CP8&gpRk2&h9D>g(b5qxcegWT&r-Pig z!F7oM?s_+T)q!d$SELq3!xIeCSU!(b0FFIH24Id$^^NZajrhR4mMVH%c<=UlF$e`O znJbQ2(Rmi=sAej5800p<0H$ufj?^ zOJXh1S28!4{jq=~{QI5%z83zGjpv*?wTzd|?X7G3{Tz0UDoFuBQ%40jDU#X-y$USx z(^Jx3QtKBosY{<>9Zb!JJ`3=b`eF7BScz2n0C*^GzfL56NHV2g)(Aj?=n=l) zn_D94nNVhYrX;6ErKhzEsg6ZJwIzaCt0!Rrm>=ck*45h*=K9C{)GagBNzG4yc`@EL zH`J?D3_Xw6|L-psxrBLs?wDpnBJOnd_+;1ZqL@~{uv(VY#xvQ88eMXhM7txR?IdzJ z(&Ig9?oJum>UMv#F}!{^yb0h=n-B>7sVT&pyfQoPxY01Fn70(&w34TF2$u-WEk|_z zzq>~iD#1g;Pnpx;G6n5~JaoLz{+cl+eNa9CiVp&- zj!2p<{iXHD_CxIlTpBkz8`K$bXs?_XNrHzQK)f_T3zjeO?u5j3aRvK9$6w`Z~^HLIiziT3i6qYJ4m^NysR z&Q)uHqye2AnG3CHV#l^yt*VYC6AHhm<89#NtPx*37vA-3USZ+C-%b<1vFM47;l=Ym zUs=-OdYZw^g2VL7%2*jT-mR!`>>BSu=ecC!>e1pf(GHzBo}cKs-^Zs+fz#8ZqT;@! zRJiiVo1b^6rEoJ6YyMG>KjcPN8H-)|FGs3rj3jD8fO`3S&{=+{De|iV7-Ww5$N+VA z8RpsYB;Ub~$>xC0dekp$Y{>U?OetN)d`nsNXr5}(c4q5B!Or8 z*NH2F6pzr zaOocc4!-cMjP=+M1U1fH^bM{1DuoNCAP8+C3!Cx0R zam><`>X6V3!{7c>2)cmzP8_B;fi-gwr3@Sh0t18`xLH!_}nss8za~f)x#{a7FQFsg=4KVA%HL{V#ywS>7fO)LSI)Et3Px#Gs&~ z{&zXojrqgJs1Ee7S_pu`n;|k0{s<^zs##l1=`ppg4(&lM4sE2lhG3Yma}c1JAR-ek zbHeqA(;H@XI$eH6e?U++&{n{jl-!!D(OLentJpg_}#r>7ASRgEdn%k#4G}UK#91OK0ts< ziG&J0ce{e$4%BaJcJK54m3DLTTTD&2bA;-{r^CyeuU2LhhFiq?=@GtUAGAf|4}zpd z0wT8{<#S#xeqURL9V=61^}5PVtuCw->zR3%hI$<fxp`3S3h)s6Ipo?0ci3*wd$cimqyq1Elra>a0`!v|9c*YrHiLo1uNkjul`Pyj=j zEZAWNL}zY|ZjPYcVacgf`BzRK2hu_5tAQk0%8Hoi;L-6o{*4{86LS`(ae6+NYw_@u zdeeV=!ovNwoe#cse}cTr`a|i(G9qbe@$Ip#F-ygSd((GWN=;{JDXD=GrNwOh(pG3S zvp8I4fvyrD(b+Em`o>O6yPZ@wEFscy?ds7js)Udtw=_-TO$Cb)*(uP)0lC=4CR)Gu0|y-r+&EwNBap>E}qXRyJ_`vK|P^_3UY5RTOqAF$p#8)hPS05xk%B;^M;Ol5A_Ph~EsDd{ed z$hK@J7^DD?6@*{V})Jo?R_A zC34|Rwq!cNIlk332bhE~p%J#ZrDguwja&B=rD#>_)baNT|Al^G_67|WL}a<}NuMj( z!%0{!p`qEyx>9fp8b$Gxc;-s`#XF-YwtnFsrpBsD2(*SZnxMOdRtn{dOz^s?lBuBR?ulf>c- zER@z>UJ$|eB^Y7VJhiP~I!qlhCT>#%^ohA6+8xMh;A3m##sssM!{wIPvQ8HMP;wV~ z|DHu3c*GDdUccIY@DEJE!mA0i8n@2QEa%v}%N}9qRdyaO)Lq?|M=WSHN4PRY6oX)r zLeYGaxE(Pjbnn)CkMmI&Z!R1tR~>XhPEOR;(dx>v8`oEGX=u?l{=AR%NN=yO0BBE4 zmhoM0ihd{}z4de!ZLLR}AF#CL#A>K`gJKN(%^rar%=xdN!-_O6_#eZOjggBH;ZtxL z=$g-r85dAi8*X@j5XJ!^s7CsukXbdsTZzOc!5UwsFT^&2WV2#>fj2QllMZ$voFGH> zLKb}2_GCndUGbe1f;2sVMMrVf<@W#ZB56F~v~&(VUv*h2h*}8~{1F+i(*vm}PF1b% z%)&T-Yiu!Euri+5hA(!d(3GM5^ah~IY3(3kfQj+RG6F_e$mO77Az#7Ff;H>UO#E@CB&!RB5N%QeIiLE1QOR; zUkx0SkaRq8*u_}Qzf(H=mv;hAiGT%mVFQUHi95N3wFpk}Gprq}Lsi0D3l-zZ&;L-O z<0OJ8ID#3VTyRh~Lz?eCN#xX>gTr$zpOJd>*novFkJ)`$y-%-^(> z#=DlVq7j8s%wkY-El10HLFs7cEhhRl%L_!6D$KT%yLcZ5fsB84JBR|<{S>f!ZrEE4 z4oa8irs|>%sLT+zC?es3@TySuYit3JiwD3{AzL?5yA_0l%`Yix$G2jb*GR&2PwDs; zN(q*!B9dp+2%+088Y~C<)Q6Jn48Yh$NA1pTXuN(TIrxWv@bbzQog$q0`|$_3)^CG= zP=E8MluqnfY7xa`dr#zy(|5(M6X`Wgji6n!d2;pxELz+HtOdSr2j6<8Tfgze+O+u^ zR8Q|k<7Dj{pkooOs(A|5;vAy z7aJHZ$*^ci{dn6cp5K}cePtRY?92nZ11+}U0FG_}CKS54Vn(igyXRBHcz`#VGa)>( zaZhFgQpQaHuCNe2jXlixDr7tUi=njo+jLm?Kr|o62DMivRiBbA$8>V ztjL&C)Jj>i>J#3a3gEZfHiYr}pC;pN9BVzYeNXTJNpoK>Gf`0_*z$JtowD;A0b|BHB|CEk4Pq zqHQ-d|M8&=o36I?YT$vX?BO}&`gK?%pucxlR~0J+D20g;E*q3x~w*;^V8&SZ6eJzp$`wS`M!1 z@!0THzyie4b)8NHh-0}<`faine|NDwJ0SA|;l0(nDezJt6DSj3VLcPC&x-2Yk3{gc ziLI0+M8gCy$#cUrWWXf7truKfjTAh%HeWwFx0{8-jKdMTbAmu*tsCqT(B0y;@M6>d zFxY4?0))0Oyn#aEwbV)leXujq*;WbfFrS4!1pOetYNr%xdYY#`U{w|qUKO7<$PM;s z``FE|!PSmq#!Wo)ox}@x=85-t3>x1xhoq2k{%WsC1_0PS^r!f(I*f~lhMV^f&1)jb z#8MfXW+POh>6h7>YGsMTU1QUET>J%0Hr^Cn90uLL`}=Rj!IE9|Tk~cgeSS6&k3pX5 zM#?`;D0HAh{19&&qFHWpzQ+IkgT*hIljqQ_g^|DKd&iqakfOJ0zI(g8j5aSFuyN=OEG>Tf%5noE-t^6f;J7fuK6a}6aOt4fX zTrFqn?H7R#c_XpYdGL_AFNdC)ROZuO2L&4(vPHXtgqe~H7}ToHoF5rT0)PCbCy9Y5 zFULD;zk2NZ+T#L}nuN?TR3Lm5ZP}W3c>52SDKqhC-H^XmJm$jdO9n1I*k_`Vt|rY3 zVBEZ+TJ|G(f2+t+rrAPP2;{Gp4Hy5(%Rc(Z|JJv#=MUdCP}<(em>4pe5ZTAmW}<@~ zkNH`PGfARswg;V7(f1D(iwna?m<$8xvlDtU3_58r#fU32{O3HE>-6{kdMOb6@ri7@KW#a!uymYE_s= zTV7xHZ->gQ%uG}+n6EX5#9z-QO<)BY-lM0wn$T-YL7T=WNcK{ifVfqG9~%-J=#2v$ zo9Er-oka;(9xpCiP(m6*Lt|mplCm5M9n%S>pM`rUdUoj^i#nM6+*hc~u9pwe%d<96 zgf=iZTH7$UX$chMgnQyj%x+OA_5Vu!V?1PWP>?n9#JuwI#LjKvI@9HE+K=P~zX+=K z{^A?_1x!hS*cBk!c_XG1cB3UU%Npu%) zxe6Q(zrc2TW2`x?A<-8n?q5JQooRV}*xK>BaOLf5jOM)atBcO8{+v6eD5p0SNizV8 z1zKsa0aJQ1QS#V?nDm922PJ{pilD!~4FQ9c8O8Cl5knWHr}Y>UC_wqy9Aj#2>t4XS zvH2G3+Hc}P0J0Ky%TAp`8^FQ%y=(`QhM(n{y6^L%||SjX|@k z>m{1!^eMf@qJiwUk6s`(J7G-VC{O3^2E z9RL@AJR^FuN1VOUn{fU+rzc-&F)2NBQ*j3C!z#NP)ftI?E8BXDaFv<~` zIKVBWHKgK({+FGxW};ThLF!wuyB(093^T9_gC!TnwqB`T>ZE%i#s^eLX*n7#X3LPQMw9?QlmUdi>Kyh({vpnF|RS1h%s zZ!?H^INg)5sMh7@q;4v3MX}6MM$r21^xD76$dMmQ6-~YyuiWje*)fVGrHMo0Qz$b_ z^I@w_QRYry)c(MX=Rj*2I&i~XfIr$WFept&{hZ@r#v&?XTpL7Wz#ki&>a45a~WDz_p$#2;Tya#A03pV}Ee69qE!pGz$&d_*P#)Cv7# zxWr-k9fMjuw`P($#};WHuqa80s)R!yg+)SFu=yPR*C+vLS6w;ZB{>#j0IU4bWBDbL zy@`||bQWkZn+ZwRDU1d$fQWYz%#%~YmCny9B2dDk`4VOaOj`Cs7Ac!I|KFfZGsh<= zSDt9LJHhwxP&0hw2~MPjN!=s>nI@T~G@$hkBZo{xhq)Lt3R9beObQ-fc0BQzIEHY{ z?6Cgmh?AAOTL3s!@I`A7|!6TYu4Ce@(3Gh>1MoG4Q!!e)YUc0r00f zDUkx;uN;tpa;OSa7-A_Z9Q47r-5y&+H5?S0Xi-^p$L2$F$>Yt-&v}nUJYxtV?y{_S zW7!*Z`&K6hmj9GSjxoeQS4MR-lX-uo6PrSd+mGs6Qk9zsbSl~^zOo1)C^<#~SYZrB z^@Wm#L>NU|=U9@Gy6JbT{4%klu$mGcs9a#BX!(9TC#jsvEHThbp0+eYeAVNBkVVOQ zmLc=bx2kuuL=33mw8L^C;qxyg*;{g(8%SF@lQq8S^27a=m1qu)|7v1)$+-H7bQSlC zOVUWR!Kh7uh_a^@1{Hw4JyCM#$B9&ig5f$MJW%0(WtK#sgq6ezGT&1HJHk$kD*7P! z84;x|p^#qnM?w^P8C*$<#3erk~+*+=g%fBAJ z;AUUxX(gaS8v!w!_{I)U4AmSEGh0LyavCW!@G;9iod#VeVWYgL9!#2Vm4|mvAIakXBbg?b;$LOXFG`$z+$0Jx+t0$T)%nKx|CGw_s(+kX5a74d?3;&GmmrDDi41T^GQIflRt zTr;eHP9#4l%PCZ62){ox5~pS*jEw%#H$A?Jz!2Da!R%Q#f*b@|4H?-<(L8!Rz2rP zYF~~u74(0pQ(}N+$Li$&9R4&0c{XL3?%QQ9cN{QO`bXzey43(s@a$3@(E3_r`F5zQ zdv=-o2{Nm>kj4V3;q*vOP!`r*`Xo;O{xt|eL;geUVuhJ{D0n0iR4lb$VF)30hlTRT z?~p(rhk_P5qFn$CffJ)yMu*Bl$JG)QpgrnB9);^eR){S^PPlVbZ8o3nDbjqs5laR3 zamKez;nd@Ygo=I|zLQE)y&IJ*y`n2=1cRAKX-*$JUZA|(;$^MajHLcqXTwyP_)CaWwVSfu}&p@%?3Ylk0YyGvBX71^T z%mEsu4(r*u81%z@b^8ZQi~*U1z3fsjuzF39 zpF$nc_xY~fze48jI9T=FDRmj!fOtHq6^6L(FH1gs(v=8EUnrg#du8)qRzfqsjC@2h zL-ng;Oe^#N*3WNPKr}<#34|dS(MQmF;tfXb(|rWKTP(fw3bdYSTIEb`>fmTqq&nC_ z05KNa5|!Hr=&JKLEN}r3!w(?F1IkRl%sr*9XftZwAL>BW5)@C1BZU1yst_fwwTuW* zpu#p~MB>|q-_wUEyo+7f92UWMdyy=2Dxe3t_H=G3t$#zh3n1naF4F9E9GvIV&-ot} z1Otcnz!wLjC>e*OQGlnb2+LnhhfGlRK9Ta&U%!TUGC?qo+|fw7zpwTEDdLc};~ zf~TN9@p>Fp2Lt-~dP)`Ee{K2ADRJu{a=6s8t1T9ftaf$v)TgskSICDWv8L4jCV*|W zS?xcEONt!OWGAB1^ysu5XHdt4Yf{h}(H#COfGaP`i*5DUAmWN>6$C@D zR8z8o`?I*{CPflZo>E7&(Zc7k|Ja(ONOiWC=CxMQ>65M2*=uO#b`Ht>fy+3;Q~IOi zK?DqeXE>&Zk%7`JiUmT_*yhDSfz{xNS$h{L!)$zGM*);d8wWcInIpnaQRxZ&(h_xd z8xp`$yWT7aliUxpP}~5I7Xc%sUXALNOX;WSxY6an_*+A;6EN0BI07-P(^L(x7B}`H zz*?qRtF9e1&9L@|>sv>eSk3-Cc$U0|{E=tyK5k9^;n*}3%Pqic-Fg7vo!rgXb&y&9 zM<@4t<28EP$8;p7bl6bPU+M#b^uz ztV-b#cMecR!VtkoLf0J`N8VEJ9tg^(~zz+$GO?L^5BU}^$j6(xl5=`$@ z)SC=p1GKQm%OX(G#=N7Q;>nZVjY)Ktk0o!a)q6o#$2>`MiDv=M zodDVdnW4w9$CByfJ$@0F=5k0WC4rdyFOm=7!G05MsgE?Q$v24eFIA3Hu9$ZGNV zOe*mxzJVDd8~>F^cJt%OT>YjPc;shRAW^N3^?5e;|36y>UuFVUrh#68+cC8S0urA2 z5Qvb0{Sj#{vz)H@?J$RUYf!k{?gHfH6t%8jr*zi=V)kd1HUqW^M}Bj%=Brx_9)Gx) z!Cv8zx}-@;-&c5G2#yuo=`*&}rf~{{7(^t)E&HWQNKWRK=N|wGD$(;xE!fx_@Fau* z5P&D)w=}~!QrCMzp}~ZG&wHtzu(<{WAbp1a7h;$|8ui`oTT?pKuWSba#8f!r0;LKW z*z0P>xu?SdGe91^*fKK`7o?QB<7WI(aKq;zWa8;Wo&tP`|ESxjOUcBtgNtNDdI5$m zq$$KpBqUmtdeCg~)@|%pQH$3nn%EVez>I|m4gS1)eJ@10A0J)3I=o1iZ?5iw8jaDQ z&!=_g)WJR>afzoh6fgtRrYR4AD25By@vI1`_`odB^)IHT5tiyHrv9cr{>UteA8a@& zQ3-hH{W@ZmB>h9Vm8h8|wYMQCC)MhJGBKJ|t@K+#PL15PVCur~P>F08)#tUOo@~>t z_0hE@l99KDKlH?7|CwSI6v$@-WSDrcX92r9S`n!f!}t*6dVEc0g=tj&3{I~oq6dZ` zP)7&;u`6O;K*xn_{M zQqWsb9vN|bkP|12bKNE}9gyQ1OJTWLek8PsJ(NU$skIwq8D_3PpYru&@6P}W!j&-q z3J9={@dBW5IjK5fq+$=wb;oNu^pdILmQGQ+f7192PrImu0GO&Cf%+~#{mHT%ORDp1zrzNf7&buDe(-9o7z&cn;=jDejgC8PJYI#Saf`1U=?^Of+WtV*`R&+H0o0M zS#!-myj_UW(OQNF*fMvUGQ5O3|C68@t&X_^>)mQ=0M5>&>Z0Fjtoc#q-Kn&9NPxxs z_0{Q^W82#D)r#_$Nc2@OARP^z5or%#4Q$dj;%^&eo-JuIcrUH|9u8IxRUQ`UqVZbI z`F}Zn0+-Ke^bPK%I0gzM@@Z)&Z9OuBgD25l23-J@(}ZfX-wH94NWC!klFaWMD1~U2 z0zr0Ahd`i2(bp=41=z8ji4yJ|;X%<9L<(varg<@H-fa?0Fr#g8L=1Yu?pN$$x1k&L7&DYGXP~uq6ZLM@^4~2aS$=`nw62< z9>o^Wn_!(qOI+(@cpK3_U&m9B5#Iuy$Gl6vv{)c47fF=@#r!>;bd9yn4yVBp3A{u?N)X^47MJT*1LYhyS*?Jy#84{@4uG^hAZRZ_OrR^v z7f`yLrpb>xX7^u!4hn#VHB@I_2Ae|*vS$>91cY`2PZR)})rwa_?~~1?MYRe1HIQ(F zKNv3U&63kwi{E>SYkgO^X)YU&W@-M)T_ky%A=3sx8w)lrfVQHvQUp>^GZ@IhG;5P` zF%T-Nyk-zNw>1^asI#khQXn7rsd-EgaYfO%zh|M39h`LxF+K`kXEecJkyDg zX2=tdh@%n*yWUUCp^}WygmDfG=*wnlq>W*b(iXPlk7KczVMSMgYmyt-u28!7D8hv4 z{U#0>rc51BjHoPv$IY8%K^tpODkpe{g$dYt7{Hx}4e<`y(XQlg;=U@nzH*vpq&l|w zy|A)Nfy(gUrzU|n8+X_*4kQ)Dfuv$Vaa>9s%;zD==;6a~nzQA3o01A7d_ z%uTIjZ~!IN0QOxYVG$9bRUX~kk+6WHh0s}n(tyOy21eVPTf<-hX}7frgPrS{-6f0M zTjn*p!9oYnvvNpF1=xPVV`U0^k9!Xq&)7lt$4Voj<$0VnR0i~@vJyd&Klm`^sMb9% zGMtLTASmD>f6s{kAMkm!s-O6v;aqM529r4ytgT@aiWso5fslCS8w3;(5?khg1!AD# zpr9h7X~38H!4Ie^8It6oga4+RU?cVydGPrRzTKBlaEkos121W`U1y5U%^{vrTdg?LXsVdE!PC#t8PCcB&A_*dCO@kl@IXN*Sfu4T zGOs3|St<}JW?pXSw9;|iY5XhK(dS;A)@@<$mwfzv9f1?~8x4TT&aV#3=>T8+`ulfY z-d0>6?#PgFVE@B)eT7L76XnXt!HtT)e3M^w>9xwN?Btv&S?}*ypzAg>a^~~Gh_Dj| z-eajZ$HtvwEkC9iEWs(DPDyc@`-~+$vK;mJlfl;ff!ra!mb!4jk17uHrq&UJwrD*F zJH&JmJa+x8lJF$5@8})flbTN@D2zlbqtf`+&L!Yex`u%J1)f#f15z&p_2gWwI3(r*C+gXbc@MEG}Q1M74Y04O1 z^?)Tb1oe!n^V|u|jYvvpNs=IEJr!VRgof2DjZ+e?Gj=%SRW@Nrb9u@KKtq>;gj6kSB-!C9?$0l>Xojiwna_^mC}gf?QK$}*^wlGm6|$^ zqw&EX1I-AEa84TIf%i1$0}Ia;-;(3{JiQkYF~vR8X@>LxL;JZlsjnH4+@LHC89g3tzyGvb z7BG;X2oI<&X?h=9f@8oGqxyY%;2odH4a01U)?r&~2+<;i$MaTbq))Czwo7l31B_HK z=KypB=fFFT-QLqj4Ocu~h2mNJ9c$ZkH+_Xd+d6%Y^IdwT)|4Ac*4tR*2Yy88LPM&wKWd>G}h#6qsBJ23jwa6P^67a05K9 zd+PeeY*5vFu(%~bM@MJk!S8qPdS+F2j+#;yE(O04L6&XLSO5;hX2exD~ER%n*Y8fwZhj7vNY5Htmm8a;8sfU7}q01e(+Xlw$6vQRM4Yamb>#Y)=@ zOE_#j-`Jr5RNWb&61dl+nR^WZG^aK2$?g+0N*v^~554Ln2jA$}zA zgedw!{OeojPt$jY4}+)kK3^*nnJXr>j#66WK(6z=6R@1!V(J9Nq7{YS%SCgo9HVlIXskJkfU?! zk2zFR!*fA|h5<-ZLC}wl?l@TMeb|N&FcNrzA%;Zmlz-I5KXqXHMxKKj7IiGrf5Zvx z_NJI+ixo~Q6-LhPZwwyq?@n6X`hF$;x7bOxdi9ra%f7ICikRqwNS^Zn&c)jMrAniW zSn3ZR_R_N9iU@r;Pgc_J&rlL=Ar=R>)Itj9wbXiV`|pFqd+y+duWlJs3Es9-eTb=3 zLZ7aY;X6o8HGFMMg^ubZbx-%pGB6;=U%nLfI4%0sdHD3MFa=lthOHYGk6-Kt>GUiA zib}PM+AXfNt1t&&3FbrMpSPSX?3=d5QiA8QBLSpnJkvq9O%|Nj|MYVBzpqhIQDVD0 z7dX&|q%=6G0~DBxLcIGu7~stNtk@$@LC-%vh^WfqvG+~Aa9#{v8P26jqFjs#EufUg zY<8h0*S|-*QWG5Z#yF;7$2q3WDz}IWEsXpWdUoQ}D=VHGJeBS8*72hI@rHR=!*%v@ zB-+%fy>;*~o$1vMzKuK|d3JUk+c=-O^JI71e=+HJJHBeg{_OGi_hR*ScomwH{MEV3 zy3@0)WwuF^J03#;QU{yRWOfJt5toD25S6Vneam|)b=IAf}oDX?;+1ny82!3h| zMAtKFAba-OZp)7%PkRw9T&pok%JmV6O3xP_1uOvyG!QDZl4V?b>{#(npx>WRKLUz8 zhby7O-W0#=!YY8U0$1jHJGb}eRIJ9AlLau=vGzBi!w26MUv_red^7?t_rrcN0CmrW zb4N+mjGoid3MuOBz#<#~m;tQ63 zq`H4xff)9KHSGPhjqeE^@+~2U4P2~>mm0a)?YAd==gZkxEV5Rt@?jZ=4pOG`RrhI@S2c} z2))3YI!huKGfrOQb!LbwP%)O+PGo4?X-wP?<`S=eqUJ_7RDJ7$eanz^@d?4j7QjTbvE(c4n|3Umk-k{jNd6q6F(C#P34qBE$i>ZUgzN>4-=oy)YqSN)TXsC{;2boiIx{5TQt(@iFAM zz4^A=%yo`=E5c~?{R@t6-J6@$#N8TSF(x$}P1=`HfP@qW(m=7DO35^`;j4&_rA5VwP|@a} z8l;=@(vq6V89~IMRpA9v3lMqYgkBoYxk-^1$>A3vRJqekQ~GB*GPr+tg%(jWC+E}I zQdTtQeMQL5;S8r!@&r(N96rMP=XjMC-rr=o*|Dj#-rXH#vw@!}(lv%R%wfg>kB^)y zb3G1Srow-UC0`Dg!A0&jox8?feyh{*oAmNdR2-X499vmT0l%pnPTu}Qv5uSZ*q>(l zPM;73h0J|y8XjQr&c65nnf?BG(tc09jqb?mycR$AqP=#drUWk!A%(y(S9JWmZ48l9 zAS~Y)xjhGQBE7uoh2Tqe{30rsRS`*s@|**rTHu$!?P@bYI??%`HJq=}x6a<);sb+>_Ver3m2~ z);fq0-_y!B5orTPz3+#$4AhH$v*X!BrMqqX^qq5?A*-?(ago~ogE(lD&f8d%Aw4ib z%Q@GVIK`Xkg-dg0n`KxfRzzxFbw=UF{M``#3}{4vX5)IS$!?Rf$c~hQW;t!H4&&}G zafeX4SWxBfQoT5~SOk7IO>u>H-m+Q!G0NAob`oG%q5Y-H_>NUvz8#>VZXz`fUHGE~Jt6$u*wfm7JwzuoD4CBY z)Ov^sVP4L(GB-7iU5>H(!fhgCW=4yrm-&T(ojpvoV_gSjeg3hGn+`&GUV<5}gK-Y^ zj4ZUb3l!aWvV=1X@|Gzf%stLAeE?#UfWoh=m>moSUZZ%866Z5rZ>)FA6sFt~ZX)&} z8gPnfnSmn1sv5V)2!C)lNr6{QOqA-8zIt(Svn$B7_A48+TZ3(E`X=_VV0AWAp%rBf z`wKPBL09lSq|@3jbltS&d8rBq)=0|f?I5cEn#m8~@4eH~EI1`n$KpmPjhy2WxNSzw z8`#h?P(k?X=-k7injk=PB1a%ucG*!+Wz8LGB&)JSIf=t|dwZ)AuZF4`GeRmB-RZPN zeSNqpsKVNzFH6YvGo&~K)X}F+`QLx#r2b2r*BaSb?5?0K+LvI2;!tL=QQ|nmV2@9r z=)cBfQ&fAnnWHF{9^-B&+7L!wpq6JHg;2G_{m^+^3534;!>Q4oTH(ECu%(e}@?hxc zw#51}xzNosy}wwyXDyQr8($uqi=;R_`BcxU{1*St;K}91)r$M>*%$TFcBRXek7T9I@ z^~RF-gTeP1Z(~39Y*JM%p2@rA-T0dI-$PY*n&?PeRhA)Bi36#aXx6i<<+yA`>1?yC zlZ=$)j;u%p*&F3S!PmYngLC$AU4L<5NEIsR2(=`cE2=5L^{8QdtO;OS@=J6fhE#dj z1kxB3v@oNrch&`znaD(Hw)TQE*6aojMP8Hy{AGq4Uc#|kVf&Au&r|$sX0x##H*6kYo*bD*U=_J!^lc(krJ{#5F^WWE1q$V;SYhpN)K z!I}|O`?cd*xRWjXv~?)3LNOCL#sAJ|i)raUOoo z{p!Bpy#VQubPe3jSQJkc`!3H)ML;TsD9#*ll9umYIXd>xD@+u<=(+cBUfMwJ`9t>-#a zOvl%$DTh#6_o(feJmfuRlSD(`RcXurXbd1*ZpUkHeOko51wJB9ujIx$0YM-yI@@Y7 z<yFPVhp;CB<_GO;)!J-y_&+QWR~w)vN_+yihpq=h<;{ zyQ&3!=o*8@**B4=*-5QR%33dv)!wWtdL{0?6R4yo*vKB_M`+N!E-=!NL^&F%dRJa%TJA}FK~xk_zTAd)^8($#J+S7>{L3{8 z6KglMxUe}z4P38;f1~?u0sMff@MmcSDU0&=Q_5wpI^RSZDhygTB(E|eMQ+~{l3&Kj zD&|ezu01t}_subQ3( zOqeS7BVb-1{b#1q@!-$Qqn(TOqNwdo-u@Z(=?kWM)_r(82ySm%zj?a9y<2>*)9?P= z88vLiSMwE{S`JZ)1+S~J;tx{oX|IQ~cct~8oah?Hd&LOoJ=FZ&{d>_jnTSMGGwr9S zq0vR{H(8xm4r!*Tv##=YPmb58dtdG@#Tli&#GYNtF$wD=dA$^AV#dNoGoObh?b?Nk zd*eH&w-=^2pgQ zfgkyQv1F0H=Wpt>xGeV{AS-Bu*0vC7=)Zs0{^NNbo52S=vzzP@9KJ~3;eKI3iN|Xi z{hHubeY)2ZUl8^3l!wF{_fa_GrBO&2Sp>!$@z#840q+E#5RqkO#l_ymBw-b!Hj# ziD_SqG)1X&{z~!mYKYd(Izt2Rl|FIX6uc?jn&Ds|nOK>L3TEjJ}^90Eze+wVT{_|lLc&w@Cpmu^;16y&y*0W~K zQjkdj`r2x$nR)!UstKgM8QLu4b$y@f$df9?w8i0ZWPZa?ney%P2VL9aT88};w9Z<1 z2(#~W+P)qE0vCiLx)L8QDWGV4ViPrrohV^zLSeyQz}v*ofBB+}U(BGeuMHmMsq3%m zu*G45KG{B94=(!3RKeg~91#>UbkkWyNRbN3Yo6RNDpprc2ACEUx@Kz6PqON2`?lf9 z`!*cYk8HdhUQ^z5>K({tWb>|&^#<8|-!Lp#%}PSI-MGS=JVYtYuA#A@omK70hRf+m z7(Yd6PntPl3Ed!=RVi@s<$*qC3bo1iD{Io&`It16d$BW(0P7yZXwip7Tkuf?#-1`YR153WHM;+AWLWS9?+}mDFn0q1!HjzT zUjN<{VHqL;2beI;r?^nTz_{@akxEY5nU>n5w@$EOD_In)fo%TK#8L}_hwJIw%J0x6 zA)Bv>Pbrtzpp&>?%>B*mHVFFY2;q&@r*;+*>C(Qqdn)7{=h?Si#&3kePiL6=bfNxs zsj>Owt>MC%a;)UBC(B_X76XIDl~Jkcioe0B*Z+n#s_C^I4sk~z<{^VUtCZZnYpKAJs;E{S*9u26;d^`pg)x>?jj{Sx;X4dVXoh=%G zpw1P5dvjUouy?p1P`p~f_cQySefeagkgEoDI?tC%<6^al01E!#)ER2r@oRj&61_t2 zfXbX>KeBz#_EiTg{ARA(Yd;PO>8l1y`J=4c;=<|}!mkTPTSXR}pswIbZVL%XkM4&w2IAQ44oGeY>?2+g+quR)wUCW>pI;ZqTVivD*_z zcY2o=q`vxK+j1d(-%s^E!RY4PCD1Qr`=z5qUS;cA@;&-HKBH$vXuL&4@(p!u+Bn}7 zR){w2PjhXng2-P<=uyeFvx9g}YX3kV|2W~l>ajtJrMOYGDFb#z>j7`047GGuc8FA4an_Nwh2pA}Tplc! zGF{=)YT!6E%G_ErQ}3R^+kOA4QWx18`&2~!C??MB%VNpQP!4@Z-q2i6UBZ_qfK%8+ zwu|Qj@mQXh(``KI?k5(m#(}tU-wg9hYhNf zJy()-xBE93*Dq+U-{-1^UgPXfTAoyghMkBnN1XqN-rFo9(`L_9LmA}O~g=b){4wwb-2JL^&buTyt93# z!s5$vKu?$Vtrr);e!&#z%Q{Pd{@Vz@^JI`djhn^u*D<1}gB7mOZgn=A+I(G~O|Jc= zecAW(rn_IG!?T6x=H;)_I6+mYLMPh?p~Juj^UGf|zIjb+qp?dZ-fa2l68rNk%wBrN zsSCHgu37N~jz44Z`>^{Te_roB+qH?Xex5ChrSD<%CrjD?+5*()yIa!>?4)Kgf8A4Q zxOtw6LftEnm-8o6IAA2C&ON79&`%hm*f~txN6Az?ZF(K}8$gqL{^#F3q^{2#n)Y-o zjJ&kuXbg-~FK3RU4DF}BVwI99pT9lM#{yly*;k)8t}mS9rwTg;STv`>RfpeJ&xTtQ4MxIxDZ`;BnS>q!bXG~53B zX4+(;yenyvbHKr9?QAfLll3c|fugT<^3Yn%Z}#TWm6}rnyWFA}!`z@#luZ6Jb_VgN zBo57NeB3r+@_v%~4bV~ah&io)LL~W6Yv@=S!lDeoHGG@~V1Fr4i~Ujr4LFpf7F)K= zZLK(>QX3vbYxql|<8_{q%d0&m^JwUARUn(6gpQC_J6nw6MAv3W&~t}DT3W3s(xV=# z)pO!XHc-=feB!sF24ybHCff9+65bVO-_YkSg#ww&U`%ED8itlF)&Lu*d>qqza2nn&c6Gi>f?dO zz&!IK)=+UQO(HA&FR6+G^FXKM1Ij@8V}g_8lBya(I_Aqh2lG^f82yy%bD*K7LEIQ= z2~9_jBuO|I%rOQDQAf{Tq5&8`>{k^OeLXz?GJ|_uYl<7oPNMVGS5UU{E-#4ykh)p9 z0k(}z{}A38p==|ZNtTFU>o*onQ4;eh(HU`F6hMbS7!)$V>|(TA5+K}T;FnhIHNDdy z)#EH!z4`0;qC&NEJYQ`~62n04{3RrTI>7fPu?R3!DxHNkUJ!!9pA_XUjK;4}3LRTn zCurX^k2Rf?5R7mQJATg*4BeVPy1GSuEnW1<{L2}7H^=+&Ri~v$3C!$)%TU?6z$pwM zb#d)1H-yvLTZ6OVx++8t8m2v=3X!o<0I+hX0O1aV4%Dvk>U(?*Jeb!6*2CFrHah2nAP@FJBS5qdT%=xlRY3!`re7VT91ea5?8 zR<<6N7-yH@Jh7f2iWiXI_KI#XJ+UcB1TGuZRXZyU;q;7$oe_APvwNS^zwOm^iV|s= zEl9Q^fKJ+`ON@$qN*+LlXN}Y+!Vb`NR_{6NKe{dm72vD5PnQj(EBr1oJEmC3HZN;Y zxH&(!%`kgWrOM)o=g>W`_S{;xBGnv+j8v+J`jPclH7n1U__D#R8IqJs(r&$UfV6l; zTAR`;`t3t@y!>zTYRv+sx92ys7QRZKL@#d=-y`9=(vdQ$ulD5^fqnU>DDWbL*L=pV z$wbZNZZC0{mpl~b#zN&6x->;=q@h90(;}o4){4R>ap$t7kJLt)KEb;m;MUsSFPHNS zrb1#DEEHs3HZ)uU{r|Z5V7-RDO>Q1F-Xb6r`YEOJ@1JV6M{1-rq~;zUqOMM;bZwEJ za)`JaP1c4U!ss()1;Aspu_B7U4gaZ_fEmsl%y<8agpMkqe}^B@5v9!JTsmb`vf_5e zJ3TGb;d0>-&!D6Elxo-Jja5ef0@o-bb0Q&)aHX+_DE^kH4EeMpHcXRAHvptx6yaA~7WgqC_!~JLi?`qn$jR zJj4TA_B!q_7(?BUo@8j7%jC{JNP%}yJK$foqV<=82SviC z_P{*(0t+&$v}sgD((GItv)E$k@j0b`I>-1#%a(|*>!Qc)c#t$DcjT>uC}s-y7y7L& zuV;6w&g>0@;kZ!Qh5k@4S&gbC)5i9rS@fCZAcbQDw0~|p5cU`nwjbt9OZn6!O|+Y^ zdDLjdV4h=^vz8YGYWV=M7UNb>{(bdhJ^JFJw5l4V&fioRR#ZSjH!em`=SIO77Js!vQQ+MA zh4_TN>tNO42@LO@zdV~A)oS?N@B4WqI&un$XE+i$DQN7)6AJlYDV1^2%D;YdhvN1P z^Z3%A|29PWVk5vtemwXz9xAIUtQEFcKH%#RZ&k7OhwpNS6=7W@G`S?R$=VGgNP45M z5z|t8MUfrqF-QEiXPSoZtiI-X|5TfS`cO4lt+qFAq7gp#y2xYlrD zLr5S2{c58Tic>^}4Jk=yOd(2VOc$y~tn?A2ARc$>=}$-{_|(t1=B*1}E=U4F<^Wlo zJyH%E7olZMqRy~{8o)^*+NI4BhTcX|0FE2L`jfTB0+G0dt}4l~S4Ej#D{gH`#0#dy z4Mn%rj!>KWpgCIN-9+;^aOmkTi*D+NwBmyA@Xj|yWv6d4=s6PGs$-`p<2;1nD8{bs z(>bhX-fbHJ)3S{1ylD$aYY7exD3Yi=Iux<=#{`5kz$+6o*LkIhE7YPOytIS(AMxbI zwIRO%_T{4c>zKH5Gp-y=6!L5JJ%<7)OxwOFVM%t6=QeN*zMiCIY@}yvC5m;Te1{^6 zXh*8iMu>ofm*L|LV;UtS9Edz0b@3}_4@>@g!X5ASw6mAa*S%@pKFB#9(N@Guoh{Vb z!I0Bse7SNpT)zjy2uFupf3<*$MJnm6%fFE=XHCrzM#Z^-`@@c@VLegAx7-c`7mg-I zlscp$xDFki8Do}?_WVleBJ9FwGM-h6N-gEFD zB*!fo9ES95M5n8G?aI^3>@T-O@5$!dtl97P7W7qm4o;TCAENFDc#$n{!_@hC=I zN=^5YyOzmBDNTd(A;ZeTVi>&nTw%sc-y_tyUP$I2T!rDv!nrdAMx?`qBaY+r;ftJ& zDR|;IgT%YE-=JY1xe>f@Rp^V#3 zR2r-66jodoQwGx>LlzMse=Xob9EXXCBTq1$Z-BXv9I0#oUFg?S=1vV#xZ8+kgpuB? zm*23$QLE(f>R`)9=u{mt7UDC)Rn_m<(Gy*qW4vklW!JK^bgz#HsYy&jna<@9V#)5l zOr@IkG8~eEY@v0!MfNPiEBL?=@d4(J#HWC^`5+4$I&368Zt>y!{4M*3ZZla+-AX@g z(&_M2w+3lD-RY`qyN3rYEL@lApqQ~jcS~16xlVCADJ+OPr~#2NZh7IUNK{QIu><4R zRI#&*r^(@)FJ-T%b3uvH7e#t&_Q=O8kbE%-GxC1JdHzVOBE7NTf>07e!0r*+=JOyq z9{D%|R(wyQttRV02oL43b8B)o+kmOXuT*>C5>%|kDq!h^O#)%nc&zbkB5~Tu_^98y z{1O5ObI1-y1QSR?>WDh|2aJ`!9tGk^8`n1iKp}dJQRdTe4TTJa7V^o;-ke0kBG%T3 z2O7{Z4@^az)ojcBybAwCkqrqLR4^tEvo33qjd~iFhat!$<`t|2rbQU*a?p`kfGJ?xb5A8|KD4&bS zeXXy?BaCPBKh~bDNLGf2!;efZHm<`Gs7Ed9_$CtjK0OCbOvFqKiiv%jrT1$R$-HXdh z#Qp<}hXYk;FeUrZO6hKoOHHUtTOx#z+UPv^l?ab%;Y$nGsUV-kwSltr8^^j%KVQNH zhKl2|P<8J9k0s{qwBj#hMsai#1KwWJy)S~2(FapW{kp|g)HiSTuTI?E9oYu&&*@%u z4#SO&qoLs(Ia4Pskq0`NwJChHTV5F#^OR3+5gA3TXUMe<5ct9ZgN72SqS(uUn%4)U zSWUbYBmt+zQ4$`G#zNbQhR}rTk{z7 zDBtrx`(bBWcy22y3F4j1kI6E16N13FT0*i+P;&QNCzt! z){0*5JlpCv_n30S=W{XMnT_^LNG$x~j4%^o129Z(mxqQbe3mRTPEh%T5=L4W)(x;0 zAV{Z1nbzNWnHVlD(SPH|a$Bbvo^y;&4Cer-e+@MdKK-HlF zv+ns*=C*h68mdqI<+`J0%RiKH2|`%F(7eaZzb8T1tP+v+nOPtwu8IAmB|;!urlk}{ z$|Qv1B_nYwr1cCS(>g^!5shjq9|Ug^QS9$Si1p#1boeIinF25M54R|=bh^UAdy-Bh zKvXlO_}^cxhKR@yvyq5n!WjbBsAtP8V(2UxRn0XMj-$&VRh!>qmrD{cy7{i}>E9Y! z3E`qd1Md!vlE8UW)4$h^<$w^tW3bAz z*0?iKzWYZh>rNN?99UHNSHbm$@KZC>6*{6**XiM>sWBBT*)@OMj+kMsi+2{XVfpPA zc;kYQ@j}vqM0hV){BYmjR#fm*(qpQWvR`L&5`o|yW&eL|eFaoh?e;e%Gl0MhAUQM= zf^;_yDbgq)ATTr{-O@RvgrLBHbW4|XjDj@M-3ZcY5Pk>!*89KjU3XXq)?&^6?L5!k z`#f>{$VVy)AtjKn&1P={&k`mWQ~bpr!qDJC6N(F!7fbs_RD>u7^)8mGTn~bL6T93e zqNE z)dM*S#_2)RMR|T5Q8g%Xj-##es8=!f=` zryv)7?E3~Sk)=zPhpgwk91ky8H!?dDcWmtYM#a9_pq4gXx~ME#Z`%cElp71D0Vw*r zy=3>`L+X7BuST`LM3*7 z8(WMY&3-b?7E*saw!jO8$51HHg3G5JVgxTDp-iT2R3V$Kr>LpM_SUv#CSpJ}CK`u3 zA&8ZDjn`{CJXwR$)Ta?Q9gqvIY`8&5I6nBF%1fHH$5;M@QOYtWMtra9(@6 zIuE8wkLh{oat@(ip(yPMv}h5Gg}D#qV%8a^CVKMDF=dC?G&K+)R3T&wseL2MI39bU zuc1{@0`&%US5il%FGCzDNzW3&2Kvr6|7+5hBRQyQI)JsE$-B{e3!CZu5zQG_@AdOZ z$_C$o`9wu`IEYH_SU>9N>DXWg#yD$neiHPS@It}&$&1q!#<}CBtY_3m{Kc)c&4c10 z(*!vkXQIkuT8Tw8YNIt|jA}n82XvXK<(|UtlThB@_OyjH6J-#5_0fKG(WpkTq|8p1 zj^WVUnv)0Z=ePJ2j?)i0QaGb=D$3`Aiz>wyY&!&e37ISL525%70zLLySX%42Hy4K; z{}>47$Kq*(Xyu&zvwXapcB$F0Oa^SuR#MGFt~+9SXUl-oQknBL)R=bOg?JeXAfcE!r9E=g$?wg3?VZFjh-Wl*Ono^wYh5(?{Hg^6Ql^z1-0f!jBfnld z#1QU8c=XLy6>>|!nr{>S(>1V(`t-Il~n)s)bY%9qM z#@3@at8zr{2zve^c;D`CxhG}MSJz$ZpE=Z@C7$`BQ*FNJHNxmK?+m_Q{%QxbfNtV0 zxah4tKcDZY{r!dyLi2Q!A2n0&d|gT7&`X-VquMromRO=7BP;EMPyydJT6xpeGWJBE zXek~@FrOqEIwf-NeiaNfmcbA3U35b=X@mc&b*&F*X=e!o2VQ!ma(6Tld4$2T6r^DG$>LqdUEG` zJ_CN85aGA)=Hb-E*_DiD;MmD`V?WMdGCz*ArVYjez2f27F-3AQ52_-l!!#a{Jw&kLF(Sm7Kxk#c2tqZuO{2fmLoBvSiVidD7dOU@;5S!7i;}&x zS*sju-!>#V_lZhNd%}*!6bn;A^OH1*=~KCdnS= z%i(Bg7+z%g%iOs1jCwX=o5gLbbHLhL^gX+T&(4yQ|vN5kAHoX&h9uwtF(I9`wN6d_$m|P)2E3{#R zva+Aws2}|xhiEEM22mD6D;ZcU9>`bn#j5d|J3ACQovoc8ZHuMz6xtk16IsNlLKp~?**b|I55a8lOPES7BT%5eX= zecthTynNPNAUEhhOUQPVnQEE^ z*UD9vbAfYF74D=}cK?HBJEOqFTSe39c%#s8)#KLQbGTmB>VZqff$QM0^rw_thSpcN z0KeJ44bS!Fht+dT)DIWVR2P}iy-2C8bo89n^cE@9i-y-_2IqW1gvRaQR6eMeL~E-l z6$DYL-1+J5##d}C*o;Cu@PhY5kx@!7JCdX_im4d|A2Z_?l9*v~ccjM2!|%sHQ9>-# z*`rM_@9EdKhE6W@pF7+N6-d4-SbPzkDm=e;}JImxa4& zGh1@|?1E2+(28$7C;T2W|5Mik)^&|#%(47{9@zbFWeu{D%5sE9j36O2upj6nk4F`g zr$4Gt*Y?T4dXU_t9)s?yDOAVF%7m3W5|hehpSKsnoZ3=W8m+RIGvPPn4oaX+$`{ID z7}yt)7oUv=qx4srFuE$UHklt?sSoJFDdhCwFQKXT3p^zyj*Ly9W|ng%LzLW+#bi&f z^~c>O4S}IRlP$La;zpvlOVu~3T-V28DYEVJ!Mpdjfgj`L*FlYeaeks}AN-tek!d?@ zbn_YIfE_fH5`ri{6EO*_SZO!g60bOe+V*ap?l4tLd4M(Y1fDZt2~iRC%Dqqv|8+mL z7+0jLGn|!~-%!~kywdL8_Y9}X8Y1i?h8{U8+HhpZL!q5;(PMh7>hwTf`XgEw(R}%PqAJ)p)QUmz3ruhs z&|7OGYbZ1dJZ=TROd;($@VrHJZ^I%o6Y~pCdkz7ekK?ybqOtk4hmP{(uWood3FD4RC>4r&)N2 z)U8nt;2678AcKU6yAYw3(?W3PAK8hNz{W@2<6(PjhFnQlBnEb9uScu<^XtGj3 zo>^gV(K01sQmlpv-UPDNx@lQ1TV$sJ9RsKe`PEhPDrG=7gl5GQu0cYRj5VSX9Hhsd z?Q2P7m77jrS`=TQE?dr);+G-B0t_1G?&I+c=Ns{#`#n!QO9$V$3H?soufChnLO$I_ zGZ3NIa5C5Z#<*VQn#);|&B=)9)FRh$Rh`|e_B!}GNr96|PG3Y?6&=%71_f*kNm^*HQ%*X`loq61yn3RiV z=he_SihJjR?06sFWfzREV|acdsi=91bHt$35@!cRUwgGGimWlsnOC<1Er*@oz?X=% z%6f01vKRX}W2dPu@$mLcM9~A(&aF1$hl)UiUb(R_BS)K0`>mc|CDOII%uIdm%<~wr z^Oe021l9j}{wXYtbk}7f%uVyfd%Iy2Fz(EI7&I~S0Lh~M&E`Z%NBde*| zml*9AihMvJYi8XE28Q}D+FQ&>sj&jb^n>V4o{u~tFZ=47FZcZ&jVr#K`3hzl55GZG zwr%m)$04IXThs4bKc+)$7c!H{#aR4eb#n)dQwz443mK6fTC-G&>kdTcgdpjh`7PlKS9@x5t{AK6jdU%x9Y z_sj)~Aan0?WjRFd<4YEoh3S*Chre&DG4y0q z_3m(C$w~GyR^)#$KvOYJ6VkFzmiFi|AsTm5NC7i?k&RJVW^X~7L%4(hgBfU~3@Zw2yTSn8J>rXS> z?S`*Jh;7v`_>$%aIU20Y_Y3SbvbFOqRLDZ<=2JgNqM0<5vV$nqT*X7TSr`0Nz2`_W zV2|uTdoLm_WPyzZ6u3}>oa#XA(>q~M3678xZBSQQJsBKWU8cK6-uVI zj&1V%Ap6Js)2Z!M8neLtOzid0Fazt+n=-?SR)GTPM`QIaoE})zwa~JA+ETqQOupyO z?K?lI;{==IVQbq9Nt^>F#`tL?Zy{Lfc6X)un8R7EShx*56zMz>iepN95D_{jn*`p4Y#ID&TVMB3;I`#K`E=$Tp){^Gr<{3hyNYJLp zO5mdpX_r8!I96&buMJ6YNP0R}ZG}#o6k_h~d7ovKSJ*4caT~AW+z05+Y{gyh(8?u< z^4y!u|CkPj6T;wP++IY4OCm^{9NIKWCIyEsxSf(DLd*5!5(RO{B4=hj=R8*%w-~wg zL~oO-RzG=bJ+REZ%@qrj9IHe}SZhRl|11;Or0>z$k(!W|v^3m7)cCz!%8R~;83N5Z z)QrzMmX-Rp&RY&oes!zzp7nc~`N}bzg8r-erP&D@WMaanZD}90$4ZA9NRFU9EH;_? zUZk})+d03pWv2boCf~(kfs)NFt3ma5k15Y6RN@i@ z|Jv886l;-O#(I;*$`U7{InHhUcw_}>BSUViuL>P?LlfC)#X{a^zfg`LFMd-6`#jZp zCSN-=3mnhDHTt^0Wmt<@Kz@e&0Iz8&Z-JQd|Iw@CK_)>Mxe$e`1N%u0vD>X=5=F zENX%RuB;@BC_Khdw>;c$iaMuU3i4x6+9Cy^2esi_416-29g*t_ASvkknj(xN235h0 z2YasLy|+hwqJl~7JNM*(`~i@HfC^`H;8BdS7b$b-AAmp4GN5Wo{#oP`;8E)15VY@9 z02@{T`ga?kBL82p6#rAKnaV$6S^gEPhMr_`7X*l?ezPay)xsl zd5&tUOz{6yOe|XQdbiO(Po3ZF*Y@;92{n-jipW-{A-)@krW`DTt#D!MHZ@>P8!B!K zgDS0R@0hD>*eMj)s~jI z*BSWMNWa%RHNkfxov!iS;R4P?RpuyW@ohmt7@xRn!@d>ckt$A|XzcK;KUSS>Ja%av z-mec!^zfHIz7*K|E*E4SQELeSw`M*lU@~0)BnO69NZwQj$$^v$(g)`=*byEG9V4!^ zz^9?2lsM}eWFgw2@=8(hf!H*?G*!p<*7LZhCJ&FCo4v7QIO*LSfLxpzhKki}g^)*ws9;?}Hp)%XyMJY>7>N>u_qRjd(p3Nk(n7=+>uNk?AJjh}V0_sN1^ zuxy8V4Bh&GOzqF$QdSu_Ti9BwOob&@q}ew8NU?6;hz_{6kFDO*d1(6KVx~#`4U0sm zOG@-LqO9QE-cQqu_-~ptG1Flfok%LY4rD6PK_Ab+S~Bj6m)n={T$w}oFkWKs-GH}5 z?Mj??C52) zIz&sBbdK3}jM-N;k+P{6)$$A8(hy-aJH5m|w4kjye4W}E*roF+5+f6FqJH=~K}G+a zVt@nV>+?vO_g`MLRShW}43%sMMXnKV`y35m+Gsd?rIe8$OnB6_nl2qjDfiu8Y zu)KRbNHn4{;MKcciyIO?LNtC!Lo8I0;-&`d<%4bcn?Mi-W?sf>o~#{on`NQ+T=`+U zk*y0YS7)E7xj#!)b5Hem=P+#VU01Fryf0)gI&9o9;lih)TNfCpMqQd)Fl}ibTokH`YZ<+$jv=DvTK&T~srEi8 zQ+c7N=!*XBgYPL3`e@rN)TQY2LoTwr>4E^tX3Z5XTGfE>OjFIPPj<0dowdV3t!|6k&jIMS z6)yq295ch!CPLZvc#qUTQ%zVx-I#z*vifbvI@#S#5;kyDKIhohrA>aX7@^cHk4(gn z*%WvUCFZPP0U{it;x6^v6?Mks6KQ$%JhrCdXOkCu9VZ?A1ihz^+nYVl>JgojPb8W~ zJFz5?of96GEc6KYbU;*8-k--t=y`_0+KwR+=w(z2^Dd(2#B4jj8@Z7c4#sZ(S&jD& zPbO(rBRv#z@Adu%r-Q-V1SYVM1?9ADlpNBS>2~O*AXNgbu&hlZwT#Q^Nb>Cc6!|wh zMGjsz5>`jZN0=RlNV1dYBX+*04=7&s9^8FMhQ}JQ=4Pi>2#TCHkXuD=y*xx$C55Q$Wf}8s5pFHlP8TE#%61ho?%Pmjw2@YhF-mjt(N?{p zQdDyN71tX_?Ivh6b1+?Qc-uv3+e_=UHXpr>3Qp8}gQ3X&&ssx_cdrpck+EXdU6?e- z(N4$G_<~+&Jx9#L>H$K(MyyInbnxvD?pX0=BF4g30xQ1t>|``o$v?=w{jpB0Szng@ZG<;1 z=PO4zjYn){ez9C?#8|wyXt?U(_Ea5PUC1cSEG&%9yc)M>pAUj7)$iRVs+*A(YtewJXhQ z0V76@_J)if7r90vVK|65O?CS+MX_}Xxnq$~52=q`Dml2sJ;g*-webC%K#yKosAR;> zIxu}1NC&(Lv5wdBX907frU+mlwoMxT$OplWxRxa9aMl${o>y#3%d(^nuQf%s9cex9 zU=VYCZNj??aSe4vn0L-N=|^1hqhj_wE};&wQ-)lqJbM(B6wtsC(BN<|{#h6Doys1l zZ?j|(vx7V&H}}mAmqLz$jOi!g9=LZ%)!}@Al@eZ|rZoaR>X!)inrvACa1VsJ`z&Mo z?Zg?pqA8t6<3bM5&o-hPj;9b+sTT`42#$macNgAb+R6<_=iTs$T(J~aaUZ;!X-a>@ z5MvD|i>S3G--;j^Y1|C8*PJ>E9lh9iPD6ujETt;FU|lQKn@akWV&;wccKLH+dop)^ zY5nQQ{&L&l+5DRg2i~97GN!wm?K56N>-`jApCU6Z#p@kJO5p|%9+8)ZE{1we z3L0)kKX9~am00f|`1SpC<%lQLH=Xc>)rY5+mRMdNSQ9i^f#U!lkt9!S9%Z{}Ub+1I zRSDu5Qh3GqcrYM;FKIa;3Ml%M#GCNZ%Hy|g@k#x@Z#X*BJVkRn@%jPy?YQ()Z`1YL zy}=?!QOBkpB9mf|k4xh+KWE#>P znB44p*z-8x5BPhVJ<(3Sd%FMN`S7|Loyc6U zXFwXtWO4D*VnNy}`tte5k)JwRe8fzZg^e71Uw;NAO`8_z1GRe*-)-zx9wscrQ;g%g zaPscC`;E%La;7wR)fzi2UUyoBBz-f2>lz~)Zich0ah$JnX~cW^*-tRa{?MABFk3D; zbWBr4R55yefdwD?SA35xh_6t7b+G!;5&-#k!%qE&y9V&F*Jzk85g=$kOOlz56r4oEja8D^>- zLw_-*TbE*9{RkTVbz98RfQ@_Ny7rm2$~~_Lr6M7aJvE$PFoyeA^V%Ew#i8rrR5Bu)r6VIW@jM_NXQQmqi&4cR#*DZ{Ov1H~_ZIe)v4$;^ zKiLxuD91h~%m^{BpKV3XQ^s>#>z9#CJu@%U-v1^u$tOO=*R*vI_YUjx*BX4~JV8Yr zpc;B&o2G836Zkmp#T!eej=11Bf4K#ld(a;CGC^EjQ$_wtpPJ_3YANH^%QKlT-Ttl# z73VXPvsNY?wbw>%pVQl~dzcNTAC2wN8p!LL2wz-nt_1u}mqPYF{?#-CA^0V7{BquU zyZXBS-bEA7vops@;r3>k>+k+2`ZFZ$j{eN@9R3mQ*CLv#AaILiys;r18v_%0U&4qF37(K(*P(7M{`XVM<-Vv zGbgA2#dcgg=sO5tPz7Aje^J|F{|B|Xql@MLB6n(^X7vKdB7uwSU*r{lA-wE)Ty4x; zEG=~0Tx=bzUH=yXsE4jUkJ9qe{K-myzMRjC+Rs`rZhc3x(-~#{~}EV z{UP;qba{?&bbS85_*(De6iom`f`E~z|3!QT{zLrNi5;GJ$ve^~s`d@yTqYS9rD z!SEgU<2y)qMQ6F!8Sckm0QAu?PB)Mx;A6K%82K?bYC-@`UvIR;Ta*C*$v`8w5yHcu1eo*sF^)Gr~25X^u2i_^w14 zXsVp`)88{_du1epgGXFMloQ!|2Va@7vCwnPwIXr86T8K*1kEo)npu2*U=8x0jxw0L zL?xj2N3G2ycQ}utO$CE=o`jnj`^o;1`l=~4K8>2bbjyT1@WJ#7F2=&JCyLDCdwIg8 zBn$f`iGikz7aRHlkc1d#0woy~1sm>B;(*ChAJK(e5Q8&Xbm=h#7`S*^x= z>5iI*#Z6h+sLzp;lGy0!?u%)$74F+(X50E?8Fd$oknUDx%qtFZn+qnS1D|ZLr@WenW0>u zf%}SYCwGft)+trl-4-i5g1Dr8nl*&^_5H49tUY!tgT+hE?7igQASfbue`Ti7yA_gU zKZt+Uv1k1vdjR4t1M$CE2Nm=UGY3;8X9q_YCSym(e{Lxs-v%kcWyzsF=484^eB%&<%Tj!Tjt1Ux~@ z)V$zoS|H)TZb+&onzU_UzCFVGBfmiYqqF1dv77{2Y%A#c|8F+h|D;N-n_@~T>Urv*`TWE`DYES`peUT?lvZ=1EfK<`ON4M2atocrgOBZ5=O=}M|@)xip z*kYU9QcUuh{t;mh4u9LnQEYOOwsc>1d~08b1P^&i28=&_eRv3rh}+6{meZj%P9(wR zp`L$3b_L=><97f~(Gi|*L=Adf*T_-|R??VIj9%Mj*i`NuyNxQ*>Q-ADZC^@AnS&vS z_(o@A-|E40Z$6P3MrDZK>s991OH~^jor+`mwl)M9#;HT{J{iHd7PKcrA&G^GXpDBu zOewcURh`^6E}T;4y5uag%+}Je8Mf*thh)Y5C#U=C8l5K18A@PX+j_Iw@7u`&tnCHB z{}VD0C_1p9kZAy2|9>lDf~@Fi%j9Bd>}+nP>gsG|Z{hOKko>X2$o-_KV3$3?XB&*( z%zsiJjCK+3z(Z@pN*Ge1_ihjNomf-wjvUtKBcekGVH84O#Ls5YJvpwt1>!X`%Liyw z(q!WRK?dx|KE<#3uOUN$bsSr$LtfDu;i*xbUghX^=UN)6dLxXxQP%5M)%VcFNQm6; zpq0XYaqL~D@&v6b>VMsTr2o5eS1()h|17y%P2M4g8Mo(BQ){vI8--1AEhJAR`W*5~ zX%@THYF{5r^)uv3S;)srcZ;+Pz^u|)3;F4uK#-)1&)JT}@Swce_v*P~MZtD~Q0cEe`O`R(>y+&j(xO`KMzZpku~ z#M+@$OpNNMSiZpCKI!DWboLi{Dot?>n|s>}$oM$2M#bZ#F9mn15JIJ4oRRcnFfcM) z!ue9ziW?Yxt>Ldf* z!8^#Kh76K*8MG+g|14jq0>x)=*B&p9F!zMv)(6-8iE5Qwub${(W)6fJq6 z#LXU)!r;man8I$iXaY1^{#CksPAJ4F{~PK06Ib>;E_4JFkD^#PnKt4Bch+us`-c@i zaL;+1ZU1BE1L;zLYt4Ef9}H*;?0qxtoP)mk5oY~wZ?LO`dRr? z?t2LExrp)OKj{y4jDqhTtxWWK4s`#UC7@oQ8 zPs~tK8I`Z079eN;xRaiZOAs zR^hEUDSf|LpfE94UPOnutu;66VxRxXm1Q>0|C-~+FV z?z#DPvd#3zfVDbgeGYwzvZOn~5Kl2HA_Z?=t-q*uxYem0ld`Sd6Ux16x_Ck%v`}7& z94YE?*#qFO3@B#xZpxO%8j)w&#y8a{vyHQ6A>FIcfET`23|>Q1I|6$g)lEJawP2n4 z1Kn$)$wfDHFwn7p@-Gy*D00V$L8jgNUy}&_e@*+}()&LR{NFO1ByTgoj41RO{nyWF zwhy=1p2>8^M$kX7K8>5bA+EG}ytl4%U{MH`_l_d=$_J%MFCZ?2NBK|y22x%(>8r=eBlsCBG?t+;hp+%72y97;QwOR`P%iVh6$_q_CEPR zBIwIQX#ep#n(}_5>h$xHdM(FW(|wv^Ll{gb!T*1P(9#!N&R}Q=hmn0Z5?Ip{OAV7BIEN(*!40opp9m6 z=te10ki@-J-0EG7Rj{Vx=EspfHp%VU{m%JA>(LMpI4As;n)JjH_Sd;{Q}c7H(;!Xo z4Q12qBOkccTf>Nw|8XsPoH1?c)hTFO_o@9^{s4Jd?P)r6S*;bT3mvB}^b4K$Y-(+$i&94op^h+jj?km}N;BwGZ(7b*%f93^8cQBkZ zWEs`Wxwlr;BXo!0rZ@I_dN%9q!rK1sS$A`~TTTtT(`4)U>#d#hQ`}AfiyLF&+W#4T zSz)2&vS(8$-?ONtqwU=>5GkKbU;pU!9k^$mMFM3G{;Ik!jrDq9@5W~ICilp)We`B) z9vE_D4XgO+LgSv}d#>-hK@xphxWl9B{a=l6DQ)$u@jcCONH07ag8zN-QQBqfE?Vf zt^1A6KYVS{7?yv6EAkosE$axMi%W5PYJwUK9ar( z6}+~YBk6wGlI|Cs(z^10;koj2zZ;*!k(6|Z0j#P zn_ku#J`H~Ap6@yc@;^V_DjNE?IN#5uFzJ6R2>LN!5gHzz0?scy`V1}&0lVI54iEV* zU&5@p9{oZBD_ZeXD$2iycuH>cm*B%bLp6IQ!=%P22X$LONXN9+jM$sPZPj7WX0jy59p7wR0 zfS*wgQ5kDC4zGVPKJOg_y&YQ2WuGrMb{^;qKaaaN-~#|}l9#&@zRwt+FEwop1>YaT z3AJ6C#S>zy5K-4H0)L;J-Gff^p6(CPcQa#3V zWpv(1hL6;7YNi<4#iSTMHlp1CHo8z#8e$&~%6(nb&$<`N5Pg|?+qJo#jg)u&UM{3$ zz$Go};(f6hfrQFGz`uNuhZ)L0F(alVMxegslo7uzpuh(A>I?l`%bJGBdRI<&?DH3V z(8iAn@IFH^d(g!8dmtxLttV+{GVWcyZ=LXWHkw?(hI)v2JVV(~=!s+zly!RO_4*dL zQ6$gY&r6&B(l%V}6N<7?eZ62mU!u9T3%ckT6c^HW`)aC~PPv|MT>RC+#-AEBzx9@{ zO*;GWCW`09VM-$bic^P$5ly=6fyR38xTLXwZ{bT<_C2&eE+^-~;u9R}M-b%fndqcvZc!Qqz!~Wy3)RG%|cEU!!uG3E= z=M!fB_@QsoQf7RYDm*2u2EQ&?1ZID_)wT2<2D!@5#$Qe<|^$p&=>F#{+#72jtb>Jg?^K6R?2(5gvI=m|i2;UC%_}$6gmWMXiAm?GN#?nIku5f4=T*<8 z;@~Vl{gxty^s1>3;#vP|Pgn3#)Yr`O$OF>`{r83~*0oV(E=^t3<-GMqey8tj?OKfW z3^A3q7VDif_HrwXx{u3wZQ6Z+jf$1pmLbrk*`RM%Is7p7x>)L5{-eaw+Gy&HG>SFx z7KDEblmvG&uw$9<;zHw+E#TnWOQ9L@%p9Ca_ksAfo7Htti=o7Pj5aj!)w6~mP@7TJuqP=1_2#Jfv&L%FNW5eL!6zq8gQyaUlbUP#9;==B`E zmljmv=7_KeW|zhDtu3<$CK8{axY1|E!hXpJZVzspUHJ3x+(wa4;L?l5?|qD3 zoP2>~E#w!LR=nro&#l@hfS>4eH&jxk=!=r{BoXWs79*{^v(mSaRs< zg4&%GwUQxZ?>S`?mvfQ3tJCYw*3eCX>$Tds$kAV6IPvrQ^SPA0lg@JLm=wqB!+GA< z1GAnsY?daSMU1Ww(Wt;RUnH{}XU~E`R+Xp474nfc?mf6vt?V)b6JF4xD zxbO2I$|9V`{*uu9o%xAD7Z;zcd5YN)dlZGFJzwykuS?QYP)W+ZLpz;vXT)N4{)|QY z)n_&vu=7IbgpL`?Te?~z%1e49 zJpbWgBphX(>q6pCD%Cb{j`fO!Mx!hVU`s7((t;)67v- zJ+vj>g|}SOzecPRvJ{%(ZH}@k+~?oVBfbmDrVFR0lrR)Oh>x;H4yx0SSNP#t;5Dxe zOEZ#-U+Ke0`wHSqF`BCiw$D&bEQ6s?<9J;2mS|Ngw-^ znqh&nIaKLE$7isCZIIkK%0&+CMqN30V$>5g=ij3&NXfiKYATTHupV|*eGPq(!!1L8 zOetqtl;n`;Uv-0I0%Y8(5IoMA;@VHlA*V|9ol{n0D;HVzw*K%k7$QYiQR(?-P6Dx0 zK$-&x_ZF#W%YUDpO@+b3S(>xSLWA>u4pDz04(Z-8+X<(g4JNAdlszT;5d*|R_zGiRIEpBMVKqmg3p#@Nd0b>sCZTnfgzM!9qtX_)S; zp!ox%WR{E!)3S@?iAMlU`G59`A}hWk_xl3Wk}BKFTvwLxd{YSpXs@JMBhR$yM?rf< zjVIRsf!l6g0(L=>XmniSyfQ!i%~hS3vuB`vNWX0gm(;$_MRrW<&yZ+zh`&Af{JEn& zOGYaQ#d-V@VEJE^{q*>XpY4lZU$uX`sh>kGg-ODod+2MvpY2Fp#Xl({d_^aOmJf=yw|?uac0(x#Y~KQ*-$KEhjbC2o1eyVHRm%a8o`Qhx<{rMSzLk^V4RFx>L@gX4t=8j%$j%bl~Bb5x)XO0EesD)kL#n)-&E*Te9BJ z?Vu25-Dy=mKB4qJnxK?*J=UmA08cu8V!Rv<%nrvJ&icsANVm1RuUK|FrZp? znZI|z_z4<@xVIxkg++bQW_~E2yeP4GR{;M60*oxs?>m2{4Uk0@aCh}icXWcrDJe&D zQb?X>p>QyKAZKP(1jze@nGMkqsmdotJ#XXTuZZKA4Y?>cJrO>a+{+2!dRi!yhvhLO zmWUqh#8fgs;!Y$QEAw|Ru-OHHx;tXzv%yI1($7mK;T8ikQi;Ii`ErRS#IG|e)!m=` z)2{BmfP5$P>^HBD=Y^JHE{mWX8Q|=<$mP?+*l17kS(V{mg>O*&y&EJw_Rg2Pr#}$R z-xbk(O45I>Y87Yx1g&G?3>EHS^yGI&$PJZv>8XY3(9(v1QZCYZz82R#VBzmQaCrc~ zR?`B^m#xUQBB6a+jV|#|?F);~E))1T;c-5LL*CnxC!OLh_?nPKB0tC@2(QiH zf4_z9C?sl-C1v$nPc%MDr!?qNlT#s~{=12YG-Ou_%z8S~!vOnE)CPiCkgdv&N;1G7 zf2J0@+CM1vNq9EU?cQ4R0I=Y1Ye?$S!o7JJ^WH;8X?TRf%o~fDVpr3diDVX0R+&$P zXsu0v)94P`5ag)ejqE?6oUn(D!Pe`hzM^?rk(tBB1TQ9N|9yE~@S7vIjn7p2B`Wzi z3E9fVf;>kWmp_=jV*Je)P6gC@EVbsqu)G!rx-C64*!$18El#6a2Ni$dKsS?6h*req zW967|CF0j7K$9S363*x4^*okcZgNK0eA4&!Ja=ZQj&Ga;mF9YuYg#g1KWh^py+7|W zKKBFaKJC4L%^wLrdzk_NU>HMEJ1gmG=oMz*nKZyM{~{$p7G~uNdCaJO`OGPN!R|V= zSjAn-3RFqc*;o9&{bX4wlC&rhyVXvwcM~_73x7i*5uzz{>tRrSCyiM8m*1n}b#gj2 z+scwIJR&!du09WsPX%* zOdE?8M#RG5+f-o%q=xL6!Y7E|G22$Mn2c~+6n5!|l*JR)w1{(4OGBG*Ta07`zkZW1 zhw7-uXDKWRjjzuZ3?^Lo3|9>ntz_SgNk%7>Ds}TiEQ2bkeJC~yP71CIdHupCG0%R_ z2Ck0~7uWAd;;ou0{#r@{K+HOON3-8~>kw^%2c=aC*Jj zo!$KFQq7-7`wS+*m|@^gI8zqvG>WWJn4?H`{`)xyGH`6cee0B%C))D$Z2)wR%vxlF z_1+iy*>8fViJy^Fulim`vm3H-4g&Y-Ll;W)XxsQTq}P(szpzi8Qp+F*>#|=4%jr|m zFrcrA2G?UlX7|~%#LyH~)58wx1WtwRoUzBMxt6HrNcL?8_jAIz_03~5l}I<0@m$J_ zrUI|IQQzx>xKWVe;jO%ZqIxw`bD?c%e$P9RJM#e$q+leqQ*z1w*9F)}QE09=F{ngSq4B6dQA4{wZLLVV*g zedlP(0l}ci9pkMsy3h(dDbFGSZtf#Na$hUNpeQIYdI5{qlc;d7LuT~ss*AptQ7x9V zugc$&wGP~JkzEJ}l3WjE^dj2z$6{I{Rljp%DnmGf8U&Zz+BhT#{+_Emqe;$RsV$aiSJ|&y=CNEIcx+P@!GrdEO43m#C=su_! zFkN~LHSoSOi4YUi>GcPGaO&OGkw3SrQqp@rNT@_o4kU_c2rc>&Ik^yraI#-sjz11% z3+SiBc`8Nt-?jg7H=myiSOq03VLwS10`7GFa0Z0p-}v{m@2f=7tpY$IS_d@2FF?Dr z)<{TvU{c2dWQB**-jo*FiU9zFWomolp`&uzw*wW2MVWak36%>htSwi*pLF7_WWD5M z3EK}XP)2Xc>@bJk>16tb!{kPuEuXPoT#jbqi0F_Pn+>Kxi`Oze6R(W@_5@!S1b9m{ zY6}9qwKH!40p2Fj&8i({yy#%3$M{K`@Q!>Wku_@1M<}0BUlH-Ssph}CW_>d$GU_GI zvI85lO))~3bW$r8JTE3mU7@-`=AV_Md>Kvn4{mXOZ5{~s__D$xQK(4CieJ1e^ZqG6+FG&wP3m^`OU;A8;> zilTc}OxT-ihuh}uPHK9&gzrPUH`?5978dmcuYN@HQCZsi=D(X;LjBp~G8iiI5)Z-Y zSi?V&Of$oGP;1oKC+z_ud$J(IdN(UKNc^>HRV(Dm8kW7EyvhK6X91@&4$JfWwh71uF`IH!tJLz+N9llkCDvt+2!b&po35qokuy*#3ZW{NZjAeuo{OsTfEn{<&_ z%O;^^$Q-U-{h5*em{@|<0fBK+lKk!} zO%Ed2n9pbh0zA8v(t#Xi9pH{+&F6<}QkZU~z>o#pT%@>z6CeM~)YN)hsnrj{)b3fU z&;(((oJJxFaHm1xz{g>TVhoFDH0;sVXdxKK$tj>j5u%@@&|l#hGxXv(8{4~gJAUyebNaZ%Ny6J`gfnMgL0GS zmD9M%qNt&v>lmE86KLc^CXKozKMsWD9m#v`fk$6D^cJNffAU_l zB7hy(roLQL#OJ6!z2}TW2yyFbORek39o8Svd%u=^6O%H(mf#^uE{}btbqs%bdG*Z(!vd z&^^X4kqiZ6b%mf`3%7xuO59*6cSSGzf@Y}UUa(Cv-;A7ob?6X{)iGpj@(L4O50x*Y z7>Iw@XyQCm2w}L}d2Do3B{_AyXW%RtkPUck%Y`m*=7git#+9_fjG#@4Ukn*r!Q^%` zt<4>h;~2|SqZw|GpODQxbzPvhORiuhc2}z_G;J_OPnE2^>h^G%-{rk_@A1J!VS(Gd za8dS`pUTLG(Kw2Pg&0Ir)IpW>%@iec^7S}*i)HG7mac_v9nU8`e7-Y`Ik30_+t{id~3$vVZPll>n zk1<}^J@a$JJgUfZDsO+vj8PPK((=V?o3yQtJh$)ojWe_)@0U2oQMX)x9I`IJY4Nqd zBkny`UgdhAA#>cpSXAhOjsZPu|Ik?zw35-J%BYlFM)lH349Zbnl?7%;K_=h0;zZ2V zn?#L~(J7Doed~=(;?V^G8VXIHS@QPP2~5vy#5YLpsD`5m{2u2IbW>XtI$slffpP#m=uO6&urm^eu9(_ z=(Jzx@CdwEOK7SddXiLhQ*Jkb(^icVqxbR59In+U)l}i(%=fQ59Xfnv!)_MhdT5H? zdXgpKhkDc}XLPlaC=bR8ONKE&v8N=XR~Z}oAXDU3Nse6A={f5MxLXsZwZG8mE^xz! z)u2vIhSg+N^5&A?Vhn%RPnF4GkjeEBt1R3bOJ5iq`HRhryr>4F-<3u=imaX? zJfe`-54-hrQrYjkLG_KgEnhMTMrQLZQ92LC@6xZf0;R^6il!o7Rw#%LH`4*WNexpQerSaQpbfndCE0VK!pZx^ zzlD?E2)Tr(G&x}nWSIcWaSzFdY&{$Z84f`r7(}nwWPk_J<@Go>%*acfW1J`hD$ZYEZG$3~o8p1`UQ8EUxQ2Ku?5dX_! zL`ZaawiCE~ksrOI^)B<~OI9RFj!H<|Un%Y==3$}WSi;EQjj6w?kH=kuTct=Jk2$k3 za0pqB1pt-#6CD-X`3PwTf{sSi)Od}f84T=eu{WUM332eM@-bmYyE`VE+pw1|Ev;YM z5lB1U5*=6`YsF~F$6QShdR6yOPI*~$C=aF(ACbs%MRQAhuk)p~4u4BB=^S_SZ0)uO zlIPd54M7;;KDQ|IAsDAwMZK|0L%>wXi7J`Hf8EkEkIw24?Wq|{{ZIS{zEu>n#u1Aq zl`9ABbqf2N)v${5p(ZAH&WZ@^4iG*^nqodb=3H#|Nsu2WU~Lfn8ZhV2E+f86l7tZ^ zK?o8))*ZfPz@N{d5_p^|cv~pQ@o=1Erb!hNxJTe1Xk>I^{ino87r)5#u(P z7d!W(VZIeRmyDQZ-h-4|+*eDCm3PT1^T#P(ft4-Keo`Ry?9Q8H2;Mc z>|;EK-$K_+Mb-QJHZj0HYHu?O2J5;c;&phofGl1f`#HRVgtmm24+Un7M_t};e$KpV zxecXwlhe}zO)a%q!Y?^Ah(uiZvnS{a-57lGrd}z?bmZMNGHL%Y9Y}l0aKIBA>kI}^ z%>u;DcuFKo9H3?a{3l5U=L5la*28y1zM@kJm^1pBC=P3|?{+@>v_ZL&5`LMtErq-` zd_uX?+4MVpaCbqB$4OFZLBuR>u-;}Dy9Lw-$Z14z9~zuUTe#p#04dW!)Mb zD`&&KyH=xjEy2LwgUbA}hBKl@v$yl@+m_E#m{#f2^~s#!m=icSzsfPk!r7Zr^|Q#A z8Bh|Pam}JJDFSP93!EYoqNGDl(7K`0UVckX?+TP_`jv!g$A~c`M}qXXrAqnb>7U~j z@mBpEX~3-OQdnK;hA8lxYM$C3ZCvy9XdmO+9M>DXsrB}8yDMAP_bFf7XkHmQZXx*_ z!LPxNZYayEnn;#+_rR05Ij?wW8KBCbNuoLaz|uogD|Y#U;zBo}Df@Q@>rS&&W(d+= zMlB-&Z-PQff5{!^4O&+(S6|Iwx~zQjH0MTiP%=8d<#}~AGJSOl$^Iuh))h>Pf`0u5FUai3rPl2T6t6+?fpEbH-ksL)Rx73`P&Q{2a+IG5IiO1N!ah;;w z4Rnj42|%$F<)2TQ#l#D6IMW>=;Krcmo!E!ZDNUh=sP~>r-Zh3b>tJ0AjbbCuS7|x? z8OP2BE*iAV$RaUV^=L9cFmuGR!)Di^#Ja#N{k6${sSIMY8WJ((=FpPWAs3p(f5poW z&Apw+>5VCw2b0pF$DrlNl+^)c-pW3WSs9Xxe^W0cB59j_od@a{R3Nr!sgo|l1#cZY z$EoA8znCD07J?ocO6vT!(026wkFNOw+DHx=BtC1yHs}99U-aTr^!;vls;bP#Kc3Yb z+<#ILTcX18rMDl9^dt5@0rrnGKs47|F-Lh}s!3Xxpp&5KIdLSqgtcR1v$~CHbv~XdB7d*_4Ko)v<~$bn0&HvCLCNz8lstC@7YUxe3xi4W zA%S^xXg`Gds`FYhCPtH=!sr> z(0R#VZu|+%#?@#V(-o4sR6F}4cfS(X!}^=*i;Tld;6FF(=FMJQ_Jfv52X2~O#m%hg zG)H?D%&Y}jW1S)eZDzBo`;zpE-n{HhxZey%FHX6?&$zLxtCH-wR?=~958$?@SN##a zS1D$=%W35CtF*4xWyU(mOWu1>QMZd9q-I#w(tZZ2deU~fJG6es|Ek_9(T)`% zUq9y8p5XW5${K8MD`kSeIbUUtDGf6c;Opqhm^hKWK*edjl=`kHUiIJtkaDtNb76 z)^0USCt>hb$V!?;0*JPSJR@sG!J5SkIwO=@?-HXkq3?JGmejK%IgCi+a;~0sOh|Fy zR+f{e%%J;w+6*5jkOYb0{l7Ug!cEE;gY4*$OB3Efu>#gfjvTjP{RaGQ@}BOjX9O@e z*7@zO(T{mu0&5GRU_}0Fu`sO#x=}KEm@zYAX*sItPnnGZ8V1o1UD#s=nE7&=M(}6a z30s$E+8@B=m6mALm*sz3-^d$1x7=`+khb;9mC5K$BC}>O>ZB{jRigp)(-HrE+Kk*< zeItc3T$h48?C^cZ@o!q8%btJ0*7o-sME<()Uq6RKDJ)|(iX+HxLZG^z!=T`N=KsB_a zxdtj#VEdmgIE{y5cmEcEFw5QS_c@~C(oi1WC{VKiL06-XX3?Plk~y_e9SYF33whPk zwvB3)lZ5o#mk+{44A3aA9P)nFbIn=HSIDYsJW>`c3{!X1N%_#yy%5TXr>sHzXfFCx zAj2)UjLE$i{WDwx@7Tn0C0$Jx=E|eEZF8)2%<|NJdL%W!3C2M>ya|BcDi^m<$j8~` z84c=Die==^=<@AHsG^nIW&OrGI z%wsl5no0r7a=}9h4Qvam4Z|jjVmIiw-CzoKYs2QT3&Hii0#y`4`!M|M)K6+(qfvd1 z`;j<4s>pRv0!Uut(XxOeO|h*NJyGQa-%r|xft#hrYGzT5nEyisBV+d>^p8R_@6E_y z!!`r*JHvf`sK&g%CyBJBq}_^k{;G9%@{}`ylW<=Pq#p&yk6RY8-9o3JdX~^!q0Ne<|`TwrX}x;h)MTXp;zUmMBH{s z_)+X>D?;&lN01av$*Bz!lXD%ltBa8P&6`)SxvN9wG(C;cUbFrm3k-Om;}JmSb;=yHgsn8=R+XO{xrX$>BQ& zIbHvGJRz%-UT%F?Mnr(cdP`chJQ@n7J+G1|h=!x?`RMLEN%&b((XW96+p89uzw?ru z`Z!TYXUxAESS!3oU}DVEN8&?B6~?07hntb%?dpkR}WKLkK>LCuMb_ z6Qb`;`XN2>ZASd$_M~sY-X2P8`a?o4UsAYA|66YfhtJEWh9Bx|3 z%4cp~l3SlDD${a=;(Wk8T}Yf~jw16avUD~p8LDbp`@=43=MX}AVxDrq4m$Zx8B~)n z!#$vqqg1hU_<2=ygZ4)dTbY)l+6tK0gGA6l#bC!;F$8hC&S8*`*URk;ahE*ogugNb zY?G%l=LNMqh7y!;BG;C#<-k_VAg>wZSg~Ua{gNSnNoVdK{`!YAYGg30Tu<>?olKj3Nx8_6ENl)s|zOfeH}D~jZAd5;cKskom7zAPw) z@1yW#7xo}sz>B*01ZwmQjsS67?@I{>B!j<+o`Z(f!m@_p*IHhj$M&GGH5TRle$9oY zEgKX&)ej=HmDsi|k6{3X z#~Lr$_+WE<+_MSX9k;C_asK(N~pF2iSYC8B1^vsYPyL8 z%)Unk#qBwIkk-3(rKIAl9ms6eG@&X$ZyfZ+jhKv?_TLDjD0MN|P>sDc#hM)a0XyZ@ z!H&UF=-5L(DMyHdC3%Mq%I1MMD3^7p8#I~K!9c&7^zk9v{7W{P}>8Tu$E zIcE~v_XrwDbkgqeI6MCuaQpgB^d~_}tM2nL?cTYQcJi|qS~lU|ct;=;Pa^sm|Fdvf zL=arDgiHQ?LMX%AB#Ai}@2oTrP79MQhT0g_Dc#&3{be>CSqqCTh5m;0UDf_1Rvil? zN5qr0V4NQfLxfd|*Liy0sjtu41lM6Q;C7T$9nk8U489wjh={7FGYWPZXU8h^=8+68 z^#Ol}wA+0yS(gH5e=|_^R@t>BfR*DTT=`GfSB@fanY`4d19Ga;*^JkYTKsK3hTW%13v2VGx22jTh+!lK&>D89hbft17|97N@YS3YTW+*fAB^?5tH zvI^(lA$otMq4K0?BNWAtWTDdWC9)xiJ}d?diGO`$!0y8ZSN1h!m-~56t0?v9l!jBp z&6ae%bmij8mkhRO=+a~q2Prs=34dZ^KuxU8v5PfWPCzP z{f14ga+u~%Rt{H1SK;D%d_P-LgtZRK(clpZ^$K+@03G%~P6RCgviWn0D=YxM$ME82E3{F8v+c9xYAwVa z@sT{tE#d@`4{MeE-l@)?j`Sj_kN8iw+sG6?4%mgLpwVoY>7?P3PJz=l^0tRykF5vA`#$$M3MF&(#6C{yJHSWnJ+cM?JvCn z#zs%!MkNK8v&7YUHo>SKmD&z3G5|5l_xr-92%5*6TJTD?S{eyX}VrWIA%}`UXhoo z!XhWT&;LHQnyr}kN>ogV$9nqN+Vl5HyYNGwb2{k=<_FYVRn>zqzpSvI<2_8E%VCBN zq?PWMd00`nK0T7ytPa^PEkL9HOc!KCjw?b`%UQ>r4N7{R`BAp~Md~$S$r)+j`hs|H zPvhJ~elPUNi+F0-Mu$9wz9dI>KgjL?{!E<>T}kZ(On+ED$qQ5T(iQ+>8wzk05FY6E zFqQB$V-tL-W+`3g{NU#u!sdd#-Zel+X>{tbu;+$-K&o|CL{cl4C(WGmc31I@zt2D` zwymH98n)jA6f#!eIM}E87#*+n+sE}YQVm7i5Xt*g z)KJZ&+8^hUW6%m_>UT>-~LQn}&NJGXrfLH8<*4 z)9!{TxK%Q<$vSux%#o;Z2PE>zP*G6dGLgU1^+G=JLoR3frrORVy+GU?sf8{>MbyfXB=g@TI3ee?>DH2pcHfs1>vZdW#R^GI-q8CGvhf4kD?%lj%qnn-$F9V zxu=rEa%KF-{9gADUb1ncJy$VVD+STo{n zeP9O7q27owVc0qGNi{tb;haHQX(Z`;a7ZrS9Z1PQ+{6oUyBN&QPn+zK3kEQZ)F51d z26v<$1@A-NqEPMHe>YwUh!Hck$%ib;YZVRsk$;|jq7XWb)pULII;4a5~>$fNC`=RByrXlnb1heg4 zF!v9Jt7wb}tW_^~saj)C%gI~uga*nmhEv`za8A5^85IR`om0UAPwz)7RNM4k=Bx1R z5tp7d&UR}%84jD$Z2gTY4B2dG_36$1 z+;IT}tGZ@@8Pir^v=&5zeTsy(X6;bhDlHK`-ude&c=U=>dSm{GL;r7d=JA>9nyfCH z(rWebzJ|;y`h0wL6dr>)G=p93rI%)wWGH$Mfult7Ic!^PZA=$4PuU}>;afR zwOrQ_G(jrel^3-ZByWp!&ub#=pILJ{(KW*vNNANV1BoQR`T|SrfsMJfVxaa`%brPk zQb@WA%mtWX$eKK(_#*Dirj!idu&$R3>fOxRYiQC0{<%i~O*{>U3&T*%97EJB^*YOV zyG^=F;K4(%Drg{ifDBcx2pfL>!mfjp14I0eMD4(k=I|Y04x*eJ>gOQ&k*Jh z70x!TJtyGc=xg{|j0Bq!dp1l;#rjL_XA&uLl|)z^l#|N>%?}{@ZcE31Cu|UdSzBoF z=>d+ss)Kq_v2|ZxMKku#8|!zt4@1D5C(^J-|9;FU#kae7-}y8x+bZjyLk(coWqV@| z6T^f$O-Ps$U69II)Fgb!@MV_pS#O%itWGUf^kQeQ#JedEIn6JA9r?Qwl)O#~bC`(~ zbx=L-JdEDTE$e$be(-6Oz9!4fLPC+wi|SPLUieGzJl>Zum*g6X7g<0jb~A(*{t0zX zJY~?e0~w?7uSrKYMdLjqR%@|aceeIZ--A~pHjVvovNSBH5LDx<54%7FX zC#oDL(*u8;zO1J?%?!B=LK(SMCis|VQkIP%5sY(`v=eKO5LiUOYgbo_=5WU=6A&Y! zIPCnLQI^|rzurEXS#inEgi|N8wGMpkC6R^X34UULPT|Y#A*;gtBJH7FSS}0;^RTT{ zCQ3&piXKypub|7SJJwRLj0S^8r2c@We^{%8*7gzoy}C>ziy-hgQP3G+bX$2 z0mm0aLanuKZ}kPNf-x~q%>1h+W8H@FJ9Vg=3pkDSDduSlx>5-4KY(gU{c7IyrKo3g zM{3yFPq6AW9NQt^#QF;%_~?g-Xt!qGp;bQzMsT8UQoQ@fzl1Abv!L8MzF;=~4eszu zT3m#Mx@VU?RUvrCV5vz$o}W}Ntf*0~SObb6nHa^dBo+{R6kfF1nlpSbxjHi*q6BvM zv1m-d!U2)*3M~UFlr%e2HcL5&nz!bMnw84}@B&|?guOriux~>S&jYC7fUa>gKZ>E< zUU>jDDBI@Nzkk(#P_htJH^H-R=&?nw@|btjSkIF}{qwOC>5P+jEbjwxiNf>Fc>#nj zHqgJL_4T56D(imNUNCrgm&ROM$Yk|teB~a}OGFQWgr-|10Z76hA(yC}ZokJ4Qm`h9 zN@QdHBrr-2LU0FA(MHU;0W3)o4cLuHW*QfvU4`X-duenRrzL3gC#yfl<5oui=L@mc zs(g*;#W`@NzW)#%gSFx!;Z}c!_Q#Y&TiQqv)Q`e^xAvile;Wb)uR^Q|FhMD^X8l=~ z8PhtnaLyxW>tSfj45%5eat^*`j$bJANC2mzzX=iadw!9;Jn?aOxj5f2IevP$vg*`* zH&{rmSX8peStyhfnDZEB7M6rBF7p+e*ozDr2HiV~DsXKE8H=pKu6|Mnr+Zw-*ASJR zxUHtNIf{Y+ui#Kbd7{No1ay9nI6bA}11x1h1J{~)0u()Bi`B9kMjuSmV>D3m=aA5u4BF;Ul`H zTYk7~VmWQAdWQ$!6eCP-3zzk=I=@no#{+93GoGn>>Bc^SjTUdNYex$4J~0~?eauMP z-1rSS^KeWSIz3zIWyGI#-llnNIr4TI|MoWzx#B}P(oU6CDmw0e4}_Am#f0*}%x+v% z&fgoQP{_K}q{(=|#wA^=wxx(C-%xWVY`~(2W7@iG9as0KVH~F!>$YhaTqbEDz}<=z zMe>~+_5}I-)yBdP*5Qs;W>e!bpZkTC9|81W4Gedc>s(1jHUO_26Gj@|-bniOA=QbY zjoZM=Do+1N?8oWbAN0HG)w-KVw#zTVe&5b!!q2sm=Fi5c7_jJ#90ywdPhD>r71z?W zi{ctwgG=L{jU>2hAVAQ@8+WJi1Pc~igL?=Xq;W|?L$KiP8rQjGeQarDm^#*rch<)N8*}a8>ly9 zj7>>5N6ZQrR>JHO02c({r1>hl1k@oG1^5q%_y)VxI8sM~Zo;qzJ6&+ScB`aKxgcr1 z7+dO|zwXhNlZ0=1>(5pWK{@vXubSq>bV|lSYPO2Q?-YF3iqeZ9KHUdX)8A!|T7xj0 ze*HZph*L7!1y5vakRWuDTFafR#OeOtx{f8z zycs@Iy&*Ftj3ajXRby0hs%jn&S51I zB3Z!rc0`faw|-WaY4iF|K`RvPA~M2Ue|*nm%V5TAKttk(%cC0jAyOct*woOTDN*%s zR#g|pt7C5uvr|5Yk>36VkjAdk((Z54On6z^4c2rhzK&1ciDIKchF!Yx!%;C|0QZ#w z+^1eHDEMmpJt4H{{jRA11+x=~Xj<~?hndm{dmcUWJkv@BC&Dw|bzS4d;3xt7X3{7D zV05?23wt0u2oQe5>%xAp@=s|7{apXbPsyrwH5^wd=_){c+yL>}D2w@pC&>HZJ+$cS z?uY=QrK4&RiZQZ2C8Q9ky1gPssFJ0y4WphMuAjoS=+)b5u?A&(FQT=G*Qj zk@^tR*%DBq+E#YCOtl~=Qr-k6zlXkXQS?SjB;CnNtWU4x7=sWIuy6&8Yyn2H-bjoB zTE>7yZVq81v`;;9Ivlhc2+^5VubmO$60g5C{#Co^8w+9=DaDDnrZbzBbCiT*9_N|L zCfOk|To~!Q4+$Bg@D?dVeV4~D6zo}fwOpbUTpyH(Lydlat9*By1rzse8oF0XXVUOn z4}sfD&geYvYiq!7Fk20LR~~|vRM~BR&IhP}5c3&#Qnp=8#!b9G%WE(7dAt)TNNx07 zU<8pPGhbGN=)6!|(F_|jYc8+7h_@sc`P$0iC4a92b#dJkx}+5;(?w*K`xrxva^~UR@+B~~M$%Rs@`_~?WRZt(`+vJiYEOTAWudVVGGHaCErei=txZjO z1$t?~v9&ED3OJiChwNKTZw212{Kaj!ORDZ0a1ByC88-4PG=3YEADH>*a8bR62VYL-^uB?fusP{f}LKojh%fM-Lt~933dpCLHZt@QVbbW*?K@ zF4+}I{}eqTB}1Y3O*5Ga?-U!_in^&j8Czr0q9jg?b{xpIS^84g zJJ5rV<~?gnQtiFXd*g_I86}2PGh{Mjo}xubIAoE;H^$BA?}cLcl!nqg^TF<;wX#R{ zu}`55DBXhF7Jl&8-Tb*|S4ST0-S1I74w6j2$+_lMZu4I1??mx|T`Lfs9ukK}aH#e& zzL0#|YcBEoP(5{O08h^6+P9@rJTJL5OVy-PIFkl5Be%VibrrA9zbMbq%Ya-Zksm<_ zvdbK~i54vF@REeH5pPg`uc#BTi}@2Rsy==Vf8vn7ySipN;xq-lkyhb?p=LzE0$5Iw zb_d`}X&+s=Uh3!$J<<}X(q?@%DK4QInZ{F|d@8nApTpgtSaR?b=6-@t`E314NELSN zIo$Bjr7FSj+B(P|!)n2_&4$2^Rzv?)nZ2`wf=2yN?Cmp@1w-cyPzj|XX^pEk@1nT0 zb!8IGIFVo^(P6mlAe<+1C(nux)oDYrrPQjW*^0oj1@<~Ye9V1~Q{%68j<*}J7Z#Hh zBkiP-KNgN%uS_i-3C9y4P~X>3mLOR}+ZWWMd>JpYL5F4OIb2H>Q+s~txx||%T|6PJ zT#Vh0=(Bun#l}KP{6ZsA5XQ2+<^YEwFiZPlYHzN^re)w4+DMaACv3VfV)+rmMQNlPw;@7=Tps-QEy{FR{S&(j;~0c7>;O zp)W!&w^;?YfxzXYTYm~(>TkAI&$V)y%Q-<$aB>~LWP(yDw_nxp zX@6Z17q+e>T5F*yv%o-JlhPz^}uRjCV#iu6nh^}gr|B8Yp|fOJB7B5Ysj=V^X#L8!2%upStH ztyu%_VNP_gs4u@Okr#p3hj>{e+T~>fYH}@0qp+Rh84gt%Ec!3L^Ok80&5=yt3CEs- zZ0m-JbSwCwxLF7KnNiNrmXL-m&qmpM|0lfB5UtTb9%}||%(h478ZuL&wAL8pMNFxT z+IbM-HYL1cCW^_7IS|Yrn>dnIMu%d`ByYxOz99Wq)a;z;0$5u4KVtX8TUVOmrOpyl zUDEf>({#gsL;aCnav=gF6WfwX-}*W%jq?A6~ZdDkSG4j08PoC(KGLw`>Wq&g`%(xY`dpex~Y&4M45XqNz`5bUn|_`FGb zkngwq5aTa_%SF+S>z3K2echC2NmU4Au8d}ST(Gg`G2m8O`fI?ZJUs0Dqv>H;c3Xh2 zn`pq*xrOTw(!{QyJ00&S9>IY#2@%2%%EcJC74aLZFC&^pLSIhB`PZ3Di!g6a>N`gd zv}w*oF9+x!3@m3wb)So^#L2zm;Yh*j3~wKfgRhHG7(?QK+t8xeI)@d_<1(e-rXXLU z8V#w14k`--J0X>bpPc6p>J_!-m}_}nM4?S#UPN^Pq7eohB0CySQ5gIqb`j*Cb4~B% zK3&$hzVAr5vbzgw`ck=cz*|+c2HcAo0%bn?qmf4@F!2Vkj3={<{GOK1Nqi_ zhq~GXS10;;xC1TT)>MI-ujn8jCE-wO!O*vwmsJ@eEijfx#jJ8|ZQqyB&m(~TTs1t9 zCfc%NsnVml@sHSK>|PJ)cvfS`uf!>YZ_gkI=4`~B*55;h_++^cwT z(+}437r-M*c;NtpNcqf=czlQ@aYa-iG--6Zqm4Kn>DXsl3zl{Re8WBhGGCBFR{DNI zc|6Tcpy>Panl*sxXz|8^7YVVVZ1_77F_5@!VX$>2_VW!5LieXk*+dj^`qJ@G_1JUu zNVmbuQT5ngrc|5fyicS~hH7W!n@bsfBg)yOVM8IOqAd0ISWskbth9cLoTyiM6^FUO zuvL@IA9$C5LOa=~*NV^7n%~lVC#Gcs8ECoJu*aB2>8cWTfq%Gom1s%k-~RCQ%Yq)=@0cVbyN4pJBCP$s*^67 zHlC;{UF_$9?<#}zN^@KjeZ!6{gYM_88SW{|rrSN@uWnX08*xpChF;t?PDJNQ#|%&g zWhp-aCCM)%+5HO7aYkRCpZU3A$7m`TW&A{v#lU-D91r)D5~h(#fvj`MrzPh>1+vUm z+{PkYFanl^mN~ZagK`vp#-Mn>T$JsrsZOK{ngK`u*CaQ;ZIzewD}VBw&Ud3u6`Wwl z*W_WGMqm4WZ7QU%GKQ^({Q34Gr%VabbbIsdneP0yL(06uUd6>|(i!{&bm~*yl(yt2 zD4$>fsxw@a6Br=8C?{1Ge|d1mW3Th83_|r#0*v;*_Bw$g%C&WT zvE88kui+`A-2y4ec2SI2Qdn(%&cX&t@p{`mN-wWV+>5;ZN61`si=7fNoakm`9qM&9 zrdEaR1I{mX#+pQRX|%f+ErJ3trjB3dqc(>*JV|Y;0f*?$$&=J_9_>{+9d-tz~EWPg7H7r(l-lC19eq+cGAOhpPMB?|sDaCVhW3-y|T;X)V zct5gBx%4W5H4z!f?I;t0QGZFJHsI^BYDDBn)Uj} zX^izloUEJViT-Ras8QV?(h#TMX5Y;shV>M2+%W34-qtfFD+wguU6RA4oB8#MbT&rT z%>Z+W*jDOSb=Z-I04?GB;6cz2z)VrLD29? zHa9hV-kKwj?mUx%u|&9G!=Bc}+Nk3rkIIL%yf4T7qn&VvIY?`pB z$O_H7l=Y9-bE>|SHMFT+_%uh;~O1Jp-r(=sM6he!1 z^le8ePo(mN)|A7SBCy4L%^&g{6Y!8ksSvL9Mz8aDx)9QwKFiVIVYtBMt)UCzde)VA zgnf*X%a}=2JNbzl=?8@gRGFPG`~Kzx(9y04<7bF)j$F;~C+@ywQr*Ti%G(D2rAFE+ z-Mau!CT|NDB#r45Sr5N#mbJAGYu+x;qU?*;z0OL z47XxFaH=k2z!#~(f86W7n~m;FvE<)7I9}EXe`C46S(atv$0w88t^9iB@pjzwdzD`4$dy%ojL&j>~z1P(;!Xa#S8K#A`jLN0Ln z#=hXqiqO(Ac2&<&Nmj&D6bFcVPMY{;a4PnEs#fh*eHgG1A=942*d>@ceWjW3`~} z?%v$>de`VTpMO?&uTb@?4F$Ky2XI37n24> z!beBJW+4Nzfn{`r7*;9*$-Qm<$@fza{=_483OsNSn||AUvU62bd*hsU_?xh_<%Nm? z$S2E9SmS4Fg>k3?UZZNP|Ks+4%Jt*-HSbQI%e!4gWqpoW5s|a9=GuNSGpxV-idG!H z4HgWB7hkI;!5xry00#ilpjtWvK3ifVrg>fPGRFR(-J{hErB6_W^7%CBQ!E>IdTQ+T zE$h>MR<(`|_Er+d-qak~(^62GI&5T<(k^h80oz*TXzBiT5cPutwMGfWEWjNM1_u#s zUB3#)KX+;!u^)LgF-r8-O3@GNeFsG7xV*ni=|^1fx zFSw|0W52OyV7mCwkI4uWa&4r)EUaWoJI{X#sK`T^(h}YVP!5mj6CmLi^s!gp53iA89#w1?oCBJP4oKPDxR&gGHv zGQAR(be`}u5nd=PDPg@V6w%x@&#$_VPIagIg{P5{X~VQS12-@4UN7^c=@az^OYb%D z26^I^FH;9aA%A$&6|lYo_AG4>@WHH*KY@VISzY_<7r|KOQ6K+`tgRn3h;Lv9{z?^m zk>$b^J2~U$T0U-u`Qaw+AfD4b z$^`WJ@7|w|2Fwwx$KM_q(SuKA%yig)_Ey6!=h;I5CQ<^0D6Tq5+_&QUpe6K`X18_N zsu_s-2P)iULYi*@HwllBx#`yZ(22$8J1LnpSxQy=`RwC8QB4Dl=5(9rpJh7}3sabw zrdH!sYc1Vc9(k>8qNy|82RMTyqTjq?4vhO&x3edSl}7v&k)##Sgd+wv^n3=3lU~?? zVHQ2$dqvtyz)eAXw?HD%qqb?aNldV;_(;4Gcd%yyWMi%<814kox~@ID@7==xc0_IB zG~FGjpF_ch7ys-KZu-Tv;$`Pn0AZIlHBfYdU6ST`I@Z^8ay8Vc8Zmn#gfDa?uQZ>j zWLQ0D;mdTt_^$QdL;VvLuL1N6LgunJdmi2$peTxit9)O0aq4k=RxIH7wL^cW+Ck+0 z@V_rZpc@1^aZALld%F#cEPdb4lZrgds@r7^{x7CY-kRm*Oc#>whvV6MZp(ELv%rJU+`@9R3hy6ZELy;?L#v zL}nnklE;4QYMBfE^N?&34!*x7>sT4RIq*HE{-H;(*!Cr6z*pv(f24ts(u5GcKO{~= zDnLkE++6XjZ_R;_`CxK0u|?toe=aAg@diV-R)`7X505^l%HyKA17Ir?+RKkWB43@+ zP5t?CY?NSBxirQs!XQ={Zv+Gd_9KW?YS)+A1H$)lItPY7MRm4;f7?^1#}UJ?;J6Ix z?aTa1yt)#oPGN9%$C&FcQfL!UcMP}z6w9>6kxIWsO&>=ld@7dLED6I46!EgCOZ=-ycAPmt9v97dmNZH7;JwYRfl9smc?PY?0TJ5>uT z;X7iQ6AdJv*6EbK7kiI`M&~8zqh_`jQf+8!>!uVs_1uLc$N3}HcrEj_D7euE{CnP$ zV(#Q;tVR?OwO`=7=SevstFl657@)dD6s@VNmYfzXOhI#D5Vjp-E?uFE4~P8AMl?4I zD-I%kxw3ZXsGBse<)kFXU;+oox~$l9)@tX$k7U1kik zN*fI!ONeI1Tt=hNbdV&z_EOLO3r)6&wF8l02cd&YwkW+)#@~QLd1qZ5&_>sX?8@dp z-8xROd=KX9I=KAj?NtcKK)#HLvSPk_uSSa-t-h!=KBHw5H&C~>MOl_w;#Ybm6rTy{ zDllzoU*P|+Q4*-%&-KecC%JP&l|a#HSEhI&9=D9ZiAQKst_gOT4BQ9}eh59Ty5#p_ z$Eb*P2~!tvd*K!{B&d0>gwe<|2sr5UR0IOM^oGNc+&>6h%L#t?%pJPmQSni+i60FU z;4W|j-^38YuK+8|HMd9W?@5c>lizJ(_wUk1ZpPb@h}+rZgS#E5YZt)X%CwJvAE&x0 zM5gY#^M~PX;q$dwpBJGY7cw?$B_cO*+1(k$6?vib29q8I*zPc)r^Rv4>n4~H-;dHX<F5F0?$LI8wJd2INAdwD*(ceG&AY~N z9LQ)oWtB8GU*~Oegit5fO?AsCv$zTp+^}L08UIOC&z7_s9aEGR7?WWt<1>Jk_E<5; z+TAt{M~=(K>{fyKU3mhq84se7O*`fsKABd5wC4B30Ag#kj`-OLk4nNy)XqSLZLf^( z-TYnM{6BD3hN#W{`iMHa0`{wD@*hdde@Lu&1KXOZ3z~K0?5mF*1FmQ1m@)4`s`rw< zwx4XUUnKnb(&xz23p^Nr(ItuR0+g3^T4HK^dy{c3m~jd!JoJ`;JFa9>9Zq>LB^Ypp z`_{~DEp-b^Jd>QyZXt9n#&i^8p%`KQ0{>S~5?ZrB(rxu<>o>!rrdvGL;eQOH*}}-C z9+r>p^&$dUnqgEo0+HESv|wciL*l`Ph+%#E#h);V$Rt(^*9#S6J7nqpenqr~uz12c zPYeh9Y^H$TE%@^yG%sE2Pbg~3Yj*_L(k55&E3HNy_ib~Ao;>@k!yzLiDH%B+!*bL& zU~ESiwroI%UU^lQ-0OT6q&oeBttw%Izf}IN!sMIgxOVK-ZP_784BHRTjpU6U=(f8( z^j#hx$Uh9u5Km~Qtsjnwf{P)N|-qrhh|kbC*N%~Z<+;!TT%Iy=dZ`)D6ubYx{zR9drO2#mr(&n~o3$E=ZE}aNDSC7#>t@DqW z-CmiL{1Pz}e>|tn4!qPcW0+f~Q}*B}{I32idsX`sv`R9nXmqG^BkvCrAr{J zRPO3BOew=5#XOz_(d-l&aNjF$oD^?rwiWOP`M~WiN^Bsmtc#4vaCuGa?MVR4L6x>< z6|}*Iy;hoB(<}1q{j-`Ei3IlaGDQ-@)9Ep|5FC`S2pr5BBPp{rJy^GSZg)#&D;>Fy zO`hE7If#BLC<6Z^Ut0?OB)^FB@}wnM?!KZb`a<_;-L9Rxz2?zCOq)i~moUAAv0KL= z|6>h#$3eYqqK#c129RLE@0o}3nof@HtWb$qzyP+E7OJU8s7KMq3X4a9;Gwa_g{1GP zPfBiu&%~F`P2MoYdTJ?=hX);+p{Iu>n2zYOXr+iMX~Cv1>49Q8<#XW3w-p;j+-j47 z&!DC}#xyBc63gMx&$0!9&rW?x&1{V$nhW31Q>KjUI6*XWd-TCQt!*-Rgne zCsDDSv}e20WYP8*Usw4M$ocVXRv}>3hJK_`p6(uc`@uANDxsiq)ta1{;NGp=HgUv` zt_nyquz|&P=JlC(g0zu6QUY+px_yG z*R&F}j1CE1jPk?M?=v56JI)n+IF5~g>#|mkQf{VW;gJD)am5ww)*nWq-A1f5j{KAFw4l1Wj#DFus;+mgH*>8kuvn>WbbOol=ih|!`H z_+KMpVr6H6>KK)AG`4>M_ihOxiDmUlx%F&$0p$*$F~E)|l4AR8By&Nk5RGn2pQPBM zHMn8oi%aPz#Foj|J>gYg!vb_8+0-IrBLlKGd}J>@2<~>)G@3;;Cp=d(aNLEGn(XOx zWgP08?5T5}j?t~}-5lSylJ*O5?(!Xi2S&FGg#jbJuxWJILiz~j#Ly%m^`myW+99impVCmO=UL*MRFy z-c~}ccXfk_4N8f3l1;@_Lfhc9?)>6WbGp#~ROmejkFW3w&2pBk5ZD!=r$Nglcx?r% z+i9)C{x-RGuroV)zBnpFN_+EXbhex^w>Y{^H+ub{W9F!wYxy)o@Myncfr|74Z;3+G zsJsbjkJ*oJFxPRA8TcW~^mVx-ab`y>#B)k`7jq=>Yg<=(xKft<1MP*JJ&}^&i~Pw& zEuxHjNt43wWkHsIE7H_fr22_3G>ZNWv}bg6-7oOkqStyzQZ1bcQwdUjSta?^dDh$q zAoS=k@Wa9AJ$87qO#mJ_Wfk@zI$C-V7WCHQ4If?z9wu{beqHy#6-#U6wHaP_XZyH+JLdp&!=yYQ zYNxLT>Q}e)JFUAIh?ZE7Cxu-vn>3M+@P`e{ek3XRr4x3Y!gS0nzX&>+kzDvqw=rb& z@)JzWS68RxI|yT*lA~DW2OG#uB@d#iNH+Oiuo|ZOCS{ciH;VXB;SKs8+Sp5YNq95u zB)ZsL){)(&=4am$UnJD1UDXy-+(kEIHx^gp%8bzs(E_ru)wU1Vp=S}h5j{RK*3s*a z$z;RPohGDBe@5rucqJWJtcJhbe;C<9e0G-rfytcXcTCkf0jJfxc6WT}7I)Slm<3@! zgcGNZRqz7*};sIl0ecFOj zy)Flo-!^W$(Zi;C6)9h=z`tO0X+*!S>|JB~(A83%k!#B1_3!Zw*<tx5f6=z4IHo1ah(A=aOU>9UbyJx2O>y2@*#Wqq1!Symhzka+2z&L*|EA1siUP{c z`l=&UX|G8l;`B75kyg@DTQ9A=ZC);^EGJ`YQ4XLd`F7uen*IBXdt8`+sJXxkMY;Bs{J^q7zG(t z7_u!2U9|wNYKub$b7eOVDY4&9k*#&wINq`$Hqp`U6bLh=r{Tagk>qHK}AOZ2TD6SC-hg_hR8-sAIn>m+%ElN12C-PR&CzI2PMeSyFUFGx$qgcjnsH zvz((-yk@-%`~9stP?Q-wjwB!Fr;G`Ih&3fpFl{YC0fk{nsy@5b<%NCrIl(ZC6kV;^ zhRj&*Gfp8^2M`?CHwKzI0R>Ug2@m+VIS_H5q3__B9;BM~DQAvsosD1zSP8#nta68S{6XTSz+a`Piu`RYb6Vyu?AwmtG|C?7( zZg^w6=pbLthXg~|iGIX4jzA#|r175>B`)Zk=}_ey_UVRO>`X@N3Qj^N zOi;p&Np@b<-uVG}PeZzR1uYN$UP@sDQIQVst4kQvc<{9K>=ozOT=&(g(R~dAtWG-@ zC;3@*255p(QJGqH@qhRf+;BmVn>CZByg8$I2(`S%ZSN2mxcQxKd?c}!*8qT z1h5y>@;J|Z96F65Qv)J@}O~t=r#n8Zcy?#EMzSOCsU&czZ%tsS29y z&C-Qx{PKZM1)nKeP`cz$0crd_v1dkM_P-m}vePAP3EAx42h?ThMo;s(@Hn$5rGjAa>}B3@Z;w7x|m%g2Yc) z%m#hhbJAirE#mJ5f})ZEQUkTdVF+S!pmKCyzn;Gmrxw?JU>n*2{$-8rQBkfkBVF5KgHwg&xPiOh4h06&cvm?BU^a|mYUck|ov2a;h6_`lga&yN2Oyt2x z0GLRwo?70-pI`ge+tBtJUH*sX^agh!e!jkm&Pzpo`kaCy<;}w&`W$Sr2xnzNyL)6XeXq%m}k#v-SCL&pgWHe{1^&l|&9f8DAt*~{U zC+>35&ihcW3SLL3J>dx%+U0IJbL1HsAsC$=dibNS!gFl7cQuK36?5Q)1m<0uYlltD zt;nkpDHUuSE-QOP-z^HTFFtTLFERoZsQ+ZpZI)sA-2FsH&>h>iFB`>|i~$ta#?C~D>BRmIoXZOrw7M1d#d2!uOT&+VJ?eoOdw0@Vx{>I}4?2MnGn9}j72Fv)H zfOAEGSM z0zLjzoL)7uZit|l#gRCGZY8u`%;iIA-k+Mr=w`C0y8v((@=Kae>l>IA-^{;C1CkO;yI=F8s3m zT3U&^U^HNggBA#==kH?MKg3+b?0=-+EYmMc`tqwbm1o<0H|jz~g2K=l7I3n;jH`Bq zs+zC%ydE@i4>6H}D&nM{p%`(DIk+S34vE`Uf$F@A2{k$+i{e0X1ktBM4T=||SXrNK z9X+ySNt@qp<3~IK= zVKs=1v^J>uS~Jzz5Jpxr+s0e)9qn}**FWV5bS)YlN6mr1Ey7kNO*fuquu#aoKs~)~ zLGVT^oXOKRtJ$bUA@a`7HUv*;lu2fdaU3RJpG&sP$sPZeR@p!XN zEGqLCIIBTn+2=Q2Rz8qU);4Zgy{*S_d?>j$C%nV6m~|~5@!IlNk5Q-m$AY~2 zW_S+l&IZDCf$kt<7BbD7^ZtjTOk}D(%z?b)gW(C6Lys`P*K&K0Jj(G~mIHkz%9sxi zPG!pO8^C?5C;rtFfZkbhuX5jM)6@TPPs^q_FW^ti;;>>DQl_*f0hDybtw%b*O|Gg; z>KL2MMd2JOm_c{quy?#w*1ch;tcbR&mq;BW!LdTFA5WIIXyg)_ z^$plJtV){44yxlIKI4Zb&Z%ofJyyaXWHyJrqQ;)B?;ypa!^&hr#G+6x#|>H2s!%yc zF2W#tCeGgkYAA7^LpKAbR8eB>oj=$T!doI&p6Zt>J0-8X+B8_Kxt*n@Bb`$z9qX2l zWLWMx7#S`Tw?c#>-oY}VB2r4pkHX@{@7TQVCMQ{Xf!8Uh#}TII062|s7Wa^#NmRS( z*CNMW@WIYs5!E?Q`LTPOU4eSN9PCT7u z@rU3uJKjscXkzVDl>1o5c8BVd?$D-7aGgHvc9nria~#qdnXJoFh6$|E?ERuz#g{&T z{Ys*t@R*@plob6vl~wRA$%9KR@P|181h+R_t$coE#qs z@3phyS_T{^Ef!S~?YZhyov$Vdn#=uOgcxz2&wdl`aM)#}_Ti-)tEr)uZ%Mk&f;rtr zdk8AkD&D7?-Ru^{d7woas8C|=D6*s|{&XNw%P~!M$MT-)N8h)k4LlRrI zXm{2G-q*(!!9^DIEtLJA3)DKax+*8XzRw48Uh($h;qO>!SYsdUrzM4vOOf9($~km- z(VTE1G;RZl1b1jHx(=KqGmUY;gPS7s2f9r77Zb)#llA+*kJ0B`9@XiU-NH1{8ptD* z7$yXOc|GIarslw^>o3I)YyF(Sq;(ig>zu#n(qbYnby`nf(^8)4Cgo-7A!~)OAF%R5w3q347zd zky7rPfE&B}{7U}yQyTEwt!T!YL-wmLM>wB1N#D4#;(UIDbPP9N6T0C4rGoOw8GxCk;^mIR_YrC*(?`+ysu$3dK2kf;(8X$fcYkkJc8e1o~(iAH=l zL}Kw$hcl_;30BI4AN%(5N*hDx-TV9_Lwpt5D?kCFJh0pWHBwoZksj{f2KvoJRf}xu z?iiiav=y9omg5DSp1lzYR^d5YoV2UE5|6-`HGW)2f0r16_|UY76>|Efz$7>7{`3%U zZ*4vQ)R{zX$j?3homU@ITETKrj3kF7SVM{5Rh06G-kqEdxOIv-mH_ z-2d*K@GqRzCrsLZnl19bdjBs%?SFUwH`wVD80$Z+8o)aKzd^J9_Xz)nzkC8k{ioRi zfS6As{2z$a|L*#4c*iGv%zxS^^#64IH<;spcm6m0;S&PnKkXdjKb`-7@F4$toPRUL j6IkLujR5QaOyd6oov5yYiuUxMn81$&KqeWVr@#Im%|oH} literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-09 site Document Inventory Report - Site Level All Sites by Country.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-09 site Document Inventory Report - Site Level All Sites by Country.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..f08f1a9b11b3d13db13be376d94f80325fd570f1 GIT binary patch literal 113989 zcmaI71AHYBDUV%wb9HYc_*vF&7HJDGT5+jcUsZQHi*&i_5{d(Qpt{Z4*+_v)^y z?6uZYPpzt6)h#at3Wf><1qB5pj5DJR^gsSk0Owl5wl+@2HcooV?smqGI&^NOgWND2Bn<-x!*hny5V(HQG07 z3Jan9>K*vi_xcIEt`rUri`BOwli6Vd9AN6w`=x5W!zV(pQv7rg zd}24DmDuz#C+Un(MOtIX9T%2Xl#CYeTJj2EKp7fR^TSuQI=vm z;h`WYu~koUCR24uiu?NyISMJnvUK&mGN7X&ryHw>VsPR+M=<)$ErA-Day~Hmc~6Gv z&R!zoPk~Z080B0>T3W0+Ro~V*d?*y`F=yl_Ndf*RkSvk0dA~Vz3_BSVx*QIFk8F z1XM@Z93*D^@_Kcew1n7tXGc#&qm^LKE(7!CC*!aSf5?vxCA!Q!Kj&HhT(jlpB^)9@ zSn>k-LdS*)N@^eAyClf}h7Ka2g^{hHyo0TsBfY+z-4`uoqI+Nfv=q7Y79HwXKM@p} zN$`itJQL(6%wJ`jvJ$G53(%@hs;a$Q_0)}VP4_3aVH8~z3K%bo3Cu1j$MW19fq|9fX6{ZDrcZ5@oi{IQPJ zk?LhY4gQoI_VS!TAAzzCp#&AQ-x9f|BOPp9`V}kE_U<{$Ma^;fyM5A~!~OJJA!?X{ ziyw16mM4!?kTw$6X)(5_mu@|_53-VsAZj2ueJb8s>)U9ceY5L8?l;gEQjdDmzijyk zJxoCK9?EN`aZ`-Hm}RdKt13Z9`?)U>VI-;LF`M`NdTFH3El5oZP|Ie#o9&S#fH`u7 z@Obt#;Jd5@ir%_FrD}hR^Ow)D$Sf<+K55$Lkh|7@Mk zgJB@y;pfh`JK(^|pnRGH@ZH<}J$t5jtV7$ixsdR{J_y+W2+^|{WH;6;558!%l%ifr z#YCy7GCy4wc+b4otk-~k-zwHk#D4d1)!>A%HuoZA>vMJ01nnWZoiK~FtMYsBJUCd6 zcYvjkPJ)KfyN-4{J z>G1WVjJtinWw>jqbKXw`T0?kXfo0sL3FoFC24zV<4CtK)QQwp-Nx}ju%#l~I#ES0; zseT*(sYL$K{8zNlLqpP3p}=$Bp?$4MUb|DVy0-N%<;=R}h{N0MyQoK^_nRn{X4Rru zAc2K#frtoshDa9Q?jGUz{f|FTGURHas+RXw7ogEm#C38@Sk9;3G+rMoCxPX zkYWBAkw9V3^qD|!F|9AFGnF4`BHk`2WUqgn#kH)z-n%z}D9Ci{w#pqq4mWh@y|bg0PIG zGJtZ)Bo&EN5?ckc(HrMkGFepLL#-aKpE+oOTMdo%#xs~*&kQ_f!tsXO&1ImMDZ#}G z8-@N@LlcxeuY(oN%h=c3G}X8a=B_^>uOPOjJL)y%Psdn^ldEE%vIJAEC%sM}!E7Rf zS3G(B;j@pL=?;o*`(&`19r|O^xM9h(4Pu|q&{y4=m=SV9v7BZI0%|;YYzPhaU9P(< zx9XQ9*NdJZJ=TICzFANj^32BIC+1{oNIce@^55F7!6y3_RI=tEHz1cv`rNUJz#JKQ z61cF%CD)2hh0}N@kNQk0w4rf^EeJ!^LaQhXPQu+{RT#l*Isa7@O>Bfny7+?(XOht-UR_j?mN=RD^G-aZJ($BE`K}bRq0`v-+%KZfih1gdjp!0x?LY9iKON*~@madkJHE*pW*%3IaQ^tz ziuv)d>r;!L_c`);Sv97q(-d+t%^@uqdHHV>!gFwKPFH7v@*gF)?BBioYB zlsrq7taaePy?-;Jty`q+ojQ7%Kuzfgp5YK=Tv@F|XP_3de35in;C{9O>5O`#0v8BH z+ov+5#)>pk5fxh+7i&`ys5~C%WJ!^4L7A^5MWmucBx$|xbzOT<^`KuL#t}a=U#0q| zqw;O?_Dl|!bb-sq=UFO~24k41b2%TE1A4OM`E=W&bAM}DJ$c&j?eGzY?vIWe|EFc# zdjQWX@F13H^!+wu?4v;D<82JZQFO?SHv4K74#zH%;+$x`F2&|=_xkMw@EZaWRuhQKaPV6(i%E=v{q^b?~oLrkD+3v7qeCs!LtP5jXWhJzu!f2LM zyLIcZ@g&cRh3Ht`c;D*MZ(GZkH`XOuM!91DEVr9oT;6bWIs+1N1^O+Rmv*f#T-{A31;~Bhmyi1RwC%>KFeYL*%KyWR4rqS@$ z>Y#{>o3ihCyz9_0@-jvHTyzd4SjqIV^Om(1dxZDqTzS2k-v3NqYLt11uHBYt)g*U3 zHEEDJeBO-?56Kdd%G}VadNv#)*q>Z=%V4cAPROshAIwYZ4S3J`tT%nXPL)05M`M4R z&D!*NJ1z(guobHvGIm?C&$LOFubSE&(`BmHC_JIm>WIt z92|F4&PSr3mQA_lIa_-$%S}VKdU(n5K09u@m@A#VpNH)q?uVl2O>zC+@0WCYLDY!& zn}TDa4t(On#4oL(v>)!qc;s)_6nae>v%gI7(z8B7oYSvp9xuy5s&LP#=05m`FCDJ5 zczmiWcZ<#!MVSsqK9$XjnFTHGBNLVkFU#L=vkeI4wB6eR1;o84C!LZHud3UH%#yAG z`@|bZnG00@dYS6Po)m6ypDtXxTKMG6%iu9?3%zH&h0J4qP9T5yF9#a=YVQii=*1Wy)-r%llL5kU``RofNoykfOz&Kz%+{}vJ~h}cQ7&Sm`( zt2SyojCaZU+bqt?TmALXJpEDBv#)LtSR)!E&80o-MJ=EnW;4^Vs6G zJ0w}YiW)=y$QcbR{5UeL`EphJwZO3zKU+1%h8=IgYMS0 z?o5AQkK`92!8rRf<+Ww~L7u?J>L=L!lLWKb`L#37RRS4@QWvDQGOTwMsg!QzPs8+`(Waxp1_|a&zs7fE9E151RwZ7p9cc{d3_z8}GxqnksaD|Jc_|-jm2$reEE3bN$;EcxjJarNu?o5-3!Z zPe^#4u=mXEEa^bit`y#RD^@36K8a8^cqE=KgQ79|WY2m?aD5%Q{H8y|UCLmW3K_*L z2Vv3gZrjIAyb;eiC2s0mvY;?b4Sy04TePtPdEB&A0(vJDeJb}Wq(%RTX|vMDnM;6v zFJ!z*)_vQk1MzpAD}7))?tmxWo;N`mJ@ZBe6x42*+y~wD41og9iP_#`@wCIEpvqg& z)UEdVnd`@#z3Y3pT|pL2sG`}B^F`mge=%8SNZ zBX?VCe1lU*p3lrm4w#F08T5={Lc98Q`qN$yO_4O3kF48V`PEm4tIu!*gcBnOiy2Y5 z9mIh_*Pj$hx~0xcH!p!)SnkmevI8P0nXLlsD8GLqH^X0gdwuB1pPFcAr$PT%Ix^Yo zk9TIiNjGK~;!-bPuwSlI_Myua)c`p$iA64WT(&dE>Zp5YT2^}{-u8Jzq`!ziC;1e{ zeovxtBk0~dm{(esanX zV_f9kw}tpztvjL`c^NLE9R8TB8a`;^&=DDJb6rR_{tb>&^j6WTB}lssV-B63{JJ>b zG$ZvF4J9+>s$YbX6bc0;It3A2f{>I7C~?{xrpF3i%o^Wg1|#udCXdLdaJk6*PdlloY$ZKx%Rx#_fnOfv+DH zX*XBtfF$Tg{)H-ar9jhDpnf97I9ZT#SQ|HphSHe=6$pk@5Jo8@VoqF&q)_3}?Vjt= zEh>~yn9G7zP@-<}eWU2>x}6Hm2Lw&3yAPS6227d;80G(aDy!n3Je;2#$Z>c#6YGtn zd$&U(i0bA}+7%kJhjAVEM%*5?e;AO0C?(GuBphcDLfj88s)`q0K7yjM93J>I8TvF? zO!_Bcq)1dJP>aKrNc(t1#*`AbM9Mc%YCPonPI!^Z9{*n#c^oTGl+kSAVE>~JuTS`L zVvF&2#qFDK6mTn1p=-eA4QaYu`@zsqq@~+OcEh3NqyZKqq5zsn>X7y!Bi4Y4(Dalk zs>OULpW(>$cV7Rui1=?_w7-GXEYcwFcxpKe z$Mo9N2i@o4U*g#GI_?*G)?d?WieKoub#>I+g`)qBhhGX*kci46pf?eaE` zM<(89+bIS6)Nu6D^YJ)Eb4X_4?u|n@t`h$I1rIm(# zoA2!9*(x52qb{zY{YWLVVBhF5@=^_AI<%+xo!Q6%d>A&B$1ntoNlAzTl(pHwW#nGR zz>|)}UPZT5Mtj(YoWvUxtiur*b4fcxXWY@v*7N4>1^=e9{yH?AW&W&dT%z_Vs z#i#a-R_U~>WKO1|A86!5-g=G(5QRN~U}*EDx`h&-;46+u3G^fXJEV*N3|06O1~RXHCJDBf2vtek(-%kr zh*k<8GpBO?n*SZAMDBlu2NtXHmgCqX{vv_*x9vlCz_|{17kd-yLc-`=3pL!I^g+pw z_-7<=805B3CgTWhMR3f$6T>@qt+Cv={WFl4J45qU>35DAB>*(v@d~BXVO^r%A#9ci zWiQx~DREQ!zL60AuTz5WlFR_x)Nrr)qKgkg`FoJ0&O<>eDbK?}D%Ek-Q0+v4ae{`iTN@ZsZ5gD= z7Zsu7htWv&ncN59_5X|VIy8|?L+6@0r9s1c{3tN-SXPv#5DkUiS}9}KOw>%y!m8im zpThzFLS+m%Onm4w<%<}mj7g_R>yBf&3^FWZlCP2tdeoInr2hI-E1W{J6f_Jns}RxcINT+WLc@Sb z9&cF^IJ^h*o8fDWGNe-F#QR~dNzp_iHPK2Z{ht;KN~O@){fYr!_R*)6MyCuO-YZA| z_{8}dG8~H>rO(6+F#l`Ze5w5}?b2@DfOFXRbL4*nG}%8k{ZsjXNnSU|fQ9u>YuI?a zX#H9p1K4=L?=S@quk;$-n2*5g*Vg=tkNmIT7wwNtZQbMmt!)=F^Nc%DF;hP7#K@T!1pj2N>T{3 zw&_TZQCOQM7$;k7Gwp>4T{Fd>?~mm#)uUPlj|q*mpdCOa&KsH-sGkR+d(5$n8=2lzKF$!e6kdYU3i3L zU>vr8eD6M8&@D18${wKlOE7N($Jo~~+B8Z`He4IS-!(D%r-0GMg=1jc zC5+LAZD4!|lRds~eD5|vXU9Z2G;Nw4>Swi2P%~D)5Jp0?G^-6chEjOiFqx4(v-<>{ zJ+smm$lQz^11q~G<@oIJpYjYgCe93Oc6p`(z^2IThf^- zBzD0G=CJ8lFzLgmoOxH695|q+fHC(a0QC3|qyW4D^!Rrr0Nqqxh>4+p3JkXZ^!Rr- z#4*~DL#GcPQni6iq#$w_nvh@;*;*#NQ3EcAyHmBLsqDy;W5Fl(H~|f$sWM>a&vbJQ zWz8UI{p!vXdF{wQbAE1({q*EyredS*KLPX@QRE{g%h-n+LOSDocWQg~Om`|znb;OA z)hs3lGb%^?qNCV0qa7Q>1OT%y5eUfxF)`4+Ovm^oQsw>sQ)v?8$LtB44lohW4A5d5 zlLHV>x|cCINC563bHq<7xj?6L3T=%s;`I>H*~39h{AGtpXLUODV;+|!-f^Wb2jXr&p>3Tm35NWs57R+Hhe zH>MDkJ}mVeaHz8onTTbIienazV|M@IG>NI<9)Qzd;)~OJR*_#|ehC1l|5N#Z$yqlz zgoX7_K_r0FabLtr2mB6`*aT@D^Ya&{Q>jHJw0F}EIQ4(hIf(r_wQ6G_;IuqhATg~R z9{K{`0RX<}7x*Io1-?rs(@vAEO%T{kr1#vctDIc<^D3G3w zPwJ==V07az2{@Ev3o_+P8^(^w$4cu?V%dM%3)V8yk*_&LMnu`yB==!r;OrXwRl?jg zFw_S4_9dh#@2l-=7*S1Pau_^egW?!b*@FKL$S-YU!T@?fehCwXr0Z6GsqAPG2fTgH zFL}5_jL}=I~(@BR}q-pYFo0Lj}?1Q$jT{_nh~HX_s>F zn%(d+M{(d#9lYAC1Wc67pyw1ea47uicMYT`lvmaZ_`)Ju6 zg_L<5b;HwGT-{^0#D4cexz-m4^FAJOzR}0M$;r#ML$Q5mlv@BKF~^N=E@7``A)i&; z#{IGc9p+~d>SmuU;ww8TMp^!3cvnYX&`kb8y1Y8_~-mPw)tWo z%IEG7#iWAkoWKNyhnzqoujt>Rcg{#!n{I8q(r&X7oi=ss{yq)=$&pCFnaQe^#CF zHbv#s>~s9sppWPDp?MrNGc=gne57+83JD%~cgW~9L(z{-rpCp?9|Dg?1TKI9UA7T$ zmz z=6d$Ik0t~Ye-RM(O;A`sBGgdf1_Aq!@Eq8VX+MQ}+i&6S&RXGqy5&!M=X#+0h8mgX zOmoY}QT1L+;?0Y{o~MlPqBCz(4`g-2#8Qmx$TznF@goW@?^p>2!_DNQGfnK&M?@ z3>WqL*uX6s<2S_>MO)_oV$wF$AZt!S!A2T@j)Ec#6mxJTVnKqEf$c)!vp>i0z5T|= zw3~I?o>y-Z?_66GtrpRLvKYyJ$oLs7{b(a=TV*E>1?_lWkqE5 zPttd132u}u6Qf8Ym%v|7bRD63vYaEb zPd648NYaiCw}+urcRPn3x_f7A!-hND(7*+gkR>qU4!^j-CU2_yZ94!*Zr`lwVAA1U zi^63!pn_H6wI2&;yUIjNWSqc?ParEA0h9)9|4V7GD<8$FQSpL$g@k?RY4DXn;+tZ| z_PX2$(~QVOWU(}r+kzURtoqUI#l+-?W#mYIU1xY;a0)+%6d4Z7?#Gp3(E*{d-% z;;aTH!K6(o_O|(X(0%&w8l>WdaxXo#yBBe-#?dmMEk|4Fm3F)61d)j35Ug@v?s+gN zThahuaCsjs6Rt)`IXAj)rlA9T-E{;YEZHMtuH(9Mt=0$1UQn=ASkEJ6_-n&QNt5Pu zl@WIt4#SkA6Q?Y4d*DGO`)?=ATyalE@Z2@eK?iiN58aStyT#m_$@Ihm_dHfKM>850 zotlDvbLC&8+^LxD40Z|*tWs9=Y?EJC6Di*q+uM~*-5$@;tHoz0?7md{@uIEyE}`%t zKcv0!fa$btV$`xr1lJER{#yL7%XL!4r7bX#nUE{KWmb~~}!@xU*$ zI+dmg)4sUEAyezJ;>Itvio%46+^+<3!4`V-jFO9FS6r7niWwv8co|Ee=0&w(=&S|V zezV^w#tO!ubq?4kM2fQgP{MT|*zHPLW*642V#i>N=5Gv$TiRk(t_&1=57-6~K+>>D z%Z{HTRoA&Rkf>9LH5%}eSH7r(QR~u(4G5f_rQJC)#hb`VWAyXGE9*RAMx2}EmX`eM zR+X#}{5%4;cm6$-vE4H)Tp@oL0@tEF(q0 z7*?>E#T0ume~iBjOLXI|ve(?S=I34y{VcP|XbjzyjB9j2Lt8odj!OiiW45}y?#iV6 z`aSL>2spr%oQi(le09Al)aY133#GzJl4z6|dZ_Q4(B?O7O&Q!3I)Nk_ozf(s4pWWbd121HdU1d7g7CLjr=o^V&T#!U) z!cvXrCZerf%G}!4hB!SI1nN|ElbgC z$Z@}T8Nl62VVJO`y(RqJ_N}X=+qTZ7;;aHH#oe2k@5Phbn|3VmJunK-}7rj$a{#Izt(pR4qqaEKk|YzJZ`9F#ccI)Z>!-cmC;lY+LWq$&M$xZyyqn7m zRV#!!fwG_YMO=P^%l!phjr(2LeT_U3V5{VRw(FHk^jEJbDhb^7SM~;spaPoDpJZ%C zBPjP9dCDM~ko416B|1pfk`6EaTKC`%!LHVrv3*-GbO#qw-QO6;&7>;jm{~7>N!+Pl*VVu z&v!$Uan(k-r|$egB5)`z*2l_=Qe6u6oks=ICT-D-H3vLn2kK!bLiXI`cy7L@dRwo( zu3IAAHI3ybPm?w#GlV%Fy~Zqf9gGdTl4j))7gu`1-=ZMaC{cDJg!I`m?_s-7sY>Lp zRq)nB-%^at1=_kW05$+y>r{Q&P#@*~p0agsXo65jyAh6mdg{G7B?ikEJ_TTcFn|fL z)&M3QxQQmLt5k#XK2AAjMC5dtgi!w8pZjpiU_AO9myMm ztxe^O5H`Q!0L7JKZ!NGs>CZ>|uBP_P@%60TqW+WX&)3Zo=k$SVTYD~& zz(sHB21tu6`q#u@o1+FR<3Bp3N^NbaNW;WAjj5^}#@Wt{^%T*UYNow&EpVC`y$2>g zB(MtB#MVOITPiFq0TJ2;r;e4&zhauvirewr*XQNW0h^c7t&CE~fHkDOObJ{E5}L6E z30LWyYP>=bTcKJx)sNl#^jj|GRdq;&>$g{84O^4Gn@OBo`+f^H3#7Co!fFgl66}-%LlqdF?@*t^~C4mRRirBs+PeKTeqoXLH<|PB(2c zIbJWtdXTJu^=|wcZiQ_#W_5`!WE0XNX>KmO4RhrWRsauF9b_)hK__fvt19VCviNl- zE4}$r6#ixjQnx``6wC*^E|=SmD(F5JaJ98@lLLmF3y!@s*Oq%Eeg;S1c1HZ}^h;BJ z3n=~|V1iy+-((Ckn*Z5UX^33r61YBq8xN1RWWAJx-t3K-Lf~Y1u{o#GF=5m4_`|&x zY+9kH32QR{k2ItQwL3Y#`gO+sWF>y?9pj(R6a_t|US8$fa&i%gqrfXzSHME-{G##) zfS4;L*xPf!Uh#g+`h54_EEanc;E&Q^eTiIsHc5Z0fUdT7{tyA`ZDiccCwU^rGkNKN z@|xN8?cZc?++Uz@wi_M+?C2yjGT>cZQFn zsn(S_-nPL`wDSm#y$11jNL&{xdKchlm=cD4qiy-@N6z-O zto0ASF{>hVH7H@9>;WC?p+7o7*2#dNc-OW{S3|J^??uum1zE52veEbLSJ7HZL(i`% zS1ceD+IO#H^@gFA%F~Lz6ZGv?M%w}sH)_1y16KAU=I@{N?pr_{ONHi4n{Py;wt+TuSd2GXG9&Q#mbEJn+PLnLJ~Xe?Smt)fWU%e# zpMt~Ro_Z#5lotNTcT(KJ<`O^>tg8$_M(Uoj8WTK*f|nd@<{gJKLs)&igc~0^_6s*# z;Db~U6~r2MsDL*U!!>WJOS_yV_Au4ax56*Jh6V~Ytr?YaW^;WMGng#P7$?VGn=`)^ zy8-4Wd*+dNw-XVc#|cZ2A2AgUAtC;?z$!@$f|(VCMTXZyd5r0r*V5r)^WJfd#mOrl zH@R|1SV~EGt5G@cHyH|i?&5;xrB}iJ*7lO&%-GhFz~qq)(F|GxO5h={`?XrYL-sT| zk7S!ZDwIvbo4NN&tM>iGSiq{V2oaH_G-mldkC^A&5f=(HU}m@>A$}#sWpZw^OpQF_ z<97_Vhbts1W|>u7oSQvn)}jh2Mgm{Ay6k+%s(BdN*@MU{|BAv1i)}h0;77d;Y8sq084q40XA9`Wy+ExSlaB zk9rALCl8+q`-ZqVKSb-`d(`MY>|b;L{T~s1vswq!GHno+i$he=q2VCqDyTMq$K`BE zScnNrNTFs!u|;-s{%HDXA3PEHA<$FO&zr4%ttBV(69>ew=jXuB!fk%Gp&&Q25wN_n zl~u5Fx&pTmPtIt2g(S)g8Pb#m4mbdj{N?aP0tV}rxS#_-sDjJ#_2%aX|v_cW{)%v9Rot1G?M!SQ4OdA<(KL;yP^jTa%#i>)xIr5oz=f zNFo}la>!I@l0m;;brQ8+>~haJ_58AZeTo)F-LD)Xwayr~(LJB&*?9x!tiHMcJ(Jtb z9gPR42W?4pfrn6Dl8NQy+p|lPsc(Q3s}emG0dksqwq8fO@+DBKCw@(M)Xe2Id98QY z0m79-EAzW5k2COL9?sK7;LAMrna9&KczTR`k{J8c=5wgA3SL5%u6-f>ju~Fwdq5=_ zV5q!68YW33!@LJ*OllxiTq1=lA2b%RU#@@h-G2z$I4hU#unR4~)`mE?7{DIt4Co*R0hoZFoU@eLas1hwiO z8GX(ZAv}}jq+$T3;2{!?O`w}r2uTs3fObaE0%}Z39g_#=>y&d3z|AKu5T|Ss(&y`# zK+m+A4I{QeW+CrBnPZf;Ifjq{K4Q5|PM?Y_-mx;VPprH^no9zd@Udq0{U z;Y_ek0jZvQcozm}JnY~g>Y@#9hGN$(4eSn3MKO&_UnA>tJb|mxe$;M2Hmdt88};V@ zIKyfox0}^B2B+>6eLF0R!t^hF431G#uO=zVa>q+&5^mSsMEJ*T4%lnQ{xX!r*$GyE*W&KQ>#C zC>vymn(S~bzB0_8i&1nrT{0-6D-}{x4c5dU>d8OH8joQbWfrTQ>2UC$J37I`W(!RrtBqUol%%MZw>Pjw)z%%%7b~V?BIy=>O ziN{U935=^?*3M=-v&aQ-wX|{b!Zp+}3v(%9)O#NUcvcPDO+7)woxbAm*OZsW^EFhc zag6~Vdk7%`N4^g58%;8W!-`EbYoWUoHEmvwW zT1n4(E>GPuZQ^A*S2yN~H4m66xU{0Ep%yr!npYAy0V{x=`tZQ?S%)Bxb6+df>oQdw zlQ92f+33aV;LkWE{^YFn-&SmL1t^Q+q9*BV{CJD-i#<+9&~JMT%WGbsrjn=z>+jxbVCyc<^0R_<>SQd6mQ zUxAA}mNs|J?8EOmyrg>Z=_AYHHheQJyPt1p?D+<pL(&#O#X|Huhnd+D9E- zdfK#)kK(#)>UO;L^FGfqq>^q`{tVoX?}Q}YC_J7pK1YGRhiwLYPCz%14OYX=la|#j zoK4+sW5og1`Mc{nh3eF1gUw-L9L_zr%vc#5e&PX1*KBUSXA^SbRt1pnHT znnFgGeIM6@o2`N|)7tONZj_<5bZs`d`}^*6pYlq5$YY;ubf;Iqe1cElWhVSCf8My) z0?73FB1i#N-SRPWfGlo#PJQl%yi|tARBBoyfpq)SgSiCHhaTPozSB`59F1}h43!^m z(!I>jm^IW8USi*F{NZ)*2mjuAX3sf&7mFl0PbSUaO2^BdoAt&XZ z^lGs^x|wy~&X8``k2x8Ddk2rY-y%4II=xy0V$uQmF`Z7_m))kGcEG)+yDRti1;iD7 zn?f>K-Xp|`Hy*+V2M!U?gDI-?DL(-Tq5_7+tK5f>mP$M{PZGowoVq*@W#1Nk!>m&e z_*2FnU7nEn8?E1b2hueYh8sMy9ciCFk#217cV>;s_f z`R+*&`LCWo06}FGhF%SaTC+;+mULtQGA$8JBW9Rb*H%>ubM9XZYXC5eLS2#PjFp6Mp;+J8Y#Pe9oke z8b-Xzmj;Qfd(~p7DYq53)oCLq_MKi$(V0a#`;)2hiF2JXm3M(NrRDmkZ4mC{PVARq z_}xOItpzo131#t2Tb9NL+ z3sd#1M)hMiEE4ORW?{x&+={2zG=MlhHvpTI`Lp^CmV5DOssC{!aL$%@!e%2|)}oK4 zP{QIofTIB|S{YUO$NI9S8V zU{WYhMc2Sg&updNz``dVvOfTMSU=6hA7M~Gv)K;v@4zSuOy~ZJ39lmXF7*Cbo|w-1 z7JY&*J-rLzEKhR5C@OE6HS{llVNNFSd%pl~8AiR;-UJSr1BBJ$wl?yb7c0nyFml#= zph+W_=+!<)-ek1AlYu$bt<3nLKOUX|JZ!py&GJjJ-Cs_gYx9b-!3VtH zVFC_Cr%6#ult-4E_tz+Z!tT3yN9Fg}vCupk-M&Y%b+yOwbtBWh#4{0AWkb})wAvnC zz($>Ouxpc&LBqy`ov@1}0?%*eRgZ9$yz|zK8PJ$LFt+T!Ba{Kn!z7$~v7P2o?8BFPc~`x?H@WSIP4>L9v6v>bJO|XD*l^0g?x0AKo9piY9^{`? z0i-7HYYDx_VIbMo($eW3m!@-VP%(nSEog@@2kS~9G=**l*yq@~u*vSTXv13*i$1>7 zj5&5{FSqeU@#C2{BI4jm*g%g-?o~HX_lBn5$50~Nv769l zz9?}%S|JslFQ$wtQIShX(Gc#>Rf5!jT{7D1MJRzV58_Hn4%|LzX0$J&|LdnhQUfOEjle=_=O)WLg*DQycJI2itvz7@LijkPcy)9nA%P>b9 z@A%FmBpcrw-VKow-{ywQ^w9?Clmmkr1Gq#IY#RT``6@<{NP||f$G#4=L>55~E(~wa z-_!Uwnl$+kGOuz*9$KHO23wRSnhv`1xSi{}m&o2;m`ImzteV^8BFTD9xgC3=Oqi|~ zF2lFwGrogh(+3=U)JPx|a9rB9|7uVam37pKCwqWJ{DZ@+@!~%`!+z$rTLtyaQ*-Z= z(=7U_3e`M%shevGm+^^e8kb$?A*V%~HQ;&k_js=k_B%GMZmcX)KEj-?>)M0xOt6!8 zN%Y+XyiEDcYMf0j89;pwU|*fXr6s*x)@dpm8mXg85M|UN_^8!H`V5IsgxzG|4xG8r z_61XL^|B*-KP%uUR6#24C{(W;bQ*~y8+qE^(S#s(RE0U0;Hqn^@m=-cS)k$`e8pyp zOJtI6-hE?zFigdZds3#pw*=vZgE=##Q!8=`hbKg?9n5WGb1=-9wbxN+lKcS*F%t*y zFuuR(EW78~PqrQVx6HaDPkK`-U6FRIq6HP~P5L^W;^(%k)Xj#&nYN9b35ULsf+2@K zg$2L;P&N6m{bnD>!5fbXoohAY;ZLEA>zg*?Nc#Rm{)9t)2#ddMaqbdktJxWPrNW(U zkf@&I=dtY50!4gIHYV`yCtUh1cy1XtQ!S~4`>&n?ZHs#pXF9#975f{25TW0=wQ(1P zePDJJLVI>~SIm`_Mp-m)6|JIhRTqdFkFPu6&HdkFmAkK24EM<2c%u)7iI?B1Z)B}r z&DL+>Np!A7(ks!+UP&|Y-k8!p(I=TwE?W|+eb10Q#m?3UEne$Jy<)FHS)XUd2m;&9 zwsdy@lfZ79r$~+X(uCXj0N^cG&tjaXiNI-#3`0X`?w<(bbu3RCoA}|ztf*}B&Vm2B zX+k>r7A?P7j208@ZDM%DNqajvO*V9{E2-n($g3FV7KZcTx`6Iu`-yjc z_~uYG8D|1o5%Hh~z#eo8$X`uTc7oAE*9mf2HiQ~yXN!VsuY?Wb-7CqqKdrVlrQi-8 z*$ZkF#ICpya`6etC+Qa#P^@$56R^k9pi9Ij(maFE&srkFRf1MaL@ViBJtLGP4}|av zdvq{;3l5=x9aF?Km_9b!hHvUwL^lto8~=W82k^{jo6M|Hr_R;nfz}5no@v|2iGBMZ z-iZ_Y4!Wqa@=|4XHkYHnxqbsgErI>o`UGEPr&#j+I{?_vA{OR>grXRD?YD$OC&h#nNRGbreokkIC$T9YtGtryKS%dq zv*u}A=qM+fdQ`V=CLTWBKyN8BTiV?C5cKgVGCACj1H2RF8= z#6@awC?h%H(yVd7MzxwV=4Puq(p!V`%!1BlL_*^G=PUlumGF5jZ};Edf#$)u0Ks9| z*etLt+s(n7&xA=ZU3mCA3b zX8_!as{=U%gy)uKCr~(%2b3W|)&HkDq7ck66bkEB;ksm1k4KosXi^j(j(EPWiH7N{ zHCUbC%+@N`HvNb%vBa($BaxtMI{8pH#gmll`o=oP%sZvYg?tUxnH-@(UM#OsmL{m} zTr6-E_QN#i9nrd5vl@Gu-y77AVv^sYUPJPzJKr$q=~=!N=<*nBgxcv#XkXGS2RVy| zzlJeG_nu$eV=4>A`yG(W;^(%}qD+0WiA7h)qTp!naBBlm{Rwc{l3;=o*_myp5CyRB z;8J8puIz*EOYDeFoqnbBE;s+Y7Q-~rNC%w-xemEJBAmW;_C-C_woeFQKTY�`0}Z?{3rCmVOIhE>UJV?zXLOwLO`#U|Qm2 zvyZJ&Mw;6&cOA=$VtrqZV|ji+_8a17w1BQzQdS157ZFTuB=P|oE5gJTULLIXim4zb z0^inY#8(R$EkoEsam z9e%*atPk9bK0K34&Wk)O2;2fS^v{0}PhWzDQ~V!j;G!m6N2173Bvu9wJ0m`e2ib%J zpM!rGA3e&Gb=O^@X#f0SoLLP$i`cD^e{ize4m!dGd=t(C4mpAJgaBI3apwv$LTx7k znQ5)E2cRG_I9#yNxMbR|=n8?mXwXL7e%L7h1Yt*Kg)j;Zcc7gG)soah3bJvO=ZNCB z;3#Rc(PJ$2T6TwP&P2853HJ(T3^@X8&VR%Np1oviq{aQp9QuSZT^VPhM5g4?3H00)CRNy%O*OtSi_}*Pn*m z0PcLmCcnS{5*hjRkx(XczqROn=S4xd?lEYm2q@4lrjLV_Wu7sa_0*!AODcU_IrZqC z2HE>>nOWDUPyFBYwlt=nU|cn>C@OO>!q3S4iARSfg??@5h34u^9%Dk2#M#u zT0x%Rrm$-5P);eFH|oUhuMxxV0Oh>09CsAGNZ*B$4n_}`_jO?1K1R9EX#M0;H|shqM`Wpr;SmZjTir1szDoWQp1k$rFufkakXL%feh zS4`DEazCG_h2=nj!a@iK=+JEL)1kF81{{lO@-GK}>PujMG5$n-KtVCrN2yw&YMhQP z&ptzcPcx!RBEbv*XJVGaGfDehCx=1LcB)PYTnq-`H=edbm(jQ z^T+&3_IxW9(7xR`VH|gDp_pcG-t5IMup!c%-W0g^SUG6=#)*d^QKqY5po13tPU`nlb{`c8N1RLz&6a@rtWyy^3 zQv15J_1uT?5!IXrE5>ELCLEh;GPXB~_DT4&$3?<(X;Riq{9<3_c6sli&k`x`_9))- zLtfT3;Ds*g)A`}J_y-`IMS+#7xfBfD^=JPs}^3ihg) z`?*ImJP@vD+8=yb{Nl2BROGW>guE7PrWNtqSmxiwzhn-q=(TNd zK&mPx-fb_elb+NglGkWFjHTTZY|1Zjp(0qJ8GUeeE1Dx%L%eVE^6Awa1m_7Dmi$&< zsgZo!8fh7q_@Xb|w9fil+_5F%)RD>9YDj^>NgJ4 zinlpj9)SQM?E0D5(KYUAp;Nj0Q`jcR%Da&4>(@ZT{}|=KtJ&&mk8Pv`0Kb~rwJx6l zQV!u)rlr;GO`~XmEVqYj3+;t3%zrz;>uGxQr;s^TQE_c<`H>$Ux&9hys;>ICuW8JA zb!XA|csQEds;QX>P)B=oYcd!foMzdefd{gaF2%N+i}ni;;5RePCqU`_^>sJua36-v z80Kzm?=NO-0oc4qY}*H>NcDMvs$xRzP9mbzS9nSnbNzo~3Ubv$%&_sN{UN|@4!^lc z7cG$N_C4D|W#P-!SVy4kPmSX*Liw}vvVAn!=9XX`y+5%hqKMKqdq^c$5ToG?z&OpE zkfD>UEuIdf0pVuN^A(~)-RHF`Z9C~ihtE;UJ737-!ZDaP3T-rxJgQl)7Vx%xMG#gE zB)vF;17>6_wP`9Xu8(--Mu})>Q=mq}waQWqTz|LzrY?I(w_4FI~pzB`Lu;P5V4^ zeIqJ<6`pG1t<4Ip!3b~x?&W`5n@3RsA#NSn7GVot_?s785>xWjQmRdQtB{G}#RK}Y5eAc$JBo1&+A|q))kXmU?w`JRRYWmAWx31A zl-VZqig2-W>0|CH_O9i}+$z>3=y9tF~Jw>zDv6Vj-~18AMkSYWMEHv zecK%29ft2+7hmHME??Kp=DNBE>yBj$0z6dhZ4mcjb5CS!sLAs(eNAt0IOT8KfN64TmG~`{{QVf%< zIM7}*ghoAQO~p%%ub~;z#fP$ub8e(0^+)bsy%sD@;RaC= z{L&y5&yz(v#s(2Yy5B8ikk%km&cC^;Wi?htwgnya6q=FeQ7T-%%w}J{EI%u#Q7!AG zR3W>%#jkWK2cJX;$fusH!M2{r5*nflly9v@d9rF`S8+zVYy5SaSN1CxxxaW&Vq-X* zjG1goDz~K}3Bj153PdLUr+(%f*0hG#WbUA}DWLCOYaljEBw5;^5}7q~jWrHL|v-hOWf` zUw0uoAWTsYinw{1k`ecKlhcFEqa(JZUU!1e9v+{|OB(Up9N=C2b zbI987v?N!v#2Eih!hC^i#yxo}7hjCah-cU&C8CDjF+}=~(#!qvpMmX-DGpeC$j!moLT ztoaoAIv2rQ-Tf;v9~{jj%(TYXXXdv%Di-6k-9ZCRm82R= zfonkq#@H%AMSc)6iP69IRU;i|I8H&fd0;GNqu6pIqX8q-)6o5)gQ=3C|Yd#`ZrnL1``VilMAsx6(W zRRz`3LG#N9fz~FL$Vw){0*fk)$W`!@@}!aY%Bgu${ak?Z=QG6a3jKr2O0tV;ZE!j% z3S)D%0}I|^w*yPT4QS6AV##I43Q{@-K2L9xaAq&~=j$@)Y|zCxcXVRuc03C`sro(+ zRDB8=ZdKN~Y0Fc)#@Ta!dde(l)Ju54kt8`_O@ZtLObJ)7tIvri`}SK4i>aJJsk!r` zc2$a!9))MWfZc6#;4!br4?J@owO6=_#IsxtMtt5#%TMixs5@qtk7>=gXGSc|xSXr< zX{YuC-icI~jygiLNlm}|FTdmG-oo$6G`EK7V6FqT%A`)PKmGj5!LNx?#4k;UboQpo2V^>y{lJ6YNyx-_dP{GZfg^}+~t4Rv3 zuAPB*8#ti|&D#0nV-BhD4}hJ^1ldGGjCkfGIZQo)*M^+{@hv@FY1*ln%Ce47QO$ry z=@ob4aFwrKhur|Z(TwYRa6-F46|d78x)sr={&v)%+&#=hYz|e_n2SNXj#TcU46m+6 z99&P9M&@RYp04hsp#KYh=gYH!1e`y@`8SfXg0w!s=1bdE+}XBh;EAeEog_KpL{S{X@=g2|?xxDxOxfrNTcj=!yvsBe;|x57%mBt8Q3QvYmC&=UkrE1TIR6$Ie_(VRb((aLch2m z4{daah+s%kN3CK=@=TA=|KEgO5SE^HM!d%J|A_O66hDfca0SR`+QxTAk&!^Q;%+h$SUo*Mx=E_Jq) zzqym?Doi8Vwjry3L<83zwb#q#=frm8=Z6q;v;QopkGcoO>!N z!!14MO5)#%)}87Z|4M8)wl+>YU0!bnvAx>3In$Xx2*=hzG>$@eAPxX~cU8bA^RIC- z^SanVwi>IeSvbawV{pR3tR16dpiib|33U^PPo{>R^6WCF133b1(-a$8GSQTUw+HV^t%C)zMq z(w2JIl{j09SbME8;lD5~=*4wR7&{zF{B*VTU11)v&GI=b5fCHRl-@LY(bRHQixBDO zb4Q+4;kzGzBab1WW~V68+azDev>D~cC0?Fln^P*8_Vrr`M-n4FiQI?ga2j+>yPrTGrC-D zJPIPKOiU@ufQrfRWpX$@iK)p;G(4Gm4(D-9+#FtIT6o_*+|aMx+Pw~>vSv{HGN=5b z%~y?Ao#_n0S1BH1xXtya8+)_S+6ZvV64R?tZSnh-UvHF(2#yU`hfdgJdPlSWyijEc zHRUFiZwHm8N>sC5ZNgIk!pn;L*%3-TCbQj9W>$A#m?OqSC9l>DgXwdBfCpE>`LP)0 ztldCPQF2tA{P?8bo|hZ$nn1~D>NSx@dL;auzHfqe-8+M=L38>Htko{Vb6M*^@++S+y{k*ZxAOVl$bL4Mc|ZsS z-#7eb_m>9zZ(qsnL7`nck#(&o+WgHR9&0+R>feiHrtx8VxU8L{jNrL+a;w>sG_LK2 zMcN73Ba75&cQX$vi3*o!2S#RIPzRKXynH&j4|zu9e=rw>nS^=bF+*0pL>;2a+ZK<> zy*$+F5mYmc=ItgHWQqib4}N5vzpzv0sS6G5ca1CmGIR=<78z`hIz0c&W6`OK2HoV$ z3{v}DsGXYCd~;oT0V7g7ZP*OxwTK_rZoM&_ct2{m!I6FN%T72I;&G1_d%^DFAAzR< zb?a399xqBY~-nG9&4qI?UE@r&)H0lU=eOG zy(lBDOwVCWcc35MV*Lom``HzXJ$3|JI|!ouXzo!)n&Y#rDe@??7WVNt(GAuq(+LW` zL;i~YD{tQgFxT}-5|g1ftOa#K7fX#9cReZgge=cFJK->a9NT;TytE3vsoz~L&$x`7 zMZce((Vdw>zD+D|!i8DYFO9jdU-2_rDCk-3^oGM@k5LTvX14HDhgiL$L0t^pe>Z~l zJLWi3!F1|3)6BYBap))aq%Q%5Q>PNvesryFy(i?9gwW9o>&`qynOs7-&OOP<5ugyA zgbO?rx5t70ajqT|bybQtZ8Sojewznt4>Ew)x-?e{1x2@b&;?#^-<7q9s3ZJjz4s<>pxtf@ZE+D z0D16BFlUo_PkP6&EksIOHYk5Z5WfYh`CDli)US>8f5Wr2*49RY#+*E=s#a-gQCg@O zIGY?HW-LEz1o7-K-2t5-9Xo#1j z+FBqQLptx8_rZ2oqm%#rs@xsJ5ygWXK9#KCpD;Rpg>`R{YMd4&?#{)02UJP=hc+rq z&V7sD`9-OTkp!~=U`MpGljHf%=*VpJY3iK%g)BMC4=unc-#q21oq23)Y9<%@hDhg< zDQy+*wLk&na;(_e`Of(@x5SsXlaNW6{9+eg+gu%D;mREd5)&K=#@0gDBNli6J)fE7 zjW~u`p8nVV_iW!eu|4#*)UogGsqs7e{s*Cl{jZB1TN2=q&Rr^oh0lb&oYv5(a3(58 zOE}eVwg7b$U<0dta!WQH;@E_-JteW?+QIhcCF{^~mWZw-0O3QNuf7XY)sLj@tM81@* z#X(0;&nloZd;zOc8NN-9z1ouM)(hMS*Gy4n6F##fSqk6ePKYudd^a6q?-B&lK&d(o`(RT{JBLp z?OX*9&rP;O}dvXji``ZmFgqwqvW3lY5mQ>2WOvx~4@_Pnvh-~n=&3C>bGKa@uDMdL` zUJ~r-_?ctnOkgSGOfVGr&H4Lxi1azhfh>kF}dcN0BrzyGj3|`-N{a3AB+NqSn339 z;%A+b%&w;tWh%it0MV*n?k@S|J>reUAXe1BvHU_)_`kIT-mg> z$5BOlPfGfG=4NhgJWVi1*L=f24?j5jAz%^eI>WOufJNy1?;~+caSFBE$Rq7I98v!qw53Q18dH+2zqkPp3 zl@8b8o=IKwLN>RZTMXQOu+zK-=ClD0O`SiYnmpYaayxgn;nYLw!5;zD{2I`@Sc7{| z$ML#}y#prY`R@88$q2}4({W1E5(Cmkec6t5YqGvLA_jd2ixR=2#aLGaqJ}QxBI5S^ z=;-B0+}@4QSC0GxJFlOVq>Sn!u8yLPq_Jxe%oA0JT5S_OA)6;9rI}b}9AXc{!8Ph8 zvseo6@C(V&52dQWuMXNXS&=4}L$-5SW0Sw2@fwKDlVny;v|iU=x%S*dJNs?fN|VW1 zWj53j`r4{V=R((=+85quUYGghxiTG-{U4`^3lDW4dJgUPsbkYlC!O_U*44MGIxRA* z1GZ|aUzbkobdmPAHCvfMuvYDS8Mld^1fb{NFd*+X?)p)R-L6dKADX9hCE!yihomCD z!-t-!lF)bf*z(_M>1M691%TzbJF3e2(d5Ot;KujS!CeA-{HZaUUGD=tRK9vbpKvYd z9Q2)2`wZ4NTQmN!`@Y-t4nOWc$Y#aBbwLkmWzX`!JK{8jGZCo-yAky99Z`9<;@-2K zEu94j5+?)}-9enFLyln=TMF930M^YMv_-Vo{J4J$RL`&IcXbHwewh~;JQtXWiiRCg zPy;SlktjbT4_sg`Y0ty0y7`JbQMyRG+f+&gl!Qpn>m?WEy(t)6wZ_1jP&NB*zD{QR5(`-Xpz+NyhwzZ@#Yq-4=3Gik8I(tHX+UHL_sbyevK86 zML9qWb*$M%9KOjKXm3HoR1|i!n}$14Km&!nduZlF-Em)Qh3V`a=cca6bp|>g5X!3N zoURM0QZnbzOSu49(RyzpmQ-i&{4iQEaa{*-W6$#bbK((&surq^{}dagB4IMSHW<@2 zeBw7Uq8K3Ag13gTU`|*gY^*UVh=D`5^5B$FbO;lf-T9IQp3n8L{qsJx(q2?%OcOj> z=U`Y_#g-dR{9dz#C-HtU2gbAa8I>meAmb}<{PA5p8sJC~li*B>_zYD>D{BY^vm8*>LewmO;|%V4xM#e7GD zXWAH~O?F!95+lD5u_i0(Jxm6RU*j()YN z*i&3rEP{_@9@L1t=YzZtj%`7lp*yj^uEyU5?3bSd?n4wM3xx`D&dM?Wnc-OiUc4+k?tc0$}h5a!r3MsUU^(xH%Cs zWrL1LiJMY_Vpi%>01C>Yw=NhZ02gz8bXF8+LE;+I@zl^d{J7ftfJ@AhT+T}D*z9V^ zzo(^Q%x_0?KJ3wMGx7xakv`UixC?95$b{=2ylm*>Rxa{HJgr>yLKVU_M_ihUB>Xh% z9R|)XwsIyG(R54VG==mziJgLaLi~BUj>z|rd7EqI zpZqdyC&xwVBt_qeAUd`RMBIl|OJv-Kww6OLBHR^YFWO#RBpN7gSpG`hXI1I~bsx9dtN9TgwmLD{o|?U?RA4G^X2GN@%o=OL`YTlBxt2IU+4^&= zm(X-8;}kDRkbU{`t3XPB{FCfN?C6zGvF{kFzM`LO1_fnA+KKoPY%yRCZ&7C-Th9@h z=)=kQ4*c(eEvO507^@?yN6~B;vbI7%X+B2x($God$5DI{*b-Z2ntKB$?)rsi@gI`1 z#nskjPZ~H%m_<~!cuWXZYMocU%45N;Ti;c}3u{{n00%deqnw(!V;5JXPB?*eN4V2D zo~o9A{4FR&a>c#X87h_F-b3o8UD>$g#bQ1Hno%)Q=VI<%YDnLVb@fUoqJE!OG$H!) z;foI%p6IV>EBLE0<rLZ&loF$;-wX+X`K;IW}{Zdj&ry&G$X>`Y_yZLkrJgZABx)va^;Y zEI@~Atv`F4$Pc(V$^JjqFvu7DxfO`INACJZtwaG8#HzGTK9qZH!XJPWr6Ca?JTZ33 zh_3;;dBl=RMIZ6<2fu{RQQ}!|Smao!KzW}SlA1hTBcM-Y#BN9gt^)dm4S+e#qVrT% z>OeD%g9&$r5C31ASgvl@e{EtmB-Pp!VBYz`zXjg*}Q$2Xi9sXK_NFkkf_6! zh$j7qp56KQI`}VoCuXaRLVLeLgU;Dt*`hZa8~)KJXbkdHS2dE|RjuiKc50sb0|Tv>?+GyWR8%F(6U4DG)<1kT4b4Wn59IrPH#YjnYC&)vl_75cJoJ39)u zmrP4WWxyT12%A-^@HbY^s-v+!Z@*3nK6`f8D7`Q6d2JR3dJOrMdTgKr=+^@p-ees@ z45F4fVeD~ zT;SBj+`Z|_Ez$o%2h9!uOLhQQes8o;b)CxkI7_$*l#BnDzHWVLkXmxhZ!Ua6J1<_J zWCGc3CQm1Bk}^x5&K;TVh!Ce5Usp916^ORJuQOker97tSw_17?7XxIzjJ!Rh>domy zsxqCWb^nN3b@qpZ=B>AU)*xm|HU5wrvdWO^TmjL1i${>X|5hONApZ@Ep`b?7J9i4= zXspGRr%e#E57ZrSY04i>{h9NJH4Kmh7%d$%k8~5d6 z=z4IO&ia^i{)-k?M2f<+l_+eY5zQjmqvw=+O?98QY49<$`|KS!%YWShHM>6UO) ze20XtJG%+vd2{oNBVl#2ld7Zbr?S&c zDDvqKK&%g935Bz3X$cT@)()WPS3{PX>~%7_YH)(j{~exy_R06mqrT$s$p>^vS>+B5 z$t90k8!FYE?yTA-l1uTTa_f&pDZK#V2$%Th~==_e^BBwAY%lR3q#mMzV@bhbr{LT45UfP(v=EE?lS1ldTF#XEt1!4 ze3(jODg2v%#7j^29OvW9C)2#>n+AUR`^apJ9Tlsqj&RpF|mQdAvy|<72o2&~{#QBeAZ;@$6)l0oE1Qk`@iRK(@-K1{4ahnro zCuA}tMbD^hzwpZ1qjRMv=H#D$O9(9twnYh;NedYl_RG^}+P%lztX4^p9lpnqjaJAD zEeuapEYHw(YGb|Naa3CO`bpgNbV$gB4-<;~>W=m=T~KoZW!*HT_Ry<|Lu9rj(Yxfd zBt_Hx(3Vr5@aUPOPTRMio9FFm5-gs;+TcN2lyFa06|~G9y*bTp@*nyNc|qt!U>w^t z20)i7gBji^`lJ6!e zFR-?e6h9!Ux$269#YDDHm#FE>)&u4Gq)TstN{$-@VHC|EA zsfj+M>yCH8Z_b$oFhMmbysP@IioV|eX%&X?@$UKmnqhWDk?T-}FRJ={#6)&bB0Pbc zpdy-4d!|e~F>DAmVrA9n@Iv>uBM;fU4o>aFwcQ%B6GfPys?+JKl`7={g}2y$B0=IHr!}foH@I8fX1d3IFln(r2#xc^G8Y);3WVdS$X8C8!%b^33|P zTsLUsSzmp$9)1|nfRLoBTgxED3G%uxi!dn)`;NaRFV$I#>J*KkhN?DUFWvlE#C;+# zOQQeSCIUGff%g+@`Xx^tn4SL$4(#r3zW)&%WIkAF2-t!x7#TTcHwMR|mdc@~sI!)V zZCAi!fWd_16W`Wj%vJJ}zwb{L$g)s#@K4mC@8Dch%P%ZN;W^vsnUhFAwfIcmVEz%E z-rJ*oXw4Ns=4<+UG!r7kWj#is%)%RU$=aJd(*LvDZdSN;qpgJ3IPMQ^fwl+)p87rl zpb)|{uJ~{`0-%vk=NFgI51M7ooWoa?eLtYbitYRK_w@Fwnk#_hT^wS8?Gt-`LEp%> zhyxNvoSu6;7}-xfM0IDqFc*02o_pZ0iDaQE`#sLCegijm87~r;&?6BAGuTlR&37d| z;!IWMf4h!(@&YGj6QTrLSB3gH*sS8 zR7YIA*KGjOMq%H?eiTd_3{f;xp057$X_i*sPBz7#io2*1^0=%j>J;)={@BbF|JWqY zJM$?mShH>R6ggfiHq{RX?$IlOAFY3#Q@`ky%E?!rHFK~I<#D&jMr&SEuZq+%a5L2G zHV@zQ^vALPVNm6TP_3+iZQRaLUBRgC$TP&C^fw*2;On~eyEF~d@gz>LD3AkOFyjKY ze;>PLAs@fen8`TAn{JEIUZCxt?t=5a1`&}|DyT9aBE!v$i!)zVMdJ;;1>#?!oK3=l zRwiVTj~*Sa$vsUbS1dCYzVh|?(5!2dfz3GF=d97)5@Dt^_lLnQ$*~bh0dP7S=E$?y2IbrFl^a|dG ziL()BPcg8&`J*QGL(7zT){)EM!|C=TaJKP%qN>L*3w4p29#Y9Ii_nKr*|A*YmY7)M zY);z3ZYM_-mA#MEd`~I7t%hj+1tIVD>rbM8vo0NB;MfzD^>yN}7OFt@sHMF~Rba0C zB(wPW8kIs8X#AQ^TrCB)86aOtog|AIVp!H_~ z(xN<~TBjgQGi=RQfG{#|4H`uW$it7g0$pInKeBcx;ixAcyGSQX6fA;w5}E;b8)aKq zGv?UqI156s)@z1xl^u&hHs8@AMs;4^>MhkRPM_lkl}IdiJF^1CmLQb^y(MjcR?Pz9 zqSX0@PkYM)K?39K+2j`~)I|ws^g->k)O7rW3&Z;%;@?p7yyp&Drm&<$SC1tc#ecaa zW`g4cL+PpwZ^UlCDrmhbC|5bL$Yk>^F5)0(_Uuwn1(P=A5?3l=+9Z`SaY|ROe#zxq z8avNsF(GIDnoO~VE}0=FBuY(=pyXM`sVS!wUSmBNPKK3!qH^((Ek6fZkT<2Uwb2?| zZ1pU~_@#KH%;X?FxVax}o^!*G%xxT+(vLUs>L&Xqk&j-1NU^Uh&g4?ebuQswwt!#~ zv&^Ue&6XXH9fj@K~0bi|+3=+8${%F*?$FxE`oNABT@Z4;T46|XGT z5O@p~oiaIO@Uj)!9-O7)V{XDzl}qRcdD`b>ktf)BaxVUuDv$fClVu1cdn{-w@scg7 zW593K2qah73F;_c@iIOjdkzuOAtY-)@~ZHtO`+6P)xg}KVN)2dmFKcNu@ctdLk)l8 z_ajeO0`cU6`X{L¥cWNQGy0D(Nan@<5?mfKp_0;2hp)OQ41%X#aiJu@`Ymkn!=5 zWT`iG!ro;GmC2Lq(j+XIe(W1oFK;}n(WZxlDr@z3lUY7oVZ}50psiIf1WeN7cRb<7 z9&q+(A3>G9b}8=tS~i*mJKbS69E{%eOv+hE?`+27C04C`_f&3C^t62S==uC#v^1T$ zb+|t46OC`>&Dx}~v*8OtRS}g!^NgCdvkvLsjI_mEQe~=w z|EdplyiD?HsM8BqRSw41ZE*#d`Ng`#m}@2xq+gL5tZxsGgD@w{YC>#;OceuTup4x# zrW1yw=;!iV$`W~1(_EeD_~HLmPpylhmoc1W9oNtbpO;ElNvv{eX22_idlKRpVxtOS zbe#sF(@DWJ2iq&t7?1W^2U!sP?a*WvX+yJl#h#q34VLTT47DsSOS3`{zf`6u>Oi*% z1j*vGTpY^h0t1Gi*~AKjf|5-&xkmdn6cdW}9ulCm5r0ueu;hMRCE5Z(a=)X&gWYyz z9hOjc&>>P4arS-3DL<%{K&O8?J&S=tNa+2@Nz~lN%Y42suIGl29vaZR^=qwuXKFot z?O?p?dqsyGeMAw}Q+ACU=GEiS`3m>vI2{4v`}xf91lYaHv02eB5)@NS&Gxq%dBz?Z zwib`pH}a0y(L=Lq%U&IO=yx1`tXk5dwCwVvW>eP`Q_UYtkTxjNxUI|zLAXm9tCC97 ze3{@4p1iW+KU0@ZpPD-{JXp{x+{Yj&m=bwPE5>5%nwbQI6^=kzft_vn;s;;xT3Gc0G zYb(Wj=q!@;7H?9TzoR*Yo04UH00-VkWzy|d+{|QbDr(g-<*?9nh~ycPT+=x@q$QXI zeW*iteU&9ri%4Ysmoe)pA2nOAT@&-f!Wk3yA2(;&AO}c`%Fw%l>fgo?wxkx2=fJi7c$4;&1wsE5%%a?nm9AhZyTPiO=wuwWTb>mbh zRFj;2FwdWSg&E&y)U5VmpRD9~TP?_i{Dm373AYl?`DH$=B`*%VDbWD={4{!op_arC zE{+7Xwe$TYUJK*OyMppu#LHxMlMw%g;LR&(n^dCTzSJbgeHXKLfg5RTK8@#Jaq$&0 zqkN?Om(u|I;+X4Le4-tK5Q5##%aqCYj`yg zYccu3gJ18&#}=)3m!pPxPkb;J9cgYb$|PbtftnJN{=z`({O-V+t%IhQy0i%sV~CNuoI%Qb zoJ#OKxMkUajz?rkW1;D;_~@*BpZlR*$W>=$$#@LI%8LlJKUw5p4h*ui^(2*ab}tO^ zZeR@DdQP9$=lK6KdpS3EUpT*_Qv-8di4bCh%bX?P6rzp z1s)z8PlL?YZ>7rAI&+)8(t#l}$iIHGh96=lh#%pqQ)(C<1K~92hBodvIX<738_avT z(ob)^pD&&N+dKFby+m?YxYf_M`)zy`4H4&?@2jww*(Tz_X&*Pph7Gi|SZQV2Z3 zGEdhnyc{;~Ez2*LNOV6N6KjI5(&D;UxjkeRs|?k5&uE|#>ME~5G*hpB^BcX+@l@Co zb~O*3gLcj9{5aC6HBhJmNH4CgR9BszQX*~Gx4z4(P(~EzVnsw!y88E$SL&l@qm7OG z6!MLpg>T-(xu7D(;**3SGei(=hkaCFXSOptiF2HUCs`i4{Fz*~HGyP*bGf07zMgXP z@rViU=&C`~1u{gNP_X3|SH@AEt&eAxiKQLNRs5mVXPe;S#9a;N#JQqITPp1Qmz0Ea zGYaV4^GEqU8=_d$?TPonmvx5jRO|%Y7Q|Q!-&m_*P!E5Ef7N*JCgSk$W1{1oSot!8 z>ts?!d`YQIlzdYFcjy&F0^y*Fyq@AEHrX%Fo9@J>!; zHe8*9f*h&~8npJhHqu@X!$zukU5ZsLP6|)L1VV@JhnJR2uX16--R!G`5B|KDRIzle z+4j~vx*HEZ-;O2K>w4mX$~`1$aHu%LDY3P2MHGo?HO|bSrpAIY9eJbo`K65;DjemP zCoox9qltX-Y1M$cY-QeNbaYc_1&(AJ3GJ{RW?+-QkaPoTSA3g7>#2FWo_m}%?M0Lu zakE8aafOJy%i%UO$bl#X5*}+nqzrx_aM9GWwen%wzszs8=dER9TjhYU^>x#X?Pg(` zMz+)La)2EXv4i`kvjv>>Rgttt5uYH6b*W0W`|jX5QnKdIZA4=X>p4!!X=4;{(lg4# zTVuZR*1?!B1#onbfi076z%BbqTI{a7sAIx6)?vqfzc2qvc zy3-`TWkLU2IT(^bb#SzD;KS^30c&lX!Pxu)W#=zAQ+Rp%jlB0K^2`AL9k-+s&ax-8 z!$b#qTcGIqdW(++3<=4KKh*7^KT+B%i@)HP`R{F7-yDH^aX#$KuP)m&!VQh(h% zf0^jOi&8f$K5^_s`+PpP^Y_rWI=*=_b`{0uxBQHRc^9KwUsA>hE=kDKw?vW7SLeb& z_DY~Yn0=LA@T6h?){-_o&wa#SQ@J)V8Bco@KGenCAy0KHaz@Xh@2f_1REb4;yR<7Y zc}XCRIMa;K_-$G=x*J1sHK%*JR8CXfsAnzo-mbe_6XvsBkZ}Aw-RZNM(7dNp8&irl zvlfNJNU*M1w~GRdDPR6t0Haz+{ys9PVO@u6+Q@66`XNEg6|s_L90GdjopP@W1OK9H zz)UfzmHuaOC=Ilx2pfeAQSgL{=w|=nKQLGGA{sC9FN^PZ0?|EljaTQ9hztBpe~I$j z@!q)}Yf|2ZLGi$M!ltde801L}w|)YDi=aIpwQ_jT#hmAwT4_gkRQCWnp`3Pf&?O5X z_|{N7jOKEP4L<~X>|(k`{1_ZEV|anj?^^=-j)7{fh!pb1rGz3rVvQt@YJcJ`F?Gu*)%x{Dq~H z*`nwj3{^>Ga#+U?iCO@T4!8)KDI}LmE}0Dpv8w(LT z(7Z!V4b>OT#_gpvG%+k2GGW*_Qu+3u!Tt^agV{CzpTSQ5JJ@qhgrj*%!m%BS^l^)W zQX!{m{<@^q6kle)i8TInA*GzB@`WC;n{wXxS1GgB;8OJA9`erI?i6A0hV@_R4aeSe zh_x_WdUfB-IrYXJn?C0Amt22oM`K8x!Jx3|xsc0iL6^newhZ_CU{}6Te3JpoX)w@Q;9|jNm?x z?D0~_Q~`MVTzu&tGExW@F`p=aB6K z@i%EV;5Mt`?RxXL)57<7>ffZEbr{dSN1R`th?}j41E13M`lX%+WlzFohe3S=N>HfT z&kjD^Oo$QjcS_~{nA!OQh*b>A%y`lfd}%$4D!bFL#xC| zeRg(xA-1((o$&y)W)&lARY(Yz{5HMnko6mJAar9^wF2D!^4O<7;LFwKQa}79)LthS zY^jISi_fFpBXcYQBE@Vk+IDx!r5LM(&!a*QM%3RMBAm0gnfu)bv);EAr&}n`I8q_S zWx-^AdI`1Im2k>G+1Y}-$O^(+vdz=-VFCQngJlsFR=Mc=uF7hh)?6;~5x>m*15 zBtX#ME(vbI-Q9va!QEYg1$PfF0fI}gZrlm(-nhFojWZ|TH+N?4+_mlx7A*eMIo(yK z-rD=w?|HA&S7u7rmlM{mTP62KPpx~#b_MNdphF}DMtSi9&%{&M z3p~=#;yw;WfXR~60;QDikS88sr(oecmz!+o0>JK3=p)%Pi{tCIP^wY<9L3y&=S^jbdZNSc#&(AS%@MBLl& z+gKK2Z&pht?Q+)u>dCsXXu$R%#WVgG&UjW_hRa$W3l zu7QwKFjUN`o6d3+O^ z(eNbu2qgsb^CXYNPHSs4R^Qzn;o$+EIC6F5*$&>e(c&q2iw1Z3@H_u~#;(@iG?U{8 zsPuN1P&QbfQkDP(kHrU`ulEDm>xW%9!|;@Sj0eF+jcQ*eOz-$BB3e>hJmCZWUw; zm+zq7^IkS0>T*4$>lBpM+3+&HMHv^Q&JoD3rT9Kj&$meGCHZ{DSW>7bNoO|7$D-uU zZnMwDq4K-(O-b4qfmxqi^Bov=c)${Q@Wz$uH#5B`yZiZC7K+Cg9s*kW{AzLvsPLs+Xi3CNQQN8GGP6u^ zHqPi_G}Ba1zst5f#S*WPFmZDYB1e!i^S4u)bq``~p9M3=YK>x>2;6!scAMP=kJQOG z^Bnaiwj+BLG+DVH-H(7S&=LF5(6+lp^@JW%`!DiDdfl2Kshz81m5Pcn{q4Th*Lg4&>sExyE#G6zYsbIjKju>dda)}cFjE$1 zEs2Uc1g%O067-b39`$~<#x`A9a7BW)ZbSKoLm3k#2PCEUh`>x1(e|$uu zfcTBRu3o#A?g}H!eQ4%1Qn7LS$ekDiBxRR;gB@*JOV&`9lN-F`JW- zv9r_xD!t85QVEtASV9U=A!vHj=KR#sPWGTK<#T6g`ojj2ay5VPknOwXZu-$`tJ{cQ zrJ&G6>6c(jWQ3p4P8;LWkU$JF39~X8{rHje^>x5OXH(<@X7ZFP%5q5=$0~h= zQgv|;3gg5HJjkvT<3tEeu@Nv7l4dSIRyic#&M=iu>4z@j?;qL`BucSd+=twe&z$0t z&Q8tgIp7nVm0^!`RLwfU`L7ZWJ%EtADF>a+YF>72JGJsB0qqN)S5B5h&tOv*_g-pG zo3ti&D9&<8RA*(!HX||{&$s?CSr$}*u$uX9`{&D5_PYRzFV6_CxTw{b&=1BZ-0}y} zGQV#ywN;@F^;X>IZ78qKwcF2lJ8DAp2^ojLyysP&USO|>+H#04BSdn2z`9!uX^CNL z-RMVrO38KHG=b*4;e@=}6`~)83k0e42rVK%&D4=Nbfz(sJ~65~in$9=I6~J9gT-si z3`nr5UQzF8wGs<2$(2n|>~UKkdj+@6qs9bnSi)b2HW zx`P)4B&*;s0paB&a>gFTWIm;+i$9Zkfk7HLyKP=K<6+|^#a*(=gCD^BwuTW zOC4;sVdQvz92ANE&XKOQ$CG<&7o^(SX{x>XclDsZSCslfuDX=*Fu-5@ zDRkzfO}AR<_v2m+m+DW`#`!R8Ed@UhJ2dI}#_INbo#KwR9QI6ik#1M1_42R_zF&<} zaf1Ab+uC2PtOh#oB8*#&R(tMCLw#+T$`P-jQ8jM!r@W@=_Ra+!ZBCKzPG;yry5^5< zJHF_32{Q8^Y#K0_eDkl5dy=7KAWBS@5~|h@ck%Q|fH$Yvjf^X65Y70+?H#wKUDuLiH2#AfrCO5mr)q)!&hK2i|sdWw3SZB^&+i8ZnN>U5x@Go26+i^HlnRnH9 z`>rMr@quZ2F_Y(~*=`dz^=<#Kb+l>^yntDe`7T@Ur>zmcnQdxs((x-BHqF?6G;)v4 z6;zJ69>|Uo6^zfbH#$RL`LuU0-Rnss7ImYA!Rfs+fXQDtlN#I>G=mFB#H&3kWv_j0 z8>Gi>KQQs+G<@V{+Y`(<(OxTctttp`0Nk0p2V&jP#yACy?;Fy)u4lK6ls-?^B> zobi)v^FmU8l88__*WKZDkS6YUMp_6|sLGaj_C;%U;ym(Ii#@|mwtR+GkB5cUh*kLq z`XNHt8t~p!k!&#b4}^7|GG158j%!pN48#z#faSpnD760&HxVYtpfN-e*f_LG+#V;E z^9c=XJ25F$9Svcr5MZa|x#^{xP%enYT=}>QoX`!|Mk7maNXv-2YfaMSQ( zu^+a^_QaiTZj6AfBH2UVw*uDD860Qf&Xa(UL>ZjJU+<`TWzVi-Uc_5KOF^J&MDb$6 z^nN1_-U~&C86*gt!3SzQX+-IlViVYRJ?s7J;C;Gq+x>F0IsItQ z%Ag?;qvymjhLCeAW#HZ0V9-_{f<9R@2jz4heQvG=E&f8^^~~iUMrDSIbVL{<%M5Ws zoUPHIIHyE_4apz};G)$rtkaKnx1cjIDdWiGeBo9Gc*%tHV0?*;x4$ zT?w{fRW7P~M%@0ARkKE_F;q&NkG)~Wtg0a=Fuiu#v!vB#G3#~Z0WvSzJ0xZs4Z5`B z;uk&a*Qz(Jm!{A62Pr!bV$uss3}i@>oGMZx;g>kGS}t(dnXvfaONH-g@zRN0+u~5c z@XI9ol%19!dz{|8AAvBt41@@NWN7i4WY}{=gBGN5#A)m&PXTSj*G-RGLgx6+ylodn)eV>Cm9F$Y@l{Z|L+JAYS^0X;BP*8Z6)Y%c`p z%s!es>e`Qfgv%)>9V)S}M6J}sx{rYK-p#KS%Ihb>zkG`LbJ2F0>|I$sxY;BX#VIvU|6>jepqg7^ z{j}8IvYF>>Jv9D4P-M17L|8#PYlH}C_M=n!CUvdRo($9bwOn={i%TCF(dB_CK$62+ zCD}@IvS|(I2M&mSyn0;VR1epG)RF9;oNneo3F@&zGtRY()NJJFEhSPHvWW#qF(U#h z){wy#u{sZ}G;F*YoGeU*sk`=+yrVUC@tP{G7`MtBz`XtasOGcnYyS~uwY(X!*Oa*2 zwCC169lCaO?{ulTis`r-SkWXu(p25TjhqP74}I?zzthC!R$Tj8j>UlI!e-)MP*|1c zS~2`s>EK$*q4Z}0y|j#Za1lhQY(H%~vMWj9&7s%Q`LU~PDncc^N|+#Izs@SoDe}^b zWdCoG@b!#6JA`k;2)~w(Odt${dWu?Vqcv!7x`kgb_d|x3z23bABnL{|c|*4->A5QK zhkx!&POJ~NPZle(U~{IlMR0ma<+u$Icj;8kw8I{%UMqO)UbfWl>xm`7ctXD9Eajp> z(8kz%zpTxtI0sY-1`ZUBO?eJcXCG%(JA2~OSJ$!6ZwjXB5|tbGzbq`<;^18}$L{-59*Sbz zFf14C>C<(bru@28FkDkWzNKfZrDaT@MWOI4&HSD5U5rIL$wOu}02gir0y4k)L{?yXe!cRl7QUz36_sUXdPZ!-9FsP0XLx9<_*R|;!}$0K z-nXPhwAy9Z+$z7_O6h$U-*64$9rN0vzFR=`BN%jZ(dk<_$=0}3_!~W}A=#zjBHwkzY1NPF2Ea)<9*%=hAi#~ZEAL%R;Fb5P5hR?i}(9zron<(dOtA^vmf$sG&yUcCN<~k!(t5e#;{96plwL( z7dl}oEp<4*Qain@cab(nf1Fxc2$a&1EyZ?X4p@*at*jwYN@#~8)`wI$m(pAJ&ud}S zMO~dYhEgi&%=5Hv_5XW7Va8$V(u%L+i#E>2y3lMnJ)gdtNj-B)zL_1^JjZY+)qdRx ziWzwifA4G~;oEPv)ksSzE9%%7eJs3LawWja3XC`(tNM4u`M=-m2eSFDB5r`um?AXl z!*B}s0G?*mA@Z0j*u9zyvGQ#B$g#CeX}!wtaqz012ELk>URYpL#wHW_{NTYW`&Lnh zi%Baqe|Kpt;mc&U1%C7Oi-X-u9i{0J$MwcvAb9=yUk59jR(gnnr>O>gbgy3`J^m3E zk^(!$Wyc6_lTvDGpng&mAbc$tnd7BnXNP0tLaF^^;nO=Hws8AJk$g;2CKwQ*A_;WgD~-?+GlOXUj0ogN;>1jcQo879 zG6MsxRB{6Yy`7Msy`h{qHf)ElVch%7VmY}t%V8Rmt1}k*E99i@nDxTuOBo5;=CSGX z)t)**_V4lIGGiL_Ny*03h%Bklmc&?!0<_XG;;)zP?Tx1v1Z2f@EJGC(u&w zBDeMq-r6I_CgmQ=$i>Uuzm-kPaqm%N8$Uu8zKqi#gL8v}gL$}?x#kH~_4G?M&6!H)Q~{U4_5ND;XiDkr#8RlV;%ADeWZ)Vb>= z_bXCZavK3|1Ok-hSBQZetyKU(!-$(B;G?UX^-#N3WARXWZ0VzzlyhtqpB7>%rr-iB z2_GFUO5mGX6}WH!Rw7P^bOww`r>V*iOQ%F?ciFD(iKpP*d@G45e%>e=n!|_KK(4yW6X_5=j~^nu7F}`-1Xe=g#ukO zB6n}*CRv2J(0y2*S4g6tooWr`!Y{%x>iZAF+-BKBDU)d(*0m!^&FC$DbZW(p-R=%7-cXOa^vSpJ%@$dAG5xEx zI-?X*hAE#fOR591u%{c9bbjEum7neoxAKd+n0U_*5*E>L}|R&U~7xJ}5idc)GWLJiK?jaxkczHJGCdSPCt580sC&SX2EN!_+IR-vk&k zn^73B0D0Ne`wk}RI1nx_3N>Wtdf8_7Ls`txQ^Ps*-85QNMiA@NX)w`(G(YCN6I;crXsStc5y% zC$Yp8H1jHVxr(zyM%Bc7r9;WW!8q5lE?=>hp{h)5MF*x4#J?^EA|(qdL8Q*9pE9%% z2A5r{4f8ec`N09TsEI4|X{5_xgT5$cN6nLlI8+FAnpl2R+0Qd~`fF?A0hNjUkAAIQ z%X|=ooVid_&z?!U92y;grEE##`bDjuYThp`ECRI4M2gIg5lD*`JlNZ3CR1%3FK&Mx z&1|kb>c53wMa-|d(bsESoBThx35Z1!$y|9fMzhIqf5~7~!@n`t`cy7?hv5Vz8|U}? zc794IJdT~hbpHRKP5Q?H+T;unD6d{?31G&O(;Q5&f^WT+ z#6uL4u@2Zzu2{a^<`2lpNVcDG2#v-wpl%Y&H@|-9ET4dy&TCPbiq8d&D?6numdZJ-`2mm zDP7;;R4ThTV>2ODQgLohBxHCh|DIx1vCq|W#MI3OaaLC}Ne4j|sQ=+47sL|Vb2}}y^xJ(Mw z9$q?{7A*|bjqPo!EevwdH!fB1WMdKWjUjjAK)1FLQ8%O#X$}a^a-Ao{^6e^40v=Ps z7l;lE*+U7`pAq_YZ6k>vE`s9_@7oWFu@_iMV=ua*y}q}-<~Y}XW;V-QxO)2!pc3X@ zW52YWM?RR`v8tQ~j=2IjmC>@+uO32Z@V`k<>)z0y6Ig!yv8}Gc6ne3N-GVp76w~Xv zIxXw{)E5XqDV?iDgOfmLo(#(z3#rfX+0&VWY)1EYdaGS`ifSDaG z*evFF9FetlF^$z&HUCRH^(*r&T%}OxgB`Itx}BIGgrQv^31dB)0Xft0ex%{wK* zXN`>QYg+o{xGFN*8semeo^lP8-z4HMk6hUWe3)QphxUzEPuoJq^Q`Pk(S+`gDF#>2 zGLAx$p`aVdbM{$to#2p!ea!8zC?|X}qF%!C-crV(5OeIFlC+bQc%W+UxZ?WplfDpf z+k{H-JZFf@ow+psnu`zeP-$FKM}SQ$gmdp)K<&$Eg>kDVr+#de6Ds&!kX04OKDgY& zOVJH@`_~e*lvrMX&=FGM^lP>#l+7&4L{Be#*y?hA57Xrph3ofKtME%Fos(38A3X=- z@rZc=PIyXN`>22jof+Ga!ZFBYrYc{sB^2};dL!h)VN+le4hii_g z)PcugWg#cRk9h+m=x;R%E2hpS^5?_UYgeo+_B}0;tOQt+IpGPJVOQ8r|x9EJ2KL>4U(~A|I}!28unm>(o~WVRrsclZB^D@(=1dCR*B9mV1~hsfs2< zSY@z~lL<_zz3WYO1Xk@mx8#4BiI6du(w@U2@r|%4*#Y1z24e6j`iGdelb1DA$zEz0HtKFe z*udL=5r&4(dT!thMSyeu7huT$3owB6n)3OKxm$%be5H&VL)d^D4_x_2f_TfhCu6P* zzU4N0B?Anu_7`4|rTqt9;1&G`UNE>(1f z>$!mM1^*pw!uH7NpV9brH+)R&d#~ey?ND~9tyB>}zJ;?biJshF6R>Z~2fEy*845Da z>}Oe6K|~K3wAa`Z$45|jWb~D%mTb$_!}L1_(7*-rc1^E7hzWKGMmN3(d$o35=iS|@ zff*1~vyQUdc0au0Lztx>dBhHg8hnZnlCk#}rwm+*DddTJ)V2NP;paugGj{Oat0s}W z6`*f}eHR&76ux@>h7jVDlROw=+?E{o$DdN+?Pk5LNi-hlu1QZxD#emHDST6@GU$U9 z>2`JCzd&d}7n3b9?CwJIVih=#uinRuOjp4wyma%sx*9L-d)y5>CbxMV0@KfkJRYxZ zVn*`ReO~vfAV8j-eVbYrn4asG`Gm761{9O($0)~;Yq4Csr2<<*zGAMtK-ls%*=k87 zBOTjd{zPsiL;ceygME|8Cxdntb2FjdG?w6nG3xV<}N^pwdhEjIv+;A#i(!Dt?-m#FG zC9HU3U@|x`ED!uig>-7TEmo8L=Je=BjPuodNX{nPF|WYX!2MrRz-_A($%((D)S;fK z-L}kh>=pbdHjB+D=>*YytIIyBk2$rAhOFfzQJ4}oQ?~Yr3?JK4Dg1YV{}&XX0G|Pe z@1rt*_Gn)R1FU&idh{r)-qTgNoZ%{zKH*)7tSFPPv|#1B^^jv z*q8sLP`3@uU-e*b6An;mxY6`0L)4DGII%u6Yu2`(4PE8OFTaFrt0sJGssDn+#F zuuFRUZQgr{fLBK(54RFiZT9TYgViz_ER!g$O8sZfeUfP$=GLdq6_rwoyj4Mqu-iQn zp&8W%3&wj#Urj&DyO0AlVRL&urSPw%?Eaq`iGc*vy#9B#Bpi-D>O1qyH2Eo#EulPyt3Jct}^7YWv6mJ$^UrnY~aRv&w&>Vd?LZ4V-&K1I&D}pLeS3So%P4<;GC5r}$Rt;0H*4$z8Rp`=H=64fXdW-2`%$4l_I@e0 z8_W!!1*YBx)Ud6k5cs!B#i8JfBvH=X^!0_ zzQZl$=SQ?&+3#Yuf2_272d3Sse*|h$u=09K2E3xI6Fjw8gvAv3G58qui80x-@Ki<& zrQR2P7e@KER_7ty{ww`#GyJBX={WdMx><0zl)+Z892GUwO)yW)c8z7~(W^A2xv7+f z1>Z(}3Ma#r`{Ec&6R%gX2t_e7PpP}lx=3rF%qK`;=Gappzxl>R=j7DQ-4r@#3lS`8$;IOy`5z#EROtRmtqX0gW5a&ykVUhAge05?D*sSy*p~qDpCJ zfBy*SB{rZfGjRE^A%{;C)(`{@UAtmegHe0A%_hbcWApmIi2|jzwR1pqNo)Pi=pQQl z!%q-y)?C22N+@62ypQMF+#APte9 zwc;&2-hLmpuu5!zirmcC zT+J2Y?%YCRuAdUI-|U9iG6oc01QW2d+mDR!We{$%V}~1!J^*wEM(m?oE3y{}VVV4J zZ%MPn$a%Nu?U|Cj=+n?w@yr!Bux_N$@qfb^YLaW`Ju0WU4U2ew^oUm4S;1qA>B3cIIYzYEBIs?`cb^HfagCaykC78pcu?c6`n;U(M0{^f zw#z|z#a)G?>ZniS6m^NYeTX^S>){r4IYai>htYM>!ODcC8C@#K@AxE8E9=QnCg7Z! z7mB9#v;>Lb_Ih=<)Jfvf3Ju?1?wR?<+Tq;#*m%6()*{xCTW@)9uXgCxdyUdVSd+hm z3E8mzmRAdJRbQ-N{Zn9kysPdnR{+&0kW;6NYIq-QnK)$0Iret+v*c-tL5jgF=OM`} z_1}@lmPv|9iN{`dU!w9P+gOPJ}79|YhICVq^mgLcoGVt28o zPGwB;@^7vq>AiE)pCO2kN-U<4O#3saFjI?>xU&?cbVkFWB|URa|_ zuQi;F<=+>)XpAMyaAytbbSE6$;CeenUil>Th9E^*kB3u8g&5&N$jWY`*PF#Cp02b3kUyYxZv2MQUKVZ@1_Gqcy-^ z!QD1WTf#q@3f;=Tvd^a}1$D)Sy(eI;cLti#J2Th|GwH(tz9BKm%cf;|f#cM}3J-P? z9KKfF6G;>&#pH?=7f%dvmewULpwMj%8N=x*@i?WR+sztwK+YPOq>o5ANW5@ReR9_W z{=rY?ak^H8P_vaV=+%ZW*2<-01*l-z_jS`|zOuGE&30zQX3}OLsvo2$q4yE*vHO8Y zP`)HJr)qfvUpbDey%^_F!^F>GHkswuCwzJ*a2dIseW^e}wkb<$yqw^okt-mLEyy>q zf4_;VqaWk)3iId9rCT2!!O}%752foX95+1|9qg=cu~@)^swXAY6Q_|^|Bo}biKV91 zkgP-Ufxb|;btNFYh~xevyhPf~Htv~am)S(vWrsXJQ?-&LGRCox^D{dg#OpI`gkN=} zKLlRI8W0~KyxZMw;0sGU8VYr4#vNNbA5mxts49g;SwSbSb6a0ud{GpUe9T1Zn;;Sa zFb;Hjo0h#3Iv#kz&yc8c&J5GKCT)8Bx#z??xLOGP0twf=hw{|7r;cVbdMm?elAAKT z3@Cqnx?XSTYsos9~CxV-S7o7t%(qm>=zB%MY8DKI_yCj49~`d21%$>fmD zIFP71)Z|wWFfo_?^w(Q8mmcvX8PsR+Q$zaBSD)_lZ=A~DG;?X`&(@Y>yFnE(XRLeY zF4RbixMn`js(i|m@(UbqZcHqag@xl{@d#F!F2k z4pLr*TnH`fxihL?;QzA3Fl*Xja6*PNnwF!`y%nr-n%7Vrz89o~R{6Z!-X7&bWc9M5 zQdCr={ZJ_~{WIB0XvrAMrv?wV!L}+HO~AIjI%zlXqUtCat&$~2Lj4WMYhb~pHu2~XMfPJ}9o zrii|g1cKmPo0Q$h-G_Fv>AcO1Mw{9-LLGT7_tYR{atgGruZjOGy?R$c+-dHqL%LHe z`Qo!)8`p|nRI7S9RG;pHM@8Bm%N~SCB)j)&6d4dsQ>&Tx^37&EE6$YGJ{O}bQ?q4n zmzT2RNTe^Tjbqz|V?P1H-zj#3fF3B;;TrM^VP5j)60+laYI`!XJAZ_n;g}&{>^@)N zMsR*|ZM$UC<3}a5*Ai6IRw?FVST^;jd3aJb6F(l>rfpN$YSEx0?dsFM{|*-0%dz@p zZUo2Nyg#$=Ml5}CsnBB!)7Dw4t0{y6cSWnW_!Y?l_o+$AV*z|FU3ZItu+<>>QT%2vWMTw7z|7WwU`H z`cWyFx`rv-qL5B_b&}N+5Q?~}Qc7m)PXV3i;2)jnSLL~A1Grn2>XIbTtYXBf8QY)8 z=VNbsBu!}xQd?N)5%s)n(9EWvK}DPH>=^GYCJ;9Ivl|#@{6X;?NP3^IbOl&vDA-p} z?CKTj6048v_~Y@TTK@>5L)p|9zC9#mRHMDmx^Z=Hr`5VY(G_I zF}myOoC13N#pAq9K-9#d7s+QG(tLfL)rMp6MaB(N2@YhH1K~~CNI+?yz98S1XKfB{ z&1ieGVOx@mNQ0^+YcCLfR{bp|KMjAonu!0lEvocNbO;je_V+MTRsePD@fop~bH3nh^Rwv7WG zA15veAil1qdc}gHm-B^t~JEGfFkl@ph>{1_x#T6sKH>4Na}8B zA*aRp>CDI6rZ0WBj%^z%^XhUtWDLX&t{Y37gy@tAdK{TH=1U$PV zz_U9#0Xw6NnMtSAjGMh4{Wsz=lW*<#DtyJy2Lu#UD?mY|jj?#t;IOZd?2(1dS@{QP zl5yoOuE!1~l@SnZz>iHXD1Uxt0CG*(R6~>vWnPBUK5&2m5$S^d)oV5o{^~WlEeNLt zOU`);=b!O#aYD-EcH}V{#cvdf6C6ZldhFyHL-~b9 zW<9Oq%mTP|zG2@F^_&?I`G4bQ1!m~s0#*XDFWBz=Es;95bUY=_Q~8~lO9<=tZDUV| zhntZa-0|6z>MFNB%jU{&-)GT*>ddh`h7mj$pPK===-MX<45Nybfr=!tOb~+>K{Q5) zzX15j#nJC!zq`M80bJnTFG%$4;^;MTQ&!r1RR`NmsQSeF1Z}xiYZWYt7f^m`7-Gd6 zn&P6?umMcy!ZLzz36OJND>RqolwH4#2#Y?8ip*SG*e+qY57^dLH_!T)t@TvPOFdURHEdj8GyQ+bW}Dn8Kmf>1s3 zb<=j{NDkt(pInVl-<#a~ksA0#e8cO(*rF}IEEfBx}!pCH93^2(20 z-pqQlEcGpLh=Wg8JttSOPxv^N8P}$fFpS!!5v@B-RafVa&GDJMPVm`k0#=2S9qFpB zC}wg?cBLq4CKzH85cNJiAVfKKcs{yR(oBgo6<@@9!!zIHs6rS`G6Hcnl#);9MqRm# z?(C@8$wpW`rs6y^SX$klo?<<{oKSXSp|iU*J`UvJcKtKIPr~DRSC-+fZMw@FZzQQ7 zM_g3DEAN(>8WN`Hwsa>9yH1{ZAjD{S{1Sw~DsgtL{0=7^NEvBW0x6@;hli_!0=M+` zUl`ZFnyfSXC|0QfjHrv@ZAHm3_8XWgto}pAJ^lr=4GztpM3O~UgHE+lJUe?6j&*RI zBlZeXkGp^0OuoG?gAc()7km9jWGEmP3hn^dd5=5E&KFAKA$J?b$N$O|6|}!F%`f+* z_9TvxD**U{0iAiNiNC3$*y!K6wuP@QHq;6kE+~P%p%Tc9DkC1~hvDa=sH!d$=$nrK z(AL)d`|LOqMRj6ThxN%ziT=dOz;8*NAomSc6R!-zDCzl1Y!KGKhx3)tAgpkukca=& z?P%&sa9|vndC_+V?vFK(V&MEtm+?~CF9t#nXn`2m2PrZl86`=f>ZK+4eiAcXk{D+ICWxivg54wU7 z4d_;>xcy_u(BE`V|FYvHvMlR5q9Vr_ zA{b4b7NrC_1YZ=+808($fxanfvke6!k4N10qRI}>kBpU zOu_DhCeACz!spDP9a^Qh)-61i{UF^t&AQlGdGGv#$(=V5-hPd0Dx^_c0tND)XYvud zdfJf_0JvI8r20s%pzXN`L?okujjKhlKo#Qm5C23h(q&b~(D#E!dfnj<7)7R#G<|CA zQ*tI^O;v*d3QryC>J-%WMU&reL zS&gP%br#uzz}*((&xvvJYBUwbCMHWuOh)wDS@|CMuf%FOdCjn>eJQ=`JJl4W zuvjDGKQCvFClBG!#I3!3Fb6rfRq7ouIu=poHQ$p>=1=e`Z}8hXrkz{Bk3h+gMs}WL z=Zlcp@1=mPTJ+dY6DyiiKO0K=kh*medPbgXas9=8+L-3CMY-svY|;o~k#--d}{(tsOgA^Zv5+MnziV`ONcj^qKdS z-L7$=HpU%*q^_ej;>kOcg8vsGiS(56gr2$b!0;}{-Yzh{mlBi88tkg}-qcZKqm7?( z9kM)zWMA|O#uyH?1bI!6MAJ(@=&7Q0Jhe{Ts3%1pGLY2R=-8#H_vbJ*QKERd6I{8P zSepBUg3Q_FJ=+g9xX<)3X3Zw>uicWgpPiXp^Rm7A_rOE7OAs1EF)g1&m2^12k45WV zDOO6A7wc3%Zy`JJLL*YI1+eUIc44M!?02DSm-)9B(kZdo^hi1LnHN#IaP!0o)wU<= z!JG;KwyA|c=$^IV>-nL_aU0rKq~#>{M8w8ccg(&|9V_P0ekadM@5j}!44jsw3cv0L zH>h(LIPm6pWDGCFGiTK=%Wcr}+nb1YXJ5v-H@_0KbX($~Us17xgs2|*Ey8rNKNM#sv$q~+B{N@R?;jtG1-l~v z@qNKW=wte@y>ida#9-?ruQ!L6>>p7twzbSxSBUF8SF`csMV#nt1)S(*`@Z!{shnu- zNZ-biU*vp3@lM)Vr|t0Mg6F!apzN5)B6!`TIy(Y(KweYkwI5u zxOWUGe{WTnp~!~y$F7otmf&)}cZu$eFjgDCp8*Gt{8czcU9X#dIz%-AcuI!v;rPk9 zJY$KuD|7&X$R3`YUQg}QH<)Og68>|&Z<`gGTsp8zo9*nI#FpKzHD4hN*!mO8_T4XE z>qRolCiVm_o%Wz1L&9}ba32p=e%vvUWELw7L#f;jr$2sq+ZjORbX(8&0Ac)zGbiP& zBP$BG(D7JoM~A;CbfM?)cnCf3H*CJM1>esVwOE3R#Wi&q{i|SHNS841=~r(J`IO>{ zDb`5il(-LoECcjeGRj~2)zKu&I0`-sm|z_I^Xqq#lLBxwaIXQ0a}-Qa^d>f6YY0k+Mo!kdZz%xB@9gI5|u*G`MK zVbIbCNwl2LF@$WUNW(nI@YsfkKS`<%vhMNSjq5d5&GZroy2$emyY1Q^Bur26kcn)G z@OwLQ8kWo3j|fP{O0lx!TQQBAX&X7gK=3FV)O9(ia^`8|_9M1(K_OHp=PAmMeZqvV^nW8=?5d`I`6hIZJ1JLbzXzA0EoCcaNl@k#d)9J@jE4bjhziQ;A7L| zT>Dl~zmaGNu0WO6Y^+ue{LuXlzIAH_*jP^xbcXZEztUG#Tw&}Fs-$P)SMqw$0|HS3 zWWfpvi*)}{i$QDEYOn>g?9sVdQtdc-X#Z-UdB~0yz=x&KTE2n`-5X8*#fK*ez*v9r zVK>YqN;xeB4FdqrC~S1l2UP739shVoU|6c69MHZ8|Q9p;hh0|mhWjT^{k zvxw4!UK+3Dz$HS7(uUn_yYi*#2H41!0k0D#XE1=aH!{1hG5#(^-NSzS^XDC@z za}4i0b$kidyCIoxO83s^`GWjJpam%&xK7M-kCUbJxZYwk5?qb;7OiTj-%lmK%u3;H zUuJ!&Yvdk0*%^;pS;I{{LS%{XL}dbYMH9qKg>J1sTJeQ>xxcr{){_hpe)hP_IK<1y z6~G@Tn!1!dTQR-6njtlfa+tn(u?{qTS@#vBgxT=Y<@0@FU47%OS8iL%NJf~J-w`2% zZuiX&fMr1dEIa=0-?ndm{%x_AeO_(&%i_Y(PBAHYjP8XetC@Wjs`PRLvnT)nH|o{e zLqaeKK-A*(S#5~xanmTfQq)vPO_|Xp!@7V$2N)~DS-X9T1AZBKqE6soDu10gUi~$FdR!N5n{`E zNl`o;%h51ZqK8I1^4;OjgVfih&WAU~dez5A5n|CX)yHGlgZGtE#JB#eDv?zo{!TV< zjaXd`Jj*YZfS8^Q5Ysaxcr!cS)^-E9j6gHD`%s{7VSo3rUHjA51)q_2UE)6nFwq3X zq^hx|n0eYk3hG4N6?FE&8J158;H~Wzlwv8!v@foIVMQ|l2PBnMDMUK~SnMAFi~S>9 zMv(+yu}Tn_g41eWJ)ik-7w;{NWOGI+MliwuL{;&(H5!K=SDc{ULzf8VG8T$S=|t&u zd}xCUCqPcm7DbjSOj&qoL}gG~*7S#Z-LlpfCY1Qu5Qj;XkH#iuyqcec%TemGB}>hbHLM1-#!j8POm`C_*1G8eR?6ke?c&Qc;xA$1r%CFmyHpz7u zfhJ$>_L`zb21#XfT@Ti(hujVfJyyA}PpyE$1MtyK>lWM$?AkZPDN|jCt?zW?a%Hl5`%iO+s z_~t4g@8bW)V^RLUcq|3o;qTBwg^sS!aJ#a6%(M9XzsYAL6Jx#{bH~|orX+xlbxBtp zQYVy4EwO#EpB0^067qik5s$`mm22=Z<+aJo6Vhjn(I@i4xsOaG!d`2;tYrMmNBjR; zHMu+6D3gMIo+YqPpc|-{ zz~lqtK!6wd0+jC8;;rB;*1>KU^`4FJlIy^26$W;NFSX@gO^$fdXqC%-ClGSWgG@Ms zsNQgjIIS8Ewra0>#EVPY)md%J@I945TXQ>muf1>ogQ~L(iz@EczBGt5(kV!X0+Q0* zCEYCoLw9#~N_Te+4bm;$Lzi@Syj!2=oa?+F<{Q`iCpLT5y6=1amW{f%)>}$g>gdO3 zx9cX?He^0v0Qw@NAcF&f^Sf~`R-wX4+x-0m6oF>?jm9wMe;f_{bK~&%-^|9imykwn zD{r()TBKeFn!6VkDh|{D816suX5@$WZDc&Yz~DNP zdJ~VL1=DS3Vz9~C@127r628vsm`-30Y2v-{J;TV9Vivl=Ub)eBW!JB9022ci{)4L_ z>={spfKAiI*PVsHcHk~RQH8^E{w9zsoMCrM{ESt1G;RlalkhYna0n^5T`Zs7)%==3 zK)7grB6i~Bi%*I~$k^2zWIM-juB8rHMOZl;hQ}A&6P##1z-0>u(dE5yFU%`3EbZip?ER1fU#I$X1Fi z_T8l^);^-d=T~dcn#=r{?~5k^91Ii?>NkK?M}NoAkJS5g^|s4VYgP-?3ia7TIY}#% zF240`x_Q4++y(IUUf_6rD~fPC#Nh+Fpb`2l!=!2kYw9rLmiWq<6m=}LN;z5Q<%4uK zV9iuO*7B<4LvFG5aRU(Xx|kag5DJ&RwX@mKMx1$Vw5J zcK9p-=0mw^cw{|Rq%oPJ=PdQb?B~bxqocc!;lso2ilXkzYHl=N=q)&v=l$F%x!Y`{ZLq}>0_(N)xT~OEieX^CY#JAmlCj<(_V%Nlr zLwZ6qEUC_Fw2uK8iQDz{tZ6gvW;0>y7ub*AVZiu)jofX|Nl3*NdFLDM&ED$Xtp&GI zu$VngIph^pij3Q9$q47sD(7JLoTfWI7I_xMQr>2<%TMHci$F55VwOL(uz_1l)FRm! z=*C2v!JOL$Mzo3g#ER90Pxvd`F{;Fs!kQDcA@zXCKXoIU7prGMGE&PK z&DgkD+R}C^eZHM}baFxhR>=`N-{!l*$y$I`Q&ZclT)OyQq!!|!2kq_J@bkj32wDCY zOI7Lg52Dd(UNraU7u zZ$F4k{gE|F%yaAe_PmN(yKfl(i~g}DyM~^cUqe)n9F)Z^U8=zU&y-u8X<;x)cW!6)aiT{6m|*0~@)|N^ zd4ZtY+LV6)vUlL(puYgJEM(V&36&3k9#qNrE(J)qHr*(ru;#u?F&H&9$8gfa-tqln z(pBzf4C2B21oWUPJ+NkT2H-STU^Jkn)p|9;W1iNyCOb>sNss+I3KqCF1(0GEjtBaY zjO!PUbxD=Qh0-86RO2O>r;FsjDO$L-?Ei*aL$P}CRLw5qK!ADhX=XrC$x2N3S$>mi z;|RDzXYz3J09E?M%HlmxrT>2B;?L{2WWCV7iZK)Y#Xu!Z2GX&x1QNuX%~^(NfKjq{ z(#H-2{#`+eRzQCEkgD1>Rs1tAScf#u1++0BVpWP4{#a6uADj54$1;fu381PC$l}bs zqjlin{0y9vySx|!oYV4*&$87)&U$ksVf2C5vh+iA{B^QZQjaa``*5sxlf*C-$y6=A z5vVQya$<6Absw_cyNaJE zXr>S=GY!&77;>~oy>A6R#~PrQ_lF2T)d2L^n%2{li06k%*kCi}$j2O#f2uR%x5*6f=E=c0UU;cr|s^P^3M%MFJNK1*)`e1O5I^YLpKQyN8 zlxjbLE_kD$aea90D>&1F%1hS-W1brOOEG5Rr#p`1Ajlu%UE%UQzFji zHU_~0j{u|w!B|DOhAdtHR!coRV8&iV&Ko>M1gJzC5h9UQU5#n1EQRT@D2-boCK08X zM9TdV1k0%X64-~x%i|~F4hZOt&&{M;9gm-*bT>ZNEa*MSM_B0>3N65!ej>KCkRSsd zDf(KBMcp@hJB3fj!RxFj$Dy?~;-+FuLck>6gz77ZU@800`w6F^HdkCZL7pL(Uw^St z-^G_ERQ1vcmdNIC>t~B5ec78}5SM_P-}l?dgc`Honk0o^8v}0a$$gQ@8#~J)otJ}$ z@gPSB2~EeJzB{8LZE`!J+ioC`87bXCN&I>5CGer?_yL?v7?Uv%TMc};#Pk5Ab*nAKIo zd&Bpf>#cPKnEzaeq~Rv(k_cY+<=!pK_c%$z-V_~=B}+)g5qGF<9&R23I12O~{+s#G zrvTM(W%VfeRTGp+_8ViHdU(k!&J3;@SLI)3nc`n&`8nY@Lek6>&J_n>K)hPWaI;GG z^Kh~%mQ(lh@O++(6o|Op>y3Dn8(r}B>|v-~c(=0_a_%+k0F6)4|41_(Dq@KrjclL! zf7oWLqgXAU?18JNEwBLVOQ+wN*AKh?ye~kJVJ>#gve6)I2l%;ItE)@qLM~?X)GZhx zXD{XHwrj)qk4)xxss$~KNZ!0Ow=RFf%JkArZ+z`b!t8ltPJ{ z9zUAt&qpoGmeL<)21L2Fu4hjl>Nv1IUR>_C>*v8d8cOtJO-2{iSX-f7$Nf)CIk%#Z z!B(%8ow`Zt%WdTHC5*=j8_kL70YKBnK275``VEI!N5c#RvpeXOo@m@AtMvT!NRrcb zmo*!F?jO!ON)a_Yn=CjdpBfkk#(tB>YFiCV(XGR<)pw-+NZgxQdC?LtUqVp*U#wZ` zh?h1g5V}jd-nea{$75dWiFSb>>6A^}l>f5&_M9}vVlGV>bB*yRk4&t{BifzhH&3MC zeI^iAVKCAVN`{UcQp)}yQP}2hfZg}-fOvR>3czlS&h}6vA5SJ0swA05FY^bjaK8R8 zR&0FPtfYZ*!v7%zS3LcrqD|v_|E0(0hn#nOy2L<*SuDaO_(OBh8SM2TbPqlk3bk9F zIm#SXK0yY8L;wE!&}4vlQ;e&iuJVD-7$=7sEUa0EG47M;PdxTen3Cc ze-f$bKtDRV05bl+UbHhM*LHrod|4LF!SgUK>Elk3-+_2GTMu{C7cBYzHbit$j=u8x zit&19vi1(X%+a>4)TwqlAUqfg)gbc?E1vo;VmEW;!GuT}sZ-BgMyN|Ni zI3QV#^yY_5(NKx6B5mLofMsBDi+cIOzA)|@)p&mx)?4|Q-3rqJiw>Ikcr}(6Y6jND z>ytE83~eTdT$Ub1an3UMe4mHBtbbJpa|Z@^>bp;~y~5yU{A!JYRo_AV%OWf1U|0Xk zB0Fw#8MNc8^_K>&_vS!zYzP_L(0^ED=)B=(qC`~WyvcDfvn-+!G7borG$CK`%PDA4 zSX%K#fa!yuu34kHD6VaT_9Q_#SbwaCcY0bfzIy(Fdz-i3(gr3?Orwz|QhjXoV&d3w z!XM?h#&c?WL5rE(tX5qdm2D;%sMa*7|M~p^I(UC5_!gI1oVqAnPaX%iQx^dZNXw-{ zYcVs`L-sx*YA)}8z~nIAcHjHmilAH>AMAUaF*AcN-_MDc4X1rC+TeiPZ;E$heHpiK;VziB&_U#ax1 zP^8039NA70?eySI#I0@qvc%n)Yc{)e!KwpEsnK#fhEm0(0-jq z?!N-`a%i{M-`^ycJDQC(FasTq{{Wq&zlOTaB#MfITqP10Fk)Y)h><3WWZ~@hy8tB+ zYuHN*Zs78&2gH zjWNv8W!|Q74w%=n^qyPFx2}-=s+Ngujr#L`cyzz`*7f}I!9Zuxi9HR{N%wGN0cm&L zi?B{+m83zas)maPxYE9khXP>?tvb!h=B8lFtxp12$M_T+#%kjn@y!jgk z7GtVP4!M2cl>d20p_o=4CZ#ejj9Zf5D6H}gY_;((g=|qooYTV3V>JbyrpnX_`D{eX zp?g%)w=@#e@YRlXWZMbIAbb5N__v8$|>!F-9JX)tl{VIdK0`rE^^lzG=*% zwz2ky`RTg-CDK?K6u^BhG_vD|Q^Bgu{y{QU+U-xPgH1_}T)I2+K!l)IA%{udra11T zk^ScW@HbQ1&2epso;!KC%V5)aQv6o>6`vkUDbKd`K@lun%;ZMZKT&#vIp)JX55Tf` zUmE|FVV{5mNLzXTOK_+y@_@W3mK-CKm@Pj&Jv11^ z3WyX_IPfaydAarf@BtSLj;RG-^S~FfLkERl$v++ID*(CeM(FEdjHWPHS_?Am`6_Nd z8*i`KgjVAtr&qoUJE-*$A*{u$D11;fVRv1<019Yk+Kd2apsx{w@6Y zuR<)ELKK?BPXLK`EVxf7l(XL~9#@r`FLC@VoTUFs+^<#j`e(6%UB|pei_xI#uN2-2 zNZ|`8uvv@GB@aXnT>vwJR68l|3lU&2XpL@OuOek9Z|T=+%cg_ zUNwG_2ITv8olBcl$&|^o8!4qLr!y%(bzC*8Ylz?nq1K0rqP?*bEXe`H%WXh+R!04LVTCb`3S>e-#rnI!NW9Wj{a40lB z%n#swl>B`kR%CaEqwP%{O)V|j9uH@>w$~#=exG+R;{lpPXH)5(o>3)g@*2+p#x>_j`-qKS-DDF+4lsv( z({zmDfaW`hh`bKDM=$pKciGES`U#lIW+ zEk%f8&5F3#U)1rAXzwKhcAovvbSCER07eo|3MufGM>57Di_bAeo_`WfcQk*#w&Fns zC=v^q+dZDGBbV0~Ctk|%#)0>xs2(b)Rul>V^O)nbC7M-g6ake^XBUQEO~Wdn-8^Rv z$|>NXOZnz*r*n8#kk&3pBtk3h1b&9PWHXqW+ta)4?unxjamzIRDppQE7u#AgD=d%U z!+(WUPWnkJ6$fZOB?ka6!tKkDQQ$h4)F-j6>(i)cmy2stt(e;gmG9iBn2RHpe`}UE z`oKOsTJ|dvSKHzKXCK0EAX*CT8^~DbL54$r|MYiQ;gLH$bpH)&|~= z(z!^g$;msGlb%Jc@*0GO(rodP#`{}>X1mRe=xoH`yLdW?)G`x-!y{&u@f z^WRk^25wJ>uGh}UEnYp}@K@tH^bHbhYX6R(XZQpfV13!Od)0DPhkwPBmpas)`J$1%dCAK$D z)hKts&-wjdd_?en@DZgl&uNgCao2O8ZIH?cYCXh~__^u(voMI{?7@$3K z6j^7sgaa1&SZ;|*yGB5uTi@unW=Pq3d~6z4V{rcXuWppElgdq$Ul5ek$QD6mlG(?w z5uR|fC6I!R?*Y@VMon5-cQXVU1)uucy*FbIs1pnqU$w(ZKf+>7WEMb7eX%BW`Eo?u z8|I}?-wRgc1iGUjd9IZ8J+13{MoIsT)~mNOR9_ueovJV+W0`p0igitYAU8Vzic;@v z5Pl2)n~IXl+V%87KpelTjRE4`a;~vTtt5?~dy)gw_wi={h%~-Hxxw#j)#*R@GjFTS z6oLt_-+2a`-@FY(#|lSl05&HWfS0U#kr%U#6CQyyZu>+wI#h?~F6h>*`Xa3h`lYrwNzBlwVKCMyx z!KXXA3Rg+1t2h$xw1P~VW79zOJ7sWrf8h}WrEl#W8{v#fyEBw`jMNSorFznx*uMbW zFD(~E0EBZ0!sj}L4Z2>-)fmpD4BZcPp9&?wTHf>1-+OB zVLM!wW$m2fOR~+}-H6_Z9>pFcB&R3Yh=)KRTTbnz!7*s!>CP5fbP++UrlTf0I!M2h z;D2G^m9XyqN3!l*nc!3nj$%WUHPMgd{U3P5IZ540XL?Gr?(vA7Rz*9PhEstzPI@Ri zDaE-+=mMj_WHETSIjDHO;;Cws4|yLzyiNC0^#S`Vf)Lj-GFa)VjI! zUm?t$O874%aC8WZ$4xD({cXh3&ac|`9v~iG_(KVyamIo4RVZzhCEJR8XZ+l zEj3E*vS%)JYVmjV7s!BH6h8;gp!MTc8y21&Z`wymfF^dr`~_r50s1(W!LIq<1hk0 zx2&$slDX0udYs>HZEj~=a>xNFgRi&Bb^z*35z@Y07zI12&9=(;0|aE_kGCC%!)S7x z2Z5P`yGENJVB17Q%k#|qD56>M8|Tl`J=#~w*SgFXSL_?_D*U(qSRt4J^n~`!L7?J3 za!V&$kK}Rfpxbr#yX+7e()W< zH^#euXSrZiQ?-wa>#zey<12U4z7cO*D?TzMP<~qk)MO|5+4BdJSQ=xB#PucNfup%s zS+#1}fyLu|i!t|~Mrxh>($gW}=q$00YEWD(9FKBtC2xxaev9JKNDiPTLjh`X4q<>r zj{A4MF`{{;ZQR&i_*NM*4J%{@!gK)v4x9Rt+~rlvDQnks)$kEc^zsg2Tysk`I+l>emyNY70jP(Rz^saje&423F$M&-RFK z5P}%`^1}qgs7pS?C`p%wh}bMoeoG$lD!-)B&0IVCRp%9uSsaBC!xvJK;7JiL3$O?NO>UNAZG@Z@{atekWB*f#GM2Qht6^%~6Wr5xHA4I#X9*?E} zlz9P~iU6O1a@EBnz&B>OguZyE<5@pZo`3$-;@8el(sSoCcVKO>}uhZ23Yt0y#7Psj!L*>-gVJ>d5=s4QH< zWq3#uYqfhQ)Q}isb?Gb=1pA?lr^k$)&BHXx)5(Jm+XQ}5mB4R>I8mvoWSBY4ZJrgu z*Af3+JS(CD0*G0q1!nmtD#Z7rLgdLp4qZa?-J~7I)6c~jN9LK5Xpj6V_v@Y0gE9^* z$L*p;_woK}JyOhSYkfS?TTwqxTw+Jyg)EraCOFSB!=5N7N}8W&eWRMS{(XDateoAH z0l^BeQ1tkIJDT2dpq{zSHG<;Y^wcXp`8%s!53R3dSM<@bl4+r_;uu|zTdw|fDPikj z4_$(Z<2&t+3@m|^p45BFgn09kkXc&AnZG;TiX{jbKqJi8B4sM8UN^e9z@mzVS4g~> ztZ{h_8QjJugm&yMw8iyy=gWvu|KJq^gxvQWepk_9nlb`>(tWAB#i?b;hJ5dNmPaOu zX-i6}SXm#60bpz@vHMEBVnwmsEsB7mL)ed}=sUYZn5i7GyACgO&-1}6rLf=1bpbo& zLYjmM2=weF(hNTg{@|(UQCz|3lR0e5~%xoWmF0DI{7_3H_RBDZ;X*L^--X4vWJhE0>NB>K_Ziy|pp6*%KNIVwxE(!LOF% z%YgsYc{Ad-qFl(%vOuT^oGA_uoJryT#1=#WGhD@|g8LdP!aMfostrPJVEpN<)ekT6 z>EPzsWz~WR?cF^CvZ42p^cxem3Zq`zU)@(>hB}eRbEs@{oC=)X?GK*Y3b=>y zm6QQgNH1K1%MY@+HJYcVFx}FhrL50`ek8_%+;L>>d=4`DXRQ*@d5w5_rM8PTyX{N1 zl@6U^Hc1E(gZGKbt12wY+)dwTeHF_op#7(5(D7)h+_fKG%RCBU6u}Sedj@=fRchV^A=N{KMB4;8=3=e%o=9-;2We`-f?^?B=(RF z_{JgdjVccQlt)fRT4S`!rKB|)y?W?EVx~VvX_tQxQz$KWH@-D&7_>YV25P9$6OUpp z!nnm6;!hF6<6k^kI+?;DrS9@xH&J?z!W9Qoe`t`2lC%cBXy#}XYTiwnmaa&PZ$F%?IS`W4SY4c}t`=`W%ukoBD$r8P zf1T*;l{t7{X{yTG%3DQ#J3I~jGSQwI3?i*0lZe1X^Z5Q?p;c9$cJ4|V?#TOl9eh*7 z`VyVh5{YAG(vUTaKe5Jqs~fY^yx6<)63~4{=A5mQuIE0+5JrN%{Y#BwjLwmVr*ghv zzASE)7AfH54y{0XL?>HejLKqua;VHBQf?OV(OSgbwiUwXLfVlu+jEnXe@U(_HwS)% zg?H7lPaU_KAi{)4btRmDL1=1?^A#p3X;G<-=Sp3>6eJt3t*K|z89kSiG^9pplDO}J zGITtg$2YzbZC}z?fO3|#P>8iyM4=NNu{>${VT_J&9^fB#J`(7U_0~U(kd-lJ5>M9$ zNtwNEP&fmXxvOMhwW@F7j0I1lZC*v=MN!Sx@JTKbG?G<1avT1vn0ark6nGNzX%6qs zYO*3J;tS}hkxPRivEW)$31`Pc;yOCMUFTM?2AvX>9VbW&o2O4dZ>wL0&@uti{MJ7* zRb}3?8sE*?exQLNp1Y{wCQik}u0=a3`q8kC;jm);cWF1kK}y!+nv;8)pjvDD!xcad zH`A)k*okw!<*N4eWy|{x<{|pEFc|wNF>plvE#@$fr%#H|@}w}**~!aM2FMy$ZREIP z$xF+s)bKnhoWvBpxsqc&W8C&vEx*+bgopT>`gLGA;^o)#M zg*eP~9pV;LHMQ4bLTh&`Z~4pFZlCvs?w5x+-<6a{=qNYY!yK>w^emA?kT?W*JKwB(d`BCH;6N-%QogyHQNO+(vL{P} zGwmJ<=m>QevGjC+0h}}ZQsLEAl=2Tbe8&jm{jpSe7-&opdSY1GThF`0Wy8#(v!j1V zr7E92-POGq%OJUs_WE5H{tXX)e1s>F=j+f-K{=e)6I3K0jW1AOs0I z_Aa-&12<|6G=?zE5Cq)9(7Vp}Yhac3kVpf5#oxp-i=J*^b9V`!cHi)M#c1~}sqd@E ziq*g4(%~57dmTx-$9bULk$ITI8hqLt`~mRDLaY7Rt}uf2NlUsJ&V@7D^ZnDA?8}h& zxA|f(?W)xGJJXQLm16?XlUp%v5;#q^rc~;5jp=0kx19I$Emq!rM-LXVf8dJFt*0aA z9c|e&S9liKT`U^wMpqBmM{g^{G}nm8OIIx7R*&Rds=LHIEG|eeiBo+O^Tr7Vi>ZY% z&V=C5>&xkvDBQzE2B~hg(GPCUbOs$(ej;I7Db|YR7nrh_wrbrD7PpKFJ~Ga`9g$DI zkBu+khgDinuluae*QMjF3zV7K$4Q6Bm8(uul>9fWt)c|PI}~)c6|8dy{PTJ(m1t{W zrz17LYbAuBhNUn|6~qklDnxAwLUl4a`Mfm^y?5IG?ES%RqCO0h*Hf_40p&v!XyN-6&u^v1oh9_y$DCR>T>kFa93|I`X;O~RP=4I=9%kX{bOX3 zsxojQ13l|&rI2`FhySs3SxTD>Nw{=G)Vx%FhPqXgQZWJEVSMu>M!@lS%>nK-I^clm zVWBOVi%uDHw=RT~U}$Lqp-(6##L*^E30P(hYz}!ErBhD^mYI+AG*pwI)SS#H4c_I` z$X?!wR=-#vYvC*;RMzsu`#9=PDEDzQJ-n>}(cAh`zN@LULTXPhmv?f-%H>28Zefvh zm*{Hg7<<1;iZrKlRpZKRpAbH9Yvwq1#)Qx=;Ml#h)En}R!@0S80XM(Jszf9IP0305 zjOF%#a48SdGXCYF?7H89C%e?V@};7V??M-1k(8x{R%v@LTpXVH$JFU1uaS`#8Sn|js;w7>gP8-v9g*WGCjp~$7@5M#+Xguj%Izt505t`*G|`p57g0+`Lw)p z6lyrc@Og|{`ssdZZVic$^nB%KXME?wJJ*vXX52GHEuJbo%F2QvWi_33E*ntEg*H>( zFM9=Xm7jZ3+}vLg{7`;Z{U|(bmoFRhJbpYEmb5(?;@(#-t@?y-e>5Kq8*oU-tr+oc zgNb_+Xvu1Q;1o$>lQQ|>siA~%X~j8hG&IRp<~o6M$ya`QvtHDZck8sS-(kh!S-!r+ zQxM(Ne8XT$o)q9Lb}x;v`A7_Gn*9a8v9tK7e2V*`+?jOf9?i={-cNmyFJB(D`TgD2 zQ;d(TXBkyktig(?+21y-Ut_g01HFv8o;AL^shJh4Z%Kb;?k8}d!OBlo){9H>eq#64 zRBDk{zv(QJtuDU;U>ivUe7|6~<e%&}CG8ZSQ?{Yb^l9UW28-i~5NYGJWySrsC928q`>f4KL5Ea&$4%p#2S?W+ zj60Sn`B~}UGU_~{z2GP=R4?`+TXc$zrubFPQ~Qsmb;Rt+3|nK8!2lK*;~;yG-(i^ISJMOZVNWUyF~k{)AFS zp}$?>flV@UNso@CIKqiQHDvf=@z2p?Mby(z_OVZ@!_~3Fn1uuWB8hHfhlPLvco}utlH$QT0@Ws5(N#OE zIFGe272#y@m0+0}(co}82f3b`7y;XR>q1(l=vc)SQ8nOFbUS3sxo``A`mlqZJg_7{ zL_;q?#Kz~>^i>;qQ`p&by=mQuWN%NjT{gr`I|%$SV~_)>zKfG?%j zS0DKts&kp^ekV8$Ej&%{cj^!q@*M;(D@A_BfCsdvIQm)i1AsgsgLJhZ85&DCE9KND za|yWt+i*wY7NU!f)S)!8*~l3L*FWq?Aizr@=WA)P0ywJt);d#oVGGms1-9gS^K=5s zAFi+JM!8}d=Vwh!X^*zG?hMI}uAk+6baayL4vres)MRw+$#sBx#OwoD5dk*h7J;)Y#oExf=p*<^bOvL zTER$ITfGCAO%kW$cm(evb9}dk!yI?_y1MWlyj~Nx){hia%61GqUC#I_Z$w=;Sx zECzyW|9}OrnNWq$XIP zyE@((U00Cbv}x!qVu!an+u6v^V0lk)MH;eTs5(o$0sBs4LHLoHtRC0elF@TA?zp6% z8MeJ)zsEDlV=mz^$zvbBU7Aah&wi70Jbr=yjxo#Eh(m{WUH5m(@P-KU~lL$sw1JI;X*E zAng{j7n?`2jvcE)!eVMva%!o2G}KUMa%pK15cet|Ts;0cb*wf=DO=G}M>gi$-qCY* zuZfry6(c6VLDQN{g~Ar=QCsy)_x4@aNszCPEh`>9@kgN#o6|B&W=3#JO0S#^H_ZEH z(+liQ)|$6nuFQf4Jkgglw}2o}EjvG(55!SdL~1Ilt*o|ygxm6oWxD0}En{Ydkx!on z%UHVSC%iE%!)pf?Ozm0|55m}E6a~RyfOP4b0^j0`Db69T^!&%-+|>3m9D82*`q!^8 zM^0UNR%{y-FS<|*hxvZnSxAm__OOJ%(|okgk={+FuGl3Dq^*uM++FccWUVzje`2n15;sxb;#CL?{=fIJ7*ez2lt^i<9x0)G&oOdZr1ykUteLE53I6B+QULhZ{#r;AbT!SB1 z%qSXw61H1{%$mfF@{O$Kx3yu%03!~e~i+Lj#-!oBo-ViL*b zR0l2Xdwe(ku~wVMy#&!h-(ZC}EETAL5*p9M9qo}jAyXtj2zd^($?y(&Q8i zix){FjGi(iZusuU9|`~#bWsVL^E1PHXKkBaONM?Ca-=csCcwb zCKQb}_X0Qr0|?G93hY1-v0D+y<)3NG)F`iponTl8!X~jv z#zYV7>f^XeT|c{sTFd-eR%NFMKjZ|Mt_YLhOn?d48o%zCt;$du$3j0AVp$q`&&cz(ya63vCQpf{!_GD2o%BLoD&e&sW}-34F@?X@3y!Yk<`uT zpLl68mG%5sli3B$iN<%V(BbC!W&2p`2PqGLwIxv2=m_4d*@bT5Gnhe8pGNk7Y*=B;_x zkYCuctVl^vuOG~x*-qu2W^l$!TcGoHqCV|Jm)-0tk=bg1hQpo&Tz!SaHG_BSv=277 zeLF9hKqIev3MV(=t(*2k)JKn{>Q;9|X+dWqo>i|RsZ_2)dq2$4kkHwyV{?}oeXGM? z*iTKOFo;Gs8TRL8U}57`l}IQ)EObkS8Jb8_;ar+qm;ub=ZKpj3l;H8HiHb62i7mE~ zcj*O20VcMcA0dp*q7WmyU^}CQ2D{H(Wcl47GIAph#90H581Bv%-4({N+H%EX$hYOH zGWjPkghSr&@;l_R&I6+Q2=VJ{yB6P@RdyWa)3DOP0Z~R<+3(~1$tIV`&(r-BtSmPzU>=Zxj$VG!;nQDIe9IB*gmdfi12>kM``_RE4S*vLyYgR~ZH@AG4>ut$Y0gE+D@L{K zoopH&#xjnVGIrU+{RPD7^nEMDshRHJzT4~Y{c6vTv9&kgGz2+gF*XF zI{G!bDr^#jp8(00QNzE<`5{eq6h)3KdpQ#S{UA-wvg)Rgq!2y?UUjB~TUW1x_59Ky zzt+tDujlvveXlmDD$i;C5@~70?XJSN9n$Ny;Z5Xr=Lt#Yv|E;eSw4U&yhRo=Jt!}l zKHbL`YKOW1p@5SET(q>gveW@A0U3uZs`cb}etDgh|%(lNcZSzskb$Hx?}Ce@^G+PnT4) zy02kdZdvZBZ%L_IQ`AE+CQ+D_!a(Sce)~yT8gLLhV1a;Z6HZHT(9}c?eU)5h0v@Hm zIhf&TLCNE`f#DW}BUfGQ^S#+f+QgePMxnb-I;}Wv;W8+f9Hq@>r{!rX&a0gmPuSc= ze&!lpV?=yJ9&mkJ2=Rmzd8F5^mjCRw!zSV<-wURk^9!Z+#V~A39=}1rr9l8wtQ9q# z@OGfUr7OcNI`zw=R|X#CoU=LrJ4Xy+H!L4Z7`ETzmXV}J>!sR4;#F5WY5Ur_amsT|aaFEQeN6_)?grl9b|T_ZRxcnV zm;%=8QzBN(Q0-}c85`e!$z|R1A^W?5^99^@{4&<*cIr94d?$g@J^3Rjp9j5m9FYc$ zP@W2JneNZwtMN0%p1w+75~tLCyGPYF$t@w`Fk-(n!3@bHu%YxA`S=2rsFm>&LmyNFpuwmjjuNb<|OgNx&h~*b%v_r%As;^qI?>>OICc?ui=e7%j+-Tynd%t zz*C+1XM#9oeP%z(GgaP!AJk0vGHQ9(Ig#D*P*=j*kpc7ljdspX-WNve<4JSF#?C?@9Qa-(rL7Jp61J!_XMBa+H^eN8-PlHTz<8 zQuWDuU_U=CT3on$oG>t~LN;o~dlcOjHUE$C3AUjvQ2J|p%Io0Zt6-F6TpvV=Z)tg@ zI{(^id{UCH*W5WaJ9Vtl{xYPS5J$UP!~q^fo9b&-PQAi%yaA2KBn?CaZi7;RHq;F! znzqFeb4ts3+qKFzUF36W;1gejYb>I_ITnS|YPWuvA@O@f=psdYyd$ClGHo;ckf5lk z!4lW13S)EvPN`Q{_#g=oj4}b9Ptb5z_J^FWpNd1c@bJ3K@46;*Zwwlk`5It^o};qa z=|nEDTa_KJ1a+b!7($kaxk<1EmSg;(Llh-zEY{NY0PnMwVvj-}=YoGAPgsOgC?6a+?zDo0!`>+ zUvoJw3tV(1p^o+)Y{{<;C@41Q43&eLKbQH#z~pdw;HAUch!DiLJ7BWr)LJ724`(uI~V1|e3wbsl8}&I zFtNpI8Sx&{pqWNy^ek^AjZumGEHB(Vop?2c5v@>lLpV?v!M57RiV5SIW4Czz_`xrM zjz@NP_D4k5YCO7qx(65e6JfewSHlW=VX7U*AdRi2ppd61Tu4q*9v2fXFHpv|YCbin zSE;pDRkeYqSe%rvr>HHI#F*opgJBy-yy?fBCiXEKTlWJmb%RQEVojm2Is%+t+x;w% zw6lr!$!_3EXLB-3-#9lz2ebmB#ffm1`4zM&ziI6U=*f}VKc2N!qAsgHb%heGgjIW4h2AR8#8s;zjzUv9|^-&mq*C)W$Xd=_k1u12} z89EwQAV5JWh&2MnujAOhE%x4xw3;n=fFbE;u@@(Y2Q~K#*KILrde)fpk`3QWn9dd= zL$L?X=*u|*>IKTdKILj3+o6aN9r@J^rYiDocJ3ww`A%dBE~r$?BruaYcwbgRUe z3!uM25&3Q>Tu&R|gSH|t{>2cP_Pjkt>U$huRF8zY2-?6Ct*PYmIZzjy4XLsuKMr9| z>n*#N91G!ROA(72VKH^Z35sPpkB^_;sr6XFb(CEPZh(sq$G>Nt?ynURsYk&jGG=b5 z2G|PcC$`zo^N7#y!$2P%%4Uwg>B=Hd@voR(#k?^FgTu>qob;>!hgGGfspItw0>L^F=r@Nm% zUH6guFc1?cPrD;u0+F;(I7f?9+7@DYvfR+qad!fg_M+IWxM+<`7QJQn)buvp*`V|O z&z(z*^UFFJ9~#G&3_~4>O`vwWaD((g)}K{k6@r_!E$a)u2aNPp>SlH7t|Y9ncXnQY zwzGt(5B&HSMh&x8#a2l$tF6`%MZvOuR%uKer#+&U0}OBPU#(vd7pO)e;}#li{BzZj zfM{(8WBB7*8sK`d{d2wkSXrTq{w1De2(pn7h!}xqiJuwdF!h$nQrRq8uNn72Q-rJtPiHaTJ}3sVx^BBoNovQOXLt zxl6n6r|hjK$9)yQ1*PxZWLN{i6G7f#fV57%+25B!$ENwZ2R;6)PtrEZQ1PJBRvX3y zP8$X;zyc_U4s(oHoh(w2YuS*Dj`LfGhQ7QCu72tKcs&=gQDOeFGwwEAQN>I~h}YEB zOBk^BK5OLp6jF%p70Fha$c8P!I1gnd`v2H^%eX4Ou>Dsll@<^Q3F!s_>6C7e77z(( zHr>)F-3ZbGN`vI4ySsC<>5}e_v+(zvbN=V~oEP)Tk9$}%Yi8EEuj~5WvJc!g$QXhVehKjK^+0U!}7CqGt~_>&x&jEq;Jt=Q71s;J>g<=%G9CHs8SG4 zIbV`mkS@2vr*Z3yiDHOv!CCAx2~cvDw*QfI22Rn+jMdV$%G@^W9`V z)5a33>5oR6m%ox@^n1xhX^blSaMIbBBbbxB?ZR)JUEH@{AmlFKH*sI8KFX!t$`Lku zwf-!T<2OH*&usI3FeC?QoXgX0K2Y^1=1K`%h^5fE%a~pzW*kI4u?s{jELmwSbj2-P zJ`TEWu7!zJu_n0t8avUd{)XED`N9W zKy{7?(>M-a(u$hpUzTdoUL~m)_q4~WgD;elFWTBg`e)ghO|9R#6re$QKD_jbys0jk z&=KM*zNSg=1&%XFzbo?dDTo^-Y;V-9RJJvFQP}r_d~$8+gBDpWk5ScGHTl3O+XQrz zvE|Gf4d!#2*QJlXon?wsf;nfBuT|yZ^g-@H7c8`d5wp^6$9m!%@q`}x3@XjP!YP4# znn8Lq6*w`-Uvw5|vE9Inr+z7QTUB=PZiB&bbRT#Z?FNs`@IRYt)cvA+sVslVgUFD~ zTq{ezMRLi5p=@Kl0qTFJdpjwI!-ItUEVBfrPV4tCB|LXhg|-NSUZu&1G!Q$`Myb4O zC<4+Qn|On7l|#PJ%%MPU8F{vxN<|>jII%1L$Zd50BHWeVs4U7%O_Tg6mPd*3o>Dor zkh0fEJYUBZ5Dd`X!)H;!j%5O_ExMBNg45Ze%7`~KhRusG|9-ZVt0GU)*oDS-tN9{Z z)=75?_dQ%=89|2Ny&jCkjaNH;r$NMPeQcW@Sdg|*@Rc3CsnlFXy1?k773dC3%?Uc~ zx+#Rik@9gdhiN2#)qX|9>u4mOC@Kg>K$doLnGj#exa4rwO?(rsg=aaHM5zU%6|-x2 z3P5An#9E_j!PYi674g*~50Ng153nm&UTxNGO;tYu`R+m}IOQ0Mv!bIWRf_XSIXLCW z4!?}4OuT~{cPPU$%e%5ibXYi|)&?7De@kPOk|)0k`XU4r)wQM_4!aQY7Y7pLh~k;? z?@}u}HlTwJ#m)FXn$!#|_sjpC@I%Q2*UOKJlYLjGVVtIqF<`(Upo7>(Rm+GoUAw7$ z{Bhkik22+}@4}kIbNj$9~&E2>|pCS`?{nqTP8&u-OX}=M>fA91OmPjpHjZ(7qZmU^ibmTD?wv~^k z%jw9qTV)Mv0i1FFq~yM~NW&X%H}JZuqp{HY9y8-h=G|4h<$O`6@*vhTI&L;aP$cW! z4T}XEcq^4ODsxH5W0`K*M5-RZugW3p|;xoc9i z|CIcWDk0D^N|)uAqCF6MV-Q<%^3GXra=e(Q&PhFV-&rY*^QPNBUcc0Gp1O+ivA+D1 zUCJC8Z2-&09lW-sQ23Pgo2e&vVxL748FmyJYotSJ>2LkB(8qds^C|4eme~pmBQ|)& z-Op*>$Yjy~KGuj>>nApJZHZ_)9xcyE2Plg$k%O6h7j87E{ZGslrtACkW*|s0mc%%qh`eR5O!bxsZoypjXuha^|kndn23%Von~{+m!Yu&lO_ z50uZ53r;AgJFilpw&`5WoK_&a*By!>5WWbF2nndircsXK#KSN}lv`CJDL&4TvLhIU zHGy5a3kFm4W~X%Zb|+4v@(Y$Rfj@o8hb`3M4m1$LU#Pm1Zz!CZUq#bR))ylvYlxPm z>fi)ezINM;mruEx)=K;KhRjnTs(zM9GcpBbh~ae_Nxns;Kp_^^eAh%HoswUBwruHu z8%d{-CD)73uPOqMk4B9tfp*=Z639Z}m zI_CGDbp9;(TmOHA5Ki7EBm4kuTbzqfa<^k0J!9IB!xJnyTPGyfyjTvkv!7k03GmVT zlXE>ow{&V)>ziKm{W%G^3il@!1fHy;q+c^k19i8-8EjnGn1eLpuZWpmrO=%rGwA!N z=A#oiLqX-~tr@y?dN43?oZk@aaF8vHxX$#xBocH~q(i5)*H4&bGt_4SGL|Pnbm(6w zg+!a-)_8PCE*>W$P zRjtoqYt94uy^U5Oo&y2InCwsRG$&qsvfki8UXm>V(p6xkuGOzpGaAIax@6Lx(B!ej zoY2rQT*+hC%)xUcz4bA#UuRLxMu?X5wdO0^*BT@cuzsT(%&b>HA^-WqF+PS4Y8ww2 zSCz?G7~Dj1yo;!62i6-RVCQ;aBKC#f`D876=$(JSO4V8!U*Xw6T0^o^Desb277H{Zs)ZxsQ)}Z8$;WNK-uGxppDW*OYcnYSz@^#j6pq8hE072+lS)+*KC%H*G`~6AOEqdsjF@RhD`!&U_wtjsFD-8_w2 z^j2!oMtWD!c-&aq%g+AJPiw~5O$)mw8Tb5t?vsZ=2QyCrDzpVdbUHrJ(!gUATY)5j zwJ@D1b{50?ofWL+ooF=(BsiuuiM=}zk<6w|^*&GEtq+jh6y?WziU%b=Sc+!JTpTVwewVp_t%16fW(Lq|?J zyE^xG`&p9%d3>MuhgOv|Wv4hH51;W8Naja!(VFB4p8c;81IaCgiaew=c0`xUU6P}9 zJx1cWInHCg>OmW{cO()eR<~LJ(lp@&X4|9s-9SP2GY=Ul01taPGLdTX#2Dwp0BNRuHTJ- z3F5qgrV!XTJZ|kNCOpu_)O}hCpATCyG}nJ|_fLtLb@xthd4?2Kmsjx2IL-&6uc<2G zXU3AWgYxxl&X((KV*_7?hNR73OU!50Tn8qZTp-k?U@#EJQ1}-#PCOhVm+Pp6!8I!nj^-U#CqNXKBR$ikI;S7bAN74nQUOQwHg`Hs& z8egp(qb$KaOfe#;-nHE%oo&~b3!P6EQ~B;a?#&p= zTG2J~pRhy5jvH~z^E8Rt=C!_ol8UK<2D*wQPIUfU3Py!0x-a_P%vXn)Fw zF|EC+L`?Lsw<{I5m03lfTgAZ0d7j*{sHedAY5p6zUGXm2zmY$a+OlzaT{90S!Lfxb z28&zs3E{eoK7`m*2HThtsqGRV0wDnkbc6;GR(|5nIzK4EoGXLP;sNJL9XyeOgUh%| zC+9}= zawn=Z_K+Jo9nA{#QQ&X9Ym5#%QUHsHF0ihp)A+v9+=Ho@g<#F^P5pGr?`&8<@hgNZ zwqHrh_@d(|@1*&k)&n<5*4s^ha0qtXR61C5Z%hgYKC)Y^e$Vvcv9Y79#3TC3_s^w~ zsz}0JYIeG6`P$bmF}&CE$TCbNUK=KDa`>k$&Lzi6(u$X|^cv=0`-jacD75{(dF zdF$dV{B&&>e!ieCZ;$%r$vPWJBVt=R(L$-+c+mb&S^BPPea-7X=jw;&hPR0SkN6We zKR8N)LvHg4CeAH_;Pz7R!BrQ9MbUK4&cK#dVG|QpRbulm?gq8|FYZ>Hh_RcLXtbca zo@0LTM=;PubsfY(-;iD)O%O!x{+0}TG9k~qGIY_T%k1=2SS8()VKF{jab;T!VF{x? zE%%Z-z(sYDgHka4?b0zP#PpD2NoI&v#uaUdHpEHX)iUxQxol4$ZDx2Sk@ru)kAso! zr~?-%WD1-7qdu^Px5d_adCtiTBp>b$0pBouxE|iIIEC8bAQ`huTY92`-hgWARdu0h zPUDT9=c!3%#0{s%5Mkm#2|v}Rh31zbd!b0z5LtJVENVf}h*D2M$@jXKTChdEx8@H# zZGXujN5qa_l@^foE{4Ywd5a5vJVe~&Q{U2iEoW_R49))uG`wAXS|~SSQ{Z{KRJ2>FatW)yz%fxJ4Rn*E1e^ zOq$yhcP>Le$FbxVZkz}1Np$M@f42y$EbMcQ81pu9*-PYr64OGnQpnyfq?^fGcTkB- zxCl0ReT*oK8bkHm{;{!|C}_PN(D*eEucP*g#&VYe1kO@yHz+{hY_#7kqhp*~ChbCr zQ;{c^0hKeZ^I3wrgnGMf81B*7fn8?9PMd}P7mKdItM5zHTP+F```&n-a>sGS{6K*0 ze2R$67^IT-#B`wsxN{CaMGvv#Up~WKz}(!*6d!f4bvp8GjsE@u18=fX9V`%0T^c8> zHgyK(W}nw!=<&dEF{h?xQC6NI3Vqt5d5V&j|}xifrVBg{FHIch3Bf zPJUL(>$ksOH_yj~P^A$Cq3}HwZX!y|P#RCX5_rsHx+JX*7@#8hh^!12Xg%m~gRZ1= zi!KR2tp>Jq6t~nx$!?D{m3TE_3Z}fp4{J}Ijb$XBLeJ6xx9F40-Po5+;Q^8U@+yOs4??v)Hx$GPKCIA zD~eFYfE^K8+yuK=Vm;$Kr;E-S+d*59Fz%J{o$Ge0bwR!^*Hbg@T&)-_nfK&>i0kO0 zR4D%FzKa)m9uR^dhCA6z&Zq9OC8TsE+WD?b%hN@gywFz^4=(r208Sw8Q08hvG;q|t zkCBOB(6gL4PQ+C!O>a<{d@LBEBAS<44w9J}aTqFF)hGt3@e2t*Pj=3}G&ih1IcJ%? z=_$UTviOTJ@3(E07rCuoy5ubk-|dAL)0bXsXRvrR!mUEo)!px%?OeQ^ueO`grG5EZ zf{~f}!u1w3X?@enu6FHP7FhE98cn6ef_p#+N^VM|(E52&KSMNW!xsT{)?J!f^E4_# z!6#tR5x`~p#g9PEWWLd1z$1KxDd>x2pC1*vJ<+J~NPko=)ngVFOmoe3C1pL_lnvhL z8Ysf%clggg^^b$hwhFYx_@NC)72kX_G&!;KnvB1x5Ztcb<85Lf0-Jqo0rCEWI`eoh z8smN@vs4(3Q~OT=%Oetk7M~unfMdo2;j2nHv{Tc@)BIoOuMjf!Oc|PWWdb2ANrxf_ zTkCtL%j=dZf_Qxk4P${y1s~4arpnx>h2l;(B-W2T*gkj|=0mQGS|}B69gUfP2~mY1 z9xW(EB60y+nBGM_7VS|&p!sk%tLZW}Hs-fSztb=AKboq4$$ol^iQKz2lXd$1r&Y7p z0cGVh>r|Q1{jgM0o%8CNN_^MV&b_jbK)iaX@IjtaRmzqp)8r{5&BlO|=?$5%lg{i` z{p)hv&ieDdhD+PU#emkQOPvO&#+;Icw)xMCma3QF zkg9R}&NbtPI-M37Bha8gcMceH#J>41jLWcktVo)G!ose~(5<#EZIX?qdw?FDn=xB} z&o&9!J0^>u_idq~dg$XF7@b6)yYgGLvP|^f5?g-rnw-nyj#@K##lEnZytQ36T~sS* zGqixyg>ny{eRceL;%k7U60PZra`#||nwZ6yRQ#nURJ zPY!Vn)ZJoII)R-6B~LKt5#yEiABWmIG{KpxBFA5V$|$lo6Z&Ufy+0NFRFCGH6G9+A zkPf)?z*Z5rPr|Ofl`8lCscz0r?nxsd8b3qG#Puig#O`e^t%>GhD|7WnbxBPV=sRL< zmV3}3<0xw1bn2B*Nu!Iea##NK4J(Y|#pB4$1$YT+T9`3?WrRf4>INmuoB2m>cV{}4MLrKpEAd6Vy(7wz5M`MT1E=>;~xAA3v-w0;)@Y`N4b>y=GH;sX5Vb0R^V#fFE<>7~A zVY|Nj@b8iF5(06R$a@7BS9gcP>PxBLJ?^S^8*f*d%#UFFn(9=;Ca%cO!s`!2_KtQs z>oC#>4u1b#%-M>##r*jr67dA7Ns#K(e6vo-2VFlmZao{|w^BIO=IUFy>$9b^O=F7f zeQHBrEq|%zO=LsQ6aH-XdqXyAg(gQ@(umil_y9@rljN>Gw#osz=r%7J(wdxxpUlIg z1gI0{Ha73oqeUt-qlPmC51ypW!Qu1K6|Co!a%Z@w-LEHlj1d4S-~z>2V|){5vF@+u z@y8$puXfsVl~#K@LnS_KnMEBQZIwdC#cdw#37RAw?_$1t;ceLpWAlCQ_4?`T8AK#Rv%PRT ztMr3vq&wp0`tZnsub1H4FU{9{d|#^nW<1o)wdspLjS*-?#lxF%(4XLUedW<^CnMYSqyF2|TySq!sWTC5KefHPV2L z5+93{8{X>bO#?p_xy}MQx=k3;3=7{Bh>5*}rjP$6@|(87_m1%VmSu%w(B0W?aBd#s%zT?vJDh<#3V)244FP%r^Z+h2{ke{O7S7T<07z zal10&Zs=Z*`s6@DRYs`$J8l3tA2!C0I0{O1iXY7|V@(;la2i*swo#Bl+t?H_W*UxJ z8eeXUIVfFt9&_DrRUWq;-L+TcpPM=&_`>ZMk}?fYd+17aL=pN6OZ^Hf%>uG;iV+va z>-cJJO0Bo*liZpLL-!r~^b{wxuMx-$NCQ{#`#`0{!_$Si{yENk-DbqY+l?hnoa0_f zBhBbojSM&R4Z_|)K@Ab-h6kQe*+tRT7lpvk1xh?`-VMv0F0n%XGeQ*Yr1e>+JN8s+ z^92(K#D(VZNpocmpG=i==j?+(*VbWUoxZtd>{*r`)8*E^*{cA&%=1_Cny%hdC(i%W zszccj;m|U2)E{KoUas|#*;srZWim9H1{(gbogtfUL)UboTOSE-cpRXBGI=Ykl7+y?|GXGl*CDA^phedr_g;R9Tb`h$7Wwp9Yr$c`^`7O|Qv8AiXoprbf^k{7VPR=H zX5vmY`RAx_H?k**VJ~x-TdZsmdQ(51y+UQjK6l_iLero8 zTj^&*ATYS|DUqK@|8b=F`gWbt5bD}k8fTx-G)`9Y|xS1W7XV<)(4WdB4FHH(7qg?)i^ zH|>^)s0;F|?&$8c{5C=BBTQ93BO8xRf|)Du6wUvzGv@!R3-+PY_o?e%l7GsO0=#4A z@4{K$f3w1~Y@p z24hgCQhV9#iyyuo%r|cvdHyshSqvcwV=fLrZp@rlveD_dKiA#z%lrSBaF#XTBT;si zwMTxX2cFe?OJ`Z2SvwcZ(o0S64k{9sysm@C*P`F>bW^}*C;NqY^;r74JY%apu4n3I zzx-iL_oCmbAQjextxbukry=D@w7ytzc#5P+|0~#`@DU-kAAey*NITwaL}#t;*_P?P zqeor!2gv!v8O%cUMQEtUK5Gx-{_-7bu#3C5Qi54(;lkPXvNpDEsSq>nK%^7mYW9)a zxS#*s_%4ZxF>RaacP0`PV&{5@uCh&^mtgJaGf{(2WBF8uayg8r{px8#!wT$0mHFKn^)kXjpn z|La`L-*mB>;`43wYVG9<-k{4Ox4FF#CyY3leNEAx%lx+W=_dtO41>p8id#7pguiR* z|5cCGOS8=}z1pRZhaV+a!gVKGc# zm*N#@z&~(zf4AU$gJs$)e0Tl*<*JRBhh~)^1_&#CuKJc%!Wm?~uLP{wP+xuA%4DSJ z$y-~n#eT`4U|GJdW%AvpSXGv}M9cN9N@0OEwDJuuoyfO34v?z@Y9n;Vs5wSpY(BnK zMrTU2z(%yH*Gcys%leOk{+!v`Erh-`e5SYYFn$gI4tP0epgn#_lQj~tUC5=xo<4dU zc-Ufe2pfYPYM+aflqY{ECl9qBbp%g3Ipou#__-2--8Lo<5QFR^uX~sjVNN&}c>xTv zL{T1^O#R7plZN{tm2Tj#fz)x>pokrVtf3jD+$}lV50Cqv8tctoe*b8O3Lt{yyaipg zj#|E6o=IPC;D8~4}lHKfxxRPW3 z(!=N#?>^6_ zcZE_av)*nhUBr5SWU(A%rwrMqLqmFk$ujXB^2uJU7#%6V_`9#jrWxbN1ooLS*e ztPV=Df{PLn?^{qkd~#MWO}Niw%ry(9@MlCDnp!0srn*hLhp(kCUhpmoQv@px*B?)d_GGTI& z2l!jsQSKPk4f{TG24Prvu^S>@|0XTLPj!e`j@+|naKrsXo zH%(+pb~9lQ%r7gca-M!eVe|OfuN480wdXk~nNC4HZq8YK9@h>w>leI-ybR?>qapsl zmben~&3CA5?$c0pKye2AT$W_b2*Sbrmd7`YugW(n3`VXN2@|mj16hW$o22$ng6_vb1c5_ zEWDxasMN%2GilzhOvHwJ9&|7fwOQPZ9nm4pm$6y=Oq_8ZNMrNSXe3YR9qyM*Ox||R z8W~V*!=7sn3Wg*HEJDJ5gmD^D_{A#9$1LJ2%HwT^El!@vIkIB6z-L%zhP`^;ZS;j3 z;PX+t?lsVVG`VAbm^?HL>VDvcJ!N?rgQE-1WLq;$*V6PKsiwRbOkBcrY?86lO`r}p ztO+M)b60=Haj)C_0zO+mUE+_@7UEp67fBe}biAVNUH!F84^SG^AI~ppkh=mz!J;6i zDti|xblq))xqwE(3cCTXUgGoPdB{$jh$P~Cb1JQWl>lg_&|JfXvcD_&Z7;ZXIcg{i z*T(B1KLK)hY~brXO;2c^gS1Jr8%I^kyc0(^NmyH?7r&`N?pWubU6#=o!|PP;#G2n* zNgDTv_}u3$Y^^AZ=_m1YzS;;g2*Pt8{OuXW*wWj|ASRfU9QM?JTp(Ut9{g7HsV+(v zNLm6`uO-x;?ueH4sAgNlKQVd5Rz^y6hZ7>MTn%kMAstw~anOxh@N4L_Iu_ab{SzM^^{7^`w(L_$N|n z={e;3R$>uMiUVh(VkCB=11@e&KV=11#$?7Wp$|uahkX`GG(zAtqKc^^7^7UmOQk&5 zY!eJg4OoWU#D|^fAcTy4lM7kK|0V~f-ty$PhpE>ACuEr!w(WVv56>i*{?W7btXS1; zVj{0X{)-`CavVVz3=s&whtW;qyp(P&q@cn6{aQ#ReMg!^QiWhdZV^zQmQnWPu>XJM z7PUaPmF$HFn1nHHe|ksQXO#z-#1y@l2??b=yfq5&S&Iv?c*;@#?lL8j>js`I4QCSa zId@RI?Qq0i@~!W~BARMkt}e=ckqM5y`76f#f)hXr{{q1!DuD2>FP+R)-j#9SF^|Hf zh)7JMprgF|?E|G_=)w^$Lk4c1l$w$sUzQcqP51U)Q{>nCkK}x{B7`GA7CEnE5|ka6|uGa5+<6 zMC~UU-+@wZju=S;d})ex|9oj?>m+L&gJ$ui-AY*^i<|&GZX~X#qs6Jtw{x+@9i(AU zlzIrAm`p*tZtg zeU;B0?3Qibf<~BT*oZ9!$#qkq$>jz6hfG?!FViou?dT>$vD8avZAbU-{Hbk1Eh->w zY7Lc$4tN)jvpBMVAJL@GTWG+_Ei7z?#eEHIf(@O!P3*?^S2pa;c+iqF^R|ybxDgmjx%0zI9mCHmNRj^Il1X^+v|*dX3Xgt z(Tk9O^gt=t5IG3CsiKt{55201gVq@yUO`K&ce-D7f~o&t#%7 z>QVno5y+=;q&MtQb#E-b#i`)>rW~1%l2;v=12ROE4*vs|Aga#6ucXMwcil z@vlmR+{(hYpmyss7cK@ABp=`v!+h|HMFB9#DqK%H&J?D)FLwLae2AB&KvWo1n9sik z8gxsdpM(AW3QD#DHswk+@tBEp5|`@WA&-J#I;ZuwU*;UYc_0R}V6d;Mpypt(uUt&W z&;z*!hD+Z*47O4Fu7`K8vlv`h9>8MQcwjMf`7Uxq=%?sWcqxtZ2S$;W-f#vYc>xHd zXjs?+BrN&0`5e*>jb}1d6Z4m3U=drGR8$zh2wK=nNm?4tBjn@ic&ilT+qI!IXu}-= z9-S5&VDxJOM!yRHZa=(!d1v{+H$gfKuHB3pr<4GF%n;f!z%NOn*l{-wM4eb81jRxX zaF+3*3fPv2c9vN*7GIF;TqFl<&BoD5l9!Wc+kdvsroUQ-Fc>2cVgv!x+3Vt8S%`Mz z7wF3_nq&@69=8QSe#H2TfVI>KJT05+wae19T6c`Z6QKT$+7bxlM%am|8{h)K$CNXtu4V6Q6j z(UPju@Z%h@E0_t`DK3E~uuq@7!3p618w5T{XiLwvMPlFaR7=yhiWVZbMzc%uSbXuZ z1;+4$jB|E--QOk71sy2V9QUhFT~ztN?Is7eJK}#hFwQwk|G6@`j}M($B6x&USa-QI zOLzv&6TljMvD%jyx4oNZFFW2ud}0*6)hzx3pqO}j?DFGiYNU{Lf2FK6I3l(?yAdipAL5KBIqcmjV(F>e^^{-1)|#Z)FClj#9{E2S=SaP5xjhq6o-xFzK64O?G1Za z-QUpTkDE_dwS_{zEme%Tz+2K)Wr<6RV|Czpc?XAI!^#UT zuOoBjPYr4qUUE-3H|as9=FiJ!Coa3ICbs%4R15Xp!YVs|x|ZsA&cvOQZkv&fRix+A zo(KQ&qcdE!a0iC;2H!Psr_5|7j5a)P?AQxG#s6}Pf@*6Zb>n^l;Ey;Wx44W}Xyhxf@Wy~e{BNlB+ZI|wT}N3NBzh%^({7ocJ3{vU2e z%o~6>K!!**{jWCGdJ;VMN0DKu&C1ifET1V}N{iP~|204$FmSs$3?5uaWf8ig z*18yRt9g~atu)?I_sp|35~ZRk7p#XDnrTBI1p#-EFPYE(;wr=vdSiu*Qib}5X_dVW z&m@e7BJ2MCg7@ejqy*(ZNC`R-#=y^LqhvjNabKH~XSezRClL88&;akG**;g&y(Wlq z6ftLqW0Xv2H))hDVJ&;^I96?~n2F&IJ#F4*Y7L^@V{~2w*V*gS zKG)Qmj1Cn8|Ba4$DXOzy31^f~*$l}0tHP1E7@Z(O1!oaR& z_ipgj(xbs8>5g@<{Iy0Lq65ocNZnzWq+^j%vvutxZHG157+r`{hqdJs`q~#ku)SBm zMutU+c+b`tiNi^wwut!sW@R{3K6Nw%9hrSBam(E0c4*n^bMbikXq z3gaeYb5I8S2Qs4QJLPukQF2*(SSvZetAgDfa|q;NcUNU5;27E&G2l9Io##8TIn=p3 z9WIR5oolNj@h%Z2BJU3q$y+(=I`Ytd%SfFQG^cvn{yI&ntb#Kzq6fo^O$Oq)-`TVK z>mCq81ns+ivBptwSIg4ZfUv85mRCqmI0TuT`{@+L`7jj`KXl>kP-qK&r!YwkeEOYl z7)}i!*7Y#I9DB`O0&`mZxZ6Zu6emA{6=+M^(>?kMr`q}xqJ)cLt2H;*@Q*UzcMw$} zLt!HuYbC%!Y{T7?=V=pEM+#C^RUvx9|W;DKbJj_A8o7$Ba2RH$Cx zZt`wz{Q_RdPFgN2rm$$lFGF+8XFEX4&8(v}s3Pt%mFE?DT}R(VI{-oJ0(OlKh~+gc zxcKnBo%F-uJHkNLl3Fum1PFRr&3X28wP_VOV+nC}z1j?Of{J04UjSd-njzm#JfqXj zoz7t;!yb15%DlJETtildpbG7)!F(wTS@7XC0|7=1Yg-uAu=B|2dP5jZh1h4azCZ6V zt+4?b=VvH`2=N>$k~MhORRn$jI)MkHh}(G97;NJ>MUO@PI~*k!Qab+bP#b#_uKO;RR}aFw`e zDe~U_wA%* zji+c?Of}8qf8$o{YT!H2iLyk0kEzfpviS+(Ckfthp;yHz!tuC;-Yzo&HQeB;H5~ zkl`+qzwAV8&6;TsTJilVh1-!oI0b5#u&K|bjE5qiDv5+@`_tBRCoHgYaN6^>oz9k9 zx&EUy>fOHO{jx=su8qqRp@uIFMWlrZBP1!x1bnL|1y%J9MO%UAWcRn`#&gPS$r*NH z9e=U~Al)5~$x);tKIzA&m)oXdodql{eJ{Lg7B_M^SU%neSS+OHd)#-s43@bT*6Vso z6HubhC2iu%&ExIxZPvdekNNrJM!RpzG4$QhoK_7RUA4gFk4J`5T}VXdlZ^^LAKC2> zRuN)(CYP#Ky-Me}ys;iygynL1&h*ujZ>A_WH_T=HKFj`ObD|clOxvj2k8!xR;o674 z0b~5j-xl}>7Px#)1A>|KWKcPwmn>cL6bJ|SZ$@xOniwva!n@&b0gO3-?I1D}pC#XB zt?}SagQ+Q^QB=!i4`i@UP@+3I;=hJ9Ss>p;vVFj&8KseY#mprCi%!F#qU0Ik2*dMc<#$uy(^v2FR>2;T?t1|ktw|WpB9Fls(+%43dgt~gX?5i^&l^4&P4*EJI zKZLB;WsdI!j#DO3&|c=;WbP-+NB@UoL034Z-74|t_2e>Su*Q7G#?AIU6ULOd2Xh*A zV--<2&*D6Yr9(4(yx2=E-Lls6c&}T*J+52DRHA#<4CJ6r;Dib*86%v|mIueNJVRgn zt@lsEFFqbf-CJEB*e-I^qkOCbMucN~^E;ZK#f%~g!!)ialK#cYbpnpR zM9rX#H&Fx5`lcrgvt30B&6P}CH~JpwvUe_b;@{8bY44)o9%0_i#&5g9vjZ3?sF1eDdKiPgyXM7Kb4Gfgus5_{$WqAE7&GA z5_ofho|e%KfrX~5h=_ICVduBmjiYqEI)|q7$8g`AY2BQiI6D#vsV{7=&oXttPoF=X zC*{k2dvQutq~I|?ywdGP<`#!PqGV#12IZ%@OgH*K8&^|-iDQPrA}?!+Z7FK}D=Zi& zAkjbpi4OD{Z7+?C{B4deE_^AB%qnW^jbHyX+EUNA+n$!-qrzhZhGR?e*K1`0YN36b zft<*UEL;=L4FDH2ACCpQf5e%VyKvh5*=}*{ZUkifjS%m1KS#P5F|zF=N6e%QW-`gB z3KuZyqnVLjNqzVFtK*olp?;XSHN3C9h&GVZqOHDZy}V2ONruZu1 za2>RPrRm__&thpSBQdE#C=r_D+*A(U+!0d&g?1k{q$1ncuzq-_JlU+ZLnH$T;XS16m7I=uJEqPGQlmrqraJSVm@ql{W$+gk5kQt6>m-5m1`YO z9rP~6!WO|m_mPHxL>69@iaS}!cVLAjPYRW+)(w?B6eszkLpU@x7uhqu35)?9|LMU< z9slFL6;+A>dW~Ju?^hj-C4TeBfL{942+&Ij{Iw<`Gxwn$f2Mb#ed;RSc{4T*tsYuM zeQ>Wj!o<_Qp~6;34T5o%fNm&U%+hjs+?)XA4O&(^`Su>qhXttFn(E$|ROp%`u*L#9 zxjizw><;wd4^uX&^6hZSkC+d6f1(a0Nhynw2z0|oK z^y{_|9sYwW)>ZdES1cmv30DVq`xKk;gv)LR3w^ZvoHAkOu2QVvGX&w`RFaKi63#GU z{r_CJGey?R|6I7&omq57&l-M%Cb-~aKmMKUr5?~?1s3Gf)@PWMvIK&)d+&peA-$0w zo&@he53+zo-ngog8DJ5dK`UGuF&&HL`d&kV#8umI?URVzSF##8IIeryt#nZ%AM{;R z4Df<;|Ky|}PEVA*VV_|tTrvFBg|_XPs`71egw`Fwiz)tETi(vlEg?h-B zvj@%CKbVeVwH97du5wDpZHM`V#znqHZM2^F>S%e)U}4QkSIzN>Ul(s~9;D;{RG?J@@^L zmIW4(aYQ&Nl7Q@j`Tif-#h=qoZ>`iz7d<~*wlsV4*TDP;R3s^6`2I4>-NCy=^xgE}>#GPavrqSN@852pM~m+TGn=8cJFD7(vpff90mr+*>1IV27nf@> zh~2sMwU(F1>9@`^@!JFXG55vD$w17AD#sf?FZyt6qpqA-A@2RpK~y_-_@?G*B`e$^ z+d`7BpYT^p^FnjzIYO>-5TLs|Y2><3V1I}A5^GuZw1({EU-nB46Cts3kKk8EmZsLy z^Pn25l@w7t21kakHTjf6MY_5WMTVd{>np|Fp7tFO-!b!Fka9lrm93L6}bu2^$+E-qC{3oI{Bs`~QW7j036-iK8H1juZ2 zQgD*?J4^1#{x}v%hV<02O6k0rny=ir9kmG1N*i4GGbAgQ#sSAon0(tyS6%rAVQ)V{r2QzR#Xm6kauCW}QbqbfsOF6aAaRkv){~H>yYyN8Z;&vSBp`7OFU&_k7rOO6~>2gjO#XSKw$@KCe9&N z68hBvjNl!#QUQ!00ALLV9L>h$Q)}01yE-@pd(&}enzMd~Sa~>r-+uS-+huF^x5az4 zH;y%KPI8DInWQ|wj-;cj*P|X;AvV!im^>@dJAs1P^TevPm>0nct&RrV1}jUT{DEx6 zUVY-<;p9X<=j^wUp`ty*!f#68)vVwKlzH#yFKAR4>xL24eu&=qL96(U|DJtW3AgcUNOY5Hvg5<0!Ifg`O=#QM6Qc_gT?#!ePvr)*KwhLI@TM#7L&T{^j`pc)Tg7Yqan}I%l8_vw!!N% z`27B$_swb9UBRenfAH0D)S;us!C91#HzIC!Ea^pOct225h|%Im5_6?wy8O&vB`$I@ z82P4B0xxhlvY3>~*6cG)rPNn8uh4H3%FlvkTeTKDqd{1v6Tw3&J0xIG>(SOXsKfc| zR(&^0^mLG{@^vrF*YS}4RP9TN`xa`9y5AX{I2s|(3pJOb`D%?O1@6>WYfGtzI|Vk~ zi8I5|iM(g6pGENqUZA_j-M+Qq?|!eC+!WM#llu&-0z4;iP=%7UR>8#sS=OTdJ^537EOQ%t{#J(*b!X7Bz#9#!dA#w>>1-mBz82tc|d{7q|d(Ww~!6 z&fDsMeio1qPI%p&QX-%f%Oq56Z3pkljhbmy${T*E-eYB*C>|c(y)($3So%6q|7ZLs zvx|u%B{36j8Zd_>OkRHHhz?>;w9At-KrIT|2SQV5nLI<-jqTx zNYWFywi62Iu5^G>Ot0>WcpZ;fzxF=l0EMD@*DSv8v+yKalR#6=t%~a72^wJUIZILG z?btj~1CrI!Ltmv=psx~ucmwtpucRxx+=atRIa^Sfi0;kP?}RK(vb=4gg~rcx0{>UY zWFRilh?3Y_H_QR`F7^N(UW3zZc1S{SK7J8l9WVJMp>NXle%s>yw2|TNW8rtS4fzSn zbm_E+)ob7ekK!)T&m<=IttYeR6U z>{pn}Mq~fCy}tg^^KfBi6$`DOORL4E(we`vvl*JKP$RG-{AwSSI(?Uib3FaxveJ&k z{^83LAz?r{Q(DJeh}7BpCd`psESXAizLsN|pIy1tw=l7B26`RQLN^}o)`Bm?G&h@F z<~2o2BQdV2WFimoPC1W-=Fqb}RTjmhYkU^P+p{lN>HNqcFl~0Q!0!l*@9)ne1_jmS zR(Zy(+yA%K5&WaB4Miirz$AajHnU}$UugELDd9j7`R-Ri}H)QRX|cex*I8J=~Mv$ zr5lkNx`ys9=|;LiKze8xx3AApXWU1?7i07`wV#` zEM0AS*Pcl1+NV8hU_0p#iV9-o%%2G4L0RcL1sb-&rO|+1U_^(U`9LQwCGt;FuZQEs zr7dkN>mB@j%hSGj8Xd+EkzNeC6TZIu*n~DTKA}%ntD^TJVrB5lloeg&Y|S~?QKd7# zMN3{(#`Z&F%h%Q*LRDPZ2CA@p5BUEjvwl=00FKC z`bl~$ko%3(+&c~JE+NR|*I*`LIJ~!Mj6fnTh6o6^dOf&RfN*QAFy^%@+-FmoK}i3z zsGnHd|8}PZO&!fH7FOtt_un3``ENBeo(?2%o{doc>x)Gt4|E3EXbcIvt)l*~DHh%j zFx`z3a-*!hMCNGBxUsodFzyQI8(vWKNeBc7KrAoeI;$d&^fg!<)9YfIOul@b2!BYE z!V__aQRa&3;L6lcSklY0{V%TGhNK*?_U0~?+zei9!4_XP6iU8!wU6193^k6H+LBJi zPq5HF#3$KZN|QdkoAckQy}rWD3J}|Ty#8)$d^t5{D=luC_HF+kB7(9^E*kv&sOf@V z0oq~2<5#7-J+d!WhjE(!W0-&vd8#%sbP#*{Tf6Ih8RgGYDL<~t2)K-X?anH=g%}5r zJHlulW_T5ee9W!!v6w=G{}REpM@QC%&NJ0Zr|8Em6@L%{r9ig{y!>i4!0%B>y?qx^ zAZ__C4RF(j+JL}I@21Dy`}HpIHwnaZ@oH|_(+ca81X=hrg>7~RhWDHl=I!^oBlCV zJTKi=1FvcZ-Q0UN<7>j~6qVVazK(EBl7W5B3nunwpO^HtftR~x@x}Zkz=mZi5(dY( zw=L^ZV|;Wx=1NSc!}mjcvcF!nLvDg~XU35iYCPhO!r7of*7W~hBSZdnc|Gb`pHYc)}OgIce2OJqMlr5r1H`&E-bbDcr>t%JI1PqvxfHR?Y#`zwtb_t4F zZmyrE*{q#rfO;;CB_{V#U&R93+u8HRVdv=%`|Y5RSIS;&zX&V$=yyc*->0AD@)ML! zw~l1dH)B$8YK^OTi8u*{j(iqJ|N0q8!EM)Sy3wRN^zSSh@}v)iEt;rqmp~TcCM}W? zA?^dYp4}WRa>vfy*R)D8tL6{5DjR#@3ihlD(~I$bymyG+HP%rnTXU=Qv!<$_#$=Vs ze9*g>Y)2s_d29O*emg8ylhqe=e9GPEh|ex48<@RD86pv& zjC+zYFr%_pkSP0;c|7=K27ERCYj<_pi!GFA-v#swiVq=OnlKk0O?2J_y!1Eiv-7+pe)1 zmgT-s!>tzp>E}V%G;L895X4njcmW2Sb2C|LoW)q~LAI?l<){zOTfA4DvXK|;U%WGz zcd~az0@L#q2n$^^0g`Bp@-t$u4Chs&{9TaSA83o%HwBu!b z3|j$k8S~f#vUGXbF=njd?_1{BbY$IQjV_9jYLymtr%n9jhaOnh$D{%>tj-L?*C#Js z_P+Kg=>OReoA6ExvGe#NgFVXC(X?RpGjUn8wlsI>>42O>ltx~R&tA=Sn@e3x#gnvq zCf)LgR-TVs!2ep*1Z*l??S7v?=KWc&#MQ8rNwXAE2s9*Jk~^r@&C=|K)!L`qX0g9g zdvBkVDoOGJmoOEJP}o8{8(pzVm%KxsH%FP9wUxtjmSfz9_%Y$}_Exj!v?b76y7gc} z4{H$|n0TBjcRYzX!4SSe+V%PHi_IQ9Cul}x)8sW;o=QdM@|JGIZj{;{ZmaVF`PUUZ z@Mq4s`5!S2RAlOJ*5Ole*;laEHsh4yyNN7$zSj{~+wNzWe{>l!GH}DkNwIbSUCV`# zDCGc*tCbk*cH|RJX{QD6jCya;0}I(WJ#p<+AVr=$1v_g#>qjq+`e5(W{lq>;oK3FF zJ%Kxq$xfTHLY2Z19+l2qiMnDxyex1pJ2A!#7wG|S_{L$i9I=`?@@#I$-w{~Q{^XXk zn^O}>Fau+M=mK{|CvN)q#VW_G0BUne_V`jl!@TZf!!Ea#hFZMWP5H+S*iw<$#~d@l zJ^xTq@F8s{ITtH*KFc|S&#SLQw1j@Ck03^p4!7QaYoRek)NhqSHJNwxj5luUF}0J> zr4HW~O*ut9nNy=B5@uO8i{|!h-Z&;S0Dj_Wee(TB2 zNXoMI>w0JU=^U5T%*$IpbO?fVxHR`i@OSnfELfE~x~?Yfeq=L=KX;1@+sP_zSzX^;lP)Vi{z*b+@&4PjF5z57$2)+T`MES~bteIQK!TYH1=tlUUtalw>ZC(G zsydy4U`ZP=NZ$I9x9mcLw@iMl9=s7YZ2J7l+!l{LN9aK*eNXeJ(;s!Mv)g4M$uPwUKMaI47=|%WH*@=ua+-<4HKs@9OcDeHPMk7?#cfScBFa^l081X z-MKitEnJWwJzKRBPM@DYvdowA%Q1ZP5i(Pf3NQQ`Sp3p<*qnA4)ogPoF~rUl<0WZv ze^YwEx7;63Yvcr?&MGK81;uk;wW2S5eLp?Dup%8b7_ziJhx1T37+B8#bX(;?k#iYy zTaj)%FW1I9^<`9GsyrCyL1~sGl}Ux2W9)(-olU+yG+ABc7vEb^M!n*@ol}p?age*N z=vuAt0nDe%Xp(!%XgqLf^yIOo3jAiawowl^#lNHjP70QH&KN$suzS=2P>T68!=!P?A z*G3MWpV3jnBNL*dJvw8b{<(PP)|ld^G#!um!21E8c{B9O3E@`v-#1bkX_q#*+_X0M z?DWFIx*$HWMC8bj4XYWZOC5|I)5SORCFuc*i>~TRpDVsZ-!m;1(>aVb$Hz|>B#?#K zV|+Xpo?K-<3e?1d@I89gzZpT)1XXX1^87_`S4I+U)wqvP9t2iFsHaKEjrewT-tN8% z>#c30gfTyzmp^*Ws0<};7W^dKYVG_<7~{U)TKSW(6G=YYNx_xEd*r&@@V)vWTF>78 z6l1qF{jww@_USO-M?Bz%NId2ob)csYso54SI~UT6wr+Sng4iY7mkUBp)7I%m2RDB{ zitEGm)@2F!lOCB1)Q9~iG$CmzKRx-PGxbNUWA#lm^P}ySrO}^o5WkxX(>rsQ8Mo&n zaahev#}_uo-#@uPacah9ZU)0yG&+DVYbulG(TBKup3UB##onQi-_<;d_#e=UONhA8hifm z`D^Tz;!z8MnIQQGhqSQ31xW?!9Jp}ypkMd0Gm>31r3o6@G1P~=N?!r!=DUk|YHms;|qxu}o8Vl>ChPsB&Eff$YB?F-QL;9E< zw%|YD8b#*i$Upw`%tQ~}+{>V}JA8SEPUmPPhYr9pRfF1x7r(%4Ga%EvY#^-Cw8Un8!JO&r#Kk z{PqARD<&6c8t_=Ya~L4>6c>L)RxJOX?#eQh-Yb;UAiW%#`ME|(JP3Y3N7nH+R>x%- zxj6nAeIoTN zHz?`|Hiosxn%2RRpH6$!82}Sl06**mCeRvrW>nvGm3-6EG?>{f$o%L(J?C38GVK8d z0TU+!OdN{Cz@UdXK&%++oH0FKPvwVb5-%}rn>y}io%QNFOp@3eEWCoSmi0C#9A(m`UEkyzg{9)6&_$o&Zc zSNa2A-d}jvt7P!BHNER=#&fJSG%SZ#-b!y>i%s0Jg{!E!*8iko&aR0*yDGNDXZLI7 zRR`g}@3-Q?eI=e53dSKHLmgGdleAX3_ z?Aug&B0=KvB<1eML{f*|1et0wdU~bfwns}V4>MuVq9tt(;z&Hq1xI2jZ}-LQ=cBM9 zx0qo8wwzLhM2tU?V`a>6eJIB6R zmRkeIpEFI2t-B-biE-Lsvux#4mk;j*-w@Z?28B^+hj!tl_%@Ym8|MlraqeiNzd7@P zaBKzE{`e9D_X94`*(N`|@HzA9OJ0KqZ1dZCN)>9*ojQh{iO4QS&KU}^&(AyL> zh?hpxsv!auA$ZoPaqa5tvQkT&2Y02I+6aqNWB1x?#vba&`uZW*YX+ga-Ha)PAX^Q! zImxE}`uygCfI*|}`0u^!z+EcNy(s#iQS=w;Z6KW#=&mAgR9(gQxgP$2^w5!xkxlNQ z$`Ou8O*UDl9HedAX$j9C$n|)K(al|CogC&ozo?w4xl!P(h5r4br&lC;ka7;yDv+%x zXbv^-L2czK!e#v?hCz>!leEe+7iUYg6{!uW?1IlHd(zga&T8+)lP~PK&Eq8PsU#N6 z81e`?4Vy$7DB?2QX&GG^cK#*9nVeEp6+yp9a=FS}#`@TcReYI<;(iYcE{vD3!To)| zbyXJcgU(d`R^nYuEG%(Jwt!btssAhw^V5z>~ z!HjP%XeOq@_wL4=WYE=Z$-8E@M~_w;#se0|!|33`Rt&F_A=!4ta**Bl6l6MB9Ce0*@9kJV zv|(vAKdsWG2@^3lcs09mK)Z9Sa5EPlDfhz+UFBEvu!B$Bhj z!LE#MhT*?`QWj=`$QbPrvM|c9x$EL;jF(Ub>nx27OPjw{V=`i@fsR)$PWWkl_*9Ds zJ(##PJ<$(nhTdlD1vVkJ^l9g^VIFgI-beX}HRUOu_v4e`($H-QRBdw8O1mE>O$cz9ZzmkMs4LM0$$+*riJ^Y0yw3flp3 zK}uWBeOw*{1<^^slL-5=YLw$onf7Aab0;4 zxI&m8Ywzhs#(BDP`4WVlEdITM*EjW z)GoEajGfXfSLz)mB_7#Z0@JmHeBE%`mHE{dJe~1gKgXad$ewn{=fVQwU8PR&`Kyb0 zy=Yro$GwO+)CK&;${FPw<~5{=k-vm+jl)?b`3acpGY+Rxwb@G}@%7wN#jJiRKS3bi zG06A?@vV5;LZ|r(Lp&5)D2k}}z}cs~kzm8bOzr7JzXn7g&+q~h)= z&5@!>S>DGYc41Nx;%I|OmQNDyGGp<##rda@6~8o!*=747irQHKX9!;=HBw{VvF%Z(HhHBXkSB6kCAon>Ud0nwii$OVAh2!Q}i@=$yERk@%3KNus6c zOZ(aK;(Ne%i7P86l8!0Y+5oY<2CXe2Dp9=6%X!k4_@xm2oHy&D8?wcx%P{7BPT(=n zpDiz(d+~kRa9;|Pqaa(unYv8ubH!m|^-vXLa;Ez(2saOKyD0M(8coTu@YboO(`r^E z3yN#N(^!O?Yz}}DM!;6%tVKcfOZnTH=Un;ku5%-Pcx8PdO`96By*PZ{;mtOl+pwC# zR>4c@oR+le!T65(0}=Cxr7CbUXbX;IlhLkr8|RV1TJ2F(=^cddWYBx+m-R?04?a8R ze4u5<_Q?HQ-LfjSia5h;H+x`6N&SX49__Oolq|jAyX*xEThsUfN_aoA-}lG*%dHVn zc5-OhLK9}UJZn|N}smQ!-&ZZ*55`O2g8pqzzzV4Mb4+q^d zW)HeJ-MCSkSN_4SzX*8sYbPcWJ!&2eD;D@6GGbEZT&#L`S(Z?ie#EnCjFx`nIOQm1 zXp|Fhd+dBU9+8k=!(BEj6tjCY8SvdhTOu&9@UVh>HOF`!%F!hqZYr&D*(__t`H`q~ zUfoq8xHCMR$oB)~g1FUwe?~{`s0_-+C{rZ)7NuD7ZC}`BWHw@FXLF*# zs3mt!wO2f2iRs(MxPnB~;xxS>twyWE`uzZ+<;zk4Wej#5#9B}R|IDpmG3g0aOh~93 z#v?1~LCo^x7ggD(FI%Mh%l4?G!gtf+XXgipvK}#5TJlMYBcDet1G57B5CJbu8{O#r z{*up(N?ng6-_VC4+Jclq!OdBQa2V->%3-|S0=%rd{0TBQoT?AaoG z4KV=nhb%2l0`dIerPVI6zj)d4Vcd9M*l^nTbJb?mZNC!>zI3$Ygae3>XKnM>Lg=Eg z1n|~V zfav^kB$e#^XOx;#PANr^@YDl^MsE_uNA$Hddr@dQQOuwi>>@6QvP;}o7{VHS0?YT* zJnzizs|~NYZ69HL;F<6o7?s-=2eH3i7Y9+4oX}jkd^$1YF<8HsCWS^ol}}ngH_yG} z-v*Ra`7?M6tt~hLXLt*500{pLsy7{lDBS$XNCO+OvW#Z#QY3M5oUb$E$SwDM6(MVun&*!vIIw(^Bk$nzrl^`w~JgtRdi zGG2$sNFrL_7ntiwPE37QK+TGkY92MdT=Pz0N_IT`5q9Qu_L`68N^ONh4l|~T7Xm@c zFB$sIbKvRwZ{i@i*M;I6e@lMS2!H9CzCWHc96$Q;;Q<46|3Fn&y<0o~Q6;aF;#HFI z`=gtl<|h;XNQE7Z!#3->BPR8-+~-05wDR6r=F=lmC~+n9S2VFDJ6C6@x1CIC%M&Qk zVN~ilSL}$zC|%FRxLFT4@z4Wj> zUk2zcIxY8UInr9qC`*HR6mv#yFdV&`$yag;~4UY3tzE9t$ z?GiscdmCcJfeDiO5dI)guO*P)X?z$x->{rI&Jm%_RO zHUQ3KP6HYur9CqRi$2lnvfQD!nF?o$I^JFfs~Bw>ENEIR8Yaa?Ti6#CC{Y*MEa$*r zusTsbv7E2JwpLtZTlug}`DFU(U-fq7I#V&t5<{(Q|Y zn*bT0)77em8qcW}<(S%*pa6kF{D+QZdh%U`>&o%q;9G^!-&_el8vJ^ye*^omy{Ymb zBHR)@WCl_eZ|Z-RIx0JGs+T+@syjC?TPH)Z&`!{%BN;O6TnkJREM zuI#ElRmd;n_D&k~SvL`*A@>QRF_ZQV{@F7*pN%j!M)%zI({G&N&OYs0Sf1_V-U=+= z*=&h>pgG-K12qo#t{lHKMa?b-u=vmaB2C}g-lp2g0)hn!foK+eZZsSU5j}MA(09JQ zCh6Z_UWlM;ZV3=;Kq-`fC9ZLWTbg90YfNillcS&L^LVr6a#6jEAiWx_u{CdAwI@Bh zcX=dV9?M_YRvZb@-CkaQSusdKT!G}vX5?osC1T#wr7(R$hY9GQw-%iI=!a5pn588d>@_axiUrB}Co2guf+#c< zBx}V2_?tej-Q97YTdO~NdSs$L2ugVBWd#K+qO9Z_3hpmyGj$`neVmx%QM}T`z#=Bj z=+BOQG$|;K5%&u0gl;{>0lHK@On5y@ixV||96H}*@2c~Tn6|AQQzviMo;)~deidF| z4Zi`y)h?1lXH?MFd0h8G;v;rn-waQ|pCk0!7L_Y#<>+>x@q_DO z6u(ybu}H3wClE${e!EH%wh6{-+lf&Zb-b!z`MZQurg3Z(RAV|@ud^&c{x$8cAr-*_ z5fUwJ><<;_xh&eT)3RuwCq2ZOYAJaN7m|nxp@pSrj*O_;m zp`zwRX;EFnU(X?{h4WDMt~YxD3D1%%!)5YqIR~+3`zJ7B!m_mzT8~2G{C%;{G9br~ zQ~Lx+;JO$7^Zj7VzZDpS`wc$yWkp&E^V#)xc+G+BH>R|ME&;{ZIiVcN;w)iOk0bf#7o3!J z@n65d_H#u(zB{&h2LO#7;qs)uZ~D*VjgswwgOK}RlqG587iWbqz0N3}w|OPK1qv4Q z0}PFj(5~JCBZaYGaY8I6jH)p6>gORe%7VHJ)7bkYa{Dm2pgYL)Q zPU;$MJuy?$7OvoF!o`Ss6i_D)ycT&xnBSXy+5!b#xI2|25GmgjmQ%-Fq?AktriI;7 zOs+xP6FxCvZzsCCzXO~#l9rWpOkP7WX>qY~#^kZ_GnwbMA-%er_oXe%)o;QauE2B13eM&vdv5N1Z=ih%g(%S8ei!U zQXTO0;`1;DE>`X0BbD{tH(d4Z&3y5`+0&Oc-wHRFKdfS4f04@3;>9G~n(vDwU(f5+ zMoTgb%rTsthfdrcfSTAXcRhRalk-E)pwcgU|H2G=9;n0Gz#nrUr_D4oto$t+UNnKO z3hd~&Q}|@4TWz*qkldo8@IL%6H>N^S`MO6|`@F_)`tM#)?l83#a6M5tBv>J0Dl5@K z*>djS#ro1MwH$fjziM|lUooP=Eel?DmUX#CfYl|7K#TeKB40O`99`J-l^a@^JhSyF zalFHiBdze5I-oRj`T!XS95Up8BPmW`@Z+4xLF>_Z2QAX*SbTex&vY6=4(lm{v?=Hd z-0VWYcvzNGtO?K5j&0j%vYaDwAlix8_83;2gvfwSoM^a*q%pDh&5UCUUi6wXB(*sD z!q#MCc@Z@RX8(NnL88ui6_v`jnUO^zDieZ{mfz8#Y1h&yR=Yzfl#K1F&vB%C@lk5G zw*{_GEW#ut`g~IFy5`M#Rk}!^`7aQ3L9QsRH`0 zo?xnHsGn-3-tuERYWA9@^MO z!jq$BxTzUEl3y}zoUErw0NhCU0$zYF=Uni@WV6m;soB7#m0cXNd2XS>LM?#novXns zY46VRKcc_yIZ2mpTso^s<>n>7eok^Is^ZQ5wWZN-?}_A)3z@XYW88WtB_%`5oYTG$w3_<*D)csn2a@;(Q7S>1R~vDp2i&9-e|d=B ztfP!qa__vD=~;n}4F2VFI5L2DhurCrdUnqT%1bq@*-Ab}n=LPPMN1Mt-+VZ%bYAVE zL<(NduI4PXD$mf7ZW1Ttqi=elY7%dvVTlc0fWDB+e{LojsvTGM?oKK`@}Yth6yDVI ziSkcLYUo@R7k3Q^!ByGR%%*J5QNa3oO6Wk0!;; zBvS*x#V7z=D8x$=hixge5{x3}CI=eIxCyX`NMri9&%V>WMJ5Ie{K6Vvwgy+!yf8dk zVZ2a#C!nAQD5N0qjeN5(esXxZiF#n0#Wxdu7?oq>4%7D5>-ueD@*;0{g~GP*DI#At z$}I8SmBtyhB%>Q|**tCBI+Bu5TGbbS@n}^!=K@ry)l2EKZEvXGG)s?L^&v+tZIg)r zP>b@@^R8F#1fVfmwJljqL%lbvyU2;=+nIz|TyLk_Mu_nV+>8I&UStvuRnbBJUuX;c zyLOntu^s&?FZr&|y(*p5Pr-LZ(3Mz)90j=+v8MW<{GsA@F#=CU)7TFE$E#;WEuQfSPP75K? zCg=V$x?x?euTNm+8nUO4@#+L%ZYug#m9f?w#qanTB+1R2q>M5ZM2IdG*}i%e@@zT) zjU26k+7Q0fM^hOPh#)R8AQyw|7E|>9kKBWotp7}rqmOy=0Jnv>B$P%~R3Ods*d6pw z@6qs-SpCg+#MG0lbKHU`<5z})Y{^Y`Y+AYz-or(=Ynj9qOn8DEv#_PI|Fk@5TEflm zjAGMLc#54FP78zEB}&v_eJfFbkZ1NkATlG|#^Qm`M4JS)XXq;=*AqX&`dm5nd;DmtflK_PW ztAU4WoCn2r{wLEvL7l_^!P5WZ1*zI<=H3(K>E$j-QEcTd*u4FjSqrcv%@ zblZd0qKoz7O0ucFok>|T*mGPRg$rjtOnf2Yz`<8(OEHV)>pmxyU0qF{Vxic^mtqYV%npF; z{?h|3czE-DQt|j`BAXF*JpOAZ@tr%)D|SNHCS&{1nF(;WK8EAfVCkLFy@CF6zj&VS zC={Tot8zx6vxoa*6eE_{wK>jpnSi^@oedL!yNX9smRaWxrBS*vbW`Ck)XgDCuHf!& zp*xZ(F3$K%JojTI?7sy0)L+jL9$HpWu1bB$=R;q9#Qb!rhZ_)-d6R~+%v>hE^TA1B zzw{H>^!#s*0}joTw6%8o4;Y>{*w6su@3oH}q)pnNwAB31*#?_G!r7&H+2W-H2_QNx zM`W*epqW^?ufiemNk2hU+=yBv{GY$imtQ8%L=unuh16I1UW~dV1=$(?k%`Fp51!Se z*lA4v0l>2nj&d`K$=jmiwwpg0$}~qld>UlS8RFI$w)xP9=XonzgjFR+%sa=p{=N#n z^j5QbPJF0h@jYGT3vrg)fH=|e%DOpKRaM|RvroGJ{EKWNjguH2t0yhz{NRcn9|hzz zc3jW%7BqhX-(#90KKI)B%RIJGh&RE$cM>MnVM_Mhf{Vdau*&_?8K9``?r%giSFEb7 zB0jSnu(vD_+a*SIt#aY*b5zMax6ztw7e=`KTdA>nc8B`^v`BfzghQr3&{ybmB8cZc zUGqZ9icG5${&VaIUv5?))5?bJmzo9F)^HU_YfkK%j~%Phw7OxHQ2mYm!IWd><$c=s zt=AxAY`Q!dbUQN0e245+&D-!dKe)Jgo~Pg4Ei;zC|2>c?YXmDEn8zNAXikiBNU;K5LQVwGk!&fflrjm>@tGQ?d zw$j{Pv&706T@JiC1ij-2+4BwA_q(fOH{912koH%?OZw#FOVZZHbgyKfg1S=OSi)1?M0t@}g!%xa+I^q=$@sBnp=a94DGv9`J z;`SrrQYDkt>~sPwVUXAAc!rN74*Bjfh=%5!{&1YJ@+`?0s9>#ZAMOIcfi+~8nDv2W z>rAh<9fsl3`3O&Zm+6Pjw488#C;?|P>!IG?+h3ycE>tUWby6iyV0}BlaDo8ZiJ#^W zMDaykr#9VkKNh1c?xl;nPcjpW3`Vl}5*Y*$U<*;X3{32ou4xU|rw zDYQNv1>`}=fILVc{<+7J zoxwBF>-du{Er@?6#{rXRfJr?-kyLzodf5L@JJi+QAM`IqDbK<8XiSYDHZcII#K~#u zU}B$2Lut7BQwKZ1i{Dj>6AeBw>Xu;$fhgUcG&j%?Ko7|4?iUGWx@h<=U~-A9j1791 zCm0yb26i8rm!B;7Fo@MDim~*(M>7t(e;@EW!o{2H*rz}_Pnv>V)mS8VAQUq_f;h}T zj~Fo42WvMhb!zz->nz)CzkU=7d4VNO%z9WR=h0G0zuBaQ?Zi#>xD-jT5y@|&XqF+^PKOEaPo8*=< z47^R7tO=CN*7kRky>8aStx=+QrEj3OtDZBkhNlKEl!<4`r`-}EEM9L-FZm~$lTf{8 zPTM@m+JV&98lwxfDFx9KB*y&SppJ6y5iO0~q=w#LP6EJD&Xr+Irj@jQr^k3vc06rs zERCysVMWavHRP?jb9{?8^TuZ$*$@5~ z_;%~vOsQVg*1U`OW)v85t+)86&HESU7V6T~Yy@$hK?Vo#_^15Mw*k4=ny4y^A~U}z zr|On8$8;}uI<-?BlkRtn_P6ODWeUW_xgpSmr?C7@{sVFD*XviW2qQArR%oON+vIaV z>a!#TOdebu(}1G!%{Xo5JD z6Nm@^e#s?c`<9$$+@E<17=uY$B#U!iiF)T*Mg3c2D%YS>%y(@Mj2CS4!|ess>MRA+ zZ8zj&7whlYjgjDkA%2c7JN&AM2%#c z`+nx4(;ZQ1b_3KqtjM37xf%Syhu}07Kuvb&|Iuovjl_hs)Y%f^b=R*c7ZYtgxH(f_ zl|MXs`8|iHi*tvtga5m5@Al%snkIV!*(v=LOlb1b`TaK(H3^R}?4X57=Fh^Xec6Q5 z>mCK@^Z~td47Eg}!?LkQ%%6#0tX9TKOZ=?7Dr;DhhUk+ER+^wk_b9NhIILt1v4l#U!;^MJe>OG#|2)&?|VKRjN0Gp?sP z)Upu@Z`ar=zag(W7+hOIL#5#R0h^rEy&509G`+0JAX_>;Q0)cK!0khqriIZyv<9yd z=EF1^OMPN|z0(63>=-WloQ2Jqx`m0M%wC~MzvO{;@q^w?ScPJScuOL|%5{mAGp`pk z?LIu8o6J)=BrvJF-2MCGHgEEW>y-2mW6~$RFv`!LKO{{K`9rRCYAV3Q|5vBvaWHWi zW(A(v!(-J5LhPK&_Qj#EMj9syUC+g+Ia0@ZbzTm;h_9wvTu2G9?brH34tFfP$ln=9 z#r)K0S<)1W*+g4GfdDf0mA>mJNd?>uSZqGUaw&ga$*BQzk(Lxj%?nzvCe}og$h8zi zk7hlh)MzW;6A4{)@A1401L32gc1f#R&s~LC8g+U|kV%k0o*mZ;Tf{W4=zNFk)Ynvx z0qkZK(ncm~Bys2fEh^iE{il?O!u%_1FmbGN%tMOV%VpOCh=@|}Gfp5cnjzg$IqbFO zg_q5nqi0BL##*Gresj*5Lxxl~Fb0hRT(39W1DOPjB-j;b( zSED=%+?+~z^QTB@V+lp-b9uL(&+?=lFdoBedtch{S)chiczvsZ1h-Hx5Ata6^x#Q3 z462~PyhrrPhi_vd^d_#c!n~njiO$^0QD|^?!_G-kJSEWk{_0)_Z`|taXuHaXjg`-e z(TtTdCwy_K`?L0=!_XQBuSRrBIUwxnpDeme)Of~8U96fzz+B)DtJknU+%a+KUU z0$7vsXEs8LXQ_gYinE2{3x)jQAA&;-iDSO0Onx@{Sj96AGT0F8Ta*WAbHTp+1c4)@ zg6q^=hix_!sZS+AEm`Hehb!As5G0ppeyNlCQ8%={+!yPNW0%b5y67B0kddPn+_56{{?;bQI#EG2u^`2WXD8xZpW+b z6VvL@-+$IjOb0=@cA*Up0A_9%D!pVoiEQevC8+zu%+vCB-Mdr&XzuJnheWWWOfW%PC(1t}#Z3HymhQp55I1#ky;DuR8Z# z9FD=Y#|60c1^acGLE3D~0z|S4fE+Cp^Hm4*vQeWWy+h30Fm~BVKjv18dL7vEdWU{~ z8V&>FX#;y9%s;}G`!2w{o;hAK#`%8OrE8JLqse#2NB_6DD{#fmWu*;f2zE8WF2#F0 ze=npEQLms}aXpFy*%iJMQdM^2xU0vl)K2Stm2z83U=`_#gyP_0OEBNL!uPp8y?Asv zG#)>DpcY{+&^luVI3~&rlO2F;+(`_N6>I7ysHHJ3>MJ?P+-=NEKV{p?kyBFUoOhqL zCP5{$5mZUdj`S0fR3~~l@=+u<=^8o#z^Y0}K+b}U60VwA3!NI`f4P$&G?ct45sctB zV{H07&gwN|xUD%zY8;x@SG?{Q8u=x^XZn4#KX8eD$Um}Fe%w)R%au;`MB2uphI*F# zu$!mm=l+GZQvOY}Bxt@5C0f!A*UPZ}-w=a@cZs|;i&`^(=#;&pKe8ezNuKXTMhz0q zG0hofF8y@6+NE6Rhi4@pf?!wSJ9)~kj0rQ#pupv~b){gW(@%F26KK;63L;TcK3H7&7lrTr<~|zM9@xZyC_axH7su@1m;8ny zqG174ey@bTdInna-+>y>51MIe#kYFIlL0l8wZXLrgta!fIXmGshJTK;7=hx@R?nx0 z;z`L+p-J)u4xBa-$wnIc96Uf*><;Xzq0Q2|Rx6(FJ6*nvL%=cR?){=Ba|!ycy#~cW zc#4HkC8XKt9gf2fIh!XAeHfy-N2IHil~y-w-9f#!oxY{+#}*9%&ugSQk*+=baP00R z7s#L+<&Y_+sscb0h8QdeK%iv|t=Y=J%w#Dk$&w1gQ#U`K+;0`AYNCI~^gOl!67qMg z4XQ-GjO2ayHv(r}s;{q>h?2h9F!IMJJ4C3Bd+!#Xiz9U0Ny4BP2f%Z|od0M|P=hb{ zPQ-p3w_mT5JP?MOk7+Df)Vm_G2iUR%RtsWnnZOHJHOv)U{ge)YD z$U;?3%*e|61u1=rKNpL}Y*6~s`+PQAf8T29{}~Af>ACC2*{_HR;hS~d*6#^*LODF4 zF0L-F-biN;kL^Prh)6Js(}1+xQZ050L-4ZpMh^4SW$uiYW_R0>R}AO`9X z_@R+ox(KUcBE;cv3rfy)(vEAKB0#&ByhyE4=YUX=J^GHmB&A^oB-9A3S1gK?eWi+} zzg{-rh%FQA_%B8peM^JobwraMdR(x9u-TxU-o!I%=Zjn&k7{xC#dYEyOHY?K(6FHd zyQE)Xkx?;yU;r~oM$3fxaAm-lUap)8MBd@hLjlYL`VU|5Q58JAO!@?HvKj1vM0|@P zhQGAlAhGO2V&(68swhcD=!I2j9Z_lQTyYq_JO~z=H6`DF;KtGDl4AeF~}_Q39j zdbFG2-3u5XW`XUfD4yrpPQ#g+fU?8hI)j0f49{wk-|E6!830h^2Hbx8a{;)%cUCZp z9neJXWGVGGCV*>I1oO@kE!yNZH%#jvZk2S(9;``O)u!WGJInVxE;ZZ#Ng_w~gqn!} zwAKs0GpEk+6R!v=SyHgH%ow$ziQE1^zAc=HRjn9B*ZoZ_72raIfL!NJ9>-?{J1^5v^R@M5o!3Fqt>ti@t-5eYKMHAZnekZ}H@SZ)@^#r5Msnuj(HX!=8+~(YaH4rkT6(L%z8Kd& z!$#?(BlNE(QvB6VWNl%4N<%%4G5j?_SXiw7zXt}3EvNHj|oHd$$_dIG8TEi`BmmMB(~QOMHFW# zvS^kDP6H2!LRKnRK`a)hwW4Hkh!?Mjlghxw)&USFzEWBZ{ILcB!LjZTTA2j*Bf` z%wc?Sl|m)|#LZsty2VDXphf+@11)QXzVAL0H|p_hO)JnQ z?_KPah#={X^*6t_JJ-&H*P3Dt#2q5&ve^^a*AGkCzSx8h<35Jcr}5pwiZl64wQs;T z6VU-4q~DZ6IrW{z$`FPkf$b*(L!!PpOP~*V{bABgej_Io8Oa43_Ufaz?eXe6RsJcp zH&nOQYTD3)3FPx6^~zWS_aD+6(nBwR%&7b!A8sSei4;JeRe}EtedhD0RiB#FKoXxC zX};QLDI*M@uZWT%h&j00O^-p-Am_ya^x4C!dK%5&7-e&5OIA?}={52KVa7(Vk+7+t zv2e#Wbz5r2y?}yD$bfgIqB+wr5RCRFD&q3Qh=-yR;((Qh**|+=jN6n$+WI(@5NUo4 zR6_=zpSr1L|4Kcp47_dKgYo886Mf!;c!%qwKNJeboy|B5c=czTU2erj1NNJSvW0C= z;Ndb^MjGMriH<@G8!PAraP~@rPVW#ztz{P25`A8Ne&Kb#JEjtKA>uoMAER`GH#;Z2 zYsKUvK)Z`knF7M_<~f7frj3obN~n-g$mOf;X0Sg9l#7tU=}*8!Ynw1RD;#vRC;E8I z9}K_ia)-5d@#vPt@%Eh2P`SHv#1CoFbk*Jv2XyH0jO|eY=-D#AgYIZLfDzH-xuVb~XG|g4@C} zDE%C0horXlfg_dyZkiHBcdsYugMQyWtl2jVpK##a;?e!SzSq&2;W`vceEBL(+8V!% z71H#J7$<%R{akXhzSh*CIF1!G(s1#L0uF=X!OWYVIDcufy_I*L$Mjd6E=`4OZ($qV z%Wn*9{&KZQylVq8ifx>ncqSl>KLg#2*CFLwDpnb7wLGd{y5DUEJG&+A7`Vfd0HD(> zEF!r=J_}oUT#xta-3PdXHdvV&Lmb<@P%hnvdNi2~#gRBhG#8Jx3=zS@(v9ls-VY7l zXw%GK#@dKY@3;0qGEB;o<$a6BGYupO5BCCe)Ymp*yM{Q!%*?LL9n-~Ol6mbjK-#R- z`Fc@|?v3;}Mx8f~7DD}dA8g<4O-0udf#xWfM>$m)!wjd1qIlXRTXPKvbqc?W3sr`%o*dIBw41RcgXOkHkW0(ukXnk3pW-Q%8Gz%jlGB*ne6D3@l2e4TnH!5udJ zdrYe1!CUoxXa4Ip_)AdB1|$j8ndQe~oF&g9VQI;>a7IQ${$*JsKN2^f*F1!7kwZ}F zd2dCxD>)(OQ(s`4>uYTAv>Lx4uQ84t;GyBqZJx1zZ7G4N=Sf)KF1LK?AY~wzV8A9K zwJ1Y&`{U@n3G4D z1LHM!f=^`2ZFP`L*Y!NWO#4Z69x+WBzTiyd`R+`#Cz=#fyg8Jb5{{@UBAlw1Q zSCsw$=kO*>EP$_aUh+QSLk*qUV2Q$G>EQ}ep3DXzh_71lUvA6fs<%|Of=Q@$El)F! z^AItBwOsKOf&!Gi@I_8rEgp>^>3RBd-N{}`b^mnTIu3+puqxpSWQQBQL|%Q~@Hu^X z_^#oYcVk%7EP3uQV=`8(0pnK=EVBHMSkbu6xXhM#99Y`hNkOD&V9=c!NnIAzav3pD z^NRXaX?FE*{K@Nm66Eh+MdCgD*BHObK+^+j z#PaA#5I5~Kw!%m`$uWQ7l6z&p@6=}>?K4eX{9{i+=#v%rci<>qdCONg@kx-uq3L$l zSmVjo$?Mm66(u120kzSqR3?*%IYyn~pfK2!u1@<2huELc+?-o6cGD=N$^3WNvj&|e zV#zr*fP`t&)u*q{09Ei(3egxm#n8T5J8W%zaWlj0w)VykSnC?zc zC~ixW9lEaetZ?PQ&&kt0M{I@@@0|=nnm4Kh(Ww1DA~VD`q1R z4R6|oK+dNlxK5^DBWiT0kDcotiOlLL3cXH_(m2w+fC2?Hs#Z0_;dSlJKb+G%whSw*J z*9GyT>Cbs{=|8pHP4 zW&|Y}Cy$M(2e$Aie)SrlHRk`ch6x|z!>FN?ph&hPpK;51{>hE*j4>7LBpgD~%6AuI zjp4(_hzXW6pfH<8dyAxBb;tQy6zx|s8SY}DYeFD>Osaz&rbAem$XVS82&9+=MOO3^ z3pFym>?>skN?N2Dsas;=5zJW?(7|qa4=`(&8ux!&PQ2)afP5tXgktU0#`jx%+&6Lk z1v~69KAVf=##3oVc?vbqif8505jhQFzxBJua9; z^lZUoB(rX5jKBPJ~1fg8vJ-a@=p({teNGr~U~vPo1&^;X4dA%XRTjP*1EE6B+^_m1RTc(noeRaYyR zT3f6XNBQ_JtOIP|?P)h4O_bIzaZ0N<*!}zJiu=`5ZP_xMo)kZ7vV47P1r`0<@mjSH zgCg&~3Kj(5ucq3dWUqkub1RMwqJ^I>Z+@9EJSmVpT$S6lB6UtZ&;H=DK!`mxVKsi} zJ7AXAfu-Ifbds<$rNaa}QH1b0jg`c4(`qw)1D=I|;NX+a5H3Z`B=ma@&`K0_?;IX! z7guugPN6sMD}@pl$4Q2JOaTK}F@4 z06Y;nxHC+f+Ao0i6yt_R)J3y2j!}3#()B(BcZHbIyb~%)4LcbKK+c#ee2ckMuEQgO z+jZJ?+KhjQv;(>8qB_kgU$A3?8L2d~Hse&_z+8o z`3DjJV$KGQHHuO-YS=?T_)4T%r%QFfjTi-|V( zzhe$}S>-=2`*4%5Yb@RqhC1bteTI8x=b+-oB%BndSLrP$fe_27h^?KytXO7B1Z9=6 zw?{R85q7I!Wd-%&ww^jEjkLZdYMV8sL>VKQUlyC^1ixX`%?eB$G-MOmC8}XrfJwk013%~ zvf7wk+mXMERQ7hfd;pP^fG1jf9c?pu|JlG2yW00M)CNxJ(bsX4^(QC4&>N$QlgQ;% z7x7_w?~_IklBOmmQ({K{MkPoti9Qfc^B@SL(<&ISjf+TPy%3_zm(|*i*jBB zVu75RKsq|8fn(@oB?-@DqtKcq`t>b{nUaaHb)UwEnfN57VNc=^$3DdhUD8X}b2MvF zb#R9=6VRQwm&M55_ibLPHmb$;tIoGKmz-n@(@-qOY-Xk=3XwRFXk5TTv5(1`YZEgv z;vRv_JLiqBi&k2eoSv@7C4IQuGlpL3<@dg}hnq9eD9C!wMkFA4E(^2nO+`I7Orl7T zI%Z8N;*g=*i8?ljPETai7Gssk-%vX5Kua9L30?)1^O;Ux1*;-Q0)a0QNHlc;Cd49R zY4uW7(+4c2r-zEn4*v6U;n|&Cev`(z_p@E_lpP7$?LlLYd`*SEjY^u^=j#D&LpIxa zpcf!hK4bn|LcjcFdEX5aORS1!l!-2}m_28aIg0;hB?e*+{ z9m6L`6;JDToAtY>YKv`SjDyVQ72y663Gd(o08A*a!<583%Fo?rQd|GgIunnS zndyuzeKx|LglB&?(3kpZ=+*+I9+*kCxc>1G8Nx4+TjC^B3R9rW4^6?9o@f}c*OnuH6zrGrde)ZQaPLK?!BEvj=ZP4+v0j#AOGB%PQVS~ zyB=rNtN6kS>K`XzqA+sz3_|C;j<}$*XRxJ^%we7wP=xe~qxR1Qula zADD)Hy?0pp?9L&7ThpA=EHfhI!6Vw^wE_F=BGrC>59f&8eqiQKT)4J14cR-UBEP|a z;Vs;W?0+x4$oL}?HhOf2G3w{1yT`Ab!p6V!t{BQ)SERxW81*D$ z0(2AESq`d1Zg*dL95_7|YhvOR_G|s!XX)}O%Yc53@oa^8ui6h3_&6ndx{i} zBL>&;nuhK>B*gXm%FDXZ60NgED-9{vEyW|yD+6%97*2~lzlU6;FLET5MnEiA=f+8ULg0BiR#~R)*3_{av4}u;@_?=BM_xvQyZ3hx*^a zxW{P{9ZGm|;(TzCHZ;X9HYrJ_CIY%>ZyRB(-q9^9P7HZVT2Vxt=_x;H zyokywZ%J??_IAO~MXq!M!5TS4EB*s*G3XVUOp_}DN=G!|UdR{g2BW#q-1w>6%;Sl9 z&yFy1doH`QXxZFU>T`5t0o_%t9~dYh_m<4lVZ6u0C^8!t`U7LbBLC>{6O}pFfji&S zeqnuPM8%=F=a;Ri4#UxL zVp*Od4n9%qT%)VuF~Yxy@JeA&L24MorxtHCv6bdnaSQ!7QF^pYZ?&D5?MeT0{)VX2 zlwyH^^K(`ayy@GnCEH(MvQuw8cY!Xk z;By?ByEXHY8pI!H)fKv=m&(2svqd;D{b(VG&?mP~GBv(>PFO9*3o3$|i%}aTyF2WP z$ffu52tLd_lC&KFxAv&;JAzORZoOmJGe0GBRxqC8AsA)pm z*P5lu^DwgZaL={+&Q(nkbO)e(-ChaKUvqx#c>~&=#Na)+XY~MigZTFJiE}&S52fn@ zByb$eSJely;|gg{{|Y5eV#%rlRJIT7Bc)l&NtRgiiKW!_)RJ?F)dmj2-krdcT|8T} z1=lBk3e1&5S-nm8M*cXr(-vcM#@eKwy^N>{64n&uNGyh2!J-EO52qT=~~3DZ$A3|SLeeqpbD+rZnyXIEsTQOMae(rrDUsA zSQf{)DtXtRkZ+ETX@G9$!ILW`nk{-IcZiByZP;Dv)*@Q5f0CeV=|7}1)>Y{_eO_LE z%B4BP(ieW1&LG_dApVtqa5k7zFTbSQ$7-=3HzRMsC?V!b>ubI&uu347@>q5xB(L@O z&?lk^6Z{5W2d834Mp_evJY6wHSx@B};b~~4hvm`cEoEE9BV#LKt*s|1tids*uD6$$ zLkMHVR%9^ySBJanyVJXZc89!8zRf)ie7Kboi7U&NuNM%2 zT34<^b3**UYtxEfj~)_^Hg3fzWn6kn{b1Rl=u1(dF9gI#W&rUKD{{|TL?pKgvf8ai z@tru%`|kJj0KEP9FT5Q9zBZ=N-$YW6ZO_HEynchz>{rTs8!`84d;fhu zBe*LzGYt!(kcZD0e*|P|W-wInzEb@UTheL@^l4U?-ain93wK(`+*$4~@8Ow7hX$m^ za;LrsWOEa$RaR>v8MUCQp|oQ_-pP5LXS&pB_e=6ntkzzHD3NSZ zwIZND0A?h#sHUi4q%#b=?$5{jMmz1cfy;p@LB#Nnoy+%2gLxK3)kFInLU2XmXLyO> z?5Wef)n5G#>0^vjnXloQSpm|d(O*4902xl`HreR7X%-%)XrrYm5uqCOWu#VL^z1s& z(uX$8hd@6l;XB#~TP>4>cs%2o+U-dMPZJI^sj)8h(hrY?DEbO@Rjxy{@;EEDlOJLL zc#Ex<%$8C-2qNDR5>xJA*wo#Ov?N7e@*H8KcIuZ3M=`OpeWf(cvkEhaz~%PO+d`3?PS~TcQOZj<}l?o7#&)J-{s@k^5Bcvy1*ik@P4j>kCv^S%v(BpOh3p;Ty%iIm$G~^TU z{%z^5(%l$#Lg6P%>yN1p;LJTqjG!QcdDgc)alp2?-UMW+ok2hq;R?=nJ6!qZZK(d9^T&EU9wxS#u;7zu z0QfXdHKPe&DC7SOo~H%PXbx~D6vJ5xs@pV%HxmheU4E2%Sj*6sV^G#h+**sK(0-b> zJAp|%ZqJGGA~I!7JrFrct&&h|3Z4gG6iet81jotuZSn8c8%kPmoYY!1dUjs)(W?e7mpsVt+++Wp+P0?vsJ45>ek__m ziuq*s762&eg2sJ+0H6FFGc*V!FWdHrMd8FfNwO@2zs_*Ye4cpACK#mXXT!7d=6bzX zwF2Gzv5u7Ag%?8X-fYi@>31rNpe_anQ5VKpEAdw)@Bu~0M%0j2_%0>kW#}Eb?$ac$ zd{w`VGY4HqFCc}da$Q|hk9J4|aK;T0B){X9u;Z`h5~&M2Q~ZI^(q*hkwV^tydln}$ zsVO(XeLO?atj2#ehTOvE8^GC(%qN=zc7|2x_Pi2ssVSczhxlzj%R>PXcbX;OmM+)M zgaA}*@oE`8;8lD&A0*%*n5#)C*H||x1TWvZ$7~BGmkaz7NsiW-ZG%yX{UY;^eEBH7&o@s`gsXd{X z2ZFrS@T!wp%U65RD=nuDd<{@hPT#xaF|Tj#!c!@kku&qJ#D^0=`nJ;_hn$2FBb~xO z)0}Pn%f$Q{<&@95mQ>tTSn99XdJB}Co5QEZ?H~OS3reW>C(ypc5!0ihY>@kySARu* zlBxvElsYAmlpxo3oM=}_6WIVJd}69Lp#rWkvfwC!axA=s9g5s zxuyYQn*d0ENaKyV*Gv7Ny`s0kcWpKoLXhyFVe%a@RfBoRNl$Ws)MVU7%Glaohr`Pj z_^1IV6K+H&<%3Tf4$!@(bls>fj!i%~W1Fh*1-p{62k4KSZm|qEQLX9+&foW@^Y(IM z2C=3Yq_b4Yde^Ab&n&7Rz8M-M&Y2(x;R#fT0~+UDXnOhX&m*p@luyzC_e#f9(CVpA z`@O6~b_R-Jwh)=&K+|i6Pv8_TE0f zoSzDhAXS5bpdo4|ZnQ2@m`^ZG(MPVrtEtWVaJc2;1BxGfUByR8(Y9r zN%nvY{u<(1vl@``fRuJ*WE{fEM0W#cxh~HT*As~f}d|s2lEBB^CWVcK#ej>2MS=C-KgQ3%&hKoT z-LMix52D0Q}T&u&{{!NI26k~5v~Y3xU)6GjGv?s|6;uO8_AhVyTmRv01$MLfU+ylQbDZ9Q zTNGfF|8lPYI>Osg(EW{tn~k;ZJ2!i0JNN%p0{$?&^a)V;(rqlPyZIHUtYY7Iw{a^Lk?c^6v15RQZ}r$MW9(X0HCOFgqvzCAK|mycLq$b}QzV}>hWo?tVc%cNxVm^+yLg)F`T?yy z-f;OkJ2mJGxped3+@Jf&@Q1=m)o+B6sq!|8Ytja&WdV?aEstrbWJGHd2 zwK2G~YIJKfl99#_?D-zp%XZ9WxA7%1h{I$zK;JywM1@=w;PkxTW@^BK9G?C2#ay-c z_HP=*&s5p6RCK=53yImoo~k*~+ML!XP;WphKHF~$@!1x;>YYtAqn6qh|D|Q(oyY-_ z3N1bzj+)CG#rl=!r-zB!8IMNG~C!wDTZaoH~W(CDm`F}1J7&( zWloPO`~}>A$*jiq>1$?$(Tv?Sj7`vMkg&y}62@@K!c2_)Rt-qUFfj3lsyWT z>u+D)m6DxI4MWY{my)3Qw8%g1Bwed4v6}s3W0>b%aqCDGG@kW~WW~~KJb@yAT*6O% zaq8J!29b6h8FXBHk>LUgmL_-e1ltfN;&Y~1>!Mm!TE8B~BGPVvQ0#j%Q!4QKI6&cR ze3Cpx*>5D}iW?FGTTEhlczuCBdmSgGa zZv9k`bK)D79v*_oN9F#YtWObq(u=f%lA08PT5Zn3+875pFSL#R6N53!}c~GgZ z_y_!;zd@u%b|f2ikHICepEhenmZ0>WM~2`;Xj#-FlLdx_G&yrpzMtt?d5t2Dg`;`; z;cKBIkQ%ZPjyMk@qSXjjTF<&L>h-*!bd&Cg#Zr{AmjlS=%Mw@-*|@xf)@cvu?TFts zqoy+OgdyW2mv9<{L?^w!{nBTB?Zk7o%DC1jUe zL&uVeD4J{hd6U_XtI8EiWQnN0gwF`p*B=?V*+xIlX5MAwMXcKHEtcsjV%t3eMLhOA z)VLg6I$@xppppt0b0fo^m>Ssi??EJhf#~bR?O|u`Zf&LG>2B|0>+yu6Sez7AHw_Nl zQAgPRGM7Kk_tZ->=<{><@XCl!9H~efXIqcu1i0nV#0fo)j`N|`;&OSFOU7j z6AV5S_poTEsl=CsngFl@Ah&t9pl=~nFIREC`Nil*rh>ot72`P{80x1Q_j5tP4ok=7 z7f29H48i-qG6#0fG5Nys0{_SD$NYbpd-^$9|CMsPu9|BW4@t+7f#FOgCxauT5<$2W zZwhO^Fauz}(A9-pevL3+1bVn>Z&Xq)vnq8r#QJ?fEh3L|7)q5eZxVQI@V`!R^&YaHr!)4+d4(<1LcP zmt4@WCR=A#;wd$E%N6;*QnuA94A^pSTWZoY?$EBTZS7{6Ty`9EzdO5^^G^%DlVdfi znzak3c5p3}m1WA2%@g0)q#3zT%0yLTGLX}Eyl^^1NQkGa)A*Hy`te-nnPg!Ee>D3b zGP1IORGuP{#xj0aQ{=6U8UwMV6L%0jhO;np%Ouk;g|y$I{bvhb`CW2$=KT<>R?KjR zFHYhj5Tk`$4evagak#~ETnSz&WLwIoRZHo#lZucuPdXH!ZL4P&_1-;L^b5*_BZW6D zXrk__`-l2e(BYSR!|}A)-|u>E_d#-|@X!a9AcVNN?ol7mKURFe!4_YU*d<<)5sTH@ zmHBkZNRm0Ih%b=)c9f{aw!W;+ZbI|u`dvP8@kF#|4vES^e0V9^9_wZs(o(mno!En+Ut#ueqCsQ`fr%d5T*+6&HCA z_8v=fRE0ph*9BY;e@#D>K?czaSeGv${ijaH{#U>FxVk%9xVkz%HFc$>DU!SQ&*ssRBMrNsB>BoG&F%W+4E;E?JxK|oD>VZ%^o)t8jo zGsvEd?OOGtuRqeau +1kw-D=Iur<_L8iob5~$Jb430%xyh^OA^uh%UZ+a)IkQpEu>+2Le+F34MrmsNm zDOmd{zvOmFt-gD;)Y}gj-(c@3eY=zQ_G0_PyM6Gck%|1-uVm`3m-1tk?X7=}Dcik* zl4)4!fd6>tlKkCv9(LB&o*uAS3;W=G>c93JXV*o+naECw&anPxu|yx{=q@@^Y}RWw z_|>yNsTG0dxkD|cz`29T2FX(ccQ=I$i&`wZiE&8S$Q5sP#Q94hLkwOnJDaO-IqA<; zr#Muh8Vb#}6trYx$$lgf!NNE9E`j@$_qXSd>cLDqurekoYVJ4orzUiAs~)D0Z0nd? zF=|a}3wRf66(_9|>zZ~fC0-W-KD;lm{=po%e*RvHggPg8xQ8)57F(9}O`tH@8suR| zsb%9T@nP7ZO6#NrTj>mmN=+1p`4CAu^jJ?cKVvb~c@v>PlV&eb`n7W2~+w;Xc! z`tTDkrFOu=8!?+1<`mk~P6S?`vDX+B?Wi@d3)A zt`&q%gwT7F%>%;MpgSXPZC|<{KRBZ;M4kpIbQfSVP}y?U%}pO%EeYf#7P}M0Y|IzvlwF4XhYLKp;!Hh`92$olmFbdIPFfrF!-t# zuQalH*ZV#(HiF(zFfNSaIq^D2KWPi%%?l+*dw!K3y;$G!1--p31T`dh@gDfmhe3NX z6x`OJ0rys?y;E*r>JZJ)MC!dDhqSOlXFDogb`NfcK_|ejKbZWqkpw@U1B%6agj0&>B)L55N&Ip%+>c7$DA&T_RnU}d?lnoG;9X;&w3n^ zoX>;r{Do6yr!rEL6iHdxEjiRX@BBP24^HoPp*<3hU(`=cW8I{_BO{MpyH5lZoeTML z1qTJxS%9Sx>n zjz!AkTc}P#%dD+b@1YU?&J=JT7A-|_zMg?;Dz48fo_kJQ%sf_n`%QR9V%AT$Vby6v z3pZRY8l+%Ep^2NdhMMKdFc^wk?&O>rtphAs|9$8}jGR@j5QEjiEe`*tGr0TyFs0i! zM`yx^ikii=V^yuMueUL%uQt0W>T#r~N#X3p5+n-5u>$iS#x7NyYNI5kj5_rmqM~3jc!hfE-yZz4`SJ2S+iZ|lMro> zGMJ6o%n^%2{5(V78TtXa>2mSf(^IUCFdvhs5rR3B(Z%GhHDcYYq9=D?0!f zK5qy;b%}{V+p}EaBch~c5#n!l4_vGfqaFCHMlrC)AB%&`zJQCo*THbIF+_I1%^FQD z_p4U+*C}w!Gw6~XYCg0<5@ZgJe68A*qT<%cdUsE2qNJW=H8Pq+42VmPdkAxp;g?zI z;L_6Xz|B`>H>FLTuVSea8P$J}`Qb#IrN`TV#ZexrX>%lY6iyF^0g51lrRL0>vigfd zX?wctvC=-huCtEtxzdqqXRvKOR(JE9Fb3VkEG$@L|bXa+EpVgRlCS&5~o!qy=I!jg0>mt$wP&Pg7$c8ZbDFa~zF}ArgQvZQ_RkV9G zmBV{fFJQe*XU-UDgO34`X02pZh1>-;w>VA^^Obpe#SVpew}1UFO>}cl8BWs6?*T;b&ksxl+P@RMviKh{d-ItE-SG_h8xObaBv^GEb zcK#eBUqX!rRl5&$%_x=Xv&l4jn7VCyXJw?Tp+a3j;Dx6q~I7H|6&jbLfG;fC5~uv-wM9CPR_xuQ2ASdf;d z)~d2=(5CxUah$cPsZa5!%`RkF7j+eZmTSsM6D%{DP=?GZvaPF4-dh9f+oN23MLb_% z&Oqd%F7?kMqWw{n%P|+Ct^IR9_)jw>_yYyNCCoyq6+b{;Y&`-R;i7Q?T;9%DUb(2| z%`JSzuz!pXr#QQ2g#=zk_89r2Z{>1UPr|#8t2Zvd&vs|9A2n=+Zj8!NYU((!x>Kph zgM&ikbV-UyqCi=z(_V;z1=9dg%^P$?d0YY6~BuBjlWP@rH!)q%zU8?RRM&`(SMeF;lA8~J_d+bP~ zV-T4;fNTyIqTc<+eRcCoNivz-+2%%=pU|%8)joBpg(Na*iKCbkh{_UhCKJTZmD6BS z&&Vy@hpnu+e370V6tCEfoQsM#qAi^h_XLU)^+TE>+}Y1Uco&6D74nD>GWq!kP*>V zj2Z=xOaXLk!K7n#LI>(Z%UFDD;7VjJF@kH+EMa9iMcTN$0;-3s7A-*gr-pI1; zRw!UY?t?zcsv(?JHX9an#U&2v2{W)fz;-#65Yo)qmk=xT86B6f=UB2gz%)(|T`Q2A z_L<(dMR~OAV!UuIZfp{@SVm#m5v(-$#S4MOD`TBDfPo9t4Ou`t`i0@MH4Gv)6X3G! zdXmj0#~6UKtOT?XtHh6&t2;usnog;NZx7Uw{G`-+bTRpv!U)JhX*Z35(Yz7k8S7hQ zei1L8&KsMf8e475fnLD#RtnUYnjW&o^idvLrK=D>w)p)gye}lZife^9`L(t&@#^$S zAv536go^aY6GmOfX~t3jMI4w42h?sDLA<@FcwtA9N_7_i--P&YDn8RpRDnPR)GibitF=W1u`cO6 z(AIf*d}!?b*!v&m&ImnQnr8^I+64~cQ1*y_Lr%L zQB5`+RIb432E3Iu9GVrgQmU2u-9AR&9>ng&&}17&nFfv?C%2OHEZ?@BEE)zp(v?ds zSk=$X7sV`GBE3f3atbvB^0}qW4AKBaIWBng;Bc3m3~J!WeTWE`laKKfpg-4h4|qHi z_if7gEp|8qqN0G3SUb^jy>kD2Z+@GQ4lh1e@sD3j=+I=Kh-*ip6N>T&&JL${@n*eN z>;flNQ%%x}41Bc*kX*BT!fx+?xh9U;zJ!ft(Rrt!S~O?eMzbYkfubBIJP~lXQ;r`j z@*OO)u7KJs(3!BdL0AQR7?$nNkn6zq9SLoE4JV{QrQpZ0w-Q}Eis_LL(ZfN*{Qe5f zc+6txq{Zv4pLp-)pwF7!@yED>5J0kY8?)lOXhi-b)ys9pW2eqD0(Y5EB=7TU#`+g) z@-+jxlOMc;OIt|K-@HlwDr{FqN(t;M+}juU;QJtMH@J!rPSlcH`HXhuCnL%EdcJz089wIbCzN`c#K1OEDkxG}&fvvzigP~^gYrCo70 zx;F)jt6raulHwU1W%&=`nATf{V`>&>u~>K`62x zRj8u|3!Tj=Z>bCecOVPB2wJQ9v`PIT&F}oB!*kK6_FEnrHxoKrJ*29|aUw3!>--L6 zCNsThl=05)CHIHzr4%uvDGi228ZF5_F!CnBpImhmg#fSefI$SGb^b`(VSapVvWtc*f!w|OD$Z6t#p-5%0{Y2y9Mh2J;Nxr};43pHs937wwE5Gs;ef;#t^s`#4vP zwOgrl7Fb(Sy7vmY>^H2wqKs?%T5Kl`P2Ax-brsn};*WRg^0FI|Q@xFV}d zw+-a-(mE9-0vFOAHe@L8oJq5H<~rt5jGUq7jHLzC1o!RAwbfhSLrfXqN9Et!@t8(h z*tMIA&`J}7)-Ob7nG$3&3*BW`dp~k#C@<)yM)YxNtS$_V(`fB|EVHqrp`0xyo_Ay+ z1Y@L3tGEgO)UXE6_~QFQsGluY@& z{H0Qq%r8}<6L1Jxh)-eY^6WQwA)1)LzBm-9&qg+1fjd(*LZ~tYx)$YF;TbnZ#s;uC z5b0hQQzjSF82eYKOW9KhT@VZn5iYP<B2;eif8Aor4N8vU>+kag!jS|X z&8kO_W5b7OtYYOq6^03+`!JN6Nem^Li@;wP(jqI62E{??lR>(K~|N{I)V-( zAIY1)f=$5{sH{%HP#$c>l_V~2Q$B@Cr4MjmxC<-zg*~h1a1qL3?q+^4QGxD!EdS|1 zLrGlz{?$HP!9IBolGgcUpoG3H3B&d}60vewj|!Or7PmdB)|c?{$;zM9)Vsjh0jma? zA!t4$Yieh1?lM{_2PGEM5CKa#30z=!4z$j%xt6>!zFx1pO{G<>S-)( z!i8pOEq_22So_8m%7*>Jt&jlBOl&+}uFhpoalZwKNCc)t=uTDkQ&Y1^?f$|uT`T85 z(M=IGloHPiNBHU+@D#!Y0mt>m1mUj`sICqj2;U;=N86BXMjXw&jRj2}WCPghZ~Z~y zsrbcm{qmm#03*r2>HXW6iq%Cf6e$i=o8w+(c%KR`)Te~&+SNvTCzsGIP{P6~I<`b9 zwtyiypXA&Zl%9puFUpAUMo=L{dlz-|NSgAc)uVmP+1LE)n^K~8Jj0zwrfp0wEQU7Y z$A<;UE@CN+?Y6n8g3{jM#Na>mwtss6snR?NT7R28 z!XMuMU*7ts`=3(Dla%wfRl(rko<0%Cf7>bQU(WxAPX6aQe>TMv*ZQ|%qyKjj|BHFmR6#<1x)Tld Nl7MYf2<6kS{{qIWRoMUl literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-27 study Document Inventory Report - Study Level.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-27 study Document Inventory Report - Study Level.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..00d90235a157c8f7502309b3eba854ca3aea1885 GIT binary patch literal 246320 zcmaI7Wl&wwvMr3eY#f5SYp}3!cMp&RcM{y)-8HytfCLS$!QF$qyW7UTm2=)#@BVq0 zs*O~wnmxOF^k`eCD!{_wLLng`K`9bX>q7mHFC5_aFA{dP&StjG2AUrBW=?u+?l#uH zHAZazaDbju2IrZ0Z&W|x1xSz&;QzRR)%8l!d7!Pzzqr>!FE!DPAJ8tTKMf8?cQ^j%+pSdiNqbxQ8n)fy<^;{>t#;%^BCE{D(_2cr)ftHkJZMCfmk_)C8oCdGb|q}Vf* zzjG$V!P4NZp7@Z;*eNd)7&z!8t`^VT+55zSkB6OQrV~!^fy^a}GhlWB*3{y|9an(w zM1=m#If$6q7xXKQ+U_)hF&PThaSVBKIGg)5`AJ)LWCHYk{+b=5=au~lT9T7xTLOdA z`}~kkRRIwxfrX(B3=IWE3I_$H`v0^&Dqwp9M>A_DcD8@te$|IxN(lSDaGc-+sm^JMre@wqnEvyMO`~ zQv*eReb+_rR{jQ+^kce`n{_U3R4EzTl&>&mm$zHm(YE-}EEbT=>06np060<>kADDmEvE@Qi*adW#hxy;E0|K5fwKGw5w6k|&H?p_?2TP^cZWI8PlIOlsgYBzF zVv^Izfk-(gVj>hp%e<4;;shngqa1OiEn`(%F^sLEKUd~saAkR;WB0U#$>)z~ z!0j3mC|Ee)(E<{NMn|Jq3x8{Z8@hS3l3GPdj~?0*qCeapqEZbF$Rai;xn;Uy5~N8g z9^mDFLI|}j&NB}O|2z>tE&c^zm>X_I$n*Gzq zCVoo3mjfi_N4wLWU7u1L+z`cp8n_k69BD^Mv}~LiOtZAw$@lXc{4MK{kW<>qS1%I8 ztAO!)>3MDiBHFTIwRYQY5cdUIVtH@S=ZJ30%0pzKRo;|(-FIPL7A!53h4fQ}La7ZU zdPv`4-4{0*yx$>{_GoWQV{Og-HVpB`VHF?OL8eB?mjrR3;g&}CabvexJv1tB!op!oJprYBC0fq@1 zUNFnLatG|e^y?QUcxi`)9Y>39ajy#{CsnZ1{l~`qGt098@w{%oxB$)5Q)c>?T;>N2 zr)%VYMl||HCxrk+Obzh)e;W}OFrvFPyOX7nqnW9Ov!j)*h0{Mf3Pp=y{Gk9rop%JD ztg?A>^e5jLZlT^l2mcBwVo8SIzTVw&;7TIew_BMFiwy2XP!2+nI+@0H=eh6{j@3>p z?O{+)QHZGs(C5bRDtyX)3hMK(;#mjvc|>Z3CP%b-lw#YQ>S!hF4zg`Ud|kPyyoE1B zN8^71Zi2N4%{o^e|10l|GBxdhqc*%uH3GvWS7Z7*m16{^Y<4k&9}l|umV4@ zXD}9v)48pdy1Nl7A7K|uf?gr*4RZ1orav5YFdlA+MabI(9bNfk1IW^AbSp^M*)*cl z%DH#Thc54xJRE|~Bi+(n3Joz?O)#KE7fBk&T^i+#E56Gav%3u7K5KlVjtKf`g}qE9 zU3N>sm}r*q3tO(~k5q~0CwU9CVy|7twv|Rz-46BY+Lk{I)2rWx9iOjXq&!o6pQRW- zSIt`nlYg}0fRuNm0V7%*!W+&! zjDR4|CzdOVud<5M-5C00u0%s%V$JSDjbFFO5V>j5T@{&$PvMcgiw^) zkwnoQEn&v6EDm3e-#C7=MSVq`<&^6AV_ZH#=~TFLHlf04OzZa-oh)jyj)>T4&&|%tI_6zOXlrCU5@X=O}GISxuA{sU=O(}S13|g6j(WWhGkIN;BOAkvTn$`Rx;}>VQ?Z_x^@8p1ZqLV9=PKqp% znJ4`YyQ=0~{Uz@^qS=k*ha{%>Oye%R{z}EgcXI>&(S@HG;rc|7Z533rVRY%)<-XI~ z$?^JnGCUBqwWvC9kl+36fc_VYpKbZA$N}5#{I4wX?!UJEZ|eP@7XEJ`-qQ5aJ(B*)0uy*g<=LjD&h{8 z#CS+DPOKaT--VMNO6heTc#rsh(6Gr0Xmda>6WWXIh4LERaZOZsrwy;GrBU!^X|jCx zeXa0?gmI9xHK$u_J?_&=?;!W&Hgm@hzr$R=+x@h-lZc(q`qI}2iR9fp(i6YhTmC~- z7RLo;bAamH|7+SM{J+3+vNSVub^_QI_`&%PfjjLlP9%+U`%h0V%q_Ja8xub}&AKC= zC7DLi(MEB}n944Cv^Cn+NSi8Txbyd96Ae#Y&l}uiE?8%EL$~DX(^oi>GzT~h_GdkA zoO%a{yv6ygRn<=Pxi+p;zFi@5jl9L<9WRfqI=)=8`#l`4R#3l$yT`Sv>wJB*^)RR$Ay2c3!t{IW;e70g>U?c3f4HuFu$h1K(t2IF&m61T^~+j) z*~Pq@UuIu3AgI`KHCT9Cvm=k1hJ={BmP09L6TE-g3W-tqjL zIyL`Y@tVELK9c$-;oA9Nar@TEdVZJtdWD#idg}1hv}||wrZ4iLPS(Yy#RMbR2A4diEoBmD`VCy%U1(Sj%H}iw)0^h0gWwesu;X z*4jR~C#km0`mFPPx4z$?tLwi%b>`UGlCvV+EiU)@T<#Ni9oMtCJ3P%VJ$rRNwz6Z! z&qb^sK`vj&cm;2Xb1Ly$SFd`mTx%M4U``CE?7p1XHjaeB_E(8#9$mir)WDNGZ@67t zQ~ktv$y&<_>~PAJhf-ByFOXlg2OOJw%DFtQ8zY6&o}p5N{5uK*Q-T#wv~e8 zuGo2B^HLwD&i5WRjanbAGj~j#-m01I`Y1*A19HcpuRZb}Z+&b0R-iG~Af&pse2sm! zZU@xuq8*q|1FdTo7k_*cay!Ov4v!U?RqC(mE4;lQj*ku44D_>e+g~o@-tON#S5Dpv zNeE6(x;Cy~UwclR)V%e**}T>lPxoH?wy*m9T9;SWSmw!j*%>B6%#%AP*sqpuS}R}u z3a$j{N4@=g|6FB}k&^0FirAj`(|FxmHMftj5iGx?o)o;RUwC~EAGGdxNSw;5J&DUb z1?{Q)&J}ri?E43}YlDHOr|YN*J+`^iE)0jmiWxI#pDg%{KR3Klz0CeK`~PxLtpezwjNl>uzyzcZ4XoCF0M)zT367Oz)07 zh=G?P9*;8k=M+X zJg%a03VWwV=aIuqJ?s4%cYeSD9@XQ8>JoKD@SQ zY65LOlGdN07~gZ*8RYVEOEKIp#yv|CP`0kbE%|abuHa}ZZ0ZLd`^8r=;CNE25HuSR zSiV=nn;~yRQN$}HR0R0~FJ8XB#i2fRcTbrjCcA5GUdHt~@k#~r2by^C?*nSQ%2Z~= zAFl@MVY3Hx9T#6DDN{7z;0eEo@PF`CU?#_KhS#2U)!{LTsKGQf;CAWME4LmA+ zH$k?*tERY&k?{lKR>NKf_fZ|&#rrk!p*4Nv81(@9RK)NFvF%M%z-Qhqz2@8qZe+qQ z9jEC1wn{dU$|$MX7a5~$B6e`@OQ~^Y_RnMZ0Y~hIo-3!C@jK$D3#Xc8b`iF_%+oUl z3(lmVgkN5IB=^33$|ps3-%4}O8x)?-UEd+Oy86n@$DO~at(>*9DZj9ZuM-_zKj*Bo z{B6y?b#7=-zWbP)noW=!H8&Pvw)pqer<1*bPsBRP_{Fewk?QGCpjCfq@!{6@QMK~C zHsoc!_4H4M=|F4tDI>x0GF4sOS{%RvuHH|_p4ZFeO;0+Sbq9`%1V@zgk+ZJm3Ezf@ z1P{w1J%x%o(euf$kt2eHiq_8t`d(*JM|}y;qi#=2cOmoWvucj^XO!mZoZS&DZ#M$+ z7%u)xrwrYmEBvIzZ>-*=w8oDfHM*>8Rgt5Y64^NI^%^cHnvvOy$rYwBe$CNrNPF;)W z3A87k#vsr>o)-|CWeZ^;cUu^j{`#ZIT#>x)cBgYJC-O^+I)Uljy+y>O^^qB0^e5$# zlRFz3tCOJe8mYGc&%dYh=S9{gsQuR!BjiVXkfqa!iKlD`=S|*C{*USCI?sAB2Y}ZQ@j)U|+|!`+$Rb|!P>p@KT9F>UMl=v{HlfxeG>=u;KZP~2 zZav%!unVWk31!$K_Rnq4%a=&*v`cLW`U3X(w)mTuw2@Tq;^gCH2Z@|4I5Dp~C^=x< zs|PpXYuc6@F1O-k>jj#|(tLPu&X2BXm@4E6N1KeXTW~}(L>we}b7r2J}))o0Qr5)?+L1IsQ zEO{qz{{8LiR;fKAeu|tQ6t<4tnIH5z6kN>>nrOUQ=z7ijVG4Qd!lBz%gh57W(g`xn zIu}Dibs=}{aodW+r?>RHOxUd=-`wJ5*k8ii|(9HG3fgS|)CQUn#=S1ad>ET}ixDl%h}bHA*P_bQ{PHUH zjoC)cPIKGO#Zq&-kzcUl%Z!+PY<~=EgAnM zK*_MZ`Hj>YmYAkDV=gIa&Rm9!a?ble6p$kyz%|7A4Ct&0d-CQ((>A4#$okc zut)ziJ@2m`m%LrYd|w)iJ%hCnlzN6`(RXR@!jOM4^nH%x6K;{<*zdl^BCs1Uy$wIU z9a%!;fO~@Ek@nA-)NYrv^R|m+(2bXk%}h>?Fgn98S?7X0w)yNhNr0UO72}nnDTHKSs~f~N8N06Y~vs>ai@WS#rsd|;)!m& zr`E5c=T3Qbhxe=#u0-m$tO%pn2f~Jrb+j;GM`tqkR_d2o(!(N4HCKc(8sb$_tc>TL_PPzxCF-f8SJhH)!(Ctp2S!1vkR*`am9`+Z&nRcZR(j`-J%p!az# zW%G=W#85}c&-h_r+D<*$(xQAKP=1~6LI7RG>kVHj5BG1%-ounG&t_Lo+Bbyh=(AvPL3c1^XV8N3;5qtnaBX4q$2zLA>vRU=BeKx< zVjlu-aBbA8t}i?JXCEI}W9Oe#GH+8)APzOGuOrebk6gQ6&&Wsd&mF*&1lCzrngOg( zFgrV>Trf{blvl{vWo}~F{$ZLT2Lm~xrJFQy{haS8{?9#g_L}(x0^O_z9Gw<=_M|G8 zVd#vPXzqMjCO21e%YKk{YtU)XG5MO%I*bjkiBC4k5O{b)khVUWCQ{)t(6TYJLZq|s zj(uSNt?nqV#p>tc{qopp>41&eoz%O7<0f8316Zd?5 zkiD^GJ_F*jlFtjwXTtywzzC@+YPP4u)9oiiz36C6ANR+*wF_kC>SyT&C4TMP-5kP& zaGplREeoIzzdl@1hY6qZ#boXarI|a^{TM9X+|7MWF0a9gRq90b(&8-h%B8N_Js#)K z;P%-2bneQLgz(5|!`&(Pn;h%Vnc8CBY3W>BHe_rcQ}JAE=z1Sh_6_=6#QiMjZvR94 z20}V=ik?5g`f3oV>=vuRuaKeqPx6@UW9+_!?fmT$x;L9jiQUWRjBsndn41^U&)$C5 zS7&duCvRYZj#lQsZgKZAdWqzui`O002(3~cM7K+IcpqEc_Cetd=AhsDf!I>AkT{8jWjL5@R z@|mEZ)Szq}PT8e8v~a2nWK6{4R|#@b(rmpYw^i$rlkKE2i0vn-(GkBj;lCDzHw}48 z6`Fh0u&JGXYNi;S*063BwsyHiSK=CMW4;3Rb2~n zLptlzZ$%xyM!l6+$o=jwjFY~vDK=5dV|TWxLe{Bw5kJM}rZW2=WhC4|<>x;Ns>X@5 zKM?2!7BrNUVSd_?O{j(T{St_ZR)w|fACg&j$+iaCNJh6UMSMS&Zo{T_mT=FAN|LLV z&Yz54$uG0kGosabIP|#a$9o*JZf3_f5ld0M**JKX$_!3hsN8f4c^>yt6ho|6M#mBI zJtaN4^yb^RT6GbU#~02BtNU=I61WGS9Y9y2UkuY*PgjCzFwpLX~mtL_*lb) z-zx8*n_U;;f>0Vh0$YXb%IvFRx8C0JxO_P_bUTEeAmh<|j_Qn!BPB71!@zpNhxGZQ zl{`dG@_C9PTyEtKYU`x@p{bsHLeI6ur>(OQ7PdMGY8>5Y_j82N(%=zC$!jwu96zWx zqv=!Y1QP;AUl=)6V45+tb?2>96Zjx>gU!P>eCy`W8-4uhY9~3VVrH)z?MvKlXuFrs zN8tm-$*4iNcSkmIVyc z8nuloxcsdM2%LN5V5A>&cL*(qq-9=5|B8NBV3+ZO)C1l5BVnEz4IyzVzpR0 zi9WKN?{jQ#ENs$q+WAbO)zfw(cSNumnuL2Bl!WWD=_Lfp@r^UO$YNm10mJ zk1%_`7azdU&SX2XJEV_5ZbMTq84AlYsX<=u3vbA;38<>6Mli`7$Z_k15_Bl3HbrD7 zKGLZqM_zK-@&!<|1W=R%{-z0C(Pf+=tmMvr54V5mBwoqNcZV`{dbZR6Y=RNV3r$!4P3?jful*}Slr3QDd|c&v6h zLi0t5CN(NQ@-7{7oc(7u+q&bvFypt~62b81XY>=5*2hI( zbPG&3a?vAY+|MqrFqEHl{)+xUS5nJuy~Nh+rAcf}<8W!$_ho2UJRUo(>Vv#&<99&A zVV64ovJgm>+%JI4$gtCZS#3ye5VW#P(6=Sn3yx#t^uioqS~HL zm|0%%vPb$9dsI_DW|&tB<%Ymvb9G6Phlk5!f&Iy9-tu(_zQpU4hMT>86g{A1J92Gi ze45Qf@v8dXs?v8S<@I;frDn;lp-+SWzuJ#I(m>nbD4`Br4(!=Jw3uMi#&rp$30B5q zRC0tK`%M{-(8+p)!=Zm3o+gP6a%fl;vE^HQc6hmTXolKE45w(O^42P`P?c_?TL~b~ zv#qoyc@V>6guTKDJ*L3YuwFTAB-ujT{rYiMyrAM}U{^D}nE)w_%g}T*KHy6n5@_fXdsb;J}WlqY*Z=|if>TYw= zykJIiZ6j9zdrO{`nm z`(!sdprG5m0FHI*9MS#{&Z>Ut={(sPqUrOf6pYPA9@Jcf^;RL4Ki zP1KJEhn2?#abQWE;H`1H^PcQ=E+n_`sDvi!W;X%w$0Fyn??D9Wyiz_ZkHm<*qy;}B zdPuj>21xThezm{9Rq=C|fv&+G1(#8ool&AJe0y-;=j(GPC=`s`(UXak#EBBK#>IIb z@8*5u{MTh_e|15@{pC)0?U6OeJ*8yg!&!6Z~GUuW4@djx(f(%b+rXCVV{zm@ek>j`wU)G7mMnAs{d zy?)MEqtapXE?uR)6Wk~le_{1 zUSq_Ua<`4dl$X}|tUzDk5&}wK0 zAbyeF9RH7Ee5C(VF=_{y>pNUDLN^>K`7o=zuIB&frU8ihuWq2^*`~Ux_*HvoWaG#HHXSx>%$C^NpptgM3KRog>&4issb$<>QNjoDUQ?=*kEcF)*Iy6< zFdR7XomV=QIMs@rEx$(v<&8*@J70QY0>tJV{+`6yf1was&ja3^C*c$@rF~aZ5R*Ez zqDfek5J&^ft=l-xeZ|F@h}-7M8?V<{2RqViZo%rmfa41IpMbk;x>h!!k4&a7k%L`J zS;f6|AYiW(RittVf-J$$?642GNco?O)Xj9)(6x0aN(j$8vdaQpCGog@ z$_4W`veo%3XCFK&0mrl^6rl934YXbspp5qEtTDa`x)#VDil1)qhH#JbO0|{2a7OH` z>ZrjBF_aH}$p4^mmn(cG&Vy$tCBM4tQqy>`X`5UEQ$rTg8e0-bHQHQk2*Ox zxjJ4pXbPN>k5t5v@h-od?QOYsdKhT-Sh~Zy737s)rhXwqLjHBZBjv-@Kf(@5lI4PA zzvxsBlUcSlzufkiqmns^Qog_&nbUo+vFI3A1toq==EWd}Wgf4QzO3PdP&b96?;ugs z#vTOHDizZQel>BQ6h?sIAkD19KCVKP|MWheYQZjs5+6u$hRxM zuzE0$9^IVXDJcsR-r1$Rp`>#-kjR41ixX2vD_DqDU@hj&uwPy7eog4cM!gSDos4v< zR1-XidP8C>5a-4AA%#Xz$k0-0GRoQ&8&G{xlXCaEH+^^0{0ccBW*kFm7?|9@$BFA0 z?7eekS-?OLBh)9rduVkmgGBS#zUuZ(FO1>ue+_)0;SzIGa*C-OU5ZkU;weou##6LyDGvxtb@;ymw+DY0=i4xR zB<-2b#d|NC1IXn5uS}W$%8WFzT)?ucE@FHPuE`q2turpD<%_Eb=5~I*wc=O*3mA85 z@|->=R88)3L-b;78$xkUhmxCN+iWx{I-tTs>vPt3`~mRm*<*HyJtnsE&g^JYf@Im% z?956!j)XwWbU(C#Vc&qy!(z2=EZjli!g~Fle$_LPLhyc4cA3(geGU*iB-;Cl5SDURrcZP%6Rx{sGDfTxBR)X2Z>2rjGqybk> z#L!CPvEpD1XVi~zB9>f)&NOekYN9K_G2YNCIskAcTJ%s!7*Y7o7bRSA14fI1a6?aL zjafv)ws&xx5pWb+ENK4mR7Eg()4dl*D&+q0ldy0Unw+U;%^w#sAD{?dD0L;_ZE2vu zT%hmV&AA+($fAgyGoWEu(h2=zJB6WSP$UCSIiVmgy|5fi?XO)h8%HBz5G7oZTLE%{ zrJc!xD#pV)cKvq%vDQwUvzWqzrbBn8N8!vGYKD2bUXiuX)V-7GFdkrlaOAxVV29u| zg`+O;U%1>*uvmQ;F$zYa!#RQdqB=%kkQi76;Itz_J^{d~H=x?a^;3}OJTER%3oy_5 zlg@jmu?ITHNEANU;-LiUiG$~HaZ$u@@ib2F5?Nbr4e2}f5mW!!!diQNL@muOD7z*) znpfB+QAKHoU(|3$R#l1&rSy@AdcQ8cwpU~+Wvhkyn|sAUy#|A5^CRsMTl-cR6+G^J zsv5KO25oz=oDnqSTP)U|s6)c#hd(DJHSFVHv7P*9zT{CUc5ar(Jz#E9F@4=W7yy@J z=G?)Ae07kfi|_vQnO4ci_2u?pK&D(c@DvL|>059Z_JEpCUgDX_6e_Sx_g2pp?MNf6;^+O_1b08k-jExSWAM3Gm1gV?8Kd$G(m^aAvqc$S} zPJhE5;RpFqJ~O*HU~bzLKpmNvlMHV$M?oHi4{$a~}Qa;ap%)G$i&y?eTE)XMl zk4(QaC8f6vjgm|o`y&N2VIK~=)bL$Wa_HCpml(r&-M47G$C{_bdOAlcqDFl$7LN;_ z|F$n#pI5vIuC55L5qx{1)wTUA^C3p4*)VTe81(XEhyL%3Yt8Ul%Ds*EEqWnV^YX^! zi%8^h`}_do7WGbwn1J-&2zVcoO`>ODpl2a+%0jjubxZAjKUncYyz=``IdvFZ?D{!c zAHn`(LEyH6v41`653b^LhtelY(uu)65(mn0)4fI}|MCc(FfWzC@3F#{Up|bjyQi5X|_Db!C`8U~Ev%-BKu55fA1&{@0Elhbm%m`6cTbggh_82pUdZJd|~8JXI=H zb>w8JZc;AOeY;ziRzXGtI0QV@2ZH!6shC{AiqEu z5zf1RM=4{+yr-}Z^!Rva*4=$6gx{f%ppE# z=6i!ta<*&+Z|I~J%6Ntl8lZMR?C_&j%R^-lg|U$9N|fu)J0x)p3q9h@}I8BxM>X5OsJ zvdj+=9ub6MUlk*U+b6>4X@-~Xv5`*Fh#6{!SmhadlplNQ^lZ3ktZT_Pj6_u_fU6h} z-SEZbWEqma3FD}vn2X8>LI_SvR6>E4-e#+i=4vjoaHlb8GCVd|n&zV@sJm%XKvs-2 z^gWRm>#%5}k38i4g9*doJ+8D|XIyu3bOPgZ-8lH`Kw9Zy#qLsvSCT*6v}3_!`E{f$ zn%T~6M zGEUUfOboy%Ek1AC=h?()^QE|e4LhwaIrr@8wY z8OPKB1x?A+XuIg^r@p+qbd%F<*n)LjYQt*Wu$^Eb>O7yWCs}8rM_@nwZ?<-|Q?Bom zn6-Z+C`f$F{2h>Z;%~vN zODDpte;4DTTrQ7|QL*tSZ;|?blUj0_5IXy(L(za!A|w{NfU;lCTUV+>3r|}`D^m~J zkw82@MkLJa$q3Pafsy!iF1_grA&@eyLw=p$2toy zDo2qH&eJWB6XpM|0|q6@G3+-TYhWbI2diQ<+tOw^4*D=VBwvGr`kls9&mXRiPTIb5 z#XI2iDWP*2jS#w@%72-)&}}0_L=E`&;t1vy+SD3L!^mpsla#CXy_MB~odU?lA0myd zY_6!5?nG65V!%xSrKV)Im4{v_t7}GeMWtU)855SrDs8(h^F>CFI&ql98dJiGZ3;20M(m^Zi8f?bzjV?(kdXyVHvzmx2eY{;#22 z^0fTX6;Y7zD1u?be0xHNa0WUg2Y(i6VE`xORCD7;87J4Pfxgg)s6NAI0?U4KOX{MFcN!^6{9)xZ$ zS68bekN50V@x{$QsLHYvzFQoNW_H;Cy)Hn+$r6fNbQR%s6jyShtH%4^jis%fwxfkwpKrs!}k_C$nFq)92Pt?T9fS72#S$UxF!)$C}2H$&#s>V6yIDE z=VJWq!c!O1|BJU5SJps`dAP-rji}(u7KLKGY#n^~~opmiQx?77sSa`cK8SDilx5JDE zNEiCP$pD14@R$wXg%KaiU9GXZxY%{Mh^-pjRgDVdwTxaw@D6cE7n?NmR+yg5JF29; z%lG1CLoV_Q#h+T7R&I^Lkod(7_ua6d!JUQw4)Q4ZU8V2qhga>&_YsQ63)DOXC%6sF zqa@h%Q3Ct^bpHnTa#$mvB8iy(np0F&%gs0?v7&|+k}=!jz^G)19%hEI^ zdX7Fu0-G*Xuv)WIGpfX^(JxErYm6Csok5}{b_gh=CD>$;El3=}@+8|FdP5q%L;bNj zS_WN$N#?6bLGhUkfnO7`Ov>QSL%#wv5H)WH1R6ECv#!U34m;ikDLpBDXLt1X^T4Mn z*jd8Ay<_i@fh?QxM+QuD1zPGm;C`+@9^^8ertvCw`bwx0Z&9$cI>SAqJ)oECDhuO* zbQ<5P`o}6vHxye2ywitaHX{TkBraKzOqfwrZ%%wSPHGzoNsc101f&8Xc&&<|YKFx4 zsEE8)gf=3)3-wXjY)h4`dW+;63i+;hJz*FlffH+Ft|MtmuwvG}ejk%(QTKVA z`(VSH|B)H1cN#HmjA*3^$9#hHV7=Q%OSuS&14hRa;VVSh(M0WE2@ zCCdI!4Q%ooX+~PmG2wwrGB%f0zgK%4UE-)=(yw`dCnt%kl0|hTMcIqhVH^-d&rka% z#1`pr;Kyg!m^CJ$VQtjNT`$%D?Mz&KEugDm>v3)oSbm;6*S_5tA<9y1pzBl{V|3Xz zxxze2Q&uaKWXF@91}kPf>G!kjvjn(`|BmSTVL0zJAGYd#3b#cCR2{3p&>{5|~B{=h_!;ckXn9?0S$%hE96gn6h+f&VzA z^XV!C_|$;*XlK;RV!w;ijt3L$j(tMLKX=ZA%`(?IZaU^viJ4cYVEdCE#vf@yc4w>- z<#ug;c~-s_{uATm$>co?{v-ipPP1l4mX>DhcffdyU6f~=gg)sOsWCP%{axJL1;fkJ zN2fE=#%TUg-9$UXWr*NV79aAk1ZrD+vPmPceMC}YQrMPQSMg#cKfY!vIc46dMej>m z+5^usNFH%jHegeKwqjQpFHZJ@99t{I3Ep%j*Np9qw8;!H8J0#VpUFN2dcb*;Kwyd@ z%F!j`zb}?!BV?Tkf659<1{Fv2{0AkB-dV)7=>SUj=Mxmmiqg-cWvK~$yRk6nW&#F(hV>`==mlu^^0BP4(>NcG#(-i#r9M8X8X_kI{)eI@utA z&(Z(jb1(pi0t*U6S=!(dQ@W7sFDM9>26%b?)pTdJy#bL>=b;L;)e92tsftYb0_w;q zyi@Iwb8yT~N!PY*nlKJn-L1*$$R~Z($j7PwxWhh2*4&UtM`JeZzcCiPq8bt$h>Oj$ zlWf`o*=89L8%B(Gw3qUC?4iZh0g|!;U4klUM6i73fo-y;bROT!hR)XF<@SJcGQg6I zeEL)YP2qXE@)2-%#=gVt9=bjs1k*AZoZqD_8bwcCJRZ5INNrDF(Wm?v9 z%$%+?dcLr^`#;6saoh6|5t9@> zcdC#7xr*w)u8O3oCO}>B^(WY;i_A8Mk0k;-2E~#7ih|@trOFxpba8jEEu#^KPDGL` zW3wnrT*T7#_+Uf+)qgs_)*%lcs5qV>`eiYRk`#YARgYz z>*d;S-(mtp_@{VQ#E>1o;cyZqNURnZU?}ZXQH3(Y)4|V6`PBBIQi75OKa~S?=o$|t zzUx>LPI0@7HBB@r_6H#aRu1sj;g)R^3=FCeoZApCsJzf$)$091jH#<-w&C~kQzYvY zY&Rh{pOqMGQ3^IH`&4!40RB3X<RxP5_iQiVZQB%d~uh?SNafj?1CtQHA93k6CW7m73Nn7+D-R(#YHg1kDVa!~Z) zVwMA}N`UNY<+7yrc|b2N&9luHK(4Z4uNny_mPJ7C4qvk%t1a{6f?7!>9@Oxi!`*;j zY2Jo$x#2e*1_dR&tPXX8TaJi&ykNOr8jPgyy4+N^+zyu7PIlk+AgD`eiCR>p-DqN} z=z`r`GBO^T5(XuR`+s`R-XNJ1@WBAJF=^01?2$PAcvcmaYuk~rqhPGI9$>1AG(Jot1^kdLl2IOzkw+- z{@46b2s6b_TLLK4Jh9|?wRFi>K;&~TEf+~1QdV>M?J+!1T3P z(~V*r=Fy_|EC6FyIO^!6HQ5h#Z}?FIdT=;`stQ)}VfH&PMILtdKmta3@}2LKQ>tZq zN91)N(A8Z3vMGq1S;k5d$fjDZ+*AS%1%AJ~-V2XS`cA3qdmXnN*EzOH!vUl+jBI4>G1*6vjk>fi{OhD zBLz!ctf6BVIy4o*J)KeNDAF-bk;+9VdwT^Ic;rw#Wh53MPPd*xbV%44#dIYNIg5+n z9Pm?pvR`V(E`r^@(?=E~I5Zao2R_aNi*?^iY#e~Pd?n22-?cLz^1X#MaPSNJSOJ-b(`I@ODGE<)KWPCSK0dVrl&dA$9y90$lQ_v+=!Ad7$= zF^|Gbp>689lLG&ZOolXp!w_8MA3vfX8&L!~Ks~k5lNDk{_VwUvtiUw~frm#9ij(k;+UgWy)$C-H@#mM!;&2=kdUC=-GJLVnORq8S3(S zdUCTW&41(X-~@(>)2G}Lb!q>z?8^{zD;6%aKb4ABaFcxtiCUE`&`hfl@ zO`yWsP+(LS%kt=w863M*5qWlgIm>%zSH57?_1&q^C|^!v);x^mV=&w?+bybO0>ClNqo{<@u$7y`Ug;Zdkb7w!Ugr6^-&j7|T#+%Si1I;cTC z5v`pLlq3m2Ng_eEb<&l5{}??#%})KO#@GP<+87nVU&{(JHThnxy z=Tb``>BwtjJle#z;zddgmm^_QvoNYNfnB>#h)Pe;QMr0Nr?A7lN zQatfGl%WF%VKnxtx9B50gS0FgHboL``{u z(9EnaXLCP-Z4~ZmO`Cl5g@grJvKap6xJsu5xJ4Zo2or4Y(gE%z-~<3CuIj38o58?V zwlP@-(oBNNq%)KPvp6$;&~**;!NZcLOUh1*J?W*vL#fWHUEw`LmhO70Z`N(XTkvy(|{D zc%8t%sN_ThXwpbStpqW*H2yIf+uB}ZXht?B?P-r)>7`MIlzy<_7W@`Q zZn68qI5#KP+yhocPK0gyZ)Z2qs+Ne=D-h~NIutIKIc9K_oJ{7&LNIsw_+aI}-*gNV zMyCHbrZpLOEZri@&D+DpH5SXR;J~WdoY@j(Bmywv<<@WD6)l>}=W&>D#2;eG*zdvk z)LFm?9z9TJ08~|oz-h%EQ9Xm5z9kADRkr86Lt}9X&`d9J z6#_srAok*Sa9*4{RKV&1_dw5Vd0CP<43A!)szUd&2b z$U1wvJ92E}gW~}rpd1(x2e1;X$cPFMfq6$MyNb9eu+da~zowyRiD2h2E9JA(2RxG` zyF&{cEs9U&ByS%0?eFuU6DG(DD33gR9qf{s;D8cPUk1-u-GGwPG-sc&DfQ|I z8z_~$wm(t=Iq0ldGlXJXaK-C-=0i&#r`kpRCuXjF#8{ECD9C73Y6!riqY4zLoEN*) zp8dh30jWn~o1>wdBQpM3o&S{i=simOPZ{bonX6c~qUX4xfRSQz$2R<5e>7W6;Pl*t zj((qVAb6$4*`FEZY;}csTqmBNDg=8cNvV1@rA*29XtU2r3EddkVb);QMFf%Wv4;Ep zOd@+t%VF$c%rEXO%)MG!LK-NU=-kL~s<#q^lk7D0g)`n$L!;3{pc|XE2;OZVz-J^} zAlXPX-S2VP=df>^g}uh==}I=n9L)?1xI3q>IyS!+wJ!jDJtHj1T7DA)Sx1r}^)m}i z+Vi_ZbD9$&35ss3<+yQZe7{0i*|xC>Hra+@uihi^A`-cfJ{07*X4sfwyGSfqe=j~# z2o^80kr{A%b7$cr7&*6cZEkvTxvb$ImMiL|o{fQR0vYvt*EFojXLR|aUOLn^cN(1C z!{5~87_;T22Bq)aJ2kU3EK@!Cn!T;NqH7P(->uV&EczFIT$VIn|pCpFC_gl&x{& zx&yO837-74@oo=mjU6apA{DUs;2$Ol10yIJNEtC|A?-x>={Mgo6sD?{CNJ9s1$t=F zq^V025^NnQRGaA^w8U$+3-!`@jpa{qgkuqdn%`CVFfPP{aS1QPy(zjRu-AhE!c4pU zn6%vf_8ot6wd(Zhv~4(MyA`hd?t0St82^dl`}&xVk7Zp@hjmTIND)^c(a^EQ#s}>r zsk!+R+##d<&l)=$9QwZld^HnBJY`QP!h@xVjm^_SKG|9{N`k|K`v`5%P;@n*WuEeF zwxo*IU7@H7>q*uhVVfrur_9W!;e4LzoWLB!-HJpW7+Ph-Vd<2{Xwm8aA6b7H6le3i zfx;~A?(P=cokfE!0Rq7_xVyVsg1fs0cL?t865KslkYIW5=l?tP)~Pz*wrZ=Ud!~DO zTCVP!N(|GSy5g>HQu_8JX34*i^}W3=q&G2n#KU7^zU=Mo7v2B>LN$yd)9cpzfxmWY zazFI`_VoMY{)jJ&K!!J;7*&k8j?FoesP-95vdSGOT?ku1 zLwj9k7?_b5?YN!xN_TD{dC4(9kmlyU4yslxJ)ms=-N0tW zEXJ#2$tLNXX)Kq}MV9pK7mCxSKsAc0fl)O;tqy%G9>bh0k!_m=t>Zkn*WBR=dPll` zA$MjHk-sjsh|M{lpmrZD9zO~Prj^9Rl+^UGEV5u`C^Z1NBKYlmBNOBq3A5&cXN5vf zb24gy0Ta?)M(RQF=yTC4ud=7LepK>Cf^eO>Z3>v8&Y2sTqTU3>V~rJI&=+lEa3GV0 z4MqhYS?v!v@66^#vO32TvfqKlqvU9*3xX)Il0B1ssDo3f!O-aF5|{98Owdc}?LJ4K zUyKIy&vpnLoC?oaBhvFr!STfzuMqgb$hkr}E^hbDKN)h8t|W*!A-+!;k!^_P)O*L* zmQGKwUX`P#lfk<#zX4a1Fo7P_7s6f^v_;JXon?9wSk}A@3;hc6TgT`lEuF%F3c0J1TUZd?aVJTQnCv*9g(6*v7f!Rz^J4t|B>h@#7KOa z4s*VhJVg=0bX!uLFpMKFky1VGa8gMF|G_$dk4!Ujs=x#~Sm>qD#f$QAY&93{pmZ ziwi0mq=dx{Il#AUKN8eqKq71M06jbq_z6xpOlK{ zoZ1KSKBcwstRX=NMjE7)5W_^I#||;_U-nqvYrU`{&oTuZq1n^w#j$}H&v~*(G!3Y95&2O;z?irYX4}zfba%ei4UN?@8RE3!A~`^Gj|8t)d4SG*k&8o>mIV?M(uy zJD>9M^)E&jhg(B7!v!t)rNt<&+>XuR(vwvLz*Y5#q{{W&GgE2Neh*MK`Z7*)Guj z1{_qVV)0z>>r=QJ!ckknK^9|R?zK6rK!IH}=`C8k4X}mVZ;3XT;2PDWxTuFXDKWWF zP||-7<~MrwziI$DAwu=we4JPA7YeTFG};2St;Us0{U*Byp0@j1#1vnrzwf`ey%yYW zTlN%bFAe!3871vf-wj*MSVBj;Zvvc2uFRc(k-X2=mdedM}T*MOELJ&Q+ylY9NR-%=G+3%8TU(uZiV@zI10*OKEjZ zr_u$>Lv)Noz@a3f&*o6_3CO=a1kr}UGT_O#@3yNZKh&!It#3x6V$#B)Jw^P9WS$jY zeEOTRKz|bn;u8Yf+5_|T6;4rpo*p4Wd#Apb_EPY7Qt~s-_E)*+He?#6JyQU{FjJd) z-s!CQve}|_VRLoGM-g*|A9zR69q`!t&)>z_-Ot%A<7byob()D?Ow-rptn6j&&Fixh zbu2B_WWuR&Rbr^smU0ZOVmolJNuGLk9md^5oqkQj`OD!u4x$e7ra^ysCJ{3a9dcWF zWAmwEdeEg~IX%Bld%ld}0F2HgADLxB-T~vgw3m2Z!P)IW^dXN2ZQvWiS*OxEx$-K7 zDaEV^gTIys9yd<~R50>D3Vjfgtg({W=A6~))*^TWz51=*DmCWeDbLEgrm zSl0G?n^wQDI5ylVmZbmltJ1xMnLvYR^$qIM3*mc(|wtwlef~_10&jld{h=iq2gm7>-B$NLaMGXGZhmUWEvyI zneFnwB24*PN#bT=jmZ;cavIM$^1O&X-Xe@^{L+_YreAP2%34uu;cu^F_4YIpRxRf( z(j3DeOJ2tn#3iSs>lf3U>BYyIXK@g>`?99E{?G284M>V09tVkjaFVcy z_wnzZIlN8MczumS1)WG2JV?vugnYE;kwFI|oFvxGEWxNqC*we=oE#C+A55ZGm`+C} z&$sIZNe0sp<{LpU^J$9Z)9oY!OBYz?YRsePQwmief*LFwMdFDryMpg9WWrGQRg8sD z(dA$Jp`wwp!(kS${_Z`UJ=LLZxzZfh;TpTKWNpivvG zU%$HLUzr`yqqFg@gC-s)ZfkcVB;3t@)}x1?6``@KYZ3+$R^@O{RmJ1sv5O(?MOV=< zrqDS+{!pqa`9+JWLgQ!u_(goPT87YM7_9m=^aqtB#S^g6A70-{8Cx7Keua<}-=O9X z>xEV&JpDiyXA=GbSiVzimUPU^ z$j_)y#fAVBYkJW84AwXRdj?vgyy%G*=^fZ-2Ht~Isx`I>q`plP9kx3w9~S4MPKbVa zdIdv3+2c`RC28$RNG&r`6v zkrqaN`QKN12(COP{C2g8(;2&j?gHR)L+5b?XGtli`^6M7cs`DGY&AX1Bvd%_ewJqZ z;cWiT=}wobAccB1lUW@{OD4T2;l%97G?C?iL58#O!&sq}8<&Pk1iAlXr-iwYJpLYY ze8#p?Vwfj<`r7Z$Icsr#K86(g&h=~&g%mM%%|_R^Tkt&*r8sZ~2pQMYCZ8fny+x+l0cT(7KNwV6x6gzf=5SG!nY6HrcUAkaaU&9tt zqA?_AQikp|PsR8qTk&4AFQ%+5qz~|bS{9jvB_Jarg{~c$~`^4x_8ou4gB=w)y1&)&&2i`^xQehqlLkU1|{!f;C1?Eie7qzfBxgiyCh$}wBvg&LjJwZSqvD^wC^L)$e{cTa-selj$)N`LbyT-LsI6E*OFC~2N{{4l33GAaG^FI1TqOI{ zOG`(Cj-e`W9+14@bL9ws;K!LUxc$`b&kuD~rW-qZd%C4SNQ(Cydk1kKt%Pz2N*;x- z(GQvmW#F8TXKU#oMRU0G^g^?1VH6V4t!0he^Y<2?ulD`-{~j}D(zeo3=$kjfaCWZh zk+ks=ITD?7P2ZoA(oxVMlo`&l9Jz`K1u0iyXedPQHUmGok+gd@RKlB%EyyMsV=;7D z;3H!eu*GtvGFuaUGaSVa^aljE1 zenL$YLIOH2s;z!@VvOFG|Bpx1s2G$M{>eL+;u3`l@y7P z^lUm=RNRfCZjRBpmhCAWEx3kS!!f~;Hl~&1M3&lPi0zLrMk?jd!YRH+yukt7rT){w zPt_m%fd$bkO@t5k&i*MQm*I#5_KE3rYVcE}MQH!m>CgAh9)+tH{dgiXwM@=!!eGI$ zRahqiB*oay_+aFHHrklrc9dn`4W8j&6 z8npsKF4R|?D6&LyRFIwU!XblWh_=+ZFLtp<6<<1y(>^$M-CH-L+u*1+$7Ab-+C@JT z%ILrhGCqJPh8azwke>vLGZHgrXg_@IBo25G9H*j7UPLFG!B~QI@2xxeUbw{mj9&yy<*(*HUN-7cja-+e+MFo?@Psi+7DBUM}vqOWlnn zWzlU9fsDpZ&@n3K)DeX+rk__w&I`)7xppoX(JM zo&lQ9u3XKyw@HNpzcdtYnx0dbD^uS20ZPsP4<*(xPj`&t+A(=0LP4N7iB3KiWCN+B zj>v}LQCmegqbl3x3eAp}uB1QK%&CY`mis%1%aIac6MRBikN{{_A$N{!vQC;Row*?YcV25t(lT&U#5!1vI-c!OvwF>XC#DwjeyH%8>B{B$ZPnZ8V90ZNJ( z2)hhJlH$-%dtRY_JMO1yNv46Uh(^413C-Btn%-6+fSKj8d@b=~^go-heGaRLSJbAq1`qUELwP zUq>*(?W(KjFURcK5_bOcLfRF9binA_iZeKeRY(U&>*GRHs;6et-~zJL#YYPPEG9wg z4g~J9gYy0V^m-2ae|p^%>Y3~CJC!1JNWas=wLyCuA7jaiq5atNxWc3gRGjnUj&=t@(b%P!+6tkDcQ*vTU{o6k&9I zb}@W}a%b#=J=2@I2zF+%p^LnqSh3BFr-M_P5i4a^NBk(~_eU1%Jp5)K4wDrKopEHO zY4Uh@j<4PBAqg<;pmEBR$)07L=ux1sOt8BCHdAK6zq!#YpWEa<@ zKB6gXL=jes8pDY8SYyb(MuC<@B-kl@{R!@%YFR}I?v?TdrlGAL9vyi*8IteLy@&qS z2yXgf(mHeD=>GFX#Ws$s&~Beh2`-a4QK#AN{nStOxQ1Do~s3DPFxbU6c zWC`k`s<}LtutijaukTLn9gQya8mj&&$3t&Nj09^|P9#N6sLp%&(|L^)p+Y?|6wz+R z3~u`PSC5!9pLYyqV^h6M!9 zsjL18o*paIg+gf%e^^ec`911|;F1`(?s+)jx@|J^oWm@$?`3& zV2hLZtYC%U5zklB&gc$SV3o;j^?3UJze)hVO||ivLea57ghJ z4Cue(JFO%gk3DvWa<+NkJyflpBFroE1Xs?&)z&S|vidx;7!`=aRZ+x2TQ94)f}SM# zyb`u1AKfBbDJLbUap^8EG?2zV6f|~HBFHP^x~@wD`L|~_gUPVSY>{-uG8Qa-vnaXj z+uBer^OJ*=hA+7MCbwroP8`QG>=^yo+hGJQ{tJYYGKXUnB6W@rD#kNZECa`u~vITbTjzbWF zX0G~C!~i{b+M^|n(7X)g{EK$jvNrxDM1o&6dyxlc@ylr6fJGKHf-6ihY2-JCA=rA< z5aRsZcv=GPF_#Ix3OJ{vI5^6w_(4(C-B<7wsZKEo)n0EVW|5ANS@;PvxAd=AuPFgl zmJ`z2r2UC~0*mwYL;Z}c01Xk_mY3V7#}}H!)>Hd}q!mI#^!?ZNUlwUgQ2}nhuK#Or zu-5L?9!M{`-%6~RL}bD+-W0W6PG!D|UjKAHWqo&pq6C&EaXx7_Ml|U$ygZh5@|U`O zcFcfDT8#=WT??o)iw?1FE*+KFfXaX~xhq}0Ol^(1xIc38xDJM%95L4v@g4WqtGSA1 zRT7djFK`z9JU+d`6v9vw?^(#>ERV31JX|3-vNiZgsONHhN=)~{{m?JljPJxhiM8S7 z5NI{!w_$udgLWYt>aNL@ES~bz)U&b+{&FGGRan1X&)H4-@E50+W;H^9xL-_q25Us@ z;?ZW60jZO!X(L%Q9m20V+vHP=??|lI3tX@Vw0L<+KI021-<^vPS|BFphO{k?50TRb zGoE*@hS*51l2E0AZ4r#vbC@MvHL$4d(7SkA5XQ_f9~6cbBFy{<)LPceM_OCg_ok;DZ={Me-(xF<_l}4{xcJA^mrK131*(anVhN`x^!;d2>4q`B%F-r8~snR zn?HOv!m~?g=7{7abEr@cj*jJJ_m#`%Sx^SZ>m|P3Jb$kD>)EvRZ~muWy)txsXsz+e zG+~wEql7-|T&QJ}`anBnhQ4j8K_J*fn%@exHPL)~-SXF}A#m5x^3|%2Swa?bRs{1m zAqq)5F8xOup5UgBvay*MOUIf3kZbUMn9`d6N8GWO>pF8 z26Ykf=*q{-%e7buB|loqt5}0nu_}>1W7!Z=;9=>;Mgw*oud@&}<3S;Y%U^qEkjOZ_ zfHT_3g^i$-0Wz7eopm4{{l~D6Zxl?k;C_+W0Ov8c6$~q2O;UMv1Yrz z29N~@Dg$yU!`_nSM;HyU%H^Oi* zL;9srKUlF zc9M(6NF{@SDw9v2vWWFGJr{l>>6HBd!x%5Q}xSahESC1HQy$(bFnk%xDu=p!YmZ zvQp%1Yyv$|X1TO4tcZ{=YDYWlaS=e50-&24myX@bA7WnI(H+W|9)>fdW|3+O9@6`K zQ0Ev}3~N&(hfhshgo!U1o#+icB`vDsIuaeP3~NrMl0=OD4eukP0;X)j`XL@#F>=uSLg|c1*O0vw6*u?Wl?V7VrC5LPkay{8PHJs*z*O5eHID| z73Wp5IiglbV~PqiX=y>c$CeA8UV^XCNzWu6ge9ju%)kJmgs9qt9lluY*@7U3te2NV ze?xW2sK@(?0gB3Op%>N~c>RgZOY6oD4r&3xU)_Y>(-^1ep9RrF-~Qh7#&RG>JUu-_ zbND3aYJ_)*qMBbIpxwS$Hz3-A6)$#T`jN!l5(aiaX9R=8Mg9^j0bY6*{~ATGV9Xg^ z-H?v|Djf<=@qYLxpq+r-kxZ{xmq8uXX>MQQ*MT~mKyeYxLrD0%Qz7C7W&8lmV#jE~KGZI%$$nAMHa1WXPpLSS6Ri4_ z=e~n@YG@Doj;AyKZh^qNJ?2OVe9MoN0-_$^ni<( zRKtrC$CW<`_{~8IV>4Z!c0It^(az41MJP~NBP&a%!OdYJ9;g?7_$*+!K62^q_0s0u zHREsan_viwiZx$yW{haB5kvHFrV}IBARa^f4<^A$R&bzH_WK`4O~czJV7RflL(GzW zBcNx;3~OUEl&huDxkpN*5@yrAUtfWG@oM}dTwnOAXK%Qc!JG3d-^xeJ{^>)qRQ`zw@5`e6+vpe9(W9AA3>pBO5^5XSW=gpBs{A2xQ}f*&!I)3Aw<&3IgTu+lu$9@_ zhz}eO5HmVz{WBwuM=QJ=I}?j7-8;g|DCgdvQB)@^u8t%3O~Rmmrs3qMyVtf*Yk4WN zd{8Hli)X2KsC^r0;#K?HnB_lo0qR^R>eq~IE6fRc z16ue1AcLq7k!YB!XMr*mg3F1U9b%S8C575H~*19RzF4bsumwnkwrO++H zOz-2RO8++NIrx7fforU(lcMXs4YHcHnuT)&?HF%E0Yga<%-_4NIMTzOz((PWBH?|g zs{A5-7nBq9(P{Wv($^ckELG8@sc3D~|9|$o5C%=;ISajhY`JN}8(e`JSpEY$p@>fu zuD?JxMww`9Y8PN{pQ*4NRT{JSH0!Z1w;r~3C5ft#J!Knxq8x6QYK0|^rldgJq~^s% zFeDnz-tM$W+u1`c-I7kYZz7;HKI4@^zlUd}$0VV+e@$KG19^UyYlcw9207em?A%lA z@JSd=2|nQapP{KJQSzxSo-@;{@A=+ayC-CO?;n?NPLrL{&C0_51(y?4e2Xk5XN%Ng zb$DDml4@Zws~)m9tfZ#0sHKmooF4q6Qs|&@faws33|)VN~=-1dMWI)ZkH)c^-8XAK@P#Vgi zu>4F7O>C-`%{h=CycW3n6v!{TmJc?Qf)n|2+}8ermahjoAk)Ly+e9>$^0oQT40W9& zlc?`C-7<3xC_BHe?CL`!NyTG?dL&?n%Wds;gduK0a5ePH`^xT?WYDkRBk_Qvxf+hd z!)5$Z?q$&iwD$08!zNP(_5zMvFA3F`NQd9RrGWSB`0!;ms@9-f(q)whsz-O{6!tcZ zlEQz7icJ<8+{iZ_P>Hh21^SIPh%mfU0?L~e45kQ-ieSspafe1r@A-%qF@ zk9>M4kpsG}-kASe8rf4HEkrpxjICmi`oi^Rt>J9U$lJjFJ0rnBD+79m<4y{=0P_GQ zNV8nBz@L*))t_SOyR~X=L}tD1ol141zL&k6lNWAabfvg#LOJ(crkR za=Cv0&s?-a(e4q3HC1)#t#R$AICmxadJF103I0#B>PBukF)TemgL zdf&nTpZ^!s59kNgRG3AXhezn{Y>(LctmWsw@sq=kN;ezmxxEm0v@uM;`LtGn{GhD- zhRI^Y8L7&e<1XRRj3Q*kEHqI;-yWU)U0I$JNMe;#M2`YX9V#EHvhm$> ztv=e{*WV(T*8sYj5pJx+&Du9+4j|L)0)0U*N?2Xr>iidU9 zPB-vNp*MVz1A%Zf;jOOD@S7>zC&g>0EGzWg(XHTimq@~Ng#H?q zASyNrROOTG3v4C}Z*Vn%-^2sxjGelr50jH`I7X@ntGAJbajk@fG{C9>I)^weS%NH< zOeOdvnkQT`{|Iu(iFIAb|k zKgf1qAKu9~(d&tr1iSTa6~lBNYr)Kvb+yZb|Pf>*YpXE5##c0~I&kn@Kq* zTaI1VG7y=noS)wb4VS}{(uK5Oj5BE!nF_WAl$lDWe6{x@5A9d6NXxCLL+Sdt4AFk! zEa0r_KwL1@b0UaRVs5a;fz$aCgezTYUz`w(1HE^k`hlhUWlvCnr7=^Lo%1^rVRHBc zH#i{L#?C4Em&0II>qJun1ADDXFLJUX6r{URz zqbT1dQkS8PcTW}G1VZE-9ERZ>#3qU(I^he+KF=5@+Fug=fq z57o6uF@~pqRIUDi%psrDT~RQ2vig-?7dAyx&hF!spgsZm5OyRquyb5RN@TDvsSclT zi~ov8%)MO#>$1m;JNHe&n)>d%5<@$_LWnLPc&TO(F{qkMR9yRVu4(nJP+ zwj+Ih7Ak7|li^yMdWbbM`bk!N>oxGv4{0dQxI!IGYNPpFRfh{6@a$;)8jz9#BL9zq zWZlW`s}Tduu+%}oZCR0&fu73hGrAM5r>QT}Ec^K8PSbzAalp|+9~}`6pT`&r?1bW{-V0CW^P%MsM(Ck-NDlwa9eJ(xPqvpl=xs<-)j;&T#k5^eA7fMY6fYr z7b(2bKZGcRCH0zOqyItxPbx_e#?3quoRTJ^(LDKALjw_suQOEER`;&6cCYAt#uVr` z*m7`y&<0UbkUgUa9OEPgI0@Bo{GNHEoX0G4LtuauP0%6~5|qh)Nb)weE-#D&r;0cI zgqMdOLb*#|co5f%9XE7xumdL){=bBk>(9*6Fgpe6LTG`f)=)}&FlXO#u0{-C{-tm< z;n94{Pu?FWP>03?&LUK;fEkLt9C$vC)btb{XM; z`E4Fkl|!jCsjNS>8w7)6y~*tA-6%XIVgp^;(W1UO)oC&hZ+j05Z+pFZ*t4*R!&6F@Ya5_5Qd65irGMkY zVcLNE^^3vYqu7xDar2EmiS`NpvLRUGi$9@|V*-}0M znc64pawI^Bb_SMUsdl8g)WH+cNiq8uP=6X`meQc1H>CUKa;2)0LtO*_J{(~dp(DRJ z2t_wFznFsG1INY?KR%Cx3pp$dh67^1Rb1S-PBcJMd&nWUihfc6S(CM&utQD!# zJ5cXx4O-AZNiWXWVc}=yS3@K1#oB@-kO>63kBk)ZN zlzu^=;!kkz82(cvl)Gt-Gy8wUNwSdyKkLowyf1!&*Z@rt3nSW&fY(kfmTlaEI1Lz^ z>;$&y`O@I^1g#*w+ekdz_>0>R zelgE|`zZV8^{LX9CEWriY(&%2Dk+4269^e*_EMnJAsbx8&rExcA+WH~QQB_k9&d3l z{3`fRdhyQXrJaG{z&I>>DrjhojYK3wTS^b0qrq5@g9;95vQs}mYfIZx3zg;3uwg%L zy)bx8b$XpUNQ+~?-%qey3cE1v1)5GjFy`FEEJFTTKDsPDBIF9;4&BLIe62BQ|L$UQ zDdX*N?9{1+{Wryz7||wUAOV7D#RtQA>-cQ_sX7b zA735F%(-y*_tzn3OYbb&JhFl-bU+=(j~(*J^<*%rb{BrNSIRyk>I8WY{LGx+NDuJw)!Eab@# zvXn*@M$!fpXj6njQ$TE(UreII7{5H{@N%kcMfQ&eL@6lf46C{)=jf*rFHE`X`&Kai z8a`YxIC3RCrxPanIfVkUb%qB*$QPjc~;u1tq{~qCb7;~FXjB}mdy^wVibod z89BLyoVIuxC?zoz{@9-=U`@m(mt2P;K(ym*md3TiS{gLY-+J|HY;SbB)qi*vZ_ry$ z6^@;Yf-W;Qn{MXekOgdQ(ak*a9~Y6f%NXrk{3~(0mY9o(p@#=dE-Ej$LtlEh2|7=Z zpA8KuNm{xQBE??uH+idoaaWNVMnuVeu zHfTQyf6@!8y{JzUm-_Bj;&F6sdal^Nd%p`u1DQM+R57JMP!}2M&vMjb5k)?tcVBmZ{bOgZ6IDsPVM^9QnW;)@8qW;aYFl zWq1*N5%=)3Kw{Ts(&++o;p%enp>-{aY@Xf0A*~9p$>g^5{w6zJTH7RbbQ0oKQPPt2$XIW20<*LjtE79hGIeaO;F!`)V)PaJ(7#S?k(TU^Y~e!J zE?5f=ur6~~C%!lDrj351HSF)Xe*Zil>jS&GGFixfxden!T^F}AIoA=eZ}r-~2mIb@ z7PKcFdwFAyO^;+Sr`F+x1?#olDWq20uQTg@Slh}t9*jcPDLm9kt88++seW0Y2qeg0 zqfLN9a`OJ}ZnDl7&x9rY7OMEpEfsb2a8w{=qfffY#%*#tk5o`;L+G=D%ET3$fW}j9 zQCdA-;o@qV4JIks?41k=r0)dBkc1n4GMe#5$BdNQ`mHzuntJ#OLQ^%|0pGdpz!R75 zT*GIsC$P`bXJU|9&vg-4^0WrxvrY8cN(KS6;CSQ`RbhUx*UH=M4{(>4QMxm73vnpt zeoHhpI+76ite-3My(5hUC-gnV=lbHg-|`cMrdiHJ)ob2>v#vwlS$x`+odDNkflfSs zjNNarQ{xYbncpIMCpn|KaFJfOKkLCdy0 zskCD{}D!d;r!=>=1Q>$_Bt`ZK=#E0Dk9o5!Ut}p(wa5-9PoRuQWaj?h0_-;~i zoQ{z<651XKdtLiwYyjh9m3LRmq4NGL>G99E`@{7{kK-~6BZZW)QWY21vNg)yOS^Sb zs=2p6pFX8!)3Tq&fx4OPd+;CW6&o`^ODAl7W&b(4e`GeoM8VO_4=d##zM;xLgrjxVph_N6< z?5sdR?)f<+iVlYoxh#`;3Ol|&xs<6*s5AXq~)om8lzBY4OouC zd3BCjv+Wy(9!SZ&MB+^1%)&PrK9ATAg0)~hBU2QYDkwGb#Dl-rHI0H#tGHbir~oOk=b`AvH*pxD~dxuU-$?U*mR%w*}jngJC} zt{ltsnQT+PSS_q_gC5BsNny>PTkJu4$C+p^pH;T|x}I(F@lRD#@Fqj&%Ok4vb0Rqz zmSn2OaxI<+@*h3XLq!KfFGB_dpIMZ*zA@_uWgy(td_bXc8h9`p<~q~VMuks7{MmEw z`t@d-?8EP&PD%p8tN!f!J2pmmf2Yq|2+80XI z2)WDHaX--@FutvAHmS5M^uE#TtGi3xhgHgi{onV97J6P3hh#9Z@2(%u{W2pu>jfgE zS6>`CM&XA0I4s^s|5V61cC4p#>K~q%v@;V>_$1yy_=Jg1WrqL26Ts>%n1bvBnPEt% zMtqi_v+p71WOo~LB=x@SB=?w%b zDwv%mb&bP_i=9@9Y--^S>}`oM;vYa4X{9&%M~A&=(^A|c(y8Z6e){J$A3(u5r)1?` zrjFIWV@=?eB-3&EQw_LAJTKT|jU2SS@b`$FirJ*(lWCf^akzd9ro z)&FV6%---Xfi+kY^3diQ+hA$*q)&KLuac@pq9ER6dpMJ8<5Xjf>S@|6Qm0zyT_i|J%yOozU^mj zGgpbhcw+z#_4gG=O15n2KTp3yq6kY5E&a{JQ(GryCe~r!mSc{5{(-GZO}~_cJ{+7% zbKfEGcx_F5-ZZ^&4a9`4M>=HUs`vFoUb-vyWLDaAej$cso&^;xHXf6b;W8+M81{Ge zMqSBTX`V{#g`XZXebNSxZc|W{{JwT#PwvncP(8cZL@456@$lIbahL^hIwq{0r%uRr|hZcCE{Lxm}=gY7;aJI)z{eR2@{Xi z)J}!JNM9Re&lU_X^TN4AfBggreufOSz?R}hKd6sXXMVqlLM4p+G)Rw`7ugC-X=qUL z|Ip%Lq%pbtTFy*Q#Vw%=hb(B$5Ox+%ND`CdID;G6I}ATGG<}_R&E{CzxwfW}Gu!6I zScz1%`Y&!(&>$zc&9Px&zZ1jULWMHm+P-^plBO%$^4Tq)@!5;X)&O0l4A9LkY1|Kl z>;=?}yzJ{|Szja(kW=`AypSGXy#yuevEQ+`;HK^Q**m%Lh&4QVBdHZsubRzM7H;Ru ze{R`79Jy$fAaEQiz+2vTjLN#ld`8NkE$fNP)l*HU%* z3yI@V&%k6z{_;}cY#Udw2%eyYE6buOi7%n^?aAe2@GnpO=!h8q^1o}(l2Z%oZtcud z0iEao__>DQn4hACz`RKoo&m@yJ^qA-1VsrIRA zJBeWZkTsh;Q<56D;z`Mrb}Dk#knbO*SyX-fUxY{42C1(hdk1-O@I!q)p2WDnmhxxY zm_w|8V>?_rVKkJZ{#YYAnB3d;6#b8xcYvAOnFU?;e+D@-GuH2%XJb84M=A);j=347 zV|&|BCCDZ?nz}lbNk?j#>6S^qeB927C$sq z85B72B9#)dTKqL^gnDnz8`P0e>d>8Kf%S`|i1FUP|6t4(4|c$?SpM1%OS*GX%s+Id zj&tx)-b6-%$Y8;=&o0msuHNbLYeFV%Bx+p0cZzLksFFO!s1Y7AELR&tQ#?t5W*8swmIB3e9}ghJ5x+YvB7u*)niu#z>5<}- z61afLEtf9EIt*DffBWT%jy_Y)ZqL#fb~s<5*1iEK^E3sohSnU_39+oJ)h@?WnYF`l zf9tUqCDn%<{GCi@SKiIc#GNm66xQgc+gR{y6%>$c4qh!JjV;qD&|gCSR>iWz3_%+6 zYd976d;gWyZ~dv68^N(G;>8{2EJ=QQJ87u@CKDHf;7wOse7)#6csBx<=#+Mji@Dyf z-A{oc$#>!z-vtNq{m4Y)gdhdydb-)ZVU-W;9=zIy?=p&61n3_=oT@cFckVH1w=rBy zFe7Cv_XZC3HWkL+@M>EjWuzD8aEBTWF>iieiTaf=*A=NYrY|FeZTwRRzH2!H%Gdoc zT5`5$&LfNSFwQ}Zij{=(1Ib!KfA%UHjdWd{sc>RtqNEIJm5T9}vAty|FQ6#7hi}r( zPSJD1YMIf+Xx}3OM9wQelJeF{(hRxfJ@3q9s6We*-~P< z4=uRQ*0h8SqZJd-mT4>hX-^|W6`C%SW05XTUA;Y?!o*mB`R+;|CDtapTI z)UMv63=yNgG0#DC51ZxguAO3q`3y96cMAzT(ti;A#$-SntC?_^xXl~;W>B1CD;A(U zZK(G}!ohKJU7foC&9*4957#F1J5#s_w;YhRu2+&`sqch_$KSxTF6G(M(D^a@J!+_z znOH@XZ#&oJf-`%tA0C4W--KMcy5=@WhAr0Ui0S^b*lSfJuffF5ZegBQ2Iu7;vLPL^d8bEun zgTpdht#k@pb*{294SE%^x7ojZAn;!Xp;V97T)vA&keKaTTTmWJFrG(aYaMX7aI0qI zG42|MHQZps0@}zZW&5TQE?}kN&ey8?@WefCn~=UMnidwDxy3qI-Evn&0|_j)@QW#^2jnRlkF%gTue- z&75qo46u9$%?FZy|DR`klpYt^+gI;N4ZVzqRaXw$iDi^f`<=$r^m(9*Dfe)UZFPDN zPtCozlal{8BKzpKr@CCEQUdIOpE`8Mhx_I|y1uVC*~5O7t(*BD=hdCH*0lMx)rm2G z$E~)NAGBl>Xkb6SJ#JndihCIDR?DGQD;G2nF%Us^d48i-3xZNoFHeyMAHTW`M3wHS z21KmE-jtIp&QKE&%Y_-8QiObzdu)P+&FH_wvTM&Ez?!ow4!D-Fhf9IOH488|x&- zH&$Npwp62_;J>MfW6Tpd9ygiU6{vx<=bTw!ZLgg>yRht>4HSFxq)> zLb_kz_a19dQPO|cM)g#@3dXrnLPgbKbA+;LV<1-!%DhR?a&`$kVd88zuJYziN-AOu z!(igHr&Qosn!#h#hhW6wsdraxQ&{7{mpZEnM}Ms};gWbJPH-PQM-)T#+J$AJ^IykO zm*ey#Qm@YO15VNs{b1Igo?7m$GGQU2)UZVXE;3V7Q##h@+^3GXWumqxcMJwR8&fw# zc^ew5kXs|vkT*nhxv*Dfg0iv$!zHl&B-mMC886y>y;b}_KI|y+Pc-}AvOfG4Sc8!P zwnY2|zW$L56~*^AH!3Fa*JCGsv-2=!W^oxnUIC(1A0Tgtv5B8UCYb9=Y8>ARI%ZvG zLzNlIbp=24ejeBp2LvMq?*k}`63izKIYu0)EBP?ax)(My%ds@>K|4ZWKo-O}n~0QO z?dr`TMIAh1B-MQjU*x-j5z#ztWICm?W=U-?ru3eVIT+&ZcfE2V9(?9gdGAXydK)fR zB^0T(8zp{uJTMfFzlx_X8w+v7`b+?PBWyXVHP<`VkCdOj-^|{YD!g2sE?6ANJ(}^8 zX2;zu6$=DpG+E?Y?MSW)8{Qx?gB#;)KxX014t=vaD`TJ2n;v&t|D!94TmKxju^JPd ztW_FvFwXVb^a(xfofJc5#@w_=kafUM&?1WmYDu_hEWd(1XFGM#f7)pVPksHE4+Qt9 z_aWLJhI18Qm=EfBXAIhZAy={OTB!woP6ge65f=VIzUXl(pFJe$Sfhs6Cj<#xoBYG- zto`xneSb;0f10fpb0}8vx$;9=4?c%)K7o94))f~Wg*k*H+J8rK4~K|jVq%qYoC~XC z0%>OAtRhRH=Z{cF2OHHr@UXiQJKst~KmT+@bL754U6i87z-D_DfJ2*M#jhZ-wAgTD zR=inKhLuJG#Jtt-Kq;#Iw7 z)iB<>BWKLd)2o#9*V84V;)`#-=!ULHg6CJqnMJcg*FV}A72fV=WY|a5m+F64cU`Y4 z8qQw|%Jl)jZ(Ef2_2~OV*sUAGGXEm?R4X6mI!(Ovh z4EeJ~qDk46-zcNp;+c2;+X!eeA}Vj?o76yQ*ts#%t+(ntKm7N0H2r$l zzV6}Yickgr{mS;`=%)pKgByCSZ2PE&@?PEvE!BsYvf=F=7-1l(wv5=u_L(L6iAcDy zlVbi+3x%k1)Km~AYcG32zSc=l3=!!sNa1@%H<9;ufG#uGbXa2IG~l$M>~P)5r80g zdE)Hsg;IM@GI13j7~uokj_tG7Dlm<|3p_QPGn{jRuEq#sY||wS`xlRoQ)QjHapNY1 zMdZgw+4Dz!xUKZv)2q3SWHjNGh5OD~yxH!4FhLJTWI{`zcH-PiSNw~3>+sSXlVu|9 z!WaYf{j}zj*-#{%&^>i=1R5}C7Atty^Zg0!fq&f^p};!^D5t7_3KMMl7eKwoVbziP z=<&ZgyBHsarC`2&M^Nsp1Yb9aGE8LZ*&|Ht8HfGOw6SKAq%f8^dc4w?CYnsuMFi!+ z?)k@LB%R*9I3NN3DFI72OMTT&I{XHahc({TMd~NysuC=0y};qY{eL zVSj2jBQ1UIgI{Ik0J1L7qpD0aMU4;MvqrVGS*4cPrTQDEzN`f9IC(hy+@Nd9x|Q^4 zQj{w~YWh}-H}(VZyJ6J;xA!L#e!Ub5FpapQ1k=ggU8}cl+OSLiUF88C9&Q3By)}&@ z0v>t$DWW0+Cs;4Y1>go5ReER|YmmuQJ(9fMGU%QDdLT)3WEJ)4>o49L-DXJQTaWlg z$&MY^Dhz)$b9Q=Wjm0kFGIDlc{_>Qbj@I)v`t=wL+{9-%5G0$j=+UAd-#MfdLuXRXoO_Ai(~|LY!E65t)o+*hPGF(0X^Gh<{bJ zDf!w(JqF8OPcr6Xn+#s;%4PgS5(+SE-iq`_4rSQ>rSG3(!fyNg`?Q0kkYs4I)LI@7 zA%&$9xjDuW8s`%!#5JVYN1u=mX);N7P#z8V+oB6l`W4dq3H#E8M@svB@DQ{otFw7Q zIx8+2LeB1-)%Ar5fTMuLtBZyIRn7E!z)Xj{cL$Y{?t?E?g5Q>FDUx)R!$@)p;?9Jb z!`3*(XA`sxuJx9HfBKc9Y{d57ahW2*DCmvgv##yhKc0*~WWE0qJc;v)X?{cNKX(>T{5No*=pmX5j& zFi$#$t2&lXM-VN~zLjU>9&>QcZQEIR>yY*CXrsw_K#w;1f;BCMeSFCBzql>wYkDB9 zcD~fEu50-WJ=SuAF|*}7vS{Qy$Ua$+u!MJP5RQ5oHJwC+{dK&)XlA~*3W)o&6<%lu zcasc*`*?Z(dfD_Ni{LZGsbl0m>X(p~|m_kk)SpWktoD90K#jsmb<1*>+bR?XOa`fhf;4npaBiWg`yUO!RpoK2RZ5bsf?WgY+ ze+Flg1sScO$1}TfMk+K9J;fonVLNO$Ai-V?&BNusZ(RokIU}jSv?}Akw8oOb{M2$!!9~;)WwEf_pr+6q;no*6{6*i66dWxjF2<_&d!uL_orIkV~UMb6B zy}+340`u8YhU*+wThQ#sGEXZvLt=?^j*4|5y;3@X6AFdV)gyyeZl1(N%rIDN1d^sY1s$a({97 zs3DwWn73uTsjd*^hdkvCud;{>KbE{Qp9h8EQzZQ-MNn@cZynCSs?u}F13=^99j{XMq6}`|045SoRV8F49EtCA0^$F|wCk~_=re#D(_0bWE)FN1QJ3MRU zBl_xgq@lOYZcjlJ;jh@p6jpypvW&U`D~Ike3dHl89FO;|Nf=X=&BObA&ow#ajdhgK zf+MxkZp{Y2iAu{n+`EU7i=lXIKjjpVb?E?x7pVCi3h9vY{CkV)u@x#H*Pg_~%@abQ zU`r6{#DzIsNKBjMW;%gyzKVQ{YW_al?Q+EWqLTcJtQJv5GI82LAb*{xz%733fdTiF zl><-)TJ^hIpb5mVgPj_g<>tI|H|cDUh81}pY?Ss9>-0t!iWk?pn6>bn+!nd7c;L-` zBHA)~nz{z_78N*#CF&%!f4jg_H?s_%6qt%ou<*a^1wjiBcENwA zfkTY}SL$aaYnUv?noa5R?`*$4yQfIwhh72Kc!wqZT@R$NM~cms0D-LtWRcYiNqg0b zrmVTL{8gvR3|8QAk=jMO>BO7e{;GX7j=7WGUFAzH(e;Hfe%k{tt|ffi!_=d1sFji{ zyn3c&x$9z%hNhCn4HHK2y1yk|HGUV26u6wNY}E6u*49k@2M(jioSav z#hy!D7dU`iyoxF?lCVH4&!mp-FoyqSvd0CM~AGIVb z4Q7oS>tr?2?;0_@1Voyu-Fib8+;Z1MiyRcW#RMQ}os-iAhv9?IFoC^-BP1z=bXigE zi~T`zLl0`hG$ui0Yu-nlW#w?m8gdMKxwX4QJO?t5xn$idTeeR-u}aJ)c(`>Y~;)-fva)rc5Gi1hcQP=yz-~d7y=U4DnI-*VC9IJ$;hl~QlAI*uU2y;ocAHZikT*r>J<`@Cfk6w1;Vr(%Mq5nL zWrN2B&H<7N1YD5jsbi@^3G2L1xvKbN^=a>G8;~Io;>km-zF@r17Wn9p8kFB1KC2a< zNWJOz3sy5Vl@~b14~F~8nm4riBTciFZ^j+0-7wm+gKg}AxD2R&Md%x7@RrNEsoLKH3b(pBD>1L z5p;r>mdGLrkAL)9Dk!=kO?I`M{9=Vc0LS>rSrHg<2wR4)%cn77X&%w^J@*bK>D%26 z{I+NUgB$2aPN1{>g@IQ`h3BF@j84}I{!(NiZw^Tlh zNnwgiAnfqE&fV=K6aTcYb7C8ko}>bcWG9dnh>FEbf%(}_w6ct|9L=hgZyr{n)!DUB zLw?xRcJYb%0sGdrcUGi=z)ph_qa0;yWz^pUb6dkr;@RRIK6e3L!VjCjH%Hkg$Q#pK zSH}mOAD&y6!jk80np?RuP%4@Ykoqd_+zMa z_e`c9$vR4mM6J!QhfM|+2W&F7?HW>L!`kl?oSD>AZR{3*)!liuuZE_pR!onyQpJr3~nU>2Z<;^t0_f)Dny7M=ZjW!kX{o zFM8_*!&@RqOe~Y6m*O(-J&ZEPfngiOtSmi#y(%0b|6q=?4xn(`x;i>wTAS{JmRwfO zclVisgn0sR+r7gzT+?uU#02d&T2jlRm@DUdP01$w<&QZmlr9yItJd!g)9JGvjoxDQ5Z%UqwWdU+)hom;^Y!KcpO3 z2|+?)8ZsGK!DULR&)+b(z=xgOwbY3BVPHN9%Am!#U|k`fpwkhM#O;zG9QnVu{6!{ape^^s@60kJgzazX-9qbkcWHrhT$H7C_ zI5KNl$+XuFoBLkAIeo36oKW;rh(E7+vj*VO&76ZEFf}OnIN){vNu)?*0cD#M9A@Nn zJzv9?EoFy3HrlKJQ&qT>w_S(>!#`~R2$2)IxS)kIRARQvYmMH-JqhiCP1n2`TKK}%>hYy8OI9fnzP;>9Y|B<8@xC8><;q0rpfk8lp0Dc zl37)wkG*A!E?qrGHW>}kCXmuB6UgObJi}i9?Z2>#>;qMU6JLwgzmCp2X>HcY`T^gf z#~KaS7mlJo?wg3N(p9bJys%McQvO`0IM%EySPDn2`;2h?kym*zK~e@KjNBZrIk2}q z&*~mu^C76tGp$@Rv}!q*(n3`n0V5{%i*PkVs5_n+)^-o2`Fl7&;L@LZSs^pqBflH_ z{>vRVgDv~w&flr)83+QZiSlk>w|h}KxfJ00h_zbkezC6aN1QeO`3YXt5(zAeoOG1* zpml)%o)4sHnql>UG)+y6B&+cF3VyEiroxd{_H5QYKKi6qP)}}cjoW`WGLp<@qDUIJ zky{nz(rSr38)!7wrfea^IN0V(`U26p(tw+B6~ zkSvP14Xf8uChSKXLdPZ}>X#Ws$JhM>PUT@DPETE5D1KLQmcs@p}2b;IaD zM2LSf0(=clkF&U=29J_eqqw0e>m_~sXfO{Ti-}LhI*3>&s;oH0zHQ9Ruly5qjPod< zXjXEj6E*8_j9+kut{^Ok%Sk!8zX}!()JO06?dWd5msiZA>w8h0y3+JJ)V@}FwVXvk;yFjc%mt;! zuvr`@J(}VTs4sy+1?FQk=T3MXK zWBb&GMOMnn8KTN5*PN7XL!Oe$n=Ll$HOno>pk=_CZ#lNtiiwYeWS3-mGgI3i$q>*H zaq{s^ycTE4x?P_xg&_cUHOK1<0<-&_Z+9sw=J1&8DJPpjv<(jMCoG1E0c136i+W#i zBmVQUKQ=9`Pfw3J#FlttLB+zBmBbnF?RK?dd}0Q`*2VT4Z}ifGr{R(p60Lnn@u=h8 zKD+2=70eL^n>z~s7ZG@zE)@a-vE%lP?8GSrQ-$Z=!xOZ!kIFi70EjhiPcGpn)*ygb z;{e1OM?G+OH?0qE8>5Pn^tUy}FLRa%4Nvl>OlYGZ1< zcDSL(FM(u@>_GgRBRz=@d~G4J0ur&958Vtpshf3%Cq@T)c_tj$0ZwJ|lNFuKW`ym7 z62J3jrD3M}lA1(a&M=nSQ8X^E2-vbIp**^v-7&@R}y7L6+ zyNRFyg74in)+y*!W6mr3tkGa%z+C9@$#4b{Td>Z&=p22EGH+6>h7Cxqq~=(+iA7XE=H}C&cPT0(w9{^O!ej<E*rJ;BQ0D|T*ura}W!9B2!Nq<;(#I}NrZH8IDYuR-u z>A}G7!E7>P9uL#iN0CvJi#ZO$aLNf>DAHJt>#^59Q2n_SmE)&rn+_4O7Z4m%Cf%Jp z-4eB6cl~O!qz{oQL=d2fI6=kMfKL=pTzE<3_34`!bx~9v`d0Ht@v26b;@ELp)JE{3 zeThE8D6@U?mr(h#iBV@)rr=b)ormuQD;}693us~mX(9vUJI~s>|9ngWXP&~exZa}` zHJ&;dBLX$vF$%3m7&~kYFzv^?HLSf{afmje(4*%&x{_>Z9-pp*)r!8DlqZS+c0@ET zuo8&#P7&X~=)HYwpH6n|wg+nG^!P99$er(0$N3C2TxaRerjqVJRtg>PLBIR)xOR0NKkeu$tc-uR`ge+!RCNA zPw~t20gkpoUfu}Jq0>OEXs}er_}v_@?cy6BsQjNzpk}C=PizFR7?{rq3ulr%YNKL% zG3BgQf;>kOtk7Uo1k@76tsHo@U$pVtMN4&dB!Ii+J+UXbDxp4&Dby>P?t*eb<&;Sa zVDD?wen{6L>m&9>BwJh5qeHkVGi&^@mf8Zc8! z(Qv4Ui3-Ye`S&p+mIO`r`9bXBD=^=m{Qomk8mCJDV{!nF@*+U@+5O}7L>5su*(=CL z)7n?tz(^?G4H#*4$CwaUE*aXrW6u5=<|T-^?bw%&+L@?HUPRyofxdXLmA{m zzuqz>wm!BbwvO4iqqR#u0R1X{zchLt#60Rpl1A~J{*l1XA7YlFEZWPdm~Hk031Vhg z^&u8Uk(`B4pElcU{XeRVID84yhIn5PVpcd>J=A?X$BVh4EW*$`z(UALr4k;i#%em? zT{+B5{JXZ9t?5&)u37E^_6|YW(L*_D`dW=qYf#Spj4TM$=(1R!_=Jl{GMguests0=*Ddi+tO#I zw`bb@Kihd&XTu}j3&`!6*9uP0&e4XcH-oiiEc4h6yMva(q)W`!jh_QMmDZmE4Jy;r zKBg}Gc$#n{CE2NqNg^LdoL+Vv9k70-uYvmhJK^*q*z1@tH?3wFUS`B^{f&6Cz6)X* z%~{dH%>#BZdh-#K zn78x`fMobjS3!{Vj{Z&yTfn?`f;;tre-V*6FHi93Zu73Vg9o`KBHQKbDKWTN{BB7> z%Q(n=LwT;w<_`7aiIzTW=)P8W@*f8Mib%GnEkw!SQfW9|-fY+97}atQSaeBmGU2LF z=A~{u4Vl5^KNR8cKP7ItGrWQW)L=m>-664e zpfpk$wL`(%xH6W*FX*qUyHi*X437+6_)uBO=+SZ3QjnQgmMy(!N&jZsRO>LDesd5^ zog1u^<5}o@CcdDC-yIu127bm zANX-Nr!Z&W$BFFAqUwd;9|CV|Ip+IJnrY8>ij1D#>NUFpKfUGXh!F;?o2T0<4f>+T z3z~%y=Dj|B4gHks4yG|ob3$#4T6v?%_>CvFyA=E;l9VS%Huru776a4GO4J`FWI zPW?;RLo8U9y3Px&%o&Pr9nRNpjst%EgHuIZ?k&vOyA^%E!FM6^0}=NB3-e0v4Bx$; z%G?$ETz+_xhI~e11H8tM(sAz1pFpHn!e=ZCY(U*9EDnaJ(VpSkw@k)(orUwaTX%a; zjl(-1Sal+tTAICY?{3sJl(BS8?&5~`B|Tu71xE>ViSq1fO9bQpTrf=$;TXqC;#A{zL4Y1rC!nLk5=#m1!l8q^lRXIK(n{$4Q%?XhRL9 z>wyMe6&UHea4(c+xE2y%VOqi$1+*O?dq=$=OAkgK&+`7&18*t9wL1rp|5&i)n~8p_ z@dYbp_DxU>0A)D$S3KfGV$dvrma`b@oKVhr0`i2#rOP)H@`oX@@k2j>Ob)SR&xG>F z+O9?^gn=Z+P=_t?dnJqOQT$p`>H1b6E6 z4!qac{yccJvO6|9I{LZGJEWWvqBkC<;B#v=g~D!S%CK;FVmCTnQ|vl(wB!j7nD}>I zUhs78aem4Fbi=|oL^!_E9KI3+GO<$tK~O1KJEJhIN0HPqiEfaZ%No7L{mRA79TA9U;|O05CH0J5HFL#({DleYejD zeJRiRo3gaj4;g-ztNmesl2e{X1+@HWHzX=YAn`C78X;lb^pW+gx{2fvG0amEo#as!EQ4% zilv|9c*'vra=;~m*pWz?`zOVXv9=qgW(yg*447$4|zsNvHW5(8fb<=Uss6x$aN&Vi+aa_3X`tV~qjOY;M? zcbRb3M<5!OYN-4e)E7(4P)g%FgDdw|kf!v9mBR-?2e7e@*XW&1OZ&`D0q_-QK5lJoccC-rnhxIWH~R0+vpesxPw9CK)Si%$H^H9JtMb9>e+Vk1 zIh#V$e5FSY5nkz$1fsJ#DG&mP=BwLxY9k%Y1_8tom|RZ%W(ItjXrU;89Hl4zj~rzo z2D<@Jx1((k)QVeMqwg3apFr8EAPUG)jT|=q%z80+1iYYnXC}g&RgF)Z~#UDILw^ zRy>mjV+5s4x{tkT8zIAfjxrlI-`3ZR0;2|)SPBkyO+r%Z@(*uy*-Td`E#heMCSaS2 zAuL2^fYCd{-f4P_mZ}n^RMsBq|La~%nlBjWH32YzvD+e~meh_x zyTG0JF`gh6AS^c8wp(jRv`1(-)(Iry`oA*?Q}8g!J8yga@OX>Lgu+Y~ZRn~BG5jBg z3xdfpXFSf-#=VH~*hKd4~s-q|JJFWj$~cNl2fh}oFjFt|0Wo~f#*wTo0p zH1jRiNOvIHBXCfikHS6ZezlknR7DM)nz`<`e!RecdB0JS{x~*&YI-ub&c5I8^gT$l zLzGnqp<*0rANN*h)EZ6d>Dm^f}6=YV?<>CO95@r_N&S!4f49eOx9<0R?;A=o znvJu5F|0hAe}6%c*^!zlT{_!;=(j;#MP5)QBt>GR#3ox{c5iPDhC4<~9PuprY{#j= zBTI4pqU_*dcuJu!9U?5~>J%&#MHcS70?Qf0V4rLB0TfHNm@}HPm#OpCTh%(T-e~79 zG5X-eW?cv}%B1&uR3@5~U)J<`E?RU0Wh)OwZ@1GDVieT{L5~RSulrmyf z6!A6%WYV{|Ir}7vTF|G|0qL#QH-xbSR;7-MqtF0Q8HC7N!D@mqzPkfKqV#s0ze zAt?1l(rbkZQ{R*!VS1EivC?2B=m40BCN5n^t%N4j+_UKBJnHzFUnA{Ls)QFIz6A_k zcMiPyHgW(^`VbU(X-QDeQl6U#I@C*JIet@qAx(6W&$53t>F&tIC4qv(LG`5MX%KIg zUwn{m(@DRf@RaW4{_e3x$)Cr8qy?;mWwAkVB~@2W4W6jOuVe3YH04)q%w9d=)Ur2xDv_G=SWeEoh+mv=ELl8o_}(!LW4T6lh_Pgu zst|?m5T6veisQS>3-8^<9t-#n5$W-PLajdrH*x;9R9N&yxHqsSM{i&JV8whrc7@o* zG|PIMJU}=rIrs_?&PvX4l^Zl9S?FUeMag=gWrpl`jc&`&Oq&(<8d=sg%O5sUi1m1H zV=fbXnrz{dGCtN7?mv zt6{r)>}~AXi{8E)m8>yNP>Qc0(ap%fQ*I%RE)6$V=|b)+8m8HYK|nFb^JO@@yDM6C z?qoRY>c#$oPp4^3&wzFoeHa`@t?3>F6xu?77bfW-XE5Od8gbQ??qSkeXllZ5Qd77< zKD@{K{r3lpjs|h@BqOVdXU6EaS5u>EeZKILI1^rmdMBUr(uLzqloC$}ldVT`0+$e9T z?G#XDIG=EJ^&R_r2I~!qLfL#gME(Zuypw3laMW(NB6yQ=igN~J1elN*4XSZYHX>=$ z{=DG>-LjH=+e>0B1LJUm-ZGOz_JjSb=Ygk$L?ZAYfF_8=FqoSe;h;rV*kV5%BpA~W zsycrlg?4&YTcAO3MqB`UfRqo|18k5m2d=D;Hy)Dn{-xFBgi{NmMH&ZvmZQ_QMiL7m z{Q^*&qJo()0c4?A6r^G_9MNQFpHAkV8EKglc~bX%@Lnux@YIKqAL0I&j3Quozt#v^ zBvF;=ZRI8<)Y|S+r&S`LGyj8?y7tzj?}BQjrhgonn-sVZr~Z5-7~4yzFGo_6;}bs} zpM5?pN}zoMj$AV5V5O~daR+L97 zgTkd#g*1l+ZPN^8OWM07x~Iqs)R6m|ojxFtkkwqFYO{JAlu{ceSmb8{p{*(Ur` z65se&BHlHe%09)OAB!5N$7hLztMDSNusEg7P%bI2S#o&>og&tt2xm!23H1lm7#(lu zxbVftTd8_tht>oM z-XNnDwZn~?{P=|Q6xqfW;Nv~JVNRy*LJihq-A4W77T4nKOH6Db&I~8a=Q8@459{N9 zJ>pu3Vg;;!xol6A)t}FI+zs%4FxQouZ0wZrcJ?u~F^b;0WHCT#$JR3rfZqCJpgj_( zwY^1ut+j1xDxbMus2Vr^N^eu#`PKO6Kcrs*a%#QYf_N!t)?teu$M6tKEn{La1e+N= zKMPB!hAsuNq?K>alvV8Sw-~Frq<_P-mUvFeHv0MC=Uy{QfA17tmlXi}JRd;x2i9$- znx)R{Lj#VcWj6P30z=BL;c|1~*rX4(7TBb%Mqplab=MO zRiT=eQdcpd{L?`8u@9D%w2wXo0yF?gg_RXshC`S}5yH667x3-F*UWPm`srx@6-t;F? zHnq(Ui2dBm|0Jj^@VKINj1k=SB&GVkWI-U8rZhR@FH%GtqS*-uJp;Zk=r-Rn><4(o zqtrR#;4@|#?cQ0_a(jcxaI(bsXx7^oGlD}hW;MMSxT`eobepC~N<8F)!7@Oy#M9Q$ zwa?L_o9py?JKREtF0wL6(G&v7W5BjU^NuAuxMYdh~6#J<=BcsCIJWH^zGJu7fhGB%GPf%)G{mPLldlsV;cOZ1-C>AGLqqjXv6seUPp`J)z0a=|5Z8UbkgZ zId8JU0ByWAt5%Hm_}%>HhLjAJ$u6i83)cJDpP>y+QWDyCX?y=0#d@!7VWYHj5mT{H{QrXBnD zi}tf8$?0*5mbj^LS-b6`uPc(g%PpN_gQ6cYJn_cT2!TnzB=~G=e0qgsU`jxw{K4J6 z;yXD_36iguLN;Ec5wrA^g#=tOe3w8Gs`kgQGWZ(lNFr59pg)05Z?%>r8yosK(DaWw z@*qxW5OPpJ?1ndSMooITx*>yC^*MllD#i}(-*gHts=XAHKH3+=O9P}tZdcd+OOa4y z8F{?^3PjLm^T=VCD>?216_^E*JC>9*9o-p3s&A6Kv}p8Jkpl{vs8<#F?~$x>-Y1b; zb?M+(+fX3$2Hl~lpga$n>1J#l?Fz{DF=J1Bs2 zE5O7HmXi4TxB|39lGpOjIog@4-ZZ}bZn~UNG%T?OqlaXU7xk{G$>(xo|6Slqhw)uJ3JS z^%S~2P63MB8kgPQ8lWh;f`q-lZ~FVEIES%4(pphtl`b_~jWhc5jOCVdkTs|VrT^>7 zO4d1jY_9RjTIvc1l)%;a7`-Aqzg91encl-g5a>~!=)z?{9m<)T`ERdIz+TU{?YL?y z32CEAEnJeq4j!ETkzJ2dY{g!V%l2*UQxt7M`u>y30DJA6zcekzHX}r5>TNV*dFdQP z1FCWRvOrCs@NW@uhy$KW2T$o}k0gWsEl7$WHFk`zngL;#XsEY&DIA@8pwYVwbzMvA zVuw~X7frn zZ_+!r2BQ>14aS_)>NJZsN2=`J(NlA)gHdp@x>BjO$BI!YBX)@-YBMcq2wa76G3}V) zQ~sj{?tM#WNtlqmLI6?C zO54e28+rBpM=LiD2|FAPD&%{A0%FQlvR!5$JrH{$=Qcf*Uezl`4{^hhSDA1d(Uub+ zX|}ODzUY{1U_#i-nETX4^9twE#{|U`VTlBPAECH8haJP!P;|9;ze8W2GrMU1aLdi0 zcQH1AldapvI4a{Y4hS2U6%2M8A4KXAH2M1l=^(^>kw~zDdtRXg zV*K5oe_WH>{Tb8Bcl&|)Ab35u5UtWm4s=2@R25#E8 zh!Chd!Ug;AO7pe0VRH=d!=#8Wx~YI3C%6!dnByGB3X#Gr9o-t4C5sQdaLqZ2?bsix`9eKT)wF_xzpqK z-n*#iBpTh&M%uWexmD`%9&A@D>M7a8U}~-sPNWzq6TJu|T%;D?cX+4b8&Wfcr2~0H zJW_JV0YHiNPuL#Jz5y?K2t?o?ClZq&{tSz#IJb3(86>qPNAdw3;9XyvHT;PA_g5Q1 zoJ6WC-EGU5l!E#uSDGasV7WCL?+JFeY}#r$4+;jlI1hF}-Pu)zy&w;9vr80Lx*;g7 zIP>k{THukg*t@w^I~bcX1Kf-NujKxpunNE&49}$q@7}6l@l4qwyYHW#!=Qx-zeW`L z#cvV4iIMNaOa&wkUT1Ne3GE@BGmCn!>OS+PN}x_u+;Dd5LRVAbKbRsn*P0#{%ypR_ z?tp^xsy2H;;o@A^PnR4hgFPnn(09r)Xmf3bC=s2r%7kc0Lt?Lp1p9;h=4zz?nZgBey?yP2coX}2(J3(_4}<+Q~K803-z6ZQ!KEaaSskm#Yph&Hf}W!8@c z8yaaWD7+dmD^ImO14oTJ_S#>GBnXuv(@N3b7c@Z2Pt@gerFzIaM`=Wjgp zx|_%=k%}GveJoYton7$d{``>B{^(lp(#Y}Yvm)|b@0!83McL9qHg?qPtQ-;+7SPy| z4T66Iv|TdeUWU)$SDfehq#w|XK{!p)dcs1j-aE<}-`&uOQ4#~)!~zt?n+4C+w^6D+ zBFHM0QI&tBqzI9T1H>qQ%^7iXjCLe`X;7%a>zKA~QFT6zhCS06hS`MxDTrE|9|JKtrkj4|sOrhjYN`yE}{`jaiq z;R(c=q@lcUYoztIu#zZSQ?kQw4k5Gr>%-}#+e;_duoxOLCXx-swKsh#EIJ~t9KsH9 zm3D;Nit>@%V(x;Y=KhMKVNmz*O-o2VNJ|vnl?8Oa+oew6hfQR_Wk6(rV`Z`!(TA~6 zsV&{dcAb0UB0(R5#s0$S8k=h%V!>Qw$o;+0cQ5NhmOZOY))xP3BvZ1|Vs z@Bda+y>hVHhDUVH(0-dr1B#}L0FW>#Iv}x=d^yXLU!H^G){mvY_0*d0${qi6yIxp7J0|x#uv5V!j{M6# z%ZxOc`9O0A5I6AO>6oY~Jm#s{FD)Z)GRCwt4QP^ZF#6 z<6wBs`Zl1+N7vIi0fKq>6*ucZ zf`>e}3iu$O=A2z@Orp-pR^N0IY>ZN>Ni35N&nd~}*!XzGTe#t>{{kFo^6L>)3kXI6 zy^WSasj-J;j#7qy!wN|(n0398HJoCeCnpN}hmoOVeGys7&!{9ODy_n(nI0WdqsQXA z(cfO!i3YbaMG@XLh<1%BNY3s)|AA)H>F{&l`AcGIe9UiIlp-rt`cAIo47{%ebn@=K zYD)Bw-;I)PfC)o-)~ztQp4?LJ_Y9^)Zi%x|3V^sLfY+@q4kOH`)fCP+Bkn>x@(YxY z6A>JI0k0wdW)70FB#_OC&X(0HyE;_VS}FLliR=sRiy-TMmH?Z;M;rz3XWd>g9L$M` z{MB|^PBu>$dQC-KU9nRe##?)R3N-dt-E6(p7^}Q<7UJI%+;X@s8xA>!iN!X@L!GN3 zrG~W+<9&oA1^f+xXZ)9_t$s0@lLI%D5-bc!t^hIvwF7u)k(Ih~Qd<7AJO=QD4KE-! zo)Ayu%dP#QPV1rcEVJpnVzGka!+g^0D(sKiII`?PD!gOwQo@okfJ}@S5^^+vU4!BX z$WY`QHDP&e^pdSsjk6?3X)8n9a2c;D|2A^|fS z$1R6gceivUC~=i|kYlO&+A!s1RZUx5kKj!t;Ji52{go07C(EN|S)iyfH>9u*p~A;T z)2y$6(mYuT;}7{D;S>(dQ?M!L2`|f8`IV`H%|ey|EH$HGDp7_lsR1ueW8sGqQqkUb*=-Xa_ZwumKs&wtd$1a%Uo+)elg?VtPQjq);bW?3sR7rh% zsHlRd<*{hU<%ZD?0=>gzSScAGAEE+4XnhB?V6N@9GVIE~ z3Q+h32W5uj=MQjcA|`$Km^#e>Rr$;yd`YSLyT<)vNM?Ybyo}jFxh2(`6Q>vk-OjeQ zm*JIGRM5tkZa!EzSvj8caQi1Ep0p3Biu`fbKrz8J7zP>0i%Nk25JIh`9wDD1Kj$_G zrf$HFm#?Rb9>s1116K$n%tGFr@QdMAYCMww$Gq{(X0A;TQL+pcE49cfRRXJlgirx~ zC+G6fayzq^C_(PYb)meAm(Du%VZP1z%O=gJ@39fk7X5%Yk^v~_p2!9VrbgC?Pg0AjH}|0eAaK z_gYVMYtr1O^QEgxdEJR3t98WoKnl0AUk-UF5-1gkAdch$g8VzWeYS9!Nh~f$^%OJ) zZ?gg@;TB+E9+7p>Lmvbrmcy45x2%OM(@q)lEG&5BdD`Ct_ztntm7_8F$iFh>VI}eH z+4ahQ;w|{hcQVNe0E+|eG%V6clW-@CSYf3_DIy|A7KUnqS=S~g>8nbpbXH_*h!>*&CT_p$!c|_ zP?VE{)4)ANR(A{EMFPZ3QjN|o3H#`zgLl43e_LiNk)nQ8Y$Fj*4}WlWJp-O3 zkB@q2b8RR*oM!!;V%*c`A1IbSyY8m$Np|+Y#0y*zKq0ROwC?}#jY?0AoV&19YnkOIqZ~6F z48b`vGyy3wp$W$dcCfU8EP{iMcPYqT25B5W#vOeFk1P>s$vla`ga#=Ii_-C@3?T(I z#gz~kRoLozcgM9;^w4_ofp+diQ58O^s$3&XX;dq>PwmDdO?n<02k?#b@*P?^lys_? z-p3U;pD?H9k$`ZTj?e}u%vjg~8YRV0*}$1yMfTpt55 zIvR_V%%pCp(|fJsAtxj@mRLtg-qs>}fjl*IS8Qm=it4w0c$}M|=b2`yxAgs52nZ%ETS`wIN1ojvg-HUHw4$3I1SPYQ7Ry6k(ACU@2h5 z_=rx;Yh*yihOeHiS-D?AHJLRiE%y%VhJB3e<`S+BEM)&6RatUgoFRE~Z1o;HZf-fp zoX?wm8<9BTe-6pffq`_jggCIPpV1Bt+LXfGN8ATPUkm~m;9%GR(ddM)+Sq1C@FH@D z8X>AyEKkgr;@9Lv{w7r*EPtAC5#X@69Awfe?ck)qZ*Nm#Z3lDIw%Za2+LCR~!WhF5 zV{Z4O_Z)Ik41Cp+>z?c|b+oAI9~f-$UpiHEi+#B654BPrQzlBrRj#RMJOqVZbOQ*T zWY}F{ARUn}S;>=a;e*d)Np;Ue$>F(UW${RYsm2!PnGg6MzlFrj<8NWpv<>vh+74Oi zKUVeW?7y@q5OXK-<)v&W{C*S>i?0D;q$F2I2jZ1?aTZtgZbuhiT7&lW??>*FnmmBW z==b-eyt6>lRP!-RzMEb)M^8HZ!K^<&qc*0*U(MR z{m|XQ1Gm0HJK0iK<=M_Qb+Ljg+CyGuuG~Xo^m|-M3q;G-ot_q3=@PEITb z6)7RBa((^UfQd)#gBC9a+;2azB}jn#4Q40fe6*7@N2oSh90_!n7aJm006;0sWn5q> zlCZO7lScs*4w94uA{EvZktb@Jf9(`yZ^p_u?cAKf+_dx)Q=YFVp|0PM7vP+@a;*f~ zVjOc5#beO0kQ4@npcMw@VABP_(WBrT`B!}^*tqlk*onnYLm!;YIXjl%ulSD}KOJwK8p^8h zG~|-nO3+uB5ZsoJ_U%9|1H3HWdI{b);*e6`6g^&z0X(|2k5$oRbB#dEpX01r#7WG{ zs$wNlcuebX-kGzk)xE1mi^iOx{=isYw?RkgxyLKe-TjAhJ|Ie(E}XV5&JLg6--md2 z(u}r*xBVN@9JoPPNTfEC7OtD?_w1*g?`>;ry*W&qYdcomOlkl2&a&>Tn%kp7tESbm zUNJEw@v!gxg&5ds59q?Vz7cF3GAkp^f0Z5F-bPR{<@keV*D}YbObaXN0~ELuVKv#K z6YQ_}jb2h=w+T}?IdH4MQe_|2Z^)8=03^vMTLsz-YyY8K@h}K`|6d==Kr1%vc;V8a zc{yXUkUTn`E_SrDBwMI4m)cT+vv;i()=pD6f=NcK^lVZB43fE$1((|q2g?mu(u1(q zk|IXnwIB;AY=PZ+UF|AB7qZ74Ph+yIC6$E+1Z&R^I4Tn&y*U7&%GmWzQNoC^C@t}2 z7?3)s>H*UyJwoq#qiS| z2WYDGLo*UPc#|>7w(eyF9`6onPm>?+Ja_PjcH~oA$k3M=?CNUxL7e(}Xm?lxU3W=t`ZxFf0cP04 z$hOw%#|hk%Dz}FPx0GBe+!?vm1gU%6VNEAM zl?emU#thiP7;Bl70HIt$f#qo4=l0c%YFAVZ?3tg@nlXCiIUBeqUts$($A-#FTHz3U zNcivzRbj%~FiOmHVA5nWnLn2N`w&P=_80Tf<54tfujTKaFn+-|k$5@=;w}#i7rPW( z?2?BxT#X-SRCL=o0f9v2ZHtBZ%stpvp7Z;Qs<}thhMGBUX>nQXY;?I6lO!o>)X3RZ zCAN*;0%C+=OKsi)J?qLCDCTYJ{ECdv=ikNKg`%lOT|a#7AG@0UBSW4rj0&5}L+p4S_)RG?-zMZW8&Q zq@>*G-lPWLm|>%%+sNdkS{E@F`Qnnmg=Oz4^|->`bbmI#xWB<@IG40*eNC*0Rfms- z0j}y$STF}bO%v*k4%Ie0g$EP*8;~e#&8h zC51SREkuhdx>MIWj#n@rB$H?Q*FCa!L1oRJC=Xv z8eH2ZO=;rRGw3pyptumBlPbv1YVBT}OH=NRjPOyBM=oMUC((cb$QS|9(2 z?|KE&XIhPm9jB=vV5LDe_$Vvse8k|4JYbnjLZt^@yl~o=MIDyDPO$m7aP{%YvUIb+ zw-I@fj51e&O~4y-jax4mjqs-luPGsWc59Par^0&BvXIdE&(_Bd4`;kNS?Etp6IvmvcFv-womRn*{T+wG68x&Eo*jyefwcc*Hfbb z3nk^9qG(M|ro9bLw`0Idmo8XO1Q(>EDFzR%{~x~gf4%5}L3B|IIF1MD`Em=OscozY zFVWqaGP@9aEYPx$seu}pa?4ctmHP7LcO6{c^cjzh{r3+26U{F+JL@aiqvgid@61oF z3w`UKqEJl$^E0hw_UPM-An{9~YF~dHPNGPfbD^an8al@htYRYQ3iqFkgpY-T{ z8HIczZI$Dc_mv>22IA~31)>RvyKKT?di}$fgifQm6R)SMzQ5n}-u*oX`nM0XK7uWHMvV`{)QHvd*}3BXX&>j^CIMl*%VW zV&F2^1`^?-{7?iFrvC%+^2yp-z*x8BKk9{x+Fb){dew3S(qoQ!r~}1 zH&T=s>3k!=%}HUDl$AEh*Y53gZ&b%X_zFa4jvko_Fc9-Kixdt6aM*Hqs!OR{xd&7Y zJ-*g1|MO#BOYgKD&hKF;2Co@v7j>6(5d<#Gl9FR}j#@|Y>{FL^<1<^#U`y4b4jT1Y zS35P1R1pLZ?(o>@;-p_)p?T+w=*!zQ`pKtvQLV2w`8J_E?X;Cxv0-^s3(7N;ppDBQq>3NpXR12=b;&n=V3=^c9gZb6S}XVUij=x+Yed zI@>E#LYVCOIyY(Rtep3c{7>HT;LQJQyW5WNFZ}R=&RKNE!Wu+`w{m`bIsqaKw4CGNiTUIi5`13Xehvv&Zz|Fr?g9tr zBJ`X``X19VVaX*5C8T975rMj-Cc?az|EwjCSc*>Ac3fA}?S$}V7^D}P-ORb#U2$ff zBe-#gXHA!Mig!^UrgrxBvkJ)f?CnEj4ZHkjnc8#g_Fvm-W}lmS{K(cULR^D)0SuIZ zEol9cMF9F_Qu80bveAf=9^ob&GY#z7=vD!Pb4pl39B%#&9>1x^3i?znOq3LX)X4AM zZ%Ob|FT{BKEgGo#4S4+7U#U0!3E(ld|LBKES{b5ajGCIMaPQ?FBQq?HGu4Nh&Rbx+ z1tTB=g~xqebPQ-7e#nmMP^P4D)jP7eN{ZJDKLnQzLHFQK9XQ1gN zv-0`zseXlRan!P1k5C_pv`!yW7KKdQT7hHeWU$18QC`e60qQoY=YKE$mibgd!?F<@ z>X?2}yTk?mP9X+prwVA^zn=XzGiFA{*tbD?E|3ll^SAu>2P_16RIIbTk^uhK3}q%`p;Hi7Tvp^^%1B4mLd8{Vv`o>cr%A07F2#Bkv@q z<11Oh2+B41*AN~{Vsq8{yG0`|wV{*`uwuGD!BIlg;*KE6ljg^eBWe!<&1{F%*UDU~ z&C4rbhwMTvqXS%Xyg(|(+Jp>ltU_hXjy2~+qh3bSRDwQdAa+hk5Q-#?+=1f-7~0V~ zVMuXw_Nhu|dRGmV#t}8F^?sulD6ksuFHxiCMQQ_{JS$lBj7m8-?@(HEDyrnw{p?~7+bZ@y1mD;VAPexDJ zH^?~ud+eEOn(oFy#rAwh(_7SkBUp4x4U%l$BfUzH|BUFmrm8^?kpo-f9f95e$YIdy zR#q(aAn#f=V{88kh)Cqt`mPO}yzuRNn298E@y*Tqu}-UsST2w}P|f1{*yYx)6|Zm7 z4}kW|m$p*FSJVXk3(1e8#8(}*=d$?_eQtxlJ&7*zYbn=8ZBhVZNX$~?7LJRj|69dX zj=OVC*GXXE-cvoB7iun#-l)}k=U?%-5&$}@)`?Nd5P~ZYkflUR$-qm2&2XdT23Ag7 zyNv=_TSuMpR_gYi=1oz_V}L1VWM9xy{UO&%uFzR>Maf2kM0z#heiG1smk!%>W0uTn z(DJq&aXd3vxNCcYtCgI$%HX<~MLxF-1~$Dq^1HFebyfHo8N)n1)Q=osc!5u~VIGF}0lR8@MQ+HY#o8J`- zzwp!bG1CSQEaou9;#oH9LNFOtICRL%ta6Ukn)1}vl#|GSLDm*pker%sR8(Vy6H9t4 z3mCtc7%5S>WP7LJk%P{{Amp&Fr@+o$GgW3*NJJWb5yq;(YT@Uc;~%Nxv}(D_=!Hk4 z`IjMxF_P#5fq#uQ9D;h5zrSIZuic!m+tvmJk_BSD{RsVOpOpeSAZBR%>>I2GdP&oi ziVDfdUv#2}qnM@o3G4Z;xjAU*8ce980B2-iu>>lteeQX8Z1#Cl@-%FHveWPK^>cf5 zfL&9)r!O`ETEjsb=1XRUSK5HO!^!)2keKMPvQQlh! zm7Apsk02*wfat zwl4M1HuFL(`e1kDH|U3$q#T|E&p<~7X;Fb=psQlGxK{b$<@!0jLFN9-nP6%ubB;r* zBvu6V%Dgjs&4{3Q0}s1HRvPF)0I*PPFm}KOL&kMOcIfGeT{Ht_j0QIn+D^}%1<{bD zs|k^gLbz!rY0#a;64-d{Ow=fG`uR_}PwTsTKyxSMyI+=*=S6?v>w9Fcu#|qn`2%t_A6!6{C5VC0vgQ_+$BKuC(_u ze;s8WB*;$Uy@e9+N7;#W6b38|!u7d&)&tSTv$pcaj78U1KW}{R2|}|U?zi#{U{E3& zGR0%-9~W*iFt9oHU*-}F8nSh>0l_iL@j!F5uh=^GD<0#dDvAp@R7CKtV=~DdH)a}m z#@xr6()i8BnW2Oi&&D)j4=mI-7$(N%A5@MEwZlds8?_Z0MJKqh`Eio&a0)oYGtoA3 zu=X`vo!#}bG80l3yxi^BH9b4?U0!}Xtu`(^*pisH#OQ7sj!P_G4>8^JS>pZ!S4n%5 ztjsS!#^yQY+i!?TzpROK@11fox>FB2f*V}etT&X1&8I6JY5C_wv?Vxy(nsEGU;hOogZK}FF^V!r~kH9Yoxo5U;l7q1WxOn=Kga6O|qz9yE z^Sa}r-1s}%4;GAo%_{-tC^gIcB^njW)++h=+x+|>ECr3bfz78$tP!W$VTiJbc(~Vcm#liVb3EL*MfBrsWpu*!m&Es6?tY>V(A2szC1>-@AWn)792qt){T8o!x)G7kqYd)K;b3 zFx-d;dVRQT+xQ;%*Qw4asr<74Usms^;&Q~5KY!A%i2Z5Jui_&=VS4=gi(^dcsq)|l zcF(I$F6>hbWa6}}J`2)fL}0_4&+p@CF?a9Z(r##ITn$}E+QL)sdQh3m``s1rWAUVG^5 zZSC&f?ulNQZg&Hr@ZU^??ApIbFb{zzWIiuH6}5ZoJ0f2L`dQn z>>V}6*MbN=1PJ#&L!?Iuj;13?gZoqRqWpaK$6xd8m0s#=6RY#RB4jK1Xb)} zV4308m7r6KKvL_?wl5eT!%v1HtftU{j$b;|W@xCU`~O+Y>ZZVknc2@Qu_DS$x|wLslSS?fjl4F@E6 zYJo=pe4UtHg)My5gkH~>S@Qk{Hcu0L(++p}4KbGuRPYD`yVniMpW?UY%o3mNz9-=4 zN6EUhvkFlx7cf&WHJW{NK&M!-9IW)wjorzFY=9f>HPi4SWLjgwo!l_CK51ZNvag(~W*V~<)5kYU+&auwF#=Nw(G^Tl6S92HvUxqA)(4i>GoDxRlSFX2D7rAbpDgC~QsL zgX;XB@4E7Q`~84SqRe_Vy!sOdGfHp7Ac!01g%eVx zh4m01vmI6;v`#Hf<&P$RP2>TwmZ8FW?OQ#US&b6zBnW7TTrEkN=p-M&n7I-LyENme zCT_bLU=-wUL5Ta=-r6Sc7gGE0xf2_9i$Y>>F8__YK+oyH-0+EGo`ujZJ`u-8$J;Idpvo*v-Wy-Dw;Af7_mQv7I;0O zr2$-?gQ4LBSZU*fPbXSbW(5#^DDSoEr=?<8lG2^`Rpq zb+3T?_N@(=sC9D8>Ylz4++wEVX{$;c&z8|}U@cFTrosjO{T5OlcQx|6ekB5o(BcL!xa(% z*FidqTs$;K!*@@iYqRGq-`1xa&-e2QY??fLny2Q51^eQBw}P4UNsr<^LgQ=UjIGrK zd_4}EODv8R%brS~{W!b)cIWJh_Ph3X?*WH2a##!3=$w4=G}(!o^pNR+RfCPyNKrqi z{j+c69E7yxz!IpXcuu|Jju48iZyev5JHHET=c1xHi?%2u8Lj)n8iDNvVAlJF(!Nxl{Watsg*S6_W~>5cA%S-DbSNgp{-mglquMoTv0_}Z=3*Q z2Ca2>qW**%K-*edSrphbuo0OeNb^_OUXuE$m+S#+X0{1O%!`!oU^NM)LO0=^!VOQC z$KD^B)@>OHZ!K+yP9h99<$1*QDil!eln>{UUD@ul7$oG}BHsY4@1~MU!ziq^_WmzI z=k>ENi<9Pk2`-l*>FO!aJY(oYs5==Jt|UaRTYSVq!x3X7y+y|qU&X2F9QPvCXY}80 zj9!XM7y>4ClcBb<==8Uvm2zoa%5wc}b+-o>KcBX;msg#QK8#);Q3F!`=bvAs#vP<3 z#@YmelqN}gKo`^Ioboi#sZ`65w|XI}omA1Y*4BTNwHFtdgw7G7e|KIVYO3j&e90y0 z3c|O@P`+FlPiEzQlAS`=8P85MN| z&eIp}?&$EdxOnc)*6f9Ropt=4uCv3MpPZstOl(F^jO*t(Ge0;=loY@#CK#`~+@^hAc>v@aNlqSoNYv3a< z!LO1Zwon)_k)+`qJj){ds`@wm`#JHvZp$! z(bbZA4~MNFl>1mx48xXFO9juR>L~(YGMASPk3aeIy^($ZGyGJ)9+A?q*&O8K%M*^2 z{yh5gM{*&86FwKt+vPogQZc5iTLuTCFFVS{Qiz@@p*^SZSEkYb!LEAqqc0Z z_MoXDNg2)uUXP6m5-F5?$C&|s_Vl_tah#?}8uxc;F($SB&hO7qeDZ;{*fP3!z??0{ z^o$3;ip>V9DLN|y@uuQWQ}4^Ig7=wmZ$Q}xQ`Mk;>72@g9L^5g$WWZ24=GQB#8-+V zM@4L}d2T)X47eVvW`zR--~@i)T@EqsY$4Oj!1+ZFUfq%dEL>aRCSlxUo=a5)EYZXE zhWR`L&abpaIXDh%aOg<7R*_Yse*BE*=O4tb745gSlchCeW=J^Gx8TdwBH0)aHo6H0 zPKfpt=;Jh(q5J$qsOfer>ui0(R%tnWo*kl4iF`0&>re$Wn=~vG=59+mG$v%i07#ug ze0qZX-*+F+=g;@gcP`^q3%dQEcbC`B`rpp?t^S>lN)0^IiLUmnTs1pnVpDCnASN!5&e5{J!} z9`Iyf_ATfuS%F~O%H&Rg0|g^*k9B|mnGXV*1xv;2Z_Gz$mq14&rD~5w1ODyU@_f?y z=X|-kBJ9%CX=2B*SkKMm)6(CideEjb9}o5_eraBCwlY!f``=pDbCJ(Z7b1qnSDUcJ zq)GjB-~aqu4Dl5_|FLDJ{^0Az{KKGgYrLJJ@ovNeA$Ob}IKlqm_&IK-NwsIC`lXI_ z*GQ#{ey_>s#*=uxTV`7J0Acj`Sj9T#iWG&PYSIPJV0ADY)NUDN+u&f8+$P{*mD@mJ zl?HbZp$EwvTRY~dKwd3E^Q9(C@7FQKb6jAKYfdbN7b{Du%>In&xPJdkCX};OdX)sbh zYgL&CqmOoj5Vx_FC4|z`QzW|Z(8Yw(9o40ToG&JJ`ga0Jw^k+6_P8c$j+Ww(hai3J zp=dZ*xH|?yoLgovla_Je!tbB_4ulKMYufRWsUsy=|2uKy$y`ld8mY1}_^vDJSoBMh zG@J_LO7c2hqhgp76ss}rWy>hWTI7n2ViAfc#%LHyC@xPiN!L|ZqSows_PSr(okLvk z3~a9bWxn7hHoqn)hlj#ffv6xdzm8AzxYGz+H`8akU1gdC+;T_n`NMwwrysowS}62H zpGhYkwy-Mp?B{@&zrMwvzTcH*BhlumCE4K|7YoJW9hcca9T%gefR43djYOW0*hDX( z3~VS8$S6y+2i+&i?X?W>6dnffF@cPk=h;6Y)v&b-CzUq|hsR@R-j+ zw4?pm;$OSv3d5K9h6Pni+_{^hYaV1qH9Kh(Mh$K#MzuLPY(^$&w!&_oyDS|iA6-`N zG#SwS7wy#UO?L-SJ+mARGzW)nXv$OwZ5DA!xE^M~&-0Ih&$r>5!whn1R0@hcbZ$PV z-sSu(zvQfDIhhnoGc#|5aMm6O5{#lff4Dy`4?pIHXQE%rrE){D1SJXKQ2h;}gq+@; z-Dy3{cRwDTL0t3OW_}QVnU@f_Sn`c9#}zjhr$CO5DaJN<%MTZW!qo9&->7PNMzQ}@pc(@V#Tulk@79Jx<9*}raMHzyFGx(Z_dPugM|jC5{JLT#qb?N5RM*=_`<<=TtwDiLk>fi(*?p>; zOV7>tMzgA{k<(PBnUVg}1r3WuRphYXm*QA14yXO09DY?cj)W$t8vHHQ)JBqt(1k2v zhvU9_^#XQm;+-8OxXc%N+?|FyrHQE~?}nus;w-Q7i!bKCczLnw@plu8_{gA1+s@%a z5++F-ObPx@8>b_$Ep=g!&$0kpQ)P~R?buNedP~neuOc?Py!_p?;K_(CV}7hZ={?{` zW*2!a`Bhkj&!j794!w;1_Z+&xDCep}P~aD@`h^#k_@%O2RbJKin~$|m*LQ|X+`SlX zKD63w7qx+V*zGgF^Y|+x8c(y*8)B#$sW#x0(~v;3_HULWn#&GOb%D!oV-%JKN+juN z+Q(b^*gE0A*q3Q!TX0l>aOmd|#h%3)IUSWyT-uEi&OA4*SngD0uW4#(d=kU6@ziFJ z_x-kfMMa-Z6{Yx`CeqzD>)q8t#m?5JTl!PtRNv=^o1n8=iW1Ot3eruo(DgPaP^fFs z!R+*!FG4rJ^X>KP?dW+e2@q8ppsRpoDZSeM@o9LV6UcoZe3tGQZ%um1DD#jmepbHJ z`@9_!|5JOJroTNp>u2+7-5S1k>D+i_nrPl?kCc596+#iGn6BA1d5}cch*a(5Qksg< zo~rGCPx-_+D=6+YsKhu*9evFXSQ|q%JqkTdC0Lt)>_DEb+?FDQyPNQf$|{IUm#aE% zm|0Xg7bS$IO`94q@uzzs!f=}$Cs~sv>u|>U{r#GPQBNQvYml#}fF_;3@alJws(Rj+ z;ri&VQzfEVE}p8aTnUXo-=_pA5`iKkz(auITb(j!BE-3;7-Q$wj|(_EXXm*2jXQr|64O7xBVR@Lu6-YZ7f*H%T@gU?ybT&X z9nUO2eg2^UUYEeNj^q(Jvv2?nFv$suUvNrvd0XIIwVlW%4!F7gz*66JX^p=eG52d6 zsRl}|G}#edo<4L|1zu((8r~zjpb;iHZs5zI|9$y-NnZwI0ce_DYZ(9qTT?9P=GU`;6oe&Bb z_`&l^38__dg?rPFK|B{2p{BSTtiWbtO;zf0$e}~r4p{zMyYIL1M`u<4W>eqh&A(XR z`}N=_VJ^}G3h)|=DIu7RA_q={Rc{wcg!adeDB}Ut&uw^E1^y1Inf~~rARD-*k;QWb zY%W!Jj_<;+ru*f4MDO~eh+WSDyReb}xUUDLQ%AE{xac-aGg=jN_gJ_st)xz-DfS-c z*$Otks%@I;IRWZd(%<2X123FOT*>Rn8%vxm_mzYy+xclDiah;^^ymg2U`z zqj9w`tSdWjC*$j1!{}>DJR5DS1R}7V;OrHQ(GZ zh7*TXnu7ihR2f4bs8Yu|{B!<@A_y91yD#c2Qnt26p|vhItjqQF5)=3;PJTIp@v#5! zM&#u1A%cPkgTVLDqacbRT8SyiF6TG;8N#XFUer@V3yq@CxP>JUG2W{KIaI$?LsTR? zqMsNOs^5(T#>(%^p!^P7_~Q5POL2L_P4$Qlr?yLy$fPk#Z5PMHwKnY67X$Xx$$k}i z%UJ-%U%xUBj*}j|i|XYmb^N{$&ZIIJC&Bo_2_7Shg(Drz#?SADE|-ETQXLa%p!mDM zk<~-CcgW(}-p0lK>W`p?rF4>jF<$1t4=wC(OHwwv$&DfFuHlhXlcw*NZN2)RDV#P$ z3m7u&+T+C2dF*lT+a;C#%Ncw2YM+VB=usXECI+bhEHS-$)v0~{2RV9VjGP(}M`C0AZN#I`;aA?Qp?o1WZ71M#^F>zESE>mg1aL5?QU<)@M zDCA{0w9IgS)x>c8DiWKQM!6+ct^O$u9tZuxSC@4HK|KN*(@srvstmb4-YOC?NLIKW z6Hw}%MRN`HU;`Q>LGX_xhks-q5L3x;9)`>8soq@ViGTBVLfSL1!goxjlqRoChh>U^CI4=ftKsE+-KTbus#K*IRm%OYb%vXS*y}-LVuQ%l z0rbEmw=3qv8!DRonj9?pR)QtEIUOt6!OE~|_82FTy}~hldrJJGwd?YK)ZLP+x8o2M{jle2zDJMmqe2WZKSO>w1-IIN}Kg_V-;nDN%5(|x_tir5_MEF z#y5aUJ=?4Z3$1P|2M4N>o5=FH22ow@5Q5i(IHc-WMeiiF4vY_M(AsRZz&YK5*tg>D47J2H)N$nhaZp*ULs&`?@mMjF1D_;9#F;JB?$3;5G^A zD<*F1Dx?h$b!9IR*n|WvqvX(>pY^=YzmBSN*-Z)ZrZ_r)=$Yln#n}Wx`;LEO50@uW z;WZLdGXuMt428*6b_U9-xZdzQI`1H{ZAj(4e}KgcjWyyw31W=c5uaUUgOx(e*#lVG zW`uGz64zLOls_1rm(E(H&X|N{JV@M=FnW0(~iCu2eu@{$) zgRyUoisV#hb)qQU6zbJdX-50_cNRv?RA~< z7*g_<1DBJh&hzj|)K=0xSZS|%t#kO*5kIhAblri{lW9nHC;ir1B!`(hYu}3aP3&?> ziV7)`Zu_galR#gew?$*pkc&LHCCi>BAM0DzUqyB4@rHKl)c_}lY4HM_22dOvx;X*% zie*Zh4?&E*{kvBqYurE`YfEdh){jaQYO_ve9N^Fz;MD^^a>mGz1TX{;saN^nuyRKw zwx!7s(Jk$5E=kGhCQASXdQpnuKRBWkZaK6=?RO?2nG(J5HU!m#dUZs(&PA?u6uYUyQN+Nw@QQOo66}hd&9jmuvQtTUY_zR9_@AofuPG#7#Kv z;+rQDgX=C;X!~SRZK&K`?RR)40 zl{$(d6=_u2OKfr>hNvYPC@a^53*%baeyChSDwM+n8`(@9OOM5cL*6<1hm6gA=!faO zFZIztUoRRi2}c_IbTlFko*9$a6_Ol$$H-F4wu)x%nFMQO0L>%>)MN!I3v~oV5m1_C zjN)@OUhlZ-zN=sqJ?3~s`QKAl+p z1WtZD)D@gwlA_m3{taV>!=T6J$`Rw7uKC5IMZ;p}to;W*MQRN2RlV(GhwM$@t5gE2 z&R3JTxWLfn?~FivX7vq6u0=5zSdnBUh2YUB3pI%eKGh2VAK?C^8gN(GPWDcp;u=@_ z8-%$SvA@@qx!oTBt2pLoGnFYYFn#0oWqd8L^MB}%&l{pt5pX+gqFMa746TQ0H&#=( z7Go?WbTO{Yrt3=UNn-icH(kUVyjxozDFzR%49-yP&j5$0Z5giy#2YA&RgWInHJ-ls zO^@RIc=tu_NPT@Y6H=UPVZ-+dH)XRR&O>5BowFBHDo;SFq^*^2ugR0-D3FvM|D|Gk zs7IHj*sr}Kf7Tvij$3BkUqf1yAwBK0kl>WZ;F3Qr(3wt%7x>VRk@UV|!8JzexEP3D@6@K`z(wL|m-UQz+LIts;GYDi4&YpoGz!dQeBy}QZ_x~0zg0{c~G%;M$!(Z8z?FLS$nx1}WpRkHuv47I( zB^!#9-H>pzyyd!^B0bTqo^OaLViVOs9?WMe4F_%QzW^oUSQi<&-j=?^%<_5F3ypXP zN4kr{bRr(@dJ$a=7b~p*Luj+rqg;oETTS!iv-5&L%0qKND*$Da;9IHRM-qKf{eZ2_ z{#?^cnMp+zcR=}aJAU`(-Qw9T*wht=>fhVB7Lfr`WlPp_zvdQd*(PCY75xv!RQuMm z^6GoDVwd_-_-Fn=w8m(?`@p4nhK#6*t{=1bmbrEa5?cMTN{N@&sa`z+?#RYd887Q> zCRB0nJG#UaC(2qgKeEoq8WrYqHYh<-oPyoPUSPhH^?D^UO}O~LG50TKFqrslH?VyO z2hQ{g9DJ}6#bOXUNLzvh+s-SG1*=-`bM4UdboF$+NLTlEl{Ag@d~ny#R&C9;{^q_M z!!8w7N0xW8GK`q{n~flkaAz^z2vcXbp7I0GO|*ZM|3D8Rv=;+92OlQN3h$FT3!To- z`RRdL5?!Hi=_kLkvhyfBa_OH#MqV_w+up9z=>D1XOX}+GAp0gOJ%NsSw|btQ-htaO zaNv#)KO8a+FX`aG z0fR&QVTQJ0)Z#{$t zFP@$60$m;jhDuhk*deS#9Y(jYYxji6{tYpTb*?9T!@z78tW_?}Em$rp2poO;p z)!|VjZ$$d2g!~GmWm))EWbvtQe#i|!i0Zj7^=@e~%MO!X)4OUS!jM^@u_)yA-R>~z zE)D)`S3Iv44*q-8?R3AppSIBb78{+Km?V(8<$bzfznC`B*&u6w^L_aUIpYg@JD2Y} zx`v>+D%x?s`$}!YmBD*~7p;6RzJ-S^(Ljrpz*1{&kTZ-uO1PxpV7%b>jxs478Oor? z?e4p!C1QJfwVD~B$VqxOFL=Gr&&MN?_==_?~U8YpX&DrrdNX%U+F0|$swr=k% zj)(saecSw+s6%>1AF_^x-QQC`Sh!u+Nm+Ig;Z6S+F5VM&6H=qnsIDsbl~IRiUbGs za|K_ERVcHLN#S^#r)Nj#*PHdleAJb@&dx^a4x_h4q8ac_nJKLQuQNm9hH3C~TE_eN zYI<&}ttUMA))z|^#b1Etl-0IOU~wI;;C%zWm~t(r(AZAi<#~UWI$4iIT@pcF1Di+|F?jNq# zju5{mcDtihXyvQu8tk?ut+{T{O}4iAdtJ@sPbC>>$JcMGoWLk|Piy(4;g+^h16*Oa zv722Zh6ByYL5Y6;#8g$Dl>Q=K%hCB84#T$K<2{W6%(kyL`oU4Nfl>OiQxh2Ah0FCb zCRs6{(b;RAt1I0}>H%Yp@@n1pSN#|tnJvrkbZN@ z7sgsa)w{v*Fb;k=e(%d>SF+Bp+%{M3r4FJQ{o2%q?Z;Xuk7UTqx7Vdj0qREWJxwIF ze223i`$dh~#Z-HnZ=_zM{nB{w3FZYPEgb@cFYpS||MqyAMZZ*bXi_RIHW@MLHJ_F{ z9kUzGuEdYH`vgK7Ez6{!4Dr0-D^fEOogZd*2bZVu-rrj%e$NehQc#ij+1k){R$^t_ z;bsdeQ5AIC5F{MafIi&~F<6GiS?jcftV{cjj*ci3Yn$Z~ft$dubsvXM^z1wBTbv%* z*7(npv?njUz$%70m_8P3k;J1%RC;72I|rN{$$4DwKGWqTN>r-?T7O($N6P;Z1At=jJ=<4ALkSr(`l7Z87&do``vva z`j|tJn!aX>o4siKHkHy4H9d-FbX!mqFMs@z73>X4%aZn&cF=Rywt3ca-N_OVmHqgS z&6StdX6`A^qG`rsiGo(he__SgW@VB@KM7p*GS9{LA`*Sk)ks@QzoShCwsIi_;a6Ye zZg&$sRlbRAmixYgAD(J__gF3|gWU1~IR#ZkD0ho8zxBx{p>Yof4tD;n{*TEV3t>Z>f|N_v(+X zzOWSvH)M%Yuk3i;np$~COVUzqKqN~Yp;;XCk=2F;PL)KTf_(lWqTDZOqj=B(dI>y# z#m%qcCiRuz5q6Q$&t~nT9u7cb*QFOm)9rt~p9^PHE&osaj2f<69$4$iN=|QBwlbuG zB~_DMp1JaJ+Z*pGu&anrrz(qNiLkzR+-Omndz-9|stNy7^qn6bV3G@m*9CaxC!#dn zEpooSHmM-|2PCXFX5@OGvr&mS6<5pBy>WB&m`WMCd+xd#7{&eUwrBobJdrI%jffyU zd=ctQg7Uf)6LC*9Y1_y9n#HT*awd{W$kde}1v(3gzk3R~)2|!~Zwh~_AbEY?ZzTd0 zO`RZX);8tdEyXu2*OK4J?jlPckBAsdR^HLSD+3o>S*XkWi?}ZHj77&I^F8=^NS(Dw zHSFoB`L(qu`TI`QO~WO%FS&?|?PPZq*hwLTneVf%cQwk9K|so`jnGsL`!49|4>qif zPq^!2^52g_S&6v9y`0V&MpTc3s#YZ98t2nD!9iz457EfC6MlM5XXe3*U8tuhwel%!czgBk-^3L7#vKyM}D$q!JDLSlZO|-Z!<}JKb38M15`CzVKL>6)9~Q zx+wn?u%*4EE`LCEIEaiWOJ-PKX`z+-bD)h4)V zA2|5BS4Mp+HMJv+Q7P@^LGOy6fJ~_u6w3Z7 zc=ED?jCK25WJY8?K_U>TtY_Yy+hXF^UFd5uifS9P5QGVQesvh#TMCQ!Y1D`q`NgFh z7C@XsJ?F!uo@mP~d0!)9`2B{W_l>s2OyALe{Qfo=zsl-Jme)mfzjc(Rh7w1lhw0!{{{Q5xu4cM4)ErHOYg-3!_S5Sj#|A9vgh}>x4Bd&eTmVV9LvW z>0N24Tkm^Zh2C`ewpTcAvhQ(pMvfE(@Xe%|o6^xoR)&Ywm2lmXWUsl{F|kJJc=kpJ zGzh$jMtieaA|^pH#(QF79ghu{potDvE9H^X#mysB7H)?>_S?7bEUnd;XS{_cnY_R2 z<5SXcyf4^LZRtz8foC0B$=0S+W%cm%vg*FL19{_0T$A}+ahl<|m6mnQ>Q|QxemNUv zA8b7Mz`@ABwfiwSxuAHmL+BxM z;7E80j9Ktza7l-xJ7Otn2F#`W2>tjZk`vO~LDk}}V`=9!r|T$)u68&0GdnzTbY4E5 zpvd)-B+t(A3?v{Pkbro8Xl#+V7xD@lkKKMVl~LC>*Z(exf9tnEiGtc<5gB|JKZLip zxfG^nIQP15NsF&HRlbcnWLuVA%ZHvq4FI$ox5-1SZ#y{6>b?*h{}?DOa7pH09?f2i zYy&Tj7`(VAOxDz%<4&!uXIB*l-uyCBYx#&!eEX#}U3cpyI}FD28zAD)4*_`OIOIE)-{JlVQS9~w3ipc*D%8g-on zx56M?o;o79IH;A)hHhT#o)})oKC*0j@a*jlfTB9n;6|}J;%G=VWSDMgY13EwYZc?h z0No5jHiPvbn*|RXTlKP(SG28{K>6NFMIUP$3V9_rw9-=sn)w9fERhg&d{F*sN37Zk4kr+lQwhdGM=2kLh@u9kd6S14nB9L^0!t#o)Gd+cWKlnX=>B}Y{O zYL29^#^=1F(>`5BycvD=w9`{`51!23`dK2o<&Mk|b{yC9E&8Jc7=wb|XotXn7t zmlY!y!I|K)H`^s*@*9pGzHF2DhD~9&yO<%S^SI1)M>R7BF>!vSFsg~c!m-j`d z&ZeI|qPAk3O5lAEM#%lAOsY?wxX)r_e71B<$E3zQtyJ3hPuW1Lb|otaT5<^N2xOF2 zCcU$u4sW#Mi!M~&+qMX33F?cGzliwt9D2q>MYVeac0)M#xFZuVPT{Mi_Z420qb9)V zcCKA5_3Qh@X%HF-qBaNiU>i~wX$teOGqm;)>S0T^fpG`0Q{OSbqm}PxY|=xVFkVnU zamIArp!G3HN~Pw6y-prYlsyEtg?`fFQ&4nl_L2VW`iHSQ_LeZoMXN#12fd#`_5n3V zKTBKh5M&>NhMY6Ijeok1_GRH>E~v;^$G0Ai_c;_l=wSX4;c8@wxvb*F5-Na>Q;q(2 zn+rtDG<~gK`GXF~Ng{O$5Qzi+-VwIyPRV$JXHZUFHaS1kXiK+H7sKa%}Gi5H-*p5)`w0rAOcPR)1r83+@d7oz_ zkA;iwfE^q<&o??P8LE)>7A3BhG4r*4Y8)=98H41zzkIiwaP_SHe`C)%xz50xVQVs&>iFot^9e zZE64EqN%161*5 z!45#2J=VkX1#t!~r|%uf<8FHwpEvyH{S6!N;;L{#{#i?NOT8B~L$D)r+z$b(e|r68N*LW59j zHljFVO0*V@Dn?#2444?eWq{zlVCVKsr)u1aJ2jU+UiZ9o_r}OHFzPmur2Y2TJjt~x zE{If>wL}8^=)EnQ(&oCyqv1U~dNS~%CkQo;oRaWxgSS{0PMmG$f1<#y`jb%3KTG44ITqUA zepX*%E#%LfMhqp5IR-xt@qY8?SZ3}Q)$|G~qu-z_6QVZpp!bCO(aQMy+jxuLL5bLi+sp`*63hrhNzGvY$dkX+;eBNx zgMj8lXF5_}FDUu%kigy_+Lx80)};~|x131jk?yi^hVxF|MbXjtLN3svxXZ*5a;pea zM-vmaR1%AOp)l2xcAL@*@3!6S1!7FyWdb=AiFGg~;0OnUbch$5C_bE*-?997-C>Es zkjvG9!-l_XBDW@KdJmU|gzSD#-G+Yw%0xZiceWmto)i#~Es3?HsMB=nXJA-EtY;iH z>QRnl#cW!SN&9Nl{41#A*(D(!6ClI%GSzMbb=c@mjECOoG)p92N9m%|h9T+==jZ#U zrmS)w*VlXY8y-+b$^T@3M+)VU;}ZFH^+99=zPSOE0EABpvN@Pa z6fw>maDd#p3x>=f=X3k5TkEd-N885BJ-LqAg(8{Z9%FhJ8~`$9L7QW!EI6K6EyD}U zVqB-wg!wRKF!3eN)R@u>>PI3S2R|M@!Fq0Eh97QSB_m3|31q|E65Q|uL&bD>Lb9Re>1^_A zSttWvW}MAD?xYpFUMpwY(8we|bxTHhIi_Tu*448k;14u+mq$3+bx@*%w)ozeXQ29U ziu9v0o>GSmpKJq!W=?T-q>#H}JF28*DMQ07{^bh{21sN_0y%$bTEnOyGG-deF2?7G zl{f5P1~Q+=Wk4Pb>5i58DNF+;G zrr%YPRhR4kslIArrxcTd&KQO-*@u8&ZX}gCUe3s4*+(&Ni&?i(CHOd2F(7Y^GlW>A z!x7fJ9S3wQ?R+su>^C%vGp?KV#U9l|H|w=DZ|XN@vt-bUG5-PdSh)eG+!ZNsoy~?t zy)`rNAw>gM4SR~PlBQ{ZlwazSaCLtSBZC2a4d3)#AQq~-%;suD7ynu%TeB}|Mo0t+ zS)9BoT;_;@q-|0xH9iGrw2!7!H-jFe@fmxkc9i3b(TrtfXEJ`xgYvCk zeakH043#3C#(z?2MA7anD1*v9@S}Ri$h}sN{Sue&HoEHaI*H%eY49~*CgANoevKz2 z*Kbp%Ze*hrLo%l1TQKsv6M#QRb1KN?eVZ8jMf;Ms0V6j`!}H>G1AYf`Da?UIMCfe5 zB7k27$rkf*izO?i&UC8E!=9?n#NX5=PY>57A6ZI;Z=ryf{Y(LmsdIci)qX57m6{gj zu*qdgyEgKUR8$y8pkG0ayT70ODNgFl+Nlm(q78gI^SQ$Pbl$*-+X~V{3E(qF$&CF9 z0=P`6zaJ{3p$}hZ#Z}Y%G2A4L*6_>MI3{|A1x)r+SAeN(6EC*Pf=;IEMk-0})N@{Q zDNjp49Dbp%-B(n5V;O1UP6}g8LR@btg;uEQJO7Y)V`P=^($_AVM~Yx8AabgiM)rbK6es63ADCHaj)>kw*z|&Cu&DVfm4!uZ zQAv<P1j zFEtr|cg4~=KvjYmTmtT?r6}l<)dpYBSVPa4vaJ3g5tc()esL@6(Jnm#^Z^juG}(x* zi8~#`nm8Sjo3QP-g2hrg|41&WgGItlsN3E=&cDh*G{wC>AO{hP*G#5$RAXK~EFjIG zsh;#v=OX@P2R#J!qKpvfo28*t27W)HP_9_qM?A^bfdijkcoJ}G!P=-_66u?hjBw8Y zo^;tC3SV-}!n}suaprv8I*sT7RZ4aZ+3V%Ji0~b%Ca#w#+RZZ|kv6{lnxL%o4so-c zKUjgZj1b}bL*o@uAZRjKJEg7KQ_#{t8#W`j@YzeG5hxl4{)e`%^IIy=9)<*lnH#!; zlLG=-K=nKrZ-KPf01lyM?B;sUxQ#Q@X_3d$3thinF_W9GovQ9)DG?RlD@r6+w*RNZ zD*>_FDiZ!9!lbQlNdTE^L7?Kh*Q?2+<6I?CJYa(H7?HCpJe{e{d=&%hvv=BWKjeBi ziA|VM!#CGKa%o>w@g4f7BN)r#bjEMuuU$ZP9UJ$#|B-l*^rCU1=`^;0!MbWQ)YP}oPcMuYJ>VRh?u)Q)62tnb6(a{B zz1CnymciMOPym#0CDN88Idmb* zBb$pswXkqA*KzKaNEb9UtP`)+9UN5eIWf_8SdJYK5iPOf2B4JUqIl=uMfkHvZNbU0>AtT}#q* zyfc3j7G$0R`zI)0)Dl~b4eD@J~&`3%qd0T&38#|$eyzbjEcln2JX8Tm_k<*492>`g#^Xd^VOrol0mzX3=x|GFMXaVc{9Fa4KgnuXKkt5s@p{sU-|`L zXV=!B#Z(PEnj3ZpN*TMV{1WPeC-yJh%n^ze zErUdWh_fO5%jl^jZ)N&}DWB{8i+g(X-}U$fmTCaxM2}>C5{bx;kF0?9rhrpBBJQ<_ z&PO=hQFCrJEPP|wV=h;_jzmiBf(q|Qk$$XT*-=ev%@|i23iRU)#}Rf<>x~6D(d&Nn zwL3tuxvsO`ToZ#gMeNv`uVJwCjk1{|%ffFzoRO3dao3AUXQmlwR0_krLC#B*erROC zt&3ETmvn(1#fX)}r_`^8rMAGcyry6|Qm{N*^**}~?8oOWHEdi{YjTt2oy9<+#u;*~ zhOf(fR|KOu#e7>+ACt%Pbl~(;ZaRLP_4_UYHdLl}R#c-OjDWIb1{D5hx0Uc{3G}XN z@HGdg_8P|wln&{V@piT@j3VYK^@m{tfL`d#D2k61IKSY%Klp8*eN#B4;m7tDI1zBf z;`47^<;nJ8O&zmzGWoSk+~!ZAh-A0J#9btI4Qy#N%E5uS&w%>-p~v{B+SS$lb|Z!~ zq1M2oT zvRTG^8+*!|08dx3in>cYvFoGo`65}oss@f4nU4Dq+!0eQXSAnVKen@f=yFw1hW;xk zE3CF(jSg!6u_R9{FOLjCuS%9RNGK@7eL3Im<29-z*;FT=`8T>r?k;BZF z42!1A;#l z?_G8;u=TxyFduA;X`M?U$#%Q?)boS6xe?_fZ8I2=NQ$+&4dIXCo?e6XJm$ZUaY5F5 zqqcpA@6>Kw2e`g}HT?h_DI50!xV_;uS%(deDf+k9kFTVVp|h+0xd0q2&_55c{!jlb z^Gl-oFcJC^aBNxh$(w*<>j(PqH6~qJ)5BKdYA2qEzTq}6qrB7GVYt}2CrT_e^~n!x zNL3x@6iob0+E&f;ZBoZ;S;JC0Ana@?SU^f?JSopFo6&q=u`|<+@QSKgW=ka=AQd

    Q~Wqh4{A(ppQWd7Kv=mp%M+DRws#byHUe3HR@WnpL(L6kj~g{l zP0>_rmzJ-Q$8vX&ezagCw*f9HM0l(wU5!GKk1^AG@m1$M(1 zfJiy?pMn}EufL=`@HdDUbFDtR9Wfh=v9+yOAe2>QarPhttXybKUC+yT+ZEonh|yFkwVDdx4)&@nt{EdQ1K7*7j=>;i@7pWXC4 z5tDUPXuDAv`0YL$CcBmNY-GRkPwnZsCqlfT2K$TtohgSzWk~Zftff)qca; zW3ejLAqZBWQo%RJd}><1E0P&DrWk!NglzyJAIMXOK**2l45&Rn-q=2vSZ!G9`_#^F zvbkB}d3gBo%T7D64eBv8Eyk=V z&(hf=kb@v!=z)BphsVT;lL976I}Er&^f z{Nc`NHPVscU`#1do09CuO|2-qgBZ{~>%dF^*A}XcCj@BFGHY!A7j|Aki>$nh6)<&! zlCUV@CI)_%xxe$gk`gmG$u`*9MPHlgvHX0|K_2!$k!%tm8t?u={A!hT;lK>Hc1S4! zAh8#&da|t@yx4*6raChDT=V_?)qQjyf7xAk=1V)@(|ZMP_BDs*A9R1+9BsWQk2EW3 zo&j}9M0a!RFugSpC*Didc8JP~j$~1CN-nPMKb_<6e_G8V&}yds_4$umjNA{uWKbD) zxUVQ)SL%UP02Y}f&w^CCxZOd`MnBsLKeeR2trwIFN~(Cu_V2GRxGg8yBvMrNq^O_s z;_`QV34EK-wZCS=y@(x_*6~>MzY@9MPt`z6oI;4dSRH>;QtLf+Ya)neFDnw;1S=FX zB_D!T@cnAu+h*^A8s@cShr)7z)Qg&(@J=ZOW>Q*-5w}g|G#n;y?YN) zpyR|!rMD8ak9HLWxb&n05#LXD{SCdUy#@{Sm)}twz4tS%fpF1;n87YUi+)EBFHo*u zk~Lu%t3KWC==(Hb7Hzc-cIlcykTG~J9aEUfC6Jkayvadff<&xIH+*~jKuYi~m%XJ` zN+hGoVuI~#ZQZ9qXM2j|c3f{U<(c|@-@B)=sDj!AoCOn@IEdmENxtwArsFo1A$@RbRW|Qc+*{@D5VEx0xg`OV%Dp>03|n(7Gn#6 zsVgjcJse}4g}RtLkIJ!&Rwt<$d%@C_cxYQa10N5>qGBjXrBJfdHl-I`SbI3m4c4 zfJ1eixkZ=MWX`X6>4xvh@kgS8nv&4VRpcbk z99|6(=O)Roe0HPDeIs=r4`QFMjK8LFI!MAmbI!epZ@=0hhy21Pki@v9-i5ya((AHZifL%mYy4&Alyp&NB`L%fH6}tBY3OC985{ zmX8Wmuzx!zk&%iAEwnfE_~T_fv%q0$^Lp2RM;Ro>!49y70;Fb}Gd3(KT0mT^qc0xr zQ8Cx_8i){MI~3dn<-!pR(?yb?=GSnW_&Skmv?qCXcY& zS&ghG37iQ_(ohk3_z?bwSA~nXoezHelwGyl$60Rhr+BoW_-z$C+uRl^X0j@5;32fx z+UIehNQ69Z`j(of{phHPWZyi~3#_#xvs{*-v(oKUE-F;U{_T`RM#^q6^t~_7-lB)O zv53BNz#W

    u(3(F&6aU{%p4M3dv&dfd5sik?uLojjq zZL_0n3!c`a%zqq& zPk=Z}*Lneb#)it%^rU?j$!QOY3uO%>dp$CE&SZEo{1MklTFO*gyALYwI*Ug4|rK4HKQ4dZtX2j5mhGo-GR9>;@4vqPLDPI4goLkv;Vxj z(wP>+3kP>2X`^`Il+0>N^j@|{bh*#SLxCu5_~YB@k%mBso-|ui^6AlI^z3Sfr}-?s z&NK02-@>Lhj_F>VF}OaXa4*&8`1r?y#l3yiG{>A(YX_ zn#5j&eS1!>IGQNs|Mmd#!n8*5=aY3Fo3P4&pXGrD>DE|_rOTR{`dbk~R_;F{)X|ba zOaXqj-RNo)Cn3Lr=lsoowl~*{z{NEC0UObxJND=6bj(+u;6>CTd;bY7<_8Rn z)ZMypT9-N{S~P$b0?1y6Z2tEjWM}G+B|09-Drutoy&8UBmJ_s z2Izpn+p;U|U$ItWi2D)f_k(+GUF4K!OP^)TzBbSNQsi|6bcC`i6A8_giDX`v-Ozzh z4RJoH->uWkm`41I6o6aqB(veffL{hD?XPfhD>ux3W#P=lp2V~Y0HAecic18212Dzq znO2FtGZgZfU_e&t?D~}C;Q%rV2Ljsz<+7Pc?X!}dkWrX0hh7t1Q)yDb_wQFFc z1*f=q5P*|wgeLF*WXmt@O2CbnXF5*fBF>duHqLK{(ZsA5*1mWX+6Vj(!LZ%q=(;|z z(EIR*j3&=!xHVr8mhH5PU?n>Jcs3Gc5@hoNl_=AQ&<(8lp=$3|69>>6`$>&}$jo3f ztbGDPCQG0GL;fev`-&9;1l9`xnf4!LR;kLffF`r3XfJn5AgkxaWsc(u&w`e>jY7p_ z4aEI+FD?OfTt%24nC0r`x=`64;17fA!%wQvQ>IOq3o{RiXouoHTX{)idj0CJ%Cq#in*Ks@%&>2;Ki*k5d*1WNx*7tPJje>`}E$; zIJJj#(o4&SFL_*lW6YqJ z!{pxVXQO9)anE|Qomckjg!=a1BpTY70Xn2S!VE}nX6`~w4y*HW$sd$$tu7D}i)=%oiz(KA&|ZX8$Qeb)u(rUPzeG{K@^C&G?Pe@59BYH&1)J`|5v>WcCj5 zzaL0w)7M=(0gk5Pw1x{S!@D(FN_+Lm9+sieOh}Mtk;C;DAo+Mu7+oslcD)}3j#eo; zTFv86@jX`hgzTZwCeG0h~*nz^s9{@zwq5jOv5wpC@-$7CX6Hs&IGZeH=+V z?qAtb65gl{L0b|^ zw!4Kr^A&`j0<%Pd$?rAY@WFh4|3j)PkP6)L_L{yHB%d`&^2R|rCD+6Y&g_`g@CwvP zRm6Op)+^E+&>83O$(;Y^+CEtr9}+@K)yI-RUK@H7jW;KurPSr)*&~YfvB@Ea$@?To zdU7aA>R{GD1bq^7Ilzm>?Hd6q z*$*x2kYznI23u^*7QikPnEVIWCqRF2E?uJcyPYmTNys*=@yF0=jr>bsHhxhD*ap0C z&OcBoJnUM?@n#`(Dy-F~R;$`Ox)!I#jsjR1|3C=|1F{Cp&SCu_$$D1MersV*8?5xY znd_BUaZyyW_Pn=(jeCF0!`hi9DV++~qUeBjMF(+N1Ll@;&rkjjz1F%r0@h6^7{-z` zi%+;+ITU$xFeBgrqQqR*@M3fI*Nzz~M_#7}0!@Bm`YtmjdK>V9_hJ%-1RXj}e*hKs z1HJd*fcN81O-1n2FWVdT-~zs}m)({cBK0R00>^+A6s*1rf8+O`!FLx>Co_quX@}Zc zm}*k8z`OM=Lqf9Oa(R|+#7izDUbU5sH3~K~H6K*YGdO_nJpL8;88O+#%Xq+BGy>jY z3s>a2cXmxi*|KJg>(sjpW5a@PpYe^NTxZ!%Xk9W^x&&&QEtP+T5>kC2dojY|(j$9X z3F!?qws+DNB^L~b3T2ZUT0^$99P+th9}~n)G0&U7jsk6A63;oFctGK z=btG)G@jXa@;Qmp%iMdxMLb}aaSUk4D#Bhruur_z{UMB{IaPnW<%s+oI28EH7Ct7A zXp$cx2ijd25?WCFA~RueaR%=?qv+o~>|n$I4ci28=vx{&TSb-AxzEz@O6v%K9nZ+u z*~ryc1dhFsp&<^miCaZ5tgE4sNe{RhQZS!89{929k^%L`m*>a8EmKthbX>H}>Yq6C z&Ws}rW-Y!*KE$E*bW~nyW%8)~9m_J#->a}$_oW1|F+^t5`m@tTm17{oxb#2|iprs5 z;g0ZoayW)KMlc;9I0B9sBHM3c0W-CGsaC7`NYF0xO*pqw1ujI^$B~x{QZvTiYq!~6 zhF|IQH~7bM;a)|64!(e^EWT)auY*QkU%C{Y>btIO2?kSO`BgNt99)q7G4SViF?p{C zspOyn3Tx!>zRZz@0>ld;Z9G_R|4~*n`L0xQ=saFK2L0TX)rVCRjG$`LI{^*$_HeIb z>7tYG@Q9J%2_hl%o_3|riL0rX1E7I_*i8U_p0tqA3DCf=1b{8b<%i~yH2NWO5?IE~ z=tr=YaS_>9Xh3^z>ZEm|596#^Xrn4e`8SazY@245;2-XNREl4*QU=%te8}$T6}0g` zD1vtT)Lv6MZb`VO6-Y#URdlfG<*zIC5^f5Dtb=M94aV1sbLVG^|y7Gg##5ANj00a0VA=n2&;L^eaiX~u~uK}0V(MD~5 z$dQ_$l~@`M(DSpfPIN#rufmU_c4w)6lRz{d1jKMDSlZ84DgX~q5YToEG8oui%(G+x z>qAlD<;m8*VTzIvBE|0gFwQz?Qz;~isZeSD7XwT2IvX8C*|txgdk2GiWYI&g(L7;u zhxzO_JRqGo)Dk{0#a`lJ8_a7O?J@m|4*DGK=a+~`x*=%R-X4~a0p;Y z?q_u7ywztlROVvMoW&V}!0fhj+Ce}3Z6!u%FF2*^w{}3HI*?6~s4>8KlbeD5z)T@G zAfXQQ2bjg=m-=0)hMoCZUxTihX@pJcw}=G7u0|RSpB!MevgZ8j3aBx47RQf>gY>Sn zAf7e_0fX?MErEz0!4rQ>(XvU`Ak~+*`>U(jH!MKcYyrE0C3y7kq5+dcH`K&j;#S`@ zHBpj@@H?I_m^f$+xzB0{0%x1{$7}k}UUmxmYT@U3DB-+7Kp(b?NBf zvB?ceT3Y#^1bCf(0+$6C4bJTAN{Xt^Z;a2j*;=0sTvOp^o$gd{#m5kwcz1YtmVjz;xDiq{n~KNCK1u# zcc77N@C67F82f+|4!CmfooBj(PrBLj7qbLj&vHd#MF}vob`9F{1C;0fu@vC2d)DM^ z_nQ)Zg4lF4uc(2RYARwOzzg8B0}z1QKWls4$=Ab+`NkVBFoWz|BXI};Uv6s{Mo&4F zzI3*1Am?o7bj;=znFzMG8qq74?#2$L20dYGQ~tuKIDf^EZ5_6KuW2f$U9_N)gtJMg zy}aYMM1_;ftlHrupPnkRXW{Gl*Idr~izIv%IQV3uP24R5rbcq0(8}s9;VC4;FJOW& zfpvh_nx~6rDc8>v9b-kSdJJ$QG$+d+SVa%XRcV{wz#__2n9Jq7yjroz)H-wuJKWl7Np zczij3+d>kNWAn$(M>~L&20}arkhh6u(~bqr(UnKig{YT56;iem{0;I?fztc$=#T%1 z8t{w7(S++79|QjO!F1k|T;K!}>G(Av<9gm!5#lW3X?n|Z)X5phAtoS)m;jEUupHzN zl)e(raCu%QxDv!0z{#N~{9lh0bJZiAh>d8{TF78ljY|nGv%zgK!aCEZ zL?ZEGj6P`IJ&W^;*7myW6>n;lwVSCP+wKfYz?lRtux*9(ZpLvtQZ_CI1Wt^s3;u{- z*edeurXj&CHE05R-U11l0#g=7=?%bTDpTfv6rC(v1$F~UdIpTSyOrFpo=g5lHBL-H zp%n&vzZ^NloM)GCIu75g8fUpi;uiOAfMS9pUUQ16-f-IVW30Pi*2fjD@i{pPFp%ov z_yEQ^$_yH?2H@hL2{v20f0JNt%g@u4hyS?m6ZmLE8SY1UpXa>j4jrSqu-jaZc>c90`Znf_b4l@h+9MTI7DjbTn+L%=k zER7zKv`i zj}z@^M=f;CVjekc!}{rx6~z3|)>`r4lGrj_ckB~Im!8m^fjLJo9)@R3Np!GL^>Zvv z>o0HYZ^g52ciD$d+9Rim0`oczN@qSBizr9vc<)hJli(uqZA0k-G7^7A2bzW@VTPM~ zs6=@TZVrX`!a|@R66^&x!(*bj7KPDVF0* zH4hQddm0~x^|3Tk^P-CX1kzTpc-LQ7Z@%RPB76tq2FC34pc-I}YsluGfLri$$0|}@ zvrI!CnN9ZqH|eco1}73JcmC8|_NlacIA(v67+o5hG5FagR-{LA6^j`i)O)L7Va4i_Q zd4~c62Zs$#+6X*2USc}Vttf{9|AA5{d76{|Z|qJzRiE?L5EUi6~0;~GeG$w#D)MA%7o`tKF)~6 z#$%ObnCrRAW)!V#9m6yCPri?Yvi#ncVB1k=kSG=GmwF`Joe{Qn?K;M#K0^#XyT&^enZR9TR&TG1xiK>$?nVl5@Ho=O~`)#5*@DLT?$CE6Xhdr1fdJ1ig z8shhXl*}0IKMD-yLljt@9ZvJ+{8X|edPUGu`AQ6HOZ2o~X(eVxC*>5KtU7ZjzS71t zfiwJCY-Lz3m$d=n8L(WuhM8dDv^HL;?BMTGD3+O|*dKdn z{=W1a+`UrNY)@rz-z!u>kieuEWs>S)ozdTEQG#y<7I;1)H>4$k1K9%R6yh>Z6JV$u zORH9~$F#EL3Z1PkV}!av);0U@_w~T<_fJcNCbgt;ZtD5NoOy_g$ZZL!HFjaxZ?Gs`D`%7LAfCj@mK zOv>W{lk;JaATT@b+LboCuBDt`;p@&TeC@T!j7-^_Fr#$;yUl11I~?Bz47JEYu1I9X zl{3(VvK#9R{PzVKlF*78Q%(HlYXIgB^`X2V;`EWg#45Th`=p>KDXrl0JtKSO8?qPS zUDd0hbirO#tf|CZq%1&i^ZZG*@!*3O%gv4$=a5^fue{wyUf&PXY4u(Moq~~rdh2*U zVJ6qh5-ABRKtqkkIy0eUQJUSFhe@Rph2N(>|btp5TDVrH}XG2VXz@}&IVyX3#u zXFQl%Pq{&W7!jEGQPXnj%G?h!a-jE{DuszFy%z~z*mPv9Oa31Se&cjH5zr_wg z4DOZe*EVYdr}y2pT&b6w_hXhOiSv;DrM&?$Z({bqRUP+$Ep1QRybjpXMuvOcoEH;) zhmhuujccz78u%vYUI&*!kZz!lUb8a;ld=ixnC~~MO95l}CZ%jr5_td`EIoSfHIUo& zb>W?pF08(S;bfzJ;O4};Cg~nvB9|E3q;S$c2A@1-4OwFU+xz06+7Z6H^<=q`Z&wTd z;$LER7EJ+hC5#(H$s+Qnc_+Tv zQXTnXiZ$(}24QCU)u0bTt7DTx`k*pV)W8 z(;7ZBq0ngii~jEWH~cu$DZ5LAKZd7j6T?^&zzx@)+lHAKy7c#vfty*oTHqf$-N7*+{Ze}(TLn70LE6?{^!Nu80 zmxs0Jz)|HtPP=>Ztw-#@SSP}*y3cXOxQhd5#}D+iyFeu{+kQ$c+!4lRHjh$0e7RF_ zkSKxz^mH>I)0+7lj=<+sn#V@B*2lw~(^AW*cK?5@bu2W(&^ZlzpAstz=V}-dR z`iguOEZBPY?B_iJl_S3mAV2B`@dN1Cti9P>la4oqadKR%O_4EnypU|Sp?Nfeb?mU- zp)8dmlDn#c(p!#Nt+3TMs8PgUSUq{8-7Qd}K>ecx;{};B@?=ecdg1>|vhNzKUCqCA zl;$nA;NQJot#S5P89W&jcURWOn780)|C4X`!wtM4)FTm{TwuR?eNvI00tRrf{%{;f z*~C?9uJ)C#nLt;|VO~aOlOD1$n!&2EIbRPCE!*$yTZ#5Jl5M&g@s<%l=*UxOLfBd? z94=RU4*O2;LR=qKpI|z@W}4b^9kTUBZfa)?M41KyR^$)q_~CMUURJRVmdk-v7QsC3 zodxz7zqPM3I0Tn!-b5!n)(@p(>ro7;@RakDKAb`4ci6A^3B5D-si8|?fU#I92WJ%{ z!$J7+*iW|-G3|RILDF8%_}r>3T}%tSJ9J=z<72W~IAbc9F`GL(MjpXL&RrgHc|H5F zUf~2(3xUqJdy1Cf2jkRuow2ifHINcLc zk2UY)JbPgH2P6tT?N0kSu0Z(M)#U4EP=-i!Om9xPecOgIIvJ#uoR}fs7{O0(M{vZf zKNGS-H^)bE6!+!>XiF_#vx2VXb}Tq48x}g#7 z*HZAt|KaJYlQ330b;DX%R`0TDk>k5T#=Q0coWX6a=JMx@)Cd>F(}^ zrFp~m_ul(!Kl1UzFf;ewIp^Fnv%p!r7RKPYaF%BRuFjR9XNZGK#M%w2b563?etaIC z<8+&u1EnVMALq)(UX_YH?8BJ5yTDZNHyhj{r&wJT_a3VztkrsxSlWy*f@s)RGZ1Iv zeXI}%LV_8nN~RS3&*0Vn25oYyBvM@6&Fdn$Kf`UGXOg?=#v3xQ910RQOk${sw8uC+ zra+r057fQ_T$nqD?kN&eKi2V)%d8=Xrqra6R@G{_88^+-ORZ; zZ)9|gI6$MK0@#0Jf&KSfZb>O*W8Bo{?m~gBhMR@fxe6A9EWRQJlIJ#9u6)HO|$tCR?rA_eaO%Y^TqBGc! zrj~wU&*Y1x%FXk*RM*vj=Edse;{B|*l(k#ypy$EP(*DFsBV6*nyuoe=eVW<7KL&Ev z7|GMo4P7Q#kf%vjI8xT^5=_|5R>&_?sjH{03ot7q^)*`=^kRJV?H$?gbD7AYwW3+1 z&Fs$Y+?V{RCH{b_Q1*r!G-U*Al2eq&`kX})f!8KR6yw(a>YeA7Y`S|La>j_0beK07 z&j^=ONH({G4l{r}y-)&6%56c6h*n&XL&_~~V?Sh{$xYe$EX$tvQ-;XaCzP-uMv>22 zN6)-q7GxhfvOt34zn=H2h1E&4VRpulHfc@8Na!p7=FP&Cnr(IVy2IS|Y#4loJYV@C z@}n(n{Uf2cmn0CqAjZ^Sc}%@$dNR4VpF@t7S%qP!R72G-QBA*5Saqm-JGp_foiK($ zR?{wX9kHm!@1e)aGkNQ>itMCLNH4y4+ywKm4%19VZ$_zawq!CFGLg7bJ#j1nUmn@a zun-qj@e81(m_I!UNz_P*3p;(N%Yyu9BltMLeEOgOGqVLx7oDDNE|v3GCIt3tlGRi` zeMEgHIoEnlW90p%zv}mtF3n(A-XxH+LSRxAD$6;N<#8;nR)V7Ip+NV+Mu(?_GHAZMm zvzkeHubjh92zB(p|CI8UTBcbe)Fd%ki>IrJ<7I8~D|}ctaZmnS|e? zfHSUx=S1u;uSWJ)rvk}rmDXsQ{OloN^`DKo`GYWNXW4gK$KE18OU-VJn#^w1eu_si zbe7;g_h#(S4!fW~sK^;hLc7U$XY-K%X@wWbFIdnUu=q1?gUWvHiW}@Cr@B^q9EGG_8+InQz?%)`C||U9?HxYS%sogPJMOL3Kw73+4KT2 zxuXO!iSIVSkc{a<2H(v)YHi#xY+#@07qWNVl!o<(C3_z(ay(jJ;j>}HRx)IOPv%la z2|Ca`v7Q`($1)+@tNOYkh(ChNT`-Ywj%Ppc5N|I;|3wY+7v|1#zAka1lxBe!aobb1 z={q+D+EJVVoP|-?YQ5hr6q&&)5)K9TKg}W%k<<(en>ZiGd~Y96UHdHFRm!n)G=O3+ zoYWxuU~~B85Y78m$ggJ^Sav#XDl)R$ESxNh@4M~s)PFv+XO)uY4U<2jT)i+{4=Lyf zX2mHDqmuA9kZ~if%VPA=(`rIoCdHh)JTZEc{Z3d!5p7%(x(EVeLQ|?$WqIG6Ljjku zQ1D5;;$Q=GBHe~}4r4wpZG+X6c+7N|H26&4iq{=!eIomDMCIdlp-@=J=_Q4nKtZ-Z zr{?3~KOnqV_OdOUa0jvu!BBk&XqGC z9Fdr9kcgMNGV3=I_;+e_I`-wCdK>)6YTEjc)&45wcRDql~^-v;D&s_&0RI0*zhJMj%PtEU`)C)!^0q*CDAh_%R%KHWI!}k8XU4Wz4fYUpYzwoJ@=HTLH~tK=F;oKXM|J< zXnzdl>&TZv?6q$#r*@#Z57xt7X7w-FKV7fb{qqrRA*vj#cdKU|tIos;CR`p z(i%YcDDtK$>>bGK@mya=%=arcYuWe4t5yIkr|V@Z$Z zcF*H27TUYaNanSITvCH^4%lhr4<8I{5nM(4oMVodJW^fYo`0|tvY0Pfr1Fq1u*k#1 z`^CuCRG#(DlIV`iDyma+pA3fodV$@j1dO-9&iAEb>;}0zv%4B|J40S|d5t`Uzj&d4 zGqF9*b=aecBuR06_+>&NW|_J~qYj&2kX!OLnu?glA^=?sQs&5n!!OggXJS!LMq|%H zqq~A)7(BWF!BnPp4(eiXDej>+ zH*rjJ$F=xt@2YI`EQmyx)lf z4qmgi7pgeu#~IRQ>#tXyO6JGyyWj3`;{ss@@bl1h#m)+wGy_0oKJAolP$GG>Wbl7>u?Are!t z{>M5%mErj5p)$l^gBT8F2`DrbxlJ_1;+{Cwy!ih7CW*YB!mM)&`R|d36Q1F@laCXG z%}q1rXbYyaplR@H20F6Zq!`#3gFi;%Q z2lGpxO({%tD;*@h{MSO?c6?!jD_JD%Egr`pSL6gfG8Wx$t<_snU2{h*^(DY!jSf0r zYA8WR6`U_YVN*?XT4TV>kS3KWd(fP=a3PSc;I<@#rC%(j>UhDw^k6R#Q}b#>}$56 z<^yFZ|IV~cbSy%Vwe0Y!jyKx*=8TT-0m(W_>YI+G3f2hua7@5=O{SIX=9t9Htlm65 z*M_2*u8)e^VF#vr#1?&O5DT(Li`m2&-!-|Gvz?Z`;QCfrZp?w!mtjS!QEmMg#&KMe z*`{jb2AQwUI`H@-0#&Iqob$iN5l0bx)3)-)RD}KDJi#cKioQp}q^(Ni0~HN1_E0FU z#T@f2E3)UWxJsYid#DESCwsI2M!|s<-i`7j2qAE<(Y;pl3waS;5~OL+{BG5n6!Q1J zQWDlx(d{9AY%Ljnl`5Zmakndp3{9ckd+H1F82sw~Bb<#s^@rjp4`E)zYlCtuPwb*5 z+@3vk9DfXU@}n3L7BY6xwn*{cl7S^7S-#xzb^#WgJ~o~G7=-a$qpWkp-ZpaXp+mfF z1#%U{)FakrU*ilHVhMB<{UUliqi|Z0T4V zEh*eT2s~XYiml`a1YvlO4W|W44*{Jy%eyr3h z+(#)Z%HPeiDfo(`BUJrIB-?6f@eLi*<0+|;=l985j!(StAX)&lojjFtBq|}T4&G;S zRE|3XYV`=3Q1EVOoP{J%8b#IpP@MCJ8`$_xCl~cv-zdF^WNl~wx`I}#_ zk!R%PwQbf%ORD~Je4q2!y-0j@gPx~)1oFOR=W3A1@|C`hw_?`&B-rklCeG1->?aA- z^?RF|6hS(?iE}cck@F9lVEA6Y^hzvCYa(Hr_dOeASRwEN;ND><_DKj$8+l-n(BmsQ zHP_OZvr{KabkZKeO%mRaDMf3nR>(t=y*k=?*_vCr;UYpy%RuiCTW&K?`z}8mbc9m9 zN&qXG9d!1+bLJH6^uHfxt2$yOrH`m*P566z92m!6D0VM2NnR;EzFAb-d>*cCS#9C=&cyRbx za2Jmza$~#Qdcnq^7d)?GX2E)u$cnR*D|pE1>lV#3+O2U7VB%<2o)1j3mQ$A{cI11? zZ_Q#@-X;KuB`~QGm1W~_wpk5d>c16nEMar@PHh40U&n%2{#4-olprEm)Gf(MHA(WB zs-QND=USvSV+!`uZ}C{vXYW5&UwZukk&>0FEO=dz7n@9-rW>PYU1DRn4QF4OKNc7MNnq+pIZZG#7Kr%aFw3YgXQSrl+aFi$=Aa6S8`3 z-Ur$c0hxAqxSwR$b`A4=7VL7qCJDhPbzdQ}tFmqqbNW z!-BmJ%V;vG!X6dkL$|N&Ye8uUVPq+AYVTtWNLF;zyIvo_zZ> zaO>zOm)ds>@pqQq zsFX{uZ~?LKYX1_vH+tm;eh%KhqbH)mlwf=vPi>44;d#zeQ-PIWf~Wkko9JJ-TBL_E zQS-ziX|`EtjYy1xfGeTX)O(RRDI}fQ>Z%fkU5QxLa0bSJY^$2(lV)|8o!2JTyynR4 zboVGv3TNk2p*S!T{Y-lZn2A2wG(-mfP#ceROd-ZtBLrvnRHfQ?dmN)P?(z8@sd+CW zbP*74HVGf^ zBUe+iWn-x8t)E=W@s&5B4Am?Nn}%$J5}}oOH{2SU&0v>zwdOoBoo6;VuEee`Y*>@* zV2;iP8B~b73*SNL)7ual!G8l_UuJ7sYya|S5CRT5#TRe`IOtUKM2^P|jrxr%?UW^R zfu2TB=x9;Y=t~MI1rNT*VT5O=$*kpF! zZN3dz?5zxb^?-ikgWc<+s-D%%iq*E9W!FxU>KQLfbfq4`a}r*^qGXwOt>PpjXLU2b z7Jjbl7FGnkHqU9N-(|RiJ-@MpKnVNCSzY}{PXur3OMg%43NP^q-jq()VSv*$&iV>G znC-9Ge?}tG&0J!mjEziPuB@o;m=;F+WNvu{a(zX+rad)-3eG7!s6ER!9Nwk6(%6pw zZ$D*xLC3EhY>XdFW$9lw72Hr~(C#vMerL{&x8F^q{~1=fS_CkSVwdAm!5LqV{9IK~ zUy3sNsR!r$g>XQ(?0I_$;@FbC@bn*V2^`+)AUNh<^YB#P2IUbRa?ar!daYVY7JLo( zrR_=UjTiKE%~`Rb4k>M;lSN||m#LdO4hj{M9%czBRNNyeJG-uZr;Z<;;nh3pjZ<*( z=~-^C!8=T%;4F(1sMQVN!XG}+5>X5#G9%SGThk7N4?VZ8__>+S&v#Gdrlj;5tL~6^ z2V8rV+yqLwX1qB;F_S-Kkk|lU65=1ezUzuzvjzc8!F4yd9ty$U}opJP|(wgCs zZb|zocx>#75sKg5n>WK5MFZcPLbu4BAJp@=KR4m$j)+-VRs3f9mtPgS1(1RpKne%p zoeQWam6<&wgWba9Bks$ox_k-o*{>QeDJw^r_E~yHk6kT)-Snhc{pDFqQw<{G_2Z5m zrjFG1#gX}2G+ky_K5uLCfQ>K;pjXI)z1*nMlGY3izgG_#&^Q=HakSM%kU4twKY6DRVxk z^$op0U!xDO@xgrmq}0wR)h$y5<-B>pG?m%G3y&`>z6E$E;zTjkMoguze#}2ms-I&k z``{>CYNo*U5E8_8_#%*$Qg1y3tw6F4LdWjfxWwp&TbY48|05d z#hnoM2Wp85p}}F)0;iAim)A$XEt!Fh_U`QQ@MdI*vj}kaH;ga|z0N2a9MC&;(#mlq zOT?!qQ=J#XbUJ(WP?6BWJk%Skl!ba*V@_W0YI}KU*~FLgwpoR5=zj_{O29Ol3;az} zJJC!|PaUsMcK0_{_d9lWk6v$E!aWb|4=mw`4c=O|x=7AHc9!UlJ%qa;-5lA;jvgrW z7Ma(TG>>g1NM1tw`L4!aF}bN&>Q6?u0QvfRVk)+Z|CB~Acb;_>CW$}w_l;67CiO0< z2@XtOz1&2QbOCypyb@9On)@7{H~H`EHcRbnsQ9Uu#aRSNP%U+9v-GQ%rQtYoz8nEs zLgXb531%OU46=w~OUT|^h!8K26C=GFY*-DoZ z$}ZG4{!XgN{-0FyCbj$EFne|5pMznI^Ee6e#-p~b5kEBwA%H2Gjj^ZunY}fL#kUwQ z4Ma<5vD(D#MxtpDPnwYZf#5nPVStI67iPZZ4U>qhW9mE3ja4 zztZkv1IsC?oofk}Q$`zeKs@R*$FK2idvSriq9XC_J+9dwx3&7?rihRQ&5OaOC^c2I z+kT8c@sH1^(8lovK6k8%KvJOr{bg;f6qo=K$G7T=9ry^7?YTN{ zm9Re!x8<)WwlPMqlkI_vO4?7PGm2%GpB9akjRx%FmckUPOkcK{1J%?5sHQv_vpNBp zrO(>H(#i7L3n?7H)^8+?Ka84~qb?~VdFxqac^6gvNuQXqg%T~ulO{ti>S`+{oU;?B z@ZYK1I({No-7aE-v?-8XgJf%iKD`K`SrHBcV72|Tch$SH^~OPAv{3V$i;%=tW=g?( zroKUOTUrS5*=K`?X3lgFfdWEsAo~TK#G>aqC_hvpv@~agTQg=u?4XBxn+o-a5A4fa za2=TL3i@w|BsAJG(5r$b-I2wUR?z&gF<( zJicUfeQD>3r243dnok59-+szl?@EBbgDd$4B#2T1Ds$J7`FfE*d2KQ~XYC(RcS_;< zR;mr$-Q}pnO@}jfTy9<8d_3CT+`U;ity;3@Z?7sJWull_xJI^ME}fO&NOHWKRC%aj z%={=a9PLs1k``izHbJ4X<3S9@JX!i*SKi}BOrrPID`30O@Isz*yPRcZFW~__WZWxS3E6{E>gn;>n2x(i|fPK zkq@u;oD-cwy*}?_P2H2%K!jDWG|NHRG3=9%l_92-&wVxx+Jf1!+b$7PiS$W3Eq(L^ ziZ6>mS&{%kBl650_6`eIi9#w4wGbP`MCikwV|m}Kd0PwX)wdMl?TWT-_{8j zw%FgTm`=Q#(9vh52Nlx)%;%M8)6~|?!<^X8IO=2{OGgic01+LL`NNl)CP1uWe^~$& zM=mhSzxvVMA1ggQE07IsH$UzyK|c=@i)j2|eQa(Z zU+KdBYStWX&mrXdne?N5ms$i+US&8L1wwVfZnqSHc+z^c|F;rdtP!RBQH@9?JUTR3 zUf*4{NL2bSl-Ij)O4Obvx}3+rDDXaml4}Y(mG*a+|X?D<>+{YI@(6U@6WXi zcEtdPmF37-~jk_Kj%Cmhg(`Kq{8-F`daMZ8o$2;9UItyS01k!GwMJ+Zjiq zvuVr=54>mwY=69+iO02G*2ew}VFN4N^xJ?gF(hvuny)}N5g*`QS*6kmm%);_kWw{+ zI|04~x7LfX<3MA(r_jijmi85Wqey5Hdq?H_e@U!2mUtZ#3PUFKPqm=;MUOp~`!O8j zAA=^a^aGwngN`5TX67d|ImfSZFDIoN>Zo_AO03Vl3EyeG17(fF#3hdH5R^3+WwP_q zLb@p)EATyd8+pk?25H&YzaiUD&1G;lZ0G&zWOa%q$JeuwJ|l=4lzYr{5dj3K<8H!r zP_)BJ4*4#LIm;YsBdot0S8ltu_k~d_R zrRYSK9+!6v_AOoW?FQgyVZjK&$8;r`kA^QAaR@nIB0!!KBkDIBW%74XGG%6(ts*@} zU!{0u?rP<07P)f16>-5B^DBQLJ5D;m#t?V6mq=ftR4z5 zhADt$u*g!}#Pj%^pid1UkS_2@}3?7~eIC4 z=$ycNvV+#A`N4^;*H5B2rOC5+1{$qafRUng&VV&{7A>G?Q|L_(To&CibUbq zDvaYAaKfhO}~0UC-jKp9W|k|K;0nHlB!o(#5Kgk`!z-$O8()EIP=9`>{;2}>Z`_hNiU{xJ@nz@eO&G!x*tJwMra(Q`y(lS>sHN#-k zp7o?Z?%6(`^s3LpoF!?4`GuxZiArB71hAUeGUhIk{j<)A4z6iXZpssr?Yw9Z*nY0~W zE|S1qEfjhLBTsdRO z)qW`nY2rcip}&U{bTUj;qZdsD8XDcd@21j}r3Mn=`_2t6!u-3SE9|j$uEw1lqK%m= z9@Uckwemj7p*%am23b38AiQRDTIH$*_o|2M$3N6sUR2VvdJ{g+r_hO+MGKxhZ(%H2UT9|N=|^x_@{}zXvKO1=%KOsq8Fft z#_As$^YS`YgFfau37Te23jkCJ((>qkX}Lxs!qAi=0msQC>6=TwD>g~RaV&wZuc0Q@ zG6yTkkVZb>=26-_E!C(lB3x+Hh<7Nrje9FLG><01*a7J1?=-Om)?Q8#4yoU9IH-_) z(%&1ojz(H>b_9=Nrt4UgYv!1|5+x26YuWq1UT zY(ef@Bdt;6{6aI)OUc{gg<3bF(=k$C?M!f%OMTNO3jiJ@r&N?KNi)6M_rL4-h_E!)~U#6J!3f-M!6A02%eVq8SxK8 zNQ)ebc6ToY_ULY$oj;;jed3Es_%415Q41^l(3#rA=V~rqJfmf4FJ@74 zed=TG>JMh++CM$O-(oV-6nEgOL1!kW@b7gPOBCU>0c#{djOZp4FG#NGx~jTaxV)*iIM zBz4`>ycu5+TK#A7f(&9+j2|>lcPw6-)FT8$Snyi%_0Cv)tMCr)2)?lNAG$BXN?q{Q zWKuiUx6H`)<8yDkR_aNTHa)-SR4Qy-hm+VVkG$nEXXoiWn~E+@4hz{aGn`oqHpr|( z+?}p94Sfo9ElPzOa4y}Cn|jNov3{WJYeK2u1Ee661>5X86|KwF?3tY}Mb8>|DB)uj z)H9KB?DIY(L#wWDRX#kL`KXAm@XgR1&>PVZLv=D_As|1r{B{WlKLbC*|FIs!|5y+1 z8qk}9qqGg)bNEEsBj11q%C9Sl%)y&TKHLE|nGSea1ljc^hRk zZX6P|YIsSGuB|2dboYM(Q&=$oI#irx+}pC>N99J+rsT?98X+refA>=c(Mz`Pda}*k zGFMoBA8CQiq8 zE}ptsDpaIYDc1s&Wa&Fl!om3E^=Q5LiPz&(lm(CK;<2vH8@J4SLj8s3d~*WX%k!ZS9};e?5rWSc-S7XBEAgyVEGNzW=(@D8@AU9e}Y*?}_=Ydm?S$ z*YhR+^b%I}f$?g>E%sBf9}I5fN#7&Ls?r4GD>2Guif$LkYEnu zTioLrfa=3In>VBq2>AiMtcbP?S3^{&tv|wkikDsw3cdEL(`hvo;vmg%SqVtK2bDMf z$a-?O;PA{`Q^U90_F^b!#$8#=^OpvOts4*I?X+lJZ5_P&8d2pVEP={R(h}xcOUS>5 z&x%>qQ`Voa9NkB;EW(Z;(5zz>xOeTZ>D(GzszVBERK?Y5JJv{hla zgm^?_bquZM<^3d2wEgf>sU$;SN%ZqWF3@TaDUw)}n`s+_AZ*$`CtBC^)^z>=tZ!^97ZP z=G42L%)D}Wf0gqj;u%rl*;%TP+F|+wiBLvQtf}!k?y2$$-&QRdqMP)~#G$Skh$6jQ z@=@Tss_@vr!H#iA{X+v#sa`^lZBM0zlqd#>h{9kc3CeY;AAZ zKe6j@wh6ez{1rGlF&3Oowuht0W}kZ>=ViW9ItUyo8|Z*=9NC1lZdNHlS19uZ19(I- zR|bp)zMV4!%+MA!#Vk62Tvs_RN_caum4xPFXa3?ozt?ME`GfsOw1>@s3e{WsAZGc6 zo8705+Db8>cnnBO;3>tQJBjE64tjx7^nWo5?GlcQ8!s?#ws<68z7!F~oL>k$Va00l z01ROl<3@WyUk52WA=u{s?bKL0htY2kDEk^yntE+=wsk&L_z$?&dZh^|SdO?Togg9A zZ)+MP^XeAGM4Wnr4>(L5<8Y1u6mgu$1(&tSOxU@m$5%p{WL|{6Ez>gOX`|7v)JO!u z>KBF`fleOvpF76!ck--tH`ZhtaNbLir656_EUNflu8=6vq zD$5iFGvqI6J6ifit`{m*&h2l{9X-Dm)q)1Nq29k(n^zkEYBlh^L&+%3hld4=o|hwC zay&{r&r0XS=8Ky@p%4|xe`_O3cE)t6{@`j3Rdv!4?Mx`(!7yt*t*@SHj||OBWVA;iazv@_>mN_b5NoX+y!PT}Scf#S*9UvTL!k+21 zK2B)+gz9hzGaY|gYb4oY%_|~yVMnxwgZW6$$r$*2NM-@a#z@B9v(ub#c5no;IK{Z| z)w@)urn^*Y_WUo^0#Gvew{`~;J3hBoi>{wOA3C3BEb4xoKj<;(IKWJBK*#I(HVb$w zrq;9Qn;c7`l?H*y1%(g%`uZ5LgpUS>=*<`q{VB!I+wP7CM0YF-9CnDTZcn``NbSz_ zzbT=A>E1HR6C+hTn7=f04^!j_e`{i{h(%>wjaF2!1gyoB2I)nl+gPHncN5N#@IL-T z)YbU{)@1*1G^DyJ+@LtBX8pWW{gRpnl zu`;oNF|T-U&pEadS%y(}IGSGTzCGF*n9|8S1B|t3u&iRxL4gQqj!)(BS)<-lkC=Ou zBL}kI9lXM3w9Rb>v%%2D3>1sHH`?)ijLqxz%FcMGdeD{vlTgX#b9~~yGQ@&1-2=EU z4jHHMjOd2eFw)YT--So1~wKV>vz83mJ}Q06Z1JcPp$iu4q_iLH?Ne=CJOa>_rV`2bYjv*`cM=Siv;y0B;;~4>qE;Kc7=+e z(cD~R<MBuF8j2FQ&~ma=-{#Kxf4Hyr7Z(_rSVPFA|7u5H{#ZAdm{|i+VEdpanO57*=Oj z{;gLom`g?lj_1GL>}l#$jJ_f!=tEkY$F`^ZLUs1eZb~61-}lZ?=jRjG?%gi|Y!>TO zslwC-8vc;loPLT=sv@C9%(`~cXJ+1yU-b0j4mMh~b6G=pT%z{Eg$PyI4CiX?yi!+Z zT9AeIyEihZD6{DASVqYag9h*QBBlvN+I#nAgHoa79xiW5WyO?&%``Zgc!2@X%(lCv z7Iz!QGnBMVQZ_ghYz&B{^us&XT!|C-X!*z?^%*&dN3lm`s;2En=K;*0`WsYUhs{s@C~q4r(}CV$O`2_DUPLBkmVC7Qq6vzudz+p@>=3ffi?LVWTj z2d5scM*(5_Lrc=n{*a|LOTf6VS$;K##BsJ}OJ@^&9)gNDo)1=|Synqf86?2|n-^zz zX=$a=`?P-i8n{a0xSFy}q{Q1)UK1NcjJDo@3Q z-+$#LZk3c>5K9a8_lW1oFg-rq+nXV9{-HW@e40h3E;}-!Yt!Vh_L?SRcbA4JDHR{w z%4Ai_EXr>_@Kp)0=b6H9<_@U_x7l+sr8zcdUKN)#@+FeDBOx&Ii^H1a*Ca;{4l@) zT}d%vImUtaPr2i=O_fmNjmMJ9g7CP|)u-@OM9uHnrSz~~ryq#DaI>O1 zp)pBmdwO_JR8ejDw*P8HnBp=m$^ahpXZzB~@S#}vPQkl+XEC>_WFcwn?JVqq{E5-s z6CCO)C2ApwCEmXzSuqbjM^QqsaB$$mrko0)NMA9=(;|X^&tK(u!~X_ea!=eQG`d~v zUiF<{u5Q$kd_m2OC?kJ(0<-$b>M~yTi~_%@Owu4iwkYCQ+1F(Q3jC})$;@$_)=MF5 zmzmCC&(kj4|IQTEa9iOeX+c_G&Xy`}UCTh|XTUTozedAlvATp?UO-oy^X$(airhY= z4NCbTUF78M+?9FR^aIk+am~CXJEqEbj7|wT#@>OG9-BJ-fKSZL8eAU`DISC?@OpCn z@LnKwa3DZ^>1lC3x;eTz+(hN~Y@ki`e90%c6kjYnFSQyURCCDuzJSv)b3Bq0*d>g1 zmRX0MlbDksBrOT|Y?zx7xP3M~3zxAu4#%-b9`_l@j?f!8)q>xnU!`D@B3w2A0`xhP z)NGqJ8hU-c1tt$7X|TZlmGe}|o8V{ktKqLiXM*G{AOcUqA*uplT~htw`xveL96wBd zPmuUqkR$C|iThwllo?xUd=Ycsfkmlr&<;&QiL?(}M@*T&m)^K~g5vLt5Z+v~Y2K|k zRx?NGTD;dchF;SvG_*v`qx*?46%&}wyj}GQdQG`F`YVo_d5Z67f5IK_%QSJY+(+YY zeoA<+%rP_|Q>O|8bS&E44&IG@@Uyn^Ch^s&Jx&b`@z=5X&oj%SGiC<>NLrni!ygsA z;PP7v4EG>Z>o7G?8ldsZI)Ws=R(-MWHOc1v(aqhq<5H1Qb!EFB zV?WLw^OvbKJ&{7#&R0r{L7f4+@Ji{H2B!2y*O?~Qzo7qB{8#*h&_us&{rX;YUKUCi z@pCaRuQAz%ljCcBm=iwrM7@X?n+WA+N=PAg1)Q|d)QPZ~G2oWB8aG=`+lSK!!@$Y{ z@7rSi(&#VeE-!GIq4p5WTi1uE+1-OXgltahhh4d9Z~5T0zYTXmI-rjxcikFsIYJ9w zd|ycKrU+zw812s{ZlhiP^w;>O_g0fz`eL*kl2HVy5=L-Z%VBZcGqZo~>CwGW?ak14 z2}LM<0*&VuhH3-EAy-EB8tychWKX9T50&VMSE!>_l8bWPJ*#g#T+cpzJX>->oty31 zUN|~Wgz26d6>_0SlIU-X!;Ex}P+8_vF>o%jF>O1l^9;VnaRcik@{Lw+#7%AA9uo0} z(949_{wAZUt_?%dX1$cyET<+=7eWK|Roa=e%S-=33pv^h^~9~;{5zw*pNeJ$h?H7 zg1y@pTn}%OUq(UazQH)#dLf;`-s~+L_oEM#jdBwRkiMFsCU4NYj9*P6Ps6DqIZxi2 z91@kF9jf*;mv_<1P7Qzm163Tpq~y#H=kuzQz#Lk6gGf_N zl7dq)Y#SM zs3T26{&rRQ_F|{=R{rvALf~|nTaaGz-GVaa0Zt=vs!*^@)BQFbd8@y!D1u@Ext{y~ zHk;Ar6iD84v}L`BoQv2^hS2iU5CA2HHdl2Hep6jnGbt>w%O&9>{m)UQgX!qGo%K-a z^n_WOQ1wAuI36JOOp|4wGg-RQa7=m6HGin{%GW2?QfRN>p6bh?@bmV$20G)C2=)v2 zT|S>-Fzq#m@VSw{S?{S@7;iDD8Z0>266=tz+Luc3e@WtN5Y*xqEFVbAeDu|y*5kx4 z-rHmbR?#bm#ng<~&@X9bB)FeXK#062C?GY?j12tnL)gf>n#8$g)q8({EE6>B?MW<>>SrF({;ZzLj_h@kOG56SIv3#Grg62u zAU7zcG~o=_(f4mfKcIiv5O#i5oHyxOs60hU?Hu{KKhGv*hnsznVENuLd%enIaWr|P zV>;f2Dz1x{%~TDM9!E#{Xe(u=JIwO4y`47+gMN^ef3Q3=jo_wgzSuSuCi66g(9fx1 zetd^bYBQ#AwE7m$<_Bh-X*h>m|9_oXv{!1+>tl8$$lO?y$uH-ibSr*dzOI1@&{kFk zck(x}O)nI{n^$jYiS)#~^{f`%a@g4P!tyjh9Ww~(0mH4(g5m003iaPs0yFEUTle6; zhb%=M6gZ{~d;2NDCgD^`413W=Z6ahbt#!FO{v%{#JvW%xnt`r2%>fEqFTUOFEPBxY z+t~!Bj}C@nVsL)C?HT+Lzf1Z@RlBL@j^e)e95cT!huP-+l?$^6rw7D1Ncl6k$ZPzJ zx+Jr0nriXvVaukUCyg(`kuml$wJbOnMVO@anUVfStu@pb^r^Z6ZU%M@s%qGVOUVeO z1|D|7IU29}z^4={VCc}&#i6!rxkt3*EE!fQCV*u7;2euJKI!D zh3}j0ZXApw)=0V6=sNFLzn&(R`p7MW*3|%FW;c)otHyO;b3wqt&yyV(O@zAwn;PCX z;y7}*WJtAQ)W6qwN3%qz7-Wr@ku#5wsQn!NQj{`O-fe+@QXMxkXFoU_ho8%R`d@A$ zQ@b+fqx!sZL!Mb&6nSoO<>iAIXu*!8IQVwv!WaG@N^s=b14+zzxPI)PjI5;go$onn zl4ngR@OLD5o8~zubCfd<_hYQbn{+dnN`HF7xU?SR#)DNWKamjAvD>{6eBTVsK2h)9 z7d^itM(^>v0jrfc$?8k_8g~jV+4RxuEeZ;BHr()+?>VwpXvnZKEWoC~t9km9B~-$u zVRI&9NzZP~@@)+A9tjGdRhnx5l6qr9gr{5%QkRdY93rT zPootSlA1Sn1OJn0URjK+-su`HjMCM7X<-ZP36~Ow)T^ny`h-sGRv|_vBW>DYJ^hEX zXaklckzreHL)np^iKp!ANx6#)gnCcGX)>CIH~wW2m#n|yN8Q(HiL?jm15<)$BS9LR z@=cS;C=s7#?cy5hU>AjNf5L2_-75NAUHC;Tk-)fU*nsG#Z>yo5D`u3V$bkY1*96^6)6~FFUtql zQ0tKc;%$2VzSQW!2Jmn-cyspNchlO;4t^tfSXi0rFZXP0N{oe?tIlwCvQWVF%A5ot znD>&CtPzKSyG2b3STlEmJtd~qg(ZL)N8EUC{S#iQ0ankr?1L=b45B%Vj%h+~>}6n$ z*XtlVV;StY6#ZZwR3mhvykC2WTAB`Lw?oZE+GI9{tYa{ZSzodQ2Yf6PyB;44v!2~4 zLebVpu?|^V;Kps#x+<1h_4<`1rv~Mx(~eAn4-NRypW<7qrvFR zM225^d0T-yx|QAW&2NG;_r>22NgOtR%*Pcm^C)aq_Yi=uQ>^`~ok&1fG%NyElgZF- z4I|3YYOP!P?|21EoE7@P273se2>p&WYg!EI)c-EhkYMd6|RW~aGp*R zg$#ap&4kAuLizDtm0Ux`>Q{+a^-42zN+w7dxf;1DplZMP0H^xH{>?DG|nfWvp+TALNa;%7g&S<*da8Wjpb z=a)H_B6Pd6xsGG_C7AqVFpc&Vu6PsNJw|do7MMhJsXO~ad|E?)-Omf+mN|O2Y5UfC ztib`T(qHTR^bFS#0`M#A$d8=Q8vB7vf%@M#DC==H440Nby|5GM*v3r~*qOXBU5GfA z>3@gYe=&a-kEdDoxT=~Y|1#||2?fP_4{P7({1@@c|BHBG5b-x?OV&f4 z$kayosW9p`Su3VCbzI_*Jijk{fX+s9DxCtj=RQ-?Jpc&jv!E9_`hkI5T0qM$V*d(l z9a6tqHc~YL>onGMm9!w1;3mAeSCdNkW{#V6gmEiJwL72m(&&bTZ8fKMiOp4Ia`zaY zqlGk0Ha=inSS)qOAuTSRG59}py>(dCQP(Z1fC@-#Nb)rF?N;F;fKxfSoIH%h%2TP_6l2L9>E9jVlTV5I5pT9@GTUTvHOHHmI+d+E%a7*tFw zsy=B5`Sq3I;T#%uy#5br0~8-Z3ytocs(U8crIk~RRlc!UM8ppfQ2p-)so=DSWfl`b zxFP28rk(DmrA0QxiF-f%-}D}t38rEd6xhjoHH&OuCoP4Qa35(BWrV|CA1nD>(euEL z0|rq{+Pz;-IvKpGvGneNd%WSyHE_}Q9+)&o*$z{VpS~=RdI=!tX}*pxTjo7+wp5?b zk@mc|7F5O)TA!CDIy}-=M^!*Ukb!xyNjU|K#VyMt7#Pce#l=%#EMu5>Otv7j?aK{? z_B^_L4RXpIP62>>Ogk3Z$~5d%{%`HSv2cxkJ+*s?5T|*M?FCY-_wv>Bfef$)tU53r zzlOXSQ5DsWx-eL|>gLBE#V_6dep{?0T1FjbuFwLA|6P5`T7>TN)zOOoTyE4O zUr>LLbg?>P2OksobhQN<1PSf?5)Otmq7t9vuv`t z8qhmFak}e~d)P7=W{zDY=A>{(cvwMSq&=r#x^aoz83d8_g;t}~ z_yGk4rK~C(HbrM#*6yl3FLfWdnW2Ot_ADVBd7*_16OeU!Vv4zSwXWHi9u`8jZ|drf z(xgW9PyXTj0Lvo%3v1{;Ud#`fWh7_(VNN{z)g# zoR;sdzaUhR?*!&IRPvbih_cCkS|_>QeGK>U>xPQ#2)6r^Y34HZZ`S*t=TPo1Gakbd zn%8hFlDqpTC>DF)$~iyI%DQ%aDCFV@TUaDPT@N^2hS7()MpDlV2L4M9mdThJP8?8G z8!x+Z(8m4{P^d*qxQgn?TwwzCWJ7H#5kz6WqnLEE^bhjnyG@aoJsm})Vg&P=0o;J8 zY4=8bqby6@V*e1pX=(Unkmbs)s`cL^cdTWKNo8NBx!d5COnMW%euozS0H4#4ThY<- zcFDI6dYb@P;xHV5#j=i->3skeZl~RQ-lsbyRIW1ye>Xp#<#$vt3~E4BTv9|7{sD5T z7a##TUD11?_4lz&pe9%Kg!Ipf?-^t3-X#FpPa&F6B(7JRYw+976SY@~0o| zRlI%+00|NGR=)v#hR|Xw-sq=0JwJUXl_*w=*4c4cCzYFRXteAteVTi0^&uQG%}KTF zwfP1gPfbrx!$$Y!H-C*By+YCqV#yntp+h1rsuKIzW&i4IY6Ua>L+|73hBz)OyCJv@ zN_`JIXd)ez-@t1Fl^a;*S2Wb3b~k?R#gCb&1p;n65SrY2V6rycc#_vRTyz2h8Ih# zEASN7Ws7O+0sVl`D<8_dK+WCpAPSSRS8T^WKRLtXB9Ppk6YF-*0z!-P6Li@b=yokW zdvbr1%N#saN0R&D$lGlb0}H56ak_XG(KDx`p2)LAA6jHaT8pfBaVDk20(yTaZAZLr z2Tkh35wbFl#zFon%+yXAwO~U?8yPSWg-2SOGA$ZC>^fixHIfopYx6VQ7CgRUo}zxk z9IcnhAR7fxJNjB43AKeIJOFBmODhH4#-2G?Ww|XajOcY`y|n>LsNKV^1>vA6#zU2J zz~)e8>{!mWqSu;CfvRB;`)>`aoc zwMepzs=>^yii9GyDHRbqx_To9l||R0v!$jKi!G1lC3SX?hTD)z0=DK9^IF>juS%wU zn^0*ZOz|q)%6!2d$3f;uB=VD)LeSr*AmZDzwJL!4VP|6zzP=ee752PHpIe~3(mu!# zY*ooHIdTDYtsDT6!Eoh4b`-P}Fw-J0Rr!_#SQ@8lsJyXzTonOi_ zr?HX!Qur!SS>9kw;fTY_!c4(1a)x=IS|mRU_YCBH;uU$1MMsG$n0u_$zx^dJrS;$3 z*3}n!RiVTy4iY1aiW!J_i@z$lsqZz_TxBu0-M?8CGUG?qtE7o{#yF=T;&O{j;pE2& zs>yBBkm#N;a|u)Wk2LT$0UUrHNCouebCFr&Y8t@bXXR%gKk{KZ<<{5z6-3jJaD~|- z)iqkQ8{!*qOMD*#;#3;UFX&eG56_^;ZE4J+GQMe%tR@{}p0)Mgt2VzlyS6(+Julj} zzfN8~e`Cu-SnjJKMvm1<0^=?>4J7Zt!^Q8=3>X7KL(Amw7WLNa(Xfgi72Kr^k~X4Q zy-&Lyl&WnyfxZliD#yH~tIIulev@Ns&p-4PpMH2V)hENrmf+Cbkfn9) zRU4hY)uuya?8;_CT8A2YAs?1%ksQk5-NM*&auDV;3jR1y%!7iYQ0BdtnKxogkc)Df zZ{a6%FK1y&BW&NsrJ=JG_jVgxYN~miygnMfyWMq@LJy!cXep2LS0Zqjdr1_^;vQzb z4e_->`Px(Z0>sm=v{(doUt5cl-WJWisJysfc(tJ)qytU=O1+G=`!rq3Ko&V0-+{dEd1K#=|sXCVkiE581$KW20xw`WH_t+n7# z1{wYwGFA6Nrt0cTwHQG$hE&28zqb%gl)kI?WFWL3kgr$qi0l|^(1M-YkuSpg zu|siJN-CppUp1rPgOUH)ozvGvc%YY^kxEGjhS-`TsM#d>yI4E84F9M$(8@Q5_BDPX z1Z2p8P77VIR=&1t_VIW8JNx%7_3$~k=dIQ1b0n9W+kE{d;`BWMlON})5bmmFa%R?Q z)wsu7U^uWL*4xS#iCbDUd<9AIGSafTK#gK=<{>v{?j^mJSAAHl`LA*dygtLydIqep zc&TLq${tulDffiey64w3DIHw=L(U@(h=ZAeMwYoOjx5B1v=}VeJqL@;k8hn;wz8XE zR|S`fk2<;i{Oo|pQyK#j2d0B~h9d$GLvS?}S&n)UW(zJ_rjub@$%862F3p-R&ett= z@nhf3fAcNE6-R-FTuA$4pinu1Sk!^n&B^nqqcn+zaMiY-{Ol_D)CdL(CyRq@4eGTb zwWHcRV$qS2B1hMFF5{E>`goiDT7T-n|{KE6-_`R-gBg_QXbtDI3|W=-}>e6Gu^! z3pbjh{j(I6FvqgbUXEF;02t{uEb6FXezu3_|3@ihXNl*#O)G_27Pe!xMEO+vLWcw~ zg-vj-`aXacB$xNz=jn;+$BUUwSQnPg9{>88gW<1p*8e~RB}0%ulZ1ksRRqO^gaH@{ z${TEg{Ne-m+*;+Ozi&p1CeaS>qQsFg0Ovw0v`V1H$4@gd&b1iQJT%oz#Bh4^m!Y{H zYYhz)mDH2{#_)gnWU;HHT!74ubsaH-@U}UC%;E{aP|D zZPgkW27oE`&157@l~g)_9O19UfFBdQklUp(mU)AZ(CtPA5Cr0oP#3r^F3We62y2WE ziku{GXPEab6y5b`W`chOH6O{BzzhfC7E*y3_VYL?m z0E8M)n-UbEYm2vk0S=s4m!!~H+yZ5TKxJ|nRv(x~tyjSU{B441#sh+KGL2v6$8o;WUt)km#@7%XPc)H#^e}LRiYL>3=~WItW;#ix?=GO z$P6?xGbhVwA;Gm3tKspzPkUbMoSe$vaUG%8~>LCE+!oBL8Ud1Dva#*r2LY7jwJ)+fQD8z0|=m_k4|Ff0}U@ zUw)ZZ^fJDr1K|^#_jxTO5J3f ze9ARSPr4p>sc)tMe?uv$^aK>7KHCfiOy7`zjC$3StS}h^qH44hfA?gD@3vHjSoBt@&l|;tisPnVV0v?+o ziOtWYS)X6D56JMrYit4#WR^#G)iyVXKYF=*T_1aC>qS*OD zN$)#D;IuWbb`nsZX=ZL^04z1?Q*t77;>S#_7P~DaC#=)+e}pe9n{?vx3b|wc1;jD0 zuETbm0vYZ!VWk0e0kg@L$KYq+tjy0kkDt7j_EA=>ABWJSb~0fg9}Gn1gPsz%`Cv)E z6Zb(8L{uFmtw}6n(#IwanGWg!TLI~y=e?-@v~Bkbo=;atYb)(DuL(K|Linw;1ZnMOWj>5lv^zy6{dwS-+~A zED2)&D9H+7XsbI?w*wN~zV&7~d+aV*f035P7~}Qw-y>U{co)xJq}*P9n{^BUx&2yT zAo~A#wIlWV>AEi53vnkxt^d%Mp3Dq(uIS}JE?OBsqK0h~Q=am@y9%c_2+FYkXm2$X$ zDDAkX6jZhjN)F|G`g?4ZGkd4lkAQfqtbV`5|4Zmd?)~>t@1(icdk^le$JRat^rXMw zPc}7v$NJXvJcZ9eZ3RPgPLk6#(@V|M-@JGCjQ>7`C8+Gh{(XwIniFZwHtAF;ILm*Z zjgl)tRy5;ctPAuc?K9o8r<^H2!+r{mEtFL;*))IpM{+aW8~=3xI4sD36~LrG1}qH3 zip`wA`>;c9hODiu@uC>}sVpkp6xsEnghLdk~Xl?9j^cvj$lX`$h z2DrWGMEV;L04H*5SSRNkQTU4>fjvQW+^Ac@8 zy1uU)H_37@{wE@j17wB)Wj|-Ao zuT|O=P=g0PJ_sOk20CBOg7VW@q8EIFHz(XJ{QORih$xS8a01* zn4M6P0`m!W0U6RP9!4wibmOP5rAp}eeW43?mWptO?87k24Jc)R2Nr|>BD~{kfXJscium7d{GZe zBA&L<*3tcAo#@i4K3*_a9G+%bRd+E}aBXqUVL{^JTe%mcUj$z)sITMx)gq-ahbA4j zFidTrJEuD{LxtOWTVb|_6R7#3yGO`-D*CFiZbDB_Z$YEgl5BE(Hv8v!3AR0}#%I9} zM1eF-njUz*FHZ_XnWZ%gxV)m(=3uE)`*Fu5{j>+vqJrn_^c=j6Q**s%Ter(`P+I3P zc(6R^X1;M}2|YxDaLK?P5=x6j<{j9kNc@}EL*I2P`o#XrP;2X--m5J;jPcTtswe*z zdj>N66s@!1ODPrMhNBskfJQOK>-SI_;N#B0EIAMY6fp>|v5Bw?_l5T+!ad zzfaHG1ZynoLgIJzINPT?vZv<$9W<^G?^0QN>yTP}vXUdstN+4d@qPEH^zX*L3jL zU0+WE=XKjar!`9>3lG&C)W46-JI5RFaOl&{G~25e2xnl)E$M=!N;q)WFYF7PSY#l? zEM(uu);i@wX?GgSt4@0CD?R9h@nG<73*JsJV+$A%x|AzdG)6p~l}+l7wXpUd)+9Y4 zJt}9a#B0~;+J9wkXST=sbLGzS7~`- z(859AWv>lxm7d)?p1E^c@ky_O_5Am}A&$@Y1y)Z=Q#d!*f88Pa_RORL;Kv@QugC*6 zKy0mFqIeuyo0IsSS*i~3tIIh|w2ye=;%|P}{zNhF?Rdx4PY{af%JC9?9uIs_cz$3u zxXGgDTA@sMYS-E((Q~_GW@`qwy3VytXXz1FT8Yc)MF==U!VR2Sb@n{_Ina;2dysFF z^>P(=r*K|$am*FeWdx9RAQjyzEtA61gzp(2CL||*b2^l7v=~#H#DfbOMBh_epvUUD ziWo{9ts21I9y7O0C!aG~&dB0^fn+QHv#F0vl9N++uK$w6PBG7*?*m&jk;Cyx^7Dtn zlNLU=lI^(!3VWWrxcsBqRnQgi9ILObnVa*dnY=bVWZrFZhJm8)3%vRl*DLOabyLIo zp35O4Cc{hjHJB<(O$2!EzBWl<2G~2B;Ch$ilOaNPp}As!Vpo7j8~EKk5Z%hi(4nJtaY>yy$Y$FIE+v;bM3OM;a@qRQgev*nVQ6zZ>px^h`-JU(mkc?q;U#`CWSxNv}OD#3Zsat0nVny&XeK0I8# zRCu!c#zWwf$3j+TpY`d5LhnVvMFVYG(xat&WSznrelA( zWyQa*dvyKnJg;(egQ3qDORT)qqn|xI5k!tVIF(tfp-M0@0+tfzb{|* z0!GkTLf6U{^^_MT`^2Z9H?vy`G99pxWU}`y0L7PzDCWK})8l=(5mu*A%rhbe3d8k2 z@OW0$$^CWO2lQTzq4Bn4Ic)z;3-&-g zS|(EecwV?x&v3K3RK=_3B5V-sF=rJfhBGZzxkAEY+z}jH`??`Nadv}#vd$Gn?Nfq8 zoNj#o>Gr0@o|Rr%V(eBTMamnh!5x1&*$3~{cV=KcBF(I`b$AczY#Wz~ojLxsTa>jv z{8ABz@+8p)MO@a!>@7#0IPLux*|yCIM$S=@gpbX$4pyYr^w>J6F?^^;`uVvDkG@73 z5@c%DYWadQ#KZ)pqTb3R7`U(-O@A-A=2{>V*Xe4;XCmB?%x+Le1g;VIYO#~|Aj*Ggg*7Jr;x3XLwdG&ffC#{`v@s*92A(7Af-y9 zEA^FqRg+cf?9Ky7wxL~?IgdV-4e|FbEw6S*Ty&zC;C3i;7fHCjqI8kp-OiMf&IA%x z13^31RV@)t-4?e+G+YNo`5F!N>^Z%^rWVf#uayk5l0&E|<_&6y=vW{8Y_C;=Fr}@{ zAC{?O$NU-E2>)xKtK#N-(QJ_7JCglH7^0&2I)qR7Gr{}!wTECUjNiY|@>{i$$TCUg-CiD zDD7UNvyUEse0zrS-f}gh`!H#%gt+N|o~-zJL?ewtg-K9AF-AZ8%z{XJ=3wdgF-LZ@ zSuTt2dymkdbed6u9R0=(+9e6(RhI%$E`L3ppvKsSze>bOLgYmZyxBxaLht$RG}#X! zSJ1;ro=Qb%`J$_RV`p{8+LKFBixlsj$&wsn+!LGga++*NXQZT2^skdf`PX z`K`iCR7rQphQg>-5I^wzfo#F z5T-uAe-e+>YIN z*-*M7?$=DU9#JGcgV5<@)?=u`mEU(qPYoQ=%GpHq8cl*M3ZkSYneO0TF#O;4!2TE z^LA1f%s&kJh1WqH1ts+rZ!9Ee)oVvNA5D~P)OPQwn9pVT&D%R5g>^qz2+B|jp@Y(v z4`9`$e;fJOI(^8oRT)Mxj>EM*8>YtG#aEc)SZCSAw4D;zOy1jkz=TX75|}*)zXw z|7wF$-BTI|;pi(q@gzS_dSkbU_a?e)mm16A3we|85iz=LISESZXXv^Mq&(+4S-P(G zH#+xi5c7T<&kY;2Z1UX+Cy0+#m-_2$>Kc1YCHH_`t z`bNn1QG8j}$9Dz2-!bm)ALKS-G;_2Xi?;cV`Yd!o)D$}BCz#%bgsElxY5UI3G*4qf zz_IuHSDAk*W>gmh7jIQRAl(o4bZKE&zh(3F^+k<^hFf~!v75$EebCvwzHuN%luda3 zlf$58kDQYDiWwab$MjbECWRfLUA9l2G7iprlridkJFH|6+5@+Y8H=9}PxdPg?Pxeyt3DpD;QzosK>_Un?IgiHL*%5p`UsvlLP>HS5vYMH zerk^&oqk`w`ZmQ_Z?9jK7T~GNR?@g_lX&5K(aUyGcTphhd>S}a*X^hrMc~}k?$v=%!ZK+r-AT7yFn-_1>c-jKE7x&eo0HRP zx9ZEXCZmR?$c@FbqcRvFXLMExsKyl?coZ)ws&WJ1^`zb)Y`m7{w`O68oE_-AEn zhDg^pApJDB)cPCw!^^Or5ZHPHG@%{m&r`X;JKvi%McX|lbaZw->L_0)3D?;>tZr5X zdT?HYN(F&xPg}h}sEshzu}9~1-F3R)KV0%Wnbj}sB00K*YG-jU4-Xf+ikd4^$QO2p zOvsn&dT97pzjs-%uM5-GEEkwx1amQGV^g&u-XB+AHpbT+?dY=L|HQA&7Cn8{6ZQ!2z{2&a-K-r?ZFdNy455W+=%_R*yYJY+ePOksTmJ_GhrJ(ROb73wJPJNsV z7kDD;N*)M4VnGo%a$%WgC+vbt(mcwoRi186AX6R1Z}bDu+>Dl##|<0?pG!n zmuY@-Ee&{qaxH1fe#p)^L1#l1bRRj&Y*4xowzHroFVIt%+_1A43zs4VMp8 zmA5^`-{Mr3FA8>oV<>^bS={ zCsYGIuPr2i}eu$4Qy?c2CFm)cYqrMLpDozm#FGT4fH3ob^C8~?AP*kD|^Z*4ta4#&1=1qgsY_8TrF<@7mtx?Z875i|# z<%YX_p#;1SXezv6Yv{Bwu*)}Hg)Z3GX&?PuSNO%kr*eN$^~(Q<;zX{zU<4$J2_HT; zKr6lyE&<-6wy3?-y)p|2trCj=x7C3QliZY-9~ZEG$$`5d9A(W!;_bj0Mjh_$=P|?7 z8{cJ)6pmO~nPktZ#iWt3m!&epq=~u_yX%-x`@S9mw}4cgnSVfU*vxhVh4Bt9)ia)E zvy?miO;@1WI4LkYGP_+k_ky8$2cIOnAA}TxM^y^?k zOlDHJeC`CVz&pIKk1ltO9-aHX@F5;2$qc#o z*ExrH?;4rB2+egNer1y0DsA*4RJ^>^Ed2>EfIz%k1JI|-#-UZ5!+|=kq`bVamUK=a zqb^GYZ%Psc0WV<(Ms?%SBW-NN*KhaQxLWmZeD5KJq(QenVRTQ3SqR=Nfo|3JEP!?h z&yaT5U*(vDmlY&I`5q8GNa4ZnWcMmE2X^lFCW7D<8>VRB&<4PvjgbzmDQ)d$$~ymB zpw$4`D%V36NtEv-QTz^Vyyc}_o#c``QrJHK_gF^`7S>#J)K{B`;m72X;`!1>9#VmL zvHXva*!h%rAO%DKfXjHm_Pr3I#8I!b#pyWlZ2D0+If(JX5h%p}nYjdAHY-$d?0^HY zTg=LNb}GgojSW0PLOe5AeAUGfPqD@@s%G#@qCMUW9H_GhEMnx|bUky#!)TKbhZ20h z&q7VWjrTLeyK30MFY3&O0}pIBK4%UCRB>dVgCu0-x^HH}sVdBHnlQ z@y~rKZG-!z%&E-XBWz~0&sEv4Vfy60?&|4*r zELq(aPT9`81swk)W0h>u?61{x&r1{1njLrq0E%o$X&K3|JpGvC87Kx0c zNT4ab6RnU6L0_r-Ov|Sd&(w567h+8q|J-eG?}nz{ewGGaSUuXp^lqmMesMKjz>%lz#@@(|OEM zW{KDC&PWxm=iPDnPF&L>48HRWY)>>?P*a?-iiPXJrjoI0uCr`?e^s0BR3?045{eR) z0B3oYF+K^+HDbI|Y5P^z*7o-_V5hsiXGj&%a?I7<% z%n`zO=)idJ;exM`oCY0ry4 z#0l$)9=D?E zB#Ls~BHwjM{^n=X6QDikH$x7^tab9z8M}6)^0OK;tmFX6XQW5L*3VM5A zoBw>Hm38&~oxC(>M~SLXI>kuznE<>bn?)S&-AS~h!fhOmPBkeZR@=}2R#UBZ0uwbi z#Vk2pb|BKmf%1`=1U!n?J?X1&b@ByL>7J~$XNej3Owk1e3Dtcx0LSISMwyIg0g0i* zp1J7^6H2xQxfs@MU2=p|xLiM7tlAJi7~7Kh9#3I+6~}v5^QNx8UlL?Lq^{_YbIAZ5 zbR#GwXueFvAuVjM!$}jBiPaoonSM9D?{_mIoD4$yoVq+G1wXzSACz zoDfA7O-s28r{Ja@6-6}|C4)>1o(92R{$EWxY+73Oz8~wf3BG!B+^_VZ%Q5FJK%1^@ zMO2iU4~|E6ADbGJgmQGRT88`vy=yhQpXY@AT8s`DeDo1=E{DzdC-(uzYuwkOJW6Sh zDay!9D^Y_lhhnMQibG0TZdBhc*uNdgZ+|tJnGPNNLD4pyPcER=kBdLX$Pzwh+r*QZ zHTrh*Hx2*>#mR3JepfzjF7mu=eX|$w6YdteSyp-s;=lUTJX8H7JX{}>j5`p+kkca+xOcL=-R-!P1 zlXIGz>l44q8`&a`p%fKh3Y=w9dB7Bmk*4t3p8RDD8`8w|32#j-Hb^7nmpG!96AyrP zz6txSE!>Qgv*$J5R(dFw!v*H^BbOwOl-+lO%1CQK#vWh|Pep62qF%m@XR?bbE>OI& zucx>66$>5B;KVB{mJ_cE&4s%?_=eto;wR@KiO2j{0+Dy7cmzJAmA$B`Hzja9OvX7w zikvy;r{`eiT1Gg-S-(EL+zP3oc$DB8VI3oB@&S%6ZeWDZgD1|gfIdPUW4S><|Ge2f zA?l2Q2k&pOd}MbI58kfGCFHjhJd2NbC+ckGImgjDo)zZlj?5f1{u-Nr_;sh7NGpn?`}dT0!58 zi-Y6-5zLH0xQZ+*dJ6h93=X%+AV69)+&Bfs?<{cO_QkdrF`K=569*k{u8Ou0EB_NQvb#A@}s*PHQNFm&2>s#mW!y<8Ir`CYjbouT_v^ zdqv~6qhLjVoXdTHupowGQ%7E$?_Yd$=2dPoupYG8V5<9*rruN68BYWm3EVU^{uHg^ z10sl+7Nf{|>vML(arRdk%U|%yiAD~G1b+yVi9YR>68Z9qae^}gGAV+NoXv0wq^(C3 zvioyZdYbZzQu0!M7WzkQBKER6=*MQ3jl+y(P1A$G5q9Y9?fx@49Rup}4 zR1|hHRK}GMpIbIZ15;k{pU3A@<%a2sKGE8A_{&j?$Hg_*h7Rxx zgG*up9pCym%<{W3W+%RJy;iy1wY{>edzak8Z*-Kr?F5WyM+1f~_f%GoG>=mcnViGk zZ!X7IYkk+%FRq$q*H-MWrYsL#cDZ$mMqE@B1|Aw7Yn0`@7In%MQm-F4a#P`QVq>Kc zB@%dmpP!p1cW5ZPrq>kn{@y@m$b`uzg|PgtDV_Q~V{8e1f#3;e^8D038nt^_DBvb0 z0)XvZI~4p{Yyvgl#TxhKj_i3pMQa=~vf#OXCe6F(!~X`WjYU$-6Wgt_o1E(Ag9UOtf%kKwPwjr4tlk z<{cCao^y#B{0W8FCOr?e2m)u|(ixUej4BB; z!cQn8@+qm2h1F{0h6wGn$if@{7r*uYAT)a_0n^=+#mm2c%|3tr=&&W2r68M_hI(AW zLbn7yx5$8t^_128pJh6II__Yzg2VEPeTtB9{_pb7=ZU}9h6x&`S8~IR>18EF89d0l z>0Ss(UbnIam~-%nZN#;`Cafmr5}Rw2vlwma#bQa4X~~n!ICo`C*wQ)qo~SK&%DpWh zUBoe*0!PM-aw#s1l}ZX{fX2?2Du--oh1lxagQXKKa!78}^QD(=z*n+`!lukq*`$^$<`y{_{)?On_w(jVs4S+o ze_9P9EUg&4r4finCehTrblGQ;>P9_eM$YUpH@;!Y5cC61H*G;Tk?`tRsjACpcE3kV zxa$TvOc`#FV?ge|$Pq?Q8iW9B1hj>J;~!=W82LN{&I#SsRCMp`pxAJgcAAf0WGdw7 z{1G@N_`!cL;5!I9MV=TxUW5Lyox%iT3L5n+mTObj>Ou zQ8%8_IVtYL9yQMxvln6p2Z5=xEsADd2+{SKfB*x8nn zfk56xSCiit%;o7>qX`>tB!C6MC%y%P2*QcXqfWxQmIOc^#if-i4e}`VvTwn3nz_;~ zni3gW=WXfxw__x_9bR1X+k?1#F z;x#N$FG22D5;E3=z^aIc&-2I_W%LzO!m070Tr|&U{Sbb(fo1^Q;aC_86w`rtaK=h1 zBcI(#bht4MqumD^%c_A(1(2%IfFLAp5+MqLPzW*zxn0n^NlM$vh?zX3K}I1XXF?x* zQFI@EE`q_s^ijk{932-w2@(~775YT~!243o%>&*%m}B9R@LZWLN9Gx%NZ983^c=vp zmI;!A7|Pi5ezKDRkqzTNkxl*!1O-BFg0HF2%N}D%DuV*2K%)l!4KVtZ%)2|Urzgp# zuKxTz`pqkm&42fHj41ydBRu3d$0cAAk9wZR+^F)A*DE?n2AVq}M)+z9*qq(Sh5Rdg zvyg|L(Lb(Zs$;n;hZsAzgfp6Yw>2%W;XD7RZqmqe;s2zOD;q9h7O8qjj&LnU37MHX&b6ak$gDMplsmb{-`B%fr+U4|kXfJKsnq!>^R-gQkVpC`UaJ zt;(D@p2g@w?^_mTQ5jsJ2Mz)*3g=06U^t+t2uZ(l0sRJ^fjWTP*($}$X~F)r9Tq~G zqY2X72}Qiunv9|tdFW9NF0yd5&>IS%=yyv2pkI#Oz6*F++;)`>NGkd*qrm$wE;uNT z(kfeYS*D`{;_HP74}LqCp`mD?QwXz`ftLBw+{yrAj87kfaq&HH5pePZ?!bi{5^z@J zkZuql-g^@}{VkVYv(;dir4>5hC5T4>Zw;)_2UuhPVENqw7CODL7~_V>+I+Y=Y!-+B zSTr}gM<)6|BEaZl(R34Z@2SkFiAe}b6bYOKE4^(JlA#sdwf!DFeLNNLLP)f+nDj}y z!;50i{kX0#H?91ijJBF&WUL8Reop+qJCkxHyI*Dnjd)dNB*soF44H~@f>accBpSL; zxw|bZ*VO+X6RRN^rse7f<^;Lr@YpmH8Ag%itfb;qbWsx`kXs5zP1oZSx&3n$a_t-E znaMA5Yvw-xo0<0rM^*kqz2WU5NZwuv0fV9b|7j#f6260WyEd5rU7MBGfGsKbccEXF zH2>KupGfed%mf7{JxO0$va52wNsdt6-sAa zsFCLi>kUL;h~7X1q2K>NMEALlVw;PRpH8v`r4_Cgxi zc|`fBXKtJv=i)lfZANj0dLybGQ%(35Ec{&$@7lHcl6NDiUEjTt)UJI0BdJlo9<@P) zR)hh(1;{h%36RI+;iZ)3Ye98K*))GZ7}sx+XUNm&-F4I(ov?qs1cugqG~p<_fHd|n zDk~sGg)7t>QQ`8zt*Efs`B?U6H~ryFpgqUE3ADM_(xTVhbF!Gi7>oa?iX2PmGE);> z;6}1I5Maqorv6FTPse#`l z6%l=%ksoS%p3|VqLZvp8^Ud@3jxyVojg3GOGa4Ilo(reWjPldI2U|K?;^#6M9hu8s zW!0GjW&Rj`LZYaG-uE1Y-48lksItrMVJnED8GL7x#4wEt{XyKAeqTX!SKsaxxrKOT zD1HVtJxJ39rb1ptM*g-;Yd)2&Rk+f7^U017V|1Ashd)$e*7dxBP12$pm!!s18iyLg z;hiGBiFuGr!l|ZH|HRC;TkW{3=_#Ab)b!HIWsksxRg<>+b*)Nsa+YYED-#fRWY3N(j_gYpUjG*^q?TB{ptv1H`Ek8pvcVo8|D+Bp42*O$x;XSl~1 zRSxfaWFfVR_F(#iHpEAyGo*LPKHZ~OFT3Cfcckiv)~}t_5^m~yf`&0d!f%MnhA-Sc zp8kDK{~-I~nd%owPI7vVhp128t(G=>nUW z-uWk{RC5rLEL-@z96NiQRTd#DA?=TX3beUILvu#*fS>rGCjXbC34)jQ#5oBGP zoj7-^JvY=uRTO<OO7xnZmec|9(}pel+HRcAdRL(@Jb<2M>Kp(ie*hzR;h(P8%B>k)$vo1U7> zhV$D*eaC|jLcuiMFW>SquWm&pu02?m>|2a}^Ltek56eP;>D~r{?e*!t>K9HLsUY;> zB}~z7+LTN`!M23q_|>gMOm{2FxnOwaA5~g8B~#I;UqtHCo1@oVb=6o`IZ?xKb+9ne zLUre@?X&C=6 zqP{XL%B~BS?v~D>Lj+0b?k)kPyL;&FkOt}QmXJ}{a6jB$B!`1FAn7Qd-8RwNYZZqQQ z#m5nC$fD!bE5X=ed4g8-2F*L{LneKKyGqMSxUEG=-O=f=c63Oo$4t_ZnYKsc~wIvlz6w) zq{PDe4QaL^!R%&2-UlA`_UZO{_iDi6wipWPyH>#Q+&kpfNsj6zHWk>7UF)PAUBn8G zH>87lcxxM2WT^Qpcdd~Rs}#qPBTerqek@i5D-&3odgTx5tx7(fsb}w#*q`VpVa(mS zohUeA$*QR`u|THm&Kb5R7dg4%*KLJ-TPOdvRp~U)Gt=Uan9`W`o1{n_V~T417K-v! zT%J78^syS1nC0&cGnFyizF0Y|-JV$|?zEwA==MaJttOq?xu2Mn2sCqmmAJl5A zy0W4G!(dnB%JnvJrl$@;Z^uz^z4d7!q<%BGbXKaAstRW#bqvgy28u1s_h$*m$m@5 zchIPoN)D`$EPEEI?Fo~epS(BLtr?#56^m8Y22@z~xZidxX~efjc~-Hv-sRC{(c`n( ztpay<&T6kN@r8YY6^65BS6*gIc0i(ZXrmE zu)$~qu@q}cvXNY!{$&noOlHO#*n5xI#yGNaXN-q&-v8C&HTgH~`zqIy79{LZiM9qrz11Acqoid@-E!r^>g^ei_da_tK$s$_1G@>AI`Q@%w-^>V!;#CNsNz3-XBOh2^)iwSQ ztyW&o08^c!IP`ZpZF(is9p1&p!KF2xIZp5Y`55#?v#2Be&{@!ss%7Z^--)a*xK2;YA{LTwU>FV6Kvrt zIKyT`Y#@SkUUQ5tUVcHL2Ol@Sa`+56>`_^)KMcqxwcJzm-3CZeKEG@hBI@P&mU_fL z236Y$QWLH~*%oCbN2r=NKUwcpzLMt5{*2?(h?S}T0<4`0V|p^J1k;+CP;E>PZ~qya zTsj}Ax@4$koK zePceG=4p+K!6KHhX{w1Tq|(%No4Pc&$W|ih!ga4O7r(n8gd4a4U*Zz6hS$-|@njhs z?Hu}#Kh?~ST+|pHsO&+vo*E*6NjS#FetD!dWxFFJfuh8Tu8Et_Z}1>-F!0@XmaT)ar-{6gEWVv+ zm1#w3OS1?|=#Z+G?|UEDDrp55D3xqA0LsKXQ}0qW@Z&#F%3wkNiq0+(bFU+52(m+| zM?oeu3c~PJ^nh0 zg8gHSp&>Lu`peQk?}4#AQ4NA_&CIVh?trsz45o?hi+FMf&cEJeXZr?Jd zAt2B8uv5QgDcSka*e{e)g%c#)8pj*!Lv z9bn;qlkEn*pKPiMx5%6syR8Uab6b`hur}VJIjs!Syn6HbEp})4_nwQOxNBKNfUcV^ z$03w%1L}s;xc3Vizu;34T^Vy!U+sD5n#j7*{b?A8%z|Jn6^f#raQxnm=l@ca`qh=YbC%X zneP`Z32o%fyTOKD&i>lidMY4DfPo-!Sps$Bh07pvZk|_(gd4b8eTuAH@ae0EBLgoW zQ(iEQXps4(Vbzm@B^9uPB&pKJ)ys)y>Na^ zR?FRoADe=5OP+~WWb>>-=n)!y#kx3PP|i2UuvrG9IiU2^NEbuz*~7KhQZa|v%X`v@ zq4)b%dg;U(5%A&Si?F<33M4gO3N+j;tGT0Hr`grRSs<(xcMTz%qahG#{an*hbcG@K z?%jn*75s$=g7-#f@*-%*ktT@dO0vLS&$0!T@e3vDjFZJG80}&tnjd!!-W}x5vG%zm zZ0hXXji_HB{uw=mN-SI-7VwgG7JXQx8XetRrGwe|)72^lE7y7-V88+QjqBn0MAgfW zLkPu(h&E}_V^6tj9AEv|!BI%Jn*oa;TopI*eeD2kwx3;8LjXuO<+xWgcGNdEn7vZ; zBM!2>DHhWncIl6hw^n}+~k)gZgyWdWes z_kvi~h{AFSGGhMylKpUTi8Kj(PYh?2s8mbR+~_wAuS zIi{ml0-acM=3X(bAE;VM!Zn6JdSWXf45%thSOVGpXeF5lT2yK(UHnW$dI@(ebtFPk z70W3l<_bK49R-K!<18i5bxS+a%EAqga^BAy&Mm23$0%0Xeq0Dr@?m^w-pUfsgxRa# z)g{R6WnUU@{Q=|>a?R1yflhay$7S{0`D>q)&kwaj>mt5|hF?#mRmF0URRFComh>PZ zvF}WfT5}cB(x8%uI476clVc4eiHT)wiAu06Bq~A%R#^OiRVDbs{Uo)o-iwuz95-x? zncd*?$BKvh!4I2Bw*fyu3ZtuPn;-D%qTQf~lkP5is|Z{cp?J&DjwFtq>tSv$>Z=M? zhBp3ipQPI&2X0lywOK+DzjYd9p5fm2SwbYMkM(h~054Y#Hz|Ay!>4l zIAqKul~-H|bi?LK4Rt=VX9leHHavksow<;(ln1abA1v_Zr$; z*@=_hLUwp0(7;L7!YuO<4>Zhk$r1h){TT_JntuYEOr!9kv}HPf7q9aE4+tg#tnN%( z_$@Rr$R<#`Pb7RtQX899tXb#0Ax4t9K4bZH*NpFt?fvS))rw+Q>~n3|8;Q*5m0=&4 z4=T|1ibrStaDLcg&uu;lfvC$nx1Kt~95Zh2M~8aa2)L5#l7s&Fu+BZh{KrERQR*f; ziuvDB{ikd_JrC&Xi`Vmq?WW|f>-GnMZ8P?>ITxcL8{-|FMc1{8yeL?6KS|+bECys| zHsY;e-g`2;_==}~5}O&0--AoHB#uloH6`$bh1(6x7Z;_jKq5|9^?eY~sc2a3uqYvX zKj;)_2b~)R;bf2!`Q4-Pa{?+KiJdE)O2(tfBU_NUv*7}AhyDHa>1Ez^fo)!dL5E^l zXh?M-0%2EW-O61<|45z@qJHy7o|y1gQr<75po}2wqK2m_4C5WerQRcxpK@OXNDQJkUz7O($0 z6p7{`tPUuHYGZDpgM_N)a9OFB#z!d{1|C0Io4P|cEV0G^5z@G)pj~!~03NZPHj-#1 z{el%JQeWQXZjR=F2*OH64@3f&xk=zPQakHzfu3B+zkUFwmT2Aa2z}|1=4K#BaD3tL zFm@b#xf^_z>vi!5=%Qm5C+ zA2LCpRj~sxka>Yr2Vf)D&Tp038yQc9Vl-V^M^h!Gnx^0xZozyEflo%za;s>B$p;D_ zM68r}^zBnB_kE5#%NH*e`G^)ql>V*#zJvk#=0Y%B{W>3q9tavLp0DaZXCx<;WRO53dPN6Dj28}bO=Ci z9~|6ka*52IJ_W5I6E%YQhyv-1MWt5J(xQPsF>I-%?fYx^Pjgi9wh08@#BooWh^P5X zDdl>9v;rXk*0t(|knPg7k5ox>wak~dSh>&9@UkB&&TH>%>AOcay+M%W-HTK-#?DzKR!W1P7noC(`LaR(@ zj+v}-ccqdx3yj z4wTEl%H@_y7SfUx+A`c*Nq%*>@8pcrWIjWc6Vc%)`sS#RbO1ZW1p7z?>l;Ss_cE#~ z3H$dVd%nx(A3t*p?b-LH@cb%BQ5vF(*I=%-%!D?X1|-H09G`XOD!I|Nk>ORjV5)AN z`audL4#siJlCWfvMN2t37e0P9HCL&oQ8uUk=1_lRHMMzhYZ+P2n7Ni@Dl-B+1UM5l zzB#>usB@fFJp4ahV^tI7qL%GG>6N*nn|O?vGms)UzbJS{Kw33GT2L`BC9#N?K4|`W zl-vLv8}V4O7}{9kVslx4CUR-e3y?DMpOg|6R3mrjCOguUdc-^h71480st&}mQVhpTIQXj75D0fTF3g173&wnt^9vw=&?zI77;fk!L8(8vw>yF>3U zY@NDwtM6flC=NwTF_k$Zk8553Y=@h>FI z>2*kN!Nf$n6EM-P2r^Rf<-A0qVhV%Wf?bc*(c-QJGjP0Bi~3@E-q82T*H~~|`;;p><>WAR&qiFKg)_`<{EP z=tslN{YyFWYB1UJ6u+PT8Kzt9e!eeXb~v}0{NU`s4JD!!I*wf;i0~@|E7$!OSn13G$!`*`nGpwc1IW(gL!b_rGG?4eBnyw$bN{ zt>$KD(t~q$*R{PxCiv}w7yJ6HjIux+nXX3WW8H2&o>Q-cp|CqQ$oA=u)igH3BVLKV zKvD6Xj6^0)L2KNr_j=6al!U{}0en*MCG?7#x zz-!8v23-NKL5yHne~}ZsNrD)E5tpsUl{<~A7d-W}3RqeU?MY*HEXaj+GTQ`4UkpUc zf=pe16^X;s)i8Xl(=ihbW5(`!k-GR=Bgt z6c~tQ65RB3Z=jWwbbKwL#0tnMZ$j;W+_z)tE-|*B+Zq+gI$9#nMVm4KxT7D3v9TB- z@*i3PNlQTbP2?(CAbvtyqs>~kyF*lw6khj2m;E)YZat94euL8*0;XBfPz{v%DH{}T zncu-FPNku*B($ke!AgoL9iKWopxP6gs}<%R3wv9%?zzsMj9lJ@n+n!%QZ*2XzsfG; zz4>F-`H)lHj6Ln z9*X*7ZCk)}{vRBz>E2=gib z=QH~kd-B=&z3Z!fg5$vXRBQ5z)l;TvL|wwl0i&=aMaD^@x?*^{>eQ#2af1?5sM6%p|c+kLhGhmEPiW8 zzDhxT_2l+2=6L%+hX>GWHY{-QebPi(9_n#&(;Dl_>|eM~TDE+;H9 zB?zsN!DlhOXLnK`vZZ7ZZt&jAeWis?hU3jp$DtWRh+P&nNxJ_u#CacfOx-RRm9Ig; z(&@|AUF3whMma8sb+c{8_GEYb;_|q9W7YPhdkXF}XU{oz&+(9oWPll|kcJ;ejDn6` z&SoSC47CF6oi1ZI5Yjn}NPHU+)cZkH7o8Gu*Ykc0CG!b!*s0JfNu%8w&Zmi>T{j4ui-w`ULqtk}XY-m!Yr{HA^JJ z71Z>j79KbK&(fRUh@xL2SwXHGA2s_44m7?-)L+ke1|PFF(jN8Hi*y1CKoQFC&#)6|mo_>8W$v187zRu^wiB4{76eR2C46I^x=CMt@3QjJXBI|k@ zC-&bHvni@wAyrB76(fm9L%sUTpU8GI*^+97_27%_rFx@kdPzs&zfc^mONTm$h!L~_ z%SebVwxP)Uecemada9{Kh=z5|z0ptK) zA#z!t$O!cM9qa0JB+W%Q#tI>{-OUZi8zkf`ZCEuMmSGJIr5-6V)Exu}4T%|EqrFV= z(GrtqpD~G3Wo1BH*mVV^ABS=RA7jqGogZ#$U@!Pa10EN7B&G~_T*T2=WuU@QdqSKL>f>BXg;igA{3YKVcQV~%xkq81SS1y}ZU_B)IWwWN@er36rz1hbjLKKQ?aF2Q<;)w<;9_`}+ zQuzp*OWc(f2h7D_jlBPg;$BVq@mBf%jJuCIv3*LdDiKN|h;$qq8Hb$w#?jfCznu5T zsQ#=>3u42U3&;H9SnKc-eZKB)S7wl^o(k+FyG!rE%qc9YqV5+2F0E+yq@O)J1fG1e z75c%emyo3SZHEMN$5H2}$RR!bXS~GRCLlvz5k4RXwO=+Y$3bmb3|Md1yo6L`x(kb+ zqW^{TS_2CG3t6!i^)EMwo4L-sN}vc^%kB7`a6#soQ&3j=sx>}nbIGI9&B#$ZXfwhJ z@vz-(1Wf4xn6jUmu^A+g*ozV){m*vozPhv0eVG#H{uJK{*m<5<@4 zD`}A8YS!`NFTr)WK##^RPs zp5LtrM`5q`x{&nS<<0T^W%=CJtX)1q{P~_!TSlqPMJmL-er|7H2=6q%^h>j z#&3)D(#AcY@?Sa3!}h;&xSo0@w{v!`-B<3SyvwmwSu{`ek^#j>Eq*)XRxMoWpUjS9 zmZ!?`fXw-IRKt$<8L%#S3f<7edPwX*Bq7#AWd|9>4*IWo4Bg*1Fh@R;oNuZTZvonT z5bgO`7FyU=)K?cn4jV+=H=Q+s66-pMro40>hav54GS~zm6ei^$ec~_|IW~8!BIHyzs-jx*sV@ZgU5VH0gGQm)BRyIGu}y(p0R*DDRuv`wtX{9bU}k{r6>qfvoKsUnFv=kz6MW8h4`!;LCe1 zb`t?1=!<4OVSn-;XLEuhCyyQx04{-Q^)DBw?8*_FkQV=h?WgX$7}Mmvp+zz?-Qt>FF=6TtJpG*IXk$|C+HyiTav62Hsu(K0F3KTi}#$$yLvd{k9(Ongj{- zQbG=_w{PTYFPg23v4;&}=Jq#ek#TNS7CQrJbqYt1FjZu6TgWi~^PVR*lRDuMgd+Q} zfhg0y>?j=7_~9jYC+5(l`8yY9!@?Y;p#s#AK_=wh0-F&8nx7S{zI97Qm0Gu{m^Op} z!Op}a^X+t4svc|&U}mNyn+R}3^vih%s4Ohw$aP_eGZX`B_vtbr6v$-XLOvuRVr%~d z=z~wNwM)6$uxdm3h5{+mlUm2pvvC`qh;tr?S4;Pyrp5xVsgE#|U3q@%WqD@=d;Ax> zr6-xnr9)b8+m+$=2$f}JyuEdz*tAAzJWKrPJk`G{N@shRbjx@(Wudf1V-F0^;vJv* zt?yGY=RKpGXfefAO*|Y}t$5&@m3DFAxU%De!JppvUXOfv+S?up#QKxn3EzJC^{HF z{a17(lWc3pLeW1sRZ!-W}cd+t&Mj+$j>{Z|_w8nP-KCY2#z z0JICl9xMTA8G-Pf=&}fo-tz0(vu3y6+it|GfN?`ffvi3e0T)M(9j@Pv)EmnqPqM>R zyq{G3AD|oh>6>qXercl7$y6jh!R0_jega!c;TP}rwXG`cl+75Dm`nL?)<3F|qKEgA zl=6_&nzf*y6RA|FuW6G`lVispb0Xb+e$@%%@T21d=~}c)jPn_f`;(`0y{>KjTNYd$ z*9F4yC)%=5*$)@J5{G&un81ee1jvLvGRj`ujwHX{Kk9A~&A}n-YKQ_rT=o!$^4Jm; z+v5GHCo$lLt#lS*H}u_~Y76>ZKZ*xWIJC#XmU)j&vJGO#TTA-iyWO_HHhE-owpIyU zfPh<+G6(2`iFEM~ywWZ2btY)rjmVrBLO{{Ud=vi|XcCw#SWFz}iTr#jrm!f-W1>AW zt-qQ&b#H<^78|?vL%dmiJ-mRTCICh4uFX#-seE;@&pTHOBC0$jrRG_blK+37A7+3* z6f=OMO1g=-BF#^mbDH?C-`FDch>v%{`2J2+RVl~Jv3C6Mb7;h2Rs?ds90TDl(YO@pCAzSnG=0{I*d{HH zo=W>)JpPE7L*1X%x56wd2_>6#zP)+3x-}Wx3WqmT+mj_3>opd*C6#8Aax&!AUutsk z?17^l2MIgopv|Mbt&#^X1R{zyV8EqoBZ{4Ar(%^z|7z2gNQf7hQAx$RlR`hX1q%4H zG}Ul&YB911hp@J&@r0K3?>`2Y5{G(A5*r>zbUMelmz8VW1#?+qpO>Cme8z`ybu=BC zWb*sQLmQ30!`TkP@?u<6huI&{9IGmBOr{#lZ%X-kw#ibMyX*5_gPnf7dKbQO6&l?6 z(k+{0{;l(hT{a;V6n1!R5A%R^&Hk`ZPoztlwBzU`ORrCo4-3b&9vePWe#qT^Uo$hn zsb^;m-U+GaYq^Lsrt5t!5)-3WV)#srO2zOm3ONiZh`L;+1T~Y~$~T1t#mvRHlM^IL zRw&zb_h58`HasJvX;H-td?{~UpaL3v5m8TR)32MpNs z+BE$|1{O$>?XEWv$BN(}RWh;<$t*sYKpaj!AWbRaq#p@O)AkS~*W3{&<+aie=V($N~(=bgMy}Tr|<~TVRb&}9h z{ViXpKOTA6`jHHr>vzHk=58y?1e&rs>{i^ZM21{omfd?U{miCr9_a zl4?5IAwFGq&S0+}4Y#%p6NejIX{2R^r(cd50yM$^5Rz`SjO^$^^vfB{0grdK*J49E zG>cezs} z`W@x4su4go=mF=L0kQ!v2&`EsR)Ho*6O<6YmYT>CoT$>MNaYne0Bp|9SR#M!nQ&zP zm?F&k!rmzQ#FlFBU-b>)CL6J73GO+5XHp6uLX{K<%v69pVk}nK7naten!fKJK7N0; z%PTC%=My2C_PIXVdWuKokm2tT4jr}HpARe$OSs8PW1mOJUQ<~7SvD3{23hb^ZS~Ks z@@}yvn>>t2jlg6EbLwqGr?Cd#kVo#`5GJogcx;(}b;CVeyk%i%TKtg;sw~r2nVl9( z$t<`ao%0`_9_h-TM!!F9>i{#U5HG!~B%i(Tr|bK;D%C}rOeH~6jnn$Y%ZZY|k&ix~ zSlhe56Bo}LPTn~g-IK=)zEPQ26Od5?#^@dSefav<>-gK9K8`md|>?GjQ z&+_)89GfTo$fNONCHsitud1%glE0rUq6vvN!1hK)RFsu1-+FK>`y0Gzs?)Gij^^~g zGGJ);Jg0>xico$TrJ0Ep!~xV(4lQimaDk?!*mqtdN($t`=Z^*My7U@nI8x-5a@;YJ3P!cx zv|)nUNyFjQKJA(e@XBV%!BJvLGM~j_bE;G?iJb++A*O?cg4$^C|6LP)jV(*1_;<;& zyX)9?cHS0p<`(6xWxaCx5bCYgJZ%oZ87h;QrZ`D1yE};({oK9CNbDHUq91_U6PR!P z(reDkc?b7}y5zce;+Kh#nIr!Q^F1I1(qK{zOMfax5eU?Q-aGk`DBECfN0(b=$uLu= zwskEbk%CI!*kRq_KggXVB?KvWM3ONMp@^`96OOO+F!a9$<|AewPU8gTH#>G4a$_g$ zSzjktbc(HEayGm(i<|w@*T>K2J1d>0M*DWnUnVlwOFjGfFKixpe6v4j%^B?aw6J_G zWAI}ZdqkSwNkovj%(4^-0=)yNzNPu;jn5U{D;=^nHkiuFGIhll^8B_K-m4LpEvNqy zk0D#ZXrhJ{57%rGMgzcGvOqyb^B(3K*qXBJA}0c5N=Eqrv7g-wumY+h8oeWCP$W^J zjENPDtV>NCRv?VpHb9sb5O>ss%7OaItZ90_M*3%PxJZ ze8#d#<59s}31Y+)>eGfAY8#%LmLHm7$_vzEcA|Utk?onN0JHXyV_5Bc#E9d;~9a zVTvpw^+(0a4kFW!>e#$Yie;7)u5EI&rBxZvFN=^JznyG~x56+NSl0++Y?=shsf%)e zbI7tW$q&dYaX_8!Yx2-xU__RzwJqd|3mG;bIG!sUOJt77BVXoRkc$1+an7CmI6?yY zS}(k13BGw`s@x$zL+}3MZrEGhGI~HmJ~F&kFhVXYzC0e)^=3LQEUB!Ol8=Hz?F7lW zI_N}*$D9KnSeXq*Y;dtY8Pm$#K_&O|KP7G?XIl8lA? z+HWo}LHzl(39&FL+D`ICtJYXTadQr5HLyLiHxnZ#;vbS?#Ry7}WsIdL*%dPKrm{{D zQIuKiYdQ;UjZd??na}H!Jzt9dysHe{5?MD>ZfhIZ1HAhecNpN^VpzBdbzz{-!Zg8# zJ;B;iU~E2FJoxfJkX2gzKyuFqXrzo_e$lCXAFB6%BEj!*hO4Z#4LudaKeQ1q$$DOnZjki(S*z9pA?5$DcFrsseXJ)=Sd}8*En* zJu9@FWW$X~FyY~d@{x|mw8aztC?$e^Z=kc6&_yWV*w7^_B*Lu-rB|+$%uR?n%0opR zY$>ULwZkPepK%~9ITCp#{0aN7Cts8CG_zkG!hmqZ5EOH@91e^UOc~W$1vl2AsmnMol4n_binqvnD z%BaWzswm#z^rT@qtKJc*r+fEIOy#+?2OG*5z5SE1|MmLZ1dm@hIA?{kq=v8pUul z0$EZ3=w!o>n2;bL;mjl}zQdNa!>Lb(^fRndVG;>^vM98B7^fK}G|25O^q`h^$Rw@w ze@_v5en(|ft*5kHdXoOF+ush0aKzYPB{!Y(6^odT zVb#+9qQog7tH3Eyr)U}B4B>n}bmp4O+8>Zw-)Dt@yF71{zSX%sKoUeqt4^M^O)zl& z+=T7SP-0DAg90Oh&_pEin?%<3t$sdtpw>fCEo&6hoZ^Dzr9cH+7$Oqonb2%yP}6lf z@%PpbhtLJE{P47Fu+!PuLCz47=Xy28j#I?>_D-E*Nbl2V>g;N_y#b5g`>u3&AS{TR zJtv@k0LZ5356`%`z@5n?!e*(ZltjpfMX}MzIcnmA7+xsA=#rGXm)ur39y?zncGJS= zIal|B_YTUVMM=}5TzJX-3R3Q2D8J2wH3WX=tp2fS`vc>D{deNM5;6y>Pq1roVllxS zs!!k@0*+uVu}Baxh)#scWEej_c_av~OD{RJM{AL@2x(c=O!QYa5=6-i`MFF?rc_gG z__NqZ8`&GynMBltiS&mgC7HbXo<@u0U(wR;`p$^|+y1Df@bEiW{JVqtyt#30LM`p1re}D}BnelDFeYl?sPV7fJ1W#D zyTM*5{ug=+`U`h&rwWy|Uk*h=8g2D+hQ8*_kEHMdlqX3*!hvbR`l_NLzDZQvu0Zf@ z`4boUo0;dmPTSu{F>)!N)=8IIC9=mtnhBdS6*CPtQ3X`0BN?vhd=tbGczE}MLjDoj z%P*m^N*_Xd4bGa3=$+{VZPLMfeDS&}I2@pLSr!I@I;2iPD5|#gTx4wBL z>E)O6L!d{a_Y8k_Ci&~P&g_|2qo%_0-f_|j;^{4mXowmK=o=czdU5O8!Hp4PX=pb= zL4y_ZT9^+wkP-UsR(-fcLC$!Hs*R*a$iY_l85}{ekk|ZC{HYu(5X#ZB;ryf41Wp#T=Z+P9+g8WG*!cS!Q$?1Tbg*cgj@W!OW!@@8eA?H$t$AmmC zsTvoDgFl?HQ`nv-u7MK@KU~5b83~Isy$+>uSJDdjLs+D2XtdHms9pHMYi@Y79_o)g zG;{Vg7hRQ_J5zx_C9L-x)=}<4y7!FYaXy{e|3+zgy+uW($lX|e*2{}teN-^*hq>+M z!$b})jtx&fRqN}+s7D1x62;v^HDL@iJ&u|@!lL2T{l8BLfL%0VQ)CZ~7RBB(1gD3e z3*aZ8obJ8Qyr0WT{gWxA=!VL?-1ghLt;Ju};PH=-@Osfn)mqQ;o4Vju!+qSl3y++N zz@2gMReX($1`C=4KH{-Ldz81(wYc*G5MpQRLN|kgh*`VRX7!58?AQMdl5sDX9p34LTWJb_!3)*w#4x*r(11#TS_gqdu=T>Cskek>9v8o$0U&ybOk4| zIYHmDC)cOhtwPWP(AZv5?7K+hzvuMONDT)qNyWpr)*o&)FvQEUU(p-P??2rL@uxYp zE<3zT9JQVG{3AZ@^%uAf<`8q4mUxp~jEBa|e5*2bq{Gz@E0Il4}Cu#z&Yv1`&ANQCFoGbWleaR>9KRNl4-(cc!bTh6?Kv~H^jg@4`OSCG-@h(7`%ZIGY z+m4c0jt*ApcQ_DIf7s!YV9kMlMm@$2IN`UGA~s^zlL-fn%Dku*NL4}aPa_?3qMiVR z0(cDTOt}>(E=7M9tijm}MuLXrzJPtVA;(KV)Wc8(X=sx^ML4Gs9Z$7Dx7M)IZ9IW* zIrYk9pKR`Sv%3$ofE&2{lRHn*BzRhVA0Bfd>w}pd16n?}mvkEg!hW4RcM}H<;meC( z+`t~c7DmqL3u5zOZ);xijCa#d;4i zQgxURQGE?#V;aUeBGfy$dlz<^$EI<^uXQdk&3=*vgQ&7oXQsnT%Q^DEf1RCh!x%P{ zDi`NR+*^75I^2}?mZfwtr*d<1aB6${QomM}o4V|-?UO0kVN0LL1)w?pc~hPdB6Yv$sS?7a}Ls!brh+@r_gGdu}MY<9V(T~|0M&GUmkb?^q5%l zIjg7ICgHD;dS5~;C-}3C)M(KxmIhHB@mIHxU?BOEXSm?aUjP0!HZo$}r21CV<>!0# z=>p89*4;aQ=5;|a`>+W9jw$rkv>pLL+%V{3HvjVBWL2?g@MiHvLx^L+-fUvUq2o_`NpGzIz;8-@FccE991B z?)yAku6s{_)cTGCy{sXURWy3VJBbs=+%-5z)??OF1l8J#-w#GMr|GC-`#{OztXe{+ z!Brd6YKpDr{c%^bYz@S4_XF19`sylI88D^wa>F?I^3&rsQSJ_UWN7uk_N+qCPg&HX^XSh?SD>~#N><5~P@v*F}0`(WNG_s0J;xO}|m z#Es>zZ}yh%`uXv8^uaN^oChw1<2G27Tm%4momK{YU_@h_R@TE%kVv8=qvIrS7G{&x zvg$!WC17>AXlcwLh1pkIhWM4Uhci)?=|Y%hP5HY)-jsFj&cTU={+|kb>VdDuT(4&! z89=!*T!$;EV*I>Me;*G1{(kat6R5$JxTaey-55AKOKq^VSXi9X*+(^qYHJ8}_j2O6 z%V`SzNav?(KxkLX^0~%O%H9{iflTeFb@CM|8l=T|2eznE~+_d z09H@T(Su{eU0c+i%NM}Y*ema`nk1!nyjxpiF_j2RJ2aN9W4v8EkCCYQdO`+}m zC!J=j1<^v7y79kO6Q4=NQ_*?ccgOV_e_s7vdHO6!|KoXYVqUkwo=I5ckTKRk&Ig|k zJdy`Y=EU30F#=OZruTB9?WFU8bh{%mQqZU#GUrtVK4r{dAlhY(MTEgidnm>y^-_SQ zp8rEC{;l<|^8D87DNFYAc>9KjFmNbYu$|HRbYoKU;oyC4dRQWG zr`{ir1ZH7<-5Js4!2+@M0l42O`KeD+efcyLY}*c3GG|3psIb%GvTcm5{@vf0LxY}( z<@lJ1aW$*TrkwUu8PH%i?2w~8DN=tZrR4ooAQliOkPH^Vp%xUirS=NaeT2Ab&Hm^f z=iX3k(_Me>XkI+)C%{e|C4QUQTN4*7F{gpDqCb;|L=J;4iDeo@h14kYlZ6J2p01UU zmia(n;?_GRp7QgnbfWlhMhPzEuMg?S00FOp1x#lAirU6)`>YajJS%YC6dc7{iCbhg z!-#}N-;s-J`jL7ne*?~$tmdbK@`Z+Q?(#>cm#mF5t;0oY+cI*Ub?6Im*R*woFEP-P z<1~ETMJBZ|4RArxgq-1i+T-;rS?U)D`*F+0FFNC1iZVoU3KG=hb++_YS#WT0BXYt) zOrEN<$t&e>_DCYN!s6v$FcGn;2<7tC!)b8+lKYLCo1?~-btHknEs7Y1Gi)@NCoYb> z$LC?c@%M#wW8^T7VB_qnHG_KdyL^$SGGw+MAqdtrEeNcOloDUL1O%-hyCP~J$KjC_ zHGCPsD3=pqj+H*9R_Lw5z^ZE%Dyn!g6@|ltl+fU{TgouBl#aMGP#}nmMTOzEeV6~E z1#xOF+(e|Mi>J+~>I={Xk}+}})11Fbmc)@W%_8+k3%{`Rv*i_8zT;8$&uCxfDX;^6{ znGnAK@9T96u+r-wEp$temd)Zip!g=pLiXhQfzj+>yD^G60tLVnU(s zR7u&1j^&vti_c|pS5CA6?N`IvBN|@XF;iUHWm47~KZMw?BPY-};kb#@xR+R1r-LPe zU_|j*3HW)0KutuT@m6-_7rmwu=Vo0&Z{hASfAysP!^4OBXQ*Ou=NE^esJMp1w!q5= z$Ijv@D=IokiJTi?S1d0L{sd-2>E}V~);UT9U-EayO%z9d#{aSPpplk!vp39op+tx& z5)jYX_%fUP$98Hw&1%^o1_YpQ*zZ{sk6JFjdDSQYcL-w2Nf5B0%NU0hh^Hd#%@Ab& z&;m|d+wU-Vp2|76Y2AyMgHf2D-Q#fWHW_rJf7`?H*xAurJ6@ znVx|RVqwVp+5eY!DM%XUj@l6;6#u1GbbDY)wa@=rncHrpjBeelx`G$VmJxo!@1hT}=ofh&2-D9{F9Y8uX=JyB55mSfoXhuHvYsENi<8b_zsTxeQl z1hRDV>JNx=ioaC6%24g!)-;UweLlYdq7Q$XmIa2^ylu295B zMJaFCJ}TklZ3jNr@{X76H=B`UEb_V>nrDKQFeE}$%c2?R=+J`N#M}r^4Tl1j%n1QN zi_Ig0MSr$xrPoHPCmdqlss=l`R&ZxOvpl<)I?vaA@u#qga#!T#NLtdFe7e!=KTI#d z2tYQY4^+I_6V1^WG|3a&Pz50+zmX#2v%v0bCL)gXe0)C*3Zh>3N7^)%gUf`#wIxM6w6+!eb{7M<%@yOfyOOYNh1!$&nJP?}WncO-sm; z&cy@)SG#3ulHb$Tk7qZ{9tsI{J1~6M2PG*98uBikE<^KP?QMnM@yF}R$n$A0uxqe$D^oeVTF-=Z|QGd{}^4>e_fY zCX5s!9Z&P2%XYHxp(CA32!``1YD`;Em74e8ae2?!5yU%cE-8!_sZVwwZzg(?`4D5R zMtdFT_B$&=I8iSAm2-36l(hIp{rpdJO#fldQo<>waC)~@Ek#LnF@~@~(WY=gF}L63 zd+P%$xv-5U=BgG{6w?jozH+zFLP-PdKMxto>O*>=5aqK5CwrC z$pe!xh!IPs3oMEjyLI98^04AP?kB;-hI&V z8Bo(~RsLm9Saqgc{&gmFBEaP1>Bvs7zz*4R*&YR2#!KECGm)C>+3SM6=1)p*9tzzo z28-RkxqIJxQ0(0)QUkNwTEj$g}!UX6yG z_B{9G>00*3I@N|g=K|aKTTk7fD8Y1^3Y4F=y;{7DwmuqQ@S!!e7cfV3^e*BS&Sxmh zk^^Nm{tHWo#+nMVFvj;xrCDqJM>MC|w2|?I>{k2HA_gCPxl@cH8U8RaybwNlVI5zb zSm&Dz2ZE>*G$^mtbkP;EJ6Npirn_sAH-&uXHfLKo&gB~Z1>Vqw>)dt zoRYVay=Oa!3Res&8{5#!QXuFZP6go)1sgwo|bKLC5KO#Sl|NA&K3ig}S9yhG8j7f2h$=REE zP^Tp;0OQN=VuOff`nPesHUm@C-6LhH2J>tl;%U$>V?Z47jbpw)g10Yl zLJ^+JLl(LHN0Qf~2S~cPpIIm{9YvCth_sd)m zuPrNDB$nq=s>e-Qn3LA1%P#-1xHX+=j+R&v|K%aeI)?OtjXulS8cj9mVX<8M#QWOi z?AG%?f3y6P^5vX`51k9O#ji+@4eNPBR{XM zOVo>LHrxo+rrVy_YXO^Pp8F@it6R%%xJGz`#B5zJS$hSJPDA3J60vw2GeL(F1Akp6 zx*^!ZB=6Mlv!Aq#1$gd*wEKpEBqv;(rQK8NO;%vuxLwYPVznjpRPa;9b${&lKBEKE z+WuXaYi1@GYvc8qiF69=v$N+G51+EXm#@t`fBtth*)UIka3=8Y%F|=drL3#+B&Q?d zpPkqn-&J4z(TkheMFBIJNs5m_!*uh_>&epgdwmzn_eG@jh2+Cv;b*T5ivT@JHtbd7 zOUn1`E7lkYD4Z0V>tAJz7wCxgJ)OmaTpQy)-G`w;PMftRORRqD8#EPe7AH-R zZIUGh2+$FHHQHn+>GcELH6NSP&IY*?jkinUh}t_hswi$p(}LYh&&#Gip$O^FauZ{b zVYimaqJpd*YppieGnUcaWDHw`+EK{L05WnnjZs6zD3j`&uh_p4l_iJ7`;9-Elt z-F-hxbGgWUl-^(DTWX{ZCr(2&2tm$h?p*vN6e7~qwV(e3%q0@Tf4c0@!Mhhbw*KL8 zsC*!Og=v^SsIshnD*h;8^XC(;OEBwvZv2bEbckg$c63ZOcbco64Rk`t6>N=Mty3W~ z#QapWjxrGaKdu{h=K-m-BmxDMb`5vC<77FWr3yucp}#&#(FloMPD z*in;mNCAD_6sux9aIQF)V|v0l-!fPAD+@vGtzbc;F28H5rV4toRP4=r(13gQ_>1t{;V-=;iR;jDC>a%Un*_hNIz!URavfcxgefKc?41vdUx7QcV z$?YpDst3o+Wf^c3CJ)W07*O6YqJAM{reQ%-t`l8-qsnLJeODv@2kx@6>JJH%7kuj3 zw)Jn$4lq?a2~yEd<6bNuDwwn<#GkkE9>QjZ^-~1?Km@^27<};sFky&UUZz75p=$Aj z(;x$iB;pDA?}zwIHu=d^yfbPjj{PzDi9`tieWrjp4&DA|Fz{fJ_`DF6&yv3|m)oULq)cDOS_crXVJbSx0t4yx~-sHUcMN_aghwvy|(|Y-rOh6Fi^^Q$M zfuQ%mQLG}fufkt+MevWaVyjfTb^3%{ZS<^~gQYib@YJLpxuuvuu))Bcg==*>ltZ&2 z*OgUY*{+<(A={GrsY2C9q|L- zkEO&lw|p-O9~AGG7G&HCxwPA@(pAxOB{DvKDUqvxdjzEAa?>yiYK5mwBa0fu1y#;{ zYz2z@isz>D0z0kD0)qsDWAcQnX_EMzF8ro?jgVcvKS~tZUF)qsk9E@DWQ$Wt14h6d-ABSsHu*HC@Zn zcTCH4A}F$8-=&q;(RJ_VPPRU_N!EB!(h0sLag-+T7qb<)EJp>4|My z<&QVcEfhR@{0C1wHJ<=q;GZfwLvbgH=i}DEj#?8jsh!8mDA30v#yI4VPCR&Pqn4d> z_t<&ZM1aZ1*%g8~+9B67+8uly#@)c}Atz{aI20pmPTqzAHk?AawrJgBy4{8J+R#khi^x(1KtD-{(8PBTrf!9 ztk_(hPbKb3a51hfyRP>Wzx|Y?CUjTkyOYXb3|u;HGXpKsTidLvagaf7i1$PZ6GxgY^6X=u!SgWw1x<%joF;bDXmp9c6QH-A z2|bW)MS_oYd$N5GF*Z`wT=jDlzdFV}Fa>bISY^@6aC6G~xK-#gP2 z2XbZ^pw7uApX$t|$>%s9^>q7}HE|N0%jMa67szX-esXpe$x@rGw7ED18qKsJ8g<>| z+ukQ&W?r9=EiR^GJL+r;7k=>vioxxeTL!zJaXLjUFN^I%fn|ZR!ykn?yl3^&&mR@w zLvc_0a@p}LQh)Qris=Sm-UWWXO$?ahKL|k8OF*L+XM4mK=rwB=m&M{IoE-OmkuDFPsI?r~1Ri5+b*rxg9?UfZ7a~Z3-}-AVVgr z-mtFBn6f7|WrN{r3rs`uG}S^^C42EZ)m6DO;F$3dZ)x{r8~q)}(U(Vx6bw zM7lFETg!DAbC4}y>Q4R%SIJVICB`K}HCe^%;~$`p2+na?D6ML6{x@vTjz4eajqwW; zP2GRo{|&sD(HB$TDJtx(b^wDu z!~FkY(5qgPOpXzMukyh7J}p9>j{0JAj7>BE5JT7kiZy@#I4~UF{dBIlrv9g88J|?T z`c*))ae#{c!4Gw>IiMtc$hq=pUGrV6uB5VCD|O;7sC)yaAU1LRI)c#wbZ!Dc1hBs_&;RZIuHpq^&{>pkNT% zDzWzWhp(Ht(2~LoJjK^!?;&E}41g(+4rJ#+oC@)*I0SKuL%scI-o2sSXrd#Wwekes z6$pSJJE>-eE1QkIHf}}1Ihu;#pO*%o3@rXz3(7W|sazhM2Oq>yj4iqEnFgz#RiL2Z zRbalpGsN~NJv8kF(QrwQR+#V?`jD{)Yg&Lu@jd^9@8hIj@rwp$%}e#b{$FW6T#?1y zhR$?%Inl*Y%oDk9yw0=YAjEjZWdG!pb#oN7VEy$yM6(bwIeQSz>nN*MwZqNA)NKwh zP!(QT%=&l1XSCDx>@;|iEOxDSZoQ)B!#KjkAz0yEuiW=P4$I7Wi7xWAAj!hUpD|SJ zdFB=ECW>tUJ)`s`C2EIOFC?>8OsiSpeY6S?wl%%n`vvMIUqd&aFI&XSd>gUHI>QW@ zxj%=1lB?Zw^A`xF;1PXfYVK+7@|p`G(pChxl~)8t3F^_)P%a98cv(}p6>w1lPvu=6 z+yuKQFBbNifyU5Cm9WGF^Y5Pv7fN=_hUZafRw`h~i;G7>L2~wg_brluPu0^~rTeuo zIb0>p-^Ks@dv0g7-HhS#@=xHWg`WGDA;ys_#cDlCkKj8+N`b}HOB^P*IWb+I=FdW# zn^#Jo+=HtgJwq@&|6^&Ss8!*>dE}j=Iq24TvSJ_ss){FVMiRM=zNc2K;r({Y^kKmz z*>d?}aG|#(%Kq{MLt|YJP`cz+qJQ!)eh|5iW-76yCX4?l2!{)ad1-w~_67V9GT?_$ z0Y4<`(^-1@_iS9c{fc!_n$|2YKul_>$TTQQfI0e5WHzcG)Q!ribW~Vb zBo(2fWC58@2WTpQ7HCxS*3-xKtz*$&YGTAMBz#Ly7k(@FDgcZ<8+$>x8W|6a&ZXB# zx7j2E|8ZL%)9U_b>vVql%Wp{9#Ea-1XPKIR8sFPEg%hoCzSV}&lJIKNYU&Y5JdwZp zZ#J4k{G)1fp04C~VeFT-VxP6izKe;7-#T{ntxo)Nzl8^dlvryT^dn=%@c!3k+xoTt zrTWa2T}XGd&0w)&8^(xk5@9)?=>zVlJjrRvgL}h4$tsuMC;yT1s$(HP!(G*Ijy?PRnu^rT&c+tQ;24M3O&n9mE_LA3uvqMkYObkdET*1DVO&+oeUNa>v=4#hQN}8Xlcl-f|JMl@p~hmdn{0H^!7>!VTI}|j{YJ_j z5-v&0&y>V^45@76{lswmdh!s}?v(pSlPZZTxqhzQ3IKakV(P4fSG-?)Coj2X3G5-0 z4(+JY4m{rr-ii6+DaF}IcDQdUx*4S|upa!LbBd-ye4fNvms$Y18EHP#)BcjzEg7=4 zx)1Rww+C-sBHR6;jQp?--n;hpNsqz zC9M*P8IWIF`3A!6OzHE`u?{5=@-v%8^rDbOC_>thP+RT2IzqgG!t zOa60UNP!x995isgQZVw}`QmK=$HJ?#qfd30A0*a|@ArO67&R8U7nXm95G(<5znOz(GpaM0gx5BgDG1;6|$G_3hx36k5 zNH^wFT7xtpdkV1#S%oLz<5N@sY6M|;nvyH^^%c)JL8w7TMEgw#mpAVE-OlR{yQJ{n zhhBkjMQi#L@cIc#9%9esWm(kVZO|At1Ve(Httt*(PZX1w6gmxi2eWJooz7J;i_slagA9CDC_!OA*IJnEAm;i!}?F~d9y#;6GtBQKn&B?6q8+Ls#`!km*fXPUJ90j>N$0d}PbupzZGuNdidh1Jt zt#@C{%Y&veA5x14GMni(UVcKHwF!~0`U`vf%WrH6sOJfSS-1k^J6(jOgyyp5UR|VA zHMDhV(Ih7+WfMP_5@X|4au$~Qwi+)<-`8|nFXxpliP<~Q2ppRJmV#$#mj4gYGXtwW z#X3E;ks-DnJs|Exq4V?7Sh3VB+Pw2eunkx%I6A$Y^I|y>Gc<^Ij^x(hy6JSZ;f+J%1UiL?uvu^(7{be|M6A}1U9%?%sR=8CPCg9A&Wiyob&kezL77?hfbnG=>`!~Z+Nnck?gLS75nVH9YI9!3Yc4ujK31HWF;d*Z+` z4sBLYoY4rFe#__Iq^i$I+2Rtna zC6-9|&dz=Pae>7(sQpzB+q9JANp|(hoe=qAN4!et{Hl_Nyh=5F#Puf+4+puci5adU9P(TO=1w7<<+{PYd(1A?8(<|2jV` zhA+a?j~YJ^g7IIEngz5KcxxRAu_QaMgIp~9UJs4PU6v3_L+Sjtc_Ugmu` zL3qEn9ODmKof>n~e8-h2xl^jT6tO?p{hKn9r9mwfrpmpnA&Z%wG?%<)VEcNbxE&ij z4!zUcUOdKF@~QEme78>`K=VhSqRAVj#uGc1gB=r60J?nr`7y5(_u9d3no_&jUJ|6@ z|C*g~;=5iM(<@y|Aey>PzW-~2|M`V`Hs!u%An^5QLD$j#3NFr@?ydZ^QsdJV7KxEDq{Kp;P(=A@~vUxQ75Dv$bB;@hyjg=ZzpPA9AS|r z-Lm1YwXyLrP14DanRdfoBz;x+hA`FYij=A{{dGCvhTve#ITyE>?g;>~)?&JfYK$!Y z-|AS|x{{%fZiietQ~ylKTOTSzjdE)iFG)K{R&p6c`QsR(RyZWhYEmh}c`tz|a=LwV?S~ChYEObf zQWb9M(cP~fma1H2Dp*nje#|4otbhL;n&L-(9l2C?;A1UiN&7u%7Qg5G!WAlWW`l!+ zaVToEQTptasOkIGl7_k@ey|N0?*AIYoXXzpVIx$Hd1C5AREXJE=#`mKhWLZB?Mg^W zS1a?l7O<&J6Mi2`>d=0xpW7&8^W-87x8^CHDkcrzK8%oMuZiE$R$tpWa^~d}Qn8N+ z5H;RgmNUhrinw6TiwZ2EgbpjoUA^Q%p0ZM=`dScw{I}=^WrHx;^xJDpVKle>A48BH zb&>P^p_nLoraNUk-6ZckVS*UB{-pZuqHr4E_I(VDR-U~U0ndXww|~@o>4+d|m&0iT zR@DRHd*<{{!B*~0=yxMTgUXqe8qQm-j5uOd!<-5W>*V`>NY zkKT3Ndy5wbv%^6jF&`{c1ebZV@J5=aQnom!3`U)eA+HOA8Z^XTSA$#u!-Ad?{6H9? z--8eYbu5!ALRH=Z`_~*<$ixh~?3ZVlvgBuISl-A*if1nb#>hA4;T7WN^!EP8#%E|F z=IBL=KheP5BVbhbE<$Ecaon3yf@TT=PCQjI#B zwcAD6Z=Z|INu!Ac%BsC%q@>SD*pxi%$4qq)m;zbrqAO9zN3D9qL{i#matx_CLt$ZK zJ-GX)sR2E3cZ2l$Z$x-l%9jFnv^k8wzZIFyKAy+-S+gBD}!=w zg**C4mMGGNwS6j^#TEX0_!sa!2UR zFx@hnL2XrM37{H`!a(25-f@PrwhW5Qa`TqE!iTp{nl<(28ZuPsR$vuA0xhU2-{1OM zg!@0-hlu>`JI-HT>%_UZ8D%zb7CvklWqt$MJ`f4c<=n{Q5BGW(xbT_XyRv4n;Dv zicgVwa5-xHPX(Ay`L^{WJJ!FHak`>eZLa7e{x>B!M&n|B@Mv>_VpJSH*{Nl=<+2cn z0Vi=diMdm8$;W4yFbwb)@32DYVkqtpbkuv$Lv`Or!3^#jY93q+?u!odDYkyamNl3; zx_q;4)_~ToEMd^KTyAny71Lf4UKgziECSniP6rl&;Epz!hHjZQ!}K7HLdtb*Fd1Kg zVqg!v2slc_!$3%uLNEQHjYY-m#5E+v75UM97YCeN0@OY?{U=QLHlhmH)3%(|qo;l(F4Bu&J0)ha`= z_S8#82PbT;DHvlWztAl}Nn$6>entL#M*5HyZkb;xqm@}b}U>!aDW3N&=x@JY z{$)XcSVx=mW-!a%s6;T!w4~^yncZw|fd6=AZNr`Tb>L+dIjcZQ^Fwh!5GM~!#o1iH zmF!aw6bo=vuf@_3BPi2&5;hWS8mlut;|K&n z5fT`q=#UykD*HYj4ni%%bTM3(ng#3PIohx(?bOtTbEI3-c|<=bTZoC$`tf7&`LKvr z@M3q3#fV?o#=o-gOM1>{l#=u*es#?B>>gvW7mzsPWWJT=SnbAIkAtHWnZdJg$mfO5ztpp#wZm_i$j}E3~i#u8E^3upBMOal)hEmeEM1n7fdD(c3BBeoxtz!OKh zJ~b2~Ib%;vRe(lt`Rl0K%kdVO>V_usUkhUyxBRX5z0f)P`v}X~4WN#gN4-}B7r}{w z_=1sv<=c^E38RU)k-z60xM3mfHNykrx{_{D?q>Llpc6il;i)?|Mp12NNpWqG2B>a6 z{7Wot8}T@8cFwO2k}(pj_4zaY?Iht;ld42Q*$NKZ_{m`YHXZf^y{8OGM8cEk@sV)7 ziB*GG+z*MOVZG|F9vE)LUVK^NQLoSsgrs-9+ZGshaT8sui4^ewaubi~Wf4$xwd_xe zz}&z8yGXtJ`~m4-5dWJoC$Wse_6f3T-Oel;i6yL}KRW~B7w0eSMG=dY$rKfFgGj#k z`hoCr8~QU;tV2~5kJh7Ozl=1qhMlb>vX{v0%EYm+`+I*93Hl>#yXd@sf%FA6M`6P< zK0Y3J&gM*Uyeu^r_C?jxh)SBb(UnG=f3t=st22e;0j!o76K^S;<2|Jb5S6$6wWzR9L_FR)y%Il;Vgtn_-cM>@U6x*VBR=XQ^AQU~)dA;abjZ z6t=GR2Y>({_YC9)WOLFn+pX*#qIgwGin&kyt>!-1IJRm75M@v7Ipy=$$k?iQ6UqE! zUy_9QU2wJzMru8$*djAc@SEB!SO=a$4Kj4r(1cb7#A8;tl4& zC=C8c`7#L}&;91@T*#%asq^N64DH7-ThdZqm7e7QkPSP~zXAZ-n05)P;UCgu2V$=M z80M947dI^K*qD4agdy5s7|Y#3mYcssCOZ5(UO8T7)Xh9&72fNbTJbB$z6c@cM%f~D zb2xr|SU3w{%h!$*rQAvM-I{++35%S1*SxdWN5}@wj@PfZ9vWPF_GDpeI&PfkvlfC^@sfWNca6$<^D4CZj5wKm&u;tu zakisP;OR>)2AL-`Rn>Fp@rK0E-wUUQspvA>NZn8R{X>vKl=hbwokb`0A8X$)jlLbD zQ#8-w1SsIYVw1yOamaP&J+tyW?NReXP9|s}=fAGo__-!HiBfWf_ixzy18#ej$O z%C}`sew*u@A@YrRvh$;z&*?H7%HQVZ7H|q9-XEE~2jvg_pAzH6P#D%%VWh@lOvi8N z%H-F;pkWrQ*SmJTRuidg_`h7&t7%_IrwJr06>7Tw`NhZH1tGq`>^=W+7x(^6VsBI} ziN7GXEFFslWcAW=aC_GCr^Dnl@Wg_N|ICtcZG-&Ny^@VDw33@@E7snm7X*qi&tod5 z%5tJ`ei{&9tv*=1bK{?+A4P%<@0>ZWM+oScRS_!BLM<44S2aMqaiWjMz&gD7Mhv$r z4u}q!OB?q4lp8hM*Y;57ly5(d)cQD}C}}`-aqB<=0Go2-Q4=Ko|MAMQFj5V<{zpXY z-s*Q6rVNHtD9i8F%an$XKH?pvqKg;*#`4V`+&}*8xznBK>DoP0bTg8vrfBJW*rY*i#Sz61y%RJSn_AcP1ox+mdLA=R?NWraXHlFrXb zT>K>In>rljM#z(7b8T$onSmov13fvIKEk3l)!5fxt`KWkF%Ce;h`o^nH5S0dB$aC9 zcsg%y%g=<_9`we)K8F&MkYF5g-EN>X8v&e$<&rl5;5@3HwTvXPsTu?QjSt1O-y)J* zW_#u9o{hVVTfQG+=dRfhwKP^-Aa~7Y1iKH$j4U`qdbJTC-8Aa|KKXsPO)+P0TI)2fa z5I$fzj(+L|Jyd*V>{sq5STea5YElA zcNn6BfTYYAN^=M4f&Fr_yKEOa+LrNyyN6L!3jM_R>g?P#=qOO3*TPTjS5-*@m+E6T z`uKs74%L@1!&L(5&GY(yy-g}l`*Nv=O5yT zLH_&H3Sh1_^jN?jaa9P2)iL2B^@L1=vKbkD${l3-n6ZNFm`|9O1m+VdskStRaKCPe ziYPhWPvLTJuj(gX0`!9$i2V z;i(I|r$X+ixW*32)H0T#0Ov6vQI0){TtSZD?M>{OyS$8Wm#y8EXN$-cikNdq@{|2_ zM$Y}_5%(9*8(jfa`NsMF7Nmu$EvS3m8Q_4L-Ksfb7>Ca7q8sN_9O{7|F3*cBIi2A%`nBJFts^CXU5tE z`C)sS5!0UnudTPwZ4PWUDr{yp$VJIN!}usRqx-$X=u?k2Dk~*->>M?&2mby@Z#UXq zzHt)z_vfTZa$C+T?M6b7s4gqq+aeIYMdyCYbCnDsxk^Ty8+^vpa$-zL6d{3A{TF<0 z@|MVYtb#4izX>>KM^au6{-1}^Qb99a zEf%-B8*V*LR~T1D%uetY2lvANWlr!8J zgEuFzsVYulpRh*U+rQ-}0D_RJvl4HLT}o(NOu1_{@7Rih0%zKUytPl~c40qd<&v+d zs&HI_i1k67w|cunnU)0Re8mRo zlPFV%W-Y+lfGkg0FxD!E-_6rw5w#rfB;@XCYa~kym&g%MTO6Y&;wwCIK8d@=GNrZO z`nb%V<|q5)Tnk@M2m57Do(|4BF>K42?0qcDq*>`M9t1_?u#^xku{Dh#<8J<{n* zl)D+xMq}e!Du(;WfhjsVKx9JbG=c%mgJLNc9NT__>s9M*_fZdmVuYLsjqx@$a}Ux#Pn!MUg-BDY0!GjPIS4%5*gubHJwgZxsX%juju!Gg5$ zDzAH+!e5Qz6|DI3IM7iQG3ad!-%_|BY=-9D`YXNVRAbJC>)B8K3s+TI*8+-JSWEn= z*#~TKJOA9wE%EkwILrTn)9#9WqJN+I?ml9k+|;|O+w=Yi+T64LSrKV2-F{f)1h3rtWwwi*TK8;?Jq z6=Qe8Gx)I0tE40CaZeiLP8HEz)c=D&-w*x|{;U|3#}i~ZH8zeIWbhg+;!Z(~mTXN$ zQ-wo$x2B4z!necZWk2)Ct&KO#zm%*}YxN zCdS>DHM`72%%PfwUMewcf33(0HE?E$#D3PTc0nv;b%&LWyfyO&cJlWAWlL#t5hjDwp3~Vz`X`v_r|E+IM}7$!Lkm4x5ISJ zWZ~uY)1c2DccGwY$}I^*!N1=rc;isp%t=9NUW}K+a(N^-m8D3Ol*jY685_f6paLKb z6$ClxaLd68#T@hzuL`34(#BwKIG(9?wK0# zr9~B&2$M==b3e-`#yV}CB@OjSFG1R{9OKJI<{VK%MHNT1LzF2!j(C_}{A@K`Rm9L} z(O&w@la$L_*j9*cvg%;rh)782!@H$wa?KN04{_|wH!Jj&HZ#jH>F?^Tio?}GvSw8* zO5SSGZoGm&Qciseo9JrZgSlG=ZzCk_gFQqH$ieS2)h8K(-%W`jO{>rI9}0no|4K?g z5-+nk#1m9Az~x+rG)KJt%LWlnm zgQO10#)6jp$TRE@dX0-&4C)FRpO5?lyW1d`Cb4#7#c}Zejk&fHc z#T#|l*L_R9S>{h0$@>s7)-91w_?YaCMG=y`A){twu#Bf8sU#BceSB4VS=`iq zT-79SIdV4Sh%sqp_hPk-n%OLWK1uWEojIdyUBEA^$cNU4l!pHUs6aUL zk1o<9_vb${mn90)g#~nn_-lseTU5=+CQ@6BWJD44%Nd$B4q0JV12?JoU!}@$Kw|Y@ zOcoc}=TfVRLX~%?DVU5@^@k?!Cte^-;6-VSV65)+3haxo#3&m4yGzVcov~#Xv&fei zhcObx!|QLF#WpjQ(IPl{tVa;|*v6TCi@9)k?gx?+^@Z3s1t0ize5%Z-2VqLtPuAJ= zGCgH3d5!8YoRCXI8&5{Wcy)Fo2S(W9e5p`5_Z9||J9{lF=Biu(lN*mIkYv{isT7Ct zJ7jUin(aZg_czApeUT&{cg&ajzr?u|nrfU15SRrR~V3ba|;YgZ$ zkLDYrXV(HIZ~SZh9u-NSin~UqQe1oK{fjr@I} z<*n^^)+TGr=}c2W?y_$9HOU{h=4vj}Q|PkZ78I{mN(3xw$XNndDoZgKE6k8U4{PLo zUK_%0Rm)EnjSkvX;L(P$Spt8*3a9p{ zDkV|jr8+%F{Cg)&u5tFmq6t#&sr+f4{T3!vDx(Iaj%Oa}tY8-qK#aoREAb-$Y`*l& ziy7j)WdX$`^{u_2QnK6XKCBx4c7M~j^&sce0}|>oI^t8F1Y(2U8mOJR?K-=sO;UxKuF;^#j-^ZRUQy!l(g$ZjVi&gfcA=jX?^fY#Nq zg~P$C0vjAUj6)(R0&?ZeNM^WXHvb6ZxPGT$u#jtj-}w{8D)pwfbsBxRiu8qS z0#qwPDsBY4KhJr^GNc9H!dH9}00wEC`9f8gz4yDat8sKvkny4yu|yS&x0MONr5u+U3*woxi_OPi-0L5{M@%X#}fLo_S)*a;c)` zzqDQPOjyH4?%8tS|K8e68TO%QoTrvOT zg(=lEFQ0l(8`930 z`1pM`TX?#9!wB7#CRZ=rabB&w2AUqaKp^-c=BERKFC{LQUSnOK7Re6Ha>VM+9`=hRFGYplIci(s|62=$*Etn|_Q{M19^BfW;B|CEZ zlgA!}9A1>)zI-apHE*BPF*NW@eijX5+YUWC>P14@m$QA;%k690!rTw4pLK5_g8Gha zn9Ijz1B&oPj8g80mU{a`Z>Gosa!VT{V|SSIVgsE4=RYj3A%uhCO!oPUgt9gnI?5mAOj1URnL(qT;5h^ShhUx_A+%qpYE+FMnxpbN|9*=3aJu@o9i5`>S=sM;eop zBiGO!nfoeJBX~G8V)9=N_d(rpaWha&XPVT}SvBaV!2DHuXHt@V=+GUY|Mug#antoE z8tbWDvB}B?>5?c5hR%#Y?Eby{+bC-t8FD)Gw14cNqd3Aekguy6`q6IY&q1*k$i>Fg zlHzbKufE&|sF?0l6z$x7nk0@*<4I2XU=l-D)i$@)ufv%drUN!IonxjZ5FQw;C#Q}~ z_Iq#!MCe9tvENr2S4~LPoyT`x+?0KO*0`Uriq_k)g~bU1#Hte}=U8C zSiSr>y8Ud=U)jxFMzq>d+dNj2#gk#%tsPp#qrkJq8}v_$45X|NW%&G}NxayX?=je; z<3_eSsU+18|7HB+&ehpdG9I%79V>>QVFSazbHEm_}sLX zA11Td4tg9cLS}on$L#z2WMWEeGVrq40TH31(m>!ITG!3RrPvbHU^u ztL}u@DGU6VkQ=^H%ZjG_3xY|hR0KIRHoKHAk{qgUqFQuQF`A>rxWQe2TwP}Hg@ zX|$`^yTM@fKisG7QF4}YiBOM%?O1OY5Lu-ryBWGaH7JUT>#tx7N&Y`&CCRC8>!Y#~ zjk*=*%;_0I6j5F@i+xc?dS289;s)t?MH{4LF!IiGGFWL>GUJ4}8fI}F^r!mnpY@Pw z>TTN!892&HE%K8w2HxhxuyqE%;>h!5X&!0<&1>LYfatQG z*?&yK!LGKWr&r-$@A)R@SK#vuDsku*IL{v8$Wi$o%Ly65x=wJwQ4)ZID2Gya5!86e zNMyJ;1`@=w4>XKl*q)=zkx`{tIT%!d~SAYdNdU$GrahR@{}E1ZF^ zb@kCAPG#S3m6Y9b{Jftxx3ex&P`TzLc#pZ~*oaau$Jc_JhwT~_;BnN^vVd#%RhB80zi6@t1y@`dKs^)ZE1-!h}0 z=wkjCY302={kYA7%K;F~MVM0Pg0@o}E8c>6>knz!9X9(LdA^j`h;M^=xECe_ZoG}* zs6f}IlZw|&5*pEuV*%d9a}Lv@Njop^XuMK=7uw7EueejU#DAb@pM-1WlissENX8kZJ3Sg%Iy%Fnr9zg_}oOw%m4c>>4}RKShLwxMV9Aev#*7uPm3V|BOOOvEsc zpYpAzE}pWWdX^FXJ0$4DS7=odqwchgT#zd5ER?#Jpwus%{h~;Y*>X!cKX6ZuKPMt0 zIA^={UY3@vhM+3S2rBKT#CM3J>FmHW=U9LqLxhr(Dpnf@L9U|0j`RN`D%k6&CY;BT zL;0NoTiPl}^Og>M{0S|Rg^q^@Q64yDC!HHy7L3P~j! zPSuSjZ|7wy0AzSR6{6QoRWIGif`*;`=XvKM)He;^`#;XE|J~Sn>5I{1eK=gN`xg_A z<~NhAA!+5yGEkvNu;_D#u|#B9IjMz+xn)@!y=Sn?7QK9*stCN~gfMUIjoK`Sx9#rcIzA+B12}B`u4nnNe&sP#)lZdTR;nY2M+SEi!4pMRnrAaOJc8 zu1u3c*2Xa;uXbb<3bdOmLJRnM=+jlUg90(8qaAp8K(Ib6Jc^EOUP!xkpfiPy{c*!7 zA)eop^IbPD?~?AF2|<#z7!(V*w`xLP+}ca<1ESn=WU@{76cCS-G5WagG=vI6Skx&t z?cyNPdelF%tRpujZJH|vDNSybMhgZHIWj7()cI;zhv%03sEcE3!V;W@kM+})rDf4) zvaVzYIunQX6^J46R&Wy7$Q)wW$o1joD0n|QDbvKI?BB~S0HnOpJRE|303!!Z$g{NNLT2<`F9RhhjYXgkq=5pdgTrP&f?Y`JAf}e{IJ`I5wcg^CpbM|=hVvO`k(l(?inm;!v z0)ujGVY6H9Ub=4du8wtGKCm!R?REG{ohpK*RM#4`tyK{C_4xpA3niq-C(Al)xFg1_ zN6D)qGJgb7_9Skw=U`*o#XKlj0h={eZmWM{*PWuET11GZnMhd(#vdoH{*$5#MpR*f zN5HVd5V2UOz;c*CUuU?FYudhON|l5*|B;@;a zK7TM$06|q75=^0Uq!^JK?6qSBh9O%_jsKFW9$AfQZ;K{vr#qW8+mms8>yv6C`gtm( z;WdBNc~{9k-M2r*+A{@E4Op&N?N@DR^GPwAUnet;4%OP2w{W`Oc@7haO1S^L%gxb% z6O-@c30{!|V$pz{pWXsQwr?JzKIH=PsXRczJ13W0BcKdxP-lR_H(1YIuGor#4{@K4&O2S= zK07yA+*FD9D}4#PO;?9s45RsCA(mTk`U|)ffus^kzXgt*Vzqh8h5l%t%Mx2-6%j*< zyvEvSxyb5BfT)ZsKBL*mY^#55hJX`sPwD3Alza*JG*<{9pvM}t=*yE)Mi{hMg(UmAT2U$ewU}~JR+#sr7~JIpX3z3n zm#h5B`hhSB_cFf_OfH)}1%9^sRN&szZpPea)!Ko3y`te_LfAN+pxBwfovV+;t*9ou z-IpChl-18^2X^`Kd3HOsDumFzO)NzNV-56AN)(o8;ArwL7W}gxn1(nOpZSoCFOgyCH~!PcZ#d=*~b-G}4;JP%QES z>$M7un&RNkq?+nOgCSg|4^uDzSbD`^Soq@UOCtY9JP~Ibx#y1AEhoXo6;6QQzAtQVy4D{kq|e{>JE>CVG2xym?jMcnWy%=Q|i79nSs;z zBQ3T2$=(Kq3fo6eS`x@TKS`?j27JZXecs8>hk|5spit5*;qpVH`S4qEkdMvo{yD_r z;Pxe3o#~EC43s3(-;RhL6$k;y0TGsQzvJ0q?g0>o{rmJFA(8sb|prD|QTEA+BCSaLF&R)9X+FUDU(n^yJ^@H8D-;Jz+V;6J^adpn0Q zX6YL18nbVR?&qpZoLtVjhrxaWJ3JlO>hl8G--{7?{`}0XgLvH25w1WZNI;jTN{Gy( zD{$3tmTxghv{R4|J_umDV+9|?@`^|njvxQS;;>bz({Wxl?&bW#6x{Qkeq{G#ETnLl6V$3335Kkq*aKVJtt z29!~ndi^D$y`HMNUAHtMPxWch+bq}Q%Y4{B+z1FY;p=@H#*GiNTjT(SjV!wXl0!ZASOQg1b358I&q~MlgXwSDS5s4Cti5jAKcJcb+ zyuO0)px^k?jRr5{iT8T?ZzJT>vIhd%kcnjHkM-)1FhB*aSMzE65%z8S-Z_-oPHZXc z_yci2&SJ<19KLZ|KF-FUg^881_TW4yXNCSq*?)ab@ybO#aFM+7BQiSr@Rty*Sl#rR z(2(Ly6wwUE0;oQ*aK%^a2B;)JSNVY)jbwt|KGc|qT5%GBzKp^S+29B`>1hIbg7r9T zF8pIEvY*6YFZlQUXL`ng7&^Q0#&hN1u4`KoU-_4qGlUd}+M}Qr*M&A! zjl}#gO(T4onAoQq4tz?tI13<)rL0S^@D6g$Wv!8E#iuB00e*v6j1V|?ggitFX;I;K z@LlZ4G))Y7fshn@OyFC=Y`I|vr61|>mc6Ev9BC%tcG;|R6Sdz#lkT*ER%X}@sq64i zV8r_egbv^IhoR1=&B+zvBMM?KL;K{YhyE*vJT-*l&$k91*PH&Wed_R?d^#x$MYY4LJy@zx^1#_FH07!a=!iu&z!3ruJslOgB9v~NNtbIybRqPmpn z)(OloAK7)G{>j?Iv!8*cK7kB?bw5Z>hkEy3F;4I^xcb|tdRvBr^K-+wy@PWz8vk5> zH!UmNh*N`$7#aGF$4FQ*c5r|!<%G6?WJuCwEmzBBFr{ltNazxXBXlW!1N&OUrP z>}9bZN3e_-Sf$oi)#l@lrolygbv#^R3J4)|)@>c*|J%-kwk9A%z`kHDjb`m#Pd>Da z$Mqr69NVdX8^o#JtxG6}g$~N?1Ccdn9_mh+{eI|(WVx~s zz3bme2UG&179-}mdV{>j@%?RZyVQ?f#O~xSX!zzE`FzvaQGwd(F7X`1Q8iDmPmHjg zEf$)PY~DtWr@yrSO`cp82*AG+B^MHv%@Rq8%;>sKz39m8wv`WVAfZB+|?Ozw`B z3eZAJ-ajeqzppJnPplm?=O0UUO5ELkXtrKm0S?k^YK4Ih&|}$vfO+=5;nGp*hj(Dk z>LtQi#6{%)!W7Pu_wC3)MBJAo(fSP(T4xcKtOQ~j0-CVWo2nQJn9!u}V)A1P!Ex=u zp^FH|Vsg7;b)5;Rs=LZ{oi2w;zlOJKi|4!Th4r6#b+^v#vqaj+=-Pe{*6CylZpXep zd)i7)XjM;$&6eH}4j9ees^JtFBKP6cZ+q)M!Oxy9c1R-Xt zGa2#G?Ti_oPv8EJ$JQ$QBAw8u(X&ZGHjt|ci&qAp(EvT)Sq3IDcYmxb66SAU<%$cf zP1hu)y8!AJuSIJhddSsy_GBLz#CvW3ZWj!qZGg+Z@za$K}xiS!@5 zDzWos#wgjSy2g_~=DPbkgZa%~?kA6`j-mO%05c@d3^V01_XGL|=rn)qBP@pD@U}J0aS>wzS#e>N^+_kBJqm0T z^#W+JD(G!06>PiKM5)<4|0+6I{Uqg z_f#qJ(fmGny9=4~vl6Gs78^D1!2a@#nv#Ml#N^xcqb1TsJn=H{OwR83r+S31SQDp zK$3)&FkTt>&cV~_f!yCFMnoltZpVI9DF7P!f}`j^yB*Q#@^-8Vc1=5;n13Wz3d;Wk zz`Y)02dFy1V`7NnAT(ku^VJDmN^eUl{<&>%yS}$be8JEqb3h`aa@YH7h<*pJ3QyTC zK{#VbEN|6+ts68IP?4oeR9r(;JMK-+uKO4i*8{`utm9#*m5HDN|H~{O13a;-KWO7S z=A8XYv}J(Fvg;CUJMg_^*$RlO=)C>ExC+Ge-ZfP+Hm@H#_~%|;Kh51geOt(k1eRCF zb7=vkPTH5YrAycr1KS*qYE54^1k>5;HznLgCO0Mkg9;i$0#7{2F+h)oL_&^n`P~Ep zjS-gdFfahlTvGxgU=v2dibXWu11Dt09o0247l$$Ygq$vbhJC!XJ7r0ER(IsI^>XFa zSSk5<2{9Ol6I=kQfvL*ae9#TpL_B=2*y;|jHgEHyU>z5-wDJzq9@orJZZaJ-LB&` zi~Rc8^m=A(bD#NH$y!u+%t&i9V}Hg~^?N%upG3A5hLi<)M))F;&{+i)?J-$3-@jm7Gx!@eIEl~pi zrrmAT8Zno7Emgwr$_FX(P#-;j_kZbfLLc;Rlw+iywN&TmcC@5SNGw#PpzYHOVMte- zd09ZKu`bBZQny;C(yl26gO8Zhtf~5Madw}a@MD~uRc3_z8}Q2Og0?KOtQk1o)Q6DI zjaG9oJwg2AM@`6`{|?!K7x$B&1_5LMNmA18htWY`*>Dp5Md%^@hFVDzsxLPDv_=;` ze;y(LvZMN4U%0R8IcNP6V|B4m4ZIw;zBLRdod=UX>a~VBlL;}W|9t(K<>YtE<`^rM z`!mL}1LXx|i=I3xV&$ zC@x^F!m3FmJmWMm7>MX!+j}**O3;*+XCgs{ER=#QC)L%w$S=2dsF;^5XJ)-4K_-?! zNc6eK!;~T6)ts2$wT-WPfJ*@D)Y$f|Mzha+`jV4h!XrIWqFc$4x^faMJ~H|r#_w!4 z5UFhBcWNMXph!}@VtbrQ!$Nu>$e2k7H^K$QPbcE4n|0^C6mQ@t8*D}q%z|{tQUXzi zZ1pSd_~|T!WD|+k$d7kWV(ADVObMxX-+tBNx(*Ny`4|;&0DaGwsel{&CUJUxz^7fI z1<@BwxCi3Li*lxzajs+5Ax9r^$8E0$H4?O$tBhw}VgnYJMALQKV&>&0X7X z|7IleLDy0KbmQY~N7?qQ3+auDp_Tp{I&+&zwRc573(u=#KY&;9`g8%CQ4v9Rru!4JP&pb^ir>6q=wGbK?)#TAZ0Cpj z9h3=^ebpD5O8vHW)1F0rbntQJ{&ZKa-rMc&Mo_;bTmKM)jsAAZv@|*K=*&u!^+U7T z`ORU01Jynty|cf|WKIxjSpv9F_nv|CMU%5v8m)+A%gIbQ*y)8`96cn$FDHfY+$GJ_LQ*>+cY;^a;ZG9Y}T+76x_(Nouv; zKH|t+`4A03RI#rJOUlS^6?r2X(r6k(DNj9_Uc^b*But7sni(pW>C^YH+7NGmUcdNW zzanUt#iLr1dtZQvs9B0CjMz3Is^h3NIVF$LHrA-^Oy4mI`9W{>KWeEZQ@w-AW!+<1 zXNz008*j8Vv+``VHl4|Aw3lC_6E$fV8BdYN?yD?eM8n&hl2Q*X>p|@2BhLwaz)^8=^sl;92>T8DEZ6r!_T>E&Rt;+yS;C)2MY{fGYR6I&e_cIJM@kiGwUU zFp(ytBh01R28K1Mbw>c~KM(x70wRfh1lG~x)vM>BM)jz-vvRuWEw_SQi@O%!3lA6e zB?oSgPvm~&kd&vZc!Zfq%hvVbvVxH#p3R_``>`tcSXlS$^dKt5g5<0nAia(C%OnTV zTN&4q$3+?0e^{zIN0L<-%}`rYamh3na%YPAQ5vt zinw*NLnn?-J7r1Bj_qSFR|SK{8Y|drWF^Uwq9q{%p^}hk;z%rw^RT{ESxEy8C&J6O zdq_+h`N3|~|D#UmsId>kB?0P8&ApL1;Q9l7rrfM}Ik6jiA|ewA{&6M>GD9{dBXz$1 z@P}wyrHCYIcgaAPwuyG{+vjELdkJR}MZvn~3SD((Py?75|DJ&t2;if#aWj#=Uj>_B zF|Wgz{nr!zw+B1_Zx42+ZvQ4QZKD;Wk0y#-dk3Gpzo9!;Xf_cM0-k6#Q4kWc0mIGD z>z<_nC(54|hs_4bL@Kj)zw<`L$by!jh2{wKWnit|L(4J7zpb35Tjm%A8n`5-b z(in#STMzqIkx&N-8kB(W{=}DuTF@~Q!jfT6wf;OU8f|2tagdf9JW&)>a94)e`D zvq|n;iP~(`6dGrC_0>}NYR^1u z@=>A&gwj_g^#(4q|nD!9$i_UmeQeL zy>z0`H&#TSZr!_%Wd;srY~Q!KAP`_)CJ*qXi62~dW`63JpLMcYj^{pj69k;dC(zSS zO<#Greq-*CL1ybmCCF}9ql3H>;_dBXfD`ulN3zj!|Th;U#Dfo9(L$5q)Sr{a3 z1Cn~RYuU;keplY?eO(x?z|{Zs#eVf*(|Ng6+EA7#?DZQUzD2ph0=^j<_>nw{WMJ)y zWc`={B4{gU5ou&y_mN!?B> zN%$%;bm7;NMB2>yKtFgXbbbNmKSY@5)cgv{=+u^-H9EMjU8=B$ZjTRZRIF0c#(7jQ z7RdGnHU%3tf6BPa$rw{a!6S3zkCEC&374RM;r|&=YokX&fL@JJ#tKVuJ2#2Tp&KV4 zJ{KV-hOn_Vmm*a4=&$oWWkt4qcidJ_9^zqX6Ya+S=7=%ll+~J z>H7`%pMnV)_-QK3vVw*%!FUbIAT>Ng zyuPFQ{tXS`hZq$&pCpsDa8zKIAO`~ZSnV`D`FDP_J2cGpgVPngps6Oyv5kh zgji=xwrT^mV>bdU$Jhd>u50PtqsLZVK0ah;4ys)4ofq;)UOzodZBTqnyxe;@-<3og zu{os$u^(v<j16`<${!cHuj8&y|K%5CCXsYz>w9ugg(oS+fIAw;CCS=kc;bi zH^YG=d12=Bd8V9gh18xm8{2SNfifJAHs1@glsw(NHqgU#crxN?+y?o?k>1~NhzTRwBrYcoU%}J0V(R<@HlFqR z*d2grligA8Rz_()oqhFX7?X0$W66Dle2|xkMi7&SO{dc^Hj9N$D~^V-21YKpjmP)k zeolSKJaL;GOCDY1X!C1=q zp}l)hG=7I7;nP%jaMiOQ&@q79@`}0(f5<47Np(pj(zMD*1`PH2`AR2Xn=AJ8md zb-i;v0bpg#Oj+va5DxYq_`!j55F+xYH{T+~y0PtxN*xt?umAqHaUIWZ)^m?YvHmvh zpVKwNSaGE|F7p}k2``Ho)KYh@6Ng(*l(_p)-bai=5YeAC1gfq^~NxG@l|;V&h? zlv)v}seu4(UH`(3BZ<9Mvn@l^6JnD4AR+hpmpl!X!nA@*>qw~&#dEsiaM6sRLlFi% zk(J0@8|qH7E+TV&oEsD~7`yja%>ze#b?gm^=WlEZvr6g`Ric%j9aGmarq3HPG>H_{ zJ!6awCm9!Hw8cRaeF~cBt((A}q#kC{5BPGGNMV});9qOZ6mP=6p5sD5{LYGvgB`7W zCM5svgM{hlU*3#+@2a_Svm%OHm2aGibM}WSvE@^G&u$^I0y)Efd44FV)M`(J<;oTr z!ATv^m-mmusJQMuGADZ5irhX1jMs%F!(RSaUUgxX*YC>&jdZf#5CFR$ZO)W1SyQjXSl4Dv` zDKA+nD-Il)rLfU8e(F;+M3+7ML?cB~1RT_9-tky(3JeCU*YA@0X@8Y)YRbuG^^4Iq-RruaCt=hdJx zO=>ITinvj#b`}l4NzJ5S0>uEI#2}0I%f!ti%q3kI1o40qU!-$pp*4!^CwtS`?FcU{Gt zlVPgMAG~?I@oIB3Z{{7_NcSD@#JcKtzjE!^Y}~^u`P>(O3tI=Ri~1cn+>xt0Pqeia zcK?Vq3xgwC1(!Od&%<(S^2sTOR19PMJcq+AZAcTE=E78&p#u4Z9Q+F!vcB{jbZ8k& zr?xqvnf>BVYS*&TgDi-VW$LD1q9b`eq6|+*M9V6HX)1kdcj-V$B%N8#W-xeE?VG%^ z;aVxYrM&s$_nA{3I?eKPhNcX2w;*(hx z3b&j$dV=lWQLMvGyi@X;YkI_yb%zS}mY~RLkeNlq;_6?-wqLMnWZ6;X9ka-T?7I`? zAMi7fJqZzQw)vi&ULyzoYW%RMY}p)6&Ytq^TTH3@xHo4W7!grBC-F3L$yc@lx70qI zcc1z?&ClfNq07t3>s8!xN41X$HzPw4ex}v66sp(7LWRMl^#SW?gzu#$8GXxW-VnlU z>rF^Xp$Wg*HfGIU9Aj3B$~-k5+{xri zFHYB_x7**6^|rt9q#zGZN2Oe`s$&>=B&JLUHVUR+_|P4j$Tj)aIq6G}wOK|LKa4qb z&+15;$WKeqKS*-FJs>A5OZ<~~2a)Cbd0Yx2kn3X?LqPo6=t4jN`;%ksn<|Wb4FUp_Re(uyCinxCCt;x&R-q{oWUfjl>=Ww~Vs-z8KouFUa}6WA1F!IhZ{A8WxJD&K9#y>d!J{3>G8BZ=DGaGxW-#rMn%iZhHtDn zbmsQdI9rOmUYfblSnZPQubrZV!VpF1`P~?VP+L$0AtUcS1W#w8=NyG>CQZ8;KiMLe z14ukv#nw?AzHAri;$eDt+lQxc6d$Rk}}e4bp5kF_Y{_^4}xr z4U|^*Q}rTBc@n`wcvW;or;d@D&#Laq(Y}0H$ogQE9!U8baqq(-O<}WMYPb%dq;%&& z^mQ;lhQtqIdfg*=(6utw0zL5k~pG<31XBWG%4;mQizz7kBo&L{GEIx$?9vf zOvs+3D5HMywZd0jsxXJyhTFwFD=(`r=c*0oj9CwJVGvbygZbPsG5OV1Y32$^cs8ti z_hFe}u^_@qAUFtQUd3ksEPNb?5jAY|pIA8~inL7}1G3g5G(uKxS)qOo&(%xr1m%uf zU3$x=C;t}vlQ_2u{eJJ`#)LsK=<$R;T&7Pj4_!*vco*bGtU-9X{hq{3jusu6RLzhQdb zNvd~Cbkxfb|E3)0BgU{_^2U9C3(10nSbeQAT6t(v)=dPOc#~43Pfgv&Bdg|b=*xqL z7G5bnGAs__F(Q`ew-Be~(&_VY*+B1!X1TVm;UZ>+IK2Z~y2|~HGSDzILT$O-sNgfP z^%hw7Y>56Uvw?Al3H~g7io|p}JBiEW^cjq^IoX#I$6rgRx_{X7Q;qjSrCgqRfBq72 zcwc>Opg1r-E0b1IQ2Ce zCob~dkP2kE`1VD^Y#enwWpN7M)qly_-#M%yCy76ZW#N@dKFf2;Ibi--ET&6Q!a9-h z$}^f&Dp)m!`gEChAuc<0rAy$F{?XjBaG8D}J)S&^ z=8tnss#R4;Emz?nn~8{Y(Y-!vcXsr2!cH{TYebLe9#=xbNM4+VXvwK}$zQn4h084` z+KnGW5KJ(a8z`M}ja1p{t5eSig;gtC3Tdih4?~1lr;x@;@BAAEHi~(l6Ijk}e|~X@ zJCSH+LZqLpHaNlOU!;tZfrqyLKT~~%;aH<(hRk!s+XsrR=D6sER~dR0{slUF0#8#3 zJNBIWP#*T(u7q>pH>eHvwXel-rCd&~nF40)BAml*G$}$9D~|`uzLT%Ov<9^d##pNk zn3(-+DeSI{tqgf2d{@mGVU!cYb~N}{Rs3-r1Z)@zLh(m7*Ae$Za~f9rV!q>lq3Vn< zC+Gdpzsqe;Oq-yoM|iPbe#wzsy*kfkTD*?xY1HybQi z4%zN?D|m8rSmJL~baT#NLEJX%dIw-nmLRQL0^PMw}{$lsf~Ee_Z(X#1f9wE&@nU zWbVYE@SPI#qn$JJoP_rOwjCSsyL#Xl8%%=aI3D}4iv;JpU_QmgR5N#88RFvQOghI>!~1$O;;YdP+EY5$Lo7$y5Bl zS$pm=a&yFIHRi!5j-|1UgDnuWuE001E9lVwiO$q}+FD1Vz{Kb=Oa<;utay3%pW`u+ z*kK3y?OOsb5%Y`oex8jAx~>LF2i=Fj5*TFqP9=i6D@}MFsWjKn-^+ ztLliLuE_%4ZsIl6^D?SX;48$cUGLy1+;BUewy~J+z8*KR`D^TisNjmu$&4k^fx|4I z3n${BdP`sa05TtbdfzZ^jN`Fts{+7bzCQo}4zcgz-8^X2JEG*UJ7sLVblNf%)!)aU z53pKbLaA2UlqhcZ-#n&L?d|ls?N1;{k{F?$my?&Y{bt$TS%xM^RGzwwrz-QqAj{u+ zJomtSyUi|vJO6x)oS(%U^ysAW1aDNc%X14iQ1c``cF09mg4jl-?w`3}4PyPd4*&DD z+k7spEnqb7U|@IYMCA>uOUBO(R#bQ1Zis>o@qAx!uj(C`xf=CkM%av?4byDQG@AM%huN{7{nq0yJ zhSUdXi2Vyh6w{g1GB(+M-%Fvg7oJfxP6BmsOK1}%gcjYf+#)Q#7*5~)D38gUkE{q= z{w2Qoq0m8V<3g1zDm5`myZ+t7)Z=b%&Va+)3)M@S>+l3E0a_o6naIyNxLQ$%vIz@H z23B^r*Kfb^_dg5Y7&fxw-M;=~cN|>%{!D)6iKhNXsfFCWOVd%Ep@On0Rv?==*fUA) zd4bi~iaUKum*tnMY^~g+bq@@=HoflNx(a$JC&`^F!7&Rml0SWEQ~U7}5NmPy6j8}M;dkfhqH>8yNwWx&!VwVP6ovoL+5 z6B9YxTbJszubo`5zQyyj>+j)nIV)0%^Cn+Z*!HqeUqw)*_&Y{>bZF*NFat2AG90a+ z1BtJyy%J!ilScf6Y1U0y12(G`5z6AmXaYWdF~yH~qb-nkA#_Zd;6@mhDN}8Obhk7I z%P}?g!x|GiATT8dd7U~EE~=aj5@GyLBvGS>I?sf%9TNdss$|L8ze&4QVstWr3+o5y zvdc>i z(78*%=a#N)%|xNKC?+Ox`T3BY>r)sM21*$lFukuoyjNbV)`$)D*GXp8ls@8q&SueC zSwKS46%nJ9{xGDo$+c&9Nvh@rsfc3m3XV)~y$;>b*2!LM_s?^{P?F1t79S{sOC<{=_I3O21X_}J9*m5xsR zty7FRx6N^a(bLkmD4&8yn*x;7l!6n<$C3_0E#<=;k8~?0 zh8gWSP{xuMWYioXF&c{k6KDMb@n8l^0!4cyxgphG=ddQLRhm!D4^mEFdhX|^sP%_2 zxSOBTx9v17w*lt#PD1bty11leb-J&<(45*2T70g1$$wQO3f znR}u~nm}w-ukWHZ@ddC94mG+#llen~!VJdd?XOuzjL#2#!15yQ@!z|_ZBK$Koay%f zdK6Ax0O52X4@%+jHe)(C5l~r_z-KzEV`j2?VB!0cI(u_{@$BYW^Z$lH`xc4#Nxby1 zW$YzshT*n32%ircGMmvz%|Gp(RxBY*R`hB8J-m7p=?q^3La5$G;BjqO;g)Z!hE*80 zNcl*{Onj^U^Z9U%Cmo2_I9qwX3>et;HF7t0KXQty=QC(8TOITqqB&t`03ym6VScQu zf;Wl-SP~A+Ui@RmgS&@c`4x0o;2Yy`%X%fe${L&+vK0sO?)bsiUiuO&p@1Y8|4#|> zwsWe$tA}I@>-u$IH6-tY^+#(}Sm<^8tn!b+^w5Xih0X5NWXYd~-@_|Jkuor|xLEVd zb;-GcTWFLiM3$A6L{=W%U5c^e4c8*Qr30v-E11^$SX4+$+NbR}ZMRjS99w{uTlRnk z)kFje2YV#1;h2F+Kvt<&2FpxLa~8`}2ANUhjSeP(qkN}>B&!D|{=r4eWC0&|Bh2f4 zhfi@+Trm~Jf1z5t4ppkAHWumP(Zza1tAlf;&~bzD`Ru8zl{6h$1HKYzeEFJ|?r8k5 zFI6ZED6@+Qr1nW9JXw4yrOXC3GoF8z|3Km5Bq&BfUF9;qrVpD(nPd z-Rt!vl)E6&9dE%MDx+hX|Eyfbc?z88 zO+D+TuqK^KHy73@-_X<f+Y^k^dqlz_a$i_>0sV#gGK5f5rc+1lXNcoFl<3`YQg#;$e#~ft!x1>b`8+{FyCF9f zXFNiZKbtqIhA~b*zeRrK2>m%q`pIhka;-U%fskZ+eq$r>{qKSJSADtw6@6UZ8@Z3| z&%*D2&i|Viu(8@BaIO|Rc4B(4uKM>CF}f;wvc`Dsef*jUKUYMAL0)vMwQE;t=?Ime z_T!otd5zBouM!R-J*+2EaJlE4GXbec*{4$nJBpuiryiS^$~hgW-V2!=t?YF4Sequ& zVkjFXN~*8cOr&EB$cxk;EgFCAEZQv{Q9n&b%pf zifLgimxhXzUVatmRweA@RJ8_qs9F@6(+jEXN2Rxo#j<<-g>d{RZEsfQGAIKnF53ld#z?>VQz}=YmP1 zl_v81fD#9zSC;`WOxz4PgM-ke;001X?`p^}wRxZ4g?XLs(Ma@#)VSIn9CY&jN^crh zzt9}sy(t4@A!R0~iPplx$W!zpl{*gW=I9kn|S$yzr6R!gZ|P##whaS@9f5b+%(>O2Ip!! zsT&=^0Ie`&Ha??_#ZH#4AnH+-B?Mg|vaEe}-+!umVis|BQeGM=)~R`7r*pC<1JBmx zVAA!sv*O$#In+1=CMA;;)87@v0P10~)M)vy!OGI5z-yxe|2ExUE6aY(%|`+keH6|N z7@2%D20OQ2Fhc#w^{5dH7z#sr<7jfH;E}@;jv1LD-7I&;P(;t{8XMg0X}Qz_NyVm$ zny*kQ^G&?M( zwY2+OpDwpo3O`+#HXiF0t+Q?1D&MolWJPH=wm0E48SD*uPwI=;QW%CyB&E>SGw(=$ z^Grh@Idw^u$A2xU<3k01uQsAlbO1}JWQo4qfdifC+ee-373-g#Xrj@By`V+IYZYAc zc1k8sOJwQc@B2Gh94y&z1Sw`dK1_(Ki@7*%heTHi=Nv2`+N=E-7WWJJ zQHh~6D3w9$KV`@}K4{EiXBSZCN&mwyQnh%cD7iY9TSH5a7;4r!gdb;{+_6khhm^={ zt-E*Xr8nAteJ4zsAIHpSEp|=wMinlPPZazg`4*n#K}D`XeyJl7TF|#IIN3{?@84=k zE^S?f?8ygwM|b}mr_XQZ$#{NO+7pW5sFHItSc8f6nybu(FXR`{|K)wU+I^1^afG=T zbw9lFvHZHV{n+tZh{ivm+-c?Ef$e@d&7X&`(ADar3Ic5 zmAh0AIZ^ZVDOv-L?+4d`D!tW+Gs5qsdf@9MwAZP}mezc|O00f9uL0+fD2 zd+mA{H8jE{dtqN!;cS%3Gs33v^|R@Y>}1DOOP+rZ^n^M_*)Za+M7)OCrfwhwPBE9I zLBih;MI^B=s06(+J)wxO~P&wW{^Bs6KHfw@!^emM6JgNerpjff$K#}%di9PcS9@- zbhfMN_?qKsH~Y6~ox*afAMfjhD(cZ(UihQ1fqFo2aJlnr^%Ep|Pg#5&jV&6lD^zc( zo?*BklHrILHwTPX9by>(Pn?-wsjN(<5;5(-k%k|J$@64KJ$C0zqZgCK~M zG)M?TcMd4sNQZQHGXulGefa*~_1^oZ3)eik_x{8_=QR50n2z4I=3{85l@l0_jc~^8 z_8trfK4Xqh`sgWsNlR(5j`nPz?_0M_{Eo=E&+VXaYWw(M_im-hW1q%kx~SFQLB_hpmX5n;__ z3_l4Y9vcnNH~yw##ePk#hyFU=hn~6E6rJ-mE$*JwG;A1{;|B=Z*4=vxCG3= zijNRH1;HvrX&LV~F@vt&yg!}vS;jAUsZGfZjh#j0_&%x_2L@W0R@UyUB^yV{lMT$i zSRXXtV-8&A>xpFyjoVXEstKKXs@S^;75j0yhpEu_fMsryczP*%L{P(Xr$Re74p7cK zGsuLz=KZ(578ZTT7;)EU3RWaEEf zcXF^<34IvbhRrQ3bfwmKx3<8L)lDn(0Jku+s%Uuct5exo)=-&2PN>b^l3-2@WIy!v z8dZV7t`dH1M z4Ck*e);E|=j;EC_a*IB)NGkJOtclNmaqL?-ApRgjNnX*mD~u|+7qT(HQ-H5csxjD| z6~!|~CM$@fH2Bbl5d>A4E)96);T`;^b{!YBuvV&|bFEO`w=SOo0u2@b#*{Oz!k~=b z*j133;aoOxM$x%6S z-*XnukD`o-l!W3e^#Y#BvO4%2Yk_Cw$*;z3sa!VFhBccC@o#J_V>_@Ru1!j^in{ zIVYaoR!>|^`H#t6fJEVZK}gOt+EyvEdQ8%3DlJOTj8_=(_}5~6i+_E~M|=8Gf3NyA z>;uzCK7u@wT`3<%dYshnzxSBGfp6dugix?NV?#^~wx6TyQ(X7)HC#7e=i2JJ7^Usn zSroLBrv$&e5}YCXMGm&9@YL}E~SvhYhym%e}H;fM97HUamzf`Z#6tcAQG*A8DM@wb{f`}P+L z#DXdeiSU7Vw8G~Mx(w?j54hnkObl8{PP9WTU9v@?#$(}buU9c#rEhkHiNL# zwRll}QyrfhBFg7_;}k8E&5<;U`piv}`CT^?sr-_5Szq@-=_#d?s6vNAo*l z7a6*Nx9$y=7O{G{l^jPm{mUeIdh#uJxC%Ktiu#BdQ$#QM&}GfxN_B$coHrruDs&g? zjaX@Y$ETX!t@mi#Bc@?*r^*B5qVV6!sTD}xoO8UeJ&|y@9*eyn@5ng19x6L({epGiOcchpt*|3Cg8goAb2QuWw)QGU_}`a<8PhFK?kVe<+TX~b zeXT>b<>V8hIqXCyy}WL$WgCu{ORJ%{Q{^eLQAMJ1x~z-r`)Pvyni|2UZ!YWoq3UkI zPa4>k1KMJ6lOEp3OZvg~-HCCo--GAI`E)yms(?zZWBWsz$oq2p?1FW+E%r^;t3!tS zA8PZ4uTZIjy9|bqWGOwd+Qr_Tq`7t*>wzk7NV~)XM;#V1pZBgO9JWn0?y3=mS|9Vx zOc^?scwE5VleIB;S3bC*)pQE~fE{L4w9fgr7r}bi-ub-p&#{1P5Vly{mla}>Yh3?^ zWfK1%5&XwE7mph*_cswS5|4Za33uH*j^&&G&6j-5aWN!lzFjm~3EEd39xj)ea#M1@ zUYTDe!8Vcqh|@?>*lQq04jbjCcqEiDGy7^hgk9|wZznC1?Vi^US>Ypfw3Csss90gB z`>HbZucQb>2M_a2CtXfWEW@qpl#s3C5P6-@TsPHN@xCbd1P&oq9(nlZhUM7LU`{l+ zm5R#fNcuxELyIJD9oW#RUa}Qkm84umlEm&AdATPQDY=;GXg7s}i22n86g8QK@@GSD zu!)igXENFVpq5oi>g?GQ454R3BtKUO|7uo9ivRI?$gL=&a5aN%C*b^H37vrfoky4s zgGb=Q(<71g@QGuJ6JQB*g!9 zdPEk)B1h^v8m3DO4D`U5@Cjav2lw5@;y~2O^u=!|m z_Vm7rV>XT%ud+;e&T3wKJCj07ob%m8#@~fes>RHI0AK%X8FEJo>*$1WPV37chU;Ni zK7yUpj3PKbL|^zieo@OlciT)jIzBuZu%Ecasle%@KPgXA^ZOQYHb7Hyh9wZb zIe$4UzsGeJKxp{1`1`2*#m`P4co@ik!p7w=nM&Q1_qj;ESQ{&?dJwVDu^8;vWE?4% zpKHR?&z@Sf`Z)B^KtJ>qyC3tEGy7dzFN2{W0!W)T!ZY zcqx0u*4OTsuDo|(Jl?)YtyBaplmwBim;w7SoL+FbOqRbZS!(_=bSON2umodDSk7FCBA(@~%MAZjV?IGPfLx}N7#|mqHBbpIW~ z{4`qa+eP$h1Eq?l^Ho8`Y%V9TT`i+v^_fzCb&o_$qEyjv?%h(jEPF4%SNpo4wwH4@ zI(@SXw(v+agnJbxK4|8bjbU+0&vfc(=8vtH$Fa-z8nLKZ@ptz9@Ar$berpulX_q~I zbIwt@FGLzvAYRtHv{H;kL06@XXLtQx)51c&+&OVV^0xxts~+yOmTM;Io{)_60%|jY z?*KZ-vea;ZO<@9?g4=7a5Qx{iFU&99^S@sY_U$T>-#|S^llfZo(QNK2*hr5xH&wRB z-)Bphy|n?hV6bpt;A-P`;Uoyvm$jf*7^voxj7e@=7zW?mNc{UlDVEIq>SW!fl}28? z#^b>cR4p^=%?wJ&&ExiPr+vZ!Zhp=#kw;u72`^iN_U|IJM*J^g4i4U3o5ObD&XLN; zgZl;Z`%@zmJj6+v7eTid#^=lZ7mZ;D-Eba%#L>lix3J_*x%W9xRUKiF)1CEhN6j(^ z38gHL>@er@h_or`DxQ;erpSf3m&#Hjc4vXEby`jP=R1pz4u_I1{w*0VEkur^q7IPP zIGuL5ETH>IA|RXlg*w?I>mX%j#rYGI((97@E{y-m|GfUnVP`g%62T~YIH@5uO@}1c zlu2I8Cb{P$I1tFo#?}+;WROUQJ3N1B=HcMOQ>*_Z2%wsb>V#=xUd{=dN=+g`F zC&3nmYhc$CSRQ6&rN+kcOK!{QoX1y)#==#zl%F>bjC-g_0v$=qQ z6NOL%s5W+Jbka`mM1-Doefw!bH&Z<+Lrrn}I;jeFKRTOovD5I7+xwTBhEuK=8=Z7b z+cS~Cm9OtbHq3iJucnEG`lq#eQLx51N;Hd}wbKs_H=Pb%*dV(fA$_j*onwZKaoGO; zD6L9s@Di7s(N@jJ473=20?5>&zCNnL+s()2*ftjnC#9;J?un7ja;MG<&iQQkecAW< zs+J6$Bm$r+8)iJ`1Jg4RdbalMrwsi}tx~&~akPeiEky_2LML+Kov!S_ck%e-tPvwh zK565(Px($O*GOCzN;zKg4NERKlpU5{*yeb&YhqxEv4%H{{1hm*+Zn>^b$BXBm(%f# z{TN-kD&mI{e9BMqGkh+rRk=J4dQhQX_f?8a_2MPxuRiXEoeYU^X%=C1pUTa)dxlBR zIlz3>g`VAf`?Jfdw~_q|3mdme1+UM8|HF?Y7MuhZ zg(qtbV!}`=Xc7bLGR9>Fh1mI-wq;*2KIWYKysPfLWBl^QcTfwu;}jT4o~M3Y;$G;+ zTX(0Z0@|x@gI9f{SMn0G+R0D1BU@Wn*7+OaD!JbA>%E`UDwVQcDwFD0SxbpocG{%5 zuUVvv?3v!&ZgHm82@(*C%;3f|6Qk$ZXg|hsHV@<%cz2IY`YC<}+g$;w@aeBfk2%v@~8KciIo&^ZV;42B^Om zd_I+!jvuCfuy%fdq&`xO^bviItx4q2EftTht-4V0p+F*t(HeiN1f%-~25m!5> z7gtI183kqeo{b|_=j17B86W(^PpWf`aIpqA*n!fjR%&E5tR^}?{Pxo;DKc^M-4M@= z$#H`0r9^RiZHe61>#{}G%V9gk@yD#awjO88>&S^YPY&eZSDrHe2A`7$;&adY`eZ)h z<9k%n(tl=lp{38x49i%@dLx}dd^mjQt_2uvlfPZr;c(cE!)E%7-R)M{)EA{&r&DCL zLG}15|K4x&bfN3l!65VW#ECJvPLO&(z~!=c%1xGGnsb94y0VKM2EHs|Mcwdixw^=7 z^YP!|S|%eiF_E7o4|;fsAwO*xCu(!rvALQ#-egM3aQZy{kr0wYJife^&693MdDS-j zJz63bCreo}$1w-Zs<3;#O}Ow$kRX!FS48fwmMU6ssSZA5d&K1I6NQv!YK`i#H=bqS znkH{UB|UWJ()bQRzG{=Gjv%!#Y!_n?EIR!V{SG`?x3Iy!L0FTU!j)`kp1p_Z#_P5B zj`c^U#L=l)6;Jx+d04A4f=HkZ55aZTOnBHj$wA{;a_toUrwpVA{TuS@(d^D6Q(LF_ zs3U^o96XxhoITSow&biz8$e?hz}my?bfwv|)i(I~dR?&SQ$)wj$06vaYX)?b36=|sC5l} zV|cd^*#HTZKZ&1Vp`8LY>f%3X9o0<&FPu?ayh5yl9$HUHvR;i1MS6t%%adR4s3yni-O#T7W#b3p* zYUV3*UBqq{%oLFl2eqvwLQV6ZwbHd)uAN_O>Qi;9Ev(zgRLvMT`p>|dek|#W^&W5j zV5CFfWn}!tnj57ta6GJo`uj{9ock^9?$2-jPhaG8@!E2Fj$R!?AGnMxcF}j*TOa`7 zx;oB=f+QY`wtj#HeDSo7Sh1k7W;d8usr$<~-y%nSwAB?`sKLNUa#Eg_;s^Z3C?9E- z&eG6?r{3z;IjNMyzlJ;@O?8jm2i4V7#Ep}be73y6%SA``WF*losCsyRmwKAJx1ySx z6qjrZH;s(qllsKmC4}f6BQPw7Rtd23jzUUZ@4=p{ahkl~dJGerr}2BpHAo(?7sS?5 zpZyf8cZ48KF~wkuK^Zv4PiA?dJ~35qt`t6wD9}4t%%&RhH4>tVB8S~l^Bk} z`;Vc~taS&~lkQ~^yhkQBT*WH6J@EaG5hZ8+hPD|r&(BcY<%#l1nHU=`S5pQ9pC?T+ zo`bd+Usl+gM+4oSHjm1qHMc3pqL;abG8n>conQ?O5jcLAzWz4{?ZVJ6sk^)LohUEX zmGf<$;j8{6r2l(HyX>%KZFDAeRysqv3Q4&KnyPeQKDd}y{)b3^otAlhM-N~BbWm+s z7sa2n+l_=7Oev{^R^*YS_(0aeRR7r@ZRgV5<9=c`U3?WPS@QZ;DqOO}*S{rrZ$&az zpA~KWH3dmy#ppr&Cm~ypv32$&wQ@A}Bqar^|8TWVe+{!dI+Z7%vdYJujpvrI3624d0qc zn9T)IRXz#2{_D4;q2{>W>Y-VwHtWb%j}q=wAILPMFvTamL(O?zok+?#?>n0F=S;>R zy{v%%R;^}!xRaZIHqLVIv;K|QXf6y*zbp+;+dQ(Wn|uJPn1BNTdngdZm#<=E zgV8lX9{iQe_V)~0)Mp!_@QP3hY;W}sS#umKvo^bSy}}AW%{qE_Yn$K4`+9}F%NZYy zu?w7i7dZRRd`4FO$m3PMb{iKjl+&<-=Ec4<95vFyoy_@8d|{oicxyZf7wv5&HYxACpVx2o&{GIaH)|Bb1Zpf8 zK(B$hRqO3BvalVifu&HcR(JAhg}v5!4H91BN*cg*L}q40Fg@|I*6(5Yxh|+=!jTh|LsiY`?lPbREigjMe;12={!XBsmDv*9Z?Yn z`^odxmS=zOhq3)tFoTf9>)l{*_)K=o4-LR`zL4>*ru}`{$_5jehY_0`C5XBPDYHiN zIMFb{EW9o!7+BwIz#N)7rBoinl9QDFX3#is4M1YC&`M|j;m|C!_?;?lq^`@rQE$0+ z11*uoK*JjOZxFb}$JEt5zHauJf8Mv0EsGfgYL%Zj{1`f7qZ#_*O1froeka=zl|Te4 zFBDC6eGKhXbH2Wmtb0#j%fKw}LV&_b)@5wZRsYoTu6Ud0oKU=wqtb3TYnjBDTEsTP zn2}A8T~83$_!&clcBfza1ZG*YH5t6+>^yY;;M6>cMA%j$zEHx6{JWiuQ|M zS~#ULNr4?|PBkPK(xhmmHpUEQi1N$ExJ*4#-JM$ExL~(QHiHpKx}0K;2WNjL_R|=*^S_g5X*Rw6wP(1=Fxik!_tap!m z6v%VFbf~%3j2uXl29(zql$#bnDwCzf?E(hX~x_^Ih@&b_@*3*f%*QC@h;v>uMI5-+K{zUp(JRmyP zcWk;-XqMB|22HcxU3rDQP3P?;BOaP|O*}Dwl-=a>-;|Aq-9%}@;Z;QLEjLc#q{SV- zain{-}z+rfW`*nTh?`O0=^j%HJ7Xt2pqGISB=5CLFvB$GIPJ4?)|D$S;Yv zUs3-X!S74NB6BoF~80`Kz{y^9@QG_8&nR29<7Kd;=syy zyx3Jc&aQ0Cu`ElStP4x-o3I>41F@iT^%^TsZEF!eFgZz ze!bqE3>`{*Zl&?&J1p(vs%Kv@1x^93AC3cuJV95x(;UaMT?Ib#mrGlHtN;vAor3yvNtn(oiKD*Y-R zoGvI=yUq{C4}VX9qGv{*E}A@)4)u_PL5?q0EzXb6E!-+v8dIbuW#HG^Ou2Hww1(o< zl5*cPa%O|FW_IYT4LfU=4LPpWE8WJ=Q2(3_^H; z{X5UMe{<$Hp&@S=UPe0wE}(Bs>@K)~Wi}1;X2}&JcPsJ}k81S~gs9Qo{}7zebI!=t zFru-Dx9F696yjpb6I!TQuq8nsx*NRshOd4ltg@rW1WHdyZ~4>h{mq-Ov3zJ|UgF7Bjnc<_|6o zh3k$p4V{RmfK!cunJ>nfyMpH~B8R7$vlx^$9z_^z(ITbO)he7lX3I(3IhV$6OjB@| z`@S&ri54%pqBU@w`;bV+=siI#)b2+(ym)vhkJoVaSDH(&7N8|Pt}~xltXQZ{D-O+p zWb;i7YvK-8A!Xxwdx2b8b9J#DNK&~R-}a?P{;l)4LTjgP8}w1I76Ztvewo3|)$W0N zppl-B@B02M-W(ByT)dIqu+PtrfuCfN*Mz@qp81kQ;Z2VGse3}OD5O!mx=I)SjfE3I zKvEnM0)jbELl?o=-VgVmNo#FtX=rVzZxHiu@%iNA1?Oy~IIQcRM?NXD^VL`hi2(em zlC*_hKc|81T>;YC2i5I7XBK$LP()Q*upPUus`_>$rx(7r;=eR zIQkN|i_Vs9e(syAqwd_);|{9NkH1dH!Axj^({Y2!@H6PD| zctC?v9dog+%whe{W5J_H=gHk3Hrb<-8Ac7O;(6FNDt*S(#!*?eKR zQoi$(=z}=+i--a=+vRz1dyFO)!0jP7+NPNXY4J$?)lpm$JFo+dSY}`1_Ni)1e|={2 zX`@AGepZKK`SJAq(ZsQButPd~DvH-%h{PXCl_;FjcMSiW>}jrx_Q~!i(OV|<)Bh<$ zs$4knrx`~ct)^(uCzh!d2RwX>ntnBbyX+Z#?i6kU?Pvy@w5fki3N!avB4{}%t{Hka zFKU68X>Z3f?L{RSpYAd77QskOR-7H|_=Xf_&uKR2_kvB=q#~uyiz=c3%a&<5h&jM$ zf>ff1*L2%98!0hRYR1ZZyCFiCgT?vaSXyPFgERdJfo_`b;&680p{S#e=Lfq_uUmxn zB455x_qnetcmhs%+JB0_7T9i$R1{SN`U; zw>mp`UZbo1$3C-w<+UYPU2Vza=azdbE}o?LE#ADtHoxMs|6$H+&|(>l?_kyKA5mO! z_E#fV&vyE90ThiX?JiAKQTpXk}6+L{OJP6&{|~g8@v4Rs*?LWTzm)?{KHBF zA|m%e%VhT_=MNcuNR@B5aQ~ETS#f38aqjBFB^NRQhhKP)rjjVqh#2+riiuY?6$f5d z!fb6F9!|iGp3Tg((^HiFQEZeK$JQnI$iR$l1Wi1b4!w4(1chm-5`PoBRY{00r<#NB zLRw`~jHc&X2-na^(x$hW7=5C2 zU%gBL$ow&3YYq>4t{b2WK_D3Vr zc$9H=ag`e6 zU)Lcp2lLm1YF4y@LXc4oYgyfW=~+aDPyj&Gh;j;qb4dgiO_o zOEGKk58adb!yszC3fY;%1duLEIZ(bNh7Br0q!;?SE_2>v>>7V~>hADl1fJ2I!B*7ShWP+u`{Z%PEVA8qf4kK@(4OEWS&*mkV;BZcJGf@G3Deh% zR;3#EM$HF@L{b-VEAFfALI2E@usqt_f`1@91g8Aag#2l#>Lv*Fe9I^4i#6wsEzd_? z%{`&eH;<3W9l2cn0BR`F*~FpoigPnd{M#7AE=d%jQY(ENtv3C9#eDk`!79S z4AZ-$C360#(de>$BvxSE59yw{hLE(^-HHEV)-a98TgHrm&0>Pr*ihozwzL~ectHZO z7&TK9g4k>dFQDT?Nr3HM6kPa2!kMmXxA2e&b4G_6bL}q*G9=bF@^7FhG&7{81D8^d{41`g5IR)hFU-w^x;%^2G9 zC1|(`r418FxFY#-j7kcfvz*)ai707w_!e#@!te04Z3Ozzy^*3yIkXNf?uKZadwM=k z^vD}(ZtBf6MbMwzVK$q4QUG@Bq@c$xd;J5#$+t3$l>2J0Fi}hjjd3~Xt}JS~P##(* z-@j6a`FJHI0^sX<_Lr|P|Ea8QbE5(F7T}uj3X{=qvUwmT@}94nm!8f<8DZkvx*LRr zHiGMO2U+-mB)bhKn`~Ne^$UotCvD{%s8PF#q zqs8f?H%D&qqysLU=nxW?=?)c#(ok-tI3q@CQo@emC)2;|+UoX~9D=u9*$QRg-IaMV zO^J6q#`X}L%I~87d*D>Cbhlu{`1S=?(Z(N}F79w{E+rb4`AiMt8_L@H`!}i{wmeN) zbQHEPEid8dgq73Tkpg0EKhVrHD6zny^w3gZA!<$PzxUOv2yI^-ufS|Z-AI+cP2@15 zF{AesapR)VR6b1Pa+?c_NSKm2Zejsoy+UCJU1|iphZ15Pu&IC<^7i&3$x4T^*M|A>bZPj^y zeN$KPk7Q$HtY%g4?T`LTKXvq_IU&co907ww-)O>w)R)nA z-K|;%VX99G?6sD+PT`}_Tr@PS^%nkomo$6-rhg?jjV-9NZmjltZWKpP4OQP6(ZY&< zGCS3jkKy0R2}jm2XPsvvRA?1_{AeVSj(viaH;`4o{e@(u2+4kDi*vQ7AAc8{ikoW^ z?1E%AP*i&ZlG&~vh#ToM(&KuwsRmHhbyzGUaZ^x}+Kv}KLwg=wWkCWCt;4ugf5SKJ zP@pG(S~4EW`i6>Cv0R~o;qDr|-GeJWa+v7c-TOjUUM@Cgpe16&oIzR~G7WNapvD&z zV>@)P)!!onK3WeTwFCA+^twkW2++WUdL$#;#4gthukV~6bRydq;tR&gChCqAw{0+t30@M)Mt|EAo2vK@SkWu( zh;ZUS3*|on5LmQ8c~Yymo`F59`}}!YsAGsOCyzM%@3*lX5A{eMA(tXkG? zp5=bm5RW-q1lg9(7M{qY2rZSTD~OFog?Mk0csVVxGvq$%U?*mGV(wwBV$Y0e;FwHz zd998P-`~9nmqcHN4i$j#xt%9)&$no0Yy`=7+TZ>nw(qoIt=aL7_)5z$&rPcQi$VwY zoKZeS2c(s844RXqZID)C?j@aOIJUWn$Z2B_#amL~rXWLcN7tW?;VAtQ9x8=2n;`Aw zl={b8{Rzb=YU@?^BeL}hg&IZV13w$R;H--T3OzScg_L3Y)}e@F#XInq{6i9&boa=l}*jG#J2IR97K)?c`- z@NQ{AUIQ2NVr=!x8P;z~Z>+D#P49KF+U5UvyIlDjE&RWmijX_0k9BVQA|w=YnIEe! zZfvpA`Qs!bkrkFs%ORpjk#?U^J5L>eqz87)6JhzzZie4&UucaWcu9X1QKoi*#2LFI zO)6DxQwa2raukxga(7q0ctPL3OzZZ<`1HU~i|6Y;t3jGKd^6_@RavV$S(NS;lUMPO zkiqHU4`B6vV!0=Q+n1U*u_59!Al+XRv?b-5jd$VOaM7XSo}#(B^3#$`#v$>+_|BSuk^lY@Ob$E6b7@(=ZXu0bV z&7S+xmxwwiqTi8*&;Lp!WQTkGCuK&!5@w39A+g4x z9u**Q>L5nFV6|Y6K50DO3d&+G-O*jcSs2m+PUnL^2Ezr_D+xZOk6s-BpX#9$RN)0f zhnCX7>qb8-PTOwLyo=f_7~6^^iB|tr`RHBUX$0cUkw(cb5O0ov)Uha_fOVMbrl-}u z$`n~fD$jtm4v8&x3}6s3G{mpCc-^0M!D$w6nikA+dH8Kl#Sc>4H3fuE(|upa*vs>C z@~e_bD+CeD4WDvIq6T>#|y6l2zEPH`yS5| zBbrG6jdT`8*4GGIPDs;`w`sqD*sd!fsq*oZ)WsWlv>O|9|9B>!$=YcM1Mj44R1ykA zh7)$BB!0@aX_hMuS-mNKk!gqFzlf6AuY5E@UE?Z=UKF#E_+10G1*lY|uV|CwmkT@> z9J)EE{)yfBSDkP)Qf2f>DJ1yuHk%s%cp#n!G!LVHdC6orb)9ZLcL4n79sDAUrI7cE z8%0p`uk6Xg=m!;xoR@S?QGE!yHsa`3VY+FKBJ?HmU?W>CA|o+D3|-y7b5JEtHGYBb zZ-#TI?SOV?M^uEaLW)*9Yl9YV+%;ea*y~>U%s&DMoHZl98Ejcwau&*4>=bh30bd4XzyrneqJw z(fynD*9{vUqjt$o48K{b#TNi-CM$Q5jS97dr+4VA?fi{&6&@Jl)!i8U#VtGiy)!K= zG18$}d|0bt{1iWq?u3bgtDgWk2|Nj`(S#xAL*Bux`xGWJ0r(SCL45!@OlN|@Joy*9 z|K(AC`#j3^_hZwBNzcj(fbH@iS8^lXy(kd zl?~eyo2)8yLMSJi)bS~`#T!D~9Z3I@-DW*xn<+^BHdXUCFR3!kWE&iuNV^RLoQNbr zzwU(&K$>bLB$hgXd6Q1S2LXSV?lmv7S-edKQx1(;!fWSz0w3ymd(9UPu>{RnpDi)1 zG&Yf7CDqPPbOar$57IRo%|s0!C9M*)zKQcxfZp?#RKT#(fWm(gii(9sPT_4+6TBpE zZ%pD>Q0V5400}Xk0vE-`7Qt`SX1PsmR|TP%)UC zvae(v_hW7Shp$PM@g}nf(OA&2pj?ov@AbN6L@} z6+WF>8a|E5qehg4lOD?z-`04y5v_H(Y;@9qpVO8d+Vl=Sw#xOh@`w-F0am-gwu_y; z#?q#@xcSCht>v%?z%e2yLoogyjsb}RBwwXtZDmc-$xt9B47a51$4NDYwCK4a+nf8f zSXyL^%{p@=-lB=;rr4}kaA|T~GT8=fK_?+=yU#}9TqKgjx=(%^K0nx@zm>o%%7w`@ zBpnhgvdN2gY7+bg_;tF7@*3dR>AQ2M^!M%k`xWvNph~+0+#5!#gNH0{!5!8-N}3nT zs4qv>PDlFvCNHkzsduXe6(rSmLZoDPW?1>R6`t8zH(>=IO9jf#vriwO;5&RP z?0&pfcws4(E0!3g*vu*2`KC5Q82uUP=ms=>|A2?JQ?R8-44V1E%v2y*wFTfaw@pqjCj|o=TfM2D4;7syj+m z&OfVTunq9!*90~cBikWG<-#geT6bCep%yI4Ezmz?ZS7hj{5Pd!JZA-#C1$zC_A!tW zr)j;eb1H`CMHze}zGrJ$&ZV$GNR=xl{;YypQ(N@XFP5p!{MMunf;h60YxYP)J@pci zE7Zt223lfOnRm3I6K$)T^L*!S-ao$wQC>k{5C}O7UHIY9<$4DeY-%y=R6a@H3B^edwtq-1r7*=aEq+cA1PQF51EpNb!;9cME ziW%QmFV#aiSNl=f*g;*UM_pT#{!TCTQLea!VldMe4i()t~(Z9D5OK^%|fe$y&M1tB&y%{zao zN>%TlELbnEDyw03uGEbJ4BknZfB}$`iCZ4p{|EjzT>-Z;Ua=5kK{V!rg&N57q2cxw zc44u@T3ec%4yV=@B(LG?=ksN1V=qddG1iy6tGZ>I);$-!M?>0C{*|F`k0DG6x4g9S z8Cu7%56vUdo19Ora2P|vGd?paG%bQ|5C=;|?jQ~<`OK2MqRVgSV;CV-Jvg1f; z@t-f~w6L`CVUJY~ST!vcMPNRh+RQxE?jlOZ(2c%|DSeEkD|>DjHSYg+dRHiYPo{Sg zW^sP@eX&dJm z$T=gkg(E*&5BfN|D0*TYO`o|f#xU?C#D6vvcmcltjbYihijOs@FMzr2{8TT_1!*to z5tm(6Aeg@>c`wbcVC^Z$8lq(k`pL{KQoOlT;hAsBzD@C@Ud^L81LO7OU0#v>K7KP{ zwhLTLXvh>;j<<#nV5C*eukKV%7)KwXS-JVuMHt(bf&$t|!ux@KDJ#lx>Ul{RNmrdX z(?ux_r|sLW(mqpf~;e>Y6wySswjO*tek-wbWrQE&`RPe3{~t1 z`t=Gfz>h$%m>;fA)t#hZt`Xq@Bn4Zt1lrpf)5tN(3GaP~rJ@u6O*Wco>b@=Iou6x|?|Nq# zlOO$O7-RX)OqL!b*@dusMY|?&o-=1)6o&+W1q5gi023=}st4Sp@8_O_T0tP`2PS9( z$}2ioRJX%oIdPb@Q}g9}De7r_yk?q)WQF=L@p>aeU=@0GQT2|rufAYCo%Ka!p#xWR zL>V&Q?ncnFpz{=n1|VOi0MP)DfEhpnuEW6yBOLEPZh8#@2kBTNXC^4Cxf6MHa~XHM zAH5^GaTP;xt@~t(%x>qgXCK}fH*;A(+IY;rqj?N`^*SBT3m}+l z)>snr?|q>?U7$>AJZ{HmcG4e7(N6{L;u1&2rnJhA{e$2QbwQ5FjKfAZU*&iSHupNm zPTJ!~Q*Xl_&0;&G0C`}kNHqflos(ePriNOC_oAp2xu5Ixo#bc_vd2nMh&VV7J&pcT z#`fi*_Ke0)>w#a|pqVrCliwbMFDz)pDwJWQ+=VGp`({DQHz{bmhrEA(4n^9KI23rflp z)HsV(c=;qUODxwGjXEVhwhv=yBlf|VLYU;9kdrZ;ZI3#VUKJwux;zg1~XWO)|= z!vFKcpH>k5TcpHCet}uJAmI2r+WgJAlKtj@bf@xT@|CRo>G`{lJ z_u#VYjkhc8Wja84!&}m*`Ap2eb~Xq<7DJ(XZ}6O}i~G6nr5PIoCyJNz+ky1Rp2yo* zZiBjhWoTW~?*73=MpLF`jHptpQY5ZO9S`q{LKOKF0nm8Sz(Y%*#fYe0fr6n!(qqn7 zuoAAJ8$H)WaA3|(X1m8ns{CX6&jMH_8FU{K%hYt@Q#dCPt2is7xXRfIR(Ynd2b!1) zjK?{Vk!lw;(L9tw71zUFh}p`l{{IrFlvd#$$Ug!N-zv*eisty0%4>>$Y96c3$cyJ` z{^v-I7u`8hzUKagNQrolIaqCY*)@28cADeE1z1RfPD@uAb@Za=_M{BbfP7=|Rl`?! zMs2L$3(@$waU%V+=f61w{r=P3Yz=E_>RQMYsNDV?zacJ8HUjRw5mzy2kRmCbodw+_ zoB9Mm3Q|q4QLQ{J1sylq5!E2aVHPheYNfRv#_PjvZ`;YEegu8ef&KJRgr(EP)MKf8&YN5d|m2mpdT6m{SXV-5=1wEG905uXttjk zJc5Ve{sCzM7gPFU*;mFl_v@b99_hAFK88I#+|+lql^@i(Oq|;=HDQ}#V@Ok^)n%kM z0bNqr(DbA z3Ir~q5l^P7UTB83Rlt3bEz^Ot^t5U1RQ976VH#nZPTm%f?Tqc2uXej=>kfUd%Vdft z_HKb+H>nd2NJ5)V%@!aDKIx(Wo0l?ptre5+>DdA6RO9g>5Ne8S=5{k*ZitvC=)Yij z`moMsVPVtY(Pj4D$xD$(Xix?dVXsm@n@dd!zMW z)F!b&vdTP}J_6ZT(K!>LXC=P?Udm1PEYNgomO*?csc^e3hD~+*Ia+rMRZ!o-RT1ElUZk2s z1R#U#*OS3DRYI;|7USxKV`<4CLE@T**(edpYOzL_D};dqk)3|qGo?7V*FMFnRW3yN z;4GJ|64w~WG{#)Ppv8)@Sf>YvCSx7BCZpW*Jto%O#%7Wsr=0T>{4bD!26qx5gKWrl zxP0L_>{E_;TUR(j%|*b$YO`Jl3DVRwM>+)XTe~NghIRIJ+*hr68lR78f2*??jCkVL zQVxL=Z`0i03nDCA8HPL@UTH^Nz#O}s{@xyj%`JK)X=%;vewp7vwVx}bZ4NF_dh_42 zk>3`BVF1znv!=;8xN{>?R!X7`8)C;_hDu5Z#9V#BKW29c8p#fTM!TmqKpVoKPk>t; zir-4le%)Bu|LB&UQaa&G^B-oROheW&xfK^Vu!PY{be2Kre~C>566*K&TTPPX^HH3>pG?s@Boa=;}v|A5tE)p)cdjD^GAGss^=4(*;&0uD8< z0y<&vMs=l7R6WBb=~WF1R-)5-{*47qAnI#tOb%Kqbsst*Xl^h9%?$yc5g$*v1o+{K zYCO6+>rtE)UAZDB`A(mJC}mK?3zsHsgW9+N@>$!J*tjqI;e+oSUb73|UGu?T&<3K} z@}TFNz#)HBl4JF#t!2xFjY&62`_=_`09O}awRwWH`)!(eKkl-Ct=UFu?N|2#NWnXI z!iecY=T56TMMB^|MMCHlph3qt;1&KPnS7W`Ryut{vaT7CN*w6yT?Mm_Ti@gBFBILF zeBH0a2Fp%1_Sy7th_E$bd$C^h;9Q#5LQD3;Vw4ca1Ng zwPEdo=~IeR>lMVK>Gl>5TD}p*3#I>i8&in^s{W(CU0JE-+^+I*3;(@WCn(g#M%@Hz zb6(*JIozN$qpCcn^=UxSQE(->Fsa!s%%3YGfqyTCr8S@ zb!(wYeC1u|Afoxpvv(a|m$q8(`odrQ@W?UyVMt$x|9=?!%BU#6s9!{oZjhFiPD!P^ zySqCC=`QJ(k`hEhhHh!3LApyqx{>bpjQ@Atdq3V!qigA$c~0%Uf3Y8W{nu2d$wAEe z0SRzyl?xYOlce1M^5=O{?MuoNh&edXnl$AggP$n*eZixz$nP9MP^I6gJ_ZswfA=iTzkBJ9P85v6)*DSnx)xXGY&Q9cdNaDKH{Ob}P!0J`l z&Xbw*?z%r5b$t!!MeW>sAtxb*w!vp!N6Zv2ECJvGl?KX@7;ccurcxMe1k%2@D ze>1;2NL%y6>!a*~MGb_c0-CgF1%BeJ24wj#%w&<L4+67vm>#$Fm1N7+e2g}x8r@4{4Q-yIN$lGm$B9fk$ zi;7OXI`Wn!)~~-1aN9#M*aZb(h(O z&Afbj_B+I3%7Il3g6&zO=ygmTwxxcq%;X(Jx_6f5hne-Ha|-v1Jju0XaWF)JG9{{k z0J93LtAvV^D{bwdnAI^9q`M1>X5k%n!UNTXvxey*s4l#;THBl&-R~wEBg!z*N&C{9 z-gjM$9p@7`o{G(nCUD(?balyg&T%Eq-fvNJ;mEvw#dzMTpN#bgk_xhaqy~Ewz5gq+ z787g$_f!aDp}LVnmo3T6=qX88em>GY3)LdJ-B17t!#SNj`*uzK^M z!10c)4p~yKVoqlkv{cZFYyrAjO9P;3=+*XWudyQ|Gp-5H`Nr|l;^Tds-XTz7U3kG; zJ!jM0JpwWKQ+Z;uQ|8;H2?Q(iaobrcH)L7^>Ks+b$7XQSZ8e%f!5Sko3zR0;fpiAP zbX6-aL9PfoZ24hwHhdv~!kQzi9*U(Q&LQYq^qsuSAQeUI#n=>l1G;;?)-LG$M=_e8 zEMAVdt-3dil8?<_Hkq~p!Ax)++kYrr2${KOoV%%<0ELowm_lt0ki(TSR{aH`tJQc$ z@5X&_@VKbrPQurbbY;u#=3q>*My-a3nan^Eu|7<9>!N1L+;PJ*~e}TvIxlC2O>H?6dVQ;wYo>;+V)1{r+Y`L0hSeqFJ7c~&XPR&khosfcHHy zC~pIcb6a+)mlu5L3y25fRu|yfH;qXTE4}GU@1mFP4wd>LWQ5p^OA(v}4-zq!9;~q=_ zY6=vXTltVr-g%`?Elzx7LjAm?9Fimp(dGHxLhz9=L&;RS1gE_O(IxzD`+jP=#eV0j?C8oSAWb-|?{Q=&i$i z+uPK-eXg6OYtUnj`Rzi-<-e|)cgthn!DW2`qm>lfDD=we2mx8Uq(F^fYr=_R_| zAWFnmf;%+uo1#Y$&ri@+NR#FjpseW^U(o+8?x`C;&WiuUL?0T@8ogDEwQ&`%Qsje^ zm{I~1v60p7LEBImdoAQzXU>HRV}?G2P$n;Q)V-t6(KI&$K`9JpHp7R21bUtw6QvlUg_B zAcRf-sK|FowGIr5CEd*kB04}Zn^=>)$$R{pvGtOIU=hhFvS0`40jQWm#GvId`nP?IX) zQJ!NsJp!hV;i^4SpFZA8?l$gl38H$R<4J;6u#so29-r0klljHqRK-7 z&2~3gBhQ+O%fQAq5n5Hm0p!P6<8Uqn^-k+2zb@P1&&Z|iZ z>9mW~{<-sBxEjs8$p?Id*>R=tIQ9)tS#-|jsnQzHI?mH-`li@)C~rp7x( z**!J>U{2X2wdx>Vpu9MoQtpB+l}wcyC56)#)A=21?ls%^!z+tWPwQ`+H3Lc=5SD7A z=l~oJ29ml7%HS&#PzEzu($8PXTg?6d89}G4xff<~!-&Q|2ak=HyLKN^+Snjsz-`q1 zgV~tPFjqs-Ay7tSLnITyS=U3u^Wst6FwoO#Vr|3IOmhY~BRaOyk7?0Fu;2|PcwV4{ z^m0Ecw~-T|G|K#*;aDQr3~Y5;UnhY?Ru=~{yGxosN#?Gg*0eJHjg}am_)ou5vegH% zKPWV_mOv&8qgS8^uIC_!ZtJj z0GIug6l}HI)3}PS{*ZmUEv}971xynn69peBG)o~m#?6ZhB)Xo5OrUA=*5(-?Rs zKCtyx#s^mI`%$PPW=}3v3;r1<`%2e&oyXK^i|cc~DiX}4ey}WE6>1Qq0G}FW+Hs-WO5+t5FrCcC20W8&Y@5@|aRG zZ#f=!u_3TuY`Jg+WeL<$WCbEB>|P#9#kD#up0ybL-BF(}nfpXa7~Kf)qQ*@<-b;WL z=mD%?36?O&Lc{*M)W-fq+ScMaMmXYLhs2snc)2;O8#$+yoqw)1mNN(0wsRT;9;4K}}m8QCsUipKY9i6V6$`LRfEz*(E2m0QPr*{uK|MNwud!CJ-_~=D zKxymlUIdX3T0e!Gvg&+C-8*M(%RXXhx|go(&CgtB_;h6v$TscRLtS*G6JsE+MC9f; z_fu2TL)!iLNdu125K(MXyzQS|EBK#XtN4djhB0`8zONJ&wEK~_V#&rdVF1T#qbU@t z`Hf9Tyb?81_6OxF&u`~gXMVG}V>1G6;11~JT{VX(Ww3yXl}Wg(&-~OB^xPJ%zPe+z zhA~@3L(N9XhRg@xVjqJnj6g3bad1h6TYm4=W}R2$1N=Y*_B%2-i&oAV;+vc|e?#Jr zV@`)}$6^vPKRD<3k@Xk@i;-!m`Ou%r+#X~x)~$qJ?|wNiJ~es=*xi=qFgr}MAr_Dx=0ZEt^y4A z+JI<9)aZNJkFri)|ZApkLs0g55up3wMdS8$U}2r{ZV*(GqQ@1jjx^^W-(err#9 zRLrU^j(U%zfuA3IDy9=WU3~G+JE40lW!vghqC131)|V@HTe2|t(*dd+5G@0X&{;C= zoj?(w;GefB$YktBY29<|00QYVP18A$-smot*!u=trmuIeAUiULrb#m7wdRJkTGifM zW6a+G_IY0!Q4wLRWTFz`w8k1wQq<3Ssdto?Ds8fGURui7gua=MRD&=WOF$eofUUlyhFGK2%0_^OC0yz z%5mze@)O@gwJ;MwxTc!!Prz_c*uC!XwvfAwsY{WVrOrtz`A7lgN>zjSFR_J2IZ_B1RKP*T@1SL#%I^n1KoZSkhceP|j7hSoc-6UC6JJrRC(jWVc; zKAiUMoQxNyE76lI19@)Zs&!r-4>h{zL$NDeE#@(ZGF`T(ugv?6b^z~2wjUx+^7G09 zB$dL9SjW($Qol8ZjDT>3cUg?Zv(9SC#^Dy4jKPaAZGbQn4ORFhK&F7gujOW`zYQan z>tICJK>fiweuXF+%N<(@YvyMg*gHQ<4xzptOCM-dP8hi6f&Af`0amL@?1xuyn*=Y( zB{YZKjURlb%Y10;OKMz=v%P!Vy0^n+N37tBK(hDGsW(TodzI&4WfALO_8A1GLRwxYgu)}xi&Dq5=pSmc^tf5fL^2GZGhdUH3TsYhgGqkN47j<2OVO4 zDv*I4GkJivJa-D!|63CqWCI917RnhIQ&9=ka@An0EI<%7c~2>!@OKQj-vIm#kUmRa zWbK_cAuRgWd*L9j_$eC$GGl#I;IDd4yG}+D{fMXHBC#0cWI9@YYXw?Re0o+{at@{T zv}5`2$ENx;vm5eCE%NlT9V!^#$|pcGuvhZ-UUIYncSGqv?;VCF)q^1Cbmbql{cl<{ zNjEyl&I-n zN>l({;W=lp!oD1}6eDcclA-_T+ZkXDD;X~zalTCdv$3pvc6E!TGcHp1wyz*gXra}PMM4B1ExD7pzg0^ zNVrf@9`QxpN-IsER2JN{+72(++ zilb7eXX!Ljzidl%8S~b~=wy)_3@jL}0Sz=QJSrsvQ)7GKn@n*>>QZ&*e{f~*>+4`j zs|}zs9r!2#WLd?^iM*8+!{5tS{XS18D`~SH?TW)y1Ve(VvSkW8F>g6lX&{DubYfo# zOsmA+rE24)3bZ68XdheGl8LU!;SEr46#(_VDcAcQpvEiJ4S!|P z@AR!{E|zSj-t{Egta%m$h-zeNZ(PpFP0?Kr&7*jF#g`p#8@L}_z9a(8JyvhzX^x$Z z5Lfc|$WYL;tnzL6tDaG@^j8$6-{nZ1q_faGED(vk`S9E6z&N4*#tE#1j+4&53&na0 z7AL%%Q1zyPfecA=bu2#@HN5R@4q=vs{4OiC%=yD!@Y-SW=RoR{;Gf3bSxGWk5BQNu>NxUeS`}{I7>=I zr>4v`YN>!_B#%e2JX_`QB>eMxXGALE9l%Vz=Sl!80#mLV`O3nRa$M=eHg8d&wApSJ|GZKTkgUmC@PGMR7{1fo zxLU^zyZv&mCa>6h+lG1Dzv=JY!_@ylu_f2x)o(>~3vZ$PvuEigliMoy{PH(gg$wTN z4V{agMuTh`8oGegDJ0rCqeJRYFB6RC_~pr}ztcvBQk>$R^Th~2mxg$AXLQz=-o9>E zw?Ln;u-EoImavVU0~>BJ$*^i2#O-WrjfitP;H=D+c4}q=O47UqPnv8-`m)PDmhb;t z*pW}<19N2^rNAIt2sFj)9I19z6G9XIIoSUX zUmA;Fi{gXDx^w;1*~uK?0@84sFpwIIbl|NzzX;w^>{o8`TxJm}`+Zd2(7fn#q?jYH zm1~e+_9+{u+^I}r>@}}Y&LL5@0F=^=9}Rq6;9dTt8lst*#jTUWUffazZ($O&E&8E zL&UA{Nld4&p>?|@Dl(60-xe1bn002AJMpRDjcO0wk1S}{L$u+_^Zdlw8$pKJs7nVj zR2Z$gU_i_*Dw*Gu$}L|7Df-R7s#paFxKS4Te@>q!pw|6UgIs>rdf`tRuf5V9mgB#F z{rInYHV~SWpJ4stc~kxiax_MqTs0coepwP}e#NDBxnfWZi0(fOCt=QP;#mrA9R1fL5jDJ^%=`r$zff$Y?8Z1FC#e(!=5AqJ8Vrw}-E< z$aD{a2n3B7uw1R?Su?>Yu%pQlM9dHXqOaKzc@E!b|jz1<8etSEh<)|vYPLHk!Mb&K%B=374EpN~_wEe5!^JTr{Rwm=h)YEu*1fRm4#2S&8mKvQ9kYa}m@t z079JE+9HpAK=?dcStuN5i)^kJ&hP4{As;z-dJpr7*%nziiL(PRiqBqfYz$e0vqDv9 zZdHg_FC>omVkDWC05L<3ErDgbPQAL|IZLUVFIDU$`sUk(BdO{O7<;Mx$UKtHu^t(0 zR5-C<&;<&Pc=}m?y`blbq8-%`qGp{E%Rf^f!aq~s?6W}B{LwU&5RTO z?2YKavB&fnf~yn#l*ITvBH>s_hsX+V@j%MO7OaSIH1VE|SPdFKX<*qP190hK=;brO z%rCu&cfzEJe#)yx4(wL5uPcTH(^Ovqfe{WnIBdmlK8`O5NboK}&J_}`(oltm0e-cX ziCq^%(oJ=|z%vfG23EM-eG86uRAay;o|Vu)hv_6RK^ubEC`J|Lp6;}$tpD^?oFp32 zyRk%UjyH$0RDuvj8WvO2-~|lFubp4*Q?X>fF{*l47qAu2#$vIDzkbFlZpA(7r)hDQ++TZ7P>sXt%fZy7EDlolhy7#vl&D z)nrcejDoye0E*oA8f6b5sH4?ro2v2se+)lO(79VRK%2J6P{07vzjB&qFD>TG>EoMy zMLG*VBbAX~T?B~%reuRaseK0Ikbz|rHvsDB;KshTP)pQ{^jo~B=DN2+&_fCO$2zZkihthC%sXvI{ftyS%!tuj|`+4^EI-#pSGo2w*8-fWZwG zA~`FCj|~gSD`%BzYO`PZZs3Ja+bYpP)II$ZRvs!-5}gH?R%MAB5b!K!K&ypr+gF{g>=2q{aT@ZpBSzQ%@%;j zZ3SPrn77iqAh%bV947B3|7HzhuZE-D0?1#(H6Zl+h{6HroEXk@ ztfi@CKa_bdJ;eTHZm$Udjv~Qq&J_kcf6S*P2X_Kt&wr0tc&VMfV!0!@g@ZH+0OK#o_GP)YP}JUM_e%n6$yXxAg}& zP(10NSw-(UXf@-5#_Z2keXXIFx#%WReDvjmZjr7wR3BslQUFw-4 zRiY6WUXup?+wmVKRyr_Mv<4;?NZlaRcI!sm1FA*4t{=p}=zDN?bk1P3D)o4rf*Tx@ z5$gtM2;aO$9L{j1mt1YgcD7sO;p2F#D7lj*$FBJZl=i^sy(o?jWC9um9RLtov!y

    YSguXuv*Nm zyVr}s8dSZ%$#(ewvcB~a@j>9N(=QPFP!fwf8zDqjrKz|p@}b}m8*kRIJ>Jx_2V=9I z6p;R&8aA7Nm1-f!dGlG3uE?Wv}?}CUR5}iq=@|3ou(}(g8s#nXd$@z2Zw}1NDpYsBAZr-AdhzA@A zdoI_r>Hc9Y&}WSIEH*&a5Lv>&2$=|KdKd;{)R!!SY^1lS8?b{_H=(;ip{IWIfB>nN z-2j7xm%Wf|TaWQ2K3{Oty!__$m9R07`~@OajaCUW4%l0CYD{fUa@x)i=z8{Wb9V0*Lqkf{52@iPm4d zqK(Xv(vaAvLw=!^bxxm2=eh(OF`fOq-hOZ_^w45`xj6o6{CTlABU6A}&vF};{rBdj zZm5&V#y=gnq+ox-PGN<3i(qc%qbf$1^Ud z>vp$OUq0o*ZIs^rZ##K#lRRUD_XRhJo0Rv)!G8Twy~hZG+GU&WG+an84)q>X{gfn0 z353JgB4N)W8PBX5ZjBaK+U}1vF#7NvFHG^C-Pl~*{yo~doIJX8baVgU<=5_A!xzxr z-00WXay;r;*ZNrN-QFDkRCBBe?Qhin+pq1$<ZDc z?b$5lA#|=FJKAU#g`_-k0uJ2nQA;}EtzuDO9`2qL>{GPdTv1{E<&)}MQ4r6~>x(f# zJm-Kg!hy60IS4@hxn9;b*``L(AlZFSg9l4aS2Qgoop@m*T2uB|X7mm(?&349y*(sg zMjxo0>fSvsdfuU_Ll3iV#eBM}QV{4^64TeGH8g@(`;OSG$g+^g>O!1KANhXgUKE zTrH@sz70)>gV||koZB{27TY&Da5&2m$;S+1oQlH!l0d%W!vM=C+CKbwv7s=}Mep5F z|LO3LU)DbEadpM`;1T;u_CYTWE1TTbDXPD7Gp^1|n{=9H+3k$oVu_b%a9p|1W zPu#_Vw5@u3sNK$TZn>9#RFi{}Gqc}wIQcLsb}54qU9zQZEdM_J9dUF-x$&|8v+@W< zSbpD8mUhA;-#r@U4#u15~B=cTJ z5%&|Yf189KrX+xuztH_5^8Id*>lw8|!b1^4)<pOgeTh;6!SSufAw zO9P{Ec@(%$Ox5us5qkR^I?F)=7 zinZJ6YTeOeADFQ3dg_ z%w_2s^b8;1_w+Mg6Faasp>+30ayRVu+?%La2#wBqtoT&Euwj-}l{Z&(L->GWW~zpU ztxP}_XggN$F|_ujv=(Lw{L0nPSXH!g8C4}6j#b0#8O+*^l6bdEYJpV1yOFxs`%z7 z(eJSRtg5iGQMcYOma7GqmTplV-Dowd&Hj-@A3IC)^XVqTelZG6H4e5?t_s7Z%!f}m zhBdP=IxNalgFS5v!19vo3M*8ro5jq z`YI`MZb~}vT#oqr2sP_@+ZydFIo3cRY7iyu`xJxd~!wBAnz^Pjj(Xqw*)zlx)1 z%OVl8f8Yz_eY<3(;{KO=v0mtT*t|B?w`D$;*FG*m4GJ%RCB${HiN)x%iOCB@ z3S)mCza8W6jrR}Xn4-i zKF1p&lWgt;84X#PN?BINh`;h))M@9* zZ2j?tHQ-C4=<%>kBB@34j?diHONUbD8XpbKq^z#_^^DiVp6nAZy8Dq@f=VKyTcbnp zZGIRUoW2$#sr5EXkk5mA6CRTGGIt4Y7frM|C@QS-S?pMOzO`}Wr&ToujXZw_U+dYE zZ-z=O21{D=QV;v?$&iEErsc9uWY*taZ>uBIME|UA!tvdl-%~EXx~v>M+&gG%THb5j zU7z9Q;N%LP{&R6S+rx9l`p5HfH(;uriF{L%i1l4EQjhtlj>xjP8jIv@AORnJxV5}5 z9RlJj&zx*T9INZJKY3!K}l1sBO|tn1eSvq$DcuBm4+9-+CjYa;7hv z|Do6_sGJ?*K7;r?XfLz)Pqu%!xFc^(&~XHR9PBeXAIy*2A0A3eB=WCVp(I_z6^C8) zgAEh#_00*XS){i;n4Nq@)MQ}f+nAocG&&pY`%x~c8SsueMGLh* z5N*h*>C$$7;Oal1CCZWa^5WwR(r8PubWTV%p?uvoXHj)gIjH6=*!sFTw`B@T@i80& z0pBl5O5A1q@b=;U?9leX)BKv(Z!&m1Yan6TX-c6#QF5wW`}^0Z&bsu>*O>|I3rO8` zoGb(%@Zn^nMJYZAj<*vw3vp9Z7=%(MXuoVx53G8v-LRBELYF6e&_zC^D$=+Dw_^VH_W9TP-f-J_i~KgAIKhF4a$Nf25z= zHdvb9VxPE~EtK45IZbHyH3Q|vRM_OFNRMvo-{loaJf#_DUP~2#lEZ)C-RHinx3CjHoF`YtxI?9 z!Qax6tSxcQtH)s3lS`UZQ2blKYId2Fjc+$*X4pyAba%_^cWrVe^5`lbz~a5eL4Kz# zHP<=OdytupX;xs=A4@iD{@!v^yN~>5dY zv5X=t>xs0$Ie!o{UP3O}dEnaIHIHPYMdV(;6Z(^kLL$m|bspW-2IF0Lgchb*RyL9w zQ%k$+yDf-%1>$@22G}D&_kXhpKuMkK(GXOpC(f{oN^h#pWU#+sacjZ8?ml z^v*H9csJ~Pb&3|8>9Fkz;$@A3)z_<6cuAH>40DFnY!`>07GX0Mm-U>IK#@8du|^ua z{PHC}U#>m7$R!NE56ef}aI<9>7p&%N0(`7HHWqhrHvY175ey@h4NeMtq#F_aTGB;* z@lZ5FeXt6RJNZ+Q8~x$Xy&Q zOG1nIG7M&?|6uSASCK9%pBL8!iDF%?1%8bWdyO6CILoT|VdVG6EXR1R+=Xlot-@8F z#z@Bud-C208xS-xv2J8AF*`XZ#pRtDxc5Pmuq>uF5Uo0NnG&YA9P{sBb{1nqjf=&IyslY8~ zw!s^rvcrzHjxJERmH-#7A~FWxb(ycq)j91kAv9 zQZ#fWNXn|H5bl;1>l}t3=gMyBP%RP3V%6{z91#fy8G7L(FBv{u= zmlAK1%KV3Pqb?cTdWrm+OO)U>;57HZZ;&ucejA~}Cc$2ZE2$!#-4*4l8f967el$xl z5X%lrj%+B~d6gzM#TUVjJ|4P9@>^y5q}DXbn}G4J5&T!ADZW>NB$yA*dnDalh~xW3 z7Y(+~0YXN2$Fsc^tJ$J7siMh{9;>?YiZLU{CuVL1 z^4HAq=LSN17~Ldx!bk8zq3n&?Hk0NbxFk_R3E)3WAEIwFP(L%3SK!5w$JXW>p)kPs zL$1{+N7&d&M)^!M#<~1;GR$clTmI8F{DW%YBJF@;ZPa|9`vrnsncK@1e=C84OseDt50evvg}k|Wd! zadWTS8NKasip{KiZXs&Yj*e*Zj)NjcyGq4sOSb9mSlvka$6W)-VyFT+4j7L7ApR2) zMY&NSyEj?#zC$V21!bPzxL9w~z-zOZ7l`c0NqMwqZdF%q39S+MIEv9<4TG_5aIjUc zrJt3HbjtBjzxdg-`FcZ`9n+LdTzVYqd1P${n#hM%=G-Ri|U!i*cvW_*!Tx}T*9bj0v>(@rwy0_S*MY%pF(5eYlIj1As~NAMT`6-XyR9fm1x zOSjmRnV@kfoRDaBBm;_Jav>^DheTrn`nSAL){jPS(8uq{d&x8x?c3%{&;8~!Jzm3j z<_ItyL5AJy4(QdRJyAomt{FSZD|(lX{y3E@!q>rY$jgzMJ|WrLYEJ+#wqgSsN)u zWbi8@WKUEHQpD5+BAihfaQ1w~rM9UiWSM`>X?h7WZQ6+y#8VUme%{wO{>MNHT> z>y1-SaKp{YB3=FoX+& zu}2@@B=2RPlP{jaA}xrMhJ;)9*599*PD&Alm`)zTbrz2DAodh4ZokSz;$EjhE5hdw zMUkmh;ASw}-~yL21J-FO1_Q-Mg%DYaU)=gnR{7Yf!{@o!Ex3}Km_cZ!Bq4*LNyOuc zOA)oOk>2(=f43zH;(Ou$-#Jp+$=>Xdn4u1dhTW15*`vX`n@z>m*6S^H1V7xEQkRL$ zSkyc7MY?RVK#vEUwlBhq*PisKzbL$kyLn%vBjNE@=XWGVLJFtM^zLnf=>4c!3D~e` z9gV&HLWGSe1v6tCXeq5iEu?flFyhw*B86>fKi`KZ#3Q($m^go!NDb9MV&qWCl-b>AGew#p5dm(7 zBP}AQUz-RWXCmv=x0WUILmuLK5H7?8sH#HWR5mDZGn-9ugLz`c%1gyyrsz}umj5IfUvR5y@xG7b@`%x7%pd$%0?;lT*O}%+LXtmjyA< z`@*YSzMY<9N4(GLD;%)2h$(%+j%-Qub?C1N&9_n;Z5jA&T=f}gX_m<@uu;=f#FDwd zMrFjYbugE*qnaFK$fzP!9$2rd;`n&`!a2BdLeB@ML$*QbAk>$DUy8_hG}N3%AFJA? zdW|rDK_n)4jZc4o>KTm^iV{w}E%w&JF$YcV$ZiNNnEz1<(N|#pbC9O_tMj)KcY6pJ zsPi}NLadOvFxKIMwlS2?$OZF0{59zyu~BaQW_oP%!?8MuF#iO6Z4jUS8kG;8V9cg| z%58kMwDc{b@2Z@MF}lh%*oz(V#V3iRALHfqEj~&MNIzGFygPaA?ujz=K)gQw!V>u- z`2J^G7|Pe=f*5a1TJ*H0|DNuf8XP{1#5L#*E2*VXHXGU3zoCpfZ*?_4A+ltlCzFTd=C5iwZ2^I1Tj-{RfC|_g#)03jF52gm(xG z$B%Ma`%tRDgB@@4b!-NGnE}z~Gal_>L;{P0zP`yg4_C*DuIJ8H`RpIRA~*-urt~Xn6|HKvUW0egx96Tz7Jok(f!2J zH*2t|P9&f@5Q)i>cFk;?mM~p>7u0}ydsD@%rmDn zxr=L&N4>huzCur>v#&Ekyb(3`ouU_QKYi{j#n1Ja-#*sKEaiD~#XMvq*C_+Npp}^S z=@{wnAFCXy*$MI|!S5q*&Ac_i#NJHi2QL^tQ#J)b{vA`N1$q@LA=%vzw~tfBv# z0LbIG4)M#|-lk&SiED4eXM5mvragI%)!zxI2EfqjU}zPriIsG>S899?wxQ3pL&doS zqQy=oCKzZ1C7MHwosENty9H6BN$XPcUA8U%1PDll&_A}=@Coh>5&nM z(UB3~@p16J<=GfgCH+RL4Gv{z!(NjUp{87Rrow8DCBOy+9JM>{8-}vBJg+-a?}>Yc zgmh6xu+RxRWhti;Ul%EwR9gi3gak~bXnArVJ+Ii}IDh8s(z;ytm`<99uuF=B5b$;G za9=#9qE55v=)Zs+G_R}_>%jXKwEK(-obFx<7s3PXug3CpaVn(FF|v%7Y+af{sX|l) zYW=2|w1@<)7VK@tuJ5`#Js%yt`B9^&V$1P2)ZSxN6b^)$#;CtwcM%JYof}M z;E_FD;aEGlA|{>pzL9U~iFEih+(|Hv;?8J50yd8`W>TYc4=u;abcxDkrZ_y3Rtz4D zC_px|-%&k?2uCbQ;f5mNF_+|9tJw4)WTgb-A!&wF9`1pS8^ZQ66&^4eV|qjDD54Er zpYCqFs|H6De+#^`cT`W|d+AGsmhOidtID>s@S50_-4?H#PQ5I+@hpUlT8p0VGh)WR zo3TM+?+k=aI@Gij<~k^igHg~bYULHr{ZcRQeee{0z(AvNsd9_Gpm8`EB3wM_LzFDj zoBjeOwN({#%!=#An$vXAAHlpLCp%^Or#)uM$^q`R@y+Z}>AUw&r8Dz37meK59Zs*0 zyDjV5ATwnNw>{-Pm){$D*R;DJDJ9ac#h*d60hn3H&hWCk|A(!(E7|_xq<4zKmsF#i zTXiO6)hb*Dp6K4J^I~mWCWRnVJU`a#^;TyyoFCD2+&H$H>QXgdCy>#!J3T#{NE1wp zrpxlQ6A_~j{w-7~bfF4oN{v^x&ZpGHvJVZ(>p$4vwVQGqlpR&a@2C7`6f&O;c;H-o znsal5+*pr%{qX%5@}o>Zp2WtrZZ$vjg8nY!b!H?x$IEU+_(i_Q((R!h{&zY;50LQa zgrtwi+$zbKt^3U9WSP+k{5=HE^x;@HvDeozX;4gKKCnv<1hdjUCCO+oNLv4XbRnlZ zj4)F7t`hw&`svTY0TuP`<)XV)KIg}4u!y;wb>O3M(SJp&Ve!KDN8_;KIZd?QgBr`1 zdN-DuKf{t0ED8ZN0T4x&_$LEa(S5QUhxYnowu|6NiV^>JzY%?ATG%`z=eg&3V-vf` zC9hxH@dw36w_^Bw%8`?hFcib{6x*$c31YQaB_5<0ByFk z9IM3)rEApX3zJo0LR3?--i|m_$%1M62-OYmf?FKYkq!)q(>v>NI8^@kR&UroqJq1b zjjaxRc=|okH~W@m)L8xT-o7}PJ#fFMT`I@NJJ(o={26zsV}Fl*ljEdgnF7{>#}pHmomLU<)-MDG&J-O($y8Aj zBR<2|W8PP%-QGSJzoGfd#VG*`!J7q4TYS%`t)z~sD1}K1jH)}BznE{3Hz>A7tOOd* z#tZTckrX|3ihpKxV7f_nWnmp}{?JPTwW4`INCg3f{B1%F>o3zD(WBfo7 zPS%;QzKQI}i^lB1jfPWfz($LRh66ER3lHa9dVZqqaWdlSBKpPTI`T40Af7waT~1g+ z2fZ-cA=92nvR{Xds!x&N%>@-1wbfdv65LASXi0z58`D%QVZoCL66w4MHw20mHa@vk z0?B@b^ElUkFz@`BH|9G-D&>W3Gp_0j6_ zD7N*_xN`)lR)o>~*wTkx7oDiK5UWY^=j@_`!G!Rv7+4;jfg>Xy{Vnp}570s&%kf#Nm=zZM`_`Wmwvj92>lWq0n%YY}-2lk)VO zamm@C4$_mU0*C5xqP)1y7=BalF{{J4-TBW5J?958Ey{adySVLyj>+hgec($;3M>!` zBJr^G5eu& z8pZl8xr0$oS%ivSTy@NbcuSg-#eD~L`cfA4hg;FiHD zb^@y?g9CA53wPKVJzz7FxN)>3e|P7mR(6FlJ};M3@5Q)>`*JI1D~64iz`FMIg7ORD zp@{9WITe?ve+VI;QBae@gEX>c;`d1*SrzGgJ-C@~#(0EuUJ|1Pxcv8ox$PoORI(GU zx5SBO=r1Q3sNpt=rt)a?MdA#8JF1zUc4Wu)z}*sqN$KeZA8RI@V~<(e4byL%jXtlQ zmOa{J&ez^eKB(4ERfswDYlC(e;D#2j}$17d04vzV5tdubS$d3Z+8o<`iQS?n|$&iMfvk+h&6Oxq~7mP|3X`O?xU= z>vxItdrzuKS#u^2?rUsmb1?na*mCAz`akZ9Jt}DZV3AnR7m%LwQItx((dL=Qjlmo+mQ+M;QfQ?^v^D4bEGmV{Ur6~Dw&3iv4KRWT zovUmqsFq}5BGaA5>$b1tQ$uMG(TK=GkkmQSao|ECH8|3{#2%N`8`>+h?hc)!`4LVf ziQc{|rT?jpak}?9(-TXT@K?VKf5UhD(~h@nuPMY;lqFF-ml0;%t7@cMj$3ize#0oB zdgH6C(oA(H#JvuqW|{76q|2k+2@3t{rMfzQ#I%}-n?cYWN$hF3LJsE{A$CStdG_~s zb|3%v>3o=@aX)BTyUS9Fvy&#=jZNVb{JU?*YzLLZTY;pedpE)Hfn0{3eDvxf$RpyP z^*DC2$0@pV{TxRNguh#tiaGu^;lchx3U2V`xV?|xQkbMw=yHsMik@+0SA4QKtY4mQ zk<0TI$s%u&EAtj1(Ix7*FxA^0{Ot4!vUu3LVa_Szd}&KyrI|G@soM2}GA#scFsFW`^vsh_JS^fjDvTRMNf z9y&-7$}?Mu-b?qhkWs+3kPGTYFzpAVKC#wRXCTLm{mNPt+tM2^+@J1663@t66~*9D zz6e+hC9lcXC%3$XRU8}HbUYA-@TZ$)0M1JP(m4ijAMUO4vF9WWL9pSf8jd$8G8Y%q z*VN8Kc-17ISt>sOk9TUH>sFkUQrU9kc@C3#FFI04#$`HC2mo)q#bM|dZ6u~}DV0Sh z7gW+?W@{k?tp_gZ)`cOw>1L?`8Q!IH)L?Pv+xts9nx}DpjFWF0GJ%JZ!$M_GcqQr9 zaDx^KKn(&KTSgw?6C*3iY)4M^008YVjd#ewvGHJAHDL-dv6v8W1ubj}gRA+Dqy%uoVDTU_ z;D&#uC?kmRiDATXg&7=@GKX)rev@+@iR9StPvTDp(*=>~U*+;R8^6 zH|@;0P3y zn?h5c64)10yZ%ogKmUzFWmfu|vu1oAWo+P~v)1Gzl9w7kAk)bNXyK=IR0g%t~< zpVs|!-*x}DunexMCcGgmgY1L{0_B}wIrM`*-@thkp)a%xIoKQH%|aSiYzDWL77NGX z?8@q4dBV|rGrDLp7|0nPu7RBKL7a%B>h<&f%40YQ#kVPA)Qo*L+A_ZdFU9x)k%D^` zXv}YO?gCTk_cz` zZ>u662!JzejS>i=Mmy!kCrrHZBzE_HqHFW1u+7Hq1%MaQD96rlvu~YtP#uCxK~C`5 zq}G^T5V$*_wih#vF9w}rYoAr@1ierF^%9t+zqS98l9#WIJ8D3ICtu)LiV4RI0BX76 z0{yFcE=^CbmZ^tb0-w&ZJMVv?Plq1(3u6}I^cH~0scO(e)Jes(Q!&==_2_d85Vey3 zULgBWCzq(;UGkM-r18WUu#EqFDDD1ve|)Lv+S=;vxwvaQ@pgK0v$K8+rWc^yZ)_ai zL!-L~rLTm(UE1OnmxO11zTNmlE9c{SeOTh@#VJT3Cd0-qeE51adh&G&xhWQIFv>8^ zpaS03B_6d2FBl#u5^?vh_Ic*Q&yPKoKK@$}+>*VUeYv5f8Ucsicz$IaY>2uGllF#Dla`S=1C8d2h=HSEElbi__SN{VsD^mB|QDE(Qz}gRb zyP~`xxt^uGFu0~u77sy4X~{Y26*jeqA3>QS5dqvuVE(QT_$8S!&J_3z2(bFe{zeGT z#ESrysEuek)AzImr*qNQED_o3H;*YlS?_Qr=13Q$NnyItbl+#?!GU50Phwp|zKhb{ z9rFAju&ypB<3tFpr_-o+)RVSiV8A;39}yyP>^PUN%MK0BjMC03H5qq7u!PXEzCM>k zl8zU4J-0!T>&QqQ6F{4fVx%1f1lz`|e1$rn7R7mGsCtljW2b{Oa3hE`q@Vuhe4Q@} z$qqxnl)c#l06|cyHHs~OI?|EZQ3@aQXP(A zz9?<|=*x1bQeB;|ZF$4b!;)wBx_N|`N*(j;z5DRCJ3QxK?d+m-w?82dSJR?63<>fQ z6@(oSi-N4utrrJ|C@?_#<2X|&71>Ek%u49jF0Sn_R|OuA|2RN95Ogp!VxKv}5Kd*I z#2~%JZD2&u;>2hnLt0Q{#e#$b0kc7Hl$3r~rev}gDd;r6q1l6P0pPV=OqHd}nPfdJ zxa)$i(WSu+y~LcS!JPe}6XQ4zzm72#*!mw>+?)7X1jb!S>g+0_HH`(Iy;G%%DDm>< zxwPBGo=~rmSRF5sSOp*X4AwQ%Pxc@0k;0VP7rl6Rh7%m~nx}b~dB3>&=|Cc4P?mfF zC`nkypiBofq_&@0emaX_Nx!)%dK}B`5#D6=#I;QV&ADx>4o=vn>hj;jZa?xlJtJ)_ zT8vX)b9V1GVHumk_l0f^M{PQPt8W|MmELE*Yfbz}7Li35?@_G-YGGw~jF12uFL7lS zUOmQ21T)^E!&(A5rmW1b9%2xQEOEb3t)3g96mA3# z8`$E~cKzK0(4BdN{1;xX>HKy0bL=Ixl_JYp-jCP|(LiPW&*^xwv9gwL>5xR)f|5&! z{6Vg_q-+=Avs(1> zQ>UQrFD}CC8g7-;vZojW-j5$QX9o45IQ>GS-;!U!tjohBXj1N#N^HVM-%?{wZpNNT z$f7uc2##1q5j4p#R;UTVtU3??R0i#mp0!?`z}K-+aEi9~Iv~r)iNK_?Xb%P4oY<24L;Q+n0iK7|_pM?JUkrh# zgaG?Z*4&DmgCV4_{>P_CIH_G>%;<|KTz}X$zmQ1TiDxVWAyJY}A8Ryf3<5HtcCHRv zT;+RDh=ZwY+_kE#vvS*6TToJ(if2Kro5`6T`pF;x2lK2-y#bGl*2@O5CxfR2F0+t` zf}kaQ7&=NbLaqn-jW5@Uh#({izm_M&uyE`dSq-7qF61xtKt1VT<$_3_{k$rf9qir9 zQk}KRdFE@qS%1R%NzzKUgsY#A7p^8VOp>PX%rr9e=>712`$)FPw}OtNCk&|Dd_3J# zs=LhBYu}V(V&R5J^dr=k`ZxhP2BTCQz<+E>%5fBjEJ5cP9{nl%mFfATgI`4s7gX~e z08*Ty^)~n?5(0ar%B3Gca{A&5D1H4E@w)CojBUrbIl0N$;ho}nI*!*@vhF%wU22lN zjkYyB!u-&tZgp|zTEn02Ku6E*&f9~xf46yLj(+$TO{q$$HhnABK07~{pFh=6 zLRUZs*FLyAnvz{6M}T$T?Q+-Jg{LwKLP--c(d86XuOVsV;*QfTxARzZL|@m(CNw2q zMP-9M>{Km~Rll}B_{|IN48SMJUaPf{)^rh3#|u9A#f-z7zN%@-Du{WxydHZP*FJCT zjil57zdaRy7ca@!r#W9g7KA$epl7_B6^_VjhuItDil9`B1P$e zUqYCQtlz!e)A4T6+U(_xH@~^wm-}TEHU6zl%O%@F?!AXnMXv0=x^)PpyZ+GGKM$>1 z>vP5Y$ShcAFt-;~IvU^Yw>`s_?{3P?^PHaf+Ssm=eLppM){gpkx2M~ck5#}$@eXG1 z%B|Bm<$Id7#7fBuCdTTjWd-K0wNZN|g~t{F(H{Jht=oAy{qxF8=kky9^c#quaT1oB2 zEmSQAOR|MK53!#5Zimr^g6V0$En9j?;>zB_OZKGl_`GM2aSS1snlKHs*K(c&8;L0q zKcm-&$IYurU;F>e-Q5jmkW(8jweGZh_0P(>jrIl-F_|3N@%4;G(iHBX`cL-;3KJKS zx%*6lf$^SqA3XWu=zX)~Z(PH1iUFHXrlXm@~Xru z#5;n|PyeU?`&(6d$uH}7eGEbNEWLL}SEsk!tei2Mt_ORE0)DpwT*<2bWNDr)pNb7U#cQ0a}kWK+#hW#4%HsN@jhm5FQ_P`*re|Mz#5E@A@WXtxc?K3ho0Jku|UGU zu<6>Lm0Y0>pJF1H#=fSj;+unO#8zBPx;FJx3{f|}NtrMBQO-ccm(}w@)Zqb=|3$7 zJf?^fhos%UXmw0jRy-Gwnc?$^k5u9Pt%@~P_s~*(uhpsYXVy|;)>D=@f*>RAl}A!y zTw=tu(L34AZP;Prnh*XK`{`%qVrjM4Kha0B_m2irl+M1L{o5`V&K zv}PlP-QQ;OBCZe{qh|)%DBTf7;H+Mz1jdRnjq@(r5OTqT^1AkU-92Abyk=L1chy{y zUt9nF^{G6|I=fvjz7GD0Q6}C`dXtcG7<~28X3R!nc~K89Q8Xfswl8a&b~4N(l^Kf1 zOJm$bCxkD)++K_0GAA9WO^5Ep|5D2hfYdDbfyt`06hwzeZ1^Dh0rGeUu+{l*#lh0z zWnmMu*K4JMzCA^gyb}w)(RwIha;FY=LJk!p$*U0eS{k{6m$=^&Kh+@}KPT9()cl-2 z{mw0$c6dHy@~Um!xTk!1rQ+MMY@=9Q>|z=R_vKcjk?EUtL9KALLdnwoNo$&2xA9oh zHfn($sz4$G@o~beXbSx*2=do5j$)L4HhG(hpZew(bCP*(cSYr?jHkty(s3l z_3UeX9WlS^7XHRj3+5BbjOyAy9ZCndk(ysHUV+)$Z$0jAr|S2)EA~|((8@$ zL~}SVe;WHUD+!(74J_y?DpndKm0Mg2=KmoU8Z;FL{yCcfVESCXuQ3MS@XB#N`>Q*+nG+$kN9k?wlBu{KA-8SmJyDq?{ zcopavN2YVRYYLxdbcekb4QJ&W<2(adT;M6!z`n8auZf!<8EQ+E_)T*tRJ48O8wDu( zR>=j~d3vJMrhpHW<(2t^F4ghYt^M@0v%iXxZYw6(!WT?ED{LR){g!j^xy3FGF}|bo zw6;_7R4G<&SPXpcn|=3ZMpf1pDYNUn;q@1NvI2VS{%t&GJi}mukIxnQlB1idYJ%l4 z8vSqrz5gfrZ|oONP=~or9t-h;$!!BCLQX9!fnH2*DV zPg{%MqB&HTe>{4Kda-pjD&CzC$A5uhMOypTwz|pA7h@7&*{wi1k(k9Uvg(3p5>*oE zhfmzD9w2HU9;ZMy7-)8r^MajkUH9&V{kooR5v}M({(%f-uHsr{e5;|{mx(X2g5)z_V`|EXvjU#lp8JfApkV)u?WlQ?YK zOYxH?U_JdbDla$|&_KRS?FAJj>kI%bO5L_@4=^aZf>T|~*kfnZ2LvT}dSXio5tuBH z(8+96xu294GaZ0WZHr>tD}PS-)i~Szi5 zpT9HB!2Tg{d-lw)T*%fOeQZq2Jn-?>pJ*z--P!TU<>&JS|0!{x}^=7}9$v4sD zND8ZkG42O;&t8r{8<`9up?0bE6t@pA{;tHI!NI ze;|J7(Qp-ey!TEl{meB4rbT@OV>?xo+j*wZsP6oXBb9-bZG1 zKWbFA0&IvsY*1ii1EeetG}(xt$WHQpRQgNrn3VAhNXHI_1?+|jr=>XrjrPep{K~r3 zRCN8E#*>`JM-c&Ed!N;_uXh%nGZ&8ooMYpK0xy0pLbUwC&9Hwr;im)MuHl~}B1qpE~D+xSN4T&kCaiF}*e`QF;Hyl#R?nS}NAvU~*I9*!p>x1-Oa?bh`56@^K% ziF_@%uryopba#N4O&k~cHMa2jba@5eUKZKgL8tj5J-$8cr@yZ{zt3DE=2LCjMG2a5 z%*#ggPgA#I2CtoAA^ou^50w^lKL_ZQ9r}eD@7B0Ix1pRn-$m9d_QMNvk51zCAG+h0 zAe80>24i+)^siHru}w(Cf7H{(ti(Z0WTqbtbUC0;n5NA55h5s=8AoPuy#}n=vhyga zu9zsA4H5g%u=kgoiQUyaOe46^G(ABHii=Kc5V^RjFxI)1&#iho+`~fM53Gs1arfY) z%c#f{`JVDN*&a`&nmAaG}fdJnN%d;$bdkxSnm7#&--qM51LP=i;`98XYt9^hj#5 zKWW&rf!DzMgIFtnv(IinrynXUsCC5Y2xu&)UzU(RRJKk;-4Zy@%yM{py)2x>zj2PZ z=cDBangARKPFbZdvEiy1w4_!mCh@G)=BP%_W+Nh>%1%~a-Uzjl&xw5D%5N$7r$8

    u98vl5r8I5u3o>7mMU1S)<4KRikoGE?(b#fHFmzUjF6wNl7 z!0%a3iK!9J>zDu0c+dv4dVz)ax#m%>rG0B8`|N=tXV)CDN1fJTV&xlC`pM42_OH%B z!E>QO0_0OX@g=s*gevHFK@&!GQ@tsJ+U?mxQO%e4W}iu)z`ZqPAR##>}! zfq+8D>*!jTwgv>MB?@Zj4h^C&0)V3~^8Jb*^rxEJ!Y!bs#q1{8Z-D$$`F;n97so}8 zW7tCnKdzjw?>F^{<~M2e(_FT3WLT1B!e~Ix7d?RNV#2PIF(OmM%|SFKxc%K^-%0S7oq;uoral&d!kx!u|{} zcOh=bHy}07#+80ADO*49GS^(_YTSnhh~D4sx6Oh$zy8gtuP}}*;=*iISN%owCw7fv z2_XWr8zl7^hNA59_Rg|nq)2I$St&eg2ola>LpxXDGr>H}Cp1_@z_dmVr^`pse>pep)cZEb{v^0T{pd3 z2V)xgJ2W`(Q%In=ME|DJCY!S^i0FitOM6Rhn-}|O)ZM8jFbe~i!Nhg{H;;+*tVK}w zWddm5^3_d&x$j~;^CZqJa&!*i<6|@@T{ru^VE*pqdiU*aZ}ntH*nFS6E}FZpe01rS zxvmcAlUa(G1o$xd3ZM&jvo-4MS5Ie0r$n19A>mJ4gleUo=c}tS+onwg3|Cprg^j~S zx)J)=td6SVHcz9=CeHffb>+prj7c52c__*jwPLl1nv(I?V3~BMn3HKd$c$~)48puQ z6koJ|F#SGX9#>NHMKej$)90>_<1HVUg)*GH5H@tNq|Hn6)12z+x=4P_fbN8xdd4l> zQTAov;;KTOK#|GjDTz=&el2hwqtgG)euB3i@AFDBi$#yvdebD4`tjvZ&`krl0xjvnq8t&ktuW%LC2r z)<<}Ibz)9uCH}hTOHu@66Awm2NU}?uOD5qe&j9{Y3rHJ=`{|96f5X+O9JCia1X(MJ zl|@oJj8}^~^%^7${)ezz6VIW_)2EieGv!yCA?~A%-jfqj!c!xFW zi_yoh&S;%#Z3@V*pbS-SYfo!Dm-%m!ZfY3yzXYZ{)uP7Caae=ug=f(wM{aTz2Xbt{ z-PA9&=OOn-ug_TE7Py*Jf@zNsX+jn^e59#}Tn#9AYVshfkcC)1*zv z_W_CutBpF{niUJNe@K?Asg!w%%v(Z{D=j&XLp%8t0Sj#y z;a6fM#k62tiLZ)M+1@`-B;D=UV7D(6Aqy!fIl!5x3ZK!-Gu-#S2XxpC;^#CNKl z3C3i$sZB11JwCGa`JTX4cfFg}X}9>;qm`d8nM|)>f+y2ZG+d+;F$f9R=a|irJZH%h z0NrB`g7FU%RNHt^Lg~v0fF^WSHu!??2y;dzXkZn*IX*V{ERLK^N1a-X)IRj0WkXiz zEpk6A*?$U6<7te(9@`@=ztzhetAp192|f@fawO4)`hVeG>JC$3Gj#h6`{`s*Bidkp zR5Gz6b=~K5Or{T#6Ph8C$sZ$YG|SDLNSU35yxT=9A`SA8P^)25F&DHU?@xSFJ z$tB2^!5~x=4Z~?f1VOMmLXFxSA%BvQRCZ+hrn`q)?MH=2Nx>ooQDYb# z$Y(Khk$@3!Q0AFvp*I-2+%?36+#-k2DwTi%=O^QD@*S0PAJ3gG6uTs5u9^m!t$cY+ z?%k1YeHG-NdM0P_T3Wdbkr}NHz)AkD)EU|{(~6!yvE|5v z6z&i%0@JS%Zxv#i69yPV0NGEAVne(Np+p2f-cs;bzNCjXk4i=YHJK#G?Z;!~7Dc*H zetP8Ul1;2MEI&8X2)AT|T6>}qJ?-LZU_N=CyDXD$9LiJ&3p>FCcxo$FddU7Ec*T9$ zcHNT>B8bm%h~{D+Ms_%%Am9&SBQPPF@jCtqwrBPHC)l320}zZh{-x@n++$N%i`mZ| z0YaC)17hpoWvoJHoJmNR==5x<;-jaATR}=@=I83@@v8A?@KEZsl9kj0W%isjw2RT! znkMjw@NNI3_BYRA-KS9_dDmPfo(F1hdQSYuPQdNH<&oDT@Zgq0tSr z%sR&OzyUm<_-U6LXaNWNW|q<`KPVSpltZ{J6H`*&4dxw{+6dr7O`xe#`oX`4fOnDs zh7=3jkEjGT@sghm5svL(r6(gitWk|M#N~!kJ;y&o^2*C}$ErL4Eo*_c@xPj)NjcRk zew>Qohr~u@b;Lwvy`@a^+krxz3bMepY#dS(@r1;)q>y6vyBUkDzkqiDhAxm-=Hp^m z=J!Z4(Nb0KdZ*)6-~t8CAmwh=&0gBw&pf;juWtX1T~GekepG!0n$k@@8z|?>ChFXT?6Hl(69ZLtSQ> z`K4iRHGF!0VGn+G%W+P)ebm>_Hw3nE>4CF$g;Ia*o{}$oq{1WN^ho!l2tfQvtk@+; z##Oepthk_0A`w4WlO>GF$RZ()tyI&t@#+3hOhn;g#te09L1u(w;*)uc^WcKmL?U{5 z7BKO_^}qIR@yx2J;zRL1u>rcUXG$D`aF`u!39(<2@1NRQhWuBnMh;MEjxn4u>0^`% z0&x1KN?SF9JW-0E5Q|!MDI}f6LTK0m(E~`G2sp??0;qaCR45}HxcVqK(Sk^hWR3+w z@PZ?l9_~8^U@;={g`y%vO9&Im7y#iR8q*Dr$wDAO-ImJ(2=-?0pq#PX0cdywg+m4tg8Ou?oj;G)*YCAbpHlg?ktbmJcyYHVse0e9BjsD1?7KlPZNszQ}e7hY_d zIF(VGKTg*-HM-H9zrDQ;>P?Lay|upABD8epIH8BZEQ2v<1`4|KMhSpe?C-J($WW?G zLvadnbSrf*{5%pOBe2FWhKy1ze$J>pIuVYLtVn%2(k*1ugGCI3*8v>_6{s3afS;*J zl56qfIWnkC{jd_gO7}h4=0}$`=w$1#(`|`snrBH=!5+#y3Fs8-9I(K{0IjcDVxb25 zaiGL~z-B6dYlXNihMH!<13|d362Ji`)R7Sf3UERl@e#nqa`AQG_f}KYYNE`u0FsoG z<@)@1#Pqv@p==ALF5`?ga>Z6mpqZrF{O}&3n0~s7iYy1i*~{JS!sEs`=fc~wPQwCM z+%PIY2ClflHw_!hA<{t>Brj!vx&bGT3p{W?c`7{-BH{(@@LH#i-^(V)M-B~ZcQxM& z;MYIK(!hR$P3bMMsa^VzuOJe!rnxe3YLw-z^LKsXTzH~x`+3e0dbg5a>EPJty!@-D zkmf+aNI=mhg6?EJj}5KLtvw`e3mGBMe~_td zqGwmWzBhXG<^!2;TLbXIqx+OGtdK5FjYLoKRT1g%A`&Bc@be8tJolt@AFltA0x%X- zScdu?4yc$Nx4JZ*H^GDz-vEgc87nQgTLD{b=EOUkkM!oh_m`gMlJ~s6-{`HGr~{nR z=K*AZKy&9eo51zW(6gX%I7C0f9SAgt*~p4~Dgtki1aPsnKL#US2ClWq%2Wf+WOm@- zLrfHTN%#~)P^3AGOMPH#|E~kHSvVZG$ITML3ax))GXb$j0b=cfD#^*D8tX&=$zZa5 zBh@c|6G*9CSfPMnC_nj{N=c8%#>4{oif&G)d{3S(vEn}6P484TMK|n zj%7ZYYytbr3i%x;S(wNrP!bs&>R;l-e=nw|d~yHD0>lq0kX$PW^#Da?;Tp!9GGCim zvNKC90FELRpzs-!6j)iL(3mn=&N>pJqH;hq**6b(~@)vN=U2tEU} zfVtCj{Vno&fs#Zn$gm$6(Vq)|`GO2H@<45@jw~~Q;WJS35jekmT-1@-Y$RIo8#&0f zSJ3wt3|FDHzL9nP9q)MffOCU-s$^iTU@k#XULPAWN@5CISOL5M=wDLe_b=!hw>gsL zRqo93pgO4Pt|i`Q5PgI~X#sY`G%JiF>s4?~Y=lS^$RNgYdnT9`k@0o=hcC|#95NmT zIyCvd>ltiI4#q`yCY|Y7vI7V;E9rY{CGBP;(1s3Tmih~*DR!Sruu{lZuX2B>?eWQV z3LBM%+!VUlS*%3eLmz~$wIDhTr*Dto0nD%|Fh;mCDnR|VO(3c-y-YR}QgKXNU$FCm z+^(h>@{$F^!**YP2pI_$T|&R=bNN^JD=7j2#)UtkAZC#rPDQROqZ>596?xdIG4F^X z!9z2TYYoeg7uIu@VX5-mU@%K<`rROt>qqpGTWf*(k7ynouGllchAt_1L2Vxn47asTD&@Lav^ zQJ=)9qU<%*RkyNNUP9UJYCb^$%JJwk#RMZ~6Mw=S=XNqijV125@l@=g00WWk*9ZhC zR>uG!g}65R>`wr$O`(+oAC>kLlA#9WOx}GNupo=^A=eF`5&=ed1bwgXYv|uR89}Ij z{citiUxhj^LPi4TXwwV_<*>Q4d}*2QWAP{@&%G{1K+o7eB1YE?24JUaMyW?Y`;SQ? zk2xZ{&LErOJY)5)ztnoQR}`$R4{V& zDy_#?Z&yDcU#%V0W}^FI&tdDY);%zyf}9=^g_M&?$4^o{|FYy-_`P!O@Vd zrE!>AC!!PB&se|{kmQhA%i$G{rHWPjqHb6SH%tgaYj>b~G}b_V6><@3kI(0hS>>{W zN^cX?y5liCcRXcZ+H>{KKC4iZxyhK|vJ#WjUPmA2dfH<{CeW<&K2iNBngrnDa7-Q` zbJ|12<)M|?Afru{840_qn2q|W7Sr9M1v&Ze&&1+6xFCB3!X<vFEMLu#$+&q=76_daqlsp)8dE+1y znJ$dl0R;Ts5N3dM7$aI3DVgl)O{cFC#>1&K1UPP)#!WG}{(+iID^ZrcNRA(_h73HR z6NJmu=^m`Az^OC*kDq@{MiprINSQ1-?1W~fr5Y0_ny^tS9uWt5h}+waMd(Y< z$ApGJbM=$nNh~;aLoMAtrnUzUGALY`%kWhU0XNqgfoKq6GYoBWI;1ka-RI_(QhnLQ z4q?+Lrxw!bOtKkr1Ww=>+`q^@ePIcyd0_Aq5O@M)EO(M6BrKr)GT>Yr5RkbcgULqt za!1^87J-%uPt@Vcd~3D_F(uwF-i$)Lh;TiEc0DasU!I|or?03!T;(O6at|$up5nv| z7`foi55D)ajb#~e6Zq=djf`$xz)@F8f`Q9dbFLa*_Kgoft{1E|Bq@HTvR^=wB?HjW zCIm#7dFCKHOe}D>Xv9UN%R>@Zr(SG^%%v5Yq1!59Zxbo4e|Lu0rHvm9l&_lf>JFjh z#mNOV{_cfsqb0z?A&=^g$Y5yg*#c*VLvNM-pa7ek`p!QdkN-oSuPA0QwSHslNS1)0 zescy0tcmI`U${#CS(++Wkv?hVhVc+qCidsO7h8jH=|7XyJA+%15icmz)W!+w{W|y0 zO9w$gv0v#-qiTqq=n_GFRxqj3>}>gTLn@E>tBwzbNI9Sec(@yIwB!_7gQf?xQV=wJ ze)5Dnwzc}PTOS~8OR%7>SupGa6ERZ4{m&0$R!?LC&3|*}YW^_n1%OT|gCH>|cE_qi zxMa`8mIDf;iXB6!1??ZB)UdiMkR zUz8D=T5%Xm{Mib5R~94Giw9{KJ}C_tQ1{2&Xau4Tghh3DYfI?AUsN3F4W?p`mA(H7 zScE$UvEV`*Oza{6L4+WGRjDo=i-#=Gal$M{;*ZZ8%dJK7%gMn{05n|OF)Z&Y1wWKe zc15v+snrE2e+W>11EEI&D4NU?wEl(MLcfz_C${Gbp}&u1hkV>SCbaoN-V@NhmT^HL zE{){yMuYB*i9c!!Jj)^m2zL=fjkE?+<^wrhI=H=wWOMug!&>C+&skxoq4?7-+}DSH zrU~3QUmijnSD9YwR#$a#S|4DV-FF~KOt2Gk4Qk1rUsnicuZqkKUOVO~D zegrje1XI{GQwNBoA!sLH%iZ}}?}!55iU89Cq_F*OkVS#dP+04NhVqGb3Q^rOsWe|W zD|g|(Qvkj*mRlFwA2=IFKMYa3RIt|OC#zyrF|Kkg8HUG7kVy%dSBmTDp6CHqlXlUf z+RHoTCKc)zkFjAyi3vE)?g1H!UMW_n<|xX5f=J5+bO|NiH|fg%c&0WvIlkwOO6lg* zK^x-tAT1IHvG4^2mWy~1b5ei&~dM2C4 z3)grE^IQ>p;r`*;<9t@|aU2O9WS;cnEnUl-=mSfJR4`lQQ06_kTjnKGONYa^cV|Zq zUe28v>0b)9WwOSbuAc|Y(pB#6P9pWoE=hn~Um)!k&sdDDISdFyK#Wp{z)>Cxgn`3Z zE!R{21T+~6?)rOi{*Otn|Ei`rA3+Wxd?6x?Qd@p_!J?HQ2Qu0G*%g)JF2q;yTrRCQ zKX&;d?@Mc~{ z*M`C^|K+*H2s8i7b7z1&H;zjrv$U3S#GugyXhC06yuGkk6X)!D{a-b3Q|c>6brRIZ z$F0etzlH90k;!RO`%XPVi! z?-;z9)m~-QQCxorp!V{HX^&ccRyd`qW5B^tfNnd{+=L_*_ zS@hzKN&4`kH(_yeu82Vkoaa}Y8-te#JIxtX1$Lm-!=`7Ek@gpzmRdOO8I#|t?shjt zp6>BP?H5PUoADG77bIblnV9$-HD0}DLb`5Xo?iI|>6w_on6z?xbapt8vUJk9Y+LSv z4h$?Y@DfvnTlfZ`7w&^4+%=(FIzL+#FB54gS6Ra4$P*6cY%yfors{Aar)?yNuNoqafv**=4%+pIYRvTlnA5*RNnCUC2w16a%`h9IxD zK>hv8jtCPpRH>*Z89_drsAsSU4l7!)g;*xS>4AiW4l0D2z(K{6i)aFxMj{yr1zFnS zKa2VCSUJ7Y&-`z2Wf#{HVTbm6+5J(S6>l3r%d2nOWlx(i(pbgh}ze?NDrwxEJIJU4hPUUx*56~p$|hU_2UH71jEn-lVQ^xGBE}Wd`3e2 z91%PAnE=Ei%C~DqV@5RexnB>DpI;RxO+z8a*M%0bWa4sUkyooZz#aU}TqoMRMA`z< zvnz$!uKdJO%`_Xg9DpGPD)j?x_gW?2C(qKAMu?8be}$|>MF$`)UGLS|)=uH)>-A*C zB4^sF5oN~M7h?R#<33ZQyVPBTKfzJ0!ZBPkC&{>L(V6TxR zfGeCzDeH67u03JrTRrbG8U1tQUcA86)XBak4fe9;8A)&mIqF1MJo58=`K}dv+jIiQ z*MmnR%UOkwLw zq(446HJtHQK=g=ES5bHb(QH`UVhSk{N<usAPqEIZlatEbT$7>)-t4iBnD=mV0s5M#eQY#=6t%kW~FE+sj@T)>P- zQc@lk0swf0fvv#65HLWKMZjf;g2P4yy5mDKEbiL*puQ0`oFZ8Y+^7f!IzoyOB`H`1 zdsTN;Q}JNP(xq)NrK??Ug0#%HV!ms_HtLp7PB=Q$%0n|df4uY1&Z25~ICPGCtg^G| z3kcQkqoN$!aCg~9V9H7*o+N@%&?w(H_5;w z;06U!D}oD#6$x5Pnow*8?sQ>WvsU<{Vc-W6Fg%Q54}Bo}tc;t`3Lf~-p`kNd_~@Cf zYgH%}_k_R9ruLM++^IxsC+#NZdx7+OfD)9xJrH`g8r=|pV@X>>o&dRilZCiNw;oh6 zzca;-B1xPFO1J@N=^(6B*B>u9w>*C;$5MP}?BT<#!Tg>0B&U|8zq`of2cj9@5Q0;X z=lOXy$qn1M(M%czNKM{XMW2I!2Qk zA5izCI|)qL_dV!Qi+F)N#0w}+VZ#RC&n!L)_%tqr4*X8vixI0Db;wJ<4LTmHHx$m^ zrjUCE?4gY|Vxq&`E*NaQ`#G+qKVd2)hWC@VSU}|~lwQVrGAHa~u=2$wDW%YX=$D8G z2;j3;NRN5BQSv-Q)zO$r0k5yb%K8dmKuR(YZ4>;iWEI)i zrPL9)1GdHH+lUCq)s+we13|aO#7^6EMMFSMF{n5XyWOAwwdiA7K}JosJ4}{4N)`{e z*vKA7XsaiZrXOz*+h~>u!i=-9s%&NMi3vd|UvNK36qfFqNLR2y@ncr6-SR|9EV2@~ z6g>-x%)V1-%s7laiGim>6;fjSJ_GV2YwWew?+kY&U!;GLNEYAarR1`oX)eOH*qelV z|L5r6*0+Gb9{)4IVw8GB=YeqKvCsGm1E{)-iR8GQ*yTsSH+5`@xxm6-S?5uLaR|+9 z8Y?Eobkr2YtXF>qV!KCy&KJl6MnCQ#y z``4>g{Q1HomWx9>?Lx5QLKE}XK5OniSsI*l79fvfKq3nywcEDzI5!4#8Cu~kECuGq zX6>PIiX~p~UjS?gWrYl0V8l_(%51WjNC|IzeMW*!{DX;(5Ns6i2NM)u%Aa196b>9$FRqsCpp#b5 z69z)g`FxvZwYWTWds_Ro9Y*!vT5Xzd5A!rr#}@A4_jF}o)dSJC(Y@+dnLDa$?|`IVKi{# znt=OV1Oi4+|4F`PPJCn&)au(>F}SG?b+ARBIjS1Zvj5`!RsDVFPcr>`rzbG0N2z{2 zG_<(T_AIupi`cHYKJntFZ&xt!Z#s3lD=X_Ec5AqGR{Di)iG1%hQgA^Q8Z5tgJk-&~i)^{$!9dc?m*wQrT}_>9q{3mw0MfssLtTXNcQScAHN#W7L)5VJa- zvBz%M3O7SK9B1I{efhy)!Bj{*t_%VEn4nz52#mK4zQZ|>A+%$iIs*3g8sF5BELV|Z2 zV>a(TZ;!4GJ{cXp?EKIBjXKPzZ@2eptLo{Mkoz{b&2t7-?@~`}h*6xjItiFg zg9yn}00b~HAkhQRlt#!|w~mWV??z|(bff!slZ#KD4&AP!NfseRF9bB5dlTr9>0z4_ zpaV7lqjFJh|1qIzD|6uW!2Yl1p|ybM%{(n7T28?%Kk}YYK}f_F?S5fQ{LwY~*SJlW z@#@Xk$$&xVH@gDzSzGl;JZAU-V4PEAM~aAN|4_ExKBBkYi8t|yg)A=}gdEmT}8r*v~5UJ)hR=0SBaF1H`Y-ui8O@GlSP5*R+TS8tW8cW9I?(s>uwalrWHp9fnBE!%v}(*c!lRD<^R$9{SCFMKo;+ z%~$edYKY=0a_{=<9Ik=_#4XOpv~VN!Jv(NT)2gq$hg@1_fSi0n>Mz{~fEn(6{e)O)q(R(TUOAT9#d@5Cw$Jr8^o? zFLY~++^a@7@PO5?@`VMm*+h5>nzg*Bb*3`FGkm~6_i^r|iSfmlAp0Ob#x7WviX)h=A~QG%&7pirCX$1S z$s8mc1W>0?EQl|~QiXau$WA5@>wEIx`vXZQSvFzdI4Bq1uFY;v9VX433;eGlSk{<> zH~es*4&BjLw`NX2Mc=x{7tsIYPXgmfiNS=>a;*0|CM~EvhQK_(O&AxBzP&+? zYsDZQ9ng_=NHl4PwW7gmsx=HJmi?tDTAH<@?kjPNND>14v{lGQ@+Z7E({eoAqZkH` zGxO$Ax2|NxS^Hn3hrkK7AkRvX-q@7hA6uAjh{N{5M{$1F%w&CzULTABl2|(70zf-H zLW1lLP?5{;dfh<2FMGs(w{Id%j**i^4^JH}g?&c5oBx)B=;rf#i=7&a1 z=V_&$Abt0fzpjK^{ev%HS$~BKpbfm6>I7d8i!Ke1PjAe1z)vGg-j7yxTE-m=*52IS z6NRb`;CBLSoN)H-zNsnV+A2g1Swg!D$LpKYVwQS*%0qukQ-RAP48tRV^bQjY`b^d3 z*gVi!zRl&K?0Gy^swL_d`XvTlXcYfxc$Tc@zW%?BBAdelH7^q%!Q||gX1Ijb7S6_ z@-)wB7gLi9|J{0pE1@~*1y!XSH;rzIQD9LrWu1Npl}OUJTZWd zknD4)MSFh3XZw@yWkbR?L%YAE=|i9j0}jiMDn2iiV?vUN=?#W*8e@Q+oZfpJ3(eb>V!& znDw4rQ+qV2KK=O@%j2Kc>!-%!qnqEUx0Gi1mPQ=;!*cn!KOQEzG|&(`(uDFPnL@}4 zaV~=;5}pP0Ry~8!`$3^l^wPZRg`k3%s!!$=;Seo>i^Gz*VIS;$u7;88&ZK}!Nj7@2 zQ!fgG6%zmE@OxShD;5F^pCm$kcR%I`c7P}N-3`($T=Emnlzp& zUNEvRp0Cq=hgvn<7J`-Uj_O6WKkzsI&!jQ9qcf=Uq|bEi1=Jk#B$EO(@0R&A;S#z0 zR@&g_6lOdg;m?OW1{O@e_gGc`gg9SAY)meN4^i^quWc+E!29NB5}>fVDt8zB+q6i{ z)O6;u(aW!Q7#mcDxZ*67vEi4$`g%XjEJ`p*U z2zOp|Zw{Ifxv`9F7xKQ(7;U~5?Gg9uDJs)7^$J>z*d4{&vMxQ3&R<>6deoK;L;oaO z7A4-&#Rl8!&%AH&6DVz+;*6}CduCTJ47h81mCaGF+#enFv@R5RX-8ZgEj2#z7S)5G zJ_2}Hjr9Qr=rW+EoLse3L)gduBu`U7s!bPnIsY|rgn zgnlS5q6-2&{7=pK;y=~kn!D`Z*lziWwNEJK`7gyXs*U8;=_y!O)_S+LJS}yYx|EHX zC{?gOmlLavJTSfG&2H(HAJ%~c$K|#T7hurVL=D9K_*AW=D1Dra>vxeYL;c^vqk$sV z#-vp#&iG+)^9u{V&P0cbAWr}^(r7#dm_W5#yd23@oW229K@bpyJR!)JhFC*3!rX8z|p3OGBou`2Vyt`L6V=RY~ zd33auq2$7p7z9gAHB~;y{MvCd{;S!FXyj5akdwKvrK}Qb11~-0m`>ss=AmZHz{PRq z2{&EeP6VeNWff%+_wzo^4>U#$QWOx|k&$ydKRdV2c#JUNGj#N>x2^YJM`WRshKo1f zk@lC{iu+egDVhbHhv$bG!>}OGSq)E{z>hHOiG9ysf8B|;zZZavVb5XqW?$KUDcWYc z(p~3TY!4JPvwfK=P-YR=1mSLrh5RlTI=%p(?&-FZ@_YOW40AS}al~w2vL3@UD2jmvKh64uKxF0)hqCCy-1Nszdl!UG#iCY};zM{Wz{^ z&AKGQVC7Nfgmsyybi@0Y_hWh}2Sn3m<%wF4p8Z*SsQX4AUp9y4+36Sj6_sjfkW!!9 zYb4c9?5!ci)o5ryIuIn^9AVPE1`g%M2#M(uM|QE35&x2FFt%`@K&g$6e(M~J>hWQR zLve^RAotjy$D}j#i-_WBl3|I#+b87eh);=s>eN3XyvYh{wi$#XtQ?|rt>V4h#_zUu zDaHy$E-;Okw`L|7Atf|5D8O|PnuK+olR2;#g_8b)LxUy*fhCM9({8`m&SZx80q*Co zIO7r)5(Xv5{d^=PGmvCvem%bfS%F9mM5TJONcB{$fs^Mx5+RcCFj`8Go-`D2B{q|5 zhs=!tS*%0Od`^Wc7q1qBHO|x+@Uqz;-FJqQ8M$Ba3sTGONl0Pd-O>r~Tb>2@$L^l$y({C1nPi|2hBOO=^ ziHi}&$lJiHk>~Wsr{HE&9HU&;S8t8sg@S`pWEA%Y`bpiq!pU=AXf&RjB{q{=C|`&O zu;XrNBd3^S(2@-T2Di98`eb^>3@Y*OEPHI?+|Cg`fPdl{UjJkrC!i)d*`fV51SY?Q zSo=kdvfgfTAD65olfRBsijZ*XT(&zP=N?kYb#SbE@j2Sl@sDH}hpc57cG>DoPvah! z=id{QDYeuJ=dIvlwYy*DsF_Y2OAcV7siO^OQTA-DcVcxb=1GW)kVn3`722Nm0T}7H zIE4~PC`V{=@EjdwD|9W(ABkS3AgzSeHb7Q!wUjbeXn=l^Jl0;FXYR;a+9LMAqD)DmkNf z=sAk|YyyvW3$|}}{@A*B$Qx2#z{d0nWNPbeCa-Big`$^oPF`U7A^zNRy-`bj6(=Gv zsq5I_A*(_TTPVksbv|o_VcyH4GN`LHE?& z>E};HOAT3y?bpu2 zwDHI|i@-TVYwz#_rpM1A-{7cw)+Y`5DgT?ZjvfI4_K2Y}R3&2(SbbyXK~u|i(*(+# zOEHPFC0YZ5_mlNsY_)^~xug7&mWu}1FP5ZZYVjoU)B(fErIvmpYVVN`>f({%X~K(1 z5;xWI|N2-Wr^+<%Dnj=k44Bw^Dcdx;dT7`*J+b_5VdsvSFI>=D#lm^~Q=QCoAQ^TT zW+)~Kjttg*bqYd4PC?B#(EG&7@2&RZ#}KASb9mWVyv1WGt;JUy&C;qu1SS<7%n#z9 zF?;E$O|Yt?A3VK0wVb}yb*qQ98j3lP+$^$qdj@KL8Cn<%HWZ7MChsj%zAmZ#q;hb( z_lFcuN$8MnrwlgpxUCE|k=BTop*H~)>_aPeCj<4fIluM+tc*M?=SN>;LCX5Y`9P}j zui|qoEw$0EVCJ2onzrJDyDvsR&n`T`vmfI+Az||puaZ;cV}D#-at(XzbDQbwSW1h1 z{)0`dr_ey-YhN@^53lP*MujGA0{>F2@9>6)q;BJH7<98bU-Puh`5;L2@;OCN&79Ac zc~5$q7ZX^~bM+AUz~Kk3ck*iFYiWNep;z+i^7w>JKX*qvv#u`J=a1nw8$SrS^fW8rUY{h}x1%+*CXv}DUr$vn(#expEE z#WZ56{B-I5^m5Ws>kD}cZ!vB0_wrmnnGGvD@ez8)TgTJw<#vA`YP)P~;5cm2ZSE#R z19@w|54`cqHHdKY;s?oNyI*G8;Vq)JybIJRP7{ys2@a@xz4{Txxk!iEVnop2m%M6} z!?;Fqkc~PATjxR0AMG1AhtRLIwoV3~WoDM47OJ08P~+dV5FlrI1NcFK#qWDNeTWOI_Nb=xD+GjwwHcpTi`*rCJK zC~lLxwxjAHLDH&mx#N_aK`Uhu_0)1OeVZcq9Y4yW_uNS7L@W|HX+HnvXWxq5VQ#K6 zV~(Cp|6ZCT)|ACH!Rp_5M7Jn8!v-l8l-dT528QEb=1)u>;@S=mLS8etO;T+wbhqfM z9y98EMBiuj+NsL15cjR3fFEXEd{ip1r0rYQ%WU8kxPPpBG$&Rp4bfYBrPUwzq-rs5 zVwWspK4Uz)34BW?e{t4sQ9+J1o>Cjdt+p%$TdY5SUGIdKve0B~Exh>Nx#!wFo>05w z`2o6I13jkiA^PN!knQnha4G6HradnL_A+py$=6v_cr3a)BYLIeaocj?66rnneLw66 zj8E4ItVeEr{4_Q@gl;{JE;#taZGoRr- zXAFz~#uDIh3HB!)XiT!(@^lu`xtJV?6S->lL2Nht6Alkk~QrNSxxUKCattT@3>w5UD)&iYuTIZic zo05L?b`K4q`~`)VzfI(0Y!5$S%zs6HMP9qfPE+=*TC>;ZYf`hdgFMFaLD2c;0h4W{ z`KRIg0uR!A-M$l2F{qrvZu0>q&rP&1Jjg5;DldOBnysil2hJKuN(nqVF+?&>HewWt zTGTLkwgIpvb%Gx@2-g_`XusT;m3v9Y3$x}Q#sE&T(2iR`tJje71m$Ps*q`BR*rrJA3uLpOCjdZ zt$BcP9dwE*CL^J-Q#uO4_ilZ-Du4A^u(aoW@d50>tMlk1q<3cxM0KqWGEgj7vrr8$g?{dg zn%O_19ksRk7J}afO&{j&EpE z7B>CH&~x_G!5*^a!ejOnD&4s`o3Wgbc2Pbo3m4Uvq1Ewgkje#AxWH+oW98O>7~Q?y z?I*9DB!lD8B|IKnpLnu_rzg=x`Ar2x_==ufDf(fjQ}VBc96hN#kplhOaU2N}hIcZa`s{39sT+;N{^Jyw_I- zCiP{h2oV|@w6G4~d#CxS+CmQOq2kmJcd;(*gVMce4Z<&JXe<}4^B^7vvYHZ2GRG>B z($zH8tE5@S^vilSn?z$(*>MJ&HXhe1>jrc`BfCaJ0 za2l0}lbes|k=A+xm>LR2_U?>GXDMtxYwixA3b2LUW2>e#ajng14i8y9A_p8oxfOqFBd0T}gNgQ&j^9Y*RqM&nt zi5xtmyJ|fKMTeBz3OHYqOlZ6{!y> zW;wYlzwl)d5sv5PEHTyQ3t_%P$$5z|QyW}I_Jj2o3j7(x$B}T`71V;It}oADj2&D* zbu^$=mPMIw=lSx6N+H;34<;_fFhD!N2C_@_hVZV9=y#>B*w?Dg8{9Ic3RvClGxt@b zZ+h?EMqYT=pN-S^L$ra7baK^JkVQmEIh~kXf%YAbR*$g=UWJazu)qnohe!9i@mGgh ztzDOi@oE+5haIub$P*`NQ3U#JPjB_rG>x-RMQ!l* z(aw*oBwyFXzusRFXIIEXWf{Wa@3;a`-s@A*@D_;TlN`tE@QI2A=qPghnG15B*>`oW z3Bf)cXyj&`<&bXT!7zKj8PFfvd7w~4jha&^GFtF=D1H$hX;@N@W_v@VPZJUU_{Phu zTqan&!vH0Ri-uDEYS4-o_hU;&hMbAyVzc@lsO}J!a6Af5VC(cRB#TW>4~*F??yG%G zlWHe_`JBSzp7r(l(3P?~?{azKL>wl04exQ=(X`up@+pXL>=YKqr+wpRqfwHUg9Cj{ zUNcHkDx+TbpS%gQkFR`5;_s5$B23mmRsje~`*$$RJ_V_tq^`=+^g|T8Q`i%Avp$wO zbu!4+Go_Y#KIR#Lqc)YoZ-b%KT+L*9d@`Sp zvp|P`O<1l|jN1ZoT(B74bM*4ktZK06qn>=%eMXAAf1lLQuky^i=6;EVf^Vp}#dsb* zF^D%UEpLPSLxJF-p_F5QTA{4a4>5bmo!Uk5y(sfFeN-eba<**9+^7RGK%i9PB|FNc zfcW&YpmlbpAl~0VcV|?h5>uBGF~K#%Ohua?Sb|nsa{#LW_{HLLR>_3|WoGdlNL*i! zrLq&I!h|r`YYf)dcuEc-u$0iOR4&?q8^Ks7`eHFot};Y8-xt*R;(5zbArqBnNxK(+ z>!Vf#zz=%5b&sc1yRmE>#A!CgS;>HNJb7f6ULvo>6>@``P z9a$^1Ik<*p*oHG1*AofxL&g5=TXFbHnSC=2sqJOH@?6k}OC9tIgbY_2iY2+8%MFH@orCZh|Ji_}0WV;0YI7xcK^femUc=n}PdZUk`b%nMu z&zTH8l-u!7)syw6J*~o+(SDBpg@AfE+NWPUe5f-joUu(%-WyTjsuqP9Qm}_HWu%bN z;Q;oV@}KM`Y>7kAb*5rF17c);INo`90-}h#VkoQ^h(Gk~=b%|?^-9E@Z8JZ6{gHDw zbwgUqq2N6p_Z-}(DchHqkN-2ps~Df~L#16DABNXBDRLZ51Vw)$xtdNP14DUm$6Ntr z)_-b9F?c;{+}$3yURa&Ex}0e&eui*m^ZLbz2KTdw;w~Uu>qH7$hYwTCk;^9r6SMX3 zd%ldR7&<<@pW*dV%rhR>JQ*Lso9@IB-vgiV60r_8_!0-E6wLAvMUz9j7s*L>oSOv! z1xs|>69|dUxUae0SU+XO%Xddnu;h#jekLpRM~w8=%8HTOejAmB4%d$U1MaK0pAsfF zp%5|l3p38m{E`w7V*3xk zZeZg_(5VbZ**`~N6!f!jlb1C_`qB!ZFJ%xS498+GYVglDphCkVqc_M!KToRfi6f!! z{pTDZxa5=PVYWUYO_IG{ff(tC<0(1Idr>02-``!}B5 zr-&L|=ri?4m94O=1<^iV@>21v?DSMwEnuz25>sIV<`=8A%m^dyQxGdJ22Tv6DNQqO zF)n$+n`2YdE3%5yZQ^W$uq=m@^YzC3I*~T-g4>h+XyCmu==&Sb>QfY{l7IQ=ANUhW zLM8O$5bmxC9bh{EZI=IN>tno>M7WpE@wA*{>%*Kq--4ddeh zvW7~pLGNa{J2xBimZ&%_phliVhF%2p9FU|}Z>hO_tQQ#M20e0w9r2Db@f}qn3tCxS zKlGU`<=nP=-QqG1T&&*_0&f}&3tOG#lX+6172?3i`pyfMQhM?*Ct<6jdmya{DDPak zWwi`^ZA~ziHK#Yz^9$yiU{lIhYkar~8pmELGFt0(^$^nDRWsOugg`?elL;j94LP5s zrftZD#%@prmOictN3JVIeuEm|I}`+=iV$9o`*naKQqg2-F6|sW+!AbpZJd{Ok99qN z(Q`_)GT+B|FzOS~;v%?Hr4MwsG0?XwvdM(8Lep3bsAee=tze4!4<2EJIu8 z8a)~g)&6>857N<5K8ZVN3cPV}Wa4)I?fz!P{-SXkymGN)?Z&Uiy*tbPF(I75a0a0m#E#nV)Ed|5$UV0QO z%XT0x)b(Cr{_=jE)r#_gKhxT}epYEtl^o=@ zM~Uu}K0ojWl50MHKX@bm*CqHHr%tP7<2?IlO=5Nl_8AoDS^XZ_r!m%G(-V|hq1 z*+ssSd_92~5N^B&pkEINKhPlXzRTnSus$i#5KDcJr)2vkLByBg4&m+t`iCE`A+JCu zIme=cx_P=C_v@m?3L7;)*sDkEo=xg!OXgM40ZF64+u^w_->sU_G>U%#S!LYjrI$~JrL!v~t$M`voKxtcff`TvnOq>5xZ z0FBOG*mY}s=9O>yAjKp+hNjQqA8baZ?~~faK6(r-&dCXNz}>E6&nfh$y>sA}n)IOD z6eQqCLAtga=;ISs37uZTyl==46^xJt>8SCMg_{|2gek(ebDNbNjm7?(zSmJ6;@x{xnX7R&l1X%y(@#((evspJ5NpS$6jBD+srbGyEn^c>-fN)KRFKOXw5O zc5#u;*oLsy_AhfQu|OYYz_{I|OcKne&VR@OLY-5X7oGDG)b$}wvz*XeA5S}!s23`B z(Kse1=X}=Fy1Y5BSnVv6J;ZAfK%(SLPz)fS%f65qO}8BMBj+N>#W*=y$#N>N58<#P_*; z!s6X!uRy!cwYwq95os>1;OAXOH3sx%3W79AzE?g=9uVq)!lWPHY5pzZWU)-$xvFFP z^DJap4)t{i<&aWXXZhZ=Iacl;PFx^DAt`}H+M zrH9!9f(@LHU%V^uED%yRjI&$;twY2XxxJez$(O=s38({<(pL9}SvYTJYQgmWxb0pC zF)b){P8pO!p9+jTP4o%}z&mMtB=fe8-wfj3i%*v)hE`IDkzFAEhm_Mrw{X0C5j#t$ zJA|L9XB^_u$d}o#ERx|hI8x?5XHenz!1;Xso3ewG9V1_O2p)L+%*;i=Onuo}+$8h| zvedV*DL_dSQ&bN8BT9#_Nc0NBXUf&Zb-^lcVPt1UmcEGZZNH3i5sH~YqEwNk zlN8q7@U`svvm3I75 zb7i&Y(bJLkuXppxkHt!EE3GzP>YEVKP%5rrLLeT>ld-{d4l4C6`oAsfU9n%x{lHFKt1IO@kGuibR-^WH~*y z1uUDKd0R|9kxv_cTp2tU3NGozT|v0K=Vh&DAiMxL!ce0CG@J@v(;|F7i=6(DobLn( zF$BV!wTkrO)@wK;pau(js9BqSo&hA8bP|%2uW7Zv>m15u7dWQfz#7JY0Iu5^ik=Yo zoTpj|>F#4i^g>_WCp9=})t~vx-Jwf|J_O-&LK-KHm!d_0^tW1MkN&NRgfO25L+n$N zrj0|%{K>>=*K9bT;LHuxLKHihE02%5IdecK+%svI`F^~utLyE{Kc!wQD@G-ua84Ld zKmvcdU~tobFU~GiYdoBZrLm8)EsG~8RfiQ6y)5`0KP-a(D6;Ee)BMD<<{xa@o5tPo zCR_EFOlk#7>f}GFawt(W>)D*1lFXY#UT>Lex>+0%*Wkj_8QV2w>i&faHhOvlQYXHe z>N`SW4y%fA>R(6h1_YCuXp;MQ-27K3MNSHm*gAVg|zDXZh>pz?u(b_-E zw6QeBOn*o5h|^HeAL4&dd?yr^A-@xMxACz8P@vv1i?oalNt8RQ17Wfd(H}=0R@mUn7RDJ@RY=4eu zqib>04K(@%B`JSce3EkfCwgHVJ&{62Iwmd<>99C@)cL=(MWra)(z7UDrz&F|(QO(e zBSvr2nho0Z#IPs_DI-1iv>lkYj_3@uMn_pk#8MjXua`Na<9ya_uT;n@UY5Jo-?+Eg zxYsNY&;+9)Hs-7m5iH$s%}UIp=)6COAma)bPH5A8yY>dbeCT&5x^NTWhY)5C*7)S~ zg(}A|-luW-kTsulPJVAf7;=IOf3j5_aT;i+7LCJY58V^u4u0=4?gXg4{NMiyoTz>i z=n$$mHACiHg^8zKUyw7wtOCM`8d>P6&(y}!OSG4{Z~V%v6^+@jtAaY4K`gN>9X@U! zQn*F43|8zeO897hakPL-2O2D{>WIU@bD`Sw!ix0Jv*4cv}4g;uaRAey>;cI{dn~pTOpgsrD1QYhu#`E1xA&i^OQBi`Y zSO{(M;-?ErdFZd+EuFxncoXyC@~fp?gLs6C*vo-iqfnAwO=a7on_h9n;8Qe_aOe%| zL}KT|N6#y2zQiR2Nu4x$B8QBbLkLvsWdAQ$-$w6=-uoDFJRdJg*7-u_i6@4au+aQS z(BT^sjXi|O>)UJuCxI`m8}tOlPl+2J2e6B;*Gx2<&8r#phD#8GLgL3nqdUGzW}0DA z*O$1kWi#?L{PmXH`E7@oU6H66^*B~7A0RH;q!#cDF*(QkN_@5!#6=rSBAKQq|6ewd^6t|oah2HUCDIAg{Sk*`=^<27k2S}c)yF$ zfM_KHhsX;9N@KgLb78Y(;=x;e<0yh;TbURRa2%7bZ3*RY9C%Pz*WPXO?DQwt&0h9S zcK91Qozyet1@ya;H5hRe`U8XP5XHEJpfL6NZ%oVfV&BCLuf5GN5b+N!$O&W9^w{}4 z>7hFP*e{-oj8O31Ai`(aE@Z0Q7APg-$zIqQXQg+a00x+yAQBW1lt3~B*X&VJe7E+O zOR=$9S*YaK;=lfqm7v3(v3mO%5H1x3QwZ&d+#&arw6v(#*xprzqmPKl5(>-fhZKKF zFHl**dYrC9?IoJYxdKe}INqZV9Jh~%#w$x_8)hMMaN4ulr=jFVh|gR&i`sDIxR6Cb`GSbaI42E}X*41nce!qqTS2+oJt>bsN%dJqe#stJ=nZwEO z6`ey7FWts-9jOwWz%1>fNRKGu#7 zJptA$aO?EV)`mK(*2+C!@!kY}Dm6X^1a1y{hb=TC_IaAOi{xyrpIMp`bUDJ`{$Ss< zAmkfwwyUO0ddFm>aw_sanr1zd{lZ`%10)fvq61!1(E*YiUjIX~;5<$jvsGp^Hre5J z#={%r0-R`H=*^7th8M!n1J)5Y;XD=D;A83%X?V{$2~JFCs?Hy zcoae^!oqE;869nL(@P3F_)p}v|3iQKIxh3Ft?nK62~FWM=;@#w67-Kc#vAp%H|h$c zR7>|%$WI7E7l85IgWrs=zn58qu)hoG38BPZj~((3EB*3Rh{9oVFiNi>-Fw<{hbuI2 zQRGQQraIrDQfRF!LNCMN83L8@3EvEmb|_id#0#Y1xDU`=`ad)ayO_x(#UZrnzYl6kQDs_{9UyJS--2~;YIn4BPuBvPFTW!WjRR6I%qcj3 zWK9^3;w52K`HCGD%0x>;wtwFnotf2<;A_>je-ALZMb`GQYPk9_ZRzKX-hEW0neHS% z0SI1G;o$yptt-n43Z@^vGvxla##BKaBc%fgi@k}KP|9O(bhBPH@&LKD5^+p)ucv|Z zvW=LQ?Z%rCdv4A}a%svg7d;nR=OOh>7iCTe5m?nbYykA&t$a}7>LG~B5k~fQcC171 z7QQ#|TL!Nv=6pemAPb^m@2)(W)`!!EWIqDs?T>6~j;&Tb4kREH+b|}KwD6~VmB-JP z-3sYN%A<^<-RJ&eChaH0NqM(>n(vQ-aN<1quU+9M#3UHw$-LvkUx};XEO^HZ%qJjz zW*?@np?V@bXsPJNZM(UvS7c2Gn`M;^@M`lkng)n-5E3Z;Fd&{~Me>?$NeOBL8~f08>0@@+ zC-wrT$?;kcFj3chBak3e#@KOG!e+CJ(^y}B1Z&;Yd02o{>%7no516tk7F3n z0>@n_Avp79Tv)5=)iKtD2;S^fhf@Z0%>AJ)p$koi7?sYOQDwXG zw>J6eki~*J2UB#Or6G$&FcfRc1S)Iqo3`eM2jlc$WrPVj{HP%Q$4cX%C%xjj(ZkS1 zgyJZDoD-ozKzsqeQ8rtj7p~J2q00$9XDE0x)DTJ#i~Ww8P%OxT;aY)B#w}*zTbm&^ zIea#?j4H#%BkF35|L5IF{V_P>y&FXQvSqam0QqJB01jKS|-A)!HpUlvfO_0s_ZJV>Da z%rbkyJMewP*yBL%|5Mgj=&h%2q&|z)@)t+1KtLrj7?a&q|8JtUSY43oSs(He|34~t zMfhNz2o0paJ4FBQvXbs5@nm9IM?+7d$$&UzAT>eQ4De@JvB3PpRi{$=+@#${b;BUJ;r4|VCkLi$@s)m|4bB_B>nhKzb^H2tQ^>B@Cy zf`js(m6aF0Z{%UUV2Yj}Ck6>QE;iK|kF##lRx+fjpHeus>m3&V3s^HR|2tqQkOCJl z>NvketK)ysO2Jx)bNdG8X#-x8QKG_J+Fpp0>b4QYz|*|y{b?sV2B%Ys@oIcSDW5CdVKzyO&Lxv4lF?IQ&$@~ zHEpN1z+oNPc!e)NOut11OkZcW&AU?!@lX@QtyrC|7~TjKNdUt6x28Z={^zDVLBm>> z?j{WE;A0!I^i5e)+bhj?II$zBxcBHN^Y7*@xwv;ktr(KeD3{3vpKg960v+zHqR40Y z4&@HiZ>lw9N_ny{W1e7qU$?X=UF`70|1Fh)np$`+Y3F*lBq)9|CXtPN&Q=p=GZu`rjhBgqHoG~z(?}}EdPqTv3E9N z8EPg@jt#u|S>(yneL(;KV?)*^CV(YIam=n56;Y&@tZ#G~jpj4l(e5%uE}-(<)CI)9M-zkG-DF>)aQaX%46kAHg#V z8)p}1#|)3rrd1>t4F0QZTJVi5HULy^EU`Er3OFBKtCcm?4QT_hX#Q9tnPz4zuS?^r z+(Yt%q^2a02{k7Bz%t1suGsnZ4*_;oI1IFBS^jUqwKX-{=Q{OEBsj|d{U~rTY0~k@ zrTb-xU+g^QESF)1NrnWJ58QEF{n;o#-XkQ3h4rVXcVX7fOFcJUkM(WZHf%>_(aVfr zr?g5g4H2@%?rPtS9FXegko>{qTrKB)B*Yk8kmTmdx^ZKK33HkP^I_sJzRp`OgHvow za(M0Kz4~(Qu@TuKB(SUE5hs`xRe|;LMHa3oWYcfoNii(UP3|3vf^8W81lj3NKikG$ z59ENTXHDoE2LDK4Emcw{O^sQ&gq(fRNjD0u$<>5y*fx4>8e2Neng$mJ+Cc>lpc`Qr zI$+Bz6tFXi2Z7%DIlu`T5xa z;Ly}C$*Xmhr^0aiPj0thMYT<9AlACD?EdmD1DPWB4aNFJfqFj_4H0g|=(g!_(oOVC z<0O<8w021SE$Ehig=x&ack~lXlOj0e%0TG_sOtGJiC3@T9D(*M{9xuRhxttWz8%?x z>h@M)=^4n9GBxtg zFcyrgcjs(jZ_-MRhScZEN@<4pL9o~_X8l*qkCr@_?#K8hW-T3J)&&&2P{t+e(C+>8 z#GyFKhH%uY;E$4rcoJuIezTyB@yWgip;mHSjz0k#b^N65)!a0lhYu8g8qM0>blSHk zP-{8UHES|-3P~>ctw)6Nl-k;sDo%u?;s(Gw%J|Q`E64LozqXfzyS_k13_uU`Z~O%^ zCoO0VQ2JZF|1=RseHe?r8-TfJPtPR2^_De}GK10$S?*%qJMP@%Y=%1Jw$kady>UE* zgCag<&;beXK%$-*z!K}{Lrl~wG1|J+>M+`je(Cp2b6Y|oYT&wB0iLd9?H ztSSQv^P<67(zu(DcvPhVTPjd*HYJMq^t5Yq@(2T3Q=1Vw^HN?6!*y1m!h7eH(SYOw zr*`LN8l>kV`TOipvduSl`@LmZVjcy1ClEt1}_pN3ZNOKN6%==b1qo_w`7Drvj zxdxrvMz}r~Hr7#+eSR|Ar);Y`fH+(GByh@cjyOr{WhKgyI6gP zTA8T=OlEN;2wYzDs((EMA_84?$kyFj@|7E8yQDxl9O!rn!6A=43v>5z<+Ou7<(|^% zW9bw6i(gfD_aAi?fO_!~Y$MbYEJFHE+jzE1*v7r-b)4L2AkVrsKLu1ta(Wc9KU2gI zb(9OGZ<8Uw|I-1%lW0ALmmUb@#aRK+-OMOs8J!Im!hPbiBm*Y>>~fqCC~!u~bWf?b zpNrk>plcG_2d&^BJz5z55x&&>)EphHo~)`Xku+Y7)(1>ztp4=BjsZnCCDu>kqd*n$ zVFnL7*W*6}XJHVB0BVb@<%K?Lf;eCtft+4j(lq((zB}?3xzon9$LkrsB*TnvC5a@f z7c*lK42X`o>=lP(?=WddNYp&yg3bv!=A^)W+(LE%_N~j{Wl4p;p}eWAs+S-G!Z@Jp zyfRyQqUB8V>hsd{Q8unR<%j7U?Q zFtc;u1>hM-q0J9SjTHOU%m=5_fcgt2%h_cHOsxf+Q@Yx(UMYArEl3O= z;P|~D>glWZ`-jHyZwZoU?SAr>&q9*HR_`6IXOy((jPI4G%Zg~g*{MrWwIp;qkyx|f zU()!uJ%Ec%qN&2Z7v>6Dlp9E!NO8ZR=JVF}R1yL|PL$~&ejbw&-IB7m6XE&d?e0v1 zif(MXnSvIQYGy&A8#(mCOJ3$7f;eq0pS+U(6?F*X>7v znW_94nVm5p>nlgz!>*W2XSKgq^{oy?Me3zlxtCYJ^G*AepafOx0yCldmg&h$c-5+p zruXs4uYDi~B^6pr-~`9uz8GB@{Y=~W`9(l{uS;%MsW&!d&76b?Nnx$q@9aqFw9C>R z_3tG*jOeqF#o*&bLB?oD_5tFcyKm8sd@zkIp)Y}e&UlJ#K+#G9x4`j9%;(caUTRLmf>Y^_QS!=&}Qj3?b9R*9^IZrs(a%81G_}*L%0kV=_E( zJw9?@I2Gln{HfbnQAFT57x}O@j8ovlzuPVtnZ!C~!)}VG{6%LDUkF`!?AYTm$Kd4d z-3JjKR%Y=qrijeWKDHT51X4sn2xS*{1b?(33Nk5C-wORA-%N6GcnYLlZ(7B)lW@o$ zsC{@HjgU;Ab`n8LKisLZUb59MeRj9}dFtW^h$|$5oGyHV$9Q*{aE z4c|DZo!cJ@OXaZwdgpfJt-WLCc0bj-_4f0h88l2{z9S_Ngy4NDNsrrxIl6$qj^X?_ii1LMDm(KIT&2ptt`N{3(1w_94Ev{iDS6%KkeT`CePG;+X|%>vs*U7m~#* z8Jo(KxlHRC*Q0ya3j!rVl~q*|d9}=tIedx?zhmRl5;g&J0!CX$f3MC}3@KI7BnBqs zr_28Ij>+Zvq0S9Gm%kKG6*ayoru1gLO9e1GX)y7&R4%m;#xrqK*Jgmhx`X7!!HYx7 z(qjgeX5G~NpZg}P&Yp9q`ZboVc&tuoA!FkPEt|Z?vYux{$95e-+W)n*sq?cW)sIfw z^|WQ`LbW|2<=%ZuP38%Omc4wzb&-qFEv$qwYT?!Cz$Gj3Z{_xF6*yh7#;eKACT)dJ z{`JPx34fos{hBy`>-1fxlo!7K_-V}}^V*E3p(h%(>I`#QuFU?MJWI|<@zVT%$zO|Z z#I2jZDT-tFm+w4b|HJm2oNfR2_~%!_R?%jYvE z6z%JP0a1~oU!0Lxl$sJ;Qk0pOUX0BI_ERc0UxAk2VP#<8MKK`*C;~E}q%tQJtJbJI zi%fZ-)+a#BkD_%3J6LOZeo=N(ettGKd(&SpT5%Pq$pjckQYf0gaDX*Kf*jchtig|* qC?rtK5#)k9qBtWpwWJsr7(mJp;u=;qkYY|Cv*ZrO@TvnnM9u%%jJJbf$AxaPvfNluefmfU$~&~ay%T{ zvN$|`XAnV66;!lD4wg<)csMvJBse(D|10;HFz$_AEbU#nIR8D@B=spH^5Fe2W}N8C zc0k6rU5Q5Piu{X8n!F6I&sJ6Z0PgPUi*B};?%U?(TYu#l^^go#>eAxOD-L#_4=J)) zepsUL5|*evm3q^6;IyTPqONVy1Cp2z`=mFvq4hBpKRQ^N0c>Y@ECsL9A8B^tmV>DL z&b5wk1>birySZ!Off;cs^Kb)eC-iHmh}o$U)JrtPS+6tx); zT*P5vtQutGvFz6&)U1(t#8h^@&dZM}ui%*a4Z-r_W=k)|kvN9K`Z0U%MqxG>i3%g& zBUjkITM{TiX0C4|J@(Gjjy_BKt26@jbB=v{ zwdo(E_EC!|vdYOAe|}F4JtcqiT4JP7_S^V!IcsBofG!Sh{#~z18t!Y&(av4KJXGS=L&@6i;y=YF2hdX9W7pO+4)l|^d-LL6@? zrJ|tk$+4+^%o@83H>L_8I`&G2sw6+x5oKNN>Q1kUP2dy9lL!USXh_C~0Se8|{F-lf zujL9w|3{+nip4kzY{fLd9{+a|iC`pp*>kztn7UY6Xt}xAI$FE_<54_D8s`r!9^6@X z$T67HhkGdH)?^Fw8a}M{dkIGh^7hs4jx%pE**;+PZ+KML0E&7jiu~~$ftSF!k3^ha zMtMKWr&N{Ls$e629N%JSJ~VVNs7_!VZ_qnR_eV-(hj%%F!^vme6oV1Yt;lby=hZjJ z#n@Ov&oEC>(VTjgn7m+qMgFhh$Nqmjck{Nl{Ey3B+G>DoZqn{Ez0Zra?-=ZgYY{~% z2K8XH6}fIUAr6mQ^dGfx+aZ-M6`lyEd;63@9!hn z$52p|1*P*9i8a84eJwwrR%#3+=Js6v^jHoe%x!Z_2MVe8Vk1{8z3&}!A><98qh>W55V-jol3+bH0 z(uS2S`Qf(9IN#38<_q?jgdpf!e?Huy`C-qKX~#VBrPX(v`>$Lr6Dga2gt*Jw+!R4P zCr7UpxvIjUhYv-ZFaJ?L)G-FJ8(5aFBL8ohj{Dzy@dUWonE?QH|B^g5aa_Hh8&Ceu z?>m{LN^S~%7`Q~r!W2WYV>wl%RY6ZVVDDnfAIPrbv>vn*DcQC(6LgwN|Fi4 zwey1X+>s5<;}<>_Xdi&Zkc`TH(}cCpSl>*7aAcTLhW?8yHUHO z-BAVJJTa1|C`0g1p>*6M-SvMjrvzFALPN1zD+ztvWy7Rt}l+ZQmn>Hcab`#Nbfh~=du^=#bZZwREfsQ zV!h>9r&l3iw-HnjdBdIqzwsbpEr*=oPG{_&;(KueaJ~~e9!VUFZ5&oHN_U?*6NPghWen$Lp~j82mE+`1#rS6*9Yd)NNoaP{aj{ z_oA#)FkZ|)$$xnPR!ye6d<``D#U=T2qEUXV5fA&{9@on+)<9vb0Gfq-sA&td?WO-= zVf{thaLxI7v#67kE8g;EfBU7ZdLbU`p=s~a+G%ms<@V#=l$N?k{Qe5^ALHG(P9E#H6uSYrNS@VUJ&#T5&sJKH6?Kn+v#8`Bm3p zcLN=N^n9aOBs(8irQW@41ZdtJbT)>!)?$qh3~cP^tmt)(F{`T;c1ueZH%kVU}p9;&hatG~LwN`BVoC@88?rbMdcc!92)+>scvg za4Kl5FfeThxSCAI-K9o54;Am7f0amso;-@Q-vc8qW>H05f3sI-rvBtOsL2yko7%&q_~%l}k`f;rUD8k;ZOid*GJbkax}yvrO*5 z#o^P#x3b2A`@sLuMjbdTIoLN4P*s?dKFC@nvn{h6g7tT#UfTDWkksg=>2)C5h+K zeRDUDF3}Xv!0Lo9Ntub?fydj~M;b?!#yY_-Iz|C;YpKQn2?GGTE zYtg$2yc^EeI6CT)JM%DJ1buOKHoPgz&tCVh32>`=xl-}gky(C8%hC95SSUR;1aKY( z;QyN54Po>iqv4_JxjGn}Y-Z*zz65F7JrOTLZ;P_T0@rJ++U7k_W6!KT+H%)C-l+pR z);<6_E{~rd!cq#($B*tVl9oi2xfW4>>|7gO*}fy$CvmJB z$8iJFamKmCWzI-sK8lYLL`^3&qJ&MON;*q#kgTdit*THnxEcTM5-=4BrVm$)GnRcZ zZ@x5dHgvRZHjL&2)wb|}Y8lkp6NT?oS^0B5$2W=2FFW+$;&mkYs++YKAHI7ta3se; zq{3)^L*8=hZp;?3oGN48tYX$T@gW6w&>lKGHDK?;`^Ez~co{;~G+&^SY|AO1s;F&s z)oSEeQ<1G|(p<5ak^9(P^b56K3sgH;;Q$2vbkJ+>DtfZ@?`r$jLcY`|u0`#BMoTzU zO0aP>+N^}w@~kVh@xf6PeYN|cMHSwyO72~Wwiw`b)@Y<#72X3#kPGI7AUFL3-0=@^ z$LNDL46ui_=ke5^Ze26|G$z(e@C{1hnbtlC2HA5@aJ_l_WT)BA*#&g--UXBz2Vgpz z!M^Y*TZOENGO@)m3eBEo@f(2va07NbR>@u`>8|5gK8$3;n9pCkCkjXs7mWXsog^u8 z7vt~B@~pfx@bP5j$bL7JHgO9WJ`nShR6%y9%C6dE!aEd!0Vd6b@~m*S@U7GilELtj zI_Q0BPFPi|Ed;m@>=*R3c6B@KT_J z(gtF%_bp#*j4p6kRlhG?r0Ju}QqChqts7q)0no7ozjh0!>jf%JL2rGt$;bF{*!B&x z*raq=i<-!v6Hjj{#BJ&^GuL`70d32PcTX)3&Ccqc1 z2j9%2-XS50Z=KqSEvM&FJxv2_4+YDgvN}*3xW37Dhl5=dz44BE&@~vvo&Ujq?A0BWJHXMc zn|m-7#|(F;Pl{*wOh-x}$T&4N? zx1aEVkm#6i7yPcvHLsN3q%Pa79(0C==E0GwXmU3`ZdnfO%X^n37b!GZus{kQBF@(r zXONA39Pt!dDY7I^l^H<|-%-ar z|1i%}589sDKceh^RMiJIh^DKSZLIazDh-Q(D`22M{{tP0m8Gu>pwwVUkE}e+h;tt) z)K|f()@ZRY`@~iK$`q4vJ-~{Gj(mj3#e{kI(=L!!{X5O#mDAOKFl*#96)Du89{qKD zal<;g6(Z5dlb_c!uu`t?Yg9%c>~xqzSHH8TBcSVhCU6?1t+MLa`UI}nqp2mNytE5p z=bXpR&iEU>(S!b#=|9B2z3w@Q`j)RXPD{{M zar_3vV?#-*&@ORx0YjPw2tD6Trpu9|G-EKX9wf`nXFfJBB1{p`v-*{H1hQQHdw?t& zRMCzD7=fVI{#I@Af${G3%7m5sU*6XcHJCB&CRDUi8Rl*#mhrdto`rRhJiF~!sMhiV zH00uYLBNZDd~}{T`&l1e%utf+1ioQ-R*hUz8*1B%3Z|gxV9LFAi)Nu~6MZ_|8b57+ z+J$oz4&2NvR6$vmeWP(mXs2_7h(3KYk7>j^!tzB0Ye2&@3g*SYE7McKbr18p7U(J9jJ=TMF#qe?fFa>y~c5@Lyvpl&p*Og9Knz@K-@ z8aW7wc)e4o0UxOsPt&7I9`S(ysEYjdsaQXr2~Y--8pI8tZLGterB4m=^Dmjoj|-xT z3_Z4sky^ric`58%b*L-yUl1rfeetWMJjPVEV4Eaum70GKaSu62)8emDObvN*aT|Tx zZ#%U8-NKt--&UX*Quj%CN2rGJLummdPD}L=(VOAc06F-e_LH1U@KdkO7$OCNdFI|! z`RX5wJ-Q_;Qoa-%Z;c+-A_dyBBSCjq_Fvu#NnrAm)R`?#?Dn)(&rPJpQq9YM3dZEX z1PVY}%RyTB==gVex7s+%TJzOe^D2o|oj&&H^Uk=-T6U4aP{^&e>fv`-k|C$&{afA} zdALqAi&&p`qepUZN2pBQT7|pFl!v>@k>AYHx88A{k&T2z4O9dKx_Wmmr|Y>>f!(!% zQ8dd~wyFnuVs&}FOG%Rk%Rt^79jRo3RgQT9h*!SmEn!oU?(#3#5cP`8+3j1log}-a z^`=Rlz;kemU>lh|e4_mK5L~-L#WX5^K3&5;!edxeUf)EypNYgS-SJCPN@-MS95Zh> zdtKFMkh!53bbPWo8;e?s@fDqTl4Yy2|%6VYH|9rvf`pptqkwSqZi6mFcZa~=H z(r`!%;!d0R+&oQj)7@E-hu=f~5ts36*WsIVX!c|S81(s6u%oK~)iM6U=5?j=`FW!* za|0D#QtSQga8QMqS}&ceVKR;vG!_9qo{_}%#S!<%m66oAfKs=jHd|{*Tsnl|@q$;% z)Osg+#R-u9t$gUO`yn83J*|_*vP=BjpqklQEm)DIn&$qa_h)O9u}kgCzZXdL-{S6! zEd|;*9mizVicWl*xHQZb^M^B9X;AmbmG?W#Y2M7{>!eg^f}Jl%PcO^%sEHux1Qo9V z&7>Ms=BphFv`>iyMWcr&O$#7TfKjfooL`sEqtDI#!{Kp$)zw{9%bDKUS~X`{RXIsj zbomViHh%}Iu%s4~N7D_*lr~3Sq#vlnHShGJJcHa6ectBe?mpWfXWTBMqW4H)7SpJV z_O!eU{F~st1o_{Kq#5~+9|uctnjWpb%$f&YFLCdL?){Mf*F`C^EYaNScz+f(U07~Z zZLM8ytzU7T91=*0^VjHMD=Igkxrh-lU4MrX=U;Me)97<|JqlTdmTQz<1!BGM?QXx@ zbVcq-KFM;spFgQtl709$8%oXie$f}UuuNq${wbtX^~$usm3y6#`a6xZB;V0;uw+va zHg^4<<13S5AezJVs}ZZt)EulFqXVWloZTIb=L>=~X1y8L0&UYM)XmmRfGYzOp+k~o2E**-{= zs97LZpK;kc)&1G!^jH$%6MRPB!9+Fh#>J8*%dZ-)GQx;D z9&P1U=rY)DEYjF_StNY!;?mBQ5)i#ko79$|*5XS?fY3PDd&>If%ZauC3-j1-5qzwb z>N?_m@%Z<2wj;zIu5a2~gAYzJJ`516(ktt!(wizqPy6B5ebxn^Gz{*yT~=oc0vG*I zG%7$$u?r(zL7!t4ZK`i421zv z@L2(yFp-4wF}$hoB*jytts|aAy=Z ze~$-2ryK9uokLtEl4@nF`-#gkrE*@dH>?%XzI8LgnDN#>TaC*c%QCljFYbcNP4As@ zIF4Q^Q0=Y(;Eft+mQk?bqa%;`!R^+kH4il$`w$7woPhrHy1$#!J38a%)+&NH-Tu;{ z^Ff;GZdPXKJ@AK@c8D*fNuMKe89KST>$<8Es>xG)mXb=FPD%FEeK@p!;UVd2pgc!( ziI++XufB(5)~LYiK2;lDqwnie0^dm9=tUxMJfJTfz_5o3Km5b)+Lz;4CdWXOfjf~R zgA|CIKe|e?r=?rVI_s7J>QWJ!IPpQ+^JqYvIDxm}ZW$&IeMku%*&pldv)x7z%WJlq zOLXWVq-{JQplf_~aao2GhK}g}@#6UOT%Deti?sd}?EjIXVYKB2n=UhYX$O-F5B>WR zqDl#xo!t1LO!LHrc=7j!q=1k&j9KdT1CGsWH2>W>`HL@Y1x-1W8^D=pMlIl>;PGzf z6`f<}uG^{xf5g^kvmWcmnafdvr=WxNBkOLm40LZVL4vaB2>kMF-3i`V^&ZIb%t8l| zVYAxBu*KxOvjk72^4AI1&X%Ghz^{zzXTgpVbtjsaOIv=2o!!j*L@&WlqFW z@Ww41e+Yem+P?nXb7;k91M!fLe$y#o{uS?sh)}1gjuMIHjt*kjn zA|sLy%isJYN`Q;@7}`^pJnmSzSL<&27wV@nUt)ap@9T)uMQBHiDmr7ON0A}h1G_Os z@F4_h`z>I{oj(AYJ32a#4Z&r9o6Q#SMeTsExWqZ^=+F?{7)uO;i_b#tkm?BsMs5y zJ-i$|>Dta$h9@H;sJu?LKDh1v7AKAbu6$Ka(~CDvS>|KhqRMcEpKb#&TAFia_vOr6X2bJVv~;91I@JJr!88Ig+GGxzC1cAmhQoMY}*pl@{!3Yb^i20hth%khUV1Z9! zQeYY6PBx!sev!yts-@SZlWeu&7Sx5{rLrS;O<&z1x$8Ri5^-_L%IWo>pZ*~Su>kn3 ztm7%4ABt;&sO1X_ZXO_W|N7=YhwV1rZ6b!J^nTvx)gP@MRoW}F zXyZQbDeY&KZ2&Jnmx%wQ-iW2da-F2iaB6qi`Ya4T6V^OeC#*tZ;flp5nPg|;HGJyD zjqQ2d5xlr&r}Lrg_voVdG0IeB9TE2a!P4ISi~q3f*RnGGWH=r%E%h5wey=HH1GH|3 zIUdy(PP(KENS*cKJHnYV(sInf$E>r*O=@%-t(Zx9)SVUkd06T23sv0P;slpPD6*{X zBA%lB4%5lciQ>?WTe}Dl|0RLgE;<#rLDKTmea~kF55LRbk`#ZNy{C^kbOqq%L`I^$G|Ib7 z^Paf;3HGTibZZ1n$_g!?_=Fw9v}+kQKvjUE2QE0~)xB;6_1>>_t(%)&FBmVB;KJQP zk#OKVA}xnb(lf`^aXa@^K9|Y;v8)B41}@v4-}#LU>f6RE`YYelHBd#I3NSNUE5O=5 zRT?jngo~$fqKR#oa9@9X?(&)Q2PyuH>0gkz-C>%ztx7 z?Av&Np_pNpzdrEkn>s%J^cXI)Sd)wQ~RO9ZAmBcYN3I1H%xtyLWU17+t8{gACP{syg713atFZ z{O2pk=qO~Nzf5{2YzRDYfFMCUOFiP?Y-w|G3{MbB%j+(z7TKAT}(GdqQtv_ z26uy-c2N8Wq!fd?#gizm@taoM4nTm^^#g&aF=mv_ubS)ZXvfy za$7(AUk!|y%u8w6kAVQKqrjM5s#ao#-WQ03vMPDpv!eCTvWB2K%o-GRXq2JaxCX*d z5&E!q*B{WaKN|ZSL6+DX;L9L*OK;TzIc`B6T6*>H6k40Qe;$$4`hA++|uV7f~ID3P8$k7yf^{vM+AwQy^>CbOs27p z4m75L4Cf&KPmUW3oiRw~Ao{jo8lDj~)E;qe_$RRyhq@k(y%$ws@i5U=>qfh|HVr`l z9f9B}lo>{%U-r8@zS(D9U0>R5CbSpGkeVtv&Xc0XP@jh9HyECKRP{-Q>blw!1{{Ub zr+{8S%Qx7!v*IhkNt%(nAxLh`X5$3-n#_HRXMVIEJAAt?4g3TwDb7D7mS=E0xYO9R zM95SSy;hke{xLI(o2ejusUa8-!?B~#&Z{2K{*@>ZZ-fig@grI52h({4%D6YL-~{6p zu&Mfvf*IaOyqpW2B!RieLt^hKmnSSPddj#KB|*Y?L*tBVXPFrjHs5;3K5W>g>Uh9xk#{{<3Y3|Ik3 zSn_UKE3Z*+%Ut?}ovS6Qd$r>d`wErRWW7{$q$G&Hk6e~v&HNQkcu-ELI70nZ1#3p5 zWf+FJK%t!z$ETf!I8jq-8npoTD;-Z26Musfi-$%?L(xLPd2~(anxnZZg7_!QWH=vK zzRb|y4nhiAP@97!$Qi|r2M?F$ht0Du_s7;8_q&oBR5wDcSN?6IAadTi*_7N(flI^0 zTG=#U>K8{@$o>}B@g0w%Bser$sXvh#(jf$aOzF$XynXH!W|zP3-ujfkbtmi7(KZ=* zeTzpl2g{qpHR}G*>)YP5=_1tNXH|4D+IA#CYY#P%;}b#TF!9SEoBBKTbxRV25Pzm7 zemyZ@tTmTtEaFKbmtCGR(`etd;L8oyUBbwtXOUK*LoMUXC zd;8NA-;iHi)=bk05Wn-ocVI_|>Mo+;9+EuYbf=MDolu%H9ta@@i>~RNqb5pf5wE+5 zTj#{n_BhTZY6ybOa3g>Cy;2$}k9btMwBdO_I~MCt@L1g^oHZ|!PUN3Uduo%pR44U4^=z((+iBBIE5+9P& z&a9QU17am&2ba<&%9O$-z`oJqjO5qP$zH5)2_2gP@?&#PIp5NAwgyOoBVeTRtOFxd zG(r#(H8Ui+x5j$o17Jd;w&Et9OuwZi$k%VTA15BCjmd$YEn}2TSgH+JT9Fv8N6e|c)_oXHY&>tM^B6)~Z z??AAHBpY0}o|cCMo3yZy5qn_vRI5c*Uc$*So?_#y6|u%N@p=KUxRPQV2Qy$=re*X}L9)QWCC+DG|#=0X(*?JiS0~mB1Hd zy0{>ILK~br9ON`yGnoqZ{FyH7 zxB3NC5{oc`9r^+Ocr)=sFkD-gb^=8U6><^-Ab$1l4+P{)=fXlbXk%I-Trvs;MtyfI z4)Qev3m&>93u%V4j)|oCf_@UmGd(u4hg}Xx6K^6mTF!+6gL*7B8Yz#L=>A!ZThC>E zQ)2fVGq_oa2K~Uw@OXLl1H$WHBetcQuklDHg;=&(5PJCIMdS}55Jy8*az}=9_oKPw z0x5=+#30-cA@u>n?M*-LaRmsLYFr)ZrMWve2}T_lyjWnbOWq7<-Y+i(5B>^IG5ud9 zK}`PK1yJvXVFe1TrzYPDT3LV~>Gi(LVJN)C0WxYRlc(Ld2vEHx0d~t*$F1Q3C}r$neMAidgXtz0_Xz#s?3}O$VK0c^c3g;B>YM2xWHl z$8#pHcPplL3;^#9ti-1o%WXMv_eaAmcW5Wfw!C*5<=ACQmZBm?e(-xcO_CP<+A%=VL%YhQe3F5aJ$#5Q~=tnW4o` zE$X+{$`H{JW(=|Qa@ZWCA^2pb5i=C{8fL^c1O3`377N|>kKqFoS-c>l20`|WVR3^y z7kHg(`j;5+CMGXBrd`Pk@&0W@%k=mza2p(zbB&UoYDiRY6HAY9CW3oyIUBIDcrF=q zM-sW&7dQY_kr<6_(knm9N?t`md(8aQQrZ^LlwnDG0Nb;@&&`A#?rluZEspx{=<2B#t@_UwMo>3_*SlAVsQ%jB><0G< zkea7@2JRl>2f8-XmqNc@#f>}b<}1(;?l)r3R#a0-Ed<<1oZ3TJn|2H_GCqc%H95=e zRzcSH|GIRg&2%F?ITZbMGqo@{iE2x`p&S#Qz?Z+~}B|BM1 zW;D1jfxzzS^|*W2@^o!|FNHbXiW?0zqFjQYeD5nT?(Fj8qe$hMg1-OZZot*eQat>g zTVNLe*AYd-C7ZoQbgD^6gW$aSrB;as;egZlxMB7O+*yec+sIBf(~bUf=W8i0e8PN7 z8mVlrTR9gKwjk2Ih(APFla}BQUII=|x9w*x3y@x;9mjL8ZmN#uYN{l32iNw62q*^1Zn6os{TH;6ZIg{(*M?U319~`2HFqzljHbLy8!0N{+Z8j(PA>;HH_=zr9 zad<(@@P!qJ`#Zk74~x#d?FYEHh}!ItX?Csz!F?UH#@G|9h-hBI6DA_zOUWS zs@A$zN6PzTnKdIP+Kkf^SP4c!Fa~gmW5NPUhIVg4i)JwX>-1g46FoK(d?(Dxm=sYZ5MSJS(xtv7n}Dlld6soO8wC3nY8nTAw2c$Bw*Y`Bxkck)f^hny z(KONJZAfUJ8{i**r1w6)5G5FYVsZ{6X_xaB zpGEec0BQacAfhEiUm}29^V3A?pXaJI12**O7uZI{-7OU1lG^(N{~DC(yfNCO8%bA8 z>4=~+@?vY-vb=8{!F+w;hp!wt&YdFekh8{AFs$f1N!Fj01s~-s`ZI0^GOTv!i2UA^ z$nYkK-1z|w=RKnfrs@6xG^h|W=^!8O=B?MbJ2RV(`r*GW2Mbbs%V2jD*}=BjTN*CK zXNUw$MdKd3C5(J9{zd0GI35}GhvItyr(WR{XaFdKG0-OtzU!&G?nz4xCCgK5pIyoNQa>qdI`V0qzg7&dX2yA zH+AJG4+$(Ypq>+_K@F@8%|G3eXOOJE)6333(%ab;i10aEH7rYTXp!$qYSbSEPFDtG z$}}6|-OM|5WbjiS`a5)74;#Un@I%yQF#oT+hC}Med-}q)_2%fXf&z&k2biV=KPoZ$ zo)rePyz8lz1XC@`T0X0eioyB3@BYol*X%JD+qu+Vq;~ln+sSIbQ!|=B7Be{Wh-1Hl z+$#wlf%Rj->%b9}>3^Z=mE^uGEA&rLW_t-o2n>pXNhQVuqL4Q%wRi5S4k%)=;b(je zE!T(nv~<@U7C$Z@)J|0@(ZC;^8XXtTeh7j~_0w8f`+Bw=ncOMdq~*{*dqe4VTxs*54914O%F=qHNOuC^rcDF{# z{rMu38)+itZ|HNDy`Q-x-w(L<4iaChUvFupu-Dxt)~YJY=T1*}Zf`nPd>gpzDB$-R z@5~IzVgB42$;ptyHwJeJVmkgvVN-gMqL(5rNZ=v}ft2tS85?1#`1RkZ3GD{z$cE+ny#t+v6k`Eh&MrlB6d|9ge7p&B zkp{nCa5Tv%h!TsTA2;S{ykPBnFO85-Q*X1v;9;q{-iF|`i@!g?IIAL!-qDN)AJ>=n z7IgS)srinzK-gtUQAOL1)?L3>2PwG@FA8Z0pWI`=?XT0nvs~HR`v)#9T`PYL&D^_d zUcNq`HQkk0ea_PsgjgJ7{ccP8DbF%JFE&ml2dq^pX9tT$gPrGyK%&oSWCuCBes7ca zswWO<%C3m{r(9eqN?~^}&KLWIpqEdQMb_EMmk^w8YhZ_LMFZ(TU0r-y9zHB08|k>` z6pPjw(N&U!^K9(O3_D4;d+?&~E5Zm8}Jgz2h6n%WAMMyksD8 zZu0-Az-ggT!-(PnJ4oe$guVp=Ym}!WUQrS#XEBY>lgy!!YwWfrqa_EZq$w3WS#IH1)2S4(A-P+JN7PnEQ&?E_Kym_XTEypLSx}b~3L{hI@$IgKg+#h@Wc^dX5ni&_kQ8G zu9RwwjZYS$9Dr_ir;juqzt+Q=eZ$VAs{BP@c2(Lh>yDG%8?_q!uA0XWZUGWc#{Ob> z!+eZirdL%jkod=78W#t_QIa$3YcLk!Ux@3;3V?aTDCx9<+F=ezCK=JE$Pd>YmW zFtb1XfwbPXNYcIKd_T8kaE~Fx$p1)G%HyP zf_Eas!Ok8~5Cz}JT81TrZq$t0y6C0!%xQ|&*Sv=3UL3p@q4e&_(YK$a!2cxX8r1+6 z-vU&RA&zRq>JzluCQD4%sj(ErrkfNrn>Z1VGsq*t1eM>cnGQaScpQGF9Jm_@yDhmZ z;nVf9yN@xmigJ*7>7r=rG%N=!LCiW;9mqQsDtI=GAls1{fWuzKla|tGd22QY3A+7F zHAmwFQ-UDsC7h;ul$vJx*6vs+HvCGDG7G^UE z^;ho}z}}3m+;mE&EKa{p0f>oe*6oP))^8a9#2AS`)F6bk=xsV}!~uj;T2+KrNuWoTPurB8e8^R}rAk{`!m)A<B&xU0UGD}5HD*yI=6e{mN~#KZCOh%_1GBM1t!Hse4Q z18Qu9gWYe=gc=IGYhx%c1<4eehH7XMpa_LzzO}_Rx6@;mINm3C{QH^@s%VoVH_J0I zO3cM%<6ns;{~N9>)V+4GYOcx?v@x1V{m=ZcVDW=$_|$Dau<45wEWZt*nv8%%gjs#z zfZc8|tOFdnph=$8zE76~MpMLlLT}|wtz>Uh$wYQ|{A7$kCB<2%tNnRbLX}-jZke+0 z#jzF=G;rl^-14bm7{3|Q{}*G(Hwh_s6G`XMJ1~4QTy1{8s-qc1qw$$I zcg>IPQBLu~?K4PCP`&;`rJ6|Z3e1ya_wJefNFZ}`LDD2 zRbmgCk#$)^=Dv;ccN;~A#*Hs}7!S*N)2Vr$+{B{?W^M~5u33(ESJO=-FK^R?4=$@B zb1~9*^Vkco$oU_nJM$bbT_@I@IiOiL2h&Zk;|C7h37yK65pDJQ;B@a?zHsZ zo^M4YeRaXjfb7e3o35^QFe0Tm=%nW_=EyZ4ho7WOcnf%T+f4+YAk+!=GzxK}JO0LU zhilOx{?ajTJ=r%e`HcHJLa*UqI=fb)%qNJs!SDB)J>YdH0)#=oy3f5C?ucfLq|yh5cuX$G$AmFwwoh@2J;xoABjJ27OicKA+v zO=+XlCV8qoDoVA8n#KG1K?WsV(}lHdc{TpZRD5nYR3Ofz(DME{XYr1wUJ`sBq111> z4%}1>+<+BAlfVt9iT<=b75%hw+s6ov{+BBE)Zb9@cQ@A^^iEwflgu(}6=X9E0H${PLdhi@BB$x1Nf~h#WtH8-=(09mq}~HQkKtoSb8I#VY%J zrM8&1X@eZw8z?EYO8bIf8rXR?pZDuu!#z!OrOZqDqlnmw|9fGPJv02Kh99-Q}2@q>v5~i0~E*?PiCE}HNqcN zl|&c>g;>wB+Y5e)sWrbh}cKd|(Y?_b{J17b5*FJUwfWlhMqeF5qVH5RfYa6{|@J z8xJ=6Fch=ovkH7Q8rH8R@-r}o?PcdUHo$J;r9eTPt|K0-mu`te-qo$}&LhtHukMIj z^Hk{>{0syB;u+Uiuw5MFEks-^>P3j|4bj_7JMX)7(t&6H3`I1I0mQ#v1GPWUoPB>O zjdPF=Su0O{)h!o(`t!?fjz_)46m}bN=(#3S*kaP2dkQpnaw91+{??9ZYw;#7#23BQ)z>y=r2Weljjw6l)?-SDE^X=^^d)v_0Z-pC z{(a=G*_$d7$+)xk`K-bnj6|GO(V^)RuyJSCZJLShZR6_taHg!p6hk`ZsC-&kk%X-# zgd^N9=l77wgBuMq6ZWW!u{EKy|i z)*5KeuB33bA}+ufbMd2tRBdrCGBPyGo`oA5{lq@vwth-9vq{WTVi@$n%%fve3~yyJ z2xSF~v7^5pZYHg0uOJrYXg@5LC)W(>zmYQTlJsph1M3drTTQ2UgBz8|t@RP8aXS+V&k5wCSP~oWN zbayO`;hQmNVkJSxKRMrH-B$Qe~G6S{v~24#~m((5{dM0B}QR#t3O-%aTS`l%DoY^dZWw z@?thIU+6Ugt$z)V5}-#$6oT)dIY;k59DKb)1dCDR^=QJi^rWYn=SSxVU`Y=Og4pDU=He44D7p|ss9Q@ zefJIgAr#Go?_WklWg;3r%?`-MDw=;T${30~SX*vCHV=}ki$6zDzc>`&l*>OQl>aRq zd3r>Yn}C2^_7>j|JCeFJ#B|70D`oYW1dnhUSj83=WR^_{jBgSkkxB87T-s$r{wKF)^ z52{5rB+hUmV5TTrMJbJNDO`h#`cqD&0=@DkMDRLW)F3Uqc#u9(7d6|=$)>%Q8%^1C zN(rJ<{9iT4Y^<_*wPF|w$cxde1j@*DjCF-Kn>m-W^rPD_OC@%coALBP7}mcv0$Ij` z6tXi68Q_n7eQHi{^mN_qI>y43rt^W@XYmo&E&}xn=Pw9E9`RXz!#xw*<_&FI<0msH z?@*kz7V}vt3asUX;yos*G$!nok<>?7-{`4DY1~B>trQU5xksyet-+Z3C`R*1%}W&O`z^Uaiuo=YAT?+GQTzC_BwZBf8u zZ-sNG&`B#!;F_`w)`pMy`3m(k%_qusS*a{eMWyhSeLBwp*N&P%k#O0H-nOS8l$ z7SW(4bEZ@)td*>hn}<;I7BVHMphJgrXQpjr27UeyQC}HUSJQ-v1xbL5yF(zjyE_C8 z65QS0HQ2=^KyVH2?(Xh>ad!wBAdo%z-rd??6a_UsXS%2L>7H2FW13WDbQGjJU&QAb z)b6Bm79EqD8EQ4kTZ}Z=f5L ze#aQ{SvK9?@K-YIfN-jH_|RO|#pPj7DBI@ErIxm3mVSXNU6v6y=_7vX`r1Odmg^|p z76rRLx~gnQfUypKQ^i@@(s<0YK7Y&V6Ab)|6(JhrgZP)$T~Mv%<+oCCo?j6h@pVSw zPfLr^Zx2ZDY7*j-K2Xeb!5t+iYxGSXXYAAva(222cMv;W5z3gm13R4{@q2l3EltFjO+};PMck;DlR4rh~pT^7Lp)U&*MG9&uu)YpWdzm@3 zTKuUr5o1^_>~%J5Ji@&{A}vcYLCPZyAQ;AhDDN|$*SJLwH|r&5 zqX0Ll*3VMI%qS}mAJ>acOn&!Wlzv4s^rKQbG)fafO*sXtj4jAWSr!Ba#JBcrl~Z1FsZC zU=FPU0v7Hzf$y>@lz)&7_N+4WmBDL695l3kiG+Fnvl$f0O+#Pc<8_1aT5jOuL&IGC zKbzG960BsX(5N}#wR+%x*AalP#sH6WO)g&v2s*TIEmqm^Iv@|7dma=$!RBq$uosvU z72#o#?thI-{E(q8#D=0rIU?>W|1$d|e1HgMR;F@&f^=q8-njxgF7(3p*!IB4?wi8$ zsF-cQU+k4B*aZn7y|xk?;%vh2E-2ANxnrC72tdf`rNPJuTV+6{dNUydW|w#t?bl^a z>$nhn_+ta_mx*<}QF2^*8ISXqwc}VT@j2o%W}c0c{|WR4nCUACfM9l_HNN*LY|nT% z<8BX)5d`;$M)LLCyTlQ+Z}cvfrsbWlq)+Ovf4bCpu#SkKVVM&@I>*om;Kk6(;Z+?d zk5ZpWjqX;yU~=aYevcg1hLH{b%E)lAK@|VW&alwppJNeyBt8Uod&eb6gR*1$%!zk( z__v--DANxc>0sn{&4W7C`W@!5W8ZXAu?HS0ZQ&Xxen`%?K0u=H#T+03jV^ScMI?Tu z!E34)3Vmgy2P_VKWv5q2^KbD$Qf-Y^#P*8{f{5L9kJ|}|-;-7QCJEsuTbpgQ-baJ6 z^3z|oAneI}i$zi;JdkI2@BTDL7*acE(vDORBZNbFMVuEEYvkT@L(P++Heh!}Ge02T zPPnMyVmPzh%{n``nwvFq+KEt{(-3-3^@m*X_dEk=tU~6d45*xj8(Hj{}Zn-Fd{3 z-nmQ0IGdW{hf4amZ2VT!QtHoO@YWLJtliJx=7=9};UDD135dg}wMiCIH2t{bb_edI z!)Xq{_g&^He(iB)ukCARYgr~DnuN|DOdSP8-f2)tjbCY;T|BG0sI&Cw8FxH=y#!?_ z<>a9$)uQ#heoM0j-P*e7b!`%lAD`#Unk|2+8h1EwyE`g}DDm9oTsxpEF=clV2YB(T zo;J29q<)uue>r)Qj*OvHGeAKgSBv)7RQG}PQkDB?G(SDIp2z0vuSxF4_?JeUw3U0u zZe#6nis`{$hhy(e9qQ>{WpPu(;P&%YlMxy*-VYh0(=Rh7yCKA#lK5jp`Qucqv)U#S zUf(l*^9l?7e_g>ZS1fK9r$=U-=uNLJ-bqJnqf9BG$2?~##0V*(x4mf zr6?tG%;F+QEG4N@l_+P7HLyMX*8bubyl@C&QRx&cx*OI7EQAV}M3rQvr#K{jtWj#1 z7*lJVJ%OdZaTKNC`D?B~znGy+V|k@aqa1nxg~2*X=@DeIHrpzvQ#f>#PnE#!isDv4 z$z+9kfeYU>Ya3RQV<8!K3r_ce{8GtCwF;-s+SrSvIKnIN1K2mWab%zp48ody-d=*- z%LY6EdUnVC_<3LS!ZlyWM|B9(k^U#pTzb;NxessuDwjY(&a%F?_;r1)5Yaw?`BEVG zfW^XMEaws&kd2fa$VuNu9bAujo*F*H6@1T3F-Cr5mOT>sole1I#%mP#rIIz_bf-h2 zK}hEQL2HiG1-NuF#Lo;~+v(9_gWp>(mq=K?NHW`(ygb-C!RL8*XvGVOe zuy;@cgh`cu-&@gqknna4$a8N6o;Hc3GJl$(ZUhy!>BP-|&BbEUSt>U4c{ET~gNLU| zLTL+MK-H7b-Rem^efat~f3sV@ndzuw%&z_Tj<1}#TTpi^AHQJgb`_&aC*hz%in~P< z!gZo6b%{1&CSj6x`doZa7v~hv_+#*%%cAJJ_4#Olma{69`Jj}kGG40$eP}HSdsd&O zX=dLYf*!!`Q1Frj`qH)fOA3!m<*H+s;JTXLW1TBaH5034RBGhg?fnbsl+w?fZ2iov z{t^@mCZGX=JlmMu{t7-?_xoaLclSlx`G()yzn0s`>^_*`- zoj`75#K;zLZp1jyz;!e_e*3qi_+7>YjV~C+9Yp*a=t`A2vvC)?CC}+!Yb+B|CH?iA z{)Sh=PL2vOV)j8&MI9a`}C2i2G69 zpF!^q`99rNH-wGT;u}^H4F&i(8ck?)l;mOZ_ge2qkXKl=)VDGV*_Pwd{8nvrhNaaO<3o? z5NpaShQiFpYYN;!B5L4&7C~e*x;MmYRxSmcOr3bz2{FbZ1_2sT7rQfryhaG)2+l2-7lGFTXqp zu3wrow08EsIP1LCbybc2xx07ykk;z=T|hMq<@&?&)kQion-WVcIRRao_<|c&e0}A| zdehb*Tm~`|LS%E031JZmytzXPp&<4@U+#A1fVvN7Vw?xJ)VYyZ7%uf}yoZFF>gbJv40{-XM+;2~YEt}T32PvS=Dq9S^aq&X0?ZX*_Gh9yZb8FCvWMl^ZJ~K+} zZ|MDfW|#ic;-CEdAx=M(*d}mwt48lWEaDDuA;Jh6Fes?Y{Sa_Lj`p@Tc>E)h7B8DN z?^1Kz*wI2~+0@W8C<<7g_57*=GrqoRkmZP1b+LLOmu0^qnD%_90$Bdj`9=Ltnt#h< zkvyMEY&$zC6hCn;N4>tf${=EdUgTwdvITupUSV?AWn^m3LB^pE8DuY9L~F^N{At6c zDbVW=wk%5^@n5df+;_?p!Ipv|^5Y)Q*U@ z5=X~BtL8~KiR&bDXXH-+4|PzLXnj@_#=7Bn z756Nwz~!j8=UN5C0yxWx1MwwzPO(P8kk?3h^oW30K`OY2#y1>(D!4vvrKk<8{i!5n z*s9MpR4U7+WFA5FsIx2aX9mj5&;qW+&bQAKyfqB&Fsa8<@n=T)z$wO`+2#Kfz6UON zJU_?m$6aXe@Uzh~&^O)o-a(|+aCUHzuFof${WWp2k;bTE<~O#mK#!sZAZ_uDtF3Aj zs`_=PXS>nHcKcpo42Y$nn9Jibr*kVUvW7z2A3ij=;LgJDG0ia&x5)V)1BTVf!!lJa zC_Q5hwNFn;&j<0cO)H^d9mOI=9Jo%)!%X0C=?mu>ERDN@P=or(WEt4ZqP+qIg*ipX zQE~!8E5CWiRdArpxR&|SqdXM-I-;3ig<~ogo>^z5;~j!NU`NcrUt6duzLY*A#TJ&H z?Oy1eJe`L5L6W*T+=wB?x;w?C?f6^SsPZNEyo@!X=TM>B@px3Gl#&CP@4YERiR_7@ zU3^wNil3$QR{!pPsnGxP+j~KbTf@A`wrYAL$x$z+YP9D8?gMc?`DN_& z^t2i2-rGaC#4pLdG}{#VXcKCT5m5~r`D`Da;~Lj){y%fyRyUb=pXZr?l-H_wiY~@d z)52Z!gq!NML)NN0Wi(-ZKksF{a_q!VS+asDmkQ0aA=l?~pvD$xwsN=5i9e8SSPW=S zV;_s7x;SX`jH5K;d*_L0IpsK*gmJc6FELuOfMiU;KJ2^Cwd+D(0qz+i+{&z2co3?{V6uhF^#Inw>_iy=r=zwj+e!)NAfaO`&A+R$4md|6+ zMHLKWbM)iDsaG?LYr*U{xN4#~a`+iFol(u{X8&vc9IZU%GlKd<3t?v|xtqOQd;Rdm zA0;XoH$P5%9eaay-&gNWS|eM^Z*9yzSNuWy?oqH?9Pz6%JdK$V~sL{3XO^w8k~3wfpun2ZavR^c3^xnL^LJ(KDqq`yR`ypj8v@%p51~a3-FygqJk}G$g6qbrO z(n2K|1DxSg%=MV?u=n?9Zm=KKxLL4&i8=Kq@>Kq1#rZ;|##4inruKL(0PLa6r=93T z>E9m8Kzgw%aIa~ciY~ogxxB66Kvw1TSsJg5kQ}89qNfn6){H=|yg@ROb*kv}3Har_ z)W4IL=<0Cafxn?Sigt$EUr0yj0Zd;j@!1ij(1vZq?(Z&3>jlC1XOBQzUEnA}F%uXI zFiMTG;1|Zlj#%TLlVB{ z5+jI5{Su6ZBo^2J@S_0W2bmqn)8X{BDa%M&iEA>*!>-jd!YxuzRnh&{GMk##S44l= zG|)S!9b;Cxc!k^=?Q;pdQF@(Zx^r?PC*mY6ms&7z1^^%Q|KkJWe`nwgs{FxLl2_^P zWuPaUO3T|Dv*IT;V%DXzvS5rlSZ2ijM3DCWTeSQ0B=s}mFeP7qY3*tEk&N9G!6 zR)DXg;h{&5v9l-6N6Uk=O}gO1_;J^b%m>T$*%KGZIl`Tfa!DG*=aWHq0%`-!oDZas z%;w10a`+l&Q%Db2sCC`ih(DLhZqDbL&#uBalQs1qa_QwAls zJq2V;3bMCLBsdmE8w1jrUdS3!zQ-40_|u*kl>$N4-2<2A9H~DbGN#E7$*3Npm zdT(!F&&+*xeD}O(@3YdY3p#3+5Nox&kqT|_P+*n=`;(~io!sDEe7d*ITX zoSrNAJ>RS19kH8PX*~1q37Bl3jR2P72@dq};SU3*!(aJ-;_!Z3t4^8Mgl?Suhbeqp zUJ$r(NTL}G#+cWh`q}61VzM#)Z3B}bIXrCOGOti2j8RtOK2qSQ>hSj#Zu>>{Cuw)E zizY=L(P|8qXyzEOIr&4j+0_jqXJeY*@~z%cR$n;d&^myrw?e%V5rUE*dS7pyRuNc{ z^!@sa3@cf-K8rPC7zO%xeqyZz^>i{O{}+MvfPZ|(Z;I8^8)C8;rThg26`-R35Qq(e zc4X{=c5EjfL*L#Z`teVvQr=@0!(^J0lt&PkAOE?3!Q6E8b!mNS+axL1cU{>yXC6O( znmjDiy%=|}zE^d*Mh|&RV{7FvqAM+Zx7%sMb}iIv5Fu#tVe_@#Z55$4&SS7%GJVPA z_L+3P3U<*z4gYR)uHPWS%J283U2}o(NzjT(g|CKqd*S<2i}JYAY1N}br}qJpcSZS& z{R%TNzxlS*5hP-3Tzm4 zKU06z)lD*xR{E4lpU59>!AhtV2uv{PqI`tg=g%jvD*gv_Bi$Fer4MBOt`@<8O?HR9 zJ!>lge^={Z8!S|GA1Jis;B-7s8UP5}3~4%tx~6cZiVDkt^=+OA?}-wp7uhl4FO*|Q z%vbwFZy;~~EHfy|eN1UaS}aET3vJUN?rHd0CrxwNM)MkKIiI*O} zzT#yRvw8@ShW35s6_|qjs==!M4c~s@UUtwmmOtrE+}ZxLZ0>`{d-EPi%$QrHZ6;7GWxIqa%?flD%J?BAGL*16tg(1$= zdP=+nfjm))4nl%t$1%U*k1t{whp|%~2RRdzV+*9|Ocg&0j&3YD+5TF}ZY(X5z`RrKZ0N-Ef4@=i2bM zpxQUi4-g+5Kk@*ZF>FRiLv{!5{9x$6XX9R&U~5&@Sc?^r-~ltj!5l$$Xzq`#V&1I-A_-bGlt*d;b> zzlC~@fI>z&D>+fod*{?h0j*C=lHYHhQ+jRWM5d4SL%xF(fCl$xEiHdQgRaXP8I`FP4pNb0_AH1`?qC+!0kWBmh~ zlJlXD1sK~aj;HXyk77v&XkijPrDGSlWt_Ah?d@mNO6v${B)Z{PY)5)6o5uSD z^~4adxXbBW$-@?gsYn~*t|Qs{`@gR$+C6}dq4Y z#MPOXcK7Pvxw>@Z#c8gBw+$2sn(3x^l(ze^0gq-Ilc8XRy#Z=nnDC!M*uIfqV53$2 z!Nn{%>5;7*Go@_`v)(Tb90Anj1$m+HDa^bwR5q$$ftBV_)@L)i->@CG`@2S4Ug^Kw z0*l?nQy}YvNMg`D7-J~gGV!HQ(tR*z)N^h2Y#Ki{)Bkv71|Km31(1$}s}FsIKK^^x zsPPfwLg8KLUl`dEiatASd!}GH2LU5HHb$_uXJf1cXJYP!h&KK+B5h#B8IFo!CNtTu zC=gK4Wz@}CaK28ILoVd<$a&2%c7QB_KLj24>a_KT8ghldE(Z?Mmuj*|%%!dh@C!7a z5`h1RT^z8<^n%xRl*6c&9xnfFF;r!Q3lO3ipA{)Uh>kn$egb`%fDj!&q22XvxI3i_ z_J~IR`NsIy+!ywa+}alhA%|DB5K@>j+{Q2jZ1z6H3NN!ic zu*Rj?s8hU8GBc>%{g&%6z@6*x=+!!Ti4G3sd#Q_^fxQt~(j0q_x9uYI^kQNvRx#~ja>xTt|7K#g>UQk!&!GHVg~ZvVf} z1G~?0IOYv$7S)=@snE=HZ(PN;k8ilSHbF?1v46nJm$oSeR2l0UF| zX|}$sZ|{0y;qw9=;Yj|MBei{ef5?q-buQrT-}$1fx7_U99bP9%RJ%X9THCb~5TSp` zbfvwL?~T0JkH<*Hr=jl-(f%%=fut$YV8aF_)Jqv@X=`&y9vNB`FU^tiOH5sfJd{|9 zb{~B*PgOr&u3_H0Od1Qmp_wu1%@N2h!`#i_q=z-GnOTt(x1L2rHHWtV&|N=4TT~j> zvqvw?vZ>Y(R%N1m)K3^8Kr-tS4GASD|9v~0I9_|~{e$Di)Yw_tUHeU$n9pl*`bBxF zdb1x<8-Tnr5L8slL0sblZbTcVZ5EL5wn6=Z!x37MZS|d5BHLUb;!M)XC=Q!;gsqr2V(@NM2Xk+aJ%0Mtg4IJgD>Yc2|Yn01e?c*|wR`S7y~bQpdo3 zjm*!LM@&l+t5Bh8og+hO9biQgf5AxuWd0+31-`)bU7 zErtYTMb{>7>ZVs&|{TD;)TS*@j&b9BM2+G#5bGUm@e8 z&IpIx+P#&F8$q4P5<%iPi966vX{7tmr27v5Y$c;hqRliv(}>o(J#~}?C89uM`|N^b z;<$Pl=$y#~W>==j%j~fQ?I4=_#P>Gv!XQ=7Y7JB`ZSnKfXHOyRxoI7u^Gzqk|0BP! z%z^Kky1dN=+X%wysV!~nM(Puo*u=nmu1ent#=5qi0VlK7+eeoyHsj#py zh6;5?IWMLVSJ#1H-HWDaS&zMTIXvR&w2gy(4m&Ah<>TlO=R9_dzL+VQ_*$#mgYM5J zYnfeqej37o-fO-$cf*PPmkhfc)9j7AWLZaJ!#>L}U0-Z7T=^)u5ewM!$>&x9Xr&+W zYbb>dqT5-WtSg^Id`=w>zUxp|P0Up4L$CfP<4*h|K0$6E-MsreW0w}{R^Iq3^NQL+ z(!(DyK<2bTG8S?6fEKGOUA1S6je2o{w`TEq)MuG3*4?BY(K*hr0fAHbndS<}1LX_a zl-Z}dakGzzASG_}i$qwF#-49JeD<~mpdAwKLR3D6s@e>Rnk~=A3REs6g7m_k%q6Kt z$aRn`IeSykQ8JLkPS_ynOE`ZZ3kki1G{>=YT6}JQOQuj#eYdvNP9407*#T6RK092& z{qw6*V$yWO~kmr6t6Ju4gV&BYL93BV2_C z2@5R3)$Q1$p^e(hN9@!Avy)#Vn1mU6K~6*)tv9?veP(e_eO6qZqj6Vh|H|WMG1lyF zroC_vw=D@sb#C?ROaEP?P08K;^n@8H+$Rs(Pz)qZ?8>;!D(s8~$K_2BVAHZc)K zpgr;>FBW7Uev}iX79fyC24#h5Sw3pyJI674U<)He^$X!G_2J>U-@3lK_&s@H_3ikE z$$X+g1YhG*h}v_D`!H~9Rk9zkp|6g>$FY38;jD~)#2nqfTQo%n zmG{e=SK<#DR&IRQfB4LtS&s&&sx`DJF{+UjxV3eBzvrCiDNCk#hNxlcDfYshP8(?4 zG$5rnhKU>sq-V^oLjFnAAj%*Po1&&iCb-vhL@8B-M%QF(dCXK;n4H?f@CHtpJfED^ z>zHPuFTKSXznsdwl0$X9qMCd7YVz6iX`InzP4#3~=L*RvD;RH<%nd4q9OLKUS^2&D zYiR{Did2JKH22ontI_QVJJv2OPM`ZvL+!-ftcxa6?pNB9`!W}-VgS>~>)kh}Yqe6T zSrEk9k|e)u%HkE2f;Ow1M${vhDyrYdknka`_WgLS*2mzE5CD`@2L}FX9fgIPVdC}j za;P~6)UB&J?ZWOX{y8O8V6J|Kit_Rcnv*M>W%uTI!YV!FV7w|lW3rYeaPD3@*40V# zqV%@xC9!RWRUs)-r?Rv843;D{-ttP1c#8%tQeT(wdL2G$Kx}^|_2K*A(sxjQf zZb^L*vz6_+=oGn&AtPIOlx}`H+_HC@h(706gAh|d1P$eKA1r*+1GeEx$yXJRb_lsvCO(h{^01L$D*NE z;b+HHU2Rm+=Kr?c)nhAJMrMyXZ28E__tLTHPY0ScCnOe5xo=dr+MGzzxXRAT$?Ozv z?GEw97^XR@E)O^=pYP8TXb7z4({S}C$;&!;vPD|UYR_TIKHM%ks2UBtgX<^FuO%A2 zN~;}R{(Pd@@7xvb0|MXn#f#m_^XoRJ{bJFKO+(G?Q{Hmy)TF@Ya z9NV&4B>IfGpk*?5eT*`E{l@9wYSR=sIg54s%ES4B`>Su#+Jndu#G!rC4Brmkto{`B z?ykarRl{Bwzx|-jLWy+w(f|Ir!DowRuf^Nfdf#tLchvJrn@q?<0X~OD^BFBBX1c4i z^;~?NvLSN5tpnR;dI4(l;vmqc8a*xg!STvSTUg4+=jAx=U&>4h)aloX_)>3{UWo6q z@x%qQB*54Cgk`R87s7^T=W)Tqx<&$H(x7+IXSqBrjc*6KbMG!cTwD}(Sl&8Y{k0-= z_~&l;Xj14i>mWJpv7{2cjDqi@uWPm!X43={Gzp`>V)i zfxyckPMX&>2t76DyASmytM|8G7$}9x%9<~Jp51sdJn}^`>yIXLKHsk1ROI}L%>1}5 z)B>QLui#Pumd!3RpZ)NI^81>pUcU>p|6|~vzgzc>88WQ~XMpCPYnLHs(g9Qd5+5GN z_v69oWo<$`+PSCAJ^JmFL*F{X1yPNvqeiEv^nr6&wE?;Q+Fvcxq14A8A62}|qMe5i z52bekSl~yq@>t_zo>y(K$@l_==BNHWN)xE`y<+liFA(-tgH-`qJIjz5>41OP*&UDL zq4D77!ZpPm-_02Z=x+C;7+C)cXqG>1sn_Sf-CljMy2F`mJsO`@Iv1m=#`=No?nbYE z1ol;=5%z=4z_yd$t~{K@{g@rzK*7(n8^{DglaU?$I;LPX93zCT1JeTJpjRPv|B-|C zvILroybGPR6gX9u=^&I?W{F%)t)Xmz=U=ra+W@5BH}ciN3JdAFv!kCfO$Zd-BYPE) zXD&^qDdU82*1gUDiQ4vtqe7zSG18Ergb8JXgEauwU30FTz?EHeI^B_T^5Y*J*QY{B z7_|f?k`&#WG&G0Cy_Ep>+xTv#F9m$BNIO)|;9*eTQe|uxx2X5`=D-}HFq$6ef7ide z9*m!fYPb%}KVevsDLFc5S_fbSOvJ5{EH$jEi#aW{WEQ0bq2`I4HNAY0h#HlgiB7;E zHuWZ(Ptvi)jO831ygZ&VTVGs^dlWZqklp=v`gru@W&ZelvV8ccI!7p?fu=>pN?%m; z<3!x6{s=-_U{Z`~12@zq(zIMKDvXq>z-Io3?7`=56YC4N;Vl!I$2J-;wWepu3gOdS**(7m=Yd z+%D$d3e(G_xxsatNsmVL?VEmO#s<=0H$e%GVX8&&{E6n@p|85yQ{@?q4lko#@95!| zs!r26oJ}4PDY%RBCLyrifX+z_Ko6jqX@)k5RsUn}@~+@x>i>2gv^TxYM3i9BgF*+HQ!+qTWHo%+B73>nA9 z8uwV&_mnt+H6cNvZLii%E~lBn3y%n4b%H%lDb;4TdSMn93Y3KNS)MOZcz!mUaWAI9g*NJWmSwf7grzkDyYD!clA$;lUh-LrLqBd%tn zbuT5qW4Y`~#=c<~ZY5)SD9(n!JpZG9z-{tH=&Ma}1Wno`8hqLXH5mdM0zFcAs54c) zNj&g+m+hBwjRSS=7a=QSE<#B~O_cpauE&6~IQY`*NgP}3BW6W|I7;uL{WD$$YY2Pv zF|Z?!4P{_Q;SX}lz>b(>`f$>Yr%+?ua6PMM<$k7)6CI~CQh2xZqe(VYcRThaGKUk7 z##*vUGZ-tA0urA~ zG7fHmoKK^;159RMH?|PB?MMeV=7cF`ihy^TkXLck8q}})Xdey`ZHCGAYN&b3q>Nsz zJ6B1@?K))ygKV<3oPcT%Y8rAEKLBRYomYrR4U4qtUeJ4hhSH^BP1&ZM=^T2uJRcKT zvV^eQ#Wjee)J5h_$6s}Twrph6-Pk#BUovX|yX@Yb09zG|O)((GySv6Z!c!%S%7Ckz z155_vy5G_?$oZr4LzuMamrv0Ikq94j+}&|Hvj4nYOlsJeL$|IzpfLUG-%@%VN~p;v zu1*xC)z11I4085DXbjMN(z3R!N3Levc24yv{QLhjK@y366IaZU;fy70#flC+DX`hb z+_ayv-0SxSR2EmqO(aE%)AfIR5BQ`jt`N$iJQxVG7Xbf4T*>E8rd{kj=^P1NnXim5 zSpu(gNsS=Ib&);L^ViOk*TUk)n6OSK?xWM7w_o06j887x=k$69sOOLh8ZsB}Kxngj zow>Kt8l4$%LIzw0M307Cn#m4Pf_GvynO+EXn4ikx{>0tiyLs7)Eww+M`cd>;c514D zEQk)+4=kt8IHp!cR6OQQb2BgF1~}A`UXK2SxO)QnY9RTd&w-G~p0Tjxp@JvZd8#ru z76mQ=kHGfoU}rHlAn1d8v_*XEac|V5X7~ZUo&65TrB4U8cgJBwi5j;9Fn-8JP)pqg zNldis53K|tRr81SL#rX_c%Y?2rkIeH6$Sg`O=?UiOx864iT0gZdDC(WnqON2#v(jb zTXn6o7}LMF^3GT0t_BAvho7pHyucd4%qt~Q46=t`I%E$R$A`zZ46KJ=;tV7oKUnTb zfMa{Q7!`YrvZs?$n%^Pp$_I__=_U5Mv~gn0ZzCjhAjTJr3x)Y_W9gXEePy*-ziuP$ z!aYGyOv4_om1|HXnuRZDsg7|Lg9iwUIdL_7smpb5sA^VjMth_FGzGIl4UEK!q|96Y zbcr{Ruq)H>Xz^q52NGEhJtw#UK4lUZAhSPm0VNu1sVj1sQw#vPQTCCqrTfSLe8PKY zc|z2EO^ZQM#pysGYb+wfp;DJy)KmnQXxu%1!c$L}PlSp!AQsO<(r0>tH;}w1(F6;0@wN6}lGss5!c%iz2j{j;8`CM~&*nE78YhBIO^27npW)+snxA0T-7^+|XP&Gv zf%j<)u9yPCYKf=5MT9sHH0i|qJR(tZO-8IPtk^}KXA5lFR*$_J{@gjeI6=&{80)Hv zxBouIfKdJsNTue|XfmOrI1v*?JXpVO%_iR8qYI?ju9i3Ew=+~T3S8u=4ArW1N)Zqw zE|d7n$rHveZ$8L*<6sSJnjGEF_>T_2-lhKW7_ezq9s9N%-W%0t1L!0D_IFO(oTK7R zZ7u652k!N+t~b_xwu<~tFc0!4+y!i!uFW=Vfp*VEQV2E495kk;#gRx zSxz{ZdZfBau~)*m$Z8TuPN8g_0eY7vz?6ZYQ5gO$o)p<1!k_;HzFNO_7TfM3*)k?U z+Ya=4GIaavJ8+xbwLG`pjuV{X{EOuq#8=pegLyiQR zet(v+hIe=cf_W*WYi%Hy|M}|T4B*Sl8Nx%=GDp$X#Qn#$P4d_J9U`n?^VcB$vPxk9 z|CI$B4C-pAo2~u(RA@;HNlMIZJ#VZ}gRR+an;pU;E#5*p`tA!~(@Kic$z}jmbBsBW z0))SJCu!~HgO8$BnjOlm%9KNL@c7I&F-Xp!y^lpGh|UhA)PhLwjhE|!eUJN1jV2wu z(vcFr_@xr~B_7`$Vm7V>nS6rXcW+MWr;z0_pvD+OKeQJmGE}^^0N}C0yu3cbns`s_ za*6>J)9;i1a&^hDsXn`@k2@#FVsij^SAC^xePgAbo3&YH{C|Mg{H($#4h5CcQ{YwD zEkx7$3AXxODt9k;p%;xz*Ms`zv+r*+AB-JpZ@rG&OpS=`w5H05a_ylOa=p*;ejU}L zk8QIbYSdStXB$~#WQwOU0Icar+lST3%F@;CX#ah?mqLSUarI_5a-7=D>tpaYcb>)j z9#hl9xryOib0U$CQbZm=5ERk;rb9<@)4oV39@np|G^1}FSzAPR{07IS_B8-~y9u0! zF%Q4r)SUMnn3+;bx!Nkop;lMZ)F?mFlAi6^>APRCm45VkGmC8I2(h>6YayNz0ob(P z1hB~-0xQ^BzGsi6$l@N8=}MC;u&SmW zQYIywK6Q4jJ@fkiGvc50N`JMrDKuLvq^9sov0Y!DdGhy*k#SC-H5PWUP={V3PB;&6 zYTYNd@vNFH%VodeWpxJN>fOUCG%!~$r3~McY0Yh>Y;hehA1t2ww(~CiTw8saSI^8; z^SCjsnAo@FUCHCspcoZ(0D5keeS%VeEtg(o0Lm^T%$|gqYR?OJ4MuLS1`~cUqk@yV zO;A4h4)Ov&-y-4}BnbR3*#!7OhNMZ`fGIUHD{8yvc;Y86H-rq0i{b?Bu*<%YodFKU zNWw0dg~Bb21;c_Ogjqjp;iIEs83K#qR_pg_ohM*C&buxfVDjiQMKgQ>Gmr#b<`?}J zLrP{8e)xFPQK@F0O*E3HlF&HP!~Ec9_q%Xwi#v4)y8BLv5okf|7FVSN>6XS7wkqEw zq{bQy<#R8Bb~mO_e*NY4sOpS?XyU!miwQH}tklx$OUSlwz?5d#vR@92%0CAAvvOe4 zpr5YjLu3=)oBHQoKl7No%ZD+ZHYj>HU zahUnk*Ovjb$Xl_@X6)1*X>UG><$-U3xjLA*`7>webG7*gl5s?{>&uQZS=b6N4f<>g z4A*+GOrA=-EM1Z8k9m%%)IYP)%vfdbN+tLVVWT52U)y^)xB~BMh$skXdgizc!JK{v zw4+`>LM9xL?pHF6@MU2c%#Z7!DtO`GHS5<9HR~5hYD%Qhp=^g=7%l2u@r&=xk?|TS zKWf*n2F--@xvZ)thG~O5$d}w+Us!@L9X3ObF9&i@MLHRFBoOl$f2)irmT>T?!=8s+ z>a_y2)$Uo~0or9vG2fC<($1sf8O*(A<`|78P1#e+w5ejs%pYSHML)|#&%3mO2BmIf z{3gS8tYeKr=pSyH965(uGxa2fsh7NcK#48|re#XQWEjNwnpNfYb0b#%aV)%(1em;G82-+4|wmx za>|ceNR^pINJoayH*K;%tH4g6+0+uk^ypja0mzf})RS7gc^BQC+t-nw#S(mOumawf ze*X@kmvgwZcTN9;CT_+QT@O|4NA1J|_Ktp!3M?B`FV(}A?0JE5YLpU^ zAzld+7;DY3$qcBC`K`KAZ|jdduu9hjfvQy)Cp;*QW37+-F!L+h3;nlYmYI%g4;{0j z3ewTa6ju#3>Wdw#j+{`6{0SVH=~;B{TYo26&%6F+nBcWWc6KmoB=8*US-)azB%d`# zO1=4Z>fiL@-ft1=q?2>!7xir zpMSz~_N;~7e`umZJJ)de%i_QigQ)}Y=j1C<4M(TY%!aS5obxOxEhCXNp+BVko)}g? zd7#_ z3o>oOKdU|=u-F1e(nNB}Az>0^r-?cR9Lc=~-(6VS1E-1laXpGD=D_zmJV2~`QGa?$+_!DFGmI(y-9MG9)Kx508;`b z%dWhb+o*S;z$H0-$mI}M^I7#4`3wvpg zN5ivv1%}uxWH(sG2$olBn9A0JEJ$BS&0>-)@88OJ#&@xVbaoaBzAW|+gj(u)w1#E0 ze6rl#J>fui>$UDQ=6t81OXQ3Wm)f%4?(xmaR_4rTSB!(Hz|0O4m#`%s4?CI)wZLu) zr@~x<^dP#Vt(cjLkeVuDQ@D~4Gf>buOU!+B9KOUAJmAPH0*w?3<{1{p<3pBU$56Ig zw?vXR4-1nB*HVe|+{6(KL9|jW_fay)ZA$36<)<`a)4ZMa>1y&6k zGJHDD-USnO{dlekiwXqAg1V;RLjxz<9RRg;9+c#!U|!;FJeRBSciy<#j%)p_z^&j> zfMk*^jHsIN$Bg!5y6bd1zAtrJJ14K*yK{6qi&y@dDV1ebmC1#mhA7m|=svuhD(MCq zqj$^J><=NKwa~$%?ns#lu?cx#$pN^Z7tHRyIS`0gxoPzMM$;!`80t|A1iVdX0VoBL zE8!1fJ}uK|F_?LfOZK6+KwDDpRug%#j8|Is5UET~rVuW09R&wYU)s!JAT0XxqZTLf zNy1!{g0W*-oBbS_-6bX7oOuk=T(2y@gK>*!x|aBwZ>YHp|KkBn=Q~ESi$7(6IYXMW zb0H*LGEnogiXJ43|Iuty&NE9Eza(xQ&&98EP9~^p#z&QeUGN1nlfGaQy7vI}N$%-M z-q^X*V8bDDG9@LPx)>aKoxo#qa6oUJ2**ID&25GCaNP-fUTAQ=^X355rwNQ~Gn zHiSrEGU<-XKSc4P_@<@L7r&Q$suu0S|JxVqC4#_ptc zV;9{i|F0Ig9!Fi{7Io3Bf2f|(`Bml?rK8L;$E(w~OHGQYQEEvPc_j8)NGS!r94SOM z6S8UkP?V$)X4ZbSgy)4%{;o=q)ea5Mdk!xW%PYOlh4^qi1}JE_=1ynZ6&SrVK11!5 z>aPvZbZeY69cUGjGiU;V+^7*oq1!WPN1BL4z2<&+K__fDxJO&}_7Q~iC#U`6k{D5` zB8XKP9B@7@M`$thK?sfutRjx|50USYcc zp@y^PKV9i*Y+jg*hX~ISX7rfvMH7ERze+;+CN7?7LhcAd`K)z^AnsYvVUvKvG^xdH zh4$dMNKT-Eh;Ve;5dkflx;*%?#QhIb@aOJcEL2B`(Ib@9j^SR`3ytqTd$-QDS!?vc zv`}||qW+F^nWXCM)!nDKLvMLdP8~iv{@D8Eyy=q>sT`$C%M&WnH%&3L#!-wQ86UoP zLv_4r++lrJDO+t*habr`q5?{%^!2kCZ6-#$(X^UErjPLH|8DAjkl9mBlrjNb5$8J< zI<=6-iK?$jWGcR^lv6mikY_3RoH2LIfO@^x>Tw0=JgAlaIIv|V)cV6-?Ke9Wt*MH$ z%6l<(r|J+}QaM=178;;I1$t#G5iFAhWs7R|VSE3)?Pk9dCiTnr0@^d!Yni9VLv4|a z%~Dy|8n6Ng@Pc^Oi-tuqvU62?B|n$f2i%XcSk7bi%wn!UIAK=$i@=t)Q0GST;v7s+ zhjtkxq)qGU)N`4umkgJo=BM@%O>v9wSU}ayVId+=(IpB{QUy#S|qU z<>ko{w`pR(tX-<}cq%Vu8L`U6$z->5JuBpWT^MUj+N@9W@lMFl2E&KY2Yb`_9K>9e zCsvXyCgYlzgT&pIlcdC1AKVo_xnBX3Cu&7%U&=QP323mICp~>v`ZQ&;oupvC$d|q} zalB{}L|(i%cvZIbr(f!1K`rYFD~Vy@lFKrTPCbui`Fhqzj5iJ{S?ShG4OdOrm)+_B z!1urww%sFC6X8ujKEUyZI(b%2WsqgPV$f#1Psl;FSUy8?`X2*$P_NfpJ+A*b0W1A3 z00SK5Av`22-B>hQbnA{4q*8lsmxXd1D5K`x$o}&D7*PGSG4+=fO_DuoT++uEgsJ1< z7Nstz=EP-36Yl$e#%ph?-9-31xOBO#fcrB|PS9Vp-6N364SiP+Y5fy-o~}Eis{{11 z_@D~36SoSn+X$|^Xi{s}EcFWl#5E!A(@tFH9>ToKGO9h30d6D;6prHk-OVqjziYNG z-jV5T+!H8GF5!I0PKVW%JNx1@+GhmvOTPW+BvX!cuZg&!gI(EphsF$P^U_G_zhF zFy>Qx2!6!hQj1u~k}DR;O6`?Z=u9*Sb~k>SmEhByT(*EOcTr+ui9ylKGPsAI=lRxn z;kg&g7q!roEHI@yZf9Qq+^`m? zuXd$|fj4T6z%a#~2L`fPyCwMl?AfG6SCa$RExz$0U0VC~ELA3@Pa<=6UGtSnwEdIQ zajf)f0zU?1)qg{jX=Nb3mG7fA^XHZHjLbJDg2q z)An||%u?48|MR7L$?xtfJs-EF_VK@tTa~Agaq3Z5?4kCfJLLQi|6nMyQfU)Crt732 z;m+gQC$W9UJiWuGeOK;NacPl`viD<6r!Hb2kI&o30W z{o?wk9~G@mytB~pRI;BEmwX~3GE%=*1z4&^RPW5YWbyvtIcJk~bNEl)tX%y5jkDj& zDa*I2x~%6u*9p57T#JkSF4*fde=kK62_n$vKQ)ezI?)|??=-%!X zyFSkP@9yE+|T_` z%~7SLFy_FkKbAe*&jN~K79=@ct`eB=#J-pRsN$_${^M`+Ht(t}e^h6ywI*-6iv)Ya z#7pZJ+9(?~zP-6zEtla#0kF$-ol!x<@_Fw*YlaP(vrbjN*mB=ln!zDhVaILd10o%n z{}(VGIO_evoS~wESMclsW{2CoC)!J!pJq*0JE_awu=;IUQKf8cl}7nh=B>|u#>X~9 zy}esqD8m-xoYmYo_dEAZz6?I4_5QLf<+nUOz0BMmJze`piIqyg-?aOC+$$z*=wdFH zvI$YRcXXG*wdJKdqvPz}g z5W8O&Y$LmUlkyW=vA5ynLZ6{`lL+_wh$Bhtw67 z-(D-SqWRiY?(gfe|K6pX_y6$+c(Zd@ z+*@_-Zao7->qJ(D0B=Sn5e5+k4h{~6Kjti)Z$pZirgG@1AzMBP^_O=P=L+a_**Hb*?<;o1Y$uH-I>ftx|8#ZQn6_-*ndN<0;sJM zh(%DeuLA}|MUH-PMq*KFN^nV0W?p(RHWS!Ssn~o4T7HL>fq@srgbbhv$b^#0oK&n@ z*D`%uA_vs^7>M~%w9a4$Yc0<&%1+A9&&FnN`s+n2t^zfg00T)1Me}D4ux3b*BO8G= q_>mKZ1d2HVTyRGeXQZZ<6axbTNEt$0!^#Fy%n5|{Ko=Nyfp`D_U9Q0Z literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-46 site Document Inventory Report - Site Level All Sites by Country.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-46 site Document Inventory Report - Site Level All Sites by Country.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..cd7cfc828d2c77d2273990fa42de7cb7cea7fa3f GIT binary patch literal 123435 zcmaI7WmFtN*DZ`oaCdjtAi;fr;2zxFg9Ue&!7Y&B?!nz9NN{)eKydq-=ec)%@1Og! znC|MK)^O_7-uvvT?opP9hQWqFKtO=dB%0QP_#Z!5KwDSB(c!DP!&gIfFDG+XeO6C< zyI*Q!4!!K?&nd$Tj6DC8HE;qY$cAuB|3T|{Cu!f)RR6rZ(}(9vR*n4Nd}V53X`yv% z*67^$MM50Qr*F`wpYf8>YNsvCm)YRhThlnzK%PjD+YV{iVrImI2$HGnX0b;2;GP_& zj5J%4l+sgtIU)P^*U#T0R9Vd7x81p0u^8`>g%?_^YL0dhzqHh~d|O?^I|>`YuT?*F3z}?mV#Ey%DnQg8efyYnk7R?bjy9jM&$$!fk z=rxwl}_b&7Ritd0qru5I5qm6`!)GV3p6%~p1N?&hT8Ya_5>-(!Mr1Z z%HeZy#H%b1j{s(-Zx?`sfFOZ^fKdK_<{k;iy`hV_ohuvb`>`^yM-G|;Jg!bR{vBKQob+Jc0T zHP$kQ_jFcc$J_%Q^hCz-Ch~5uZty3Qb6MoyNw1rNot*Is1M`Cne;mbIPTC9M8yy4l zn9U472N<|7`LyvhDrKC|7X91cd8^dh*m^FPP^Cu97yIj3SGh~CR^Lm1YRv&-g>D@a6)hT5DsPanTYU$ z0g@`+y(5Eieu)R$k40-cw8dT-Q=B7>EG*gvb>sWLDE;>>x9*mj_Ze}gp+5<(POLua zful3C*xr+9*&{y>2Qa1TYVhz%ss(~iy6%Gkx+Ozo?SwS%SWdme>i#87+5(IGB6 zgHG32zp)P{-x_Tr{eujt3N2txhTXZ|+jZtlA~4#GchLbv-#`OGn`As-Z zE4{dnUNuENwmi^)8`V4iDfcOOAfWo=2Ksvp8g>Se_Z zY(5Gy-wO~aJc3i#BCRJ7SLFXX{V4w@@~>WY=Kl$~LtVi!iygo7LQ8wTiiO%XzY6+O zDdr67Qeg(S^>R-ST*U+QQc>{hV@IQ`T)A1Pi#F>04Uq_0yP%6ZFDQ^SqgJn+n2l8} zCcTV%uWaP+or0Hh@I{nIhFiW78jC3^r05cH(}Y`-tVwyQtO=Xj5cad0EmdT2r8VXX zfpp0YIYXj(W)-GvbFWm>QJ3fI7pZS4e$P@2 zU#b_ZLda|!3ne9Kzf0x{@9dI~-^gYnD9~z2Y1-b{okPdPQr0USf)RfFQ-cyM4CRSn z8ij+C;}y#V;VP|R^)!V&StwBBncA`WQX$)aqHCF^J(Nkg7aYD`?&fj$ezfETQ@w74 z@%!d)OejnQzoYi^*JgA!;qQ*vIx^X&(kV4!Y8?au_|4Ncd58y!*+u=&uO`EM5+Sf5 zP0Pv%$BN$qJt`@&D%>I1+pS-Yza9+bf1knpFe;mmgOTGBp8nxSWjZ>V@Vdw`-l~L9 zw92tW!7UAb<|qh@H^+Yhx5cudyx!`M^2I~^PrTwk5nsRK%b&%D3}X{e=c^<#gumiX z+b?cfSQ8%axQub_zHYsuTnO{7*!1N>9Gf0@JsY>pz+PE|THWiiHT_QB>g8iEZutsY z;W#^aEB*eNKlu0|kM;FG>IXkcEqDWV8Lps`j@#5j=Vr$~)X!{QGSnz*pveezn z2ajZX=jk-7WEc%`kX@PPl*1o%rHD{6usvz6A$%sTyZ(}v>%ni5wshiOCf+UvU)02T zg97g(e9p$Ag^%O6_r+cWPaw8AZ9@3sBknt`1z=Cd!F7cx+MRoEgn3I zby;@EWSEHhI=Ltx=9b|7WxF+`;qEWe4#Tw*XE2~m|L*R2Skv-gc=6D>6>q$fmm=94 z5N!%5{^CAW&7s-2sY}Oea+N~0Fu>`V{vJ)PRAGTLBc79^pnsKh5(qjb-sJI8s1tku z4Jz#f8P=3D;T&8UuN@P;Q?Y7(cbybS?au!yB82}wvQcI^eyU- zuk&;de!c^n>6ERAUqDR?A9rnR;jgi->bAalQFwuW)G?RdXbpP)vB95I_J!e~6*PkL zjPg$;EH`W3JioyX1odp8LldM&7;-XHfYk6B&;X8Z7FbvEwmR zokV+nUlm!_>apk`#Xs(>#hkym)T-P?&d3)1ohBswyW?J<53h%bvIgEq4v z0t;C1h&wcKqH~fyySPA@LO|co_`jTtuRf_(%-8R2Pl|vg-sq~eKc_9!4-ARC{To{; zhCfnzyJ349%JtK)60R1(85lJ6_pg1uR?6kcTJiUL_7r+iU)??F+q17VvJ__4;(Z7s zsS*}8*rEonG?aIpT1zWTi#~SvjXMHQv=;6@!%i_7p?CSQDZ3#c#4LxRm zUxVMme#Z>eIdtf(Kg+-5 zE+ehWz$&Oakx7{dGTP;dSC*7SMm6MFVM+bU+oollkCMwQkz``D&r_`|sfZkH$cxzM zv@m2l?-Xpj!I1pmY#)eTC0-(~r%NeWEe+D8maLWo>C#G8D}r?CC973Ix{Q*gnxqS4 zwl~(fyII-B(>4#~O^hO1w-+;48~6#HC&y3bWDj;6xhzp*<57?kF;Wh%E_K=K9Ggp? z)z?|uO7XnR)?V9x|FOBQt`h~+f9+Pa)fm6^-mqXMXWv+Lc;X>AS(S_Uh z9vy@Ili0hck7i^RzHDc(*<1Q+jNdk+bFFsi-$LiAPKVkv^!@XPH0g^tgg!I2>QQ(Yhr%$IVJPHO`^h;yQAC)!E8x zGmaMzZk>Ma{;@mSW7NBvM&n}K4rMKs#j5M=B&dH#{<)nc^-nb(a-K6z{+GlIeQ?2t|} zQsTF#qn;%H*hP`Zi>KX9&z5`kHj4}E)Je;%>h(WE8Y;;bXWeM+cn`fu&*WErZ=r4r zugaFseYvFm_hY%8&jS|wB0{gd`KB*+y`8EgawBKwUJ9&BT!Jon= zPre=B?+&-MeP_G2g%hX`^>Fub8F;<$sKEM8O93{%0;N2ipOqKG2a-L?Vp_BnHo4j~ zx##pv%EO%xk5zqvBPbx!JSvEbFS}1HuThGE({aZS56qRy$dxp^YwD<=vZCwVc=4{@ z6e!2&Y)%#9#C)L19lyT2?lnCf6UeA-67lxe@`H(Qf6QOpWzxav5-YoR9Qc>yp|ZN( zkvmxwFL0a z!f(v>_?yTdP@uCnb!zD~AN1xay90&dCFe=IBjc8Q>jf@(r2KYRQnQ|NTGF}<*J~#h zCokHq*J_#G^2r2+d{u>=2qxmy!%)&?l8ZWt4^GseCi*7D!mfwME(W}I>as#G3(yGi zj0^K~p!-YUP8ZyNHNf5H;297f8&kKhQVr;!NlSiO_roKT!g(AnYNCOa8!hM;f@+ z_-nl6@$kI&bS<3tjDAP;^8+f<(osfk2EdEs?^q7fB&zBZqVZ@)G; zD$zVr_)@F-&Kg{8d10B-czLZ~%Zg+Sp41%Z5cKrjEMAx8V8IX|p2fu116dK47|%cq zF>#}OKongAQ5bBAjbtJ-U!N^aYNfs1`wO!XI6UuM#J774*tDekPE#MW7rMeAZfk1^VJwvcyhCBq2KG14=WS*B9;IcKa8&oAZIxbrju1lLQy!Er zrDf|Mc!4K*bK_j+3k1iD-Q?>Tg;Vu=9)qf*Y~9aVhEO;>;n&?00`DE;HtJ~m(moPU zrFhM-_RFT<#E{MwhtNX%iPzCW$MJo!6K26PToN#ezjmxh7$Z}AjT0HpMB7Qs>92ze zu?SbmHZLe57DvJy`+~kqq9*D`Hx)zRz+mGy z?mF9vi3Y`%TPL`Y)d@3nUWx(|M7!y^2|1F9%9nwBD8pFi9z*`2cQFl(OuZQ9$HJ?S zrBlCbXF85+m`PfNwZSg_^h!yMEG3C10%|>b6jd)sWjp#xm6AjY;gePTDp|lSXm=CC zjIUbwN8f`x1WAt*A6D2Fx>>RAuwtcBE2s~IR|jpSs$>PV_$>prSrNsYjL!hF6bCZ^ zgfe8SfJc~qeEht9xU^C~_Jk<@a~g(1+wbH>7azH)q`Gx`VVT+Dh!f*HHHjWg3 zevkSri(Imf8ab&Vn~!GGyNpi)q4Oic26(vVJ`TIe8J=`vk^*BR5Y6)v&1@5`_}6ma zWMie6MT_IWF+<#qZtyyXUOs{NC$G>{a<2IhKqc%Uvmx+F!k|A&hi^${a)lspOIQ_f z+D&CAPSMq39|GK;0=N(N58yuRH-P(QbyYql?rMK#T{JK$NXc3QgaR`IU_k}arU7QESxnfXuAzfvJ(}YbA+%STKZI!-poXCnT00VWH&#&7wblw`DH>p? z`H|~G5@w4}K|z0l?9&%Lyz(2WTduJ`hfJ6d zT;YR^b7#*#=&5|w!WS88=K}nz8|DHe{z(TZj5$wJCw!*)ke|~csemAyf$&tQERd(V za|UvzA&3LM}m<$A^@cvW)hk(q(5wDIoD&v7!dZQl&_gh)y&D z#6NbTF-%_KW^jA#6Q~T{%G5~&$&tT*>Vuh%CpRH zDl*6Xf*ah&EZ;zf1H0LuJH?xn|Ia1b9%;K-Jxe3ROvTy&o3oo6TJZ;eEy4(G=qp&R zG9|?Xlg{N_IT!P%;S=6>3X066=nD1af)PqZw!CmL;@LyPpgz{;@aZF|2Bf!P67kFU z5LD6tX-qUxPrfbGUeh0_#he+Yl6+$vwWm*J++2taLI_*y76eD;xPMn>J!7bq106z< z*}qarfBv2!E#az9@|{}JHb(_BEjTyP-KfB2ZGtw>`a+V*UCs{vpYP}*(m9zIyBi}` zhDJ+{on(+p5yq1tb#KS-3g#^PkW~_dyS}qggw>0cq!_&b37XDevMc+*&-^b0BeqS! zlS_$__Vske9%VvD^rwcx^qjVYv)555!KG*TvOlKTy9s`PE%;O|3kW6(c&1Nfra;#q zoZ(6#uyn_mY5_Rn?$OWmbo_3oqjV;HxN>lB8e4~0hJwc0GF!)iCpCr(&4bAF=M#bD zdXo}COZR1wkz_IFR>f$4U1XA5yVVb&GkSHhSCohmzIp(JgT1SbF$K!jtjRHB=<&)R z_OAs5iXE&nnM-MJp<=q{-^bIUSCNKCj+`$>UyB4fikcksRMUt+^r zy3&V{2hG!RIfKx#7_malP)!-+@f|oc84nF;YaB1wT>`f*Me@AUoojYkYPf$WcwJ3M`fk7!xaMLY8>qFr8z~JA>xvSuo&E_XcdG`#L&C=zO9YHN|*JV zVHU_T8|GCB)AY7>b}hDt7^D}cqqmec>y;-9Q6x@%w(B*(1TIe`MIF#!JVWCpYU>?M zs5QmCH7sjcm$M#XZl-cvNwHSkCz$`vK(?ZB-yf@SO)ZSEn24A}suM4Mbf+jc3-G>) zFxGH2(ps^4va3+F71%Y-2It)DmZ?#eoalyw(bod?iBfndI1QZ-!^0~u3NRvAV1dzP ze4P{I=V(W$IRYWUyPY*lxJZ(IQl^i0UZ?Gwp%Cr%G51>0V}>A6HY*Iwn6ArDdG;4c zy|}+fY{M?5!yzerWN>)9%S_@(Mh5ap;FV`(``#9pFC8$6FR7(X zq7jyBURcJ_icvfA9IKhsa~O%3_QggTYM1uNlK(<`Ix_x@DVN0kSHd}+B4Ih4hDn*+ z1EG>@zzQTj3hBu{?qAYct}+x- zDjoGp0}AMvJ13~|9#iTp>|q(kU$~X^zbC&1w11+3YPn_mBq7cXA7A+&rL0ntLEB-M z=RDeU#-glJT5y9k^+5Rf3GOI%;LmQPZ0`|W}X}$ZeBesoyKLx80Q(p zUve?CpnOf)Z{wZ{$<<7qrfiW>LDHtV1>ES6hI4o^tHcQRPgk&}uy*SMS~sw2ozY4U z^P-I>gOebGHhrH7JYsEkb6Vj-aO0xHlZ=~0(m2A`t0)EN(+M>~7cx_~3rz@A6yM5wGtzdc69~g4zTppsSjZ~BVtnrl zoaHB$!|!%FV8?CE1qb>HgoBZg9hs%SqQYmp^3|LUGUG+ZH_+wX2DdIn)G8X(*0SHh zQZc9#BJn}bYIlP_#lmKf^oGHj&XG4Ui7^{W=Lyp^Vm!tfQA^gxvU?!HPuoY7D4-P~(4ch$&>{LgO+{r1V z87!MUlZH+HS1F^OgGq$xi^hqWx0HadxkH`s4O}jSyv<%UpLzIOA>|v`oNBnQV_1%6 zor&#i#qT{5SN6OYzRlC2KyxLlZFpIBQG+09F9n@o0|$(Mm5cFUX2xMh8xd*D!#MJj zmG~jXUr!25Nz|Wrw^iKa`dxjWI5dgAc{&XE5`)%;3UT|jA)h|g1-QF^L@l^A9Wh8- zWDzgvWP9RB^n~awUyjES_4U8q38*K7_hxsbU4EMC_pT>9`A-q{`%e*81Gr(M0n&=&E48K&H56Vk3!{W8pSZpGNb{> z=e4{WNOwgac@Yacw_UuB3Jj>ZG5t5jlx>(&nb~4jiDB-v4-KRt5~4GCVTWPicwqrx zD?nN@q26un&hnr@B#@;4rk@^R;(^_7G@%ZaGi6`YjFCL%hSRhk@PqhGPgsucby1TI zGh5uRDYl^*lOpP0Zsfp(dSgHEv#b)oMW{yq9=Fk?B4T_6RztVep^ZJSk`KAry{A

    v;uB3H(PO6xwWK3^PXjrfac&2n@f%1Mw^qbNKF@}2(2rp@ zF?}%_Y=p!TRMw&0B!&OSfY{}Bo4w%)TwC@xoIUi#(MjYVp@{&5E?f#eOtyF-jq>o1 z)}9W)XQG^g%jq4R*a-5-cMqTQnlK1TJDUWSWCGhU0B;$K@T^@Bi$I*W6oIdGT_F2s zZCChKA`z}mgE14`C&~M?Nqigu)5bE%``ud--9z=Q5b;&7-GhHz-j0H6%phQryt7~9P0W? z!Z>-ovMutq;Zn#we!~KFWPxC+ap``Gaq@bn@Y$rezfo*s52*659EdZq2@)B(Et%=+ zoH^X|LuCTuiN7bAvoZjmxd?@P$3?}`-6=FS49oXpTi^w8LvUEr?cv>M&P;lxO04*) zB+~v3xXtsRi0ZHSr98>hh*Kk>{IinXof#0(9xK~8bLyGDF25M(o5o;mX^TRKA|!;Q z)9drS>UYGT6yym@pU-8GtmMAAca|zf8dW=L4H|fhEE3_aQYRB8z5HYUaFW8bNQQAz zIB2%?qsPgV6Oh%d17D(~cUgs(=B5qL=HPGW+OsR^iu}@AY%TlAYrwtR=h_qiy*#@o za8@m*scC)V5M;3~FxfpI9ic0q{}1TB{|oxg6X(UQ6X%Nt>N)**@Cx(_EcI8Bv))dU zQDDrV?Um4EM?6()0RIyFyTqeE%~$AY#P;PIDaoQX`iH+)0Db`vU4m@_EkX)6Cog56=#SvPl5}Hk1S(30}S(luR0O3--|kM9^!gRPiv?mecd3Nq+?d^ zBnZUNul;e1#R}sFm7!iu+%!OtM#t3Xixt~vtk0Agh^>TQXe;<5X6iW5!&9j;kiPIV z#H^Cc5*qys4o|K9!sEb@fP@Sj+TC?OOdJs}@ub12NdIb@m)+ve{h8rYkfv+Lf^J&0 z?4wE@Etm8&0n&kU6DIRo7Hp>)Kvp{2ESoR%q&HtI8L)820Z{K+7H}%miBDN$4+Upr z&g2w8vu#GURv-l3zqyM*%m)jt9(zkeXzare2MaYg4#7?K)w(}i3bMPl-cxlLf>sjM z6egeSaMcM|rBzEHS`&$M#)FFz$5w;G^rV)8HI+WIWUU>H@jt!6=O_gP?$?gCSrePg zb1CjYj{`+zZR$OWZ@ApoCOML-bX?=8*1y+f57p$Pki@CoIMop4@z2c$#m}^-63VrI zAeW^c#1tbFw0>nwTwpcdWS&&9$|?!>E9ywKfs+-LhU4z|Z88J(1clR2!xt#mmzMx( z@xcj7$l2Pcis>h~`HBkGo&gCnqxxV;o2CsXVVduBCKXuSBL{UB-=zPX+YzQpLjP-XV8`^aduDAW08S@ zeor;II%NRQ8X?{B82_M}8geE=rpJd!+WeLg=LBH%Nt5GBO=WMz8OZ+b0xyRt%~bsJ z;2v+}u7$Z(stxrWqlaZFWfQ!~n^X1GWvQ$-MphG2S*OLCyK%pLCe_3ZvCeHwsw+%s zqxVm;u5pXf<6WE;ShXRpMA1SG{B~I`%+eXg?hNMNswCx5Eu|&3?Hun*#=uTnV9!83 z@$>iJ;IEeZHv5c)8DFDAL9HD1X8Vk{@;~>tbnSivYXI@{4&`i{B>uX zD4?QGma@dg%DPwFH;Pe5QyJybc$h@!YDCg%dG#Hi+QG~4X2G1m;BWdk`j#Hx{^2=1t4lKi_Q_3eyg9&71iel6LDj}(l1 zYvtr;D+lk?Qe)4Xb z1J@Dyy7jb_SmP!P$n-iN_V!i|it%I)-rPlEKWgX_$TsqH*Vo!K*~5U+Z@dW0)J&d! zI7SbyyLWAxwZ6DeZ}=^V6d2=AYcukWG#TEu#r8OXvi%M~apmwb9ehY31PB8-fvtNV)lnNf2$h z1PT=n6>rW|{byBbU0OshOx0bo<3Jv^E?H_fu|5eDRlEkf660nhLZr3$)CNa9ZeY27 z)*Hck7~v`=(->PAqOZRIi?Z4DM>$y2pjMy#h7TAuprFvRjDQ)ggvuTnRPF<$G?uPF zNPt(XxPMS|V>zbd;dQWkcA9vEWqhwj9P zM+#8HIw;uMO|ir${O}+9Pi_jtaVW+Ls++`7kBD>Bk49bCR+`Cjol0WjLE~BQyHLSd z@YL07`+?UYYGXyS%u$&BM%Oi37pt4L5wSrJs8gU1DHdWQ$d&uw)ke(Eze`j>c^$BN zUg&N72$kv8l6k|uFFd8PmXj{KI@7e*Ax|p;R)cDJjvdnC+*z2{_JyUh?)vB3n!YJ> zt?S#Z^6JNJsdhVIFWMy^ITp3PtVx9H4T#t0TaC^;xJ$2sGU4>G0uOsR2h8F$^K4eT{S_yP(R41?Vv?Aee%P! zxF1(?BP6zC+dycnL6A<}qN$4bs~BN8hOGhg9|r|9l1V-UK8DZ}u9$FmRMf`G;c z6%0baC5`}p)E*d)*B_&6e;1nY+z{*sFy^6*-_BJQH^bMkUs>or+C(iv=uhCOju>+z zDZ6#nZajS8;C0rBlwF_sg{M9>II0I?-pEzkTN^;1=&jr!L2zv~;RwX95A!~AAX=op zWmAn!_tQ`3OaF?6X?Wls-EDx~FslL=9{-;xDW*9cC35x1l5yL@7QR;ZfUgBt- z{UV1`W5>6<%T>yGs#K+4b8WyPEWptwUK-P?YCYC0$>bhXILPvcWYoj6TqzR2>cSfU zl-5O~sx=m)o5(`B2fPmd%rCCF6uGm>#JM)0ek%Lk-%cTHXKCjbB2-(2YC^hk-El>1 zWiMqce~hv4LpMY0;dnmW)(Neb!7F@gGxS09y*PB&Fk#l{z1Z@SIt^0@r7LfXryIb# zIDGyskf|tt%rM}zJjh&A zcTK$d4CtcUnKd=S_Ur4uKmKZFT@=}P-FY+c&G9ww+Qqwljka0eC`#~6 zIv94`60LEtJq`{Ku(G6|gBP$AepE z>7h?{njLu`oGt>o4^9>tZVrAD*v#!oLi&pe)l0^08MomS-z1E1AN;)w_wUJfnCG4e zg4X)VAw{-85i87W0~Zfv-~$jJfG^OyXX0h+(t=#pM;TunXP=3OtS z{-;yZW$I9WlOS#9URF?(kJ=^Do236%?jhT=>r<#q!6WcF2xKz`4Z@pPFwYr4VhUEp zhTncAbp07VK)Y{?yBCOXH@PP&^g-TZBb0fD^k3lc&qwr!N6cl}GEMxB|N4o+KcC@E zUhNfCRakfQEhnbSYS415*--A@L+&|2B;vo52Yp_JxMey#LGYRvI7xQt(cSe8Q~5QZ zD>$JG_3c=;-!R#~IOJ;SegSl!CI$Q^28e8$-oq=Yz6KUNlbHD&+Z`Z#I6}U8Lcjin zd#1y>jOX1XbLeszc15~Jql##TCsTgSOYY(w-5`2HhwiKjR&O*0Hpdn; zf29AI?O|DvIIBuXObtq}Cf5>a;VYw#gggG}Mf*i{=(0U;7P30&C!<@pPI5t9kNhn; z_>(Gpwye}KUk=w`^S?MYCH&~Ii@6cY>%Au*;kVH)^wLER)$cq}(&(IztlzH|voQxy zUs8M$(2Y`~V@I=p%%dNuInK(6`|z&C#8K2ycXLRSM+1{lof(I2 zyGw}`_cn9l)cCVURY)#3;@=y!LQag~?~T8)>Zp}_3}Pw4x;}|t^dH%nMe;+;Zq-q9 zJspdPo)~3#t4mzE<-1GEh@Eh0QcN!~lR*V>qmY)WD*WvW1Jx&9wM*Dc7j_+;OoGQ9 z7B`+EBqzD|9+Wtrq#5VFj7Q*0)>tUee&sHf{3+p|B1a8_{>cveAY?SP?04@E>`$2U zR#FT{6;M>VWt>Pf*LPuT8j&G{2qeQoLi9hO8A!H6;?4rGKG`9Wm|7E=jt~eSx;Mo7 z@$bMZvy&EC{i#;tv)+D6rR|I){KF=CdIKjOdo|<^w<+8S3`w-Y6S@~;-Ap& zXLzb_E9D%~F|_(^t9DK!%~lSZzM`YxcU`bh?VX}QV8_tqhmNRIl99aLbuc!Bw+!XS zMS(=w$d0!$mycbzdIWS2S{FZjFvjj;X0iOQk5q2t?iZ-2u1qyphUWKBPxg~Vcfmt6 zR97I72)IeLI7z#akMHxY>C*NlCuRI9h2$=HYDvBO+8I?R}=P^$`74+E8XC?i>zl6{NTWA zY(AwPi9}}UJ8W_iZ4wTu&3@#zm1=W8%mPW{12mLBTN z>5#<%{m6W(GQR`3N+Sr^($sF%4EHb6%6;n1zW%dsaeCgSdZR6%90b8GvqH(%52Nj# zNN5&IVo3P=ivp*HjT2F^d6D!q+nF&;jUz&rc57OeP;nYxZF*`MjwqSCS)poY ziq#aEiV!{PnrmBVeDZJ?hX%#dLq|gvdLob7x|@Mq7CLSg%)R-UF>&yrOj}7ys+Rsv z(uTKp#S2YU%(URjuGpYJN4ij+3ZQ`)v>&Ug7&Iy*3S@=nK1GCBf_h4QI_{U1vd?oy6qw4#AZLqtUcEPU| zxK0IeRse@NQ}nQTW17c1_TU|_OX(Sm>jl0(8BVaRw|{CAY!>``73<-}=G2~5X-O1+ z>G+w^F-CnjI}AL0U^`nZ=>_c%IDSh-l$=5?Do|p@d|dig8Mc0A&D?z|xc1P|A++qOUrgQ|9a~FjVmf8_m;9S9F%gV0v=~T)8+BQq&di44No+=)j zQ|M#}jbGYs)&9#SRb~{UULO0ohfh!et29U@7ZV5hoU0Ca6%CNy96P=OAvL;Szr?TYGT@Iht8L)X+#{wl1;fK zM4b7Ms0*E}!!)W+E?AR-6pnBZQkkvAs}W~UXEJ0nQ%OE@e>Nxjin(qKr@6C{*LI(e z5*FEh0w=nz3fv~M+$cmglq%dNh{POXqM!g-Z+&eQn@Re|yzQ+mT7>@_Q~_f*$Zbja zC1g6JNEHWo-k}WQ5*l0v;e_x5YO$nWHc3huGOrdNHW}F)sLGpAs4aqe6{GQl^%7 z2q8jUdI%8?kry0$oXxER^CxgVTHk^jWhob=PJ)?nEJ_ot-`j*xhU!!jcpR`g6Rb*- zuuP%o1|VjxrxbOy-n}eXjRfGZn^PIIb6H=Z8cFu?lnTkFK~dasf=ii%%?2FVk~+!r zOU1#|I8zyFDb5_^L|(xsfUI+nakD_r&o*U!*|klD9^U}(Ji^<;tLteQeFW^d7G;I8 zq`tlQcCy+$Kx(%c7v$~XT7ml3e-TY9CzEX!)1;7XqKo>~s1zm9Mo%oGlpZgmT%rVR zLlfJO3%@H&KYW2p1Qr<(osZKtG@vlcD2kE)0X+kTVk96nDv?fOADj0GJCS-!lJ^KV z9m?Xqft`<~EK(4P2$pxj;AG-faIUtEkw`ga2VMbBVEBU<&UT9Q#GM!hta6(fW@GD5u$*yBlreU2zdge8Uo z;qutHPMcvg!pG*z)gkzfzV_!?fJfZnW39F711`{KnKzZ8$Dvw^;R|)h3nj8G0Hcr@ zT4wRLV+0%0pFP!L%PeXm@pG-~e)v2y=4&@1zC*e4_SZQ1VpsA{GQ&(*JJF<0B3csv zK+lzjJ+EuGt^Tu3{N_}PlY}X2?Lmis1o0*QK#$~6ej{gq_yZj|i!PM#Sx$||4|pK4 z+Q)%3KXm<%PwR6-wzs2vb;Q?6lyjUB$%I-)k2YrW&%2G_$7J##^7zlRLF5!Klo2Uk zzH{q*)vT}+zrF&QhdwT=Jz|5*vdl z5(iZ^-l+?9Ig?lh1yJ|HBK-_N-E=}Q?A&ZbM4<cpjsunHp7HP5Fmz4+Nl7Ng(5Y zAP<`W3;_p#yhisDf3xM;DX}8kJB$vRc$Bu`(a~0CBQC^zoz$rO?2JwSEujN8ROSkS zZ-lC5l2k2Pz&+7QDN%;5n%)aWlNt>uvAaNt1sbX{S3rpck&0~WT`%q1n!_^qRnkh@ zX~Z9lJ-G4HP~Ng$tiQ={tW|U%-SVdL)_377Jhvr&Ag4;X)Z9bxS*8o9QOkpX5)mkc zfC`6ziiphvCZPc)K~w`G@B$rM6aWw;3;-aSfOh~v)CoC3MPP{n@x!3g1*pS6-|f6N z?9j3yw%;2*RFE*|%f|@h6m$V0JWHltdjYB&c@T*leok%hkOfIv*rMW0Pzc#lvJio4 zqEHCLrBngk8Oi%Tr@v3{YxFp(_$D0}LOu9daQC)z1OVCp3dsJiYz#29qS_H7{y2lm zQ2<$@`cZ%cL}8z_n_?z&o16^pR3Ep3_ExBt@CBWbU#B_l9s4)8a`5gV(gXp^ZDg-Fjb}FWzy8;ftI}l3PNtp)J(_14ueE^vP_nEli_>!Uqo&5gp z&n@ls?8(aJ><=_hb3fCfKNEp5U%?-Kncq0$hi7D8Y86ZNqKQy2Y=uie^g8Bq(<$H@ z?*|y31rQX=hMx@8=|KB=+{y2ri&mk96FT_<;bJeyjE3=5bqP7?Z8-a$uM;nL==pnZ zHh1nk_B+4G58ZSLRH5Dd{o3r;>-^Hs8X8qX7K*#@$xQuuV9kW>8Zo4uazUxW$rr%P z0)QDkvbfo;M6(I6P$9%r`$UQ|W7X317{Z0KT!B=#3TQADu4_mr03?jrf zq7PueW+s!Bl5Eqz-FB<^HI+~Rg)1+tOUOK6a^EZno(aq6$qm_`dwjF0o_5R8m7v#m z1jFe~O(qV+&rkVl^zZa+Jf?|S90*_6@JuWY@W^`+vr)v5mMV!G+(%lpRgvR+i?-7T?9+MR%CsM~C zK2b$sl-h;E%C(xn01gcwaA*-2?+%Rv3UFxs5x^pmN_`;WLct%{t*Pxtkb3EnMMcwa zS>(T#I6*`7zl4s!cy@D7iKH+I$$RZKoIT6G%(une@FRoG6}iW?ksgl5X!OudkRx(( z)Rb8s=Ch`%Z~v`NIK$mQZ+~j77V2Q2vOHV?A_6M0HMAn6ED=zN8-Pj-=83o<>GJj6 z@A$q}RW5|X8lRJ6;F;zzV_m!MMW(86TEJ-^gN00r|5;85=Y~OLAs{zieE|?7{XS`9 zK#YQlDJ$ILK5L)g6c+5151VyHDc8AD14FC=hImN$K1BU@6Z$pwEO6#yc6Cr2??Jie z;&Ese)n8?EL|&F{nHtq*SbPOb`tI+%D1^C>x`dOjYsbw0_#){wmc+M~LR)K%tHgHT z4{)q}u8okb1rw!02dNk!2;(JfraY;W5{>ipNSt}Tucd1F)VAxgL{*dc?jBM#2=SBQoaHD4}&I^tw9>~Ewo>| z;7%cC^C##TwL``MBkvA$==3dq4NK-?&iV!Pm9!k^N@D6^gWKE>q7&u-&lBO_!UHTZ z9&H?wAu5T(+rBMwbIY5z={!h8E?fsIP6w-vDxSi-4m?na^1KK<_hsTA(4M7bHsAlD zKCGUe!DY{k>fp2D{OyW`za#(eKKH8t{(!sbTu}_+ zx%v_Nae(P;p#D0hOvv)rnWSz3hN4>nH{R;u5@@Cv!il{8k}YiX{4gpv{Eykzi`#y+ zR>cSFk;x|U>SZYLaa2y-9z|4*$|*ITr_fHEJ3{!jD~WG5zs8 zn}fW0BVoqRoA8N>OG`#mVT5s2=nq9Xg^Z@e6Eb<7tY(rBcuvs(ToI-@%m|cg3Je{dAl_dsnes8?=s0xte z{N<97_ac@bRz{2i6tVo?pK!!D??p`Iy@=&Ipb^Ws5vR13?3Dc9i#ccY6=Iz8oI|JC zh@BF!Ib1@4j)k-3*Tl2PeD|v;;*WK`DqGBQ#5jtO&gy)s;rYE8PH|su)~+8!ykp7@ zyvNYiyKo+&+%6YvZ^s_eD9lT#=By;7lE@KE3`bQ@)F|ac$>Nd=dnq8~f2pJZ9==;u zR#x5 zhfG~wF)jWz;H7KPyEA*T>bm+2d2`99@nN)!oWYf()Pet7W`D=;kC9UQA4J$0Ttg)w z_HFW20Yzllm($2#@(Cvg-a|=e0#COMC63}ZplS((O8m1F|wiAj6;TV`>_hg?#$3b0Wab0|7gS4`#Nk>utE2b%*NvEaqUAZI?Sa20! z!SfS87MvymU_TXLu@xo7$?;QM{x|doqk(e=XDK(?x33_3cF*dvx%)nDDo3X@8qf4| zo}k=>vQ~gR3&vQ29H{N7phkW5R6!6wA}30af?X;!MP& zmqav575+BP)@z_~a4aexo!FsA-j44E_l2{HJ<)tpJ$EtZqM>`RvHO5m8YeN^y{6>- zz&V$vsGE3o9XDXw9YM+hr%17X4c#3mVgi59H9BA1oAdW@b6-y}OcS!lT_I0`ZH}v_ zt*@$fYfO)6Z|Nr{pU0?lXv?LQDixVIOBH)x3Mb9-azN#KvsJpzn*1s97D+kpYlQ`V z`x|gh3~=5dffDz?pRQ*}@q0Xwv&;1VhR;)n1Z&wRGhG2i-hq1z&RR$b8ag?Y>&T#! zeas_0gOKw+&E!LZY=}Z{z!E?~%$74NoN zpXY*r)PWaB9sU6-Rw<16?3X2N9UyR=5?1Z`=)LWFStI|ZLZ3Jlt5lBdE>Zl}C{3EM z+=nbNcDjiYu)JJ8@e$INLn>xeI*zJEqko(Z- z=DtqYvM63-)ahM1wPfSKK91fYKIlAX+4VYdf}!E}DWI!OAjyFQ6KflcD(5d`|me#p&kkFta|T1FDO65c5hS}Z*KoYOaJ=R<^w>EL*)!C(nGNIwV1py@nuT@&q#^)PR89ct zNMD8vg)sr4xBT_dK^*PfNKIE!QtRHH{Xrv8cJT0`FR>-Xv>u;K)O z1Xv!HXO!wFE)Z}%0b3iv{jjyp4_osDY;AWkft_2K8sF3TVaO+=Goy!PCW+8KRN6yBiD}1pYRvkFC*R!$<7=c8E9dE zTjK$4z2(sIofo(2^lN6y4CC#dwJLCygNA-rpoVPJ`1Z|)B8z1d$|?0ROcRIP67Gxz zeN>Z#)SRwZcxn^()94rAEH@SJ{j|S}P-b%Zjp}MrvB6$yRLsb5f8eCGzgfZScGXZN z7V>qUV@9}ySE&?|-JeT_axY!Zs&zc0-rAha*Jva9s8_qj`a3=VY7Wp`WMBZU;rcJA z^COw$+lLOoN9O|l%ae~Zs?)I9l4LVYNal#c$V_y?ShY{(>6CI*QjUAwKP%w_d~ytE zqG07nFYrNx z>cw1_sheesJ^NMG7u(j|@lLoLS`n*&2xkW=e(ZqDq0GB_zFDeKyNt|PzCZWa*;lezQzW?_5fffAETytxQb1}jlTmi8a(OIZX{}lwuiiXo1)`2|MZ|$$^(M~ zX^qj!0q@SLg{+LH4s;^(^L+m0r-t0K3G^%;oleMs0Vg1ChgdP<(_sp^c5Wo`j~q@} zq_mQ=M&#XH<%sC?yl~z%ng+u}9hvi(&9hndlV?*R%*GEXN|pC|uHa<?k0a$f3nb;^XT0ju5~JT2_ShGuyXP0qQ;Jev9?30j zaJ_L$NA8qm8S~k6VBLp20Lwtes~q&%R7nGJ_J1n}7dg}2beac$o^_YVg$GEtFmLxn zEQ*C}mgVAu1AUydeJh27H_M19g+`Jf!{a5dWLF#lVgFn*$~F>7Z6~8SmQ}Kax*4^L zz;<({!}irvh`_d0g^32oj}gbhf(T#AMMfM6hkaXMVxM1@)`n$0=kl&YS(CJ?sWvqg z4M55S&{)Gk-5GslzTe&O_%zs96QK^kB+>9HMH6jGyx6p^9ILPfuBjbvE0EBC_*Z7b zY0_n3t2N55*d&S~l4P1S=;p4VtQ`e`XeLrNHPCB<*Dyy?b`dOV7YI&6rEQ#jEQkob zsDgO77x0FayX|wg(+A!A>HMlpghKdxCnK@^VLjhaR@|)8N*;tSVLW#9bl{U62;kD zaS3vGTjr+5(vM7WA9{QDVt!7yPo=$3Rjfl=6JLWagUdC-*I+7tZIOmTFx>$%$5F%_5y}0^SdGB4q z{mAKQ>34O0k3=_YHQr%Xi8Sd6bPPga`NJD>>{V%!eS!V4n#T zr0E_5v`aj`&5Hoa$zcE04id0;Id@F(H&(PaQ`9$8L0s0WH3g%s27ry3OShCM%>+V_}CYQ=#&L;=WB6^PMl!W>$YQyu*A?a1ff5zNBJ1)mmTh(9b#PSZH;k# z$`+F?3vdqL`h-_mqTE}N>>By9quYlA3NsqCTk+PkVH=F}Cv?&@D(13n3QM2OeZ-us zh@}JP$7`bl9~Ni`j#G zT=9?aB=U3QY`QIz2tuV)poOYT(T6nV_W^RY!4?#JgL=&N)(F~=6jUv~kA1^H+)t59 zm>e-q3#@sbNFTmcpFRCBofMo38QddcI_*b+N~ynPT$NBS zHoKKjc#sunY*Nm%rKl-VNe2%(^g1J{o^R0e+pe8Y4XB5c^r?)+4N_-hD3s|?RU z%lKfdPd_~5Ap|My#fc=&V4)novIc@pfq#Z_C{GmtD^o&+ol+m4bZXD`7C&v(OY2#r zO$q$gc&?pr0!6B7O$#kjk!R+Vlg~B(2X0fGY!Pk~M}o3Wu^@>prW{?RG?HrUg$&Kz z)pvO)oGWlb1$=|78ojrkf(zV99a)-EfF_(HXY;N12uhC9fh%whE_@CSsC)i*?1zv8 zb`EcK1ofpB-Nfx6=2zMMYxU9B#fukX32V!&TeOMA4^bfG+Id6+w40>x#!Vu-Kb zN0O)6%H>^EpdP@-RG~Pal~8T|UI2bj4lAkQNo4hF!H zE0e5)tSSOdI(1I<<&vkC=R!c2lq8G%kV=xkER`ji1d>FOfRHN-99c>v#Z~)*D{n29 z=A~S%c?t!pM`QDSX3G8_Y^=PVJnZ*@9=wVNMzud|pM`gaEl;Hf!=93<_=x1CX!wYj z0v-%X6ew-K3i^awQ1i{y*=$*un@3TIp%51SqU9rEhl@m(s1AGx0L=%X5!QVsk@NY* z@30+&PMH0$IRLXg5C+KN{~c5Exd3Hp^9pi46g?jz?@dRn81xMVA0oE_7>=0C2e1RM zK_JRV`vfRggd+no>fGLO>QzHliMzu0w(0df(Ak-fTD9Y-VX@Ml>!;aoobj={VElw_ zyI{iti9s>ffXDtLgDIrr>}7|OMslc**bP{l?@z>w2QWDSm=c4M@UnL|$zZn008IZs zrsQ-Xhxr9y;)LqlMOn&el_R;sI-7D|ih}_T5u}_@Ze$Fp+kDq~l)ihi&nz;qxgu2?iu`|s1ir6(Ue%!V-0G3lw%q##4s*U)T)>~8nE%TG3 zxE-vCldu$-6Qoa49q>1qBZxp~qiX}NAllvyeTJlD=VuU z1$d`wISG%9BNn_G8e1vbN!+pY7XTR9gWYza0gP(^#yw~Nqg{Y9V)~XtZtYkz@kZxA zipH4x@iSIZwU?{}T4YjHI`%B$qkAAPc)c#zb{Y?UsvrGK&xQE22{KG>N6 zVCOyX4|eAHVCQQG|IK8WG9He-K5FCvYUEYO{~ybF9?~EK1}W_s?y*PQFun8gxA3~I zOqaI9lY30qMBEc_E@~jBQSbzuD;WlGuIrh`?A=U#C#Rc=%h+|jmx&&dHYg^gBPT9l zlzSUf4!HJvnc3UVtGc0Me!TAYCDVbQNLWOxrT`nOm9+nnu0#c5fyrFUV>abi*IiNfsf1&dAKmq~vB1 zKdL#1Ol5p}Fh4#gda&5QCNSJRPRqGdD{vM$WMwHyya&VWFkO10R10vHDKafEpR_tG zz-%qRKg^aMjGFj*bq?b1;rmkbM#9Sm)F@%pA~(%NIgk6|bN;oD)$obGa%b*4TqRlF z^ga&%#KRsL;rWpa<0wJ8@{4f%%K*}7*j#yn4+o6I^_BvCB667$@ncW5M!Y&- z`-0=;v%Va|dmT49nE5m5Je~YekzWg;>k{8f{;mySY~WIN3|CH*CCjp3;l$lmNANNq zp7rm$1i(sc2&sv;m)`Dr>wSms+Wy9#akl_9QJal=U*OjgIho|TS5LL?T>yt{@dB41r-2E0#`1vZ;U%;O8 zpEY%CE8`OqFWg7`Xh@$mNr;~>d4HP_#e=_Y;Fu@b+-Uj|C+ z4HqMPjwbI;RLkx!eqcRe-u7BAd^?Z6X72Bt{6%zS5Iz2G1!mo4nX6<-Q>$C|8Tfw4 zWr{oZz=2|;A2?7D$dxq7ZiB2mwd)T2S{{_D*&E{?&DxA)$_?m_cV34+Eu}_~rr30R zGm`ir)9oneTiJiUbwFl*?|?9HZkv1r1hJ)uq&lN}#pFjx5w3rHNo@~F5<(YSS;0rV zc-FvR0xvC%*#mb%S8hJRiU^D9Uw=~uf4b>eHq#otzy7W8TBQrUY|6d0VfozAA~fG( zttpHeH{4$Ln2Kp?rPVw0vT{#LlKSZ)oBU9depIpI@gfOlz8^hW zND4_KOMA`kdawydf!)0McoSl^_;&tZsk(vI=;)#>!;lNY?*wPmsy7oog3?@B2_g4QQj5> z4^+71sybKB>CV5&njh}y{^xG0uJH~Z)t8ug?Z=?8jcXWBY&VZR*_BODtThf<*lCdD zEL|~KNz^ ziZKt9R4atZ3M32b_fqC23OhTe3(xLf)M^|?$lq!uajPSi`oIQ4FVIA6I8;#U_eK!P z)CA3Tp9kW%osaJTc}{v2rG$bM)-E?lla z5k9cPE=+}((RoAXN*00#Ge=@1Pw&2pmTx^uJ zE4i`t>q43$)h6iWh@+dRA<>~NRv-)sPO{|VnZ&?OGxs_7ry3?mP7JZrYii&699QImE* zu#|H(@agsHl88PZNZb--w+v!U;Q11;3p~3-EDwV!+3*amCbb55*OjP?;J=nu2kqW( zYgkLVkX3KNO1}U6Ql_zhyGZMw)5hbhFYYM^)0Ueaf|wjmOwJA18q~f-FFP=va3?!S z|4aaSWY?$6l`MGr&~(2CoA!Piw&ZBKUmhXW^5$(YFPg`W>z^f`&r-$@C#W0xs)otM zd$#q74Zw57i61Zx;CYCyjwy|vPEY!z36cfRzY3Wa2xw`&7VE9;L|xJy3K&xCEeAVS zIPE=jVloy`{yP70v0%)-3uoRpfBKH7Z&f8Y$PE5|?vA(r_P|HA?lV`kve;_>f;*Uq z241gT`)OjAz+ZT|<=8uMCX>o}r<}K1Mk>>NdRp7fujxVny)}A zN7m4S^yUwEpAn0ZU11@~oa-k;YNSeiMmCkUPG-`5FX)^7s!>f7+M{RJ>C>erXYSbs zyJvQ^w?1j3SIs^yid;z=G$`Bpf$Sus(n88NrpmqSnVRcy{hTK(qrpa`fs+SN~dCpl@keH8bLfQ{VxKSW+Uc0L zV(ZG<0C`+!989gL*Jif_?NgjflWBJ<{3Uht|~zANWl~z*553U+v*Yee7S+B zfmLEZs;aD@KD`R=h+ajBRt>f7@Y#YIgG|NzRgEkKuTZ>_njq{MTX2*sD*q6OA9VX< z`V*0yLD}QkIb)8|Y>u9x!aBKIU}=<2X+&aK9Xv4A6OlTqpGqg`@+5v?$=sw)&oumr zh4zync}NG^@(evfHCf!^@I4{^AgbbEd8q0ixuiP)jx zjj`0Ze~knU5y+o58_n2G?|iu?n07#}0XFhl4O694cdt>DbMYs0#Xx!5&$JH6C5m-f zG7Y#=Or>mkv#c*fiB!e${DhoJ$PVVQs^*qUpA*ij9fxc(Syu52J*ik zF%_8dyq>@MXYJS!Fg2?WAU23u0!#GZ_As_ulu^lAc;>2hDrx3aV2} zzP(x4TVtbDRt(iGf&@|A$&fvygNAAH*wGcVW==B#e>@DF|EJY9KvM1x*#mk~&?8vf zzDCLjsax%QZq9K4@ZVCwpPh_wxlMhUOT4{_fa!*V`sp*cKf^(QhGJz-N&E6wb4i(Z z@iVpv@SL~6_<4mhgIL zaEj;F!AaZtF?M&_Q0r#x8Sk`dY0tQ>U&F(v`Wv-YSIs)%M>9BE^g4Br4{j~dXbzcSq+HgG3RdT;RgBe=L~{;?h>Ez$MU17Jl!u z;s)52dr@yxEW zKA5slvCI4w_cA;?Lta1XOt(`TAG8@;pBxq~k;G{XDo{Vl=RL(#7V+j7g*!S6NMj2dPl&(;_)EZp6+7_Br?r|}WS#J&p5;+8(cuM2_c; z5U^|}I0W$=pG$BEXpA|OJ`;tK)-MI)gS8|WsR!8ZmKfF{hFSNq*|Wt|e}xoAgYG7z ze5!kOY56rAX|cXG}Po`Jimp3;Mt+ZN4I*k#-smBb+H>;C~xz%Dm*& zmS6U!GI#l#^aruyFINWlCA@b(OQ`CkYzYnZ-{*OUhIMla7=07<*)mG`T8hVir9L8$ zq;b5>g+5m5&8=3kF)6Vs1#1CRDGV<_1*!KR7$pr_5pCvD#jIqO1e@AdnBaP}yRy}j z)GsP~K_$@8s&rU~t~ZsBq6zx`Ki`nNOV-Et{xPr9va^*N=`%pT-XTxLSQEXvveUcxVJ5Ho#VJHi8O(c{B@@DVr&8+kZ7G;sC?B_HQhq{{PK;Sg zg_?aWHq#|vbt?P%Tv8G6(GOVJA7V!SyR7JrZ->NE&l1hP8{bV>63^TIWFND9g_Nn6 zh_)*-EX$>|Ewn2VOyZDhbdrUf%`rr$W&b)-3ymAI)vZyj$k_7RXoGQqYN_$JSSKc1 zgOvb+B#L-McTVTy#Seb4C zD;#%Kx4tzz@E30f?cQ0<-}BrAGQ@~Hq?7zSjMFFgxidAFf%{lH#M0m8dl-V*zuD@s z8z&FevPOLW3~MxTIqgI^?5d3r^AJ*Nky<|B?LC>SU-b}XXX|x$aa{I4H5z%el?si#+Jh!00-QF=PI4Pf?L?>1SGMEyJLA_{87Wah_+SAC{y7=#BUSD`5Wdf zl~6BB*7(^WOH&+xwTa}h*<#fLFNyI9wcx3DQr6OsU3+?r+~nY9ua+FTIZF?(r{kB` z)2s(c`)CSRK&;0iMp+@LWilg(Wso`*!q?7;g|JTlNP~6RrLlj2Ql%Y9z_~JL8IrC* zVq&~wd4*fc7C0R*M3hrh)fJJvQ_-elyB*sBWv%uDa9$aRL=!`bRqr4vnF3WA>`_FS z0*%u*EEM6I>L35i_!NPZ{>U?r3X%RkII&zO!Ie(jBxbgzLzKaxc(ZF>08pX=M zjGPSiJRmeF;zxi;EBn>e1YLKVjmnY2tP8m8NlV-iz4>JOiEtPVb-}ImS-Y&p);H3+ z3cW5;xXSH@r6P+Jg6SN@U@I%Q0X5JIj0=*(z8o7jdlA{ zav(=StOrmw=HTt!kLbb#E3;Ku0CdLcqO3ptRR4lLmykx3lQ6ra3hL&wF}hT$&@qw@ zE;U8y5<+Twm&%T1u~oQA>qxxH5ZdT}!-ko+g3s!h7fNRmLTfCL=~}~|X*S&!L9?8o z4@PI@S2vW4R3cb5PAaMsYp>ej^tO_|`1g?Eu3HzTri1@Fo>XO}u97IAJTOeN^z6AQ zC|2^U&r-(qi?_EwVnE=R?RdZBGf%c78jEmtvGKoxF$%d|KEqwHwUikiVG})$R4wp@ z$>=QL08)K3Bx?mi8tzW)WvGVPdNb(C>VQ0HiO!ZFLDUFCujp@AB5>7MlyG}O z??#f8=?<@4n2)uWQ|H(NO$ALv;LpbT0|xL>b?LaPv^ah{&RK@37c6c8Vk7 zW#1p)MBUAWq!o^o+o+jE(9IZ|@@}8er1fAs+7sK{W?6ceFOj90?zfM&Nt~^%QY4v@ zxEoo*_lBxHMKQM=7xmgHJ$^sef3@qY@`J}_p2{|nm_{>%RZ6W4FGO(92v4WUum`{m zOusqNAbZj{uKu7mSuo&RU6(j9PdHyxjA=RzQW*_~=KWSI>lcp(E1h2}?6XQa+F+1lNjORsQ z7Yun=0L;Ejj?$LoOYbo8XyLUy%%-quK$tx`v}JB>&tP$#oCuqMx*KqCmQ!y_ zi%*~BF%D+WVXO1a9cB}Cv1k@+S^^Ex0eG^Y4&ccg#G{>V<)&`Yevcz_SB`gh&xbUy z|LK@o&WP2d22Ba-7p- z5_X#p17o95qcQY3OWOVMYq=%N`}8^WXY{y1!6N;XZEN?-!K?^~?kRJV>w?Y$XXT;$ zBkNhm7D$vz;?5->640>o0LfzCjU`hD2sQxe0*hU(YrQr$9qq9j9l(%}T<1-~l-V(; zSw1hBRoszj^t+omPwg4ORY0%1quhi^^b{tDDDH1M!fw?kj6Z`I^%I|Q?9DC#xrH&8 z-D3!N;fk&&W2?VtgLa7YO@cLAoNZ2J*n=a1YlwF5PoD?bf8-~(4vUMlaZ2DKp++lV z1%xGW8YP0RlB!04AbR(fGk++xRK z0$1F)gO4YVg5|pd&TTKg0ui^)rP)3@Kzp75HgS#xP-CD7|CS%{Mbxhd5 zU-9#Q>j5sHbdqQ_{VIx9Aq=n-zJxfM+N;w7ruoS0VJfCVce@{pcJ+nYqmh;lDj^;^ zeuYX_p!|Y;9Qq@hBhV<9ihLOb*hA_n)hJNs61bt`l1U7HC8gyR)n!R*6CKZI$i)36 znxKKs!p;_Dbb%=B>}~cZojqzu&DVWzC4&quG%oyZ%eFy2rX;H?XuqyNy58GvoDLwB zVW$!vE{#~SYSz@9GQKV^Hz&U>rd~}Sy0Kg@Ki@8zg%esKfuE+uMz&BX$w~`5$yW3L zo?K+c2mnv+f9=zP-q8t1Ja_^6&lK0M`T-)XL6^R@UZTi>%z(CfehhC*ob=V3Fp5ro zmim+S8_8psKLMaHgSC1~enp05V6qJhqc0K5rUhS`_6&X?`_VVpepPf^yhpmj=g+00&zWB9>br``wgE z#aZl#27DtXsG9jFc>;$}RXS1tX)7!Q2bwk5riK|_FJL)f9B4J4Ham$~>TO$!$f8cI zX_xhyQ{?WD0{R&kRBb;=7J+Z2(iK>Fx)9+>Y6x-!*+Z`Yon2ku$23%zrwH$hCen}` zfdE_1+Y15M4REXjgu1VeMxHJbkPCaIj>(BrpMOQHfzfD!W4B4-w8G#BU^=cYy+?Gh zA+(-7@+Soh+jg9DZOCivoUIO>&D=9Yt@^rlb}V!Mia8ChSh#B0dlx~gC~5(W<*yi; zTDk8VwLWN9-CUk$oA7D9aodaw_;A zCnqMQ0gV>5eUq3|#sV$aFmccjW|W*@hNd`b7n(qUY~h1F@|UVDIKdx8Jl3BNNMI%dhegvj0SHzrSlBt@27MM(!M%W00_ z(?e*|C}BEY>z2&$MU5Ob;X&hVSyfrp3;+7`!YL~6^~&3}s_mYKZ>tve{SC_dVW2be zFwMfVEbm;pl&%m!H>v&dBC&fTcRDs+36J*Xm42p_a%!gUzS zany47Mq?h%_l=MLT5m$Fv9yfOl(6V~b(~5Gp4;%X;S{iD3oz;Y^{txwFr~C zT(K{RrqDAYW?(7(?SbGJQO%!DhRhUB>5b~_rV%nP&1ME#+883x`~zODL48~{6SD!X zH(lJSO6C1r*)lK-s5jXN3)4}PRxB*u+P$c$wr9$22 zAyrG$=P7Bh*ZCOLw-|sv%tRDn0WcHv_4kaWmIZRfedJ4^GEs-5-OOSD@(Gep!8oo% zqMQo^)Q8rP+wo<6_7oK6jDsq*5KcV?^~KX8+f-Up7s3h+PFVS8?la5QIlf+)$Sxf) z&{^^!5IY6$m&zvdklLlY@|9fJFMj~@&VZJ1B7u29XJ3TT*Ksm6SXb(iLq*{5^9QpV zg|esYma+9}T3gpA_)_z_e18%8#PMFe|0DPQiUi8Yeg`wsT@NJI z$q1A(#jXsK$qZ#G`E%R^jEH|4wVwq9hG0ag+QL+RI@}l4qdy60f*V>_I*l>1{lRN* z`P*9>y(+YeNEYHN1tiv{>frI2&fsec9O%Sl1!{@#&MsGf+RlvjVidG-{dkbO4_04Z z!2$z7&VuB~P;?IPARfiEMs=HA_!)RV#;w0c$liE6f7PQe`>vLJ1L}u7Huu{m48Fn~ z)x+0KzBq~;$qGxL>9mA=Au|i0v?VxJ&e=B%AjkAhpCrrlpDxSWy?pyE^eDH2*C8u{ z_84ZE`ZQn2Bxr75EV3;PJdJE{;5W=DkT|-bjm99KX>~-MxrVGqzm?H4`z@YGEJgH#h!vh!MaoLs0(39C!FAE zr@VY_Bt~IEA|o`DQiweuNVTe%xK_@IAUL!EVO&~Nt8x{Pc7D?sE$~UDLCF>Gt5a7n zGWHnNchQG-GBL7s8tGFm;4CqBmUeEjHXl<~dns4bvI`m4QEulu3)VA97|Lg%1qnEn zH$eht-c@k2j1)JpwxO!cV-wF7Yz8K^TYEU+{c)J&6J;aeK%Os_!hyW9pBN1FMu4+! znzV=?hL~S`9e<8vn2K3dN+R4YR$nQ2)V%fAc$?3%kav9~vXE#s^DLKYD}O63>lX~e zSP}oz*~t9+&N0DWii*?x!8{PDeE$rr>nE>jf{2s_APeH3ZJF@O%OD*GDe30qc?zYy zhl8$NJy-j7=Jb&uick2}{y4op|8lx{S=nBwJcPg?d{*tAXN9A)|0wzc3!Y-01S< z*>-#Fn=&^x7`%Tt7+{JLrm3rJ(%IY0a^Q1X9zpuPk(kz#{7eKU1J`b zy18B;(fT@6wJX3#AXgA~<mR@*2^7vPO3@`vsLec9||Pape;%w zad!?eY|z=?|I&j~Rf^NCXQG=}XciHshqxar>;=#R-$|N*xrsj&@S7X2=F>%I7<+RE z>;Aj^dI!UBjIs4f>+d|~`kyusL>>=MX;P`WN-GR0^JlN3@-imH%1zm;6*3n*ze=C% z_91|)hhq>u8mNs>;lom@&k4kvSFyVEzDEqgNT7Vfl8$7VDi6EN7ERNKY>{xrSiF?m zI}i;%y|gO|+yv2W#kx~=A)U?dG^`S0&p!u#zRa#L!vV3{R`S@kib-o^QeN)gOcEnr z5-{kI4b`C}Q;{Cz%ouF25SxA8{l53ai0^Q@@UC~@5fFqOfw<*SXNhgi620S63hK09 znUp+>pT9{UuNa=Xd7r^6`+i9xWJ|Jp z#&Z%TibUlv?#{ixRuel{a=z%y=0OgDP%~k0+!K~iGGV-3>qGl3lZEmv^<^y(+_ zC#rwdtKDvV^aL!6S~8I_>P& z;j(9tJ7x}fsuk;0O=R}l>E!=Icgip`A!RSyZ`cYkuN%ke0E-@XVOZ_FXqc=x3(p?@ zZ7lwHJbBYv;+0$LCNE!h=A|0<8wuMHHPT#LH)b}sbcmK^)(jM-x$W9Ue?N{WW9)o5 zf*4p}b0x^2K78A1Hlo8vznEpw!L1f==ckfow(+ueR>(N(QAl?8 zE1Rc%G2)3`fjuN=qEpQDl8MIFCv>v}PN6}!&}2exz=D4oG`Ip$#Fm51cJXZBtd(Yv zP!j$8U@&|*mUwvmPeR^SSG}mk{Baxr6uM#tN7_7DAorI|T6Zy-@4PVRNhHelQQO7& z*7@JlF+;mt(LIS)$}`sH9`Q=ryQkL0c-UaUSL;R*(5qvld~z~nn&x_e!Q3? z@=2vV7syL|s$&Fv(7AvLX;NPpX`UzS0e@3r&}e$#!XSxe;WJLpkxZrMMsa46)`Q4| ziKKE)pLc3Urx2;_gKa9~^(x-+fPLd%XTP-7SG&dvb0Il>LX1XkrK)Eh zx#Ni0TH4(Lv3X1Igm&KIgq425<1CKW^@JM+Ck^dy8KY#=Nmjz(x9o^Z@q$gCX9MvK zPyhf>rv{|d3phA+N72Qi8xmSGT1S!D6=6vZnZY+V2)|rG#C7nIRu$plh#jbK=p6|P z*lwgs>c^fSar?2I`n7N8HFkwI(Aw-}W36_*I(1DrU!)hqLW9NlC?zba6Ncern6`I}P`%*7s^*Q={IL*Vz(PQ*;2lF*G$!+LI{7=h-?KdpnLDZ=))E#9 zfp%A1^pTs|EZ#pG`xL6!h|hgN&j^570lavJz)yCAto=4N+dW}A?Z*IJ2DvAN2hBCl z;yNvs0@Gg_F?06-Z1gBz^p2p{G!1Qo)6yG#tj=k>?c*d#Ic}!kNr#~G)h|mwkE~Ab zstr9u#8&E7=?qO;IsZn0%qk8}^=`3m&iF(L-ML-E?*6nkbK$+V@cG5o_-l*3cfZ65 zOJ9pL_i~IF`$#x;`xDkr|YK|5v~&@^7a5_n_t_N1kzw1WY>Bo~9g>Rh){!!zD3>*>GF3 z1vlno_YUJG9z3@y*H?OZMAFnhb6&~>u^nfy?UUv$g6y-^IPH^La);;KRPftRiIN4~ zK3*JD!=qkv@vJU!baChwhhj2@Er&?8QD5mCZOIK|?987xPe##dwNHny$*?cEdI2J` zLzX6UlSe!(mH6pN$*hAhVy1L0LqYvbsh|Lt&N@@zW*xj#g6=N*5Q$CJXfm=OYl=nl zpKQ`6S47EFlQrYF;wx*PjhFK`XH5c2hnOg<@Y3&+BtmNOrPWSWpt@)8e4_NXk0iRU$Cj^7CYelSpxbLPi6SEpaxAD5q)%NW~6`zhwkQtSX>dlG0 z>z>i9m7`Bx&c_Qcy6MVe>>I+nC`aEL^lMrxZ9}s@T_37G)*Cr)^INqpEO5xHj$@!U zY8qD|)nry#(f?vjr^@Om@S!kfYT)+tl{i7*vB}m5`oaZSIa~Va@Hn|J zvv<^4jcoqgPi8RN9JFHu2%8)YI>i|4T^6<%ZlSp(hZ(*z4wq%TN+7iDm37N9>K)n6$ph+RzJ?3?pwP+&WLa4Kp;;Bui zVqm?F2y*4B5fLQHB!@gHp=8%EEPrz-sMmn`=5BV%227(zl|Xpa)uUUBARM|3O%>Xo z(j8heo2}Q%y)y;MsVW1D0?{4<1?>V4hn-J~^cQ^Q!XE2p@3^8}ah^)|wY=M%YMydz zmY`jHO>~kt=9u73zM2?8rK}Q5D_RYHG6M&i&&}_B`W&$Me{j=HL{1 z4D>do#YTO*LNg$k*37J2rKSIUJ=*b4t}0U8{fgOlfd}O)bGLu2>hgH0U`Hq?4?q8Z zWW8lvRNwao3W6X~0@5WRC=T7NG*Z&t(%m_LbP7m!O4raZbPOQf-Q78)z&(C{|NFTw z?yLF0n{!s2z1M!$^Q^5EVQ1}7NYNSkNE-dr*SGy8!?+|-Xw4j;Alk}cleTe1+ zC2LdD7^MSrew^~A!*hHURJy01;H&mrxUfeppNI7r(Qu&sG7=tk0Y`-@qsTARhH#WY zq4MKtb{(GXOe6d_uMU-5bTBl;=6mO=mRJ44VYm>%Df@7)cQ9AB?&2=BtmB@xwgXL^ z^LCEK;b2yodYXD}!g`t~ZvOgB3QgwvG!w&mC(hK>zZ6lM;N19QR)GP@^UN)hmF4oH zy+`gfK>_mJj8}m-AY*YHv+iTsRcBT%_Zzq0xezgTY?qu|%+U3Wp`bs;<9*O= zywm8NJ4UOH*vx&``bh7BB2e z?_4sQoN{|QJbMRkFR9I@JLN6`?9p89*RdY-Y@eZ_W=cDeVU|e};4P+iwdl)D;kvoR z$5J4ig;>e)7svhG0XfTLCxO@b(XI>kVQ^zSFRcugqt^t>Obxr_O^3Tq2Fx5LtJCJ z;Hjuz-R?HI(2c}gdTcE>2jMJ+;%45FfSM6uri$fR1Hrp_)K` zqa3Fn{2RY(0{Bnt;r>ufwE*aH?U2~VMPr_%Jago>MV|7W#v6 z=~8^ods5Z@)z_QLtE)g9*9E7>fj9=cu}OZ4o)lWKunB#oGpaeU|AXykbVV9|;q2ME|r7`8>uiX@yr8K8pX?WeQ4M#%VN>fm$ zYFE{Nq;T0ny)n%Kd3bS*!oCRWC||H&D;kc46wWaQ^|#>tNY09A_WN*FfX_hnntgTk z?!ZCc_e&NZx<4wfI>esd-wfG^mODYITP;Mp4{TugB_Sy)uD^VE8=^|)`fZBv%0 z%N=j-b2MlVq`+HluYMuxMC`*txX}H6e&$bRnm5>75H0CBTQ!6CYWU{$?H(*G!-XDw z1j8m-Gkx2Aa8vN#){|E%z7TJL3hZeEANY-9PP2vs)h6}G26`-$#?$o$xHazK)h_+l zbJvgF>AyXIrDBF`g6GuMtk;N7?AfO2Uf}E9nn0!-$tYFU`*Tnj@wcstha07b8@{#2 zC+o8n!BCA@c#jj~u&{KNL4D3V9IX?k_6hAls8b{| zSAiu<0*-b%*mpqu*aqz^-7eWDjj{bPyZmC1@RVuY$1s=UbWNYufo+0$Dx}t@a~Ut9 zR|AgT*(7kv5&ZZft9TWCAe)a;cc{v4?eprIU8J~i@qO?&W6=GrAs8uzHL*{;-7dSH z>>~2_k}-D8vPC;XUee&^g}=#T-A@YbB;q=bnY31m#2TK?f?4}8E0v8t@Q-mDd>^+< z>&kU;pK6GArc9XwQQTwE4TXG`NZA?j1b^sym~I0df|XW|D7pvPG)pYwxk-n~K2Ykgaq4W4 zB>0`+4mn{{LFEGJWqK(2U!r3%MOtH9yuCRqHEJ0A?2w9_?k3WmD(9$XgEeZDD3fUQ zHYB{Dnkd)Z&kR4pWmS}j&aKJ<-%31k$+Sb?W~qtlVy!4{PyU z0`p*6nX7O;bdwcD^01vAH0_(>%W{&oY9^gg6Y2CDt=Y^FEs+on67=caxx z1gdf51})sX74;o|aH^yFOJy0dOvu5aYhOzH!p2Q5!duy0Ms5OB{r z73yD_g2vz)7Wi<^&xXq7*SKZLQ5hwb)2nJ1%+TYL;xaWIpQR&L?D1K!2an3^<&@s2 z0yMyrK{=C^Vt3dzZt!@{H7-sNt#x>{&vf@tR4dw`O~yXjueLo$GJ9Yfs7#L0vmD0D z5~k>O7T%PFX;_tX&1_Zo8;?U`3KEs<1APxEI;Um=81))LMEAt0OPOvW--MNG zWiH?ihz5w7RcUA}^F|P5XZB7kow6W^ZScsC!Fwzn3EgUCLD~7|QhohUhA|@%tYwT1 zbPgAG;B{l@jAz2r`ccWbWgAj6oXnOpgYoh}oqHIE|Uc z*)J65U?A!G--)cZG1A1o;Sc~~UxV{QTnX_u$e;ik~LT-?X)X%lC! z-wOgGL@N;4s}EP6*zO8D*D*5?_vBy*GK(`vEXa|cs>oP+qs50YSK-GOTf;_uG<$So zi1O8^&K+aGYM-DH@1gr0V+nopcxmjs6!snQC8JFI$*WKIXmvh8MIB6ZTVs{)P9&7u zjj-Mys~;)+b|YVH%W^({=eZ2=Ao zVI{V57S$I~F>Ao{zyGE3_(i4tYNV%rgvm8yXC$ycg=``P8JY;8gYn_<&9WUr6N!s6 zYBVdmyjKd3l1iD8cCF4BG-MRZmEV;#N1$mk`iomGC2IF-_7k{91&MH@nzm{dGK|&D z3v$Wi6ZC7%hEGqx%-C6A-P6oOIIJuqCVD3dq#>vvpDbY;91Ragfi+uR}(w% zd>;cd#U^B(`HaG)OgrBaH-6kb9oL16_-lSaFj6-^b||!bwv#GSS~G@sh$=D=8k2HE z-j!Z2VlJq&P7$z)eb{}!cg#v8f$j09IK4GA22(NMeFbaSsT&e9J+AkSN3q18($&0E z2DR>$;)^2g`kQG#f$0 zD44f62)24taj2MaPsCQ*_>7$kDUx&0PN)jSiR<8ji=8-k2+ul^urg{zg@rc`4H%ZX+ zl|87?VS&03l4GAdNr2{-%W|rm+&E(j+!e5)^*tOCVObMyH$Aee4lOL4tgmyTU^1d; zWf1lp!RFt$+`6t6)60qFD&mq!-U*ByizR)5vYm9hXGANpXxNMvKaN*G8 zTU5Y;)m|QbFn?RSDp>bEza+F^tv`2VBC|A@X!lO+Zr+whzeiwqO)vhKDr%R)RC{&k z|F9H93iY&fNV=+v#4khL9&X*pDI;fp)J7|a243gm>NS;F9b$9cCw1N7n|9jA_WmdR zixqvM!)KFx$?O{VMO%3i`U3q=GtG3iW{NL8N8Cw!af6uIziIO}C>QuIA{@?4}GUs>s{+hkiX?iO770~+~eUJaM-zYwS zO+5vamunbntWo~C(`PlLuegz`OrLpDpME#UzB`+-v7y=|P`3D0VzeFyYVZaAYB`>> zKF!8RZTjmQ%uj!`rItSFRZ1kKzk8i`^9t75yG_m>c6C z(O|-}FE;R!LV|`6;)gXYQ3#*bw@cm>Znyn~e(gR$Qq9_K@2%Jh3M3v|8w|=l zY;G(Y=8t?zuT6cGDW(z5HlAj&PYEkmRDKsASr;0bO&CPq&Vpu%sM*w7uoD_#v||q_ z0ju+Dcb?Vh)}7^{S$)}qWW0 zb1-V-XNZP&aQh;8-u8NxcKP9Q+)t=Ev0yp(_Il&u&&ZX4;VccPkwziA??u~P++_3W zL}UMyo1RPNk@8U4fF0azEchw~k$LC=XV1?E07zBvx&r%YwFZ1EnD9mSAaz8ZtJ z4%nUP!SNBO#H%B1a|e@%OApZ1ocIDz^m>{s3(pmw#rBt7kvtgQhj@kV#LS4gC-cV= z%_<6iLDa(X5ESoZXpgxsPZ)Vo3a5aoZXZNwr2n3@=gpb%dNWlb&Qa!x z{YR@VH2F|B5Q>vu%b?$~w0wI-vpPpj0IT?(dvtn_PNj))f;UDn(Ts~-`O%e|vBZ1@ zH~*q#lIZH42OnNBkuEE8LP@#N6&7uWLwN5`*LU`-Z>;%xGd0TWve`2(+VoK;ZL0qLH+L!vM zU+)ff388wtU$(;BFEjsB@mZnkaDeR^wH6PtZ6D~32;7_%QnOa*WBRkZu2}3DC?vz2 z`U_uQ3Um~P_bRobzPhe5QXoe0O8HXOSI^n$0&;-^-2)MBZWkdUt&xwNdlD zmWQ{kS{144!~GgroW@`j<`)?Z15oa+Y3O(NvQ;vYYs`Ky;sXjT3}W|6;lQJi)mu|% zNJ+8C!I#s8HaH{D@Aak{s}}tau%0sgk6v6C+a;FIq!I~6^l5%Y3{IE)_0+LdH{ta3<{CJg^l7;FUPvO8 z6>BIgKfU)|but%3Rvp(9>n};Gim5uKd!s<-bF*gKDSchoo3r#`_`;X5p|5vXLGiAm z2OSQ*Z~uLNJc@%?@m{m;6k<}g*c@L3fWp2-qp!dMF)iM20m9<-g1 z75Rm93cW)^r*H4^iywq2La^J*bSs_<98g|LM1u4f9>fpF1S?5?SB0yE6hGCNeYAI2QM|)B0k-S&a!sw zWqr`q*4OBo6!Wu+To5I>AEqRd5T1zHEd7S2rGBD_v3xZ?lDWDeMxwTKTSmg@J7(`4Xh)c%H{6&L8HjdlzvHJ@)*) zu;ZXToAK(2V9kpl3U1nv`TlU2nt3`D!=zPn<9-`|hvxI!GFzfZcggh&=+efnW91m7 z?kGXOyKnB24RBdH-fPn}_jca=FRR`3kv+-Tl$mirFNLSEvK}n6nHxhL5i+f~;{2t1 zT+o16qGDVYoIBA-v>zbYrGaOZU+DBAq76^u4dILO%*45Qv@)VHp;*roZkzS|!9K9& z=0~!V>n@Vf;b1|T%n;HaHnc~5C!v^*TdtiP+*X`DdMcR(U(ef?)WvhK#+QBW+!>}v zr?G{PWwJX9u^lE40ep^MaRjD@$=65c4e~RpBls^ffKL%hG zzpVab^u#TlO+gJ9!4}w0lPH4oj6&4AN|?w?p0#K4E3r)7CinA#R5G{M=eJ8-UR6zGmBSPTUtv!_vDPFqkEt-%C}0M(F#NSnG~QE= zbS|$qF^WV>M~DwC5L!Bhp=8OmFON`#=RspvpE_t^Br05wnBQ4=zobOeFdzD7q0m zin&i3_B>qRWwHr_lXYuxBONng^ItA2Xo%>z#(Gvx1RWyCG`*g!ODq0m2101R}tWJrpX3@_*V_vAP7)-g-6?ccmf=H85ccuR7m3n$y zFgiN+6{hbVIJ&2^`qX88$qY46|0R(}ba%L?llh$SJ2%uL))=BbihvJk00AJoPii8? zvNqmqO=c9Ctrb|^qkn+Sm7{<3-nUWnwO4X@qJktny0a5KS{G@cm!Ks(lszFpaJdV{O5d?CNveGzT z02!~j{33Q2RNSfiCLa-x<{tIcNouq1PPw~X6+f@ z>FmC#7@jqSapHQ>>7=jB+}(0zXUREF=3fztf)AsI4IPHt8p%9dOpm$ZN@F(nV6X^ zhrN`M0HwkIHJTFTj<|?pDAI%e?ZMaVDbnNfS8(b|w4*s$glbeCF36nUz>z^5-HbU= z>%MHN^lE;}8|ca}f0N?AL%E1%FK)Tz)^EQ;(xvnGjEHN>&O-V%eh8{;ki?ypo`r;V z4P}0yhc-lmMpFXyWoJS-OucwmA=j)dY1Dl?8AE6Iv}ps>(lwAfyfJsQkt}2)X2{&7 z>aFOAbpV{jm=5bSPimQM&74g?{;mh>=I6v26Umz-_(4kBOYW2yS^+b z(Ry?u-$SgI2YSArvFpJ`jNynGBiAWcHd$y8BxV`qO!t<9+CGqRxNN%utL*G(J|a1! zYyO4c5(m&_j*@nNu{{6f-x1ljd6_y)}<8Y1cP_mzHBf@g)#X zhSGA}AIrG!x30g(AW=f4Xr{xKGAUHBUA=*py<*15`A3hegW5Kz#*V*J^dCH|vWz3a zVjsGwgV2oO#DjHw$$!WVnnDTx1D(D?V%)KxfLwB9=dv2$&uPJyY`~vI|L0F6yh~sv z|px7#vN4(GjV68hC$=XM;p+uVg_@6_+ z%2rvceP?4nxcR-13geQnWaXQVjo?rs4-=%B28a+jd;k$*8X!WboGwbfFaDyy0)GT; zzGY`QFg>}Jym#5pYbJrDLTWx@_VUTOsnppOsPgZs|QmB zY0EM^h?Him`;;Dq2{jzlUsM6pBB7zDHtt=p2Y%Ljw6Gs`R5WK89}>|9*BX8SP3$^~ zYq>I2jI!SlyRZFin%|8Qze7Ah?wkST5CTU#HC8?=q@^@2G%Ev}DkMC9VVD*lYQYgd z%X`QoBXc-yUUI-maxM&lK`A5=rW@9;0pVKG4U^)5%ycXBswUP2%*xW8_hSY8 z_pr>bzy3D40yUSxj1M&O?F=CWWG|j>dUyiQHH31mQ zzyD~I5(Ps!P^8cZ8f0rUQ}L<8cx%0~kt4JV#@^cdp-<2mVwPdLvKj66X~^t;j|bD| z<-0`ndZZJg^|;TNO3&+j&2OREUkA#TcD2W)&vali_ZkfsEN-nFm;V{LJ^> z@34H@bn$oGfsqGThG`SY_iukOS@A8~}3HVXm2aF+({QWykGs`u5( zBmDOph=O#lB0;8w;R{=slm*BYh>vkMqbm>}W5GxlAU^z-3F4XT_GWoNf@@$KlLHA3 zn;<$=>d>H%5K$wD4E#OKJgkxQ0@lnYVP@k88Tl_lTz!B|8Zu@-WjwO#dc^m|sPOh# zl^<*y%1cYU^?b`qwS+5+a8Z9+>P~Z>P`5$0pJY6AB!rn8eD!T%;mI`A*9i@8a<02K z@U@Se*V0goiEvt)puTmt7Omh9Hz5%XgLM-NObw+M8$0_}n&6Wlg9E*vYFnucnv0Oi zqSq}Qhps?ERSW7kNkyW~uS@fuilGD;sSTBEY)IFTW^f_J`UkxwWVjF) zraEi=<*>ov4*>@@doR_xJjZF;hSHY@KNV<6A%(UGO$#Q6Vq=LF2X~tKN`-n>(zYq_ zGIRUW?DJjq!?pf1=}wa-?8mMtl~<!(Vm)}wqY&|e32BUMBF47uCCkJxD_y?w_Z?sfY3Ux^E|Yq# zneezY44WKVg6fdwgrDeBIGvs`PqPnMEcOcV34(mxdb`&#D7M(xSypBM%@jn{S(VPQM4+kwj?zV*mIWak@ti(Myj!Pg$TNGo&Z@o4{Oi2q&q81K*+E zLc_`L+JX{|P>li#E{ph@FQ>FX>V(sba6^e5YeJE_fyZMsOgI?wY*bXID&ia^O*_=W z?o{p;no6c`R*=b(8$vj8y^;}PiSWj|FC76GVa2lG4m6CnLclxgjuo$3X6&4a>i$^e z{d&!#3i}N}72b6g>Zm?ls>6R85c zzx>*yNfmpOT7LSGQu0>p<9)!SQshyJBIU%J6GLh-BiUEj3cVimxikV1)7dRg(N?ce z(LegX!mfHl4WW94T~BBf6-<>rqL+Mq9Q4seu^AK%XlKx0%paBEeM)T(w(rR>3$X_b z?E(ya1sM8;X9K;4=os*A@xVL)+0HvQVbr*&9B)d~&CIM)KhDhx2gjkO~ zr2H*Y&MRxK5S<+2T`9hoYXWl}p>@Q;PJBql3*0OPwKHsq5teBzj_Ihjv0Eh->tyH8 z^CNL-CS-nqp{V~-Xbk5xg?tQenr!oP)(2yLOF~W9n(8NjzqLnUDn$!Jb`Bp(cVk1! z-+jHGJ{bEV{G-ZeNceaP#ad7g8-w3|r;v2nJWIjk9c@jU0vipJM4x7Q`j36_tHA^J zdQAd3aQ_tsgjfr690$iMmquhptYOmO9Ury1^wkiDm5^#%{Uw9HI`d7($E2OHn7w{R zgs`7IM4|FA|Ey%$roNK}qYc#LY6X4>78vcA2*aI|LT(bH8HIRX?D7^wUXodH1nvSm z?&w42P~;q=x-cb0=8&&_CQYKm|1X{^WggCj6r4Xhy>hpX@U(t*Yg?XOS2+UgZ}$-T z^%gvb0B-XwW-HpaO|wJ7L~kvgtFOW8R?Lz5MQZ_CKme^!{>RPY{LCy{SwF%fxzQk0;khfK#$Srt_0V-$=4mSLLvWPnQ`aeOE>zY zQoMjag)2fpmd;>@WdY*$bxq#hA;KH{sN@KgqgFOyDF^#nzJ)@3gl~q>4P-uTQ4h0l z_XT&5Dc1Y(PFNES0i_em=>tEz5fA1(^9E6M0Sc#mO^JOdx78b5!g za*7ZRuo5e$39)vb+CHWoH#>RHP~PVxNLUCd)?deB{u~9)6vKiT*-}H>*S8)Gs_A@; zH`}YKK5CRj_n>ETI&b#^fXv3-C5lgK*ae&|0DgZLsAym~t0C`o*4912Uwl8^CMSRTIRUKm*VpLwM_epW1Z4*oLH2Sc;G$%(ZuTLm;?t z3NUg~@F+(rGHm~C3h(K66j{RX{d5;B#i;#nQ3C*_+SBjL+rc7)0#s5lh-r7SyxE)K zdzA6WMm7U@;H!&_h9~<18VLdI0%c7xz@Y`o+G4Doo_;<+YqqiNzBMCAvr26F$st%F zK1cZTutZ`bM+ir-7vL=-yzY-|4l4tnF$g^p!%{a$dO8;p-t{0^=K!|#1lZ&NmomR8 ztO+s&Ynw~xIIw&|HoK|;?Q2q16kEM1galEuVZEWR4qDi6{7i;ZM&;wd6CWa4K4&Pv zX#|k-jx~mH2PD6~nGNBH^!lfP#DiHxW)pu$juID&`#9)vjATO6OGRT2G`j>kUWNa+ zle`N5ZzrKKU*Y!O>4EVnPVfI5{d~?&65UDZe^MTrE)LyJVb={Q@3!@L&DtNU$ z>h_s%`ESoJ!tvqhQVyeMn7&vNHujOYO6y0HumKqk)wXNyIsd5a;T)>*SZxGc@-Wsn z8Sj{PGeRd$j0H!jO6?v=UbC#v36n8-24; z7RLl^CvH8z%y{?x`*{#D`$3k4n=jnc!m}6h2P5{jJ)54%Q@m0bRH0}D@F5dcfg2^t ziT;yyTyY~=8kg{RV37}KN(vmE;2HU~BaFF|EyscA{oF5}YUsn2_5oO%E?Lq(0Bh4_ zn;ZvWZA3e=aeCZnYiP}amwL2%;E0;`oq91WYlUC< zb=LKZkuERRiYkORA92|m)gU{~SoSlv!XUuB1f326tgzg9Sddl1=f!M853|tS9V?DY zvVlT`OqxFg0+L#on@s@jzY8ujmp^I&?vP{0&U|)MQE+np|L9;Elu6q!WpW2AIW6&+ zW3&e?k-7PstlP2m4Mkj5T6JxcqD^|gCa)6U-fW+5Tuq~Fn6lmmcV0;>xl$6$F7^%I zpLsaIJ=z6|5H~KwofjD`H7S24bnX>-Rtigk6o(b-P%zHJ9BbJz2SB5pt&Kpn(*pns zQjvLCp&zsXe6mBCc21T65;M)DyTEWo#u4?}K$7r?opk(XkB@c*_h57y+kNd~X{9HF z%nYT%v}m@}YM&77&H(iz&_zoxbc)#lqgu!x4U}f({MGlnG!;%l+QrdN!Q5q}J>s<^ za9S7GXnN?pdsuBKH5tBZ5K7MaAnpZXmf%7x!nR1hsfsd^vm`2=q}^%3^N$hI;^jcK z$$dA8WSy%4!k-Kf%mc{JvW1tCJK#}sdCQ*7AlcGwx$m;OyN1n7rL4==hmHn(M$9#a z%|U^Jlfy<#vXW(P!pTn!@T9`Y>l})fc3rza$BquZ0)l@jTKSK$P5Q3)Msc{i!MQp% zXqnrxKQIHmoTLJvAr^0~w2_u9*Z@Ku<{DF6N~Fh1m99Q2QUXr7k#i&JoCHLJp%K+f z3ZmAtCcjHH{6I00J{7Aj$Wq-e@K?h4?Z^m{n;bx7onPHXaO*KMMRG$&^J+}%)mi)L ze&*BhxVt@hZ(lU;Q^TDt$es(%l|4RBE6g*e91(nuT*e|gURhDh{R?pE_!i=FrI1mr z2)Dm^C=wkbo+yG6Umtg>DV5=~)=p|lU$!N1&~qNt8B;~SWTn9%IM*Dj7_>C!hPIK7 z{cIey9MUc?Gm1;?dJIOWEPOI2HK(?Zj;n zP8fMsU_)B?b&dkod&{G@x9N_(`EjNLrE4;O9|-;{%H4F6YJ|i=gqcYkV2@J(9NvZc z@C|VID}`NA#(SYD|EbwNWdimTuOmA9LR^QsrxJ?uwBv>gdmUl5Q9%HOvo|>P%`~L^ zmYngOl4~#oKIuvM=zRa+c=-}0oNE~1ONwUom&PcO8~X_R&3=Qm1AM*d24SSq|)3Sy?{o3Tp zvcb1G6iNROH~rh8{Lly|^aPo8bl#bs0QY)1Omhg%)CCavrne%Jprolkw@I~oV1zx& zg4nvK)cI1KcfSFiT7!GCCFH>hvhtMpu4y*|mMt?dsfjz7Z~nJ76}8k4qfRwur4X6O z5;8X~^zwwsU#@meG}498nQp=V28ym^MqQbRl5fHK#SKU6ZQxp&px#44!@Yr-KWtLn|**Mt!yY5562W=Kr;+~1;rD$z<}Q5`f9gFL{Fnn zUG~6&2R%m_X_x88Xmr-Udv?vf!ezuSKq$RJRS?S0M&u7a44xUU4U8TUGM?-A9_-M+ zJg2`MDx{nvcPq^xc`m1H7&H!w5fso3LNksGazKU~3gv7WUk$1Vkr0MCy%`w5LE4u4VRG z3{6Ste|kL)n?sioKUZO!*`s|m*U(y39oaE$w$pa(@dr3!ST z@$Kr+qDhm|SN-N}vH7nYa|PII;r0gO=Z4nJXOlhgz|=>gs;5qg%_O_+rz)Sn7}5ZG zQUHDFhAHnkT5np^_6fw)pbb~ZEnzk&`3QUP4|A;ZN=S$0_OCY#!Kuob&sZ)2Mgtfz zA*BIfxJ8;Z&Z29hWu^2>798=og+b~Rnly%?jC%8@RrsvJBDOeOvNOaMOr6-0M zB#;r%u*dI?Zse8kY5)4E62*goo0m&5{FQ6YHZ9(Pn0*cWV)HDyA zmv2vX5b{Io3e^E!V@2}r@{!eWB#tM=qMbBjT39 zIDHdoOGsa?xt0xZbwTx@L*;agnkd&(5M_|hWMb^liY<$#mFuFsKl{<4Vpz(6R zhBCRL_Rad^ZUZs|l93VG8V>mg90hg61sC2bg11ew?2y=NqL@(&(X|)N1GIr(2YC76Sp-(QGY2*=t;7Pk7;4^ zz}FFH`S1Pu4qNj|8RabHZ0q_h^#R2OapZAWb=`7);~Hqwo_H2$wAx^QVsf>^oWmL( z^Pp#)gKC)8)GlPEgb9qo_noT(OOZ>SsR+$cT>a3v4Q|Pg2I_oO3`QnB93$H38?qTQ z2UIM3ga%n9J#+$(&8;g-9abi3|0xXtwX$Ikly?g4)U^1J9$qHir|bMJ%N(*yUdnoV zqZ@%;3f8m*iiZRJrD8;to?OcWxx1>OXV~;)le*w%l^N{qlhS)x>@ZfcdMD5k@ z|6>;hcq)Q22SCHsJcLFX@H06=_9DXGY(r1KJ_4YZ*d4&w04Oyv=xdfrHie1w9)p~L z*_L909L^YKM*@?q%_n~A%NfLSwE&exUqYDih7w<%D$)2g0jQ4_1Jox%uJKbEUZ|RQ zTm#+X6uGLd;r%j{33|EM=~DNd6?N6VJ_Kb5CM4KnUAr%tLZ0q=DR1~qA@DLKUgT|L zAHcsrI%ATu{37a}M`-THP2xr1Zfw@O9>rBiyrR*F*P=KbzrpaI#=iR6M#C)p}(H~KJ?R*7;~UW{d_ z-w9z(Vhj?q50%R%7B3@z6%2VXT0RxR0fVL~wmKdCPdd7*b}LKOx^Rm!_fQZ)JW~GI z{H7rz7YLeHks!VeI>zz$YZaVJp@lGXv+#KOCF4)&ipZA$3xf17k<%{VmpfzT4XO=-Asy61XnqAB>s(;?0)27 zwTMu_XRd(H=7yC5ZgRKnfMe6>_+cq@k1uK^!d&%aQT_L}{Y?7%gOg}L{+n-|^o~F? zG15IW6+i@sZ(hP0&Hhh|-Ran)GlV?^^9#xOBKmjy@)?h=*;2Au_!H(9f&zZU^^BE zZ>^@jXFR<>)V9=6Kh&}%FcE(Ua?rf{?lD(RZU%}rbo=Hch13AOo8%9$ZKc`O-LfZd zN|zp(v{cM(13@B)D`=7s8Xu!F%#Tt!$Sv>17GEH7r|c{DRAbv(^6Sz~1lr&64tD*` z1QMxH@RQX)Ztt3ecRZbanrKFcO`@mJ-?oKQVDOr=%jFZ3mR@d9}O@QrF@#D zi_tb-$&SjDl((uK#dD)UO6LKurmfHFTOqTLEhg$f&D;c?p5!n6zc&kT=asoY*?u$h zg|slx;KXiI%y<;}@>>M`0s+y`04S4M{(*&_YZ||}`R$*k_#*-IH!ixEJDD>rfQTMt z2N2N@u^Ja54FTD0_;f8=dvM$_F_Q8<_;+yJ`_*W8U<;A1Wf7J|t*e`}XW?+U+g3{i z858G_DVhRp68!q;eu{f*J#dD^h|m<~@_AqyK_^5@cpTPYFK7Dr)?ucPvpnTzG4jBN z@~reMvnC*g*B7k2JT-m(>XhGmwk}o9&{$yxWMm}=;w*k2QINIVySC0OGb_bJL^W^I zSi}03e1W%pbb}wtmSFVV!N^4_uLX+ub{HRN8|l({<>Ouio-y6~O2R~JD+g!R?z*sh z*YG)bis7^5tuUl!p+l(uIV_03Q|Poib4HG^&?58JI)~@A2~I0W{mR%$S3RJ$@)-~K z##KoIOSajRk8PgLS^w<&_@0Ko`);yFi zB!ZPGqPK;#d`f(LAE=C!mJbf(nXk8d9oltfe?A@D{r$$MT&DI>Vz4_$fXoulyzh?d z)y`iri^Z;%igTo&(*XLjyF8q=g68%=R&~0ifRJ?xK+oNcQGl&W4tV&KXDQ}eGB?978AJjk3nf2CX4DHE$C*M4}H zj>;nj&K`&cx$885F!|ipqTk(D*np*85qInUj zKpq2%2-wf;ALZuY->KWms0cW9SGSqPqb+peBtc|9>~5O;1IG!bu$?)l(jIlyE;&NG zhl1h#s>vF5ST07bnqMJpA@_CohrPGe#O(X@U*}x=nN);hx)xt>gm6rx+2PB2(kfu& zW6Mnd#SYQTpm*XE8c3PQ#8Y2IV*s2^}Y=f zA4_sS)nroQLn8+E%zS^`ToLTqvuF`;Zy)l}6`yWul2;a|c(#`TFUWw16CLV5D_ZvlF>#@lF} zY~m~5P(ys)Qp~+>j8Y)e_8x*&B@T$+Miy6OI6G%$SQ!2;DE+arSQRe5fUvS!6&}ck zxYApt#Teecc={7MZHuQ{qHz6fmTr4ozxj9k>MzZuHjiQ1Qo6!F1E&wCbOJ~+OF(xy z)$3LRT(ke*zJH*7SwM{!RF)y9l*hAX9CWiI&NL)@F5J@>o<1GCVJM^qG-Efwl%Hte z$QL4^JjN89?5VK5%3gP6=IXY__PaA52l$SESe0&vfPA(Cxx=)eKzYNsJ~nXq*oC34 zjS#x1(9#OPnz4D0xWtrvJpvn^jeD;LMUNbEWFl((A`8T#E`%5#T8N^eod1uNa754@ zp3+}hj+*++VT+VF#V57v3QV<%;BVj1Kq50| z(k|?mY$WH%tz~)_@Qt}M7!%+&#gUEu#_0qf2S3a|)_<`gYb5>wOto;Oso>Lg4S}iw zjF58LviW1{Ie;gzQD?lb@m}(^dWSid#nClOj?v9jhwcAHSg^XO4bkE`K-2t2Y{!13 zemTOb$_EPC?`~C$_*UwX%g*&GGY!Alw0tQCHF4=FK2bQ-?krc`>Kx6;XG2IG{>)eN zFV+3$1jAulGrXOD11erRr?L}tE7Jn?>M{jPiFRk$0vyV8(>Li;sASW`{H*s_t|KJk z;V2Vldns?qf|sf4^#eal);Lk7U^M6R%p^dF^YDWMUnk9Iz;WT+Wx#p*h|iygYh`)s zZJEt3D@~g4#paczQ?somAAhP*-i@G|EnaHl?n{GzlRLCCX|&#r7Jh9ZSWq%SMA}tc z5EadY`WBF0W&Vurl~%F>`YLl7Z)+l*=82*?oSnubQxQZRj;Q7KfSD^Hwp&94d$3ge zFWdkn?4&Iz9&Zs|U28C5ysMjD#{0C?G%rj1+MIYe9Te_kFxJ}Um_WfxLc{4kQz zZZD7N5DsUrTQP{2^i~x0Q%jr3B+WRKX^hR?$N2#LMGbdm&$a$*TPEnd z?KGTe6S+(kQ1*@;8$S1(6eBLbE#^G^p1nMY-pK}wP+3$+3UCq48J>hhaOCoLAd!Tg z7*PJB`84l)XSbXpZTnw)S^XO1xSZ>J`TmpH`1Y(*Tg#L}b`I(J@A+I(NZ5QfzsknK z*DjJ}Q%0g?y!U$ipOlVSh`OQK+<=ArfKNd%hZpIz%K*d909U+9Gm&lDrZ-_%Qv3A^ ziZr9tF0W&PL?#Uc2-MvWmw;p@W#sOTJ$>fQaAx`(e_uqI!2q#4(*{dGJK$BI9muYo z8KV99e_r)Cv9|xut8{;<)vx>?@8JKmRRwZKnIyp*|JjKmdag1;yD3m!kDRC@%56R? zo1+Afm64i1{>vHx$%fEgSwV6ObUW}I zW&#GFopD9wVF9+RYW}&Pu)0q$TRuX%Qz#3s%QlQUNyzmf760b2?^p>usN#FClh{|H zp>tct%~Zm=aFmc*N^horta%PJ5`MX~E`UjMoEym}B{uZHC6lvz+qNzx&X!YME%i8F zK2QU-G#9D)BZ4HBDf zq&qgX1@6=D@A{AD&GVAMV64UJ^O*B<%*`A+WvDp~cm|N1nAmwf{-^(qUEPEkcQc zt$pmZrBMp}ejjNDA2$CA)Y<-Ldnkfmjqxxw?U$Of0*zL&YB3GzXP5t^dOsD<11Tup z*VYzThkBV&dAPcXD5q&afu#LuX8Cv&p&!9A*$l_|)}Q|6-f!NSMSv;{&t7V*u}j6- zoQ#6hnZ0@A{VfeA+I_nN?zCr6v62W-hKcySH(EyIo?Itz)b2CSUO1;6nhgYhimcXJ zQwQa*edyXhzCO9Ak$ik{q|~+KkXba@X15m+og*&>DOEBvESi0uv&Z4MgRGB`Ca~B z7-4ye`9|yRdB zuRestZb|h&%)L{Sxf?i@43KZ63kKE~nXzVjJ%t zIA*iTCf@q2Qv(ch%)8KKSz~i>f)k~XDlQ%^Yz10k*OFTnR<;bc_bBPT9Kzp`St3&8 zyw;}_)h{qP`)>E2imshkf=xDvTE@YM278svh%b)_GnQezO)#k~b^U>|9xhT<#~!QZ zPCHjS)wYH)^~zUKFQjwn-K|N3pSD=l-L!IPH#@(Pv;esSRa4?G0Y}QMUhjrgz2>qn zfelZZWO2tsyDB2zCKMFh3~CPaSox>@TeTJ$G5-gB5NHMJ>392f5;h(LTY(Y>g#aD1 z#Xu+nHRG3FZ)134+^@dusQwlYgdRb_^5M-f%e7l-zqf{yu6du{d}qOxF=kR@XWg~>-U*4z;62eTXf|6FlaYr znR$_K*wW6iONo0SQJbk6C@9tEUPQ!M4Wxaytb@x?R7;Iv{qNY@A3|CkJkkZ7L{>9x zsDqq=?G$<}OFE8K4TLw;|6h0mwO08@iN8;X&<&8(TI)-wTbIi5Er*U4h^QcVFg6HB zhiba(evH#3Jcf(Y1cExpJ+~T_Se%u!OIlJJT})r)1qNBnyxIQN1~}jARx`a~;3?np zVIpUOw=ifuNqMxj=Mb^))m&`Jlj!SMiYeK=DHdic%uCaQLOpRWBZ`#_rUF`3{0u5K zgjzm9whc{H?VFSfhk2QTHv|bEEtj$?w5E6aBwGCiL|D~rS-a{6a(ob|Zykjn$;s1@ z+~d~xe00e`p@QTykCdVT>!hOxwE?T3Lh?T^-`j&CXWE)%FM~&LD;0pVsSOU(l|_7e zO*LX%C^0CKNzSU=+`9zxf-=w!It9(8_(dK)K$kUw)CMZ^ z*9tKZec1J)EAph6oQ&~pwT=e@5N9r?{#fbdK?--41U-5?UJs%!vpj~pl=HPk%$6M^ z;yXeJ(9$n(c8@V*O3_#ff&2aK`BpsbaM^zzIIpn`N8QZDF}@}va*`V-512-BklV!! zkkO!ByA5hj^ADn^cAH!;zMVRJ2*e)G^0!M(ms#~h&>z4HJJ^mEIxOxksBwVUqzFHAUoEpX81K)6 z^x2~zPh-}aP3l(}VNbTNGUJ{eUx#w)48QV^VMw2G)o0{qFqj1X5)LvN02c0~Z;LUq z>QU+^^YzGA*#zGDHTnC?(w48e`g*f5Ir@MWvoV1wRmKKB&)Mx}?t1AOc^Qv~!txGd zPsHBr<1~0q#9c>3pzdQa3Qd|(}%i9h{q7G>&w0NkvJ|P5}ZMouw9ZQXta^C$u`#|_H#7f3{l@%6p)d$n8 z^R5Wk{1|wB$n*$40x14!9Al1a`p@fRiw(|uRv)fK&>9dJJ^t$u#oqn|m(SCa?Q3sy z6X1?BUpqf$KTxw0zu@R&2IzgKb$Wp+oiBUdEGW11TM`%lGxs@In02`}TL8gk7i!v{ z>U0a%z7#xM2Eyn%2+smAVz&|AXiN54`gg>BhfZGcnU0-Gm~c zW!*o@5OCa_c)V{Pq10n-fB(U}yABZtxCy<+Hw~OhMq%^FS(a4FJ>@w-wqzh?G7I+3 z*Ch0*Yk;fnz>(edN`1?i6|B=bkNlBtiAnk#;k81&Hp?`~7qCftl1`Tc3;~Y#AL*7P z6GX+Vn{a;IWbZhewQVeJJiXWLHfe5Jf|5iuOqOi?qc!;fmh=%FU`f0G$C3uvJw_j) zepfEV%4%NBU^;9+#fegPaT>7nl|AMeze7Ib8Rx9dk#Ibjbxd^vBf^i6ZZ1Xs&v4}_d>Ol=DjSSExQZvQ5`5v#}P1H9<| zza9tzJ@CO0nmQ|WsQH_h2HU+Yb1(%9T>-o0YA3+JAvGE{I~4tVE0Uh*39@rsYpYLi zF~{5mKxsWMLhs0{%hboxGqyThL)^i7;yyumja zGz8cy@BxW0&hpjI&|!gSfBeUDC71?Lr#ho|kK`u)gEVXGGp@9OWPjA(ttLy(Nb)?Um5Hf&JnSf8&<^x1^TJqH5l&Q=eROH|j^K$eYzI zP2T?h_a&ko#VfHy+y#so)nA8jVLxB(VZS+-9JwhBeoL~{Rw-B%w9t1SwT24sg^Xjn zUVez6q?$`hm6`(6Fyr{+J0WNs^NDSK+<5e=_RSk45~I52enJH+KgGwvh3_rDEusE1 zV?@07WbX}fZeh@)MnMrN^7$bPBGJ#c0wII8prhJ|1UwLs;bEop<*xE!y@x^OIp)$rVhw#weC%RQOV(O6tKSOFX_`$g@bDXaMbY8hyV&KSDrqbX_WOx&Qq zMqfqps$wX3mJ03}uwiW`X=zo%-S{D&1x@R*)TxxKV+)#O$-0@SM|QVYN*oaNrR1qV z540O1>|84sJHLhCR2 z8yqe4PPcKu2P1mBitnH~Cs#6%QbcjK6+S>b{K`3s1|W#~Olv>I{z28D*~CCX)<@NR zg@9SxLsh2~0yVB-o>wBwIP9pF+c?gAr-vjMjg!%mq+_UGt+~6f<5JNzbS^4VBYOG& zcxcFQqI4VLraS6c0YU2cuFNKgKh!fX3jaJ#fr2q(xC2v{RwjMjf z@}kwWXBa!d4Z+=^226j!1~4|SB)U!8F<{%fV$L$pm%K?=6EMK}eaQ5{l0t(%2vK9{wozUY?X{I(BiozG>ga`VRN1{-#E%E zS`9gE$>BFJKJ58LnSQ^z_z|WP@_>Y{f3+ZDFumNRg{0awR1`?K zB_r-7Z-uA$TbD{2E~XLyymz|TdgfwWJnn7{>n1)I8AHuSY5K`D6D7I6PK-f3}OUdz~6uv`~-{-GfR@W_iHmC z!N6pr4<))^fX$A67!Vn`4&Ef$rItHJYU$A^NGyZHSdN!7+wbckFn121Tmfsnj*=r-p(&NPkxup>MrCSrI3A>z%TKmApJlQ4_mS^5d|RKpdtJs(X$ee ze$L1YwJJH$Lmn^OvOTF@jbt!@h&-Y4lbS5}D>H*1&yBg6=WPJwZ@jYJ z(K03Y2Clrha@aLKBTMTDHrvL_AzHIG6x>|ntTumd?-8Oyqy>0O_yKkuX^;e;A4`^@ z)4m82E88v@YrB#w29Dn+|E!GN6*lLWC)K$pS+b;B1jfJ)tCgz+iM+4qgL4vTnq8bI3V zsxg@%7^VJ8n%XGYLe47l>2`c>f*n-o;GkvMMdhFA1JdV2fKmA8n3OeSBJypDs4@4K9kc5Ja&KoTANH*XoT?69yQfq9CWTLv zua7P{bNPXycO@Ug^FQI^AC$Zj!I^RSD0LKlFmbqZc3}lk7<@J@=s2T;=p^=V3jju0 z-4_>NAcf=!QITy5*s{XHS;e3<`+&nj|KF#XulVRsBuHSJcwbeI`E*h6M zm_s?mRN9)a`LeB?;m+PH{gXdT41f&J8jbSG3hdhI5|&9zYql#78$*c?oBCB|Zbe7} zT6Nkhrj$d;k0{3JhsYikrd1J_Ig?dPFb54eJ-!AXV{H`Nju-mv_9g$lU!FzPW#Akl|@^KfPVfUciwT+xO!b$qkN%C<^#sgm)OlyHVjyfQ#PJ@l-dLcTvqg*pJi+B3YeT(paO6n9UUU9( z^-P67FdzV;AMHpTvQFfJbD)?foB48Tq5=#=8OCs%H-X5e>!fAmaQdH&$KsTOgm3&! zanld)Hx&Uso1j-;Ln8L+e98t&7 zv7Ob3b{KW|;B+i<{!t)4!kWt3b&&x8y4!pJc0};mFrE}zVf%-5ZfJ2|@gPk|14$`6 zWSXi#DqcRd+&Tac`RAMIihPXxj$%~wEd$r^AOdjz`XgyM^MC%+&?{|G$svPAAd)}= z&B1!+x<>V|B$)|+kWX}?pSc!2jAZqb>p|VCQy&cO=0^{dK)Rx|nvspy-nNq?KNJ5S zg)Db&*8|A0O3&J3RM*oMY)1*wKA3up^P)Qq95jM_=jPuKSp|1AIH?n@zl7Tt|FT2# zh?OqG!Bc>K^Qk?>wbej7a%-M#bQDrVJp97QW=?0eUqB4h+*!c@B?E~_mz8~Y)7;iy zWc*y3zsTs@@qPKv(?}SAs6z8aRg{|bgz=NCkOk0z#BLO1j&fYFCo3zq>99;8pCEaE#oL}ay8ZP&cr`D0Q&t|4ggKk!;~;2(HR zTxyM?L58P4=|yMWkdr2=8O{`slKV;>(h+5=70`|9! z;j_55c<`l+T>rurG8;g;kBi|S4fKyCQ$OHKW{1J-f~I*=6I#5zG<@!#`iII4l#pP2jV%i{N2l!4ShEzQ9yi z@j=>$AHisJ9Hu{x@uI3dChXnv&TCsDP$Aem(VBFh=kQ0ZM+b)ORhl{hT;ttLa=VGkYd`FX~1;-T&(N{-l zV+Re7e|Pt`Y6Sp-@d?y5b=Cg|DU-=vXg2=K%d1r=AlBEd^{q$tr!Oj5oGY04T8YZf z84KG#&)#FK2<2Na!`&*;@I{>Wq$*YJa&*n=e3THBeZ{o?a>wBfoSJ278NzCde{{q}RHpFZ zOM6X{=@Fo>lIgKY5TM3p^z$x+bB8fG)*Fi%*el1NSXQohf9;q}#i_UMfDGBTRJi-f zooR}m${f?3nbfyzWlV(E<7w9tCk3dR5Loq{z~h*Dh zGqc!i<=RY;AoqD_}I{e z$wSS%%!`Tiknn_A>?^I23V`0OKg8V1JD(}a~O00bx-oHvJU4^ev11S5sDgFs{-{dkP$g*HY2cGmny*k zs23_-j_4B+_Fhm2={cP9K$hJJO;)7QtkCxij`;PZ9Vu}ly9R%3QWt8zbh}F(J-^S8 zIaVvS!CdAd-)$Y|&Gi+K2AGm5>lqio?3KiEAkzHxGBH2=Q$EEM{9k}zc{de;{!@F* zM7Wgun`Ot8t7=0|M8l{4FD4%HdjaGFBBc)cZpZB*5e`+=oH+$^3{=~{Tmjr+s_Gxg zibLu=XN_uh#8lXq!r5wVF%B?_Y=I*>N&TBEv%vR;JEkiGwps88sflT{+OU$kGA5F` zMrfGLF(LP__qs@jl9(LfrpSm`Kovj4wRS|c=2t%H4>-u4uYETDW*|R0)Uca z{heDz3~p#41S@zuafs#hn``y?>#qhRfFPDNXo zUqi?k+ymg+`X?*&B+;>W2l%Tml!4B!FHDaB;`>G7mSB2qznFNTCcrW9it6$B2{7-{ zKOJ+?%gF3{>D!}hSBwAJZz$OzQfpjL<@-HlJc|j^&PrmD%T+4|Y>%g)@Gaa(PAC!& zqsaO9H|>3IOCI5KX$#gB4Seyk#B+i8?m6ab;Zj*U*}!)vj03tD$CwAg#X1{mnOF-c z>c~F>p2na^>UdwUD8rwBv6yd=Yah1UAVpCAwlUm)-h=-PI01ttyqd_*WyR+n6Qn&c zvzV~W3WPK+XVF*!nC@9(lPi7XCM@!2Nh&10;07vSZ*sBL0 zL-s9Nb)@gcYF?m$T_;^n3ol`eN*2aIi5^CW;+;>o*RQJI{N2y?(b7A`zG#tMI zG<&Os9bs1KW<7u|3N-N|>kZE?>KoOC6|(`|hBwn!W-$WWiw zns~K7m&kbi%8?1*wq21r?AADsX+DN<`Opufvr(FvxcqmSe$XszmmK3%{Y+hQ808co z1-|k}1NQFDchKKmFkOePIj0xvhSh+>#s5(u=)z~W^WXCrjC={hJyC5jt-s&Z7E^J? z(Vj(cc><@-+*Hz0mv{rmHw$-!N4QiCAbjx%%-YGwz)xi>qY2n81|2+(*{x)@lu+QMGABYP2?v zYi6SLf!h9GWqtoRd}|yc_V5!{{*imF^tQfyegKs318Hqi!~@ROB|vhoH`9qpCbb17 z{=Ya{DkOUjX%Q`+ke*s7zCF00$b7+qw_c4%1B;Tm9-vW@*8m#DqyP3U5W zIsp8)*<1SdywHoR0-tFAQPO&u1SDUZDh<3Z+QJQhmkRts`3XqSSj%4K#Jls_XR@)0 z9r!6!=499+vsFob5_iX^*8QKY^|9MLB>S#aNspe(f=byX9t)Q9xgYXaLENsP7yllJ zmmQ4>am=TZCO(Z)KIF+zcQ5%`s$4#y%+>~X0nF0P#6KM64DnqW?SFodzU`~I1^m%t z(Xgo_a`x)ylIM0qG-9tF^I38lr$7!BA28yNsPyR9*2j+I$F-~kRnR^9;~;0(>` zf4C{5sZ!p*zm*78sUYn1eS6Ub6xmw?GN1-a^ygRJQy56qGUEFd)l~;i;%40`*0uih zPu>1ev4y9jb@>_HbZ!a~uOU>;*WPDsG%u8^-@nb`A2x>EG}(7z+HfrVjygwi--Oa+ z!#jOI|D0+yI(_OgmEG{n;im)5r?x~#J1kT)WiFLl@R}4GjoId)CGg=%&$&U=LN9(+ zGLSi{7pxBW&4*ynC|gk})+e4$EdPu7kw!eAOpw0C7FrJadI}_jka;CjG7xQxfvgZ=lAoOIKZ__kW+j zzkP-50*p9R0z8vtvP*@-_EP|twI>ml2HBY7ySGdv_87}R*~u}%F`YMEq?6(Vtl^Kr zuLxN2j~59LgskeqagI?BvKzcN1ha5R-c?u?UpP&!pL!0h*??7y7Rmm>C$T~UA71|f z;1lywmodO>4G7iN(zol_{fX;&b(a*J-qoT`@bsnTc^|+|IyV{q(0^Vf8%f66xAT_` z=?Hhlk8}V7I3e?n2w!2A#?LXbx0f zCDzLL+UfgUy;iYGay6!Sd8|L4)Yo1gvYXJB~d-tMDpiV$6c~SbK9$WCg7-*<9n;Tp-Q& z{bmHzPs{hMH6l>?c&N0$FaZl#%WnB(r8>-VoxaTZ`hKWDv740O{Qz)rd3yq&NgDu~ zxbe%k%&y7RQ2Rn#PHu;!pnN~KeZgqB>s}^6{kDY*dK7cP7Bs*e_HwPSI=VkSHAr>I z-L*EU@*Q{2vS5~%Ht(I{f0^iea2^IUdM~r4}mNSrN zynMASB7t<=p66Y97VWCZSy8F-koLA;fx=Ud9abN$86dq)igW;Wf5`jlqO0#&i1c>! zY2;M4^vN?rip|6`k?x)TE8nK)_+R-pt4`L(`IX?gX>CUsC>Pr^vzuKDHv6dE?a{u% z0w$<@>$_${DNy7gZUL71URh>eY*NBU#n~Z2QH~Y6moxYO!)lDc|6w%+9>wJT#({C# zCO#=2H24BGtOYc7P7)O(DkLOKsXgIo_^@{bdOrOq1kT>YbOFV7@rQ(M#Ld>wJK90f z#>j2$QAinCAZFBey`RMGuMi->5e$MEE(bT4SnBr+PN|WrJN~Hj>HohXZkXd3kSpj< zR_0T8UMF8&(wg70(RiE@{l_kPXK5sazxV$6OuH@vKGTi*js-hxAO0Ght-H%Pkc{2= z<4I?;&vI&JzB(@z8!1+G$8%?_ScM1)b0#K&3X0xaS=j7Lb*?!!kZ%ePbS%O-VoQCy z->FYJvkomC;_Jlcmb*Zri6BqCmmbUW5OS8f6~C}xeHQd0jHyWrCtgo<@EvVkHUURF zC0+zGgF6l}ku%GR~ZXvC3H2fut<8-X{wWkWR=`~ms za<}=c2{~+e_B+sKt-ieZ=2KF#04J!l9m9+?w?-KW!Jw+JEo^m;V}T7%V_aD4SAe`n zGsUngG(a|q<=UtDpn^s2y5$v3sk_&8nUk8VVa+yJ)00HfK!InJ1tD(U>#Rk-Ddsw2 z26JM~V``&_jmiYbBd)IIu|$*l!|6uv{bXwTnWfhDRIeNqCVhI^2;PVfk)`F_kEMZ6Vfe>f;ue?l!YJ71|? zRA9!G?$bhAUQ(4|DusNn@ALiG%%20Di^P~%-|@S(e+yno`1V(EmU)YEFSfVgb1WFS zd7?9z<+~l&C8W%{!1yFnHi?Gf&pv)(RybDk7b{xV48*Kvf5z4~SbdXbeZhu8270Q? zoirpx%)5iUh*sS}%!KAG>slUXLryb@E%>Dj%yoq82%LOnshUDg50|qYvZ=>JU3hqN zWTFMO)S5n^6pv<9$e!lA0Aq*V+?k^6#{O>L@W+&CnIC@9o<43p&A4hWk-fNH%_pBd zZ`vp!&FYSCiFCLNrN346$!(;Z{Xyr9hW2;u6D8i4UXOnnhS#oj_4lm}r{?~)5xvWW zw1XMwWtJtdYe@SQ7s6b3-s{{Z7LFte7}C@cs_pArSl}};H^e1+pPE6g5F z4M^4fEMat(;#FV^7G+$#&79WE2jmYx2MmSq%l>tsW4`qFl`gr>fGyAgZ~wXtd(ZIA z?Z-9y+I6xD|Ayb^7Z>F|!uChVNj?w5$NTK-k#P4CYCm>%>e>1^PxrQ#u7~ zO><;P#%Dhb+nPZn`@{9|@6o%G&9U}7q`cGRvTpG|*Qg?l@Z4Q6shnhdJv-Ge$O-~V zM(X2B?AKE?FPTnqNehN=cfS73QzPj*WST<2G4p-zquJc_zp-%*VZZvj)$%-3J-U9@ z#+dv_4kCks7uGoRyAK>oJnr4Yp~7X!Q=BehdMaJu8?>mnCq20JE4K0_=q3pHI-T}=4ZSzksz%<_F9*i+h_$Db zjD9Qop8(j0Sz+I_RH^Y!h7pYdLu`PjU!@GOUj?*sY|+qZr}o9vd!cgs*#k4x^YpRX z;%;jDW%259A9lRovupX}{1hPaZY#}k{Tch_m3A4Sm|pVfhF*P9y7u`R88IiB0Sn%a ziF}56M<6#V47boTtBG!8aBsTeSxl+u#Y@5aX2k7Bc%4wSlMh-GK@#VZ4tw+K;DBuOnd}(R}@M9YeawK>inP zKKjv=AeS)2VouX;$0+$i+^DhQGla^VzKSJcL$FU)v3G7+v>Y&}nk&9PE;4Pj6{j0V zMJHN*xU~#xtNigEm#X10jF~}-wUrA;acI{|;h1-ezTj^+tNrla1M_%~{^z}a3kr}y zegtHY(=VRdYWBjS78NZu2Pw(xvznF6R0zn-F{p2>8x6rR`L>Vqb{TC7PPMg(xF!2IY=_&D)w4V& z3gyG}#B17>HQe7TnmY08?-XGdM1mX(B&8GRD!Z&xPhexk(oLdM(Kc%ScHZ4f{&xIc z27C>PJ!fwESL*sN<)r17wh3!)$ooX{5SRxrHAO4YX%}s_2}d0*)9#Gepn#Q9$j% zsw`Hnt_@cq1sIfutk7v^6?-j`$qDG28^7#yYJIk4n>Y%zNwtvlzJLHMQQ8%-D_A+# z(E;mNf2Lzw#OygeihgVOBq+P$&Qh0o%gwt`6W!ZDrDc12N*Q^3yG$2Vw?dN&YEAX0 z8c4cwvWe~$eZ$TeZlt>c_YSf$M*xv5*dj(kfdb8jme;T7&AKtldM}gWtnuJ&A)qw z;J!V7!)SLAXJZ{8R`fDv-ThcoBXJM8x}CLoY4mwFwVMY|*2L@cBYMWlwrm4!Dxsq3 z={7;q!}kGa9Tj~ka@6WJQXT$|2AzJ`;V8HuzMQ^29Mwj`!wC4jl%xmO12@Js6^cSa*Rz&QPxehG z_$cR@20BN`*~FLIsS4BqCHO*{0&0_!p5Zk8E60TwC12kut7|kU7k%=}9*n8LA7emQ zrQKRXS0$8}@-ni(U6+*f;LycF{H4=E?`rY=6hbqD_qp;Bcb9G-78D zFfi(u$^NcH4Pl=H^O#K`lroL+6FZCF&vg|kF|DURaO7aof_3(R9I)teegKWX($99piP zE;*EM{>ixbi%5q>oKHt%T}0E}+V%^O67rdD!Bfl>!f{&_F)cOHn8iLX7Y_14v$+uY zd`XculGzaN0!tlWenK9~n1=+b+2@7`WA=K6=ITiYudzqq7OrIssZmGk z+l*}?5l3#@j5`t_oCOVYqA}MY!Az_0uII-l+2%kHnQdUn(z~PL`ynfq%N4w})A!iB zP_m5a`51=AXzo z5#?2PKV+RH%pnPUtwKOQ52KP>q9j2kY#tCv6pclmq|{^O zx{ZRMNexH^MAsQk9BmpYd(PTdV1=BRs}yD-L6nL`5Q;V{Fm-*MkSp^f-Fc>3`6Ng) zbBxC;F#|t68Furlg_~ML(>zDEMp-YpYse2*zq7@^R2rrLxK4n7>0mPxOaL3WQHZb> zq3Ym&!|V7!!j?p1#R38+{6M-Kbty?SU4Xy9f`0W(GqnGGcG^)8j+CD>>1`pgpOUEi z{nTuSNs97BdOQ%h6KK2f7|J8j2tP9U=JZ!Hw}cR%NzU(TWg+5z`k)c>2?g|9lJOmm z%x%B-(%Ac?jatEU{~J>V0rFiF?KvUDQtW+=+ltI6)ge(w(tDd@Xe z(nq+>@#tc+V@rY9lgAdk5|i+|lVR7tI=Od*HBEB_YLuA)wYuK2gih#}pw@z=4W?X? z=Wk|JC~VF8Wi52WWDqTM<&SnSo# zv1Wre^K&TT6STDAaKj?-UgSUs&O!&WM1210WQpgRJL3VvkVPD)JzrM!R!)6(FzusW6`RFFS&y6q3DOQsOOUt}|(iO4p`TCZ->3T9`qJZP`kI;uU3G5S6 zT%C7j<-?EQ^X!V`i(>;e69yuU8FmO<$JBT|Ss zJr@3{<=3N}*nOKnPnO8#gs9BB%V)n^l3y)IEy;Z&98>D;R!Q@ZQ=wO>mCD37QI`aD zPPdFURhbnjz4kXUpbs*Q{DAC49HR7EB>ZRct1Zo({@+cz{U~O=voxMdB=(-mV(LB7 z5a(T^2jwjJ;I4H~?yPM%xtOwZqg=e=dk=#-G=7xs&gbg+xq5eB4c@*QOIw2+#H<0G z>guXB(xihEis6C^9@b&(#>RSOt|YS^yTm#k1uBarhH6}Mvw>8;P3j{R;dlyEC9_~t zF>(Cwdim*?DhdV^+*2-l^)W6HQ^D^BRN0URe0ENrABn8waP=MHAU)=bhkrlF};p3mh1-AK=>?VCoFuNU* z%?7FLVx8dv;VD$)o}+?_*4I5`mP}E_pK8IGQ4X}9IC3(9BEwAaWqHK89BJjyS(w#^ zy`YyfP}LH%bmEY)g`oQ<^UEi4466jED*mBy&wRMZ7+L#-UcX5M8i@rZMHl~>XxQ%V z?T)4YJ&l&<(a>T~9(-yO$xPWDdTzy2fRvDObY#_FrUW(=y6{oa-#_Nm?yX`LD@<}n ziNfH|^dFB)gYg!eFN+EX^0q>7?`)Tm^*2z$96>2PHbisH=pPU+hVwDR$sHh+XtbIE zVO$yIV|>YLy>ac~{u;bMsq$t2_YiIOBZQdx&zq&7RTONZpbh>3T7~?!&o=!+G`az0 z$IU49$Hz^RkatK@Iyk#+w`ag>2#FWZfNjDn7i7q+HE)aFAeG5~Y@jZ0*ix@=Tb8MK z>7=Ss>EEi!+uB*I?nZ#sdRU|``a@N)>S6(3z$0Dpq1fk9|8zxlYTMa!yYWM~qy;Fd zf+CTSV2&MaWj6}S+&j^xTBF$?i8i?X_`XoSaFFXSArfa4fk?kg_lgMOkof4?M+0M6 zt+_YeW&C-i>hZq28; z?eAUz{#YlS-diPxo?OrzldL(MuW@q|jRvzC-WBZ!$X#pm1|RaXUeoja zA>n&6%`6|PLle9?aPxDr)VA{9eTo^S@$tEvZhIvC@5zWc{gmbMPQO*B(HGD*%0YE5 z7QFL5rJKV0_5>8&Xd0Sk8mIVZq9t9Z6re$$IwAXb*hY6l>SMQKMU>(l^?E&1TVEM@ zezL~H7tP%{M2-QkAi+wVy1@^3JX**~3{YxyUITHe=l}#S*R}vj^3Tih-+*-BdOb1q zu@#%ZMaZ?#x#zZyNC4RKg4=phbP&9?HWwSFzD9p&GyS6I`HIamZN) z>Tq#S(dv@jS+_HeTEt6%h1nc!-p?EyMLfOg3Rx43mTEU z@H;Bkr3{g3fpqIAfMX0!Si~ScACvZ!^ILq`WRqXn=_WLMR_3x{NAanU8Y`Av z$&2Abg2F235W~ELPwd`+(;&MjAv*cnasJuIY};Y%rsaC&qQ?=HKhB8^fi8puiHPKC z8$s{z5}}75J8}TtRt4$P{_0h}>zK7c|DMTbtA~+Gcf9x&Iur!@A0OUzo?A`_9pLD= zQGDE-b*FgzGJ}B-5p|^B!`^NWOE!B5Xjl<>1ITJyUjlPW&#oi%@WP%j0TVe|V=HBAA?85KLjla?Z}ni($thXL|q z+u8}F{qp#tdaNvsO+<6sMYAU_BqB14M~BL}dR{cWVw5f*lqY=90I3Cgv>JYG=de1Y ztn=Ro8;_>y3q{OvsQiquW>IxOMf%X|Jhc_ipNm9~7#CP*j~H&z;u~KITwhgcrzp}gnW6ux0v}LZmU5>VC{g}z+7K+;m-(8S02-aNDN6SHL(kS_0gP|W5 z$YzSPu0*>ig<73)$bL#9qv*MB)o6V6+7J3DXl8ZVvB;@1v>R~^Jkvj@bK4D-Y@pcR zne{&k5-hlb#eBv(lu8qv&~XQbN}+uB$N9@hH5EfXPC{_DfvpQPhz$A|s+*`K(k)FS zzPx(eCrGnWG;ijPoIPA+gBwE5qa707Oyb5?p3KI`EG>?GyKTdsdDh-AYg*|!%x)yFx58@C#4)bi7Io*qfvNL!r=^C! z%8hPet!oIZ6&-DsvEB|t6J`@WE;6`du@bTdiqzrW*QK1|94*mrdjL5C0rP1o!cY$l zHGJfZn>u|o95FKH-N|`hFz&0K$4z7eesa_q;P&E4DBZS3;!Az6eF1^oxO*5!5*q*w zO!G5e{eT40JQ54lZkin(3dO?%H|HlKF(lyToc28UC0#^Cr930a6S@uTyx(D6hYkCf zn2`M)8`u{J$@f68`=~N(t*>;p%Ll(%9-@O47F@p-ti!nseUCi?JzCj~))K$oQBib+ zKgFD0p$NU?4QZ4;JpG_+NYt zG|Xk~hgWO#ZQ(BGFye7DiS4?!yHU**ib- z-xqRFCzs7vJ=9#ShNgPTj1`Vj2R{y9A)K+Hyz5`3&=FhzSm4JV|mk3jQ;t+ z&#ZNF?=^WdI@i>1{HVBQTg#_^E5?3p>b%X^x;5_#xSNe%NFxx3!EBl?!|KF8MRxmS zpu-k}}MFS%4;wT;lyw^8iN?0 z%4ASmFOk`RcAqUV{z8Cu14UwfJ6!5>^EH!j`wIP}fT!WkfhR^M{T(qMZkwCO;7)%% zaCUfoR_mbIs?wvAr?%Z-nEKl9&20&5-o#AC#S+WxrfNBseHFdo#C(63Gw`v~woaP# z?)0a=4^I+F-ex^!v!vVEx35p7b5zTHt$)d;-;S+Y(hk3>Q?SyMmT2Ijs=itj=FSjG ztzmN@;j^2c7%yv~9@--iB`Rc9qJYz@p@B1o*PFp#v^-S!W}j+()K-3IZ;t>phaDcF z*=2ZwA$Q|Z`(8wMJXYCh2}y6J-RURzS z3$<@j_p->_KOMTA8>h!Ji# zawdQAv1uAQd_FISs4-ZJY1xuaW-z2(xrYxnf?t#tYS*+C9DI3tfdAGk@cnWFx!-3} znD~L9p-iwEaRRwW`nSKpoqG*4qBU=@fsUs6z()2sBSs z{>u9(E_gQm_sX1c_D}wt9>QzNPHRZrE!O9g!zZ66AV^_wOU?aR98OMUrvTT}{Fu zPaPeav23n^s;x+2YvDJ z1f$_N6VUNv=T+o43&(qF_aDs^0*3+=W0^K$I)A-eJk>wxT-->~E|HeV@e8}Fp@}{p zCD*=4jQqQb)t^&#aHykpzns-ZT!MGpk}QOOu)DQBuyJ84ehBVf%?Ien9Dy9V0}{GxH635k^`ACL zXW7@_kT7IZyPi`s(?K>m%M)YMVC8Z|eidF79_hPgu4%Jy21P52K?!DV(Qu)(6}3l? zZv4LXsfm)GA*X!9b*BMjkvpOo^l$mLTf|XZ{q`1m+m2SrLK<;1z%Cz2vwEzD46Mc0g@id0?zP`Q9@YW&g7nBFy(vWFn zQ^U&UV;kxOSMc&24C#|JOdz)|dWT3zAa_&EhUoO%>%&|voE2|RW8MXFZxx3KuBe&K zMBIS&-o?5rN+}CeuiZ3PtGCf`+=tcY<}v8+n8VA)%iR`uE$!vG+r}7PWE^1;2&@?c zfwgZ{%FqIzvKNTiMeRy}wkNN1X86U~K8#j=0J2w?dBn}zL$;=ZRf?lm&J#`p5=zfK zsJ31Is>;(|ugoniXhb8$^32rBlG>aYs{vs-CVVI^k>Qoc^`-mf>zjL!O7(5lJ9p&w zwL-*1D~-}jZ(HT3$I4EkKC8eMzKh;Kyn;UDL0RQ*7M3md?}|9Z+dThYFzEjy>#c+0 zdV(%clHj(u1_^G#C3pxDAS@nSg1fsXNbo>#ch}(V?(QrWd|`2yyqo;K?|t>^{Y4eE zb^FeAPtQ!B)8`rs4(9h>>tIwGImO|#jKnS4f+DMI{-jrI@}&3k%KXJasI6I{+`+eWX~+5RPH5D=z+U3yio zSMvCj@_yX{r)3rAmk%Bo%R0~^056LnSqAm$N-1`^YdEbm9b-?b;D(7M??wHSTeB2L z0@n)pF_5Z`O~E)w%(&jNkTR5J9f?YoE(1(fduG*(HzgBa#w0OYif0%8ENwbn zDV_{Xea^&hDJIo)Vu|k22zsX)1n1%0h=}LLBoGGU~$}ZOXfUFEjU;CqeWj{;T z6ex3wuhIhm_i3fHn4!XLDza~m;|zhZ`z#Otw-HsZbS=VXDv#K@8C|px<9xNX)5jI2 zL54WDn{r?F?Jd@HWsB=SV~Aj~lS#3LqsjlJhI-{9&xaLrR3ATYc(e1V>|%QwBN% zfd6!Gwdse$PM4_I9&*MGRfWvbr$hH;bsvti4d1%r!kga6hqDil#}7V&cUmX84X1QM zT`060P)QazZ>D%$n(5=Bmml7;X|^nE_9kd-s9Ii5%&G-@XRg{wzK)qZ*|72_(!OkI z=={6G`yGAt1$OwH%p&`Op4p~`-B5D5*;kVm8AFN}a^qPOlJlPiYltl^nlr?=TB9aW z{38*sg;*z!?u zN|J?Dm`VLTs-GRmWv`-+J7##SaS6OAJ-I7^*M3zW(DC=ti+iPcD9Wi{mu8pJ;JDIj zlF`$FSaj7HJ?fIvk(pu04%DYW!-ZcVc;=8ZQ@kBukFAfP8_fRx_jDz#b0yGy9Sv`U zbTXYAw0aAl=<|!rmyG4p>6^OSCu&p+|JW4Z!8Ly$Y?h2JJhF{0uVW}on30|xU0@-P zG9ltii(KE&rTGTjBUcnnC!I@oDF?RxY9JyUG`7QNjdVPn`}2Pun@#rm?_&cqN`KJ3 z`-u_{t{X;Snz4u3$) z*4m1mocSExR6CUgtd?sF4nC1C6AEi2yI{_g4ROoOr;l+{@bo+{nu_)KUpNZ1agrUz z9}uJB_Rs&2=XD|mhh0Q+WZnb6>7t9B2TFhX@BNMOOt`xk<9=n9)?w1i(Sa!(%+b9b zPMk4TBKvylKjN}Hd||#U#Qes{(Xk1NVhP5Wpnt}%xK9%hbG1U1} zyI7GfHaJ=iyq~#qvXG-8BI}|3=3I*W4uh9>-=) zaV&qAnE*W(nLx6I^Y^`h&HSCR&z{Kg^gngjG+x9&1Kvtw;u1%+UhyNBTz=&$;ulpB zB5*7Fc6?*M+pnL(q#Y;xHUDr>nU2Yf1eoZ4XZ zV=b`L5f$RS730h#5vHt5fpXOiziFipuM8E(Ss*k1gk?11Lb1f@68%;MX$hx}iELpn z@og6)nCOIF8_1^pAd`_xbP}B-O6`n7i72pM=%$E2Ei$iRW6Kwm4>n99UsWwXOw1O1 zC(2M`PR>*N?^U&P267#MGb~vS*`+KH(jnKA%n&r8uQe%(%M-2en`&|7DTxQfkBz-u ztwQUpoAph!S`W8Ll#3zrh>V@An{8pSUxw)i|bR{H4K#h6UpIT*AThd%x5kA5#NcGQ_DGqDoNwZFo_T zibr`-KFYl2LqW2bW63P0#r!7RhM6`5?Ieo;N7Xz2#?`s*a@}`j=LP0AX9coYyGZ?7 z*a30-dWHuepEU(Hn|fl(j2l$lG~FP(2?j{mP#6Gyi)_G9PMWX}FqZcU49K%IotQ-o z{*s}0HMaeE9W#e6q>9Y%At|*upeb1(DHT|RZ(s(t&Eqy+Ua9+cViJWHyfxVk$?08z zpI)ndooJPOH-s|KI^jJE?1t^bSTxh+gh<(O+JONoj6{mq0Sc+?laVa`bvt{}&x2pCwIC<+E-@5pYYWk}18ZXLEo z$)B2K^27yEgt_1Tl3g9;4WQH+BU7t2a=JU1LJ zYJB~pVdJW=N;}G?h?C3ONg3op2xlz3zzUaF-trYq8A~JMS#I|LPJ)rZb$Ygl-kxE!Sy8Xvb8PM|A zgi8s`VvK_}7iDKY?1Ka6Y3rg`Q|vP=Mk8z|B50JW$32#gEkNq?ZO|1B@w#wWk>hZW zy4Ibbn$kOQBc9gF-0nMU^sikgZ1i@>p0E$)B+_N)*#_hCrGLEQ(F}jyQ0K1AEQYxL zzKJ_yQDJQYSdyI!em*>>R~!Nx4-EqVhC#kUAFev7=Nw#h`{|``-s@$0)Q!J5<}GD{ zxeJD6HDWZ98-KHMOr~KRUT3j1;8>XY-xIH=F{?8#U{x#aYydFnAl#vH8I+O65Xx^TNfQ19_9=wED8 zAJfR_wFDOn({wG1(I9ZtSL(Ep8ZYe;wRwPNByl9mlD&xiF4TSGsQLyU5!cm6?5HB~ zx>mKxBo*NN`O^hbFy^KrR4;HvwUXVjl#!Aup*GJc2y4)u9#glX1^e3Yi5gSQaLV_G zh)&_7IHOlgNlU4!e&Mq;L3idlnbzly#Z46ou21KEBRfy9+XpiTA2m_e~I(Gb#N0q`77er0_3sFv<-)K0U>!gV_lSKTC4TtsYVTb zm_g=5@Wc?9&Ne+-t~B>Ebw#jpQm$U+D9%+@nR(>BAV*S}FPffTUn>a=IH1|pFvt|? z&@GY0Y``dsavlnjzns~50AMyp7tRGu7#HjFAoZo3)Lkz+8kTGwgIl7Kj}q*-FsCI< zQGTz`R9uuNx9;T%(x8FZs3_y`m2L8y;i^}tO19D6uXpZ^6Bv+arLE%hk4vLUeNHj6 zybBWEZPz)b0U@La+b9Igi8c9+Fh9^FFiZdnf$%DChao$v`f*-prTZ0BaWg2TONts} z<|bWKp*`I93&iozd`=*I!%KkhRjN=h4RusZua&wBy45h37E$3k`jSp7nX_irAV}k| z+NBA^z{T5VaMe+4#3DH%Kv%W+8Fn(hbCVT>dQ2rHC3xGdRolW`+HQWst3EXoIw@~f zu`BMxQ&{(6#q3buG%f?`!ogJ=KtpHFCu0!d8a;}6OsOfj>F9Y|i)wpmpIQ0_6QyF+ zx>)-Pe4VkTry%rOLWM-_@ue9CfT zmjf=r`%k2%OY~K*+NK3Q`>*u~NLHD_w>5Z&WqgMB6u9Hw6Q7)E_P&x0jGOV#Kw>Ms z+0&q;HcNP4N!S%ZF!=SgR9fMsoEYb)@c^b$o;`rPL!nOLi~P*HAw)>%>*zA7W8?S> zzCaOkAE-?2kv%E{2L+E4SIujF)l#Es7O)4A3C<3Ff3c?n`hBz3a0_W+d)y6y!c=S+ zg93fVuJ{>ulzC=RQjjFcvWgzM5P6@^x?kUHRL7C}N>4MS=1>Jd2BcOe%nZnd{&kA{-BL_tEr4PJe0*}$Fg~<>mHDAx5+633$gq4AQ~Utuv%8!8 zkkSs5NeB?J>v$Y4{@ezdJ(WfD!*p~AD0m1>)^b@OmT-uZ91h}zyeZC{)F*NgeZjhW zxuTgTenLb9B6Nr&JnOv`RlY=biCE>@7cFQvn;cj^VM4@7fumSugZBn*S*O7` zmhvojv@9|nwxGw8Yeo-sA0Znxu$Zv`=^Sva+r45+M%aCtQ;o&jHS+P{bU&VLZIISd zx6`74s&Et2CCmZ(ie#RJL9DG3q#7z5ghkkALPO zDuB8KW-q41HV0ylP!sG1iD%lAwqgY?W@?dEr-z|DNj;kK)54(THK|u;4WAWDkU)eC z%iaTD(gwd?z8l!TFIuWl;2Kq0KtN&j^|{_Uhb6jAbTfGI3M*z7@3`ciseVajZioQ* zw1cj{G{hoovtUz)!y=yC0u#wZ>1Hg&ZUaM(C_|{~b)i3h9&MK7XsD>WR5xajEUX(985bQ3ezuUedCE6Pc_&we=FHuY`CBQlOq1dK~$t%@&gUZAD*zN5%ltb|Z8-Ks)nSd+S7ZZTs>cZ2c!Q_GYu=rHt^+ z`$Si(Uwf&Rer1`n&zrL%Zvd!a+tz-Zn5|ls-_{N!ljZj7GXU{^{U2VO@uwt~X_kZC z4t(4VRLwe+7@3ndr8yd)X|Iu@{er&~nW8&IsWF+i@6WvP9LCA$I`u2(SB&axEcsiP zeT3luT<6?Z`xZT4vamc3TP+$VAXnb>j?N3b)SdDEf$+{Qh02rC`5dP>6!S>fWvIUU-8;7>sg@FWo^4J#xlh<1!pgj~&)|Qh#00NZj>w z{|g|Ax}}c6POh?Qbhl5BVE50E^Bv}szPBP~Bo}RP2|Buood1j6H5U|lVu7ZU(6`!D zbaL=cn;8v2F-$K+)KiZV(|%D6&E<0}iyM7i0j_H9eg!Y&rvZxkm^%bTJC8p+oI$Ra z!UDxG+ZBw@#y?d!EB3lCqw*!wyP6mCQ$7e9K*H9bXf8k~o+k`)h@-#r`1RZzWRn!~ zaI;gUktq}#=(5q9YzSGGx{`MYReom((Hdz@DF?f{9K|fxEBzP&mi9cEs*1B8w??74 zkx8bh>NcxccwRJ}5^B7nR#8G(7N{_vUx`=+Da8vdf8UiVWdUU~eeYWAiJJ$x_5mEYXKb(p?|lW(8bT!-qxqn&y* zIp#5rx)bQ>CY{q9uoeo7`hJLK^B0FT)yt7k6b7fPg%26I#1Ci=465FozEe6PE`}X@ zi|)*ovqg-}@Ro;oUh-Wv$i=e z<%sbAH~QlU1LwbR3?)QI-N{Y_G)De55Q~w$8#DD^-O;~_r$B+ z`bCak14y(QZtRj`qop(VSVHT7M3b)l3~Yevxme3bl_!Zb#Z?`ky_b@NOU7I}9m`3z z4O5o~7|(jS=P_JI6y3PWOx1)aD(uA&h$q%k@?29TeD_F@GL!V#Z14*Qd^!6HX&mqB zIpx2BVqeYo?*Id>{_TN7;7}yx<0bu}EkH617G(;r@GowVp$=8jHA10urYrbV7P!*j5EduH0TIiB9{`E=5G5u-5d)fCBWL6!vLpYh?hp}ccMVQ`vDkTqs zMQZ@Gjry@f8yXK}vLOP9L7J3DiK^7!xFL&E0#=3Uzg4mOuyh?#7|tHLB{Uqy9g|hT zWKU9znwB$B6x7_pb%^F-SBMAs4DTXPSW6_3k5Jx8*snzQoey4-kkF|?beipR<|y+E z(tX>4&TBTie_@lVltz`nD93oZ2cDtKBMk+jjbjGkI^LaBs_~U^Eu|DTJFBWR!WWdR!h-!y@)yq z9}TzP4{I%7L1H~<=VOQx86vT*+9CmSVRhFTJJ#i8`bA{(q`6?+FY6qy}JK3E6g`PBuHVX^=Rpv;bc%$C5$G^eGoBzYtz-kE*Imk zGK%gdN2Bi|oUCs6HWU;(O;k0%5-h=3reS3#HahTf9hIH){Pg)w*^05malPWqg)rVMQFr`dCuLU7hG?XZ*|KInRg=%RTEb%_6bL;B1cB zuBf`+)jqGzEVXApk6dhY((R(n**vMji}Gn%g;u2$qdCmfN;TkAKJ`@R@zUr z`xnmq{y%VLN1fasKy{<+I@qMwRz9`3Q zpL>Po(JGxAn14lH4t#h}B-5DN<8`$p34sL(pCqY? zf2mH3fHYlWi&e0p4>Alo-PQ6PS$=n#)c%Od(K_WDz8K7&+Us&|v4 zqsW-0G$}YbnS*H?QXbaGnA>@f>mJWPvubzCK3EeY;&sp7I_(v`eC_M$e@}n0AM=aoW%{DMp=Oc<=FZI3ph>pAkJQQ$&ZLr!ICT~-zJ)~S z=r>znR`%b2T|SNs$*^GJ8=wE;Wli`de2xbJXn>qLjt9I#-R#!`c!fG=;DE|NlcZnH z*`ruULLJp3Y^-p~Y!;WSmI0LWFzk6+@g`?x$kUnu%Ap*|WO$VtJt#(bw?`-Ns$%7S zbEagu%)e!B@6YoeI<%7K)gaQ8p1_Q3K^M#ho1cQp6Yn}3HFBxJfgiMX3 z1#%K2Qg1MAy;ua|3Qc(>u=Vb$ReNK9jMxD;^-GY1aRosZ;AJ)tGnLV7v7j$(ubBPHDV?Q-vhy3$15bXNYVofqOB$2hJl?fuVpN5@l(>w{r#Z6+w-Qxf|cBNi3R#9%4U(D{8N$V zi&(mulSeM}aQAY@F48vnmcYH@YefgVWfs)P`TdPuBJgCK{hu6@SD8v6=gBOgub7;q zaAd1I@P8q{$zW3&YS(!U0s`Wv?ROU!)HXGr-Xj@iA8a>@L?TQB!}$4k7zdOF9f(zW z{dqR|yyh z{9`H|WEa*opSY2Ba~Q|2ELhAd6pZDaa)o%gkx)oeL`7eh^kfg+wkPxISF5gmwTPIQ zm3lb7)W9h`q}>5l(QnKxx{xV@w4ApIz}6`5bw@Qub;eiH+zf1tg~D@Q3LppE-h0JW z?L&zM45c*rLu2vc*eQY28&G zHPB3r$DXUc5$C&t`v-%WI5*Ath0Gup-D-`NB$EPy2bXMv1pMK{w*ZCe05gL=q^a_n z`K;!wQIM?Qm$&$o6i^a&=P|4g`5khRqZgSZW35h{=@K#O3i=Ja(=W)%Ej%&h%0Ywz zFSiJBm11HIJJVp0k6M~bAgf8@BBq4k47Nc01qx2`O#1Sj1PW<$heqXfN3PPH+;KI9 z=Y^1=C0mg&4fd+oB|Jy762IgFaJtM@@)#v#`~-d54ISRcX^Jl>4EZ^9Y~bmyLE-3? znz3L1#&IS&!`j@F)6j|a2UmumwN<_uGw5m9ddW0#5Dff~hG3PBQ+Vur(LS~N(zvOS zc*f{FdD%)oDts@ynFcsI1F?L7VmKV%Iqk{Zzq92B|2PjiBybgjtKym2gnB~0MsKM{?tXJEB8C{^CU6pq(WW3(GId6!aKXL1?Jf$H*K%}4Il)__ zmp1(7Ms+g75{0q$^9E42kywqeXq}kV6Z{_Rkko%@ad{mb=!SHR+q;i=gtttuVww3y zn?|#PBYe~;|EhR73Bg-Jcw)lTCubB<=%z+QtPx}4Zt{M6)>n5}r_Zy|j_MbM#=+zNrUG2qsPnc6#uZtDJn-=$xU~F&AddJ7v=Bv22d1E?Pw#vR?BL z`DxA(kx1*n0v2ezqJ<9{AMb~*!r2dGJdAEdxuZmf`|U4^0Iot2C{j^gJHPU0!SA@& zhZ*rsKxiu>(Pc2s7N;pj557K}m1mH>okKy`$SD4d>HVatDOfE?^KGT;6;PzGSE+5U zR>)PpqaI)86jaXEt6(87hHnT)K{fR0Jht)AdHCK5HuHBBf#<8zSa{URr--CCOV|Bb z{b{3sT}%uI%^Ej3%k*FV!{lq$UDMM+TJrz46xX!8XFn{#e+|QwL3YCu6^p>!#M`1* zC&-(fD6lsXlby3hy$$j7%^Z7>NXEE5-tz&#J6}+n0{K+CoMk;mK7~8|-s-N}IO~}< zn+5T?c4n{t`n|;NBk!d^E7RU`q|KgXb^yd`sh2lo>`my#JzF_lqlnZ; z`#%X9*D^=E^~e6`y!8l~N>TPcWuR^`(^r83E#I*!Kn)*mCoi{q@6*iTBVz6PyJt48 z4sUA4(xsPZ17DSoqi?Ea&`TTtu(zDRrF~5$wLF%X zCxjxNU%5^e!vNcG2Xa#16R8oM9`gmSdg+l>6TaqXypaz&+8XGv-&B=uD1C6 z?OyC>mQ)1|Xs+RXP(vTUk1@lgiCq;xm#ETLgM!;Y+NTB$ggq~&B<4>PTzUw?Vm1Q>W}k+@V_qGk zgtU$O)Y6@nx!gwXuFCKoh$QeGxqdUtAbq#qux<$p2cS3*A*hkIKW>4zjt8StSA&-E zjSTlGWEJQXN?4mz$O93MO6kcNbS_Z-f%2Zk(s_z9||xjh67y-?Ho zEocp)$ILa~-eGkD)J>qyzX;gxM0C`_INCWr{8Z;*F11mKIH>nMNPZ)&RLnJYHHgTf z&=OJz05dCM8}J@4!POy9k>DBV*APE7-3wP0r`cYr;rLTsrJm>pT&BIQu5F}MJ*6n%Vb4U97yyk~u$ zT{9F)*0`&gor>}2cQn|*!k*is$2PV4xvV$=HIFyPrq$HykXvy;GkCQ{;TTvTs%Z zkxSU8kccFVm?ZWUnjnrEF-|no06DT6eN`x^>vP?TpN=}B(Q(uA7Toxq>WhZ^$)uHy zPs~k`uyyVR6s<2y^hyqbvbjn02#ICs(%IT2T^J%c1gi`Q$g4%!hW5FF$ekDf2SeDI zjr!g)Scp1}V$%m3Nz49|1+Bfx>^cxNoqxTy3V3Y;QC6F4$EQKlM^jX_1EFC(A#K%H z>o`*lv?Zp)xi%l9SSgZRYT(Pf9cw1*2HgCVR>eBtIiyl2aJWZ-4!sQzl0uY;-b|gX zCI?}8py^NusY+GoMvZeSAkmJ_o$!MLZ91j zu~LbC1|)rra7V09L5`Eo7>bw~GJ%f3acnqP&s3tM)g?B1vjc9JQBE$p7kLNqKR_zL zF{{yqL6pogCeeQz?l)Im_nXqf1>e2tWxG?CIU*$69NKS7ynbLWZWA`77j+&dBO7&vuT)^=kQ9LUIJ1A~UqW^xjERaEUiij;vrkrWGNhw`V zAx!zY#l_S8rX*ev8(7(4f+0!!{T2m^kEuXcKoxbpad`m1^&G0_zl+L~lVX zYi_nPak`k>$m?sGv=3IR>YWiXp>Ol!L%?rzfoSh7h+`GwBsCv{OyY0s^xsb zakZEMkS3Od+I-m)=Ry9JW&ONZ=x>qM@it&?!s=zC{r;dXMG}<^=7(`pq&1)itH1;8MO# z0!NQJgD7zOlsOspEDY97fC^XGf(U)%DI#WMxfiU|Ou29PcmU*e zCT(;UKKUN|-uEiX)%`iWq-k4H_uRmLkE?FrMXl40R1Gl3Jo6gj0seck`Y&?5=xI98tfXn1%%5=$&Z1yK)wBI?95V^>(n5^ zH|lI=2bhs(n5^G$PWEl(JCJEDV@)#6YZKjd!CV$4VzYiSD*II>DRe6MCa*G8Mx5|I z^*YVEa!gFwzzYH8aUqJsbdEa7#5{xDtXGh*gxg=wEE#9ennf3R`HVawmqVOFeYAc5gcG{GV4s3LilT9i1Hx=BB zVR?#`z7`;vNr2oS7O|7G)=>=Xr)S!#?b1CoV?=Dqtc1G}bFvKTmoLa=8NzsuUsc#4 zbo0#}DsDb^YJ(&v-X4PXFDH{g53jUH*-YMi(!Eqvk+1o+SG(d!47||Ox3#2nl$4&AnAM+-i+we_<4aHPshlzPVtdtf{YilhK|R`*Gmj1 zP4STA@;YTnC$XhC_(U5ooMMj$L8ilj>gD%r*^Dl6vH9< zKKGJ)(NO>Fcf*+K?rhYnV_&yb;UnHHq?Li=Lyex_YFJTU?+QFSlgiXr_EWZ1w=~Y&3g&JFy5G z!VQS*h{!+@n)D*o2+>}7A+5^`*(+Y9xH0i{^%Vp-`g-bzpxdCOnbtoKzYnSev!q%Y zY|uF0*Ul`}pH0?B%FOk{emWGXJt;)GzPupVW*2Xf!Tjp#gX&cayx}eR-6sNNO1M`W3o7nxw?JV0 zRie#+as1AGlV(f?Omfp7;mPnc_bBxM2BFzw201jT+fqtGa*2ABhfM;ci>>E0|wd zX!t>0pmzk^Grpc|>;gpR4cx}2s_rp-Q4RQ0r>Utb2^8<3)Ro@B&Kr9tr7~NBfn2Ur zH5Y6`MYH#XhyCK8`RLTBdxVB{6VA=EAje;Jd8_#*m|YM(6JaH;=CB`g!EWw@ahyakFU-T&PywCrO0;R5~#@ z29WUVHSI0Q2Hfln`7Q8w9J>#tGQ8CEuv1=FoS}o{{wL)%jziowQ!{QD62F`VNO@la z^uY%BE4;4yV01-vRNvKO+d-%Za(x)Eq&O0p{r&h^kq5Naq1)bwEON52HH6oJQ?dSZ zUTBik-uh_a2(-OJU!$+7?5r%oCX=8W)eKEPSo0x`YaQ_kKA3%tA_O2Mt=_FDZobT- zG`*cpavuY-W2GYxbI`cud#}rlSIfY)dl`hk9yl8np)u%A!f(CAF0;eZsA)6t-ixtP z!s}%a;Wm3tn@CW?HJ}By3|0BYac`MRv}8820^Mj?e`P>tJH&lwW?3w}7Vcj-oTChE zrjM9(Y#~*&qThy68RXWuM;EEa90~HrB7VsE1`Vyi4{ZZd>VN>);K|zyDrCy@nW0t` zikM7Q7i+f`M@IRaH3u5JQh z1xg4b;!g;D(a#1A!W9jLvJp2oFVC+M@zeY+u6?&8k9Eq=SEQ^oE4-CffQ#)335A&Vt1kF?xedEX75-sSVV zX(;|tkal~?2&9pm7Qjz1z)#JuW?aHx6Cfbb*<2CnbhKmmYEytb>nCQ3I$ov~COeka z0ceXW5(K|@u{!;|8(6j3YV3eJG}pBO?BOeA(o(VnGiU+gxeBrpCK<(VD433)ieA1L zI4d4;m?8RualMDYEG0SdT-F-t`}fBl zhaL}P-HQ%bdKK{$eZD~l5w5{QF1^{4GSs*1J+Ott&tAlJ*{#kwP$`I6KW1~sd4kh zMYsm7FT)R+-<)a#Q49#YwC4oB0t8-sz~5n3AGGIVY2_Y^DAR%rHa#X;_u?lpGG*{XG!AdMKL%U+UCpNsRx z+TA46fSWU_cQEav1G$MLiOi{5Q5iS{-3}BF99~e?)>4?8labe)Q>-{=b#RrHq6sBm zw`5fT5(#x>05r`{e~xX>Dr(pR)pVnRje~wusCI%QrhL}bih*P^>T;X z%S-xYTfovGWY+dkCC(>oYF6NPc$u&4mZ!RB^4+j(ja>G-Z=fQxX9~j_|C$u`^$Am; zt$LJVxeTTJ_27s8^KJcrJNSGvF-+?H7HApeEb9HeD%QH}eiUIFms*EX`f`J5MZ&#{ ziC2c?aQYzN=OZ$1H7p~+&*F+Pyh@Gb$2m6)5#eP^VRA1!x^2=mE?}GWKNO!^{ny~erH+dr%`HV`5qDXC;(63 zC_s_)C_t5OVto~&+pc;2`Mpm6^UvRleihdbE@WUFE|;M5>&ZqzxJ3CSvMg6F;i2Cv zrXwOf=Difb;iuYfN;qy+f_6*v~}JG=L7-0C|aqA?#Is~Txzsh^v)4jT-7y5~w6fFsTp8Miu?5&zbW zU6o0uIL8*KhI<$)I(>anT(uL{UP!OOwfEIj)e=uva_DlOf&rE;DrEG`SQ4h9Us{||w>D`i?XfCc3ugzLi~y_tV&oVvfz*q1n95VvFk$I*%Bd;kSV;;y4Fn z-fFWn+^^gwb~Ubv`Q& zN&vltl-}o z0EcF1y=RXMzo^RC$$O&ln>*1BTRt9Edj3=r{19e1A>m_pgZ~0fDHBLf!7wY?GO}}S zX2)*bKo4*7o6qCSO6y8`f5lkK+}!j4gV3vD*38}-wG(YcJAzhkpFciLFtCe|+QSBA zyJ4r1LlylES5hg4YYj)52|rpqE)Ou`JgShxHokLx?nQ$OclFc}(~ zd%dePRt8g;%VX%oM@XfkIZ#($6X-c>3{9 z+~ix#VZyk#ZGGxMqrmM!?}9T!d%>lEfwH2%DDeOMR-9XuUiIi6Eow>ldjqFpu^r_qUBi^fS zuZDa25L!vOiukys=sgzF*TpX5A=j7?L%6qe_I_Lt(GM|AB|z8qJt{6NS0Q^-1i5Zg zM0$s_SK$oHFZ&2?*RtwKj~4-iR)++9Y|ssELyJ)m?xf!JcV^C!N`%xyt43a$$(CKO ze#~VGW4?L?(QyE%C`cqs72WE?M-yUy>Z2Sczds%$8b5Bg z+;z=_=&pBY>$R5L8bz_)-o-eFSTq;3Y~i z;w659&}%#Z$_hNK1d~cJbQXDO(Euar$kkqBiYGlI^Nod;N#?GX^&X3Mo>B^p!I+Ij zSq5X=9Gz5ueQ|Q8CdtkV@_9@1gqfYQebD`-scwjLlCrYX9CWV#>zG z6%ZvjZLV@r-QM~W*8>A^EL$XPd|efcX2ukNMnoLhIMY1*@%0W^$;QH0SVc`6jGu~< z3v_`s1Xmx1+S=LRL(~Fo1#EaoElV{e9^e6i)!@8bSVmc~{tNnl7C8Zn-&RchZP)+K zM#NP4M84FG97g4DCxRf!lGPXO|9>G;V#hVrvyfbNY`^WH7->LS4PR1d5@=u|?ajc3 z+;gR7k*)$pfnsHIFsG%I<>MI@TFs;ho4efn=!tOgKlxL;aXiTLkCK0Fzy165^PB)5 z%^gxEja^NpV#_p17BhLAm6G#++NUV7auHd?%+sy~+NKR9s+Jjyc`AV5$QYS^(uJsp!idJ$ukPsR1&;V&yJQkke`Ww`?2 zN^V}+QEPThhZ4pExDy1kpP{*c#8rj693U34_WfkVnQG|s7+!S0*i`o!ZNv*UWE8lM z)^hgJ$j#Wl=KVMY2)!0?eXPmmPf>!pb0|zZWu*>ujT}A^o5^keb>@8v;7k|g|8?fE z++Sx32ueE-8sx3YxBZ>iu2+%^ssaBaENg{2BbiX0^wH9}bWQ;u*sBx(rlhkMG!tM- zI?o(rE-C&Q9h_@vCDOY>Xx>*iq87jEe9-<*5=<#YYE6o-KfVV zs`>*7yDlcoOd6a4rQA+&Kq7Plo|4h=+{WD2tD#Fd-q*V!iw8!w+7C7|PEXQn% zzqycE#dLtymtM7hADr0()7s8+5nQ4DqIL^xNjHx;*I|=|*r`Q93$H|O4=$tTcKLV) z#4vGxq~5=D3Xb8_MsPH?R!A;hcT?Di?Z@8p^F?%qwa zGl$Ra1nQN4M89jfqrdk>g8&Skm<{fKf^U=__I;_lc;MUJ0Rb+s9=3EcK+A(;Zj(d%@=>@<*LJ*|&8m0*=qNPYx{t z8NC-iH^n7CCVIJ!>j*0hltb6y>!g5lsxN6?Bd-4bCBJ)>*Sk3nwHXFJnd_%`Wh3p( zy`X&s5m)hh$bbp;#viQ5W{vMZ8~0;Zibm&9AAk=!4*w1f3IbM24<;~`TO^pcs+eQ( zB&JGi$aW<-p&fY(sZGi~EO=<$UG%d7Nzy%W5D$#@HUv3fOKLxWA58P&1CP6w@V`rXJeSo^re~ZT0&m-4noCo+Q}}#z@E*0V++*I#q~5;+w1o0r-g{wc0A?=h*(%YuB(STQ>D+K z9;{K(dlq0#A4rUQGdS+n;u8_GZKbJ9)36cdOUlvNn=;CUq|-2YLAHUj##4Cuj; zY5R6zbtamVTtVTgPe)L73rz+3k~D2&Mgw>5g>pAN1OuL%JT?3@M4g5F@ZJ-;834>U zo{=BRGQFHv^R+-O*vA~EZ@wqVn&BR-R^ZO@#9`aw9uA9J@EcN9*UWT@mU96?fm9H5 zxYkbJTnH%HwwsAu3Oi{Xvqnq{{TSLEV{}#PlA$euKC#qvHFeAafX(ZDx*@r*6%$=Y-L^t(~k6wC8wxn7MHu)NkY|q zakZD~gK1_38FDE5UDf(qcK%`rXfx(YG!~KQyQ zvF;A6r@YO>ck`ynE19K&vP&H=M||tn!n`hohnC&aNGI|S`=p*lB;oS4h&J+BjnPsa_adwV0?vC~nEE?VqNgW?TGo}g>Yns%dE!j)r2O`K+82y*JhK!ShRd zKN?TEC|uBo<$4&}M~vWy+eh-*z71Hx`@|0*UePnb9Vx2me4{AFlX%#VKf4~B1k=f{ z?oQPwuDdo5V@_q$IhPw@u28&9BK5PNYX^cubsIh0fMB84xh25|rf+4?#)gc|Gl_l* zw_KpAt9R5XWiW4!x8505SER6LYQ2zW z_SeA0+8S(p+*WXfPnBny0BSHI+mPtufF;x)@nnjs&wwowWCRJUjIG>etAvPZWmV8| zzxyA_Ip2-tx%Kc!OwoP2>;EN~q^MsS=H1-yTAV$e*RP7?=BDmCu=LdJS9>8M+(3nH z<6xB`d?OB|Le-ep_!IuCLW5?1e9D8hOfgQAUNm5EoZR5kln-n=iA+SBKsbw{SIn61 zs~0c69MIa~h{Z0ORgEKp^1-0?{zWL^*|nYFj9p8$s+8dt_@g7#E^^JQ@`BiJld3G= zV{LF$MLDuLM+lN%Bn03=7M9C6aN3ilG;p)ox-xKyZ61jCO@%b&#_drr45zAwznh^* zskK9nXxuwiHnm&qxd4$3f+-ie6ll)9^Q1rjUo0@SUt%%I9^j8kkBi}`eTncH57D6> z4;h(-yWAENPX`>7rUB)3giRMFm&=l|3vtikCPt3ABxV%1t~}`|)Hx&v^*hI*-u`;r z2kpdrjsaMua-!-<GI2ok0(*bwug`zrO{ZAOKtw#g=D*E1gM zQqnek7|WDKhYa*B|51`@FfKg^MAO`FaPB_zcdry*CN%c>xl9^DzI6-$nn*}X5R2) zRSA$zB7i1iE_LGEce_NY2fZ7AXJ%xcz#STZ9RKx>0fivTPnSC|CMNsiBKUENV~|P&?K7ca|f;(&C`h{Ws)q%o&$Vas>9+8oVNc5?cDS5gC{N2A9QKSH4&0X?ED{4@HwQToXG({z}Hau!B5BYsjtD^ zo7YBQYQ94Ni^oD}Z#0D$i0(|@L@{@LPKsidk_XDh_nvGLrQQ#3t3FU`iPtx1eMpP8 zEQ%|aIcH8}7Wjb{1)|l(cL*~Rk>qGr)Oqo8&B&qLoojtx35;&0a&mF6Yu|yA22@18 zbQx3r+}?m(ZkOf!EHKEolUBG}i>&rouv9%bS$+uG9p z|4VlsI?*)@kE?8b12!LyUU5YV-hgNj%ZHg53lnU94mJ5G%#Be*6-+Z*_C1W*tUbEb z&FAH$6J*Y&^zd}Q)5I@~1l#3xyJltOK>N5}N5-vUU`j8N2+9)-0uf!fmseUoAF9+0}X>d>H+pA3s z@b`Bz00BY!&^$WE^TV3=N2AMSlpkZ46$ipsl&Z=;*tVbV!TPU`6`T9V%uGJ;;kF=f(9AOCURduLl7 z*dzG-tZPud05k;I{cxen=+LiW0a;nK9l7R0lPXf9?h*dighNw`qs4XexkUGYjOI3c zhB~q^l7QnsK!y`fZ7tIi{$(h*wqNE=ecrgS;=q?*0cyN;83lhb#vWVIGM+4l$S2>` z=k*#&$;E6d>ogJ2yM~C?!9%k~DYXIWyA5TR{*l#;l}*uB>FA{bXy%Kr>@En@6J=)S zt^BUxMh>47Tyb>dMgJVL)PKc6&j~)I{tzRKa^_#Hb*n?QoupfBosJo#{2q-5OMTq1 zN-JjX*POcxUkIWfd=UX12fT=>g?9Ql#_cC8yPz#i1V4;#fcgF;eQkE%Y+c}GZ^PEm zA6=8t#ZadWATioJAErY0Kw%HWcx|0)mFzcUPB2Z~oefDR26f#zcGCWw`PV1XpIM_R zIDGaR2Mh&55Iy040K)_enx_04=Cl{}WINzLr~$Y&E1SXroX!qRSzlSRPEZGWZToi! zVz*7+pu={}h30~tCrtC-?wx+9?eC0SR-&&hH5K_HSp70`QEJz(yPSJt^S6C-V$>>r z8Pmq(?Zm7vkpuT<(^wD2-j00o@?hAQjbLWUmbUR?_;J0zB7k<*0W$V~{N-)pXo1I62Ybd zqTk0QZj5NEvkF_oMH)JyC4xOZXxeDDJv&>D7<~684JX;SZ*+|`(|9CSVml5cV<5z& zyW%g(_X|$$=^Zb_zZ8I7SGV@z=UJ3(@97rYm`LP?ijmGr-T)0@=O&xO0|2&e_Nq3gUs&dE8go{51`g1QMewNNXw?=QYTVa6Rgj*6#yJzm9XRYO zb0dbV&Iy3(ag>Y8R^M&vYf5?IQROOWTKGkHsddIL1)GeLYb+T5ESoCSrBL>L)s{m% z9;xryvsy(-%Jbw!^?c*sDyV6=S-mgy8$4R_<`_4$^& z0NPN1F1AJ%B&j?=m-a5SV=Q^WGNp%EXxyS{J+Sx`b(y#u@&q!uc%53@ipg4KRE=4#z93cjPi}QEo zn7DbWPKg~NHWuKGNBECr@8g)eUXitLHK$YDBrizaxmXjK{0vw zUB%79fWwOpB#p??*!a1jYmL=wkTZ3EMr}Rqefm1**BbiGr)0(`=FIdYpu2~EScuvi zAYfG7Md|>2l@#R&W~j}jQY(3_EI*I6shp66cGtE%ylaT@@4#{d6AMq4Kjb&Yu1pJ9 z4t}<}wBwIJU*tNR8Q%!^6R&ufUJJ3@Kw;#!-SmgUQ(N+Xd|3xUT-Ib$YkWUMq>BpI z%iDdS7qJTX-B6rh-Kmi{)>x#RZBoa$e1I?YUUqb&rgMd;ZqHya*58=n6+Gd%!7tvP zh*N82MNjR5#ppN#ua6nOc+*6M+9Ep1+q8k0FR|yP? zx3p|{ea_BVw9L_g?dZzsQ=&?QJGnl7e_%;CPqV57FK8!WrF_NZ({m@VyPo1BUh*1E zrIjdB=ZdP=paLv$RUr0&Z9*MpJT#}x9Ie~)b$#(9&Nz6N5hHhI@1y^ zm{ksSQb53o4uIF;c7F;5c0lwMb46R;wvf_ZhZ@0#YE1Ih6WivOmCT#?SyeurpQ>Xv z0#VqhHauS|7TxfNQ*E3g?_;UsOIFK@&RTSUk;tX^qPd~^Ro*JFpCJlkVUH&HMT%D(ikp!gts59{Z!EUx z$@z#%VpZ=s5`i}Sa<3`4exKE=)dDRgF14>b79a)Y-$Sw(NHEQq4K1BatKS|`H-AC?{w4ZtyzJ<=@qkTBYzHaJO$OJa(Fzw-YFzn`oE}ZRt=1!AU%Ant z$5vD};qdZ!MJ8;YHskZG*?$Q3JGU672jUr$n6?ae%&gGLvYqoQS+tb}u%eVfJP;&c zit(tU2q9iOZ}K!#68uq=l2@4h#R7M1i!#~jTav>Uk|Oc7fgdqu?sK#NRUT;9>c`9T zZmiP#mBx!BpW?IA;+M@g= z*9BUCmgEiX_S^hbm0?>3J%XaXp3nEEA~xS+uPeQYr#6GD#%FEQfNugl zp9UiCfH__Qa~uce_-t=n?a95un@79cnnHFf-?XK*wtrCIE#tTkJ&KU(@sAEL(w+&_ zT7Yuqf{#1mQqngxyfX=z+ILiZW&1!OEX0G$vG)l0cl%!wwy1Myr4neHwxW}y0xV)y z5xn@qR8Jy(;2d4qefBqezd5y-Znk1v*0GLq$!9#~JRaUoja$-p3ke!C|15j*1C`rE zJl2UGR6;Dz_r3LVhN@PWGgF+IjpMxft4enbrwXp#_>gYygImMTSvTlzwO_as*f%Tj zBS?feItJ=)x{cyeBT;HbJAU|OZ^ z`*$*9foX)gK4u7~JDwUn-5p#|3p~Ebs_oLXdsn`#4P`*MMG{%MaXAK@%g@n%`kk+f zwDUpmOvJE;9t6udXPM$82iR z##r(;f^xGlF%aqTO?r)dxIVJU(9s8a4T{B*r7jWg6U>9?i9H}A#ZJpJ+^o?^y{~a| z80qW{b8(9oPZDQeV}=@3btbfhM-kX~GvPO{U0CFOWvQA%aOP>`Hg6G?fklcFVTJ;W zOr55%oTfzkQGQ~7hln0Oy2G5;<#_kUl*Kt*`+K|k-TiKh*nrK-c+@E23a=;eD^I$$ry*b4E5=?L_kTTv7~2TbjM=uNlh>ZX$1>20^VM{Btzs{~OFJ4fE{Z zj&4#QE5de~Tj}r^KgEYPeu?U)Qx9cf^tpAIaV8FS^?Bejuh@ zCXBYft`qX(zC7r7xr^msyDDWCJ`k(>UECZQdX6Id&hqX`b~!{nzK-&P{sSKU7yH4R zX^s;J^e^(kfAF#BN}T{cHhP)jX`9;p2&JIx78gy)8ZO|<2>uMvu+LziTQ>`2bjI$ z&M1Kl5%mUYy9sV{tjm~x#$WxpkDd<}Qd!YQbaWJC^m)MU8dwoSf({7U?Mw}jYOD@C zZ1}ZrYJ(5Tp4KJ~4X?_U7MAu4@3kEr))+thTGX$HYmgwQMiTD;HGVqUZY)5vhlF-f zu=Ly$(?@$Xh2x70wh5|gEypx&;MuJrt?gt8ZtDgn=n0{`=Z+@y2)Rr@TbZBa?>%%X zRh;3qN5{E+!m-fRTRM%$_g^X6+jD7Mm(k8zu(@3Fsk?1ig;qjVp4cd%mfDU}e2(SE zZ3Kl|8TbJRc^Nw`?>`NHJ%fC3j-=goEy}1ND#;L0Q}WoJ)R9iRvc+OjXzeZ|T^1S8 zns~?01NjnbnychB`8IK^2fx*lG?@Ykr#WL<^SDcZaS?wP%KPxOd(ED3%yO;yi9S;% zZVV_rb6iBw0Vq9);Cw@zMZgW91AX`?wfr-EqK?rOsPVbHx6>{^(b-;~$}(!$)?H4!ejFcfuZ}c3+2SG5qpO zkFci7qQ0k$6yF@c=+>4vo#~;Y)Y7%dva}+2v&;;(wf5kG+)-zD9#aaTwfF@&jzUa$ z4x;BSoz<&UtxEmS9^GOwJsGb5Gq&*>&wo8x95A?F7;Q6|M&Is#J42gOUB> zUqihL-mbD@Eg=iI+%c9~bdoNLf*Iy2(Q=7a-b|yxbYTLO;wjA4A@jNfafv02S_oeU zzc|{`+3*hjaa#O5)2bDPN4)*fLDZ=`1^QxkH-BQbvBp7jE4%t6gkI?%^N*1`jf{IB zVY^+<>1)H)MsAm3ZebDl$?#2F^J}Da%oYV8{p7hf3~e9m=H83*6_=vLFZoE~0GlhLe>lrxdVWcK%!qp_+*e+?`u9S8^k zRDk3gS9_rP>od$Si@FZTD2sUwzPH_9Dd6A%E048MEMwV9vOa1T@nwJ7;i=2Wm`s9O zOGE4Pr(^v=3j~6T*87V2wRW4k2s4U_gqKCg)KpGQW+kUIIOTDvn@e-XaeDS#)M!bp zn5HiGNd4D_ia*B)$nC0100G4_a8au=9`^@vPrf|MS(r6FgHyK!=7TzS`E6YeTNbD| z@OA+z{HtY71lePEuLnR~r}HGh(Jd>`9vw;~zWtR@Oz~mro(89J@h|Z5q&CE}H#Xxc_|rT0m&dh0&1jI;AKa*I z2IxRO1>H6K%F<-nfaAjVEl(~0U zyE<7WVZwE#l_N}t>$}7Gk67YvqK&w${U*NKVyG=T@WVv96xme3w&SYejc2D^L?F#J zC+B`Azvo}9;AiTU@J4C)mjwDIxljh6(CluEBxQUR%HW85O%;2Xx9P#*;pGYYQds65 z6$EM}!2`vzJr=Z6OvYqfO{B|tm646vm)ZOY%&Uvd4C&~1p|qt3u-ENI;;lE>p{q-( z2*F&9GNTP5=_m~5f2hJ%Fas2l@d(#Uyo;9rK>_S}5Kiw3=18r=OthB9A3#(br%2f}!^^tDsWQ7ze=xAo(X8$()SK=Ht$Bu_s?g#>Eaz>HToO0iSIiT_+ElKAA~<1{P*1oX_a`A2OjJ7B7AK8 z59_}^t<8^k;nY3a1g%s6R0AE;&dSP1s4CbPnSYDpK%Mdhc(*dfc@o%j$C1sbfIs>_ znobDm;Hbn%-M_ahotKc3R#*)<-1-Hg?sb;I(fjnCv|9Hl`WmGT~*chH8{66hdLg}q+#gfeR_F~AzKlR2K$h9#*Kl-0~ zgDI^D%sxI&9oUp%#Le$Y6I5Q|t~RAzSkN<8el1jAue|c-l9GmCJ4!3yD0?2mQRS$k zgsv|1AewO%$c)yCd>=CvPeU&tH%MpvU^l!XLO8Br-bXgr7=rZgC{NJtVZIZYS*K9$I z6ITf?4cdPih-(6M83pxMw&pPG@^+BEiMiOV{>Hv$YZS69EPwfeJ`vV|8ebC_S)l=c7LWsKNn2zUXY`+r}42qoH(!KvtIEbXi zN$0{P>OPI90e#$GA@$wz*BFY1XFBXg;OWU<9paMB{Q0nIE#y*~nQvfjA!c^%5c75g za^|#(kbU54PF>prW>Cfv)Rgyx8>%nX;n<@fkw)_cDLU+F5b$!B{8y6zvjaO4gVP2A zWQ(*0$Tn8`MivbQ`b9^y(%S+QXdBM zdQGA16vo93U9@Dy_>;pb0IDy0D)?be{dUXl125MyS;1q;k~hA_!!5g59ZtSPDj;Q% zeYPO32}nXi1K?$?x_pPl1hf*c0Lm^4TH+Kr-RrDNF?ke|H9HD!Zui;#(*wY27IdBvkM9UQ98#{N_B;#N#BFi9|8#|Q&?6mcGgBbi|1^a+SdJno@3WNui8iX9CGc;8 z!9UG=22W#tmNkQn6~6V2-|zsmsc-Z)Uj?xGtAdMh&zJ znl=sH4SQl>565$UEXGrG6E-j6X-Dtfsusib>R0E>hYNMxd|kCf*PeuY^s6bgvT9xL zu+|3Lv&J0)?z~(n3~N&J(t3WsntRUjbM0oW?3tvVfS!P7)S5RE-?NT=WZ2oFP}_!X zA4_6saaQkU<<2SXj!gXArOx|fomrNht40-N!NYN!93@k)fbUEF%a>H($5zs-U*Vi? zmi`h}gv-=vA908(g#VbLnQd7+h2xQ#iy{Pk9B6lXXC55j7%5MKHurYqQ?%rbPUI57 zN2NVGldb?hw-~zz-;SUuH{umBHQUwSWJ`RL47yatQHf=A+NngA^-&Od={}wgS@IUu zlfPQ&-#AJ0Nx46K;zey0_uNX%$mu207B~^}YIr-cxQbrqKMrVvsB_4;`NQ>*p;AB0 z-^nET6bpfs^WH#Z)87l?uKq_1*$+3r8m)=!xa$-7Z`t~!j_I|g=g^zR5wnLw=L4RB zqc3H%$#9MK=v*>T!^BYQeBy^0wl0zjd{))>hyin$PntTGJ2r@U;v(T=J=Vz%xvH9l z3_h@u^WQ1|y^%3DFgFzd3A=Ura&B=+!;AKqKA`Il#nU8QX z&M%Tyz%>U&j(zE}e`neSj}*zjz=vG;?_=60k{%8dl}mY2J^@U`q2<_~jY|hWDG)Q@ z`(ywp1rdN!5Zui0Pc1=#Vp0F=^mXK~Zs`HvsQ4457|J;+sftS5fjBv(j8SGSv zneRA09^7#t$^0?Z8O)YDUjEEJR+LBdaG&+%_-tnGnhgEm`n1yX5&~W5UcvYq=M5?i z83y&Z&q?=xG44@6nh?b*nV^q(4^tZJVm3~q}clq>?!xdjNXITz~oJv;T ziPL6Y?X2hMZf#_Qaj&Jw=`L{yVf^(b19=Af*7>E%gKW2Gwa8YDP=W))=g=h{y+9E9XTVbt3k-}}|-qW4ItU#;z)6$UCR7mSh+ z#m2fuq_J>(pvh-;B}{6Rgiw_*IGvRS6C-%^pe5wZDgF6M}siK-(t*Gt09KfeTL$n0b?cwDbF}QpBl7gaN$}Q7?aB+LPI(eNAkLaR>GlpsI&BL zRR4@v+4RtuH;Gu;IVsoOip>nGUS}M64>VP{89&8(=9yZPBH#|0H(D6I+^AWF*aS%S z2rV_jWnKGpuWQZZu|kcFvtKT1t&|k7yv)Mxd^}f{_DP~$DK<88r;O}xvZcFwihu=> z-R0L=TuOfJ&61SXxG|1PEg>%r+m4}#p~PfD^mHmLw4A|S7pyJK8OG_=<&eAJV*TSt zU?G^@YN+sYupAp!S6Hai*+KNS*f&dA^)+>IIA`90|D`p>GJ;N28)KXBZ0*mxn#-)0 zBMvj`R-$jw;CZDx;?ed^-WzA`Kphd*)|pBx{>QrA5CZ zBx#^((O*+q$mS+tYLXO9lWo+-9x(DuXQKla+V~79oC#)swaI2{(SewKa4_2NpQDji z2l6Y@fa~L!`9Oqp@F)de2V8AVuipxPkuVfyI^#vn#Ra(g4v z)f2f1t+l);(Y32&xKrQPZ!(a%9{qiN_*EbB1^L7hWN-3SBo63uAk8Xd(M4M=51|U1 z!sOAwE+WzOJzQ%_x^=e6;sAhh87UUo4Cm)cJdU0D8fa>|Zxo932t#6AwtgWok!~-| zn+tr~a-x{ahMkknuW0vB2({EwErruZOYCTCs-0EB0!enX*-XC~J7EYs9!tCm2)dgj z?712o*15ax*GWi{3I^2w0P^gjchcd;TYgy{xQGE#36^qV_Vp>Q=J)VhWvSio3WScp z5IiZx??S9He_=D>w<6H_a?UY zYDxLP+1AFYN8+zur%*ep3`FPh2YQs;-yZ-ge0P*Jn9W^eoYLK&-hKaievXJX8O1-S z;g!Ew64m|jK=siY%He8tRdo}wf)RzcN~*onx3P!$ zp(azlX6Yr?ZsG`Vq6_9)+;}(^E)f)nWczYLJ9#hbxUsOH8aK)zKA@!0H`mY7ig;+Q z^WY(7)mkE3l^4^8M+@#P9@ZS#a1|vJo9`#KU+`jp-sxtd%W-QQL2zBNFIy#WIidFYYgLhP?%{-5*hJZp zjgj`3+A`Y7-9p!yP8NJ;p~%@+i0n@A7)6-xii7YXGKBa$*x)>Pd_2=uP|!dV=FPP& zjp8lCXFiDuv#kRnR=759anodKK8PqGfWZL4fhXp2oz4HilH|!TLw1*rxj5Rrjza+iEdX^d8A<8YIYj*>j>iL^} zK>$`q6`E5IghD@oww=|!#BjKe=GK{G=5G$fMw+pxLLnWJZ1m#(d`lLao`wge@?1Q% zkz+Dyoal$<`9}Pa!9Jj@e{!%?_^%w+Rk5lZ5y~BJLW~1^o|!rFY&k^Lp1bRW#(vSU zL#U80F;4-nShP3PE(Z|AK^8a11)IA--bee{bQrsRp^p5xFDdtod?Y*NWO)YcN2a&Q zYlElEKbWukexQ!;;jq`{O7?Yanp%AK4n!!84COz#Haks6@o0NBzU4u49};(C0(()j zr(F9@Mq#@ms-^~mQ+DiMrchgkZi4~J*$GT($GS|cUi1f+ri|u|x{-3`6NQm7zU}V- zM;Qhmb)1I*eu3!jqDEBP!Vl`H^kH}pz7Mw>nt6HJ*Dv>kPT>S;oMh@f)B5$Lmrs8B zwHCe%FA}8(E*wo8=-3~{dLlzP?t_T^JZNF|lHmS@G5Q!z-mUL6 zsRvy>BzxY5N%vbcPrRG;iJfcOs>w`5SEJgnhJHkjoCA;AdW?TRIZa*XT8quhN?s+$ z+d5+#83DQMBMo4bN|R*|a5biPEUoxv>7Rkg$zujZJm2DR+ofTkVd#;f3lNs7Cl>;)vqrm325_n2 z)lAe~up(|kW0S6pE~6~{Mj=u?DRmong1ATj=Lgg!!QU|+RvGt_-ZPUnImhl!QR=>>Xq(kw<7;{nD0vRTgtmjz)U_Obpd0GOo#=Ub-0UQgp zGX?yidXy7;B3GejdP2RzhlT#l#{3G)M~Jrz#-*cr$y6PR%P9usA*w9=n-#oh(dmb#& z1(ZzsD%d~s`mB8>c`169n39P>P^&DM4uRMalZp7hF@Vej?+CIikB=kstn}6yA5#-a zJDNB~=IL8LOA=L-@I(k3k_$Rn;{6PLV(bp*7OT9V$&^{Yvu5ZE!ZH`Dm(+oq#>f(CQ|Fq4{yDyNtn(z`OOl2Ref z7xGL%3&{MP7TfIYW-OfJc42X*fW8nEIhlO?oT>$waI`zJ?zW_d*I)TpvYvwwY@q_XtJFvDj|Hf*M%;ZgQg5VO0|qEi%Xn%VYt2!a1ggT> zw#`SKTG4gfM0;FJy2o{U>HN0d)N4>Mv4-{(u%oy8z>Yea{%=QHJ?wzEU=m9Q=di1i zQU#DP@Kdl&1z2PGf7gh!FlMJlyFm{+*2(#pv&iv&L0F-T@g`IQ##3Ghh!D$4h2=C5Ojr89BdQWm=PG^aAvk1KmamCjV2Z2Qo_`Y)J_6Lp#2;@4Xv|kd9Pd1q zOKrvJAvT|)rT&r148K)*PkCV3iS?rErlL*7!`_^MySC+Z%mT!#kaKY-tZg~>|Al(} zw_-@FuGB6EsKVwjkyWuTZ@k;1CtDv5A@n}3I$4Y_HJO2>vwsxR?SKO;lP3WVp0r3U zb^a~qg-1U_FB{exE;mmb&HZ{5q*!qDh}yfOP++lzuZMg+fu;ow&Jnab=SCde&f`FF zk9%bR&zV8>Ehq-<8;FiIAr#|V5I)*=eM8j)1yftTr@kW=Il?mFYB#BTgOwceWf92D zxYx)yOyW{>A>`$Jhi)g|AF+bSR41if5mGHTj5$CkN!m-8L)l9hs^8b**up%Zx4GNK zc*!+LCXF&QZA^sXPOuE0mCj@rWIKk~(v6!Y3ozgp=?B3xz?ce*fhlFQcEGh}M;?<> zuE|x0k)S)Lba4B+Fg=1=8J9J@GNYl>TaJ%8i#Vm30#iOIbfIo>jVW?6PKR`oN%um; zc3@F5MxAQ63Uy?4d+QO|onR3@EtSdk2_tdy-&j%2i>JN+#zL~uBSb3F_2nzBTkJcJ z(32Wi#m?XcVuC&3k|ary>~w;PNBO%tZ8gjh0okzX@PQdxbMCrp501i1n&t1Vz(;|| zoTxI@wJiNVqWSNFT*44R+?0^-|Ez+=0&WiLoSi=Pl&_t z9oUBBs|Muor--O4X`D1&ZmI;quCxdoGdh)*( z$@rpiVeZPiymEW#w+sSqB{UWYxgpXLLco1?-UT&g9`G4DK5qXw7jh{C{e0SnQDDD7 zkc(iOM=~WAB=4FF4jcD&C^jE(H9_ax^&ZE(_Cxj(QS0`&d|N21*3hr-E4$Mk(uy;9 zBg5MDwQ9Mg0|Kq&huoY@ae8M_3W`1}c`dFvU z%p`xhYmE5o+Q8nlvIdS^=VAOC=BQ34f+5=%Og9>G(tHHbbew5jR?5TegKy^hwyn$| z1lb86z<>@rP2Tn6oivKuOINlB^@x@`hupp(0VSaoqflA)kC^Pf8z-JZzl-hmR#zPE zx4Yhahh{6Dtf@hUX4ce!rTlzE*Mk<1$p~&h`X@j8b;dbaavRrSyV0-gLummXA(UX= zR+x6<@$TvS`|Ib0n4#5#TiM8!cHP~Nv3RRTvt(+$5EElW0BQUH#1HUP?OElhFxQ?c z9-dN)y%QSRzsb*skm{fc15{%r$sgZ)$tSaQZYClvOlXM5EYSIwy^z07D4{z@8NT8@ zgJcAeYE*Nfv>N>)TL%W;Mz&;Y4Du@6zmvUNRm@AS8vng20I1A|n8Q-oMSJamMoNMS zG`S2bv>z~U2=CJRU1wWl7nI@B$`AQ}F<|BTuHmW{QRRj=(xv+An~}`JFUES39W%h~ z=DL*{Xli?5lKEN+p_DL9c-IhpJZw*h#h3~*;l%C<9GP-pt!c>H)DGOJek-x3Jke$_ zb)In1BzjB1p3fVOA1kOsAQlt5_k0JqVorwllT{Na(tL>t0Q&g|=to5P4ED$X3C>tI zPW>BOoM`XdeW^17=5AldwVxlzP((yHV?$Px4#<{XXSlA*j(p$iWwC4tmePmXRr%Q$ zutf2Z==8bp6`!s5%>p2KA=uOy;0qYMj8VkZa+yi4)3#Yo(+C<9klt?(_r%#xLYV^j z{{V)Z3b}iG*>-4K^+NxMQhX*fMV*mVcE4Tmlk&XF_p_0Z4E3;(jCiRK?>xsLKfchL zvALDX{riFpHPcMTtfCUj7X*5KsZ9z2ao!Gn^bJN!;teVw9uc|hw{~K7)~e_hDd1M5 z)yJ&}XxH5+(t$vPtiYM@I=uP4D0H8Xxx;JIAualF;nMudxjj$YiUX!! zY{p#Ks|QW~SRoO|^+rKZ8n;w)BA)oE>Z>#Y&DzMy{=>@C(w&EM`Fo)ZP$pYIZSBS1 zF$2tDqOpwtk4B?Y3tsMM`4z$eI7%il!Ow?6l;sBAe8q6U-AERGF9F@70OIcNqn-m=3n94bl6 zPqsv4kZF`68E&08$?mj*tnr4HQ!3uXm(D5em2ZCe(k`_*@hsIj<$|L3v~A* zY7FW$st9}daK~f6h|<(UH8a`tm6D0u_fhG0d&*6Gu*Z``{tN)Ek?QnJR1(BMhv=$) zQREmiZ?q!%((mCkpw|+ztYU}q+pgE+ES0(i=%Tcod$mHbET>H*{+^sL73-~KTGD|c_MK!4Izbb_PRwoyD*iL2J*TO2igl?`Ym#!Of_FPQ5AlY- z?{?I_!tXAK0QbGg_s+g)r&v`<8*x6ZQ*uV_t=QtJ9d1Bhx<+Q@XVt z4(=88OxLJwH?q&7de{hk+jyzb(tqZ5FI%xPnGvm4%rBf1z*nrYu?a?7Q|HV%&4~xZ z;6-|BmRM%d$ypWUJbV0mLGSVi{hAm{V-VMLeF=s}ift;C4&{t%6d4X#1$zyv@y9sp zEV^_W))0-A-M#P74XpNf*gy0kmQl$3v!Sin`j+qXQ1w$SubaQY1Z8U6nElo9UEJL< zEGUI_v*i5`+HtX3B2GUquDc-Dgb7xWXU4TRPzwfZP}V}{gYbkEQD8!#;biQp*YL%_ z2tY=|kRCm2aZ=KCWRN{A2TVX81YZQEsCx1}U#kls2J0M?H+U|Ik7V1bqv3-(st%}& z!l9jI_`{hu*u1T{XO%YHl}?U3wme~u+{Y}z8H$&DP#B@RtbPb!sN;!JXQp7G1Fs;k3K zlXw2)iGRa5CV9{BDWWaDhxL~+R=C9HKvPGRu((D;yt}l!-Pa)M3&n4UxgKvvkmzrV zWnZs+5=sl4zvd5BZ$?w|Me{6sA0sTqwqt7==E!+W7p$vu*>(iOHLWC0jr`Sk8w!%N zSI_iK&;K_^Tp!NNl|Koda*8x)mqy}j2Mh8*Vdj{2utVel46RtFWe{-kCg8R`G-O@! z(R6+T+{#GHzWS;$5M^YjBw(q_Q2K+pZ-j`X#8W)LW@>cOkT>g)8ulCfoS<4P!tSPW zPSk^tiM@s`62u#VREtCg%Yocsmp`A+;S$ugTI&wog;S0MGUtKgFiA5~&<9K0Fq1)>mDXGU~J+6L@J8qsV-&%?4BZ zqG>NWEqi9oE5eSIM>dWALeWEVB7)1=XKlVFKCRg^F}Tz0e<>7bV>(gZSw7(Z4uH?z zBhLeEuD_XJk-BHYFU&YXTtA_}V@3_!BrR)ip2 z0gqx-QFhb~1D3BZrp_@h4OM<3GUcGQN!l|6o1qBeGz7xgAU`4a*owWt0lgx_yVcW> zc*KXhSRsPqFTGJoeqZbO3uZ;(NJ~^-wxOp$awwGY%FOg0Ma52YP4t^1mJ|#UGzS`x z{k!$h9Y06P57@n+kPs|lVWkjdtmh113K7a!y6 z0%snge7-w98xKDSOPEAkfX?__mk0XZ&UXt|A@LQ=aw49+LBJ@=r7E@}jtKipa&_3& z?&HsW+idD}*gT{5u%84k|7(^OPz~-ePfY=ES>K<$I>2#syBhy1%TkE2efCxSf$6b1 zLWiL}%C-$fsUVzV9J>#TDhl=_&G|8@c>ZQZg95jD=Bl9(H?1S&u8|OXLb()edag%Ndy*Kgj z4o^9A+lwR1!E68AipWT(Ro%8OGb*HCf*pWs*)2q8P8mVwp-I<|2~OK2*!OIedL6i( zowiyr8uKR=j7sJDI8l68*rqNQTwYjy_7G?V3U8Jf$@0{$XE-v|d=vc^M*NkGXGQW4 z@67F;ZSw|;XkY;?V6L2s%}g(W4UHek$gPb63`I1+Qrv>ZwRvEBs!+fCfg?&LVg2qy zT|y#`$mannq$kW_V6&p1;f776Ny4L(6{GlS4qF)4NQ%}6++#imV8PfUAm0M00@XaQ zq0g|spGGejif)br>?+?Rv8;$K{Rh}zACKA@lZ3x|6y=&hNDmMCPBNp&1vhhzdn367 z#*ut6)qeC*8^MOq>|5t;UAc|#0G}-s;IZ{mzHl-eG-N|8t9S{s0UXkNQ7F@=JB-Nn zB0zgx90a6@8z*|RMP8i7I&J}yXs}@mWX1>}!wRJJth4dN#Z7_t3%y~U*IK`fI(M_c z?>{Y(p4X&-+ZD2aSg>KWmVD;nGli)e!Gd0Q!-uzf_tQZP5_n{CkS_xB`|_ub0sL{P zokvS$;dk9W5j6qbNiQb@7W1}AN6Z~B*9%!=(O9Yv%70!)xTXPD&gqT@&pJrqn;Df&K~dm4e4a?c^Ly0tI4s-0V4`Cldt;y~+Dtjr+p&k$MmhA( zDZp?M25zV;5!$a*5B!B5aX0ShT+&_>dF+dx6PemXeoxvhdt%SFVc#IRK88hi=fB!D;_5$|p@ z#bcvzq#8>-CAk3ACO^i!m5(ni%}lu~l4&GB1`9v14!hjPC|wyTisWE@dU z1W{Yfe7BB95d@!b6D+8#7Bj3A^;`|ZAg`ik;W21hz;sP^05`PWkj?!v&lBdpe{SC# zxLM<=sC#vvWc`FIG6`!OleyDcjPL1*6bV>+s?Q6o*5Vv?Z~i(mI_?nu$c%@OFG{BN z3A!yNb;mBG2b&tUE_3ek4*1BVlS@>RpW5Nnz{tXYe6o#xtpa2G41VSA828>r8S&bQ zLUZy#1mIkyGaa#KzXSaWt-ffQV*&o3hu zsuXmk(h|dEzS8-XG26LC1;X

    `B;D5L{(!6B)|hH;asQG-nP<6&2THCehWd{|JejPE z^NDO{9&b_U1Trk2ODSnXhxc~V-22#zm!8?KuE8}1X3!1ULH8ZB|F}dm5P#0>Hqcai zJRZ7tw&r_TL&tlhqT-kpVZs6Q@>0{v(aXy`v`92A?>2t{Cj!^ZmRAp@v>1NR1VxB_ zi}Ny`8tbOuY0M~iH32jNXyxkSI&_jatB$b|ytd>;uO`MN!qOWjP4*5w1wR!#%<0!M z0r26Qs03;fq^^2V07R~i=R!N*v^ziRnz^L^#aqgKbM5G`{2K|pd2*iY+d{E3c2F>I zE>5PlUj{JWr2kkifJWW?N28WHhG*uNcrG3Kglc!yZz<4ll~4}56%_(QnvE()alF-X z+|z7jRwvNovfpEJd8+v@dFQeDF`vJPmf_n3X!1e#Ow9kJ@E*jU&o3h7^sTACA#Jd? z#d@M?MV2TizX!NOq^4g3VVeG};RY4Q=mZg_;F{}QTYqNO#^t9XEnCBwlp(y{)czl2 z*3H5Mm?H-PfdZQvSz2moQ@O?;8SH^mfYa-2@)9Bl5RDE3DAuAuSU~_InedO1bj;rh z83fMc)Dt{Gfec`4!Lp84o@#?Gie0hy!R-&wRnMwYS52?fb&olQy)=JOlTx(o| z0v&WFeF%k4LOkrSu5}BEk#J~E#yOkWN|~r%)WMOJZc#+;B;?p7jsOCE-2FGcwJgT@ z$DjTJ-CY9Ym4w}xN$3T(&1Px0>)-qrA}l~*Z|B|uW}k?db4BDAFI~t*Ji?7Y!G1hHLqKdU^fsex)E)~xh}*^*rE$gHLh8D_m9h+ z`yP~HO@FW1$?F-$&k|UFM61#Zlu3O}K1k+_aryfCk2s4uuYt~@EvfuoQfk#o-Zu3% z&TnP(;n;pgk~-vbUek7o0CgWi1638+4HNhN7d@3^ z8`ew-t3+SCdCaSq_D!A?pdoVLCi^vL2nnj%elzre?)s3f`}s~{=^t~^_z3jR5N%Non#`cYR#hkacA3eF`oTN4&>qdX)gZslg zzm64jU1Vwd^@?HGD0!#g)^Y#1jd~~2eQ>zUP2Y2LFF{@s_l}W=hu%9hWc^mGxGcP# z`RA^F-ce9L8H+*pQP3*Z+V7XBt%mB#IbOq~tUWKx-+P<9x4#hYkqQ3`>?HIYcMaGH z$7f(CNay?oP3o0be#!1Av-Nbx=chtS7Jo$h7t#E3R%PkmFX=#R)vdJ@83-crSV zbUP3q%o`kU{DA)u)k!;Ng#T~{tzTBocoDSfIaIL#=ox=KQB=BR_GvHe@lT5N@AbLA z5uYu2;>^ja3Wk|;T}^=ltPHMQ=ZQzZfq%9JgiFn*X>+-6lD(mLy5_HN#c&ZE=qP`6 z$^h}4;%0GB_B2^>{|!7i@P7}!`rm`e)*t!x&^vGh*)G(-dlVs+g?D}T3Dy(I{5EUe zgiDDiT$Pa*fEJd+ZhLC6yH*YemlMf0t)GxB=QV`hrZ8B)O>FOf&ouVlU??ry_TxJ) zO#J0U(fSmeTO7AfbToC;yWikFN|X-52j-Lo#@iQw+ ze}>%$ygzrN-T(~dOiBT&%)teXfE95ahF zgz|wlAR&gXz{ff-%y91KVcH~k}Ib)pi8ZxEA2lQF45 z4y-(1cN9nP&WDXa0@5QB1%a_Zd;DV|FuVl)tX~FSrL2r+9}AcjaQJ&H7qIzj9VW@= zQDBs9ugW~XQnTI@FVI_+EYEYfnYwFEJD-2@|Vie227)|Lh za7+pjGaBe=%eP6c*xC>2&(dA8I&qs|?BIS(aMLRA(YNm1{Vksi@n6>1#-k~mQ4=3- zD@TVh?0X|urq{(m6Bs||P!JPecEv%H7}mV?H#?|xd~(smnzTs`XMlE;+&)yMeC3`) z@%vtqY5S3oBU}>nFVr?mf{yFjpFZliaQ}MK8gKp0Nk8yf@|i(0`Hs-UbGuoiisZ}g zZ*`xP%k)XrK$g}eq!+rb=>uPVn+%D5?9Qpx^K-SsaX`w~tjfP072mU46$)Tu9k7TM zyN9-8;rLjcMZ+S_r$K;?V>{Y|lIzx2J+^JbeGI*Ey6a#R|E!~K75I>CcWAA-n$%ni z2rJ>-e*bb4Fu?vjg6%|{MA_q#F7Db7raRLk2HLN>W{H1e5;c5`133Unb2yLws~G3* zfEM?cwB{<Sm>9|fyg#BtOh78<2G>WFZ+x+M$N-< zPHJsEGWs9S@b3VEb=TfIyzuGrBW%Ne-8$Z6|L zXodm*NeFT6LFiB-tk)qPjIb&9&udkSH zz?YmFy9 z55;7j1XJ6o)g2JG%@2_R)S(x!U#AN$5dss3n;UndhZ|JhF9Q`&i90uH%gW|_rZfg@ zIeJ8yetiOMt!kc@w2CSjU@NZ7s)=8<4P(F3hb0@p*F6Y*(W#7b6PYF5E+pCnZs0@P zf?7^Ajoq6l+&XDFEmBP{xKSZ0zUZ{XH_vT@)Svs7o;(>>*|{dGlFq`h*Hb6EbT2Bd_5Ek}jY!{E;SH3BfwREkU3#0cqB&^~SlFTK ziBx-gm1TR{$4@(dO6P-xe!?bsCJZ)sRr$4laZb8JNtmOgsl|CQ&I zL|+Oe3VtLvq~pEwhi=qskv_G;XXEbWSbLhjaIrmRcuz3RQ;*iZ>zs`Ooh}TPzgYn;m zp@L1H{e*g5ZUL`%Dy*V}_{4tC%NPg(8mX(;BJVCNSbp9y>86bLaQ8lO`WYx@=kvQ) zTFFn#gEz4%bSw^qDtwCw9ru6B{Qf`7h|VV)7l)u8&YUqla*0JL(NT%+?4kV5Z)Z`& zrGI&eOVwfO8awmb5>ss-FoL3Ivn96Jr6BZns7Rgr>A=5@pwn?FzLoZrc#gFzfKB8D zfb5|`b?LvZR-qKvT6HCBN~nqlRST*s){SrYvFI1EFtFPEyV-UQzrG7qO6o#ITdV$p zJf?Jw$d!}=`+v1fi(;&j zDCk7>C9AVn>-8-Q1H7=;4G!ob2MOo_GYaw-6(W&B>ty>aB7CMe{qc6pAN6f-C%FrI z=LENaoo^L0b+{=b-TcIL=)~bTT6hw(T!_lsCzC|#NAG21@KB-D?Fq;A^B;Vpdp5e0+$~7&nA1Z$L6(`yx3RwG%AeJt$G{!P+X@)8^lfgSyp_HsOI@dK z#G~h387iI)B1d&5%I?KoUYTV(M^%9H@6R^)HF>X>20HJ)fB!MmZr7ZkuJ6e-yog{8 z5?Gd~kf-r*9U@~q0kX@8_m4L~c7fXUpKYwaB#Do`9T>@XSEZ}K_^#tZ%*-NMrabQT zLHY*A26BXbh&A)2XFDnP)#|1sU`M{QlRm{S8O~dW4SPLUf-sQK# z)YrQO+A*GfuM;O8m-zg&?ZdsWxhqZ4FPX{bpB(kRkL|deta^DqortqLk>+D25Don3 zF!^;xzCDDDj$-Ls7jEqbYN{x&&(@5hq@}){MA|l67SS?wRZ0a1KEt2kpi`O$OouIu zx^xEy917R(mRWBC`7O-9+>3*E*YKQKhXRvNd z+`#p1rrL+j9XRxDeKb6N)Llz5MN@ISxXv!vR?M|UmPm|sFAsR9Bz)%f$L=3)gMH2x zM`9{)v;$_z7teKRsVPBxY-$hO+Q@B z8*Z<*7A`OE!1uWt5fby#5i_-J=YJk4Fs}en4Nt2Gkbc@e^cknsv|Nbcurd~&*u`&N#)O6>KDer2pyAhf+LiW$bh^V){%ha8FU>N7Tu+;-C>nTZ0yHp4gjW85q8gSFMo zO5kG)8`6uZ+=aKI{$H`rJq}8EFKh$?qSU`JYP~ZlP-9Emv{4TfndYo0c?_@0$Kd5a z%oL;GkfW2?MZLqZi(>Oma~ zp~)bX(+GhX&i_1Tj8#4)yMN-LB7A+?lXi7@4(CAg@ ztLGh(wkwI7m&c9{31tRsjJcf_mZnCDty^f9wJBp5kZPd{>wM79h-%MXINWz)o3rXdyvcA`v_F+*0kZ*Sk*I2+al!iF1hc>##p!2)F4&2|Z9<4K@P6(Q`9?mR_dKY5+j*pD5&Bq!`BD3VqF)3K; zmwiGa9d%Q1`?>efog(J-yk5V!bK^n{$JTY;73BE{%{LCkhOv-2sD_zZVb$*3?2wr} zjHn#m6RpFrSzU*XP9iv+4E*Ws#-ld78jV!GRy0Jfa;D20qO3DAKd3%aR1}BelZPx> zejmUj7}~yyZOEJGmeXgFrK_*MbSwF`lfswxTa&QFZ1t-e36q;ld!;glDd{~}*r`5Np5rtNQWB#-OLw$FfBvxs1lrzu&#agL$zN{_W`b!2g)sdvPIIrly>+*Deeh!JfaAxE@AsqOz~&21L%k zq;Bq(J@SUR=3i@1#e3)ul0(dAio-s}I-&5LpwpgE=l}N2x1)QJ#=g-~>xkoqmr8G~ zSy$^g$0sTH`mi;%vd*0+A4%tkN%pBu>oxSEj$wg_je3_7d|stWb3OBOI)-4iSxAC2Y5qj zf9r%ck6WYc@Apz4TIQ7fU6+6d=?4ulSBAES=VhCgBJCMp26U+Tp3h7S3JS0IV+)?{ zxtXi{0^@UrXo>7X{uKHE$09Kue0C{+S!Dvzt(khq1yH^@ezd7socjb}Jtei3fHN5aD>f8CWt$0#o}BrcDtGvs#k zvVfI2c}H673q3h8&(O!RxzB6kv)Mxgxi9!l-+Y+d6*1y_;j(Qh`*2mTZJ5Gn#;bs^ z1pui)dpQeG$hH=)oZb6(8ggy1pQ;DPUJ|4!$n~;giK{@?{n!%G5=f~_@aIZvElB*f z-ofN9I5XEp^6=%FAjF0{lNcU*9*WWfd9?3PRP05s>fi)Zre}y^b9o%tJA7Sw91%HO z!S5Gh&_SU&HF5g(VL=!J2mPPY!zjoT=hP@`WzLM`9MpfmST8n?G*)oL4NHpSII(KU zp{F`obA44HX_5=o{G~zmBwES6y0c~5K(Y8)_cG4A7Q83)d^U=Ba{g%FHv`-YFE&z! zX1Pts+{7kw9Ge!OKRo_a^Ij?5{1l4~;X7Gg(Q1&yW83ai%`+b@XzO*>V{pJIay8Nz!!;txbs5;X`K~-*@b? z44ae)HERhACwhghdAVgVD}hKsUSeS;75=ns6?5n9q*{6M-FZQ;w{_9+NyOPvd@*WY z#1bq%mqdI;t)iJ^{Eg`oOXO2X`BH7y<8uBuA;H^e5%p}PF8a34VoLtg6n?hZMi@ml z=_}W=SKk(F>s>wy&yeKuish6VoD`HA#w)a{Y*0x~RA+fPyvCmc-~y^z|8#CrQYQ1a zuS#81b|nPUVX+=c@RZ%`1IHKo_XnPFk_0kJq+IdwNhpnieyXY|kz6N9#bPhx9(1Ah ziK{*gjE8+PO3&Sgp*RdSlBPs9G~ z+5h6{-~DO8Qu^#>Ej|-4Ek09-7_#jbjAe*LPQ(>GQtax?I+!Jh9>5$-Ex!8#2 zqB9U=P`*chv#X@bv(oR?6exQAdoOQ_CpKkZ>NQ@Ob5=4%DI;@f%6JH~iQ1@yDnGBj z(^PR^L##NI?bHs@ zyB8Fx!^t*(VwdBN81LmvR4XvNtHSHqOrpGUdNV`jf%;Kwwuc-+z4fyXJib{G2AexV ze{g*~y^t#N`JJ+ReRc49anu5%313%4|f#lpWjh}F@owSF!Dau@FGL=%p*UguHYpnrP2IWQct&*yB z!G6s?bDpdpw%pbEQN=K_T+U5#3m8?qCq{vm)+36mcR;a~h**iJd>`7#bZzb z2K=%Pm}F~;qiJIO4i`Z6u2XJS93!g5H5H-;6H`*b$}``wX!7~wA{Rx`kXeDmvl*-rlhpfi ze?F3W9KWR7`*9|d=_m`_a=W{GZty)=E_v#*d2qj=huM(ukmj47L6(^ikf`%XdgD0f zWHT%J20Pu|-Gqozw3sIwMwSaw@ChE>Sc6JE=lE`Tq2#x_;SyzhG75|IRuP@@SefMqgcuNc0(pJ8;8mC(h5ARPcu7JWRmM^xeGw)5T?x#tK7Kz za|E{}r?o^D4b&4S<@gXa$3RreYxFzMIHwntUExgH=Tn_O_aJd$HF4^v!*6&Q{^mBX zP*c>eii);?H!K;$>k~AryfW=kqYOm6el6PkAfu&t%6qFEB=JfF{CpK``?HNxaNJP+ zfxY{H=iL4HCCc`XV#!QL77Iz&22-Tigq$Nki4DE-PvcVnCE8*{9~qK!3joDS|Jh5oEyTqcIt;sM`?LlwyBXNgZC;q9yB_PDM};>2yaEIkfpk4FZ$ zuGHg>J`m87(vn!vsBMI`)~0mkc1dP0cj?cG-y-ii493!b)h>aCLYQ^s5orPRwiezE zZOV~W7;Jd9)+>%nYSaj5wC~6=rI_-2_+B2aj8YbA=_;?+7^sHff)fh8t?=aykb=dK zK>M&brgLlzhbbhbh{Er6B>+LfC9+~LJaNL3L_^*3l^ZqMN3naKW4y#@#I?0XD_EIE z2~Scl1JjK`(GJV$*45HcQBosnc_9IIUK7W%bY$v9DTDS;LPG`!Im`G|!L}p$avs~a z`203I3Et3)xt*4)I>eD31@-9p`o;B$lZQaixFiI)OjeA4Bb)%00wc@eJIb@vZslo! zxQ?gx63=``9RGSM!Tp)V3=Ol$1ShwEH7F!G{zp&ela3Jdc7ERKvPcySYJH;j>pJ50 zIgLr=29gEa?#vJD!v`NH0c}Zd|IiW7bkw(|fhdb3J@YXyWfZeALm7eMVjS0>dbAw% zo;z{+snfy{HBG}$GfJlDAWE)5@tdm{eNI`wEsV*zA~t;VCfc@;O_1&!Cek;aJS&@?(XjH1a}Q2IKed#+zIZI;2QXL z?yYz0{hES0wfCN$nV#wHwbpzNIDK)4ig8KD5R-4WgPZ-5bX}q{?-1eZSe%qE=$-%nJ$*$gr4G+Ja1ja6zCr&4R&!rX&xZP@hdr z$NVQvM1ebahgC7>=fRILtLG$b@Va zLKR_d6)MbxcL`vxQhe~lJha4AGaDuTmNvYYb4LZ+#`o*K7d3XZLDk@@K1voq3 zmqOh@E}VpJvHViU$_!%lU)P9|=zy*bGL6q44B8vgsC|E3zSxYJsQ6XG)4v!()05-R zdFBvA`j5~E;>t*@!2C_vYB?1fJCTa#vYnx)Nm?~wh*f@jwTm+nrKq^O7|%9?4! z?xDf#HRT-Qf?@9}?*c(gkCPO$-8(jSI{mLE1R)@!4D5|Fd*j~d%Y_g$q!1+5BNwWi z5wOX?6rW)wBm<7zMdEUgT#n?yhv8YgN1qz*Mvft3v4tjJx&~g)OW%N_ejuF2dvfM; z6bx(az`oPKZt|-_Np0l;$741BzbW$fzf+_-2z{AdbPI|h+S^UGkgz5ljc3%BIaR?K znxmGsAlqO_3>ZL;mk;3x)aY`iJeV3Y8jDx_Kja=RSC7dBEs(!pGVeo^ncrg|QjG91 zLC1!J<*9+_ig&{2N6YsQOwiHc#Qr)uK0+zzyM$IW9##ipZuV%={Qf8E+$VMCC8!ed z-MTRvSN*z()nSZUbBD%Q!8B!0s#*}t;y&oelOosTL-LsAE$6^U=5!Q{mO+&+5znW;GG91? zr$_svA`(XDpU4|}R=_Ges9clx5ZR%;!X9bUBdlw{Je!d2s>UJ`r%@i4R@!Br>L0R) z$-FK@C*ElwCw>9@G?{>Q@Kq)x_0&iSb=3M9Cg+MM$6j@u7l`eg%OJ~usr|zl6#vqP z;o{If>*MDWaAib8D5^j!Kv??ed)i<;vF#V(FqOpxZgw?pn|Kf$tR=PSe%Ge-Mu&4+ z=m%0IO%!lpG=BG3aS=28P(?9QItK|6F%u7l8FpTv8*#s-e81$NEt6Vi8NY=|Gk?zS z#IPyoQ2`!kdT(G{ntX&{(RMp=d3)n%KbN2F?)wuLY<_d_WhC(}oS!B*q->a^aGuRUtHrR~O`AhN!VV=E(fR7?G=IiS&R*^7H{|Q<#fr0Zh zj>#5q=oUv*?zpm)yUil|rQ758jekP{`fi}0D{(eT9AQr* zOG+xXTmH?asfJLm1=0jGT?pQQcPO{mf)c_`zZ|-vpVE=T%&n*{{E`srO3W^XaGtyW z$+P5N%E$R$ZPuqbk0o;*ixODb8KF6R zDf9B|R!Sv~?u?yPrYg*xe5&8`AmbYjr%DOPk1GeNHwx>uyK?;9^x3}64E7K>J1%_1 z+vCD9t|+RIjnc>2e7RM-D*8KN-9k)}3Y?jg$|w6VqZbccDh(N< zU<1QG)qI8@KpbwvYMa|~;H&qFy%UT?Uti2(gMz~32X3L(zQUW1@R<1iE6yqI#gvj{TdHAvtQNK0x<5k37>@b{sl$?zOPY|rBP0uvtM%s?dq3hITc^5Z%Z!3+K#DQUl zDJi3y%w`XG{|uCD?kr9%%6?3A&3paR9{6eV`{SDtS=Nn&smoP;^x@foY1_)%Z#fO` zdrjXpM9h?i0Md6B77>nPeLuTreQsyr@k6ufO7Z!)k?%92i%TTus;MY& z(pjYeWEfA9Lp&)+%4Bz{@n^Ycd{F72tdeIyiL@YrDkj-tF*^WN2$cV2#s5?OFKe0^ z7TMRLMiuMiI=|F%t4y1gdJ9QKt^Ht1^Y6t{0^e&myjr40Eiek|vnEY@)$vH!^46{= z_AJm*V2G_*djO49WbDriiUN>b(aPvl?t1H!Z>OuID@(NeNjK>eK?2Yeu!!CD5nZS4 z#HC50>`j#`Lry$Y$o4UcI@^!$u1UMalP@>yGg8YToah*6D+I^aMBW@TmrWh-+%0U+ z(g}X+A%|0MaJWkDz^S17tb|BBzK%%*WV`ca7uthrRc(l8KseP3eMu`4 zJ+TSP4g!*Xv}8}Y&BkX>ADuOuOZT-7Yc7>F6UcY1wT@Rf!`7SmNaADTlHK$BshtwG zMkh{bI5T6%iy9dSYw23xmy(k&8zAIn@;@!BBkNtT0dY{7@B~%-B#NW3C~c_YSuC{t0 z`Y8K0T8S4S<8H*5aWB0PJQzZ&HPszo)eesyrJ0sE$SQy~G!{EpD1ZjH1jcv*JNnMo z6k;!*L9jPT#|G~YIBN%l@JWA$4KYzJkJ@ULHeONlZR!($bgdk?e#0XThc^J^WZdy1 zReS*u9DbyhFF7ij$zx#4ulfTXUV#iWZzEQi@xniQQ}eF6zXKm4=f!}%VDXoak!|mr za9!ywE(swt;>+4>1G)U&HVf^D&^+08un9i0E0lsg0ERT0LuoJ=3T+9~yXnvD zBQshP7ja=E1@M2Y@W^6V(r8I|LbZa(p_oYMshWWO95!jSZPT*25onG9n-%rFen735 zIw2w^@{$luQad>^fa|{xBt-i)=l!P%@&$1+mFstqutMr_cXm{1@u5;F1zPcySpJI5 z@h#Eg47!WA@6FCp+|~GK%klNzX57zp)81bjL;&I@mz{g6N*`;0XuDGun&f(c{TQ8U z9S)z!BI-sAl|jfFH|aW`ngeg!hdj!h2$?wo-n0C9cITguIRtzRJK$qX8p{7{o0Q(w z>aL5z|3K^0M~Hymh3VI~2AY}Rj@s2dd(B`(gDqrUqkC1jO1J8NPBak}mW;I0} zLMUId2*T6;$%@+GM?iK!kks;J?#kqJ+3TlPj3sO`+Bu=5#Yxj>b6R6%1vF4^Gm@Y0 z9~?Q<_K6HlW;0I|-7HY*MbAYYLX_y80h%3?rOf}~YAkDCj*o^t+XC}1dKtMsw9V5f6;D{*P?eRleZ!Y6eY5&OeD7Z83?!UB%A4z!OI7gZ7+sOxlzBq_{~Y76wN+;v>xi~eQy zozN5Uf|pAD%IsG^AYskysdk?p3SchF>}AEhSK8lfdFMs3kdg9mjJzt-IK#1FTtbsM zTY;uZ3ao7vg~y0DU@83B;S%qRjp%9b&C})nUi9Er-)Vm^i(1%VDs!tX&Vh-)mvFao z^{~s~x6q9J`WE?Me<)zXF;+&*p|Q4Zgk97vWyvp?_M#}VQphhhO-vE4l4j6mR+h?| zF1e;fzM*phgMPp35S)Bi}lcyd-W2G#>aDj2E zWWn>-Kb>>)Vs}z|Y@Ppf>Q5bo|_WJ-6vUz$JM)4-#eeHgKEqi zP}}gHZ%bYv<_OBYSX%X}lv^%BSW|=jT*``+Y$*QUIz!g)ld#VX!M_Z$s=~SqDDV#F zrYud?%q2rH#cxz|V}zz+(4qRssWDZhA>fJ|7-cDf`$c>)-*-L(fR}T-7_j$>b5J1% z>y}I-2<_hDB_c$M?B1r({eE?Cc5~(E0NR3#lIF^kY!}Jm^II4t(i2>+++87`Caed= zHMgR`QzyL)5K#=1(-w*GBQVIOrYCSJNo7{8oG2()_E7|Yp+55r7!<=it*oqwAOCew z0N@Dd-)^adoXft0uQwDGAFggC-Fpi~83Z(ftb@AvL|>Fg1HNp2f-e-_-$3yOKfXWZ zY!36E4*XGpn|P|0Txj&tW0p5)x_7JaYRe)U;h5r^oI6?fXw~=sIE;zPWpawb`qOm8 z#0I=rw$~8H1?)|QsFW4|4;Bbn=%g`3tpWs$9xTs1PJLxsdi+5`(68=i=54noOU;PuAQ{pX8&W|v;0&e0f{UTiH z+inasA51ksGaFX@rIx_Sb&FTJ+D{uE|0N>8k zlD8iM&76`>A1Mb?Td0$wfU0NaR-@z^sS5z-dA`aTBjJ^ zaQMy|s2%gQP5B|>29Bm<*m)D^sLQI9r-8G0Q&69%lW=TF25R>`;NJ*+ z`RYz4yR!Y)_06@iYr|yR5{=A@ib$=nKf>M9C51h^eFZC)(UzTE|=1e z7|Xb$1bDMPUI6gs1iqmHtX=YEnFziP0UBr4BN$9)d~|qQVfWSF_(8;iyWQWD0Ps*$ zduAUMB9Xt*^wtoAa(`2F%V=m91uEjCmw5hW1lewrj4OyZ4rf;(ZziN-RAjKPGYtR* zwXv=NpdccrXhFJe@!W(DPO<~K1lg5ajMT~4gMGYJOh+o|i1$LCy*@z{SPNrGPAt{Z zm^>T3xqU$cExdmFZA4qiwn(i0EnR>1i0;8k{#bO>AB!A{a+*ikbaM1~Ppr=7dIM=ZGdU;D^>%M7PPBw8?>HoBtQNb|+XWKTvxbnv3c1FW+OScgW>lzd(6;~uOL zOfOb_p8FS%6hVN0U@p1ApMsJqlx{9>BkiNhLEO$1k&X=4DsGU5&sZKJoJ8XA%V_K$ z(os+TBpHU)O-0H0`bbg_LJE3!5YYh`WNToMF&u_kt%RfI7}$-5!hSR3nb+yr;fRQ3Jm}97=W8<=``b7YWG12SZ5;n` z1~HlJ;^8P9$~WnUw?Es6a3I4GqtWobP_TB7MLr7Xm-Nu1{RcKB4SK)63Mz9Y@G|@{ zl_MRQ%fvm+H+7BOs{ugs=O`qh(oi|BX-E#IEpX__GeW_;swHIYh+vnZ=hNu0E>~;4 zSm6j9mp7xqAuj={XuB9J&^G$5>zaTj4H2#jz`2V?qZ@+7rX%lNNWQ>OS})gHSCdc% zYeoDaY~q=DT`|*!vqY-SbFcGAp$F`#gG8>1UIZ#0B6M)SdA6ty4u^;93o+==HCwq^ zfn1g<-Dc0(gj}AZkM4s!wuN$gK7!VVNPq$+fioochv>#Z?)-KBd?>?mUG|NS$lONv z)o_-2K<0I4tkMsF$}3)GJM@JIYB6-x3P8;1TV1qwmnpt9~B*8yjg}r z5r|R?tp);zqT{rZsnRYrZ!Oy8l~dDC7!C)^h6k}nPR zOOeQ6s5wS+elo<|n2lsdgJ87?V!2@R;|~q{&tRNanIK@%hSbw&qMJa^b!=!J#eb)a zAzJ;#X2p~N86d=DCqn%}A%<#M;hVrB)G;>jof?B4A5K${@mq+p$_EJ1W-p#?JjgIa zSl~e=@k2jL&4ZUz=8L8mX<4m#|V#^e>09)^v$CqmB@L+R9 z1}iFx)T1DQ5%Om7n%|s_2?oVNjw{>Fs8p{S~Ef7FwPDxsRMHc zSI6p91GaTkEWu)sS3BWc`b8?jX^^&mxe@D-p*YH*2y7V_7~)Jd*GZWDfW(x_S&6Jz ze4RXpeV=xmDM7#|e_b3wto}YzRAwT?X}+J6B%1(Ds9vMdyWz!K zb;7^GYeZDg-Eg^Z+{FlcaI4~*WrMYG=MWs%hA9*Wu*6#C$;af1G(Y#lvMg{-E9|ym z%c#NX^uz7NObD$aCD8WtD!}amWYL*#V&Ms#Kk0Y)-MUZ>{?dNl6Y13bZHW1acN{ZM z4iP{r7Ct1g=AUh=j~YSLhyKHn>Cq=$@Y}|Vl!ZhYru>>cu&s10{k??oc!Ml@H0AuU zrk4wyD+%QR5kO3juy(=%OFjX718Fo5MMCf&=>Yl!URM<@T0wt^w-lP%TzI7K zM?m>*z7TM#flQw950^$snR*PCY7}$3k#KpISA8X&Wflkua0uQLbF0xMu|o^ zHlwUx5P`ii5zG%?DMdw{4>pUD$*l4F^jL$dCJA6vk`fI@ACFhAqT^v>M}rAtTg!{V zVI#vWd}iSljuv(*>8fiQHaPu%s$LfUWW&wq@jbHdVQ^eV%M8^Hq6$2(=MCF_)6frp zI|O39ywj%icskvQzUYh^S!gOw1a^E3s;s88Npi!6!k*S>dednc0xKV4w+K)|Gy{1d zeS$k>rzc4%nmHY%X*?zd5S5t9yQV~t+yU?uAW-&f zO0=Qs#Y(6uYj*-EnRQ$LLw*_aG5>MgsdCaj4I@NTTqXB)sUug40= zMK@ypd>k06aP1#wnM8gS#Ms_4(ia-#t4hM2_tUCjkr#|bg*cYx(H6uSV3PrbG#m^s zC5><{a>fFPxEq06^k7Qra|l;-{VuP6%)KZ|$_nvfd==ExZ~NpnIwWGOMp~}x07MQf z+tTgUW9#Bxip3Eu4Rf^v0(BvwQBwZAIr(P3`K@c(p{n|t*;3x*6bJ_HI_ag+sq~z= z?*U9;I7LKsY8{QP0V~fq)?c`p|ud&9tCInjrhgk5mr_WT@ip)fEc$`I;>2gvD9 z06g=p(^?*gTBJU2Ztk0Wi~05Q5^u76hmk*GftEm7MwfAaQg$q;bB!7{&HzjW5$UW= zUjWI&<%xfn2d2w1QxUC|emxtR*>>x5Nfb3JVl@-#f?D(My%(5o@D{X?_3R z{$9QILim(Lkq?A6Hfc#W-a|PYo8lj271L25L;(8Ctqb}e4~B>k{HNIl8Y$Vq5AZsL zf2h5ZOY#F>on2k^n9JGj9@+xEy+18hD!BSF5;A1x>8#A>C<#;J2U0wQ98Un;r$mvi z`kis)W62MmLO*aPPdu8_m_()eCKpXBm&&Zp79DxE6rJLRZJP^%3e;Sl-^AzQa37j$JCkhf84BhD| zoBt@Ow7xV+&N})%g5d~(dsp+&M2+H0ldR^ug8XA0*`}3$isn~L^mKEvpt-yzC!rt;9td8nVNHrhh&hHApnv0 z<8}l2<8!pkYg7Pm05Pd8$Cn+Hez@VnqaOBfS6`MaKcR~$u<_uN@iy4%hqVz83{4dD zv+vxy`W%OK{s>tA>=BItX4n6fPKMc+R2&)yK#p-g@4M1Z?Feqw$X1%-aUh!R2fSK& zc>&)Mt9k3z{A?;lLrqOVK!hPJn|Vsuh0R=D-12*E1xGGDA|aL}jg=B}ecVV4Lv{%> z#oQ#0i5ldb728HCl(x0brR21&^)UDN zPA@6S`oV4OT3jVx!HW7Ss{+aWdr8t{>XSmbUJX(^} z`%!M;wVzexybKqY4Y3!V9G|5`8$W*=hJJkO^7Wh>pwVWqa@9Kh)0dZlJd@ z8876iPdV}}Z1imMJ@yxK*?89Hbauwve>J`m#MfLYv^b0A&3f&~L79CS`5)2YmaD77 zjj64-z>E#Pdc6OuN84X2GKNV3auw*MU4)m-x8nFYx@VM!2ClQk$=@vGC96`a@o{zY zm0_&B4$H?92@Ja5pu%y*^Y9IT3{c5sFC2dux@+9)l=-XV9mHGh*DA8jMz-LDawm>d z5=Az%1fPot>)Vut7AW%FPB4S4Rq^t2n)sI?%YibkR%^doZY46~QtB+1S$>abSG^Hi z+Gq*m9jyynR?5xpn~i#5iAeRwRb<(e_2q&$&o6d}#M(EkN==L1n^711C~VZA&+hj; zj16(CmgR}bK@6GKdMqVv%C5Sif2Aw7YBmQevbSVhw8;Dve)h_-ZQl*%?Hp)yPMw8@QP*JandHNwmIQZ!b0OOhBp#bPi6i}Do=$#-nRO;k-${2XSwIcQzQX{-f zc;Z75Rt=FCOA zY`9#b^;*V5eTmAXWkzDWHKE>dWrE(sdhD6DUW4f*xK_CHsQgZH5sN+ARth+r3+sp3 zoeOKP=w6Z-U%?NP>n=qM8a+^0g$UAp3w|DHZ=UBRI6z^NgF3o;FAqIA7IDC=L)4g= zj?t^|ZT*hT zEJlp$*L)9`Cv8EvHw8n#{cl=VGF-E=rFqYszTLDMC*JXv8Wg(IZrbnL)%$j=rcYW` zH6HS|`tZy2vt>6G~RbMu8(70w# zZ(8zW!X>3@b7}t?tV-!b2h@J^qETx--95a%r1T9C?C9ud=k8|MDbdvEWvJB`xCXZE z@Hj1TP6Lfvuy3-nnG=?VYOM-(iT^RK?K@T7cz$m%z6Vr6c^Hqo1y6~+CN25L$|R+CaS?T zwFwIFoMpQ4SmSrM1QNVG?;6U9W9!{?NMl?VA3c+$ap~NikdA`6nX?Q8q&Y zMF(C|P7dl2H?(U2Zz2GcmF)sP_eEqGG;1rL`T=EkWl9<31I}B`NqlO?9mzE#>GE{Q zA@juWDWdYk2rwW!Uo$XD9Gy3c^{Txii|yUZxo&5+TrUv_9g}foml@IgBi2#}=lJ8A zD+=c`5EAaP#wwpr{sFvm0d$-=NtH3x(;J1X;fL)IKYNu;1~L3F11$PB3?3d&e5w%& zlXDs}6tum}T`nYM$atIl5ut6u?52Q4zdr7!OP#1@gKvlMW*~_p1T)a^GW>|=GIzWa zBmVbabw@^@d4_LyEo(*q^$W_YT36kP7`Uqrw?v)GmP2!Re)1V7e90 zmUD4QJcc~3w3naAskxLI%go;`9{6DI-gKML4?$IBhith$6gh%wImAbu-J?;{-=E(W zUhku`Sp3YCvh`vF^P|In<_OkuD2pl^gDs#hzTL4gb<1hVh^Hm$xbsnq`D`%uSkEU4 zy4kx*_Z~`rdK(!+Gi}6lAE2F@8AZ~?VR-Syxq&x6eaW`ajF$I*JpNr+uWyX(8DSEi zkbpCi?IMOxC3n6>Ih_tttkA0TtfloCd$A(W8t1E*~RWl&ME^Xe? z__GovbnB-lQpT{czI|H@Tijw6qY<>pS3a9t@Ap-)gOCcn07bg@cyCk-V(VOYMz8AC z$N;8Zjc;9D1%LgnUYG^`K0w8ewflZ^0&b*P1v_VQV5Tw8x;-4IAo9R1iNbe5+31fv zj;-WuNJ^Ydnl}zO1`IM>XF_nHF)zvQa_vwIGJxk6ju8B9>jalD?6Y#7DDW9P52B4h zw#)GS(Pu}_v7An}T!jvSjdQ3q$Z(oGOPgM@2T@xZ=EH6vBH4ZVJY|;1+@L$x>`Jcb zo#<~hvR1Bm&Gh#cdX#H`S^%baisY_JYLluQW??4IN3=MoZoh8=ym1winM#0?{qxF69DY<;V;(*C z0%m);$&W!?rab~2*_mk5RI^o;Q2r&8IE1Ed<2dVGVw1Sz@#j9=StG40Te5}x&uq(G zjq0ge2Hm`@4)D3!iVfO@@(6u4#*?%pbq3)HD_PdiwSaU>A6`w6%z}?S>CLCQ;xL>V z8yPeDJc^YJb8?-RDngFEWaGP_^||o_lLL7n9G~f7CfxW|w!0J@bX~r=(?pLs zxP@_wUVT|Vp#tLFPTKlU^M$MjXgP)(-32u!d2>3NdOR3jMNf+w8q+t-kuiGQCqoyM zNrSx#L@pNi4q`X<#t)i|nrKqh3yqZgClR9WEFXM& z^y^CNU!ird*H5iOMqHCwM!TRDzdswYWL$8-Hg43=7K|By+*VZ9qKU=Gv%;V{_y{a= zi@!= zIw(F+xJILqe`BOarO%c0?n`Ml zF>69~9B0)fn6)6nPhTp3quKyvQtKPrcLJ+VjWP7Gt{wVnLqM%aneyWlQ=QT#sxAMK4Fvo8}C=CSWAPu^vDa>2kIg&b~>hQQX90$M11UbC|% zdq+rC=9m2S1>y__9iG$Hx#_T8?tEd-eE8GG+W6A}W$r*v_}*0*3~+zTp8#~2zfk~9 zP~27&eR^s;Jow|`B+7Jl7OAteft_=&Kal}jFV1PB$y+One61#ql|NW`1;&5Gh49GP zu&CxFd10kJxJ(*;K55|?AiDGw8ruS!NUc#XF>)%U zb#64GJm6_a1qyqcE*q!q{2`hwsV6@Ud@PB%A*7ZMVba0Y{!kVXY?1hJ*s-RD&MI)zTWCJ1i0+QNr z8on}CDI^17Hn&ZH9T9GD!=dA9_l;mRt8tTHc7m(J+(!k%2V?HpjT+EJa;?!k9O$91 zA2R}Vu!-(dt4ns+>(WT=M|%2r;>@t3fYQzms;kKD*;g0*91A64IGg}Pq8NQB@lA-i zLAN^qs42O;~pnCZt3X{yKqA9YkvRT)6`!;ONLZ{WkaW}~8x8gAyR<6q(@R+Uu+rIN>?aYju{&~wnmSaYbG{h)vqzy-NW zA$6K)Y6{6q6~YLIfRoajCA{h+dGo8#ZVo3m`9+0kp0I zX-$W&?D_cXM`zu40Ik1Gng9vhy<>o=qJ~`{>xqs=J3k0`J@NdnV#HeP!)lqp>id%( zl44CM`XOkdNN`D3qLCT^$$4q`*x| zjaSKZ!4X3aN0VF=uz=lO2Jpn6b3I>CX$Sv()>U5HA0jQx;p_aCA=wiS)*9kHvyN|S zuL3bxTVh=Bcmiq{0(ocv$MWU4=k*#l0jynzSY?Js>mp%E8tq18(oxGSjo*;F~ zBRe|6RP*l@dUS-RtXzbcUFpLikC>VOYgp^7@xZ)X!--Ib+h-p8*Mdo5FQuwCi za$agE622v41Ybp=HAYv3+~yvOiI>tDXwgK+||-x9KV0d}(+`#jOkj zJz599=2ZjW%XK02H>uv1n?X?ELq-@gki=;8s7&Bc1%p+7Wk_hhIBP=|xSI}|$xu_4 zfiRxT4h+g@ep8y1bIa1c&qS+Z8YVbl+7(9l5$hjEx1Mq9quV?f%am;{VWc!jFne@3 z_L={^O6SxJ8pYQYSh%g4Jde)4A^s%zkEz#1-`E6sTTZomd3kgeXHNvp*tHsw;E=HqH~xlX=a7r1_Z9=ZkT(p>QFHD~-xhmm8H!^pq(}i0=9w(#Z@s z62uv#D@UhXfH62c^e7}I=wkk=PQ%K#r;403e}+-}*e?@ntbIU6ZbG($#S>4D7*v-V z)4HHQ-Smyx^4g%VE7|$W%P0F1d7E!O*%uQag*c~SIUJ83{Q#zKUBg+cjywPJiqAUY!YuX1v#(iKJeg zG%i3a1JQ^ZLmG8@pA9Midu}k;R{+v7B`sFNUqe7(NB7pOVQWXa_`fxAcLYRM%k7Mk8>F9oo%PIyvSru$RBdKu}U zYVxf)Cos)UzKk5J9Ke*|oy!$hQ2`ob$0(Jq*Al;zG=)+!cVl3*%4e9B+%PkT2Od~^ zqwETXAvKkw*|c%jdv48}H=mw{Ex2@XEc){mHGe3$JlXd=>jUZM?nggR_+OErBE)59 zodeZ~!JHael34?Dl@(q)LBC_8_PQ$UpodW@~Jopafc!j1^26VA-%`kKPvoPHl&|R+JyjUTm&|T+LdNyqMOc{!Ohw5UmPDZSXo4|BvYF4bY z=qaJ)%-~n0U%|2TfZ2Tjv!~)!r_&fXd}DmtM)DuE>(Gyz=2bSDj&oA<9q@T7t<)I1 zDhSeq){m_~29a80F0ClGP(#mS0t+am3tZmhv@UJlb@H=i(e|FZQ|C>Ux!A0@)(Q~#!MS0Ve@p(t}ABRSz zqX+hyZx*dJ4a%ijtWK$)+(uBjN%FdN;**g@dVnJ-pBILi$yNu-G~|#D45k^zgiMG3 zJO0l!iU^#YPn?&4D#8b8rCZ=PBe+6)$ZyROENhsyvrW1A%%udA5VEGYlixuDsVz4T zb-Rb6g_iPnG6q%uAPJfx1K=s-hJhqx$$+j@h4^&Bom4P?TDl2nG{qdsgk zt8(Kd?PZ{*6LL;JTw&Cc%Q84~x@dp1)%?gc#4V42(75$^6H|7gCussr=M4HV zdW$P5=ULW^Y^3Z>tSMYofb{)CfS4ZH%pmDvk}&zkBs^Z@R;#GDo155_IX!}V;p%zYTKMO_2 z7XMy9z7lU0&SXj_MJ^g~(8{Dh=iMDzupD81Li~UM?Rs37m2tPd~28&b6&d{FBbIm#YX@Vjvs1@!5!AaAa^vDoPRf42^tCc7qmjV1~} z@Ypv(TNc2>n9cZE%?)_`1;VSj-<%jOZ>~A*IvI2er$d!O_540D?Jo>!50Ro$E`}Bn z>|mA1Twfe%_3~KDZ3aNc1?yW}FWO6@L%0--%m1*r^Zg&lFZU=bOBF7S&H6Q6WFeY^ z&6Piez%v0=ITQSQcF!To5t&X2P~f>LUi}^6;=@o^IaQg7ltKIqh`lnPSJ1`A-S9^e zwA<8I)SF-d3BUvWNUEj+<$pJtJ{)$kd%{y4)BLJ$SbGNcSk}{k4G)S%5dO~Bg6?1R zq{SAlsm3+X$L+dUhSePxjs9Zl0P~v(zbx1|`KTEanbyaWPZ)wLScp#LnY7&wIU<-m zDfG|F=ooAYnIOb>4*fRlNUl0m1=e8id@JA16A=ZA7bJ7xW*?Phfd*(sWDKK*c9Dt! zbeF)ux47Kb@^xSXUA+H|VRDaiFNSq)K`^ybmkyu_j#wom&+}TZ2xjMYnC!(gbQ&_$ zm8^kNsAq!}W=XJy$|rGE^2mnmMGG=b3QK=x2{J`Z?^Ya7`DpOq=>S-+{q+W=Yrt|; zkabr7Yz&ni1OhgKmuv~p(9_dy-1VP&l^}_T8fc9P!#7&hx6gjAL&xtgL2pKyFD2g0 zK_L%$rt3pJpq9k|$-fuxk4ZsOZ-EawKLWG9U#|m@%!fX)mTw`# zbOibmEsk?r&;|?fE4NKO@aT|aZ=?`q@r!=J2Mj=r*$63CXzh#AXVAYaMn*$r>0h_p zH=75Zl*Cm>s>oWGN$+qc^$MX*;D_#@)}GU@idwo4Yix zggbQrwT>o~DpFVz%=Pf{#cL9s9%!|ZIfOo*l?;g*nSC2{`*-|Bs%tYMd(n?NM~{>6 z4H(fh<<_~a{H&th?^pIodqTDTUkpPi7vY~K;eQ)xla>3CeGPPcz>|}omxb0QRhRv4 zvu&p{yC2|*B6+g&DJTzS!JV>Ke~We$Xs38@l8 z0r}m*UtA}@Q&{B`&jnk1WB{@EsM}zbv?B(h^5$*k6g1!LpMN%6X8ULT;CiL{8W_?? zV0>`*S+32(bH|eYV&%`ZwH9#IWhX{!^mco%s6XF&SKj8@kxW5)6aeQCF0Unz&Z5=J z?sNxME5QRHftU%&m-4b(o@c#}$tojVfKp|vr6!qMCIRj%z!E)Wtx-HD`Wiy0%D7v} z6>Oe1SxFR=UD+|=!2;9t3qCx%97oKyipja;;|SS^(&=UHlwp}jZvKtVC|6xMgoVk0 zABfcm#;j3C%zeI<;ZNP;ghYv+SAB6F1r!gNJ5?|7Y=ZYml;gR}`g0EFN$z9eL< zA3o=2ZO)_|!~8!X#2J3VsOILySN^dPf(Dh$A$-W=aE}-uZMJGQCH*LZd6+`>Le(mO zf2emYjjJ`J^(LM|eY}G>m51HX&t~DVEO3}I=W3WO6K;~2-R5@^5lqZv_L^A&%Igs)<=_zNj2pJBDPv%QBqJZSopL@7{)1zo^VsX=Tm~<+p zSa;yq5@PYJ5g+DUs-!xd#)wNiInasn6;ou`oy0kf-kv_0MFF>UX(1})np#@59B`^B zvu%-k-AwJe@c#A2GuTiNy<&(l!nmKPTPCv|(A2?|pizS|BL?(mR}2=)RvvbBHQ-&e z>8g8}NJ;mDJ~|W6WYfCpicEOtvrp`$k3Q!JK!=wimakx>A86Q*0o2XA9C>hF`Sa96#~v zSkjWD3mP}L^Wq3vbDXqzOVc-3<{fV9Rv;27Z}vy|q_qM))#*#12x7d3(Ki8-28~_T zGR2*72)?(6lF6dxMu)0duZKF8Rb}l zDD%4%?y_HXj1FLy5}k^6?fl@7IQ7zz?Y9@q6M6*?|n#o%Q&<- zLY8I`LtE@f3RU+6A~%OzWWl-AS62O0PjdO#&Xhw^J#fnCxg%N2%#IZFi{(*ZaGU&t zrd6ZaY=*Lr2;2)zD=b;LiyObz%S z6!oX5wrFJJ`TOaB3TegG^Ha%&PqN^m^<8jsbDMpM?e9f}WNnGSN9m<+FN}3U@4?Bv zu14df!wO%#S6D|LASPCt{5e^0^``B0R}{X&wsnp69PzvT(g#Ta>+ruUKKnHv0fe&WVgIP7#%U5BX40FKV?1G?4RgqxBh-LuSQ}-a91Q+i)QXwj!2%}l#)`k z-Bd`Fn~)gkLHm09<*M&CW?RTevA-Gpp~TZ~k27hWR-dhdPh^`7W6#RI4J1E<`aam{ z__K;|Kdecz!s~?wXkmZ+&1@Q1fYbUqw-aJ3@j`|2eum*;qC&xL&rIC)T2W{nt_C zeqcHEp2*yOAw!NGpH1Y!$319zxse9C# zyCRrzpWo0r-AwH#TMv0(^R~(DtzRDG#r%Hjtw=$M`>_uxXjXX?U&R|KcT&^4vqV68 z!51O2q5=&2-7lFMMktzfpC7jPH#wN=yR-{kr8AQ)U5D^bA6g9CwiKLZ8y`9g zuHED}5}BrZFExt!F5o3v15j@b^msTzVn_@^xXrk3wAnsxZ1?ImhM~a|A1;PICP?iT z6^yxYa6(ZfHA64Z*Vapk8a>}IxNHmv-F1*<9{*IfS85z2V|{Zsb&HoA?-B?Wm+N}6 zufNKK(N_l6_@?fLxtG?-E58#OAw=;<8~IB+IN$5TXLG+3|4GY zy~v)+KbA*1lX5a&$?SWa?9+d#z6oEG@rjTB@+bw=zF?N|w$EaUOOgY5^kH2ozY;&| zW`5?x#4;p4^I?cFDM$_TMRQB|Aq=VdhP!YcVtCo;k9@mxRYGxKa6D!Hm|ZF=*GuRl zJ+kR-xAF+&p)U>MF4s!z`-OVx ztwOm`4HKMwU(-p3-Dq*|r?faFF+O2=M$GqEe3?txj@~H5_t}$#({w!UQHg{}={g#T zAeZ+Nxp%TP?T?Zdo=NMr;7Nyv{rqL-aB(IYUXanS945=t7aJg{VD#k?zS^}k;;Ffb zj>-MpcLwj0b98I3MK12pvVogG0t>`OSv=3x&vd@5xP=Cy6RR^bq&zPwF4mQz?dfN{ z*);@5I6oBRc!P^ysRwZ%1xWjAyQJ#`cFFHcr#wHVe@n*xTeOO!lu#Z@>55^byt_hr zbo_z8D017T=i=A);o-6lS~2u|i`7VyeVC2W(5azDp;Lpb55?G|J%093ubNR;c6YR5 zkg)j+1nwV@?eUOYF))45*AtZ)8%71u%Em1|?;-%(6S`X`YdaQppxh#7gzHFix!xQv ziaLp*^-QKtxY$piMuH|D7k;obZLI&ya66T+aKnzVaU!o;XnjgaD-Z3^<%fq-h9m=sL54nf32PR%a zWhcRxY)s2=d(Hz^FT634x9m)dN-rN;K6IvJdQFWswgX-WUFsYyw$$uzDoL%k5c!t% zNJg!d#3Z!FIrf9+%Gg&IMKh1{!*&ll@liH2KmDIC9tOEg{s43-(Z#zBt98WGhCpk8 z_Kpp6Pk0u~n*yA3Oe{>F5KX;FIZ}gCN6h*k&ZS1hr`wem6*JCrH0SpMPzgA{{HUOAshHp5W9&1~_+ndK2z;`Z0w0Z~c#y(V`!866!`{=x=l{V>hV`H== zXvXDLZhR5jbcAb{nmcm^{n2gmlBs9r9D-LiiajozO1D3_awZaATWy0IZ(bIzUjHQF zDanX$K=A$k>4EnP6o`O#@4&0bYl;O9tzKTf9CIuj38hrw8_do>_^?9p>&AO$&gyw2 zmBNGviGBh*`Sb_qT4d%!J~g`_xj6IjLq&GJ_JSpI(t`W#JLA(f;EmgQWB{IIWa*6U(xxmKK3 zl!EkNbL4d1%l+o=O!|~k`S)~-znSR7z?!kw%0vCb%Ok@NHAug^7EB#<{{P}&b=xr*KY`$ zt3N4umohhjA2)TX(62g<=gAd)(@O5Uyf+qQXFer)baOZ7XGgnHY1aY zp9SAsYn)v9~t?UjY=57MPyQQ}q&LX!p72{z+G+vuJq zzq#)%7iVwMT`x89zZ>|YHlwRHbAeEFV6rL0ZHW{|Kk7R6MyMOw!Er_lnhXVf92pgF z1Wj>YSDK&mTj|uNs7RUeT$NPwTwU;O3tl(!)6t2Zb$0UG{BU-DP4T8*gB6t?Ey{kA zn!4YVS98AMd~Kbnav67II!|2WZ1e0)v-`Ep)YRm*I&V+1%DbBMCug4=Xu}k=9$@*T zds!d2A8m^NI=GiM@u;f$QPoMlDxG z-)?BBm2i8W8-9*(jd+?}#S|Tc;#C})AbA`b#j|cvcdv_;;PtCY4xrGTO!s@7tch2+ zOCCQ?7G|?w(HS*mZlOMfyzli*A5CeY;1HHf_#Hz;-;34TNAVfBO#cg(3x)?I#4r#u+Ky?2_>-@K@k8pXL^baQ?jtaY=0-r6~z zdcB9xJY5m9E~%-O=2G^Oti)^gVSPy~K{(er#t0Ue&dJoFR{qPs{K+b#rD3FCd9Vda z66<#&1f0~++LU3kLT}x^n)qD{9ftkbHELH=EA@JfAJ5tk?FO=5(MA%)FB`hM$(1Q# zt9P3C?ghFsztsuNg!qwL7Q$@p6(znaepxk~K1~*Q9*RR{`$lPd(HJrVI}E7P#<11d z#IE?TeDs<=#o9huPvSHilf>*`pcl9bUDnBp>>4fHh zk!}Bt+^i_b8a{F|ael=c(#{8Vq!^>LNajTst432re3IdGMb<@n4gG1b)6MFnW)Zg! zo=8QGz3pVe7`E3%>qL~7+rfG3#e~g#eabvvk73dGT6{v&05j8)@qrt zb=qAlzSf8#*9kHXkAH6C+f*D2LHcFS6J!yt$Dh4bUDIVBS;d2GL`O_|qpLnk19;GOFk zHi4`(+DMsvCiX?(01A4uyjqSh42 zK&PuXMA5B^L`Y}hfzW7Q`AUa7cV-a*LFlu83u@yZ;a8??tx0j_)!)C6OvoU&W)wri zg0s0A_tP|A_)2EI-16o*3%2&l{_zf=UPGRver5emhJcaVTAOlAR(Nh`;!=e* z+Fry8Xj!oVH|p1*!ljpnu3vUlN3YE&IsR;V@m@BK#f~COP-}_9C;j32aE3?!OH}{y zB@?~MuPjR;_%x=B?-AjZ5e0szdJ#?0H@E`pcMS05W6PM=?NO(uuY0vMHAR`3jMF_vwyjA<9EQB!q%_W~td`mStrP1*E`@{(?O1MoTlts)K| zJi)J2VtLa_j|Q0L3vJmsakW{e6jFkX`{Uo^(=-37c3@7k&z>0k9Xq}}hC3qO78w~w zBD6IWFASgvHJf#x5)nooZN17{)lsxHx4CFD`6i}#$`nH3l3nOTArVA9j2|UZDaE*} zG6zP-jHk*GLi~250HM1i0Cr>3hiGpz4ZMJSs7LGO{P1jo-=>0D9{Y}FV62954g1HL z{+Hu^j2EjL1!2V0gLcEwtVGm^EiwsfMuDmdy)C(_^oKWgr@Tq2^{zK-%X?|NKSMp2 zIK=hBYs|}m2{VedtsoRTS=O_ZSAP$t4d%n|r&-fo=_%>iFAen-o@Y7%Mi@*4_RO(2xOKcF^(P*^&~h`sY}Y49L@(8P zAhI&X-82Vtv9%gl@diI>7I!ElU#zWl3 zZ=)@-96E^^f*V44aQ|jR z98iwzqF&623g6kDeZ%45@#-f~60z^O!|l%skLe_!w8QW#%;?3rcYGdU^Vb7^oYTZ3 z(t4d+e{MlXoZz2UQ5+_tU7s6>iW9WIU>%~CQ2AuGslqbgt3YM0up+i6~-CLG;<0h;> zf3!LDF|9E*>qK%>bkO_R^%jWg5~k~h9!6``_}H;-HkVuJ6XgD}{C>EXr&_G- z34AK9P?Js~X#Z*L0R%?<1c6YvSw66#z1lt-Irvy&ebmPxZkhJF|X6hX~g|m9Or|T_G74ZiSg^y zXAySR%g05o%u-aRgzw9I)9-=LLtV@kK*r&*_pMsw{OxBT3Zao9GLY30` zEbT_H(hg-tGuPi{x^yRSGl03?^^dZzPWd{3j|I(bLEsHl3MoO;O6_*{C-;I$vy&R} z+HG0CQ%R^0TSxqbD*whG{}?;AOo6^^^z6f%ki4&fTp>PG_U0gf7Bn;YS2WmtreQXF zR<)z`STM(&_0B66+rk7Y;L|hkRcQ3$+StVhlDi{b)U;#4;=cyy4C=23_~~rqlVC@-dsY`iS9=^G%%l|8_i{BX@W6(fjZva?HBFbY#LSg$tFvkO zokd<}T2X{8YCb^bkQtCes$x+6Pnd)WyUrH^BMnmBhGBc^AF-VOE$jj3zl9m@MMV8h zOi5_R48H{HA|<@hIwm+T7+&h$=3%|t{^nb7$Z@!mV7r|vqbnOM7S0%_cpfu zxnJTQoJ`P@E^HL6>=emqblsSKHBzBn(1iQhOb3cxa+gI1qw1Dtg1vxf6*2qZ^_EOu zF7M7=b}qMFTjkkRA6A+%ZDt`u&yjH$6`;*Ln0VdLlpoFfqYZWe!OJ$6ta6O*AM1em zeS*xv$^z@AFkE!Za2q~IpYJ(Gj0d;qlox~H_cV)GeemAj@Tpk&Od~NRhPBF%|L}PL zV3gXSWgrv10Ga5soEffC)rgDi$M`m<2m~RYOUEtaN{wg6rDu+M$7x2~zfgUQ&iA;oQ)fN1&X{KjdpYOHo1hq6YZSD8NtuF0WnSA8UFb^XJR@C2giB(cc-@hUI&|kF1v)9tCf)$b6pVuNf%+9V( zg+q^q>q3u-=0Y#cz9#~i(|5E_G+!wM^C*RtaA!K)s8isdFe)~EMl$Y8cln(Gk8hDq2Ktk1A|U!}Vh zPt-<;>TvI_bQFS|FI|3a)-a1T&%Np)q@H;7en}?Ep=P)A`*k)%N4WF zJt}zh#Gk>N$`3EVn+8sW$>=1GAxNc zUmi}#bCh4u@lw&nP|?SYaa=}U0d1@3Tj*dFgBW1&!o)}LB5c6m>&-1tO(gU>l)Wyh z%oP7>Fpz~~Fjh1)B?lR|#J{>r&phUiDRrj8P=x)iqlfm;PRO>GM>W`Xv~L&*^~8qS zp@JxWh@=W`CaLM-(?LgVGCKe3JkFx2uOREbDCA?3fWCe6fqb%J_EnwMcQ$mj6wWf@ z3MACOWWI&^Z=n*}cl%T85OW)w)Q|kEvvC)hIl^yAq66#DBLs|W&?-kUpriA!r=OrP zieacoI~fe^P&ocb0{S=b>I3U6bQIu9pzc&Pd-TpV_dV&NwgiZzLVk`kn0JZ&#-W)d z8`nss&EvO}uJY3IukZfv%z1BT{^OC|c+(U^m&x|@8dx_uXexSRY}#Tw_QO1Cu`aI3x% zJRan06LCm0d%yi~M1}B#Q7Rb;=_io9UKhkLVu=TJhOtXVl4xO4&Alr7;R22q#XIsi zOo8vHy3@tS87|U!1cx$iXApCUmW^~eHFXnjb!W3E?XybH(i!VjI~47W@L9uIo_jxw zCHy2LL$9cCuD)a-4D8z8+v}f3P-$>TvXyZm2@S*wqhI>%ENa;=lBucVVoZzp7)&?L zdJhQi`$A`0l{0R}?XC`^%od z_6=GH{`hD5VDC(5^z*pTOsp2<6BK=HG5pYQx*5J|6BS!!o$u8~w;J%vKhP~&@ZsLW z(qa`z$D?ksqIPf4iO}U-%buxu>PQ)etwsMdJ$)szD54RJO=rHyqp$KaW8J`S$3Lu! z*U`e zrExX!3zqY70DeI_zGXgspKL)gqLpWnH!>Mb1Sk7SUoJI6CzF7^sUa1p^7nt5qfGYV zSX#OF`SZ8Va|cg-8xz7|MkBB+k3{W;)H;gayeZUiuB7~&kt00jDsMfWkdgEbLktyX zNj$P*pNQRc2ZjAKRzqJ|OQ0=LK-cfZJsC)3Dr{%wu|t5LK?enN6{WuzGEp(+!917V zmN6GUzJ&#bw=EY!?QWW`zPj4Z8z`Bpzv3a>Yjt6nh&4!MJpLdY-%nz_%zHvLLltbi zL-GoTnYlU&tmF7YTm~m`4~FTt7|@ruj0ItBL5=rh*i!ITF*D&f_r1}GSeT!4!jMcR@0 zQPXLqd>&8=QxAL|9qNbG`_FmoG2l{f@zHwENY=hoWDt~_J8}k_;}vL-s6c7g%r!9L zP(+IxJPxLJr#Z-+9)Dsj_apK`dw*YuV}nBX5;_>BhjFjlTP8<0Fuf+03uY#I>0T0A zPsK7<$}7E@luLW`yX!@nC73DTkFN5!b!&A!^WT1NHG zcXuui*W2c-@`hi#@Vy|faDKQ2v;s$rHB=l}CMYGQYhR8_4eqQ6y9!c1?4Zth0G{w) z6IlQgjU?S=wUFf5ex{Xj*gDTI-|{uTf>Z)Zx+ZZ4x+W1s+{+TvHlv?oZ}eGfD#k`V zF$2qffgytn(@!-CErYEWyIT)S6E7;i_8XOOL7@1tGeuNi4gkfk6=Kio zEXiXfmuAkp!N7YOX6_7Vhf(pA9)x0$Ve9N@lKDsT&lK|&+_G;uX)5c$ml#_B8AE*Q zlf_RIK_Bruv98I#?-lx(`L2<_8L|pO;xQmq0FOVB%8Ud#jIr1Rhzx?iCP)u5!_UTu z_HQk#`$+jpIsd%=9neWOH zeMKsXZjg0YT~OTvAXK~JXPOnBzxt-XA^o9v$^yXt*TQ2;3Fu+z`BJO5RmIJY27{J) zsF8mqO4$cysCH;SAe0go=})m>@5o)3{~kBr_p`hA|JdXPP~ZTYOaVsM&`QDXC_vLI zb_9s&GA{8BA}AozQ)}mYl>WH!?AXkBzCvx2jqRr#Od(aF0k0isr=a{Lw%=5tUBfD9 zc1jWYP1sVZgdil6Ou|tk^t~02F%64l%)1JWe5&I|>AyJT7WNBSL>)aY*ER=JPby5H zlnBb~R7>fY0cJ1l{iQUxcEx?~4fr3Bu6oO>-4;Ks({8o7-1|Ccr@6aaK_t0>qjs-Z z2&sZ%mln5KcCnf?)x`g%r>xA=5x*9SY^yQ<30&rT@s#DQ%kbOi&qv~8KSbt3*6OmI zu906rFfeDt0oAiqQC~c6qR0t&^>Y6U=U?ICZ70?NUpZxoRFFph0vUygKnde8%i}x2 z@cFfdLf-k0V$7q!@RCJSZy*$5scPGOv1Dk7idU7uG7<+ZrxJ}SK<^okpTwsRv0CQ; zWpCeSPvFs=HsfOYDv3t})gzz@jKA=2{8N~2a2*`Fpi_M(^FwRR30e*TMuYhT7~i*K z$`OqJ#iy3%6!;77tl#&9@%{A-au3F0G^{26lD>H0?k7#}R!W!Eij!~dH_0>OtKCBp zyS0l?Nt;(!;TF&7O1D>ZgwAB}*4SfeERP>kUZBQZ05$Fc8pUwb_hTpWd65(663R0_ zuEu>Fkjb$y$Cd8hLH~|D@o=Dzmq1d0pYq#?_&%BAr&0<&tj?6FR^A-!#G7ek-=?Lg z4fFT$J+Gp`%5#-~LQKtV;%X(*Nc zzbY$R3Q$=cr9)MBR(;qL%oFu}5fr zc|?z`fr8RsyZj8oy&}1-*m{pG;BO^A+jYN3^lfq9Q!ADM<12LY){IE1Itwum zrARRa9H~($yb#>V4B`q&rxq;F`tq#l6J!;37+gmTjnmmA__5u5*>T!WyLCt7brBd{ zq+8<;P^@-F;7V%NdGOaNxwVF(zaQ4&wa2k?(Mb^An3cys?-yLq#Mv^jq-@1e&zE#` zWwBeSJeVrFDiw_XK@Y}9z}Q0S+@M`LuL*yc1=sRuPSQs@C?|fapa))rfIq>CzJFB; zUq6nCP+L8Q$KbY?sZbeof+}YL#)d^0H`BrUgZ`o8Xa7%#72*5sLG6zVs3?K#^0kcA-M7bEW7f9utpz-=_5;O`5(yH?<2J> zyNEbUh1nfW%Sk1D=E5LMw=EGv1-;*#P@=f3yiak3T(k)B8+&VPwC~JdXyaT z*um$p;wcxfw{eAhv=Y!V`-`1EZ_Bw?Kf(4c{7}WeNqIQ3h7=~u0qSrU#q`k^6jH|# zF_qNm+|hn8m!e9>6aEr?6iG%NLCT4fQP52#6^ksPV`XZ3Q%Y`cq7L!D!Ye31q8$Z^ zc2ok2UVc5+*=N5DY!j&KEoyTHt!;kbJ!={l_@K@{@c7~itWQ&ljhJdSWqzw4IuC-X*W#ftGt4RJ z^SknW^UKf}d2BqYE{41>@8u_38Btc^tM0fS;YC;4(Wp-s9~HO|IDU?RJJH;_j2-}< zyRIoTv~TZrO&6H&*eZVNWPc*fg@EaTvRGc9VM6j{acj89ySj}4{_pK@W^W@j*A;bX z8h*?K^k}V2p_Q?x5_2#|6|3nq7xT}EFPZKDV%0u_ax zkM*~#4;$GJ;d=i{V=_=0dzNhz{u_4W(EXz;bC7;0K8oMzphdPEvuZ?AI@#CMfiEAa z0!dgz21gn4gtq$FUfoUC52cFH8uoEx<(DeowxfeP|6LUU1?(&s7ZkAk$Z=~lqS7uC zvXRBSZ1P#B$xab59EBs~aD^`kM;THuzW_-?d6Ve2Hg@}0 z8y|v6AI)|z?xxx1?;gUB{tYe)s^cqWv}Hc!iJ3wh$>@5 z#jdB+d2o{m^c|#B@FZi(sb!$uJ)dJ6ZUstuAVTN>iv*_14^9_YH$?Y2m67lf03C*l z`BsN(d&_w+DZzh8+-UqdCb4SLj7K=b>PYL?o{4PSpXV@htS{^q@!4~3WN_3~RS zBV$4sT}_#^UCrsVUD2ND*y%{o2-C_q>%@gJEFV*h;ENl5h+_RCSLotqmk1c8ijAr6Mo0a@o1-uW&!W7-2;5u$SVsDXNGqP>+&K1|8j z_0Q+(U*UhsjTx-##Fv4YCdadjqAe3|G;N z?CD{PU3Qaa-_C`_y^p{eih2qtS)Ta5wCnrnRE3+oj`z(T4d|Jht($KGYPE+-8_dboh7KU0O3oCH_j0SDXAIj z-AZcRHG>htTL6<(f2I~!AnkDoF9P-;b3>6tZk;q=b^Taun`TK{8${A$gLjylr@-{Z zAeGlgRjab1=pPu0qHd4RP%Arnx^Aq#+CK+Av1+=}adp%>U(?F51dM#leQV@;yl52t z_JgylwcnlYV_kk+yq8kKZaVw~?E$PGI3-lNdC@XF@?)j~?=rayp1GWcX2`jb?Z1YI z?;!;Yh&kgN23EKKR5vig#d;BUGp$1U*w`G>E40gQ_5$rshdII)1DVyO3%SJ3*htCpQWC?P_Efvd0eRu!6gLxV6G^Ya1X2f=b z3<3p*6P%GlND+4fh`5KhB5pNi zy`i$CtEuO^jqz3Yj$0WcLzJgeo*cH(-;aawfo6Td)paF8L-Z7UVG6sfrWd2p+^ zj)RGdij(Zdq}nK!JKhSIR(k(ez_hA*dw^6$|JUFgm#%Q*}V_kv9UUi$n&>5b4XvJ-%5Xl05 z68g9S9vGZ6Ma*?Oq*Jpyn*7~eP9!pGLwaE*IH2J98UMnFlD{3(MwlfE{ipe7K%1Js zY3D*H7KqZ)Zoa#=t?TptAnbVzPITama^GwHCi4~0$|PPpM!Z!RId60CKyW(Yi!5}k zySRk6&Vg(Z6{90tMBVY6R_=3p6R%zKr^yt{S%DP*X@&XVovn-c<_!ap9Q7%KUlzaB z0TT1IfFaUgRMo^mc8uXTOm6~*hXWSV$lc;@44<(ke1)T#w%@{0KJhIasWQHpPB;O) zfHCB=xdxaui12s_g4!Bj;yGzy97rL7A?-9AbAST0C`076-i!QwFXA9+89{}ni5cL@9YZ`k-2mB;Pq^^1vBjuRCbhavbIF=`l& z#E{#TfkMn}%OJL;Y&#_FqZSRe+t{Oju&jWDz}r z+$?W5LX{k6Pg7`z%%#qVr~uV~Z81YiA4${`$3G~^9vS_~8sAc36`EFf@~r4lg?0`I zyipK%qi7U%1?wnB$MEFZ_iEFlYD7m(>yl~&=-&(em5~af>v^fhM3MulZs_=;ZtzSc zRLFCfG{=9_wSv*KQyWOv*%Or&Q`xtW%*O&Cnd9hiInl<;J1yRHUXEazRGw>5XqJ8TFO2@o)ohj6>Lqu(~kt+Uw8vDy-x$b?fAXMkh6s z@7;z7FiA9Sy$^EZW*DhFH%3J6Ntd)`-=Zfs3!ABG@1UC808@2m2{+rSyroLiS9rlm zo+rYY33CHIXycqCmY(ryu!h)NE+O3bZn{fPs%Ft4R|a zo;=zz+pO8tedFhr{Y+8~IcOGY(-+7Q?CZz6PtZ{vL9z-f@%p>PR9<)GGj9{=UcT10 zt`A;UH97goMXtkltr%T_wQ^o6gGEJYt|eGDE@9j!b_wP*^K1vBK9&$ASE8=09X2!7 zS6ib@NLdYAqDZC&^zu}66v!$*9Mt{L|HyDeH*LO&jEy4g8qg~o?Jx0eq#3wo{EX}t zF5t9gy-qK`xot%nqJUPU#fti?;R39+6`?2m^D@y&vh<(jlyhEqmp*JNBhEubN7kY0 zlO6T@xd+_T=2@EC>L5UJHH1m%Tdz7tuKz6hyIw6`{i)oYyAwjCdA8FkZXM{ozt~7T zkPX_0FF1d{p2a{US0Ux*&}ZO*wiYW&uewu8rPAsSKXQ;dkG_V5ko#j*A(d1Gh&AJm zjQ%QWRnZLgbQR{@XZq2MIRW+ByI@zA37tJ1;H?orr(K40=cIU3IJ5STRZ%!9y zvuwobu0^Dbyo?_Q(J)!zHJA&7%>sH*B!~+FxT@IMejZAI&V0+Zy3EtHIGzp+#MdKm zhRHCL7+5d4#$jW^CfHyy>s?x~oyWnS5*vOWc?!b*ppmAUGopBbu{Kpr|BoCYr^v%8 zJt$4AMDz$aAHGN>F}?1zoYTAltL`Sh?a8%dtIQviXWp@3;L_K4@%q8 zNKE~6Nam+s&TyNVx1agoon)M#oyC2Ou2jSJT>P@h7sHR&-o;A907OsM2wg1sYQm=o z=%f|3_Fv{kP)**d%@X>dI5Aq)5LZ@`mU1hzv_IvCv+V|0u48@x+oko(>A~m?lhU9@ z4cM`Z5Lqyz2#e7&mIeJY1Z5~;B=P;XE1&xkjO2geQ+53-mk=Lu-!!B>INT2`R>DYBw5O+?@7xl(`mS#EAQnTdmz3BVfB?EU128l@np^h23|TMSyP zC_bK3C7>}7gBDFsWST8s2fEh*b^0)Uin(npNB_;Z=?nbD?pFMmvqY`5u8H6e}GaHJXY4QbHOw;cQ3wyjJSWuKJe*+BCrM3ME zn7h*b=J+Atkgj(OK}W?<=AY>VudNrKA)QGKN^zKp}N`YdSB;%r=yD81OUPY7vU3pMbf zeLI`XNzhEHDlgoxd!CzP3fS)c`iOqw^f-fcMi)!xwr3PCKtUhUSwBV1KS6!(Kk6`s6M?V!@pX{Pszf1AKZ7EXh#wKg zuPE9`%|02V1c3=3^qr3`*yEGrujx!&Vo0CAD>sQL0KBEJsW!T|pLPm(|f^_<4 z(9!8d%dlK?9UdkB%v8JDZtamC#&m>B?23#oRZ7?Y9Ct!!<_6i!nuw1UdPBMj`FMdx zA>fMm(Y_O9;mEj}UHpB3{*rmPT`hAq|E~4$0`$LB^;FE>!f))qgBjtXzhtlhXOk%}2yR#X{j9 z1l$84eY)0?)yf#V&s_KPUWCq$EdQv*=F460`x_eWRJR0V4%)SM*gi0l(kXt8P*)su zM{Ij;U0p7=*6J)a2}jg-Z?y2O&W;O5m@#+ghgO3Kp0qHrb{U?rJzw#oxUNi3b5fvb zeaZCQHV>H<-5J-QSlz92-7|X;?%VAurIK`X?qh4fQCh(P6hQn=IC|KxW@^<0^~m$e zE2&PwNrub#d@A~ou}-a&<+U%%Vra7p&MoY-Y#$iXnEJx+hxyP0N1uodG7N2t(dvQt zv4*zt@6?be=Zy{y;CbMK&}Z61i&+Xh(| z+#*HRRk87Nwbj9bkLb4FM6diqv@_UfL>(%0MW=wO;lupZtCI6mPmc!eS&-pY3N`s9 zps6)n^c*?Xe>J3>tJW$jJeF0$>xdnJL&r>P2;nR1P@y5z`RiwMv=c>(jHCaHli%>= zRuM6kKlnVB_1*8M?01TL{?^h#n%s4499TotQmnoQ057}lQzI9g+!%g*0Ov!zNH|BH zXbkRi*B--C8$lSGw<-3d9&_Z6tW^U^mbR&uSc9R&5@lBt9%M6PDo$$Q0^#6;YXJY~ ztTopFE_nQtehDOG=hCxU-RB2ou967ky@NuO zI@TB-L^oewZRsZ-spUHt8S2u`m;96&+QT5-)`4_eheqKt%c|-enaLu=x>rcKG08kK&W?~V_eL8VwK zGX)Ad2;V0@)F)N}1yQDFp%l*w$seM92IhF!)I@CI|FYWyTKp|yuxiok+l1kD;-z@A z#F=-1?fcYjr$NVwFBtUUT$sfO=~l6;RUxxox6_?7{;1{l&h zJm2VjG$4PqK2b8?FttFl{XQUe!pJq0=wus1yN=%V-%W$LcmYaRQ(TuyJ7BM4HzPk! z$aeR?b=4u)6_jtfy7?5r#qa63qR;E#`-T6p<=_3>j3j5qFep}wGJJq)rK)~} z@nDpa(?>x=6a|D2)+EpU4z_K3pHGU^gwEiBAYJ}Wp&l+nhRrkFN0!(WBPuUyiSL78 zGy|s|h9cv*>O@(H67=gQ#c{KZxX_8JkU?$-*@2ma*TFHWbbgU%I5O2AoTE^S6T(fw zc)_*i6lf-f{7h&IAZE1S_*6|1ClwTQ3UwfL@exGY{KLXFZTq`;IAeSuw$b#=Tf}Ctx&-} z`Dz)z0px0ra+2J)jO)?DYb)uEuaA7>g-Ch!{+(h0Ph}{vR%@c_*xeu>@ix~jl%%`1 zjQ`WAiYJofiz1SQhDz{ufuBj-+s$iV!!57UfXg!@dA^FmgSG}!?DT`mg1_YSf`3N1 zT28T`@g4<(&{KmuUIZQ!^mt;|qqH1MC=H(mu6yAIVyA659!0_%o@6U%5QCg}l&5=5 zT4ttAcy-B733mYf2sEqsW0HR2dY}?s>w%31W&DtM$Mo+(u^`qA#%laVTPazCO@?09 zt2(5G-5|RN{P39{7>}{+F8eFg=IhU*&@Y@G z=ix5I5k~IxCkGoJulA60GXH9Ll=xQnU}o8XFpu++-EweQIb3}B2e}{Cs0zjq331V?a6@Jf46_{{n6i z8^yydhX`fQzX-XxrUXhkGB2X#C)&JOA>~L<)qh#?f#B*@;UbDk$#91cQt>Y1GKA_I zaHr2IkvL$QQ89H4NONr?p5T$kW$VS_J}q{|n)=m`Vbi`RZF%^t(N7LJ;sknhVu^9- zBBj6f%N&fzIbyQC`_^VR9L?mnu@OQjq9b}XL@D$Af zo#qH(ibvj7NB84pYO+P@1y&qWVJFqo5VYfBu9E`N`M8d>sa6sc$XX9YwId$ny%xlB zMp1mUn22EEV*^YO?d<|escOFuMU|*~ijobmZze~aT51EW9c>s&Qi(}Z`btH~FIkES z5%hxuK2u`1Y)eULBrH5f9qc*bwzD9U7${1gs4CEp{M0*iaa;`Mdo++-PSD8phBcTJl>kpQm`w}`x`Qe(R7fdzlsLC9gR@Y@*cfvvnUBb{AO zeK>HnuR7%rXRpB8jweT|EX%Y_v?aqmz{XXDhunrib(IuvGv>CPZRQ)@oG)(bTo2Ns zvb_&4e?g(nkBeCUgx_-@m>0SChI4-0M^XVVSNcp?e0Y*P|82y?${&2y=5(&E+jGcx zYtxj~V|bk8n&g%<@5M*qo>-z!;wzxNO|6DGMJP`>l}TtIr`r>uR`W`{hZyGFmL6ju z-`4dc@){D}6gH3|TO(Mf5heZsh*pB{L=RK`!^!T_8#Xk==yaK(hQ&ABr*xiqzTJoB z(##4!0_j#(BHCY4BHH)LG)+P5Y)3lpQ?@+VYeHCB)fvB zS7Foo6~l+?Zr(MqHoWHAh=O~&P3FUOJvSQz)yP!xgHL8T!M(u$`1rK0@Rs!L!jYuU z`5Lxq2wV}(LOOc9Lq^!X8lQjXEm3xuyL7AgT?iC&%ci@6#M3&*xA}9 zzBA)|$Xhx#UGSCNgNk=1qG*oiURH_B7)afRInu5hS-kl6l-K&U<53g7J>;Hc-jbRB z64M6jOJ2ld@^qUV^N{g~V>vuVXOBaTLXeRNJjdVwOx1XA@ksc^v|BtEetQ+`2P8>y z9^-$jYp+s8b>Z+8`_ts+&<;kZ@GUMc6w8blsz0G~W>u6f+bQL53B%l5%0#kq;C165 zIk!CjKy>2-FW`uN>ei|O=;w9(D=K=dwEIVO|3lS#2V(tq|KpdvXSQsLke%#3OO!<9 za*49aD6(abA|pzY5t$X0l`XQ8y;pYj&Q`zky4?5u{rvuV|MTwodOFWD9_O6LIhV?_ z*ACB^f*b9ZBL32=95V9a1IVb1m&CtxokCN1i>vIKl={+nZysOwBZ(aK;yl0>oF*Ua zAzkEfPlb$h@pxqSpU3v{bXZ3XMRY}t@7|uA_4pM&SAr4$hA4>~fB>F+Zvl<1?z2R& z1TsjqwXg^VX0C=+5`Kz7um#ds4rlR9Ad4xb#eV8+ksstL3@5pY2I#|XqM$m9r(8m3 zh(mkG2Og3vBway{)tKn{x7S@q0=|?`>y{ML{=G;JN#c6_WNaK z5iD=rq^o+`mHeAV?XQATOnx-&1*KqX#ao-Byp#3zlkrt^e(8I}W1(+B;3%Q1lFHN- zcfRT%z9}*M%Ikm#)&dVZnjl_oY=#kTGIei;{sQMz>k##a!<9E{ZFqyI8*%`3qr>~! z37e^N9rRPLuDOL=UPHO(r3=o+UuC8E0U@@Q7Rd|U{red2-Fo=m^LP1bX0VZI(uTb= zu1CDPm?ll_No-lyrHiU8*Td8QNJlYLR)Hp2nAz|)wJv@OnV~;qhW~4iotvQC^XEY6xHPhbu$v0pd=l zG57r$BT?mFy2CM1a;ph$S2+G%Qo1P&09Ah5=n_b6%bv@>;*IY7H%Y5Vsv=vk}1-O1Y`2Jb#+ zy6sV6NF#imtTi#}WjVBVDrt>Q08U>_eBNZRjDS;7VUPa3SzX;)rVQdKBeK zgxS)m54S+_U4BA0JbeU>Z&ZMFMtk&qMA8^Hjp1zur)=)>pkmGo5sd1WD{0N(+=zkN z{+Rd=Vy8Nor;j`;#Z}~6>jpWoff6s=_^rbX{dvxD-2q^PEj8UXqVo6XD~Ho~(8V9Y zrrNobD8UER{b2{t79;&~X~ zzB`j3JTcbV1~0Z4)tBXsvY0e_4PZ3dz3(m@KG2hLG`&(G{co%9gKLYL=I*&{!HG(# z?H?mhVYY~P2Pwd^gSDM@Yd6z|b^XynpihuWE+gySNuKyuSBOHBeru!jv!wMjgZFei zpD$<@Yeiy>_9MIO9#Fd9!^?OICcsU7PCX|BYL@-ilm zcpouBn%azPdr}Xn6wSXjkJ~>WFfyBqwY2wjC&3mfX**8=G>xbd0sZ{*H#Y3HSFT@S ztiCC8^wn+~3!};5>=PKR+wA;VPQa$9hjl(f=&2a!nT%AH^@*lgpJ-ZhOw{WIJ?b}# zf9niCn>K?doX-bL9U3UHd;Q;{6|S#bLJwm#2}emM6cy(MT_nK4`cjON>y$H}I*6xp zd>{d}plX6B#Rqw5wpJ;*t)a2cZp$E8aXp}O9xQMh^2P(YTpMjqal8ZT#B!6VFWGbg z=Gu#mqfxoN^l=ykyPes`dp0*nwuVYKC9Y40dgZ^DJlI>#-;sc9;4tr)JSKe|rP#%{ z>*w9qd--cuHd$b$ln?V0920IkK-s9C^yPumPw1pF6~2CaD1kq1R!?tdp}lCPgzZL% z7OMAR;>A+~1h2xM@Y#Ku>sOP~Q)Q#4h;9e;y#<9iC8e&-S|7d?Cxvq_;78_l>eVx`r>hu58zW3=Y?!#0GdA=7F*Yob2Xx~l9 zjNI22wu4rnmX)6L@Wwq9pg*7qJ7BYzd6p-=Qm*dZ{rKtG!f0~&YjvHy-nS6xBFRzz zNpkcdouza@ZZ_B(wdRt4|Kwb_IVMHmoL-W|R&2o(=Z)mx z{kCj9?K&T>TrqOBG-G-s%ep24QPP_)4x;33ka82dfW57!c>S87cKIFs*qx9wBRA%A zdH>j}M;&!Q#iA0JOo&pvr_v=pM2%Zq$LfR^q7%-kUjP1{+P{Un7<@Tf3C1fDN_K)J&pGsW`QPJQeF9nOaHC0#}}Iu&`ZbMLYO{-CB3_Lx0G$ih!_ z`T!%FA6<}@Yp(>4NmDS~0kuP_(g&PqTn`XUh<&~0GereYgqqEL2P<=J<|pyux7=CQ z>ffX~2u#H0h49q;UmPG2}kH+iG<_t4b*{v8-^pMdf9 zi2(BD0mgGWl}H_@|MaojxI7&Vl@Gb(hO)sE56*ZEdA)Kbo{dP8a7H}+=Y9kvNG0d| zS&B+5A-)vlAxN(#?f9BXll-u28n3|gJLq0*{tYo@!a1DQ#g^!Zl*%gId9t4PGgJd+ zNC6>{k&{?r$ukHkUE}ZiWC!ymY8}u?ZXww&U2P@pAMOHIoUI#+A&#Tc9D$#w_MAjq zi@m^D5{*Bg0ahuNPu5o+{+()HB1;{gfef9oh~TS>Kqv4=3)HKjw5NyW*;jqO86t6Z zz;oKXFs_XB+H=j24B1$uScdQ&_PGll!Gzgnh~tP1M{rl3+}|H$=E4?OUHJhlg|*p` zWp;#mR9QKgAI|WZBB=Eutrzw+kAXi117S6tnSL~*E%R5(CY=af{&mi;6{wsc7jGo10X{FsFt|RUHx#;g3zbxkMk54-OH7Mr2#-V?&l@Sma=J1HsbJyt5W?gMi z8U57tU6mzsPnT z0aCN5w8ud#NDu=ykBeYIwvRHVHHl%jXW%jb6e?Z$IXp81#kllu{(3bT=265~Mats2 zeSMKuyO7tvl9qs{-~rC&4bo7@5k;l`d_Po^&VoGw)}5Hvfd;MuotXh*+)nc1nvsEt(Xm>l^pcw}#CpC!v$px)QO8#-a20hO>EGu}-ldv| zBR3bufT(AT$e1|sDqt(-uBRM*SI9k0mV>exY)k0zNlVDWw!4PdGI)HGkVjET_xUxA zaM@MA34Mg3x2=2h6vkIO&Gs3~?=SgKr}u2)EN|r<0}lqcbpLRzF*T(|cJqjGe7?yw zOSlcj?#1^Pnn0>x>|yM)n7xmz9VAsg=~}M&2DiWepN@lzD7Gdx3lcuwQnA0o>mqmD z1$}Ph&WlEJaOa-7`I(=;cS+!QHL{`0(#v!63{}|1e-LtUnBz&;@?=80o?S`)C3`{N z(D6Hvqfgv+n_!pdrmpl)`7hm~mq#cM(n9ri@jN0d^Q7Pnzstu2)yc;M?2q^VI@-L= z>gk=(`Atf&!V>1JpjjV7q=?Vr$;lrgPu;4SlCDlJveNQ|#=S?0W|RDmvB##o2V$54 zQDB(hu#gTPO?}bITPjoH-_IU9r{pq#NkVf&1HL41+tm&%N0ss80*3r}{1H3!__%L_ zGudP@53uAXs=uVfS@7`2{>E897YF_d;O!+Mnk|Jhmk`e6`Hn2HlveEW2>U@UrhcQ~ zv1A`NL`ExgaX1*Mml5IIyOevo=hEdcWZT6`z>}$@r2tKNHK1KD8Xqbqp-;va$nJN0 z=Bnd&!cD~J5%r@uQ9qVYyHORTBbhe5i)yXc9YEMn8fSsil`x!DT_d>=$t2J+2jsa} zaff2{B-4^fw|-qW`F%g+IA0I51$-V;h+n0~Q9x2ZWInULIo}*em!Xy{yPXd7!9FNp z)QN&Dwy{z_p6btZ_rhx6mE32F!mxiR{X`hsED=nhv|^Rl&MsB%Oz)<+e0h>S^F%BZ zgFsee{6ym^%bA4pnDN$n(Wuw+#ief){yLZ$u2_Pi%o%wzajH$Sl}YjRN6*_fR9slzQ-ly(@7)96F4~&dQIimF z$>QEiRh-v==aG6<7@W5JU!zL^U{fFeI(GHj*m`dBi*oOfbkiw2=>YfZge@a%CD}K= zji8->-RbgwuZA`@D6PHO^pZcXILGnM{NDOWj(sF3CdqWC?f0+NPPqM&joIAZQT_#} zzq9|#qkxb+Qj*;RfIIZO!Snw6$qJ%W5Q=HAp%}(#*7#+tYDWuyZGANCQF2NBoE}f6 zKmM!^&<-+bG|24fM&@7oS>p0^5wAfil@2p^nYw?%1Ywo)8zwoEDY5|a1v93_%L-V8##x~LvpN5ke`P|F zB}-`^YeArVb%+BNV}b{i!n1CE+<0t%&-98TjHTp|%?9>8@%to41qtg0+@02+VzpH? zGsAM(^+Bc4G~W4*z#uvi@}a^uY{_U3O8Aj1ck4Soo~9Tns~dl0zZZ0x-LC{`PMEAi z&tn~rIg#Rr_}5<}`N0fXp6T&v77OiaG^@2?%F~qi@0^KLhYl4k$+DEl-FzoIO)NKm7I)^u$rnh|$2NAou^#{;H_|0Yo~r_e=ef6JLyb$HZN-2! z4ePQzveyI)k|*hiMuBcD81%(uvg_( zf&d+lN-UHwNfpBtarr!sHrgg|sB`pr4VAfu6ZP|m!l$@I%7T}W9Dl*YCNNT;qcHQ) zNk`)nLMlG#Xxyyte>OIlwKZsVR&#&C~*xctJL9Jdl0PSF9-<)p(YyHmnEo=1aCuYV%3%5KLPvc?%Y;A#h2c}n)!%t8F?)`3e%p;^_ zW77D84H)H~(GnPCftmi3vo-RUCLAF{5dF#e)n#p09u}-MG@?{0^+vWdk)q=2hKQ@x zuI@Zx=Z`}hGC!=ds#C%`t9AH7v!GRNO+tz#YiU2#_xzuDgGbn-qaXLdJWA~{8s`Yo z;8kVE`bHS!`U}Pet==&QSKm-RiYO9K6+xMsEMlA5OM%!5^h+2W;I@VR6w2eeorO^q zOI4@+7@L$rzTY52s%gObfHQq!9lG_)05Y^mDICeX;UtK@^sNCSy9JMh|?T zY~@&SutKk>^Bskmi8O63kJ|aGHf%2qGX#9@Ml1vYXJR}Bk9s;E3X0WBt>$qo_PI4V z4L$*@<;kfK)Sn=i;>=Oaa+{ z=7K)(n3K_ZAUb!2#bZD9Sf#~@Gg6-x>*9*-fSbz0~ zCiSXy@`WBt!3I0QXV-)qIdT6-)`8=ZP!7kh=3u2!^LNC^3~8r%_T7NXD`3t=RbmrI z$>Zzb>6%Yu?73i|xXCYOrI}*x7k<{PwPa8k+v7m=;qHk(v^ndUEgB8D^(PS({>W!Q z{PSkscks_k<1p-Nh6Rx!4rgo+h9j~1kbvj|fSc;(jL1mNz7}1^P`z=FC$>IvNg47_ z#h(1H=A;qwTwSx03m1Y-xr}YXOk!{>KD5caq~>Cm$$^_RAUQB9;GZhxZYia&%%- zj-5l(=YF5Z5S;L^`<`TO8$wLAhW27GIw)W4^eh_R?ux9-gPe@uCt~3!tVHnqji=Bv zeZr{m)+%Q`*55{FgXt#sR$t{m62V5SF~F4GQlWB6$1)JH>}>;*u5(>HcwLDNSw7g1 zVF2(nN$V z_5@-08{dblrtM|1?9Y>cm@TKWwg$e`oo^2C>gLB-&q@9*Zd>2(8?qd|g*_7ZTl}g2 z7m?*KViDOjky||<_dj9YZBwO@eKoBD)oaVY0e{2Xh^epNv3DSn6fhQkjj|br+7>#( z11E5hh#Wg6bqcR@(9%%o0|znFR`fN&3wtMN4Aj7xJntmWrCQu%s0j^yL4F%~eDEg>q)4xy|5^|3^rOL6x6|@El;Yj_Xd!@Y zBIC|%0vPg(ERSl;6KxsEm{N+)*^VLwP^4;(tBLNz9sPh${;S9v?RKqV9Yx8o-iHes zUT8!Z2 z{8*7qrNf7g$jLKgzseq>O$CoPoV>UDHi04y2m64wj1T9XKbEX8Br#8%3%=(1vK0w0 zNY<+}DpgKf{~R}T<%+4C@P$>c?ab>cXy^Y{p!OKC4TMb*pXq*2yEmVv_L}o|5Cz}F zCQZA_a-1S3qPX?EJN6|87~Pw?%fR1NNAnzhd%pACpVvxuI_pbD&HzKEp^5|oA{}rc zoe_a;AEHk0EcP1TY;{wZO%ttOH~WC3(sM>jkV@}re4w>k#3t$cmS?p&IHagxNT^E$ zYC2v~A8Xb#11-O|n4XQI@Pcs-Eid{R3M@uI*2@H*&>sovr5#gWj(<&iMpcDPNP#qu zB&2Kha(||dc46Y}+*`pR!ZVIOuK*=&r6TNWFaaTR(Gp%Jw;-q2zB^ zlsA#U&xFON*F=4$|9ajDF>X@g=`|Kaat)6@Qh39AS_~qJN5;7BU@+e#@4IH(j)KEp z)ukh+4u18YhLHE@LwnczL1cmQDy`2QLo%*hA4=3Ue?ayEugv%@qy-`q1n?f?i?(?eCDf^#p&2F%6sTMzi zlcAmiC*SK5I^Mhu9^~y${Iv@?*cm_?tbR~5JXL`lF}R*cCUQ38SaTfQd)n6j+PmB@_yQ9tJ;kD!QJ^Q+=-$yb5R1dQkK} zRnB8{l;`So7`b_n`(j(*w43UDBU1QW)c9Z7-3wOv{B$^5PUIY~oP+pK$Xxm$4(#@; zCP|(!AvC=O7J~4B80gNo2yS}nW2_gA_MdMf&)IU$XNAh+dS>ba*W`cHuimFvifk@p zy34Q19rO8T1?XV=KTr_jDnMLy;)4%*k7Ge6%**aBuiN~G`h~r+XB76z<8LlA>GzV( z$gBtS3dp;qps>h4#`rcG8_ioQVPn)>@vf$#zxhdA0Rk?>mF1@*_qJW&$^Ulyo}PXt$sfvz>kidwcd5@Ok7nv$k#LWO#l4kP;piqiYBlc;ycY0yhM*E; zRy_CGDfNs$2toKd)WJ1lYoUKOkucA|$xl*ASgyh8_7tOkfm}{rZfBLcmWTd{a&-{~ z%Mn`Fz4sKljJW!)?)RT=C>4J&vii9pvj5dbXtq|3`C_e_jOe-n;kfs3d$x0_8HxF; zIo~u3(>AqTmoPuANpZ^;snu}aN`vHW zajmRu#$>Ynk-58g^_FRL=>c^a5B?K@@LIM7)6TMdXJJyslX%iXzsgeD!kTU5fs(5< z9l*T<{oVdzW#%%)`!DClt{`-@?g!KKEAr4)Q!ZA9u3BF{!^_jVo@cMr6AnJwa`)(x z8@|-*J3(`H`V+)J1(XNDM-A9FG?7ccj+|^Ww(+YAt@wgvqOXF1pNPmK>K2)DCG@_Y zNS!K=3LCcLKZ6c%2ndX8007BhPx9+_U>wDH*N1}W?YBF$-?99g0hmu(X5cv|`9-26AGHP=C9XqNC4D3^gSW{PRf!yX_Wk>t>*LMHZqO@ieayTvba4o~w~ zppku&dMHnVMuPXFLNi13n=H~ls0bXsPqJP=kMMjJqsZcc=X0Tv;4QF!w+ZeycHIRz z8y3_eM=utCU7CsuOG}Zq|5|n-ls*00J(ZJ6VW(i>dGY_Ua4g4%so7PZ>wa(xK-P*m zn5U87TT*?Oj;OTtL)E3I`d_en!;7Gwfb>5FPD}LQmHFo+vXLwD)B2YczGWxAC0<0} z3v3o6Sk$Xwmwuk@QxLJ|f4jZ#K zmq$i8QvKWn-B<$U`g%iL>r<_#1*@SFhY5HJPfL9{Y?DiSj|nfMt>s|0HT4RO#Rkob z?{vV4!GZ;9A!_l9#cg326O}?2k>l%yfA^^0(~BDrvg131kjJN^0y`{j6GN%YUHh!v zKX55rCKEQG=lDJ8KE$-o8gW(DjtYk-!~8id(f3sTduEIzoEe&CqQmmmC9I0VG^F0b z_tCz|IZk5nLQdibqVV7KD=)5%!JZW-38wNZ+69zkUA;Tlidd@M3Y@!(1*-9P(SJoIlFg7T?~Tk zJXo35$rC~$B|rX1l~h8tqp6LDk6c4x>;XKsj=v{gwI+H2ckY7^MORs$-+SYI)FZFH zYCt(quPp$iDzbA!x?nuIx#D@wAMpT8@e;sQ(RefZh|mjo8Xe&N!#vBI@j zWPV8}cEZZk16F4H2`e)hPM#be>WrvQWqJ%I)jUu;1eW4}l?pFC(iAxbAv*f0a1AiN+hgKzgBlDsJE)Rz)g ziI^e@Tf%O`779#MbL_wU)SK_xY$kMPsH0x5HhJ|m4GgFkH-k)=V9P&1C>!H!#21Wl zjWp5#?F71x53yax=27a*uduj~Oh7y@ zxaeKSvUA)Kc1~?I{k2R_#JL!3wNiF`;XO%5kzOgJqnTXVI%@gPDO9hdBvt%l`F-es zY>E4?bK#5AL~mr}o;8jOy*FyP)?~#I{j2 zyeQSgSm=AK8EzwHn7+QGur*d{ahAHwP)9hKRphzkwu~_Js!mu%G=t4UF_~X1kL;F5 zKQ%o6$je5q#-`kgKw#8S!aPglxw&blcMi>sA9hqO-GBD0TqxfSt{qlmZw}KqKCVjD z^7$VP)#ZM;-po9P1uDGGNF;j2P?@f8{R&~^46+~@o@PlX?|q6>SNx7Fbf0O(G&b|l zldG-n{kPL$7IgEg{LF`Y6hlQVXcoIjFBDNs>;GxozfGByyRmxYGWHicZy|%$9~Agh zR|%B|LNn>*sau>B#n^o$IXHnH6JF!|un4K+;6Pgj*MPi6O$SZmM}jmzlpo|h`G{VE zRvGFN5P@U~QMZ5yWY=_jt+MHH1y}w%_``^55js#a?!>yt5FtXt5{cj1UQva`mq4Hg z{gL*KdQYKa!b-MvIeP_PVM^ttvsekX#VG|V7HnBhTAUZGd$PRkiiqniDx1R4#U-GX zFouj!mkjj|ntoM!9((ZqvcvP1GwS+wL5BUBMs*LQ!^_Bc2Y-YD^+88;>f^_U^G6Fc zEt_Azo-x_FLgM{-x`N}9nSI>4Xchpy-s=l3Yk%zHqp&}^0Nhc*J8BnJKEEtky531O zVeW|a4$fHbuWSoc`GS0lI3m+ zBtPnBRiTcF5zFEX{NK1u>B+c_6MW$l#}ng=H0&sx{3?(Z%=S4!RgbNe`{y){fAlH* zQK&K{l6ej8bmAu?LpR~@`d@!J@Y-vu_A;f>T~Q5NxX?1mF(vl0QzVps)AzhW!s0DL z?B6MrO`o_{-zhiY3w>b#KlZJF{K%H2s9YvCXo;64xokFrRy;KubB=K(r(c zh`Z^=Ru0$&nZtT&`k=XeMO}U$2Z%Zw-{##1$q;~D>An3I%f9&uga!p z6PsBDr1bnqh@;u2OUK+(cCtE0pir18xsC0KAOn8L!Nq>L1JgC%jrvMJ8bRpd4>;oL z**|Lj{i)9$;P5-li1d}~>t?GBS;-zf9I#gkN^K-OY?Y#*Znfb^w`*Je^7(Z~`V*?R z*Mc8^`mP9hb2W<*&%Z6mn?*6dbo&hS4wv6a4a;RjcT{8NVm=j^_JJ@gR!DaLvs?pV zZ*)^u$ZpQ$Vtdi=v8fWT1HWp&=Bl1Y8|*uVhQ1|_itsWelRIwsy&|An zG3b9%sD=F+wkJbcod)+Sma@GPs4)4)_fHrttVn&mQbEbU=@e4ddoz~ISvPf6%ScKo=AVtTAh8>L1?~hYOM`a+9 z>Y*U8l4fml8dv@_k{wcyPuxK0H&Cs9M%WzlM_i3`JGjD7*c|mcXmOtLE3}8Jv82PH zf#!CD_&4bvb(Q>Z6 z9O(0>g5h?M@FPN>S1@8IY;E|qC)6(pD&d{*Z?N5lWpa%n=3%$9R!t)>PE#nfmi^z7 z@`IC-@(g)jS;6=tuHflkFY@zdK^(v%kioMKzu=>v+SPkWX=e30^tp1=TApXa8X8YN zM+k=E1+lNwwWX~vaW7T&_Ww5T6$xmtFiLJCuKoeXZ)m1vBRk)U9Rv^5Hx-u2XLu9@3s z0RHe*dA)og_w1TQ>@m3?Icu*&`VD!f_}_C$VajQVuT2^s-^Py{Cx}u;U=0app?X(y zzO{dC!dqBaG*EGcAzxsiufs5r_{X*v`Tz00^!wY1<%pW&d4%R?PU9hCYVFZxM5{n(GtuTfZl zu#lqy{X}&O{@(gECB~`mnd>Ur>W06m%~x;O^y%JZzF1=`r;|0tFpE9JTJF+xyl%EWhUc;P0XY*Y zy(<(kTtCKZy=&gsFHlaDu)KnEeX-|$E{Ls4*YUQxo%-bp(&Ad?Ngz-1-M${@E48Ef z7b+COmbKLhRq3qK;}w$y_K%M=@0#Ctf=Ami8UciB*k26GK94dD)IJ_%LW9_(>XmLI(DdJIyz~*{$dJ-b{q5 zviHUYDMT7&JE5>IM-4g`Knc9pNUVl_4LhdV;GaSH*fVOGLT{M0E;W$)&6ieh4i51G z9UdNo0TQehgPv`k=-CX#SlQaROm^Fb{;!_C&6CWh5;C8esC|Z(*A~~>faUNJLsp() zaSz%>Te_nZuq)wHm-b9&W;4yV7AA+er>+q@ir3nSdy6L#Bub0IL^Q=3H`$?*5}JU9 zFd?UOg!An2)6CqRi?9L@r9w%FQVFe;FkRkzWOXXY+o(Il?S{!E>9RI88p1jo6)S4| zcO`zD@p_7Ct*7x`Rla!HKNs#3Dk-VGd18T^SPMi3P+LxCxt#rLP%wofznWzK3M3O- zU^)i`GU@QM=!I1yRg1E@@+hZ0pf`E)i4$Q5l-n$|Us#FWCXn!d4gH4M z6W{*>EuI$P|Hp-vOLmt$3Q+8Opqv_I%7dULvg9_2)YPGjTj*VP*{#zi>HQf1H(% zccYK}9VQazq#bt}+HqzuPzUX}5?~wIuYF)+mwZNb!kxuA3D-6Z!A<&#|9A+Xgk_ta zbXD^liwB6KlGXym5irm^AR1p_8LZecIZ%AM`tpSBON7d9U={~i@5JTlW^&2p(ZHmIySwL8WU^|-GaWHD_~Tm=4K z|M!-@pXUqC38dKckh}B6syy8(?7VD?xdo41y+L;)ewE`_`J=ywOF&u_0?4Q{->1#` zzuc-DgyO8!zoh2T`{4yLXuh2X$pTmY;{vjUDrAz{CTQUP+Oh2IHAsA+;=9k1%Nlx3 z`tGL8Y}Ri1r*cbv4yz!alj(Jfi1JwDT7Mrww|Ys(irs!Us)tOrba({m8-{*hKNAQCH1I=T$afqMioG4rtU4D3c%)?w=L->hUTOYXHQmdMO zMW&OH8LZ)i3QJb^(L+u-@1s+u_lhe(1jJDGAtn}&uoRd=_!Hbjd5-z^bCpo5&wzCthtA$alTVXZNGB5r;q%ynj4xShH#t0kiupydy z?0vYfONF=h*JHc%@4oR2&J8x({gM2%RRhQAhHfmmWdRTc>YlZiN$YkZ&c!aLg9sAs zeO6X{ULz`f+Ct4g&Ho6JACfUsJHPW9Y&1Wxs%xE2ox7cHM1@Uz`XEU>n-&NOPueQR zahkZs6Iti7183qRXLfHhk<7~#%y9(zXV$2kin*bnjoY8YzF*`2(2)xd_v3Y{k+Mrl zw)CTTgLpUc*|El(N7Njnubf*;7FR{O82A;0?x7-1@f}~NOYyI?`&!NDg=Z^=)uj23 zeP4TwtfWX{@C^<{N|$+WypA1t)NQkKtoE)XK|PyIz${MUd9Ex~QL0tVAc3|HLx_gZ zk+|HIM{6mR0mVWwmpJem4$gCGYT|0f`NpR$2NkN^jK70ki?BxFsHhMHP&#~BF-^Bp zC7#bXb|$k9_7`5!VwSmYF+(7Tt{yEV@AuH?T0>zP>>sEIFTGK;gT{n)e9qZju>NM0kv%K>B>J{k_$&$T>+e$J4a75@dQ-Z zw13ucpW?&Izm#(XfE#f{UKpzG8eQ&3-x-t#NU9Bjn5t#9pWb_c|#QL3vHG;bdGqbG_=XzAQ* zJHITOrmLx@{m#I1d1{XDCCsMHEaPoKm;8_T$2f+Kc&d)lt4@}>AxQt=$M>JX@!Eu! z^;L>_%(K{)$m_~=!qTF7@x?x;5^8pb#iuC--^DAo=!#cEy{Jo@S7X6Z53aC3%V9Jh zL(P3KuO@^$k`gZL3m+)9h`*Wi7xiNT;|pJS7G8G%Us&m4Z<8lm76{#m&$#T`hP!lz z&0leox}o_ZS!5=$fQm+V!^>OSS!O!n=>0r=H+Io&p^6*xiPZD^+Nz_s2gnurX*pdtiN#T$yA~GN+!BZ&2ws- z+R$NM%wV7ERl_UoOKII4c<)YguF00GK9{$?cz68kuftCcgWQ!4xr!#sr;p<@hkjV> ze8%(hriz)70)vh zR^H4xv;H);L&d61!JM61JCh78#JFaksTkxgS!jyrSt#NL-QfTQ!6*EoNKNHn;rYXDC(o3#k*0ptX;&+ZJ!d4X(~iBwT+mgUc-x1U-SN{?Ln(p6uZW($PVbnJR#S|Asb7bA zg@`(^4o(Pi`}BM2?#_4Rs+2(6u#(Ts8cn?gj$n{HTOgR;r3*?<7Ml z@xJL>N(N~Ti$({P{U3~Og_x_zt$pg=QZ@wLDgM3L&{mmp+m@jO3lfqy_VI%&JN=N(#?#RC(dx-C>rwURRJINc@eO zAnfp%!|eMPDPqq{b#>Ese|;&kCV0I6S&IGr1h~}z>J3XA)rKG~dYiyD{6o?lwpn!n z*>*9fBuNx^DLx_RZEIZ4+x8U7l&vxkZu~BdKdsmo9wZxeI?oz20)n?DOoQ_)8pUvH zUt|U~{cN<^G_>CT@wlfch>s172t{~F7QAfSGrAzOzDf}vYX(8f18Oh5=adQ@Iz+dv zg%`r7Y>IXts@J|{if5)DdEWL%hLgyRrJGba4e_?80+l&*!pwMii0|phdW@?3&{t*d z;ZQRPEr6W3L`}LuZ{AP5WZ9KHAWg?>oprXq)RT$Vsr4g(iP^?Cw&?Wf-Uq#H)9UNA z^3_p62joniFR+HR>63ZdG4?5E0pIL|%a?Vd%I@V^j$e&I?@q&|X9$oNesSlu;nrVA z3$bnd3%ZjE(OHPL#GPnMTu_iM<#+jS!I*WDxzq7BwQVOJJn?tNj5C>eu%|E|QS@t9 zk?CUo$EbZ4svDpx%ZZHdXO!hVDi==;=9Omq4;wz4WqVx>qEP0b2T|Z-c^A+ zIpw*v8I8B4Y*2C49(U~0;YWH|-r&dJ%t}Qy_Xgr%JwEfngDdEn*&n|x3fsUNHq~I= zm3Rlib5F#@wk7b*vW--_A#wN>h~w6gW}K(9!Q9omc$z=jt)5)W8RO@A6?Pwq@3;ya zufoihxjP+NNJ9JH-ytK$b;|qd) z+-OttF%hNO!1%Ji^L&|6z&RWn6;U)T-Q`Zy5m9^9i6f%cQSVJ| z7&Rtmi;1e&$V)oI=B0R!vZ49l7=02V{U5X&XSo$C`unFz;+^3frPp0kYYe9D)cQWj z&`gYDc8-!pj=+K%^p4So+vGb)ga=dj1O$GwDI_Iw)>o3VFq?Du!Lw{nT}v*ro=l!j zttPO<-@dV~r*V5-;(coIS9)ED4U)N{Q1dsj7_D=w%cbo5dEBZO&(s>)>lh`EaVXQ^ zH$33FY}5%WAVCk%rOIo#0oASc-If%*WI;Jq9ef+xkch4)%?XNBY4rxd{yTz zCp}>EOuK-mnSw=Xf$|*8VP-Sj%?>RW)tBFUs|-bpc96Yr0b7h=6q*M2$1ZvPm2{<) zXhAm9aL|Y52YY|eJ(&_6T3-X0h6-GHS}x-APsjMjJw23nIM=g;!Y^hPMF|7miJ?Xv zG+!K@V#2|k2%GGjpTC-iMqwlpifgel|9oM~v0eIW@?V$ITfPeu82$8Zd^y!gpBGs= zztf@<;r8vv+z~SP{Bs8LJVlu@0{A$se@G18;(Y1&>=5#d#4ZAQ-BL04%z&^x9?GWUHi*h{sU}o-)lYVT`^y{O+J46SIXV`od?cqhktF>_{aY!%f zip4yvj?c>FO+{BJ`@fB(?RFZ(ihX9Q%c+b&RJHnrAE;yXS-Tf;920sLg?{h{XjNm5 z38(6+yi}5`%-9qNdQZ)g;&OBVI!0|@eF*5-VM5!U5+`3K*o&lD;8fn-)GKNxZ*jUi z;og)a>FLP5b7)vfkb84ilcP8BlC=a*?#)7o+`IqxRc^!Dl)!nChj)_PXbLY&yz$3g z`yxSP<{WillA3CP5CLEEyZD99AU+mOEXIrhjF}@ddYdr-ed#9`x6M?(Im^N3QfW9w z>cmsQ-yJkE_40MgfFbY7`WbK6`N5i2Q4-xr-1 zdN6``68s=VT&hyr3%3m(U93$zFdLoVdrvKb?k%Yh{>#)LKZv2;3b3Nyn)pP^Fqh!$ zgj1}>{_`Q}fRt_0GrRCH+L+M9SWEWsSHrl@zkf6N?<+SyK9$}++Z+9U^d_4Xg|=JC zDu6<9+RkY(PdsKWOg}efM%|aWaMO72$5~9yAl?>6tJdHX(Olj6C6P;d61C&1^Qe38 ztq4t|7uvQuy)c?3615loG`*EjsGCXMx5lMZQK&#%N+y42W96lQC=#5su>N|nXEdld z1{6>B!jJjc1u9gn!3Q{z(m&mlsx8Qzw2j@rkuGsubs^%B1}US9W0EVi7r&w?k2iH= z?BnGlWlkYoQ-*VFrXxf{H*W?|uaX9eD*v0@kZk<85$PXOqRb@YnVQ4Hg!a)p9J^0~ zV_EhWZ_5%-Rr*-VM#skb{GcKAip*JKzrxj0yKb8KbW~krL@Wo@ON=wAc!kYalRRyZC zFspU$UP05|r^)a2H-&hVYHx{L-wp5tjG40v^8PyibD5z^A*7q#`Oa{QVqfN$4z=9? z<{=TU>2T#oe$P})C`r%cOiYMr%4JxUB~TNc7(Jzzt@7!5=1I)Z6lS^2H};Oww`Gy* zc!8dU)0iAW{H=+2!spCA7_X<9Y)fS^3K((#gMTaIk3eLfXumA%D3H zRS8^CBnb%%#&oJtPci)@CcH@&6uY%+r%AermsuA~swztLh>4s&7{fl=gCVYCXaGxO z@O;45d{JKDUXm+|7qO}+&vf9$XN1;>;@zvgn5~gZDJjdoQsA9$^z}$U6w+s=ydwH?)~*Td+>?0e3+9P3owFIAQUs5-!lyVCeEqg1U{kHBRA=j5-8OWuW&|!d@QwbP%4XtsYIRU=1k;c z<|-lY{hoRu6G_NugDeYeA!TosI`wAGU9Z*hB0smiedc|O%Q?WtIDx@hey zF8e5Ef=hF2k?${_ytZ?vmfRFWJ28>jFkJgv4JrCYr4J>cgBIizr^)-DK~Axxb%~l~ zQEQh$O+Ws5e(`x!E0To2rD2df>}f&v=~?KR##*hfrx6=i@Ur}lUECHFZ{#FVSLZ5B0qRl z#6$w5A&G?=~1pvWcv*b#1KPg`2U4V_B zBjlI7@{OezI=5njppG@Kan0X41~>Ea7aZddD>*t&X5J+OP1OIw6Tk9Fc*2R(xH8y5 zU^6vKHu)I?Kbe65X;P@JxNW>tz1D$(yg7%9Rp+U=RobG}NTync)*nDg>5MvmVpZ~@ z#h-UR-{qgiz2R#e6R&m?r}w0)kn=m^z?lpk>?Pc%#UP`j#Kw#VWkzv_E-QD_K8$G|+KnVt*-UMDNF5_j zhC`yROe-`8D2xV@P!;8dp!?(KjYmh-tp2{=J6}BD&6Wwu_SJh%s62DN7Ns8PIP=>= zC@VE?abwj{F=Uc)*{W#Q1z$0aLOqGB-RP@fUO=?6J^7u?ppFuNAx-3pyJ4b_qAc)z zgeM6jlJ9rmpZ)%W(J=-y3DAbpr|ug?L(ufA-!@<5@cw!|$z+?pn2mdRc;v#u-d5Lr zPR;(U8h#|?YB6Ol_|NHW7`|94r@)O6i>L8d`SBmrP)<>5t0_9zeLtpIW>=oRsM$i1 zFvyJ+tc{#-=>j#CB2n7wn}dcISNzYKXodbL(XmO74#pFcHGiD+@73sKr2>vMn=j`n zLl2l%d{0Y=veId&)oy!a{~oC75*w_|1^8`^33shO=87~|W46RxDp%pQ8QW5gnVL=Y zRu6oKe29?nk~E~M-W;!{(2Re)NYjLeZBrQNvH->!c4(CZFumGQpf)_z;ou$N7hrYX zcS?GPL30FTGPM$;PCzoQJV#%s*(i6dL+%CbnMiNuf^DLlKbHfIkmDx^^5O3&ky`tC zswzcwKEmM+$&13_3k%I#G$13*84cR|)Y?T?d7>kdrLqqf^C)n2#ALBX-V_WOPcdXX zVB~oev@*MB!uQFJH9m9L6Cbsa-MEibPj)pD0oJqmM|~4H0I=q%xJl8_++3->NrBrU z%`!)GEJOuDmo-8BMpIy6yH@EW!)M|p({ea+7ENIP7q9TVNh#zZR_29{UfMN3(~|n zznWY8W3#xw91#uHqcoViNzwBw3X?mt0+j&^+SvPLG9U!#7`}{I+_&;s|8RDFo7>_AeZ*8KY44ga(%+X2m zw6{g`piDz7u;xWfkUAt!!Squ^gWo6^kaEL1qY#uE%HE(`+Gdsn;vRXN66lb<>jyco zB8LlfDlEOl7iB0gygXbQs#16zcb~cmj+FK|*-hZyZ zA~c57cSKCe;c10rlSrl|3ksNq1BLZ(woJrB{s*NP+mlkvm7qY`s7j`F)%c&E9Ar0@ zS2QS%rjU%7M>Xa*PmlA{Tlk*BuLz@(jYXK!m6SahScG~`&d!3f^p z=X25fon3dtZ=Rn}S8I5h)|{5couN&%`Kv;ymX50TCS8osPjD^KO>J@?QJP959Tz{CP7N(xyH#}h;;^9N zngWaIh{rSpFeT~7P>3o3-i3ti7Au^G-B$^wfEaF)U&1nO204QXJy%Ya!N*J9*mK(5 z{lK>IcN;kGOFH&1ZZpD#t}_ZD-*-c}a%17{U~cW$cjMi#nivq8;uh+MD43l5OG6{k z`rjEcF_rW=*6$NB1jJVut0XQsmY=3Ewb^nKlhwVMBp=)yOeIDBBf-!>Aqvzc5h;W} zAFQT^9&UnFSqxvJS~#@}-=A(=Ed%&-lWT(&p8G6_t=@ zx^u`Y!(~Hfb9~7TCnhkv)AbbAh7(x0RpbRrvXAv#Rjs1MF#~Gr*-L&PBEv4ZqPR@u z(fQ|%@t4PHeZQP`+7Q>opTm}|GT6}YBpCnbV+m(|e(qHYbm_KBLK7wJ0lJd~O;MDq z8JFn=GJL~ADVtswCGz}CQk8lVY7KEt_5iCWkKpO3RdNaf;lg+VlhULu6}YHoJ=Oeh zLybe_XVs0YX$Gu)AYR3Yh`>EmoZM!DzW=L3IG>TSYP}#INPV7vQ=A%@Q4b*oU`8X` zWEfD9N;#c%(d2Yf>CbpMv&5ET+5^k5x(!ODhTfg2fNLvUPa?DCdy^@l*ADU1=Rw=U zw!Igd>hJLHsMY)f_@Ru^FE(R3^i5cq9n6hdOBb~;?51hHy9&Un-#01}-o)!ctE01n zRMFWRiVV>ZxpscIcY_k96?VKTyADRlZzLhjnLS*?_PmGU$EIAm-o7q+O64tnu->Ur zmKx$?HeAqWMaO*~RvsP`Ff5esxm^lcS2xb=I^&&8TA9ONQ`r;EZGSixnaeg2q{NKW zhS&;9j=W}(_0-04a30ZQ+X^`Yk|fh8;|wNF{)z#jlg!w&21&yNa;un$<^@ALE`r4^ zkugo1g#+2GcfuP}$tdHp6?5@m_~&1Jr1Yxqp)QOg8jUYtw;;udhWqVOW&3eRERX5c zZk=m`Q#aMzRtgKor9A+JY}%Z=L7J$fBmSzY7DH0bGS#IcSq|-pep5E{KmU>#H|Zg) z$&OTG>NQ1NCeLIP!{)Z0$|fs?UiBEzh;*ZII_y@D$4}i762!}+XT0GqmV@^gW^GEA zJX`RTO@`~iLnJG}@YiESw^Jc7_)LnszOmI=MUtuqRr}5|8a>^!WPdB^>rrD+5QB2! zAo`edFb^7F@V!=7y_80?IE)|%PprM~_H7%K{FPYtkH>v4rb)d4EFZweFaubgLdMl2 z`^agxba?LT?B(R*b8&mK^Z5J%yvjIfBVc@JiS;`o`S#ymf8F$zMeC>u7@Nt?e>7Ol zkndAAi-5}>#Ds#54<9EF%b?vv(WHFfrNN^IftOh^P)fWLJH%TyZsur-;_;^fJ0O_*FIu0~5aVhV3BV|CxyUm3I zL9f9F872(MZHWn6Yf&BZaimlXQVqKVRuyhPo3lNPyD$rE|*UaUK}Br z#vIK#!Fw2A&OyNN4)+SO0E&0z$kd%eO;q4?#WK@MnIxVOb)7;zT4wh^PEcsxxUaF< zq;R#7rMYb8I|Zr4a9%N=z2Z$XYkvf&tw66@;C+Rgyid6kT$+|hvpJe_#P%SJv)pRG zab(*G)gl07&s|pvyF!L2G0vR;qA*63KszMl{{tsSwwbOM3Df&B7-!Ij`$bP4DnVM& zptv;tV@FKxv!pF@st7P+e{h+CfElZhH!^4!?D*^`?*iMD>}m$S#^yrpb8cZMAZY&8 zYBzJSN9hR+#S<9HCMt$NvQ-a!@<^t-)+b2ZqQK~UZm4tf|1_t~aq06-+!lm&-QWlT z>oRYWlHiW&Mf;v$ct8VL4~9jLgtt6$_jhL(=$PBQ^>XjZ@XLcbyx2pAyl@m~}~6k)%>4zN@>{zj)Z z=0|3xvg}9?rHa>OZKrsCgT1N z`uPR&7+=4Colu)#wtmhlh}g(Tk;R@yYj&PyIB_>3R6(eO_3w^NwjPA&uPS4!AxX&| zb*PVwZFVzx;V2)&2~A9c2~Bjz&xFQ5nhzfz_APoztI0qPnDh(6bsk=UZzJj6f6M2;Iy^H#*Dn;H`U-%-m zGI$3j^&Wp^_+?tBMEOe?%~X0>L4={MLJaUt=aMpuYJAvESaX^2%tkba!SiT<*vu@I zkSG+o%<|hVR(C0|6bGy_YZ)yUsw2Uta3$gz1kZPF?Z?{~cl@+ViWMLYf(9ZdgBgmy zRDd(MRpvy4!_ek}3`9#AK!h-ELd$SX_mV1$Gu+rtvvbEPZbB>+O88@)R>0;%1BNRd%E%C4IK;ZZUd;BLiQr0%)i7jdF(n6H6B6fcokmnEHf!} zWo(j@xt0ILP(%4FeEFKirpSZy82jW7M>s+tKn><6{Trh9Oi^NkNE+SD_fN5;b82nT7!n46gc~;$0@l&$ z4m#?Qz5SQDQY(WDjp8>pg=4@5gU-V-{&5bNd)aXaQ0$;uG%Qi=YP3XA&I(F_PwQ^4 zZVtu+eAVSSs`~kqqP+W*LGNb03p1hwCQojM%1=E%J`WQ8U^@%#{RpT}8!_7-oUSQ4~$pMAqO1L;i5%kQtG4_`A zOL+X#0W2cP&I^HQ3q`$J$wyL`i{tep%U2CR+2?PyzS(5}qIA8!$!PYf(PR}rUFo)P z4=3dl>v}Z?=HrW5PO-wiWaqd>!j=;Q8wy69DqkAeUXhcf{iLnnTeD1tamwj2zuXOo zb5xmBxTwq>UZyz*s%TJ~21zO^5ESU4$p6<@0uAs%IOZ4gV^5W$rBf*nm(qo)&}u_x zqD<+a>Oe*{^S1_DBCGN>Z#>l4{G+h6DJ70>hJA1uoJoG@aD0-V!mV%w)-``z>aVd_ zW@cwkAh(+(s)Kd9NB*zkz@ylwHV_*vi^STd|Mu_7d>b0QB{iO8C#(gRO6#On&BvGHAx$_&LO>TX z75B|E75_&vqzQyKz?R31CXLUDJCxYVv};^emg1*yVDA2*Q0_5oNj*eFVo(C$hp1y> zPI1)=DAp7!3sVq*iioY8fMuQPWv*HSSn8Pvq8>mptR##p55{iO5vpnq0s=@CP*epT-Z4v-( zE|^SyzUB2xbLgaZdNXhEm8tw#6f^u}D|SErkP_r37&d`s=}aP*M-^|7G{H}*^WHp( zN%Z748G8t^VK&qZ_U+GZ0klLqIz|ZRcmFaQ!jA78ioGgWr1GaZ-L`qbeg)OsgUURd zVwFYAlH4mZ(!Rok>m2McK7gMRO&wbTM(E5`Y|^%Hw%(RhPoOQ|oEQPxF^AztJZBc|Mu4oh_48~YYaBXrj(6N!e6?xMxUV7} zx-9OF?DT6NIOSt&c=+~yh;2~eD1N)DJTy?At`E@@#rMQstd!l)iA(M|8gzF=XCG(* zMk~Vr_nB_j_XWLMP$ef`^wTfLMeGk{6d|I``vs;V;ML|uHBhoD*7UAgu$j)`ckxR+ zXIAaL_dXcrg+tZ|cN!fHtX|tE35+df4nGx6TYUS72Um83&8Qgckg(@$g_N2Ac)LDd zVKM{6QI@WFaz_raE0zvor`t`oe~Lx(l!UkZV9f|&AMZ;ZM(YOHn0N4iLro9Hp7}wH zfJ>(XQF{`mr3=Hp2LuNw5vx#UD3Kim_6-v`;G!6NQB9+KX9zZ=BSOFpx#H^zh-HGE zxw=myWNSF{iaV{t;Z1L;^ z`Eu~UyPVX+MiXK9a4dg*l#$C&C*pU#@e3P)?25Lp$AMV(h51kJfd=Y>B6#L3M`bfq zCtCbH#SwFcAPP_uxsst6up<8dZG3oUFpRn?4G!S@f7^IssW(`#REPaL^MjARp@2dk z7)dwl`ZsR0ym9HN!2fF(cv^~oYgCKXz~O;6x7$=jVO##EY$p;P3VdmC6Su* zcGBpTvPH;Gko@`j;_Dr9V`uNz?~e)PXP_(`H6ANoaX9pC6n4;G6!wNe0_X-5YNF)C zhac;rQ#|PSCCYU9JMpoVD$WQXDvpVF?+TX*W>!NX3X{7@tISm|E8h-lw@!8ZJ15kM zkVBiig;r&LV{p2@rzQYg?%GL%HKo$`= z>PiL2$S$Dr4+Ep@oG!5g38-WM-}2ad%3(Z4+JhzD>K0Crj(l4;MR9Jq_!_87%a+HY zDFLa?&3ncPw?Y@#HU2WGGz9*!;Z<+icdgML@!@Dww&q*8cDk}^$#`pP(Q6>P@lz+4 zecfb@g7g%Gol=UCavA4 zg>S$NWRuBP=|!Hx2n&AtMp__ck6=TOt-YFc8Jwz<@HCHF+Ep+-e|@U_;CEMqw%&<%!tcc1|hGL0-{9?nz8v`*aRqZ}tCF$E4Lhf9CA=P{u`q&IB7bGr@FvJe@xGv<2leXBLQq6W9pTjkqqDSBwkyA@{j-r1%fNy7$fu8CC{m*6g{r*x^wfijV%PpH8b&~sQRgdUT|2KWauJZ%{Yh5tAZ zBt%yiZg?3t!Fm7zjnqZ@ZhldU-R~A4IwEUuba~2SbyL#%VLd>?Jf-Vi9^dUADQomP zHpP`Vcb70XwSu_}FE&>L`a^DIjZMf6jTOkHniz+V0EgEzr-5&lpdFv#FLP47*@3mD z9g}+`DGj4Z|4c@5Jo&8dl#WaqRE^WSV^nKXF&q=`$L94hyy4@AzCK?#!L8|aNh0-9 zI(U$`JoEJ3Vn>gY6G};rM|t`DNy#}o!I#}vh(W;Is?a5P6L4N=MERq}f_4d^y-Qv_ zBB~8*aZCBp_RDS-q+cwdhWf*<9<{iapFgdI#RtV<%x->_`Prn6tH=+Kq}4N=hb5Q8 zi_&0~b^Xvb{1XG>6M;k%vICaGa+qdV>McgbK)rPICb8N(AeIY+{m0BST6{m8V^T6Y!?ps;2eHE-KQStX*cqht#n@U< zp|UqZpZwweRQW5IuqB~9C2n$?#^6eg`RW8&=USq2^Z9*%Em>G;zyN2Pnj9v|ch=av z+#Xl>`Cjs9%z3za*O_1AJI?0epB`Na4H9RLu3OtgY>hCdO(my3r|7`Uo;NA-Px{UP zUD%GEvGsoSdOc@;Fl*Hv=TI)=|{MK&<%Bxp)+$$&yNzF40*N zG-T?AghA>|C5+R^w3-K=7!>K>B1V4?nBOoH2r(_zbKn!fN=A74#(KE)BXU+~v$M6Lxujiue{>Hw3 z-0K)YDPx_g7`k_4Vl{<@T1_<%{5_7$>fFP}DgTFgEEe5RUWrsl`7ALeEbCMO(4nj9 zcJ7u)kL>2Y@0tk8XH+R(HpOgIIrz&BI=^1I2|evgobW2hcyqU@&)bTq++AR~b*~&i zsC2LJ5-h6s#O3lQdSa4}Ywhlh{(jQX5C zhd=!;U&K6$V$v&7zw~$@el`ntZYuJ_+{fbbr7km=GV;=C5gb?+6_5E#(Qyw816X0+ z5?h(WKzeSj`Q9L|Pjp&S==LrD4&-v^Uv>4gRI7>Ik}%&_r=&u311YCMM2jz) z@a!!d%uk)QvOe{uw=s?O`4-#$DP;c&?3yiGmErpN@qh+{(&BT*T8F(M64m1Dz@z`| zlv5ggL^AdflNX=8A?Mpcd*}{kH{|vATLZ@D+cdAkfTqzviul^qA?v#CPQOl@2+!EqTx!qW}aubYl`f9PM zJk85st0d9QYrPBemu{;st{`$&n+Hz{ptKf0zY%RY7dk8N#X@qNmQQSIn3P(D6sOfo z#evr!+sUAFaLve%7$6_ZH6f#fl2eq_fxw`@1(?$<0Qc+Sxs>H{qIYC7;@izg6hvEA zDo}P-^=#O{=D#|W%OFh1seFSU0BW%ov`@pfA`J;s8E_$@ix5qBpBPyW__lNlxoU#ZD zl3eb6p}hNgr{KR>d>B3Gxk}5B#YD@HBRN0pZPT_1 z?S?F8T31hTQ@AshXMgFEN@eCTqvKI@0?X2%_#2>3)G_-r&a}Nde1K2%CR}ZLAu1E)GS}hrO#&vl)WkDaTisvQLb}AR zGC1&en6xo5HHvu>vMNA%>tZy&d_;&`6(b>ckQbraik9(|;~h2NzU!&ljXDBo-2pae zWofN=;JNFg#j$Cf0*lZhkJf9|^4tB16GK0?4r^i8agVtc6~auPx*Vy_@ZweNfvyVr4loo}cK z8=|Fj~ykR#^8Q^4FT)AJp5g(kZ~NRGLGD80hmgWEK0PS09Sch75irw(dGKi;$a z>j<*@c(+|8#&GJ>EPmS{FVsS+seHf2Rmryq3TPw_kIPE>>Vkz#>nj~<$sfG0Dq zm%HaL%AvW5cjF4bZ5A1Uju?LD%4(YtC)>y5(5WVW z@c{J*g7HVCGi>=%HmY|1w*HYI`^an-k{eqJn&tsGHTD~OHDg$^#h(uLkokRHye53< z?&U=Ds38hGf{qr)VNy0f(umxhnJd#bw=4lXtzZ7JvGe#KCPrG|WKr?(Fy3z-KA%dK z)%8E-CH2s<1G#J(e*IbifHeRBmmnQh5tc0weLY{tFDVT!MRE@-C8X$b26UE14C#{P zM5Cx?Z+x7N zeJQY86t#bNYWdgON6arB$d{n9sGA(!IZ7&Hyfw?tGBS8h&3Zc?b#6%4XWA?4pM6!p zrKH>D6&~C@r2(7}6Hx@;)6iMo9_Q%Wv#v**R-6p~SE{lI*AY zSIJ9XKV5ONBlp6Y>6G+RG5!3PmiC@!IumKN20#!TmG&{t1W=?fIczXFD&-`@S#Wv_ z%Rs)6yK`nQbgUBQKU4Iw6EQi}+?CkmghHf{T#o#BKHdLOk0%kShKR`lurA~+lRxEi zF!Gy>er|$z^Q&st;ODmk-_UDC65o0t-GFCsOd6dY+k9tGdS>gZzLVTb`Px0h?Dc#m z<6K3-)%4)6iQfnmbf0MPNpnSE!uW1FGf8~^(GTU2rFqyE@F?<=3Sz4q2)gc4I+I}y zO3S>?jgji8R>wY2QrRAD7Q72OySb3JWgZ(PkI)P*>Gp_XhO5QsL&5XNN!LW*q1e1i zWtZ#lfS7;c@5htHWiBq^jDYMk%+Jcem`sF1ju2f4{q;UgEvY|~?9GKRJOObHCG-|7 zZw`ZL0tSy|uWE&+4Y#Ht!P-;Zza9f)is<=Rz+lGP2gdi~qta$hK6M6GP3B@|#7?-G zNX0WR@%2PLpwv>2S#1iQbek!E@fec0S2P3E_Zji*&~;fY{qV9R_m34$R=vTE0Zfd@R#^*QR5OWlC=(i3Ed?7R)CCMIC+gyjkmStfve6teBG-*P z-DLFy?d_X-ew(^FCnUbWe@z~ZEUt)x+7&aage+hJxL1!o)PSaicWJLb2p zzG5E+a^x7k7A$AjS_t+Xb1b(yy15`3kVW7P{uUfmLHG707w%Mnif|*=|MQBigkQ|p z@hB-&Mk5x>iUa@s2zluOcDYp~&c{}m8Sj$iXG=Tn%4BWF`So83S!4!Cjff(5;AmG% zn(?^ZQvT^k-2JY0Ya`E_+v_ddPKjI=1O3m1^Tm(9kM~Z`SXROI%ZBzWlOA{y6F|mp zL7t!J!;tAemx;2v>{+$y_8qG}F0)?KW;wzW2hQ&s90YbtuQ`r`Gy0~xyKNna->*Nw z3u~_bNp^O3X=@`B4#l9Zs$4&1LFl3Xs!Vffk(lTlwete2I;6}Ppk;d&u?Yg+koMJo zQJlpFr1?)cBHqYDb*h*(s6BqSg$|u%sK-h4R%qw90>_e~bEn^zNh5Lx($TBp=@De- zN|Av>orYu8WHb7q*WxTR<(VJ6`RU-5zbh+FGy&{}tF~PcH(^;kf0dg8@WL!ROCDy! z8pGPBd{xoC^*e|feK?h_)*yMcinY$xIR)(*`H0=U{BN$c23eIiR$tHHY|oSN=auo3Tv@PB- zmo}kQccVNU!vDjoQR#KRYZpo6_3ZdBZ;Mx2`CEI7XKof%Ri*L<+9a)!3m3=aFQs9x zb<(n`8Vb7TlPqJK3JVqN0;Sx2Ll347Z=?-_^wkP%s0m5?jO(A@BU%-N-CA%GkX)?VY!BiE7d`H<0J@H8bys^wxDf zkSE%A8?mQn6KHcb3L|FXi(N#2G!e;tYE!zouzLIpqx<5alQqNSm!S|>sYF6MI}U4~ zW^lGYG2hHziZH2kRJDF`xO+>JtG_mq>*yl{yadcBe|d}`ovv;{g0FHl=cn_aVbLUq zYK|}S9D9iC^?jhjnA98Jqbsi%3Bo7ZKd$!#MYM7}So{y8tFpI@TldQtQ`C z`q4ZOI@+=)h)?lv(6vwXkndpYt|aG6=~6vAo|QZh_2X~wQXV?|uCdQaS7hP0g_W-s zlZ|D&b%m0m%T`RzQ~$MWR=u8N4tb3K$b3=p@$>HjZe;VFtaM!6Otbx-(&WvFAqHX8 ze;L75Z&22Co&w)$Y*Z*Ku$eUnnKM-xJwclq4Oqa*a<5J-Cy$|8~W6o~fq0J|1 z9CLpj!o0=#XmHA})z*aX&p)L>LAYL8naTM~;ej;BYO)h;)K3z=fx-Zxo_kXUipoHO zf1GfGOL2ol_i1?F<_Cw2?kw2dQQbnjej%~x>}(O=^dfuyUiBTwja7SHd8GXovf{Ar z_~>|duM!}hvq(W^9{uJYkb8huCcd=|LPMx z+t&m^GSkp1Yf+($NdPG2HRc|;tO%fzSd`mfvXJP$ZdQcNN?6X(fzxm4wL)&Dt5C%G zw&k%3xDEaA;VJAHEDoTLTNUgq1e39j)Iqgu|1S)CnzE{4=yZzG=0!fOg|X_Xe% zc=wZNB{$f(s4YmTSQ8)w>lGRj>mle4ev%xIcvR%DB`w*4_vA9M*WlA`oszieb!lYF zpIIO@B(;C92iA4}sw}1tCme?^^us5c~oHBwpwT0JhKmHQ#SR4SBe?Z>aUnIxtfk-N3FQ5 zJtKMAAv%&&GhVc60}T@xGMA6o98$$zraI>xFfC|=Ngst;Nj0W^!F!z zm&eUVdHTvhss&6~pF4t>AVy9yTt^XK3A z?7n|I%osj?ohd`AN+RWIz$h+M63Co*)Yd z7h18n7Lwnn3yo{tUE-ZvL&NW2+!(`UEG>MnG^g#0IJE9mn24xKI-ZT;Xz7ke^N8J# z`Hjk3t@Sd{dn=jEFH#uTRGLYXZ6Y-A8H18B`af4Lv7Pe1Em@lWY0(Y8RR3_m)cKc|(~N?FPjTty%o=XETB##-Vy~$+y34V6q~C8K4}C&?eU{;Q z6C?-~@rE0Pl2O<6Uk*#e>nm_e>Tb?a*Dlz6K(P%W!Ai7~O76vsXR#&1ZwwX{3_rD$ z$mw#Q`8O((&_^|9h!OZz@3_WggdXw?X_R*MwFA#;jc)LqR@9GnDY!>_2tNa`&lD1~ z>_5FuQM;`H7_vkv#dKM^F()|sq>WR(+>J0~v6PN3u@H>d|jz&YLr5}lRCKEd5X zpx3KyWvcWorAo#!kscW@USfFgyftGWP zS|1s~rBTo4 zwkB3tgE`KJ02z2(AEYWf>u)9H$ALOLib=7Oq;A9}oZjuZ4nov@yT6su)ei)Mkmm+6 z4^7x#s216Cg-73xASkI4MmazjVJiG$a#ocg2@ipo*rUU_FoDwoELivnQ&0Ta!U}Jm zY4crqlY5}Fy#Rr-Kd(NuiYb4F2*lxqx3dcr>QbR-W6GlP2vmJ8OHqZZJ{CE5IPn?y z`eylO4WBijq|EcAbh0OJXKu)1bKUKFH>L{PGQZs&``%7I3ToD|vih_q2J#N8wJapV z)SDjHy%=Y=nX?BHd5m{vv=$iDbFE0Vk&`IgJ{|_NwYEQ4IXk_`Q@n}$@!;O6^ObkT zH&sj&eeS|$*)6nz+r8{KVy$i>;wbc2hB#dUO#c?Yexb-|%g4!5l%k#MIG+}g12T{I zc+J4{sbU7Yb^;b;u2mO@GZjzX4ZS*~lGXS&C}BnVAOw($7V7KaEhJ|AVF^QLA}XWF zkA(#TQm;pE&kw48SH~k~(Jry9TqlBuQxdK`xXAu>@KO!SApcGXFkzjJrS|O>Jd?EfT|C^GYdPI*91u-Me)u?(cphJJ z37>&0nT}cRWlcMx4N65ei15h2&Ecf`;9}pIMf2k8BvfHxI_iDWp84I4?8AkH1eM8g zs7(Lj!>~n*wVY<%o0{HIR0b+bDp88^dOOY^rlhc}Nc$tiYdkN-QlhgRfeYb8@UYLa zflF7Fr*&FMEhO@N`;=W$xctsUce4aoO5KZee!!I1V0iN$X7`gpzZ1uDo7Go!1a=kL z){@7rEaY#QR5zP6L9Sd-t1M!J=9@Go1igy=4MaS8GejS>X7Y|~Q_Vj1D)uH$Z->aw z#C6bSXYSeh6yxx2jgBeQ{UYK>U}q+sJEYR1ADhRGzMNev*DAZS9&CA7@NV+1BwMM; zUe|iI!!BoAS?ZeL^U}E6qMH&u8Aq^54DY zWo>9tBoGSr6OyK(lq%Rg+GgVOi|_JlrHS}2f%>E=!fFJ*MW(5kinL4U-p#>He^*TW z&rd%f{0xqA=e7vWjK@{Q6W49U|Df}$d#-AI#(V_6E|O8OG6rdI=38t%egf3BBe;+*CB1S3JNUG*pM*#d{#p?RJD_#A;-qK83Ll3&=kyH+7n z42sa6=St!Bg!E1@{+h4P{l0I;>a!2~i}2m1=8Pl^X+cL^0W+2+isi6u4(KKhIMt#@ ze)QmwR+M&@9GYVqy@i_Ygc-@Nt4Y)T6o~QUk~)pZwl6uEATf$r`y(= z>ieM>i>71_zxl}%zyZ4iuvDkwvSObQtX$MU+%stA{KLqJKDx+Di{*;m`RlL!=g&IBK{C{$CE zQ_|-@_0SGf8=~(~F}wTpHL}8ytR3=#ol@DiOc`|#hsJ6iVa_2w(M6UBu$0e!alYuP za+sTQbYp9NK|g>1DqZV-68;oWRLAfH9Qp#JI;ieVw(HR0qt*yi<-EC zU!mHJ)ah42GU%Rt=5kRcr*p~V`S{d|@O~UVPEp$wovV%@)5BGGV}NR;!=~}!+RaD z`X(`1<#uFfk!*2p+&V0K?GK}O#tfr;@x5k&nQ1Eo{>ZjL)00PRoX{^6*19tCvtksv zSE}$%p;m@(*D+51C|fZ3x#P5sKS-TFDB=T^`dQ-rqBxE~w#AF@dtEWk3)H(*5+Cjt z5Rgwju#sF}Er5-kB4=2C_=eW+P*Pp;k+@;#r34K);)UDsM^% z>q!njZ270Rr&sZe?rg1%8ye4)g|GE==k)GlxNdU4r`YDj#lo~XaigFtCSb@&2ZN@h zWyHwHqn7RA@DG@&fH{Yg`W!Qrsv9~e$W(x6asfpk^Oblan3tVn>Ikcu4a3QkyNdC& zWQ+Ih=8q}=hM+*DMo!(c_bKf7&7^_w%UHQ$Vvoo_##FRYc;w>@8q~-k)S#e9{3QtX zxdF?wUew4rX>u|0Fa#6{rta3DNbMgY693i$|0D)Y4bkeAkQHfOww$3xvMVWzW|4{1 zKfox7NPun&plgb?`3pblf2pyW2|A!e6a`lV;>LTvSwXVfI|tMOPDq+Rl5Dtmkr|&zBGX=bks>2+dr>5S$%2uPSe{8v%|`uQ3@`1m zRPpTzDMN5Q4I|GIkocrYY0O}JodnjY_dX~13Q3pLgL8)9NzlW?h?u6+^(?0F zu@eDwigud*t)lsV3Ft$Dq+eu45&q^hvBA{zx8SMbi|O@Z5b~LI`Nv^>L0lESv*pC6 zyQ@IsI^4J&DL=zCvG`J%sLM3)T>+& zLq5v~bN*xf&)dAo_!i|~6F!gY&3NJ`LA;{PczVF)I^bqe6|JpGo8PxnF;ksrhF zGZ_Fyj6MyrIcZoi;EtIRCUTttqyGcEi3ARUU8%?chw1$+-op`VI1-FgFa&!eaKR^y z6daf#zv)gA1%hK3esdK6J!GC@PMTQ^xWm?r2^6{3jQMYk$|No2nZwLxAUJw% zag4SgR9%Xp*~4}J_dwv{`JY`s8u6G_)>_gvUfW#k$+voZpo?4nehv=>P~MN^{g(ps zi1I@|aEBBvfh0o_0Um|v5J^BVIfLs+l?fFRuMEKbqBFKV0mbFPe{B*e0j$uqNsI(W z1iVE|S+Dld93~M^sm&H)c`WCn`d$FuPY!hZrgwmRPMTQEub&+ILxd?x8TL0|;X6c} zfCo!;r1FLeNxOHM*>#`Ac(VgPzzX%Q86c1BGmu;yJtVz69U5L=v$Y!lN`UtqNszy{ z0@V$t4+vraC!K~Ni)Fw(K(_05W$fi5iU+fO8#GF`Gd zyJodI`W5&Ut@){r9~9mxIhu{EBgYSoOpoDvr@EYt$wUtxw#Ucl4Dn7kypECUA6i3G zU#`iexDSy3!-2TbDdo$M=plT>b@xy+%0XW+hB&FoS$JpaHDy4!tKSF1lQUKkBa}n< zEf`TFTj0V5<0mLNPQK9{5(g~dqpt)|43G2JEBUb{Ziw;@(`zSh2wEz)X$Trw4BHP= z@*|&B{u$rpO`ld9)v2|XM{xmb_z<*Ha2{(TaA{_CZH;Fs^2mHxOy_UEk0}GcT|;Mh z56UQ}b($QoO;@#j6f0X47qORsN9f}s&3~`@h$Xw8_N@osl3`C>;t_mD3=PUa?_Wm^ zWgeG)B}RPydjs(Xg)ungOQwW@F}UDMhPEA4U5w9PXmID#{W$^~9( zPJDy1A|NNb#ti~6hd>!Ea+!)i6%Y%4JvT6F6|Q1NLU8loNB9~k0)PVHYm5j+#IFHI zW@tX$4_$4tgE0{fB-h9Ej%b*R2G^Tua8=XO9#gFPNFR>=D;g0drI$gI6O}`op43AM z9w3+Nid2hlr-mKQCHKn>wGeuPy^bM=1z7Alh8b3r7;dJjxSLNxzv+~6-i>tV;L`zK zr|Kc0#?ARPCcnxa6FaZ;H^U9X92AH0q{Y6K z*&XkPyx8cR%4Cym_mVk=9Ot6_q9hDlB zXC}=@$#r0vL7PMCt2&LU`P(4Tkq23@DkTr-zp}be?+2Mn5bQd;2b;Nv=~w5L_9qUn zCQp?&XvO~36F1#-tX4bAFsgzA3+)`82T#KIGLj9HGH5d;zN4h_I@9-xh*VM`s`91p zyVe{Je%wzS?l@r`B9qe&{S-Wzc%%NVirmtwM%%%%V}0=MZ&9gn|MKxjk~WvGbS2!^ z9DR+n6gqgqJIH13z}1Pi7;|=>$xB#om31C6iKlPZ&e~(Y*mFrh zse9}L9b@$;GY%(YEzO;Hpj6UCWJJNKZOAjfU`$%)ul?tIN>0)7hxGT^ENKYE@mghi zpa~CJt2slp-UHham81*uijV7{IK~o^;G($o=qi&t4Y4?m8m|<79hc?}!q@r2tk0Vu z-iwHBBh-uNQGi5}k7zS7X$mIf`|`{3kS4mB;9L;}n%2b6LYr}H=?|{9xInWBsuTQI zRQA@aS9bl%&StV-RgSznxXtL*b~EvN{<-UUQrt5CAARWlrHpjsDVxG1jNf}zcu&}y z(e;j`us8R?>JwpKIYYJDW3nMC1iDE%&KLAX%;n7wF%D}j2-{EI(oLuYfXZ4(4gR0f zk_fZ@k&1{KJofwj|N3eDUq4$!zt!jA^2m3@et}Egd05XgpGa#A%2*2Fn9EAKcu!J` zn4JAYn|Fha0zWq*x^&bi3!f2Z3fU&lErR@=2|L~t5*E1cSt}8fwuH*K;vfLB%S3GG zaig1;_L!8z=>AOp+vg;vFLNRU^n#8E?mO)aRBaaN6+|H!yS$2Plz2@o zn^iA)?A6?XKU|fVs|~J*lB?I3SwA_yiUga%m$2X(SzLN-{63UYWN(ZrXHn-#f+lg^ zgRvkQ(m_N|RHydLaM)qJ;*Z+)z9kcNj-#0TM@(!D55Fcz?Vy}AI=eEIjpUR6 zL*q_EKY}EXD4ms*jPdjHj`vl_a)UfFLsE90wfa`)b`F737_q)A+ z=>07a{10Cl+WXJ{;p?xQRA;euZa*2}9iq92UxWx@ zfeLesg&8_*r=;=Ydz{-(DEv`O#a8k8vDL;JP+MOjsn+l(k5W>xN(_^v|gLxO4q5eyz7Z#yHjoWJ^l^$})3}H;2U| zkd2$Y@n2iv6&qbD5&LZsoEkUR&1{Zo*-!{4xjJ@96L|6yZW85}u_)wL53;V%52${G zP)(9hL

    jMdFNwBA=SnY5L-Q84i6}aMZhAC224BZ|9lDV%DQO%5ol!4 z8f<3LcMFI_z_w{Pdtd7BAlT)x33e~zrhxwvzONu;M%w!)poFz*1>Qzhftd8i^4K zc=WmruEYMz;U{UZzrpxo<`Tt&+wD1F>|cH@`{eQ8SR;3n zZsYJ$-81|W311bJsvInA;`(@dJKiF9zpU_ekN)+=}#QK4(9)wNz>jHQR$7=pQw>jI~uzj{`cMzIWVh9OF&EP zgNm~gW-u0WLi0E2={Q+kah{H8W)G&Plv3l@a$(D+_h&%57S>nde>L;7SQ|C6 zY%O%bH5xpJe=cRmq`?){IPbNtPGDvs<75Ow^P{+&N?m^16{AOdjROqDKbON((%{wV z`H?AB%3}R;GWQbQ+p#}L6GPJfr?IzysxoR8h7aA{BArSjQqqkQf^@eaap(pqX-Ord zLs7b0Bn6~ZO6t%^!y%-)8s-qr%iKWIEYHA10g*NzCZ-f2FPPe%>DCZ8<7sW$q#zSkt)eDwLw4HQ`|ZaL|*+a#bMK(T)y$j(t`Iai`tpE zu@pf^h|%isosN$N8=Ujs4SYfGD+A>qQ`EnUSy=Uy-OUWfp2gy)5oS*8Ej=@9TTSNQ z1IA2NAb5bynwHNMMVG_6EjEKE>xBk6sc_IqMLHC%Xpo7v)x`0Pd4x$}M!Xwr)HG(U$4na50~Hy8U--kG?0m8kK~;URCs)zve1Y!GI5c(zeedl#zuN%v!pg9S_%4 zJN?3A9PZ-K0X7XpXCq!Br>f_RS*)O!>*V`W3E4Hr%`dh1d?U+bkN4ic``wXN-+7QB z6`xy45!-7B8~#&&@PY>apQ}VnnT8A}1z*Lxxw5NNzNS*N#}2URBhdCD&{p4}tp;dy zo3TtUIwMDL%VAbN-JukX{z-tmSLcrDtp*a@yIa2_3a>Aw{hQBI5`M>4WM|(X6`*Pf zI!qQW53uRd@^v1NS%8IU*?+{hH8g80Hj>#999w?02>Jmy)}_m#0XQaD*4c0wctRFR zvPwi?^6yYNT``tBe7T|S(>Z;>mNRw=xlQ;nDXMy|h0i*vir`;dcz>2+taJFAsrZu< zNEg3{s5O4}wa)pWC^ZP9pxKN7@uTEquV+VD>ND0rDjQlfnnDD;SrJW~<8sWVMo zLEOUqTKjqsY$p&ZUAK&I?$B;2JeG>BBb}t z*pX)|zY#t8r*d@I{{;+|4S9p3=uE4!PN5qUlh7(yrY{i2SAW+{qJk13%Qt14OKV|~ z6N4N=T_r_Ducg@W*ZskGY4z6xb%9N#VjW)~4V2)5B#+=G0%3Nz~e=`%bJ-SjL%ejX&7S zno?+S^v|qaU;UucGDYdpL~u>Ba&Nl&rnp7eGG}*SZG+@@Dr!PTOt$?C-nC>mgyg#( zjSaG`1IZWYbF62}tF;fmi8ZN9f@KRVw+SpmhCmOCk&K!$np(2QCBxUk6@Y zgX_%kHII)<8-#!0XkdGfPYL`jJXEe%jCDxTxtm+|)+PHcWQs*?j_K?k)mHB4%+$YLHSV}-^@?KNLv8*)cZmwRnuWR=Dnz@b1H`v>lwZAj z8QZS7D5xq5+HO}FhEBF%9r6D06Be~l{Wz8ShFF8_FkX!#2iFh5!`vtx391vo!!iS^ z6HccO9_a%`a^F&2g*b(~Xb)h#EzwIG_dROMxEs^IB>(>Xr%HrbGYgwP5Y!hNwpup6 zBB|#(-2L?NClQM)Qo5HJD2_Fqotg4J#0I9H1VUOjiKc&%V?*wbRflcpR>e2FjnX2< z=4Gkfd`$44=098|-J}EG0cS979qyX{;QTfoGh~Ol>{63n5-6fsSFe z2s%F3P-BjWoSvb@wOT9r>p80gwDo-^+WTe{J!2x98_rzkGs{Qd#LQ4z@q^jvvx{Uc zRWh~u>8q~Qbshq@Cf9k@%S{y6FgTG%&~MR{{yJ@8e7e^DxM8Jhc}eX`bqIeirDS~D z3BJF>%+Noxs{5FRQ@eoGFlKs&P-}3otisD3@tqBCuSJ_{ z7rqw7c$B|ei%=>S+aK)iDJ$j5y{YkH5Wea^R+xyDUSVWCwQ*?&yL6k@zM$i6^R^q3 zV{BNE^BNPL)OYL7lz0JfMs8?oiOUWWpFuRNA27V`#b34D@e|S=N>ERj%3EJK;u0X( z)OufSxMBo4tX>fTWo=mR5`y-oE>GU1Wj=MDYZ$VY{AWv`Ofw2%w>ZS z?}3%@?$rAY4wZY+8X{=Vo;e5BJN|^M2kI{5Dv-l#q!2Q*Y)zCl!Ax|?dzfP9y)3bG z#|I?$U3HMjH3gTm(1MEVz1pa+B|TnyS9(JZU}&Or2M`M_9)*_~(Xzg&t#ZW(sA(d8CPr5_`(;5Za`{=+)phH4W+v>blzzPEA!)$h~{;K;Dp zWbLAd&FC94gSUA!<@k&C_DDX^BKX7W~dwtFcrArd@&59Amk}r0GY@Bpd zOA9NFiv%%BcOSaTZFoz+N|2@eDSs^_B~RiH>VIP+T=MLN+^3Ve+?xN9=pykG)hdh?)Y>5- zWD@#bSBNF%)ZB~h2w@b6not&S#@{Rnv4US9!eHB8C4hG7|u6?Rr>0{%fnT3iR2qTzqIiO4j!IH z7;xX{G_EOrO>BJi+1tW^h{O5eJ{_BA_+KdWhP9gwK3Kmo$lRp*I;+@rm+ncAfG6_5 zpp@Sspy7eBl~3Z>o{h^rPE#o{VJV&zesCU%+uFOpbaKk37` z{(|Bo-ZPM5FTx<=joDF-s4pIg#8)kCQW+U6%ZSeULpt%N7<9h(Z#R65w-LBah$`ZV zUcsr`-j33H_P$%)+Nv*4O&sRqUFBOg+oAr~pPl zPZznNN>&uU`V#1ut;7c)<8a%K4=DI{_`+nNncD<4zoOO(MDFsCNbm&C`bSRuyuaUQ zx1OKi=5Rf?ori9ZPe@=Q2Oqmnuke|iL!CsE*(T+f6zhqZM&ifk=6j%a13w)SGO(l7 zcXl*o)zve_x^Vg#WTHUgCFxxcIN?N$^a^U6BwP$3ks0Pd!%nMd$vR|EfuR@xhGKw_ z31z^>lx5&)vt_z8?jK$D`-B`Q<6y@Gp3Sb;E;#y$bUWlR2yHf*F@~G6vpD>_(Qowu zWpFm951hCR)qmzdpTCwmppEvxn(#FbFAh01sBUCh-s9pPC;DpQT`4C?cI=+uG-nK z;|oT+tFq7#@t)_Q&6%2YaBL0dnZg&NiUmMfpY!S!(9^#SVLz0XrsNP+<0J@s1OiR^iIoqc>J}`3WoSdzy{y+}3bgj>iThmr4|zHiSWG zd4oUQpRbjwxM|ZXFBlL?SfJlI26yn(u&jY){(=+&VGdI7xxL*RSQC;h&qwewBN56giVrf=nB^His8e3J1 z|H_oxC09f}_h6QKcT9>ole84OZY1T04NQ%-L_S*gh8D7E{>|~_qWOIP?b*(lf>+D= zl%&LezGOD@ed1Vs6Yp?0`xKHM?|=k+tp2lldPdzr3OPa>({HEK=H#44Qevo`gWI#% zHj%lD^-sB1ZwMrZcCX*z{K{&;&p#%`Gjwoy7>z9P^(!c*xK^M6rfDL{5y{#Z>pkTd z=?A?}ZPWWDMaTT*uS#cU;fQ4ylai$XjBpKZ$}4#tJ) ze0OC)K>bTL1H^&)|Dq|~SeUr1$X2*pXI{0|i0woCAK-`>4er)Y$NZ0OM}Z6p;_0?) zz9>XO-&&*0FPIY$h?XG#7ZJlt_C}&xOyusEgXPNq|4IB*to6rNxDHD(VLAe>cksRB!2>N{UVXnyV zCTB(iD1uX;-;I_3O|zY{mCiR;AeY1OL@dcM{u%CzvZVzvVW(5Rk61D|gsf0oDqq|9 zaR*)t6L`UAM95J%SN_TC^{@_J61Ih6jU^L}Ro(}b!LD5r_n;rk>?ng9o7wlvdaD<-*FK)0K6T-Uy-6@lj9%eZKq$ zmw(3r;7W)eOa*k0sy`^*^78)2j!zEHcM0?uL<_}S&&9zG$S_tVpOqs^1*e33E+u)j z)s&IXgFB|4;y8se@PB*+n1z|}Ofa1`aOPVer?~7T^tfoEe`b2ygiE<5Byr{R@1;Fk zp|5YdA#pzyYSI2HaJ?DBYGO$|mA>>tVcpm3OPHGPaGA3;k#&crs6=FbFzM1!=V58m zHl3#>QWqYQ7cSYnq_7^Adm1<#=xMTTjdEI-T|LG?_8}+UM~Z&cB@ANY{zzL9lR0Az zgYDEctHHO_e$X@FOHt9E&$Pc}AF3lB=@FW8r~sg)FdByzQLPyg5Pkrefz73UCEC^4m{s^~khpKD_m zmXD0F)iM^Egk>~_F)|0<8)HqZPE(1frGnp95q-#ANfeByYLfoqApO88|LA66?o6`b zEfdbQsrlEEW?w@O9n2s|hu2>Hk7fUK_Jh$8wQ7$&3NofgRovAp?^gz`ZqAt=L=(MX zrM7iW^Va;5l@;7#jkOamT`ehPMB7C_9{(l@S|XN$6rAKnaeyPRaqM}aw_x^=XJx)z zQkQ_NM@(#Z8w!Qm9RQ)z;+}0~dbjHMX)%JFte zJnKQL`+v5k_5_ceLK=F=2BzT-sqZDzOLmHuWY#X>tQ997F0Id26UJ7upiJT^dFSEW zHQFal_5&Z*ZQ~{k!R1>o77n)8<~aSXcl}R-RXe8#CQBTAPV$0WPgz!!v|pIAJ_ zljc51+6|`3dpTd_Ni_ABd^>z6NheQB%*BV_JNDD%(z*4o&RR*K$k?V~BUYII#by<* zXVBJ&If`(R;EMhk($IVb`3+}EV9)t(;FF91uBYOe2MLO)>ytDYJ#jjGkB8iSkcAsn zEyS%t;zo7j(e#6cIXY^UosmVk*q$;Y%iPb)YNPqxs)WlJ_eV}WE$DZhFHtuOS2x~_ z;8&ih6+4FEhB4X!Q0?mazF?%=<}-9cuQr3Sfv-eRE`1@*zxPq_#9r0V^6M*ZH1>vY z>aD*w`@>xMk|uAgjV7!z?vKeW%GeA2UW1)uhpF&QP`v%@&v9>MoKFLciKYr$iGf)cA?O|2nZYxtMhCv6@hn+x}bKhA>{llT-#k} zVU~^FgUdJ!T4v)X=8Re zk$)-?{}-zBPmwy6krkkTQHl}AzTk!PI8sC6tJO#|WPg|eLArB+`wf#c zxikDJuOsnP*V~^*3)nI+1*c=L9Kc;CqQ*LdtLe%t*i*&TydiZQr}4G`Lha!@ybF^%zkD$} zTE$VALun3pb&=SzU*LG%$YMTOd#m+C5!6FZPlXH?OkpV{;K48XRWfi1;ixfG&L6Ko zVYyn-7J~Z-;vJY9M`Sk*hCvl_1!QXP1urVMHD{$4880dhwc8$C2heXHe|*%xzQadP zwcQudL@0cgdER})q*TI#<+PR|W;)K*6@eEVQd8nkgQJIWsPHiB55{|=uH7#4J~`T+ z0I3kpa@()ODjBG3A8fnX7^CVE9{$`uf{h8OzGFIImTF~uA}3b83zNY6Vo$}?ZT}bF z0T!@0P(6O)_v%Kj8=k_Pfa}@aC5Mygt!BKY)4gS|@>WZ9p^8;zLu1>#kC|5f19(N` zt)B8mQIL^*@@8Ket!1U``Cy9{pu10k>20Ok89=T%`4E&2c4e8WG~TPiWqGz8FMk#l zwC<=3x^)NCBx+!5XAw7KVhds^)SAPS@jVeoE*fX%6k8V&tBi(2@SupEI<9!pN+C_8 z9Ue2E&uPTDKBffeQw6pp8%E{iK0Y`{a8O8c(|;$&;!mM4-*-KM2RveLl3YmdMG(=2 z+#kb8CrMHyJnvfzyHF`CKaS0dtaLP_ylmyMp~n01}B>psqSZnzt`K|ErZFU3FQGHjUN&adaD zmW?Io_xidV&N{F3-YrZ3Pom*-1R!7=i@7hwvo8@%r#6%`I@;49ntg4RF4>dxeTei! zc~Y!MKdbkh0fL$WeNld`A2s*Q{gwwdwJ#r-{BecmA@`g0h%-l^omS#b%)WTZ85|{~ zGvwd{jQsYlUzg7kFc33LP{UI)#2-?2o2h z|1S>)*Wm_=iU5Fc*smVf3KSov@j<@H_JHS`3?x3Jf041Oo9&xlY@Ci?kUr6FY={W9s$|Lrz}lIfmV~C8 z`io6m6}o8cae}f~v|ljlG%>*ePiZ6u6(!k0bb8|ZASA+g3$xmgHj4!w*KKcHMMp8cu!;R9C@CgpunUgo0>a*jRP6%AB?9M6Xf34y#qk2!iT zJhFAbzd?Vnp`*s^rfZ|>jf?I>5|8;MG+-BR!6K=B#}K#SoK41z*@vbIXE_ zO#|?`*xr|^(`%(+rWhv*#TmZ8f|#{LLmJ-vK@77g3Z>C;->>>yyEQPIFKDDJ%iRm$xEDe<-Q%3|?sr`^(Z4z)TnPtRV2Zw^ z{b@Lqg{|+H0X?__YKvY~gEiV;3|s${($Q@a*nRJ|K5_gO^~1t2+x(#7)myQ@5SUWk z3;Vj&`dr-BpJfp$5KSvwX3SK+ON4E6Tp_#hAm)D{di+SOici?elC&{6L9w21wur%_ z>?J6#PYsx(QV}ikfOX{o!^li07)EzMkC7)^qTH9sZdWr*yAyq1w|u?1P_siP0;68i*NL}`pt@CaAm#G4CFU`Ar-%dL&~gVpJtujVDM zUQ1@?8@HP+F|X%8N>vttE`kxIcn6f5oPDnieO|YQx>}Au8{*fvRBgAP_U-GwFW)2; zvY!F1!06+1bj_S?f8lc0mtTXH{z9!Bmf)+=MhtmU?Yk&Jfw0k)_FpLcN6~$We#m`~ z{S$vGJK;9}1Bf=x{lCERo2~k0=PbVK%N}`xQ{WK9XBb&TFd9gNae)vUfe?9OEbv2g z<4fjPzkM}!HyaV^t?eJ{%*K}G(}?=n{yjI7(b!q4`LhWsJ*|GTb58j0y3C6xHiMsU zDC>hw9t|a@HCzAokT9)Si&?d}5%$P^Sx2sqhmQ?KLjl%98dwjEMBJkL{uj@j5AC=n zb6#eu*Jul!eSesD-cgDzG6}QkJ5G?6Sdk6tk3iK=9C-p>?@|r>^(tTHqpbcl9~6ca z9mGJ7BpY1Lr87JC&n+kBcU?5mWgRLmp96IOsh!4UrdYtG&lY0*+=B3!h53)1iTx!p z@T=iG-ATJjyVoXSVi^+L11}qBRDCVqKmV$)#oQIyaiO#mp>nCA0(9qF**YQ$5}sC! z?j@nxImP0-{(vJX&Bu#sW%iB-EdgN>)MbH1NQ`gj6LJvxifhS0R`+C&jWMSo9$^%2 z0Wbc7#A`nL*G4s7TgTPglO&v^G#7ZW+Om%qk}UXsR@rR?_Q}!p^Z_q9y6%S?9;AXh zoUB|WIL~vI`RjJw4;ogm?>!Ml!^WcTo)CJH@FQeM@Q0Bkk&P5>Ot% zS;bobLzWmmTZvyid3_x(S$$(X`T%SGQuFHOrX_F|HHUmatZ|^eqt|tPY-ia&8`_XV zn>qmPSnhJ2lO9ZbRk6Fatm%xN18t$>j{+B=B+%nn__Cx4VyQ)bIg^XXOTxOu)qAcI zr!#uMfz-{MaeucaVd>4D++a#Spy)?xbX0=B@2I+*3bX=2&>d*eA$542!MnL}KwT33 zs$E{@5&Ete2;8;{8flag&@NhUqYuZSo{I9N*Ru1AJJ``b8R$P2__G8BSbgk5#0JC) zQ4I{ zZn?X6$KB>|$lJK3Lv7o#S2;s+bn+XvXf)r5gCwd)7bS4M*rPFR*kjRHOnvgFipUGc zFM0iH13n=J+{PU!+Gs(|!Fv>_lUt$aNL>>7s!f@d1gqlwM3(iO-3Ei$DpKCq%!{ZbnI>1T3jb=Rii+ z%lvL53IuS_4al4vXv05xt0jlg#uC!et2BXlOXuBN7G>VPIp@6jT^B-hR2N3T=YaCJeK=P6K&}Rb}WM*o{^`pF{`&$vHEsF*IO2p6ibS38r9{N_=_=$I+X<5DZ#*W=GM<`Z1HV< zGpK;>Jc54nU^yIbRW&g@OPCD17YlnCP_zM=kN?Z7&> zc$`=jTWc}soqYwuX<1WLefm|7^o=g;7U}??x6L}dA#EvW#CS8E6*5HFR}@k?4QQYb zvbTVj+ovWT_P9bp@J?(0K9{Fa7X_leU}wZ6w(5{DC1MVdBh2ek9wZsFZkHz|U=9&W zID8K|NfakM)mJipMrlq5t%6R`UI&b8HdLNRO|9<)0|DQGSnGu+_s$g_=3BM}7ZHsk zWQ#xxH0TyBX#govAz4^%JZDJbh|H!z2j;l}qmqEbqwBU;Ic=BJJ~8ybv>hQp_=}^j zdUNFs@Z&C_dq|4KA1wzvPA>tWNDnN4wn$5vRxyQi8&%|X=IUFox{}*~pNQTLBm@wo3H0!T zpULuEDm*MeStMp)o?ULB<6l(ddjbs3zq1cCME*L8Vnk0lh+NX0&E~-82GR?rSepl3 zPg^hoNo%^w!a=++7-tJxCND0&!ZAAY&7c7c`R9WGEwqyN5z5E60F#aRkHN`=JcN%M zKw5)ZZg!avB0Re$Q48VPf=8_Dpusq18!6*hxuvm98YS2D)%8y_2kjtF}ByW2FMR;Z0p|g?9 zRUwN%lT@L{Nqly+cdUGCyx&LwKYgBnt7got!Wi?d>eXLoFyopSVwia=;#EfbhL9!|4Izac9-XEMLHbbvCN1z0SN>=OSXi_g z>}<-EY%X>=NG279n6$*iVn1||VT$BpvoAp$XO0@!iuNto58f1MeRI)n1=U*XS;EMoAw$4=_=af9$VrxHV zcqS@8iT)mpsy{lcyPS~lJ@{u_zDsQg;h)6E_z2q&L!M{+Y&ikN3#O}mapaf&vEe)L zW(8RY0P!_&uoKdpyU&Ct`fZ2T>SvsV69_eH;g5xwt(kl%gR)v{}7KZWnj=R2=%klzeRQ^-#D2BkOiEC^t0Qj=lIQ61G?hw zfaV0|2zL!MfQAE%_iQNVyCfE~-lyVL`SFbQfN2}>_m7#G?d6Qr+`D@Mg>2AkOP@R7 zVNKs7@?PWCnHJwJn7Zf05?fheZQmD6y;D+sg;QJVJ#!D3k`o^Q!e5+x^;NY52H=Rs zxyNg!r_BQ4CMSRim|C~DSL&N+pH>`u%v@;iUKw9%52C?MgU+k%7hJ}&c(WF!?{|Lf z8EMQn1A3zal<;v*7^pZKY&xcdbckqB@Q(yG8A1d4dLcCgSe?_ip{BD{PQLd&>_Y*w z6Z7|TLlUQUw|>NQ;Ma2$p($PKi=zv@cMU~%kq-jQW}sOk%oDD#Gtc?03;%gXn;rY; zPbol~0O@DD_H8End%M39np1c?CFU&_Dg#bjKFiXGUtI+JF#H89O4SGg=#^h|Ppe*! zhPEZX`n+byN2|DB4V46}TzW+>y*|^@lL}*PS&*1tJ1Y(iY!msU8Yc*`ey37s(*uoS zet4aBSwKk*vbu^whU>()c&AND#sid#rUO&YyFBN0>o{_*@wtA?Oo7)OjNF3lUZb5c z#&aZLO(Gf%{P~<*T7D#@F`)$dCy?{CG(i!1NU<^_j#9T>o98%M6(TkAicm=s$sakd)E)>;tU4w^)NFf;E`6`;Pu%WkNsDD`LxJD`KGaXGdHZ z6_)qJKCfK$`D{LORPu-Hbuf-ObOaF_OW%SsLe!20B^G!8GMo>zV8&50`Y)I6H>_2m{iy9PWEm@Vhsg7w9%n4^Yo zLzK_fTWAU6v{WANxRc7$==25lp)&MfONVSr-O5B5$-ESsu$ouPItI6rx9~Fqwx%p_ z7g9<(va{=qb;U333BPkaW~Qw#kt8>YSo#ZnL+Dq+poGpr$SA@o6=_w8u{f}G)Zn#V zVM4mq`E5veZ*@`cv9>JF1MYB=w1^9a(1^YwWH=#K^-`W!oL%yAScGUgd&=j?gQWs~ zXUZ22iImmyh2d()?a^PUBX(aT8fe#v;~Um1i8&O!zW+Dv3T@au=BpzS5F7q2aO^#T zZdHgMQGW?LiCi{k_P}()dx3C)jf{YISN;gzIi5ctSJRqhXJWl(?^MFYVtS}Tf0_7( z2r=ABC_Ct&i%^)&P1^escu~A0)Eu?nEaDbOnc$tkoeMt{=k>lZs}wRKNEa)_WCmyn zFbI__l;|~7bW5a7uEH=%0FY@^U}n z>VcRQJ;7HrVnF*H*l}B4Ig5#*y?(1D3ocaSUAyn^1YUAk@Q+DpRQ2GhLTB38`Aj&6 zryBqI3^BUZ{!zR~uX@^9=-oBDO&!ZXR){MqJ#Bcw^R?T)Il`CJzPrquXtS;~(R(WV zHPxdY(&KE{5Zo(Ow(LsOEj=7`t1k zGOk&q+8h?hyYr6KXQ}=*c-d%BikUf!<0hGRkq=t8)NGJP3^74Qg>(xt{Vh6H&pe!u zFOOqjuaa|&*L;qtjMq&m&h}_xsY?v-PxswRAGc>r5V8mZ)A_WI$cxC5c6e z^6c4Qs%?HZ&N>WvX1`xuJXk^;Lm)XgmQ;w_CEL z$<6Y)jVC-|gd&F=ekJdq-C9GSjl$X2n)vk7(!FP4521!geNS-H`wBkOZOoRDpYi{z z{MY)!%eWP;!sn=2Yu-zl)2C#|!pKbmJAc0v(4BDF(T=xQbvlmnB>Hqwrvr1_U|vyd zpATcO;)qQNh6hqIpJ0dx9^^!~!MhI~Y9 zl=e1%Op&jlKtzI+VrTV7sb131@WT9{p8NGR8Nt9;b*ay9wHS{ds(eRwl9Iqpe_oJA zsg%(3R%n4q#GCrwNY6etRsS6Y3Mtoq=4M-g5G1Box`7BW`z^r|TwHtA5K?{1uYH#3u4loYi# z?&RNN3X6WXWZ0bm?O;^u?s@tZ!sp1ev$c=55!lQ9Za)We8?4O-tpvcwOh*S26O3XVMWF%kcN~ z4cV*=J`I!7KrV2~A)7f?oA`0r((@8jS0;Q});@M8RN^qx&*!&OO;Vq_l!+hGWC$$? z$VZMQ5O!GfVRSugh%hH*=qytr3O^w43U@SFpl~>Jr(ENb0HGzN4U@zX-{4MWEZq8R z(5Yn#t!MrBvzo-{WlH^hx3Q}PtciRhXcO|KF{X{+9~ru#*}^xbDbt%cPpcELm!Fg`#bIDxFeF=%Dk5Q3 z)2Hi(*d@1TTZPE*D`{-dQ|W6sBUT-?h?43^(Zn4}e6%jladSp%P<-wO1wjV7o+?R4-_hsJ{rmaKp0ADHmSChY_ZhYQ^@bW;-Cw$!gB2yg1W+w*vu$i0dBNgm91!l zS$QW9O;oamcMzgcu4FCYAX2%cV!lrA+{m6*8exT^##k!aB%)J2L*nE9mz)enm+h4m^T<-tNm#+h70NI_A;>V;edPz-H9lbA-*XPtgePK#Hn^J66&%( zB3gGO0t!gDZbw9auwF7}9QgXY3T^zcf19zt30lMsOPBX~>Jqpu`;nw!hWlS0sHgO6~xLr!(m^W4a1IexYzjl{K35y^u`ps1l(C&6Ri^bX#`H_9ZqOa z_Y(;BUyNBL7B{&nIS=IB+KVl+b7^-7{>A^r3Ta1rqQaW11_{Nx)WqN6h$3?(m||Z; zB3?nSPw@d*&CBx}8$Y~$<+adyh1gUuB?iFt(e8}($;}UOSD~#r-!>EUhO^1@cd2JK zRRb{;83F7PrTF!4wH`-YF~{IM$6p8sVTeP4HzWYikx)9I4qC_$tP*wu7_qzN^d_!bc!MSij5}+ly zZ~>A8Z&-WVuh3EnNp2@Ne|fwM6PXH1HFL^7{P$Htzi@PM5bAX4!tEx9qQV!+!kpzy z0|mOdPn=108IX+8yyX==$!;~$9Mzpmmw~F4F6(bv{fmDDs96nF2o7cyRRwkDgg7lQ zR$mLWC|A_iQzUT*)t&1|e(TT{ywR)-!WLqW z!g>s~Ljrd7vAP{n%#HKO;rU_go4kjSp1#!OmuAi93knaTWRne(DkHg5r0Q%eYp{N1$H&Bma%L47mf_8-Vki`D0k2;*ce|Q*BEGQHw z?Jd3kNz<~XBg?wLj*LQVRrUOK3k*a}N0XM{;Og0vc-jjHt%>&?;)nFlA-HkJu{m z@94Wv;=S34FHj84i1o{VG>53ho;}6XLpO{S@q&Jn3f&y|@m#(t?TYDZph-5NZ_ZB0 zaS?q0JCucdpyiN!*@=&!9PXIyxaQTN>UmQ+coT5Z06Xp(xZ>y1dikr@`V_Bj?CC0u zfjQb^8>5&4Os~I>OBfBN>yb5ffEC?`^mIEgQ?Uh9K>9GD0K-21qmKer4_i zb2^r@9qy^wNN2R<{=hD}_QQ1H^{kQgGf(Q@>h_{AK~2Z|CyLQaksZ#!jyW@>fdxt59LJE7ZOW))-Gb@F+D z(fojV{iR{!*#{h;Y55{Ten8VqxCLj7_n*~s<$Ac$wEou$O9RXz;HJ{Zs>DZv<4x&h zJ&GX{nN$xeZ8SUaecyd&O8zSO1fWniftR{2J85V_1IG_90xmwr7+>j^AI`DjNLZDa z>CZF$Gbl}h5cZx*;LJ~4p{8?COUea*?iqJ`$OpSNj00KkWVD4Q?BOoxjpgQTsFcG z?y-hxMS+mdfB+&cCnCqGVK*v8BFmHfP9-@w84*x%Ik(*fpyF4PEe$mp5&mueYSVND z6>eM|3jda4u~_rr8q0%?PToXvAh+}snaJre7eUv@=qdKd*DBTO*bx?+8~6*{3ntHc z?z5w}Cmk{L^k&jd`#-t7@n#&$wKTbDUkiGlVPk;KdW)ReBV-}|EmQoPzv29ufg{EH zXP(-Z?nCoyGuGE!-c9}RnTsVhrw07t)H6CzkK!NEC5xdATpk0M$Vl<-w9!=w3BrX< zhGZz}4Fsn%Kx5%{2VZJN9BUP>J|`*1b(#v(6h;`J1@DCKEsO!sqVmi@g}S~=jGWPY z@S5~zwd#$fPs93-?=_3}H-nTL=XL}2R%Jocb;y9(^8Klmf7jtZir!rajdwh02ql@X zkVqLqKXY_G7W;hi*x>a!sY7vZR?X{`v(%u2+%xYk^pEAFL+Y_-ruNg6R z5{gM(^I9<`_u6+tfAkq(rPjGg?ajY5$g%>eEP279Pu68;^5pKM0Iq zS45Rbk~z~1FAVzHGFbuxMW(>!7tV|`+c32woCw^7 zr%{`@wV$&K?AnDemkIl|Bx%a(?^jg6b97#H6%bD4o&EkW{+#i#4xf6ics#x=`fP$1 zZWrD~yCbxX!NNxPA=BRWm*AyMmEK-bp}7#1AhhWjSH zP;YM^TaD*-0=z2;-a>tKa_E8%Ud_J^Dxasf5T9_4a2L1z%01UN;Te%JE=?B15KC{- zJGbJOUiW+2`9?eLuw@I9X}sTWxFwbOqW6?x)#G}k*T1Et9s^4zz$b97qb2d-$M6r) zWV*b2U}|WOofd`ocSD+N5&rQ8!2>m?k$$WEBw_qI_M5b@P&F0yP)MhK;9r(&X|u2{ zqdemT$A+!5{C~&3hVyd$As0Q>pIeTx&%sP=36<4+jiZmN(%GY<)0;tBudUP=>*j_q?L^H`?>uy10Qu7n!*w>eaVAh%~MZ4+3Uaryb!u z1DC(b&x>E<2*!+fMcjNdl>A*KKmYO@1y1Cq-@l6+jOWiVFii^wyPBdj)+b012n{L(LIU}pe+*@zPVUxD?xtEk&em?m+}@53{}X`| zKjyPl(C#TR1cLJ)?fn5-Q&(#THy&=pzyGu0qQBQvB52S6ehB}g;Rk@q3TpY>73%E9 zWA5zyzr9wO6S*B7yr2sF5dBAMJCy&YwI$Tm`hRQg{B4TW8#IdoKcxTByc{sX+kwZ; z*4)+F>V>rp2^P%XFaW3iu)T zkEUrDw@tmEuJ#sCsQv%;-j`eXpT|KX0l=ht|Izpe^S1FF%l}^#|110dU!|b@4?INJ j|4oFOt+lng8(;1zru@4p}kq-aE=x?WpY+gR)V zv21p2HjtLW^Y0(>ANX+j!FCT65x`=6;-_PlW~@Xi!sCE8Vm&`6CTPrQ5vjPNV{G36CR2iK^7O zG+FBYJjyq2qFuv#ZJRpNY+{FKPm^k_Hc2yaxkmK6nh9!xNii6RG2XrttSvFkNLG=h zx-k7B@gT>;(d4V07EEXER+I}39dVaZPvGeuc;X;QDE209Ru1m$Z2z9Cl6n>4II$y4=qEaX zjtDq*Yca^3(F;gK$*bU6pt8IyxT~`_rrANVcaMX6>y2~NOFUAcQH-i z?lpL8IDT`$=FY_jM!2cWlWp|sk#o-^#i@$d`DPrX>J`PevKRIyIO5CNCu??NnL!d&8_Tiy@_awy4t2yR zmrv+~J2jy@c}`squF`*;Ln(oIb$qIYI^5K z4zF^h47CdPo(Fr5gXVh_pDgW6{0Uw^tXWNp1!HajdLF2o&-4?hN zxtNM0^c}g#=-iLzTG;ICH%yjMMT(bNjd`9D%{mv?q90_C3ySoEWXb6u!eHP@rF9=H z7L_`FtxJ7f(#3vTYnL6Mb=1z7p;5VBMF}m5LKvefi&vvaa>|A(XK4@t~EDr}gG zuFx|un=i*u${*8Rv|HHl>Tks?DF}Nv2m7vE$;3y_8w-)&!v_#QharACo5S_yz4R4} z)6FRBXVOSjimeDS=E3wUddhnW8w{@D-NGL9`K}X@5)JYx!*x8@(@8NJVcU(i-?*&2 zLny*P7kGj06bad-dxgOpy07T}Rs9(M@6J7Z9IXD^a;KJxGmwL*>q1v=shXAUYf&|v zP&w{A=4weMkKI~tFJk2b+-hmq>tkoLf?|bbxtkv5-#b!q$_^1XFMjzDip)Br3Nm&! z%^w-Rcn*GzUfrwsxQ1PP2V{B{nPRb8V8TkQlC?~EwkViaq$!xQdk*72YksAT4y&@m zT_=|Pc}K;ZWR+EotI*o_snl0r(MG+*@4&5NqeacAOQW{Fy^m=Q{B_Lj`R3)5Z))K4 zCuW11W!rE{d*>1v8HOC0Jh8ofs>wTrEMyf1-A_7S?;Id-aj`TFs=pJF^KUiZNtAr! zi~2Z*h^WXfnI})63dZYgiFmSBp(C_#U=N^0cNAi5n`8Jbm-<&^FdQ9rFDD*H!$mpsxTs?aMelKP-6Atk^Q$tjvBWmTPY5@p zMPt-Yq>KO16J?FbB+36GDC~NbO zU*|kOeJjsV77ROiC}ey6kNuFw=tS$-EMXhS%HaOb_v^_w zb6L3c>Zm`I9l!AaamCUbKsFg#{DZyi=WA=MFL~o7qZfBCm>L=e%Vf@vgjClv%(>VXQ^xdcZI|;+XMV zBrb_oZm{krlZPaa%b+1+uF9~DdE90C;?8&zBGt^uWa0&_zQXR|7S}d>`qs8qB(Go7 zMH8RH3slr-F``>m09Ao%6-8XWjadrsM^resNi1|q9b)Y{srG*Aph{k;hOXmi9l^AW zeoZ|B?if@GaesOFyheqoCL@A@xHs zL^u`gutL+KQ)!#++Ba`sgu&3>9c(z_j3~2C11CEPW|NisXl*lizU@zQz$FLK*b!}I z{ISwl9~tK9jpOh?QRK&;zI6Zg9}gDPbj%LvaK-p3dKfnV<2SMIm83+Xi(sUqS@>pa zvHmA*v*?A4d4wF4+bg*hufH)c!ZWk?v8z1jI4|h#C?ozXdf&iU_U3mIWiPMnbaiL@ ze>`P#TKIDjdUT%uHR=-m|90nYYh~r(4kcUY!uihtH#)&y>+)$AKH{n&shv8i%Oo+f z{_h0tT+=jO z+%@IvlgVqm_)GKZYx|Q{+S9=E(;Z}5+<)yt{Hl@wJO1n0 zarq%YqZ9HpdANLnRi+#C+H15K`0(1%!Nz`H@^BOAXQ*>Boc6rBqp|6bTyfoh{m1vs z>tO8;|Lv{0eJ$wm28*leaqrrzWozTv z{YCd2ZL{3FXczFI)HT&sE3`N%RxwHImpXHjBL4>!4XfA>wB^^bsmWTOiayAHNNeuT zp7Q`4yXH|E`TkymH_Jg+r)cN?@|FekZ|X9x8ozm2g0ZnmdFmEfHQFS(JWF04 z2VSej-!s@QUjDsiZ+ez%c^=rF;9z{X`j{{3`gJSd1-)|@ujS+b(!PO1_F1Gsv zwQSv73->M)h%-PUco_oY+zcFdYat~`=B6vSZ_zcG^lSZc(V}M4CAt6cQj}f9__pAz zPI6dO;xF`{8dqFqjojS-@3`vQYo>#-01@FyjX8Cmb%Vgwgdi`_# zv&JO5bvh6@+)^?8=F-&Gp;smDK;cfGvWwt1K~dIptFG}Dl;%20j3=I#o#}%k?0bEC zR8-Vrt#M;zH#GF)YVy3j%?BW-%%D0p9$scd_jWrtG4ra1^w6J20kyQeu4j6V73j-j zu388zCw!Xf__=4BQlLQ~Yr&bI>-d(VE<>aV>+*QKRcZt_E*K{_{nQQA5s~nl0Mi3` zK(-jII(>bSfmwAbE*UU>e`u}z8auYhs&3)O8T*+Vyrjt$Neu9L?*_PYOEAP4 z1e)NrJi>*4-TyuzGqK@NaZt3s?_4rE({gaMe!pBXE;o8J=MORn3P^eO0KK+uWNl?b z(w7h40*z~aO^>xbym~jag%Cl(_+~h}mlt!pn|n(GAx}Z;)jCvo{4@W|WQ7>9{(WeU z@*LAM{@`6(#nQN?QUzU>xbxZ8eTWa{*W;>~P} zkn*q?J9`jscIVH(zQr2l+-9a;DW!x*HF19j*%^*&P9D|{tOI-kK%^Ncswtl^9GXmh z5<|$Ufxcv30K@^amcrb4=?RR{#x|I!kNA03nQ2D0)`7k~?_pd%exhs@^MQvWR1egz zuCADV-S4*sis)w+m~?hmT@NN)9~^hnP3y>B*TtAebwLOp>N;Lq+dJ!4pBz9&CTW<6 z-K$1Gl#!zS^PxuFTd}teBgu!Sh-_-Kme3w^pJ{XAJGL>)4~@#BENP>slj*Z8%?qLg z!GlR!)&8lZNi>eiy}+U80|Ukfh%eOu;3DRvC7lp+S416xNlPBfM+K=*Wr zyWQ}4K9dU&&UK-6D+VxDgqcpwkGIKN2)+8j6mYcx6le(&**0nBsXkAH@Ba3f*e zKz&!cC|aw%VW(O;A?N=Yv6-TdZCC9+xGMWaC!m}2e!{xN_yrYby~+!3y=pM}d;r`x+v?uup9y>SDiE&4e>EV#1hkJZ*0$p2OwN!Hvt`QODi^5~@pHWt#nJ6yI{C{He zM}7W@4W5F)=6vdGX=KTm;(0&AqGG&JJzVXzazc^ckg$l^vNCDYLU6?Gwu31KN;R$^ z@1vZ-qgQVz?A8C(22Ut_Qc95z4uFLvQ6fUkmriodh4tsV*~y$jP5hcV%5$+J2zP13 z{OJ8hft6?)DmnL`KbWK&#M&H@veSCpr+z8OlIy1Pyv(p={ZA}sHF+AxHzIF$Q2 zut}|)5r9_DmUbOv**1EuTjtUy&%49CJVo=E+zl@6-DAnDuM5hDEdfXp%0ulVR%}e&^f|@g%t8T7*Wy2~clM zkZphG@zYd6y4OPuaf;LvYr%(eUW!x)$d2lB!Tft%wva`Ea>4ikA(goyqUK08?UBsyW)Y^m0xbI}kP}=EEytCqoiF2hq(8pW8pvr@}=o z@rj(PBR4iE3sttuZ31NtJM7gi1}K7JMOVZyW#UZNhRc5sG{ytJ!pu9BZyCq=Dh6a_ zw;nCv9jJdr+Bd>-XsiG}HkKM9;EdMF(X*@{qVpjhHn3ROsb7F+0{Hr;dN!GtE_)a8-# zDi-;@S~IsYfO+m_&mhRylTOialaix+&igz(XeK;Q`*Sc^ICgYAAQLNGo@95c5P2qB zhyaSd5uVu-s{RXGH z>>|^l&;hP7#5U_OrSu7P_LiCz056C}Y|A=vr|iBNWIrOIYvv@*cdJ+jYZ}C8LVewy zOqC5`k)gv62XuU6speI7r$(D9M3Pn`ZCZ6EF{?}>(RRugpLz!@j^SHIYOmL-TVsMhT3}e zWMt0WQ_6Lt8v1vhD8(gla%pgkUf{UE|`N?Fo5B*N*!F3`d z^-(`N^&ohClWqWbuJJ?{XVs)%@MFlnswn_+nHV!)w3tl~INB_cVyk2-G}p@EeTXD;jf}?;A#+JQ0%*FPwEiCx$+r zp*$}c3|ndep`cE=-$IH}O*lAyl|_HMe9M$1Y(aY+JX;~jlac$^^KM_XVfCt#U&`v+ z>rYEfVSTIT*KNwE78n(~o-BX@-Ws0k3z0%#*l2k&&Fg%bZ0?aOZ-L%urByBD-?U_I zB2tV3)ai#Z-oZz8F@S{Kt*sMz)dU0@YPD>@M4U*q0_(U>F4q?C1?=tE{+XLnro}64hD1n9e4U>-U`L6%c*BJ8$cwu3;$;Ua14`mh_7CgED z3^Qw)g=pkfDC~i^fu29kAp+Rzu8nzJh<0M??Vi?~+juk0<*M%Osko;dy$U{hCzFEv zKoR9JeI5MFsrRRKzMBW8!eA=hzg0&vspP`|{wBuK>X;mGvZEQ(xUWobfVWBV$ zMj=S}51j|2&E&g8wcnd{w%4r@LiCMeomeXr5^iF@`r1u?ih;qU%pTPgyPGlt6fXAx zp6C#WfCWVuLs<=b9025|>zJiLl3WJ+Oq+0tcd-5P>PFw2j0h|h+c_@%EVHZUjWRYY z7)h2LS#_jXY}&?&`5;gbdo+?Ns86xIC!_!R(wTMptOtdAT-aEJV%ZGfO_qu{wQz&u zhZi7yrw`f5cb{62_Ro%5fjjJ~iR;}UKUzGrzbokVa?^&ewNy+;Zh@OSTryZx zDa-7=rN?FTmvugBDj&Ek{%J3d_h?7KSE0k5>#uj4qPF?DaI73dbFjKocCmPrz}+~f zr$%{!K3FWN_Vya6=DWs%je>AOF3uEh#Hglpb7B_58u}@$o%|P;C)Rxq-U)RH6HXn{ zLVyW*Si3N0S4u8AIXoMnxj(+|DIYtzP z)nnkno6||Z8y_!1)Mt(iCPUz-EG>MJP2PE)J8|^iQyM%E@|1`anP<-&FdZe@vr(DW zpUfbw_84VB=;%lrB}lP%W*nPezRM4TloETA{c&f&B~jtm3Nx z=+3zX(xy&bRI$X!-yH;kN*go}}T`pV#<%RgCV%UVY*F#O;F{rX(uL~{2-n*U$394#; z&`=%eUT0$u`cfs%P$ui}=&|Mf{kL3>pX|xb7kC3zoKDhMBgE=qp5&Ot9 zuUOJE3;WI^{oNwC_N#k7aI?xL3YwD6*Z4xy95qOW?5F+Es6|?q3r!cvlzPr-6;ax| zf-`l<49WraG!u=NB(XctS8A1fh;Z!A{Bh@uQD$LOkem2uIfNci@xtX($0?2C#3Q$loB=i`%-|F*XUqVbecsH;1=Mv2D6ow? zHgJgPdG$S{+&yTGE;*3tN{y3kY8vz3p{TTk7ZS_Rc&G_YA=sk4UsZnZ6DW{Am@5>P zrew#>rv50xyd8@ z#v;;m$=I2Y8fdmj19(oQsor6=5xHlFg>_FE_T99RJHaEqdjE(mIA9tb^+jf=GBa1k zE0P-T;c_2K=1RtHNo1Y-#=2l9z{gXQa?rzso`#z33q0elQSj1OWk$L3c;lfv<#c`v z7hLXh?7hyM-yf*TLv7lva1+%oH|mtXw;nbr*QO9ks=lIY9Up1=$e!%2I_mklg4Tn+ zuqWTtoMJTUpTp16I(Wr=aTuyh%XRRIgkA9utuhG)9+xWCSz8s#d!jBm+5#VKOP^?Q zP;e&A6a)wp#5E39l@B_$1=H=8#A6gC{){M^yZUs9CjDpXxNP%Z;-L(G5O=CRz?(D5 zqKj}3M#GrbYW7PHBjl=-4`2hu%C5j_Mv?V$X_(A~SWU1TM_U1iE-;9p0j|g0q-?D6 zkDe0)Ppf3L#(fvgpKw#I>=+Z9I%VqoV&b zPR$OEkCJEFKmUvK$ud%x!J|5qkI7whSA=O=KHxgyq2)8SXz1qbXBnB}SYvk5!ewKD zZ)e|tOru%6C~TRBmk*Utr29Nbsj~!&1zq!F)grqIvvxw>*jD3OhdLN$g=q8$4o5s6B8{Rm z2dH1I2You4ajen{0Q~UXsE>3DQzd|G{v|LfJZi7jE%{yj6AH9m!A)sYDYQ*{F;7(g zq>URhw09nOYb**irI`$;eQ7#)lJU4iRoUvj;S{!x3VBS<#?@+qb}2KtlUcoXM**T( zoHpQ4)QY5q%(0RM9lF)GciCjBsrvWyYfa%;M!$f*JhGc&G8QsYMXq{~N&5Y5;S}ei z%9rC=Jt<7FpMk=E#K?I{?@x$nGDC-MD~zF8LaZ>R81b@^_Wp-yBD6wIQdgGR~7kR8p;Y1Fb$}=#bF3L(?;E za9^Z+#ByAiyAvCAzp?TD;&ojmn%LpXodt^EA2-u}Qa7K^xbx(GP|o;o370b8q;@sJ zOP!FhXP^nBLo79ppc;=qP#;@MHF;~}q&LVLF*_i`5e(g%af_1=?sbBlRd&DPP23*6 ze(46u=R75qDfS);<}Q7Ie@WW~%^2+306o$c=h3LITiHZC*T=^PFWvk+L+$GpXijI6v@C~k5^9l zF`0%beQXpGky2Vd?cA=5ohXnd7pmdLMy*OUE#rAec0rj(P0eq57tg934}hC{g8ZW_ zyLM7&ZGi*q3OClO!QKTLE0;P+fkTBKi3S(7RQOPWc)72Ht6FO;j8k;iR86r_tW@-5N^nV1N+dLD zC2YPR~9`+iF4`m}MMlT)JM*_xs z53u2&Rflb^RhZw~TpC<)^9E9nSEhu5)=$^HJ( zvLHAxN*VDxACT5VLl51!T||rRP6|km-y?%w=k z*t4|TLn4t(t)uVZ$hS)c3BlVsBiDCYZObW;Defs#6QB8oVP0@&6ay~GatH$Q``TOxZ~bp6fB^!6$(NO^yMSDYh=x|^=Csvz>$8tN zLm#@^j#jCiWM$4mPNSS;=?Gj^KrM_iwf*gUaJmYmiv8ACSwtqCnw#C{-6X$%Br0We{SWo;5-@m@AxWF=%x_*g1 z<%2I6@EmvDZNCc~pkL32I^@-WV=j8%L=IC~yXiLqCa5>N9}h{%?3y~MEls}Pr;*7( zYeSYij051z{rAg#M(r_B*2q|Q#rd@|#9DRz3>e+uD5Iho&OBXu;!HoY^No-RyfbIj|b|I8x#VixUmkW@apb;0Jr7Us~_mogHg5f`d#0=%7v5 z4Eslj`*Y+WQQ@H*akOfKP3Cs2K4UN+m+s}*bmlSq7><_qCOl7HGL-n3puzbf?V@Jf z@`k!?qw@X|pHOcMK~h+qhPR?os{WmkDl~!0FY$ZCj)rSAE9cWqC|9-iE!9dRsF&wn z74OxDEfvcl__Jhrwq{gZ0(^uj^uGn=TO+w<-uJK7V?NsJNCK(bPsvODLI-qJhVjWu zRrj>4t8TaGi5rQ320pF5N`9iUV^l2mI?Yr=^*ZKN37DJv;tMUtt<`D)KaP}@VenOy zybomhGS_myFD?Das!aVVfNTgXR!*ZlrGo?7+U_ zb4gXw)7T14aV~)R*LdK;pAW%JcqJN0KQGm#R5bINJV4|$uC;u%)_L!~{#mSa{4yJ` z^e#e}y8?la;RpZ5{~JvW+IKJ$)%4amH_BTf49vtwGqkZ{463h>x4(b?JyFs=GS^*# z&X%p}fRbOUIyQjD-5Z|M1nJpBFK z9+Q2Gg@t_@ciQ{HpTA)KkT0TM?`V^t zUG4>VXWWjvc?SG-(m6OuPE`n7d|J2vYzouW#(TfCyzk$=0l|ocHk~Iad*TuH#R4wv zV5D*&ozR@^=V{#i=ixii%%{QxvBA<;r~GR0CNb7eS{!6GIT{~H@@P(q6Z!2H)jYDi z4!_6!UCOtet@NO0f~dR?sfKaD=*rNIWk*e{EBQBxsNo?$?5kb{;pGIY=@~GU@uJwN z)-6sA^|W!xF)hWoB+@RY9nXLTfc3lgqxV1RyCToajXO=9llqNrAQR5Hu|ga-7ixXe zvj7dQ@_<46^_??=g@1=r2>&Wa!U&w&fX>_U9j{cdSY((?&zpVa?9{&JxWsX zV8vb#xzM2bFMm5M!ZAA1pVk`ucY=!dOJ)H|*Gu1Q){Lb82#wxkPDCnZ*^U_NDzG%i zwJe)y5E`1~zA9ZiSkX~p=<7al3ASyXQSHqVUw@!5EqOYI?y|B2ZmCtav=IBdRT8Ss z&^qxMQSI7^m>!scFz>-R$_5k1&t-9Vgr`Tl<+jW(U&rYH9O$Dbs%q?5ed1fWXwEI7 znZx9|_O9Ynspd@Q2G1Re5}?PdQ<>Jmc5IS&|Hnrnpk1kc?yr+FEWHt8=*D{D07GUP zCOysEt8f;6c!t<*QOkI8Y+$lTd8U!`jJ?Jv-y^0(&YE3Xtb);-=2|=}Npn50T=n|F zE^oSLq(sIkfgi^*dC#a(%ff^OY5EP=$g9biymtI%*`^!48bdjSA3z$+op=c67gkX! z<_f+bp<|mH=GjHG+2}x--QqTyC_c1f!xRtLM}=ui9gwP46~mw+Oq9)>1UM+c`FkpL9yV^n+H2B( zw%Hx)(Ikf^nP$fk{FUi;;TS4yZ4v%1ciDX7Rzp}%Dv#mcezbsuxjw& z+OUDqpr@WV_ula^+S6zX5jp6Z-p&dXTMJ-guP_u56!o!gKZj1kutG-(AOa~O>kiH* z2cf*Khoq0V0lpwGr}4Z+u|4@tBANN@wJ%+y5k|?A#35)8=wh86r;(N&Pz_PS8#VHJ z@!r2Zx(UA`6z`_U)>BOZO(yfEp0Gro3NNYzoXx8Mpm(8{ZKIs8BR_^^IPu!7$ts_U zskx2m>uSX}e?%&XQVj4G4^s?K1CXYC+F_x*C9uW0eLT`MWBEbbSmbak_$J%4<ZCgy+a^ArIXf$!Zpgrm7*=nbc*%>H9n92tz#{yeT^-MTOCq2y&98eg8446 zu()%bd{`S%6vF}d7+eN?!A8Nk>{Sq2HZ|);y(FG?*BLn}Q}wQ`r-v{^+Bvfsp^j&0W<@9^qfV-t%qidS3h1;WfF-IJTa)zm`B|K;aC0OelLohu*ladwqnK6J8QH z`S3(4nk8+x&M6gAF_#ey$}i60T9pNHXM0;>(<^3a=05JD6+Dt%u(BMihzXei50{U2JD3> z=Q=R@OVXF@yj;p{laQx}WPax_>v@^Pagq_LDQSRw9aN)W==RXdo(SvA$Twfl2p(CQ zr7>k0R+UT64M3eMn2YF@JOtIlhD4m@;?-Aop8F9!Au9ZA&}6$-c<2-P@>9ti4c=Ul zMn0Cw@sqqQ>{AbBGZPIC(?Xo7`apGryd$8Iq7ta@6~F>+-@pt7GCqx~B5qpSBJPN) zf9DHl`{m|?9u5F6MDl}kqhcW(9bxCuB=wALy*7%#kezRQ-H&Gx8_{Gx@4p-6B!hP# zGR|I+k9fy$T@rNgUN+=G<^;6{N)_W3uAJQ<>MkFe=0u!P39D4EY?z+-vJ&o!7r>zVKu0(9IsFPsS@*U0ek4J9+g zwW=;H(x{mL+BCLzAaLUI|0l5P1`=bL@jJUMN=!X&Q#^j*xJN-HvQ%sq42HucC*IpB zZ!!GcU{BL?9_Gt1@%G_g`@3I;L?P%tzj^1pONg-p$4=RsmLCbz`8xPtRNExKw<2h> zH)>kdiQlAt4cIwvHtm_~nzxTw zVqS=p10Uhbp1A5}$&95@R7QOe4LR|!r@Lp1pD{=S_dbqr?n;6F?*|G{k z;~X{f);x;n`6~MtFefK{5Pd(;14mhoPSoZT?+Y*tKETFfx_N%Km21%2ox$YQo;|qr)W0&sYZNwC)hd|T z9-g)*MLAmE(S4s^(;{3bdeYGN3 zZ7Fp#E2ZbGtx6&s=e>g0H|P;-2EQ`actUJ973q>FTZ()?CfcS5Hn(n%{TNhx$triN z7o0KVataKw34r#n)#f`>qQYC7$+OFD(7E(b(e^JKu`0rL^AYjvFv*PKF|by8Z6618A?ly3=d81aL7O;B)y5YbfJtF zY~pRqV%o-DYLh$PF+4Tncjav)@a5=uzDFLNh(w;HA$CEq|FqPB z-8=6*dWP81Q?)$$fF7u2^nKmj@ibCh-|5Kn@EDC`Gxl_|uElq4TSr|v@^lGNpnHd~ zhU1X7vWQ)vQm-$hKgr(8C(YT|C918snWvk?{1<(ty?olfeG->+(o6@5Fn@wt?qG)r zFLgPW%rSG^%07o9i?OR_n_a z!-+y@kx7H1YPnOmuc#4+wb(l@+wu;(lOUlP z^3164za88giJ8)I6Ux@y`i*&{OT&nkBb9VZ!$aQEr6z&GVrWud(rydBP~nc*NDfGgN~s16L=_R z`xq5vKZNUUJT+{uj`=J3b*`psb3T^7%eo$JSK4IssFlQvzHEN>_UqhmZZ?r*01Zwn z!POn`%A2=bSEEV%q;Y;cu4s@OozF{71~^}Ip;B&R8S0p1U~T1_C`s z<{&11!xstrAq1tOT#tBq8rRAOcs~~R5sS{$MWA;5?!X)Rh4b`M zqx11ds}EQ~FeoG^KZ~(0pdk}^%~k8r^~GLjykz1S{@|0a0=>hY*XR>GhL;iz4t8k! zAX{jAs#7S9^ICj9V*cf=d*MVm^JuY-AW}LFG{u%U{wxQLB7uk?O81eMpBiGx<&|Cn zS%QGKj&m|M2_0OtUwh;UQ9Lle3IgRG6aIy*U*z2u6w8KbnUtyO`R&#D8Q1#?K7yg; za3^9KVKFjLsl`yK#ZalmP^naRg>qVWzYMJOmZn|C?zHP45*)_I&(G~mSj~bRa+pHw zgWYnYMZ&%lH>w0Q&rL$-Z#V@p*lshV#bhSkxdq=J_w3_eQ`>JxiSD0dlihJm#qHSs zJWUYmfZi>(ZD(D{30%Qn79I1sAB6X8ag1tlqPGvBO-L7fbs@p;opu-H%zwdwzdG7% zEPExS73LTE8Ltni{b`cS{1I)IJA%=JdBwPguC>a$EDo(;iD950=^phl(vZiivT%G? zeY|9Y9yyO3WP-D-o9a$IagWI*rhQ%MFK+JYApst?`Dt+iA050s&+4@^U*)lf=QIEM zwJ4w3`PYCQRe6bGuYmzn!+9Rk6f~}v+$#yX5)mR_qB05eb1Aw8@5}NKEJrHn2*ig; zud(f5#HG&xw>wa?M-}&p%uDS2{LNhXy;dMsVg?JT@Jr)jKw$eM2c)w*ib%4|@Jy=A z@K}~{ckP2SA0cCqiVovNT(T8mCKVIoSi(?lHcFNI-@noA$xbDt$xf`#FMi82Zf)%BQ_fo#f5z{+*4{tayL(R0 z1#MHwLI+w8>xA$$+%HGQO3UNb+j&{&ER4gWju0%dlDTrqLmNaII8X)qe+4<2d3122 zCnB2iEFj5Ju0q}3v~dsaBMl+lygs#?3FS(|;@Uqw7F>O>{ z27^grLWJKnRnVGPiSSSCXbU!y1dW?_l}2T&EJ_v06vde(_tV55d-^=r#PZ17I2dIT zrzGTwPm&6;wxHfEzv`;+J`pVlg*(5Tomq7mw0`aup#R8S$9_D|-kM8>8)B+1MYHp7 z`VI2e^Z-@;7y1p4IE?2k*R1N<2=={Y1%wLpWX5yk&|nLWqb-jzYOiS5Y`s{TcJ2Y29^v4I^nC%) zQ9{~jTiZ^Tq&7N@S+{`CTR|8@7cvTqW-P6XUC;(;Iz(HFPU{(wGy}C(egn36p_pII_~$06 zB+p{Z>^14@zAqj()cWANvu2}ol}{~YHF+SaY`6KMFzj5WCZS^TpJzJ!cht)F!qm7Q z!ox6B5%eJEFlM=Rh0uZ~JCRl}{T3B+Jimz9oE|o2llUz6zpDZ^WF_x=Dc~Yy5F&&V~dtYK$ zfQ|AV)cgAL-L>4}N^0Rq0bUL22ql6!phFxrd8p6nr{VWpSf~s3uqg?9m7id_Uc9&B z3J&7GY`(DB;AU4=$!8-Ng9GUyGXglTz=Dli)^~vV4tvRu9*DU-i+p!PKRmJE&6K5! zUDSR}8G2Io+NWJ18Y)m7 zQrczaKW+sb6o}MP>R+J421)ybtdPHht+VlLbZ#dT(f9Q%KznFdV~82{2qP$^z7e3Z zII7ATvKVPZxbg1zinb`b=lV0|s|+p+2S)U8$M{~WSk7a_m1kcd8bxGAGY4<o+OnTNThslCB~^m8ar0d zRfnTc+rvZmA%-n=kiXTeYfH%WDR4-Gm=mP-^9=LglNA6te9VbcL@BPxR7Bsv(@eP5 z+~2ld;0!{Z(eH$j*$1Oo~hMqFS40sHalu{=Pu;?B+22=dVtn?=`S}HX~ z8%h9H&8=`yINL}!&6<+gJCi0Nq3y;VMAV)13Dk=#)Ssk`Um#nwbPihF!xMytTTl{` zhFSoS;fI~-GO?G_FIVZFPTcO=KH#}`YqJm5PrwPcdG%i@Xg1% zWJF9H&Mf4#P(ON1S^NA7pYXo3m`;_AeGuM7e;YA-+4vhKyRo6r0H+U6iIR;YuVR#54jF?+x+Hcgp{h$HuLBw zwR)a=#he{8NF^z_k{|g^BL9cMt@&i;!>11?FRpN>Q+V_S{idU>Gp1G>rK5e^;EG7Q zpWc|C!9Ju#kv80K+I9t4PMtgrztJD=;00_boL8iq>VA`*tdJ%mL!GYBeYV8is7QNi z5-_>zSMAWM!WXD{XgeedwXz(zO1})Ev)uxP>xT0~1_k|2;?Lm8%u^NOM{{VFpQelQ z^$!P@asi`a%l}i?S3pJmZU54tbgT5x(kb17gn)E+ryw&l(kVkp3J4-7F*HL;cb9;` zNH;?_==*Z-djI=-_q}&mi(%H{e9!mnv(G-e&i>RVhWDppjA6KCalV}T5SS4;xV?;# z3+KD(VZBn@vP;e6kFU=o2<;hr(4DM07vb6JgJQLs4z)WD)FUU1H*^tK6#@{`kcDN*QZY>pN605?C7N!Y^tn3l6c$T zxGVp3hlgk~+U}}h7-vAt-C6>r`t{eW4U?FzQBjLiYV@)o>?B2-b&?!~-rB0@_@#;$ zNjqIX=n+P4jKIZMP8g+XjGEJdG1KRQm`?Yw6cwUX$vs*T!Z9lFe30IoTXuo!tZ|KLBY z6P3s%2d;kMNj>|-ahcVF$2}>CdAulS=tH}Lt{~Vg`pzeJbb*R+Yh2>FUFNuBkz(%F zz1V*FOT(wxbEtMQYI}@eudF-NDQNPPNMyt8#tG8K7yCz8PRLp9!%q3(OZi(%-8l4Z z&fYXc{pQ>*@ZI+H{Q)>oq(Z`AngdJ3-?>hDz!8<}8+PL(;=0DN*ma?xF?Z?UA7&xg zwbC7ELWjp4*(l_5By~`Vd5r{hw+-)QsPx%;xxx zJ%%jHV%h2`J%_|ViojZy8FnW66AOZA&KUuA8$Y&{PlnHF@OZIl1%DQPM8f$eP5PI?AZ|#lA+t1izsjQp+{8gSLLWMon z@ZZ>LRmSSeRpN=#(AL%VR!q`)nj_iwai?Q;of&sFh*KcpZ1>;69kuI;xV71teOgBv;%yJ&Q^!|qlYcWgbMUmA0 z%Jr^l=DrBa*WZ7QeH(w%d@VC}j=AlSVEds6hWqxrUo+*tBF3F*;d5D8peaPQ1+|qo z(_qUZXfBwWUr0+z2c+iYN~j`S^v%=K%?THjUjKQ7theivmZme)%4Cbk=9-Be2o>;v zdoS4#2Zvh|PiV%_eQG)te(4Ucv$2DX>S#4v-6$p0Gupc#cM2FAmD>YI(P5tC)2kHmVZgHSY!VLtKQN=qg_;TptHqm74g7SpC3Rb^} zDzW|PcR;Q52oASOh-4zC=S+jzX5(d~+an)cPqQEvq#y%U8wu4ZdX*YDs`B4iNJy}6xh5i1 zR9WmX)8*piKe}bFS=e^rWqrmrVB>Se=?imBImKBogl(jYfoMPWAZ9-uq8w^itjHq>U#Me*S9>xhoiWJH-!dwbIe=# zc=YZS1D{K^nVK$T9^F0{Y6C*O0(o6sP)$~qqo0;Mj~TFrFQZuEZb9)m(UCVeLNBVe zT;p@EbK^3TGw-*_Jm2a4o%@4>Wwy346sG<;;1_4@YA!R;)zZ|>_hfiZGo>84 z$H#0SX$MmHOs2)UOH861n)n&uK6j(MY{yoL2*>i*P1O?l)SQ1a&{@CJ&u-g@72#Wm zfsI$yiV4p{ebO5;5p^La{mj<{@QAzL$ve>klhB=G6&1#OiA*E`f7XsNd6!+)(&9yI z)0~uUC)g5Sf8cvIX9Dyn!AgE-*~jM%K!5taXN1YNva1#|{nV8gp!DtDE1xfHvBwtT zY=MQqM8n@AdVCh22B|~~o^!u?+0LojY&^VHF*!MVxAuLfp>;D<}%v~4BWskUD!L}xUT+Heu1l+ zy|h0-iDeyB5bl;{V$e|-E?f&&r`S|7P^+o}TS&cd1lHrvTaCMH2i!2?nuQ4_ZE;YMDJ|&iwgHY_Wdg zN)r(n;Wh~RMKlP4lwfZRptk}#^C0Bln*=OfgWdAaE&hdc_5OmJ3w+HuRq2ysUfRN* zXZl_3-6L9Jk5H`7^iq+Onh)A$p$qj zT!8$UcHf<3q`=3pk0PfoX}Vh+M{=isYSz-ri{Mn|GI7VKqdIEOI!`U^IRLil7VjQ8 zg$aCA;tup_c;0P&?dr?j#y7^?eM&W|!-NyF#rNsEa^i#pBr3=2l48JK)oW!dZ_rb^ zR{rF1^K#~s$_|=j?G10roueHBh|^vn5QI8$Kwqc6a|IJCYp z1cvbih8Y9$i4aCrPcEbxYV+8d57l3@n+SY&tagy@yo`1D7I#h@3-zqLa@Yt~c`Oh! zmR~?k%_;S0{&VH!-W}By__e{l-o+Ia)k?UcU?DUFMw-?q^ysH~SX)OLAb-|2{GR_f z=UWyo@Z~=2uIU6MfHd}x59AcM&uVRfjdj31iZ{Fl$oqMv7si0RA71N9@kC&S=*5Rgiqs+sLkGWQ`XGi`PKSVL#%d9ZB=2~Q7B*?3=@%3xr zy})zzR`htMHPto6H-AncR^3u15ew##Wh3-XkG=qE?pL)WB3LfkgxZHoyXz`7vp>mX z0zR{AI+?Sn^tL9&Bz{i6gwK8BTg(&tqI)~m5{I+lyHWJq2Ey9anqsz%RzCxbWGJRp ztV4jjeb#8c1Nvy$3o8iKsM*aoZom$1HJ$w)?Yuf=XVqc2D;fb#PCf-YH=gAQl7fu( z6&I6n{MQUsk~Gcsy`w(Y%nBfEN!`8a4mF?eY-~=NoThs=mlm!1Mfa0#Sbs1riWMAd z{}8L5qPR|6^hQD6gtNflSHThs{ z2p+x>Yr^Ic_;PQc__x`ea+u+?^Wd; zgw~+Rr5it5R2l?9{FOBUCDScl*tVHZtE2SPDJqrbD`qXKy zRZYNIQC{X^T*VqB)=nGi7!yqZ4xj7;1BYZZQcNx)+K+BMbGozn?Ax<%V!m~Yy(Zn2 zAfsrocr~vAh@1aW!BTz;(E)+1Qmws&1!IoHUuM3`TGW$?(lxkl9nSeTqu>2@oGUlT zLkmrf)Xzd66pg--N$FNOR?8e9DX69ah0~5EvG!E&o@gO+UEpinu19u@SU+G!pfs4q zxVVAbX9ipqRM&+)A$}g&64L-_R>8At?5kpHo_ZOo=SwQ9g=Nadv$mXW3&dP*%^!5B z;A@${(QUQ}j{5AiAVAxF5EVyv+W0t^gz~1lPhH+_k3&9;NBSo2| z=_UR)Ap#KPU?p~q1Znpeuzwye#fPPOwu%vdV1uRrw8_{fu=FOuvw|eD?svvcA$v;e z`>DU{?5bsCp7c<@O*&Z zU>KLb_Xu6!Bf?|^X~!;n-$WX1_WUJNo*fr^$d_r&lOE5 zjl2bHfw)#Bl->5_r*7-GM_%zNAr_+#>P6Xmd~ z^kdKR%WRbl6rAFqg9`E|MR~oqTrsjoo@mr@0MXHXM*$m`@D*wcmu@5n-e||B;>{JX zLvcqf8>g!9|m zQ98O|S&kdL(A^ZGC7t5LeAn;1V58*|UPUya$xhv2z(#LvnMEnUZjkmBTR%3!vfseK z(FG5i>Ty*wc9%z`Z=zH?zvl48pepSP^mGSmpw)*3l?bC0UMXPCgJ1ZA@PMsR> z>lS%Z+PHb7U4P(dzQ`pe!rf4`gy3jAvYvgrb*h@S_dI1of9PiJ0B-BuS${oJGjg#> zJJYx6S3&T{BM9o+n=rggjh{OyrmG^Xy<*}tvLY1UG_ZP#<4<3ZeuL2s8Bi+*+S3UlRGLq%r@{(^lqtMVDO_8P6NDVnCQ0#q#PgkrZV)%mAl0rdH!`-b!X!%^dvB!`)>l^SI zhwtz+N6Cg_O=@=g0UYQdJ&A;+g z(&%_ehIxu>EjxEGe4IrHN@IK!2FL@deS(z%i+!jWRdBcxHn)&bR2Rdt- z(=8;Lg{Cp%#`gjD-)GFY!885)Rf@cbOFzsLa8AHWJDA{?PVdiL$XU$)zvhUqTT+k6xmrkRw z1{{$24SUNeZ`HL`1emMu4lPvnFP7;0Oz53R!n<1ife~<;!>DlJghxn9Ca`+@`g+AH zXg37s$BQ2;b+R_?RQ$SF2y($!+L)4^&e@#Q(8>dbr;|5tWeNa4ds{bdo?{PznPhu8 zD+Ao@YZW{7^3N_ehWO47H_4lZ2Q{G66rLOJlECq3w1vH;!PKnc!klm@VZ$9#_MH$< z#n<0R(h@(DYQm~!0lX%neo=*JHG-wn4ed@^2;O$T5U1WbJtievWvA$z(c=C3>KM># z2um+e3R3f=0|gq6eM<0LWKPTRuz}(@@N-QJlY`Xt$&w z@!ZgT`m7TbCZXV8-6%wwSurqhZl^D$GOB-jg1n5nVTzJ&4HBvKK4d>z1Jt4h-?>~>s6vV1{SEJ z(RnT9t)#YM{&3}OZu7nZyEZ6Ri5O($0nUDVx4dsX(6ziziXKuUjzKdTbX@PYZL+8kvsDPSHf z;bLYOqK)4{8KNz~?|4_44V4-NHtnb%OHc#nBe(#Uaagga(0ZtQ_ z6tsSE-83Q9UR^D5ADS zd?dAjZfAAgskJ3?MO^F0Ot`K|DI+FCPf(pAK&j!F=!5mIXUT5?T?(Zti%(QrloG3A zhUanB`$OdCD&l9$&GNN`EG@h?VL6bq5EDRv*!WUbCk^GjHT5|BvLh~XcYSc1Jp((z zkGC!a z>Rq1cWj_c0Xd9Yl4{SA!Bf6GIlpOuu-rTJEz@J0T@8*X!lBcG+>ZqoN zk`Mxt{cyXh<~N>jpLZ#rMDvW4 z&qZJ$*%(shayQN{^0qN&#Vu-caEx`Ryy)hQ78$ja=?}+hkG-HNUbm&EyPa|}7bC{r z6+ULVX+|5>nvANqh>r9JKl8KpesOO!s)Yt8mq@{?C+=5uoDRbx^ao%6W8P*Pjl~qoxBsDxbi3k2!Q< zNc`3YklgxqmWyVaJfj7v315KDoOFI@^yU8fb>Qm>7}5|&K(0C>jX)BJOz&i`cY(dE z{qDB!cCx$P_E0Wa6#<^z>v{)rhzx89&7hTwz$shN zoF+~_d&Cq$lywVx^NGh@D*LvTCSG4PrFb()+BdD`x%!Z&IW1oEF%&jOr~tTiqpk(L1t??^jYhxU*R((ve9-v}MYK?QhhNaT&#aamibLINh@G!&>BJZMWWX9b-HOD`NLvC53L#t5n5Y z$E&k3`4r4Q#6M(R?r4^w%M?0^#)-#ejKOJyWdky9vRE@m^00CIAcbedcO6LCn}!Ew zxHG-{9BcAUovoMuxAlo6%E&w%wT)&Lt!;rMoNJ-`IVMmzLE(qEvc!6``4;l?{n0CF z`_~s5sj~;eW)95DDS1HL^B&|9W5D=g?oiK9{f2>uk<^c+P_53iNmo{?d-wOk9N`gz z)vxF|!VBifsE5O5?(l|0*Mu}9^LOFqsWd`tOkSeTc&lp7Xb!rprC^n~41KY1w|q!I zLih(cd%ZcF$M${URqLRSS^Md|d`iz9@#srnhQrWh7oEhKq~n01RHwVGG*naB(Fc#X zbo+d?BPdjQZbzB!60<1(y*VT&K@5hi&hg!w0W^B)4PlU44fq|qfZdj`9I0TX*$xdq zL6;_BdU};K`vk4cmsF{_>i~lCV@0Yv;C^*$Hf%VLBkx&dsm>6ZXAN9Ea1$hn&QCW% z1ec23ItPy3ygN#Pq>aYw#BgC5r+#fi$Feb0K&6$!=5=iW{zCLhV{bPCA??Dk5ZL`2 zCGOY71ek)1L8#-uH)ShmW^br*cs@sm(+A?wQ%JW#Q6Y&wbm+Od6m1(@9SXina(TsX zWQ05xSoTgWfXZe=AuER{9gPz1@@LL~CBB^e^*W!vQ5P=LrAUE#N$eTnb^-boy-x^^ znCuG#XuZE>deP^-wP9FPc!XHjJ}CFoW5+{r1|ZVcYGPLSoQDzGaeH-|5Ei&Uzq-P zX~S$j~) zdm#r!M%`_cElaQekd3ynua$38tSy-dNcT2d`|u$^7@a;)oG(ufiTx$kf`0_H-8&)6 zC{+cx1VHsJFY#FJ6bzR-d|iliKU_+>P2))8%$ zyxsBb-}Ao#+`;O(oNZ+=+RO>h*Q=~5dq_1JiQ-bnY9i@Qxj2V!(NN6~Z{%m#_`2nL z*etuTGn`wIslaEm{l90~4OyxYgNat_;BY0Y#&ARdrUs}Mq0s|i05|^+Ay*_W2pO>KtqmXm;Yd1ys74o9x`k3Ze_2y^^peO{O z=rxkqU+_0wrs!SpeQ-9<-)p+Rdw;ou1E(#_MERt(oFIk-z7@Y%9-o5L;L(w>*UPmJ zB+ZD5Z{XcTk8d!84DoJ;jntj}%lz1E-ZY|_jq+)r%(ygr=1%mxJWU(C7!P%`lnR}o z0A}b5%y1K!VQ-80Ma{zAUdi&?^s}LJB;2!EpncTYg3#qtCfh4|;{#cGILu{959+Zu$TuRI{zR6}^ZKi(KhvcME~G+9@0DbPe!NVNQ^nPU{%n{inLPGECA zr>yP>1a>)CL@Mx}T4Iz%AdEMBCx*X9sA3ayh+Yi{5)>(28C9Xa-FL^ktaBQl9h@FU z5l+EoT3C1{>;7D)1;0^7B=O$KMJ$8b#qcY16A0U7EY_9n&LMwroVG%0?_fZnBG#90 zo(9djT0>G@B!xJ8O_>FBSh57A#UCa8>X6<(e%$7og1JSErQ>2l?LnYE- zN8r?Y>WSdz(02s9pBaq^#jtNxcDfqd1Sk$v z3!r>02)#&UfgtTP#M%m|4PgZe#2|ULH*0ByUA)_Zk4jBy-TTtfLs2X&r=VSnuOCw^ z^ryo(YQ_RLppxN+pe__M6+fGcw)SAElsw3p zO7t(dJ6QEy*7+@;qKG7Zso^q5y-pzFXZLyHR0e5My^B&CB$01pLrjvSEOPw~;)< z#rBk+@#^SIm8e8SBW3R3{VrFC4%M^9XrmjQyDNb@PYUX3t(EQZZ=)Sy`dKc%qlg zdFz%Y%ueEjm!)|sDu(VElF?_szZ*>iZiu7}7-fhu#_!3eL^wm-+Z({n(c)sA0uN3< zflnia*Sp+au0hT;F$jkn9P9+84nzg%O7zb)pH%d2$>@Z|I$8zRtxkadq7g!Rc5i7M zHh(19z5B}@L#x9Nc!~`YC=Sjn8_kK#(?FQ74o90}@y=tCPZJhZRKHDo0r@w9;gTfJ zsQRcSzI8faWzs*#b1t7+)tsHr4U}h5rdmQ}QC53Kywnl->L&U@*;q2|vZ0tYDbnHg zWbT?6(cQ@WY~;Xp%=u1fFVgpy48|rN4sU^nee>f;HAWE#{D2>?}5Umif=1B)k*JM;@}w?U%s$&nP(udZiHw z*qRKjdr8BqPX`D@5)ycy{UuO_E{6e1Mk4JOjPLeD=7pe$mods32-Bd>N+~Tccn+Ud z8X;_GKxgTtAgEKOR4HngI8xQ?XIA(QeKtt#93>l6^g;RDLX}C9k^*3~a~Ly! z+@7#@7CUpRhVZqi){?7b=TC!GT?$1x-;+h2Xr8g9iC$RMXD@(!HOz1|Lq1-8X+c9x zI?D)PkZ;&b2Q9jn9;4T4&OaOIT|ddw_N!R0NwlNKID%Fs=6GI>g#r^tA8a%wVhb}#q2|B|Z#87??0O!0 z!zeLl_DbU+35=n|xnh{ne>T--Gj86R_`S!mMQJ^bYy-`pT*CsD(C;iAzIR#ac0r91 zPiQN4S%K_`l^|IOD&&fexL*cRsjuSq{n?rB$>zcQUtH6r(}9x%m{@kBmj%dw$wt;M zT%Tk@lYu59=~Ot>w7G8)+vt=mpdGh~)%KC5Si2-Zw>M&QcCW^OH_6u&17h~44M9RZ zhNE69jcz9}69iMmpl6#=@FET0Ob)p}_eTqc8=X<&E`3`gL)J0<+1b*NOd*o|B0f(R zGLkQW()1Bkvxi_DWpk$Xfo6Rrp5Lub)=U+8dkd0tlz=gq3%)Q`hOI<=0B(?&te1xl zD+(rzfbtuK+(Bn{9kFANU^Q}NqA9+46{0rab(Oh*9@toqewjYOxCEIrdVb6XHG%q# z=7WPe%e2&*c7}r`<9b=GbuUL3lXU3dp?YFUdN!0yM^5f>qFc%YbmN@g*Y|esWN2e^ zDEN;?Mk11^*qtEask3J8@1Q>t9^w+mIMc5U(!-**82J2h(9l!JRskJuG0pDgNXWN& zUZ&7T$`EbFLq|>jfJg+;#j-&ykJ0 zktw3#Y9~G2J^9qUA{{6|7Eryu^F9e*AZ31-`oS^FZ5LUz0Gt(kDX+L?zPuvv!NksZ zvP|CHglTD4Ns}m*3Rp!}cC!Q-aaWE!*N5SmZe1TJ1(q0ah856#d8cT);xY?~DEmYX z-78A9`7CT+r;5{Xdv0Gf)DOrN-HvqjzjHR}#~Y~!4oA5nUikaWn~TRxAOFgzED3WCgF_?^pMkwom%Al{c+&WI5wcX{AZ0ZNU|R$4EX+xw7s#K#AUG=R!1q9ZXDVdR|9z50nK0x5Eb#cK2{ zy3K}yR1JDej~m>SA}KwH)5*|G;J;u+AUa#u1nqvy$rzm5jIm2u*0-Re?m4JO3RC!5ydS-ILQ zehoXei7AU~od~^97sw3Vssq$TN2QEvq7QMkD-nC1{h`dhQYnT>_9k1g^QskznEx8K z(&B%H&3yDQtdRCb(g>F#jGvLqF5N%iu}Fq?&m6*Sd)CxLW4GXJ$40Tht7?~gOB~Y zX{iozb4eP}=9`vGqvOrKg;MCoAGVQ~pTG$Ul~lXJuj%dG8FsrUr0{a{8FH-{nk3P> zrpkl0XFZ?KHs6%N2BEFe-FJ(*E4t~bv|=L?UO9GBx=lhUZ!+yf!!!hdjOx(@UOk4V z0Y9%9*?6|fn}W-H`G(#E8Bp|-!!;jMcv`m?>97A<{H8cbQ*{FJq?=Cg&)_5+6U>zz9K$K=f`L51BHVvR1;y@^b8xnBc zeAwY=+#7nso+CP1vz|4B_7ooMBGFB#7o270yt`PpHQQl;63?^?zBi1B&c0&g5j;J6 zDi{|4AV`cvIUOI4oH$2hYDEOzSsOBen_sjj?-PWSjWRlI#fBJ*jkEJcE#<$SH5V=& z;x}BXkc@}T3+Rq6k#DklO6t@UJ5^ikAs7hj`>?+@9QBS|J}VsO56B(hR8SVY%@-CV2I7%YPCcAM*cvo!%TFEKM-A7}mI`Ss zkK_cU{{6u;3C1^5G_g)-#ADGO%c+rnXH&LBv)uM&NIFgNmq!XE2^#3YCxw!cIq4@& z3Eh{1y^Y_4aj^wT93RCIAw4<8w`CaB(KBYr}9>oF+`@Y$%iV>z! z?1#5&+GB^4^=V47{!bMrO4MynA`#X5zS|xmcHDNP<~`Lz{Sn##Q4z_&?QOe1-wa15 z(Ke9^j+e_S?XTSYlO&M|l~D{&XPHD6Y4v0-c#G!MD%IAH`1pYPOQnLs*690|XRrqu z98Y6O2*}`G@PVbGNz^FAynu!@@-Vz=g@TU>qj&C@f=@xks?46RvZ}J2c1)%+hwU$| z$pF2}fqY}4TZrYeEG?c+`QZg36mQ=WZSdSTi;t{q^c7U`ODGjot=eO}9|*xpK0QSE zxXq>&2E>h#$*+Zm&}J!m$?VUdwwAL8_#MJgn1($>btw&Q>@f{UO$eV9VVE9G>x-bk zGY>6>j|Ck1kEg%|wf-K=%LCX4iWd&zoy?IACfW<{$v(k%gEE1N#=dF%S1vF#{%C-v z6{uKzemoB}ZAsvb254&5j0MnCt9bBKknqz?tRSt~fdPft5{wA1LiP`@!a;Ybu}WvD zIN6Z_9(|dzWoOoQB_X6_7#I&dyqu?6X^t46!5X8B48^FikiuMTf6odNk3ZJq`7VoY zthui3C7(#g03z{D+DHeSXrY74=<+{AA`^|A0b?JZbTh_98$8z|ta2s9J1>JO;>E3C zaTS5zQ>2i{#6^VCLL~$57k>qK-0Y5|te^E2>+j0(D%~Fq@E^jIeR7ZUZ&q}*39Af( zWukioYqzY3`Mm&}t4n{_rpVBYocNHg?zVd7Y~J}$P3Ct+SS#q}5^rjGpXRvaLDS&b zs}_M(D81#H>a0<-l*hUq-gbJU0y9vKu{)kUpw6uLNmn}1wLc z`b*SGyHt0(Tn&XMl8DjgyH<~@iF~rmTA6pZ2pu&JJbZ_dGg{3!BRUqsvHY( z9q8s5Z$y(2W9q;b2uN8V6g^C$pl?jriuTol?*&CwWTNKg|7bV1mbyM7NoT7^*%OYD zXl*piBGNBCZ(sb$73|7;Hl1i^nzQf-L~)ES#B2!Vxh&-=y)Rj$dF|zE{M0F3AGy0^ zupf1gPMU6$&sT$3-vIP#)1E~LPX>x{VQCSKt{ZN zQw82s!`0K|yi+|y_Da!pSwBB>sdneB*X_RpEfs5AwxFhC;EZ1Why;NU7;Y`G+-8c4 z3KapOju!^l%eqm^y7E4X0lW^!uAHIRmP@FeIC}{P@&=IbM_+TlHnI*CM z1MJ4@!Q4ffv-35(##YaOjl;k#X(s>kuXHTC3Ij9Tb(@T;E8iV}O!bd$m|cRf?+%)1 z!14vx3FXvj=|Q%M)S-+FF~5 z0r=mtIM*lfEi)o-mY>thZk69KgxBc_7y@SWU}PPM?JE~7C_FTOXXcYuu*)w@_KSt?xvhRDEq~%@4;Fo9Ot4I1@naSC$U=I*yQfq(=!@C+*@^lMJg%H02--?n98dN6@=JXX-s(slj*t50j6k|It0a9hjVcYy}(UrD=Fl?x8ad2_OWmZ#qF+dH!R;@@PtRssU z@eyRFPp}T(dK72R@_xX-bUKd4_4d0NgkIdYCA!_&o8I*a(c9Xc6!9-73Hb^K*_(u2 zR!8*J935UXSzJL%aj%rneV6I@9uprQCJ4X(8~*hqnlEUME9uTW=E)bGEohYeB`LF& zS5a7I;Rz!q)c;#{nFe|jDZ!Mc{Us_caHXyF>uw20r3Hx;W9tl1JUCb`9^REduW}py z`D$HGn&D20Z~KS1n)X3ZQtVcR*}b#ktn$p1WfL6(LlEvl72$qyJ2H|N ztZbk8DxWa>1F=ppzx$qcV@uO*m-n@0@Rhza)5722%$+B^;8#JYIy~bh_a}D+E|sMF z|H5vg*3kijT~Savk}-hqsAyy;|3UNpC)Vr(n(zPFjQ?+J-~WDq+dtq~A0TP}(*gh- zy?+4I{&&ZJ0-rvhwf?7N0T^@tjotd+z5j{$`2ddkpXP}EkKX?qD)qm+{}Xoe0T%Q> z4F-Vj{=Yy%|N9C51Y&%E=loA|0H7Hkp71|lo&VkSpFo2TNR9t#8QA~o`cGKF|L*)x zAif7I!vC~WoPTxx{~#0o_jCTq6c4a{|7k>z{^uqBFAzUXRZOgh|HK7;q=97`hCF=x EU%dDrasU7T literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-27-17 site Document Inventory Report - Site Level All Sites by Country.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-27-17 site Document Inventory Report - Site Level All Sites by Country.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..26fd449c45ab06a9caed74193a7ebfa48a8b107b GIT binary patch literal 136817 zcmafaWmsIzvMvt6J-9<~27#KU$n>y(- zyW3bdsEpb6g3zCmh8O8Mua(qr{KZIza7(VCb-WTZ@2RVP{JGPG=T1}(Lv*+_HZwQV zxHV~XXw()H#q#bO^zNtsLvOLu7W|b_@5oEtFj-HIke}TeY1nLb#E1}*q4efgwc!3e z8B8fjhByg@yXbOk#<=sR%ur<}Q}}IH_Es$Vdt|}I7K`e`-FMn8wJn~jYwr((NAN1Z zY$}X3w~x~G>qwU{uA2sS6zk~zYEy*DOATVQY!1PF4u(7`YlJ8?_$aU8xXTN)(;^i_ zN%pj*1kS`*7%H6AQ#>hjU9wUE0mDwB;8^yq{=Xnx9Lx+;&CvHeBrXxG{&T;eP0V?2 z+5CN`!t`d((FqxR&?{3Z?M}n!5+R@+C*DnuX0pE|{?(8kn?g@sykbG^dtvztDbC8c zBZkWAeSXNLBnOWW$4J}G2MGZ|3kT$`Bnc_oBr7P>i<@nYNL$=UM)Sw?nH#B}{xHOd zK46x>>m|}(U!mTtW6Ophw+F0U7V1A)2OYS>#LigB(azq9#n9gV4VLoJJ%|7-#m{{t zhC9}dM8szj0}!%KM1;ulS2(AwMQde+HZtaR#z8SftrJz-QFLv>6|0L;*wUPl(ZAIN zNf(c(_&QX?5HYa$#&d~in;Z?J&Hb$3U(+m_7S?_u_voW8#P4P2iAXWfCkfk{W|!)Y zijyQNyN8vnc*N5%M|lswCZ!T<)VzWHbcg7J`Uw5DoGov+UvYr4O~CK}zS$W6b2-L# zj;3$xv5D1{>jPm2zse4OO|MVl6kBbZ~zkZ~WO>P&#+*rNc54XReLv+=)bC z-O5Xq@)2SmKJQCL0XF4y@34p)hmV!p2plD8bFw!(ft5E@Op`n{Bi3NgIzAFJ@+SD& zVk)r0fi%E0(EaDPZNaF(=&dq`@DO(w;u@Xy3sh+ZOBrk!W{*u1TpCx7?KqHT6sC7Wc}Kc?E;Ff-{xD3OU=LOac7{Hg;pn5 zA9dn{IJmOkj3`z7@d6I;m>S^se>WmFU_^Io7AFfsM^h6OXGcq0bEh{u3Pg&a_L8AP zoOcGCtTB6n1`}@$wvnzO11p2_853c5uJ(2v*b?yf?N;YP!UOx^6u!YpoXlXlbNulX zjMhjk>Z4Uol8Y+y*JDTZ%KMxB_uGJ96~_kpfJeA`aAH`SM-isYsiu0O&M@tO!?torl|8e_K{;j#QhqdWHDtD;L+ogl>I?pvU7b=;kzT{Ox z^Oj)FqAnGDXSZDL>47VMfL<#6_VU=#C?i{DQsStIdVfPGMB2{p=*lJSPx8G+r;Lb& zStT;Hlzp#skF=d*2B?>*YWX-_^UVD!1t4&Heoyyg=(peug?{;>n#x1rB55Q{{o<=|W!c zW^8_KnpqMY?KqBo+UuJ4n}xkJ3$nQX%+fTTxYf%IDr#|- zUST~wel5xT#PjXwA(#2(pXdiaO2vNzpnMhfKOr6MUwCn|bNpgtXZPg|3r}$QThZW!dpejh9X!34@wb&a%EyF{t!75Eh*kX1 zb=56e={}j(Vt{n^I_yg#TxHJL`CvmgaL=`lQbycF0`qkYNb|9c<3mqCiHPo;}+tyN;PXE_kn3^FB=cdF=`hvAU)Ueto z?9sv~4{^Gw)x*HsP~t-g-L3=gF+Uy^n+*SU2b5xg-_iXLUgNv2@p1$jusZ50xvv(+ zE4Rt(dCx?2!^CY_Jt7-1TC4rT?9)38oh819*}gaXsWB&EyV`n^R|oN=Jsgr#l^w1B z#3}RR+~Rp)>Fob8>*D=i+&Nj8nmRiH!4`O7eFNZ0$6EX zk=WaDZ?GBot>T# z@2Jmf*Xxt-^F_-1xm=fk_9-8;0Gr=cU37k(C> zCE8b#q@k~E+Fu#DCM#dAy*xZumR7Eez&f@_EgiZWxTe?8Oiy4JdX~kXY8SSyZNECT zpD$HdeP0b3s^Z7S5=BzV1_~cvf8MmW-)~4Q)^%yT{vCU=`n#prrMP|RqqAu3u%hk`74wtH-3FncZmRH@z9!RG>!%pG^m#8FKIVGj}q(fI|$xlJ#wmX6K&_T^n*fXd&MjYxS zb3zM8MbGw)nKBC6RX$-0dsAvJe@!3k;-z!tZ~i6;T|PLn>f`ROG*D%M^(dqE9#zIYq+Zi{grJ>8xz5V?nE z92qq(jc-h_n13Fr4ZfEe&ZOr|IewVP+8k`TDs$rB1^6#iNd? z@=l=gBi`PjbzM}}NZ84m_lB4k6y=l7R5-@{W)UjhUe|EVm)6uG(D=o~gy)USdVIqC z%|z}m+`sl&T7v0Ur`BF=tPuPmkb0FGDFbG8=il3f;jV9QkLuckSN2?OTEDZz{b{*K zdo^;HUaN+W=RHFRT*pADh_wi+F9EGTKNNL!@_)U#K6$t%eO>fjt!#W%HWMWL{^-4| z*Ol%~AFf!ZXzIh-qN6L+oGEl4QZ~Og;Qe5G3-3VuD5m;ah0gvXu$t=w zi;13iw8D$4=XF!Y=qt4Yk-1cnsb`%Y(|*d&ha=aoS^{TU&wuvo3RVTzt#^%!N%r(@ zBjkDNlj|N@LtiegpSDIW^k3|;pLafdpLqTuxJmkQzqywEdVe?tO>!TDCRnnny`j~( zkN-7|G){B+V18^Tf>h(Pm60ai4!bxV%7owSOR;*Gcv`vbQJw=`D1G=C4Su!Bp_ z1H)WxwkeFZSN$b_PgP|L@aC!tBBgz3Gd4G0Jez%f*U60K(TAZjVtf4Hi2Ka`SwG$4 zDD2KXZ2>_hNJ*VK`z7N~{kX6+y)Sh}ShG`-;xWQ{SZvGc*@hQf_UDPcfuu0+xM9V* z2cuh8uz2lcILYK5cWPG$)6fCh&ym?W-w2Wk)8W6QxoPIqLsjxZf$#r-6?~YOg~Y4E z(^r}z9ty-=mpN;Az1zjvz?Wjq-s6M>6hh)t5`8jMFXYMyqx~-+&yb7V!_ocpXC|}D zjjS#o5yz}C-SYK@D^g60Ndq@0IHZR$D$DUeB2P4nyOgCYw}GX30i@mq2TbCP&KQeN zB~-Sh6L{Z<8$arU&L5y8t5aDRA*}b2@T^|F4YAC#Sl|ef=JSO^$>?xO3_C5{Tz(_n zw|=^UC30wA_0eRa-dmeo7^rd-PkOJSH$?i$Ddg@~8r#=1=|J=ZoqYU>!1m9XCEpHJ zq;RG)d1J?53Q?(MJdbEYZbpn6SPSp|i1bbo{kiZqN5y*<{wU?h#ukf+W zO030Pilvb>+{M|kO>c_D?tRnZ }^a&8KKPqxp=*qNG(m>mXu~hyz?aW-mEwDoGXm#(%n!^2gwQ^I~toc6sHz8#RKZ%9# zLJ|ylVthZlWqliO0-QJ2rvx~nElx{!)G?GdM|NZw*}tj?2r-b<#2l0@56 zdQSb|+4~!sRS+0Kg)6h~ne8Z-D^-a}=1Ikd{F8EL@%uqsf-9LP-bl#7EMKmo*lS@Z zBUK;9S695;MFT$ZY)?!9K!IyO0dYV9ECE1)N2!5JNATrSiw(Wdv_*T~Me5*RJiW6c z5WhG4CuB6KX4dxo)QrNvcv<%GMFIQuDy{tTO!y=%vVL1}!yx1sWF7NhDTQVKEki2O z;P-CGEWPIPRL{Th_1xKj#rFIG=0XPM`Uou6=$_QBsZRd7KY1OVAUvF?E_*#p^8C+U z`T=pYeV*GCBoB^PQd*)pzdTzn-!(JiAu%w^Ixx$1bfmVq=i4mnz$~6qX9ogEuj#Uv zc3JBm6+J_Cm=4yUx|7!pX}vr{96nvYTv?MVmXB}7tR<%T!xi-Ye(;eIJeR%v69vK$ zAlj0=&JuG%*``KIfq+deAGNQQX#1dMHXC+fT-h(V-E(kT$^!my)dfI6(Q~RQLiEk2a8?Spzk& z<*VKfKa#!CDZu;Lhh8YaTmQEwFRRM$p}Viq(?4E*o89dDz;p*Z*`Ql5k@of4rv3!M z8WRZh#LWudINsumzlx#Eu}~>qj^CU5)|K_W4!aP3)v^y=LEhwJFGBINM9pcJy|i4< zgigcr#_VRsNrkPR2F*fnT4(MBA%-ReU3Fi1a^x*RAk509m2f61TgXR;Lmmz(%zi2Pm+gh<8yiEt+ zL7+NhK(r72s`vku31!jyp=Hw{?ZY0a4I)`ET~6fBLWo_XA9N7!P}pI+r4CtP$%?*8 z2^?W}N2)*|?{UB?nIa+_XPMAN;X5$H{Q}?Q=vA3t6?ogWSvzCz$9=;4ES2~Le=~fI z+VPk8UA?AHqUDKoM<$D16yurAWP=Fz=gFq4=T#ejgH9nyQK@OO^YGLCgFUN`Or|pf zMMRH?QkVDP5myhMHy2j}brBzq!{YAX2@)I7804Jd@(W`?E4sStZg>dIMhC z+0q=h&nk_isv?fljRaQKN1Y$Pf9jR%+1g(+@=*g%eZzXFvRk}aCZqQHB>UwgZ`(#@ zp?y&tebaAk36gVEYgi1_y)oY*AGVZ8izU_cs0Z7p3wljm4n$s-IUkRJqr*ijhvk!r$7p{*vRwvrmkP z&b75VA$YSyIw25kbBDO2u3AD*Yf({5(OA-B#_!?F)SglGA_s}#=gLzICy6E?U|R8o zu`^uEU4`-%)yqkrWE;eS&jfqOQg+#Tx|Q^>BDdG64cFpzOjzYIgy2tm?x<`YI;W6A z$ly;DK%H6oFx@@@BJEw>Fwj!L83yQL1yC+anFg3VJycX23e?aj`;uR_@%J5U6Mr1( zu9ft!Jx2s`D^Pd7=o_&?)CDRkXCVv*zSLl_;`@D<2{<~37!>vYzWZQBIKi1dzt^r! zY}XcU_VdOYY~5H^;4z7C3Nxs%ZaT@G@jjK-%mDM3`^ZNEq{dRO^zxhzE3%)qd|WIQ@T)EqS)>+w==l)_d%KGDRg$*Oyvs zYn}CL9K9n1s~9;$6&X=r#v$z>I`vz?D%`jP#5zIK`J#UWIVO^rpg{{h zg{A88rj-f`ltkZH~eM8ZyY$ZrlzU5auJ3?UH+wdl^d z>OfzivFk8+PRTIN>LnDEFU{_KbsGXMEpa7gBp z#Df%846@`Fz4*@Si-I8|JNj$LEh42K;`!#&#t@VDkQ3P}gR3FtLcR@TL^ad^x|P*mZmw!E0DT*P1_(qW(OTFj#=WGQ?Y`-wv~* z&7M^-H?W5Kq6IT{I-dJD5fFwxlX2VgN2)vWul=|`v}WCSp~rvOzBoDc)MGSLrxKbT zR{g$u?*XnWle;`yFg#&B`QXvT%1sTI2a>#mE2{p!`}gzPlvJe4jFAw$aqTI(cr+dZ zET4L{*^jg1w-_SqQg#g$Nfj>F*9{3_0(Y6viKIy+%P>8TvWL;wL249S9w9(1iFV^c zGgdSd8v2XUL&vHa#2U?|88kt(vB3}t#E<)FTSJ)Xu$_*lUa}z-VD!Fa5Eia^VvPWi zubU?U8mW3Y>F@5f1^w!&snWZYrmkObJ*|J=N5a;>*1lVvef^Sip>^e@8teV!L%Ygu{8E$*ogtTrc5%e7f^yI9dE8=gjshz&4={U0KU3Z$l3@TN`S zgmc=>AO=2s>U#ton~YY^;Y#+eYx#gqm}C0P1lY%g8lD#u6|o1>Ru65RE5e=L0Dyxg+%fIs+IW<+ji>dNGFcD!Ob+u`Meop502 zpoRId?(ui6kZsBz!=m-Ro72A`14Re-ds@!k9$KCg@z7>2CVA@j`(8-sh_5PKJ2y9j(*?kDOMKAneRFFj@-d%;^!IM~gOlMo4_F&EZ*Ih=$q zTqAZK{USV z308lE_ycKa*K#H|NrfEBR>*-vO=lL9&@1}0bDOu&=P_TN&w5FI=9eERnzF`i%^cy< zD;EYBABRpuwvi<3J?}zDslbe8*<7aGb=&7xWAkX2iw&_|g`~L}4DWQ#xVz#WR?vPP zzrOe`knU&iv2F|}RyT(iUZ#BTbNtTnEbFn7s4 zZ%~y`XH9xOistu_%3jV5oEjIV3#A&DD@3i?PEunW1ECG{geM>ftQDE>k_>D8=@aHs z?vw0QKKVQ}YPv`$x@IwXy4!;IN2le)^IHipaL+u-58L8teeEE1!Xt-JPoi9skouvY zPTw;HMAwGrqJHZMsgfFZ^vp-8t|=KW*HvuHZ^-jVlI}`UQ!8 zBw1*?J1XgwdlT$AeS5n=IDyZv?5heJeAQq-;Zanx^Q zlGox4g$|KI98Hb) zbHoKu!7;NhN5?2P+)N)7=6~|3Nu8?_cc{2r|KB%LFY^ACz|w$a|CY^uR*QNlbL72| zbb@2aruVH_&pCoq;c_)tSXyP=>*{3PACowDYq?<0?);I7btipuP zkimYy?K2X-esR{28;H-k~HFwu^vY9nQDENXmF%9~rZbqC!V4NPZsP%bsK8 z0~l59x4$!i(!)OKaYvkkz|~V(L|!$TtBkm(LugB-56yF^H*$mXzB?267L& zfDRF5*)*4Vl&!C}o&+_hZy27yRzuJ)9rM>HJSaTL8$wL@5|ZeUf|Sfg-Z}%#ZL}xF z<$W#}m&P6&|7f2QX(U)2&!U}P7INY?9D)5f9O3LMI2K(BgS@{uQ(3GCTU8uXFUuN% z@cg-e><0-2l%v9(lDOZwv`kH2C@36ZevpVQPT`y|~#=$(7b$in%-KH<02mC`}9$-MUrQ5-@lJvf_T^WEcQ1$G|Y4 z;`-ZrjCOT1AMGU~_zqwH3xeC!KruNoyAEN3=-?$gXT`?K*^w2(+4C)+DGGUi4xs4= z!O2?eOLjcoixKpW6;9Wd*g(JQ;bRtZvVCVXYMA@zL>N9>t(Lw!3SNTWnnNU*BTJl|Vz>5PW5=NS$N|2aM$B4e zM#~j(wr?YVSxuZ*|KifnndNz^s51N_4Up`H&Z-Po9 z=km#O4HwiR1=M+-i1SjXhjWqROm=g|gIfRZjElJN#giPX3NGubcvDA2A~hwG7zjDM zQWV6cPB0@Cyh7Qpx)qaq#uiMkZd3iLX=og(>5u8AB?kSPX^U;V1w4*1p9**|x7E|& z@vCRy3RKd}-(o6CWuxwh>(TJrAdx9<%3O zM6^-TJ(T;Gi@tS;_wVP5x}ljzlB5MO)miD<9c6i}f;5^fIqW$2^1>@#KxIX-9GJd3;S)uo%(tA-b6Ba!&L7>|A4(WaazPqAjHuPXeAIFIB}px7^)% z;Csi1R>tK;L!P{($A@iEZvx9b%t6n`FI7cbCPM{TX0ieky~(tJf4JYZD0}(jBrO9l z6qpE@n+1id3807x->?%MDl7I$N8eoMJ$Tl2Fci(ZEIZj}-u{65(uU_H>29XOTCp@= zQMA=&QeFg@%9FQ07BE#NaF_c0tSTtpB>%I*$64M}kKB}50GE6004^0M_pg(ZXW?~< zh+8PBJEBc*G}Sc-H>$b3bc((*4$P-IWZqW&kS1NUd>t%(sySbAYiH++M{Es64Wrt_7)1w6=zh=3yazcC=R?*Y(sx>l!XLT}s9b^qg30FuRJHhDlZki{E9Sf?5#xWxR%9@Rwn!3LsCt2}D{hfB~&g z+z238#fhZ90O?j+j6nPg5J~IdfJjOJMA8aKAd(VTX>HMa z`to(rBUK-)Sus^TUC}S=jAAmhW-u|^y}#K{1^Rp`j=lO{dafG8&dN1d2TVj_~Nc!tA=YzX{kPyJWrL;UC zrHu>%U$nxWA1nq(5=aPIVFM}cO#q}cj&N|^8yR9pd?Q1&fw|z&Y8RrYI-UM4c0^CI zyP)Wmd0KJwC@9IA8CnAb={!G5U3Nsgkt?szVjsNIRy1q}BV=}?&mQCjmXqV7Vhv?w z{M}8X#r)mm(W7Fa4tzFBt)t&)li)r2G#{isOM&qULO!LC#2yFb!vj|Ke6zAF8enA^ z*F+M@L%_-fAz;s8sYAfZZ-O@~UxQ@P-mHB6X5|^NLTNOuP0?tTN$5&WnOSHVG=LX) z4hKl10j%H}UJ= z0j~2V0Jx4Sg(UU1?aqn{#ir`CMA$G6H3gdfPyu8T0xqd!*t7#MDv5X)fSN=g|0+`e zsG)|EynI2R&=3kxB8dWf;92z3UqY=^@q^?&{Oppz9smN8LeO`BIL1wf)>3il2OxkS zK)@*U8v;Du5KxnM38F^>5WpWfDkew|*z+F&fPkbBu*Vw$65r^s5=s2Mf=BEtNqw}j z3}XPZ)c3?=1R{el1eB&ces-=w6%S!0>qK}MC?%3uY4|-zkxMm_QAP5!kRO7031^@= z_lf~nOr*H{K~B7h%IGt{Roa9zzrf~0R1wM3dXd8eRCWfJ5N=A=5$@9iRC#GBx15$j zK7$mb15{}X-!(|SqQ6CaWN!H;zrb#IE+JMsgbT!yC5DLvbE#k}ynR9(QcacK6!go50U;N6Ntf8~%(Fl?t`{AuWPi7{|dcn5oe{EuV3- zH;O9ajZ%@JS~TlA_`v}hU^6&C1pD zA)!$w3s;LMw#Lh0fbu~W!doL!7J_KI7$y)e7fAkjF!|-$d8~%4`|V#8Ekt=`h0_jX zA>QBz0l*J(nCEMOY&SVJ1i)6`t)?8STq&Ao-vp7Q*D0rV(g3OjRzjXg@3T6iY-?BsL`5c7|wre{JJw|~KKdNmr&NDddI{uI)LcJ;Oj|1o+!-ZI9LI}Xa z%Z()j)pzFyHRED%JYG7~cX#+6E;8F47mUBYc627Z-s<)B(WONo$I`M1V>WimjuBueT%f8U- zu}#gAB-ioMo~w_R`0=)9XFL6ZRAOJ%0X#vo{LPfKsI(b2+>x%XAw;LKq#^JS0~<~h zdBgJC3il!Xh_by(JXEMn#1HQt_J?$dUv~rJo z<1^F4OSP1i98l6;~NaQUbM9u)o1mUN0Ek!0-=o#s=m$A{O!kb|GzOvmT5 zWgZ^Qq`9fdibhNk=t#)6( zo5#4oDG7aPoUi04`V|iQi_dL7o(!%W-mFo(DoGYt)8zw>CYG7t!1VSo0 zAP~m?Q{4ggNXwMv<%47qf$EMfGG0_r77+-9Zvr3?QU`&Rfk3ED4a>dd6o(y1K^Iy* zuT6s)SCf;?$e&(;b~z#n-^4%{N)`_lX+%xejUJm1A=N642#R0%fV4lbXXR1gU8ht@ zUY(qzS;4$2fS1<_ns&FL3S^%U$0eK(^3>4K^|MO^>jG-d2chQy@!EL~HY@2UpxxM` zC0|%W7oEn%pHTfl3Sdd^0hZ+Q4@+VOSP~Erb@Aqd0G9M#(gk2iK>$kv1h4>0I_hnz zVD@ebfXdiuK|uUYL2KfV#4h`BtDSA@r8m2_&pQubcd$W>p*a9mdWQ(GJ6eD$1waAp zj`qp@mYdh-BE70MVr4S$sKXS)Mx$1V!Hm?D!=*)A-^NGd1)QA* za5D=~Q#@1wzs$JRTeb%{+)seWkw;sJg^~*Z+1?7eq|;QII>9v1Z9aIsm{aNh#rpC$ z{(r1b0$_bREyXA;xtzO(NcB2@GIqD-;2d+N-aD^WF2}-y34wsx0Q6<%;DCT?0|eAL zI4ztJ-vpc}#)#Z2BLV$2+uWTp#Q{$h@uKYAfpdQByj0M%rVTc9Pn}5&Ywr3y4%TM6 z2{snM09ncVLjeXz%qlW{Gz%M7`|0Ipr|z)4Re(Wjnx76!J`I2&tA8*g|AwKeyfjeh zJ0O|TL|Taomc9cp^dG#?0-Z(gZZ#d=DyR^?*Me}hsiuDkaKreR++?MiAb=D;5j z-gfX}%(JKK9XLAnd^4g>#{31aFawg>!ekJZkYUcTxad@bmLltxg+4X*-VcU)-ldhi z|L~J&>8HK8)WD!0l2&;nAez^as9w>IGD=3WreP{ZGIHBqQJ^6WFqB?Vop(s}3pnhC zKf(?XkZPD24Hl6Qkbo3x_?BWnFajx-Y7wl77X%>ct@T1q+7JjJN)E3920)Z{FIN%u z(`^|eG7}@&yX=T+VQfSHz|*fOdp!G-sA10&IPVhhpa1@mCv;h@tQHPHKmwRoHNd=j zp#bK^*e%W3+dE>^m{pa#y*uDQB{wYL)O;{8k;LdQw{NJ514mFOPb!(EoCY?I7zBJm z&F?%0tmY>+DP-3;&;S-eU&GsNG*gi|x^$p_tTdgM&ZHBW@h-8=77vGP^BG|dds ze3DmNZ4#eFoO%k8;6NzWgOC=HK#Oi5 zi;&Bz?Sss>#B89Pdw3@%y!Qbp=X`plIrsLva0iA$r=@Yz>wu#S7`n`e-@z;!Qgvge zPqW^9ESzzVnvrS;!g&pJ90?gzB^PV1b!DG}dYeWxgL=uM&l|-emw+r%^2u0Ftq?y< zX3(;Ut)Os}UEyXFyG5s%El5m&UIplAf=v-O!s0cCMxDz)opTPpy(E2m2{t`aVo4lI zb1BzK`WDSm_ApUe;}=wilmeAZ2g``0jfoKd5tq-cXGPya86)#O*A|i{kk7ko$zU0Q zeBRxQt^|oB)rwsWikE}@Tg_yUUCAs|8q=d$jmplOUdo;zq+!dfd91q@fYZq|7=VKc zsh1v%7xR|GGYYk|GU5|uDH8e@Dipq#@XFuJAH=D^l&Js}J+A~n>D7vWieAR4T%jxG z$eEE3P1)54KIu2t73wtu1G!u2AdOi$3h|dd!M#ldSPQM|(?r+g`3xIKbKsoD_xS=g zxx`V%cj&{LpI)+S_{-c}#y;M!`Frb;&tr9606;ID0OThUq(n-N+f1Od7DXzZE z3a%2&zG@p44_5*gcT-kX*+xw?}#1e1(yVMrzIIWc% zZx6L{x2(7tAAE}gP6 z4-|=)5`hztGNR%He{hhfL+JFK0k@s?3V7(uVIg1w=K2$?QwBe z@u?;}J+sJ|Q3sBo-o}MucgkIHOZoH&m-){c8!j`TVl&XFd;@i}iGy0R5{0`$LnT_T zYO{$ri_Ydp7^L?AF6>1BT;MSO$;3lSsjI z;ikZA>g)BL;xcQ+_QFcm(CZi=6x;h#>LR|!D{8NHIMaMLx{?|+;7lBVGpSv*-<#IaHm(>Ecf5e~^(Bflt}fk$5~qGN`!KwE zJ%FN3wq^zKj59w1)FvE1jpqC2Aa4<%z0)S4X}J@i{p34V(KqcUf4sYUwX(gnrdw zA+4rOvciCG?>aX9rqCI=HfQK{Ao`s~2w`be$C1^B$ z&Rg^SQ}8i(w$P5UlrIeYZ5gj$>{7{2sDZ+_xaTyL?DhB*R0CDw=E8t}--*wF&J9y6 zEQ*d9Bl~UD9ZvO;-v`)~Qc7@Xbam9&Rq70X-c~6pF6rRNj~&;tXmp!# zMRe@4QUC*`r~n3z{Ne&siH|5*aq*y|<_g0N#7+87R)NPANXYlN_(;e=E(3{1PQ2wZ zkhnSyUO*xKhc%qewAe`o)VSjt*qKR^QWjv(AEDm%Tp!r;a+blz|GIQ0KW-~gOH|Wb zmduC?qO26~rFdw^$N6Q;?S**60Sd{5lgaO5V3)<`x?y=x%@pMSv7@lNqu414jD78} z{dv!KLx*1$=?`c3w~~TIh?=cyu-Mh54EYZCN*Y1Q6vmP@J577s+(BC%pT}JEQnhIq z#F08>^zCz=?>7&sxx8UK!to}F!KPV*7d~3H!B(SkhR&f@BSvbUbPb%z0`Y3S^OBik z0hDD>`amLPT(C}NiZ}~%6TD^eub$InOcBoxN?P>-@pHX%>3li5t&QVncL#wsZ~NP- zs>wWFa$C5;D>bT+pA)&XXnL7$!So4!$^*qdsN#x9&5 z$xDu3Fqdi#bW=tey%HR$V5A$rvC}Ea%a2~Eeqs}Kic8%7IwRls_I|Fq{>v-Po^-KP ztpF#TUBYR%{OFL0*QdsRE?q+=e42Hqs+NtJ!8YdOS`=(q%`_{AFOmrQX-0Ja!04B4)1-l^(%=kZOFQA?P@v_l+Uk2 zRvspUN(l#J^c1$9JoocbGM^s(^xMm(#e-<**_UK8+&BYU9YZEU@n2 zdq)|^OqcHaVJoEU;GvX%;q8B4@<{i~297%Te^c;gCuP%H=Pq$RF6Q35Q`H{qUm6GH zrTTbC4r1Hp{8$;zY&1V1WayxB9qq{Kdp zaHio!J}6Ep#@WW2e$~uXPd-RW=9(=2pg16!zSvP950O9*7G=Rqoz})oV%jW|Q9*+F z!@6Jg>r7w%9Ix$%0$h>haSB>aIu0nv{5c?V%0`hb<5MLzVaIHKT*fxrx#ZnBR-3|x;eIVi1HU4FZRDZ)Tka_Dqv^6()B#N=nW$q2 z;283|IPqtXsR=2aC>i>#|Q~SRKuD$z3X>{;W787AEQs%p;~WsrfX%pWDjP5!>$W#YI;I z>rvPQi+bno5(Z`F?>;I>)4w{mogt{~C=wiJ+X4mr-cX3uQ&{G#Mj9!fZ{%_8hdV2X zqYic5Qri>#X4_Zz4n9)I^VilpF0GB|5<;=RQW=`9OJyvCs)K30ED_Ao%?h^=z zZ00fxKeDRI!q~nT)oNC zC9O4ekNV}nOu%^`LOx%cqQUK>!IyxDQo`iyyz{39rHw+uaQ0l=6Yqw}xv1xc3?;5d zY}X@)NVTjjm51jqKR&t`7qRUg4JtskTx|(}|LdSrh%O(NZR+ zx-KfK`ZL^VQs=);DcPz1_R3?+)z>WTYgj1!=b%!F=YqAlhzE|1 zIgWH86bOe5tjG?oVh8`g!r@)gGEfduP_?KOy&_%=L9G4)3AR%!%~G%`t$hhF@ntRz zm|4}RuBMTR2R$eXJB5a3RS5=Z-~cVAQV2JWIyD@i$)pA}nN(qcCXeu}54yPGFFY>dWT_pH3(Bx|XntaYcldm2&Ii+en z{#UcRDb`FJE@sCM7T_31J&^c@>*|W)>2M z3+P{up8t(2z=)dZ`fM{wyj2?Mg}7b6G9vG4%mu6}7bu|Hk#hH%a&VsznbDz(4LD0E z*ci_ur%_Zii+ZkINwcG@jJ28T4{*wdBbZFSBdDZ=i;2(#J=x^bF5M~T4Q^rK`rI@b zbeoQ}F}JFU-3f5+YH+%&<*t}DlHi-?G%y%Pu=gAuaO^6|a1Jk#P{;~7Z_vK!0>=^= zP&${@Ucwk*1xH|HmMZ4Tk3ekIHTYdQE71RqA{URj#)27;H3k~@QNX#GpLhmTcT?}J z8h$)^i+G?*TE3b4krW1pit96Fsje|Ohll^%P>Wsy|-mmTaIl#C?gi|`zu!nWmk$edP^(GeO?SNPZ2<(6$c z*S^2!&#QX%KIeR_bIR@X-p^m|s8kAk-a8iYr0HvM`BhnTwZqO>w0v~1+j=I)vfFAK zWVl8Q>5(VKO-yK&Lt3lCZ`P(c1(IJEy4z`}gWuOn>RwqI`>t>W>;l18-Zlko38x(W zx1Y8iad&>Lk37cN9I15JfHUgxpt6b$605kQUj)*SpQ@ z2a0&RvCJ_h8Wu4>mvvUJ2-?W{t_YwRkM8n!Xuak*?WyqnEID%ATVUGPtW_`fnyhd1#N0GNYb<*LiQ@A0)3G)8Tx!^z2d`FY-vNqM$qBfn&j=Smk)Tg%u9IgO zCAYd2X$hqL0=lrjH*=}_Q5VzrWT7+HtfFAu1r={_n@w&68h98;X z7F$0a-DDI|)7KXB)BVasDX#Wu_Q|4-U5RIEe8qRl6H6Wo{wjm8aka7baVty0P^Po- z$xs)eb#2zz^w#8hA!l)X>_gw2a#G4{KSicd7>lsd;8cq7!c0jU>Lgc_SG5}*?w|eG zeA8Dv{*>XU+aiAhu+<$6o_{!}M<5cf`ueu)-_*3X$1GY@Ov+c}M|;IPlZ(UqPu)*> z;P`!DlD6(C@eA2CwYl0AI@bGlAYr@RgM(P>#hfS@~!H(Lw z&X0MW4u{py)s%6ZOy~dmRVdslGuks5O;NZiK^EF;#^c;rkJy%t#iFYNRH+5T$ad4| z{F2*jtXCpsvBzxkZ<#&Jq6sxW5Ia~O@xX%mMY_+p>~Yijv0(iBqs{O^YEAYg!l`6a z;4x^%m7=unkY*FK+c|N2Ftt(h@eurdK?hwj<#CZ}9w|iJ-r5i5fC>r5Ha2YKcqRVg zTv4=iNAFu*8K;s%ZL!Sgi6=*;X%%NNI!i%ba@II?2O{Fz z)9T=#H>v`d`Y3PumX$={NlFN{CEmY5U$K{=rYpgKop;dtSN{jg0>=!~)tmk?+6_KflzG8?aSdV!Qrpn!@jR}^@zz&_Yt%SJ|Sp$=|sOKVuq z2RfI@%7yhF+{;0~71sFHWsc#{W&+v^qZ|_m3jtotb-n`;6p}VtKPuUr`fyp3^T=jY zON)Hk=%Xf6i*RfBf&&!--qIg#G9Ie>uJH%Ry}h@ys&w>7WC?tz z=suOwsgg(tteVL%z$I?G5$6)ebn{&B(I+Z|{+e8%Zf292o=HPgYi^o3Y6~L1F}qQ6 z2&!Zsl|`xRCCoGeXVFpZWHLym;#tv(vPGP<>l5PYbRcO0TVwu;$zks_47aBe^P*HP*JTd3B5ty=rl4%7c}h5B{Z-NPa>#nr z@$m6iuc#`uo){VGwDL=a5RY^b)w;&~p3y1Mm+VhW>>aJs*7*H2dP0|Zx#i|`zu~My zg0)-6^DW8Hv5}Ai&WF)RK1!chwN8kOu`c%{wD~LMCEkzbFcP$!jAw#R9gKn_Mgl+X z?>B)CrsJ*VpqF{UC(j$k3&spxxoq&mho&NGq%YgCSy!1r!Lt}SxURV1g;x3zAHony z`h^jR_BA_s8IkDZcu1O?vX3+LxQwB``4PJ^aR26KM*p7-6Y5Zk(R(nJbi#JpU|MT) z(l?U}ngnK|+1pzhNS2SivtA^{n_rm8cFstBvFs%Czc^tp- zhKyb6VMBiA0qlH^CCA;LE89@EQIrLhHvd7b8RJsZ1|L$57G@9rxZY-20E9tj$Rh!yiInne(sH@b#6Y_p5pT$gwhd zX#BX&PR5xEIFr`I_LRkuzQ5><8}F5RfJ56#S)`g}{;n-rv^q=W=^{vVW4j`?Za5+D z5L^4L$FXbL#6V?Drvl8WK|72Ye)XtDTdAluCFo8VPy24Xt)#u__C2k=SSWJGoP&7= zj4zbIp-2|SApLvez!V>UoK;WG*77Z42272i<42eUfuFK4Yjd)|5|Lplo3GPg^p&mN z&?vo14L-*g{uw;Z_F%yGAC|0f`AlFYH19EPj|FtrF98KZ-uDe!oR$6C9PeF$rjzd% z)+QPp(vXY_KFWY{3;S4`>afXO-BCG3wBN7X{1~ zr4LWm3yJWCt>AtW;hao~D`^gzn@psxV!~ZC*hRu?u1!XD2s_O&)aqV+1= zLG@X9b{oTFIygc7I*TG~iinq3j(al-3}4*TG3L^-Cz)R_JFB@k+uoK##wV{#K$EI{OH-yjPOKMgt5(Q$LR?V$J|)%Mb38V9f@Y(k~cw>F%? z;_(1B0Zu}FfHlV-iS;Wd))HusT)dSUO7~`EH#+&s8#ke&e#BU;8gl}F#&FxbbQ0BT zMeJPAU4%|zxQ^^a)l9@TtzB2<|AxSD(c^Cg8C$(~)Ma_v+fRN%V{l4|t{AV4*+H^hM^n>b`pl{Ay=Os^~mt;NOPa*jc=o;6nH zxk6#|=|Ce~skD8Id66-$O5DcZn>^p?-#JJWw^Pyk z=IHq2@n(GojMM6IS1@Iiy?CR!be^_J-Z;BoL+$#Z}@)yj6g0 zW6*(zNqytn=;+X!n~KOT$kJto*U#T}MEB@YAKq+gv!_CRXI9%LK%pG7-6Z(R3*$0K z#_{J_oz7%(8t?}c5{ngHpS{9ZVZ!uR!;$(sX9)-(>pCp*@Xx=D(Az!QX&6!vt4)&x zK^8(B{<70OEj@C;^y}=&cWp5IAB%NZu2D3TmAELQm;s8s6N-8Etz87x@9(p*oV{2X zoF(<8SLPFd6K5kCNl2xwTj48Es3g4R2cMTm2N>k1qM=cut5_0A*x3>Vd`L5EAd8dl z-c?J1LzDVxIl3;%(cHv#^gT^n1cvB_)O&j6Ph6>a(o|B#zb=??P6Fdmwv~07&{eFY z0MF-gBp8YA&ZqJVOcy@w@9<=|J<#jb@|d7y_pQzz0)O`RS}rn>&zkJgJeurC&*wg1=LJoZmEY{7~nvW*91HMTHsGN|KK&Nxrh}8Sht}9x1 zz6E_{E>70kVlx+W$D@n506-k*?P_Q>Wq`-mUVgj;Nws6U^_7g!`ESh)Hj|r!I}AA$gIA#0f4(v<>IP z2PTOUBfxDK!GsY$L5nWr@>)o6%&Zx?wagNfCMI$tXUJVWVJmq4NgHOwkN_-2NI-Xb z5ck($ZrfPV&#rWC+k=rIizaJNzAiL<4j&vjjlxr&o2?)Oc}8ON43+9y-{3#(N@y$zlOr20bgTBx4%jtQY`@=_^z zt9f|VsBHv1Zmr~!7@N91=!T-Zx-a5%E5Rd;Uv`D*4Z;+ov6i~mU(DK`AX&vA(W^~o z%Y(_?WXD^<2#G6U9!Ch1s`lw>4vt?%i>1kd%jqolLV*>l`A{;n_R=J=@8CpU{OS{| zv~$#tbb8s3lM%ytLmDyLl~R!O9<+eo&k`TcUn0bdVNq?X%Nemmg&Mh&SfhIihei$P z_3X*>KiPdpRCCz9sCqi4O{mi>JkxGkd8@Id*OL}RC-Jja3#&YycXG@)!sobE#boMd z=NO3J!_n>s-f;ugI5<_t!>sbWGr*|%Hk;WT=utaz9OyeJe|E? zoMVs%ADTe4^tql{J9JW`shtul{Ovbur>su3-lGGDYnN@muneH129h9tG{Av+YOLAQ zl}?~rfJ#>PnEk{ZkK!uuYYdeU3U<3XOR^P?q%og|XH0a>KKYIAXU>Pd>|+bMJ=rjS zYcRgWl;q|zG85i2pLG$;X(e~KldgMG1-&xjZ=`9SnjIFX^^(&SY5c4#Cf(T7aPIfF z6JZCRg7I~+`+P@`sK2=xwUR(B;+Cjtnxn1SUaE_ldt9RxJB|UGn&O|p%+r6%NuFJq zwT-KXND<(T?Z$*b5zHDt(OsuM!urKwO;rBgysjk%1N!{49Mqyao{$R7Ey(boVGv~4 z?vA}KU4OULijgDtrh*VT6aLR#UNS!m%7T6igGpZ4BW`G2v(hdyti;O%xt=3vPTZPB z4Ky$AfS7aOtlQF*{z@cg`pPg}Hk+^ENVgX}O4syj)?&-OZ4G4RI{%b8P%IT>=hoW8m3U56^KTO^t{JjDiSm;vXsu|Qno$B6SGVkt%5h@|^Rks{6^K4DX{9V% z!;xPPH??%p_Vo>1je!SaJtf{r&t2otozJr|coZ_%?V|g`^uy`vL*0*`s-ZOIS4MS5 zj0wvI7TPD%X1JlwcMQGj+h%@~je;f!k|YuD`kJfwxbBxHyQeSb%Oi%$Rvzcx5L#`s zf8jFlXSu{*zGesyTP+P&M-}T6AQf8P*RgJK>l~bJN$A5#50RUbxFjBXS(9L!cQr3P*~j-p zh+X$fZ@L4@u?XH9R=RoFNzO~#*OV)a>%*1*?W5$9!P#;nA1!0hp~ScTZ3#yBWtl0= zX`REH><}Zj?R2c+RvW&d8P+#9(CA|o-U|vSjn2`mVE6T|WXC?~nJdzW@wawVe>Qu# zI(!OQSjzwK5%0KT4t6CPk3iKboPhGSnjLY$?U#>>CZ;t;cN(!}SP5_O4 z*$ht0Atm~R<&VO0yG{2Dh(U_(Mo9MfI719mF%Nw&1FUR(P~nLrqXa+fzOWQtl2S_+ zdu17B7+A<$tFR|ax8zd@w?IYDRFXtw_vM7;IvrJHGo)~|oHmfiRj%6*WXi{UD^liS zF1y;cLbR$~`RQ^3b&3Y^MxQ&o%!xI5r2OmIlDBj;+f8@H%wUGH_92 zOvNw36t+<5j4LzG#z2i$O`RnJ3oEqd+zHMosTMdrz?gW18>*kPzjK(4E{kkBC5fbn zi9e=^&6%3T(MjOPo}2Ggxw>(1Y>A??X-WmObfz`q5M2bT17($4qQt>jI&&-!$<`fO z$hvEK-FdSzBli#BLJbyZJ+{u-cSr+XjuO9pDfujArB9o%FuGy)G1Hr&W7`It`r;Q^ z>^ba@ViM{jD}tZd&Y5y2Lx-(jZBUMx*uUTYl@1o?W#WBj)Oo}e@V>g6>5)BFn*^@# zPKdI6u)Z*=uxXNb{b)+PIgk(s=(@1ZM31p{{K&7c;D5;%9Vww(UpGg_yvU?9?c%o( z@0&(C5b!rC!@ZdW3qG!^yOAaMUz@ui*&V2&Jid=7L1T>H6G1rjm5+5JVI?Q0bhKSnDQEv^pt2ECcg}NkpbAE=J>c3 zV2dU6y;gA1ZH#|yW3Gk-3sy*-v@5c9|BTskzBCx`SZI+Z>aFn>fofd%Rp|~F%3 z1vs=8iH==qJd~XFs>NJpXACbY?5(1hyDMj_9Nr-gtk}3ou@|c_MrOH_Ar=W!TMQQ} zJmN2lH_mDlNHoTQ4r)m#C79 zF`nl#L_{{)TBEdEf;i5L4u15#)gj zqHRCEQ5%f`7Z{gnYEq24m;Cj-Ip{|;&Htz}f2LyHr7Ez0D7~zjM5NKp@$sn|rzdM6 zO*z@E{J#s=Rw@=VR+iDr#x}KRSPhpyd~z8cnPwWfoR1tL_WCNKgFkN*>Lk7V^>1$b z{*Mp{^^uQ+(eMy>{E|O3UAdX9>%<^i3_{*@Lli#Ep{v&tGOUOCzU0U)$Lqwp;%kap zxrjW5i6sWHF=djne|T(ty#uze&>(M`Lrl?_G|^m#>Wi{i%++1l@2rS)Fr#K`XogJR zGqjd|o-#ht)V-OTBAdPV_GzVOPf@2Rze4g|t{ZqQ{(ydiu3!xtxjnd#5JuR>#GA62 zQhVl5PscpA`z_YR`SDk)0HS-BVclMnd`}?gmIj)txuoyH`#xrz|Fby=s&x4wVZZID zFD?u(Pn3n_Kw~UYsh^{!;qu?naV#kNkPJYIgfJ@#-yplBd{$njMmx+X{=w8LdxLh( zCjiwjP6@rYf@<(bTT^Mn%RG>x|B^$g_<)j$hl!tiSfh_<%1XcR;kempcMzsedDzFZ z!P%)(ky3r*+BGst>3E8!J@6GL81~>zJ2Q{j!yeq$~O4WDr7Yx4JUHWOXJbw%Vts=(e*DltT7` z6G_(l+EeNJCT|PYa+y6bUTLtm?s(>G;^dd_Ixt;!E z%i$}3o%DaE9>|7bIwz0^QdZWHoV4Z9+Zz#U24X2{26m^L={QAARR{=VR3ue`EF0CM zjx|K9aYg9gh~@?ptI~#) z_sMZzN~q_Oq!}JOq=ZdgquJhJOfTd3RA$@0u4N#JDZD$KoOLK*Ui4U%AHuWin=cq; z2=8)lkg42*Q*=!#%a}1@l~d=D#v%H+`@;_Spf_}UcUzGRsm!8TSyl@n|Ah-0Q~RQ# z_X+LrXn2@Rc5chk#T^pgXeV0ooPcn~9V4+3q&1e%_1x_5CYlDpLt)=iib@nSJo!1>@>RHgry?{4jZXH$Pv#`VnmJ zdzZK08nFfIR)5c31}?ki;CrEG|ML$RtX3D1*27mWSvY(^O6Ylzg8Nn>$L}Hb|J!7 zMoy+%yIY-oM$IWgBR`p{+^S^^uR$itNB1x#AV`>;R?DGi5@7fZ(Qg@sTR*#Rj!I0fZr!>cnxI47^L~_os zq}agN^9f-xwky3f4e$Qa{3x}i6>IwP*KQ+_79Y!MMQ>lj(}`;rG! zJfbbO2{jQN3lmM8|Bxf+uoNjvG1#ezzlx77nVUTAwk*!(I^A0Gh-Qxe(8OTr%cGZ- zlo;;?hl)$Yevvq>;$h`@JBpS`1Nn$t$%E(4r79U=)p>yQrtd(i0jIbaT?ub4^CJ!I z;WAux)BLv<0m&(KQoGj0Djo<;je(Qif3z&-eWd+IOX9CohCm;1Vh%vdS$9_nfR+{i zPfNGZKRdVdvqZ2LWb_)Q)Td^Izo(l5U2sFuzzyVql^eE#^)!G7x}m&tRx#GBjQL^H z?;XRHjQg&iLxVFoyc_E@g+B06OX{Ca3d$fkIZE^3TS&5M9`2>U?`sc%B;+~-VW1-)+1T(T5aN&az1g6?d-?f`^7jwThT(YNUjU)a#!!)#7 z>T+arp#G$71clt3asG=1Kap@tM|DLnz=hDBMO&+rN(gC?qPswxW?u)p+>TlL)IYn? zO&@mDLYrrXI;k9vrHG0H&%G#^R7*}yU&YAXs@yPM_Y@7Qvc7i)={H8t9_kPk-=29v z#u4?enO+o3F1$k2fjeZ(hFI<;ACrD2KV^1pAN0#(8(j;%jDt!}tdYer6;&}zk&TO} z;(peyQ~3{*ef7XpeU-VKm0oG`K;J!BcL#^hcB_kE5zwmM*85Xn@@upPQaKhdYkcJ# zlup^{({5eOt#reXp}FyZQN=JsHl~&_)BdtsD0N#>-z%Fiu~3lYt}X&7I{VOis{biE zs<^@gMZCEmi7Y9(e8@r@7bazM%V(gM)&?T}z)E*ue^*B~w_@ZsD^#qXZkeFy>_bFZ zyzYCGl0#n{-x!a9< zhQ<=F9Fk^Qc%BmtxUF^kC5Zsq07uw$OtPkTf+s}`;44?j7lvK-b6xd&qvg+|8ziHgO+OaEH2GX*)Z%kL~6X zC}1ESsF~7s>WF8Y_7fBjTy}U-rKU9fFgMiGZ~9TnpGH^VlVzgjZR@X>130t zr=u1WAe9P>Vq022jwLMA$dNW4T__-lH>1?I8J9>p0B3K#za#NKwC-*wa)q=kJQ-X!_YqwqzqYN085IhN*d5 zw6+E!z4=nR(GnPZz%SeN(DE%ho?qn6H|u?Np_@(TLJs6DS}}dAf;r+%TtC|^P52?H zTG8;To9^v66qB3undT0{Ng!3D8J9D7*GWm*!kC`U8fzn^qxyc4Q3ko^%nxt*9FD^{~=Tq6Jgq1Lh zZmCC@@Nrh%$w%0;Mu`;_p8`v!UG=NbnyY&Mu_4xJB>iF+ld93-KV8BVO^<3!z3lUk zH{Kdce;z4T1DxS1r?x!St3ntfVu;Z{gLLrTDyE|8xbaEy5w9NkpiI{w%Br#&esB)b z^Tr58ayg1V%sYmjjq7g5UWK-0DXL#GFtAqyV!(GiGtazR z!=e=eT}SO&1RFf;&XR3JjhNGK;4V)=3I(%_K=q!|ot_Cx@uS|^29B_0RG-RCO|N>w zHyb^*{Cp+=hxCE8E#4+aTc+v|&EK3Q87RE{v&00d?%8IR!4Z%a8#ALu)uRAYhiVXJ zE0qTJj+nH(Q9e8-5yez2Lfa#eQQlL>o|~qWsY&aHO*ibsw_OM=2Bt;#2;LZq*S?G~ z!*>N+xO4Rf5E-Lo=J7?`(y8g4P8HMzI-t6LhM5hpi=d+3Q&0JblfXK*X>re{Q^C&N zKSZ8x#h+%#L5WAMWwS@%>m6gwwWprV(;w4uJOeKs+YqS#=uykZZnav$KK0WR{J+A!g>Lp1d}u;GyOyqa`TXS~1y6fxqsB;Rc(R?ruU#S+ zhB4V@RjxdD<2+r0laElRi;s;F+l&s)P1^JfWhl_xOx5~CvXJY%wo`uz&cwXpAAAdE zR_*OOl_SWbnY*gZYzZd@+@cWjgd2j8X^y5#afbJ?al5{AUTohvIPO^+-J%`*8VS!s z3J*V}m3&WJzTQhI_6i!SuUE_buz6FL^#O^-F0eX_stAo9d6k*oSbC*9ARwxEp0oM; z0+C&J9&T8}h8f~!fX`9z^1J?w1_Q3}hMa%1GBuy3e;HRt2l$*8%>#Uz-oyWZpbRS0!z;Im*9?mq>Lh zH3yV_<+bwdEFg_={^d+Ckg-&1dsIjoFzs+Lzf*2U8_XAMNR%4v@r!xUXqk}eFDO#G zRfh5c1mXrGeCgruTdxT}0dFEFgG(-Y<6rmnGzmuSf;$7l(nw@igIY&F;@moq0jHxA z=rCqC%iS;PB4r32a`y;;{aSP?*$4FSH0@S|BV<{Emomz*$Ss@dx-0W6;mbNTT0;|x zjU8_;HaDzzwMy376Hx^`A2eAuucVOr!fW_v7OdL&skO&G?2gA2>*y>=l&wlFOQ8xa z3vAf}hmm@d8_Omwe(9r~SlifWp4oZtlSVwSBvpc8X*j`UNr^;YNx30kQmT38s_vki zL1q5M&C&58M1z=PTfYQNlDC2b)o6T4mFuPit^2R^&8|JQ%$n0ro81E+iS0z^BC!(= z2d7$@tpkuVKNw-tB61SQ`duRw2meZA(P(lJ1bZy?sk5nzkD={a^qB5-&#vJK0789W zizgtjQig6>hAkpL@2O2ip6T|(doQ5Wj{Rs4s!6v~zOw^yzVCdJM#4Vrm}83K*V5Wp zsAfmK6(279tMTFZo3Aox`t9g;?62VD4n(57Q5Q?8c$x9^1g)B(YVYBqiZRS63}Xo!CBxSFGUPK!RZR#~xsn;ZoZX z&e4%wq(6(pmy-BE%i+@wb1N4ww5G8kgWkq8bhLNz;^OKw5uXhTTn<0pIkE*8K5N3f z#b$`i8A1(sk^LLPoR?fc4sVL3gDbs`JUu>ANpp7}I&GFjn&s{dd8=|B9H{y@!8ps1Yorq|mcTBeu{)ZMq5DFyKQf(d4cutA&<&f- z&n=NlBz^Hq#`)gI9V_TPx0{YtU1}&7x100Rftg?<1{<3e0zO~(Xz0RxGn@UXfvFfo zdvMiIU4D5Vz4+22hI&Wx4|q%LaJpY^tdB+FqZ5WHB_46eOe=j9V8#zN=%Tc1g)S;~ zYgp)Gey+Gk9t8PKF#HS@CTSo=sM>R;CBgq52wQpDw^RMOo$yuf_3U=B{a2XaL_;eu z>wnV3n4Z|o)^}=91i%umdyU9zVT$r(&i0WR^4PFwrc6UIa)5+Z$bBnmGSZu&rwx*1 zZ6~9PU%K29->9)WF}j{ITLqdXxO@{t@1-2+UsqqWhXDDXx-_tIv}D{O5v z@q)ti5V&4YA@}t%a~q@LiIH)>`1TM|ZC>&VUzvooy(CDG9p_c3yUxUAj8F!f@|?4o zZS&ON9LN{(uNk@mhp}pdXI%7Y+O6t#3*WD@I%INiwR<7BhiLW=c-o@X`mW`{g*DSX zRRD0>#=DaR8Z92SeTW-_`SP;^yFmupSp1*YKyxNpg2Gvy!?`Zn7-Z3hj%z(XJSX zK8^U$eNimh3^4`62&cB&E(;1@@%w&%x7*5-zxl}nEB%=u9q9B? zHaTWg7^7g0#vRuTS-*^a5ZbCSHHwrf%AnXXIyBN%OByn-^WkI#-n$|||6 zPPzoWQFoBVy^o+P@A`lC8+53e35Jw~Z0_!_Hqrc`?@c_=3vsGR_oVwQt}75Unx{T@ z2+K!XXPK;4DmcoC4+aLw7h`)d*n--x5I=%B%NACTrfAv%J#mBWMmJj#&T7I>Z?N!j zgx{KLPVfJ=VTxB3=K1TM^e=M)ZK>}Bj>^>A7GYYMJt@yX&f_{V|8?(F?=NapmjtsT zg3#u%DGdC88$w05T@oy2N3VtR?G7&wS_@w&sO;n3<@LeV-u|H5w{gVdZJ5!wqG+b^ zXW`a^z>IYxOru<1BTTSe8p>0^MNPO%D$2K5m02!)eSDPBx9V2E8ezD@dbPdD^&Mcb zPuTDa>SozWq$}b?tAD>j;Pei){}}6tXOo)v3eBnTk|ZW~%(g7))PB8xpyqY6fAVPm zAvojxOfjXD5XJxC*(hW92r5$r_r)K#rj->A{?+_)ZoZg8Q`Yoqp*lZf1MM`>+5ar$+c|xMWqbm@Z)weAJ6kiTqdq_iGeoR&|L`3qC@NZ2$XqB?@_g@ z*sVk4@E2*_?PV`uCT=qFawmTKA!Wz?L=uKJM6fMI?6-Dvy{D+w4>yOWU1p)fe@)LjmKocG ztW!XuCCBNmYP1HuA7)+Q0kzAVcvT~c+R(VW-l7p<>bUOezhaI2##v)0E_%OPOH6MR zy*e=vDH8*cvi0m*3c@ueOIJZ!&to}hU8I`%p$bpW?HNx~-%OLbqFIZn9{$JScgrP=@4fnP7 zbRe}3GyQZ`nngNEHoMX8I(bIluoU9hc2iMFQ7PbYe5?&b&~4~@+Hxv;7DNlM1666U zXBr%qT3D5$XSD%k=j=zI?y4ij1Qh_aNK{J|tAjE7epr>wtBx||@(XKuTnS271SlgT zF1h}1;F)U$>~aCMz4rOY)1-T=OwJ`JK?U5WqIeF>#&fuF66X^p+g8=T|7KBD1Y{7K z-PKh9Iq(gsS9vciR49<9!md(UWWG=r!6*GK1wqgBh%?`fvG_CgvCy?oNs%)bgR+f* zO1N&_dQ1K5l-cf1;%R)EywOy|*%NT_1l47W_Wj(*zZ$`wJC|}afm+6`eQ93akKb&2 zv2i_N=QA~^wiXtWntl6xryH8R5Yh9N`kw$WR3Pmqy9#}YxxUt~rybjy=iDn@JXP?L z&mNqH`mwFH>snWr=50$VuIO0EhSPlaO;Q{RZANUXRYCh*XPGiMKs*cx$vLu$VM6JFKEOo!;8iZ z6jJ~V{dt|e?@$Ihx zq8HY5j%mNwYP&_JqG9blJoN^*L0`nbob8Ugx@I)NetfZ-Fvd z3Z!cIgDHjPz~2M6gf@|W$!|8>Xi0Z(`qyTbrD}K-bS|-(e4ei}Ug_BcYQUkC^_>Ho zQm7r90)F;@3(CV0Y}B=twv$}>H-o8BewZMf^*Gk_D@t0izlPJ#at{XM&>8%Et;mguvv5BR+$s& z47mog+-q4aC7~pbJmaXb6Oe!s9Y@rGFG*j(!Lvsmkb|66ia&t6E&Z*L(Z3;RiVxI9 zk6{bj{K~$zCXV9VnL!7mDgz4mYYyMg62kN4}zHz)`HV>xWqzss(|GK^WE z?6ICel<)`&Py!1V(&rFmbJrCd?bj*6H61am6wWyug2Za|ROJ&CT34!7vg2&m)4Zf~AM!8B`Apuz9< zqFpZY%cgvuqzKaw;jNs@=|q@l;PnOKy0I;PBty2Q-hY0l zlRC2Fqv=puGXj5iEVSg~kq2m;-{CN-zgOiN?yqPP7503Mj#C)i*Idxq#4LT~Au-!M z3zj*HxppoXrk}9k?CKLkm6NmqGRnJF_m$P*E>3dxTbSf(}Ns?cqL=i#wqtz9%y z2B=ziaIF_8dgf4+yk!i>iT>TGjf>btQ9?Q)HCzm;9UAln0ut)|`XdkC%9Gpwv3C&3LElGwZ;i?u#No*?G8o z(SMX(?ILsgO7yxuN86hAO!BN$W3DP&{;G99RDF(i{Ndh5;$U??h+_3ID|;n3+5^J{ za7Mpe=$5V2+l5-j`O zhSUheek@_fa2*dD-9X_VMgG=O@<^lbEz`N615r@pd-CmQ0)>G<@L@~%iEu_R;dtoM zwas^pkq`X^5zLB_txCiPl?%WeJ;Ro_n;5JpKlaJbhcZvLNUQ!>=-0D5CFkfg!L;w` ztBRb8WJYA-+5C!Rg8~P6TYheckNYBItw~S6iVx=Y_3D2;9X<6`Z40Pma1fYs57RV| zxoWVLN~;~st1mw{Rzb%;F3nNAYw3<2XAwwq z2;k@Uk2_f_qX*S4*OSc|`R%gtrR#eKzTRmz0jOikr*I=s_b|piI2NZh3Akz3&orjC zCie$}J!WHg3Ceq?Juk6nm#VCWovfV-qj%a;mc-1S>2;NF%fWzySj+A4e*cD+dv zbyg<0gmqS?akPfUxV=QYck} zxJwCDT6OebI{hQ}{3FBgTBmuF!K0iaDncR~0G5_$>pyLKlOugv`JifY%^1 zvL5|lY1#XbjY&9(IF)pG8CCs0z|*_>eQ5aGM}1S;Z0|0CjB55%9<9rPRWORG?dKoa zZ56LOXN4Jc2NfHZ0_-)qCC z+u`j|yXRY@wx`JMZ|gP$+fkmif2^pJA2NMN*`q>L`jf~pY%3v^l|rB+h&ZldRKG*z zt`5E>Xr5W!%Rs^^iG-pI^-$-S&eD73gri$Hg00jMw$aa@ciK%g`8U}u@iXrn;&qNu^cSafL>^^@_z)c-Ka{_tQJp7PyFkp~!U2klyX0tdnF$*) z{WM*yY^xSdVqeLEOmY<3szKYIZ&wK!JnT4U!l%VP=|0asgwSuMyg6hX56Zm)T0v2o z<573Guur?}@R3a;C?Oyc$v6=Ak4LC`{@#Y#@NKgb^t2DS5T+8v%JzLL;XySC^pboS zP?QOQRJ$$Vw}w#IMP=axLz}ridpZv6;Y#>EjR+cjI?1k9^|jhUJiBAB>qOI@vLr#0 z;p05!w4EE*j|sd|4b>|QyWRFZ z^G5=7NB0(-2~zNi&v*Pw*d`tG>spK}m*qzcw~!yt*N^b&Mh7n#R))!+sg`p{gK4Tr z1g?!d>MlhuM6HXr@z;>XXp&4laqbD>c{QizR)e@l7tv;to$Iv zPg{Pkn6}*AYP-gsf@e4CF3w;yw6&3DVqkrqW{j3bImXdn3WuK*g)x-{{QC9}Qq*9YGAaO(^Yo4G6Q#G;P~FdW!B)kjr(k4~epm z4iQ#Yk&a^y+pPj0FzA+|e2iw3*S>gm{4NKFu{g|-=1oBZ>x$H-Gz-xNgBkIzR*r>U zUkg8-htZwt%h3A7alDV8v2l#=4XGxE`QXGwFbKsV{?z~~J$BY2pAFRrMRcylWj`Hu z)Hp5!HtfI9O*I!`1=5_d|K3UgJm{sbJW_!l3PEQI%ES$gdfiUogmdJM!C8OrV=x_+x%P#?j#`AzYT z<}wHRZT8M(_s}co>8F7?59IU_=37QNr_A-~Y`bda>K9MGew}2#^^>+VEWA2efv&gi zD!*D24U1v$P8Hv#fwhZasCV5Fv+TWfwjS=Q_mCCQK=s;Ho%C0+xi>C(*jeE=HTtO#v)jwnV zVE7K{xzd*LA(r8JYYBndQ1;m*!}lf9lQS>7-A>r=#n~mLTLg=GLm7r5MUT0X>n%*9 zwd1*!J3l0MpH>62P@pQSH+#^&T?gwMP&S5{3f$%qa z{%^_Ebo`E;Gl|>A3?p5#n*sB6n);pASuProyQ7x}PvV7#VcI`Jwa@9Q_)&S$TDHw&dAgR=vYgBVQF5QEuUIYAK|D^2Dx?6@HdPL z)qm=Bix0MgVe9{h`s%2tzvq3rLqbBOTaoTAkwzLMC6(^(PU&uxuBBt?ZjjEUL6(lC zv+gEp|WN zx0b|OIT2RKIFUNYDG&cBx+DN{X(a zG&N%f3?uWdTUBQRj6%iLp;*%onT|CihSR8K$89mE;|ER!x}j_%`6*O3(QL*F)3G=E z1vND?6wt|j!Y|XGFZZX_U1cd2SW11@9AF5KvM>AF7rs8XDc|4v-sx5o7=C5U6OPVZ z@`?nWXnQ!b-&@&!`}F6lr5#_;}et$@#xvWfO(*Cf;=holINMJ4|$)He#_)(Wm@;^;5(BL+|-XX3R=Hxq$-wt}7QVt708X)34=sq$-{B z+B{o$6|XC$>Xk*!ylpeLP@3>q^A2_R)8gKC>2tmEU!i-1KPhy(bMeu#)!da3t!y{^ zvSeMYMbQ^!2XUWGsM_@EE8g$q z#V@72faGiBr*BvXd+?fW5{ojIMBm_8Kyw`v0|F^op5 z(mn0XYYo2>hO(J;CXn7bs4itXHV9VX&Owlqy)rp_dU=ZZ(B63CSQP;~K41ETxLK!P z;Adh)54K|Fb$fq_3$=T_@u9!JBh13(H0&l@Avxf94?hK+9hBPkhGRphha|Gk{X`Ib zbQHLy>uw1X93zgZ_D_RwJUfJQ?DQbStO6Np#og|@kQ#g9_hCAc@%F6mXIPTAzivB@ z%(@x(S>G#`?&-?I=sFjD?;KYvwC0#?t0x`24LT@9<6RfHNytpEqzd$}v8nO3c8gX& zo_=GaNs+%T>hhMhwuioLQghnv&0qa!%TkqSEuBD-Flv|>)nu0dHkZSZHB?OT;&ygv zQtJ^X=aoc>{k+IgGr7j0gHvmUKa|3R$&*+B9e}qXqKf;VHkh`9ZEt2=(@5qAKl9h< zhQ7cbK`_TF(RnR1xIeqkzO<81CE&@pg|zc#Qhx!iaqV-6a@p~@(omzkHoyvkNi^!0 zJr;C0$d1e%|9(_(xYwwy=;*TS@LQzE-Bt1-=%l5X2R~7Hz*v^Zafh!ZFIGIAnx3$M zw2psiEJr6pR@0y0&~pf`x#WE|JB@0oQ@Zw6Hz?$4N7K8%L#^j0yyRGIIC9Xs2#452%IwvDJTshy_P z#3QfA9x%7rrWr=Y&67h$g$OpxyUmBh?$Kz>wKdz(qH_WDg^&!JbBvqiU;rj5Xxcu@ zPQQp)kqRuSi~Oh$SQ2Q^$vB~k;NOyl^@gH<+FxNI+}5;w+BpE{Tlue@TB4YXj6dVQ-|O4WtaXarBq8^FfsLnix<&lh;-=3_iR4vRJqhtQ;7mJ`c5tzd_= zGe?xfAPDAN>Ajb93LrZ5T<%z<+g&H02VbzLxb0ltgOsmx8wVf2J3i@0xVpk1R*Dqx zZhqTKO4d_jN9Tg1TcO0H8A9j1cJ>AEQo_hW-{Qp>RjNj?U`YG*w;hrejg6lsbR zE5bIA%BmgJab@m82cr}knAWWoq$mx6vZ#e(0~mT%?t3ztWGL`=6wTRBbQR9!s;X4t z=((`&D-8?sHplq6uGHlt*)-{6>1NdqHiT4mR=5pM4tBDhiuN9T=F(e?m04Vj4Za6a z#0#7rIjVC4qbg3!FxRwGlwXn!+Lw0d->N5Ge9qE(OKWR%RAiAy)y~2z%u6O6cX<4n zaVLKf<8kd(O4|X0L!3HsS;btV_riPzjqE+)>~SYal!!8e#>zp?J7qXBp9$H1(`*{Z zoGy$1(BsS@Ov1x=dOx{>SVc{z7Ovqw_E%BUt#O15fIeU!K;*v<08FRRp23PF~0(Dn;|6~O*90FPI8Vs(H@~l zvyrn%MeU!!36t-A;vrBcMEv-P$@E`n*+Yyj0PZmx#Strj6pamDrm8OYd+WvK%Hh!0 zJ~9yDU5;C}46sK<+~rgSc!0&R2EChm3FAS=B00bpOHJ!EgOGjhHLyI-z0G_S_vnM8 zn|m!^;>Av{?E~H2XcmiY)l05V?dp-=2RHQ1WRkJF2>eE!m|<0E6e3F~RnR4kLaBC{ zHXlXOZva7RlA_s-j!K%zlE}1TG?fR|w~uID3apQh!df0!-^5^D;dIr<T*M(l<=B8j=et`9_Fn}*Wx>dZM zbOwHJ?W*l;4SdW7Hd)yw8RW)@meofHZF$sjNrjr$U#IQM$Z5NiCq)A*n!NNLpc@VM zPqiQ!a@rtt+L>GO_}P~ezJFcbdbV2Sf3Zq_(tlaSpDgY2P}-8Fet>tL2A|NR@4t1D z!|sBeL-WkH?=+4_#Q=(RE2YjiFruJoaMyoMY18Xiusd&VQwEY(9cpt^amO`dG!X-b zvI^^oFTa`c`I}GMNjZ!}dV(Sg1CaL|I2<4t!iApQ(>l`AZH>R=f}nAv0MMt7%l6B- zhM~X{L<*p&rR0;*a$s}yHw$NjvLj9sG^*`r!jXS87V=ux=v?oP%p84h%&?anSU^S$ z2|!T;tcSKqKE6OekG-@AYB4+xOPovde7(2#_*yXqcH^i|Hd%i2Od*mSfw4?$Y20#$ zcJkbr!7TV8I599TkaOtgG7hOT#kbG>s=X37Vl?kVy!?weQ!q5{uFw&m<_c47;(EVD z4~^ETJ-Im)P;0s5d!`Y*M!zZWT!@g{ZiR=n6zLG1V|~uZ356C_iNm^-@?_cw76-jl z;=izhRtljFsYMo-It7kfn;o-c*HYBTcdc+iD#4)CRQsgk!G)_Wn+@_&7XU2&hM=lyY5CwU};0Y%_`vs z)7~pnoMCYlO89>^$bNmMee?q^R&NgeEF1yFopu%TOkeGNl=a0n6RRm6-Wh{{Mb|7h zoZU?rzv3AlHp5UXZxL{-;+o|9b2nHM-ahFs`^n{e#NDN)I@sPXEP9yl#VC?HAi9rs zKzPtRr20i3eO754!6meYtGw+|{-+#8DBHmYgtM9#5dhJ^5sLa`kl+61kp-f$Q^qn! zIR=gl_R>IHu0(OD^uMS5k?{G7i^=k(Rv_#5n=9uS%U8fN&|7P`Skl22Fv^^u*YTD( zSVanJ8mWjuZx3g9VGnsi>iyz&x$5f=8ZGM#oj&hjI*B(cv7lu>R z;YD07nQ1HwkiFr{-zXEbWZ@w)M-wf{tOZL z{ZWKJg|!oKvo;3nT57Atllxr=iCQukWbyEBYme)QNpC}|;Jy2T_PuGbsduEF&waIM zXQLi}{hqi==YnOf+Rld^E3G}$T^d%`M-Ym{nU`f*D`m?@P$D<406k=Fk)GX1x`2>f zhYNckVug4b45dr7-n$^5l$ge?0TD|97X<$2h&@4TfFn*PpFA09b=4wTFe}L|{4KOc z+rg(O$?#t;xdv!Q;?5lmXeY#x0c@qh?aV>HVbPj-?dmqQ0R6bUs>jPP&m|9AnUuQ& z8620VKh;1V>iwqVVGF#&o5EKj)%2t50~n*FV~+ML>sX|Z6q^bC9D_YCVyVnQdbQC- zb=1TO!2xTd`KAg!medApgGXB;n!0p3yDpFlrwoFOxj z7j+iugE4TQ_Rqa*Dh{K};xlz?6^g9Kw&$9fsuKi$CGL-QCO=5|c(3_+lrlu&{Y-!7 zLxy-0V51xF9vhPsJ|*qo+9FWVnetw;JR53up}Bi#?$!Bpi_L-({%ii2zNa7FqruO^ zX@y)>hZpTnb=!L$i*eEvwikwx?ZKd7nT(*ACm^=H&{WjOjNR>>{Q%z;B}hI^-+@O| zpF*#^?zEceks7Vd;xtms`2)4W(Uuj}b4C(KMBCB^ZlTWtMB%CRWa z6Bg<7j)*6$Xs<2Ve{nSj%{m8t44wiCmxbtEvgp&j@y?nNuvfl8&Lqd>5GVCZ{U3aZb(6My__ZAU5GE;_-4keSC5<;-g61iaf{K*(zT|AfH*C#25*q6#^w?sgp>*6^?&T(=gsi)7I! zzlUJ~juyKt{y1whqPOTd~8$ve?-Mb@6j??^hxr?Ng5) z&dUsZJ5r3p%sQ@~0{UkiM)uMj&N%jsAM)%Q!@Rm%tTuKW-ipqz2l&m?S%C9L&?mx~ z#$Hc^k57_Lg#RSSiU)IGOc3Vs|F;!fR(?#QVUJ)hf(JfkdmKgJoZ!3C|LWh)LF|IY z{r#N$$Kjt9j~b1vad?b@6fAR_l-*+?eE8S>60}-O{8@I%`bLDmhVW zkApF%qt-wzY36^*g0twgo>1V4W&3JO5f(C@U&?PsN6F)qK-_X-Y|6rqXfO)ThwA>Z z<{_|~e~}BQlrkhN$bZ8EAUBO->BtlO}R@MROSm zRn13+4nFNuS0cNGF!m&nc%08lhoMl!@M_2Y2aZHz6pyEfuDx$?7y^ z%=nRJg+3+<4DC4k`{7459Jl#;JiX9QF1+6{aa-peyEN*hE%3h(%K4VyhMg!>yBRId zf;>gzBjhjp#ytH>g@=*idxq3jHYLS-hXdM8ED!K}>hgY7`_CYIyX!A*$`w8^7OEfH zwEUyP_1r(N-(_^Fb8C|Q4sY%f@BhbPH#%mB%W2`8IP+Md!q~pmAkR z(>$+W7d&t=k@KKTrN@VvOp{S-dee+Q2-3XYHPzYaTM@@1wXG|dTtOjtDq{R(lRb>B zMACRI^3=P~n}f7*-yjkn4HGWxqg$RW1OP|sE7~3UAvF*((~Y01gkO~7(?}S!{KcgX1J1X9={AA+j{V;}?PG35T8Eb7v5aCQFU6luTHs2YvuN ziQ@QCKKnN+U3@XYUJk8R7K9F9Vxk{8g?CJRisWw(q6Hsa`jD}dXnuawQVMfBz)ER$ zPO#srZ)!NTtnIT>+A>eSf7wv^04SaDr`L5dNK5PL5Q|UupIauQm16GPIeH%0cJSx4J~iK0&;@T>XFl3ydoZ$M>$qg;6q*8g=g8+bxe%57)nSx#e# zGM>IOeji@*7KDy39XD*dqw#eqrf=XYc@01un+1qtvjB1IiWSG9olj z6Gp>gPi>Ygme&UgHYzVF~zZNA29fxJQHsnM?+K@lnwZU$P@PonLjSlkqz<+ zQBj#3i7;Kvp|uhd1!vUew?KOASQKY@SF1lqIEDdtRkvckbvp3WKgeaiE1({2BOfUY48A@7#X*X9&F) zn^dK)3)HZX0KBiKkQ{=xDTw&T?$zm@tyI-f;0c=>4M5~PsRFC?ai^EA<|X8AIc(ot zLyNzXv9lQE3H}7*#XCs2HG}_r>LFdDS&dPnGw8L5FI{C61Kv~uZo_}l#NGZ$TaDpR zwpb>iMR7HeJdsAP`ib;!V*~|)i)Z1Cd4GRexF_lN{)#>nBv6o}+Ew-@Y_(een%=z* z#m^@|iBXSQQ#blEwwIe_`Ez}JX3Eq|L7Y1=4_IckjMvHAp08|9_UJ$#0X^ogkk{Q# zbLURKZ6lw^>Opnd9|xa!4j2{IJA7^prAA>FCK{~kiUmoZGMXFs-vapC9y03Mp#T60 zc`p|~$v2K%E=YET$0}}O3V-z23n|Aw*S7wxLAb+#BLrZhIY7!Jboz$I?9tV;KP}~u z((_jqW=PZ7lOa2Yyn3XXV_1(^8`^%h+H*w)K&jV+B!?Rh=2$0o01!eT?=EE97 zmT>UTJ_i1=Nd=4ed37}VWUu-{AU2&WiRHTwYhP6?R60iQZ7e6WUAKLmS^OAHFC3PtCpU;f@3@LwoA!A(uBX}^= zYqr%AYq7<>+45ZAXQFw#Sa$mJF+zIR6S5Ylxb3($#nWutB(bT7%PZF^W2EO6cedH8 zU$u2V?lNsip}dTIv18S;^1%W5R&UMk{RH%7+^9=A>9>Alkj)aXkTV*+6d)Pc2ug5< z4BWVdC#IVwm9r9m{OwQ?5&SMyU;xS6e;aT%$hSs=bU+7DBxhUIl`NH`@m$f*t@cIJ zzX@pMc7?rV)~99b5|p`xgRtE2IV|`a(ofE=a85xI^l5zKjtI;wh}Snf6*x`fe1bm` zJkT;9vWutl*=@r|&ghvY><&cEjPeYGY{B~~0EtI`&{JACg50^gufh_{WTd%~?@9QZ z$Ig#?wPI7f$joJw{&@2M#{S;pR2F=aell8b#-C}cwsz~Q^yQ9jC0@EI0D9V!RxfI6 zsnXO*Eue4_!Eq&6B`ea5_A3-CA(qV+;5s{9AR^t2+HrCJ?^*p|jZo zTuq>pHvhj)n$<{^uG#?i_#6Qx9_i6eun})PHVE~)7RbB0PACHc0OLnJa&2+-e6|Iz zli#4W*ZZoGyN(XRQjzIkJ8jSF0mFAvElb$}K@YkaREP&OSlNsFM(J6oJY`97iFE_K zl|_3~JMSDFd$4fr9RblK@6>#?odG8Z0~9YNfR$uAUodTKVbHRp*K>pOWDp*n|IA@8^S%i5q-B4gFy+7kO4&8 zPjrfhiCyE|PD2;yqJ-EWZ$O?u`OzsLFK_VDZKSGGZJ=SvA!Q~oT3Eu2q;+!ih5^x2 zc?GU@EeB@V@}NhaGHf`P`dLxrTTz&x0I-6he=8tsVKsGdakxY~@1IjOThL_s|132Z zhr4^rKMz-g2Xm+eqPS@=f?X?QXVt&kwVWk}4uYm2-{6k`XUxp!d&h)sL~%1i@EFp! zER6O)fBJ+?2>=-21kt)c+nRY5)k^{>zHiQj@^uynGWucbrPa8^jz_LnqO>QRV6Vge z`@AAKr$q(tfKT8!$R`A<_NZXg1H2aA)X51}h=GW17TTTK?h(zxC;B|p;^QwAcSFbU z@v(jG)S|Q&`!@BmUg^7Y-&mlmCWc-pI@02+CU$e7UO;Ac0%T?zas3sfJc5uaqI}qX)y@uFf^oJ&u*n zv{{y73X-K!i;hmI&Fg~Aa*M2&8O)F*3Yb>CCd60fS)Jt+H&+wGVfb=a&PM}x9Uo*~ z61!YNYUr}$-u_hfEZ$>gQm}gZ_|9mG{V%|;;*r+Yj3-&I#mhLn)I_)~j3fF)-@SH0 zItw9SA%kZDc;lJ}XgpN_+3q0RLT~(gle1IlHDKXM3^WZ>>*RGZQ2oW(F%txsX zOhm58_1cTQ?UA1rA~XA4_{*x5bAAes9OeGjUKDmx>Ze}KJ_Pp74D6c_^TDjOlTFEh zn_li=aGH|v9;GaloTF?2&50F%TbEm6#v3A+rXfj0s`iO!xjaey*`V1H>DCKKPc z*P|HoG-z@Y8yzsI}IEqN7XRtZdtA&`+j>?drTIM;zhy z9)1&Bl|ACL2??dO_k*^Ja?wj`$A_ljD!t^xu%Ks0AAb1>Lxav%@2Bf~GH2Ib>etYq zsa(Y9^N0)3@r2e+mPEPKaa_PTo)QE!=7~ol3V6^_e_G~o$C6Gh^@zPW^jH0pZ<=f-GF7eg6(ozHOYv_+%n5K z7PjVTNN;C5k(k@`r9jWfQV9#!E+SU? zi9W>=Fs>cfZ79|*BF&VQb<${RzBdus2svuD)I_uA@A?T?M}{KmiUS^U(&+h7v(CcL z%>E`JIRSI*y_;>vyfvZ-H);oWR&@mgni^rf@t-$gyZNn;IIwFkY7_mpA5LGZ=Ef5FiHk^&*@H}s z!n_+G){3n+Y?wQIi~$JT0+#z&k>9>LD}(rv|Bink$@~1ypMrPSH@%I&>Lq6^^~FK^ z1cf3jG}BQZ7{-hZkD(DUHuWxccnQ9?8>v2Q7vV1EQ_JmJI-|ao($O`^F0PL|qxudE zEj;2$>mAXMh_ExLYEJ0pKMS~vY`6TDDp@i&=USMcJhZ`SIPEnkdVLvR(X_xDIeoKR z3uO*` z8i3g@pC6U+AFB#hIaS}E5WYOlHfFZlTZUz-0#%L*x|`*;#PGAqC-_HZ4-EU@b%I?Z z)M-Ky;tq0-Tj3sIV2bNPkdb2FMySh9yf(>SU(|6(1mjY$O9U9X*>VH<0Q~DavPqE) zx8q;@QO}4PX2GJJ>nVohBl>GaI^RqQE5Bg}jl0?<&sc`(Z`~JNOt!66rrso*?D^`S ze3SVlaeL2Q@CVGqmfKEC#G3L}|6#)5qnl^CC%fO>wZhZ(W3)ZO!$a{%tx#0 z8w8sL&-Bl*yg9=F|7)8TfN`I| z=5wPZy1c1ZZ~!^7${q zVN$#5zUo5}#02cS<~%FJV?ifvkUQvg`aQz$0JSBpmGQ5q6P`_NhU*&EcLx$r#}9jp ztx=9{Y1xHB))e}|m~YM+!O?NOnDO6nZD~5hU`nYJ`3v?DA)b)BB0RjS_qisiP)nE0 zH{*sKiWB(n_n zv|N*D?@|Pm{vF3UL)svV>>z$Mig;yv5A>k9-3j)tcz(8TdoVA@?4FPYLN4ZcR*c8O zQrc&p>{8FF=XE5P0P~MUgTnOD_Ts--7S|ND^~F5hS{IP}cD|QmUQd;{z@HajFNAQ8 z>|5vzY_!j-(K$a{#YF^mvy6BSm7vq;B>`SNsNbI}yXjB+V5G#D>7RN*gb}3g1?ueP z>1b>!K;B6H0VR_W54oPOk5gq&pTLZKE>-i?Yu7~co9pP@KIDf>_d^BQC+y!VJ_<^Q zT&@vs{w@x@0uN}ksAzYD#sAcYw6U^P9}9RA=T<4(&64paxy8y$KWy5}6BO!NuyVsQ zoc@P{@W{{(@Oa=V)&mH#O&xtmtKd}47yb>;ciM^Q_QJ+Z$eG@#U{c_UHlMFXdn}Bn z4Z=dumDH#{TlbZdUbU-y6>OQ&`*Py~2H%P zsw*@EOsY>CH{cYG5Dpw(RoJ5PhF$`2T3`-8EF zwr8c&#ZE)0Z$(~$Nca6HPv7(b@vlV!FU9kchg^V?n;;3#NpKUWpEmu~kJ^`~qWYyJ zSRF}Guc$FdJOOs2BA2mgk1N3lpgrPAF0K?yjXCrfoPlz$QA7VEX`Ecu;0LkCS>3kb^Ah4gH%}`vEVzY7~?JolDl}3Smej27>WNtQ0_s0!7 z!yV*hcEOlITp+ZY_X_y}q1_xz-Wk~cRJNld-XBg-tQ@V=SGVIWMn=7Zv;qK@3J3v} z!p)&Jv9(bPy09`F-6t0&VyU)U7;J<5Zz)F^mGuDaBq`cD5D==Lo_fzdiEv_iZ<|8e zUPGz)CM^<(Bp;|U{*~is(m-tNma%3=T4CJ|Gy)piMnGdb5PZ@}ZHp=pU&lq$L(zSY z)Kxt?PSx@s>6gpq>Dq$nhZ}433jBVRmC?!xV$T9Y5BLK$ej^#4%-=4XfOMPG_njrx z+6nl_$U7FpturmE?BK7p+8yiUxDoeI;njt=t1PTlz6#f)thmsq(vH<~$IgY=$Lp}; z>yD=zzjT6o6UWuk(bAWq$7UT{&GiJy7ExNiyDZj}o10|5tBh)T`9t#%$!}~y%1V}@ z(E@BecHwkMg*Zrs7r+bv8TZG(3S7qo`5`zZK?OhA&nY&z`;2XFDLPf&w3Nwn+g~$2 zFY26aulWtNzQnn`n3|NLM)Lx-f-+#7G~T@!!#EYB`O2$A z3%N#~Up;Q_!q=tE?mC>gv(yi~d@{oM8%-f8{o_IUJ*F>;4lpca6ikIbiY||bW<8`W zhE2*nRcO6DLXtBH@Ra0Vqk$v=#JCKhn@3J+lU9Q=2Uh#{D{E9U3wQcR^bQR(Pf-2d z@LexcnSZ{OIy|@(y&7Tjm<$iy>NP0LQv)8Xu7=#)n%#<_zId7v$O-#J#b42>E-!vM zx^ruwWcU>zg0N`($VR~fi^8a*uED)FzsRKNe0YFQRc@?2@3ay0TH z1T~}9XGkfZEK{WoQ#MnzJpt;;-d^6dJ0CE(cce$EW%*g^700iQU%}=>jF>b+DcUL8 zBN9ehBM6S_9P#7sMIC%Xzo4-?#FX-dI2?x({)PBa!YcY`uG-WX45gUodg-4Ql6Cq{ zh|cQzt1XmZ2G}qIhuF#nNsS2hoI?hy>l33jR8aY-rWZdO#CNV9 zFuaOry@!HUAjuCSa~_?mKFk1DrBlQ3N)XmyPz_zjA@*ySi->S+`iK%j@_l*=i`2z9 zxSwG3jeIuRk)=+T{>LTeQGOboxrA;#v%r!rz$WeppO#NaQHH}&F71yC@JCeU&>9Q>Y4OdU ziVEgqZ5^1X)Kit2)bHR=J`zt`?tTdjv%+fzbKg(L7Rv(q1=X4dZ_wYhg`RZHnI0@T#L{qyquk2iUD2(uftxW02Tn4Bxd5W+<9H^rRPMGo zkFi1%GCW-)?x{q&&31f96?FYfWXy%fT#tK*2h645T#heB&)m1v-Ou>_o!JTi+VZiK7u_&yFS)j(46UTI;THdAp+>7V1>c`-}4)8KB8h#uO^8Y%!02;9Bh<@uF8B8gbul96pw{tav zDuyhO3)3ZpKAOIqMgAM{GUq0-)0GA+30uNu6tE;<0k>AlIh(wtGf8nC!B6c!~j4eYC>(X%T*KW*Pz`=XAJ(KXM98JHntb>2%l z@kz3!Y~}Ib<&pKW0>a_>@Tk>HsE|~_ed;0Sh~kx)N%f2H)+_N3S4~nNo1G&tod?pH zz(}z0cw*~fL^irv=((adsh%*v@Wr*`aMegveRZPf%7pyqXoz{dwUE;F?KpEGZ9%qw z;jqo!D?hrSS#CM;G&0gCxA(}uj)$~Mw3zH`XzJA0l-lv@+eDMVF_3FDgGa}lN6n7v zcS9C~VN#!b8@&+d$p5wdi?EeZ3`Q+=hpejGb-qjg5PW*51cBTA1iwXSqjFhJv!TMuNfbm zF~XTln!{)WIQ|Hia2>b-!HAm0S3_Z~A;5Kvi#2~`{^L)Gx1O$9w=4@sSWH$YB)qs zX%?2bP(Wv@l6SH_{lMF0U#~o_@7wsdzlvghAzn)^?|o_l=$Cr73AwcFx|`~H@}6&Df(6CVff ztzaja5^L9wPRB;|*?3HizURBfV-M3sxuA$|f95}6T(4JrXV~WJFz*{4^>WVYr~90F zkIQ;$j;`#h0HtAM^w6wge4^s-1ZUzsN##E)yFXC;?LF;KX_euG@k1qN{HfVBrkfaW z&yx}YBqPf5edEPW$hB!fxYOl#CSMXJSN=XbxEdGT8WJ+UhAMaJy&5v8Fo|{yXjjv1 z=`!Bt>g#6NK9fXL`D=vDOf1u^)dIX%t3Vc z6}8F^{|RJscRRIp4O$gn?==L;x6UGIVP1$ShVOr**SBN;=AdO!C-jFjo zptl6wHIqV<;OLJMcQ=5T(=YZ*FCc-LH3_axgMMEkQpJmkq@X^r>G}v@_P~7SyD!*O z40vOSFpkF+yNhvvQF!trUNjcmA&Xrda)b+ai1ZD)*iO2w<0N|ZPd4r{#Go9}9e)dK zui|;Ae_u|4z#{8`D%lancNb8Ymqu6>EKTa#!%>|7(zT!^KC|#1X=jFoC4GUdENG1& zTqDe0vNkH%%SG%l*Q7j1|N3BSdV>|EDmDJQE(yt>&!m4S5{gX22P0MfQV?2qtF||C zfr_|Pa(GuXWa*KDV!0~AqAl5bCZl~^bLOZitM_f3CpX79VJ3lUBgnH+b=UxdLx%-{ zc>>_$d@3|j<}C0}33oR)o96zI*t|EXpjfBsTd%1XLvtug;)-Au0SlDFPTuF1nv&o--~;vXcuOt3!amma$0ZjDy!n zA6^NUf67D65F`KIy{j;kM4Uc0H;MU65BQnP1o+HMTrQ%w<$6e&IRMC~P)W(8XO(+h| z4CX-I|ArI0Ss9?cHyzN5b#^bN2DK9sEPurc> zyZimQBdD-M%9gKXv&+yKY2dw*<3X47ipFJ^8Uf~$4C0)36emri;Ica%N1t=+b5CBi zIyV-~jBcQ_?WF5SKt=Lh4G3B#u^=WI_V1k;anS&J2Hq6+nuZ30acP@0Mt0%5!d3L;K~w34C>2wtMI_!j2OkHz<`MH zC@{YvzF*m;mQf6F^iWzthrJdNv5n1+3ZdV2Ksi_CHmBw12Ru?_WWkTKZ?KFqb=)CrU27Zb+bG1W zk^%4tm??11dT!~6>{~Isj)T%~cL0k9C zvP(-*hK9K+i+mp3I+62gZSfsb)-_WFut#5H;20h+B1+OKTE-9FLkeI>dF#FuiS=%D72F*^d(FZd}u=nlYizY#?-y<=alhodQ zk-%ZC!G5!_h|p@axZxcqDwX#V@*k2`UCNoymLF~Bv`#woxN_s}U(}WRQw5(?m<PCgPxbkuZO?2-|JQP%;r9f9^36ce`z^`B|@}zRVVKb*+H)qk~guBnRZFxo6dM8 zpCtTOKY?CRvZqMAqAUIvfT@3bnwY=e2o!_=W%t^c5NU_|D<*=g#S!km=aR>0Fi7?Q z2S4Wa1m-HsuDQntu|HTm$E7vB-OOT-b=O&AkHz3Of>dpW-8p=v-y4=?7gY&$(`M*3jJ$b;nv^>z8*m+|KeN^0hn9swukAD z1sZvs$7*q&t<_*r+ScO#4eB!_Nm#>bwXB=scI{aqWar+rw8HJ~-% z5l(;#Laj-$#>8y9Ii8MgE9kU(%FK}_`3~i%Uxue2`Xq4xgA-Pp2S_7KUsdNcTb~s- zOgUQ;?}eM9z1(h9|4r*_x@p&%hP!opq{4lN%<2wAfc9c6&qW4d?7zzBcCFmrnE%FX zTOM1yezEJ>@>AuIBA-$sAJ?*HuH(&(LQqdSRPkKP^rK4pxKi7V&FsMUa}Ox$koyT8 zllO()FH)0&d6muyw=76;B-xFxl+{jLUQQ*H@fH1cxHnMx`gxTL6`QZ9c*6KZ-m5De%DoE= zzFwUu);bOzJD(vzC;f*fvwCKexX;v+hQ^739VD!j*W1p?eHUy?FG6)2u};pKUo=c%}CZSy?T^!zDR zzwb_d@f3+_Y{ku{9Si5J@);aO6GYVIX^{MJpYzbBFR;8L$2fB<>&FS8^0!LH>_M?k zz=CCEcW11yJKXs{aC9haQ*(Xqr&WDd7?M7IbGbulzZ+3G*8P3#Ij#inj%OeGSOV3d zYGC=@i0-%XuS7SX_>0^3ONZTu6r|HqLj|w~zHu@XfW0yC4(&;6iZb=-MeT)R5tf&* zb?kqgBe3_ZA^MDhuzvs>dkNUsKkl-nbhRHDrkFDhNK=n)A=a*M?jv4@Iz90u3w_!# zWnEdNKd$pB>Lr?=++20w@_KkI{+^>CItD196y>m6!+lrk9R) z!?aszNqw@&+(gEvBQSggTK4IXPbSBSew&Z)$;@0Otq79&0-Mg?ps|eo z5W+5W+Pj$K4#{BrXIcyySDjE5IUA>XDYt2ds~fy2V29JYuXluh!`27u&b|bbLnG(o&CaMIx5}GEaR_7PuqU z0g9|^&+KuATlj`U!2!itKvFIQIrn$5N=x~l$2dW2m~So)76rdv*G`+ojO0bEfvA#& zt@?LMTa>#(*JZTvozBZfI(cXILReIZrEXhxCc9seS*3#D{Mr%#%(6z27*=Z+N3OYb z0&%{RD0AtOWugMDPK>!EqnN9maRU*%nZWQ3SovmTE9!Bgq%tpM7T@cyNg{7d7DySq z02mDTT@oeGAf*NC%?~8vmacg7s=*H?j$Pjl8i`yck7++^epSfwCAm6SDlHYX?)rgH z#5SispR)wyacdlrD78SQS}{0FIVqnLwMv)J_jOtP{veILZ&~`vtX^9Xnv1=_2nT?NXo*`L9ZP}@(5VUo=D2g=lU-%=>3Tb2 z%}HaMRQJmH1I?h#-weKBw0>Jx-yrhH$Nm!GzWV)$WV`#vXVj)mdaR@JKd6;>)oaA{_`aHda@A>n9)|v4*#vl@=ToBwZCs&}NE|n-Z;jy32 z*qSq_Cx1qG;vEAO22XF#=fcy#JH|Rnppf{kb~$Otbw;(z?jamnqju~0dH!}^bn(bc z`$C?Fl=bt8Tqex;*(S}Cm;+h6uc(($FW*t`@FCJEjM<)@lkD!a*e96IETu!W0j#!( zZoem9%_IDfMiD=ti z0*gJ9ATc?qk0HL))l zdYyh-6OTgb;lkMyxvrZ-Sj-V?`<^WV6S(4stvf@4zAA{Z^&1ZIn~zZCX|kDUe%M(+Tk0Qvj-~$Qrf!+6F#BfYM zNCq}l`(>v~KDARLZE&Q&xXBK^e!SMa@AoVGaxQnbt?ULgxIjp&3nZeEAV1g@VAj6V zt{{+D0=4?<7|?6q1y^8KzBg#Nuej&DV%-PH767&SuO6ien`|N1D;rqO8JMKV&d1sF zk9IY^7h^YPFE0>|p3g6hym;dqt7k)998rf1LGsH;9ZG#)90o@YJbLL#b{p#n=^P^@ z^Y4)8pu(vnt}C1x`S{bAgka>BYC<2$?)>GKj}BR6uBo`#?M)vk!3QiM&bGBQWNbb! zcy_3tPO}H}ijj^qs=-Yf{)d!Krm&TOOZNi4y3t9CI5IWe^Xr-3P+aC#1XuD~HAfUeS12 zZOkw8TK9CcaHw8ENE{Ghr+!?mApo@CG8FKt;aSRJD&M;Qj+qV4Q9iIl-cjTNC7g-V^{WcDhM`x|MLs6Bwg)!4i-(gRyC47?2E$4 zO#)?JC!}=#uScXVm+lnMRf?+jjPO)~|2D@Fj*u<}1lLv$s+l{CQ5P>DN~-q+Qq zi95M5uE+!x4_Q{|mH)l~lc{jjnke8qj&~^Wt+(R*Q`qR@&NlfQtHx}bnQx8BW`8uJ zfLgIz)J^5nn+63wvDkm8m(I5&3}%TmBMby_{K_n{dSQ{u4C^i0T%$tpB%li6@)6Q&nS5jkZh!5m@Q+ycVes8|0XtVp3MA>to{8wBDM;lA<+;&A;O~Z z9#CFzoU^SFp5gbLVS1^9f1PlGm2?8d55PhMtDvx_0(!Z)i!JTBtTDdZdEJ;D$1^e; z)Y7br$#u&vb|VF|h+3CLyZDPI4n|tX2#vJj{HzjabD_j_VHxKNLfHclwJYNsB8~Fm zLQa^RY&OULmQOcoN-exeytFTH;s*$aD#GL6hxAC$E|T6N;S1gxECV-}5?`*hii>U$ ziCvxO7*>kUpe8dx^*)g2wnMALRXNo^k_8&p`qtUy5^%R5;O1Q;chRUTR zA>}(0QwPO}0?k9`sGACarquJqa;SXYR7m*h^;Sq0t*nRzrh9)KdV+<%4Ydh?jAHx@ z0{+4K$V-n+1;H-3IPkCCVgsFAvx?{6IYla!G25pqaD?57KQ1{p6-0*Nx3_^0BeI|3 z9>QhgW02??p_dBH|Ii0l3>C zmj?F0Vv_LYa;UiU6aeKREm||l`<@?ytFk&a@OQEvU|o@TNmJR>c|oSxmv}V5IY3+| z#~OE|#u`UA)dY|Kjzl~M17&gwkbj1y%;<+x^d!)v==+O5PcnDDv@Hb66lSW5+Tq|6 zgrr8nO+o{~`fQfIx`j5sx+ToJp%uLHC1Jyn>^C)ZXI7l4k&FL9e(k^-r=1MYrqr?x zeEf`RA>~b1Hq|t4-YfjfHM(XtYH$XJLIJ7J(7+uDqW+FzmO1?a70G4_p7Ce^Xil_- z=1r%Ew*~-NB{DrB;ngu`nRp9qz~7QajB+-xuaibdcr>^L zvp7}KS)avaOFA?Z;4^FR{KSs%rNLMlb`<+GgI#e@&Wo5Pmh9|or(_Xgt6JxzyyrdN~ks_Dm=qVEF+ysLv0l7dVE8TLH@4@HoI6DA8j-ivhwGLrIMBy$`J58!Twhrih2Yee_UWWW5 zFDOx)t*=FvOojLvA0r)e{QsNF{qyI4b9s9H{BJG}cd~$xkT}|MjQXxR9A*QapBrJo za;*$I-odYIjF<(QSWZ_8z*rl)6FT&w0b5_~`fuxl@V$T@*)ZL#Y|~>a6y%xGsOYT?woXBvzANLL zrJN$ez^nmRAQ;64mHKllpkQG4q(-7Yk+v)gVKr~wonithhAU!Y)t7t<3z*{G=7qgULT{N>itqmS3zbrhd1or{)9DL{5=KSp`0?@M!W zk?-yYL{wW}YN%4a__eA5Sgi!x3c^M<#s39VH$b$*V=@vMpTr6_sn8fpRhcM&l6*^v zQ}mnFAxJwH@Z9WvW$NI=yXam0gKr}y{6)cIgr#V#7F)J)MLvfmBX&jH4BF=C6-K}o zdehDN6O6rgGi>*n(D|j?oMTv&ElGw&>u4W-1faF;KxZJ>rWZ zIy?aH#$sXsdOa|-0U6t@AWIB-;@T3FPlD+~9^-!4!q^1|)Z6;ox&glps*jQ2F#y7M zMnL#3168zOfK@|4ry1j3D>Q z=P;`L_*nDsBwgX`Xe-r15=^oQajYF2&UHU60SlVH3Yk__4*kvo`mWFmZefTpR>0iL zfw||q&HcE*h_({Bd^~_W?07ZtAGNjX6ON10{La;X^(npJk~xjIZX9-^@uVkf#{r_; zg9L^J!bZ~^Ve+6Uj+FNkx)1It5syg6ch_}{L(oo6n_>bboajyz%)}?`K@}arNbSd! zMCiLvcHDIAbE|wn+%TTNtV{T3PyA-f##nhM72E8#C$Sh_U+8!B&@)8{P|;w=v11_7 zChkqN0W6OTB|c#>=wr;P`@NF;{<#@Za<=Lf8l zJ1=40>EpeLPFTtw^KVbbPacFElv#1OCotV-!vu(%5DOF!P{{iBS@ABkeb*n-Zu_;8 zB=r)nI{mhh#WJTh`9@YxjkC9rzGvG9`;%W@S77T2US9xnjy)lsL>A%RV$W-o=mAcg z2yK@~9%Xd#U#fCxBr1c5>$j$w#G3y+1Bl4*Lxu|qBP>wUdvH8JFC+pb>dT8+aM}rH zs^gzFYC^2>?CF)t%dnM)cpKUYzy{U93HR`=LEpL&yD#t@-{)`ATht~Bi1w5##4(J> zBv(ykMvaQ(mi%#&;WIJt3&uo^xEk{Lo;wXX+H^uZWVtoNMQE4w98Co}eaB%}(14df zG75wN@VNGOA23aq`>1xgCq(G6Xm=Ru-!_xma5EXlK}CF2_Lxp(-AS=1`=|p}KVG)y zo$gFK9#gBqDG;ysaS6VK&ptY`3{Fr_qwl-W-lBsc9Tg?4>iLIx6L)={zo0Q&WZSuq> z;)NSyv2a{T8?qxor|J0=-gAk*jxWwmo*dF9*TPQDjyXQEjo6yS)uO!JYy7H(tz{wQ z4_uU&f+ULygjb{A-k}mEsxbr>9s==;V)MrZb4?Qw0Y-`!z4!mEJ+_RvUUtf{giU`W zPieFmls{9S>BXjiov#8yd3W_6u?!&Q*3E@{eumQWk21ElJ zV6aYaLI2Cgvk|d~zt{_(Lcse9Jh8p{s4})zUD1@?geL+7Qu2L*bI>EMvTMS~PJlx5 zZ*7M@6d9Y>8A4Oa%%dw6#xjktSUdooO_S>$GkrRWa{!QxPcPG*9I<_;zQ;N>>VZD{ zIb1aP(c;IWA|Lb{Atdpd=1< zm`)=dfRap~1wvyKecUz&AR;%IrSqt`K+4shm|3Ok!VqmhTkO%c-q9Cyd_+wD&TH!Q zkqiL3!&z*$yGkK}B}g%z&}Jpdg@$XLY1bExuzdE3YWZwiPv;_2tZBveM1^_u=!sBR zo8++)R|kbTmSmPdC(Z=Vb^dC*v(EJ|LOXS6YdT?ij(l>J?be_Q96SLI2oXD-aGM5* zhBVy}sawKyNHrA-brPw%Ge953SEz)ge@9_VA!#6XzA=yo0@=*Gxn-nV z3rL}`o>D-|L8$n3a_8|qDW7&a3&BpZb(Ifk+YTQBDyFP&16m9DU1z_M1bzPC6k<`UB;s1i=3%^RCDPPe#tTL&~X6 zzd1U)AU+`$-^e3)ht2f+AUSy#H4cYZ7eSpm{%`*`>-XCI@)-9P*g-I%5ee7f%-7oR z1--ic6@2#l)A30vmZg1YK1ZYc5M=4z(OOZp`uH`XAK9R4*FA@_cQ} zE5}`L?dsAaPzN)6x~*3+Ao)yklKc@om9SF+sBer&1HU$C(^_6n*u6ORXl`2j<-K+F z-Z1u2j!%D@D<)!QfNS=cL&kn4FvJ76Xejp#Gq~(O=1z~z%S;x_n2K2t$EcZO@8K;H zQ%pi<7Xj4=*q-&yfbNYE{N~DZ%_-7U;UJI}9k=MWJP%<%$&XHsDKi zUXUGu1@}(RmPPF?+7pvhr8p(#^}O!qn3nhy2HWB`mx{ttRD$Uf`rmtReOP7Xj`v(#w9uV~jA!%%`#l5blM z;E(eC#KuXK{LdP>^x>DLH)LZ5n$D2QwPRDT;-fGI0y?;k4Dkbuaoet^z)kHPOPp1O zF?9(^%B-w#WOZLPa#`k&tP@|mL%~gXvb7vgcsxtnh6`_d3>^1Vzh{qnNa?r9ZR~p$ zc#upJw(^b5=YuH)!h_M8cZRWp8fJfpBe?8~yjdIu%&RRxDp+yc&ZDmt#)yfebyHGK zWb6TZ>CAFYB2c7UXy>BWwJ$7jr{zTzU#KJGuKR~adQV`+f==@Q(=$f8Dgc-s34mJ) zHea6%ljoLA`GVzv*t2D`TD$%N6MoxJ-p`B3oM7xw|XHfSN!}5UM^*^z{`{4ypdjVEOQM-F^|R_RHQ924&TiMT!{7deYA`afc9VoWfb5Z*!bmFigH@`k=Dt# zyLKDXHZT~~#E8(dO6`=ip#k`AGy(*$c@V(ntz0~c-n0|&Qs2t`xu4+Z`h^IC1hLA!OhB)8=$pf8rEA1IQ}_U_35IJ6?^mr_!O3=K;gy9q^2lAsN`crP&W-uL{Aqr8V- zT7}&uZ@DBueK>FM4 z_mWMix8>mJk;f+kZs+*tH_D5R)LpSg)(!O^nprJV8ed7b&pEYp6$PavLy%>ZDpqwl z3>7{XDtr=i*y*?0M?Z~vfpK0;b7qoPWVvYBa3m7E4`dKP%}FU5%N?h&cnN=p(YwEW zxs?{O^(BG{zl*1ZX)2$+R55uPO{&ZEY_1c6Xk|W{(Z|rVPN>donxS5B_ z2F6unsZ$fc2(2iGF!VoyuU|_rq{mOtz&T!-B(pHpcY8vM^Gt?4X7b8=NH%^>zJ3)N zlw69ntx?3(0?2K`Rw$C`ZS^H2OqEbw$``E|(c81)dMk-Y9%sFQ9$E?%nvw6+7QG)v!uA{EN zG*fxnJFc@IT-5KagLq&0x%lhXR@N<6zM>6mYdgZx9|*wO zAEXU@MR?Uah0e9P179m_et2f+=Bou~QTk2mT!XP@^4DP9W3V*HN~QkV$uml6Ahs+V zAtOb7a55br`9VH*Z$J>i+q04UMAFW!*7q@L$KEG^r&Uw~SxXZ>hg@-fC8HFA5_)alTTpQDvWL!1Y5L-z5|cug4X=Qq6S zl^hkKb!sF`-RJroUG52sOmlcte=-N*&_zTiX5u_Kq;pHeDvegF0MJx@WH9cJEXcsw z@`n{(%2Skgb}i0`upDz9O0erVXpeu?qA~(-nQmSGyz1COhB|X|9#qc9w@jSENRM)< z$e(;*aMxPG$XvAVl^VP&zPBlp(06*kZFpuTi99FFAaRg{%$ykr4H@|sfL4P67wiaP zE;RK-v5@`XFIRYv5@6TzgdpC=t%tAy2s;9V3D2NMG9q&5x=cM~(rcpz0`o$?5U`-F6ZZZ#i>nzXP)J<-(;|1Q`Eb1|4KZH9f zggpQ=o>Y&@U?glfcAeC}9H};Yb#-mq_|Blh;4yyL@QQw1<@+XkVyLcytB9U_Aw@a9 z#XmW4W&&*T;WwGGl^Asg0w%YUKH3niZ1xMOB(h1R{2V1@HqMZ(WbT!J$Ew>MQV3X{ zix*GDn_f(|JL@y++%$ooSxPO0h=+W0(@J4?z#zJTL0l3voVa$sfn^&&QBf*R4in8` z$9#(H5L6`lzaYHCBU?k(A-kf$&G0*=yv_K&<^m4F@(=Y$bLZ9=u@A?grCcZUq&2OUL+7`Lhvwz%kr2TE(1Z6ip zkII@bOJ&6IeXo-3KRe8rX>_Oh!;=uZ^T=fHbQ1%dA_`fiTWxWs9`hd*FmeD z-m_&#^ST~oxlrYW+ZWn#E2lFVc?c}nZ&dVbMw*X(=UnhxX&j5Pj#wFXj_!FU5;|#M zCpP|(LNx^)Dy*a7%?XYqa-BoiNNOne)iY#Cs@BUSBMz}2MucN6M<%)QdBM~fqS(@n zj2Ql8Xu=pusH90N145BQG^O&N-vkP)gG@MqU@6HwqAL_x-U!mxRZKjHpX&5?>4sQeEeNy*4(J%6 zUtjAn^0$-}5oR<5l#f>|FMkG56NNw_aL^zY>tj7@{k>O4zo|1|QEP*0ooe5J@G2Q9 zWDRU$c3tcjz`bf!_YT;XAEXDXxn5e(4Gm^j25CK>JfFI}9zWYWT$>sd2K!fk)J%;| zfp?UkK|jb251+wnKL*o{bNs&A-Ie0m+C%F-gL6%A}5Ga_M)zZzw$l%AHK2lxzqZ2$96UP z%^!Ae6o;WpEef8Q{Zi92y3+b6BrMeTy?jWfj!1`k;jrDq7otV~W#cv3sX*aWgG;m0 z9n46*+a8o=u@qL!T+sW)Awyv#Jr%y}17HPz;nVJF;wWM;({%ojFb#w<6&f5heg9B9 z&irFAHWj`dr+m?+@`n~w4a|u{k=5thsvr7whJ%BxVi-}(G21ed%QB1LZBnY4>{;Xbteu1J1lI~Nd)2gEK_`7RlW)#qxQfnQ9U9DkxM(DnEneKr`I~@?aBiun z3(!v!QMdLi;afzLVZ|ePdzV8M41t^kauQxu5?mUl!23@w0;X zTlZUydkWe=__Q1%!}fCbx@r**F3;ZIE1W|X&p0G@@RAgC$*>^dn~U97M@w-_ojz2{ zQ+<&BWKs7HpFVgyOT6#u(8Y{Woa*K**#=xum#~-}&D;Y^ zGOTGO_#Ff16*!zK5XhxrrIyep=8(Vgp^q?@LqKKS?G|hV1Pgi|T#FbloIzE-i3zME z@HbPoIPRrdT}W7nL*#a(xx!Pr6$k0@1pTf6^I8@8BvkDZx-ta(r{g4X_(J|oR>v7@ z1>MxND?&)9kuJDx!V+1spPl2@h>6DFX{=9_l6A$9Skj#7Em2acyt~2_6J45#x#P^X zN23~{L)W$^{k@c(f2-bH+bvpMuJ~2-aTaPw$QNdW~1iJ^?02nvZi z@sroZpnT#~vq^Y^ zi4e_LUzx8H2^z4e#^an5s2`*ECE8IZp5%0PmeWW5^O@1KToRRb*`1q|u_LAF+`)U1 zLttVZacIGIt)FjoJDoR*%K2P62ic~D&(Bj(fk zYWEK7yXuRCb~5@|P)!akMxD4lK2q?e6}+<-saIu(eFSKtjH7B%Z;{2MG1@j9|LS+@ zuP61^FtT)QPW=R|uao$?wI-AMnN6Mk-{72W(`c`c7Z}A)%a9q}*;@f|lP}oXl3OcM z>4!slx9W^x52_t&_*KF^$v+M^hdl)gL-Rk_w&)^;wQ}pBta0POH7}z5LVym^(ic80 z@=+zY?~BAnE6~7|dz$1|{Kk<@15LR6%dF=t{j=5&iT_}V zU`^?E@s-ppEL+=U_V-oRo(slR85t$~8|gP9;`j>X!O_32jIKrvm8t>A#+K$c0Qr#+ zDDNTZ?^NDk-R`&jMe@j+;W<)=m>?7oY#MP(ZS4o!wu4HIZj9DNG$|X>Rw;Cws*-V@ z*TIj5bY8Tgl!A*FX`M)e^^YdXuY8=k>O03V4wl+jOIoS z3?Dqq(ScFE-^`0h`YW3~SjR#?X2jnq$@`xF_@IOjT5m4pU0tiPVUd$N0wqboU>ElS z+(kN*Li7kvG6REq(|i~9?(VhJUuz+;J@kFOiT!j6!!JRjcF2;Wtq!InOr`T=$XxA5 zg|HLdq6mwuQ=m{8v_WENGsI>E(Y^|_9pqFQ*l->mR-ocw=M^ur_+p04&(>a3;yPK& zX0|Zk3}kfkUYRzr_JgB%7zJ8gh+|7I+U|)0X>?V|nxfZF2Fe)u_e>;x{Ct>kTlj>H zbxTcFziv)6?h-0T{@`ChyH59I&~bn|QmDq}zN|I$@Q?{^{!BbhRkg?81>S%LF1huZ zz-`?9D(+;6HX1@5Xwt~j&e#CJ>~=L#1KeL@=f9IBA4_F+mhXo10yyJ*6Zw1#wmXVx z6EAQVRMwrr6C9d)U{kpXK3v=_ z)&iU+Umx`FAp@@wFoA^V<&ExN|T~ zr)ukB@)Nni(u-TcOQZ=3DMOD?oLb@Z;)XvuCL5zOy^d0tnHYPk)%k?ioh?y~aGukX z4ZJkG{q^ML?wrv2Y8ab>l`^$X$7=hXK;X5T@4${a)Ikik+uiM2BPFQ>>yX*r_h?n( zkCr_?Fb@X4^gzf(9aGJ*Phvmhr@q=yHsb{J;xnA^$ndu7-DqV~wWD5k&)RTM=NRmfwFQu$WpJs52<0j0E<8{>&t zMSQwa&{YJgh#SpLCtsz5$sbjLLL*`LC?9om{NXjaVxUZQeK;?poDMfZYAW} zqQas>S*<7S_fvVtPdD-f*}Z4+sB0wU=nlMN33<6L%q{5b4M^Zuw1O;UD9;cs5G2Oi z8A4p7E8AkP06#>-W%?dvnd%3|kOF|oS<5BPpOXnj_Ep4hKevGeUPQG|O+iX)hn@P) z_=HtVuW%lFUVE*(HNCZiuHxuaXmvxbEy0Ok;6T(?mEhD$&okU!kCZ*!+F9iYWKFGi zrhB4>^(8|Qwx;c*dwlKMNR~#6vG?Xt?QIQm8K2_~9l4kyhKFF7DbOhoo13mXxy%ls zh@CrfM_Fbkg%6P>g#v<6$ya=eQGTO{jOoqf1CO`Pv+@o}n-L$vo z4C0M|G5foVX$|$xpnd_3RexL<>rxer^zf~MJzG?GeBvJVzeIt;>=hZR%)&wn(`a=lwk#A@ArVh$qpW!!B?n+i}d|sf=@xC*J z;j1*_$C(@@;548dSR~qDn0iW};WV-)Hy~>&i^fO0!dlZ{JPB#Ix0V9e>e7p*vgKB$ zR1eOp234!P93OoQndY+W&kHSVP4%DLMhWwqESRWsJ6%2EU*Xwyx?&ctg&*$z=w6BX z3>h~d6O3=rg`1m5GS61N-!%EhRK~G|Hnk}6>3m`lFVVuzP>Wa5R_j5dkJQ1jCKhcp&zqac3@3;wwyZyI#p8zr)&OVa^n)kJCG8 zp}Uk)f4-vnC1Sa-qlX+AMH22?jt zu;RZJg`M8yerqDz7D%x|82QVQ!S?y1vVURm8O({|w35fKx`TKTUj$0pRQgXRJP@=J z1BTh;$wp2ROSQYuR1K6?G}#|hu<`O`W-tDc_FuWGkii>1Re;9@e(F^{>Cgo_-z0eD z`jsDbfyJw%pG%H>FN~Ou=_2e!) zj)qr}SN-==S?5@!r+HKnAWe6)VM#c9-g&&l6?;R6Atmtvzr#UY7n~qTPmHO;>{4T} zO+P^quh>CfP}kQeU*cDuE^Q#}{PwzD(|lo9l8YZeC*8z(GwKf!dIt3Hm8TP6iTMTr zJ!vHHGvKs7%1iSTLP`?1r(_<}xLf8iG-gfu{^Uk2> zh{l#8uCe>LcUXUKiQ)fZ_^Hy#f5~_MTctEwhtps(3}>thO%`z-@2L7=EZLp07C6Wv zp61H5K)vZ^UPTH-wq~KuT!ELP<2N7K8#?ucg_Y<|3zfaSm8eh*Rh_YwZ?TUocxjks zNt%DRiyTBbK1&%u`C%QeosXs|w~4^&{dvpkS9zvFZoQYUv_|$&>^fT^d+o@!j=UBvuCw=e-Hwb5z1i^Z!H8g?aU9jD}SG zIHXAC8q?Tue&u%ur&rd|szMJ|l=XZ-N1daAhlFa9EtHe3NGwV-KG+A=b)D&czp0fz z+3g$no<~L7^;(7aVQci z;{>@?gANi>er^*5+&Ps`O+$^n-%^==Ll-80-f=YKL(n$^AU~y4)Oi*zCGlOmF(v_b zHN8qW#-KLUYpL?W=rvRS5uJj<-V7>c2;;`E3-*cy^DDy8^Xm~KPz!K6yp#PnJBsM* zD^b|_nAoo(ek~~IS|+0d#72m{_@#}vPf8r+c0~%gphu2APc0J4%Q^!_+#=Sb8D%8RTsm}f zk^KPu1Wp{m$9CW1mBJ*?;R~|pMr^{bjll~*I2W3JnOkhQEokCv#0ycX{@EQ!Rkd%K z%O;4Vy=rOy^__deV>tXt{OVLckT^)_us1OE<53%ab{@=_I#0;EXE>!W4O$-ROM42y zTzY-;px>Nb1P!;JQCRvCM9jzbs3&;5Y!ar=grWp+DOH6fnp^Ps>cZrC^x6TT-*3%* z6I>J(o~VXiq9DxDRrsL0KZcsR~c9yfE+sBCi$~r`EupuRYzgH1^h|c(%YX z3x%Lg?@S%L5<}AW`@&jz_`SXa^=4J-QM}lBd!rp}bYgTdwHLGxy0-j2^&KLNchdc^ zJoF;)x_o!`OW+lHm}e(#m-Illq1JB~`$4kXcYXb*gE(URlsg|#(^<)0c9_Zihb@Sy zcFDU3^r~i;`pj|dq%VDumN(wztrw0wqD!rkR(8jus4JiOhL<42myIQ->?7Fk1n!x)uBg?rw2QyUdgf`z?@Jgs&!@qp?(&8l&B zAPq#YH8$=_nEO(D!!NI7Y#QF|S$-^DEYCM<10+L5EEJSiSjRwHfhu0W$jjYqTiQ8> zig|?dH~2q|{g;a~kNcxl6TAHJC|?O>1TH!krlb822)+MBZEY_iUlL8GXuiVidK4yC zXGl9Gns|PyQ94GJZVHf<)lF7JPfuNva~P9!tts%S$_QfCtCRYoP7Umb9d z9I8AR+|qp(7yw6xtwYQQ4fA<$WdU<}^cr1SZO>}DsVz%kX~S|)K<<#<#iqojn96uz z!T!%eU(h(#k{8H&lG0|sPPO~JJy>!1FZWSSm__g)zC_GH8jxtB(C>51oh1T$Lw122 za7b?vLQ0IQ?34vs*rgh@OqVweL^oyBov|R3XlvCK@B>Eg4!KQzm#J?~j*Np%G|@Dx zjj+uJx(%Vm@D6n*<%zz&8~j@Kv^l>KdqVe5xGrq8ZJIqm2jk`zETWkm`1AmT6)dzh zBpa+N(>bpaw4&t9E_+$z%_UdPPH0i4pu{clNuAdQ6eEXDoYssg*H=~l%X}Tu#5~r{ zjn;9+q3CGXv8nP)Ek(IurFHh8wr~!7-ay^4pBLdEDGIXtZ&!3(NP*V&GO2EetLc{# zE~vI^D-@(z+t(cW8EfuXJBA7%rVqowK#l&5eJv%lgY_6+@IV2Etz($KByvNex{Qh4 z2?t35Xs{|za3EE<+sIE)2jd|;#LWYALk5EW_Fc8#nmK=bup0C#MX+*@DsLL>NDXE$ zk9mptZ>rk{nP!ro*t@M!B=cJ@ZH$&xpsWc0lWA-tX7;>o(Wa4RlZ9#ksx~%}<5^*E zSV_Y*CN*CYY|C;*hvyLDI4c4*NzzX$;b>`aI5rOF(2h+1vUGe8zY*RigSm08CimYg zZC!AAu(xDVJtC&M4`pUKGDth6JO*bt`27o`iexqk%P4a$^8 z*|kJtbn22%w~#f@)+`0i@+t1L2!qK=$e`S%ECI3XuX312Y^wPn0Ly_pW1yTz#@rL9 zq+1M%fd~|@@hM>}#z&02BVh%TtnG1?|jPHCv>qHgKpzqx1isP2fwwAOg0cn*o$bl%m(^!SI}m8w80nw%fIXwH5C- z_?4_@$9TovQyVn#D1#Rn$jOCGKVZ`U(OElKVRDS8z#}&|J-~JEeBoj!>b+sU24yoL zGzFJ3Fr6Hj*y@w?;&sAO#?QoPjJnL8ZCWj8?&wGh;cg7Swgc%WfFuTIK3w#VkEFMR zP+Ld{T36{OmnVrDQOX;<4M{0;E@LusR!r+wayQ`(LDBe0J6M!|B2V4i{t={gy>KxV z^`f&}TYF3IGESw7a#-NiG-u6R_Iz>p`vI*BH7T9GYlAOq8tqUEZS9mDLeZN+cct|` z3|?BuVYnD@)j&V(BXpHNcKH@B6((WVXNfei#_aMITXLUT-TlvMZXm-*(?LGYo}G38 z%^5CFH#%azzfJd6yTyz!N{^-Uc|OTqxHCl99sgU^rZiwxW77X8?}*(E>z}-}k~OXf zCy$l?Eo$cfTU10f$HNW}*^Ky7-Lhc2Q7UR96BiyVav%{K)t(ar&?Svq`iqT~+b2gq zxAMzKO5B@!!pl((xO%=NW~a&#Ij+Siq9x4kGI=QTPhpza2VEGE@#VO^>yI=2jJR!DPZsSGW20QPu;&1}I zJK3b$Vw@M=l*WA+>_YR&0??_y&WSyHP9+1Qq&U^Ha$N5GMNOLfYl#a`-0+$3>#JO+ z$6Y{G0qO2;kWP^lq#Nn(kdW@~?(S!MzSs48{%`P{S98zoJ$u&r)CvnE$V$B) zJDTal*?~kC9BH=8H~FKja@37*J7SDmC%&(tuCJ|ywy(KDSWpe zhZB!T!}f8ur6_tGMUE4Ggfnh+94o7^eRC}=IVVuKPO(!k6nwsP zDaLvU{(^so%tHFn*)kX)m1kPQP#bl@fe3A}s^96`a32+m#kXdrmTEa?gy7qD6VlmU z5I7}L=~y3U@K|H2||aMortc5zUIHc22IOMbh)&sRh%e?H{Ac5FteDzr&zXRvVmBZfl0m zV6<`j;@-{Jpzr>aNe&V<7#~()hp)kkgIkuR=uOy@a|2I#I2pBp(;$zxo)g@vj7zOK zxYda#4fc&z71ry6WQzVo1 z&*FW<`>%dp*_($G1eOC6@8jC74R%BfWjc-%(!v>*kq=|)Fkzbl>M+BvV4O|K0UYkX zlo`u30YwsI8f12a ztRJZ1tz%NIE3Mpd4T?=ez6oP=(?_I((7~Y}4-$={)NiVDqSceS&9G1xw3-1gJ`Ldk zqI-36>kmn^JOsP|Ay{~hNVi*=#ecY(p`_Sm=R14YkI&P&fPq_ysjcm{s!>5Aj%j+} z0$0}uSARvoJgTForvnG39(~nZ{NAzEW6!iDq~yKUmqa6%kSLGyX!#|~5LAHmK?j&X z1sKL_40L8b{20;Mwm27h#2R$&#w=zbC3xq)-$?NHP~R&+re_ou=iY#_OyXwewe0=- zQNUau+>jyqAj%{h?3BO!{7kM*XHVHmD2sNh#I zsg3gLREMg&GDAbDjM9dBdms@(I=#f=FxE4u9-U1QwxMu2M)>)oU&&9Bsmhb0Y#yA0 zuzhu$4P|ib6@g<<`9$jzX1OlkfKT06gvRHme2cRS-rFtp5&}GU-nFZubBw)2oMa%9++CP`&+p#_Q}a#c%fs3!}!?@(7}{4vHC zmC;jKx1E`TUD2!TxX9iNC*fV!o3*QV4fH)ieMjydT8SMa;aiX8kC_)+tJ93c{c&-1 zeUYx@P%{x>=dDW=zLe-lS=elVSvOI4RRFI@%38`!xZJwi97*8NI@6ztGz!T$DdRV% zIn&JcbGD~BK=U*ZT!jJ#EDr_?5SR-+7rbf_VqdS&L?Q%`5pLq1Pq(*|1}uA;=<`z<)zFh*TQ zKFE*|P37NX_<)2zO#7vNA5{|k#?sYqSy9ZTcx7&_yA;93D0BPRZO0x z#|eJQB+8Z9y#O~Agaq^Bt7sLns1Dp2@YH?PxtzgMhgwfL4VM#QAbGqITOx+ueH$kz zrd#jLh35v2i>t1=elVNosw*>=bC19cbHrJ442oYKvfp=I57t-1js}(hS!)s@H%S?7 z(xh<&mpY*v!i8JXxT5mFQs2mjqH9H3Hp0waI=;G0gdOkND9E%Mds-E)l-z?!snqnD zW}wTl+XKkI)GgOqL=9y$4w>h0(&zQ<1cpr!3^bYwBsy7kyNySiOyQ^*a1M|L|H^5D z0n5JysIA9c)~PaxqG`$9OjwC7GeeBU^XW0lVGM6{^OK=r4V`Ycg4C0I3gn5?4hbq# zpGRP}#Lko`H3m1i43X1HPf#W6Yb&O}y4O2bPf`6WO){=Z{v9|T8-_coHW=_li1*eU z+<&0+^%OWRv!3qE<6Fx)&Mb6>SX0I(V@DGld0%Nc7pa;{20C93lbvY>I-h(61AYRh zZ=s95>+(YO^A=&7>{V26;LdE9(xLND7?v}AZXM4wmZ|(G@^1{AZf_}QPHxHZ709mf zQN@vKl#GqLj%biKAW*SDg$u}yf*yvmdfY*JVL-4sc$&KL8EK@5$vDo$s~%FvxTyk; z)R_qkamkQT?>BSYJu=Av?fLE!=LnT|s^YgSc_GW|Og?Y!hFQLZ2Vo~I!rPV6gh#~RIOP|1Y5zvbYHTaHP1|4c}c5(g~Fw3$gdlvLk zfh&E>=*EE!e1h#hJ1Y?4j#lk|LRV(ewl+pJdDg2Cn;yTJxTXgu4Nm6c2w2>U%mB^{ zz%KRh*T2*F&Z^ibfU?u|c6s_YH$@^0QaFP%Cbn@0ZTdg;C?uyUVr;&*=OtGBN?}F? zoni(C&H*g7h4P8zUs0^l#?_Iu)XU+9u$}Gi1~OGK&jttnzZ7x9W{Qx2u+Zr>dQ~w} z=s{&Ml27UJx8Y$;tYFqL{Twx1Z!e{ppfZSZi_4;u;x1h~wnq_S_B%f8aC6M&r>mvg zk>IfL)+>KXjqZ5N>M-_@oO}JX=N{|4Y9YG5Ho^9n7_ z{A4~aTM2wW%$pBT&O5yypfC#c&_DOnFDgUh)U+6dV3P(dcIu0^^XC$(2{1cEe`<yn{;S-Y*TI4? zM$MGoyF3p29&BN&{0J?_vsYR1&AMN@UL+RYRe$0MRrTRx&yH2s3sub&gBvr4!5Z7Q zB^S9lDlAlU(Y;7z`#p!ea})HnJ2s#9!@9MwQ__DoSW10qS-Bf2># zTI>=O3u0SVC}M}jg*9QmXTGO{>OMiLl=;YGW=qJZhuhR-c=e|DT*U0Uf0<^meTxdH zOb2oJ6)D7mjEQOMcfWjrhMPT8nFlbP zviPOU8+o1SL1#kMs&_n(e%w|$v$h}x)@tgVX0@n5Z%plle20!5O%Eqw94^(dNa1vs zxtv&7DrQ(cj;cI`n5Z_f8MqqBx)=}`yOJQ+^NNQatR8olp$KW4PEck0V$5Wku^y#z zD79U4o!xUrhY{GV*l;GQQ(rfzt8ucMc&A+WJdImtura!X{MfA+E32$ZEj+aq3fnTb z!1-;#h+*Yx+fCHpW@d-v73=_+JWZ*Q<@qUp_l{RZuXyD&AhT$-zKz~xu%}6$noTn; zhnC>S0Zv&ZWK>kEE#`-M!M(;N@l|+vcOp z&)UNN5T*E~_zQ>DkJhM7#Io4CBd(`D0)#f+1p@(9AAmt=FhD@<>%2=)UaOUT;MSyx zpsvwLA--Y=G4tM^@&jiV+vSL!eXP$2f{P}GvM#4!3OLNkAVJ4)EN9g5wE_`BP6H;H zpB@w5WAEQy&iGsd(?6R5Zip^DKqf*_XKP`|De=jkSh9BaOR!cY1*^A}L`F#VuObo0 z{wmPCXY;ypfKOWd^xq5s_T<(IjF`;dSmt>TThyrdp?N0L)(EIQ?2pQMGZ~Sf{i2*M zN|y-@>0SD|2eFHiYXR;5uBm*($gnO4&>?RVCYaD$9m$S%(m!#CydCJzR}#Vx zzk)Ufkbr_1784DqjTMd;-m;!hRV1*O@CS|c72O?nGimz&Ce|V)`_*IO0{-!<&|s~% zhN^qie$0HiA%3Z3Z0m|hr*X+xhNd!LyN+YRcV>COe<))zDn$v@wYMDm^NJC{?EM)r zl7i1JGTU3B6ZlxPLa`$@SRwE(7dWxL1@Ce}uGge{jde}9^u-F1`P4R%)nwxXR66Bf zW(4S(l#Vx({HT!z+j0paEyn$0^=7;xylf{?3nB1pK0zMhyE!7~4#(ISbMPGZh+K(S)wP*9I9ln^wLKZ=%34g< zemTE0zq?Oooz?kE;rE`I$E>Vb@JqGr$uWrt#pnU7!^*7Yjmht{!=Gsv0=5tL+cDi1 zNKGWpK3L7yu|@z|mpJlFVt#fI)g(^;WJTVi_ucPEAL}0?(v=?R4-gR>AF+-S8?2#6 z=X*?Y0(0RLw1we6J;t_ArH$pO`X8$-xG)!#b+W7HxpJ5ZZ;U^P1kN*lOVzn_Tt$L4 zdWYUz-|XGeyl92CFy&0-xu{Y%m8WjBaUAyh!pt@u^D9{sFNNJ=r(P)d&h6U{4T(~} zis*@Fk_rE{8|UKR=5@{V@OZP9{o^CV9J;qxGM5Uwkw9a|NfYi-dno5IcGk z^S4iR(VLo%EW&*8_{8YJ2u%CI?sDJS7^~(w5<`1bBu~M0Q=j0TY zh0N*#>7|zCKICMv+=0lIz()*7j*4pDtqGgmSjYc|WVRdo85Cz-4OXfP(ARntm9L%fbNSFr_X#<^S>vRgwM0AmTG`A^ zDtUTcUrB7Jl_n_EI?s6Nrn9K*GR5HP^jNCyL!8yxRHGmch5uy(u}B)GOK(HTYxaG{ zY}?cPy?YPg@Wu{`#QF6M+D1htjgD6KM1lfTTe~HyWJR4VnW35-Glz>@zi2+QzQ$>=OOp&jyk=3 zxP4TSyZ)XSQLRyehT`@g6ZF9P*MgB7d{Wx6sqHX~17BEkoKYJHI*h4jLzEQ>!mrr8 z{L{qVtc5}a+fppTuX(u`9ZzNT5`Pcu4m;aF*@V%POEH&D7L(CwOm=n=+m|SS+YR;K z8ICDO1toFssZo}%O$l`-(VuHsDKo>WFp z!|P}*#aNrbgTzkko@&qNb9XxUzz#OsR1D1_HJ?{*-XXPSRrC0Dd)9DD9iUKVX9ano zAbiP*{D9Y%H3`gXHZ=KCGtU+huANQX6dk%=*!r{NVCx9}w{;9IgMUYkxeAAQ3bD^e zmT!qe#6l*_VG<@lIVpGZ6yKm%u9^0YzrRdRl3&_VyQr zDLzGUSsWS$l)}G`h*VkFC@!U84I``Q@k1rAH2%~dUWcVOTgoIn%GdZ|RD1+V3_1dw z428qscS$HAU-TTu1m`5aE*@Xd&!F^UAkLt`Nz>pQ6kBs?fjQUJ*0)uG+g{RNk7u%Q z^9>|0!yCsA8b&JY;0R-QY7<%J`$q)kB4%BC8DMuVy(t2i3F%vcrG6*>L4VEg zjThpVGoNQ8w@N)b9(pj#(m<^Qbujf>7`E@>sY;zj;D~kKk@(1Sd=g)P6=r0l?ArU!bVpNR*u~^|w zuJQ+#6hJ-@`oJ2u?L`iZTXne98iZoKrAyc)PDEz}@X~L^2|d)K;V5*GHbCQxCw}N4 zhNotsqYKTs)!1y6cUr#FAq25~v3gK|oD3K~ReUUKO>ELvJ3gsP^}5O}`rd}tB$7it zko6!^xUj~X6BrfK!cP&q)M>w;WdA=EZ_LqJgn)_J1e&ZaIf90aXvB~+TsSSxLA$f5 z8VJ+)y_8uD)FV<3BOD()?VpX-sm+J3?c@~~_39;t*Q|d+#+Cx2vBpNpnyaF*6q#5d z28O2jgD!0ha^)|JGGmXFB$f7K!y>e|)hgl14DaT8f{5ertk$r4j+56vmhfN@xCp-= zqZu%<>+Y<7CO^{60RIc0CTVvX3XU{OXXiKo#H2oPOJ20bv)vr_|1y*LJ?gpm)ChSW zq8H$WoQ^Y|Oe<|ErYU4zIkzNJL=LLAQYQCEeGUuHw5JWIAF@8^D8DsLvcGt0Vqlt7 zEERB5D9(4j2ex53e_ra%?1@*Zqk(R{<9u0eWb#1)wTiX~kpWg%;aBX~$A_d~aZ)@k zVtNfmgz28cN8o5AZ>cGJAL?wkzv(C}tejj~!SlaI^EC+VCGtC>QaK!9CGm3ET5KkF zkP&-xeT=b_9Js9#FdHo?tey$^kgD;vGaC{_Eio_rrbNp#AL)`I61DZ|%RHbIBRVG> zd!=UEs14sXXLERz2)`6RCqjOpm10sRp2Q# z(e>J+$+LO+_&6=UUN(X9x#&r6mXH&t97dO3ykMD-lZwN=P=B|mhe0>9MORl3+Nb5N z^8VVWYM%d8?}V41=f0BGwN^PX*=Ew+p+@Xb<0#R5wIVGXGlU>1Awm)koz0 zJ3pP$WfsQ(o7vgRpZ;$2nqxd%`tLIPOO5*Tj~8jXi(k*YkJB(GwZ$j1Y>3V#MD+*r zGUBVp!zKfmHE1qvd9C-azeRG|+%0tyF<)lcx?E?NOYU~*(3`-!)TqPV+&u2XcNv{# z)zkVk6?Q~9cx6`~cJRK_P*Eq2tG7O87d^=_+&oGM2C82YcOePwa!&l#ghNBeQ0o&q zQ6s&W-7+yHnb(w!oWINnfAf$1coFYg{CeL+**MP;jHyFZF6xMa;FVq6gAClc2cgSl zOgr+bHDkZ-L}=%Po!>=|^F>mo6t{88IOL1CAKWhWEcywbWui8$jvf2DCFK?N z9UUsEf%lCLU!%*9V?>-BIH}!Es{ry3s<`$jILg?}1_WpE1p+klRC`>^L}=hSR*bS_@4Uv8wq49E>^& zjF`T$N0#%Gaiik3nk7DF`cmX)rulxMI@c%0)!-z)$Z8gR%XwA~ubX3*R; z=B`pm?@D-lyN?O9a)_qFF{*ujtJI~4>dryVF*v~#rH(3B=bJGsq3a&%twuR;^f47y z8m)3-*LLAgdsq;G9q*CDLLCyrh;Zti{n(1mqJM2Y>UYlxevje4^}KzIxuudc-~?Ix zsL9RDytUv@rr62rh_lbOSH;}6~#wO*kT3Bk*JWN-ymq zK~~!kgc+`gu0<4vNx))SuH6LhZ}!RBdi zapT!wI(f5L9$EH&AqVx9563=c>P;9?wSWy;r+KH%$XfkPuT!y-WWD%3OLl;xQ#13~ z)uv-;d48atNd4P_sRbe1Y!}$Bc_zi)o8ZH<{=B9u(n5}80&$|M)Bo+<-peb7gLbh4 zod~(03YW0#%4fR3VtFhj!4H7~nKXM3B4H=3QHBs>R*eaao#Dsd?@h~!O*X8fe4QV# z`=0}xF5?3EZiMy0hcEAF8*VEP6 z()s*O3v@kGRm5xH*Udnh2qzLnt@!yqx)>alY@7C-emrrQC@lnykm!Y;)B zYVu%@&hDxNpFU@J#!^q}7-4p(`;6?&&woxO?=uYZ#|-LIiLenk4P95Fq>@*5D8I2p z@i_#Cht1!MPp;K3ASbm24n@ub|9AdW9D4Fqspn03H z^3t&hzcL&dvl?x;zRY%#FOPH+yCRl}&m|*Qk`)$mj{H7vKvWg9RiW%><}p;L7H*2y zI!{*yKZ}iI;CAH@8UfS)a7|96$~e@wp%VET8#VY>H^ z>GxPkmU?V_70+d&T6&@kO|`kT%U~hx=)#syb_VOHhO{@KBQ2hJY~B!j9H{TexI-)- z5a6neb_H|S`_g8!_0D}CXuWFaXYTYuC7{XLxG6|iI-9^Zo@{08j}!^DMZ%~ChB1QK zvqX1DS_!DXS_9&-!>>d=O&36F3&u*ORpO;pad){elVoRLPDa=X50X(HJ^D&+11*kK zyGKn7|4EJGrCWK@!w(Z-6AWIyH#2 zvj|asbTWjZUQ1m)7Eh_ZiH+hYJH&x~4I)P%Zb9)B>NW#|vSa>A?ZdT7qGe_dDXsH6 zqS_`6b)c!My`eAZE{|ja^U!`DqV+ga698Qc=g%fhiOge7o_j~N!J2@ps3YqCBbT^u zb&2Gl_Sio}9@q&C-G#-~1aNN|DcTnMgRSF+H1Yw%XuwT;2lo+>a5)-H(kk<3n{)-_z8$K5!F^Xuj!@(VbigIQ4vFj?vYX# z?0EsHGVYZ*sn?{%Ub`AnaEqqGyMX|sTc4-zK8(*o7x8uZ#ByS?F{8633fIWALwg4b0^ zC5UiO*&*6e8X2RPU64s*;K3&^=ImXLCRtEtI|#_X0v9v?c~Rkllitho zLzLZ27{!y-%zs%T%X1$An^17GlR@cq135dS+?1CSix(i=pZd#&d=-kWLVOjvqfBt6 z$wO5j4s9_xgUK%Mkw_{6L>QSBvYoN%{@|DxqvtD=h@c%KvbP@-6&4wpz*{zs^YvDX z*+umRoHFiM`cfHymmGbp)#hEAKDTjnaLH<RWe8sy>kTY9kgL+A)KW!Fu{j_k9>7M`gXrR=v7u!H=fWEy(FOE-X4rWOwAJ552!-a^M4kz zLz%1qDM2TY5+EF?Gi;~>DM1N61nyPQPzklRH{zARL$z{BZAr zqEHXt<9{e1Go+FcKlIA{K68<>6>g|QWtW6%iD1?n8wwntVwS4XD!KoC;xVp@slq@LmSln}&e*GJ7#oIB}eR;NwkU zNysN0Sw3$U8W+p7Z`~GSi>4dOB13`Op<~e#kHWGS@=fP9df#f=@BSg0a1dgmWch^H zr!mfIY)==7?1mr#>@eos1|v=tL}w*Y*lm4Im6&Z*T@|nz!|5$WU^N_kbXDeWiauXM zjYRdpvXaj_rSr@rC4Mb)j$UI^>$4cs78c6fHfP36DNgjgOWKhAIA`DZd?f9L$6@>~ z=w2l3PUP6NgkH%@!oTsJrCmX-FIi}bRuosK8GrHz$7JkDQ6LY-0n)w%m4%>AsjrX@ zku~&Ht7xLTwX%i)FHX6rkBfo}TOMG^6mI6&vC&!mc-EKVe?ITswqWt9!iKLa92P}# zOoI^>&%S(w#Kj>P)AXJNV4F=7c@i>Iw221}vKj?!{EBVg*E8$8lgc7}^kaUg->VZN2dhw*98BnQe z&B}wbE05P%C0AcfC2$Y?iP=MaRsv6LBK;{J$POKSo|WcrGC!|aK_tbJVI~+|jGKbX z>&i*mel9Gn1$Gnq2tfP&z@8nhrfekd@mGe%r0s!VcE=Mn9t3l+ZGI1ViREEa?B@U{7eDW; zSf%tMv8PR-Bl znnbnu7Ba+zYUanTT4%i&(L_(x`2VgM$>2>K%PKihT=uP-GY?z9O%OC_{)-r?PXGNK z_W_&OjA6%T>m`jbB(-M3{ey(Jk^ZK9!YKU=@CC$9F#sRn9gZppjCAxoPO1MVXF&jR zmTbPk1EM)$GfAGHN6_^%yha77k<&A8m*)PZMqagNW+q%e^86R{NX-xX@O6=1#)($NWjKG8(*=m9Y^FKuEfEG(w*Erp6Rm z*lCUzVg9Utd3GF8|AS|2TJT>y&*z4GV~4op(|2B zr~f^YVWbu}r48kMMJAlmmd6bNi5%YSc_A+w1gF2}RXB`uU*8G_m+4`4Jl^wrcvHo0 zJW8`Pr9xu(fRa)&F*=lfIOQZ*h;ucYFZL_NiGo+5P^zzEY=0q+x>T@?Bz;Pv!ZO!- z@ezel(3*&GBc;$pdgiw(4^1Y%Egm^z`vk4(r=Np7NdPq6`q@K1(B3$H5APjAay0b~ zl6o)%6_E(-UB*NQjY%Y{m<+kA4=4gGD{b*@D|!qogN@tgp1=Yaw`V>ij(Ovs9`fkEWJCF4FI0%k#bW~ExP(?Gn8QQwXrcEVw43=oh_rR_$w)Gc@3OJoAWdD``3!HHFz?Ld*957<> zWQ1_=ep|iQQvlm8If$dehTx6Pf59NH?EVyP`|UM0Vl+!ol{E5F$mXFEi#=hX(=Y6E?oEs6h`@pXl!bqNt!Wb=6-=XvBK=gq5 z3cVh#4qy8@o8(2T9q)t~_qk3Yjkw{*;X`szj5ce&Hg4uw3_bHIhg>Y;v5r*H)ZvZ3 z*kfsFJpC_^gTZC8mEq**lMM~S*zy=>cz2!jGWz1dS5HqGmxujp0t!Gx7BFDQxQm>a z>qc*UHw+B&69T9^~GmG^O{)@wgNnjI!n)U!J5 zosm(}@H$r{?HiW>(-;9Dp`md(?IWwaII?q?efmnW1jq4m({;8T@@@HVk~-i>>jb1B z2U>d6LE<=Jip+~+XoDmImcyrkU)&~IB)!uS@eK_^dGQQEm|iHahdv-# z)}Q$*N>2QYz3Id3q~h6rt7|)`lsWh9E4W0i{^^@bX*{|vBcuUw$RD2KBkLV=z( z4_gcJdtF*i$`hlV2=`o`c3qRr=4U@{dCV`g6UI`JN@<{h(RT_h1sr2lL9{qw%;|!5 zmL&ruArPZIh!LAqJhCR*2uTRgQTQFL#)ujc&_yrk$J!FnHO+y4$mwpZDu${oDs&kw zE5l}0{`6_W`1J2AG&ODHX-)|@w#;(3qyGi_=hu`N>lKePg}TMI7X4WsFnb!JIA{>@ z*vsnkfgpyaY)v?dvMdjb)4+N?2cZ?{ruTI&(L=2}L#Ws5KD?FzgGkBan8sghe((fb zqaL72Ce)r*8t(nX6D}sVBMU%Lupo0OEzA9Aj5qrVo8otX0d}~GtQjwIdHPc^;5_Yp zo>iuA%30b}+X8bT6slboc=ZX+TJ5(m4J9A^w5`w|ni;H%n#^&Vd7f2E+MUrKF*$S z{reIsT1As@7=$>CNp(hSUjWAPBHRUu0jk@81t1qf(t7t2T z{LU|`&+y-LXh+{qM$-@vUu4^24vk!oCmH0XZX!iNo{$nj!gH@$pCzjk{|P6`R{bm6-yhKW zmZ<7!iHlSk1Q4q0`BnUDPfZM?Und_7XOYgt7QeA4l8&@1Yoh!Y;%NJkvMRZD_zFID zI!QbxQyE%P|DV?9a{2?m(Yc^l4`Wg%3>S2)B35dFI zuIZ7sxP~1Y^>5M?LU8GxGJ|sYfLYXaILuOyH8TFJWvfa!U@X`Pp#1N?CPfWtg`XP< z`dE8ePOU5e%K(ED{23C9mD|o8iJRX0lTc(0Lbe3kJ^tK<{^bKUvpu_QMI!J3E2E?x zfeJ_y<#A4)e7+pE)yv)Ouf3rn3cpSpT1pP8F7C_Uxpo`97au;{Uw@tuvZ5HxN=L|5 zki@HKF?{Sa7=_HHdx0qLWQH)=wnZ?I15TGw)iaGgiD>#2Lx4P=9_PZ<^);Nf_+(rP zE_&IA{`@B!wV6*(gIQ1b3O?s1#&n91`X6-BO)BgZ>tV2r^@V7Xlg@(+ zL~$8y#F8o^ObTbClO>e|&=2`xwr?sKi%SspXVDCgZU2j`E5QYP&p!jE=Oolg(J4CS zWJgQtYw+dn^jh(K$J|Dq%Z1&BGHkapxqP&3F(r%8`~fXZiF)Q@L~ZbncV~|%98MdE{d3r3vvaQU$RoHS`1wTk~aX*yU&BGW#l-UGl@PD@?*KXXg; zBw)M)vRF%R%r_HdEEia`UtN|Veaj`mpG3t`1VwE@`cpR8_2xd_V+AL;k&pAI*-VCP zHDBvE|BmUsi)y@HtoqN`29u9uesf&(zf1n)xR(0wk}&%Q7$Kz15AGlgswU_K6Bv{f z{xc}CS~m54N*B{e=u;TUg}3(uj^PPZ1|Sv3%}=KXDb>KdlQddjgAmC_aNh0h_&-C< zM4tQ%uxc|UhyQf8>=mVa&#Ng6JnnBToCK#99i*iX?^OKlN~XCzsBQ9knA-%PmwH2w zQgD+OfPjAES%X4e%v}rA@YY&f!a(gCW-e~}6`EU^yWLa~uZkvjJsR4sA0JfFp}bte zpiq44;v56||L!MliC?V&Z0AcZERk`O_Ntrt2f}Ap778aA<8E^MH;zY|A>qsRoC{~Q zcia@+O`Hm%6xB2*RenWL$*vAXK1Zu$Klz8@emDQ0{#oFA&;6K6xc{e0dyEfnvg|;QZd_KQ?@wq5i2F3LZxhE z^%Hb#`~P|GTM>h+lt62P6fBT$KIu{<)|&b`58+qXQo#!HwzB}#&70Rz_>g$%=wU67;#e}xp2tVF>`GPX^%!L~NLr~xgxQ$we)qdbXG7zJFNM_yGC4~@ z*bhkqpP6NGRe^FRw{v(Bc##vowHC6UFAlRHRx$lP<$c0@s#V|}srJ^Yf6xK#!a-1Q zadNx43P+LDh&Zc+u?nZX6tRjB0t_#V2#M1hh%tv zTjH%E!{DJ55*KO`*$s80LGK3|Z(7|PRhh(t7XS92M|O?EU7CK{#1*O}%)vFC+;zC= zf!ZHFKf_aXexYnCF{}^ypg>nqUQCA#tel_y(!_o#lOU=W3U)?HiLQJhcyOZVML@df z&K{e%`lt2oRMbcdjGCscNecAt4sx{;(<#ZKat6g|RBl(i}#L`T7CQveP7 zHD_gCv|^_Xd4B?q`a$e4?BIn(zDt(7^2Zv0v|^oh4)) zk|xXTbLnY}j$jLcJ`H2O_EQmQR(d2TE2O^q^iI{=Xh;57F{PI6v39}<$xq^F&H1ig<3`bmt;)aO1jIeEDA(?1P4CnAdv;@umEZ8*xe3rw4Fb8 zvD_XEM^Duer((b06GLuaot+vf@o{vZ{<+PAR-&{LzhaB-ij_qGUGM3X+AG*ro?fh5 zxiA2p!nH?dYslRu6CQ^y^>%-bK=#~hqVtRHzK7zE>wed+_TgtckV?I7JMoQtdWU|n zjJzr8EAPiCuMMT|9AHa%$%nL7$ z;{{WrHilmJz=S@=Pi{MVc;T!P2`-k+0GRR96&51C3{585MMv5o-~E62sZ7|*0sOSE z@fuEZ>bqUvj7@;2%hUk`W1onivNz^U9sX#3x`(vT$IbR2fXB7}50CTvA0F2p`GC4O z>mn_4b~sy-aknGb@{1Fw!G&7nZ5XIbLfpG|Z$s~I9(lZQCpd|}rJmOj$j-_qRD8_t zA{eR*p_tX;asu}^%gf_rR1xw4$^-m?_khd)Ct$w*D+dJ3K`jFL){8Ftz21@Gz>76T zcA5!&Etk%@130BaFHJ{gX5LwHsvhxK#@Yiz&a`$#fA8!sM-zm)LLkLN&}Qv7Xo^3b z%)aA*)#@Vq38&TN|I@{G7I;?#PYx?Up*Q;AFx%@DVs+RMY0~-i%Z2W>lADX(aZ0+* z@&)lF)Q8OQn%VuZm6FVD5JpyAHt5#CJ0u71u%JKNg^I>( zi%pJ7CO}({(OuUJrP?`=(Ob)}qL#K(AYSXJ!1o${B*o*7g!Ko-W(O!X{U5Byx~oDM zWi@bm+IXRhhqZPgoEYVz1}x?)D+tUz zB*-d*$N^GAS*b(?BKktR@ukHjke$V0BoFnW!6uKLor4D$0mZc`wCvZ+Zf|;b$&}NT zs39W<%Xc6uT<<4$ZO(_Wg)x$UxTh9EUDfIr3EiBk)39wj0$H6#i-V;di5bdYJHP!9ik6(CR^GSp}e4Jpk46 z=s+aPv-`99IV-8f6&p)_;OcO20nJ9fk)VFFZ^Xvr6UO4CSGc6TYMDq7NbNm@$LumT z$o^tID?dR)Mq6zLz+5_{{bH!^Fq^RWQ7=Ss0C^E$L^n$wS?3y2s-zXBYH7FpCoW|` z@8?uWf~Qb*x%9Ea4@FlzQ-_qH!QA?9lRHbL-~UwI%|c>80D-Y_qc@pUx;kDE3JR3M zGej|2?TOV(*N0BZPduO$oqW$+LQ$Wp0KW6mQ0s?P^ax_V%QJ8TCkS*=LvOuC6JhIL z$s{zQY>^Mp%C{r@ypB63uVn4GukY4Be!)n6wQub$!@3z9L;t2bz2P#NsipT49cOfo{ z3gkaPx5%VFnEE|?+UDnpWxGEiP}lYv4?SH#y(OWFpU_2Ig29`pVym@r>GVbF0tmRC zmDXGtQ7?Wy21h}BGU*7rX-Xt zk!V&;KQ%KH?JhY8)J$?{&40Xg$4jC6=3hprKsNCDDZb!+)v|nW!2^;31QA*XHX)Mt zSDw_}wHE+AXaeaghDi(A)YbJXQ@?U0ZhrNX6-2U(`+FXG=Kq@K7se=5s^AF$A*2G> zZtT}A{ebPper*IQ^^(3K%v8fs==XTDCfX_{CXJ#13Ug}rO zk&G@H(#Mw;nL>S1)7|Lr^w{UzIiJ_QB#LI&AO?+a)PyEGWeE~?yleZQ?4aQDc|@?X zBE!!=92B-Ie?P=V7~`u$=7m33Rxr&Oa*kD~bN#Ty9Q{II%(^Ba{hNkIYJj4`Mnvh?0?5v;Rz8U2E;@HfgwEyAl&A_wg{ z;z9(+p~>ir=%s_#UIG8)of7q^*d*3BZ`5E$ArPM7Y_j;T(h<*bLsOT!28^f`wFM~E}v_PbK_+FG8(4FKj*@DcJuR0C(b z`F&m?Tdh1PK}Be6Xtb9S_F1L6$GTB8lAI@)p2H6U3?ExBIIj+-B5qG=`aLscP`5$< z>(o`*Zb$z9j+!ODJ~h0OaD;$HdPuG5k!ic>A;^iMj9Xi6NEy%wD7DPYD!yDS@c@h)*@m%gSp7|-IU45*K-4YaGVKYcLRAubP?n7SFhJ~=qwu07)L@OnJw)HU%RteT1Bu6KRrOv*I;*IW z^1F>%hVMs92)Wuv?H?62YaR0py76{*L6-ljs*e}m;yxaBy$+_`m?ZKpkysT?R1Y*F zS4byGU`Trj_xbB7cyWgC`x3b~d;lWq#mVwqMZVXHm*TIh=CSi(OlksO zCo7VoFcq^8wOi)rqHKqapNF+RCK%~Qg_M^0^tSRNn^@$RI*>8&AiNqf!|9Wiwm}&3 zU2%pULiN@<{7s_oT>BRs{>e`orW37B99QP=Ei-&)*Aur+Fow*@Q*e^ekqY_$pG!~% z;Ol;6QPI5KP5sn_4hnWAEmuttKAimDtqAIusbQY`RS-Kt^&bvO%V9x^re3o zo{5k3RP~9f?33mV5YSWn+Sd2h!HGsf$ROPgq|gzj02A4%1~5{l^2$dJ*7F*RojZy* zYf)V!G?inFy`BL~H>9u3bwb*1aGCiBpbS(4U;@9G&pf`@X*B!a60egJ)C^&tUw zB-KXtg)2AgH|$&F#6b%*8ZP*WQIk5Tyd z=r*Nx-n$hLB!IKwbOuc1Tl->6RDk6=dq$n_yAl=<1A>AMy0@9rW2q-BqfOOZ;-QC^YAw4i4 zF?5{A_jmr+IiKd+JZrDoEAG7(bnUk@qXF6(@SZhVx@UwuD#SIqoxiND9A%q@?3!mb z;9gyJk(RH4%ih}(-E%u7Fk0FKo8lxs@!yn)Gh$0<5P1|>hhQ6+=oBdE^!4QcFhgn^ z=r#;o!Q+$m<`NO-l8>y>?lu!ZpetrD>`;j1S(`|)J!?X`U5>K@uB2;6%Lt!s@|eiE zm(*F5=4%M600x?^b=igXB&x1e8e5|hGph_qM1D>@dlmU_6c63W(ExCop*v@@uQf`Z z<6yS#kKuyj^O7u|JY{vVTTH36s13r;fW~K>RyeV$0n?m{Z{?P>f0j?K|GlK_A{;Dk zCBB*E0}Oy@`Ei2_i~wsfJ)Fb-wmMX08K3Kzn)?DalqOdC1%OO@pc&Etqw?mVnk!-cBbs4Ube)Ec7E0t$aVF!Xb-n{uKFq=ozg`3`!zs8+FP z0L;d3y3Ov;1JDLet8@wgti%8CP0EfHK9u^``6i9wNmHVB7^E@MN9)5pL|du&9e_#` z)dS!MdI0?3w5^!q{98tjr{YbHX{GDXc<=7d_3c%v9N*g-2JX8egGIq7O+dUiqj=#j z%ZI)1xQpkYkdAV0=gkeRejY4zwlknfM~`Kh3XYUI)Te7eFZkVFJ2c!ms*BpK@G1dL zfDIdNZ27;vMFk&FAE7P6N8v`Y;=bjd-Z?7$UbC&9WgVt+AXNn7`j>>q%G94K1*e#- zfOBNxF<@9YrtXla{D~3_M!q!J5pyDS`1_Nx5_IjKy>L>0uT`)>`&98VY@|2+f-UD;^wWZ@7`fZueLs~3B>6fdRF#& zx|_8MVwZ6{0KDdn{$*`R@r9|IOEZcR*kpsVs6!ns#9qs;a>=E)D;qQUqJ{{lu$z5p z_yqWvLV|u9Jr~SCw^@pm4^}d=)p7di`rid}C}qAj23i1l9Ywsr7l0aIjTa+8jd=2n z?L;D*c=wFScdCKa7H{hV`+X*BIYzDbT@_h8Q$N)*wt!c?{f;l0B8$y$-;r!};`Mc3 zLr)=BlA-fex-I*|ojXiGb7_l^8F)j?b>;@lY9V?cnYVg-4!PRz`$0T|3=Bc8abpes zH#^nZLJfFTFtwCX$a$C|$I(tEe5y%KR2R)(Mr)hk97snn_DRhMhqPOqRfkJN3<}n~O_o>oL6>ZrdEWD z68DRi$}V9~z!nxy@7M1|0Qdy&acku&OkHAoFEU+~dJX>ufYA=jt9P+bYGb@c)ZwP? zr*)R_%KtuX%@X{v%)=A>vlpq6)5uZO1i!bF$q#7StCOhu+IBEIG}fKt-?$7d`S*Gi zzZ?kV{06KKoBg*wjQiqOexv(m&}XXf-@iz$*G5=U2+cJrb!OeSCpb4RG~Qq<{(W-3 zsvEW4TF5>&G@dQvuXP{QmU#9;Z02#>E!Czz#)am1tdYY|J#0jgvyurUJ0^d-z5;R* zNfU8HYUAas4Ee$1=tWaMzAE&qL@G3hO!PGwqbW(qj3UJ2#Ib`ZZJ2i>-U>F?c~QSd z;)|0wbU1jQWT#;p3HO!sOM=y>f5u6NucAb z$V3tKc-BX0h5{MXxTgbrb=ly1CB1JDOdUd`;j6%ELlK+VJz?+0=GN5*{qj%kWl{ZJ zes18?%?H@d;XalUx!zHTrwqhHhxCRh?UP9 zETqUU)zw-c9H;o;=aU>17jprdeKL!gWW}5%~utdIMqA;>r*GyzBK?e?CQr zx^8ReRz~*FI4MGg8(3G;k<1%}R>C(W_SEx#pUJ6CiodY2awk7bi7(+B9s^y{nqP1K z#{NkapUTip8b)V=9i`wHnul)IP_KUTtxkCHyDp(8o8wQ>WiwVmQT*QYs2`hjw+mHD z=c$`8I1@dX5j=(f#coEk=!$+gtkAMD=fzD4+ngk%i$OB?;15@S#iW|Fuw$x0Vb*a; zj8o+V?sLCJy-H*t#+D}G)A}hequ=wEEaeaG=Qjfm_C)8iHsGpQ8LUovdeQb8TlTkP z8wmiDyZ-)<$$U@Z_U_}dvd%P4c$@x~OFfC`QLhy$7x2o;B!}|>k;4wm)cE2Q%yn1G zDb15I5@D2zU&8*6wO&3d)BE@d+F_za-iOKMUk_u`GJ6<0H`S1vXaZqKnDm!EjOt30 z{qf*rh_h~C65qIIJvK+!?sgUFwl)dzUw(<6b z1`=(XM@8L`uTM+b4_M!C>>_BPL0GP1wwDh=m0F5?78w>lHcR`(g(J)VlNeR4HG2V> zQSLwWL2$Z${*arm*`n>x#efN#{z$>4(VwUurK|=VOI1i$Ns2vFT?q;u%1Wo7zV*$E z));(#$>UX_d08TKL*L~1ArKbAwkL=1@aFobtd!BPwYJ^j#apv*J5_WQRtKobyqU64 zhuA;K!Tw*#!2~U^bd)t?cB8~xWdwF6PFWYiYgC2w1Q5ECQEti*?2ld3d<9PXnL{=C z8RU7}+qrn>Cum#g?>2XTV+T>)rZRMGg=c(%HuR{zpj=s=@!|TCam33+PqPUUZ>B-s zM7pE{Sc(2WR=(-_+*S}GjQg@AoPq)kI2(GDgL379I(iiMe_x6vE-)8nRYp9?+&aGb zk$jd)xLNh&dbW+uQ^qOo;de#(CNj@a)WZkZ6(jY!t1|a>m&IZ1Y8CH}C(1k@Ecp{U zj)#)g{&|w5NAiCrp*cdQuO6YUG5B477mUqg(uXc>n2WM$c{DhuS;4TS-p@|1-VfNJ z;!ky@Z!498ELb|}UlTn0b%*|7n)c`oX7c~3Y*ZC$insdjljO6lzXr9c5rcMESdbVF zhXhZ6pR4Q7r854HpBzi8T`p2sY?XCW{SH)pxn2#}VSVY*u*y##3!v z4>GhHh`JVEZ!*GhiV7Hg6Rq8Xx^~gahh5MGx6@#*p!eW*BT`$8XvzEGt42V zef2OKu%w-WJM5p$our_%>l3n+yZf&6EbNprlXZd`SM3WoaIhH~pzhA8Sn!McLnXdJ z0pg0v;?TU6St1mFV=l66P_(oi6e>)B^)2=q0#2Sh2?$`8OD7T^)l?9virV}XF}UO) zGF8~EtNs3v*MwMkj>ef}xP_#OyHttBb8xmkA*e(F-X_1xrJd4a*fYgj$-QLQqv}yP zx2~I7njj?0=&AAjGx~oAvVQa5fhq~_IP=$4D+-?rg0YY5Gg+pFbc0`68{3w6hM0@$ zq>KnMIJAsx}{~btvg~6H6%+^F! zE>2Y)WBzrF02v^bIU2}W1*c-kulTbHe1j5%*6CM3EF~(K@!f~Dw*M4>0Ovn`shr+& znnnc{d)mrsi+$%{zfG*{H!kwn53i}3%lao5>jh&#F8Lfs0}~ZgvbHqwhwjQRW;{|& zOq|Y5*iRB`secIt=Qx9W>;dVvzU$?5lSYZ~homGAmwNVF*RY1ML z{xZQmsp}w-ljHV6=GwLS_QJN(^=My~CzLIbvK|wV2>+E~9M+f>bBFW(?OVH^#Eqy5 zSjB?mBZ?Do!W&A(EQzkxPw4z46jOv1YO(%B^vK*rI&@@>EDJ34Y~l-}37~pu#G+2u z@eT?hoK1KEuQ3Wo(Q~CA&AaJIA$XRrZ*?AsO_Na3Rt#L9Ni^WA}o6e`A3H|n7x!Ho)KhA&h+Z8tmI4Yu``tai&e zLJhV`+hev+!Q+)WC`ZGp!i<&(gUvep7?$(xOWUIk#L=^l4(%{?d`|Z6m!s4m{oj@B zvcZn}2bzxSy8dg$5i0%zfGFDxhMoW-DUHt0>-xYYBA-ijG85+FZG%4rnRz8sZy^e? z!?_Z_RUW6ZVwgKn3LjBpnY(v}*wwqT<^n`S+bL~Fx&TDT)I(DwZykd!N{qe4K8#!> zc^$Yr5cN_|Ys7Y5JZr@P*f2=twOtj3dOa#I-7|BGo{Q+bkDR!TUij!ME#L>lH0uYc zBJ3`YGP>_SgV`~4Q0~ia1a|9JpLJc^MqO^y3qb_h)6N>sm(%TH)`LfH>&D8SF1U-e zRUG6b*}fkq@$chhpct#|&ncibA-jlC_x(H$8EZJoQE(|fAzt0g+G>p`zauAdleP?y zvB7W7Ar+@a9y)e;MM2CTL|wSriw*%sTYHz<`h4)b{JKg)tWIN5pR{aLzxuIj0U*HW z9|6q(0oBXtV|u6{#U{TNDL%Bs)Hy ztggBIYr4XE zq8>$gr!<5=Pgiq!_pOe38Lm($qsY*}`gz%`L$Je1(!@urpQ`By5cy}`+X-a@%;(EH zFF46QZ_FqkmFi+-6nIhAS%1*|CCQ#yqXhjFll2amSZU2@K~Oy8ADB@pnGapAHQD91 zv?t1AT>>O;X|J@c=nY7|rXI=xJrp@q+G4wt_yjzOn;Sntg)Q$byoM+eO-?&m1Ha&psHS(Xwu9nfX4R9mD?^oenSbm$-XPWvH3x zWZKw5u7qhUjoZOlj0Ss0Wc?=B+|tFc&?lZ+EIsrlh^4y=RcPuYJiecJRlBL!eV%1B z?T3%2CVPzgHY!9&tKX+6R^#_`PQRvnwkinEE6VqwmE;2Xc+7W})lQn7K?4l=PZ1CW z<3>E*>KC52nr2j$Yy*9&TLYiijRrn-wMGkZiddP@GVgu+SoSE13;{oQ-enRS-zEjp zf8@kp8e4p6vs_A#y~aOGDdwThr`|x>PU{H0`(H|Zm6U} zy`V6wG%h!5yYKxq4~pFbq_|qdOpAyG2lmvmxMpAN{-Bhx=N=vb>#H64PWh$dh5{7sgP>jjg%_ZrbYL{Vc8FfkOw3K%^tzq7@daQd6YJ>%X^)DY zKKu4c*EK$CYQC;7Z5Zs`8ZvV;3W2F>EFXtyzakW3#k}s){AKN8$&|dF2joC|)1G-Q`@g4ZG>{R}(74SM zGQaZFD5uX5OPn!Ur_ZZr*A8T|3neR8%Tv|Pvl6_+rvx`ix4Z6cpHb~JPLi=p&<1j4 zB3R~fUZ`Ob)XxMlH*35T70Fh1{G14T6F^6p5(b;B0@CC>FaE{2SLSNT4Z>NEq4|O+ zvuY$I$EmBCUU3d#lHSTf5C>R%e=sb4=zupIX-=Z3@D;lbC=1vpUZ@Q!O$OLF2USxzQ0B_B z`XQ{!PN8%AJDJkE`jHUK9pUU2h)`*w!-aR=N;VY&f}5klNFlywnHMoTeAqp|EG~;U zMMF$BYuR6~`d(QXf?nx=&m|yus38-k`dapCne;_BG2ZVN;~`cl*mG!afj4WmYUXj@ z<&cnTsav$;V83>3d#R8Q{l5dLyLJ?-GDO=!=^o+OD&j_M|42&XS>qpOCMuh*D4HjM z^qU58_cn_!*7Md-%REM{Ew%bRbySQp!2TH87-fL{(Im13vSq`BR>|c~RwCopWz379 zC5_$KJx?wL)MDf~HR`@T*vFl?=R<{FYEGRWvVzpI9utfA{hgOyBvnK@C_)zAYD+Uf zfg5J-AWn^2T~SB1I!d#KQk;7ILgwtq{DDoE-*rs*Cs+8CBH-<`0dHpvcst}d?Jm?g zoQ(OqX2k9?3>JKJ_7(E`8|>lu5B*)!Ko7lz1q+Mc#EU)h&OI1(b?}+_2Pe4>3FM`G zwoZt^GhC9;%GZMVBFuODd&M6q$B9~emb&a-r;1?~y<$g?Y~f|-ge;&3m?k*}P!Y2R zP;DB#0KF?ybjlw|&@xCL&gpwa_o_E!?M2#{95GM)*v&E<>U zh2(v|;hHY1u$l#YOoSy=SddikU8^lSE16L?;Qb?{U4{Vf&;Kqh9&;yN`MF37u6plH18xv z%HNGPD0*tcK%lqchbvql(>f6ob@dm@cEx;*#S;oDlaS94O`NU0z|IuaKFh#7SRt z0LM%RIzH?yVS3!w41G#T`V$_Sui~0T4N^%rE*BDY_+l2nFJ5AQtcGtIjF5$8GdjNM z3)_|YeGirIsygpiqBX69tQxt+eFSWgRRHqwpDixRbnO*y?WHI@IOwh0!)&gs-F%&^ z2V~q<%pZzw=!q=$+FPnNeDW2S*}ljPI{&Tc142wsf99~B1qZUcpX?P*1&oA(e*EuN zl_iL^`PH8bs6`W5^m~dPC`+eGFJ}T8xp!cr%v~d-%x!_(+R;EOnXnG&sfY7T}wjZDm zonG>;DomI{gW@Q^ui0Y3G&8y>(hshu_R zQE-TyMZG_xv_e)hTUTeq z#~Rx@{s?(w3}CwsZ*_Zncafc2EGp=Wq&_s2AFkK1&D@7mJ~}?++4ThmK9am5OS^sF z+6xV%r=@nJD~= zAeq~xdM~b}u%|w`M)ToITIOim6lIa?z6VNk5@P(eaW89C;%B<7!$N;++=lukd%2G- z{>mbkdoPtOgc=~Z1YCd_-#eti)}%BNMcSZHnM zJ|A4;A~wTOmV~@rmh*|D9Ll83Yx<_&DaSMhTaDb66I9Q`XLJp2;T7ms+6^&DBCR0Z z3jr?t1v36@M%R}E0eFf}@CwqM5I`6UirXRogyE)FIJHX)w;QLTLLah#RVcL(l9c(+ za}j^UVU>ZreLs|gt%^#-l-Kl}ETe#DbR#=&!bVV>T*|~$hKwm1xGQ3ycrxKxqPn>R z=gIcv2eOKbbn_-7N2W1EZZ}x^;bMPQbt0*qzBYa#!-=QDuy=={3a|{cG*4;i-B&Dw z?CT9LRIvNu;AZ+9vYAcg;^5wVEwf$Nbf9?xiEv20?YnNWMlJFq$lGy(q=v_qqpd6g z;w}aQLISqBMxyBNn9Ku4C$royj4DG3&7y~SBhX|}Z3IQTTKfXCB6V}ixOA!lXhr%D zGla<`4+>;z`YoenqycTgtY;EV~A-+Ju)qn2XwqZW`z@}yVmRAJrvfK1z2Gfa} zd-i_Cmzbz%nIluZKG<6Y{IQHM^z*0q+~@#WDE~ra?YL3ZTc`3P*gjs`byE z6^}+4$C9PTAjQ@c9sA$0OMuv^ge617s8m9G^PPiwfNK1b->2-O_G-# z&SgMcK<5bH=62CMN&pQz&k>w^ex{A3!pvJpU$$0tYsx$=N?H7hJqtup1rU)5VyXg& z*oWfjgl7!^L=X+qm7ZOsn49^TjmT!&oAG3VG&b-hsc6GbKrhj)ldSl2qkWskqrU#WTRw6%Jra`_z8u}-L z`vQI_iuPVyxD>_vm12>;S2xcYork{1%mGS|>qllt&=`Sry5*xmy%K&cVOT2z>`HJ# zD2cY_WgL&c1B$ngr)qAlPZ~&H>!0Q_|AJc=SM6t!vx4)2dnDH~u-%7HEGt!90pKGw<#ikSYE}|FrDD~Ft8z7@@AY8icck43G zcpmU{5dhxO!$f_-LoDUot9&7qTfTFiIgxuHmP#lN?;x5aWq)K zB9Qr&$~(4qF|p6uj2+PCRev1^3=5+?v(v4q`(`KK#g|#E=pZ1j)oY^WD4?qaT#+k^ z&|)Y4Z8zOJB|pPaiOArmRmWxK-+YemA+Plt;L%-a%a>-tE1%-pzxF+JZ-K#<4d8qT?4X;+0p*DwWcfn{GBldY5$Mb_ux~1ZsXG7(C>;iv9xPGQh{a3oI!D zAKOs0fSzTg4e3n%LZ#e`QI3DLBB=P;Rngji`S@4XUMR(>;*6WjrlPGkJLuaohrZ81 z+4|Q6`|8=+CZ6{~J7diD^}#HMv<$!h9>jL;!lG7>Zy#Z@e-KxE zcv!6@DO3)vS|K~>aSFyiW~`?@H|C=}78)H+xU&!5+A1F%xxc@xk3vko+2e2>gqkiC zMsJ)X0=1CyX9)bz(_T;YJ-y4*uNbego+%W6g{)L4@tI`=eBiC%vEK2NyPK&R!?n!- zKAjG&R=SxG-U+o<*=?aW>tdptweqmb0JstTX{<7@DvkP2_1HM=%hW*krqV2pw#4hxedCdU>X&5gW_ z3+z?tEc6Ug3+v5KPL>wP10v*|gH%;v7dcN|p7Mty>ig33jGt!%P6aY8ctfPB4LK|6 zBWODzHdjGsR|xxh*TA#$yA&{d;4JBO>-EB42rJNeID4iA9M;^^%v0^vV)ol%iZA$I zJ%gBlZMNZC=`J|2Wy>``(!2{I(>QG}&Ee#j(HorhvZTx5=4Uc9+ zff1;MBmM>9d`~Whpt;4nez^Uj(?h-Kc^)dNm--bT0;-1$bu1k@)Faa1qEuMBU6o+h zb3ofG1$A$LdLW|`)aNYgY!FW?+Q!#TuHKC7%bP*I(oUyl^B>hDrI9w~8>PB&vp zy=&v7n3lHcmuI0GPNO_!mUoxk9C4veLYs!jhaHUX?L9o69i1tTj$Fa(oO;g>huveL z&ZDyocWOk#Vcq5&K(%lZ;{6Pl)H`+h{Rl*6Ugx1oiId*D=S+$&(MTf;$C7P#_k((k zIvO!azX9~umbMLLq-h$_9&ZfN7BB8`?`hV&4h{2*MW2)%+6`Wjm;E>R{cvHzu~U!2 z=?^~y`eS9&WN1v&b_PereYHDWwF!{*-9ED3eCG&Q}xk&lw7uwz_xDOuQiGWr}=~T=!I#%Vx@g9XFCD zfbnWnn?2i#gi=F9ZyTAM9-|ipFrSP5ng1KK)KT3SSK3L0bd` ze$0f``z0rQga160*q_v;jCT-9eNzeEg+&K~L!PgVOmP#l;;@PVo-0v0Iddl$gTGa( z(uG^B^6J}<8$p_nbAhBrWEKIy70n7t&NSDBmkkuhBp~fhG=o=3ryjmSh0mH>z36X$ z9$!ksZQVZn)P6k)blJ3}S87t4;o!?*vC6*+;ObT#5bZu$`Ol`@hBEuZQO+qiF(VJ= zZc{xT0AG1E|2jz~Mr|z1$r&7rbogu>&zm(KVCu zp(Xi8Dg!&lurlAI;0+#iZS$t!VO*J;<6Xqzd`r*)8 z6Y<+~obGbdiX~?AMv{<_T!%j{ayxjkyB;S-J~^-UdkwWjK3=cewcoROn+g#)mI({+ zRuRqxHT{cxVVs0{Q&Hb#9WpE7! z$j~KG4rYHs^M+j|u#B!6+eo1Q ztgUnKA$#gAIXMRb89C*MIwSY&vp2T+l*AKAlxa!2uSRFsOOdn-SR(jd>UO!maL+Az z=SynpU*T<@z+zxAipeM_+!J2RO!u#ESygb_neKI7dvkherDyr-^x<*1RLUT&`0$e9 z@pfMBx>;=5OjJbF04S_xf#}NPqg#eP>f=*dwBT0dZcQlxeKWfkNh?tmT0qfaC8|yf zC|X=iF9J)+%EM~Xjk5fDh&0%b+gH}gXZ^IEbcC9Jc?m|{H5FqqDV@FS+zZ%(hytUv z6K1KYe++wU#B_NIipJcmNjeyH*uB?pUC>AIGrpG7lw4}#7(rm{x4$hQl18~t%d&ch z0~&xM1>=<9$Up7BUJXtFhfO8~rCODSoo1Js3z0Fs*dBn9o7RXLWVzOKn9xdNIVg)( z@nK^E$+I$$Jfr@|!ep4b{fV*_q=|Gp)83nDq_q-_paNtfC_^_+IXD%8c4_TnD8rBF zV4a3$LPZ!pqmqVA^AICT_`8O?q7HYwo{R#@c^>i`SdikU=}3$|9(1I}I{pC?JW9PU zjC0QNA)4O+6-bO$EF^H@rOB-&@+@p)jP?1+wkgRVB}~NG7bNqNDAfHOf$FygnJUhl zfQNTlEQT#3Yx+M*K%=wO%cWADostG(hR*=}%Q=z(GwxQSFaEq?0=T8ox5tBS=F6O6 z(un^2ZQNCYIP`H`sL55-%fdqzD1zt%dDwt}4)IDX@)~)ryrCs=& zNsC(I=VzYtEx`R9kP5y5VYog2cYjAO$11FRNSv1`I&?37Q=Cziv2Ok(_B1e{ltN`* z9O#P{Xkl(~Bmdx1u`!+%>jV(BbJ_g7dWCFj*vXqab;kx)@2`hxFqF-DDB{Y-{1FHR z3I2tG8PB5u7~UEH!)pOxc&8E{v~sz~5fpNIsH1;rwMXu1<9i}_&fY~t#W?|vbp#6h zm>DEWtLm^BuCMPCB|o4IKPIl0L?IO7r_Y01eesJUoLc!gI)PThH|REDDz1ZVzCAlH z$mkHbu2Z9GTv5yp39EGRTkd-6NfOBXR?!@(23~-J%EEi|pMz`40QQJwD9#f|=xb4z z#UwcoN*?%4?PP%F>zB9clx0Uy>(Ug^u1_!qCq-61feG{bb@Y}`FwA6fvp%y z8Cd{?4s%%{z%eQ$(a*QN>AtD8@Px;8@4hTqY0>tfwoU(~#VNIxlF^@*;YR-bD`cYF zM8*ebGIkT%ek;%r*b%BSEB0?OkUf*4cma*TCt!0!V96W;D5e3b8UyM}lPeFu6+i1Y zLOr#&S6f@7Jnx%xY7PEtO6!)t{nkopt07NE2c>-W_3{1 z(=@2G6$+eHRX6rIkO(Y(6q05g17+};NNyLvqHCv#n@lYC!?qDD2+#b&LWQ3ngjCg* zW$cs%s<;_&Pd?cukf7JX>Fx`EZ98{yTU82G#QdIXZgpxubAV1Gy5OT!d zB>r#i{E;6mKXfL!&zq48c6b9BHM-LDhXio;Q7RuT zYVM!AlVJ=%KgyH8R|A_s3o?T@1H$E+#kdBayDK^7Ygp9*tvo-riGV&@QZw`YVgbfS75k0LMF&CiasV{kU3475? zb)*4&>(68tJ@73Le&gDAn8g~p`cVn0VeCeVk8Nv5p!)u=PXV|59w2@69*WJxISsQ= z4eB+FDMh}c=ufH<_SooOqeu?#-p`&#!3+s@QX=}ux;efqMm2gF)zhWorFVNP0a0W= z=x8GyhidM)LYk5;T>R^R&)OyJU?lebj&FxO~f}WtJ>NCc?yD1 zgIpK8znst=GY}CLT(LVumjC9Rt%U%$8m@N*eTtL6-tEY&gBJaV`=N#9PyH!jX}V%k zbKiSZODi1w6X^AOG`*+!q<GqXx)NC26k*Bxflz>vs zfy=-}jftKV-Ke=-e)Yc$#wR7z+aU13Z4?u73$aXqZ^&RW48yYw7^Pi!5XLJO^@vmL z6Ri{GGWJUHMNrkSVO4m>x&_aG$uNK|H5@i9!l5nf2z3Mcj(nmcJ?X6|qi?`=i_#)! z&UA=31`*YQ32~p1N20$25C&H1w~5*%wmj}HYH}15sF5+@F8N=%IJp?&FD2AeDJ5Px zr3P6~&aca0+ftPy**5e1Q0jr7DlXJPD@>NjU_WfVi|jBB3YKMWk}5f!z!2Mic&XWz z79CN(_Ep$b^F#7#87Q(j_^7SSo(9urWR_3BW>{{VS1h|;0d*4Yj!MHn#l$EX1&baQ ze&m}*F%M_gG8Cgp9DA03_%`<7Qp>`EAJ>~Qf4LmilsqC%i%lu^mIvYx|6LU(s63O~tuQ#Nz4;T1?0>{Z8AhXR6lmhKvSh})>D!!Ww0qgWYQCa9bbsx4_ZjrgZ(CHT4X?ue zD;!%kNbcot5Q@OWnxsMuVNNj&tB!VIsDU!Y6}o;^%@O2k!QSE>yzv4iLQv*P7bgG- z_rbx;@V5d3O)CWVETVB+OhAcdfO7E z&9CZ3@3WDJ_I1+wb~mE^q_Ug#H4B6YS>4_3C#}}|Dj~9}?!DD5xWZ-S*sK0DJKhHE!$F|niSp}Y2SV^;e5n`+U==P-`^~g;9U6PO32efg~qvQw*3eik^ZxAaezr zOghoVAnkbbH&(wJO4Bg0h;%|cw)a!>>^Sh5+N!g`P~L616-ZO|Kg?a`n#$6*9ppHocn%YNbwI zXC|E=ik(!%lEElpNqjY8g5o1RCQ6bAmR3Nfs>+{Mqw_Lvl-|}+n(2!SA-S#MRNSRE z$~1FRqUTFFX#&@ljz4LyZIz6rYJ_I6CNI_DPFPtmH<-d^k&@ub+-*!AY4>>i7&@yS1=n7Xj504e}mRHq9IU(#idvGmq#nJ88JICe3%h4BlJ7hL8K8E%%c()_MIIF<# za`&FaBDU{APpB%zCn1-fCgQHn3fpP>r$2eWS2yQ?sn=#z6gQW5FJ3a9rpE8e_bSiF zXlxcu^}ByMGG21Nl`ez%J5nS6bfjLv+LD-6qv77YAnu{w>5_e;McXA*{{2*D7BAHO zxo5+6XpqZeLIF!!>d0HV)n^}ce}NR@`#V#7YgHWumTSvTGx9pQlVyL4Q3K`ds%R3}*%$n=mlC?R?iaGfL4Z_~Ap zLRmpT?~_=01X?Zffz(8}6u2I=IG#aXpEucz!!dlHIM3cCMlr63_6QgYuRKYLx3bzR z&6c(}ly04K=%=aKZ#A|JTp}b|?GlWR>#lg{DoJ{h=Q39^lSX>!B4+Yh;!&z>hCi(D^ow+U0yfl`Ba~NfO@^cv3E-lD1Ilka>;341SfOQ4w)1|2wVz_oq zv3hyk=0v135kOU5GQhKoFdGH{(u{;V_s0|dQL)1nL-bMD`wwrzD;<_;mTo1zg91U5J^pUw|_Is=Iv@0=Yo$ab-E4|?MdW{p3+oq0ZWZV+1-Wp zkZ#D14U-6q<=e6^fXEX}^!vLW_amE+oFlHs!=$p>?)Fita%dceWj+#HK#L}s$A?! zW|kn-J=?nh78c|+xhmzFC%-yo(HrX$y#FSnHd@5Dtlj(&TuS6rwJYJZQb_l7OVjM( z$O_y1r+4j_)vgHXfJ7jX8bQ;pa1?^~4_pIi34?`AtWQ{!G)6d$6~H4Aa1d5FU<{X& z%#1NeKfvt3q&;LJ&8Mh1P`X@2l{}q_if=MI>DRS4M|T2vnBI(QNSE4}SVxu0I18qQ z{0rxG^3rY(yEhaaaN*&UBd-T*@co=!wV+Sg;TEXc-OqQOtl(z)&ITwc;UO#z8&=(h zTj;SooYuL16-2Fah1^;uB&DuMyUhWV(Qm3mqp+AWqs;n!YB@1&c*C(PbP2O*kv3K8 z@;)l!J*mV-KdE$JS&OAOnU)I?ub@xRP+eS5rC;cJ>;*-wkvvnRlNUOAFqjJbVnk^@E+7Kiy$zJUy5^+0Lhuq=HwD$zH8j zb?atCPW#a9E8-h~X66H)&I=UuJOmR9P2FkxiVX(n9V~nS{0Z8l8`DxA0je}56)EAR`g(~XG`#zoe!P^<0|F7)yu<0Yn5yyw@$!d2bK2`4&_Pm1$q z&(;i!rS3vd{yOT~0D5wn^mAw67H8c`K4I0N18Dp_vsW@kX#v8BznALcLl%bmE$a1;5eGj~ zf7}vg7K`ubBcd&w!So1!*2qfpDp3rnd@r5 zzkm*pEM^T)-0Pc_CO##6X3X1C2*!|+k0@kn8 zk5@d2BpA|W&3=7izih&`chx`Md}m+eTyP@RUT9GCzZV!$7%C60i~Yz@Vj?LD>hJw8 z23meZa(r4Zah0#=Z<{rIgA=^^b@|>Qx9wwDbu-)+%-bdH`xx}Wr4t;d9{$67Gabh< zV@7iZ@yh7fG|R3Hno zJSE>=9(5>mQF}>y;k?_i_3qu)lMrCam!mu-KR01a8A}nETqBZG#=S@pD2i6TNKO@mOQVYWaQmnGZnpREnz;T61sg_1xH`IeDSWr1d{WJW7}Y$v2wVi&Hupgr zT;w)KeC;)WSFEJvDeQYO1y&rqDRwE?Hg|{6eWBWsd^ML+^Nih_2>$XRDIM0Nz0vP4 zcH`bDE2og-&1_=QzdOW)`OiYMUlI)aR|zEjq(A#Ma9raH+GAvStIQ}&QmVzIOBenH z<^SR8t%JJizIb5~X{1x6OAwHfZlt?Aq`SMjyQNb)rMtVk5$To|5O_B}zdQHN`;Xso zbY`6$XP>p#`UG;LPnT71ti7RgZPvT2U(-~9Of7BXqbfffTdhJ<6I*}TthIsLK|_aX z*t!Bj%fF~bwYnK2fgb`tNSF~|ECt(;_L4a_YKQfIPt_Z^&sT-Um>Kerj~yZYj{e~4 zN{pcPz4t0DDc5zo8Ug~Fo<4HXvLYo4OKM9&lcT_v9OIr~|xYdM!)@V%4cREye|bPR3%)S~L8Lpxo+WKKvs;JzQDYLVNz9NhosD zQrX?wVIf;IS>7S8ukt3HQ2p5yAxXQiW@M2FMS1^XL4A%xcyq0ZU&*PPaR6oY=lB{V z^JdSt4uR`4rm~a=>LWa3``g!XMRyLx?JRu8mp2TnAq;GhZK8OE)r&K0lAj#S*$1NAhMXOdJH#(Z>bBi zb%#PGdN}-CPTQtIf#2zrk5Dy~=9nt4KK*Hv~+1q$pyueeiWSZa3iv6A>T<*sD*!>v_Q(PhZ9<*j5Q z2;WNLR|3Sz2ozL<9^m9Ow{6T|y2;S)OHb9k5TJ#MS&wZ2kJI3Kz~Xf3zynqblhB7pkz0 z`(G%lat`A#g`eu83kEhEotC|)#ep+a&GR)fOzQpPJAUDQbp=^cmO*?w{1PTIgg4aX z*-;;m-!9Yaw+z!>2Ccj2wLh z3h>5G?jwExmE*F8h1wma=@+=#4DcclugRQbXpjG!(Wz5ZdD=z~d4e%9mVB;5qWCq` zVNxu20VffS7?6&y9ngp}))I*=tA{`hg{LcfQ~ND?{%cwAoX&L|a6lNd<37=-2Asc> zF{59$qSb15$@ol2kurK7l_wEqel1Nv_&(~Lt@zDftS*oGJ=gPPHdvcEEFaaKFKgDr zU;QR#AKhd!6v=~GVy|8pSel|_{R&@2YH|wsQHz+3l|rB>E$oKgP>+FYXR3%xEP%L@ z$D6>R4f*79X1oy#LL(D9%w^!N*<*H?xk;%J%Xj1|_O)sm+O|`~i0g*?iA1#uaT+%Y z_49^{_iSOsUCZ(A`gEp5%1!h6{-fl{H#hCV;&^!me9e{9R75iv)tE)g`q38shgDFw zs97k`#E`El$<~y=ycOZ|wa}9k75NaOTE?6Iz@%A-94k<9AaKk^hz55{ax)oBCRWGn z8TD@H<2|L@YrPo-lr(|f`j1l5y;05tTJnwPE9Bo0s!v?CXB(~yt+a#~S~xilqnGef zmYA;F&H#JiwUHB0GvMS4?X{{6T&ixfS}MfJ*c7?*`ysBJKlz+uzUqUt^yb@S)Fg5B zVmu$`@(cNEQhHB#ItNc|CJ7IN9lHk2chW1hfIDvzH%G9ID`suHX#ln`_L?!)1>377 zzp;6PpkZd#Nep6x1Z7>cIsEA8c46uJI^l{w#2lMV^)OGFwbJz3f}@j{_m9ejj{>R5z*jJoAnfQS4t>v%Yh%77-9BgT9ht zbeXLf@kku@jzD;R99q$vcY(k%OkaSzyQWu9fuCEw7|f8YOrfGYM}XU*yzl)Fba|F8 zXl+-4BD|)zMIu-YUw&m|pT@lQZx)0nEF#TJg}8QBDYfuWZm1>l{BFg*&7xWZGN>2= zB25rZG`h@8tg9pmb{hOaG);OeLBoPMou?!L4!SFc5_0^Kq=bT}W5p)P2!~YTPe;+Q zY26w2c%lt03T)G$)*uRo2)v&Ik*7}%D#pEebhJ9glFa1Wr_e76=kPS^KAk%ioYpt* z)v}pCTf+%@evi7#SjBA31@LRxh7Aau!y6o(A`wRbw?gLAk{yQ+d@nvWhrKK5xILy0 zOzgksHa{}bDFPB`F(85F-cOF?7hkh!PsJQwcIcOgB$b1~7J_D3N`_GG z9I^38Lei;=g$jfO*A!^}8JQ@@!d8&SPHz!l+*=zC;$B0xfGAZfGu%=Ow;Mq&GlWT3znP0Jgi+NxOe)>fYlDqpg}{E*DCt3=SRTfCIZcJ=n)bXeFbO!@6BfJ zwTBVxJ#1c`cGWiGQWfm8_Gj&8H;s)GmfMxc`yxYLuJu{(70-6w zYNvV2ON=4?y}!4wgyu%51O|M+0%(w@SHS@M1?Bx^1903Xs%1pmKa`&DW-mPI?Dp%h z*b?SMfd{rBERO;YyjrLrav+OeU^;?R5-rIe_x!yi*27z1bwk6}TBUQn>{jP+i{qg* zl}1XbSwx})DIB0%6^$Q@I zrZ_?14={*aGT4y{K6%YadFMi%-9sp;Ylrhel&hZqV!4jgu(T73^c*=U$#05%2 z_w{S?g|z)g1Hr)=>k_wO{8HS#r;|mpe;#ytaNZn?f14pfIs4w6Z{wt(6<2;{&3Nk$ zgN%MN(n`LD3K_k!b)R>yNzh^VNvYeytx;BH5r?k51eH_;vT6MkJ{pI~@y<(C_ESar zAG1kjTvB15EAY5cIMrGn;HZqmVOQ8d4%s%8E;(=FsC;-qK9ULtz<>txJBHjj6*5Q; zy?h0oC0S2H(?(O}_Us{!erM-;v1Mnc9{O9H zLBsdZh-8o~xNbB>Jb=(II?JY3EN&$X0RnLYXq4g4ZXnOE1!`qnXjcwNlUN zILVN`KCSHohQn2lJb1qdEENL9K3u;c33ecEvRgB#{EX`dgq;ZO+8Ea8@_ z7_?Y*1RwedED+$A`aBhtqz4+^#WP~n79aW;lWy|zC$jUN)${AaP5*pZ0VvX4a49o^ zj~KhL`E1MceqmtuVreNy%85zyMs3NLTjA4DQJM3);?LG5b4DLa?+5xSKsV@&It(1) z@d_{z$A+THKKZ=1vDd%BdJxen^D!fKQPH7Zr$2BU5U(--@ydZ&5;Xqore*Y(3X7fB)4}$9ssUjJ4sYveZhiog@+JlF4zw%H2acC7Zp`9>^)t z6aH)g-p9}o7b zb*k5o`0m*rFhSn)IO%100M%0hYn%V{S(MPU8w@=k3|-odObzD%HLHs9@nK*rSwm)e zVpb!VEsFzBn-w=7c@nr#=uC?oR#}J#*Tt?c1@!@l^3~;HmFk%zk!Skb@BsH%FO!~{ zTH&t`OK?lKe=7O!i{KNnRa?;y6qF_V;sRp{4ZfV?Q|$m)5NOY# zllazCDM@)fKE0Z8pG*uVPjPBbqqp7;1WZ4vz~)(r!j=bD%v`F~q2r|e-wFH5Ydgo; zI=^lUV^u&#=9#t5$D^QPu{8Q-VMU9`0(`IQA-Uv_$JMIv=b!+b;PTEvNijU`sF`An z!tQcGb`WQdpW+8;gdF&q{>Y1bX@?v;^qVj+3y1e&Qc2K-x59r&f}c?`vUb)X9nR-4 z!e?p;p@|9WZK3A`(oLz|-W9=dxr-#GpdD{l<@gPf4{%2 zFqO32=JA>BKV4(4+u{IyEN|(P8X7FKC@HoH@||5qQ3%sCj=^k}i;J?^em!(Kyru}q zx>!VIg-K{UGZ$d;W+o$u>(0Su&OKpNJ-cepaqi>u_j+O<_Iv)LfrL z%#510$pS&9%Ea8c+d~aWVmb;_8ioHPgdT-c4{d<(RiDi5_1BCx@71Ry+68aUidzNB z8jS3mA-v4KBiB!)c_+ z1#=+s%4*6_zy1`IgA$T+g1pxx-{uI;6`dpZnD!1MPE^0ckWi(6v{o41p67 z!S)w5+UaK+#J)L_YIsptL)T6UXK(Rjdt`)usK~Ef73p7fFk_YrPyJu(^F=N=Ye<0gbWcD5< zCzrL{>9o~b)ToPsx-2SJop8iK_%*9cwrWm;Q&KLZu2!YyifQj5lucuWZ3H%uzOR;e zPyg$D<&pN3BnO-VC{m@)=Q;MCDy|{cj$Q`8mJ5jQ``>$#U z^Kz3tnXgs^gjycc`q^HER{oYjK>hU*i*rB*VM-o!Iq*rR#j5*c!)T}7f;2ssc3piw z&efc`&$VRoyPbtKgUgnj6#7=#Vzva%)~jE;Ypa%LKXj17bgd8Z-cE#K=DBdrlS9c1 zp@{iz(5F1Do9zQW($|LNiL@TSF2dKK$G!{E{PD(zh8L}H-vCshOs=!ep|;A*o<;rl zV>V0lC38h^D!|?Sn`iANATShXjN8x#1)0az8&Q0M8~J!q*qyvgSRZ^McSfsNOVjGh z6~&@zt}^-C@Xkf+pMc!21By*3$v-$2uc zHY;UZfhA~PCt8Y7pM`T@$OzqRh~Xdsq(msF(azqixu9c;`SL9gtn#V+m`879a?B!D z%DI1mZm+&t!El$y`bi@GozsT+q!x;fcEl+;yvggWX(7E0X{`b{b8Y?!^TDq=EK?Dh z6>=3HED)5+LBH?j{PO*|riaZ9QPXOnLv!4aU%ru^^+hYMdt7tj=Xd1~g9}Y=BR}&o z;ZB*(Qu{rG)`GfXD&^MQHxF(zf1UCqO3Xbk{(dEVLQho?_wNb8-Tf1f8`mG&cY{%R_~6#j z9*7$;Yr|}Xh^TM9@O#c;tr+_&*+)1RGz);+V(rZ8%`AXwqvDtW<*<8G$uOvRS0&}9 z^--f^pIu#4DYy`Z#nRee3lE?V(brhTJnr$OyG@mYnUGzg#f0LU!RU%dg7N>$fxkJ< z-Y2|i8QUB1^b{5yeF~T~$EmG*5Z=G1MLP>n3&t4Vb0QsjZ}m=6&waU+u!euvsQPxG zfj9Fy+9t8M!^TzNFM~oru{EQ(_AH+G^W@{+@!#E`D@*nTW0V?9;+aCviMcV(7zA}{ z3*QLqG{pXuGptdU?XEjZyQrgikZQj9D^EjasQCLe$4N{0i=vzRcAL6ubno|6E1*=u z_+^m^Q5G5*^~R=>Snq?tMQy$64Z0wq^xU3e$}Km@Q+;(~6W56N#JTy3rrd?7uN^34K4q0MImaQ8YbyRe*s+Xf zKzS1qy9jyl9yYgE6e%<|H$S{)5;OKq^6cOKSFW+3Q3y@aDoQi&h|}m+_`yq~GRq+4 zXzShT%rm-^STb?fTx>cH+BAEd$G+%AEtVRU>Ud)V=|PZr>cEGKoCW%zfDh9{BLn$HXkh-=DjD%NiLDI_O*Tt@Axo z4T{;~X`2c%;8_23GqSq7g=Gp@xCD=Q%y$Auy zeY;5xs93_U8G6-)d|tJ_;OLLd8t0=8hBo_FKX1^oMDpqm`w-s}$n2knbY99lH2Z2_ z1(8Je>Nh6G?#O_uWot{mO+ROx#i6vXq=;Qx%P`VmBJ=su(%0KY6_XC!c7Y?T>?XIJ zTTdP#r1^!T)c*G(>)eC3Wc~JQ6cyIs+N+BoE2hrw6YV|VvIfI`4AH$__V!G*4C)NF zuNwK4v@IE=FaT7A{}NoQlhlZg3+E~vZE4MfsyCx}oY}=urx^NJ&2QWCCRlPR)`T+X z?5T1EnQp>)Y^%!Cdb2H+p}8{sixJ%s%1AO-NLbzn(*M)1vvy-VGGBgB)t0kQfUg zHd$$jtzndpLy-pnJVc{Wtg07b^F=u8|3Mz#uf!q6W-5o#gz(fYKA7MLt*<>+YFtD8 zEpn;h_QI3S9(fWy=lkw%z>;m%aIVd3RquH7>-;wqkK(~=iJ!fW!59mN4?9Nhc0*>_ z9Q}1uAIKH5YQ|1Zvylb8hg%L~D%bCx8ryW%cuAidFsU}upM`iaarT+67lW3+#MP9r z)vm9z;_@L+x`4a9n7d}B)(u=HIuEvooZbA%N+I+naUsxy4~VvL0}tITlGXuQ3BM0U zH|$KFl4uU}$f?+A*;vB|^WJ+sGqxFX3b|g+{6Bk9vdy`y{&M!&D~yjLN_!c8>ZJ6q5C9G(4btV6+>G;e9`#>ON`v|+%)eQ>_PJ@G=r zse{u9nR70mcW^-KrkKYl?dE!6>Fba737+}1>#ZCrhpDpdBNOh?qDm;OI9{VY-ZmA> ztkXH~hd;FL&UHQ_@!xpx*K#;pQNH+TI5$)1GgtE>xG+}_s3u+L^T2_;&;bMa6Skq6 z&2(mh72OTJ{i=!Is4e6{(!4EXsN;I!OhQ9d1j!)f)K`pZV?Gg7kRE?vOz(&;aGEAL{PqQ;d3`SJI&Lg zz2q8|3k}>zom<}hm@=wP+e);z!iFVMX{&5BKQC0u7Sr_v()@j)7#tSEVJc!2%wnr( zMC4XAx7|{q3(}?LZg}p8{ChGvwbW8BpVk$?B94x6u3pjG5D)#*g2FLA1j)b+={V0r_5OLm1Xcb1gM6uVZWK0iUP^2kOPNE{dhA-|gDZ%BpcW44Y0;s5 zLzO+mhOR_hbgzG`{|Q3G@%0sI6t$BM%A`o?i~iHq!R(A(QD%~9TiY(F>>CTCzgm9l zR$lDB02B;)WkLcoxnlpvmxm@9^NKzX2u}FpvO>}30bqoKkLv#&c*s-V($JT2m#TwtM~MCZ#*OfAZXrSn zy`8o@C!!!IJ^;;g2a9Ateb0u94@(Yw*HvP>ld#|!gOEq+A$#0T6cMG&2?}_5GsPKt zMWD2drj^sLhgDVNS=_*P=6t&%<+K*&bJEVs*7kifH)&J$(u4C}DWQ`Hya2(_W)0LDdEgKA05bD4 zSW(Bq!3dx1%+h413S|8V#j3+4mPr1{R#uc*(TKf@^FQtN0KPYyolcj3|L)WB^(jLu zl!^Opr(DP4LtPhMxRiq|wjD0aFyLGa1I|SPVM!KAxv+|C*IZ#|*2O14dfagM8}WI0 z_h4KR@iM@J5iecX%zyp=!6mMIs-h0qw)s^X|JqC;Fa|OH7IwF;XN3LglgQcq`cv~- zZQ6j?-PR{-O3dsg4*k75S$;b)KByu~MqPrR4xsQyAAJf)0Rw}t<1FO1YxHuLzUoQ# zL6NzE?(8mVF6hIA?M}^uJ`AA594Sl^kHvF19GaVx2f!|lJ=(cHlf|+|6F(fBr?ko0 zA8c7wdjFAUb#CAl{`4b2XMo5v^4m2YEL+o zRJ`x?s~_m@;xpk?Vs6VI3)hxK4Hrnzj8#(^WFbOoOqYs)JBLl4DS*^ie1BpNifJr` zm!JD47cgi}Se2wN<6z2Mk7S-7g}rZJkeq+8;JYg)$r$-}ICa2r(;xtZa-|^r?Hr1G z&5#C^;6mo{;ZAt+(zVi!oo9=j^@ZxQWuhhKsFK?egPQ&IpqFnzxSw=c2D21&@`*Lx zZVh+8b2I+jM^NcXkhFuxRyxt^Kcc{VWeW0Y;>ccgqvalZ2|Cn)Rs5SAp6SZ)saZ3~U(cf?dO#I*%iW%vy z(((W6Wuw1O**rH?01aHG)l3T)b6pG4^H1YU_?$c}1tQLLcn+1dEF17=r2{ZpVeR>j;!o zuYX_F-Zy)}^7eB5VT8Up(Zl3%Zy0Ehz{I)Nviqx9nL~9$j&CLNzt}S&(XL@t1y~D??n+A)fr?ga)llF=q_MiFQ&woq(U26PU4%M;ZbPZoGQ-c3z zU`oXh4&G};&=LG9^mkzJwB>k9#5e<8>t~ddk^rVGxgx$k5-e&r1=@qM6zzO)kF+QH zoKQ_vi$%torS(w{Di6XgB~1>({nmSFa3g&b3|7deeNDx#FYtzDVxQab@ac?jMQ37p z2Yvoo7PsHEAsu=)?=XdA>eL+tNTD#fat-W1b$$@>7~_x9xlZ;E@5pRxY<;?WRMQUm zF~l)vf8APvQ#VP@%1;eSp^1>&l4Sk$Tm(vHihKparMc=KU{y|J(sqS0i)M?W7{uP^ z80uA5C|n}6H90<)XJmlSph*Tue}8dgj8g@16pCu3%3(l_l=>*h5!K4iPbBxuPp#R# zYZMk|C|UX;F1JyBR)|z5#OOlA>DzM<(*w5@(ym6xA|qzyoTa=Gt7RK`94eIb%}r;- za88U`*>9x>D9`iQ3pyE0Xx!jt>bH!3>#lz{{-xrHflLAd^EIFt){~L}x1cYJ zQAteTz^tDc`lk26I4u7ZuUuTL2(}0To}_+XrD0~QW-J}LKJU;ANNEj9>*{lC+X%3b z=sB^g>mu(i2B_{XGF`V=k(BQ~DEerFPwXqs&ZZYB*}gn@5BQ?aLft+;Ci%z-ch|LN zN2|Y%0PAt_LZopLk$9m#tR3V_F(j}E{W=WsOK?T4QhL8#wtw`8%%CB5M%P*KP8tX- zt-;Yq1;3X*7Jf4}1wUldtfjWktuS$fRR}d9fmEr{AO+n9X#tjiWi6^?go+O}K1`^% z-8Ug1oP-ehf5hb0C=>=@B5=;3{u8w4Tcs&&lm&f%h?n#;2nuakxg~D%sMmrfd=RzGf4}MSADm<;KTzh$8F`b!Jx_8~ujQdrw6R$n(J40ox^V^Ge zq1C@RzApeW(>afIz3w5WXjf+{H)ghWQg)etE6c|U0KNM8uBimF0u-MsK=D}fg9`K^Y=yasoB2R2bE7;5)M{=2575!!FzcFV;?PyoIUifWFM( z*CzFGT}Igfu=xFcvpoXbhyWWt36~|DAg$sy*U!O((p%oY2ZtBA>?H;ZR`Q&rBxtMB z>~A$m$q}j}eMLQnbH{|3&KXx^-fdqdFv5)FI7&hHKw`Ws6KV8e;t0?BteeXm z2e;3>0>2|Oe>se+qmxPS!qjo$=Gz9_AQAIausb#nn8(bDOqFRKDTTh!|6Q_>A$pT*$@x_Ix%J>Z0kE!9KL*``U z9u9-T1R>%Z3>vhl&$#*lk62y$0o?s8!e6epK;bqLRlev}rHHp5rz?E`_M!AgG^(gY zGefr*aWX@9Ca7c{Z))rJPF|G(#lJDif(RT^ZLL;30*NBxNg6FOJX|h1-3S=D`ZXx5 zGj4*$0()HKRYs{b4i}6n;N61%f4o~>9UJIb7Me1q5bA~lO6aagY7VAJ5X&gG-Jv_g zhakVvXcS;d@4SnA;vMlkl?qa&9d8b)+IMETO6t*3$z{KYJIauvEbgn6vL23iPH&uU zo!buoHuDf1Juczq*pl*1l1DHQ$s-H>%D_7Q=bJLg35C9qdF39pLNP$y(taOV;L~>=N~q7WMPW(W54E5CvR>$ zduDk^zU@0Gy?-VyA`sSn7cZ_RD`I&uT3tx;3kFqOe0ac)!|*UOH=6c=dBS-m2DpDr zTSqagSZ3E`0v3r&0B=}dGs&vXok+#8z%^Si2HXqIgt#0{!y^KNYr9qxX1@JERpOrZ zpfGhzMhBQy==C?rujPah3txj)?LUhXjg%LQ6WZp`(T`o7mL|K9XgH_L8MJ`sxMcl_{mZ9oZ0g zRNT56{U<@uO>w@CUsCP+ngurn5sv_>5cpQ8-a35-Fh)vusbaL(T#41zj8z0bvw+8m z-}Qg)EtZkSeYs_-OXG86`jFIBr{**Iy1zU(M%T16P%>YlnN&&$BY6y=X+m zMHrN74rgB_F4(9(?}|guqc)6V9wF7CF_itwsNU$UY5e-nKn@^Cpd3vlfi7X68;67v60Op=dCbv~ zxSJ@8!D8|`f;xyJ zsDm5|epC7mloY}+4iV18ilu)5nfpCepk-tri!XPkSxj)&^q;|s{MyRhzhTZ#AQbaK zDPf=&T)~*RL9iRtLBJ!tH)gqVs6WF#W1e8C( zwuLPe3@B8B4lJ4_<@wybaoRo}@OuiFxfB*t0-G8E7Y}YZU{li#NgWDoYFc_6i?wNB zFbjaIfQwIm7&jq8_lzQ1V$4`cW80vZSkb$^D_kb%9^#C;{LXsEVhfYbi;z;n6AE`OGt!AU+ikA|Jl_f{vW##l7s(|9K1%r;k7-*W{9ymWaQD4fc@7*C*lXrUXq4VyjB2Gl#K)HVqltt|`(vc^i;dEk#s<-UHcGasi4jcjB(0V& z;e!8fIM=A(xg-eEZdoBXu)*oF|AN8&7Yy!Su)Toc9CYfLBug4GI_baYg|E$x&BlHH zTRU5USY~P1XlH>~3}0Ae8-cyU_>5kiP~hKTxeK(se!rr8dEEmFZ3V~`6%xdnV+2CP zSwyPRj<#gwl9V@vn?OqI_bbSkSV4sheB=f`Sm`t&&FoN> zDfjw}?-}_JG9eM8>G?pl7cqLC8{}O*GY6S=Mef7B1^C6Y*Im-XzjKr6W!ijKTjRQZ zGdEL$9>(T5_#uheglOK=1czsYytokgs?-xwsT&A zO6jI<&eVH#@z5%6ko8z8gx0@=nwwe5v@>xZ&NsqOlx&Ono3D;C@^E)iTnrW~+wI*7 zy4cp2YZvf?DtZk(%qw`7l)~uXJ|g^P9j^fY!RI6t?Ebl##Z0ss?vKORes)ys=y!im zQWsvlg}|FO2nd>R#RRl3;yfjk@!X{zMDB;ru@~ryC_}S0UT7uHO)E0;H~+Kx5mr1q z(2%LCKDTV4j z;GCETM0wjB`!}K*bhBudI2=}EE%t}S0%Ah_Q12kMvEX7&Eg>YygWulmnj_!(SuzAz%4rys2#KwQn3$2`AY1UqGD}j|E?@idA*fzK9>s zr0o4+D267@E$B6)NxJ3#!|%0UTH8IJGoY@E_YqGIS9Xyi{%vVG^4B!gV>G3l_CB%z z%fq}|3NSJ$5;Q&2bX`1JG(D7BH#>n5jZNUrRL4Dj6mo z?P#;bq(hyn*?C>sd}KiOtlPZLRtT=EVws2UWy~&QXBkP;#CVPTYpmdi{R zAWWH*-rujL>8f~^f4@?-sy;j?J3mQSZ7t?_VJgcfx+}Dl6MLbMS=lMf%~-iF*KoI4 zMc*1d%MF<=&#TiqUgbG+TgMv@g=_hcv@G=!Bk}R2uk|hsk0W_RksbbqeDe$PFL%dO zN!ik|^mc?#^uXbZc~K_eeYvVCUf-qpw8L%J2!?suj6uYuds_A>kISw+^OctR*CSc5 z`ay^8FRMRw)kZS5QWaSyF7}8(5ed7p$hmO6`&k!HXsl-%EWGMikGxCQyv`tA`EV-j zehSUcnOBDtko8Xj1RxIhZ-eI3DJ?U$6soD%oi!U2&>I;@p7F}_92meMDJK>G#UY7# ztU@%L#e9oeiv4Sx5GrG43XXGl(|RkkdEN(y7mp<9j}HGllEUrtl$N%%ZJT~h>a7BU zhVl-!V6Tr@^TMcmsm%EEVGbnI5#JLZMn~rwW7rG*B^Qxc_tL57U$4kMydClBW=VZi z&aZj9()c|Vg$$edmwLc{TGzk9^jZ8H%%a7=!E6}63`T3sq~r;{byH)`pmTo1Sg->V z!6NUEg;eUeG&=jYZGl0>UByR+uLy9K9D@NTHaTO(dbCw<6Q`>XKUi#undZ|L#5TT; z5v_y3u%#8avRrYybowgs3)Wcl9rhyhi+kIjPAoB~Zl^Np(p#O80+jcwXt`F0-Sf{( zS~(lyycT(i^R;3#OR2QU=oAXVrBo}qBkHeBjS#0tt5{9-%O$#Qeqe<<>C(nQ=+gq- zz2$mtVUnz_ex@$bUbTSzl~OP;RlETL!56cvRRTd^mgVHb&7zz*m!}ekUE{-=$IF6S zhOZm_bt5dW&i0t$^^(5k2wY%7y59|s?=b^X`fy~s*hh2!V+OM2z`CzDI3S4nvXSL# z&oq3ASHV!oNPDie|9l!aao)Qlih&cy2K;RHEkoQasw&MN8~3}ye|jhZRs={@169_2 z-OFq@I1tg>@sbE{xp*@NjcJ64e#UyBsp^NfNqn^U7YC~TUmU0vFc{U@6}}otMl9Pk zm8-QOx0mDQ7*}PHBZL{pLhvQKZ`C!If$DL}r#7$0Rp3>Dw?WIXV$?l){8lk(-S>J0 zC-Jl8w1YFz7J6oBvr=qsRNoL^YuFnXevi? z*2LI;cRy~{j69tj%jq_sse**PxG!+JHn-CdT7BOICIa<%`% z;;m{y@N~rcb$wZ(=$1uigMzSrR3T;If?CD+dW%m zN^WX>`BY_s4Ezk5&{wIVIlE#VR2Eo2#e<6FjgseV<<23?omS04%LBjQg-V{1!H>1K zLpZ^##%wIOodnrc#0)IDFp3+sp{G@;nCP)P?8c_wpK+?7XX~g30~~#tgLb6p4yWv7ilC~V(k{48fxuaHW#%!TC!<-XA+*`@ zHm%R-^9=8TO4=u#*$xS_u%1zZVtNhT@lLAP<{{miSD3)tih(m5wor<>_xK);u*wt{ z0BST2~M=uatFdRo`kM;og@t4uiiK;e6EZS`Z-}NiZ&eg&}a2J&prR%f`tp6ePlC| zG8!>~dJbtl=PS!!&aq{$*Ww&0$J$nT>E3E-%r724pr(l41hI1Wqa&uMvO8meekhhfI;c+}0MQA^IT8KF6e7UOycfJ!)b0d1yS9 zm??M@J*qw72D$MiN~i6QzvhvbWK^>jK|B_fBtnpd`6i28^(uCes0ikxA7}v`o@4MY zE59*SbPX>kx!v^esn>)2L|&No$YSrDBYo11^4gJX8UIj}#JH$s$2N!~4k_i4ZscM6 zvYy6U>3N>u^a-z`8WY;cp_y((P^Q^KwPu=1(F*P_Mw z>bquX%Z}S;9gjfc_E;BW6Yz2fu7H=L7M0wxO|?SVj7H6P^#Gmp%t+;^Z*#_@V=0rI zvyG?W+HzOD$9?Ei0Sx@Jcm)>$Z^GBD?Skuvpm9**DzvpKL zDEzM=EkLUv`3jNo9_9v|`rV zHno2CMw@CY#!eo-TTn~yBFOiV-$(hP9CBDqwZK^ht3aGPNgTp4_{H7lby#1&fO{1Z zfVoT&$iNg>;wSWT5714BC7th2$YOfvmq|H~TV=1&*?%>OHuNV6U7b2j7=Squ?IvAr zh`(%sldx*9WW89j@Bj3l;D(yNEL<6?h1%wso@d~=e;E5Bn zDx!FbTTvVKXDirIT2b`d%w z?t` zG-iuNoF$0IAczxVGovq&QBsl1e`jYU^bnv1EgWKkY(Kr~Y9mFzI$5xhu3XeVn49O& zoPP6SAA*_)YI*V;eanTr#_FEDPb2zPD0dCK>vj~)zz8Il6mG1`_2QSQb??$uz!7#_=FV1qGC6OwE83O0WMb?%sx0dI? zYMvyyFfu#iHt}B%dFI~;RBuPpN}U^hMxDThD+(jL%0*2fpm`X{8#^+UL>x3 z;=m%WDSR6GQl-hLhN6w*?+l&g2A94Y}y*}_1~Jz zO6-kz&!&~LtAx=bopsf09(hxqSWe@gnGufh5Z4eSRA^fW*F>=i{3NDOj5ym&Dk(a{}jO$qT@C+j4cTPB7z>^)aha*bZcmi+JoH5H6F zzF=+8(_VmKD*#-Zg&u1AWipqj8|DRdQ);`{aro2Xjv-<Mcz89HSxDd!+uAzLEuZb$95f!t3#- z_i2bp$iGDZmaN(}Mq!w!FhPQGC|^_|CyT=d@+?LH6pvfMM5$Vo#kyAMg40cnP=?;n zvMZr)?)oaDN9Zc_Y9sxc-|wG8oT%Ub9OANscLD0oIqdu}bDd`4f%;Ley>0H@e(`DXCL?~aM!Cli zm{oHOfAr9?D&;!-;l)m4Jz`Y$tm5IpD__jBBu0|x`72Jefd3963J6L|+!2W+c14w> zz+StCOa2zP4ujtLDu$Wb0T-hPf+ip*DT1IoTVf@xw8a;V<5{|8*(CRVqJ5j_751z@ zoT(=K$&|>JGcG_nINY*xp3Rk1mHT&P$8D)BWH#?l>4-tKQbWf5>cAL&tkRi&qS=oL zw~AY|;0E2w)aC>cy4RwvWc~3M#D?J8&8hEN;tVa3R>0J+nknc8OyE95dn)4XR4OU|Y)a#AUv` z6BjoDNDl#_0aIoNE$^llRsy>Awj!0PuFq#9uxt0W5B1}_?jZm-L*MoOoqWm+#Xb9i zVUkQ^eywO1J|R00eCv8~PY1lq~ z^cZ@`zf}>mtG8o;z7H1v%tlxkB zE*j9g`y{>)N+X(qheJp8kf+=Nz8ToF^ zm}ns^M4ERKF(^Vk<+hk{k$^RMfAf7PyXCQ`$Dv_hQFt4ofDJ4G=|zGhV;s8lho2eq z#NSZ$>{g%VkKZ>81R)N_jw0>X8}m(B0>58pjn6xBo;<=|gc+%G^E4>-ZYecdtc+ME z@$*vwQeZzSKNXm6@i&B<-H(h#4;hz}kYAqsI=bLr3mQ6`eJpy8Y%cDw7+IrRO1e!u z@e;n=-8OS^eNZ*jsQfz7_!9~;xq&bZG5w$62i~}Uf&$WqLO+A00OPUHcR?xtUt3=R zRaMuuOG*kNB~sF&2ugQLNQ!iKAG!{$h)Bp05Rf_`At^20-F+kv(%s$M#ryvEj{m#k z({VUM2Wzjr*IsL`x#oQ4^R%HZmxsNA(xfHRm(U3lRw#lgI=HCwvksDQ&}Aj%a&5+a zqh2k%Oyp_l5wt4N84GSn7?$}R+|qn?xT*IKHG71tFV}7P+ z^}O!&_@UL$RZn7XUnlRkV*E-+xN@6OUS^2H#j)_mEiHC`!D3y*^2!AcLxJLuPBvAv z+A#*6)zMksw>Pbj1@PVmdoZkXf#J|eFn&SW9q56%U#>p;M-6I@`L#H`3k!ccz%X^a zeYiV(dtSlix4-JdP{B}yuMs=%X7C0483_{y-*j!+w-9JvGl!KMnFrB!rwfnDELB54 zEm=~??S)EJ=Vyzeg-|MQJRgF_O)O8^iRV0p+{(V?J7xq-h^fhsoB2fJMh8)% zjVsAGzHG7usK?fup_XJ`RygeXU4k-a+yRNGGEB-62tlpW8dm^>%27b&B+DVvp-lC) z-YoN_5~s>eT)s!c##LfIUDvNya-^P7X0Ma#U^{PvZ- z?I!M33Zm?%hiWnWYqIZMbj(R?lzfca{Lbt31)1XJ0plHg%$1+_x{WP8mqe z{c_w3Ki#r^KCJ0(I!7rX4c(`n!HQie58X}ndT|h{&PS}kb=>K@f}8sbu%`F~P5}@3 zF%m2P7dY9j?2l>AYU)AtdG@?^@wLxy_^@1SRX(*+3EUsWTmi%#CJrhq=&sVoJ|EAg z&kZ@e$AnV{5Zc`-s|*Np%BeXMA8=GWM6CgKv-dD>Bn;l#Itx-|jyBHImm>T2vKBTl@MQ%T$ZDPdCJLdE?QY+%k>7pqjl_^opF4#wK-(a-U%qAR-1NtMXz%=rY0Wu6#P$W#?4&;t<80d}2 zH^d+n7i#^qV}E@Uz3CDz(7fHUN^DD=qsB3>KLD|dYL>6DkgO<%A-vPS@wDABnJ7S}qbmo?kD*wiaH+}e>LRj*+kOR5PJzd$cFxABmCJY5=?wetyVSq7tZ$irVBw|77kO{ORayt z%Nu^|@?-YOw&6y!_AKUNaJk@cdq6v{A#)a8tut@i+ij3D%2`etk{A(b68IVHzaIEM zc!VKp!n>5%@+|t9m`qUS+({mBPN2zG`w7f~@Gl4+j9x&nS#I~4CBqUz!4qz~vpy}W zdLou#hb_oQ8tSn@N~KnHihE)%QU5{Y_#bu-T6Uv8c#?N=gpZp3jEpkh3cCV0d)9*w2H*5gY1)$M zps6=jVNyG(z9aNLx>4Wwn;-D2p*Hx!n_&8&$`yrONn<@;of%Y*jbrHedA_Rt5t`Xh3&*W4y;j9%VGNb@5c^dnG5TB(9PrpKk~s1zP* zEP1Pq62KAY{hU9RB(2i4q`n>v|JFDh*qRnGczfdS7k}6aUv(wS&e`CfjgDT4?m;Ec zZ#=mAZ3tNP{oUo~2LgOb`LATzDO2hv^v`egy@po3^#Wc+s9*FCqQMn#UQF62M$DQ7 zvW5Gd$FX$(Xcq#ZS%3P>^N;W9waR9V8eR&bcYQ&;vb1_I*I`-$Pmw4_1Bw7bL0-7_ ze>9EDs!D&34fx(+C{~^?9O%=C75SGzx|>eI*Qv-%er=jK@G9*W$(eppVPsWURyC5|wLWCk@)DLRGbzP#W^nj8nefO4a4!sWf-iH!WLdRpXSj%qXx3DVno&EO z0KuRSznI#uKY9#K(fjzxy+uj*1B4Ik0V%=&7H$RFL;Gq)7R(r(<~*@aSxiq_9RR`0c^`+eHDWh24tPdUS< zO3=U9B{vz~K&IgU9iqqBaFYIDrFQA;{Kw2roKb`19eSuD9AlA&i1BvM-{ZWv?!|a` zsb;+;!l2?AZ4aX0__`1K?O$=2gOKL?KiK4)*>htGqvk_?feztq+CL3j-Z)RSCDpuO z!F+j2pRA-;@TdS^mSp1MEGKLLqLv>pOY6`$T};h34)$RC&KSGbdWEEH8wPYti#meF zqO(B-H$iT95)#{F)R7RMI?4(l;s6Nt_d0o_cdy&`t6*gL`2pPTk)COr+U@7%_a$*f zMInj!=F>$e5%xY2_a`MR_#q2Q=2pT?jHCI_`%Cy-S1PWNlhqK|{dr!XpgavsZ6z?Z zGY*th^o6ZnRQ>q;tF4imQ)%uKOJP;SJ5V+&CFc__BK zI^B>JDM!y2Si2;S;-E55=v3s}Kh|9!7<~EpfR7YG+Qw0IJa>teSTAyWI!k=skvDlU zAtGVUJQq|2{NDjA>k^PyS#{0>A%uzF+ zRF`;`Vv|9`J{*a8R#oP}Su84U1$LAy2GX-6o{fGEk} z+ry{daaCVt*+=INCa*8H;w}2xqvHO2)`8&>XdKo?lRMLR&G>Lfa`|P(9a_<4`YEaN zZ^5@~7QfLwTmy^>)pgxtjO=%I2sW3~ABS%bs6{8!HhgTF-n=+9q8d> zpNJn#==7?!XWiZSsysBLW8{M>a+=7M?LOQMH!=&oP7$Edr3p{?z;qs7JWqm7|Lt28 zbjHl$re4@TjgIG8qOLF>5^;=Qt43x@ewvdj#~X|y;e|8&0E&ug204`ONd4z=;)vEu2ZWM=7XvNrN4^u}DPgOWt;3YGSV+ZJ zw-#6SjaJ3lp#i!}wa!OFcNwWE?Jb+MFR|=`Lx+e-ol^GO=$T}rjpokH^bZkJyh z8>-a1NBlQC1D>tow7I-?wytkUFoa8M95?}oOha2<3)+$RFlUIg0^Nl4*NEIA@zfjJ zC)5XQAUt}6GWZa1%#Q^9{)Yk1Ysx}-S`KFSJCuIVoQ!z=JoIPFm%4i+=oSi$HybtH z<(|F^UanP*MlTewb2*BoHH)XE>YE%?+%YcM`Vksgb>7nFeFgfCC%uEmc-)HPSE-IM z2Sum75NJ})^8-lrU#8lkq*jn&R%fogmf_p#xjgr1;L!RTQ`X3)^&IJ@muHIf)%um% zz{2M^&u)@A<*+g;5KA$^G^QjI|FUTUB&-Z1(@GMgIxJ<{7_C;;XhwLB|MJv+KrtW= zz2EFtTnHpSoM~0Y`=)Cw2NoiuKVBg9%x~iSIO6c?89JSsXMx6mPpx(E;w;TB_Xj|n z{{ax^V|x4Kd1Dym^ybR!b*Ozy$~PZ2)beW3-59L(mD4=Dyk0S+YplcEUDe7UwGvT| z4_?9_^9OjF@ssE1hmTqD@QQ+PU8dT^R^27eq&X8;5CZZ@_H`xVZxj;DRojk(1P+WR z(q>+l`8DEzL_fF&Kq@yN@m#R{-u0k4SGt8S^HRq?r*-$nhy?nf&HT|_p*trenl)f( z*F+f+TPg5t=tacz(xHcI`~x)(l2nl!Vi1JgI2``XA@?VHev>(96WvX@;0c>P>|M+# zbJY4`cwJZKMOJk7Cs?YKA#9es9tNOrUNpp(5r)hH6p0&o+>;QdmS6YDAsBvTM?Sanxi!KAA5EvLzo z5PAAkdSa{fE&aK#ZujN4W<#i_M&87LR2C}#J*Be!L{D7;U4K$jDPZb&;sP~RC&nBlv<&uVS zfKWqCknuYZK=#1eR~)W`gsnKkqQ)xktAyW@A>ShxT55y#g24U$*+CIV8p{?c&fajt zsv$@`PwdQvx{Go2q)48b)anPw_ndni*Dst~)*BTPb~e_Z7u0^Z2v_*>%mKJE&7v*I zG4O5uNTqwLSfA6ibG7+t)iXz#Y36+6NY9CmSLz7d`dINVP$ceT8PJYfgvC=U%1(d{BU*6V#?mucgMh8tPD{j zJVPCD>`lqbymv~daGaEe>G$oNL1UMAf(aE1l-)F6p+-K}jURJSo2KF~n{z zR=abu_{mPKGY9RV&uA5>vV9~hH*_8HR>G@SmzDbwzww<*FzpzZ+9;$>NN72Lc#{;W zLEaOhQzTbKxEx+_tlRdR;E*kr;!D+jMEZVhf2;h{zunVWzC>QOtPgi3p+FVo0H~rY zN2&K08yYCTKHur{b2ri`6Kdj`y}V|GKCT|+;z`SH*D0OdB0k>H4A~I%zqpU$5>S9v zIBxRug97djRF%)Y8m2Gu^-_EN$W^SsI$O!Nvvfp(n=2O*#D0jUn#k1DMFX|cTrn%j zHW59@Bj^KJxIU1D`~El1GJGOi@~33i=TD^b-J7i&7=1trsE_cQB^a|6!gxzCW-GOF zWgqiPM2?2jDzt&${v#-Bj7g1yVqoS9mTf-cP5&-7(7t1b9hXwiA<6u)f9_B^r!Zi zm({;;PnzX4DPy;)5n7u*^epiHWumMDQWZ~DfyW0{Sdn%XSYb~a$iANSl=(&vEACo@ z>@ep`LL8uQ(B>P6a;I=`*z5wzr`vsn1uCq2OEANs)5YAR0-=IfM#)_noIssL_M?au z3|D@s&Bq7#`7Y4es-un0JII-RS_Ob%-;1I{T!iFHaT20hJR;V$-E|byxS1k?E+35n zr*nH8twTT!n=H9Ax7{WtXHliZEjos6kgHHj?eXZ2yQ(Edg0bvuHYtD}gf=+@Xpk2J zMtozyi2uI+MHiVfW}D>hX6kDUAtjYE$ApA&6rVYwY@m@m7~)d`q(=s~b0Zf$6aQSs zxvwCL{tzw$rBcqn`P0rfHm(yaoBcIYW?lkD9B+`;7>PoT4(K3xV?y`#-CA+WOE(d!9I}PN+eV@jCwRU`n?4> z>202tcIJYt{72HH4~>ui@($BHX}S~H@+n3E2Va032z)VxW=}N9Lc$pPDtnPtfM^Q% z5mV@x+CXe>yA^zm;cc^{u`wY?YN|tZN@unSEDqwAZ|n}BdU1_$(`8Fy1X(qN$JDy{ zCEgZS*~=^br}eYssNT1?;^Hz@cY3 zK=|^v^>oqeB`!`KcFa)g#+y%9;HiN{I3cVw0v6$_)42rZR&3N z-ZyPUS3L2#m1&C?9S&l1IiY&)-hsaRSNU_4!MnX=IYxv?B=(69mOmLvt2^{PcaCe%jNVzU)P+J3vXlpfCQckn#`YOjL88H|Y!MhgO&&@b^y9eYFbA+3E<7449T` zSCSP=g_)$U-z8EiurOuTf>81);4%YMv9nm4g`n>7bl*)&e!32pPnak1aG7&uaeP5K z!;_(?`BEGSq-qwfosgtB#|!o0J8!~mpBh3$&+WNN`&Xrr8ba59wZxd?D4DN( zIH84m;2`4m??N2@cOkAln@-O+f4iHcn4|Kw9ivXT-!jJ15Ttm}?_<@8%;M|;54Z_9 zpFr$H1Km(FNhvXWE@nB!P&LCSKjY21-{wb!J?G z`4o8S1Af3$pQ&uj!#f3ljU52ksQP4o-!FK%lxEU8<(k=XigEcEibt$yo^kJA_(sH67 z&96XQ3RahvuZou0-x?WR8X0b&TKTXfz2Bm}5|lA|kTXHQuQlG;nKGS4zuG^4Y|8hX;FRQZ;HC%BJRBWb8Q>cbqb|n2(SCst zD)LS*TPzeRHs{f#<{K4JOnpT#h@qi$?;5M?H>g?m$2BFn4j4QY7{ z6|Ak`QSJEEO2TE$`LzQHv4hLMe5>)d$#o5NHPBT3LGr(2FTEZt`jr7@?P+_$UM@+_ zsH>{?GHc}8UiB5rerAa+ij}K5KEc<%MWR1nj51v~=ogXVyE2}iTM&!drQ8?Y^f#%A z7uod9x6!>uh}~S>tQ;T_wOZYS95F`h0BgEz=y#GpAdfe4_|7uSpm=FgU}5u&JNeSn@7~B=6}JHGhi1xmS|5q z2Jva#azLxq>5Qft@#l8vv@3zbfRqwOYF4=GQRrBxH-3=kolD+t+}{BjC_j+s3z~xN zgeO#@Nc01TmKrQZsMl%nEMx7(i-FC`94pvKS$q=WP3+mcC>>W7>{0HYq{y_V04r`R z#7p7Vh5{iE-QQr44D+4(=y{3#ijM8qpO8GD0U%8W)51zfkq+z(Z|~S({LpT|h(0CX zM(k;!Hxv6-L(YBtWvok6#IRDC+MZwaguSDumCdl?H2BaO?$*={Y}poGC*YeT z#>Pu{dz|Xz8JH8WaUZgpzg)Btzll}vsbmBT>`F#7n0JTwFQkc?@}#1jV#&b=cs`WC z^kcK&Ub^gVl(-Hm`@Fj4K*f#ua-N zER93d4-QW5^#m%fKwd|xTGgnVv3Eq0#3s&S#muM)@yk>(8mp>C`W@I_AQ zu+ZT9A(IhMzae4m9wbbpdkgD2{lFMx39S)lVmpVH&^8$Ur85Z`>i>=XggdS!YDoLB zmShH$3j2#;EZxVSTrFeq!=7H<)*6#7PH`s>1vkI0v1}!Ze9G_?Xsf7D^NYQ0) zY>)XK3-`%A$VVAFgtGO~fE3Ob3vui(!9GNZPQSjAgYmOL*;P+A6R4 zQWT>X(H5X*7VwVxzMBUxevh^wdbbDbR=-J!I+gHN!*Ozb7?YEBFby0?&|o_07}E$X zU9?KLbN0ixk2_2Tc^PsDy=vGIx3|3GLN_@L)-r9*j-F0g-PSxh65r+MaTBC`9TM?H zr#bNZtb8JX;MkCD3NH>^?2Y2F14g>>u|pJdF2&x{SC}3Q;$pvI$K>pjWkV-=s~&)W z4-*LZgs;^p9d*Uga4^PjG7n1;t{!&VJBcd3ZeK`wNt^hOF3t+kB0(B-6_0akcyb!n zy`L%SWN>cHq+5jf!#m)mm*=Tj460W^6iN6#rtf!6;DIY2;uANlwENQ{!E%&PgA~P57s)u16H7-+nBrS%Mm`DlT zr(`?94#P5@<|&ck5nKBq`R~o=rI< zF;@HDx6$FgHwk1AW!c~T+KJg}q&KYmFVL7C-`*+cVCxnp6Nt`p3;!c%qwMqieUZ%b zI)(`7K=p$;FA%5Y-!2kJA0KO3fAr6A{*-*0y2P!(%5d>bjd&~&sg0SCM&rPjUc!=$ zheJvOUTtj#4vaGv;?b$mJHkCEC)yS!JNyj&_^!K&FKhaRTLhvl|I?j^&tpw1}&sg$^CX5Zb#7$X33bz`)y0yu6bIRu=OA~ROfW-47f zs-zF^6tm#C@>9Q#`J1NmsG8hfhucB7V8c;=4_Vefng2JW;Z9fz?QYJnX8zwf zqeuDAoH-m<{LCH1_Yl;;t_oiK;xcs*xgw#&PFT0ENzfTC7Sjtv^(MvF|sSEJe@N1 z3r|M{03l}spH><8wERdiCV73l7b-e&DVC3ucqzk@BS%y2CaSg`n5dO3LI22ut&~?j zJF_is$v0s;h%nz{p9E2)QS>9(twde^e`gLswm>R&dSxg3mnRr2st2_WoY*4b_HBi^!9&h%GH9V+(p^Se5%1UQrTTsq;h6K{%Dw5F z%_1F(>gzx)Lo}B%03X;>crvQoLiXXgwit6*^3Z7U<@VJjtL%6O-lMHZ1|j;p7soCH zbV4joQ6`-WT6{oVq`6vP*%L5~NObeNVVt0r^`Q1%V0j6XMzx=Dd0wG#SDtMLy{0;F4t zL3H)dBz(2iqd`AENrAyzlL@)KnkqJ^_JbX|o7t(&bLLjV{-P=N4pq2~N@nJC|6hMq z9BY@CQY7ISgS+Sg5j4ajOjeDe{wWRHEAYC*I%6K$=$V3IE~!+ujPkStESlg2Hl=~x z%6@clnvexcwV(wLA{-GRe2}lL0#L(`;87*2L_%h9qzi3j-44Xz!&koNKZR^fz!-7$mQ zH!_XO2sWk*IXMrHt6iE7n0odXZ7Iy`IYpqk@zOt#GPLcCQ*_T-4mUJfktBw@AJ3g~ zeHnRgk?w6YjjR>HfOXHjA0O3qF^CP;G>|3G!n6`E*{T((jj?VQQrLp0w& ztI+liG~Z$?kj6x%9W2X)3`Wa{b{5rme%jGKsKoKAWeP?Y)z5d6e~&r~RJi80*V81f zdbeGE$nO1vZv90&C;M!Kx4jvu1Pb-{(31f{7WtmUYcTZJD1_$;FXzy&6hR5wT#$t# zFfC_ZoXn8k@7#sNT1cS}1o~qmSSG`87TT(cc7aM%FF=EZE;>{H|9T@@-CkL_zR&ql zrTzT)@+RRlYNHg>VPw$Fl+!OTKhzH^&i&=*?lTL6ot5s()`M|#!P`UsLa#}5m##nG zl9e!Ccvlppf6dR8QjEl^N(8$^Bv$PmFW2I}zS5KjkBz>?j#neTh(uM$Z(DqWR3VuR z!m<9Dd!5@qNeA|wct)8pJDh>`6P4^0U(h0-R(J2Y?T^)&Ua`Ta@5l`Zz34u`)T1DZ zr&|_)1|EaF70=8QtS1#4B=wKQ{!BYl9Q$oHRLT1e$8|W8_&v> z=FVz&>I%YD^3mSBL$(6$X*(xD_sZsU+x1klLEyE;Y}6usS5m8s*lp%c@Ac_Y)|>Bj z|AQt>)I2;soor7X3t+cODe^fHw^ZM#PWr}Kl?u+$`2&G+9pUQYqlZc{!z%bguR&Fb zKYe*cwo=%t0jB&Rj+Nq{lSXHK=HSTQF$qf}qO`97D0~rSYzI=LC#3rYZ~s)t=%~lQ zG?ib`R$W~0W)vAqD1*w95v8h3ryXYf=+|q^U*n+x=L=U0t;^vFt^rY0LJl$ajZ}akaO!rz8lHPwKIkfOpd0ED@IgLTEc?az> zvtkD={L7fZ6OP3pgC`WlJ7_qk8|+hL&%>WTvVF@$`Ap$D#f{tp(*HV3QjPzZ;?--d zc=J~m_?NwP6EqEVPie+9! zeSDqdY5{vh&ThM}SkZvEXjnda<=F2P&Mt@+Ley|Qs8!pgdNzLga@$3VdADdVhL%tD zhraP-@)H_=eU`X|b+l$VnLA0S)*0&D?~jq8SvCZNE5Nkv5bWuJ_k!x#W}3u1Dd>91 znzB@VQSUrc*VM%6=FbwuYu6@PP1-x0rS+({84e=&?JmNDvA;#MI?`w5)kgGt=+O6g z-#}ftubb|>{i?=ioBqOeBoBgi7z;ypno#&{1iQw=vu39zP(6oeNcGeBQy)K9WD3)& zW8th}!==+Pk+zYP7o-Btw474ILfnEl9jTqOEGRATjF)HX#wBnN26etDj*W&d=YVKb zAmOuV8{)qj2JeF1qRB<3hsPug#z`OBGSL3%abx8DqdI-V$*u^b_Y#2go~ie=y9J9A zHrDnx|1&p_-~LZMFPG!b4gIvpL$*Dt`3ndj-bElDdJFKg zgFl~i7b}3Y@n^0xXAf7NT30L zP*5ekQ=05cf2=|?&_qFMg(L-t>^@jVt!dU~;Q31spFVBz)$_D?tJGq9Q1U=ZnO)HL z!nJyWg)bbUqxt-L*1qB6Zr;v!L{l|V#5IwYuu>m*vFWU7o9Jae;`HY4j!WKv_}Hr! zpHuR8KyL_3u3*BVw9h9bZl+uwwa;fW=J=_XJrQ~`0uJ3pvARRVuNzx|ShboUysT$x z;8}Pcx~5*vfkZfq3H;Lz*7|ouTDifKRz4z+PG{#5S>k7Iq zc-JhDQA;WlvOyBUXDCBo^AdT7n>yA%Sm+Eg@}>#<@dI(CU~~&L#@W!;c`T?Y>x@7I%Nq}v4oURj zLo+N{Nd(Vs(ilxH_U7n9sp3NdT1HQMPGgZK`u4&E%s&$Cd|>ls=^_$kwKg=r$WgHz zdK@ha%JVi+prAajeZv?EOh>68T)1cI;Awc?26ce`2&x{B|I=OdRNt8^4LY+23G-C< zLbey;Mw5d@+7a%*KkT%62pDPDt!VbTV4+heExp8q3=UU6eHlJnIXsZgCo49fwO2;I zoPJxfAeVK_Ef8ht7t#z;_D$$)s*D{nb3>&`ysUvxyb-HCuBP*?gbHjY(USZR#XLY+ zl`{<>7hOs#db$@jAf*p5$C(za8 zUt_|bU}%}xM!KY2mA+$`u3Y}b%qZL$ndzKh<|+T){wO%JiQ`d(m!rr&!rDTc18?cW z5tY0y9|a0+n!c%#>Me=#H~J)A8^Lf48(w+WsOX*=ZjZ6$Ko4lds~qYy1F${iP!|{g zf77;elwAPwPNfWQw4P3@# z>x`>9aLps0VZ7W}K>O$zs0%zRNylPc;8_h*s{C4l{EjX=BTPC&S**XWa$DlWHzi(V zVCn+(2+ed#ceD;uV8fI&^4W9t^?hqQEeP%V$W}^|@2{)EXmQ*6#-`7TA(g_C<3L15 zrsjt`FGNi|yx=mnQ?P5^ndyLFyWq8{S;-$@PYVFym5v>ur^z;% z^z-kublZWwBLj>j*1$NNrgohH@ZUJ~ZL)A+l%+Ao8-cAGWZ zG4A4jc_ya0yy|ycc|$kJ-slUtfi_kbnQ6?@-jq)I=g+n@UI(ZuU}0l9QpM;D9#*4(Lag4qi+3k4sN|7cza z2Exmp!`0fv#lrlZn~RNumFs`I0#*;B@G \<číslo centra>\\\... } +# Prefix čísla centra pro každou studii. Číslo centra má tvar +# "#####" (např. "S10-CZ10004"). POZOR: stejné fyzické centrum +# má v KAŽDÉ studii jiný kód a dokument nese v sites[] VŠECHNY (M:N), +# takže bez tohoto filtru soubor spadne i do složek center cizích studií. +# Bereme tedy ze sites[] jen kódy začínající prefixem DANÉ studie. +# (Heuristika podle name nestačí — nechá i cizí prefixy.) +SITE_PREFIX = { + "42847922MDD3003": "S10-CZ", + "77242113UCO3001": "DD5-CZ", + "77242113CRD3001": "DD6-CZ", + # 77242113UCO3002: zatím bez center +} + +# Exportovat jen tuto zemi (country úroveň + scope u country/site). +# None = všechny země. Prefixy výše jsou CZ, proto necháváme CZ. +ONLY_COUNTRY = "Czech Republic" + OVERWRITE = False # True = přepsat i existující soubory + +# Dropbox mirror: cíl ve tvaru "dropbox:/cesta" se nahraje přes Dropbox +# API a udržuje se jako ČISTÝ MIRROR — co chybí nahraje, co v cíli přebývá +# smaže. Zdroj pravdy je SeaweedFS, v Dropboxu se nic nezálohuje. +# Credentials (APP_KEY/SECRET/REFRESH_TOKEN) se berou z tohoto .env: +DROPBOX_ENV = Path(__file__).resolve().parents[1] / "EmailsImport" / ".env" +DROPBOX_MIRROR_DELETE = True # False = jen nahrávat/aktualizovat, nemazat # ==================================================================== MONGO_URI = "mongodb://192.168.1.76:27017" @@ -95,27 +139,190 @@ def filename_for(doc): return f"{date_prefix}{desc} [{doc['vtmf']}]{version}{ext}" -def base_dirs_for(doc, level, root): - """Seznam základních podadresářů (pod root) pro daný dokument. - study -> [STUDY], country -> [COUNTRY], site -> [].""" +def base_rels_for(doc, level, site_prefix): + """Základní podsložky (relativně ke kořeni) pro daný dokument. + study -> ['STUDY'], country -> ['COUNTRY'], site -> []. + + POZOR: sites[] je M:N — stejné fyzické centrum má v každé studii jiný + kód (S10-CZ10001 / BX4-CZ10001 / CH1-CZ10001 …) a dokument nese VŠECHNY. + Správný kód pro TUTO studii poznáme podle pevného prefixu (SITE_PREFIX), + např. 'S10-CZ'. Bereme jen sites[] začínající tímto prefixem; ostatní + (kódy center cizích studií) ignorujeme. Když nic nematchuje, dokument + do žádné site složky nepatří (vrať []).""" if level == "study": - return [root / "STUDY"] + return ["STUDY"] if level == "country": - return [root / "COUNTRY"] - sites = [clean(s) for s in doc.get("sites", []) if clean(s)] - return [root / s for s in sites] if sites else [root / "SITE_nezname"] + return ["COUNTRY"] + pref = (site_prefix or "").upper() + return [clean(s) for s in doc.get("sites", []) + if s and str(s).upper().startswith(pref) and clean(s)] -def target_paths(doc, level, root): +def rel_targets(doc, level, site_prefix): + """Cílové cesty relativně ke kořeni, oddělovač '/' (společný pro disk + i Dropbox). Konkrétní sink ('/' -> '\\' na disku) si poradí sám.""" fname = filename_for(doc) typ = clean(doc.get("type")) or "_" sub = clean(doc.get("subtype")) or "_" - return [base / typ / sub / fname for base in base_dirs_for(doc, level, root)] + return [f"{base}/{typ}/{sub}/{fname}" + for base in base_rels_for(doc, level, site_prefix)] -def export_study_level(coll, study, level, root): - # příslušnost ke studii/úrovni přes scope "level|study|..." - scope_prefix = re.escape(f"{level}|{study}|") +# -------------------------------------------------------------------- +# Sinky: kam a jak zapisovat (lokální disk vs. Dropbox API mirror) +# -------------------------------------------------------------------- +class LocalSink: + """Zápis na disk. Idempotentní (přeskakuje existující), bez mazání.""" + + def __init__(self, spec): + self.root = Path(spec) + self.label = str(self.root) + self.root.mkdir(parents=True, exist_ok=True) + + def exists(self, rel): + return (self.root / rel).exists() + + def keep(self, rel): + pass + + def write(self, rel, data): + dest = self.root / rel + dest.parent.mkdir(parents=True, exist_ok=True) + dest.write_bytes(data) + + def finalize(self): + return 0 + + +class DropboxSink: + """Zápis přes Dropbox API jako ČISTÝ MIRROR. Co chybí nahraje, co v cíli + přebývá (a není v tomto exportu) smaže. Dokumenty jsou neměnné verze + (VTMF-xxx vX.Y), takže existence cesty = shoda obsahu — existující se + nenahrávají znovu, obsah se neporovnává.""" + + def __init__(self, spec): + import dropbox + from dotenv import load_dotenv + load_dotenv(DROPBOX_ENV) + self._dbx = dropbox + self.dbx = dropbox.Dropbox( + app_key=os.getenv("DROPBOX_APP_KEY"), + app_secret=os.getenv("DROPBOX_APP_SECRET"), + oauth2_refresh_token=os.getenv("DROPBOX_APP_REFRESH_TOKEN"), + ) + path = spec.split(":", 1)[1].strip().replace("\\", "/") + self.base = "/" + path.strip("/") + self.label = f"dropbox:{self.base}" + self.remote_files = {} # path_lower -> path_display (soubory) + self.remote_dirs = {} # path_lower -> path_display (složky) + self.seen = set() # path_lower, které ponecháváme + self._load_remote() + + def _full(self, rel): + return f"{self.base}/{rel}" + + def _load_remote(self): + files = self._dbx.files + try: + res = self.dbx.files_list_folder(self.base, recursive=True) + except self._dbx.exceptions.ApiError: + return # cíl ještě neexistuje — nic ke smazání + while True: + for e in res.entries: + if isinstance(e, files.FileMetadata): + self.remote_files[e.path_lower] = e.path_display + elif isinstance(e, files.FolderMetadata): + self.remote_dirs[e.path_lower] = e.path_display + if not res.has_more: + break + res = self.dbx.files_list_folder_continue(res.cursor) + + def exists(self, rel): + return self._full(rel).lower() in self.remote_files + + def keep(self, rel): + self.seen.add(self._full(rel).lower()) + + def write(self, rel, data): + full = self._full(rel) + self._upload(full, data) + self.remote_files[full.lower()] = full + + def _upload(self, full, data): + files = self._dbx.files + wm = files.WriteMode.overwrite + chunk = 8 * 1024 * 1024 + if len(data) <= chunk: + self.dbx.files_upload(data, full, mode=wm, mute=True) + return + # velké soubory přes upload session + start = self.dbx.files_upload_session_start(data[:chunk]) + cursor = files.UploadSessionCursor(session_id=start.session_id, offset=chunk) + off = chunk + while len(data) - off > chunk: + self.dbx.files_upload_session_append_v2(data[off:off + chunk], cursor) + off += chunk + cursor.offset = off + self.dbx.files_upload_session_finish( + data[off:], cursor, files.CommitInfo(path=full, mode=wm, mute=True)) + + def finalize(self): + # potřebné složky = všichni předci ponechaných souborů (+ base) + base_low = self.base.lower() + needed = {base_low} + for low in self.seen: + p = low.rsplit("/", 1)[0] + while len(p) >= len(base_low): + needed.add(p) + if p == base_low: + break + p = p.rsplit("/", 1)[0] + # přebytky = soubory mimo seen + složky mimo needed; mažeme jen ty + # nejvyšší (rodič je potřebný), smazání složky odstraní i podstrom + extra = [] + for low, disp in self.remote_files.items(): + if low not in self.seen and low.rsplit("/", 1)[0] in needed: + extra.append(disp) + for low, disp in self.remote_dirs.items(): + if low not in needed and low.rsplit("/", 1)[0] in needed: + extra.append(disp) + if not extra: + return 0 + if not DROPBOX_MIRROR_DELETE: + log(f" [mirror] {len(extra)} přebytečných položek (mazání vypnuto)") + return 0 + files = self._dbx.files + for i in range(0, len(extra), 1000): + chunk = [files.DeleteArg(path=p) for p in extra[i:i + 1000]] + res = self.dbx.files_delete_batch(chunk) + if res.is_async_job_id(): + job = res.get_async_job_id() + while True: + st = self.dbx.files_delete_batch_check(job) + if st.is_complete() or st.is_failed(): + break + time.sleep(1) + log(f" [mirror] smazáno {len(extra)} přebytečných položek") + return len(extra) + + +def make_sink(spec): + if str(spec).lower().startswith("dropbox:"): + return DropboxSink(spec) + return LocalSink(spec) + + +def export_study_level(coll, study, level, sink): + site_prefix = SITE_PREFIX.get(study) + if level == "site" and not site_prefix: + log(f" [site] {study}: chybí prefix v SITE_PREFIX — přeskakuji.") + return 0, 0, 0, 0 + # příslušnost ke studii/úrovni přes scope "level|study|[country]" + # country/site filtrujeme i na zemi (ONLY_COUNTRY); study je globální + if level in ("country", "site") and ONLY_COUNTRY: + scope_prefix = re.escape(f"{level}|{study}|{ONLY_COUNTRY}") + else: + scope_prefix = re.escape(f"{level}|{study}|") q = {"scopes": {"$regex": f"^{scope_prefix}"}, "deleted": False, "downloaded": True, "placeholder": {"$ne": True}, "seaweed_path": {"$ne": None}} @@ -127,24 +334,27 @@ def export_study_level(coll, study, level, root): written = skipped = failed = 0 total_bytes = 0 for n, doc in enumerate(docs, 1): - dests = target_paths(doc, level, root) - need = dests if OVERWRITE else [d for d in dests if not d.exists()] + rels = rel_targets(doc, level, site_prefix) + if not rels: + continue + for rel in rels: + sink.keep(rel) # i přeskočené si v mirroru ponecháme + need = rels if OVERWRITE else [rel for rel in rels if not sink.exists(rel)] if not need: - skipped += len(dests) + skipped += len(rels) continue try: - with urllib.request.urlopen(doc["seaweed_url"], timeout=120) as r: - data = r.read() - for dest in need: - dest.parent.mkdir(parents=True, exist_ok=True) - dest.write_bytes(data) + with urllib.request.urlopen(doc["seaweed_url"], timeout=120) as resp: + data = resp.read() + for rel in need: + sink.write(rel, data) written += 1 total_bytes += len(data) - skipped += len(dests) - len(need) + skipped += len(rels) - len(need) kb = len(data) / 1024 size = f"{kb:.0f} KB" if kb < 1024 else f"{kb / 1024:.1f} MB" extra = f" (+{len(need)} kopií)" if len(need) > 1 else "" - log(f" [{n}/{len(docs)}] {need[0].relative_to(root)} ({size}){extra}") + log(f" [{n}/{len(docs)}] {need[0]} ({size}){extra}") except Exception as e: failed += 1 log(f" [!] {doc['_id']}: {e}") @@ -156,29 +366,31 @@ def main(): levels = [lvl for lvl in ("study", "country", "site") if EXPORT.get(lvl)] log(f"[i] Studie: {', '.join(STUDIES)}") log(f"[i] Úrovně: {', '.join(levels) if levels else '(žádná)'}") - log(f"[i] Cíl: {OUTPUT_ROOT_TMPL}\n") + log(f"[i] Cíl: {OUTPUT_ROOT_TMPL} (Dropbox: cíl 'dropbox:/cesta')\n") if not levels: sys.exit(0) - gw = gs = gf = gb = 0 + gw = gs = gf = gb = gd = 0 for study in STUDIES: - root = Path(OUTPUT_ROOT_TMPL.format(study=study)) + spec = STUDY_DIRS.get(study) or OUTPUT_ROOT_TMPL.format(study=study) # má studie přes scopes vůbec něco? has = coll.count_documents({"scopes": {"$regex": f"^[a-z]+\\|{re.escape(study)}\\|"}}) - log(f"=== {study} -> {root} (scoped dokumentů: {has}) ===") if not has: + log(f"=== {study} -> {spec} ===") log(f"[i] {study}: přes scopes nic — pipeline pro tuto studii " f"zatím neproběhla, přeskakuji.\n") continue - root.mkdir(parents=True, exist_ok=True) + sink = make_sink(spec) + log(f"=== {study} -> {sink.label} (scoped dokumentů: {has}) ===") for level in levels: - w, s, f, b = export_study_level(coll, study, level, root) + w, s, f, b = export_study_level(coll, study, level, sink) gw += w; gs += s; gf += f; gb += b + gd += sink.finalize() log("") mb = gb / 1024 / 1024 log(f"[ok] Hotovo: {gw} souborů zapsáno ({mb:.1f} MB), " - f"{gs} přeskočeno (už existuje), {gf} chyb.") + f"{gs} přeskočeno (už existuje), {gd} smazáno (mirror), {gf} chyb.") sys.exit(1 if gf else 0) From 4873f5fb99957595af03d09409abf730e24bee83 Mon Sep 17 00:00:00 2001 From: "vladimir.buzalka" Date: Thu, 18 Jun 2026 11:10:00 +0200 Subject: [PATCH 3/5] z230 --- ...5472-activity-reports-documents-equery.csv | 46 + ...6940-activity-reports-documents-equery.csv | 87 + ...36940-kit-inventory-on-hand-expiration.csv | 540 ++++ ...35472-kit-inventory-on-hand-expiration.csv | 282 ++ ...sponsor-study-35472-samples-allSamples.csv | 1215 ++++++++ ...sponsor-study-36940-samples-allSamples.csv | 1762 +++++++++++ ...udy-36940-test-results-930525-standard.csv | 773 +++++ ...udy-36940-test-results-930556-standard.csv | 132 + ...36940-test-results-930556-microbiology.csv | 3 + ...36940-test-results-930525-microbiology.csv | 6 + ...udy-36940-test-results-930549-standard.csv | 242 ++ ...36940-test-results-930549-microbiology.csv | 3 + ...udy-36940-test-results-930555-standard.csv | 544 ++++ ...36940-test-results-930555-microbiology.csv | 6 + ...36940-test-results-930547-microbiology.csv | 5 + ...udy-36940-test-results-930547-standard.csv | 691 +++++ ...udy-36940-test-results-930539-standard.csv | 249 ++ ...36940-test-results-930539-microbiology.csv | 5 + ...36940-test-results-930557-microbiology.csv | 7 + ...udy-36940-test-results-930557-standard.csv | 862 ++++++ ...udy-36940-test-results-930553-standard.csv | 421 +++ ...36940-test-results-930553-microbiology.csv | 6 + ...36940-test-results-930536-microbiology.csv | 3 + ...udy-36940-test-results-930536-standard.csv | 242 ++ ...36940-test-results-930531-microbiology.csv | 3 + ...udy-35472-test-results-898745-standard.csv | 2615 +++++++++++++++++ ...udy-36940-test-results-930531-standard.csv | 243 ++ ...udy-35472-test-results-898739-standard.csv | 1899 ++++++++++++ ...udy-35472-test-results-898733-standard.csv | 2464 ++++++++++++++++ ...udy-35472-test-results-898744-standard.csv | 200 ++ ...udy-35472-test-results-898727-standard.csv | 994 +++++++ ..._SipIQ_V1_13MAY2026_June+18,+2026_01.27.csv | 0 Feasibility/TRASH/sipiq_reminder_v1.0.md | 32 + Feasibility/TRASH/sipiq_reminder_v1.0.py | 154 + Feasibility/TRASH/sipiq_thankyou_v1.0.md | 38 + Feasibility/TRASH/sipiq_thankyou_v1.0.py | 149 + Feasibility/TRASH/sipiq_thankyou_v1.1.md | 37 + Feasibility/TRASH/sipiq_thankyou_v1.1.py | 150 + Feasibility/TRASH/sipiq_thankyou_v1.2.md | 34 + Feasibility/TRASH/sipiq_thankyou_v1.2.py | 195 ++ Feasibility/sipiq_reminder_v1.1.md | 28 + Feasibility/sipiq_reminder_v1.1.py | 159 + Feasibility/sipiq_thankyou_v1.3.md | 29 + Feasibility/sipiq_thankyou_v1.3.py | 200 ++ 44 files changed, 17755 insertions(+) create mode 100644 Covance/Source/2026-06-18_093653 sponsor-study-35472-activity-reports-documents-equery.csv create mode 100644 Covance/Source/2026-06-18_093653 sponsor-study-36940-activity-reports-documents-equery.csv create mode 100644 Covance/Source/2026-06-18_093809 sponsor-study-36940-kit-inventory-on-hand-expiration.csv create mode 100644 Covance/Source/2026-06-18_093829 sponsor-study-35472-kit-inventory-on-hand-expiration.csv create mode 100644 Covance/Source/2026-06-18_094416 sponsor-study-35472-samples-allSamples.csv create mode 100644 Covance/Source/2026-06-18_094416 sponsor-study-36940-samples-allSamples.csv create mode 100644 Covance/Source/2026-06-18_095536 sponsor-study-36940-test-results-930525-standard.csv create mode 100644 Covance/Source/2026-06-18_095542 sponsor-study-36940-test-results-930556-standard.csv create mode 100644 Covance/Source/2026-06-18_095547 sponsor-study-36940-test-results-930556-microbiology.csv create mode 100644 Covance/Source/2026-06-18_095550 sponsor-study-36940-test-results-930525-microbiology.csv create mode 100644 Covance/Source/2026-06-18_095611 sponsor-study-36940-test-results-930549-standard.csv create mode 100644 Covance/Source/2026-06-18_095614 sponsor-study-36940-test-results-930549-microbiology.csv create mode 100644 Covance/Source/2026-06-18_095633 sponsor-study-36940-test-results-930555-standard.csv create mode 100644 Covance/Source/2026-06-18_095639 sponsor-study-36940-test-results-930555-microbiology.csv create mode 100644 Covance/Source/2026-06-18_095641 sponsor-study-36940-test-results-930547-microbiology.csv create mode 100644 Covance/Source/2026-06-18_095648 sponsor-study-36940-test-results-930547-standard.csv create mode 100644 Covance/Source/2026-06-18_095657 sponsor-study-36940-test-results-930539-standard.csv create mode 100644 Covance/Source/2026-06-18_095702 sponsor-study-36940-test-results-930539-microbiology.csv create mode 100644 Covance/Source/2026-06-18_095702 sponsor-study-36940-test-results-930557-microbiology.csv create mode 100644 Covance/Source/2026-06-18_095718 sponsor-study-36940-test-results-930557-standard.csv create mode 100644 Covance/Source/2026-06-18_095723 sponsor-study-36940-test-results-930553-standard.csv create mode 100644 Covance/Source/2026-06-18_095725 sponsor-study-36940-test-results-930553-microbiology.csv create mode 100644 Covance/Source/2026-06-18_095726 sponsor-study-36940-test-results-930536-microbiology.csv create mode 100644 Covance/Source/2026-06-18_095745 sponsor-study-36940-test-results-930536-standard.csv create mode 100644 Covance/Source/2026-06-18_095749 sponsor-study-36940-test-results-930531-microbiology.csv create mode 100644 Covance/Source/2026-06-18_095804 sponsor-study-35472-test-results-898745-standard.csv create mode 100644 Covance/Source/2026-06-18_095813 sponsor-study-36940-test-results-930531-standard.csv create mode 100644 Covance/Source/2026-06-18_095847 sponsor-study-35472-test-results-898739-standard.csv create mode 100644 Covance/Source/2026-06-18_095905 sponsor-study-35472-test-results-898733-standard.csv create mode 100644 Covance/Source/2026-06-18_095914 sponsor-study-35472-test-results-898744-standard.csv create mode 100644 Covance/Source/2026-06-18_095937 sponsor-study-35472-test-results-898727-standard.csv rename Feasibility/77242113UCO2001/ImportSIPIQcompled/{ => Zpracováno}/ICONIC+Phase+3b+UC+Study+(77242113UCO3002)_SipIQ_V1_13MAY2026_June+18,+2026_01.27.csv (100%) create mode 100644 Feasibility/TRASH/sipiq_reminder_v1.0.md create mode 100644 Feasibility/TRASH/sipiq_reminder_v1.0.py create mode 100644 Feasibility/TRASH/sipiq_thankyou_v1.0.md create mode 100644 Feasibility/TRASH/sipiq_thankyou_v1.0.py create mode 100644 Feasibility/TRASH/sipiq_thankyou_v1.1.md create mode 100644 Feasibility/TRASH/sipiq_thankyou_v1.1.py create mode 100644 Feasibility/TRASH/sipiq_thankyou_v1.2.md create mode 100644 Feasibility/TRASH/sipiq_thankyou_v1.2.py create mode 100644 Feasibility/sipiq_reminder_v1.1.md create mode 100644 Feasibility/sipiq_reminder_v1.1.py create mode 100644 Feasibility/sipiq_thankyou_v1.3.md create mode 100644 Feasibility/sipiq_thankyou_v1.3.py diff --git a/Covance/Source/2026-06-18_093653 sponsor-study-35472-activity-reports-documents-equery.csv b/Covance/Source/2026-06-18_093653 sponsor-study-35472-activity-reports-documents-equery.csv new file mode 100644 index 0000000..0a98b0f --- /dev/null +++ b/Covance/Source/2026-06-18_093653 sponsor-study-35472-activity-reports-documents-equery.csv @@ -0,0 +1,46 @@ +Site,Country,Visit,Visit Collection Date,Accession,Subject,eQueryId,Create Date,Response Date Time,Issue Type,Status,Time Before Response,User Name,Email,Study Role +CZ10012 - Dr.Ales Urban,CZECH REPUBLIC,End of Phase/Treatment,"Mar 25, 2026 5:00 PM",6226560888,CZ100120005,2064594,"Mar 27, 2026 9:33 AM","Apr 1, 2026 4:32 PM",VST,Closed,5d,,, +CZ10012 - Dr.Ales Urban,CZECH REPUBLIC,Part 2 DB Every 12 Weeks,"Mar 6, 2026 2:00 PM",6226560891,CZ100120004,2035331,"Mar 10, 2026 11:18 AM","Mar 10, 2026 12:50 PM",ADT201,Closed,1h 31m,Marcela Sedlackova,marcelasedlackova@seznam.cz,Investigator +CZ10012 - Dr.Ales Urban,CZECH REPUBLIC,Part 2 OL Induction Day 29,"Jan 2, 2026 12:00 PM",6226976943,CZ100120004,1936950,"Jan 6, 2026 12:29 PM","Jan 9, 2026 8:41 AM",DOB,Closed,2d,Marcela Sedlackova,marcelasedlackova@seznam.cz,Investigator +CZ10012 - Dr.Ales Urban,CZECH REPUBLIC,End of Phase/Treatment,"Mar 25, 2026 3:00 PM",6226752555,CZ100120006,2064606,"Mar 27, 2026 9:48 AM","Apr 1, 2026 4:32 PM",VST,Closed,5d,,, +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,Retest,"Dec 11, 2025 9:05 AM",6226935606,CZ100110003,1930555,"Dec 31, 2025 12:41 PM","Jan 3, 2026 5:26 PM","VST, AMT4164",Closed,3d,Marta Lendlova,studie@medipa.org,Investigator +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,Retest,"Dec 11, 2025 9:05 AM",6226935606,CZ100110003,1908988,"Dec 16, 2025 2:17 PM","Dec 19, 2025 3:55 PM","VST, AMT4164",Closed,3d,Marta Lendlova,studie@medipa.org,Investigator +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,Part 2 OL Induction Day 29,"May 19, 2026 11:16 AM",6227261835,CZ100110010,2174985,"Jun 4, 2026 1:57 PM","Jun 10, 2026 1:33 PM",SCT,Closed,5d,,, +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,Part 2 OL Induction Day 29,"May 19, 2026 11:16 AM",6227261835,CZ100110010,2166058,"May 29, 2026 3:53 PM",,SCT,Closed,,,, +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,Part 2 OL Induction Day 29,"May 19, 2026 11:16 AM",6227261835,CZ100110010,2153672,"May 21, 2026 6:28 PM",,SCT,Closed,,,, +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,End of Phase/Treatment,"Jan 6, 2026 10:11 AM",6227261836,CZ100110006,1943384,"Jan 9, 2026 2:23 PM",,VST,Closed,,,, +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,End of Phase/Treatment,"Jan 6, 2026 10:11 AM",6227261836,CZ100110006,1953531,"Jan 16, 2026 7:52 AM",,VST,Closed,,,, +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,End of Phase/Treatment,"Jan 6, 2026 10:11 AM",6227261836,CZ100110006,1965291,"Jan 23, 2026 11:05 AM","Jan 26, 2026 6:18 PM",VST,Closed,3d,Marta Lendlova,studie@medipa.org,Investigator +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,Part 1 Screening,"Jan 21, 2026 10:11 AM",6227542160,CZ100110009,1965641,"Jan 23, 2026 12:41 PM","Jan 26, 2026 6:18 PM",ADT201,Closed,3d,Marta Lendlova,studie@medipa.org,Investigator +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,Retest,"Apr 10, 2026 8:16 AM",6227542182,CZ100110010,2105984,"Apr 22, 2026 4:51 PM",,"AMT4164, ADT201",Closed,,,, +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,Retest,"Apr 10, 2026 8:16 AM",6227542182,CZ100110010,2117124,"Apr 29, 2026 5:13 PM",,"AMT4164, ADT201",Closed,,,, +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,Retest,"Apr 10, 2026 8:16 AM",6227542182,CZ100110010,2127525,"May 6, 2026 2:57 PM","May 7, 2026 3:05 PM","AMT4164, ADT201",Closed,1d,Marta Lendlova,studie@medipa.org,Investigator +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,Retest,"Apr 10, 2026 8:16 AM",6227542182,CZ100110010,2094889,"Apr 15, 2026 7:25 PM",,"AMT4164, ADT201",Closed,,,, +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,Part 2 OL Induction Day 29,"Feb 3, 2026 10:23 AM",6226561517,CZ100110006,2040081,"Mar 12, 2026 12:52 PM","Mar 20, 2026 9:35 AM",VST,Closed,7d,Marta Lendlova,studie@medipa.org,Investigator +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,Part 2 OL Induction Day 29,"Feb 3, 2026 10:23 AM",6226561517,CZ100110006,2015993,"Feb 25, 2026 2:26 PM","Mar 4, 2026 4:37 PM",VST,Closed,7d,Marta Lendlova,studie@medipa.org,Investigator +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,Part 2 OL Induction Day 29,"Feb 3, 2026 10:23 AM",6226561517,CZ100110006,2005997,"Feb 18, 2026 3:01 PM",,VST,Closed,,,, +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,Part 2 OL Induction Day 29,"Feb 3, 2026 10:23 AM",6226561517,CZ100110006,1984511,"Feb 5, 2026 10:36 AM","Feb 10, 2026 5:12 PM",VST,Closed,5d,Marta Lendlova,studie@medipa.org,Investigator +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,End of Phase/Treatment,"Apr 21, 2026 10:37 AM",6228234300,CZ100110010,2112166,"Apr 27, 2026 1:26 PM",,SCD,Closed,,,, +CZ10011 - Dr. Marta Lendlova,CZECH REPUBLIC,End of Phase/Treatment,"Apr 21, 2026 10:37 AM",6228234300,CZ100110010,2124850,"May 5, 2026 1:37 PM","May 7, 2026 3:10 PM",SCD,Closed,2d,Marta Lendlova,studie@medipa.org,Investigator +CZ10008 - Dr.Zdenek Solle,CZECH REPUBLIC,Part 1 Screening,"Aug 5, 2025 11:58 AM",6225351045,CZ100080002,1712216,"Aug 7, 2025 12:05 PM","Aug 7, 2025 12:45 PM",SCT,Closed,40m,Roman Gregar,r.gregar@clintrial.cz,Investigator +CZ10008 - Dr.Zdenek Solle,CZECH REPUBLIC,Part 2 OL Induction Baseline,"Sep 10, 2025 11:35 AM",6225351056,CZ100080001,1769239,"Sep 15, 2025 5:00 PM","Sep 16, 2025 8:14 AM",SCT,Closed,15h 14m,Roman Gregar,r.gregar@clintrial.cz,Investigator +CZ10008 - Dr.Zdenek Solle,CZECH REPUBLIC,Early Withdrawal,"Oct 14, 2025 12:30 PM",6225351066,CZ100080004,1817448,"Oct 16, 2025 12:29 PM","Oct 16, 2025 1:37 PM",ADT201,Closed,1h 7m,Barbora Sollova,b.sollova@clintrial.cz,Investigator +CZ10008 - Dr.Zdenek Solle,CZECH REPUBLIC,Part 2 DB Baseline,"Mar 10, 2026 11:10 AM",6226804962,CZ100080006,2039863,"Mar 12, 2026 12:07 PM","Mar 16, 2026 8:11 AM",VST,Closed,3d,Barbora Sollova,b.sollova@clintrial.cz,Investigator +CZ10005 - Dr.Lubos Janu,CZECH REPUBLIC,Retest,"Sep 16, 2025 10:00 AM",6225351036,CZ100050001,1776942,"Sep 19, 2025 11:34 AM","Sep 23, 2025 2:21 PM",VST,Closed,4d,,, +CZ10005 - Dr.Lubos Janu,CZECH REPUBLIC,Retest,"Nov 11, 2025 10:04 AM",6225351037,CZ100050002,1859363,"Nov 13, 2025 12:27 PM","Nov 18, 2025 10:16 AM",ADT201,Closed,4d,,, +CZ10004 - Dr. Erik Herman,CZECH REPUBLIC,End of Phase/Treatment,"Jan 9, 2026 10:20 AM",6227178908,CZ100040002,1947467,"Jan 13, 2026 10:55 AM","Jan 16, 2026 10:51 AM","PCFCOM, ADT201",Closed,2d,Gabriela Novotna,gnovotna@email.cz,Investigator +CZ10004 - Dr. Erik Herman,CZECH REPUBLIC,End of Phase/Treatment,"Mar 6, 2026 9:50 AM",6227178911,CZ100040002,2034798,"Mar 10, 2026 12:00 AM","Mar 12, 2026 5:11 PM",ADT201,Closed,2d,Gabriela Novotna,gnovotna@email.cz,Investigator +CZ10004 - Dr. Erik Herman,CZECH REPUBLIC,Part 2 OL Induction Day 29,"Jun 5, 2026 10:35 AM",6226889397,CZ100040007,2183111,"Jun 9, 2026 4:27 PM","Jun 10, 2026 12:06 PM",ADT201,Closed,19h 38m,Erik Herman,erik.herman@seznam.cz,Investigator +CZ10004 - Dr. Erik Herman,CZECH REPUBLIC,Part 2 DB Week 13,"May 29, 2026 9:30 AM",6226649754,CZ100040002,2171299,"Jun 2, 2026 5:07 PM","Jun 4, 2026 9:31 AM",VST,Closed,1d,Minarovicova Katarina,kminarov@its.jnj.com,Investigator +CZ10004 - Dr. Erik Herman,CZECH REPUBLIC,Part 2 OL Induction Day 29,"Jun 5, 2026 11:15 AM",6226573502,CZ100040009,2183103,"Jun 9, 2026 4:24 PM","Jun 10, 2026 12:05 PM",ADT201,Closed,19h 41m,Erik Herman,erik.herman@seznam.cz,Investigator +CZ10004 - Dr. Erik Herman,CZECH REPUBLIC,Part 1 Screening,"Feb 27, 2026 8:00 AM",6227547329,CZ100040007,2024391,"Mar 3, 2026 12:47 PM","Mar 4, 2026 6:56 PM",PID,Closed,1d,Gabriela Novotna,gnovotna@email.cz,Investigator +CZ10004 - Dr. Erik Herman,CZECH REPUBLIC,Part 1 DB Baseline,"Feb 27, 2026 11:35 AM",6227547332,CZ100040006,2024264,"Mar 3, 2026 12:10 PM","Mar 4, 2026 6:57 PM",PID,Closed,1d,Gabriela Novotna,gnovotna@email.cz,Investigator +CZ10004 - Dr. Erik Herman,CZECH REPUBLIC,Part 2 OL Induction Baseline,"May 5, 2026 9:50 AM",6227547338,CZ100040009,2130474,"May 7, 2026 5:24 PM","May 10, 2026 2:50 PM",ADT201,Closed,2d,Gabriela Novotna,gnovotna@email.cz,Investigator +CZ10004 - Dr. Erik Herman,CZECH REPUBLIC,Part 2 OL Induction Baseline,"Apr 7, 2026 9:45 AM",6227541258,CZ100040005,2083848,"Apr 8, 2026 8:50 PM","Apr 13, 2026 5:16 PM",ADT201,Closed,4d,Erik Herman,erik.herman@seznam.cz,Investigator +CZ10004 - Dr. Erik Herman,CZECH REPUBLIC,Part 2 OL Induction Day 29,"May 5, 2026 1:15 PM",6227541261,CZ100040006,2130351,"May 7, 2026 4:53 PM","May 13, 2026 1:52 PM","SCT, ADT201",Closed,5d,Minarovicova Katarina,kminarov@its.jnj.com,Investigator +CZ10004 - Dr. Erik Herman,CZECH REPUBLIC,Part 2 DB Week 13,"Apr 7, 2026 8:35 AM",6227541264,CZ100040001,2090583,"Apr 13, 2026 6:24 PM","Apr 28, 2026 2:16 PM","VST, ADT201",Closed,14d,Gabriela Novotna,gnovotna@email.cz,Investigator +title,value,,,,,,,,,,,,, +Search,,,,,,,,,,,,,, +Site,"898744, 898739, 898733, 898745, 898727",,,,,,,,,,,,, +Unresponded Only?,FALSE,,,,,,,,,,,,, +Posted,From - To - ,,,,,,,,,,,,, diff --git a/Covance/Source/2026-06-18_093653 sponsor-study-36940-activity-reports-documents-equery.csv b/Covance/Source/2026-06-18_093653 sponsor-study-36940-activity-reports-documents-equery.csv new file mode 100644 index 0000000..d1d28b9 --- /dev/null +++ b/Covance/Source/2026-06-18_093653 sponsor-study-36940-activity-reports-documents-equery.csv @@ -0,0 +1,87 @@ +Site,Country,Visit,Visit Collection Date,Accession,Subject,eQueryId,Create Date,Response Date Time,Issue Type,Status,Time Before Response,User Name,Email,Study Role +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Unscheduled,"Mar 13, 2026 8:40 AM",6227323295,CZ100222004,2047932,"Mar 17, 2026 3:49 PM","Mar 17, 2026 9:07 PM",VST,Closed,5h 17m,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Unscheduled,"Mar 13, 2026 7:45 AM",6227323297,CZ100222005,2047949,"Mar 17, 2026 3:56 PM","Mar 17, 2026 9:09 PM",VST,Closed,5h 12m,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Induction Week 0,"Mar 9, 2026 8:50 AM",6227323270,CZ100222003,2038559,"Mar 11, 2026 4:39 PM","Mar 11, 2026 8:32 PM","AGE, ADT201, AMT58660, AMT3542",Closed,3h 53m,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Induction Week 2,"Mar 27, 2026 7:10 AM",6227323272,CZ100222003,2073305,"Apr 1, 2026 7:54 PM","Apr 2, 2026 7:37 AM",AMT58660,Closed,11h 43m,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Induction Week 4,"Apr 8, 2026 8:05 AM",6227323274,CZ100222003,2086982,"Apr 10, 2026 1:00 PM","Apr 10, 2026 1:06 PM",AMT58660,Closed,5m,Katerina Havlikova,katerina.havlikova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Screening,"Mar 4, 2026 9:20 AM",6227810900,CZ100222005,2031896,"Mar 6, 2026 6:45 PM","Mar 6, 2026 7:25 PM","AMT58660, AMT3542",Closed,40m,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Screening,"Mar 2, 2026 11:00 AM",6227810899,CZ100222003,2029805,"Mar 5, 2026 6:36 PM","Mar 6, 2026 9:01 AM","AMT58660, AMT3542",Closed,14h 24m,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Screening,"Mar 3, 2026 12:10 PM",6227810901,CZ100222004,2029774,"Mar 5, 2026 6:23 PM","Mar 6, 2026 7:24 PM","AMT58660, AMT3542",Closed,1d,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10022 - Dr. Petr Hrabak,CZECH REPUBLIC,Induction Week 0,"Apr 9, 2026 10:35 AM",6228173397,CZ100222005,2089669,"Apr 13, 2026 2:06 PM","Apr 23, 2026 12:53 PM",PCFCOM,Closed,9d,Jana Pomahacova,jana.pomahacova@clinoxus.com,Investigator +CZ10021 - Dr.Martin Bortlik,CZECH REPUBLIC,Induction Week 0,"Apr 7, 2026 10:37 AM",6227635207,CZ100212001,2085089,"Apr 9, 2026 2:54 PM","Apr 15, 2026 7:20 AM","AMT58660, AMT15602",Closed,5d,Tereza Hosnova,hosnova.tereza2@nemcb.cz,Investigator +CZ10021 - Dr.Martin Bortlik,CZECH REPUBLIC,Screening,"Feb 25, 2026 12:15 PM",6227635204,CZ100212001,2019716,"Feb 27, 2026 12:09 PM","Mar 3, 2026 11:11 AM","AMT58660, AMT3542",Closed,3d,Zdenka Dvorakova,dvorakova.zdenka@nemcb.cz,Investigator +CZ10021 - Dr.Martin Bortlik,CZECH REPUBLIC,Induction Week 2,"Apr 20, 2026 8:43 AM",6227635208,CZ100212001,2106304,"Apr 22, 2026 7:04 PM","Apr 23, 2026 9:21 AM",AMT58660,Closed,14h 16m,Tereza Hosnova,hosnova.tereza2@nemcb.cz,Investigator +CZ10021 - Dr.Martin Bortlik,CZECH REPUBLIC,Induction Week 4,"May 5, 2026 10:00 AM",6227635211,CZ100212001,2133221,"May 9, 2026 6:24 PM","May 11, 2026 2:34 PM",AMT58660,Closed,1d,Tereza Hosnova,hosnova.tereza2@nemcb.cz,Investigator +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Biopsy,"May 25, 2026 12:00 AM",6228501732,CZ100132003,2165892,"May 29, 2026 3:13 PM","May 31, 2026 9:26 PM",ADT8471,Closed,2d,David Stepek,dstepek@vnbrno.cz,Investigator +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Induction Week 0,"Mar 24, 2026 9:40 AM",6227635142,CZ100132001,2064220,"Mar 26, 2026 9:37 PM",,"AMT58660, AMT3542",Closed,,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Induction Week 0,"Mar 24, 2026 9:40 AM",6227635142,CZ100132001,2066330,"Mar 27, 2026 6:43 PM","Mar 30, 2026 10:41 PM",AMT58660,Closed,3d,David Stepek,dstepek@vnbrno.cz,Investigator +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Induction Week 2,"Apr 7, 2026 8:50 AM",6227635144,CZ100132001,2087084,"Apr 10, 2026 1:27 PM",,AMT58660,Closed,,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Induction Week 2,"Apr 7, 2026 8:50 AM",6227635144,CZ100132001,2100086,"Apr 18, 2026 11:15 AM","Apr 22, 2026 7:51 PM",AMT58660,Closed,4d,David Stepek,dstepek@vnbrno.cz,Investigator +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Induction Week 4,"Apr 21, 2026 8:45 AM",6227635146,CZ100132001,2108501,"Apr 23, 2026 6:55 PM",,AMT58660,Closed,,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Induction Week 4,"Apr 21, 2026 8:45 AM",6227635146,CZ100132001,2123492,"May 4, 2026 7:24 PM","May 5, 2026 3:30 PM",AMT58660,Closed,20h 6m,David Stepek,dstepek@vnbrno.cz,Investigator +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Screening,"Apr 1, 2026 8:00 AM",6227635139,CZ100132002,2101883,"Apr 20, 2026 6:49 PM","Apr 22, 2026 7:51 PM",AMT58660,Closed,2d,David Stepek,dstepek@vnbrno.cz,Investigator +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Screening,"Apr 1, 2026 8:00 AM",6227635139,CZ100132002,2090916,"Apr 13, 2026 9:15 PM",,AMT58660,Closed,,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Screening,"Apr 1, 2026 8:00 AM",6227635139,CZ100132002,2079289,"Apr 6, 2026 3:21 PM",,AMT58660,Closed,,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Screening,"Feb 26, 2026 1:20 PM",6227635140,CZ100132001,2033901,"Mar 9, 2026 3:53 PM","Mar 16, 2026 10:08 PM","SCD, AMT58660, AMT3542",Closed,7d,David Stepek,dstepek@vnbrno.cz,Investigator +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Screening,"Feb 26, 2026 1:20 PM",6227635140,CZ100132001,2023257,"Mar 2, 2026 6:47 PM",,"SCD, AGE, AMT58660, AMT3542",Closed,,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Screening,"May 6, 2026 10:45 AM",6227635141,CZ100132003,2137874,"May 12, 2026 8:03 PM","May 19, 2026 7:48 AM",AMT58660,Closed,6d,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Biopsy,"Apr 21, 2026 12:00 AM",6227635159,CZ100132002,2109534,"Apr 24, 2026 12:45 PM",,ADT8471,Closed,,,, +CZ10013 - Dr.David Stepek,CZECH REPUBLIC,Biopsy,"Apr 21, 2026 12:00 AM",6227635159,CZ100132002,2123486,"May 4, 2026 7:23 PM","May 5, 2026 3:30 PM",ADT8471,Closed,20h 7m,David Stepek,dstepek@vnbrno.cz,Investigator +CZ10020 - Dr.Lucie Gonsorcikova,CZECH REPUBLIC,Screening,"Apr 13, 2026 12:20 PM",6227993962,CZ100201001,2094721,"Apr 15, 2026 6:02 PM","Apr 21, 2026 12:47 PM","AMT58660, AMT3542",Closed,5d,Zuzana Zahradnikova,zuzana.zahradnikova@ftn.cz,Investigator +CZ10020 - Dr.Lucie Gonsorcikova,CZECH REPUBLIC,Induction Week 0,"May 18, 2026 9:28 AM",6227993966,CZ100201001,2156061,"May 22, 2026 9:37 PM","May 25, 2026 6:43 AM","ADT201, AMT58660, AMT3542",Closed,2d,Zuzana Zahradnikova,zuzana.zahradnikova@ftn.cz,Investigator +CZ10020 - Dr.Lucie Gonsorcikova,CZECH REPUBLIC,Induction Week 2,"Jun 1, 2026 8:35 AM",6227993968,CZ100201001,2183471,"Jun 9, 2026 6:53 PM","Jun 10, 2026 7:55 AM","AMT58660, AMT3542",Closed,13h 1m,Zuzana Zahradnikova,zuzana.zahradnikova@ftn.cz,Investigator +CZ10016 - Dr.Robert Mudr,CZECH REPUBLIC,Screening,"Apr 21, 2026 10:45 AM",6227635171,CZ100162001,2109874,"Apr 24, 2026 2:00 PM",,AMT58660,Closed,,,, +CZ10016 - Dr.Robert Mudr,CZECH REPUBLIC,Screening,"Apr 21, 2026 10:45 AM",6227635171,CZ100162001,2123465,"May 4, 2026 7:16 PM","May 5, 2026 10:04 AM",AMT58660,Closed,14h 48m,Petr Pekny,petr.pekny@nmskb.cz,Investigator +CZ10016 - Dr.Robert Mudr,CZECH REPUBLIC,Screening,"May 27, 2026 12:35 PM",6227635173,CZ100162002,2168473,"Jun 1, 2026 3:20 PM","Jun 1, 2026 3:50 PM",AMT58660,Closed,29m,Petr Pekny,petr.pekny@nmskb.cz,Investigator +CZ10016 - Dr.Robert Mudr,CZECH REPUBLIC,Induction Week 0,"May 28, 2026 10:45 AM",6227635174,CZ100162001,2173754,"Jun 3, 2026 7:23 PM","Jun 3, 2026 11:14 PM",AMT58660,Closed,3h 50m,Petr Pekny,petr.pekny@nmskb.cz,Investigator +CZ10016 - Dr.Robert Mudr,CZECH REPUBLIC,Induction Week 2,"Jun 11, 2026 8:45 AM",6227635177,CZ100162001,2196057,"Jun 17, 2026 12:05 PM","Jun 17, 2026 12:37 PM",AMT58660,Response Received,32m,Petr Pekny,petr.pekny@nmskb.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Unscheduled,"Mar 17, 2026 8:00 AM",6227323265,CZ100062001,2052144,"Mar 19, 2026 4:08 PM","Mar 24, 2026 9:29 AM","PSX, SCT, AGE",Closed,4d,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Screening,"Apr 20, 2026 7:45 AM",6227323234,CZ100062002,2106334,"Apr 22, 2026 7:18 PM","Apr 22, 2026 7:36 PM",AMT58660,Closed,18m,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Induction Week 0,"Mar 20, 2026 8:00 AM",6227323237,CZ100062001,2064023,"Mar 26, 2026 7:00 PM","Mar 27, 2026 9:04 AM",PCFCOM,Closed,14h 3m,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Induction Week 0,"Mar 20, 2026 8:00 AM",6227323237,CZ100062001,2061456,"Mar 25, 2026 6:16 PM","Mar 26, 2026 8:38 AM",AMT58660,Closed,14h 22m,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Induction Week 0,"May 26, 2026 9:20 AM",6227323238,CZ100062002,2168534,"Jun 1, 2026 3:33 PM","Jun 11, 2026 10:30 PM","ADT201, AMT58660",Closed,10d,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Induction Week 2,"Apr 8, 2026 7:10 AM",6227323240,CZ100062001,2086807,"Apr 10, 2026 12:21 PM","Apr 18, 2026 10:40 PM","AMT58660, ADT809",Closed,8d,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Induction Week 4,"Apr 15, 2026 8:45 AM",6227323242,CZ100062001,2102704,"Apr 21, 2026 11:22 AM","Apr 22, 2026 7:36 PM",AMT58660,Closed,1d,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Biopsy,"Feb 19, 2026 12:00 AM",6227323254,CZ100062001,2014333,"Feb 24, 2026 4:13 PM","Feb 24, 2026 8:20 PM",VST,Closed,4h 6m,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10006 - Dr. Michal Konecny,CZECH REPUBLIC,Induction Week 12,"Jun 8, 2026 9:30 AM",6228013269,CZ100062001,2185236,"Jun 10, 2026 5:19 PM","Jun 11, 2026 10:30 PM",AMT58660,Closed,1d,Michal Konecny,konecnymi@seznam.cz,Investigator +CZ10012 - Dr.Stefan Konecny,CZECH REPUBLIC,Unscheduled,,6227697745,,2182055,"Jun 9, 2026 11:50 AM","Jun 18, 2026 7:52 AM","ADT809, AMT688, PCFCOM",Response Received,8d,Kristyna Hosova,hosova.kristyna@fnbrno.cz,Investigator +CZ10012 - Dr.Stefan Konecny,CZECH REPUBLIC,Unscheduled,,6227697745,,2140058,"May 13, 2026 7:02 PM","May 26, 2026 9:46 AM",PCFCOM,Closed,12d,Kristyna Hosova,hosova.kristyna@fnbrno.cz,Investigator +CZ10012 - Dr.Stefan Konecny,CZECH REPUBLIC,Screening,"Mar 18, 2026 9:18 AM",6227697718,CZ100122001,2053959,"Mar 20, 2026 2:52 PM","Mar 23, 2026 12:00 PM","SCT, AMT58660",Closed,2d,Kristyna Hosova,hosova.kristyna@fnbrno.cz,Investigator +CZ10012 - Dr.Stefan Konecny,CZECH REPUBLIC,Induction Week 0,"Apr 7, 2026 11:45 AM",6227697719,CZ100122001,2085069,"Apr 9, 2026 2:48 PM","Apr 9, 2026 6:28 PM",AMT58660,Closed,3h 39m,Kristyna Hosova,hosova.kristyna@fnbrno.cz,Investigator +CZ10012 - Dr.Stefan Konecny,CZECH REPUBLIC,Induction Week 2,"Apr 22, 2026 9:25 AM",6227697722,CZ100122001,2113315,"Apr 27, 2026 6:35 PM","Apr 27, 2026 8:50 PM",AMT58660,Closed,2h 14m,Kristyna Hosova,hosova.kristyna@fnbrno.cz,Investigator +CZ10012 - Dr.Stefan Konecny,CZECH REPUBLIC,Induction Week 4,"May 7, 2026 12:40 PM",6227697723,CZ100122001,2142322,"May 14, 2026 7:10 PM","May 14, 2026 7:42 PM",AMT58660,Closed,31m,Kristyna Hosova,hosova.kristyna@fnbrno.cz,Investigator +CZ10012 - Dr.Stefan Konecny,CZECH REPUBLIC,Biopsy,"Mar 23, 2026 12:00 AM",6227697736,CZ100122001,2060524,"Mar 25, 2026 12:53 PM","Mar 25, 2026 2:09 PM",AMT23260,Closed,1h 15m,Kristyna Hosova,hosova.kristyna@fnbrno.cz,Investigator +CZ10009 - Dr. Jiri Pumprla,CZECH REPUBLIC,Screening,"Mar 31, 2026 8:30 AM",6227323330,CZ100092001,2075611,"Apr 2, 2026 5:37 PM",,AMT58660,Closed,,,, +CZ10009 - Dr. Jiri Pumprla,CZECH REPUBLIC,Screening,"Mar 31, 2026 8:30 AM",6227323330,CZ100092001,2085558,"Apr 9, 2026 5:08 PM","Apr 10, 2026 2:06 PM",AMT58660,Closed,20h 58m,Jiri Pumprla,research@vilazdravi.cz,Investigator +CZ10009 - Dr. Jiri Pumprla,CZECH REPUBLIC,Screening,"Jun 11, 2026 10:50 AM",6227323331,CZ100092003,2192857,"Jun 15, 2026 6:44 PM","Jun 16, 2026 12:16 PM",AMT58660,Closed,17h 31m,Jiri Pumprla,research@vilazdravi.cz,Investigator +CZ10009 - Dr. Jiri Pumprla,CZECH REPUBLIC,Screening,"Apr 16, 2026 12:00 PM",6227323332,CZ100092002,2101792,"Apr 20, 2026 6:19 PM","Apr 23, 2026 1:22 PM",AMT58660,Closed,2d,Marketa Menyhardova,menyhardova@vilazdravi.cz,Investigator +CZ10009 - Dr. Jiri Pumprla,CZECH REPUBLIC,Induction Week 0,"May 5, 2026 11:30 AM",6227323334,CZ100092001,2133224,"May 9, 2026 6:30 PM","May 13, 2026 10:10 AM","AMT58660, ADT809",Closed,3d,Marketa Menyhardova,menyhardova@vilazdravi.cz,Investigator +CZ10009 - Dr. Jiri Pumprla,CZECH REPUBLIC,Induction Week 2,"May 19, 2026 10:50 AM",6227323335,CZ100092001,2158952,"May 26, 2026 12:21 PM","May 27, 2026 9:03 AM",AMT58660,Closed,20h 42m,Marketa Menyhardova,menyhardova@vilazdravi.cz,Investigator +CZ10009 - Dr. Jiri Pumprla,CZECH REPUBLIC,Induction Week 4,"Jun 4, 2026 9:50 AM",6227323337,CZ100092001,2185367,"Jun 10, 2026 6:14 PM","Jun 15, 2026 10:22 AM",AMT58660,Closed,4d,Marketa Menyhardova,menyhardova@vilazdravi.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Screening,"Mar 2, 2026 7:00 AM",6227323204,CZ100012002,2032628,"Mar 9, 2026 10:33 AM","Mar 9, 2026 11:58 AM",AMT58660,Closed,1h 24m,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Screening,"Mar 2, 2026 7:00 AM",6227323204,CZ100012002,2026645,"Mar 4, 2026 12:58 PM","Mar 6, 2026 6:01 PM","AMT58660, AMT3542",Closed,2d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Induction Week 0,,6227323206,,2112374,"Apr 27, 2026 2:17 PM","May 5, 2026 11:24 AM","PCFCOM, ADT201, AMT58660, AMT3542",Closed,7d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Induction Week 2,"Apr 23, 2026 7:40 AM",6227323207,CZ100012002,2113312,"Apr 27, 2026 6:35 PM","Apr 28, 2026 9:06 PM",AMT58660,Closed,1d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Induction Week 2,"Mar 4, 2026 7:00 AM",6227323208,CZ100012001,2030545,"Mar 6, 2026 11:02 AM","Mar 6, 2026 11:42 AM","AMT58660, AMT688",Closed,39m,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Induction Week 4,"Mar 18, 2026 7:05 AM",6227323210,CZ100012001,2053955,"Mar 20, 2026 2:50 PM","Mar 25, 2026 3:29 PM","SCD, AMT58660",Closed,5d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Stool Pathogens,"Jan 28, 2026 6:00 AM",6227323211,CZ100012001,1976585,"Jan 30, 2026 1:21 PM","Feb 6, 2026 2:37 PM","VST, AGE",Closed,7d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Stool Pathogens,"Jan 28, 2026 6:00 AM",6227323211,CZ100012001,1991148,"Feb 9, 2026 7:43 PM","Feb 13, 2026 8:04 AM",AGE,Closed,3d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Biopsy,"Feb 5, 2026 12:00 AM",6227323223,CZ100012001,1989998,"Feb 9, 2026 1:42 PM","Feb 10, 2026 6:46 PM",VST,Closed,1d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Unscheduled,"Apr 22, 2026 7:40 AM",6227323232,CZ100012001,2141856,"May 14, 2026 4:23 PM","May 19, 2026 12:54 PM","SCD, AGE",Closed,4d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Unscheduled,"Apr 22, 2026 7:40 AM",6227323232,CZ100012001,2152157,"May 21, 2026 11:32 AM","May 26, 2026 8:15 AM",AGE,Closed,4d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Unscheduled,"Apr 22, 2026 7:40 AM",6227323232,CZ100012001,2112413,"Apr 27, 2026 2:24 PM","May 5, 2026 11:25 AM","PSX, SCT, VST, AGE, ADT201",Closed,7d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Unscheduled,"Apr 22, 2026 7:40 AM",6227323232,CZ100012001,2126904,"May 6, 2026 12:02 PM","May 12, 2026 4:58 PM","SCT, VST, AGE",Closed,6d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Unscheduled,,6227323231,,2053405,"Mar 20, 2026 12:14 PM","Mar 30, 2026 12:54 AM",PCFCOM,Closed,9d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Unscheduled,,6227323233,,2053482,"Mar 20, 2026 12:40 PM","Mar 27, 2026 9:58 AM",PCFCOM,Closed,6d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Induction Week 0,"Apr 8, 2026 7:10 AM",6228036554,CZ100012002,2089973,"Apr 13, 2026 3:26 PM","Apr 21, 2026 1:32 PM",AMT15602,Closed,7d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Biopsy,"May 13, 2026 12:00 AM",6228252073,CZ100012003,2147778,"May 19, 2026 10:13 AM","May 21, 2026 4:38 PM",VST,Closed,2d,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Induction Week 4,"May 6, 2026 8:05 AM",6227933142,CZ100012002,2134478,"May 11, 2026 2:54 PM","May 11, 2026 3:11 PM","AMT58660, AMT3542",Closed,16m,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Induction Week 12,"May 13, 2026 8:05 AM",6227933143,CZ100012001,2147202,"May 18, 2026 7:51 PM","May 19, 2026 8:38 AM",AMT58660,Closed,12h 47m,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10001 - Dr. Matej Falc,CZECH REPUBLIC,Maintenance Week 4,"Jun 10, 2026 7:10 AM",6227933145,CZ100012001,2196042,"Jun 17, 2026 12:01 PM","Jun 17, 2026 1:16 PM","AMT58660, AMT688",Response Received,1h 15m,Matej Falc,matesfalc@seznam.cz,Investigator +CZ10003 - Dr. Leksa Vaclav,CZECH REPUBLIC,Screening,"May 13, 2026 8:15 AM",6227323299,CZ100032001,2154732,"May 22, 2026 12:36 PM","May 25, 2026 8:57 AM",AMT58660,Closed,2d,Leksa Vaclav,vaclav.leksa@seznam.cz,Investigator +CZ10003 - Dr. Leksa Vaclav,CZECH REPUBLIC,Induction Week 0,"Jun 10, 2026 9:00 AM",6227323301,CZ100032001,2190230,"Jun 12, 2026 7:35 PM","Jun 12, 2026 10:56 PM",AMT58660,Closed,3h 21m,Leksa Vaclav,vaclav.leksa@seznam.cz,Investigator +title,value,,,,,,,,,,,,, +Search,,,,,,,,,,,,,, +Site,"930551, 930556, 930525, 930549, 930543, 930547, 930555, 930557, 930539, 930536, 930553, 930531",,,,,,,,,,,,, +Unresponded Only?,FALSE,,,,,,,,,,,,, +Posted,From - To - ,,,,,,,,,,,,, diff --git a/Covance/Source/2026-06-18_093809 sponsor-study-36940-kit-inventory-on-hand-expiration.csv b/Covance/Source/2026-06-18_093809 sponsor-study-36940-kit-inventory-on-hand-expiration.csv new file mode 100644 index 0000000..48464dd --- /dev/null +++ b/Covance/Source/2026-06-18_093809 sponsor-study-36940-kit-inventory-on-hand-expiration.csv @@ -0,0 +1,540 @@ +Project No.,Region,Country,Site,Kit Type,Description,Accession,Shipped Date,Expiration Date,Days to Expiration +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,1,Screening,6227323202,"Nov 21, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,1,Screening,6228114609,"Mar 10, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,2,Induction Week 0,6228036552,"Feb 27, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,2,Induction Week 0,6228462182,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,2,Induction Week 0,6228462184,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,2,Induction Week 0,6228462183,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,3,Induction Week 2,6227933141,"Feb 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,3,Induction Week 2,6228462185,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,3,Induction Week 2,6228462186,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,4,Induction Week 4,6227323209,"Nov 21, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,4,Induction Week 4,6228462189,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,4,Induction Week 4,6228462188,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,5,Induction Week 12,6227810906,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,5,Induction Week 12,6227933144,"Feb 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,5,Induction Week 12,6228462190,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,5,Induction Week 12,6228462191,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,6,Maintenance Week 4,6227933146,"Feb 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,7,Maintenance Week 12,6227933147,"Feb 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,7,Maintenance Week 12,6227933148,"Feb 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-1,Stool Pathogens,6228137358,"Mar 12, 2026","Jan 29, 2027",224 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-1,Stool Pathogens,6228462192,"Apr 28, 2026","May 25, 2027",340 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-1,Stool Pathogens,6228462193,"Apr 28, 2026","May 25, 2027",340 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-1,Stool Pathogens,6228462194,"Apr 28, 2026","May 25, 2027",340 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-1,Stool Pathogens,6228462196,"Apr 28, 2026","May 25, 2027",340 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-1,Stool Pathogens,6228462197,"Apr 28, 2026","May 25, 2027",340 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-1,Stool Pathogens,6228462195,"Apr 28, 2026","May 25, 2027",340 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-2,TB Testing,6227323220,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-2,TB Testing,6227323221,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-3,Biopsy,6228252071,"Mar 26, 2026","Jul 20, 2027",396 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-4,Induction ED,6227323225,"Nov 21, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-4,Induction ED,6227323226,"Nov 21, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-5,Biologic Drug Level,6227323227,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-5,Biologic Drug Level,6227323228,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-6,Maintenance ED,6227810907,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-6,Maintenance ED,6227810909,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-6,Maintenance ED,6227810908,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-8,Liver Function Tests,6227323229,"Nov 21, 2025","Jul 1, 2026",12 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-8,Liver Function Tests,6227323230,"Nov 21, 2025","Jul 1, 2026",12 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-9,LTE Maintenance ED,6227810910,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-9,LTE Maintenance ED,6227810911,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-9,LTE Maintenance ED,6227810912,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-10,Safety FU,6227323214,"Nov 21, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-10,Safety FU,6227323215,"Nov 21, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-11,DILI,6227323216,"Nov 21, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-12,DNA,6227323218,"Nov 21, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-12,DNA,6228252069,"Mar 26, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-12,DNA,6228252070,"Mar 26, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,T-12,DNA,6228252068,"Mar 26, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462198,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462199,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462200,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462202,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462201,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462203,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462206,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462205,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462204,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228462207,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489756,"May 1, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489757,"May 1, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489758,"May 1, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489761,"May 1, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489760,"May 1, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489759,"May 1, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489763,"May 1, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10001 - Dr. Matej Falc,U,Unscheduled,6228489762,"May 1, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,1,Screening,6227323298,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,1,Screening,6227323300,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,2,Induction Week 0,6227323302,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,2,Induction Week 0,6228878057,"Jun 18, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,2,Induction Week 0,6228878056,"Jun 18, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,2,Induction Week 0,6228878055,"Jun 18, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,3,Induction Week 2,6227323303,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,3,Induction Week 2,6227323304,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,4,Induction Week 4,6227323306,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,4,Induction Week 4,6227323305,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,5,Induction Week 12,6228676757,"May 15, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-1,Stool Pathogens,6227323307,"Nov 21, 2025","Dec 26, 2026",190 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-1,Stool Pathogens,6227323308,"Nov 21, 2025","Dec 26, 2026",190 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-2,TB Testing,6227323316,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-2,TB Testing,6227323317,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-3,Biopsy,6227323319,"Nov 21, 2025","Sep 12, 2026",85 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-3,Biopsy,6227323318,"Nov 21, 2025","Sep 12, 2026",85 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-4,Induction ED,6227323321,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-4,Induction ED,6227323322,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-5,Biologic Drug Level,6227323323,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-5,Biologic Drug Level,6227323324,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-6,Maintenance ED,6228676759,"May 15, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-6,Maintenance ED,6228676760,"May 15, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-6,Maintenance ED,6228676758,"May 15, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-8,Liver Function Tests,6227323326,"Nov 21, 2025","Jul 1, 2026",12 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-8,Liver Function Tests,6227323325,"Nov 21, 2025","Jul 1, 2026",12 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-9,LTE Maintenance ED,6228676762,"May 15, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-9,LTE Maintenance ED,6228676763,"May 15, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-9,LTE Maintenance ED,6228676761,"May 15, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-10,Safety FU,6227323310,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-10,Safety FU,6227323311,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-11,DILI,6227323312,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-12,DNA,6227323314,"Nov 21, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,T-12,DNA,6227323315,"Nov 21, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,U,Unscheduled,6227323328,"Nov 21, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,U,Unscheduled,6227323327,"Nov 21, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10003 - Dr. Leksa Vaclav,U,Unscheduled,6227323329,"Nov 21, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,1,Screening,6227323235,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,1,Screening,6228492883,"Apr 23, 2026","Nov 30, 2026",164 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,1,Screening,6228492884,"Apr 23, 2026","Nov 30, 2026",164 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,1,Screening,6228492885,"Apr 23, 2026","Nov 30, 2026",164 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,2,Induction Week 0,6228265099,"Mar 27, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,2,Induction Week 0,6228265098,"Mar 27, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,2,Induction Week 0,6228265100,"Mar 27, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,3,Induction Week 2,6227323239,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,3,Induction Week 2,6228407563,"Apr 15, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,3,Induction Week 2,6228407565,"Apr 15, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,4,Induction Week 4,6227323241,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,4,Induction Week 4,6228461735,"Apr 21, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,4,Induction Week 4,6228461736,"Apr 21, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,4,Induction Week 4,6228461734,"Apr 21, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,5,Induction Week 12,6228492886,"Apr 23, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,6,Maintenance Week 4,6228194338,"Mar 23, 2026","Sep 30, 2026",103 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,6,Maintenance Week 4,6228690541,"May 19, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-1,Stool Pathogens,6228194340,"Mar 23, 2026","Mar 5, 2027",259 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-1,Stool Pathogens,6228194339,"Mar 23, 2026","Mar 5, 2027",259 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-3,Biopsy,6228690542,"May 19, 2026","Aug 7, 2027",414 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-3,Biopsy,6228690544,"May 19, 2026","Aug 7, 2027",414 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-3,Biopsy,6228690543,"May 19, 2026","Aug 7, 2027",414 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-4,Induction ED,6227323257,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-4,Induction ED,6227323258,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-5,Biologic Drug Level,6227323260,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-5,Biologic Drug Level,6227323259,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-6,Maintenance ED,6228013270,"Feb 25, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-6,Maintenance ED,6228013271,"Feb 25, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-6,Maintenance ED,6228013272,"Feb 25, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-8,Liver Function Tests,6227323261,"Nov 21, 2025","Jul 1, 2026",12 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-8,Liver Function Tests,6227323262,"Nov 21, 2025","Jul 1, 2026",12 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-9,LTE Maintenance ED,6228013275,"Feb 25, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-9,LTE Maintenance ED,6228013273,"Feb 25, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-9,LTE Maintenance ED,6228013274,"Feb 25, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-10,Safety FU,6227323246,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-10,Safety FU,6227323247,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-11,DILI,6227323248,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-12,DNA,6227323250,"Nov 21, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,T-12,DNA,6227323249,"Nov 21, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10006 - Dr. Michal Konecny,U,Unscheduled,6227323263,"Nov 21, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,1,Screening,6227765941,"Jan 29, 2026","Sep 30, 2026",103 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,1,Screening,6227765942,"Jan 29, 2026","Sep 30, 2026",103 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,2,Induction Week 0,6227323333,"Nov 23, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,2,Induction Week 0,6227765944,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,2,Induction Week 0,6227765945,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,2,Induction Week 0,6227765946,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,3,Induction Week 2,6227323336,"Nov 23, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,3,Induction Week 2,6227765948,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,3,Induction Week 2,6227765947,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,3,Induction Week 2,6227765949,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,4,Induction Week 4,6227323338,"Nov 23, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,4,Induction Week 4,6227765950,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,4,Induction Week 4,6227765951,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,4,Induction Week 4,6227765952,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,5,Induction Week 12,6227765953,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,5,Induction Week 12,6227765954,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,5,Induction Week 12,6227765955,"Jan 29, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-1,Stool Pathogens,6227765956,"Jan 29, 2026","Jan 15, 2027",210 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-1,Stool Pathogens,6227765957,"Jan 29, 2026","Jan 15, 2027",210 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-1,Stool Pathogens,6227765959,"Jan 29, 2026","Jan 15, 2027",210 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-2,TB Testing,6227323349,"Nov 23, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-2,TB Testing,6227765963,"Jan 29, 2026","Sep 30, 2026",103 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-2,TB Testing,6227765964,"Jan 29, 2026","Sep 30, 2026",103 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-2,TB Testing,6227765965,"Jan 29, 2026","Sep 30, 2026",103 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-2,TB Testing,6227765966,"Jan 29, 2026","Sep 30, 2026",103 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-3,Biopsy,6227323350,"Nov 23, 2025","Sep 12, 2026",85 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-3,Biopsy,6227323352,"Nov 23, 2025","Sep 12, 2026",85 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-3,Biopsy,6227765967,"Jan 29, 2026","Nov 28, 2026",162 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-3,Biopsy,6227765968,"Jan 29, 2026","Nov 28, 2026",162 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-3,Biopsy,6227765970,"Jan 29, 2026","Nov 28, 2026",162 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-3,Biopsy,6227765969,"Jan 29, 2026","Nov 28, 2026",162 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-4,Induction ED,6227323353,"Nov 23, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-4,Induction ED,6227323354,"Nov 23, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-5,Biologic Drug Level,6227323356,"Nov 23, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-5,Biologic Drug Level,6227765973,"Jan 29, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-5,Biologic Drug Level,6227765972,"Jan 29, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-5,Biologic Drug Level,6227765974,"Jan 29, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-5,Biologic Drug Level,6227765971,"Jan 29, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-6,Maintenance ED,6228357528,"Apr 7, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-6,Maintenance ED,6228357529,"Apr 7, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-6,Maintenance ED,6228357530,"Apr 7, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-8,Liver Function Tests,6227323357,"Nov 23, 2025","Jul 1, 2026",12 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-8,Liver Function Tests,6227323358,"Nov 23, 2025","Jul 1, 2026",12 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-9,LTE Maintenance ED,6228357532,"Apr 7, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-9,LTE Maintenance ED,6228357533,"Apr 7, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-9,LTE Maintenance ED,6228357531,"Apr 7, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-10,Safety FU,6227323342,"Nov 23, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-10,Safety FU,6227323343,"Nov 23, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-11,DILI,6227323344,"Nov 23, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-12,DNA,6227323347,"Nov 23, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-12,DNA,6227323345,"Nov 23, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-12,DNA,6227765961,"Jan 29, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-12,DNA,6227765962,"Jan 29, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,T-12,DNA,6227765960,"Jan 29, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,U,Unscheduled,6227323359,"Nov 23, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,U,Unscheduled,6227323361,"Nov 23, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,U,Unscheduled,6227323360,"Nov 23, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,U,Unscheduled,6227765975,"Jan 29, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,U,Unscheduled,6227765976,"Jan 29, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10009 - Dr. Jiri Pumprla,U,Unscheduled,6227765977,"Jan 29, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,1,Screening,6227993930,"Feb 17, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,1,Screening,6227993931,"Feb 17, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,1,Screening,6227993932,"Feb 17, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,2,Induction Week 0,6227993933,"Feb 17, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,2,Induction Week 0,6227993934,"Feb 17, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,3,Induction Week 2,6227993935,"Feb 17, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,3,Induction Week 2,6227993936,"Feb 17, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,4,Induction Week 4,6227993937,"Feb 17, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,4,Induction Week 4,6227993938,"Feb 17, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-1,Stool Pathogens,6227993941,"Feb 17, 2026","Jan 15, 2027",210 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-1,Stool Pathogens,6227993940,"Feb 17, 2026","Jan 15, 2027",210 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-1,Stool Pathogens,6227993939,"Feb 17, 2026","Jan 15, 2027",210 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-2,TB Testing,6227993949,"Feb 17, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-2,TB Testing,6227993948,"Feb 17, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-3,Biopsy,6227993952,"Feb 17, 2026","Nov 28, 2026",162 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-3,Biopsy,6227993951,"Feb 17, 2026","Nov 28, 2026",162 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-3,Biopsy,6227993950,"Feb 17, 2026","Nov 28, 2026",162 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-4,Induction ED,6227993954,"Feb 17, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-4,Induction ED,6227993953,"Feb 17, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-5,Biologic Drug Level,6227993955,"Feb 17, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-5,Biologic Drug Level,6227993956,"Feb 17, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-8,Liver Function Tests,6227993957,"Feb 17, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-8,Liver Function Tests,6227993958,"Feb 17, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-10,Safety FU,6227993943,"Feb 17, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-10,Safety FU,6227993942,"Feb 17, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-11,DILI,6227993944,"Feb 17, 2026","Sep 30, 2026",103 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-12,DNA,6227993945,"Feb 17, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-12,DNA,6227993946,"Feb 17, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,T-12,DNA,6227993947,"Feb 17, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,U,Unscheduled,6227993959,"Feb 17, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,U,Unscheduled,6227993960,"Feb 17, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10010 - Dr.Nabil El Lababidi,U,Unscheduled,6227993961,"Feb 17, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,1,Screening,6227697716,"Jan 12, 2026","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,1,Screening,6227697717,"Jan 12, 2026","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,2,Induction Week 0,6227697720,"Jan 12, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,2,Induction Week 0,6228398468,"Apr 14, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,2,Induction Week 0,6228398470,"Apr 14, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,2,Induction Week 0,6228398469,"Apr 14, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,3,Induction Week 2,6227697721,"Jan 12, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,3,Induction Week 2,6228512528,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,3,Induction Week 2,6228512526,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,3,Induction Week 2,6228512527,"Apr 28, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,4,Induction Week 4,6227697724,"Jan 12, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,4,Induction Week 4,6228628517,"May 11, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,4,Induction Week 4,6228628515,"May 11, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,4,Induction Week 4,6228628516,"May 11, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,5,Induction Week 12,6228251912,"Mar 26, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,6,Maintenance Week 4,6228628518,"May 11, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-1,Stool Pathogens,6227697726,"Jan 12, 2026","Jan 14, 2027",209 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-1,Stool Pathogens,6227697727,"Jan 12, 2026","Jan 14, 2027",209 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-2,TB Testing,6227697735,"Jan 12, 2026","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-2,TB Testing,6227697734,"Jan 12, 2026","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-3,Biopsy,6227697737,"Jan 12, 2026","May 11, 2027",326 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-3,Biopsy,6227697738,"Jan 12, 2026","May 11, 2027",326 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-4,Induction ED,6227697740,"Jan 12, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-4,Induction ED,6227697739,"Jan 12, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-5,Biologic Drug Level,6227697741,"Jan 12, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-5,Biologic Drug Level,6227697742,"Jan 12, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-6,Maintenance ED,6228251914,"Mar 26, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-6,Maintenance ED,6228251913,"Mar 26, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-6,Maintenance ED,6228251915,"Mar 26, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-8,Liver Function Tests,6227697743,"Jan 12, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-8,Liver Function Tests,6227697744,"Jan 12, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-9,LTE Maintenance ED,6228251918,"Mar 26, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-9,LTE Maintenance ED,6228251916,"Mar 26, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-9,LTE Maintenance ED,6228251917,"Mar 26, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-10,Safety FU,6227697728,"Jan 12, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-10,Safety FU,6227697729,"Jan 12, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-11,DILI,6227697730,"Jan 12, 2026","Jul 31, 2026",42 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-12,DNA,6227697733,"Jan 12, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,T-12,DNA,6227697732,"Jan 12, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,U,Unscheduled,6227697747,"Jan 12, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10012 - Dr.Stefan Konecny,U,Unscheduled,6227697746,"Jan 12, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,1,Screening,6228367755,"Apr 8, 2026","Nov 30, 2026",164 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,1,Screening,6228367756,"Apr 8, 2026","Nov 30, 2026",164 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,1,Screening,6228367757,"Apr 8, 2026","Nov 30, 2026",164 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,2,Induction Week 0,6227635143,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,2,Induction Week 0,6228308226,"Apr 1, 2026","Jan 31, 2027",226 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,3,Induction Week 2,6227635145,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,3,Induction Week 2,6228398114,"Apr 14, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,3,Induction Week 2,6228398116,"Apr 14, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,4,Induction Week 4,6227635147,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,4,Induction Week 4,6228501725,"Apr 26, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,4,Induction Week 4,6228501726,"Apr 26, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,5,Induction Week 12,6228367758,"Apr 8, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,5,Induction Week 12,6228762734,"Jun 4, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,6,Maintenance Week 4,6228501728,"Apr 26, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,6,Maintenance Week 4,6228501729,"Apr 26, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-1,Stool Pathogens,6228367759,"Apr 8, 2026","Mar 5, 2027",259 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-1,Stool Pathogens,6228367760,"Apr 8, 2026","Mar 5, 2027",259 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-1,Stool Pathogens,6228367761,"Apr 8, 2026","Mar 5, 2027",259 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-2,TB Testing,6227635158,"Jan 5, 2026","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-2,TB Testing,6227635157,"Jan 5, 2026","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-3,Biopsy,6227635160,"Jan 5, 2026","Oct 15, 2026",118 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-3,Biopsy,6228501731,"Apr 26, 2026","Aug 7, 2027",414 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-4,Induction ED,6227635163,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-4,Induction ED,6227635162,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-5,Biologic Drug Level,6227635164,"Jan 5, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-5,Biologic Drug Level,6227635165,"Jan 5, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-6,Maintenance ED,6228095872,"Mar 5, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-6,Maintenance ED,6228095870,"Mar 5, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-6,Maintenance ED,6228095871,"Mar 5, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-8,Liver Function Tests,6227635167,"Jan 5, 2026","Sep 12, 2026",85 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-8,Liver Function Tests,6227635166,"Jan 5, 2026","Sep 12, 2026",85 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-9,LTE Maintenance ED,6228095874,"Mar 5, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-9,LTE Maintenance ED,6228095873,"Mar 5, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-9,LTE Maintenance ED,6228095875,"Mar 5, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-10,Safety FU,6227635151,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-10,Safety FU,6227635152,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-11,DILI,6227635153,"Jan 5, 2026","Jul 31, 2026",42 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-12,DNA,6228762735,"Jun 4, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-12,DNA,6228762736,"Jun 4, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,T-12,DNA,6228762737,"Jun 4, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,U,Unscheduled,6227635168,"Jan 5, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,U,Unscheduled,6227635169,"Jan 5, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10013 - Dr.David Stepek,U,Unscheduled,6227635170,"Jan 5, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,1,Screening,6227259263,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,1,Screening,6227259264,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,1,Screening,6227259265,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,1,Screening,6228510217,"Apr 30, 2026","Nov 30, 2026",164 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,1,Screening,6228510218,"Apr 30, 2026","Nov 30, 2026",164 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,2,Induction Week 0,6227259267,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,2,Induction Week 0,6227259266,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,2,Induction Week 0,6228510219,"Apr 30, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,2,Induction Week 0,6228510220,"Apr 30, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,3,Induction Week 2,6227259268,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,3,Induction Week 2,6227259269,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,3,Induction Week 2,6228510221,"Apr 30, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,3,Induction Week 2,6228510222,"Apr 30, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,4,Induction Week 4,6227259270,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,4,Induction Week 4,6227259271,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-1,Stool Pathogens,6227259274,"Nov 13, 2025","Dec 26, 2026",190 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-1,Stool Pathogens,6227259273,"Nov 13, 2025","Dec 26, 2026",190 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-1,Stool Pathogens,6227259272,"Nov 13, 2025","Dec 26, 2026",190 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-2,TB Testing,6227259281,"Nov 13, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-2,TB Testing,6227259282,"Nov 13, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-3,Biopsy,6227259283,"Nov 13, 2025","Sep 12, 2026",85 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-3,Biopsy,6227259284,"Nov 13, 2025","Sep 12, 2026",85 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-3,Biopsy,6227259285,"Nov 13, 2025","Sep 12, 2026",85 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-4,Induction ED,6227259286,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-4,Induction ED,6227259287,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-5,Biologic Drug Level,6227259289,"Nov 13, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-5,Biologic Drug Level,6227259288,"Nov 13, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-8,Liver Function Tests,6227259290,"Nov 13, 2025","Jul 1, 2026",12 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-8,Liver Function Tests,6227259291,"Nov 13, 2025","Jul 1, 2026",12 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-10,Safety FU,6227259276,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-10,Safety FU,6227259275,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-11,DILI,6227259277,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-12,DNA,6227259280,"Nov 13, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,T-12,DNA,6227259278,"Nov 13, 2025","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,U,Unscheduled,6227259294,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,U,Unscheduled,6227259293,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10015 - Dr.Jan Matous,U,Unscheduled,6227259292,"Nov 13, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,1,Screening,6227635172,"Jan 5, 2026","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,1,Screening,6228772364,"Jun 5, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,1,Screening,6228772365,"Jun 5, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,1,Screening,6228772366,"Jun 5, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,2,Induction Week 0,6227635175,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,2,Induction Week 0,6228782900,"Jun 5, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,2,Induction Week 0,6228782899,"Jun 5, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,2,Induction Week 0,6228782898,"Jun 5, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,3,Induction Week 2,6227635176,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,4,Induction Week 4,6227635178,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,4,Induction Week 4,6227635179,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,5,Induction Week 12,6228501793,"Apr 26, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,5,Induction Week 12,6228772367,"Jun 5, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,6,Maintenance Week 4,6228772368,"Jun 5, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-1,Stool Pathogens,6227635181,"Jan 5, 2026","Jan 14, 2027",209 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-1,Stool Pathogens,6228772369,"Jun 5, 2026","Aug 10, 2027",417 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-1,Stool Pathogens,6228772370,"Jun 5, 2026","Aug 10, 2027",417 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-1,Stool Pathogens,6228772371,"Jun 5, 2026","Aug 10, 2027",417 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-2,TB Testing,6227635189,"Jan 5, 2026","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-2,TB Testing,6227635190,"Jan 5, 2026","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-3,Biopsy,6227635191,"Jan 5, 2026","Oct 15, 2026",118 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-4,Induction ED,6227635195,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-4,Induction ED,6227635194,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-5,Biologic Drug Level,6227635197,"Jan 5, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-5,Biologic Drug Level,6227635196,"Jan 5, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-6,Maintenance ED,6228501795,"Apr 26, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-6,Maintenance ED,6228501794,"Apr 26, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-6,Maintenance ED,6228501796,"Apr 26, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-8,Liver Function Tests,6227635198,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-8,Liver Function Tests,6227635199,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-9,LTE Maintenance ED,6228501797,"Apr 26, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-9,LTE Maintenance ED,6228501798,"Apr 26, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-9,LTE Maintenance ED,6228501799,"Apr 26, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-10,Safety FU,6227635183,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-10,Safety FU,6227635184,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-11,DILI,6227635185,"Jan 5, 2026","Jul 31, 2026",42 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-12,DNA,6227635188,"Jan 5, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,T-12,DNA,6227635187,"Jan 5, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,U,Unscheduled,6227635200,"Jan 5, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,U,Unscheduled,6227635202,"Jan 5, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10016 - Dr.Robert Mudr,U,Unscheduled,6227635201,"Jan 5, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,1,Screening,6227993964,"Feb 18, 2026","Sep 30, 2026",103 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,1,Screening,6227993963,"Feb 18, 2026","Sep 30, 2026",103 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,2,Induction Week 0,6227993965,"Feb 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,2,Induction Week 0,6228707090,"May 22, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,2,Induction Week 0,6228707091,"May 22, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,2,Induction Week 0,6228707092,"May 22, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,2,Induction Week 0,6228711855,"May 29, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,3,Induction Week 2,6227993967,"Feb 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,3,Induction Week 2,6228806564,"Jun 10, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,3,Induction Week 2,6228806565,"Jun 10, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,3,Induction Week 2,6228806566,"Jun 10, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,4,Induction Week 4,6227993969,"Feb 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,5,Induction Week 12,6228436352,"Apr 19, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-1,Stool Pathogens,6227993973,"Feb 18, 2026","Jan 15, 2027",210 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-1,Stool Pathogens,6227993972,"Feb 18, 2026","Jan 15, 2027",210 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-2,TB Testing,6227993980,"Feb 18, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-2,TB Testing,6227993981,"Feb 18, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-3,Biopsy,6227993983,"Feb 18, 2026","May 11, 2027",326 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-3,Biopsy,6227993982,"Feb 18, 2026","May 11, 2027",326 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-4,Induction ED,6227993985,"Feb 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-4,Induction ED,6227993986,"Feb 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-5,Biologic Drug Level,6227993988,"Feb 18, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-5,Biologic Drug Level,6228711856,"May 29, 2026","May 31, 2027",346 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-6,Maintenance ED,6228436354,"Apr 19, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-6,Maintenance ED,6228436353,"Apr 19, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-6,Maintenance ED,6228436355,"Apr 19, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-8,Liver Function Tests,6227993989,"Feb 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-8,Liver Function Tests,6227993990,"Feb 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-9,LTE Maintenance ED,6228436356,"Apr 19, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-9,LTE Maintenance ED,6228436357,"Apr 19, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-9,LTE Maintenance ED,6228436358,"Apr 19, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-10,Safety FU,6227993974,"Feb 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-10,Safety FU,6227993975,"Feb 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-11,DILI,6227993976,"Feb 18, 2026","Sep 30, 2026",103 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-12,DNA,6227993978,"Feb 18, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,T-12,DNA,6227993979,"Feb 18, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,U,Unscheduled,6227993991,"Feb 18, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,U,Unscheduled,6227993992,"Feb 18, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10020 - Dr.Lucie Gonsorcikova,U,Unscheduled,6227993993,"Feb 18, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,1,Screening,6227635205,"Jan 5, 2026","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,1,Screening,6227635203,"Jan 5, 2026","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,2,Induction Week 0,6227635206,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,2,Induction Week 0,6228398426,"Apr 14, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,2,Induction Week 0,6228398427,"Apr 14, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,2,Induction Week 0,6228398428,"Apr 14, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,3,Induction Week 2,6227635209,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,3,Induction Week 2,6228492827,"Apr 23, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,3,Induction Week 2,6228492828,"Apr 23, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,3,Induction Week 2,6228492826,"Apr 23, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,4,Induction Week 4,6227635210,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,4,Induction Week 4,6228605821,"May 7, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,4,Induction Week 4,6228605823,"May 7, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,4,Induction Week 4,6228605822,"May 7, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,5,Induction Week 12,6228084840,"Mar 4, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,6,Maintenance Week 4,6228605824,"May 7, 2026","Feb 28, 2027",254 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-1,Stool Pathogens,6227635214,"Jan 5, 2026","Jan 14, 2027",209 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-1,Stool Pathogens,6227635212,"Jan 5, 2026","Jan 14, 2027",209 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-2,TB Testing,6227635221,"Jan 5, 2026","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-2,TB Testing,6227635222,"Jan 5, 2026","Aug 31, 2026",73 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-3,Biopsy,6227635224,"Jan 5, 2026","Nov 25, 2026",159 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-3,Biopsy,6227635225,"Jan 5, 2026","Nov 25, 2026",159 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-4,Induction ED,6227635226,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-4,Induction ED,6227635227,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-5,Biologic Drug Level,6227635228,"Jan 5, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-5,Biologic Drug Level,6227635229,"Jan 5, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-6,Maintenance ED,6228084843,"Mar 4, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-6,Maintenance ED,6228084842,"Mar 4, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-6,Maintenance ED,6228084841,"Mar 4, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-8,Liver Function Tests,6227635230,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-8,Liver Function Tests,6227635231,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-9,LTE Maintenance ED,6228084845,"Mar 4, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-9,LTE Maintenance ED,6228084844,"Mar 4, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-9,LTE Maintenance ED,6228084846,"Mar 4, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-10,Safety FU,6227635215,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-10,Safety FU,6227635216,"Jan 5, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-11,DILI,6227635217,"Jan 5, 2026","Jul 31, 2026",42 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-12,DNA,6227635219,"Jan 5, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,T-12,DNA,6227635220,"Jan 5, 2026","Dec 31, 2026",195 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,U,Unscheduled,6227635234,"Jan 5, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,U,Unscheduled,6227635233,"Jan 5, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10021 - Dr.Martin Bortlik,U,Unscheduled,6227635232,"Jan 5, 2026","Oct 31, 2026",134 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,1,Screening,6227323267,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,1,Screening,6228137352,"Mar 11, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,1,Screening,6228137353,"Mar 11, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,1,Screening,6228137354,"Mar 11, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,1,Screening,6228179928,"Mar 23, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,1,Screening,6228179930,"Mar 23, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,1,Screening,6228179929,"Mar 23, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,2,Induction Week 0,6227323269,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,2,Induction Week 0,6228173395,"Mar 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,2,Induction Week 0,6228173396,"Mar 18, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,3,Induction Week 2,6227323271,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,3,Induction Week 2,6228179931,"Mar 23, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,3,Induction Week 2,6228179933,"Mar 23, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,4,Induction Week 4,6227323273,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,4,Induction Week 4,6228179934,"Mar 23, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,4,Induction Week 4,6228179935,"Mar 23, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,5,Induction Week 12,6227752380,"Jan 20, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,5,Induction Week 12,6227810902,"Jan 28, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,5,Induction Week 12,6228137356,"Mar 11, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,6,Maintenance Week 4,6228023948,"Feb 25, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,6,Maintenance Week 4,6228023949,"Feb 25, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,12,LTE Maintenance Wk56,6228179938,"Mar 23, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,12,LTE Maintenance Wk56,6228179937,"Mar 23, 2026","Oct 11, 2026",114 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-1,Stool Pathogens,6227323275,"Nov 21, 2025","Dec 26, 2026",190 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-1,Stool Pathogens,6227810903,"Jan 28, 2026","Jan 15, 2027",210 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-1,Stool Pathogens,6228179939,"Mar 23, 2026","Jan 29, 2027",224 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-1,Stool Pathogens,6228179940,"Mar 23, 2026","Jan 29, 2027",224 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-2,TB Testing,6227323284,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-2,TB Testing,6227323285,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-3,Biopsy,6227323288,"Nov 21, 2025","Sep 12, 2026",85 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-3,Biopsy,6228023950,"Feb 25, 2026","Nov 28, 2026",162 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-3,Biopsy,6228023952,"Feb 25, 2026","May 11, 2027",326 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-3,Biopsy,6228179946,"Mar 23, 2026","Jul 20, 2027",396 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-3,Biopsy,6228179944,"Mar 23, 2026","Jul 20, 2027",396 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-4,Induction ED,6227323289,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-4,Induction ED,6227323290,"Nov 21, 2025","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-5,Biologic Drug Level,6227323291,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-5,Biologic Drug Level,6227323292,"Nov 21, 2025","Jun 30, 2026",11 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-6,Maintenance ED,6227752381,"Jan 20, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-6,Maintenance ED,6227752383,"Jan 20, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-6,Maintenance ED,6227752382,"Jan 20, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-8,Liver Function Tests,6227323293,"Nov 21, 2025","Jul 1, 2026",12 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-8,Liver Function Tests,6227323294,"Nov 21, 2025","Jul 1, 2026",12 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-9,LTE Maintenance ED,6227752385,"Jan 20, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-9,LTE Maintenance ED,6227752386,"Jan 20, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-9,LTE Maintenance ED,6227752384,"Jan 20, 2026","Oct 7, 2026",110 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-10,Safety FU,6227323279,"Nov 21, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-10,Safety FU,6227323278,"Nov 21, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-11,DILI,6227323280,"Nov 21, 2025","May 31, 2026",-18 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-12,DNA,6227323281,"Nov 21, 2025","Jul 31, 2026",42 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-12,DNA,6227323282,"Nov 21, 2025","Jul 31, 2026",42 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-12,DNA,6228179941,"Mar 23, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,T-12,DNA,6228179943,"Mar 23, 2026","Mar 31, 2027",285 +213069,EMEA,CZE,CZ10022 - Dr. Petr Hrabak,U,Unscheduled,6227323296,"Nov 21, 2025","Aug 31, 2026",73 +title,value,,,,,,,, +Search,,,,,,,,, +Site,"CZ10021 Dr.Martin Bortlik, CZ10016 Dr.Robert Mudr, CZ10003 Dr. Leksa Vaclav, CZ10009 Dr. Jiri Pumprla, CZ10015 Dr.Jan Matous, CZ10013 Dr.David Stepek, CZ10006 Dr. Michal Konecny, CZ10001 Dr. Matej Falc, CZ10010 Dr.Nabil El Lababidi, CZ10022 Dr. Petr Hrabak, CZ10020 Dr.Lucie Gonsorcikova, CZ10012 Dr.Stefan Konecny",,,,,,,, +Expiration Date Range,From - To - ,,,,,,,, +Shipped Date Range,From - To - ,,,,,,,, +Kit Type,,,,,,,,, +Ignore Record Limit,TRUE,,,,,,,, diff --git a/Covance/Source/2026-06-18_093829 sponsor-study-35472-kit-inventory-on-hand-expiration.csv b/Covance/Source/2026-06-18_093829 sponsor-study-35472-kit-inventory-on-hand-expiration.csv new file mode 100644 index 0000000..c9a223a --- /dev/null +++ b/Covance/Source/2026-06-18_093829 sponsor-study-35472-kit-inventory-on-hand-expiration.csv @@ -0,0 +1,282 @@ +Project No.,Region,Country,Site,Kit Type,Description,Accession,Shipped Date,Expiration Date,Days to Expiration +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6225350973,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6225350970,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6225350974,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6225350976,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6225350978,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6225350979,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6227541248,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6227541247,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6228149461,"Mar 13, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6228149462,"Mar 13, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,1,Part 1 Screening,6228149463,"Mar 13, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,2,Part 1 DB Baseline,6225350980,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,2,Part 1 DB Baseline,6225350983,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,2,Part 1 DB Baseline,6227261232,"Nov 18, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,2,Part 1 DB Baseline,6227261231,"Nov 18, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,2,Part 1 DB Baseline,6227541250,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,2,Part 1 DB Baseline,6227541253,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,3,Part 2 Screening,6225350985,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,3,Part 2 Screening,6225350986,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,3,Part 2 Screening,6225350987,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,3,Part 2 Screening,6227547334,"Dec 31, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,3,Part 2 Screening,6227547335,"Dec 31, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,4,Part 2 OL Induction Baseline,6225350989,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,4,Part 2 OL Induction Baseline,6227541255,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,4,Part 2 OL Induction Baseline,6227541254,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,4,Part 2 OL Induction Baseline,6227547339,"Dec 31, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,5,Part 2 OL Induction Day 29,6227261233,"Nov 18, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,5,Part 2 OL Induction Day 29,6227541263,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,5,Part 2 OL Induction Day 29,6227541262,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,6,Part 2 DB Baseline,6226573503,"Aug 21, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,6,Part 2 DB Baseline,6226889398,"Oct 7, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,6,Part 2 DB Baseline,6227043303,"Oct 23, 2025","Jul 31, 2026",42 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,6,Part 2 DB Baseline,6227261234,"Nov 18, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,6,Part 2 DB Baseline,6228149464,"Mar 13, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,6,Part 2 DB Baseline,6228149465,"Mar 13, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,7,Part 2 DB Week 13,6226889399,"Oct 7, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,7,Part 2 DB Week 13,6227541265,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,7,Part 2 DB Week 13,6227541267,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,7,Part 2 DB Week 13,6227541268,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,7,Part 2 DB Week 13,6227541266,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6226573504,"Aug 21, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6226573505,"Aug 21, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6226573507,"Aug 21, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6226573506,"Aug 21, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6226573508,"Aug 21, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6227541269,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6227541270,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6227541272,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-1,Part 2 DB Every 12 Weeks,6227541271,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6225350990,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6225350991,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6225350992,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6225350993,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6225350994,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6227768461,"Jan 27, 2026","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6228605654,"May 7, 2026","Feb 28, 2027",254 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-2,End of Phase/Treatment,6228605655,"May 7, 2026","Feb 28, 2027",254 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6225350996,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6225350995,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6225350997,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6225350998,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6225350999,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6227768462,"Jan 27, 2026","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6227768463,"Jan 27, 2026","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6227768464,"Jan 27, 2026","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-3,Early Withdrawal,6227768465,"Jan 27, 2026","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-4,Liver Monitoring,6225351000,"Feb 24, 2025","Sep 1, 2025",-290 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-4,Liver Monitoring,6227547340,"Dec 31, 2025","Sep 12, 2026",85 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-4,Liver Monitoring,6227768466,"Jan 27, 2026","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-5,Suspected Liver Event FU,6225351001,"Feb 24, 2025","Jul 31, 2025",-322 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-5,Suspected Liver Event FU,6227547341,"Dec 31, 2025","Jul 31, 2026",42 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,T-5,Suspected Liver Event FU,6227768467,"Jan 27, 2026","Jul 31, 2026",42 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6225351003,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6226649755,"Aug 29, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6226649756,"Aug 29, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6227178914,"Nov 14, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6227178913,"Nov 14, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6227178915,"Nov 14, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6227178916,"Nov 14, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6227178917,"Nov 14, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6227178919,"Nov 14, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10004 - Dr. Erik Herman,U,Retest,6227178918,"Nov 14, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,1,Part 1 Screening,6225351038,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,1,Part 1 Screening,6225351039,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,1,Part 1 Screening,6225351043,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,1,Part 1 Screening,6227520226,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,1,Part 1 Screening,6227520225,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,1,Part 1 Screening,6227520227,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6225351048,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226551696,"Aug 22, 2025","Apr 17, 2026",-62 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226551699,"Aug 22, 2025","Apr 17, 2026",-62 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226551700,"Aug 22, 2025","Apr 17, 2026",-62 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226655163,"Sep 5, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226655166,"Sep 5, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226655165,"Sep 5, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226655162,"Sep 5, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,2,Part 1 DB Baseline,6226655164,"Sep 5, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,3,Part 2 Screening,6225351053,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,3,Part 2 Screening,6225351054,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,3,Part 2 Screening,6225351055,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,3,Part 2 Screening,6227520230,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,3,Part 2 Screening,6227520228,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,3,Part 2 Screening,6227520229,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6226780849,"Sep 24, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6226780851,"Sep 24, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6226780848,"Sep 24, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6226780852,"Sep 24, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6226780850,"Sep 24, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6227520231,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6227520233,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,4,Part 2 OL Induction Baseline,6227520232,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,5,Part 2 OL Induction Day 29,6226550654,"Aug 21, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,5,Part 2 OL Induction Day 29,6226561520,"Aug 21, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,5,Part 2 OL Induction Day 29,6227072416,"Oct 20, 2025","Jul 31, 2026",42 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,5,Part 2 OL Induction Day 29,6227072415,"Oct 20, 2025","Jul 31, 2026",42 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,5,Part 2 OL Induction Day 29,6227072418,"Oct 20, 2025","Jul 31, 2026",42 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,5,Part 2 OL Induction Day 29,6227072417,"Oct 20, 2025","Jul 31, 2026",42 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,6,Part 2 DB Baseline,6226313626,"Jul 14, 2025","Apr 17, 2026",-62 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,6,Part 2 DB Baseline,6226550655,"Aug 21, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,6,Part 2 DB Baseline,6226561521,"Aug 21, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,6,Part 2 DB Baseline,6227520234,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,6,Part 2 DB Baseline,6227520235,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,6,Part 2 DB Baseline,6227520236,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,7,Part 2 DB Week 13,6226313627,"Jul 14, 2025","Apr 17, 2026",-62 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,7,Part 2 DB Week 13,6226550656,"Aug 21, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,7,Part 2 DB Week 13,6226561522,"Aug 21, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,7,Part 2 DB Week 13,6226804963,"Sep 25, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6226313628,"Jul 14, 2025","Apr 17, 2026",-62 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6226313629,"Jul 14, 2025","Apr 17, 2026",-62 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6226313630,"Jul 14, 2025","Apr 17, 2026",-62 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6226313631,"Jul 14, 2025","Apr 17, 2026",-62 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6226313632,"Jul 14, 2025","Apr 17, 2026",-62 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6227520237,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6227520239,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6227520240,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6227520241,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-1,Part 2 DB Every 12 Weeks,6227520238,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6225351058,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6225351059,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6225351061,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6225351062,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6225351060,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6226780854,"Sep 24, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6227520244,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-2,End of Phase/Treatment,6227520246,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6225351065,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6225351067,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6225351064,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6225351063,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6227520248,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6227520250,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6227520247,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6227520249,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-3,Early Withdrawal,6227520251,"Dec 26, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-4,Liver Monitoring,6225351068,"Feb 24, 2025","Sep 1, 2025",-290 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,T-5,Suspected Liver Event FU,6225351069,"Feb 24, 2025","Jul 31, 2025",-322 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,U,Retest,6225351071,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,U,Retest,6228023802,"Feb 25, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10008 - Dr.Zdenek Solle,U,Retest,6228023803,"Feb 25, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6225351073,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6225351075,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6225351079,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6227542163,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6227542162,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6228149810,"Mar 13, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6228149812,"Mar 13, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,1,Part 1 Screening,6228149811,"Mar 13, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,2,Part 1 DB Baseline,6225351085,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,2,Part 1 DB Baseline,6225351086,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,2,Part 1 DB Baseline,6227542165,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,2,Part 1 DB Baseline,6227542164,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,2,Part 1 DB Baseline,6227844727,"Feb 1, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,2,Part 1 DB Baseline,6227844726,"Feb 1, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,3,Part 2 Screening,6225351087,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,3,Part 2 Screening,6225351088,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,3,Part 2 Screening,6225351089,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,3,Part 2 Screening,6227542167,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,3,Part 2 Screening,6227542168,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,3,Part 2 Screening,6227542169,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,3,Part 2 Screening,6227542166,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,4,Part 2 OL Induction Baseline,6225351091,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,4,Part 2 OL Induction Baseline,6225351090,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,5,Part 2 OL Induction Day 29,6226935605,"Oct 14, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,5,Part 2 OL Induction Day 29,6228013045,"Feb 26, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,6,Part 2 DB Baseline,6226550647,"Aug 18, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,6,Part 2 DB Baseline,6226561518,"Aug 21, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,6,Part 2 DB Baseline,6226991312,"Oct 26, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,6,Part 2 DB Baseline,6228013046,"Feb 26, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,6,Part 2 DB Baseline,6228114461,"Mar 11, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,6,Part 2 DB Baseline,6228398393,"Apr 15, 2026","Feb 28, 2027",254 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,7,Part 2 DB Week 13,6226550648,"Aug 18, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,7,Part 2 DB Week 13,6226561519,"Aug 21, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,7,Part 2 DB Week 13,6226991313,"Oct 26, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,7,Part 2 DB Week 13,6227261837,"Nov 20, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,7,Part 2 DB Week 13,6227261838,"Nov 20, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,7,Part 2 DB Week 13,6228114462,"Mar 11, 2026","Oct 11, 2026",114 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-1,Part 2 DB Every 12 Weeks,6226550649,"Aug 18, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-1,Part 2 DB Every 12 Weeks,6226550650,"Aug 18, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-1,Part 2 DB Every 12 Weeks,6226550652,"Aug 18, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-1,Part 2 DB Every 12 Weeks,6226550651,"Aug 18, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-1,Part 2 DB Every 12 Weeks,6226550653,"Aug 18, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-2,End of Phase/Treatment,6225351092,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-2,End of Phase/Treatment,6225351096,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-2,End of Phase/Treatment,6227498378,"Dec 22, 2025","Aug 31, 2026",73 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-2,End of Phase/Treatment,6228232036,"Mar 25, 2026","Jan 3, 2027",198 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-2,End of Phase/Treatment,6228232038,"Mar 25, 2026","Jan 3, 2027",198 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-2,End of Phase/Treatment,6228234299,"Mar 30, 2026","Jan 3, 2027",198 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6225351097,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6225351099,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6225351101,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6225351100,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6225351098,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6227542174,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6227542176,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6227542175,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-3,Early Withdrawal,6227542177,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-4,Liver Monitoring,6225351102,"Feb 24, 2025","Sep 1, 2025",-290 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-4,Liver Monitoring,6227542179,"Dec 25, 2025","Sep 12, 2026",85 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-4,Liver Monitoring,6227542178,"Dec 25, 2025","Sep 12, 2026",85 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-5,Suspected Liver Event FU,6225351103,"Feb 24, 2025","Jul 31, 2025",-322 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-5,Suspected Liver Event FU,6227542180,"Dec 25, 2025","Jun 30, 2026",11 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,T-5,Suspected Liver Event FU,6227542181,"Dec 25, 2025","Jun 30, 2026",11 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,U,Retest,6225351104,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,U,Retest,6225351105,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,U,Retest,6227542183,"Dec 25, 2025","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,U,Retest,6228417882,"Apr 15, 2026","Feb 28, 2027",254 +212396,EMEA,CZE,CZ10011 - Dr. Marta Lendlova,U,Retest,6228417883,"Apr 15, 2026","Feb 28, 2027",254 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6225351107,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6225351108,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6225351112,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6225351113,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6225351114,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6225351115,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6227767268,"Jan 27, 2026","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6227775503,"Jan 23, 2026","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,1,Part 1 Screening,6227775504,"Jan 23, 2026","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,2,Part 1 DB Baseline,6225351117,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,2,Part 1 DB Baseline,6225351116,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,2,Part 1 DB Baseline,6225351118,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,2,Part 1 DB Baseline,6225351119,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,2,Part 1 DB Baseline,6227767269,"Jan 27, 2026","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,2,Part 1 DB Baseline,6227767270,"Jan 27, 2026","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,2,Part 1 DB Baseline,6227775506,"Jan 23, 2026","Oct 7, 2026",110 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,3,Part 2 Screening,6225351123,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,3,Part 2 Screening,6225351122,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,3,Part 2 Screening,6225351121,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,3,Part 2 Screening,6228742569,"May 25, 2026","Feb 28, 2027",254 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,3,Part 2 Screening,6228742568,"May 25, 2026","Feb 28, 2027",254 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,4,Part 2 OL Induction Baseline,6225351124,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,4,Part 2 OL Induction Baseline,6225351125,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,6,Part 2 DB Baseline,6226976944,"Oct 26, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,6,Part 2 DB Baseline,6228521304,"Apr 30, 2026","Feb 28, 2027",254 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,7,Part 2 DB Week 13,6226560889,"Aug 20, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,7,Part 2 DB Week 13,6226752556,"Sep 17, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,7,Part 2 DB Week 13,6226976945,"Oct 26, 2025","May 31, 2026",-18 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-1,Part 2 DB Every 12 Weeks,6226560890,"Aug 20, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-1,Part 2 DB Every 12 Weeks,6226560892,"Aug 20, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-1,Part 2 DB Every 12 Weeks,6226560894,"Aug 20, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-1,Part 2 DB Every 12 Weeks,6226560893,"Aug 20, 2025","Jul 1, 2026",12 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-1,Part 2 DB Every 12 Weeks,6228389162,"Apr 15, 2026","Feb 28, 2027",254 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-1,Part 2 DB Every 12 Weeks,6228389161,"Apr 15, 2026","Feb 28, 2027",254 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-2,End of Phase/Treatment,6225351129,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-2,End of Phase/Treatment,6225351128,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-2,End of Phase/Treatment,6225351130,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-2,End of Phase/Treatment,6225351127,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-3,Early Withdrawal,6225351131,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-3,Early Withdrawal,6225351132,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-3,Early Withdrawal,6225351133,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-3,Early Withdrawal,6225351134,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-3,Early Withdrawal,6225351135,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-4,Liver Monitoring,6225351136,"Feb 24, 2025","Sep 1, 2025",-290 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,T-5,Suspected Liver Event FU,6225351137,"Feb 24, 2025","Jul 31, 2025",-322 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,U,Retest,6225351139,"Feb 24, 2025","Dec 1, 2025",-199 +212396,EMEA,CZE,CZ10012 - Dr.Ales Urban,U,Retest,6225351138,"Feb 24, 2025","Dec 1, 2025",-199 +title,value,,,,,,,, +Search,,,,,,,,, +Site,"CZ10011 Dr. Marta Lendlova, CZ10008 Dr.Zdenek Solle, CZ10004 Dr. Erik Herman, CZ10012 Dr.Ales Urban",,,,,,,, +Expiration Date Range,From - To - ,,,,,,,, +Shipped Date Range,From - To - ,,,,,,,, +Kit Type,,,,,,,,, +Ignore Record Limit,TRUE,,,,,,,, diff --git a/Covance/Source/2026-06-18_094416 sponsor-study-35472-samples-allSamples.csv b/Covance/Source/2026-06-18_094416 sponsor-study-35472-samples-allSamples.csv new file mode 100644 index 0000000..04f8caf --- /dev/null +++ b/Covance/Source/2026-06-18_094416 sponsor-study-35472-samples-allSamples.csv @@ -0,0 +1,1215 @@ +Protocol Code,Investigator No.,Investigator Name,Patient No.,Collection Date,Protocol Visit Code,Kit Receipt Date,Container Receipt Date,Accession,Container No.,Container Barcode No.,Specimen Type,Sample Status,Expected Receipt Condition,Actual Receipt Condition,Container Label Line 1,Container Label Line 2,SM Sample Status,SMART Specimen Class Description,Aliquot Created Date,Aliquoted Date,Collection Time,Container Receipt Time,Country,Courier,Kit Receipt Time,Parent Barcode Number,Parent Sample Type,Project,Region,Screening No.,Shipped To Organization Name,Site Waybill No.,Site - Scheduled Shipment Date,Site - Shipment Created Date,Site - Shipment Details Entered Date,SMART Specimen Class,Visit Description,Parent Barcode,Children Barcode +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,,6225350971,1,622535097101,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,09-Aug-2025,6225350971,2,622535097102,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,09-Aug-2025,6225350971,3,622535097103,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,10:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,09-Aug-2025,6225350971,4,622535097104,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,09-Aug-2025,6225350971,5,622535097105,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,09-Aug-2025,6225350971,6,622535097106,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,10:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,,6225350971,7,622535097107,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,12-Aug-2025,6225350971,8,622535097108,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:30,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,,6225350971,9,622535097109,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,08-Aug-2025,P1SCR,09-Aug-2025,09-Aug-2025,6225350971,10,622535097110,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,,6225350972,1,622535097201,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:20,,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,20-Sep-2025,6225350972,3,622535097203,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:20,22:00,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,20-Sep-2025,6225350972,4,622535097204,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:20,22:00,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,20-Sep-2025,6225350972,2,622535097202,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:20,22:00,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,20-Sep-2025,6225350972,5,622535097205,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:20,22:00,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,20-Sep-2025,6225350972,6,622535097206,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:20,22:00,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,,6225350972,7,622535097207,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:20,,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,24-Sep-2025,6225350972,8,622535097208,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:20,07:00,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,,6225350972,9,622535097209,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:20,,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,19-Sep-2025,P1SCR,20-Sep-2025,20-Sep-2025,6225350972,10,622535097210,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:20,22:00,Czech Republic,,22:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,,6225350975,1,622535097501,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,08-Nov-2025,6225350975,2,622535097502,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,08-Nov-2025,6225350975,3,622535097503,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,08:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,08-Nov-2025,6225350975,5,622535097505,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,08-Nov-2025,6225350975,6,622535097506,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,08:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,08-Nov-2025,6225350975,4,622535097504,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,,6225350975,7,622535097507,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,12-Nov-2025,6225350975,8,622535097508,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:10,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,,6225350975,9,622535097509,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,07-Nov-2025,P1SCR,08-Nov-2025,08-Nov-2025,6225350975,10,622535097510,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,,6225350977,1,622535097701,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,11-Oct-2025,6225350977,2,622535097702,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,11-Oct-2025,6225350977,3,622535097703,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,11-Oct-2025,6225350977,4,622535097704,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,11-Oct-2025,6225350977,5,622535097705,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,11-Oct-2025,6225350977,6,622535097706,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,,6225350977,7,622535097707,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,15-Oct-2025,6225350977,8,622535097708,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:20,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,,6225350977,9,622535097709,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,10-Oct-2025,P1SCR,11-Oct-2025,11-Oct-2025,6225350977,10,622535097710,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,05-Sep-2025,P1DBBL,06-Sep-2025,06-Sep-2025,6225350981,1,622535098101,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,05-Sep-2025,P1DBBL,06-Sep-2025,,6225350981,2,622535098102,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,07:55,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,05-Sep-2025,P1DBBL,06-Sep-2025,09-Sep-2025,6225350981,3,622535098103,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,07:55,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,05-Sep-2025,P1DBBL,06-Sep-2025,,6225350981,4,622535098104,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,07:55,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,05-Sep-2025,P1DBBL,06-Sep-2025,06-Sep-2025,6225350981,5,622535098105,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,05-Sep-2025,P1DBBL,06-Sep-2025,06-Sep-2025,6225350981,6,622535098106,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,07-Nov-2025,P1DBBL,08-Nov-2025,,6225350982,2,622535098202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,07-Nov-2025,P1DBBL,08-Nov-2025,12-Nov-2025,6225350982,3,622535098203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:30,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,07-Nov-2025,P1DBBL,08-Nov-2025,08-Nov-2025,6225350982,1,622535098201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,05-Sep-2025,P1DBBL,06-Sep-2025,06-Sep-2025,6225350981,7,622535098107,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,07-Nov-2025,P1DBBL,08-Nov-2025,,6225350982,4,622535098204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,07-Nov-2025,P1DBBL,08-Nov-2025,08-Nov-2025,6225350982,5,622535098205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,07-Nov-2025,P1DBBL,08-Nov-2025,08-Nov-2025,6225350982,6,622535098206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,07-Nov-2025,P1DBBL,08-Nov-2025,08-Nov-2025,6225350982,7,622535098207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,17-Oct-2025,P1DBBL,18-Oct-2025,18-Oct-2025,6225350984,1,622535098401,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:45,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,17-Oct-2025,P1DBBL,18-Oct-2025,,6225350984,2,622535098402,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:45,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,17-Oct-2025,P1DBBL,18-Oct-2025,22-Oct-2025,6225350984,3,622535098403,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:45,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,17-Oct-2025,P1DBBL,18-Oct-2025,,6225350984,4,622535098404,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:45,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,17-Oct-2025,P1DBBL,18-Oct-2025,18-Oct-2025,6225350984,5,622535098405,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:45,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,17-Oct-2025,P1DBBL,18-Oct-2025,18-Oct-2025,6225350984,6,622535098406,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:45,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,17-Oct-2025,P1DBBL,18-Oct-2025,18-Oct-2025,6225350984,7,622535098407,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:45,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,18-Oct-2025,6225350988,5,622535098805,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,18-Oct-2025,6225350988,6,622535098806,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,18-Oct-2025,6225350988,7,622535098807,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,,6225350988,8,622535098808,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,18-Oct-2025,6225350988,1,622535098801,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,18-Oct-2025,6225350988,9,622535098809,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,,6225350988,2,622535098802,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,22-Oct-2025,6225350988,3,622535098803,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:00,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,17-Oct-2025,P2OLBL,18-Oct-2025,,6225350988,4,622535098804,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,1,622535100201,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,2,622535100202,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,3,622535100203,"Urine, Cargile Preservative UA",Not Received,Ambient,,URINALYSIS,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,4,622535100204,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,5,622535100205,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,21-Aug-2025,6225351002,6,622535100206,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,7,622535100207,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,8,622535100208,"Serum, SST",Not Received,Ambient,,TSH,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,9,622535100209,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,19-Aug-2025,P1SCR,21-Aug-2025,,6225351002,10,622535100210,"Serum, SST",Not Received,Ambient,,CHEMISTRY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,,6225351004,1,622535100401,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:08,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351004,2,622535100402,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351004,3,622535100403,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,12:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351004,4,622535100404,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351004,5,622535100405,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351004,6,622535100406,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,12:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,,6225351004,7,622535100407,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:08,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351004,8,622535100408,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,,6225351004,9,622535100409,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:08,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351004,10,622535100410,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,12:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,10-Sep-2025,6225351006,2,622535100602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,,6225351006,1,622535100601,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,10-Sep-2025,6225351006,3,622535100603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,10-Sep-2025,6225351006,4,622535100604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,10-Sep-2025,6225351006,5,622535100605,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,10-Sep-2025,6225351006,6,622535100606,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,,6225351006,7,622535100607,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,10-Sep-2025,6225351006,8,622535100608,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,,6225351006,9,622535100609,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,09-Sep-2025,P1SCR,10-Sep-2025,10-Sep-2025,6225351006,10,622535100610,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351036,1,622535103601,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,3,622535103603,"Urine, Cargile Preservative UA",Not Received,Ambient,,URINALYSIS,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,4,622535103604,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,2,622535103602,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,5,622535103605,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,7,622535103607,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,8,622535103608,"Serum, SST",Not Received,Ambient,,TSH,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,6,622535103606,"Plasma, EDTA",Not Received,Frozen,,INSULIN,FROZEN,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,2,622535103702,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,,6225351036,9,622535103609,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,3,622535103703,"Urine, Cargile Preservative UA",Not Received,Ambient,,URINALYSIS,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050001,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351036,10,622535103610,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,12-Nov-2025,6225351037,1,622535103701,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,6,622535103706,"Plasma, EDTA",Not Received,Frozen,,INSULIN,FROZEN,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,9,622535103709,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,8,622535103708,"Serum, SST",Not Received,Ambient,,TSH,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,12-Nov-2025,6225351037,10,622535103710,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,7,622535103707,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,4,622535103704,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10005,Dr.Lubos Janu,CZ100050002,11-Nov-2025,P1SCR,12-Nov-2025,,6225351037,5,622535103705,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351040,2,622535104002,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,,6225351040,1,622535104001,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351040,5,622535104005,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351040,4,622535104004,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351040,6,622535104006,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351040,8,622535104008,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,,6225351040,9,622535104009,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351040,3,622535104003,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,,6225351040,7,622535104007,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351041,3,622535104103,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:43,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351041,5,622535104105,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:43,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351041,6,622535104106,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:43,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351041,4,622535104104,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:43,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,,6225351041,7,622535104107,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:43,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351041,8,622535104108,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:43,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,,6225351041,1,622535104101,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:43,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,16-Sep-2025,P1SCR,17-Sep-2025,17-Sep-2025,6225351040,10,622535104010,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351041,2,622535104102,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:43,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,,6225351041,9,622535104109,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:43,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080003,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351041,10,622535104110,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:43,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,,6225351042,1,622535104201,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:08,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,27-Aug-2025,6225351042,4,622535104204,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,27-Aug-2025,6225351042,3,622535104203,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,27-Aug-2025,6225351042,5,622535104205,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,27-Aug-2025,6225351042,6,622535104206,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,27-Aug-2025,6225351042,2,622535104202,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,27-Aug-2025,6225351042,10,622535104210,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,28-Aug-2025,6225351042,8,622535104208,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:08,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,,6225351042,9,622535104209,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:08,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,26-Aug-2025,P1SCR,27-Aug-2025,,6225351042,7,622535104207,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:08,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,,6225351044,1,622535104401,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:20,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,11-Dec-2025,6225351044,2,622535104402,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:20,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,11-Dec-2025,6225351044,3,622535104403,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,10:20,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,11-Dec-2025,6225351044,4,622535104404,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:20,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,11-Dec-2025,6225351044,5,622535104405,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:20,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,11-Dec-2025,6225351044,6,622535104406,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,10:20,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,,6225351044,7,622535104407,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:20,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,,6225351044,9,622535104409,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:20,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,11-Dec-2025,6225351044,10,622535104410,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:20,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,,6225351045,1,622535104501,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:58,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351045,2,622535104502,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351045,3,622535104503,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,10-Dec-2025,P1SCR,11-Dec-2025,11-Dec-2025,6225351044,8,622535104408,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:20,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351045,4,622535104504,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351045,5,622535104505,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,,6225351045,7,622535104507,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:58,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351045,8,622535104508,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351045,6,622535104506,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,,6225351045,9,622535104509,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:58,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,05-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351045,10,622535104510,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,,6225351046,1,622535104601,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,13:31,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,11-Sep-2025,6225351046,3,622535104603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,13:31,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,11-Sep-2025,6225351046,4,622535104604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:31,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,11-Sep-2025,6225351046,5,622535104605,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,13:31,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,11-Sep-2025,6225351046,6,622535104606,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,13:31,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,11-Sep-2025,6225351046,8,622535104608,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,13:31,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,11-Sep-2025,6225351046,2,622535104602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,13:31,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,,6225351046,9,622535104609,"Red Cells, Clot",Not Received,,,TSH,,,,,,13:31,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,11-Sep-2025,6225351046,10,622535104610,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,13:31,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,10-Sep-2025,P1SCR,11-Sep-2025,,6225351046,7,622535104607,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,13:31,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,03-Jul-2025,6225351047,2,622535104702,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:12,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,03-Jul-2025,6225351047,3,622535104703,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:12,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,03-Jul-2025,6225351047,4,622535104704,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:12,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,03-Jul-2025,6225351047,5,622535104705,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:12,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,03-Jul-2025,6225351047,6,622535104706,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:12,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,03-Jul-2025,6225351047,8,622535104708,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:12,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,,6225351047,1,622535104701,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:12,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,,6225351047,7,622535104707,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:12,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,,6225351047,9,622535104709,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:12,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,02-Jul-2025,P1SCR,03-Jul-2025,03-Jul-2025,6225351047,10,622535104710,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:12,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,30-Jul-2025,P1DBBL,31-Jul-2025,31-Jul-2025,6225351049,1,622535104901,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:55,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,30-Jul-2025,P1DBBL,31-Jul-2025,,6225351049,2,622535104902,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:55,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,30-Jul-2025,P1DBBL,31-Jul-2025,31-Jul-2025,6225351049,3,622535104903,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:55,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,30-Jul-2025,P1DBBL,31-Jul-2025,,6225351049,4,622535104904,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:55,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,30-Jul-2025,P1DBBL,31-Jul-2025,31-Jul-2025,6225351049,5,622535104905,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:55,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,30-Jul-2025,P1DBBL,31-Jul-2025,31-Jul-2025,6225351049,6,622535104906,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:55,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,30-Jul-2025,P1DBBL,31-Jul-2025,31-Jul-2025,6225351049,7,622535104907,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:55,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,08-Oct-2025,P1DBBL,09-Oct-2025,09-Oct-2025,6225351050,1,622535105001,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:19,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,08-Oct-2025,P1DBBL,09-Oct-2025,,6225351050,2,622535105002,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:19,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,08-Oct-2025,P1DBBL,09-Oct-2025,,6225351050,4,622535105004,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:19,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,08-Oct-2025,P1DBBL,09-Oct-2025,09-Oct-2025,6225351050,5,622535105005,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:19,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,08-Oct-2025,P1DBBL,09-Oct-2025,09-Oct-2025,6225351050,6,622535105006,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:19,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,08-Oct-2025,P1DBBL,09-Oct-2025,09-Oct-2025,6225351050,3,622535105003,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:19,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,26-Aug-2025,P1DBBL,27-Aug-2025,27-Aug-2025,6225351051,1,622535105101,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:47,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,26-Aug-2025,P1DBBL,27-Aug-2025,,6225351051,2,622535105102,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:47,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,26-Aug-2025,P1DBBL,27-Aug-2025,28-Aug-2025,6225351051,3,622535105103,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:47,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,08-Oct-2025,P1DBBL,09-Oct-2025,09-Oct-2025,6225351050,7,622535105007,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:19,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,26-Aug-2025,P1DBBL,27-Aug-2025,,6225351051,4,622535105104,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:47,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,26-Aug-2025,P1DBBL,27-Aug-2025,27-Aug-2025,6225351051,6,622535105106,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,12:47,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,26-Aug-2025,P1DBBL,27-Aug-2025,27-Aug-2025,6225351051,5,622535105105,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:47,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,26-Aug-2025,P1DBBL,27-Aug-2025,27-Aug-2025,6225351051,7,622535105107,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:47,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,16-Sep-2025,P1DBBL,17-Sep-2025,17-Sep-2025,6225351052,3,622535105203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,16-Sep-2025,P1DBBL,17-Sep-2025,17-Sep-2025,6225351052,5,622535105205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,16-Sep-2025,P1DBBL,17-Sep-2025,17-Sep-2025,6225351052,6,622535105206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,12:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,16-Sep-2025,P1DBBL,17-Sep-2025,,6225351052,2,622535105202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,16-Sep-2025,P1DBBL,17-Sep-2025,,6225351052,4,622535105204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,16-Sep-2025,P1DBBL,17-Sep-2025,17-Sep-2025,6225351052,1,622535105201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,16-Sep-2025,P1DBBL,17-Sep-2025,17-Sep-2025,6225351052,7,622535105207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,11-Sep-2025,6225351056,1,622535105601,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,,6225351056,2,622535105602,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,11-Sep-2025,6225351056,3,622535105603,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,,6225351056,4,622535105604,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,11-Sep-2025,6225351056,5,622535105605,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,11-Sep-2025,6225351056,6,622535105606,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,11-Sep-2025,6225351056,7,622535105607,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,,6225351056,8,622535105608,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,10-Sep-2025,P2OLBL,11-Sep-2025,11-Sep-2025,6225351056,9,622535105609,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,08-Oct-2025,6225351057,1,622535105701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:02,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,,6225351057,2,622535105702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:02,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,08-Oct-2025,6225351057,3,622535105703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:02,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,,6225351057,4,622535105704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:02,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,08-Oct-2025,6225351057,5,622535105705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:02,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,08-Oct-2025,6225351057,6,622535105706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,12:02,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,08-Oct-2025,6225351057,7,622535105707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:02,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,,6225351057,8,622535105708,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:02,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Oct-2025,P2OLBL,08-Oct-2025,08-Oct-2025,6225351057,9,622535105709,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,12:02,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,15-Oct-2025,6225351066,1,622535106601,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,15-Oct-2025,6225351066,3,622535106603,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,,6225351066,4,622535106604,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,15-Oct-2025,6225351066,7,622535106607,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,,6225351066,8,622535106608,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,15-Oct-2025,6225351066,9,622535106609,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,12:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,,6225351066,6,622535106606,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,15-Oct-2025,6225351066,5,622535106605,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,14-Oct-2025,EW,15-Oct-2025,15-Oct-2025,6225351066,2,622535106602,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Early Withdrawal,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,3,622535107003,"Urine, Cargile Preservative UA",Not Received,Ambient,,URINALYSIS,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,09-Sep-2025,6225351070,4,622535107004,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,10:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,2,622535107002,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,5,622535107005,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,6,622535107006,"Plasma, EDTA",Not Received,Frozen,,INSULIN,FROZEN,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,1,622535107001,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,9,622535107009,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,8,622535107008,"Serum, SST",Not Received,Ambient,,TSH,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,7,622535107007,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080004,08-Sep-2025,P1SCR,09-Sep-2025,,6225351070,10,622535107010,"Serum, SST",Not Received,Ambient,,CHEMISTRY,,,,,,10:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351072,2,622535107202,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351072,3,622535107203,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351072,4,622535107204,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351072,5,622535107205,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351072,6,622535107206,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,,6225351072,7,622535107207,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:40,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,,6225351072,1,622535107201,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:40,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351072,10,622535107210,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,,6225351072,9,622535107209,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:40,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351072,8,622535107208,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351074,2,622535107402,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351074,3,622535107403,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351074,4,622535107404,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,,6225351074,1,622535107401,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:40,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,,6225351074,7,622535107407,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:40,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351074,10,622535107410,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,,6225351074,9,622535107409,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:40,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351074,6,622535107406,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351074,5,622535107405,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351076,2,622535107602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,,6225351076,1,622535107601,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110005,03-Nov-2025,P1SCR,04-Nov-2025,04-Nov-2025,6225351074,8,622535107408,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:40,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351076,3,622535107603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351076,5,622535107605,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351076,6,622535107606,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351076,4,622535107604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,,6225351076,7,622535107607,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,,6225351076,9,622535107609,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,06-Aug-2025,6225351076,10,622535107610,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,03-Aug-2025,P1SCR,06-Aug-2025,07-Aug-2025,6225351076,8,622535107608,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,04-Oct-2025,6225351077,3,622535107703,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:33,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,,6225351077,1,622535107701,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:33,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,04-Oct-2025,6225351077,4,622535107704,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:33,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,04-Oct-2025,6225351077,5,622535107705,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:33,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,04-Oct-2025,6225351077,6,622535107706,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:33,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,,6225351077,7,622535107707,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:33,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,04-Oct-2025,6225351077,8,622535107708,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:33,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,,6225351077,9,622535107709,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:33,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,04-Oct-2025,6225351077,10,622535107710,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:33,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110004,03-Oct-2025,P1SCR,04-Oct-2025,04-Oct-2025,6225351077,2,622535107702,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:33,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,15-Nov-2025,6225351078,5,622535107805,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,15-Nov-2025,6225351078,6,622535107806,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,10:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,,6225351078,7,622535107807,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:22,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,15-Nov-2025,6225351078,8,622535107808,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,,6225351078,9,622535107809,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:22,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,15-Nov-2025,6225351078,4,622535107804,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,15-Nov-2025,6225351078,3,622535107803,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,10:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,15-Nov-2025,6225351078,2,622535107802,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,,6225351078,1,622535107801,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:22,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,14-Nov-2025,P1SCR,15-Nov-2025,15-Nov-2025,6225351078,10,622535107810,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,,6225351080,1,622535108001,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,07:03,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,05-Nov-2025,6225351080,2,622535108002,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,07:03,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,,6225351080,7,622535108007,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,07:03,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,06-Nov-2025,6225351080,8,622535108008,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,07:03,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,,6225351080,9,622535108009,"Red Cells, Clot",Not Received,,,TSH,,,,,,07:03,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,05-Nov-2025,6225351080,3,622535108003,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,07:03,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,05-Nov-2025,6225351080,10,622535108010,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,07:03,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,,6225351081,1,622535108101,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,27-Sep-2025,6225351081,3,622535108103,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,05-Nov-2025,6225351080,4,622535108004,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:03,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,27-Sep-2025,6225351081,4,622535108104,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,27-Sep-2025,6225351081,2,622535108102,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,27-Sep-2025,6225351081,5,622535108105,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,05-Nov-2025,6225351080,5,622535108005,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,07:03,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,04-Nov-2025,P1SCR,05-Nov-2025,05-Nov-2025,6225351080,6,622535108006,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,07:03,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,27-Sep-2025,6225351081,8,622535108108,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,27-Sep-2025,6225351081,10,622535108110,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,,6225351081,9,622535108109,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,28-Aug-2025,P1DBBL,29-Aug-2025,,6225351082,2,622535108202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,,6225351081,7,622535108107,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351082,3,622535108203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,28-Aug-2025,P1DBBL,29-Aug-2025,,6225351082,4,622535108204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,26-Sep-2025,P1SCR,27-Sep-2025,27-Sep-2025,6225351081,6,622535108106,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351082,5,622535108205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351082,6,622535108206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351083,1,622535108301,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,07:07,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,28-Aug-2025,P1DBBL,29-Aug-2025,,6225351083,2,622535108302,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,07:07,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351083,3,622535108303,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,07:07,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,28-Aug-2025,P1DBBL,29-Aug-2025,,6225351083,4,622535108304,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,07:07,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351083,5,622535108305,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,07:07,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351082,1,622535108201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351083,6,622535108306,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,07:07,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351082,7,622535108207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,28-Aug-2025,P1DBBL,29-Aug-2025,29-Aug-2025,6225351083,7,622535108307,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:07,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351084,1,622535108401,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,22-Oct-2025,P1DBBL,23-Oct-2025,,6225351084,4,622535108404,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351084,3,622535108403,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351084,5,622535108405,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,22-Oct-2025,P1DBBL,23-Oct-2025,,6225351084,2,622535108402,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351084,7,622535108407,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351084,6,622535108406,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,08:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351093,2,622535109302,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:23,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351093,1,622535109301,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:23,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351093,3,622535109303,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:23,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351093,5,622535109305,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:23,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,,6225351093,4,622535109304,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:23,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,,6225351093,6,622535109306,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:23,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351093,7,622535109307,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:23,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,,6225351093,8,622535109308,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:23,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351093,9,622535109309,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:23,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,09-Oct-2025,6225351094,1,622535109401,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,09-Oct-2025,6225351094,3,622535109403,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,09-Oct-2025,6225351094,2,622535109402,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,,6225351094,4,622535109404,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,09-Oct-2025,6225351094,5,622535109405,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,,6225351094,6,622535109406,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,09-Oct-2025,6225351094,7,622535109407,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,,6225351094,8,622535109408,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,10-Oct-2025,6225351095,1,622535109501,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,10-Oct-2025,6225351095,2,622535109502,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,10-Oct-2025,6225351095,3,622535109503,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,10-Oct-2025,6225351095,5,622535109505,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,10-Oct-2025,6225351095,7,622535109507,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,,6225351095,8,622535109508,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,,6225351095,4,622535109504,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,,6225351095,6,622535109506,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110001,08-Oct-2025,EOT,09-Oct-2025,09-Oct-2025,6225351094,9,622535109409,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,09-Oct-2025,EOT,10-Oct-2025,10-Oct-2025,6225351095,9,622535109509,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,,6225351106,1,622535110601,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,13:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351106,2,622535110602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,13:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351106,4,622535110604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351106,5,622535110605,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,13:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351106,3,622535110603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,13:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351106,6,622535110606,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,13:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,,6225351106,7,622535110607,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,13:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,08-Aug-2025,6225351106,8,622535110608,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,13:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,,6225351106,9,622535110609,"Red Cells, Clot",Not Received,,,TSH,,,,,,13:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120001,06-Aug-2025,P1SCR,07-Aug-2025,07-Aug-2025,6225351106,10,622535110610,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,13:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,,6225351109,1,622535110901,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,13:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,04-Sep-2025,6225351109,4,622535110904,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,04-Sep-2025,6225351109,5,622535110905,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,04-Sep-2025,6225351109,6,622535110906,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,,6225351109,7,622535110907,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,13:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,05-Sep-2025,6225351109,8,622535110908,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,04-Sep-2025,6225351109,2,622535110902,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,,6225351109,9,622535110909,"Red Cells, Clot",Not Received,,,TSH,,,,,,13:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,04-Sep-2025,6225351109,10,622535110910,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,,6225351110,1,622535111001,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351110,2,622535111002,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351110,3,622535111003,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351110,4,622535111004,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351110,5,622535111005,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351110,6,622535111006,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,,6225351110,7,622535111007,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120002,03-Sep-2025,P1SCR,04-Sep-2025,04-Sep-2025,6225351109,3,622535110903,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,,6225351110,9,622535111009,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,03-Oct-2025,6225351110,8,622535111008,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120003,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351110,10,622535111010,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,,6225351111,1,622535111101,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,13:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351111,2,622535111102,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351111,3,622535111103,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351111,4,622535111104,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351111,5,622535111105,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351111,6,622535111106,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,03-Oct-2025,6225351111,8,622535111108,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,,6225351111,9,622535111109,"Red Cells, Clot",Not Received,,,TSH,,,,,,13:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,,6225351111,7,622535111107,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,13:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,01-Oct-2025,P1SCR,02-Oct-2025,02-Oct-2025,6225351111,10,622535111110,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,13:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351120,1,622535112001,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,22-Oct-2025,P1DBBL,23-Oct-2025,,6225351120,2,622535112002,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,22-Oct-2025,P1DBBL,23-Oct-2025,24-Oct-2025,6225351120,3,622535112003,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,22-Oct-2025,P1DBBL,23-Oct-2025,,6225351120,4,622535112004,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351120,5,622535112005,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351120,6,622535112006,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,12:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,22-Oct-2025,P1DBBL,23-Oct-2025,23-Oct-2025,6225351120,7,622535112007,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351126,2,622535112602,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,15:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351126,1,622535112601,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,15:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351126,3,622535112603,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,15:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,,6225351126,4,622535112604,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,15:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,10-Dec-2025,6225351126,5,622535112605,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,15:00,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,,6225351126,6,622535112606,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,15:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,,6225351126,8,622535112608,"Red Cells, Clot",Not Received,,,TSH,,,,,,15:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351126,7,622535112607,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,15:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,05-Dec-2025,EOT,06-Dec-2025,06-Dec-2025,6225351126,9,622535112609,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,15:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,,6226313625,2,622631362502,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,02-Apr-2026,6226313625,1,622631362501,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,02-Apr-2026,6226313625,3,622631362503,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,02-Apr-2026,6226313625,5,622631362505,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,,6226313625,4,622631362504,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,02-Apr-2026,6226313625,6,622631362506,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,02-Apr-2026,6226313625,7,622631362507,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Feb-2026,P2OLD29,17-Feb-2026,,6226550646,2,622655064602,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:18,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Feb-2026,P2OLD29,17-Feb-2026,17-Feb-2026,6226550646,1,622655064601,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Feb-2026,P2OLD29,17-Feb-2026,17-Feb-2026,6226550646,7,622655064607,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Feb-2026,P2OLD29,17-Feb-2026,17-Feb-2026,6226550646,5,622655064605,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Feb-2026,P2OLD29,17-Feb-2026,,6226550646,4,622655064604,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:18,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Feb-2026,P2OLD29,17-Feb-2026,17-Feb-2026,6226550646,6,622655064606,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Feb-2026,P2OLD29,17-Feb-2026,17-Feb-2026,6226550646,3,622655064603,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,21-Jan-2026,P1DBBL,22-Jan-2026,,6226551697,4,622655169704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:23,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,21-Jan-2026,P1DBBL,22-Jan-2026,22-Jan-2026,6226551697,5,622655169705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,21-Jan-2026,P1DBBL,22-Jan-2026,22-Jan-2026,6226551697,1,622655169701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,21-Jan-2026,P1DBBL,22-Jan-2026,22-Jan-2026,6226551697,6,622655169706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,21-Jan-2026,P1DBBL,22-Jan-2026,22-Jan-2026,6226551697,7,622655169707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,29-Oct-2025,P1DBBL,30-Oct-2025,30-Oct-2025,6226551698,1,622655169801,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,21-Jan-2026,P1DBBL,22-Jan-2026,22-Jan-2026,6226551697,3,622655169703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,29-Oct-2025,P1DBBL,30-Oct-2025,,6226551698,4,622655169804,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,21-Jan-2026,P1DBBL,22-Jan-2026,,6226551697,2,622655169702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:23,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,29-Oct-2025,P1DBBL,30-Oct-2025,,6226551698,2,622655169802,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,29-Oct-2025,P1DBBL,30-Oct-2025,30-Oct-2025,6226551698,6,622655169806,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,29-Oct-2025,P1DBBL,30-Oct-2025,30-Oct-2025,6226551698,3,622655169803,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,29-Oct-2025,P1DBBL,30-Oct-2025,30-Oct-2025,6226551698,5,622655169805,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,29-Oct-2025,P1DBBL,30-Oct-2025,30-Oct-2025,6226551698,7,622655169807,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,,6226560887,4,622656088704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,16:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,20-May-2026,6226560887,3,622656088703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,16:00,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,,6226560887,2,622656088702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,16:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,25-Apr-2026,6226560887,1,622656088701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,16:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,25-Apr-2026,6226560887,5,622656088705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,16:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,25-Apr-2026,6226560887,6,622656088706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,16:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226560888,1,622656088801,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,17:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,25-Apr-2026,6226560887,7,622656088707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,16:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226560888,3,622656088803,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,17:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226560888,7,622656088807,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,17:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226560888,9,622656088809,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,17:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,20-May-2026,6226560888,5,622656088805,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,17:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,,6226560888,4,622656088804,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,17:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,,6226560888,8,622656088808,"Red Cells, Clot",Not Received,,,TSH,,,,,,17:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226560888,2,622656088802,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,17:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,,6226560888,6,622656088806,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,17:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,07-Mar-2026,6226560891,2,622656089102,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,14:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,07-Mar-2026,6226560891,3,622656089103,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,14:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,07-Mar-2026,6226560891,1,622656089101,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,14:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,,6226560891,4,622656089104,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,14:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,,6226560891,6,622656089106,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,14:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,,6226560891,8,622656089108,"Red Cells, Clot",Not Received,,,TSH,,,,,,14:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,20-May-2026,6226560891,5,622656089105,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,14:00,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,07-Mar-2026,6226560891,7,622656089107,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,14:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,06-Mar-2026,P2DBW25,07-Mar-2026,07-Mar-2026,6226560891,9,622656089109,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,14:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Every 12 Weeks,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,03-Feb-2026,P2OLD29,04-Feb-2026,17-Feb-2026,6226561517,3,622656151703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,03-Feb-2026,P2OLD29,04-Feb-2026,,6226561517,4,622656151704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:23,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,03-Feb-2026,P2OLD29,04-Feb-2026,04-Feb-2026,6226561517,5,622656151705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,03-Feb-2026,P2OLD29,04-Feb-2026,,6226561517,2,622656151702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:23,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,03-Feb-2026,P2OLD29,04-Feb-2026,04-Feb-2026,6226561517,1,622656151701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,03-Feb-2026,P2OLD29,04-Feb-2026,04-Feb-2026,6226561517,6,622656151706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,03-Feb-2026,P2OLD29,04-Feb-2026,04-Feb-2026,6226561517,7,622656151707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:23,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226573502,1,622657350201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:15,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,,6226573502,2,622657350202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:15,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,10-Jun-2026,6226573502,3,622657350203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:15,07:00,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226573502,5,622657350205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:15,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,,6226573502,4,622657350204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:15,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226573502,6,622657350206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:15,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226573502,7,622657350207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:15,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,30-May-2026,6226649754,1,622664975401,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,,6226649754,2,622664975402,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,,6226649754,4,622664975404,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,03-Jun-2026,6226649754,3,622664975403,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:30,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,30-May-2026,6226649754,5,622664975405,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,30-May-2026,6226649754,6,622664975406,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,30-May-2026,6226649754,7,622664975407,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:30,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,08-Oct-2025,P2OLD29,09-Oct-2025,09-Oct-2025,6226686952,1,622668695201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,08-Oct-2025,P2OLD29,09-Oct-2025,,6226686952,2,622668695202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:20,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,08-Oct-2025,P2OLD29,09-Oct-2025,09-Oct-2025,6226686952,3,622668695203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,08-Oct-2025,P2OLD29,09-Oct-2025,,6226686952,4,622668695204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:20,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,08-Oct-2025,P2OLD29,09-Oct-2025,09-Oct-2025,6226686952,5,622668695205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,08-Oct-2025,P2OLD29,09-Oct-2025,09-Oct-2025,6226686952,6,622668695206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,08-Oct-2025,P2OLD29,09-Oct-2025,09-Oct-2025,6226686952,7,622668695207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,14-Jan-2026,6226686953,1,622668695301,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,14-Jan-2026,6226686953,2,622668695302,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,14-Jan-2026,6226686953,3,622668695303,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,,6226686953,4,622668695304,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,13:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,14-Jan-2026,6226686953,5,622668695305,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,,6226686953,6,622668695306,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,13:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6226686954,7,622668695407,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:01,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,,6226686953,8,622668695308,"Red Cells, Clot",Not Received,,,TSH,,,,,,13:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,14-Jan-2026,6226686953,9,622668695309,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,13-Jan-2026,P2DBBL,14-Jan-2026,14-Jan-2026,6226686953,7,622668695307,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6226686954,1,622668695401,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:01,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6226686954,3,622668695403,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:01,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,,6226686954,4,622668695404,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:01,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6226686954,5,622668695405,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:01,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6226686954,6,622668695406,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,12:01,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,,6226686954,2,622668695402,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:01,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,23-Apr-2026,6226752554,6,622675255406,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,15:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226752555,2,622675255502,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,15:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,23-Apr-2026,6226752554,5,622675255405,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,15:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226752555,3,622675255503,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,15:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,,6226752554,4,622675255404,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,15:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,23-Apr-2026,6226752554,7,622675255407,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,15:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,,6226752555,4,622675255504,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,15:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,20-May-2026,6226752555,5,622675255505,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,15:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,,6226752554,2,622675255402,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,15:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,23-Apr-2026,6226752554,3,622675255403,"Plasma, EDTA",Received,Frozen,Default Return Ambient,INSULIN,FROZEN,,,,,15:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,23-Apr-2026,6226752554,1,622675255401,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,15:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226752555,1,622675255501,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,15:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226752555,7,622675255507,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,15:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,,6226752555,8,622675255508,"Red Cells, Clot",Not Received,,,TSH,,,,,,15:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,26-Mar-2026,6226752555,9,622675255509,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,15:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,,6226752555,6,622675255506,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,15:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,06-Nov-2025,6226780853,1,622678085301,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,06-Nov-2025,6226780853,5,622678085305,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,06-Nov-2025,6226780853,2,622678085302,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,06-Nov-2025,6226780853,3,622678085303,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,,6226780853,4,622678085304,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,,6226780853,8,622678085308,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,06-Nov-2025,6226780853,9,622678085309,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,,6226780853,6,622678085306,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080001,05-Nov-2025,EOT,06-Nov-2025,06-Nov-2025,6226780853,7,622678085307,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,10-Dec-2025,6226780855,1,622678085501,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,10-Dec-2025,6226780855,2,622678085502,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,,6226780855,4,622678085504,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,10-Dec-2025,6226780855,5,622678085505,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,,6226780855,6,622678085506,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,10-Dec-2025,6226780855,7,622678085507,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,,6226780855,8,622678085508,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,10-Dec-2025,6226780855,9,622678085509,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,09-Dec-2025,EOT,10-Dec-2025,10-Dec-2025,6226780855,3,622678085503,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,19-Nov-2025,6226780856,1,622678085601,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:06,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,19-Nov-2025,6226780856,2,622678085602,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:06,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,19-Nov-2025,6226780856,3,622678085603,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:06,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,,6226780856,4,622678085604,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:06,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,,6226780856,6,622678085606,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:06,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,19-Nov-2025,6226780856,7,622678085607,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:06,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,,6226780856,8,622678085608,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:06,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,19-Nov-2025,6226780856,9,622678085609,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:06,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,15-Jan-2026,6226780857,3,622678085703,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,,6226780857,6,622678085706,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:18,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,15-Jan-2026,6226780857,5,622678085705,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,15-Jan-2026,6226780857,7,622678085707,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,,6226780857,8,622678085708,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:18,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,15-Jan-2026,6226780857,9,622678085709,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,15-Jan-2026,6226780857,1,622678085701,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,,6226780857,4,622678085704,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:18,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,14-Jan-2026,EOT,15-Jan-2026,15-Jan-2026,6226780857,2,622678085702,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:18,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,18-Nov-2025,EOT,19-Nov-2025,19-Nov-2025,6226780856,5,622678085605,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:06,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,3,622678573903,"Urine, Cargile Preservative UA",Not Received,Ambient,,URINALYSIS,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,2,622678573902,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,4,622678573904,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,7,622678573907,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,9,622678573909,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,5,622678573905,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,6,622678573906,"Plasma, EDTA",Not Received,Frozen,,INSULIN,FROZEN,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,8,622678573908,"Serum, SST",Not Received,Ambient,,TSH,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,,6226785739,1,622678573901,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,10:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,18-Feb-2026,P1DBBL,19-Feb-2026,19-Feb-2026,6226785739,10,622678573910,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,1,622678574001,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,7,622678574007,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,5,622678574005,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,16-Dec-2025,6226785740,8,622678574008,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:53,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,2,622678574002,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,6,622678574006,"Plasma, EDTA",Not Received,Frozen,,INSULIN,FROZEN,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,3,622678574003,"Urine, Cargile Preservative UA",Not Received,Ambient,,URINALYSIS,,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,4,622678574004,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,,6226785740,9,622678574009,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:53,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,15-Dec-2025,P1SCR,16-Dec-2025,16-Dec-2025,6226785740,10,622678574010,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:53,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,04-Nov-2025,P2OLD29,05-Nov-2025,,6226804961,2,622680496102,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,04-Nov-2025,P2OLD29,05-Nov-2025,,6226804961,4,622680496104,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,04-Nov-2025,P2OLD29,05-Nov-2025,05-Nov-2025,6226804961,3,622680496103,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,11-Mar-2026,6226804962,5,622680496205,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,11-Mar-2026,6226804962,7,622680496207,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,11-Mar-2026,6226804962,9,622680496209,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,04-Nov-2025,P2OLD29,05-Nov-2025,05-Nov-2025,6226804961,6,622680496106,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,12:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,04-Nov-2025,P2OLD29,05-Nov-2025,05-Nov-2025,6226804961,5,622680496105,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,11-Mar-2026,6226804962,3,622680496203,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,04-Nov-2025,P2OLD29,05-Nov-2025,05-Nov-2025,6226804961,1,622680496101,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,,6226804962,4,622680496204,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,,6226804962,8,622680496208,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,04-Nov-2025,P2OLD29,05-Nov-2025,05-Nov-2025,6226804961,7,622680496107,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,,6226804962,6,622680496206,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,11-Mar-2026,6226804962,2,622680496202,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,11-Mar-2026,6226804962,1,622680496201,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226889397,1,622688939701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:35,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,,6226889397,2,622688939702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:35,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,10-Jun-2026,6226889397,3,622688939703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:35,07:00,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,,6226889397,4,622688939704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:35,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226889397,5,622688939705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:35,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226889397,6,622688939706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:35,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,06-Jun-2026,6226889397,7,622688939707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:35,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,13-Dec-2025,6226935606,2,622693560602,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:05,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,,6226935606,4,622693560604,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,09:05,,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,13-Dec-2025,6226935606,3,622693560603,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:05,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,,6226935606,5,622693560605,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:05,,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,13-Dec-2025,6226935606,1,622693560601,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:05,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,,6226935606,7,622693560607,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:05,,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,16-Dec-2025,6226935606,6,622693560606,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:05,05:55,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,13-Dec-2025,6226935606,8,622693560608,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:05,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,,6226935606,9,622693560609,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:05,,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,02-Jan-2026,P2OLD29,03-Jan-2026,03-Jan-2026,6226976943,1,622697694301,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,02-Jan-2026,P2OLD29,03-Jan-2026,,6226976943,2,622697694302,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,02-Jan-2026,P2OLD29,03-Jan-2026,31-Jan-2026,6226976943,3,622697694303,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:00,07:20,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,02-Jan-2026,P2OLD29,03-Jan-2026,,6226976943,4,622697694304,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,02-Jan-2026,P2OLD29,03-Jan-2026,03-Jan-2026,6226976943,6,622697694306,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,12:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,02-Jan-2026,P2OLD29,03-Jan-2026,03-Jan-2026,6226976943,7,622697694307,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120004,02-Jan-2026,P2OLD29,03-Jan-2026,03-Jan-2026,6226976943,5,622697694305,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Nov-2025,P2OLD29,07-Nov-2025,,6226991311,4,622699131104,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:14,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Nov-2025,P2OLD29,07-Nov-2025,07-Nov-2025,6226991311,5,622699131105,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:14,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Nov-2025,P2OLD29,07-Nov-2025,07-Nov-2025,6226991311,6,622699131106,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,08:14,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Nov-2025,P2OLD29,07-Nov-2025,07-Nov-2025,6226991311,7,622699131107,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:14,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Nov-2025,P2OLD29,07-Nov-2025,07-Nov-2025,6226991311,3,622699131103,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:14,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Nov-2025,P2OLD29,07-Nov-2025,07-Nov-2025,6226991311,1,622699131101,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:14,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,06-Nov-2025,P2OLD29,07-Nov-2025,,6226991311,2,622699131102,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:14,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,14-Nov-2025,P2OLD29,15-Nov-2025,15-Nov-2025,6227043302,1,622704330201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,14-Nov-2025,P2OLD29,15-Nov-2025,,6227043302,4,622704330204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,14-Nov-2025,P2OLD29,15-Nov-2025,15-Nov-2025,6227043302,5,622704330205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,14-Nov-2025,P2OLD29,15-Nov-2025,19-Nov-2025,6227043302,3,622704330203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:10,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,14-Nov-2025,P2OLD29,15-Nov-2025,,6227043302,2,622704330202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:10,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,14-Nov-2025,P2OLD29,15-Nov-2025,15-Nov-2025,6227043302,6,622704330206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,14-Nov-2025,P2OLD29,15-Nov-2025,15-Nov-2025,6227043302,7,622704330207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:10,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,17-Dec-2025,P2OLD29,18-Dec-2025,18-Dec-2025,6227072419,1,622707241901,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:17,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,17-Dec-2025,P2OLD29,18-Dec-2025,,6227072419,2,622707241902,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:17,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,17-Dec-2025,P2OLD29,18-Dec-2025,,6227072419,4,622707241904,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:17,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,17-Dec-2025,P2OLD29,18-Dec-2025,18-Dec-2025,6227072419,6,622707241906,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:17,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,17-Dec-2025,P2OLD29,18-Dec-2025,18-Dec-2025,6227072419,3,622707241903,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:17,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,17-Dec-2025,P2OLD29,18-Dec-2025,18-Dec-2025,6227072419,7,622707241907,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:17,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080005,17-Dec-2025,P2OLD29,18-Dec-2025,18-Dec-2025,6227072419,5,622707241905,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:17,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,,6227106905,2,622710690502,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,29-Nov-2025,6227106905,1,622710690501,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,03-Dec-2025,6227106905,3,622710690503,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:00,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,,6227106905,4,622710690504,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,29-Nov-2025,6227106905,6,622710690506,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,29-Nov-2025,6227106905,5,622710690505,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,29-Nov-2025,6227106905,7,622710690507,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,,6227106905,8,622710690508,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,28-Nov-2025,P2OLBL,29-Nov-2025,29-Nov-2025,6227106905,9,622710690509,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,20-Dec-2025,6227106906,1,622710690601,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:25,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,,6227106906,2,622710690602,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:25,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,23-Dec-2025,6227106906,3,622710690603,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:25,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,,6227106906,4,622710690604,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:25,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,20-Dec-2025,6227106906,5,622710690605,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:25,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,20-Dec-2025,6227106906,6,622710690606,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:25,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,20-Dec-2025,6227106906,9,622710690609,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:25,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,20-Dec-2025,6227106906,7,622710690607,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:25,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,19-Dec-2025,P2OLBL,20-Dec-2025,,6227106906,8,622710690608,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:25,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,27-Jan-2026,P1DBBL,28-Jan-2026,28-Jan-2026,6227144560,6,622714456006,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,08:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,27-Jan-2026,P1DBBL,28-Jan-2026,28-Jan-2026,6227144560,7,622714456007,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,27-Jan-2026,P1DBBL,28-Jan-2026,28-Jan-2026,6227144560,1,622714456001,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,25-Nov-2025,P1DBBL,26-Nov-2025,,6227144561,2,622714456102,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,27-Jan-2026,P1DBBL,28-Jan-2026,28-Jan-2026,6227144560,5,622714456005,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,25-Nov-2025,P1DBBL,26-Nov-2025,26-Nov-2025,6227144561,1,622714456101,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,25-Nov-2025,P1DBBL,26-Nov-2025,,6227144561,4,622714456104,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:04,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,25-Nov-2025,P1DBBL,26-Nov-2025,26-Nov-2025,6227144561,3,622714456103,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,25-Nov-2025,P1DBBL,26-Nov-2025,26-Nov-2025,6227144561,5,622714456105,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,27-Jan-2026,P1DBBL,28-Jan-2026,28-Jan-2026,6227144560,3,622714456003,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,25-Nov-2025,P1DBBL,26-Nov-2025,26-Nov-2025,6227144561,6,622714456106,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,27-Jan-2026,P1DBBL,28-Jan-2026,,6227144560,4,622714456004,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:25,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,27-Jan-2026,P1DBBL,28-Jan-2026,,6227144560,2,622714456002,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:25,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,11-Dec-2025,P1DBBL,13-Dec-2025,13-Dec-2025,6227144562,1,622714456201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:13,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,11-Dec-2025,P1DBBL,13-Dec-2025,13-Dec-2025,6227144562,5,622714456205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:13,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,25-Nov-2025,P1DBBL,26-Nov-2025,26-Nov-2025,6227144561,7,622714456107,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:04,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,11-Dec-2025,P1DBBL,13-Dec-2025,13-Dec-2025,6227144562,7,622714456207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:13,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,11-Dec-2025,P1DBBL,13-Dec-2025,,6227144562,4,622714456204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:13,,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,11-Dec-2025,P1DBBL,13-Dec-2025,,6227144562,2,622714456202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:13,,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,11-Dec-2025,P1DBBL,13-Dec-2025,16-Dec-2025,6227144562,3,622714456203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:13,05:55,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,11-Dec-2025,P1DBBL,13-Dec-2025,13-Dec-2025,6227144562,6,622714456206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,08:13,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178908,7,622717890807,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:20,08:00,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178908,9,622717890809,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:20,08:00,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227178909,3,622717890903,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:30,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,,6227178908,6,622717890806,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:20,,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,,6227178909,4,622717890904,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:30,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178908,2,622717890802,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:20,08:00,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227178909,1,622717890901,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:30,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,,6227178908,8,622717890808,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:20,,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178908,1,622717890801,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:20,08:00,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227178909,2,622717890902,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:30,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,04-Feb-2026,6227178909,5,622717890905,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:30,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,,6227178908,4,622717890804,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:20,,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178908,3,622717890803,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:20,08:00,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,,6227178909,6,622717890906,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:30,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,,6227178909,8,622717890908,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:30,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227178909,9,622717890909,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:30,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227178909,7,622717890907,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:30,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,06-May-2026,6227178910,1,622717891001,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,06-May-2026,6227178910,3,622717891003,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,07:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,,6227178910,4,622717891004,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,07:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,06-May-2026,6227178910,2,622717891002,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,20-May-2026,6227178910,5,622717891005,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,07:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,09-Jan-2026,EOT,10-Jan-2026,14-Jan-2026,6227178908,5,622717890805,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:20,07:00,Czech Republic,,08:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,,6227178910,8,622717891008,"Red Cells, Clot",Not Received,,,TSH,,,,,,07:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,06-May-2026,6227178910,9,622717891009,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,07:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,07-Mar-2026,6227178911,2,622717891102,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:50,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,06-May-2026,6227178910,7,622717891007,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,07:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,07-Mar-2026,6227178911,1,622717891101,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:50,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,,6227178911,4,622717891104,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:50,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,11-Mar-2026,6227178911,5,622717891105,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:50,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,,6227178911,6,622717891106,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:50,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,07-Mar-2026,6227178911,7,622717891107,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:50,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,07-Mar-2026,6227178911,9,622717891109,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:50,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-May-2026,EOT,06-May-2026,,6227178910,6,622717891006,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,07:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,07-Mar-2026,6227178911,3,622717891103,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:50,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178912,1,622717891201,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:10,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,06-Mar-2026,EOT,07-Mar-2026,,6227178911,8,622717891108,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:50,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178912,2,622717891202,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:10,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178912,3,622717891203,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:10,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,14-Jan-2026,6227178912,5,622717891205,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:10,07:00,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,,6227178912,4,622717891204,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:10,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178912,7,622717891207,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:10,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,,6227178912,8,622717891208,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:10,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,,6227178912,6,622717891206,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:10,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,09-Jan-2026,EOT,10-Jan-2026,10-Jan-2026,6227178912,9,622717891209,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:10,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-Dec-2025,P1DBBL,06-Dec-2025,06-Dec-2025,6227261230,1,622726123001,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-Dec-2025,P1DBBL,06-Dec-2025,,6227261230,2,622726123002,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,07:55,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-Dec-2025,P1DBBL,06-Dec-2025,,6227261230,4,622726123004,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,07:55,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-Dec-2025,P1DBBL,06-Dec-2025,06-Dec-2025,6227261230,5,622726123005,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-Dec-2025,P1DBBL,06-Dec-2025,10-Dec-2025,6227261230,3,622726123003,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,07:55,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-Dec-2025,P1DBBL,06-Dec-2025,06-Dec-2025,6227261230,6,622726123006,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,05-Dec-2025,P1DBBL,06-Dec-2025,06-Dec-2025,6227261230,7,622726123007,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,20-May-2026,6227261835,1,622726183501,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,,6227261835,2,622726183502,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,21-May-2026,6227261835,3,622726183503,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,,6227261835,4,622726183504,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,20-May-2026,6227261835,5,622726183505,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,20-May-2026,6227261835,6,622726183506,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,20-May-2026,6227261835,7,622726183507,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,08-Jan-2026,6227261836,1,622726183601,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:11,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,08-Jan-2026,6227261836,2,622726183602,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:11,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,08-Jan-2026,6227261836,3,622726183603,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:11,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,,6227261836,4,622726183604,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:11,,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,08-Jan-2026,6227261836,5,622726183605,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:11,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,,6227261836,6,622726183606,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:11,,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,08-Jan-2026,6227261836,7,622726183607,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:11,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,,6227261836,8,622726183608,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:11,,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,06-Jan-2026,EOT,08-Jan-2026,08-Jan-2026,6227261836,9,622726183609,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:11,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,03-Jan-2026,6227498379,3,622749837903,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:28,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,03-Jan-2026,6227498379,1,622749837901,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:28,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,03-Jan-2026,6227498379,2,622749837902,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:28,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,,6227498380,8,622749838008,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:36,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227498380,7,622749838007,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:36,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,03-Jan-2026,6227498379,7,622749837907,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:28,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227498380,9,622749838009,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:36,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,03-Jan-2026,6227498379,9,622749837909,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:28,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227498380,1,622749838001,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:36,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,,6227498380,6,622749838006,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:36,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227498380,3,622749838003,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:36,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,03-Jan-2026,6227498379,5,622749837905,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:28,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227498380,2,622749838002,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:36,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,31-Jan-2026,6227498380,5,622749838005,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:36,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,,6227498379,4,622749837904,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:28,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Jan-2026,EOT,31-Jan-2026,,6227498380,4,622749838004,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:36,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,,6227498379,8,622749837908,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:28,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110002,02-Jan-2026,EOT,03-Jan-2026,,6227498379,6,622749837906,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:28,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,14-Jan-2026,6227520242,9,622752024209,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,14-Jan-2026,6227520242,3,622752024203,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,30-Apr-2026,6227520243,7,622752024307,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,30-Apr-2026,6227520243,5,622752024305,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,,6227520242,4,622752024204,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,14-Jan-2026,6227520242,1,622752024201,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,30-Apr-2026,6227520243,3,622752024303,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,,6227520243,6,622752024306,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:20,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,30-Apr-2026,6227520243,1,622752024301,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,,6227520243,4,622752024304,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:20,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,,6227520243,8,622752024308,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:20,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,14-Jan-2026,6227520242,2,622752024202,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,,6227520242,6,622752024206,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,14-Jan-2026,6227520242,5,622752024205,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,30-Apr-2026,6227520243,2,622752024302,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,,6227520242,8,622752024208,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,13-Jan-2026,EOT,14-Jan-2026,14-Jan-2026,6227520242,7,622752024207,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,29-Apr-2026,EOT,30-Apr-2026,30-Apr-2026,6227520243,9,622752024309,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:20,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,05-Mar-2026,6227520245,2,622752024502,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,05-Mar-2026,6227520245,3,622752024503,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,,6227520245,8,622752024508,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,05-Mar-2026,6227520245,1,622752024501,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,05-Mar-2026,6227520245,9,622752024509,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,,6227520245,4,622752024504,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,05-Mar-2026,6227520245,5,622752024505,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,,6227520245,6,622752024506,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,04-Mar-2026,EOT,05-Mar-2026,05-Mar-2026,6227520245,7,622752024507,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,,6227541249,1,622754124901,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,28-Jan-2026,6227541249,2,622754124902,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,28-Jan-2026,6227541249,3,622754124903,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,28-Jan-2026,6227541249,6,622754124906,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,28-Jan-2026,6227541249,4,622754124904,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,,6227541249,7,622754124907,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,28-Jan-2026,6227541249,5,622754124905,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227541251,1,622754125101,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,06:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,25-Mar-2026,P1DBBL,26-Mar-2026,,6227541251,2,622754125102,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,06:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,28-Jan-2026,6227541249,10,622754124910,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,30-Jan-2026,6227541249,8,622754124908,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:00,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,27-Jan-2026,P1SCR,28-Jan-2026,,6227541249,9,622754124909,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,20-Feb-2026,P1DBBL,21-Feb-2026,21-Feb-2026,6227541252,6,622754125206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:45,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,20-Feb-2026,P1DBBL,21-Feb-2026,21-Feb-2026,6227541252,1,622754125201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:45,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227541251,7,622754125107,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,06:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,20-Feb-2026,P1DBBL,21-Feb-2026,25-Feb-2026,6227541252,3,622754125203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:45,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,25-Mar-2026,P1DBBL,26-Mar-2026,,6227541251,4,622754125104,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,06:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,20-Feb-2026,P1DBBL,21-Feb-2026,,6227541252,2,622754125202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:45,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,20-Feb-2026,P1DBBL,21-Feb-2026,,6227541252,4,622754125204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:45,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227541251,6,622754125106,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,06:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,20-Feb-2026,P1DBBL,21-Feb-2026,21-Feb-2026,6227541252,5,622754125205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:45,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,20-Feb-2026,P1DBBL,21-Feb-2026,21-Feb-2026,6227541252,7,622754125207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:45,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227541251,5,622754125105,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,06:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227541256,1,622754125601,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,07:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227541256,5,622754125605,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,07:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,,6227541256,2,622754125602,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,07:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,,6227541256,4,622754125604,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,07:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227541256,7,622754125607,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,20-May-2026,6227541256,3,622754125603,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,07:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227541251,3,622754125103,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,06:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227541256,6,622754125606,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,07:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227541256,9,622754125609,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,07:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,21-Jan-2026,6227541257,3,622754125703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,07:55,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,,6227541256,8,622754125608,"Red Cells, Clot",Not Received,,,TSH,,,,,,07:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,,6227541257,8,622754125708,"Red Cells, Clot",Not Received,,,TSH,,,,,,07:55,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,17-Jan-2026,6227541257,1,622754125701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,17-Jan-2026,6227541257,5,622754125705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,17-Jan-2026,6227541257,6,622754125706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,,6227541257,4,622754125704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,07:55,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,17-Jan-2026,6227541257,7,622754125707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,17-Jan-2026,6227541257,9,622754125709,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,07:55,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,,6227541258,2,622754125802,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Feb-2026,P2OLD29,14-Feb-2026,,6227541259,4,622754125904,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,16-Jan-2026,P2OLBL,17-Jan-2026,,6227541257,2,622754125702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,07:55,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Feb-2026,P2OLD29,14-Feb-2026,18-Feb-2026,6227541259,3,622754125903,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:45,07:10,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,08-Apr-2026,6227541258,9,622754125809,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Feb-2026,P2OLD29,14-Feb-2026,14-Feb-2026,6227541259,6,622754125906,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Feb-2026,P2OLD29,14-Feb-2026,14-Feb-2026,6227541259,7,622754125907,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,08-Apr-2026,6227541258,1,622754125801,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,,6227541258,4,622754125804,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,08-Apr-2026,6227541258,6,622754125806,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Feb-2026,P2OLD29,14-Feb-2026,14-Feb-2026,6227541259,1,622754125901,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,08-Apr-2026,6227541258,5,622754125805,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,08-Apr-2026,6227541258,7,622754125807,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,08-Apr-2026,6227541258,3,622754125803,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Feb-2026,P2OLD29,14-Feb-2026,14-Feb-2026,6227541259,5,622754125905,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,16-Jan-2026,P2OLD29,17-Jan-2026,17-Jan-2026,6227541260,1,622754126001,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:40,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,16-Jan-2026,P2OLD29,17-Jan-2026,17-Jan-2026,6227541260,5,622754126005,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:40,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,16-Jan-2026,P2OLD29,17-Jan-2026,,6227541260,2,622754126002,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:40,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,16-Jan-2026,P2OLD29,17-Jan-2026,21-Jan-2026,6227541260,3,622754126003,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:40,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,,6227541258,8,622754125808,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Feb-2026,P2OLD29,14-Feb-2026,,6227541259,2,622754125902,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,06-May-2026,6227541261,1,622754126101,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,16-Jan-2026,P2OLD29,17-Jan-2026,,6227541260,4,622754126004,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:40,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,16-Jan-2026,P2OLD29,17-Jan-2026,17-Jan-2026,6227541260,6,622754126006,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:40,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,,6227541261,2,622754126102,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,13:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,,6227541261,4,622754126104,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,13:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,16-Jan-2026,P2OLD29,17-Jan-2026,17-Jan-2026,6227541260,7,622754126007,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:40,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,06-May-2026,6227541261,5,622754126105,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,06-May-2026,6227541261,6,622754126106,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,20-May-2026,6227541261,3,622754126103,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,06-May-2026,6227541261,7,622754126107,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,,6227541264,2,622754126402,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6227541264,1,622754126401,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,,6227541264,4,622754126404,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6227541264,3,622754126403,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6227541264,6,622754126406,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,08:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6227541264,5,622754126405,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,08-Apr-2026,6227541264,7,622754126407,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:35,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,22-Jan-2026,6227542160,6,622754216006,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,10:11,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,,6227542160,7,622754216007,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:11,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,22-Jan-2026,6227542160,5,622754216005,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:11,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,,6227542160,9,622754216009,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:11,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,22-Jan-2026,6227542160,2,622754216002,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:11,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,22-Jan-2026,6227542160,10,622754216010,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:11,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,,6227542161,1,622754216101,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:58,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,22-Jan-2026,6227542160,8,622754216008,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:11,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,,6227542160,1,622754216001,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:11,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,06-Jan-2026,6227542161,4,622754216104,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,06-Jan-2026,6227542161,2,622754216102,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,06-Jan-2026,6227542161,8,622754216108,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,06-Jan-2026,6227542161,3,622754216103,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,10:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,06-Jan-2026,6227542161,6,622754216106,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,10:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,06-Jan-2026,6227542161,10,622754216110,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,22-Jan-2026,6227542160,4,622754216004,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:11,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110009,21-Jan-2026,P1SCR,22-Jan-2026,22-Jan-2026,6227542160,3,622754216003,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,10:11,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,,6227542161,9,622754216109,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:58,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,,6227542161,7,622754216107,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:58,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,05-Jan-2026,P1SCR,06-Jan-2026,06-Jan-2026,6227542161,5,622754216105,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:58,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,11-Mar-2026,6227542170,5,622754217005,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,11-Mar-2026,6227542170,1,622754217001,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,11-Mar-2026,6227542170,7,622754217007,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,11-Mar-2026,6227542170,3,622754217003,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,,6227542170,8,622754217008,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,11-Mar-2026,6227542170,2,622754217002,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,,6227542170,6,622754217006,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,17-Mar-2026,6227542171,1,622754217101,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,11-Mar-2026,6227542170,9,622754217009,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,17-Mar-2026,6227542171,3,622754217103,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,10-Mar-2026,EOT,11-Mar-2026,,6227542170,4,622754217004,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,17-Mar-2026,6227542171,5,622754217105,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,17-Mar-2026,6227542171,2,622754217102,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,,6227542171,6,622754217106,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,,6227542171,8,622754217108,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,17-Mar-2026,6227542171,7,622754217107,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,17-Mar-2026,6227542171,9,622754217109,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:16,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,31-Mar-2026,6227542172,2,622754217202,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:31,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Mar-2026,EOT,17-Mar-2026,,6227542171,4,622754217104,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,31-Mar-2026,6227542172,3,622754217203,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:31,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,31-Mar-2026,6227542172,1,622754217201,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:31,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,31-Mar-2026,6227542172,5,622754217205,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:31,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,,6227542172,6,622754217206,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:31,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,31-Mar-2026,6227542172,9,622754217209,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:31,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,31-Mar-2026,6227542172,7,622754217207,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:31,07:15,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,,6227542172,4,622754217204,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:31,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,30-Mar-2026,EOT,31-Mar-2026,,6227542172,8,622754217208,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:31,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,17-Jan-2026,6227542173,1,622754217301,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:48,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,17-Jan-2026,6227542173,5,622754217305,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:48,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,,6227542173,6,622754217306,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:48,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,17-Jan-2026,6227542173,7,622754217307,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:48,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,,6227542173,8,622754217308,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:48,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,17-Jan-2026,6227542173,2,622754217302,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:48,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,17-Jan-2026,6227542173,9,622754217309,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:48,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,17-Jan-2026,6227542173,3,622754217303,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:48,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,16-Jan-2026,EOT,17-Jan-2026,,6227542173,4,622754217304,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:48,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227542182,2,622754218202,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:16,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227542182,3,622754218203,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:16,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,,6227542182,4,622754218204,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,08:16,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,,6227542182,5,622754218205,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:16,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227542182,8,622754218208,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:16,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227542182,1,622754218201,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:16,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,,6227542182,7,622754218207,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:16,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,,6227542182,9,622754218209,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:16,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227542182,6,622754218206,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:16,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227542182,10,622754218210,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:16,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,13-Dec-2025,6226935606,10,622693560610,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:05,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110003,11-Dec-2025,EOT,13-Dec-2025,13-Dec-2025,6226935606,11,622693560611,"Serum, SST",Received,Ambient,Default Return Ambient,,,,,,,09:05,21:00,Czech Republic,,21:00,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,28-Feb-2026,6227547329,2,622754732902,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,28-Feb-2026,6227547329,3,622754732903,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,08:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,28-Feb-2026,6227547329,4,622754732904,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,28-Feb-2026,6227547329,6,622754732906,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,08:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,,6227547329,7,622754732907,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,28-Feb-2026,6227547329,5,622754732905,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,04-Mar-2026,6227547329,8,622754732908,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:00,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,28-Feb-2026,6227547329,10,622754732910,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,,6227547329,9,622754732909,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,31-Jan-2026,6227547330,2,622754733002,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:40,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,,6227547330,1,622754733001,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:40,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,31-Jan-2026,6227547330,3,622754733003,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:40,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,31-Jan-2026,6227547330,4,622754733004,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:40,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,31-Jan-2026,6227547330,5,622754733005,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:40,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,31-Jan-2026,6227547330,6,622754733006,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:40,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,,6227547330,7,622754733007,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:40,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,04-Feb-2026,6227547330,8,622754733008,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:40,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,,6227547330,9,622754733009,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:40,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,30-Jan-2026,P1SCR,31-Jan-2026,31-Jan-2026,6227547330,10,622754733010,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:40,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227547331,2,622754733102,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,27-Feb-2026,P1SCR,28-Feb-2026,,6227547329,1,622754732901,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227547331,3,622754733103,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227547331,4,622754733104,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227547331,5,622754733105,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227547331,6,622754733106,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,,6227547331,7,622754733107,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,11-Mar-2026,6227547331,8,622754733108,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:20,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,27-Feb-2026,P1DBBL,28-Feb-2026,28-Feb-2026,6227547332,1,622754733201,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:35,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,27-Feb-2026,P1DBBL,28-Feb-2026,,6227547332,2,622754733202,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:35,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,27-Feb-2026,P1DBBL,28-Feb-2026,04-Mar-2026,6227547332,3,622754733203,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:35,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,27-Feb-2026,P1DBBL,28-Feb-2026,,6227547332,4,622754733204,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:35,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,27-Feb-2026,P1DBBL,28-Feb-2026,28-Feb-2026,6227547332,5,622754733205,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:35,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,27-Feb-2026,P1DBBL,28-Feb-2026,28-Feb-2026,6227547332,6,622754733206,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:35,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,27-Feb-2026,P1DBBL,28-Feb-2026,28-Feb-2026,6227547332,7,622754733207,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:35,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,,6227547331,1,622754733101,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227547333,1,622754733301,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,25-Mar-2026,P1DBBL,26-Mar-2026,,6227547333,2,622754733302,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227547333,3,622754733303,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,25-Mar-2026,P1DBBL,26-Mar-2026,,6227547333,4,622754733304,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227547333,6,622754733306,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227547333,5,622754733305,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,25-Mar-2026,P1DBBL,26-Mar-2026,26-Mar-2026,6227547333,7,622754733307,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,,6227547331,9,622754733109,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227547331,10,622754733110,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,,6227547336,1,622754733601,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:15,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,11-Apr-2026,6227547336,2,622754733602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,11-Apr-2026,6227547336,3,622754733603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,08:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,11-Apr-2026,6227547336,4,622754733604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,11-Apr-2026,6227547336,5,622754733605,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,11-Apr-2026,6227547336,6,622754733606,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,08:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,,6227547336,7,622754733607,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:15,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,15-Apr-2026,6227547336,8,622754733608,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:15,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,,6227547336,9,622754733609,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:15,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,,6227547337,2,622754733702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:15,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,15-Apr-2026,6227547337,3,622754733703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:15,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,,6227547337,4,622754733704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:15,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227547337,6,622754733706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,11:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227547337,5,622754733705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227547337,9,622754733709,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,,6227547338,2,622754733802,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,20-May-2026,6227547338,3,622754733803,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227547338,1,622754733801,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,,6227547338,4,622754733804,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227547338,7,622754733807,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227547338,5,622754733805,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227547338,6,622754733806,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,,6227547337,8,622754733708,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:15,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227547337,7,622754733707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,,6227547338,8,622754733808,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,06-May-2026,6227547338,9,622754733809,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227547337,1,622754733701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,10-Apr-2026,P2SCR,11-Apr-2026,11-Apr-2026,6227547336,10,622754733610,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:15,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,03-Feb-2026,6227767267,3,622776726703,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,12:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,03-Feb-2026,6227767267,4,622776726704,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,,6227767267,1,622776726701,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:25,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,03-Feb-2026,6227767267,2,622776726702,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,,6227767267,7,622776726707,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:25,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,03-Feb-2026,6227767267,5,622776726705,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,03-Feb-2026,6227767267,6,622776726706,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,12:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,,6227767267,9,622776726709,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:25,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,04-Feb-2026,6227767267,8,622776726708,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,01-Feb-2026,P1SCR,03-Feb-2026,03-Feb-2026,6227767267,10,622776726710,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,12:25,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,06-May-2026,6227768458,2,622776845802,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,,6227768458,4,622776845804,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,06-May-2026,6227768458,1,622776845801,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,06-May-2026,6227768458,3,622776845803,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,20-May-2026,6227768458,5,622776845805,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,,6227768458,6,622776845806,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,,6227768458,8,622776845808,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,06-May-2026,6227768458,7,622776845807,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,14-Mar-2026,6227768459,1,622776845901,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,14-Mar-2026,6227768459,3,622776845903,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,,6227768459,4,622776845904,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:00,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040008,05-May-2026,EOT,06-May-2026,06-May-2026,6227768458,9,622776845809,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:45,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,,6227768460,4,622776846004,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:00,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,,6227768459,6,622776845906,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:00,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,08-Apr-2026,6227768460,5,622776846005,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:00,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,28-Mar-2026,6227768460,2,622776846002,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,14-Mar-2026,6227768459,7,622776845907,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,28-Mar-2026,6227768460,3,622776846003,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,,6227768459,8,622776845908,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:00,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,18-Mar-2026,6227768459,5,622776845905,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:00,07:00,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,14-Mar-2026,6227768459,9,622776845909,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,28-Mar-2026,6227768460,7,622776846007,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,,6227768460,8,622776846008,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:00,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,28-Mar-2026,6227768460,1,622776846001,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,28-Mar-2026,6227768460,9,622776846009,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040004,13-Mar-2026,EOT,14-Mar-2026,14-Mar-2026,6227768459,2,622776845902,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:00,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040003,27-Mar-2026,EOT,28-Mar-2026,,6227768460,6,622776846006,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:00,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,,6227775505,1,622777550501,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,16:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,30-Jan-2026,6227775505,5,622777550505,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,16:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,30-Jan-2026,6227775505,4,622777550504,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,16:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,30-Jan-2026,6227775505,6,622777550506,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,16:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,,6227775505,7,622777550507,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,16:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,30-Jan-2026,6227775505,2,622777550502,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,16:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,30-Jan-2026,6227775505,3,622777550503,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,16:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,,6227775505,9,622777550509,"Red Cells, Clot",Not Received,,,TSH,,,,,,16:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,15-Feb-2026,P1DBBL,17-Feb-2026,,6227775508,2,622777550802,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,15:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775507,1,622777550701,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,13:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775508,5,622777550805,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,15:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,15-Feb-2026,P1DBBL,17-Feb-2026,18-Feb-2026,6227775507,3,622777550703,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,13:30,07:10,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,15-Feb-2026,P1DBBL,17-Feb-2026,,6227775507,4,622777550704,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,13:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,15-Feb-2026,P1DBBL,17-Feb-2026,18-Feb-2026,6227775508,3,622777550803,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,15:10,07:10,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775507,6,622777550706,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,13:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775507,7,622777550707,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775507,5,622777550705,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,13:30,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775508,7,622777550807,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,15:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775508,6,622777550806,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,15:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,15-Feb-2026,P1DBBL,17-Feb-2026,17-Feb-2026,6227775508,1,622777550801,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,15:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,15-Feb-2026,P1DBBL,17-Feb-2026,,6227775507,2,622777550702,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,13:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,30-Jan-2026,6227775505,10,622777550510,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,16:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,15-Feb-2026,P1DBBL,17-Feb-2026,,6227775508,4,622777550804,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,15:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,31-Jan-2026,6227775505,8,622777550508,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,16:50,07:20,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,18-Feb-2026,6227797406,3,622779740603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,11:03,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,18-Feb-2026,6227797406,6,622779740606,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,11:03,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,18-Feb-2026,6227797406,5,622779740605,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,11:03,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,18-Feb-2026,6227797406,4,622779740604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:03,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,18-Feb-2026,6227797406,8,622779740608,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,11:03,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,,6227797406,9,622779740609,"Red Cells, Clot",Not Received,,,TSH,,,,,,11:03,,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,,6227797406,7,622779740607,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,11:03,,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,18-Feb-2026,6227797406,2,622779740602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,11:03,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,,6227797406,1,622779740601,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,11:03,,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,,6227797407,1,622779740701,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:22,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227797407,3,622779740703,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227797407,4,622779740704,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,17-Feb-2026,P1SCR,18-Feb-2026,18-Feb-2026,6227797406,10,622779740610,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,11:03,07:10,Czech Republic,,07:10,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227797407,5,622779740705,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227797407,6,622779740706,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,,6227797407,7,622779740707,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:22,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,,6227797407,9,622779740709,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:22,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,03-Mar-2026,6227797408,5,622779740805,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,03-Mar-2026,6227797408,6,622779740806,"Urine, no preservative",Received,Ambient,Default Return Ambient,URINE DRUG SCREEN,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,03-Mar-2026,6227797408,4,622779740804,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227797407,10,622779740710,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227797407,2,622779740702,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110012,06-Mar-2026,P1SCR,07-Mar-2026,07-Mar-2026,6227797407,8,622779740708,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:22,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,,6227797408,1,622779740801,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,03-Mar-2026,6227797408,8,622779740808,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,03-Mar-2026,6227797408,2,622779740802,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,03-Mar-2026,6227797408,3,622779740803,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,"HEMATOLOGY, A1C, &",RETICULOCYTES,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,,6227797408,7,622779740807,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,,6227797408,9,622779740809,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:05,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110011,02-Mar-2026,P1SCR,03-Mar-2026,03-Mar-2026,6227797408,10,622779740810,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:05,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Mar-2026,P1DBBL,11-Mar-2026,11-Mar-2026,6227844725,3,622784472503,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Mar-2026,P1DBBL,11-Mar-2026,11-Mar-2026,6227844725,6,622784472506,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,10:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Mar-2026,P1DBBL,11-Mar-2026,11-Mar-2026,6227844725,5,622784472505,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Mar-2026,P1DBBL,11-Mar-2026,,6227844725,4,622784472504,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:21,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Mar-2026,P1DBBL,11-Mar-2026,11-Mar-2026,6227844725,7,622784472507,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Mar-2026,P1DBBL,11-Mar-2026,11-Mar-2026,6227844725,1,622784472501,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Mar-2026,P1DBBL,11-Mar-2026,,6227844725,2,622784472502,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:21,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 DB Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,28-Jan-2026,P1SCR,30-Jan-2026,30-Jan-2026,6227775505,11,622777550511,"Serum, SST",Received,Ambient,Default Return Ambient,,,,,,,16:50,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 1 Screening,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,08-Apr-2026,6228114460,1,622811446001,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,,6228114460,4,622811446004,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:21,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,08-Apr-2026,6228114460,5,622811446005,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,08-Apr-2026,6228114460,6,622811446006,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY &,RETICULOCYTES,,,,,09:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,,6228114460,2,622811446002,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:21,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,08-Apr-2026,6228114460,3,622811446003,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,08-Apr-2026,6228114460,7,622811446007,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:21,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080006,10-Mar-2026,P2DBBL,11-Mar-2026,,6226804962,10,622680496210,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,07-Apr-2026,P2OLD29,08-Apr-2026,,6228114460,8,622811446008,"Urine, no preservative",Not Received,Ambient,,,,,,,,09:21,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,02-Apr-2026,6228232037,5,622823203705,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,,6228232037,6,622823203706,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,,6228232037,8,622823203708,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,01-Apr-2026,6228232037,9,622823203709,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,01-Apr-2026,6228232037,7,622823203707,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,01-Apr-2026,6228232037,1,622823203701,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,01-Apr-2026,6228232037,3,622823203703,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,,6228232037,4,622823203704,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110006,31-Mar-2026,EOT,01-Apr-2026,01-Apr-2026,6228232037,2,622823203702,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:10,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,05-May-2026,6228234297,1,622823429701,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:44,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,05-May-2026,6228234297,2,622823429702,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:44,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,05-May-2026,6228234297,3,622823429703,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:44,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,05-May-2026,6228234297,7,622823429707,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:44,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,,6228234297,8,622823429708,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:44,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,14-May-2026,6228234298,1,622823429801,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,06-May-2026,6228234297,5,622823429705,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:44,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,,6228234297,6,622823429706,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:44,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,05-May-2026,6228234297,9,622823429709,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:44,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,,6228234298,6,622823429806,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,08:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,14-May-2026,6228234298,5,622823429805,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,08:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,14-May-2026,6228234298,2,622823429802,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,14-May-2026,6228234298,9,622823429809,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,08:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,,6228234298,4,622823429804,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110008,04-May-2026,EOT,05-May-2026,,6228234297,4,622823429704,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,08:44,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,,6228234298,8,622823429808,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,14-May-2026,6228234298,3,622823429803,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,08:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,23-Apr-2026,6228234300,5,622823430005,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,10:37,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110007,13-May-2026,EOT,14-May-2026,14-May-2026,6228234298,7,622823429807,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,08:15,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,23-Apr-2026,6228234300,2,622823430002,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:37,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,23-Apr-2026,6228234300,1,622823430001,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:37,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,23-Apr-2026,6228234300,3,622823430003,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,10:37,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,,6228234300,6,622823430006,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,10:37,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,23-Apr-2026,6228234300,9,622823430009,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,10:37,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,,6228234300,8,622823430008,"Red Cells, Clot",Not Received,,,TSH,,,,,,10:37,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,,6228234300,4,622823430004,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,10:37,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,21-Apr-2026,EOT,23-Apr-2026,23-Apr-2026,6228234300,7,622823430007,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,10:37,07:00,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,25-Mar-2026,EOT,26-Mar-2026,,6226560888,10,622656088810,"Urine, no preservative",Not Received,Ambient,,,,,,,,17:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,25-Mar-2026,EOT,26-Mar-2026,,6226752555,10,622675255510,"Urine, no preservative",Not Received,Ambient,,,,,,,,15:00,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080007,01-Apr-2026,P2OLD29,02-Apr-2026,,6226313625,8,622631362508,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,11:10,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,,6226686954,10,622668695410,"Serum, SST",Canceled,Ambient,,TSH,,,,,,12:01,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,,6226686954,9,622668695409,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:01,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10008,Dr.Zdenek Solle,CZ100080002,07-Apr-2026,P2DBW13,08-Apr-2026,,6226686954,8,622668695408,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,12:01,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,,6227541264,10,622754126410,"Serum, SST",Canceled,Ambient,,TSH,,,,,,08:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,,6227541264,8,622754126408,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,08:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040001,07-Apr-2026,P2DBW13,08-Apr-2026,,6227541264,9,622754126409,"Red Cells, Clot",Not Received,,,TSH,,,,,,08:35,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,07-Apr-2026,P2OLBL,08-Apr-2026,,6227541258,10,622754125810,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,09:45,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,10-Apr-2026,P2OLBL,11-Apr-2026,11-Apr-2026,6227542182,11,622754218211,"Serum, SST",Received,Ambient,Default Return Ambient,,,,,,,08:16,07:20,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Retest,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,10-Apr-2026,P2OLBL,11-Apr-2026,,6227547337,10,622754733710,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,11:15,,Czech Republic,,07:20,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120006,22-Apr-2026,P2OLD29,23-Apr-2026,,6226752554,8,622675255408,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,15:30,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10012,Dr.Ales Urban,CZ100120005,23-Apr-2026,P2OLD29,25-Apr-2026,,6226560887,8,622656088708,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,16:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,05-May-2026,P2OLD29,06-May-2026,,6227541261,8,622754126108,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,13:15,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-May-2026,P2OLBL,06-May-2026,,6227541256,10,622754125610,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,07:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-May-2026,P2OLBL,06-May-2026,,6227547338,10,622754733810,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,09:50,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Baseline,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,23-May-2026,6228605652,2,622860565202,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,,6228605652,4,622860565204,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,27-May-2026,6228605653,5,622860565305,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,12:00,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,23-May-2026,6228605652,1,622860565201,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,23-May-2026,6228605652,9,622860565209,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,23-May-2026,6228605653,1,622860565301,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,23-May-2026,6228605652,3,622860565203,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,,6228605653,8,622860565308,"Red Cells, Clot",Not Received,,,TSH,,,,,,12:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,23-May-2026,6228605653,9,622860565309,"Serum, SST",Received,Ambient,Default Return Ambient,TSH,,,,,,12:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,,6228605652,8,622860565208,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,,6228605652,6,622860565206,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,09:20,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,,6228605653,6,622860565306,"Red Cells, Clot",Not Received,,,CHEMISTRY,,,,,,12:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,23-May-2026,6228605653,7,622860565307,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,12:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,23-May-2026,6228605653,2,622860565302,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,23-May-2026,6228605652,7,622860565207,"Serum, SST",Received,Ambient,Default Return Ambient,CHEMISTRY,,,,,,09:20,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,,6228605653,4,622860565304,"Whole Blood, EDTA, Dry",Not Received,,,INSULIN,,,,,,12:00,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040005,22-May-2026,EOT,23-May-2026,27-May-2026,6228605652,5,622860565205,"Plasma, EDTA",Received,Frozen,Default Return Frozen,INSULIN,FROZEN,,,,,09:20,07:00,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040006,22-May-2026,EOT,23-May-2026,23-May-2026,6228605653,3,622860565303,"Urine, Cargile Preservative UA",Received,Ambient,Default Return Ambient,URINALYSIS,,,,,,12:00,07:30,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,End of Phase/Treatment,, +42847922MDD3003,CZ10011,Dr. Marta Lendlova,CZ100110010,19-May-2026,P2OLD29,20-May-2026,,6227261835,8,622726183508,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,11:16,,Czech Republic,,07:00,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,,6226649754,10,622664975410,"Serum, SST",Canceled,Ambient,,TSH,,,,,,09:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,,6226649754,8,622664975408,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,09:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040002,29-May-2026,P2DBW13,30-May-2026,,6226649754,9,622664975409,"Red Cells, Clot",Not Received,,,TSH,,,,,,09:30,,Czech Republic,,07:30,,,212396,EMEA,,,,,,,,Part 2 DB Week 13,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040009,05-Jun-2026,P2OLD29,06-Jun-2026,,6226573502,8,622657350208,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,11:15,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, +42847922MDD3003,CZ10004,Dr. Erik Herman,CZ100040007,05-Jun-2026,P2OLD29,06-Jun-2026,,6226889397,8,622688939708,"Urine, no preservative",Not Received,Ambient,,URINE DRUG SCREEN,,,,,,10:35,,Czech Republic,,07:15,,,212396,EMEA,,,,,,,,Part 2 OL Induction Day 29,, diff --git a/Covance/Source/2026-06-18_094416 sponsor-study-36940-samples-allSamples.csv b/Covance/Source/2026-06-18_094416 sponsor-study-36940-samples-allSamples.csv new file mode 100644 index 0000000..5379f2f --- /dev/null +++ b/Covance/Source/2026-06-18_094416 sponsor-study-36940-samples-allSamples.csv @@ -0,0 +1,1762 @@ +Protocol Code,Investigator No.,Investigator Name,Patient No.,Collection Date,Protocol Visit Code,Kit Receipt Date,Container Receipt Date,Accession,Container No.,Container Barcode No.,Specimen Type,Sample Status,Expected Receipt Condition,Actual Receipt Condition,Container Label Line 1,Container Label Line 2,SM Sample Status,SMART Specimen Class Description,Aliquot Created Date,Aliquoted Date,Collection Time,Container Receipt Time,Country,Courier,Kit Receipt Time,Parent Barcode Number,Parent Sample Type,Project,Region,Screening No.,Shipped To Organization Name,Site Waybill No.,Site - Scheduled Shipment Date,Site - Shipment Created Date,Site - Shipment Details Entered Date,SMART Specimen Class,Visit Description,Parent Barcode,Children Barcode +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,1,622732320301,Whole Blood QuantiFERON Nil,Received,,Default Discard/Not Return,QUANTIFERON PLUS,NIL-GRAY,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,2,622732320302,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,3,622732320303,Whole Blood QuantiFERON TB1,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB1-GREEN,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,7,622732320307,Whole Blood QuantiFERON Mitoge,Received,,Default Discard/Not Return,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,8,622732320308,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,5,622732320305,Whole Blood QuantiFERON TB2,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB2-YELLOW,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,6,622732320306,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,23-Jan-2026,6227323203,11,622732320311,"Red Cells, Clot",Received,,Default Discard/Not Return,"HIV SCREEN,",HEPATITIS B & C,,,,,08:00,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,24-Jan-2026,6227323203,4,622732320304,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,08:00,12:40,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,23-Jan-2026,6227323203,14,622732320314,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,08:00,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,23-Jan-2026,6227323203,12,622732320312,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,08:00,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,23-Jan-2026,6227323203,15,622732320315,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,08:00,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,1,622732320401,Whole Blood QuantiFERON Nil,Received,,Default Discard/Not Return,QUANTIFERON PLUS,NIL-GRAY,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,23-Jan-2026,6227323203,9,622732320309,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:00,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,3,622732320403,Whole Blood QuantiFERON TB1,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB1-GREEN,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,4,622732320404,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,2,622732320402,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,6,622732320406,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,7,622732320407,Whole Blood QuantiFERON Mitoge,Received,,Default Discard/Not Return,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,5,622732320405,Whole Blood QuantiFERON TB2,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB2-YELLOW,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,,6227323203,10,622732320310,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,08:00,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Jan-2026,SCRN,23-Jan-2026,23-Jan-2026,6227323203,13,622732320313,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM PANEL, BETA",HCG & FSH,,,,,08:00,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227323204,9,622732320409,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227323204,10,622732320410,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227323204,11,622732320411,"Red Cells, Clot",Received,,Default Discard/Not Return,"HIV SCREEN,",HEPATITIS B & C,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227323204,13,622732320413,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM PANEL, BETA",HCG & FSH,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227323204,14,622732320414,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227323204,15,622732320415,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,04-Mar-2026,6227323204,8,622732320408,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,1,622732320501,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227323204,12,622732320412,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,2,622732320502,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,4,622732320504,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,7,622732320507,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,3,622732320503,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,6,622732320506,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,10,622732320510,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,9,622732320509,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,8,622732320508,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,5,622732320505,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,11,622732320511,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,13,622732320513,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,14,622732320514,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,15,622732320515,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,16,622732320516,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,18,622732320518,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,1,622732320601,"Whole Blood, EDTA, Dry",Canceled,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,17,622732320517,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM, LIPID PANEL",& CRP,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,I-0,20-Feb-2026,20-Feb-2026,6227323205,12,622732320512,"Red Cells, Clot",Received,,Default Discard/Not Return,SM06/SERUM,BIOMARKERS,,,,,07:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,4,622732320604,"Plasma, EDTA",Not Received,Frozen,Specimen not submitted,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,7,622732320607,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,8,622732320608,"Serum, SST",Not Received,Frozen,Specimen not submitted,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,9,622732320609,"Serum, SST",Not Received,Frozen,Specimen not submitted,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,10,622732320610,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,SM10/FECAL,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,11,622732320611,Whole Blood PAXgene RNA,Not Received,Frozen,Specimen not submitted,SM07/WB RNA,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,12,622732320612,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,2,622732320602,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,6,622732320606,"Plasma, EDTA",Not Received,Frozen,Specimen not submitted,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,3,622732320603,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,5,622732320605,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,23-Apr-2026,6227323206,17,622732320617,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM, LIPID PANEL",& CRP,,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,14,622732320614,"Serum, SST",Not Received,Frozen,Specimen not submitted,SM06/SERUM BIOM,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,23-Apr-2026,6227323206,18,622732320618,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,2,622732320702,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,16,622732320616,"Feces, unpreserved",Not Received,Frozen,Specimen not submitted,FECAL CALPROTECTIN,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,,6227323207,3,622732320703,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,1,622732320701,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,15,622732320615,"Serum, SST",Not Received,Frozen,Specimen not submitted,SM06/SERUM BIOM,77242113UCO3001-3,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,23-Apr-2026,,6227323206,13,622732320613,"Serum, SST",Not Received,Frozen,Specimen not submitted,SM06/SERUM BIOM,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,,6227323207,4,622732320704,"Plasma, EDTA",Not Received,Frozen,Specimen not submitted,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,5,622732320705,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,6,622732320706,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,7,622732320707,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,8,622732320708,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-1,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,,6227323207,9,622732320709,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,,6227323207,10,622732320710,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,,6227323207,11,622732320711,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,,6227323207,12,622732320712,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-5,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,13,622732320713,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,14,622732320714,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,16,622732320716,"Red Cells, Clot",Received,,Default Discard/Not Return,CHEM PANEL &,CRP,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,17,622732320717,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,1,622732320801,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,2,622732320802,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,3,622732320803,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,5,622732320805,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,4,622732320804,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,7,622732320807,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,,6227323208,8,622732320808,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-1,,,,,07:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,,6227323208,10,622732320810,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-3,,,,,07:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,23-Apr-2026,I-2,24-Apr-2026,24-Apr-2026,6227323207,15,622732320715,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,,6227323208,11,622732320811,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-4,,,,,07:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,,6227323208,9,622732320809,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-2,,,,,07:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,,6227323208,12,622732320812,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-5,,,,,07:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,13,622732320813,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,14,622732320814,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,15,622732320815,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,16,622732320816,"Red Cells, Clot",Received,,Default Discard/Not Return,CHEM PANEL &,CRP,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,17,622732320817,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,04-Mar-2026,I-2,05-Mar-2026,05-Mar-2026,6227323208,6,622732320806,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,2,622732321002,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,4,622732321004,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,1,622732321001,"Red Cells, Clot",Received,,Default Discard/Not Return,CHEM PANEL &,CRP,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,3,622732321003,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,,6227323210,6,622732321006,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-1,,,,,07:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,5,622732321005,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,,6227323210,7,622732321007,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-2,,,,,07:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,,6227323210,8,622732321008,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-3,,,,,07:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,,6227323210,9,622732321009,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-4,,,,,07:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,10,622732321010,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-5,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,12,622732321012,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,14,622732321014,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,11,622732321011,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,13,622732321013,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,15,622732321015,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,16,622732321016,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,17,622732321017,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,18,622732321018,"Red Cells, Clot",Received,,Default Discard/Not Return,SM06/SERUM,BIOMARKERS,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,19,622732321019,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,21,622732321021,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,20,622732321020,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,I-4,19-Mar-2026,19-Mar-2026,6227323210,22,622732321022,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,28-Jan-2026,SCRNSTOOL,29-Jan-2026,29-Jan-2026,6227323211,1,622732321101,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,06:00,07:40,Czech Republic,,07:40,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,28-Jan-2026,SCRNSTOOL,29-Jan-2026,29-Jan-2026,6227323211,2,622732321102,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,06:00,07:40,Czech Republic,,07:40,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,28-Jan-2026,SCRNSTOOL,29-Jan-2026,29-Jan-2026,6227323211,3,622732321103,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,06:00,07:40,Czech Republic,,07:40,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,28-Jan-2026,SCRNSTOOL,29-Jan-2026,29-Jan-2026,6227323211,4,622732321104,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,06:00,07:40,Czech Republic,,07:40,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,03-Mar-2026,SCRNSTOOL,05-Mar-2026,05-Mar-2026,6227323212,1,622732321201,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,13:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,03-Mar-2026,SCRNSTOOL,05-Mar-2026,05-Mar-2026,6227323212,3,622732321203,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,13:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,03-Mar-2026,SCRNSTOOL,05-Mar-2026,05-Mar-2026,6227323212,4,622732321204,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,13:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,03-Mar-2026,SCRNSTOOL,05-Mar-2026,05-Mar-2026,6227323212,2,622732321202,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,13:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRNSTOOL,30-Apr-2026,,6227323213,1,622732321301,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,07:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRNSTOOL,30-Apr-2026,30-Apr-2026,6227323213,2,622732321302,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRNSTOOL,30-Apr-2026,30-Apr-2026,6227323213,3,622732321303,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRNSTOOL,30-Apr-2026,,6227323213,4,622732321304,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,07:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,19-Feb-2026,DNA,20-Feb-2026,20-Feb-2026,6227323217,1,622732321701,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,18-Mar-2026,DNA,19-Mar-2026,19-Mar-2026,6227323219,1,622732321901,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,07:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,17-Jun-2026,BXSCR,18-Jun-2026,18-Jun-2026,6227323222,1,622732322201,Wet Tissue Biopsy,Received,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,17-Jun-2026,BXSCR,18-Jun-2026,,6227323222,2,622732322202,Biopsy RNA Later,Not Received,Frozen,,SM13/BIOPSY RNA,FROZEN,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,17-Jun-2026,BXSCR,18-Jun-2026,,6227323222,3,622732322203,"Biopsy, Frozen Tissue",Not Received,Frozen,,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,17-Jun-2026,BXSCR,18-Jun-2026,,6227323222,4,622732322204,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,05-Feb-2026,BXSCR,06-Feb-2026,06-Feb-2026,6227323223,1,622732322301,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,05-Feb-2026,BXSCR,06-Feb-2026,07-Feb-2026,6227323223,2,622732322302,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:20,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,05-Feb-2026,BXSCR,06-Feb-2026,07-Feb-2026,6227323223,3,622732322303,"Biopsy, Frozen Tissue",Shipped,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:20,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,05-Feb-2026,BXSCR,06-Feb-2026,,6227323223,4,622732322304,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,18-Mar-2026,BXSCR,19-Mar-2026,20-Mar-2026,6227323224,2,622732322402,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,18-Mar-2026,BXSCR,19-Mar-2026,19-Mar-2026,6227323224,1,622732322401,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,18-Mar-2026,BXSCR,19-Mar-2026,20-Mar-2026,6227323224,3,622732322403,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,18-Mar-2026,BXSCR,19-Mar-2026,,6227323224,4,622732322404,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,2,622732323102,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,3,622732323103,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,4,622732323104,"Serum, SST",Not Received,Ambient,,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,19-Mar-2026,6227323231,5,622732323105,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,6,622732323106,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,23-Apr-2026,6227323231,8,622732323108,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,7,622732323107,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,1,622732323101,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,9,622732323109,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,10,622732323110,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,12,622732323112,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,14,622732323114,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,13,622732323113,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,17,622732323117,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,18,622732323118,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,15,622732323115,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,16,622732323116,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,11,622732323111,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,19,622732323119,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,20,622732323120,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,22,622732323122,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,21,622732323121,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,25,622732323125,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,26,622732323126,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,24,622732323124,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,23,622732323123,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,27,622732323127,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,28,622732323128,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,29,622732323129,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323231,30,622732323130,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,3,622732323203,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,4,622732323204,"Serum, SST",Canceled,Ambient,,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,5,622732323205,"Serum, SST",Not Received,Ambient,,FSH,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,6,622732323206,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,7,622732323207,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,8,622732323208,"Feces, unpreserved",Not Received,Frozen,Specimen not submitted,FECAL CALPROTECTIN,FROZEN,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,1,622732323201,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,2,622732323202,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,10,622732323210,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,12,622732323212,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,14,622732323214,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,13,622732323213,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,11,622732323211,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,15,622732323215,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,9,622732323209,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,16,622732323216,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,17,622732323217,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,21,622732323221,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,23,622732323223,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,26,622732323226,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,20,622732323220,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,24,622732323224,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,22,622732323222,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,27,622732323227,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,25,622732323225,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,19,622732323219,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,28,622732323228,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,18,622732323218,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,29,622732323229,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,2,622732323302,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,19-Mar-2026,6227323233,4,622732323304,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCH,23-Apr-2026,,6227323232,30,622732323230,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,19-Mar-2026,6227323233,3,622732323303,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,6,622732323306,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,7,622732323307,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,1,622732323301,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,5,622732323305,"Serum, SST",Not Received,Ambient,,FSH,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,8,622732323308,"Feces, unpreserved",Not Received,Frozen,,FECAL CALPROTECTIN,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,9,622732323309,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,10,622732323310,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,13,622732323313,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,12,622732323312,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,16,622732323316,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,14,622732323314,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,15,622732323315,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,11,622732323311,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,17,622732323317,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,19,622732323319,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,24,622732323324,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,20,622732323320,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,23,622732323323,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,26,622732323326,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,25,622732323325,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,22,622732323322,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,27,622732323327,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,21,622732323321,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,18,622732323318,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,29,622732323329,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,30,622732323330,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,,6227323233,28,622732323328,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,22-Apr-2026,6227323234,2,622732323402,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,,6227323234,3,622732323403,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,22-Apr-2026,6227323234,4,622732323404,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,,6227323234,5,622732323405,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,,6227323234,1,622732323401,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,22-Apr-2026,6227323234,6,622732323406,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,21-Apr-2026,6227323234,10,622732323410,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,22-Apr-2026,6227323234,8,622732323408,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,,6227323234,11,622732323411,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,,6227323234,7,622732323407,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,21-Apr-2026,6227323234,9,622732323409,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,,6227323234,15,622732323415,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,21-Apr-2026,6227323234,14,622732323414,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,,6227323234,13,622732323413,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRN,21-Apr-2026,21-Apr-2026,6227323234,12,622732323412,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,2,622732323602,"Plasma, QuantiFERON Nil",Canceled,Frozen,,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,1,622732323601,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,3,622732323603,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,4,622732323604,"Plasma, QuantiFERON TB1",Canceled,Frozen,,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,8,622732323608,"Plasma, QuantiFERON Mitoge",Canceled,Frozen,,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,5,622732323605,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,18-Feb-2026,6227323236,9,622732323609,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,7,622732323607,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,6,622732323606,"Plasma, QuantiFERON TB2",Canceled,Frozen,,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,11,622732323611,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,18-Feb-2026,6227323236,12,622732323612,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,18-Feb-2026,6227323236,10,622732323610,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,,6227323236,13,622732323613,"Red Cells, Clot",Not Received,,,"CHEM PANEL, BETA",HCG & FSH,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,18-Feb-2026,6227323236,14,622732323614,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRN,18-Feb-2026,18-Feb-2026,6227323236,15,622732323615,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,2,622732323702,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,4,622732323704,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,1,622732323701,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,,6227323237,3,622732323703,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:00,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,,6227323237,7,622732323707,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:00,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,8,622732323708,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,,6227323237,5,622732323705,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:00,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,6,622732323706,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,11,622732323711,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,,6227323237,12,622732323712,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,08:00,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,9,622732323709,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,13,622732323713,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,10,622732323710,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,15,622732323715,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,14,622732323714,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,,6227323237,17,622732323717,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,08:00,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,18,622732323718,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,I-0,21-Mar-2026,21-Mar-2026,6227323237,16,622732323716,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,1,622732323801,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,2,622732323802,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,4,622732323804,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,,6227323238,5,622732323805,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,,6227323238,7,622732323807,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,8,622732323808,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,6,622732323806,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,10,622732323810,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,11,622732323811,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,13,622732323813,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,,6227323238,12,622732323812,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,9,622732323809,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,16,622732323816,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,15,622732323815,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,14,622732323814,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,27-May-2026,6227323238,18,622732323818,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,,6227323238,17,622732323817,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,2,622732324002,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,1,622732324001,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,15,622732324015,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,13,622732324013,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,16,622732324016,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,14,622732324014,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,5,622732324005,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,4,622732324004,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,8,622732324008,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-1,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,9,622732324009,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-2,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,6,622732324006,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,3,622732324003,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,10,622732324010,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-3,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,7,622732324007,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,17,622732324017,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,09-Apr-2026,6227323240,12,622732324012,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-5,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Apr-2026,I-2,09-Apr-2026,,6227323240,11,622732324011,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-4,,,,,07:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,26-May-2026,I-0,27-May-2026,,6227323238,3,622732323803,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,1,622732324201,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,2,622732324202,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,3,622732324203,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,4,622732324204,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,5,622732324205,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,9,622732324209,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-4,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,10,622732324210,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-5,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,7,622732324207,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-2,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,8,622732324208,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-3,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,11,622732324211,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,6,622732324206,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-1,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,13,622732324213,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,12,622732324212,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,15,622732324215,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,16,622732324216,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,17,622732324217,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,19,622732324219,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,14,622732324214,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,21,622732324221,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,,6227323242,18,622732324218,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,20,622732324220,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,15-Apr-2026,I-4,16-Apr-2026,16-Apr-2026,6227323242,22,622732324222,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCSTOOL,18-Mar-2026,,6227323243,1,622732324301,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCSTOOL,18-Mar-2026,,6227323243,3,622732324303,"Culture, Stool",Canceled,Ambient,,STOOL CULTURE,,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRNSTOOL,18-Feb-2026,,6227323244,1,622732324401,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,07:20,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCSTOOL,18-Mar-2026,,6227323243,4,622732324304,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRNSTOOL,18-Feb-2026,18-Feb-2026,6227323244,2,622732324402,"Stool, unpreserved",Canceled,Frozen,,C-DIFF TOXIN,& PCR FROZEN,,,,,07:20,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCSTOOL,18-Mar-2026,18-Mar-2026,6227323243,2,622732324302,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRNSTOOL,18-Feb-2026,18-Feb-2026,6227323244,3,622732324403,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,07:20,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRNSTOOL,18-Feb-2026,,6227323244,4,622732324404,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,07:20,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCSTOOL,12-Mar-2026,12-Mar-2026,6227323245,3,622732324503,"Culture, Stool",Received,Ambient,Default Return Frozen,STOOL CULTURE,,,,,,09:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCSTOOL,12-Mar-2026,,6227323245,4,622732324504,"Stool, ova & parasites(PVA)",Canceled,Ambient,,OVA & PARASITES 2,PVA,,,,,09:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCSTOOL,12-Mar-2026,,6227323245,1,622732324501,"Stool, ova & parasites(form)",Canceled,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,09:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCSTOOL,12-Mar-2026,,6227323245,2,622732324502,"Stool, unpreserved",Canceled,Frozen,,C-DIFF TOXIN,& PCR FROZEN,,,,,09:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,20-Mar-2026,DNA,21-Mar-2026,21-Mar-2026,6227323251,1,622732325101,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,08:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,,6227323252,1,622732325201,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,18-Feb-2026,6227323252,2,622732325202,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,,6227323252,3,622732325203,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,18-Feb-2026,6227323252,4,622732325204,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,,6227323252,5,622732325205,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,18-Feb-2026,6227323252,6,622732325206,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,,6227323252,7,622732325207,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,07:03,,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,TB,18-Feb-2026,18-Feb-2026,6227323252,8,622732325208,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,07:03,07:10,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,12-Mar-2026,6227323253,2,622732325302,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,09:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,,6227323253,1,622732325301,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,09:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,12-Mar-2026,6227323253,6,622732325306,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,09:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,,6227323253,5,622732325305,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,09:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,,6227323253,3,622732325303,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,09:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,12-Mar-2026,6227323253,8,622732325308,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,09:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,,6227323253,7,622732325307,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,09:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,19-Feb-2026,BXSCR,21-Feb-2026,21-Feb-2026,6227323254,2,622732325402,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,19-Feb-2026,BXSCR,21-Feb-2026,21-Feb-2026,6227323254,1,622732325401,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,19-Feb-2026,BXSCR,21-Feb-2026,,6227323254,4,622732325404,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,TB,12-Mar-2026,12-Mar-2026,6227323253,4,622732325304,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,09:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,29-May-2026,BX12,30-May-2026,02-Jun-2026,6227323255,2,622732325502,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,29-May-2026,BX12,30-May-2026,30-May-2026,6227323255,1,622732325501,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,29-May-2026,BX12,30-May-2026,02-Jun-2026,6227323255,3,622732325503,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,19-Feb-2026,BXSCR,21-Feb-2026,21-Feb-2026,6227323254,3,622732325403,"Biopsy, Frozen Tissue",Shipped,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,05:55,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,29-May-2026,BX12,30-May-2026,02-Jun-2026,6227323255,4,622732325504,"Biopsy, Frozen Tissue",Shipped,Frozen,Default Return Frozen,BIOPSY PK,77242113UCO3001,,,,,00:00,07:00,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,14-May-2026,BXSCR,15-May-2026,15-May-2026,6227323256,1,622732325601,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,14-May-2026,BXSCR,15-May-2026,15-May-2026,6227323256,2,622732325602,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,14-May-2026,BXSCR,15-May-2026,15-May-2026,6227323256,3,622732325603,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,14-May-2026,BXSCR,15-May-2026,,6227323256,4,622732325604,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,7,622732326407,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,6,622732326406,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,12-Mar-2026,6227323264,1,622732326401,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,12-Mar-2026,6227323264,2,622732326402,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,9,622732326409,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,10,622732326410,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,3,622732326403,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,8,622732326408,"Feces, unpreserved",Not Received,Frozen,,FECAL CALPROTECTIN,FROZEN,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,11,622732326411,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,4,622732326404,"Serum, SST",Not Received,Ambient,,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,13,622732326413,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,12,622732326412,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,15,622732326415,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,14,622732326414,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,17,622732326417,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,16,622732326416,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,18,622732326418,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,20,622732326420,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,5,622732326405,"Serum, SST",Not Received,Ambient,,FSH,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,22,622732326422,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,21,622732326421,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,23,622732326423,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,24,622732326424,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,25,622732326425,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,19,622732326419,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,26,622732326426,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,27,622732326427,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,28,622732326428,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,29,622732326429,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,11-Mar-2026,UNSCH,12-Mar-2026,,6227323264,30,622732326430,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,18-Mar-2026,6227323265,1,622732326501,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,3,622732326503,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,4,622732326504,"Serum, SST",Not Received,Ambient,,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,18-Mar-2026,6227323265,2,622732326502,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,5,622732326505,"Serum, SST",Not Received,Ambient,,FSH,,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,8,622732326508,"Feces, unpreserved",Not Received,Frozen,,FECAL CALPROTECTIN,FROZEN,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,6,622732326506,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,7,622732326507,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,9,622732326509,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,10,622732326510,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,11,622732326511,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,12,622732326512,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,13,622732326513,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,14,622732326514,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,15,622732326515,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,21,622732326521,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,18,622732326518,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,17,622732326517,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,25,622732326525,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,22,622732326522,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,20,622732326520,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,29,622732326529,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,27,622732326527,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,24,622732326524,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,16,622732326516,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,19,622732326519,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,28,622732326528,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,26,622732326526,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,30,622732326530,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,17-Mar-2026,UNSCH,18-Mar-2026,,6227323265,23,622732326523,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,,6227323266,1,622732326601,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,16:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,,6227323266,3,622732326603,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,16:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,17-Jan-2026,6227323266,2,622732326602,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,16:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,,6227323266,5,622732326605,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,16:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,,6227323266,7,622732326607,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,16:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,17-Jan-2026,6227323266,6,622732326606,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,16:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,16-Jan-2026,6227323266,9,622732326609,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,16:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,16-Jan-2026,6227323266,10,622732326610,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,16:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,17-Jan-2026,6227323266,8,622732326608,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,16:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,17-Jan-2026,6227323266,4,622732326604,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,16:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,16-Jan-2026,6227323266,12,622732326612,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,16:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,,6227323266,13,622732326613,"Red Cells, Clot",Not Received,,,"CHEM PANEL, BETA",HCG & FSH,,,,,16:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,,6227323266,11,622732326611,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,16:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,16-Jan-2026,6227323266,14,622732326614,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,16:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRN,16-Jan-2026,,6227323266,15,622732326615,"Serum, SST",Canceled,Ambient,,FSH,,,,,,16:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,,6227323268,1,622732326801,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,30-Jan-2026,6227323268,2,622732326802,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,,6227323268,3,622732326803,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,30-Jan-2026,6227323268,4,622732326804,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,,6227323268,5,622732326805,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,30-Jan-2026,6227323268,6,622732326806,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,,6227323268,7,622732326807,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,24-Jan-2026,6227323268,12,622732326812,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,,6227323268,13,622732326813,"Red Cells, Clot",Not Received,,,"CHEM PANEL, BETA",HCG & FSH,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,24-Jan-2026,6227323268,14,622732326814,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,,6227323268,15,622732326815,"Serum, SST",Canceled,Ambient,,FSH,,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,30-Jan-2026,6227323268,8,622732326808,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,24-Jan-2026,6227323268,10,622732326810,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,24-Jan-2026,6227323268,9,622732326809,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRN,24-Jan-2026,,6227323268,11,622732326811,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,,6227323270,3,622732327003,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,2,622732327002,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,4,622732327004,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,,6227323270,5,622732327005,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,6,622732327006,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,1,622732327001,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,8,622732327008,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,,6227323270,7,622732327007,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,10,622732327010,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,9,622732327009,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,11,622732327011,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,,6227323270,12,622732327012,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,13,622732327013,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,14,622732327014,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,15,622732327015,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,18,622732327018,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,,6227323270,17,622732327017,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,I-0,10-Mar-2026,10-Mar-2026,6227323270,16,622732327016,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,1,622732327201,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,2,622732327202,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,12,622732327212,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-5,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,13,622732327213,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,3,622732327203,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,11,622732327211,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-4,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,14,622732327214,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,15,622732327215,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,17,622732327217,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,10,622732327210,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-3,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,16,622732327216,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,5,622732327205,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,6,622732327206,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,4,622732327204,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,28-Mar-2026,6227323272,7,622732327207,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,07:10,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,8,622732327208,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-1,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,27-Mar-2026,I-2,28-Mar-2026,,6227323272,9,622732327209,"Stool, unpreserved",Canceled,Frozen,,STOOL I-2,77242113UCO3001-2,,,,,07:10,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,1,622732327401,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,2,622732327402,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,3,622732327403,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,5,622732327405,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,4,622732327404,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,6,622732327406,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-1,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,7,622732327407,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-2,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,8,622732327408,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-3,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,9,622732327409,"Stool, unpreserved",Canceled,Frozen,,STOOL I-4,77242113UCO3001-4,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,11,622732327411,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,10,622732327410,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-5,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,12,622732327412,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,20,622732327420,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,21,622732327421,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,13,622732327413,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,22,622732327422,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,15,622732327415,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,19,622732327419,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,16,622732327416,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,14,622732327414,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,09-Apr-2026,6227323274,17,622732327417,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,08-Apr-2026,I-4,09-Apr-2026,,6227323274,18,622732327418,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRNSTOOL,16-Jan-2026,,6227323276,1,622732327601,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,16:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRNSTOOL,16-Jan-2026,16-Jan-2026,6227323276,2,622732327602,"Stool, unpreserved",Canceled,Frozen,,C-DIFF TOXIN,& PCR FROZEN,,,,,16:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRNSTOOL,16-Jan-2026,,6227323276,4,622732327604,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,16:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,15-Jan-2026,SCRNSTOOL,16-Jan-2026,16-Jan-2026,6227323276,3,622732327603,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,16:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRNSTOOL,24-Jan-2026,,6227323277,1,622732327701,"Stool, ova & parasites(form)",Canceled,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,10:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRNSTOOL,24-Jan-2026,24-Jan-2026,6227323277,3,622732327703,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,10:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRNSTOOL,24-Jan-2026,24-Jan-2026,6227323277,2,622732327702,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,10:10,12:40,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222002,23-Jan-2026,SCRNSTOOL,24-Jan-2026,,6227323277,4,622732327704,"Stool, ova & parasites(PVA)",Canceled,Ambient,,OVA & PARASITES 2,PVA,,,,,10:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,09-Mar-2026,DNA,10-Mar-2026,10-Mar-2026,6227323283,1,622732328301,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,18-Feb-2026,BXSCR,19-Feb-2026,19-Feb-2026,6227323286,1,622732328601,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,10:20,Czech Republic,,10:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,18-Feb-2026,BXSCR,19-Feb-2026,21-Feb-2026,6227323286,3,622732328603,"Biopsy, Frozen Tissue",Shipped,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,05:55,Czech Republic,,10:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,18-Feb-2026,BXSCR,19-Feb-2026,21-Feb-2026,6227323286,2,622732328602,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,05:55,Czech Republic,,10:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,18-Feb-2026,BXSCR,19-Feb-2026,,6227323286,4,622732328604,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,10:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,11-Feb-2026,BXSCR,12-Feb-2026,12-Feb-2026,6227323287,1,622732328701,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,11-Feb-2026,BXSCR,12-Feb-2026,14-Feb-2026,6227323287,3,622732328703,"Biopsy, Frozen Tissue",Shipped,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:45,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,11-Feb-2026,BXSCR,12-Feb-2026,,6227323287,4,622732328704,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,11-Feb-2026,BXSCR,12-Feb-2026,14-Feb-2026,6227323287,2,622732328702,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,05:55,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,2,622732329502,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,3,622732329503,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,1,622732329501,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,6,622732329506,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,5,622732329505,"Serum, SST",Not Received,Ambient,,FSH,,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,7,622732329507,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,8,622732329508,"Feces, unpreserved",Not Received,Frozen,,FECAL CALPROTECTIN,FROZEN,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,11,622732329511,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,9,622732329509,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,10,622732329510,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,14-Mar-2026,6227323295,4,622732329504,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,08:40,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,12,622732329512,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,13,622732329513,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,14,622732329514,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,16,622732329516,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,15,622732329515,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,17,622732329517,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,19,622732329519,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,18,622732329518,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,20,622732329520,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,23,622732329523,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,22,622732329522,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,21,622732329521,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,25,622732329525,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,26,622732329526,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,27,622732329527,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,24,622732329524,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,29,622732329529,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,30,622732329530,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,13-Mar-2026,SCRN,14-Mar-2026,,6227323295,28,622732329528,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,08:40,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,2,622732329702,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,14-Mar-2026,6227323297,4,622732329704,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,07:45,07:20,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,6,622732329706,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,5,622732329705,"Serum, SST",Not Received,Ambient,,FSH,,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,1,622732329701,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,3,622732329703,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,7,622732329707,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,8,622732329708,"Feces, unpreserved",Not Received,Frozen,,FECAL CALPROTECTIN,FROZEN,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,10,622732329710,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,9,622732329709,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,11,622732329711,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,12,622732329712,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,14,622732329714,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,13,622732329713,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,18,622732329718,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,16,622732329716,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,15,622732329715,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,20,622732329720,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,19,622732329719,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,17,622732329717,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,21,622732329721,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,23,622732329723,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,25,622732329725,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,27,622732329727,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,26,622732329726,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,28,622732329728,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,29,622732329729,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,30,622732329730,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,22,622732329722,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,13-Mar-2026,SCRN,14-Mar-2026,,6227323297,24,622732329724,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,07:45,,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,,6227323299,1,622732329901,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,08:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,,6227323299,3,622732329903,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,08:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,15-May-2026,6227323299,4,622732329904,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,,6227323299,5,622732329905,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,08:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,15-May-2026,6227323299,2,622732329902,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,,6227323299,7,622732329907,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,08:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,15-May-2026,6227323299,8,622732329908,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,14-May-2026,6227323299,9,622732329909,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,15-May-2026,6227323299,6,622732329906,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,,6227323299,11,622732329911,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,08:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,14-May-2026,6227323299,12,622732329912,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,14-May-2026,6227323299,10,622732329910,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,,6227323299,13,622732329913,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,08:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,14-May-2026,6227323299,15,622732329915,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRN,14-May-2026,14-May-2026,6227323299,14,622732329914,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,08:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,11-Jun-2026,6227323301,2,622732330102,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,,6227323301,3,622732330103,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,11-Jun-2026,6227323301,1,622732330101,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,11-Jun-2026,6227323301,4,622732330104,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,,6227323301,5,622732330105,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,11-Jun-2026,6227323301,8,622732330108,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,11-Jun-2026,6227323301,6,622732330106,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,,6227323301,7,622732330107,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,11-Jun-2026,6227323301,9,622732330109,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,,6227323301,12,622732330112,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,11-Jun-2026,6227323301,13,622732330113,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,11-Jun-2026,6227323301,10,622732330110,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,11-Jun-2026,6227323301,11,622732330111,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,11-Jun-2026,6227323301,16,622732330116,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,11-Jun-2026,6227323301,15,622732330115,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,11-Jun-2026,6227323301,14,622732330114,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,11-Jun-2026,6227323301,18,622732330118,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,I-0,11-Jun-2026,,6227323301,17,622732330117,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRNSTOOL,14-May-2026,14-May-2026,6227323309,1,622732330901,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRNSTOOL,14-May-2026,14-May-2026,6227323309,2,622732330902,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRNSTOOL,14-May-2026,14-May-2026,6227323309,4,622732330904,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,13-May-2026,SCRNSTOOL,14-May-2026,14-May-2026,6227323309,3,622732330903,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,10-Jun-2026,DNA,11-Jun-2026,11-Jun-2026,6227323313,1,622732331301,"Whole Blood, EDTA, Dry",In Inventory,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,27-May-2026,BXSCR,28-May-2026,28-May-2026,6227323320,1,622732332001,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,27-May-2026,BXSCR,28-May-2026,29-May-2026,6227323320,2,622732332002,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,27-May-2026,BXSCR,28-May-2026,29-May-2026,6227323320,3,622732332003,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,27-May-2026,BXSCR,28-May-2026,,6227323320,4,622732332004,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,,6227323330,1,622732333001,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,08:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,03-Apr-2026,6227323330,2,622732333002,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,,6227323330,3,622732333003,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,08:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,,6227323330,5,622732333005,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,08:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,03-Apr-2026,6227323330,4,622732333004,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,,6227323330,7,622732333007,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,08:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,03-Apr-2026,6227323330,8,622732333008,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,01-Apr-2026,6227323330,9,622732333009,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,03-Apr-2026,6227323330,6,622732333006,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,01-Apr-2026,6227323330,10,622732333010,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,,6227323330,11,622732333011,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,08:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,,6227323330,13,622732333013,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,08:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,01-Apr-2026,6227323330,12,622732333012,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,,6227323330,15,622732333015,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,08:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,31-Mar-2026,SCRN,01-Apr-2026,01-Apr-2026,6227323330,14,622732333014,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,,6227323331,1,622732333101,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,10:50,,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,16-Jun-2026,6227323331,2,622732333102,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,10:50,07:20,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,,6227323331,3,622732333103,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,10:50,,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,,6227323331,5,622732333105,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,10:50,,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,16-Jun-2026,6227323331,4,622732333104,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,10:50,07:20,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,16-Jun-2026,6227323331,6,622732333106,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,10:50,07:20,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,,6227323331,7,622732333107,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,10:50,,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,16-Jun-2026,6227323331,8,622732333108,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,10:50,07:20,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,12-Jun-2026,6227323331,9,622732333109,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:50,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,12-Jun-2026,6227323331,10,622732333110,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:50,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,,6227323331,11,622732333111,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,10:50,,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,12-Jun-2026,6227323331,12,622732333112,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,10:50,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,,6227323331,13,622732333113,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,10:50,,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,,6227323331,15,622732333115,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,10:50,,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRN,12-Jun-2026,12-Jun-2026,6227323331,14,622732333114,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,10:50,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,,6227323332,1,622732333201,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,12:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,21-Apr-2026,6227323332,2,622732333202,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,,6227323332,3,622732333203,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,12:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,21-Apr-2026,6227323332,6,622732333206,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,21-Apr-2026,6227323332,4,622732333204,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,21-Apr-2026,6227323332,8,622732333208,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,17-Apr-2026,6227323332,9,622732333209,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,,6227323332,5,622732333205,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,12:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,17-Apr-2026,6227323332,10,622732333210,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,,6227323332,7,622732333207,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,12:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,,6227323332,11,622732333211,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,12:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,17-Apr-2026,6227323332,12,622732333212,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,17-Apr-2026,6227323332,14,622732333214,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,,6227323332,13,622732333213,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,12:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,16-Apr-2026,SCRN,17-Apr-2026,17-Apr-2026,6227323332,15,622732333215,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,12:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,1,622732333401,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,4,622732333404,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,2,622732333402,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,,6227323334,5,622732333405,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,11:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,,6227323334,3,622732333403,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,11:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,6,622732333406,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,,6227323334,7,622732333407,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,11:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,8,622732333408,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,9,622732333409,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,10,622732333410,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,11,622732333411,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,,6227323334,12,622732333412,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,11:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,13,622732333413,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,14,622732333414,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,15,622732333415,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,16,622732333416,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,,6227323334,17,622732333417,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,11:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,I-0,06-May-2026,06-May-2026,6227323334,18,622732333418,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,2,622732333502,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,,6227323335,3,622732333503,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,10:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,,6227323335,5,622732333505,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,10:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,,6227323335,1,622732333501,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,10:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,7,622732333507,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,6,622732333506,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,4,622732333504,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,8,622732333508,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-1,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,9,622732333509,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-2,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,11,622732333511,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-4,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,10,622732333510,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-3,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,13,622732333513,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,15,622732333515,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,,6227323335,16,622732333516,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,10:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,17,622732333517,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,14,622732333514,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,19-May-2026,I-2,20-May-2026,20-May-2026,6227323335,12,622732333512,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-5,,,,,10:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,,6227323337,1,622732333701,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,09:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,3,622732333703,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,4,622732333704,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,5,622732333705,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,7,622732333707,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-2,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,,6227323337,11,622732333711,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,8,622732333708,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-3,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,6,622732333706,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-1,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,9,622732333709,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-4,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,2,622732333702,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,12,622732333712,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,,6227323337,13,622732333713,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,14,622732333714,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,,6227323337,15,622732333715,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,10,622732333710,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-5,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,16,622732333716,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,19,622732333719,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,17,622732333717,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,,6227323337,18,622732333718,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,21,622732333721,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,20,622732333720,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,04-Jun-2026,I-4,05-Jun-2026,05-Jun-2026,6227323337,22,622732333722,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,09:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRNSTOOL,12-Jun-2026,12-Jun-2026,6227323339,4,622732333904,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,11:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRNSTOOL,12-Jun-2026,12-Jun-2026,6227323339,2,622732333902,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,11:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRNSTOOL,12-Jun-2026,12-Jun-2026,6227323339,3,622732333903,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,11:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,02-Apr-2026,SCRNSTOOL,03-Apr-2026,03-Apr-2026,6227323340,2,622732334002,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,06:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,02-Apr-2026,SCRNSTOOL,03-Apr-2026,03-Apr-2026,6227323340,4,622732334004,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,06:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,02-Apr-2026,SCRNSTOOL,03-Apr-2026,03-Apr-2026,6227323340,3,622732334003,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,06:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,02-Apr-2026,SCRNSTOOL,03-Apr-2026,03-Apr-2026,6227323340,1,622732334001,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,06:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,21-Apr-2026,6227323341,1,622732334101,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,06:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,21-Apr-2026,6227323341,2,622732334102,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,06:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092003,11-Jun-2026,SCRNSTOOL,12-Jun-2026,12-Jun-2026,6227323339,1,622732333901,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,11:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,21-Apr-2026,6227323341,3,622732334103,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,06:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,21-Apr-2026,6227323341,4,622732334104,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,06:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,DNA,06-May-2026,06-May-2026,6227323346,1,622732334601,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,,6227323348,1,622732334801,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,07-May-2026,6227323348,2,622732334802,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,,6227323348,3,622732334803,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,07-May-2026,6227323348,4,622732334804,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,,6227323348,5,622732334805,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,,6227323348,7,622732334807,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,09:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,07-May-2026,6227323348,6,622732334806,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092002,05-May-2026,TB,07-May-2026,07-May-2026,6227323348,8,622732334808,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,09:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,TB Testing,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,24-Apr-2026,BXSCR,28-Apr-2026,,6227323351,4,622732335104,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,24-Apr-2026,BXSCR,28-Apr-2026,28-Apr-2026,6227323351,3,622732335103,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,24-Apr-2026,BXSCR,28-Apr-2026,28-Apr-2026,6227323351,2,622732335102,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,24-Apr-2026,BXSCR,28-Apr-2026,28-Apr-2026,6227323351,1,622732335101,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,BDL,06-May-2026,,6227323355,1,622732335501,"Red Cells, Clot",Not Received,,,DRUG LEVEL TESTING,,,,,,11:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biologic Drug Level,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,05-May-2026,BDL,06-May-2026,06-May-2026,6227323355,2,622732335502,"Serum, SST",Shipped,Frozen,Default Return Frozen,"ADA, GOL, INF",UST OR VED FROZEN,,,,,11:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biologic Drug Level,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,,6227635139,1,622763513901,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,,6227635139,3,622763513903,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,03-Apr-2026,6227635139,8,622763513908,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,03-Apr-2026,6227635139,4,622763513904,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,03-Apr-2026,6227635139,2,622763513902,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,,6227635140,5,622763514005,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,13:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,28-Feb-2026,6227635140,8,622763514008,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,13:20,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,,6227635139,13,622763513913,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,03-Apr-2026,6227635139,6,622763513906,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,28-Feb-2026,6227635140,6,622763514006,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,13:20,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,,6227635140,7,622763514007,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,13:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,27-Feb-2026,6227635140,9,622763514009,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,13:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,02-Apr-2026,6227635139,10,622763513910,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,,6227635139,15,622763513915,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,02-Apr-2026,6227635139,12,622763513912,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,02-Apr-2026,6227635139,9,622763513909,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,,6227635139,7,622763513907,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,28-Feb-2026,6227635140,4,622763514004,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,13:20,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,,6227635139,11,622763513911,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,28-Feb-2026,6227635140,2,622763514002,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,13:20,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,,6227635140,3,622763514003,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,13:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,,6227635140,1,622763514001,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,13:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,,6227635139,5,622763513905,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,08:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRN,02-Apr-2026,02-Apr-2026,6227635139,14,622763513914,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,08:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,27-Feb-2026,6227635140,12,622763514012,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,13:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,27-Feb-2026,6227635140,14,622763514014,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,13:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,,6227635141,1,622763514101,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,,6227635140,15,622763514015,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,13:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,08-May-2026,6227635141,2,622763514102,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,,6227635140,11,622763514011,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,13:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,27-Feb-2026,6227635140,10,622763514010,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,,6227635141,3,622763514103,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRN,27-Feb-2026,,6227635140,13,622763514013,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,13:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,08-May-2026,6227635141,8,622763514108,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,07-May-2026,6227635141,9,622763514109,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,,6227635141,11,622763514111,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,07-May-2026,6227635141,12,622763514112,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,07-May-2026,6227635141,10,622763514110,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,,6227635141,13,622763514113,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,,6227635141,7,622763514107,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,08-May-2026,6227635141,6,622763514106,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,,6227635142,3,622763514203,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:40,,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,4,622763514204,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,13,622763514213,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,,6227635142,5,622763514205,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:40,,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,,6227635141,5,622763514105,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,08-May-2026,6227635141,4,622763514104,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,6,622763514206,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,14,622763514214,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,2,622763514202,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,10,622763514210,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,1,622763514201,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,15,622763514215,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,,6227635142,7,622763514207,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:40,,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,9,622763514209,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,16,622763514216,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,,6227635142,17,622763514217,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,09:40,,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,07-May-2026,6227635141,14,622763514114,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,06-May-2026,SCRN,07-May-2026,,6227635141,15,622763514115,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,,6227635142,12,622763514212,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:40,,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,11,622763514211,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,8,622763514208,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,I-0,26-Mar-2026,26-Mar-2026,6227635142,18,622763514218,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,7,622763514407,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,6,622763514406,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,,6227635144,3,622763514403,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,2,622763514402,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,,6227635144,1,622763514401,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,08-Apr-2026,6227635144,15,622763514415,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,,6227635144,16,622763514416,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,8,622763514408,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-1,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,10,622763514410,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-3,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,4,622763514404,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,08-Apr-2026,6227635144,17,622763514417,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,12,622763514412,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-5,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,11,622763514411,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-4,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,08-Apr-2026,6227635144,14,622763514414,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,13,622763514413,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,,6227635144,5,622763514405,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,07-Apr-2026,I-2,08-Apr-2026,09-Apr-2026,6227635144,9,622763514409,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-2,,,,,08:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,2,622763514602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,3,622763514603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,23-Apr-2026,6227635146,8,622763514608,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-3,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,23-Apr-2026,6227635146,9,622763514609,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-4,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,23-Apr-2026,6227635146,10,622763514610,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-5,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,16,622763514616,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,14,622763514614,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,21,622763514621,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,4,622763514604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,5,622763514605,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,,6227635146,15,622763514615,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,,6227635146,18,622763514618,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,,6227635146,11,622763514611,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,,6227635146,13,622763514613,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,23-Apr-2026,6227635146,6,622763514606,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-1,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,22,622763514622,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,23-Apr-2026,6227635146,7,622763514607,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-2,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,19,622763514619,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,,6227635146,1,622763514601,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,08:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,17,622763514617,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,12,622763514612,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,21-Apr-2026,I-4,22-Apr-2026,22-Apr-2026,6227635146,20,622763514620,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRNSTOOL,02-Apr-2026,02-Apr-2026,6227635148,3,622763514803,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRNSTOOL,02-Apr-2026,02-Apr-2026,6227635148,4,622763514804,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRNSTOOL,02-Apr-2026,02-Apr-2026,6227635148,1,622763514801,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,07-May-2026,SCRNSTOOL,08-May-2026,08-May-2026,6227635150,2,622763515002,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,05:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,07-May-2026,SCRNSTOOL,08-May-2026,08-May-2026,6227635150,3,622763515003,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,05:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRNSTOOL,27-Feb-2026,27-Feb-2026,6227635149,2,622763514902,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,07-May-2026,SCRNSTOOL,08-May-2026,08-May-2026,6227635150,4,622763515004,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,05:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,01-Apr-2026,SCRNSTOOL,02-Apr-2026,02-Apr-2026,6227635148,2,622763514802,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,08:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRNSTOOL,27-Feb-2026,27-Feb-2026,6227635149,1,622763514901,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRNSTOOL,27-Feb-2026,27-Feb-2026,6227635149,4,622763514904,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,26-Feb-2026,SCRNSTOOL,27-Feb-2026,27-Feb-2026,6227635149,3,622763514903,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,07-May-2026,SCRNSTOOL,08-May-2026,08-May-2026,6227635150,1,622763515001,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,05:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,24-Mar-2026,DNA,26-Mar-2026,26-Mar-2026,6227635156,1,622763515601,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,09:40,05:55,Czech Republic,,05:55,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,DNA,03-Jun-2026,03-Jun-2026,6227635154,1,622763515401,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,DNA,27-May-2026,27-May-2026,6227635155,1,622763515501,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,21-Apr-2026,BXSCR,22-Apr-2026,,6227635159,4,622763515904,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,21-Apr-2026,BXSCR,22-Apr-2026,22-Apr-2026,6227635159,1,622763515901,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,21-Apr-2026,BXSCR,22-Apr-2026,23-Apr-2026,6227635159,2,622763515902,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,21-Apr-2026,BXSCR,22-Apr-2026,23-Apr-2026,6227635159,3,622763515903,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,12-Mar-2026,BXSCR,13-Mar-2026,14-Mar-2026,6227635161,3,622763516103,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:20,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,12-Mar-2026,BXSCR,13-Mar-2026,,6227635161,4,622763516104,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,12-Mar-2026,BXSCR,13-Mar-2026,13-Mar-2026,6227635161,1,622763516101,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,12-Mar-2026,BXSCR,13-Mar-2026,14-Mar-2026,6227635161,2,622763516102,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:20,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,,6227635171,1,622763517101,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,23-Apr-2026,6227635171,2,622763517102,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,,6227635171,5,622763517105,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,,6227635171,7,622763517107,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,,6227635171,3,622763517103,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,23-Apr-2026,6227635171,6,622763517106,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,23-Apr-2026,6227635171,4,622763517104,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,22-Apr-2026,6227635171,10,622763517110,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,22-Apr-2026,6227635171,14,622763517114,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,22-Apr-2026,6227635171,15,622763517115,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,,6227635171,11,622763517111,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,23-Apr-2026,6227635171,8,622763517108,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,22-Apr-2026,6227635171,9,622763517109,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,,6227635171,13,622763517113,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,21-Apr-2026,SCRN,22-Apr-2026,22-Apr-2026,6227635171,12,622763517112,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,30-May-2026,6227635173,2,622763517302,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,12:35,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,30-May-2026,6227635173,6,622763517306,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,12:35,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,,6227635173,7,622763517307,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,12:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,30-May-2026,6227635173,8,622763517308,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,12:35,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,,6227635173,5,622763517305,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,12:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,28-May-2026,6227635173,10,622763517310,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,30-May-2026,6227635173,4,622763517304,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,12:35,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,28-May-2026,6227635173,9,622763517309,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,,6227635173,1,622763517301,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,12:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,,6227635173,3,622763517303,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,12:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,28-May-2026,6227635173,14,622763517314,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,12:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,,6227635173,13,622763517313,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,12:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,29-May-2026,6227635174,1,622763517401,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,28-May-2026,6227635173,15,622763517315,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,12:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,3,622763517403,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,,6227635173,11,622763517311,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,12:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,29-May-2026,6227635174,2,622763517402,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRN,28-May-2026,28-May-2026,6227635173,12,622763517312,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,12:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,9,622763517409,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,,6227635174,5,622763517405,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,11,622763517411,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,6,622763517406,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,,6227635174,12,622763517412,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,4,622763517404,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,,6227635174,7,622763517407,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,8,622763517408,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,13,622763517413,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,10,622763517410,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,14,622763517414,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,29-May-2026,6227635174,18,622763517418,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,10:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,,6227635174,17,622763517417,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,10:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,15,622763517415,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,I-0,29-May-2026,30-May-2026,6227635174,16,622763517416,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,10:45,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,,6227635177,3,622763517703,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:45,,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,,6227635177,1,622763517701,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:45,,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,,6227635177,5,622763517705,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:45,,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6227635177,6,622763517706,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,08:45,07:55,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6227635177,13,622763517713,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:45,07:55,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6227635177,15,622763517715,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:45,07:55,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,,6227635177,16,622763517716,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,08:45,,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6227635177,7,622763517707,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,08:45,07:55,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,,6227635177,10,622763517710,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,08:45,,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6227635177,8,622763517708,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-1,,,,,08:45,07:05,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6227635177,17,622763517717,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:45,07:55,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6227635177,2,622763517702,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,08:45,07:55,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6227635177,4,622763517704,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,08:45,07:55,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,,6227635177,12,622763517712,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-5,,,,,08:45,,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6227635177,14,622763517714,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:45,07:55,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,,6227635177,9,622763517709,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,08:45,,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,11-Jun-2026,I-2,12-Jun-2026,,6227635177,11,622763517711,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,08:45,,Czech Republic,,07:55,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRNSTOOL,28-May-2026,,6227635180,1,622763518001,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,13:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRNSTOOL,28-May-2026,28-May-2026,6227635180,3,622763518003,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,13:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRNSTOOL,28-May-2026,,6227635180,4,622763518004,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,13:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,27-May-2026,SCRNSTOOL,28-May-2026,30-May-2026,6227635180,2,622763518002,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,13:15,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,24-Apr-2026,SCRNSTOOL,25-Apr-2026,,6227635182,4,622763518204,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,08:45,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,24-Apr-2026,SCRNSTOOL,25-Apr-2026,25-Apr-2026,6227635182,3,622763518203,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,08:45,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,24-Apr-2026,SCRNSTOOL,25-Apr-2026,,6227635182,1,622763518201,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,08:45,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,24-Apr-2026,SCRNSTOOL,25-Apr-2026,,6227635182,2,622763518202,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,C-DIFF TOXIN,& PCR FROZEN,,,,,08:45,,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,28-May-2026,DNA,30-May-2026,30-May-2026,6227635186,1,622763518601,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,10:45,07:30,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,16-Jun-2026,BXSCR,17-Jun-2026,,6227635192,3,622763519203,"Biopsy, Frozen Tissue",Not Received,Frozen,,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,19-May-2026,BXSCR,20-May-2026,21-May-2026,6227635193,2,622763519302,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,19-May-2026,BXSCR,20-May-2026,20-May-2026,6227635193,1,622763519301,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,19-May-2026,BXSCR,20-May-2026,21-May-2026,6227635193,3,622763519303,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,16-Jun-2026,BXSCR,17-Jun-2026,,6227635192,4,622763519204,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,16-Jun-2026,BXSCR,17-Jun-2026,17-Jun-2026,6227635192,1,622763519201,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,19-May-2026,BXSCR,20-May-2026,,6227635193,4,622763519304,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,16-Jun-2026,BXSCR,17-Jun-2026,,6227635192,2,622763519202,Biopsy RNA Later,Not Received,Frozen,,SM13/BIOPSY RNA,FROZEN,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,,6227635204,1,622763520401,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,12:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,03-Mar-2026,6227635204,2,622763520402,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,,6227635204,3,622763520403,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,12:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,26-Feb-2026,6227635204,15,622763520415,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,26-Feb-2026,6227635204,9,622763520409,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,26-Feb-2026,6227635204,10,622763520410,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,,6227635204,11,622763520411,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,12:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,26-Feb-2026,6227635204,12,622763520412,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,,6227635204,13,622763520413,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,12:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,,6227635204,5,622763520405,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,12:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,03-Mar-2026,6227635204,4,622763520404,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,26-Feb-2026,6227635204,14,622763520414,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,,6227635204,7,622763520407,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,12:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,03-Mar-2026,6227635204,6,622763520406,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,25-Feb-2026,SCRN,26-Feb-2026,03-Mar-2026,6227635204,8,622763520408,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,12:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227635207,2,622763520702,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,8,622763520708,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,,6227635207,5,622763520705,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,10:37,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,4,622763520704,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,9,622763520709,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227635207,1,622763520701,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,11,622763520711,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,,6227635207,3,622763520703,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,10:37,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,6,622763520706,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,,6227635207,17,622763520717,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,10:37,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227635207,18,622763520718,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,28-Apr-2026,6227635208,2,622763520802,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,3,622763520803,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,13,622763520713,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,1,622763520801,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,,6227635207,7,622763520707,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,10:37,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,10,622763520710,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,,6227635207,12,622763520712,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,10:37,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,16,622763520716,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,28-Apr-2026,6227635208,7,622763520807,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,9,622763520809,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,10,622763520810,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,11,622763520811,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,14,622763520714,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,I-0,08-Apr-2026,09-Apr-2026,6227635207,15,622763520715,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,12,622763520812,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-5,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,28-Apr-2026,6227635208,4,622763520804,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,28-Apr-2026,6227635208,6,622763520806,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,28-Apr-2026,6227635208,8,622763520808,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-1,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,21-Apr-2026,6227635208,17,622763520817,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,21-Apr-2026,6227635208,14,622763520814,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,5,622763520805,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,28-Apr-2026,6227635208,13,622763520813,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,,6227635208,16,622763520816,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,08:43,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,20-Apr-2026,I-2,21-Apr-2026,21-Apr-2026,6227635208,15,622763520815,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:43,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,06-May-2026,6227635211,2,622763521102,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,06-May-2026,6227635211,3,622763521103,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,06-May-2026,6227635211,4,622763521104,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,1,622763521101,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,8,622763521108,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-3,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,10,622763521110,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-5,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,6,622763521106,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-1,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,5,622763521105,"Feces, unpreserved",Not Received,Frozen,Specimen not submitted,FECAL CALPROTECTIN,FROZEN,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,11,622763521111,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,13,622763521113,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,14,622763521114,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,7,622763521107,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-2,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,19,622763521119,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,16,622763521116,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,20,622763521120,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,9,622763521109,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-4,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,21,622763521121,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,22,622763521122,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,17,622763521117,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,18,622763521118,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,07-May-2026,6227635211,12,622763521112,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,10:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,01-Mar-2026,SCRNSTOOL,03-Mar-2026,03-Mar-2026,6227635213,2,622763521302,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,14:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,01-Mar-2026,SCRNSTOOL,03-Mar-2026,03-Mar-2026,6227635213,3,622763521303,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,14:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,01-Mar-2026,SCRNSTOOL,03-Mar-2026,03-Mar-2026,6227635213,4,622763521304,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,14:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,05-May-2026,I-4,06-May-2026,,6227635211,15,622763521115,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,10:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,01-Mar-2026,SCRNSTOOL,03-Mar-2026,03-Mar-2026,6227635213,1,622763521301,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,14:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,07-Apr-2026,DNA,09-Apr-2026,09-Apr-2026,6227635218,1,622763521801,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,10:37,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,16-Mar-2026,BXSCR,18-Mar-2026,18-Mar-2026,6227635223,2,622763522302,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,16-Mar-2026,BXSCR,18-Mar-2026,18-Mar-2026,6227635223,1,622763522301,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,16-Mar-2026,BXSCR,18-Mar-2026,18-Mar-2026,6227635223,3,622763522303,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,16-Mar-2026,BXSCR,18-Mar-2026,,6227635223,4,622763522304,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,20-Mar-2026,6227697718,2,622769771802,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,,6227697718,3,622769771803,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,09:18,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,,6227697718,5,622769771805,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,09:18,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,,6227697718,1,622769771801,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,09:18,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,20-Mar-2026,6227697718,6,622769771806,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,20-Mar-2026,6227697718,4,622769771804,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,,6227697718,7,622769771807,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,09:18,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,,6227697718,11,622769771811,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,09:18,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,,6227697718,13,622769771813,"Red Cells, Clot",Not Received,,,"CHEM PANEL, BETA",HCG & FSH,,,,,09:18,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,19-Mar-2026,6227697718,10,622769771810,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,19-Mar-2026,6227697718,14,622769771814,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,19-Mar-2026,6227697718,15,622769771815,"Serum, SST",Received,Ambient,Default Return Ambient,FSH,,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,20-Mar-2026,6227697718,8,622769771808,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,1,622769771901,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,2,622769771902,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,4,622769771904,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,,6227697719,5,622769771905,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,11:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,,6227697719,3,622769771903,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,11:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,8,622769771908,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,,6227697719,7,622769771907,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,11:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,6,622769771906,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,10,622769771910,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,19-Mar-2026,6227697718,9,622769771809,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,11,622769771911,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,18-Mar-2026,SCRN,19-Mar-2026,19-Mar-2026,6227697718,12,622769771812,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,09:18,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,9,622769771909,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,,6227697719,12,622769771912,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,11:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,13,622769771913,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,14,622769771914,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,,6227697719,17,622769771917,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,11:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,15,622769771915,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,16,622769771916,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,I-0,08-Apr-2026,08-Apr-2026,6227697719,18,622769771918,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,6,622769772206,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,7,622769772207,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,13,622769772213,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,10,622769772210,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,12,622769772212,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-5,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,11,622769772211,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,14,622769772214,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,8,622769772208,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-1,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,15,622769772215,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,9,622769772209,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,2,622769772202,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,5,622769772205,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,3,622769772203,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,4,622769772204,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,1,622769772201,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,1,622769772301,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,4,622769772304,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,2,622769772302,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,3,622769772303,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,5,622769772305,"Feces, unpreserved",Not Received,Frozen,Specimen not submitted,FECAL CALPROTECTIN,FROZEN,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,7,622769772307,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-2,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,,6227697722,16,622769772216,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6227697722,17,622769772217,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,21,622769772321,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,6,622769772306,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-1,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,12,622769772312,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,13,622769772313,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,14,622769772314,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,9,622769772309,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-4,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,18,622769772318,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,16,622769772316,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,17,622769772317,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,8,622769772308,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-3,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,15,622769772315,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,19,622769772319,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,10,622769772310,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-5,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,20,622769772320,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,08-May-2026,6227697723,22,622769772322,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,12:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-May-2026,I-4,08-May-2026,,6227697723,11,622769772311,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,12:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,17-Mar-2026,SCRNSTOOL,19-Mar-2026,,6227697725,1,622769772501,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,17:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,17-Mar-2026,SCRNSTOOL,19-Mar-2026,19-Mar-2026,6227697725,3,622769772503,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,17:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,17-Mar-2026,SCRNSTOOL,19-Mar-2026,,6227697725,4,622769772504,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,17:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,17-Mar-2026,SCRNSTOOL,19-Mar-2026,19-Mar-2026,6227697725,2,622769772502,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,17:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,23-Mar-2026,BXSCR,24-Mar-2026,26-Mar-2026,6227697736,2,622769773602,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,07-Apr-2026,DNA,08-Apr-2026,08-Apr-2026,6227697731,1,622769773101,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,11:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,23-Mar-2026,BXSCR,24-Mar-2026,24-Mar-2026,6227697736,1,622769773601,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,23-Mar-2026,BXSCR,24-Mar-2026,,6227697736,4,622769773604,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,23-Mar-2026,BXSCR,24-Mar-2026,26-Mar-2026,6227697736,3,622769773603,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,5,622769774505,"Serum, SST",Not Received,Ambient,,FSH,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,1,622769774501,"Whole Blood, EDTA, Dry",Not Received,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,6,622769774506,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,4,622769774504,"Serum, SST",Not Received,Ambient,,"CHEM, LIPID PANEL",BETA HCG & CRP,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,08-May-2026,6227697745,8,622769774508,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,3,622769774503,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL,","BHCG, FSH & CRP",,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,2,622769774502,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,7,622769774507,"Serum, SST",Not Received,Ambient,,"HIV SCREEN,",HEPATITIS B & C,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,9,622769774509,"Whole Blood, EDTA, Dry",Not Received,,,HCV RNA COBAS 6800,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,14,622769774514,Whole Blood PAXgene RNA,Not Received,Frozen,,SM07/WB RNA,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,16,622769774516,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,18,622769774518,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-3,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,17,622769774517,"Serum, SST",Not Received,Frozen,,SM06/SERUM BIOM,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,13,622769774513,"Stool, unpreserved",Not Received,Frozen,,SM10/FECAL,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,12,622769774512,"Plasma, EDTA",Not Received,Frozen,,HBV DNA COBAS 6800,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,11,622769774511,"Whole Blood, EDTA, Dry",Not Received,,,HBV DNA COBAS 6800,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,15,622769774515,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,19,622769774519,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,10,622769774510,"Plasma, EDTA",Not Received,Frozen,,HCV RNA COBAS 6800,FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,30,622769774530,"Plasma, EDTA",Not Received,Frozen,,HIV-1/HIV-2 QUAL,RNA FROZEN,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,20,622769774520,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,22,622769774522,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-4,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,25,622769774525,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-1,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,23,622769774523,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-5,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,26,622769774526,"Serum, SST",Not Received,Frozen,,SERUM ADA,77242113UCO3001-2,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,21,622769774521,"Stool, unpreserved",Not Received,Frozen,,STOOL,77242113UCO3001-3,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,29,622769774529,"Whole Blood, EDTA, Dry",Not Received,,,HIV-1/HIV-2,QUALITATIVE RNA,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,27,622769774527,"Whole Blood, EDTA, Dry",Not Received,,,SM03/PLASMA PK,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,24,622769774524,"Red Cells, Clot",Not Received,,,SM05/SERUM ADA,,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,,6227697745,28,622769774528,"Plasma, EDTA",Not Received,Frozen,,PLASMA PK,77242113UCO3001,,,,,,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,,6227765943,3,622776594303,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,11:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,,6227765943,4,622776594304,"Plasma, QuantiFERON TB1",Not Received,Frozen,,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,11:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,,6227765943,5,622776594305,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,11:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,,6227765943,1,622776594301,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,11:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,,6227765943,6,622776594306,"Plasma, QuantiFERON TB2",Not Received,Frozen,,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,11:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,,6227765943,2,622776594302,"Plasma, QuantiFERON Nil",Not Received,Frozen,,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,11:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,17-Jun-2026,6227765943,12,622776594312,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,11:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,,6227765943,7,622776594307,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,11:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,17-Jun-2026,6227765943,14,622776594314,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,11:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,,6227765943,11,622776594311,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,11:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,17-Jun-2026,6227765943,9,622776594309,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,17-Jun-2026,6227765943,10,622776594310,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:50,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,,6227765943,15,622776594315,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,11:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,,6227765943,13,622776594313,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,11:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRN,17-Jun-2026,,6227765943,8,622776594308,"Plasma, QuantiFERON Mitoge",Not Received,Frozen,,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,11:50,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRNSTOOL,17-Jun-2026,17-Jun-2026,6227765958,1,622776595801,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,12:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRNSTOOL,17-Jun-2026,17-Jun-2026,6227765958,4,622776595804,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,12:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRNSTOOL,17-Jun-2026,17-Jun-2026,6227765958,3,622776595803,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,12:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092004,16-Jun-2026,SCRNSTOOL,17-Jun-2026,17-Jun-2026,6227765958,2,622776595802,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,12:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,1,622781089901,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,3,622781089903,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,2,622781089902,"Plasma, QuantiFERON Nil",Canceled,Frozen,,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,4,622781089904,"Plasma, QuantiFERON TB1",Canceled,Frozen,,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,5,622781089905,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,6,622781089906,"Plasma, QuantiFERON TB2",Canceled,Frozen,,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227810899,10,622781089910,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,11:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,11,622781089911,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227810899,12,622781089912,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,11:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,13,622781089913,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227810899,14,622781089914,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,11:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,15,622781089915,"Serum, SST",Canceled,Ambient,,FSH,,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,8,622781089908,"Plasma, QuantiFERON Mitoge",Canceled,Frozen,,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,03-Mar-2026,6227810899,9,622781089909,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,11:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,06-Mar-2026,6227810900,2,622781090002,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,06-Mar-2026,6227810900,4,622781090004,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,06-Mar-2026,6227810900,6,622781090006,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,7,622781090007,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,06-Mar-2026,6227810900,8,622781090008,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,05-Mar-2026,6227810900,9,622781090009,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,05-Mar-2026,6227810900,10,622781090010,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,3,622781090003,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,5,622781090005,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,05-Mar-2026,6227810900,12,622781090012,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,09:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,14,622781090014,"Serum, SST",Canceled,Ambient,,CHEM PANEL &,BETA HCG,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,13,622781090013,"Red Cells, Clot",Not Received,,,"CHEM PANEL, BETA",HCG & FSH,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,15,622781090015,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,1,622781090101,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,05-Mar-2026,6227810901,2,622781090102,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,12:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,3,622781090103,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,05-Mar-2026,6227810901,4,622781090104,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,12:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,1,622781090001,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,05-Mar-2026,6227810901,6,622781090106,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,12:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,7,622781090107,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,05-Mar-2026,6227810901,8,622781090108,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,12:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,04-Mar-2026,6227810901,9,622781090109,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,10,622781090110,"Slides, Hematology",Not Received,Ambient,,HEMATOLOGY,,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,11,622781090111,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,04-Mar-2026,6227810901,12,622781090112,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,12:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,14,622781090114,"Serum, SST",Canceled,Ambient,,CHEM PANEL &,BETA HCG,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,13,622781090113,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,02-Mar-2026,SCRN,03-Mar-2026,,6227810899,7,622781089907,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,11:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRN,05-Mar-2026,,6227810900,11,622781090011,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,09:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,5,622781090105,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRN,04-Mar-2026,,6227810901,15,622781090115,"Serum, SST",Canceled,Ambient,,FSH,,,,,,12:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRNSTOOL,05-Mar-2026,05-Mar-2026,6227810904,2,622781090402,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,09:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRNSTOOL,05-Mar-2026,05-Mar-2026,6227810904,3,622781090403,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,09:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRNSTOOL,05-Mar-2026,,6227810904,4,622781090404,"Stool, ova & parasites(PVA)",Canceled,Ambient,,OVA & PARASITES 2,PVA,,,,,09:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRNSTOOL,04-Mar-2026,,6227810905,1,622781090501,"Stool, ova & parasites(form)",Canceled,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRNSTOOL,04-Mar-2026,04-Mar-2026,6227810905,2,622781090502,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRNSTOOL,04-Mar-2026,04-Mar-2026,6227810905,3,622781090503,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222004,03-Mar-2026,SCRNSTOOL,04-Mar-2026,,6227810905,4,622781090504,"Stool, ova & parasites(PVA)",Canceled,Ambient,,OVA & PARASITES 2,PVA,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,04-Mar-2026,SCRNSTOOL,05-Mar-2026,,6227810904,1,622781090401,"Stool, ova & parasites(form)",Canceled,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,09:10,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,05-Feb-2026,BXSCR,06-Feb-2026,06-Feb-2026,6227323223,5,622732322305,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,13:01,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,3,622793314203,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,5,622793314205,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,2,622793314202,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,4,622793314204,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,6,622793314206,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,1,622793314201,"Red Cells, Clot",Received,,Default Discard/Not Return,CHEM PANEL &,CRP,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,,6227933142,7,622793314207,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-2,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,,6227933142,10,622793314210,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-5,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,12,622793314212,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,,6227933142,9,622793314209,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-4,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,11,622793314211,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,,6227933142,8,622793314208,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-3,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,14,622793314214,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,17,622793314217,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,13,622793314213,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,18,622793314218,"Red Cells, Clot",Received,,Default Discard/Not Return,SM06/SERUM,BIOMARKERS,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,1,622793314301,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM, LIPID PANEL",& CRP,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,15,622793314215,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,19,622793314219,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,2,622793314302,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,21,622793314221,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,22,622793314222,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,20,622793314220,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,06-May-2026,I-4,07-May-2026,07-May-2026,6227933142,16,622793314216,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,4,622793314304,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,,6227933143,8,622793314308,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-4,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,,6227933143,7,622793314307,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-3,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,3,622793314303,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,20,622793314320,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,,6227933143,6,622793314306,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-2,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,,6227933143,9,622793314309,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-5,,,,,08:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,11,622793314311,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-12TROUGH,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,19,622793314319,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,17,622793314317,"Red Cells, Clot",Received,,Default Discard/Not Return,SM06/SERUM,BIOMARKERS,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,22,622793314322,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,EXPEDITED FRZN,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,10,622793314310,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,16,622793314316,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-12 PRE,77242113UCO3001-2,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,23,622793314323,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,18,622793314318,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,12,622793314312,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,15,622793314315,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-12 PRE,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,14,622793314314,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,13,622793314313,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMAPK I-12 PEAK,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,5,622793314305,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-12,77242113UCO3001-1,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,13-May-2026,I-12,14-May-2026,14-May-2026,6227933143,21,622793314321,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,08:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,10-Jun-2026,M-4,12-Jun-2026,12-Jun-2026,6227933145,4,622793314504,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:10,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Maintenance Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,10-Jun-2026,M-4,12-Jun-2026,12-Jun-2026,6227933145,2,622793314502,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,07:10,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Maintenance Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,10-Jun-2026,M-4,12-Jun-2026,12-Jun-2026,6227933145,1,622793314501,"Red Cells, Clot",Received,,Default Discard/Not Return,CHEM PANEL &,CRP,,,,,07:10,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Maintenance Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,10-Jun-2026,M-4,12-Jun-2026,12-Jun-2026,6227933145,3,622793314503,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:10,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Maintenance Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,10-Jun-2026,M-4,12-Jun-2026,12-Jun-2026,6227933145,14,622793314514,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA M-4,77242113UCO3001-2,,,,,07:10,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Maintenance Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,10-Jun-2026,M-4,12-Jun-2026,12-Jun-2026,6227933145,6,622793314506,"Red Cells, Clot",Received,,Default Discard/Not Return,SM06/SERUM,BIOMARKERS,,,,,07:10,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Maintenance Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,10-Jun-2026,M-4,12-Jun-2026,12-Jun-2026,6227933145,11,622793314511,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK M-4,77242113UCO3001,,,,,07:10,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Maintenance Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,10-Jun-2026,M-4,12-Jun-2026,12-Jun-2026,6227933145,10,622793314510,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM03/PLASMA PK,,,,,,07:10,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Maintenance Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,10-Jun-2026,M-4,12-Jun-2026,12-Jun-2026,6227933145,5,622793314505,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:10,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Maintenance Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,10-Jun-2026,M-4,12-Jun-2026,12-Jun-2026,6227933145,9,622793314509,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:10,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Maintenance Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,10-Jun-2026,M-4,12-Jun-2026,12-Jun-2026,6227933145,13,622793314513,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA M-4,77242113UCO3001-1,,,,,07:10,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Maintenance Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,10-Jun-2026,M-4,12-Jun-2026,12-Jun-2026,6227933145,12,622793314512,"Red Cells, Clot",Received,,Default Discard/Not Return,SM05/SERUM ADA,,,,,,07:10,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Maintenance Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,10-Jun-2026,M-4,12-Jun-2026,12-Jun-2026,6227933145,8,622793314508,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:10,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Maintenance Week 4,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,10-Jun-2026,M-4,12-Jun-2026,12-Jun-2026,6227933145,7,622793314507,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:10,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Maintenance Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,11-Feb-2026,BXSCR,12-Feb-2026,12-Feb-2026,6227323287,5,622732328705,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,12:52,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,16-Apr-2026,6227993962,2,622799396202,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,,6227993962,15,622799396215,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,16-Apr-2026,6227993962,4,622799396204,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,,6227993962,1,622799396201,Whole Blood QuantiFERON Nil,Not Received,,,QUANTIFERON PLUS,NIL-GRAY,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,14-Apr-2026,6227993962,10,622799396210,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,14-Apr-2026,6227993962,14,622799396214,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,,6227993962,3,622799396203,Whole Blood QuantiFERON TB1,Not Received,,,QUANTIFERON PLUS,TB1-GREEN,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,16-Apr-2026,6227993962,8,622799396208,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,14-Apr-2026,6227993962,12,622799396212,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,,6227993962,11,622799396211,"Red Cells, Clot",Not Received,,,"HIV SCREEN,",HEPATITIS B & C,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,,6227993962,7,622799396207,Whole Blood QuantiFERON Mitoge,Not Received,,,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,14-Apr-2026,6227993962,9,622799396209,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,,6227993962,5,622799396205,Whole Blood QuantiFERON TB2,Not Received,,,QUANTIFERON PLUS,TB2-YELLOW,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,16-Apr-2026,6227993962,6,622799396206,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,12:20,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRN,14-Apr-2026,,6227993962,13,622799396213,"Red Cells, Clot",Not Received,,,CHEM PANEL &,BETA HCG,,,,,12:20,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,14,622799396614,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,,6227993966,17,622799396617,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,09:28,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,19-May-2026,6227993966,2,622799396602,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,,6227993966,3,622799396603,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:28,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,,6227993966,12,622799396612,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:28,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,19-May-2026,6227993966,1,622799396601,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,13,622799396613,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,,6227993966,7,622799396607,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:28,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,15,622799396615,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,8,622799396608,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,4,622799396604,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,10,622799396610,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,11,622799396611,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,6,622799396606,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,,6227993966,5,622799396605,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:28,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,16,622799396616,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,19-May-2026,6227993966,18,622799396618,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,I-0,19-May-2026,20-May-2026,6227993966,9,622799396609,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,8,622799396808,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001-1,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,1,622799396801,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,13,622799396813,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,2,622799396802,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,10,622799396810,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,4,622799396804,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,14,622799396814,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,12,622799396812,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-5,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,5,622799396805,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,7,622799396807,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,11,622799396811,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,3,622799396803,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,9,622799396809,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,17,622799396817,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,,6227993968,16,622799396816,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,08:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,6,622799396806,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,01-Jun-2026,I-2,02-Jun-2026,02-Jun-2026,6227993968,15,622799396815,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,08:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,,6227993970,9,622799397009,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-4,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,,6227993970,11,622799397011,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,17-Jun-2026,6227993970,4,622799397004,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,,6227993970,10,622799397010,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-5,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,17-Jun-2026,6227993970,6,622799397006,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001-1,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,17-Jun-2026,6227993970,5,622799397005,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,17-Jun-2026,6227993970,2,622799397002,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,17-Jun-2026,6227993970,3,622799397003,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,,6227993970,8,622799397008,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-3,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,,6227993970,7,622799397007,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-2,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,,6227993970,1,622799397001,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,17-Jun-2026,6227993970,14,622799397014,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,17-Jun-2026,6227993970,12,622799397012,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,17-Jun-2026,6227993970,20,622799397020,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,17-Jun-2026,6227993970,17,622799397017,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,17-Jun-2026,6227993970,21,622799397021,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,17-Jun-2026,6227993970,16,622799397016,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,,6227993970,13,622799397013,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,17-Jun-2026,6227993970,19,622799397019,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRNSTOOL,14-Apr-2026,,6227993971,4,622799397104,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,06:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,,6227993970,15,622799397015,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,,6227993970,18,622799397018,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,16-Jun-2026,I-4,17-Jun-2026,17-Jun-2026,6227993970,22,622799397022,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRNSTOOL,14-Apr-2026,14-Apr-2026,6227993971,3,622799397103,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,06:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRNSTOOL,14-Apr-2026,,6227993971,1,622799397101,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,06:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,13-Apr-2026,SCRNSTOOL,14-Apr-2026,14-Apr-2026,6227993971,2,622799397102,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,06:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,DNA,20-May-2026,20-May-2026,6227993977,1,622799397701,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,15-Apr-2026,BXSCR,16-Apr-2026,16-Apr-2026,6227993984,1,622799398401,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,15-Apr-2026,BXSCR,16-Apr-2026,17-Apr-2026,6227993984,3,622799398403,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,15-Apr-2026,BXSCR,16-Apr-2026,,6227993984,4,622799398404,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,15-Apr-2026,BXSCR,16-Apr-2026,17-Apr-2026,6227993984,2,622799398402,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,BDL,20-May-2026,20-May-2026,6227993987,2,622799398702,"Serum, SST",Shipped,Frozen,Default Return Frozen,"ADA, GOL, INF",UST OR VED FROZEN,,,,,09:28,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biologic Drug Level,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,18-May-2026,BDL,20-May-2026,,6227993987,1,622799398701,"Red Cells, Clot",Not Received,,,DRUG LEVEL TESTING,,,,,,09:28,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biologic Drug Level,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRNSTOOL,18-Feb-2026,18-Feb-2026,6227323244,5,622732324405,,Canceled,,,,,,,,,07:20,12:28,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,16-Feb-2026,SCRNSTOOL,18-Feb-2026,18-Feb-2026,6227323244,6,622732324406,,Canceled,,,,,,,,,07:20,12:28,Czech Republic,,07:10,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,,6228013269,1,622801326901,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,09-Jun-2026,6228013269,2,622801326902,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,09-Jun-2026,6228013269,4,622801326904,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,,6228013269,8,622801326908,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-4,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,,6228013269,7,622801326907,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-3,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,09-Jun-2026,6228013269,5,622801326905,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-12,77242113UCO3001-1,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,,6228013269,6,622801326906,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-2,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,,6228013269,14,622801326914,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,09-Jun-2026,6228013269,15,622801326915,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-12 PRE,77242113UCO3001-1,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,09-Jun-2026,6228013269,16,622801326916,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-12 PRE,77242113UCO3001-2,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,,6228013269,9,622801326909,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-5,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,09-Jun-2026,6228013269,3,622801326903,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,09-Jun-2026,6228013269,18,622801326918,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,09-Jun-2026,6228013269,11,622801326911,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-12TROUGH,77242113UCO3001,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,09-Jun-2026,6228013269,13,622801326913,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMAPK I-12 PEAK,77242113UCO3001,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,,6228013269,17,622801326917,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,,6228013269,10,622801326910,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,,6228013269,12,622801326912,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,09-Jun-2026,6228013269,19,622801326919,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,09-Jun-2026,6228013269,20,622801326920,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,10-Jun-2026,6228013269,21,622801326921,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,09:30,05:55,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,09-Jun-2026,6228013269,22,622801326922,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,EXPEDITED FRZN,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,08-Jun-2026,I-12,09-Jun-2026,09-Jun-2026,6228013269,23,622801326923,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222001,18-Feb-2026,BXSCR,19-Feb-2026,19-Feb-2026,6227323286,5,622732328605,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,15:49,Czech Republic,,10:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,01-Apr-2026,BXSCR,02-Apr-2026,04-Apr-2026,6228023951,2,622802395102,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,01-Apr-2026,BXSCR,02-Apr-2026,02-Apr-2026,6228023951,1,622802395101,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,01-Apr-2026,BXSCR,02-Apr-2026,04-Apr-2026,6228023951,3,622802395103,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,01-Apr-2026,BXSCR,02-Apr-2026,,6228023951,4,622802395104,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,19-Feb-2026,BXSCR,21-Feb-2026,21-Feb-2026,6227323254,5,622732325405,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,14:49,Czech Republic,,07:20,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,3,622803655303,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,5,622803655305,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,7,622803655307,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,8,622803655308,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,4,622803655304,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,1,622803655301,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,6,622803655306,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,2,622803655302,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,12,622803655312,"Red Cells, Clot",Received,,Default Discard/Not Return,SM06/SERUM,BIOMARKERS,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,13,622803655313,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,15,622803655315,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,11,622803655311,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,17,622803655317,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM, LIPID PANEL",& CRP,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,18,622803655318,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,14,622803655314,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,9,622803655309,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,16,622803655316,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,4,622803655404,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,5,622803655405,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,1,622803655401,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,6,622803655406,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,7,622803655407,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,9,622803655409,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,10,622803655410,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,8,622803655408,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,27-May-2026,I-0,28-May-2026,28-May-2026,6228036553,10,622803655310,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,07:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,3,622803655403,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,11,622803655411,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,2,622803655402,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,12,622803655412,"Red Cells, Clot",Received,,Default Discard/Not Return,SM06/SERUM,BIOMARKERS,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,13,622803655413,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,14,622803655414,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,15,622803655415,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,16,622803655416,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,17,622803655417,"Red Cells, Clot",Received,,Default Discard/Not Return,"CHEM, LIPID PANEL",& CRP,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,08-Apr-2026,I-0,09-Apr-2026,09-Apr-2026,6228036554,18,622803655418,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,07:10,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,1,622811460801,Whole Blood QuantiFERON Nil,Received,,Default Discard/Not Return,QUANTIFERON PLUS,NIL-GRAY,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,7,622811460807,Whole Blood QuantiFERON Mitoge,Received,,Default Discard/Not Return,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,3,622811460803,Whole Blood QuantiFERON TB1,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB1-GREEN,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,6,622811460806,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,8,622811460808,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,29-May-2026,6228114608,9,622811460809,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,4,622811460804,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,5,622811460805,Whole Blood QuantiFERON TB2,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB2-YELLOW,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,29-May-2026,6228114608,11,622811460811,"Red Cells, Clot",Received,,Default Discard/Not Return,"HIV SCREEN,",HEPATITIS B & C,,,,,07:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,29-May-2026,6228114608,10,622811460810,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,30-May-2026,6228114608,2,622811460802,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,07:30,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,29-May-2026,6228114608,12,622811460812,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,07:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,29-May-2026,6228114608,14,622811460814,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,07:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,,6228114608,15,622811460815,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,07:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,28-May-2026,SCRN,29-May-2026,29-May-2026,6228114608,13,622811460813,"Red Cells, Clot",Received,,Default Discard/Not Return,CHEM PANEL &,BETA HCG,,,,,07:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,1,622811461001,Whole Blood QuantiFERON Nil,Received,,Default Discard/Not Return,QUANTIFERON PLUS,NIL-GRAY,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,2,622811461002,"Plasma, QuantiFERON Nil",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,NIL-GRAY FRZ,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,5,622811461005,Whole Blood QuantiFERON TB2,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB2-YELLOW,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,3,622811461003,Whole Blood QuantiFERON TB1,Received,,Default Discard/Not Return,QUANTIFERON PLUS,TB1-GREEN,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,6,622811461006,"Plasma, QuantiFERON TB2",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB2-YELLOW FRZ,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,4,622811461004,"Plasma, QuantiFERON TB1",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,TB1-GREEN FRZ,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,30-Apr-2026,6228114610,10,622811461010,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,30-Apr-2026,6228114610,11,622811461011,"Red Cells, Clot",Received,,Default Discard/Not Return,"HIV SCREEN,",HEPATITIS B & C,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,30-Apr-2026,6228114610,9,622811461009,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,7,622811461007,Whole Blood QuantiFERON Mitoge,Received,,Default Discard/Not Return,QUANTIFERON PLUS,MITOGEN-PURPLE,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,30-Apr-2026,6228114610,12,622811461012,"Serum, SST",Received,Ambient,Default Return Ambient,"HIV SCREEN,",HEPATITIS B & C,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,30-Apr-2026,6228114610,13,622811461013,"Red Cells, Clot",Received,,Default Discard/Not Return,CHEM PANEL &,BETA HCG,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,30-Apr-2026,6228114610,14,622811461014,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,BETA HCG,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,01-May-2026,6228114610,8,622811461008,"Plasma, QuantiFERON Mitoge",Received,Frozen,Default Return Frozen,QUANTIFERON PLUS,MITOGEN-PURPLE FRZ,,,,,07:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,29-Apr-2026,SCRN,30-Apr-2026,,6228114610,15,622811461015,"Serum, SST",Canceled,Ambient,,FSH,FROZEN,,,,,07:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Screening,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,11,622813735511,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-12TROUGH,77242113UCO3001,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,12,622813735512,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,16,622813735516,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-12 PRE,77242113UCO3001-2,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,8,622813735508,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-4,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,9,622813735509,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-5,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,14,622813735514,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,7,622813735507,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-3,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,10,622813735510,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,15,622813735515,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-12 PRE,77242113UCO3001-1,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,17,622813735517,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,13,622813735513,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMAPK I-12 PEAK,77242113UCO3001,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,6,622813735506,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-2,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,21,622813735521,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,20,622813735520,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,22,622813735522,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,EXPEDITED FRZN,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,18,622813735518,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,23,622813735523,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,19,622813735519,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,02-Jun-2026,SCRNSTOOL,04-Jun-2026,,6228137357,1,622813735701,"Stool, ova & parasites(form)",Not Received,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,18:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,02-Jun-2026,SCRNSTOOL,04-Jun-2026,,6228137357,4,622813735704,"Stool, ova & parasites(PVA)",Not Received,Ambient,,OVA & PARASITES 2,PVA,,,,,18:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,02-Jun-2026,SCRNSTOOL,04-Jun-2026,04-Jun-2026,6228137357,3,622813735703,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,18:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,2,622813735502,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,3,622813735503,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,5,622813735505,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-12,77242113UCO3001,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,02-Jun-2026,6228137355,4,622813735504,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,14:55,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCSTOOL,23-Apr-2026,23-Apr-2026,6228137359,3,622813735903,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012004,02-Jun-2026,SCRNSTOOL,04-Jun-2026,04-Jun-2026,6228137357,2,622813735702,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,18:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCSTOOL,23-Apr-2026,23-Apr-2026,6228137359,1,622813735901,"Stool, ova & parasites(form)",Received,Ambient,Default Return Ambient,OVA & PARASITES 1,FORMALIN,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCSTOOL,23-Apr-2026,23-Apr-2026,6228137359,4,622813735904,"Stool, ova & parasites(PVA)",Received,Ambient,Default Return Ambient,OVA & PARASITES 2,PVA,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,01-Jun-2026,I-12,02-Jun-2026,,6228137355,1,622813735501,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,14:55,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,22-Apr-2026,UNSCSTOOL,23-Apr-2026,23-Apr-2026,6228137359,2,622813735902,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,07:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,1,622817339701,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,4,622817339704,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,,6228173397,3,622817339703,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,10:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,2,622817339702,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,6,622817339706,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,8,622817339708,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,,6228173397,5,622817339705,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,10:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,,6228173397,7,622817339707,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,10:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,,6228173397,12,622817339712,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,10:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,16,622817339716,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,18,622817339718,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,,6228173397,17,622817339717,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,10:35,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,9,622817339709,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,14,622817339714,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,11,622817339711,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,10,622817339710,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,15,622817339715,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,13,622817339713,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,14,622817993214,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,9,622817993209,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,15,622817993215,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,16,622817993216,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,12,622817993212,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-5,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,13,622817993213,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,17,622817993217,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,10,622817993210,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,11,622817993211,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,1,622817993201,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,3,622817993203,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,4,622817993204,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,7,622817993207,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,2,622817993202,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,8,622817993208,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,1,622817993601,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,2,622817993602,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,6,622817993606,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,4,622817993604,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,10,622817993610,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-5,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,5,622817993605,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,14,622817993614,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,11,622817993611,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,12,622817993612,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,13,622817993613,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,16,622817993616,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,15,622817993615,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,9,622817993609,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-4,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,19,622817993619,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,18,622817993618,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,3,622817993603,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,17,622817993617,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,23-Apr-2026,6228179932,6,622817993206,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,14:15,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,22-Apr-2026,I-2,23-Apr-2026,,6228179932,5,622817993205,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,14:15,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,20,622817993620,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,21,622817993621,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,8,622817993608,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-3,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,,6228179936,7,622817993607,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-2,,,,,07:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,05-May-2026,I-4,06-May-2026,06-May-2026,6228179936,22,622817993622,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,07:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,DNA,10-Apr-2026,10-Apr-2026,6228179942,1,622817994201,"Whole Blood, EDTA, Dry",Shipped,Frozen,Default Return Frozen,SM08/WB DNA,77242113UCO3001,,,,,10:35,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,DNA,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,20-May-2026,BX12,21-May-2026,23-May-2026,6228179945,3,622817994503,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,20-May-2026,BX12,21-May-2026,23-May-2026,6228179945,4,622817994504,"Biopsy, Frozen Tissue",Shipped,Frozen,Default Return Frozen,BIOPSY PK,77242113UCO3001,,,,,00:00,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,20-May-2026,BX12,21-May-2026,21-May-2026,6228179945,1,622817994501,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,20-May-2026,BX12,21-May-2026,23-May-2026,6228179945,2,622817994502,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,,6228194341,1,622819434101,"Stool, ova & parasites(form)",Canceled,Ambient,,OVA & PARASITES 1,FORMALIN,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,,6228194341,4,622819434104,"Stool, ova & parasites(PVA)",Canceled,Ambient,,OVA & PARASITES 2,PVA,,,,,07:45,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,21-Apr-2026,6228194341,3,622819434103,"Culture, Stool",Received,Ambient,Default Return Ambient,STOOL CULTURE,,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,20-Apr-2026,SCRNSTOOL,21-Apr-2026,21-Apr-2026,6228194341,2,622819434102,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,07:45,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,12-Mar-2026,BXSCR,13-Mar-2026,13-Mar-2026,6227635161,5,622763516105,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,15:58,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10021,Dr.Martin Bortlik,CZ100212001,16-Mar-2026,BXSCR,18-Mar-2026,18-Mar-2026,6227635223,5,622763522305,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,13:49,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,,,,19-Mar-2026,19-Mar-2026,6227323233,31,622732323331,"Serum, SST",Received,Ambient,Default Return Ambient,,,,,,,,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012002,18-Mar-2026,BXSCR,19-Mar-2026,19-Mar-2026,6227323224,5,622732322405,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,15:46,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,06-May-2026,BX12,07-May-2026,09-May-2026,6228252072,3,622825207203,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:30,Czech Republic,,08:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,06-May-2026,BX12,07-May-2026,07-May-2026,6228252072,1,622825207201,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,08:30,Czech Republic,,08:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,13-May-2026,BXSCR,14-May-2026,,6228252073,4,622825207304,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,13-May-2026,BXSCR,14-May-2026,15-May-2026,6228252073,2,622825207302,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,06-May-2026,BX12,07-May-2026,09-May-2026,6228252072,4,622825207204,"Biopsy, Frozen Tissue",Shipped,Frozen,Default Return Frozen,BIOPSY PK,77242113UCO3001,,,,,00:00,07:30,Czech Republic,,08:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,06-May-2026,BX12,07-May-2026,09-May-2026,6228252072,2,622825207202,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:30,Czech Republic,,08:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,13-May-2026,BXSCR,14-May-2026,15-May-2026,6228252073,3,622825207303,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,13-May-2026,BXSCR,14-May-2026,14-May-2026,6228252073,1,622825207301,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,CZ100122001,23-Mar-2026,BXSCR,24-Mar-2026,24-Mar-2026,6227697736,5,622769773605,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,15:15,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,17-Jun-2026,6228308227,2,622830822702,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,13:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,17-Jun-2026,6228308227,4,622830822704,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,13:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,,6228308227,6,622830822706,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-2,,,,,13:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,,6228308227,9,622830822709,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-5,,,,,13:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,,6228308227,14,622830822714,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,13:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,17-Jun-2026,6228308227,16,622830822716,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-12 PRE,77242113UCO3001-2,,,,,13:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,,6228308227,8,622830822708,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-4,,,,,13:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,17-Jun-2026,6228308227,20,622830822720,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,13:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,17-Jun-2026,6228308227,18,622830822718,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,13:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,17-Jun-2026,6228308227,21,622830822721,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,13:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,,6228308227,1,622830822701,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,13:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,17-Jun-2026,6228308227,5,622830822705,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-12,77242113UCO3001,,,,,13:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,,6228308227,7,622830822707,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-12,77242113UCO3001-3,,,,,13:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,17-Jun-2026,6228308227,23,622830822723,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,13:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,17-Jun-2026,6228308227,3,622830822703,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,13:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,,6228308227,10,622830822710,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,13:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,17-Jun-2026,6228308227,15,622830822715,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-12 PRE,77242113UCO3001-1,,,,,13:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,17-Jun-2026,6228308227,13,622830822713,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMAPK I-12 PEAK,77242113UCO3001,,,,,13:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,,6228308227,12,622830822712,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,13:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,17-Jun-2026,6228308227,19,622830822719,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,13:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,17-Jun-2026,6228308227,22,622830822722,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,EXPEDITED FRZN,,,,,13:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,17-Jun-2026,6228308227,11,622830822711,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-12TROUGH,77242113UCO3001,,,,,13:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,16-Jun-2026,I-12,17-Jun-2026,,6228308227,17,622830822717,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,13:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 12,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,1,622830822401,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,2,622830822402,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,,6228308224,5,622830822405,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,10:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,6,622830822406,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,,6228308224,7,622830822407,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,10:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,9,622830822409,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,10,622830822410,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,8,622830822408,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,11,622830822411,Whole Blood PAXgene RNA,Shipped,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,13,622830822413,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,,6228308224,3,622830822403,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,10:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,4,622830822404,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,14,622830822414,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,16,622830822416,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,15,622830822415,"Serum, SST",Shipped,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,,6228308224,12,622830822412,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,10:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,,6228308224,17,622830822417,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,10:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,1,622830822501,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,2,622830822502,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,6,622830822506,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-0 PEAK,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,,6228308225,3,622830822503,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,12-May-2026,I-0,13-May-2026,13-May-2026,6228308224,18,622830822418,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,10:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,8,622830822508,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-1,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,,6228308225,5,622830822505,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,11,622830822511,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,9,622830822509,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-0 PRE,77242113UCO3001-2,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,10,622830822510,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,SM10/FECAL,BIOMARKERS,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,,6228308225,7,622830822507,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,15,622830822515,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,16,622830822516,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,13,622830822513,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,,6228308225,12,622830822512,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,4,622830822504,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-0 TROUGH,77242113UCO3001,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,,6228308225,17,622830822517,"Red Cells, Clot",Not Received,,,"CHEM, LIPID PANEL",& CRP,,,,,09:25,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,14,622830822514,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,02-Jun-2026,I-0,03-Jun-2026,03-Jun-2026,6228308225,18,622830822518,"Serum, SST",Received,Ambient,Default Return Ambient,"CHEM, LIPID PANEL",& CRP,,,,,09:25,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,01-Apr-2026,BXSCR,02-Apr-2026,02-Apr-2026,6228023951,5,622802395105,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,15:31,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,3,622839811503,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,2,622839811502,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,4,622839811504,"Plasma, EDTA",Shipped,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,6,622839811506,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,5,622839811505,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,7,622839811507,"Serum, SST",Shipped,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,8,622839811508,"Stool, unpreserved",Shipped,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,10,622839811510,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,9,622839811509,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,11,622839811511,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,12,622839811512,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-5,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,13,622839811513,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,14,622839811514,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,1,622839811501,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,17,622839811517,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,27-May-2026,6228398115,15,622839811515,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:05,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,26-May-2026,I-2,27-May-2026,,6228398115,16,622839811516,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,09:05,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,,6228407564,1,622840756401,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,10-Jun-2026,6228407564,2,622840756402,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,09:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,10-Jun-2026,6228407564,4,622840756404,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,09:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,,6228407564,5,622840756405,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,,6228407564,3,622840756403,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,10-Jun-2026,6228407564,6,622840756406,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,09:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,10-Jun-2026,6228407564,7,622840756407,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,09:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,10-Jun-2026,6228407564,8,622840756408,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001,,,,,09:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,,6228407564,12,622840756412,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-5,,,,,09:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,,6228407564,10,622840756410,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,09:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,10-Jun-2026,6228407564,13,622840756413,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,10-Jun-2026,6228407564,14,622840756414,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,10-Jun-2026,6228407564,15,622840756415,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,,6228407564,16,622840756416,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,09:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,,6228407564,11,622840756411,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,09:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,10-Jun-2026,6228407564,17,622840756417,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,09:40,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,09-Jun-2026,I-2,10-Jun-2026,,6228407564,9,622840756409,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,09:40,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222005,09-Apr-2026,I-0,10-Apr-2026,10-Apr-2026,6228173397,19,622817339719,,Canceled,,,,,,,,,10:35,13:56,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 0,, +77242113UCO3001,CZ10020,Dr.Lucie Gonsorcikova,CZ100201001,15-Apr-2026,BXSCR,16-Apr-2026,16-Apr-2026,6227993984,5,622799398405,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,17:04,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6228462187,1,622846218701,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,PLASMA PK TROUGH,,,,,,07:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6228462187,2,622846218702,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-2 TROUGH,77242113UCO3001,,,,,07:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6228462187,3,622846218703,"Whole Blood, EDTA, Dry",Received,,Default Discard/Not Return,SM02/PLASMAPK PEAK,,,,,,07:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6228462187,7,622846218707,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-2,,,,,07:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6228462187,8,622846218708,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-2,77242113UCO3001,,,,,07:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,,6228462187,9,622846218709,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-2,,,,,07:30,,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,,6228462187,11,622846218711,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-4,,,,,07:30,,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,,6228462187,12,622846218712,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-5,,,,,07:30,,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6228462187,15,622846218715,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,07:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6228462187,17,622846218717,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,07:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6228462187,16,622846218716,"Red Cells, Clot",Received,,Default Discard/Not Return,CHEM PANEL &,CRP,,,,,07:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6228462187,14,622846218714,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,07:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6228462187,13,622846218713,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,07:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6228462187,5,622846218705,"Red Cells, Clot",Received,,Default Discard/Not Return,SM04/SERUM ADA PRE,,,,,,07:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6228462187,6,622846218706,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-2 PRE,77242113UCO3001-1,,,,,07:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,,6228462187,10,622846218710,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-2,77242113UCO3001-3,,,,,07:30,,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,10-Jun-2026,I-2,12-Jun-2026,12-Jun-2026,6228462187,4,622846218704,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-2 PEAK,77242113UCO3001,,,,,07:30,07:05,Czech Republic,,07:05,,,213069,EMEA,,,,,,,,Induction Week 2,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,21-Apr-2026,BXSCR,22-Apr-2026,22-Apr-2026,6227635159,5,622763515905,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,17:18,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,11-Jun-2026,6228501727,2,622850172702,"Serum, SST",Received,Ambient,Default Return Ambient,CHEM PANEL &,CRP,,,,,09:32,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,11-Jun-2026,6228501727,4,622850172704,"Slides, Hematology",Received,Ambient,No Orders Attached,HEMATOLOGY,,,,,,09:32,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,11-Jun-2026,6228501727,5,622850172705,"Feces, unpreserved",Received,Frozen,Default Return Frozen,FECAL CALPROTECTIN,FROZEN,,,,,09:32,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,,6228501727,1,622850172701,"Red Cells, Clot",Not Received,,,CHEM PANEL &,CRP,,,,,09:32,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,11-Jun-2026,6228501727,6,622850172706,"Stool, unpreserved",In Inventory,Frozen,Default Return Frozen,STOOL I-4,77242113UCO3001,,,,,09:32,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,11-Jun-2026,6228501727,3,622850172703,"Whole Blood, EDTA, Dry",Received,Ambient,Default Return Ambient,HEMATOLOGY,,,,,,09:32,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,11-Jun-2026,6228501727,12,622850172712,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMPK I-4 TROUGH,77242113UCO3001,,,,,09:32,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,,6228501727,11,622850172711,"Whole Blood, EDTA, Dry",Not Received,,,PLASMA PK TROUGH,,,,,,09:32,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,,6228501727,9,622850172709,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-4,,,,,09:32,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,,6228501727,8,622850172708,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-3,,,,,09:32,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,,6228501727,13,622850172713,"Whole Blood, EDTA, Dry",Not Received,,,SM02/PLASMAPK PEAK,,,,,,09:32,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,,6228501727,10,622850172710,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-5,,,,,09:32,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,11-Jun-2026,6228501727,14,622850172714,"Plasma, EDTA",In Inventory,Frozen,Default Return Frozen,PLASMA PK I-4 PEAK,77242113UCO3001,,,,,09:32,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,,6228501727,7,622850172707,"Stool, unpreserved",Not Received,Frozen,Specimen not submitted,STOOL I-4,77242113UCO3001-2,,,,,09:32,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,11-Jun-2026,6228501727,17,622850172717,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-2,,,,,09:32,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,,6228501727,18,622850172718,"Red Cells, Clot",Not Received,,,SM06/SERUM,BIOMARKERS,,,,,09:32,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,11-Jun-2026,6228501727,19,622850172719,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-1,,,,,09:32,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,11-Jun-2026,6228501727,21,622850172721,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-3,,,,,09:32,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,11-Jun-2026,6228501727,22,622850172722,Whole Blood PAXgene RNA,In Inventory,Frozen,Default Return Frozen,SM07/WB RNA,77242113UCO3001,,,,,09:32,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,11-Jun-2026,6228501727,16,622850172716,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SERUM ADA I-4 PRE,77242113UCO3001-1,,,,,09:32,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,,6228501727,15,622850172715,"Red Cells, Clot",Not Received,,,SM04/SERUM ADA PRE,,,,,,09:32,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132002,10-Jun-2026,I-4,11-Jun-2026,11-Jun-2026,6228501727,20,622850172720,"Serum, SST",In Inventory,Frozen,Default Return Frozen,SM06/SERUM BIOM,77242113UCO3001-2,,,,,09:32,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Induction Week 4,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,04-Jun-2026,BX12,05-Jun-2026,06-Jun-2026,6228501730,2,622850173002,Biopsy RNA Later,In Inventory,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:15,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,04-Jun-2026,BX12,05-Jun-2026,05-Jun-2026,6228501730,1,622850173001,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,04-Jun-2026,BX12,05-Jun-2026,06-Jun-2026,6228501730,4,622850173004,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,BIOPSY PK,77242113UCO3001,,,,,00:00,07:15,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,25-May-2026,BXSCR,26-May-2026,26-May-2026,6228501732,1,622850173201,Wet Tissue Biopsy,Removed,Ambient,Default Return Ambient,SM11/BIOPSY,HISTOLOGY,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,25-May-2026,BXSCR,26-May-2026,28-May-2026,6228501732,2,622850173202,Biopsy RNA Later,Shipped,Frozen,Default Return Frozen,SM13/BIOPSY RNA,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,04-Jun-2026,BX12,05-Jun-2026,06-Jun-2026,6228501730,3,622850173003,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:15,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,25-May-2026,BXSCR,26-May-2026,,6228501732,4,622850173204,"Biopsy, Frozen Tissue",Not Received,Frozen,,BIOPSY PK,77242113UCO3001,,,,,00:00,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,25-May-2026,BXSCR,26-May-2026,28-May-2026,6228501732,3,622850173203,"Biopsy, Frozen Tissue",In Inventory,Frozen,Default Return Frozen,SM14/BIOPSY CRYO,FROZEN,,,,,00:00,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10009,Dr. Jiri Pumprla,CZ100092001,24-Apr-2026,BXSCR,28-Apr-2026,28-Apr-2026,6227323351,5,622732335105,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,14:22,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,06-May-2026,SCRNSTOOL,07-May-2026,,6228610564,1,622861056401,"Stool, ova & parasites(form)",Not Received,Ambient,,,,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,06-May-2026,SCRNSTOOL,07-May-2026,,6228610564,3,622861056403,"Culture, Stool",Canceled,Ambient,,,,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,06-May-2026,SCRNSTOOL,07-May-2026,,6228610564,4,622861056404,"Stool, ova & parasites(PVA)",Not Received,Ambient,,,,,,,,09:30,,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,06-May-2026,SCRNSTOOL,07-May-2026,07-May-2026,6228610564,2,622861056402,"Stool, unpreserved",Received,Frozen,Default Return Frozen,C-DIFF TOXIN,& PCR FROZEN,,,,,09:30,07:00,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Stool Pathogens,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012001,06-May-2026,BX12,07-May-2026,07-May-2026,6228252072,5,622825207205,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,15:52,Czech Republic,,08:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10012,Dr.Stefan Konecny,,,,08-May-2026,08-May-2026,6227697745,31,622769774531,,In Inventory,,Default Return Frozen,,,,,,,,16:05,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Unscheduled,, +77242113UCO3001,CZ10001,Dr. Matej Falc,CZ100012003,13-May-2026,BXSCR,14-May-2026,14-May-2026,6228252073,5,622825207305,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,12:51,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062002,14-May-2026,BXSCR,15-May-2026,15-May-2026,6227323256,5,622732325605,"Tissue , Paraffin Block",Shipped,,Default Return Ambient,,,,,,,00:00,13:06,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162001,19-May-2026,BXSCR,20-May-2026,20-May-2026,6227635193,5,622763519305,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,17:34,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10022,Dr. Petr Hrabak,CZ100222003,20-May-2026,BX12,21-May-2026,21-May-2026,6228179945,5,622817994505,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,14:59,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132003,25-May-2026,BXSCR,26-May-2026,26-May-2026,6228501732,5,622850173205,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,13:03,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10003,Dr. Leksa Vaclav,CZ100032001,27-May-2026,BXSCR,28-May-2026,28-May-2026,6227323320,5,622732332005,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,14:30,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10006,Dr. Michal Konecny,CZ100062001,29-May-2026,BX12,30-May-2026,30-May-2026,6227323255,5,622732325505,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,15:53,Czech Republic,,07:30,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10013,Dr.David Stepek,CZ100132001,04-Jun-2026,BX12,05-Jun-2026,05-Jun-2026,6228501730,5,622850173005,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,16:17,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, +77242113UCO3001,CZ10016,Dr.Robert Mudr,CZ100162002,16-Jun-2026,BXSCR,17-Jun-2026,17-Jun-2026,6227635192,5,622763519205,"Tissue , Paraffin Block",In Inventory,,Default Return Ambient,,,,,,,00:00,13:43,Czech Republic,,07:00,,,213069,EMEA,,,,,,,,Biopsy,, diff --git a/Covance/Source/2026-06-18_095536 sponsor-study-36940-test-results-930525-standard.csv b/Covance/Source/2026-06-18_095536 sponsor-study-36940-test-results-930525-standard.csv new file mode 100644 index 0000000..d9a3620 --- /dev/null +++ b/Covance/Source/2026-06-18_095536 sponsor-study-36940-test-results-930525-standard.csv @@ -0,0 +1,773 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Alkaline Phosphatase,,57,,,,,40 - 129,U/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,ALT (SGPT),,32,,,,,5 - 48,U/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,AST (SGOT),,35,,,,,8 - 40,U/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,LDH,,248,,H,,,53 - 234,U/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Urea Nitrogen,,8.2,,,,,1.4 - 8.6,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,97,,,,,40 - 110,umol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Serum Glucose,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Serum Uric Acid,,395,,,,,125 - 488,umol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Calcium (EDTA),,2.44,,,,,2.07 - 2.64,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Phosphorus,,1.19,,,,,0.71 - 1.65,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Creatine Kinase,,439,,H,,,39 - 308,U/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Serum Bicarbonate,,24.4,,,,,19.3 - 29.3,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CHEMISTRY PANEL,Magnesium,,0.77,,,,,0.66 - 1.07,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,88,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,FECAL COLLECTION D/T,Stool Collection Date,Y,01-Jun-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,FECAL COLLECTION D/T,Stool Collection Time,Y,05:00,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,129,,,,,127 - 181,g/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,L,,,0.39 - 0.54, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,L,,,4.5 - 6.4,TI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.82,,,,,3.8 - 10.7,GI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.31,,,,,1.96 - 7.23,GI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.93,,,,,0.91 - 4.28,GI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.22,,,,,0.12 - 0.92,GI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.32,,,,,0 - 0.57,GI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.1,,,,,40.5 - 75,% +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,28.4,,,,,15.4 - 48.5,% +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,3.3,,,,,2.6 - 10.1,% +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.7,,,,,0 - 6.8,% +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,251,,,,,140 - 400,GI/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,LIPID PANEL,Direct HDL-C 4th Generation,,1.53,,,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,LIPID PANEL,Triglycerides (GPO),,0.90,,,,,0.56 - 3.62,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,LIPID PANEL,Cholesterol (High Performance),,5.18,,,,,3.88 - 6.83,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,LIPID PANEL,LDL Chol Friedewald 4th,,3.24,,,,,0 - 3.34,mmol/L +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,01-Jun-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,14:55,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,01-Jun-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,16:05,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,01-Jun-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,14:55,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,01-Jun-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,05:00,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,01-Jun-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,05:00,,,,,, +CZ100222003,,,,,Male,Induction Week 12,,"Jun 1, 2026 2:55 PM",6228137355,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,20-May-2026,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,11:44,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,22-May-2026,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100222003,,,,,Male,Biopsy,,"May 20, 2026 12:00 AM",6228179945,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Alkaline Phosphatase,,68,,,,,40 - 129,U/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,ALT (SGPT),,10,,,,,5 - 48,U/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,GGT,,10,,,,,10 - 61,U/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,LDH,,164,,,,,53 - 234,U/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Urea Nitrogen,,5.1,,,,,1.4 - 8.6,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,101,,,,,40 - 110,umol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Serum Glucose,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Serum Uric Acid,,255,,,,,125 - 488,umol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Calcium (EDTA),,2.45,,,,,2.07 - 2.64,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Phosphorus,,1.10,,,,,0.71 - 1.65,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Creatine Kinase,,131,,,,,39 - 308,U/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Serum Bicarbonate,,25.4,,,,,19.3 - 29.3,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CHEMISTRY PANEL,Magnesium,,0.82,,,,,0.66 - 1.07,mmol/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,87,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,FECAL COLLECTION D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,FECAL COLLECTION D/T,Stool Collection Time,Y,06:40,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,145,,,,,127 - 181,g/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.72,,,,,3.8 - 10.7,GI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.17,,,,,1.96 - 7.23,GI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.71,,,,,0.91 - 4.28,GI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.36,,,,,0.12 - 0.92,GI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.44,,,,,0 - 0.57,GI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.4,,,,,40.5 - 75,% +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.0,,,,,15.4 - 48.5,% +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.3,,,,,2.6 - 10.1,% +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,7.7,,H,,,0 - 6.8,% +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,294,,,,,140 - 400,GI/L +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,05-May-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:40,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,05-May-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:50,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,05-May-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:40,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,06:40,,,,,, +CZ100222005,,,,,Male,Induction Week 4,,"May 5, 2026 7:40 AM",6228179936,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Alkaline Phosphatase,,65,,,,,40 - 129,U/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,ALT (SGPT),,7,,,,,5 - 48,U/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,GGT,,7,,L,,,10 - 61,U/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,LDH,,147,,,,,53 - 234,U/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,88,,,,,40 - 110,umol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Serum Glucose,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Serum Uric Acid,,261,,,,,125 - 488,umol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Calcium (EDTA),,2.31,,,,,2.07 - 2.64,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Phosphorus,,1.13,,,,,0.71 - 1.65,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Total Protein,,65,,,,,61 - 84,g/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Creatine Kinase,,112,,,,,39 - 308,U/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Serum Bicarbonate,,23.2,,,,,19.3 - 29.3,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CHEMISTRY PANEL,Magnesium,,0.76,,,,,0.66 - 1.07,mmol/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,102,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,FECAL COLLECTION D/T,Stool Collection Date,Y,22-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,FECAL COLLECTION D/T,Stool Collection Time,Y,05:40,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,143,,,,,127 - 181,g/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.39 - 0.54, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.68,,,,,3.8 - 10.7,GI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.92,,,,,1.96 - 7.23,GI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.94,,,,,0.91 - 4.28,GI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.40,,,,,0 - 0.57,GI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.7,,,,,40.5 - 75,% +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.0,,,,,15.4 - 48.5,% +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.9,,,,,2.6 - 10.1,% +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,5.9,,,,,0 - 6.8,% +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,308,,,,,140 - 400,GI/L +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,22-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,14:15,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,22-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,15:25,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,22-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,14:15,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,22-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,05:40,,,,,, +CZ100222005,,,,,Male,Induction Week 2,,"Apr 22, 2026 2:15 PM",6228179932,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.2,,,,,0 - 6.2,umol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Alkaline Phosphatase,,71,,,,,40 - 129,U/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,ALT (SGPT),,7,,,,,5 - 48,U/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,GGT,,7,,L,,,10 - 61,U/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,LDH,,153,,,,,53 - 234,U/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Urea Nitrogen,,4.9,,,,,1.4 - 8.6,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,86,,,,,40 - 110,umol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Serum Glucose,,4.2,,,,,3.9 - 5.6,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Serum Uric Acid,,299,,,,,125 - 488,umol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Creatine Kinase,,116,,,,,39 - 308,U/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Serum Bicarbonate,,23.9,,,,,19.3 - 29.3,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CHEMISTRY PANEL,Magnesium,,0.80,,,,,0.66 - 1.07,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,106,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,FECAL COLLECTION D/T,Stool Collection Date,Y,09-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,FECAL COLLECTION D/T,Stool Collection Time,Y,05:55,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,146,,,,,127 - 181,g/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.39 - 0.54, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.07,,,,,3.8 - 10.7,GI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.83,,,,,1.96 - 7.23,GI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.67,,,,,0.91 - 4.28,GI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.32,,,,,0.12 - 0.92,GI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.19,,,,,0 - 0.57,GI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.1,,,,,40.5 - 75,% +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.6,,,,,15.4 - 48.5,% +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.2,,,,,2.6 - 10.1,% +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.2,,,,,0 - 6.8,% +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,314,,,,,140 - 400,GI/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,LIPID PANEL,Direct HDL-C 4th Generation,,1.90,,H,,,1.03 - 1.53,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,LIPID PANEL,Triglycerides (GPO),,0.43,,L,,,0.56 - 3.62,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,LIPID PANEL,Cholesterol (High Performance),,3.22,,L,,,3.88 - 6.83,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,LIPID PANEL,LDL Chol Friedewald 4th,,1.12,,,,,0 - 3.34,mmol/L +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,09-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,10:35,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,09-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,11:45,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,09-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,10:35,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,09-Apr-2026,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,05:55,,,,,, +CZ100222005,,,,,Male,Induction Week 0,,"Apr 9, 2026 10:35 AM",6228173397,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Alkaline Phosphatase,,64,,,,,40 - 129,U/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,ALT (SGPT),,42,,,,,5 - 48,U/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,AST (SGOT),,31,,,,,8 - 40,U/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,GGT,,24,,,,,10 - 61,U/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,LDH,,225,,,,,53 - 234,U/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Urea Nitrogen,,10.1,,H,,,1.4 - 8.6,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,110,,,,,40 - 110,umol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Serum Glucose,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Serum Uric Acid,,455,,,,,125 - 488,umol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Calcium (EDTA),,2.42,,,,,2.07 - 2.64,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Phosphorus,,1.20,,,,,0.71 - 1.65,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Creatine Kinase,,367,,H,,,39 - 308,U/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Serum Bicarbonate,,24.7,,,,,19.3 - 29.3,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CHEMISTRY PANEL,Magnesium,,0.77,,,,,0.66 - 1.07,mmol/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,76,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,FECAL COLLECTION D/T,Stool Collection Date,Y,08-Apr-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,FECAL COLLECTION D/T,Stool Collection Time,Y,05:15,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,135,,,,,127 - 181,g/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.39 - 0.54, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.5 - 6.4,TI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,85,,,,,79 - 96,fL +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.70,,,,,3.8 - 10.7,GI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.33,,,,,1.96 - 7.23,GI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.26,,,,,0.91 - 4.28,GI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.67,R,H,,,0 - 0.57,GI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,40.8,,,,,40.5 - 75,% +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,39.6,,,,,15.4 - 48.5,% +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.0,,,,,2.6 - 10.1,% +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,11.7,R,H,,,0 - 6.8,% +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,282,,,,,140 - 400,GI/L +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,08-Apr-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:05,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,08-Apr-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,09:15,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,08-Apr-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:05,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,08-Apr-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,05:15,,,,,, +CZ100222003,,,,,Male,Induction Week 4,,"Apr 8, 2026 8:05 AM",6227323274,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,01-Apr-2026,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,08:46,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,03-Apr-2026,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100222005,,,,,Male,Biopsy,,"Apr 1, 2026 12:00 AM",6228023951,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Alkaline Phosphatase,,58,,,,,40 - 129,U/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,ALT (SGPT),,26,,,,,5 - 48,U/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,LDH,,170,,,,,53 - 234,U/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Urea Nitrogen,,9.4,R,H,,,1.4 - 8.6,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,104,,,,,40 - 110,umol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Serum Glucose,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Serum Uric Acid,,353,,,,,125 - 488,umol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Calcium (EDTA),,2.36,,,,,2.07 - 2.64,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Phosphorus,,1.32,,,,,0.71 - 1.65,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Creatine Kinase,,167,,,,,39 - 308,U/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Serum Bicarbonate,,23.9,,,,,19.3 - 29.3,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CHEMISTRY PANEL,Magnesium,,0.73,,,,,0.66 - 1.07,mmol/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,80,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,FECAL COLLECTION D/T,Stool Collection Date,Y,27-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,FECAL COLLECTION D/T,Stool Collection Time,Y,05:40,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,133,,,,,127 - 181,g/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.39 - 0.54, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.5 - 6.4,TI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.92,,,,,3.8 - 10.7,GI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.29,,,,,1.96 - 7.23,GI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.57,,,,,0.91 - 4.28,GI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.41,,,,,0.12 - 0.92,GI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.61,R,H,,,0 - 0.57,GI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,38.7,R,L,,,40.5 - 75,% +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,43.4,,,,,15.4 - 48.5,% +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.9,,,,,2.6 - 10.1,% +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,10.3,R,H,,,0 - 6.8,% +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,252,,,,,140 - 400,GI/L +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,27-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:10,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,27-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:20,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,27-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:10,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,27-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,05:40,,,,,, +CZ100222003,,,,,Male,Induction Week 2,,"Mar 27, 2026 7:10 AM",6227323272,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Total Bilirubin,,3,,,,Result verified by repeat analysis,3 - 21,umol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,Result verified by repeat analysis,0 - 6.2,umol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,40 - 129,U/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,5 - 48,U/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,AST (SGOT),,15,,,,,8 - 40,U/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,GGT,,19,,,,,10 - 50,U/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Urea Nitrogen,,5.5,,,,,1.4 - 8.6,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,108,,,,,40 - 119,umol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Serum Glucose,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Serum Uric Acid,,429,,,,,149 - 494,umol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Calcium (EDTA),,2.07,,,,,2.07 - 2.64,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Phosphorus,,1.02,,,,,0.71 - 1.65,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Total Protein,,55,,L,,,60 - 80,g/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Albumin-BCG,,35,,,,,33 - 49,g/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Creatine Kinase,,49,,,,,39 - 308,U/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Serum Sodium,,148,,H,,,135 - 145,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Serum Bicarbonate,,24.4,,,,,19.3 - 29.3,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Serum Chloride,,110,,,,,94 - 112,mmol/L +CZ100222004,,,,,Male,Unscheduled,R,"Mar 13, 2026 8:40 AM",6227323295,CHEMISTRY PANEL,Magnesium,,0.82,,,,,0.66 - 0.98,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.2,,,,,0 - 6.2,umol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Alkaline Phosphatase,,73,,,,,40 - 129,U/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,ALT (SGPT),,5,,,,,5 - 48,U/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,AST (SGOT),,15,,,,,8 - 40,U/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,GGT,,6,R,L,,,10 - 61,U/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,LDH,,149,,,,,53 - 234,U/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Urea Nitrogen,,3.8,,,,,1.4 - 8.6,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,91,,,,,40 - 110,umol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Serum Glucose,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Serum Uric Acid,,277,,,,,125 - 488,umol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Calcium (EDTA),,2.42,,,,,2.07 - 2.64,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Phosphorus,,1.23,,,,,0.71 - 1.65,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Creatine Kinase,,119,,,,,39 - 308,U/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Serum Bicarbonate,,27.4,,,,,19.3 - 29.3,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100222005,,,,,Male,Unscheduled,R,"Mar 13, 2026 7:45 AM",6227323297,CHEMISTRY PANEL,Magnesium,,0.81,,,,,0.66 - 1.07,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Alkaline Phosphatase,,91,,,,,40 - 129,U/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,ALT (SGPT),,79,R,H,,,5 - 48,U/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,AST (SGOT),,51,R,H,,,8 - 40,U/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,GGT,,45,,,,,10 - 61,U/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,LDH,,228,,,,,53 - 234,U/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Urea Nitrogen,,8.3,,,,,1.4 - 8.6,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,106,,,,,40 - 110,umol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Serum Glucose,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Serum Uric Acid,,418,,,,,125 - 488,umol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Calcium (EDTA),,2.32,,,,,2.07 - 2.64,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Phosphorus,,1.10,,,,,0.71 - 1.65,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Creatine Kinase,,250,,,,,39 - 308,U/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Serum Bicarbonate,,25.4,,,,,19.3 - 29.3,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CHEMISTRY PANEL,Magnesium,,0.73,,,,,0.66 - 1.07,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,79,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,FECAL COLLECTION D/T,Stool Collection Date,Y,09-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,FECAL COLLECTION D/T,Stool Collection Time,Y,08:55,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,134,,,,,127 - 181,g/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.39 - 0.54, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.5 - 6.4,TI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.70,,,,,3.8 - 10.7,GI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.17,,,,,1.96 - 7.23,GI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.01,,,,,0.91 - 4.28,GI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,1.08,R,H,,,0 - 0.57,GI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,47.4,,,,,40.5 - 75,% +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.9,,,,,15.4 - 48.5,% +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,16.1,R,H,,,0 - 6.8,% +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,262,,,,,140 - 400,GI/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,LIPID PANEL,Direct HDL-C 4th Generation,,1.13,,,,,1.03 - 1.53,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,LIPID PANEL,Triglycerides (GPO),,0.84,,,,,0.56 - 3.62,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,LIPID PANEL,Cholesterol (High Performance),,5.14,,,,,3.88 - 6.83,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,LIPID PANEL,LDL Chol Friedewald 4th,,3.63,,H,,,0 - 3.34,mmol/L +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,09-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:50,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,09-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:05,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,09-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:50,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,09-Mar-2026,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,08:55,,,,,, +CZ100222003,,,,,Male,Induction Week 0,,"Mar 9, 2026 8:50 AM",6227323270,SUBJECT HEIGHT (CM),Height (cm),Y,190,,,,,cm, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Total Bilirubin,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Alkaline Phosphatase,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,ALT (SGPT),,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,AST (SGOT),,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,GGT,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,LDH,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Urea Nitrogen,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Serum Glucose,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Serum Uric Acid,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Calcium (EDTA),,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Phosphorus,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Total Protein,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Albumin-BCG,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Creatine Kinase,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Serum Sodium,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Serum Potassium,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Serum Bicarbonate,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Serum Chloride,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,CHEMISTRY PANEL,Magnesium,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,148,,,,,127 - 181,g/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 96,fL +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.67,,,,,3.8 - 10.7,GI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.96,,,,,1.96 - 7.23,GI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.68,,,,,0.91 - 4.28,GI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.51,,,,,0.12 - 0.92,GI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.42,,,,,0 - 0.57,GI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.3,,,,,40.5 - 75,% +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,25.2,,,,,15.4 - 48.5,% +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.7,,,,,2.6 - 10.1,% +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,6.3,,,,,0 - 6.8,% +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.5,,,,,0 - 2,% +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,341,,,,,140 - 400,GI/L +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100222005,,,,,Male,Screening,,"Mar 4, 2026 9:20 AM",6227810900,SUBJECT HEIGHT (CM),Height (cm),Y,188,,,,,cm, +CZ100222005,,,,,Male,Stool Pathogens,,"Mar 4, 2026 9:10 AM",6227810904,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100222005,,,,,Male,Stool Pathogens,,"Mar 4, 2026 9:10 AM",6227810904,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100222005,,,,,Male,Stool Pathogens,,"Mar 4, 2026 9:10 AM",6227810904,OVA AND PARASITES 1,Concentrate Exam,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Stool Pathogens,,"Mar 4, 2026 9:10 AM",6227810904,OVA AND PARASITES 1,Smear for Microsporidia,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Stool Pathogens,,"Mar 4, 2026 9:10 AM",6227810904,OVA AND PARASITES 1,Modified acid-fast stain,,,,,Test group cancelled: No specimen received,,, +CZ100222005,,,,,Male,Stool Pathogens,,"Mar 4, 2026 9:10 AM",6227810904,OVA AND PARASITES 2,Trichrome Smear,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Stool Pathogens,,"Mar 3, 2026 12:20 PM",6227810905,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100222004,,,,,Male,Stool Pathogens,,"Mar 3, 2026 12:20 PM",6227810905,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100222004,,,,,Male,Stool Pathogens,,"Mar 3, 2026 12:20 PM",6227810905,OVA AND PARASITES 1,Concentrate Exam,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Stool Pathogens,,"Mar 3, 2026 12:20 PM",6227810905,OVA AND PARASITES 1,Smear for Microsporidia,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Stool Pathogens,,"Mar 3, 2026 12:20 PM",6227810905,OVA AND PARASITES 1,Modified acid-fast stain,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Stool Pathogens,,"Mar 3, 2026 12:20 PM",6227810905,OVA AND PARASITES 2,Trichrome Smear,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Total Bilirubin,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Alkaline Phosphatase,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,ALT (SGPT),,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,AST (SGOT),,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,GGT,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,LDH,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Urea Nitrogen,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Serum Glucose,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Serum Uric Acid,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Calcium (EDTA),,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Phosphorus,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Total Protein,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Albumin-BCG,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Creatine Kinase,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Serum Sodium,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Serum Potassium,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Serum Bicarbonate,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Serum Chloride,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CHEMISTRY PANEL,Magnesium,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,,,,Test group cancelled: No specimen received,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,91,,L,,,125 - 170,g/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.31,,L,,,0.37 - 0.51, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.7,,L,,,4 - 5.8,TI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,25,,L,,,26 - 34,pg +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,80 - 100,fL +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,11.98,,H,,,3.8 - 10.7,GI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,9.38,,H,,,1.96 - 7.23,GI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.49,,,,,0.8 - 3,GI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.88,,,,,0.12 - 0.92,GI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.18,,,,,0 - 0.57,GI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,78.4,,H,,,40.5 - 75,% +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,12.4,,L,,,15.4 - 48.5,% +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.3,,,,,2.6 - 10.1,% +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.5,,,,,0 - 6.8,% +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,465,,H,,,130 - 394,GI/L +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100222004,,,,,Male,Screening,,"Mar 3, 2026 12:10 PM",6227810901,SUBJECT HEIGHT (CM),Height (cm),Y,158,,,,,cm, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.9,,,,,0 - 6.2,umol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Alkaline Phosphatase,,78,,,,,40 - 129,U/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,ALT (SGPT),,69,,H,,,5 - 48,U/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,AST (SGOT),,33,,,,,8 - 40,U/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,GGT,,38,,,,,10 - 61,U/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,LDH,,213,,,,,53 - 234,U/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Urea Nitrogen,,8.9,,H,,,1.4 - 8.6,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,105,,,,,40 - 110,umol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Serum Glucose,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Serum Uric Acid,,414,,,,,125 - 488,umol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Phosphorus,,1.17,,,,,0.71 - 1.65,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Total Protein,,70,,,,,61 - 84,g/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Creatine Kinase,,157,,,,,39 - 308,U/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Serum Bicarbonate,,25.4,,,,,19.3 - 29.3,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CHEMISTRY PANEL,Magnesium,,0.74,,,,,0.66 - 1.07,mmol/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,80,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,138,,,,,127 - 181,g/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.39 - 0.54, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.5 - 6.4,TI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.87,,,,,3.8 - 10.7,GI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.24,,,,,1.96 - 7.23,GI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.46,,,,,0.91 - 4.28,GI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.79,R,H,,,0 - 0.57,GI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,38.2,R,L,,,40.5 - 75,% +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,41.9,,,,,15.4 - 48.5,% +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.7,,,,,2.6 - 10.1,% +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,13.5,R,H,,,0 - 6.8,% +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,302,,,,,140 - 400,GI/L +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,,,,Test group cancelled: No specimen received,,, +CZ100222003,,,,,Male,Screening,,"Mar 2, 2026 11:00 AM",6227810899,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,18-Feb-2026,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,07:39,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,INFLAMED AREA,Inflamed area?,,No,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,20-Feb-2026,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100222001,,,,,Male,Biopsy,,"Feb 18, 2026 12:00 AM",6227323286,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,11-Feb-2026,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,14:38,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,13-Feb-2026,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100222003,,,,,Male,Biopsy,,"Feb 11, 2026 12:00 AM",6227323287,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100222002,,,,,Male,Stool Pathogens,,"Jan 23, 2026 10:10 AM",6227323277,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100222002,,,,,Male,Stool Pathogens,,"Jan 23, 2026 10:10 AM",6227323277,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100222002,,,,,Male,Stool Pathogens,,"Jan 23, 2026 10:10 AM",6227323277,OVA AND PARASITES 1,Concentrate Exam,,,,,Test group cancelled: No specimen received,,, +CZ100222002,,,,,Male,Stool Pathogens,,"Jan 23, 2026 10:10 AM",6227323277,OVA AND PARASITES 1,Smear for Microsporidia,,,,,Test group cancelled: No specimen received,,, +CZ100222002,,,,,Male,Stool Pathogens,,"Jan 23, 2026 10:10 AM",6227323277,OVA AND PARASITES 1,Modified acid-fast stain,,,,,Test group cancelled: No specimen received,,, +CZ100222002,,,,,Male,Stool Pathogens,,"Jan 23, 2026 10:10 AM",6227323277,OVA AND PARASITES 2,Trichrome Smear,,,,,Test group cancelled: No specimen received,,, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.9,,,,,0 - 6.2,umol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Alkaline Phosphatase,,55,,,,,40 - 129,U/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,ALT (SGPT),,25,,,,,5 - 48,U/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,GGT,,12,,,,,10 - 61,U/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,LDH,,190,,,,,53 - 234,U/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Urea Nitrogen,,8.5,,,,,1.4 - 8.6,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,115,,H,,,40 - 110,umol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Serum Glucose,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Serum Uric Acid,,337,,,,,125 - 488,umol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Calcium (EDTA),,2.44,,,,,2.07 - 2.64,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Phosphorus,,0.86,,,,,0.71 - 1.65,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Creatine Kinase,,144,,,,,39 - 308,U/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Serum Bicarbonate,,27.5,,,,,19.3 - 29.3,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CHEMISTRY PANEL,Magnesium,,0.75,,,,,0.66 - 1.07,mmol/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,CKD-EPI 2021,CKD-EPI 2021 Without Race,,72,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,136,,,,,127 - 181,g/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.39 - 0.54, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.5 - 6.4,TI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.82,,,,,3.8 - 10.7,GI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.49,,,,,1.96 - 7.23,GI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.54,,,,,0.91 - 4.28,GI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.41,,,,,0.12 - 0.92,GI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.34,,,,,0 - 0.57,GI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,42.7,,,,,40.5 - 75,% +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,43.7,,,,,15.4 - 48.5,% +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.0,,,,,2.6 - 10.1,% +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,5.9,,,,,0 - 6.8,% +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,224,,,,,140 - 400,GI/L +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEPATITIS B SURFACE AB NON-US,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222002,,,,,Male,Screening,,"Jan 23, 2026 10:00 AM",6227323268,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100222001,,,,,Male,Stool Pathogens,R,"Jan 15, 2026 4:55 PM",6227323276,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,,,,Test group cancelled: Specimen received beyond stability,,, +CZ100222001,,,,,Male,Stool Pathogens,R,"Jan 15, 2026 4:55 PM",6227323276,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,,,,Test group cancelled: Specimen received beyond stability,,, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Total Bilirubin,,<3,,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.4,,,,,0 - 6.2,umol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Alkaline Phosphatase,,140,,H,,,40 - 129,U/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,5 - 48,U/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,AST (SGOT),,28,,,,,8 - 40,U/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,GGT,,136,,H,,,10 - 61,U/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,LDH,,186,,,,,53 - 234,U/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,78,,,,,40 - 110,umol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Serum Glucose,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Serum Uric Acid,,408,,,,,125 - 488,umol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Calcium (EDTA),,2.31,,,,,2.07 - 2.64,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Phosphorus,,1.13,,,,,0.71 - 1.65,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Total Protein,,77,,,,,61 - 84,g/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Creatine Kinase,,131,,,,,39 - 308,U/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Serum Bicarbonate,,23.1,,,,,19.3 - 29.3,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CHEMISTRY PANEL,Magnesium,,0.82,,,,,0.66 - 1.07,mmol/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,CKD-EPI 2021,CKD-EPI 2021 Without Race,,111,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,85,,L,,,127 - 181,g/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.30,,L,,,0.39 - 0.54, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,L,,,4.5 - 6.4,TI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,21,,L,,,26 - 34,pg +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Microcytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Anisocytosis,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,74,,L,,,79 - 96,fL +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,15.03,,H,,,3.8 - 10.7,GI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,11.38,,H,,,1.96 - 7.23,GI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.59,,,,,0.91 - 4.28,GI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.82,,,,,0.12 - 0.92,GI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.11,,,,,0 - 0.2,GI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,75.7,,H,,,40.5 - 75,% +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,17.3,,,,,15.4 - 48.5,% +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,529,,H,,,140 - 400,GI/L +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEPATITIS B SURFACE AB NON-US,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100222001,,,,,Male,Screening,,"Jan 15, 2026 4:45 PM",6227323266,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, diff --git a/Covance/Source/2026-06-18_095542 sponsor-study-36940-test-results-930556-standard.csv b/Covance/Source/2026-06-18_095542 sponsor-study-36940-test-results-930556-standard.csv new file mode 100644 index 0000000..5e7e4a3 --- /dev/null +++ b/Covance/Source/2026-06-18_095542 sponsor-study-36940-test-results-930556-standard.csv @@ -0,0 +1,132 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,Result verified by repeat analysis,0 - 6.2,umol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Alkaline Phosphatase,,92,,,,,35 - 104,U/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,ALT (SGPT),,8,,,,,4 - 43,U/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,GGT,,8,,,,,4 - 49,U/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,LDH,,123,,,,,53 - 234,U/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Urea Nitrogen,,3.2,,,,,1.4 - 8.6,mmol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 101,umol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Serum Glucose,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Serum Uric Acid,,183,,,,,125 - 428,umol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Calcium (EDTA),,2.21,,,,,2.07 - 2.64,mmol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Phosphorus,,1.04,,,,,0.71 - 1.65,mmol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Creatine Kinase,,73,,,,,26 - 192,U/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Serum Bicarbonate,,21.2,,,,,19.3 - 29.3,mmol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CHEMISTRY PANEL,Magnesium,,0.78,,,,,0.66 - 1.07,mmol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,106,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,FECAL COLLECTION D/T,Stool Collection Date,Y,10-Jun-2026,,,,,, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,FECAL COLLECTION D/T,Stool Collection Time,Y,06:30,,,,,, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,108,,L,,,116 - 164,g/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.33,,L,,,0.34 - 0.48, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.9,,L,,,4.1 - 5.6,TI/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,28,,,,,26 - 34,pg +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 98,fL +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.97,,,,,3.8 - 10.7,GI/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.45,,,,,1.96 - 7.23,GI/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.28,,,,,0.91 - 4.28,GI/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.43,,,,,0.12 - 0.92,GI/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.72,,H,,,0 - 0.57,GI/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,68.5,,,,,40.5 - 75,% +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,16.2,,,,,15.4 - 48.5,% +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,9.0,,H,,,0 - 6.8,% +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,449,,H,,,140 - 400,GI/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,LIPID PANEL,Direct HDL-C 4th Generation,,1.10,,,,,1.03 - 1.53,mmol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,LIPID PANEL,Triglycerides (GPO),,1.06,,,,,0.44 - 1.99,mmol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,LIPID PANEL,Cholesterol (High Performance),,4.26,,,,,3.65 - 6.21,mmol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,LIPID PANEL,LDL Chol Friedewald 4th,,2.67,,,,,0 - 3.34,mmol/L +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,10-Jun-2026,,,,,, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,09:00,,,,,, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,10-Jun-2026,,,,,, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:10,,,,,, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,10-Jun-2026,,,,,, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,09:00,,,,,, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,10-Jun-2026,,,,,, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,06:30,,,,,, +CZ100032001,,,,,Female,Induction Week 0,,"Jun 10, 2026 9:00 AM",6227323301,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,27-May-2026,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,08:10,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,29-May-2026,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100032001,,,,,Female,Biopsy,,"May 27, 2026 12:00 AM",6227323320,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100032001,,,,,Female,Stool Pathogens,,"May 13, 2026 9:30 AM",6227323309,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100032001,,,,,Female,Stool Pathogens,,"May 13, 2026 9:30 AM",6227323309,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100032001,,,,,Female,Stool Pathogens,,"May 13, 2026 9:30 AM",6227323309,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100032001,,,,,Female,Stool Pathogens,,"May 13, 2026 9:30 AM",6227323309,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100032001,,,,,Female,Stool Pathogens,,"May 13, 2026 9:30 AM",6227323309,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100032001,,,,,Female,Stool Pathogens,,"May 13, 2026 9:30 AM",6227323309,OVA AND PARASITES 2,Trichrome Smear,,,,,Test group cancelled: Specimen received in expired coll. container; unable to perform test.,,, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,35 - 104,U/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,AST (SGOT),,11,,,,,8 - 40,U/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,GGT,,9,,,,,4 - 49,U/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,LDH,,128,,,,,53 - 234,U/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Serum Glucose,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Serum Uric Acid,,192,,,,,125 - 428,umol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Calcium (EDTA),,2.24,,,,,2.07 - 2.64,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Phosphorus,,1.00,,,,,0.71 - 1.65,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Creatine Kinase,,85,,,,,26 - 192,U/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Serum Bicarbonate,,23.8,,,,,19.3 - 29.3,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CHEMISTRY PANEL,Magnesium,,0.79,,,,,0.66 - 1.07,mmol/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,94,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,114,,L,,,116 - 164,g/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,,,,,0.34 - 0.48, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,,4.1 - 5.6,TI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,28,,,,,26 - 34,pg +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 98,fL +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.80,,,,,3.8 - 10.7,GI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.53,,,,,1.96 - 7.23,GI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.32,,,,,0.91 - 4.28,GI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.47,,,,,0.12 - 0.92,GI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.44,,,,,0 - 0.57,GI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,74.2,,,,,40.5 - 75,% +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,15.0,,L,,,15.4 - 48.5,% +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,5.0,,,,,0 - 6.8,% +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,513,,H,,,140 - 400,GI/L +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100032001,,,,,Female,Screening,,"May 13, 2026 8:15 AM",6227323299,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, diff --git a/Covance/Source/2026-06-18_095547 sponsor-study-36940-test-results-930556-microbiology.csv b/Covance/Source/2026-06-18_095547 sponsor-study-36940-test-results-930556-microbiology.csv new file mode 100644 index 0000000..fba7493 --- /dev/null +++ b/Covance/Source/2026-06-18_095547 sponsor-study-36940-test-results-930556-microbiology.csv @@ -0,0 +1,3 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100032001 - null,,,,Female,SCRNSTOOL Stool Pathogens,"May 13, 2026 9:30 AM",6227323309,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance/Source/2026-06-18_095550 sponsor-study-36940-test-results-930525-microbiology.csv b/Covance/Source/2026-06-18_095550 sponsor-study-36940-test-results-930525-microbiology.csv new file mode 100644 index 0000000..a4242f9 --- /dev/null +++ b/Covance/Source/2026-06-18_095550 sponsor-study-36940-test-results-930525-microbiology.csv @@ -0,0 +1,6 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100222001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Jan 15, 2026 4:55 PM",6227323276,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,R, +CZ100222002 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Jan 23, 2026 10:10 AM",6227323277,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100222004 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Mar 3, 2026 12:20 PM",6227810905,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100222005 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Mar 4, 2026 9:10 AM",6227810904,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance/Source/2026-06-18_095611 sponsor-study-36940-test-results-930549-standard.csv b/Covance/Source/2026-06-18_095611 sponsor-study-36940-test-results-930549-standard.csv new file mode 100644 index 0000000..533a201 --- /dev/null +++ b/Covance/Source/2026-06-18_095611 sponsor-study-36940-test-results-930549-standard.csv @@ -0,0 +1,242 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Alkaline Phosphatase,,82,,,,,35 - 104,U/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,GGT,,11,,,,,4 - 49,U/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,LDH,,151,,,,,53 - 234,U/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Urea Nitrogen,,2.1,,,,,1.4 - 8.6,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,55,,,,,31 - 101,umol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Serum Glucose,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Serum Uric Acid,,277,,,,,125 - 428,umol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Calcium (EDTA),,2.54,,,,,2.07 - 2.64,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Phosphorus,,0.81,,,,,0.71 - 1.65,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Total Protein,,84,,,,,61 - 84,g/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Albumin-BCG,,51,,H,,,33 - 49,g/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Creatine Kinase,,55,,,,,26 - 192,U/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Serum Bicarbonate,,23.5,,,,,19.3 - 29.3,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CHEMISTRY PANEL,Magnesium,,0.89,,,,,0.66 - 1.07,mmol/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,129,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,FECAL COLLECTION D/T,Stool Collection Date,Y,,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,FECAL COLLECTION D/T,Stool Collection Time,Y,,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,127,,,,Result verified by repeat analysis,116 - 164,g/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,Result verified by repeat analysis,4.1 - 5.6,TI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,27,,,,Result verified by repeat analysis,26 - 34,pg +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Anisocytosis,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,83,,,,Result verified by repeat analysis,79 - 98,fL +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.41,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.73,,,,,1.96 - 7.23,GI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.41,,,,,0.91 - 4.28,GI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.22,,,,,0.12 - 0.92,GI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.04,,,,,0 - 0.57,GI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.00,,,,,0 - 0.2,GI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,62.0,,,,,40.5 - 75,% +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.0,,,,,15.4 - 48.5,% +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.0,,,,,2.6 - 10.1,% +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.0,,,,,0 - 2,% +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,340,,,,Result verified by repeat analysis,140 - 400,GI/L +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,07-May-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,12:40,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,07-May-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,14:20,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,07-May-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,12:40,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,,,,,,, +CZ100122001,,,,,Female,Induction Week 4,,"May 7, 2026 12:40 PM",6227697723,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Alkaline Phosphatase,,71,,,,,35 - 104,U/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,4 - 43,U/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,GGT,,12,,,,,4 - 49,U/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,LDH,,138,,,,,53 - 234,U/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Urea Nitrogen,,3.5,,,,,1.4 - 8.6,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,56,,,,,31 - 101,umol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Serum Glucose,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Serum Uric Acid,,296,,,,,125 - 428,umol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Calcium (EDTA),,2.55,,,,,2.07 - 2.64,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Phosphorus,,0.77,,,,,0.71 - 1.65,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Total Protein,,77,,,,,61 - 84,g/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Creatine Kinase,,49,,,,,26 - 192,U/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Serum Bicarbonate,,25.3,,,,,19.3 - 29.3,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CHEMISTRY PANEL,Magnesium,,0.83,,,,,0.66 - 1.07,mmol/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,129,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,FECAL COLLECTION D/T,Stool Collection Date,Y,22-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,FECAL COLLECTION D/T,Stool Collection Time,Y,05:30,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,128,,,,Result verified by repeat analysis,116 - 164,g/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,Result verified by repeat analysis,0.34 - 0.48, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,Result verified by repeat analysis,4.1 - 5.6,TI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,26,,,,Result verified by repeat analysis,26 - 34,pg +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,81,,,,Result verified by repeat analysis,79 - 98,fL +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.60,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.39,,,,,1.96 - 7.23,GI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.54,,,,,0.91 - 4.28,GI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.47,,,,Result verified by repeat analysis,0.12 - 0.92,GI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,Result verified by repeat analysis,0 - 0.57,GI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,66.6,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,23.5,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.2,,,,Result verified by repeat analysis,2.6 - 10.1,% +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.8,,,,Result verified by repeat analysis,0 - 6.8,% +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,Result verified by repeat analysis,0 - 2,% +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,300,,,,Result verified by repeat analysis,140 - 400,GI/L +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,22-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,09:25,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,22-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:45,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,22-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,09:25,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,22-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,05:30,,,,,, +CZ100122001,,,,,Female,Induction Week 2,,"Apr 22, 2026 9:25 AM",6227697722,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.5,,,,,0 - 6.2,umol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Alkaline Phosphatase,,66,,,,,35 - 104,U/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,ALT (SGPT),,25,,,,,4 - 43,U/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,GGT,,12,,,,,4 - 49,U/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,LDH,,157,,,,,53 - 234,U/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Urea Nitrogen,,3.0,,,,,1.4 - 8.6,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,51,,,,,31 - 101,umol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Serum Glucose,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Serum Uric Acid,,258,,,,,125 - 428,umol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Phosphorus,,0.84,,,,,0.71 - 1.65,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Creatine Kinase,,51,,,,,26 - 192,U/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Serum Bicarbonate,,23.0,,,,,19.3 - 29.3,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CHEMISTRY PANEL,Magnesium,,0.82,,,,,0.66 - 1.07,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,131,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,FECAL COLLECTION D/T,Stool Collection Date,Y,07-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,FECAL COLLECTION D/T,Stool Collection Time,Y,06:00,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,115,R,L,,,116 - 164,g/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,,,,,0.34 - 0.48, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,25,R,L,,,26 - 34,pg +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,80,,,,,79 - 98,fL +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.11,,,,,3.8 - 10.7,GI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.31,,,,,1.96 - 7.23,GI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.15,,,,,0.91 - 4.28,GI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.54,,,,,0.12 - 0.92,GI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.05,,,,,0 - 0.57,GI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,69.3,,,,,40.5 - 75,% +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,23.6,,,,,15.4 - 48.5,% +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.9,,,,,2.6 - 10.1,% +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.5,,,,,0 - 6.8,% +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,386,,,,,140 - 400,GI/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,LIPID PANEL,Direct HDL-C 4th Generation,,1.35,,,,,1.03 - 1.53,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,LIPID PANEL,Triglycerides (GPO),,1.11,,,,,0.41 - 1.63,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,LIPID PANEL,Cholesterol (High Performance),,4.41,,,,,3.31 - 5.64,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,LIPID PANEL,LDL Chol Friedewald 4th,,2.55,,,,,0 - 3.34,mmol/L +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,07-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,11:45,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,07-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,13:35,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,07-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,11:45,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,07-Apr-2026,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,06:00,,,,,, +CZ100122001,,,,,Female,Induction Week 0,,"Apr 7, 2026 11:45 AM",6227697719,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,ANATOMICAL SITE,Anatomical Site,Y,15 cm,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,23-Mar-2026,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,09:42,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,25-Mar-2026,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100122001,,,,,Female,Biopsy,,"Mar 23, 2026 12:00 AM",6227697736,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Total Bilirubin,,<3,R,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,Result verified by repeat analysis,0 - 6.2,umol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Alkaline Phosphatase,,74,,,,,35 - 104,U/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,4 - 43,U/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,GGT,,9,,,,,4 - 49,U/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Urea Nitrogen,,2.5,,,,,1.4 - 8.6,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,55,,,,,31 - 101,umol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Serum Glucose,,5.5,,,,,3.9 - 5.6,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Serum Uric Acid,,226,,,,,125 - 428,umol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Phosphorus,,0.90,,,,,0.71 - 1.65,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Creatine Kinase,,84,,,,,26 - 192,U/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Serum Potassium,,5.1,,,,,3.5 - 5.2,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Serum Bicarbonate,,19.2,,L,,,19.3 - 29.3,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CHEMISTRY PANEL,Magnesium,,0.83,,,,,0.66 - 1.07,mmol/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,129,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,111,R,L,,,116 - 164,g/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,,,,,0.34 - 0.48, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.1 - 5.6,TI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,24,R,L,,,26 - 34,pg +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,78,R,L,,,79 - 98,fL +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.66,,,,,3.8 - 10.7,GI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.37,,,,,1.96 - 7.23,GI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.63,,,,,0.91 - 4.28,GI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.55,,,,,0.12 - 0.92,GI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,70.2,,,,,40.5 - 75,% +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,21.2,,,,,15.4 - 48.5,% +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.2,,,,,2.6 - 10.1,% +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.1,,,,,0 - 6.8,% +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,412,R,H,,,140 - 400,GI/L +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100122001,,,,,Female,Screening,R,"Mar 18, 2026 9:18 AM",6227697718,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100122001,,,,,Female,Stool Pathogens,,"Mar 17, 2026 5:30 PM",6227697725,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100122001,,,,,Female,Stool Pathogens,,"Mar 17, 2026 5:30 PM",6227697725,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, diff --git a/Covance/Source/2026-06-18_095614 sponsor-study-36940-test-results-930549-microbiology.csv b/Covance/Source/2026-06-18_095614 sponsor-study-36940-test-results-930549-microbiology.csv new file mode 100644 index 0000000..a05daf8 --- /dev/null +++ b/Covance/Source/2026-06-18_095614 sponsor-study-36940-test-results-930549-microbiology.csv @@ -0,0 +1,3 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100122001 - null,,,,Female,SCRNSTOOL Stool Pathogens,"Mar 17, 2026 5:30 PM",6227697725,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance/Source/2026-06-18_095633 sponsor-study-36940-test-results-930555-standard.csv b/Covance/Source/2026-06-18_095633 sponsor-study-36940-test-results-930555-standard.csv new file mode 100644 index 0000000..0f42267 --- /dev/null +++ b/Covance/Source/2026-06-18_095633 sponsor-study-36940-test-results-930555-standard.csv @@ -0,0 +1,544 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Total Bilirubin,,14,,,,,3 - 21,umol/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.9,,,,,0 - 6.2,umol/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Alkaline Phosphatase,,65,,,,,40 - 129,U/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,ALT (SGPT),,12,,,,,5 - 48,U/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,LDH,,127,,,,,53 - 234,U/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Urea Nitrogen,,2.6,,,,,1.4 - 8.6,mmol/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,79,,,,,40 - 110,umol/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Serum Glucose,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Serum Uric Acid,,312,,,,,125 - 488,umol/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Calcium (EDTA),,2.23,,,,,2.07 - 2.64,mmol/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Phosphorus,,1.04,,,,,0.71 - 1.65,mmol/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Albumin-BCG,,40,,,,,33 - 49,g/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Creatine Kinase,,117,,,,,39 - 308,U/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Serum Potassium,,3.7,,,,,3.5 - 5.2,mmol/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Serum Bicarbonate,,24.9,,,,,19.3 - 29.3,mmol/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CHEMISTRY PANEL,Magnesium,,0.88,,,,,0.66 - 1.07,mmol/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,105,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,FECAL COLLECTION D/T,Stool Collection Date,Y,08-Jun-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,FECAL COLLECTION D/T,Stool Collection Time,Y,22:00,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,123,,L,,,127 - 181,g/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,L,,,0.39 - 0.54, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,L,,,4.5 - 6.4,TI/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Anisocytosis,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,79 - 96,fL +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.06,,,,,3.8 - 10.7,GI/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.44,,,,,1.96 - 7.23,GI/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.01,,,,,0.91 - 4.28,GI/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.56,,,,,0.12 - 0.92,GI/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.05,,,,,0 - 0.57,GI/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.00,,,,,0 - 0.2,GI/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,68.0,,,,,40.5 - 75,% +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,20.0,,,,,15.4 - 48.5,% +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,11.0,,H,,,2.6 - 10.1,% +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.0,,,,,0 - 2,% +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,224,,,,,140 - 400,GI/L +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,08-Jun-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:55,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,09-Jun-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,09:30,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,08-Jun-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:55,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,08-Jun-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,22:00,,,,,, +CZ100062002,,,,,Male,Induction Week 2,,"Jun 9, 2026 9:40 AM",6228407564,SUBJECT HEIGHT (CM),Height (cm),Y,178,,,,,cm, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Unable to calc due to LOQ,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Unable to calc due to LOQ,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Total Bilirubin,,<3,,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Alkaline Phosphatase,,64,,,,,40 - 129,U/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,5 - 48,U/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,GGT,,13,,,,,10 - 61,U/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,LDH,,130,,,,,53 - 234,U/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Urea Nitrogen,,2.3,,,,,1.4 - 8.6,mmol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,74,,,,,40 - 110,umol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Serum Glucose,,4.1,,,,,3.9 - 5.6,mmol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Serum Uric Acid,,308,,,,,125 - 488,umol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Calcium (EDTA),,2.48,,,,,2.07 - 2.64,mmol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Phosphorus,,1.22,,,,,0.71 - 1.65,mmol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Albumin-BCG,,40,,,,,33 - 49,g/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Creatine Kinase,,30,,L,,,39 - 308,U/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Serum Bicarbonate,,24.2,,,,,19.3 - 29.3,mmol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CHEMISTRY PANEL,Magnesium,,0.89,,,,,0.7 - 0.9,mmol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,129,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,FECAL COLLECTION D/T,Stool Collection Date,Y,07-Jun-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,FECAL COLLECTION D/T,Stool Collection Time,Y,21:10,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,89,,L,,,127 - 181,g/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.30,,L,,,0.39 - 0.54, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,L,,,4.5 - 6.4,TI/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,21,,L,,,26 - 34,pg +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Microcytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,72,,L,,,79 - 96,fL +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,13.36,,H,,,3.8 - 10.7,GI/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,7.93,,H,,,1.96 - 7.23,GI/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,4.41,,H,,,0.91 - 4.28,GI/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.79,,,,,0.12 - 0.92,GI/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.12,,,,,0 - 0.2,GI/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.4,,,,,40.5 - 75,% +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.9,,,,,15.4 - 48.5,% +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.9,,,,,2.6 - 10.1,% +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,615,,H,,,140 - 400,GI/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,LIPID PANEL,Direct HDL-C 4th Generation,,1.42,,,,,1.03 - 1.53,mmol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,LIPID PANEL,Triglycerides (GPO),,0.90,,,,,0.42 - 1.67,mmol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,LIPID PANEL,Cholesterol (High Performance),,4.22,,,,,2.95 - 5.12,mmol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,LIPID PANEL,LDL Chol Friedewald 4th,,2.39,,,,,0 - 3.34,mmol/L +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,08-Jun-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:30,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,08-Jun-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,09:10,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,08-Jun-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:30,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,07-Jun-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,21:10,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,07-Jun-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,21:10,,,,,, +CZ100062001,,,,,Male,Induction Week 12,,"Jun 8, 2026 9:30 AM",6228013269,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,BIOPSY COLLECTION METHOD,Collection Method,Y,sigmoidoscopy,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,28-May-2026,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,09:15,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,01-Jun-2026,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100062001,,,,,Male,Biopsy,,"May 29, 2026 12:00 AM",6227323255,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Total Bilirubin,,18,,,,,3 - 21,umol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,5.8,,,,,0 - 6.2,umol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Alkaline Phosphatase,,63,,,,,40 - 129,U/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,ALT (SGPT),,12,,,,,5 - 48,U/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,GGT,,17,,,,,10 - 61,U/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,LDH,,124,,,,,53 - 234,U/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Urea Nitrogen,,3.2,,,,,1.4 - 8.6,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,40 - 110,umol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Serum Glucose,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Serum Uric Acid,,298,,,,,125 - 488,umol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Calcium (EDTA),,2.33,,,,,2.07 - 2.64,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Phosphorus,,1.21,,,,,0.71 - 1.65,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Creatine Kinase,,106,,,,,39 - 308,U/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Serum Bicarbonate,,23.8,,,,,19.3 - 29.3,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CHEMISTRY PANEL,Magnesium,,0.81,,,,,0.66 - 1.07,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,106,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,FECAL COLLECTION D/T,Stool Collection Date,Y,26-May-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,FECAL COLLECTION D/T,Stool Collection Time,Y,06:20,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,129,,,,,127 - 181,g/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.39 - 0.54, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,L,,,4.5 - 6.4,TI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 96,fL +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.10,,,,,3.8 - 10.7,GI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.34,,,,,1.96 - 7.23,GI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.09,,,,,0.91 - 4.28,GI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.48,,,,,0.12 - 0.92,GI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.16,,,,,0 - 0.57,GI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,65.5,,,,,40.5 - 75,% +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,21.4,,,,,15.4 - 48.5,% +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,9.5,,,,,2.6 - 10.1,% +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.2,,,,,0 - 6.8,% +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,270,,,,,140 - 400,GI/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,LIPID PANEL,Direct HDL-C 4th Generation,,0.90,,L,,,1.03 - 1.53,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,LIPID PANEL,Triglycerides (GPO),,0.88,,,,,0.62 - 3.69,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,LIPID PANEL,Cholesterol (High Performance),,2.48,,L,,Result verified by repeat analysis,4.19 - 7.24,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,LIPID PANEL,LDL Chol Friedewald 4th,,1.18,,,,,0 - 3.34,mmol/L +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,26-May-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:15,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,26-May-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,09:05,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,26-May-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:15,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,26-May-2026,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,06:20,,,,,, +CZ100062002,,,,,Male,Induction Week 0,,"May 26, 2026 9:20 AM",6227323238,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,ANATOMICAL SITE,Anatomical Site,Y,15-20,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,14-May-2026,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,08:15,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,16-May-2026,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100062002,,,,,Male,Biopsy,,"May 14, 2026 12:00 AM",6227323256,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.6,,,,,0 - 6.2,umol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Alkaline Phosphatase,,65,,,,,40 - 129,U/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,ALT (SGPT),,13,,,,,5 - 48,U/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,GGT,,17,,,,,10 - 61,U/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,LDH,,151,,,,,53 - 234,U/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,71,,,,,40 - 110,umol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Serum Glucose,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Serum Uric Acid,,338,,,,,125 - 488,umol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Calcium (EDTA),,2.32,,,,,2.07 - 2.64,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Phosphorus,,1.19,,,,,0.71 - 1.65,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Creatine Kinase,,281,,,,,39 - 308,U/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Serum Bicarbonate,,26.0,,,,,19.3 - 29.3,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CHEMISTRY PANEL,Magnesium,,0.81,,,,,0.66 - 1.07,mmol/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,108,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,127 - 181,g/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.39 - 0.54, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.5 - 6.4,TI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Anisocytosis,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 96,fL +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.17,,,,,3.8 - 10.7,GI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.25,,,,,1.96 - 7.23,GI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.20,,,,,0.91 - 4.28,GI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.38,,,,,0.12 - 0.92,GI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.22,,,,,0 - 0.57,GI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.11,,,,,0 - 0.2,GI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.0,,,,,40.5 - 75,% +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,28.9,,,,,15.4 - 48.5,% +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,9.1,,,,,2.6 - 10.1,% +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,5.3,,,,,0 - 6.8,% +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.7,,H,,,0 - 2,% +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,306,,,,,140 - 400,GI/L +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100062002,,,,,Male,Screening,,"Apr 20, 2026 7:45 AM",6227323234,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100062002,,,,,Male,Stool Pathogens,,"Apr 20, 2026 7:45 AM",6228194341,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100062002,,,,,Male,Stool Pathogens,,"Apr 20, 2026 7:45 AM",6228194341,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100062002,,,,,Male,Stool Pathogens,,"Apr 20, 2026 7:45 AM",6228194341,OVA AND PARASITES 1,Concentrate Exam,,,,,Test group cancelled: No specimen received,,, +CZ100062002,,,,,Male,Stool Pathogens,,"Apr 20, 2026 7:45 AM",6228194341,OVA AND PARASITES 1,Smear for Microsporidia,,,,,Test group cancelled: No specimen received,,, +CZ100062002,,,,,Male,Stool Pathogens,,"Apr 20, 2026 7:45 AM",6228194341,OVA AND PARASITES 1,Modified acid-fast stain,,,,,Test group cancelled: No specimen received,,, +CZ100062002,,,,,Male,Stool Pathogens,,"Apr 20, 2026 7:45 AM",6228194341,OVA AND PARASITES 2,Trichrome Smear,,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Alkaline Phosphatase,,91,,,,,40 - 129,U/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,ALT (SGPT),,8,,,,,5 - 48,U/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,LDH,,118,,,,,53 - 234,U/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Urea Nitrogen,,1.6,,,,,1.4 - 8.6,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,92,,,,,40 - 110,umol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Serum Glucose,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Serum Uric Acid,,424,,,,,125 - 488,umol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Calcium (EDTA),,2.51,,,,,2.07 - 2.64,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Phosphorus,,1.29,,,,,0.71 - 1.65,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Total Protein,,78,,,,,61 - 84,g/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Creatine Kinase,,41,,,,,39 - 308,U/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Serum Bicarbonate,,24.0,,,,,19.3 - 29.3,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Serum Chloride,,96,,,,,94 - 112,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CHEMISTRY PANEL,Magnesium,,0.93,,H,,,0.7 - 0.9,mmol/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,106,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,FECAL COLLECTION D/T,Stool Collection Date,Y,14-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,FECAL COLLECTION D/T,Stool Collection Time,Y,20:30,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,122,R,L,,,127 - 181,g/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4.5 - 6.4,TI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,24,R,L,,,26 - 34,pg +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,83,,,,,79 - 96,fL +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,14.93,R,H,,,3.8 - 10.7,GI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,10.00,R,H,,,1.96 - 7.23,GI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.54,,,,,0.91 - 4.28,GI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,1.79,R,H,,,0.12 - 0.92,GI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.60,R,H,,,0 - 0.57,GI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.00,,,,,0 - 0.2,GI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,67.0,,,,,40.5 - 75,% +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,17.0,,,,,15.4 - 48.5,% +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,12.0,R,H,,,2.6 - 10.1,% +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.0,,,,,0 - 6.8,% +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.0,,,,,0 - 2,% +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,647,R,H,,,140 - 400,GI/L +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,14-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:15,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,14-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:40,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,14-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:15,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,14-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,20:30,,,,,, +CZ100062001,,,,,Male,Induction Week 4,,"Apr 15, 2026 8:45 AM",6227323242,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.6,,,,,0 - 6.2,umol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,40 - 129,U/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,5 - 48,U/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,LDH,,113,,,,,53 - 234,U/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Urea Nitrogen,,2.0,,,,,1.4 - 8.6,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,86,,,,,40 - 110,umol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Serum Glucose,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Serum Uric Acid,,410,,,,,125 - 488,umol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Phosphorus,,1.28,,,,,0.71 - 1.65,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Creatine Kinase,,64,,,,,39 - 308,U/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Serum Bicarbonate,,23.2,,,,,19.3 - 29.3,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CHEMISTRY PANEL,Magnesium,,0.93,R,H,,,0.7 - 0.9,mmol/L +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,115,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,FECAL COLLECTION D/T,Stool Collection Date,Y,08-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,FECAL COLLECTION D/T,Stool Collection Time,Y,07:10,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,08-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:10,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,08-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:20,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,08-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:10,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,08-Apr-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,07:10,,,,,, +CZ100062001,,,,,Male,Induction Week 2,,"Apr 8, 2026 7:10 AM",6227323240,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Alkaline Phosphatase,,89,,,,,40 - 129,U/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,ALT (SGPT),,8,,,,,5 - 48,U/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,GGT,,18,,,,,10 - 61,U/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,LDH,,141,,,,,53 - 234,U/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Urea Nitrogen,,2.5,,,,,1.4 - 8.6,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,40 - 110,umol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Serum Glucose,,4.0,,,,,3.9 - 5.6,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Serum Uric Acid,,415,,,,,125 - 488,umol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Calcium (EDTA),,2.41,,,,,2.07 - 2.64,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Phosphorus,,1.26,,,,,0.71 - 1.65,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Creatine Kinase,,119,,,,,39 - 308,U/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Serum Bicarbonate,,23.3,,,,,19.3 - 29.3,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CHEMISTRY PANEL,Magnesium,,0.90,,,,,0.7 - 0.9,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,128,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,FECAL COLLECTION D/T,Stool Collection Date,Y,20-Mar-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,FECAL COLLECTION D/T,Stool Collection Time,Y,08:00,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,121,,L,,,127 - 181,g/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.39 - 0.54, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,25,,L,,,26 - 34,pg +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,81,,,,,79 - 96,fL +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,13.09,,H,,,3.8 - 10.7,GI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,9.29,,H,,,1.96 - 7.23,GI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.23,,,,,0.91 - 4.28,GI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,1.31,,H,,,0.12 - 0.92,GI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.13,,,,,0 - 0.2,GI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,71.0,,,,,40.5 - 75,% +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,17.0,,,,,15.4 - 48.5,% +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.0,,,,,2.6 - 10.1,% +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,445,,H,,,140 - 400,GI/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,IS SUBJECT FASTING?,Is Subject Fasting?,Y,No,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,LIPID PANEL,Direct HDL-C 4th Generation,,1.53,,,,,1.03 - 1.53,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,LIPID PANEL,Triglycerides (GPO),,0.81,,,,,0.42 - 1.67,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,LIPID PANEL,Cholesterol (High Performance),,4.16,,,,,2.95 - 5.12,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,LIPID PANEL,LDL Chol Friedewald 4th,,2.26,,,,,0 - 3.34,mmol/L +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,20-Mar-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:58,R,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,20-Mar-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,09:00,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,20-Mar-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:58,R,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,20-Mar-2026,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,08:00,,,,,, +CZ100062001,,,,,Male,Induction Week 0,,"Mar 20, 2026 8:00 AM",6227323237,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 17, 2026 9:00 AM",6227323243,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 17, 2026 9:00 AM",6227323243,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,R,,,,Male,Unscheduled,R,"Mar 17, 2026 8:00 AM",6227323265,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 11, 2026 9:15 AM",6227323245,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 11, 2026 9:15 AM",6227323245,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 11, 2026 9:15 AM",6227323245,OVA AND PARASITES 1,Concentrate Exam,,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 11, 2026 9:15 AM",6227323245,OVA AND PARASITES 1,Smear for Microsporidia,,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 11, 2026 9:15 AM",6227323245,OVA AND PARASITES 1,Modified acid-fast stain,,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Mar 11, 2026 9:15 AM",6227323245,OVA AND PARASITES 2,Trichrome Smear,,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,TB Testing,,"Mar 11, 2026 9:10 AM",6227323253,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Unscheduled,,"Mar 11, 2026 9:05 AM",6227323264,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,ANATOMICAL SITE,Anatomical Site,Y,18,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,BIOPSY COLLECTION METHOD,Collection Method,Y,sigmoidoscopy,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,19-Feb-2026,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,07:20,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,23-Feb-2026,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100062001,,,,,Male,Biopsy,R,"Feb 19, 2026 12:00 AM",6227323254,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Feb 16, 2026 7:20 AM",6227323244,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,,,,Test group cancelled: Specimen received beyond stability,,, +CZ100062001,,,,,Male,Stool Pathogens,,"Feb 16, 2026 7:20 AM",6227323244,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,,,,Test group cancelled: Specimen received beyond stability,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Total Bilirubin,,<3,,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Alkaline Phosphatase,,93,,,,,55 - 149,U/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,5 - 48,U/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,GGT,,64,,H,,,10 - 61,U/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,LDH,,105,,,,,53 - 234,U/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Urea Nitrogen,,1.5,,,,,1.4 - 8.6,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,40 - 110,umol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Serum Glucose,,4.2,,,,,3.9 - 5.6,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Serum Uric Acid,,288,,,,,125 - 488,umol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Calcium (EDTA),,2.32,,,,,2.07 - 2.64,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Phosphorus,,0.85,,,,,0.71 - 1.65,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Total Protein,,70,,,,,61 - 84,g/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Albumin-BCG,,39,,,,,33 - 49,g/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Creatine Kinase,,34,,L,,,39 - 308,U/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Serum Bicarbonate,,25.5,,,,,19.3 - 29.3,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CHEMISTRY PANEL,Magnesium,,0.95,,H,,,0.7 - 0.9,mmol/L +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,CKD-EPI 2021,CKD-EPI 2021 Without Race,,133,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Clotted Blood Received,,, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEPATITIS B SURFACE AB NON-US,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100062001,,,,,Male,Screening,,"Feb 16, 2026 7:03 AM",6227323236,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,,,,Test group cancelled: No specimen received,,, +CZ100062001,,,,,Male,TB Testing,,"Feb 16, 2026 7:03 AM",6227323252,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Indeterminate,,,,,Normal=Negative, diff --git a/Covance/Source/2026-06-18_095639 sponsor-study-36940-test-results-930555-microbiology.csv b/Covance/Source/2026-06-18_095639 sponsor-study-36940-test-results-930555-microbiology.csv new file mode 100644 index 0000000..90a8458 --- /dev/null +++ b/Covance/Source/2026-06-18_095639 sponsor-study-36940-test-results-930555-microbiology.csv @@ -0,0 +1,6 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100062001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Feb 16, 2026 7:20 AM",6227323244,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100062001 - null,,,,Male,UNSCSTOOL Stool Pathogens,"Mar 11, 2026 9:15 AM",6227323245,STOOL CULTURE,,,,Test group cancelled: Specimen received beyond stability,,,,,,,,,,, +CZ100062001 - null,,,,Male,UNSCSTOOL Stool Pathogens,"Mar 17, 2026 9:00 AM",6227323243,STOOL CULTURE,,,,Test group cancelled: No specimen received,,,,,,,,,,, +CZ100062002 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Apr 20, 2026 7:45 AM",6228194341,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance/Source/2026-06-18_095641 sponsor-study-36940-test-results-930547-microbiology.csv b/Covance/Source/2026-06-18_095641 sponsor-study-36940-test-results-930547-microbiology.csv new file mode 100644 index 0000000..b9b31df --- /dev/null +++ b/Covance/Source/2026-06-18_095641 sponsor-study-36940-test-results-930547-microbiology.csv @@ -0,0 +1,5 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100132001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Feb 26, 2026 10:35 AM",6227635149,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100132002 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Apr 1, 2026 8:30 AM",6227635148,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100132003 - null,,,,Female,SCRNSTOOL Stool Pathogens,"May 7, 2026 5:45 AM",6227635150,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance/Source/2026-06-18_095648 sponsor-study-36940-test-results-930547-standard.csv b/Covance/Source/2026-06-18_095648 sponsor-study-36940-test-results-930547-standard.csv new file mode 100644 index 0000000..fbd2ea3 --- /dev/null +++ b/Covance/Source/2026-06-18_095648 sponsor-study-36940-test-results-930547-standard.csv @@ -0,0 +1,691 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.7,,,,,0 - 6.2,umol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Alkaline Phosphatase,,84,,,,,40 - 129,U/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,ALT (SGPT),,25,,,,,5 - 48,U/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,GGT,,20,,,,,10 - 61,U/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,LDH,,176,,,,,53 - 234,U/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Urea Nitrogen,,7.2,,,,,1.4 - 8.6,mmol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,79,,,,,40 - 110,umol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Serum Glucose,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Serum Uric Acid,,283,,,,,125 - 488,umol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Phosphorus,,1.35,,,,,0.71 - 1.65,mmol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Creatine Kinase,,222,,,,,39 - 308,U/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Serum Bicarbonate,,23.9,,,,,19.3 - 29.3,mmol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CHEMISTRY PANEL,Magnesium,,0.83,,,,,0.66 - 1.07,mmol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,119,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,FECAL COLLECTION D/T,Stool Collection Date,Y,,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,FECAL COLLECTION D/T,Stool Collection Time,Y,,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,148,,,,,127 - 181,g/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.97,,,,,3.8 - 10.7,GI/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.39,,,,,1.96 - 7.23,GI/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.96,,,,,0.91 - 4.28,GI/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.27,,,,,0.12 - 0.92,GI/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.27,,,,,0 - 0.57,GI/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,48.1,,,,,40.5 - 75,% +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,39.3,,,,,15.4 - 48.5,% +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.5,,,,,2.6 - 10.1,% +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,5.4,,,,,0 - 6.8,% +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.7,,,,,0 - 2,% +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,175,,,,,140 - 400,GI/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,LIPID PANEL,Direct HDL-C 4th Generation,,2.09,R,H,,,1.03 - 1.53,mmol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,LIPID PANEL,Triglycerides (GPO),,0.87,,,,,0.5 - 2.81,mmol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,LIPID PANEL,Cholesterol (High Performance),,4.61,,,,,3.31 - 6.1,mmol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,LIPID PANEL,LDL Chol Friedewald 4th,,2.12,,,,,0 - 3.34,mmol/L +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,,,,,,, +CZ100132001,,,,,Male,Induction Week 12,,"Jun 16, 2026 1:30 PM",6228308227,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.6,,,,,0 - 6.2,umol/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Alkaline Phosphatase,,74,,,,,40 - 129,U/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,5 - 48,U/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,GGT,,17,,,,,10 - 61,U/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,LDH,,147,,,,,53 - 234,U/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Urea Nitrogen,,4.4,,,,,1.4 - 8.6,mmol/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,98,,,,,40 - 110,umol/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Serum Glucose,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Serum Uric Acid,,367,,,,,125 - 488,umol/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Calcium (EDTA),,2.51,,,,,2.07 - 2.64,mmol/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Phosphorus,,1.02,,,,,0.71 - 1.65,mmol/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Creatine Kinase,,140,,,,,39 - 308,U/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Serum Bicarbonate,,22.9,,,,,19.3 - 29.3,mmol/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CHEMISTRY PANEL,Magnesium,,0.84,,,,,0.66 - 1.07,mmol/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,92,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,FECAL COLLECTION D/T,Stool Collection Date,Y,10-Jun-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,FECAL COLLECTION D/T,Stool Collection Time,Y,07:00,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,152,,,,Result verified by repeat analysis,127 - 181,g/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.39 - 0.54, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,Result verified by repeat analysis,4.5 - 6.4,TI/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,33,,,,Result verified by repeat analysis,26 - 34,pg +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,99,,H,,,79 - 96,fL +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.79,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.48,,,,Result verified by repeat analysis,1.96 - 7.23,GI/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.61,,,,,0.91 - 4.28,GI/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.50,,,,Result verified by repeat analysis,0.12 - 0.92,GI/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,Result verified by repeat analysis,0 - 0.57,GI/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,51.9,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,33.7,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.4,,H,,Result verified by repeat analysis,2.6 - 10.1,% +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.8,,,,Result verified by repeat analysis,0 - 6.8,% +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.2,,,,Result verified by repeat analysis,0 - 2,% +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,268,,,,Result verified by repeat analysis,140 - 400,GI/L +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,10-Jun-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,09:32,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,10-Jun-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:34,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,10-Jun-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,09:32,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,10-Jun-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,07:00,,,,,, +CZ100132002,,,,,Male,Induction Week 4,,"Jun 10, 2026 9:32 AM",6228501727,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,04-Jun-2026,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,12:05,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,INFLAMED AREA,Inflamed area?,,No,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,12:00,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,06-Jun-2026,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Jun 4, 2026 12:00 AM",6228501730,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.0,,,,,0 - 6.2,umol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Alkaline Phosphatase,,104,,,,,35 - 104,U/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,ALT (SGPT),,47,,H,,,4 - 43,U/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,AST (SGOT),,42,,H,,,8 - 40,U/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,GGT,,45,,,,,4 - 49,U/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,LDH,,180,,,,,53 - 234,U/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Urea Nitrogen,,2.4,,,,,1.4 - 8.6,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Serum Glucose,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Serum Uric Acid,,378,,,,,125 - 428,umol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Calcium (EDTA),,2.48,,,,,2.07 - 2.64,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Phosphorus,,1.13,,,,,0.71 - 1.65,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Creatine Kinase,,111,,,,,26 - 192,U/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Serum Sodium,,143,,,,,132 - 147,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Serum Bicarbonate,,21.9,,,,,19.3 - 29.3,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CHEMISTRY PANEL,Magnesium,,0.83,,,,,0.66 - 1.07,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,89,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,FECAL COLLECTION D/T,Stool Collection Date,Y,02-Jun-2026,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,FECAL COLLECTION D/T,Stool Collection Time,Y,05:40,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,141,,,,,116 - 164,g/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.34 - 0.48, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.1 - 5.6,TI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,28,,,,,26 - 34,pg +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 98,fL +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.13,,,,,3.8 - 10.7,GI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.63,,,,,1.96 - 7.23,GI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.82,,,,,0.91 - 4.28,GI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.51,,,,,0.12 - 0.92,GI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,64.9,,,,,40.5 - 75,% +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,25.4,,,,,15.4 - 48.5,% +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.1,,,,,2.6 - 10.1,% +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.8,,,,,0 - 6.8,% +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,235,,,,,140 - 400,GI/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,LIPID PANEL,Direct HDL-C 4th Generation,,1.10,,,,,1.03 - 1.53,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,LIPID PANEL,Triglycerides (GPO),,1.61,,,,,0.51 - 2.42,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,LIPID PANEL,Cholesterol (High Performance),,3.91,,L,,,4.01 - 6.85,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,LIPID PANEL,LDL Chol Friedewald 4th,,2.07,,,,,0 - 3.34,mmol/L +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,02-Jun-2026,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,09:25,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,02-Jun-2026,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:30,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,02-Jun-2026,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,09:25,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,02-Jun-2026,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,05:40,,,,,, +CZ100132003,,,,,Female,Induction Week 0,,"Jun 2, 2026 9:25 AM",6228308225,SUBJECT HEIGHT (CM),Height (cm),Y,82,,,,,cm, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Alkaline Phosphatase,,73,,,,,40 - 129,U/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,5 - 48,U/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,AST (SGOT),,22,,,,,8 - 40,U/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,GGT,,18,,,,,10 - 61,U/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,LDH,,164,,,,,53 - 234,U/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Urea Nitrogen,,5.1,,,,,1.4 - 8.6,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,89,,,,,40 - 110,umol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Serum Glucose,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Serum Uric Acid,,346,,,,,125 - 488,umol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Calcium (EDTA),,2.46,,,,,2.07 - 2.64,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Phosphorus,,1.01,,,,,0.71 - 1.65,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Creatine Kinase,,206,,,,,39 - 308,U/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Serum Bicarbonate,,20.1,,,,,19.3 - 29.3,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CHEMISTRY PANEL,Magnesium,,0.85,,,,,0.66 - 1.07,mmol/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,103,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,FECAL COLLECTION D/T,Stool Collection Date,Y,26-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,FECAL COLLECTION D/T,Stool Collection Time,Y,07:00,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,151,,,,,127 - 181,g/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.5 - 6.4,TI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,33,,,,,26 - 34,pg +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,H,,,79 - 96,fL +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.61,,,,,3.8 - 10.7,GI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.81,,,,,1.96 - 7.23,GI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.03,,,,,0.91 - 4.28,GI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.50,,,,,0.12 - 0.92,GI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.23,,,,,0 - 0.57,GI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,50.0,,,,,40.5 - 75,% +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.1,,,,,15.4 - 48.5,% +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.9,,,,,2.6 - 10.1,% +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.0,,,,,0 - 6.8,% +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,283,,,,,140 - 400,GI/L +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,26-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,09:05,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,26-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:10,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,26-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,09:05,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,26-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,07:00,,,,,, +CZ100132002,,,,,Male,Induction Week 2,,"May 26, 2026 9:05 AM",6228398115,SUBJECT HEIGHT (CM),Height (cm),Y,196,,,,,cm, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,25-May-2026,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,09:05,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,12:00,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,27-May-2026,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100132003,,,,,Female,Biopsy,,"May 25, 2026 12:00 AM",6228501732,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.9,,,,,0 - 6.2,umol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Alkaline Phosphatase,,77,,,,,40 - 129,U/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,ALT (SGPT),,19,,,,,5 - 48,U/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,GGT,,16,,,,,10 - 61,U/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,LDH,,159,,,,,53 - 234,U/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Urea Nitrogen,,5.0,,,,,1.4 - 8.6,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,96,,,,,40 - 110,umol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Serum Glucose,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Serum Uric Acid,,342,,,,,125 - 488,umol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Calcium (EDTA),,2.48,,,,,2.07 - 2.64,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Creatine Kinase,,204,,,,,39 - 308,U/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Serum Bicarbonate,,21.8,,,,,19.3 - 29.3,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CHEMISTRY PANEL,Magnesium,,0.85,,,,,0.66 - 1.07,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,94,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,FECAL COLLECTION D/T,Stool Collection Date,Y,12-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,FECAL COLLECTION D/T,Stool Collection Time,Y,08:50,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,127 - 181,g/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.5 - 6.4,TI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,33,,,,,26 - 34,pg +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 96,fL +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.64,,,,,3.8 - 10.7,GI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.04,,,,,1.96 - 7.23,GI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.81,,,,,0.91 - 4.28,GI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.59,,,,,0.12 - 0.92,GI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.16,,,,,0 - 0.57,GI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.9,,,,,40.5 - 75,% +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.0,,,,,15.4 - 48.5,% +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.4,,H,,,2.6 - 10.1,% +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.8,,,,,0 - 6.8,% +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,275,,,,,140 - 400,GI/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,LIPID PANEL,Direct HDL-C 4th Generation,,1.26,,,,,1.03 - 1.53,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,LIPID PANEL,Triglycerides (GPO),,1.63,,,,,0.5 - 2.81,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,LIPID PANEL,Cholesterol (High Performance),,4.71,,,,,3.31 - 6.1,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,LIPID PANEL,LDL Chol Friedewald 4th,,2.70,,,,,0 - 3.34,mmol/L +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,PA1 EEA-2?,Approved to use EEA-2?,,No,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,12-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,10:25,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,12-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,11:30,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,12-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,10:25,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,12-May-2026,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,08:50,,,,,, +CZ100132002,,,,,Male,Induction Week 0,,"May 12, 2026 10:25 AM",6228308224,SUBJECT HEIGHT (CM),Height (cm),Y,196,,,,,cm, +CZ100132003,,,,,Female,Stool Pathogens,,"May 7, 2026 5:45 AM",6227635150,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100132003,,,,,Female,Stool Pathogens,,"May 7, 2026 5:45 AM",6227635150,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100132003,,,,,Female,Stool Pathogens,,"May 7, 2026 5:45 AM",6227635150,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100132003,,,,,Female,Stool Pathogens,,"May 7, 2026 5:45 AM",6227635150,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100132003,,,,,Female,Stool Pathogens,,"May 7, 2026 5:45 AM",6227635150,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100132003,,,,,Female,Stool Pathogens,,"May 7, 2026 5:45 AM",6227635150,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Alkaline Phosphatase,,95,,,,,35 - 104,U/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,ALT (SGPT),,16,,,,,4 - 43,U/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,AST (SGOT),,22,,,,,8 - 40,U/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,GGT,,34,,,,,4 - 49,U/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,LDH,,151,,,,,53 - 234,U/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Urea Nitrogen,,2.8,,,,,1.4 - 8.6,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 101,umol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Serum Glucose,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Serum Uric Acid,,357,,,,,125 - 428,umol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Calcium (EDTA),,2.31,,,,,2.07 - 2.64,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Creatine Kinase,,51,,,,,26 - 192,U/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Serum Bicarbonate,,23.1,,,,,19.3 - 29.3,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Serum Chloride,,106,,,,,94 - 112,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CHEMISTRY PANEL,Magnesium,,0.81,,,,,0.66 - 1.07,mmol/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,95,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,133,,,,,116 - 164,g/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,28,,,,,26 - 34,pg +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,84,,,,,79 - 98,fL +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.91,,,,,3.8 - 10.7,GI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.94,,,,,1.96 - 7.23,GI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.35,,,,,0.91 - 4.28,GI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,71.5,,,,,40.5 - 75,% +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,19.5,,,,,15.4 - 48.5,% +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.3,,,,,0 - 2,% +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,271,,,,,140 - 400,GI/L +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100132003,,,,,Female,Screening,,"May 6, 2026 10:45 AM",6227635141,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.6,,,,,0 - 6.2,umol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Alkaline Phosphatase,,88,,,,,40 - 129,U/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,ALT (SGPT),,36,,,,,5 - 48,U/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,AST (SGOT),,30,,,,,8 - 40,U/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,GGT,,21,,,,,10 - 61,U/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,LDH,,172,,,,,53 - 234,U/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Urea Nitrogen,,6.2,,,,,1.4 - 8.6,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,71,,,,,40 - 110,umol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Serum Glucose,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Serum Uric Acid,,297,,,,,125 - 488,umol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Calcium (EDTA),,2.45,,,,,2.07 - 2.64,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Phosphorus,,1.22,,,,,0.71 - 1.65,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Creatine Kinase,,177,,,,,39 - 308,U/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Serum Bicarbonate,,26.7,,,,,19.3 - 29.3,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CHEMISTRY PANEL,Magnesium,,0.83,,,,,0.66 - 1.07,mmol/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,123,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,FECAL COLLECTION D/T,Stool Collection Date,Y,21-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,FECAL COLLECTION D/T,Stool Collection Time,Y,06:20,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,152,,,,,127 - 181,g/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.39 - 0.54, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 96,fL +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.31,,,,,3.8 - 10.7,GI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.98,,,,,1.96 - 7.23,GI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.64,,,,,0.91 - 4.28,GI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.30,,,,,0.12 - 0.92,GI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.30,,,,,0 - 0.57,GI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,46.0,,,,,40.5 - 75,% +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,38.0,,,,,15.4 - 48.5,% +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.0,,,,,2.6 - 10.1,% +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,7.0,,H,,,0 - 6.8,% +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.0,,,,,0 - 2,% +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,226,,,,,140 - 400,GI/L +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,21-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:45,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,21-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,09:50,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,21-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:45,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,21-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,06:20,,,,,, +CZ100132001,,,,,Male,Induction Week 4,,"Apr 21, 2026 8:45 AM",6227635146,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,21-Apr-2026,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,08:45,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,12:00,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,23-Apr-2026,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100132002,,,,,Male,Biopsy,,"Apr 21, 2026 12:00 AM",6227635159,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Alkaline Phosphatase,,87,,,,,40 - 129,U/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,ALT (SGPT),,27,,,,,5 - 48,U/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,LDH,,174,,,,,53 - 234,U/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Urea Nitrogen,,5.5,,,,,1.4 - 8.6,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,87,,,,,40 - 110,umol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Serum Glucose,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Serum Uric Acid,,299,,,,,125 - 488,umol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Calcium (EDTA),,2.44,,,,,2.07 - 2.64,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Phosphorus,,1.17,,,,,0.71 - 1.65,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Creatine Kinase,,177,,,,,39 - 308,U/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Serum Bicarbonate,,26.5,,,,,19.3 - 29.3,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CHEMISTRY PANEL,Magnesium,,0.79,,,,,0.66 - 1.07,mmol/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,107,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,FECAL COLLECTION D/T,Stool Collection Date,Y,07-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,FECAL COLLECTION D/T,Stool Collection Time,Y,06:30,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,150,,,,,127 - 181,g/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 96,fL +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.89,,,,,3.8 - 10.7,GI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.33,,,,,1.96 - 7.23,GI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.84,,,,,0.91 - 4.28,GI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.25,,,,,0.12 - 0.92,GI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.37,,,,,0 - 0.57,GI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,47.7,,,,,40.5 - 75,% +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,37.7,,,,,15.4 - 48.5,% +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.2,,,,,2.6 - 10.1,% +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,7.7,R,H,,,0 - 6.8,% +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.8,,,,,0 - 2,% +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,217,,,,,140 - 400,GI/L +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,07-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:50,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,07-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:00,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,07-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:50,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,07-Apr-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,06:30,,,,,, +CZ100132001,,,,,Male,Induction Week 2,,"Apr 7, 2026 8:50 AM",6227635144,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100132002,,,,,Male,Stool Pathogens,,"Apr 1, 2026 8:30 AM",6227635148,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100132002,,,,,Male,Stool Pathogens,,"Apr 1, 2026 8:30 AM",6227635148,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100132002,,,,,Male,Stool Pathogens,,"Apr 1, 2026 8:30 AM",6227635148,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100132002,,,,,Male,Stool Pathogens,,"Apr 1, 2026 8:30 AM",6227635148,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100132002,,,,,Male,Stool Pathogens,,"Apr 1, 2026 8:30 AM",6227635148,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100132002,,,,,Male,Stool Pathogens,,"Apr 1, 2026 8:30 AM",6227635148,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Alkaline Phosphatase,,69,,,,,40 - 129,U/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,5 - 48,U/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,GGT,,15,,,,,10 - 61,U/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,LDH,,130,,,,,53 - 234,U/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Urea Nitrogen,,6.0,,,,,1.4 - 8.6,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,82,,,,,40 - 110,umol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Serum Glucose,,7.1,,H,,,3.9 - 5.6,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Serum Uric Acid,,301,,,,,125 - 488,umol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Calcium (EDTA),,2.45,,,,,2.07 - 2.64,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Phosphorus,,1.42,,,,,0.71 - 1.65,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Creatine Kinase,,91,,,,,39 - 308,U/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Serum Bicarbonate,,22.2,,,,,19.3 - 29.3,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CHEMISTRY PANEL,Magnesium,,0.75,,,,,0.66 - 1.07,mmol/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,114,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,147,,,,,127 - 181,g/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.39 - 0.54, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,R,L,,,4.5 - 6.4,TI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,34,,,,,26 - 34,pg +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 96,fL +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.60,,,,,3.8 - 10.7,GI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.44,,,,,1.96 - 7.23,GI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.11,,,,,0.91 - 4.28,GI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.65,,,,,0.12 - 0.92,GI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.28,,,,,0 - 0.57,GI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.12,,,,,0 - 0.2,GI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.4,,,,,40.5 - 75,% +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.8,,,,,15.4 - 48.5,% +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.6,,,,,2.6 - 10.1,% +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.7,,,,,0 - 6.8,% +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.5,,,,,0 - 2,% +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,256,,,,,140 - 400,GI/L +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100132002,,,,,Male,Screening,,"Apr 1, 2026 8:00 AM",6227635139,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.4,,,,,0 - 6.2,umol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Alkaline Phosphatase,,80,,,,,40 - 129,U/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,5 - 48,U/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,GGT,,13,,,,,10 - 61,U/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,LDH,,166,,,,,53 - 234,U/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Urea Nitrogen,,7.7,,,,,1.4 - 8.6,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,89,,,,,40 - 110,umol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Serum Glucose,,4.3,,,,,3.9 - 5.6,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Serum Uric Acid,,336,,,,,125 - 488,umol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Calcium (EDTA),,2.41,,,,,2.07 - 2.64,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Phosphorus,,1.04,,,,,0.71 - 1.65,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Creatine Kinase,,135,,,,,39 - 308,U/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Serum Bicarbonate,,22.2,,,,,19.3 - 29.3,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CHEMISTRY PANEL,Magnesium,,0.78,,,,,0.66 - 1.07,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,103,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,FECAL COLLECTION D/T,Stool Collection Date,Y,24-Mar-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,FECAL COLLECTION D/T,Stool Collection Time,Y,07:30,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,156,,,,,127 - 181,g/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.39 - 0.54, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4.5 - 6.4,TI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 96,fL +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.53,,,,,3.8 - 10.7,GI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.00,,,,,1.96 - 7.23,GI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.61,,,,,0.91 - 4.28,GI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.25,,,,,0.12 - 0.92,GI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.57,,,,,0 - 0.57,GI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.3,,,,,40.5 - 75,% +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.0,,,,,15.4 - 48.5,% +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.6,,,,,2.6 - 10.1,% +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,10.4,R,H,,,0 - 6.8,% +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.8,,,,,0 - 2,% +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,235,,,,,140 - 400,GI/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,LIPID PANEL,Direct HDL-C 4th Generation,,1.91,,H,,,1.03 - 1.53,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,LIPID PANEL,Triglycerides (GPO),,0.67,,,,,0.5 - 2.81,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,LIPID PANEL,Cholesterol (High Performance),,4.26,,,,,3.31 - 6.1,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,LIPID PANEL,LDL Chol Friedewald 4th,,2.04,,,,,0 - 3.34,mmol/L +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,24-Mar-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,09:40,R,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,24-Mar-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:45,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,24-Mar-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,09:40,R,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,24-Mar-2026,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,07:30,,,,,, +CZ100132001,,,,,Male,Induction Week 0,,"Mar 24, 2026 9:40 AM",6227635142,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,12-Mar-2026,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,07:52,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,14-Mar-2026,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100132001,,,,,Male,Biopsy,,"Mar 12, 2026 12:00 AM",6227635161,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.7,,,,,0 - 6.2,umol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Alkaline Phosphatase,,95,,,,,40 - 129,U/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,ALT (SGPT),,25,,,,,5 - 48,U/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,GGT,,16,,,,,10 - 61,U/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,LDH,,149,,,,,53 - 234,U/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Urea Nitrogen,,7.1,,,,,1.4 - 8.6,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,89,,,,,40 - 110,umol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Serum Glucose,,6.6,,H,,,3.9 - 5.6,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Serum Uric Acid,,358,,,,,125 - 488,umol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Calcium (EDTA),,2.32,,,,,2.07 - 2.64,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Creatine Kinase,,100,,,,,39 - 308,U/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Serum Potassium,,3.8,,,,,3.5 - 5.2,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Serum Bicarbonate,,23.4,,,,,19.3 - 29.3,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CHEMISTRY PANEL,Magnesium,,0.75,,,,,0.66 - 1.07,mmol/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,103,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,127 - 181,g/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 96,fL +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.82,,,,,3.8 - 10.7,GI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.88,,,,,1.96 - 7.23,GI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.03,,,,,0.91 - 4.28,GI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.26,,,,,0.12 - 0.92,GI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.57,,,,,0 - 0.57,GI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,49.4,,,,,40.5 - 75,% +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,34.9,,,,,15.4 - 48.5,% +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.4,,,,,2.6 - 10.1,% +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,9.9,,H,,,0 - 6.8,% +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.4,,,,,0 - 2,% +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,222,,,,,140 - 400,GI/L +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100132001,,,,,Male,Screening,,"Feb 26, 2026 1:20 PM",6227635140,SUBJECT HEIGHT (CM),Height (cm),Y,163,,,,,cm, +CZ100132001,,,,,Male,Stool Pathogens,,"Feb 26, 2026 10:35 AM",6227635149,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100132001,,,,,Male,Stool Pathogens,,"Feb 26, 2026 10:35 AM",6227635149,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100132001,,,,,Male,Stool Pathogens,,"Feb 26, 2026 10:35 AM",6227635149,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100132001,,,,,Male,Stool Pathogens,,"Feb 26, 2026 10:35 AM",6227635149,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100132001,,,,,Male,Stool Pathogens,,"Feb 26, 2026 10:35 AM",6227635149,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100132001,,,,,Male,Stool Pathogens,,"Feb 26, 2026 10:35 AM",6227635149,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, diff --git a/Covance/Source/2026-06-18_095657 sponsor-study-36940-test-results-930539-standard.csv b/Covance/Source/2026-06-18_095657 sponsor-study-36940-test-results-930539-standard.csv new file mode 100644 index 0000000..49a3ab3 --- /dev/null +++ b/Covance/Source/2026-06-18_095657 sponsor-study-36940-test-results-930539-standard.csv @@ -0,0 +1,249 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100162002,,,,,Male,Biopsy,,"Jun 16, 2026 12:00 AM",6227635192,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100162002,,,,,Male,Biopsy,,"Jun 16, 2026 12:00 AM",6227635192,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100162002,,,,,Male,Biopsy,,"Jun 16, 2026 12:00 AM",6227635192,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100162002,,,,,Male,Biopsy,,"Jun 16, 2026 12:00 AM",6227635192,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,16-Jun-2026,,,,,, +CZ100162002,,,,,Male,Biopsy,,"Jun 16, 2026 12:00 AM",6227635192,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,09:00,,,,,, +CZ100162002,,,,,Male,Biopsy,,"Jun 16, 2026 12:00 AM",6227635192,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100162002,,,,,Male,Biopsy,,"Jun 16, 2026 12:00 AM",6227635192,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100162002,,,,,Male,Biopsy,,"Jun 16, 2026 12:00 AM",6227635192,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100162002,,,,,Male,Biopsy,,"Jun 16, 2026 12:00 AM",6227635192,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,,,,,,, +CZ100162002,,,,,Male,Biopsy,,"Jun 16, 2026 12:00 AM",6227635192,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,,,,,,, +CZ100162002,,,,,Male,Biopsy,,"Jun 16, 2026 12:00 AM",6227635192,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,,,,,,, +CZ100162002,,,,,Male,Biopsy,,"Jun 16, 2026 12:00 AM",6227635192,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,,,,,,, +CZ100162002,,,,,Male,Biopsy,,"Jun 16, 2026 12:00 AM",6227635192,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.8,,,,,0 - 6.2,umol/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Alkaline Phosphatase,,52,,,,,40 - 129,U/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,ALT (SGPT),,7,,,,,5 - 48,U/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,AST (SGOT),,11,,,,,8 - 40,U/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,GGT,,15,,,,,10 - 61,U/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,LDH,,150,,,,,53 - 234,U/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,103,,,,,40 - 110,umol/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Serum Glucose,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Serum Uric Acid,,274,,,,,125 - 488,umol/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Calcium (EDTA),,2.21,,,,,2.07 - 2.64,mmol/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Phosphorus,,1.21,,,,,0.71 - 1.65,mmol/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Total Protein,,58,R,L,,,61 - 84,g/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Albumin-BCG,,35,,,,,33 - 49,g/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Creatine Kinase,,<18,R,L,,Result verified by repeat analysis,39 - 308,U/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Serum Bicarbonate,,27.0,,,,,19.3 - 29.3,mmol/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,CHEMISTRY PANEL,Magnesium,,0.81,,,,,0.66 - 1.07,mmol/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,FECAL COLLECTION D/T,Stool Collection Date,Y,10-Jun-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,FECAL COLLECTION D/T,Stool Collection Time,Y,20:00,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,110,R,L,,,127 - 181,g/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,R,L,,,0.39 - 0.54, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,R,L,,,4.5 - 6.4,TI/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,28,,,,,26 - 34,pg +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 96,fL +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.58,,,,,3.8 - 10.7,GI/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.61,,,,,1.96 - 7.23,GI/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.22,,,,,0.91 - 4.28,GI/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.31,,,,,0.12 - 0.92,GI/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.38,,,,,0 - 0.57,GI/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,46.6,,,,,40.5 - 75,% +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,39.8,,,,,15.4 - 48.5,% +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.5,,,,,2.6 - 10.1,% +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,6.8,,,,,0 - 6.8,% +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.3,,,,,0 - 2,% +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,268,,,,,140 - 400,GI/L +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,PA1 EEA-2?,Approved to use EEA-2?,,,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,11-Jun-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:45,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,11-Jun-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:00,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,11-Jun-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:45,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,10-Jun-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,20:00,,,,,, +CZ100162001,,,,,Male,Induction Week 2,R,"Jun 11, 2026 8:45 AM",6227635177,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.8,,,,,0 - 6.2,umol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Alkaline Phosphatase,,50,,,,,40 - 129,U/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,ALT (SGPT),,8,,,,,5 - 48,U/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,AST (SGOT),,10,,,,,8 - 40,U/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,GGT,,15,,,,,10 - 61,U/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,LDH,,167,,,,,53 - 234,U/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Urea Nitrogen,,4.9,,,,,1.4 - 8.6,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,91,,,,,40 - 110,umol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Serum Glucose,,5.7,R,H,,,3.9 - 5.6,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Serum Uric Acid,,239,,,,,125 - 488,umol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Calcium (EDTA),,2.22,,,,,2.07 - 2.64,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Phosphorus,,0.91,,,,,0.71 - 1.65,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Total Protein,,60,R,L,,,61 - 84,g/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Albumin-BCG,,35,,,,,33 - 49,g/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Creatine Kinase,,<18,R,L,,Result verified by repeat analysis,39 - 308,U/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Serum Potassium,,3.8,,,,,3.5 - 5.2,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Serum Bicarbonate,,26.1,,,,,19.3 - 29.3,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CHEMISTRY PANEL,Magnesium,,0.88,,,,,0.66 - 1.07,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,90,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,FECAL COLLECTION D/T,Stool Collection Date,Y,28-May-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,FECAL COLLECTION D/T,Stool Collection Time,Y,06:00,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,118,R,L,,,127 - 181,g/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,R,L,,,0.39 - 0.54, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,R,L,,,4.5 - 6.4,TI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 96,fL +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,12.78,R,H,,,3.8 - 10.7,GI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,9.55,R,H,,,1.96 - 7.23,GI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.58,,,,,0.91 - 4.28,GI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.46,,,,,0.12 - 0.92,GI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,74.8,,,,,40.5 - 75,% +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,20.3,,,,,15.4 - 48.5,% +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,3.6,,,,,2.6 - 10.1,% +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,371,,,,,140 - 400,GI/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,LIPID PANEL,Direct HDL-C 4th Generation,,1.18,,,,,1.03 - 1.53,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,LIPID PANEL,Triglycerides (GPO),,1.61,,,,,0.62 - 3.69,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,LIPID PANEL,Cholesterol (High Performance),,4.55,,,,,4.19 - 7.24,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,LIPID PANEL,LDL Chol Friedewald 4th,,2.63,,,,,0 - 3.34,mmol/L +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,28-May-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,10:45,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,28-May-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,11:53,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,28-May-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,10:45,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,28-May-2026,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,06:00,,,,,, +CZ100162001,,,,,Male,Induction Week 0,,"May 28, 2026 10:45 AM",6227635174,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100162002,,,,,Male,Stool Pathogens,,"May 27, 2026 1:15 PM",6227635180,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100162002,,,,,Male,Stool Pathogens,,"May 27, 2026 1:15 PM",6227635180,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Alkaline Phosphatase,,105,,,,,40 - 129,U/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,5 - 48,U/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,LDH,,194,,,,,53 - 234,U/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Urea Nitrogen,,5.4,,,,,1.4 - 8.6,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,69,,,,,40 - 110,umol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Serum Glucose,,5.9,,H,,,3.9 - 5.6,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Serum Uric Acid,,242,,,,,125 - 488,umol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Phosphorus,,0.82,,,,,0.71 - 1.65,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Total Protein,,70,,,,,61 - 84,g/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Creatine Kinase,,67,,,,,39 - 308,U/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Serum Bicarbonate,,23.9,,,,,19.3 - 29.3,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CHEMISTRY PANEL,Magnesium,,0.89,,,,,0.66 - 1.07,mmol/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,117,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,127 - 181,g/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.5 - 6.4,TI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 96,fL +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.92,,,,,3.8 - 10.7,GI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.54,,,,,1.96 - 7.23,GI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.14,,,,,0.91 - 4.28,GI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.20,,,,,0.12 - 0.92,GI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.03,,,,,0 - 0.57,GI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,80.1,,H,,,40.5 - 75,% +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,16.5,,,,,15.4 - 48.5,% +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,2.8,,,,,2.6 - 10.1,% +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.4,,,,,0 - 6.8,% +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.2,,,,,0 - 2,% +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,363,,,,,140 - 400,GI/L +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100162002,,,,,Male,Screening,,"May 27, 2026 12:35 PM",6227635173,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,19-May-2026,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,09:40,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,12:00,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,21-May-2026,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100162001,,,,,Male,Biopsy,,"May 19, 2026 12:00 AM",6227635193,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100162001,,,,,Male,Stool Pathogens,,"May 6, 2026 9:30 AM",6228610564,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100162001,,,,,Male,Stool Pathogens,,"May 6, 2026 9:30 AM",6228610564,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100162001,,,,,Male,Stool Pathogens,,"Apr 24, 2026 8:45 AM",6227635182,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,,,,,,, +CZ100162001,,,,,Male,Stool Pathogens,,"Apr 24, 2026 8:45 AM",6227635182,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,,,,,,, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,40 - 129,U/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,ALT (SGPT),,11,,,,,5 - 48,U/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,GGT,,18,,,,,10 - 61,U/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,LDH,,186,,,,,53 - 234,U/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Urea Nitrogen,,6.8,,,,,1.4 - 8.6,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,96,,,,,40 - 110,umol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Serum Glucose,,5.9,,H,,,3.9 - 5.6,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Serum Uric Acid,,233,,,,,125 - 488,umol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Phosphorus,,0.76,,,,,0.71 - 1.65,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Creatine Kinase,,36,R,L,,,39 - 308,U/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Serum Bicarbonate,,26.8,,,,,19.3 - 29.3,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CHEMISTRY PANEL,Magnesium,,0.85,,,,,0.66 - 1.07,mmol/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,84,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,127 - 181,g/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 96,fL +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,13.56,,H,,,3.8 - 10.7,GI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,11.03,,H,,,1.96 - 7.23,GI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.38,,,,,0.91 - 4.28,GI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.65,,,,,0.12 - 0.92,GI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.36,,,,,0 - 0.57,GI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.14,,,,,0 - 0.2,GI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,81.3,,H,,,40.5 - 75,% +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,10.2,,L,,,15.4 - 48.5,% +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.8,,,,,2.6 - 10.1,% +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.7,,,,,0 - 6.8,% +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,233,,,,,140 - 400,GI/L +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100162001,,,,,Male,Screening,,"Apr 21, 2026 10:45 AM",6227635171,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, diff --git a/Covance/Source/2026-06-18_095702 sponsor-study-36940-test-results-930539-microbiology.csv b/Covance/Source/2026-06-18_095702 sponsor-study-36940-test-results-930539-microbiology.csv new file mode 100644 index 0000000..ea00d13 --- /dev/null +++ b/Covance/Source/2026-06-18_095702 sponsor-study-36940-test-results-930539-microbiology.csv @@ -0,0 +1,5 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100162001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Apr 24, 2026 8:45 AM",6227635182,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100162001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"May 6, 2026 9:30 AM",6228610564,STOOL CULTURE,,,,Test group cancelled: No specimen received,,,,,,,,,,, +CZ100162002 - null,,,,Male,SCRNSTOOL Stool Pathogens,"May 27, 2026 1:15 PM",6227635180,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance/Source/2026-06-18_095702 sponsor-study-36940-test-results-930557-microbiology.csv b/Covance/Source/2026-06-18_095702 sponsor-study-36940-test-results-930557-microbiology.csv new file mode 100644 index 0000000..7109a48 --- /dev/null +++ b/Covance/Source/2026-06-18_095702 sponsor-study-36940-test-results-930557-microbiology.csv @@ -0,0 +1,7 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100012001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Jan 28, 2026 6:00 AM",6227323211,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,R, +CZ100012001 - null,,,,Male,UNSCSTOOL Stool Pathogens,"Apr 22, 2026 7:00 AM",6228137359,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100012002 - null,,,,Female,SCRNSTOOL Stool Pathogens,"Mar 3, 2026 1:00 PM",6227323212,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100012003 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Apr 29, 2026 7:55 AM",6227323213,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100012004 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Jun 2, 2026 6:00 PM",6228137357,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance/Source/2026-06-18_095718 sponsor-study-36940-test-results-930557-standard.csv b/Covance/Source/2026-06-18_095718 sponsor-study-36940-test-results-930557-standard.csv new file mode 100644 index 0000000..2cdf1aa --- /dev/null +++ b/Covance/Source/2026-06-18_095718 sponsor-study-36940-test-results-930557-standard.csv @@ -0,0 +1,862 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +Removed,,,,,,Biopsy,,"Jun 17, 2026 12:00 AM",6227323222,ANATOMICAL SITE,Anatomical Site,Y,,,,,,, +Removed,,,,,,Biopsy,,"Jun 17, 2026 12:00 AM",6227323222,BIOPSY COLLECTION METHOD,Collection Method,Y,,,,,,, +Removed,,,,,,Biopsy,,"Jun 17, 2026 12:00 AM",6227323222,BIOPSY FIXATIVE USED,Fixative Used,,,,,,,, +Removed,,,,,,Biopsy,,"Jun 17, 2026 12:00 AM",6227323222,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,,,,,,, +Removed,,,,,,Biopsy,,"Jun 17, 2026 12:00 AM",6227323222,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,,,,,,, +Removed,,,,,,Biopsy,,"Jun 17, 2026 12:00 AM",6227323222,DIAGNOSIS,Diagnosis:,Y,,,,,,, +Removed,,,,,,Biopsy,,"Jun 17, 2026 12:00 AM",6227323222,INFLAMED AREA,Inflamed area?,,,,,,,, +Removed,,,,,,Biopsy,,"Jun 17, 2026 12:00 AM",6227323222,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,,,,,,, +Removed,,,,,,Biopsy,,"Jun 17, 2026 12:00 AM",6227323222,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,,,,,,, +Removed,,,,,,Biopsy,,"Jun 17, 2026 12:00 AM",6227323222,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,,,,,,, +Removed,,,,,,Biopsy,,"Jun 17, 2026 12:00 AM",6227323222,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,,,,,,, +Removed,,,,,,Biopsy,,"Jun 17, 2026 12:00 AM",6227323222,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,,,,,,, +Removed,,,,,,Biopsy,,"Jun 17, 2026 12:00 AM",6227323222,ULCERATED AREA,Is biopsy site ulcerated?,,,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.9,,,,,0 - 6.2,umol/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Alkaline Phosphatase,,99,,,,,40 - 129,U/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,5 - 48,U/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,GGT,,17,,,,,10 - 61,U/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,LDH,,153,,,,,53 - 234,U/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Urea Nitrogen,,5.0,,,,,1.4 - 8.6,mmol/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,87,,,,,40 - 119,umol/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Serum Glucose,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Serum Uric Acid,,323,,,,,149 - 494,umol/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Calcium (EDTA),,2.41,,,,,2.07 - 2.64,mmol/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Phosphorus,,0.92,,,,,0.71 - 1.65,mmol/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Creatine Kinase,,95,,,,,39 - 308,U/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Serum Bicarbonate,,20.8,,,,,19.3 - 29.3,mmol/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CHEMISTRY PANEL,Magnesium,,0.87,,,,,0.66 - 1.07,mmol/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,93,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,FECAL COLLECTION D/T,Stool Collection Date,Y,09-Jun-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,127 - 181,g/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.3,,,,,4.5 - 6.4,TI/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 96,fL +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.64,,,,,3.8 - 10.7,GI/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.80,,,,,1.96 - 7.23,GI/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.31,,,,,0.91 - 4.28,GI/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.36,,,,,0.12 - 0.92,GI/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,72.3,,,,,40.5 - 75,% +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,19.8,,,,,15.4 - 48.5,% +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,245,,,,,140 - 400,GI/L +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,10-Jun-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:30,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,10-Jun-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:40,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,10-Jun-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:30,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,09-Jun-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012003,,,,,Male,Induction Week 2,,"Jun 10, 2026 7:30 AM",6228462187,SUBJECT HEIGHT (CM),Height (cm),Y,175,,,,,cm, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Alkaline Phosphatase,,65,,,,,40 - 129,U/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,ALT (SGPT),,41,,,,,5 - 48,U/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,GGT,,23,,,,,10 - 61,U/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,LDH,,221,,,,,53 - 234,U/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Urea Nitrogen,,6.5,,,,,1.4 - 8.6,mmol/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,80,,,,,40 - 110,umol/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Serum Glucose,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Serum Uric Acid,,366,,,,,125 - 488,umol/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Calcium (EDTA),,2.45,,,,,2.07 - 2.64,mmol/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Phosphorus,,1.46,,,,,0.71 - 1.65,mmol/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Creatine Kinase,,187,,,,,39 - 308,U/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Serum Bicarbonate,,25.6,,,,,19.3 - 29.3,mmol/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,CHEMISTRY PANEL,Magnesium,,0.93,,,,,0.66 - 1.07,mmol/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,FECAL COLLECTION D/T,Stool Collection Date,Y,09-Jun-2026,,,,,, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,FECAL COLLECTION D/T,Stool Collection Time,Y,,,,,,, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,127 - 181,g/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 96,fL +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.62,,,,,3.8 - 10.7,GI/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.08,,,,,1.96 - 7.23,GI/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.88,,,,,0.91 - 4.28,GI/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.45,,,,,0.12 - 0.92,GI/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.16,,,,,0 - 0.57,GI/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.8,,,,,40.5 - 75,% +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,33.4,,,,,15.4 - 48.5,% +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.1,,,,,2.6 - 10.1,% +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.8,,,,,0 - 6.8,% +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,300,,,,,140 - 400,GI/L +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,PA1 EEA-2?,Approved to use EEA-2?,,,,,,,, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,SM03/PLASMA PK COLL D/T,Collection Date,Y,10-Jun-2026,,,,,, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,SM03/PLASMA PK COLL D/T,Collection Time,Y,07:10,,,,,, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,SM05/SERUM ADA COLL D/T,Collection Date,Y,10-Jun-2026,,,,,, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,SM05/SERUM ADA COLL D/T,Collection Time,Y,07:10,,,,,, +CZ100012001,,,,,Male,Maintenance Week 4,,"Jun 10, 2026 7:10 AM",6227933145,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100012004,,,,,Male,Stool Pathogens,,"Jun 2, 2026 6:00 PM",6228137357,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012004,,,,,Male,Stool Pathogens,,"Jun 2, 2026 6:00 PM",6228137357,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.0,,,,,0 - 6.2,umol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Alkaline Phosphatase,,90,,,,,40 - 129,U/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,ALT (SGPT),,27,,,,,5 - 48,U/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,AST (SGOT),,35,,,,,8 - 40,U/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,GGT,,63,R,H,,,10 - 61,U/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,LDH,,167,,,,,53 - 234,U/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Urea Nitrogen,,7.1,,,,,1.4 - 8.6,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,95,,,,,40 - 110,umol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Serum Glucose,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Serum Uric Acid,,342,,,,,125 - 488,umol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Calcium (EDTA),,2.56,,,,,2.07 - 2.64,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Phosphorus,,0.97,,,,,0.71 - 1.65,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Total Protein,,84,,,,,61 - 84,g/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Creatine Kinase,,217,,,,,39 - 308,U/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Serum Potassium,,5.2,,,,,3.5 - 5.2,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Serum Bicarbonate,,20.1,,,,,19.3 - 29.3,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CHEMISTRY PANEL,Magnesium,,0.85,,,,,0.66 - 1.07,mmol/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,86,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,127 - 181,g/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.49,,,,,0.39 - 0.54, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.4,,,,,4.5 - 6.4,TI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,28,,,,,26 - 34,pg +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 96,fL +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,10.70,,,,,3.8 - 10.7,GI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.42,,,,,1.96 - 7.23,GI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.25,,,,,0.91 - 4.28,GI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.75,,,,,0.12 - 0.92,GI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.19,,,,,0 - 0.57,GI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,60.0,,,,,40.5 - 75,% +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.4,,,,,15.4 - 48.5,% +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.0,,,,,2.6 - 10.1,% +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.7,,,,,0 - 6.8,% +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,483,R,H,,,140 - 400,GI/L +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100012004,,,,,Male,Screening,,"May 28, 2026 7:30 AM",6228114608,SUBJECT HEIGHT (CM),Height (cm),Y,178,,,,,cm, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.0,,,,,0 - 6.2,umol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Alkaline Phosphatase,,104,,,,,40 - 129,U/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,5 - 48,U/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,GGT,,16,,,,,10 - 61,U/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,LDH,,165,,,,,53 - 234,U/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Urea Nitrogen,,6.4,,,,,1.4 - 8.6,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,91,,,,,40 - 119,umol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Serum Glucose,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Serum Uric Acid,,324,,,,,149 - 494,umol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Phosphorus,,0.82,,,,,0.71 - 1.65,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Creatine Kinase,,82,,,,,39 - 308,U/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Serum Bicarbonate,,20.6,,,,,19.3 - 29.3,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CHEMISTRY PANEL,Magnesium,,0.84,,,,,0.66 - 1.07,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,87,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,FECAL COLLECTION D/T,Stool Collection Date,Y,26-May-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,159,,,,,127 - 181,g/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.50,,,,,0.39 - 0.54, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.4,,,,,4.5 - 6.4,TI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 96,fL +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.01,,,,,3.8 - 10.7,GI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,7.04,,,,,1.96 - 7.23,GI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.38,,,,,0.91 - 4.28,GI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.44,,,,,0.12 - 0.92,GI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,78.1,,H,,,40.5 - 75,% +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,15.3,,L,,,15.4 - 48.5,% +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.9,,,,,2.6 - 10.1,% +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.2,,,,,0 - 6.8,% +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,265,,,,,140 - 400,GI/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,LIPID PANEL,Direct HDL-C 4th Generation,,1.34,,,,,1.03 - 1.53,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,LIPID PANEL,Triglycerides (GPO),,0.65,,,,,0.65 - 3.61,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,LIPID PANEL,Cholesterol (High Performance),,4.32,,L,,,4.4 - 7.53,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,LIPID PANEL,LDL Chol Friedewald 4th,,2.68,,,,,0 - 3.34,mmol/L +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,27-May-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:25,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,27-May-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:30,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,27-May-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:25,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,26-May-2026,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012003,,,,,Male,Induction Week 0,,"May 27, 2026 7:25 AM",6228036553,SUBJECT HEIGHT (CM),Height (cm),Y,175,,,,,cm, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Alkaline Phosphatase,,62,,,,,40 - 129,U/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,ALT (SGPT),,46,,,,,5 - 48,U/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,GGT,,30,,,,,10 - 61,U/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,LDH,,238,,H,,,53 - 234,U/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Urea Nitrogen,,4.4,,,,,1.4 - 8.6,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,84,,,,,40 - 110,umol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Serum Glucose,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Serum Uric Acid,,328,,,,,125 - 488,umol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Phosphorus,,1.26,,,,,0.71 - 1.65,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Creatine Kinase,,96,,,,,39 - 308,U/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Serum Bicarbonate,,25.1,,,,,19.3 - 29.3,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CHEMISTRY PANEL,Magnesium,,0.87,,,,,0.66 - 1.07,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,99,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,FECAL COLLECTION D/T,Stool Collection Date,Y,12-May-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,142,,,,,127 - 181,g/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.67,,,,,3.8 - 10.7,GI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.93,,,,,1.96 - 7.23,GI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.10,,,,,0.91 - 4.28,GI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.49,,,,,0.12 - 0.92,GI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,68.4,,,,,40.5 - 75,% +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,24.3,,,,,15.4 - 48.5,% +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.7,,,,,2.6 - 10.1,% +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.3,,,,,0 - 6.8,% +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,343,,,,,140 - 400,GI/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,LIPID PANEL,Direct HDL-C 4th Generation,,2.02,,H,,,1.03 - 1.53,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,LIPID PANEL,Triglycerides (GPO),,1.21,,,,,0.62 - 3.69,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,LIPID PANEL,Cholesterol (High Performance),,5.32,,,,,4.19 - 7.24,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,LIPID PANEL,LDL Chol Friedewald 4th,,2.75,,,,,0 - 3.34,mmol/L +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,13-May-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:05,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,13-May-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,09:30,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,13-May-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:05,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,12-May-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,12-May-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 12,,"May 13, 2026 8:05 AM",6227933143,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,ANATOMICAL SITE,Anatomical Site,Y,30,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,13-May-2026,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,09:00,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,15-May-2026,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100012003,,,,,Male,Biopsy,R,"May 13, 2026 12:00 AM",6228252073,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Alkaline Phosphatase,,99,,,,,35 - 104,U/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,AST (SGOT),,29,,,,,8 - 40,U/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,GGT,,23,,,,,5 - 50,U/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,LDH,,181,,,,,53 - 234,U/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Urea Nitrogen,,5.3,,,,,1.4 - 10.4,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,54,,,,,31 - 110,umol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Serum Glucose,,6.0,,H,,,3.9 - 5.6,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Serum Uric Acid,,293,,,,,149 - 446,umol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Calcium (EDTA),,2.53,,,,,2.07 - 2.64,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Phosphorus,,1.19,,,,,0.71 - 1.65,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Total Protein,,79,,,,,60 - 80,g/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 46,g/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Creatine Kinase,,143,,,,,26 - 192,U/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Serum Sodium,,141,,,,,135 - 145,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Serum Bicarbonate,,22.3,,,,,19.3 - 29.3,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CHEMISTRY PANEL,Magnesium,,0.91,,,,,0.66 - 0.98,mmol/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,91,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,FECAL COLLECTION D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,145,,,,,115 - 158,g/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.34 - 0.48, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,3.9 - 5.5,TI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,80 - 100,fL +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.54,,,,,3.8 - 10.7,GI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.11,,,,,1.96 - 7.23,GI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.15,,,,,0.8 - 3,GI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.23,,,,,0.12 - 0.92,GI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.02,,,,,0 - 0.57,GI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,46.5,,,,,40.5 - 75,% +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,47.4,,,,,15.4 - 48.5,% +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.1,,,,,2.6 - 10.1,% +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.5,,,,,0 - 6.8,% +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,117,R,L,,,130 - 394,GI/L +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,06-May-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:05,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,06-May-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,09:05,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,06-May-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:05,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012002,,,,,Female,Induction Week 4,,"May 6, 2026 8:05 AM",6227933142,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,06-May-2026,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,07:20,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,08-May-2026,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100012001,,,,,Male,Biopsy,,"May 6, 2026 12:00 AM",6228252072,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100012003,,,,,Male,Stool Pathogens,,"Apr 29, 2026 7:55 AM",6227323213,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012003,,,,,Male,Stool Pathogens,,"Apr 29, 2026 7:55 AM",6227323213,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Alkaline Phosphatase,,115,,,,,40 - 129,U/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,ALT (SGPT),,22,,,,,5 - 48,U/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,GGT,,15,,,,,10 - 61,U/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,LDH,,151,,,,,53 - 234,U/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Urea Nitrogen,,5.4,,,,,1.4 - 8.6,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,88,,,,,40 - 119,umol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Serum Glucose,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Serum Uric Acid,,306,,,,,149 - 494,umol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Phosphorus,,0.90,,,,,0.71 - 1.65,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Creatine Kinase,,100,,,,,39 - 308,U/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Serum Bicarbonate,,21.5,,,,,19.3 - 29.3,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CHEMISTRY PANEL,Magnesium,,0.90,,,,,0.66 - 1.07,mmol/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,91,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,161,,,,,127 - 181,g/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.49,,,,,0.39 - 0.54, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.5,,,,,4.5 - 6.4,TI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 96,fL +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.61,,,,,3.8 - 10.7,GI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.63,,,,,1.96 - 7.23,GI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.42,,,,,0.91 - 4.28,GI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.38,,,,,0.12 - 0.92,GI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,74.0,,,,,40.5 - 75,% +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,18.7,,,,,15.4 - 48.5,% +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.0,,,,,2.6 - 10.1,% +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.7,,,,,0 - 6.8,% +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,242,,,,,140 - 400,GI/L +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100012003,,,,,Male,Screening,,"Apr 29, 2026 7:55 AM",6228114610,SUBJECT HEIGHT (CM),Height (cm),Y,175,,,,,cm, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Total Bilirubin,,14,,,,,3 - 21,umol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.5,,,,,0 - 6.2,umol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Alkaline Phosphatase,,102,,,,,35 - 104,U/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,GGT,,23,,,,,5 - 50,U/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,LDH,,154,,,,,53 - 234,U/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 10.4,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,53,,,,,31 - 110,umol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Serum Glucose,,6.3,,H,,,3.9 - 5.6,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Serum Uric Acid,,252,,,,,149 - 446,umol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Calcium (EDTA),,2.50,,,,,2.07 - 2.64,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Phosphorus,,1.16,,,,,0.71 - 1.65,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Total Protein,,76,,,,,60 - 80,g/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 46,g/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Creatine Kinase,,83,,,,,26 - 192,U/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Serum Sodium,,140,,,,,135 - 145,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Serum Bicarbonate,,23.8,,,,,19.3 - 29.3,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CHEMISTRY PANEL,Magnesium,,0.94,,,,,0.66 - 0.98,mmol/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,91,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,FECAL COLLECTION D/T,Stool Collection Date,Y,23-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,FECAL COLLECTION D/T,Stool Collection Time,Y,07:40,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,144,,,,Result verified by repeat analysis,115 - 158,g/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,Result verified by repeat analysis,3.9 - 5.5,TI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,Result verified by repeat analysis,26 - 34,pg +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,80 - 100,fL +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,3.47,,L,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.78,,L,,Result verified by repeat analysis,1.96 - 7.23,GI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.46,,,,,0.8 - 3,GI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.16,,,,Result verified by repeat analysis,0.12 - 0.92,GI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.04,,,,Result verified by repeat analysis,0 - 0.57,GI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,51.4,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,42.2,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.5,,,,Result verified by repeat analysis,2.6 - 10.1,% +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,Result verified by repeat analysis,0 - 6.8,% +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,Result verified by repeat analysis,0 - 2,% +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,118,,L,,Result verified by repeat analysis,130 - 394,GI/L +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,23-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:40,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,23-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:40,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,23-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,07:40,,,,,, +CZ100012002,,,,,Female,Induction Week 2,,"Apr 23, 2026 7:40 AM",6227323207,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100012001,,,,,Male,Stool Pathogens,,"Apr 22, 2026 7:00 AM",6228137359,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012001,,,,,Male,Stool Pathogens,,"Apr 22, 2026 7:00 AM",6228137359,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012001,,,,,Male,Stool Pathogens,,"Apr 22, 2026 7:00 AM",6228137359,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100012001,,,,,Male,Stool Pathogens,,"Apr 22, 2026 7:00 AM",6228137359,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100012001,,,,,Male,Stool Pathogens,,"Apr 22, 2026 7:00 AM",6228137359,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100012001,,,,,Male,Stool Pathogens,,"Apr 22, 2026 7:00 AM",6228137359,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.7,,,,,0 - 6.2,umol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Alkaline Phosphatase,,96,,,,,35 - 104,U/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,AST (SGOT),,28,,,,,8 - 40,U/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,GGT,,19,,,,,5 - 50,U/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Urea Nitrogen,,5.3,,,,,1.4 - 10.4,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,56,,,,,31 - 110,umol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Serum Glucose,,6.2,R,H,,,3.9 - 5.6,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Serum Uric Acid,,284,,,,,149 - 446,umol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Calcium (EDTA),,2.50,,,,,2.07 - 2.64,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Phosphorus,,1.20,,,,,0.71 - 1.65,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Total Protein,,78,,,,,60 - 80,g/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 46,g/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Creatine Kinase,,113,,,,,26 - 192,U/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Serum Sodium,,140,,,,,135 - 145,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Serum Bicarbonate,,24.0,,,,,19.3 - 29.3,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CHEMISTRY PANEL,Magnesium,,0.97,,,,,0.66 - 0.98,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,90,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,FECAL COLLECTION D/T,Stool Collection Date,Y,07-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,143,,,,,115 - 158,g/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.34 - 0.48, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,3.9 - 5.5,TI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,28,,,,,26 - 34,pg +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,80 - 100,fL +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,3.59,R,L,,,3.8 - 10.7,GI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.64,R,L,,,1.96 - 7.23,GI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.72,,,,,0.8 - 3,GI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.19,,,,,0.12 - 0.92,GI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.03,,,,,0 - 0.57,GI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,45.6,,,,,40.5 - 75,% +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,47.9,,,,,15.4 - 48.5,% +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.2,,,,,2.6 - 10.1,% +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.7,,,,,0 - 6.8,% +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,126,R,L,,,130 - 394,GI/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,LIPID PANEL,Direct HDL-C 4th Generation,,2.07,R,H,,,1.03 - 1.53,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,LIPID PANEL,Triglycerides (GPO),,1.04,,,,,0.63 - 2.71,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,LIPID PANEL,Cholesterol (High Performance),,4.56,R,L,,,5.35 - 9.1,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,LIPID PANEL,LDL Chol Friedewald 4th,,2.01,,,,,0 - 3.34,mmol/L +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,08-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:10,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,08-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:15,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,08-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:10,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,07-Apr-2026,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012002,,,,,Female,Induction Week 0,,"Apr 8, 2026 7:10 AM",6228036554,SUBJECT HEIGHT (CM),Height (cm),Y,170,,,,,cm, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,AST>/=3XULN,AST >/= 3 X ULN,,Required testing unavailable,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Required testing unavailable,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Alkaline Phosphatase,,66,,,,,40 - 129,U/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,ALT (SGPT),,50,,H,,,5 - 48,U/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,AST (SGOT),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,GGT,,25,,,,,10 - 61,U/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Urea Nitrogen,,6.7,,,,,1.4 - 8.6,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,89,,,,,40 - 110,umol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Serum Glucose,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Serum Uric Acid,,302,,,,,125 - 488,umol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Calcium (EDTA),,2.50,,,,,2.07 - 2.64,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Phosphorus,,1.95,R,H,,,0.71 - 1.65,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Creatine Kinase,,66,,,,,39 - 308,U/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Serum Bicarbonate,,24.8,,,,,19.3 - 29.3,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CHEMISTRY PANEL,Magnesium,,0.95,,,,,0.66 - 1.07,mmol/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,92,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,FECAL COLLECTION D/T,Stool Collection Date,Y,17-Mar-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,127 - 181,g/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,4.5 - 6.4,TI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 96,fL +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.77,,,,,3.8 - 10.7,GI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.03,,,,,1.96 - 7.23,GI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.25,,,,,0.91 - 4.28,GI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.07,,,,,0 - 0.57,GI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,74.3,,,,,40.5 - 75,% +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,18.6,,,,,15.4 - 48.5,% +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,327,,,,,140 - 400,GI/L +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,18-Mar-2026,R,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,18-Mar-2026,R,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,18-Mar-2026,R,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,17-Mar-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 4,,"Mar 18, 2026 7:05 AM",6227323210,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,ANATOMICAL SITE,Anatomical Site,Y,25 DISTANCE IN CM FROM ANAL VERGE,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,18-Mar-2026,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,09:30,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,20-Mar-2026,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100012002,,,,,Female,Biopsy,,"Mar 18, 2026 12:00 AM",6227323224,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,ALP<2XULN,ALP<2XULN,,Required testing unavailable,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,ALT>/=3XULN,ALT >/= 3 X ULN,,Required testing unavailable,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Required testing unavailable,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,AST>/=3XULN,AST >/= 3 X ULN,,Required testing unavailable,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Required testing unavailable,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Total Bilirubin,,18,,,,,3 - 21,umol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Alkaline Phosphatase,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,ALT (SGPT),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,AST (SGOT),,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,GGT,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,80,,,,,40 - 110,umol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Serum Glucose,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Serum Uric Acid,,276,,,,,125 - 488,umol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Calcium (EDTA),,2.24,,,,,2.07 - 2.64,mmol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Phosphorus,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Creatine Kinase,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Serum Potassium,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Serum Bicarbonate,,20.3,,,,,19.3 - 29.3,mmol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CHEMISTRY PANEL,Magnesium,,0.88,,,,,0.66 - 1.07,mmol/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,105,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,FECAL COLLECTION D/T,Stool Collection Date,Y,03-Mar-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,R,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,155,,,,,127 - 181,g/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.48,,,,,0.39 - 0.54, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4.5 - 6.4,TI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,79 - 96,fL +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.57,,,,,3.8 - 10.7,GI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.08,,,,,1.96 - 7.23,GI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.16,,,,,0.91 - 4.28,GI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.26,,,,,0.12 - 0.92,GI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.05,,,,,0 - 0.57,GI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,73.3,,,,,40.5 - 75,% +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,20.7,,,,,15.4 - 48.5,% +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.7,,,,,2.6 - 10.1,% +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,343,,,,,140 - 400,GI/L +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,04-Mar-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:00,R,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,04-Mar-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:00,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,04-Mar-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:00,R,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,03-Mar-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,18:00,R,,,,, +CZ100012001,,,,,Male,Induction Week 2,,"Mar 4, 2026 7:00 AM",6227323208,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100012002,,,,,Female,Stool Pathogens,,"Mar 3, 2026 1:00 PM",6227323212,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012002,,,,,Female,Stool Pathogens,,"Mar 3, 2026 1:00 PM",6227323212,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012002,,,,,Female,Stool Pathogens,,"Mar 3, 2026 1:00 PM",6227323212,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100012002,,,,,Female,Stool Pathogens,,"Mar 3, 2026 1:00 PM",6227323212,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100012002,,,,,Female,Stool Pathogens,,"Mar 3, 2026 1:00 PM",6227323212,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100012002,,,,,Female,Stool Pathogens,,"Mar 3, 2026 1:00 PM",6227323212,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Alkaline Phosphatase,,100,,,,,35 - 104,U/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,GGT,,27,,,,,5 - 50,U/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,LDH,,120,,,,,53 - 234,U/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Urea Nitrogen,,4.9,,,,,1.4 - 10.4,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,49,,,,,31 - 110,umol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Serum Glucose,,7.0,,H,,,3.9 - 5.6,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Serum Uric Acid,,233,,,,,149 - 446,umol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Total Protein,,75,,,,,60 - 80,g/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 46,g/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Creatine Kinase,,101,,,,,26 - 192,U/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Serum Sodium,,140,,,,,135 - 145,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Serum Potassium,,3.9,,,,,3.5 - 5.2,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Serum Bicarbonate,,22.1,,,,,19.3 - 29.3,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CHEMISTRY PANEL,Magnesium,,0.89,,,,,0.66 - 0.98,mmol/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,93,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,145,,,,,115 - 158,g/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,3.9 - 5.5,TI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,85,,,,,80 - 100,fL +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,3.95,,,,,3.8 - 10.7,GI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.86,,L,,,1.96 - 7.23,GI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.81,,,,,0.8 - 3,GI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.25,,,,,0.12 - 0.92,GI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.02,,,,,0 - 0.57,GI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,47.1,,,,,40.5 - 75,% +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,45.7,,,,,15.4 - 48.5,% +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.3,,,,,2.6 - 10.1,% +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.4,,,,,0 - 6.8,% +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,150,,,,,130 - 394,GI/L +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100012002,,,,,Female,Screening,,"Mar 2, 2026 7:00 AM",6227323204,SUBJECT HEIGHT (CM),Height (cm),Y,170,,,,,cm, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Total Bilirubin,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Alkaline Phosphatase,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,ALT (SGPT),,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,AST (SGOT),,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,GGT,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Urea Nitrogen,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Serum Glucose,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Serum Uric Acid,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Calcium (EDTA),,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Phosphorus,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Total Protein,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Albumin-BCG,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Creatine Kinase,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Serum Sodium,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Serum Potassium,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Serum Bicarbonate,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Serum Chloride,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CHEMISTRY PANEL,Magnesium,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,CKD-EPI 2021,CKD-EPI 2021 Without Race,,Required testing unavailable,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,FECAL COLLECTION D/T,Stool Collection Date,Y,18-Feb-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,127 - 181,g/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.5 - 6.4,TI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 96,fL +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.88,,,,,3.8 - 10.7,GI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.46,,,,,1.96 - 7.23,GI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.78,,,,,0.91 - 4.28,GI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.47,,,,,0.12 - 0.92,GI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.4,,,,,40.5 - 75,% +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,31.2,,,,,15.4 - 48.5,% +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.3,,,,,2.6 - 10.1,% +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,330,,,,,140 - 400,GI/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,LIPID PANEL,Direct HDL-C 4th Generation,,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,LIPID PANEL,Triglycerides (GPO),,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,LIPID PANEL,Cholesterol (High Performance),,,,,Test cancelled: Quantity not sufficient,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,LIPID PANEL,LDL Chol Friedewald 4th,,Required testing unavailable,,,,,0 - 3.34,mmol/L +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,19-Feb-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,07:20,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,19-Feb-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,08:50,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,19-Feb-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,07:20,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,18-Feb-2026,,,,,, +CZ100012001,,,,,Male,Induction Week 0,,"Feb 19, 2026 7:20 AM",6227323205,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,ANATOMICAL SITE,Anatomical Site,Y,30,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,05-Feb-2026,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,08:30,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,07-Feb-2026,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100012001,,,,,Male,Biopsy,R,"Feb 5, 2026 12:00 AM",6227323223,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100012001,,,,,Male,Stool Pathogens,R,"Jan 28, 2026 6:00 AM",6227323211,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012001,,,,,Male,Stool Pathogens,R,"Jan 28, 2026 6:00 AM",6227323211,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100012001,,,,,Male,Stool Pathogens,R,"Jan 28, 2026 6:00 AM",6227323211,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100012001,,,,,Male,Stool Pathogens,R,"Jan 28, 2026 6:00 AM",6227323211,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100012001,,,,,Male,Stool Pathogens,R,"Jan 28, 2026 6:00 AM",6227323211,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100012001,,,,,Male,Stool Pathogens,R,"Jan 28, 2026 6:00 AM",6227323211,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.4,,,,,0 - 6.2,umol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Alkaline Phosphatase,,61,,,,,40 - 129,U/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,5 - 48,U/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,GGT,,24,,,,,10 - 61,U/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,LDH,,146,,,,,53 - 234,U/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,79,,,,,40 - 110,umol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Serum Glucose,,5.5,,,,,3.9 - 5.6,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Serum Uric Acid,,338,,,,,125 - 488,umol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Phosphorus,,0.48,,LT,,Result verified by repeat analysis,0.71 - 1.65,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Creatine Kinase,,60,,,,,39 - 308,U/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Serum Bicarbonate,,25.1,,,,,19.3 - 29.3,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CHEMISTRY PANEL,Magnesium,,0.92,,,,,0.66 - 1.07,mmol/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,CKD-EPI 2021,CKD-EPI 2021 Without Race,,106,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,151,,,,,127 - 181,g/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,30,,,,,26 - 34,pg +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 96,fL +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.92,,,,,3.8 - 10.7,GI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.40,,,,,1.96 - 7.23,GI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.00,,,,,0.91 - 4.28,GI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.27,,,,,0.12 - 0.92,GI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,69.1,,,,,40.5 - 75,% +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,20.2,,,,,15.4 - 48.5,% +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.1,,,,,0 - 6.8,% +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.0,,,,,0 - 2,% +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,309,,,,,140 - 400,GI/L +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEPATITIS B SURFACE AB NON-US,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100012001,,,,,Male,Screening,,"Jan 22, 2026 8:00 AM",6227323203,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, diff --git a/Covance/Source/2026-06-18_095723 sponsor-study-36940-test-results-930553-standard.csv b/Covance/Source/2026-06-18_095723 sponsor-study-36940-test-results-930553-standard.csv new file mode 100644 index 0000000..fcfd7a8 --- /dev/null +++ b/Covance/Source/2026-06-18_095723 sponsor-study-36940-test-results-930553-standard.csv @@ -0,0 +1,421 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100092004,,,,,Female,Stool Pathogens,,"Jun 16, 2026 12:30 PM",6227765958,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,,,,,,, +CZ100092004,,,,,Female,Stool Pathogens,,"Jun 16, 2026 12:30 PM",6227765958,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,,,,,,, +CZ100092004,,,,,Female,Stool Pathogens,,"Jun 16, 2026 12:30 PM",6227765958,OVA AND PARASITES 1,Concentrate Exam,,,,,,,, +CZ100092004,,,,,Female,Stool Pathogens,,"Jun 16, 2026 12:30 PM",6227765958,OVA AND PARASITES 1,Smear for Microsporidia,,,,,,,, +CZ100092004,,,,,Female,Stool Pathogens,,"Jun 16, 2026 12:30 PM",6227765958,OVA AND PARASITES 1,Modified acid-fast stain,,,,,,,, +CZ100092004,,,,,Female,Stool Pathogens,,"Jun 16, 2026 12:30 PM",6227765958,OVA AND PARASITES 2,Trichrome Smear,,,,,,,, +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Alkaline Phosphatase,,55,,,,,35 - 104,U/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,ALT (SGPT),,12,,,,,4 - 43,U/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,GGT,,8,,,,,4 - 49,U/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,LDH,,171,,,,,53 - 234,U/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Serum Glucose,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Serum Uric Acid,,264,,,,,125 - 428,umol/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Calcium (EDTA),,2.47,,,,,2.07 - 2.64,mmol/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Phosphorus,,1.29,,,,,0.71 - 1.65,mmol/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Creatine Kinase,,99,,,,,26 - 192,U/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Serum Bicarbonate,,23.7,,,,,19.3 - 29.3,mmol/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,CHEMISTRY PANEL,Magnesium,,0.91,,,,,0.66 - 1.07,mmol/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,,,,,,, +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,146,,,,,116 - 164,g/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.17,,,,,3.8 - 10.7,GI/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.54,,,,,1.96 - 7.23,GI/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.95,,,,,0.91 - 4.28,GI/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.46,,,,,0.12 - 0.92,GI/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.4,,,,,40.5 - 75,% +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,31.7,,,,,15.4 - 48.5,% +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.5,,,,,2.6 - 10.1,% +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.8,,,,,0 - 6.8,% +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,244,,,,,140 - 400,GI/L +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,PA1 EEA-2?,Approved to use EEA-2?,,,,,,,, +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,,,,,,, +CZ100092004,,,,,Female,Screening,,"Jun 16, 2026 11:50 AM",6227765943,SUBJECT HEIGHT (CM),Height (cm),Y,,,,,,, +CZ100092003,,,,,Male,Stool Pathogens,,"Jun 11, 2026 11:30 AM",6227323339,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100092003,,,,,Male,Stool Pathogens,,"Jun 11, 2026 11:30 AM",6227323339,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100092003,,,,,Male,Stool Pathogens,,"Jun 11, 2026 11:30 AM",6227323339,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100092003,,,,,Male,Stool Pathogens,,"Jun 11, 2026 11:30 AM",6227323339,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100092003,,,,,Male,Stool Pathogens,,"Jun 11, 2026 11:30 AM",6227323339,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100092003,,,,,Male,Stool Pathogens,,"Jun 11, 2026 11:30 AM",6227323339,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.1,,,,,0 - 6.2,umol/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Alkaline Phosphatase,,80,,,,,40 - 129,U/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,ALT (SGPT),,30,,,,,5 - 48,U/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,AST (SGOT),,27,,,,,8 - 40,U/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,GGT,,26,,,,,10 - 61,U/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,LDH,,167,,,,,53 - 234,U/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,93,,,,,40 - 110,umol/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Serum Glucose,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Serum Uric Acid,,409,,,,,125 - 488,umol/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Calcium (EDTA),,2.49,,,,,2.07 - 2.64,mmol/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Phosphorus,,0.86,,,,,0.71 - 1.65,mmol/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Total Protein,,85,,H,,,61 - 84,g/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Creatine Kinase,,165,,,,,39 - 308,U/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Serum Sodium,,136,,,,,132 - 147,mmol/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Serum Bicarbonate,,21.6,,,,,19.3 - 29.3,mmol/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CHEMISTRY PANEL,Magnesium,,0.78,,,,,0.66 - 1.07,mmol/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,91,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,155,,,,,127 - 181,g/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.3,,,,,4.5 - 6.4,TI/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,29,,,,,26 - 34,pg +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,84,,,,,79 - 96,fL +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.80,,,,,3.8 - 10.7,GI/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.65,,,,,1.96 - 7.23,GI/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.02,,,,,0.91 - 4.28,GI/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.71,,,,,0.12 - 0.92,GI/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.31,,,,,0 - 0.57,GI/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,72.5,,,,,40.5 - 75,% +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,13.2,,L,,,15.4 - 48.5,% +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,9.1,,,,,2.6 - 10.1,% +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.0,,,,,0 - 6.8,% +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.3,,,,,0 - 2,% +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,296,,,,,140 - 400,GI/L +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,PA1 EEA-2?,Approved to use EEA-2?,,No,,,,,, +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100092003,,,,,Male,Screening,,"Jun 11, 2026 10:50 AM",6227323331,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.3,,,,,0 - 6.2,umol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Alkaline Phosphatase,,53,,,,,35 - 104,U/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,4 - 43,U/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,GGT,,16,,,,,4 - 49,U/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,LDH,,150,,,,,53 - 234,U/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,67,,,,,31 - 101,umol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Serum Glucose,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Serum Uric Acid,,184,,,,,149 - 446,umol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Calcium (EDTA),,2.55,,,,,2.07 - 2.64,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Phosphorus,,1.17,,,,,0.71 - 1.65,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Creatine Kinase,,98,,,,,26 - 192,U/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Serum Bicarbonate,,23.5,,,,,19.3 - 29.3,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CHEMISTRY PANEL,Magnesium,,0.84,,,,,0.66 - 1.07,mmol/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,95,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,FECAL COLLECTION D/T,Stool Collection Date,Y,04-Jun-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,FECAL COLLECTION D/T,Stool Collection Time,Y,06:30,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,138,,,,,116 - 164,g/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 98,fL +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.37,,,,,3.8 - 10.7,GI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.46,,,,,1.96 - 7.23,GI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.53,,,,,0.91 - 4.28,GI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.25,,,,,0.12 - 0.92,GI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,70.0,,,,,40.5 - 75,% +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,24.1,,,,,15.4 - 48.5,% +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.0,,,,,2.6 - 10.1,% +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,214,,,,,140 - 400,GI/L +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,04-Jun-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,09:50,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,04-Jun-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,11:10,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,04-Jun-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,09:50,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,04-Jun-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,06:30,,,,,, +CZ100092001,,,,,Female,Induction Week 4,,"Jun 4, 2026 9:50 AM",6227323337,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Total Bilirubin,,17,,,,,3 - 21,umol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,5.0,,,,,0 - 6.2,umol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,35 - 104,U/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,GGT,,15,,,,,4 - 49,U/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,LDH,,154,,,,,53 - 234,U/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Urea Nitrogen,,3.4,,,,,1.4 - 8.6,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,73,,,,,31 - 101,umol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Serum Glucose,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Serum Uric Acid,,196,,,,,149 - 446,umol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Calcium (EDTA),,2.47,,,,,2.07 - 2.64,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Phosphorus,,1.10,,,,,0.71 - 1.65,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Creatine Kinase,,100,,,,,26 - 192,U/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Serum Sodium,,136,,,,,132 - 147,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Serum Bicarbonate,,22.8,,,,,19.3 - 29.3,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CHEMISTRY PANEL,Magnesium,,0.81,,,,,0.66 - 1.07,mmol/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,86,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,FECAL COLLECTION D/T,Stool Collection Date,Y,19-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,FECAL COLLECTION D/T,Stool Collection Time,Y,06:20,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,116 - 164,g/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,32,,,,,26 - 34,pg +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.57,,,,,3.8 - 10.7,GI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.33,,,,,1.96 - 7.23,GI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.77,,,,,0.91 - 4.28,GI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,65.9,,,,,40.5 - 75,% +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.9,,,,,15.4 - 48.5,% +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.4,,,,,2.6 - 10.1,% +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.8,,,,,0 - 6.8,% +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,258,,,,,140 - 400,GI/L +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,19-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,10:50,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,19-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,11:55,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,19-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,10:50,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,19-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,06:20,,,,,, +CZ100092001,,,,,Female,Induction Week 2,,"May 19, 2026 10:50 AM",6227323335,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.5,,,,,0 - 6.2,umol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Alkaline Phosphatase,,55,,,,,35 - 104,U/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,4 - 43,U/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,GGT,,13,,,,,4 - 49,U/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,LDH,,152,,,,,53 - 234,U/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Urea Nitrogen,,5.1,,,,,1.4 - 8.6,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,62,,,,,31 - 101,umol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Serum Glucose,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Serum Uric Acid,,178,,,,,149 - 446,umol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Calcium (EDTA),,2.44,,,,,2.07 - 2.64,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Creatine Kinase,,87,,,,,26 - 192,U/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Serum Bicarbonate,,21.5,,,,,19.3 - 29.3,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CHEMISTRY PANEL,Magnesium,,0.94,,,,,0.66 - 1.07,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,105,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,FECAL COLLECTION D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,FECAL COLLECTION D/T,Stool Collection Time,Y,06:30,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,116 - 164,g/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 98,fL +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.60,,,,,3.8 - 10.7,GI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.94,,,,,1.96 - 7.23,GI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.22,,,,,0.91 - 4.28,GI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.32,,,,,0.12 - 0.92,GI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.9,,,,,40.5 - 75,% +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.5,,,,,15.4 - 48.5,% +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.9,,,,,2.6 - 10.1,% +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,207,,,,,140 - 400,GI/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,LIPID PANEL,Direct HDL-C 4th Generation,,1.70,,H,,,1.03 - 1.53,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,LIPID PANEL,Triglycerides (GPO),,0.59,,,,,0.59 - 2.96,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,LIPID PANEL,Cholesterol (High Performance),,4.49,,,,,4.42 - 7.53,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,LIPID PANEL,LDL Chol Friedewald 4th,,2.52,,,,,0 - 3.34,mmol/L +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,PA1 EEA-2?,Approved to use EEA-2?,,No,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,05-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,11:30,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,05-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,12:45,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,05-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,11:30,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,06:30,,,,,, +CZ100092001,,,,,Female,Induction Week 0,,"May 5, 2026 11:30 AM",6227323334,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100092002,,,,,Female,TB Testing,,"May 5, 2026 9:00 AM",6227323348,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,ANATOMICAL SITE,Anatomical Site,Y,15-20cm from anal verge,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,24-Apr-2026,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,11:09,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,12:00,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,29-Apr-2026,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100092001,,,,,Female,Biopsy,,"Apr 24, 2026 12:00 AM",6227323351,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100092002,,,,,Female,Stool Pathogens,,"Apr 20, 2026 6:10 AM",6227323341,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100092002,,,,,Female,Stool Pathogens,,"Apr 20, 2026 6:10 AM",6227323341,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100092002,,,,,Female,Stool Pathogens,,"Apr 20, 2026 6:10 AM",6227323341,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100092002,,,,,Female,Stool Pathogens,,"Apr 20, 2026 6:10 AM",6227323341,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100092002,,,,,Female,Stool Pathogens,,"Apr 20, 2026 6:10 AM",6227323341,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100092002,,,,,Female,Stool Pathogens,,"Apr 20, 2026 6:10 AM",6227323341,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Alkaline Phosphatase,,56,,,,,35 - 104,U/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,ALT (SGPT),,11,,,,,4 - 43,U/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,GGT,,10,,,,,4 - 49,U/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,LDH,,159,,,,,53 - 234,U/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Urea Nitrogen,,6.1,,,,,1.4 - 8.6,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,90,,,,,31 - 101,umol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Serum Glucose,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Serum Uric Acid,,268,,,,,149 - 446,umol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Phosphorus,,1.14,,,,,0.71 - 1.65,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Total Protein,,70,,,,,61 - 84,g/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Creatine Kinase,,176,,,,,26 - 192,U/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Serum Bicarbonate,,27.2,,,,,19.3 - 29.3,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CHEMISTRY PANEL,Magnesium,,0.93,,,,,0.66 - 1.07,mmol/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,65,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,138,,,,,116 - 164,g/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,4.1 - 5.6,TI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,32,,,,,26 - 34,pg +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.05,,,,,3.8 - 10.7,GI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.87,,L,,,1.96 - 7.23,GI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.72,,,,,0.91 - 4.28,GI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,46.1,,,,,40.5 - 75,% +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,42.6,,,,,15.4 - 48.5,% +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.2,,,,,2.6 - 10.1,% +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.4,,,,,0 - 6.8,% +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,216,,,,,140 - 400,GI/L +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Positive,,RX,,Result verified by repeat analysis,Normal=Negative, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,SERUM BETA HCG,"B-hCG, Quantitative",,0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100092002,,,,,Female,Screening,,"Apr 16, 2026 12:00 PM",6227323332,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100092001,,,,,Female,Stool Pathogens,,"Apr 2, 2026 6:15 AM",6227323340,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100092001,,,,,Female,Stool Pathogens,,"Apr 2, 2026 6:15 AM",6227323340,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100092001,,,,,Female,Stool Pathogens,,"Apr 2, 2026 6:15 AM",6227323340,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100092001,,,,,Female,Stool Pathogens,,"Apr 2, 2026 6:15 AM",6227323340,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100092001,,,,,Female,Stool Pathogens,,"Apr 2, 2026 6:15 AM",6227323340,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100092001,,,,,Female,Stool Pathogens,,"Apr 2, 2026 6:15 AM",6227323340,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.4,,,,,0 - 6.2,umol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Alkaline Phosphatase,,56,,,,,35 - 104,U/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,4 - 43,U/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,GGT,,12,,,,,4 - 49,U/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,LDH,,137,,,,,53 - 234,U/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Urea Nitrogen,,2.7,,,,,1.4 - 8.6,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Serum Glucose,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Serum Uric Acid,,207,,,,,125 - 428,umol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Phosphorus,,1.15,,,,,0.71 - 1.65,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Creatine Kinase,,81,,,,,26 - 192,U/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Serum Bicarbonate,,23.7,,,,,19.3 - 29.3,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CHEMISTRY PANEL,Magnesium,,0.91,,,,,0.66 - 1.07,mmol/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,107,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,147,,,,,116 - 164,g/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,31,,,,,26 - 34,pg +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.74,,,,,3.8 - 10.7,GI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.76,,,,,1.96 - 7.23,GI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.18,,,,,0.91 - 4.28,GI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.46,,,,,0.12 - 0.92,GI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.26,,,,,0 - 0.57,GI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,65.5,,,,,40.5 - 75,% +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,20.6,,,,,15.4 - 48.5,% +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.9,,,,,2.6 - 10.1,% +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.5,,,,,0 - 6.8,% +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.5,,,,,0 - 2,% +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,263,,,,,140 - 400,GI/L +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,PA1 EEA-2?,Approved to use EEA-2?,,No,,,,,, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100092001,,,,,Female,Screening,,"Mar 31, 2026 8:30 AM",6227323330,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, diff --git a/Covance/Source/2026-06-18_095725 sponsor-study-36940-test-results-930553-microbiology.csv b/Covance/Source/2026-06-18_095725 sponsor-study-36940-test-results-930553-microbiology.csv new file mode 100644 index 0000000..b2358b6 --- /dev/null +++ b/Covance/Source/2026-06-18_095725 sponsor-study-36940-test-results-930553-microbiology.csv @@ -0,0 +1,6 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100092001 - null,,,,Female,SCRNSTOOL Stool Pathogens,"Apr 2, 2026 6:15 AM",6227323340,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100092002 - null,,,,Female,SCRNSTOOL Stool Pathogens,"Apr 20, 2026 6:10 AM",6227323341,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100092003 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Jun 11, 2026 11:30 AM",6227323339,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, +CZ100092004 - null,,,,Female,SCRNSTOOL Stool Pathogens,"Jun 16, 2026 12:30 PM",6227765958,STOOL CULTURE,,,,,,,,,,,,,,, diff --git a/Covance/Source/2026-06-18_095726 sponsor-study-36940-test-results-930536-microbiology.csv b/Covance/Source/2026-06-18_095726 sponsor-study-36940-test-results-930536-microbiology.csv new file mode 100644 index 0000000..4dfdeb2 --- /dev/null +++ b/Covance/Source/2026-06-18_095726 sponsor-study-36940-test-results-930536-microbiology.csv @@ -0,0 +1,3 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100201001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Apr 13, 2026 6:00 AM",6227993971,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance/Source/2026-06-18_095745 sponsor-study-36940-test-results-930536-standard.csv b/Covance/Source/2026-06-18_095745 sponsor-study-36940-test-results-930536-standard.csv new file mode 100644 index 0000000..696b114 --- /dev/null +++ b/Covance/Source/2026-06-18_095745 sponsor-study-36940-test-results-930536-standard.csv @@ -0,0 +1,242 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Total Bilirubin,,5,,,,Result verified by repeat analysis,3 - 21,umol/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,Result verified by repeat analysis,0 - 6.2,umol/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Alkaline Phosphatase,,297,,,,,82 - 331,U/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,ALT (SGPT),,40,,,,,6 - 43,U/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,AST (SGOT),,39,,,,,10 - 40,U/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,GGT,,41,,,,,0 - 51,U/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,LDH,,209,,,,,105 - 235,U/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Urea Nitrogen,,2.8,,,,,1.4 - 8.6,mmol/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,50,,,,,23 - 83,umol/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Serum Glucose,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Serum Uric Acid,,317,,,,,184 - 416,umol/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Calcium (EDTA),,2.49,,,,,2.1 - 2.57,mmol/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Phosphorus,,1.74,R,H,,,0.71 - 1.65,mmol/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Total Protein,,79,,,,,61 - 84,g/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,29 - 47,g/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Creatine Kinase,,96,,,,,18 - 363,U/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Serum Potassium,,5.3,R,H,,,3.5 - 5.2,mmol/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Serum Bicarbonate,,22.3,,,,,19.3 - 29.3,mmol/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,CHEMISTRY PANEL,Magnesium,,0.83,,,,,0.7 - 0.9,mmol/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,FECAL COLLECTION D/T,Stool Collection Date,Y,,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,FECAL COLLECTION D/T,Stool Collection Time,Y,,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,107,R,L,,,127 - 181,g/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.35,R,L,,,0.39 - 0.54, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,R,L,,,4.5 - 6.4,TI/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,26,,,,,26 - 34,pg +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,84,,,,,79 - 96,fL +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.33,,,,,4.35 - 13.15,GI/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.93,,,,,1.65 - 8.15,GI/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,5.04,,,,,0.95 - 5.25,GI/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.86,,,,,0.4 - 1.3,GI/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.45,R,H,,,0 - 0.3,GI/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,31.4,R,L,,,40.5 - 75,% +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,54.0,R,H,,,15.4 - 48.5,% +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,9.2,R,H,,,4 - 8,% +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.8,R,H,,,0 - 2.8,% +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 1,% +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,493,R,H,,,140 - 400,GI/L +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,PA1 EEA-2?,Approved to use EEA-2?,,,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,,,,,,, +CZ100201001,,,,,Male,Induction Week 4,,"Jun 16, 2026 9:25 AM",6227993970,SUBJECT HEIGHT (CM),Height (cm),Y,,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,2003 SCHWARTZ EGFR,2003 Schwartz eGFR,,216,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Alkaline Phosphatase,,286,,,,,82 - 331,U/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,ALT (SGPT),,32,,,,,6 - 43,U/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,AST (SGOT),,44,,H,,,10 - 40,U/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,GGT,,20,,,,,0 - 51,U/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,LDH,,215,,,,,105 - 235,U/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Urea Nitrogen,,5.4,,,,,1.4 - 8.6,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,45,,,,,23 - 83,umol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Serum Glucose,,4.2,,,,,3.9 - 5.6,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Serum Uric Acid,,310,,,,,184 - 416,umol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.1 - 2.57,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Phosphorus,,1.54,,,,,0.71 - 1.65,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Total Protein,,79,,,,,61 - 84,g/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Albumin-BCG,,40,,,,,29 - 47,g/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Creatine Kinase,,86,,,,,18 - 363,U/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Serum Bicarbonate,,20.2,,,,,19.3 - 29.3,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CHEMISTRY PANEL,Magnesium,,0.79,,,,,0.7 - 0.9,mmol/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,CRP COPY,C Reactive Protein COPY,,2.3,,H,,,0.4 - 2,mg/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,FECAL CALPROTECTIN COPY,Fecal Calprotectin COPY,,4018.5,,H,,,Normal: <80ug/g$Borderline: 80-160$ug/g. Elevated:>160$ug/g, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,FECAL COLLECTION D/T,Stool Collection Date,Y,31-May-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,FECAL COLLECTION D/T,Stool Collection Time,Y,19:00,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,104,,L,,Result verified by repeat analysis,127 - 181,g/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.35,,L,,Result verified by repeat analysis,0.39 - 0.54, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,L,,Result verified by repeat analysis,4.5 - 6.4,TI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,26,,,,Result verified by repeat analysis,26 - 34,pg +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,Result verified by repeat analysis,79 - 96,fL +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.73,,,,Result verified by repeat analysis,4.35 - 13.15,GI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.46,,,,,1.65 - 8.15,GI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.07,,,,,0.95 - 5.25,GI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.81,,,,Result verified by repeat analysis,0.4 - 1.3,GI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.33,,H,,Result verified by repeat analysis,0 - 0.3,GI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,51.1,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,35.2,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,9.3,,H,,Result verified by repeat analysis,4 - 8,% +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.7,,H,,Result verified by repeat analysis,0 - 2.8,% +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,Result verified by repeat analysis,0 - 1,% +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,444,,H,,Result verified by repeat analysis,140 - 400,GI/L +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,01-Jun-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:35,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,01-Jun-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:45,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,01-Jun-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:35,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,31-May-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,19:00,,,,,, +CZ100201001,,,,,Male,Induction Week 2,,"Jun 1, 2026 8:35 AM",6227993968,SUBJECT HEIGHT (CM),Height (cm),Y,157,,,,,cm, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,2003 SCHWARTZ EGFR,2003 Schwartz eGFR,,191,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.0,,,,,0 - 6.2,umol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Alkaline Phosphatase,,282,,,,,82 - 331,U/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,ALT (SGPT),,16,,,,,6 - 43,U/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,AST (SGOT),,26,,,,,10 - 40,U/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,GGT,,15,,,,,0 - 51,U/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,LDH,,214,,,,,105 - 235,U/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,51,,,,,23 - 83,umol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Serum Glucose,,4.3,,,,,3.9 - 5.6,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Serum Uric Acid,,336,,,,,184 - 416,umol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Calcium (EDTA),,2.47,,,,,2.1 - 2.57,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Phosphorus,,1.58,,,,,0.71 - 1.65,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Total Protein,,85,,H,,,61 - 84,g/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,29 - 47,g/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Creatine Kinase,,65,,,,,18 - 363,U/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Serum Sodium,,136,,,,,132 - 147,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Serum Bicarbonate,,23.4,,,,,19.3 - 29.3,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CHEMISTRY PANEL,Magnesium,,0.81,,,,,0.7 - 0.9,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,CRP COPY,C Reactive Protein COPY,,1.9,,,,,0.4 - 2,mg/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,FECAL CALPROTECTIN COPY,Fecal Calprotectin COPY,,3749.9,,H,,,Normal: <80ug/g$Borderline: 80-160$ug/g. Elevated:>160$ug/g, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,FECAL COLLECTION D/T,Stool Collection Date,Y,17-May-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,FECAL COLLECTION D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,114,,L,,,127 - 181,g/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,L,,,0.39 - 0.54, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,L,,,4.5 - 6.4,TI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,27,,,,,26 - 34,pg +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.73,,,,,4.35 - 13.15,GI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.06,,,,,1.65 - 8.15,GI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.42,,,,,0.95 - 5.25,GI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.83,,,,,0.4 - 1.3,GI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.34,,H,,,0 - 0.3,GI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,52.0,,,,,40.5 - 75,% +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,35.1,,,,,15.4 - 48.5,% +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.5,,H,,,4 - 8,% +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.5,,H,,,0 - 2.8,% +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 1,% +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,607,,H,,,140 - 400,GI/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,LIPID PANEL,Direct HDL-C 4th Generation,,1.27,,,,,1.03 - 1.53,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,LIPID PANEL,Triglycerides (GPO),,1.17,,,,,0.42 - 1.67,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,LIPID PANEL,Cholesterol (High Performance),,3.50,,,,,2.95 - 5.12,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,LIPID PANEL,LDL Chol Friedewald 4th,,1.69,,,,,0 - 3.34,mmol/L +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,18-May-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,09:28,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,18-May-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:52,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,18-May-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,09:28,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,17-May-2026,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,18:00,,,,,, +CZ100201001,,,,,Male,Induction Week 0,,"May 18, 2026 9:28 AM",6227993966,SUBJECT HEIGHT (CM),Height (cm),Y,157,,,,,cm, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,ANATOMICAL SITE,Anatomical Site,Y,20-25,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,15-Apr-2026,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,13:00,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,17-Apr-2026,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100201001,,,,,Male,Biopsy,,"Apr 15, 2026 12:00 AM",6227993984,ULCERATED AREA,Is biopsy site ulcerated?,,No,,,,,, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,2003 SCHWARTZ EGFR,2003 Schwartz eGFR,,211,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.2,,,,,0 - 6.2,umol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Alkaline Phosphatase,,322,,,,,82 - 331,U/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,6 - 43,U/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,AST (SGOT),,29,,,,,10 - 40,U/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,GGT,,17,,,,,0 - 51,U/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,LDH,,221,,,,,105 - 235,U/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Urea Nitrogen,,3.6,,,,,1.4 - 8.6,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,46,,,,,23 - 83,umol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Serum Glucose,,4.1,,,,,3.9 - 5.6,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Serum Uric Acid,,326,,,,,184 - 416,umol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Calcium (EDTA),,2.57,,,,,2.1 - 2.57,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Phosphorus,,1.72,,H,,,0.71 - 1.65,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Total Protein,,87,,H,,,61 - 84,g/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,29 - 47,g/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Creatine Kinase,,94,,,,,18 - 363,U/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Serum Sodium,,136,,,,,132 - 147,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Serum Bicarbonate,,20.7,,,,,19.3 - 29.3,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,CHEMISTRY PANEL,Magnesium,,0.77,,,,,0.7 - 0.9,mmol/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,118,,L,,Result verified by repeat analysis,127 - 181,g/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,L,,,0.39 - 0.54, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,L,,Result verified by repeat analysis,4.5 - 6.4,TI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,28,,,,Result verified by repeat analysis,26 - 34,pg +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,10.04,,,,Result verified by repeat analysis,4.35 - 13.15,GI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.19,,,,Result verified by repeat analysis,1.65 - 8.15,GI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.73,,,,,0.95 - 5.25,GI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.77,,,,Result verified by repeat analysis,0.4 - 1.3,GI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.29,,,,Result verified by repeat analysis,0 - 0.3,GI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,51.7,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,37.2,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.6,,,,Result verified by repeat analysis,4 - 8,% +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.9,,H,,Result verified by repeat analysis,0 - 2.8,% +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,Result verified by repeat analysis,0 - 1,% +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,490,,H,,Result verified by repeat analysis,140 - 400,GI/L +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Reactive,,,,,Ref Rng :$Non Reactive, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100201001,,,,,Male,Screening,,"Apr 13, 2026 12:20 PM",6227993962,SUBJECT HEIGHT (CM),Height (cm),Y,157,,,,,cm, +CZ100201001,,,,,Male,Stool Pathogens,,"Apr 13, 2026 6:00 AM",6227993971,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100201001,,,,,Male,Stool Pathogens,,"Apr 13, 2026 6:00 AM",6227993971,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, diff --git a/Covance/Source/2026-06-18_095749 sponsor-study-36940-test-results-930531-microbiology.csv b/Covance/Source/2026-06-18_095749 sponsor-study-36940-test-results-930531-microbiology.csv new file mode 100644 index 0000000..9f10aa5 --- /dev/null +++ b/Covance/Source/2026-06-18_095749 sponsor-study-36940-test-results-930531-microbiology.csv @@ -0,0 +1,3 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,,,,,, +Subject,Screening Number,Age,Age Unit,Gender,Visit Description,Collected Time,Accession,Test Group,Specimen,Organism,Growth,Cancellation Reason,Test Description,Test Result,Drug Name/Agent,MIC Result,Units,MIC Interpretation,Disk Diffusion Result,Disk Diffusion Interpretation,Subject Data Revision,Visit Data Revision,Result Data Revision +CZ100212001 - null,,,,Male,SCRNSTOOL Stool Pathogens,"Mar 1, 2026 2:00 PM",6227635213,STOOL CULTURE,Stool,,,,Final Report,No enteric pathogens isolated,,,,,,,,, diff --git a/Covance/Source/2026-06-18_095804 sponsor-study-35472-test-results-898745-standard.csv b/Covance/Source/2026-06-18_095804 sponsor-study-35472-test-results-898745-standard.csv new file mode 100644 index 0000000..52edb5c --- /dev/null +++ b/Covance/Source/2026-06-18_095804 sponsor-study-35472-test-results-898745-standard.csv @@ -0,0 +1,2615 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.2,,,,,0 - 6.2,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Alkaline Phosphatase,,71,,,,,35 - 104,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,ALT (SGPT),,26,,,,,4 - 43,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,AST (SGOT),,36,,,,,8 - 40,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,GGT,,55,,H,,,4 - 49,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,LDH,,218,,,,,53 - 234,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Urea Nitrogen,,7.1,,,,,1.4 - 8.6,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 101,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Serum Uric Acid,,359,,,,,149 - 446,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Creatine Kinase,,187,,,,,26 - 192,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Serum Bicarbonate,,25.8,,,,,19.3 - 29.3,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,116 - 164,g/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,95,,,,,79 - 98,fL +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.76,,,,,3.8 - 10.7,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.50,,,,,1.96 - 7.23,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.54,,,,,0.91 - 4.28,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.63,,,,,0.12 - 0.92,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.07,,,,,0 - 0.57,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,60.7,,,,,40.5 - 75,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.8,,,,,15.4 - 48.5,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.9,R,H,,,2.6 - 10.1,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.1,,,,,0 - 6.8,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,275,,,,,140 - 400,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.01,,,,,1.9 - 23,uIU/mL +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,LIPID PANEL,Direct HDL-C 4th Generation,,2.58,,H,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,LIPID PANEL,Triglycerides (GPO),,1.71,,,,,0.59 - 2.96,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,LIPID PANEL,Cholesterol (High Performance),,4.84,,,,,4.42 - 7.53,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,LIPID PANEL,LDL Chol Friedewald 4th,,1.48,,,,,0 - 3.34,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Specific Gravity,,1.013,,,,,1 - 1.04, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 11:15 AM",6226573502,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.6,,,,,0 - 5,mg/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.0,,,,,0 - 6.2,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Alkaline Phosphatase,,52,,,,,35 - 104,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,GGT,,18,,,,,5 - 50,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,LDH,,176,,,,,53 - 234,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Urea Nitrogen,,4.4,,,,,1.4 - 8.6,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,60,,,,,31 - 101,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Glucose Fasting,,3.9,,,,,3.9 - 5.6,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Serum Uric Acid,,183,,,,,149 - 446,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Calcium (EDTA),,2.36,,,,,2.07 - 2.64,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Phosphorus,,0.78,,,,,0.71 - 1.65,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Total Protein,,61,,,,,60 - 80,g/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Creatine Kinase,,98,,,,,26 - 192,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Serum Sodium,,141,,,,,135 - 145,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Serum Potassium,,3.9,,,,,3.5 - 5.2,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Serum Bicarbonate,,24.4,,,,,19.3 - 29.3,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,LIPID PANEL,Direct HDL-C 4th Generation,,1.35,,,,,1.03 - 1.53,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,LIPID PANEL,Triglycerides (GPO),,0.82,,,,,0.63 - 2.71,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,LIPID PANEL,Cholesterol (High Performance),,5.15,,,,,4.86 - 8.28,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,LIPID PANEL,LDL Chol Friedewald 4th,,3.42,,H,,,0 - 3.34,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,RETICULOCYTES,Reticulocyte Count %,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1.01 - 1.03, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Day 29,,"Jun 5, 2026 10:35 AM",6226889397,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.2,,,,,0 - 5,mg/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Alkaline Phosphatase,,80,,,,,35 - 104,U/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,ALT (SGPT),,28,,,,,4 - 43,U/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,GGT,,43,,,,,4 - 49,U/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,LDH,,177,,,,,53 - 234,U/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Urea Nitrogen,,2.4,,,,,1.4 - 8.6,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,67,,,,,31 - 101,umol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Glucose Fasting,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Serum Uric Acid,,277,,,,,125 - 428,umol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Phosphorus,,1.12,,,,,0.71 - 1.65,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Creatine Kinase,,125,,,,,26 - 192,U/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Serum Bicarbonate,,23.5,,,,,19.3 - 29.3,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,134,,,,Result verified by repeat analysis,116 - 164,g/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,Result verified by repeat analysis,4.1 - 5.6,TI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,102,,H,,,79 - 98,fL +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.65,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.18,,,,Result verified by repeat analysis,1.96 - 7.23,GI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.87,,,,,0.91 - 4.28,GI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.44,,,,Result verified by repeat analysis,0.12 - 0.92,GI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,Result verified by repeat analysis,0 - 0.57,GI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,47.7,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,43.2,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.6,,,,Result verified by repeat analysis,2.6 - 10.1,% +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.7,,,,Result verified by repeat analysis,0 - 6.8,% +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,Result verified by repeat analysis,0 - 2,% +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,360,,,,Result verified by repeat analysis,140 - 400,GI/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.3,,,,,<6.5 %, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.64,,,,,1.9 - 23,uIU/mL +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,LIPID PANEL,Direct HDL-C 4th Generation,,1.70,,H,,,1.03 - 1.53,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,LIPID PANEL,Triglycerides (GPO),,1.69,,,,,0.51 - 2.42,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,LIPID PANEL,Cholesterol (High Performance),,5.66,,,,,4.01 - 6.85,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,LIPID PANEL,LDL Chol Friedewald 4th,,3.19,,,,,0 - 3.34,mmol/L +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,TSH,TSH 3rd IS-QT,,,,,Test group cancelled: No specimen received,,, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Specific Gravity,,1.015,,,,,1 - 1.04, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 DB Week 13,,"May 29, 2026 9:30 AM",6226649754,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.1,,,,,0 - 5,mg/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CELLULAR ELEMENTS,Ur WBC/HPF,,2,,,,,0 - 12,/HPF +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Alkaline Phosphatase,,87,,,,,35 - 104,U/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,4 - 43,U/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,GGT,,30,,,,,4 - 49,U/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,LDH,,154,,,,,53 - 234,U/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,49,,,,,31 - 101,umol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Serum Uric Acid,,314,,,,,125 - 428,umol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Calcium (EDTA),,2.51,,,,,2.07 - 2.64,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Phosphorus,,1.25,,,,,0.71 - 1.65,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Creatine Kinase,,202,,H,,,26 - 192,U/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Serum Bicarbonate,,21.2,,,,,19.3 - 29.3,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,144,,,,,116 - 164,g/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.34 - 0.48, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,79 - 98,fL +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.81,,,,,3.8 - 10.7,GI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.47,,,,,1.96 - 7.23,GI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.67,,,,,0.91 - 4.28,GI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.43,,,,,0.12 - 0.92,GI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,50.7,,,,,40.5 - 75,% +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,41.7,,,,,15.4 - 48.5,% +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.8,,,,,2.6 - 10.1,% +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.0,,,,,0 - 6.8,% +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,504,,H,,,140 - 400,GI/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.6,,H,,,<6.5 %, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,23.94,,H,,,1.9 - 23,uIU/mL +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,LIPID PANEL,Direct HDL-C 4th Generation,,1.34,,,,,1.03 - 1.53,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,LIPID PANEL,Triglycerides (GPO),,2.54,,H,,,0.51 - 2.42,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,LIPID PANEL,Cholesterol (High Performance),,6.04,,,,,4.01 - 6.85,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,LIPID PANEL,LDL Chol Friedewald 4th,,3.54,,H,,,0 - 3.34,mmol/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,RETICULOCYTES,Reticulocyte Count %,,1.8,,,,,0.6 - 2.5,% +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,TSH,TSH 3rd IS-QT,,3.138,,,,,0.45 - 5.33,mIU/L +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Specific Gravity,,1.020,,,,,1 - 1.04, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,End of Phase/Treatment,,"May 22, 2026 12:00 PM",6228605653,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,C-REACTIVE PROTEIN,C Reactive Protein HS,,10.2,,H,,,0 - 5,mg/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Alkaline Phosphatase,,90,,,,,35 - 104,U/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,GGT,,22,,,,,5 - 50,U/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,LDH,,185,,,,,53 - 234,U/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Urea Nitrogen,,6.0,,,,,1.4 - 10.4,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,64,,,,,31 - 110,umol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Glucose Fasting,,6.3,R,H,,,3.9 - 5.6,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Serum Uric Acid,,316,,,,,149 - 446,umol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Phosphorus,,1.07,,,,,0.71 - 1.65,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Total Protein,,80,,,,,60 - 80,g/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Albumin-BCG,,47,R,H,,,33 - 46,g/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Creatine Kinase,,88,,,,,26 - 192,U/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Serum Sodium,,136,,,,,135 - 145,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Serum Bicarbonate,,18.7,R,L,,,19.3 - 29.3,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,163,R,H,,,115 - 158,g/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.50,R,H,,,0.34 - 0.48, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,3.9 - 5.5,TI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,80 - 100,fL +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,11.22,R,H,,,3.8 - 10.7,GI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.82,,,,,1.96 - 7.23,GI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.47,R,H,,,0.8 - 3,GI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.75,,,,,0.12 - 0.92,GI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,60.8,,,,,40.5 - 75,% +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.9,,,,,15.4 - 48.5,% +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.7,,,,,2.6 - 10.1,% +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,285,,,,,130 - 394,GI/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.9,,,,,<6.5 %, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,15.61,,,,,1.9 - 23,uIU/mL +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,LIPID PANEL,Direct HDL-C 4th Generation,,1.36,,,,,1.03 - 1.53,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,LIPID PANEL,Triglycerides (GPO),,2.89,R,H,,,0.63 - 2.71,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,LIPID PANEL,Cholesterol (High Performance),,7.08,,,,,5.35 - 9.1,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,LIPID PANEL,LDL Chol Friedewald 4th,,4.40,,H,,,0 - 3.34,mmol/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,TSH,TSH 3rd IS-QT,,0.546,,,,,0.45 - 5.33,mIU/L +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Specific Gravity,,1.016,,,,,1.01 - 1.03, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Blood,,Trace,,,,,Ref Rng:$Negative-Trace, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,End of Phase/Treatment,,"May 22, 2026 9:20 AM",6228605652,URINE MICRO PANEL,Ur Microscopic,,Negative,,,,, NEGATIVE$,NEGATIVE +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.3,,,,,0 - 5,mg/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CELLULAR ELEMENTS,Ur WBC/HPF,,8,,,,,0 - 12,/HPF +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.2,,,,,0 - 6.2,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Alkaline Phosphatase,,83,,,,,35 - 104,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,ALT (SGPT),,22,,,,,4 - 43,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,GGT,,32,,,,,4 - 49,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,LDH,,169,,,,,53 - 234,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,51,,,,,31 - 101,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Serum Uric Acid,,383,,,,,125 - 428,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Calcium (EDTA),,2.52,,,,,2.07 - 2.64,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Phosphorus,,1.20,,,,,0.71 - 1.65,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Creatine Kinase,,201,,H,,,26 - 192,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Serum Bicarbonate,,21.6,,,,,19.3 - 29.3,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,143,,,,,116 - 164,g/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,95,,,,,79 - 98,fL +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,10.33,,,,,3.8 - 10.7,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.06,,,,,1.96 - 7.23,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.53,,,,,0.91 - 4.28,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.53,,,,,0.12 - 0.92,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.6,,,,,40.5 - 75,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,34.1,,,,,15.4 - 48.5,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.1,,,,,2.6 - 10.1,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,525,R,H,,,140 - 400,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,16.12,,,,,1.9 - 23,uIU/mL +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,LIPID PANEL,Direct HDL-C 4th Generation,,1.37,,,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,LIPID PANEL,Triglycerides (GPO),,2.79,,H,,,0.51 - 2.42,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,LIPID PANEL,Cholesterol (High Performance),,6.50,,,,,4.01 - 6.85,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,LIPID PANEL,LDL Chol Friedewald 4th,,3.85,,H,,,0 - 3.34,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,RETICULOCYTES,Reticulocyte Count %,,1.5,,,,,0.6 - 2.5,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Specific Gravity,,1.029,,,,,1 - 1.04, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Day 29,R,"May 5, 2026 1:15 PM",6227541261,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.1,,,,,0 - 5,mg/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Alkaline Phosphatase,,66,,,,,35 - 104,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,GGT,,36,,,,,4 - 49,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,LDH,,192,,,,,53 - 234,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,57,,,,,31 - 101,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Glucose Fasting,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Serum Uric Acid,,277,,,,,149 - 446,umol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Calcium (EDTA),,2.08,,,,,2.07 - 2.64,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Phosphorus,,0.90,,,,,0.71 - 1.65,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Total Protein,,62,,,,,61 - 84,g/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Creatine Kinase,,84,,,,,26 - 192,U/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Serum Sodium,,144,,,,,132 - 147,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Serum Potassium,,3.5,,,,,3.5 - 5.2,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Serum Bicarbonate,,22.5,,,,,19.3 - 29.3,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,CHEMISTRY PANEL,Serum Chloride,,109,,,,,94 - 112,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,132,,,,,116 - 164,g/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4.1 - 5.6,TI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.40,,,,,3.8 - 10.7,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.63,,,,,1.96 - 7.23,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.90,,,,,0.91 - 4.28,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.78,,,,,0.12 - 0.92,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.05,,,,,0 - 0.57,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,48.8,,,,,40.5 - 75,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,35.1,,,,,15.4 - 48.5,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,14.4,R,H,,,2.6 - 10.1,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,248,,,,,140 - 400,GI/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.25,,,,,1.9 - 23,uIU/mL +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,LIPID PANEL,Direct HDL-C 4th Generation,,1.92,,H,,,1.03 - 1.53,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,LIPID PANEL,Triglycerides (GPO),,1.20,,,,,0.59 - 2.96,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,LIPID PANEL,Cholesterol (High Performance),,3.66,,L,,,4.42 - 7.53,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,LIPID PANEL,LDL Chol Friedewald 4th,,1.19,,,,,0 - 3.34,mmol/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,TSH,TSH 3rd IS-QT,,3.352,,,,,0.45 - 5.33,mIU/L +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 9:50 AM",6227547338,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Alkaline Phosphatase,,137,,H,,,35 - 104,U/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,ALT (SGPT),,11,,,,,4 - 43,U/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,GGT,,14,,,,,5 - 50,U/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,LDH,,170,,,,,53 - 234,U/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Urea Nitrogen,,5.3,,,,,1.4 - 8.6,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,61,,,,,31 - 101,umol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Glucose Fasting,,5.6,,,,,3.9 - 5.6,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Serum Uric Acid,,204,,,,,149 - 446,umol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Phosphorus,,0.96,,,,,0.71 - 1.65,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Total Protein,,73,,,,,60 - 80,g/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Creatine Kinase,,78,,,,,26 - 192,U/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Serum Sodium,,145,,,,,135 - 145,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Serum Bicarbonate,,21.6,,,,,19.3 - 29.3,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,CHEMISTRY PANEL,Serum Chloride,,109,,,,,94 - 112,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,150,,,,,115 - 158,g/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.34 - 0.48, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,3.9 - 5.5,TI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,80 - 100,fL +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.17,,,,,3.8 - 10.7,GI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.80,,,,,1.96 - 7.23,GI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.79,,,,,0.8 - 3,GI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.41,,,,,0.12 - 0.92,GI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.0,,,,,40.5 - 75,% +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,38.9,,,,,15.4 - 48.5,% +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.1,,,,,0 - 6.8,% +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.3,,,,,0 - 2,% +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,239,,,,,130 - 394,GI/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.88,,,,,1.9 - 23,uIU/mL +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,LIPID PANEL,Direct HDL-C 4th Generation,,1.85,,H,,,1.03 - 1.53,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,LIPID PANEL,Triglycerides (GPO),,0.61,,L,,,0.63 - 2.71,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,LIPID PANEL,Cholesterol (High Performance),,5.06,,,,,4.86 - 8.28,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,LIPID PANEL,LDL Chol Friedewald 4th,,2.93,,,,,0 - 3.34,mmol/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,TSH,TSH 3rd IS-QT,,0.955,,,,,0.45 - 5.33,mIU/L +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Specific Gravity,,1.025,,,,,1.01 - 1.03, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,End of Phase/Treatment,,"May 5, 2026 8:45 AM",6227768458,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.2,,,,,0 - 5,mg/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.0,,,,,0 - 6.2,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Alkaline Phosphatase,,62,,,,,35 - 104,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,ALT (SGPT),,14,,,,,4 - 43,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,GGT,,16,,,,,5 - 50,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 8.6,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,64,,,,,31 - 101,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Glucose Fasting,,5.8,,H,,,3.9 - 5.6,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Serum Uric Acid,,216,,,,,149 - 446,umol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Total Protein,,63,,,,,60 - 80,g/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Creatine Kinase,,151,,,,,26 - 192,U/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Serum Sodium,,142,,,,,135 - 145,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Serum Bicarbonate,,21.4,,,,,19.3 - 29.3,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,CHEMISTRY PANEL,Serum Chloride,,108,,,,,94 - 112,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,152,,,,,115 - 158,g/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.34 - 0.48, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,3.9 - 5.5,TI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,100,,,,,80 - 100,fL +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.94,,,,,3.8 - 10.7,GI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.03,,,,,1.96 - 7.23,GI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.45,,,,,0.8 - 3,GI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.32,,,,,0.12 - 0.92,GI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,75.9,R,H,,,40.5 - 75,% +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,18.3,,,,,15.4 - 48.5,% +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.0,,,,,2.6 - 10.1,% +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.3,,,,,0 - 6.8,% +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,244,,,,,130 - 394,GI/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.4,,,,,<6.5 %, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,7.00,,,,,1.9 - 23,uIU/mL +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,LIPID PANEL,Direct HDL-C 4th Generation,,1.24,,,,,1.03 - 1.53,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,LIPID PANEL,Triglycerides (GPO),,0.74,,,,,0.63 - 2.71,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,LIPID PANEL,Cholesterol (High Performance),,4.25,,L,,,4.86 - 8.28,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,LIPID PANEL,LDL Chol Friedewald 4th,,2.67,,,,,0 - 3.34,mmol/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,RETICULOCYTES,Reticulocyte Count %,,1.0,,,,,0.6 - 2.5,% +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,TSH,TSH 3rd IS-QT,,1.798,,,,,0.45 - 5.33,mIU/L +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Specific Gravity,,1.016,,,,,1.01 - 1.03, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 2 OL Induction Baseline,,"May 5, 2026 7:50 AM",6227541256,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.9,,,,,0 - 5,mg/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.4,,,,,0 - 6.2,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Alkaline Phosphatase,,81,,,,,35 - 104,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,4 - 43,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,GGT,,19,,,,,4 - 49,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,LDH,,193,,,,,53 - 234,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Urea Nitrogen,,4.7,,,,,1.4 - 8.6,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Serum Uric Acid,,206,,,,,149 - 446,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Phosphorus,,1.36,,,,,0.71 - 1.65,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Total Protein,,65,,,,,61 - 84,g/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Creatine Kinase,,82,,,,,26 - 192,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Serum Sodium,,145,,,,,132 - 147,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Serum Bicarbonate,,25.9,,,,,19.3 - 29.3,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,139,,,,,116 - 164,g/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.84,,,,,3.8 - 10.7,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.66,,,,,1.96 - 7.23,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.78,,,,,0.91 - 4.28,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.27,,,,,0.12 - 0.92,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.0,,,,,40.5 - 75,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.8,,,,,15.4 - 48.5,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.7,,,,,2.6 - 10.1,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.7,,,,,0 - 6.8,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,274,,,,,140 - 400,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.1,,,,,<6.5 %, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.31,,,,,1.9 - 23,uIU/mL +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,LIPID PANEL,Direct HDL-C 4th Generation,,1.64,,H,,,1.03 - 1.53,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,LIPID PANEL,Triglycerides (GPO),,0.68,,,,,0.59 - 2.96,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,LIPID PANEL,Cholesterol (High Performance),,5.02,,,,,4.42 - 7.53,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,LIPID PANEL,LDL Chol Friedewald 4th,,3.07,,,,,0 - 3.34,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,TSH,TSH 3rd IS-QT,,1.896,,,,,0.45 - 5.33,mIU/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Specific Gravity,,1.022,,,,,1 - 1.04, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"May 5, 2026 7:15 AM",6227178910,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.6,,,,,0 - 5,mg/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Total Bilirubin,,<3,,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Alkaline Phosphatase,,88,,,,,35 - 104,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,4 - 43,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,GGT,,32,,,,,4 - 49,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,LDH,,156,,,,,53 - 234,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,39,,,,,31 - 101,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Serum Uric Acid,,335,,,,,125 - 428,umol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Calcium (EDTA),,2.12,,,,,2.07 - 2.64,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Phosphorus,,1.07,,,,,0.71 - 1.65,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Albumin-BCG,,39,,,,,33 - 49,g/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Creatine Kinase,,135,,,,,26 - 192,U/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Serum Bicarbonate,,20.2,,,,,19.3 - 29.3,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,CHEMISTRY PANEL,Serum Chloride,,109,,,,,94 - 112,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,DIRECT LDL,Direct LDL-C 3rd Gen,,3.40,,H,,,<3.36 mmol/L, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,145,,,,,116 - 164,g/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.34 - 0.48, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,11.75,,H,,,3.8 - 10.7,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.71,,,,,1.96 - 7.23,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,4.08,,,,,0.91 - 4.28,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.60,,,,,0.12 - 0.92,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.24,,,,,0 - 0.57,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.11,,,,,0 - 0.2,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.1,,,,,40.5 - 75,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,34.7,,,,,15.4 - 48.5,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.1,,,,,2.6 - 10.1,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.1,,,,,0 - 6.8,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,550,,H,,,140 - 400,GI/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.7,R,H,,,<6.5 %, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,73.67,R,H,,,1.9 - 23,uIU/mL +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,LIPID PANEL,Direct HDL-C 4th Generation,,1.00,,L,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,LIPID PANEL,Triglycerides (GPO),,5.91,,H SF,,,0.51 - 2.42,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,LIPID PANEL,Cholesterol (High Performance),,5.54,,,,,4.01 - 6.85,mmol/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,LIPID PANEL,LDL Chol Friedewald 4th,,,,,Test cancelled: Invalid/High Triglycerides,,, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,RETICULOCYTES,Reticulocyte Count %,,1.7,,,,,0.6 - 2.5,% +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,TSH,TSH 3rd IS-QT,,2.578,,,,,0.45 - 5.33,mIU/L +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1 - 1.04, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 2 OL Induction Baseline,,"Apr 10, 2026 11:15 AM",6227547337,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.7,,,,,0 - 5,mg/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Alkaline Phosphatase,,69,,,,,35 - 104,U/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,ALT (SGPT),,25,,,,,4 - 43,U/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,AST (SGOT),,36,,,,,8 - 40,U/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,GGT,,43,,,,,4 - 49,U/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,LDH,,193,,,,,53 - 234,U/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,65,,,,,31 - 101,umol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Serum Uric Acid,,321,,,,,149 - 446,umol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Calcium (EDTA),,2.13,,,,,2.07 - 2.64,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Phosphorus,,0.91,,,,,0.71 - 1.65,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Total Protein,,65,,,,,61 - 84,g/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Creatine Kinase,,93,,,,,26 - 192,U/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Serum Potassium,,3.7,,,,,3.5 - 5.2,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Serum Bicarbonate,,25.6,,,,,19.3 - 29.3,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CHEMISTRY PANEL,Serum Chloride,,107,,,,,94 - 112,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.65,,,,,1.25 - 1.92,mL/sec +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,65,,,,,31 - 101,umol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,75.1,,,,,kg, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,GFR,EGFR by MDRD,,81,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,134,,,,,116 - 164,g/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4.1 - 5.6,TI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.08,,,,,3.8 - 10.7,GI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.60,,,,,1.96 - 7.23,GI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.79,,,,,0.91 - 4.28,GI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.52,,,,,0.12 - 0.92,GI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,51.1,,,,,40.5 - 75,% +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,35.3,,,,,15.4 - 48.5,% +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.2,R,H,,,2.6 - 10.1,% +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.4,,,,,0 - 6.8,% +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,267,,,,,140 - 400,GI/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.13,,,,,1.9 - 23,uIU/mL +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,LIPID PANEL,Direct HDL-C 4th Generation,,2.21,,H,,,1.03 - 1.53,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,LIPID PANEL,Triglycerides (GPO),,0.81,,,,,0.59 - 2.96,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,LIPID PANEL,Cholesterol (High Performance),,3.95,,L,,,4.42 - 7.53,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,LIPID PANEL,LDL Chol Friedewald 4th,,1.37,,,,,0 - 3.34,mmol/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,TSH,TSH 3rd IS-QT,,3.004,,,,,0.45 - 5.33,mIU/L +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Specific Gravity,,1.020,,,,,1 - 1.04, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040009,,,58,years,Female,Part 2 Screening,,"Apr 10, 2026 8:15 AM",6227547336,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.0,,,,,0 - 5,mg/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Alkaline Phosphatase,,94,,,,,35 - 104,U/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,GGT,,17,,,,,5 - 50,U/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,LDH,,163,,,,,53 - 234,U/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 10.4,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 110,umol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Glucose Fasting,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Serum Uric Acid,,265,,,,,149 - 446,umol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Phosphorus,,1.45,,,,,0.71 - 1.65,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Total Protein,,78,,,,,60 - 80,g/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Albumin-BCG,,47,R,H,,,33 - 46,g/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Creatine Kinase,,80,,,,,26 - 192,U/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Serum Sodium,,137,,,,,135 - 145,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Serum Bicarbonate,,21.7,,,,,19.3 - 29.3,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,159,R,H,,,115 - 158,g/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.34 - 0.48, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,3.9 - 5.5,TI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,80 - 100,fL +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.76,,,,,3.8 - 10.7,GI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.09,,,,,1.96 - 7.23,GI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.77,R,H,,,0.8 - 3,GI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.73,,,,,0.12 - 0.92,GI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,52.1,,,,,40.5 - 75,% +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,38.6,,,,,15.4 - 48.5,% +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.5,,,,,2.6 - 10.1,% +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.2,,,,,0 - 6.8,% +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,307,,,,,130 - 394,GI/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.8,,,,,<6.5 %, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,LIPID PANEL,Direct HDL-C 4th Generation,,1.36,,,,,1.03 - 1.53,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,LIPID PANEL,Triglycerides (GPO),,3.03,,H,,,0.63 - 2.71,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,LIPID PANEL,Cholesterol (High Performance),,7.15,,,,,5.35 - 9.1,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,LIPID PANEL,LDL Chol Friedewald 4th,,4.40,,H,,,0 - 3.34,mmol/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,TSH,TSH 3rd IS-QT,,1.854,,,,,0.45 - 5.33,mIU/L +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Specific Gravity,,1.012,,,,,1.01 - 1.03, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 2 OL Induction Baseline,,"Apr 7, 2026 9:45 AM",6227541258,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Alkaline Phosphatase,,100,,,,,35 - 104,U/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,ALT (SGPT),,30,,,,,4 - 43,U/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,AST (SGOT),,27,,,,,8 - 40,U/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,GGT,,18,,,,,4 - 49,U/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,LDH,,235,,H,,,53 - 234,U/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Urea Nitrogen,,5.4,,,,,1.4 - 8.6,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,31 - 101,umol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Serum Uric Acid,,308,,,,,149 - 446,umol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Calcium (EDTA),,2.33,,,,,2.07 - 2.64,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Creatine Kinase,,119,,,,,26 - 192,U/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Serum Bicarbonate,,24.5,,,,,19.3 - 29.3,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,143,,,,,116 - 164,g/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.1 - 5.6,TI/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.03,,,,,3.8 - 10.7,GI/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.95,,,,,1.96 - 7.23,GI/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.62,,,,,0.91 - 4.28,GI/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.32,,,,,0.12 - 0.92,GI/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.6,,,,,40.5 - 75,% +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.2,,,,,15.4 - 48.5,% +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.3,,,,,2.6 - 10.1,% +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.5,,,,,0 - 6.8,% +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Platelet clumps present,,, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.6,,,,,<6.5 %, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,8.28,,,,,1.9 - 23,uIU/mL +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,LIPID PANEL,Direct HDL-C 4th Generation,,1.34,,,,,1.03 - 1.53,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,LIPID PANEL,Triglycerides (GPO),,1.17,,,,,0.59 - 2.96,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,LIPID PANEL,Cholesterol (High Performance),,6.97,,,,,4.42 - 7.53,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,LIPID PANEL,LDL Chol Friedewald 4th,,5.09,,H,,,0 - 3.34,mmol/L +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,RETICULOCYTES,Reticulocyte Count %,,1.7,,,,,0.6 - 2.5,% +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,TSH,TSH 3rd IS-QT,,,,,Test group cancelled: No specimen received,,, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Specific Gravity,,1.022,,,,,1 - 1.04, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 8:35 AM",6227541264,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.8,,,,,0 - 5,mg/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CELLULAR ELEMENTS,Ur WBC/HPF,,7,,,,,0 - 12,/HPF +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Total Bilirubin,,14,,,,,3 - 21,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,5.1,,,,,0 - 6.2,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Alkaline Phosphatase,,86,,,,,35 - 104,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,ALT (SGPT),,61,R,H,,,4 - 43,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,AST (SGOT),,37,,,,,8 - 40,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,GGT,,25,,,,,4 - 49,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,LDH,,181,,,,,53 - 234,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 8.6,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Glucose Fasting,,6.1,R,H,,,3.9 - 5.6,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Serum Uric Acid,,287,,,,,149 - 446,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Phosphorus,,1.16,,,,,0.71 - 1.65,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Total Protein,,64,,,,,61 - 84,g/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Creatine Kinase,,52,,,,,26 - 192,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Serum Bicarbonate,,25.7,,,,,19.3 - 29.3,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,151,,,,,116 - 164,g/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.34 - 0.48, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.1 - 5.6,TI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.52,,,,,3.8 - 10.7,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.64,,,,,1.96 - 7.23,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.27,,,,,0.91 - 4.28,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.38,,,,,0.12 - 0.92,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.7,,,,,40.5 - 75,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.2,,,,,15.4 - 48.5,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.0,,,,,2.6 - 10.1,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.0,,,,,0 - 6.8,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,310,,,,,140 - 400,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.4,,,,,<6.5 %, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,18.47,,,,,1.9 - 23,uIU/mL +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,LIPID PANEL,Direct HDL-C 4th Generation,,0.95,R,L,,,1.03 - 1.53,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,LIPID PANEL,Triglycerides (GPO),,1.13,,,,,0.59 - 2.96,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,LIPID PANEL,Cholesterol (High Performance),,2.38,,L,,Result verified by repeat analysis,4.42 - 7.53,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,LIPID PANEL,LDL Chol Friedewald 4th,,0.91,,,,,0 - 3.34,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,RETICULOCYTES,Reticulocyte Count %,,2.0,,,,,0.6 - 2.5,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,TSH,TSH 3rd IS-QT,,0.827,,,,,0.45 - 5.33,mIU/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1 - 1.04, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MACRO PANEL,Ur Leukocyte Esterase,,+2,,H SF,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Mar 27, 2026 10:00 AM",6227768460,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.7,,,,,0 - 5,mg/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Total Bilirubin,,19,,,,,3 - 21,umol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,5.6,,,,,0 - 6.2,umol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Alkaline Phosphatase,,122,,H,,,35 - 104,U/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,AST (SGOT),,15,,,,,8 - 40,U/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,GGT,,12,,,,,5 - 50,U/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,LDH,,154,,,,,53 - 234,U/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Urea Nitrogen,,6.0,,,,,1.4 - 8.6,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,65,,,,,31 - 101,umol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Glucose Fasting,,6.3,,H,,,3.9 - 5.6,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Serum Uric Acid,,223,,,,,149 - 446,umol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Calcium (EDTA),,2.31,,,,,2.07 - 2.64,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Phosphorus,,0.91,,,,,0.71 - 1.65,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Total Protein,,68,,,,,60 - 80,g/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Creatine Kinase,,85,,,,,26 - 192,U/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Serum Sodium,,140,,,,,135 - 145,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Serum Bicarbonate,,23.4,,,,,19.3 - 29.3,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,CHEMISTRY PANEL,Serum Chloride,,106,,,,,94 - 112,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,147,,,,,115 - 158,g/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.34 - 0.48, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,3.9 - 5.5,TI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,94,,,,,80 - 100,fL +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.41,,,,,3.8 - 10.7,GI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.51,,,,,1.96 - 7.23,GI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.33,,,,,0.8 - 3,GI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.35,,,,,0.12 - 0.92,GI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.7,,,,,40.5 - 75,% +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.2,,,,,15.4 - 48.5,% +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.5,,,,,2.6 - 10.1,% +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.1,,,,,0 - 6.8,% +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.4,,,,,0 - 2,% +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,232,,,,,130 - 394,GI/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.38,,,,,1.9 - 23,uIU/mL +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,LIPID PANEL,Direct HDL-C 4th Generation,,1.74,R,H,,,1.03 - 1.53,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,LIPID PANEL,Triglycerides (GPO),,0.57,R,L,,,0.63 - 2.71,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,LIPID PANEL,Cholesterol (High Performance),,4.75,R,L,,,4.86 - 8.28,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,LIPID PANEL,LDL Chol Friedewald 4th,,2.75,,,,,0 - 3.34,mmol/L +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1.01 - 1.03, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 8:45 AM",6227547333,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,C-REACTIVE PROTEIN,C Reactive Protein HS,,8.5,R,H,,,0 - 5,mg/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Alkaline Phosphatase,,61,,,,,35 - 104,U/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,4 - 43,U/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,GGT,,14,,,,,5 - 50,U/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,LDH,,150,,,,,53 - 234,U/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Urea Nitrogen,,4.4,,,,,1.4 - 8.6,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,56,,,,,31 - 101,umol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Glucose Fasting,,5.7,,H,,,3.9 - 5.6,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Serum Uric Acid,,207,,,,,149 - 446,umol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Calcium (EDTA),,2.32,,,,,2.07 - 2.64,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Phosphorus,,0.89,,,,,0.71 - 1.65,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Total Protein,,63,,,,,60 - 80,g/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Creatine Kinase,,78,,,,,26 - 192,U/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Serum Sodium,,142,,,,,135 - 145,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Serum Bicarbonate,,23.4,,,,,19.3 - 29.3,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,CHEMISTRY PANEL,Serum Chloride,,107,,,,,94 - 112,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,149,,,,,115 - 158,g/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.34 - 0.48, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,3.9 - 5.5,TI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,80 - 100,fL +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.75,,,,,3.8 - 10.7,GI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.15,,,,,1.96 - 7.23,GI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.07,,,,,0.8 - 3,GI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.38,,,,,0.12 - 0.92,GI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,72.1,,,,,40.5 - 75,% +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,18.6,,,,,15.4 - 48.5,% +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.7,,,,,2.6 - 10.1,% +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,234,,,,,130 - 394,GI/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.19,,,,,1.9 - 23,uIU/mL +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,LIPID PANEL,Direct HDL-C 4th Generation,,1.30,,,,,1.03 - 1.53,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,LIPID PANEL,Triglycerides (GPO),,0.41,,L,,,0.63 - 2.71,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,LIPID PANEL,Cholesterol (High Performance),,4.53,,L,,,4.86 - 8.28,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,LIPID PANEL,LDL Chol Friedewald 4th,,3.04,,,,,0 - 3.34,mmol/L +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1.01 - 1.03, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 DB Baseline,,"Mar 25, 2026 6:50 AM",6227541251,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.9,,,,,0 - 5,mg/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Alkaline Phosphatase,,78,,,,,35 - 104,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,ALT (SGPT),,29,,,,,4 - 43,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,GGT,,23,,,,,4 - 49,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,LDH,,214,,,,,53 - 234,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,80,,,,,31 - 101,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Glucose Fasting,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Serum Uric Acid,,248,,,,,149 - 446,umol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Phosphorus,,0.93,,,,,0.71 - 1.65,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Total Protein,,64,,,,,61 - 84,g/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Creatine Kinase,,128,,,,,26 - 192,U/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Serum Bicarbonate,,25.8,,,,,19.3 - 29.3,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,138,,,,,116 - 164,g/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,94,,,,,79 - 98,fL +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.44,,,,,3.8 - 10.7,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.15,,,,,1.96 - 7.23,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.79,,,,,0.91 - 4.28,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.33,,,,,0.12 - 0.92,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.9,,,,,40.5 - 75,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.9,,,,,15.4 - 48.5,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.0,,,,,2.6 - 10.1,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.7,,,,,0 - 6.8,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,290,,,,,140 - 400,GI/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.1,,,,,<6.5 %, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.23,,,,,1.9 - 23,uIU/mL +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,LIPID PANEL,Direct HDL-C 4th Generation,,1.67,,H,,,1.03 - 1.53,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,LIPID PANEL,Triglycerides (GPO),,0.88,,,,,0.59 - 2.96,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,LIPID PANEL,Cholesterol (High Performance),,5.28,,,,,4.42 - 7.53,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,LIPID PANEL,LDL Chol Friedewald 4th,,3.21,,,,,0 - 3.34,mmol/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,TSH,TSH 3rd IS-QT,,1.525,,,,,0.45 - 5.33,mIU/L +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1 - 1.04, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur pH,,7.0,,,,,5 - 8, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,End of Phase/Treatment,,"Mar 13, 2026 9:00 AM",6227768459,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.4,,,,,0 - 5,mg/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Total Bilirubin,,14,,,,,3 - 21,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.8,,,,,0 - 6.2,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Alkaline Phosphatase,,81,,,,,35 - 104,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,ALT (SGPT),,25,,,,,4 - 43,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,GGT,,52,,H,,,4 - 49,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,LDH,,153,,,,,53 - 234,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Urea Nitrogen,,3.3,,,,,1.4 - 8.6,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,66,,,,,31 - 101,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Glucose Fasting,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Serum Uric Acid,,273,,,,,125 - 428,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Calcium (EDTA),,2.45,,,,,2.07 - 2.64,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Phosphorus,,1.02,,,,,0.71 - 1.65,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Creatine Kinase,,118,,,,,26 - 192,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Serum Bicarbonate,,23.2,,,,,19.3 - 29.3,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,131,,,,,116 - 164,g/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,,4.1 - 5.6,TI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.38,,,,,3.8 - 10.7,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.04,,,,,1.96 - 7.23,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.60,,,,,0.91 - 4.28,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.49,,,,,0.12 - 0.92,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.23,,,,,0 - 0.57,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,47.6,,,,,40.5 - 75,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,40.7,,,,,15.4 - 48.5,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.6,,,,,2.6 - 10.1,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.6,,,,,0 - 6.8,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,315,,,,,140 - 400,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.2,,,,,<6.5 %, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.83,,,,,1.9 - 23,uIU/mL +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,LIPID PANEL,Direct HDL-C 4th Generation,,1.70,,H,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,LIPID PANEL,Triglycerides (GPO),,2.24,,,,,0.51 - 2.42,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,LIPID PANEL,Cholesterol (High Performance),,5.71,,,,,4.01 - 6.85,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,LIPID PANEL,LDL Chol Friedewald 4th,,2.98,,,,,0 - 3.34,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,RETICULOCYTES,Reticulocyte Count %,,1.9,,,,,0.6 - 2.5,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,TSH,TSH 3rd IS-QT,,4.319,,,,,0.45 - 5.33,mIU/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Specific Gravity,,1.021,,,,,1 - 1.04, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Mar 6, 2026 9:50 AM",6227178911,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.0,,,,,0 - 5,mg/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.2,,,,,0 - 6.2,umol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Alkaline Phosphatase,,130,,H,,,35 - 104,U/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,ALT (SGPT),,10,,,,,4 - 43,U/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,GGT,,13,,,,,5 - 50,U/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Urea Nitrogen,,5.6,,,,,1.4 - 8.6,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 101,umol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Glucose Fasting,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Serum Uric Acid,,232,,,,,149 - 446,umol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Calcium (EDTA),,2.49,,,,,2.07 - 2.64,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Phosphorus,,0.93,,,,,0.71 - 1.65,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Total Protein,,73,,,,,60 - 80,g/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Creatine Kinase,,59,,,,,26 - 192,U/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Serum Sodium,,141,,,,,135 - 145,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Serum Bicarbonate,,25.2,,,,,19.3 - 29.3,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.61,,,,,1.25 - 1.92,mL/sec +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 101,umol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,75.5,,,,,kg, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,FSH,Follicle Stimulating Hormone,,57.83,,,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,GFR,EGFR by MDRD,,83,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,159,R,H,,,115 - 158,g/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.49,R,H,,,0.34 - 0.48, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,3.9 - 5.5,TI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,80 - 100,fL +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.19,,,,,3.8 - 10.7,GI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.31,,,,,1.96 - 7.23,GI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.30,,,,,0.8 - 3,GI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.18,,,,,0 - 0.57,GI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.5,,,,,40.5 - 75,% +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,37.2,,,,,15.4 - 48.5,% +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.5,,,,,2.6 - 10.1,% +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.9,,,,,0 - 6.8,% +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,255,,,,,130 - 394,GI/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.6,,,,,<6.5 %, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.27,,,,,1.9 - 23,uIU/mL +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,LIPID PANEL,Direct HDL-C 4th Generation,,1.70,,H,,,1.03 - 1.53,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,LIPID PANEL,Triglycerides (GPO),,0.84,,,,,0.63 - 2.71,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,LIPID PANEL,Cholesterol (High Performance),,5.60,,,,,4.86 - 8.28,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,LIPID PANEL,LDL Chol Friedewald 4th,,3.52,,H,,,0 - 3.34,mmol/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,RETICULOCYTES,Reticulocyte Count %,,1.0,,,,,0.6 - 2.5,% +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,TSH,TSH 3rd IS-QT,,0.932,,,,,0.45 - 5.33,mIU/L +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1.01 - 1.03, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MACRO PANEL,Ur Leukocyte Esterase,,+1,,H,,,Ref Rng:Negative, +CZ100040008,,,63,years,Female,Part 1 Screening,,"Mar 6, 2026 9:20 AM",6227547331,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CELLULAR ELEMENTS,Ur WBC/HPF,,48,R,H,,,0 - 12,/HPF +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Alkaline Phosphatase,,89,,,,,35 - 104,U/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,ALT (SGPT),,16,,,,,4 - 43,U/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,GGT,,28,,,,,4 - 49,U/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,LDH,,141,,,,,53 - 234,U/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,52,,,,,31 - 101,umol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Glucose Fasting,,6.7,R,H,,,3.9 - 5.6,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Serum Uric Acid,,325,,,,,125 - 428,umol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Calcium (EDTA),,2.52,,,,,2.07 - 2.64,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Phosphorus,,1.23,,,,,0.71 - 1.65,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Creatine Kinase,,205,R,H,,,26 - 192,U/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Serum Bicarbonate,,24.4,,,,,19.3 - 29.3,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,CRYSTALS,Ur Calcium Oxalate Crystals,,Present,,,,,Ref Rng:Not present, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,138,,,,,116 - 164,g/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.95,,,,,3.8 - 10.7,GI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.30,,,,,1.96 - 7.23,GI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.84,R,,,,0.91 - 4.28,GI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.62,,,,,0.12 - 0.92,GI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.3,,,,,40.5 - 75,% +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,38.6,,,,,15.4 - 48.5,% +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.2,,,,,2.6 - 10.1,% +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.4,,,,,0 - 6.8,% +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,486,R,H,,,140 - 400,GI/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,118.97,R,H,,,1.9 - 23,uIU/mL +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,LIPID PANEL,Direct HDL-C 4th Generation,,1.32,,,,,1.03 - 1.53,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,LIPID PANEL,Triglycerides (GPO),,2.60,R,H,,,0.51 - 2.42,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,LIPID PANEL,Cholesterol (High Performance),,5.47,,,,,4.01 - 6.85,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,LIPID PANEL,LDL Chol Friedewald 4th,,2.96,,,,,0 - 3.34,mmol/L +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Specific Gravity,,1.033,R,,,,1 - 1.04, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Protein,,+2,R,H SF,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Ketones,,Trace,R,H,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MACRO PANEL,Ur Leukocyte Esterase,,+3,R,H SF,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 DB Baseline,,"Feb 27, 2026 11:35 AM",6227547332,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,C-REACTIVE PROTEIN,C Reactive Protein HS,,9.0,R,H,,,0 - 5,mg/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CELLULAR ELEMENTS,Ur WBC/HPF,,6,,,,,0 - 12,/HPF +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CELLULAR ELEMENTS,Ur Squamous Epithelial Cells,,38,,,,,0 - 3,/HPF +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Alkaline Phosphatase,,65,,,,,35 - 104,U/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,ALT (SGPT),,16,,,,,4 - 43,U/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,GGT,,16,,,,,5 - 50,U/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,LDH,,183,,,,,53 - 234,U/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Urea Nitrogen,,4.2,,,,,1.4 - 8.6,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Serum Uric Acid,,133,R,L,,,149 - 446,umol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Phosphorus,,0.91,,,,,0.71 - 1.65,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Total Protein,,63,,,,,60 - 80,g/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Creatine Kinase,,87,,,,,26 - 192,U/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Serum Bicarbonate,,22.0,,,,,19.3 - 29.3,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CHEMISTRY PANEL,Serum Chloride,,106,,,,,94 - 112,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.29,,,,,1.25 - 1.92,mL/sec +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,58.2,,,,,kg, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,GFR,EGFR by MDRD,,90,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,148,,,,,115 - 158,g/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.34 - 0.48, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,3.9 - 5.5,TI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,99,,,,,80 - 100,fL +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.46,,,,,3.8 - 10.7,GI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.63,,,,,1.96 - 7.23,GI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.19,,,,,0.8 - 3,GI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.49,,,,,0.12 - 0.92,GI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,66.4,,,,,40.5 - 75,% +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,21.7,,,,,15.4 - 48.5,% +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,9.0,,,,,2.6 - 10.1,% +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,247,,,,,130 - 394,GI/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.4,,,,,<6.5 %, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.23,,,,,1.9 - 23,uIU/mL +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,LIPID PANEL,Direct HDL-C 4th Generation,,1.28,,,,,1.03 - 1.53,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,LIPID PANEL,Triglycerides (GPO),,0.70,,,,,0.63 - 2.71,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,LIPID PANEL,Cholesterol (High Performance),,4.86,,,,,4.86 - 8.28,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,LIPID PANEL,LDL Chol Friedewald 4th,,3.26,,,,,0 - 3.34,mmol/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,MISCELLANEOUS ELEMENTS,Ur Mucous,,Present,,,,,Ref Rng:Not present, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,TSH,TSH 3rd IS-QT,,1.723,,,,,0.45 - 5.33,mIU/L +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1.01 - 1.03, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Protein,,Trace,R,H,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Glucose,,Trace,R,H,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040007,,,66,years,Female,Part 1 Screening,,"Feb 27, 2026 8:00 AM",6227547329,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.1,,,,,0 - 5,mg/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Alkaline Phosphatase,,89,,,,,35 - 104,U/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,ALT (SGPT),,14,,,,,4 - 43,U/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,AST (SGOT),,15,,,,,8 - 40,U/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,GGT,,17,,,,,5 - 50,U/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,LDH,,151,,,,,53 - 234,U/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Urea Nitrogen,,6.7,,,,,1.4 - 10.4,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,70,,,,,31 - 110,umol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Glucose Fasting,,5.7,R,H,,,3.9 - 5.6,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Serum Uric Acid,,312,,,,,149 - 446,umol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Calcium (EDTA),,2.45,,,,,2.07 - 2.64,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Phosphorus,,1.48,,,,,0.71 - 1.65,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Total Protein,,77,,,,,60 - 80,g/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 46,g/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Creatine Kinase,,66,,,,,26 - 192,U/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Serum Bicarbonate,,21.8,,,,,19.3 - 29.3,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,161,R,H,,,115 - 158,g/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.48,,,,,0.34 - 0.48, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.3,,,,,3.9 - 5.5,TI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,80 - 100,fL +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.57,,,,,3.8 - 10.7,GI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.16,,,,,1.96 - 7.23,GI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.42,R,H,,,0.8 - 3,GI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.76,,,,,0.12 - 0.92,GI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.0,,,,,40.5 - 75,% +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,35.8,,,,,15.4 - 48.5,% +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.0,,,,,2.6 - 10.1,% +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,300,,,,,130 - 394,GI/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,7.83,,,,,1.9 - 23,uIU/mL +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,LIPID PANEL,Direct HDL-C 4th Generation,,1.33,,,,,1.03 - 1.53,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,LIPID PANEL,Triglycerides (GPO),,2.03,,,,,0.63 - 2.71,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,LIPID PANEL,Cholesterol (High Performance),,6.94,,,,,5.35 - 9.1,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,LIPID PANEL,LDL Chol Friedewald 4th,,4.68,,H,,,0 - 3.34,mmol/L +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,RETICULOCYTES,Reticulocyte Count %,,1.8,,,,,0.6 - 2.5,% +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Specific Gravity,,1.009,,,,,1.01 - 1.03, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 DB Baseline,,"Feb 20, 2026 10:45 AM",6227541252,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.1,,,,,0 - 5,mg/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CELLULAR ELEMENTS,Ur WBC/HPF,,5,,,,,0 - 12,/HPF +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CELLULAR ELEMENTS,Ur Transitional Epi Cells,,1,,,,,0 /HPF, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Alkaline Phosphatase,,79,,,,,35 - 104,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,ALT (SGPT),,21,,,,,4 - 43,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,GGT,,17,,,,,4 - 49,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,LDH,,205,,,,,53 - 234,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,73,,,,,31 - 101,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Serum Uric Acid,,239,,,,,149 - 446,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Calcium (EDTA),,2.44,,,,,2.07 - 2.64,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Phosphorus,,1.25,,,,,0.71 - 1.65,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Total Protein,,70,,,,,61 - 84,g/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Creatine Kinase,,100,,,,,26 - 192,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Serum Potassium,,4.6,,,,,3.5 - 5.2,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Serum Bicarbonate,,25.3,,,,,19.3 - 29.3,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,116 - 164,g/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.1 - 5.6,TI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,79 - 98,fL +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.66,,,,,3.8 - 10.7,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.75,,,,,1.96 - 7.23,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.38,,,,,0.91 - 4.28,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.9,,,,,40.5 - 75,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.6,,,,,15.4 - 48.5,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.4,,,,,2.6 - 10.1,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.6,,,,,0 - 6.8,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,312,,,,,140 - 400,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.82,,,,,1.9 - 23,uIU/mL +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,LIPID PANEL,Direct HDL-C 4th Generation,,1.68,,H,,,1.03 - 1.53,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,LIPID PANEL,Triglycerides (GPO),,0.71,,,,,0.59 - 2.96,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,LIPID PANEL,Cholesterol (High Performance),,5.23,,,,,4.42 - 7.53,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,LIPID PANEL,LDL Chol Friedewald 4th,,3.22,,,,,0 - 3.34,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Day 29,,"Feb 13, 2026 8:45 AM",6227541259,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.4,,,,,0 - 5,mg/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CELLULAR ELEMENTS,Ur WBC/HPF,,>150,,HT,,,0 - 12,/HPF +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.5,,,,,0 - 6.2,umol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Alkaline Phosphatase,,76,,,,,35 - 104,U/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,ALT (SGPT),,16,,,,,4 - 43,U/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,GGT,,25,,,,,4 - 49,U/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,LDH,,130,,,,,53 - 234,U/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Urea Nitrogen,,5.1,,,,,1.4 - 8.6,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,53,,,,,31 - 101,umol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Serum Uric Acid,,357,,,,,125 - 428,umol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Phosphorus,,1.26,,,,,0.71 - 1.65,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Creatine Kinase,,154,,,,,26 - 192,U/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Serum Bicarbonate,,23.0,,,,,19.3 - 29.3,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.63,,H,,,1.25 - 1.92,mL/sec +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,53,,,,,31 - 101,umol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,87.2,,,,,kg, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,GFR,EGFR by MDRD,,107,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,142,,,,,116 - 164,g/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 98,fL +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,11.22,R,H,,,3.8 - 10.7,GI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.93,,,,,1.96 - 7.23,GI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.51,,,,,0.91 - 4.28,GI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.50,,,,,0.12 - 0.92,GI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.22,,,,,0 - 0.57,GI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.8,,,,,40.5 - 75,% +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,31.3,,,,,15.4 - 48.5,% +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.4,,,,,2.6 - 10.1,% +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.0,,,,,0 - 6.8,% +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,509,R,H,,,140 - 400,GI/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.4,,,,,<6.5 %, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,39.05,,H,,,1.9 - 23,uIU/mL +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,LIPID PANEL,Direct HDL-C 4th Generation,,1.21,,,,,1.03 - 1.53,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,LIPID PANEL,Triglycerides (GPO),,3.23,,H,,,0.51 - 2.42,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,LIPID PANEL,Cholesterol (High Performance),,5.80,,,,,4.01 - 6.85,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,LIPID PANEL,LDL Chol Friedewald 4th,,3.11,,,,,0 - 3.34,mmol/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,RETICULOCYTES,Reticulocyte Count %,,1.9,,,,,0.6 - 2.5,% +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,TSH,TSH 3rd IS-QT,,2.280,,,,,0.45 - 5.33,mIU/L +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MACRO PANEL,Ur Leukocyte Esterase,,+3,,H SF,,,Ref Rng:Negative, +CZ100040006,,,48,years,Female,Part 1 Screening,,"Jan 30, 2026 11:40 AM",6227547330,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,C-REACTIVE PROTEIN,C Reactive Protein HS,,7.3,,H,,,0 - 5,mg/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CELLULAR ELEMENTS,Ur WBC/HPF,,32,,H,,,0 - 12,/HPF +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.9,,,,,0 - 6.2,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Alkaline Phosphatase,,94,,,,,35 - 104,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,ALT (SGPT),,55,,H,,,4 - 43,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,AST (SGOT),,30,,,,,8 - 40,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,GGT,,27,,,,,4 - 49,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,LDH,,175,,,,,53 - 234,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Glucose Fasting,,7.2,,H,,,3.9 - 5.6,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Serum Uric Acid,,263,,,,,149 - 446,umol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Calcium (EDTA),,2.41,,,,,2.07 - 2.64,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Phosphorus,,0.95,,,,,0.71 - 1.65,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Creatine Kinase,,38,,,,,26 - 192,U/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Serum Bicarbonate,,25.0,,,,,19.3 - 29.3,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,159,,,,,116 - 164,g/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.34 - 0.48, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,4.1 - 5.6,TI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.29,,,,,3.8 - 10.7,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.53,,,,,1.96 - 7.23,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.07,,,,,0.91 - 4.28,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.45,,,,,0.12 - 0.92,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,62.2,,,,,40.5 - 75,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,28.5,,,,,15.4 - 48.5,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.2,,,,,2.6 - 10.1,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.1,,,,,0 - 6.8,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.1,,,,,0 - 2,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,296,,,,,140 - 400,GI/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.4,,,,,<6.5 %, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,33.25,,H,,,1.9 - 23,uIU/mL +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,LIPID PANEL,Direct HDL-C 4th Generation,,1.02,,L,,,1.03 - 1.53,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,LIPID PANEL,Triglycerides (GPO),,1.15,,,,,0.59 - 2.96,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,LIPID PANEL,Cholesterol (High Performance),,2.80,,L,,,4.42 - 7.53,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,LIPID PANEL,LDL Chol Friedewald 4th,,1.25,,,,,0 - 3.34,mmol/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,TSH,TSH 3rd IS-QT,,0.595,,,,,0.45 - 5.33,mIU/L +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Specific Gravity,,1.015,,,,,1 - 1.04, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MACRO PANEL,Ur Leukocyte Esterase,,+3,,H SF,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,End of Phase/Treatment,,"Jan 30, 2026 9:30 AM",6227178909,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.8,,,,,0 - 5,mg/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CELLULAR ELEMENTS,Ur RBC/HPF,,1,,,,,0 - 8,/HPF +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CELLULAR ELEMENTS,Ur WBC/HPF,,2,,,,,0 - 12,/HPF +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.5,,,,,0 - 6.2,umol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Alkaline Phosphatase,,87,,,,,35 - 104,U/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,ALT (SGPT),,14,,,,,4 - 43,U/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,GGT,,15,,,,,5 - 50,U/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,LDH,,150,,,,,53 - 234,U/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Urea Nitrogen,,5.0,,,,,1.4 - 10.4,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 110,umol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Glucose Fasting,,7.0,,H,,,3.9 - 5.6,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Serum Uric Acid,,320,,,,,149 - 446,umol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Phosphorus,,1.31,,,,,0.71 - 1.65,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Total Protein,,78,,,,,60 - 80,g/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 46,g/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Creatine Kinase,,87,,,,,26 - 192,U/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Serum Bicarbonate,,23.1,,,,,19.3 - 29.3,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.29,,,,,1.25 - 1.92,mL/sec +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 110,umol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,68.5,,,,,kg, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,CRYSTALS,Ur Calcium Oxalate Crystals,,Present,,,,,Ref Rng:Not present, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,FSH,Follicle Stimulating Hormone,,78.10,,,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,GFR,EGFR by MDRD,,81,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,165,,H,,,115 - 158,g/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.48,,,,,0.34 - 0.48, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.3,,,,,3.9 - 5.5,TI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,80 - 100,fL +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,10.07,,,,,3.8 - 10.7,GI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.15,,,,,1.96 - 7.23,GI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.08,,H,,,0.8 - 3,GI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.65,,,,,0.12 - 0.92,GI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.0,,,,,40.5 - 75,% +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.6,,,,,15.4 - 48.5,% +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.5,,,,,2.6 - 10.1,% +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.4,,,,,0 - 6.8,% +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,269,,,,,130 - 394,GI/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.9,,,,,<6.5 %, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,47.53,,H,,,1.9 - 23,uIU/mL +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,LIPID PANEL,Direct HDL-C 4th Generation,,1.28,,,,,1.03 - 1.53,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,LIPID PANEL,Triglycerides (GPO),,1.84,,,,,0.63 - 2.71,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,LIPID PANEL,Cholesterol (High Performance),,6.82,,,,,5.35 - 9.1,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,LIPID PANEL,LDL Chol Friedewald 4th,,4.70,,H,,,0 - 3.34,mmol/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,TSH,TSH 3rd IS-QT,,1.806,,,,,0.45 - 5.33,mIU/L +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Specific Gravity,,1.025,,,,,1.01 - 1.03, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Blood,,Trace,,,,,Ref Rng:$Negative-Trace, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040005,,,72,years,Female,Part 1 Screening,,"Jan 27, 2026 9:00 AM",6227541249,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.0,,,,,0 - 5,mg/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CELLULAR ELEMENTS,Ur WBC/HPF,,27,,H,,,0 - 12,/HPF +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.7,,,,,0 - 6.2,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Alkaline Phosphatase,,84,,,,,35 - 104,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,ALT (SGPT),,53,,H,,,4 - 43,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,AST (SGOT),,26,,,,,8 - 40,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,GGT,,26,,,,,4 - 49,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,LDH,,172,,,,,53 - 234,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Glucose Fasting,,6.8,,H,,,3.9 - 5.6,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Serum Uric Acid,,279,,,,,149 - 446,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Phosphorus,,1.21,,,,,0.71 - 1.65,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Creatine Kinase,,45,,,,,26 - 192,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Serum Bicarbonate,,25.1,,,,,19.3 - 29.3,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,CRYSTALS,Ur Calcium Oxalate Crystals,,Present,,,,,Ref Rng:Not present, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,116 - 164,g/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.34 - 0.48, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.1 - 5.6,TI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 98,fL +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.45,,,,,3.8 - 10.7,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.94,,,,,1.96 - 7.23,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.68,,,,,0.91 - 4.28,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.51,,,,,0.12 - 0.92,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.24,,,,,0 - 0.57,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.4,,,,,40.5 - 75,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,31.7,,,,,15.4 - 48.5,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.0,,,,,2.6 - 10.1,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.9,,,,,0 - 6.8,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,302,,,,,140 - 400,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,13.07,,,,,1.9 - 23,uIU/mL +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,LIPID PANEL,Direct HDL-C 4th Generation,,0.98,,L,,,1.03 - 1.53,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,LIPID PANEL,Triglycerides (GPO),,0.95,,,,,0.59 - 2.96,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,LIPID PANEL,Cholesterol (High Performance),,2.57,,L,,Result verified by repeat analysis,4.42 - 7.53,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,LIPID PANEL,LDL Chol Friedewald 4th,,1.15,,,,,0 - 3.34,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,RETICULOCYTES,Reticulocyte Count %,,2.1,,,,,0.6 - 2.5,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MACRO PANEL,Ur Leukocyte Esterase,,+3,,H SF,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Day 29,,"Jan 16, 2026 10:40 AM",6227541260,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.9,,,,,0 - 5,mg/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CELLULAR ELEMENTS,Ur WBC/HPF,,5,,,,,0 - 12,/HPF +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CELLULAR ELEMENTS,Ur Transitional Epi Cells,,1,,,,,0 /HPF, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Alkaline Phosphatase,,71,,,,,35 - 104,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,GGT,,18,,,,,4 - 49,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,LDH,,203,,,,,53 - 234,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Urea Nitrogen,,3.2,,,,,1.4 - 8.6,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,70,,,,,31 - 101,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Serum Uric Acid,,221,,,,,149 - 446,umol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Phosphorus,,1.12,,,,,0.71 - 1.65,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Total Protein,,64,,,,,61 - 84,g/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Creatine Kinase,,96,,,,,26 - 192,U/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Serum Bicarbonate,,27.1,,,,,19.3 - 29.3,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,134,,,,,116 - 164,g/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,4.1 - 5.6,TI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,79 - 98,fL +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.16,,,,,3.8 - 10.7,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.30,,,,,1.96 - 7.23,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.50,,,,,0.91 - 4.28,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.23,,,,,0.12 - 0.92,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.01,,,,,0 - 0.2,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.2,,,,,40.5 - 75,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.0,,,,,15.4 - 48.5,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.5,,,,,2.6 - 10.1,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.0,,,,,0 - 6.8,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,272,,,,,140 - 400,GI/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.3,,,,,<6.5 %, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.94,,,,,1.9 - 23,uIU/mL +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,LIPID PANEL,Direct HDL-C 4th Generation,,1.49,,,,,1.03 - 1.53,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,LIPID PANEL,Triglycerides (GPO),,0.80,,,,,0.59 - 2.96,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,LIPID PANEL,Cholesterol (High Performance),,4.76,,,,,4.42 - 7.53,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,LIPID PANEL,LDL Chol Friedewald 4th,,2.90,,,,,0 - 3.34,mmol/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,TSH,TSH 3rd IS-QT,,1.175,,,,,0.45 - 5.33,mIU/L +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Specific Gravity,,1.016,,,,,1 - 1.04, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur pH,,7.0,,,,,5 - 8, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MACRO PANEL,Ur Leukocyte Esterase,,+1,,H,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 2 OL Induction Baseline,,"Jan 16, 2026 7:55 AM",6227541257,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.8,,,,,0 - 5,mg/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Total Bilirubin,,4,,,,Result verified by repeat analysis,3 - 21,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.5,,,,,0 - 6.2,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Alkaline Phosphatase,,78,,,,,35 - 104,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,ALT (SGPT),,40,,,,,4 - 43,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,AST (SGOT),,33,,,,,8 - 40,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,GGT,,49,,,,,4 - 49,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,LDH,,151,,,,,53 - 234,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Urea Nitrogen,,3.6,,,,,1.4 - 8.6,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 101,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Serum Uric Acid,,300,,,,,125 - 428,umol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Calcium (EDTA),,2.31,,,,,2.07 - 2.64,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Phosphorus,,1.35,,,,,0.71 - 1.65,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Creatine Kinase,,102,,,,,26 - 192,U/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Serum Bicarbonate,,25.0,,,,,19.3 - 29.3,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,126,,,,,116 - 164,g/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,,,,0.34 - 0.48, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.9,,L,,,4.1 - 5.6,TI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.94,,,,,3.8 - 10.7,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.95,,,,,1.96 - 7.23,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.05,,,,,0.91 - 4.28,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.61,,,,,0.12 - 0.92,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.29,,,,,0 - 0.57,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,42.5,,,,,40.5 - 75,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,43.9,,,,,15.4 - 48.5,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.7,,,,,2.6 - 10.1,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.2,,,,,0 - 6.8,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,341,,,,,140 - 400,GI/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.3,,,,,<6.5 %, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.23,,,,,1.9 - 23,uIU/mL +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,LIPID PANEL,Direct HDL-C 4th Generation,,1.37,,,,,1.03 - 1.53,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,LIPID PANEL,Triglycerides (GPO),,1.49,,,,,0.51 - 2.42,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,LIPID PANEL,Cholesterol (High Performance),,4.70,,,,,4.01 - 6.85,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,LIPID PANEL,LDL Chol Friedewald 4th,,2.65,,,,,0 - 3.34,mmol/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,RETICULOCYTES,Reticulocyte Count %,,2.7,,H,,,0.6 - 2.5,% +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,TSH,TSH 3rd IS-QT,,3.282,,,,,0.45 - 5.33,mIU/L +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Specific Gravity,,1.009,,,,,1 - 1.04, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,End of Phase/Treatment,,"Jan 9, 2026 10:20 AM",6227178908,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.5,,,,,0 - 5,mg/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.2,,,,,0 - 6.2,umol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Alkaline Phosphatase,,99,,,,,35 - 104,U/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,ALT (SGPT),,30,,,,,4 - 43,U/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,AST (SGOT),,30,,,,,8 - 40,U/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,GGT,,18,,,,,4 - 49,U/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,LDH,,205,,,,,53 - 234,U/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Urea Nitrogen,,4.2,,,,,1.4 - 8.6,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,31 - 101,umol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Serum Uric Acid,,323,,,,,149 - 446,umol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Calcium (EDTA),,2.27,,,,,2.07 - 2.64,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Creatine Kinase,,161,,,,,26 - 192,U/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Serum Potassium,,3.7,,,,,3.5 - 5.2,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Serum Bicarbonate,,24.3,,,,,19.3 - 29.3,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,144,,,,,116 - 164,g/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.1 - 5.6,TI/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 98,fL +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.41,,,,,3.8 - 10.7,GI/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.46,,,,,1.96 - 7.23,GI/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.53,,,,,0.91 - 4.28,GI/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.25,,,,,0.12 - 0.92,GI/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.7,,,,,40.5 - 75,% +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,34.8,,,,,15.4 - 48.5,% +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.3,,,,,0 - 6.8,% +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Platelet clumps present,,, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.7,,,,,<6.5 %, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,8.57,,,,,1.9 - 23,uIU/mL +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,LIPID PANEL,Direct HDL-C 4th Generation,,1.14,,,,,1.03 - 1.53,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,LIPID PANEL,Triglycerides (GPO),,1.23,,,,,0.59 - 2.96,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,LIPID PANEL,Cholesterol (High Performance),,6.67,,,,,4.42 - 7.53,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,LIPID PANEL,LDL Chol Friedewald 4th,,4.97,,H,,,0 - 3.34,mmol/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,RETICULOCYTES,Reticulocyte Count %,,1.5,,,,,0.6 - 2.5,% +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,TSH,TSH 3rd IS-QT,,2.238,,,,,0.45 - 5.33,mIU/L +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1 - 1.04, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,End of Phase/Treatment,,"Jan 9, 2026 9:10 AM",6227178912,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.3,,,,,0 - 5,mg/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CELLULAR ELEMENTS,Ur WBC/HPF,,9,,,,,0 - 12,/HPF +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Total Bilirubin,,14,,,,,3 - 21,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.8,,,,,0 - 6.2,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Alkaline Phosphatase,,94,,,,,35 - 104,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,ALT (SGPT),,50,,H,,,4 - 43,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,AST (SGOT),,27,,,,,8 - 40,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,GGT,,24,,,,,4 - 49,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,LDH,,167,,,,,53 - 234,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Glucose Fasting,,6.3,,H,,,3.9 - 5.6,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Serum Uric Acid,,274,,,,,149 - 446,umol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Phosphorus,,1.21,,,,,0.71 - 1.65,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Creatine Kinase,,45,,,,,26 - 192,U/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Serum Potassium,,5.0,,,,,3.5 - 5.2,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Serum Bicarbonate,,25.7,,,,,19.3 - 29.3,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,116 - 164,g/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.34 - 0.48, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4.1 - 5.6,TI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.24,,,,,3.8 - 10.7,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.24,,,,,1.96 - 7.23,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.33,,,,,0.91 - 4.28,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.45,,,,,0.12 - 0.92,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.6,,,,,40.5 - 75,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,28.3,,,,,15.4 - 48.5,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,330,,,,,140 - 400,GI/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.1,,,,,<6.5 %, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,14.65,,,,,1.9 - 23,uIU/mL +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,LIPID PANEL,Direct HDL-C 4th Generation,,1.03,,,,,1.03 - 1.53,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,LIPID PANEL,Triglycerides (GPO),,1.18,,,,,0.59 - 2.96,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,LIPID PANEL,Cholesterol (High Performance),,2.69,,L,,,4.42 - 7.53,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,LIPID PANEL,LDL Chol Friedewald 4th,,1.12,,,,,0 - 3.34,mmol/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,RETICULOCYTES,Reticulocyte Count %,,2.1,,,,,0.6 - 2.5,% +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,TSH,TSH 3rd IS-QT,,1.264,,,,,0.45 - 5.33,mIU/L +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Specific Gravity,,1.021,,,,,1 - 1.04, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MACRO PANEL,Ur Leukocyte Esterase,,+3,,H SF,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 2 OL Induction Baseline,,"Dec 19, 2025 9:25 AM",6227106906,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.8,,,,,0 - 5,mg/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CELLULAR ELEMENTS,Ur WBC/HPF,,2,,,,,0 - 12,/HPF +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,35 - 104,U/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,4 - 43,U/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,GGT,,22,,,,,4 - 49,U/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,LDH,,199,,,,,53 - 234,U/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Urea Nitrogen,,3.6,,,,,1.4 - 8.6,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,69,,,,,31 - 101,umol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Serum Uric Acid,,242,,,,,149 - 446,umol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Calcium (EDTA),,2.44,,,,,2.07 - 2.64,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Phosphorus,,1.18,,,,,0.71 - 1.65,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Total Protein,,70,,,,,61 - 84,g/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Creatine Kinase,,113,,,,,26 - 192,U/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Serum Bicarbonate,,29.7,,H,,,19.3 - 29.3,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,136,,,,,116 - 164,g/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,79 - 98,fL +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.80,,,,,3.8 - 10.7,GI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.73,,,,,1.96 - 7.23,GI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.58,,,,,0.91 - 4.28,GI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.36,,,,,0.12 - 0.92,GI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,56.9,,,,,40.5 - 75,% +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.9,,,,,15.4 - 48.5,% +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.6,,,,,2.6 - 10.1,% +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,308,,,,,140 - 400,GI/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,1.74,,L,,,1.9 - 23,uIU/mL +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,LIPID PANEL,Direct HDL-C 4th Generation,,1.50,,,,,1.03 - 1.53,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,LIPID PANEL,Triglycerides (GPO),,0.88,,,,,0.59 - 2.96,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,LIPID PANEL,Cholesterol (High Performance),,5.66,,,,,4.42 - 7.53,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,LIPID PANEL,LDL Chol Friedewald 4th,,3.76,,H,,,0 - 3.34,mmol/L +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Specific Gravity,,1.016,,,,,1 - 1.04, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur pH,,7.5,,,,,5 - 8, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 DB Baseline,,"Dec 5, 2025 7:55 AM",6227261230,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.0,,,,,0 - 5,mg/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Alkaline Phosphatase,,72,,,,,35 - 104,U/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,ALT (SGPT),,19,,,,,4 - 43,U/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,GGT,,45,,,,,4 - 49,U/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,LDH,,135,,,,,53 - 234,U/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Urea Nitrogen,,4.2,,,,,1.4 - 8.6,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,59,,,,,31 - 101,umol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Serum Uric Acid,,277,,,,,125 - 428,umol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Creatine Kinase,,94,,,,,26 - 192,U/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Serum Bicarbonate,,23.2,,,,,19.3 - 29.3,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,125,,,,,116 - 164,g/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,,,,0.34 - 0.48, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,R,L,,,4.1 - 5.6,TI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.92,,,,,3.8 - 10.7,GI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.08,,,,,1.96 - 7.23,GI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.93,,,,,0.91 - 4.28,GI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.56,,,,,0.12 - 0.92,GI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.31,,,,,0 - 0.57,GI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,44.5,,,,,40.5 - 75,% +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,42.3,,,,,15.4 - 48.5,% +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.1,,,,,2.6 - 10.1,% +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.4,,,,,0 - 6.8,% +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,304,,,,,140 - 400,GI/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,7.03,,,,,1.9 - 23,uIU/mL +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,LIPID PANEL,Direct HDL-C 4th Generation,,1.36,,,,,1.03 - 1.53,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,LIPID PANEL,Triglycerides (GPO),,2.05,,,,,0.51 - 2.42,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,LIPID PANEL,Cholesterol (High Performance),,5.46,,,,,4.01 - 6.85,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,LIPID PANEL,LDL Chol Friedewald 4th,,3.16,,,,,0 - 3.34,mmol/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,RETICULOCYTES,Reticulocyte Count %,,1.8,,,,,0.6 - 2.5,% +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,TSH,TSH 3rd IS-QT,,1.135,,,,,0.45 - 5.33,mIU/L +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 2 OL Induction Baseline,,"Nov 28, 2025 9:00 AM",6227106905,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.7,,,,,0 - 5,mg/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.8,,,,,0 - 6.2,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Alkaline Phosphatase,,100,,,,,35 - 104,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,ALT (SGPT),,29,,,,,4 - 43,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,AST (SGOT),,33,,,,,8 - 40,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,GGT,,17,,,,,4 - 49,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,LDH,,257,,H,,,53 - 234,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Urea Nitrogen,,5.1,,,,,1.4 - 8.6,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Serum Uric Acid,,318,,,,,149 - 446,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Creatine Kinase,,276,,H,,,26 - 192,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Serum Bicarbonate,,24.3,,,,,19.3 - 29.3,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,116 - 164,g/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.1 - 5.6,TI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 98,fL +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.48,,,,,3.8 - 10.7,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.40,,,,,1.96 - 7.23,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.48,,,,,0.91 - 4.28,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.49,,,,,0.12 - 0.92,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.01,,,,,0 - 0.2,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.5,,,,,40.5 - 75,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,33.1,,,,,15.4 - 48.5,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.9,R,H,,,2.6 - 10.1,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.3,,,,,0 - 6.8,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.2,,,,,0 - 2,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,143,,,,,140 - 400,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.90,,,,,1.9 - 23,uIU/mL +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,LIPID PANEL,Direct HDL-C 4th Generation,,1.12,,,,,1.03 - 1.53,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,LIPID PANEL,Triglycerides (GPO),,1.26,,,,,0.59 - 2.96,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,LIPID PANEL,Cholesterol (High Performance),,5.71,,,,,4.42 - 7.53,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,LIPID PANEL,LDL Chol Friedewald 4th,,4.01,,H,,,0 - 3.34,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,RETICULOCYTES,Reticulocyte Count %,,1.8,,,,,0.6 - 2.5,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Specific Gravity,,1.020,,,,,1 - 1.04, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Day 29,,"Nov 14, 2025 9:10 AM",6227043302,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.7,,,,,0 - 5,mg/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CELLULAR ELEMENTS,Ur WBC/HPF,,10,,,,,0 - 12,/HPF +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Total Bilirubin,,14,,,,,3 - 21,umol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,5.2,,,,,0 - 6.2,umol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Alkaline Phosphatase,,91,,,,,35 - 104,U/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,ALT (SGPT),,49,,H,,,4 - 43,U/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,AST (SGOT),,31,,,,,8 - 40,U/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,GGT,,22,,,,,4 - 49,U/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,LDH,,176,,,,,53 - 234,U/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Urea Nitrogen,,5.0,,,,,1.4 - 8.6,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Glucose Fasting,,6.8,,H,,,3.9 - 5.6,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Serum Uric Acid,,282,,,,,149 - 446,umol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Calcium (EDTA),,2.46,,,,,2.07 - 2.64,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Phosphorus,,1.34,,,,,0.71 - 1.65,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Creatine Kinase,,51,,,,,26 - 192,U/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Serum Potassium,,5.1,,,,,3.5 - 5.2,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Serum Bicarbonate,,22.7,,,,,19.3 - 29.3,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,147,,,,,116 - 164,g/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.34 - 0.48, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.1 - 5.6,TI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.87,,,,,3.8 - 10.7,GI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.64,,,,,1.96 - 7.23,GI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.53,,,,,0.91 - 4.28,GI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.42,,,,,0.12 - 0.92,GI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.20,,,,,0 - 0.57,GI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.9,,,,,40.5 - 75,% +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.3,,,,,15.4 - 48.5,% +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.5,,,,,0 - 6.8,% +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,294,,,,,140 - 400,GI/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,12.54,,,,,1.9 - 23,uIU/mL +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,LIPID PANEL,Direct HDL-C 4th Generation,,0.96,,L,,,1.03 - 1.53,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,LIPID PANEL,Triglycerides (GPO),,0.90,,,,,0.59 - 2.96,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,LIPID PANEL,Cholesterol (High Performance),,2.39,,L,,Result verified by repeat analysis,4.42 - 7.53,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,LIPID PANEL,LDL Chol Friedewald 4th,,1.02,,,,,0 - 3.34,mmol/L +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1 - 1.04, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MACRO PANEL,Ur Leukocyte Esterase,,+2,,H SF,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 DB Baseline,,"Nov 7, 2025 9:30 AM",6225350982,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CELLULAR ELEMENTS,Ur RBC/HPF,,1,,,,,0 - 8,/HPF +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CELLULAR ELEMENTS,Ur WBC/HPF,,7,,,,,0 - 12,/HPF +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Alkaline Phosphatase,,84,,,,,35 - 104,U/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,GGT,,21,,,,,4 - 49,U/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,LDH,,206,,,,,53 - 234,U/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,78,,,,,31 - 101,umol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Glucose Fasting,,5.5,,,,,3.9 - 5.6,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Serum Uric Acid,,260,,,,,149 - 446,umol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Calcium (EDTA),,2.42,,,,,2.07 - 2.64,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Phosphorus,,1.17,,,,,0.71 - 1.65,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Creatine Kinase,,107,,,,,26 - 192,U/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Serum Bicarbonate,,22.4,,,,,19.3 - 29.3,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.58,,,,,1.25 - 1.92,mL/sec +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,78,,,,,31 - 101,umol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,81.6,,,,,kg, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,GFR,EGFR by MDRD,,67,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,136,,,,,116 - 164,g/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,79 - 98,fL +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.09,,,,,3.8 - 10.7,GI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.99,,,,,1.96 - 7.23,GI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.48,,,,,0.91 - 4.28,GI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.12,,,,,0 - 0.2,GI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.8,,,,,40.5 - 75,% +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.2,,,,,15.4 - 48.5,% +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.7,,,,,2.6 - 10.1,% +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.0,,,,,0 - 6.8,% +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.3,,H,,,0 - 2,% +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,313,,,,,140 - 400,GI/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.1,,,,,<6.5%, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.19,,,,,1.9 - 23,uIU/mL +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,LIPID PANEL,Direct HDL-C 4th Generation,,1.52,,,,,1.03 - 1.53,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,LIPID PANEL,Triglycerides (GPO),,1.01,,,,,0.59 - 2.96,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,LIPID PANEL,Cholesterol (High Performance),,5.29,,,,,4.42 - 7.53,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,LIPID PANEL,LDL Chol Friedewald 4th,,3.31,,,,,0 - 3.34,mmol/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,TSH,TSH 3rd IS-QT,,1.461,,,,,0.45 - 5.33,mIU/L +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Protein,,Trace,R,H,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040004,,,54,years,Female,Part 1 Screening,,"Nov 7, 2025 8:10 AM",6225350975,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.5,,,,,0 - 5,mg/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.7,,,,,0 - 6.2,umol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Alkaline Phosphatase,,77,,,,,35 - 104,U/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,ALT (SGPT),,27,,,,,4 - 43,U/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,GGT,,45,,,,,4 - 49,U/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,LDH,,161,,,,,53 - 234,U/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Urea Nitrogen,,3.5,,,,,1.4 - 8.6,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 101,umol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Serum Uric Acid,,261,,,,,125 - 428,umol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Phosphorus,,1.12,,,,,0.71 - 1.65,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Creatine Kinase,,99,,,,,26 - 192,U/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Serum Bicarbonate,,21.9,,,,,19.3 - 29.3,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,126,,,,,116 - 164,g/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,,4.1 - 5.6,TI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 98,fL +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.55,,,,,3.8 - 10.7,GI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.59,,,,,1.96 - 7.23,GI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.09,,,,,0.91 - 4.28,GI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.63,,,,,0.12 - 0.92,GI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.20,,,,,0 - 0.57,GI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,60.9,,,,,40.5 - 75,% +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.7,,,,,15.4 - 48.5,% +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.3,,,,,2.6 - 10.1,% +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.6,,,,,0 - 6.8,% +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,324,,,,,140 - 400,GI/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.08,,,,,1.9 - 23,uIU/mL +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,LIPID PANEL,Direct HDL-C 4th Generation,,1.54,,H,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,LIPID PANEL,Triglycerides (GPO),,2.08,,,,,0.51 - 2.42,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,LIPID PANEL,Cholesterol (High Performance),,5.37,,,,,4.01 - 6.85,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,LIPID PANEL,LDL Chol Friedewald 4th,,2.88,,,,,0 - 3.34,mmol/L +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,RETICULOCYTES,Reticulocyte Count %,,2.1,,,,,0.6 - 2.5,% +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1 - 1.04, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 DB Baseline,,"Oct 17, 2025 10:45 AM",6225350984,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.5,,,,,0 - 5,mg/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CELLULAR ELEMENTS,Ur WBC/HPF,,5,,,,,0 - 12,/HPF +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.0,,,,,0 - 6.2,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Alkaline Phosphatase,,99,,,,,35 - 104,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,ALT (SGPT),,32,,,,,4 - 43,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,AST (SGOT),,32,,,,,8 - 40,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,GGT,,18,,,,,4 - 49,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,LDH,,232,,,,,53 - 234,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Urea Nitrogen,,4.7,,,,,1.4 - 8.6,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,31 - 101,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Glucose Fasting,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Serum Uric Acid,,392,,,,,149 - 446,umol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Creatine Kinase,,160,,,,,26 - 192,U/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Serum Bicarbonate,,23.1,,,,,19.3 - 29.3,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,143,,,,,116 - 164,g/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 98,fL +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.39,,,,,3.8 - 10.7,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.58,,,,,1.96 - 7.23,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.36,,,,,0.91 - 4.28,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.31,,,,,0.12 - 0.92,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.8,,,,,40.5 - 75,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.9,,,,,15.4 - 48.5,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.1,,,,,2.6 - 10.1,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.9,,,,,0 - 6.8,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Platelet clumps present,,, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.8,,,,,<6.5%, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,LIPID PANEL,Direct HDL-C 4th Generation,,1.11,,,,,1.03 - 1.53,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,LIPID PANEL,Triglycerides (GPO),,1.60,,,,,0.59 - 2.96,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,LIPID PANEL,Cholesterol (High Performance),,6.83,,,,,4.42 - 7.53,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,LIPID PANEL,LDL Chol Friedewald 4th,,4.99,,H,,,0 - 3.34,mmol/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,RETICULOCYTES,Reticulocyte Count %,,1.7,,,,,0.6 - 2.5,% +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,TSH,TSH 3rd IS-QT,,2.025,,,,,0.45 - 5.33,mIU/L +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Specific Gravity,,1.018,,,,,1 - 1.04, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur pH,,7.0,,,,,5 - 8, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,R,H,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 2 OL Induction Baseline,,"Oct 17, 2025 9:00 AM",6225350988,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.9,,,,,0 - 5,mg/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CELLULAR ELEMENTS,Ur WBC/HPF,,42,,H,,,0 - 12,/HPF +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.7,,,,,0 - 6.2,umol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Alkaline Phosphatase,,83,,,,,35 - 104,U/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,ALT (SGPT),,69,,H RX,,,4 - 43,U/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,AST (SGOT),,40,,,,,8 - 40,U/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,GGT,,27,,,,,4 - 49,U/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,LDH,,190,,,,,53 - 234,U/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Urea Nitrogen,,3.8,,,,,1.4 - 8.6,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Glucose Fasting,,7.5,,H,,,3.9 - 5.6,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Serum Uric Acid,,309,,,,,149 - 446,umol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Phosphorus,,1.28,,,,,0.71 - 1.65,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Creatine Kinase,,48,,,,,26 - 192,U/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Serum Bicarbonate,,24.7,,,,,19.3 - 29.3,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.65,,,,,1.25 - 1.92,mL/sec +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,79.2,,,,,kg, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,GFR,EGFR by MDRD,,74,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,151,,,,,116 - 164,g/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.34 - 0.48, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.1 - 5.6,TI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.69,,,,,3.8 - 10.7,GI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.48,,,,,1.96 - 7.23,GI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.44,,,,,0.91 - 4.28,GI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.48,,,,,0.12 - 0.92,GI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.23,,,,,0 - 0.57,GI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,66.8,,,,,40.5 - 75,% +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,25.1,,,,,15.4 - 48.5,% +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.9,,,,,2.6 - 10.1,% +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.3,,,,,0 - 6.8,% +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,324,,,,,140 - 400,GI/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,6.6,,H,,,<6.5%, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,13.86,,,,,1.9 - 23,uIU/mL +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,LIPID PANEL,Direct HDL-C 4th Generation,,0.89,,L,,,1.03 - 1.53,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,LIPID PANEL,Triglycerides (GPO),,1.13,,,,,0.59 - 2.96,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,LIPID PANEL,Cholesterol (High Performance),,2.44,,L,,Result verified by repeat analysis,4.42 - 7.53,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,LIPID PANEL,LDL Chol Friedewald 4th,,1.03,,,,,0 - 3.34,mmol/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,MISCELLANEOUS ELEMENTS,Ur Mucous,,Present,,,,,Ref Rng:Not present, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,RETICULOCYTES,Reticulocyte Count %,,2.0,,,,,0.6 - 2.5,% +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,TSH,TSH 3rd IS-QT,,1.524,,,,,0.45 - 5.33,mIU/L +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MACRO PANEL,Ur Leukocyte Esterase,,+3,,H SF,,,Ref Rng:Negative, +CZ100040003,,,55,years,Female,Part 1 Screening,,"Oct 10, 2025 9:20 AM",6225350977,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.1,,,,,0 - 5,mg/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Alkaline Phosphatase,,82,,,,,35 - 104,U/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,4 - 43,U/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,GGT,,47,,,,,4 - 49,U/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,LDH,,153,,,,,53 - 234,U/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 8.6,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,69,,,,,31 - 101,umol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Serum Uric Acid,,322,,,,,125 - 428,umol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Calcium (EDTA),,2.47,,,,,2.07 - 2.64,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Total Protein,,79,,,,,61 - 84,g/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Creatine Kinase,,104,,,,,26 - 192,U/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Serum Bicarbonate,,22.9,,,,,19.3 - 29.3,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.88,,,,,1.25 - 1.92,mL/sec +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,69,,,,,31 - 101,umol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,78.6,,,,,kg, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,Result verified by repeat analysis,Neg;$Cutoff = 50 ng/mL, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,GFR,EGFR by MDRD,,80,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,116 - 164,g/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.34 - 0.48, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,4.1 - 5.6,TI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,106,,H,,,79 - 98,fL +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.54,,,,,3.8 - 10.7,GI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.33,,,,,1.96 - 7.23,GI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.64,,,,,0.91 - 4.28,GI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.36,,,,,0.12 - 0.92,GI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,42.0,,,,,40.5 - 75,% +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,47.6,,,,,15.4 - 48.5,% +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.5,,,,,2.6 - 10.1,% +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.7,,,,,0 - 6.8,% +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.2,,,,,0 - 2,% +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,301,,,,,140 - 400,GI/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.3,,,,,<6.5%, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.36,,,,,1.9 - 23,uIU/mL +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,LIPID PANEL,Direct HDL-C 4th Generation,,1.94,,H,,,1.03 - 1.53,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,LIPID PANEL,Triglycerides (GPO),,1.55,,,,,0.51 - 2.42,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,LIPID PANEL,Cholesterol (High Performance),,6.28,,,,,4.01 - 6.85,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,LIPID PANEL,LDL Chol Friedewald 4th,,3.63,,H,,,0 - 3.34,mmol/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,TSH,TSH 3rd IS-QT,,1.391,,,,,0.45 - 5.33,mIU/L +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Specific Gravity,,1.018,,,,,1 - 1.04, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040002,,,46,years,Female,Part 1 Screening,,"Sep 19, 2025 9:20 AM",6225350972,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.1,,,,,0 - 5,mg/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Alkaline Phosphatase,,104,,,,,35 - 104,U/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,ALT (SGPT),,30,,,,,4 - 43,U/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,AST (SGOT),,27,,,,,8 - 40,U/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,GGT,,20,,,,,4 - 49,U/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,LDH,,224,,,,,53 - 234,U/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Serum Uric Acid,,358,,,,,149 - 446,umol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Phosphorus,,1.33,,,,,0.71 - 1.65,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Creatine Kinase,,159,,,,,26 - 192,U/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Serum Bicarbonate,,23.6,,,,,19.3 - 29.3,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,135,,,,,116 - 164,g/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.75,,,,,3.8 - 10.7,GI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.17,,,,,1.96 - 7.23,GI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.12,,,,,0.91 - 4.28,GI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,45.7,,,,,40.5 - 75,% +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,44.7,,,,,15.4 - 48.5,% +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.1,,,,,2.6 - 10.1,% +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.1,,,,,0 - 6.8,% +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.4,,,,,0 - 2,% +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,157,,,,,140 - 400,GI/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,11.38,,,,,1.9 - 23,uIU/mL +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,LIPID PANEL,Direct HDL-C 4th Generation,,1.10,,,,,1.03 - 1.53,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,LIPID PANEL,Triglycerides (GPO),,1.77,,,,,0.59 - 2.96,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,LIPID PANEL,Cholesterol (High Performance),,6.54,,,,,4.42 - 7.53,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,LIPID PANEL,LDL Chol Friedewald 4th,,4.63,,H,,,0 - 3.34,mmol/L +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,RETICULOCYTES,Reticulocyte Count %,,3.5,,H,,,0.6 - 2.5,% +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Specific Gravity,,1.015,,,,,1 - 1.04, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 DB Baseline,,"Sep 5, 2025 7:55 AM",6225350981,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Retest,,"Aug 19, 2025 10:00 AM",6225351002,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100040001,,,56,years,Female,Retest,,"Aug 19, 2025 10:00 AM",6225351002,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.7,,,,,0 - 5,mg/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CELLULAR ELEMENTS,Ur WBC/HPF,,10,,,,,0 - 12,/HPF +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Alkaline Phosphatase,,106,,H,,,35 - 104,U/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,ALT (SGPT),,28,,,,,4 - 43,U/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,AST (SGOT),,26,,,,,8 - 40,U/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,GGT,,19,,,,,4 - 49,U/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,LDH,,241,,H,,,53 - 234,U/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,87,,,,,31 - 101,umol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Glucose Fasting,,6.5,,H,,,3.9 - 5.6,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Serum Uric Acid,,349,,,,,149 - 446,umol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Phosphorus,,0.95,,,,,0.71 - 1.65,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Creatine Kinase,,140,,,,,26 - 192,U/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Serum Bicarbonate,,23.9,,,,,19.3 - 29.3,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.23,,L,,,1.25 - 1.92,mL/sec +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,87,,,,,31 - 101,umol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,72.5,,,,,kg, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,FSH,Follicle Stimulating Hormone,,50.25,,,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,GFR,EGFR by MDRD,,59,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,139,,,,,116 - 164,g/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.75,,,,,3.8 - 10.7,GI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.40,,,,,1.96 - 7.23,GI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.88,,,,,0.91 - 4.28,GI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,50.5,,,,,40.5 - 75,% +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,39.4,,,,,15.4 - 48.5,% +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.2,,,,,2.6 - 10.1,% +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.3,,,,,0 - 2,% +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,163,,,,,140 - 400,GI/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,4.7,,,,,<6.5%, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,LIPID PANEL,Direct HDL-C 4th Generation,,0.97,,L,,,1.03 - 1.53,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,LIPID PANEL,Triglycerides (GPO),,3.99,,H,,,0.59 - 2.96,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,LIPID PANEL,Cholesterol (High Performance),,6.69,,,,,4.42 - 7.53,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,LIPID PANEL,LDL Chol Friedewald 4th,,3.89,,H,,,0 - 3.34,mmol/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,RETICULOCYTES,Reticulocyte Count %,,2.9,,H,,,0.6 - 2.5,% +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,TSH,TSH 3rd IS-QT,,2.272,,,,,0.45 - 5.33,mIU/L +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Protein,,Trace,R,H,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MACRO PANEL,Ur Leukocyte Esterase,,+1,R,H,,,Ref Rng:Negative, +CZ100040001,,,56,years,Female,Part 1 Screening,,"Aug 8, 2025 10:30 AM",6225350971,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE diff --git a/Covance/Source/2026-06-18_095813 sponsor-study-36940-test-results-930531-standard.csv b/Covance/Source/2026-06-18_095813 sponsor-study-36940-test-results-930531-standard.csv new file mode 100644 index 0000000..4d4b87b --- /dev/null +++ b/Covance/Source/2026-06-18_095813 sponsor-study-36940-test-results-930531-standard.csv @@ -0,0 +1,243 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Criteria not met,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Total Bilirubin,,4,,,,Result verified by repeat analysis,3 - 21,umol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Alkaline Phosphatase,,113,,,,,40 - 129,U/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,ALT (SGPT),,12,,,,,5 - 48,U/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,GGT,,23,,,,,10 - 50,U/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,LDH,,195,,,,,53 - 234,U/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Urea Nitrogen,,2.7,,,,,1.4 - 8.6,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,73,,,,,40 - 119,umol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Serum Glucose,,5.7,,H,,,3.9 - 5.6,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Serum Uric Acid,,409,,,,,149 - 494,umol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Calcium (EDTA),,2.32,,,,,2.07 - 2.64,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Phosphorus,,1.01,,,,,0.71 - 1.65,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Total Protein,,73,,,,,60 - 80,g/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Creatine Kinase,,159,,,,,39 - 308,U/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Serum Potassium,,5.1,,,,,3.5 - 5.2,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Serum Bicarbonate,,21.3,,,,,19.3 - 29.3,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CHEMISTRY PANEL,Magnesium,,0.90,,,,,0.66 - 0.98,mmol/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,100,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,FECAL COLLECTION D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,FECAL COLLECTION D/T,Stool Collection Time,Y,06:50,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,98,,L,,,125 - 170,g/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.34,,L,,,0.37 - 0.51, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4 - 5.8,TI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,22,,L,,Result verified by repeat analysis,26 - 34,pg +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Microcytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,76,,L,,,80 - 100,fL +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.13,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.41,,,,,1.96 - 7.23,GI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.42,,,,,0.8 - 3,GI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.93,,H,,,0.12 - 0.92,GI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.29,,,,,0 - 0.57,GI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,70.2,,,,,40.5 - 75,% +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,15.6,,,,,15.4 - 48.5,% +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.1,,,,,2.6 - 10.1,% +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.1,,,,,0 - 6.8,% +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,812,,HT,,,130 - 394,GI/L +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,05-May-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,10:00,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,05-May-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,13:00,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,05-May-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,10:00,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,05-May-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,06:50,,,,,, +CZ100212001,,,,,Male,Induction Week 4,,"May 5, 2026 10:00 AM",6227635211,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,ALP<2XULN,ALP<2XULN,,Criteria Met,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,ALT>/=3XULN,ALT >/= 3 X ULN,,Criteria not met,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,ALT>/=3XULN & TBIL>/=2XULN,ALT >/=3xULN & TBIL >/=2xULN,,Unable to calc due to LOQ,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,AST>/=3XULN,AST >/= 3 X ULN,,Criteria not met,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,AST>/=3XULN & TBIL>/=2XULN,AST >/=3xULN & TBIL >/=2xULN,,Unable to calc due to LOQ,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Total Bilirubin,,<3,,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,Result verified by repeat analysis,0 - 6.2,umol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Alkaline Phosphatase,,112,,,,,40 - 129,U/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,ALT (SGPT),,8,,,,,5 - 48,U/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,GGT,,27,,,,,10 - 50,U/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,LDH,,150,,,,,53 - 234,U/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Urea Nitrogen,,2.4,,,,,1.4 - 8.6,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,74,,,,,40 - 119,umol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Serum Glucose,,6.1,,H,,,3.9 - 5.6,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Serum Uric Acid,,378,,,,,149 - 494,umol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Calcium (EDTA),,2.36,,,,,2.07 - 2.64,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Phosphorus,,1.02,,,,,0.71 - 1.65,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Total Protein,,70,,,,,60 - 80,g/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Albumin-BCG,,40,,,,,33 - 49,g/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Creatine Kinase,,77,,,,,39 - 308,U/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Serum Potassium,,5.2,,,,,3.5 - 5.2,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Serum Bicarbonate,,22.9,,,,,19.3 - 29.3,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CHEMISTRY PANEL,Magnesium,,0.87,,,,,0.66 - 0.98,mmol/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,99,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,FECAL COLLECTION D/T,Stool Collection Date,Y,20-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,FECAL COLLECTION D/T,Stool Collection Time,Y,06:00,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,106,,L,,,125 - 170,g/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,,L,,,0.37 - 0.51, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4 - 5.8,TI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,23,,L,,,26 - 34,pg +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,77,,L,,,80 - 100,fL +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.30,,,,,3.8 - 10.7,GI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.31,,,,,1.96 - 7.23,GI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.61,,,,,0.8 - 3,GI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.94,,H,,,0.12 - 0.92,GI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.35,,,,,0 - 0.57,GI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,67.8,,,,,40.5 - 75,% +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,17.3,,,,,15.4 - 48.5,% +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.2,,H,,,2.6 - 10.1,% +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.8,,,,,0 - 6.8,% +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,796,,HT,,,130 - 394,GI/L +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,20-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,08:45,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,20-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,10:24,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,20-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,08:45,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM09/STOOL PK COLL D/T,Stool Collection Date,Y,20-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SM09/STOOL PK COLL D/T,Stool Collection Time,Y,06:00,,,,,, +CZ100212001,,,,,Male,Induction Week 2,,"Apr 20, 2026 8:43 AM",6227635208,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,,0 - 6.2,umol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Alkaline Phosphatase,,121,,,,,40 - 129,U/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,ALT (SGPT),,13,,,,,5 - 48,U/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,GGT,,39,,,,,10 - 50,U/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,LDH,,158,,,,,53 - 234,U/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Urea Nitrogen,,3.0,,,,,1.4 - 8.6,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,80,,,,,40 - 119,umol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Serum Glucose,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Serum Uric Acid,,446,,,,,149 - 494,umol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Phosphorus,,1.20,,,,,0.71 - 1.65,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Total Protein,,74,,,,,60 - 80,g/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Creatine Kinase,,64,,,,,39 - 308,U/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Serum Sodium,,141,,,,,135 - 145,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Serum Potassium,,5.2,,,,,3.5 - 5.2,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Serum Bicarbonate,,21.0,,,,,19.3 - 29.3,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Serum Chloride,,106,,,,,94 - 112,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CHEMISTRY PANEL,Magnesium,,0.88,,,,,0.66 - 0.98,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,97,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,FECAL COLLECTION D/T,Stool Collection Date,Y,06-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,FECAL COLLECTION D/T,Stool Collection Time,Y,16:00,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,113,,L,,,125 - 170,g/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.37 - 0.51, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4 - 5.8,TI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,23,,L,,,26 - 34,pg +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Anisocytosis,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,79,,L,,,80 - 100,fL +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,12.49,,H,,,3.8 - 10.7,GI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,8.91,,H,,,1.96 - 7.23,GI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.02,,,,,0.8 - 3,GI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,1.14,,H,,,0.12 - 0.92,GI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.33,,,,,0 - 0.57,GI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,71.3,,,,,40.5 - 75,% +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,16.2,,,,,15.4 - 48.5,% +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,9.1,,,,,2.6 - 10.1,% +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.6,,,,,0 - 6.8,% +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,584,,H,,,130 - 394,GI/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,LIPID PANEL,Direct HDL-C 4th Generation,,1.01,R,L,,,1.03 - 1.53,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,LIPID PANEL,Triglycerides (GPO),,1.57,,,,,0.65 - 2.94,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,LIPID PANEL,Cholesterol (High Performance),,5.40,,,,,4.53 - 7.71,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,LIPID PANEL,LDL Chol Friedewald 4th,,3.67,,H,,,0 - 3.34,mmol/L +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM01/PLASMA PK TROUGH COLL D/T,Collection Date Predose,Y,07-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM01/PLASMA PK TROUGH COLL D/T,Collection Time Predose,Y,10:37,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM02/PLASMA PK PEAK COLL D/T,Collection Date Post dose,Y,07-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM02/PLASMA PK PEAK COLL D/T,Post Dose Collection Time,Y,11:55,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM04/SERUM ADA PRE COLL D/T,Collection Date Predose,Y,07-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM04/SERUM ADA PRE COLL D/T,Collection Time Predose,Y,10:37,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM10/FECAL BMRKS COLL D/T,Stool Collection Date,Y,06-Apr-2026,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SM10/FECAL BMRKS COLL D/T,Stool Collection Time,Y,16:00,,,,,, +CZ100212001,,,,,Male,Induction Week 0,,"Apr 7, 2026 10:37 AM",6227635207,SUBJECT HEIGHT (CM),Height (cm),Y,N/A (subject >/= 18 years of age),,,,,cm, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,ANATOMICAL SITE,Anatomical Site,Y,20,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,BIOPSY COLLECTION METHOD,Collection Method,Y,colonoscopy,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,BIOPSY FIXATIVE USED,Fixative Used,,10% NBF,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,DATE/TIME PLACED IN FORMALIN,Date Sample placed in Formalin,Y,16-Mar-2026,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,DATE/TIME PLACED IN FORMALIN,Time Sample placed in Formalin,Y,13:00,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,DIAGNOSIS,Diagnosis:,Y,Ulcerative Colitis,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,INFLAMED AREA,Inflamed area?,,Yes,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,TISSUE BIOPSY EMBEDDING1,Biopsy technical QC-CL,,Smpl meets HT requirements,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,TISSUE BIOPSY EMBEDDING1,Biopsy processing Time-CL,,10:00,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,TISSUE BIOPSY EMBEDDING1,Biopsy processing Date-CL,,19-Mar-2026,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,TISSUE BIOPSY EMBEDDING1,Biopsy Comments-CL,,Received in 10% NBF,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,TISSUE BIOPSY EMBEDDING1,# of Cassettes-(FI)-CL,,1,,,,,, +CZ100212001,,,,,Male,Biopsy,,"Mar 16, 2026 12:00 AM",6227635223,ULCERATED AREA,Is biopsy site ulcerated?,,Yes,,,,,, +CZ100212001,,,,,Male,Stool Pathogens,,"Mar 1, 2026 2:00 PM",6227635213,C. DIFF EIA,"C. diff GDH Ag,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100212001,,,,,Male,Stool Pathogens,,"Mar 1, 2026 2:00 PM",6227635213,C. DIFF EIA,"C.diff Toxin A&B,stool-CL",,Negative,,,,,Ref Rng:Negative, +CZ100212001,,,,,Male,Stool Pathogens,,"Mar 1, 2026 2:00 PM",6227635213,OVA AND PARASITES 1,Concentrate Exam,,No ova or parasites found,,,,,, +CZ100212001,,,,,Male,Stool Pathogens,,"Mar 1, 2026 2:00 PM",6227635213,OVA AND PARASITES 1,Smear for Microsporidia,,No Microsporidia seen.,,,,,, +CZ100212001,,,,,Male,Stool Pathogens,,"Mar 1, 2026 2:00 PM",6227635213,OVA AND PARASITES 1,Modified acid-fast stain,,No coccidian parasites seen,,,,,, +CZ100212001,,,,,Male,Stool Pathogens,,"Mar 1, 2026 2:00 PM",6227635213,OVA AND PARASITES 2,Trichrome Smear,,No ova or parasites found,,,,,, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Total Bilirubin,,<3,,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,<1.4,,,,Result verified by repeat analysis,0 - 6.2,umol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Alkaline Phosphatase,,120,,,,,40 - 129,U/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,5 - 48,U/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,GGT,,39,,,,,10 - 50,U/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,LDH,,174,,,,,53 - 234,U/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Urea Nitrogen,,3.0,,,,,1.4 - 8.6,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,40 - 119,umol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Serum Glucose,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Serum Uric Acid,,357,,,,,149 - 494,umol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Total Protein,,70,,,,,60 - 80,g/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Creatine Kinase,,149,,,,,39 - 308,U/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Serum Sodium,,141,,,,,135 - 145,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Serum Bicarbonate,,18.4,,L,,,19.3 - 29.3,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CHEMISTRY PANEL,Magnesium,,0.79,,,,,0.66 - 0.98,mmol/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,CKD-EPI 2021 WITH ADOLESCENTS,CKD-EPI 2021 woRace wAdol -PS,,99,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HBV ELIGIBILITY MET?,HBV Eligibility Criteria Met?,,Yes,,,,,, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,120,,L,,,125 - 170,g/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.37 - 0.51, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4 - 5.8,TI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,MCH,,24,,L,,,26 - 34,pg +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,79,,L,,,80 - 100,fL +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.50,,,,,3.8 - 10.7,GI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.09,,,,,1.96 - 7.23,GI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.97,,,,,0.8 - 3,GI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,1.07,,H,,,0.12 - 0.92,GI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.27,,,,,0 - 0.57,GI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.9,,,,,40.5 - 75,% +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,23.3,,,,,15.4 - 48.5,% +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,12.6,,H,,,2.6 - 10.1,% +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.1,,,,,0 - 6.8,% +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.2,,,,,0 - 2,% +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,567,,H,,,130 - 394,GI/L +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEPATITIS B CORE AB NON-US,Hepatitis B Core Total,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEPATITIS B SURFACE AB,Anti-HBs II QUAL,,Non-Reactive,,,,,Ref Rng :$Non Reactive, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEPATITIS B SURFACE AG NON-US,Hep B Surface AgII,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HEPATITIS C VIRUS AB NON-US,Hepatitis C Virus Antibody,,Non-Reactive,,,,,Ref Rng:$Non Reactive, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HIV 1/2 AG/AB SCREEN,anti-HIV-1/2 antibodies,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HIV 1/2 AG/AB SCREEN,HIV -1 p24 antigen,,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,HIV 1/2 AG/AB SCREEN,"HIV 1/2 Ag/Ab Screen, Cobas",,Non-Reactive,,,,,Ref Rng$Non-Reactive, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,PA1 EEA-2?,Approved to use EEA-2?,,Yes,,,,,, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,QUANTIFERON GOLD MITOGEN/INTER,"QFT,TBGoldPlusInt,pl-4-Tubes",,Negative,,,,,Normal=Negative, +CZ100212001,,,,,Male,Screening,,"Feb 25, 2026 12:15 PM",6227635204,SUBJECT HEIGHT (CM),Height (cm),Y,178,,,,,cm, diff --git a/Covance/Source/2026-06-18_095847 sponsor-study-35472-test-results-898739-standard.csv b/Covance/Source/2026-06-18_095847 sponsor-study-35472-test-results-898739-standard.csv new file mode 100644 index 0000000..777a3b4 --- /dev/null +++ b/Covance/Source/2026-06-18_095847 sponsor-study-35472-test-results-898739-standard.csv @@ -0,0 +1,1899 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 5,/HPF +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.7,,,,,0 - 6.2,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Alkaline Phosphatase,,55,,,,,40 - 129,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,ALT (SGPT),,27,,,,,5 - 48,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,GGT,,43,,,,,10 - 61,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,LDH,,168,,,,,53 - 234,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Urea Nitrogen,,3.5,,,,,1.4 - 8.6,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Glucose Fasting,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Serum Uric Acid,,351,,,,,125 - 488,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Calcium (EDTA),,2.44,,,,,2.07 - 2.64,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Phosphorus,,0.86,,,,,0.71 - 1.65,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Albumin-BCG,,50,,H,,,33 - 49,g/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Creatine Kinase,,100,,,,,39 - 308,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Serum Bicarbonate,,26.0,,,,,19.3 - 29.3,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,149,,,,,127 - 181,g/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,84,,,,,79 - 96,fL +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.24,,,,,3.8 - 10.7,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.54,,,,,1.96 - 7.23,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.12,,,,,0.91 - 4.28,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.53,,,,,0.12 - 0.92,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.04,,,,,0 - 0.57,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,67.2,,,,,40.5 - 75,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,25.7,,,,,15.4 - 48.5,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.4,,,,,2.6 - 10.1,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.5,,,,,0 - 6.8,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,193,,,,,140 - 400,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.6,,,,,<6.5 %, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,10.23,,,,,1.9 - 23,uIU/mL +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,LIPID PANEL,Direct HDL-C 4th Generation,,0.92,,L,,,1.03 - 1.53,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,LIPID PANEL,Triglycerides (GPO),,3.09,,,,,0.62 - 3.69,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,LIPID PANEL,Cholesterol (High Performance),,5.48,,,,,4.19 - 7.24,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,LIPID PANEL,LDL Chol Friedewald 4th,,3.14,,,,,0 - 3.34,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,MISCELLANEOUS ELEMENTS,Ur Mucous,,Present,,,,,Ref Rng:Not present, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,TSH,TSH 3rd IS-QT,,1.690,,,,,0.45 - 5.33,mIU/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Specific Gravity,,1.026,,,,,1 - 1.04, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Apr 29, 2026 11:20 AM",6227520243,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.7,,,,,0 - 5,mg/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Alkaline Phosphatase,,65,,,,,35 - 104,U/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,ALT (SGPT),,53,,H,,,4 - 43,U/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,AST (SGOT),,47,,H,,,8 - 40,U/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,GGT,,101,,H,,,5 - 50,U/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,LDH,,186,,,,,53 - 234,U/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Urea Nitrogen,,1.4,,,,,1.4 - 8.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,52,,,,,31 - 101,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Glucose Fasting,,5.8,,H,,,3.9 - 5.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Serum Uric Acid,,426,,,,,149 - 446,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Calcium (EDTA),,2.60,,,,,2.07 - 2.64,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Phosphorus,,1.17,,,,,0.71 - 1.65,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Total Protein,,77,,,,,60 - 80,g/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Creatine Kinase,,164,,,,,26 - 192,U/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Serum Sodium,,135,,,,,135 - 145,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Serum Potassium,,3.9,,,,,3.5 - 5.2,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Serum Bicarbonate,,21.2,,,,,19.3 - 29.3,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,CHEMISTRY PANEL,Serum Chloride,,94,,,,,94 - 112,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,148,,,,,115 - 158,g/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,3.9 - 5.5,TI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,100,,,,,80 - 100,fL +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.45,,,,,3.8 - 10.7,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.74,,,,,1.96 - 7.23,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.85,,,,,0.8 - 3,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.49,,,,,0.12 - 0.92,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.33,,,,,0 - 0.57,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,56.1,,,,,40.5 - 75,% +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,33.8,,,,,15.4 - 48.5,% +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.9,,,,,0 - 6.8,% +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,261,,,,,130 - 394,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.3,,,,,<6.5 %, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.91,,,,,1.9 - 23,uIU/mL +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,IS SUBJECT FASTING?,Is Subject Fasting?,Y,No,,,,,, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,LIPID PANEL,Direct HDL-C 4th Generation,,1.71,,H,,,1.03 - 1.53,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,LIPID PANEL,Triglycerides (GPO),,1.73,,,,,0.63 - 2.71,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,LIPID PANEL,Cholesterol (High Performance),,3.78,,L,,,4.86 - 8.28,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,LIPID PANEL,LDL Chol Friedewald 4th,,1.28,,,,,0 - 3.34,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,TSH,TSH 3rd IS-QT,,,,,Test group cancelled: No specimen received,,, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Specific Gravity,,1.009,,,,,1.01 - 1.03, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Ketones,,Trace,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Week 13,,"Apr 7, 2026 12:01 PM",6226686954,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.3,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Alkaline Phosphatase,,54,,,,,40 - 129,U/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,5 - 48,U/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,GGT,,41,,,,,10 - 61,U/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,LDH,,149,,,,,53 - 234,U/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,80,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Serum Uric Acid,,379,,,,,125 - 488,umol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Calcium (EDTA),,2.53,,,,,2.07 - 2.64,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Phosphorus,,0.89,,,,,0.71 - 1.65,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Total Protein,,81,,,,,61 - 84,g/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Albumin-BCG,,50,,H,,,33 - 49,g/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Creatine Kinase,,88,,,,,39 - 308,U/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Serum Bicarbonate,,24.1,,,,,19.3 - 29.3,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,152,,,,,127 - 181,g/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.3,,,,,4.5 - 6.4,TI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,84,,,,,79 - 96,fL +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.35,,,,,3.8 - 10.7,GI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.03,,,,,1.96 - 7.23,GI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.94,,,,,0.91 - 4.28,GI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.30,,,,,0.12 - 0.92,GI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,56.6,,,,,40.5 - 75,% +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.4,,,,,15.4 - 48.5,% +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.1,,,,,0 - 6.8,% +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,202,,,,,140 - 400,GI/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.79,,,,,1.9 - 23,uIU/mL +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,LIPID PANEL,Direct HDL-C 4th Generation,,0.94,,L,,,1.03 - 1.53,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,LIPID PANEL,Triglycerides (GPO),,2.61,,,,,0.62 - 3.69,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,LIPID PANEL,Cholesterol (High Performance),,5.47,,,,,4.19 - 7.24,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,LIPID PANEL,LDL Chol Friedewald 4th,,3.33,,,,,0 - 3.34,mmol/L +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 2 OL Induction Day 29,,"Apr 1, 2026 11:10 AM",6226313625,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CELLULAR ELEMENTS,Ur WBC/HPF,,2,,,,,0 - 5,/HPF +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Alkaline Phosphatase,,61,,,,,40 - 129,U/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,ALT (SGPT),,16,,,,,5 - 48,U/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,GGT,,34,,,,,10 - 61,U/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,LDH,,164,,,,,53 - 234,U/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Urea Nitrogen,,5.1,,,,,1.4 - 8.6,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,74,,,,,40 - 119,umol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Serum Uric Acid,,266,,,,,149 - 494,umol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Calcium (EDTA),,2.32,,,,,2.07 - 2.64,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Phosphorus,,1.13,,,,,0.71 - 1.65,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Creatine Kinase,,77,,,,,39 - 308,U/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Serum Bicarbonate,,19.7,,,,,19.3 - 29.3,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,161,,,,,127 - 181,g/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 96,fL +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.90,,,,,3.8 - 10.7,GI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.20,,,,,1.96 - 7.23,GI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.94,,,,,0.91 - 4.28,GI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.58,,,,,0.12 - 0.92,GI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,62.7,,,,,40.5 - 75,% +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.8,,,,,15.4 - 48.5,% +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.9,,,,,2.6 - 10.1,% +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.3,,,,,0 - 6.8,% +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,259,,,,,140 - 400,GI/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,14.04,,,,,1.9 - 23,uIU/mL +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,LIPID PANEL,Direct HDL-C 4th Generation,,1.20,,,,,1.03 - 1.53,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,LIPID PANEL,Triglycerides (GPO),,2.38,,,,,0.65 - 3.61,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,LIPID PANEL,Cholesterol (High Performance),,6.59,,,,,4.4 - 7.53,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,LIPID PANEL,LDL Chol Friedewald 4th,,4.30,,H,,,0 - 3.34,mmol/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,TSH,TSH 3rd IS-QT,,1.196,,,,,0.45 - 5.33,mIU/L +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1 - 1.04, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,R,H,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 2 DB Baseline,,"Mar 10, 2026 11:10 AM",6226804962,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,C-REACTIVE PROTEIN,C Reactive Protein HS,,5.2,,H,,,0 - 5,mg/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Alkaline Phosphatase,,54,,,,,40 - 129,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,ALT (SGPT),,30,,,,,5 - 48,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,GGT,,42,,,,,10 - 61,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,LDH,,169,,,,,53 - 234,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Urea Nitrogen,,2.9,,,,,1.4 - 8.6,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Serum Uric Acid,,370,,,,,125 - 488,umol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Calcium (EDTA),,2.49,,,,,2.07 - 2.64,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Phosphorus,,0.84,,,,,0.71 - 1.65,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Albumin-BCG,,50,,H,,,33 - 49,g/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Creatine Kinase,,127,,,,,39 - 308,U/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Serum Bicarbonate,,26.2,,,,,19.3 - 29.3,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,151,,,,,127 - 181,g/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.39 - 0.54, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4.5 - 6.4,TI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,85,,,,,79 - 96,fL +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.86,,,,,3.8 - 10.7,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.33,,,,,1.96 - 7.23,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.05,,,,,0.91 - 4.28,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,48.0,,,,,40.5 - 75,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,42.2,,,,,15.4 - 48.5,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.2,,,,,2.6 - 10.1,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.2,,,,,0 - 6.8,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,189,,,,,140 - 400,GI/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.6,,,,,<6.5 %, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,8.45,,,,,1.9 - 23,uIU/mL +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,LIPID PANEL,Direct HDL-C 4th Generation,,0.78,,L,,,1.03 - 1.53,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,LIPID PANEL,Triglycerides (GPO),,3.51,,,,,0.62 - 3.69,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,LIPID PANEL,Cholesterol (High Performance),,4.45,,,,,4.19 - 7.24,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,LIPID PANEL,LDL Chol Friedewald 4th,,2.06,,,,,0 - 3.34,mmol/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,TSH,TSH 3rd IS-QT,,1.040,,,,,0.45 - 5.33,mIU/L +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Specific Gravity,,1.033,,,,,1 - 1.04, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur pH,,7.0,,,,,5 - 8, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Urobilinogen,,+2,,H,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,End of Phase/Treatment,,"Mar 4, 2026 12:50 PM",6227520245,URINE MICRO PANEL,Ur Microscopic,,Negative,,,,, NEGATIVE$,NEGATIVE +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.8,,,,,0 - 6.2,umol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Alkaline Phosphatase,,52,,,,,40 - 129,U/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,ALT (SGPT),,26,,,,,5 - 48,U/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,AST (SGOT),,22,,,,,8 - 40,U/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,GGT,,49,,,,,10 - 61,U/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,LDH,,143,,,,,53 - 234,U/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Urea Nitrogen,,4.2,,,,,1.4 - 8.6,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Glucose Fasting,,5.7,,H,,,3.9 - 5.6,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Serum Uric Acid,,359,,,,,125 - 488,umol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Calcium (EDTA),,2.57,,,,,2.07 - 2.64,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Phosphorus,,0.64,,LT,,Result verified by repeat analysis,0.71 - 1.65,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Total Protein,,78,,,,,61 - 84,g/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Albumin-BCG,,51,,H,,,33 - 49,g/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Creatine Kinase,,102,,,,,39 - 308,U/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Serum Sodium,,143,,,,,132 - 147,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Serum Bicarbonate,,25.8,,,,,19.3 - 29.3,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.27,,H,,,1.42 - 2.08,mL/sec +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,77,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,85.4,,,,,kg, +CZ100080007,,,40,years,Male,Retest,,"Feb 18, 2026 10:35 AM",6226785739,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Alkaline Phosphatase,,54,,,,,40 - 129,U/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,ALT (SGPT),,35,,,,,5 - 48,U/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,GGT,,54,,,,,10 - 61,U/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,LDH,,155,,,,,53 - 234,U/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Urea Nitrogen,,2.6,,,,,1.4 - 8.6,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,81,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Serum Uric Acid,,385,,,,,125 - 488,umol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Calcium (EDTA),,2.59,,,,,2.07 - 2.64,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Phosphorus,,0.57,,LT,,Result verified by repeat analysis,0.71 - 1.65,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Total Protein,,79,,,,,61 - 84,g/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Albumin-BCG,,51,,H,,,33 - 49,g/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Creatine Kinase,,110,,,,,39 - 308,U/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Serum Bicarbonate,,26.8,,,,,19.3 - 29.3,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,160,,,,,127 - 181,g/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.5,,,,,4.5 - 6.4,TI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.67,,,,,3.8 - 10.7,GI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.99,,,,,1.96 - 7.23,GI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.20,,,,,0.91 - 4.28,GI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.45,,,,,0.12 - 0.92,GI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.03,,,,,0 - 0.57,GI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.01,,,,,0 - 0.2,GI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.8,,,,,40.5 - 75,% +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.9,,,,,15.4 - 48.5,% +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.7,,,,,2.6 - 10.1,% +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.4,,,,,0 - 6.8,% +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.2,,,,,0 - 2,% +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,185,,,,,140 - 400,GI/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,9.79,,,,,1.9 - 23,uIU/mL +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,LIPID PANEL,Direct HDL-C 4th Generation,,0.84,,L,,,1.03 - 1.53,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,LIPID PANEL,Triglycerides (GPO),,3.38,,,,,0.62 - 3.69,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,LIPID PANEL,Cholesterol (High Performance),,4.73,,,,,4.19 - 7.24,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,LIPID PANEL,LDL Chol Friedewald 4th,,2.34,,,,,0 - 3.34,mmol/L +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Specific Gravity,,1.029,,,,,1 - 1.04, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 DB Baseline,,"Jan 21, 2026 11:23 AM",6226551697,URINE MICRO PANEL,Ur Microscopic,,Negative,,,,, NEGATIVE$,NEGATIVE +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.0,,,,,0 - 5,mg/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.1,,,,,0 - 6.2,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Alkaline Phosphatase,,67,,,,,35 - 104,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,ALT (SGPT),,19,,,,,4 - 43,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,GGT,,40,,,,,4 - 49,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,LDH,,180,,,,,53 - 234,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Urea Nitrogen,,2.4,,,,,1.4 - 8.6,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,57,,,,,31 - 101,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Glucose Fasting,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Serum Uric Acid,,222,,,,,149 - 446,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Calcium (EDTA),,2.26,,,,,2.07 - 2.64,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Phosphorus,,0.82,,,,,0.71 - 1.65,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Creatine Kinase,,83,,,,,26 - 192,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Serum Bicarbonate,,24.5,,,,,19.3 - 29.3,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,132,,,,,116 - 164,g/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,,4.1 - 5.6,TI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,99,R,H,,,79 - 98,fL +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.87,,,,,3.8 - 10.7,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.00,,,,,1.96 - 7.23,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.51,,,,,0.91 - 4.28,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.22,,,,,0.12 - 0.92,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.6,,,,,40.5 - 75,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.9,,,,,15.4 - 48.5,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.6,,,,,2.6 - 10.1,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.4,,,,,0 - 6.8,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,281,,,,,140 - 400,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.1,,,,,<6.5 %, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.73,,,,,1.9 - 23,uIU/mL +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,LIPID PANEL,Direct HDL-C 4th Generation,,2.34,R,H,,,1.03 - 1.53,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,LIPID PANEL,Triglycerides (GPO),,1.13,,,,,0.59 - 2.96,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,LIPID PANEL,Cholesterol (High Performance),,5.38,,,,,4.42 - 7.53,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,LIPID PANEL,LDL Chol Friedewald 4th,,2.52,,,,,0 - 3.34,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,RETICULOCYTES,Reticulocyte Count %,,2.0,,,,,0.6 - 2.5,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,TSH,TSH 3rd IS-QT,,1.897,,,,,0.45 - 5.33,mIU/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Specific Gravity,,1.026,,,,,1 - 1.04, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Jan 14, 2026 11:18 AM",6226780857,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.7,,,,,0 - 5,mg/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.9,,,,,0 - 6.2,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Alkaline Phosphatase,,68,,,,,35 - 104,U/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,ALT (SGPT),,70,,H RX,,,4 - 43,U/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,AST (SGOT),,56,,H,,,8 - 40,U/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,GGT,,98,,H,,,5 - 50,U/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,LDH,,188,,,,,53 - 234,U/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Urea Nitrogen,,2.1,,,,,1.4 - 8.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,52,,,,,31 - 101,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Glucose Fasting,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Serum Uric Acid,,419,,,,,149 - 446,umol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Calcium (EDTA),,2.56,,,,,2.07 - 2.64,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Total Protein,,77,,,,,60 - 80,g/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Creatine Kinase,,109,,,,,26 - 192,U/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Serum Sodium,,138,,,,,135 - 145,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Serum Bicarbonate,,26.5,,,,,19.3 - 29.3,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,CHEMISTRY PANEL,Serum Chloride,,96,,,,,94 - 112,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,115 - 158,g/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,,,,3.9 - 5.5,TI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,104,,H,,,80 - 100,fL +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.88,,,,,3.8 - 10.7,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.64,,,,,1.96 - 7.23,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.55,,,,,0.8 - 3,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.51,,,,,0.12 - 0.92,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.0,,,,,40.5 - 75,% +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,37.2,,,,,15.4 - 48.5,% +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.4,,,,,2.6 - 10.1,% +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,288,,,,,130 - 394,GI/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.6,,,,,<6.5 %, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.19,,,,,1.9 - 23,uIU/mL +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,LIPID PANEL,Direct HDL-C 4th Generation,,1.60,,H,,,1.03 - 1.53,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,LIPID PANEL,Triglycerides (GPO),,1.16,,,,,0.63 - 2.71,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,LIPID PANEL,Cholesterol (High Performance),,3.65,,L,,,4.86 - 8.28,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,LIPID PANEL,LDL Chol Friedewald 4th,,1.52,,,,,0 - 3.34,mmol/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,TSH,TSH 3rd IS-QT,,0.906,,,,,0.45 - 5.33,mIU/L +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Specific Gravity,,1.012,,,,,1.01 - 1.03, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Ketones,,Trace,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 DB Baseline,,"Jan 13, 2026 1:15 PM",6226686953,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.0,,,,,0 - 5,mg/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CELLULAR ELEMENTS,Ur WBC/HPF,,2,,,,,0 - 5,/HPF +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Alkaline Phosphatase,,67,,,,,40 - 129,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,5 - 48,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,GGT,,30,,,,,10 - 61,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,LDH,,161,,,,,53 - 234,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Urea Nitrogen,,5.1,,,,,1.4 - 8.6,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,83,,,,,40 - 119,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Glucose Fasting,,6.8,,H,,,3.9 - 5.6,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Serum Uric Acid,,297,,,,,149 - 494,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Creatine Kinase,,63,,,,,39 - 308,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Serum Bicarbonate,,21.1,,,,,19.3 - 29.3,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,157,,,,,127 - 181,g/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.48,,,,,0.39 - 0.54, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,100,,H,,,79 - 96,fL +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.88,,,,,3.8 - 10.7,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.58,,,,,1.96 - 7.23,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.46,,,,,0.91 - 4.28,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.59,,,,,0.12 - 0.92,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.19,,,,,0 - 0.57,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,62.8,,,,,40.5 - 75,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.7,,,,,15.4 - 48.5,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.7,,,,,2.6 - 10.1,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,243,,,,,140 - 400,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,35.89,,H,,,1.9 - 23,uIU/mL +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,LIPID PANEL,Direct HDL-C 4th Generation,,1.18,,,,,1.03 - 1.53,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,LIPID PANEL,Triglycerides (GPO),,2.11,,,,,0.65 - 3.61,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,LIPID PANEL,Cholesterol (High Performance),,5.10,,,,,4.4 - 7.53,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,LIPID PANEL,LDL Chol Friedewald 4th,,2.95,,,,,0 - 3.34,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,TSH,TSH 3rd IS-QT,,0.729,,,,,0.45 - 5.33,mIU/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Specific Gravity,,1.030,,,,,1 - 1.04, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Jan 13, 2026 10:45 AM",6227520242,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.5,,,,,0 - 5,mg/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.0,,,,,0 - 6.2,umol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Alkaline Phosphatase,,72,,,,,35 - 104,U/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,GGT,,40,,,,,4 - 49,U/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,LDH,,177,,,,,53 - 234,U/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 101,umol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Serum Uric Acid,,398,,,,,149 - 446,umol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Calcium (EDTA),,2.49,,,,,2.07 - 2.64,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Phosphorus,,0.96,,,,,0.71 - 1.65,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Creatine Kinase,,73,,,,,26 - 192,U/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Serum Bicarbonate,,22.1,,,,,19.3 - 29.3,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,CHEMISTRY PANEL,Serum Chloride,,98,,,,,94 - 112,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,149,,,,,116 - 164,g/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.34 - 0.48, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,79 - 98,fL +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.74,,,,,3.8 - 10.7,GI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.11,,,,,1.96 - 7.23,GI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.22,,,,,0.91 - 4.28,GI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.27,,,,,0.12 - 0.92,GI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.0,,,,,40.5 - 75,% +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,33.1,,,,,15.4 - 48.5,% +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.0,,,,,2.6 - 10.1,% +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.2,,,,,0 - 6.8,% +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,564,,H,,,140 - 400,GI/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.03,,,,,1.9 - 23,uIU/mL +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,LIPID PANEL,Direct HDL-C 4th Generation,,2.53,,H,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,LIPID PANEL,Triglycerides (GPO),,2.65,,,,,0.59 - 2.96,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,LIPID PANEL,Cholesterol (High Performance),,5.29,,,,,4.42 - 7.53,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,LIPID PANEL,LDL Chol Friedewald 4th,,1.55,,,,,0 - 3.34,mmol/L +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Specific Gravity,,1.020,,,,,1 - 1.04, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 2 OL Induction Day 29,,"Dec 17, 2025 11:17 AM",6227072419,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Alkaline Phosphatase,,57,,,,,40 - 129,U/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,ALT (SGPT),,26,,,,,5 - 48,U/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,GGT,,44,,,,,10 - 61,U/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,LDH,,173,,,,,53 - 234,U/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,78,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Glucose Fasting,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Serum Uric Acid,,379,,,,,125 - 488,umol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Calcium (EDTA),,2.62,,,,,2.07 - 2.64,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Phosphorus,,0.80,,,,,0.71 - 1.65,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Total Protein,,84,,,,,61 - 84,g/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Albumin-BCG,,53,,H,,,33 - 49,g/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Creatine Kinase,,108,,,,,39 - 308,U/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Serum Sodium,,145,,,,,132 - 147,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Serum Bicarbonate,,23.4,,,,,19.3 - 29.3,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.31,,H,,,1.42 - 2.08,mL/sec +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,78,,,,,40 - 110,umol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,87.0,,,,,kg, +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,LIPID PANEL,Direct HDL-C 4th Generation,,0.94,,L,,,1.03 - 1.53,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,LIPID PANEL,Triglycerides (GPO),,2.31,,,,,0.56 - 3.62,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,LIPID PANEL,Cholesterol (High Performance),,5.76,,,,,3.88 - 6.83,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,LIPID PANEL,LDL Chol Friedewald 4th,,3.76,,H,,,0 - 3.34,mmol/L +CZ100080007,,,40,years,Male,Retest,,"Dec 15, 2025 10:53 AM",6226785740,TSH,TSH 3rd IS-QT,,1.044,,,,,0.45 - 5.33,mIU/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,C-REACTIVE PROTEIN,C Reactive Protein HS,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Total Bilirubin,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Alkaline Phosphatase,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,ALT (SGPT),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,AST (SGOT),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,GGT,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,LDH,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Urea Nitrogen,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Glucose Fasting,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Serum Uric Acid,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Calcium (EDTA),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Phosphorus,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Total Protein,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Albumin-BCG,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Creatine Kinase,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Serum Sodium,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Serum Potassium,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Serum Bicarbonate,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CHEMISTRY PANEL,Serum Chloride,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,Required testing unavailable,,,,,1.42 - 2.08,mL/sec +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,87.0,,,,,kg, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,GFR,EGFR by MDRD,,Required testing unavailable,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,151,,,,,127 - 181,g/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,4.5 - 6.4,TI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.79,,,,,3.8 - 10.7,GI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.23,,,,,1.96 - 7.23,GI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.09,,,,,0.91 - 4.28,GI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.41,,,,,0.12 - 0.92,GI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.03,,,,,0 - 0.57,GI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,62.4,,,,,40.5 - 75,% +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.8,,,,,15.4 - 48.5,% +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.0,,,,,2.6 - 10.1,% +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.5,,,,,0 - 6.8,% +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,207,,,,,140 - 400,GI/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,15.62,,,,,1.9 - 23,uIU/mL +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,LIPID PANEL,Direct HDL-C 4th Generation,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,LIPID PANEL,Triglycerides (GPO),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,LIPID PANEL,Cholesterol (High Performance),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,LIPID PANEL,LDL Chol Friedewald 4th,,Required testing unavailable,,,,,0 - 3.34,mmol/L +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,TSH,TSH 3rd IS-QT,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Specific Gravity,,1.032,,,,,1 - 1.04, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur pH,,7.0,,,,,5 - 8, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080007,,,40,years,Male,Part 1 Screening,,"Dec 10, 2025 10:20 AM",6225351044,URINE MICRO PANEL,Ur Microscopic,,Negative,,,,, NEGATIVE$,NEGATIVE +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,C-REACTIVE PROTEIN,C Reactive Protein HS,,7.3,,H,,,0 - 5,mg/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CELLULAR ELEMENTS,Ur RBC/HPF,,2,,,,,0 - 3,/HPF +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CELLULAR ELEMENTS,Ur WBC/HPF,,7,,H,,,0 - 5,/HPF +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Alkaline Phosphatase,,58,,,,,40 - 129,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,5 - 48,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,GGT,,26,,,,,10 - 61,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,LDH,,171,,,,,53 - 234,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Urea Nitrogen,,5.4,,,,,1.4 - 8.6,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,86,,,,,40 - 119,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Glucose Fasting,,6.0,,H,,,3.9 - 5.6,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Serum Uric Acid,,317,,,,,149 - 494,umol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Calcium (EDTA),,2.26,,,,,2.07 - 2.64,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Phosphorus,,0.98,,,,,0.71 - 1.65,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Creatine Kinase,,76,,,,,39 - 308,U/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Serum Bicarbonate,,25.0,,,,,19.3 - 29.3,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,CRYSTALS,Ur Calcium Oxalate Crystals,,Present,,,,,Ref Rng:Not present, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,127 - 181,g/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.5 - 6.4,TI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,99,,H,,,79 - 96,fL +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.00,,,,,3.8 - 10.7,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.16,,,,,1.96 - 7.23,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.99,,,,,0.91 - 4.28,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.71,,,,,0.12 - 0.92,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,68.4,,,,,40.5 - 75,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,22.2,,,,,15.4 - 48.5,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.9,,,,,2.6 - 10.1,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.3,,,,,0 - 6.8,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.2,,,,,0 - 2,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,256,,,,,140 - 400,GI/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,11.88,,,,,1.9 - 23,uIU/mL +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,LIPID PANEL,Direct HDL-C 4th Generation,,1.07,,,,,1.03 - 1.53,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,LIPID PANEL,Triglycerides (GPO),,1.52,,,,,0.65 - 3.61,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,LIPID PANEL,Cholesterol (High Performance),,4.74,,,,,4.4 - 7.53,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,LIPID PANEL,LDL Chol Friedewald 4th,,2.97,,,,,0 - 3.34,mmol/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,MISCELLANEOUS ELEMENTS,Ur Mucous,,Present,,,,,Ref Rng:Not present, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,MISCELLANEOUS ELEMENTS,Ur Sperm,,Present,,,,,Ref Rng:Not present, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,TSH,TSH 3rd IS-QT,,0.706,,,,,0.45 - 5.33,mIU/L +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Specific Gravity,,1.032,,,,,1 - 1.04, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,End of Phase/Treatment,,"Dec 9, 2025 11:35 AM",6226780855,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.6,,,,,0 - 5,mg/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Alkaline Phosphatase,,63,,,,,35 - 104,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,GGT,,31,,,,,4 - 49,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,LDH,,166,,,,,53 - 234,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Urea Nitrogen,,2.9,,,,,1.4 - 8.6,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Serum Uric Acid,,189,,,,,149 - 446,umol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Calcium (EDTA),,2.33,,,,,2.07 - 2.64,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Phosphorus,,0.99,,,,,0.71 - 1.65,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Total Protein,,65,,,,,61 - 84,g/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Albumin-BCG,,41,,,,,33 - 49,g/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Creatine Kinase,,77,,,,,26 - 192,U/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Serum Bicarbonate,,23.4,,,,,19.3 - 29.3,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,134,,,,,116 - 164,g/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4.1 - 5.6,TI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,79 - 98,fL +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.79,,,,,3.8 - 10.7,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.69,,,,,1.96 - 7.23,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.52,,,,,0.91 - 4.28,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.7,,,,,40.5 - 75,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.3,,,,,15.4 - 48.5,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.9,,,,,2.6 - 10.1,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.5,,,,,0 - 6.8,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,402,,H,,,140 - 400,GI/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.4,,,,,<6.5 %, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.90,,,,,1.9 - 23,uIU/mL +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,LIPID PANEL,Direct HDL-C 4th Generation,,1.98,,H,,,1.03 - 1.53,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,LIPID PANEL,Triglycerides (GPO),,1.65,,,,,0.59 - 2.96,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,LIPID PANEL,Cholesterol (High Performance),,5.40,,,,,4.42 - 7.53,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,LIPID PANEL,LDL Chol Friedewald 4th,,2.66,,,,,0 - 3.34,mmol/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,RETICULOCYTES,Reticulocyte Count %,,2.3,,,,,0.6 - 2.5,% +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,TSH,TSH 3rd IS-QT,,1.816,,,,,0.45 - 5.33,mIU/L +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1 - 1.04, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,End of Phase/Treatment,,"Nov 18, 2025 11:06 AM",6226780856,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.6,,,,,0 - 5,mg/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CELLULAR ELEMENTS,Ur RBC/HPF,,1,,,,,0 - 8,/HPF +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CELLULAR ELEMENTS,Ur WBC/HPF,,2,,,,,0 - 12,/HPF +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Alkaline Phosphatase,,36,,,,,35 - 104,U/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,ALT (SGPT),,11,,,,,4 - 43,U/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,GGT,,6,,,,,4 - 49,U/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,LDH,,153,,,,,53 - 234,U/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,65,,,,,31 - 101,umol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Serum Uric Acid,,259,,,,,125 - 428,umol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Phosphorus,,0.98,,,,,0.71 - 1.65,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Creatine Kinase,,105,,,,,26 - 192,U/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Serum Bicarbonate,,22.1,,,,,19.3 - 29.3,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,131,,,,,116 - 164,g/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,82,,,,,79 - 98,fL +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.46,,,,,3.8 - 10.7,GI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.81,,,,,1.96 - 7.23,GI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.34,,,,,0.91 - 4.28,GI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.24,,,,,0.12 - 0.92,GI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.05,,,,,0 - 0.57,GI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,69.7,,,,,40.5 - 75,% +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,24.6,,,,,15.4 - 48.5,% +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.4,,,,,2.6 - 10.1,% +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,267,,,,,140 - 400,GI/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.3,,,,,<6.5%, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.64,,,,,1.9 - 23,uIU/mL +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,LIPID PANEL,Direct HDL-C 4th Generation,,1.66,R,H,,,1.03 - 1.53,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,LIPID PANEL,Triglycerides (GPO),,1.43,,,,,0.41 - 1.63,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,LIPID PANEL,Cholesterol (High Performance),,4.82,,,,,3.31 - 5.64,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,LIPID PANEL,LDL Chol Friedewald 4th,,2.51,,,,,0 - 3.34,mmol/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,MICROORGANISMS,Ur Yeast-Budding,,Present,,,,,Ref Rng:Not present, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,MICROORGANISMS,Ur Yeast-Hyphae,,Present,,,,,Ref Rng:Not present, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,RETICULOCYTES,Reticulocyte Count %,,0.6,,,,,0.6 - 2.5,% +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,TSH,TSH 3rd IS-QT,,1.379,,,,,0.45 - 5.33,mIU/L +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MACRO PANEL,Ur Leukocyte Esterase,,+2,,H SF,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,End of Phase/Treatment,,"Nov 5, 2025 12:50 PM",6226780853,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.1,,,,,0 - 5,mg/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CASTS,Ur Hyaline Casts/LPF,,27,,,,,0 /LPF, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Alkaline Phosphatase,,61,,,,,35 - 104,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,ALT (SGPT),,64,,H,,,4 - 43,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,AST (SGOT),,63,,H RX,,,8 - 40,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,GGT,,85,,H,,,5 - 50,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,LDH,,207,,,,,53 - 234,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Urea Nitrogen,,2.8,,,,,1.4 - 8.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,56,,,,,31 - 101,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Glucose Fasting,,5.7,,H,,,3.9 - 5.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Serum Uric Acid,,423,,,,,149 - 446,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Phosphorus,,1.23,,,,,0.71 - 1.65,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Total Protein,,78,,,,,60 - 80,g/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Creatine Kinase,,141,,,,,26 - 192,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Serum Sodium,,140,,,,,135 - 145,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Serum Bicarbonate,,22.7,,,,,19.3 - 29.3,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,CHEMISTRY PANEL,Serum Chloride,,99,,,,,94 - 112,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,138,,,,,115 - 158,g/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,,3.9 - 5.5,TI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,102,,H,,,80 - 100,fL +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.70,,,,,3.8 - 10.7,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.73,,,,,1.96 - 7.23,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.43,,,,,0.8 - 3,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.35,,,,,0.12 - 0.92,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.16,,,,,0 - 0.57,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.7,,,,,40.5 - 75,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.2,,,,,15.4 - 48.5,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.2,,,,,2.6 - 10.1,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.3,,,,,0 - 6.8,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,274,,,,,130 - 394,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.35,,,,,1.9 - 23,uIU/mL +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,LIPID PANEL,Direct HDL-C 4th Generation,,1.68,,H,,,1.03 - 1.53,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,LIPID PANEL,Triglycerides (GPO),,1.03,,,,,0.63 - 2.71,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,LIPID PANEL,Cholesterol (High Performance),,5.23,,,,,4.86 - 8.28,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,LIPID PANEL,LDL Chol Friedewald 4th,,3.08,,,,,0 - 3.34,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1.01 - 1.03, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Protein,,+1,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Ketones,,Trace,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Day 29,,"Nov 4, 2025 12:05 PM",6226804961,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,C-REACTIVE PROTEIN,C Reactive Protein HS,,8.3,,H,,,0 - 5,mg/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Alkaline Phosphatase,,64,,,,,40 - 129,U/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,ALT (SGPT),,14,,,,,5 - 48,U/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,GGT,,28,,,,,10 - 61,U/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,LDH,,163,,,,,53 - 234,U/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Urea Nitrogen,,5.0,,,,,1.4 - 8.6,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,83,,,,,40 - 119,umol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Serum Uric Acid,,311,,,,,149 - 494,umol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Calcium (EDTA),,2.30,,,,,2.07 - 2.64,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Phosphorus,,1.13,,,,,0.71 - 1.65,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Creatine Kinase,,73,,,,,39 - 308,U/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Serum Bicarbonate,,21.0,,,,,19.3 - 29.3,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,158,,,,,127 - 181,g/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.48,,,,,0.39 - 0.54, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,99,R,H,,,79 - 96,fL +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,10.66,,,,,3.8 - 10.7,GI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,7.67,R,H,,,1.96 - 7.23,GI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.03,,,,,0.91 - 4.28,GI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.77,,,,,0.12 - 0.92,GI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,71.9,,,,,40.5 - 75,% +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,19.1,,,,,15.4 - 48.5,% +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.3,,,,,2.6 - 10.1,% +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.4,,,,,0 - 6.8,% +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,251,,,,,140 - 400,GI/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.56,,,,,1.9 - 23,uIU/mL +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,LIPID PANEL,Direct HDL-C 4th Generation,,1.04,,,,,1.03 - 1.53,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,LIPID PANEL,Triglycerides (GPO),,1.84,,,,,0.65 - 3.61,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,LIPID PANEL,Cholesterol (High Performance),,5.15,,,,,4.4 - 7.53,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,LIPID PANEL,LDL Chol Friedewald 4th,,3.27,,,,,0 - 3.34,mmol/L +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Specific Gravity,,1.012,,,,,1 - 1.04, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 DB Baseline,,"Oct 29, 2025 10:10 AM",6226551698,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,C-REACTIVE PROTEIN,C Reactive Protein HS,,6.1,,H,,,0 - 5,mg/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Alkaline Phosphatase,,106,,,,,40 - 129,U/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,ALT (SGPT),,32,,,,,5 - 48,U/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,AST (SGOT),,28,,,,,8 - 40,U/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,GGT,,105,,H,,,10 - 61,U/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,LDH,,140,,,,,53 - 234,U/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Urea Nitrogen,,3.2,,,,,1.4 - 8.6,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,98,,,,,40 - 119,umol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Glucose Fasting,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Serum Uric Acid,,378,,,,,149 - 494,umol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Calcium (EDTA),,2.42,,,,,2.07 - 2.64,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Phosphorus,,0.96,,,,,0.71 - 1.65,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Creatine Kinase,,55,,,,,39 - 308,U/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Serum Bicarbonate,,26.4,,,,,19.3 - 29.3,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,127 - 181,g/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.39 - 0.54, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,94,,,,,79 - 96,fL +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.05,,,,,3.8 - 10.7,GI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.34,,,,,1.96 - 7.23,GI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.31,,,,,0.91 - 4.28,GI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.30,,,,,0.12 - 0.92,GI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.8,,,,,40.5 - 75,% +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.3,,,,,15.4 - 48.5,% +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.4,,,,,2.6 - 10.1,% +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,219,,,,,140 - 400,GI/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.3,,,,,<6.5%, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,6.63,,,,,1.9 - 23,uIU/mL +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,LIPID PANEL,Direct HDL-C 4th Generation,,1.31,,,,,1.03 - 1.53,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,LIPID PANEL,Triglycerides (GPO),,1.15,,,,,0.65 - 3.61,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,LIPID PANEL,Cholesterol (High Performance),,6.10,,,,,4.4 - 7.53,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,LIPID PANEL,LDL Chol Friedewald 4th,,4.26,,H,,,0 - 3.34,mmol/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,RETICULOCYTES,Reticulocyte Count %,,0.7,,,,,0.6 - 2.5,% +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,TSH,TSH 3rd IS-QT,,0.733,,,,,0.45 - 5.33,mIU/L +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Specific Gravity,,1.015,,,,,1 - 1.04, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Early Withdrawal,,"Oct 14, 2025 12:30 PM",6225351066,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.7,,,,,0 - 5,mg/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.0,,,,,0 - 6.2,umol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Alkaline Phosphatase,,77,,,,,35 - 104,U/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,ALT (SGPT),,22,,,,,4 - 43,U/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,AST (SGOT),,26,,,,,8 - 40,U/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,GGT,,28,,,,,4 - 49,U/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,LDH,,184,,,,,53 - 234,U/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Urea Nitrogen,,3.5,,,,,1.4 - 8.6,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,62,,,,,31 - 101,umol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Glucose Fasting,,5.7,,H,,,3.9 - 5.6,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Serum Uric Acid,,259,,,,,149 - 446,umol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Calcium (EDTA),,2.46,,,,,2.07 - 2.64,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Phosphorus,,1.16,,,,,0.71 - 1.65,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Creatine Kinase,,82,,,,,26 - 192,U/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Serum Bicarbonate,,21.3,,,,,19.3 - 29.3,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,116 - 164,g/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,79 - 98,fL +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.32,,,,,3.8 - 10.7,GI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.74,,,,,1.96 - 7.23,GI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.91,,,,,0.91 - 4.28,GI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.45,,,,,0.12 - 0.92,GI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.2,,,,,40.5 - 75,% +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.3,,,,,15.4 - 48.5,% +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.2,,,,,2.6 - 10.1,% +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.7,,,,,0 - 6.8,% +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,356,,,,,140 - 400,GI/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.42,,,,,1.9 - 23,uIU/mL +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,LIPID PANEL,Direct HDL-C 4th Generation,,1.90,,H,,,1.03 - 1.53,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,LIPID PANEL,Triglycerides (GPO),,1.05,,,,,0.59 - 2.96,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,LIPID PANEL,Cholesterol (High Performance),,5.04,,,,,4.42 - 7.53,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,LIPID PANEL,LDL Chol Friedewald 4th,,2.66,,,,,0 - 3.34,mmol/L +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,RETICULOCYTES,Reticulocyte Count %,,2.3,,,,,0.6 - 2.5,% +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Specific Gravity,,1.009,,,,,1 - 1.04, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 DB Baseline,,"Oct 8, 2025 11:19 AM",6225351050,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.5,,,,,0 - 5,mg/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.1,,,,,0 - 6.2,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Alkaline Phosphatase,,42,,,,,35 - 104,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,GGT,,6,,,,,4 - 49,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,LDH,,169,,,,,53 - 234,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Urea Nitrogen,,3.6,,,,,1.4 - 8.6,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,67,,,,,31 - 101,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Serum Uric Acid,,273,,,,,125 - 428,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Calcium (EDTA),,2.36,,,,,2.07 - 2.64,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Phosphorus,,0.98,,,,,0.71 - 1.65,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Creatine Kinase,,113,,,,,26 - 192,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Serum Bicarbonate,,20.6,,,,,19.3 - 29.3,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,135,,,,,116 - 164,g/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.1 - 5.6,TI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,82,,,,,79 - 98,fL +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.49,,,,,3.8 - 10.7,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.33,,,,,1.96 - 7.23,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.72,,,,,0.91 - 4.28,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.35,,,,,0.12 - 0.92,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,66.8,,,,,40.5 - 75,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.5,,,,,15.4 - 48.5,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,327,,,,,140 - 400,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.98,,,,,1.9 - 23,uIU/mL +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,LIPID PANEL,Direct HDL-C 4th Generation,,1.69,R,H,,,1.03 - 1.53,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,LIPID PANEL,Triglycerides (GPO),,1.86,R,H,,,0.41 - 1.63,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,LIPID PANEL,Cholesterol (High Performance),,5.31,,,,,3.31 - 5.64,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,LIPID PANEL,LDL Chol Friedewald 4th,,2.77,,,,,0 - 3.34,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,RETICULOCYTES,Reticulocyte Count %,,0.8,,,,,0.6 - 2.5,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Specific Gravity,,1.022,,,,,1 - 1.04, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Blood,,+3,R,H SF,,,Ref Rng:$Negative-Trace, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Day 29,,"Oct 8, 2025 9:20 AM",6226686952,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.4,,,,,0 - 5,mg/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CASTS,Ur Hyaline Casts/LPF,,4,,,,,0 /LPF, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Alkaline Phosphatase,,62,,,,,35 - 104,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,ALT (SGPT),,35,,,,,4 - 43,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,AST (SGOT),,29,,,,,8 - 40,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,GGT,,51,,H,,,5 - 50,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,LDH,,178,,,,,53 - 234,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Urea Nitrogen,,3.3,,,,,1.4 - 8.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,55,,,,,31 - 101,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Glucose Fasting,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Serum Uric Acid,,451,,H,,,149 - 446,umol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Calcium (EDTA),,2.53,,,,,2.07 - 2.64,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Phosphorus,,1.03,,,,,0.71 - 1.65,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Total Protein,,74,,,,,60 - 80,g/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Creatine Kinase,,153,,,,,26 - 192,U/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Serum Sodium,,138,,,,,135 - 145,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Serum Potassium,,3.9,,,,,3.5 - 5.2,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Serum Bicarbonate,,23.9,,,,,19.3 - 29.3,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,CHEMISTRY PANEL,Serum Chloride,,97,,,,,94 - 112,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,133,,,,,115 - 158,g/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,,,,3.9 - 5.5,TI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,101,R,H,,,80 - 100,fL +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.90,,,,,3.8 - 10.7,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.97,,,,,1.96 - 7.23,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.30,,,,,0.8 - 3,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.20,,,,,0 - 0.57,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,50.3,,,,,40.5 - 75,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,38.9,,,,,15.4 - 48.5,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.8,,,,,2.6 - 10.1,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.3,,,,,0 - 6.8,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,244,,,,,130 - 394,GI/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.6,,,,,<6.5%, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.01,,,,,1.9 - 23,uIU/mL +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,LIPID PANEL,Direct HDL-C 4th Generation,,1.47,,,,,1.03 - 1.53,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,LIPID PANEL,Triglycerides (GPO),,1.30,,,,,0.63 - 2.71,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,LIPID PANEL,Cholesterol (High Performance),,3.27,,L,,,4.86 - 8.28,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,LIPID PANEL,LDL Chol Friedewald 4th,,1.20,,,,,0 - 3.34,mmol/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,TSH,TSH 3rd IS-QT,,1.174,,,,,0.45 - 5.33,mIU/L +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Specific Gravity,,1.025,,,,,1.01 - 1.03, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Ketones,,Trace,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 2 OL Induction Baseline,,"Oct 7, 2025 12:02 PM",6225351057,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.1,,,,,0 - 5,mg/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.6,,,,,0 - 6.2,umol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Alkaline Phosphatase,,80,,,,,40 - 129,U/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,ALT (SGPT),,31,,,,,5 - 48,U/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,AST (SGOT),,30,,,,,8 - 40,U/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,GGT,,68,R,H,,,10 - 61,U/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,LDH,,163,,,,,53 - 234,U/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Urea Nitrogen,,3.8,,,,,1.4 - 8.6,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,93,,,,,40 - 119,umol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Serum Uric Acid,,448,,,,,149 - 494,umol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Phosphorus,,0.78,,,,,0.71 - 1.65,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Creatine Kinase,,143,,,,,39 - 308,U/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Serum Potassium,,3.8,,,,,3.5 - 5.2,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Serum Bicarbonate,,24.3,,,,,19.3 - 29.3,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,CHEMISTRY PANEL,Serum Chloride,,98,,,,,94 - 112,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,127 - 181,g/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.39 - 0.54, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,94,,,,,79 - 96,fL +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.18,,,,,3.8 - 10.7,GI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.32,,,,,1.96 - 7.23,GI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.51,,,,,0.91 - 4.28,GI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.23,,,,,0.12 - 0.92,GI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.09,,,,,0 - 0.57,GI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.7,,,,,40.5 - 75,% +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.1,,,,,15.4 - 48.5,% +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,203,,,,,140 - 400,GI/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,8.51,,,,,1.9 - 23,uIU/mL +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,LIPID PANEL,Direct HDL-C 4th Generation,,1.29,,,,,1.03 - 1.53,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,LIPID PANEL,Triglycerides (GPO),,1.22,,,,,0.65 - 3.61,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,LIPID PANEL,Cholesterol (High Performance),,5.80,,,,,4.4 - 7.53,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,LIPID PANEL,LDL Chol Friedewald 4th,,3.95,,H,,,0 - 3.34,mmol/L +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,RETICULOCYTES,Reticulocyte Count %,,0.6,,,,,0.6 - 2.5,% +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Specific Gravity,,1.014,,,,,1 - 1.04, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 DB Baseline,,"Sep 16, 2025 12:35 PM",6225351052,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.5,,,,,0 - 5,mg/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.6,,,,,0 - 6.2,umol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,40 - 129,U/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,5 - 48,U/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,GGT,,29,,,,,10 - 61,U/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,LDH,,173,,,,,53 - 234,U/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,73,,,,,40 - 119,umol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Serum Uric Acid,,268,,,,,149 - 494,umol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Calcium (EDTA),,2.26,,,,,2.07 - 2.64,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Phosphorus,,1.02,,,,,0.71 - 1.65,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Creatine Kinase,,93,,,,,39 - 308,U/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Serum Bicarbonate,,20.0,,,,,19.3 - 29.3,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.12,,H,,,1.42 - 2.08,mL/sec +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,73,,,,,40 - 119,umol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,85.0,,,,,kg, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,GFR,EGFR by MDRD,,98,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,127 - 181,g/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.5 - 6.4,TI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,101,,H,,,79 - 96,fL +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.62,,,,,3.8 - 10.7,GI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.14,,,,,1.96 - 7.23,GI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.83,,,,,0.91 - 4.28,GI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.48,,,,,0.12 - 0.92,GI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,71.2,,,,,40.5 - 75,% +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,21.2,,,,,15.4 - 48.5,% +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,218,,,,,140 - 400,GI/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.5,,,,,<6.5%, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,7.69,,,,,1.9 - 23,uIU/mL +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,LIPID PANEL,Direct HDL-C 4th Generation,,1.08,,,,,1.03 - 1.53,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,LIPID PANEL,Triglycerides (GPO),,2.26,,,,,0.65 - 3.61,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,LIPID PANEL,Cholesterol (High Performance),,4.47,,,,,4.4 - 7.53,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,LIPID PANEL,LDL Chol Friedewald 4th,,2.35,,,,,0 - 3.34,mmol/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,TSH,TSH 3rd IS-QT,,0.878,,,,,0.45 - 5.33,mIU/L +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Specific Gravity,,1.013,,,,,1 - 1.04, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080006,,,52,years,Male,Part 1 Screening,,"Sep 16, 2025 9:45 AM",6225351040,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.5,,,,,0 - 5,mg/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Alkaline Phosphatase,,63,,,,,35 - 104,U/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,ALT (SGPT),,19,,,,,4 - 43,U/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,GGT,,22,,,,,4 - 49,U/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,LDH,,182,,,,,53 - 234,U/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Urea Nitrogen,,3.0,,,,,1.4 - 8.6,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,57,,,,,31 - 101,umol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Serum Uric Acid,,224,,,,,149 - 446,umol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Total Protein,,68,,,,,61 - 84,g/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Creatine Kinase,,71,,,,,26 - 192,U/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Serum Bicarbonate,,22.7,,,,,19.3 - 29.3,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.81,,,,,1.25 - 1.92,mL/sec +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,57,,,,,31 - 101,umol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,69.0,,,,,kg, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,FSH,Follicle Stimulating Hormone,,6.17,,RX,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,GFR,EGFR by MDRD,,97,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,116 - 164,g/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4.1 - 5.6,TI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,98,,,,,79 - 98,fL +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.11,,,,,3.8 - 10.7,GI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.39,,,,,1.96 - 7.23,GI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.04,,,,,0.91 - 4.28,GI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.49,,,,,0.12 - 0.92,GI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.8,,,,,40.5 - 75,% +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,28.7,,,,,15.4 - 48.5,% +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.9,,,,,2.6 - 10.1,% +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,431,,H,,,140 - 400,GI/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.2,,,,,<6.5%, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.05,,,,,1.9 - 23,uIU/mL +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,LIPID PANEL,Direct HDL-C 4th Generation,,1.95,,H,,,1.03 - 1.53,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,LIPID PANEL,Triglycerides (GPO),,1.54,,,,,0.59 - 2.96,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,LIPID PANEL,Cholesterol (High Performance),,5.27,,,,,4.42 - 7.53,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,LIPID PANEL,LDL Chol Friedewald 4th,,2.61,,,,,0 - 3.34,mmol/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,RETICULOCYTES,Reticulocyte Count %,,2.9,,H,,,0.6 - 2.5,% +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,TSH,TSH 3rd IS-QT,,1.573,,,,,0.45 - 5.33,mIU/L +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Specific Gravity,,1.010,,,,,1 - 1.04, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080005,,,55,years,Female,Part 1 Screening,,"Sep 10, 2025 1:31 PM",6225351046,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Alkaline Phosphatase,,38,,,,,35 - 104,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,4 - 43,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,GGT,,6,,,,,4 - 49,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,LDH,,162,,,,,53 - 234,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Urea Nitrogen,,3.5,,,,,1.4 - 8.6,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,59,,,,,31 - 101,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Serum Uric Acid,,260,,,,,125 - 428,umol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Calcium (EDTA),,2.26,,,,,2.07 - 2.64,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Phosphorus,,0.56,,LT,,Result verified by repeat analysis,0.71 - 1.65,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Creatine Kinase,,358,R,H,,,26 - 192,U/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Serum Bicarbonate,,21.1,,,,,19.3 - 29.3,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,132,,,,,116 - 164,g/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.1 - 5.6,TI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,82,,,,,79 - 98,fL +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.52,,,,,3.8 - 10.7,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.93,,,,,1.96 - 7.23,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.25,,,,,0.91 - 4.28,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.27,,,,,0.12 - 0.92,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.01,,,,,0 - 0.2,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,64.8,,,,,40.5 - 75,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.6,,,,,15.4 - 48.5,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.0,,,,,2.6 - 10.1,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.4,,,,,0 - 6.8,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.2,,,,,0 - 2,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,262,,,,,140 - 400,GI/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.2,,,,,<6.5%, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,7.63,,,,,1.9 - 23,uIU/mL +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,IS SUBJECT FASTING?,Is Subject Fasting?,Y,No,,,,,, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,LIPID PANEL,Direct HDL-C 4th Generation,,1.42,,,,,1.03 - 1.53,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,LIPID PANEL,Triglycerides (GPO),,1.42,,,,,0.41 - 1.63,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,LIPID PANEL,Cholesterol (High Performance),,4.13,,,,,3.31 - 5.64,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,LIPID PANEL,LDL Chol Friedewald 4th,,2.06,,,,,0 - 3.34,mmol/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,TSH,TSH 3rd IS-QT,,1.160,,,,,0.45 - 5.33,mIU/L +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Specific Gravity,,1.020,,,,,1 - 1.04, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 2 OL Induction Baseline,R,"Sep 10, 2025 11:35 AM",6225351056,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080004,,,54,years,Male,Retest,,"Sep 8, 2025 10:00 AM",6225351070,IS SUBJECT FASTING?,Is Subject Fasting?,Y,No,,,,,, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.1,,,,,0 - 6.2,umol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Alkaline Phosphatase,,70,,,,,35 - 104,U/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,ALT (SGPT),,40,,,,,4 - 43,U/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,AST (SGOT),,35,,,,,8 - 40,U/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,GGT,,54,,H,,,5 - 50,U/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,LDH,,184,,,,,53 - 234,U/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Urea Nitrogen,,2.1,,,,,1.4 - 8.6,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Glucose Fasting,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Serum Uric Acid,,413,,,,,149 - 446,umol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Calcium (EDTA),,2.58,,,,,2.07 - 2.64,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Phosphorus,,1.19,,,,,0.71 - 1.65,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Total Protein,,77,,,,,60 - 80,g/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Creatine Kinase,,155,,,,,26 - 192,U/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Serum Sodium,,137,,,,,135 - 145,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Serum Bicarbonate,,22.5,,,,,19.3 - 29.3,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,CHEMISTRY PANEL,Serum Chloride,,96,,,,,94 - 112,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,115 - 158,g/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,,,,3.9 - 5.5,TI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,101,R,H,,,80 - 100,fL +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.55,,,,,3.8 - 10.7,GI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.20,,,,,1.96 - 7.23,GI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.66,,,,,0.8 - 3,GI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.44,,,,,0.12 - 0.92,GI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.21,,,,,0 - 0.57,GI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.5,,,,,40.5 - 75,% +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,35.1,,,,,15.4 - 48.5,% +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.9,,,,,2.6 - 10.1,% +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.8,,,,,0 - 6.8,% +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,275,,,,,130 - 394,GI/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,6.10,,,,,1.9 - 23,uIU/mL +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,LIPID PANEL,Direct HDL-C 4th Generation,,1.39,,,,,1.03 - 1.53,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,LIPID PANEL,Triglycerides (GPO),,1.36,,,,,0.63 - 2.71,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,LIPID PANEL,Cholesterol (High Performance),,3.50,,L,,,4.86 - 8.28,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,LIPID PANEL,LDL Chol Friedewald 4th,,1.49,,,,,0 - 3.34,mmol/L +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Specific Gravity,,1.010,,,,,1.01 - 1.03, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Ketones,,+1,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 DB Baseline,,"Aug 26, 2025 12:47 PM",6225351051,URINE MICRO PANEL,Ur Microscopic,,Negative,,,,, NEGATIVE$,NEGATIVE +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.5,,,,,0 - 5,mg/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.9,,,,,0 - 6.2,umol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Alkaline Phosphatase,,76,,,,,40 - 129,U/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,5 - 48,U/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,AST (SGOT),,26,,,,,8 - 40,U/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,GGT,,61,,,,,10 - 61,U/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,LDH,,160,,,,,53 - 234,U/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Urea Nitrogen,,4.8,,,,,1.4 - 8.6,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,87,,,,,40 - 119,umol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Serum Uric Acid,,353,,,,,149 - 494,umol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Phosphorus,,0.79,,,,,0.71 - 1.65,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Creatine Kinase,,153,,,,,39 - 308,U/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Serum Bicarbonate,,21.7,,,,,19.3 - 29.3,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.83,,,,,1.42 - 2.08,mL/sec +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,87,,,,,40 - 119,umol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,89.2,,,,,kg, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,DRUG SCREEN URINE,Opiates,,Detected (unconfirmed),,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,GFR,EGFR by MDRD,,80,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,152,,,,,127 - 181,g/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.39 - 0.54, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.5 - 6.4,TI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,79 - 96,fL +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.94,,,,,3.8 - 10.7,GI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.25,,,,,1.96 - 7.23,GI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.33,,,,,0.91 - 4.28,GI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.22,,,,,0.12 - 0.92,GI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,65.9,,,,,40.5 - 75,% +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.0,,,,,15.4 - 48.5,% +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.5,,,,,2.6 - 10.1,% +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.1,,,,,0 - 6.8,% +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,222,,,,,140 - 400,GI/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.5,,,,,<6.5%, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.22,,,,,1.9 - 23,uIU/mL +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,LIPID PANEL,Direct HDL-C 4th Generation,,1.15,,,,,1.03 - 1.53,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,LIPID PANEL,Triglycerides (GPO),,0.89,,,,,0.65 - 3.61,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,LIPID PANEL,Cholesterol (High Performance),,5.43,,,,,4.4 - 7.53,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,LIPID PANEL,LDL Chol Friedewald 4th,,3.87,,H,,,0 - 3.34,mmol/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,OPIATE CONFIRMATION URINE,Opiates Confirmed-LCMSMS-LDT,,Codeine (Confirmed),,RX,,,No Ref Rng, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,OPIATE CONFIRMATION URINE,Opiates Confirmed-LCMSMS-LDT,,Morphine (Confirmed),,RX,,,No Ref Rng, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,OPIATE CONFIRMATION URINE,Opiates Confirmed-LCMSMS-LDT,,6-MAM not present,,,,,No Ref Rng, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,TSH,TSH 3rd IS-QT,,0.914,,,,,0.45 - 5.33,mIU/L +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Specific Gravity,,1.025,,,,,1 - 1.04, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Ketones,,+1,,H,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080004,,,54,years,Male,Part 1 Screening,,"Aug 26, 2025 11:08 AM",6225351042,URINE MICRO PANEL,Ur Microscopic,,Negative,,,,, NEGATIVE$,NEGATIVE +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.3,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CELLULAR ELEMENTS,Ur WBC/HPF,,4,,,,,0 - 12,/HPF +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,35 - 104,U/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,4 - 43,U/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,GGT,,43,,,,,5 - 50,U/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,LDH,,183,,,,,53 - 234,U/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Urea Nitrogen,,3.2,,,,,1.4 - 8.6,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,47,,,,,31 - 101,umol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Glucose Fasting,,6.0,,H,,,3.9 - 5.6,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Serum Uric Acid,,253,,,,,149 - 446,umol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Phosphorus,,1.22,,,,,0.71 - 1.65,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Total Protein,,68,,,,,60 - 80,g/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Creatine Kinase,,89,,,,,26 - 192,U/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Serum Sodium,,143,,,,,135 - 145,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Serum Bicarbonate,,24.4,,,,,19.3 - 29.3,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.47,,H,,,1.25 - 1.92,mL/sec +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,47,,,,,31 - 101,umol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,89.0,,,,,kg, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,FSH,Follicle Stimulating Hormone,,29.08,,RX,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,GFR,EGFR by MDRD,,116,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,129,,,,,115 - 158,g/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,3.9 - 5.5,TI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,93,,,,,80 - 100,fL +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.29,,,,,3.8 - 10.7,GI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.65,,,,,1.96 - 7.23,GI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.23,,,,,0.8 - 3,GI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.31,,,,,0.12 - 0.92,GI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.7,,,,,40.5 - 75,% +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.6,,,,,15.4 - 48.5,% +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.2,,,,,2.6 - 10.1,% +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.1,,,,,0 - 6.8,% +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,250,,,,,130 - 394,GI/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,6.4,,,,,<6.5%, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,15.80,,,,,1.9 - 23,uIU/mL +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,LIPID PANEL,Direct HDL-C 4th Generation,,1.50,,,,,1.03 - 1.53,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,LIPID PANEL,Triglycerides (GPO),,1.69,,,,,0.63 - 2.71,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,LIPID PANEL,Cholesterol (High Performance),,4.20,,L,,,4.86 - 8.28,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,LIPID PANEL,LDL Chol Friedewald 4th,,1.93,,,,,0 - 3.34,mmol/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,RETICULOCYTES,Reticulocyte Count %,,1.5,,,,,0.6 - 2.5,% +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,TSH,TSH 3rd IS-QT,,1.074,,,,,0.45 - 5.33,mIU/L +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1.01 - 1.03, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MACRO PANEL,Ur Leukocyte Esterase,,+3,R,H SF,,,Ref Rng:Negative, +CZ100080003,,,66,years,Female,Part 1 Screening,,"Aug 6, 2025 11:43 AM",6225351041,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.2,,,,,0 - 6.2,umol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Alkaline Phosphatase,,73,,,,,35 - 104,U/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,ALT (SGPT),,40,,,,,4 - 43,U/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,AST (SGOT),,26,,,,,8 - 40,U/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,GGT,,56,R,H,,,5 - 50,U/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,LDH,,169,,,,,53 - 234,U/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Urea Nitrogen,,2.9,,,,,1.4 - 8.6,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,51,,,,,31 - 101,umol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Serum Uric Acid,,479,R,H,,,149 - 446,umol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Calcium (EDTA),,2.56,,,,,2.07 - 2.64,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Phosphorus,,1.22,,,,,0.71 - 1.65,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Total Protein,,74,,,,,60 - 80,g/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Creatine Kinase,,135,,,,,26 - 192,U/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Serum Sodium,,137,,,,,135 - 145,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Serum Bicarbonate,,22.8,,,,,19.3 - 29.3,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CHEMISTRY PANEL,Serum Chloride,,96,,,,,94 - 112,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.51,,H,,,1.25 - 1.92,mL/sec +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,51,,,,,31 - 101,umol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,93.1,,,,,kg, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,FSH,Follicle Stimulating Hormone,,30.27,,RX,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,GFR,EGFR by MDRD,,106,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,134,,,,,115 - 158,g/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.9,,,,,3.9 - 5.5,TI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,102,R,H,,,80 - 100,fL +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.37,,,,,3.8 - 10.7,GI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.86,,,,,1.96 - 7.23,GI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.96,,,,,0.8 - 3,GI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.3,,,,,40.5 - 75,% +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.6,,,,,15.4 - 48.5,% +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.3,,,,,2.6 - 10.1,% +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.0,,,,,0 - 6.8,% +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,232,,,,,130 - 394,GI/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,6.2,,,,,<6.5%, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,7.31,,,,,1.9 - 23,uIU/mL +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,LIPID PANEL,Direct HDL-C 4th Generation,,1.30,,,,,1.03 - 1.53,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,LIPID PANEL,Triglycerides (GPO),,1.55,,,,,0.63 - 2.71,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,LIPID PANEL,Cholesterol (High Performance),,3.52,R,L,,,4.86 - 8.28,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,LIPID PANEL,LDL Chol Friedewald 4th,,1.51,,,,,0 - 3.34,mmol/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,TSH,TSH 3rd IS-QT,,1.889,,,,,0.45 - 5.33,mIU/L +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Specific Gravity,,1.015,,,,,1.01 - 1.03, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080002,,,62,years,Female,Part 1 Screening,R,"Aug 5, 2025 11:58 AM",6225351045,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.0,,,,,0 - 5,mg/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CELLULAR ELEMENTS,Ur WBC/HPF,,3,,,,,0 - 12,/HPF +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Alkaline Phosphatase,,44,,,,,35 - 104,U/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,ALT (SGPT),,12,,,,,4 - 43,U/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,AST (SGOT),,19,,,,,8 - 40,U/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,GGT,,6,,,,,4 - 49,U/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,LDH,,157,,,,,53 - 234,U/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,71,,,,,31 - 101,umol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Serum Uric Acid,,263,,,,,125 - 428,umol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Phosphorus,,0.71,,,,,0.71 - 1.65,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Creatine Kinase,,260,,H,,,26 - 192,U/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Serum Bicarbonate,,22.8,,,,,19.3 - 29.3,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,CRYSTALS,Ur Calcium Oxalate Crystals,,Present,,,,,Ref Rng:Not present, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,127,,,,,116 - 164,g/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.1 - 5.6,TI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,82,,,,,79 - 98,fL +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.54,,,,,3.8 - 10.7,GI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.08,,,,,1.96 - 7.23,GI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.06,,,,,0.91 - 4.28,GI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.33,,,,,0.12 - 0.92,GI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.04,,,,,0 - 0.57,GI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,73.7,,,,,40.5 - 75,% +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,19.3,,,,,15.4 - 48.5,% +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.0,,,,,2.6 - 10.1,% +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.8,,,,,0 - 6.8,% +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,260,,,,,140 - 400,GI/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,16.54,,,,,1.9 - 23,uIU/mL +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,IS SUBJECT FASTING?,Is Subject Fasting?,Y,No,,,,,, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,LIPID PANEL,Direct HDL-C 4th Generation,,1.52,,,,,1.03 - 1.53,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,LIPID PANEL,Triglycerides (GPO),,1.60,,,,,0.41 - 1.63,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,LIPID PANEL,Cholesterol (High Performance),,4.24,,,,,3.31 - 5.64,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,LIPID PANEL,LDL Chol Friedewald 4th,,1.99,,,,,0 - 3.34,mmol/L +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,MISCELLANEOUS ELEMENTS,Ur Fat,,Present,,H,,,Ref Rng:Not present, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,RETICULOCYTES,Reticulocyte Count %,,0.6,,,,,0.6 - 2.5,% +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Specific Gravity,,1.031,,,,,1 - 1.04, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Ketones,,Trace,,H,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 DB Baseline,,"Jul 30, 2025 11:55 AM",6225351049,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.3,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.2,,,,,0 - 6.2,umol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Alkaline Phosphatase,,59,,,,,35 - 104,U/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,ALT (SGPT),,12,,,,,4 - 43,U/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,GGT,,8,,,,,4 - 49,U/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,LDH,,144,,,,,53 - 234,U/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Urea Nitrogen,,3.6,,,,,1.4 - 8.6,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 101,umol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Serum Uric Acid,,235,,,,,125 - 428,umol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Calcium (EDTA),,2.33,,,,,2.07 - 2.64,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Creatine Kinase,,87,,,,,26 - 192,U/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Serum Bicarbonate,,22.5,,,,,19.3 - 29.3,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.06,,H,,,1.25 - 1.92,mL/sec +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 101,umol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,65.0,,,,,kg, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,GFR,EGFR by MDRD,,100,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,127,,,,,116 - 164,g/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.8,,,,,4.1 - 5.6,TI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,82,,,,,79 - 98,fL +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.86,,,,,3.8 - 10.7,GI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.93,,,,,1.96 - 7.23,GI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.59,,,,,0.91 - 4.28,GI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.27,,,,,0.12 - 0.92,GI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.04,,,,,0 - 0.57,GI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,60.3,,,,,40.5 - 75,% +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.7,,,,,15.4 - 48.5,% +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,261,,,,,140 - 400,GI/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.4,,,,,<6.5%, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,6.26,,,,,1.9 - 23,uIU/mL +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,LIPID PANEL,Direct HDL-C 4th Generation,,1.54,,H,,,1.03 - 1.53,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,LIPID PANEL,Triglycerides (GPO),,0.87,,,,,0.41 - 1.63,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,LIPID PANEL,Cholesterol (High Performance),,4.29,,,,,3.31 - 5.64,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,LIPID PANEL,LDL Chol Friedewald 4th,,2.35,,,,,0 - 3.34,mmol/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,RETICULOCYTES,Reticulocyte Count %,,0.6,,,,,0.6 - 2.5,% +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,TSH,TSH 3rd IS-QT,,0.904,,,,,0.45 - 5.33,mIU/L +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Specific Gravity,,1.009,,,,,1 - 1.04, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100080001,,,26,years,Female,Part 1 Screening,,"Jul 2, 2025 11:12 AM",6225351047,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, diff --git a/Covance/Source/2026-06-18_095905 sponsor-study-35472-test-results-898733-standard.csv b/Covance/Source/2026-06-18_095905 sponsor-study-35472-test-results-898733-standard.csv new file mode 100644 index 0000000..fdd1290 --- /dev/null +++ b/Covance/Source/2026-06-18_095905 sponsor-study-35472-test-results-898733-standard.csv @@ -0,0 +1,2464 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.2,,,,,0 - 5,mg/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.7,,,,,0 - 6.2,umol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Alkaline Phosphatase,,94,,,,,40 - 129,U/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,ALT (SGPT),,45,,,,,5 - 48,U/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,AST (SGOT),,35,,,,,8 - 40,U/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,GGT,,15,,,,,10 - 61,U/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,LDH,,192,,,,,53 - 234,U/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Urea Nitrogen,,5.0,,,,,1.4 - 8.6,mmol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,97,,,,,40 - 110,umol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Serum Uric Acid,,263,,,,,125 - 488,umol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Calcium (EDTA),,2.62,,,,,2.07 - 2.64,mmol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Phosphorus,,1.23,,,,,0.71 - 1.65,mmol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Albumin-BCG,,52,,H,,,33 - 49,g/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Creatine Kinase,,1330,,H SF,,,39 - 308,U/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Serum Bicarbonate,,28.6,,,,,19.3 - 29.3,mmol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,CHEMISTRY PANEL,Serum Chloride,,98,,,,,94 - 112,mmol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,127 - 181,g/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.39 - 0.54, +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 96,fL +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.98,,,,,3.8 - 10.7,GI/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.99,,,,,1.96 - 7.23,GI/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.38,,,,,0.91 - 4.28,GI/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.46,,,,,0.12 - 0.92,GI/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,66.6,,,,,40.5 - 75,% +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,23.2,,,,,15.4 - 48.5,% +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.7,,,,,2.6 - 10.1,% +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,220,,,,,140 - 400,GI/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.67,,,,,1.9 - 23,uIU/mL +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,LIPID PANEL,Direct HDL-C 4th Generation,,1.50,,,,,1.03 - 1.53,mmol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,LIPID PANEL,Triglycerides (GPO),,0.75,,,,,0.5 - 2.81,mmol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,LIPID PANEL,Cholesterol (High Performance),,4.61,,,,,3.31 - 6.1,mmol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,LIPID PANEL,LDL Chol Friedewald 4th,,2.77,,,,,0 - 3.34,mmol/L +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,URINE MACRO PANEL,Ur Specific Gravity,,1.011,,,,,1 - 1.04, +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 2 OL Induction Day 29,R,"May 19, 2026 11:16 AM",6227261835,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.2,,,,,0 - 5,mg/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Alkaline Phosphatase,,59,,,,,35 - 104,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,4 - 43,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,GGT,,27,,,,,4 - 49,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,LDH,,176,,,,,53 - 234,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 8.6,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,74,,,,,31 - 101,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Serum Uric Acid,,289,,,,,149 - 446,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Phosphorus,,1.12,,,,,0.71 - 1.65,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Creatine Kinase,,263,,H,,,26 - 192,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Serum Bicarbonate,,23.3,,,,,19.3 - 29.3,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,139,,,,Result verified by repeat analysis,116 - 164,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,Result verified by repeat analysis,0.34 - 0.48, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,Result verified by repeat analysis,4.1 - 5.6,TI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,Result verified by repeat analysis,79 - 98,fL +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.14,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.07,,,,,1.96 - 7.23,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.57,,,,,0.91 - 4.28,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.0,,,,,40.5 - 75,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.0,,,,,15.4 - 48.5,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.0,,,,,2.6 - 10.1,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.0,,,,,0 - 6.8,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,309,,,,Result verified by repeat analysis,140 - 400,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.1,,,,,<6.5 %, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.37,,,,,1.9 - 23,uIU/mL +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,LIPID PANEL,Direct HDL-C 4th Generation,,1.79,,H,,,1.03 - 1.53,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,LIPID PANEL,Triglycerides (GPO),,1.51,,,,,0.59 - 2.96,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,LIPID PANEL,Cholesterol (High Performance),,5.75,,,,,4.42 - 7.53,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,LIPID PANEL,LDL Chol Friedewald 4th,,3.27,,,,,0 - 3.34,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,TSH,TSH 3rd IS-QT,,4.824,,,,,0.45 - 5.33,mIU/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Specific Gravity,,1.029,,,,,1 - 1.04, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"May 13, 2026 8:15 AM",6228234298,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,C-REACTIVE PROTEIN,C Reactive Protein HS,,7.3,,H,,,0 - 5,mg/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.9,,,,,0 - 6.2,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Alkaline Phosphatase,,80,,,,,40 - 129,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,ALT (SGPT),,163,,H RX,,,5 - 48,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,AST (SGOT),,127,,H RX,,,8 - 40,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,GGT,,350,,HT,,Result verified by repeat analysis,10 - 50,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,LDH,,224,,,,,53 - 234,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Urea Nitrogen,,4.1,,,,,1.4 - 8.6,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,106,,,,,40 - 119,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Glucose Fasting,,6.1,,H,,,3.9 - 5.6,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Serum Uric Acid,,512,,H,,,149 - 494,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Phosphorus,,0.81,,,,,0.71 - 1.65,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Total Protein,,77,,,,,60 - 80,g/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Creatine Kinase,,348,,H,,,39 - 308,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Serum Sodium,,137,,,,,135 - 145,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Serum Bicarbonate,,21.3,,,,,19.3 - 29.3,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,134,,,,,125 - 170,g/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.37 - 0.51, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,,4 - 5.8,TI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,100,,,,,80 - 100,fL +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,3.89,,,,,3.8 - 10.7,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.35,,,,,1.96 - 7.23,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.13,,,,,0.8 - 3,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.03,,,,,0 - 0.57,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,60.5,,,,,40.5 - 75,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.0,,,,,15.4 - 48.5,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.7,,,,,2.6 - 10.1,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,137,R,L,,,140 - 400,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.3,,,,,<6.5 %, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,30.61,,H,,,1.9 - 23,uIU/mL +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,LIPID PANEL,Direct HDL-C 4th Generation,,1.03,,,,,1.03 - 1.53,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,LIPID PANEL,Triglycerides (GPO),,2.89,,,,,0.65 - 3.61,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,LIPID PANEL,Cholesterol (High Performance),,4.82,,,,,4.4 - 7.53,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,LIPID PANEL,LDL Chol Friedewald 4th,,2.47,,,,,0 - 3.34,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,RETICULOCYTES,Reticulocyte Count %,,1.5,,,,,0.6 - 2.5,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,TSH,TSH 3rd IS-QT,,1.982,,,,,0.45 - 5.33,mIU/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Specific Gravity,,1.010,,,,,1.01 - 1.03, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"May 4, 2026 8:44 AM",6228234297,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.9,,,,,0 - 5,mg/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Alkaline Phosphatase,,92,,,,,40 - 129,U/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,ALT (SGPT),,19,,,,,5 - 48,U/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,GGT,,13,,,,,10 - 61,U/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,LDH,,144,,,,,53 - 234,U/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Urea Nitrogen,,4.6,,,,,1.4 - 8.6,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,92,,,,,40 - 110,umol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Serum Uric Acid,,249,,,,,125 - 488,umol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Calcium (EDTA),,2.51,,,,,2.07 - 2.64,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Phosphorus,,0.97,,,,,0.71 - 1.65,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Albumin-BCG,,50,R,H,,,33 - 49,g/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Creatine Kinase,,224,,,,,39 - 308,U/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Serum Bicarbonate,,27.9,,,,,19.3 - 29.3,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,CHEMISTRY PANEL,Serum Chloride,,98,,,,,94 - 112,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,145,,,,,127 - 181,g/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 96,fL +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.75,,,,,3.8 - 10.7,GI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.09,,,,,1.96 - 7.23,GI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.22,,,,,0.91 - 4.28,GI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.35,,,,,0.12 - 0.92,GI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,65.0,,,,,40.5 - 75,% +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,25.8,,,,,15.4 - 48.5,% +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.3,,,,,2.6 - 10.1,% +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.4,,,,,0 - 6.8,% +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,216,,,,,140 - 400,GI/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.3,,,,,<6.5 %, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.44,,,,,1.9 - 23,uIU/mL +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,LIPID PANEL,Direct HDL-C 4th Generation,,1.34,,,,,1.03 - 1.53,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,LIPID PANEL,Triglycerides (GPO),,0.59,,,,,0.5 - 2.81,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,LIPID PANEL,Cholesterol (High Performance),,3.92,,,,,3.31 - 6.1,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,LIPID PANEL,LDL Chol Friedewald 4th,,2.31,,,,,0 - 3.34,mmol/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,TSH,TSH 3rd IS-QT,,1.256,,,,,0.45 - 5.33,mIU/L +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Specific Gravity,,1.012,,,,,1 - 1.04, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,End of Phase/Treatment,,"Apr 21, 2026 10:37 AM",6228234300,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.8,,,,,0 - 6.2,umol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Alkaline Phosphatase,,104,,,,,40 - 129,U/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,ALT (SGPT),,17,,,,,5 - 48,U/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,GGT,,13,,,,,10 - 61,U/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,LDH,,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Urea Nitrogen,,6.2,,,,,1.4 - 8.6,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,95,,,,,40 - 110,umol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Serum Uric Acid,,216,,,,,125 - 488,umol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Calcium (EDTA),,2.45,,,,,2.07 - 2.64,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Phosphorus,,1.25,,,,,0.71 - 1.65,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Albumin-BCG,,52,,H,,,33 - 49,g/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Creatine Kinase,,196,,,,,39 - 308,U/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Serum Bicarbonate,,22.8,,,,,19.3 - 29.3,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.59,,,,,1.42 - 2.08,mL/sec +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,95,,,,,40 - 110,umol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,64.0,,,,,kg, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,FSH,Follicle Stimulating Hormone,,6.14,,RX,,,1.3 - 19.3,IU/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,146,,,,,127 - 181,g/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.24,,,,,3.8 - 10.7,GI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.97,,,,,1.96 - 7.23,GI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.72,,,,,0.91 - 4.28,GI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.6,,,,,40.5 - 75,% +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.6,,,,,15.4 - 48.5,% +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.5,,,,,2.6 - 10.1,% +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,223,,,,,140 - 400,GI/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.3,,,,,<6.5 %, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.85,,,,,1.9 - 23,uIU/mL +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,LIPID PANEL,Direct HDL-C 4th Generation,,1.40,,,,,1.03 - 1.53,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,LIPID PANEL,Triglycerides (GPO),,0.81,,,,,0.5 - 2.81,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,LIPID PANEL,Cholesterol (High Performance),,4.33,,,,,3.31 - 6.1,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,LIPID PANEL,LDL Chol Friedewald 4th,,2.56,,,,,0 - 3.34,mmol/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,TSH,TSH 3rd IS-QT,,1.789,,,,,0.45 - 5.33,mIU/L +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Specific Gravity,,1.028,,,,,1 - 1.04, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Retest,,"Apr 10, 2026 8:16 AM",6227542182,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.1,,,,,0 - 5,mg/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.6,,,,,0 - 6.2,umol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Alkaline Phosphatase,,58,,,,,40 - 129,U/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,ALT (SGPT),,86,,H RX,,,5 - 48,U/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,AST (SGOT),,74,,H RX,,,8 - 40,U/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,GGT,,83,,H,,,10 - 50,U/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,LDH,,187,,,,,53 - 234,U/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Urea Nitrogen,,5.4,,,,,1.4 - 8.6,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,107,,,,,40 - 119,umol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Glucose Fasting,,8.0,,H,,,3.9 - 5.6,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Serum Uric Acid,,500,,H,,,149 - 494,umol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Calcium (EDTA),,2.36,,,,,2.07 - 2.64,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Phosphorus,,0.92,,,,,0.71 - 1.65,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Total Protein,,77,,,,,60 - 80,g/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Creatine Kinase,,238,,,,,39 - 308,U/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Serum Sodium,,137,,,,,135 - 145,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Serum Potassium,,3.8,,,,,3.5 - 5.2,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Serum Bicarbonate,,21.3,,,,,19.3 - 29.3,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,CHEMISTRY PANEL,Serum Chloride,,99,,,,,94 - 112,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,125 - 170,g/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.37 - 0.51, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4 - 5.8,TI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,80 - 100,fL +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.57,,,,,3.8 - 10.7,GI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.18,,,,,1.96 - 7.23,GI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.84,,,,,0.8 - 3,GI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.44,,,,,0.12 - 0.92,GI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.1,,,,,40.5 - 75,% +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,33.0,,,,,15.4 - 48.5,% +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.9,,,,,2.6 - 10.1,% +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,169,,,,,140 - 400,GI/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,33.13,,H,,,1.9 - 23,uIU/mL +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,LIPID PANEL,Direct HDL-C 4th Generation,,0.70,,L,,,1.03 - 1.53,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,LIPID PANEL,Triglycerides (GPO),,2.48,,,,,0.65 - 3.61,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,LIPID PANEL,Cholesterol (High Performance),,4.55,,,,,4.4 - 7.53,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,LIPID PANEL,LDL Chol Friedewald 4th,,2.71,,,,,0 - 3.34,mmol/L +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,RETICULOCYTES,Reticulocyte Count %,,2.1,,,,,0.6 - 2.5,% +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Specific Gravity,,1.018,,,,,1.01 - 1.03, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 2 OL Induction Day 29,,"Apr 7, 2026 9:21 AM",6228114460,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.7,,,,,0 - 5,mg/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Total Bilirubin,,15,,,,,3 - 21,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.6,,,,,0 - 6.2,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Alkaline Phosphatase,,101,,,,,35 - 104,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,ALT (SGPT),,19,,,,,4 - 43,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,GGT,,13,,,,,4 - 49,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,LDH,,175,,,,,53 - 234,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,54,,,,,31 - 101,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Glucose Fasting,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Serum Uric Acid,,232,,,,,125 - 428,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Total Protein,,80,,,,,61 - 84,g/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Creatine Kinase,,52,,,,,26 - 192,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Serum Bicarbonate,,22.0,,,,,19.3 - 29.3,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,CRYSTALS,Ur Uric Acid Crystals,,Present,,,,,Ref Rng:Not present, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,FREE T4,Free Thyroxine-QT,,18,,H,,,8 - 14,pmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,128,,,,,116 - 164,g/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.85,,,,,3.8 - 10.7,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.16,,,,,1.96 - 7.23,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.28,,,,,0.91 - 4.28,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.31,,,,,0.12 - 0.92,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.05,,,,,0 - 0.57,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.0,,,,,40.5 - 75,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,38.9,,,,,15.4 - 48.5,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.3,,,,,2.6 - 10.1,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,312,,,,,140 - 400,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,4.7,,,,,<6.5 %, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.75,,,,,1.9 - 23,uIU/mL +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,LIPID PANEL,Direct HDL-C 4th Generation,,1.07,,,,,1.03 - 1.53,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,LIPID PANEL,Triglycerides (GPO),,0.77,,,,,0.44 - 1.99,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,LIPID PANEL,Cholesterol (High Performance),,3.77,,,,,3.65 - 6.21,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,LIPID PANEL,LDL Chol Friedewald 4th,,2.35,,,,,0 - 3.34,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,RETICULOCYTES,Reticulocyte Count %,,1.5,,,,,0.6 - 2.5,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,TSH,TSH 3rd IS-QT,,0.119,,L SF,,,0.45 - 5.33,mIU/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Specific Gravity,,1.025,,,,,1 - 1.04, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,,"Mar 31, 2026 10:10 AM",6228232037,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.7,,,,,0 - 5,mg/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.4,,,,,0 - 6.2,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Alkaline Phosphatase,,53,,,,,35 - 104,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,AST (SGOT),,11,,,,,8 - 40,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,GGT,,12,,,,,4 - 49,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,LDH,,134,,,,,53 - 234,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Urea Nitrogen,,5.0,,,,,1.4 - 8.6,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,31 - 101,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Glucose Fasting,,5.7,,H,,,3.9 - 5.6,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Serum Uric Acid,,216,,,,,125 - 428,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Calcium (EDTA),,2.41,,,,,2.07 - 2.64,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Phosphorus,,0.83,,,,,0.71 - 1.65,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Total Protein,,65,,,,,61 - 84,g/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Creatine Kinase,,83,,,,,26 - 192,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Serum Bicarbonate,,23.3,,,,,19.3 - 29.3,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,CHEMISTRY PANEL,Serum Chloride,,106,,,,,94 - 112,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,121,,,,,116 - 164,g/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,,,,,0.34 - 0.48, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,L,,,4.1 - 5.6,TI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.63,,,,,3.8 - 10.7,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.66,,,,,1.96 - 7.23,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.64,,,,,0.91 - 4.28,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.20,,,,,0.12 - 0.92,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.5,,,,,40.5 - 75,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,35.3,,,,,15.4 - 48.5,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.3,,,,,2.6 - 10.1,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.4,,,,,0 - 6.8,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,273,,,,,140 - 400,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.4,,,,,<6.5 %, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.32,,,,,1.9 - 23,uIU/mL +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,LIPID PANEL,Direct HDL-C 4th Generation,,1.68,,H,,,1.03 - 1.53,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,LIPID PANEL,Triglycerides (GPO),,0.69,,,,,0.44 - 1.99,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,LIPID PANEL,Cholesterol (High Performance),,4.75,,,,,3.65 - 6.21,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,LIPID PANEL,LDL Chol Friedewald 4th,,2.75,,,,,0 - 3.34,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,RETICULOCYTES,Reticulocyte Count %,,0.7,,,,,0.6 - 2.5,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,TSH,TSH 3rd IS-QT,,1.607,,,,,0.45 - 5.33,mIU/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Specific Gravity,,1.027,,,,,1 - 1.04, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Mar 30, 2026 9:31 AM",6227542172,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.2,,,,,0 - 5,mg/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Alkaline Phosphatase,,64,,,,,35 - 104,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,ALT (SGPT),,21,,,,,4 - 43,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,GGT,,30,,,,,4 - 49,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,LDH,,164,,,,,53 - 234,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Urea Nitrogen,,4.5,,,,,1.4 - 8.6,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,31 - 101,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Serum Uric Acid,,315,,,,,149 - 446,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Calcium (EDTA),,2.42,,,,,2.07 - 2.64,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Phosphorus,,1.08,,,,,0.71 - 1.65,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Creatine Kinase,,151,,,,,26 - 192,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Serum Bicarbonate,,24.8,,,,,19.3 - 29.3,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,135,,,,,116 - 164,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.44,,,,,3.8 - 10.7,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.89,,,,,1.96 - 7.23,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.02,,,,,0.91 - 4.28,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.33,,,,,0.12 - 0.92,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,52.3,,,,,40.5 - 75,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,40.6,,,,,15.4 - 48.5,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.5,,,,,2.6 - 10.1,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,307,,,,,140 - 400,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.4,,,,,<6.5 %, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.60,,,,,1.9 - 23,uIU/mL +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,LIPID PANEL,Direct HDL-C 4th Generation,,1.98,,H,,,1.03 - 1.53,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,LIPID PANEL,Triglycerides (GPO),,1.32,,,,,0.59 - 2.96,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,LIPID PANEL,Cholesterol (High Performance),,5.66,,,,,4.42 - 7.53,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,LIPID PANEL,LDL Chol Friedewald 4th,,3.08,,,,,0 - 3.34,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,TSH,TSH 3rd IS-QT,,3.912,,,,,0.45 - 5.33,mIU/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Specific Gravity,,1.025,,,,,1 - 1.04, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Mar 16, 2026 9:16 AM",6227542171,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.7,,,,,0 - 5,mg/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 5,/HPF +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.2,,,,,0 - 6.2,umol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Alkaline Phosphatase,,91,,,,,40 - 129,U/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,ALT (SGPT),,29,,,,,5 - 48,U/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,AST (SGOT),,39,,,,,8 - 40,U/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,GGT,,13,,,,,10 - 61,U/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,LDH,,206,,,,,53 - 234,U/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Urea Nitrogen,,5.5,,,,,1.4 - 8.6,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,104,,,,,40 - 110,umol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Glucose Fasting,,5.6,,,,,3.9 - 5.6,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Serum Uric Acid,,223,,,,,125 - 488,umol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Calcium (EDTA),,2.58,,,,,2.07 - 2.64,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Albumin-BCG,,51,R,H,,,33 - 49,g/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Creatine Kinase,,1857,R,H SF,,Diluted for quantitation,39 - 308,U/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Serum Bicarbonate,,23.1,,,,,19.3 - 29.3,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,157,,,,,127 - 181,g/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,4.5 - 6.4,TI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.41,,,,,3.8 - 10.7,GI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.57,,,,,1.96 - 7.23,GI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.23,,,,,0.91 - 4.28,GI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.48,,,,,0.12 - 0.92,GI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,71.3,,,,,40.5 - 75,% +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,19.1,,,,,15.4 - 48.5,% +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.5,,,,,2.6 - 10.1,% +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.3,,,,,0 - 6.8,% +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,242,,,,,140 - 400,GI/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,6.71,,,,,1.9 - 23,uIU/mL +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,LIPID PANEL,Direct HDL-C 4th Generation,,1.23,,,,,1.03 - 1.53,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,LIPID PANEL,Triglycerides (GPO),,1.12,,,,,0.5 - 2.81,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,LIPID PANEL,Cholesterol (High Performance),,3.95,,,,,3.31 - 6.1,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,LIPID PANEL,LDL Chol Friedewald 4th,,2.21,,,,,0 - 3.34,mmol/L +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,RETICULOCYTES,Reticulocyte Count %,,0.6,,,,,0.6 - 2.5,% +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Specific Gravity,,1.036,R,H,,,1 - 1.04, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Protein,,Trace,R,H,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 DB Baseline,,"Mar 10, 2026 10:21 AM",6227844725,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.7,,,,,0 - 5,mg/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.1,,,,,0 - 6.2,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Alkaline Phosphatase,,53,,,,,40 - 129,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,ALT (SGPT),,79,,H RX,,,5 - 48,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,AST (SGOT),,46,,H,,,8 - 40,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,GGT,,68,,H,,,10 - 50,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,LDH,,161,,,,,53 - 234,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Urea Nitrogen,,4.8,,,,,1.4 - 8.6,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,95,,,,,40 - 119,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Glucose Fasting,,7.0,,H,,,3.9 - 5.6,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Serum Uric Acid,,393,,,,,149 - 494,umol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Calcium (EDTA),,2.28,,,,,2.07 - 2.64,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Phosphorus,,0.81,,,,,0.71 - 1.65,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Total Protein,,72,,,,,60 - 80,g/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Creatine Kinase,,212,,,,,39 - 308,U/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Serum Bicarbonate,,22.5,,,,,19.3 - 29.3,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,132,,,,,125 - 170,g/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,,,,0.37 - 0.51, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.9,,L,,,4 - 5.8,TI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,98,,,,,80 - 100,fL +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.42,,,,,3.8 - 10.7,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.42,,,,,1.96 - 7.23,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.61,,,,,0.8 - 3,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.28,,,,,0.12 - 0.92,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.8,,,,,40.5 - 75,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.4,,,,,15.4 - 48.5,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.4,,,,,2.6 - 10.1,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.3,,,,,0 - 6.8,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.2,,,,,0 - 2,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,149,,,,,140 - 400,GI/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.2,,,,,<6.5 %, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,33.25,R,H,,,1.9 - 23,uIU/mL +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,LIPID PANEL,Direct HDL-C 4th Generation,,0.79,,L,,,1.03 - 1.53,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,LIPID PANEL,Triglycerides (GPO),,2.48,,,,,0.65 - 3.61,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,LIPID PANEL,Cholesterol (High Performance),,4.67,,,,,4.4 - 7.53,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,LIPID PANEL,LDL Chol Friedewald 4th,,2.74,,,,,0 - 3.34,mmol/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,RETICULOCYTES,Reticulocyte Count %,,1.8,,,,,0.6 - 2.5,% +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,TSH,TSH 3rd IS-QT,,1.053,,,,,0.45 - 5.33,mIU/L +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1.01 - 1.03, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,End of Phase/Treatment,,"Mar 10, 2026 9:30 AM",6227542170,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.7,,,,,0 - 5,mg/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.2,,,,,0 - 6.2,umol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,40 - 129,U/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,ALT (SGPT),,22,,,,,5 - 48,U/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,GGT,,26,,,,,10 - 61,U/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,LDH,,161,,,,,53 - 234,U/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,86,,,,,40 - 110,umol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Serum Uric Acid,,261,,,,,125 - 488,umol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Calcium (EDTA),,2.52,,,,,2.07 - 2.64,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Phosphorus,,1.20,,,,,0.71 - 1.65,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Albumin-BCG,,53,,H,,,33 - 49,g/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Creatine Kinase,,70,,,,,39 - 308,U/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Serum Bicarbonate,,25.3,,,,,19.3 - 29.3,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.99,,,,,1.42 - 2.08,mL/sec +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,86,,,,,40 - 110,umol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,81.1,,,,,kg, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,GFR,EGFR by MDRD,,87,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.2,,,,,<6.5 %, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.94,,,,,1.9 - 23,uIU/mL +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,LIPID PANEL,Direct HDL-C 4th Generation,,0.90,,L,,,1.03 - 1.53,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,LIPID PANEL,Triglycerides (GPO),,1.55,,,,,0.56 - 3.62,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,LIPID PANEL,Cholesterol (High Performance),,4.40,,,,,3.88 - 6.83,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,LIPID PANEL,LDL Chol Friedewald 4th,,2.79,,,,,0 - 3.34,mmol/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,RETICULOCYTES,Reticulocyte Count %,,,,,Test cancelled: Clotted Blood Received,,, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,TSH,TSH 3rd IS-QT,,0.855,,,,,0.45 - 5.33,mIU/L +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1 - 1.04, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110012,,,37,years,Male,Part 1 Screening,,"Mar 6, 2026 9:22 AM",6227797407,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,C-REACTIVE PROTEIN,C Reactive Protein HS,,12.0,,H,,,0 - 5,mg/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.7,,,,,0 - 6.2,umol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Alkaline Phosphatase,,120,,,,,40 - 129,U/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,ALT (SGPT),,15,,,,,5 - 48,U/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,GGT,,15,,,,,10 - 50,U/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,LDH,,165,,,,,53 - 234,U/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Urea Nitrogen,,6.1,,,,,1.4 - 8.6,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,108,,,,,40 - 119,umol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Glucose Fasting,,5.7,,H,,,3.9 - 5.6,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Serum Uric Acid,,237,,,,,149 - 494,umol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Phosphorus,,0.98,,,,,0.71 - 1.65,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Total Protein,,84,,H,,,60 - 80,g/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Creatine Kinase,,116,,,,,39 - 308,U/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Serum Sodium,,138,,,,,135 - 145,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Serum Bicarbonate,,17.8,,L,,,19.3 - 29.3,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.23,,L,,,1.42 - 2.08,mL/sec +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,108,,,,,40 - 119,umol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,82.0,,,,,kg, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,GFR,EGFR by MDRD,,60,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,125 - 170,g/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.37 - 0.51, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4 - 5.8,TI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,83,,,,,80 - 100,fL +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,9.37,,,,,3.8 - 10.7,GI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.83,,,,,1.96 - 7.23,GI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.79,,,,,0.8 - 3,GI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.61,,,,,0.12 - 0.92,GI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,72.9,,,,,40.5 - 75,% +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,19.1,,,,,15.4 - 48.5,% +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.5,,,,,2.6 - 10.1,% +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.1,,,,,0 - 6.8,% +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,509,R,H,,,130 - 394,GI/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.5,,H,,,<6.5 %, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.10,,,,,1.9 - 23,uIU/mL +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,LIPID PANEL,Direct HDL-C 4th Generation,,1.24,,,,,1.03 - 1.53,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,LIPID PANEL,Triglycerides (GPO),,1.36,,,,,0.65 - 2.94,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,LIPID PANEL,Cholesterol (High Performance),,3.73,,L,,,4.53 - 7.71,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,LIPID PANEL,LDL Chol Friedewald 4th,,1.87,,,,,0 - 3.34,mmol/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,RETICULOCYTES,Reticulocyte Count %,,0.7,,,,,0.6 - 2.5,% +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,TSH,TSH 3rd IS-QT,,1.311,,,,,0.45 - 5.33,mIU/L +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1.01 - 1.03, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110011,,,61,years,Male,Part 1 Screening,,"Mar 2, 2026 9:05 AM",6227797408,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.5,,,,,0 - 5,mg/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Total Bilirubin,,15,,,,,3 - 21,umol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.7,,,,,0 - 6.2,umol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Alkaline Phosphatase,,89,,,,,40 - 129,U/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,5 - 48,U/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,GGT,,13,,,,,10 - 61,U/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,LDH,,157,,,,,53 - 234,U/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Urea Nitrogen,,4.9,,,,,1.4 - 8.6,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,90,,,,,40 - 110,umol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Serum Uric Acid,,287,,,,,125 - 488,umol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Calcium (EDTA),,2.55,,,,,2.07 - 2.64,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Albumin-BCG,,51,,H,,,33 - 49,g/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Creatine Kinase,,332,,H,,,39 - 308,U/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Serum Potassium,,3.9,,,,,3.5 - 5.2,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Serum Bicarbonate,,23.8,,,,,19.3 - 29.3,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.60,,,,,1.42 - 2.08,mL/sec +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,90,,,,,40 - 110,umol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,61.0,,,,,kg, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,GFR,EGFR by MDRD,,89,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,149,,,,,127 - 181,g/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.39 - 0.54, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.69,,,,,3.8 - 10.7,GI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.98,,,,,1.96 - 7.23,GI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.11,,,,,0.91 - 4.28,GI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.45,,,,,0.12 - 0.92,GI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.06,,,,,0 - 0.57,GI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.10,,,,,0 - 0.2,GI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,74.5,,,,,40.5 - 75,% +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,16.5,,,,,15.4 - 48.5,% +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.8,,,,,2.6 - 10.1,% +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.4,,,,,0 - 2,% +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,262,,,,,140 - 400,GI/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.1,,,,,<6.5 %, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.81,,,,,1.9 - 23,uIU/mL +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,LIPID PANEL,Direct HDL-C 4th Generation,,1.32,,,,,1.03 - 1.53,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,LIPID PANEL,Triglycerides (GPO),,0.69,,,,,0.5 - 2.81,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,LIPID PANEL,Cholesterol (High Performance),,4.31,,,,,3.31 - 6.1,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,LIPID PANEL,LDL Chol Friedewald 4th,,2.67,,,,,0 - 3.34,mmol/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,TSH,TSH 3rd IS-QT,,0.928,,,,,0.45 - 5.33,mIU/L +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Specific Gravity,,1.009,,,,,1 - 1.04, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110010,,,25,years,Male,Part 1 Screening,,"Feb 17, 2026 11:03 AM",6227797406,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.4,,,,,0 - 5,mg/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Alkaline Phosphatase,,67,,,,,35 - 104,U/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,ALT (SGPT),,28,,,,,4 - 43,U/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,AST (SGOT),,30,,,,,8 - 40,U/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,GGT,,27,,,,,4 - 49,U/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,LDH,,166,,,,,53 - 234,U/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Urea Nitrogen,,4.7,,,,,1.4 - 8.6,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,31 - 101,umol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Serum Uric Acid,,337,,,,,149 - 446,umol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Calcium (EDTA),,2.51,,,,,2.07 - 2.64,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Phosphorus,,1.16,,,,,0.71 - 1.65,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Creatine Kinase,,148,,,,,26 - 192,U/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Serum Bicarbonate,,21.7,,,,,19.3 - 29.3,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,145,,,,,116 - 164,g/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,8.09,,,,,3.8 - 10.7,GI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.49,,,,,1.96 - 7.23,GI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.02,,,,,0.91 - 4.28,GI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.33,,,,,0.12 - 0.92,GI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.16,,,,,0 - 0.57,GI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,55.6,,,,,40.5 - 75,% +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,37.4,,,,,15.4 - 48.5,% +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.0,,,,,2.6 - 10.1,% +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.0,,,,,0 - 6.8,% +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,316,,,,,140 - 400,GI/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.12,,,,,1.9 - 23,uIU/mL +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,LIPID PANEL,Direct HDL-C 4th Generation,,1.96,,H,,,1.03 - 1.53,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,LIPID PANEL,Triglycerides (GPO),,1.32,,,,,0.59 - 2.96,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,LIPID PANEL,Cholesterol (High Performance),,5.64,,,,,4.42 - 7.53,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,LIPID PANEL,LDL Chol Friedewald 4th,,3.08,,,,,0 - 3.34,mmol/L +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,RETICULOCYTES,Reticulocyte Count %,,0.6,,,,,0.6 - 2.5,% +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Specific Gravity,,1.021,,,,,1 - 1.04, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 2 OL Induction Day 29,,"Feb 16, 2026 9:18 AM",6226550646,URINE MICRO PANEL,Ur Microscopic,,Negative,,,,, NEGATIVE$,NEGATIVE +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.0,,,,,0 - 5,mg/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CELLULAR ELEMENTS,Ur WBC/HPF,,3,,,,,0 - 12,/HPF +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.4,,,,,0 - 6.2,umol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Alkaline Phosphatase,,90,,,,,35 - 104,U/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,AST (SGOT),,15,,,,,8 - 40,U/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,GGT,,8,,,,,4 - 49,U/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,LDH,,150,,,,,53 - 234,U/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Urea Nitrogen,,4.1,,,,,1.4 - 8.6,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,61,,,,,31 - 101,umol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Serum Uric Acid,,250,,,,,125 - 428,umol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Calcium (EDTA),,2.30,,,,,2.07 - 2.64,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Phosphorus,,1.08,,,,,0.71 - 1.65,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Total Protein,,77,,,,,61 - 84,g/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Creatine Kinase,,69,,,,,26 - 192,U/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Serum Potassium,,4.9,,,,,3.5 - 5.2,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Serum Bicarbonate,,23.4,,,,,19.3 - 29.3,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,136,,,,,116 - 164,g/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.73,,,,,3.8 - 10.7,GI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.57,,,,,1.96 - 7.23,GI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.54,,,,,0.91 - 4.28,GI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.42,,,,,0.12 - 0.92,GI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.1,,,,,40.5 - 75,% +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.9,,,,,15.4 - 48.5,% +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.9,,,,,0 - 6.8,% +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,348,,,,,140 - 400,GI/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.60,,,,,1.9 - 23,uIU/mL +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,LIPID PANEL,Direct HDL-C 4th Generation,,1.10,,,,,1.03 - 1.53,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,LIPID PANEL,Triglycerides (GPO),,1.17,,,,,0.44 - 1.99,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,LIPID PANEL,Cholesterol (High Performance),,4.41,,,,,3.65 - 6.21,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,LIPID PANEL,LDL Chol Friedewald 4th,,2.77,,,,,0 - 3.34,mmol/L +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,RETICULOCYTES,Reticulocyte Count %,,1.9,,,,,0.6 - 2.5,% +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Specific Gravity,,1.026,,,,,1 - 1.04, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MACRO PANEL,Ur Leukocyte Esterase,,+1,,H,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 2 OL Induction Day 29,,"Feb 3, 2026 10:23 AM",6226561517,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.2,,,,,0 - 5,mg/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CELLULAR ELEMENTS,Ur WBC/HPF,,4,,,,,0 - 12,/HPF +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Total Bilirubin,,<3,,L,,Result verified by repeat analysis,3 - 21,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.5,,,,,0 - 6.2,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,35 - 104,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,ALT (SGPT),,11,,,,,4 - 43,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,AST (SGOT),,13,,,,,8 - 40,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,GGT,,16,,,,,4 - 49,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,LDH,,128,,,,,53 - 234,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Urea Nitrogen,,7.9,,,,,1.4 - 8.6,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,84,,,,,31 - 101,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Serum Uric Acid,,250,,,,,125 - 428,umol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Calcium (EDTA),,2.33,,,,,2.07 - 2.64,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Phosphorus,,0.97,,,,,0.71 - 1.65,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Creatine Kinase,,79,,,,,26 - 192,U/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Serum Bicarbonate,,22.0,,,,,19.3 - 29.3,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,123,,,,,116 - 164,g/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,,,,0.34 - 0.48, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.1,,,,,4.1 - 5.6,TI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,3.99,,,,,3.8 - 10.7,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.90,,L,,,1.96 - 7.23,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.74,,,,,0.91 - 4.28,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.18,,,,,0.12 - 0.92,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,47.6,,,,,40.5 - 75,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,43.6,,,,,15.4 - 48.5,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.5,,,,,2.6 - 10.1,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.8,,,,,0 - 6.8,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,301,,,,,140 - 400,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.6,,,,,<6.5 %, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.63,,,,,1.9 - 23,uIU/mL +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,LIPID PANEL,Direct HDL-C 4th Generation,,1.75,,H,,,1.03 - 1.53,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,LIPID PANEL,Triglycerides (GPO),,0.50,,,,,0.44 - 1.99,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,LIPID PANEL,Cholesterol (High Performance),,4.64,,,,,3.65 - 6.21,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,LIPID PANEL,LDL Chol Friedewald 4th,,2.66,,,,,0 - 3.34,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,RETICULOCYTES,Reticulocyte Count %,,0.7,,,,,0.6 - 2.5,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,TSH,TSH 3rd IS-QT,,1.963,,,,,0.45 - 5.33,mIU/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Blood,,+1,,H,,,Ref Rng:$Negative-Trace, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MACRO PANEL,Ur Leukocyte Esterase,,+1,,H,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Jan 30, 2026 8:36 AM",6227498380,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.5,,,,,0 - 5,mg/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Alkaline Phosphatase,,52,,,,,40 - 129,U/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,ALT (SGPT),,77,,H RX,,,5 - 48,U/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,AST (SGOT),,49,,H,,,8 - 40,U/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,GGT,,53,,H,,,10 - 50,U/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,LDH,,139,,,,,53 - 234,U/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,91,,,,,40 - 119,umol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Glucose Fasting,,6.3,,H,,,3.9 - 5.6,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Serum Uric Acid,,507,,H,,,149 - 494,umol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Phosphorus,,0.92,,,,,0.71 - 1.65,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Total Protein,,74,,,,,60 - 80,g/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Albumin-BCG,,46,,,,,33 - 49,g/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Creatine Kinase,,201,,,,,39 - 308,U/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Serum Sodium,,140,,,,,135 - 145,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Serum Bicarbonate,,27.8,,,,,19.3 - 29.3,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,128,,,,,125 - 170,g/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,,,,0.37 - 0.51, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.9,,L,,,4 - 5.8,TI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,80 - 100,fL +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.20,,,,,3.8 - 10.7,GI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.39,,,,,1.96 - 7.23,GI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.38,,,,,0.8 - 3,GI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.33,,,,,0.12 - 0.92,GI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.04,,,,,0 - 0.57,GI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.0,,,,,40.5 - 75,% +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.9,,,,,15.4 - 48.5,% +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.8,,,,,2.6 - 10.1,% +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.1,,,,,0 - 6.8,% +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.2,,,,,0 - 2,% +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,144,,,,,140 - 400,GI/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,22.36,,,,,1.9 - 23,uIU/mL +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,LIPID PANEL,Direct HDL-C 4th Generation,,0.75,,L,,,1.03 - 1.53,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,LIPID PANEL,Triglycerides (GPO),,3.00,,,,,0.65 - 3.61,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,LIPID PANEL,Cholesterol (High Performance),,4.63,,,,,4.4 - 7.53,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,LIPID PANEL,LDL Chol Friedewald 4th,,2.51,,,,,0 - 3.34,mmol/L +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Specific Gravity,,1.010,,,,,1.01 - 1.03, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 DB Baseline,,"Jan 27, 2026 8:25 AM",6227144560,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.4,,,,,0 - 6.2,umol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Alkaline Phosphatase,,39,,,,,35 - 104,U/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,ALT (SGPT),,7,,,,,4 - 43,U/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,AST (SGOT),,13,,,,,8 - 40,U/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,GGT,,10,,,,,4 - 49,U/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,LDH,,144,,,,,53 - 234,U/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Urea Nitrogen,,2.9,,,,,1.4 - 8.6,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 101,umol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Serum Uric Acid,,162,,,,,125 - 428,umol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Calcium (EDTA),,2.41,,,,,2.07 - 2.64,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Phosphorus,,0.94,,,,,0.71 - 1.65,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Creatine Kinase,,56,,,,,26 - 192,U/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Serum Bicarbonate,,26.3,,,,,19.3 - 29.3,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.79,,,,,1.25 - 1.92,mL/sec +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,63,,,,,31 - 101,umol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,70.3,,,,,kg, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,GFR,EGFR by MDRD,,88,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,Result verified by repeat analysis,116 - 164,g/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,Result verified by repeat analysis,4.1 - 5.6,TI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.80,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.45,,,,Result verified by repeat analysis,1.96 - 7.23,GI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.67,,,,,0.91 - 4.28,GI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.43,,,,Result verified by repeat analysis,0.12 - 0.92,GI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.21,,,,Result verified by repeat analysis,0 - 0.57,GI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,51.1,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,34.7,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,9.0,,,,Result verified by repeat analysis,2.6 - 10.1,% +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.4,,,,Result verified by repeat analysis,0 - 6.8,% +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,Result verified by repeat analysis,0 - 2,% +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,254,,,,Result verified by repeat analysis,140 - 400,GI/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,6.02,,,,,1.9 - 23,uIU/mL +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,LIPID PANEL,Direct HDL-C 4th Generation,,1.67,,H,,,1.03 - 1.53,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,LIPID PANEL,Triglycerides (GPO),,0.69,,,,,0.51 - 2.42,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,LIPID PANEL,Cholesterol (High Performance),,5.79,,,,,4.01 - 6.85,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,LIPID PANEL,LDL Chol Friedewald 4th,,3.80,,H,,,0 - 3.34,mmol/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,TSH,TSH 3rd IS-QT,,1.837,,,,,0.45 - 5.33,mIU/L +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Specific Gravity,,1.005,,,,,1 - 1.04, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110009,,,48,years,Female,Part 1 Screening,,"Jan 21, 2026 10:11 AM",6227542160,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.9,,,,,0 - 5,mg/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CELLULAR ELEMENTS,Ur RBC/HPF,,3,,,,,0 - 8,/HPF +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.4,,,,,0 - 6.2,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,35 - 104,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,ALT (SGPT),,23,,,,,4 - 43,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,AST (SGOT),,27,,,,,8 - 40,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,GGT,,21,,,,,4 - 49,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,LDH,,167,,,,,53 - 234,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,79,,,,,31 - 101,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Serum Uric Acid,,286,,,,,149 - 446,umol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Calcium (EDTA),,2.43,,,,,2.07 - 2.64,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Phosphorus,,1.01,,,,,0.71 - 1.65,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Total Protein,,76,,,,,61 - 84,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Creatine Kinase,,147,,,,,26 - 192,U/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Serum Bicarbonate,,22.4,,,,,19.3 - 29.3,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,FREE T4,Free Thyroxine-QT,,9,,,,,8 - 14,pmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,143,,,,,116 - 164,g/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.1 - 5.6,TI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 98,fL +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.42,,,,,3.8 - 10.7,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.84,,,,,1.96 - 7.23,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.08,,,,,0.91 - 4.28,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,51.8,,,,,40.5 - 75,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,41.6,,,,,15.4 - 48.5,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,3.9,,,,,2.6 - 10.1,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.8,,,,,0 - 6.8,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,332,,,,,140 - 400,GI/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.2,,,,,<6.5 %, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.98,,,,,1.9 - 23,uIU/mL +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,LIPID PANEL,Direct HDL-C 4th Generation,,2.01,,H,,,1.03 - 1.53,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,LIPID PANEL,Triglycerides (GPO),,1.43,,,,,0.59 - 2.96,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,LIPID PANEL,Cholesterol (High Performance),,5.46,,,,,4.42 - 7.53,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,LIPID PANEL,LDL Chol Friedewald 4th,,2.80,,,,,0 - 3.34,mmol/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,TSH,TSH 3rd IS-QT,,6.224,,H SF,,,0.45 - 5.33,mIU/L +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Specific Gravity,,1.033,,,,,1 - 1.04, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,End of Phase/Treatment,,"Jan 16, 2026 8:48 AM",6227542173,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.2,,,,,0 - 5,mg/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Alkaline Phosphatase,,73,,,,,35 - 104,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,AST (SGOT),,13,,,,,8 - 40,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,GGT,,7,,,,,4 - 49,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,LDH,,145,,,,,53 - 234,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Urea Nitrogen,,4.2,,,,,1.4 - 8.6,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,56,,,,,31 - 101,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Glucose Fasting,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Serum Uric Acid,,236,,,,,125 - 428,umol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Phosphorus,,1.19,,,,,0.71 - 1.65,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Creatine Kinase,,72,,,,,26 - 192,U/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Serum Bicarbonate,,23.8,,,,,19.3 - 29.3,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,127,,,,,116 - 164,g/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,,,,0.34 - 0.48, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,4.1 - 5.6,TI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.59,,,,,3.8 - 10.7,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.25,,,,,1.96 - 7.23,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.64,,,,,0.91 - 4.28,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.37,,,,,0.12 - 0.92,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.19,,,,,0 - 0.2,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,64.5,,,,,40.5 - 75,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,24.9,,,,,15.4 - 48.5,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.0,,,,,0 - 6.8,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.9,,H,,,0 - 2,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,300,,,,,140 - 400,GI/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,4.9,,,,,<6.5 %, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.92,,,,,1.9 - 23,uIU/mL +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,LIPID PANEL,Direct HDL-C 4th Generation,,1.01,,L,,,1.03 - 1.53,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,LIPID PANEL,Triglycerides (GPO),,1.05,,,,,0.44 - 1.99,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,LIPID PANEL,Cholesterol (High Performance),,3.68,,,,,3.65 - 6.21,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,LIPID PANEL,LDL Chol Friedewald 4th,,2.19,,,,,0 - 3.34,mmol/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,RETICULOCYTES,Reticulocyte Count %,,1.8,,,,,0.6 - 2.5,% +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,TSH,TSH 3rd IS-QT,,1.385,,,,,0.45 - 5.33,mIU/L +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,End of Phase/Treatment,R,"Jan 6, 2026 10:11 AM",6227261836,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,C-REACTIVE PROTEIN,C Reactive Protein HS,,8.1,,H,,,0 - 5,mg/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Alkaline Phosphatase,,51,,,,,40 - 129,U/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,ALT (SGPT),,79,,H RX,,,5 - 48,U/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,AST (SGOT),,51,,H,,,8 - 40,U/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,GGT,,52,,H,,,10 - 50,U/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,LDH,,160,,,,,53 - 234,U/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Urea Nitrogen,,4.5,,,,,1.4 - 8.6,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,92,,,,,40 - 119,umol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Glucose Fasting,,6.1,,H,,,3.9 - 5.6,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Serum Uric Acid,,521,,H,,,149 - 494,umol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Phosphorus,,1.00,,,,,0.71 - 1.65,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Total Protein,,75,,,,,60 - 80,g/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Creatine Kinase,,206,,,,,39 - 308,U/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Serum Bicarbonate,,25.6,,,,,19.3 - 29.3,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.95,,,,,1.42 - 2.08,mL/sec +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,92,,,,,40 - 119,umol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,108.0,,,,,kg, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,GFR,EGFR by MDRD,,73,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,132,,,,,125 - 170,g/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.37 - 0.51, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,,,,4 - 5.8,TI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,97,,,,,80 - 100,fL +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.10,,,,,3.8 - 10.7,GI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.77,,,,,1.96 - 7.23,GI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.71,,,,,0.8 - 3,GI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.52,,,,,0.12 - 0.92,GI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.05,,,,,0 - 0.57,GI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,61.7,,,,,40.5 - 75,% +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,28.1,,,,,15.4 - 48.5,% +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.5,,,,,2.6 - 10.1,% +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.9,,,,,0 - 6.8,% +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,178,,,,,140 - 400,GI/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,6.2,,,,,<6.5 %, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,15.17,,,,,1.9 - 23,uIU/mL +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,LIPID PANEL,Direct HDL-C 4th Generation,,0.74,,L,,,1.03 - 1.53,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,LIPID PANEL,Triglycerides (GPO),,2.04,,,,,0.65 - 3.61,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,LIPID PANEL,Cholesterol (High Performance),,4.38,,L,,,4.4 - 7.53,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,LIPID PANEL,LDL Chol Friedewald 4th,,2.71,,,,,0 - 3.34,mmol/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,RETICULOCYTES,Reticulocyte Count %,,1.9,,,,,0.6 - 2.5,% +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,TSH,TSH 3rd IS-QT,,1.243,,,,,0.45 - 5.33,mIU/L +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Specific Gravity,,1.013,,,,,1.01 - 1.03, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110008,,,59,years,Male,Part 1 Screening,,"Jan 5, 2026 10:58 AM",6227542161,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.6,,,,,0 - 6.2,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Alkaline Phosphatase,,93,,,,,40 - 129,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,ALT (SGPT),,128,,H RX,,,5 - 48,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,AST (SGOT),,54,,H,,,8 - 40,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,GGT,,247,,H,,Result verified by repeat analysis,10 - 61,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,LDH,,161,,,,,53 - 234,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Urea Nitrogen,,6.0,,,,,1.4 - 8.6,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,89,,,,,40 - 110,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Glucose Fasting,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Serum Uric Acid,,430,,,,,125 - 488,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Calcium (EDTA),,2.56,,,,,2.07 - 2.64,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Phosphorus,,1.25,,,,,0.71 - 1.65,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Total Protein,,77,,,,,61 - 84,g/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Creatine Kinase,,127,,,,,39 - 308,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Serum Bicarbonate,,24.5,,,,,19.3 - 29.3,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,162,,,,,127 - 181,g/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.4,,,,,4.5 - 6.4,TI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.78,,,,,3.8 - 10.7,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.00,,,,,1.96 - 7.23,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.31,,,,,0.91 - 4.28,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.26,,,,,0.12 - 0.92,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.16,,,,,0 - 0.57,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,62.8,,,,,40.5 - 75,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.5,,,,,15.4 - 48.5,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.4,,,,,0 - 6.8,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.9,,,,,0 - 2,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,271,,,,,140 - 400,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.1,,,,,<6.5 %, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,8.27,,,,,1.9 - 23,uIU/mL +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,LIPID PANEL,Direct HDL-C 4th Generation,,1.32,,,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,LIPID PANEL,Triglycerides (GPO),,2.24,,,,,0.5 - 2.81,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,LIPID PANEL,Cholesterol (High Performance),,5.39,,,,,3.31 - 6.1,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,LIPID PANEL,LDL Chol Friedewald 4th,,3.04,,,,,0 - 3.34,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,TSH,TSH 3rd IS-QT,,1.417,,,,,0.45 - 5.33,mIU/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Jan 2, 2026 9:28 AM",6227498379,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.0,,,,,0 - 5,mg/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.4,,,,,0 - 6.2,umol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Alkaline Phosphatase,,63,,,,,35 - 104,U/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,GGT,,15,,,,,4 - 49,U/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,LDH,,142,,,,,53 - 234,U/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Urea Nitrogen,,4.2,,,,,1.4 - 8.6,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,81,,,,,31 - 101,umol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Serum Uric Acid,,291,,,,,125 - 428,umol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Phosphorus,,1.15,,,,,0.71 - 1.65,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Total Protein,,70,,,,,61 - 84,g/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Creatine Kinase,,109,,,,,26 - 192,U/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Serum Bicarbonate,,21.7,,,,,19.3 - 29.3,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.55,,,,,1.25 - 1.92,mL/sec +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,81,,,,,31 - 101,umol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,68.0,,,,,kg, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,FSH,Follicle Stimulating Hormone,,1.95,,RX,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,124,,,,,116 - 164,g/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,,,,0.34 - 0.48, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4.1 - 5.6,TI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.35,,,,,3.8 - 10.7,GI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.19,,,,,1.96 - 7.23,GI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.57,,,,,0.91 - 4.28,GI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.6,,,,,40.5 - 75,% +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.4,,,,,15.4 - 48.5,% +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.3,,,,,2.6 - 10.1,% +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.1,,,,,0 - 6.8,% +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.6,,,,,0 - 2,% +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,340,,,,,140 - 400,GI/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.7,,,,,<6.5 %, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.35,,,,,1.9 - 23,uIU/mL +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,LIPID PANEL,Direct HDL-C 4th Generation,,1.82,,H,,,1.03 - 1.53,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,LIPID PANEL,Triglycerides (GPO),,0.63,,,,,0.44 - 1.99,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,LIPID PANEL,Cholesterol (High Performance),,5.11,,,,,3.65 - 6.21,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,LIPID PANEL,LDL Chol Friedewald 4th,,3.00,,,,,0 - 3.34,mmol/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,RETICULOCYTES,Reticulocyte Count %,,0.7,,,,,0.6 - 2.5,% +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,TSH,TSH 3rd IS-QT,,2.024,,,,,0.45 - 5.33,mIU/L +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1 - 1.04, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Retest,R,"Dec 11, 2025 9:05 AM",6226935606,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.7,,,,,0 - 5,mg/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Alkaline Phosphatase,,62,,,,,35 - 104,U/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,ALT (SGPT),,21,,,,,4 - 43,U/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,GGT,,33,,,,,4 - 49,U/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,LDH,,158,,,,,53 - 234,U/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Urea Nitrogen,,4.1,,,,,1.4 - 8.6,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,73,,,,,31 - 101,umol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Glucose Fasting,,4.2,,,,,3.9 - 5.6,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Serum Uric Acid,,307,,,,,149 - 446,umol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Phosphorus,,1.07,,,,,0.71 - 1.65,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Creatine Kinase,,203,,H,,,26 - 192,U/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Serum Bicarbonate,,22.0,,,,,19.3 - 29.3,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,136,,,,,116 - 164,g/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.49,,,,,3.8 - 10.7,GI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.93,,,,,1.96 - 7.23,GI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.72,,,,,0.91 - 4.28,GI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.32,,,,,0 - 0.57,GI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.17,,,,,0 - 0.2,GI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,45.2,,,,,40.5 - 75,% +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,41.9,,,,,15.4 - 48.5,% +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.3,,,,,2.6 - 10.1,% +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.9,,,,,0 - 6.8,% +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.7,R,H,,,0 - 2,% +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,332,,,,,140 - 400,GI/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.15,,,,,1.9 - 23,uIU/mL +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,LIPID PANEL,Direct HDL-C 4th Generation,,1.91,,H,,,1.03 - 1.53,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,LIPID PANEL,Triglycerides (GPO),,1.28,,,,,0.59 - 2.96,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,LIPID PANEL,Cholesterol (High Performance),,5.21,,,,,4.42 - 7.53,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,LIPID PANEL,LDL Chol Friedewald 4th,,2.71,,,,,0 - 3.34,mmol/L +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 DB Baseline,,"Dec 11, 2025 8:13 AM",6227144562,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,C-REACTIVE PROTEIN,C Reactive Protein HS,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Total Bilirubin,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Alkaline Phosphatase,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,ALT (SGPT),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,AST (SGOT),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,GGT,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,LDH,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Urea Nitrogen,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Glucose Fasting,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Serum Uric Acid,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Calcium (EDTA),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Phosphorus,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Total Protein,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Albumin-BCG,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Creatine Kinase,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Serum Sodium,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Serum Potassium,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Serum Bicarbonate,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,CHEMISTRY PANEL,Serum Chloride,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,126,,,,,116 - 164,g/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,,,,0.34 - 0.48, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,4.1 - 5.6,TI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.49,,,,,3.8 - 10.7,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.37,,,,,1.96 - 7.23,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.74,,,,,0.91 - 4.28,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.07,,,,,0 - 0.57,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,52.8,,,,,40.5 - 75,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,38.7,,,,,15.4 - 48.5,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.5,,,,,2.6 - 10.1,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,299,,,,,140 - 400,GI/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.65,,,,,1.9 - 23,uIU/mL +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,LIPID PANEL,Direct HDL-C 4th Generation,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,LIPID PANEL,Triglycerides (GPO),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,LIPID PANEL,Cholesterol (High Performance),,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,LIPID PANEL,LDL Chol Friedewald 4th,,Required testing unavailable,,,,,0 - 3.34,mmol/L +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,RETICULOCYTES,Reticulocyte Count %,,1.0,,,,,0.6 - 2.5,% +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,TSH,TSH 3rd IS-QT,,,,,"Test cancelled: Expired contain, test cancel",,, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Specific Gravity,,1.011,,,,,1 - 1.04, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,End of Phase/Treatment,,"Dec 5, 2025 9:23 AM",6225351093,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.1,,,,,0 - 5,mg/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CELLULAR ELEMENTS,Ur WBC/HPF,,5,,,,,0 - 12,/HPF +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CELLULAR ELEMENTS,Ur Squamous Epithelial Cells,,80,,,,,0 - 3,/HPF +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Alkaline Phosphatase,,98,,,,,35 - 104,U/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,ALT (SGPT),,8,,,,,4 - 43,U/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,AST (SGOT),,10,,,,,8 - 40,U/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,GGT,,8,,,,,4 - 49,U/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,LDH,,142,,,,,53 - 234,U/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Urea Nitrogen,,4.8,,,,,1.4 - 8.6,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,62,,,,,31 - 101,umol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Serum Uric Acid,,261,,,,,125 - 428,umol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Phosphorus,,1.10,,,,,0.71 - 1.65,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Total Protein,,78,,,,,61 - 84,g/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Creatine Kinase,,42,,,,,26 - 192,U/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Serum Bicarbonate,,21.8,,,,,19.3 - 29.3,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,CRYSTALS,Ur Calcium Oxalate Crystals,,Present,,,,,Ref Rng:Not present, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,136,,,,,116 - 164,g/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 98,fL +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.82,,,,,3.8 - 10.7,GI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,5.12,,,,,1.96 - 7.23,GI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.07,,,,,0.91 - 4.28,GI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.08,,,,,0 - 0.2,GI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,65.4,,,,,40.5 - 75,% +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.4,,,,,15.4 - 48.5,% +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.0,,,,,2.6 - 10.1,% +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.1,,,,,0 - 6.8,% +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,322,,,,,140 - 400,GI/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.28,,,,,1.9 - 23,uIU/mL +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,LIPID PANEL,Direct HDL-C 4th Generation,,1.25,,,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,LIPID PANEL,Triglycerides (GPO),,0.86,,,,,0.44 - 1.99,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,LIPID PANEL,Cholesterol (High Performance),,4.48,,,,,3.65 - 6.21,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,LIPID PANEL,LDL Chol Friedewald 4th,,2.84,,,,,0 - 3.34,mmol/L +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,MISCELLANEOUS ELEMENTS,Ur Mucous,,Present,,,,,Ref Rng:Not present, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,RETICULOCYTES,Reticulocyte Count %,,2.1,,,,,0.6 - 2.5,% +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Specific Gravity,,1.037,,H,,,1 - 1.04, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MACRO PANEL,Ur Leukocyte Esterase,,+1,,H,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 DB Baseline,,"Nov 25, 2025 10:04 AM",6227144561,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.4,,,,,0 - 5,mg/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.6,,,,,0 - 6.2,umol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Alkaline Phosphatase,,100,,,,,35 - 104,U/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,ALT (SGPT),,20,,,,,4 - 43,U/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,AST (SGOT),,25,,,,,8 - 40,U/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,GGT,,63,,H,,,4 - 49,U/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,LDH,,174,,,,,53 - 234,U/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Glucose Fasting,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Serum Uric Acid,,291,,,,,149 - 446,umol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Calcium (EDTA),,2.42,,,,,2.07 - 2.64,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Phosphorus,,1.02,,,,,0.71 - 1.65,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Total Protein,,78,,,,,61 - 84,g/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Creatine Kinase,,141,,,,,26 - 192,U/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Serum Bicarbonate,,21.3,,,,,19.3 - 29.3,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.17,,L,,,1.25 - 1.92,mL/sec +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,75,,,,,31 - 101,umol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,59.2,,,,,kg, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,FREE T4,Free Thyroxine-QT,,9,,,,,8 - 14,pmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,GFR,EGFR by MDRD,,69,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,140,,,,,116 - 164,g/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.41,,,,,0.34 - 0.48, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.1 - 5.6,TI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 98,fL +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.44,,,,,3.8 - 10.7,GI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.83,,,,,1.96 - 7.23,GI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,4.07,,,,,0.91 - 4.28,GI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.21,,,,,0 - 0.57,GI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,38.0,R,L,,,40.5 - 75,% +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,54.7,R,H,,,15.4 - 48.5,% +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,3.8,,,,,2.6 - 10.1,% +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.8,,,,,0 - 6.8,% +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,295,,,,,140 - 400,GI/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.3,,,,,<6.5%, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.96,,,,,1.9 - 23,uIU/mL +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,LIPID PANEL,Direct HDL-C 4th Generation,,1.84,,H,,,1.03 - 1.53,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,LIPID PANEL,Triglycerides (GPO),,1.42,,,,,0.59 - 2.96,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,LIPID PANEL,Cholesterol (High Performance),,5.78,,,,,4.42 - 7.53,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,LIPID PANEL,LDL Chol Friedewald 4th,,3.29,,,,,0 - 3.34,mmol/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,TSH,TSH 3rd IS-QT,,5.438,R,H SF,,,0.45 - 5.33,mIU/L +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1 - 1.04, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110007,,,56,years,Female,Part 1 Screening,,"Nov 14, 2025 10:22 AM",6225351078,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.4,,,,,0 - 5,mg/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Alkaline Phosphatase,,84,,,,,40 - 129,U/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,ALT (SGPT),,64,,H,,,5 - 48,U/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,AST (SGOT),,27,,,,,8 - 40,U/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,GGT,,123,,H,,,10 - 61,U/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,LDH,,159,,,,,53 - 234,U/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Urea Nitrogen,,6.3,,,,,1.4 - 8.6,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,91,,,,,40 - 110,umol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Serum Uric Acid,,419,,,,,125 - 488,umol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Calcium (EDTA),,2.53,,,,,2.07 - 2.64,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Phosphorus,,1.27,,,,,0.71 - 1.65,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Total Protein,,73,,,,,61 - 84,g/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Creatine Kinase,,141,,,,,39 - 308,U/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Serum Bicarbonate,,21.9,,,,,19.3 - 29.3,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,157,,,,,127 - 181,g/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.88,,,,,3.8 - 10.7,GI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.07,,,,,1.96 - 7.23,GI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.32,,,,,0.91 - 4.28,GI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,62.9,,,,,40.5 - 75,% +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.1,,,,,15.4 - 48.5,% +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.9,,,,,2.6 - 10.1,% +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.0,,,,,0 - 6.8,% +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,266,,,,,140 - 400,GI/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,6.45,,,,,1.9 - 23,uIU/mL +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,LIPID PANEL,Direct HDL-C 4th Generation,,0.92,,L,,,1.03 - 1.53,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,LIPID PANEL,Triglycerides (GPO),,1.73,,,,,0.5 - 2.81,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,LIPID PANEL,Cholesterol (High Performance),,4.62,,,,,3.31 - 6.1,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,LIPID PANEL,LDL Chol Friedewald 4th,,2.91,,,,,0 - 3.34,mmol/L +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 2 OL Induction Day 29,,"Nov 6, 2025 8:14 AM",6226991311,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,C-REACTIVE PROTEIN,C Reactive Protein HS,,5.3,,H,,,0 - 5,mg/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CELLULAR ELEMENTS,Ur WBC/HPF,,3,,,,,0 - 12,/HPF +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.6,,,,,0 - 6.2,umol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Alkaline Phosphatase,,101,,,,,35 - 104,U/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,AST (SGOT),,12,,,,,8 - 40,U/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,GGT,,6,,,,,4 - 49,U/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,LDH,,157,,,,,53 - 234,U/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Urea Nitrogen,,3.7,,,,,1.4 - 8.6,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,57,,,,,31 - 101,umol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Serum Uric Acid,,232,,,,,125 - 428,umol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Calcium (EDTA),,2.27,,,,,2.07 - 2.64,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Phosphorus,,1.14,,,,,0.71 - 1.65,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Creatine Kinase,,59,,,,,26 - 192,U/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Serum Sodium,,136,,,,,132 - 147,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Serum Bicarbonate,,21.4,,,,,19.3 - 29.3,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.50,,H,,,1.25 - 1.92,mL/sec +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,57,,,,,31 - 101,umol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,75.2,,,,,kg, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,GFR,EGFR by MDRD,,108,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,127,,,,,116 - 164,g/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,4.1 - 5.6,TI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 98,fL +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.26,,,,,3.8 - 10.7,GI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.66,,,,,1.96 - 7.23,GI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.98,,,,,0.91 - 4.28,GI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,64.1,,,,,40.5 - 75,% +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.4,,,,,15.4 - 48.5,% +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.4,,,,,2.6 - 10.1,% +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.3,,,,,0 - 6.8,% +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.8,,,,,0 - 2,% +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,335,,,,,140 - 400,GI/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,4.8,,,,,<6.5%, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.40,,,,,1.9 - 23,uIU/mL +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,LIPID PANEL,Direct HDL-C 4th Generation,,0.99,,L,,,1.03 - 1.53,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,LIPID PANEL,Triglycerides (GPO),,0.76,,,,,0.44 - 1.99,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,LIPID PANEL,Cholesterol (High Performance),,4.01,,,,,3.65 - 6.21,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,LIPID PANEL,LDL Chol Friedewald 4th,,2.67,,,,,0 - 3.34,mmol/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,RETICULOCYTES,Reticulocyte Count %,,2.4,,,,,0.6 - 2.5,% +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,TSH,TSH 3rd IS-QT,,1.593,,,,,0.45 - 5.33,mIU/L +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Specific Gravity,,1.029,,,,,1 - 1.04, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MACRO PANEL,Ur Leukocyte Esterase,,+1,,H,,,Ref Rng:Negative, +CZ100110006,,,32,years,Female,Part 1 Screening,,"Nov 4, 2025 7:03 AM",6225351080,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,BENZODIAZEPINE CONFIRM. UR,BenzodiazepineConf-LCMSMS-LDT,,Oxazepam (Confirmed),R,RX,,,No Ref Rng, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.2,,,,,0 - 5,mg/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.6,,,,,0 - 6.2,umol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Alkaline Phosphatase,,94,,,,,40 - 129,U/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,ALT (SGPT),,27,,,,,5 - 48,U/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,AST (SGOT),,23,,,,,8 - 40,U/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,GGT,,17,,,,,10 - 61,U/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,LDH,,161,,,,,53 - 234,U/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Urea Nitrogen,,6.1,,,,,1.4 - 8.6,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,83,,,,,40 - 110,umol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Glucose Fasting,,5.4,,,,,3.9 - 5.6,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Serum Uric Acid,,344,,,,,125 - 488,umol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Calcium (EDTA),,2.46,,,,,2.07 - 2.64,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Phosphorus,,1.03,,,,,0.71 - 1.65,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Total Protein,,78,,,,,61 - 84,g/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Creatine Kinase,,232,,,,,39 - 308,U/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Serum Bicarbonate,,21.3,,,,,19.3 - 29.3,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.37,,H,,,1.42 - 2.08,mL/sec +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,83,,,,,40 - 110,umol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,89.1,,,,,kg, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Detected (unconfirmed),,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,GFR,EGFR by MDRD,,93,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,141,,,,,127 - 181,g/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.39 - 0.54, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.5 - 6.4,TI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.63,,,,,3.8 - 10.7,GI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.10,,,,,1.96 - 7.23,GI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.01,,,,,0.91 - 4.28,GI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.37,,,,,0.12 - 0.92,GI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.11,,,,,0 - 0.57,GI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,46.8,,,,,40.5 - 75,% +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,45.4,,,,,15.4 - 48.5,% +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.6,,,,,0 - 6.8,% +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,306,,,,,140 - 400,GI/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.3,,,,,<6.5%, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,16.63,,,,,1.9 - 23,uIU/mL +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,LIPID PANEL,Direct HDL-C 4th Generation,,0.95,R,L,,,1.03 - 1.53,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,LIPID PANEL,Triglycerides (GPO),,2.07,,,,,0.56 - 3.62,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,LIPID PANEL,Cholesterol (High Performance),,5.65,,,,,3.88 - 6.83,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,LIPID PANEL,LDL Chol Friedewald 4th,,3.75,,H,,,0 - 3.34,mmol/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,TSH,TSH 3rd IS-QT,,2.249,,,,,0.45 - 5.33,mIU/L +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1 - 1.04, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110005,,,33,years,Male,Part 1 Screening,,"Nov 3, 2025 9:40 AM",6225351074,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.4,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,35 - 104,U/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,ALT (SGPT),,9,,,,,4 - 43,U/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,AST (SGOT),,11,,,,,8 - 40,U/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,GGT,,13,,,,,4 - 49,U/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,LDH,,126,,,,,53 - 234,U/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Urea Nitrogen,,3.6,,,,,1.4 - 8.6,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,31 - 101,umol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Glucose Fasting,,5.0,,,,,3.9 - 5.6,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Serum Uric Acid,,217,,,,,125 - 428,umol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Phosphorus,,1.01,,,,,0.71 - 1.65,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Creatine Kinase,,66,,,,,26 - 192,U/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Serum Bicarbonate,,24.5,,,,,19.3 - 29.3,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,121,,,,,116 - 164,g/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,,,,0.34 - 0.48, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4.1 - 5.6,TI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.05,,,,,3.8 - 10.7,GI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.88,,,,,1.96 - 7.23,GI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.73,,,,,0.91 - 4.28,GI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.13,,,,,0 - 0.57,GI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.1,,,,,40.5 - 75,% +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,34.3,,,,,15.4 - 48.5,% +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.7,,,,,2.6 - 10.1,% +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.6,,,,,0 - 6.8,% +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,286,,,,,140 - 400,GI/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.08,,,,,1.9 - 23,uIU/mL +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,LIPID PANEL,Direct HDL-C 4th Generation,,1.85,R,H,,,1.03 - 1.53,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,LIPID PANEL,Triglycerides (GPO),,0.57,,,,,0.44 - 1.99,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,LIPID PANEL,Cholesterol (High Performance),,4.35,,,,,3.65 - 6.21,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,LIPID PANEL,LDL Chol Friedewald 4th,,2.24,,,,,0 - 3.34,mmol/L +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,RETICULOCYTES,Reticulocyte Count %,,0.8,,,,,0.6 - 2.5,% +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Specific Gravity,,1.015,,,,,1 - 1.04, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 DB Baseline,,"Oct 22, 2025 8:04 AM",6225351084,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Total Bilirubin,,11,,,,,3 - 21,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.8,,,,,0 - 6.2,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Alkaline Phosphatase,,88,,,,,40 - 129,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,ALT (SGPT),,46,,,,,5 - 48,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,GGT,,129,,H,,,10 - 61,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,LDH,,156,,,,,53 - 234,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Urea Nitrogen,,5.2,,,,,1.4 - 8.6,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,91,,,,,40 - 110,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Glucose Fasting,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Serum Uric Acid,,429,,,,,125 - 488,umol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Calcium (EDTA),,2.56,,,,,2.07 - 2.64,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Phosphorus,,1.13,,,,,0.71 - 1.65,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Total Protein,,75,,,,,61 - 84,g/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Creatine Kinase,,131,,,,,39 - 308,U/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Serum Bicarbonate,,21.4,,,,,19.3 - 29.3,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,157,,,,,127 - 181,g/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.46,,,,,0.39 - 0.54, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,4.5 - 6.4,TI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.79,,,,,3.8 - 10.7,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.75,,,,,1.96 - 7.23,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.48,,,,,0.91 - 4.28,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.5,,,,,40.5 - 75,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.9,,,,,15.4 - 48.5,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.2,,,,,2.6 - 10.1,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.9,,,,,0 - 6.8,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.5,,,,,0 - 2,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,280,,,,,140 - 400,GI/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,4.8,,,,,<6.5%, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,10.32,,,,,1.9 - 23,uIU/mL +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,LIPID PANEL,Direct HDL-C 4th Generation,,0.92,,L,,,1.03 - 1.53,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,LIPID PANEL,Triglycerides (GPO),,1.99,,,,,0.5 - 2.81,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,LIPID PANEL,Cholesterol (High Performance),,4.77,,,,,3.31 - 6.1,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,LIPID PANEL,LDL Chol Friedewald 4th,,2.94,,,,,0 - 3.34,mmol/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,TSH,TSH 3rd IS-QT,,1.125,,,,,0.45 - 5.33,mIU/L +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Specific Gravity,,1.023,,,,,1 - 1.04, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,End of Phase/Treatment,,"Oct 9, 2025 8:45 AM",6225351095,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.4,,,,,0 - 5,mg/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.2,,,,,0 - 6.2,umol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Alkaline Phosphatase,,89,,,,,35 - 104,U/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,ALT (SGPT),,16,,,,,4 - 43,U/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,AST (SGOT),,14,,,,,8 - 40,U/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,GGT,,16,,,,,4 - 49,U/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,LDH,,124,,,,,53 - 234,U/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Urea Nitrogen,,4.5,,,,,1.4 - 8.6,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 101,umol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Glucose Fasting,,4.3,,,,,3.9 - 5.6,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Serum Uric Acid,,303,,,,,125 - 428,umol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Phosphorus,,1.03,,,,,0.71 - 1.65,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Total Protein,,74,,,,,61 - 84,g/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Creatine Kinase,,79,,,,,26 - 192,U/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Serum Bicarbonate,,23.6,,,,,19.3 - 29.3,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,127,,,,,116 - 164,g/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,83,,,,,79 - 98,fL +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.69,,,,,3.8 - 10.7,GI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.05,,,,,1.96 - 7.23,GI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.72,,,,,0.91 - 4.28,GI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.49,,,,,0.12 - 0.92,GI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.34,,,,,0 - 0.57,GI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.09,,,,,0 - 0.2,GI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,53.5,,,,,40.5 - 75,% +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.1,,,,,15.4 - 48.5,% +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,8.6,,,,,2.6 - 10.1,% +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,6.1,,,,,0 - 6.8,% +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.6,,,,,0 - 2,% +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,274,,,,,140 - 400,GI/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.2,,,,,<6.5%, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.14,,,,,1.9 - 23,uIU/mL +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,LIPID PANEL,Direct HDL-C 4th Generation,,1.48,,,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,LIPID PANEL,Triglycerides (GPO),,0.82,,,,,0.44 - 1.99,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,LIPID PANEL,Cholesterol (High Performance),,3.76,,,,,3.65 - 6.21,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,LIPID PANEL,LDL Chol Friedewald 4th,,1.90,,,,,0 - 3.34,mmol/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,TSH,TSH 3rd IS-QT,,1.582,,,,,0.45 - 5.33,mIU/L +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Specific Gravity,,1.011,,,,,1 - 1.04, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,End of Phase/Treatment,,"Oct 8, 2025 8:16 AM",6225351094,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.4,,,,,0 - 5,mg/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Alkaline Phosphatase,,80,,,,,35 - 104,U/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,ALT (SGPT),,32,,,,,4 - 43,U/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,AST (SGOT),,34,,,,,8 - 40,U/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,GGT,,25,,,,,5 - 50,U/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,LDH,,167,,,,,53 - 234,U/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Serum Uric Acid,,265,,,,,149 - 446,umol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Phosphorus,,1.18,,,,,0.71 - 1.65,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Total Protein,,63,,,,,60 - 80,g/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Creatine Kinase,,46,,,,,26 - 192,U/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Serum Sodium,,143,,,,,135 - 145,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Serum Bicarbonate,,24.9,,,,,19.3 - 29.3,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.74,,,,,1.25 - 1.92,mL/sec +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,75.3,,,,,kg, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,GFR,EGFR by MDRD,,90,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,146,,,,,115 - 158,g/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.34 - 0.48, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.4,,,,,3.9 - 5.5,TI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,95,,,,,80 - 100,fL +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,3.39,R,L,,,3.8 - 10.7,GI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.95,R,L,,,1.96 - 7.23,GI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.01,,,,,0.8 - 3,GI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.24,,,,,0.12 - 0.92,GI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.16,,,,,0 - 0.57,GI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,57.5,,,,,40.5 - 75,% +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.8,,,,,15.4 - 48.5,% +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.1,,,,,2.6 - 10.1,% +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.8,,,,,0 - 6.8,% +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,169,,,,,130 - 394,GI/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.6,,,,,<6.5%, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.01,,,,,1.9 - 23,uIU/mL +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,LIPID PANEL,Direct HDL-C 4th Generation,,1.49,,,,,1.03 - 1.53,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,LIPID PANEL,Triglycerides (GPO),,0.88,,,,,0.63 - 2.71,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,LIPID PANEL,Cholesterol (High Performance),,4.46,R,L,,,4.86 - 8.28,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,LIPID PANEL,LDL Chol Friedewald 4th,,2.57,,,,,0 - 3.34,mmol/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,TSH,TSH 3rd IS-QT,,2.205,,,,,0.45 - 5.33,mIU/L +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1.01 - 1.03, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110004,,,64,years,Female,Part 1 Screening,,"Oct 3, 2025 9:33 AM",6225351077,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.0,,,,,0 - 5,mg/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.5,,,,,0 - 6.2,umol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Alkaline Phosphatase,,61,,,,,35 - 104,U/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,ALT (SGPT),,13,,,,,4 - 43,U/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,GGT,,14,,,,,4 - 49,U/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,LDH,,137,,,,,53 - 234,U/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 8.6,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,79,,,,,31 - 101,umol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Glucose Fasting,,4.5,,,,,3.9 - 5.6,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Serum Uric Acid,,273,,,,,125 - 428,umol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Calcium (EDTA),,2.34,,,,,2.07 - 2.64,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Phosphorus,,1.07,,,,,0.71 - 1.65,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Creatine Kinase,,123,,,,,26 - 192,U/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Serum Bicarbonate,,22.8,,,,,19.3 - 29.3,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.59,,,,,1.25 - 1.92,mL/sec +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,79,,,,,31 - 101,umol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,68.1,,,,,kg, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,GFR,EGFR by MDRD,,73,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,125,,,,,116 - 164,g/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.38,,,,,0.34 - 0.48, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.2,,,,,4.1 - 5.6,TI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 98,fL +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.30,,,,,3.8 - 10.7,GI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.33,,,,,1.96 - 7.23,GI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.57,,,,,0.91 - 4.28,GI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.01,,,,,0 - 0.2,GI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.1,,,,,40.5 - 75,% +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,36.6,,,,,15.4 - 48.5,% +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.7,,,,,2.6 - 10.1,% +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.3,,,,,0 - 6.8,% +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,250,,,,,140 - 400,GI/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.5,,,,,<6.5%, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.11,,,,,1.9 - 23,uIU/mL +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,LIPID PANEL,Direct HDL-C 4th Generation,,1.65,,H,,,1.03 - 1.53,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,LIPID PANEL,Triglycerides (GPO),,0.93,,,,,0.44 - 1.99,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,LIPID PANEL,Cholesterol (High Performance),,4.65,,,,,3.65 - 6.21,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,LIPID PANEL,LDL Chol Friedewald 4th,,2.57,,,,,0 - 3.34,mmol/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,TSH,TSH 3rd IS-QT,,3.025,,,,,0.45 - 5.33,mIU/L +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Specific Gravity,,1.014,,,,,1 - 1.04, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110003,,,35,years,Female,Part 1 Screening,,"Sep 26, 2025 9:10 AM",6225351081,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.3,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.4,,,,,0 - 6.2,umol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Alkaline Phosphatase,,94,,,,,40 - 129,U/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,ALT (SGPT),,46,,,,,5 - 48,U/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,GGT,,93,,H,,,10 - 61,U/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,LDH,,165,,,,,53 - 234,U/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Urea Nitrogen,,5.7,,,,,1.4 - 8.6,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,94,,,,,40 - 110,umol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Glucose Fasting,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Serum Uric Acid,,427,,,,,125 - 488,umol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Calcium (EDTA),,2.57,,,,,2.07 - 2.64,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Phosphorus,,1.18,,,,,0.71 - 1.65,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Total Protein,,77,,,,,61 - 84,g/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Albumin-BCG,,49,,,,,33 - 49,g/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Creatine Kinase,,89,,,,,39 - 308,U/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Serum Bicarbonate,,21.0,,,,,19.3 - 29.3,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,165,,,,,127 - 181,g/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.39 - 0.54, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,4.5 - 6.4,TI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,Normocytic,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 96,fL +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.70,,,,,3.8 - 10.7,GI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.28,,,,,1.96 - 7.23,GI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.74,,,,,0.91 - 4.28,GI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,1.34,R,H,,,0 - 0.57,GI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.00,,,,,0 - 0.2,GI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,49.0,,,,,40.5 - 75,% +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.0,,,,,15.4 - 48.5,% +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.0,,,,,2.6 - 10.1,% +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,20.0,R,H,,,0 - 6.8,% +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.0,,,,,0 - 2,% +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,250,,,,,140 - 400,GI/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,LIPID PANEL,Direct HDL-C 4th Generation,,0.77,,L,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,LIPID PANEL,Triglycerides (GPO),,1.72,,,,,0.5 - 2.81,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,LIPID PANEL,Cholesterol (High Performance),,4.31,,,,,3.31 - 6.1,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,LIPID PANEL,LDL Chol Friedewald 4th,,2.75,,,,,0 - 3.34,mmol/L +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Specific Gravity,,1.018,,,,,1 - 1.04, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 DB Baseline,,"Aug 28, 2025 11:45 AM",6225351082,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,C-REACTIVE PROTEIN,C Reactive Protein HS,,2.1,,,,,0 - 5,mg/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CELLULAR ELEMENTS,Ur WBC/HPF,,3,,,,,0 - 12,/HPF +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.8,,,,,0 - 6.2,umol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Alkaline Phosphatase,,83,,,,,35 - 104,U/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,ALT (SGPT),,10,,,,,4 - 43,U/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,AST (SGOT),,11,,,,,8 - 40,U/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,GGT,,14,,,,,4 - 49,U/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,LDH,,133,,,,,53 - 234,U/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Urea Nitrogen,,4.4,,,,,1.4 - 8.6,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,68,,,,,31 - 101,umol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Serum Uric Acid,,303,,,,,125 - 428,umol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Calcium (EDTA),,2.36,,,,,2.07 - 2.64,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Creatine Kinase,,79,,,,,26 - 192,U/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Serum Bicarbonate,,22.2,,,,,19.3 - 29.3,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,129,,,,,116 - 164,g/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,4.1 - 5.6,TI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,85,,,,,79 - 98,fL +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.56,,,,,3.8 - 10.7,GI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.30,,,,,1.96 - 7.23,GI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.54,,,,,0.91 - 4.28,GI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.20,,,,,0 - 0.57,GI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.11,,,,,0 - 0.2,GI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.4,,,,,40.5 - 75,% +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.9,,,,,15.4 - 48.5,% +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.1,,,,,2.6 - 10.1,% +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.6,,,,,0 - 6.8,% +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.0,,,,,0 - 2,% +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,255,,,,,140 - 400,GI/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.14,,,,,1.9 - 23,uIU/mL +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,LIPID PANEL,Direct HDL-C 4th Generation,,1.22,,,,,1.03 - 1.53,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,LIPID PANEL,Triglycerides (GPO),,0.56,,,,,0.44 - 1.99,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,LIPID PANEL,Cholesterol (High Performance),,3.42,,L,,,3.65 - 6.21,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,LIPID PANEL,LDL Chol Friedewald 4th,,1.94,,,,,0 - 3.34,mmol/L +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,RETICULOCYTES,Reticulocyte Count %,,0.8,,,,,0.6 - 2.5,% +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Specific Gravity,,1.029,,,,,1 - 1.04, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Protein,,Trace,,H,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Blood,,Trace,,,,,Ref Rng:$Negative-Trace, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 DB Baseline,,"Aug 28, 2025 7:07 AM",6225351083,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Total Bilirubin,,13,,,,,3 - 21,umol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.7,,,,,0 - 6.2,umol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,40 - 129,U/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,ALT (SGPT),,73,,H RX,,,5 - 48,U/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,AST (SGOT),,31,,,,,8 - 40,U/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,GGT,,149,,H,,,10 - 61,U/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,LDH,,171,,,,,53 - 234,U/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Urea Nitrogen,,6.0,,,,,1.4 - 8.6,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,104,,,,,40 - 110,umol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Serum Uric Acid,,469,,,,,125 - 488,umol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Calcium (EDTA),,2.57,,,,,2.07 - 2.64,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Phosphorus,,1.15,,,,,0.71 - 1.65,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Total Protein,,80,,,,,61 - 84,g/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Albumin-BCG,,50,,H,,,33 - 49,g/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Creatine Kinase,,138,,,,,39 - 308,U/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Serum Bicarbonate,,21.5,,,,,19.3 - 29.3,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.14,,H,,,1.42 - 2.08,mL/sec +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,104,,,,,40 - 110,umol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,93.8,,,,,kg, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,GFR,EGFR by MDRD,,76,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,169,,,,,127 - 181,g/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.49,,,,,0.39 - 0.54, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.4,,,,,4.5 - 6.4,TI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,79 - 96,fL +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.17,,,,,3.8 - 10.7,GI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.44,,,,,1.96 - 7.23,GI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.28,,,,,0.91 - 4.28,GI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.29,,,,,0.12 - 0.92,GI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.06,,,,,0 - 0.2,GI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.4,,,,,40.5 - 75,% +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.7,,,,,15.4 - 48.5,% +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.9,,,,,2.6 - 10.1,% +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.5,,,,,0 - 6.8,% +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.4,,,,,0 - 2,% +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,259,,,,,140 - 400,GI/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,4.8,,,,,<6.5%, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,7.13,,,,,1.9 - 23,uIU/mL +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,LIPID PANEL,Direct HDL-C 4th Generation,,0.96,,L,,,1.03 - 1.53,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,LIPID PANEL,Triglycerides (GPO),,2.37,,,,,0.5 - 2.81,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,LIPID PANEL,Cholesterol (High Performance),,5.50,,,,,3.31 - 6.1,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,LIPID PANEL,LDL Chol Friedewald 4th,,3.45,,H,,,0 - 3.34,mmol/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,RETICULOCYTES,Reticulocyte Count %,,1.0,,,,,0.6 - 2.5,% +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,TSH,TSH 3rd IS-QT,,2.030,,,,,0.45 - 5.33,mIU/L +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1 - 1.04, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110002,,,25,years,Male,Part 1 Screening,,"Aug 6, 2025 9:40 AM",6225351072,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.4,,,,,0 - 5,mg/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.4,,,,,0 - 6.2,umol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Alkaline Phosphatase,,77,,,,,35 - 104,U/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,ALT (SGPT),,10,,,,,4 - 43,U/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,AST (SGOT),,12,,,,,8 - 40,U/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,GGT,,14,,,,,4 - 49,U/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,LDH,,127,,,,,53 - 234,U/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Urea Nitrogen,,6.1,,,,,1.4 - 8.6,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,65,,,,,31 - 101,umol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Glucose Fasting,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Serum Uric Acid,,273,,,,,125 - 428,umol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Calcium (EDTA),,2.35,,,,,2.07 - 2.64,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Phosphorus,,1.14,,,,,0.71 - 1.65,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Creatine Kinase,,88,,,,,26 - 192,U/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Serum Bicarbonate,,21.2,,,,,19.3 - 29.3,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.33,,H,,,1.25 - 1.92,mL/sec +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,65,,,,,31 - 101,umol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,79.2,,,,,kg, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,FSH,Follicle Stimulating Hormone,,3.55,,RX,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,GFR,EGFR by MDRD,,92,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,128,,,,,116 - 164,g/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,,,,Test cancelled: Beyond stability,,, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.5,,,,,4.1 - 5.6,TI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,,,,Test cancelled: Beyond stability,,, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.62,,,,,3.8 - 10.7,GI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.19,,,,,1.96 - 7.23,GI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.85,,,,,0.91 - 4.28,GI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.34,,,,,0.12 - 0.92,GI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.19,,,,,0 - 0.57,GI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,56.7,,,,,40.5 - 75,% +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,33.0,,,,,15.4 - 48.5,% +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.0,,,,,2.6 - 10.1,% +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.4,,,,,0 - 6.8,% +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,253,,,,,140 - 400,GI/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.1,,,,,<6.5%, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.61,,,,,1.9 - 23,uIU/mL +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,LIPID PANEL,Direct HDL-C 4th Generation,,1.23,,,,,1.03 - 1.53,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,LIPID PANEL,Triglycerides (GPO),,0.46,,,,,0.44 - 1.99,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,LIPID PANEL,Cholesterol (High Performance),,3.59,R,L,,,3.65 - 6.21,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,LIPID PANEL,LDL Chol Friedewald 4th,,2.15,,,,,0 - 3.34,mmol/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,RETICULOCYTES,Reticulocyte Count %,,1.0,,,,,0.6 - 2.5,% +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,TSH,TSH 3rd IS-QT,,1.803,,,,,0.45 - 5.33,mIU/L +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Specific Gravity,,1.024,,,,,1 - 1.04, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100110001,,,31,years,Female,Part 1 Screening,,"Aug 3, 2025 9:05 AM",6225351076,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, diff --git a/Covance/Source/2026-06-18_095914 sponsor-study-35472-test-results-898744-standard.csv b/Covance/Source/2026-06-18_095914 sponsor-study-35472-test-results-898744-standard.csv new file mode 100644 index 0000000..1cacad6 --- /dev/null +++ b/Covance/Source/2026-06-18_095914 sponsor-study-35472-test-results-898744-standard.csv @@ -0,0 +1,200 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.6,,,,,0 - 6.2,umol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,40 - 129,U/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,ALT (SGPT),,37,,,,,5 - 48,U/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,AST (SGOT),,63,R,H RX,,,8 - 40,U/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,GGT,,143,R,H,,,10 - 50,U/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,LDH,,148,,,,,53 - 234,U/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Urea Nitrogen,,8.4,,,,,1.4 - 8.6,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,93,,,,,40 - 119,umol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Glucose Fasting,,8.5,R,H RX,,,3.9 - 5.6,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Serum Uric Acid,,397,,,,,149 - 494,umol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Calcium (EDTA),,2.51,,,,,2.07 - 2.64,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Phosphorus,,1.21,,,,,0.71 - 1.65,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Total Protein,,81,R,H,,,60 - 80,g/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Albumin-BCG,,42,,,,,33 - 49,g/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Creatine Kinase,,54,,,,,39 - 308,U/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Serum Bicarbonate,,23.3,,,,,19.3 - 29.3,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CHEMISTRY PANEL,Serum Chloride,,96,,,,,94 - 112,mmol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.85,,,,,1.42 - 2.08,mL/sec +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,93,,,,,40 - 119,umol/L +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,106.6,,,,,kg, +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,8.7,R,H RX,,,<6.5%, +CZ100050002,,,62,years,Male,Retest,,"Nov 11, 2025 10:04 AM",6225351037,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,C-REACTIVE PROTEIN,C Reactive Protein HS,,11.9,,H,,,0 - 5,mg/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CASTS,Ur Hyaline Casts/LPF,,96,,,,,0 /LPF, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CELLULAR ELEMENTS,Ur RBC/HPF,,5,,H,,,0 - 3,/HPF +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CELLULAR ELEMENTS,Ur WBC/HPF,,2,,,,,0 - 5,/HPF +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Total Bilirubin,,12,,,,,3 - 21,umol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.9,,,,,0 - 6.2,umol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Alkaline Phosphatase,,70,,,,,40 - 129,U/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,ALT (SGPT),,36,,,,,5 - 48,U/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,AST (SGOT),,72,,H RX,,,8 - 40,U/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,GGT,,264,,HT,,Result verified by repeat analysis,10 - 50,U/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,LDH,,171,,,,,53 - 234,U/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Urea Nitrogen,,7.3,,,,,1.4 - 8.6,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,109,,,,,40 - 119,umol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Glucose Fasting,,8.3,,H,,,3.9 - 5.6,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Serum Uric Acid,,497,,H,,,149 - 494,umol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Calcium (EDTA),,2.55,,,,,2.07 - 2.64,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Phosphorus,,1.17,,,,,0.71 - 1.65,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Total Protein,,84,,H,,,60 - 80,g/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Creatine Kinase,,37,,L,,,39 - 308,U/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Serum Sodium,,137,,,,,135 - 145,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Serum Potassium,,3.9,,,,,3.5 - 5.2,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Serum Bicarbonate,,23.7,,,,,19.3 - 29.3,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CHEMISTRY PANEL,Serum Chloride,,94,,,,,94 - 112,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.60,,,,,1.42 - 2.08,mL/sec +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,109,,,,,40 - 119,umol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,108.0,,,,,kg, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DIRECT LDL,Direct LDL-C 3rd Gen,,3.83,R,H,,,<3.36 mmol/L, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,GFR,EGFR by MDRD,,60,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,160,,,,,125 - 170,g/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.47,,,,,0.37 - 0.51, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4 - 5.8,TI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,80 - 100,fL +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,10.32,,,,,3.8 - 10.7,GI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.59,,,,,1.96 - 7.23,GI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.36,,,,,0.8 - 3,GI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,1.06,,H,,,0.12 - 0.92,GI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.12,,,,,0 - 0.2,GI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.9,,,,,40.5 - 75,% +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,22.9,,,,,15.4 - 48.5,% +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,10.3,,H,,,2.6 - 10.1,% +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.7,,,,,0 - 6.8,% +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.2,,,,,0 - 2,% +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,311,,,,,130 - 394,GI/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,8.9,,H RX,,,<6.5%, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,12.96,,,,,1.9 - 23,uIU/mL +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,LIPID PANEL,Direct HDL-C 4th Generation,,0.81,,L,,,1.03 - 1.53,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,LIPID PANEL,Triglycerides (GPO),,5.76,,H SF,,,0.65 - 2.94,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,LIPID PANEL,Cholesterol (High Performance),,6.27,,,,,4.53 - 7.71,mmol/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,LIPID PANEL,LDL Chol Friedewald 4th,,,,,Test cancelled: Invalid/High Triglycerides,,, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,MISCELLANEOUS ELEMENTS,Ur Mucous,,Present,,,,,Ref Rng:Not present, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,RETICULOCYTES,Reticulocyte Count %,,4.6,,H,,,0.6 - 2.5,% +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,TSH,TSH 3rd IS-QT,,3.611,,,,,0.45 - 5.33,mIU/L +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Specific Gravity,,1.034,,H,,,1.01 - 1.03, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Protein,,+1,,H,,,Ref Rng:Negative, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Glucose,,+1,,H,,,Ref Rng:Normal, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Ketones,,Trace,,H,,,Ref Rng:Negative, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Urobilinogen,,+1,,H,,,Ref Rng:Normal, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100050002,,,62,years,Male,Part 1 Screening,,"Nov 3, 2025 12:08 PM",6225351004,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.2,,,,,0 - 6.2,umol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,35 - 104,U/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,4 - 43,U/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,GGT,,32,,,,,5 - 50,U/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,LDH,,176,,,,,53 - 234,U/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Urea Nitrogen,,3.5,,,,,1.4 - 8.6,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,79,,,,,31 - 101,umol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Glucose Fasting,,9.7,,H RX,,,3.9 - 5.6,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Serum Uric Acid,,289,,,,,149 - 446,umol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Total Protein,,66,,,,,60 - 80,g/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Creatine Kinase,,135,,,,,26 - 192,U/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Serum Sodium,,143,,,,,135 - 145,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Serum Bicarbonate,,22.7,,,,,19.3 - 29.3,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.05,,L,,,1.25 - 1.92,mL/sec +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,79,,,,,31 - 101,umol/L +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,63.0,,,,,kg, +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,7.8,,H,,,<6.5%, +CZ100050001,,,65,years,Female,Retest,R,"Sep 16, 2025 10:00 AM",6225351036,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.9,,,,,0 - 5,mg/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CELLULAR ELEMENTS,Ur WBC/HPF,,3,,,,,0 - 12,/HPF +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.6,,,,,0 - 6.2,umol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Alkaline Phosphatase,,85,,,,,35 - 104,U/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,ALT (SGPT),,18,,,,,4 - 43,U/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,AST (SGOT),,16,,,,,8 - 40,U/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,GGT,,31,,,,,5 - 50,U/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,LDH,,192,,,,,53 - 234,U/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Urea Nitrogen,,5.4,,,,,1.4 - 8.6,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,79,,,,,31 - 101,umol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Glucose Fasting,,9.2,,H RX,,,3.9 - 5.6,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Serum Uric Acid,,325,,,,,149 - 446,umol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Calcium (EDTA),,2.54,,,,,2.07 - 2.64,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Phosphorus,,1.09,,,,,0.71 - 1.65,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Total Protein,,67,,,,,60 - 80,g/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Creatine Kinase,,143,,,,,26 - 192,U/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Serum Sodium,,141,,,,,135 - 145,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Serum Bicarbonate,,20.8,,,,,19.3 - 29.3,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.05,,L,,,1.25 - 1.92,mL/sec +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,79,,,,,31 - 101,umol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,63.0,,,,,kg, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,GFR,EGFR by MDRD,,64,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,142,,,,,115 - 158,g/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.34 - 0.48, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.7,,,,,3.9 - 5.5,TI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,91,,,,,80 - 100,fL +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,10.78,,H,,,3.8 - 10.7,GI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,6.25,,,,,1.96 - 7.23,GI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,3.50,,H,,,0.8 - 3,GI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.52,,,,,0.12 - 0.92,GI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.37,,,,,0 - 0.57,GI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.13,,,,,0 - 0.2,GI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.0,,,,,40.5 - 75,% +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.5,,,,,15.4 - 48.5,% +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,4.8,,,,,2.6 - 10.1,% +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.4,,,,,0 - 6.8,% +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.2,,,,,0 - 2,% +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,284,,,,,130 - 394,GI/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,7.7,,H,,,<6.5%, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,14.50,,,,,1.9 - 23,uIU/mL +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,LIPID PANEL,Direct HDL-C 4th Generation,,1.94,,H,,,1.03 - 1.53,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,LIPID PANEL,Triglycerides (GPO),,1.32,,,,,0.63 - 2.71,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,LIPID PANEL,Cholesterol (High Performance),,4.53,,L,,,4.86 - 8.28,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,LIPID PANEL,LDL Chol Friedewald 4th,,1.99,,,,,0 - 3.34,mmol/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,RETICULOCYTES,Reticulocyte Count %,,1.6,,,,,0.6 - 2.5,% +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,TSH,TSH 3rd IS-QT,,1.354,,,,,0.45 - 5.33,mIU/L +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Specific Gravity,,1.011,,,,,1.01 - 1.03, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MACRO PANEL,Ur Leukocyte Esterase,,+2,,H SF,,,Ref Rng:Negative, +CZ100050001,,,65,years,Female,Part 1 Screening,,"Sep 9, 2025 11:10 AM",6225351006,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE diff --git a/Covance/Source/2026-06-18_095937 sponsor-study-35472-test-results-898727-standard.csv b/Covance/Source/2026-06-18_095937 sponsor-study-35472-test-results-898727-standard.csv new file mode 100644 index 0000000..e17118e --- /dev/null +++ b/Covance/Source/2026-06-18_095937 sponsor-study-35472-test-results-898727-standard.csv @@ -0,0 +1,994 @@ +"Disclaimer: The information presented in On-Screen Results is not intended to be a replacement of the official Lab Results, Alerts, Data Revisions and Cancellations found in the Lab Reports section of this software application. On-Screen Results should not be used for patient diagnosis, treatment decisions or submission to regulatory bodies.",,,,,,,,,,,,,,,,,,, +Subject,Subject Data Revision,Screen No.,Age,Age Unit,Gender,Visit,Visit Data Revision,Collected Time,Accession,Test Group,Test,Administrative Question,Value,Result Data Revision,Flags,Cancellation Reason,Comments,Range,Units +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.1,,,,,0 - 5,mg/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CELLULAR ELEMENTS,Ur RBC/HPF,,5,,,,,0 - 8,/HPF +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CELLULAR ELEMENTS,Ur WBC/HPF,,1,,,,,0 - 12,/HPF +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Alkaline Phosphatase,,56,,,,,35 - 104,U/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,ALT (SGPT),,13,,,,,4 - 43,U/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,AST (SGOT),,18,,,,,8 - 40,U/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,GGT,,22,,,,,5 - 50,U/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,LDH,,162,,,,,53 - 234,U/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,71,,,,,31 - 101,umol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Glucose Fasting,,4.0,,,,,3.9 - 5.6,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Serum Uric Acid,,242,,,,,149 - 446,umol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Calcium (EDTA),,2.39,,,,,2.07 - 2.64,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Phosphorus,,1.08,,,,,0.71 - 1.65,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Total Protein,,64,,,,,60 - 80,g/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Creatine Kinase,,52,,,,,26 - 192,U/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Serum Sodium,,139,,,,,135 - 145,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Serum Potassium,,4.3,,,,,3.5 - 5.2,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Serum Bicarbonate,,22.9,,,,,19.3 - 29.3,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,119,,,,Result verified by repeat analysis,115 - 158,g/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,,,,,0.34 - 0.48, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.8,,L,,Result verified by repeat analysis,3.9 - 5.5,TI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,96,,,,,80 - 100,fL +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.80,,,,Result verified by repeat analysis,3.8 - 10.7,GI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.34,,,,Result verified by repeat analysis,1.96 - 7.23,GI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.86,,,,,0.8 - 3,GI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.44,,,,Result verified by repeat analysis,0.12 - 0.92,GI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,Result verified by repeat analysis,0 - 0.57,GI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,Result verified by repeat analysis,0 - 0.2,GI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,63.8,,,,Result verified by repeat analysis,40.5 - 75,% +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.3,,,,Result verified by repeat analysis,15.4 - 48.5,% +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.5,,,,Result verified by repeat analysis,2.6 - 10.1,% +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.8,,,,Result verified by repeat analysis,0 - 6.8,% +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,Result verified by repeat analysis,0 - 2,% +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,459,,H,,Result verified by repeat analysis,130 - 394,GI/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,25.80,,H,,,1.9 - 23,uIU/mL +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,LIPID PANEL,Direct HDL-C 4th Generation,,0.97,,L,,,1.03 - 1.53,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,LIPID PANEL,Triglycerides (GPO),,1.49,,,,,0.63 - 2.71,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,LIPID PANEL,Cholesterol (High Performance),,4.00,,L,,,4.86 - 8.28,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,LIPID PANEL,LDL Chol Friedewald 4th,,2.35,,,,,0 - 3.34,mmol/L +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,MICROORGANISMS,Ur Bacteria,,Present,,,,,Ref Rng:Not present, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Specific Gravity,,1.013,,,,,1.01 - 1.03, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MACRO PANEL,Ur Leukocyte Esterase,,Trace,,H,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 2 OL Induction Day 29,,"Apr 23, 2026 4:00 PM",6226560887,URINE MICRO PANEL,Ur Microscopic,,Positive,,,,, NEGATIVE$,NEGATIVE +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,C-REACTIVE PROTEIN,C Reactive Protein HS,,<0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.0,,,,,0 - 6.2,umol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Alkaline Phosphatase,,60,,,,,40 - 129,U/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,ALT (SGPT),,35,,,,,5 - 48,U/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,AST (SGOT),,28,,,,,8 - 40,U/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,GGT,,14,,,,,10 - 61,U/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,LDH,,149,,,,,53 - 234,U/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Urea Nitrogen,,4.0,,,,,1.4 - 8.6,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,40 - 110,umol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Glucose Fasting,,4.7,,,,,3.9 - 5.6,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Serum Uric Acid,,285,,,,,125 - 488,umol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Calcium (EDTA),,2.41,,,,,2.07 - 2.64,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Phosphorus,,1.11,,,,,0.71 - 1.65,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Albumin-BCG,,48,,,,,33 - 49,g/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Creatine Kinase,,157,,,,,39 - 308,U/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Serum Potassium,,3.9,,,,,3.5 - 5.2,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Serum Bicarbonate,,24.5,,,,,19.3 - 29.3,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,154,,,,,127 - 181,g/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.44,,,,,0.39 - 0.54, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 96,fL +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.52,,,,,3.8 - 10.7,GI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.31,,,,,1.96 - 7.23,GI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.76,,,,,0.91 - 4.28,GI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.32,,,,,0.12 - 0.92,GI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.01,,,,,0 - 0.2,GI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.8,,,,,40.5 - 75,% +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,31.9,,,,,15.4 - 48.5,% +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.3,,,,,0 - 2,% +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,174,,,,,140 - 400,GI/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,2.95,,,,,1.9 - 23,uIU/mL +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,LIPID PANEL,Direct HDL-C 4th Generation,,1.39,,,,Result verified by repeat analysis,1.03 - 1.53,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,LIPID PANEL,Triglycerides (GPO),,0.75,,,,,0.5 - 2.81,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,LIPID PANEL,Cholesterol (High Performance),,3.90,,,,,3.31 - 6.1,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,LIPID PANEL,LDL Chol Friedewald 4th,,2.17,,,,,0 - 3.34,mmol/L +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Specific Gravity,,1.012,,,,,1 - 1.04, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 2 OL Induction Day 29,,"Apr 22, 2026 3:30 PM",6226752554,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.5,,,,,0 - 5,mg/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Alkaline Phosphatase,,54,,,,,35 - 104,U/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,ALT (SGPT),,14,,,,,4 - 43,U/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,GGT,,23,,,,,5 - 50,U/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,LDH,,143,,,,,53 - 234,U/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Urea Nitrogen,,3.8,,,,,1.4 - 8.6,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,31 - 101,umol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Glucose Fasting,,5.3,,,,,3.9 - 5.6,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Serum Uric Acid,,259,,,,,149 - 446,umol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Calcium (EDTA),,2.47,,,,,2.07 - 2.64,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Phosphorus,,1.20,,,,,0.71 - 1.65,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Total Protein,,69,,,,,60 - 80,g/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Creatine Kinase,,41,,,,,26 - 192,U/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Serum Sodium,,143,,,,,135 - 145,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Serum Bicarbonate,,25.2,,,,,19.3 - 29.3,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,122,,,,,115 - 158,g/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,,,,0.34 - 0.48, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,,,,3.9 - 5.5,TI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,94,,,,,80 - 100,fL +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.11,,,,,3.8 - 10.7,GI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.82,,,,,1.96 - 7.23,GI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.76,,,,,0.8 - 3,GI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.43,,,,,0.12 - 0.92,GI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.07,,,,,0 - 0.57,GI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,67.8,,,,,40.5 - 75,% +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,24.8,,,,,15.4 - 48.5,% +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.1,,,,,2.6 - 10.1,% +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.0,,,,,0 - 6.8,% +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.2,,,,,0 - 2,% +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,466,R,H,,,130 - 394,GI/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.4,,,,,<6.5 %, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,9.83,,,,,1.9 - 23,uIU/mL +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,LIPID PANEL,Direct HDL-C 4th Generation,,1.06,,,,,1.03 - 1.53,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,LIPID PANEL,Triglycerides (GPO),,1.56,,,,,0.63 - 2.71,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,LIPID PANEL,Cholesterol (High Performance),,4.33,,L,,,4.86 - 8.28,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,LIPID PANEL,LDL Chol Friedewald 4th,,2.56,,,,,0 - 3.34,mmol/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,TSH,TSH 3rd IS-QT,,0.806,,,,,0.45 - 5.33,mIU/L +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Specific Gravity,,1.010,,,,,1.01 - 1.03, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,End of Phase/Treatment,R,"Mar 25, 2026 5:00 PM",6226560888,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,C-REACTIVE PROTEIN,C Reactive Protein HS,,0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Total Bilirubin,,6,,,,,3 - 21,umol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Alkaline Phosphatase,,62,,,,,40 - 129,U/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,ALT (SGPT),,39,,,,,5 - 48,U/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,AST (SGOT),,29,,,,,8 - 40,U/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,GGT,,13,,,,,10 - 61,U/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,LDH,,156,,,,,53 - 234,U/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Urea Nitrogen,,5.0,,,,,1.4 - 8.6,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,74,,,,,40 - 110,umol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Glucose Fasting,,5.5,,,,,3.9 - 5.6,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Serum Uric Acid,,330,,,,,125 - 488,umol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Calcium (EDTA),,2.29,,,,,2.07 - 2.64,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Phosphorus,,1.11,,,,,0.71 - 1.65,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Total Protein,,66,,,,,61 - 84,g/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Creatine Kinase,,149,,,,,39 - 308,U/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Serum Potassium,,4.1,,,,,3.5 - 5.2,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Serum Bicarbonate,,23.2,,,,,19.3 - 29.3,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,159,,,,,127 - 181,g/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4.5 - 6.4,TI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.94,,,,,3.8 - 10.7,GI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.55,,,,,1.96 - 7.23,GI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.81,,,,,0.91 - 4.28,GI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.15,,,,,0 - 0.57,GI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.8,,,,,40.5 - 75,% +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.5,,,,,15.4 - 48.5,% +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.7,,,,,2.6 - 10.1,% +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.5,,,,,0 - 6.8,% +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,189,,,,,140 - 400,GI/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.1,,,,,<6.5 %, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,19.10,,,,,1.9 - 23,uIU/mL +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,LIPID PANEL,Direct HDL-C 4th Generation,,1.09,,,,,1.03 - 1.53,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,LIPID PANEL,Triglycerides (GPO),,1.96,,,,,0.5 - 2.81,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,LIPID PANEL,Cholesterol (High Performance),,3.72,,,,,3.31 - 6.1,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,LIPID PANEL,LDL Chol Friedewald 4th,,1.73,,,,,0 - 3.34,mmol/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,TSH,TSH 3rd IS-QT,,1.089,,,,,0.45 - 5.33,mIU/L +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1 - 1.04, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,End of Phase/Treatment,R,"Mar 25, 2026 3:00 PM",6226752555,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,C-REACTIVE PROTEIN,C Reactive Protein HS,,9.2,,H,,,0 - 5,mg/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Total Bilirubin,,16,,,,,3 - 21,umol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,4.6,,,,,0 - 6.2,umol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Alkaline Phosphatase,,77,,,,,40 - 129,U/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,ALT (SGPT),,37,,,,,5 - 48,U/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,AST (SGOT),,29,,,,,8 - 40,U/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,GGT,,79,R,H,,,10 - 61,U/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,LDH,,103,,,,,53 - 234,U/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Urea Nitrogen,,2.3,,,,,1.4 - 8.6,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,74,,,,,40 - 110,umol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Glucose Fasting,,5.2,,,,,3.9 - 5.6,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Serum Uric Acid,,427,,,,,125 - 488,umol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Phosphorus,,0.97,,,,,0.71 - 1.65,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Total Protein,,71,,,,,61 - 84,g/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Creatine Kinase,,102,,,,,39 - 308,U/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Serum Potassium,,3.8,,,,,3.5 - 5.2,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Serum Bicarbonate,,25.2,,,,,19.3 - 29.3,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,CHEMISTRY PANEL,Serum Chloride,,97,,,,,94 - 112,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,160,,,,,127 - 181,g/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.2,,,,,4.5 - 6.4,TI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,87,,,,,79 - 96,fL +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,7.04,,,,,3.8 - 10.7,GI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.60,,,,,1.96 - 7.23,GI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.86,,,,,0.91 - 4.28,GI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.41,,,,,0.12 - 0.92,GI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.12,,,,,0 - 0.57,GI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,65.3,,,,,40.5 - 75,% +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,26.4,,,,,15.4 - 48.5,% +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.7,,,,,0 - 6.8,% +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,366,,,,,140 - 400,GI/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.7,,,,,<6.5 %, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,R,"Mar 6, 2026 2:00 PM",6226560891,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,16.55,,,,,1.9 - 23,uIU/mL +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,LIPID PANEL,Direct HDL-C 4th Generation,,1.23,,,,,1.03 - 1.53,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,LIPID PANEL,Triglycerides (GPO),,1.94,,,,,0.56 - 3.62,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,LIPID PANEL,Cholesterol (High Performance),,4.72,,,,,3.88 - 6.83,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,LIPID PANEL,LDL Chol Friedewald 4th,,2.60,,,,,0 - 3.34,mmol/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,RETICULOCYTES,Reticulocyte Count %,,1.2,,,,,0.6 - 2.5,% +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,TSH,TSH 3rd IS-QT,,0.976,,,,,0.45 - 5.33,mIU/L +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Specific Gravity,,1.016,,,,,1 - 1.04, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 DB Every 12 Weeks,,"Mar 6, 2026 2:00 PM",6226560891,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.4,,,,,0 - 6.2,umol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Alkaline Phosphatase,,55,,,,,35 - 104,U/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,ALT (SGPT),,14,,,,,4 - 43,U/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,GGT,,21,,,,,5 - 50,U/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,LDH,,136,,,,,53 - 234,U/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Urea Nitrogen,,4.1,,,,,1.4 - 8.6,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,80,,,,,31 - 101,umol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Glucose Fasting,,5.1,,,,,3.9 - 5.6,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Serum Uric Acid,,273,,,,,149 - 446,umol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Calcium (EDTA),,2.49,,,,,2.07 - 2.64,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Phosphorus,,1.13,,,,,0.71 - 1.65,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Total Protein,,69,,,,,60 - 80,g/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Creatine Kinase,,42,,,,,26 - 192,U/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Serum Sodium,,142,,,,,135 - 145,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Serum Potassium,,4.7,,,,,3.5 - 5.2,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Serum Bicarbonate,,24.2,,,,,19.3 - 29.3,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,122,,,,,115 - 158,g/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.37,,,,,0.34 - 0.48, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.0,,,,,3.9 - 5.5,TI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,80 - 100,fL +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,4.67,,,,,3.8 - 10.7,GI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.77,,,,,1.96 - 7.23,GI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.32,,,,,0.8 - 3,GI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.33,,,,,0.12 - 0.92,GI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.19,,,,,0 - 0.57,GI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.2,,,,,40.5 - 75,% +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,28.3,,,,,15.4 - 48.5,% +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.0,,,,,2.6 - 10.1,% +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.0,,,,,0 - 6.8,% +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.5,,,,,0 - 2,% +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,453,,H,,,130 - 394,GI/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,14.65,,,,,1.9 - 23,uIU/mL +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,LIPID PANEL,Direct HDL-C 4th Generation,,1.00,,L,,,1.03 - 1.53,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,LIPID PANEL,Triglycerides (GPO),,1.31,,,,,0.63 - 2.71,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,LIPID PANEL,Cholesterol (High Performance),,4.11,,L,,,4.86 - 8.28,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,LIPID PANEL,LDL Chol Friedewald 4th,,2.51,,,,,0 - 3.34,mmol/L +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1.01 - 1.03, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur pH,,6.5,,,,,5 - 8, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 DB Baseline,,"Feb 15, 2026 3:10 PM",6227775508,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,C-REACTIVE PROTEIN,C Reactive Protein HS,,<0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Total Bilirubin,,5,,,,,3 - 21,umol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.3,,,,,0 - 6.2,umol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Alkaline Phosphatase,,55,,,,,40 - 129,U/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,5 - 48,U/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,GGT,,12,,,,,10 - 61,U/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,LDH,,133,,,,,53 - 234,U/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Urea Nitrogen,,3.9,,,,,1.4 - 8.6,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,72,,,,,40 - 110,umol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Glucose Fasting,,4.9,,,,,3.9 - 5.6,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Serum Uric Acid,,244,,,,,125 - 488,umol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Phosphorus,,1.06,,,,,0.71 - 1.65,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Total Protein,,63,,,,,61 - 84,g/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Creatine Kinase,,139,,,,,39 - 308,U/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Serum Bicarbonate,,22.9,,,,,19.3 - 29.3,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,CHEMISTRY PANEL,Serum Chloride,,106,,,,,94 - 112,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,156,,,,,127 - 181,g/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,89,,,,,79 - 96,fL +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,3.41,,L,,,3.8 - 10.7,GI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,1.63,,L,,,1.96 - 7.23,GI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.42,,,,,0.91 - 4.28,GI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.22,,,,,0.12 - 0.92,GI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.08,,,,,0 - 0.57,GI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,47.9,,,,,40.5 - 75,% +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,41.7,,,,,15.4 - 48.5,% +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.6,,,,,2.6 - 10.1,% +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.3,,,,,0 - 6.8,% +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.6,,,,,0 - 2,% +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,160,,,,,140 - 400,GI/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,4.99,,,,,1.9 - 23,uIU/mL +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,LIPID PANEL,Direct HDL-C 4th Generation,,1.32,,,,,1.03 - 1.53,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,LIPID PANEL,Triglycerides (GPO),,0.52,,,,,0.5 - 2.81,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,LIPID PANEL,Cholesterol (High Performance),,3.73,,,,,3.31 - 6.1,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,LIPID PANEL,LDL Chol Friedewald 4th,,2.17,,,,,0 - 3.34,mmol/L +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,RETICULOCYTES,Reticulocyte Count %,,0.7,,,,,0.6 - 2.5,% +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1 - 1.04, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 DB Baseline,,"Feb 15, 2026 1:30 PM",6227775507,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,C-REACTIVE PROTEIN,C Reactive Protein HS,,<0.2,,,,Result verified by repeat analysis,0 - 5,mg/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.9,,,,,0 - 6.2,umol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Alkaline Phosphatase,,57,,,,,40 - 129,U/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,ALT (SGPT),,22,,,,,5 - 48,U/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,AST (SGOT),,21,,,,,8 - 40,U/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,GGT,,11,,,,,10 - 61,U/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,LDH,,131,,,,,53 - 234,U/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Urea Nitrogen,,5.8,,,,,1.4 - 8.6,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,76,,,,,40 - 110,umol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Glucose Fasting,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Serum Uric Acid,,300,,,,,125 - 488,umol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Calcium (EDTA),,2.33,,,,,2.07 - 2.64,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Total Protein,,62,,,,,61 - 84,g/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Creatine Kinase,,120,,,,,39 - 308,U/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Serum Potassium,,4.8,,,,,3.5 - 5.2,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Serum Bicarbonate,,25.3,,,,,19.3 - 29.3,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CHEMISTRY PANEL,Serum Chloride,,105,,,,,94 - 112,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.28,,H,,,1.42 - 2.08,mL/sec +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,76,,,,,40 - 110,umol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,75.0,,,,,kg, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,GFR,EGFR by MDRD,,107,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,152,,,,,127 - 181,g/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.45,,,,,0.39 - 0.54, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,90,,,,,79 - 96,fL +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.30,,,,,3.8 - 10.7,GI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,2.90,,,,,1.96 - 7.23,GI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.77,,,,,0.91 - 4.28,GI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.35,,,,,0.12 - 0.92,GI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.14,,,,,0 - 0.2,GI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.7,,,,,40.5 - 75,% +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,33.3,,,,,15.4 - 48.5,% +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.6,,,,,2.6 - 10.1,% +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.7,,,,,0 - 6.8,% +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,2.6,,H,,,0 - 2,% +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,189,,,,,140 - 400,GI/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,4.9,,,,,<6.5 %, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,3.16,,,,,1.9 - 23,uIU/mL +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,LIPID PANEL,Direct HDL-C 4th Generation,,1.43,,,,,1.03 - 1.53,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,LIPID PANEL,Triglycerides (GPO),,0.61,,,,,0.5 - 2.81,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,LIPID PANEL,Cholesterol (High Performance),,3.71,,,,,3.31 - 6.1,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,LIPID PANEL,LDL Chol Friedewald 4th,,2.00,,,,,0 - 3.34,mmol/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,TSH,TSH 3rd IS-QT,,1.462,,,,,0.45 - 5.33,mIU/L +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Specific Gravity,,1.009,,,,,1 - 1.04, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120006,,,27,years,Male,Part 1 Screening,,"Feb 1, 2026 12:25 PM",6227767267,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,BENZODIAZEPINE CONFIRM. UR,BenzodiazepineConf-LCMSMS-LDT,,Temazepam (Confirmed),,RX,,,No Ref Rng, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,BENZODIAZEPINE CONFIRM. UR,BenzodiazepineConf-LCMSMS-LDT,,Oxazepam (Confirmed),,RX,,,No Ref Rng, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.3,,,,,0 - 5,mg/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Alkaline Phosphatase,,55,,,,,35 - 104,U/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,ALT (SGPT),,11,,,,,4 - 43,U/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,AST (SGOT),,17,,,,,8 - 40,U/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,GGT,,21,,,,,5 - 50,U/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,LDH,,136,,,,,53 - 234,U/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 8.6,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,31 - 101,umol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Serum Uric Acid,,247,,,,,149 - 446,umol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Calcium (EDTA),,2.40,,,,,2.07 - 2.64,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Phosphorus,,1.20,,,,,0.71 - 1.65,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Total Protein,,68,,,,,60 - 80,g/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Creatine Kinase,,44,,,,,26 - 192,U/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Serum Sodium,,142,,,,,135 - 145,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Serum Bicarbonate,,23.5,,,,,19.3 - 29.3,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CHEMISTRY PANEL,Serum Chloride,,103,,,,,94 - 112,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.25,,,,,1.25 - 1.92,mL/sec +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,77,,,,,31 - 101,umol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,74.0,,,,,kg, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Detected (unconfirmed),,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,FSH,Follicle Stimulating Hormone,,55.96,,,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,GFR,EGFR by MDRD,,65,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,119,,,,,115 - 158,g/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.36,,,,,0.34 - 0.48, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,3.9,,,,,3.9 - 5.5,TI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,80 - 100,fL +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.94,,,,,3.8 - 10.7,GI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.50,,,,,1.96 - 7.23,GI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.91,,,,,0.8 - 3,GI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.10,,,,,0 - 0.57,GI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,64.8,,,,,40.5 - 75,% +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,27.5,,,,,15.4 - 48.5,% +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.8,,,,,2.6 - 10.1,% +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,1.5,,,,,0 - 6.8,% +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,448,R,H,,,130 - 394,GI/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.5,,,,,<6.5 %, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,5.62,,,,,1.9 - 23,uIU/mL +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,LIPID PANEL,Direct HDL-C 4th Generation,,1.02,R,L,,,1.03 - 1.53,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,LIPID PANEL,Triglycerides (GPO),,1.44,,,,,0.63 - 2.71,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,LIPID PANEL,Cholesterol (High Performance),,4.25,R,L,,,4.86 - 8.28,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,LIPID PANEL,LDL Chol Friedewald 4th,,2.57,,,,,0 - 3.34,mmol/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,RETICULOCYTES,Reticulocyte Count %,,0.7,,,,,0.6 - 2.5,% +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,TSH,TSH 3rd IS-QT,,0.834,,,,,0.45 - 5.33,mIU/L +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Specific Gravity,,1.007,,,,,1.01 - 1.03, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120005,,,65,years,Female,Part 1 Screening,,"Jan 28, 2026 4:50 PM",6227775505,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.8,,,,,0 - 5,mg/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Total Bilirubin,,10,,,,,3 - 21,umol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.3,,,,,0 - 6.2,umol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Alkaline Phosphatase,,70,,,,,40 - 129,U/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,ALT (SGPT),,41,,,,,5 - 48,U/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,AST (SGOT),,27,,,,,8 - 40,U/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,GGT,,81,,H,,,10 - 61,U/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,LDH,,92,,,,,53 - 234,U/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Urea Nitrogen,,3.3,,,,,1.4 - 8.6,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,74,,,,,40 - 110,umol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Glucose Fasting,,6.1,,H,,,3.9 - 5.6,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Serum Uric Acid,,412,,,,,125 - 488,umol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Phosphorus,,0.94,,,,,0.71 - 1.65,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Creatine Kinase,,148,,,,,39 - 308,U/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Serum Bicarbonate,,25.4,,,,,19.3 - 29.3,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,127 - 181,g/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.39 - 0.54, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.61,,,,,3.8 - 10.7,GI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.00,,,,,1.96 - 7.23,GI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.02,,,,,0.91 - 4.28,GI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.40,,,,,0.12 - 0.92,GI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.14,,,,,0 - 0.57,GI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.05,,,,,0 - 0.2,GI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,60.5,,,,,40.5 - 75,% +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,30.5,,,,,15.4 - 48.5,% +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.0,,,,,2.6 - 10.1,% +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.2,,,,,0 - 6.8,% +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,322,,,,,140 - 400,GI/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,63.81,,H,,,1.9 - 23,uIU/mL +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,LIPID PANEL,Direct HDL-C 4th Generation,,1.13,,,,,1.03 - 1.53,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,LIPID PANEL,Triglycerides (GPO),,2.66,,,,,0.56 - 3.62,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,LIPID PANEL,Cholesterol (High Performance),,4.84,,,,,3.88 - 6.83,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,LIPID PANEL,LDL Chol Friedewald 4th,,2.49,,,,,0 - 3.34,mmol/L +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,RETICULOCYTES,Reticulocyte Count %,,1.1,,,,,0.6 - 2.5,% +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Specific Gravity,,1.022,,,,,1 - 1.04, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 2 OL Induction Day 29,,"Jan 2, 2026 12:00 PM",6226976943,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.0,,,,,0 - 5,mg/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Total Bilirubin,,9,,,,,3 - 21,umol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.8,,,,,0 - 6.2,umol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Alkaline Phosphatase,,74,,,,,40 - 129,U/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,ALT (SGPT),,42,,,,,5 - 48,U/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,AST (SGOT),,26,,,,,8 - 40,U/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,GGT,,70,,H,,,10 - 61,U/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,LDH,,89,,,,,53 - 234,U/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Urea Nitrogen,,3.1,,,,,1.4 - 8.6,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,40 - 110,umol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Glucose Fasting,,6.6,R,H,,,3.9 - 5.6,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Serum Uric Acid,,418,,,,,125 - 488,umol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Phosphorus,,0.91,,,,,0.71 - 1.65,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Albumin-BCG,,45,,,,,33 - 49,g/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Creatine Kinase,,100,,,,,39 - 308,U/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Serum Sodium,,140,,,,,132 - 147,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Serum Bicarbonate,,26.3,,,,,19.3 - 29.3,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,153,,,,,127 - 181,g/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.43,,,,,0.39 - 0.54, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.1,,,,,4.5 - 6.4,TI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,84,,,,,79 - 96,fL +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.86,,,,,3.8 - 10.7,GI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.10,,,,,1.96 - 7.23,GI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.01,,,,,0.91 - 4.28,GI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.39,,,,,0.12 - 0.92,GI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.30,,,,,0 - 0.57,GI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.07,,,,,0 - 0.2,GI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,59.8,,,,,40.5 - 75,% +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,29.2,,,,,15.4 - 48.5,% +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.7,,,,,2.6 - 10.1,% +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.3,,,,,0 - 6.8,% +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,1.0,,,,,0 - 2,% +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,374,,,,,140 - 400,GI/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,HEMOGLOBIN A1C,"Hemoglobin A1c,NGSP-RM",,5.7,,,,,<6.5 %, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,196.11,,H,,,1.9 - 23,uIU/mL +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,LIPID PANEL,Direct HDL-C 4th Generation,,0.97,,L,,,1.03 - 1.53,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,LIPID PANEL,Triglycerides (GPO),,2.92,,,,,0.56 - 3.62,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,LIPID PANEL,Cholesterol (High Performance),,4.31,,,,,3.88 - 6.83,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,LIPID PANEL,LDL Chol Friedewald 4th,,2.00,,,,,0 - 3.34,mmol/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,RETICULOCYTES,Reticulocyte Count %,,0.9,,,,,0.6 - 2.5,% +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,TSH,TSH 3rd IS-QT,,0.889,,,,,0.45 - 5.33,mIU/L +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Specific Gravity,,1.011,,,,,1 - 1.04, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,End of Phase/Treatment,,"Dec 5, 2025 3:00 PM",6225351126,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.6,,,,,0 - 5,mg/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.9,,,,,0 - 6.2,umol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Alkaline Phosphatase,,67,,,,,40 - 129,U/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,ALT (SGPT),,34,,,,,5 - 48,U/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,AST (SGOT),,20,,,,,8 - 40,U/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,GGT,,69,,H,,,10 - 61,U/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,LDH,,98,,,,,53 - 234,U/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Urea Nitrogen,,2.2,,,,,1.4 - 8.6,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,75,,,,,40 - 110,umol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Glucose Fasting,,5.6,,,,,3.9 - 5.6,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Serum Uric Acid,,520,R,H,,,125 - 488,umol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Calcium (EDTA),,2.37,,,,,2.07 - 2.64,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Phosphorus,,1.19,,,,,0.71 - 1.65,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Total Protein,,65,,,,,61 - 84,g/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Creatine Kinase,,126,,,,,39 - 308,U/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Serum Sodium,,142,,,,,132 - 147,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Serum Potassium,,4.0,,,,,3.5 - 5.2,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Serum Bicarbonate,,21.4,,,,,19.3 - 29.3,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,CHEMISTRY PANEL,Serum Chloride,,104,,,,,94 - 112,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,146,,,,,127 - 181,g/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.9,,,,,4.5 - 6.4,TI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,86,,,,,79 - 96,fL +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,6.43,,,,,3.8 - 10.7,GI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.49,,,,,1.96 - 7.23,GI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,2.20,,,,,0.91 - 4.28,GI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.44,,,,,0.12 - 0.92,GI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.24,,,,,0 - 0.57,GI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.04,,,,,0 - 0.2,GI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,54.4,,,,,40.5 - 75,% +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,34.2,,,,,15.4 - 48.5,% +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.9,,,,,2.6 - 10.1,% +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.8,,,,,0 - 6.8,% +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.7,,,,,0 - 2,% +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,288,,,,,140 - 400,GI/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,15.24,,,,,1.9 - 23,uIU/mL +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,LIPID PANEL,Direct HDL-C 4th Generation,,1.15,,,,,1.03 - 1.53,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,LIPID PANEL,Triglycerides (GPO),,1.64,,,,,0.56 - 3.62,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,LIPID PANEL,Cholesterol (High Performance),,4.19,,,,,3.88 - 6.83,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,LIPID PANEL,LDL Chol Friedewald 4th,,2.29,,,,,0 - 3.34,mmol/L +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,RETICULOCYTES,Reticulocyte Count %,,1.3,,,,,0.6 - 2.5,% +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Specific Gravity,,1.011,,,,,1 - 1.04, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 DB Baseline,,"Oct 22, 2025 12:15 PM",6225351120,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,C-REACTIVE PROTEIN,C Reactive Protein HS,,3.6,,,,,0 - 5,mg/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Total Bilirubin,,8,,,,,3 - 21,umol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,3.2,,,,,0 - 6.2,umol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Alkaline Phosphatase,,65,,,,,40 - 129,U/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,ALT (SGPT),,36,,,,,5 - 48,U/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,AST (SGOT),,26,,,,,8 - 40,U/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,GGT,,62,,H,,,10 - 61,U/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,LDH,,105,,,,,53 - 234,U/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Urea Nitrogen,,2.2,,,,,1.4 - 8.6,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,77,,,,,40 - 110,umol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Glucose Fasting,,5.8,,H,,,3.9 - 5.6,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Serum Uric Acid,,472,,,,,125 - 488,umol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Calcium (EDTA),,2.36,,,,,2.07 - 2.64,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Phosphorus,,1.14,,,,,0.71 - 1.65,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Total Protein,,69,,,,,61 - 84,g/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Creatine Kinase,,132,,,,,39 - 308,U/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Serum Sodium,,141,,,,,132 - 147,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Serum Potassium,,4.4,,,,,3.5 - 5.2,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Serum Bicarbonate,,21.0,,,,,19.3 - 29.3,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,3.53,,H,,,1.42 - 2.08,mL/sec +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,77,,,,,40 - 110,umol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,130.2,,,,,kg, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,GFR,EGFR by MDRD,,98,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,148,,,,,127 - 181,g/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.42,,,,,0.39 - 0.54, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,5.0,,,,,4.5 - 6.4,TI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,85,,,,,79 - 96,fL +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.89,,,,,3.8 - 10.7,GI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.47,,,,,1.96 - 7.23,GI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.93,,,,,0.91 - 4.28,GI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.30,,,,,0.12 - 0.92,GI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.17,,,,,0 - 0.57,GI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.02,,,,,0 - 0.2,GI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,58.8,,,,,40.5 - 75,% +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,32.7,,,,,15.4 - 48.5,% +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.1,,,,,2.6 - 10.1,% +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,2.9,,,,,0 - 6.8,% +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.4,,,,,0 - 2,% +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,369,,,,,140 - 400,GI/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.5,,,,,<6.5%, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,16.15,,,,,1.9 - 23,uIU/mL +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,LIPID PANEL,Direct HDL-C 4th Generation,,1.24,,,,,1.03 - 1.53,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,LIPID PANEL,Triglycerides (GPO),,1.40,,,,,0.56 - 3.62,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,LIPID PANEL,Cholesterol (High Performance),,4.07,,,,,3.88 - 6.83,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,LIPID PANEL,LDL Chol Friedewald 4th,,2.19,,,,,0 - 3.34,mmol/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,RETICULOCYTES,Reticulocyte Count %,,1.0,,,,,0.6 - 2.5,% +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,TSH,TSH 3rd IS-QT,,1.099,,,,,0.45 - 5.33,mIU/L +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Specific Gravity,,1.017,,,,,1 - 1.04, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur pH,,5.0,,,,,5 - 8, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120004,,,39,years,Male,Part 1 Screening,,"Oct 1, 2025 1:00 PM",6225351111,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.4,,,,,0 - 5,mg/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.4,,,,,0 - 6.2,umol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Alkaline Phosphatase,,84,,,,,35 - 104,U/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,ALT (SGPT),,36,,,,,4 - 43,U/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,AST (SGOT),,24,,,,,8 - 40,U/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,GGT,,44,,,,,4 - 49,U/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,LDH,,220,,,,,53 - 234,U/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Urea Nitrogen,,3.4,,,,,1.4 - 8.6,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Glucose Fasting,,4.6,,,,,3.9 - 5.6,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Serum Uric Acid,,295,,,,,125 - 428,umol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Calcium (EDTA),,2.42,,,,,2.07 - 2.64,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Phosphorus,,0.89,,,,,0.71 - 1.65,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Total Protein,,77,,,,,61 - 84,g/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Albumin-BCG,,47,,,,,33 - 49,g/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Creatine Kinase,,92,,,,,26 - 192,U/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Serum Sodium,,139,,,,,132 - 147,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Serum Potassium,,4.2,,,,,3.5 - 5.2,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Serum Bicarbonate,,23.7,,,,,19.3 - 29.3,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CHEMISTRY PANEL,Serum Chloride,,100,,,,,94 - 112,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,3.78,,H,,,1.25 - 1.92,mL/sec +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,58,,,,,31 - 101,umol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,105.0,,,,,kg, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,GFR,EGFR by MDRD,,114,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,137,,,,,116 - 164,g/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.40,,,,,0.34 - 0.48, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.6,,,,,4.1 - 5.6,TI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,88,,,,,79 - 98,fL +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.91,,,,,3.8 - 10.7,GI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.15,,,,,1.96 - 7.23,GI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.38,,,,,0.91 - 4.28,GI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.33,,,,,0.12 - 0.92,GI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.04,,,,,0 - 0.57,GI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.01,,,,,0 - 0.2,GI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,70.3,,,,,40.5 - 75,% +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,23.3,,,,,15.4 - 48.5,% +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,5.6,,,,,2.6 - 10.1,% +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,0.7,,,,,0 - 6.8,% +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.1,,,,,0 - 2,% +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,241,,,,,140 - 400,GI/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,4.9,,,,,<6.5%, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,15.68,,,,,1.9 - 23,uIU/mL +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,LIPID PANEL,Direct HDL-C 4th Generation,,1.23,,,,,1.03 - 1.53,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,LIPID PANEL,Triglycerides (GPO),,1.78,R,H,,,0.41 - 1.63,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,LIPID PANEL,Cholesterol (High Performance),,5.53,,,,,3.31 - 5.64,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,LIPID PANEL,LDL Chol Friedewald 4th,,3.48,,H,,,0 - 3.34,mmol/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,RETICULOCYTES,Reticulocyte Count %,,2.0,,,,,0.6 - 2.5,% +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,TSH,TSH 3rd IS-QT,,2.503,,,,,0.45 - 5.33,mIU/L +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Specific Gravity,,1.014,,,,,1 - 1.04, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120003,,,21,years,Female,Part 1 Screening,,"Oct 1, 2025 11:00 AM",6225351110,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,C-REACTIVE PROTEIN,C Reactive Protein HS,,1.4,,,,,0 - 5,mg/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Total Bilirubin,,4,,,,,3 - 21,umol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,1.7,,,,,0 - 6.2,umol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Alkaline Phosphatase,,69,,,,,35 - 104,U/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,ALT (SGPT),,5,,,,,4 - 43,U/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,AST (SGOT),,13,,,,,8 - 40,U/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,GGT,,<4,,L,,Result verified by repeat analysis,4 - 49,U/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,LDH,,143,,,,,53 - 234,U/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Urea Nitrogen,,4.8,,,,,1.4 - 8.6,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,56,,,,,31 - 101,umol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Glucose Fasting,,4.4,,,,,3.9 - 5.6,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Serum Uric Acid,,193,,,,,125 - 428,umol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Calcium (EDTA),,2.29,,,,,2.07 - 2.64,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Phosphorus,,1.05,,,,,0.71 - 1.65,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Total Protein,,67,,,,,61 - 84,g/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Albumin-BCG,,43,,,,,33 - 49,g/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Creatine Kinase,,75,,,,,26 - 192,U/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Serum Sodium,,137,,,,,132 - 147,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Serum Bicarbonate,,21.2,,,,,19.3 - 29.3,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CHEMISTRY PANEL,Serum Chloride,,102,,,,,94 - 112,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,2.06,,H,,,1.25 - 1.92,mL/sec +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,56,,,,,31 - 101,umol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,65.8,,,,,kg, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,Yes,,,,,, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,GFR,EGFR by MDRD,,105,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,131,,,,,116 - 164,g/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.39,,,,,0.34 - 0.48, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,4.1 - 5.6,TI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,92,,,,,79 - 98,fL +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.06,,,,,3.8 - 10.7,GI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,3.38,,,,,1.96 - 7.23,GI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.11,,,,,0.91 - 4.28,GI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.35,,,,,0.12 - 0.92,GI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.20,,,,,0 - 0.57,GI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,66.7,,,,,40.5 - 75,% +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,21.9,,,,,15.4 - 48.5,% +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,6.8,,,,,2.6 - 10.1,% +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,3.9,,,,,0 - 6.8,% +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.6,,,,,0 - 2,% +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,182,,,,,140 - 400,GI/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,5.0,,,,,<6.5%, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,,,,Test cancelled: Hemolysis-test not performed,,, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,LIPID PANEL,Direct HDL-C 4th Generation,,1.77,R,H,,,1.03 - 1.53,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,LIPID PANEL,Triglycerides (GPO),,0.71,,,,,0.44 - 1.99,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,LIPID PANEL,Cholesterol (High Performance),,5.82,,,,,3.65 - 6.21,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,LIPID PANEL,LDL Chol Friedewald 4th,,3.72,,H,,,0 - 3.34,mmol/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,No,,,,,, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,RETICULOCYTES,Reticulocyte Count %,,1.7,,,,,0.6 - 2.5,% +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,SERUM BETA HCG,"B-hCG, Qualitative",,Negative,,,,,Ref Rng: Negative, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,SERUM BETA HCG,"B-hCG, Quantitative",,<0.6,,,,,Units: mIU/mL$Pre-menopausal$<5.0: Negative$5.0-24.9:Borderline$>/= 25.0: Positive, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,TSH,TSH 3rd IS-QT,,1.847,,,,,0.45 - 5.33,mIU/L +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Specific Gravity,,1.006,,,,,1 - 1.04, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur pH,,5.5,,,,,5 - 8, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120002,,,40,years,Female,Part 1 Screening,,"Sep 3, 2025 1:00 PM",6225351109,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,C-REACTIVE PROTEIN,C Reactive Protein HS,,4.6,,,,,0 - 5,mg/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Total Bilirubin,,7,,,,,3 - 21,umol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Direct Bilirubin Gen2-Doumas,,2.5,,,,,0 - 6.2,umol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Alkaline Phosphatase,,71,,,,,35 - 104,U/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,ALT (SGPT),,24,,,,,4 - 43,U/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,AST (SGOT),,31,,,,,8 - 40,U/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,GGT,,79,R,H,,,4 - 49,U/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,LDH,,144,,,,,53 - 234,U/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Urea Nitrogen,,4.3,,,,,1.4 - 8.6,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Creatinine(Rate Blanked)-2dp,,93,,,,,31 - 101,umol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Glucose Fasting,,4.8,,,,,3.9 - 5.6,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Serum Uric Acid,,405,,,,,149 - 446,umol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Calcium (EDTA),,2.38,,,,,2.07 - 2.64,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Phosphorus,,0.92,,,,,0.71 - 1.65,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Total Protein,,72,,,,,61 - 84,g/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Albumin-BCG,,44,,,,,33 - 49,g/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Creatine Kinase,,157,,,,,26 - 192,U/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Serum Sodium,,138,,,,,132 - 147,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Serum Potassium,,4.5,,,,,3.5 - 5.2,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Serum Bicarbonate,,22.8,,,,,19.3 - 29.3,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CHEMISTRY PANEL,Serum Chloride,,101,,,,,94 - 112,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CREATININE CLEARANCE CC&G,CreatininClearancCockcrftGault,,1.33,,,,,1.25 - 1.92,mL/sec +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CREATININE CLEARANCE CC&G,Creatinine(Rate Blanked)-2dp,,93,,,,,31 - 101,umol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,CREATININE CLEARANCE CC&G,"Weight (kg,1dec place)",Y,83.8,,,,,kg, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,DRUG SCREEN URINE,Amphetamines/MDMA,,Neg,,,,,Neg;$Cutoff = 1000 ng/mL, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,DRUG SCREEN URINE,Barbiturates,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,DRUG SCREEN URINE,Cannabinoids,,Neg,,,,,Neg;$Cutoff = 50 ng/mL, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,DRUG SCREEN URINE,Cocaine,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,DRUG SCREEN URINE,Opiates,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,DRUG SCREEN URINE,Methadone,,Neg,,,,,Neg;$Cutoff = 300 ng/mL, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,DRUG SCREEN URINE BENZO NON-US,Benzodiazepines Gen 2,,Neg,,,,,Neg;$Cutoff = 200 ng/mL, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,FEMALE OF CHILDBEARING POT?,Female/of Childbearing pot.?,Y,No,,,,,, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,FSH,Follicle Stimulating Hormone,,32.96,,RX,,,Follicular:$3.90-8.80 IU/L$Midcycle:$4.50-22.50 IU/L$Luteal:$1.80-5.10 IU/L$Postmenopausal:$16.70-113.60 IU/L, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,GFR,EGFR by MDRD,,54,,,,,mL/min/1.73m^2$No Ref Rng, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Hemoglobin,,117,,,,,116 - 164,g/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Hematocrit,,0.35,,,,,0.34 - 0.48, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,RBC,,4.3,,,,,4.1 - 5.6,TI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,RBC Morphology,,No Review Required,,,,,NORMOCYTIC;$NORMOCHROMIC, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,MCV,,81,,,,,79 - 98,fL +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,WBC,,5.93,,,,,3.8 - 10.7,GI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils,,4.05,,,,,1.96 - 7.23,GI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes,,1.14,,,,,0.91 - 4.28,GI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes,,0.46,,,,,0.12 - 0.92,GI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils,,0.25,,,,,0 - 0.57,GI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils,,0.03,,,,,0 - 0.2,GI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Neutrophils (%),,68.3,,,,,40.5 - 75,% +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Lymphocytes (%),,19.2,,,,,15.4 - 48.5,% +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Monocytes (%),,7.8,,,,,2.6 - 10.1,% +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Eosinophils (%),,4.2,,,,,0 - 6.8,% +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Basophils (%),,0.5,,,,,0 - 2,% +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMATOLOGY&DIFFERENTIAL PANEL,Platelets,,157,,,,,140 - 400,GI/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,HEMOGLOBIN A1C,"Hemoglobin A1c,Variant(-70)-QT",,6.5,,H,,,<6.5%, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,INSULIN,"Ultra.Insulin,EDTApl,FastingQT",,27.42,,H,,,1.9 - 23,uIU/mL +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,IS SUBJECT FASTING?,Is Subject Fasting?,Y,Yes,,,,,, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,IS SUBJECT OF BLACK RACE?,Subject of black race?,Y,No,,,,,, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,LIPID PANEL,Direct HDL-C 4th Generation,,0.82,R,L,,,1.03 - 1.53,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,LIPID PANEL,Triglycerides (GPO),,2.78,,,,,0.59 - 2.96,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,LIPID PANEL,Cholesterol (High Performance),,5.73,,,,,4.42 - 7.53,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,LIPID PANEL,LDL Chol Friedewald 4th,,3.64,,H,,,0 - 3.34,mmol/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,POSTMENOPAUSAL FEMALE?,<40yrs & amenorrhea >/= 12mo,,Yes,,,,,, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,RETICULOCYTES,Reticulocyte Count %,,1.4,,,,,0.6 - 2.5,% +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,TSH,TSH 3rd IS-QT,,1.091,,,,,0.45 - 5.33,mIU/L +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Specific Gravity,,1.019,,,,,1 - 1.04, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur pH,,6.0,,,,,5 - 8, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Protein,,Negative,,,,,Ref Rng:Negative, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Glucose,,Normal,,,,,Ref Rng:Normal, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Ketones,,Negative,,,,,Ref Rng:Negative, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Bilirubin,,Negative,,,,,Ref Rng:Negative, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Urobilinogen,,Normal,,,,,Ref Rng:Normal, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Blood,,Negative,,,,,Ref Rng:$Negative-Trace, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Nitrite,,Negative,,,,,Ref Rng:Negative, +CZ100120001,,,56,years,Female,Part 1 Screening,,"Aug 6, 2025 1:35 PM",6225351106,URINE MACRO PANEL,Ur Leukocyte Esterase,,Negative,,,,,Ref Rng:Negative, diff --git a/Feasibility/77242113UCO2001/ImportSIPIQcompled/ICONIC+Phase+3b+UC+Study+(77242113UCO3002)_SipIQ_V1_13MAY2026_June+18,+2026_01.27.csv b/Feasibility/77242113UCO2001/ImportSIPIQcompled/Zpracováno/ICONIC+Phase+3b+UC+Study+(77242113UCO3002)_SipIQ_V1_13MAY2026_June+18,+2026_01.27.csv similarity index 100% rename from Feasibility/77242113UCO2001/ImportSIPIQcompled/ICONIC+Phase+3b+UC+Study+(77242113UCO3002)_SipIQ_V1_13MAY2026_June+18,+2026_01.27.csv rename to Feasibility/77242113UCO2001/ImportSIPIQcompled/Zpracováno/ICONIC+Phase+3b+UC+Study+(77242113UCO3002)_SipIQ_V1_13MAY2026_June+18,+2026_01.27.csv diff --git a/Feasibility/TRASH/sipiq_reminder_v1.0.md b/Feasibility/TRASH/sipiq_reminder_v1.0.md new file mode 100644 index 0000000..b54fac9 --- /dev/null +++ b/Feasibility/TRASH/sipiq_reminder_v1.0.md @@ -0,0 +1,32 @@ +# sipiq_reminder_v1.0 — připomínka vyplnění SIPIQ (.eml draft) + +**Verze:** 1.0 · **Datum:** 2026-06-18 · **Studie:** 77242113UCO3002 (ICONIC / DAWN) + +## Co dělá +.eml draft připomínky vyplnění SIPIQ pro centra na KROK 6 (SIPIQ odeslán), která dlouho nereagují. +Vřelá prosba o vyplnění **co nejdříve** + odkaz na dotazník specifický pro centrum (`sipiq.link` +z investigators) + datum původního odeslání + bezpečnostní věta „pokud jste již vyplnil(a), ignorujte". +Skloňování dle pohlaví (oslovení, „vyplnil/vyplnila") — žena dle příjmení končícího „á/ová". + +## Příjemci / odeslání +- **To** = `email` + `email2` z investigators + ruční `EXTRA_TO` (z reply-checku / STATUS); + **dd-proxy adresy vynechány**, dedup. **Cc** = koordinátorky. **From** = vbuzalka@its.jnj.com. +- Tělo **BASE64** (Outlook čistě, žádné quoted-printable „="). `X-Unsent: 1` → compose. +- Výstup `…\UploadToJNJ\pripominka_sipiq__.eml`. +- **Draft ≠ odesláno** — STATUS „připomínka SIPIQ odeslána" psát až po ověření odeslání. + +## EXTRA_TO (18JUN2026, zjištěno reply-checkem v jnjemails SQLite) +- Jungwirthová: + `a.jungwirthova@liberascientia.cz` (psala odtud, ne z egk.cz) +- Krížová: + `Viera.Krizova@fnmh.cz` (psala odtud, ne z homolka.cz) +- Mudr: + `petr.pekny@nmskb.cz` (dr. Pěkný komunikuje za dr. Mudra; SIPIQ šel To Mudr+Pěkný) + +## Použití +``` +.venv\Scripts\python.exe Feasibility\sipiq_reminder_v1.0.py --names "Matous,Kojecky,Jungwirthova,Krížová,Mudr" --apply +``` +Bez `--apply` = dry-run. Mongo 192.168.1.76:27017, pymongo. + +## Stav 18JUN2026 +Vygenerováno 5 připomínek (Matouš, Kojecký, Jungwirthová, Krížová, Mudr) — centra >3 dny na KROK 6 +bez posunu (Drastich vynechán, dovolená do 22JUN). Reply-check (jnjemails SQLite): žádná reakce po +odeslání SIPIQ. Čekají na ruční odeslání → pak STATUS. diff --git a/Feasibility/TRASH/sipiq_reminder_v1.0.py b/Feasibility/TRASH/sipiq_reminder_v1.0.py new file mode 100644 index 0000000..bf66c13 --- /dev/null +++ b/Feasibility/TRASH/sipiq_reminder_v1.0.py @@ -0,0 +1,154 @@ +#!/usr/bin/env python3 +# -*- coding: utf-8 -*- +""" +sipiq_reminder_v1.0.py +====================== +Verze: 1.0 +Datum: 2026-06-18 +Autor: Claude Code (pro MUDr. Vladimíra Buzalku) + +Popis +----- +Vygeneruje .eml draft PŘIPOMÍNKY vyplnění SIPIQ (studie 77242113UCO3002 / DAWN) pro centra +na KROK 6 (SIPIQ odeslán), která dlouho nereagovala. Vřelá prosba o vyplnění co nejdříve ++ odkaz na dotazník specifický pro centrum (sipiq.link z investigators) + bezpečnostní věta +„pokud jste již vyplnil(a), ignorujte". + +To = email + email2 z investigators (+ EXTRA_TO ručně, dd-proxy vynechány), Cc = koordinátorky, +from = vbuzalka@its.jnj.com, tělo BASE64 (Outlook čistě). Draft ≠ odesláno — STATUS „připomínka +SIPIQ odeslána" psát až po ověření odeslání. + +Použití: + python sipiq_reminder_v1.0.py --names "Matous,Kojecky,Jungwirthova,Krížová,Mudr" # dry-run + python sipiq_reminder_v1.0.py --names "Matous,Kojecky,Jungwirthova,Krížová,Mudr" --apply +Mongo 192.168.1.76:27017, bez auth, pymongo. +""" +import argparse +import os +import re +import unicodedata +from datetime import date +from email.message import EmailMessage + +from pymongo import MongoClient + +OUT_DIR = r"u:\Dropbox\!!!Days\Downloads Z230\UploadToJNJ" +CC = "AKocourk@ITS.JNJ.com, EBartoso@its.jnj.com" +FROM = "vbuzalka@its.jnj.com" +SIG = ("MUDr. Vladimír BUZALKA
    " + "ICON plc / Performing Local Trial Management Services for Janssen – Cilag s.r.o. " + "/ Global Clinical Operations
    " + "Mobile: +420 775 735 276 / Fax: +420 227 012 284
    " + "E-mail: vbuzalka@its.jnj.com, vladimir.buzalka@iconplc.com") + +# Ručně doplněné adresy (z reply-checku / STATUS) — komu navíc poslat +EXTRA_TO = { + "Jungwirthova": ["a.jungwirthova@liberascientia.cz"], + "Krížová": ["Viera.Krizova@fnmh.cz"], + "Mudr": ["petr.pekny@nmskb.cz"], # dr. Pěkný komunikuje za dr. Mudra (dle STATUS) +} + +CZ_MON = {1: "ledna", 2: "února", 3: "března", 4: "dubna", 5: "května", 6: "června", + 7: "července", 8: "srpna", 9: "září", 10: "října", 11: "listopadu", 12: "prosince"} +MON = {m: i + 1 for i, m in enumerate( + ["JAN", "FEB", "MAR", "APR", "MAY", "JUN", "JUL", "AUG", "SEP", "OCT", "NOV", "DEC"])} + + +def ascii_slug(s): + return "".join(c for c in unicodedata.normalize("NFKD", str(s or "")) + if not unicodedata.combining(c)).lower().replace(" ", "") + + +def sent_date_cz(status): + dates = [] + for ln in (status or "").splitlines(): + if "SIPIQ odesl" in ln: + m = re.match(r"(\d{2})([A-Za-z]{3})(\d{4})", ln.strip()) + if m and m.group(2).upper() in MON: + dates.append(date(int(m.group(3)), MON[m.group(2).upper()], int(m.group(1)))) + if not dates: + return None + d = max(dates) + return f"{d.day}. {CZ_MON[d.month]} {d.year}" + + +def is_female(prijmeni): + p = (prijmeni or "").lower() + return p.endswith("ová") or p.endswith("ova") or p.endswith("á") + + +def build_body(jmeno, prijmeni, sent_cz, link): + f = is_female(prijmeni) + greet = "Vážená paní doktorko," if f else "Vážený pane doktore," + vyplnil = "vyplnila" if f else "vyplnil" + sent_part = f" dne {sent_cz}" if sent_cz else "" + return ( + f'

    {greet}

    ' + f'

    dovoluji si zdvořile připomenout feasibility dotazník SIPIQ ke studii ' + f'77242113UCO3002 (DAWN) (přípravek icotrokinra, ulcerózní kolitida), ' + f'který jsme Vám zaslali{sent_part}.

    ' + f'

    Velmi bychom ocenili jeho vyplnění co nejdříve — je pro nás klíčový pro ' + f'posouzení Vašeho centra a další postup. Níže najdete odkaz na dotazník specifický ' + f'pro Vaše centrum:

    ' + f'

    {link}

    ' + f'

    Pokud jste dotazník již {vyplnil}, přijměte prosím poděkování a tento e-mail ' + f'ignorujte.

    ' + f'

    V případě jakýchkoli dotazů (např. potíže s odkazem) jsem Vám plně k dispozici. ' + f'Předem děkuji za Váš čas a vstřícnost.

    ' + f'

    S pozdravem,
    {SIG}

    ' + ) + + +def main(): + ap = argparse.ArgumentParser() + ap.add_argument("--names", required=True, help="příjmení čárkou (pi v investigators)") + ap.add_argument("--apply", action="store_true") + args = ap.parse_args() + + db = MongoClient("mongodb://192.168.1.76:27017", serverSelectionTimeoutMS=8000).feasibility + names = [n.strip() for n in args.names.split(",") if n.strip()] + docs = list(db.investigators.find({"prijmeni": {"$in": names}})) + found = {d["prijmeni"] for d in docs} + for n in names: + if n not in found: + print(f" ! nenalezeno: {n}") + + subject = "[Připomínka] 77242113UCO3002 (DAWN) — feasibility dotazník SIPIQ (prosba o vyplnění)" + done = [] + for d in docs: + link = (d.get("sipiq") or {}).get("link") + if not link: + print(f" ! {d['prijmeni']}: chybí sipiq.link — přeskakuji"); continue + tos = [e for e in [d.get("email"), d.get("email2")] if e] + tos += EXTRA_TO.get(d["prijmeni"], []) + tos = [e for e in dict.fromkeys(tos) if "dd-proxy" not in e.lower()] # dedup + bez proxy + to = ", ".join(tos) + sent_cz = sent_date_cz(d.get("STATUS")) + body = build_body(d.get("jmeno"), d["prijmeni"], sent_cz, link) + print(f" {d.get('jmeno')} {d['prijmeni']:14} | To: {to}") + + if not args.apply: + continue + msg = EmailMessage() + msg["From"] = FROM + msg["To"] = to + msg["Cc"] = CC + msg["Subject"] = subject + msg["X-Unsent"] = "1" + html = (f'' + f'{body}') + msg.set_content(html, subtype="html", charset="utf-8", cte="base64") + os.makedirs(OUT_DIR, exist_ok=True) + fn = f"pripominka_sipiq_{ascii_slug(d['prijmeni'])}_18JUN2026.eml" + with open(os.path.join(OUT_DIR, fn), "wb") as fh: + fh.write(bytes(msg)) + done.append(fn) + + if not args.apply: + print(f"\n[DRY-RUN] {len(docs)} center, nic nezapsáno. Ostrý: --apply") + else: + print(f"\n[APPLY] Vygenerováno {len(done)} připomínek do {OUT_DIR}") + + +if __name__ == "__main__": + main() diff --git a/Feasibility/TRASH/sipiq_thankyou_v1.0.md b/Feasibility/TRASH/sipiq_thankyou_v1.0.md new file mode 100644 index 0000000..c1ef097 --- /dev/null +++ b/Feasibility/TRASH/sipiq_thankyou_v1.0.md @@ -0,0 +1,38 @@ +# sipiq_thankyou_v1.0 — poděkování za vyplnění SIPIQ (.eml draft) + +**Verze:** 1.0 · **Datum:** 2026-06-18 · **Studie:** 77242113UCO3002 (ICONIC / DAWN) + +## Co dělá +Vygeneruje `.eml` draft poděkování za vyplnění SIPIQ pro jedno centrum (čte z Mongo +`feasibility.sipiq_responses` + `sipiq_questions` + `investigators`). Draft otevře Outlook +jako rozepsaný e-mail (`X-Unsent: 1`); uživatel ho **ručně odešle**. + +## Struktura e-mailu (domluva 18JUN2026, BEZ Shrnutí) +1. **Úvod:** „Děkujeme za zaslání vyplněného dotazníku SIPIQ studie 77242113UCO3002 (DAWN). + Vaše odpovědi uvádíme pro úplnost v plném znění níže, pod podpisem. Odeslaný dotazník již + není možné editovat, takže kdybychom při dalším zpracování našli položky chybějící, nejasné + nebo nekonzistentní, ještě bychom si vyžádali upřesnění e-mailem." +2. **Podpis** (MUDr. Buzalka / ICON…). +3. **ÚPLNĚ POD PODPISEM** = kompletní výpis vyplněného SIPIQ (sekce → otázka → odpověď, dle + `order`/`section`; vynechána Confidentiality; jen neprázdné odpovědi). +- **Shrnutí se NEpíše** (uživatel 18JUN2026). Větu „Shrnutí je níže" z původní šablony nahrazuje + odkaz na plné odpovědi pod podpisem. + +## Příjemci / odeslání +- **To** = e-maily lékaře z `investigators` (`email` + `email2`), fallback `pi_email`. **Cc** = + koordinátorky `AKocourk@ITS.JNJ.com, EBartoso@its.jnj.com`. **From** = vbuzalka@its.jnj.com. +- Výstup `…\UploadToJNJ\podekovani_sipiq__.eml`. +- **Draft ≠ odesláno** — STATUS „poděkováno" psát až po ověření odeslání. +- Generuje .eml přímo (Python `email` lib, multipart text+HTML, UTF-8) kvůli velkému tělu; + není přes `create_draft_eml` (to je pro krátká těla). X-Unsent draft = Outlook compose. + +## Použití +``` +.venv\Scripts\python.exe Feasibility\sipiq_thankyou_v1.0.py --last Bruncak # dry-run +.venv\Scripts\python.exe Feasibility\sipiq_thankyou_v1.0.py --last Bruncak --apply # zapíše .eml +``` +`--last` = `pi_last_name` v sipiq_responses. Mongo 192.168.1.76:27017, pymongo. + +## Stav 18JUN2026 +Vygenerován testovací draft pro Bruncáka (To obě adresy, Cc koordinátorky, 13 sekcí SIPIQ). +Zbývajících 15 center na vyžádání. diff --git a/Feasibility/TRASH/sipiq_thankyou_v1.0.py b/Feasibility/TRASH/sipiq_thankyou_v1.0.py new file mode 100644 index 0000000..7c4a2d4 --- /dev/null +++ b/Feasibility/TRASH/sipiq_thankyou_v1.0.py @@ -0,0 +1,149 @@ +#!/usr/bin/env python3 +# -*- coding: utf-8 -*- +""" +sipiq_thankyou_v1.0.py +====================== +Verze: 1.0 +Datum: 2026-06-18 +Autor: Claude Code (pro MUDr. Vladimíra Buzalku) + +Popis +----- +Vygeneruje .eml draft PODĚKOVÁNÍ za vyplnění SIPIQ (studie 77242113UCO3002 / DAWN) +pro jedno centrum. Struktura (domluva 18JUN2026, BEZ Shrnutí): + 1) úvod (poděkování + „dotazník už nelze editovat; při chybějících/nejasných/nekonzistentních + položkách si vyžádáme upřesnění e-mailem"; odkaz na plné odpovědi pod podpisem), + 2) podpis, + 3) ÚPLNĚ POD PODPISEM = kompletní výpis vyplněného SIPIQ (sekce → otázka → odpověď, + seřazené dle struktury dotazníku; vynechána sekce Confidentiality; jen neprázdné). + +Cc = koordinátorky (AKocourk + EBartoso). To = e-maily lékaře z investigators (email + email2), +fallback pi_email z odpovědi. from = vbuzalka@its.jnj.com. Výstup do …\\UploadToJNJ. +Draft ≠ odesláno — STATUS „poděkováno" psát až po ověření odeslání. + +Použití: + python sipiq_thankyou_v1.0.py --last Bruncak # dry-run (náhled) + python sipiq_thankyou_v1.0.py --last Bruncak --apply # zapíše .eml + +Mongo 192.168.1.76:27017, bez auth, pymongo. +""" +import argparse +import os +from datetime import datetime +from email.message import EmailMessage + +from pymongo import MongoClient + +OUT_DIR = r"u:\Dropbox\!!!Days\Downloads Z230\UploadToJNJ" +CC = "AKocourk@ITS.JNJ.com, EBartoso@its.jnj.com" +FROM = "vbuzalka@its.jnj.com" +SKIP_SECTIONS = {"Confidentiality Statement"} +SUBJECT = "77242113UCO3002 (DAWN) — poděkování za vyplnění feasibility dotazníku SIPIQ" +SIG = ("MUDr. Vladimír BUZALKA
    " + "ICON plc / Performing Local Trial Management Services for Janssen – Cilag s.r.o. " + "/ Global Clinical Operations
    " + "Mobile: +420 775 735 276 / Fax: +420 227 012 284
    " + "E‑mail: vbuzalka@its.jnj.com, vladimir.buzalka@iconplc.com") + + +def esc(s): + return str(s).replace("&", "&").replace("<", "<").replace(">", ">") + + +def build_sipiq_html(db, resp): + ans = resp.get("answers") or {} + qs = list(db.sipiq_questions.find().sort("order", 1)) + out, cur = [], None + for q in qs: + sec = q.get("section") or "Other" + if sec in SKIP_SECTIONS: + continue + items = q.get("items") or [] + pairs = [] + if not items: + v = ans.get(q["_id"]) + if v not in (None, ""): + pairs.append((None, v)) + else: + for it in items: + v = ans.get(it["key"]) + if v not in (None, ""): + pairs.append((it.get("label") or "(odpověď)", v)) + if not pairs: + continue + if sec != cur: + cur = sec + out.append(f'

    {esc(sec)}

    ') + stem = esc((q.get("text") or "").replace("\n", " ")) + out.append(f'

    [{q["_id"]}] {stem}

    ') + if len(pairs) == 1 and pairs[0][0] is None: + out.append(f'

    {esc(pairs[0][1])}

    ') + else: + out.append('
      ') + for lbl, v in pairs: + out.append(f'
    • {esc(lbl)}: {esc(v)}
      • ' if lbl + else f'
    • {esc(v)}
      • ') + out.append('
    ') + return "\n".join(out) + + +def main(): + ap = argparse.ArgumentParser() + ap.add_argument("--last", required=True, help="příjmení v sipiq_responses (pi_last_name)") + ap.add_argument("--apply", action="store_true") + args = ap.parse_args() + + db = MongoClient("mongodb://192.168.1.76:27017", serverSelectionTimeoutMS=8000).feasibility + resp = db.sipiq_responses.find_one({"pi_last_name": args.last}) + if not resp: + raise SystemExit(f"CHYBA: centrum '{args.last}' nenalezeno v sipiq_responses.") + inv = db.investigators.find_one({"_id": resp.get("investigator_oid")}, + {"email": 1, "email2": 1, "prijmeni": 1, "jmeno": 1}) + tos = [e for e in [(inv or {}).get("email"), (inv or {}).get("email2")] if e] + if not tos and resp.get("pi_email"): + tos = [resp["pi_email"]] + to = ", ".join(tos) + + intro = ( + '

    Vážený pane doktore,

    ' + '

    děkujeme za zaslání vyplněného dotazníku SIPIQ studie ' + '77242113UCO3002 (DAWN). Vaše odpovědi uvádíme pro úplnost v plném znění ' + 'níže, pod podpisem. Odeslaný dotazník již není možné editovat, takže kdybychom ' + 'při dalším zpracování našli položky chybějící, nejasné nebo nekonzistentní, ' + 'ještě bychom si vyžádali upřesnění e-mailem.

    ' + ) + sig = f'

    S pozdravem,
    {SIG}

    ' + sipiq = build_sipiq_html(db, resp) + body = (intro + sig + + '
    ' + '

    Vyplněné SIPIQ (kopie Vašich odpovědí):

    ' + + sipiq) + + print(f"Centrum: {resp.get('pi_first_name')} {resp.get('pi_last_name')} | {resp.get('site_name')}") + print(f"To: {to}\nCc: {CC}\nSubject: {SUBJECT}") + print(f"SIPIQ – sekcí: {sipiq.count('{body}", + subtype="html", charset="utf-8") + + os.makedirs(OUT_DIR, exist_ok=True) + fname = f"podekovani_sipiq_{args.last.lower()}_{datetime.now().strftime('%d%b%Y').upper()}.eml" + path = os.path.join(OUT_DIR, fname) + with open(path, "wb") as f: + f.write(bytes(msg)) + print(f"Uloženo: {path}") + + +if __name__ == "__main__": + main() diff --git a/Feasibility/TRASH/sipiq_thankyou_v1.1.md b/Feasibility/TRASH/sipiq_thankyou_v1.1.md new file mode 100644 index 0000000..375da78 --- /dev/null +++ b/Feasibility/TRASH/sipiq_thankyou_v1.1.md @@ -0,0 +1,37 @@ +# sipiq_thankyou_v1.1 — poděkování za vyplnění SIPIQ (.eml draft) + +**Verze:** 1.1 · **Datum:** 2026-06-18 · **Studie:** 77242113UCO3002 (ICONIC / DAWN) + +## Změna proti v1.0 +- **OPRAVA KÓDOVÁNÍ:** tělo se kóduje **base64** (`cte="base64"`), jediná `text/html` část. + v1.0 použila default quoted-printable → Outlook zobrazoval „=" místo písmen + (`=ážený`, `=ladimír`, `Service=`, `jnj.co=`). Base64 = čistý text (jako `create_draft_eml`). + v1.0 → `Feasibility\TRASH`. + +## Co dělá +.eml draft poděkování za vyplnění SIPIQ pro jedno centrum (čte `feasibility.sipiq_responses` ++ `sipiq_questions` + `investigators`). `X-Unsent: 1` → Outlook otevře jako rozepsaný e-mail; +uživatel **ručně odešle**. + +## Struktura (BEZ Shrnutí) +1. Úvod (poděkování + odkaz na plné odpovědi pod podpisem + „dotazník už nelze editovat; + při chybějících/nejasných/nekonzistentních položkách si vyžádáme upřesnění e-mailem"). +2. Podpis. +3. ÚPLNĚ POD PODPISEM = kompletní výpis SIPIQ (sekce → otázka → odpověď, dle `order`/`section`, + vynechána Confidentiality, jen neprázdné). + +## Příjemci / odeslání +- **To** = `email` + `email2` z investigators (fallback `pi_email`). **Cc** = koordinátorky + `AKocourk@ITS.JNJ.com, EBartoso@its.jnj.com`. **From** = vbuzalka@its.jnj.com. +- Výstup `…\UploadToJNJ\podekovani_sipiq__.eml`. +- **Draft ≠ odesláno** — STATUS „poděkováno" psát až po ověření odeslání. + +## Použití +``` +.venv\Scripts\python.exe Feasibility\sipiq_thankyou_v1.1.py --last Bruncak # dry-run +.venv\Scripts\python.exe Feasibility\sipiq_thankyou_v1.1.py --last Bruncak --apply # zapíše .eml +``` +`--last` = `pi_last_name` v sipiq_responses. Mongo 192.168.1.76:27017, pymongo. + +## Stav 18JUN2026 +Bruncák draft přegenerován s base64 (ověřeno: 0 „=" artefaktů). Zbývajících 15 na vyžádání. diff --git a/Feasibility/TRASH/sipiq_thankyou_v1.1.py b/Feasibility/TRASH/sipiq_thankyou_v1.1.py new file mode 100644 index 0000000..3d8a8a3 --- /dev/null +++ b/Feasibility/TRASH/sipiq_thankyou_v1.1.py @@ -0,0 +1,150 @@ +#!/usr/bin/env python3 +# -*- coding: utf-8 -*- +""" +sipiq_thankyou_v1.1.py +====================== +Verze: 1.1 +Datum: 2026-06-18 +Autor: Claude Code (pro MUDr. Vladimíra Buzalku) + +Změna proti v1.0 +---------------- +- OPRAVA KÓDOVÁNÍ: tělo se kóduje BASE64 (cte="base64"), jediná text/html část. + v1.0 použil default quoted-printable → Outlook zobrazoval „=" místo písmen + (=ážený, =ladimír, Service=, jnj.co=). Base64 = čistý text (jako create_draft_eml). + v1.0 přesunuta do TRASH. + +Popis +----- +.eml draft poděkování za vyplnění SIPIQ (77242113UCO3002 / DAWN) pro jedno centrum. +Struktura (BEZ Shrnutí): úvod → podpis → ÚPLNĚ POD PODPISEM kompletní výpis SIPIQ +(sekce → otázka → odpověď, dle order/section, vynechána Confidentiality, jen neprázdné). +To = email+email2 z investigators (fallback pi_email), Cc = koordinátorky, from = its.jnj.com. +Draft ≠ odesláno — STATUS „poděkováno" psát až po ověření odeslání. + +Použití: + python sipiq_thankyou_v1.1.py --last Bruncak # dry-run + python sipiq_thankyou_v1.1.py --last Bruncak --apply # zapíše .eml +Mongo 192.168.1.76:27017, bez auth, pymongo. +""" +import argparse +import os +from datetime import datetime +from email.message import EmailMessage + +from pymongo import MongoClient + +OUT_DIR = r"u:\Dropbox\!!!Days\Downloads Z230\UploadToJNJ" +CC = "AKocourk@ITS.JNJ.com, EBartoso@its.jnj.com" +FROM = "vbuzalka@its.jnj.com" +SKIP_SECTIONS = {"Confidentiality Statement"} +SUBJECT = "77242113UCO3002 (DAWN) — poděkování za vyplnění feasibility dotazníku SIPIQ" +SIG = ("MUDr. Vladimír BUZALKA
    " + "ICON plc / Performing Local Trial Management Services for Janssen – Cilag s.r.o. " + "/ Global Clinical Operations
    " + "Mobile: +420 775 735 276 / Fax: +420 227 012 284
    " + "E-mail: vbuzalka@its.jnj.com, vladimir.buzalka@iconplc.com") + + +def esc(s): + return str(s).replace("&", "&").replace("<", "<").replace(">", ">") + + +def build_sipiq_html(db, resp): + ans = resp.get("answers") or {} + qs = list(db.sipiq_questions.find().sort("order", 1)) + out, cur = [], None + for q in qs: + sec = q.get("section") or "Other" + if sec in SKIP_SECTIONS: + continue + items = q.get("items") or [] + pairs = [] + if not items: + v = ans.get(q["_id"]) + if v not in (None, ""): + pairs.append((None, v)) + else: + for it in items: + v = ans.get(it["key"]) + if v not in (None, ""): + pairs.append((it.get("label") or "(odpověď)", v)) + if not pairs: + continue + if sec != cur: + cur = sec + out.append(f'

    {esc(sec)}

    ') + stem = esc((q.get("text") or "").replace("\n", " ")) + out.append(f'

    [{q["_id"]}] {stem}

    ') + if len(pairs) == 1 and pairs[0][0] is None: + out.append(f'

    {esc(pairs[0][1])}

    ') + else: + out.append('
      ') + for lbl, v in pairs: + out.append(f'
    • {esc(lbl)}: {esc(v)}
      • ' if lbl + else f'
    • {esc(v)}
      • ') + out.append('
    ') + return "\n".join(out) + + +def main(): + ap = argparse.ArgumentParser() + ap.add_argument("--last", required=True, help="příjmení v sipiq_responses (pi_last_name)") + ap.add_argument("--apply", action="store_true") + args = ap.parse_args() + + db = MongoClient("mongodb://192.168.1.76:27017", serverSelectionTimeoutMS=8000).feasibility + resp = db.sipiq_responses.find_one({"pi_last_name": args.last}) + if not resp: + raise SystemExit(f"CHYBA: centrum '{args.last}' nenalezeno v sipiq_responses.") + inv = db.investigators.find_one({"_id": resp.get("investigator_oid")}, + {"email": 1, "email2": 1, "prijmeni": 1, "jmeno": 1}) + tos = [e for e in [(inv or {}).get("email"), (inv or {}).get("email2")] if e] + if not tos and resp.get("pi_email"): + tos = [resp["pi_email"]] + to = ", ".join(tos) + + intro = ( + '

    Vážený pane doktore,

    ' + '

    děkujeme za zaslání vyplněného dotazníku SIPIQ studie ' + '77242113UCO3002 (DAWN). Vaše odpovědi uvádíme pro úplnost v plném znění ' + 'níže, pod podpisem. Odeslaný dotazník již není možné editovat, takže kdybychom ' + 'při dalším zpracování našli položky chybějící, nejasné nebo nekonzistentní, ' + 'ještě bychom si vyžádali upřesnění e-mailem.

    ' + ) + sig = f'

    S pozdravem,
    {SIG}

    ' + sipiq = build_sipiq_html(db, resp) + body = (intro + sig + + '
    ' + '

    Vyplněné SIPIQ (kopie Vašich odpovědí):

    ' + + sipiq) + + print(f"Centrum: {resp.get('pi_first_name')} {resp.get('pi_last_name')} | {resp.get('site_name')}") + print(f"To: {to}\nCc: {CC}\nSubject: {SUBJECT}") + print(f"SIPIQ – sekcí: {sipiq.count('' + f'{body}') + # base64 (cte) — Outlook zobrazí čistě, žádné quoted-printable „=" artefakty + msg.set_content(html_doc, subtype="html", charset="utf-8", cte="base64") + + os.makedirs(OUT_DIR, exist_ok=True) + fname = f"podekovani_sipiq_{args.last.lower()}_{datetime.now().strftime('%d%b%Y').upper()}.eml" + path = os.path.join(OUT_DIR, fname) + with open(path, "wb") as f: + f.write(bytes(msg)) + print(f"Uloženo: {path}") + + +if __name__ == "__main__": + main() diff --git a/Feasibility/TRASH/sipiq_thankyou_v1.2.md b/Feasibility/TRASH/sipiq_thankyou_v1.2.md new file mode 100644 index 0000000..3b0f86c --- /dev/null +++ b/Feasibility/TRASH/sipiq_thankyou_v1.2.md @@ -0,0 +1,34 @@ +# sipiq_thankyou_v1.2 — poděkování za vyplnění SIPIQ (.eml draft, dávkový režim) + +**Verze:** 1.2 · **Datum:** 2026-06-18 · **Studie:** 77242113UCO3002 (ICONIC / DAWN) + +## Změny +- **v1.2:** dávkový režim `--all` (+ `--skip prijmeni,...`) — iteruje po `_id` (rozliší i dva + Konecnyovy), názvy souborů u shodného příjmení doplní křestním jménem. `--email ` + pro adresné cílení. Filtr na **dd-proxy** adresy (anonymizační proxy, ne reálná schránka → vynechat). +- **v1.1:** kódování těla **base64** (`cte="base64"`) — Outlook čistě, žádné quoted-printable „=". + (v1.0 měla QP bug.) v1.0/v1.1 → `Feasibility\TRASH`. + +## Co dělá +.eml draft poděkování za vyplnění SIPIQ. Struktura BEZ Shrnutí: úvod → podpis → ÚPLNĚ POD PODPISEM +kompletní výpis SIPIQ (sekce → otázka → odpověď, dle `order`/`section`, vynechána Confidentiality, +jen neprázdné). `X-Unsent: 1` → Outlook compose; uživatel **ručně odešle**. + +## Příjemci / odeslání +- **To** = `email` + `email2` z investigators (fallback `pi_email`); **dd-proxy adresy se vynechávají**. + **Cc** = `AKocourk@ITS.JNJ.com, EBartoso@its.jnj.com`. **From** = vbuzalka@its.jnj.com. +- Výstup `…\UploadToJNJ\podekovani_sipiq_[_]_.eml`. +- **Draft ≠ odesláno** — STATUS „poděkováno" psát až po ověření odeslání. +- Pozn. Baláž: dle STATUS preferovat `balaz@bystrica.sk` (skript dává obě adresy). + +## Použití +``` +.venv\Scripts\python.exe Feasibility\sipiq_thankyou_v1.2.py --last Bruncak --apply +.venv\Scripts\python.exe Feasibility\sipiq_thankyou_v1.2.py --email konecny.stefan@fnbrno.cz --apply +.venv\Scripts\python.exe Feasibility\sipiq_thankyou_v1.2.py --all --skip Bruncak --apply +``` +Bez `--apply` = dry-run (vypíše příjemce). Mongo 192.168.1.76:27017, pymongo. + +## Stav 18JUN2026 +Bruncák poděkování odesláno (STATUS zapsán). Zbývajících 15 vygenerováno do UploadToJNJ +(`--all --skip Bruncak`), ověřeno base64 + čistý text. Čekají na ruční odeslání → pak STATUS „poděkováno". diff --git a/Feasibility/TRASH/sipiq_thankyou_v1.2.py b/Feasibility/TRASH/sipiq_thankyou_v1.2.py new file mode 100644 index 0000000..8353c69 --- /dev/null +++ b/Feasibility/TRASH/sipiq_thankyou_v1.2.py @@ -0,0 +1,195 @@ +#!/usr/bin/env python3 +# -*- coding: utf-8 -*- +""" +sipiq_thankyou_v1.2.py +====================== +Verze: 1.2 +Datum: 2026-06-18 +Autor: Claude Code (pro MUDr. Vladimíra Buzalku) + +Změny proti v1.1 +---------------- +- DÁVKOVÝ REŽIM `--all` (+ `--skip prijmeni,...`): vygeneruje poděkování pro VŠECHNA + centra v sipiq_responses (iteruje po _id, ne po příjmení → rozliší i dva Konecnyovy). + Názvy souborů u shodného příjmení rozlišeny křestním jménem. +- `--email ` pro adresné cílení jedné odpovědi. +- Kódování těla zůstává base64 (z v1.1) — Outlook čistě, žádné quoted-printable „=". + v1.0/v1.1 v TRASH. + +Popis +----- +.eml draft poděkování za vyplnění SIPIQ (77242113UCO3002 / DAWN). Struktura BEZ Shrnutí: +úvod → podpis → ÚPLNĚ POD PODPISEM kompletní výpis SIPIQ (sekce → otázka → odpověď, +dle order/section, vynechána Confidentiality, jen neprázdné). To = email+email2 z investigators +(fallback pi_email), Cc = koordinátorky, from = its.jnj.com. Draft ≠ odesláno. + +Použití: + python sipiq_thankyou_v1.2.py --last Bruncak --apply + python sipiq_thankyou_v1.2.py --email konecny.stefan@fnbrno.cz --apply + python sipiq_thankyou_v1.2.py --all --skip Bruncak --apply +Mongo 192.168.1.76:27017, bez auth, pymongo. +""" +import argparse +import os +import unicodedata +from datetime import datetime +from email.message import EmailMessage + +from pymongo import MongoClient + +OUT_DIR = r"u:\Dropbox\!!!Days\Downloads Z230\UploadToJNJ" +CC = "AKocourk@ITS.JNJ.com, EBartoso@its.jnj.com" +FROM = "vbuzalka@its.jnj.com" +SKIP_SECTIONS = {"Confidentiality Statement"} +SUBJECT = "77242113UCO3002 (DAWN) — poděkování za vyplnění feasibility dotazníku SIPIQ" +SIG = ("MUDr. Vladimír BUZALKA
    " + "ICON plc / Performing Local Trial Management Services for Janssen – Cilag s.r.o. " + "/ Global Clinical Operations
    " + "Mobile: +420 775 735 276 / Fax: +420 227 012 284
    " + "E-mail: vbuzalka@its.jnj.com, vladimir.buzalka@iconplc.com") + + +def esc(s): + return str(s).replace("&", "&").replace("<", "<").replace(">", ">") + + +def ascii_slug(s): + return "".join(c for c in unicodedata.normalize("NFKD", str(s or "")) + if not unicodedata.combining(c)).lower().replace(" ", "") + + +def build_sipiq_html(db, resp): + ans = resp.get("answers") or {} + qs = list(db.sipiq_questions.find().sort("order", 1)) + out, cur = [], None + for q in qs: + sec = q.get("section") or "Other" + if sec in SKIP_SECTIONS: + continue + items = q.get("items") or [] + pairs = [] + if not items: + v = ans.get(q["_id"]) + if v not in (None, ""): + pairs.append((None, v)) + else: + for it in items: + v = ans.get(it["key"]) + if v not in (None, ""): + pairs.append((it.get("label") or "(odpověď)", v)) + if not pairs: + continue + if sec != cur: + cur = sec + out.append(f'

    {esc(sec)}

    ') + stem = esc((q.get("text") or "").replace("\n", " ")) + out.append(f'

    [{q["_id"]}] {stem}

    ') + if len(pairs) == 1 and pairs[0][0] is None: + out.append(f'

    {esc(pairs[0][1])}

    ') + else: + out.append('
      ') + for lbl, v in pairs: + out.append(f'
    • {esc(lbl)}: {esc(v)}
      • ' if lbl + else f'
    • {esc(v)}
      • ') + out.append('
    ') + return "\n".join(out) + + +def recipients(db, resp): + inv = db.investigators.find_one({"_id": resp.get("investigator_oid")}, + {"email": 1, "email2": 1}) + tos = [e for e in [(inv or {}).get("email"), (inv or {}).get("email2")] if e] + if not tos and resp.get("pi_email"): + tos = [resp["pi_email"]] + # vynech anonymizační proxy adresy (dd-proxy) — není to schránka, kterou lékař čte + tos = [e for e in tos if "dd-proxy" not in e.lower()] or tos + return ", ".join(tos) + + +def process_one(db, resp, dup_last, apply): + to = recipients(db, resp) + intro = ( + '

    Vážený pane doktore,

    ' + '

    děkujeme za zaslání vyplněného dotazníku SIPIQ studie ' + '77242113UCO3002 (DAWN). Vaše odpovědi uvádíme pro úplnost v plném znění ' + 'níže, pod podpisem. Odeslaný dotazník již není možné editovat, takže kdybychom ' + 'při dalším zpracování našli položky chybějící, nejasné nebo nekonzistentní, ' + 'ještě bychom si vyžádali upřesnění e-mailem.

    ' + ) + sig = f'

    S pozdravem,
    {SIG}

    ' + sipiq = build_sipiq_html(db, resp) + body = (intro + sig + '
    ' + '

    Vyplněné SIPIQ (kopie Vašich odpovědí):

    ' + + sipiq) + + last = resp.get("pi_last_name") or "x" + first = resp.get("pi_first_name") or "" + slug = ascii_slug(last) + (("_" + ascii_slug(first)) if last in dup_last else "") + fname = f"podekovani_sipiq_{slug}_{datetime.now().strftime('%d%b%Y').upper()}.eml" + print(f" {first} {last:14} | {resp.get('site_country')} | To: {to[:55]}") + + if not apply: + return None + msg = EmailMessage() + msg["From"] = FROM + msg["To"] = to + msg["Cc"] = CC + msg["Subject"] = SUBJECT + msg["X-Unsent"] = "1" + html_doc = (f'' + f'{body}') + msg.set_content(html_doc, subtype="html", charset="utf-8", cte="base64") + os.makedirs(OUT_DIR, exist_ok=True) + path = os.path.join(OUT_DIR, fname) + with open(path, "wb") as f: + f.write(bytes(msg)) + return fname + + +def main(): + ap = argparse.ArgumentParser() + g = ap.add_mutually_exclusive_group(required=True) + g.add_argument("--last", help="příjmení v sipiq_responses") + g.add_argument("--email", help="pi_email konkrétní odpovědi") + g.add_argument("--all", action="store_true", help="všechna centra") + ap.add_argument("--skip", default="", help="příjmení k vynechání (čárkou)") + ap.add_argument("--apply", action="store_true") + args = ap.parse_args() + + db = MongoClient("mongodb://192.168.1.76:27017", serverSelectionTimeoutMS=8000).feasibility + skip = {s.strip() for s in args.skip.split(",") if s.strip()} + + if args.all: + resps = [r for r in db.sipiq_responses.find() if r.get("pi_last_name") not in skip] + elif args.email: + resps = list(db.sipiq_responses.find({"pi_email": args.email.lower()})) + else: + resps = list(db.sipiq_responses.find({"pi_last_name": args.last})) + if not resps: + raise SystemExit("CHYBA: žádná odpovídající odpověď.") + if (args.last or args.email) and len(resps) > 1: + raise SystemExit(f"CHYBA: nejednoznačné ({len(resps)} odpovědí) — použij --email nebo --all.") + + # duplicitní příjmení (kvůli disambiguaci názvů souborů) + seen, dup = set(), set() + for r in resps: + ln = r.get("pi_last_name") + if ln in seen: + dup.add(ln) + seen.add(ln) + + resps.sort(key=lambda r: ((r.get("site_country") or ""), (r.get("pi_last_name") or "").lower())) + print(f"Center ke zpracování: {len(resps)}" + (f" (skip: {', '.join(skip)})" if skip else "")) + done = [] + for r in resps: + fn = process_one(db, r, dup, args.apply) + if fn: + done.append(fn) + if not args.apply: + print(f"\n[DRY-RUN] {len(resps)} center, nic nezapsáno. Ostrý: --apply") + else: + print(f"\n[APPLY] Vygenerováno {len(done)} .eml do {OUT_DIR}") + + +if __name__ == "__main__": + main() diff --git a/Feasibility/sipiq_reminder_v1.1.md b/Feasibility/sipiq_reminder_v1.1.md new file mode 100644 index 0000000..78d62b8 --- /dev/null +++ b/Feasibility/sipiq_reminder_v1.1.md @@ -0,0 +1,28 @@ +# sipiq_reminder_v1.1 — připomínka vyplnění SIPIQ (.eml draft) + +**Verze:** 1.1 · **Datum:** 2026-06-18 · **Studie:** 77242113UCO3002 (ICONIC / DAWN) + +## Změna proti v1.0 +- **BEZ hlavičky From** — do `.eml` se NEdává odesílací účet. JNJ Outlook pak doplní odesílatele + z adresáře (GAL) a **odešle přes JNJ Exchange** (jediná možnost) → správná GAL identita, + žádné riziko buzalka.cz. Pravidlo 18JUN2026. v1.0 → `Feasibility\TRASH`. + +## Co dělá +.eml draft připomínky vyplnění SIPIQ pro centra na KROK 6 (SIPIQ odeslán), která dlouho nereagují. +Vřelá prosba o vyplnění co nejdříve + odkaz na `sipiq.link` + datum původního odeslání + věta +„pokud jste již vyplnil(a), ignorujte". Skloňování dle pohlaví. Tělo **base64**, `X-Unsent: 1`. + +## Příjemci +- **To** = `email` + `email2` z investigators + ruční `EXTRA_TO` (dd-proxy vynechány, dedup). + **Cc** = koordinátorky (AKocourk + EBartoso). **From** = NEdává se. +- Výstup `…\UploadToJNJ\pripominka_sipiq__.eml`. +- **Draft ≠ odesláno** — STATUS „připomínka SIPIQ odeslána" až po ověření odeslání. + +## EXTRA_TO (z reply-checku jnjemails SQLite) +Jungwirthová + liberascientia.cz · Krížová + fnmh.cz · Mudr + petr.pekny@nmskb.cz (dr. Pěkný za dr. Mudra). + +## Použití +``` +.venv\Scripts\python.exe Feasibility\sipiq_reminder_v1.1.py --names "Matous,Kojecky,Jungwirthova,Krížová,Mudr" --apply +``` +Bez `--apply` = dry-run. Mongo 192.168.1.76:27017, pymongo. diff --git a/Feasibility/sipiq_reminder_v1.1.py b/Feasibility/sipiq_reminder_v1.1.py new file mode 100644 index 0000000..880bda3 --- /dev/null +++ b/Feasibility/sipiq_reminder_v1.1.py @@ -0,0 +1,159 @@ +#!/usr/bin/env python3 +# -*- coding: utf-8 -*- +""" +sipiq_reminder_v1.1.py +====================== +Verze: 1.1 +Datum: 2026-06-18 +Autor: Claude Code (pro MUDr. Vladimíra Buzalku) + +Změna proti v1.0 +---------------- +- BEZ hlavičky From — do .eml se NEdává odesílací účet; JNJ Outlook doplní odesílatele + z GAL a odešle přes JNJ Exchange (jediná možnost). Pravidlo 18JUN2026. v1.0 v TRASH. + +Popis +----- +Vygeneruje .eml draft PŘIPOMÍNKY vyplnění SIPIQ (studie 77242113UCO3002 / DAWN) pro centra +na KROK 6 (SIPIQ odeslán), která dlouho nereagovala. Vřelá prosba o vyplnění co nejdříve ++ odkaz na dotazník specifický pro centrum (sipiq.link z investigators) + bezpečnostní věta +„pokud jste již vyplnil(a), ignorujte". + +To = email + email2 z investigators (+ EXTRA_TO ručně, dd-proxy vynechány), Cc = koordinátorky, +from = vbuzalka@its.jnj.com, tělo BASE64 (Outlook čistě). Draft ≠ odesláno — STATUS „připomínka +SIPIQ odeslána" psát až po ověření odeslání. + +Použití: + python sipiq_reminder_v1.1.py --names "Matous,Kojecky,Jungwirthova,Krížová,Mudr" # dry-run + python sipiq_reminder_v1.1.py --names "Matous,Kojecky,Jungwirthova,Krížová,Mudr" --apply +Mongo 192.168.1.76:27017, bez auth, pymongo. +""" +import argparse +import os +import re +import unicodedata +from datetime import date +from email.message import EmailMessage + +from pymongo import MongoClient + +OUT_DIR = r"u:\Dropbox\!!!Days\Downloads Z230\UploadToJNJ" +CC = "AKocourk@ITS.JNJ.com, EBartoso@its.jnj.com" +FROM = "vbuzalka@its.jnj.com" +SIG = ("MUDr. Vladimír BUZALKA
    " + "ICON plc / Performing Local Trial Management Services for Janssen – Cilag s.r.o. " + "/ Global Clinical Operations
    " + "Mobile: +420 775 735 276 / Fax: +420 227 012 284
    " + "E-mail: vbuzalka@its.jnj.com, vladimir.buzalka@iconplc.com") + +# Ručně doplněné adresy (z reply-checku / STATUS) — komu navíc poslat +EXTRA_TO = { + "Jungwirthova": ["a.jungwirthova@liberascientia.cz"], + "Krížová": ["Viera.Krizova@fnmh.cz"], + "Mudr": ["petr.pekny@nmskb.cz"], # dr. Pěkný komunikuje za dr. Mudra (dle STATUS) +} + +CZ_MON = {1: "ledna", 2: "února", 3: "března", 4: "dubna", 5: "května", 6: "června", + 7: "července", 8: "srpna", 9: "září", 10: "října", 11: "listopadu", 12: "prosince"} +MON = {m: i + 1 for i, m in enumerate( + ["JAN", "FEB", "MAR", "APR", "MAY", "JUN", "JUL", "AUG", "SEP", "OCT", "NOV", "DEC"])} + + +def ascii_slug(s): + return "".join(c for c in unicodedata.normalize("NFKD", str(s or "")) + if not unicodedata.combining(c)).lower().replace(" ", "") + + +def sent_date_cz(status): + dates = [] + for ln in (status or "").splitlines(): + if "SIPIQ odesl" in ln: + m = re.match(r"(\d{2})([A-Za-z]{3})(\d{4})", ln.strip()) + if m and m.group(2).upper() in MON: + dates.append(date(int(m.group(3)), MON[m.group(2).upper()], int(m.group(1)))) + if not dates: + return None + d = max(dates) + return f"{d.day}. {CZ_MON[d.month]} {d.year}" + + +def is_female(prijmeni): + p = (prijmeni or "").lower() + return p.endswith("ová") or p.endswith("ova") or p.endswith("á") + + +def build_body(jmeno, prijmeni, sent_cz, link): + f = is_female(prijmeni) + greet = "Vážená paní doktorko," if f else "Vážený pane doktore," + vyplnil = "vyplnila" if f else "vyplnil" + sent_part = f" dne {sent_cz}" if sent_cz else "" + return ( + f'

    {greet}

    ' + f'

    dovoluji si zdvořile připomenout feasibility dotazník SIPIQ ke studii ' + f'77242113UCO3002 (DAWN) (přípravek icotrokinra, ulcerózní kolitida), ' + f'který jsme Vám zaslali{sent_part}.

    ' + f'

    Velmi bychom ocenili jeho vyplnění co nejdříve — je pro nás klíčový pro ' + f'posouzení Vašeho centra a další postup. Níže najdete odkaz na dotazník specifický ' + f'pro Vaše centrum:

    ' + f'

    {link}

    ' + f'

    Pokud jste dotazník již {vyplnil}, přijměte prosím poděkování a tento e-mail ' + f'ignorujte.

    ' + f'

    V případě jakýchkoli dotazů (např. potíže s odkazem) jsem Vám plně k dispozici. ' + f'Předem děkuji za Váš čas a vstřícnost.

    ' + f'

    S pozdravem,
    {SIG}

    ' + ) + + +def main(): + ap = argparse.ArgumentParser() + ap.add_argument("--names", required=True, help="příjmení čárkou (pi v investigators)") + ap.add_argument("--apply", action="store_true") + args = ap.parse_args() + + db = MongoClient("mongodb://192.168.1.76:27017", serverSelectionTimeoutMS=8000).feasibility + names = [n.strip() for n in args.names.split(",") if n.strip()] + docs = list(db.investigators.find({"prijmeni": {"$in": names}})) + found = {d["prijmeni"] for d in docs} + for n in names: + if n not in found: + print(f" ! nenalezeno: {n}") + + subject = "[Připomínka] 77242113UCO3002 (DAWN) — feasibility dotazník SIPIQ (prosba o vyplnění)" + done = [] + for d in docs: + link = (d.get("sipiq") or {}).get("link") + if not link: + print(f" ! {d['prijmeni']}: chybí sipiq.link — přeskakuji"); continue + tos = [e for e in [d.get("email"), d.get("email2")] if e] + tos += EXTRA_TO.get(d["prijmeni"], []) + tos = [e for e in dict.fromkeys(tos) if "dd-proxy" not in e.lower()] # dedup + bez proxy + to = ", ".join(tos) + sent_cz = sent_date_cz(d.get("STATUS")) + body = build_body(d.get("jmeno"), d["prijmeni"], sent_cz, link) + print(f" {d.get('jmeno')} {d['prijmeni']:14} | To: {to}") + + if not args.apply: + continue + msg = EmailMessage() + # ŽÁDNÝ From — JNJ Outlook doplní odesílatele z GAL (odešle přes JNJ Exchange) + msg["To"] = to + msg["Cc"] = CC + msg["Subject"] = subject + msg["X-Unsent"] = "1" + html = (f'' + f'{body}') + msg.set_content(html, subtype="html", charset="utf-8", cte="base64") + os.makedirs(OUT_DIR, exist_ok=True) + fn = f"pripominka_sipiq_{ascii_slug(d['prijmeni'])}_18JUN2026.eml" + with open(os.path.join(OUT_DIR, fn), "wb") as fh: + fh.write(bytes(msg)) + done.append(fn) + + if not args.apply: + print(f"\n[DRY-RUN] {len(docs)} center, nic nezapsáno. Ostrý: --apply") + else: + print(f"\n[APPLY] Vygenerováno {len(done)} připomínek do {OUT_DIR}") + + +if __name__ == "__main__": + main() diff --git a/Feasibility/sipiq_thankyou_v1.3.md b/Feasibility/sipiq_thankyou_v1.3.md new file mode 100644 index 0000000..fb0cc94 --- /dev/null +++ b/Feasibility/sipiq_thankyou_v1.3.md @@ -0,0 +1,29 @@ +# sipiq_thankyou_v1.3 — poděkování za vyplnění SIPIQ (.eml draft, dávkový režim) + +**Verze:** 1.3 · **Datum:** 2026-06-18 · **Studie:** 77242113UCO3002 (ICONIC / DAWN) + +## Změny +- **v1.3:** **BEZ hlavičky From** — do `.eml` se NEdává odesílací účet. JNJ Outlook doplní + odesílatele z adresáře (GAL) a **odešle přes JNJ Exchange** (jediná možnost) → žádné riziko + buzalka.cz, žádný „holé SMTP" artefakt. Pravidlo 18JUN2026. v1.2 → `Feasibility\TRASH`. +- **v1.2:** dávkový režim `--all` (+ `--skip`), rozliší 2 Konecnyovy, filtr dd-proxy. +- **v1.1:** tělo base64 (ne quoted-printable). + +## Co dělá +.eml draft poděkování za vyplnění SIPIQ. Struktura BEZ Shrnutí: úvod → podpis → ÚPLNĚ POD PODPISEM +kompletní výpis SIPIQ (sekce → otázka → odpověď, dle `order`/`section`, vynechána Confidentiality, +jen neprázdné). Tělo base64, `X-Unsent: 1`. + +## Příjemci +- **To** = `email` + `email2` z investigators (dd-proxy vynechány). **Cc** = koordinátorky. + **From** = NEdává se. +- Výstup `…\UploadToJNJ\podekovani_sipiq_[_]_.eml`. +- **Draft ≠ odesláno** — STATUS „poděkováno" až po ověření odeslání. + +## Použití +``` +.venv\Scripts\python.exe Feasibility\sipiq_thankyou_v1.3.py --last Bruncak --apply +.venv\Scripts\python.exe Feasibility\sipiq_thankyou_v1.3.py --email konecny.stefan@fnbrno.cz --apply +.venv\Scripts\python.exe Feasibility\sipiq_thankyou_v1.3.py --all --skip Bruncak --apply +``` +Bez `--apply` = dry-run. Mongo 192.168.1.76:27017, pymongo. diff --git a/Feasibility/sipiq_thankyou_v1.3.py b/Feasibility/sipiq_thankyou_v1.3.py new file mode 100644 index 0000000..bf677b6 --- /dev/null +++ b/Feasibility/sipiq_thankyou_v1.3.py @@ -0,0 +1,200 @@ +#!/usr/bin/env python3 +# -*- coding: utf-8 -*- +""" +sipiq_thankyou_v1.3.py +====================== +Verze: 1.3 +Datum: 2026-06-18 +Autor: Claude Code (pro MUDr. Vladimíra Buzalku) + +Změna proti v1.2 +---------------- +- BEZ hlavičky From — do .eml se NEdává odesílací účet; JNJ Outlook doplní odesílatele + z GAL a odešle přes JNJ Exchange (jediná možnost). Pravidlo 18JUN2026. v1.2 v TRASH. + +Změny proti v1.1 +---------------- +- DÁVKOVÝ REŽIM `--all` (+ `--skip prijmeni,...`): vygeneruje poděkování pro VŠECHNA + centra v sipiq_responses (iteruje po _id, ne po příjmení → rozliší i dva Konecnyovy). + Názvy souborů u shodného příjmení rozlišeny křestním jménem. +- `--email ` pro adresné cílení jedné odpovědi. +- Kódování těla zůstává base64 (z v1.1) — Outlook čistě, žádné quoted-printable „=". + v1.0/v1.1 v TRASH. + +Popis +----- +.eml draft poděkování za vyplnění SIPIQ (77242113UCO3002 / DAWN). Struktura BEZ Shrnutí: +úvod → podpis → ÚPLNĚ POD PODPISEM kompletní výpis SIPIQ (sekce → otázka → odpověď, +dle order/section, vynechána Confidentiality, jen neprázdné). To = email+email2 z investigators +(fallback pi_email), Cc = koordinátorky, from = its.jnj.com. Draft ≠ odesláno. + +Použití: + python sipiq_thankyou_v1.3.py --last Bruncak --apply + python sipiq_thankyou_v1.3.py --email konecny.stefan@fnbrno.cz --apply + python sipiq_thankyou_v1.3.py --all --skip Bruncak --apply +Mongo 192.168.1.76:27017, bez auth, pymongo. +""" +import argparse +import os +import unicodedata +from datetime import datetime +from email.message import EmailMessage + +from pymongo import MongoClient + +OUT_DIR = r"u:\Dropbox\!!!Days\Downloads Z230\UploadToJNJ" +CC = "AKocourk@ITS.JNJ.com, EBartoso@its.jnj.com" +FROM = "vbuzalka@its.jnj.com" +SKIP_SECTIONS = {"Confidentiality Statement"} +SUBJECT = "77242113UCO3002 (DAWN) — poděkování za vyplnění feasibility dotazníku SIPIQ" +SIG = ("MUDr. Vladimír BUZALKA
    " + "ICON plc / Performing Local Trial Management Services for Janssen – Cilag s.r.o. " + "/ Global Clinical Operations
    " + "Mobile: +420 775 735 276 / Fax: +420 227 012 284
    " + "E-mail: vbuzalka@its.jnj.com, vladimir.buzalka@iconplc.com") + + +def esc(s): + return str(s).replace("&", "&").replace("<", "<").replace(">", ">") + + +def ascii_slug(s): + return "".join(c for c in unicodedata.normalize("NFKD", str(s or "")) + if not unicodedata.combining(c)).lower().replace(" ", "") + + +def build_sipiq_html(db, resp): + ans = resp.get("answers") or {} + qs = list(db.sipiq_questions.find().sort("order", 1)) + out, cur = [], None + for q in qs: + sec = q.get("section") or "Other" + if sec in SKIP_SECTIONS: + continue + items = q.get("items") or [] + pairs = [] + if not items: + v = ans.get(q["_id"]) + if v not in (None, ""): + pairs.append((None, v)) + else: + for it in items: + v = ans.get(it["key"]) + if v not in (None, ""): + pairs.append((it.get("label") or "(odpověď)", v)) + if not pairs: + continue + if sec != cur: + cur = sec + out.append(f'

    {esc(sec)}

    ') + stem = esc((q.get("text") or "").replace("\n", " ")) + out.append(f'

    [{q["_id"]}] {stem}

    ') + if len(pairs) == 1 and pairs[0][0] is None: + out.append(f'

    {esc(pairs[0][1])}

    ') + else: + out.append('
      ') + for lbl, v in pairs: + out.append(f'
    • {esc(lbl)}: {esc(v)}
      • ' if lbl + else f'
    • {esc(v)}
      • ') + out.append('
    ') + return "\n".join(out) + + +def recipients(db, resp): + inv = db.investigators.find_one({"_id": resp.get("investigator_oid")}, + {"email": 1, "email2": 1}) + tos = [e for e in [(inv or {}).get("email"), (inv or {}).get("email2")] if e] + if not tos and resp.get("pi_email"): + tos = [resp["pi_email"]] + # vynech anonymizační proxy adresy (dd-proxy) — není to schránka, kterou lékař čte + tos = [e for e in tos if "dd-proxy" not in e.lower()] or tos + return ", ".join(tos) + + +def process_one(db, resp, dup_last, apply): + to = recipients(db, resp) + intro = ( + '

    Vážený pane doktore,

    ' + '

    děkujeme za zaslání vyplněného dotazníku SIPIQ studie ' + '77242113UCO3002 (DAWN). Vaše odpovědi uvádíme pro úplnost v plném znění ' + 'níže, pod podpisem. Odeslaný dotazník již není možné editovat, takže kdybychom ' + 'při dalším zpracování našli položky chybějící, nejasné nebo nekonzistentní, ' + 'ještě bychom si vyžádali upřesnění e-mailem.

    ' + ) + sig = f'

    S pozdravem,
    {SIG}

    ' + sipiq = build_sipiq_html(db, resp) + body = (intro + sig + '
    ' + '

    Vyplněné SIPIQ (kopie Vašich odpovědí):

    ' + + sipiq) + + last = resp.get("pi_last_name") or "x" + first = resp.get("pi_first_name") or "" + slug = ascii_slug(last) + (("_" + ascii_slug(first)) if last in dup_last else "") + fname = f"podekovani_sipiq_{slug}_{datetime.now().strftime('%d%b%Y').upper()}.eml" + print(f" {first} {last:14} | {resp.get('site_country')} | To: {to[:55]}") + + if not apply: + return None + msg = EmailMessage() + # ŽÁDNÝ From — JNJ Outlook doplní odesílatele z GAL (odešle přes JNJ Exchange) + msg["To"] = to + msg["Cc"] = CC + msg["Subject"] = SUBJECT + msg["X-Unsent"] = "1" + html_doc = (f'' + f'{body}') + msg.set_content(html_doc, subtype="html", charset="utf-8", cte="base64") + os.makedirs(OUT_DIR, exist_ok=True) + path = os.path.join(OUT_DIR, fname) + with open(path, "wb") as f: + f.write(bytes(msg)) + return fname + + +def main(): + ap = argparse.ArgumentParser() + g = ap.add_mutually_exclusive_group(required=True) + g.add_argument("--last", help="příjmení v sipiq_responses") + g.add_argument("--email", help="pi_email konkrétní odpovědi") + g.add_argument("--all", action="store_true", help="všechna centra") + ap.add_argument("--skip", default="", help="příjmení k vynechání (čárkou)") + ap.add_argument("--apply", action="store_true") + args = ap.parse_args() + + db = MongoClient("mongodb://192.168.1.76:27017", serverSelectionTimeoutMS=8000).feasibility + skip = {s.strip() for s in args.skip.split(",") if s.strip()} + + if args.all: + resps = [r for r in db.sipiq_responses.find() if r.get("pi_last_name") not in skip] + elif args.email: + resps = list(db.sipiq_responses.find({"pi_email": args.email.lower()})) + else: + resps = list(db.sipiq_responses.find({"pi_last_name": args.last})) + if not resps: + raise SystemExit("CHYBA: žádná odpovídající odpověď.") + if (args.last or args.email) and len(resps) > 1: + raise SystemExit(f"CHYBA: nejednoznačné ({len(resps)} odpovědí) — použij --email nebo --all.") + + # duplicitní příjmení (kvůli disambiguaci názvů souborů) + seen, dup = set(), set() + for r in resps: + ln = r.get("pi_last_name") + if ln in seen: + dup.add(ln) + seen.add(ln) + + resps.sort(key=lambda r: ((r.get("site_country") or ""), (r.get("pi_last_name") or "").lower())) + print(f"Center ke zpracování: {len(resps)}" + (f" (skip: {', '.join(skip)})" if skip else "")) + done = [] + for r in resps: + fn = process_one(db, r, dup, args.apply) + if fn: + done.append(fn) + if not args.apply: + print(f"\n[DRY-RUN] {len(resps)} center, nic nezapsáno. Ostrý: --apply") + else: + print(f"\n[APPLY] Vygenerováno {len(done)} .eml do {OUT_DIR}") + + +if __name__ == "__main__": + main() From 4e06ff583f3e85818668c1758d6eea1d72c101d8 Mon Sep 17 00:00:00 2001 From: "vladimir.buzalka" Date: Thu, 18 Jun 2026 11:20:52 +0200 Subject: [PATCH 4/5] z230 --- KPC/_find_kpc_attachments_v0.py | 46 ++++++++++++++++++++ KPC/_process_telco_v0.py | 77 +++++++++++++++++++++++++++++++++ 2 files changed, 123 insertions(+) create mode 100644 KPC/_find_kpc_attachments_v0.py create mode 100644 KPC/_process_telco_v0.py diff --git a/KPC/_find_kpc_attachments_v0.py b/KPC/_find_kpc_attachments_v0.py new file mode 100644 index 0000000..a7465fc --- /dev/null +++ b/KPC/_find_kpc_attachments_v0.py @@ -0,0 +1,46 @@ +"""_find_kpc_attachments_v0.py — DOČASNÉ: najde e-maily s .kpc přílohou a vypíše obsah.""" +import sys, base64 +sys.stdout.reconfigure(encoding="utf-8") +import msal, requests + +TENANT="7d269944-37a4-43a1-8140-c7517dc426e9"; CID="4b222bfd-78c9-4239-a53f-43006b3ed07f" +SECRET="Txg8Q~MjhocuopxsJyJBhPmDfMxZ2r5WpTFj1dfk" +mailbox = sys.argv[1] if len(sys.argv) > 1 else "vladimir.buzalka@buzalka.cz" +BASE=f"https://graph.microsoft.com/v1.0/users/{mailbox}" + +app=msal.ConfidentialClientApplication(CID,authority=f"https://login.microsoftonline.com/{TENANT}",client_credential=SECRET) +tok=app.acquire_token_for_client(scopes=["https://graph.microsoft.com/.default"]) +H={"Authorization":f"Bearer {tok['access_token']}"} +HS=dict(H); HS["ConsistencyLevel"]="eventual" + +# hledej e-maily zmiňující kpc (subject/body/příloha) +r=requests.get(f"{BASE}/messages",headers=HS,params={ + "$search":'"kpc"',"$top":50, + "$select":"id,subject,from,receivedDateTime,hasAttachments"},timeout=40) +if not r.ok: + print("search ERR",r.status_code,r.text[:300]); sys.exit(1) +msgs=[m for m in r.json().get("value",[]) if m.get("hasAttachments")] +print(f"[{mailbox}] e-mailů (search kpc) s přílohou: {len(msgs)}\n") + +found=0 +for m in msgs: + ra=requests.get(f"{BASE}/messages/{m['id']}/attachments",headers=H, + params={"$select":"id,name,size,contentType"},timeout=30) + if not ra.ok: continue + for a in ra.json().get("value",[]): + if (a.get("name","") or "").lower().endswith(".kpc"): + found+=1 + frm=m.get("from",{}).get("emailAddress",{}).get("address","") + print("="*78) + print(f"e-mail: {m.get('receivedDateTime','')[:10]} | od {frm} | {m.get('subject','')[:60]}") + print(f"příloha: {a.get('name')} ({a.get('size')} B)") + full=requests.get(f"{BASE}/messages/{m['id']}/attachments/{a['id']}",headers=H,timeout=30).json() + cb=full.get("contentBytes") + if cb: + raw=base64.b64decode(cb) + for enc in ("cp1250","utf-8","latin-1"): + try: txt=raw.decode(enc); break + except: txt=None + print("--- OBSAH ---") + print(txt if txt else repr(raw[:400])) +print(f"\nCelkem .kpc příloh: {found}") diff --git a/KPC/_process_telco_v0.py b/KPC/_process_telco_v0.py new file mode 100644 index 0000000..cca2905 --- /dev/null +++ b/KPC/_process_telco_v0.py @@ -0,0 +1,77 @@ +"""_process_telco_v0.py — DOČASNÉ: Vodafone + T-Mobile v jednom KPC (osobní účet). +Telegram potvrzení → ano → KPC → Dropbox → přehození kategorií obou e-mailů. +""" +import sys +from datetime import date +from pathlib import Path +sys.stdout.reconfigure(encoding="utf-8") +sys.path.insert(0, r"U:\ordinaceprojekt") +import dropbox, msal, requests +from Knihovny.telegram_notify import zeptej_se_telegram, posli_telegram + +today = date.today(); ddmmyy = today.strftime("%d%m%y"); fdate = today.strftime("%Y-%m-%d") +DEBIT = "2100046291" # osobní + +# položky: (účet_formát, haléře, VS, banka, KS, AV) +items = [ + ("117292", 384200, "1029503118", "0300", "0000", "Faktura Vodafone"), # bez SS (formát SS nemá) + ("19-2235210247", 47920, "9953395180", "0100", "0000", "faktura T-Mobile"), # /0100 dle historie +] +total = sum(h for _, h, *_ in items) + +CRLF = "\r\n" +lines = ["UHL1" + ddmmyy + " " * 20 + "0" * 28, "1 1501 000000 2010", + f"2 000000-{DEBIT} {str(total).zfill(14)} {ddmmyy}"] +for acc, hal, vs, bank, ks, av in items: + lines.append(f"{acc} {str(hal).zfill(12)} {vs} {bank}{ks} AV:{av}") +lines += ["3 +", "5 +"] +content = CRLF.join(lines) + CRLF +data = content.encode("ascii") +fname = f"{fdate} KPC k platbě [Vodafone + T-Mobile].kpc" + +print("=== NÁHLED KPC ==="); print(content.replace("\r\n", "\\r\\n\n"), end="") +print(f"=== {fname} ({len(data)} B) === Σ {total/100:.2f} Kč\n") + +msg = ( + "💳 Návrh platby (KPC agent) — telco, z osobního 2100046291\n\n" + "1) Vodafone 3 842,00 Kč → 117292/0300, VS 1029503118 (BEZ SS — formát SS nemá, páruje se dle VS)\n" + "2) T-Mobile 479,20 Kč → 19-2235210247/0100, VS 9953395180\n\n" + "FIO: obojí nezaplaceno ✅\n\n" + "Vytvořit jeden KPC a nahrát do Dropboxu? Odpověz: ano / ne" +) +odp = zeptej_se_telegram(msg, timeout=150) +print("TELEGRAM odpověď:", repr(odp)) +if not odp or odp.strip().lower() not in ("ano", "ano.", "yes", "ok"): + print(">> NEPOTVRZENO — nic nevytvářím."); sys.exit(0) + +out_dir = Path(__file__).parent / "output"; out_dir.mkdir(exist_ok=True) +(out_dir / fname).write_bytes(data); print("lokální kopie:", out_dir / fname) + +env = {} +for line in Path(r"U:\PythonProject\Janssen\EmailsImport\.env").read_text(encoding="utf-8").splitlines(): + line = line.strip() + if "=" in line and not line.startswith("#"): + k, v = line.split("=", 1); env[k.strip()] = v.strip() +dbx = dropbox.Dropbox(app_key=env["DROPBOX_APP_KEY"], app_secret=env["DROPBOX_APP_SECRET"], + oauth2_refresh_token=env["DROPBOX_APP_REFRESH_TOKEN"]) +res = dbx.files_upload(data, f"/!!!Days/Downloads Z230/{fname}", + mode=dropbox.files.WriteMode.add, autorename=True) +print("NAHRÁNO →", res.path_display) + +# přehození kategorií obou zdrojových e-mailů (tvoje schránka) +TENANT="7d269944-37a4-43a1-8140-c7517dc426e9"; CID="4b222bfd-78c9-4239-a53f-43006b3ed07f" +SECRET="Txg8Q~MjhocuopxsJyJBhPmDfMxZ2r5WpTFj1dfk" +app=msal.ConfidentialClientApplication(CID,authority=f"https://login.microsoftonline.com/{TENANT}",client_credential=SECRET) +tok=app.acquire_token_for_client(scopes=["https://graph.microsoft.com/.default"]) +H={"Authorization":f"Bearer {tok['access_token']}","Content-Type":"application/json"} +BASE="https://graph.microsoft.com/v1.0/users/vladimir.buzalka@buzalka.cz" +EMAILS = { + "Vodafone": "AAMkADY2MzQ0N2JkLWE4NjAtNDNjYS05OTVlLTQxYjhkYWVlZmY1NQBGAAAAAACkV0glv2dZRLb1sPnwFvdvBwAzGo7b-cvrRoXjMGfWnzDsAAAAAAEMAAAzGo7b-cvrRoXjMGfWnzDsAALq4shJAAA=", + "T-Mobile": "AAMkADY2MzQ0N2JkLWE4NjAtNDNjYS05OTVlLTQxYjhkYWVlZmY1NQBGAAAAAACkV0glv2dZRLb1sPnwFvdvBwAzGo7b-cvrRoXjMGfWnzDsAAAAAAEMAAAzGo7b-cvrRoXjMGfWnzDsAALpDXp1AAA=", +} +for nm, mid in EMAILS.items(): + rp=requests.patch(f"{BASE}/messages/{mid}",headers=H,json={"categories":["KPCzpracovánoClaudem"]},timeout=30) + print(f"PATCH {nm}: {rp.status_code}", "" if rp.ok else rp.text[:200]) + +posli_telegram(f"✅ KPC vytvořeno a nahráno:\n{fname}\nVodafone 3 842 + T-Mobile 479,20 Kč, z osobního.\nV bankingu stačí podepsat.") +print(">> HOTOVO.") From 7aae48d8d8a7f0a1410488706e455ae76cc2e379 Mon Sep 17 00:00:00 2001 From: "vladimir.buzalka" Date: Thu, 18 Jun 2026 11:53:53 +0200 Subject: [PATCH 5/5] z230 --- KPC/_process_telco_v0.py | 5 +- KPC/_process_telco_v1.py | 54 +++++++++++++++++++ ...-18 KPC k platbě [Vodafone + T-Mobile].kpc | 7 +++ 3 files changed, 62 insertions(+), 4 deletions(-) create mode 100644 KPC/_process_telco_v1.py create mode 100644 KPC/output/2026-06-18 KPC k platbě [Vodafone + T-Mobile].kpc diff --git a/KPC/_process_telco_v0.py b/KPC/_process_telco_v0.py index cca2905..c4bdb1d 100644 --- a/KPC/_process_telco_v0.py +++ b/KPC/_process_telco_v0.py @@ -39,10 +39,7 @@ msg = ( "FIO: obojí nezaplaceno ✅\n\n" "Vytvořit jeden KPC a nahrát do Dropboxu? Odpověz: ano / ne" ) -odp = zeptej_se_telegram(msg, timeout=150) -print("TELEGRAM odpověď:", repr(odp)) -if not odp or odp.strip().lower() not in ("ano", "ano.", "yes", "ok"): - print(">> NEPOTVRZENO — nic nevytvářím."); sys.exit(0) +print(">> Potvrzeno uživatelem v chatu (ano) — pokračuji bez Telegram dotazu.") out_dir = Path(__file__).parent / "output"; out_dir.mkdir(exist_ok=True) (out_dir / fname).write_bytes(data); print("lokální kopie:", out_dir / fname) diff --git a/KPC/_process_telco_v1.py b/KPC/_process_telco_v1.py new file mode 100644 index 0000000..1ec4876 --- /dev/null +++ b/KPC/_process_telco_v1.py @@ -0,0 +1,54 @@ +"""_process_telco_v1.py — OPRAVA: doplněn specifický symbol (Fio ABO spec). +Položka: <účet> <částka> AV:. Přepíše soubor v Dropboxu. +""" +import sys +from datetime import date +from pathlib import Path +sys.stdout.reconfigure(encoding="utf-8") +sys.path.insert(0, r"U:\ordinaceprojekt") +import dropbox +from Knihovny.telegram_notify import posli_telegram + +today = date.today(); ddmmyy = today.strftime("%d%m%y"); fdate = today.strftime("%Y-%m-%d") +DEBIT = "2100046291" # osobní + +# (účet, haléře, VS, směr.kód, KS, SS, AV) — SS="" => prázdné (nahradí se mezerou) +items = [ + ("117292", 384200, "1029503118", "0300", "0000", "38630302", "Faktura Vodafone"), + ("19-2235210247", 47920, "9953395180", "0100", "0000", "", "faktura T-Mobile"), +] +total = sum(h for _, h, *_ in items) + +def polozka(acc, hal, vs, bank, ks, ss, av): + ssfield = ss if ss else " " # prázdný SS = jedna mezera (dle Fio spec) + return f"{acc} {str(hal).zfill(12)} {vs} {bank}{ks} {ssfield} AV:{av}" + +CRLF = "\r\n" +lines = ["UHL1" + ddmmyy + " " * 20 + "0" * 28, "1 1501 000000 2010", + f"2 000000-{DEBIT} {str(total).zfill(14)} {ddmmyy}"] +lines += [polozka(*it) for it in items] +lines += ["3 +", "5 +"] +content = CRLF.join(lines) + CRLF +data = content.encode("ascii") +fname = f"{fdate} KPC k platbě [Vodafone + T-Mobile].kpc" + +print("=== OPRAVENÝ KPC (se SS) ==="); print(content.replace("\r\n", "\\r\\n\n"), end="") +print(f"=== {fname} ({len(data)} B) ===\n") + +out_dir = Path(__file__).parent / "output"; out_dir.mkdir(exist_ok=True) +(out_dir / fname).write_bytes(data) + +env = {} +for line in Path(r"U:\PythonProject\Janssen\EmailsImport\.env").read_text(encoding="utf-8").splitlines(): + line = line.strip() + if "=" in line and not line.startswith("#"): + k, v = line.split("=", 1); env[k.strip()] = v.strip() +dbx = dropbox.Dropbox(app_key=env["DROPBOX_APP_KEY"], app_secret=env["DROPBOX_APP_SECRET"], + oauth2_refresh_token=env["DROPBOX_APP_REFRESH_TOKEN"]) +res = dbx.files_upload(data, f"/!!!Days/Downloads Z230/{fname}", + mode=dropbox.files.WriteMode.overwrite) # PŘEPÍŠE původní (bez SS) +print("PŘEPSÁNO v Dropboxu →", res.path_display) + +posli_telegram("✏️ Opraveno: telco KPC nyní obsahuje specifický symbol Vodafonu (38630302). " + "Soubor v Dropboxu přepsán — prosím znovu naimportuj.") +print(">> HOTOVO.") diff --git a/KPC/output/2026-06-18 KPC k platbě [Vodafone + T-Mobile].kpc b/KPC/output/2026-06-18 KPC k platbě [Vodafone + T-Mobile].kpc new file mode 100644 index 0000000..d2a9371 --- /dev/null +++ b/KPC/output/2026-06-18 KPC k platbě [Vodafone + T-Mobile].kpc @@ -0,0 +1,7 @@ +UHL1180626 0000000000000000000000000000 +1 1501 000000 2010 +2 000000-2100046291 00000000432120 180626 +117292 000000384200 1029503118 03000000 38630302 AV:Faktura Vodafone +19-2235210247 000000047920 9953395180 01000000 AV:faktura T-Mobile +3 + +5 +

    t;iHyKSQ$4+6R5tRbmDo~ZL!)f$6k)hdqdKi2I+ z`5XFAOxEc@6mF44o0=PNBNaxd|57W}aE#2T-Z0%aM9Tam`gyt$Q2zy`nvSaNv5fW$ z3abEB8{kAZ^{k6Y20X{ELEZG$uN$1H`KfFNUd@oBdmb}KR zR+Q1J(!ETbB!1gKH$*RJx%Q5*NakH&KAuDKxLk?~L-;+gjoo051KqGA{h;c=aq!SuWC!D9 z2&11*qcxHI#P?bUz+_^e5Gx5M5wQS15k}~pj<g=Jpri%>=0L>f9hEhER(TzJoOa}nM~A%Ww-tF3 z)1OC_bO|W0khLj||wYr25V z>W{CloeJ;|=zKn+qfryFfwMnq&$}xnyOZKf0?vtflFdXoW|E!a%Q720Nog^J?2%VR!#G;zb_Rks{^*Dvdf0)Tx5wdOsfL?wu!?kp1xawBx!^b z{rTreKNsEw*XfAtl zvZvQF<?%e)yI$iMmY<2+K3fWLamf)w~zdVdNdEJk@I z?M`7<+%JT!6%qY_B+Apf3cc6!or8y3&GJtSK@{1)87JAOI$9wFUvys^v3_kfN4Ka;SU+!k3V9#`OUz`hNcsyx=?vE@ zB`^4QG!BipmZ^nk?UBpC7a$tnXBU+k>;Bu!@DC8YAB}_N@ip{Y4Y}Dh^Qy`fD<7o$ z+CfLpXPm3G3ccBM)T>SX#$0F%esHAA@Db})%+cu#uEH^}?wlYrIR<|NT09vv0%6p^ z!ka`!NW?v>bYyWEI^rk^EW3aG5-~AhJ8!?9VP5J1+{P@HaVNex_ma;NhLsG1=~6d? z9Sf3+EtV`kuiTZp;wePk$?be`%7x)qOP#r?4(O9_xx-gZLc@jpI% z)8Ca$G{;1^7B{;nzXr`MT3zu1U=*R#kpkA5U?q47$d)a@g$rm04eWfl_0V$213vN3 zOgbo%yRW<^eB|^=WU!+nPq51rau)Jv3|sXLe+Z3)ylDZ%t{4F#gDK8A`9_d*xec9L zU1H|BOv+DjjV`234?sY)_x)_3Qii$WgG{d#e`glMeA&D z%Tg%F(W#TsR`bh=bHGAA)Jp+g097J`3RCaRt9TeVxXfi!D{pucabRCD2r`Zh7VSp_ z14<20Gu=nlrEVFJZ98$JXT@z1mGRvt0{^oXuL-kyP2G4twSfm!#5ggN0=33O)V$AV zXkxD7Kw!|gxbh-<=DWDMP zhN8q6R^8_v=Kd_e@v&a#hjp%GB;d27>2Nnte%srBUk_wfxA>f`uAD@yQS_cWdoFyr z@+O~U8XSrHn~zttdE*ark4X91jY}^mwWEgNeF6;ulun=oxZ7NxckWZyYq!_E-G&{a zKL}LIKA&u;N=&$awxp4^eZEAeY!~*ST0RFY&iDJY86_N&K$NZ;kU5VHUUSr#Ekgxw zu9nEGm#2nRjl7h-Iltr*cOfv)=*)1XuSggD$a^}Ll1sX{C_f2+ayHZ^QI72d-%nz3 zD(}89NUabzx6AuVe{6&afxE0qK6-`CrUI8p!O1BsbJiqy%-Vy${vR&f+O1)`gkh>Q z==hMLu!ymYU#&;s*mu(LmkUjwkMp&JZo28>7;a}lI3}I)B8I(F;qj$c-oHogIoj44 z5LdT6&@sK4_OVidG6oovR`o)j`xrA;7ts5x7Y(XpbUpJNJr)%-9hk#B=mGqD|FSB| zCwFCq2au0*1kxS24pt=NvoQrT3qxF9yE6~7GV65S3C4HrlM4oiI2xO9N;Gz+&FXDU zOaCSU&+`lc{!(byp0>G;ZVcxJ@T~;KoL2&d-2ZP#Dff{q>UgT5n%rOYImbuI*q0Nu z&-3~Kz*E4y5-9(hSEg*4b@)`ohB+FTq$uV}J6Ca&QGnsZ)r8(nXNUUSBNGcknMil; z%UpzH5#X)Q!k|9c!4MLWsN{{@(=7^SQn1CXrpUrmuu%@K*VV|_*lUzk>A1-ag<`r-llAh|f;^U`Xq&`C%gKjX3Wh zl`~UGj9^d_t~F8Ys_5_ZKeVQ_)KahyAejI_eMmBJ5L`kGEzGKRtuesP97qWpav%Z} z*-jnj}m_u9URo;{8KgEi?+rg+;$Vx(@ptI zne{&@h#r%F%UIZH-^gbwnE5S^C)q9Wh`=93h3|XR7soQK@;jB4Z;TifL$r&=vg;}mnWs>iJjS!%~{R+pU2!`Nkk^IEHA!-kD; z>-EU-*#qpj7|lw4Q1ch**OM2Lvdf+%h0>qnVlDnIi_2nd7~cVwBcUL#X~2<^$B;&q zH7h*M7iqUrbX$<{K3W&$mq8E+g4?I-@q*;g_fBw%5mZbuzL#?0pDDB0631j2ez$rH zm$Gx+N>e+qzoxC1)3H`)A?Y7zR}_wz+Y$T)0|s+thIOK2ZUkPQoWaH*-rt{WAH3%; zI<0KiF{P-DLj7WfV|t#@g5*lu&9Y&$@W7HX8^X zCZ+~*!g)+{niNx69sjRP1MHupbdT=I~s&jg+(DMOi znpm6bOy8_7@>B~}tJeQ;*DJA>V97xZa5W!*Gk0RC$UO(4EFlPr$Q~PwchoGE z`ysu%6#0DdbkDOs2qy0cd=c+36}IMiWWR(BG?JV#T9 za>&LF`f&$;YCPCMDZ15;_Lc+k=|?GtMLd(m*A{VKSt7->K!XFct~ncDc)ZdBw18yT zlo#TDUmw{EpE*$}phWv2q@$S&7+{-u(J8m1#(V)p#Vc*$|5&MjyWE&LagDYmf9IpID zX@<$FP0;Z6sUecRyA6be--irn2YYz!(x~T~f<+8aGhz2&*_&llsqN`N+|eUu^KZ#0 zl6<722vX@lR3gG0+PRMo$+`ZIzgp|LCezUgHA3k{7vFw>#9tnet(LrqJ5)f8wV@M> z6`s)1>G#gHM@@`t(1^PrZ_vOa4ZBz)(70fEI}NHWF7%JIegC_I$0ZSuMkP!b@oV$` z{nN?F4rC%H#?Xn6lUk^1Y$=BPdT&%3>yy4rWm37!x{2YZg-R!=bzO8q9&;znIP&}V z^&q^uBWRptYaqe@O!FkmmP{%^RQQ*XPL)X(`nnM!e8{cbY#v!JvY5bUe2hsM%9YDV$PMjQQBQ$q6Iu;wv?O)w2V)FfD< zI+zdY;3eUNv*pLvYPa0jT4;i<$Ww_SGBvOih&_G;w)>WjLM{m8C30pG?^WN-g#+{Z z_1rR^`(1%O)?V8iY9UtqX#pY&1nRl}MxpelTF)($kNfm+E6ZW*v+ZN_o#-sRvEBN66oLzsdQF-KJy>63@eyKi(w0x%A4sqeg=Ihm z$9lI6DP`Z<7wi;ID!g;_*d*c`hD7H%Ot$qN4ZA1(z;8|&FS;M}tAT^!hQF3Q$$W5f zV)*^v#0Q-w?E8rtl!pt3+a2$Y5*rsbtu+x5A%}*$9{A%_98lnWQRVOO&C5MyddxTB zv?B+>--cX$aM8>r$^fPM0Xs!RkYw$4rp>Ch_0Uad@B_V*u!PomU(WQ}2-RI5#oV#= z_jY5a@%04(+EG4*+t|1^57iy2#HWv`Wq?s^T42#$B_0EsvXRvV$OpPQM){!E?KL&R zG)(mu!#>VmeOf?uv$o$Z)>w3BgNnsb_i`2PSeCh}-o}QDJ+`=!POo$?J19E^Vit&_ zZj>OANRovFfAIzxQxfEgPi9GaqJl;O3{UnPhURXQK2Eskv381ht_E0eCX!!H%IrTH z=f82vF&bWbPqPPG0YtYA;}#_L#6rENbU?Aer(d9n7Udm%#qXI{q4=T^+fBB=**dFUx&aIb&CpE7KML{GJT@R5g8ln z3;YCZ9<>y!%^6l#Rm>BB${S??-Ch4C@Ffpeb^rsCb}D?X7V*xe%OFrFhlr`j$F4zqE&1*Fs` zp^dDAb|*;@?4WOG_X^Zen@&^&aE}{YJtEldGZJM@Eq(Zj)gv5?s~Tt=PsN-+(%h~f0GV8#MbKqM9x}cG_O^90ac4W zke)E(*<702x^lih_f0kdJ>L@1?+K?udTZy!)HU*ErPIEUOTTR4<(-|1rMFm8E97 z=0V?H=L3S1)Xt=NX`nq6 zy<``ekyFKy^a3e>M;F_1j_|^vE(P`JeR%u@64S}NLS_l8@wg@>jCTlpug7_v*{n805m$X{Hn;2gDAh=Uf@+>t4pF+L!ij^~Vv0!eDb7vCFo zlqvH3Qfw(2LjPWh!>*}kY8cx7I=$-C5I_(~9C>yb~`Ve-f|d{Z)}W zo4ZwCBl1Br)Au!`Q+;J%%uFKlmv;bDzX(32~h6UZi)we7p~n}4qR4Fh4>T*8KNAN zRZ~>I??JBxv;_-nZi^QJ*~e`LnB}iJim)Zf=Ls`hc7QaQ7-dP;Xm6as^FSqKJCdNFzPTqoIQJ$9JQ_-tV^Pdv#vAVek=M`g( zW=<4rwsfC%orO2bpa|n3y3`U(IGT9#=DSvVkrJ@FtV%)+ho^g!klQ)W+G{FMv=vi$ zfZ?&h)Ugld*D)W2%q2%m(cZApx8J)&M>mG1VvuXnT9+zU)_0GV#u#rlprt?6%N}{? zpw~Wi`VOGY@If4sb>Ks19n;frHiE?OZf_GX3NDwwwTkC@9jT+;K=d5awD{L zRxbd|)M?l4{>#slD=2N(SH+JLEnnuptfg3$=|hk=IZ|+3tug_5_%li%i;q~M8rx$t zKXC4oI=-PMjIv@H`*j;eyfaxIs($9n=dNIg8 z82@CU+X!AQxC({_+yF=%hHvdUjOpdWm~1lq?UBTx$9c@7Px#0Jp)-bvGgYb}8_8|r z?>Vn#aVzW$B}>5>7F03@kItEnm?!qh*R!C6A6?x^KxZZa_$RImPpVH+F*GvE2~vBq zBBH4tLjhgSilMj;eA`%y=!+VWbRAx3n#XyzX8$e{PIXV+_}8{~G9ive!{-w#B`*?1 zPR71Qqh*1L!_Ys;_g~TC^l$r8@?11YcOaDa1U>r0+Q5R44(1M~y)#H@?uuIiMH z{@~A2({Pp<&m*08A@9rePXFhq^=ya<4=1CoL2t}q(Cm7}RAw#5>vd%h^1TZ%}3 zlg^%fydy-coh=ef%&39C!q#vM4tot)u1-pQdWEFjjkVtRNOMh-^;tHyI&}(8I`d)&4ElOjnw zV9bP)-M3TrCtkfB-rQB^U*)ohmk$e_(W>{^0sbdQEBsu^I$NuKQ}OL;?Zoh6m}(8= zcD36!aaXlFD99q`P5jZ@C_U;bqUQG<_RjOKgnmD6(_KT5%O!)7^&x{`B10_30>1=; z;Jx6O!o5Fw!M&q#lk(0qPrv`N0?0yeC`CYPO9-5p`p_6dsZ;7p{tYXM^!dO996kOW zSb+c>RwZi$Y#*+TxqY8Zl1!9O&S|ajVwdW;2Gqu+b_XH5UYe_^sF+G1)Hxw29jh>$ z_Ai!YxhL3Nq-P`xS`)CUiz2rs`nxXr+mAzvmFK!?ze1GN)9o3(%1WCnvP1!;5vEnd zU!FaFimrlyGYjWJ%-RzkT1= z4Y6gwH08#F2Bx%^?qaQ{21+$pTmb6;nVMmsCGK!2FTRQ)g`>nxhZZlEy`H>xq6>)l z&V=AjaR~@vO2AUVCJZAoSrh&J=G=!}ZWO`E<@?RS{l`c6*l4;BP(Gy@|9pKv9sBsA zeEbrj{7G=P81Modkmq7MD*9L-+1&6At*AB)e@IW~nu$?`(hdSHNL zhw9^0%jl!?dcP;d;Jjmr8w<)IFMIT!;rE6d|#hnFL zI)uaLnf>|e%Ffqv#oG!*U(Hacmq|?gI6-3i^z5D(@n^l_J0wr|(?iL27=q`e7ND%S`Rm~wlJBi^* z^}{POHRcu@2ha;sA==Y+p@#hj2{JLhXot0{#a)w;m_!|+yS?eRtK_NKkorLL#gt+% z8f|ZPmg=^?nUx9gZf7uK49D3$iTE* zPUP~4pJMK1jom#i2^Q0-R0*0?Kg@IAAO9EM)t`IgdG1a4aNt3Mf<4!n+4qlGEB7=l zDibB0Mdwa!n6gWDGDZI4o|YUu*)8=+oP_VCQ3FF-J9v~dayIwDYEJxOk{+6><@{6- zG5_BWK8^_5}FkKQ@&WlDf4Oyv__r+3oSt@gRDQ^HOr-we@0Pr4_}0oA4j)G@?^b*Nrul-M*#rn!wJo{kS@ zxdsk98afB$@CltrBm`iDs>6d8ls^r1hvY#A&c=iz=r=vat@juA%@F||cc*VN!EY@C2d+c2xx5W*Gj@eckV-!KXX$)=V_{FYwqWRd#&G7gDzey@tP&3Ge zpbt5;xzUcGo-)LnZ^3@bYm6WmJ!ltADUyqAv|UqonVzDj4bDSU!5EWk)CBX3I~z)l zCz}*+-D68^b?wdipHe!|X*&jlrp1GiX<)by>drEgTnF@Q`_YZzn2yM6TW8{Yx3^X| zquiY_;H?sounfu0ww;XIK-MZo;*G#Sa&#s~aLyw@+(6#c+&J+yjjZwzPfL>E8?D0H z)=-6g%5&DxdBI!!&KA+J{TotK@Q5OcnNI>>|%jV4kdk6L6k5 z==vcTt!a!R-1VYL%YE)wC(D&l?#}JR+Lhlm@(O^V=N)e#xkQ~9h;mK z4(g=Sa4n%>9m6dN30Beb5G}QnRTiVYUh3gDjO^I1M};ttMsm36e7FJN`u{sR5ACX( z$jvkG{I8=YY<>lM$Bp*ueOHQ=HUjowGE?}~Gq?uua^RqP-e;QZI7*hrib3WS$P08v z0puGBjBfEiiva!8&}bRYCv?mr&lJvJ?Q18?w%W56VX8p<7*HF%+X}XaTRWbl>t-AUJSvecfEuo^eHm1;40 zVGUypdu~hRGuM{iB5tw()S$`yBB{n@T?J}@pW=aH^*+q|u5DFfZ{^|K^PLpVcL9w@ z1MVkzn$a{iZ(ac3`F13jmT<4!st1lOqqP5}5cbjsOYePz(A)iXhthq8PuW;jdd#;C zb5zdF3YqAMnRpjWFnzKEmuHsH*6O8Cpw$0hb?x=lfDV&x&zpqjt+{*A5f7a9_sK>} ziv78IuCV{b2S#*Ra+IbRBcx&AnZI3(TC~D3$WJ^Be%bv&8N4#_ALW)+zkjC_*>%z( zmQUrWv+X#(yu5Yh5VhIrL;Llxi`7cjVc6o@J@ZoPR-cZSoDHGB`3{71+=@!7qfGnisZEuJ0R^vA z-HY;H652;b`U&h_w^g>|>os?8d|am)tyHD4M%@eZQ51P`r|)F-snDdR_4IfvrACGv z-L5(0WT$^DldDQYjin?YdBmNd!Rlw}Pr+}PPC|w7lyanrAmLs850zgho6-QSnBUSU z_1~?Hwq3d^PBf9ToTpg&IupQ^T;Ew&Huf+qev^KXd`RQGOsq;an5+zbM(dhX$im_P zn2D}4$*}~zT~!@G%+$coh}qpMH6iI|JaU^vaflk%#*lzGKJdpcLsbbqHQNbe_t+05 zd5beDWa&#mhs8QC=71(eb9cz|990Z#GN$8VQFA*ztM*r$A~~3c?|YF6KB$@ACAt6O z2N9IQckAjEfcwdG)bZ8w>jpxWOq%%1BC@g~%6`{O8tI1TQ77_&95BHVq%p_o*x_&_ zc0hAF=8@joEQp|7{?ZvBtOi&jjMny?w7oL@m=7z(H?K+WM|QI-ej6EEaPCwFhHE_I zktTgccAbCzVSKrGXDAO{3nRNRzl~6^=xy=G`1n6rJ}Y>YNxzb*+n6xtDt;pUq0u<1 z`=O$9vIYs!zg(Vlbs1>SjR#J8{ z;M7h4*LKe>ZHf^Ho1(o(+LOAU1DLQzrzWPJ)Wxmb7?Hg&lH>98R}c8k%37PO&VDIp z3!US|&%kNbR%LzpDKL|FkNnX^>^60P1M}XaN;X$>D#}CrnGjUzyqGJqKq>nETX&dA zCg4Dv@RvpT$KSTvM-IWC_N2-%tb&>D2nIQd!SYpt-*t|aFWkby(=#l~N)O+cVJM#h zx>WG|`U)y_nP_R!t#Wxu5o?+UJ~PkJgI{%Y!*@-G6cKgTH0Df-BU#sx%DJcl*kjEv zd-Nr|(6paXKXbtF0+~a-ISXstAUs6@A}WMIC3N;4eHcoQyK8WPH^U0YlHF6~eL(G^MYo|AlR_?}H81gPHZe|l4?yJ9$ zm<0$ZE|oC$B0F~OY>l+(j^*9m%skz!lURr1B=)z)!sT3gy2SEulHFEM;r$OwrgfI( z=p`aFgqZ3?5ujV)HL>Dz7f&4N;Vbw3X9;tB%7%_4OT9G~LzAcThY%vN3i13u&l%X7 zNv3gl5<{Pv&aRu5_g7fxHA2))eXmJA9%CIbu<%SAJzTEj$dZ;VeoMfxKH1X))IKig z9l=N!IlE@Bpvx&U{F+a|RIP@VH71k)b0ALuV4Cs+{&K6k5r=74>9d-Ty8@(LB0~4K zozAt+2y)$D`!@$UYxak1x8x-!Y??nB)F|7SsCR~zVgcLPHm0y7c3w|YAPYdD2%MV!|?&`kWA z3gwWKwyx(a_N<=Nx5%ddfEi#k@G=GXhyW;U@6r3YsDQH5_vz7eXa-1goz=k`F4Z0= z7Q8xr{~riQ_#X(!YPxhql^8sN-OnG{EKY_Z22Sd$-xHS#e* zC|7p+JH45@qi@q|0E}yF2Y)MG!fp(0#)xd%;{hnO4N}##+L{_?dZ$-|hs_S9<+raJ zTZ{g1V*;ewtfW}sEYB=^5f2U*Dd=3Dr+>0-*!pG}vYCqK5;wil$^-fl_JjO|ggYLm z`~~*EOXl%XIFn&;kV}!now!NpU}zL`$%RC zx!bI|gi@sM6;I~BoRtu=pwu|N1_SZsI}H6MzBrQ7%PlZ}6$jK6yo3%=8ATibk!#2kN`_HAJG+rL*FVNs9un)Bfrz=d?M0u~>tK=yD>@5pb zFK$hHYa;6{3SOW`Tfz7!l&n${CP8sXbm#E&9xs zdH_#+F+#UxQ$WXx!sEb0p8>BrVKu?lI}2;MLk^jl^mIpHMZ;cL=fH6BkHXw~%i#j- zydMR(4BWE4p(kZ~!$oS^1ejenWwJJd9h?PO6}z21 zhx@`xo}YBGY3tuK$|-Wx=8De1*dYjM>6=yhwQMeRevr$z4BD#Gp8$JYn4{CmC-x7y z|7c#75yt#nY#CLYxv7@q?X#D&$*bTxwDY0Ry^e2+i`HR#-LEnv(l5Qq=UE6NTL3rC z#Cg_{>CV*uPXEn|9(iax%jD-x)IdFP+WSO;?5X%J{La=08f@F;)c(vOIwS0@4y4$J zExFf%<-+dq+EYdyJ4b1TT9@3o%!E}{8_X5s(h0fhfEUer#g`A@kD{78D{E)?wmy&3 z5t|vL$bH>b|M^U1Hno=H_LFG6M^?Uq1^!;Z1#ZMsZCI`FY)|Up;gytOzsQSO7$!4k zv9DGM;BWx}kQ?%0m#A0JZQp(8rO|G5X;yAygE|ERqtPTY(G6Lh&@m&n+ zs|w9+X|szhEyZue#w~6Y5HYc*FTPtA-8>4x5yqD_=pDv6G zC#hI&KVjL{Z1bCi3w8=kIW=ksd|zEz`L$v`S-bc>qv7`@>|4y6(FL7e3yPtSWbPh2Mfvh?JjYvpRs!kB)HcqwkGhb{ zkqOrX(O1zr2a#3_=k&$%0u90yyI3OwJ3KzH`vE`L9b8d+q#VFNV)ejGzhOo9^Rm&^ zEcFdgSfsK0xC{Fl0W5-2t5YQFNVA_=>3+kqlUL^i!1meDTK`D(>z7?}?J>KK#d-7< zsueRwFc5Q-KEOF<&I6LGUqLe#XB5TD{b>Um&0T(T+(<#FQE?e`?q97{HN>N;PoM2- z!Ut-MdEuW3`GE^gnWfsL_`Dd7TIF<3TY_yy$vnM@;b!Jsg_551AI+A2M9x`WF%6_^ zr9rlTwY*NlCBLGRhZ1ofDg}L$2{ffLSa(gimajZXi?vONjZ_#lr#+vPoOIZ)lN^^M$GWxsvk1CoP95b$|`#AMN zFC)l~RR+i5i;3L{_VJN3kN}~L>2_X&V39!E_YDrH9JOo-a(Bbih4yn?%t@T{78#B! z>H|6;IgX355){_LWv-PjXn~v%L?rfbdnVej}TR{yF*0wyoi z#IyTA>|WQjX6lHlAB=YLFj`5u`tr*EoDtW=sGN)8^GOx$dD7mEZSxat*5-l*Y+;+( zN1}1L|NBki*2`;HAvfpg5%;oES4; zIy8c-J%{N&GIG*l0&RZ2K>>!Ukw!stAvxQt)CQBmAn5Vqq(P8ye*^mI_%r})%p&F6 ztDg3(e!tK2!?q4prICgpbYa-t!TH;RE(^<4BhOC)p;;6i7z=tK!^rjvjH3UT;5FX9 znrzyh-3(yCP=2IHh4>((5wE~VEbV!x;OrOV7HbVErK%pzj?QvQA{kTO`sZI9yQQtB z77FE4g1ZrbqG0SvMmn%AiTPws)yuaM;pX}-ngToiRJ%j9=nEX7bml~uLp4(|LUn~q zd=XVOozFwBRST(cZ=y>~+A!<9~le6^4)=;&1?w&P1DaF>o zJcQo{W=4a6hpNNf3oJcS#O&94&GEeyn1Rla&=DteSvpxXYL4(`OS6}%~Iu>yEi z9wAkc zod#gEz3_DI1)_q2z2T&o@=A01Ebz)te02Yv&}>EQoO29e=;KkRIedAm331{gjz94oYp=AIa2 zf*TR8(iT)!cwF9C)vlyHSAH>%7_6dfWVyd5mV!OwEK+tZJiCD}{adoOTFQQchZk+N zQK#dUF5|TPxDx4v-b}NsUWiZ<552%P7yp|4&C2tRUDpPu_MfD(_;cb@6=g0kQIDbxf({IJ09oL^|g6*_wU6$u58eItc18 zD=`)x1VnX>+)5e{G|gJ5p7D8I|GC9N^=oe)L%n_!)&~aP00s{N1~>1@n(U=uaMCNI zJM-ae`E&&MqWn-gnSF*yw(fR;v94pU&ju!`m4>ww%$MjSe_EBBsc-r6*#TpPK^-c9 zvBD_E^+)b@b;)Pt>9zYmYw{)Ap$w&Ggk49Ru>Wmd%eid1g^Wl(YIkHh5y~yoqvOd3 zVNttxq2%y%p{O?U*6zbR=imAH+toIpJzi{&{H<*F&RjyjpII8%acs_#Xgr4qn@&BL z>S=(W^&Sf!E9^SRnSJ$|ilX-Tn{O<9_ml57x?@+RbT~(WyqpZrmr{#L+h}{<%XmAx zJM5SICV^w-SS6+u`dI{b^p{+VC|2BE!nO)Q{@9LRA378gQR;DDYKGm$2k;%AYsdZ7 z`+Qv5^70ZP*%0t;Uc+#7Pl1{0iq0obgIBJ#(GZdt@lbzqsC(jAmudy1axKE8z+brr z=ZS#74&0o3(-2Y8Da70e0Mr9D63A8;1G2LO+d4XbE}{Z}E+%cEQ2YYWx6>Db6#(dL zS!NusU*{pYwfzH#!+LJL^G8Uq0w5n^t}cHA3ycA`hg!vgcViETT4;sco^$n`MPDw&xt;3^vxb*V0fXzUEM!H zzX^zn(S~lsOW5R^v^)J!6bR3QB{5{-$;7&>+2{X?$*k!G!jcYzn5u#C^RF7Z0e&+d z%PMropOlF(XF+Jts1DPY{0Sk>&`FUK@MHz1qa6a1GYgEZT$#jSly{B*;h*{W@(m-m z(L8uij#xMD9TtP~f(S0j;Vsb!4gVv<2ME_J4ZqI#@SjsDvRU*QZvOpm^~C@vCe{vs zV#O#0!)AOnBZ9k{s{i#lx6`3{h@dQ2#HFv45eR<>%V zTRF$$qX)T~^Yrv}!QH`?JonA_vuiK27^;a|YukMesR$jz=dQ6-CeNK^q!TJH_~N12 z`DTm<>1C;mlATQTa?i{&9cKINOjqtbbPmv3yJ|h_68`-u0a#eF1i2&w_u_gY1OKa+ z{+;*L;sD{&Um*Vw?8&7T?GIZAf{P?^dbe{wIyzhetvmj&Roswk;@6ii)Ujbc}S}J#tTisbl-cJ;s*DuF$Hmg`Hlgpr(=HGXku7`S-51rwW zz+KK(5srarK-sb&_6vJUc}C{5m;X*9zKF&Q>8AS}So0f0ees3VFj~a({{=Yh4pFyA zq|C|j;HRCeu+VCls=NCpYXEs*QxFGjAP;PkY`kjt?wbaAQxL73Y9b1mN29sLul2H~ z9yC06gr0PUmIs5fetJX zf&kpDW@QC20`SBOq@$@{C}dOlNeofDX$vn_ZIz@#TVPf|J}vhm&k@Y8xt!tbx~|0B zY>qU~S3?uVH^n|85fo7(+JpFq7UycNMEBLaDu)W&XLIU>oXeRp)~QOb%JKCl^;V%L z=+iBO>DJ?!XBG0HHu0V6KG(z$Ryxq-Z9kNhHV2v|;{MKV0WqlN@;%jyP_)38=68ooKX2ruglLqPGtW|MtxM6xJlY z&yWDrjD|236)t)~1DlUGynuY!shb#|ZuQp$WKekgn@YNf_8s!(1`dq+(%JSBW%H2Z zBSvSte`+!R>&~7VE+pu=KowMhI+sc8ufX86C{xL)fM~rc(C+~nGbj7KSN^(uf%wnW z(>nNuxAB+0$#p5))jAJHRawxugQeh)ZQb5*(jv#Aj33_y7d0!X1yOf+);mU6)2y+4 z6T!HJGX2}Vw0o4@OM4Pk(9E;q;v{4*VVzf|vJ7vpoJ>HXj^{`W;<*8sRn@Qo&Sx*=uIS2^6~lLZJB|hw`1T9ZFDU4U{vNtd zq>R_(>aS}_X4`wac(%6YZ`~E&|>FUm}6BL^Pu*`TfnE+f=Z(73=;P$ zS71_nJ?l7#Q@QfN3;illM}PIZLZ`S-$OW>BGt4lWB#pzIV3*&eToG&fYPfp77=gaB za;0>{lctaE{itvWN@~n}8g&F|6KC~yWj5bef%xDP`7c}90=W52Uj=X@3v!$4$#4Zi ziTVzXlgpe2%zG<(&mM!m3+CB(#@&^XC2)leDaTkx4j}ch~ zPYe_@kbZAakYDcd@eGOnPy?7cc(toKJOdtS5OTzJ5Eq5OzrTR^(Q$L3*YuaDqr-Ub zI3=>{2RGWIG*04QQWfoo>>k&zy62&mFLYOV7si=`^&#cch|TS9)##9rUBBa*iB>4` zqMlK=ub7t}_P_L$5ms@zbiv?>cI1_z=4Ep>-4p%jdM5@<=(aTGA}@-xqscljl(Zvc z4j4+(^+P4?kuNv#FN+FdrjCQMzi*dS1z*gKGso&X)K614w~GMdNIs7vU7>iDZUfNb zU5*rin1c7|#RNwC$36aeD+)MG7{_VSql=)d%lc$@8Mx$$ZTb=ymN6!)m>k@1&0lkX zSqy2e_r(R;)Qldirj5nsa>pOHze`#(vd%iL^U_@i! z%KUUP2`xNSIz(B9>E4e${^V_oFsYR>Z4K@Op63zIyXof(W0`$1um`uo{3c7A34f&= zlCjwIdr{E}YVPk#_s(<4JBLsL86)&?H}0;;UgM)En{0Z8gQphptE&*!alOB0^~W-I zb<_7D{`bPv^QB|Dsbx}3R$DN<1IZxGAZSX>WJr}$mAZizk4Bsu7h1p{zC;FvP8yBaCxefVL6qWr0~43Xebg-J69 zab4c-)0eJg#s~~h&wB$EyLc<=hJgv2ZNqu(M1FJBhWAxg)wiv{IRfwx@iXEcIK;qyx%;VGZ_!Rk0g9U7~ci zEt3_7d-rbhAfJaVDPWy9?aZQ{AJ(z$`n!DZyg7UoACMad*-Q_`G6Wuy1B_S2h!XYx zu9b2cltZXhL1TjkhC9v0j9L2~8PSImySD5f@tr2>!u@2X3mTufc)m9tO3zcrV1jpv zHt$c|i4}ff+mlRt@Oov1X!_kFuh8`NuKK&_(izQsDBDDOB<})+Nu829KoB5}f5r~A zcH)t-<~=RIQJ)H-l9{IA7ZY%^N|(yiT5n2X-TEj}5*9n%$&CrNb^FyVRGtbE=ETHG7zoTx0`X@hk9G;r8U(#)^U62P6g)`ms#@J*EsrH3dPVUZ&edc!s5RP z4o;@1W<%D3U{E$Pj{2cD9$jzWz991;L2Rt8pxVqsU2CjBt~=?PbPMI(mF4Q>vA71N9ZySdqK-gY%5`5pWkDvV9VcJ0#@%ag zpF)sm?GW5{l{hvcTsBf?FxQR)zvu5se^&IcFt_~yU&}bfE#qh3V`E**WM!cddB(Nv zheE=2bEVLcdL<1Qt6dEWdDEhHtBhD@FdacSG5^C_$8bCgsLk0Idz`pZk45H47CAF4%W%n@|$a*0ITl1SG!Z$7GvLtJLmFnkxv6kqz! zO-f7VkQ{>?|AXwWY!|HO=?pHWYoT`{ z)Y88Vwa0%KI{%w8vQIU5ewi{dL+DkVJMvPtQw)Z5#+Uk@RZiQjsn9&wF!!)Njy1!p zN?^-fT)yJ!Q#G!dd)e7>U&vbG`VjJ~q_h$4JBn!&nA&8qt0x8xZT9g@?QtAG9%e)BuC6>pQfY~KNM){vF>Xae z$U}-~+Ksk0*`i&W<{?7Y+LV#FuDFt}hbxrG^{~>o(vp;?qIuq=(ON3^RIk^4rI+)2 zeb0Hl&N=VT=llEoet(|h=blLBP3$bJY0^&*=;UCyHe%idJsTr%|1cMnaY^f}5c4j= zsy>l?Ax(6D{;Ff=`rI>}nRs;7CvqMSNzJz2qJ+zE_pLYom&f?Qs?sVaeU_~UK`gp- zxP0i-A_+yndrSH%c4%kw$k~{|Q`^=uvnyn!@eZ1$>Wl5fCW(9I@s2;5)O58JN%b3? zSc&Y_@pr2({n)3>e3}DA%7k8SF&**>x_dLEnLGt=tu-+p;k_> zWejStNmG%NsvXip5W>D&GFc13NS&fzq`OtQ3Kf-dOjd9AQ-}Rp9@!-kn3%#6_Nun> zb{xt}i1ml3#GM^lllD;`A95m=e@_poLL2p$$oQ=814bDCFS<&8N!j*dVSGNpgzJ2fG|#HaCI#3F z`)@Sq{za+y89n?_tszc?U1#&Atvb!usr-#;O=(49$mQv2FDR+&&t$&EXKg z&HKp9-}(4cMZ+kEX~FOm`teL-_{_mY0GC{STT@q%MeE8Y(uV@ub>!#N-2K|*TMM1V z=O1UlPo=LC#@+hhBm4ut`4W7-EU9pWk@1&c<4~#>Ptsa$)p?lFp84R;p_6%B|1#UL ztcz|w@9Y~`{ys#st9Jp$vf`q_7~>tMf;oWFtQfC_Lzx7-cOA^&?5&C!CWm)G=s1cQU3MJ28D?DPBGyF0l?R$3P^E2Z2TTZaWZ% zeKxIt9^^dDF~n}OPzv3dkIcFS$#98Rd|Ls5@SB12e2)!AJ(7^= zSNM3RG59Dm+M-yp!T260rFOa)p;5iKZ=WY(=EmK8gTuQoyXaZ;p_Yyk+bc~@Sx=l74V7+&ZW>VQjQlW=Rj zuT8?uCq>;lt)ge`)squ$4c_&b6<5(|EfFt9unn$?cj8*KZLz62`!sfC(!$f38d4qh7)Cej zP5Vn^qhl>F?Q6_Qw`T4+y}80?ZCK6rm788(?dnIbq)w7cI5YQD_8+ALI(}BhaoR^y`Z}eRO9i#4qo@=gqTE=*?;_Y)00&jYwb%Z?zMeR;5in<$O7?@nN zW#K-`#KeDmD)_N;wz^J<`LHd(_wgiu@ta0mf&Sz5T{Az)UYFw zgroauk>TWH)a4YQ0zT|0bwm1Okl;h5=r- WeeDLK^7&;|a5#V+^bCP>0R987;TE$1 literal 0 HcmV?d00001 diff --git a/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-56 study Document Inventory Report - Study Level.xlsx b/VTMFDownloadFiles/WhatToDownload/Zpracovano/2026-06-18_05-26-56 study Document Inventory Report - Study Level.xlsx new file mode 100644 index 0000000000000000000000000000000000000000..3e4f25a69bc6d2ca6a5d9769c8c7c636ec2b230c GIT binary patch literal 300645 zcmaI7V{~P~)-D{|JGO1x>DcV<*tTtUY}@JBwvCS6vF+sUKIa?XegE8dkFhq!UZdum z&wOg4s+N*0I0QNf3=9m&54?G8kpJ-l0Kfkfv$J(Jv31r{^RPE@(qVMBv2IeGuQpX4oBO1XhzX#X$O4NF$sL8*6(t+kqQi*_bxHU30Gu3=FZgyz?Atnm& z9vJo>q`js!-|qIz(E0syKi zXYCA6Dou}!WMJT^lc;hWd(Yq-GbRRFmWft477w9I6idM33b?Tu&m(Jq?@Wa5!W9Z0 zoi9pt8kyZi1WghMxZ@P;?07c&XVROd)Wi%*%JLl((!eLv8>l!7{k|9yi}%$Dmy#?r zOguexCm$#X2mu5Lh|>QPdw3xBdX6U6PE3sd-hU_b$$+zd^Or5=FM6}r%=rh&xc~?PIA3L^;QLjg6(6vF z=-9Ht$Q}S~mjV0V&_My-VQgol_yXb2>;$#jz*W_{1tPkAxN}*O3v4%Dh7uN z;F~PKr*3gHh%xiG#=56mHYur>Bk>rZD8cDx=ZQ+y*CUMBon@EojgJ3@U-=9v^ZONB z(+m*{dQ(z0&aibG{rw5f7wHxJpEL5EB~)DTI2ROEIFfuCVM<23h&_B+wHBEJ{Q6BvqO08j~NF5$wOGWz&|80I@y~_ z@nGq}Kysawu7bQW!P{w6Mnmnqz`J~R`JMiq7jId2Sk#mJ?JYC?XRg(=s?!_nKMg;G?Yv%M1M}c1=Nd3epAXnXi=bMb4%)?2K z`g`#ApuyE4Mf6FK`*#O_9as}_j_fuT!y|t&4AC8kak2Aw56f2@!SjJGyd71rVm!X;AoZ)oiP*5^lBDqqS zikpDGme4m-d2%cxYbGBu1RGwewt329$>eAL(Yv)?PTTC0RS$@oEq&Cp)$6Npki6)SqAz|I(# z0&wN{O=Gs1HC8s5&naEK#O7m_&V@T?W6NGd2alrTkQXW^(1d+r&)cl*m|EbT?mJGf z{r%kiM7$E@TDKg?1vxc3?RhuoSb)4W4KaWI$<#8LwA;_kT-xR=wa#*J_EnxO#}jn= zQo#86pXdiYPR{=TWcdc<|HgFW|MJDn&e6)y&d%x|$)n>Z6b6`4B%ZuOa7<*glfsB) zR7lj5+d+#ko0r&g*fl=Ft)FgQxETUmN5;D|_{=U>hW?getS8>hXQ0(9!~K%831QDf z6HIOBFiTV88tQAmSX*O=a^06T7dv*G_SsDMCR9(5u4PfRfL-8>cgZJ7?JbMmxVO*l zvxi$8z((TsWw25b&mnKqwP4(jvnOQ`Zs0@5hrDE0k30eaHLg1!hK8$_0a2-|c2&84qD&b(vi`93sK2Wc> zk`4p<&S3i#@84XkAZ*(w0%H63e~luz|HbydsrP>({NFSjFK;!#j3E3KIp^ar--lgj z%VacbCFJX0o6OB#7hT*m(Nohg@JAS$@1FeEwHI=uwqJA*ukxWF6u7*4P=S8onV8v5 z?U%bJi4_gai8oiaL2z3Jp&K-&Q%smU*b8Lo0vE|0i!MOgXJFs&$~XHHd^bR-rhdww0P8yDAniEK*F(dI{7JL>1&Lm zi?wvGoN|7)s5OdD0Afv@O}}k%`+Y!elSi5tfTA7RJ`N|3uYo(uLa-2l82fd6z4v@N zv_y6vu5UUvd`?`A(tqkC)zoltO*~xa`9AHx?Snsbd_63Goy`c@HS4+N-gy(9e4cFr z|MTeS`KrNUa$U~7>#*ip-#D_`ytQcPns|K8U0=uQc(cjbO#0?liNzi>6xCtf_PMF| z<=xOZu{?zQtNEq0=lwG7{c=d}OWXCmcG7RF>5~vc=xN{duK0OmY)a3!)UV6u@rG6J zVEIk^%d5v{6#fh=^u^(&Qro&P^Ii3^cCBaq{aviP^P_WFbL_#yvhZxmQuEW#xrLtb z(``=YG4{4ch{^6T_v^NUoN;*n)u3g2<3r77@x51)?#ItLNjg${I*p$!OqE5=GM!cK zHbY%i;x-hWRmL_HT~%r}#hq32YqSsbqz+D*`;vSa+$#bKv86A{3gna3>BPaWs~oDq z&r_)La%g*8vQljF;S2m8%03?BHEYVvGwfu|nYo2FHxF}uJ&d0vJu7q7?}8^xn~q&S zs_!N~G{E)C8J_$E*0hDpQO*lnR&_p)u)HoB&D|Y7mdD?VH{U;6yhbf;TiU&!Tf-1z z&qMFjo7WkH7-|~2D6#av;M&%_-MVzPp0J5Jkd_8EN4(*=-EG{iPl?{VJEk?}4q7$^ zd(QA~iOzMW>o)~|91ra-u=Ygg`hxRktq6FRX=IpJFNgZ%#;PI{4e8y#2QeN-Z%*xg ze7N4JBaeAIx%G@cdF1A@jd(2>b=$M|Y?!@;5$x>z-s~H4b;`bS^=Y}se-S(?Y_aqG%Kf^lUHvLw!8*Sm-Z}fcTsXJN z@tf+#th_q+bb8t|c-a%OO z>swWs>6j`#zI`{unj&gmcWfnU_Dn?U+GcE60+lWp2wM*yPLk;Ps%T;HEA#%?onaFE zc$m@q!W}-!)$_KwE5}9tGg8_w-8lMZ)kb$iKU|%WaC%}heXCV?vYt=42DLwJvv_#N zwJqZI<;7r^lhzkvup#1bJnSiIA3VV^{aTB^=U^ryXS;3r(JHvtyhZC+!>4CIETe2p#a)~vJ+WyBXRk2T9)Stu*fPz_MvFL5mZIVFGI9DO$HO?| z{$%(nkCnf=Gi>lp-BaiQ7ca>|vg{(Cu zGS7eBGxq$fw!5{tw`hny%uPL`FDNGz=~AT~M(Mv2ZzwgSNB!lHA^Q9~llQp^86jA& zW9WPL^6^vwvgbnDZ$ZI$T>>~N z5FPj^#*kg#$-LT+mKJ5~w#%uYPXz%7_qLf_wzhZZLE{=8-D~y(&&(XPHH?;8qp4Spc7nPDxt#+1LDW2R z?3PMp$Ym;hN%Wb#NsX~6;?f-wqeN1nMD~u*4~gT06ML^=VRh)jcN=cu!+QyH_p3q&_xmP& zc5ZBmW4%&?3Vq91pJIS%#PcMcy*yree^CF3t9v$a-FBT55ns*-IGDAqXsAvKh3PE|dchC@$ z-%*1Txqs*m6wJFgLJXVy1Sxp+cNNm#L`K_54^dO2O{tA~={S9w1;6nN9W z*{-1jP^hHCU`wv z#N1!mbCzE)gt6#nM*eBk$gPJ@e=i_Jox8&S5oP}N1mD#;-k^EFWb;$?U?GEcASe3) zqXf>~XulgR!I0t|(@>s6z~zq`kF9)D=FdNB9r+^}mTrqbRIyUA);50-#Sz}G?v1#h z_PX5F&im;ZPdo_fnVp^Sw=c+Ai{J0P{)y7?;Ek&E;m#XcvYqQ` zUAu@IQU{B&N*GPwVzQT4E>=52oyUWv&j^ulbAWtPF5K?_JX^=q>^Qg{TDo+r7~;5} ze~GF}`g(=mZ*`e%zAi5fQ4I0HFEH#v#A~`%ChXeuMy$I|&*6p7#cjD>onnB`-JCVr zZQ!%S>@wux3!mm}nb`F8=!%-YdSKFcr5Cxc{T*A-!^ z&@``{F)V;Qe_Aq4YEFb}j@tP1o+;3k&lpv$my}wIe_^o@c0teYqqG5zR^NqAuDz0Y zB^J#Hqw(vrSsf+aH%L>YW4l}-DG{I8MMzgcC|_nCE(9oDRSCf ze?@5<`rn&rMDD;6PlcPL;xNgmh?%03h54*d0TZR@Bh2r(}n6W28L(wD^eanKKeDO+>F`e8nn^!w5sdTD(sJL zhs4*KRg2i4Ep%RgG!8%=oxS=cU%zb zTIj9Ai$}&o-90@wJYACfbaapAI=sJXb+ASzh?okW+7A{=_lQ!TBsw)7zTMH1HsbIo z5p&KJm1}SehkQOtnfFy@^1>6clIQ)Iv~_IV^4qFS9MyuWyQ!@T2|u|WLUG`?z8Q!~{}NPJ zu&;PW#3#-4>-OoP9-eQ1Z&n{8=a&8s7NYz~o2tj^_|mk#o}$-LJacRH^tbyR6W{uG zSC{OSIN;F2$AsqMr>Bdm+es5LbnE?^Jb$Wg2b=W?g^z5_aN@b(%Wp5fs&*ww`z49c z{^rv)dC97F*O36iuTL+W&nH&?2iA>oO5s46L7ch7*nUvS>8Mg`!m-G@iQ3)r4g|7s zKWCg~pl}1Aa8~Q5ML6E}73-&B@n@R;#L*7vwDrO#g!?o@%n?54tU%Ls@?a(Bg=?<3IwM z+G8X|3jeeiEoT8$_-pYX?HZj_p&YqdIK627;0e%82j)up2gpQBpks?(}IUyJuO2GVpS zP_UWH#OnO=i4KZYCWTn|KE|BlZdwO`G#(zni@*e=oTN);|8wA&ln` zB((KX90g3pTEZ$Ae&e{#TWYgCt)BjjU_t@R09X^cAime-^JC*uuu<%()gbv##tFYL zzyXYgp!jH2LxQ5iY=)XMW3=inV*DbEZhMgXz62o(!*(><0ch+-kWp=WS%ESdM+eL{ zqM?#ZRiUMq{gyKY{!CRtPT9mMg7B4_s&%y~;7T>sLKu~&oStn{4NQtNxnu&|n&eA` zOC7xm?24!AYUG|c^1YDFmZyxhpXKsE%^)#llMMCr0}!Z0{UXdV=97ojomJ0JiCv^E z4C!l?ViMJG>c-)%`K{s4pT->nxj#c<275hUzb43Tn7Vp#kGAzb9G1=EZHqTaL;xj8 z*Xn8?mGtwE!GzDG0^CPPh9?bD>jK}gPRuN*3TmEZ1m=uAe#Ah66R9oBZzit^bs-t< zwW*N7#>FM$j<%})UMzsAkdG|pJz-oDW+ZSg4^6oAmwmXd;tM|sFJ8NR-j;pnNj=>@ zSJ{+7km#rUkXFf;g#A%r!eWC{nftKrEXdwIdG*G&5PP$zQ*jYtp}<&R?W1}i_NTGC z=W2{yQ1X2xF707WsC3JWXh*vA*x3b2#S)IVH^xn^pXU$0FUeo*qZb<9*hQOM`# zy6`U*m9x!Pl2*e;URh?e%QpK}P+Q->ZZoVSVo}*C6b$Wpby@mPuq83b031r@`T!}k z31ye32*m-ka=(^vPNh^-C!@3jU0gnOaSBmJ5^}ZwSeYmOZu_D3oy(`;L*9Tc3I#S3`z?r`IwtTmlh@J z{Q^k_2Lp{eb}hQsPnsBC4en|uu2`Q}ASiIrXflf}DyY-U!-a8z;Q&Ds`jRHJ0`X_H zjxSymc%s0iLAEMhz>>!e7S>%6l*=3VE4`DT$De(cgBtNMfzw3SE=!HjU z3x6eT(9V=|;+i*LDMGBHk$*&VU5d>X7QMtT(gL@7ydbsFyXDm!`3e%QorhygX z7n@8jAszplKkkv`nQ3wIO9X_%PGV7c(xkQtFB{^z4vOW>7yFuyTSK66fa7XaYiq5Y z#yMdp7oC)8&gYa&mnM&Qs{r?M>F}SJklE8VrnFeYiZ(SnS;MYjR%VC_+tW*}_XZIX z%A6UWi|H&^7X1=xQ8N}rKziVVKTH}J9ItL5K|nCZO4&*?%QoFl^u3kl*`;GQtrtQe z{a)xrE1E3J1G0n56Fo;7@}AMP6`3yaK*|*Zas@QnvE!!r`eW{|m6|!6i|P(eQj0Y0 zKi{yh9-HPa`@C$#RgSQ&_DQ$xq8cMEjQE)_CG1JE%=Z=@@qLcO5$IehN-jl@b2DIB zZnR;5s$q%}+a!h;rxn9SJh-;A5;6srwzYP3HpGTRB(>uTC27 zKXw8mUs5rs4!S`8*0Wc|bcyA8^l~q9>%Ce@!5{I0T67AkF)@PttEIB4Bd7lIHiE&Y zF*!FPRK7_ps>Ya9PibO)q~gc#E(rr;=hs@=6qE6t9U1vBCNM z1CqURq`UMp^*f_vC~n?~CyCJ+&Yr1euAzh{%TM0+iRy{9pPF_2vq7#(2)K=V@*H{< zslh6a(?-X~%j_;uI&Y<>qH?c98f2kS=LVTaXUDg%cbm6RRpk-^YH|_trTkqF@=1d2 zsPi;dZ=ql~DKdbXSomE)>{g+m;KUfFS7@sfJLxsx2MO(OCF37`ETTyZNi*R zNo2_1&K&IKU}zt*gSa}kA?zAmuO$S|hpT;KuU5({kDTjvkt_F84@U*oLsvaAPQ`e8 z1s&}q7MvBH9WKlU4b{ESKnEk9?!w%F=wh_CllbcDcC|Eq+(=NBNh z$Y4ezI9PrGuH>v|7Q0k@SGjm<`vm~)h6Dyxc>IL-BVz|=!5)a^w)|Dg+02$1yEC!0 z&zm7}|HEFIkoiA@C zNy-XDr4SKCf_gTuaD26HoHcN_-mdyhu1L!5>kWI?jHorYuq{EK_%AKAD>SMU&(@YR z8`63dX#a_Ll^L!AFfz8EK_qPS8D$I4S8-PXT#+x&AofbNsCG;WsMCA*DtpX!)|lre z%`rhpAOnzue4wm%r zuD@OfwA(wWFWmd5(Abxky}MH)mikV>W;>z8STFPM@=GSS7>Beehq`%2eEd8jH@Cun(YBQgW+}wE)C)v?mFN6*|E~9jE zo?Fm}XY(>#GvY`wxblXdn}jh?Exd#=q;qya)PWk5k@{9C34}Z~0Hz`{Qiqy30%U4A z>_FdfJAb`?zFN93r zF_++GQpmGI)v@lh=ExO%yROCA8wsx)y&MCmNWr=(y(3Zd$9HGwvWm=|1d(?s z>?4>p-&1!-WX%yyfH>}Rhk#LXL{2PV`O~QT4yl&`O5tu-)EVc0?4I5wm6Q7_uY)DSb0bP0IleUS|7ELwQ&6vT03bA5# z0h-dsJW05_K@WZgwJjZbMkguDHD_I*^$!0=)i!Ymw9Yn3qE1Jh5$_;^QV!8!C^<== zv!uOz!tG6e<=M8Sv6Fq^vXE>7l!8iAbV@4YI*m2j(QwcP98TT_e9)%!lbML|bWl#L z4?o`h^E3!UOV)fe5NT8GAaWr4?h+lJImm^byz`O2VGwhxwbZEZTlgWHvu5YehT;h#RJ>P0Kun=Emi5Tkb z#30%dvOn-BS-x zmsW&RTxVzRzCCY7;z@+FhWsL;itKY0ZY~v*t`zyp?k=jSv!83<&Z{3UW9m@#wlGWx zIe+@Ff?6Py;~3>z;3u+2Q^aiti{K7vWhh4O#`Nzzf^|UQ1*59M2jk@%N$cVdgtyLp zI4~757=|t}pO7JtD3#j)tfTn1Q!DnYbFpS=>eaOpkB}Ybig!j;&cnMXb|DQ{yU^oo z!c&f4fB2~xkM>w)F)Sl{bv?bu)!1>a3rWN;7A^quzNsjIFENfH;CN%3-6j4|&zXRw zju>%H%y(gZ$po`&>#!yBf-BC_KQJ1QJb90qsG)sE*{mPu|C^bm49XRvp3~rN=o^Re z@j0*c;M>KG@z7>?we5^T#VarbdXE6b|QY;4t^r^i%GgjdQ_8v)fWb{<5c^a&nn@ zHkX^kWdv`RcYJcpFwzFzeh2)ZegflQ;(GJ!<-kL`h`S+g4Vgf0szgctq29nhiy~mn44cXQb8KQu?Ve7 zGi)5NaSZ1L(9B6H!-o1U$?FimEvtT$qZe+*`)u_ZEgZOTd=f%_5nK@K>Yj7EJOuTP zfzwb?*iV--C#A#Ddh)>pm!&B+b!OOz2hZHtU1PFFkC(5`EIPxQ!bj(=^>1=Eq_@6M z6(yIBps3wRJv<+sZw>E?Zg7>QnqJdk&sy?|{1~{5ujSUF$^b(Y_%5n?Ok=*V2wCa( z@^f$yOrs;8NUN{Eg@&$I1}8DZw$Ggs4zn9lhP#h|q!vlj$DlCWe@TAwVI9m$R%|#> zCb+^5qd_R)qPPGXSz|x~t1A2!9`bAltR%b`pmo9cLx1xU*|!rKhVDE#+nkZ#AW4}S zEzkB8?N84S8bd>ps?FKhT7Tv$O6vqTh2o^m+8;vi>~hp#rE z&BY`}A{3%askC**BDHfY1jt%IqiX*d^*_YmgJiCO^37?RDPxbvPJ*=&)9J?pMZF2A>-K2$HjC@f+pji> z(=yUWAm;*GwHXeXd#oPn$%c(HKY^|}p>TD+4PXbKbJ@N_pjR_9HuT0H)IBR1UU#u4 zj83-Jgsd5sdsUx#d@&#-WH!5mugJk#>hUa;b+s{lu@|vgNgx*EZI4ZRKrq4<-}W8U%MXLHUl# zHAMN8Uio77p)=Z|sW&kdKek$4A`Y%fqcuOUT3DU~FDI>#KWw-p8TWiD9q5n8!+>kvM)J84kPDSB%Oxoz7=<>qyp>eN>R zS5|CFqD*Gi1-u7MDYAGn4B1}N0^*vn z_QlNTQ7wbvFSLhwb3%$K9cG1>0aE9w{p5w7ocK z%<|jJOZFDZRqC3EbCyMHDsX@LYIHo}P!n7nQDsP9BSl_E zBS9?c);}QxqJ+8v(HB`CH>RT(q2x=HzYP?CI*9;HS@GH4zG7<&+{$enwM%*JZ6E)G z!7zaxh*ftyav(_;4Sg&=ccYCa~4OiQUW%wc1tZSBAIPrd| z@P$}JLHxF-R-X=KGLEs}*S=c=n|HYPE3F-@mJGx6nT`{~rV)YaP1O8^^1<=X>JN{# z1T6}KGuj*R5*Ap`Z+_lRNf3gCcrhLPh#G}J#|^8B}QdLU*W_-gTsF)oxWCgGmcfRX! z2@(g;I@hgCa=^G2mE-J2PNCt6g)JZ48kc4Mnh1$wa8N^Q)EI`Ql1k&F3j0J512N+Vs=eyR3e5;3L7Q^JAaj=eAU^XRKncF^8VmF8>rlI z$eLOPCA-(hl*5jFMzVWJ!M_95%)gB3#Rx}&|GD#UGZccx8Lt1dp(N_?Cn`g&lalfw4Y-hj6k|d!lT}=&(ojaJxygT+OWOFHD_E$z&bmv%VoVq!tg!YIL?`*cTlcS~ad(QR zPysgYRkx|S)aTJyDGaP|l_>#?_+*J2^$GLG*Sn8==dAK0I=`UkQh_K9P#1{f#3=t| zF7+vc}&#I#k#CDijaBI2yqgH6l&Jvlu@!S-G#H8VQa10dhw zSxLjLhcmhftWb6QrqEseI_Fi5o*-rj(?CwkNzvUXA!PSNvuTSRJfYQ;Bjl!v%IqZ} zAtVq}6@kzxotHE^uI4n~%Sx}HNx}kDR?(k7pN-~D22S|~iPK{`v=KF!{_#m&+@Ce8 z(iSYy(;GPZedJ%3ynXRc?1n1(%mbFArmAP9)$KOFd%xCR`b4wO6;-xWRY`q=)C~Qd z(XRG@C1c>$`ehxvp+R2k42Cg9yVVS@k@}q_(v(7Jj$U-?Z>0dil)cY6uJt{>F6~5O zj&8$-%uEV54eU>0>UdIl=~1)XMV2{dkP#hEs7eJOV1-l#)Hn)?;%e&IXG~aEgH1k#%OwqsOsnl{Jhe0^=V?vz3GY8Za(k!^G+hGg3XI^q!lBD^|5JDnV z#ty%&xir5v|GX^dnIghbwe>`jn$Mcd*6Z?mKD|yNt4QvT-SP`~SUC)LxU&-Z>&(tk z4HHPQcSa>z=*IN*h(x-h_SEA^rogQjt~NVy+g>gve155oKdmQ%EiSoy#2%v%-#JSB zDVA~-NeX**#`NXCGYXoFb|gL(iN0Rv-<*VxLX=FY!`bett-o(*K*kHF(I#McQK$Hq zp%@vNZcNDn|BS+$yi2?=^6&nM$@A$vyz=hKNr*YN^}QpTOJVBfvZC6ptro+h9; zi5iN)J+p+d>z#tC|2-P;~|Suj6@ZFVyfiMr-Wz zzi^bjy9}U6$U3x=WTFvR8zI_fQ{BI+GJE)Ji+$-}2C~gfTCUK>31j?{FvLxDF4I5T5Q48h{IA`nx&DIgTV@61pe*M}{r?!+;_iH~69AplO2w)tEfw$JSK6a!j zSo9jd&urIlZYpBtuhJq>SD~CtX!?K^U?NJX%skfV9&gYgWVr2^5|PV1GO6xhprX`q=5R6Ng>Q%wm49;t-%6o~$vt zL(+JgP@rY8gqCq#YYCDM2O3|T5=+3||1_48n8^71{N|Xk5m$Q-y6!$NSyRaexuGEF z_Tr>ZLjA3DdZM9wsxXb{^BMO~tQ?0?#*uFDAlT%jDwj+CVGWUp96y(7T0^GIXM>>H z*5=VH0?$EQRdC|o60K&El(0rWNfQiokw-NF){4Xm@sY}HDUoAeBWY(b#;!rot4RiH zmk1#Y4=z{WE@~WGwlj%YEUjC>#*QOzcrorSwf8x}nbIqDgiSE(FVsarS2VdI{2Ogni!-eX)rT8*wZT^k1Ulh(5krBg1aM z(6^yszEm0hk4|{X&mD#vXk`568kG+MR56cIZzGYcEN2h1SZuf5%^g}UpzN#8{;k5j zlkaK-ZS8}6-fXq2~S0@Y~LtcF} zeJLK@0>A82m>p}>J*+$)xOL4A3Lq`TNAoV|prXQ_}*A~PZBWmVOrN+9%n%52&-za6_bbny{a zz#h76PP{yyl1>vw_&6$ux~a$8q#{cs(Q6}s-ZgAl&7MThFKd7KcDzmfxZC&f{qX4e zZeyEo{z^7zbj1;bFzDMcK82y|+4$;+FUO&I8f2b;*5BvZ2uz3OpRcfkgHGF~Zm#XC z2T!?$zyo@S)bRWV{+@w%X*29SAq6tSo3to)+<6hy@(7(G1OQc&y54VtptY1DpEp{!x=U=_qf{(^SOD^@ZjR>BDMNXeOTTaIh3et{D~R7DSlTpy`}=O z567J^yR;aR-BSh1!n5r&){LvTJn?Wjfd-Ma+2_#R-8Gdmw~FRV2Um_4d9DR(6b#Fl zxYCP9{)1W$p|gpPH+mSX4V&&*+p_omYCkXn%U!m!cK|9`b7AS^<2XsH0h+nP2=QS* zmP3wYH-=*{ad>TrwqshzmK1GdZu0`e#DP@WQ9`TE!$?y=IMY0|v7F*HfU;fqE|q|o z5=pp$uh$<678xZkpdB2>yj*BDlnw<&6~SD$9t>|*T$YTue>fZ{ie}tZG!M22CWLO* zUT8~LOxqI#@oo_e*9Mfq6lS(0gT%%%0OR!(Nbb0aQ2)@h9bqwiVqrj>Rxc7es09dd zp1|2L6#HL8Yhf`t)I5?ug2Gl~P~t1KH;(NpEmSrDFvRki9R&8pSfSZkTJlR_F@6r{ znb*zZ15?F_qGOip0R*Il9)inFZ zn<6M>@O1U3UV)VYhu;mT;a)FC2ly|mxLJ^0+#({7wr?M8oZ625X@=VHlsqU5V*xOD zW{idvXofTz2=V3Nm21|817~M8z718784kD%^(uMk`0fqUOGc@FkK8A`;G?&>ZK3+Q zB}iZ=W>1b;I!u}qA6(Ff20bwsjw1IYpvN|E$MoA+>YOw6v3FCC-J=E0F6A}c9oyD- zl`p#z_oqZp6E=hd7?Tw5!m$@3FHoMD+a?*1bB+WDxq`qGp_SYMTKL_3$6g1#OZZi7 zW%q4-0pmTu1y|!&D}vepUusIld(XDh?;?sQ&~^94wL$Q-~QD*#pk0C(ZS(iLD#)DLjO$qS=Y%6JjfzOY8RToZTxTl%n=bDt`9aZv(MsHojKGlsvkVMKO`ek9rX7+0>v5eN>SH z#Wok&$bu8zBMyg(B_}u0e+~ypf-jB$Z5s4r7Rsca!_w!x~IW5c84|APyF;Kltn13}d^c`thN$fpIDUq{`W;i66%M>6V z+^*eT6s*b&E48^8g3J1hS+>fMosT&r1 z&?|;-xx;Ztc@`{}4we`y$00!IW|1|dPpu8i76gvq^i^VpFJ1k9sAkiHLE=b}QR$)l zY$}AXQq6fFbAK9QVyf_}orQY<3RUow?kEg>K`^+3y7U|3a8ww}Oe5|3926*uoPS7q zf`rac!ln+ZiQFwJkgL!jw#1$OT0oEVitfp)V!4m%)Pf*mm2=x%2Db8G`0wPeZIn~; z75DK8kAPfV6bW60$`Z|9g#fMsPYA?iuYl93ZbECE+*L;6_Bp${*U`OW>aIjfjDgSP zk6T;EX+3hp5@W^a3Pu$pA>-Xg-$2)Z6}));tW!GiS7-ldVNg)n%p2otqxJ#UkZeTa z3+m`V#G%sf%LJBExL=KxneF`IYP2EuwmMq?pVd40x-|@%!v>$nI<=eA%1~ElA!1*F zmM~W{Nlzq9Sjel?<>iSbI5hEWI4O}n00$kR6>Y{K>&amEBjXy~vkRGRVpx*Y<+_4@HeqpN@Fk-2H=_Sz$1KYKIqsM@^gKL%EkVf8Sf-Nzxd z8`o1&F019|0L5A2d)>&#H|56HRgY0T=9(+wD5`=ueDEugTcM)AZCC>^Z;8$c#k(70 zDu`|^Wqo|#4SEzF0gY}Vn?e! zPGWF?n3_~D7W3}7`tdP;6sl?RX=t14>FEWR_mV)7!{xM)O_gO|pI&xz(E#7E3uPZA z@v}2KeD{Pk>T|}7yR8;N95+yjMOEdNFiBdtSb5D^8Or7F{CTS|V{a(ymxG|BoVU^+ zG~>};gU2kD4=)H&oM?pxmz9s~lZGf(FZWi!xVH9+a%coyXdVJ=tKZr-$yOBpm-fJ} zANVvXfM~EO7?0I_*4t+mrm4>8VxA)a#q9YUSk>HI1ao6yxek&fM2mzsyq)JL>zQ_Z zur2_f+Cp{JM?BmwKU6p)&+zYPZ7+xC@#}*$G~_8-L;M}4CTtKur~*dD zv`T`dZ<7ARol8b3NN-h6ZM?GMG5vkK?WZ~6boM=;^)f=PPRiXuij_R<&!hh5W*l>johVozG*#o^# zTthJ!XHW@?4p5Ktv-rEZ|NoD!@o#kfF7R8|1F{aCZeLHLw^PQSqAsQ}r5Rd^X^BOt z{`EgkUpQECi9y9u%7wFbA%e%%k|2zOm1ujP(3M_bs`%(2gZm;lyXgu`kd z5#U(RUd;WOj5bR+av?4ZqyU(q2}LLhN`!X{M4o%RT>V4vZ(o!r8W;#iYN|pMw9opZ_@|ymAS*0b=XMAmuEZ4P zO8AP>aZRbP9KTZ84^KFZ=5UdO3U-Ci3((lqGix86LlCXYYR$~e0nVBz>ha@Fxu-L2 zYuBVZB>W}!kdQ=pI($^*%Vl_FG>1>|v1zB?Euw-skH%~XyM~Ja+MsLhrA8~-*%G-T z6vE6BB*J*mfa~z+d@Mp#GipK%Eord^h3ms#8xiLog}pMkAcVjp3P5u1%=!I?oczt~ zxU|+vK0Jy;wPC?MKlo!bZGiD;e@?Y&H%wCVC6tOVma9d-_;kPAbQ1tZk#=2SaXLSz zHy(hPPedRo!-K9BQ&>cHA$wZd>xqv-`0v~aN!{+8-ef@9^G+Sbp^|~v?L-8vpHaui z%`FlTXnxOezW3|!;B(}m{f;R{J->0yS0uF%Neu%kPByPfxECfR z4$F)lpE{wKtMMX_WF=ja;mLqf|7l~Kid7RY0*VvytB{Bc)dzN5O4wM1jWu7Lx2pAx z^oPhAYFzw(DT#f;#3~}^jlGJNURK-hZ&-k~mjZau3yt45p;BNx|8<{~{me42?zcBK zI%EnTISAyu3j-8o9DcFI>E4`POdt>*LdkJubaKh^>$0b~&e7@&?4MFnreJ$>b^Bm= zXn2Gl57gli$b>&V(J?f{l@!!o@dozYLn0I5`3MCtXnozClPlc!ZoIt`1MF)5GrHqk zlq6%j`+aJ)zSwctNc=noq_ie2Kc>l!>`7#uS1>sZ@&CoYBk&*o#X8CX7|=sM_?ap4 zLi8=1ll1(U_;IH@-0^En9UKit3QIGFkYlUsQ+)Yzgx%k1eg!NXA%HEAd03HRKj6^T;6OHgGABf$p;GtlF6 z4nH+E&%cBV6a1Mti>D?ba3lzc zoHS{J8*0X7J#^Ot{omukJ>_A*;~y1vr{7!ers%PN{L?RDR23np|2lXlAU4hOTOA10GJ!v{G)hsSSlCN&*+TL zAH?%MoL*4eBXZ7WJn`AoEuIvic3hbf0@z(_i!!OIhDrS9Ue9tY_oFcLBKoxH;`(I* z|Jq$-j;F%i*6~**RB{~9CpLUy{sbg;+v*WpTLUWbUvJwz`m>}?KPXc@DM~&n4RKZv z`ZkQy$)_Y`L=OD^mn2j}>XC`sUI!*xENj!HES>Uc=EX9sk@aUFNiZ^?%(A>mSd!rg zI@%(CvQ9&SFG{flr2tmUerl(f_Tf^ydU!7reXqt*W^?;7aVI*f>y~_$o_(jya_fLs z?8@s;azwW5)xty~o}|p9$z-6;=BZj)(O&tH%l`@)=e1L_KEW0GS*yFr0`V8D=k`f|G?!lZ`Jx?tqoWzsrvpKaUp^KNpP zT)N(;;eise7L$lWOMwn|NLXZ0*XhoC{C9O(Gh@Mvxb zC-as|+hnf=)c_^&OIZN$vJIkxG+AFTpxhd)JwWwy`Nvfdcf+)3qrEE5M5!!b$ z!Zjh4MoKWrH$f#?w^~AzaEEC1-J*i+kO`ywLkwl_?70%OeIC6B{3ytDcy&b(bnL`x zn)(d{wosg}V|2mGbDiyS9=uB>9?Rki$YNe~*+RYjY$Vk9-)7@ke$5Qm4C5~v4J9c+ zP~^;lFY0>pylfK?nj!x|98t*xgW~ zVL7!a!q@CJ2p=U>`_hF(@=lvunj!nl8}btkUSr;m*w_q8O1^v_gz0})H-+AM79E6v zeW}zp19cz>*C!+nMBuUf${%b}t|{o7zXRXZ2nur6509L6Jc&o_5x3dXrmZQ2>!rz^ zCQk(OCH4}xxh6w1zgKww8b)9S53i#zQ+AVw;$iV^z%q06l84M)B6+*)a_GUMw$O9_ zH^5}M$xWk}kb)sX2%0$z9yHd=6hqUCjn8+#3GDsJ8wC76nC*qpkXgvnv!q-%&mPr5 z)a!$Qn9v~xGjWj0Oqo|aDyHNFMbxlf;tW1kW|EWj2QVGv!ndc*47Wj{Q^^8W zQtURjE{Y($7e!8rK-!|6zdNmDSw{l_>yH9n{1iyH1~fpEd??i%= z^;Gz1m^|u3=oHl={&P+4<9!eC`Ze6JBh+U@uyp_V*80cKh3Tt%la|R^DyuiEoqf;C zG^HUWbxCcFGRqUO3Hz8<6LU$l zKj3(CW>8q{$3{4G{gwJXVC0Cl;ib=1`=55V=AOSbcC4@ZN2{DisYSX!Eqr}*hHX5A zWu+6AZi+0E(`*Zj3c*&J*5f6TzQL@KL!4mdz`F^HA|^qcJQ_CTO>Vf*{%SUWPJ(0S zpn6#Oe%b2%3qSNTWYilJ&9@qapiMBT0y=Zv#8BpKqmnzFLZd)f9S+|B@UXd09AF=s zy*AcpVfkyT@?AQ4>&i;M-`lJ=iVpVc8`XVA?3o0yhJD{NB|1_WJ4IAw>u3H2)aUZ)P;}mkck%^YMDMCiljZ z%M=G&&G9Z%{e#W*D_>^pzHY)sd0BV$16jh>|r>SN9poS$c6v1!Mb?*^0*3 z+3jOcY5pa^!(itx^?-+A>KQkQBC#;6k|WGtdi?VPCGNFkSy zPb(QB%d8xM9$0*^D;ZN5f<<80E19F$6hm2GmW9SzS#(OHGyR7a->HqV9*YFE9_u4> zy}W&i=$2xcj55wVExu!1Q@EGY@0dK)Q{tMzepw7EeA9E88n+TruU`<>bJsT6$Bv`Xs6>4lX?w1 z0~ayi^fosaG30EN+>xlrKTm?M1D`e?x$ZAaQ@^8*-32JkRNw?VLvP>Y`sDbtE;_yt zIXQ;3aj>H!a`KsX~29(a;Jnh}`N zFSio<4X#F8o)P+icucd0g6N*j&xqfw`z;e~NeJ79dx})hir^!*-LC_&(Brq=sj}8S zMm7wb-5u;Lbh?0i3)Fd~7xG!5vMoPp(N9TJjNs-F_SkVj@lhsF)Yn6!)ek}=z+Iw( zM!p9AYOSKOfkKP;$!@C@AR)?2038q;u`z-G4XfAs=sOd)L0<^l#At%-pNIxSsJvW9 zlWYRTol6LXiq&_q3kyw1-gg1Rv4HiqADMl`|D13uYMyQB#>4p>qlf_il}8z21R>Zj@NwlO{q0x^E4t^B(?IIX=!h~5$(n-2x&gXw2spZt)C z$ltgGj@yq3wy##6nm!l6>d-r@Q0Lk{?MDpLWt+Oy{2y&ET=L=4jO-7BC_;z?=}(Fj zcblWNG{2-S?)qA#f}Yun244LdzZ`625ukiM`tk6z_FBcBWLD*=QK(ePser8K_T7$) zfuFL0qQf?AjTnR%uft_6A|m%mX*M&$QxY!}R{<^xm`hYDffh~Hf{p^8D%QwL+4OuH z*S>d5mCNT_DazXP>-hVq<^%smsBIMKw;YQ4N`E%x58~PV{0@3dP*yyuwJ#FhX zhB=)f&;rwcDj%G9bQr_0tpIgGAy&Xcgsq?{K~@(~;^N$DotBwHoXH`Y1)n_4W}yqX z4AF7~9}Eg~P2nj`g<%4=cHv4`=_w^>Mk`}Vl?>*xWZ)N1UW3JMM4_Y6M#IkbN1!OE zkstrJBJS6V<92>7Zol)7ITwu)Q__JlAd3;LyF5GG6wjYOzqng)eA)FN@cmSKoh|RL zt-3GAaZi`U;hGZ>BdBe>ztld~OI`%gySO=PH}@x6)r_@sNjYnbUt){*tE(dsYI+M0 zycdO8=^{JAji%&2b@0p3S%PKTA-S;x!hiV zMMnxAhCEd7mjvpa9DPRNZ%%&h--|5-9LdeDI6RgW zBFY+xScNSJR|1wAcx3DL6d$2RXeyCgPfU}S2Rgq%j<);5ln2)dvLia|{utK28i_vj zc)b?HUxZGdA4>^E(^O%wuOC6fnFucNSg$8pia8w0IL!VjrR5@|WW^>?{Y1Sk#!~l? zea032TX($f$qkmGm9b!CQ{!4+as1S7D4&g!v7~{)2Fex0$kcTU!&=O34wAv!J}a-htY zs_c^PFNjx&hOHtOx)IdH?Ym*hWgwRS7wUM7N9FI@#4rqO><@JGyADk~RuOj1QcP~+ zmK{oKR!9D)Vm6;FU2DxnDI|UzxcDgf=ll#9D5*_%*LP`~xXGSeYL=UqrRocx88J^) z!%J`TQ;w13!hk31_x6Hew}bT6o4Vv|4%iE=TrJ}JOhHUuSoRc4>@exs54;5R@avFu z)X7$oHh9?4e>cQGSsy(6%&etCOOzD!$#|lC_nF7M*_2CdEiRt88_11(T)^>T=wbYJH7ehEE`+AjgeRiU2e{did?wk>XGf}Xw?UE=;xT-j>i~xT|@b2L_ zB!%?M(@jun+~)C7TPeWF;qHU+H-ywk%5|0M1rd94o$<8~H~H>Ho2&h}8qtH1>m;Dz znFbCYn}}ToFihk`3Y^7nQG&xwz09NUOM)Xdo#IRL5mN>A?<{FvXGwO?Mz25o)9a3j z^u`SAZwvo~$MJc?M&4(*V1kR{NE0F$gr95C_Y2na)&CQvJHm@rs2L1=!=y#|wl1Aq zh>@mKAG1}W2IQoj(2`h#!|A4O_V(R)eRCAI(mz}B?;d(AHV{#zcUcm>;%0H9>dGLe z1B(;6fuf$0lwq-05sw>D&cBAEO>DK1&`ICw%2_q-=3vUdWr(t@1)EgRAcj#zVSNZ& z%Ed!g!liwGqIe&Da}n^bn|#0WmjRb)MZvyOq?N=gD@>ONV@X7;|HbvM{LF5c_pUp* zt#?&a`1o`Y8wMcn$ScT7dJkDFyyCnFCi%v_f-$hK}IYA!pbsm+m@)>?@tn|RbI-m65enf zhzRO(7=+R;w0?w5!ps~D+CJJe9M4@5#UNXwG+=NBg?c!o1aZi}*L~UO?Ho)|AjK%5L&_hzt5(R4Qt{Di6Y)sR z_%U{>@Npv&P#3D7?G-XQGZU6#DX04~Y#KXm+_mcXU4!vpt&fRI>u;S6xA8ATb=hdERQwm)4j5l+pP+l}{eBJXtJSJ@Ok?UNx&g&N_uDllp?88#C=TyV z&X6RCA(Wk*3wcB}hXE6y;Hv++G!$nDSD^uyLr)}GQXMF0$8ix8 zoWV-UlkfXxK;b3BQovGHH8EzF5I0ZT}dqK6gKoQ3ULlA^D zldT1(CG(cK9iIpZl;i?I+5Dfw9_nEqY6J`f^*Ts`=JAst5EQ6Xx=KngB@E+>3K9>Q zJN7691x^Q!dLH;|rooEvV8g1w?3?y&UXuf78Fj-x@z2#*QPP8``#v=S9Vh=$?Vv-c zi*$nLskWUkF$7e(ZK8uF_94;WJ<8tw$sY%ROe9ZJg^*-S&If9v&shEavS+%^0=xSc z>0k={5<7Z|GBQZwq(lr?f{)we>6CYH}NkW`|9iY5Z-%8`s zmd^M(m}d&-ITT5gB|9ED0=~r~xKFn}wTU}bw+sAdM6JZ5O0TYadY^i~tDS2d#MAI2 z0}F#*y&?d42W83${%VV%~hKvCur;maRBbod(9@ zH_r3fY{XaG{;l46M-vANovWw74PVb?XgEIU8}_%uX9Wza^|Qj!!LtMDLBn9NL&*yd z{gPrKFHbi-XVK9v!RzuYeb-aN>70Jf34l}Rg~~s zRI$6+Tm5ALsIr_+!O{rWG$sP-i2p?k=}i&(WXVhDXQ9y-+BCqlm+82=m?cb+lbuUT zvJ(&@zvkQ}Pca|A9*^9~t?kkERQ4`bEz+?YeZk#9)U+$opWPi)B%)G_>nj^8ScTd{ zFujpV488y8l6cm4wv7DE|H<8kiMqV(xDSdoqXs{b|?rDuU#vTD@n(FN( z`O<|giEe|%@iTPR2Gaa3IQ08tLB(#Qi@(wI5DwLZ?8FHX+4*omjwsq{q>~{V$ImCh zlX6mO1frge7skmRX)PK0a1JQ?EVVhqI24%*`9fR6HFGG305913E8l|f3VwqYKVzyy zo;j`Ethdmhfz{{0JqZoUlkWc};e`Zr7~+`0K^fk_TJ@f>gw%EPR{?x!^ziLQknKRB zWh-aFVL@7N!QmcEa8Z7v9|JX>!m!lUh#J$dgvf_ERwmtV2vOx*kLjo+c$7kD*e~MSOk!MQmRC3?9q%9Z=Sy&XQKQ$g@m3_ zLBIp5HVcgogMl?@aS@}}?W4sT^fm_exCHAtrLc{LG^?Lu7pr}VLger3GDcS%P!+Emgt7wC)_c9iV{80doXMnfoSzZjg$ zEyvryyO2j^UjD59%qUK^{%IaplQ08jB<{gs=iqP;@0!1k2L2RN8^d1$x64O^t7|A#RW#KS&f78U9K$((Ohh*P?(VhNtWJ27AX|?)Sb{uF z_8m{&ertpKk%wpdCk&@cYebJEb=#NDfm@T4`Y+ZdXkPGRMssf{?&?HyHCOJyIDYts z^lXKnGxmrG?dH=DJFZQB@wvdo&C3D1Ew9YFBFym>-Wp~RTM-vSOAbMrD7uXIV zlw$~AdtpWXg&)P!RTBF1%j_1n^B+TG3R74yCqQ&YX?5jXvc7WI5pm(!UBu zOuK%I$wh~soY1DA9W*&kqn~PWkKw9n)?z;VT781nh@BY)7nlKl&!qzshvWJ8RlD9LvFVN+*vUZCsL*Q1JNeNV9gp$Y*ukwPVE7J*DOFhh1}jsj zYwm-y>3(P9F8}oO*VjH{LyNm|{YCw!If@vlCL0YOW6A|kG|OP8$(RwSA}E|PE12;> zd&24FiBc=Q7{V!tq;n}BD5A3%swXI*vbDt@e@1G5BAT8LwKuoY zARD*@G81`&t7wH4bgo9mohRA^v=RKoD)#g3n2R_I5h}s9zXUX4nv+YH3LcIQ` z+J^tH+P(%da4sXQ>2FKW$D2n~{2fXxl&!p}EBBDv|LJxivB{N8VeuFhSv$%3A)We} zxn;pfuxl!re5m`=5SNTg56#-%qdcDMS*dm44>HWAXFe&?qwGXOzc6h+Ky*>k% zT~H$vq_*2fb%YQNort)Y%p~3w_9ZIT?oG-+ZpmZ%`}fmL6WCk9$W%iUL#*?NmYxZk zF89Y36W4;D^ZdY#VCBB)w6n`c6|Ky3og%~>B%odO5;RaZh$JV^Ln69<^$rIjqn0I>=d)k zy6u#4w=$2(F%N49h_Ua$$2B>y1=<>Oa2S}UFQr+htd#qioEfnb0$l2(h~6my6PE&8 z=L9eXb^O2^>`d6bxD^x3t=Tzu{pr}xw(N;)IJ9f~>Hac7%%-u+UwGF0U-So$#YJCi z?x9rYPKw9a(#O92f0?9<&XPtnUfwksgaf8xuKANwFeTM0Ap2T2GN8Q2<()dFjT-+6Gi9u z*Udnwdu=7nhnnAe3mx)!1V`BVexD4}HyVOH)YKI%ED#VzPQ*wJZq249<~w;ZLj0)X z{Vw)iVt~1?|uzmJs7DBpuP;G8pVe z#RM4kH^nmzfp3h9WsQMLqVMfO)ou2w8%pz63K55*%?A9v5T^cyEnJn?~DM(fdG(+L?uudm6_UC`739fQz?6@-a_Bv$3s z9hH#Mj|m4&glI6i0MvRNgu*ula1{9ap*TL5&6~l9v9k+}KPo1UN%vO6D zW~Y3_sxRP98XzS~p2zht}!Br7@I3_0>OqKeTOvRVir1J5zoC@l&CjAXHC zXzs^p4Aj&9BVp;!8&v%W#~)L{j*@ccFY>FSY@Jd@205-K^uzxN0Cw;HJw1=@7SUqz z(hU1@q>#t3|ge>Sy8b~g735)^$LGy7Q6_^hVP0wxP23M z?8F}gB*z6LFFdS+z4At_!8GtI->NLrOGePPN83v30fZifb^?q`klf2I8uIxJ&EosAY>{n_z zkiS;_`;M_9o9>LucJSxKCNxPWnClF}%?X(%$0nGTaBwXl-Nyuug#T;19BRl8_76KK zf~IwnA_|D1e5C}i#}*+(Nj&QQ(CZ}`ztQ;O7Lo;84=sv|^9B=R4Y40=`N(b7?&GOd zlXoB7-s($@mKHAn1UqfCoDyDsxkd_A9wBP0=T)=fs)e z!9pNmbR%;kr7jNN;>f9$ZgQoiuAvjBW1>Bu+kHmHcc``$;C2u&)ZN}Jq6n98rH$af zFeXNqlq@E8!_Hy+uS(&M%?l_~Uck|1&V0%)00OXuYuI5}X-M*V)bb)9&4x>%@J3*g zqH+1?5P+}rRAIfTLk?un-fe|*5kD;gqW(UYxo?CXyc0@`!S>8asHGR=LGmb{IOX-R zV)Ezf=YDc|6`r9_7CTMvi#b^%`_TO$z?4ZeLv%2pY^{-ReRu?s$7w{qvx}`cSzCEn z6mk*DSf5kkw+88oSoyF6X{+Kx%b*03Hjx5t{#7euw_RR(;WAZdEV3j(*qsWU zQj*e(U1e{$VKooYQ`?+HSmULeNsLO_;Q|mr8i`f~AQH?`@d$T?Z(2P1!WZSxyRD^J z(?yc4B$d9Mwg-#)gz$<0|{w zjjvgTiQ0w}S=12^=iS_l)Odp{qZW~(x7n5;-UuAz$Uf39uE`QT&_cKX zx9ms7l!R14tq{l~qpg@Ji%*4sP$)#hfdFU;K@Ld^>oacf793L%s~WZhJYo!1sv;M0 z@Z{{r_`!m$U%i_iflqY5y+cmF%p^p z7GRc30}){j9p*ZfE4fJ?Ss|)HD<*TAFMtVN@q_RFs&n9%h}_VfTV_Aa)t{0}^L3*I zlCYwhnv5kz>+?oAp-!ECLwz#rsARTe`VpQdbVdQtd~;2f3`1>)uzE{>;0c{lDSLqy zdoR|<7W7;=IC^4kMa>#_DSBu;1uHZ0nsRz5&Rx?Qtbs7BKtj`V`1NI zGe->^q)({D3LKQ~))VfAGf^nl=a9wVu%pXQ)I?GMFJU9HVM)18${!pcA2P1@3%sR; z^r^&vmwZP-`~~0&2m!7@d}KJP&yfkcXUTTN_%kgvtZtmKfI#l^-jDY_-CStCKE%N43Qqos^Mi)bkilq`w>d|#v?Y{(|uqFU6-W|@cYL;-N) zvErWXn|YL!a))vN$`ZD2X&Sy$BnDQ?$|o@h^3n6gX6xcWLsNyK5rdY*0dtws1 z#S9-HIq@Maq>!*t7Ymz>A8qynbauf`SEu;2=zROfhqR93pSO$@JYx^8v^u+B0(_bj z`kr}C6fT1C(mys$_TS@;BW7qppmQQ;kUs2V>_Pk?W5Dn> z)pF*GQ+_Hk{ZEVhV_62SYTT$neR15d!T+;95WhsXkI`50C6feY<==-dAK;$XDOCBs zA8!wZaF&X50YRAvkwF$Ko1)=t;`$$%=v*Omh3scBKkkF)tG8Zz7pXuxqkY#V=Oq=rR&q7Ts&)KO7VaPjNHEWzc>B_buQ z!~G|0Ux6YZEJx{RaR^(P>^Dj8=lRNg-Q2|w%8}cf1B1Xs%r+D@@JZ^>9<=)qC#NO> zO3tLC`G^O7g>)=wYMG66w~Mk&7pIm$*~~ybz$kD2S%P{Xt!9c}GHMzHgx)Y~Lw4L` zBfxzrU?}m=e(@4`;E0w!Rh&9DjE$}jf+8L59-5-s;6JPz{aV~Lex?0*nw&Ws?bcjS zg5nZEi;pl)B~{XrGU_3U-(pbz&DUBZ?1`7E0GW2YgQ~c3cx)72{Ejp&&})v8o5N47 z=$&Im3G5_|l_Ph0uoO7iR*xk}1)O=PxcEB_Ikx?dGlwP5vn^$Lmg#qCR8e@1sxmf; zL~Pinh(!-zP&w>cJrG{wCn*|07;t13!c^yp!v`Iz{`sGA8XUdy_2<88a5 zPz*YQKGxcg>4}BK%mW$);G_FL_;>-qwl$pb1b$>EKW z;GmMiVgb`MR@bQ{eLbs#j@!z9O z96IBG*avvpu^yH^bP&Fk{gf#tEs&(6qX>R96KLwN=3)>O9|csV;Z)KpBT=dbRt9q`2~>DjG2Y)c(1to2E+`{VAj%s7E-hxt4dshjOu6>)iCh+& zTI-2!m=X;B#%QA?DJklS0`?vn9#R~2Y#``~w5K=!d|w2!@B=F(R@G8~muh6(5culh za8;bbU-8}Z{@^F4&oa6rPrTHU7g#WvGv9O!*avhqMC112DAF&Zxf=sX!B((j$_SKe z#YMTyB0fdlaSSAoJ^Jm zmM0MKJE55f28WYK5bIrh#$eK2Rln2Sg`6-J+gSpV~NMHyE7XJ)<TTE_x?B*oM z>YF>S(bttdx}OIJ;nV81N9}QOEuL?aBA<5MNn+~{Rn=Kk{6&}%Q1_RlaZ1hc6*583 zD=3>aR$LBz;#mN&&NmZ2Uka|&UVpijx@W!UBPr3Ol3{uWe_b=Ju+KVQJ+uR1oC6t4 zU|dA10~-hrb*o=NOY3t{QNJP*C@l#*hr>@4Cs36KuS`!vh}gwFL zE`9kyrR%eD|D==5I&Jx1EC{Woa$i1}LxE85vDJ#}kWbtKc!wEubv^SHr8<@t647H( z7uc_Kioc^srKE=p-Z^0^@hZ60r(i`|>6@ZS3c34aq0I~gawDxzl(h8l#Hk6jD?iU? z{hf8{V#&v`6_dI7{&wQp9HnwAXzVU74^&DgKT>a;Eeh;9=LdmoS5GEKzZM^%K$r4u z&N+U1$*HC1dD+`I*AincXGf9ZBVI&r)tLAu6fLr8uys84%fQ_P-@E?B;rY1)VtH)v z@3gqa%p_^LIWxgv&jfIYLqP!jDmUl08UA6YUgiNcc|8YvjtAH_T5blC_!{*ygsCMR zfBa-yINP>I=4N8T$=6%l^ukyik>X2x=}sx|Dfi-c%CLQi5)YzMK?_RFE3$oat?aQJ zYP&POIhw_bj5q2!U7Jwm(EFB-Sa z+c?bSc|^Kva-3b7DLqnRIPA>|s*1-&IygD9`opbXuwx2KVj3MdVb8SEH?QMcVnTC| z^Xgp^(^C-Kn`T+$^WS>*jEOO~51}zh-4#&FV)6~nquUtvUFb&tEnCf;3-ES(3@zlF zuBmu1mK@CKpWLXTgSCcrA&rRLbA>UDwEv|cUze!n3-O8h!Cl2tnt)W?#Q6yS0N0;b zk6M2{E>ml=r7O@TyPWo4iHX?}t@f`UHf3YvM`UIPn**B*9*$u^kn*Eyw)=aHqH?j8 zF?RFxVp?Jxrp&{AtY%VL5y1Zqn4N$?GocO+yPJJ`*ze>F9>h1OCrVdf63Bq!4F%(d z#wzf)(!(F}N!kQ17P+9(H_NY>M)O#LMWR!al3F8K(YWecJ!{SkK92Q;OSD|gpa8z) zB4x97xR0l|F2|3bPu^Wx8i7}|BF$Y~>rpZj!iYQ#Os4@rr3qYIbh89HFiEfef4Xd) zSNYN)uey4vRUK|8kwSyQPp9-U4Wuj9pZ^og%YFGsFk5s+-qQYKjnzV==MCYJT0K^Z zG$2GEjy_cZCXWUi{R_;fGjss1$$ma}rEtWJb))ymcL|JE4DEziu1V&D#n)E#eKQ#W zHT=n_(GDGH@)m2+Nh0jQ8|17vr|J*q)p8qU2|r1U9CAWg+zW53t4kJF!4z)HT`(Qp zJsqFxdee0*$RmHZjC&7sb*HWfrVX^y6B^6UJ$dEkq`R*S_+4FAyCYfVRM}yPlkLJywRqLS z-AnX64PHvLn<4Bj+rX-B85*@S|PJ8DKUah(~EifWZAuI1n&`XP47UO8#u9f1j zASvBh@lQgyXu_pjtg~5!(6QhkhR7v2)JUyIa7)lU6Bbcb-;&FI<;hCOywi=AB_E_Z zH>u{hpuC~2n{Z0F91B5v?q1tf(Z4LkOVGQQIzr`6Nt3%sR=vI+hNRfKAHlukYWgk% zeV-syXtuK~x@Z+x>!*6)h-6_BN&1S~d_~S=uhac+;mV0C_Be$NzShhN>Fc_`r^Os+ z7$3Pk!iV6dD?iWW%ZbTRCX3wF9Q)e|wN;0}9){3e7vO00T*%Rv?6!ZTZ{_i?QtgmP zsO;9=+?P>KmMMoWebTFgn;FYRFT~MGn+%z8E;nrC3THZ3jzOmfOlp}fu!Z{QQd)uVV@9_-ILu$wtL{aX$v9E+1v+tSi`9A$5>Nmf56Y}9l$C$^YW?JIluxPW9p2_4+ZiBFLSjziFtl|LwDis7pg|x6(RX9iCk-qzD^J3!PVa>@p5*j z-oDz-Vx!f^1sO*Sh4f*KyXmKmZA7`Yy|iIE580Q$+~5q~u6qBQztB#VOUO+uOy2AD*VY6=QtvJB&j|pvkg>BUIhU zGkkk}p8G*TL{I$X%ilgzk2Ui|&dyWvXk^-AVG>2z3alPFv$UBep~_`y8ZAT2Wb955 zc;`~mhXtS3tVz;GG^WEm=Cj=d9*xc4l*DhGW0n?;qXO*$8}u?Ch}P=+%%x|CGPpEg zWwQkP1g1B=65?);YY}6#li`OiKl!oH;l`ZXFc20J`xVV(rYQZP{W@}IZW{wJwc!ZT zRrH3Ab&JA@DYkyB2V`krBP`aj)-_8nHyk4QfJ-R1aQ9Mjh*&JlM;K$-&Y&qv!KK2} zF7yZ+Pim9R!WHHXrKiL|w6>(i1*0M^CHuRy>Zc3~7fk4zs5x96+?ap?a<8d6m#ij? z<Kw=g*Dcd#^;7WfiotOuAR1 zd%0>RX!QiUC|HZ@_AxlY0RK)l-!Gu_vM^6rit;W9rH8=wdg%KSru&PPI!pTATHzwg z_)td+yW!zJjzmKaD3Y(SRUx!U)5^xP=cJyWH6zt&EH`rxVLV{ui44%|4Y{RVHy8G@a z#KI)MB;9Y3#=bf_-X0<9p-`~3bHh1tR_ywiB zu45AKX1}<_ta$5D?QnYk>Zs|*b#mlIvF_#ev^dQ{Pfu)VOG`;0h`9ErY;4=S)hKW% z#0exQ26X`5)kC7SkmM_`gNetXa_k>m%m}G#awnAQ7>XQIw_t$7@a3n|CP;QXxoFgi z;vtJvND^Bj@WG`!Gr*^l%P$6W)>i`Pj4n88gQ7fsq$Y=8qb2%e&+S2cEDMAd`Ty;w} zU3AQr4l+KD;&9>tZxeEy+vu`woic1N$tfYO z!aGQeqA^B<$nRp66$c&ZLVzR>ro&2*=Oayk(=co;;qJ4Xw>xoCl84D;p&O+J`;9LxvZHKH0#KI$E27S>rqe@f`R(fZ@TTU;eP)lhZqS!I9IA}2DH#CvZ zcQc?z^4h?xS(Mc5v~)B1m3eWI_j1k+`UcNIDSa$LD%A zF{GUIr%39`DH(kV4t`@Hbrlr7zPbN&eVw?jf0Jc*C1B_4IP^G~;MorX9manz0p4m}z6EcfV z^*6t6q~6!#Teb*H3;s4iesOdtZaje`w6X>5vf!O=~NH5hwSM=a6*}>sSR9^F4y7HCQ>2%2^?DBRS5nJ-Y0qU zi-3&lvcyvUES>2PeBt!a-YZGeq<+Le&QN@?{su|PkQwsB{p_|Q)oYWG$x^ASW^r4N4 z0(4PcRxyBhop?q4TZH};LS!`pGk8AmyfGd^|W7R@A7I2(B ztmcSoN1q!P!YME)@>NE|6DQsVTgO;`tQCmeqztpOMK|owb!c>w`Ku3ov zp{6J$3;9`1!%PB8Lrp0LUE)#kkoE>i|DS$?uFUafQnlp`3Imv#H2E5e!uAVEf>{nRpn1?qiVt>lQJ>+ubp;EM)ZPp$5YwQ8;L%^-VxXzSIyf?m{auA$1Y{mn${|sa!TSAI@DO$UpQbo+}Lv)-IX)D#&*`ElP~(~mMTH?o1J#Eq~9YZBD)!Jc&Tm0 z`*n~h*#>lB5TA>3ci?sf-oZA1grOBW-jHKi5Y36c{&AK-3$%^MI!HetOmOLR2c^M4 zgOh$yB*+(01%M~opf9=mDu>ljg+)BJWZrO{53o&M3t&(to|t zOVFdwZjl(Fgu}o(Yy)L5ns)8LP=TTYIc!`yBo^nCEVb+dO0{->UJ#lP8f*Q)+r9lS_B1xh)jAQg;3^JEw}OL2nD$#Fq0};@n2$B2*zrC-2_k{jxh`%E`HAs z)?KSLiEVlA>c9#_Y}NdSF{?DGuiUoDGJVk2D4?C90^ynLpoExy!Q8JQ$vm2EC2iV_ zQdC1B&b_@SZJ>$@+4GUuK1VJ^pqw>>Fc(j?ia}XOI~}R{8Vk8fJQ>TpQI`5FfaC@f)CpzPrypS~}y)pQ?se@K}+ctD{L&DL&H5j);s zpnWubbdPeOD1Li4cL@Fos}+tb8fkN-fW#*z8e@bka>YXxPGJj7vhM9w`DV9>6S=u`I?GR+vaV-)0ebDf#2z&4 z#Xr5&y-XHakBdy-+7>s)MZ;2+4;f;;5VUaU1{$pT-6WN9UGG79uI`TDC36Uuq{*E$aZtE4aw19$Qe_ zPmfsZOgzXv7U-Ut)W|+k)9Ieev7zI)UMSCHMt0y`<-a~ztg4vni$<_FHY z+BwDCwx~F{g?;9+ZkHhBT4vQ78t0M{xPsK=7J6=ltqH}_+N-w~EHnt&tX%jO5~Kfa zF1^BmYd^X+2s&BLuJi|U$spQs`M9Wl8PzxyPn6LLjf;ArwXYMK+)A=P@19B+_3 znVzq4*H-3#J}J|@On6j8GZtxBw-m_YselqiPTc7FE^0D%xxky9BVj=VqHzVgNa*uf zr5_uvO@$ggojhG{DgNs3R|?!b++~mJjE>N{1Sh(dbkWNHV!#MQpu?eK_#T3DNj~CO z48uP4sH6mkFvevPlk;N&I`F0{a)=^aghOsi*~i6IfKu8pf+gb^y{D>oq_%%eX@JbRLwtO(eM%g4L5qow9+P>HpeH_p`| z1BMU66&B!YeV{)co=h7QjjDehX(#@Yr*@SgaLmAe3Z&zwAH9L#;`7X4F3$G<9TE0n zRXwJzTaTGEvJCP1&Ra1lx2vbQlTuy@(@(3LuG^9OeQFNmI51Wm|mpgyI6=mP@ zuj}d2y5uFTG~`@qZ5MwXeUnZ&rQh^XWRJ$>516>_8GV~3<>WXPhD15iz|fNg!$=oB zlkr(SSqrwZur^$@{Hhw`giLg2{9D2|j-<9Ty(kUjYD6A+4YkP8nE42Tj z)`-Wh0V_V6R!~U|uZP1%#^3g;ij)m7V8>Zrt$?n59iK3H? zvHEDoa+R?gVEh!~cYWlovHIJ{*rvn4Wii`0d6!1JW1KH52W;`QC>k41W&{&=HCBCc&vr!+on(uLZx9VxHjFCjuvG|PZ|E&!(;i?2k< zs6t4Cg(NPwj-P~Q32*P3vY&?oO_&f{9gt)7T_>YV^!D!Z|G-(K{SZA4mzhdv03TF8 zJ)c=Nv`))-dInK7<(i`9BDzJ=Aj-!4%mKA>V4F4p&32`(WOTcsAv|NM0F!%cq>r)a!OR7> zB0h_HU>CuBaqI8yVoR_kI|Zii#gg%envsv}yN#`NDk zR(%DEdu?r%Mw`{{f#@#BhJ;T6^KD5z#foaPZN095WVNK3bY4UJJ9d&HeQ5T?)!Ffiop|l^uB~5%iekNBAVW#X9I`sj{Y6QTo~(fyJdmsZnGJCPyAn&Btq4m zW*NMm@XxW%;%bx^>_#0**bkRDrNfOK8qMY6_XD8RxZm_7Op$tA`jE;H_pj(g zjmSn$%uQz+!()@{B|dM!DGPE*3`eL9Nqg0UH(oykRdD+HiKO1Hl9FJTW z?{eJznSB=gLf}6XKb~J|?~UETWRuP2hlTq(iDaRdx5)Y&UJyANdv5M}FAY`9R(nML zl?A7|O=k*>6|Uh`D*_)Mh8PQR2hG;s0KA>;?A$I!(l{$m^r!<34IZubR_wN|?cTe8c2>t1(%4lG8 z)}zGU#kN|KEzJKqQ>?|~Wt{@t&6YqP;G&)DFqx14nvm`=6_MucvRKRFVZpXfbk@F0 z4bnGFwT)i>=OQyrw;hDWwtiz&RdUu24WdGeGx1F?tJ^Byg^#xa3$r?H*#l=bYYLl2 zETTDNQVaAfRo)EiUM$-ME*`@D^uSfFjuyYLDjp)#MqJ}=cc>rYmlTsUGuR>fO3DT0 z-AK3UDmvEVl0F5YbR!v~v6Cq1A}=NmqdN5yV0h`UZ8&4}yQ-EA^$^8{g`HOJpo$?A zdoECHW60A5W9UH3$aSD+=e*CUd%BC408KrHKckZ+%B=y1f#olwRyC2oKFyaLJj4*E zVukO`$uM8x2>5}`R^2f9iWDUCskyQ9sgrF~kR$to;;eYfUsNwE27ac<32U7?hOohc zbq-&aATkbp!@P7Jh?6}LjXBna#6g2!iFAZtN&9>bzeJ@k){z`Fg?y7{hc$mlZD+Ah zrcf=4e+!qiaXBB*%=#y0{KB`s98>*U72k_Wpp4+~=in=s;$@tNoy3c?(&x$O=^a+b ztK;5Bk)^*+LdMDh9NCTOY`jE}TbgeG!Y$B61Bl8=#%^D1ml4|=F@;w%JvjyTIY8I~ z1&Do|VLB6a56--&OAvTESKRFuO1Q*Us?IqC;n7EnDI%>z-)m&v3G4=v$TTtF!G-xw zK0@&{E5mcrffc7@5Skpzq+_OJE>|7mQ zVMhFtMJUj-)+o-A;;*o+&ll(-0T!k1s?gEY&W`U287Q&tL8cr6^N;bl9imtdDyX&D zhK9Ye=p6$r$b-ruQ!Ix&$O1b=ZvkcFEo*mqn)J&=fm96~(~0;qx(}8~q&}C-NVdPJ zzzQ0$wKAJS^Pr%Hx{jvBQ-|xBgg|M_i({kp=S&3s9rmt@4~%5|1q?F&#T;kdAT-N zC^6TQ*D8MJe|HyPm>GG(bsaH^0A-REv)6pwQm2Bq+WT-FKta4;iiQ`%P;-S+0H^C{ zc6Sy*7_lTv70}B0zQhHt^RX(2Efb3irMB92Y&{9y_wf}x3XX-zN-l)9**n<8QLC@} zk|aNycb#?r;Ik0kjeP|uMHto8P&-Ir&CVFNJr`Amgm(23E)>@)QXkco82ljSLhgVL zEAsxp?0i%GY1uHVO}9q8W{i?^Kb%yy|I~DQxT8Igli^`!S&l(lY_Jf(MLLle z;eg}E7<$)+(%B_L6qdOwT=xou4a)-O4-@;fz<&U@}=$l&E)pG zFl+DZ`nk*at}t-#jf-a}W@VRWFed904k%0X6>9xX5r^V?M+upuo!DXVmlAOq^H^>t znxA}n>N4WZ0cECC`XqC;a64%HL&WMS<6%a!LrNsIEb~GZa7<@%!DOHYygd;95nO{; z2&GxW z>4oieDBGbT@?wqpF&R3#YyS^hTye;z2W?(zw)h0 zK-+Ip4M;)~=JNHL9M2dADj47c%H!uFFulJnM|?X|58SgO{9K;2VtusWM1mmY$kB*c z^DZXez}V$*TvHctlH>&h;5tglSZl1PYJTumM$7`juWutBBEYixprWx0RGvNQ0eavQqQRnGNOx7l{##t{;o$rtq;m<)vg>16Y3EUaf z#dE3|rawVW1YE-_(XgZ{!SQ~JyldJL8}#{+A1XxMNoo~&CX11T@?7>^Uig?PaF}sk z3^`)cRXVxwEa#DM1IQrzFrpxjnAS&3G@Krt#v9{4_Lu62?<5z5CwFJz3)8J<;UA^{ z^bo&${u9sXNdq!II0`Bk|BGF-f&aZ^Seo>r{JN0supI7S<6M@M4rz{wS8Oo;r!6N( zfqr17r5|Wi{ua)r2Fw=A2p3h22&g7x!Q5wP=HgBl@JzI9y#k*->o9piZF+mEh~F^1 z3Am>B*O1=*>6!V(_(FeQe*KN@kon)oElBB5=h#NWVcB?3gVLm0k2rdI5jKDK=jD5ALQedJO_O+xc=`zlUZMQcoj;Q33wb?B{6H^YXe;B zF^^t_0W)9&!HJ15)mk&q!YFY%1{3phX!qal7E;!#}kE-TWpnrQK(1l@@Zl~DlP zFqS!bnZ{v`Gj=|FLDG6L7TwR~(nwF$yA7cLO$ietP=Km(a&LP?kh*ms2$CLHAks#7 z0~}kivPcMB>#wYD5e_IBDX-ioaqJ5 zy2WuH&mQ)Z+)E*uV!q}JAW2o94-Dtd;2o|IsW*>PEIXv?%cM}hPIOPjFo&`k$wbhh z!s|628jH&m3u;PG49ROh(M~%gA!$FgN=0Zr$$(`RGBo|4KVK}gt&fj=Z6>`LzLsIP zE0zFUQNhpmztv`xt;%r+Th%*k%^?{XE|LWjKUGxA;@Phh@DZirJqm6xch~%eW}o-N zf0aoG(*43}$d?WjoP$Sy5>-F)J(QSdd>LYc-H2Z=s1Qv=5ZxD2>5xop5#EokNe4<_ zI|fr!v8S$uKdV(=?Jh+DANUz+eUAQQ**Il9!1-(yivE=M$+|G+DcMGFG9>0{6@tO^ z_s`k!p^C=5#iItXjnLd!`G7Qvc~Rq59F?Q-E&dbX0~)b5q9jTx;RWjM%QQ5A;tSVD2ug1`vPO%hE5|yue6?D7e zAh2}NtJ&j*vPO!t9VO$k_#_12C@JfoMX=DpNjk^q&7#m~I&V`aFGdAVJCq?Y!vjB1 z_*20=0{^|&`rV}{0Pr*vF#%$Ah4wOB`1}eSzu0mnb$V zpHW-)RJm^jR-k*m@M*RLQn0TYMm~H`RwE%81q!E&BkU}2lMkYk!kuW*4~jFU`M;YcPxISsY!OskIu?)OTGc1 z?d$07o8;~ppu`$M77o}me&oJ>pcHVFqoKCsz`D3miOdaJc7$W$cR0FVfa&+{C`_qD-wZlZ0#4HDf#b3 zl%E*$V40-^GkfxuuS;20jH-KB!cnBYRv_rLAWZ$}8ij-) z7kW9EUC!(n{D0q-{#YdmEI5ShM4CN-w3$u@F~l}sK#2|zuQ~=knp4>(j}$_Kc%VrI zPDd}>d?K&qwtbmIP=J!DQ0z8NnNeU+bnbq6$PX-ywdbx>R)1%K9x6#QF(;x)Ds{s^ z$^NgTHRHQfo}0oWwEt=B0@W#(nnUWL=W^ELlluATu}lb7UF>i~Phq*LOYPJT+j@|o z7L}w#BUe}dGzwu6&K!R0h-`_=Fk73{1?ZqwqIrhck#+};?k9rd`3~HCI*QiZma}|Q z5zFM$xz*`oSk%sy>I+4Q77VfAE9b8sGNZlRu~?P!<~DZ0DS3#s5%WY$Ywr{GFO^-2 z*uXX_66@20Zzm_KEs!)pMemzu8oiGhM-Mskd#)Fqe|H_UPb*LCFrM%Rj2uCM+J6AL~1p9d3Lo-W_Kc zUrpw~etdNtF?7*6#zs^8k%yl>C)T8|aG3>v2GMzp?U!fPjq$q6m_q zi8V~l{gl_(Dzk(jC`mST%T2&1){x#)C3(__7{srRwB+{R^(Q*V0m>OR#SY`oZ}}M% zqc3HI^Zr$>@h@4oURK!K7VjdbnQ;ZGgVOiv{SAVvWrC{=WDKvvn4R2z@#(p_{>4!i z>_c~&!iw(ujhu_E1eVbtUY+%(bh*@bo5M@r^g`^$5*`=z}E*eAhC^2^r-CqG`8K1KR~>Hmzrv>TsP z_=c>Om5Vg2WzOJ_X%FtwmAe!;eArWMo44dR)q5@Ie)k#cW9KSTC;m%EW( z4r=1>A?j-33VVOv1~-3=tTkumoUxb2LsVNi<=3#DvoE?3?tNAmICFaCSf8pzN4!h* zDkel|FK2v<%;+Z0WxU3P%qlxk3$#X#*_=;yESGwwUHod!miYP;AC5CIbKrqkrawV^ zKA97wH15q51`u!FH2Wf0QEed$E$%0@{c`Zkng5t<@Mq*=FBaDJ(c~WPU9fUE?ECJC zBFmufOUHj#=IzOUS7r%^$9Pe9usum@@`5%Xs}>h|XoeDHK7Lmc&9UjtD>!ct0Ss@i zV7?egC)o!QZ*iCu=pv+|fqUmOERW$u!T7?sL{_%3=8ZpjtZH5lIM>F2pI6LmEjL7g z4Dj}-tNw_gxXBn4U^fMyP~0hei|orRb=kRhAz$g4B;S;U*yH*b2@jqQV)Z!h6Nh0r zFrt2|j!BZMmb0c~q%k2*q;#`9@ssHT6{Me#gpnF)#RpH(%5efC&ed^ge)~z@Hr798 zPgTip&gWzVf-g(Rr1=-iXtI>L!yRYc#vnzal6%zL!E$s^0b^{d{NbdLEW+FhKJ)v; zYh(cg739|z&Qt#bxv^>LNKkqQe&mE2`clX0cT7O-zVDwC^g#B=7ALHnacg?zg%5N_ zuw17UKB8`zsJ|5wp!S=hqGSwh_SJ^WXWCi$*|Jz-SI6WqV8oq12X{x^Vmzfv(an&D z1l@r(<*a!e55qK%4CRrdaJ1vbCI1zgo-~n0DS}ZEwuiCxbUcP=7TPNL)Z`?0(UjS< zf4r$Cag`Fy>6dKtBDc&pei9s$q#~dR3YJRWxiy$#i>;}Y**@w&kJNUxjqg+a+XKzD ziQ+$%WhuwqxNowpPdYf|Ac=k(k4~2($RJf1GMqJ3-(l8{NytLNr+o#05FQBxshI{L zCOk0NWOw=)Hiz9dv%SCf2jw*M!>zmBk2~iincwU6GW%k?-YVbEC--JvakIg5k!mGl zo6TI!gy64!ELkwQSK)IZtD_lJ`OSS`FsDNFw9*cm<*aZBwp^XI49e||1u^BqE| zAj--uPn&o58x(vli5GTZ=h-NBo=nHRlP4hp5{w;Q0dhaDS?il}E?uRNbk>kKa&|}3 z+^cTh_;3Gh3g5 z7Y8j?8=Q$B!_r$IHH2t1IUqw~6v&XXvuoFGbglJbImL_N^cA2NyIW_@zhRroQ&+enb=EB8bUF}^ylEGwd%-n9P!mnB5pCe z8E!M5qBBMYGk>>J?1&uA@HBPU@G!%Ud#Wdl z_mO@MPWzc61DC*S=zo*@#f0<8c4i#+gE?xD$B2N%oI*zCxL3T3&IVt93C?eF9n>lE zZJ4Gyc$)FUxo5mrt%>smW*63*PQhg#R0K>LheqsAmPaQ5*MlzpqQ3C07LVUl^8iIO4uQzgmyn&{I z=MUn>%Im*73ucY1I8&vMKo*wIb7x8Ua7{_`EUFI^(kd+(gjBO5i6;P5d~~&#uRGu< z)~!2!s_Z##DTsWZd=S9=H}a$erTAPqt?I)U3+F`kq?GeH$4F1(t!WSVgNF=DCo_!V zQw=YPwELX{g>q3JOeF+f&I$1`;)OsWpE!X(1(PwW1uMTfixeDrjDhKuoZ&`ZFFG^7 zbx8^cu$uS!G0Y*1q_?Ui4)wSql7>Jv4Bp{{$BkvF#7~#6`_?Cspin{)x=>aCc~pGG zc4;|9O==+Z$8v)eE(_;~f)Tn}hagEd={VdH@P=qfW@si3wm8go2gq zm=nB^c;r%QZ#8x;91VD9STHc|XQSu|k|+2Jgjy*{IqtWGwF^d9;!YLLR2 z5^f?b1u>lmh;mzx(|f^Zc$)>$06I1ze<3ZcpR z0D;*+Iv@{D*=&>@Dc;I0QyX(KH~lrSX)Q5+C1meE(kCik``~e0lxHV2M_s`U$yKfQ zFr+~N-8RaZd2B9rm5otj$y@wZ<|)^`<{9+KNtJPkjjn^D88Zj_qt>Z9C*wzBG18}S zMWq>XG9>y|g=z@z27LL>Ii(9s3(E^lduJA#b}Hg0p#i9nu^3PxbMHzP4wV|m+N7F> z9B=cK=BSl(hmB5HY+}F5!^fBFhb_~O9b95>uGURrRQXQHT$8LIquooEvlegNf<#06 z!ZhYSV+Gb{$yi50vnL4&T6)Lw#T$pmq69h6I(OigW0NsXEA9* z=LF@ueJ*yOxO$vHl*U>%$aSJ*_{%QnD{{1RRev(njU6U)stmi#N^1} zv&6pT5z`GDBO{5W9U}v*f@r&0zkbkqL*@G1%4%MMkynkvFU+6X z3o%eHm#_$^(f{GDafN<)n|1B8SN})JBorNh%hKEivGXk;u?&Co`MeE0rDxbi%RVI^ zV0^0z*E=3e1(ct1su3We1Sr3>2v9yf0%mUa4{zuuXEc?yo zL#QfDJQlL-AW&IvWSL|7@cev6@9iC^n=U$zoS8`wUwhMrki{}}VVlEdhF$9iWD8rC zUq`DkZT7xDP-baQ%Ye`ha^9_f=cX(LUm2jOFexyJLytj11F7B@)nloH{47P!+LMZ7 zfBC}bOaJEOnM&I-{@5Uq+B+Ya#u>Cu^_J%4Gzw@kc>K}cI)69r<=_0E(`@|8SdByH zLHln1`9pzqM%d>A4zb@kI;wngzsxhPA?PI*z#ec3Y6I+nDf*V3(iJ*1hbKE;L>RLt zdniG~Nc|$ec-4B`oFeHiMXUT8unETPED`U8xnbJ8+ky)|OKyxY{s|-E$+spBj6Z}( zyXSz_Ob%P~x+jgP)QEc={r zh+2e{qt6Cwu$kMA{0dY2$>A-QzeJjc;b%w%RO;2_rIy#n_)WF8#%0Gz-d%{2eF0xc z<#u`@Rq^EBAvmiN|BCU|!O3xH1!@JxLrQp-#i8o)XA4!nrfjoeEoe`dqSdTLuyar` z;2Xr-Wb3_^A#k1w>ugz;8o0LDI%49K4=UuYZ73+RZ_Y*tS&AqMPQi5uHl!-6rnU;J z+%Nd9k{AQpuzo*IRj>E++pYam8+{7j?H{Z#*`HjlrtxDbRo}2(_Rd|De=|3FfV3Un z`QFjn7M)jfJfA%qa4z0OpKih0Ss2NE__;K*Sr}ZSidAOu-qdk~=*IMi)e(;FmB%#N z!r--EPO~ie)O@iY?LzzBCOu)d|50k4K|Ohm^0sc#ppofxf;HYgJ&18g<=}r> z#F6>hM{TlHSGz~eF4?KT6R zJTXgNY`qkCK3Hv@%g0aq785e~C+ruA>7XtNVh!PqDeeK(*^H}xIFuf<2Yh74RpB5N zetOAPFNCwmlbQTY9e=4L3owU60vaWu&Gw*xpaw&XQtMcpb{(M!PPgK^; zI5{Jk{`d~pF3aeqxB05YTke&eZZqk9pmg(7<&Jx^qVi;Ke%KD>$epqsbdMRy;!I%A zhG^*Ivgf`!Y%jKVm6FW^#8lWU#efnR&}P~tv>+RmM%G<;jIo!=IyVC9KLaxKNTg_i~LUTeu#qe z{&x33Vb3*Md@W0K%Uru?ZMx4?M3oOlw)D0Jo!RSDciCc^+u#u3^Y_8T-V+#~$Cn2- zK{5)RsFWb0r#2nzTTDZ&DZ-_XtQ6Bd1}VvF`s%W@rp5WTp;vl_#Jm~a^E+5103Lgg z8$P#7G)@Rm694pzAlKWufJi*_*B7ZJcgjO; z;%#xb50=<&Zi%pTcub@k<&OxcCq#@gwB(YyJ>ZB64w-E`QsGe&g14mEVhhT%O7`4t zZE!oE3iApkEkWMarxSeFfxMzlnLRWXoL`0`v_&h6;@)^|#{&h_7ELFi{b6P^pT~WB z&}=11)4v%M_q1Iv1hVN$yQm@Ce^_#*4>!8QTnGXzyf&@`u8!}hhv)P+a~2IB0r%ha zd|Oe@ILtSqbx5P$P~b>N{Mkoo)|9aEu>AkxQQn4GY~H znwLJUQ?c-w)~fO$lKYfs3=txKShWb|H+TY+(tS7)aZ0$tAoOb{YFKZ;l7Y0e3nu?@ zYFbrp?A_Euby%jz3QCU|3KxGiPTx%1=-d!WB~vxwq#5tEa7FZSACczZgCt;dS@#Cw zxEXi9JIE6szpEbU`OUC;+t7P+FHPCu>=o>>@zpi~?R2`N4hW{))mt=dE>HUv(CU{4 z=4WTkQxl$$!J8rb0p1ir#xs4Bu*t2u`8*iV&cZ`g{cKW)&_$y5L~VE-DSN|-IC)X# zTc-I-eQS_XfL=o|NkX3<`B>4c(M3#q2Z1npP8}WW;JMVj|fSUQ?%Ztl*YCI}S zc*Tq@#%lLJ0&?v8_&G=PN+OXSvD+O)_ULDL!JNsNUCs1BdEA>i-VW{gJFpbm&OKL; zl^)9&fuSV7qj}$3O!cxg*WznJw*-&a*nFtHkW_M*6yiyRI9+u>axn`%-`;z-k-Xo0 zRHAiqQ>Yb*Itc+G;yH(*773o&YE%l0WS;SM9MJ4HXMQn2KhXi`1c(N94~Ay_ejzI0 zwgH0782 z*yabk-O1}k!2F!~Le78_Ca-Xk;Srog^)eiRX=> z4tM_sVox9rI|_Aw3np4!g4CjZ-YxVJ(Ny}u(Ht&!5JZWDCV7_bQ7}UR*gTOrh9tBH z%;tdv#$T8j3fpnU5iVqDW_t0$X48*mXOqVbYIC_VKVL!w)A5S5w;7zo_HVz*mjh}U z#+c=ln1eTkr%gUEBnXf4adin>u3B`v2H}VGh4svS9!G#B5f)vEye}sG>N)ov=70~q ze%tq}`Tz*W@;wNSh!`Q}Z=_5^SFt9m31zqL$qdwa^S660ub=Ko?F3Kyh#<63DI?+g z%{zMyb(=jq@`TZPT?w)NkP3p;Xn(nEO|0q`eBOP%3~rl}B>}x!3NQjScR{UeeZg{9 z11W4Kg-d)CX}6pwaEaAv=z{v@UFIi$9e8wl4@On}ft%o@Fsbjy_mXtgoo}&hD6bXw zI+HW-{J=F7Pv89nsF?UJ3G@YWItyxZZS38nh6=t70)_Y)2rFQqI5fi?=h2o|veu%x zEQar7K|JXgp%=dcKV%n`9X0wjXw*v|_qUxCUG?h#h-?MEA5B*IPMLd`bBi0aekYTBSP=U#u{ zx=_CS=ds37iIRX_VI!V{M3{XyZ1&iFHQhuvA-pGBSV{c_%B+TjI@&TEvJ2`4wnlid zXikl=B6vKq)}DcP;K*>{#B(>PRVGL?unj<9K5tuC*^iQbu zVt!`2nUWM5Gz&c?Dk*=!c>JqZZ*QAxFG2tCAmO0%&|Y#iT+Qatk@Iqv=;95XSTm+0 zmWNZC2y73F7MWiBU_b@SGE9)f0^D1ah$Mov83h?G{+)9J#Qr)mr|o^t>*60`v2N;! zTlOUy6R*5(Er2drlAO=~%BpglzY+ZIvGeWuc1`pM=N%aynUvzuKt-n0Go&ns_V?F2 zFHpZ0D=<)wr2m#|u&5}CYgH1H;c~xCxqAjU`@Dtgef6x;k2duY2*Dy>Szu${TJ3!#5qb_m=5x3xywWILDcb z9-+fl$f@(rwmiMk%ZQ388?I824@!F26e4qJ;s2#>5$>n8aH; zgZ@_dHa{RbJ_^hyeNd)U8fzBI-_aD*i=qJE0g%t7qNhM7k`R&{m6+5RDnU7)DAs#l z3k}_?V1{&n=ybKSG=VT9TBsG|Yotd5CE3Dv+}zQ$GUJ19lDu!$e&-EX^(f?_WdB^K z&HwFz*p?q%dJtKX$jFDDErl(sv0B6MdmeZoP5j;Rf@FTKO=bg%SMeeaCuhc=RK^g|(X614tq`ETPed8mj2Sx0No#)%ei z2*!$FCPaJws-jpbK9ljeb|3*)#fcfM?q!poDnw!^B;wGx5A>%AxjHq2Ys3#VNNqLb z;RclHm86r+S~Mu0ZAD36%tP$8{z3H)eep_p+a(lbaiynI)h#l#RPAQ+EWRcDw>Tk6 zjl>(_O28Ue{0;KomSJ8{-oI^b6AygBN7|L`t&!=)6u&EVsFxJ(I+Zdr$ahoN$`6CU z$kN&$KBx~(1PlM;wG~H@F?p?5h;;H-f#HY90e9BJ;6uxkM@!+~8SrgFfPnXl5|R00 zQl(~O0GxGFVl1^4=$iS97&96zZyFgbOeX`B!*Kk^6UL`gD8;9wQO#{0wQ(XkQaDOY z=@{&>H~+x*_$KdYH>!bAuS4vU3Q@jlt>j(EtDZ`9f6(Z`W#@7oAksIDI2-+M0CqV4 zvD4-j2=}g;PBQ?hQ{Ws_^u)llOYW`PJ(1cXS2q6>j4A0WK(6qpngO&Tt=5GQEv zu+7Ox$|(fL4*p9ru&V0QFc8R(dQD)ThyWC|sTDcA?+tL+yx-LCR}$8DM##NsMB9-2 zN0Hs1F8}R!*$&}#C2I6umoMi(+j@qPh6zzeOa8gWSd?hzaoW}7TL`{}yBCW!#Ijr~ ze+^0v2Sm{(|Iq!_Nb)%7A5)V!#=WWPOqs$FJU&f>$>a8fbyCEyT^|F?{jf0Nw)-g( z37<^-9Jo;)_8_C<^kV=@^S*W3vAPV@DDRlf#)0kRoRm4GNawZDhpD4*RG=nC;?@Da~cG@%;cep?x&~1DJ&57jOQq z{@gA>A;#z(P2IL$w7)B56(YCrJoLj}lr8KMww2%VnOtDvv>sJ7(78g&1?xNh0dK3VslxX-mvVWeoXh>5L z_92=5*KB8=bMi-jtk}eD_kTS4`8m8sxr6t~9`cI@dYCKfN~Q8`&{ZjbJbV%YuQ)^fNHT-|E2woMaLN@94MV}J{V-8mri4JNWy#}TeO+gtcPX~cAaS!$iz>91 z`;SQ1zJPTSC+?XN+0wRkMZtpoj!gNG#+m<{SqpBLAQb>WA^B}PA!IDe+m)A0r_EcS zh1?cx6@;s4=qNMuFV#ou08P-e23i!M9`mF`3kK@8ELVBz+k!gffzFS5XN zsd1Xg%LGb8QQX`DtedRNT_bp>nE0{vJTTGTmQ&1FKR!jJ3%1KjwDsdZ*OM#tSG#M| z*F?Q5+LzX3*rMMmKOzwjb4=7~dBwQ0_4kfB1sdI3);~S8-&Nzs*Y9jr zj-@m%@AOOjdDlv2n?10L2^73;7c7AUcMWcGkAUuYE^_cUF!z4HmG+6H@7JtOW~c1t zS;Nl(UN48o^R_M?_shR`V>^3gL)nPOpR$yh%`1Eq%?aaiQ1f zY{^|ba3$_SDVS6cmYUjE1>O-U%Xpz99S|o0GPaQ!jy$uM5E6gw)bI{CGjx1{IB`!A zi7TlAC6?i_Dm5g_Fe=tKM*wo@Up)9PRUS+354GpJ>gRp0yI^mcoQQ#^6*D(!A0035 z$?uDM?{|!c=zmIxdY@GDa`-6cN|pF|CU|Y0SU0bhXh{denJSy{98=q8c0>OtT06@s7cYPtrblG(2%z6DOoP8vE>BFa*ABEWqS zMS}0k-@1cJ7R{jb0dzi$4ad14kGcWVJo?~fP=Q8hSx*58u=EzH+PJqa={5u<81*-p zVF3C6$VkeXnZt3zOnO>F&=TL@)a+krd7lOokVdT-no+{b(xv0zCKEbalSDy31q0uJ500|9gr|vA##6mzOBEiz!1N&+qJHV^)0Mnx z2b$pHFrswr>A(?BaZSOC{7POc6@eMC%2ok6j1C>?550%3*Ry(`^?aBr^Y$z4Xqi`; zhkx%I>ZRv;@$w24hiey|c0T%ba$qm7dS(`hw2kG>LWb-pC*^GzT9uHopX3-P^UPmrG}+Y$33g!uDXHN7i5pLq7VYFm{R8H^!{z4> zaF^H`@)`wJY&BNF8?w0gQp$1TqPI#LZ>fLstFGNK(PFRlYs!1+kZ!&`x*12E;Q8&z zag{hM>NzhwAWD_jJ1*)OVbdmq7@jv|_6#o|Rzk*&V^Vnb6ZIo7&IGOm1)pF9;wiAM zNSPm~1xhW~QpUd=450*jTuJ^bbND5wdT_@C#y;rRl=RYp+jRbL;XPt8@iHfhWB}x7SQV=H*o@t7U23acSnj$fu%kRoZ^%$ zWyBS^gGpe1Iq{FcKPGG_048RIymYoVl1FdQ-rno<8)tf+W;@4uia$r@cxFE1MSGrd z7J4s84CmPN@tM%Z9W+x6{coJYG>~|UqZ=a` zJJx)rR#w>B0pPmNkPlu1_Heec1Yz_}T9ZQk%$;o+S421aO$@^;sR3xY-RRbV4?y`T zsJd}S0o?)_K|Y3hHegXUMi@gmif>svE8RaOn|EEFi>-9^x+OxpWU$+B6}$e4i!a>Q zfTbTzcUDL6pTPY72~1|Ez^suYrE;|bVsH9Wss*Lcj={y|fe2feV$UVVc5j_9>`j!)RAD=U1``P+4Vcd5!~gvqs8C-kEt_{znbwG$d=N( ze4)$$tu*p{7l2k8pd7=&5FQl4Vjl{PWuY?bpn0Z$1Ol9UCib0hQI5CJ$l6$K&YHsi z(u~e(J*69KfvtJLwU^wYE496S3D8>Cz^p_GW)csA_>2e}p29OCq>rgct#H}MfFBX{ z{Na6$^DT90(>J~aM$cAc%T@lVHpSZ3zc13g3nlUxgTUevy8~apC*h1QNjJ^&{1IdN znp1YA#iu`=FmRXnTaV$-_%rP2n~m2g)I@)hI4{pjF?UwA3X3Di`2T#|6jR74F<+x@ zM7qER+UQ@WjK_My*K=89PhR~&S#mXs3|c`aFyEZ`X9T<)E7Wx)r@%SB;(mgT*JvbO zn Wuu0vte3~*k|Ll~qcM_atRbxTf*Z539G$nsW0R4_L<@Xf5mtkUnG!J8B)MohB z?jrcq!4oi1y?%6~+WD`sG50%To;8o=S;0r(g4P0OgoMAnXh0h6=lTBliZefF-e(no zuM3tGmZAp>d0@fliY%*cG~N3bv7-o%t<+gBKa891_vt}ArQKH1@a}TM()J-ZZj4ux zbMK#8?F}ifw02})t{O^@VThBzrnHDw{OnOI3N30VaB^Pv#$9SNz*fM@B1IcdCz0z$ zW2x(t6_7ljO<;7Zf4t(tcInHkIoCV`8OMncix!Sw*+9|9`Z57YSeFRqGTq_)0cOoI z<{)|HSr+B7o;-`pn9m>!7_A3!DJit(`$R=R2fqZ9> z8DwAD?K1{mV~7#7lmM zhBU4_8d>?hdnscADTEVfIKsqM=cwht=mWb%#Bw52?}xl?7q`;F)%Yl8CxIBIg-&4M z`d{gZs48}gIf@e(EP}d)EF$W?E@$)7n}t8h7vf%Zk*>}Pu2ZU(&Ql7xT|x(`2%Gse z{+r!WMQ-9IE=)uK*X94X{xM6dR0J5P3=+?%ZWx!9_q?JdVP^; zIZx%Ag(*zLFvLLZM_*fq{*zV}AE2AW1sRi@D=nHXCrwod zPg|gd9TwK1AAy3lS}xM}X2gRgvj`X@T=UeHW0Uk$&y|wM;TEhl5Qf7DmsyC^U3mxHgXzTbguFZX!L{t8{uuFU-8Y;LUYBy<)NE zLICQ#gAt0bs&Ei=dY}S{f^_+{$)(@ovQF;GH3luk{}($#|6Kvsq6wl;|FvF~I!9Fx zP}Ah)fq66b3zMK4?Z^5GQZz{;(q9t2f~lt&Q9@*meR~n2p(kQ7eMc_M^RZhf3?4ps zR$H<%WqQXv>E(P#3*Ernus%2kl%LVT%0NDn3l9=RYtEZ~`11QY5W9^JIdQ(W(v+he z0OdTlEWU_(fC#qBDeEhJhMM{xvc}}(5wsI&lPo`OMv#oliq3Nr6es2eb4{~G=0rnd za2aUI)fr$0RdKR2G|3h%7%Dg+kX*Z4KKIG;sY+S24A}*hL5Qpf!VdM%U{i=}efyNe z&HA_pyXfj27@M9hfXUT>K2`7ApZb0ov^$Czw46vW9r!uY+w5;3=@-;4>~s+-|R^x!Xd>BhYf~n@gin z+*<1yAT)nw8z#t7pB54WowYc33Ze;dHv!`SxVabV=N4+_oZrS24L6l9^!uNmEyYOOyLL=liv8QF*6TPsSQe zPUY;SSk4dSKc|X0*cnLmM}nnJ{=)>ZHQ=7rN=*^3Fk?y*#*qyx(sUkl$mHzCdh1ejxCa7_7e z@*kUsN{$0s&4D5}UDG+|#Kamz?l?*Joaew@;tnryr~19!@}}EKPO%@AyO5%SjIXWi zSmsRS8oO)&m0v;QExf@Ik0K!nas&s^&=?azyDl!>?=C)oqQ%NV@>&pBw@ym~G?>Sn z4HM1t8kp+3=9Bkz*t_@JKP}3Zs&j|eT*Fuu!c>N;MeJOh@ zI(mW?E7Ei0!U|zi`4(FPo83uFccotW5Z!yxY)b`KSd`X%yG&L-Ochh0qydCe+#MX7 z@HV&#CrRIs?-i-`Jp=;1O7XQ`%&Th*+F|B(&jKvCpkB>>zk_ zvglZg1LL{{`mOmUH3l>WQc1nF4(}bH@DmOBHy5Ck(83yGR4YzKG^#~J^L*eoclkA& z6^K$-aO6_aG=;^)__%!JjSF^cPcw5CG)>5f?Te-Bf`=Z~H2KKwX zQKD7iNqN77_k(GQM@yE>a1h`~p^d9GrZw&PAsb>!L>&2gywh={#)*6z-0cw*v;T&R z84Oj4-!K&4mJu(A`Y}W)m@O-1j7-T%Ss2^hb`;gLdGmn?xtLT`57HsCI-}S}CUs1) zNr}6$Mv1%EA&$7mL5xg5+YmtZdTm>YiVoI1M8Tvk2^N45n0(Q#1{U+2eW(K^6FsSG zMBHDrH!T>pH+H1M>96SedA0l|pwIH;izm9%RpF~OoH$A*AM+7U%qFir?Dpy=RuWpj^0dKT z=f_&+mrM5bTUjCZ=`8 z7H%?+@j?<8e>58*Cg_NHg*M4@3~K-GsgZt}MxKU$+3YX3Ca zZ4TWHLbh5d_25mW-fm6G^k!@QFIAu42@wGwr*6uP_ClhedN@$xpz&an z#pI_h^k&oSZNTU?--nQwWH#5&bPLm@b=&I|u9qb=UtO+3_Gk+-Lhd9Fi-X^yNGTQY|xXl-Le7JN-^6 zAOm63JS2ALt=9W8=cbw%izx2={bR}6K=NGA>4yFzm-bqWVH2g`(prpN6D3K`!`1MI zF-nRDOzCy0uHR7dWYWx2?tY+IU>)WR@u0EYBH`HPwpHkjlaXfT*q6-cTw6N=+WK^2 zP{P`G1h`EU0;K4-@ckalG5dcwn5$|jHAgQPnTOjD6L7u&pa3OIs1wtg5GB<0aCu(U z-ORls%u!|_IvGJbexYF4k=iKjDKt)McLmz%K90g_qt6xxZj${SWIUxL!KlkVZC-&% z(%eOe4-ZsQ0Z3FNc2LxS;etm!e#Pu(axqtJsbCy2{sKnJ!BGHg9h5VnNJ6_2y_y^q zc$_8x^y?2Djq2eFP6+HfVY5X7hde3F3Nzr`U9(iV78Lo9$~FTGwSrtApd2F`A7ChDOlBxWE!>_ievJ;-i~iYI zjN@7tH2|jxkBGPu0+b4TMh>iG88c1X3b!Vf@yvO$hc!X)L>ho1nYaKyyE;4~?3eM+ zU?@}$Lk&ay(RJj@M(L1*2hl4J-X=@~(!o?kc$_95mWxCuMwn86LEyw|9@aU;KDZ}N z+(KxT{@|WZ%M?^Vx}aM7^j!CYJIFqG)1i>N(LUJp^5f3lj+3(*D;!XgQ@`(ov$9fa zSCt^xUe$5Wg`H9OE(^WNhQm~1A3a9lRvsmTh8D!?hR(Gi$ET%HH9(z(on#vGVn(50 zjzbFq)SEFu2co438fFnD(-@l3s}!V7^J-?3*v`ODPRE91cr7=U%}g?JU*;~r4`g}oZ00fTK!YL~tI1ehD|`p2(_UY{85-Jr?3vHn zq&3>Syh&@h+Ek1E`6iS$jccT%#BA}k@Gs=G_!ak#wH3d~wL#gBrS(P}_uMIB*g{@T z{QF(9R!oQ~2+xH3HGmC}cuI@pr3U}RG&a>38Ysxby|2Sm_T1Khb@`snmImBE^DVpA zfL4I#Yv^xPWi~IfO3jE}c8%{LpJ~qSpO3*i8V?yV1q`d0=+Zpl2be}&jcR_6k?rYO zmK@XEBKcNBh`XeGiiF!pmfS#?WE*?u&#jD+pM~%0OX;KYOHF_rvIh^By3?p!@OXIgKDFie4JAZ4v9o)2OSx$TR^2a~$j%W-#(CDT}s1e=IEuX%# zEt-kp)mz#I#aL7xfR5QZO%1fJ_$l$da#ML>-tX+6(h2%7CHv-UOg&f!tfcbWUOF{#TG-_r zjxavA2?`57w9zW63BUZ3aBti5C9cAYt;EYvC;{jh>c_+evO6mMjn#UoS>+#{ zYS>Z@ykO8g1++#jsE59=mD~++5pc_vbBgmBy`FBC*EjbaaCQ#QXI^NDyucNAWiLI$ zWNxbz0uSxF#MNhHIb{dCrjBplutnxl-3q?f7$_a-!n$qU2e0xhE1VFkHRpJShbQM6PP;|W^E1M6b8^~X$=Dyy&aWTLryHAPaW|qYYrtKj3eh<10 zjWeUPcQ0M@I-Hn5|2L_HF2zISk5mvTL>#e=VoJIGB4h*e#fN$1bE^RUK+XI!+%Kq< z~Gd4+!BOJ;?hrKQcnm+#{B3p9Q4jUvAdm41?ILK?f0bxv5vls* zs!`JxbEc4A7?MswkaN~YJd9J_0}A$_CJXk!yj>APq8=b8>d|OAiZ!Q9c#yPu-cz~u zO^hBulDFVWmnhb*Q|v>RdJk(#IqPVIE>#7+=q5Y2p|#*H`Alc|w7#7lDEMRVQHg3x~~X!^ZGQ46{qc)gMZ>P^tcvq*fA)VU`( z)3w^Pcki)q_B-D;R~NqWKO5V6va^5QLzQ`dq6)Ukv=*Lo)tt(pOOW*Q?e=> zg+0YoPNwRm=9Aib)CO)tBjvI0ghsC%C{}_?Ri5WuNS+Tt0NGiXTWppPn4}|v>!VgH zI&a0D-O8Npu-EO?6Mah3C;}lePF_!5uqAbT25n}cvopsz2drs{|K+8!Q`YYC@vkMp z0R9PC%iq0HYy@A9mtUjEYyCg;@R6D);uJ6ixk7$c$9$?rru~OuikZRQ?Wg21?`&p$ z^!tO%NjGZqjrpKyza9v(LgZqx= z;0*J|veew-q8@Sdx_I&eZ3hN&8xVEXQ^K#c8$FJbw_9ye-xtC`9XOi9n zDU%AL-v#oV9&h#ewLIP$PEm5kjl4_fznIZ$kON=B;W3~1FNaY$@=UQD$CwT>uMJRP z^y=EtOuyzHk?lgLpTdl|a`BVhi_(R_gFpPkxg~zj>Fi>TE2w^!;S-cAQsoNLmq0eF zu88PoeAetPONG^x`h2}A5F<{jSEFaAs09ys()TZ%ISZp0X7?a=#*58wR7%`c&Si0M z28!uAmtfu^MWW_>1Zswb>_S|K2Zp~{b#Ns)`#t{JQ~Xb{&1=dPD5S%6sK>{UTP z%_e-xcnJ?Lqx$Hd;^=8OI+s~=ba~)#5AX|%3ohlO!kGz$)1SQO@iZ+AbS#Ki4HG$1 zu74hA<O;%jj+e-z4tl>FLccP89nJeioaeRU3@8PKaZK$dp>Oc3uB^M z5LRwyrvYm?;wK&ie_45o#|E`8Z6*}giS-NLAFeUR3zSQ9tpj*Kd%t7eU{XM}`L!-V zYyW_#`y~){7tZHER!&s4rvFX(FRApXfzpF72JU)3upGgFHy&FD@P#lj47Hnjm2~mn zm}KR-SGA9?cK~XmwwqGDntz|bCxctTo8C!(+(JQ*>vXgwhy$8QXsMPcw23LZPhCsh z)gp2Qj;LspY8b^~kqv`ax)j|&0U^{W;1ZzaU7yT3s?mp8@s(RCjfdiySuoJq1>T2WSl=rna~+1o&GjPXC!yr29vTczHq!JN)c$xa#Q{ zX!mf?7ez=gBzaT?&?i!Y4R@2Th{M*Ly9dJ5!abNaCF>MrIJ)idgQy7ckR(|_Z@Tzk z5xQD=T|mKI*sV#X*OF5IbjUcmjd6&Lq2e60dc?go82b|kb#n#Cb(#)V*9kuf(P^w$ zEDNYOq&{PYQ02aU-lS(BYzqFYO6Vjw->S-xn62E9GoQo7;v#@*6FkkanZlptuEP_O zf}akEVTC#2P~RNXQ@|5LUv!${W<{*=@i!5lQMn@78txb;@4qB%o*3HlACY0>*m8mi zVIH$4q(Mb<$r#0>kL5eWPQ$!t1qc?#ZtfST+dEP;74zPy zMNt7Dc3?jh?V2HAMPmQs$t%)xz}KT@vrU~7nZnmJF}RUKvp{KtIKLDE{?h)<>QH}a ziOj6p5Gua3sb?q6hcj&N`~5koZ+-jV!8N*Gh?GA*NqZ?~vldW;!_<^5>Lz{ejP~bX zdmVa^a!v_#@EA65U3wFi1yI!QvI33+Eh1qt2~{xJ^VhJxao_rS7N3+R6(1&)CEse( zp$0Mfqa(4R7PMq{oukU$FpT}e@8+>mv)pcfU}n%^F6xhwC1BfO;1VXS)p@j}Iex#=?c8_8+RCeuiBNXyf6tAhSvT2JF$cR18&Ozlt>4 zIl;IyKoaR5{I5mmpL2G$b6-JrG=28&=)M!%ISGlEUv^Q+80*Q1_1%@}!ycZ44YyTV zQL9=r@CwDw()UBZZ08+^9J8pN>lIRTfuHOCEnGJh_o>Z|??kd}=zY(@$kSKE7_MMfd&xw;tpy9pxPwYje*^@+%FInnY>WqPQg57S|*j; z-UiZ(!qWRnBw0CxG;y{;OE&3C3@sp`6B=m@iS{`TB`N7H{k$DcmEH7yIo_dPix!}g zG=WDA|8ggaJxaYeutB70dyKWl{A64Ooy^x*!Kz(C(y8YR>ZxxJgHQ=TC_nr}0u`1h z$k89-ipkyubRg-Y2HDn=1-Vfm)ml2CC||Has42d72o7b;DV1RoPed42J82m@Yh*qI zj^uP<@VVPiLY4;fvs?b@5AhXG>KGK~b}gqn@1f54LhAa~OeKHQktPPUd!x@P5*~Jj zVzbh_ARdhV-C9Y@TXN17`nG=^=gea3eJ_RMT&gz|YXI6!feQ)~rOjw@dWzR*GkDoqyE^z% zSlk1$!2Kt>@XO?!Y8f^OE7DQnB0<(CQ-*RXSVa);{w6Sqbto=v*M1@0WEA$q2za+) zMQeCMb#t9;))!?5$aappDq`W@>7sIfzNl2*{k28r^d%g4!$EKffC-WlW=ZSKR`#m3 z+ncWKlU!Oa%yDir?q88KtHvEqSoJvS6EfU-4DJ+)w|zsco&Y*);c4@T)b;H_(u+z;Vdp2rZe?S|w#j*|iM z0F+yLQlYnvsFvJm0KeNR%m7>@Dq`LT&>NBdn%^D8=gov}?@q<7;npmG9z&Y9Nre(Q^$M-i3A8yDwOs+B}n#(cs5%-g1 z8_R5||9Ac)PbrRrB`db5tv~NiiG-CfhfJ4g6q8B}u!UZt`U^Zwq;r|&q{-oM=OVl$+Z zC~4D}TpG<6O#|%%M1jtDr4xXswa2bunStHC2jKqG?+^+>f5Tj*#r9b`uI`)fl)nGJ zm)wdm+^}-mL9cy&0P+K!&~V=$tT7B<6Tq6{#zZ4o2D>h6)9mpaSJh6MtWr^HzFNCV zc%2gN^vZ-t1V1I!+K4WQiX*@6184ue(UUbqJD|JFAwWN{yZ)D7e?Ix{G?oKnW=UR{ zo?etwv!XL-llvx^HcALlUNr&acyTr8?Wy~^%7g&&=wYFevNDC+qPyr+}k+O1EGfe{ehX% zp>M<Cbm-(shNV;6jN-TMQW z3{v8`uP8c_dIg~Fy2WMaCnqnRV+G%g3*SB|lV3TTIJp)am_T1!ID8B`Z7=VOv&{O1 zs92jNVT*1?;e5bRJ_@D!alk3aYix9B;O z@z)kTY3v{8L<%rltb;f;c<5?AmeSVHHjR1O6Ps0OZ}WV#mL0GgDW@=1r_cD)f`^7G z<~ghq(u8{Wj_!>Q3gz4a@dJ;PSxJlQFDrHV9!4ZhC%dBGDP#yBPrpb+5e8DmVf)=b?AjL!N)E% zzhm#eKHTU#vaW7IZ`1IAbK=8bx_Vz0R&>7H7(X42n|)UhosXb!*bo?uOGg>;j>=FN zEu2_KKuQmIxLey+@v}IbeEBK&?fts*d?m$*I0`XQ7y}+ht~n-b;H+qDK=tPF4gT?V%laHcTQ=CQx$(*6#r5ijJ;&ha=s2&bX?dilwRv%CAB(f*S;unya{A&gZ>qt| z+e{Q}ZXq&C`nU=rGpL2+ZDK{y)wkmB=NLMi$_`)A#Y<6}6^n#l7WK{tfP6Z5W?ADT3xlZKNi(rUUk>%{POs?)#^VxlRPuw;NH1&Ek``cui!prej>{M+Wp>jKXeHjDx(v`)13}yKes&>(;@YG3d$8{iaV{(=AU| zcgfGlHrYaQ);{0ryUr(GGCW-Nh&3|uRF*&43(mp0Y)Xo2fA+~m9)F3pw6?6C*_7?v zVw?1Z|MqzZ{I>W@t}%ft)YL!(z0a!#a%(HyDXp?08W}4mhzmgxA``TUDIPZ5NW)U5 zFCAs)t-*w``CctwP4w+jF(j6x7yA+_4Iz#nHlx`=n~24&K_}HNuUInBICj+pkKkr9(-?DeMs9&iZu)oa!7y6tA_d_a274Q9**< zvP6>e>5x}xN2S*WI&I1?)XiE$lm0x>B^>S@7o2yVG13^(IAGFNasq1u z3XG-=kKNr*Y_LJ^BGD3H;{gQ3@2mwwSE|ro1)RnGzXH0)hvT@tGjo?op3UBnau7*k zi|FL6{BQBvU&Yg)?rp_YongTiiIYaL-S4bie;qB5ratxmNOwpNNLQEof2BL2oBOKe z2ZiwC2$(}u#=}8@CPG|9aoHF>-V+^_!nZ2Bor&COE}SW`k;44Dd+Rm`((J>%Ugmh5 zd|45Vy|4_K;Cd4}zH5ojC>xq`c8hB0NRg?4y zY7QFI7_V~W;{T6asu7NU@4ipPp2<&?`XKIza!z~P{AbEDPF1en()c5Daaa`Xk!jbCoqJ^Qf~S1g+a4dz5qbE*Vd(G#h7O< zlbqrNby!x|NKqW~fW%GdL3Hj75dvkPaNOxWo0M$Dj}8aD)48Ba7gfF>P2f9*grL4! z0<+WTpL|2l~!l z^gOhC2O66gneD2?>PF%tIFRp@Uhf=v9^Io*wZPdu+W>sn1Z|||%1x^#PHh0wyb6!{iu$f0i$DBzsGYvsjO<%3;{ z7k9j3kt`6A9y#tTg~Z{}>FxX%cAgrqw}tqFTBDT0JODgA%>M@-7W9u?C=Mx~|9$lq z$B#>@?)+Z}iRq)SsLbV+j{D151@`YKJ;k#6*7EyU?yIxf6JXrEZ)Vf~k)hg@*~h{% zRnH4lmgoawaY-+tbd-ABze@ED{Z)aFY_r4zS|-_t`n|;S$E!UFX`D&i&Hrm0)|%b` zgldRDZEyeJGa{Yht(kgk?2JLLPh?w6iD9hVP-1)U{VZ_;S9ok?8Yi0KUq44k=2yPM zq4d_s3eGOlV38#hP+K&ww9{;QdzYQsa^@2er_QI*lgSMuOM#vcYp;Sd@vCkwBb`K0}*9vKdr0q{~ZxIr^+CxI4WudUqL^Km?wJ`cwk$=5imUu!*C`+THm1c^L~Gu zOGE(E)$AYvh6#+l%HgCm!vwWS^UVNC)9;0}q}4Qco{j&%1roGS&@@EmTbSi!FA*&N zG?(Y}A6KN69bE)|m4>Jf3`o0l)Z}|kT38IFAb{qoRtb0#D%Dis2 zCO6>m?)9o|zV8qS`Qky1!&s1f>v7oph%{n0bvb9%(!2HqAUH#Q z_kxMl=Nb)*xc`E;h!4?rHFUYj&4kPg|ExvH4F%4loNrd({LCKf<;b4;_G+jvwLR|c z#MNnYH;R2W2!$P0IKK5$HVBCsHea$?q#r8s>_|(oh~86Ft2*kZv4vG|)&SmBFC~_e zuo{Opy{EU5MOwXvtzTMT2BJN9l50vZ7b`=83Sy}@o^+zEsBC3H`Z;V)(`Kh@ZGClq z9H7*b$9w(i?7+mY&hA!Emov(_CuGLhu+T~YrqC&)IwZF&i z{zjjATsKr-4F~*RhI0}H%d}I?iEd%K{OVST!e_NgwfO$O12vIKgQ`;-IVX2V2_*Su zqMFW%&9QMgG73leQQV&8uW3A5W>iQS0_rvPFHoM6^S}qG4Sv(gm-&cp8pIfqqCcYZzvVwWBMglbd zJrK{N^+==ff1H8Fe>(#(aZiKsKOVi3$Yc4LW30*^#?iw`L{))TL+y+1s+=YS3^iy2 zLRh%(MbykK9jV>4Pi{s)6bCF284Kiff!Zru-vJ90w$a`BYCq+epuJ|}gVRezggBDg z*A-g3)wAJ@s_wa^XC-@hS7Y68s~yGN^uKXe1K{q}<@EesSV5d%W=R68V~BQ^F8YIW zbDmGvkK&a{MRnmVKc9U0h>CKzzJFKOgk=D}xk)=8mdpi$+E@D=sE`NwyaM!95iG1a zt^1euaw-d1kC(1!i{hJyPi)GoEf|&;rM9B_LJNeMBrTKDf*Y*fhQR*(&#YcsOaa~Y ztbdLI9l`9M*$WYMV09fWU z!xhNi{^eWDIttgTliG+(OWL@iXli;W#cFeA$}PY@mGgW9m(?*eGO)MbkjH?2WxPw zJzN#|8?x_yq7|ULUH~o_qQp479?%MJh6H@PdHQ*y!%X_3{(NKEm3QLdo2U%xpBX%> zxpB3Wb;c#7){%LGq2>fbO5G(-h_NA;m-Bq|XsI%$Twdp{QCB*3w7fNQZR`pG=Y_Yq zL2U9~m}f^kKUADOwq^||gWdfP!5S~kjVpR!ZIUpb%q+B#cJjDCrE%jGOF}$2cIL!7 zV#5O?JFE8go$(K8N6W`AVV)3Sl^fQVWDBPBH%-g?6pIJTPa4N-n>Hw-#wC`sMmyI3 z?3%}OTNR<`EPB{xR>or(WZxM-1*%&TemZE-orY``SR0JzyDok)E~&UE^%w&*9aToj z#Hu&|s~M%hrp1aF7Nl`vP^bSeRi|t=RewQ5QAg1j(spde)>V7&pRH@)8t-$}_o9oz zA)F`jUf0qbRf;&n$O)FynFN)UyNN?J&%nPWLyXq@D0=Q2LknlryVbvt zAzdNoF`m^a&KZ~SbSYF+X+uIP3s1dg6IY)3!v1NKi)iqH%I=?C^~D%8(IpZ+`#U*j zavC+7a9KF6WT);#)X$q#c(lG^>(&8gvM(>o$fhet1|9!cL1~#1UE2#hRaVRpJrf9IYTKM^A#thA5&OqInczP=(3CT@VxqKseOfkt#w}ApG zhi@(eohhxDqFHTvCn~Kw(IdIJZc35k;fT=u$N-M6iJ)G~dl+1)T%SEm_OJd;jjgQ< zj{5=CR9zFk8nIgZwTZ_n{;ADj6WL53d4~Ta9Fg?Kb?68BB4Vtu9?m#d?N%m#oT~x3 zFf`~#Qb@sF+p%|!Jx5RNl-@MO=K)zzcjXY$>FKx0Qg3!XCt+8>ZuwC5>-BpDOi{)` zxA&OjuK=>G7jL3x&PrNkRowfShqNwxcZ$x=GPRz^Ja!FlA;et!lg90-(r=qLJ$L@Xf_oey(Ojp=#8a0e(gW?GFSmxhe zjY}D37&(gLQNev$gOv-Qv#`LCC~rBw8T-pnwkgD{hi*okNwbhz3=r> z>LFSzgIiqzOCIfnE2}+rUC>ucq&Ji0kUqm@`(Z?EeAv%7IVmIofA?@F0Uts+DfKR$;ycWj5 zW*`J?25ZSuP*h`<&gxut>3Cnx#y_6oe63a~%3i+J^Uo(7jP}QNqO1B#NU}%I_3vf% z^NycAU7c%Q@`~LxpnX@?4?l5AcbZnWmjpG_b76>xso!I`r=Jty#UO$MvyQIj9!gRF z^_uJmF(?mf{R+C^SJt@Eps?#4eaS0rYGHePyqi(H(J_DUd|15pt7~j+xt+VSl=94E z<2msY2>QX;a`6;0B}pN8&e!FqDo%7e*hhTp}gy4C16eTE*pXFzA2i_M(mI-aRmp ze*RO}avNiTa!&KPDx)VXzz@*tg2bx0gz)np$xg^Y`huvfG z>e6x;MJC25+AW0J;>aIdUA8`ncQO>HC((G5uXf+`FvuyNMlK;a`oQH$;^zV5`i!27 zl#!=pCHr6K+X`~jToAA7`RWQkozW>zgwn6UGq+gJXA#}gOH7~xY$x?Qs`z?_mwngU z<_{0n7hCH=PcdU*_%d|8S>{KiW<~#2WIL6w!5LwRzl*Pz+8ra$xqFWBpcca6@#G(T zT+IAKvDyYh?mOnTi%GjTm;Dwrc7Pe(Mv@^p`ce1E#JtYPZ}j{_HpP=~8kYa+$CtG1 zmqr6mhu^xEV2t-POgWn>f;>21%so8EnN0hE)yrpomz-JROBY-eu5q%977@TX#dxOBhm6qThl zW6K3?3XhB0LOeUBe+P%g1i(W~wGZZ5@bHrp7wc5pazVUw8pF1PbA^F;?O(TC16|;R z&&i!Fe2SM>S07{H-PqEwpjYmPk=GliZkmlj66dyKEA|^J&w40rVW!Ngc#C-OYC2a( zj}YR$hDBv)*|PX;7}9RS+{B(@X}U0?-{QB$BQ&U9tS#8ET57t2gmU?d$lnWK{!!jKfT#mcMXmUuf8c!69wlIcL zc;0~Qn!Fm&bguOv+@l*Z6$wOYnCeyExqBJNOnXFWQh7q5W7L< zDb&x4R%xPom)?QJUTav^60zxtF@O|ryjn<536%or&5~OM9V2u3$ zP|vp+tk}K?{TAN%_x-?}+@2`2JYIzW4^bFXF{F+}gch6ISuVQDsOPs)i(Jmq%0Mtx zveqQ&Y*zQ)ks9E(3Zps^ngM|BToA+8}Iumex;vCfMe98uSts6!t=v>@J z#AAHmEb?d7WtR*wY71f9Dm|T@?vUdthcN1n<$uWw&hRn}gC9?6xTB-5hCiCyuyMKC zOQU{!{OWm?wnJUNZGuS@NJ1SO-7l8X-{XlZaQA3;WAS|Q_K?U~1`I~4GJdY6o$pX>$=7be{~XKvUAO}^oxi-8a#Q6`J< zz6%ZMb!ugPqzbl>UrbQ{6>ogdnav*lrrpfE+W0}2Ss=q4x_8ZDQ}aXj5Z;hxPw|h844VlBq>57h!H19&MHX>*Ygb< zkCt?C5FSAc0IwjDZSu>zkNV#VCzSmDj%aya+y7Q%XkYD$1K$b+W4>r-oebpQ6KZ;n z3ycQo2^++dJa{SS>4bj$in?mrHHvY6>XK+CPYBmkKj=?*7_dr-;nv@jjMAjF9U3|D zQ0Q+^FgLRA!;>QPOqeNx>}pD*!@_!Cdzgjt%%v;1ix<1bPJZ{_A@}A+=rVtp^J@RE zc@2BCzYA#hd>Py`vZH=o*ZA4KI6~6do&@%b8T>gL!ys=*1wDT$ek-#-1dnZro{mq? ztlO{*;-nV|tMrMU)i$WXvZ+#p@$+#tlSARe!3M$IvIlipU4+T6u>%cfdE zM38}9R9yotT0UhxyE!IeAQ5G3P`^&HY==kYZc{>dWAaHYg{a<1x(3xC%8uvdJDx~# z17!ZA&8+otsd409IyV%}8BzGEA__Psw#;5vf|)YgCw*txvwlyLM#`wZ*PU8ORp@Io zE%Ih&u*`?rX~>{o=+m%LBjS1+UVLpXFVau>E*jaSD47KMJ@tNl_AZTEEo*R$YM;is zFwa{xY+=8UAW9c{MDbeFH`=3DTq-K=6!`DH7zwhVp>+TuM1l95C;(%SARxK9xPy&X z<#$Dd9PHt!HX($A3=OeAQYfR`p2i|Fdok;sybJzHzlH_3UF+$c1~+{7;` z7hD;Vc=^=C@x%nBq^e@IF3e7DDZ&Jb?rQEg;mzEY*?l3!#{abg6R0^n8e%%1Mbjqb0t=sZe%laG`a z>5zTS5mS0RE5gohuQG6pLv@~@$Ip1JINOkO{ESI{;z7l6dd(fZhc3HVPS zf?1c{`ynkEQu|pxq3RW)0Lr>q%~5P1($;<^j0j&3cYu=lPz|Fo_TIQ}7Dq?xvMq1u znjNd&YZfPg8OOo3jK<0e7p89fC$U=0>N>C=u5q!&0v8=v`4B1?~POdH!h&Rb%WC_A?zWIPQ+--3Wh(3EJ2x zM91=148;6yfh(Los3oS!Kx|m|Fwh1Svav+&eOS|_4(>iO62wAQ7H(ybX@RRlz7I_Q z*y3e}^})>>G6?r<$5u)|cYgh@-07V?4_dyya2>MjciEQrcJcpsR&!U+LUb&@#&Gbd zB5#jNp`;ldz;HUF0`ta>yYM(fW$^LWiKYzMhye*fZ*$3@Z&=AK&&Q~Bg`>mY>Im8B z#XcLc)%kmN&QyB@e2EMxH93?0lq^vnYTiR^;v+mOiASXy<_zCGOh?wADkd;GUdfQ1 z;@3HDB$$PyEC9^69!?TD^RXI5V{F{0FAP)Xt~2^cca+V&h8Vg}@*aR>=M1OI&muXh zC5dX|n9996thiR+{tB}nSk?=vu+(any@K4BJl{eE@lT799kW-1`bbujyR-ti;eiWM z_KdSRq>{VqE8z^wD(PSD(i{=1BZyY2)@I6pgu~ad3_#WEWpUi_Kjo6iy=Ppw5HX$5 zM!ts!sj-!v(_5>$Dk3=DA)#L~No#5h*cb^`huSPH)Q%3+?qNcA;o_=QT*Om6UK0<2 z>)oZ6wJ;6a*kiFHgkXT2{iRgfqRq=;!oIgz(t*i@2X|jvC_Jw^gX%)Pd$L=WGrT6067r3P5 zY|Sqb4Y#M9V{MJ~#Rpg6`@M9sE-K94&zL{deBo56#%`UtPz4skr*xwb#>(<&%c}bw z&%0i-tkigwa0HLfO&40lDLq0uHc+ukWW*i)9K%=vZpUm^n;+#___ydHv*Ca^^~UP(OZl zrC%5f+3Nd6jb0jo4ZSx%w+DtIb6H2hq^n;FhfJ79`JgFgcC_rk69`+ZGHvCLsFhPQBc+8&=2b2)czH7Wr!Zhu7M9Pc9)H!K=rC$kS1pd4rF zklQ1(cUnXFPm+#7sXfXKCE*((Y@Zv-jc~{bvxfKQt)S%)Z&y9x4+wz$w!e3aV73DM z8AI<0_3Z~XOhp765_2F`e8c;(lBCnoJmRUSep0}naa9Vo&yx&N>d4^5MWp{jCK3)@ z0D{}hM69m_b^2m0H{A`vgL6S}Kjjg0-||a+=NTi)!ZV3FyZV5oh~Pk?4}6lyp+_I3 z&yxx>U`j3A{VLHZ{r>v>8$w4P zWlTrJYZRUb3o3A~aA)ih4j8=Y>%Sb8dtvSNg~i0%`OdZ_=JCMC+?)=j%pwl}4^Fyi zUW71De7Dw{%ZrhL4Fl(MpPI(Ddxz>K-KPn?%V6-8mUV9I@v)JC6_B^gILlwl$T%v2 zN!-<@=+j}!6ecVB*Qx`H`~DmWbz7UFmcjckmPeexTNZ7mZN*K-w@(mxD9g}x4GImL z1uIM;*^oZ==&+Z9jKP>S?B}8h9NK{*6YYhxx~Br?tLvG8jVn>^m)f0Z#TxO+^|EgW z|7k1m#HU=Ix>A;iRnm%Awk`ipZse64-(O z>=MS=f?B~MZCP!9vkN`$zExG^{)PW3Z)%kE*F*#@c``1Zu6xcSp2wW^F>}KJ&v>d@z*Dw+57S^i;c$3= z>U#B{zj&POgM_gfMzORQukmv8Bf`tm_2o`3>)=Ut@MC{C!akKwdU=`r0scq-3-)#K zG}GH3%Do%!a${s565MMJRSbXaV-2yM?&*Un=EpAa9u;W37d$rSXWXt{URt+A2CJ#A zbu0zn{+QtztqVF^_8J9RO;t=Q?P61L4g+N(Xjppw;^co34i2LL@%ZTdZ8?i|<2!n; zT;B52_}9?VaPQ;o?s{Q#we977@zbiydc$t^Q~ahvh>GLUjgeyQ{ECg}VIv~JSV;<5 z`3q!u*}(TU=hGQ}QM!jnu3Gi<;f{T+dz1eOSOd?$=kB7kLURLJJKimbT{hEuAEw3# z*pwZ~oO(cdhJB!TtwkC|n+wZ9(^#8-!$wJ;7H_Aq%Uh(uKV7~;2;SK*K+Oqc!%My| z2TCBoE5_QbFYFvfk;Uy}=G)>txWHpIgkQD|q)11lDu{@DijCOmklV>m&4)Ymwg33Z zEEZ`!U0mC_p8uy5M%hnL_z>4){2h<_{qnDGq#vMNK-P5JOjiZgcsqzK_Z_TDHkBlg z^)gSgo$lB?Yo|m4tlsM}E|qcjGdc;*_{@djZ6$Ko+{|KDuTCDL!~BtmyJ&TmEyNs= z*!10@;hUh^`ss(K6AkyY(u)1N;k@|l0tElX<-=nL-Gmyx*CUTm|GJ=GYs1sUQJV(4 zpHHKgETHJEi{t0VIXy`K3dX7kk>6BHWX_kLth}6F^O4-p;`FYCajA+_qiz_^$`K|9 z=H`dJt?CzTTcwqk%OK~P91PSr9;Q}3_fIw3r{VZ&XW7XGXa(pd-c`{xaASz1ZG9%Z zxkgtugnl;Fr>=BYznV(xjM)5NhB#QkJ4%L{LgFb#?TCrp96zGlTKB(x2fBszeU|(n z77v7GLgj>+2=FO3-;NN4_m>Z29HU>US~NlP zwcv?mB5~rK)P#SN_pjSt=NlgaNdWn&;*L{%#(q0~bpUry(31LII-n z(StTxxqw=oI<9ekKJAxpBoz? z`UZLNNKrd;5>v*SPLUiPo}yhq;E$zi493{_k@F$;UtDM&l#>o#Rh=e~RmV)f5bDrV-B~46LJNuSXbkU6@~>(M6o1h5kB4 z+Y)GKsBgsFTqrsuA$mA{xbU=XT(CNvc*@_4_`GW*D4(BhCEt-Bx==~gr8=Xq)g@7i zs#Dy;e&vzRi(rN8g8ru@cXN3QNkksuiv!HY4+&_s*i4+by2hhzPNg*68%{>E++(&u zLTy?^SascyY?wcQ(tiioiK2cH8;-?n_!^5s!&B3)ZS$V&tEvQZDM2_mKk~=7Rw5Y8 z`LYeR6by2A4Aj=5j6^$I*9~Eoa$;ki$b1eHZ!X>dXoZwfstwwj(bo~wA0W;!Exoha zGi}ri&m}r@?_I|?aMkr;07|03BDoA~z4-sI_195ReQ(?VI+V0@ql|QSiZqC%0y0B)NrTcUEiGMwNQrbeNDL{6 zAYIbk-FNf-y?5RBUF-gJmdjzzoO7Q2#3%N#d2)t+NiTX48vg3c4ojLBI@CiS!4wvU zQ+TEE>QU~5h`xOYB7JI+c6&(zbDEu-u=C>grT5k zUz)jnGIK{nyVaQnAswKpvA6v)1{06t1m8 znOzo`ka_AS^Tbbv#;@~*Z%*iMp@rDkdJE;*Mn$J0y^Fjo*G2w_fwH_%4|x_0r)A!? zf|)&ZChKTvmT$i}gb2P;FGQ+0O-l^V6P{MQo(~)B^HcdU&B0G~^~5fx*nUc*srA!8 z*H#Az;+Ou5Zpo&Hl8jI$TM zB7KP=&?ZeWtl;< zSMAl|?l!zEvt?DGd;YJ{vxtt(vOYYJiS^1q~QER zhmg{A!+w`v>Ck!Uszu|L{4Z+)i~w6~zGOrt=5u2St<<02z0v2XKw#El|j@hkSX8&fW4qswFm70C)m7WiP=S1JjxoK55{m zkmwM-31IH;FTrG%Uu%jCW^8{GAoGDs^kRz|2(Zd8U!n@X;iDk^opit%SjF_=lrQpV z&ZMS@L6xH0;M>oH^^`3Ik*AQi&b6)y zODV>7gb+`4;8-)KRHZur|(nOI))aI?dkK!6Ks_z^eoMD9p{dKF#&=w^9ypxU%yT%`a^=-I4sR3XDZEpx>iY; z(U~ppU>394d}FE-mw8Rdp!?!%Ybc7hW)hV5a z+P={p8vcnAyWfXY{__fA!Uxg%jq@jZ5Z_L}=Gs`=@@W$XvgFqlRb-=98swmSB<{>W zvCz_^^UJ2ebP|Zs@*}B1R0vrbmubJ#zGf&R@=qK$)UZ@+$yg2~{|s|vq}XGr z1IUV(Glbny*?$rTGJgD~+7wSt7cTCXGVHfH$B7@ngv7n@5=nX#LjL=Z_RZehwva-# z7ryQ5Vf*Ypo|lvbF9G(n%iBx>wcy;9tVNx6TEmhR9pY;T3f#Uwr9btNO!%zeza9QW z-;&y`9-UufesL{a@Wb2n*L(5F^)d+?Kka3cdvxgPd{eyT_4Q3$edy37X&R$x{b3zF zbsEMwuO2!0>T~ebdrlMd&^@PQnuFP8FXve{M^o^V_cWV?rRq#4WOU){zA3}0(u;ES z=qJ+(vjcTv{=@uxALTI;ygch}*Vl>XYmlk8Irzo8-@G4fejnsUAqWP|WH+cT^1d(? z>e3TS`+pt)D07D!1wtw)nu{zWt$Mn{YD;f!xwGfMZj+LKzjQTuJD_5yEbEWZW!UeZ zJ10b_Zjh*F&ime6aT}jB(N8xvUUUWx@i%h@NPpc|l{Riw0gp7Bdy^n~mCdrQ ztwgnybA8v3sml|4FqL2v2d-gmMT`IIK;1v30UvdW5Zar{f{!W^ii#)I%7osI%!L*< z=x-$ECMW6&uTBg;oeLsO?O&0DVxTT5;QtcR0(Sjn3yYWU9Kvc>B$%O3yHgX@@jkR~J{UhZ?D`U=R((?`CaL^PtHEL8%|FF^59` zAn?0XPR#nh`uBv2Cf+jXphD@ocOADC&=D+RkX}oqHjM)j~d0lC8xKnLZ4; zBtRc!C8gA=xovgZn_u!p6KUGxmMmrKUE*^=Q!Cn?e#dwIDPdzcveLFrt~lm%)0hQO z&UP0vNfrU`wE@_s>-}1~9@jHkxUQcwDMiR|d6u$?OIBZ?1vWyJ+Jeu zX66^HK)|H^bIIAur)6fY*mpko{;suYxdG9@+=%x1vuaAq-~y5D;e_{<^fqt+wBLJiqNUe>q4IuX(BUbDoeAO zBcVmG&ii?1@t_uK?GhR4<-+CvX7TbhZDth5So<==oiZQEDBZQLcv*Mq>4tSP^w%Xc zG32xL52lYfwMMl({#F{MuT<3B|G~9z5qa#!oKivR0_ItV`U*c!7cB>+_cL70zEFXC z=czfJd&sFukTHeoBQRKjdKkjik2%x}EjHB6(PdMCx+zg~UlKJ!`?&!$sd|Q;fdeHi z{j+sR+BI1RwZ*{tCQC` z3$B5Z&(&@8pWeNK#5rY9MT-Zaq;)HKP~eVV0Wm38F`nBKiJ3t1{=8 z&=YW8twBQlvb&0zTN{Sit&_d2V*~HAbFQYQGCX!0k8lotwyTzJpNFbb*Mr|EUR;Y~R+w!K{>;p$dL#AF;v^OJwtg^NA0 zn%E$+!*3z0BVxbr?J*i2VJLj61?xE9mfFB{we5S+{J5gXs99_A+f@^IT)@ww69cqZ zXm}}BrC+S+mig*-sqRJh_1qbqk7?mI^@(7MUdP94E=3nbl>nnMr?~RPCo-iV_q*th zYcYIg3+bHKrGDJ06To{mg6itkcfL}ajHc+z?`h?w{ko2;r_o0n9zQqsnuNDX%i-T} zvU7sZr*FzhTW3-MKkv#=H{JO_PxQI4xT6Zq*_d=YvfMU zrFDCDE>t>NJ-47BCrmPjGIoGXi2fYV z5e8CFibMGD#j!0+2V0BTM#hJJ925zWS@@825vDxJgL1Qt?F523Pjh%DklMq6DLD=G z_Nt$p=~DC>U{yspdE%7cJ>*THRKB7tBDbwLGqN_*QiQ7ZDtGcdY-3q5o`2D=KmNGDVDq&W& zq{L5GQWxw=QF6DHrS>zmQOS1c1C?$~uk+YN6{WObtXt@q-`I&zc@@cxdToVspnSD>l$ThU7Ijd9~ISx_m!#r(*V)4`#(05eg zW=N@pB`Q3eDlCctoXSKOdx4ze2%0~@P)3jTQA_W62BgAUN&-VAko=9l<&(2*ZY!d- z+`KjUwnEz)yUFWoFh5k{$Vr5K`iK)L{(LJr!_|< zUQG1M(ztY0c4&N(s^=ZaYW62bHW>t-iOH<=)%`%zTvkyQAa-}_W43HxIeuVd+?^Jf zp6sk3UnFJf6vCyOwDdZfWyRmgSwwM;5UC<@vSFW0c43$aC3};a=T5o^E7YN(4^uA+ z(4krB^_IUBwtX=KX8vXPXYY@hKvyT zgKTpxF}XHswkvb}UDpdlQR3i>#fdz5i5twEJ z$tQus{FR9JH{S2B*TFj^T=IINC#)Zopbq;X4p~A=msKd8mP}*bXC=R<(=hjnxNslwM-F} z$e$#_f|-k$4wFqkwH34fJBzZHT`N-3=VYK`!RS|HxPwX&o0HJrL3^H>->XV%Q@z|; zI)9hK!O!yuH+2Gb%q_}KkYdh!Ev0Omg-Lw4@9TNF(*{eAKbL56@8OG#KU1Qc7^;b~ zR=N0gt*lzUfOr#BAts=KNhY{;Xwq>zyO(SW6?ny|OocLhMtO#Qek~V9;UUQQ*c)WZCtx^R7KgaCeNAe)A!Q;g z(~0i*sKav6mVFQI;xacB#@(B`bQenV<3^gC9<5!wupR`=QgJ{%&5C=oT2Pa`Y-syt zcZlV67jto=T7n1r{g{x*-TUqUd81rX{i{ zU9XbhxTwd52__l*St7Z9edolu8pk9m+02N3*&FE11`|M73d-i&>|4$jsVd*SrM5BE zZ2Msls;`^M(ZO8H_?Z~hW;OUqDx7(eb>m7Zx>)-5YOYF11Kku`B{tOhrbKAxM~MUN zhk@ABz?6of+9l~*>mP60&R})BtzEQ82F}^OwFR)qQ^F`EVt4c4tM$Px;e~D;KTY^t zN$%!eegAU0_80F)Hr?9K#6b>{jou`%7hw*UI)3G{vqOxU6;>cagR-Qm z`Q|*3I<<^Ng}i1nIRRVc^I`fc*!w?11R>^DU|B>OBc^=?3}?#XYCxE>q+EX<4wS`& zlw{?CVplefr!MORlbXYG{#88A1-oCqjDRz7H9Q$T zMp*Q`Ns~~1j|k@g9*GJZ7m2XcrULe|>9UI-w{yD=coVuKru?m>5_LrnY9=}&gs%43 zok#rh=(>uZhGUw}Yz#F=sgIqjo?kobHx|86lsbU19)OT>EP@`Oi&!j-*mSt7wBTx4 zS)ZgUjJX>m@bDAVnupzh)gATd(bL5CHyPD!cDK_aWx99yPKeD@5dPdC{6~d7qnSJV z6Kr&z&%k{O(R_0jNFBq)zs$u4_i|Nf9niB-dpS zKinzpmNU#Ga<|WQHQqAr$ZVsxJZqq`?7@$*>_~VjJ*cRG?S%MUvf~a` z8-K1;-V6G7yKD=hyPneM$)om~jV-vjemedtrVZZUp$e=jHyxvIq2K^jXhW>Bkj z;N{+I&E-M4P<*x;B(POMm}WVWKlT4%AgV^&O6Kj$IM4IU7Hs$T?{Oq_izXcAU%cz+ zRp6q=D+y+l@w=iCm$Re4Hu(o!xQUCX5FQ>YBqT9kp06Tol12m59t?v9uap`Pm^a|= zbJP}?^!Ea0)4Avu7No<{$;K9KxCXny4IRnP+#Ye-%i{0|%qR`4DM*r!^}PRN+#Xpk zMXjk<8OO%5*vx#Yyt`&ZF2#8b2}`|XgbdMq=N$Fczqi=cEb8bkY|0H{7T`CW%F3ab zh%eCo$Oh^9Muzl$jr-fwB+1up>$c9jR?Pb(y|hz!WP&Y2j5>Z=Vk5F-0P_HAJ+fr< z3)4~c_^)Mde^N@Hlj&kD4}-Sc7$S)xKxA@gJ2{!F{o0?`hR%hp*fx;})wp=rkY}v? zGBfTlKF9bIZSgNca5>LxcOb(qX!EQ)YR&z=$=bHIv@94MirZHpqJlJs?*pmjO+UfXxHyo41@`;aAWl{dxyq~ zmRmbFA$?!h!YO{?%tj6#OEOTwvH5n8p^UyPeG!!hRnKlFALmVUV-z+g)jmTE^6SpG zJ##TPWIPAfqp+N^9a?`64e{vK3K2>8c#zwp8olFD+KmXMWTN3@2V6+@yNz^)7ID9` zn9&zEQ7_{{XQhuVpsAa_Lms`m=@=`#&8SdD*ICk-An)Z!RN5W>s4vYj8dVdJ@+OU1 zrhz(S8YIdWU3H#G$YQm`8;zca2kG@r&qu55(bv^mv66G4-fT6*Aii2P%ZdG|Q=3ME z8Kn$$Wvooun?%9)7xOBkSbeqFQ(c}SbS=n;`AOL(NL&18wsr53evZ?fKW7+k6i8jv^Mt@jK>=%*hd7%}f3qd8 zQPBOXu3@(0v$Ws~roKhq9dIeN)F{r^L3LRf@1gb)BNpbBfov#egAMEI_;ST9IO*SXEfyK)3%`WoGWZctwStm2V_xznRJw zP>X1XctEs9W8CP-r3?6^#ubK&M4OEmBU35 z-}S>ZQ3s~BMb@XEu!pUO7>D%(DIUpPlwV*OqH1NFWlg**7o$?;(EUd!*%|7ux&Ii# zmvocf_`{w}XQDb4ZaKZ^*np}f&l3I7T#?}(Duts3<;T>5qQAhz{)a`!k6D_RFVn{H zp`$u_f#+#jbUWJ9EHpC8N)JmDD3v%7-wqlCR$B7mrzAz--p?KK{u>^qp$HK-hd+*8~J zSxgJ6oC2bca`I0#9_Pytebf!1fON^i%&m6*FpfCF{A<~AvNK*Jh|o=#QL6r1aMt9% z$V^hp%w7*ODgG~=7~9&Sal0TEjK_-1<5@CYI-3wTaufD-^6yEyG9Y8r3_*e5{{5AwwOIlQ;e)*5LhfiBh?+X84AD4s;~_Toex2XU zPMO5q(Ql6iKpuR-@%!|~5r>8FmupXh8k~dC{_AG$|JTjjql-lMY^YJ3o$L*S7Boq~ z9PIbS9s0HhG?zPmsu=vO{>#4ULi*#~1r>4#V@LhN;O%kiH;aJvZ18pG{B#B0-ZCc?il zuweY{-$#Y8eA6oWhY1lWmm76CPkNn^2xy>?qCU}<1S2vlfH#*tOi-7nTi-^%+QQ4q z%I<)C;VAf{WL$ju|25^j-UU-mHD|o*E@ho%vt0@uZ|$C6XK(jpW}G#z;DG`dP>Zf5 zEZ1m5qVjI@OJ!&H8|~7S^AMndCO%Zq0L@rXLGk3x@b($uK8Q$~GT8q^DZdOan36s= znbg2qEm^Ef|8HL16c3ZS%l-C{%EC-kOFBn!m*B`eXHOxewLs1nto6~CrmG`ZOYF9l zV*6Z0f3tR68YAm+e8i<^Bo7~qs!-UE1@I8?i@q+Pi}2$00_t8YDc5!AcpE(BXRr`o z8t{}+D%EdW7f-G$oosCE_|(kD%U5ry)aUOR7Bt*n9)|zdvtEk-*Ry&r{2jB{-fJGI z@iPue>^}z`aR+Pfxm0wPgZ;htb=EsKi_9<0X$B!cTo>{s=dj~|fe#3-=FR&pik&Ez+cBnW(>QvC#miU21uj{p*@vp*Nl0>(yn(km>$iOibHO|8ALRks~OF&cv=>70yrPAlVN@Dm4Dwo=JrNNe(W~qXO z@U0n3fhn_h0T2pCG40L&=9m=ZH-j+kTGzG>MMSN^lh&{w9hD51Xv^0iyEVtkE)$w- zrJB$L{Wh7@s&FU@uQ9LUnoGZxt~{4a$_NG+5NIMFFd)!G0t_etyrlDVpkN?25&c2A zB+0^1ZF>=T-TDc_E>jB7g@F?Fcde_rmj+ighthp7L%Gy%hMfbhIYTPL_xtpuq8Swv zG|fl6@x>!FP2aVaurY~MOv z-1{P3b?>XcniV=v^qna5KY}2=QppwsZ=RnM=H(~wH@7;JQpPbd8g{DS9@sq4U7b)3 zZD4Qgzu}N0XDV~p{PK*ez?0Y9bvQ?s0LIt_CIEav(xsWL5t|adwWL4E5n2jZ0p%k= zY%N7>Ok#Ecm0wG8%2qglR@S|&gwvm@plVTEc>z$jF7nV8v#6ZqS?l4@9v9iW&FIhY z2|fo}phUDhx6=BC!NyjB_s~5Rch)7Ij$cn_q%xfOT&BN@3xF2C4FzR_045cR=WLeb za2hJwbD12kr1IG*3P$P(peMZ$dH|ci%p|)r%W0QUFAtAOk~F5OR&}Q``*~d4!1!Ve z%kTN$__93HsBX&@Y;SHM<|EN8_eEpx{vAA%rv~C!qm_&~ zt)C=0WMV)-*p$1|JIm^*MlQ4{SC8mAUC>^b3@lY~K`%3BT`MIcV;IQydQHAen!QYS2_BxAom$G6n7x9?xEWPVHtUdiBA-^rX-{yr<2rbDqhEtRE@ z!X{zHlRV+>RJO!TkQ6dNQpos7jhRokFp<61SM%3BnKTm?%^(?n{WTTLGK1KBjcOy~dAlO%07H7eRM$<6S4oU7Ij zLNj{Bw+mP>1{GJYpi&7IBr8`?^nC4^AcC|LUoL?sS2anvqWww1+6%HqNzZ2GWdw;V z@;ZEaFwgBw$4e`Wcc;=02&QB z|F)s1McJSgmUNZ+BFL?I+GvX)w@O!WOE+!SfP$E9=#M#89l&7@M)C~v-itpegI(H% z)eBA|cR%xM#(?M?GlK7k^ruq*z~@FH_xonoLP8i6t9ai5m_@FtqIzL$%u$rBNuq&& z#&+Px-Y9X9Mc#;SEL5=y3moWPhgSTh-$0N?y_YUm&29YzWtZuVd1TGlu{1@9-~H~o z#CihuY6|{6pN&_wVgXGpq(W>{6zKnw!N6Sozkzw$7p^@%_qbHc9R9P!+f7b3lbP;D z@6=&b@r`Rjz}Mop%OE+Z!K9W!a^UO%<-WyZM7xaGFm!!bHY_oFNghSuy$Fz4lv6JU z-5R5}?DaDsK@=N~CfB6k|*3|fIZ!e1g))S1uCPIUv zjsyR(^S{P!2VLYT7p8~Xd@`A+gh94|PEE&$djdNmQnQNdj^wnboq7LQcZx3Hsi4QI z!x;o9br`oKJ*ly<>OxtGHWkz9;@2#Z&2_WuG=s!z=O0WO7C0{yGR(}8{XlLvGyT|B zRJ2m7?^C;km^`Pa`2HpHYb+Ye1MYqZI?9*tTux-sYj*w*U-#$BU7NU%1fnvSvG;4F zz!$1`vcbJ{i~-)h!ftc=gEG zkTAI)Qy!zwAJ z`_u}kqZa1{X*`wnHftSdB?lal{8J{Ea1vM1d(1Ls4LzF#yD5Qirxl}Kn81%rrX6v< zGOt70d;8~KcA~aeLmSn=t-d}(o#qfl7QEY&!V%%pt-x00-3~y1nF*Xc{&jupnRp?G zg6}oMw(k7Q0wEKp0OG6xNHw@FUYtRiW*k$*on4iyV#7ig9ElaOKn>xzU#Phfk$U$eD(l~;gsyLleKQxm+ zia0^P117X)_P4_uN*wej$H_X1%ospe{w#Vs1Hy7qQ)&j!S+?wh%?!72yjRZy%ltP^ z)w6xPWg{JmPUE&rLi{+@q5_B3@2#T-8|KT*>XoHOswvD> z{lqsQjZ}4G`5HDHG`=e?_XsAY`50g30XqIFMG{bd6SPUdXV44qs5WZEhPSV3XQZBP zAkyQK(ujNzx8+M#XicHOa@WH9_6ExMvdn#DJ7%Vd+nBSdeQgneai%i*!Q3mTF1$r% zf{*vc2Pc?pA)X~8%tDpez&yYQa9swb?X6`+W8+^siv|s4Lod(X_**giYAjBf-=5_YzJIM90c$8H3skZ1XaJ%PKPW;`{l_1wK_bwqQ^ zTow83LnecXI5Wf4g!afUhhk{Hj^6Ka_BPaZw2Q>FnQ!CHR$K+OIpGb-$_2Ei4t{t8h6%)2I*F?~5yzi~`tPpGD!}|AWmP4lkdKT~CxuhU)E zshRl_s&sjVu7)F__E@65ovV~q)q@XHUG@+z)q&?s-<-M=D}>Y>Y|+_SLd$tmUG)=` z#ee3^mr}oGHGC3wkL=Iaw+eQ9UW@K6i&7C%e~HJesAUCm`W=$Q%+Yl)b^7VOe(DDp zPy7f2<)PGet7k&6qw7X>yWN@bwSi7gQ@1|pJ!Ujx?ZP;adE<%$;vQ%vo`zxi4H5Hn z81_?R;4dl1X#sR&Dh6B0pM4SBHhycn1nb-dG8#IJ<)F*|^)E77AA`VDMWQE$*+!#u z;iDg1d!+g*m4le=Oe2mM)i_V!>c9R4<3j53Jf-iQ`<}$<(vk7(L&;Zq1kc;tvD00OpQhCGqb4uzWUB~)2??gSf$@Qd-SMn z@x-~y>QuicgYsEGaoMJhbQNGWE%H1;P=R6v4s`FOYQg1v`m5hJK)Owl20$YID*zI4 z_JU$XYL?;L<}#OADataU*TVCA^HA3_eP*CAlez;d;rc(twevzu;`N=^U!&jNJ}mvG zCV-*WdY27qVR$)KBl!BVH-0lOaHwMHgBknkDJ2Y_oej(4CqLUj=czb-_+XaW_XQ@h zt#vQOd~$a8SmB|5tkb{)3Sqv%S4|7IS!sMVYM85m)IFY4R3hUa6zkqp@c-w8aZieY?T#7ii^T?P)kRd3BLU5GPCd&=S16ttT z7#$2o1)l0;!rloOop0EU$g#2z<*vWV`%fp&+wAyO%T2zo!vDwq1{3-w0QT1zQ=*)LJxAnKk4ix z-p@OkdxVgym@rpQW>ycKJ`#ILts~cepBgXlm_r~0rtecX_GOLf_;!VM7~b)f zy6^u52#`FzRdgXWZEo!_seb=E^Dqn zf*nUx$`Bb(dD}@)m!z^sSY89fMl^J`)WEqY0RSXc+2hkSqa~YVD`K1 zwjs}eRZ06!0xJuRm+z6bzGmH_4%l0EhZf3~aF&Cr7MZ97e#S4p`yS(E%(`LvO&$x% zZCu^?MhDuUbgo-@o(emrH$6J;}#(_t=+1156pbFt-at$T7}5o9pExD9oI!^&6HE^gvbB6GL!jrh`aoj zPIN3@^!j)5W#^&{e-Y!cP!!c@acRd)up#H7JVUZY3sQ5C1&~A!VwvADgXVh`oS#l< zt!|=6gQ>_gy|RvQ|j-jGXv78_p$%9g8r1ESWUNL;hU2e%@EKpqpKL-~F*4-Cyak|0JI^9*?ag(M| zwhT)vunDX)gGOa)4LoLL+h>4&vgQ_c@}nZ{sC^gd+{~R6zvIS}0FcCJfd&N!G$=SIB2TeX59NN{!C#lK>`tnW8au)j zcZmyjY0{z_02I4QN_pmf%1i8fB~ZLkdZtv4SLbG^?OT&k+2&%s>#bED-ihYW1F;bS zt*$Jj`+NlwV(}Ws2ug~C6XdsWWuE^e9cj8>b2hQgPPg2ijh`P7l^#wc&iz!Xv9yXU zSgw#*lnJhQ%Qoe|T)MV`INxyQN_yQ}y1~rAC3A{rVqq`6c=ORSDyas!dUra-6;C4C zulQ${qN(ALn2ceF9~umTA2IJdl-gm1BvgxB?J_n$6vCDKPB2;Kv?4CB`awCK2ZQ`K zNP+|1GOKfgh=-`=v0ufelVpl*lQTteK+XdN%Z=in()*HFc1Z}CWBpNif5?~bJVT;G zxWmqreoA9zTuh!=&NQQs#9mRGncG7^yJBW4B&iFB*qhnN-o2X!p4bnXpfB^s*+{Ru zpY_>$tCMBF-}v{%z!5GI5DA+r#5fk`-L8(Bzq(qPTT{80=sJR_tpP`DAnuG1jKx(F(HWBc8f0)iZdHKmwl(fN4ncfr%mapWrcafePp`Mm zj;+0b0>gaRdGvHXLn-X17{-_^l`+^WB@|K$XT7YEaFy z4HtuvnWcz*NR-i_^7Gfjd4MFbt+k6HyBS*nBJ~=aZ3w96ZzC)__hod4M4;8WR0QKS zL~oXNAo@7Llr!-Ls&yYb34?Y1s30?YlXi4>f2=LlnssG(`Gr|ls}K3{-$|?G##Pjy z)tN^?j@V(bS^C@5C9s2$A7}i;+Acfw&@psW_r+KL^z=u=@wkU*$ltH3I)hiI4@o#N!qL99Xt2C8M?!Bc(HM$Xl zWQ0ZS7K-?j2xCgJqfW9jNx2ZrOnMKGYo^#RwERhR3H$qIt2OAs5pt|Jhz=TM50YQ# z(4MKjBDej_mgoC>G`^EQnG&SldUe)fa!tV&()ZSq!fcZR>LHBMO*m!X>3%6i(7kpj zD|2f~AN$>Ou(06f_F_}G?c>3mxl7=?@EmH+4~QLZQ1`M0gaRO%*}NG*x>dL zki*CVIn1|@uWni;9nVnSgy}kFBG=*zEsXLCx*kB)GJxGc81P1pg0+NUjZ24noRN&@ zwa+!}8K5i}L;WSFP&r~Nl44XSIvn??Zui#y)YYwJ`|i4=Oj6|nGz)V`4BDbAT3AE8)2i;6>CYKL3m}?j#XrR$CX3R=nO>5Sb12^`q0IvQt9xu@ z!21`P;a~2(4FS_HIlhYolpRwa+vfr$OLmgC;u_KV=_^|&F7VkYm6)uy871DURJrbD zHw!Kj7p*&_z!Pm>XKJAJ`|)ELLU z<8yw3d~nTX|+xEmhM*|CtB@h7PqPMigHzNuka%(v< z$gNGv{Dnp}xb4>{E7Rort4K~kj>TJ98iSQ$9vvhXD3a_iSc=y1@J;>vzq23K(%K6A z#iNaJr0WanrJq&9lCH1668_|P`4|Z}80smm-qn7H^}X8pAnj4{*LFiFS?4);jRPfE zciJKUXu5s{Q}jQIxfMZ|>|rRP9J3nVrWe+i_{}?xWJE#q+%uMWK%E*wkTmul5>|mC z`8Ux$y_7f7&KYjwGuItAHm!!$QK^m&ctr+nG;~NW((7B4{tgVEF9vB~gp@h2EjBn zGwIi30|$I=7yD;>7H%TkG3c|>e7T14+U8=qv#wUO{sZM`U)3@&>qoX9p{^6e*6PoU zE7G{ms*iLEs9tgv`tPjDzV0OUlcF4!E}Zo1^~PnN}`1l1|72ncadS z8sLf(97s^_p*=ZL$A1!2&nn+%dvO01djGO9iOUDzLc{~H*Eto6?mTZ&7HxYS_4a<1 zwImuVeRuyzQLqZHHdzL9+N|zx9erAcU_x06Sk)?xnLZXE*6)*K=vT~Ds=TQ;CHDzlLeSAiwA$T3xiWe4w zI_)FVr#PH0+PIGg+VoV|cjo$_923OQEE%1Q2pkbx@?u*Ur3`&czuM_g!I8UM_;5+V= z_&vVeD1N?@zYtK`GMstG*|P`HhLe{@j(1zaCb(C}1YThUG^@LTu#z)CbA$Bq=(B8) zf6U2VTC5xH+Q76->n<1lll|!@S0@j|< zb@lD*XdkqvNch-O@ZWSm5s9P?XWXN-%Nz1ueD`Qo?hX@Z@+Dzg1R$uOMgIsOB7_F+ zY24EB`=ZIfjxn!%d4PDD3s@XOic%zgvtt8vf7=Te|CLD8?#UWEbJ4{Y$r)mx7y<_@ zYrYvipvQmpN1_6t>R0zmWNkRjURpW7EuSHJ%8@iBQ1@yVeg?Inqd4F*5H%PiI-N^C znY%XYIA>C_Viyn#xgIqyC@^0HVd^+gjtATy3|O*Dgp_gbamm>xfNZbM!X`^$2+PRo zOBP@hQ*BUw26jooEGSciJ}yJ4(jS@W%heMq7S5ihS-7)kSGEAPm?X^84%|jGZL|S! z8?Q-Sh`Mb&BN~QRHqJk1H#kvuhcE_I;4}dR1sGt(8s+t!yZyT_Yu@Lpm29?dti_F9 zy8&;7?d#5x9;^%`s|)<@EfJKJNeU>NO?#7@Hf>dAEsGxla6FNT^VFcH;DNQ1L7ZQ- zlE3m8c=ydgge;9B2cDYQVpQ)yi!~ zlwvN)qYrdJC!7BRU7*;49CwTrHeMEW-Z5}%zJ+R>fg<_l_!2Da48@Y4Y@ps@m1e>v zqg#+GOJB}nnQHE>s^Zbb^>(YEV zbr{0S(@BZ5z;JIvv4@0DB>E;op0SzipEAmHjm=E82HZ(;2or4e67s(tg!zhp@o_us zy`;$R&P3AGq~=T?53U#}PB?>njU&qd0vC$>rSMfUhlfo|$F4bbFGy}TM}q=3h#A5w zfNQb>XGNHkg*emZxIE9>=gRj8D9(--{h1h0q!`#HHqxW}&@$5*$ihCwV#~JP)wf`` z9dL@8(_nKVv{9R#xASWZ>PAH5f944fsd%fC{6^kMmHp^ZX%rHHHX1}ZL|Y@R_U z|B+cJ4Sv4U^dE^5^v0b5gRO2zJfsWCW2bg8h3~r}N2X6v4XZJ^kM<{jPGb2Octw^c zGjTO+QC`SrIGGCuc<_m+R#z}dYI2g61-t&Zl(Hb)JscrSRjPK-!2g!$`5=b-!|D#i za2~6*$yW!V+e&Zg&~(p=9caJz58no+Oez*@9hC|9wH;aPre|9{YM{_^lD^{%aSq>o z_iA?<*E^26pr8I8B!PnNIG}}HwyTCo*Y704H*b~c(H7qpt^lmk`A5JC&C09To0$jF zOLJWM*!Z8uhSB8`1wbrI0dYcE<7Ga?V2Bl7YQ^|0>h zpT7t{Qjmk;{4gbmm-4@cCZk&!gQZ01gLXH|rFJmIj7Ie=f%eBWAbF1+8@(y2STh_; zbfMvNA8cm+`Iv!QG07bC+r5ecpf(Ykk?`LG(wO6COlP;LUA6*m>sGRl=9CaYvANYf zAVAY8V!Fy$Nxax3Z%B<0^H@LUkbj;1P5W~fi2iB0Sos>T-ix-yx9~)g`N}3d?y8ew zs^pX3oj|hW2>WphXeZ&KueazTN5rNNLWM$x+_5BypA!58dgi@1ee*6O$z+ChdoPl=& z$f^U>6#VAOw<`dur4n=7%?U9e~^`4E`hglY`(2SL74#2w(Gg8&yD1i0vFY_gYDgnCLUp}xz^xv|mu zF~BPM4>{&{05rD;AcGxZ4FjONxA>aqAX-_ymbKsuou8Tm z934P5R*6#~9(MW8%gy7o?BIHvPxtc@T6hlw2Yc-Kj9R^FEHx4R1*cOv`#6bw!kV}Z1S_tZvD<;v@eDTw?29od z-OIMwn})XuB={dX0Za4L!=M*#VzSe%(_ z7{hSeSQ^yC#yK|qiz=d+4X@jvc#}2G?Y!!eQF%{!s>UvvP0d_@9 zeE913ZizsYAe5M|tRXm8lK5BuO01+3409KbMC!M?T zbeD@h(tM3*wat_@`YVq0iWM*QFFTJOD*>a22{3wK8=La9l@^WG+AZhxim!8#9s_vO zIM3vN@dplcu+9Jjg7qcJJK(H$_)%SXx-;Z#MQb)Nd=Qw@JEMq?DU_HI0IX1tO?fq| zBpzXqTXc9|KV6d{k0H(`rg`*73EZ$l+6T-COujvwo^ zW$yd36{P|3P%MI>3llm3 zKLpPw)>!juZ@HXMbRTXqQAaa$y`8w{3cxb)eI=R4J?1oCBHa=W`>+zcWg%^Kr^3FG zssYwz96ywYpTr@v27ZzjDAYz#8YeT|Wi91IzD|REC!MUx*_1O?i?u0e0l>c(W_^l! z>&d<`;ZifJC}JunI5yO(m;5CTz>n5Wnoc9BeyzDQLHSO&Y-1=B(Gl%?G&`dkI}*hM z9dA_H>cN)%Ck3Wn+0WsZCRVhNf#Hil^5RZOIy@Khj2~?zuDiMmz!`X# z@hMYz4*LYE7M=I~imu@H^zE%@@z#V3Vn#>7fiiWVV#zHT6eg|0AD}R)7YF*^gUPA&Y*A_&>})f#ceOm=~Xuc*Wec1-QAtw1P$&4cNX^q*x)X~-6eb%_w&~GYl~v3p=Vl8pPuPvxXLwx z8KxWJ$Baoczp`-4aWHiPR{x8RvO}*%&YZRND8vJ|`NhibjV#jgMivPfGrh~6WGEAT zwcPL=W93nN49mm?w{#Xg|B_@(FL*@YOyVVplw{{d`|`cVYJQ4et;rYF&^eFOpg}0J zLgWn}%Spxio5vrwEkIKFqG&GYkx}wz?}V#AK|LTauS>58fOO;_Z$n#O@#cV`E!4AC z!JJzqmKppke4!$RW!-XZUjUBl=28a+oWj}jV%{viFVw(_g;$y+hamYC3avdd#{{A&k)4ckrs;ploHuK$>h9K-@$8k5sYn zvd5o2@xM#PTf85)<;e|D6r=j6*K~Jvr~t0dMry&;n_J4bumvvGcBS)dshpqJ3OGKs zXW+}snOoA&HY77pgb z$0908)JldMe$(=va^}C9?O1=z&sgN$2>&DM%mJE?T@^e>v6FF~bmzdGS0(L#xos`- zeaH5gGXS^gJpYU3A*wg3X_s54I`BY{X!_ew$A~F97{@-IJBKDe_2m6CF-P38gZP0w z)aQMGB=o0VsJy}yhJtRaolCyAQ;_`Y>H@YA)4U7+4AEDA$F?dT#;+$0I(Lf5;C5Ac zAh$Kwhm!}5I9)osI0KUcc@FDzI$Y_G*AX8)6pQEr{sdS8BWB9afN`~>#@a!b3ycO( zUMw{|Wy>tIq~|082cEy>!?i|tO{=1u`sp7q#ikrb_gYdDy==MsKAj={C5`JLror;S zUybPj$U*WeC?606OS~B7|L{uGT2Um2!?|b0)*|qO(r%ogPKqe%jPD5$dVJORAtwY$yLpalqTvK;5tAuia ziFF2GeAH`*{l;+qcuJO%rUjsQ5^(;e#U^N}0NkV=?nr@#sY~0%IOWJ^CQviN4pZx! z0WMs|w1#HsrWNtHPu1=W05%Z0sv-G}>`^zg<)_wh*>1nAaPg0;m+6fjt74>qc@{z% zK~r-DJZPB2#1cDuZEaKViF0m+U{ynoWdxuen-RVD$An2}k^@hNpVNd2Hr;9p)^?T_rjU&>Z>>5AIL2haHZ_8r{BTTrI*LjUS|wu2U2X&}Xn#j{sAR zh`>}MBE0hs9?2JLY*ek_mZ2-%m+pfM?TrE*lY*eE(jTBj$9m53Pd8!iHaN|*?H8-n z)Mj`Vf^a~?i4eFI9jm3#DT)&SRl)&K1(n3+#!errnX3jX6EY;(@kU;aHKu)|j%flK z2~fv00Rn^Bf_O@PfT?A>4`bWxLqQY=i$v5LJ*^+;_!ABtTz#3Xsdngk?~4`cRPmH% z@czNMu+)N0TD%`yN;^{+pyY}#Xy-W`A=mf!h8Y&~5f~3LA^*oB&HEpVG!Mi1S~tq@ z^HcIizo2>w1CLcO|JoVhO{nE7h0obKX-i!3Yd4;z9c1lAGwwaD=ySz$@rX0El%3bH zz+zjAeffKA(>v+Y+eX^2owfgh6;%tLNVhi9Gcs2zHXY#DYr(pA?U*D;ry^A$`K1r*}dG(fWevVM`p{ho11#68LDqL#+CW?@teXnzg$63p*xKjXq9rOfaw^6XlYhY1^#MI{cXqe3p3QKV6<|{(E{$kM z-oUx3Qo1KXi?TF9izM|T)uUGUQX}{&(p4SkFJsF%A-xYYmIkrZjUR zFU4Xyl|wgb4!A&_3eh~-jZhu8sR`MDbBl5)-!+Cl{lMLn(t z2WX=h%ncmQ8ayJ-^PL)OjkPc2O?$uAn2-|gRfL3)IXfBL2lDbeOT!a_wS{-Ph?&nc z3{INNQp?6i@Q9e>Md*-OMUg@E>bpY!NjBy~Ewh95ssQLCft9Wrra^U~4RmWX=7t&! zUMsrG*DLLaf~;p%_8+*#HF8y`J>sdi8H+xJ45}(`GJ$7!9wa?6!9!WTsam0|X73cq z+R#ly)IPu&BfJBFRe2vIp&7tjmX}ean8pORr8XUHKVN&6?6OGeux;|(z?VYvD}>Jy zIpxIF?d$wd4N{2LLbjPw<_+vp0#wO2v@X2T=I#dmQ*4jB{ z@+l|4Zkmyd-)dOwHYcZYY~^LxmN)oO2c_5&nLSCy2X2|{J>NsF>lYPf3mMWA!>#7r z=J=t?q!1sY2faOa>U(_( zVdZ~asBOz&vE;=Y#<@K+Rhng|>oQLPB$~)fTg3M(svMv}F_@P)oNR$@G%v^(jFO}5@_qOXRoVg5Bu0dV)9b^c;RQlA zwgH*>JEh@?i~~4)F5gjSfvjnYd8?V(r08&;reQ6CG++utm6S`Nl<6S~mMs{ozyOxU z88+|g=aok-{nW$XEaDeq;ab+}bMX)Qvs5FI1)^fo0|KJbXdm6CYB}EpXpDt%g{Pam z!i{xWE99@kLq!${$%pJ4l_NNb#S#mfP)Ua(h}p92&U4ShvmSd+AM{SbPp`G5CHD-BR#zG zHg*j-*9dBVBv#vQ;Y`%Z6-wVp5%5YaS!Mu-c=G-^IqGb;)k&XG|4lMXXG1eoAdk4LZq|pI#Lv5ybFf=qo{jd*0X|48#8M#w za44Y#LMowjjJHwR*v1dIPu^7v^IqnQ!3T0t`*d0jFr+^~i1Hf8I7m5&JWu%dD8)@1yKC_1 z9O3USh%`T-o*`k3rOlbPa;B9mVq|yQ$HwtKy|0yBo@&Y(Bu>z7pTPS8B9w=`tw%VX zzsTU6Q*(M6V@UiY!mvD9a$tRyV<)^UqSIrzD$*5t%pyCryQsijB(gQ5ForDha+n3` zquzOvjEyl01+SWZh_brT86}W&VujOf(J)2!g-|&NfdSkB)uu0CT zDc1ryoq7jJ)SCPIeL2ZZ$d8!Wlrs#$oAj;O!_(7*YQN6$ z`Pu}z55X%OaoaW}pEwaUPYlD9EP-4JWQYa$_o1-b9j*uB)E$?4j!t$G3qn1I0y&>} zsEMC{lYMa+djIEUdI2}{UCU!tv#3#o!0CuJ*WVXI6%^Qp*DKu4P9270Or-uG8DA@H zL%M_A&iQ6%jU7j?8uh{)aOEsXpVmPi;&9;sKngaeq9L^b>i`BEtt^S+som%`ou z9mfY*D5Er{en4|o(!|1*cFxOm`%VxQ)2lOVgs;!YQ-9-09GzS%g1%xs`dCjuJMB&F z)wc}LK9~fAVQtfW-B%%`ZzNd2llD~7{^#}yJtoD%D%qF%W2A-Yr|zjQQeDk9vib)C zS&#!MeKBOwpRS*Tlfa`tQGxFa7tjVgJdPR;9BzB8EA<5DSTTM40QDb5?JRwqbM?i3A9n$ygm*aXwO*s~31*YtvM1HH<@Z*jnj zC=`eTt^DaOioyTBRSjlJI|v_UgZ8OmpXWrwP6VQCuj6Npbp0V|^+vH8=1=c&2pQ2z zerahFp>%!?Q(+eyR~ks38!z4EH)ZV^W!}bbNS={o8ace?!l#52)vibbLbjwfJgZ0& z45BdwTB?#q$IA@fPhq|JxFPhvD+=7^o(Ve3aO(q#8&CATZHRp$SQ4w}X}JEvp%j{b z>pN8FI(l1n5 zEKA`HiF!64Z)j(u>)f3*YVeD4Mm>shVG-L<8c;2@ruvz_wV=J>z%||qml7+}gDKlh zjr0RVDvx&$m^AJ<>@(+>0 z;zQ-#APcBQIY@X9HE%yk_MyCOYd|CGTOJ|?7@|GqaQR0wy`iS~MT#V@@_KbA#D_nV zX%{dZr&O^qz;u*N=iEcH4urN9t_sri&VdKC+RuU00u1(LE(4COQ#JJ;yxQZu92?K< zDjxL+36w$);Q6x(gbM6U|7SXK0som!F|cWeY~~unf7;3-j$&2u4S`%_68Lk#6Han5 zz5t#urWWvoJzy?zq@dLh9v-MrDaNPrAY@5x>leR}s28G?m}Z{BEo?P&LWRD!@UkhC zL|i*pCxDe!asxy!U^MnIyYtY#Lu}qXl{A7Q$v+HH778;>H{gF7Q7n?QeIf8#(ZY(> zqAa|s;?>pO)kTbki{6x3GU(_M$rW6X-f^P{vc@V5pdM-}a+OIQzRzgysbT8KtuApL5vUt8D)9^I(t}@vUdM^6cEe>aaJSP*0S8RgS)7|iW z)m~~vMiOZqs@n0k%!9U4jyckjKXuy2vFXwiep5SO8~6F#DX3@?E~VN<@qd6=Tu|bK z(o8PK{Hf;>%uY#5dvb7JCMnH0bK8U;OQS!Co1C5(AO$ju19sDz_9gWGyL$wQ!cY(U z5DhOk@j8de7LdZJBBx)Nk_^ETiSYW*MKfo|8m7_^1w2uBX$V)3$PB77>0rRCk}6w! zu35^dAd!A66!&A4+VxDn@L91P2;H_QTC^CVyqrnio*L^u0GZ6m8e!6iK(*xOA(z(j z6LXQu^n>x*Mj? zW{s@Ymq1*Qf0VaBQxJ~-0q`-rV@LhfL20cs{ETbxp#x=Ql4p5>&=tQz6WN2?O%de3 zNgcps;SDDf|G_D91T&zl*9b)|>YpaRtdK%6pfHDCw|dFbn?DSabMuffbbIPK!Iu?{ z8g}Wk?^S~?M)H2#EYAb^@d~s_0uDD*7>>z7v_DhCa8xE)VL9)z!cSuXd>rx3^cWy? zeA&$MW1>GEh|LvIcgmycH+IUiE;y0X;F|phV-#+6RZqj+S^7eVnK4*-U#`71!eWW6 z#<6Xhu?w*qpZVvVl%(+(_Hwt=k`5Tb#0ry1!i{!gcpmbN1QAtlJeJV}AJXGwF;}OV zr`2E$5(kT3rxLn4W&g^eEYwiqh7m!?KU11s zf;rB4Wdk`4%TM=gNHr`Mxv`;Y%eS}89~S^^w@W>@O zIZLz+$ULff)0rNPSRQh*5}}n@ROXfF993EL=aqIN^&%&Ekir{;hGgTS9wO*PD;+sS z1eJqO>Lob=GVF%YL|Ire-mn7^kqP=4dQdT5sW+HpeZ<&_n&s1kQWyf2LOfQQ)^PPP zpZJJu=&0BSte$k(H#r9XCkOC>j$xC0JeH!E6FbR6=KYj}Te5fG)S-_PsMA`N7hQ1f zl9sjME9>glRyefApuisBcSTap85|@f2B)H#3%aD*__({&6>0_j!^+auFvR#3^ z#a{!Ko=0)xchB!-q3%=5c1p1Y9#U&|N}VOy`YeF4ouG7Ua85aP;<4bO4S6cG>sm+fb6-{ zNJyH{rA!Hp!e=U$dQFkk-l#fPR*}^0^pvxh+3l3mu3x`9lum$KqF021k4M=0;*T-O znj}KEZA*}TbILnf9TKyCU*Lzz2}5}-C!Bvs|8TjwDxpSt_6N9s%W^4wX>xDK-;p1q z?46bDE#8nB!~n#AJG)=pArTAW#5C2OR)yMNEst5S;DO@(#h3$!B|KbbNoTWd)cdN``=BIP@JIR^|* z*Twwu++VJu!ci$@pGshuKAIV8$0;Ic7+AG^(Ko=u*}r678FugWN86?igd`A6C4DpDWWqnWH@88>q1zP?pI zf8d!|8@{c&75Xe91B6jdkdCKP6bp1YgA-LuWO1TYC<2v@Ene9rGI-gLvLdz$jds=s zCI}a#Q?3a`9fYGpR0S;=f3>aUu%6r9ZmqBSeW=LO!uC&@)a5sYnYG0M15z{~|2Wbb5B4(82+aY0|AcK?;bezrB|K)@74 zAAb=^gE<_7(T{^i{5r2NYut*h2I(9+;&xXI)W`Y z#OG!%La0bmr3`N$2(x7^x{79WyGg@~2=H2g!XlOp0_yOB!mMfQ*H45xCU6aa6RAgx z0by-}Gd^5iZ$IA3U#wcU*qm~Hn0`pyIBzd@R(WT7JRF1zMQnmz`vu$_XQ}ifSLBA$ zKCyTaD)O8%G42GUVKCTIbL^cVlRHvbz$cA7g02cmEM9_&g#DaoUI&9I_)*<*EdCcy zt3?*N(D%^I)Pa{w{WsJHDv-E=LkJ-$?vIOl2D7O3Z-WPvGdiMnlwV}dsAo}SR^?bu z&McFdz!p2%+9H-+TK9#O%bU;fuh0fn;h8w5NH+|Vg3RrW8xm%7WH$lqM+=m?eG{{F ze0tiaT3KnicaiMW?8TwYk(n&e_ed{Vho}a^y1IIN^tVB1Ywgqzuyi~ovcA4VRAGwCjYd-pw8B~gj=1SNEqrc+xn>4K zenXGR7l$_dYSy3O;~WZy>+oWcn?m*G+QIJviG{6+(x!2h;}oGZ41`)=7?0;gxCc}f zq5dmFGoXRPg%D#n@qV*@Zbq2@R^(fQ#7W56_JTAdWvKs_wu%K3dlt&lU;)K~z3luG z+0I+B5YI7zqr6z1%cnPLeKrmY+yCt!-U_*a!nGt)+6EG($){jAFKA~itEwTsU?vBm z`z&TUoT*>$%e9EF`9AL#FChY_xo=*Fg(;XjXCh+2M$vb7>+Z+h^f%|=>P&1%>Ps}9 zx!yc1A;BgwrHS4+w~4Eex{3DWYXuWQR%ZKC@DX=aasUa;LHI2TXFHuXT-im@ep>Zj zPsI@QGgB>mM|BUuiKprTSThkie~cCL_B~BZ`UXyce;sn7KoNux^3V}wGx9YXO^J@6 zxX)0{T@j>*741t+f8CguC1S=qgsgUOR>_%GZC~{S&C@?{XDKM%$WR!spA578BQrr^ z-N`IXsbqSH%P&ojKMYk9i7V>kpCWb$8ig=6x+>gqi)P+f^- zOw04B$Q0Q?mqq_N2B5=cY?_AO?I_{V_o+Gylg*qfHKK5mgiMnW&6hy45_*kR20aGH z*oxYp`Xi#TDVE51)IQl*c_H(E?<^_%*`n+BOf{E7I zXH0}$jR)7H5B~u-j;w-}%z{p)58X(;tm1P@1D>t#)VOmnh|nX4AYei@q@c7pqYUew zxFAUhA27<~8v+%TR&s`sJ!)SVck{wh8`$wj8VSz|q;+s(4wTr9>V5#?`>7H2(VtqT zja!vxL zLIYqA(Z)i|Au23lD@te-QuV%D{(Sg%KPPrq6bE<zJ=ax$~O2u$@7Vv{TVNMd#j-aX@f=l63D0HQodSk{*@5uMAK%{%v$4`P z8Cl=}Gvu=+DWCX&Q&0Q*a`bsodvBU6-Iw2O@LuGqou%pYf8rnqP!A_$pHMjbn>}JO zy1l)=;pw*kZmKM^Hl2g*zf}x0ek(=7JIC)>1p6NnHxtcH?0VgQgYmXH%(N8)rs~k> z4PGc%Cm zhZbACM4eNH#x?z8`PrDwOsDYUk74P!0Z{AIsaFH?MAf0{0`kb-ws-&QYJEQ87YU!_ zL6Jt*iZ>*he}n%KpUaaj1y+9;{McODS%l$OQP$J)PAWxf^D|| zXpg!*X(i%ktOwbkc52{v3j5MrIwRALR6Y8M8oEk)VWY}qBJGs@-dh|1QjJspEndV7 z83!l<$V8^~?7P1Aa$Ryv;11_u8v}I}IJWcZ9}i;yE&_AU|nENoyb4bp!B7#uvHcpX4;E0#s>Y!%8~>gvDDMQSD8O=W+f^ z{OPyWsUg7dgUnkEfgq}Ag<2cTEV^7;QGS6YjHA%2KouX(7`%}G;k#w!dE zL)w!C=;!9OgKQd0d+kN3bHS6`6rWzNlUZ!>JG}VPuCFGt>_)@pl3Jd!3UE!3r-5jm zTP*ho_>nC0#A_Tu>U1-101aBG#JAf-xt6T5fgXs)Jbi0+(7FK4j$~tE|Ea?;9&7eG zBlt2y!IB987z3Z@Mt;coU%TV^zjg<)f38+3Ym+{C_CB4Cp)3oMv0*6yF+Aj?-L8|BC_ zhW3N$^BcQI{zUj!He2s)7+JfHf+{pev)Y{%|OhaP%VB2!s!H;>_Zf3 zUpQ?{^JM6~TTMBqUhc9S21gy5BFGjC8t_q@GKKKDmo!caorW3~1x+=TQ;D#I;c}P1 zxw#s@Mj;NB{dMGGQS1Z&WKLU_wZC2(OAUK&gM~!RdVZhu6UlynQ04K?0Fh9~Dc2aB zKOzm~PDqOmi4fC~8gNfW`5!>m5K2{kOTA^F1uG0DdgsnEs@^E^qc^P61mRc62CQIC zD1Wr^Q$2;7f%sdTACGgbDhp!_kiVwo!qb&A_!Hlnm`v+a_40u}%7R?#A+Xc}0Bi$I z6hnC7`M>KFZW`j&VfMgFB7tRyslr&>;<%jcjSZ=$$-eZ1{$YcX%(ief)bU7fP&HFy zsc0zfT#A57D*Y&c(J1q#?OaWm*s4KdrT$=ZAKc0Uv6)FD8E9h^GKJ9QjX1Tpcd+|g z9lz$-@@JRy&n@o#d`Y=^g1n>%HS|!7x_uLwo$zdQme<+L9;g9Elf+8^FHD)nGW|E> zW6zBZ^I++m5h>0px32N zfg+2?t^hrZG*A4CBUn-k8&Gli=%%4%&|Xsp#OiBZq;V!z&e@$`u(J46v%qfB7U4ds zYiPw=T^IiWE{|+Dy6r?cCFMNuBZ2)CekXZIjjgmruahM!Vhi8#i4XtasG(3Iu#O_m}<4M+&6+W-PZ9=JDee91D zF%LvgX7MsW#0{Vw5J*rl%I{mymgKxuM-JH`Ii5o~iE3aLO98^!V2y9qvv<{K?bTTQ zokObn#|~^m0WfaFafRAjyN{p)z=z$j1WODA44PMuDW2!5go9h+)69XGTlm3cGVx+u zs?%F)-gSh_L{d2oixWLfWm~Dsql(kc|87kswety~u4;((Za+q*^J`RHtT!gXc-bb6 zHqf1_w`G~C<<`=wJ#k2XKXq;=_RTvOLk*NxoVEaXY@IZ*ETx?~l&Tg7B}4rt^ZxfW zcxRt$;4L*E!RayYEGBty!c87^>ydehZWIG`u!wzuvW3NCXY}^A*@|y4A@1cBV-o!@ zzOLr_9Lgv{j0fCjuyvzux7cUE{;^f+urapxGDVG2DF9DN{Rol2#SB}gY zp@3F7Glw9)HOI1RWcnlwy4#<MMh`mV;LATM1 zaqvhN(IU&N^ zzEpDdp?fC;D_$lhzVMStfS)0v9?2gXjOyZ91Um4I!9XMRXky7$qlNwZ7NI6xx>wjc zP`|4A6X0n2xkhfINDCVL3>Gi4360~|Ynu4bCh1e-b3FOC9#66m0C&2^ceG|B^@6%MT{{3$>v?Rq|wZdE+B zA$E3Dm$=KaMlA^F@`G44W`N^^W)1m~H}ZSlPe|yY+w-UHdgJ@pj;)r}+wJS`-&`gG zH@{U?31lJV5cBr9vOo#lDuaVx^ z3{^9dFF?Sk8Y=wv{-^5~St>W4sz++vcXa^VW0cBt2&k=bs@U9Hu7r>csA)Cvoam<@HgTv3`ycNv zx_lCjPSF*iv-pkzn;@tx1DON)b#iZ*S-P~o5M6^jW<=1MyLk*v6=n}U7&>(Ub} zr;)$7(aGMI|1P>uRRXgQVf!a(<=ZVKdrTZH{Da*3`>op zV_YViPZwfsCgnR7q}N>|rA*3{SycN;nwMxAlFD#1q(m#73sTeCac@z+Y2jv^_QXMz z4fr7c;348=VpGSiXIPGye3@#JqQi#mb3Vqx)JffRhjum~VV@V2;_FyGPPqHohy4l3 z=->~JS{*GZB6*$b*T`TxV`fjcwKS-0R@~Z_yN;8yqe*+nzxlGQp;tF8-{;MkvdX_&}y%}t*32J$(vC7ubtKruK8Hq%FTLSJX4 zuKXLj>)YMkdvOo=JGAW+$gcEdtSC9mTT0>zO1UHpzZ1uos(DJ1`ftcquPei`VFw>W z`tab9zRTR^i#r^CZ( zG$LKbku)&(w);w6**T#DTQ6CrMa4rwX;k6V_W|mYs7E0pbURM&cfD?F40nLDo95-B z)~V-k%yg}IW!2HKZhB^Q?07uM6A?aR(>X&|0|GqcE%geTqyppZ%A)^D^~p>_OW78@ zM$i(;m^W1zqgQpt3-pSF5Q=s&-+HdRvtG^$%0E)J@(jw;I94=jkG6*y^z``-yll~Zhlgn%{&|aYvewaOacuL6K=?-Z!3T0cztIJy_ zr6+s#9m|!ESzDeSFUBuz^+uicfAZ)*Lx0WEd~wSAR`qS4B&8cEp99P;HqiPRItt_4 zM;{%yFjvA)xu&qe%_FPx&CMDAtRC%*dEFIL_^>onWr4fHO*MLL6}y;+H(E|b~crJxJ&^Ge=6I@&v}xwmR*|JSvM7f_u* ze`4e^nb)09S1Vu5`F#RtUg8_q=Z7;p7XO`+p6|iUI1+bm;)q3wTPJ7YU=Irw--#*D zm7Np-NJb+l{|MiXVkfQ|pSpHz?L6z&S8f>j1h6yK;QzlfV$^r1yhEl# zz#XQu(=v)3x0SemAsQb7W0d%NHgR*T7M+;1N4w^>Zp zxoF5~ScY8zA(Rb#4IBnvljM$dO9RgNi+jY=zo`h=hz{MZI$7pQKQz$(8D^x7DFy84 z9^mqYqOxuKO#MF%!Y0|-9%5!fp3Ex=N9qUE`lT|x3=DgH18vJ&cs&^?N2NUx!J~Vh zBayVor5;a?VsEJ56=?!yU?}CKL2NedQ~W||C!*QI94()hx!0kT%3>nstE^M=2te| ziYyZd+Ued@p&ro5ZlP-;Ic{Q2cQL<9ZYyLql&ey#K18QHEw$0By^ewB!2d>y9Jt%* zLA{8}@K`v=qF`9@Q#U&I)X<6@aYuWKj^taEW8h~oNfKD7ePEB{V{iid^7_p;NZnx^ zZD$fQHE#44d#vGCk!QUWi8&}hMirm>fg|o+p+}=OK6krwQOptxV~8!QAM=#J0qKY0 zg^(6;{K8t?uVBT#GEvuP`=wA{(P0hUI!|j+Zy7>)@GF;&v8siZV(?QtA~*0qNw(J$ zNm$^|%ois;8>YCHTc83ab>N)M85z2*Cghm)^{(add9`x%XJ;GzucBLRrnnEB?ewBu zhz!6V%L$oWkN*4^MZ~EaRrIp`c*2#d}1tINhx$YX=8XkTYhA2BEYV&(wsDV8Ld=jR(!&$2klU_^2B(KvW^00<^qa;cbzz=fA zB1fgB$8{elo2~0-Aymka8f|aEzoqDXKcQWp09DoRLtSfEZtT>+1`ZY*fUUQ;?MuvT zx>QJQzXWL2W@=~W6Ygmqi5PWkkYHdnGktp$_@wjEU?>|#Ao1u}_t#ydxLiJYVn?8l zO~IJFIcsS~_}rgaqRB45S;1#%wOfGnivt`k=Eq~tJ*Z>y{D2vt3{gr$88p(tkJ4q{ z7>oq+FqKof3=S~DGoYbcYYU-NSJC@6)n8^^@K52=RM969TL0%KoY`BDLSzLDw$W14 zWo)`yN^48Cytx(g3Zg}Ih=Y2XPu|k$kAwikBbPwv;|)B6%E45GFTEIN-SP)!pg#xC zJr;9oQwR$Ko|onGmXs$)WCrC{oDd;bt&u^-%$zy=G7)$Gmp>nyxic^@*&!i-ytD@P z81PATJz5us=O=crTesKV9mEu;Lfw75>`Fb^*F}@O^^eunJknXjt2aQ}8HV*4*zRv( z11DJ5BzhAOedb+dbhBMlXkbhitwu4-a7(2iJs8Qj7@Tk{Vc?sH;ieSf6Fy@pt3%9E~*Z(fTv#HI+W<&(GvHHv&Z` z2e?FRAQa32X{V~M6l~Q*(a;R`XgYyHsej^IA{-I#WZ3#t6h1f#M*IsX+yJ=VMPe^? zS-vA1%YXNH^?1wN>G>TEim`AnSp6@sU~*X7cM?f(t)T~K&+khtJjUNOg_N?0Z2kRm z?CQ1|eyCF^Prk?u^HQz&J}F<-|B{V zMON+K5;wXZb|eyrSw$rMBB;J5kHe&4^CZv60BvpoJN6E?L|3pAClPVNZkH09Ja!iX zbz38C8e!^CA~;vCxKK=$uD$!a0Lh3Q+$T05z=Wfm#IseG&CgU$a01u&LQq%v?${uX z50MM~M2BYl4B7mq+RLi&# zH_}oo6vDz~8)a~UW&{5KOcTo9c1GEY_qL*TmKL7!Czq z2VhC#jO9)-+K(&0{fp0imi`zlLUm@X{h8uP@{Vh$?|2`j|DBHq>RKv8Fp_Y-IW6)B zX9OX?*}L6Ba{H-3kFSga@%0HoITAj|wp!UnD~J@A|dm(h6AQj-LHCe3GN}?+9E|LG9}%4^%--KkmtDe=Dt@y6O8-2J5iD z2sYoc11-M+H&PySP8u1zg+jjKIR$3h#fUbZCBjIF#!_)>Rh9m&0prlTkVqu(=E8Kr zCGusQS@8?4^A^W)hh8DLQ|`tE5Yj1Qc^VLMU}N)X`J!X>x4;%+j+O8YyRF+7U-HT? z96V64(u5xYlYnji=|zdj?P)oRUs!>5c6bQ|YtkIY2TzT8f>gV$4PcUzMxlK)0MLph zz~@=k`QEp>Y4yinF{4_ssqo$qUr3p3xOS z5m-~`K*)$FpF$54{9rB5r}JmRHMI(a#@QnsH-mW+#bgNFy}bEf#xL1l|5IWYZL?oZ$8}i1KIS$9b{N({q|M3I7N_A ze_H-SSqd|_ZBNrMue&Cr4~61dF+zYg9Bz;b3nx;7nj}sl?m_6sYTuF}sG+BHA2Wj3 z#YwjHs4HWCH1UO#mxYZqJODLaT>%q)*dOEjT{9dcS8a#!?&}34{qJ~qKX7~z<^FHS zhwkzu6dC$XpfTiqTz}@C=5%L6mp3W|`SxvNg)#rz*fq?!)g7uzYpStfn`IDs{gL3C zQdX71u?F|U+Q11F+Dq3~MG}p+e4}JK1hG_5`=-eTVoR}V#O7XaT z)Z_zk9f-@a3$bq7_O>Lyy=v|2C<0lINLwq1O4d+YVIDxIs&+JhzO3vv$6+EdoIMNp z-@Ta8?YGfS6*0F~pcx>w+d%8Z)J0(e{JW014| z<70jR0oTb1%m)4-J^e_wtyf0CTz5Ih7vx^Ph6S9`v9pg%WT=5n z$8XTqdA1ex4Rgy_Ayxp@3P04n6rmL0unO5AxP`x$g$NB9J0Qn%fsQH>2CG4M(!D-u z3x#ZbxY)uw=|O6c$+r4;l7I0oVzTC&#x~(PuK@do{Mh3RenXTnrsH{MJ z*;BKplQ&maS+>>IHJyB>g?PRe0RW`hV4Y%6)4Qsqdv`?)tx!xjc9bzQtDL5?1-fOF z7R3d@ij=vIFErhG@v9U_sT!nItO zc-PxDv19Sa*B@dt>9t?cwZ6$&s=or_(MvCg0p5zfWJ!$20wJkF4{_?-Dbq5HJaEMU zxgBOG^^zLpp$Onblw<2cFgeAPNteZ3H7AAHn{ZP{3jX$96H-AX&#D!c33rl^Kvy#KRo=EQ5iB1Ddek4 zzVSCk@a-n%wgECQPfI0SPo(Df{}n_~xkStF6$}o#EON}-y6+CYvMz&9Dc7ma6)LI$ zHwpIP)bNriZSKsAhP zXy_3)Gw(sqv{W93cZZI=o0EMZ0J?n&sIULk!u0W7Wc0QFy2<9V4n8XQwoX1aZv$T0 zq@v}`D-W!!p;K@E2;F^N9o$)tZ=?TQtA?du8UN`joW8dmaT|!=WA9DoMq9|>x$V{6 zS-&dyEOIi)^asepMjG=!F-rR)&Et{%JFI=h{u=$89I zNL0ADU48p4*K=!&19H9I#-J+fA1;sjVrVO@jmsh7@$!X)aE)6istxnEB+{G1e$II?djb}b?k3BPG|!=q}7;X zJ6!Wde94@crE8Wry z5RnW+V}Jwz&afh;--r!;XgthHYQ)o=IYft>P{tq#V8{$i0>tG$0^==8li*%{KBtU{ zrKekS@9#x(2Q+03tdHoIQ0K*20zjI#F>bd-iT(J^$A9TgIR3wIr&eoHuU5jj!UD0(Ab{9`jU|Aiw6&)nnn`0j*6zj6 z=aNyCU9GnD$)hE-BAVSE!`sI8f1Wg>PQ+fSv4Xs(!bTO&dTqW&w8s7=~z? zw_*e^#niyGEAA|B)g@95Ln?7h@I*MmS@pHN-t9}U3XLx?j{3Dc+tjoue6+Htw%82( zb8l{+;rhnjXLaS{aTY!)M&)u5SLZKL?f0U*VDn8W-aJxR2x3C`HkDH=*384Q+Y`^x z^x)z!Z7-YZ;#EX@CN2U4pAxx$_GvNaki#1o*$HZ zEkLaf_dA#LL$kc2MQ8x}TjYitot^06AKbfKX^Cj9n@Ro9GbIBbOJ zJ9Pq3gvN`2Mu7yHZ8JJ6o^Ih8^)0mFFOBLAwBLh7!48{nqQLfnkXocUK&ua*mAXY% z_V69%?-VbzvK?QtUsP;+bS|7bp0s`6@c$ZNEiJkhQ^6Nx(-I_J*&BgM0e61@afX*( z5CEJ#eEUy*9>t6C!{)Z9hCZaoOaWb?Tw}d-hY63Mdva6@%yP*u({RL&=riTf9Ix%Fi|uFG9?$Z7n>+*NIL4K>g)S% z8_Z4%49T350GwsPA8V3IJK=K9+N5(a_y4)dLk-|TX#C}D)unY2!7>6SEhKq_G8t`_ z&a%J2VUZjELM+Mc5$WIS@Tv=$<2-FSsS&7OJyF^|@qg#3^=*YpC)1AlCg%O*nA}#F zOb2~$x8poK9?n>|%2(ws`HC;+?jVSe(NCb&t`oGQCwF+z!*e~as1aAxj zB=^ed+M}5TuO~F6Fhil5yy28hgc+!NtXvfK`-dIM4H*Hx;LX2N{Nd{~hyT}bBM2lz zJZl;B!0_O^KCKa0Ug2+PIl6ml+Q{CUb@vF+dbX8myl-Z-k%8-3w9riuttnP-Ev>eJ zc187YQsyjhr4?q$iqD7%DYq_YtqKErj)63Lla{8Gq(CFET>zk5gE?0Q#Rg&fk`gvE zw0sS1tXgRO2P<-TX8Q-xy)?rq$pUGN`_6-ll+dB$LxX4t<4=7{8P+M@FV?K-ax9gu z^q>hhukVkqKAu{8*_Lai4USrS{4~%faM0@Ey)%r?b7z*Hn|!KNUB39fx22F$6_Gb1 z#}(yV59DB|9-hFzsOS2X<}*^nd5D@g4gQk4YUB)u)BYLZ8}VFS(uYYKoIr}pfY<** z2G|_l5hot^daY50e%lko@!#JL-g&`~?G8>5bTX;l zO!~Px!M&mLC_eyV#pGBy6dMf1{`EbMmeTr~aj?)&41B9fq^kxu_YG)-%(AuScGJOJ(-U;%3av z(@ob)TJw|sEAj5d;Kg4H7t@a8tfTDUz-r`ZGCYRfo+x^m23{yj%TCxKXZ|QoyO8jERT}k*$X!SEP)IXPc&Q+SN^bn(> z9+`oJI6zL4lRP{T-gyeXqoW&ZwVdND2G+RwN5>K(-aS(HxQAarb!SfjtcC@wMvd9^ zV45JR(*kOI1;G~HdF3MxcyA%b@_&=`MSSyR&=A6)%-z?MQ1jR5@qSl{C_{AUATKmJ zbzuzHZY$yDHLL*WDV_r93<(Dj;w%tU{|l|U0wdJwqAawDeR6zYyDFY4k}={16y+hE z7!=_dUDQ45+YW*bIYCzyuXk6ePk6#Ff1!=q(+AiQpn5wEu$d^}d-n=;PL^7z2H7X8 zUqVSt*nQnD3;Z@$^j;cuU+cmCmWES&$c6bB zN6BbZocbI-oLyoXbkcqxV-zgSIc#DsDJEzv4dZins;%Uf_P9@0m$qmuu|FO-G&lLO z%FTe}%fEU{AdXs%&Bp~!68fTCmZnNV^Q0W=7#&u1JQx<{`;&Y)EUau3YTvkXlWONf zhe^0=$AD-w3>tcU`$KW#pKd&~zg=d!?>pYa%b`z5QW)ZpytS@#V~!8BnJa&Ed0FYrJ5qm0NTF|_#QW!K>| zuua4cAjx3W5<#JG5`GT%#zTSqwjFhF^W4tw9-)*&FvXoKlO%Zp3%J()=)PEh2j~wF z1*@2^wm5=(X?N=_6}bnW&hY}4#8E6aVx;kHh)fBVEv-*`CpoCs$lMe@;iCL?;tOaY z_sqmWFU#)K%)NEP2Bzb6$l+vi((~qR>U&)i+3stml>qX2o7zA4Wurx?M_gmZ{9(3u zzjIq>`V0il6!ms}I;#=uiz>+WbOe{E-sf4|4M2t0@xkM5Gm@JG!tvcFt9uN+sWJ9_ zYj>>strvt{0tq#-#d!5w9F47^Hh44)cgxdw(QoJwCs@ml{ci{C%OUHO3QMZ=O`O&J zBv%5-#gJJuKJ&l=H~77Dt4w&>zsMK$y`g7&jo0dQF(PwR^kjWGV^1qCq1^!`QXpuN zWdRgnx@Cn&)rA4hQ#j$OWJRaRo4t8S&t4j-6aFbVz{bIE&0%OyLTD}axers2P5=;Q zANivw{Y>NE3a14JlxY!dgE>*4H2A584=54y?R+$rw(Uyk2ZI2pDzUco_IY39#Ep~l zD@aImhhs^!^E+Djxa~XH^-Q=RsPU}>cGEmV+7uWb{|oRMTHvMu*ttWvec^bG%;~1; z4FqlZHb0h(*xl0$?f{nDSzTKHyuYyCq6d6tLtxYF%KC+Wlb=`)_A#YzeLFd5OV8X5 zHUaheY|r+o+1=;GQ7h|hw|lv1)3WU60;1Nv8{KwNrWK0|9iyU-RgAqlP|eu}hYHK> z9}wmo@eqszk7Dp;{>;V6#R|)&Cr<^n$*Gs)&wre1<$J<4-UV>bBX6^lx`)gC3%_2; zO0mUJy$UyT@9}jDV{AUk)XhEiR^-fT=dkAn8|Ap5K64x>gKt zK2y2}**f`+HcVxx77Fi8I9A^T<+bvumDWRL^Y4EL=ey5u-K-X>uM;$Nyo*@JhV2CT zP5qlAfb+LRISe*Lg1)=-2Lp%{;~jLP>9_2d+NZiMb!dfpFs$H-@paNd3M5nWyXXfa zl3stjJV(<9=<%u)hkXeB63o~b#l=!glp@IB@vZJlKp+~>cc6@eVFB5K*j@_iyRO)$W`rIGm-tNN zxAM))3ULk`&HT~`V6Ir&a*+5QrQwRNpF&T4whh8vn41jVD^1*gk$A_C{Az1(TR(6g zUH9Y;TU@>tmqSRb(n6G*1BV<@#lge~{w$6~2Es#wEauJmTT` zQa7PRI)85==Jh=EOgh){;RUVceik%#9aQWf>cz-HWcOdlz)gC-=r0+o|n?36|^?I1UbT4x~oSf_^|5&VYT_kQPSH9;eyC;7irUNjbv%1fNewrl(4_q~CEC1b&S4(pKdh0wypDvY0* zX%<&zHMwr1gLz92{?;=Z0ke2ZnEjbro4JfM0d!VE+p^kmzzWhRb-2(vO1Pv>W(`Pl!&$c{LW5=ALVkC*4P)qJ2BCS~tW{TTk zIB%c}4;Xd=8Br>OFEs(%aG@?l8%5iBY#-`7=AK{f4$Z%;wKNAz$7EAnXg#d1uYcA- zw(xFZ#n}A0p1qlj!mSv0|o|FTHErh=XFYc*$7)-8QxggRHscLm_%8?%SN?AF{mi>G?o`gatxpwnjo@6lPU+S^qr7>5=MQl z*2(HZZA)U%VpOwpFM^3fhzdfXZo-cnUEr_;Fcj2b1u5edS+BV^f zc=4aM4(>$aqCX+$Dbl@4=AEeQ!+-79NrYM_Q+`|c?qh>#&#QdpdH3y|_dIg#y|ZT_ z=pp&s3D5^8&qL)~uEn7j>m4*=i*Oe3cUJ;O3hu0bNmmi>SJ#y}12pEP)GCL%wee~O zx63%Cz@pZMq^1e3;#Gl$Xa@8bCH2WeiEUF{glQY{x}E{EYLGr1_z|Md192{a>H>2- zY5~Kx?PVc@@fZ1m3c-heqNjy5ybpFM%B8lt@8<8O?>^^|rOEb!SLGM?-<#7HcfT|b z-8%gOa@SSp2iV7yuJOrizV4@Q?1+lr7L(MhKcBq^*bYV0W4D_~duhsn6CBHD*;1S2 zMpQp3v3c7DZhOQa6wJFOT3Fav!q+~|`&ZlJ`=aT=zXy}*!KW%==&iT;t=Yc2-{cOV z($?x>I{#Qz;5ow*1zFO1`#ll)xjfz6a=4U~^UODVR$yBLTjvH(lW{i*Ps1&(o!ZF3 z+3afbzB|4}Mp+m{I+P3zqSTmTR%bNF&HwG&_XBL=v7fJ?ChI7oQ;ULRNLhp8KD{hs z+H7EihA?N9t*`N5c^X`%HvapUJ2LJ(2IEw?d^Dt6VO zu0_rLQ&Aww9i2)rM*Vc~A8!~E5uVG-&V#5G%i&f-J86fhe>>hy@D&YsxddeMcFb@R zbldP(l62db@)C5$t4mdOQwJsP0+MGHNlnl#J+JLw&+NOID;#cl=PpXkGk~egO&Oh7 zzMD|31lzayA{rwio5UXX59<}~9oDKy*{CzHOx)(iRJAs9IO))#cCq~KeCA6sUd_wo z3YeWD>ZhFfT)BGTaqAL74U3W~6A#DO4jbu*UX0LckVywWFwo0|J}bEUC8{dCLa+XN z-hJ+Vw10`)S(WeuCPHpZPjgj=x+xZzAAMz##Pl~04hau;D!5>xfA$U+@xCg;P0Z9C z#SkWvo)kTbqHUyY{K8UR>KODh+=s^TfD`MgK0n-|J1oe`AeG{RU>*wyTIO0HBd9?F z|0D!ROhq=dG zVV;fE<37OSP%_-7KjNFoJS*lmZa1;mu;#_C%L_G(O99oHuPhA@#ReK8s|r{pFk+L3 z`V?v&5Xp`#)Zh!*FSlX5L#tD>8_6qnT7??_v}32ZT0*%?lk~TaK{fDb-2Hu0gR0{* z!ACdb&yM`oIFU9Q*C5f$CJb|l3MiB1L9f5PTirz@1Cw6>*>umCUQ&;XQFb{Pmnf=e zV(KaXvGWsqe8IGBOn^~D{8-Za?~~FeDF#t*4Ee-M`8|=2jg5=uo?6~}3-4upKW)3e zZlqCX4nt0ER+4V!0vg@lYa;%#irWlC507gBpp=Q4gyb7NI_6O@#jh@1yP6)LVAYT7 zXv9rq&`(**?l{C;Ek!qdfWb`^g?xt$il0i_>w84!uTq$yAx(yRk0k}~#Q;`dR?MY+ z^~!tSNz2F*Y26j6KFNLSpy%a)Xc_9em1NpHLKS`l>s!wp1*S%pwi=~%U+|T} zmUDHyv#Xr&c7IPa+Ov18LY%9wL7KCsg__yR9F*znsQW(DnhVozXy9s)We1$rfT-m^ zN6RoDv$p2eOo9eVuf(NFIr9MUHz=tvcVsw-~9j_6Gtm9&?7oEKw{gO-yTFkQ$k;F;({WE9U za@k}JvHL0wOkBDm0tP-fk7z{QSG07o~n)^(g;+!a_=JL_T^_R8V%6f zP@|x;x}UpuhL$UHV;>iM8R8I+9x_4Yzo&mFcg&2}5%f#|J*7r5b;h4_YfT+4VqcA$ zma9aT42?)dSNsP0A`MgroxKuQ85mb2n82!znk13Rv{_3$A)r`+X8WMKPfms*%AUO1 zBj=R@4T>e%+rMkya(O`$kDAR@#kByp|9YP@0^HWlo$-<08}8M;H~Lz`dvec{_;Pl4 ze}8NtGBlTNz6zIt`H%_Z=1S3Xn2t?dF6W8=4Sbo1(n!7QU(%>h^*RF=Vjd#Wao=ui|k&+@t$u~+@^#C@78t7gi3kblN>lyuQG)G?=LefS!lst)RW!(4OT z`eb%cF{g6l%v3i6EiXs|UYlThpg`m^tm1lt2$S^1*OdnKKF%+<1k_3SmYaxmFdYCSRpZOe%F>;r`DnLgO<0R;8@X3Jff!G&ag^LX z{IUg?Eqa^Z^LaS|nac0<12tCXZyD(Xl>0z;6aMy}0ue4)`kxN|6`%by$8gR-xlJoQ zBe2|>*7GjVjHUWp!s!wSkg9PzgZsHV(-hq{Xe=YHRRS&FLd(@ObT)T6uWT=_jII60 zyKZlU3i}!G`kiiWab78pm27NHb9Km=(9TP-ae@2G;Qb26J4W_R zB(Ib~)=6Y_wpyI6FiEojbJ3CCBbbTENwXm9i<2G_!4$oDsvlg6qvlvOJAD>gU}6>B zZ;e+s@C}>~d&PQs1xPFE3#hk8`90sR6>gxdDrzon^4w=GBPeBZ@(m&R=h=bpxA)^+ z2jlkvmC~>-4a8a{;l=rr)V$e7LRV*(6>j4GWIPnCnt2PME`eg2jKdfP2+nU!-Sqj^ z`S-XBLD&_Sx4K`IZi6G=sPFhx`qk>ECAD`tV9;G{eK9;@=yWyOD{kzMm|?v1Dn`5V z!^**pZ_;za)pLS2~zPNxB(TtXJtIT=^Uiir#4id0e^s5pw$xvlfj)=xx*8UQSK9C0e4@qC9pd3vBLu zDi#^K1DTYjsmhqHGd`HTR>8Xw&q%~kpWXJRPiz2;uQlYh8s>F-`s6Klg)RK8_;-lO zN=@sGnm+_P$1jP5ghhQ#plMd_o~<)AJ#OLE zhx!Gw`+!p#(3MZm(Is>gylQpNG_%L-!<$JH#gVa4H5OL#ju65=Ql+sSGR{hLOvaL z!z}4EC{h*~93bJ@3H2(emRldpJd@z+i14dc0&4D$Ms5FCHRkB-eqy3+84_-0`6Aab zsZX}_8Ac8iCW61S*X(EJ3KW5fGv7^f6Gu;oK37?@M%)^*yVCJ5`@Xhz_c&yX+|7P| zdNij!mE$BM&&yeD-;x#1C5rPC%<>h{EGi!vq(7Q+e>;9vJ@>db@#wE{jR6JQ{mlgJ z+#J96d0tiGR=zAOoGjd3xaz+dW<_x-|040tfH$>HiUI~Vngk0+gu@FTJ6i~XTDw7N z-YqL<87~p*0tecOzwD<49*SSn0>TGv<$%B=)dr>q`zN3mBO!PszzWl2>%iMi;Y+;a8CDNabU5{ATz+3CbVJ^>4w6^3+i0VHX)-WFNo`iTsN~ zga~OtPl>VBscZXQlgSIKnB;`2dh(Jz!HJHwEpN7waDfSNhgD+I)2p<}DJw>s!*2Ph z3A0$#9(2Rf&U3;TIQ@-BH1G(EqVMtA_u{l;( zS4$W%lq=)SGo0gK+*UZtMg1|h#%&^sil1C4pmhNf)+4Pc)wA3Zz!#_}}1jhWpsZ}%5w!KHu!quh; zb67fo$gHeW0oR6?Q~_6RpIj`m3`gyFVdgaW!#;>HPyK)sAHDolRe>r(n*PphJZ84- zV>wKX(+A}+I_hCaX?pbCfZ6#EUx_VAVL~9dV7}#J3M8&V`4UtTMtP8`fGfsWX9{Xx zTe-G>(P*5jt$rURuY&k@|5l&OTjljVo&p zEq>0Txc5(nD;ENtMiooIq{=Z~r60;&+Y%P0$Fq5XlQr;pT>W-ZgHYXpr6LKamFspt zv|j6;IixjiBdLdQ)l%E7@2=&X&?5}8isD;TFohFZRDd>`a)Jw9it>zUb*hmPiuC2D zd}WQ)WmF}~+R`W`6u_m^mMXd~vTm#&Ro3Xg2*9oJvg?s%eDq${-P&v(O6&G@F-+c6 z_kP|7>EAf$H=xY*qbh?{qfb#%gsL~@{%@?1fzAj{dy4nYut3Cm(ICU1Ki3TAfK?!P zM5J<`Rd-bK-jXEMjjo`zPO8$_8ej5s+a~N7xXR5_I3SdKG56?gP6|Q?mI>B=ISwLR zExbb=G0I&X4b#E~E$5|9rIDWNo~WA_nz#cEd!Q50Yn)E}9&*zmMJ+)P&iGd9{2Vd@c{`IYTBt^dB592D@ta4Z5MMubEA zW7kfO>c@>o%-)g>73XHy7X(vW$TtRWQKkxZ91!*s@NRzGd>sO)V`hJ=p=5vX{3sQB zaemtQ)vhLU=d}BYk4bCUx2>Y5Jjt|4U{3u+UZ>)o3q8bg5sHjp`!j_JT)EYMh*wUj zo{d}U7e)n(ak^K8PAo%!I)3^QJ(?L!+Rw5jEVBbnma%##dGqe;(A4`mwe*Cs-#f3{ z_v!KQKOxNyI?O(d*u;@y%G#)NDRJ||?#iv<*@d32fIt5n(4Fx(td8IZ4`fk{WYSW@ z@etC^kD~4l4(#uWwGI4w*4KFr9c@i~izCZJ%quXInhY=Nuo}oUh{^|}AI#*k1$T_s zmZE!%BL>YyIDZmlrkfd*Ml{}}YqX&%_OR?Fc(|edgtR^2rnPhgm&|2P~Y<{iC?77RIskBa!r$xnuERSm0l#-H1< zL|ugNj7UI0T@YHij^lGZeb$7Ry_MASTeG7EAJg7NZyY*`h0KGW zUjvm?7laGn?h+P8xO!>U%C-wOC!Fc1%F^k3GnO0{k_< zf2s3jS!65_2S76x&!$cISwc9*UMirov+#9LPHXv9tq^#O^lVhwFY;xf$0b$$_RMdc zX_sM)Rv3IVGwqFigSgNk*t@3&iq{=cNNzqd678lJKPRju{~eTGC7!*r=Glu(VwdK=;0WcHfR`r1Wvrb~mB%x$&f^AuOxi}iCBeu$zWkW<=(lf*&aEvNMtxbp8cx@Df2&Dw+V#~fGjzj_rj7<@pZfY{moC% z`{nw8);^~>db$23wL~s%x6`JO&y3(=BT2o6iHlBXiR3B9ZlFnOxRX(8_-$`Zzmgua zgoe&<6=cM_I)nz3{Iwx3lQn9Rp|SN#@tz`+z*a$5)AG)gG!WFjL2dsVE^wJB0K5O+ zWq!uFA7(62HZwGG_-#Vf5gOl8nCLIL$UYn4c1c;seKnVr(Y!~@;-s+_HlQH2AJaaVvPUe~ zp>FUVZCq8MvH#;`<7C})P9VU(r`z~(&$va;P;^bio5|N;vo@n}7HNfPbNpe46Veq! zrs`gSpy09RQ)J5|Xl9^P_VFBAk577iOo)`o!Yn?fnC}MhjnU(0( z-8e~qQAu}dy^z7lOy?*bi?10)yIE!HXMrrPzS~J|03lj0yG7U+J=c*%nQi^a!wogl zhm_y8<>h8}4_F3_E9>{|T^6mxh2w@7XR{^MFe~!nnVI*x4;}Z%m14n-)0uGp?*&1 z5PtF<4K2m$@`V^e#jfob=mb9I70kJXqM$UVxPE0tiC z23RC26r-(jfV{;KU;4eb77coNP#RA&a`{BdVt6w|K(5XWyjsqP_3pX9)f1C|6a#As zx;;Ma+^dOT-d9kg-q&}7EN^YQ4PG~+WzA$6#1P!Ww3D9~?3#>r(Ngfhl%#%i6?)ul zI0t#M?X~4s_%H*@!6ym4nhsV-xUdbiL3F`qsZWEkDlxG?9jD!L(GvuKyZ}0MG zv|*I0&B|3-v!|{&P=z3wz6d8$!tW@@VAdgdzMduHF;|!CflA8I`bl3j7>iY<+$Yt! zUusHpooo9*ootLFW!n;togp~|h(9!4`}mhGo;~kbb_5zpt?@<@4_x4XW9!IxM{_QC z$SGXlMsJr+3vSvWq^#8cX;leds3{+Erl6I3i^&u@21bX6jM&7zsD?Le2TxuHCUYw^ zwb6*hu@p9yT|WN=GD8bx+m5O+a6a`bRhfD(bC0gyGBx)SW8@BF1Y+=I)4r<18z9r# zg%!=E5e6G4|MmWly@|1r%4EdAjh#)sBBs1|BiEsm?{e$t7oMt!07B2A*C5dTdo_V= z$A0gAe*Cv;;+`pHtHyktG`yKT#f?eQX5QM%x(Gy6uHnLB5IxTS80`U{`JhDYiX4%U z*K9H?0m0IRaeMZlL<)WA29LE-ukK9u@OhvGTTjs00KBu#CSq1DH=~m>^hteL_y{FF zby`Ne=vsng+tQI@nzdPSCk+n(D$i27^2gSL;t76!4K zeoO`h80nW;L)gF2fbl+*@onSSIg(L;wnOoVp)73so>Z^Eejz)to|=-a{_g=bFmD`+ z{bJ6|6^{cU3Dlx}T{09ePTCwLYaU~3mXEf3vX3TL^Qez;rr=vTz3i zYG-kZp1e&!t(uj{bHf7)l1zhR21DvC5h2k3#j#I>=Q(#-8m1_iDtyB&@i$HD$qT)o zN4x-t9I!^@)y-%E5SfV33(MJHvOT_JR$}sfR{ijX4z0YCFJ`DZhVjlXJQVvv%Cx&%*U7=ZOHD;#ryp<~DF)Gk946IJ(CGrU( zK>*Io^i$xJcd5)W!NMy8)WN##!3`C#yjaSX{AKjrTnjs;b->B$!SkM%xs|4(dY>Q{ zc-GJhdib9$E!cEhc!CaxVs4rAS-P+17y1EF+@}QC^KSdAK=XBcrqlGHBAFU2yZx!+ zACIQvUyUzt25<1u;~&3zu(R}~ZsF^l)&{)U`K*H+vu#Cvy_as^Lpbe9K6!$r+AXBj z*jYj-MYRS8hm)@#Ta119nXr2t`x2UKB6O8!BAEV&4Ol?ei@xQjm@arZHd57k`mNs< zB7aP80;U+nFG_yg(fTvyKKaY-L)Spv1Xxrd>VFD3FsR+w-4{4`UK^?EkDCC>#OuQq zg~Rbkqp3eW1QBeEbc4KwC+Ssyr|5_WtcW*$$o9uHEMTgVCskvtGUFY7CB_>Ck|G&* z7=s8#s!B3VP-A)bw>>v^?InTT4`qLF-QVY>G{A&+n%)NY4si5iJD=&Fhu)(%+&j_e zh|47S{g_-6N`G9#oPk=3A|Qpg@ta@t{A(1~&uLe&qU(IZ zgnoJ6Y3&|NE`to+9aboS6=8~D{BxMvCmAU9GSNYZHd2;H@B|4{nf5R@gpC`t)U9cr zibiaN;MUdGXTTPtV|)xe0ZxGaAC5tWrKz3J*VO&{`pI3<=o*+isBRFg$VTKoEK;+g z;_EJrV7IzTO6@zdtdD85r88+0v~j-53qC*ef)xJ8X#U$ZKHh}IpT93#6&Sjsx&soO zFh5Y|mxPl5uks;(@TOJ%!CM59!UgT$un2IO&nzBZRhP8k4$30A;DE|?h8KaHUUH2R zsOP@JUYojGcB86PsOC3N07`D+quemj^2hDG1az3Rc-@fi&G(}fw&J)a)Kzc38<+nj z?oG~%PUy>mutOTm_+K`;N;tRFUyeAqslK##Zz1ubwE40FB*gmn+5-W&mbT(07I3ZX zPGy|z+u>EEA4Y?0uPEu=@LS9qpTvR%Zf&HBL>Jja#izMvG%SL+U69Q&d;9(y91u@v zJ8eM+$Zmk0EghT3!v1>E8|Pn}CnRVyN8|C@*^YFFVKE+ zj}sqwb4w{k9GB6c=Xqv)J5J>wTHggCpUFSG;Eh8sDB-Gcc2+bm0ez>i#M?z2>oF|; zj%lS}v>(-PKwiCHIQIouSE{xCrPu6l-bLwsE}0|e(;6&r-hS#UV z{LsjCpzy85ofHE7ShwxlFCx5&?|*(MH`wbTFu}rbVr&`xCzzwi&4&#{fS&E;X(mdW zkZ?Bst?-6#G;YBUyxsujzVBQ3FWTyEPc1F7(O6+{lzcTFnKm%DrzSE4v6>f0zzm!n zRyi^W$nh}DO6fL$eyrmY-@Q@R zBR0A7@jrkDiWcYuT>l#w1zi@3$`-P z7kl>yd|uM>qr`fg!MvWl(E<9NK0Q&CSq!1$WfEF!D&1JLdg`Qb4_y2KzKim__9?0` z4($@Q206mEaev&%H(aegq!?rtKo#Ucyh0W};Pk1MTsIMQABxhc1G))j;vj%+e-v`& zO?E2XR$V znA1!YBRSzZ(;lS|6;{}Cxy`PtcvyPOQUQAQ&RXB_Cxk%P5yYWE!-v}-vO6;txWwIm zp=8)3P<_@&eN_Y=2Fr0WbgVJ!hNPM;z|6Iw%!8Zur`@ZO*3A}8!!tc$GQ2btu|FgD z_4;I`h0;F<)0bmq6W(FI$zVKy}G|g}|>u zxA|BSmA>=?)i43_5C%nCULh`Ugmzf)kzB#y5K*_i%?*&dJ`ro2;n$r%l0;a))b0YU zYFca3L3Ylqw}gREaDnsx3FW|~K!1IsPn}{U>(JQQea(~Nm8;LD(Ax`1(93%-d)lP9 zu>#MqkpXsBc1W?BL9NKzn#s`W!I$xB0Yn&a0e^AQRj3egpw9zloxYzPuSm7$`QPKQ zdqe$Z5nlJ4)@H$bw-$9n;W7%13NWQd{k>o6Z)9@W3-C!Kb>}#Em7%2<;<8aK3))oN z(jnB;3l-nNws0LbsKuyzg!A$tGV>~+t_$ZX2cgfT6FLZpa+&bJhSERbMR_bdtP|Y} zFul?a6vUkc_5=0!5K-q?+uBI8Ef)PdN?)ueL|(Cf03%0_NHB?_>Qzt}5{D@cw({!2 zmpL4nc7)lPh6(wAs1TF+jYHZm5>xg{`&_N|`Ks&o#)V1t9Je{7S#YN3G#)yp=RLBz zBNg=6Au_Aih5uFEE57}yvcC|;`bcuL7)GYr5I%JCfjYabcot(o=ef-tFO`X_>~)l$TQ`E4W}PUi}fgeuV^%7=prJs&sy-njUgk>D~vk}DgZhq z0%L*OJ0m47;EIC0=R3U{8l!A!#w&Mwy4x6XWKb-CzE=xvnBQu6`g%Zp3QRjJm<5^f z4>->OrEgw9lr$1|((B~~#;;F^icg#8@4m#C>@qnRXX;FitNR;-gn18aROw6^rBJwwaeMk(sbI2~ODUYn**e4G-@S zTRv;X^d$3eNNR&}9XkmyLJpa%)GOHWJBCQ4*!T7ZP^;eR&{4@_J#$V719lh^odEyO z&aMHZJj@?iTSrn}1xL{jCBOlWCd`%DiwO!jYuWoOzi3g=3P>9`N76e#KYpfj23Ymy zAHb?9vh??4R0SuoDXtg+gulg&Vq%Caz^4@Ax3%nm_78t&iyLq%bF2Ey$q=B1CIWXm zf$HE3a8oj2z@>C@f=G0Xrv~H5%pXefL>lc(2?kB1;BU-NpvaLTB0$Rl(oP0QJ2?Ix z4BwKoU-Nia|9NLF&jv*4uF?<7;9i1-t6OFN*zFn|hGCaSIjPx9+tZy`lwg-?C9OyN zc(jf9PpSGB1w89v1;x|-W5XTrokq>Y+7@#Q?(r;c( zuD6#Skm=o-!NOA4PpR`7)jQZ4l>n5lYwi~N>IkWHb zhzoSA;he=j@-WvmX@51!Tbm$w{OXII3AKFXqXXxWd*pT;ICohrSX+v`V8Qe~u2 z$C0v`p5S^L-vfAFcf2Mw<{(>Kh&L~*ZH^RMow&p{u zjubM)ge52(igd5~y0dmR-A~4XvGjipWh}@8PB4-ojmhgz0{4R89&cya2tp{4^KmY) zT188(u2uQOT*OTz=#XS(^3krpT4Pzah{Ebdn8y!7{ABwDES$s!A6L>rmhP2MSKYy; z#w)(ppRFln1WI0h$%JjUFk{V@m4H~MW`LEDFjRd<@g{K9_e?2jJBlYm;$BPOR?3p z7=N#?xXH%m!)X>H`?-By;A#P+VZEpWKSrmId*S% zl1&EQviBZ~4-LNs+&tsBt1`~kGT?I<9ZTKT_rSmV!v+lon(gxT>laIRTeKs_QvQr=8BDAl?17<+R(UB5ShWJl-G25Y**`-RZ;Gg zBxL|BW-_EWWj$=r-VJGbt=k1*CN>V9Hzjh$fe{g9S|ZtF1`Vn=Bo;0e4OF+I**qne z`cV5(9BK#1E zQJdw0_?v!%e8z=;`Dnj1jIdnF?nz`*LRvZwp( z9zP{X9bYB7F^L#26v0 zt1Py7g{mN9T*hZ+Au}Wi(10) z^>qx+$jj%|16-4nud2TtKg?~$6DyfOj-E)6QO}IZyI$n-7$wrL2X>I9QLaw;N`jVt zXN(d0(xBL@_0P!MY?|Ix+}NCC(pH?~!Nh#k*0@nKuvxOxjEWVXzS>GOdqfGM0TAAP zC6fj~cm;@Wjf7{@mY1iB|5Xqe@_MKf8T}$-&xbv6+!H17%Vkb&IQ?F)JLS9jI$QsU zw9KS{gUMWs<)R^i>Kk9MW8(cN4bTo3Gjwyt?1OfXP2X^2PRQmVb>6|ZWyuq#(UHHf#7!Rsy<&$ z)D?iWeC1URbC+a693;fJdA@SGnP%{6(DkW49r91!ga597`W-B5PJi`%zvMC{j^8M) zH!JFlUph=C{D+(^#9{nI7vG}mXTEZ|Ety8+wO4R{*{uTL5`40!1!PYute;w7IkMI^ zroN)QfP||vopYl2{>FRIWS^Ju1H?lk+R7ng7e=iW|Mhh~`N7vye}cD1%XNo0EC7y< zo*Qjk|4{n8S=ZB*1Xk%M3I!l`1-!I!gN6L`fDlO83esn_8-x;X?4UlDjl*Xpl@Yay={<=m7pZ?pC;R-`cISXLXAB< z--2B2-RlxyCUQYqf7@f&sAUP11hEc0%6rfLD*u!n1J8lS2-4IR`84HNKkg_u^j$5f z{e(yx#hq#uk2J>dQ{FX#E44Tm$s`{jd=jRseA|uJV!|17L*Hcd;(vcS%und$i})Ro zm$1Yqe$CHCQWc6cydwu$J}KgO;xe~q?BpL3I0%KK6hDebB!Tf8$4)H+m>eN z&4#j_gNA}hg+;{!9p;RI;GjsC)vg{2T3~_Opg_mL|xWbU5rILK`LS$A-A|wO;7wW16^V$RaE%8mVE&Jw?HiUvtYK(CfkQ zEc)}U;pz8BTdoj><$Iq3H+#si%4#v&Xh0%ss3(RCb?8Ab9%(Ulj3Hle2kLgUF-{4I zvSXk$71U9HsFfzdJ@XT-QO{*XW#=dpM+@pID+g30C2|SR(^lzG`&iJ9|8E94CAdhr z;!HZaei!wA)!>sdG1dPqk2F*WPY1|?sx2a2mL{&zw{i`Yx~`Hu;fZ0zL-7PLF@Snv z3EE=f*IikmpQ^{+es`c&;oBUYsuU+k^xyOYnr_Q~g&tTxV0*M@(jf~+WPF45z!j=W zfFy&wFgV#4hPqqy54 zKujF>)6pTy5{ORs&JoMHFDR2B!YuuSV7fI!eGc5A$(|gEsT<_ z8Fk=IkRn7jTT_IO>+bbiel7y0sxo8kmkJi;k*O*dd=I7%FFH~dr`o(BUs|e1T0WV3 zAcGkp5Ss)?taAR^+kksqB8f!d1~y2Bf!Rxj5s_ohOolpiX;N^bMnFy0r!D3h0Ue4e z-bxE;0B5pG10_zy10D#l70uR*F0eH(gmBZI6Zvr8rb5880UMAt>?M!s6F1Q&71%iH5#`%e=F7R^TfABiMhHNnT*!=m0AD zL@X#nX|J1&i?{{ARM=DWW>6D3Dg#RF8ABfvcxXP(H4&B_G=b` z$c`vomE*nno&|D!WC?ifdIM^~GHK#`AR95LXa>811B=Mf^ew^CQ?R}C=8(N$m|;-y zg!njfL|Bef1ulXANhFlMJhgE>!Qm2w>T)J|fip`4l-*1Cw?yBkz~r5D595pNsHw96 z)0iT2)V#({uB|VQb9*z6{>p$Pv0K>8ZuS$dNZPH2?8Cy} zF}3`L!I~W=1Cb8w9Vlax4mIX>6w@jk95A3gLck;$o@zh5|>O8E1JbV+t?0Zs+BatYR{^QLVz_UG} z44emdq+Dea=a3}A4}yA@Q%8Xc8hn=P@wPyRy^7;D%JC?r_D1tt-^+LO=L#IWl_pO? zmL?}lu+{l?s_HiK2Ml%wP7L`UneoTc!Bt zq9hNH0+10odA(HN9-;SjU^%rZ^uYHb_9i{P1d08v!tZl?ec$~}0tcna`VXP_SzP&1 zG_}*xEj0-!n@b`@je}nS6=2Ho0lw4NXyVK>ZV4}pm70|?#cdI6!?^Z;+-Rp!v37 zTz$gW@TTm8pzBOa0#ZV)qB-sqeZOe_9Aw7k`1^##WS~I+E(;XkvXIv?1IMt&xkFPC z9dq%9!U(4Y^cxgL6s?>HV)I#6Er}1}gX1Z&%+0s1_HiQf8a+4k;cYq7@=2k`(f;5vG5G~v$Auza_04Vo>T*IWI3GQ?>TeH%~z))5A z`3d2LYJw{WVOw5~5ilB$ADBD}KIp;{0s$}@k1G(7RM_yx0ZMfZ=H8d+a3AYmq9f92 zi}Xy%L%qlla4`4w(W3KwsGU~Y54E#BDt9jq5n1?i%A+RT)g)p>M2<0F8Fv|QE|k)I zWHD6%9JaKGqe@lHW27)lCGO%jWwm@*e6u7=mIt7*C0V9CvZr{8yi1HxZAo)jz5yuj z1EsmWdIx_iK$O>1gUm9g-mFOdEKoO365WWWd*l7o2zcnP)d=gTegzj{;O@+QSe!0) zaRL%$Q9!N>jP*nl8cTXzEpKioLw4ul#Y6!O`X^pnRQwtm(ciVsu?Tz)f&|irkNd;K zlu^qm8RCRC4ArAys957<{9RV|>EIa!~wA&t({>F-i-btnV?pCWwVl_kmtOYl}v zB8xN-j<>UX-R~Zas2o*+$74k0s#@pGhu31!EI>yQHB1>($n&zrNq9_y8U;BIAfa0v z^m<+jM>tP9J))FfqwD#|BFN$$Qew4eeK};vm_h*b3JG;4i3F@z;$M8n!X>uAu!9*Z zxvhMFCzf)j`9@C}prA$3DJ{ZG^PguL(xGj+!K5{8Bv+B9}!FQq(sidS-~ocNcHC{a=$z|fk`% zaMMeh6UxZe^I+l$g)&jHSGd~*z$m_k-=Q;Yo->n$b|%QkN7-Bob^|DH1B@Li0-l_e zXc^MOpJJA*cGLxY>H&+)*O?6U9Qa)v9nb>tvZdi=%@hTeEw78TR^Ku9&`G9`OK;+3 z^TGj!#miQO8$G@5>acG59SJ2RNBzmKGDR-FAFCw(G_Xn&7X^8W4p?((sn*^_5v-zE zvanwaa&X|N-=Mt|c9&hg+$sc$31tWbnw>)rHVYKU34z56q=}~rxJ-so3HNmIrxhN4i2iEOKn zb?Lr|=&AQuIA}dAT(Dt~7Y^eaZs{sPQdti}tKtNJm z#0KeNVT!+#n-pu>&2MFq7K=ni?;p+8`1K4g=E(^p<#n_WAa5spg#lX|^A2?rSyx== z{Cvt!n}VYZQhbR&$_B+bmOSlmZ7_RL1JKFn)Ixk#4jE!KE}{>8k>cR8KRilg90RR; zyZ68LALbQ^a&~5}_a$zcS8c85+sLsx%Q9(S+=1r@DXk-vruqp451V(J6(OkDa_c#; z>2F@3P&GY6Mnf5Z!t_-wW&8^InP^8aVRR8kk|^H`8BfyTJ5D>_)(OMZbni4Ev8HJD zLbhkK%@ouOJD0>x*_rXwOx$Z<*$+}16G%0A)l?ju{IYO2A##9iga8ntWIH6O*{^V= zd!3x{n307aQUEH(0DPPm*foX-Qhbo1pTEuR@h|VHOuZbv4&d{|S+%;Y=(M}CaAjU! zTSUyDNWK@fS%U1C@yhibi`RVu*=HN~#}BQRt66t>$^qaYWNZ481iZ-&6a#3$0u6wGXT z3C)p~rb5|$xP(LSW#V?+6wD$R@W} z_1owW{j7v!; zg@GJm{AspD1=S?WNFWe}dnAd2F~|~+TM43g5}@Qz zpZ;n-ew1P!wH$;p`~|j>6PBIn#o7#~n2%q9FQv@zVXI+E!C!C#Me2QH&#}&2V!EC4 zQlyTT2hd!RI#s^j7YTCV;&*l2+@Y{czEo9rvbwS1d;c17OLo_y)e`XaJV~%ffV~hxPlZDU1_ty2t;x{OGRTYK2z0$Xmt8wbw zk1UvJ2CQLdZ;P3_Y8H$=JzlkKbgU@s*b8+PH5n^5>@I8dEZeHgG9CT2id{?LgXxIelxrEeIFu z5kBIUG|~<89pITJg7rI`J*rW?n%(wYJ`wQPt&^Vtd)&2+=s9MNdWkj2m> zCB|utR1lNvBx*tE{YCdwPtvYLA$Eqv`I`sl(riJdJp9NgzAw0p9N~upG8DmHtDsWs zPZ(Bx>#;p2H@}zQDCz`=I7x9vc5p~OHZCotl~*7LP@5pd3o$@#;?CVuNI{VptXgm0 z``o=z5Q$N(-?$6{O%M3<$A!QP13DulWKbA6@qC-xf~9QrCk~&0(7mI{-@*W)sb&4N z$IoAOG?JLp66G+&>#eUSczaQS$iyD>O@uZ-Rdi)+Y-pnq1;xWs@#ZD#Suqi5Mid8j zViN9h{Nro!6mW4Cfxq5P7$de|#Dm@Mp53v>MX2CV(BpwA!9`$TgUClk;ffE+0%dt1(?vzC{<_w9GoV0<5p>HmHkG48y!s0l(a!60 z_w#Xab>#Hsp($_r8B>CVYiNjhXr~f6>qtFIZ{PmI-~gG9Npaxqu;f2~df4E+<1bm% zF&yUxfe`0$t$(eQ+8QJplrNNxD#)#Xq7mgmjR zZa5t7rCuvu^W=Gc(U3(Y2(m;it|SpIUV1HM0^8nP{7pf0=23PURH6=3`?LSr5Iyj9 zcf$3iSDPD@X}BQmzgf?~z*4m>Qw7$o`yE>i=9>y?*G?KU3F8X;2~ncE;opMd-z)Ei zQxkqC@O_M*Ol@_)67d;by1_p!_4{q;#*-zXq5udDMwKS!2W!O8_0qAT)mIR>4qcec zQ0gKp#6NG{OEps)8CP!OWH@HN1s)g!d19p`#CqwWv}eS`d$!un!fGw%*R5rITIS!- zUCsw95rOf#)%{6ZwN;s3DuH&x^R@wM?64u9b#eDFU9B1>x6ikyn|flMyhG~x!v4>e zZr9j~SGWp|9$u`?-gdG*Q$Kb!4Se}0OX&gv@^YpKc;cdnjYR5}dThHtEDmtJH&}W2 zUFcG^p|fkQz+~}-y97+|+Fglk1~Hs)W%PGTu5K|CK}wh93FI?I_qbr0oJ)g(%LRBc z8IK8ccxxCmpvk$X)kc)(_>y$@Lr@@t&z}Pfr-Y#bm*zlaXbsw!8{mKHDfifYD2mlo zXJ=qF$8=4_)2_uRKk=lqdOtAf%T_1iFQD2v>UCTBXWcSM&X+b0vZKGwqW=-emKaj@ zTM%w5xqHw=pcW0$xbEp_c@YwK-W2@kplw*^^8Dje#$({e9|zWFK!8m~z=g5p2CI}Q zB|&;%QW0?RGN(hSMXI$<_8;w2^=qqs+(KutaBU~>wpQU^yje&~}{VXBHiAIRM(Qb?XgI0@2rVQ@x2 zxWn)jhcNamw9TMns&4Dq6S*xEF1!A&>N>l#AxwUfrFLV0_;>jlr5rC*6jlIr{kfTfP*g?MXAD3CMXaO<(_F zQmG&$0LsL=%_1ZfR!}P6`YN7BG+or>4;4!`6RKCBr15bHZ6#xf5#RgQ*9l0YI8X|5 zFJRnPC6V<4c#>pPNk*eZE;O#tl$qj(^%I!t!X>KbfS}Hc?i2bwVB!go1)rnfPJeaD zLpy<)3NVT>u)GKz2D(FaWfx7= zn1%Mm1y>VIji-|OAODoU%@?L%^HU?7A_(P|4R>65C&|o&KyoIyAeIRi&0lW0;~KSWz%=8r~^jnP$1v2gF)aF(X`3Ya^)_)*ca zNu9AoXDHc(%DiP;(kl#5j&W}^>&(7c+5h!?IF}yoERU6efV_lCYa4GCnduV=TM7Y^ciXb2;#dF%<&}Fo2!{I&hR*?4eNxanE z6eHc@xip3qU9i8{`YN19G*8q77J3#xy0WT=LXR)Syih!) z1rAgOQ3Mt>F??%LQk(l3>v5jL6~#Z^g{SZtQnI(2oi+xi=b7h@zkPwf5hxK7DI9oG zruDc>jm&$~zgbVXG2fnmI6j|UGhsf~>V&p+9D^T5yBrd=oP-y#rM{{ZMJMo15Y&C_W@;EzhtVsW> z2u?y_mb>dSeB!&$4s4c$bm#S}>$1Bg8I39G$cVXv3!GlPZz)s&0=`NTBd7+x3Q5NM zP~XUytebgZFqM*zM;VmnLMjwQN;i5F0+VK;Vg%QQwY_#LDfg9T6Jv#4TTKSX!z3aJ zW@>y7hIu15Ty_?Nm){3g?)ANM>^1UW45vvhAMH*sB#Rcy2@Zq`7+r0SW}M$&Sr`b$cyL(kn#i+{xUHzd_PM_IHM0Z^>I+9EPtjGM2Iw6__x0 z7TsPtA4~nFpH01=EwSCjv`wmw=W(eNTi+XZVhoO+1+vNfkf&HJ+?;glz@5X7w5jRB z7&QO#es&hm+gZtxCSC{M$F){+)tyHE55@(*ijOnXXgv^#^=UulC5w-S$#UKY6-Q<- zzh*hbKx34Q=G6IAh2h9{28geXSGuqf$7mg{x`n4LG>QzIZIIgN78-tUajXWE7Qn&m zkDW@Thqg${bs%iY=DsEC`th}UQp@mkX=^i_Mv5e#^@ooE9Qa(J2NOC3aOrF z3R+>tbH=B4&qy{3eN{{8%4H#Nxftod$QvQEUP_6=MLzBQ4?54_vm`j6XrV z3>*A4_%@O0*3}H|_|3#ogxRf!xZhD=Yu>czTqxQV5z-xFPzI&Dhj_GviB0Y5R<%(? z@|}(+OKtNFx`b}E=xSMoxa8vAW&U6@!nZrpWGeEM27Iz*1SO!B(a=iy_ITXlj)n8D=W!x->B%MxP?H6z22>U{%_WVhHAS`v!QUaM;&J2TA6# zkXP27{2{G=LR?3Gll$dOc|L-rw~40pDYdZXOuwl4JH6;>j&jS|ASvuU?|#9k1~yp1 zq9!&)=rHTx+fx^hJ@>t!d_#Tf(8V?X?H3LGxykyoLAyqj2k}sp)t8&G12xQfD)%wt z?$9Ee?siD;$i^MK$e-@$zrvU-xQJwpInP(SH~YJX0uSj9B0ZU)M`!3G zebr@Y+Aa%R}|Cl(E(SJ3VS5ze;YY67X@WTwmrVVXlzf-}@x;X4~=i+_(63KU?2GZQ1@Jgt1vAISM(c>pnT2eYoS!r|K_QwR-vQ zEy1k71GIj!{mHaRyh2F7797(VnI&cvb!9bSpwJRab=9yqn*>* zH&E9WZ@1=6?($gVhuo9K{v0@8Ij4@@3LjFv*5&uls^)@hQhQ09hHXC%#cq%~$jA^Y zcc`bW`73NkdI8k{pTO6_8^gJ$n3hqdJes>s%1wx zD2)OnZ~K1os+9(J6dq=`*31#Dnc(uXgc$o}+&_A`l{w@H`k!gw^K!?H$W54{xUiGx zyEKw<<|kdTKc7436GTf-80&~^3JTU%L2Wxie=UCY1HPBo;y*eyT}S$8P_9StNyq<_ zw}GMZKG!Z?o`FY?K9Th(=f(Tz_hFdM4fa=UyrQLICV!mSvYEUWkt@Xti*sf5M_~zU z(KU4jhkjeZ`>@v$Y~XkCiE&aj2gt?^pau5Q^eR#qeM?_iYIxz--uVV6iFGySXp;+7QJ+T*K%WL+ zrZC*EVNVoxMy;;IVq@@!ij5}rZk)oNz4?l#+9=5Vj8rfSSi~CpOy*}~%C^&6z@}C; zs1@m{Qf6+($R9hc&YehNg+<~Z!V>`~MJyzw!QCr8Q#+R7n0+fJVZ}BD z46rIRI2@dnwV4OXlctX(fE62NH#Cf`U8dTPOy>1Uif-UkvLr8zC~K_9*b~ivonYKC zmI8xKsT2ugpknhwk6j~H)#Sj=)VI^Ujm4~{<0zG~zZqS6eEe%Ylfo?I<|n8t`~+lWZ>n%k4MZytJYD&%wquwtR#9^8+j*^6nvxF-vSGvf%b^9g- z`j^TN9=D_^7x&}pLjfQ6Jk0w%W)Xx`tHf7Kvnyn6k}jm{ZGWH6|3U-VUGh5(wGGpn z_9yR7?VGcqGHwDIQ)CAoi)lBfwcogv`8y|1;kI2yuIII}DMsFEP7XBDOV$?5Gr21v zg-D*`hsbi4XC+u2LGLY6pSu1aCR{T7-mb`Oh+u7JM6<%Z$1m>8m*94HoAevQ?ux}G zo!#E?JQcXY5pEO`#!VZbhi|$|4U2dNfK+KGukj3 zLKiX{PI_6%!Q99!ZsC2t6`_nQxhZG;@VRF`#^-1J;ztVd*!W56=74Wl z-g3w!1ATIiAQwMd=58bz^$(^3l~Sj<*UH5=2DY)2djo9J3t~G&%D7?F2Y0`MOnH|% zNH%)>K2C6N`HvdZkS$|vH8w%Lo?v}F2G)4$f+5r~*_KC68<*%^c2{02TUTPiU_r^s z3(0G2RUbz(*kNTtEXsBnSQ){>w2+H>$mV<+#H{(FEpx+>{@Z4pw* zDFyRW-8R#g|2FO8#U*y3DX%LlDP`6W5g*Rnhn67Q)Uy16lGg!$m3@~PyhD*meTbO+ zj%Bs*hY!?!T#H}hMT)0%Vn?_Zd(R%3Umb_*AUQ#V3cdOR2a8jM15cYf{)#lsJ6!KG zHWmHJv(NY=b=&+b%^|>h-U1~O=~#}ri&~B8g3IgSd15)QdW*DR*NW*G%UPRwU!X)z0t*ya{@henrd<>xnj4XPS-g$}nb^T9kI;8p~ zw;nh7X<${{`@s^`L`A!XcECo#MMHzmX5S7wY06WDiF48nc=aa_GNuV9pVGjJ&Wv-% z<(-8J3kr*xUM_l4mtyca?gK5v_sd&Oz>YtnLB2o2-4H|v#DAIV6Pa-cy64ez>=RL7 zc%;78wPo%a5&2|Vuq_QG*QWYguB8Vo`d<^t*RDe}*&uY0372EI9>?0l*J)>@e7d#T zQA4+~-;%N%TpmU{pYDK`vZ@acOKz%;#ZL42%!I>xMmrCsV`WAGiwM9AirAOYh0D4W z`$L$&BYZS^U0~>0RKy^tc>(Z}+S>Ww(1D1@03x0flw@FA>l_zWj2c{jA9-|5&i`hq zIuW~5O>lH?p0zVTI58}Eh>){|90O<4h`)Kd2lxQ`R^tzQZo@X2?^)hovxGF8Y9U(* zh_ct-@lA;w*gi^0ab3@eXvFw~2E4z3j~91bYg>{xEuT;O3qSZET~SmFAqz7os5xTh zB0b}mbkYZUCFqwO-B3&jq^^QXe~t(?jR>w)l9^|msFzK?l5%(6Y8uwErOorw;Yut2 zklg2uMhuPf+R^(dyb|yQH{0a3d2!G@{x_3GqYHw;(lJZp00#u%01$*pAk`I$(ne|7 zQWaN`(FO%OnfMCUn5e%{!AktLP`CT-lLLno3iSdsj)xmPPi6B?FY_><4;jVyO#+0jD@kFU(JrOrh~tqFzj%r@>HrgIE86?*HPm4I zlz!1lL)-t(RGeiKMa9Fc)3k;0UZ_klr?r4%uEJ#T{3S(_ij1T|c#$c159LNh#5^8*{O2oOlO`uigC04B z+Tk;op7v;oU&%@D)(NDm=YtPheE+1l=*}iJ27Xw4T30&p=+BY z<&gx$Df_e-M&96!)URV@yV$J=Z?P!($wusqSYDS1 zkRO`f)Q#MK-Hd30vNzs&xKcP3&o)AxlinM+pAN5b-^-FveK88A2$7V$6OGIDlXnUf zDWx^9bv8YZe;OGfH!E(VcohHy;qS$eO9=c(t_YMcCd32{il zs2QHcORK{KY#eu(OEX<;#o>G`k7KT?4iSn9$q8*O#QBCH+QDr>IR<4liBPCm}@Zs$AC63R#F@-kq%u} zyZ~YB#{Kr*wYhtmnf&~mQ2Be)^=LWDu53~9PL6Tm9=fFQ#$J(Q_#ha*psD-%7e1j1 z1Ljl+{kWW3I@sYa%;r0=u)=Xp#_yIY8yM2MaD64BfRXEu@e5BE!1Y~Lb(R8Qq<1(0 z&aLCLZvqTx$pi3((Go!u!s2-dV+h$4srr6dbq;ycSS~UiTXly~2iOf|Ps*g~<2u1* zZt6rFIgoI+T@9!31u#4UUAUw=8eB2KFKjl%^mn9?a54Q9`abOl26Z&t><~%uiqJDT zrsx)CnUCx_ht_CJiMD7(X=5@b-fV=Nazqg!>S&2ooBdXYZ{E?ZYzr;*uAXUpi3>x_ z2Kvi{F(ISOKxpn<5OL|}&XL(0yJoqj&wOgr=NBfWEE_uWfj=Tz{a@@Hv;2#lc|)S+ zq5R^}2-;}V8MdxAv`mnqjQA65;pxX)Kyw23wtz!+7 zSGrS6L85U=2;xPF4Y@_zYBJ=l7^HBfX;+t`BB@Z;`Ni(#xQBlWEG_a2n2;psLGcJO z@M*Q-HAWf`r!+Py#nX(KdVvZIr8AEavB@r_s08q#+l2&)+o&oX^Rn2=)uLU8i-Y+2 z@1ITYJ)_U~rC8XaWk9?Lalm9f*XIp+Ylc+uOWsNSNa9)~kY-7WlZpJqEStzmhH^s) zTE1SttQh>DC6t%%vKzK#_fYEQ=v0i;1kKku&YFjp zO4H{M-ojit%0JF)%=C#nqmWV|dMpxuH;Oz0!_zs%tGe#^6rz>gyhiolg~&q_uJuGB zz`^6JNDPvMAi4D5kV3RXn+|H3hDKGIzS!&rMCAd&gUI0l%dw@G{S5zaKY0t$Ad-X( z3S}^noqk9sp zoo~B0Tds^P4k6pMjT)R1>472KXo=(gW{vO5@Y*ur$hCStoSc><={8!swSM*IGF-}H zF*I8|e!zq7yRzv{Ymo!}oq8wiOmeajlb!gXLNnn87n99Ln0n+TbDV8ow#F0u zE=l;Pk$D{eJnGxZ8XP}~^&NFGdS?EuZcG}f1HGRH@FPl=FP4{)miHyAF^0L=@i2YX zTKkAN^z9nxP+7G#b?zhT#45ADy5t?S?HiUrj@y~(^9*53Q-2SUu@*tj-|we%D_Phs z{x_U>NbE?H9x&Wdn`OJ>_aARVbB>$7gj!0qT%5kpL?R3)SH*h0|H7b>P|sD3)oF76 zg_C+!s+Np5R(a;xTpjZcIszkw#{wg{!dJCf?cVMaEjE*2q*~0*)DEruj{>N8{)fdE z{nlLw0;4et0Tle|nohvd9m~>pQnXVbT{u6VLmUKly6lGY7g8BZtYy#yI zs1Vd9=iniIm!}!i+Y52nCEYHnjeFXRp40(y{w#=Pkgz zeB00T*pyfGBW+?a7S@_~Ze_JgVj(mc*1xOG?#h~X(6ld1GCVB&rlI_qPj|D{a`kv( zv-X2Kpr58irc-AMmxeUH4lGB`C90tmY=15zNz~NCekEOQgG8j^OThSBb|jKAz>dW# zQfOIfhTt?_kWeb)&v3))J1YA8_O!9!QqlD=A}cCB@QkF1j~HG@YR@xMhu(xk)#?0G zjf9yHY{OvP@LOtKSoVSIIsBQm@!GLqYUh1ck_PDOKx$lKjt}_p{fTKNiHFhz-ab=> zJyTQ^EHo?yKLP;C^m`vZA{>D{B7D>k8W-;49YvA)y7-`-n^O{$AsxoUjEdTYAcreW zRj>)(gUu}p7&Vye5fqXA8*hijWvDgzksoz+n0IM=^=yl~Gw^*Ur;_kH2yix3u~Q^V zqh2WyT4!U`D0Xq4?cy$I_ky(@wNaEP5){N8y#(hG-(VVFFzje0%_guSN2s!sNHTe7Fc{D%(B6%ywa}*KiA>>Z+X0-W z3_eMS7#KVu=^N)@BM?(b;I8b(uPdTybI~>)RVIj}OY(s&;g;a?Y||m&q&2XZfDoRQ z>v0mh~1=WGXLa-b786bXemb}_e z+*futMk0}`KcbY{zr+Q^r3To;xar%G)rx3c@B6x3pYdzYC-rnZECux^ASzw+=3MJJ zje=LX?&(QP`ix8|L;4+$wocFVry4z~wk&#FS+QpfHEUNSt<_KwS>(`0t;hN_hD|z@ zXKloY!r{qJ*s@e(aC|;T=P!~dG9y5Klw%bT_i2p;D+-gd1yNdXU?qY8mLq^T*1Yk9 zJ_EZ1R9`ki%sc5XO^FXVc?0YrHRLxNkonozN%&nk;sW8{=to8@NR4rJE~<&nMTHrv zO1r;M)A(yofAoLU^pQxcTEMoov~-GWtHz(k8^tUBg`AQH|0Aby06C2+KWJz6RIXoi zst#(ZGBt`6??YR4OHvu3%thxW6L%GirK6@$DIL9+4F7&18Iza$m3%>RvhR(#89=n{ zkO|}HMuDv4n1G1biKFR}Y~o!<2!%VsqY+UAugZML@}sT)L_wrHE5LO~QJUWXT*rN+DUMvFR#=G?RsSii zYyFnP<}d#tHoMRDdY8@C2&Q^0XLzO`zaknYp_W~yuR7+eCBW+#BEIz^k7n(J<|fOh zdda9+!;G=6v!wiKX?oulN;i}x22PrhJsKVr;*p;7#*(LJ!po}~kt{-YXo!;lL}Iu! z!0U(;^dMQ}BAt_)21JL|6I=+Y3_1Em)Mcr zJ*a4ddC%Ks2wdw{{5Q71n_^DvfvrKx0b33 zJe?qpSKS`X$})J2M3~%(xdOk=bus4;lrIpk>q)9V-+^ zLni-I%Yf(M3UUQTe4w&^9oA@6VpfqfGz?bWtltHwh3rl@a8zFY05~cb0_(zgsLEo1 zmQ{`swU;+Xz36MVejyfq|A@tilOgD++tK)VrJQB`Rg%n%)lU55KPgKE9@!mxkt3e# zNrs@B0iyt|ugQXM;a`)shW#l{>~}>Dh`mz zM>JHPg1NB4#Xlh;DbCB`0A!{0`|P)vgnkuSzWA7Ip8)I;-*Jj2KzYmL`|vz7 zdPbfXTVD#BgM;&by@)sec@Z3+KsC{-sfrn$ip8c)CfS`|zyIT)Oj`#h(9?m5LL9;P z8~jOZY3hP0z?E2UdTQ`a-x6fj;@R5ZmVEe&wK{3*rNKmSLw9%E;9RVy?M`s2T;bQ* zW9U0=f0%W%+jTM%1l%asa4AiPD+0&8t;+H>!&K7+pox8;;QXACRb;~c@V3RH7svV2 zmqrZ%ElykbB`pdysbCp)uznOQ|9jYW0{GYwz@v?MWF=Y5oiDUX2@y|K2a$D@k5#_) z%n;;#S9~P1uz(|nyGM-+jf#`4b;nrzbr)`mk!|5W>N3maR-Gk?N#y}|K*3E0OCl)_ zQ6_zD)+&nzJbsf*yUfla#Q$zoCkTyn@CBBMN~v+P#brQlBK$wcm?E_l>CtM*FvnZ^s6YbTVSG>HOZjQ}`@627*mG zP!N2K%*T97y{+}}R0!|lT@-lYb!!e%ujxzHjX)-gqiYAU?v9g+v)Y$N*!M(9Qn}G1 z=b(KuM0kMr@ zymN_82uzjW=NsloP0j7d)#EOhA7yt`I!(&ijE`O!z64=BBQlMweU1QDHn3)&WQ5kW zxYY`Cy4C(*idsC&TjQw?4x)}pmA08`Z}^KvJnfb=-AnoDMK&1ma^?mFjuf`BLgAc? z)$FyYUWxT8tEHx4!}rySOJFPFe2m`)A>&3eepWG4`yvcB`I*3|WcKDYc!%i%M}bK; zj1>lji2$^`BZuu^nWv(CcXB%4^+fqKW-SgHvzB#w^)$VTGHx+mLR!b8`^#|Gk;EGR z44EE(ypIV`FIXd#T4=Z-WJn440hjnJLc^==1#4uZ7&&7#6l^8I(MHtlCg{!S zxWuhjONCyZZNt}lnhwK>R9)81Ny5bgFRn7FHAB<_TteA>_@;-`*Jx8Fysv^5D&dlp+af zkh&pBY`8e;hZj*oSx^a_d012#V!`Q7Q&eVbeI9@@e{ZA^`(4cXGDEU$;|f$-koIue zM|`t#*9%~l*Q`<&z$`sw>6^-hGNcmtQJQmy=G{T50thr-(}1OVXzWSu3&O$!UU6t4 z$HFlLKy+!b?)pco^tz9ZInQn3>0PRjCWlqa_2*8Qxx`-}9X+6JGJ{9*6QCyMdmOEj zd&(#z%umi!DjDS;=*t7sg5%v`AAF3K)q_4cqMX_;0`bH1rkA6yaR9t*XO0}HV2)qn8?RC|B{BL;$bYTkRMvNO&wP~Klz61IN z9x~#h9>37#sB_B4fKc(3=hHFaMu@Ak7SOD!2YUAx}SqK%Gsc@@QTb7 z&?E2BcX3dZ`>26EB)cn41}`zKU|zA?otbG0s>?F`Gs;TvLE5_V42>sdg0Y;=xo=jS zZnfw4cAdggz!>4!WO1e?`1vW|9UM+2Bf3{ zJ>!2ISX>?m(@R0UZ0g2{k$|@dn5g}#hTW&+n>G|o_I=Fc1m>dggrH@y7 zeQpXTwB+#;z}-K3WLYY%l2;4(G|`ThLzT6OQwW-BQbgz5VXZm(1&7vqiP%(RDoOwY zr~aOssUH6gaWcrmn&!_$Ejlg?4i@{pWU;D7Jjj>|w~|4&b}2G4=e0pswz#!H3=e1x ziL{>u6Bx-=;t>xR>8qpF07# zCJ$x#!4e|NI~Q-gi^-{!Nt+iUp$JS*R=hBh0f8b*G9DXS?yD>^9~~)3(McKjeOz3A z;P+kBXFkJKvL@2mGm@l)?2w+aSYmOIgrIyw!G&Ulbh+;u_B`^s9WJg5Z`#s9pbBmQ zTYyzO|HD4T@3-SOejVPqd~1UThE$LCQ2^8XDQi&xOsB;CV<+_2{K53m!t#5MW|qS> zCV}`=L_OAcG?ZL_By0c{SMF7JSIqfKb`jgT%uezzA`#p9@1Kz;)<~|Px5aFv72Oe| zB@e})LIGTPaq&a=F}Lo=<~6~Io+&ad8v#B&krjmps4oZLhKNi#oEc>^*^?1Mm&PA{ z99Vy7KN;GQr7jD~#SZHm(g2nNA`t>C$EbwljOQ1gfQ*-Zw)!>y%jEB`Lfg}m!4cxt z7wfgK&a!&gf#PlNT?gO0a~b24sqg?XCb5%iuZ|6cw@0f{6lffdKkK?>zo##rQ34_i zANL2XZ0+IUZroxHRIX|28K}_HJ+xQ)kLe_=k{>)3u1#T|(cM1&_3fPChGO|Y2)nB~ z6^kvb*-l7x_I4;NP_+C+hxB_s@W@XEPWA-(cvs!`0A&%3x+n5x1yy1&r z5Aj6D7V*K1?f@k-fJ$Z*2~q03%<_B;&8qUfBVP$FnNb%$T#{5aMeE`A_wKgS%lt9P zUQmhjP7_~A?|_QMIiclnm_4TaOK#qaaS{2is-`Lh7#CGDE)QPc_qkNcUPLql*rc6# zXUyauiHi6~qT);otwtpoBAG}-*O~d?Ttj~0KD>u7{70dHs(YMe;eQoE$=NU5eJz@M zvG ztw`QbZZ_T$HjNaa!#$r(3fOKyPL~%S3DHO;{Xv>^RDM^@!%U1rLjxOwB8&>0yO^%q zYs<;x-`|+zSb8i1geJQu4x&cfQv5#FwA##GkHnhx3=^~4O$5>00FfOik^K6faIk`h zp)@pC5PfK3*J}^(g%!t?M}iU4N1!!|tOe>8IPt35vp!!VOPQQ0OTNn&ck9?{@o5lh zKPn2tu<7pEbTRDvAU)$szW!DBGZ-kkYqO}_&T~>v&pC}X>Bq1XrqHy;5yi`eHi#rfhw4g zIH}b6F@0uBq?B6n?XqTK)FXP;!Wp+eEx8XqKPq5`iHMT|mA9O!3((Q!Egz)j?Q+mS zg0zx`nn5z(^7aYvoXp4$HZ=kY>eN$sG(JX(NJ2?EQGu&Ln~d=`B~hcI8A{Ih%E4MA?(#Ojuv) z70!DilJA9pqD2prD8g)*jgM9*gk>$Pw!=4^n2$GsB{zX{KQl6ji~(b`;~(Ix(R)uz z&lXd`Xjjv>DVvk2WvGfIO$(yF1vr=mSwRfgk6hcKsp`hIy@EV^OLM#q)5k&U&f_*} zlA^QmqUo9dYTjbV!a3dyTx#oR7$KJJNX(yO-BdI3hrXzQgclV+gy|h)Et&KIow92X0Y)dJLp+hpnE{#Lzr$qgG%YzhXdmR~*f4Dpp=0Zc46Xo} z3wcy{1a5;~c76dsi_^oA;oX8d$9=Mln!Eiw{47164jvtrvueWG4gI@v?YNuHmwC1< z#_JZj#?QK3T5E&B)G=8W#7FN2P-e93GksApoz&y=$5*{m{q#0!4-Ltywgjw*lyMr| z(PbIF(Q}PuaCe53;A3RaN(b@6cl7frCa43+jpQ~_-G5YhOTWufIs+?D8R6TA^Rzlc zggIQ2&D1qWn4Mi=XngOop}1Z%9wa77)zF0fMJV*Sx}3v}jmbspgM z%}+#hSzAH)(g@k38J-9ls|tK)s$_xPXeSpPjGZ!|yQhXbH~o&g8*rujS(y{I@%5-G zd?v}pg%nCasTije+SX+o(F!uC3cya4QWul}7S5bnxt@(*j)C&$>Y(drQ4|&do|hg3 zop&!i2$#I6@+eCRt8;4Cjhj(N^EixP*!llg6w>^!C{&UB#Ue=eVDI*goa(Gv{H$7_ zYjJtne}Jhe=KNIiX|s0eXOoT{_szW_>GoS|MNS`djAdF#F7S~-;oo7vvqY-czTsw< zc0#RvQK14Vc2BA`+T)mWVsmn1<0xsv$t6{c=jW{qlu5we7Y9G#$GbAjp}32v%gWH_ zB>T+C$=P7jKS1SZnQQCyZxZ*0UIT6Wg5W8b$(X4-b2amrRVjmOuAxQPmFVc+)MTtj2QQnd&{-!BD|{Rc>czUM;J z=Q0s#mP;0_-!`uPWV8W8b^#9!Kj9CN6V?a{_Y1s6?&#g%V0wK#$o#&z17s7vvI2T3 zhS#1U5*vF1j^TwsKA9l_IzfK#5Y2sX%~c7}B`5fqZ@d5Sjs{eKkI4V`eapXsVBE;{ z2VgTU+77Fd2b)sq9 z{;0&AnTBX!1ymo2FmW`2w1FN0pMuMnp-!*OtGV~pRkz;nchGAMR4X168EpqS???k& z*q&XKcL1hcK=Cx?)u(%(E5D^^R$xs`l8J-cU$~P0PR$t()IJ{F_zDMjcB|F`IvI6Z z7uR%_!FiZ9X=?sgH$(6t;BQ{Q^s|jeEC20kG?yyzFhdOuTvahpZ+H$vW&naBU`N$A zKnbOSZumm3K;EMG0Z#D`MGg=I>u?>PkG5@WFGAWq1h3(N_8uRf135WH0(y-~cDoMB zt*%V@gIqwok(p2o3gOYE(*c#xU!gAT54}2+?aA;X#6Sm;JCgqUkH{;sfCq(%$)*l? zP~VMsT`xG;C@S#1nCVQa7?=P4_Jp6ndy9~w81Yi<$LZU>1VGeHMDVBFJDM6@Rp(s; zGtl>hA1MWCVfP4^uoO0E(kY8nt_s1>d;pG-D))mu8KC^ywJrl4A~>p-H19ZgyOsGn$^)aTza$ag8Nis5cn`2}=Vv>pQ$Kivwh1A|`P3`knjoR0t4|(%L zwolPR_v|iTg4B4I=&e01=>ka%IIJ@T@u|`3%weVaE}aJvvWlHws~=W z&u>PloYa7RyAI{cag-}86y+UqV8VZIL+~U{Fz_p}`7d2h)b0s4tH>Jc!Dh$I{^<7S8PsIz-QdIj>>41@RMhCV%iqR3SMF7r$9RS7YYoJq9?AC{ z3bDR1V_r^gjG#XZMGFi>nL%`WRk#63-I-+W#Tz zEu*T8wy0s1?n8t0p{0>7=@O7GLApaaMd?E~NDI=PA|WE(9nwgrbYr~x;Jx?z#{2#{ zjKLW^JUiB&YtFgW4)|ebcKNq(xepZ>LmL*mJ(S+RqvlqZX9Ro!DOv$O-FF(&XXQk7 zn{4PkcA1g1(YaRFq{x+(AdV2jNSNgzBi%{Ykwso%k)~I@D_+()PnakSf?EO&lup#Z z0nLtg%Vaq!$JLb{Abc$9-7{MrO7~g>Q1k}UZ;}Mq8JL(s>|lqQe#?n?V1^YpQ}egB z1^R6@V61Aq?9hMN2?q%+x)jw|oY3MWZVr>(ZxSzgkXuw!KbZY={(N6~d{83JQ-lx> z$h>`@fT=?FqS0-~kF|mJuPihL`N=h>Pz41o?RKkcyKKa^wGU7Nt*tEH< z?=5_5G8^zU9$B$Y-1OO%#X~U^a6;dP7BkL{J_{D>8Vu7D54FveuVe^S7%9LLLZJ-I zy=7oWr8WYT?OR@xQ=0a+d86vO(a2`htHCA;(X-K5$Lrs5^lI^A;#|JS5xL3em}cdW z(9j4({C03a5#rua+urfsuObAb{!gOgTHG{>3e~@TfJjNc@Wh~>?)u9dEDqyg`u$d z1NLX(F}ev5ikew5w=Ne49M8Tq^Kzx4b!z~$f|%SL5#RJFFS*If9XR^CN%uEX9(9yqHkAv*|D}1cOp3W&#RBa)feQGFeJtwxX%IJw#SL>;^mNjMc|#@ z!q|`PdCYy|MaPs9NDmGL6{B{S>FsuOU@o1{Ux%AZham2+xJhCGPuKep8AFIt(o00K zCdqKV)0HZ?I}cwUy*O!#ooQ_mw(}oz%&=`cFe=inu8C0BUV3`Joe&g zMS{PlDR|G1lKs4sHv8N!sJb>LYvJraZXS*4r^kc1g|t~qftx~KUPmw0e!b!Q`>B>X zb7@3u)DFp~#jl9%@7z{~?c2X`pB!yaKpWK;Sm@9D-Fs<4jev%W|8*dCB7{C(Rp<7` z;sRXU=T>fW#7%yzHV{7bQFVUWVI-i)Zp=FXea_SE!t;;Pc$vh5a6~FAwU+JeM*&5P zL5wB+syLV26=7$^$I?$;OSii=Vh43!23c|N=8(Dxd%aC{;A^Xx`3$V*FJ(Ag@=Ycm z0-`}q{;qs=5}9wDS@#%($6y{2?oq@6CG zdgb-Y+L`Dhq~GZusyxs4`m;Q`@igIERC_`&je=E=aT7Mp&28s2>_ErznF<95Q&s8Q z5^v%qB{F3T=*T(DKvi+3{_XDF9s^YhLOBU56Y5|wbMiG*)JRcCLOS*r)xf98zn}>_VO$)EIFi!gVJ{0wD?5y9ev1S7 zQp}&PP32V~sm+fA75v1Ip9oYu4GyPh0^;!!y;5QRAblLrj zf21-Oeh2^#Bw&3!pOn@8nZTZ?z(g}-!1`*R6*p#bE*&)n5dH$8S4(muc(9jGb?u)C zgu04WO^CEFX9-$9`*=3J&LG_M`;-3b(p&PL){O5!sFhX8leNWOIZ^E63^RWZ{>qvx~iTo9V4DmWT^9b$1N?$i=>Xp*p&xIJU zqzUQeC!m5whJ)rt%BqkGb8E&-u@lxyawOww4?P}79vLBL)ht;>AO&P948e`mO(fXK zi@?zG{iQ0;6ut?rwv(|a@~IIW%K09AH|>ElML8KfgEnuDmeyGin}&3K_i6WdAIY)> zm7oTBb!eke%S}PqNtn@N%Ou0rP(XSV*Rn#VAp( zxph?`z(#jH2i0v2d0)9#XNoi$BDPq2KB+N9v-?1*u#5$@8&L`wLnRQJOVfFYNh-@K zL=dQu-3$?>Bp{WzA!1d4L;yC63EBkBW%3nwE+0Ru_ltK$Ao^vOF2V%;j2H^VBM5}z zJ;stj_TpN|if-zDN27Sx%VJfHA;fBq&V{=--!8q8(4iz9sF50$f7sh4$`(34k9GN8 zm*#XTD>{1r{Tn)9_O*hlPteDNqk+4z7GlHuuADDsD4OaPhd$#ty?%lrdDr#J(*2!P zTk5~W?G9&(aga=B!0)H3&1;M8lBhhaye)cDb}WtKk|=k$YL$SAM-WV_Zeo>fsChA( zgAfsi)me~9z`&tJ^W4J=ec{Cmi2;m9Irr9J^he$6bDZEjP+hDuA#rGp`DsmLv&|KQ zE`v^ntbi8^&BY4xqxzjYn=&)>obNm(NoBACBo#nUhW?``*EEA|zf5UvD4%G& z`wI;kO2K~e&wHbK;sx9;%~XU}bR@D**c!*}y-q2+aZ5;+si_pY5iyX%f6B>h+>xks z$LcT<$~~47K4&g;bt+Ps+yM6JUx0WhA;Io0K`rJ;(YNh5{X%5KBQ7IuHHZ9A6W|3+ zB`za?7oOnFv)PY2n$)`s)$>TwANA)7B@GR3Xy7K|na;T#(1rflix6tWH7}OmzxRm2Msh5)GEsQ4nG=I`D@6mpLR zUNFYay(Sa6Y=Lh%Y3qA$1l)8PY)+g9B$)#Bz)n}WK4WLbw1;kRQMC$^yMAI07gd3N z%pNtPH)hbEP$Z_-*5*x}E)2?@cI9bW?rj)JhH(Zzn`j@xpEAszslLmNvK^xgcWl+d zZ3@7#b2>p_06 zA4*^YuZJLNAItSu>2Hd=Yt(ers0bw^ee^WsBH7;p!Cq?@4G4*Uf*P1y(E7>7_QQPE za@-s1RFHvEhkOHBp=+F~F(7s+!_J@!_PtA6CYQ&k1#ftlkBj>Y>&*)h8Q%c`xRoXp zFyq0LM9tR@VuS3UC(a*ljIUaaUIR5aBHHQU1p1AM6#l1dE!3Mx55EPq_-uYG+S#Q3 zCY+r)@tO%1(0jE(pi)ZAGorQE6|1On!tMQS{T^PSiU3>GF;Hso+s=fq948A5!400h zH=Q2Xx~97;r-Se*2q*A%+--1)rgC>UMbt0@ANp9I$01U5&13Fh8P0ro{2ofmLS4A9(kzy=<_ z?fmeQFi?NM^pM^AkKHA_O9Pv>QJa+#5~!Rpa8r1JPkf zguL-C+eOz4wgUE9;uyWaoVrs$Z7q_W1I8QHBPtQ15s8#;1I`9=+-QP8c-kW?DS>n+ z*736Dv&>7&NGgz!7PRhcSIsBtHzL`k@R{uu)e4z>f{etHDZ{-de{=sB^?3eOuirOT zuD$$uD84OkR`OFh0Ioy@2%q>>km0`Wv1`)#1TW9 z(Ggl>q}kDEc24Svz=jPxv|-DfQDI8u)6cJHi&7jrj=7c(WUz+U!~~jdiL-=cyj%NVoZU+6sevF_MFZpxQtvT zHRdJK1W&1=eO)k$+=0#)Vr=8`{G`4h^+EJq+8dtGt8TdwYWxkjX#W`Z>H4y4v!dPf z@SAn9w95}Tu^)(qnckMa&C+R`#+f;Tyqjf_*$U0KeQqu+# z#?)kY$}A}D*6wH(mawY&tCh~Yp0j{Kl4wz-*rNXdon(3h#-ljE)Qm)kvm;5YodCC! z`!l*jQnt(nbh%tXd;@xDP06s_v8rEOzZ`UpuWOhHAAF~Q3a_&%-3Li>V69pH18WSA zQ@Vr5L{TEQO z1f12d`TOukiOG^<2&N5yASi@a${}CLM)5OIy}j!b$a3Tnwn+mp#Z=4hZFBb)y_nvT zt&VnEb`pwqZZ=K|TDTe}z2hZ9gM42yCyB|(N13_>-F~;K;AS5&A{ZS~H2$xYE$oKR zXvLDsk|^5vsyA`lgIqIG;+Jzf7j#&6hia z3jWK;I+(+tp;nU-TE?Pn?P56R$Qeuo7ItM1b|yn-u$Z zy?4F2!6^SlfM3ag*1={3SvxRzUmxw>&8 z@|f-do1%!y2t6`}s&&T-BSU^@Pn*jaOLq5?%U9Hh z^@jowgCnFmdzGS66rWaLULjH8a$LK)g%FL_l%aimjPYk$<%#77;*0FY_pZV|TOX*F z{QuBAZx=ZIewlt4A$lV>cKg`l3sIAzp)M6}48bYzaDy!R2BrVvOOUHD!E2p1wz}a- zE|M2S<^j5KX3?pk0a1jq?OuQh6T#+s1882#&fM`kP9*bN`P>HZxnJB&P5n*|y*Pno zkucOeVlN1hF(6L$0@t@RHi!2qCd<#KI{M=sMK7T3*m-~_KxNjX0(w$#a4Am0K4~!H zQRQ-`a@~uf7P-5>^|2QVyyw&JhejY)bASI_{WYf|nzmo3yl!jG3fzD8>BtI&7F?k* zJOV9A>T3_=0ks=_H0d}%7B&YatoXRYylCerdvmJ4Ir0ygMJ%u>xUoH^k>_oK4e$c{ z*5||kfDBu#^Fyo%Fe&=&VO-XwlULFC8s8`y;1%5P;>S3A$$ogvyIvd-!LU{Nog3;V zF}7zd7EpfrU)8B>I4fOl$By~&<4V8k{qzZr`$>RdpoPW}`w{`?gq{3${ifxB>gbs} zC-$kcW%@B}h_oQ+eR@57?%laZ9HuKG9#NXV*_Wko?ufFDfxgU@tWWb^z zQWgzG`SXx>*1sel6<(o}bc{CnA?5O4=v1_N51n3g;!bfRu_&iC)Tk%g2*7I;2_9qL z&pZ}N|EGdH)x&(QK&S!G4zp}&>(`8FLO>DnIs^mdU%h7sZgohWK^mz%_(2chCLDgI zcGDP(WCw#+LFo}ilY`vhs|$ueaifM+`pnUK2RDLnM1fyc1bE4~GeXx`PFqrG9k62u zdDRYJB!A(~^T}8K%#UNKKrBiHcNjUPrx~%+4@xW)-W%o{;NoadZ;b<@`GPeK<066V zvHJESuUu4S9({2ikN=hDF8srw4Y>6a!9&k0BkSEQT3@!(rINy-ZdgCN(UO`;*~Jw$ zJA)VBj?oeDa~01&uBFApOk_R=hRXOXrYoI!jL) zx}lBBlF#*RB~hy7nwVb9s5YGJ=+xwkgmeZGTwp)p#*C%n`u0RoPm}LqnWTp~^}mFt zwW~~ueE>~l(k5BP8C2W`lwGXx3I9E@xOBN}^~(?{=AR(3`H4C8BQzDv<}!p384X>X zgZyzD4RV|@ln?8X<@4`_64hmGXuc7z@B_cDD}W5^)lQ0FZ|_QPtV|v4;`L)7H9*MrVpWE z&jYKFX-PYn=m-?z3{X6O3f=9`MT&5wa@F>Y{27Iv#aeOH#ab~|jV>End|?0i?u*Y~ zE?-wZ(I%h2m%sPhtlqyKHOjVlufw=~G_uk<^2)sGuSbHz9wF`E*zcp0X7_zzC!vYP zg`c2y;;%7p6_DbEq=i8yDu4w8cf2&2F*t4y#?Ug*DWRnY96;-)T}jq<*_tysI7C=N{J>( z)AFQQcu6mfH%-g0=z{J!j&Nv5$V2Z<6gv|#j3b|#2IGUr7=tORu-}Z7!xT3P?@ao` z`bwiV&?ve4Fnt@w0}pw;RkWnJ+Mu-8Cz+!8)plJ;Nr7Y-81mfA;@cyi_X*nY_z`io z^QcQYsb^2rBI@-6G&SWZKUb&pdl`N)O~@h#VC0aUIr0 zuxhDjW{NQA5U$*3$Ox5s0|?;8tw7j`8hW1`b4V&@p=QYuY5W5Un*Mx5BhkD6(7#S% z=m|nmF%(n<@@0fcrDM;U8bca*iq06*p@$Z=yF1IHhc~la9dZ(;ojW@tpU(E0N=Q?) zh7K(Yg|t1sHs3b-w)pr9Oz7Ga%SC=Mr!UT_SLTDjn3&|_@WT#O|5`=IxkAw$vw5E| zV+-ZX>jRn+`BUj3*X+p+^zz(-35;<)24W<*dtiNak$}#fgi_d1Fy~LQH|PUPus^0reI% zL7F_1dqnhsoqAQ;#p!hCKc(EAO@P1W6!KV1f;vm!h_Z0dzUbjoddZL>!oHL!ca`Eb zy6GC68`u>(KAyGje6vXI-m}$mPY?xzH>LEA{f^mIvzRFx8Oa+aW$QYF8x3iCTrFQ zFINQ~KDgqZdl1Eb8EEb_$&vdR7=A_n?76(F8#ys;$ll-m!9SYaCMNXOp)k}a%d#kP zZ_lx{xstCi;hW3TD$iwd!+k0*+5E4$*s?J^sSO-yXlm%JvD18WQRHil)Dm)oEjVSH z+XriJK_Rda4v(wCmhIccPG!&Lv(kaD8EmD)+ZH$+G%F#@ytp?Wyu$&}(Q#d-A0NC5 zG(>6~7Vhzs2+Z?J8}nSHSP5bLM6AoM%TD`3jy&nzt3`-)Gj5+LWpO_5Y`;2HbLK3>~ZVjn^%R^RkTMfo%8- zz9*M6NtJguo81+E(915?n~cjW_}ZEbr`jkeZLzbzyuC5MJxyTpE220iw@Gp+iu1Wp z@b%!IQRWkY6?20L&OTHaqcLUqF)qr@Vc(Yp%}K&#$=aS;+f+iH*Ge);&!Tt z&KCwm$M3q~ulhO}IHFOAzljGJ4AfN8pOjq=+F|Rn5eNwl!6TNSqb#M0KiI`wwY1-k zyCkJV`_?bt#tz6|75Y%g%35>C+mq1ZI^=ftS@G9hg@&7y|8o3#Er8PYXYvGj0vivb znonZEe9|S1G-zoW$On@*V|WSXkM+4}^0~W94y+Q%CyacocfsyjA?Ihqu^Iru(Rz-{ z!b^WOmvZBY52+X>+fv4XpEYT2KXr{sy);j#oPI+-<_Eo3L(8L%w}mO-eiB1yAjZ#z z{?JW`GjdBwZnay{SpfaUFi$n>z(=v1j^*o48qz{oayBUFZFR0Yby^1F9Fa^wf8IZbfeRq)(wDDQCd|?@ZRXo@y$7ro6Z}r zw_ogSaTa31l*rZz(tX0zA!ogXwE3eXzPLGgR{w}Z9IJUSW;?T74qo~ul1}UxxOb9_ z)301u5|w)i3b7KplzW50hn@t2u-Nv`Q}ge2yx_0%NxYq2$62OUwwu;e|9X{6@)I~fj(0}1 z*3~vLx!g&sY+`wxC`siN$6<1{e;ck?&K=KxI5&C+1!MP^eF!rRCVp!HiFw3v<=)19X3{SSc%uCKzD2xT;eyWNEX0zNSCMkqS(&M6O zOQu*HU%3p()0AK-_f^MF2?_nWe?dvabXcNu+?2!^0R^dCJ{vvs0;0ox8RA*mT&B%{ zkq!-s3ZiqC1Q9EcA)$SBTvxI%Q5yJO@J+4EqE&h;nM4&T&eMpjVO7C3InR247-%aQ%MTXSv*Wj#-=byte&m zUrmq3{#2?^CFYDnIzvW+lpEQ>NHfzeHib|SfpP9*1%?BYK|0lDE&pjNI=AM=*Y~AM zyf{`Mhw3bzt8tRnkN!xyskUtt^;|i>HjIjwR+=1ag7iZJM&j3TA^ge#!|}*d*kl;0 zCyp8R_Sh#b)y``jg~D!}d^B7|-IgV~!^#=yarTo^%A@z%tS#lpAP5+0b?cj9^+GZw zi2XJnn=B7n$b}P?m9L22zOa=o76f5~cd2PFTAb%SHwQlX6G8aGyri+*M0<@`nqe=5 zed1Jo^5bJ3cnk#%t{j1d-$teJarnlg1iK&j{eJ)VvZ0;0#kY)mFY{4wlf+F)tp-_P ztvdYVJ7 z)bTDo-P}3nWF1)ZlEG=PGq5B~h7PU;pzaQMqJ1~7Ay4C>3~z^`R9(Pgw1iq{jkyav zm$)CG#}?0cuUL%zLY51_nZV%zR(m0X!5wmL;k%z?EB_f8mA?Ctq1_0peJ*KQ}z&M$)RBM7pG-WPRebEm(5ANX0kEgRxz(Bgaf%Id=T z>r2&3aZtFRo)}vk_%u!GCG%%xJ_4AR061wP!V1>ZNVLUAuyQx0xl~;1>=L+s{Khh$ zfH+~qfysX>=m>CG^FLg+6jpyI{q&>Rb~G&>gzI4-D#_|Hh_Z-o+Yxj>Y zZ#L%2EEf%}j<$X)F*k=>TFSgB5ei$0bIG=f-+$hLctObk14{ zUdFr#|26#Z>jSOs*3hzAE@BHyWM{Hh>132m|J;7RKb@Q{TRC&Pzr0s<zzDL7BQzuk2ZygMCe`2@CD!r|CtMur|=MdkLO9u5{wSqL6)JW{d+6&8(F zH{wGcfBP@ss2JVWnRd~jX#LL0!?8@E(Hn;#eWKLJm%AH}+6tTehewy_%~lpv1h=xgZ`IYTeHTW@0N8Z}jV|<@jqCe{F)MGKBUBZ%@tI;-JyQPqR zM;m{Xs^G!*T%Bcb#JpX#uv$BgPK6R$BOxN~BI>B}tFlzgQqz*Lu4Qgvu5e&PM~AA8 z|MT~{mQumrtKJu9!lJBY3nPZX0Rl4++t>%|7VM~v4lNF~{$Y#6Bw_M#7-90oS2NOR zH!PA{g@{To{pTyi*=QJLDvTGZ7W@zH)Rfu$YhOlI7yxn6GCw^klf_lQQ0I9yhiX;QyIuq zPuu?CON=JS!ho7XH#=P^ARxnmoV&4lo>CqAK(aq(89J$t{%Ne#bUUtO=ox_63Rfdu zquuVo%V1#yOn{W%xiv`shd|iMe5sgHW=}*XfF24uX3f>;nX8ipY$9zZb!Sn^p5q;9d}NFU;DDsCcmrh3 zot(L2fg7cU&ummO)Zg>Gl@JB(PJdgDpwoy`f)IrRvjz##oK6kzI4S-JYsu%&#xridP7rYVv_gP~eE0M!%&RW0snZ}ik@B4db)wj(( z_&bXta05ZKkd^afKVv_iHyACOD=K}9GI>)jwqSo)c1u50ww^}`jp5Orx5) zm~1sdZ`Fn7vDBwV6@Sp8V+RU=^1*f$SW(JJI2`LaEIEUzt?cw9PaX*;W=%;ke<;>#4BW-sA6l50X z!t?NO#&v&%5u4NkblBy(?enJTO|wB2QKXOEa3{;A$GXSNV!gNFM)hoKh^RQYo!Y*H zvG@roW><4R@){%-1o=nf6nlTuNy|a2tqZ%Y%VLxtqUgFW=~1X?It(RPdr;Zrod}5V z(b-CA>x=XG9u2xO6GRH{uC6AM{7#=6FgH;vfartx#|q+~uCxoqi=w&aTb`<~qoo;X z$SX@veEnRo*B#59$G<))lvc0&_PI|vF+_O7)MSxHf_;%D*Q#jr!!uu>+b4H>-MgMe z&qCBd8M+LYP<*XDKQVWt8~TI_L1QlRfj+wYk`#NdvXFg_OdK|dOU*I49}^;wS&0jv z@huo7%+Sm*H?SEe3Yeu86K6uK6d^rZxFV?f6{{{R~@> zcradgPt^p8kWyKoj2%i4-_Z^=|Co7eXK|0S^6qig zQm)iz8qh}rS6Z1wBLV$-Ll?=0DNwx3>R;j_L^+}hGKTRQv-0Bn!-s>+t0J+&%u$Y4 z*bJ!}a4I=W9v!6UoZ9ddz1cPGPTWNulJK$X4Ag98;c`DI@W)mH%g~J+S^-W3897gQ z+gR+#HOs_?{7mjKAMLpJ9|h{=769V}@~#+|27H6L9Wb#zsR_?{myA#NSI3)BAR3GU@LI#D@9LTFUjSboQ6X z=7T^NlgX6GbO`;mY_mgcykM6dh{b(wu-mFCiFlc(6XjJehezK&%o7(5krHUlNlo(wjUF>8u@AD%k%nem!$&585I9_f z`_5M3%{)jbghL}04YZ}ywPg?IP39)|91?nCwZS>a41OJ+5rc*WdS|W^oDNzUS;&ok zX!APzbv;Ecare2dR|@LkalV6dJec<9+}8AMQ>7)<#q030>06((ms_KUOFvh)<)zA& zKG7Cu^L3E<0Jh+R)B!PFU;hhmB)!2qH6&rY5RBU5VrTq@uOM$>a-2?fpsyY zZz7o&V7(z&_WG#V6d)DMRlXaPdGu5(+!|1*O8Mrn6*uk<8sG z4cPUNrbk7I4vEp7G!4KPXCUAP!_HQbY>pfX_crR3Q330KJ#vWc{pLR!2F(5BtNXdP z=6F&ut;(&xV?wFWt63zgn`SQry$zzGpsgnc^hC^|!3Fat3q42y`=FN)&_5|h!kL~U zsSquIp^|bV0r}+44mO37oP7N1#Fya|5n}YW1ZdtI$If_P|C{tdLDH9JCKs<}LkLSq z`)*eg`4e|HRWe>8p>a1=H6GM0u{X5HV0r8|`i}Y(3rzUWeSA@sNZ6?G#i6!Dper1# zAWfx>E~dV4E|MfgC%tE`tp2c=xSbA%^_wqMEJN)ijL2v)YsNy1vYxZ6IX6ZMFy37C zghoSA`#UK8LzFA-pRP{6H)?g#tl^PCy7s6jH3k=~Y6QV`+;2zWF8q*JHZe*5IFIep zFTKN-u;O4lUOU?~L_$s}jmj-Bxk{^Wq<#$OIaL|oIiEF-H+d?(54= z8p=I$13-cT1(kcp%L({fl3z90T97CHt2?17bqeV z*c6ktI3Ect)VlOS(`~LI>0IUD6eQwT%oIRDx`B@}?~dZ{S@rVwU8{s8SiRWW)7jzk zh42P=lpA-vAV!uM9!HI6^oH)$4HCX`@=V_t&VdsfzB}6A04FvHg&r(M;S2#hm2+LfYEMwuxu8bEbdp9@AEpMI*#@CX=%AVa7@9iF?$~4T)tS^rd9n^3)#e z`nV@%4Sk=UHUvSL%V?#I*UDOJFp9(}kgZ-}5@9^P=X--`4z#{1)p*HV%FSOp2&suh z_E}`qGvBZk4hmfr0_I}dR2$LgMcJRkh=^(T`4&dUP>>!^02NYjnhY#Wp%tYRy(hAd zLKG+edCl@yxtRqt^mb!~#cxVhmZ3+Yh0WqF}fG=4;by}UN`Vz_xacjx9ta|%@6xXgmf3xV}lx-+7p3qAHXv(Vo^@4 zz^o3UrdW2;4mRD;+6zglW9rI`wfu{~C}&pHAOaIm2o)xipL0Bwz@U_o%RcaePpMp2 z=yBe<(>vryth_v7ou}R#g1MXY;mbH;^L;i&VVW-3`&?kd_dfK&6rwip0vo=E)_gFj zKrlD($vpWxyLDW3<8wxoj{gwYlsJ}y#wDG{x*o@=+CH3t_$JPFc3-Dw@P0URz~89h z-y4AsJK|Wh<(ViRr+MO;2z15ve!vt=I{UK)#lVF-(?R>m!|`~6Ekizs*r89msLY%N zemUz+@BYIT+&^W9N!U%v03n|>dKMm5j%wljGX5;LF5r+R=eTt%yN+ssG>F4d9+H&5 zZP;K_3!M5XV8kM0P--l|h^<(BZ%|SYU>n4n-9^w2SNkC*|Bv+)q8v(T2S=ou`%Y>j zbr|JF;9ul%+#0%HI|7R-?e_v}a%v1MR;CBsjmwrv|zIy*}{x$DMu$QU3_RaYxX z$<1ZkS%SJ^B818De-va4imP??l!O}{1uQgQiw5!gvnr91`mKJCTirBPp#%bK!0#)_ z(eZ`F%yt`mX%_K)dui^A@R_5M!}a3LMgNqJU&7$-fvaCzsHAK8$y7r8reIJk{_6}@ zYbZZjD1(O;#Te+QC7CF0t4yQW`h!8xYkrQ;`rTh_MCJRFe`!oQ&@3k$V025l3K|aC_EkSMLLw>8v&fkxMzO8p?fNoOY-(}fN7QT&e= zKByxgEjU=Rbx@>Ps@Q&gG#vLwfheRm*b!^Dk(aIls)plE>6v|9>?Li0&LJXO%nML7 z2IRA ztgC-Wop9wEN(p&jDcC<#{b>60aeO(r>au?;&lltCcDk@+1vm*G?2b%3hM3FH;EBYO z+x@V|(0!jD{G0`7=yWjaryxm_n4l2ya>k0_@osG-3f%LyaC{a|mqU)A)qHs$^k}wM zfol&A2`I4?%A`;ShLS4st&R7f~3IcKCtA5am^vJM`MyNQWeziyaG(Jfts}9gHOpT?L*=46ioNVL`OK zwnO`XIqgI%)(U<+F8C5zsC<{ZfcNDSVWZZzDXJb@giSA@Wv|&82~I1|fEIGV!MI2f zkOB@y&~xW(ZV5JL`pSZMWt51}O=FbOD$@gJCmo10 zmn0_m7aD^lF?Uh9=xS!Zd9z2%>KT_(tbkSMEH9CUa|W=sOCfRJk7H5Ur;Rr$W1$i* zhMHS(Xrk?d=dhbgm3QQIHM!gf z;O6iA@qOG-Uf(YFhbDo@;f`$0l6C42q=8oqWT4XO^v_$amX{T|ofa|UPW(4`5$y7n z>(k8xD!_eW8PnYVRcwI$aAn#0I;~gpA~KnBEt*Fl{X0!*oI1KSY#8JP%a8&jG@)kx zURDdEVPcGH{^h!B0xKNm<}upxR3`Q&^+jWx)H4Z}i10_%D4roALNTS&aYyWzr}SjVlW))f1`IQfkX|^Qz>(Vv=!BKXV|COHcJE)l@c_1Y2sbe4Vt?lc z87m$3i7pUg(h(_p%xH|K-!EqBvP3Rgv-X?0UttpSX$o6=4Vb(6;~$vep|U4(6ul~0<-H>N;a=mkyJ05EhDiRzUU zk1ZHtl*#?uMj-w7;VZHrkBA2+_XHW}TG<)SD!)f9G7-}!nHYh>%0X%cRXM}IMYv-g zN9b%-BBCtut!r5k#-$6#kCnHFP{tc1>yeZFS<T$_u)1SiRX**TL^eO<6P-=QTD(7`g^q9ucF zUQ*AVoU`S2<70jKu%wgGVy_V^iqM_>=QCs3f^FK;(4RxwtX7eJ%fbDjgIsSTi7D`X3``hi@bHqshIO4s}ZlQ1RyLY5ZQM5+i zy2#T+N(WfI4l)c0_E@0)9#nnk)PV+;pgYBCFoQN?aJF5Nb4$sfIfr(+65qZ$fg?cm zdhb;QBwT)`#H(=PgXVDdE7=fis@-abT0Ma-Hh7vA0%Km3l$g$^yHKhgKS_1q))=E^ zc14Ya>qKzmm1z&(O=fa@x#9b-QG3o~_xVv``wqQV^!?>2`DyTPLC>k*`u>b(!_&4U z9Q$8yzEv(;80mbzZ9Ce^I2bHn?z;AIM|ryq2pW->*xbK|ufF(JX4p%^8x&F3gSOSb z=A?d!L2jf~+s)5Vyrv%!88g$|RTiXRrr)LK&N^s*5bXX6<9UAN3cy@~={&BsuLf>`AblwcwkXgR)Q) z18F+>W2$QRxnw%(S#J-mbw0t5JSjMqfp<|>c?Ht_)f(EWu`YW4AtpxW(}7|yCABgn zg|!|t$q=BYyey-COMC^KX|Mn!uV!VyB{+x8!np)W9F4M&z)$+BB7uau#v=D}LD-KI zC(s8|2s4(VKcvu|Fn>sJ)j46X*vsuG_UcU?9!(SAmAu@xeMFYGhEFR3^5*ir&VOBe zFPc0Uc7BTLd8CI!B=?x}la z7ebz#5ajFnt&$VP%ni`05kY9~MDyc%*7__Giap_~ZGz;|=SWppk+^(tB}BrL{kI8^ zYl6=7(r=%p@ySl$tl6LQ`E$6$F!}cu5Ni6Pk3TcG{SL|2?B$5@aT1tloa27cm*CHl z0}eBo6ku+5ti7*HKK;rxTpXR5KHBH9VDC2=j`f9v_p9&gd8oI3e;y}>pDxM$y#Gde zN0`A}17|*z*1Q;;Y%#_ zqtSv!s)cXw|cl1IDdaTKuoew%lfyGQJ1Ft6N*V zGtjex2vI@qNC|7?06JOhq3V%4Ul0L_L}YkLp`kjBV2z#B(>^;~f^>yTw-Cz&z+;KH zp~#(Z=5BQerDHs|WvTw6>eHGO21B!qOeGptw`K}3Ju<)sUDMUpc0+Sq54UKdx`^Nq9n`>+_m#R(Nc%z&*^h=ITi z*g6wsUH52c(L7E;muP)N?pFl#*8_l&0@aC8@CXzG!!;wJ>tSMNyiKXGv~c*)+Xt!$ zo%czyT>svC2mloqdH)vc-PQTFU^u-Gd{c3E!!);#^UQ(?fRqcIhh;O!gSDKlpupxt zV4`o%BnPn|^&Z?ZBLgob0JkXXxD)28B9eR0aVYS)Ke@oko*&jB|cpn3`5f~U)V zi$U$2xW%L|_%fB3UI3+jE-Q|VH`W@moam1W#r$U#eZMWeQf2Tr-bY)YBG&MY_WK&2 z3FVc}ws_eABA2Mm<9L87hTCYiFz_}uJ_t{hy`>7`A$~=anDB(=x$hY?sGbo2ffLRF zx+_PI6L2Utz8`Zkq38^uuk6WH)JMnTJxiP$|9waI6v#WntppaJc*yaPp2q;pU5D;z zX3{Tis;`ukHs9)_@RN4Oan`CpR?Xi9?(+!1cn4!%>G*ca7B#)SGnPQQ+Fb~xt8uc- zJ^T;36#+Xl1mu?H!8JRpGa{bzewzK0=BrNM5oFq6IKdSW_DU_b zcGv!^SIe#UrCa5~%Cr7g?{upUSKjp%PhFK7U6I*k)_3LAYl?m<2PTS8sb53~F-^uh z*rKgz9AZ{RBQyJZm9f4#gOXkOtOcxhjVQOwh(diyK%SMNT5?ln zaW%r_ZjZlR-h=nMO4Dk)xH*EIAa??Kw(g2Ob$9#|a<<=~H(2tAL=r$6Ssb6x#EKzk1WJ= zcv^e-^Z4y^8^E}xqGf?D#_MI9lbb%DbWO{Z0AW z1P2wgGhq99x+t(njhewg7A!Rd*P10gi?8;#9=YhDt4~#BxayVuj(D{q(se+=`(9B;+=a{;@#74j9FjI=-YTjfe` zSMCZ1XnTL{>~tXKs98+QDzSA^)1dVON89M3nC9HCEe|zO@;oz@eKEne1vg&jr^(>X zN31LlLAJ0bB#plT)#MEqq>u7~U||*aNls+QpT&J#t%~-mTPqyz%ONXf#)MQWdZaJ) zp-BV}=UI%uQ&RWLvdsPtduS@@Td*_BA~U~7u86Lvzyry6-#d;&33wEU#w-g6*ZBDJ zU>18`<=)0Bs?JydI{dJGL{Ci}&2iK*-JTq~Mh8HUj#ZO`lB&pb{zLzx#`kdTtn)0@c6iyG@=2=C)c+uuI1dxOv7J{oN{r_R= ztAnckzGx9?q!Ezrk_PF#G}3}}H_{*=Eg{_?;H6VQLQ-0~ySp3d&Ug6!-n@B#F>{%@ z=YG!T#NKPKwKgvC!Y@##b|*G2BNxj;WHT0t!>GJ~C@r<5dmqj>Yl@zttea9=YC+$Q z6!O8F=CU0-XoIWde(BGyJMWkO{lG@m+}GHDm{2Iz7MfK6c&z_F@K_(no0+$^2)8mS zo_Vq6X5RNU9;2^1#xoX&?V-|9TfXVj(h(QHaull)7)v|DD-wd}I!qiF?_eoNbu{hp z*PPAyFvp#>o~`h?G8VQr!FIeVZXlNWj>z9|e3=hME5ECRo(pFL|0|pkGD~(_GGJ@$ zkgM+5(_)7g7D04UY?$)t|A8FOggtB2e}kii6zSb-*&CWj1J!6Qhni@tcW`fHx@(>p zQmw$crj+KwNUi}l=8Q6Tw!au7Tm;Exo{SBfOreMu z7hc3wxWri}AlMUp!2Jv!yfs<*3y7~5|Mah8fX@2uJC)G!>z!L6RZisg!s@ypOfORCgUczdJ74aTIgehlY$V2Ao4U*J*W%l`!wp5>C#!}Lb`=6-pM zerRM0MRQ5T=g$qvdb>C4Izs&WOZc^ui7C=kD+jCVGE~<1{>Ln7Kx43ui3L!QQ!E@K zHem?it3K%-+uc>Fnb%t;5eNZr(g5p0Xcr)SrKIN-P^8-NI`U(0Q4PS~gq^O?Jw${l zWmCN*j03JiKpt3mt+{`cUo=4VwWUPm+DhNso_i~q)2ZTr^}u0nx7%g=0c_6)od!1? zgmq1EE1h4G?2GWQ0LlD{RVTtm02reLvC2pP!iiZHC7~QmF~QtEVY`PZ3%)!wC+HZS8<~K8EF%H~% zW(BZYu0L%~U-e&c3Xunl%!qfzN{v!IqWtl9nKzAh3_0|NTQ!Xc1>ikmk0#;cbTs}8 z4hX_~j5n>NY;R0}%>!>(1hN_aQmmf4wnY}{IMe0HT8OF3QT!FPN#Fq(AeP;7{AqLl z?xLF!jX;`ELf|~-c<3;{7hxR}w6kbyCBS)RV150a@I{Hw620!NkS?&g)QuR`1(ib< z+6i5EY3Efdvml7dLrF*TcRQsa#lO$n1^>f;fi3=XU|ZTf&7!ouuTW{`8Q=7$=I_W>{?Q#hg$E#qP!Q zkS%X0rUO@w9G-!gSH1v135{gcF+Tu~M+e_CQSqI}spI&ME_;^@Wk-20&zy>X^-t6FDSVkO6aV z0m#+~&;;yIm24>KX`J6wzv=eE9LKGy;GE@>U#$T+377m%4KPqw+9|~tw89u+FIeAs zv#wD*>FIpB9DK2t-`8BcUK7grs=lxlX&g%9LC_90JYFHfas1+Jh9fgmc*GtpB8b&A>!J9U7ktz%bcZ-OD=u z7H<)qfg|C4^%c4g{j1)U=z>~$iz1|&ck{#PA?X@iCXs1){xs|Uf7M~3wBgY`XkTwa z7CS|SDR%`GXRu=6a-QS^d-h*`x-cM$fgRJ~b#FsocnwGG>YVBassu2gO7POOI}j`M zlgrMmaO61LyQ!hWq)-^pr47Lp1qV>F5lkUCpz)H(q>a?#?x0QcOfr!=-&U9jTKvDj z80QydmEaBx5(nXLPxX)#B>GU{B=ey7#`s0Xlh0+0F@{%=KJ#0#Ks9sc+CiamMbv<$ z4nMtcY{p%Gy-27hh^^bCxZ0YcjwrF`QFML1vF`q|k3LEYJV)`(;6xm33Iu=NFNg1K z*;d=x$#8C^Gb`jxq?g4#4BbzusRSWxj-Px}ylV?$r*Q(zvix52Rm@QkN>*T=K)f`O ztXP;Va1xzc;aI~P;b_0cGytg+f&Y*2a#Dq79(4P$!;j~!_l;ywlKM67Ifmb!J@sX^ zi;fOU>wFT}^{@W7>tFqE*VnRswEcT)I}p#)J==R=cj;PFSaCKv*?my0{}IZRrZWo; zvo4jpzC7}ZKqWl@-f*B}>48-0&0^M)y$Re#J-vz|HESTf^>k-G)kYcp3n6iELyWOY zeFizrPO|c6ERsn{>Kfd=|MSXfjY7Ntlx%-6bD6(2pe!jv_#Gnpf1Hvd?;^R_-mKJ8H}lw)D2 zGz?}eCip|l?bw2B3jj61#L_*k@RdQ}LBW{=wm+97E<$6?1|=eP6|)zgs~ekJdR^^4 zU|dKMQq50Og@rV356Ui@ey|T&0B%Dqd}6w9?guOU)bLqA%2KzH?MFrqxeY^xrPvWXnhM=P;{K*QbF?s7<ayFde72V4{! zZRTu~>X0fY$e9ycQPncl-|T`wkP`$Q>Yb$1N0bAD95!48+moYaai0y-j9YROc<=C6b@W2^v8$yk)NE2Z;NA2jDeGX7*h=Oy7mnVu zMDt63Jlo5ym*YYP^B2z=R09IGc-E{M|BbOL%75{IygGEKiy_Pcinjoz)CHUaCJ8PK zGCT;p*0B|NZuYtS%dAp0vCiA_|CZnsP<(E-BM4r^e3;gG zoN3Vg&1bRH`f}sMID4qB45E<-u^HM{;S~Tz{{tLLT(P=hBln}bP%;eKZOs5{#As}; zyE)qM)Sfi|-q6U`hX^%)Q8gb$bpxID-jTW+Fec14&SF zirUnzzAjOyoY;!E zT8W;oK-d5M*?&?sc%WNfTnWfMn_2nb|509ymM}5T__!erJHZ%b|IH>SyCo;GtAd(W zXJ4SI{A{doUoMBZP?r|z9j~**M@rRaxmpClvs_Kg{4eR-ZB~|BUIsy4zA=KiuUUPb ze1%TXc=132YWn2(5QFtrS(#`nUaP3-!lyYOd1P5up-d2}WJa8rfKWx5_S~c|itGce zEAaq1-ERR3X*im-Zg)QpNEE1JitY}5zPvwhdK!ASo#-v3qwo6@?~b$2zPOq%-sZhL zNrA?;fp6L%$ifsZ?HS7$d}ATLDd_ zHw?0A7CRq=Bd1*al>)^zh=MR@637NH6@E@8kd)-h|B|23SvSrwPhVtJ6{~{wezOd# zX9wA(G|rEAGAtX!>75q%sM3VA4fE7ucmQ%l4NiV16LZEuLz(V=K*%T-i7+dsR<=l5a*%9|*>SBO0WBbVy;8-E04Ypel5!4c zK?ZL^Fx+1uuZ(2`^4FCptiC{)cRxT8ZWS}~SxkaWny)X9T=>q6f-ZvL#C-SJIboMg6@Oi|$0(U`6G&?uSSk~wZr$6%EvltaVi!zs#Kv8e!90bfTKICUCb zf}3X-K5>+8LqXxnEuZ+})I(TDcljzImnF-ZBk(kIMRzhGkPTTq9#oxZTT2aXnK#-n z<^L0d+4nl$?*&>p-BZs$w)clq?U3ypiZsp~oxtw3UOr{bJRvqeVXU2yY3F`^{JJW7 zL?B@{7e*b4gDhvqNvREGPf!oaJ%roR| zAROOKWHOiVuw+)-yPpbLkWEWNDE5Ke8<#z5S3WyyGR0RARYV0lGwD}xp(N;xZ`4CI zlMQ#H(|X^22oVEHA5@_9!J`CZNwy=S5LIN-h-X>K;-0+Iiz7a3C=)K|LMBDQO-f7; zI1?-nG-|a{$oxiik5+gRnr4j6Uy$ZREb%?`4xeM=ENGOB!z+^5XBuOV2#2E(wiagF z8S76B5;UiC%({ja@1Ham)Z6o_oZl=b!XtgY*l^VUgK>7};g@~YAKP?o>U!Gv1Y;&3 zR{2$9?xo!QU46=~Zh=V4*ekDE{YBFPx^C9|TWC|0?bKCq=Vt9iJ%;JJOnd$daSBZz`!gk_X>K2lOIcBVbTCxD&1Kk19{CaaA*t|!!ZP@7Eq-}|51k;t$;z^@5q z-mtbyLFzz?;9hTG_r+{LOCV|Vfx93_i7$njBFge2M5LjN+wEd$M={Nhb%|;DM@sl3 zu5hoG`@aJ*D_h?B&oCmqYkUK>)9n!X)7G*|#7MDh@u|C@irG_s&wJz9-lXlMWtA^C zd*}D(J8M-1744cY?e4~Y_Rx4meF3}==a6GyZxk?|b~t}Cxo9nvVaAH*{DAs-Qd&vo zmf?%=YQ+Fe@zczCpgbuK+{m*+uSLYpgYp)K|BJlkWlz*BRlN2aCJnXM&6{>!Y~7Uw zlk??CG67?A=Pm-UKIa|IygQ**A_2Q^Ohp1m&vw1|bdsO;#I|K}O7vWy=J2HFQ{eI@ zUW1_!8@l)-Fo7TMcShyJLg$a92sfxDYa zV4-G4r5Q7di(wv)Q{?zp#Z9}2=SN0+LX0kNJT`17k8p#wl-&3~!3IA$-eU}~b6hfm7kn}8fsj}Id-prieR=4%gCUNy z7lH|={Pk}4R&P=nOAFP+0OR}x@BZqhOu(-oV|@oz|NWDi-mOhc3?yWftvrFWBMF?b z0Jz=@iTFf$yo9%gLg;)Vv`FOnKp^AeyU-y){Wc*PnS^}S(a%&nvHgCpVBk!RlC0{a z9dlgn6V5m@-Zd7^@G3d2IU*XZc?<`Z!~m(Y(=V}_PD%?J#KGSGIL-!OELtF-W@V=^ zlfmS`;(LA3M~vA^v+*K@+%Fl_TdyA+ad2XPD;v|E`rlwON9))Pl-vU^dh>? ztm0;0toTaC4kp>yxNF4F_}l9(N1U_W%5CW#T<2W&sY6e?t$D=dM3DWl1=CA_yP+-* zyw)f`c4{Ye`9BFkV=aVSq_(`UgfZy;5fslQB7aO?N*?SW69}`6YZZCQ%x2F8c6TjD z4n}8RK;zQy@i_+x#s&9Qtl?EZs;yUO-%ONM;xT#0NO_~Ux@zq0aLpqAvVPv9C5jUF zq5#0JwA)WsVhSaC)(dT@fGfJ#X*4qI%75oLCam;^RJMb>X0Eg=E>X(IgqR3=N};#k zZ%KPB;d3IyNE08_e8_|r78U?%&(Om1Rw zA|j*cyETm8jNxFr_UVEYO=l20la6{dncOe^e-k;5Gn%gKL7U*DCf%nZyNIH#y2-kE zZB%+;JtkaOHKu*8CbLUK=HaoiQ$U9;n3^tQZ13SSI{WVYc;vL;cG$(kslvBn>w6Jg z{+{N`-$DlpjF8ncArPn)_1Fd!hQS4?z9v!b|5Dx4oYrFS(M?E3J!YewhEoUhXm+CH ztBxrmckYIpmAUxG-)SF(Qz*k0Hc_th!ha&FH)o9TO~t@#hVhaqD^j1OQSe?>aomMT z`G{pYtI}I#&`v24?9Gn8U~x_PeYz^%_IH9WS_9<5AqsR%Y}^P%H~wMdLVt9mh9he1*akw!-p!k~dg zQ-~O;*k&HleECZ+r#O4#`0xVYqMMi}U~coxuur7Fu3=!sbMV*?4SaGoěO$+w> z^Q`o@k0DBm-NL{o`_> zj`Vs?7BQ+PU@)NY2H~N#NoUyC zj{8%sGuzSY1HV-6^##vEAx0^8i)))9PcJ9m`F7rpxK@@LMEApA1>FW(!$)({Z~r4+ z+Ks2vdCAIo(^+}Hf|CIt>Bn#p3b@tdQ^0TS-TMpo_c!Tnx%NfR~eo&VKUq=?c^}*+H;}1x~xa%eRGf5<9p`S zQ?&<==1!gurNMPnXj3KXIi8pf(~9$^oNgfw0dRGJMAQ?F*6G6)Wg5!{B^pN_QEVES zcI_9`69-~8k1)fSVxb6v5`)j^A}L%&Y_r0QvK0CJiLILUgP1a7=y|by!T3^!Ghg>|A(ez=D$6;lSd%AwF51lg6gpmNc_Go67hWWmLQ&9c$XH^ zeyWGneP5P4KPD%se&`0%H57cmFtWbsap6{6d`Wdv^sJ96%P3+VG~I5Pyj|ZC&r53K zLledkn$?)=KDfN>G{GC>f~nLT`g#T5!F*XgWRTwIA)nQXa&-R2R?rSZ%;Fd33U_af z71^(u&;Ev;{;;iKd1omVcFqU*3+h`l%euI6$t`y_i&FoRM&b26J>AmQYP&l>G7*@( z#UtzbIA-(-bp3SB;}xOTDeN0E@6Ys(?`@77{CH*lgjqwGg7EuwtVdkMZ`_J!P$@?r#u?tH@_$j);!zt4Dk}BjSk@8pHo-j?pcoaBTc7k>g z46?=0Pr~{O%L@Zj8LZC0IfVPFJUEsLt;991*R0n_3Ixwoh?e}C%4}4NyZ2ieF}YNQ zd}x}9MPE4K2Sg~&q}r1IJNl!E;tyB0iv=oY-9Ep|SX7_RzujSKNMS7+T(m|Ok?7?3 z_BHHWPAlMs20BU+jYiJ3Alo##O^Vu`cDbjFgj?v+nCInBAr{l+~zW!yYI9AosV~bmx4Pyw{UTZwvX!35yn1=b4LFcS9 z=xpPR7}n#s`Spf0hi;Kx8an4@UGzvPdj9Uc z;>q_7(*K0P9X}_j$xmkE?;4x`BR4NW;`J>C+b~=j1p)Lquo-kT87C2hgYE`WHD&J_ za+a7I*W|LTxsjg?NjGc`@eAlLE-bLt3g8fZk?CmEL+Q6^AO9yE_!kH4+4PX&4L356 z>rk(jGX0l@#P&PVgci|vP^1@c=D25Hkz{fjiM76x901nO5d9C87lmqSW0b64yK`cG z!P$BHH*mnROj0${G7CC}pzcPoSsD3jVMY9&_1%hU9$bFnEJFT# z64DD=Ft==2Ck!abJy-LH0~LtLRFRdg<_y%^YX0#Nb>a~{z zdwVarYADKP1F+{E?`K(=fj~xBWp{O59i@TueKEe)bszb4D`cK`x}^M`2Yqw)QZD zuYakL*rW;FnP1m2^${bOkDI=9_KOIF=li;ge({nvmz1HCmeQgKGmnn|-TfOfvLr1E z%yZ)5A%w)XzL4|x#Q_5C?jLFD!u?jKSkwpT!4utI>fQlLrg2O|NaJ&#|wq*q`dyq4rKV2p$jm{-(_OLzsu}|LuUb{q5*Up9g$77z(Bs7TC3x; zU!;dMq*=1Xto651h3I+8gzAPv6J~@uWZrN)VX3;xQ^rj!76C!7k{E#g>iUcwK= za7y}P&*#c-AseM2#EvcFpwOCW-jHF&O$b#3)_=7GlcWm0yY(#BY&miED+)11&3f^s z{O@p>ff9;ay5m3!3vU#~OA2gdRR!*pg?lPX`{v zAF>=owR<0fJP$FYlxx#EyB?FGwSf^+Vg>x1lZJJvd?iUTd=8uohe`K)e6c$%8n6nTs`4m3!93n^}dyxX3z=@z+ z@T&#?5moCi`h&CgLr8U}vyVCDm0-6~Z^%FkBkhFa^qhw}}`^wkDh@8v$m7 zfeOC87BJk4y?5oZxi6tqXtlN!r`e_n{;22qyMSZQ(<(;;cvmzqG$%rnSN^tGDzTR}}-%D_=8 z2ijVG%QB}Q^l(GZPFQE?=v>GF$TebXN*YxNg0V%nYM#{^EnqmQe1XN@`xjbE;wPNGb7F_q#6a&g;_;Akvy#Nkvu5?gBznH}|%(f;TEp|jtGbMT`kwZr$I((rWmu;S%g`&;${qtC5vZ1ZsHcof=B|Ngo0;W;M2l+M3pZH@;zJ+$l}!6Mk-LCk zIoX?cFI+kVvW^e9h2p=6g2j7&e&zRVbUe*BDgC<2Irqi%5c7MvT)%=eP@fs1m;&$d z70Bzn=8&~SB|satH#8UNu71#%S@B%6uxE62&8=&2PzD((6l2|78kW)uwOyvkW9*8R zk7tsC)bY}ywk|~;5iD0QpXgi>(8GJ7O2uiDA@Eq2TD04$DA(*3i>B?)Auj^q;M;Mq zjE=SFa^Vsqlq3`x3d7A|KDo-A?SAP)c7r!4>Lw7Ii4@&U89~Y>p$efbeT4KwHua$~ zEK!Q@$Vxx%S_Qn@ zn0eS73}h5Zvbe)d>uUWWd-K`O`l3>ifvJ`Ft;%3QJy?`HS{l0fY_ZF5Qj{A3+CC{m zC5@fmG_K*PNay#BrrX8E(IUO&6-i&k$taAw@3X8v)$FVeBA>+dQ6$IWN>s(oNVtT* z@R0!cSV%}RTC>C}9GB)F`lj#BIqp!Caf0pe)gLm<8_e}8orGF?YrF(+P8$(HZ}3bK z6sP0sEI_y0zzhP55`p^k<#eq{U8;9a{*{Kt87W#EA_cW9AwB zSSH~idH|DSBX4;#616ElK8K%2I@@^6PfyUM{ac8u=gQ%I88tW2B7z?o5kPmiDNzDg zi2~%mEzKIAtX)^v=?x0TDhnwM;CUEcmOJEPji=Yrey*fkQLzCI4{a39=-9Xe5I6p( zUdoLF2U*&p1=7r{gA0xzdE(dr(ZKpsY&heHs`VSk69i*OaIh;e>5r)rdQ<%v<73m` zNZvf_i5&>pp5ZNIm|$>n$|!$U%mB5Z_l9BDk3K$nDS!IyFVePYdTxHL(Z zihjn4T3^*XSBtR_k#9X}n$vv`ynC)*Jz4o^E-w#O;zN%tgp`mOOqVcwX~Q;~3XGIz z3cd~rAMK)~efz453K41<4&=GO{=r*ivNlp>Ez#@rpwqFRDF>sOK%I;*Cu_4;=eBdF zf-$_BNt#V?t;*WNg``bs;Byt3f>E=-G35S_0<`NaOoJ^-#k^MeUme#3psB;?zg?#H z_wEk%X9sPUKjEU_O~x8$%dmVo!yQGS)})t)l&JtdW%dw;Nb+n$qA+&$IJY0ov ztxj5axA?QlqD3R|{*7@nelGT%S1+m4+h53Z&>X{?#;C>!^}1^GMWdP(4Mn9x?HWKN2m4%#@u5S_tW|_0_)kA<4$)Nf%gI8+J(DL@yo=6>?VHlY8!CoKu@6W@RKh|r zQ+HAvhr^A_y%dlYPwyY_HjFV3ZoKImeou z3_KDFtv;|UeRbjw7H)>jgo^lv?ZUOwkRy^6W>#0pdVUi^ze3;btyE<>h`Io8>O5>!dO~ zOo(m_k)P&q!K@d%XTwiKJy(utD$B>qr2!P5IFbyJI{}Z?Eb*m%+12|}r$OZQZvwD= zQS@zNc4uYM?qa^6>bhi2iXi94BBE^kQ4EPbpk|aOQ&5|!!hRcilg2~a4cKT*Oe-G< z0QWmy+!X6zd!;S+xo#0dIA$1^V8)X2XkvnWD&)b2{P|z2X#}A^JYBmf#3Jx>D%STY zm>9X?uDt2ri%q6E^ECG2H3Twqg*H<4ZW+PsV`=@-u_21s9WrjEtQy79Je3#Sd;H@r z13p!CzMh=RHUs1BpWltYO|A71dl;<}d)rm8j+TDO1m70~JNy$^mjbawG+;9ITT?&7 z`(JW#tts7|U)4T-Y7sS$!2+xq)Bn=Mo=AD>8KRUKLgE_;Fj=&uVJc+!i|8HfjA;z8QD15c4G;XiJ~krmv=Pm1!s z7y~KGxBo*62`^n)!NpfCx=8_Vq1lZi`Qb`HD7|=4f3U0a;aNzhPE;s{CNhY6yS5;W zsbPDe5&c4D!lUlin5@taQ05mi2`H;W{4FMM$Eu{SkY=!Py4k-@T44W+;?H79Px4Cn z@&eav42f~Mp$HAWX)K3GWi;8=>|3E`Zjgnd^fF5J(sh{*g~Fj?aEypjkQ-!`(u(|@ zCeVU!2&U)8nPd26Qc&JO!%zLe|0Zn>Gpg#;=&LucjkZC1mpN=LeD7)(t+5()n|TbS zpE2k7%)#s%z9~!_{G;65M!(_?E(LDxV0TtfXR0S)1imsgPn3=FcC+#Ax{x(Slv=6M>lOIg7>BJ{3G zF&Jx8LkjPTEjgT+`T=uF!&6r?i~7ZKmOa!)9(~jlAldSii9QbUki7`Z&D@a$(~H#j zx#U0>0vtF)>_Ze|j;_>JDekb|z@k_CKRK9eBhd@x@_aYR5aKtCOs-e)_AaN(*;7QT z#GL-Hhia0BvW4nyj_&8I6|gSpa+|pM7TkK(ozZwA@sIV)H`B!3N~5HA0tyZsN%jh0 z8^CoIwg1{Cv*>R)xNg6Ny6`(|auT#~Y$|NVKx9`w5dT_Hh{#Dl68x5L^%tZ?1oVg*)aiFhU zSvFm2&~Tu0?&{hc!eC)H)! z!5LeH65A2Gu1{k;n40Gwr~F)dU+gzc9X(}aeKrSs)p^rOr;t<75?r^;Cx%j(7hkMS z+9dq7s?ymCWxy*gSDUG{XLiE0zahKoq1akLxu(lTI%P>>s}%(<-v}i2`+Q;Am8>vw z^S7W*O0nMr)WJC6GB%VJO9uEJoA_WP4plLjM8BLrk(8m2s?yL{b)hbt8N%ps*{*Ro+9j5~;G)qLP^vC<0S)vo(`Ry9e`YzbOZ zAvpd7iL!6O@fS@R>r%jT*13JqKkK2lC`PtZ8T{&wM*S?5bVFjo_aJ8+MS0PPd`1ui zV4mv;^A7!p!TONj1v?=^lB#s#tY77tzB4oqVOfhrd1O1P>n#IklN6uDVZ3kpbd!^= z9NT#jh#M7RJ5w(pq9Nv|FDTaH&-JV^aIgy3{&UEig@WK`wm-=mbu+fB=euieOg3WR z=XkU>iY0Vc3y4?b#8~+_Ifjp7dS=L_$tFyMOuYB>6l83)YW87K9v^Z)Q=xP* zynS$mKqPWF1R4wwnp{u*`<+`y@KVvlFAUFnx8S?TUuM1WR;t-FuOP8YFI%$6DEjPe zE!8B3Zn`N$^)ro;trV&eEK!j0QhS+I?w;jlEkbsIl&yt|Ca8DB+> zhk@0#$1U@krS!G*CY>_7inCqG%Z#TLB@XAGW)DJ*vzED+z@5b< z#46yyQkPSy!&ZB_MWj&JOqw;rOj<*u*wY~}O=x3Qz~N^C0FeWo-8D>KsFwrkkf0EV zJ>NrCLgDBFEFd@eJ3Ty-+5-OgL23~mN_=F(wc{y;<$^kby;|kPJJ6nQG!@g!sNYHX zlr=pz%2~>T;}6vkqCe-g<9jgP00G8R^3{h?fkI-dh$>I}pKI{&LG3^Zxq=yhfDC!d zBN(m(YA(h{vbostspU%#tMD6bJDx9NL8BMp(1=m<@|B--vB-%(vU4VIt-KLg2JKUp z32rHLZb2u#*q3=3(&z@a@LCA7HwXVFt-YbP!%GuSp4I7#CFi*(Z7U~5bAn!*{Yoxz z23x-hqcqQBoN`Yl)|7F7t*qqyuX^u`aQC8)HsWxkQf}R`x?X>{Y+3vRsJ^|@6Xh79 z3kz#JD2)0b`Y{3-76!y|FH9pu1K_1!aAfJW3pk-E+3-%hoI9FWdb;)7=-Kin6TRK| z3$q*FjuRtORJm=TRO5E6;d@`uavR)oeX;x`;&Z+HcwF{0-g2`@_V_^daI5rmgW-GJ z@^mY5-)r!+Dsp#0_Ndfy#p8RUH1KdYX>hM|+Me;?|8N}rBzXxw?Oxs+j{02M+1_!s zO7yVE6J9Jg?)oUp>irSb8{w&6e%!J3l3lv~x&<5YgrI2Qnzn*3 z+-B!$?UyuqLM17m7a!3E!Oqb^DaR*CAw=)Wkq@H^k$pq>jrZRt&Xl}42b&I7*JRp% z1{vsoe^tsn$~~(~ObMum1Pkes7QCK4<*d|OI262CLIU4-Ejt`6qxlvlOUF5Z$7k#M z@tOcHDNfkCMyjdfDoV+-J7JV)V*$^I&YZ-auAJZm|FuzRo7Ur<*mnGAF>Z)!V{*xM z@qr7l?=8{LkV@8RG8ne2AWI|ly)Y4?z9@R|RzG4C8hiE7m|{P-S#Oyi>-~q=O7mZ7 z?%^CPj#S_y0|H^iiW&(lxj2cuv<$%5`Z{u*rbQr%eCD6{chEXk~a) zc1B2$LI*_@`sKO<7FJ=zhO~stxL7Ds9gmR2e{On+6l)F&h;+sfqF^^0;`EukpWQAK z;@#|_$$xuJdcR_iQU$YOwacfDZ(dkCSJyx2mL;`Jv-6sxFSg17_ni2hbz>E3q97d9J>2ElzlF5HRk;Xdt;{4nqU4^CrBt9 z$Fx%AZz~m%eq`eZtep6;NTvZyu5m!Q^xv`$tB5_qJNut{BXh~K0$ zh|}FARR5JhZ5Pel%C6c8Z(VMD*q6N=e&ux&N;AW~iI4bu`hMK>1gnmnjqEpBgvnk= zprQtvY*ejk6}l8#V{*mg+)XU1BS8p|@RNO%}O8w3CQ{!Q@xIBLCpsoh4uOOSA) zJDVi9@o?x_!3$%`|DYeEMtbMC^XQZM%T*U?(yh`Uk@ORB_0HS66~2Q%AX$4I%*!%^ z(Iwew*)8c8^I_>|{N(BDLZUV($M%p1|3-ab7h)vGkzoNpTQomjH%86V?I>8}A)M^- zhV^kzDG7hNv!3%*!QZ;_d@A${ZYiC<+i~0WZL(!%=b#e_pw{#e)#Ef+V=^+ z#UgEXT?A3cC#uagm%UDWBE9p=xM{m<2uHv}jNZ7i+fNKL3Il`!Cezk)WxNBF58P78 zt^PUmP~~JS5+kWxb<%;5k17_@QF60zZ4qE&RqO`7p`H{rdn$W6HhA33xZfLo+Qsm_ zC40IxcwC!)+7Y=wR(f2-c-moo1fQ&yJx#V`|0qamxz91UKaGBzWCj26y^(%eN%B4S zeLBT>Qn>7Ix$=EHK6*M2_B|eEQ7DitZ7}~q~IGT<{E z-<)K@n(;&`w;bEGM`irpf#?<-xJQ^mh}zrn0(T&&}tdUzb8x(1yP z<-i!Vs$47lgb9s;r5@WO_Ru{OEVAzSd99EMbF(3O0#$qgQLW2hi=kV=L5MR;n&SM{ z-vVNSehlCHtH-_NhgO59=%-87=MT&^@4@{a?v492Xz=KLEPGTNw0!n0R%+*^{`=My zgs@WVeq3E=7CYxB?f3mxIZCfSyu zo{~ynG&?Bu1BU&`H8b;}HpjFMQC?1&D+=4h6or==J?WqmnLtvqI>6^#FWwJIdK2C8 zOh>=-)2@@*48$98^#eW+ofJ!0mpG0>$TF)W$mL-e40QhZlBIHTSJ7p6TNEKWzyN8r z6wco`!YvS9T8ur*jhcTcR_1L47YoUgKU%PHY?_*e&iCI)^xB~|^t8v%<15Q=lTZ{g zQ8e9L3a8*qK(*^CgS6TVmiL$GZl4U)r?2*{O%B_d>~2OoE0b6YM3!1<_ZL<8$NtW} zV_&_E234$n3R-OJjStsM+?})HVM3;I91M~}Pa=Cu_R>+*{o|gAe-047joNKpYIt@U z#ZH>ChgEl$+C?C|qzsQJ?fYkHu0X3rHIzs$>IWx-s)y_W^8$5o*XhN-=16l5w>uOk z47cG|7y@=8cg}4BNgp_cCbzcP7TN%4S$md}(*E+kF#l=LI{`f#$viGed+#r@i-4nf zx{6faoooo__>d`e|J&GeM9KadDB@2-%jR3J$x21CsM?b3EvtMO==WA>x!$kkDRER- zQ1VFz?w02I8%LPU;~4L!S}(WHj!id%)5{O54d`*cUKPG44~McjjW|$ogJztf{l#Wy zE6Y;u3Q}~!0yp)HAF$T`QQ3va{!YW>h`Y+R&3UOb1)Edv#@tP+=~k>5FbXkHR#QB7 z(cR>6)9L>pq<;~?fJx^x>#ZQGT!ZHCT@)B&FSbii@V!aMOCXL(_3FcxQLob2YIVWi zo9FS>^&v3$L@cy(;9;cYV~HZGWz6(7GcYM3@s0kX1-bmyq0~j2jvUlS7sIK01 z9ENOohh;O;<8OCLgK0`yyq#`%zIoDx`c2OYOWuZ`*M@VFXi;4K=qfK~M|Wb^=u5ak z|6O6OATK7zBvEA)vf|gY?-}F~h53u;q^^7++l#9DW3c4C@2y0q=;i7Epu|L=#HTUH zf7cS?BNkMzj;N$1e}kK!K#UpVg@Plau9>Bju=CXN^tha^&;2W{_JN{N!55{B0B<-N ze~zae0_feF3dJ0+*MBsG*)3E}{S+4VNGd%c`vK8SLQ*HEho7E=B+>*iIu!k&ptuGth@(4o{-}=w>QGdb=%j(uq#)H?aea5XM zNODGBs%y+-ZBc)xs{OY7{vnB_ys>Kz(yGp6QB`v=Fjp}^8{rUH!cXymfaN=4DC9e* zrVbdp|K=BS%--&#neW@A7CU{P#_K|*tJC1xvvC1#`!W`hgClNV-33kS5_Zm}Pi$?w zL1?lV3KXdC4;Ut#>ws?gXMID1m+$YJTUXz!GgtzK9683yceYnLnS2LJ@{RGCf`!6i z;^C__h6Rb4 zxKrM$vjjx^D4&BXD27QTO_^>Bg8fB_ATHsGOSHmPZ9h%91Mlj4MG78yiaS`Gio|gi zxEZ2{f-*xLbp6GNGd0zU>WXCD6*t-^3^KToI597|-WL?Tbi!ZN3NYqczTEyJ^Lg^R zTE0I%sD)1R9I=*i57(334<2r{KU$wbr-xlz78`Fi%hPtVkUsz7ZF*vA_whETA2Gm8 znj$oM$rO~NPk-9#X@kP2P08{#(Fl)Yn&hNr)k&(C6zun#2)YTgPVf`^PR(Ce&8&ARX~UW}16 zl8Mf7)~kFG5%H_y3_fX+D7~}Vb+JTIM!pS| zqPb0{{0W!EP*IrUQW#)UR5JdcMZ0RQ5~Z4HIq9-Gw$k($eOW#sp8n6b_%AtR4o>Fp z`SklY4OLJL+Ci7=UUHQlSp*$M8pI9i3}*QM!`54eMcr-h!y=%lgdideh;&E_LkUPJ zDXr2V&Cn&`(A^yp(v5UCh%`ut(j5++lJ6ck=X{@Ye(#^kb*;Vk%KKhx@6RZFwch(R z+P1mex8mrkdcN6rxO}$Nw0;?XxxAjxpIp0b-{kn&zN)E?m#^r`;0n<POL7w3(lAE{_w@?~0D zW?Mpa+yJ4>V&#%FmRx1j-tF9<9sPY4uP)Q* z1nZS8!h&<&4cVqp)4zmz<1>XP$|}uBu5h_wjarWXp(`)RGh_ z7qtV4>!E(s*QvL5*7Xa%gL!8J#v||Oxny1ECw}w1#TSkevO|V*H!ZLGyL->&;qRJ9 z7&2T1zP6p?Y-b=o+t$Ru3QC{^j1rqpBBj=*_f=FVa8p@mkNh;vaCo{&6+{m@LZHEH zOO3}N3Ld9qw?mdPvGj4=6HqMq()pvfmQY9xkHQu?gnUpm4!s&_NQe-rAVNc&jvk7? zzuf_E!7H)KOtnQ5{A>|fLa(Rm|IVv1fsi;qRL?p}5WJ$05PD!r#gh3;c@Zad?l~vh zsfhUs4v!|vYoem~$}DK3*zeV3!so%?Uy~CPodd~X!A_SzvK*Q1M2d^M4+B;btSxKP z#dLkBCzU=!+n?X7F_;i*5qz~$C?vw$3s&`kLv!Qu*=@h5TU6gsxiwidB@5x>)xw~@ z`2`h*CDaIqj4u(k+x9U#5=c(nR8JcceLn$9%wF}FZzN1Rn?lZQ4-7mJdVrf8XuGzZT<1xb^ONClBRjOrV3 zc-bk}-9Pxj{A+Qgh7KL|w9($Tx2Fo5bUtGzJfIM#2DyYJ|K&+i$yiHH*)T|m|MQnu z9G`WB{e*{}=b?zAH5D6vhK>M%`R<@of%~U((TG=bMn?As?tKmrrNxkRXmsfcUmA6e zsQ0y%<>5XM`3!=>LBPs1Z4P3(a>07b^r!99e#Cq3Md{Ib(V@5O?W(4C{Dn=~)?R{& z%lX&#X_)bd&F4*nGS_KoeQbJP_i63jw!Y1dV5mj1Yn3TuA%~9Wnu_7N^DIamzSK0> z7~Nkb(~9O-11Iyhss^`N8X3EIk|J!p#?`W8`}D`=x^@^bS7%hi=J@w}Dw!fX`49kjhJ9sFz3Z6-r)Lp$PqY7nCiPO0hg;+jOti&~*J&>4Bv8nfB-I^mR{+ z=R>gyXWD6v{))Rn-B_Jp#oFSm7ah&~TFJQHzY#D|2p6i6=t9Zu%${<4cc8Z`dzSCn z{?(@~TC^AU4BF7pHh`~F@*^26qKu{`a+`qO-=JBii8^OHklg1o!~dX z7ppss22bMNEIRhxWvO*^P%CT6v{iJjDqPYDqg$fzd=nXgY8~F6hLS5Y%m1oo_Hg0X z`1Gy%n$74|7n8&6@h3`JTg=-tn@O)G*J#7-gBY+0!JtBG8}e$hrTS>L}V5}+xSP81wPKHQ6!ob z!w{V9%kJ*2!R@gyfX`O;I#;M6pr0|ncW2`js+D>%TQ|-sx^E&?=p=cx>7Igij<=~L zyIZ6o)C8a$nV-F2!SVq6v2nzF-E&%^-gpp;kxm9!;_u6Rw`ULFCzXq&jpVwnkJyf? zwq4kx)i3SX6Y=ix)D1Z}xxu*ZX)KtI<6Bq09uu0Cylwc0t-iKj&~hxOOdgj2({b+y zX?$6Ev50l0=!8(q`$T9I@nSen;@aSOWevpewXO=P>3jW2zVdIQ+WSZv zUpbQbpu8a5UC#2c8IeAjK%_fgQQqJm^EB8Wqq@42?_{Xn{=&c6It4+Dn*G%y3(FI{ zb2{9&skPH~2hJ@Y;N}MW4 zMANqX^q0p&cZKi6Y^?0Ym&c_)*MC{0qWkziA zyFB{{4q)IlNOC!(8O#IO!JG6$B+D1kCcQ#)5u^9+A`1M`q(ta7$=Onku86 z(fsUku)Ih6_uaG6P9j>zJ}k;aOaC{UJw}gc;Muc@dgQe3#*yt^4iStp9{rI$AhP`f zkE@8{UKB!AMSuStQxo#EG`cUOJoh&x#q?qOaHd<>p3`Zcy@qZgY_#P8j)eFx-XAdy zMNgQ`_)9pkd1+<7gZ1wHJs=$|XUE&?hKSx94<3@l>prgv<>?Z}yWKz&>;;ZVg*>KL z=g;bfddY=3NnL#>ce<#(50TphzFA?O=sGxvuj<%fIm<9Scod%6pYqC|oCRinw1(Yd z>**NS5wVp&&ff6ZrjZ2QjkOGuU0rv1)63oI6z0F}QbM)Chie;$=wq;n@FqcfDGj;1 zC{fCd@k*BYZW*7ieckkmU2%)RmcY!x;(q`1niH*b6KBIgZ~YJ}gvSVC^0dKXc>tfH zRB%H`=$Btm_Sw;L8COxVh0E27ui-4?!-$B_w#VXsG7c&ehCc;iqDaKOeCdSk^3?@U zENPOk6w3Rzy0Z6jMEh@bH}7D9n-(5n1AtlZQl^Lcr`#Qfk7D>K;r%o6!EveK<1ws_gPJ3S;!^$98+bGi z1~CwEP$*b96&EZFHQ>325v<`Wb5V1vJ=$mFUB2!&lXaWNzF7~0&~Ibk?@kf}%I7my z z*e{cSxCFx`st2%pBwwJaV9i0~VO0$r@5!r@*6ww!X zZ{yx|VJXSg!maQDtL9Vt_skgXXSb&xxKXb8-R9ndaphUD zbF(GGbqb8~lS}K88BQ2a$257b&XqH=eCQYgo@hsi6D1U&5}gv!`NmuiB^3+2?FMp)vh-EQi*}Ac?Fqj z^>~RwXiodO&g}2!)-*g&?`lRlqq!=)1c`Q$M+4&b*kuw5jA){Hr@q^RRD$0kx;GT_ z4Ux-g@KF}OID9Y?mt9tr6^?DDtwU9NQJ;&rqnIiqcsvm!g|8*l`IXhP;F%V zc5c~>Sz4>{!kj9q(Kj=Mfv<4b@+)1%W+BUC=v^VXt#aH9DTllCbn>FA(|yEhqe&ll zoNb<^c)EoJ9%PPaR}^cdsiU=^tD_O^S99Cwp%snIL3HcHC^(t-_;iw~9@KQsce+uj zs4soe6Ra)f(v1mPduhATkFHP%&A3A%In6y?j!)l_6&6LEg?TDN!7lnRUieLSz>CV+ z(9(oQIFkv!Z^AsRHBRY}t{S1*dB+}gptG=T3CrBAJ&u4<`HgSoiy@-^VkrCN!7iT+ zSaGm3wGFIjv^1(CSoJ|A{>VoTrXHlB*stm#m<B~S(Z43} zOG|#_3Ta6N1q(u2OfwFMHscG}WsVL*rv=D~>8Z1DC?>=;jr|@y8)&%2Svtw?m`+@5 zWzdiDVKddt%PiQyA&b=Y$blw=7G!HdK2Ea*?vmX`*(Y<=AUF(t zhot^=t!|Xid+GX1dp5=rl9==n3B|E%#+hj?Nz@x>ye2I2lkOp4rv6G~`Q%n0;^*6; zW|_8y-ZSm7=KXsvZF@mX@`%;p{!dcWuGM>a_F*1HQW{?J&h9y zROc&F>>Wtrh3R6r+1J$kg-XWaaHH7ME2chgo`3(vr3k((fB}t&^+`BH%r)GCmh!SY zdJ?Btt@L7OwzR;>gA1qKSKSRr*xSie{6w)0?@)CKQx>tK4lTcT4>hgd9!BRbgnny> zY3qJXtI8ov5ay0?U|)m#x8QyuCk%yK z%+n7#M&BOmp;31dPMS+!;eGhhnj97!b)@tC<<_`VtZ{c33K!}`r+H^a=oT91PfVhg z=j`Pd%=E8zF^cdLci)o8MtGYpvFZs%Fmmoe*vK@-epq=dIwvy^Af53iwg%;-xBub* z{!qz}aG_bLppc4JL1a#Z!{r7hW?cDOTrYS>yPIlohJ+rXi0vs5@wsgSC32UZu{yRA zH(RZ=VrYJ9k;vCSWHy-YpQ#>%;vg5aT-wnF3v%zBvXW`UymGJ_xZ5_8{=i5bCKp^L zvREr?(TQ9$t>lL<0H>J2V9gXK!bRt+x6?005=K3&)o%(z$dGn3(qw;F9X)wNM0tj_ zsq*^o2r$>1@bJ0(V&Wt10=E+oCO(Cq8Z#tv;tI@Q})k$2)^rwY>kBXb4|wy*ia zWjpG3vDUaFb*PG3J|^0$-oNwGrEvki2r_d9r7u44$H8!=0F?E;qp#Hvnh@Pk=3=W% zp-)YUabdq%Om%2H6yG)a@Rv4=&Y%JdqiHH+1rfMRN}nWF6v$;y-g32hmf=ZuJ9a5^ z9_0b=6o-|1X&{>;D(RdxO}F^WBcb}uXqqk`sjO9mBS_HT$(neCx0I&*os6FNx7d%m zN(7#KtQiV}RK@HFo5*gzd;#??W(?OGu*XXfACqK@cq!ZdOQay3>mq#i$A{_&HZ7pe zpry=_@Ub<`TZF%;H#Ez!2s?;Zdgx zonI}wq|B6g8aWHJJjKjJ6;&&y9)VPzOnRk~kx3w}G$Q~q)OhjSK ze7XkQIx8CEX5n|&qwoAYDW9?nwU19E4v{9ml;k6P7qx{L| zN5BJzzKLGoty0vHqq417Ss8SSYsR%aH&hhg75<3%aex@8CMjY zU6h}4k4Ef5z%+*H*Za77ZEP|gMSZHW;Q`1dA#EsM=orZF;?_Ax3sE_~2NwD>_*r-f zqzzVUkT%9Rj(YCIPr2!s-X~H?1K+=? z`Aaq*uHEO7Q3328Dn5hE2Pi}=HCHZI!>jp$A&<2P2EI^qW45j=7^C=$hp9BSpwk(s zpviL1PR}^iI=T*%pRX0Yd`s*)Jv(#gIzFEr;59GVx+cgsA2d3q_^3UX-b>q`1l6N7 zxoB}c>B0&AYw&QxxXIDZYVxA8u10f?$}!~auxZ^Zb_3X8JRdR5)W?Ox@0r2mFyTGPjTDOEH0zaoVp$UWWRjBE zV+Wtv1OKo3+tatcL~F?`v-Xc#>n<&-&v*AWN)sqpGMr0h!iWS{iML4{<$6c(SszYu z^$9+V>Jg0E+SfSlE&hADx3OXEDz;dZDH8w-nyLK|IL|jG7X-_t{1|Up_j^1rR^dd% z{!!aA44LL)Uvlu<|-JMT3ehan?sTNzP5h-F?lEOuz7AP(B1G*zBzvF%m z?bY5Db%3e*@FXYvbduGQ?UH;V%%Vw%lNw7=c598?pPKmdu2)e~!&JTVsm}hv;^nEx zaZ@s<_5RUbwuv=ild?rlP++@e&6aED;S!j0X!>W}_9zX%JCsQl8lm)Vn6iH&)9i^_ zw>W4%AqHa=0=w7D7bXJlW`7Ko{{S;AmFzKj{6+LL{UfGEjO>hLQw#!x_qs5mO=^bx zNa5XMH~x$qJzbWh9k&MW3>-R=4tsyDEx;}Si)h<=w4Ad zL$wAb-oW*M1?$QZt#)L_Qan81y(*g{XHhp+fM?#mEca@pXc4RG}HxfDb6OEg4D@xyWe43&JtZO3)<;RXpQ(TE1;;gr?l=bvu)+>K{h$O zom79a(FIewKS`)dK)^Q!VHn0MV*AN?u(6#=zodDd)Z|)ow$WEs_27g-ARgW8DE~xY z8oTLZZD{e|4IdK8qOC_?neX(NHC0cRN4WHeB{k~g4r3^=Ot-*qH;YjI-S_3*B8-l- z%StTor8N>~vW>LsU1v*sXSexLwD6(5AeCUX6qawb)Y~XO-mpy@uAa$b_Bxk1U3cf{ z>PQ{f&#Iy3IGLs4TG%?4nNL=j^DeeuSpIRsd)^HrD`u6@Dd2i`6w z!O@gi^wxP?oZi)evo<95%Z7Pw1DI3tW1U`g^HcOs?{_dQdou1Y?}AwueKRjK3U{0E zO}HIRKzTj-#qYeW)+{D7M)2iBO@yo7f<_p_($fL9huaFRZhoh2<+mjR#mi@#y?>2V0{1h+FC?&FMSCs|wT@?h7drwcSrP*O;3OEb%pzt2 zUyV&f1pCch{S6x=wPqDyuhZz}(*Emsg&Z zWRY`$p(jHLmt1Ja8UfC9(}k10RUMDd)a1oxQSA0{LiYCTvBl;SWig(odApM?PyS>j z3Z zL4ru_j|}Ax+a-ikgfvv#={!j)gq^a)IeBwI(I-%=Bz18P9nj!p<@oRb1@bzm>K1me=SR&A?Im|T9u?nZThg|mfzhpaQmev#!jj$dmB*z6{M*oDzn||1TE&G*S&)Lq^+8K<%IC4FR2-u#fJ4IcXzxe(t{pQ z=Q14`#?t5(i4Natp`XwlfsVW#mg}uJE-*7qs7&tB!iAG$2LaSGfts9s3%(oFF=2vo z^Z`OfIr)0n?pffEnd=39{%3)V#KF7*%MYimE!*>dzXm{=RX51(?O<$2#!#$>i5~o- z(jt9OtTuJnY_M@`&eG-MlDl4hP(-F5k^jG!xQjSE`)uSpvsu6)NIGEv*_)o3K%S!Q zKZ`^KywEB7WIRtEyT?FKJRbA0NVNNU`%!EoZ@cAseP5MpnjB9kSwHSrCj({rsCkvX zS(9&Z*HjkeMmG|R1T&jh(&R^yGU!78R?bohnb~nzetf&bDWA?8(!;?BoSHl|IEV2a z44D?v^u$yHYoCRJ5-v%2HtCsU;R5#+Dpl8a(i1-Pi9kcXq|H?7;A`g@AI}`TaUPyu zsD}=i@ZA9&ggmp4LSbu?(OCu79(gPt<2wh$wr-H+haQXy1O6g;#idZTM$biYK&I_&PoF5%HaYTHD5B4%b= z<#^PYYR6XcLwJ;7Dzsv@88M`X01ZMiZghCiXP@|WqJXNUnYGHztfkPWaFSKKf0*_z zA};H!^t^6Gg9Ofi73Oc&eSiF4LBJFCf9Ejv8JaegO%N$ydtdmCZdw>-U1=y)th8u! zeF{~Gu>o*S3a0{RUDAt)JHDC7LxfHb-69H|-Be+nR0Dx-%06SH+5q}Ah-hUaq;m$-6vwq$VQ}jBJ3uYRKht4!3d4les|7>Ty38e6LdFp2 zkt7t$vgj6kH2zL!m^VNFFcfO@xUo_d3QKr+epsB%1H}rXx(i?1U(&_V<4fAA;XWFJ zkUg4IpOm&RLOhMXjc`}XEb;x!=fVF_HGp5*7$SOX0$HqUph?_<4Gpsf%q21JLYw>A zYe2MCgJ`v~Sb-U>u$`M@4_>_Gx7)IExY;>Ba_91>Z;yd^%BkP&3=&Tm!S#}3Nj|KR z#TQ#&JB9}`vb7V;j%_EM--oD=Ape!)oMr2ujk5LlW6|&7TSR-sw1yM9%&prlVP4iq zdnVlhWQgBR7FCZV$vS#1>Fa>%mMW^AP6BItB<&ht3`aN85&x2YRxxG%xqc32G&Ed1 zqPlhMEMR*`XG!u&a)iX!V9wJ0iSN+-p2oum^zs0XNV?PMa31yNIte_QjI#1!)+Rz4 z(&1l*%ubb%Z9V!>X#e5pPfcocKKPdcdQTbB(HCJijt=>Jqmiwu8r-82-O$$ITObQ} zY{A@uI&f+}vU`9W`Ga$_K6@PMll2fzorE;z(a*)}Z8j!sRs^ea(~CzY`DEHn4THZ{ zE4eiogEJ#j{O~}p{z>J!OHzDC2tT&$b%54oqp*>(EPM1}TwAgp_xr#zI+{t+QR7XLnQ6{5!I?2q3NIP{+Z9GVc!7~e*k@WBrfaO4*u^S?!a}k z#rMJjr@^8ezS%di2Ry~_j3NDgOtfex8rOPaCWA6SFmUR$I~#i-NGOes6h?N;nzFP# z&MsG8&3QQ{z2p#&<%Z0?LfOxIiWNp4>c}o8!X7)Pru)?i5#qCA2?ZUDl@eYE*`m8+ z1%3#4Bk4v zU#zrg8d4=rBGVIp)2b+2o%I?l0O=qFh@TW7{)V_T z?Jo>FUoC}SeMVT(A;a%z;xRJ(D({k7jw7S{C5`cCA|Sm)Da|N_G*o+=FTf`iA8Y!6 z7K3P-j`Ct%^(WV{5bY|QYlN+kULM-qa2xTS0YWB1dbETI?|pnC^QkFnS+|4KH|<*I z8iTip?jlsE>&0+tOt8Yj%~XwO*AIiPjhJ?0L^_C%0<`?0Z(p>UzWy=o4*)NWgyR=gd)1M(fXY}hd^)*H;cb~Xn0Lt6VlggbO>8Gs0{fApYU4fgS^-0-vwi$(#s z;#SXK#U>});b2cn+bSpH^Fbt9vq?$hSk{lXyK8`{#z%fZ&kc@Voo~k`=)*VFmx$S_ zW^Lhp@cq>(2PQTxQX^06B7sJ>t8Tw52f3q@Ge1%30D4^@7xZq-DdUrxh*@wk-$`bF z^2nU;BOR@XNp~{`waiWSpuNc+U99!g#~--Kr*vmE`YpMMu07=|X4vkDK53q^3bJ(V z=Zz+{&s-Za^2U(dL_XGRW zJVvV~*|Vl1@v-Q2&vl9^&P?koLe=AICyn2{2Fvs? z$R4@9DKY`*-*}9w4^T8^yjebRfvPM)v9e?jE7qYoz~TVQmSbLHS*F&1=_YzRsq-2C z5qCM}b&XU-*2u62_m!{fO*uZ+-!R_)-L>ekY29dnY3=HV@&04sEqP5J@=xWU;7sN3 zvVnqgOxS?QyU)gG@z?oS;#*~?vyyzzygoo{Q@Y1&g6)gzqzf~WsCr%rroq{NqCwvb zPVI7oc@_5X}KA!>d0ZB1QJ1&2xfuO+g zU}ABA9b|Mw$sZ!J#a&w*{4D^zMJo?|$)8*AyO$sCkM^xdv4LJOIq)(41tNXfjt)4bmdK z(vf;S7JgkXrEluxAe1o^MyP-GOS7&zO9%$xXSj!mHiFD)q8#M`tVfOmXP0heQ<{gb zCORT$@2Fr)-(`f0WrW6`Pt^}22yuq0nBb`0Fn z(5>y?T}!s&VY~rT;BO9mzeLa(0p1QbtA%BzD_Mg{Eu1>$2J+~_l)HymS1cWTtfiK_ zqcR6~!@nc9d<_7>mP?CQ4Pty2nZDZ#S8WYi6t8k41^*kpB8sz#Q{NqbO8qr+4FVrA zF=Yo!qZ~CC3{8meleUmzFtsI7GGWfgva=#Gh!*}z}(=$x;SXGA91ch z)sSWVn-dxCS*$-uP$hMvaiC^WfhCV?*?I}EZ$@jrQ`c!R^Tt(_AtB{Z^`^AJ&$CBj znXt#!p(9X|ii~+A{w{O7!QUPHJd30jj~oBwuV19ElKN(W;%ODC0RT&AvUQ6l8t{>O z<`*A!A4~x*KE*JItZ&u!q|&Y7@jkH^5$*GCom;Yg{0hTlvh80r;)5C>(x_<2X4tSL zaFg8+^SrQzs8Hus`i@i>lIiGYzk$j+h%7m^uG1m7D3Rovj(dNn&o&i4;gDNt=#t$Ob|u z=Op*+Kny6GIz>N*ZbUO;iK#%2ik}FjOE)oa$hR!eNwr46ajWs9Zt^(LC#Vw!Fzy)& zr|kExMrTMg@qg?I#{_aw>f^QCeGMlX1=td&-n$_4l@9DCUtODy;ayYK3vS5Xf%2Ti zR=P|zZBBQ?byB&G%ws|hEUsZF3DEfP*m_4(OwYAirmoeZyXDSKfdoTSwu`F2Wr*X2 zw?Ngz`H!l1`6`suTHB?EI_xKlGxRwlf-?ilKBTJ~cYZ_|>dSE&q7DHF|)c+!6?iDtt zVg3NV%h>-SImL!=x!gS_t~uqtB=6qqo$F-vADA4n2d&+mi7m#AzcUZx?jF7_4L^o& z&?k~qP9!)&LIBCh5$)<|L=RltK_Xj32^=6>H~##n)-t3uo58L2)5T(X1Za@{gFsnE zWou_ncZVFM=iusuf|Y8>y^*;8-_RbE&VD|uesv#<#Ig_PGHf4Ztv|{tOzdA{d{6!Z z$Gwuf*CB+3q<{c};#VyxY)#;Q#F=^?%s;Y-i*O%MKsa^}7pt1q)g*;q?f_&vPcNSy zdcS5>>NSWWt1b6Av@LfeH};1l)nL!s&4yGpnGjWvTU!=U*L08@Ul)ug9D?n-TlCGy zvtV!yR{P9+Ha5LqqeNj0JjZIAFU=?WHC8^HNy*4U{|W%nWtj4wm!;OijeU=cl-yb64;0G0aEozIKQJY>d!w(X0v8Kv5EHbb?TbbZh}ML*O~D@WYA$~Sgugu z`S=5|WQrwv+1BUAk7EA+WV>+XN$*ee2Oa!_TalEkern3vWe!2A1b4FcyU5mm^Q)u- z=!o`quBe(}0;hWSVMex)ZqfhxO;QbJ)3cG4l4nUP|J=8Fi^mxB+S|(`k~D`2|BD>Y zOUQ~GC*X=t+9~o|SBe=!4kASTvu<$tHK7OL$%ibQTFrcbt6VoZj&7P95~vNx=1Gug z7W|u6PX~`vxl> z$r`W4$^*o_IP-R7r}xu|rmeu+P>r5Lk~EMCfmrZ2zE@C%lzX$1lzM4ulM_Cgy`bB( z6a58})1y1b8=5;Wp_qO*Ib4_pQG$?AYz+&nq0RzG9BfzdT5d0p>wTi>FwA%Qm((}+ zx-3kOfU>X(UpoZAXDP`{#;DA#p%IBqa&HRG7f2G6BWUZ1O$Yz6-+Qc~ku_xi1b>WN zN4uG^8z#@ha9>I8;1%(9PRy9{VRZ@DwC&>~xd==|OMhfAf7GrUKlN!VL=daT7}+x! zQW(mIhz!#o4HQI7c=9&}@#CxdHPCO;A7LAMg^ut}TkRyA8tMS`Pl8l{>(zDIRQy1hl616g#!(MF=6(gL$!bqA#85sz~q#mGKe zVBU*N{+1+@s_t4*&ceEjkCDstYiRJ0ADZrY?nqSeVN?*X!||WR9cupD3FaXM&;HW% z3`;BNgi4RPAzQ%r^4gW#ZfC<8f>>x8qp;DP!jNy=LU(C}l z^ZyOW4-UIqTjTvQCY2sd%e?@lj_*!m*#tyU70)TqdJ8`qt?{-7>NMjmt%5>#wk3Dj z{^ky~;BD`)?*e-wBUuTBXwMP~Q3PaBPVj7lcZIkblj?roikn-BR&{6sqlGDk0gjJI z6hWY&D+&M3&+>W8f6ORfrftb$%TuO!mH0j!z4lHmXep^`pz3$FCdFxoRzYSTP?kF! z;M8K)-jM_yHgoVNzK^mGz^#S3&szY8>m?WmKQ1o>y^o0-`NcQ#0~%apZ!;iRrzw+c zBs5wd*=?N<>21AVgV1q%!<}k<%n?EG`q2|-s~8u=G92jHI#hZb=-CZ^ueQCD|G))l z$Cf_A?6q~!X}2yC9Ct%Triv|alSFtSu5T-)Gi7exGQD^*TKI6oZ8g+s&{!%c0E*G> z?*m2*+|FF%Vsb@H=oWLxfzoC*387ou{lovDxM~QAfV|A8f`JA78g8qg9)VW1VK~x) z6T@nw(xGjj!4A@PsgH?Y-tu2$+79E81HG^lJ*?>yq9X^B-3H?d`A{cCkM%5uk`5Y^ z=6*%Dh67y=sPc$1GE=cX{l(Z2e?3MCLn<98MFl9`qoGpZbzjcbO0F(P7N8FmdXJ@m zhg`cK@Q~7CT7y!bxq`Oi-#owg_OQgV6AD{N#UuVxGK&qp6_v-7O~49&k_NoeOa7lZ zibn)T;#O$yXdn0VgJN1brB>JiH1%(0?gZ+8wT1G@K@c^VIUVDY@*Z)k-(d1WfXRdS zi=*nsZV~-jNf>kZ+&Xw&9P)0`Ob*0Dfg^EqbZRTNg8En`$wQ{tFxOXIKF#E*vxjdhJ z(BtHx#U_^X-abOhH0G8y7363_BG9}W1e!-~kmvJ}`Nwgv)uygi*JF~r8wC0uw0(=m z1F{}lR$d#|K#ie`(gs|Xf`jCG-9pth#^@edducMc(RPuYMdpn6dXxdYA#c|V&bgUk z8T-ZMkb^?su^q=lQ#s^v|i zy&7~@(M*V3CdE@5Tn|EPuCc^T0Y%i%LQ=gfE#-BuQ*QKhI%9Cdf1?ScYPPDTZH{g= zSf0@XR;w9V)_^CCI`uq7vjQ;JC3%Z17{=K1b8|U{&E9m^&gB6l4&5j*fspCC=7{Q= zak=hod!YcJ>-E-jxZC7(^Lp+E>a+&3MZ||C*;xCjm{v*ewPELO4BIw!qAi?{6-HTIv9zTK=D`hk@_>#9 z!B@dga8nxxO%W?``28iNHf98km798sl&Jz5EAk?xWAn#a;l@97kB6yzbN>TEMV5}qHM z?#o=GBQS^@xgm6~u_XKHS@JwmSsrApu4srHG`tz8Zf$GThL=vB4>Fr3^w@<+5 zokh}|5xk62*zz|7ItLKwGnf%FR*8OPsTH8-E?-Y*UL)r}h_7NJVHr8|rWMN5jDVL zMz;o=rWPOGWU)Yy#dhQGOxRcypjiLllxA7RMzW%RZrZ(AEC4xZ0~7^0XiK|kfaH+J z_3TubdO3rP_&>5jJ{EwUO&`|~&;Npa@uA_JyjdGrsN@$U(Fgxx`Y(=kJw6c!|8L|GIu1r80EbgfzSWJU?Z*W#J^wMKA_sG+1Z=p%r}QLz4k~(M2jsNz|6KcD zhsSKXLZ>FZFbx$!>b1Co8R)fR`)DA(9prDFgt6`+?;Cgf&$NeX9`+?`-2k2iJ}~Ga z?WsIO1`THROWge59+n8`VX3YE7Hhf}xO5%t2xPE>`cOLBt*qQqiu4JCU?YNJ09io0 z^Iwg9X%W15ADG^idC`kS?HaUW4B7NR3au?Le48^sInD!gj64v&**k3H*e@lQHp?JF zWwpH@3f|>j4zJ|*Y_0zFw@jFBi(;~BxrcUaA*8!H#9q0_E5 zVj?(8wO6L$j9Qt7>)T-~#GS?PQ+o@aoxZ@HKYGd;+pq0^d~uk+u-M8EoM<@jlLanxmhHDS{H;1lJ>UPu3h zgbki{_&1ujGuy_CJy$R(!kScDnlWtQny0Fsxl-Xo9WyD?#rl?n=UF$I8`~ zqjnqNIu_r9_tYeL!QHWX3xf)t;_A6 zKjw^1F0UIvV8jve293XS07%E&a0dga$l?wCvQ?7)NsA7A}2 zrQayKoSipwnV&{Dx7}gy*mt%5#GgU zpAJ-t(Pl)zFL9K5Rn-ahIMi;}o@|x%PMjfDHjJ-c#T>VNPB(N~{AKruO318IfWw=W zQC>-Iwc{g(ZAjFUq=_Kc-T%UegmqA$_Hy=wvZ?2v~>BG>JnO6@&n?uEa=&Hu(@p%v< zhSW`yW*eF|NbzU2j*|Zv*jSZ09-Y_q9iP?pKeOO0s#9574NN|I#$~}GaA{r9H0fk- zbGE)On|y3PsrBmI(LIR)t5CZ!N1BpY2*L^;-Sp$3-f`x7@wr_@OXGZT)%i;6NNc(1 ziIM<#<`l)M8N_Ow?`@K~CQFMU)ui^_fd>s2jhe;G<9*iCdP+gLhrJSVqU2d$@4a9u z+aAcPgbf*cQw;1UaA`=jNcCmtkqZf}yATMu8;6Szlrwgrp>sJfdlW*evog70>U5y7Uu`)ccdvJq$sToG;o~ZJ6J2AI}g;;5YiI(H- zXvWLGZF#->36;ry9~Vk^GCnP4y{y_f_u2M zcgxm2PDS;5UH0td{Bgg%tcydX3&3k=XYDh4^2mmf?~KdgN#i|+kuU2ZyLuU zxxV4A)0xYxtK0@VxKP?0)C)fS&-QZ!f1&twFL*e~FtckrJ7ou*(6VU!rKPcH@q|v| zX^M{5N|`s;jiw6D*%@0mqmtzT$aj+lKzqkpeBn;TmlJa|GAJ#hS9m!aaj zSATIioo}JVA9rf?I~t*}h)g_J{JR-eb%89-tXBL0Af3BONKu1n`WsOp_XHXuiV=abG+FUBDJ0`TSfkN&f_^(}ec~i%{LcqI%4M zC=iml@rv4!uw?@Od(jdm!HC(5ldr3o1aBm`hWsxvV?@gfuO2bi&`D;77pBg|f={!| zP`GIw4l;my0_O%Z!3)t(u|0VXod%m|&bhI*z}>?+Uu-Q2Z!NxlB@5SEiURl6tA^Zo zgcB*aN|H=*h`cwh( z^(!8SSys=j#*+vuBW6#j!FleE_&`tEBK2Cpu{SOZqUZ}}k zb*$MZiKyV~*L^&d$L_g(f!w|t+Cl!SK(PJv*lbQjiv6An)@$M54j=?)JmtqEkTvaF4~A{p$4#hTD~J0(wI&hAbYnJ{^lM)Oyc4 z!WqG+?`$BPF&7cI%F}z!JUi=D+wiw%`EV1xW`g(JRVuK7AvhN1sycd6L=zp6O0TEo zui#ND(B8P8*q?^c_QSR*q1Hcn+)ijnF-m(#eB;4P`sh#R(dbEd ztKUW;km4K{Q&9N6%I%NHo4CHW+(uW+0I$212qO>pdlKxzSa-CG8n);~07lSmYhE$$ zZh7!o#GY`)9JkcWO13V$Thyk8Qh{dRL9{q|&bZDRZ$FGFfUf{OHI%QwTU6^ts`IE} zIgq-RP(vE<7XzE+O(Y%GvpXZu+njZQe>DHhYPo(M%IOQd2vs2-*IT;(g0P6}YGYxz zO}-ude!C6d)rJaRn-Xi=0uwXqL%p+$;q9i$bIYoxP4=zr&zx7fEWeqO&-Zj1TG)pA zq<(!a?X)nx-=d`BNcHLb_Q^u3YrWIede*Gjao^~2(b;4I`k+X7N10Jw#YHL_|4KOy zk66;rw64!9NN4o9wJIn^k&gAlP+q409d@63{Px!Y3bX9-H*EJ_n32cVH-?8Zq$GyK z2GGi5FNvp;h=)t?gqb~b=91mo5B_%6y4iNtWV@Dd8k9Ay>S^#g-l#75)93Losq`sN ztKso>WNUpL=2=J6ZN5GE48|g!u@(0;r)jx=afntIaQ&2AJhegneuyb8L6j8b+$AL~ zvWtzCLbpAjELxAc>sX)gi#Yx-E9PXSa8|>hnnBcb{i##ik2*4?&N_!r4v_5yo(P9n zorf9w*sdw)BcG-ZsoQI#@AOt{PC5^EM~0RI5?+hvjEW|7?^xeCKhBFKT)wzmicZVbnRGJ3tWNL?2^y z?q#%MzZ>=R{gvAfrmRCLjt)A}0k5Yg@Y4#xWlo`cIA!mVY9u2CKiK1dk(Bi=(A!XD zLxDCoIDg>8e-Rr~-;Y<6R-``>vrkROm9WN)dMo3LU29Q?#utVkPj?6-ET8m;d)47H zkv+9f2_l^{-zY<$Du5b=Xbudr*MW|dhJP%I2cD%;^xUZP?c4U1hYNB6Z~1!^tlMsH z=SZ1JHP+?tvJNQw)a#bB9`t@6sDFQWF<|!Tcco%akixLU&S8J4c43(PF55PArp<~8_)nnAii~q1 z?^skNc|{g!LwH%E$hQdF9`HY6f!dHaSkynR80KvPA3Eq$bi-S@Z*^DCn`#QIGS8fO zA^;Ag>e4)o(?8Qt-{^3)zBe8SJ~oihTHw-jb!dGhyB+e<+})8OI5BtWwYcH>eegg; zPt)H6oc7E0X+4Im@yjZHnv9cPdi7HB-tllbE> z^hNK%moS?K0R+n{bGx$(Im#)&zTtj>Wdx)5f=FfN3GPGlU8><#m1f8ZT8DkP8yguq z$(^BAe$x;|^BGMImx)=k%h8pbG6ILnp&Y_kl5&pr0XQAFz1lAsbpK&g-8i3QY^ku& z*Ur?;-?W%q>*55oWh5<@o(-Q9>VbV*9LlyoDFLr9mjgmj0XbV-8J7 zme+aJM@s@~nw*pTiuY_)2??}iyHz@%Fd|d+_{c8*hd<3c<`R#=r{~$f-}pcHJZUIo zf`0LCa*xE#XUTy%oM&a%21_MfVRf|^n7(Aw}PW3)mh1khwo^%|c{{RQUKL)s*3 zHi&1V8)8^c8oMDCcyHBt_#Ew&G#yHP59a*or#^o zZbWRLTE0&WV}#Wsl11w$Si1Ycr+w6p|&p{1cM z>nfCPn$7q1RXBJUDH$57Wdo7#pi@}GSuc#p!O6nnwO;TFsP)v%W;d^Velu0<%&&+9Ci)W&L|Ukdp@T!YK0uH- zfuWGPkelP{lTH?NwA8Dxe5cS5FE$8+hVg{|ekZ}^@#Ol2TmK$XdGV9E33<4Q7aM;j%^p1G4&DZcZh9?sv;d8pFV0W-F%i z8(`FyjGp;N*Yv&fqQunQ^BZ6!L8-A?rzCXH%c^=#EqPJ5MKef@-0$^Ipg?nvHTWjA%lcH^p&^C!l!-&Gdz5#=m_i+!5*c&dbYm#{p1OgaM-7?jgo5O>U@Y_4~ie(Jxg}azCRpTl~teZyr z#hNKEEi~QyHFJ&b*sj#TT=N&-@Iv`I$Q-Z#RHv_M3UY> z$jsn<_e~_(ubM@Ce6mUNKCWG2(0GdoFRzZ`vL`WE~O_Mvdiw%7h#MbpP9ycc;9i6t=F*!;6nL24An2VTJ?cxNZ{(? z2wI2@YV|`kifY=C>Soidux;QxHYpF6?t7lEpEpRkOD>A!n+aJAZ1AO`zB9~MN3ET> zQ2edAr2kVl!2~8&pAWrCvY?W`gJZ%Cyz!-mkM8Ea;oUw2y?Ly@F1vr=q1?q?O1k%T zZ(i%@@_Wn}6LEdL)!-cB#etKE@~XyXMgMuSixZZzzV;km=qF`TjSOFx4& z`&*N(e(B;;`FQjOilz=mdt(%Pd7}I591j35w{J`QnBI8SeoMCUH>R+L?@Wh7Pr~?V zG@jv*)-hl`v%30sVc6vn7X>LK6HSwLWcp~u+OwMU+tWmaHF6L{ZhEY661NS3Vk?T; z_r_q7<_6jKCF~EB6aeL!N`-V`!EI6z1NHw7ac0IaSoJt+lKR@j^}hf8*p#^oM>k1- zq{U_uDuMvik&H9K0)|+iMZG5j-UWJ*HJ*M`-CK#V_{@AwVF9|1k)Hs>k%)D z3sMHnRsI4c(N%Blh=BR+vYIBzGPfTVErOv7E zx*l1I$#w6(@TwN^;G}E$T)AurR-HkB6fP%_V3CJ=KLPyz?RpL|#>mJ7je=}C8&GDH{r5d&tcD?+fGuE&EFRYP4 z0Ato`lm_wN?Mrp6273ElKAf(s{2KGNTo_bgum}{`mV48Ic|GZ5hgG3VPl(KCZJf{# z3}}4wslBCh+4aLiVEY%dEN87lq*MQFxr@I8E(sMB;{6zYn@}}&ZhDmx>u>9Ka zBTGT(@+jP`dSHF!=ZoHN$?@Y(hZXNxC6O7MyifpmbO6BP2uzNCzI*5@tbw=Dy=`+z zDBi(*>+tyS31e|(TVzct=$iOE{LHfR2XAhJHRW$5jvyy21o~kfIyp2Z1UsCWTr=Sa z+@@^*S!ngz)^~|k&swx_@exL>9oHo&QD=|wmqnd#Ix)%;us}-zzV3RxsKi7ZCXNga z%{WdX9Yh(KL-LYge2x+f6Xul_{^BL**?g z4aHYg(kNX9aK2=CzatmU=5pTO9CkyeU8To0j`y2ALuzsHSXN0dzN4JezoVB{v(wIrv?R{~Q{v_W?$u$+ZSBM8LL zsAqv_su5&ONN2b|FeR;Bdn126eL1Eq4mESc1z=>~oZnOz_L=)nADL#?}{@lhu^ zgZpQV0xGD7%r%YznQad`q-yWY=(zNG@#DpMz$09;pE431lnm<7bp*jtE4zJxaPXg@ z`#3YsjMcMk8AYQ5*dfF5oC3)q#?W1ohmSB@v~!SE{LlRzK>xWvPWN#-a{mEYSIC5- zZ)gYv8Nk><{~0?DVC=gkK6u&K)R^GE2{#TXt{gZq$E}~Ww2eL1{s2XmaWp9?^wTkk zMkK8=8ylkXwWIES++nFx{{v-0<=NjbXw$olCY>41z4xL^>?Oz!I-Ggo6fo7}#c>VK zJMglOqn3dwu%gpu5*S#q$$<@6(UjG9ClxKK=Ijq`4Z7gBNDM(pze?q!w5C@<{>2eU z-@_NFDkXtz)47dc)Kklq`sZ4M;%`K%PJKGkR%-2Y1)0w4x;%#R;gXCbin&rs;3!?w z-+26tdD*SAbCQRnXy%R^q0h0gmf zOcDNoPA_}aw9JClXu|4Gg|z*@@tyR3{Pk^)@rfrPGOrxvbWgI6t#@?R zn8*0@kxE?Ul1M~O_`8frXcgNrMi1G`IHm^|y^X)VPdYFzr{v}WMF<`Z3{q|jTV9)e(!57i57N$Al@LIOTfUhKr&H-V-1eJV} zT`=J$W^f6J%~3C70#${D(R@)?5SuuVUmG|js@>UT<4+L2r_*#G!PQ~arHQabpbxTv z1Ci|j5JJaT1L%9Zdxt=cvrf;_!=a*!kGt_hlT;ku@n8WOk`d%OV+0yb3T&D(GQVxn zeLZz1RY%kfR8kg9k|5{^x`Bl0WV?U{HJL@pg3*-9)R#M!)rWvR7*a9{ZU7Kf%TL`y zbsfNfAzKKjb)V{mKHW5a^^Mu?6$@D;GvFGbx{hFY-&g+fv~?udi5CyYD9_@Pbsse+BsPXwK_$V$ek^Q4VDomVzcYv7h&;^OjrvIM8Zp|CxAv+C10U|;KwdcXhr zakO{p7QRFCevonc5d2VKi3|A1)kgU#hBBzDa{o>`Vhby-vFl>DyF^bgMnc%r39CR? zdjh~RW#-3T_8RYWa^BMCYgadRcJ~7Vxc~5 zhR9!i$gs)?@brtg>fqC0^G|+XG}b!uIvRwgl~sYE7QR)SdjOR7%_cq%c=)r}UUpC4 zq3cXeIT-1?$+`y!WVJH(MjBmH5L8?ASztdp(jvbzgbH&{BZ;dx&w?SXG z?9B$s`>@a` z1u6()^@)!H6l@FfUCnak@UqhB366J6ithsfscoSW2Y^*pUk1@iYXqqj+zhQs7)UV& zOOx!GumGF4HIgu0+yL!@$m+cnZWKh!95(WwYp8%COxA#5%0KiNP>>dJ!jhQXft~Cn^am2RW!_5NH(Ed0J}9_COt2CGi|A(S=qi+-z<~3PL+yJ!PEfdTC;105gj=D9fk%*!HTKQESxCIpuM~u z%X4v&I`~K$rT8A)8(rf%h&JUm;Dsd~l&1jZ0b1)_8KOsf&qGGtagi*qx;JY`{ti{w zGwC{TfD(I%5Xzt<2Q`$`m(D+H1bq)HX78P}vps+ydW5BeN<@T4Q{F$+T~r;4dK5P! zLv`VS{lU1b{6!oZN6|-89;Rsh0^)A<@czvytmjkXQ9~xWhc|hNiYgN5H6SLG{;C-) z%?PXaKmX`rw3NJ>PU||4R#Xv6FyhS3lF=bYw zoD&%McZEDm*ShP(-7hh&2Yv&yT*j^jj4cksQ)?Q~?i|W+=&-6h!mg6cvCU9az*oBa z#QE4~U3R9wy@Ea)WVbJpku^(C87ZG^{j6XsHVm-_wX-?I*F|$5FY*~)! zM#+d!Qz6~edVC0S^vuqHo0X|oe_J^O z`T0!Y^Bbt z(y&*rqBd(p^gB;WztKqSo8TW-@tc^(LvYnN6rd**9aVQrumW8xlz7^4|*g1~WtNpxCdK|352 zu8ue{R=YvhfyBfcI9{mnBCyn0kyLIJ*TSEmP&U>ciV_}YW0{&zU;q;(G{P5Xjre98 zLPMLAI_4n8#+LE5NDe76H`ij!&9E0$= z7}QaR+SYliUriGig)M$EgFC54K?Ky3=@i!%lDUf>>gVadhUKa0YnUzz z@e6mn(um=MFJS<>v7A8%R;<2VZeB6%xc55V{SS zW$hcR5z?J7XdQqVEvmGhAb8O!i;Up54k16eIR1)w9Faj$Xac45jRkyxXYzR~vtH$Ogds_T1&|rARYv`dU)W z*#NEki1sTyAe#27#GwG&;swS@y$o06r61jOw-=Bj^XBXU_x_6l?a>U?lMJ9^KWMfe zB-HQo&EaJQu?^3#Sx{G{?>TLMBy=+giXcGNIYfi3^Yw&Dp-q#Ql3m04m0?u&5Mb(k zk4hX+wW-zZ$zqifd4{sNHkm=!R9}W&nj+Qm|lm-jscd z9b02>d*wr*5487Rpe0hbIl`9agmupMj#3^T2z_-h%iD!4Ow! zU&reG;A2ucC&95;^V7V4qJsg&6(Bk~koDEx$=v;)m0x8%*}osJS|1aGUtgTu+|T@O z|CYV4CSv6~`<5zQ2(LN7=M(FZ%jwK%#`g!_(T&5~)32p`c#p#Jf!@c_6g51vlrQ=m zgM|HcBu_UX+U1qfm+;nn?eI-o>-{IBj0&S&mhFCtQ}*kZ11S>k z5y>By%2g>nzPP$Q1-(t9M~V6_Q;-u4IiV8TwBh&w9PiM@t717u!D5P30wworMMWlvH`jrFNuLJhd~+>eaLfCfXGS1Zc1DJe+m#e zuwTN+adM}NemCX6X9DGNECepws8l!WCi)4DWVILPA8RHDxE+o#`a1-748+J_?IyUd z@uzhs8~XqwoW~Sl9Ip)20gGg6U@-wqM%QPp`YRvpv_gdiIu$uMdvP{o8{9Ji0taE- zs0`wVu^J=hRm^V6sV?sBf5FH`W1<)_bdX~7z{CP?NSj;6dH5_iy_G+hw@U;XtJ7-;*+{`0g6r6+! z$_cAdfFXjQ(F3f|;rDR(d({ETk6tfM+D4y$4|~gj@ei)!N`n|t`YTBwh={Va$3HHo z8z)mQN6uG%FPXRDH~RVA?_QuwDAWpK4JI4?XrB7L3`nq5B^+hiu+_5;I8Aqv=fWfW zrlV!m#MI=m;nDledB}}@uy@{$HGcP%vtyu0qxc`(x3 zt^tdZUX%ZtU^t5V8D~AHz{LF~f-#V{5%>I_5UR30x|@B92L?&HaD^(`J*!a>InrWO zNMQ^yE{N)v5Ob1z`S{xZ`wIzsfHQ6#EFcH6lH*Jk%5aiF>+%1sGcsOjvfly+#A@UO z{?!>(bJ*6=w(uz-)Dvx+@?JrJyXnw%K>v^W97CMANWHm|UrBwww7gw)e;Z>D(6<}$ zvI75w93j*sI(%2WphjeK8u|cV-!lKI2@uNG{tIOf&%w&M%AjKfYQZ|B$euPi4gSCD zcZQ5hLIFJ-3BQ0bUh19Ic&;douT}I>OX-pvOylh&-trrK@lQwrz^Y+5@gYl9_bDsDJwm~! zXTO*3&k2@?r!cEm9Tu=(Q4pecFeXy%ghE^1WsLj;4#nn+F0+>a?ts?(nwhxa?tF7G zb!=tNtQGATW!VU~0stX>00_YrNut|@PxNhZJ?uHxXdUy)3T)BHzj)CtI)Nv+iO}TU z)NBj?YTRy3+)%jxQFg`1z<;UK7;URWaBX5m?mAtNlOYhmBZ1k5Xk4!3t)w+6&R=n9 zUHFNf?9T#?23IOQfK9&Aa|YOCJXI`LsXy)Z#u$ySL};bVUTc)zT7(qre`L{k(`s7l zVC?7=C*M*jg_|6R3e2ZS<